{"meta":{"query_hash":"c73cb4f6df46","filters":{"topic":"Diabetes Treatment and Management"},"cohort_total":3896,"direct_labels_cover":11,"predictions_cover":3896,"exported":3896,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c73cb4f6df46","api":"https://metacan.xera.ac/api/v1/cohort?topic=Diabetes+Treatment+and+Management"},"results":[{"id":"W103558615","doi":"10.1016/j.jchf.2014.04.005","title":"Sitagliptin Use in Patients With Diabetes and Heart Failure","year":2014,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Sitagliptin; Medicine; Internal medicine; Odds ratio; Heart failure; Clinical endpoint; Type 2 diabetes; Confidence interval; Sitagliptin Phosphate; Diabetes mellitus; Endocrinology; Randomized controlled trial","score_opus":0.005864318617124739,"score_gpt":0.201372353265506,"score_spread":0.19550803464838126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W103558615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181205,0.00003031317,0.000004597434,0.0071307602,0.00004042511,0.0007057339,0.0000054056613,0.00007666815,0.00019405778],"genre_scores_gemma":[0.9888246,0.0000010267045,0.008524881,0.0019365906,0.00007108149,0.000048153357,0.00007167433,0.000034575045,0.00048739096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869376,0.00005524106,0.00019260398,0.0003706294,0.00026921774,0.00041852987],"domain_scores_gemma":[0.9992817,0.00008431109,0.00003727995,0.00034893036,0.00006317472,0.00018461322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015578793,0.00022824148,0.00040576365,0.00016766276,0.000057575675,0.00007369106,0.000044343713,0.00009447911,0.00008598016],"category_scores_gemma":[0.00006982106,0.00016917347,0.00005016884,0.00020378438,0.00005653152,0.0002679166,0.000065171516,0.00016549994,0.000083133156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039270133,0.00024336956,0.9601412,0.000073691604,0.00005220878,0.0000017765017,0.000061015882,0.0000022498527,0.00016282687,0.00009366981,0.03843375,0.0006949947],"study_design_scores_gemma":[0.003273867,0.0007177759,0.772536,0.00015197718,0.00006893441,3.9158715e-7,0.000044392313,0.000039022056,0.00018500416,0.000019672007,0.222807,0.00015598578],"about_ca_topic_score_codex":0.000024066318,"about_ca_topic_score_gemma":0.0001821819,"teacher_disagreement_score":0.1876052,"about_ca_system_score_codex":0.000042635478,"about_ca_system_score_gemma":0.000016372782,"threshold_uncertainty_score":0.68986934},"labels":[],"label_agreement":null},{"id":"W1480180324","doi":"10.1002/dmrr.2603","title":"Short‐term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps","year":2014,"lang":"en","type":"review","venue":"Diabetes/Metabolism Research and Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"European Association for the Study of Diabetes; National Science Fund for Distinguished Young Scholars; American Diabetes Association","keywords":"Medicine; Type 2 diabetes; Generalizability theory; Intensive care medicine; Insulin; Population; Diabetes mellitus; Term (time); Intensive care; Internal medicine; Endocrinology; Psychology","score_opus":0.18748006889271585,"score_gpt":0.4166349322982586,"score_spread":0.22915486340554275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1480180324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074812127,0.9783176,6.1368917e-7,0.00036620194,0.0004862996,0.0127574615,0.000098346805,0.00003788955,0.00045435329],"genre_scores_gemma":[0.00017432458,0.98537475,0.00009947613,0.00078674604,0.0008272042,0.01001115,0.0010959739,0.00015157946,0.0014787766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99391353,0.0011232634,0.0014489064,0.0011685987,0.00066044834,0.0016852673],"domain_scores_gemma":[0.99505585,0.002319839,0.0003393588,0.0013029139,0.0005344111,0.00044763822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046508033,0.000939611,0.005012332,0.0008659605,0.00036385647,0.00018556991,0.00065464206,0.0004371974,0.0001303905],"category_scores_gemma":[0.0016485451,0.0004944015,0.0009238614,0.0012523481,0.0004366571,0.000110810564,0.0005243495,0.0011105177,0.00028897153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000360208,0.00021421685,0.0021415255,0.021496097,0.0005802035,0.000008132168,0.000104318045,4.7836295e-8,0.0000039791826,0.000114295166,0.023941262,0.9513599],"study_design_scores_gemma":[0.0010958359,0.0006329604,0.0005250288,0.021598244,0.00093406177,0.000001186856,0.00002424476,0.000010781695,0.000044165678,0.00014030334,0.97453,0.0004632202],"about_ca_topic_score_codex":0.0000063504745,"about_ca_topic_score_gemma":0.000012617792,"teacher_disagreement_score":0.9508967,"about_ca_system_score_codex":0.00021089651,"about_ca_system_score_gemma":0.00012167403,"threshold_uncertainty_score":0.99975073},"labels":[],"label_agreement":null},{"id":"W1488133404","doi":"10.1002/9780470910016.ch12","title":"Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes","year":2011,"lang":"en","type":"other","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Incretin; Type 2 diabetes; Diabetes mellitus; Dipeptidyl peptidase-4; Medicine; Pharmacology; Hormone; Endocrinology; Internal medicine; Chemistry","score_opus":0.02131570883646324,"score_gpt":0.25431341531704277,"score_spread":0.23299770648057952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1488133404","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022680284,0.0016140586,0.000026762627,0.00007389455,0.00030627934,0.0028228,0.000095433184,0.00024348636,0.99254924],"genre_scores_gemma":[0.0041665556,0.00029477637,0.0031793255,0.00008167897,0.0004000684,0.0005011977,0.00039047303,0.00039132198,0.9905946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893695,0.00000892288,0.00025355467,0.00034365852,0.00014466414,0.0003122277],"domain_scores_gemma":[0.9991691,0.000031808584,0.00018183394,0.00046106806,0.00003181896,0.0001243693],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003505798,0.0003792008,0.00079533196,0.00032499677,0.000014815299,0.0000055067085,0.00006174433,0.00018333452,0.0047173845],"category_scores_gemma":[0.000008060303,0.00025468474,0.00037977524,0.00007187064,0.00006804087,0.000017432245,0.00002538488,0.000018799039,0.00015326736],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004272914,0.0018179553,0.008901049,0.0008067783,0.0021210383,0.0000055436117,0.000087180386,2.6673403e-8,0.0001536344,0.00092092913,0.9440926,0.041050587],"study_design_scores_gemma":[0.0039083115,0.0033589208,0.0003977093,0.0004749574,0.0016698623,1.3593173e-7,0.000038264265,0.000004306203,0.005569016,0.00004578514,0.9842879,0.0002448141],"about_ca_topic_score_codex":0.0001456771,"about_ca_topic_score_gemma":0.000076231256,"teacher_disagreement_score":0.040805772,"about_ca_system_score_codex":0.00008154181,"about_ca_system_score_gemma":0.000033175253,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W1489159393","doi":"10.1111/hdi.12127","title":"Anti‐inflammatory effects of linagliptin in hemodialysis patients with diabetes","year":2014,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Linagliptin; Medicine; Hemodialysis; Diabetes mellitus; Internal medicine; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.003222289053146517,"score_gpt":0.20337789227688957,"score_spread":0.20015560322374307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1489159393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940937,0.000025463185,0.0001576318,0.00018350895,0.00019203656,0.00034146223,0.0000040104414,0.000032862656,0.0049692793],"genre_scores_gemma":[0.9979716,0.000009866783,0.001110878,0.00016794696,0.00010779308,0.000063319545,0.00018538677,0.000020944011,0.00036224976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857813,0.00005164652,0.00033891355,0.00029118545,0.00052651024,0.00021362469],"domain_scores_gemma":[0.99913,0.00016529406,0.00017206783,0.0002848116,0.00017592766,0.00007186672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019663494,0.00017783123,0.00046819827,0.0005001659,0.000020473655,0.000017644112,0.00014379705,0.000058422116,0.0001080667],"category_scores_gemma":[0.000173248,0.00014199133,0.00015381473,0.00025527345,0.00006169839,0.00011683169,0.00006692966,0.000079770856,0.000035156794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007136653,0.0007114932,0.9827236,0.00012683803,0.0006451604,0.0000039990628,0.00008334237,0.00010172055,0.0005975183,0.00035692347,0.00014627136,0.014431774],"study_design_scores_gemma":[0.0052519566,0.00022217592,0.97959775,0.00019112628,0.00045204881,8.326537e-8,0.000008007102,0.0023028033,0.010476165,0.00009423613,0.0012562157,0.00014741282],"about_ca_topic_score_codex":0.000008327695,"about_ca_topic_score_gemma":0.000011418349,"teacher_disagreement_score":0.01428436,"about_ca_system_score_codex":0.000104246086,"about_ca_system_score_gemma":0.000020018271,"threshold_uncertainty_score":0.57902384},"labels":[],"label_agreement":null},{"id":"W1489303051","doi":"10.2337/dc13-2339","title":"Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia","year":2013,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Internal medicine; Glucagon; Medicine; Endocrinology; Glycemic; Incretin; Diabetes mellitus; Glucagon-like peptide-1; Type 2 diabetes; Insulin","score_opus":0.025733811646917053,"score_gpt":0.30604223585065665,"score_spread":0.2803084242037396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1489303051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950205,0.0019469868,1.8871677e-7,0.00031594257,0.00010723736,0.0010778712,0.00004533114,0.000039951115,0.0014459895],"genre_scores_gemma":[0.99903744,0.0000708673,0.00024905262,0.00018369405,0.00003026762,0.00009930422,0.00009927504,0.000040263327,0.0001898339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984456,0.00009000618,0.00039724365,0.00029903636,0.000264619,0.0005034973],"domain_scores_gemma":[0.998716,0.00013269379,0.000113025286,0.00054345786,0.00029241972,0.00020239255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001971468,0.00025402935,0.0006763188,0.0004088124,0.000015105489,0.000012123953,0.00015923477,0.0001096114,0.00036074105],"category_scores_gemma":[0.00021404208,0.00020618844,0.00020884642,0.0005512035,0.00006033573,0.00011918116,0.00012016408,0.00010783007,0.00031570633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006136501,0.00044944198,0.9167786,0.0005603475,0.00032265545,0.0000062063846,0.0020987191,0.0000420855,0.04649126,0.000018266956,0.0020869132,0.03053183],"study_design_scores_gemma":[0.0028559116,0.005834637,0.9437172,0.0005511225,0.00016311886,5.479339e-8,0.000969436,0.00010193506,0.04423531,0.000057823025,0.0012750723,0.00023842094],"about_ca_topic_score_codex":0.00008352589,"about_ca_topic_score_gemma":0.000019703515,"teacher_disagreement_score":0.030293409,"about_ca_system_score_codex":0.00024131531,"about_ca_system_score_gemma":0.00009005545,"threshold_uncertainty_score":0.8408121},"labels":[],"label_agreement":null},{"id":"W1505125090","doi":"10.1111/j.1542-4758.2011.00605.x","title":"Metformin intoxication requiring dialysis","year":2011,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Dialysis; Lactic acidosis; Hemodialysis; Creatinine; Renal function; Metabolic acidosis; Bicarbonate; Internal medicine; Acidosis; Acute kidney injury; Gastroenterology; Diabetes mellitus; Blood urea nitrogen; Anion gap; Urology; Surgery; Insulin; Endocrinology","score_opus":0.040210824456129335,"score_gpt":0.28026793805828715,"score_spread":0.2400571136021578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1505125090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55495495,0.00008439795,0.0066569205,0.00060317357,0.00048137267,0.00026121666,0.0000050560498,0.00014587062,0.43680707],"genre_scores_gemma":[0.98254,0.00007167139,0.010689067,0.00032359923,0.00019104425,0.00006480735,0.0001498392,0.000013091777,0.0059568593],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999091,0.0000133090725,0.00023503239,0.00022511499,0.00029566349,0.00013986757],"domain_scores_gemma":[0.9994671,0.000018341101,0.000086655986,0.00024914808,0.000104124265,0.00007467208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017265519,0.00010785578,0.00018286284,0.00030238068,0.00003798453,0.00002071559,0.00012825656,0.000040143215,0.002376485],"category_scores_gemma":[0.00006584469,0.00009447475,0.0001872639,0.0001828178,0.00003195972,0.00018627268,0.00006770771,0.000052080573,0.0003566306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003969668,0.0020337834,0.28854027,0.00005495624,0.006691738,0.00012243891,0.0031583807,0.000015393662,0.008711809,0.04311704,0.0054983944,0.64165884],"study_design_scores_gemma":[0.010706781,0.0007251655,0.48860973,0.00022956825,0.007516318,0.00006139217,0.000967513,0.013261261,0.2593031,0.015534191,0.20183465,0.0012503221],"about_ca_topic_score_codex":0.00003516767,"about_ca_topic_score_gemma":0.000008527852,"teacher_disagreement_score":0.6404085,"about_ca_system_score_codex":0.00013347881,"about_ca_system_score_gemma":0.000016688879,"threshold_uncertainty_score":0.99853545},"labels":[],"label_agreement":null},{"id":"W1506095972","doi":"10.1016/s0083-6729(08)00615-8","title":"Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)","year":2009,"lang":"en","type":"review","venue":"Vitamins and hormones","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gastric inhibitory polypeptide; Internal medicine; Endocrinology; Incretin; Biology; Enteroendocrine cell; Receptor; Signal transduction; Protein kinase A; Chemistry; Insulin; Hormone; Kinase; Biochemistry; Glucagon; Medicine; Endocrine system; Type 2 diabetes","score_opus":0.025247020420589402,"score_gpt":0.27676158605772727,"score_spread":0.25151456563713787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1506095972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002361159,0.98814946,0.00001410429,0.00011447333,0.00025509464,0.0013474375,0.000042270363,0.00014459925,0.0075714174],"genre_scores_gemma":[0.0034835723,0.98651767,0.00035420168,0.00025710594,0.0006597126,0.00010065506,0.00023151268,0.000092390386,0.00830316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760115,0.000043549524,0.00070767046,0.0006439177,0.00041991138,0.0005838216],"domain_scores_gemma":[0.99863994,0.00006287804,0.00030455372,0.0006108118,0.000049792372,0.00033199415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012201364,0.0007963192,0.0019742008,0.00064268935,0.00013572117,0.00009715218,0.00017028523,0.00032153458,0.000076079676],"category_scores_gemma":[0.00002087215,0.0005853484,0.0005004993,0.00026653724,0.00009920278,0.00013301724,0.00018456648,0.00035943437,0.00028598122],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001582283,0.0002899607,0.00007931546,0.0031401857,0.00047726085,0.00018783711,0.000050303082,2.774707e-8,0.000016265312,0.00076329254,0.00093324966,0.99404645],"study_design_scores_gemma":[0.0012278319,0.0011941857,0.0029767393,0.004798723,0.0036219414,0.000103276885,0.000043238553,0.0000014374237,0.000015208026,0.000038931987,0.9854177,0.00056077435],"about_ca_topic_score_codex":0.000048028473,"about_ca_topic_score_gemma":0.000017330365,"teacher_disagreement_score":0.9934857,"about_ca_system_score_codex":0.00014997947,"about_ca_system_score_gemma":0.000105214574,"threshold_uncertainty_score":0.9996598},"labels":[],"label_agreement":null},{"id":"W1514327690","doi":"10.18433/j3s304","title":"Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Linagliptin; Pharmacokinetics; Pharmacology; Pharmacodynamics; NONMEM; Type 2 Diabetes Mellitus; Population; Medicine; Type 2 diabetes; Placebo; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.020737052744158352,"score_gpt":0.3301995819472927,"score_spread":0.30946252920313433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1514327690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959416,0.0011144647,0.0000022717686,0.0012393751,0.0004601314,0.0006894349,0.0000051948364,0.000011809862,0.00053573295],"genre_scores_gemma":[0.9985403,0.00034122998,0.00024243667,0.00064934534,0.00010642741,0.000011505957,0.0000070461574,0.00001337918,0.00008835368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972111,0.00017497633,0.00080378115,0.00025972322,0.001099887,0.00045054776],"domain_scores_gemma":[0.9985238,0.00016360189,0.00050869246,0.00014289176,0.00039709124,0.00026392183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006790647,0.0002363791,0.00059296534,0.0006908645,0.000090116395,0.00005355048,0.00038443788,0.00003111976,0.0008978802],"category_scores_gemma":[0.00007441238,0.00012923963,0.0002593333,0.0031356595,0.00031652558,0.0005360944,0.00010426877,0.00031856235,0.0000113305405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026746865,0.0009281104,0.9376134,0.00008125809,0.0009231026,0.000006704378,0.00016568102,0.0014930064,0.013275894,0.000013511935,0.00020900177,0.045022838],"study_design_scores_gemma":[0.007106518,0.00058448856,0.91814154,0.00016575889,0.0056171548,0.000002183444,0.00009452049,0.04786345,0.016499944,0.000025252486,0.0036714703,0.00022772788],"about_ca_topic_score_codex":0.00010334474,"about_ca_topic_score_gemma":0.000008443193,"teacher_disagreement_score":0.046370443,"about_ca_system_score_codex":0.0001396316,"about_ca_system_score_gemma":0.00007582209,"threshold_uncertainty_score":0.98311585},"labels":[],"label_agreement":null},{"id":"W15149348","doi":"10.1096/fasebj.24.1_supplement.231.7","title":"Effect of viscosity and fermentability of purified non‐starch polysaccharides (NSP) on kinetics of net glucose and short chain fatty acids (SCFA) portal flux and insulin secretion in porto‐arterial catheterized pigs","year":2010,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Agriculture and Agri-Food Canada; University of Alberta","funders":"Alberta Livestock and Meat Agency","keywords":"Propionate; Internal medicine; Insulin; Chemistry; Endocrinology; Flux (metallurgy); Fructose; Food science; Biochemistry; Biology; Medicine","score_opus":0.00863637932548675,"score_gpt":0.2545872623124296,"score_spread":0.24595088298694287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W15149348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989185,0.00010119435,0.000015165732,0.00010826868,0.00011468678,0.0006368959,0.000029676245,0.000004423251,0.00007121167],"genre_scores_gemma":[0.9995683,0.00018067406,0.00012599047,0.000018601308,0.000054003714,0.000007499028,0.000026026306,0.0000101542255,0.000008785559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998872,0.000119999386,0.00042649978,0.00016472304,0.00024584975,0.00017097499],"domain_scores_gemma":[0.9993616,0.000098455246,0.00018818898,0.00020524985,0.000040768624,0.00010579211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010427478,0.00016510791,0.00047322724,0.00011983875,0.000037759626,0.000016350854,0.00006779402,0.00007048423,0.000044341643],"category_scores_gemma":[0.000057462534,0.00010601243,0.00006422884,0.000077661585,0.00027052138,0.000064615735,0.00007569998,0.00024038208,1.3738644e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002971943,0.0003048835,0.15916628,0.00016619125,0.00009243868,0.000014165553,0.00057543424,6.539252e-7,0.8264817,0.000011361358,0.0000024345986,0.010212493],"study_design_scores_gemma":[0.0033057574,0.0035116505,0.449684,0.00009135835,0.00018828857,0.00003019738,0.00006393035,0.00009624339,0.54293156,0.000041177685,0.0000020191271,0.00005382357],"about_ca_topic_score_codex":0.000057083817,"about_ca_topic_score_gemma":0.000045143657,"teacher_disagreement_score":0.2905177,"about_ca_system_score_codex":0.00001904993,"about_ca_system_score_gemma":0.000021412901,"threshold_uncertainty_score":0.43230614},"labels":[],"label_agreement":null},{"id":"W1521227597","doi":"10.14740/jocmr2149w","title":"Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Internal medicine; Insulin; Dipeptidyl peptidase-4 inhibitor; Diabetes mellitus; Body mass index; Endocrinology; Type 2 diabetes; Type 2 Diabetes Mellitus; Gastroenterology; Hemoglobin; Regimen","score_opus":0.3053837093833423,"score_gpt":0.4972788017055125,"score_spread":0.19189509232217017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1521227597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946626,0.0010963521,0.0000025529228,0.0023427864,0.0001686066,0.0010144481,4.274787e-7,0.0000041009966,0.00070816855],"genre_scores_gemma":[0.99933296,0.00031709595,0.000022413229,0.000043481985,0.00015554224,0.0000070590127,0.0000034307532,0.000011194955,0.00010684507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662733,0.0007556202,0.0010192117,0.00015707435,0.0012254718,0.00021527092],"domain_scores_gemma":[0.9950942,0.003116871,0.00038481972,0.0002179943,0.00094720605,0.0002389358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055503603,0.00012551695,0.00071078225,0.00031651167,0.00003909984,0.0000107557835,0.000120702636,0.000053486834,0.000013305824],"category_scores_gemma":[0.0037381055,0.000051871197,0.00005465654,0.0005091381,0.0003193345,0.00006964962,0.00005113469,0.0004577435,0.0000011730502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015246713,0.0056040804,0.9179876,0.000025181404,0.00040764138,0.000023498887,0.0017271079,0.0000023376156,0.0000030568947,0.00002532029,0.00008356396,0.07258596],"study_design_scores_gemma":[0.024168791,0.076288514,0.8930544,0.00034193732,0.0003445747,0.0000010644643,0.0051723286,0.000072324256,0.000018210721,0.000074433585,0.00042710322,0.00003628807],"about_ca_topic_score_codex":0.00006628804,"about_ca_topic_score_gemma":0.00003014436,"teacher_disagreement_score":0.07254968,"about_ca_system_score_codex":0.00014049625,"about_ca_system_score_gemma":0.00021716615,"threshold_uncertainty_score":0.44751316},"labels":[],"label_agreement":null},{"id":"W1526927233","doi":"10.1056/nejmoa0802987","title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; GW Pharmaceuticals; Gilead Sciences; Novo Nordisk; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Servier; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Glycated hemoglobin; Internal medicine; Type 2 diabetes; Retinopathy; Nephropathy; Diabetes mellitus; Diabetic retinopathy; Albuminuria; Incidence (geometry); Stroke (engine); Confidence interval; Endocrinology; Renal function","score_opus":0.0069322527232655055,"score_gpt":0.21006929412226033,"score_spread":0.20313704139899483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1526927233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497926,0.0021155765,0.000010001866,0.0023047351,0.00016229853,0.00023435285,6.03144e-7,0.0000063245398,0.00018685941],"genre_scores_gemma":[0.9973421,0.0006016428,0.00018851565,0.0013961518,0.00027722146,9.983115e-7,0.0000056430176,0.000012044855,0.0001756503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904525,0.000032929147,0.0002967105,0.00009957184,0.00035730258,0.00016823765],"domain_scores_gemma":[0.99911326,0.00010687372,0.00014799902,0.0001090602,0.00032477375,0.00019805842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021378363,0.00013875419,0.0006128887,0.0002153193,0.000021722875,0.0000030913473,0.000043693806,0.000030222374,0.000036055986],"category_scores_gemma":[0.00031565788,0.000071970695,0.00003688799,0.00012022049,0.00009080408,0.00007241795,0.000011829511,0.00015400958,0.0000015970379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052911794,0.0002302941,0.9854238,0.00002195335,0.00078401674,0.00022810577,0.00044297802,0.0000024184108,0.0000778221,0.000009196016,0.0008098155,0.011440472],"study_design_scores_gemma":[0.15431999,0.006494056,0.83529174,0.0002972063,0.00087290874,0.00002446698,0.00006614866,0.000005571175,0.00004658077,0.000030789626,0.0024872913,0.000063254374],"about_ca_topic_score_codex":0.000017126007,"about_ca_topic_score_gemma":0.000006999806,"teacher_disagreement_score":0.15379088,"about_ca_system_score_codex":0.0000218093,"about_ca_system_score_gemma":0.000042990338,"threshold_uncertainty_score":0.29348797},"labels":[],"label_agreement":null},{"id":"W1543970037","doi":"10.1196/annals.1375.022","title":"Characterization of <i>PAF‐AH Ib1</i> in NOD Mice","year":2006,"lang":"en","type":"article","venue":"Annals of the New York Academy of Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Nod; NOD mice; Spleen; Platelet-activating factor; Gene; Complementary DNA; Pancreatic islets; Biology; Endocrinology; Gene expression; Islet; Messenger RNA; Molecular biology; Internal medicine; Diabetes mellitus; Immunology; Medicine; Biochemistry","score_opus":0.050830980954230616,"score_gpt":0.3062831506783609,"score_spread":0.2554521697241303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1543970037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778862,0.0004114519,0.0000038862713,0.016620815,0.000040203253,0.00021315526,0.0000040868117,0.000005728461,0.004814486],"genre_scores_gemma":[0.99670434,0.00011664732,0.00018972711,0.00091625773,0.000047418023,0.000002057324,0.000001953809,0.0000030398398,0.0020185364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908054,0.000020670539,0.00029465702,0.00013036639,0.00032739612,0.00014638559],"domain_scores_gemma":[0.9995996,0.00003093199,0.00026439477,0.000060609276,0.000019311114,0.000025193287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003707886,0.00006978447,0.00020647241,0.00012257816,0.000026459185,0.0000045418233,0.00025387006,0.00004270788,0.000015304582],"category_scores_gemma":[0.00002119364,0.00004451654,0.00007198094,0.00057237747,0.00025472496,0.00011469756,0.000053853415,0.000049627706,0.0000022620466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007098062,0.000428011,0.09559726,0.00016705699,0.000048457878,2.604921e-7,0.00033704122,0.00007190214,0.8709763,0.0073423903,0.011764977,0.013195364],"study_design_scores_gemma":[0.00036291,0.00012288429,0.30943123,0.00024971136,0.000032274955,3.0020905e-7,0.00004388044,0.000045885787,0.68238556,0.001883935,0.005398197,0.000043240994],"about_ca_topic_score_codex":0.00017312457,"about_ca_topic_score_gemma":0.0000048439683,"teacher_disagreement_score":0.21383396,"about_ca_system_score_codex":0.0000043047085,"about_ca_system_score_gemma":0.000029430568,"threshold_uncertainty_score":0.18153317},"labels":[],"label_agreement":null},{"id":"W1545460826","doi":"10.1196/annals.1317.006","title":"The Glucagon‐Like Peptides","year":2006,"lang":"en","type":"article","venue":"Annals of the New York Academy of Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Assimilation (phonology); Ingestion; Gastrointestinal tract; Glucagon-like peptide-1; Homeostasis; Digestion (alchemy); Glucagon-like peptide-2; Pancreas; Nutrient sensing; Nutrient; Glucagon; Glucose homeostasis; Intestinal epithelium; Chemistry; Biology; Endocrinology; Internal medicine; Epithelium; Biochemistry; Peptide; Medicine; Insulin; Signal transduction; Diabetes mellitus","score_opus":0.06527131808651727,"score_gpt":0.32707147156307304,"score_spread":0.2618001534765558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1545460826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84660405,0.007490734,0.000002759043,0.109663956,0.00014600628,0.00035084801,0.0000021205544,0.000022164846,0.035717364],"genre_scores_gemma":[0.97809255,0.00035766128,0.00026325503,0.0017189345,0.0001205121,0.0000034287175,2.746944e-7,0.0000038077412,0.019439565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889195,0.000023979106,0.0002332928,0.00014478652,0.00047079648,0.00023516713],"domain_scores_gemma":[0.99952435,0.00011934757,0.0001861933,0.00010615219,0.000020820187,0.00004314457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005993067,0.000086402535,0.00015954979,0.00005001004,0.00021262259,0.000020390366,0.0004975423,0.000035920322,0.000013750768],"category_scores_gemma":[0.00003872209,0.000038964212,0.00014037799,0.00039539716,0.0007701525,0.00007742958,0.00009985787,0.00007118086,0.0000099592935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006129142,0.00019280883,0.027514279,0.000054447893,0.00015419557,3.09088e-7,0.00020875376,0.00014096254,0.007377204,0.054219525,0.8539343,0.056141924],"study_design_scores_gemma":[0.00057116395,0.00038233146,0.21091075,0.00026559923,0.00014845643,0.0000019781273,0.0004419786,0.00008073097,0.23570935,0.048973724,0.5023861,0.00012785156],"about_ca_topic_score_codex":0.00016156303,"about_ca_topic_score_gemma":0.0000075032112,"teacher_disagreement_score":0.35154822,"about_ca_system_score_codex":0.000004430269,"about_ca_system_score_gemma":0.000039939103,"threshold_uncertainty_score":0.28376588},"labels":[],"label_agreement":null},{"id":"W1556145647","doi":"10.14740/jocmr2237w","title":"Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Glimepiride; Type 2 diabetes; Sulfonylurea; Internal medicine; Diabetes mellitus; Glucagon-like peptide-1; Body mass index; Agonist; Endocrinology; Gastroenterology; Urology; Receptor","score_opus":0.2077250450160159,"score_gpt":0.5059915490533072,"score_spread":0.2982665040372913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556145647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949637,0.0005230313,8.738588e-7,0.0023296373,0.0003775745,0.0004010131,0.0000010316336,0.0000038940657,0.0013992228],"genre_scores_gemma":[0.99747986,0.0009952886,0.00034787413,0.00017823206,0.00071789767,0.0000015464243,0.000007697693,0.000016924878,0.00025468678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956626,0.00053483294,0.0019685612,0.0001968827,0.0013140752,0.00032303133],"domain_scores_gemma":[0.9935227,0.003239623,0.0005461242,0.00026904113,0.0017348145,0.0006876675],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010635363,0.0001257051,0.0012743575,0.0003970387,0.000016475355,0.000007650912,0.00015977959,0.00012509823,0.00003574788],"category_scores_gemma":[0.019064786,0.00006954236,0.00008013149,0.00046959618,0.0007698209,0.00008557574,0.00011108792,0.00095409434,0.000008402434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037712199,0.0020174177,0.91883624,0.00009641438,0.00027311587,0.00009778921,0.00013869167,1.4833526e-7,0.00000453807,0.000012274001,0.00292862,0.07182351],"study_design_scores_gemma":[0.020628843,0.028784126,0.94518906,0.0012453571,0.00023308967,0.0000025180595,0.0002006247,0.00003508889,0.0000068795357,0.000058429356,0.0035593875,0.000056589422],"about_ca_topic_score_codex":0.000013915776,"about_ca_topic_score_gemma":0.0000038695616,"teacher_disagreement_score":0.07176692,"about_ca_system_score_codex":0.000045928085,"about_ca_system_score_gemma":0.00030161205,"threshold_uncertainty_score":0.989198},"labels":[],"label_agreement":null},{"id":"W1559320341","doi":"10.1016/b978-0-12-381517-0.00002-3","title":"Pleiotropic Actions of the Incretin Hormones","year":2010,"lang":"en","type":"review","venue":"Vitamins and hormones","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Incretin; Hormone; Biology; Enteroendocrine cell; Endocrinology; Internal medicine; Gastric inhibitory polypeptide; Insulin; Receptor; Endocrine system; Glucagon-like peptide-1; Islet; Glucagon; Medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.03718037483539456,"score_gpt":0.31070071238802666,"score_spread":0.2735203375526321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559320341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003674493,0.99039,0.000001983584,0.00014748468,0.00021866495,0.00084362,0.000037642854,0.000028226628,0.004657908],"genre_scores_gemma":[0.0019604473,0.9932492,0.00010543635,0.00002581085,0.00014802879,0.00009293633,0.000050434806,0.000031689902,0.004336062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991172,0.00003059217,0.00031564312,0.00019503357,0.00016177224,0.00017975255],"domain_scores_gemma":[0.99914616,0.000081083395,0.00021160039,0.00045885536,0.00003271509,0.00006958574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006885798,0.00027296794,0.0009751977,0.00015182757,0.00010145341,0.000021563957,0.00012509518,0.00020114702,0.000027762348],"category_scores_gemma":[0.000033178712,0.0001442947,0.00034759342,0.0002067139,0.00014299428,0.0000364602,0.00015328734,0.00025353805,0.000016366852],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003433653,0.00010845187,0.00015802548,0.004526854,0.00028504842,0.000003182801,0.000041255124,4.052861e-9,0.00003511997,0.0011446051,0.0011279628,0.99256605],"study_design_scores_gemma":[0.00027086324,0.00016134087,0.0045737317,0.0021575105,0.0030877604,0.000015107957,0.000038757487,5.3135494e-7,0.00001522664,0.000024689438,0.989522,0.00013248507],"about_ca_topic_score_codex":0.00003244584,"about_ca_topic_score_gemma":0.000029941395,"teacher_disagreement_score":0.99243355,"about_ca_system_score_codex":0.000023004073,"about_ca_system_score_gemma":0.000077916186,"threshold_uncertainty_score":0.5884167},"labels":[],"label_agreement":null},{"id":"W1559664171","doi":"10.1155/2015/129891","title":"Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D","year":2015,"lang":"en","type":"article","venue":"Journal of Diabetes Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Montréal; Montreal Heart Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health; Universidade de São Paulo; GlaxoSmithKline","keywords":"Post-hoc analysis; Triglyceride; Internal medicine; Type 2 diabetes; Endocrinology; Medicine; Insulin; High-density lipoprotein; Post hoc; Diabetes mellitus; Lipoprotein; Cholesterol","score_opus":0.03151981886836043,"score_gpt":0.32061390800292705,"score_spread":0.28909408913456663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559664171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942664,0.0007199385,0.0000021995138,0.0038012338,0.00017880517,0.00086508214,0.000010848731,0.00001067894,0.00014482306],"genre_scores_gemma":[0.9989351,0.0000714591,0.00039970237,0.00020671524,0.00011009245,0.000020476595,0.00000814849,0.000029624476,0.00021864942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953997,0.0008916067,0.0009798417,0.00030830575,0.0016932742,0.00072723115],"domain_scores_gemma":[0.99660015,0.0008453475,0.00028489047,0.00059126294,0.0012796873,0.0003986638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077289282,0.00022028812,0.0010010242,0.0030976343,0.00006419424,0.000055387718,0.0003746309,0.00012972228,0.00002693154],"category_scores_gemma":[0.004046047,0.00015844067,0.0002598697,0.0051946617,0.0001314673,0.00023129974,0.00038670105,0.00080175244,0.00001352512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027431073,0.0018890181,0.7775158,0.00037873385,0.0038966618,0.00041823066,0.007370505,0.0037163578,0.14253569,0.000032156768,0.0017408024,0.03307495],"study_design_scores_gemma":[0.008115616,0.006142944,0.9400331,0.0013150222,0.0007376815,0.0000017196226,0.0022870745,0.0022445691,0.03825666,0.00010269334,0.00052375504,0.00023920342],"about_ca_topic_score_codex":0.00025778348,"about_ca_topic_score_gemma":0.0003717562,"teacher_disagreement_score":0.16251723,"about_ca_system_score_codex":0.0008990717,"about_ca_system_score_gemma":0.0006253419,"threshold_uncertainty_score":0.6461023},"labels":[],"label_agreement":null},{"id":"W1562939424","doi":"","title":"Efficacité et innocuité de la canagliflozine comparativement au glimépiride comme traitement d’appoint pour les patients atteints de diabète de type 2 non stabilisé par la metformine : étude CANTATA-SU","year":2014,"lang":"fr","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Centre de Santé et de Services Sociaux de Chicoutimi","funders":"","keywords":"Medicine; Gynecology","score_opus":0.027534840218873674,"score_gpt":0.3024116062238619,"score_spread":0.2748767660049882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1562939424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96096236,0.00050857593,0.0063403035,0.0050588273,0.00043741646,0.0018305352,0.00013884337,0.00012801374,0.02459511],"genre_scores_gemma":[0.9776825,0.00040694303,0.0053590406,0.004088644,0.00038595506,0.00026829765,0.0005299825,0.00011746077,0.011161199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945754,0.0012003385,0.0010044685,0.00072853063,0.000690489,0.0018008166],"domain_scores_gemma":[0.9967538,0.001023986,0.00035382042,0.0007306209,0.00026171323,0.00087606325],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003180465,0.0008538512,0.0011197941,0.00028594167,0.00023600856,0.00015008899,0.00041689366,0.0002605236,0.0009800381],"category_scores_gemma":[0.00030225408,0.0007420482,0.00023851791,0.00040738285,0.00036663454,0.00022215355,0.00036362096,0.00052225013,0.00019850816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076619233,0.010186786,0.66226244,0.001474195,0.0031938527,0.00021201356,0.009370876,0.002185053,0.0036721332,0.019124195,0.04734155,0.24021074],"study_design_scores_gemma":[0.016415356,0.0034015256,0.51204604,0.0010973051,0.002490662,0.000012013797,0.001992445,0.010713166,0.0153618045,0.000540312,0.43483588,0.0010934931],"about_ca_topic_score_codex":0.018730843,"about_ca_topic_score_gemma":0.014767419,"teacher_disagreement_score":0.38749436,"about_ca_system_score_codex":0.0027284552,"about_ca_system_score_gemma":0.00079038215,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W1579878066","doi":"10.1161/circ.130.suppl_2.16709","title":"Abstract 16709: Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension","year":2014,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Renal function; Blood pressure; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Kidney disease; Urology; Cardiology","score_opus":0.008317638440084669,"score_gpt":0.19326948733491575,"score_spread":0.18495184889483107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1579878066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99920696,0.00014482098,0.000008147138,0.00003573261,0.000026130718,0.00029325657,9.2861296e-7,0.000015250625,0.00026879605],"genre_scores_gemma":[0.9997997,0.0000048339234,0.00008311552,0.000030148194,0.000022136912,0.000006653634,0.000037706122,0.0000071111212,0.000008594688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995222,0.000013176217,0.00010847634,0.00015053742,0.00012490155,0.000080686965],"domain_scores_gemma":[0.9997004,0.000034320296,0.000077040524,0.000078924226,0.000078714365,0.000030559513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007097189,0.00007589033,0.00013368363,0.00009225857,0.00003580705,0.000010130757,0.000008547668,0.000030939034,0.000004591665],"category_scores_gemma":[0.000036384754,0.00005279169,0.000006683822,0.0000982857,0.000039480106,0.00010497112,0.000005020968,0.000043779266,4.4936505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000199734,0.00017050043,0.98573464,0.00008592738,0.00022326557,4.0847254e-7,0.000061396124,0.00063175004,0.0032872094,0.000046886253,0.000006493231,0.009551781],"study_design_scores_gemma":[0.0024358202,0.00090169505,0.9943642,0.00033080493,0.00091668376,3.6279022e-7,0.000024860234,0.0006002256,0.000307808,0.000036120575,0.000024402822,0.000057012185],"about_ca_topic_score_codex":0.000009050192,"about_ca_topic_score_gemma":0.00000497415,"teacher_disagreement_score":0.009494769,"about_ca_system_score_codex":0.000005071861,"about_ca_system_score_gemma":0.000007042303,"threshold_uncertainty_score":0.21527825},"labels":[],"label_agreement":null},{"id":"W1585960718","doi":"10.1002/pds.3704","title":"A cross‐national comparison of 17 countries' insulin glargine drug labels","year":2014,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin glargine; Medical prescription; Type 2 Diabetes Mellitus; Hypoglycemia; Drug; Diabetes mellitus; China; Insulin; Family medicine; Traditional medicine; Pediatrics; Internal medicine; Pharmacology; Endocrinology","score_opus":0.026757117631774123,"score_gpt":0.3731652230177486,"score_spread":0.3464081053859745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585960718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9315016,0.0074540824,0.001672482,0.027941823,0.00056101027,0.00083850673,0.00011040356,0.00015371174,0.029766347],"genre_scores_gemma":[0.98850703,0.0005686168,0.0013285939,0.006319496,0.00019294121,0.000026823991,0.00017277259,0.000012478163,0.0028712377],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832267,0.00031744508,0.000595217,0.00030230748,0.00017427444,0.0002881023],"domain_scores_gemma":[0.9978915,0.0014600977,0.00021222416,0.00014966515,0.000147069,0.00013946969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025479028,0.00018685819,0.00071488944,0.00009866117,0.00011690377,0.000005264333,0.00008539795,0.00006706928,0.00038738988],"category_scores_gemma":[0.0004882186,0.00015132652,0.00008984362,0.000098842895,0.0002761332,0.00008685497,0.00008581254,0.00018472291,0.00004724249],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096176803,0.00046228376,0.8560576,0.00024337659,0.00039488598,0.0000022361087,0.0003698512,0.00024612813,0.0002621507,0.016875487,0.116617724,0.0075065247],"study_design_scores_gemma":[0.0077118822,0.00013887972,0.2823061,0.00006631384,0.00034062855,0.000005245036,0.000037603015,0.009644048,0.0021183048,0.0014265015,0.69600326,0.00020121716],"about_ca_topic_score_codex":0.000044931377,"about_ca_topic_score_gemma":0.000008443388,"teacher_disagreement_score":0.5793855,"about_ca_system_score_codex":0.000043101998,"about_ca_system_score_gemma":0.000038874077,"threshold_uncertainty_score":0.61709166},"labels":[],"label_agreement":null},{"id":"W1588301406","doi":"10.1111/j.1476-5381.2011.01714.x","title":"Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts","year":2011,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Danmarks Grundforskningsfond; National Research Foundation; Heart and Stroke Foundation of Canada","keywords":"Glucagon; Internal medicine; Endocrinology; Agonist; Insulin; Glycolysis; Chemistry; Carbohydrate metabolism; Cardiac function curve; Metabolism; Biology; Medicine; Receptor; Heart failure","score_opus":0.010318857963071705,"score_gpt":0.2393260907272551,"score_spread":0.22900723276418342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1588301406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97753245,0.02080629,0.0000047126814,0.00014075908,0.0003694613,0.00053320086,0.0000078100475,0.000017106639,0.0005882228],"genre_scores_gemma":[0.987319,0.011462852,0.00036001718,0.00045033995,0.00021768647,0.000044849046,0.0000063920916,0.000026365144,0.00011253414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859136,0.00017503597,0.00041327009,0.00021210035,0.00023193746,0.0003762873],"domain_scores_gemma":[0.99929667,0.00008159446,0.00020871556,0.00007190384,0.00010393837,0.00023718586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029377194,0.00020983008,0.00076933816,0.00023752113,0.00007684445,0.000030980984,0.00007499461,0.000060754952,0.00009091812],"category_scores_gemma":[0.000025346875,0.00017887163,0.00010318022,0.00015580676,0.00015145497,0.00018027861,0.0000685474,0.00029542315,0.0000035523676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015191747,0.011026241,0.49858707,0.0023141417,0.0067155994,0.034131072,0.0017034573,0.000009879176,0.09429966,0.0003187762,0.008188874,0.3275135],"study_design_scores_gemma":[0.010837389,0.003368376,0.93693495,0.0006372203,0.0017734466,0.0014437463,0.00008462814,0.000022324059,0.040148806,0.00002495515,0.0045174146,0.00020676148],"about_ca_topic_score_codex":0.00027000162,"about_ca_topic_score_gemma":0.00007243017,"teacher_disagreement_score":0.43834785,"about_ca_system_score_codex":0.000073148156,"about_ca_system_score_gemma":0.00008417102,"threshold_uncertainty_score":0.7294173},"labels":[],"label_agreement":null},{"id":"W1601919277","doi":"10.18433/j3fg7g","title":"The Lidose Hard Capsule Formulation of Fenofibrate is Suprabioavailable Compared to the Nanoparticle Tablet Formulation Under High-fat Fed Conditions","year":2015,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Fenofibrate; Bioequivalence; Bioavailability; Capsule; Crossover study; Cmax; Meal; Pharmacokinetics; Pharmacology; Absorption (acoustics); Dosage form; Chromatography; Chemistry; Medicine; Materials science; Food science","score_opus":0.13555660681755585,"score_gpt":0.4018649526032142,"score_spread":0.2663083457856583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1601919277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617178,0.0005948755,0.0002193458,0.035405178,0.0004991797,0.00056779856,0.00001260613,0.000015274682,0.0009679599],"genre_scores_gemma":[0.99612904,0.00009771049,0.0006209988,0.0021714554,0.00018622863,0.000011839288,0.0000048154106,0.000008199126,0.00076969387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979547,0.000105254214,0.00055579055,0.00015532046,0.0008536432,0.00037525888],"domain_scores_gemma":[0.9986429,0.00016925145,0.00028536416,0.0001448474,0.0003892888,0.00036833124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014869573,0.00013738195,0.00024935792,0.00010787962,0.00041895921,0.00014606408,0.0002951278,0.00001881273,0.00034069762],"category_scores_gemma":[0.00009407637,0.00007090603,0.00010923606,0.0006496329,0.00019831106,0.0006410686,0.00008556979,0.00013418368,0.00008115932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026888852,0.001665219,0.03130792,0.00010695737,0.00094435416,0.000028542298,0.0025274332,0.010743643,0.6785154,0.016312616,0.23357412,0.021584941],"study_design_scores_gemma":[0.008214593,0.0010605046,0.00800771,0.000084731,0.00087826466,0.000027638875,0.0010962712,0.05254176,0.6765518,0.0025281021,0.24880995,0.00019866643],"about_ca_topic_score_codex":0.000052228246,"about_ca_topic_score_gemma":0.000009583046,"teacher_disagreement_score":0.041798115,"about_ca_system_score_codex":0.00012982727,"about_ca_system_score_gemma":0.00017322789,"threshold_uncertainty_score":0.37304},"labels":[],"label_agreement":null},{"id":"W1602119989","doi":"10.1186/1472-6823-3-3","title":"Glucagon-like peptide 1 improved glycemic control in type 1 diabetes","year":2003,"lang":"en","type":"article","venue":"BMC Endocrine Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"London Health Sciences Centre; Amylin Pharmaceuticals; Health Research; American Diabetes Association","keywords":"Medicine; Gastric emptying; Glycemic; Type 2 diabetes; Internal medicine; Insulin; Diabetes mellitus; Glucagon; Endocrinology; Bedtime; Glucagon-like peptide-1; Area under the curve; Type 1 diabetes; Stomach","score_opus":0.008537646469876219,"score_gpt":0.24372337536688504,"score_spread":0.2351857288970088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1602119989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706189,0.0020932776,0.00010784015,0.0004404902,0.00045631538,0.0012119866,0.000004354189,0.00013283263,0.024934027],"genre_scores_gemma":[0.9936283,0.0002868789,0.0007325257,0.0008865113,0.000027744241,0.00015197873,0.00005267898,0.000041768908,0.0041916166],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985891,0.000048028236,0.0002707549,0.00035070517,0.00015388244,0.00058754906],"domain_scores_gemma":[0.9993449,0.000085508036,0.00005953096,0.000360472,0.00003611517,0.0001135002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008892858,0.00024757025,0.0003695109,0.00018986536,0.00003662953,0.000019095034,0.00008861556,0.000034233035,0.00027262483],"category_scores_gemma":[0.0001659739,0.00021941664,0.00012490193,0.00031946212,0.000052152296,0.00008885655,0.000026936745,0.00012234628,0.00013591305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007799794,0.0012008855,0.9786512,0.00030105762,0.00034885862,0.000028934319,0.000106544256,0.00007877237,0.0032315499,0.0019352486,0.0047035976,0.008633326],"study_design_scores_gemma":[0.101075836,0.0052122623,0.23727089,0.00037542215,0.0014329214,0.000012606313,0.0018686492,0.005625805,0.0036973376,0.003170873,0.6384084,0.0018490003],"about_ca_topic_score_codex":0.00007083189,"about_ca_topic_score_gemma":0.00038044708,"teacher_disagreement_score":0.74138033,"about_ca_system_score_codex":0.000081303304,"about_ca_system_score_gemma":0.000070024624,"threshold_uncertainty_score":0.8947551},"labels":[],"label_agreement":null},{"id":"W1603245870","doi":"10.1111/j.1756-5391.2011.01158.x","title":"Effects and patient compliance of sustained‐release versus immediate‐release glipizides in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis","year":2011,"lang":"en","type":"review","venue":"Journal of Evidence-Based Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Natural Science Foundation of China; Pfizer","keywords":"Glipizide; Medicine; Postprandial; Internal medicine; Hypoglycemia; Odds ratio; Insulin; Diabetes mellitus; Type 2 diabetes; Meta-analysis; Cochrane Library; Randomized controlled trial; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.08992171394064337,"score_gpt":0.32841836815324693,"score_spread":0.23849665421260358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1603245870","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000950497,0.9944469,0.0000079912,0.00033128457,0.00009844838,0.00413415,0.000009991644,0.000008370157,0.0000123841555],"genre_scores_gemma":[0.0048941425,0.99403864,0.00029471132,0.00049653987,0.000038128597,0.00013630223,0.000033501292,0.00004437529,0.000023685638],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955909,0.0005481972,0.0021946526,0.00042150944,0.00086142163,0.00038329005],"domain_scores_gemma":[0.9926136,0.0023790926,0.0031182035,0.0005236668,0.00090590975,0.0004595081],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001286995,0.0007095203,0.010535303,0.0012435116,0.00003165996,0.000013337312,0.00021058045,0.00013278148,0.00007386451],"category_scores_gemma":[0.0024609985,0.0003328584,0.0007552041,0.0014680788,0.00028598352,0.00021932379,0.00006523581,0.0003876368,0.000002447438],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060995156,0.0004715877,0.0005470939,0.91018826,0.0715746,0.00013511884,0.000060440583,0.0000010564696,1.1381498e-7,0.0000088669085,0.00013269448,0.016270224],"study_design_scores_gemma":[0.0029216532,0.0063087116,0.00021841093,0.40480345,0.58451444,0.0000024404835,0.000032305878,0.000004109467,0.0000017372363,0.0000026727498,0.0010007331,0.00018933529],"about_ca_topic_score_codex":0.00002424417,"about_ca_topic_score_gemma":0.0000045274587,"teacher_disagreement_score":0.5129398,"about_ca_system_score_codex":0.00020182681,"about_ca_system_score_gemma":0.0003037367,"threshold_uncertainty_score":0.9999123},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W1604448406","doi":"10.1007/0-306-46826-3_21","title":"Analogs of Glucose-Dependent Insulinotropic Polypeptide With Increased Dipeptidyl Peptidase IV Resistance","year":2006,"lang":"en","type":"article","venue":"Kluwer Academic Publishers eBooks","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Dipeptidyl peptidase; Binding affinities; Dipeptidyl peptidase-4; Amino acid; Chemistry; Receptor; Amino terminal; Biochemistry; Affinities; Stereochemistry; Biology; Endocrinology; Peptide sequence; Type 2 diabetes; Diabetes mellitus; Enzyme; Gene","score_opus":0.00784794895390198,"score_gpt":0.219108869711508,"score_spread":0.21126092075760602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1604448406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77093065,0.000715602,0.00013800726,0.0006885642,0.000100072655,0.0008875939,0.00002227748,0.00022964345,0.2262876],"genre_scores_gemma":[0.9464909,0.000012291374,0.001560673,0.0007766979,0.00024100147,0.00011366282,0.00013639961,0.000073881594,0.050594516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996991,0.000074682175,0.00071641617,0.00065791083,0.0008668898,0.00069315004],"domain_scores_gemma":[0.9983187,0.000081134254,0.00037631945,0.00073216634,0.00019963377,0.00029208776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036247188,0.00043014518,0.00067350414,0.000427867,0.00009311114,0.000093221635,0.00038075945,0.00027624745,0.00012825515],"category_scores_gemma":[0.00007249871,0.00033813372,0.00017376238,0.00028141806,0.00029501712,0.0005010943,0.00013056942,0.0006395133,0.000029205701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00441929,0.0017044059,0.58553755,0.0014633221,0.0025712608,0.00089384714,0.0010069432,0.000040168634,0.0703271,0.019324763,0.2955471,0.017164214],"study_design_scores_gemma":[0.03748689,0.0021694454,0.57771987,0.0023237197,0.003393068,0.000070124275,0.00107507,0.00012632509,0.096441306,0.00659242,0.2703246,0.0022771684],"about_ca_topic_score_codex":0.0006166404,"about_ca_topic_score_gemma":0.00022543302,"teacher_disagreement_score":0.1756931,"about_ca_system_score_codex":0.00027537197,"about_ca_system_score_gemma":0.00021350692,"threshold_uncertainty_score":0.9999071},"labels":[],"label_agreement":null},{"id":"W1606810773","doi":"10.1111/dom.12498","title":"One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Johnson and Johnson; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Merck; Takeda Pharmaceutical Company; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Medicine; Insulin degludec; Liraglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Basal insulin","score_opus":0.01926542420580191,"score_gpt":0.23143813045442665,"score_spread":0.21217270624862475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606810773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970183,0.0009995585,0.000003341732,0.0001004825,0.00008345448,0.0016174299,0.000052272146,0.000022305616,0.00010288329],"genre_scores_gemma":[0.99836314,0.00022998653,0.0011676805,0.00007228907,0.000018966433,0.000017247712,0.00006778154,0.00002374132,0.00003919835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983922,0.00012520877,0.0005328644,0.0003383411,0.00034682913,0.0002645614],"domain_scores_gemma":[0.99885154,0.0001529647,0.00025031672,0.00025855968,0.0002792786,0.000207351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071480905,0.0002011,0.0008596076,0.000337893,0.000030588133,0.00001124912,0.00006026572,0.000093823124,0.0000021583635],"category_scores_gemma":[0.0005544782,0.00016761624,0.000036257483,0.0004064564,0.00013614762,0.00013028576,0.0001289059,0.00009212589,0.0000014876829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09169029,0.015161521,0.82250226,0.0012791195,0.00093865464,0.000004841476,0.0053031472,0.000025779867,0.004561906,0.0010195305,0.00030692338,0.057206042],"study_design_scores_gemma":[0.10019892,0.004680919,0.8894945,0.00046291723,0.0004442572,3.890339e-8,0.00008852967,0.000045113553,0.0039922004,0.00019126531,0.00025662914,0.00014474831],"about_ca_topic_score_codex":0.000077405595,"about_ca_topic_score_gemma":0.000022518938,"teacher_disagreement_score":0.06699222,"about_ca_system_score_codex":0.000024068055,"about_ca_system_score_gemma":0.0000505202,"threshold_uncertainty_score":0.6835192},"labels":[],"label_agreement":null},{"id":"W161487184","doi":"","title":"Abstract 1489: Mechanisms Underlying Cardioprotective Effects Of Glucagon-like Peptide-1 In Ischemia-reperfusion Injury","year":2007,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto","funders":"","keywords":"Medicine; Glucagon-like peptide-1; Agonist; Ischemia; Glucagon-like peptide 1 receptor; Receptor; Incretin; Type 2 diabetes; Pharmacology; Internal medicine; Reperfusion injury; Endocrinology; Diabetes mellitus","score_opus":0.014997159181990393,"score_gpt":0.2742174587397708,"score_spread":0.2592202995577804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W161487184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678833,0.00012925746,0.0075579677,0.000032823296,0.00018344303,0.00095380197,5.433834e-7,0.000044422362,0.004309407],"genre_scores_gemma":[0.9990333,0.000010746317,0.00073445373,0.00006569962,0.00002612181,0.0000258308,0.000026641364,0.000017369346,0.000059883565],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99906915,0.000011988837,0.0002558781,0.00021802471,0.00025076332,0.0001942164],"domain_scores_gemma":[0.99951273,0.000055846926,0.000107832,0.00020131662,0.00006925339,0.00005302267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036356496,0.00012298874,0.00023278152,0.00022420718,0.00003322773,0.0000068151544,0.000033902215,0.000097114644,0.000016228856],"category_scores_gemma":[0.000066723114,0.00011804795,0.00008997536,0.00022567275,0.000017664612,0.00010856268,0.000025233297,0.00010010974,0.000014397851],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104154395,0.00017751448,0.015619869,0.00041094562,0.00009740974,0.00003710944,0.00037987498,0.0000936974,0.91840714,0.00054961676,0.000023527511,0.064099126],"study_design_scores_gemma":[0.0013015829,0.000120602985,0.6225068,0.0003471821,0.00010904859,0.000001359165,0.00016105297,0.00016445095,0.37417403,0.0009647927,0.000046166977,0.00010290309],"about_ca_topic_score_codex":0.00008788854,"about_ca_topic_score_gemma":0.000010722719,"teacher_disagreement_score":0.606887,"about_ca_system_score_codex":0.00023243137,"about_ca_system_score_gemma":0.000023209153,"threshold_uncertainty_score":0.48138556},"labels":[],"label_agreement":null},{"id":"W1615542701","doi":"10.1111/j.1464-5491.2012.03624.x","title":"A randomized non‐inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin","year":2012,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Novo Nordisk; World Health Organization; Eli Lilly and Company","keywords":"Exenatide; Sitagliptin; Medicine; Metformin; Type 2 diabetes; Internal medicine; Placebo; Postprandial; Nausea; Endocrinology; Gastroenterology; Diabetes mellitus; Insulin","score_opus":0.01709637035927511,"score_gpt":0.26333354222337313,"score_spread":0.24623717186409802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1615542701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914847,0.00027854383,0.00022318949,0.0005805341,0.00031258332,0.006474009,0.00001855384,0.00006591705,0.0005619618],"genre_scores_gemma":[0.99635094,0.00001311699,0.00084886834,0.001585442,0.00022847227,0.00072063814,0.000107834945,0.00006921424,0.00007546299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957249,0.00044469346,0.0011846237,0.00067600363,0.0010729663,0.0008968099],"domain_scores_gemma":[0.9957477,0.0022694487,0.0004584254,0.00073517684,0.0002659854,0.000523306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025614032,0.0006237069,0.002234775,0.0005900523,0.00015368227,0.000041356885,0.0002868695,0.00009114649,0.00014872519],"category_scores_gemma":[0.0023602245,0.00036054684,0.00008523417,0.00088009814,0.00015117244,0.00031032405,0.00019833574,0.00037779054,0.000028106751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07287597,0.0023663684,0.8531429,0.0002715615,0.0012210987,0.000031222295,0.05175217,0.00009753384,0.005659224,0.00006761529,0.00043681686,0.012077474],"study_design_scores_gemma":[0.2718446,0.0100589,0.69305533,0.0029244637,0.0023747715,7.9628217e-7,0.015227238,0.0014635898,0.0021050419,0.000033737564,0.00021838013,0.0006931808],"about_ca_topic_score_codex":0.00086087413,"about_ca_topic_score_gemma":0.00028290655,"teacher_disagreement_score":0.19896862,"about_ca_system_score_codex":0.00026720032,"about_ca_system_score_gemma":0.00005430755,"threshold_uncertainty_score":0.99988467},"labels":[],"label_agreement":null},{"id":"W1634349104","doi":"10.1113/jphysiol.2012.234914","title":"Regulation of glucose kinetics during exercise by the glucagon‐like peptide‐1 receptor","year":2012,"lang":"en","type":"article","venue":"The Journal of Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Vanderbilt University","keywords":"Internal medicine; Endocrinology; Glucagon; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Receptor; Glucose uptake; Biology; Chemistry; Diabetes mellitus; Medicine","score_opus":0.010777315100634594,"score_gpt":0.23979131134625026,"score_spread":0.22901399624561566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1634349104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961081,0.0023183567,0.0000123431155,0.00075513223,0.0002991176,0.00016667174,0.0000015443235,0.000004775977,0.00033396643],"genre_scores_gemma":[0.99730945,0.0007896166,0.0001354174,0.00011335849,0.0003000394,0.0000022788256,0.0000056881445,0.000010439356,0.0013337203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992769,0.00008526207,0.00027288648,0.000042154355,0.00014745325,0.00017537341],"domain_scores_gemma":[0.9992365,0.000080308404,0.00033632212,0.00021426665,0.000080794154,0.00005181194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029994507,0.00008723484,0.00023956777,0.000042669366,0.00004283365,0.0000022502566,0.00012575283,0.000034138393,0.0001819195],"category_scores_gemma":[0.000022483748,0.00004157984,0.00009126383,0.00007892529,0.00009648936,0.00006974939,0.00004948018,0.00010935949,0.000018878147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004501387,0.00026592537,0.00039976469,0.000042233285,0.00015613182,1.8941648e-7,0.00054247555,0.000025851352,0.9843521,0.000049314305,0.011561504,0.0021543347],"study_design_scores_gemma":[0.001962912,0.00077904627,0.31926236,0.00015465806,0.00092389376,0.000023148461,0.00057161157,0.000020204669,0.6630686,0.00031337872,0.012836047,0.0000841289],"about_ca_topic_score_codex":0.0000051407796,"about_ca_topic_score_gemma":3.772841e-7,"teacher_disagreement_score":0.32128352,"about_ca_system_score_codex":0.000036478777,"about_ca_system_score_gemma":0.0000092170085,"threshold_uncertainty_score":0.19918911},"labels":[],"label_agreement":null},{"id":"W1686271004","doi":"10.1155/2013/460958","title":"A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Calgary","funders":"Alberta Children's Hospital Foundation; Crohn's and Colitis Foundation of Canada; Hospital Research Foundation","keywords":"Glucagon-like peptide-2; Signalling; Glucagon; Medicine; Function (biology); Crohn's disease; Disease; Internal medicine; Peptide; Biology; Biochemistry; Cell biology; Insulin","score_opus":0.030420272097219182,"score_gpt":0.22869063872970735,"score_spread":0.19827036663248818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1686271004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985478,0.000053800704,0.00008445707,0.00045338197,0.00024112315,0.0005458549,9.861695e-7,0.000004087673,0.0000685328],"genre_scores_gemma":[0.9994632,0.0000049117093,0.000036483125,0.00025691223,0.00010357552,0.000027730022,0.000003394957,0.000012726866,0.0000910373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897814,0.00015662462,0.0002894627,0.00014233579,0.00012521759,0.00030819213],"domain_scores_gemma":[0.9989999,0.00012288148,0.00020326902,0.00010520592,0.00010906351,0.00045966948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028778726,0.00012361689,0.00020562303,0.0004643271,0.0000883133,0.000044358003,0.00008188718,0.00001483056,0.000040725783],"category_scores_gemma":[0.00019825542,0.00009223443,0.00003141761,0.00012268736,0.00007502001,0.00021792778,0.00002586155,0.00024442485,0.0000045148945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005416625,0.0002813639,0.9978348,0.000016962184,0.000058028047,0.00016656185,0.00017034201,0.000033899752,0.000002648747,0.000003713788,0.00037530606,0.0005146914],"study_design_scores_gemma":[0.0025561007,0.010479508,0.9862097,0.000056818324,0.00032014513,0.000009061922,0.00021068133,0.00006329489,1.2160385e-7,0.000044992586,0.000009198268,0.00004038932],"about_ca_topic_score_codex":0.0015252501,"about_ca_topic_score_gemma":0.022911463,"teacher_disagreement_score":0.021386212,"about_ca_system_score_codex":0.00013303939,"about_ca_system_score_gemma":0.0001292575,"threshold_uncertainty_score":0.99491787},"labels":[],"label_agreement":null},{"id":"W1695464101","doi":"10.2337/dc15-0074","title":"Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149","year":2015,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Position statement; Diabetes mellitus; Association (psychology); Type 2 diabetes; Family medicine; Statement (logic); MEDLINE; Harm; Diabetes management; Endocrinology; Social psychology","score_opus":0.01165681921047243,"score_gpt":0.25013324805956577,"score_spread":0.23847642884909334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1695464101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8637023,0.002526898,7.8984414e-7,0.12019368,0.0006310157,0.010618468,0.0016410796,0.000051732623,0.0006340144],"genre_scores_gemma":[0.88086843,0.00031050437,0.00014109412,0.11353044,0.00015634214,0.0017840577,0.002936937,0.00017797336,0.00009421354],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922784,0.0018496083,0.0015507148,0.0009629417,0.0022063998,0.0011519201],"domain_scores_gemma":[0.993355,0.0010040198,0.0027631307,0.0014481903,0.0012961486,0.00013353869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026870493,0.0008988381,0.0019352505,0.0004567352,0.00019167608,0.00010711154,0.0007735263,0.0002106542,0.0000054517045],"category_scores_gemma":[0.00033258396,0.00056475337,0.00047379453,0.00092496467,0.0002055296,0.00014024378,0.000815699,0.000819468,0.00001238505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015764532,0.0008931817,0.48346502,0.0016561197,0.003926255,0.0000014694007,0.0045029735,0.00014997798,0.00006530979,0.000012707478,0.4988659,0.0063034217],"study_design_scores_gemma":[0.033053022,0.0146614555,0.38975772,0.0053455974,0.012702927,5.5996427e-8,0.029864483,0.00070246233,0.002906634,0.00014238889,0.50887597,0.001987292],"about_ca_topic_score_codex":0.000049463597,"about_ca_topic_score_gemma":0.000044034594,"teacher_disagreement_score":0.09370729,"about_ca_system_score_codex":0.0020851146,"about_ca_system_score_gemma":0.0000912354,"threshold_uncertainty_score":0.9996804},"labels":[],"label_agreement":null},{"id":"W1702520603","doi":"10.2147/dmso.s79450","title":"Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol&amp;reg; on glycemic control of subjects with impaired fasting glucose","year":2015,"lang":"en","type":"article","venue":"Diabetes Metabolic Syndrome and Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; KGK Synergize (Canada)","funders":"","keywords":"Placebo; Glycemic; Medicine; Internal medicine; Diabetes mellitus; Cmax; Body mass index; Endocrinology; Blood pressure; Hemoglobin; Gastroenterology; Pharmacokinetics","score_opus":0.03570732585402635,"score_gpt":0.296039300369992,"score_spread":0.2603319745159656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1702520603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873981,0.0018691414,0.000014634017,0.00013893741,0.0001992396,0.009598372,0.000013358319,0.00006700316,0.0007012163],"genre_scores_gemma":[0.99871534,0.000060492323,0.000032173728,0.00015346137,0.00007087631,0.00074567134,0.000019112453,0.000043546894,0.00015931093],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958692,0.0012513022,0.0009906872,0.00057362346,0.0007672067,0.00054793386],"domain_scores_gemma":[0.9943251,0.0037527608,0.0006458453,0.0007957327,0.00016478392,0.0003157729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0058098244,0.00054287555,0.003938909,0.00028277186,0.000101851445,0.00003525601,0.00022827514,0.00013583501,0.000016879236],"category_scores_gemma":[0.0010442571,0.00027351305,0.0004862039,0.00039168334,0.0003965284,0.00008752636,0.00009683281,0.00032380104,0.000027236374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52210164,0.0016709468,0.4697857,0.00011904159,0.0041526114,0.000018374978,0.00022453409,0.00002692594,0.000041273524,0.000119452554,0.000028780736,0.0017107321],"study_design_scores_gemma":[0.8954976,0.014876519,0.078680724,0.0003248773,0.0069205374,0.0000041675758,0.0001536027,0.00026139242,0.002955412,0.000030727857,0.00003993216,0.00025446888],"about_ca_topic_score_codex":0.00005526095,"about_ca_topic_score_gemma":0.000007903992,"teacher_disagreement_score":0.39110497,"about_ca_system_score_codex":0.000030031926,"about_ca_system_score_gemma":0.000071830706,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W1722754131","doi":"","title":"Quels chiffres tensionnels viser chez le diabétique","year":2013,"lang":"fr","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gynecology; Medicine","score_opus":0.00999823506264909,"score_gpt":0.2287976366199979,"score_spread":0.2187994015573488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1722754131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4761822,0.019193107,0.00064070063,0.07592762,0.003141734,0.0025755842,0.000008261171,0.00031154286,0.42201924],"genre_scores_gemma":[0.61228555,0.000999562,0.0012239554,0.004117776,0.00059518643,0.00014280995,0.00002854222,0.0000384789,0.38056812],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981957,0.00008112483,0.00032914206,0.00040533105,0.00024098641,0.0007476962],"domain_scores_gemma":[0.9988524,0.0000947389,0.00006706228,0.0004921204,0.00012188802,0.0003718203],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020661055,0.00032631916,0.0004359977,0.000119696815,0.000106742395,0.00009998264,0.00013533216,0.00016668461,0.022253785],"category_scores_gemma":[0.00006328607,0.0002527028,0.00018340889,0.00017909425,0.000169149,0.0004029133,0.00015877752,0.00014824531,0.013194343],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018415385,0.0021996256,0.01896025,0.000502847,0.001004915,0.00011749178,0.0006052246,0.000024115981,0.012534526,0.1079566,0.691437,0.164639],"study_design_scores_gemma":[0.008112269,0.0013987576,0.2428539,0.0015189715,0.0014125413,0.000015126169,0.0024712335,0.0033619523,0.090671204,0.015124185,0.63182265,0.0012371979],"about_ca_topic_score_codex":0.002754314,"about_ca_topic_score_gemma":0.000065062515,"teacher_disagreement_score":0.22389364,"about_ca_system_score_codex":0.00010322198,"about_ca_system_score_gemma":0.00008721354,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W1744729460","doi":"10.1002/0470862092.d0209","title":"Islet Amyloid Polypeptide/GLP‐1/Exendin","year":2003,"lang":"en","type":"other","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Islet; Enteroendocrine cell; Glucagon-like peptide-1; Endocrinology; Gastric emptying; Secretion; Internal medicine; Motility; Peptide YY; Appetite; Amylin; Glucagon-like peptide-2; Amyloid (mycology); Biology; Chemistry; Insulin; Peptide; Diabetes mellitus; Cell biology; Receptor; Type 2 diabetes; Hormone; Neuropeptide; Biochemistry; Medicine; Endocrine system; Stomach; Neuropeptide Y receptor","score_opus":0.010564831598241778,"score_gpt":0.24680730991735625,"score_spread":0.23624247831911446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1744729460","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021513204,0.0012833497,0.000046548197,0.00040669317,0.00040480724,0.00068891636,0.0000117094805,0.00040597827,0.9967305],"genre_scores_gemma":[0.00016040025,0.00041370993,0.0023984541,0.0023707163,0.0003265112,0.000043950586,0.0001870821,0.00043462188,0.99366456],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989607,0.000014168457,0.0001480429,0.00033584845,0.00022819008,0.0003130628],"domain_scores_gemma":[0.9992918,0.000008257197,0.00007408723,0.0004886565,0.000009521694,0.0001276902],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004750841,0.00030770892,0.00044831718,0.00030413852,0.000015673097,0.000017597355,0.000076536744,0.00014177029,0.07539297],"category_scores_gemma":[0.000008009475,0.00023085703,0.00014987211,0.00011655599,0.000037141857,0.000014234095,0.000036247588,0.000104052226,0.0059618526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000061654387,0.00017921449,0.00045688509,0.00011787682,0.00052604853,0.000061008705,0.000006007959,1.759906e-8,0.000024852972,0.004326949,0.98992825,0.0043667],"study_design_scores_gemma":[0.0011764385,0.00013097227,0.000070277376,0.00018501247,0.00044740073,0.000003535437,0.000022104809,7.850559e-7,0.00019025157,0.000049413076,0.99750656,0.00021722626],"about_ca_topic_score_codex":0.00017010275,"about_ca_topic_score_gemma":0.00005617097,"teacher_disagreement_score":0.06943111,"about_ca_system_score_codex":0.000062806255,"about_ca_system_score_gemma":0.000028706447,"threshold_uncertainty_score":0.99481213},"labels":[],"label_agreement":null},{"id":"W1746906608","doi":"10.1016/j.diabres.2015.09.009","title":"Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study","year":2015,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministry of Knowledge Economy","keywords":"Medicine; Glycemic; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Clinical efficacy; Internal medicine; Safety profile; Adverse effect; Endocrinology","score_opus":0.1306649977416238,"score_gpt":0.467910833139303,"score_spread":0.33724583539767916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1746906608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993849,0.0021134904,8.395013e-7,0.0005109839,0.00006262484,0.0023858256,0.0000062958147,0.00001781642,0.0010531241],"genre_scores_gemma":[0.99738145,0.0010327502,0.0008471448,0.00036789794,0.000049641407,0.000029207475,0.00005223669,0.000033986773,0.00020569215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964903,0.00089657377,0.0006170471,0.0006490351,0.00082884333,0.00051818066],"domain_scores_gemma":[0.9951703,0.0026868952,0.00016936284,0.00060650194,0.00083064823,0.0005362992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005236916,0.0002009778,0.0006721993,0.0001861987,0.00008274102,0.000113386865,0.00020509714,0.00010656834,0.000023393522],"category_scores_gemma":[0.0041662687,0.00014112743,0.000017876953,0.00052156975,0.00033321913,0.0008025355,0.00038253472,0.00048344742,0.000011889822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011445767,0.027968423,0.87230855,0.000042641615,0.0004988122,0.000017435665,0.00022224596,6.120717e-7,0.000022165652,0.000067028785,0.00035636802,0.08704995],"study_design_scores_gemma":[0.04016216,0.05852315,0.89639264,0.00012455136,0.00020443501,8.776727e-8,0.00063300674,0.00017556688,0.000021031956,0.00015433719,0.003454182,0.0001548438],"about_ca_topic_score_codex":0.00013102383,"about_ca_topic_score_gemma":0.000032330936,"teacher_disagreement_score":0.08689511,"about_ca_system_score_codex":0.00006427018,"about_ca_system_score_gemma":0.00011231046,"threshold_uncertainty_score":0.57550097},"labels":[],"label_agreement":null},{"id":"W175155385","doi":"10.1007/0-387-32824-6_13","title":"Relative Contribution of Incretins to the Glucose Lowering Effect of DP IV Inhibitors in Type 2 Diabetes Mellitus (T2DM)","year":2006,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Incretin; Type 2 Diabetes Mellitus; Medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes; Internal medicine; Hormone","score_opus":0.0161481112080913,"score_gpt":0.35829944406644804,"score_spread":0.34215133285835675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W175155385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06675708,0.9305781,0.0000024586504,0.000068671594,0.00037280904,0.0015114204,0.000007274318,0.0000076817205,0.0006945039],"genre_scores_gemma":[0.21834135,0.78115374,0.00002483611,0.00003837017,0.00009871078,0.00013669413,0.00018133881,0.000011770278,0.000013188528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848187,0.00018521817,0.00067310245,0.0003081376,0.000099012585,0.00025268036],"domain_scores_gemma":[0.9988987,0.0005683371,0.0002759472,0.00018317063,0.00002724647,0.00004660787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043388718,0.00029754447,0.0017549512,0.00031750606,0.000017303248,0.0000012503671,0.00009180539,0.00015367809,0.000012692097],"category_scores_gemma":[0.00020334701,0.00015593194,0.00009310533,0.00045183036,0.00032074485,0.000055274297,0.000112352,0.00017708291,0.0000022044821],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025199118,0.00022297584,0.0077466406,0.0033918626,0.00019360149,0.000014382121,0.00029048813,0.0000011148688,0.0010928204,0.00054590864,0.00008130882,0.9861669],"study_design_scores_gemma":[0.0033690624,0.012156605,0.00019757828,0.021211093,0.00063081767,0.0000035127655,0.00019554974,0.0000036480728,0.015053658,0.00007332879,0.9468621,0.0002430408],"about_ca_topic_score_codex":0.00007610984,"about_ca_topic_score_gemma":0.000029843022,"teacher_disagreement_score":0.9859239,"about_ca_system_score_codex":0.00013072968,"about_ca_system_score_gemma":0.000018817263,"threshold_uncertainty_score":0.635872},"labels":[],"label_agreement":null},{"id":"W1758972255","doi":"10.1016/s2215-0366(15)00310-7","title":"Genetic vulnerability in antipsychotic drug-induced diabetes","year":2015,"lang":"en","type":"letter","venue":"The Lancet Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Aripiprazole; Quetiapine; Olanzapine; Risperidone; Medicine; Clozapine; Family history; Antipsychotic; Diabetes mellitus; Population; Atypical antipsychotic; Psychiatry; Amisulpride; Psychosis; Internal medicine; Schizophrenia (object-oriented programming); Psychology; Endocrinology","score_opus":0.03478572597819136,"score_gpt":0.2893213877788715,"score_spread":0.25453566180068016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1758972255","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3640315,0.001525298,5.4861334e-7,0.6198856,0.0022890456,0.001004116,0.000016139678,0.00011132232,0.011136392],"genre_scores_gemma":[0.10125868,0.00017639161,0.0008144193,0.87634385,0.016008336,0.0002649771,0.00019339393,0.0001246234,0.004815309],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726415,0.00027385997,0.0004505796,0.00065231946,0.0005179965,0.0008410947],"domain_scores_gemma":[0.9978835,0.00010723113,0.00018019245,0.0016978362,0.000045461788,0.00008578624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005430641,0.00047472242,0.0010565663,0.00019001284,0.00005916068,0.000052562038,0.0004967417,0.00035273173,0.00011441439],"category_scores_gemma":[0.000046001856,0.00030987803,0.00021170186,0.00033016066,0.00009446099,0.00004384587,0.000095854586,0.0016899694,0.00033350117],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004626187,0.00018940831,0.10802963,0.00057722727,0.00019032133,0.000044959423,0.000075534525,0.0000013634284,0.000014557503,0.000028613575,0.8889425,0.0018596648],"study_design_scores_gemma":[0.0053345123,0.0002958788,0.140962,0.0006664217,0.0007723235,0.000007214826,0.00004340391,0.000050071223,0.000030188898,0.012664804,0.8385764,0.00059680064],"about_ca_topic_score_codex":0.000026765783,"about_ca_topic_score_gemma":0.00005196075,"teacher_disagreement_score":0.2627728,"about_ca_system_score_codex":0.00015693833,"about_ca_system_score_gemma":0.00016852745,"threshold_uncertainty_score":0.9999353},"labels":[],"label_agreement":null},{"id":"W1760729454","doi":"10.1016/j.pcl.2015.05.006","title":"Pediatric Diabetes and Endocrinology","year":2015,"lang":"en","type":"editorial","venue":"Pediatric Clinics of North America","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; TIMI; Myocardial infarction; Odds ratio; Stroke (engine); Internal medicine; Confidence interval; Randomized controlled trial; Diabetes mellitus; Meta-analysis; Cardiology; Thrombolysis; Endocrinology","score_opus":0.014384318529655828,"score_gpt":0.2892985933414045,"score_spread":0.2749142748117487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1760729454","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29092228,0.03252196,0.0000083584755,0.00023782653,0.6709822,0.0014866668,0.0008393019,0.00025177965,0.0027496293],"genre_scores_gemma":[0.006115301,0.118676424,0.0011671575,0.00018169907,0.8690678,0.000121245,0.0026286084,0.00013909691,0.0019026723],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963486,0.00007582429,0.0010650675,0.0008042506,0.0009743193,0.000731917],"domain_scores_gemma":[0.9954851,0.0016941504,0.0010580211,0.00073211984,0.00059621973,0.0004343508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027051475,0.00056060904,0.0017030078,0.0006784102,0.00004943822,0.000020895652,0.00029638628,0.00042789243,0.00004704174],"category_scores_gemma":[0.0022839985,0.0005097821,0.00030363703,0.0006839243,0.00018638655,0.00007256324,0.00042982757,0.00079463166,0.00011790839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004948281,0.0003124254,0.34473398,0.0006734311,0.0002047404,0.000031961466,0.000025586998,0.0000012179922,1.6484202e-8,9.019386e-7,0.626503,0.027463224],"study_design_scores_gemma":[0.0025621948,0.002390801,0.019520918,0.000014298271,0.006070285,6.0569903e-7,0.000014275274,0.000015736658,2.1653877e-7,0.000048979975,0.9689416,0.000420054],"about_ca_topic_score_codex":0.00003174964,"about_ca_topic_score_gemma":0.00000967643,"teacher_disagreement_score":0.3424386,"about_ca_system_score_codex":0.00008052902,"about_ca_system_score_gemma":0.00071767205,"threshold_uncertainty_score":0.99973536},"labels":[],"label_agreement":null},{"id":"W1765479650","doi":"10.14740/jem.v5i4.297","title":"Effects of Sitagliptin on Pancreatic Beta Cell Function and Microangiopathy in Japanese Patients With Type 2 Diabetes Mellitus: Follow-Up for 4 Years","year":2015,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sitagliptin; Microangiopathy; Internal medicine; Diabetes mellitus; Diabetic nephropathy; Nephropathy; Gastroenterology; Renal function; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology; Hemoglobin","score_opus":0.00812019580284327,"score_gpt":0.2166372664217731,"score_spread":0.20851707061892985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1765479650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859761,0.013130238,0.0000035516089,0.00006509754,0.00035705193,0.00035475465,0.0000018345285,0.0000035957933,0.00010779385],"genre_scores_gemma":[0.9987751,0.0004978423,0.00034037695,0.00010742324,0.00005567918,0.000008834848,0.0000056378453,0.00001045126,0.00019864182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993591,0.000041293857,0.00020797837,0.00010685719,0.000104512466,0.00018025811],"domain_scores_gemma":[0.99944514,0.00010832678,0.00016882263,0.00007129464,0.000120803685,0.000085629035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011068804,0.00010877275,0.00043719995,0.00021925352,0.000011917316,0.0000048329516,0.000030339988,0.000039869014,0.0000017078607],"category_scores_gemma":[0.00006158441,0.00007467055,0.000045560875,0.00007677187,0.00006141763,0.00006985177,0.000017833656,0.000082954015,0.0000010105085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010779592,0.00260865,0.9136475,0.0011373289,0.0018785826,0.00012035705,0.0025759768,0.000009030893,0.00907801,0.00112765,0.0015370268,0.055500317],"study_design_scores_gemma":[0.026246537,0.005742865,0.9536045,0.00017684684,0.0020635473,0.0000048836605,0.00028884428,0.0000032860546,0.0071034357,0.00026476613,0.0043945285,0.00010592588],"about_ca_topic_score_codex":0.000006094013,"about_ca_topic_score_gemma":0.000002196477,"teacher_disagreement_score":0.055394392,"about_ca_system_score_codex":0.0000131919405,"about_ca_system_score_gemma":0.000020686568,"threshold_uncertainty_score":0.30449766},"labels":[],"label_agreement":null},{"id":"W1769729678","doi":"10.25011/cim.v37i4.21730","title":"Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus","year":2014,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Malondialdehyde; Medicine; Internal medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Endocrinology; Type 2 diabetes; Oxidative stress","score_opus":0.10353686928828995,"score_gpt":0.33127169653626953,"score_spread":0.22773482724797958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1769729678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840561,0.0013906609,0.00002084287,0.00891752,0.00041837376,0.0006083376,8.341384e-7,0.00006204969,0.0045252927],"genre_scores_gemma":[0.9946727,0.00037168927,0.00095837814,0.0027065969,0.00062542415,0.000028895956,0.00005392393,0.000020662874,0.00056170096],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99784595,0.000212637,0.0007823588,0.00051916746,0.0002757361,0.00036413243],"domain_scores_gemma":[0.9986635,0.00034489384,0.00018673661,0.00028475287,0.00010578192,0.00041436672],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0016284091,0.0002602794,0.0009250387,0.00015738628,0.00007215031,0.000012758728,0.00008929679,0.00013906772,0.000064306354],"category_scores_gemma":[0.0035530243,0.00017772125,0.00007558351,0.00036932918,0.0030905292,0.00012806916,0.00009781874,0.0003447415,0.000030250994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024627236,0.0007367167,0.3778033,0.0006958859,0.0005208922,0.000117015195,0.0012744562,0.000006231387,0.009588698,0.023814453,0.0024136333,0.58278245],"study_design_scores_gemma":[0.010102293,0.005507443,0.8730704,0.0028953678,0.00065213226,0.0000057449975,0.00038689666,0.0035871146,0.014481383,0.082932174,0.0058286423,0.00055039057],"about_ca_topic_score_codex":0.00011592756,"about_ca_topic_score_gemma":0.000030102581,"teacher_disagreement_score":0.58223206,"about_ca_system_score_codex":0.000030985753,"about_ca_system_score_gemma":0.000041012772,"threshold_uncertainty_score":0.99962246},"labels":[],"label_agreement":null},{"id":"W1794576454","doi":"10.1210/en.2015-1361","title":"Chronic Exposure to TNFα Impairs Secretion of Glucagon-Like Peptide-1","year":2015,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto","keywords":"Endocrinology; Internal medicine; Proglucagon; Hyperinsulinemia; Glucagon-like peptide-1; Incretin; Tumor necrosis factor alpha; Glucose homeostasis; Secretion; Peptide YY; Glucagon-like peptide-2; Glucose tolerance test; Receptor; Biology; Medicine; Insulin resistance; Insulin; Type 2 diabetes; Diabetes mellitus; Neuropeptide Y receptor; Neuropeptide; Peptide; Biochemistry","score_opus":0.022778011822780865,"score_gpt":0.27684754052906596,"score_spread":0.2540695287062851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1794576454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97220707,0.0011617666,0.00018453047,0.002246468,0.0005629084,0.00052465074,0.0000037532159,0.000104283776,0.023004591],"genre_scores_gemma":[0.9910737,0.000054244254,0.0006406078,0.00033654293,0.00019965012,0.00006139214,0.00004589829,0.000016309468,0.0075716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990547,0.000029574063,0.00019598324,0.00021539815,0.00014828423,0.00035610862],"domain_scores_gemma":[0.99936604,0.000018230452,0.000053705895,0.00032435232,0.000075028074,0.00016264421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006310965,0.00012550586,0.00027937483,0.00016419233,0.000016518923,0.000003837023,0.000082238155,0.000043544864,0.00015886394],"category_scores_gemma":[0.000040236075,0.00010786807,0.00006961806,0.00013530941,0.000050600534,0.000041069936,0.00009939084,0.000072989365,0.00034174407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014459515,0.0018605577,0.3196652,0.0008406099,0.0025462355,0.0012114384,0.0048385966,0.0005671376,0.040285837,0.032335907,0.27124214,0.32316038],"study_design_scores_gemma":[0.0114391055,0.01782834,0.119409144,0.00014930918,0.0005992678,0.000121492514,0.0013445059,0.000077643235,0.027663045,0.0006976094,0.82025415,0.00041640046],"about_ca_topic_score_codex":0.00005946635,"about_ca_topic_score_gemma":0.00003842223,"teacher_disagreement_score":0.549012,"about_ca_system_score_codex":0.00017419395,"about_ca_system_score_gemma":0.000084581785,"threshold_uncertainty_score":0.43987325},"labels":[],"label_agreement":null},{"id":"W1815628349","doi":"10.1016/j.biochi.2015.06.003","title":"Identification of phlorizin binding domains in sodium-glucose cotransporter family: SGLT1 as a unique model system","year":2015,"lang":"en","type":"article","venue":"Biochimie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cotransporter; Phlorizin; Phloretin; Chemistry; Binding site; Biochemistry; Sugar; Non-competitive inhibition; Stereochemistry; Sodium; Biology; Glucose transporter; Enzyme; Endocrinology; Insulin","score_opus":0.03090563660766172,"score_gpt":0.2693865153113733,"score_spread":0.2384808787037116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1815628349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989858,0.00021180704,0.0011694846,0.00017883249,0.00015865512,0.0006775427,0.000019592633,0.00007536192,0.007650723],"genre_scores_gemma":[0.9974757,0.00004490294,0.0005704801,0.00008447041,0.000034629913,0.0000693015,0.00013806636,0.000021267011,0.0015611718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988922,0.00002526164,0.0003857472,0.0002337779,0.00026404264,0.00019899092],"domain_scores_gemma":[0.999376,0.000010527307,0.00012253749,0.00030937436,0.0000648522,0.00011672931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003517861,0.00013903985,0.00027404493,0.00026764095,0.000018881068,0.000012851024,0.00008794312,0.00007517067,0.0000041583517],"category_scores_gemma":[0.000013843809,0.00012214822,0.00007164469,0.00022619848,0.000036595487,0.000087291286,0.000023046705,0.00006228521,0.000118704455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015320107,0.0030819464,0.0517957,0.0025575017,0.0008258889,0.0003754376,0.00542034,0.00074227375,0.8466537,0.07344626,0.007745004,0.0058239345],"study_design_scores_gemma":[0.02482712,0.0015333431,0.04697656,0.00234333,0.00172419,0.00002223602,0.0076362314,0.0442713,0.86406446,0.0021069453,0.0033995882,0.0010946789],"about_ca_topic_score_codex":0.00007568105,"about_ca_topic_score_gemma":0.000020142432,"teacher_disagreement_score":0.07133931,"about_ca_system_score_codex":0.00022395948,"about_ca_system_score_gemma":0.00009993991,"threshold_uncertainty_score":0.498106},"labels":[],"label_agreement":null},{"id":"W1817571654","doi":"10.14740/jem.v5i4.289","title":"Autonomic Diabetic Neuropathy Impairs Glucose and Dipeptidyl Peptidase 4 Inhibitor-Regulated Glucagon Concentration in Type 1 Diabetic Patients","year":2015,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Internal medicine; Endocrinology; Glucagon; Medicine; Vildagliptin; Diabetes mellitus; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Secretion","score_opus":0.012952147027423784,"score_gpt":0.24222309451517532,"score_spread":0.22927094748775154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1817571654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903962,0.007779566,0.0000023086338,0.00041846812,0.0007732582,0.00028964458,0.0000023174975,0.00001475934,0.00032346128],"genre_scores_gemma":[0.99807066,0.0011207025,0.00015379944,0.00034853956,0.0001415503,0.000004863476,0.0000123499285,0.0000137480465,0.00013379096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987625,0.00011817441,0.00045327417,0.00018525423,0.00014964363,0.00033117476],"domain_scores_gemma":[0.9991742,0.00004586261,0.00023073435,0.00012378067,0.00016887925,0.00025658912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001802621,0.0001828163,0.0005035809,0.00023355987,0.000032720553,0.000022245213,0.000053530417,0.00006829607,0.000009177575],"category_scores_gemma":[0.00013098259,0.00014413278,0.000053303615,0.00013638125,0.00012564084,0.00021483183,0.00006145403,0.00022252384,0.000007050463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018337171,0.0020434633,0.86066955,0.000133978,0.00061241083,0.0006931674,0.0017418459,0.000053139916,0.017460559,0.0018439476,0.0018850728,0.11102917],"study_design_scores_gemma":[0.013956307,0.0015832025,0.966752,0.00009714579,0.000575304,0.000067178284,0.00014994855,0.00013317181,0.0064574527,0.00031689912,0.009743214,0.00016817488],"about_ca_topic_score_codex":0.000007897637,"about_ca_topic_score_gemma":0.0000022850345,"teacher_disagreement_score":0.110860996,"about_ca_system_score_codex":0.000059904414,"about_ca_system_score_gemma":0.00008186612,"threshold_uncertainty_score":0.5877564},"labels":[],"label_agreement":null},{"id":"W1834728684","doi":"10.1111/dom.12582","title":"Frequency of cancer events with saxagliptin in the <scp>SAVOR‐TIMI</scp> 53 trial","year":2015,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Forest Laboratories; Johnson and Johnson; Eisai; Daiichi-Sankyo; Bayer HealthCare; Hadassah Medical Organization; Gilead Sciences; Medtronic; Roche; Merck; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Pfizer; American Diabetes Association","keywords":"Saxagliptin; Medicine; TIMI; Internal medicine; Placebo; Myocardial infarction; Randomized controlled trial; Cancer; Adverse effect; Oncology; Metformin; Sitagliptin; Thrombolysis; Pathology","score_opus":0.018651721433678856,"score_gpt":0.2511753008881978,"score_spread":0.23252357945451893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834728684","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956097,0.014182214,0.0000010540581,0.023319097,0.00065676804,0.0023331621,0.00014269601,0.0000388898,0.0032291086],"genre_scores_gemma":[0.38813144,0.0068523777,0.0015867526,0.5606712,0.013054066,0.0031082903,0.002794791,0.00038479245,0.023416288],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720895,0.00024664862,0.00047716062,0.00054833054,0.00083542254,0.00068347907],"domain_scores_gemma":[0.9984842,0.00024858903,0.00036052725,0.00063152803,0.00015775411,0.00011738339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006973495,0.000526487,0.0013313233,0.00034460332,0.00006513822,0.000040974952,0.00032997585,0.00045724318,0.00003424741],"category_scores_gemma":[0.0001436791,0.00032145678,0.00019771098,0.00037885664,0.00017054175,0.00013846104,0.000098171484,0.0009081242,0.000014092179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018462053,0.0012817709,0.30027616,0.0015341522,0.0021384598,0.00021182078,0.0017652045,0.0000020774366,0.0000657896,0.0002597572,0.68687034,0.005409855],"study_design_scores_gemma":[0.036966622,0.000532927,0.18544437,0.00069397176,0.004574652,0.0000017438281,0.00015673277,0.000005263229,0.0002948661,0.00123218,0.76985985,0.00023680947],"about_ca_topic_score_codex":0.00044985875,"about_ca_topic_score_gemma":0.000102790975,"teacher_disagreement_score":0.56796557,"about_ca_system_score_codex":0.0000637816,"about_ca_system_score_gemma":0.00019402566,"threshold_uncertainty_score":0.99992377},"labels":[],"label_agreement":null},{"id":"W1834728951","doi":"10.1016/j.clinthera.2015.05.496","title":"Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Medicine; Liraglutide; Glycemic; Sitagliptin; Exenatide; Type 2 diabetes; Type 2 Diabetes Mellitus; Hypoglycemia; Glycated hemoglobin; Diabetes mellitus; Intensive care medicine; Internal medicine; Insulin; Endocrinology","score_opus":0.17725695700058516,"score_gpt":0.40807014869875863,"score_spread":0.23081319169817346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834728951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712384,0.00095784105,0.000022275348,0.0005365396,0.00015366188,0.00081538555,0.00000451086,0.0000070167157,0.0003789094],"genre_scores_gemma":[0.9977046,0.00012979894,0.0014086692,0.00052298134,0.000032768156,0.000029093579,0.000009544615,0.000014576301,0.00014795487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890846,0.00008325775,0.00041289447,0.00015573142,0.00023348365,0.0002061449],"domain_scores_gemma":[0.9987301,0.000599739,0.00012241375,0.00030349338,0.00013798982,0.00010626957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005212437,0.00011218852,0.0004101658,0.000033492255,0.00001467984,0.0000037969487,0.00008442395,0.000026528323,0.0000101085],"category_scores_gemma":[0.00014995754,0.00006387516,0.00004793268,0.00022696998,0.000040500163,0.000015179923,0.00003653166,0.00006579527,0.0000023968728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030466513,0.0003199542,0.90080833,0.00002650368,0.00038164688,0.0000026953476,0.0004599597,0.0015347194,0.000121739715,0.000016886217,0.000049710183,0.09597321],"study_design_scores_gemma":[0.014174241,0.02056643,0.87120235,0.00046669794,0.0015643121,9.588438e-7,0.0025454117,0.06168917,0.007114389,0.000106528154,0.020205138,0.00036438304],"about_ca_topic_score_codex":0.04896872,"about_ca_topic_score_gemma":0.21609654,"teacher_disagreement_score":0.16712782,"about_ca_system_score_codex":0.00029913065,"about_ca_system_score_gemma":0.00071803294,"threshold_uncertainty_score":0.95736426},"labels":[],"label_agreement":null},{"id":"W1851216557","doi":"","title":"L’étude DREAM : la prévention du diabète, rêve ou réalité","year":2007,"lang":"fr","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Gynecology; Humanities; Medicine; Art","score_opus":0.010619101375179152,"score_gpt":0.2642038268187975,"score_spread":0.2535847254436184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1851216557","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14791854,0.011125565,0.005068958,0.012489656,0.0035641973,0.0011368414,0.000008116127,0.00026455682,0.81842357],"genre_scores_gemma":[0.6437892,0.0017112237,0.0011715132,0.0012730387,0.0011223207,0.000025724998,0.00009217766,0.00004037886,0.35077447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980718,0.00005942285,0.000407184,0.0003616174,0.0003660117,0.0007339994],"domain_scores_gemma":[0.99898446,0.0001884671,0.00009446379,0.00036731645,0.00006946964,0.0002958441],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010729277,0.00028016145,0.0003202602,0.00017127853,0.00007724261,0.00005403725,0.00010832898,0.00017835593,0.0030861618],"category_scores_gemma":[0.0000687093,0.00025003505,0.00021377312,0.00027558874,0.000108909895,0.00018964989,0.00010536169,0.00015030018,0.0020082714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012319839,0.0036595098,0.08056215,0.0006329438,0.0012421529,0.0007800924,0.00056936167,0.0000059971453,0.0003390707,0.25721878,0.11402849,0.54083824],"study_design_scores_gemma":[0.0036076966,0.00074176735,0.20818959,0.00055203884,0.0012954519,0.00001383791,0.000555621,0.00016297604,0.0028801477,0.0017766444,0.7799028,0.00032142948],"about_ca_topic_score_codex":0.00027544776,"about_ca_topic_score_gemma":0.00034734354,"teacher_disagreement_score":0.6658743,"about_ca_system_score_codex":0.00021679244,"about_ca_system_score_gemma":0.000032012336,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W1862306556","doi":"10.1016/j.jval.2015.03.401","title":"Evolution of the Market for oral Antidiabetic agents In Canada after Introduction of Dipeptidyl Peptidase-4 Inhibitors","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dipeptidyl peptidase-4; Dipeptidyl peptidase; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Business; Medicine; Data science; Chemistry; Diabetes mellitus; Biochemistry; Endocrinology; Computer science; Enzyme; Type 2 diabetes","score_opus":0.02902168888322419,"score_gpt":0.26516004712297164,"score_spread":0.23613835823974746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1862306556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956554,0.00035235597,0.000008968454,0.0023291782,0.0004574072,0.0010561778,0.0000144968635,0.000003727546,0.00012226152],"genre_scores_gemma":[0.9991902,0.000017951195,0.00028966085,0.000101704376,0.000082608174,0.0000539999,0.000010846923,0.000009162756,0.00024382959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892104,0.000111198104,0.00037969634,0.00014298216,0.00023351156,0.00021156603],"domain_scores_gemma":[0.99952364,0.000027812039,0.00013981198,0.00019018564,0.00005152123,0.000067018016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000602222,0.00007899927,0.0002469678,0.00012326492,0.0000101786045,0.0000013990523,0.00004603481,0.000023729153,0.000013380357],"category_scores_gemma":[0.00010596235,0.00005932326,0.00003702656,0.0002749118,0.000026473434,0.00003920891,0.000028179184,0.000057534402,4.768572e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000250673,0.00024348203,0.9666373,0.0008430203,0.000021639062,0.0000016782457,0.0002720981,0.001003886,0.000045629753,0.00008830438,0.028489482,0.0021027746],"study_design_scores_gemma":[0.0028581885,0.00045498338,0.98653424,0.0005120223,0.000035555273,5.966437e-7,0.0005040914,0.0039332528,0.00096236647,0.0002522229,0.0038818445,0.00007065977],"about_ca_topic_score_codex":0.5829128,"about_ca_topic_score_gemma":0.22752151,"teacher_disagreement_score":0.3553913,"about_ca_system_score_codex":0.0016276013,"about_ca_system_score_gemma":0.0009897962,"threshold_uncertainty_score":0.7865742},"labels":[],"label_agreement":null},{"id":"W1868928463","doi":"10.1016/j.jval.2015.03.365","title":"The Cost-effectiveness of canagliflozin (Cana) versus Saxagliptin (Saxa) among older Individuals living with type 2 diabetes mellitus (T2dm) In canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Metformin; Medicine; Saxagliptin; Type 2 Diabetes Mellitus; Post-hoc analysis; Sitagliptin; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.04172977108381095,"score_gpt":0.2832846464763343,"score_spread":0.24155487539252332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1868928463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308914,0.0033114953,0.0000022777283,0.00046621115,0.0004677996,0.0017537766,0.0000093407425,0.000015177399,0.00088478415],"genre_scores_gemma":[0.999244,0.00026229137,0.00009889346,0.00012390247,0.000030648924,0.00013827358,0.000018227885,0.000027070728,0.00005668998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977394,0.0004887343,0.00038711185,0.00027472782,0.000492357,0.00061771116],"domain_scores_gemma":[0.99792767,0.0011759133,0.0001880627,0.00034603282,0.00009308449,0.0002692681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019890699,0.00019038022,0.0004909304,0.00017343828,0.000052288276,0.000015819765,0.00014364277,0.00004239094,0.000007607632],"category_scores_gemma":[0.0003316826,0.00013446146,0.000025198462,0.0006352531,0.00006213935,0.00006744527,0.00006210863,0.00018610172,0.000002188358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013926397,0.00012276537,0.9863316,0.00044414875,0.00014014632,0.000016730113,0.00045527887,0.0041250717,0.000001521345,0.00025257753,0.00056301145,0.0074079074],"study_design_scores_gemma":[0.0038354855,0.00096631533,0.9875806,0.0019396348,0.00005793305,3.8700475e-7,0.0016170042,0.0013739036,0.00012805081,0.0000347039,0.002308456,0.00015753001],"about_ca_topic_score_codex":0.92081785,"about_ca_topic_score_gemma":0.93055,"teacher_disagreement_score":0.009732141,"about_ca_system_score_codex":0.0025414398,"about_ca_system_score_gemma":0.0034969836,"threshold_uncertainty_score":0.6645777},"labels":[],"label_agreement":null},{"id":"W1870937734","doi":"10.1111/dme.12867","title":"Risk of new‐onset heart failure in patients using sitagliptin: a population‐based cohort study","year":2015,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Medicine; Sitagliptin; Heart failure; Internal medicine; Acute coronary syndrome; Odds ratio; Cardiology; Population; Myocardial infarction; Metformin; Insulin","score_opus":0.02641606880884795,"score_gpt":0.2868280950277219,"score_spread":0.26041202621887394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1870937734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687445,0.000073060255,0.000033083983,0.00062664197,0.00019199622,0.0018949494,0.0000062350027,0.00003372146,0.00026585112],"genre_scores_gemma":[0.99774915,0.0000012799578,0.0014145134,0.00030600443,0.000084426174,0.000026165171,0.00019525271,0.000024051402,0.0001991806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980966,0.00011909732,0.0005125333,0.0002960069,0.00070299907,0.00027278758],"domain_scores_gemma":[0.9988682,0.00007200528,0.00017972538,0.00044643023,0.00014529288,0.0002883078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006835425,0.00020115926,0.0006963883,0.00037304452,0.000024341862,0.0000047581043,0.00007502811,0.00005480725,0.00013772836],"category_scores_gemma":[0.0005747585,0.00015350053,0.000052462154,0.00047151643,0.000047270267,0.000054967408,0.00004010399,0.00011913668,0.000014821258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102033744,0.0010488897,0.9917806,0.000043058753,0.00015071341,0.0000052214846,0.00044693242,0.0001082862,0.000010831608,0.000003420733,0.0058307275,0.0004693192],"study_design_scores_gemma":[0.0140636675,0.0021905038,0.9808286,0.0002471199,0.0008641353,2.3588012e-7,0.0005112477,0.0007943631,0.000036998306,0.000055643697,0.0002943766,0.00011311484],"about_ca_topic_score_codex":0.0019153614,"about_ca_topic_score_gemma":0.000119320655,"teacher_disagreement_score":0.013961634,"about_ca_system_score_codex":0.00017386206,"about_ca_system_score_gemma":0.0000865536,"threshold_uncertainty_score":0.625957},"labels":[],"label_agreement":null},{"id":"W1873998655","doi":"10.3109/07435800.2015.1038353","title":"Does GLP-1 suppress its own basal secretion?","year":2015,"lang":"en","type":"article","venue":"Endocrine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; National Institutes of Health; University of British Columbia","keywords":"Secretion; Basal (medicine); Chemistry; Internal medicine; Endocrinology; Cell biology; Biology; Biochemistry; Medicine","score_opus":0.11454108630178378,"score_gpt":0.41886533952327254,"score_spread":0.30432425322148876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1873998655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77539384,0.00079324155,0.000017671302,0.022227662,0.00058043073,0.0014379545,0.00002025059,0.00020432715,0.19932462],"genre_scores_gemma":[0.8564822,0.00014803497,0.00025764294,0.00012375454,0.0004945722,0.00014695026,0.000092447175,0.000026644715,0.14222772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768806,0.00013195824,0.00015936,0.00031565723,0.0010453332,0.0006596617],"domain_scores_gemma":[0.9986231,0.000108719374,0.000018385448,0.00042769205,0.00039987097,0.0004222718],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006260326,0.00012828744,0.00021106454,0.00028339657,0.000080807564,0.000058316407,0.00016405471,0.000028164352,0.001295478],"category_scores_gemma":[0.00036718138,0.000073094125,0.00006226328,0.00034159343,0.00008614409,0.00013018484,0.0002947626,0.00027160873,0.0015684013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010249756,0.0019436817,0.060419697,0.0006125464,0.0006839111,0.0025174671,0.0010822752,0.000010789334,0.0065287217,0.009277021,0.8874994,0.02839954],"study_design_scores_gemma":[0.0047244555,0.0010486726,0.009329547,0.00008758961,0.000063981315,0.000011199193,0.00070036843,0.00037198953,0.030422715,0.001195472,0.9518738,0.00017022197],"about_ca_topic_score_codex":0.00008195182,"about_ca_topic_score_gemma":0.000013179408,"teacher_disagreement_score":0.08108839,"about_ca_system_score_codex":0.00016035211,"about_ca_system_score_gemma":0.00011492685,"threshold_uncertainty_score":0.99961746},"labels":[],"label_agreement":null},{"id":"W1874041614","doi":"10.1111/dom.12469","title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Janssen Biotech; Novo Nordisk; Merck; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Metformin; Placebo; Randomized controlled trial; Type 2 diabetes; Clinical endpoint; Confidence interval; Internal medicine; Diabetes mellitus; Insulin; Endocrinology","score_opus":0.016243730977527217,"score_gpt":0.24011760220982117,"score_spread":0.22387387123229396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1874041614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842253,0.0038853649,0.0000028984434,0.00013218161,0.0005357986,0.008622793,0.000016914864,0.000050829254,0.002527969],"genre_scores_gemma":[0.998092,0.00034247563,0.00025245995,0.0002423312,0.00011652638,0.0003916592,0.000105356914,0.00003818313,0.0004190363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968874,0.00046897426,0.0008509523,0.00055479544,0.0006240383,0.00061387103],"domain_scores_gemma":[0.9970873,0.0014522565,0.00043525174,0.00039476098,0.00025698464,0.00037345086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018024971,0.0005212276,0.0034795313,0.00042471298,0.00008890889,0.00005887034,0.00013866505,0.00016678045,0.000020061614],"category_scores_gemma":[0.0016609782,0.00034531145,0.00020823079,0.00037801755,0.00028572787,0.00028575867,0.00011458878,0.00025026713,0.000010508124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9759441,0.002220636,0.012638028,0.0001000301,0.002247157,0.0000048502784,0.0005281444,0.000013078324,0.000022610004,0.00064413965,0.00007188988,0.005565327],"study_design_scores_gemma":[0.95603424,0.004655071,0.033693917,0.00020787264,0.0035386037,7.0123804e-8,0.000092708455,0.00021409776,0.0002857408,0.00011095853,0.00083604536,0.00033069807],"about_ca_topic_score_codex":0.00004294204,"about_ca_topic_score_gemma":0.000017360398,"teacher_disagreement_score":0.02105589,"about_ca_system_score_codex":0.000100060795,"about_ca_system_score_gemma":0.00012412656,"threshold_uncertainty_score":0.99989986},"labels":[],"label_agreement":null},{"id":"W1878747716","doi":"10.1210/en.2015-1110","title":"Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice","year":2015,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Mitacs","keywords":"Chylomicron; Internal medicine; Endocrinology; Postprandial; Chemistry; Glucagon-like peptide-2; Nitric oxide; Triglyceride; Lipoprotein; Biology; Very low-density lipoprotein; Cholesterol; Biochemistry; Insulin; Medicine; Peptide","score_opus":0.01940024928356558,"score_gpt":0.2507711432439383,"score_spread":0.23137089396037272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1878747716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978213,0.0008924232,0.000049326438,0.00027496638,0.00014688325,0.0006423064,0.0000048359093,0.000022925089,0.00014505905],"genre_scores_gemma":[0.9981709,0.00011609152,0.0012955058,0.000038854676,0.000050903247,0.000019278556,0.000028275097,0.00001651971,0.00026366493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885607,0.000086156324,0.00035506018,0.00032135204,0.000117655516,0.00026368015],"domain_scores_gemma":[0.9993764,0.00007734154,0.00020189946,0.00014169786,0.00011305562,0.00008960066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014955504,0.00017019274,0.00040729693,0.00044141096,0.000022017366,0.000005933134,0.000041070874,0.000054458695,0.000009687515],"category_scores_gemma":[0.00023880089,0.00015994003,0.00003423863,0.0001995679,0.0001821088,0.00014418345,0.00007435359,0.00015036893,0.0000026664395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007804837,0.00054318126,0.16739003,0.0003439711,0.00026482128,0.00020281653,0.0012328688,0.00042414753,0.8089319,0.00007045982,0.00015392689,0.012637057],"study_design_scores_gemma":[0.02140506,0.008230167,0.3878413,0.0007576517,0.0011400887,0.0014631652,0.005221419,0.00062767655,0.5718328,0.00044019267,0.00043967195,0.0006008157],"about_ca_topic_score_codex":0.0005754497,"about_ca_topic_score_gemma":0.000027999946,"teacher_disagreement_score":0.23709911,"about_ca_system_score_codex":0.00010522649,"about_ca_system_score_gemma":0.00004842049,"threshold_uncertainty_score":0.6522165},"labels":[],"label_agreement":null},{"id":"W1887464935","doi":"10.1186/1472-6963-6-159","title":"Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001","year":2006,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); Institute of Health Economics","funders":"Canadian Institutes of Health Research; Institute of Circulatory and Respiratory Health; Eli Lilly Canada; Alberta Heritage Foundation for Medical Research; Kidney Foundation of Canada; Canadian Diabetes Association; Institute of Nutrition, Metabolism and Diabetes; Heart and Stroke Foundation of Canada; Fondation pour la Recherche Médicale; Eli Lilly and Company","keywords":"Medicine; Type 2 diabetes; Metformin; Diabetes mellitus; Health administration; Emergency medicine; Internal medicine; Public health; Endocrinology; Nursing","score_opus":0.0806243026476572,"score_gpt":0.40363378894991114,"score_spread":0.32300948630225396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1887464935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957458,0.0015652817,0.00002459382,0.0002943228,0.000013583785,0.0009784856,0.000007797487,0.00001722616,0.0013529187],"genre_scores_gemma":[0.9972195,0.00016224245,0.00207017,0.0000738486,0.000030362304,0.00006558078,0.00011550156,0.0000119016,0.00025090607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854565,0.000114237555,0.00037874895,0.00017034174,0.0004445615,0.00034644583],"domain_scores_gemma":[0.99909204,0.00033257945,0.00011562399,0.00017229276,0.00020354072,0.00008391183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013847502,0.00006804157,0.00024533045,0.00034930772,0.000043819273,0.0000071766963,0.00006604882,0.000042407817,0.000020686712],"category_scores_gemma":[0.00003459448,0.000059338192,0.00001264156,0.0006122936,0.00008428122,0.0000655554,0.00006479563,0.000080067744,0.000002901464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023695546,0.0002500334,0.9662904,0.0058779824,0.000007772791,3.9450876e-7,0.0005980689,0.000012430128,0.0006988506,0.0001045452,0.00011523605,0.026020603],"study_design_scores_gemma":[0.001141711,0.00039050018,0.98500216,0.00083069724,0.000009704082,1.4995e-7,0.0038923242,0.0055449223,0.0024151856,0.00025948012,0.00047547984,0.000037686164],"about_ca_topic_score_codex":0.0047087325,"about_ca_topic_score_gemma":0.007500263,"teacher_disagreement_score":0.025982916,"about_ca_system_score_codex":0.0000790459,"about_ca_system_score_gemma":0.000246097,"threshold_uncertainty_score":0.7118226},"labels":[],"label_agreement":null},{"id":"W1900294710","doi":"10.1139/cjpp-2014-0457","title":"Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Internal medicine; Endocrinology; Lipid metabolism; Cholesterol; LDL receptor; Glucagon-like peptide-1; Metabolism; Hypertriglyceridemia; Receptor; Chemistry; Cholesterol 7 alpha-hydroxylase; Biology; Triglyceride; Medicine; Lipoprotein; Type 2 diabetes; Diabetes mellitus","score_opus":0.01909018276672194,"score_gpt":0.27120439327485346,"score_spread":0.25211421050813154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1900294710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690104,0.0004201723,0.0000031821733,0.0009792096,0.0011634119,0.000291581,0.000010321849,0.0000034044106,0.00022767056],"genre_scores_gemma":[0.9982952,0.000056996545,0.000017814767,0.0011256769,0.00040551595,0.000009206953,0.000012873084,0.000009140125,0.000067612826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916273,0.00012324512,0.00024304625,0.000121636906,0.00008060515,0.0002687438],"domain_scores_gemma":[0.99901456,0.00005624421,0.00021608765,0.000060802235,0.00012165899,0.00053064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002152647,0.00012683755,0.00038421032,0.0002075059,0.000034697972,0.0000045642328,0.00007543642,0.0000992559,0.00024871534],"category_scores_gemma":[0.000040349434,0.00009747295,0.00006993778,0.00006514012,0.000090902635,0.00008985604,0.000012104329,0.00021411848,0.00000511996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013001884,0.0001316673,0.0028210655,0.00014711585,0.0009863045,0.000016552356,0.0004908049,0.00003964011,0.97696644,0.00026560124,0.0052094096,0.011625206],"study_design_scores_gemma":[0.007053677,0.0077509196,0.11202115,0.00005499682,0.00051359157,0.000011416399,0.00005291545,0.000013987938,0.8550903,0.00014953114,0.017186781,0.000100715624],"about_ca_topic_score_codex":0.000066266715,"about_ca_topic_score_gemma":0.000155792,"teacher_disagreement_score":0.12187613,"about_ca_system_score_codex":0.000082568215,"about_ca_system_score_gemma":0.0003540944,"threshold_uncertainty_score":0.39748317},"labels":[],"label_agreement":null},{"id":"W1900609545","doi":"10.1155/2005/971971","title":"Risk Factors for New‐Onset Diabetes Mellitus in Patients Receiving Protease Inhibitor Therapy","year":2005,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; Saskatchewan Health Authority; University of Alberta; Capital District Health Authority","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Body mass index; Retrospective cohort study; Logistic regression; Cohort; Endocrinology","score_opus":0.0055547935490613265,"score_gpt":0.21953090023979518,"score_spread":0.21397610669073386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1900609545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943163,0.0036949087,0.000014491481,0.00096563075,0.00033529647,0.0005525416,0.000083696854,0.000007728491,0.000029453295],"genre_scores_gemma":[0.9979053,0.00067244633,0.0000548437,0.0009486783,0.00028181385,0.000012621774,0.00006065889,0.00001444638,0.000049154743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990128,0.000060673054,0.0003397206,0.00015188866,0.000061891034,0.00037300808],"domain_scores_gemma":[0.998284,0.00013999581,0.00015662592,0.000080566715,0.000087167486,0.0012516767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016198134,0.00015182444,0.00036184888,0.00030449894,0.000075085394,0.000018369157,0.00006166586,0.000119716235,0.00016701031],"category_scores_gemma":[0.00078559376,0.00010921059,0.00013013791,0.00008767291,0.00011731367,0.00006665007,0.000009799344,0.00017059306,0.000002321746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077471945,0.00020932939,0.8890882,0.000023229104,0.00016453012,0.000010230165,0.00011726534,0.0000018714339,0.000032604952,0.0000070484057,0.004818258,0.10544996],"study_design_scores_gemma":[0.009921024,0.0026204619,0.92737705,0.0002371183,0.00021453475,0.000013889392,0.00005228683,0.000011440594,0.00023922908,0.00015272005,0.05899235,0.00016790055],"about_ca_topic_score_codex":0.00095056446,"about_ca_topic_score_gemma":0.0035852625,"teacher_disagreement_score":0.10528205,"about_ca_system_score_codex":0.00020309637,"about_ca_system_score_gemma":0.00074266765,"threshold_uncertainty_score":0.44534785},"labels":[],"label_agreement":null},{"id":"W1905197431","doi":"10.25011/cim.v37i3.21384","title":"Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease","year":2014,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research","keywords":"Linagliptin; Sitagliptin; Medicine; Renal function; Internal medicine; Incretin; Kidney disease; Dipeptidyl peptidase-4; Diabetes mellitus; Heart failure; Cardiology; Vildagliptin; Endocrinology; Type 2 diabetes; Urology","score_opus":0.04915724837795253,"score_gpt":0.2980757229273517,"score_spread":0.24891847454939914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905197431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96719307,0.00079123833,0.00023484361,0.02858067,0.00035622704,0.00069411023,0.000003501533,0.000071209746,0.0020751553],"genre_scores_gemma":[0.9891225,0.00021362331,0.00009713347,0.00801719,0.00097255205,0.000037716665,0.0002696879,0.000016975608,0.0012526229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983537,0.00014096103,0.00056927867,0.00044789212,0.00023487821,0.00025324273],"domain_scores_gemma":[0.9986425,0.00010290268,0.00012750881,0.00023216862,0.00006053672,0.000834352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006532369,0.00020950045,0.00048735924,0.00014204982,0.000058045236,0.0000094902325,0.000037177524,0.00008013652,0.00015108904],"category_scores_gemma":[0.0017288789,0.0001418385,0.00008354453,0.00017982378,0.0023679025,0.00014586907,0.00005954207,0.00025056678,0.00004475754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042794234,0.00078063656,0.8883912,0.00097005046,0.00028061075,0.0001735293,0.00020451027,0.00000422724,0.007629506,0.019695003,0.031799585,0.049643196],"study_design_scores_gemma":[0.008689291,0.0040261457,0.9092143,0.0016438053,0.0005424103,0.000002037928,0.0000622108,0.0014257698,0.00038197765,0.02660484,0.04721639,0.00019081554],"about_ca_topic_score_codex":0.000023399802,"about_ca_topic_score_gemma":0.0000104984,"teacher_disagreement_score":0.049452383,"about_ca_system_score_codex":0.000077940604,"about_ca_system_score_gemma":0.000095805684,"threshold_uncertainty_score":0.8724635},"labels":[],"label_agreement":null},{"id":"W1905492423","doi":"10.2337/db14-1830","title":"β-Hydroxypyruvate: A New Diabetogenic Factor?","year":2015,"lang":"en","type":"letter","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Medicine; Computer science; Programming language","score_opus":0.03007113673081351,"score_gpt":0.25543906903346236,"score_spread":0.22536793230264884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905492423","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14886448,0.009557825,0.0000065680315,0.78308696,0.0024834194,0.0027470305,0.00024429214,0.0011472119,0.051862195],"genre_scores_gemma":[0.007890006,0.00011577655,0.0004108778,0.7953938,0.008324066,0.00017206332,0.003984537,0.00028712445,0.18342175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967847,0.00005452147,0.0004319184,0.0007690739,0.000845753,0.0011140394],"domain_scores_gemma":[0.9981392,0.00009917719,0.00020305146,0.0010298049,0.00013107988,0.00039767587],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000119441895,0.000738243,0.0011872143,0.00040586063,0.00005361779,0.00009850672,0.00032168784,0.0008165174,0.00095977285],"category_scores_gemma":[0.000092251736,0.00061679626,0.00047221218,0.00030707865,0.00008341235,0.00012675086,0.00018944015,0.0010778025,0.0019449808],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000570159,0.000108897344,0.012739492,0.00035549718,0.0012515015,0.0002224853,0.0000656785,2.6955908e-7,0.00013745631,0.000007584866,0.97529054,0.009814918],"study_design_scores_gemma":[0.0016535601,0.00059254677,0.00077953836,0.00027840736,0.0012294494,0.0000011447388,0.000005868137,0.000020280346,0.0017771998,0.0004264352,0.99265474,0.00058081385],"about_ca_topic_score_codex":0.00004062908,"about_ca_topic_score_gemma":0.0000016324237,"teacher_disagreement_score":0.14097448,"about_ca_system_score_codex":0.00033798788,"about_ca_system_score_gemma":0.0003492306,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W1905847794","doi":"10.1111/1753-0407.12258","title":"Dipeptidyl peptidase‐4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell‐derived factor‐1<i>α</i>","year":2015,"lang":"en","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Myocardial infarction; Dipeptidyl peptidase-4; Cardiology; Diabetes mellitus; Stromal cell; Internal medicine; Cardiac function curve; Dipeptidyl peptidase; Cell; Dipeptidyl peptidase-4 inhibitor; Endocrinology; Heart failure; Enzyme; Type 2 diabetes; Biochemistry","score_opus":0.010836008306875191,"score_gpt":0.2279164084000327,"score_spread":0.2170804000931575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905847794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467313,0.0020854287,0.0000046526384,0.000091925795,0.0005428756,0.0002899038,0.0000087447015,0.000016296406,0.002287061],"genre_scores_gemma":[0.9990389,0.000032816057,0.00026896835,0.00007741058,0.0004338459,0.000014609521,0.000023817383,0.00002174883,0.00008793014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984938,0.000071406015,0.00054069894,0.00015167537,0.00048501228,0.00025738913],"domain_scores_gemma":[0.9990378,0.000035939025,0.00038428057,0.0001484357,0.00019428499,0.00019927503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025483477,0.00019120853,0.0005436051,0.00031807172,0.000024655312,0.000023654911,0.00005431095,0.00008693629,0.000031807314],"category_scores_gemma":[0.00003256488,0.00016231467,0.0002874934,0.00017711885,0.000058149362,0.0004227191,0.000049213173,0.00017892302,0.0000074777818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022740463,0.0006474465,0.22788548,0.00004367626,0.00029083993,0.0000048868333,0.0005310073,0.000019711475,0.7655101,0.000018877829,0.0008100599,0.0040105],"study_design_scores_gemma":[0.0059902393,0.0055466397,0.3098874,0.00019729875,0.00038022324,0.0000017457038,0.0039613983,0.00004083955,0.67139286,0.0001051129,0.002304616,0.00019161473],"about_ca_topic_score_codex":0.000013077047,"about_ca_topic_score_gemma":0.0000011261162,"teacher_disagreement_score":0.09411724,"about_ca_system_score_codex":0.00022224175,"about_ca_system_score_gemma":0.00009783946,"threshold_uncertainty_score":0.66190004},"labels":[],"label_agreement":null},{"id":"W1906681517","doi":"10.1139/cjpp-2012-0300","title":"Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Internal medicine; Medicine; Endocrinology; Exenatide; Adiponectin; Adipokine; Insulin; Type 2 diabetes; Sitagliptin; Glycemic; Resistin; Proinsulin; Insulin resistance; Diabetes mellitus","score_opus":0.01424117162530024,"score_gpt":0.2735655151871767,"score_spread":0.25932434356187645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1906681517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667984,0.002066453,0.000006739694,0.0006286485,0.00011167628,0.0004116318,0.0000018326066,0.0000018646164,0.00009132316],"genre_scores_gemma":[0.99855787,0.00023625512,0.00019948467,0.0008784982,0.000031973064,0.000021212249,0.0000030827027,0.0000075939297,0.000064007596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993748,0.00007077112,0.00022605872,0.00009677499,0.000046127006,0.00018545915],"domain_scores_gemma":[0.99937344,0.00016540913,0.000166773,0.000039777595,0.000060104452,0.00019450502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011994751,0.00010903872,0.00042834465,0.00038571816,0.000029281568,0.0000034446807,0.00004387715,0.000059314854,0.00015907348],"category_scores_gemma":[0.000010523767,0.00007773868,0.000025834384,0.00008233993,0.00014373388,0.000120821256,0.0000056099843,0.00015262551,0.0000016489735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016003342,0.0009033268,0.032092493,0.00095990766,0.0019266291,0.0004067586,0.0019758884,0.00008276753,0.86004037,0.004284705,0.003955867,0.09177098],"study_design_scores_gemma":[0.020768687,0.010874584,0.39660344,0.00021421073,0.0005891191,0.00007854469,0.00015183006,0.0005296321,0.5624349,0.0052574426,0.0023011684,0.00019646865],"about_ca_topic_score_codex":0.0004584496,"about_ca_topic_score_gemma":0.00028129516,"teacher_disagreement_score":0.36451092,"about_ca_system_score_codex":0.00005588776,"about_ca_system_score_gemma":0.000108381515,"threshold_uncertainty_score":0.31700915},"labels":[],"label_agreement":null},{"id":"W1909273102","doi":"","title":"Type 2 diabetes and hemoglobin A1c targets.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Diabetes mellitus; Hypoglycemia; Hemoglobin; Medicine; Type 2 diabetes; Hemoglobin A; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.011122788292083694,"score_gpt":0.1950187956790185,"score_spread":0.18389600738693482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1909273102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558914,0.0015085412,0.00000102283,0.0021751805,0.00015762565,0.0010957205,7.659263e-7,0.00007769047,0.039092068],"genre_scores_gemma":[0.98413867,0.00008438539,0.00021911337,0.0010566557,0.00006489717,0.00094753853,0.000016285803,0.000011432642,0.013461038],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994124,0.0000069693333,0.00007803812,0.00013928555,0.00008492953,0.00027837695],"domain_scores_gemma":[0.9996649,0.000015219861,0.00001877067,0.0001330025,0.000029503639,0.00013859378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006283362,0.000083012004,0.00013584319,0.00004748563,0.000022847611,0.000028050681,0.000029363098,0.000026500225,0.00017382657],"category_scores_gemma":[0.00003497154,0.00006272183,0.000023400287,0.00008108119,0.000030344654,0.00008142895,0.00004374117,0.00003419206,0.00017916544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010089686,0.00014635912,0.2192966,0.000083333805,0.00022470302,0.0000064860283,0.00004107239,1.0280096e-7,0.00011448737,0.00046347527,0.06940044,0.7102128],"study_design_scores_gemma":[0.0007545728,0.000058686088,0.93802917,0.0000060199955,0.0000938269,4.9270636e-7,0.000019303772,0.000025682624,0.001034296,0.00052446354,0.05937487,0.00007862874],"about_ca_topic_score_codex":0.000009860949,"about_ca_topic_score_gemma":7.2196895e-7,"teacher_disagreement_score":0.71873254,"about_ca_system_score_codex":0.000024371384,"about_ca_system_score_gemma":0.0000036651365,"threshold_uncertainty_score":0.2557722},"labels":[],"label_agreement":null},{"id":"W1914664397","doi":"10.1111/j.1742-1241.2011.02859.x","title":"New medications for the treatment of diabetes","year":2012,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Medicine; Diabetes treatment; Type 2 diabetes; Endocrinology","score_opus":0.1068775197512099,"score_gpt":0.49700881893586824,"score_spread":0.39013129918465833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1914664397","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34958288,0.02872451,0.050018422,0.50272256,0.026147107,0.0023243236,0.00004093799,0.00004081714,0.04039846],"genre_scores_gemma":[0.94724435,0.0038184216,0.038812213,0.002262011,0.005353536,0.000014205709,0.000009300762,0.000012472633,0.0024734987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986269,0.00004817991,0.0007498577,0.0000532664,0.00042023062,0.00010155754],"domain_scores_gemma":[0.992311,0.0060007134,0.0008434745,0.00012570323,0.0005695714,0.00014955361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010678518,0.00006355934,0.0002422917,0.000057019937,0.000019429264,0.000011846625,0.00015235024,0.000036224606,0.00013910208],"category_scores_gemma":[0.0024563347,0.000034367185,0.0003161532,0.0000419312,0.000043462172,0.00029061717,0.0000141065475,0.00007772318,0.000014163544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009570578,0.0057103643,0.108547926,0.0000105634135,0.011449527,0.000007946773,0.0003604404,0.000007631444,0.00005194867,0.006475113,0.033462223,0.83295923],"study_design_scores_gemma":[0.0033360373,0.0016072042,0.07065121,0.000037087728,0.0026104695,0.000013990337,0.00014416232,0.000051597413,0.00028829637,0.00025765254,0.9209706,0.00003164915],"about_ca_topic_score_codex":0.0000064766655,"about_ca_topic_score_gemma":6.9172444e-7,"teacher_disagreement_score":0.8875084,"about_ca_system_score_codex":0.00004822317,"about_ca_system_score_gemma":0.00013309234,"threshold_uncertainty_score":0.29406396},"labels":[],"label_agreement":null},{"id":"W191621842","doi":"10.2741/2797","title":"Dipeptidyl peptidase iv inhibitors and diabetes therapy","year":2007,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Killam Trusts; Bundesministerium für Bildung und Forschung; Canadian Diabetes Association","keywords":"Incretin; Sitagliptin; Dipeptidyl peptidase; Internal medicine; Endocrinology; Dipeptidyl peptidase-4; Medicine; Type 2 diabetes; Pharmacology; Glucagon-like peptide-1; Insulin; Beta cell; Diabetes mellitus; Hormone; Chemistry; Islet; Biochemistry; Enzyme","score_opus":0.034382747076291915,"score_gpt":0.3117131289208577,"score_spread":0.27733038184456577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W191621842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010997663,0.9943506,0.000033244844,0.00005369533,0.0010779775,0.0013268689,0.0000091456695,0.00005547273,0.0019932303],"genre_scores_gemma":[0.00010298685,0.99387014,0.0036173193,0.00023990634,0.00012584185,0.00008735377,0.000034868004,0.00003381501,0.0018877753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978956,0.000046182256,0.00043576505,0.00068255933,0.00035314306,0.0005867319],"domain_scores_gemma":[0.9991613,0.00005222047,0.00016577997,0.00039805545,0.000021976366,0.00020066742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005166261,0.00042742083,0.0012634351,0.0008081814,0.00007404195,0.00006204152,0.00022844513,0.00020460776,0.000013996814],"category_scores_gemma":[0.000048035097,0.0003004761,0.0002105822,0.0009293092,0.00042256294,0.00013517668,0.0001218457,0.0002523825,0.000016616228],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004251756,0.00012505059,0.007954155,0.0019623253,0.00006143075,0.00003305736,0.00003392535,1.5270526e-8,0.0000017488952,0.000017869117,0.0074892812,0.9823169],"study_design_scores_gemma":[0.00054815237,0.00023641944,0.0009075184,0.0063078343,0.00020302625,0.0000022237039,0.00004129503,0.0000103431385,0.000012895354,0.000031638534,0.9913971,0.00030154563],"about_ca_topic_score_codex":0.0000044389362,"about_ca_topic_score_gemma":0.0000014611418,"teacher_disagreement_score":0.9839078,"about_ca_system_score_codex":0.00020800975,"about_ca_system_score_gemma":0.0000990815,"threshold_uncertainty_score":0.99994475},"labels":[],"label_agreement":null},{"id":"W1916543933","doi":"10.1016/j.amjmed.2015.09.022","title":"Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c","year":2015,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Saxagliptin; Hazard ratio; Myocardial infarction; Internal medicine; TIMI; Stroke (engine); Clinical endpoint; Heart failure; Cardiology; Type 2 diabetes; Diabetes mellitus; Placebo; Randomization; Confidence interval; Randomized controlled trial; Sitagliptin; Percutaneous coronary intervention","score_opus":0.015232903882613212,"score_gpt":0.2609513916908713,"score_spread":0.24571848780825806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916543933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985618,0.002536617,0.00022598065,0.010194953,0.00020342266,0.0002531467,0.000004833961,0.000007032653,0.00095599616],"genre_scores_gemma":[0.99687666,0.00045889974,0.00040806353,0.0017993323,0.00014113559,0.000002951802,0.000013070481,0.000016984039,0.0002828967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795496,0.00018215028,0.00062401476,0.000109793706,0.0009239353,0.00020515623],"domain_scores_gemma":[0.99850416,0.00013402614,0.0005162531,0.00037307458,0.000266904,0.00020560542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019021522,0.00015943855,0.0011684415,0.00020685417,0.0000130017515,0.0000023731263,0.00019799548,0.000016323538,0.000035847665],"category_scores_gemma":[0.0005066255,0.00008055959,0.00021180631,0.00038574063,0.00038982273,0.000052848503,0.000044349734,0.00016947983,0.0000053389927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013116763,0.0010601904,0.6496754,0.000052910113,0.0030619444,0.00014628068,0.0013136768,0.00013787877,0.0001664071,0.000027033619,0.08835218,0.25469443],"study_design_scores_gemma":[0.054798767,0.021745102,0.79425406,0.0010363695,0.0056074606,0.00007865101,0.008284155,0.00019501505,0.0009324178,0.00035146184,0.11230853,0.00040800378],"about_ca_topic_score_codex":0.00028601728,"about_ca_topic_score_gemma":0.0000035029154,"teacher_disagreement_score":0.2542864,"about_ca_system_score_codex":0.000119204335,"about_ca_system_score_gemma":0.00006138179,"threshold_uncertainty_score":0.3285125},"labels":[],"label_agreement":null},{"id":"W1919604920","doi":"10.1016/b978-0-12-381517-0.00004-7","title":"K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease","year":2010,"lang":"en","type":"review","venue":"Vitamins and hormones","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gastric inhibitory polypeptide; Incretin; Internal medicine; Endocrinology; Biology; Protein kinase A; Secretin family; Free fatty acid receptor 1; GPR120; Glucagon-like peptide-1; Secretion; Hormone; Signal transduction; Glucagon; Kinase; Biochemistry; Type 2 diabetes; Neuropeptide; Receptor; Vasoactive intestinal peptide; Diabetes mellitus; G protein-coupled receptor; Medicine","score_opus":0.019994573587954534,"score_gpt":0.29034673811021006,"score_spread":0.2703521645222555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1919604920","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015601822,0.9826866,0.0000021278436,0.00028392335,0.00008739168,0.001090362,0.00004578794,0.000028813087,0.00017320747],"genre_scores_gemma":[0.0022309795,0.9957531,0.00016964709,0.00022424036,0.000089396875,0.00007780694,0.00008894359,0.000038540697,0.0013273512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987864,0.000038296526,0.00037438003,0.00037854668,0.00013506164,0.00028732364],"domain_scores_gemma":[0.9989633,0.000058611233,0.00013694192,0.00024599416,0.000010458001,0.0005847211],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001111263,0.00034428822,0.0011209286,0.0002688381,0.00006428095,0.000056565677,0.00004543502,0.00012318155,0.000005529452],"category_scores_gemma":[0.000025157547,0.0002473629,0.00007666194,0.000094595845,0.0000859664,0.000057325004,0.0001321606,0.00023224595,0.0000084936955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015044932,0.00016657704,0.00084405893,0.013688953,0.00007804075,0.00007150277,0.00008013468,3.9948937e-9,0.0000034948168,0.00032768748,0.0001404613,0.98458403],"study_design_scores_gemma":[0.0012336966,0.00044393353,0.0052683265,0.0049451212,0.0006485931,0.000013149847,0.00006223816,0.000003220856,0.0000011339805,0.00006240024,0.98706305,0.00025515564],"about_ca_topic_score_codex":0.00009010132,"about_ca_topic_score_gemma":0.00007327866,"teacher_disagreement_score":0.98692256,"about_ca_system_score_codex":0.000042834672,"about_ca_system_score_gemma":0.00016404146,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W1920830047","doi":"10.1111/dom.12589","title":"Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk; Medtronic; Sanofi-Aventis Korea Company; Janssen Research and Development; Novartis; Eli Lilly and Company","keywords":"Canagliflozin; Medicine; Placebo; Incretin; Type 2 diabetes; Sitagliptin; Glucagon-like peptide 1 receptor; Internal medicine; Pharmacology; Endocrinology; Adverse effect; Dipeptidyl peptidase-4; Urology; Agonist; Diabetes mellitus; Gastroenterology; Receptor","score_opus":0.009532739788251,"score_gpt":0.2029113262920717,"score_spread":0.1933785865038207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1920830047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965313,0.0020383673,0.0000011639781,0.00010481298,0.00005820317,0.00094427576,0.0000070336423,0.000020806485,0.00029401385],"genre_scores_gemma":[0.9990466,0.0002174369,0.0003369982,0.00019587019,0.00001961667,0.000022997603,0.00007150628,0.000019601492,0.00006936711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988586,0.000084852974,0.00022696097,0.0002828869,0.00024961506,0.00029712523],"domain_scores_gemma":[0.9993778,0.000065392676,0.00009218755,0.00019656675,0.00011347559,0.00015461697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033082228,0.00020954663,0.0005826811,0.0002616771,0.000025825571,0.00001784646,0.00004861872,0.000067152905,0.0000119483175],"category_scores_gemma":[0.00005085954,0.00014425784,0.000017543502,0.00031073135,0.00013178222,0.00015129981,0.000041370946,0.00011105317,0.0000016834448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008107373,0.00054929586,0.9890313,0.00006905934,0.00017908473,0.0000020917796,0.0006300297,0.0000054447482,0.000091549184,0.00009557781,0.000033953078,0.0085018845],"study_design_scores_gemma":[0.01933286,0.001278772,0.97635424,0.0001798919,0.00020879529,6.297492e-8,0.000068933325,0.000034496752,0.0009002206,0.000079740494,0.0014002402,0.00016173416],"about_ca_topic_score_codex":0.00025875904,"about_ca_topic_score_gemma":0.0001722557,"teacher_disagreement_score":0.018522123,"about_ca_system_score_codex":0.0000350647,"about_ca_system_score_gemma":0.000048255522,"threshold_uncertainty_score":0.5882664},"labels":[],"label_agreement":null},{"id":"W1924115782","doi":"10.1111/dom.12574","title":"Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk Fonden; Boehringer Ingelheim; F. Hoffmann-La Roche; Novo Nordisk; Intarcia Therapeutics; Biodel; GlaxoSmithKline; Osiris Therapeutics; Halozyme; Sanofi; Quest Diagnostics; Novartis; Pfizer; Orexigen Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Insulin degludec; Medicine; Liraglutide; Glycated haemoglobin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Glycated hemoglobin; Baseline (sea); Endocrinology; Insulin glargine","score_opus":0.04835495310799587,"score_gpt":0.2811609730836879,"score_spread":0.23280601997569206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924115782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.460965,0.5380115,0.0000018421142,0.000013513766,0.000068720066,0.0006530854,0.00024610263,0.0000078902685,0.00003234257],"genre_scores_gemma":[0.22678217,0.77219796,0.0003246466,0.0000152346,0.000028738863,0.000021535987,0.00053198927,0.000025673065,0.00007203204],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782,0.00017347775,0.0010250973,0.0003602252,0.00039460603,0.0002265965],"domain_scores_gemma":[0.997497,0.00017195586,0.0012544786,0.00031738347,0.0006157527,0.00014342632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008966934,0.00038322865,0.0027642867,0.00049209566,0.000029377688,0.000010179786,0.0001014688,0.0002855496,0.00000822719],"category_scores_gemma":[0.00034029182,0.00031361473,0.00015007371,0.0004287993,0.00021928502,0.0001384135,0.00018930796,0.00014978337,7.1462216e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057125777,0.001277306,0.04714717,0.047557082,0.0015474082,0.0000012556508,0.00022595134,0.0000018495246,0.0002676583,0.0014134783,0.00012199904,0.90038174],"study_design_scores_gemma":[0.011707533,0.0017738306,0.83091503,0.033657305,0.026341313,0.0000039203346,0.0001711372,0.00025102208,0.017173668,0.00086409366,0.07602709,0.0011140576],"about_ca_topic_score_codex":0.000044359975,"about_ca_topic_score_gemma":0.0000122069805,"teacher_disagreement_score":0.8992677,"about_ca_system_score_codex":0.000024966725,"about_ca_system_score_gemma":0.00010544664,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W1935699626","doi":"10.1111/j.2040-1124.2012.00214.x","title":"Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels","year":2012,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Japan Diabetes Foundation; Sanofi; Eli Lilly and Company","keywords":"Vildagliptin; Alogliptin; Medicine; Internal medicine; Sitagliptin; Type 2 diabetes; Docosahexaenoic acid; Eicosapentaenoic acid; Glycated hemoglobin; Endocrinology; Diabetes mellitus; Dipeptidyl peptidase-4; Hemoglobin; Dipeptidyl peptidase-4 inhibitor; Gastroenterology; Polyunsaturated fatty acid; Fatty acid; Biochemistry; Chemistry","score_opus":0.009296969331849429,"score_gpt":0.2167458893971066,"score_spread":0.20744892006525717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1935699626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856406,0.00031975884,0.0000027008607,0.00015920395,0.00019710467,0.00065070594,0.000009731847,0.000016929564,0.00007979334],"genre_scores_gemma":[0.99857134,0.00001500756,0.0010933683,0.000055920962,0.0001336764,0.00000834641,0.00006156178,0.000030484887,0.000030317511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979192,0.000117190335,0.000774639,0.00016971226,0.0006599877,0.0003592717],"domain_scores_gemma":[0.99756545,0.00008408563,0.0015143628,0.00016151444,0.00048463608,0.00018996048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007232305,0.00022910214,0.00056801847,0.00044556573,0.000043310836,0.0000196299,0.00007098308,0.000114004055,0.000010208655],"category_scores_gemma":[0.00027200964,0.00017151685,0.000063012245,0.0006692446,0.000118326396,0.00081636175,0.000035593835,0.00022539934,0.000001331042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017383609,0.0005732991,0.950769,0.00026949146,0.0004274293,4.1283278e-7,0.0006719061,0.000043064392,0.04294856,0.000008128742,0.00006609902,0.0040487424],"study_design_scores_gemma":[0.005588128,0.0025965408,0.7868006,0.0013383973,0.0005580556,5.767922e-7,0.00014201393,0.000042041396,0.20276791,0.000023967117,0.000019346675,0.00012238092],"about_ca_topic_score_codex":0.0000028271859,"about_ca_topic_score_gemma":0.0000023607136,"teacher_disagreement_score":0.16396838,"about_ca_system_score_codex":0.0003520322,"about_ca_system_score_gemma":0.00009224075,"threshold_uncertainty_score":0.6994254},"labels":[],"label_agreement":null},{"id":"W1937989175","doi":"10.1038/tpj.2016.4","title":"A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials","year":2016,"lang":"en","type":"review","venue":"The Pharmacogenomics Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; AstraZeneca","keywords":"Furosemide; Acute decompensated heart failure; Medicine; Diuretic; Heart failure; Pharmacogenetics; Regimen; Internal medicine; Pharmacogenomics; Clinical endpoint; Randomized controlled trial; Pharmacology; Loop diuretic; Cardiology; Gene; Biology; Genetics; Genotype","score_opus":0.4364697394533179,"score_gpt":0.4954083222103491,"score_spread":0.05893858275703118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1937989175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060687913,0.9903261,0.0001277839,0.0008104124,0.00027485462,0.0021615478,0.00018518238,0.0000111769605,0.000034162455],"genre_scores_gemma":[0.0036132992,0.99493,0.0005817873,0.00030067156,0.00029585804,0.00008131928,0.00006998299,0.00006459489,0.0000624485],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9906213,0.003135075,0.004963421,0.00039835813,0.00048368835,0.000398101],"domain_scores_gemma":[0.99278915,0.0023157415,0.0038497208,0.0005428385,0.00020888179,0.00029367203],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014224856,0.00054040516,0.009612075,0.0013023125,0.000055854467,0.000030839623,0.00053045165,0.00018670065,0.0009362402],"category_scores_gemma":[0.00031389637,0.00027335988,0.007504657,0.0011557713,0.0002409184,0.000058648624,0.00014697647,0.000729633,0.000027660322],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022501031,0.0003709801,0.0002785313,0.0015762204,0.55489475,0.000049560236,0.00008078337,0.000039544648,0.00094390917,0.00002317426,0.0010708265,0.44044667],"study_design_scores_gemma":[0.00248213,0.00019840752,0.00006457843,0.0007230544,0.808434,0.00008388811,0.000007008701,0.0000922278,0.00029206334,0.00019201414,0.1872118,0.00021884686],"about_ca_topic_score_codex":0.000010659218,"about_ca_topic_score_gemma":0.000019201956,"teacher_disagreement_score":0.44022784,"about_ca_system_score_codex":0.00021767411,"about_ca_system_score_gemma":0.0006231719,"threshold_uncertainty_score":0.99997705},"labels":[],"label_agreement":null},{"id":"W1940665595","doi":"10.18433/j3tk55","title":"Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles – Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin","year":2015,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Alogliptin; Sitagliptin; Vildagliptin; Volume of distribution; Pharmacokinetics; Pharmacology; Allometry; Dipeptidyl peptidase-4 inhibitor; Chemistry; Medicine; Endocrinology; Biology; Diabetes mellitus; Metformin; Type 2 Diabetes Mellitus","score_opus":0.1513553291027484,"score_gpt":0.43107013619631407,"score_spread":0.27971480709356566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940665595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179345,0.0062892656,0.000023193283,0.00021582199,0.00026478816,0.0010358823,0.000018291743,0.000025077277,0.00033420784],"genre_scores_gemma":[0.9958855,0.0014311561,0.0022145424,0.00008698776,0.00030386267,0.00001200139,0.0000016081847,0.000025461919,0.000038888615],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99664265,0.00022438506,0.0011216451,0.0005220211,0.00096134894,0.0005279383],"domain_scores_gemma":[0.99727863,0.00020302687,0.00091866276,0.0001181101,0.00091318856,0.0005683751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022065567,0.0004026461,0.0010354102,0.0009131028,0.00028629508,0.00007426635,0.00014917992,0.000060194525,0.000026334748],"category_scores_gemma":[0.00051624444,0.00030081268,0.00013404261,0.0012091226,0.0016955639,0.0006153291,0.00030977142,0.0004168738,4.6450916e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011078138,0.0015271557,0.76809293,0.0010061708,0.0015139695,0.0011328302,0.006525582,0.00011995478,0.19052745,0.00036371915,0.00026084157,0.02782159],"study_design_scores_gemma":[0.0764162,0.02930896,0.13800277,0.0022934389,0.01841707,0.018561203,0.050532743,0.03419293,0.618863,0.0023160365,0.0083555225,0.0027401552],"about_ca_topic_score_codex":0.00014359546,"about_ca_topic_score_gemma":0.000018450453,"teacher_disagreement_score":0.6300902,"about_ca_system_score_codex":0.00029914564,"about_ca_system_score_gemma":0.0001852453,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W1941427190","doi":"10.1517/14656566.2012.689825","title":"Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea","year":2012,"lang":"en","type":"letter","venue":"Expert Opinion on Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Linagliptin; Medicine; Metformin; Glycemic; Sulfonylurea; Regimen; Type 2 Diabetes Mellitus; Hypoglycemia; Pharmacology; Diabetes mellitus; Internal medicine; Type 2 diabetes; Incretin; Dipeptidyl peptidase-4 inhibitor; Endocrinology","score_opus":0.04079503441523548,"score_gpt":0.3364745502938849,"score_spread":0.29567951587864943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941427190","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16799584,0.251362,0.000040627052,0.553613,0.005709144,0.012052562,0.00010873794,0.00041906716,0.008698994],"genre_scores_gemma":[0.021130987,0.23940285,0.0026297937,0.7245193,0.003641231,0.0011845699,0.0013525145,0.00035826067,0.0057805115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979656,0.00012180149,0.00045153234,0.00046806785,0.00045167073,0.000541365],"domain_scores_gemma":[0.99903834,0.00015726715,0.00021657186,0.00036890456,0.00009436044,0.00012453133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036840653,0.0004536899,0.00077262655,0.0007137858,0.000041066833,0.000031181527,0.0001536102,0.0002803877,0.0004211021],"category_scores_gemma":[0.000014358067,0.00037558717,0.00011244846,0.00039739962,0.000043635268,0.0001582277,0.00003897482,0.00043510777,0.000028778539],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008089589,0.0008799768,0.0007717891,0.00021089721,0.0006477964,0.000016485588,0.00219271,0.0000014492223,0.009331723,0.00019837596,0.757244,0.22769582],"study_design_scores_gemma":[0.0051691565,0.0017659521,0.00018710262,0.0006007748,0.000018746718,9.577783e-7,0.00004864967,0.00004613312,0.03241328,0.000041655032,0.95938015,0.00032744958],"about_ca_topic_score_codex":0.00005104326,"about_ca_topic_score_gemma":5.3604543e-7,"teacher_disagreement_score":0.22736837,"about_ca_system_score_codex":0.00018326912,"about_ca_system_score_gemma":0.00005056002,"threshold_uncertainty_score":0.9998696},"labels":[],"label_agreement":null},{"id":"W1951484771","doi":"10.1007/s00223-015-0037-y","title":"Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs","year":2015,"lang":"en","type":"article","venue":"Calcified Tissue International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide-1; Glucagon; Receptor; Medicine; Exenatide; Glucagon-like peptide 1 receptor; Pharmacology; Chemistry; Internal medicine; Endocrinology; Agonist; Diabetes mellitus; Insulin; Type 2 diabetes","score_opus":0.048066701492611365,"score_gpt":0.3113736116756965,"score_spread":0.2633069101830851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1951484771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997177,0.000118400305,0.00025013,0.00047861462,0.0003431969,0.00037474747,0.00015933033,0.00001808259,0.0010804965],"genre_scores_gemma":[0.9885531,0.00006540503,0.004141914,0.00030723022,0.00006200343,0.000012165718,0.000127168,0.000021218368,0.0067098117],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891955,0.000030380668,0.00034446342,0.00020647413,0.00037640307,0.00012274041],"domain_scores_gemma":[0.9989515,0.0001159343,0.00022972135,0.00024314954,0.00031931608,0.00014040478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009633962,0.00014090707,0.00036708915,0.00017765048,0.000011662028,0.000017388862,0.00010656155,0.00006601809,0.00022635658],"category_scores_gemma":[0.00020222024,0.000120933684,0.000060816437,0.000098414464,0.00009519992,0.00013527538,0.0000799332,0.000072788454,0.00003680898],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046080733,0.002161539,0.6920415,0.00030481748,0.004880247,0.000042953347,0.007653285,0.0013822954,0.09876512,0.0029388778,0.1627217,0.022499613],"study_design_scores_gemma":[0.0042521283,0.0006939482,0.08432043,0.00044088965,0.00044787882,0.000006255549,0.00034742148,0.00036257342,0.16288315,0.000118510055,0.74588984,0.00023695204],"about_ca_topic_score_codex":0.0011122273,"about_ca_topic_score_gemma":0.000012819662,"teacher_disagreement_score":0.6077211,"about_ca_system_score_codex":0.000059446822,"about_ca_system_score_gemma":0.00004314453,"threshold_uncertainty_score":0.49315324},"labels":[],"label_agreement":null},{"id":"W1953794210","doi":"10.1111/dom.12543","title":"Durability and tolerability of dapagliflozin over 52 weeks as add‐on to metformin and sulphonylurea in type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Dapagliflozin; Placebo; Metformin; Tolerability; Medicine; Internal medicine; Adverse effect; Type 2 diabetes; Diabetes mellitus; Endocrinology; Urology; Gastroenterology","score_opus":0.015671699916392244,"score_gpt":0.2562610136405628,"score_spread":0.24058931372417056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1953794210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922786,0.0050145555,7.4773266e-7,0.00043728008,0.0001735436,0.0008593373,0.000029750061,0.00003564061,0.001170583],"genre_scores_gemma":[0.99816936,0.00029635063,0.0004295803,0.00073961104,0.00005360302,0.000041295156,0.00002776403,0.000017685057,0.00022473032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982853,0.000100900135,0.0003789291,0.0005241337,0.00029312956,0.00041760298],"domain_scores_gemma":[0.9987682,0.00016943563,0.000084220526,0.00040264823,0.00012095786,0.00045454045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095802435,0.00029103376,0.0008906838,0.00024639769,0.000047168567,0.000035890273,0.0000772301,0.00012801189,0.00004065226],"category_scores_gemma":[0.00059527473,0.00023833432,0.00005801137,0.00033341566,0.00019418582,0.00020481896,0.00019837837,0.00015730334,0.000009901941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020026659,0.0006971322,0.96260935,0.0003202915,0.00016360833,0.0000050872836,0.00080543524,0.0000018074619,0.0014956595,0.0015929325,0.00048737222,0.031621046],"study_design_scores_gemma":[0.0028781232,0.0007018813,0.97321206,0.00010113651,0.0003088575,4.904121e-7,0.00013720233,0.00006531659,0.010824176,0.0028324923,0.008702658,0.00023560198],"about_ca_topic_score_codex":0.00016109367,"about_ca_topic_score_gemma":0.00006332619,"teacher_disagreement_score":0.031385444,"about_ca_system_score_codex":0.000043109605,"about_ca_system_score_gemma":0.000048490776,"threshold_uncertainty_score":0.97189915},"labels":[],"label_agreement":null},{"id":"W1955483128","doi":"10.1016/s2213-8587(15)00329-0","title":"Heart failure: fatal, forgotten, and frequent in type 1 diabetes too","year":2015,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Population; Disease; Macrovascular disease; Ageing; Cohort; Internal medicine; Pediatrics; Endocrinology","score_opus":0.034930682609626285,"score_gpt":0.27431237131636005,"score_spread":0.23938168870673376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1955483128","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33126742,0.00922433,2.3530349e-7,0.6557211,0.00065542135,0.0010487328,0.000051550025,0.00017409158,0.0018570686],"genre_scores_gemma":[0.070927665,0.0011628815,0.00067448686,0.916363,0.004652312,0.0005509148,0.0013951334,0.00017909578,0.004094497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957028,0.00022084762,0.0004672428,0.0007477334,0.00037807768,0.002483267],"domain_scores_gemma":[0.9980928,0.00032770255,0.00016625698,0.0011823886,0.000113024566,0.00011784328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040727342,0.0006290365,0.0017098725,0.0003424657,0.00007625519,0.000072655,0.00044935994,0.00043465005,0.0001128812],"category_scores_gemma":[0.00015650147,0.00043589386,0.00014398339,0.0003019393,0.0004108171,0.00010290549,0.00044696746,0.0016138111,0.00027819996],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022742806,0.00006267819,0.091207534,0.00032827567,0.0005343737,0.00019808453,0.00005314849,8.443457e-7,0.00016701437,0.00018579321,0.9045511,0.002688454],"study_design_scores_gemma":[0.002414936,0.0007023494,0.011644,0.00018777579,0.0005508534,0.000014698856,0.000032568933,0.00002121057,0.00052672403,0.001960191,0.98153275,0.00041195017],"about_ca_topic_score_codex":0.000044687415,"about_ca_topic_score_gemma":0.00003783928,"teacher_disagreement_score":0.26064187,"about_ca_system_score_codex":0.00020234252,"about_ca_system_score_gemma":0.00009377844,"threshold_uncertainty_score":0.99980927},"labels":[],"label_agreement":null},{"id":"W1955912841","doi":"","title":"Incretin agents in type 2 diabetes.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Incretin; Metformin; Medicine; Type 2 diabetes; Glycated hemoglobin; Hypoglycemia; Diabetes mellitus; Exenatide; Pharmacology; Cochrane Library; MEDLINE; Liraglutide; Internal medicine; Bioinformatics; Meta-analysis; Endocrinology; Chemistry; Biology; Biochemistry","score_opus":0.021892920551749857,"score_gpt":0.23968291044631576,"score_spread":0.2177899898945659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1955912841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94612336,0.00006866722,1.6578355e-7,0.0008207405,0.00043259666,0.00064588716,6.7709306e-7,0.00004532393,0.051862583],"genre_scores_gemma":[0.993086,0.000018735213,0.00010495243,0.00074828963,0.00008475711,0.0005143038,0.000021590551,0.000011839791,0.005409526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993508,0.0000084855,0.00010080676,0.00013682262,0.00010989161,0.00029318378],"domain_scores_gemma":[0.99965864,0.000015205419,0.000020528018,0.00018757096,0.000016635136,0.0001014281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018818541,0.000073693205,0.00012827184,0.000101447215,0.000011409899,0.000011741748,0.00005350739,0.000042196923,0.0001800235],"category_scores_gemma":[0.000096551805,0.000061641724,0.00002791458,0.00016935889,0.000021931124,0.00003930283,0.000042289517,0.00011315547,0.00012282176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022751274,0.0001783668,0.70760536,0.000026325599,0.00004930825,0.000024895133,0.000023982348,1.6086634e-7,0.00012990115,0.00023571597,0.007641982,0.28406128],"study_design_scores_gemma":[0.00088708644,0.000022299082,0.90176195,0.000004673425,0.00003577653,2.4256792e-7,0.000003821076,0.000017089318,0.0006967296,0.00007569867,0.096440196,0.00005443379],"about_ca_topic_score_codex":0.000011869973,"about_ca_topic_score_gemma":0.000028305718,"teacher_disagreement_score":0.28400683,"about_ca_system_score_codex":0.00002880223,"about_ca_system_score_gemma":0.0000074638424,"threshold_uncertainty_score":0.25136766},"labels":[],"label_agreement":null},{"id":"W1958078430","doi":"10.2337/dc15-0733","title":"Erroneous Diabetes Diagnosis: A Case of HbA1c Interference","year":2015,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Diabetes mellitus; Insulin glargine; Metformin; Glycemic; Hypoglycemia; Internal medicine; Type 2 diabetes; Family history; Insulin; Pediatrics; Endocrinology; Gastroenterology","score_opus":0.020559896724903427,"score_gpt":0.25695915008671905,"score_spread":0.2363992533618156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958078430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8707658,0.021697156,0.0000012800398,0.08731587,0.0017180168,0.0029898062,0.0016379497,0.0004511795,0.013422926],"genre_scores_gemma":[0.7888802,0.00018128651,0.00032225845,0.19964041,0.0019860642,0.001434244,0.0046849204,0.00025024058,0.0026203387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969989,0.00010702959,0.00062017154,0.00079541205,0.00053556915,0.0009428914],"domain_scores_gemma":[0.99738824,0.00024230641,0.00036370996,0.0011980132,0.00058221875,0.00022551262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013666431,0.0007529374,0.0015002694,0.00047642362,0.000057940855,0.000058390957,0.00034122702,0.00071342103,0.00027532785],"category_scores_gemma":[0.00017108297,0.00064922986,0.0004819898,0.00029096758,0.00022153926,0.00010330033,0.0003259505,0.0009584142,0.00037455696],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009010052,0.00013418843,0.13494842,0.0039947336,0.0010994553,0.004819251,0.000755342,0.0000011537335,0.000017212747,0.000004113694,0.83691156,0.017305585],"study_design_scores_gemma":[0.0025322633,0.0027816717,0.0010054006,0.0038900326,0.005425474,0.00003942879,0.0014823041,0.00005276619,0.0034428334,0.00015104165,0.9780551,0.001141655],"about_ca_topic_score_codex":0.000035200293,"about_ca_topic_score_gemma":0.000021823784,"teacher_disagreement_score":0.14114359,"about_ca_system_score_codex":0.00034423062,"about_ca_system_score_gemma":0.00015635762,"threshold_uncertainty_score":0.9995959},"labels":[],"label_agreement":null},{"id":"W1963922290","doi":"10.1007/s00592-008-0049-4","title":"Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals","year":2008,"lang":"en","type":"article","venue":"Acta Diabetologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Université Laval","funders":"Canadian Institutes of Health Research; Université Laval","keywords":"Internal medicine; Incretin; Obesity; Diabetes mellitus; Endocrinology; Type 2 diabetes; Single-nucleotide polymorphism; Medicine; Odds ratio; Triglyceride; Dipeptidyl peptidase-4; Metabolic syndrome; Disease; Cholesterol; Genotype; Biology; Genetics; Gene","score_opus":0.02409863990089667,"score_gpt":0.22903501858994743,"score_spread":0.20493637868905076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963922290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951668,0.0037856733,0.0000039880547,0.00008641971,0.000040567327,0.00062409055,0.00008549619,0.000027157632,0.00017982323],"genre_scores_gemma":[0.9971778,0.002267114,0.00021950029,0.000118884476,0.000015900314,0.000045952074,0.000067047076,0.000012416086,0.00007538966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984281,0.00018129444,0.0002961763,0.0004157665,0.00037345418,0.00030518923],"domain_scores_gemma":[0.9987121,0.00015847401,0.00012438375,0.0007852234,0.00005886026,0.00016092535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106679574,0.00022879522,0.00082578434,0.000296057,0.0001049089,0.000009082998,0.00016042129,0.0000725234,0.000063085514],"category_scores_gemma":[0.00015622447,0.00013799134,0.0005559912,0.000819402,0.0002655852,0.000046711637,0.00020374104,0.00012752174,0.0000030346926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015504938,0.0002754058,0.99134755,0.00003429187,0.0063439207,0.000051427134,0.0003252739,0.0004664345,0.00019937885,0.0000049028795,0.00012749872,0.0008084038],"study_design_scores_gemma":[0.00095348305,0.00010174447,0.9887787,0.000022861297,0.007962924,8.068869e-7,0.0001328701,0.00020157227,0.000580418,0.000031938896,0.0010970333,0.00013566241],"about_ca_topic_score_codex":0.00014489821,"about_ca_topic_score_gemma":0.000008089963,"teacher_disagreement_score":0.0025688715,"about_ca_system_score_codex":0.0000344863,"about_ca_system_score_gemma":0.000026122098,"threshold_uncertainty_score":0.5627124},"labels":[],"label_agreement":null},{"id":"W1964080099","doi":"10.1152/ajpgi.00024.2010","title":"Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut","year":2010,"lang":"en","type":"article","venue":"American Journal of Physiology-Gastrointestinal and Liver Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gastric inhibitory polypeptide; Enteroendocrine cell; Proglucagon; Pancreatic polypeptide; Peptide; Kexin; Population; Internal medicine; Subtilisin; Biochemistry; Proprotein convertase; Biology; Peptide sequence; Endocrinology; Somatostatin; Gastrointestinal hormone; Chemistry; Peptide hormone; Glucagon-like peptide-1; Hormone; Glucagon; Enzyme; Gene; Endocrine system; Lipoprotein; Cholesterol; Medicine","score_opus":0.007660519873012452,"score_gpt":0.23645468900815464,"score_spread":0.2287941691351422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964080099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999288,0.00012098994,0.00006263136,0.0001615561,0.00009758843,0.00017008555,0.0000029711623,0.000011645186,0.000084489635],"genre_scores_gemma":[0.9933176,0.00007212864,0.0061741387,0.000116160285,0.00025615582,0.000006327316,0.0000069101693,0.000016986332,0.00003356424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99862754,0.000086703185,0.0005278397,0.00026297887,0.0001486421,0.0003462847],"domain_scores_gemma":[0.9987659,0.000088285815,0.0006658333,0.00016368521,0.00017579134,0.00014054382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089308254,0.00022743159,0.0008242012,0.0002449061,0.000036386624,0.0000062874055,0.00015360094,0.00003615137,0.00008617497],"category_scores_gemma":[0.00006328914,0.00016458423,0.00013364454,0.0001631078,0.00065536634,0.000098731995,0.00010832949,0.00051323924,0.0000041601984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010183833,0.0006655296,0.025355339,0.00011040465,0.00008269633,0.0000392553,0.00015266222,0.000008376367,0.9426003,0.00016335744,0.000015382266,0.029788285],"study_design_scores_gemma":[0.0021783987,0.006298141,0.9795709,0.00026444226,0.0001654432,0.0005205594,0.00034500062,0.00024612265,0.009796717,0.0004346725,0.000047741516,0.00013185908],"about_ca_topic_score_codex":0.00009921077,"about_ca_topic_score_gemma":0.000018422043,"teacher_disagreement_score":0.9542156,"about_ca_system_score_codex":0.000025262958,"about_ca_system_score_gemma":0.00010206403,"threshold_uncertainty_score":0.671155},"labels":[],"label_agreement":null},{"id":"W1964165815","doi":"10.1139/cjpp-2013-0095","title":"Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Aliskiren; Internal medicine; Endocrinology; Endothelin receptor; Diabetes mellitus; Insulin; Medicine; Type 2 diabetes; Endothelium; Endothelin 1; Receptor; Chemistry; Renin–angiotensin system; Blood pressure","score_opus":0.016244772260615024,"score_gpt":0.2719876890456915,"score_spread":0.25574291678507644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964165815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552935,0.0014325057,3.2034228e-7,0.0019400924,0.0006115006,0.00026035839,0.000007675616,0.000003555869,0.00021461507],"genre_scores_gemma":[0.9977973,0.00050161744,0.000032967033,0.0011930172,0.00019984209,0.000007794331,0.000015822521,0.000011176249,0.0002404309],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99921316,0.000116677824,0.00021345448,0.00013507114,0.000035542427,0.00028610407],"domain_scores_gemma":[0.9992785,0.00012676636,0.0001052712,0.00006336544,0.00006561195,0.00036050097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015020178,0.00013968992,0.00034284664,0.00034119678,0.00006451077,0.000010476945,0.000047069683,0.000088724344,0.0030589628],"category_scores_gemma":[0.00002197597,0.000096702,0.00004533917,0.00010635423,0.00013454638,0.000088899425,0.00001057282,0.00021228608,0.000038106253],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059981016,0.00015280728,0.067649186,0.00010952021,0.00059251965,0.0001007657,0.00094346487,0.000066421,0.8725012,0.0002565422,0.034743503,0.02228425],"study_design_scores_gemma":[0.0102872,0.0060094986,0.7942041,0.00023132809,0.0003902813,0.0001608023,0.0002560549,0.00036411028,0.15534775,0.0034393836,0.028859569,0.0004499228],"about_ca_topic_score_codex":0.00031933162,"about_ca_topic_score_gemma":0.0001600571,"teacher_disagreement_score":0.72655493,"about_ca_system_score_codex":0.00009738265,"about_ca_system_score_gemma":0.0001846933,"threshold_uncertainty_score":0.9978524},"labels":[],"label_agreement":null},{"id":"W1964298425","doi":"10.1111/bcpt.12240","title":"At the Centennial of Michaelis and Menten, Competing Michaelis–Menten Steps Explain Effect of <scp>GLP</scp>‐1 on Blood–Brain Transfer and Metabolism of Glucose","year":2014,"lang":"en","type":"review","venue":"Basic & Clinical Pharmacology & Toxicology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Neuroprotection; Incretin; Endocrinology; Carbohydrate metabolism; Michaelis–Menten kinetics; Metabolism; Internal medicine; Glucagon-like peptide-1; Glucose homeostasis; Dipeptidyl peptidase; Diabetes mellitus; Receptor; Biology; Medicine; Enzyme; Biochemistry; Type 2 diabetes; Enzyme assay; Insulin resistance","score_opus":0.03670356669476969,"score_gpt":0.3761592882033209,"score_spread":0.3394557215085512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964298425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4265878,0.5675661,0.0000058922305,0.00067747233,0.001085999,0.003517878,0.00013957937,0.000026024309,0.0003932602],"genre_scores_gemma":[0.018699354,0.97608745,0.00008624607,0.0031462463,0.0005074459,0.0004246122,0.00019098437,0.000105144725,0.0007524884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916383,0.0035858292,0.002629969,0.0010583979,0.00036397288,0.0007235449],"domain_scores_gemma":[0.98215324,0.015730359,0.0011006866,0.00056496885,0.0001334674,0.00031726056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038971123,0.00084940525,0.006256146,0.00037657865,0.000101329744,0.000006389643,0.0004318082,0.0007827789,0.00015737713],"category_scores_gemma":[0.00087280944,0.00054281036,0.0010788483,0.0002578034,0.0018344416,0.00004037247,0.0005469571,0.00081575924,0.000012768537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028220313,0.007499533,0.005089785,0.045364887,0.028601652,0.00027441897,0.0006665624,0.0000023498728,0.012267531,0.0008483094,0.03577223,0.8607907],"study_design_scores_gemma":[0.02390554,0.0127869295,0.0010832151,0.0031286175,0.045517504,0.000074537995,0.00007625201,0.000029003657,0.006115198,0.000019181774,0.90697473,0.00028926638],"about_ca_topic_score_codex":0.000019735922,"about_ca_topic_score_gemma":0.000025615944,"teacher_disagreement_score":0.8712025,"about_ca_system_score_codex":0.000061113846,"about_ca_system_score_gemma":0.00011813061,"threshold_uncertainty_score":0.99970233},"labels":[],"label_agreement":null},{"id":"W1964575982","doi":"10.1016/j.bbrc.2007.08.115","title":"Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat","year":2007,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Islet; Gastric inhibitory polypeptide; Receptor; Medicine; Downregulation and upregulation; Insulin resistance; Messenger RNA; Diabetes mellitus; Insulin; Chemistry; Gene; Glucagon; Biochemistry","score_opus":0.04467969071408641,"score_gpt":0.35504136209460807,"score_spread":0.3103616713805217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964575982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758642,0.0009323564,0.000018745011,0.019859152,0.00000858812,0.0005038936,0.000011684958,0.000010024759,0.0027913738],"genre_scores_gemma":[0.9952569,0.0004602298,0.0030485743,0.00019070756,0.000040894076,0.0000421546,0.000091909664,0.000006523081,0.00086209626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988957,0.000106832245,0.00020315035,0.00020333953,0.0003483779,0.00024257014],"domain_scores_gemma":[0.9984995,0.00057892996,0.000028778479,0.0006544051,0.00011606726,0.00012230905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008365204,0.00008387812,0.00015588933,0.00009606755,0.00011851391,0.000023315037,0.00025021145,0.000059365248,0.000009137111],"category_scores_gemma":[0.00032222888,0.000057339454,0.000030731586,0.0005543113,0.00045973534,0.00004410985,0.00023997092,0.0002468978,0.000008132289],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025655865,0.00040737537,0.00042469453,0.000055756096,0.000018723682,6.013127e-7,0.00041807003,1.9845746e-8,0.9524979,0.0052525164,0.03635439,0.00431341],"study_design_scores_gemma":[0.0028812373,0.00093753886,0.05134071,0.000813122,0.000117172916,0.0000022705515,0.0012987686,0.000109970184,0.7320487,0.00222596,0.20786138,0.0003631601],"about_ca_topic_score_codex":0.000107640306,"about_ca_topic_score_gemma":0.000017831077,"teacher_disagreement_score":0.22044918,"about_ca_system_score_codex":0.000060068352,"about_ca_system_score_gemma":0.000021550795,"threshold_uncertainty_score":0.23382351},"labels":[],"label_agreement":null},{"id":"W1966210362","doi":"10.1097/00005344-200407000-00011","title":"Formulation Dependent Pharmacokinetics–Does the Dosage Form Matter for Nifedipine?","year":2004,"lang":"en","type":"article","venue":"Journal of Cardiovascular Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cmax; Nifedipine; Pharmacokinetics; Crossover study; Pharmacology; Medicine; Capsule; Chemistry; Internal medicine; Placebo; Calcium","score_opus":0.011520908003989553,"score_gpt":0.283094210097798,"score_spread":0.2715733020938085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966210362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9192052,0.01096807,0.043363336,0.015280364,0.0051001483,0.0031208568,0.00001461473,0.000042286512,0.0029051108],"genre_scores_gemma":[0.99327964,0.0010034273,0.0013313631,0.0022513075,0.001708827,0.00006851524,0.000008811266,0.000029774184,0.00031831776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862385,0.000049443406,0.00044282063,0.00014877666,0.00043566892,0.00029944116],"domain_scores_gemma":[0.9991606,0.00005781142,0.00021289842,0.00019361456,0.00026002977,0.0001150708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007941038,0.00017236933,0.00049567263,0.00015990136,0.000090827154,0.000023463184,0.00015998531,0.000061401486,0.00018324157],"category_scores_gemma":[0.00001548599,0.000093879986,0.0011594507,0.000097146236,0.000040612213,0.00016558327,0.0000476369,0.00018813577,0.000024326559],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008088245,0.0047147656,0.017589344,0.0024833253,0.21439768,0.002915731,0.002779169,0.082462914,0.121308886,0.002050358,0.15788239,0.3833272],"study_design_scores_gemma":[0.04677352,0.0013676904,0.011054982,0.00009519178,0.029410847,0.0009274654,0.00016275945,0.00026785507,0.14880462,0.002259853,0.75853413,0.0003410937],"about_ca_topic_score_codex":0.000004186055,"about_ca_topic_score_gemma":8.1429016e-7,"teacher_disagreement_score":0.60065174,"about_ca_system_score_codex":0.00019231647,"about_ca_system_score_gemma":0.00007146348,"threshold_uncertainty_score":0.38283148},"labels":[],"label_agreement":null},{"id":"W1966393035","doi":"10.1016/j.jcjd.2014.07.076","title":"Assessing Barrier to Carbohydrate Counting in Adults with Diabetes on Intensive Insulin Therapy","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dosing; Insulin; Diabetes mellitus; Intensive care medicine; Insulin delivery; Carbohydrate; Endocrinology; Internal medicine; Type 1 diabetes","score_opus":0.010550253161475981,"score_gpt":0.22944979658076872,"score_spread":0.21889954341929274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966393035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950263,0.0004760165,0.0000039500014,0.0018064042,0.00023661423,0.00031438647,0.0000038460375,0.0000095300675,0.0021229598],"genre_scores_gemma":[0.9930398,0.0000068892637,0.00032638744,0.0063130953,0.00019556587,0.000013587412,0.0000067511182,0.000038622416,0.00005929367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985538,0.000063963416,0.00035938807,0.00020503222,0.00023716259,0.0005806255],"domain_scores_gemma":[0.9983211,0.00013535886,0.00018540051,0.00020221555,0.00043117863,0.0007247361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043810124,0.00022438982,0.00049158966,0.00082050933,0.00007499769,0.00012843765,0.00013666874,0.000060843897,0.000040207353],"category_scores_gemma":[0.0004200222,0.00016487754,0.00008128803,0.00038103276,0.000065941604,0.00024455463,0.000009650788,0.00024623144,0.000013971824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035822854,0.000047948863,0.95097446,0.00005808795,0.00021868534,0.000055562094,0.0009376366,0.0001485336,0.0010432993,0.000071464856,0.0006518049,0.045756713],"study_design_scores_gemma":[0.0067929085,0.0046873437,0.9629698,0.0055675204,0.00015898896,0.0000012741478,0.0016292414,0.00067261554,0.007892344,0.00014668133,0.009013288,0.00046799125],"about_ca_topic_score_codex":0.00022958966,"about_ca_topic_score_gemma":0.002873085,"teacher_disagreement_score":0.045288723,"about_ca_system_score_codex":0.00024312519,"about_ca_system_score_gemma":0.00035476638,"threshold_uncertainty_score":0.67235106},"labels":[],"label_agreement":null},{"id":"W1967064223","doi":"10.3810/pgm.2014.01.2720","title":"Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor","year":2014,"lang":"en","type":"article","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Medicine; Placebo; Discontinuation; Urinary system; Internal medicine; Population; Diabetes mellitus; Renal glucose reabsorption; Incidence (geometry); Gastroenterology; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.027617436561785915,"score_gpt":0.32611297743754386,"score_spread":0.29849554087575797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967064223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857251,0.0024705725,0.00011317788,0.0054023494,0.00055222993,0.0016832211,0.0000052683076,0.0000797265,0.0039683534],"genre_scores_gemma":[0.9948532,0.0028970274,0.00007627771,0.0006715576,0.00034350663,0.00015366716,0.00017990638,0.000030462901,0.0007943673],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997807,0.00016962948,0.0009129919,0.0003384004,0.0004232598,0.00034871194],"domain_scores_gemma":[0.99878556,0.00031297337,0.00026535484,0.00032322112,0.0001556203,0.00015727305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014206651,0.0003158675,0.0017850777,0.00054733496,0.000042828226,0.000003839439,0.00006162724,0.000066708824,0.000079396144],"category_scores_gemma":[0.00037605726,0.00021177293,0.00019941467,0.00032864162,0.00041929405,0.000101247744,0.000020823829,0.00017387334,0.000014900903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43158066,0.037960745,0.21422541,0.009573735,0.011254794,0.0030572745,0.031245578,0.00003294941,0.03593718,0.0034825236,0.037972197,0.18367694],"study_design_scores_gemma":[0.935128,0.008607894,0.025669452,0.0023434162,0.0035659452,0.00004365626,0.00051383994,0.00065002893,0.011847874,0.00071583706,0.010503359,0.0004107344],"about_ca_topic_score_codex":0.0015516304,"about_ca_topic_score_gemma":0.00017148149,"teacher_disagreement_score":0.5035473,"about_ca_system_score_codex":0.00011361596,"about_ca_system_score_gemma":0.000038348026,"threshold_uncertainty_score":0.86358494},"labels":[],"label_agreement":null},{"id":"W1967225560","doi":"10.1096/fj.02-0243fje","title":"A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells","year":2002,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Killam Trusts; Canada Foundation for Innovation; Health Research Foundation; Badan Riset dan Inovasi Nasional; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Pancreas; Islet; Receptor; Gastric inhibitory polypeptide; Pancreatic islets; Downregulation and upregulation; Biology; Insulin; Secretion; Carbohydrate metabolism; Chemistry; Biochemistry; Gene; Medicine; Glucagon","score_opus":0.02462059966813528,"score_gpt":0.23518667566066653,"score_spread":0.21056607599253124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967225560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463385,0.0005322152,0.0025604982,0.00066567253,0.00023380815,0.0005189711,0.0000101187625,0.00001083359,0.00083403074],"genre_scores_gemma":[0.9913371,0.0001869365,0.0049908473,0.000114686976,0.00017367164,0.000017156615,0.000007998084,0.000013141245,0.00315844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991813,0.000029745086,0.00028910013,0.00009735739,0.00022696797,0.00017555951],"domain_scores_gemma":[0.99949336,0.0000536704,0.00017315269,0.00016859961,0.000049772698,0.000061441875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023827919,0.00009443547,0.00017790047,0.000111160756,0.000059839644,0.000014932572,0.000086024644,0.000038293332,0.00028732303],"category_scores_gemma":[0.000030951862,0.000058097903,0.00009238681,0.00008775103,0.0000245805,0.00007603324,0.000026008482,0.00011577695,0.000019430958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015313466,0.00041086687,0.0009464302,0.000029627781,0.000044680968,0.0000031461493,0.0003830173,0.00007060599,0.9766951,0.00008367249,0.0012177714,0.019961929],"study_design_scores_gemma":[0.0047081043,0.00047216672,0.007684173,0.00027220178,0.00007214384,0.00001295226,0.00018952174,0.0009891412,0.983332,0.00013796936,0.0020592997,0.0000703588],"about_ca_topic_score_codex":0.0000057080856,"about_ca_topic_score_gemma":0.0000035253097,"teacher_disagreement_score":0.019891571,"about_ca_system_score_codex":0.000090431065,"about_ca_system_score_gemma":0.000015253911,"threshold_uncertainty_score":0.31459856},"labels":[],"label_agreement":null},{"id":"W1967256054","doi":"10.1038/nrendo.2009.48","title":"Incretin-based therapies for type 2 diabetes mellitus","year":2009,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":649,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Incretin; Exenatide; Medicine; Sitagliptin; Type 2 Diabetes Mellitus; Hypoglycemia; Diabetes mellitus; Type 2 diabetes; Dipeptidyl peptidase-4; Saxagliptin; Pharmacology; Bioinformatics; Endocrinology; Biology","score_opus":0.05721304953315942,"score_gpt":0.37895844427258946,"score_spread":0.32174539473943004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967256054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013551335,0.9891496,0.000007949611,0.0006349573,0.000764784,0.0065888823,0.000028353534,0.00016159003,0.0026625863],"genre_scores_gemma":[0.0000026778243,0.9890713,0.0032216725,0.002822588,0.000560254,0.0011984039,0.0013536314,0.00009656643,0.0016729246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969146,0.00029494066,0.0009231838,0.00078959804,0.00018850973,0.00088915054],"domain_scores_gemma":[0.9977694,0.00044764215,0.0005511075,0.0009592662,0.0001364664,0.00013609548],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003137906,0.0008607685,0.0049539297,0.00044427207,0.000076605575,0.00002661697,0.0003628072,0.0008392352,0.00013964555],"category_scores_gemma":[0.0003837574,0.00054962625,0.001502274,0.00046193332,0.000092498,0.000031963926,0.000060327817,0.0010076034,0.00030699832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016532027,0.00014191633,0.0000068136087,0.031013075,0.00070554885,0.000024582478,0.000003413259,1.6370432e-8,3.546927e-7,0.0016402141,0.01880447,0.94764304],"study_design_scores_gemma":[0.0008021446,0.0009025406,0.0000054265297,0.012179603,0.006823214,0.000012512155,0.0000010401413,0.0000010348524,0.000005969942,0.00011971349,0.9787418,0.00040495658],"about_ca_topic_score_codex":9.1961215e-7,"about_ca_topic_score_gemma":0.0000014689906,"teacher_disagreement_score":0.9599374,"about_ca_system_score_codex":0.00019421005,"about_ca_system_score_gemma":0.0001991896,"threshold_uncertainty_score":0.99969554},"labels":[],"label_agreement":null},{"id":"W1967442749","doi":"10.1016/j.cmet.2013.04.008","title":"Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action","year":2013,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1459,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Incretin; Hormone; Receptor; Glucagon-like peptide-1; Biology; Type 2 diabetes; Bioinformatics; Endocrinology; Medicine; Internal medicine; Diabetes mellitus","score_opus":0.039661154981641904,"score_gpt":0.32374206820079743,"score_spread":0.2840809132191555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967442749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054138224,0.994997,0.000033810604,0.000022076241,0.0005672114,0.0016982744,0.000015954529,0.000044311,0.0020799278],"genre_scores_gemma":[0.00019631788,0.9943817,0.0010011306,0.000092628194,0.00025292477,0.00031949338,0.00017693272,0.000046834582,0.0035320101],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875546,0.00012063885,0.00039280127,0.00036134387,0.00012076508,0.000248988],"domain_scores_gemma":[0.99914455,0.00006078653,0.00037163522,0.00026177452,0.000047379614,0.00011386427],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015380766,0.00036182825,0.0019342784,0.00023730527,0.00003057963,0.000007919134,0.000100757905,0.00026144972,0.00035581243],"category_scores_gemma":[0.000007815051,0.00025699785,0.00027959552,0.00014866925,0.000094630734,0.000052280197,0.0001493842,0.00022881936,0.00015804569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016563303,0.00024011168,1.6765246e-7,0.017148195,0.00091526937,0.000006668859,0.000015839816,2.4471026e-8,0.015359466,0.0009958615,0.008602692,0.95669913],"study_design_scores_gemma":[0.0010102256,0.00013018677,0.000034039767,0.00045019298,0.010698917,0.0000053719136,0.000014194016,0.0000023618234,0.0031625966,0.00032251916,0.9839874,0.00018199185],"about_ca_topic_score_codex":0.000016518004,"about_ca_topic_score_gemma":1.0853071e-7,"teacher_disagreement_score":0.9753847,"about_ca_system_score_codex":0.000027461865,"about_ca_system_score_gemma":0.00004642949,"threshold_uncertainty_score":0.9999882},"labels":[],"label_agreement":null},{"id":"W1969520817","doi":"10.1001/jama.2011.946","title":"Fibrate Use in the United States and Canada","year":2011,"lang":"en","type":"letter","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fibrate; Fenofibrate; Medical prescription; Diabetes mellitus; Value (mathematics); MEDLINE; Family medicine; Internal medicine; Pharmacology; Statin; Endocrinology; Law","score_opus":0.021445550928138827,"score_gpt":0.213592080006893,"score_spread":0.19214652907875418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969520817","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28034043,0.00011343449,4.650103e-7,0.71514976,0.000112517715,0.00045001664,0.000043240303,0.000015482643,0.003774631],"genre_scores_gemma":[0.0032397949,0.00023088627,0.00003931484,0.9774506,0.0003315277,0.000031747488,0.001923189,0.000019266598,0.016733687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939644,0.00004134738,0.00009655201,0.0001370233,0.00014760319,0.00018104834],"domain_scores_gemma":[0.99958265,0.00011018486,0.00003804405,0.00022685931,0.00002037858,0.000021903503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056521953,0.00012932354,0.000162905,0.00010176537,0.00001701043,0.000047638572,0.000066725945,0.000102443344,0.000065797074],"category_scores_gemma":[0.000019059671,0.00007570935,0.000017423814,0.00008141412,0.000022477849,0.000040270425,0.000029782148,0.0003489708,0.0000061653577],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010290329,0.000011516297,0.00826607,0.0000940906,0.00008391109,0.0013677183,0.00013739396,1.9829402e-7,1.967589e-7,0.000016840368,0.9891074,0.0009043941],"study_design_scores_gemma":[0.0006981729,0.00006203185,0.026570315,0.000089812194,0.00012609398,0.0000029633272,0.000060914103,0.000014461639,0.0000060658067,0.00004107801,0.97225195,0.00007612423],"about_ca_topic_score_codex":0.78737104,"about_ca_topic_score_gemma":0.4312227,"teacher_disagreement_score":0.35614836,"about_ca_system_score_codex":0.000052557138,"about_ca_system_score_gemma":0.000054623426,"threshold_uncertainty_score":0.579156},"labels":[],"label_agreement":null},{"id":"W1970177788","doi":"10.4021//jmc.v2i2.143","title":"Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50 to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Glycemic; Internal medicine; Endocrinology; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Diabetes mellitus; Type 2 Diabetes Mellitus; Glucagon; Meal","score_opus":0.01594281236806576,"score_gpt":0.2710979690301371,"score_spread":0.25515515666207134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970177788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912005,0.00184677,0.00026755346,0.00449512,0.000586506,0.00086111063,0.000012766767,0.00002534336,0.00070434343],"genre_scores_gemma":[0.9934525,0.00013620939,0.0008880111,0.0048134183,0.00053309166,0.000047402464,0.0000068189365,0.000028725728,0.00009380909],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974778,0.00016192395,0.00066167815,0.00025821567,0.0010096392,0.00043070051],"domain_scores_gemma":[0.99771124,0.0007957459,0.00021108243,0.00023787325,0.00014736969,0.0008966969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077874446,0.00024774138,0.0008041882,0.00036429786,0.000030263629,0.00002193637,0.00027338436,0.0001638467,0.00053786626],"category_scores_gemma":[0.0022134837,0.00017605675,0.00016440147,0.0003146992,0.00004855332,0.000117815776,0.00011919581,0.0004743261,0.00012981879],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089210585,0.009315094,0.35162374,0.00041816663,0.0051203053,0.015731463,0.008290284,0.000035375688,0.009644591,0.00034634979,0.052188393,0.45807564],"study_design_scores_gemma":[0.038943395,0.05994395,0.8395174,0.0041814568,0.0023035817,0.00018489017,0.0012563172,0.00026026825,0.0053846487,0.00082149415,0.046495363,0.00070724165],"about_ca_topic_score_codex":0.00050480926,"about_ca_topic_score_gemma":0.00023293587,"teacher_disagreement_score":0.48789364,"about_ca_system_score_codex":0.00020698179,"about_ca_system_score_gemma":0.0001794654,"threshold_uncertainty_score":0.7179386},"labels":[],"label_agreement":null},{"id":"W1970520068","doi":"10.1016/j.bpj.2008.12.3566","title":"Cellular Association and N-glycosylation of Glucagon and Related Receptors","year":2009,"lang":"en","type":"article","venue":"Biophysical Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"G protein-coupled receptor; Receptor; Glycosylation; Biology; Cell biology; Chinese hamster ovary cell; Glucagon; Glucagon receptor; Biochemistry; Intracellular; Hormone","score_opus":0.006060048893079304,"score_gpt":0.22146092200932907,"score_spread":0.21540087311624975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970520068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970837,0.00010084921,0.000025735128,0.0012964655,0.00008307977,0.00007748886,4.0063307e-7,0.000009823071,0.0013224573],"genre_scores_gemma":[0.9988553,0.00018617314,0.00019598994,0.000051060975,0.00008851608,3.2587e-7,0.0000054812954,0.000003301277,0.00061388314],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9995511,0.000018191608,0.00013380406,0.00006907299,0.00014435127,0.00008349122],"domain_scores_gemma":[0.9997239,0.000017298697,0.00011282371,0.000037891263,0.00003898098,0.000069116686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010388483,0.000054758304,0.00013235067,0.000048306498,0.000033771208,0.000014787243,0.000011903843,0.000041115436,0.000019528676],"category_scores_gemma":[0.000027712702,0.00004250438,0.000036934995,0.000069383845,0.000012781562,0.00007016244,0.0000066232215,0.0000798992,0.0000041975977],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013619114,0.00047557292,0.025168194,0.000028923865,0.00026734683,0.000023253584,0.00027793634,0.0000015288348,0.8353202,0.0019648634,0.0010572298,0.13527879],"study_design_scores_gemma":[0.0050392873,0.0031893163,0.819938,0.00019864924,0.0008531543,0.000023628016,0.00008601922,0.00095713546,0.16226871,0.0031448521,0.0041025346,0.00019872138],"about_ca_topic_score_codex":0.0000012668017,"about_ca_topic_score_gemma":5.985362e-8,"teacher_disagreement_score":0.79476976,"about_ca_system_score_codex":0.000050816678,"about_ca_system_score_gemma":0.000006466011,"threshold_uncertainty_score":0.17332783},"labels":[],"label_agreement":null},{"id":"W1970885981","doi":"10.1503/cmaj.112127","title":"Essay for the 2011 CIHR/<i>CMAJ</i> award: glucagon-like peptides for metabolic and gastrointestinal disorders","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Insulin; Medicine; Glucagon; Endocrinology","score_opus":0.008707894112379943,"score_gpt":0.2396204588445517,"score_spread":0.23091256473217175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970885981","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36359525,0.03130413,0.02683593,0.5507106,0.009465192,0.0072998144,0.00040092226,0.00017774857,0.010210399],"genre_scores_gemma":[0.9355868,0.0020699862,0.006801426,0.03201932,0.0088292705,0.0004821137,0.00011239123,0.00009942534,0.013999267],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840236,0.000050383715,0.00025942945,0.00012005598,0.0004903066,0.00067747926],"domain_scores_gemma":[0.9978623,0.00050793006,0.00014929366,0.000086050604,0.00016989844,0.0012245639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019214324,0.00013836421,0.00023649956,0.00010642531,0.000427936,0.00006492512,0.0001044448,0.000088183144,0.0003306221],"category_scores_gemma":[0.0011437023,0.00009361338,0.00015352269,0.0000671502,0.000052706575,0.00013500801,0.000014584629,0.00029050666,0.00002589011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005183613,0.00013069683,0.41908205,0.000047394817,0.0006951902,0.000010280599,0.00044689246,0.0000015493516,0.0000088085935,0.0017957959,0.35254443,0.2251851],"study_design_scores_gemma":[0.0022255348,0.00015086005,0.12746274,0.000057126053,0.00047425725,0.00012218326,0.0005220595,0.00021836533,0.0000073637248,0.00020866843,0.86845016,0.00010067014],"about_ca_topic_score_codex":0.00059891166,"about_ca_topic_score_gemma":0.0053323205,"teacher_disagreement_score":0.57199156,"about_ca_system_score_codex":0.0003256916,"about_ca_system_score_gemma":0.0006785464,"threshold_uncertainty_score":0.38174427},"labels":[],"label_agreement":null},{"id":"W1971308827","doi":"10.1038/sj.jhh.1001591","title":"Analysis of Gly40Ser polymorphism of the glucagon receptor (GCGR) gene in different ethnic groups","year":2003,"lang":"en","type":"letter","venue":"Journal of Human Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Società Italiana dell'Ipertensione Arteriosa; Heart and Stroke Foundation of Canada","keywords":"Glucagon receptor; Medicine; Ethnic group; Gene; Polymorphism (computer science); Receptor; Internal medicine; Genetics; Endocrinology; Glucagon; Allele; Biology; Hormone; Anthropology; Sociology","score_opus":0.03842120021543685,"score_gpt":0.2627788056437187,"score_spread":0.22435760542828184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971308827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95165014,0.0028400656,0.00000293573,0.044430748,0.0005531096,0.00032268802,0.00001152961,0.000004194062,0.00018459729],"genre_scores_gemma":[0.8993311,0.0011322014,0.00014804925,0.09432444,0.0010714257,0.0000071738555,0.00018817071,0.00008714263,0.0037103111],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99717605,0.0002053389,0.0012039928,0.00023950792,0.0008982605,0.00027686523],"domain_scores_gemma":[0.9975144,0.00008367778,0.0014311294,0.0006133148,0.000293117,0.00006430921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003223799,0.00034646923,0.0018630285,0.0013057225,0.00003841071,0.000007987732,0.00027359172,0.0003854125,0.00041837062],"category_scores_gemma":[0.0000527411,0.00018867133,0.001231198,0.00065529207,0.00009366881,0.000054437754,0.00008937568,0.00097589,0.0000027388326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029216174,0.0018042532,0.031496197,0.0006148519,0.012791971,0.00094846985,0.00042171244,0.00002953306,0.16329472,0.000017273458,0.78531206,0.0029768012],"study_design_scores_gemma":[0.012651426,0.0044375444,0.7842759,0.004620999,0.07172743,0.00017189728,0.000355027,0.0001035916,0.04955977,0.00019958953,0.07096514,0.0009317215],"about_ca_topic_score_codex":0.000043139502,"about_ca_topic_score_gemma":0.000021583104,"teacher_disagreement_score":0.75277966,"about_ca_system_score_codex":0.00021070818,"about_ca_system_score_gemma":0.00004795493,"threshold_uncertainty_score":0.7693794},"labels":[],"label_agreement":null},{"id":"W1972122781","doi":"10.1038/ncpendmet0552","title":"Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?","year":2007,"lang":"en","type":"letter","venue":"Nature Clinical Practice Endocrinology &#38 Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"","keywords":"Vildagliptin; Medicine; Metformin; Glycemic; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.009509653999994644,"score_gpt":0.3204809537132019,"score_spread":0.31097129971320725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972122781","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27939165,0.021886636,0.00013469708,0.6620288,0.017503668,0.012587353,0.00076537486,0.00037032488,0.005331479],"genre_scores_gemma":[0.07676882,0.0033711637,0.010019811,0.9008882,0.005258444,0.0002911535,0.0016342411,0.00022663249,0.0015415524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99442875,0.00058402505,0.0016826016,0.0012312479,0.0008931189,0.0011802654],"domain_scores_gemma":[0.99247205,0.003956916,0.0013369715,0.0011108151,0.0009202523,0.00020299305],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00089980767,0.0007698158,0.0024492315,0.0008710744,0.00004755722,0.000028211685,0.00042075396,0.002295659,0.0002738015],"category_scores_gemma":[0.004171787,0.00046190128,0.00038720624,0.000599292,0.00035094813,0.00038039524,0.00012141584,0.0066666743,0.00010152205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045581017,0.0063093617,0.032091618,0.0006710133,0.012306255,0.0017579137,0.00014468805,0.0000039679453,0.00013748274,0.0007406119,0.6629694,0.23728663],"study_design_scores_gemma":[0.01806314,0.003599075,0.026513536,0.00017955268,0.003272412,0.0000030716044,0.00003208918,0.0000031900645,0.00032570842,0.00015517614,0.9473728,0.00048028442],"about_ca_topic_score_codex":0.00002762965,"about_ca_topic_score_gemma":0.000012260062,"teacher_disagreement_score":0.28440332,"about_ca_system_score_codex":0.00014557279,"about_ca_system_score_gemma":0.00017275519,"threshold_uncertainty_score":0.9997833},"labels":[],"label_agreement":null},{"id":"W1972969234","doi":"10.1016/j.ejphar.2014.05.003","title":"Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction","year":2014,"lang":"en","type":"article","venue":"European Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Myocardial infarction; Medicine; Metformin; Cardiology; Internal medicine; Toll-like receptor; Ventricular remodeling; Receptor; Innate immune system","score_opus":0.010181660323132011,"score_gpt":0.24690539386580382,"score_spread":0.23672373354267182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972969234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943675,0.0017425575,0.0008600163,0.0008299684,0.0011326707,0.00027285804,9.025896e-7,0.000025478312,0.00076807523],"genre_scores_gemma":[0.9969443,0.00044391138,0.00070430536,0.0002797537,0.0012309976,0.0000037395926,0.000013614521,0.00003003144,0.00034932914],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885255,0.00029373995,0.0002971676,0.00016180363,0.00017487342,0.00021985614],"domain_scores_gemma":[0.99944,0.000073689254,0.00022509602,0.00006938841,0.000069356865,0.00012245904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005104643,0.00017322486,0.0003468901,0.00018743495,0.00008824206,0.000025545301,0.00005099567,0.00001988919,0.0001547846],"category_scores_gemma":[0.000012603829,0.00011721723,0.0001413262,0.00007333277,0.000039009486,0.00016567485,0.000027396098,0.000115373165,0.00002532534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024887864,0.00086088385,0.041068994,0.00021094545,0.012058462,0.0035997105,0.0008469845,0.0013857652,0.5713231,0.000027592667,0.013628273,0.35250047],"study_design_scores_gemma":[0.027849143,0.027430726,0.0076076076,0.00025667477,0.008264959,0.00095009926,0.00021131875,0.00036779384,0.12723964,0.000008988936,0.7994649,0.00034813964],"about_ca_topic_score_codex":0.000002076577,"about_ca_topic_score_gemma":6.1317513e-7,"teacher_disagreement_score":0.78583664,"about_ca_system_score_codex":0.00019414937,"about_ca_system_score_gemma":0.00004105899,"threshold_uncertainty_score":0.477998},"labels":[],"label_agreement":null},{"id":"W1973109904","doi":"10.1055/s-2004-826159","title":"Nutrient, Neural and Endocrine Control of Glucagon-like Peptide Secretion","year":2004,"lang":"en","type":"review","venue":"Hormone and Metabolic Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Health Canada; Canada Research Chairs; Canadian Diabetes Association","keywords":"Glucagon-like peptide-1; Secretion; Endocrinology; Internal medicine; Endocrine system; Glucagon-like peptide-2; Enteroendocrine cell; Glucagon; Digestion (alchemy); Metabolism; Biology; Chemistry; Diabetes mellitus; Medicine; Peptide; Insulin; Type 2 diabetes; Hormone; Biochemistry","score_opus":0.07172332847872111,"score_gpt":0.3872769289649219,"score_spread":0.3155536004862008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973109904","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002020069,0.993392,0.000020342342,0.00010225669,0.000054388263,0.0024051378,0.00003588897,0.00002411221,0.0019458185],"genre_scores_gemma":[0.0042648353,0.9913988,0.000084999156,0.000027588903,0.00017186493,0.00030456568,0.00016743339,0.00004431771,0.0035356104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975811,0.0002223096,0.00051183294,0.00048893585,0.0006241559,0.00057166914],"domain_scores_gemma":[0.99879056,0.00016355576,0.00014662238,0.00042829785,0.00017645005,0.0002945197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007595132,0.0003391863,0.0018953133,0.0006976328,0.00009369169,0.000046102057,0.0001112652,0.000131552,0.000025119809],"category_scores_gemma":[0.00009250774,0.00023611488,0.00024638753,0.00050360884,0.0002753267,0.00008729306,0.00018588093,0.00046033994,0.000018305747],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012045013,0.00026569687,0.00003999083,0.012741131,0.0008429663,0.000089213805,0.000056488283,6.2153454e-8,0.000046414778,0.004226164,0.0008010567,0.98077035],"study_design_scores_gemma":[0.0035943203,0.0007026331,0.000426191,0.0023788852,0.0023408255,0.000052324827,0.00004224721,0.000009996501,0.000018581495,0.00013530071,0.9901352,0.0001635058],"about_ca_topic_score_codex":0.00013815211,"about_ca_topic_score_gemma":0.0000020368755,"teacher_disagreement_score":0.9893341,"about_ca_system_score_codex":0.000051871506,"about_ca_system_score_gemma":0.0001921281,"threshold_uncertainty_score":0.96284854},"labels":[],"label_agreement":null},{"id":"W1973273599","doi":"10.1016/j.jcjd.2014.12.002","title":"Weighing the Benefits and Risks of Diabetes Drugs: A Call for a Unified Global Approach","year":2014,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.019999597144182778,"score_gpt":0.25573506701617305,"score_spread":0.23573546987199026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973273599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48543546,0.044791162,0.000038686438,0.0019414589,0.45719802,0.0028774529,0.0020657051,0.000034630983,0.0056174276],"genre_scores_gemma":[0.5771679,0.00032493734,0.002013734,0.00062191085,0.41822824,0.00013916276,0.00060250895,0.00017807726,0.00072350475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997589,0.00009078592,0.0007351701,0.00031335143,0.00053144514,0.0007402431],"domain_scores_gemma":[0.99652016,0.00086267316,0.0008173058,0.00038732984,0.00064830837,0.0007641988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010933648,0.0004346724,0.0012306815,0.00033356738,0.00016873129,0.00011954542,0.0004313492,0.0004441345,0.000009299103],"category_scores_gemma":[0.0010595892,0.00029865265,0.00040216735,0.00021198543,0.0002667446,0.00010495482,0.00004650702,0.0004949189,0.0000014086955],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018465627,0.000072446644,0.035018083,0.0012968491,0.0022468655,0.000002960236,0.00030115817,0.00002457848,0.0000056962926,0.0005077825,0.93472254,0.025782565],"study_design_scores_gemma":[0.0056404113,0.0021571985,0.008297335,0.0027743934,0.0057570445,7.860783e-7,0.0003180882,0.00033457577,0.000084521766,0.000792932,0.97326094,0.0005817561],"about_ca_topic_score_codex":0.0005397478,"about_ca_topic_score_gemma":0.001392784,"teacher_disagreement_score":0.091732465,"about_ca_system_score_codex":0.00032432316,"about_ca_system_score_gemma":0.0012479727,"threshold_uncertainty_score":0.99994653},"labels":[],"label_agreement":null},{"id":"W1973933567","doi":"10.1007/s00592-014-0565-3","title":"Disproportionately elevated proinsulinemia is observed at modestly elevated glucose levels within the normoglycemic range","year":2014,"lang":"en","type":"article","venue":"Acta Diabetologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"NIH Clinical Center; National Center for Research Resources; National Heart, Lung, and Blood Institute","keywords":"Internal medicine; Endocrinology; Proinsulin; Diabetes mellitus; Insulin; Medicine; Impaired glucose tolerance; Impaired fasting glucose; Prediabetes; Insulin resistance; Plasma glucose; Type 2 diabetes; Chemistry","score_opus":0.04565996417393326,"score_gpt":0.259236630702911,"score_spread":0.21357666652897772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973933567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643845,0.00029196453,0.00003418748,0.008280649,0.00018531678,0.0015929493,0.000034004643,0.00039141922,0.0027510538],"genre_scores_gemma":[0.9903111,0.00008116715,0.00066293374,0.0040189,0.00009543292,0.0002847353,0.00029793775,0.000052489504,0.0041953083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741226,0.00014198667,0.0006060502,0.0006620913,0.0005128573,0.00066472584],"domain_scores_gemma":[0.9981264,0.00019367639,0.00035349172,0.00091620267,0.00019426332,0.00021597634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000540431,0.0004496542,0.0006553871,0.00009798251,0.00029731146,0.000055980676,0.00038343613,0.00022024385,0.0005671033],"category_scores_gemma":[0.000406364,0.00026018306,0.00021050165,0.0004567882,0.00020241378,0.00015435326,0.00025344206,0.00030088102,0.00041926274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026832581,0.0025177973,0.528517,0.0005602041,0.0025101642,0.00017047518,0.001155452,0.00006805897,0.40599677,0.006919459,0.03447776,0.0144236265],"study_design_scores_gemma":[0.008278058,0.001538209,0.8524092,0.00016126253,0.0010730613,0.000021370153,0.00007435942,0.008229011,0.099837065,0.0029070375,0.024702014,0.0007693717],"about_ca_topic_score_codex":0.000030249523,"about_ca_topic_score_gemma":0.000017764587,"teacher_disagreement_score":0.3238922,"about_ca_system_score_codex":0.0002058512,"about_ca_system_score_gemma":0.00006174516,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W1973967551","doi":"10.1007/s10439-007-9274-1","title":"A Mathematical Model of the Oral Glucose Tolerance Test Illustrating the Effects of the Incretins","year":2007,"lang":"en","type":"article","venue":"Annals of Biomedical Engineering","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Incretin; Internal medicine; Endocrinology; Glycemic; Insulin; Glucagon-like peptide-1; Glucose tolerance test; Hormone; Glucagon; Amylin; Medicine; Diabetes mellitus; Insulin resistance; Type 2 diabetes; Islet","score_opus":0.017063347841579767,"score_gpt":0.2614208350803321,"score_spread":0.24435748723875234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973967551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239224,0.00028266522,0.004498889,0.00162481,0.000096291595,0.00043722944,0.00000497873,0.000018409602,0.0006444856],"genre_scores_gemma":[0.9985429,0.00002142175,0.0010468861,0.00021892966,0.000041447613,0.000008300797,0.0000010590397,0.000011249894,0.000107770866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889666,0.000012856721,0.00035294137,0.00009118483,0.00042728035,0.00021908648],"domain_scores_gemma":[0.9989182,0.0005336642,0.000113052876,0.00031817498,0.000051972253,0.000064988715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005631762,0.000110067645,0.0002606074,0.000042255448,0.000026884529,0.0000029565922,0.00021486964,0.000056746594,0.000006600297],"category_scores_gemma":[0.0010729019,0.000049604332,0.00015796302,0.00030039187,0.00021111089,0.000022610446,0.00012076883,0.00013413238,7.193389e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013751061,0.0028864485,0.006302015,0.010569817,0.001117807,0.000026446329,0.0030827404,0.0048569473,0.8892729,0.023087343,0.0025357201,0.056124263],"study_design_scores_gemma":[0.00161964,0.0006030557,0.024981668,0.0033420606,0.00033598632,0.0000058100272,0.0001340088,0.36813587,0.5994005,0.0005494407,0.0007195656,0.00017236435],"about_ca_topic_score_codex":0.000007291779,"about_ca_topic_score_gemma":9.808444e-7,"teacher_disagreement_score":0.36327893,"about_ca_system_score_codex":0.000008716813,"about_ca_system_score_gemma":0.000026828398,"threshold_uncertainty_score":0.2022806},"labels":[],"label_agreement":null},{"id":"W1974015476","doi":"10.1016/s1499-2671(09)33258-x","title":"Why are older patients with type 2 diabetes treated for dyslipidemia but not for hyperglycaemia?","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dyslipidemia; Type 2 diabetes; Diabetes mellitus; Intervention (counseling); Type 2 Diabetes Mellitus; Intensive care medicine; Internal medicine; Physical therapy; Pediatrics; Endocrinology; Psychiatry","score_opus":0.011423554386138703,"score_gpt":0.21824379425647902,"score_spread":0.20682023987034032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974015476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415535,0.0007649261,0.000013921306,0.0033930254,0.00029882946,0.0010031031,0.000111877765,0.000018170394,0.00024080012],"genre_scores_gemma":[0.99088764,0.0000038362246,0.001421806,0.0064401054,0.00031167304,0.00003327889,0.00012239342,0.00004671597,0.000732569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848104,0.00001660987,0.00039099326,0.00022004498,0.00019462813,0.00069666276],"domain_scores_gemma":[0.9977242,0.00012458379,0.00031608294,0.00021741187,0.0008624527,0.00075530447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016718626,0.00027236156,0.00062534545,0.00050982495,0.00014052275,0.000059348004,0.00015424867,0.000108033426,0.00004633205],"category_scores_gemma":[0.00028139623,0.00020112342,0.00019428767,0.0002892251,0.000060794144,0.00018884234,0.000004708655,0.0001181822,0.0000038245357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076228345,0.0001240867,0.9168983,0.000119499346,0.00056992046,0.00000605034,0.00004580376,0.000010773688,0.00024043821,0.000050442504,0.06825047,0.013607958],"study_design_scores_gemma":[0.011537259,0.0076704337,0.90727276,0.0010657366,0.0017402545,4.977566e-7,0.00010670211,0.00008540191,0.0069218646,0.0002466493,0.06290298,0.00044944652],"about_ca_topic_score_codex":0.000019759837,"about_ca_topic_score_gemma":0.00035949156,"teacher_disagreement_score":0.013158511,"about_ca_system_score_codex":0.00023945064,"about_ca_system_score_gemma":0.00029502282,"threshold_uncertainty_score":0.8201575},"labels":[],"label_agreement":null},{"id":"W1974051196","doi":"10.1210/me.2013-1047","title":"The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity","year":2013,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Biology; Cell biology; Interactome; Signal transduction; Gene knockdown; Biochemistry; Gene","score_opus":0.015987248159677146,"score_gpt":0.25408951771206745,"score_spread":0.2381022695523903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974051196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824893,0.00025085342,0.0010157152,0.014137196,0.000043511875,0.001186611,0.0000022597114,0.00001870917,0.00085584325],"genre_scores_gemma":[0.99795574,0.000058866714,0.00020091968,0.00015331549,0.0000103088805,0.0002918611,0.0000056443705,0.00001021803,0.0013131221],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993975,0.000046700694,0.000100121266,0.00015809461,0.00011145335,0.00018610651],"domain_scores_gemma":[0.9994741,0.00005050324,0.000102673075,0.00029353233,0.00005209919,0.000027098775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006720456,0.0000907808,0.00011900564,0.00003512998,0.000063068605,0.000024514933,0.000089025496,0.000021198586,0.000020109039],"category_scores_gemma":[0.000039952814,0.000044998676,0.000029438423,0.000060369068,0.00014340752,0.00005399012,0.000063401734,0.00008904387,0.000016374082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010420583,0.00022425849,0.0013147973,0.00004408078,0.00034401592,0.000012842433,0.00013547482,0.0000019901545,0.9405979,0.0047542453,0.00058437244,0.05188185],"study_design_scores_gemma":[0.0019549031,0.00072614016,0.102735296,0.00004213319,0.000189845,0.000034708457,0.0002980598,0.0002145201,0.8783043,0.000087888766,0.015299103,0.000113082824],"about_ca_topic_score_codex":0.000055716206,"about_ca_topic_score_gemma":0.000018981495,"teacher_disagreement_score":0.10142049,"about_ca_system_score_codex":0.000018416677,"about_ca_system_score_gemma":0.0000133546155,"threshold_uncertainty_score":0.18349928},"labels":[],"label_agreement":null},{"id":"W1974250392","doi":"10.2337/db08-0121","title":"Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity","year":2008,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Internal medicine; Endocrinology; Glucose homeostasis; Insulin; Insulin resistance; Glucagon; Medicine; Chemistry","score_opus":0.010180477559872279,"score_gpt":0.2168051820337235,"score_spread":0.20662470447385123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974250392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555624,0.0005989337,0.0000029110859,0.0018433912,0.00025561932,0.00046046637,0.000017529826,0.00016195906,0.00110298],"genre_scores_gemma":[0.9934858,0.00011814472,0.0010412238,0.0022759102,0.00027881283,0.00003530452,0.00013141324,0.00003395623,0.0025994496],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986981,0.00009279786,0.00021788634,0.0003901361,0.000172163,0.00042891025],"domain_scores_gemma":[0.9992047,0.00019652407,0.000050604165,0.0003127572,0.000053522068,0.00018190342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027985737,0.00025040674,0.00045098554,0.00011611573,0.00014517865,0.000033451248,0.00003496755,0.000085541906,0.0000620799],"category_scores_gemma":[0.00010676989,0.00021818826,0.00010010043,0.00015268987,0.00017155652,0.0001440981,0.000084077765,0.000095835196,0.00007469344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002853643,0.0020993676,0.34359208,0.0004360604,0.001693229,0.00063114427,0.0011252859,0.000018930821,0.53488064,0.0001871539,0.09725246,0.017798292],"study_design_scores_gemma":[0.008126368,0.0010432751,0.7885824,0.00020782827,0.0005911272,0.000043025775,0.00007064365,0.0012267948,0.15934047,0.00017371775,0.040049165,0.0005452246],"about_ca_topic_score_codex":0.000021947078,"about_ca_topic_score_gemma":0.000007051501,"teacher_disagreement_score":0.44499028,"about_ca_system_score_codex":0.000022103572,"about_ca_system_score_gemma":0.000031954703,"threshold_uncertainty_score":0.8897459},"labels":[],"label_agreement":null},{"id":"W1974540375","doi":"10.1503/cmaj.081713","title":"Thiazolidinediones: Do harms outweigh benefits?","year":2008,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Women's College Hospital","funders":"Canadian Diabetes Association","keywords":"Rosiglitazone; Pioglitazone; Medicine; Glycemic; Diabetes mellitus; Thiazolidinedione; Drug; Intensive care medicine; Drug approval; Type 2 diabetes; Pharmacology; Endocrinology","score_opus":0.011848624042939787,"score_gpt":0.22112900171816563,"score_spread":0.20928037767522584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974540375","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014523244,0.0017160842,0.000005694494,0.9664867,0.003120979,0.00034357916,0.00008052806,0.000057856418,0.026736252],"genre_scores_gemma":[0.0010529392,0.003746879,0.0001076568,0.93672884,0.030825775,0.00002748657,0.0004876156,0.00008412783,0.026938666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99435836,0.00011987318,0.0007058813,0.00036616973,0.0033542223,0.0010954681],"domain_scores_gemma":[0.99657047,0.00015964321,0.0004556295,0.00027926618,0.0005514175,0.001983595],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0007705769,0.00040259404,0.00076766236,0.00066355354,0.00035399105,0.00017286316,0.0003387283,0.0021324346,0.009402674],"category_scores_gemma":[0.00086912786,0.00033733514,0.00044905028,0.00028156562,0.00005392955,0.0001256645,0.00003345403,0.0045945663,0.0014866545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000042297875,0.000031453703,0.008424173,0.00004033609,0.00086089876,0.010276032,0.00009327442,4.4986285e-7,8.2265e-8,0.000035951147,0.9601052,0.02012796],"study_design_scores_gemma":[0.0016139146,0.00013033628,0.0035096633,0.00040752505,0.00040410642,0.00092369056,0.000048917682,0.00001209446,0.0000015633982,0.000059224676,0.9925893,0.00029965845],"about_ca_topic_score_codex":0.0008711952,"about_ca_topic_score_gemma":0.0012722224,"teacher_disagreement_score":0.032484144,"about_ca_system_score_codex":0.0030525036,"about_ca_system_score_gemma":0.00393822,"threshold_uncertainty_score":0.99990785},"labels":[],"label_agreement":null},{"id":"W1974658403","doi":"10.1007/s13300-014-0080-0","title":"Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden","year":2014,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Lunds Universitet; Vetenskapsrådet; Novo Nordisk; Sanofi; Eli Lilly and Company","keywords":"Medicine; Metformin; Internal medicine; Endocrinology; Sitagliptin; Insulin; Type 2 Diabetes Mellitus; Diabetes mellitus","score_opus":0.03225883259212647,"score_gpt":0.29655709969669153,"score_spread":0.26429826710456505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974658403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947404,0.00026035975,0.0000051287243,0.0003060376,0.00013245933,0.0032535521,0.000039791423,0.0000929132,0.0011693469],"genre_scores_gemma":[0.9961921,0.000086179156,0.00055237475,0.0013024032,0.00007783391,0.00065501634,0.0004105305,0.00007630191,0.00064726046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964627,0.00025777883,0.0008851926,0.00085599616,0.00057320844,0.00096512947],"domain_scores_gemma":[0.99791616,0.0003917475,0.0002706709,0.0009092648,0.00017937015,0.0003327816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009351201,0.0006225133,0.0016984938,0.0014685099,0.000066129156,0.000060195503,0.0003253363,0.00015688138,0.00033561618],"category_scores_gemma":[0.00016050483,0.00044414797,0.00025790956,0.0033338913,0.00017300586,0.00019860393,0.00009222119,0.00031266795,0.00006789309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003822907,0.003137696,0.92733485,0.00020077199,0.0022122324,0.000030443045,0.0010981523,0.000680137,0.004827523,0.00004697436,0.00085571664,0.055752583],"study_design_scores_gemma":[0.0109035475,0.007989169,0.90217084,0.0006859748,0.00073138915,2.1382486e-7,0.0003027758,0.0039583645,0.0658451,0.000048348687,0.006684886,0.00067940785],"about_ca_topic_score_codex":0.00019269928,"about_ca_topic_score_gemma":0.0014179725,"teacher_disagreement_score":0.061017577,"about_ca_system_score_codex":0.00022979475,"about_ca_system_score_gemma":0.00012712837,"threshold_uncertainty_score":0.99980104},"labels":[],"label_agreement":null},{"id":"W1975269508","doi":"10.2337/db13-er12a","title":"Direct Effects of Exendin-(9,39) and GLP-1-(9,36)amide on Insulin Action, β-Cell Function, and Glucose Metabolism in Nondiabetic Subjects. Diabetes 2013;62:2752–2756","year":2013,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Internal medicine; Endocrinology; Insulin; Metabolism; Amide; Diabetes mellitus; Cell function; Function (biology); Medicine; Action (physics); Cell; Chemistry; Biology; Biochemistry; Genetics","score_opus":0.005781096605757119,"score_gpt":0.2065397438580685,"score_spread":0.20075864725231138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975269508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776766,0.017324047,0.0000016560998,0.00035731454,0.00044803054,0.0016883257,0.000011203791,0.000121752884,0.0023710898],"genre_scores_gemma":[0.9955076,0.0020006734,0.00014051501,0.00064724305,0.00012374716,0.0004892165,0.00006939414,0.000072513016,0.0009490999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975315,0.00014661027,0.0005207954,0.000689922,0.0003654845,0.0007457374],"domain_scores_gemma":[0.99824464,0.00062939513,0.00021885664,0.00049388857,0.00011539252,0.00029783673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030153274,0.000518529,0.0010012334,0.00067301776,0.000112640795,0.00009469313,0.000115702605,0.00018254932,0.00010367372],"category_scores_gemma":[0.00019515512,0.0004385341,0.00013076386,0.0005028889,0.00024609265,0.0003851758,0.00012503142,0.00023403876,0.000101370926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015803306,0.0022481654,0.72226447,0.0034671982,0.0008585038,0.000013985429,0.0005104967,0.00000897628,0.19950666,0.0003588458,0.005069562,0.0655351],"study_design_scores_gemma":[0.0044137943,0.001025332,0.6881519,0.00036312878,0.00059963984,2.0903558e-7,0.00006810899,0.00014734673,0.30187976,0.0006060131,0.002402759,0.00034198948],"about_ca_topic_score_codex":0.00019570359,"about_ca_topic_score_gemma":0.000024164561,"teacher_disagreement_score":0.10237311,"about_ca_system_score_codex":0.000071895316,"about_ca_system_score_gemma":0.00003544947,"threshold_uncertainty_score":0.99980664},"labels":[],"label_agreement":null},{"id":"W1975698464","doi":"10.1016/j.jcjd.2013.08.130","title":"Comparative Safety and Effectiveness of Sitagliptin in Patients with Type 2 Diabetes and Heart Failure","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sitagliptin; Heart failure; Type 2 diabetes; Internal medicine; Population; Cohort; Diabetes mellitus; Proportional hazards model; Emergency medicine; Endocrinology","score_opus":0.00513105286209068,"score_gpt":0.19866147461235611,"score_spread":0.19353042175026544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975698464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832314,0.0008891738,2.9499995e-7,0.0001652517,0.00003972343,0.00040090052,0.0000068664162,0.0000019731085,0.00017269715],"genre_scores_gemma":[0.9995999,0.000003875486,0.00027264433,0.0000762744,0.0000125767565,0.0000038677786,0.000009233173,0.000009377774,0.0000122782485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992931,0.000065075736,0.00020753834,0.00010159797,0.00010264098,0.0002300715],"domain_scores_gemma":[0.99914765,0.00013254113,0.000101088,0.00007880264,0.00022420843,0.00031571952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018013865,0.000121182165,0.0004876192,0.00026151017,0.000029737515,0.000021568037,0.000037983147,0.000037082787,0.00003805629],"category_scores_gemma":[0.000042896325,0.000087401095,0.00002546978,0.0001589319,0.00013019759,0.00017260699,0.000010371651,0.000098014105,0.0000020548136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022132077,0.00004515873,0.99823976,0.00014891772,0.00019060822,0.000001177183,0.00016098749,0.0000050636036,0.00026690308,0.000027497916,0.00026940933,0.0006224048],"study_design_scores_gemma":[0.0025647585,0.0016068225,0.99365,0.00061061967,0.00010562993,1.9517944e-7,0.0001342391,0.000012721121,0.0008266634,0.000051216604,0.00035410808,0.000083021725],"about_ca_topic_score_codex":0.00014507795,"about_ca_topic_score_gemma":0.00074350723,"teacher_disagreement_score":0.0045897355,"about_ca_system_score_codex":0.00006391554,"about_ca_system_score_gemma":0.000110541,"threshold_uncertainty_score":0.3564113},"labels":[],"label_agreement":null},{"id":"W1975699299","doi":"10.1016/j.metabol.2012.07.005","title":"Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells","year":2012,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Glucagon-like peptide-2; Apolipoprotein B; Glucagon-like peptide-1; Internal medicine; Endocrinology; Glucagon; Peptide; Hepatocyte; Gene expression; Chemistry; Biology; Gene; Medicine; Biochemistry; Hormone; In vitro; Diabetes mellitus; Cholesterol","score_opus":0.01751186199231653,"score_gpt":0.24485260829094502,"score_spread":0.2273407462986285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975699299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420506,0.003963654,0.00007874226,0.00009321127,0.00034407008,0.0005214107,0.00001064137,0.000030814415,0.0007523845],"genre_scores_gemma":[0.99237853,0.0003421221,0.0045405296,0.00011478642,0.00019588738,0.000082263745,0.000034689492,0.00002131752,0.0022898628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989467,0.0000464803,0.00026789628,0.00020636876,0.00022173235,0.00031082172],"domain_scores_gemma":[0.9994826,0.000024498915,0.00011125147,0.00021578687,0.000030344037,0.00013552501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025148247,0.000174288,0.00035627405,0.00017918237,0.000029317747,0.000010351523,0.000054441753,0.00006844256,0.00007292413],"category_scores_gemma":[0.000030204885,0.00014080983,0.00004974405,0.00012761568,0.00005977628,0.0002018789,0.00008901981,0.00011242028,0.000021043881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111870344,0.00044465213,0.022010904,0.000100571524,0.000041530024,0.0000037652871,0.0004101211,6.1971565e-7,0.95821476,0.00013997969,0.0018567353,0.016664494],"study_design_scores_gemma":[0.0016165752,0.00008012128,0.052052107,0.00010001053,0.00014928618,0.0000052088944,0.00014260392,0.000021028858,0.9276981,0.00003329936,0.017979607,0.00012207887],"about_ca_topic_score_codex":0.000389139,"about_ca_topic_score_gemma":0.0000033430188,"teacher_disagreement_score":0.030516686,"about_ca_system_score_codex":0.000032795673,"about_ca_system_score_gemma":0.000012357855,"threshold_uncertainty_score":0.5742058},"labels":[],"label_agreement":null},{"id":"W1975715952","doi":"10.1007/s00125-006-0310-8","title":"Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY","year":2006,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Peptide YY; Endocrinology; Internal medicine; Appetite; Anorectic; Dipeptidyl peptidase; Postprandial; Chemistry; Neuropeptide; Neuropeptide Y receptor; Food intake; Medicine; Insulin; Receptor; Biochemistry; Enzyme","score_opus":0.012056006618179353,"score_gpt":0.23793941674310784,"score_spread":0.2258834101249285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975715952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658778,0.00013165186,0.000022785945,0.0006413305,0.0001027359,0.00067179487,0.0000082056995,0.00005079998,0.032492906],"genre_scores_gemma":[0.9966642,0.000021416501,0.00026314735,0.00024170981,0.000049643248,0.000085085405,0.00003172936,0.0000141213795,0.0026288975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990834,0.000050543786,0.0002473671,0.00017829043,0.00021300455,0.00022737526],"domain_scores_gemma":[0.99895054,0.00044392698,0.0001504813,0.00036002346,0.000056284745,0.000038735063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012486656,0.0001554094,0.00035094217,0.00009240217,0.000050480074,0.000005677687,0.0001005382,0.000063877305,0.00009093047],"category_scores_gemma":[0.000111362395,0.00009446777,0.00017333668,0.00020179001,0.0001515257,0.000034777106,0.000044520744,0.00010658033,0.000050061913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033977014,0.00627661,0.6085137,0.0018957887,0.0015761493,0.00007590214,0.00046079163,0.00010250553,0.1306671,0.09184302,0.14028086,0.017967798],"study_design_scores_gemma":[0.0016674749,0.0009623941,0.79022366,0.0002464248,0.0004957543,6.816478e-7,0.00011179088,0.00004880984,0.20129049,0.00070913375,0.004113619,0.00012977427],"about_ca_topic_score_codex":0.00006533494,"about_ca_topic_score_gemma":0.000009195915,"teacher_disagreement_score":0.18170995,"about_ca_system_score_codex":0.000041843363,"about_ca_system_score_gemma":0.00001930287,"threshold_uncertainty_score":0.38522837},"labels":[],"label_agreement":null},{"id":"W1975929001","doi":"10.1111/dom.12121","title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( <scp>GetGoal</scp> ‐P)","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"American Diabetes Association","keywords":"Lixisenatide; Placebo; Medicine; Pioglitazone; Internal medicine; Adverse effect; Metformin; Type 2 diabetes; Randomized controlled trial; Clinical endpoint; Diabetes mellitus; Endocrinology","score_opus":0.009655752413255798,"score_gpt":0.22764533074075968,"score_spread":0.21798957832750387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975929001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825202,0.008795057,0.0000013653253,0.00024410813,0.00036397303,0.0020606501,0.000012681453,0.00006226792,0.005939652],"genre_scores_gemma":[0.9967822,0.0014154385,0.00032581738,0.00036134812,0.00008504704,0.00011237067,0.000043141437,0.000030472218,0.0008442106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978992,0.00013495644,0.0005042824,0.0004989927,0.00035249183,0.000610088],"domain_scores_gemma":[0.99788845,0.0011453277,0.00018892459,0.0003736523,0.00013887562,0.00026477495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049843575,0.00037086543,0.0011928156,0.00039185368,0.00009928878,0.000056487883,0.00012457388,0.0001408912,0.000030955816],"category_scores_gemma":[0.0008553099,0.0002992194,0.00011151114,0.00039565185,0.00020944433,0.00021497435,0.00014483702,0.00022664167,0.000043111155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057060192,0.011323931,0.8078892,0.0017779156,0.0048258267,0.0000421921,0.0048264065,0.00016192772,0.03466424,0.018910583,0.0045956452,0.10527606],"study_design_scores_gemma":[0.055829406,0.0010311604,0.928163,0.00029098714,0.0007062239,1.7023957e-7,0.0002741272,0.0005046675,0.0065702186,0.00020269465,0.0062488057,0.00017854429],"about_ca_topic_score_codex":0.000041978426,"about_ca_topic_score_gemma":0.000007588371,"teacher_disagreement_score":0.12027375,"about_ca_system_score_codex":0.000043141274,"about_ca_system_score_gemma":0.000037359798,"threshold_uncertainty_score":0.999946},"labels":[],"label_agreement":null},{"id":"W1975934991","doi":"10.1503/cmaj.130507","title":"Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial","year":2013,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Angiotensin Receptor Blockers; Medicine; Angiotensin receptor; Intensive care medicine; Internal medicine; Receptor; Endocrinology; Angiotensin II; Renin–angiotensin system","score_opus":0.0036004154769778206,"score_gpt":0.18610148995657969,"score_spread":0.18250107447960187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975934991","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016415311,0.00015475643,0.000020444171,0.9785505,0.0021089525,0.0015042595,0.00020559641,0.000025420666,0.0010147678],"genre_scores_gemma":[0.0037359325,0.000024425459,0.0003374676,0.96934205,0.016178738,0.00008615816,0.001053071,0.00008607696,0.009156062],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627554,0.0001152336,0.0004404089,0.00028266973,0.0018768387,0.0010093275],"domain_scores_gemma":[0.99691737,0.00044319706,0.00048634192,0.00020798887,0.0009990615,0.0009460498],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053905585,0.00034078155,0.0005882057,0.0002385499,0.0003506377,0.00023450445,0.00024149142,0.0009292714,0.0034473417],"category_scores_gemma":[0.00083647657,0.00020042494,0.00030189124,0.00014299621,0.000078846766,0.00011731101,0.000018320008,0.0014938997,0.00020781926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012943183,0.000039526574,0.023072638,0.000025315958,0.0014487668,0.00009308729,0.000047697657,1.5557445e-7,1.9461292e-7,0.000006685547,0.96926284,0.0059901327],"study_design_scores_gemma":[0.004325791,0.00034607123,0.010221973,0.00031091232,0.000900444,0.0000045087145,0.000018086397,0.000057769685,0.0000014861967,0.000020803398,0.98355865,0.00023349468],"about_ca_topic_score_codex":0.00025601254,"about_ca_topic_score_gemma":0.0006900096,"teacher_disagreement_score":0.014295803,"about_ca_system_score_codex":0.0021349797,"about_ca_system_score_gemma":0.0015189687,"threshold_uncertainty_score":0.99746364},"labels":[],"label_agreement":null},{"id":"W1975988459","doi":"10.1016/s1499-2671(09)33265-7","title":"Two years of treatment with liraglutide, a human GLP-1 analogue, offers sustained and greater reduction with HbA1c, FPG, PPG and weight compared with glimepiride, with lower glycaemic risk, in patients with type 2 diabetes: LEAD-3 extension study","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Glimepiride; Medicine; Tolerability; Type 2 diabetes; Weight loss; Blood pressure; Internal medicine; Diabetes mellitus; Canagliflozin; Urology; Endocrinology; Adverse effect; Obesity","score_opus":0.008421805482413619,"score_gpt":0.2155480412962324,"score_spread":0.20712623581381878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975988459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794585,0.0005326513,0.000001020909,0.00012976641,0.000027567898,0.001235495,0.000012883416,0.000012276452,0.00010252264],"genre_scores_gemma":[0.9993258,0.000017376438,0.00034845498,0.000073467396,0.000037125857,0.000013949892,0.00003653243,0.00004760401,0.000099653276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821603,0.00008043026,0.00039049677,0.00040562547,0.00035016995,0.00055724714],"domain_scores_gemma":[0.9982267,0.000026743264,0.00042861508,0.00032791626,0.00046994546,0.0005200925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016991355,0.00041092298,0.00087570713,0.0009062816,0.00012130472,0.000056895235,0.000084722335,0.000051528692,0.000010210682],"category_scores_gemma":[0.000010327787,0.00024003981,0.000034542307,0.00065897935,0.0003158541,0.00027833393,0.000009466919,0.0002037153,4.798068e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015853727,0.0005838619,0.9923519,0.000039242404,0.0011628713,0.00022588966,0.0007778405,0.000104269486,0.00006059636,0.0000034485874,0.000056616595,0.0030480751],"study_design_scores_gemma":[0.02241555,0.06897531,0.9039608,0.0010904789,0.0017057922,0.0000075506246,0.001264456,0.00002429469,0.00020257154,0.000010201134,0.000045342298,0.000297651],"about_ca_topic_score_codex":0.000661111,"about_ca_topic_score_gemma":0.008415146,"teacher_disagreement_score":0.08839111,"about_ca_system_score_codex":0.0003995175,"about_ca_system_score_gemma":0.00038591286,"threshold_uncertainty_score":0.97885394},"labels":[],"label_agreement":null},{"id":"W1976067058","doi":"10.1007/s12325-014-0146-4","title":"Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials","year":2014,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Lixisenatide; Medicine; Hypoglycemia; Placebo; Glycated hemoglobin; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Postprandial; Diabetes mellitus; Clinical endpoint; Randomized controlled trial; Endocrinology; Exenatide","score_opus":0.05755748832539071,"score_gpt":0.37941524918592817,"score_spread":0.32185776086053747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976067058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025502747,0.97305214,0.000095909825,0.000038288224,0.00022360361,0.025766198,0.00016352361,0.000030822463,0.00037448437],"genre_scores_gemma":[0.00063930696,0.9860941,0.0013462332,0.00016930365,0.000062244464,0.009522734,0.0012091716,0.00008805145,0.00086880877],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9934668,0.0020133762,0.0027724574,0.00074210553,0.00053154095,0.00047370768],"domain_scores_gemma":[0.9826694,0.013256974,0.0028675913,0.000760382,0.00034363873,0.0001020254],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0032086843,0.0010544477,0.046678398,0.0012568602,0.00004141187,0.000031064537,0.00019453287,0.0001951091,0.00024771754],"category_scores_gemma":[0.00093397946,0.00044261897,0.011173444,0.00077801076,0.00013896367,0.00008851309,0.000014568255,0.00011029654,0.000004617895],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06368486,0.001395668,0.0000372763,0.0010940391,0.5430041,0.0000012838942,0.000038893122,0.00054821116,3.2942545e-8,0.0001047635,0.00001636231,0.39007452],"study_design_scores_gemma":[0.3639641,0.002388952,0.0000022710128,0.0006270842,0.49963143,1.13529435e-8,0.000004406037,0.00018284004,0.0000050912527,0.00005955809,0.13287866,0.00025560614],"about_ca_topic_score_codex":0.000008120689,"about_ca_topic_score_gemma":0.000016055801,"teacher_disagreement_score":0.38981894,"about_ca_system_score_codex":0.00019058223,"about_ca_system_score_gemma":0.000106246975,"threshold_uncertainty_score":0.99980253},"labels":[],"label_agreement":null},{"id":"W1976208658","doi":"10.1111/j.1751-7141.2008.00006.x","title":"Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS","year":2008,"lang":"en","type":"letter","venue":"Preventive Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glycated hemoglobin; Blood pressure; Diabetes mellitus; Hypoglycemia; Internal medicine; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.006606203728331417,"score_gpt":0.21415379585902788,"score_spread":0.20754759213069646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976208658","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3681557,0.4779816,0.002086811,0.09576824,0.0032292895,0.010820975,0.0012518323,0.0006049118,0.040100675],"genre_scores_gemma":[0.56279373,0.13109408,0.0012293374,0.273469,0.011232447,0.00209669,0.0022022214,0.0003918198,0.015490696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973396,0.00050326274,0.0003215207,0.0009337319,0.00026070123,0.00064117246],"domain_scores_gemma":[0.9986489,0.0003040229,0.00016711903,0.00065031974,0.000115638024,0.000113998845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003481835,0.0005423426,0.0021298877,0.00024217583,0.00013571669,0.000020251571,0.00010260913,0.0006099947,0.00001863422],"category_scores_gemma":[0.00014053688,0.00045680493,0.0007745832,0.00009161099,0.0004237228,0.00007724801,0.00018149312,0.00096940534,0.000024310015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007707835,0.000030494266,0.27326125,0.00062456256,0.02534227,0.0016867167,0.000056604746,0.0000063028806,0.00003593151,0.000010154746,0.6683227,0.030545954],"study_design_scores_gemma":[0.004735956,0.0004890813,0.064571574,0.00014935962,0.0077989036,0.00009134852,0.000019416455,0.000007971016,0.000028709012,0.00024044658,0.9214576,0.0004096656],"about_ca_topic_score_codex":0.000011777686,"about_ca_topic_score_gemma":7.019254e-7,"teacher_disagreement_score":0.3468875,"about_ca_system_score_codex":0.00006084689,"about_ca_system_score_gemma":0.000035853118,"threshold_uncertainty_score":0.99978834},"labels":[],"label_agreement":null},{"id":"W1977144451","doi":"10.1016/j.cmet.2015.02.005","title":"GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7","year":2015,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; National Park Service; Merck; Novo Nordisk; Intarcia Therapeutics; Canada Research Chairs; MedImmune; Ariad Pharmaceuticals","keywords":"Glucagon-like peptide-2; Endocrinology; Internal medicine; Receptor; Biology; Fibroblast growth factor; Epidermal growth factor; Intestinal polyp; Incretin; Growth factor; Enteroendocrine cell; Glucagon-like peptide-1; Signal transduction; Cancer research; Cell biology; Endocrine system; Medicine; Hormone; Type 2 diabetes; Peptide; Biochemistry; Diabetes mellitus","score_opus":0.022512345865186037,"score_gpt":0.243852383578982,"score_spread":0.22134003771379596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977144451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9098368,0.003976066,0.010784341,0.0008375202,0.0013503567,0.0010518287,0.000005692747,0.00030173245,0.07185565],"genre_scores_gemma":[0.9622537,0.0001349652,0.030929005,0.00044961701,0.000310252,0.000051714054,0.000033471937,0.000047218942,0.005790063],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986389,0.000033432378,0.00023750622,0.00036317616,0.00031092117,0.00041601487],"domain_scores_gemma":[0.9992105,0.000030665313,0.000092008195,0.00025432452,0.00012496926,0.00028758476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022105215,0.0002568212,0.00039593605,0.00008912151,0.00007719199,0.00006457596,0.000099471974,0.0000647733,0.000043721604],"category_scores_gemma":[0.00012023818,0.00021049181,0.00006663143,0.00016379575,0.0000761378,0.0002505966,0.00017988817,0.00015083146,0.0001453925],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028013191,0.006632363,0.014929523,0.005369034,0.0027895141,0.0045092064,0.024279546,0.00007359093,0.26497853,0.4989943,0.033522934,0.14112015],"study_design_scores_gemma":[0.038100444,0.0044581434,0.029154243,0.0009389021,0.007676752,0.00052273547,0.0019832216,0.0026757638,0.5535086,0.100639544,0.2578094,0.002532299],"about_ca_topic_score_codex":0.000049707196,"about_ca_topic_score_gemma":0.0000032555413,"teacher_disagreement_score":0.39835477,"about_ca_system_score_codex":0.00004793192,"about_ca_system_score_gemma":0.00007094121,"threshold_uncertainty_score":0.85836065},"labels":[],"label_agreement":null},{"id":"W1977334025","doi":"10.1007/s11920-014-0473-9","title":"Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed","year":2014,"lang":"en","type":"review","venue":"Current Psychiatry Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research","keywords":"Antipsychotic; Olanzapine; Clozapine; Risperidone; Epigenetics; Medicine; Pharmacogenomics; Schizophrenia (object-oriented programming); Bioinformatics; Genetics; Psychiatry; Biology; Gene","score_opus":0.05231829153960094,"score_gpt":0.3576869465321562,"score_spread":0.3053686549925553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977334025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012878605,0.9805459,0.000045081266,0.0001747563,0.013148489,0.0034392474,0.000010676393,0.00013928654,0.0023678076],"genre_scores_gemma":[0.000036969126,0.9961094,0.0009151649,0.00011316949,0.0012079299,0.00017014302,0.0007288545,0.0001664924,0.00055183494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532,0.00017574891,0.001942202,0.0014275461,0.0004961513,0.00063830893],"domain_scores_gemma":[0.99608886,0.000041534997,0.001461277,0.0017874629,0.00010359883,0.000517236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059029023,0.0010126245,0.003160957,0.0004847317,0.00012091734,0.00007885559,0.00018057035,0.00036922508,0.0001201773],"category_scores_gemma":[0.000057194167,0.00078454433,0.0009401988,0.00043129924,0.0001178473,0.00004519622,0.00016577108,0.00046080363,0.00010821132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000068896884,0.00039926436,0.003531439,0.06004431,0.0010231254,0.00007833984,0.000006491447,1.5706021e-8,2.0190483e-7,0.000051369876,0.025430223,0.9094283],"study_design_scores_gemma":[0.0005393639,0.00025810683,0.00043902657,0.040873587,0.009084348,0.000343965,0.0000026232115,0.0000042901934,5.105037e-7,0.00014866609,0.94764477,0.00066071947],"about_ca_topic_score_codex":0.0000015965591,"about_ca_topic_score_gemma":0.00000206717,"teacher_disagreement_score":0.92221457,"about_ca_system_score_codex":0.00010738246,"about_ca_system_score_gemma":0.00033917362,"threshold_uncertainty_score":0.9994606},"labels":[],"label_agreement":null},{"id":"W1977389467","doi":"10.1517/14656560903222281","title":"Dapagliflozin: where does it fit in the treatment of type 2 diabetes?","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"","keywords":"Dapagliflozin; Medicine; Hypoglycemia; Type 2 diabetes; Glycemic; Diabetes mellitus; Regimen; Pharmacotherapy; Drug class; Intensive care medicine; Concomitant; Clinical trial; Drug; Pharmacology; Internal medicine; Endocrinology","score_opus":0.09096050532522067,"score_gpt":0.42677421191226106,"score_spread":0.3358137065870404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977389467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000089780355,0.9920801,3.4257718e-7,0.0016244579,0.001032535,0.0026950059,0.00002119747,0.00004937892,0.002407205],"genre_scores_gemma":[0.000016066106,0.9939102,0.000080768106,0.002496294,0.00078893657,0.00050357747,0.00020748228,0.000072513176,0.0019241392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784595,0.00022974356,0.0006314549,0.0004950857,0.0004059788,0.00039178767],"domain_scores_gemma":[0.99874085,0.00018284308,0.00027325726,0.00067447015,0.00003618537,0.000092375936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016516326,0.0006334053,0.0016908739,0.00032965202,0.000044599794,0.000028887054,0.00029244868,0.0001746556,0.00083538995],"category_scores_gemma":[0.0000036384079,0.00029825457,0.00060823245,0.00044262328,0.000049453043,0.000052229665,0.000009937946,0.00016604346,0.00010073919],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009129817,0.002757612,0.00001123482,0.0009940299,0.00057946955,0.000017985769,0.0007599703,4.1736487e-7,0.000011797527,0.00005421636,0.03680135,0.9579206],"study_design_scores_gemma":[0.0027867225,0.002672318,0.0000050432786,0.005845109,0.00016644971,0.0000014654493,0.00006379566,0.000006841077,0.00016158567,0.000010260254,0.98800695,0.00027346844],"about_ca_topic_score_codex":0.000011300701,"about_ca_topic_score_gemma":0.0000027477058,"teacher_disagreement_score":0.95764714,"about_ca_system_score_codex":0.00027833576,"about_ca_system_score_gemma":0.0000916402,"threshold_uncertainty_score":0.99994695},"labels":[],"label_agreement":null},{"id":"W1978039326","doi":"10.1136/ebm.11.3.86","title":"Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes","year":2006,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Fenofibrate; Type 2 diabetes; Medicine; Term (time); Diabetes mellitus; Cardiology; Internal medicine; Endocrinology; Physics","score_opus":0.04127168741339334,"score_gpt":0.2964328759875801,"score_spread":0.2551611885741868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978039326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55927825,0.007768282,0.000008403699,0.42666173,0.002663709,0.0026739193,0.00004257449,0.00019477219,0.000708333],"genre_scores_gemma":[0.64372283,0.0008680602,0.00031899617,0.2552186,0.009020794,0.00057428924,0.005860491,0.0003474556,0.08406846],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9927313,0.00040371847,0.0014907153,0.0016870392,0.0020592667,0.0016279899],"domain_scores_gemma":[0.99627185,0.0007943857,0.00070858677,0.0015748226,0.0002699083,0.0003804342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009796572,0.0013189767,0.0021641576,0.0011699058,0.00013605127,0.000027491666,0.0006359086,0.0008770502,0.0013551252],"category_scores_gemma":[0.0005043926,0.0010621875,0.00037543094,0.0009498235,0.00036517176,0.00042651437,0.00023570472,0.0017600748,0.0005349944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008992508,0.0005883454,0.20313789,0.0034180228,0.0007076733,0.005349923,0.00006113845,0.00002018518,0.0035078304,0.0000030296435,0.77199394,0.010312792],"study_design_scores_gemma":[0.01286888,0.004896184,0.8864531,0.05158808,0.0036505503,0.000056588262,0.000032137632,0.00008425318,0.007311981,0.00008253389,0.031374205,0.0016014834],"about_ca_topic_score_codex":0.00036418464,"about_ca_topic_score_gemma":0.000019432873,"teacher_disagreement_score":0.7406197,"about_ca_system_score_codex":0.0011326623,"about_ca_system_score_gemma":0.000609267,"threshold_uncertainty_score":0.99995613},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W1978063542","doi":"10.2174/138161206776873671","title":"Glucagon and Glucagon-Like Peptide Receptors as Drug Targets","year":2006,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Glucagon; Glucagon receptor; Glucose homeostasis; Glucagon-like peptide 1 receptor; Endocrinology; Internal medicine; Proglucagon; Gastric emptying; Liraglutide; Glucagon-like peptide-1; Glucagon-like peptide-2; Receptor; Enteroendocrine cell; Incretin; Biology; Chemistry; Type 2 diabetes; Insulin; Diabetes mellitus; Agonist; Medicine; Insulin resistance; Hormone; Biochemistry; Endocrine system; Peptide","score_opus":0.11968270375138337,"score_gpt":0.41278382893776694,"score_spread":0.29310112518638354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978063542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013247221,0.9884911,0.0004133923,0.0001354448,0.0026399049,0.0038503187,0.00002444702,0.0002496774,0.0041824416],"genre_scores_gemma":[0.000013526493,0.9875563,0.00072769105,0.00020891023,0.00065742264,0.00048438637,0.0007290866,0.0001464308,0.009476287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996103,0.00039262552,0.00089334155,0.0010822392,0.00059954345,0.0009292743],"domain_scores_gemma":[0.9980126,0.00038252032,0.0002695797,0.00051101187,0.000075195014,0.00074909226],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005596213,0.0010364248,0.002218065,0.00038626732,0.00013828426,0.00011295444,0.00026708044,0.00024280568,0.00053814636],"category_scores_gemma":[0.00007650096,0.0007942861,0.0006547825,0.000422117,0.00022342804,0.00013529467,0.00024553388,0.00087498117,0.0013088506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047244812,0.00072473305,0.000009266385,0.016318034,0.0005455445,0.0001054038,0.000020086009,3.1882973e-7,0.000001123319,0.00026956986,0.13893948,0.8430192],"study_design_scores_gemma":[0.001528805,0.00023695792,0.0000036193505,0.008589458,0.008869289,0.00003719742,0.0000057289885,0.00006133723,0.000054507713,0.00009859483,0.97983265,0.00068187644],"about_ca_topic_score_codex":0.000005456662,"about_ca_topic_score_gemma":2.9792722e-7,"teacher_disagreement_score":0.8423373,"about_ca_system_score_codex":0.00036185194,"about_ca_system_score_gemma":0.00026898395,"threshold_uncertainty_score":0.99946874},"labels":[],"label_agreement":null},{"id":"W1978181046","doi":"10.2337/dc13-0553","title":"Association Between Glycemia and Mortality in Diabetic Individuals on Renal Replacement Therapy in the U.K.","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Adler","funders":"","keywords":"Medicine; Internal medicine; Peritoneal dialysis; Diabetes mellitus; Dialysis; Glycemic; Hemodialysis; Hazard ratio; Renal replacement therapy; Proportional hazards model; End stage renal disease; Gastroenterology; Surgery; Endocrinology; Confidence interval","score_opus":0.015424463087753389,"score_gpt":0.2683710613654341,"score_spread":0.2529465982776807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978181046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441624,0.00023089013,4.020145e-7,0.00095396524,0.000045820525,0.00077002874,0.00001794391,0.000024141249,0.0035405515],"genre_scores_gemma":[0.99796903,0.00006219661,0.000023187085,0.0013796872,0.00009229048,0.0001603382,0.00021781196,0.000013226015,0.00008223029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858975,0.00018394364,0.0002393886,0.0002774414,0.0003850911,0.00032437383],"domain_scores_gemma":[0.9992279,0.00029373064,0.00009250331,0.00031033394,0.000027600092,0.000047928952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007517973,0.00016073031,0.00031001592,0.00014085785,0.000039617295,0.000042410265,0.00008930363,0.00008576389,0.000018102946],"category_scores_gemma":[0.000105064326,0.000111637804,0.000050255247,0.0001993899,0.000022748667,0.00005194415,0.00003421889,0.00016497755,0.000022317017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014053705,0.00008799385,0.9794792,0.0000485065,0.00013524425,0.000001193628,0.0012491294,0.0000028667473,0.00003197153,0.000067609035,0.00045679882,0.01842541],"study_design_scores_gemma":[0.0033241143,0.0008742997,0.98962486,0.0001301298,0.00012351038,1.6944242e-8,0.0003480202,0.000019196572,0.000796589,0.00026066217,0.004389446,0.00010913423],"about_ca_topic_score_codex":0.000018767556,"about_ca_topic_score_gemma":0.000035249406,"teacher_disagreement_score":0.018316276,"about_ca_system_score_codex":0.00021441281,"about_ca_system_score_gemma":0.00001195821,"threshold_uncertainty_score":0.45524576},"labels":[],"label_agreement":null},{"id":"W1978297557","doi":"10.1210/en.2010-0289","title":"Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance","year":2010,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Internal medicine; Endocrinology; Insulin resistance; Insulin; Biology; Glucagon; Insulin receptor; Glucagon-like peptide-1; Glucose clamp technique; Protein kinase B; Glucose uptake; Carbohydrate metabolism; Type 2 diabetes; Pancreatic hormone; Diabetes mellitus; Medicine; Phosphorylation; Biochemistry","score_opus":0.013905639465382232,"score_gpt":0.24409898312213343,"score_spread":0.2301933436567512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978297557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844808,0.0003873112,0.000014040133,0.0048494916,0.002178272,0.0011250112,0.000045017867,0.00037961657,0.0065404307],"genre_scores_gemma":[0.96861285,0.00008458802,0.0053166747,0.00077310763,0.00062596356,0.0003729291,0.00024483446,0.000056333774,0.02391269],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801254,0.00007185913,0.0003480738,0.0006561634,0.0002199411,0.00069139455],"domain_scores_gemma":[0.99866545,0.00010626082,0.00019087704,0.00075242633,0.000112729766,0.00017225112],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000048045295,0.00032503382,0.0005422837,0.00016904018,0.000119529424,0.000023507164,0.00024295966,0.00017831525,0.0012943795],"category_scores_gemma":[0.00018472958,0.00028719357,0.00011024272,0.00021310376,0.00013897203,0.00008978574,0.0001708928,0.00057983404,0.0016172337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003529682,0.0018265614,0.019126987,0.00024762627,0.0017576073,0.00096478366,0.0007769764,7.5346384e-7,0.8180775,0.0052000303,0.11277477,0.035716716],"study_design_scores_gemma":[0.00843123,0.0010576824,0.16778499,0.00017039994,0.00042767287,0.000008146921,0.00036843342,0.000007501281,0.16761747,0.00085011707,0.65269196,0.0005844246],"about_ca_topic_score_codex":0.00035897983,"about_ca_topic_score_gemma":0.0011595408,"teacher_disagreement_score":0.65046006,"about_ca_system_score_codex":0.00009113464,"about_ca_system_score_gemma":0.00004480617,"threshold_uncertainty_score":0.99995804},"labels":[],"label_agreement":null},{"id":"W1978654244","doi":"10.1016/s0149-2918(02)80072-8","title":"Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Novartis","keywords":"Medicine; Nateglinide; Metformin; Glycemic; Population; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Type 2 diabetes; Cohort; Endocrinology; Environmental health","score_opus":0.05894874644330557,"score_gpt":0.3410450214186669,"score_spread":0.2820962749753613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978654244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931759,0.0047477633,0.00011335778,0.0007497776,0.00009879154,0.0010025477,0.000039851468,0.000009798481,0.00006218076],"genre_scores_gemma":[0.9943411,0.0024087445,0.0017393443,0.0014236282,0.000023402008,0.000010210276,0.0000052814357,0.000017300506,0.00003104305],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99852914,0.00009508016,0.0007965935,0.00023473617,0.00010450652,0.00023992301],"domain_scores_gemma":[0.99852216,0.00082721806,0.0001964293,0.00019516567,0.00004726387,0.00021177401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005523346,0.00015268412,0.0009383655,0.00014414509,0.000013542506,0.0000049814407,0.000056859888,0.000096320044,0.0000064907395],"category_scores_gemma":[0.00015012958,0.0001281622,0.00007782458,0.0001250601,0.00008601565,0.000038221388,0.000058346137,0.000105663006,0.0000026793236],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00913833,0.0026943935,0.096878976,0.0015545773,0.0024188785,0.000014172113,0.0029637276,0.001062052,0.011308568,0.0016211979,0.00007798954,0.87026715],"study_design_scores_gemma":[0.1255221,0.17316534,0.11821752,0.0047287582,0.003925931,0.0000075130297,0.00059587794,0.49767137,0.06646023,0.004624644,0.0033089384,0.0017717851],"about_ca_topic_score_codex":0.0000147997025,"about_ca_topic_score_gemma":0.000012539479,"teacher_disagreement_score":0.86849535,"about_ca_system_score_codex":0.000043307333,"about_ca_system_score_gemma":0.000050827624,"threshold_uncertainty_score":0.5226303},"labels":[],"label_agreement":null},{"id":"W1979078348","doi":"10.1111/dom.12393","title":"Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Tolerability; Type 2 diabetes; Placebo; Medicine; Randomized controlled trial; Pioglitazone; Clinical endpoint; Internal medicine; Diabetes mellitus; Pharmacokinetics; Pharmacology; Adverse effect; Endocrinology","score_opus":0.013940990441817559,"score_gpt":0.2524403988908831,"score_spread":0.23849940844906553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979078348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807145,0.014551398,0.000030517615,0.0004614886,0.00039383592,0.0032409297,0.000027849013,0.000027375969,0.0005520978],"genre_scores_gemma":[0.98746485,0.010374862,0.00082323607,0.0001498259,0.00023291292,0.00015799499,0.00004937645,0.000022778102,0.00072419277],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99854124,0.00017266722,0.00047847786,0.00029570874,0.00019907771,0.00031280916],"domain_scores_gemma":[0.99758995,0.0015651358,0.00023613425,0.00036536556,0.00012968309,0.00011373002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009896145,0.00026291626,0.0014715475,0.000114397124,0.00011048455,0.000019128096,0.00008263051,0.00008977088,0.000015342719],"category_scores_gemma":[0.00039061852,0.000152717,0.00027105602,0.00014764875,0.00036058598,0.00006306713,0.000041652143,0.00005155638,0.0000016257742],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33636966,0.0048300982,0.014109092,0.0010029422,0.0068227225,9.1273176e-7,0.0017574525,0.000017527942,0.003786697,0.022079164,0.00034602598,0.6088777],"study_design_scores_gemma":[0.8498256,0.0022510348,0.048532385,0.00010738373,0.0063991332,1.2466992e-7,0.000034813344,0.001646204,0.011032953,0.00096841884,0.07898935,0.00021259971],"about_ca_topic_score_codex":0.000020004834,"about_ca_topic_score_gemma":0.0000027801225,"teacher_disagreement_score":0.6086651,"about_ca_system_score_codex":0.000012927669,"about_ca_system_score_gemma":0.000025213558,"threshold_uncertainty_score":0.62276185},"labels":[],"label_agreement":null},{"id":"W1979601574","doi":"10.4021/jem.v3i3.171","title":"Effects of Sitagliptin May Depend on Clinical and Laboratory Data at the Baseline","year":2013,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Baseline (sea); Internal medicine; Insulin; Oceanography; Metformin","score_opus":0.02832988625619021,"score_gpt":0.3194677746599843,"score_spread":0.2911378884037941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979601574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770583,0.018228777,0.000009678807,0.0036687234,0.00041036523,0.00024174785,0.000007777366,0.0000042767033,0.00037039054],"genre_scores_gemma":[0.9883767,0.00826533,0.0006056659,0.0014895867,0.00032491158,0.0000047304857,0.000005628719,0.000009019023,0.00091842323],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901265,0.00018361275,0.00037581378,0.00014194501,0.00012305393,0.00016294619],"domain_scores_gemma":[0.9987336,0.00056433346,0.00022853544,0.00027474156,0.0000955812,0.00010324504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046110718,0.00010401993,0.00043307364,0.00008548387,0.00004139663,0.0000072270914,0.00011464478,0.000048592316,0.00007578676],"category_scores_gemma":[0.0004108993,0.000055515884,0.00005039225,0.000047512025,0.00018686174,0.0001019575,0.00019505649,0.00021595064,0.000012970465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017174359,0.0024060719,0.2399781,0.00054713123,0.005281884,0.0010926251,0.0002795527,0.0000023910382,0.019546937,0.010018191,0.15735015,0.56177956],"study_design_scores_gemma":[0.0070986953,0.000905468,0.6589511,0.00007550062,0.0018113647,0.00013215473,0.000072699986,0.000018597171,0.0072992346,0.00021262388,0.32333577,0.00008678346],"about_ca_topic_score_codex":0.0000071934237,"about_ca_topic_score_gemma":0.0000041561007,"teacher_disagreement_score":0.5616928,"about_ca_system_score_codex":0.000004394202,"about_ca_system_score_gemma":0.000025414482,"threshold_uncertainty_score":0.2263872},"labels":[],"label_agreement":null},{"id":"W1979726443","doi":"10.1210/en.2011-1732","title":"Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue","year":2011,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sitagliptin; Internal medicine; Endocrinology; Sitagliptin Phosphate; Secretagogue; Incretin; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Glycated hemoglobin; Chemistry; Secretion; Medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus","score_opus":0.06989227828879731,"score_gpt":0.2813291732105181,"score_spread":0.2114368949217208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979726443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9591973,0.00016234479,0.00009410453,0.0004597417,0.00073765626,0.00061354187,0.00000891255,0.0001187671,0.038607646],"genre_scores_gemma":[0.9927277,0.00010549244,0.00091243314,0.0007020692,0.00015305117,0.00007932704,0.000028909713,0.000022310001,0.0052687144],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99854994,0.000062905085,0.00033744884,0.0003751979,0.0001806924,0.0004938042],"domain_scores_gemma":[0.99905384,0.0000589626,0.00017200103,0.00054212945,0.00007676864,0.00009629329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007923118,0.00023750254,0.00039179038,0.00012721043,0.000080940146,0.000005501613,0.00020527258,0.00012352632,0.000644631],"category_scores_gemma":[0.00009265474,0.00015007642,0.00022997247,0.00019561015,0.00030137636,0.00007060891,0.00026596765,0.00023222981,0.00023586077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016606076,0.0057806773,0.35281718,0.00031362014,0.0022856744,0.00032106863,0.002976609,0.0000045274332,0.5256432,0.050513014,0.013751078,0.043932743],"study_design_scores_gemma":[0.008215966,0.004285062,0.5627282,0.00019880319,0.0008119936,0.00039580153,0.0020001126,0.00003406493,0.3032128,0.0013693791,0.11618227,0.0005655311],"about_ca_topic_score_codex":0.0002124389,"about_ca_topic_score_gemma":0.000043482156,"teacher_disagreement_score":0.22243041,"about_ca_system_score_codex":0.00006845398,"about_ca_system_score_gemma":0.00004876905,"threshold_uncertainty_score":0.7058257},"labels":[],"label_agreement":null},{"id":"W1980821438","doi":"10.1016/j.molmet.2014.11.005","title":"Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction","year":2014,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research; Novo Nordisk; Canada Research Chairs; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Alberta Innovates; Alberta Innovates - Health Solutions; Louisiana State University","keywords":"Glucagon receptor; Glucagon; Internal medicine; Endocrinology; Myocardial infarction; Ligation; Medicine; Glucagon-like peptide-1; Cardiology; Diabetes mellitus; Type 2 diabetes; Insulin","score_opus":0.006173159155069622,"score_gpt":0.2294927531705344,"score_spread":0.22331959401546478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980821438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429786,0.0011664918,0.000820809,0.0003464816,0.00030048293,0.00055273954,0.0000020695827,0.00008263464,0.0024304304],"genre_scores_gemma":[0.99531054,0.000018134228,0.003331052,0.0007267453,0.000119150944,0.00011695128,0.00005161084,0.000043914017,0.00028192336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866974,0.000094375064,0.00021907812,0.0003524759,0.00034804543,0.0003162589],"domain_scores_gemma":[0.99949735,0.000017845516,0.000061407816,0.00027606942,0.00004064747,0.00010669014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019465497,0.00024743812,0.0005244193,0.00022046364,0.000041731564,0.000036178477,0.000072473544,0.000055779874,0.000035987272],"category_scores_gemma":[0.00002438597,0.00019563835,0.00016687799,0.00020302564,0.00003966296,0.00010562,0.00005069546,0.000110936955,0.0000465217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003785705,0.00053008035,0.024810523,0.00004735663,0.0014250024,0.00006373081,0.0006197025,0.0010178775,0.957291,0.002069316,0.00012349407,0.011623342],"study_design_scores_gemma":[0.007824074,0.0003594314,0.061202995,0.00007900168,0.0007301131,0.0000068683376,0.00022452378,0.00039434026,0.88645256,0.00008029897,0.042195786,0.0004500062],"about_ca_topic_score_codex":0.00013542734,"about_ca_topic_score_gemma":0.0000025549928,"teacher_disagreement_score":0.070838444,"about_ca_system_score_codex":0.000082727805,"about_ca_system_score_gemma":0.00002000719,"threshold_uncertainty_score":0.79779005},"labels":[],"label_agreement":null},{"id":"W1981199085","doi":"10.1503/cmaj.1060216","title":"Inspired by Banting and Best","year":2007,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Medicine","score_opus":0.00797719103155837,"score_gpt":0.22836400517469588,"score_spread":0.22038681414313752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981199085","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051493845,0.0010845109,0.000011847813,0.9687366,0.0008133069,0.00019350977,0.000035504298,0.000019791032,0.023955582],"genre_scores_gemma":[0.0008770827,0.00055754575,0.00009078755,0.9644734,0.008110039,0.000004827356,0.00027188373,0.000040053543,0.02557436],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971126,0.000061789004,0.00040914468,0.00020560117,0.0015128864,0.0006980219],"domain_scores_gemma":[0.9980665,0.0001276921,0.0002622725,0.00009712498,0.00019399574,0.001252445],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009852336,0.00020673408,0.00039774246,0.00035372848,0.00018791303,0.0001231376,0.00010834636,0.0012585848,0.0019521309],"category_scores_gemma":[0.0006447691,0.00018515253,0.00010855803,0.00013973894,0.00003976975,0.00006488007,0.000018523095,0.0026490004,0.00016984032],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000015183989,0.000016772337,0.011887185,0.00003698563,0.0003511387,0.003675732,0.000027886244,6.4867054e-9,8.3959105e-7,0.0000036028666,0.94131154,0.04268681],"study_design_scores_gemma":[0.0010285306,0.000110933564,0.0010667474,0.00028081788,0.0002755526,0.00019751242,0.000041731633,0.000009798229,0.000002542087,0.000012728776,0.99681634,0.00015678126],"about_ca_topic_score_codex":0.0015566994,"about_ca_topic_score_gemma":0.002452484,"teacher_disagreement_score":0.0555048,"about_ca_system_score_codex":0.0012566469,"about_ca_system_score_gemma":0.0011293561,"threshold_uncertainty_score":0.9996519},"labels":[],"label_agreement":null},{"id":"W1981316849","doi":"10.1038/oby.2008.229","title":"GLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide","year":2008,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; National Institutes of Health","keywords":"Amide; Cleavage (geology); Chemistry; Peptide; Glucagon-like peptide-1; Internal medicine; Endocrinology; Medicine; Biochemistry; Type 2 diabetes; Diabetes mellitus; Biology","score_opus":0.01693809586306048,"score_gpt":0.2336817718398279,"score_spread":0.21674367597676744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981316849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96316653,0.00090332073,0.000021443126,0.0006227642,0.00022743583,0.00087040284,0.000018621806,0.00018282581,0.033986647],"genre_scores_gemma":[0.96548975,0.0003016055,0.0010589388,0.0008110962,0.00024075851,0.000032273227,0.00005424595,0.0000450679,0.031966254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997883,0.000050834475,0.00043015165,0.00058516307,0.0005615221,0.00048932777],"domain_scores_gemma":[0.9984301,0.000037638893,0.00019432697,0.000985574,0.0001347563,0.00021760754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024884235,0.00032940356,0.00064912514,0.00018361791,0.00014994046,0.000012050303,0.0002019596,0.0000939058,0.0003380752],"category_scores_gemma":[0.00007243991,0.000290889,0.00026674155,0.0003451157,0.00026577734,0.00017880893,0.00017348169,0.00017431525,0.0003933456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004995281,0.0023794826,0.76080644,0.0006841021,0.00071068114,0.00039718716,0.0010271254,0.000005224386,0.006555507,0.00073616643,0.21528016,0.010918358],"study_design_scores_gemma":[0.0020591351,0.0004500654,0.8748798,0.00014906748,0.00039241463,0.000022663742,0.00007429424,0.00003750946,0.0847345,0.00018108508,0.03673796,0.0002815462],"about_ca_topic_score_codex":0.00019987713,"about_ca_topic_score_gemma":0.000040610288,"teacher_disagreement_score":0.17854221,"about_ca_system_score_codex":0.00016893816,"about_ca_system_score_gemma":0.000100714846,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W1981484869","doi":"10.1038/tpj.2014.35","title":"Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children","year":2014,"lang":"en","type":"article","venue":"The Pharmacogenomics Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"rs4680; Blood pressure; Medicine; Internal medicine; Genotype; Endocrinology; Catechol-O-methyl transferase; Population; Genetics; Gene; Biology","score_opus":0.025172867325790164,"score_gpt":0.28549433940820285,"score_spread":0.2603214720824127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981484869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526054,0.000886867,0.00025188882,0.0022553322,0.00023455113,0.0007391008,0.000021635748,0.000015382951,0.00033469425],"genre_scores_gemma":[0.9962865,0.0016677651,0.000109416476,0.0006687656,0.0009207166,0.000024386538,0.000042020463,0.000025055368,0.00025537953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988852,0.00021997426,0.0003126468,0.0002075266,0.00014568362,0.0002289357],"domain_scores_gemma":[0.9994388,0.00008859287,0.00011601822,0.00022602113,0.000024787218,0.00010578125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074036716,0.00019953394,0.00023258681,0.00013474733,0.00022366567,0.00010281412,0.00012352722,0.00003807127,0.000088880864],"category_scores_gemma":[0.000008956687,0.000107656626,0.00008874767,0.00009051946,0.0000366267,0.00008676488,0.000019389534,0.00030689387,0.0000132557125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013740407,0.0029756092,0.10590968,0.000056023222,0.016297001,0.00011660736,0.0028475542,0.0029189254,0.5033613,0.0004897512,0.0015965514,0.362057],"study_design_scores_gemma":[0.047191612,0.006712966,0.3496949,0.00016908444,0.029925736,0.0028501877,0.00013360534,0.010128616,0.5143184,0.0012237676,0.03669413,0.000956986],"about_ca_topic_score_codex":0.00002274857,"about_ca_topic_score_gemma":0.000009376779,"teacher_disagreement_score":0.36110002,"about_ca_system_score_codex":0.000070238115,"about_ca_system_score_gemma":0.000022343671,"threshold_uncertainty_score":0.43901098},"labels":[],"label_agreement":null},{"id":"W1981523468","doi":"10.1016/j.jcjd.2013.06.010","title":"Cardiovascular Effects of Incretins in Diabetes","year":2013,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca; Canadian Diabetes Association; Canadian Institutes of Health Research; Novartis; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Incretin; Medicine; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Glucose homeostasis; Type 2 diabetes; Diabetes mellitus; Glucagon-like peptide 1 receptor; Receptor; Hormone; Internal medicine; Dipeptidyl peptidase; Endocrinology; Pharmacology; Insulin resistance; Agonist; Biology; Biochemistry","score_opus":0.014459895902739776,"score_gpt":0.23880703485929575,"score_spread":0.22434713895655597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981523468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025141124,0.9721953,3.1692505e-7,0.0000298182,0.0005118074,0.0011840417,0.000016291015,0.00000585431,0.00091539795],"genre_scores_gemma":[0.005821373,0.9931922,0.00018572416,0.00007407872,0.00027540277,0.000082671366,0.000041862888,0.00009055035,0.00023615778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739635,0.00021165423,0.0010826329,0.00024965018,0.00035569866,0.0007040066],"domain_scores_gemma":[0.99753714,0.00033276016,0.00062206574,0.00051958195,0.00019238313,0.00079605065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005878714,0.0004760306,0.0040399204,0.0017553199,0.000030652856,0.000037194095,0.00034734883,0.0002872705,0.00008613564],"category_scores_gemma":[0.00045675473,0.0003613533,0.0018695603,0.00055629644,0.0001391536,0.000128881,0.000034750177,0.00048176057,0.000035437464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[3.6515559e-7,0.00006166941,0.020475946,0.043971863,0.0055263466,0.00015560392,0.000049880397,0.0000012900879,0.0000019559359,0.00003367247,0.002162314,0.9275591],"study_design_scores_gemma":[0.0010737786,0.00056989596,0.0025150455,0.0516782,0.008727385,0.0000031231973,0.000013804027,0.0000016547459,0.000054929344,0.00003366655,0.9350139,0.00031462315],"about_ca_topic_score_codex":0.0003863471,"about_ca_topic_score_gemma":0.00032645723,"teacher_disagreement_score":0.93285155,"about_ca_system_score_codex":0.0004560335,"about_ca_system_score_gemma":0.0014221148,"threshold_uncertainty_score":0.99988383},"labels":[],"label_agreement":null},{"id":"W1981671332","doi":"10.1111/jch.12425","title":"Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Research and Development","keywords":"Medicine; Canagliflozin; Intravascular volume status; Diuresis; Empagliflozin; Blood pressure; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Adverse effect; Cardiology; Endocrinology; Urology; Renal function","score_opus":0.00747390044131917,"score_gpt":0.2573378970816243,"score_spread":0.24986399664030512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981671332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985025,0.00056168804,4.5367568e-7,0.00032344987,0.0001689151,0.0004025947,7.869266e-7,0.0000044778208,0.00003513154],"genre_scores_gemma":[0.9992998,0.00019296762,0.00019009839,0.00019184654,0.00003207632,0.0000012584537,0.0000035188418,0.0000148484,0.000073588664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843657,0.00026493744,0.0006253853,0.00018966703,0.000331164,0.0001522908],"domain_scores_gemma":[0.99879855,0.00037367138,0.00026212478,0.00018170729,0.00016558311,0.00021836883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011169872,0.00013922811,0.0007992429,0.00015418987,0.000017658254,0.0000030943118,0.000047401696,0.00009971995,0.000007171507],"category_scores_gemma":[0.0012109809,0.00008218776,0.00008428855,0.0001354912,0.000042666004,0.00005417025,0.00003697599,0.0002023627,0.00000228145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032770275,0.0009523639,0.9511447,0.00020152303,0.0012240767,0.000038296683,0.000029524846,0.00006122191,0.00020996854,0.0000041484227,0.00019004446,0.042667113],"study_design_scores_gemma":[0.011998005,0.02688292,0.9554491,0.0010645483,0.003606495,0.0000024884944,0.0000043232526,0.0002558725,0.00036082615,0.000020031557,0.0002757512,0.00007964197],"about_ca_topic_score_codex":0.000011097327,"about_ca_topic_score_gemma":0.000002870337,"teacher_disagreement_score":0.04258747,"about_ca_system_score_codex":0.000007645836,"about_ca_system_score_gemma":0.000017751776,"threshold_uncertainty_score":0.33515197},"labels":[],"label_agreement":null},{"id":"W1981875401","doi":"10.1053/j.gastro.2009.05.057","title":"ErbB Signaling Is Required for the Proliferative Actions of GLP-2 in the Murine Gut","year":2009,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Canadian Cancer Society","keywords":"ErbB; Cell biology; Cancer research; Signal transduction; Medicine; Biology","score_opus":0.03789321765397385,"score_gpt":0.3095896526115355,"score_spread":0.27169643495756163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981875401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562651,0.00006897336,0.0014750656,0.040204063,0.00007735557,0.0012130738,0.00000913562,0.00001401135,0.0006732357],"genre_scores_gemma":[0.9925262,0.000019670468,0.00054611365,0.0064100786,0.000078413905,0.00010107522,0.000015617132,0.000004700223,0.00029816802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935186,0.00004351911,0.00017975298,0.00012530609,0.000082363375,0.00021722558],"domain_scores_gemma":[0.9996023,0.00007349386,0.00006685913,0.00020310978,0.00003556256,0.000018648441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018352896,0.00008478292,0.00017822148,0.00006235871,0.00004701565,0.0000057294524,0.000098168166,0.000023867226,0.000032694028],"category_scores_gemma":[0.000022757313,0.000045328507,0.00008071166,0.000067033245,0.0000532851,0.000031997723,0.000015502104,0.00006874676,0.000002947532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020040488,0.009795662,0.65856373,0.000430493,0.004368224,0.00014522916,0.03113302,0.00077652826,0.069616705,0.01722108,0.1139913,0.073917545],"study_design_scores_gemma":[0.02121762,0.026403299,0.9054668,0.00018769316,0.0017023963,0.000072958246,0.0046595675,0.0021766187,0.00921846,0.003632703,0.025071338,0.00019054631],"about_ca_topic_score_codex":0.0000075176376,"about_ca_topic_score_gemma":0.00003242285,"teacher_disagreement_score":0.24690308,"about_ca_system_score_codex":0.000021916145,"about_ca_system_score_gemma":0.000008497694,"threshold_uncertainty_score":0.18484429},"labels":[],"label_agreement":null},{"id":"W1982028492","doi":"10.2165/00019053-200018030-00007","title":"The Economic Value of a New Insulin Preparation, Humalog?? Mix 25???","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"Eli Lilly Canada","keywords":"Willingness to pay; Insulin lispro; Medicine; Confidence interval; Insulin; Human insulin; Economics; Internal medicine; Microeconomics","score_opus":0.01617676700983851,"score_gpt":0.31315808945981577,"score_spread":0.29698132244997727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982028492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9336195,0.00081596576,0.000009878627,0.0018790794,0.00023859754,0.00049366313,0.000011561151,0.0000418698,0.0628899],"genre_scores_gemma":[0.9682375,0.0032220578,0.00045369568,0.0014055663,0.00035565544,0.000029484083,0.000046916586,0.000027167218,0.026221946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925375,0.000015776457,0.00032772936,0.0001816899,0.00003832919,0.00018270334],"domain_scores_gemma":[0.99948645,0.000046475896,0.000095466436,0.00025597663,0.000010712138,0.00010493937],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014186658,0.000120292345,0.00020312371,0.000037778897,0.00007610454,0.000028718843,0.0001276222,0.000027763506,0.0018124565],"category_scores_gemma":[0.0000040977734,0.000096801385,0.000101445505,0.000026130505,0.000047064572,0.00010754044,0.000026415382,0.000055979992,0.00085660274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013347534,0.00034741833,0.0041610547,0.00008010153,0.0016949712,0.0000068409895,0.00092970894,0.0073159067,0.0009765653,0.016320975,0.34778342,0.6190483],"study_design_scores_gemma":[0.0031215162,0.00018892769,0.0026067665,0.000010458324,0.00027355066,0.000003448208,0.000026861533,0.008839464,0.007879651,0.0008480839,0.97608185,0.000119403296],"about_ca_topic_score_codex":0.00008331564,"about_ca_topic_score_gemma":0.000015940414,"teacher_disagreement_score":0.62829846,"about_ca_system_score_codex":0.00017045895,"about_ca_system_score_gemma":0.00012717838,"threshold_uncertainty_score":0.9999213},"labels":[],"label_agreement":null},{"id":"W1982089393","doi":"10.1016/j.jcjd.2013.08.085","title":"Efficacy and Safety of Lixisenatide in Elderly Type 2 Diabetes Mellitus Patients: Subanalysis from the GetGoal Program","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lixisenatide; Medicine; Metformin; Hypoglycemia; Internal medicine; Placebo; Type 2 Diabetes Mellitus; Odds ratio; Diabetes mellitus; Sulfonylurea; Type 2 diabetes; Semaglutide; Body mass index; Endocrinology; Exenatide; Liraglutide","score_opus":0.007183846499996715,"score_gpt":0.21358983789327396,"score_spread":0.20640599139327725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982089393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120015,0.006200501,2.9896984e-7,0.001413664,0.00012618914,0.0005892358,0.000013035403,0.0000056974736,0.0004512018],"genre_scores_gemma":[0.99898326,0.00011907602,0.00038851157,0.0003004483,0.00007490809,0.000014102814,0.000034725996,0.000017681812,0.000067275505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866366,0.000070711416,0.000520487,0.00014613666,0.00020973597,0.00038924214],"domain_scores_gemma":[0.9985392,0.00028054923,0.00024885975,0.00021886804,0.000298282,0.00041424748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002137953,0.00016738674,0.00048993353,0.00029619565,0.000054825596,0.000059712962,0.000167123,0.00006186939,0.00024683552],"category_scores_gemma":[0.00030287326,0.00011022997,0.00011459799,0.00035903434,0.00015233208,0.00017103046,0.000019152567,0.00017033904,0.0000076290166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000083526365,0.00012825469,0.81669784,0.00002477161,0.0005157758,0.000003225807,0.00023226519,0.000005339307,0.000035439356,0.000020822994,0.0012157036,0.18111221],"study_design_scores_gemma":[0.0024516163,0.001131363,0.9895157,0.000287569,0.0005049468,8.493614e-8,0.00015714599,0.00007547538,0.00021797666,0.00020404445,0.0053460286,0.00010804945],"about_ca_topic_score_codex":0.0019768637,"about_ca_topic_score_gemma":0.004335086,"teacher_disagreement_score":0.18100417,"about_ca_system_score_codex":0.00010936183,"about_ca_system_score_gemma":0.00019170418,"threshold_uncertainty_score":0.44950476},"labels":[],"label_agreement":null},{"id":"W1982615647","doi":"10.1016/s1499-2671(09)33266-9","title":"adding liraglutide to existing therapy improves glycaemic control: evidence from a meta-analysis of six large randomised clinical trials","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Type 2 diabetes; Clinical trial; Meta-analysis; Internal medicine; Randomized controlled trial; Glucagon-like peptide-1; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.2024087426938351,"score_gpt":0.40286511029975763,"score_spread":0.20045636760592253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982615647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97359645,0.022008846,0.00016263648,0.002790186,0.00020484324,0.0008506635,0.00013058214,0.000010354006,0.0002454551],"genre_scores_gemma":[0.9945431,0.00010857574,0.0013937937,0.0034869637,0.0002837396,0.00001531139,0.000015034197,0.000017008499,0.00013647543],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960849,0.0006988232,0.0020750992,0.00027972177,0.0003427954,0.0005186028],"domain_scores_gemma":[0.99288034,0.0041095936,0.0012484627,0.00037404877,0.0003624803,0.0010250738],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007586195,0.00026306172,0.0038739964,0.0009309737,0.000075706026,0.00006824293,0.00027714213,0.00010039852,0.0004290566],"category_scores_gemma":[0.009114804,0.00017904799,0.003121989,0.0006124521,0.000052676318,0.00018237678,0.0000096073945,0.00022261002,0.000004760059],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024339831,0.00044374744,0.28204712,0.000042716958,0.5974315,0.00014593922,0.0010096548,0.00023203845,0.02587913,0.00016244438,0.006546992,0.08362476],"study_design_scores_gemma":[0.051696967,0.0042863833,0.3066172,0.00048580524,0.6246095,7.790219e-7,0.00028171315,0.000942833,0.004089972,0.00028029972,0.0061919135,0.0005166519],"about_ca_topic_score_codex":0.00047047957,"about_ca_topic_score_gemma":0.0016519461,"teacher_disagreement_score":0.08310811,"about_ca_system_score_codex":0.0001097687,"about_ca_system_score_gemma":0.00046470444,"threshold_uncertainty_score":0.9992318},"labels":[],"label_agreement":null},{"id":"W1982905493","doi":"10.1111/dom.12273","title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Canagliflozin; Metformin; Sitagliptin; Medicine; Placebo; Pioglitazone; Internal medicine; Type 2 diabetes; Endocrinology; Adverse effect; Urology; Diabetes mellitus; Gastroenterology; Pharmacology","score_opus":0.0058425061165601816,"score_gpt":0.20625429057641928,"score_spread":0.2004117844598591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982905493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996344,0.0019359934,0.0000015440902,0.00007135732,0.000081404076,0.00062884623,0.000018515992,0.00002107734,0.00089731364],"genre_scores_gemma":[0.9986344,0.00036269822,0.00032655048,0.00035962093,0.000040100582,0.000013166858,0.00006342719,0.000022191296,0.00017786586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871725,0.00006379279,0.0002527305,0.00036426727,0.0002372436,0.0003647198],"domain_scores_gemma":[0.99924576,0.00015914437,0.000095000774,0.0002537894,0.00006236013,0.00018392102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003313789,0.00025971478,0.00067727896,0.000231986,0.00006493923,0.000026777616,0.00005220433,0.00008548043,0.0000215869],"category_scores_gemma":[0.00006929234,0.00019191387,0.00003100032,0.00021860411,0.00016156516,0.00015840592,0.00008933088,0.0001231803,0.0000028208005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028812027,0.0006165051,0.9647123,0.00024664143,0.00028594647,0.0000011378612,0.00014498596,0.000001335439,0.00014056964,0.0021034149,0.00007529476,0.0313837],"study_design_scores_gemma":[0.008789946,0.00089709833,0.9832776,0.00018306125,0.0004830634,6.707671e-8,0.000023733315,0.000058747893,0.00069501065,0.00017187416,0.0052207494,0.0001990038],"about_ca_topic_score_codex":0.000079018224,"about_ca_topic_score_gemma":0.000045434874,"teacher_disagreement_score":0.031184696,"about_ca_system_score_codex":0.000022354101,"about_ca_system_score_gemma":0.000014069149,"threshold_uncertainty_score":0.7826021},"labels":[],"label_agreement":null},{"id":"W1982999222","doi":"10.1172/jci78371","title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk","keywords":"Endocrinology; Agonist; Glucagon-like peptide-1; Internal medicine; Weight loss; Receptor; Glucagon; Glucagon-like peptide 1 receptor; Insulin; Diabetes mellitus; Chemistry; Gastric emptying; Hormone; Biology; Obesity; Medicine; Type 2 diabetes","score_opus":0.04995993102065931,"score_gpt":0.32967399250644447,"score_spread":0.27971406148578515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982999222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97197336,0.00019490687,0.00023102763,0.025576968,0.0005677553,0.00023249832,2.6544419e-7,0.0000070773453,0.0012161509],"genre_scores_gemma":[0.9886161,0.00017170761,0.0016109066,0.008630767,0.0007341306,0.000004339916,0.0000052598252,0.00000890766,0.0002178863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819386,0.0003049332,0.00096690096,0.00011927219,0.00028885013,0.00012619956],"domain_scores_gemma":[0.9979301,0.001176264,0.000517469,0.0001328994,0.00009461624,0.00014863144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036378568,0.000098171746,0.0004055249,0.0001052766,0.00003631142,0.000036693178,0.000086089734,0.000082491526,0.000013716519],"category_scores_gemma":[0.0019312898,0.000057580884,0.00013122012,0.00012338637,0.00013056793,0.00015579077,0.000017711853,0.00033341668,0.0000063059024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006044152,0.0006366523,0.8572306,0.00012784089,0.00060154486,0.000030875042,0.0011691097,0.00002492154,0.0005048803,0.010485106,0.040554043,0.08803001],"study_design_scores_gemma":[0.016892644,0.008676424,0.6826887,0.00079697353,0.00079239334,0.000039426115,0.000493499,0.0036613625,0.0003920625,0.021848518,0.2634986,0.00021938563],"about_ca_topic_score_codex":0.000003161719,"about_ca_topic_score_gemma":0.000010617264,"teacher_disagreement_score":0.22294457,"about_ca_system_score_codex":0.00002164379,"about_ca_system_score_gemma":0.00004889643,"threshold_uncertainty_score":0.23480803},"labels":[],"label_agreement":null},{"id":"W1983068468","doi":"10.2337/diacare.29.02.06.dc06-0006","title":"Gut and Adipocyte Peptides","year":2006,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Endocrinology; Internal medicine; Incretin; Medicine; Type 2 diabetes; Gastric emptying; Insulin; Glucagon-like peptide-1; Glucose homeostasis; Liraglutide; Dipeptidyl peptidase-4; Diabetes mellitus; Somatostatin; Insulin resistance; Stomach","score_opus":0.005617760099335168,"score_gpt":0.2136238523422724,"score_spread":0.20800609224293723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983068468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94687015,0.0037552142,8.671624e-7,0.0002146714,0.00006040675,0.0002282751,0.000011360433,0.00009213851,0.0487669],"genre_scores_gemma":[0.9961506,0.000029116021,0.00041584717,0.00037426557,0.00012345808,0.000034174656,0.00016196693,0.00001670931,0.0026938482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999402,0.000006988668,0.00009205773,0.00017500797,0.00010550929,0.00021842222],"domain_scores_gemma":[0.99969995,0.000017900278,0.000021760201,0.00016134654,0.000039010876,0.000060029248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023646115,0.000112958005,0.00016712425,0.0000652046,0.00004358863,0.00002641343,0.000029163728,0.000033564786,0.000049825314],"category_scores_gemma":[0.0000069478556,0.0000938398,0.000052150554,0.00006673751,0.000041307725,0.000050859897,0.000036890426,0.0000384251,0.0001464673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000051116367,0.00004268089,0.9580498,0.00018164425,0.00007181768,0.0000123936625,0.000096402226,0.0000013170618,0.0020349447,0.0005810336,0.008867363,0.030055512],"study_design_scores_gemma":[0.0011875776,0.00021787985,0.89669245,0.00008810638,0.00029703698,4.6990675e-7,0.00030464798,0.000027453154,0.0060293367,0.00021514104,0.09479916,0.0001407445],"about_ca_topic_score_codex":0.000010621172,"about_ca_topic_score_gemma":0.000010503175,"teacher_disagreement_score":0.08593179,"about_ca_system_score_codex":0.00003521974,"about_ca_system_score_gemma":0.000007884355,"threshold_uncertainty_score":0.3826676},"labels":[],"label_agreement":null},{"id":"W1983368629","doi":"10.1016/j.jcjd.2014.07.023","title":"Lixisenatide is Effective and Well Tolerated in Patients with Type 2 Diabetes Mellitus and Renal Impairment","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lixisenatide; Medicine; Glucagon-like peptide 1 receptor; Type 2 Diabetes Mellitus; Agonist; Diabetes mellitus; Internal medicine; Type 2 diabetes; Liraglutide; Exenatide; Endocrinology; Glucagon-like peptide-1; Receptor","score_opus":0.0027747305346793017,"score_gpt":0.18119583380339238,"score_spread":0.17842110326871308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983368629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692416,0.0015806487,6.3242516e-7,0.00041038878,0.00008426948,0.00037343253,0.000004739799,0.000004573432,0.0006171335],"genre_scores_gemma":[0.99893737,0.000022316433,0.00017082736,0.000707046,0.00004535944,0.0000060824605,0.0000104106575,0.000018114613,0.000082466206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905145,0.00005252204,0.00022909205,0.0001601431,0.00014869105,0.0003580935],"domain_scores_gemma":[0.9989832,0.000080512924,0.00011975476,0.00010727734,0.00016445221,0.00054481503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002242801,0.00017046276,0.00038084373,0.0003653935,0.000050401577,0.000047689944,0.00004828002,0.00004858077,0.000043338667],"category_scores_gemma":[0.000056944154,0.00012382225,0.000031415162,0.00018563683,0.0000950613,0.0001253329,0.000012394909,0.00013072847,0.0000039233178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002447688,0.00006428466,0.98157704,0.00006571892,0.00023583655,0.000007848636,0.00028043045,0.0000036826946,0.000035098026,0.000018320454,0.0010046042,0.016682642],"study_design_scores_gemma":[0.0041052015,0.0037960215,0.98641455,0.00047150996,0.0002105894,4.086784e-7,0.000038972936,0.000114866925,0.001112262,0.00009511633,0.003500746,0.00013974804],"about_ca_topic_score_codex":0.00010896873,"about_ca_topic_score_gemma":0.00075930194,"teacher_disagreement_score":0.016542893,"about_ca_system_score_codex":0.00012559799,"about_ca_system_score_gemma":0.000105130595,"threshold_uncertainty_score":0.50493246},"labels":[],"label_agreement":null},{"id":"W1983616459","doi":"10.1136/bmj.g2366","title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","year":2014,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Hospital for Sick Children; Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Odds ratio; Meta-analysis; Subgroup analysis; Randomized controlled trial; Observational study; Type 2 diabetes; Relative risk; Confidence interval; Diabetes mellitus; Endocrinology","score_opus":0.03412727947425863,"score_gpt":0.3191964012004547,"score_spread":0.2850691217261961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983616459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055690203,0.98053354,7.442605e-7,0.000018822968,0.00000904531,0.013686565,0.00008499539,0.0000067224128,0.00009056405],"genre_scores_gemma":[0.0010121544,0.99651265,0.0002558411,0.000028903323,0.000005712746,0.0018098982,0.00016723199,0.000027570784,0.00018003167],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970761,0.00061334466,0.0014854315,0.000412598,0.00023323699,0.00017928779],"domain_scores_gemma":[0.99638313,0.0012969268,0.0015494641,0.00052389875,0.0001626512,0.000083947634],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0013259151,0.00052376156,0.016474145,0.0004314561,0.000023965626,0.00001066662,0.000054093503,0.00008409016,0.000022060753],"category_scores_gemma":[0.00054691377,0.00025342105,0.00075325987,0.00048058125,0.00013239005,0.00003290903,0.000059664904,0.00006252895,9.88297e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002900714,0.000122131,0.0033880887,0.58894306,0.40258285,0.000002053627,0.00007242287,1.2183656e-7,1.2015881e-8,0.0000022768631,0.000040012685,0.0045568747],"study_design_scores_gemma":[0.023925008,0.0008388121,0.0005645816,0.05676497,0.91696346,3.2765635e-7,0.00001636264,0.0000038889884,5.3694293e-7,0.000001598678,0.0007355799,0.00018485117],"about_ca_topic_score_codex":0.00004355511,"about_ca_topic_score_gemma":0.000025939098,"teacher_disagreement_score":0.5321781,"about_ca_system_score_codex":0.000053136417,"about_ca_system_score_gemma":0.000030792784,"threshold_uncertainty_score":0.9999918},"labels":[],"label_agreement":null},{"id":"W1984664578","doi":"10.2165/00024677-200201020-00005","title":"Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1","year":2002,"lang":"en","type":"review","venue":"Treatments in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Liraglutide; Internal medicine; Glucagon-like peptide-1; Endocrinology; Medicine; Incretin; Diabetes mellitus; Metformin; Enteroendocrine cell; Appetite; Glucose homeostasis; Gastric emptying; Type 2 Diabetes Mellitus; Proglucagon; Neogenesis; Insulin; Type 2 diabetes; Insulin resistance; Islet; Hormone; Endocrine system; Stomach","score_opus":0.05906743904910236,"score_gpt":0.3391125682522326,"score_spread":0.2800451292031303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984664578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003426956,0.9892358,0.00000603854,0.00010244456,0.0005319542,0.0018113682,0.000014456859,0.000054195323,0.007901004],"genre_scores_gemma":[0.0016203246,0.9860767,0.00013043542,0.00009168524,0.00008540622,0.00043965026,0.00013921295,0.000070447466,0.011346098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976528,0.00021114195,0.00073098403,0.00051764754,0.00022738683,0.0006600406],"domain_scores_gemma":[0.99858713,0.00013435134,0.00037509785,0.00081739423,0.000028221355,0.0000578198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006286385,0.000572148,0.002060389,0.0004349617,0.00006608203,0.000015363908,0.00028709404,0.00018996489,0.00032952294],"category_scores_gemma":[0.000010456586,0.000326626,0.0005995847,0.00033823692,0.00023302881,0.000045879773,0.00015569462,0.0003059757,0.00022593756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019095603,0.000941144,0.00023966975,0.0020852685,0.0027315586,0.00054029236,0.000055601864,9.626451e-7,7.0985476e-7,0.00035877177,0.0002951324,0.9927318],"study_design_scores_gemma":[0.0025566814,0.00052993634,0.0005023859,0.0030464826,0.009922254,0.00024082718,0.00005162012,0.000008151719,0.0000057646957,0.00009103776,0.98280245,0.00024242654],"about_ca_topic_score_codex":0.00005944352,"about_ca_topic_score_gemma":0.000008271197,"teacher_disagreement_score":0.99248934,"about_ca_system_score_codex":0.00031905537,"about_ca_system_score_gemma":0.000084362386,"threshold_uncertainty_score":0.9999186},"labels":[],"label_agreement":null},{"id":"W1984956794","doi":"10.5539/ijb.v5n4p29","title":"Measurement of GLP-1 in Impaired Glucose Tolerance Subjects in Comparison to Type 2 Diabetes Patients and Healthy Subjects","year":2013,"lang":"en","type":"article","venue":"International Journal of Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Impaired glucose tolerance; Medicine; Incretin; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology; Glucagon; Hormone","score_opus":0.02210589120303846,"score_gpt":0.2934108184535516,"score_spread":0.27130492725051314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984956794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963866,0.001142983,0.0000070456845,0.0015803815,0.00046835365,0.00027839787,0.0000017522538,0.0000024377684,0.00013205486],"genre_scores_gemma":[0.9989498,0.00012973242,0.00026035318,0.0005879835,0.000046570392,0.000007900735,0.000006269265,0.0000049249784,0.0000064516476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990175,0.000051048868,0.00046256577,0.0000994235,0.00022080098,0.00014869466],"domain_scores_gemma":[0.99916685,0.00003765518,0.00020432867,0.000053329975,0.00046192692,0.00007589019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002599948,0.00008167977,0.00031475094,0.00036805682,0.000005216541,0.0000068882914,0.00009813714,0.000038725215,0.000022958506],"category_scores_gemma":[0.0001511187,0.00006426333,0.000032505915,0.000108914464,0.000025632942,0.000066854824,0.000042666485,0.0000724459,0.0000054642323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004578522,0.0005923844,0.963286,0.00002319346,0.000107374995,0.0000058609544,0.00018952547,0.000015970738,0.006516311,0.000035819092,0.00036725815,0.028402463],"study_design_scores_gemma":[0.0036103283,0.0026319323,0.9879859,0.00023469934,0.000014388084,0.0000013083463,0.00004359849,0.0001102964,0.0047232145,0.00014426488,0.00044865807,0.000051411385],"about_ca_topic_score_codex":0.00011686608,"about_ca_topic_score_gemma":0.00016020023,"teacher_disagreement_score":0.02835105,"about_ca_system_score_codex":0.00018310749,"about_ca_system_score_gemma":0.00004778655,"threshold_uncertainty_score":0.26205826},"labels":[],"label_agreement":null},{"id":"W1985097668","doi":"10.1007/s11255-012-0180-6","title":"Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus","year":2012,"lang":"en","type":"article","venue":"International Urology and Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Peritoneal dialysis; Glycemic; Nephrology; Diabetes mellitus; Internal medicine; Glycated hemoglobin; Retrospective cohort study; Dialysis; Peritoneal equilibration test; Surgery; Type 2 diabetes; Insulin; Continuous ambulatory peritoneal dialysis; Endocrinology","score_opus":0.004779562770163975,"score_gpt":0.2183577350549282,"score_spread":0.21357817228476422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985097668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455667,0.0010188485,0.000016260825,0.0028517342,0.00022589086,0.00018124505,0.000008173064,0.000014519375,0.0011266465],"genre_scores_gemma":[0.9966394,0.00010347648,0.0000610439,0.0029288486,0.00011136215,0.00004002193,0.000052771626,0.000007782045,0.000055338365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930304,0.000049243798,0.00013036617,0.00017459445,0.00008677164,0.0002559958],"domain_scores_gemma":[0.9996471,0.00013041546,0.000042267722,0.00007053623,0.000034099805,0.000075583324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010397119,0.00010938551,0.00024255647,0.00015154578,0.000025369356,0.00000581986,0.000038656017,0.000087295084,0.00007549259],"category_scores_gemma":[0.000021606927,0.00008443429,0.00002044959,0.000041700026,0.00016718854,0.00009134073,0.000039991104,0.00009623691,0.000009152233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015914922,0.00027335077,0.9912579,0.000005464865,0.00042122492,0.0000075689936,0.000099160134,0.0000013389376,0.00007417733,0.0021091208,0.000047048114,0.004112162],"study_design_scores_gemma":[0.006837932,0.00080151676,0.9814256,0.0000026063822,0.00020562531,0.0000037276957,0.000010016936,0.00016942565,0.000009889896,0.00017632726,0.010286176,0.000071170674],"about_ca_topic_score_codex":0.0000147642095,"about_ca_topic_score_gemma":0.000034663943,"teacher_disagreement_score":0.010239128,"about_ca_system_score_codex":0.000018536892,"about_ca_system_score_gemma":0.000006703471,"threshold_uncertainty_score":0.34431303},"labels":[],"label_agreement":null},{"id":"W1985975881","doi":"10.1016/j.tem.2007.06.005","title":"Incretin-based therapies: mimetics versus protease inhibitors","year":2007,"lang":"en","type":"review","venue":"Trends in Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incretin; Dipeptidyl peptidase; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Receptor; Internal medicine; Endocrinology; Gastric inhibitory polypeptide; Chemistry; Insulin; Biochemistry; Diabetes mellitus; Glucagon; Medicine; Enzyme; Type 2 diabetes; Agonist","score_opus":0.06770167351672597,"score_gpt":0.3669911391571497,"score_spread":0.29928946564042375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985975881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004318274,0.98832554,0.0000038444546,0.0001584759,0.00092419045,0.00085686386,0.000020961264,0.000104861625,0.009173437],"genre_scores_gemma":[0.00028788068,0.9949105,0.0009835514,0.00016847668,0.00032536968,0.0003521979,0.00030391393,0.000066394925,0.0026017532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976101,0.00018171234,0.0006462354,0.0006159193,0.00020387888,0.0007421327],"domain_scores_gemma":[0.9988148,0.00024643756,0.00022642783,0.0005117024,0.000030802872,0.00016981586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023755645,0.00061949645,0.0021421635,0.0017245146,0.000058404796,0.000016164839,0.00014925766,0.00036879117,0.0002189957],"category_scores_gemma":[0.00006243519,0.0004662934,0.00039632994,0.00064275356,0.00027635595,0.000038136208,0.00010793743,0.0006329875,0.000043243384],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016208911,0.00029059398,0.00006558492,0.001974645,0.00065148703,0.00035957087,0.00004996912,9.342206e-8,2.8363146e-7,0.0017918281,0.00040263147,0.99425125],"study_design_scores_gemma":[0.0057790233,0.00023725587,0.00027393445,0.00134232,0.0037918526,0.000020358057,0.000026736996,0.0000014570514,0.00001378394,0.000026022433,0.98814803,0.00033920226],"about_ca_topic_score_codex":0.00003240747,"about_ca_topic_score_gemma":0.00001618988,"teacher_disagreement_score":0.99391204,"about_ca_system_score_codex":0.00008356108,"about_ca_system_score_gemma":0.000102692546,"threshold_uncertainty_score":0.99977887},"labels":[],"label_agreement":null},{"id":"W1986255434","doi":"10.1002/oby.20042","title":"Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study)","year":2013,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Manna Research","funders":"","keywords":"Medicine; Glycemic; Placebo; Internal medicine; Metformin; Weight loss; Type 2 diabetes; Diabetes mellitus; Adverse effect; Nausea; Gastroenterology; Type 2 Diabetes Mellitus; Vomiting; Obesity; Endocrinology; Insulin","score_opus":0.0020611083686956815,"score_gpt":0.1864673460024293,"score_spread":0.18440623763373362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986255434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719965,0.00018365176,5.431486e-7,0.000037075635,0.00006044106,0.0018501065,0.0000017728489,0.000019222405,0.000647537],"genre_scores_gemma":[0.9995126,0.00002215929,0.000031202875,0.000121577235,0.00001335429,0.00006484836,0.000011236874,0.000011912474,0.0002111111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992519,0.00004062561,0.0001320028,0.00019631597,0.00018019137,0.0001989634],"domain_scores_gemma":[0.99955463,0.00007604373,0.00005471757,0.00018014599,0.00005749339,0.0000769752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057504814,0.00013758989,0.0003128085,0.00009997987,0.000021799327,0.00000647822,0.000042714677,0.000031030206,0.00004311473],"category_scores_gemma":[0.000038322924,0.000093258495,0.000021042,0.0001317476,0.00003298047,0.00006868522,0.000031506534,0.0000688684,0.000042263928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034059287,0.0029911308,0.9936955,0.00016740311,0.00018410012,0.000009347169,0.00006984426,3.493109e-7,0.00054626586,0.000022299499,0.0002885729,0.0016845776],"study_design_scores_gemma":[0.011642919,0.004557529,0.9822558,0.00015293379,0.00022808046,2.5415215e-8,0.000014734807,0.000043434753,0.0009064319,0.000034540717,0.00007775506,0.000085785985],"about_ca_topic_score_codex":0.00010392687,"about_ca_topic_score_gemma":0.000023329854,"teacher_disagreement_score":0.011439688,"about_ca_system_score_codex":0.000038832117,"about_ca_system_score_gemma":0.00000841586,"threshold_uncertainty_score":0.3802971},"labels":[],"label_agreement":null},{"id":"W1986522335","doi":"10.1021/bi0014498","title":"Biological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo","year":2001,"lang":"en","type":"article","venue":"Biochemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université du Québec à Montréal","funders":"","keywords":"In vivo; Receptor; Chemistry; In vitro; Secretin; Glucagon; Biological activity; Glucagon-like peptide-1; Endocrinology; Internal medicine; Glucagon-like peptide 1 receptor; Peptide; Glucose homeostasis; Biochemistry; Insulin; Biology; Diabetes mellitus; Hormone; Agonist; Medicine; Pancreas; Insulin resistance; Type 2 diabetes","score_opus":0.01675697021728593,"score_gpt":0.2497599687336935,"score_spread":0.23300299851640757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986522335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909832,0.0005991195,9.0639156e-7,0.000121394485,0.00001620929,0.00008833036,0.0000055769506,0.000012526453,0.008172772],"genre_scores_gemma":[0.9977459,0.0003835583,0.00016167131,0.00006641431,0.00002370674,0.000013642141,0.000027146838,0.0000040064997,0.0015740016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995293,0.0000068456616,0.000120459474,0.00015027258,0.000059276867,0.00013384102],"domain_scores_gemma":[0.99979687,0.000025017851,0.000028836776,0.000107586966,0.000006400022,0.000035276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005842642,0.0000830412,0.00018620213,0.00005658559,0.000006185391,0.0000037907384,0.000031449665,0.00006315712,0.000036255246],"category_scores_gemma":[0.000019190898,0.0000673093,0.000027715781,0.00009906836,0.000072323695,0.000020145777,0.000038920152,0.00004729693,9.2019064e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024184871,0.00027126897,0.17865187,0.000091846196,0.000027806567,0.00006366692,0.000047776215,1.6337054e-7,0.81817573,0.0000061443457,0.0003614441,0.0020603968],"study_design_scores_gemma":[0.0012146769,0.00008180424,0.045023784,0.00008850222,0.00001942521,0.0000059781555,0.0006226169,0.000020470814,0.9514718,0.000029231356,0.0013391132,0.00008260799],"about_ca_topic_score_codex":0.000043641896,"about_ca_topic_score_gemma":0.000008655477,"teacher_disagreement_score":0.13362809,"about_ca_system_score_codex":0.000050825085,"about_ca_system_score_gemma":0.000012802838,"threshold_uncertainty_score":0.2744794},"labels":[],"label_agreement":null},{"id":"W1987019089","doi":"10.4021/jocmr1256w","title":"Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Type 2 diabetes; Dipeptidyl peptidase-4 inhibitor; Concomitant; Diabetes mellitus; Internal medicine; Sitagliptin Phosphate; Dipeptidyl peptidase-4; Adverse effect; Hemoglobin; Gastroenterology; Combination therapy; Pharmacology; Surgery; Endocrinology","score_opus":0.23989513740321558,"score_gpt":0.4736287439737221,"score_spread":0.23373360657050654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987019089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789333,0.00019681374,0.000003022939,0.0006705213,0.00006598143,0.0009959547,0.0000066887874,0.0000069121784,0.00016076687],"genre_scores_gemma":[0.9988474,0.00014051115,0.00013739611,0.000041391762,0.000108949615,0.00001086229,0.000058240577,0.00002732186,0.0006278763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964982,0.00027266904,0.0012827248,0.00020590724,0.0013855348,0.00035495844],"domain_scores_gemma":[0.9905528,0.004286648,0.0009220131,0.00030132043,0.0036331723,0.00030408223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023757855,0.00016650396,0.001654475,0.00112091,0.000029790235,0.00000901721,0.00019125402,0.00011668501,0.0004948537],"category_scores_gemma":[0.006166978,0.0000731521,0.00026020478,0.0023751378,0.00042454238,0.000090699294,0.0000295695,0.00035246916,0.000001457687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038689533,0.0025702203,0.95740825,0.00005091413,0.01290557,0.000006839592,0.00019057794,0.0000073408223,0.0003185453,0.000002361861,0.0023437368,0.020326702],"study_design_scores_gemma":[0.0155329555,0.033778682,0.9457343,0.0007607822,0.0029159707,5.4283493e-8,0.00025023363,0.00006821877,0.00070490566,0.000010345067,0.0001731801,0.00007035318],"about_ca_topic_score_codex":0.000021796186,"about_ca_topic_score_gemma":0.0000074431387,"teacher_disagreement_score":0.031208461,"about_ca_system_score_codex":0.000060590974,"about_ca_system_score_gemma":0.00021622333,"threshold_uncertainty_score":0.7382894},"labels":[],"label_agreement":null},{"id":"W1987067408","doi":"10.1111/dom.12399","title":"Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Boehringer Ingelheim","keywords":"Linagliptin; Metformin; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Randomized controlled trial; Population; Diabetes mellitus; Confidence interval; Gastroenterology; Adverse effect; Endocrinology; Insulin","score_opus":0.017033997711860458,"score_gpt":0.27282690052652775,"score_spread":0.25579290281466727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987067408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936865,0.00088509545,0.00004463164,0.00016659663,0.00015540287,0.004840417,0.000014818409,0.000035150435,0.00017138886],"genre_scores_gemma":[0.9945844,0.00058117026,0.0037235322,0.0002424504,0.00012335484,0.00042392543,0.00022820603,0.000033992346,0.000058965357],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742746,0.0004653738,0.0007774647,0.0005379053,0.0004085261,0.00038328592],"domain_scores_gemma":[0.99755746,0.0012769579,0.00047124323,0.00022863058,0.0002640848,0.0002016386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014527185,0.00040312042,0.0021197384,0.00035786527,0.000101053774,0.00006257089,0.00008870566,0.0001955284,0.000012314378],"category_scores_gemma":[0.00037273482,0.0002761729,0.00012836729,0.00025564202,0.00044914044,0.0002862178,0.00007801542,0.0002627247,8.8153416e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63662684,0.0028421415,0.33252713,0.00013035904,0.0009967472,0.000002333752,0.00025762562,0.000006745423,0.000014806392,0.0012527062,0.000010674538,0.02533188],"study_design_scores_gemma":[0.62204766,0.0015678242,0.373498,0.000104149054,0.0009056221,1.4355459e-7,0.000037036414,0.0012115376,0.000061062805,0.00022236149,0.00014289173,0.00020169333],"about_ca_topic_score_codex":0.00003474016,"about_ca_topic_score_gemma":0.000045874865,"teacher_disagreement_score":0.040970862,"about_ca_system_score_codex":0.000021707501,"about_ca_system_score_gemma":0.000039413473,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W1987885913","doi":"10.1111/1755-5922.12005","title":"DPP‐4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes","year":2012,"lang":"en","type":"article","venue":"Cardiovascular Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Canadian Diabetes Association","keywords":"Medicine; Internal medicine; Sitagliptin; Cardiology; Myocardial infarction; Diabetes mellitus; Heart failure; Dipeptidyl peptidase-4; Cardiac function curve; Endothelial dysfunction; Ventricular remodeling; Endocrinology; Type 2 diabetes","score_opus":0.01779868698759369,"score_gpt":0.234695889526835,"score_spread":0.21689720253924133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987885913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757837,0.022016432,0.00023875394,0.0000624927,0.00046320492,0.0006951674,0.0000016524205,0.00007940801,0.0006591786],"genre_scores_gemma":[0.99830115,0.00048021998,0.00041490886,0.0002477938,0.00029625784,0.00010538345,0.00007465241,0.000044989098,0.00003467198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986372,0.00010308164,0.00019318482,0.00028358502,0.00038356526,0.00039935857],"domain_scores_gemma":[0.999479,0.000022081907,0.000039125454,0.0003160051,0.00003888333,0.00010492121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050434866,0.00023684266,0.00046999,0.00016539326,0.00009208704,0.00002486543,0.00002243622,0.0000973351,0.0000031611642],"category_scores_gemma":[0.0000055938604,0.00020244507,0.00055309635,0.00020426945,0.000046641988,0.00036903555,0.000038528746,0.00013121177,0.000010096176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003408736,0.00054321636,0.79994035,0.00017926053,0.018966133,0.000036245787,0.0024433173,0.0011315668,0.09368349,0.00011262137,0.00004243991,0.0825805],"study_design_scores_gemma":[0.030893624,0.0024505418,0.6296003,0.0015654882,0.030290829,0.000056977853,0.01195649,0.004222386,0.23205829,0.00014143027,0.054045442,0.0027182347],"about_ca_topic_score_codex":0.000012226424,"about_ca_topic_score_gemma":6.756583e-7,"teacher_disagreement_score":0.17034008,"about_ca_system_score_codex":0.00020413441,"about_ca_system_score_gemma":0.000016700307,"threshold_uncertainty_score":0.825547},"labels":[],"label_agreement":null},{"id":"W1988049600","doi":"10.1038/ki.2013.427","title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","year":2013,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canada Research Chairs","keywords":"Endocrinology; Internal medicine; Diabetic nephropathy; NAD(P)H oxidase; Incretin; Medicine; Chemistry; Kidney; Oxidative stress; NADPH oxidase; Diabetes mellitus; Type 2 diabetes","score_opus":0.007061282597769432,"score_gpt":0.22952623725879776,"score_spread":0.22246495466102834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988049600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98968405,0.00021892233,0.00043115302,0.006422693,0.00019105322,0.00078980526,0.000006383404,0.000018736642,0.0022372059],"genre_scores_gemma":[0.9982084,0.000037243837,0.00034323407,0.00047953558,0.000056992954,0.000147977,0.0000128242955,0.00000916374,0.00070463144],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99935126,0.000024676629,0.00015978582,0.00012738751,0.00020941386,0.0001274663],"domain_scores_gemma":[0.999662,0.000032697364,0.00006310374,0.000088228204,0.00009257792,0.00006138367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012059504,0.00008302553,0.00010816326,0.00009221071,0.000039537357,0.00004088549,0.000083711915,0.00002822456,0.00014938915],"category_scores_gemma":[0.00005429069,0.00005539601,0.000038163067,0.00005617142,0.00004981113,0.00006720922,0.00005264065,0.00006692,0.000017343807],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004569045,0.001394907,0.051028334,0.00020829352,0.002917167,0.000052752235,0.003063469,0.00009027658,0.5998364,0.13984914,0.0015489471,0.19955342],"study_design_scores_gemma":[0.015196381,0.0019117092,0.2749019,0.0010837861,0.00069948635,0.000029850404,0.0030133054,0.062199812,0.2653474,0.36929205,0.0056406315,0.0006837173],"about_ca_topic_score_codex":0.00007103609,"about_ca_topic_score_gemma":0.0000067091664,"teacher_disagreement_score":0.334489,"about_ca_system_score_codex":0.000051222887,"about_ca_system_score_gemma":0.00004132637,"threshold_uncertainty_score":0.22589837},"labels":[],"label_agreement":null},{"id":"W1988468478","doi":"10.1016/j.ejphar.2008.07.070","title":"The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat","year":2008,"lang":"en","type":"article","venue":"European Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Crohn's in Childhood Research Association","keywords":"Crypt; Glucagon-like peptide-2; Internal medicine; Endocrinology; Medicine; Atrophy; Parenteral nutrition; Short bowel syndrome; Dose–response relationship; Pharmacology; Biology; Peptide; Biochemistry","score_opus":0.021726222461094687,"score_gpt":0.32852061746708255,"score_spread":0.3067943950059879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988468478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569815,0.00017201711,0.00017867879,0.0015125504,0.0002356394,0.00025819844,3.9901184e-7,0.0000013925646,0.0019429801],"genre_scores_gemma":[0.9986415,0.00050673063,0.0004107752,0.00027783663,0.000059148915,0.0000024120736,4.7364594e-7,0.000005140314,0.00009599071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984628,0.0010477077,0.00024513964,0.000056311655,0.000107795146,0.00008026493],"domain_scores_gemma":[0.99891925,0.00071947265,0.00024318724,0.000060307426,0.000034957422,0.000022811033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011595673,0.00005958172,0.00016494766,0.00010799718,0.00003068984,0.0000028445859,0.00007371209,0.000009880371,0.0000065320514],"category_scores_gemma":[0.00008457717,0.000033278346,0.00004062277,0.00011134057,0.000054789863,0.00004296834,0.000017600549,0.000155824,0.0000010221322],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055884,0.004790497,0.018641995,0.00034246055,0.00076149777,0.0034063742,0.0075828484,0.00008594621,0.820095,0.0009948009,0.01101672,0.12669346],"study_design_scores_gemma":[0.01253395,0.009380885,0.8599469,0.00014815918,0.00054523663,0.00017086825,0.00021034104,0.00028776188,0.10940244,0.000043607077,0.0072495025,0.00008032626],"about_ca_topic_score_codex":0.0000018432511,"about_ca_topic_score_gemma":0.0000032053974,"teacher_disagreement_score":0.8413049,"about_ca_system_score_codex":0.00002126756,"about_ca_system_score_gemma":0.000036113368,"threshold_uncertainty_score":0.13570516},"labels":[],"label_agreement":null},{"id":"W1989069545","doi":"10.1074/jbc.m113.512046","title":"A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice","year":2013,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Lausanne; University of Toronto; Ulster University; Diabetes Research and Wellness Foundation","keywords":"Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Glucagon; Endocrinology; Internal medicine; Receptor; Agonist; Peptide; Chemistry; Medicine; Insulin; Diabetes mellitus; Type 2 diabetes; Biochemistry","score_opus":0.015879343865499277,"score_gpt":0.2313202070687385,"score_spread":0.2154408632032392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989069545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962344,0.0014209871,0.0001315845,0.00086574466,0.00020320404,0.0005593262,0.0000117597465,0.000046138804,0.00052682665],"genre_scores_gemma":[0.9953716,0.00094702264,0.0014873467,0.00031645218,0.00031924978,0.000033010198,0.000028961718,0.000040269817,0.0014561279],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975224,0.00007963816,0.0007277639,0.00059285836,0.00044881963,0.00062852306],"domain_scores_gemma":[0.99827397,0.00015672884,0.0007091074,0.00027600722,0.00015757071,0.00042661864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030939467,0.0005240079,0.0009466603,0.000116682844,0.00016722102,0.00012570665,0.00020529123,0.00025168867,0.00025369972],"category_scores_gemma":[0.000108035376,0.0003480034,0.00018435599,0.00018617096,0.0002914596,0.00022116989,0.00024063239,0.00067288673,0.000011827298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002663091,0.0009946146,0.036258534,0.00021625422,0.0005255441,0.0002428458,0.000089969544,0.000008230611,0.93499947,0.000004090503,0.00019442078,0.02380293],"study_design_scores_gemma":[0.018200321,0.004025117,0.25262603,0.0006562614,0.00075056416,0.0011880916,0.0010102325,0.00026467306,0.71746707,0.00012580391,0.002756292,0.00092954474],"about_ca_topic_score_codex":0.00026827064,"about_ca_topic_score_gemma":0.000021046468,"teacher_disagreement_score":0.21753241,"about_ca_system_score_codex":0.00043165707,"about_ca_system_score_gemma":0.00008088781,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W1989188472","doi":"10.1172/jci43615","title":"Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Glucagon receptor; Internal medicine; Endocrinology; Incretin; Glucose homeostasis; Glucagon; Receptor; Glucagon-like peptide 1 receptor; Biology; Glucagon-like peptide-1; Agonist; Insulin; Type 2 diabetes; Diabetes mellitus; Insulin resistance; Medicine","score_opus":0.0892509425484842,"score_gpt":0.3407440297576234,"score_spread":0.2514930872091392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989188472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592096,0.000049526257,0.000009538128,0.0030515047,0.00018902833,0.00023270358,6.044824e-7,0.0000016830086,0.00054446113],"genre_scores_gemma":[0.9981893,0.000102324804,0.0009608614,0.0005972491,0.00009630986,0.000002886422,0.0000015529511,0.0000039036386,0.000045664365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982631,0.0003726807,0.0009502728,0.000080446865,0.00025498818,0.00007848966],"domain_scores_gemma":[0.9985221,0.00060850196,0.000645791,0.00007831482,0.000093654744,0.00005164335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024741478,0.00006543729,0.0002620228,0.00009621958,0.000019326113,0.000007956943,0.00007981106,0.00007483299,0.000014661237],"category_scores_gemma":[0.002828839,0.000034974775,0.00007200486,0.00020388936,0.0001983568,0.000115151546,0.000027578222,0.00026353044,0.0000012084163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035202398,0.00037670173,0.9827303,0.00007269093,0.00004876549,0.000009371197,0.0029294412,0.0000045136526,0.0013502475,0.001247824,0.0009783024,0.0098997615],"study_design_scores_gemma":[0.0014691798,0.0006884481,0.99040663,0.00036013703,0.00011900475,0.0000049318724,0.00038596927,0.00009388145,0.0030420967,0.0031865805,0.00021073586,0.000032387892],"about_ca_topic_score_codex":0.000052498664,"about_ca_topic_score_gemma":0.00005684056,"teacher_disagreement_score":0.009867373,"about_ca_system_score_codex":0.000028380542,"about_ca_system_score_gemma":0.00006081865,"threshold_uncertainty_score":0.3386589},"labels":[],"label_agreement":null},{"id":"W1989405402","doi":"10.1503/cmaj.045292","title":"Metformin's contraindications should be contraindicated","year":2005,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Metformin; Medicine; Diabetes mellitus; Type 2 diabetes; Type 2 Diabetes Mellitus; Drug; Intensive care medicine; Internal medicine; Endocrinology; Pharmacology","score_opus":0.047342607631254544,"score_gpt":0.33651004205632634,"score_spread":0.2891674344250718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989405402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024898986,0.94550425,0.000015785343,0.026322164,0.00062433886,0.001000965,0.00021555982,0.000059340273,0.026255108],"genre_scores_gemma":[0.000013793823,0.97283053,0.00012750363,0.014085933,0.0026566116,0.000091995025,0.0007687252,0.00006894982,0.009355956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952668,0.0002130697,0.0011786671,0.00033538096,0.0020260385,0.0009800208],"domain_scores_gemma":[0.9944901,0.0003298733,0.0008783455,0.00027134578,0.0003249559,0.0037053782],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001982732,0.00044989778,0.001830407,0.00092160824,0.00033535733,0.00015243416,0.0003806192,0.0013722881,0.011788279],"category_scores_gemma":[0.0017529234,0.0003526792,0.00084794604,0.00054533046,0.00007485071,0.00012449066,0.000025872361,0.0020523642,0.0008208994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000012196988,0.00007538879,0.00003063643,0.00024281809,0.0017836976,0.0006316688,0.000033214208,2.4085715e-8,5.0640674e-9,0.00041666807,0.1918507,0.80493397],"study_design_scores_gemma":[0.0014543247,0.00007754134,0.00005261722,0.0026220982,0.003677139,0.00070897606,0.00003989141,0.000007066965,4.313767e-8,0.000016734177,0.9910575,0.00028602695],"about_ca_topic_score_codex":0.00034540106,"about_ca_topic_score_gemma":0.004922712,"teacher_disagreement_score":0.8046479,"about_ca_system_score_codex":0.004452484,"about_ca_system_score_gemma":0.010792931,"threshold_uncertainty_score":0.9999571},"labels":[],"label_agreement":null},{"id":"W1989600614","doi":"10.1503/cmaj.090252","title":"Cardiovascular risk and glycemic control","year":2009,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Glycemic; Medicine; Diabetes mellitus; Intensive care medicine; Internal medicine; Cardiology; Endocrinology","score_opus":0.003691489237117908,"score_gpt":0.18974754694680146,"score_spread":0.18605605770968356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989600614","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014346188,0.0055882977,0.00008831214,0.98344916,0.00085108704,0.00039982103,0.00006967815,0.000031741296,0.008087292],"genre_scores_gemma":[0.0071318015,0.0029436168,0.00005200402,0.97279906,0.013054289,0.000011106276,0.00011773693,0.000037585014,0.003852796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965503,0.00020585975,0.00038374917,0.00025833744,0.0019369833,0.00066477375],"domain_scores_gemma":[0.9979038,0.00012271965,0.0002500337,0.00020320236,0.00023309664,0.0012871191],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011039604,0.0002492591,0.00072246115,0.00033573085,0.00019524226,0.00011473016,0.00012628648,0.0013118483,0.001098931],"category_scores_gemma":[0.0008120684,0.00021315367,0.00046366197,0.00011394234,0.00003515394,0.000056332075,0.000009083978,0.003505468,0.00015361658],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009608624,0.000008232707,0.004610459,0.000020474952,0.002613906,0.0057601975,0.000017691455,6.7247964e-7,3.4050814e-8,0.0000030881947,0.8877073,0.09924831],"study_design_scores_gemma":[0.0042113513,0.00019361546,0.004237049,0.00015291374,0.0021849906,0.00036878054,0.000012875191,0.000038438284,1.4759014e-7,0.000094134935,0.9883265,0.00017921343],"about_ca_topic_score_codex":0.0015540194,"about_ca_topic_score_gemma":0.001094277,"teacher_disagreement_score":0.10061917,"about_ca_system_score_codex":0.0015590303,"about_ca_system_score_gemma":0.0015271872,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W1989633716","doi":"10.1016/j.diabres.2004.07.006","title":"Controlling diabetes: the need for intensive therapy and barriers in clinical management","year":2004,"lang":"en","type":"review","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Hypoglycemia; Diabetes management; Clinical trial; Disease; Disease management; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.2219009278284254,"score_gpt":0.5277611770666032,"score_spread":0.3058602492381778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989633716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002154196,0.981828,0.0000057662446,0.004883252,0.00035495913,0.008901929,0.000027898368,0.00003848732,0.0018055086],"genre_scores_gemma":[0.0005195817,0.9925155,0.0007347344,0.0034102376,0.00043655117,0.0014748864,0.00010168692,0.00008918503,0.0007176142],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99302036,0.0018223359,0.0020294036,0.0012024959,0.00070833514,0.0012171017],"domain_scores_gemma":[0.96513677,0.032144193,0.00051488326,0.0008179448,0.00069181377,0.00069442723],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.016119726,0.00054197566,0.002764086,0.00040267987,0.00030059472,0.00028548326,0.0003812507,0.00052962493,0.000023082082],"category_scores_gemma":[0.019657647,0.00032427642,0.0007291569,0.0005914408,0.0011819786,0.00024919782,0.00046233842,0.0022125128,0.00003456576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046234237,0.0006675535,0.0028859724,0.0066810953,0.0041120634,0.00006727056,0.000038795737,1.0214885e-7,3.4431686e-8,0.0012369436,0.0018708614,0.981977],"study_design_scores_gemma":[0.007904634,0.004105977,0.0007675382,0.008479011,0.0025145414,0.000001624821,0.0010137488,0.00007390648,2.0554273e-7,0.0010893197,0.9737421,0.00030734547],"about_ca_topic_score_codex":0.000012066812,"about_ca_topic_score_gemma":0.0000049848254,"teacher_disagreement_score":0.9816696,"about_ca_system_score_codex":0.00016398232,"about_ca_system_score_gemma":0.00036186466,"threshold_uncertainty_score":0.9999209},"labels":[],"label_agreement":null},{"id":"W1990025047","doi":"10.1161/circulationaha.113.005081","title":"Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus","year":2013,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"American Diabetes Association","keywords":"Empagliflozin; Medicine; Renal function; Glomerular hyperfiltration; Internal medicine; Effective renal plasma flow; Endocrinology; Renal blood flow; Diabetes mellitus; Tubuloglomerular feedback; Plasma renin activity; Aldosterone; Filtration fraction; Type 2 diabetes; Urology; Renin–angiotensin system; Blood pressure; Diabetic nephropathy","score_opus":0.003918426627373016,"score_gpt":0.1937316932782741,"score_spread":0.1898132666509011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990025047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998355,0.00007561956,0.000045356563,0.000027273987,0.00003825168,0.0009643092,0.0000014760219,0.000021971324,0.0004707693],"genre_scores_gemma":[0.99927014,0.000004684986,0.00006733922,0.000030313427,0.000012026456,0.000038324528,0.00054959697,0.000011728422,0.000015832627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940324,0.000021426253,0.0001561884,0.00013306717,0.00016146828,0.00012463835],"domain_scores_gemma":[0.9996947,0.000017309461,0.00006167032,0.00012585837,0.00006754654,0.0000328836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062249375,0.00009367136,0.00017926049,0.00011559716,0.000011867819,0.000006484671,0.0000122262145,0.000039927843,0.00008399776],"category_scores_gemma":[0.0000061638184,0.00006949144,0.000030308036,0.00015724383,0.0000229718,0.00013887459,0.0000045156435,0.0000389027,0.00003416465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010336847,0.00016771749,0.9832967,0.00014323309,0.00005525663,0.0000013505597,0.000044951586,0.00007447142,0.004699416,0.000019207933,0.000022151993,0.011372161],"study_design_scores_gemma":[0.0035198177,0.000547872,0.98571515,0.00016463311,0.0001404473,6.6380295e-8,0.0000021392352,0.0011551465,0.008612393,0.00006351636,0.000012567863,0.00006627354],"about_ca_topic_score_codex":0.000017718246,"about_ca_topic_score_gemma":0.0000044744725,"teacher_disagreement_score":0.011305887,"about_ca_system_score_codex":0.00006497666,"about_ca_system_score_gemma":0.0000074243067,"threshold_uncertainty_score":0.28337786},"labels":[],"label_agreement":null},{"id":"W1990079700","doi":"10.1136/ebn.14.1.26","title":"Intensive dietary advice significantly improves HbA(1c) in people with type 2 diabetes who remain hyperglycaemic despite optimised drug treatment","year":2010,"lang":"en","type":"letter","venue":"Evidence-Based Nursing","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Type 2 diabetes; Medicine; Drug; Diabetes mellitus; Internal medicine; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.022316382111799916,"score_gpt":0.2646658404745412,"score_spread":0.2423494583627413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990079700","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5574555,0.0065863123,0.000019468695,0.429199,0.0012609608,0.0040447284,0.00002907251,0.00039300756,0.0010119496],"genre_scores_gemma":[0.35988343,0.002186324,0.013170919,0.5930463,0.005163734,0.0014860795,0.0031737802,0.0008865488,0.021002848],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954912,0.00028583937,0.00070915656,0.0014180079,0.00079268933,0.0013031234],"domain_scores_gemma":[0.9965363,0.0009704446,0.00046429806,0.001267695,0.0005011854,0.00026007058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039109495,0.0011424915,0.0017058288,0.000899613,0.00016768047,0.00015533956,0.00035900399,0.00080313336,0.00011797554],"category_scores_gemma":[0.00027775345,0.0008716288,0.0003463841,0.00084884913,0.0003531487,0.0004085269,0.000045960755,0.0020827975,0.000076054836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041028066,0.0016983224,0.036337852,0.0032546096,0.0020191758,0.004486121,0.00440535,0.00032709556,0.018264512,0.000004036061,0.8130358,0.11206433],"study_design_scores_gemma":[0.052282773,0.057796236,0.107976966,0.29654622,0.03686092,0.00014310546,0.0073618973,0.017590145,0.07209818,0.00040723584,0.337862,0.013074309],"about_ca_topic_score_codex":0.0004073659,"about_ca_topic_score_gemma":0.0002563405,"teacher_disagreement_score":0.47517377,"about_ca_system_score_codex":0.001679325,"about_ca_system_score_gemma":0.0007292932,"threshold_uncertainty_score":0.99937344},"labels":[],"label_agreement":null},{"id":"W1990327895","doi":"10.1016/s1098-3015(10)73565-8","title":"PDB21 ECONOMIC EVALUATION OF RAPID-ACTING INSULIN ANALOGUES FOR THE TREATMENT OF PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS IN CANADA","year":2009,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Type 2 Diabetes Mellitus; Insulin; Type (biology); Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus; Biology","score_opus":0.04562122178715243,"score_gpt":0.2896453177501117,"score_spread":0.24402409596295926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990327895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918255,0.0064808493,5.8567986e-7,0.00032914474,0.000072276474,0.0012152259,0.000010953406,0.0000020767088,0.00006335533],"genre_scores_gemma":[0.9977761,0.0018691103,0.00018381994,0.00007411395,0.000012037682,0.000018405803,0.00005677934,0.000004912991,0.0000047028234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933356,0.00005341608,0.0002480835,0.00011060167,0.00011571701,0.00013860865],"domain_scores_gemma":[0.99950975,0.00014489196,0.0001321007,0.000113494825,0.00006851812,0.000031260945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003240827,0.00007212622,0.00023713429,0.0000740978,0.000016393684,0.0000020665527,0.00002159169,0.000013213223,0.000007088243],"category_scores_gemma":[0.00003353574,0.000046151803,0.000010958304,0.00011793371,0.000011899867,0.000023562208,0.0000029020155,0.000018442517,1.7039507e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024760337,0.00031822492,0.5689745,0.00012000185,0.000079843754,2.3330321e-7,0.00053179334,0.0042791357,0.0000031944362,0.0000551074,0.000040632993,0.4253497],"study_design_scores_gemma":[0.0041935896,0.004896375,0.9719157,0.00014391984,0.00010722703,2.4741416e-8,0.00021472122,0.017434519,0.00018446703,0.000087155815,0.00077378313,0.000048514226],"about_ca_topic_score_codex":0.21780941,"about_ca_topic_score_gemma":0.12799571,"teacher_disagreement_score":0.4253012,"about_ca_system_score_codex":0.0007750507,"about_ca_system_score_gemma":0.0007037894,"threshold_uncertainty_score":0.8879161},"labels":[],"label_agreement":null},{"id":"W1991798879","doi":"10.1038/sj.tpj.6500346","title":"cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects","year":2005,"lang":"en","type":"article","venue":"The Pharmacogenomics Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; Foundation for the National Institutes of Health","keywords":"Clozapine; Endocrinology; Internal medicine; Dyslipidemia; Atypical antipsychotic; Incretin; Antipsychotic; Haloperidol; Biology; Medicine; Diabetes mellitus; Type 2 diabetes; Dopamine; Schizophrenia (object-oriented programming)","score_opus":0.012443905455430653,"score_gpt":0.2794358790168472,"score_spread":0.2669919735614165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991798879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828843,0.014670086,0.000055075896,0.0005536354,0.00038436105,0.0010777015,0.000006349858,0.000035138353,0.00033338484],"genre_scores_gemma":[0.9923953,0.0053481646,0.0006991785,0.00031605636,0.00084543804,0.00004435418,0.000015362873,0.00005770587,0.0002784507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977352,0.0002992975,0.0007110061,0.00030938405,0.0003780617,0.0005670188],"domain_scores_gemma":[0.9987905,0.00012986432,0.00035074307,0.00039099215,0.000039572868,0.00029833106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055230723,0.00036698856,0.00072651566,0.00031507833,0.0001565437,0.000025559151,0.00027949625,0.000066705834,0.0000855182],"category_scores_gemma":[0.00003006837,0.00024594218,0.00043789216,0.00023409887,0.00004084913,0.00018870157,0.00006371024,0.00038322463,0.00006877435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011590942,0.0010558848,0.010293941,0.000044205375,0.0007347262,0.00014130067,0.0005178032,0.00018363234,0.93857676,0.000026041394,0.000043048283,0.04722355],"study_design_scores_gemma":[0.024218177,0.00050631375,0.030892998,0.0003491674,0.0017633983,0.00008712184,0.00009610938,0.00041858596,0.937332,0.000093313865,0.0039935578,0.00024930222],"about_ca_topic_score_codex":0.000043139466,"about_ca_topic_score_gemma":0.00002116609,"teacher_disagreement_score":0.046974245,"about_ca_system_score_codex":0.00075451116,"about_ca_system_score_gemma":0.00015605036,"threshold_uncertainty_score":0.9999993},"labels":[],"label_agreement":null},{"id":"W1991984011","doi":"10.1016/j.ahj.2010.05.019","title":"Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs","year":2010,"lang":"en","type":"editorial","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"McMaster University; Hamilton Health Sciences; Heart and Stroke Foundation of Canada","keywords":"Medicine; Clinical trial; Diabetes mellitus; Rosiglitazone; Intensive care medicine; Pharmacology; Internal medicine; Endocrinology","score_opus":0.05261127710242883,"score_gpt":0.42212054433546214,"score_spread":0.36950926723303334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991984011","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15672399,0.03729934,0.0008828612,0.017011596,0.7720276,0.015659587,0.00015681029,0.000038019156,0.00020019365],"genre_scores_gemma":[0.5007117,0.024909616,0.0018767435,0.00042518385,0.4706224,0.0010816412,0.00009073296,0.00010237239,0.00017967346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99607164,0.0012401689,0.0011465648,0.0002300609,0.0011046609,0.00020688653],"domain_scores_gemma":[0.9727138,0.024322983,0.0011362518,0.00070527504,0.0010249574,0.00009668487],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01993093,0.00022005188,0.0024550168,0.00012370665,0.00016699483,0.000031048578,0.00018962876,0.00016563643,0.000006563898],"category_scores_gemma":[0.017360382,0.00010002386,0.001988932,0.00015624122,0.0008580294,0.000036940386,0.00005868992,0.0006182678,9.817926e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005211561,0.00034086048,0.017229678,0.0004670973,0.01978104,5.927351e-7,0.0003121376,0.000009664469,0.000055692475,0.00011057348,0.67817765,0.28299385],"study_design_scores_gemma":[0.026634464,0.0019162915,0.17333111,0.0005220079,0.08345129,0.000010865648,0.0003904358,0.000116983094,0.00015733481,0.0010673823,0.712134,0.0002677998],"about_ca_topic_score_codex":0.00008541872,"about_ca_topic_score_gemma":0.0000026674688,"teacher_disagreement_score":0.34398767,"about_ca_system_score_codex":0.000038408252,"about_ca_system_score_gemma":0.0004736562,"threshold_uncertainty_score":0.9909168},"labels":[],"label_agreement":null},{"id":"W1992085758","doi":"10.1016/j.atherosclerosis.2010.06.033","title":"Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia","year":2010,"lang":"en","type":"letter","venue":"Atherosclerosis","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Postprandial; Insulin resistance; Dyslipidemia; Internal medicine; Hyperlipidemia; Endocrinology; Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Lipoprotein; Obesity; Type 2 diabetes; Insulin; Cholesterol","score_opus":0.011877605624417484,"score_gpt":0.2430044139966325,"score_spread":0.23112680837221503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992085758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87421924,0.00060713734,0.00000803292,0.115281396,0.0028443078,0.0033484998,0.000081259546,0.00022286052,0.0033872423],"genre_scores_gemma":[0.82636267,0.002294416,0.00093907135,0.1410868,0.008028654,0.0013825449,0.004762878,0.0006630975,0.01447984],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774,0.00019774926,0.0005226388,0.00058273406,0.00045580894,0.0005010737],"domain_scores_gemma":[0.9987019,0.00015192895,0.00033127415,0.00068273046,0.000063599895,0.000068613444],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003493763,0.0005224367,0.0010651019,0.00034172533,0.00004894969,0.00003939687,0.00021076163,0.0015142671,0.00043787606],"category_scores_gemma":[0.000045532674,0.00041757838,0.00037369836,0.00037315275,0.00014378797,0.000081399245,0.00005869153,0.0018524646,0.00015310281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021390764,0.00070244004,0.01822172,0.0017236235,0.0019568957,0.000029369317,0.0007188108,0.0000020729028,0.21682568,0.000013788834,0.68187946,0.07578709],"study_design_scores_gemma":[0.018488985,0.010389366,0.034772664,0.0028797667,0.0035752938,0.000009370633,0.00004443631,0.00002262398,0.06323601,0.00007332253,0.86530185,0.0012062814],"about_ca_topic_score_codex":0.0002728101,"about_ca_topic_score_gemma":0.000011669151,"teacher_disagreement_score":0.18342243,"about_ca_system_score_codex":0.00025254057,"about_ca_system_score_gemma":0.000058329257,"threshold_uncertainty_score":0.9998276},"labels":[],"label_agreement":null},{"id":"W1992116679","doi":"10.1210/en.2012-1937","title":"GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice","year":2012,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":346,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Endocrinology; Internal medicine; Steatosis; Apolipoprotein E; Agonist; Biology; Receptor; Triglyceride; Lipid metabolism; Glucagon-like peptide 1 receptor; Medicine; Cholesterol","score_opus":0.04380102791348758,"score_gpt":0.28964287583703113,"score_spread":0.24584184792354355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992116679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974602,0.0000620265,0.000032412412,0.0006415149,0.00038879938,0.0005405393,0.0000043758073,0.000048758662,0.0008213615],"genre_scores_gemma":[0.99430865,0.000085460575,0.003387802,0.00015008426,0.00011449396,0.00017065887,0.00007843728,0.00002157857,0.0016828325],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865174,0.000077836325,0.0003984146,0.00023012656,0.00017046054,0.00047142647],"domain_scores_gemma":[0.9994166,0.00010861254,0.0001813508,0.00018267651,0.000042367737,0.00006842228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014262798,0.00017409913,0.00034814715,0.00027273112,0.000046310102,0.0000067485676,0.00008068191,0.00006942219,0.00023174497],"category_scores_gemma":[0.00008112151,0.0001387684,0.000048279915,0.00017224529,0.000054342305,0.00017821105,0.00007460829,0.00010091068,0.000113369104],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014919786,0.00060485303,0.4956988,0.00012638562,0.0001790793,7.729181e-7,0.002154233,0.0000035463172,0.45105827,0.00010382248,0.00009028777,0.049830724],"study_design_scores_gemma":[0.0010229208,0.000100472615,0.39498985,0.000085705644,0.00005525866,6.654773e-7,0.00019278988,0.000011980351,0.6018899,0.000006761576,0.0015452384,0.000098482415],"about_ca_topic_score_codex":0.000062171726,"about_ca_topic_score_gemma":0.000021804548,"teacher_disagreement_score":0.15083161,"about_ca_system_score_codex":0.00019334705,"about_ca_system_score_gemma":0.00003554368,"threshold_uncertainty_score":0.56588113},"labels":[],"label_agreement":null},{"id":"W1992391104","doi":"10.1038/oby.2010.198","title":"<i>DPP4</i>Gene DNA Methylation in the Omentum is Associated With Its Gene Expression and Plasma Lipid Profile in Severe Obesity","year":2010,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University and Génome Québec Innovation Centre; Université du Québec à Chicoutimi; Université Laval","funders":"Canadian Institutes of Health Research; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Genome Canada; McGill University","keywords":"DNA methylation; CpG site; Methylation; Endocrinology; Internal medicine; Genotype; Biology; Medicine; Gene expression; Gene; Genetics","score_opus":0.010427951376107502,"score_gpt":0.22604546199668585,"score_spread":0.21561751062057835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992391104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963174,0.00005222252,0.000005731867,0.00046866928,0.000076176744,0.00091134064,0.000015425725,0.00003242614,0.0021206397],"genre_scores_gemma":[0.9978432,0.000041869043,0.00042546805,0.0002504609,0.00004578546,0.00006547155,0.00010557541,0.000012075176,0.0012100831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895686,0.000085338346,0.00015989832,0.00028285806,0.00027654535,0.00023847588],"domain_scores_gemma":[0.99950516,0.000067557,0.00008483713,0.00024047765,0.00003974563,0.000062223495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004666058,0.00015663983,0.000238895,0.00009117944,0.00007905014,0.000026552068,0.000081241036,0.00010265079,0.000086916996],"category_scores_gemma":[0.00005792668,0.00010182954,0.000027815782,0.00024245698,0.000029044715,0.00014519501,0.000066801054,0.00022463298,0.000018649773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012912472,0.0013165107,0.8935999,0.00006411199,0.00006405366,0.000053132735,0.0012924648,0.0000023625405,0.10039269,0.00007367664,0.0010732115,0.0019387542],"study_design_scores_gemma":[0.0029696838,0.00020709228,0.8162041,0.00009311513,0.00008491595,0.0000035610003,0.00008032183,0.0002496068,0.17927761,0.000074345066,0.00062479754,0.00013089679],"about_ca_topic_score_codex":0.000035943187,"about_ca_topic_score_gemma":0.00034201637,"teacher_disagreement_score":0.07888492,"about_ca_system_score_codex":0.00007034553,"about_ca_system_score_gemma":0.000026600508,"threshold_uncertainty_score":0.4152488},"labels":[],"label_agreement":null},{"id":"W1992595721","doi":"10.1210/en.2008-1137","title":"Acute Dipeptidyl Peptidase-4 Inhibition Rapidly Enhances Insulin-Mediated Suppression of Endogenous Glucose Production in Mice","year":2008,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Sitagliptin; Internal medicine; Endocrinology; Dipeptidyl peptidase-4; Incretin; Glucose homeostasis; Insulin; Glucagon-like peptide-1; Glucagon; Endogeny; Bolus (digestion); Dipeptidyl peptidase; Medicine; Chemistry; Diabetes mellitus; Type 2 diabetes; Insulin resistance; Enzyme; Biochemistry; Metformin","score_opus":0.02179514897928817,"score_gpt":0.2503947438368187,"score_spread":0.22859959485753054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992595721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402237,0.0011190709,0.00001024445,0.000762776,0.0003180834,0.00072945,0.000010935968,0.0000961605,0.0029308987],"genre_scores_gemma":[0.9947943,0.0034476703,0.00043109397,0.00012219635,0.00011404603,0.00011229995,0.00025595463,0.000019336247,0.0007030719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985574,0.00007558269,0.0003958065,0.00037183866,0.00018784631,0.0004115611],"domain_scores_gemma":[0.9994047,0.000054590255,0.00015257909,0.00025029908,0.00007436044,0.00006341983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006171011,0.00018622863,0.00041593987,0.00037013335,0.000057533387,0.000002587335,0.000064401785,0.000076458666,0.00009915837],"category_scores_gemma":[0.00009414843,0.00016260493,0.0000762599,0.00029545382,0.00016888302,0.00013221534,0.000070019865,0.00016502748,0.00009267215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054057554,0.0011024587,0.009787328,0.00009689241,0.0001771611,0.0008320215,0.00084829464,0.00000687512,0.97821087,0.000072318086,0.0012510587,0.0070741395],"study_design_scores_gemma":[0.0036216502,0.00086587627,0.025047388,0.00010494337,0.00012232097,0.00028189548,0.00014068406,0.000012196271,0.9674331,0.000056230678,0.002185362,0.00012836768],"about_ca_topic_score_codex":0.0000615451,"about_ca_topic_score_gemma":0.00002786145,"teacher_disagreement_score":0.015260061,"about_ca_system_score_codex":0.00008490528,"about_ca_system_score_gemma":0.000050499057,"threshold_uncertainty_score":0.6630837},"labels":[],"label_agreement":null},{"id":"W1993252135","doi":"10.1152/ajprenal.00259.2012","title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","year":2012,"lang":"en","type":"article","venue":"American Journal of Physiology-Renal Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Internal medicine; Natriuresis; Endocrinology; Dipeptidyl peptidase-4; Chemistry; Reabsorption; Diuresis; Glucagon-like peptide-1; Dipeptidyl peptidase; Renal sodium reabsorption; Type 2 diabetes; Renal function; Kidney; Diabetes mellitus; Medicine; Biochemistry; Enzyme","score_opus":0.006316278779686491,"score_gpt":0.23792722664255847,"score_spread":0.23161094786287198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993252135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932905,0.0021770825,0.0000014860468,0.0033100557,0.0005994922,0.00050578197,0.000019141457,0.000016774808,0.000079693935],"genre_scores_gemma":[0.99472445,0.000656141,0.000066153596,0.0033611467,0.0008693856,0.00003960694,0.000043809618,0.000035588775,0.0002037097],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972895,0.00084918813,0.0005741331,0.00031172868,0.00026015425,0.00071531144],"domain_scores_gemma":[0.9973749,0.0012349873,0.0006374056,0.0003839165,0.00014099856,0.000227784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006121235,0.00036972555,0.0010118878,0.00015610493,0.00010954056,0.000012334266,0.00037090908,0.000108520246,0.0002257079],"category_scores_gemma":[0.00027617218,0.00018813495,0.000208982,0.00046996598,0.0011451134,0.00014480975,0.00019378387,0.0006502295,0.00009646133],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017217499,0.00032434388,0.0038988278,0.000056783894,0.00060105324,0.0000034263178,0.000398959,0.000004887885,0.97076696,0.000010635285,0.017717047,0.0044953017],"study_design_scores_gemma":[0.009664331,0.021749433,0.68499327,0.00035616365,0.0016717352,0.00008456819,0.0010278457,0.00021613023,0.24501178,0.0003900047,0.03402136,0.0008133737],"about_ca_topic_score_codex":0.00015517723,"about_ca_topic_score_gemma":0.000004962115,"teacher_disagreement_score":0.7257552,"about_ca_system_score_codex":0.00009443641,"about_ca_system_score_gemma":0.000051702504,"threshold_uncertainty_score":0.76719207},"labels":[],"label_agreement":null},{"id":"W199402436","doi":"","title":"Abstract 3669: The Glucagon Like Peptide-1 (GLP-1) Metabolite GLP-1(9–36) Protects Cardiomyocytes and Endothelial Cells From Myocardial Ischemia Reperfusion Injury via GLP-1 Receptor-independent Mechanisms","year":2009,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon-like peptide-1; Medicine; Metabolite; Glucagon-like peptide 1 receptor; Reperfusion injury; Ischemia; Internal medicine; Receptor; Endocrinology; Cardiology; Pharmacology; Diabetes mellitus; Type 2 diabetes; Agonist","score_opus":0.007973323579821093,"score_gpt":0.22127762398539697,"score_spread":0.21330430040557588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W199402436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99145883,0.00094257767,0.0011519543,0.0005598406,0.0007944052,0.0022611083,0.000062655374,0.00019399318,0.0025746285],"genre_scores_gemma":[0.9964933,0.00029266154,0.0010441458,0.0005864812,0.0008045386,0.000107702755,0.00038306208,0.0000459715,0.0002421488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975854,0.00009696526,0.00046466012,0.0006966048,0.00072710705,0.00042922422],"domain_scores_gemma":[0.9987032,0.000067020796,0.000248449,0.0006710453,0.00011507188,0.00019521591],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048774685,0.00040607972,0.0005330775,0.00014984497,0.00024423355,0.00012969208,0.00013956388,0.00023366221,0.00013258298],"category_scores_gemma":[0.00004448189,0.0003117461,0.00027558606,0.00020086486,0.000055039865,0.00028866334,0.0000843523,0.00029112335,0.00011962478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036237546,0.00013971463,0.001014301,0.000038798335,0.0002812679,0.000017109352,0.00037866758,0.00004401202,0.90727407,0.00023789205,0.0005061486,0.089705676],"study_design_scores_gemma":[0.0033396294,0.0003406896,0.17300159,0.00016374851,0.0011014789,0.000008345823,0.0001774125,0.0005608097,0.8016574,0.0027815495,0.016328895,0.0005384912],"about_ca_topic_score_codex":0.00020385737,"about_ca_topic_score_gemma":0.000005011928,"teacher_disagreement_score":0.1719873,"about_ca_system_score_codex":0.00020820479,"about_ca_system_score_gemma":0.000057549827,"threshold_uncertainty_score":0.9999335},"labels":[],"label_agreement":null},{"id":"W1994294400","doi":"10.1111/j.1464-5491.2005.01448.x","title":"Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes","year":2005,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"","keywords":"Medicine; Metformin; Hazard ratio; Internal medicine; Type 2 diabetes; Proportional hazards model; Combination therapy; Confidence interval; Confounding; Retrospective cohort study; Diabetes mellitus; Lower risk; Cohort study; Endocrinology; Insulin","score_opus":0.030319985664972578,"score_gpt":0.25633256308354707,"score_spread":0.2260125774185745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994294400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994045,0.002553447,0.0000070785,0.00049286464,0.00006581345,0.00086241984,0.0000034624945,0.000084672705,0.0018851963],"genre_scores_gemma":[0.99789697,0.00027001434,0.0003605651,0.00048768922,0.00011891351,0.00006611158,0.000135804,0.000038443002,0.00062550814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980651,0.00008411168,0.0002961763,0.00045708768,0.00060150324,0.0004960301],"domain_scores_gemma":[0.998841,0.00015633268,0.00009063385,0.0005392321,0.0001290308,0.00024379985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007195994,0.00030467528,0.0009093529,0.00022060545,0.000045309615,0.000017949844,0.00006843724,0.00008400232,0.00007822606],"category_scores_gemma":[0.00037796574,0.00018871989,0.00005665348,0.0005890344,0.0002592128,0.00018286181,0.000038037684,0.00018478307,0.0000074617633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011077055,0.00040082095,0.9839385,0.00015376715,0.002518636,0.00020427135,0.00035682734,0.00004218632,0.0006186676,0.0000621818,0.0005869518,0.011006433],"study_design_scores_gemma":[0.007921082,0.0017222086,0.9816026,0.00091039494,0.0024832697,0.0000049503155,0.00011506414,0.0003669225,0.002644257,0.00002715172,0.001933976,0.00026814258],"about_ca_topic_score_codex":0.00020873288,"about_ca_topic_score_gemma":0.00036731662,"teacher_disagreement_score":0.01073829,"about_ca_system_score_codex":0.00015051775,"about_ca_system_score_gemma":0.000057674988,"threshold_uncertainty_score":0.7695774},"labels":[],"label_agreement":null},{"id":"W1994681362","doi":"10.1111/dme.12214","title":"Trends in selection and timing of first‐line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006","year":2013,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Work & Health; Institute of Health Services and Policy Research; University of Toronto; Western University; St. Michael's Hospital; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Pharmacotherapy; Metformin; Diabetes mellitus; Type 2 diabetes; Population; Internal medicine; Pediatrics; Endocrinology","score_opus":0.01288447913693886,"score_gpt":0.2622432988902778,"score_spread":0.24935881975333896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994681362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705094,0.000945586,0.0000040164355,0.0008974676,0.00004033289,0.00061800145,0.0000026130494,0.000017222548,0.0004238139],"genre_scores_gemma":[0.9988522,0.0003094388,0.00013075495,0.00023658636,0.00006111238,0.00006606563,0.00011035387,0.000021562886,0.0002119613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897015,0.000028545135,0.00029949247,0.00024124961,0.00019790724,0.0002626255],"domain_scores_gemma":[0.99951357,0.00014040466,0.00008573616,0.00010562033,0.00004690687,0.00010775995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014659822,0.00017714693,0.00048750758,0.00051336526,0.000019005973,0.000005628819,0.00003241654,0.00005000922,0.00042486525],"category_scores_gemma":[0.000029898503,0.00012237222,0.000013132728,0.00052616897,0.00009498871,0.00008718742,0.00001896275,0.00009695423,0.0000017140976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027151182,0.00023850614,0.90119714,0.00014319454,0.00007725246,0.000002105607,0.00035915646,0.0000021234591,0.00023181993,0.0000024134567,0.0006497763,0.097069345],"study_design_scores_gemma":[0.011614742,0.0014837658,0.9844568,0.00062451366,0.00017937772,1.0009033e-7,0.00004163505,0.0005579329,0.0006040192,0.00002758886,0.00030038203,0.00010918665],"about_ca_topic_score_codex":0.00024284526,"about_ca_topic_score_gemma":0.00008123194,"teacher_disagreement_score":0.09696016,"about_ca_system_score_codex":0.000036603193,"about_ca_system_score_gemma":0.0000062773165,"threshold_uncertainty_score":0.4990194},"labels":[],"label_agreement":null},{"id":"W1995468535","doi":"10.1016/s0168-8227(01)00325-4","title":"The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial","year":2002,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Medical Research Council Canada; Sanofi; Eli Lilly and Company; Canadian Diabetes Association; American Diabetes Association","keywords":"Medicine; Hydroxychloroquine; Diabetes mellitus; Randomized controlled trial; Internal medicine; Refractory (planetary science); Type 2 Diabetes Mellitus; Metformin; Type 2 diabetes; Intensive care medicine; Endocrinology; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.04152187753043398,"score_gpt":0.3819417957747172,"score_spread":0.34041991824428325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995468535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865612,0.0031339515,7.601014e-7,0.0013232334,0.00016913434,0.004154086,0.0000052022465,0.000018582454,0.004633883],"genre_scores_gemma":[0.9958957,0.0028094756,0.000098140314,0.00024150267,0.000108081476,0.00026834224,0.000021283236,0.000029027133,0.00052845036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939875,0.0031686926,0.00072283455,0.00049191114,0.0009558505,0.00067322055],"domain_scores_gemma":[0.9614937,0.036598876,0.00022861623,0.00054764724,0.0007992064,0.0003319985],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012908312,0.00020838044,0.0011030419,0.00020166718,0.00013801584,0.000077846285,0.00019035644,0.0001250902,0.00004359786],"category_scores_gemma":[0.032365028,0.00011859337,0.00012612423,0.00070573087,0.0006173396,0.000264667,0.00017493442,0.00063143,0.000048752667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.722528,0.00535547,0.24129,0.0002224983,0.0010848632,0.000012487388,0.00004052146,0.0000010479184,0.000010587833,0.000266024,0.0010251448,0.028163347],"study_design_scores_gemma":[0.68629026,0.020385629,0.27166778,0.00081245514,0.0004393034,7.327586e-8,0.00009049398,0.00014895972,0.00014464535,0.00032403535,0.019489644,0.00020670072],"about_ca_topic_score_codex":0.000019510302,"about_ca_topic_score_gemma":0.000008742437,"teacher_disagreement_score":0.036237728,"about_ca_system_score_codex":0.00007454624,"about_ca_system_score_gemma":0.000039129194,"threshold_uncertainty_score":0.9757858},"labels":[],"label_agreement":null},{"id":"W1995648785","doi":"10.1016/j.jcjd.2013.08.078","title":"Efficacy and Safety of Canagliflozin (CANA) in Older Subjects with Type 2 Diabetes Mellitus (T2DM)","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Canagliflozin; Animal science; Body weight; Significant difference; Internal medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Endocrinology; Biology","score_opus":0.007178724129539899,"score_gpt":0.20169537657583828,"score_spread":0.19451665244629837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995648785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068063,0.006036486,5.5539556e-7,0.0009390459,0.00012673726,0.00047983593,0.0000065696113,0.000005113521,0.0017250099],"genre_scores_gemma":[0.9989113,0.00009987511,0.0002852528,0.000372051,0.00005881107,0.0000075384564,0.000009605368,0.000026943548,0.00022858658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986818,0.000040723015,0.0004005444,0.00016114821,0.00019384864,0.0005219539],"domain_scores_gemma":[0.9985294,0.00011330149,0.00019459787,0.00019610875,0.00023938168,0.00072721957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021498905,0.00019559759,0.00055660843,0.0005923667,0.00004127238,0.00003509886,0.00011684545,0.00006735659,0.00023183796],"category_scores_gemma":[0.00011177412,0.00014782081,0.0000554312,0.00039839375,0.00015984876,0.00018172023,0.0000135006185,0.00017045253,0.000007254396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023684808,0.00007577467,0.9775967,0.00016203888,0.0004193013,0.00003729095,0.00029141377,0.000018080726,0.00026701513,0.00009946019,0.0023005954,0.018708618],"study_design_scores_gemma":[0.0038739261,0.0011737086,0.9888408,0.0008046764,0.00027632943,0.0000019334502,0.00020242519,0.000037281825,0.0018206842,0.00007632629,0.0027203092,0.00017159655],"about_ca_topic_score_codex":0.0033269892,"about_ca_topic_score_gemma":0.021834217,"teacher_disagreement_score":0.018537022,"about_ca_system_score_codex":0.00017418733,"about_ca_system_score_gemma":0.00057266746,"threshold_uncertainty_score":0.9960148},"labels":[],"label_agreement":null},{"id":"W1996585036","doi":"10.2337/dc14-2868","title":"Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial","year":2015,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Saxagliptin; Medicine; TIMI; Hazard ratio; Cohort; Myocardial infarction; Internal medicine; Placebo; Population; Diabetes mellitus; Cohort study; Type 2 diabetes; Sitagliptin; Endocrinology; Thrombolysis; Confidence interval; Pathology","score_opus":0.039878469364421444,"score_gpt":0.2944127749420762,"score_spread":0.2545343055776547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996585036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939249,0.0010211263,2.2917317e-7,0.00044447585,0.0001037414,0.001221592,0.000008866791,0.000013825133,0.0032612316],"genre_scores_gemma":[0.9993425,0.000026551861,0.00005596217,0.00029753242,0.000056616333,0.00009647125,0.000050453058,0.000011344554,0.000062582105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989346,0.00008893906,0.00027038573,0.00018411689,0.00021364746,0.00030828366],"domain_scores_gemma":[0.99943656,0.0001384097,0.0000538317,0.0002514853,0.00003763204,0.00008207432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035426093,0.00012359551,0.00032666052,0.00011045894,0.000013807494,0.000012748044,0.00008191282,0.000051840398,0.000017154287],"category_scores_gemma":[0.00017736135,0.00008264709,0.000043061136,0.00021013264,0.000056396944,0.00004884706,0.00005326729,0.000088348424,0.00001618018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026113468,0.0005781483,0.95712674,0.00015097359,0.00007104974,0.000017910037,0.010834573,0.000017269796,0.000059653983,0.0001264564,0.0011446949,0.02726119],"study_design_scores_gemma":[0.10360934,0.0011335373,0.8829047,0.00030795077,0.00021757303,1.2038637e-7,0.007220939,0.00008426849,0.00058030145,0.0000609406,0.0037388809,0.00014145962],"about_ca_topic_score_codex":0.000020038075,"about_ca_topic_score_gemma":0.00005671233,"teacher_disagreement_score":0.10099799,"about_ca_system_score_codex":0.00005932014,"about_ca_system_score_gemma":0.000036176894,"threshold_uncertainty_score":0.33702508},"labels":[],"label_agreement":null},{"id":"W1996731332","doi":"10.1016/j.jcjd.2013.04.008","title":"Use Patterns of Antidiabetic Regimens by Patients with Type 2 Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Diabetes Foundation; Canadian Diabetes Association","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.007817404102202172,"score_gpt":0.18502312862758133,"score_spread":0.17720572452537917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996731332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979913,0.0006918421,0.0000010529529,0.0003718018,0.00020151284,0.00039096436,0.00004427086,0.000007803587,0.00029944754],"genre_scores_gemma":[0.9983469,0.000016375348,0.00022648988,0.00050837535,0.000045725785,0.0000069353146,0.00006433717,0.000037912392,0.00074690115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986031,0.000035968013,0.0004003319,0.00015289207,0.00027633915,0.0005313656],"domain_scores_gemma":[0.99797684,0.00007972763,0.0003202584,0.00026922455,0.0006259981,0.00072793785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010234908,0.00021184943,0.00051016593,0.00035930562,0.000049464885,0.000060410828,0.0001505199,0.000065546665,0.00045155617],"category_scores_gemma":[0.000107519874,0.00015465922,0.000104914754,0.00022456498,0.000102535334,0.000383103,0.000013997476,0.00014024005,0.000028865454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000033370738,0.00012191735,0.9757701,0.0000924761,0.0005072728,0.000004177617,0.000061948485,0.0000017994669,0.00052701123,0.000011019675,0.01964202,0.0032569212],"study_design_scores_gemma":[0.0017044754,0.0020179048,0.9846335,0.00052648503,0.00044065103,2.0520051e-7,0.000050880608,0.00001023608,0.0051524513,0.000026975493,0.005256843,0.00017936568],"about_ca_topic_score_codex":0.00049516675,"about_ca_topic_score_gemma":0.00024984003,"teacher_disagreement_score":0.014385177,"about_ca_system_score_codex":0.00010701182,"about_ca_system_score_gemma":0.00023097257,"threshold_uncertainty_score":0.63068205},"labels":[],"label_agreement":null},{"id":"W1996837305","doi":"10.1186/1472-6823-14-37","title":"Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","year":2014,"lang":"en","type":"article","venue":"BMC Endocrine Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Medicine; Placebo; Tolerability; Internal medicine; Diabetes mellitus; Adverse effect; Incidence (geometry); Blood pressure; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.0169745551517157,"score_gpt":0.30644844000267824,"score_spread":0.28947388485096254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996837305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770504,0.00076228613,0.000029364051,0.00008026335,0.000026391368,0.0008140883,0.000006419125,0.000015784422,0.00056035677],"genre_scores_gemma":[0.99863845,0.00033541283,0.00074601284,0.000049486396,0.0000062738923,0.000025472076,0.000109831395,0.00001531635,0.0000737689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864054,0.000097072894,0.0005066623,0.00028888334,0.00023795644,0.00022886641],"domain_scores_gemma":[0.99887466,0.00043015866,0.00020679798,0.0002864984,0.00012987491,0.00007203121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018783088,0.00018254438,0.0010392366,0.00030815334,0.000019793919,0.0000036441309,0.00006087893,0.000019001307,0.00002014029],"category_scores_gemma":[0.00020284591,0.00011930047,0.00007763868,0.00067857734,0.00020101483,0.00003990054,0.000052197247,0.000063971405,7.1503405e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026591509,0.0010878139,0.9841166,0.0002736328,0.0053275917,9.270428e-7,0.00021961723,0.00056027377,0.0000013612417,0.00006835029,0.00006358076,0.0056210766],"study_design_scores_gemma":[0.023028132,0.0013374895,0.96859175,0.00020513416,0.0050388942,2.74152e-8,0.0004596145,0.0008738409,0.000020410305,0.000008080744,0.00031440475,0.00012220025],"about_ca_topic_score_codex":0.0001940447,"about_ca_topic_score_gemma":0.0047314325,"teacher_disagreement_score":0.020368982,"about_ca_system_score_codex":0.000019683692,"about_ca_system_score_gemma":0.000030692063,"threshold_uncertainty_score":0.48649323},"labels":[],"label_agreement":null},{"id":"W1996839988","doi":"10.1074/jbc.m205055200","title":"Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway","year":2002,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kinexus Bioinformatics Corporation (Canada); University of British Columbia","funders":"","keywords":"Protein kinase A; Signal transduction; Kinase; Biology; c-Raf; Adenylyl cyclase; Rap1; Internal medicine; Cell biology; Endocrinology; ASK1; Mitogen-activated protein kinase kinase; Chemistry; Medicine","score_opus":0.023609334739104985,"score_gpt":0.23023595839520433,"score_spread":0.20662662365609935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996839988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179554,0.0026640927,0.00010195254,0.0022526847,0.00011404438,0.0005244213,0.000017210188,0.000075356,0.0024546876],"genre_scores_gemma":[0.99449676,0.00064981304,0.00041894408,0.0005023959,0.00055115693,0.000051974224,0.000032488864,0.000028486227,0.0032680002],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99764144,0.000088249726,0.0007569102,0.0003634814,0.00061749923,0.0005324368],"domain_scores_gemma":[0.99832976,0.00014554388,0.00058291847,0.0004527001,0.00015390475,0.0003351777],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033986286,0.00038467124,0.00064584345,0.00006471782,0.00012602712,0.000060660463,0.00041735527,0.00028457653,0.0016290395],"category_scores_gemma":[0.00032335942,0.00020676183,0.00037918263,0.00023595008,0.00017042167,0.00010272952,0.00016824648,0.00072829815,0.00018041019],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031005236,0.0013807757,0.00455104,0.00008047086,0.00047689737,0.0003887397,0.000059523412,0.0000074230443,0.97879755,0.000008577825,0.0005094712,0.013429481],"study_design_scores_gemma":[0.004434685,0.0010354131,0.010304502,0.00021878247,0.00021773938,0.00021817174,0.0001507506,0.00008853252,0.9632578,0.0002498504,0.019475643,0.00034816904],"about_ca_topic_score_codex":0.000008698211,"about_ca_topic_score_gemma":0.0000013151733,"teacher_disagreement_score":0.018966172,"about_ca_system_score_codex":0.00025153623,"about_ca_system_score_gemma":0.000038303937,"threshold_uncertainty_score":0.9992836},"labels":[],"label_agreement":null},{"id":"W1997416444","doi":"10.1001/jama.299.13.1561","title":"Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":847,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Universidad de Chile; Cleveland Clinic","keywords":"Pioglitazone; Glimepiride; Medicine; Type 2 diabetes; Internal medicine; Coronary atherosclerosis; Diabetes mellitus; Insulin; Cardiology; Endocrinology; Urology; Gastroenterology; Coronary artery disease","score_opus":0.022683126386017997,"score_gpt":0.27798549802002537,"score_spread":0.2553023716340074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997416444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981422,0.00010982954,4.6689686e-7,0.00009497699,0.00003881354,0.00046413482,0.000004674428,0.000016445307,0.001128469],"genre_scores_gemma":[0.9992152,0.00001923172,0.00044945598,0.00007416634,0.000012002556,0.000015309082,0.00005625367,0.000014080714,0.00014434062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991967,0.000020751624,0.00022134696,0.00013732207,0.00027838358,0.0001454642],"domain_scores_gemma":[0.99951553,0.000036090332,0.00012538016,0.00019732048,0.000085075255,0.000040623567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005349799,0.000102960774,0.00034649463,0.00009990098,0.00001688324,0.0000017576189,0.000048031045,0.00004307565,0.000033474003],"category_scores_gemma":[0.00002312497,0.000070314134,0.00003301883,0.00018367957,0.000073222145,0.000049682643,0.000029442868,0.000061005798,0.000009903621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010462756,0.002791261,0.9778481,0.00009695237,0.000080507896,0.0000020991681,0.0002549034,0.000007495839,0.0004511329,0.00001670513,0.00082960085,0.016574945],"study_design_scores_gemma":[0.005075317,0.007449308,0.9713038,0.0005621367,0.000059788443,4.105631e-8,0.000028942335,0.000034628367,0.0152253965,0.0000038751114,0.0001956361,0.000061139275],"about_ca_topic_score_codex":0.000007889411,"about_ca_topic_score_gemma":0.0000020368332,"teacher_disagreement_score":0.016513806,"about_ca_system_score_codex":0.000040200703,"about_ca_system_score_gemma":0.000015068723,"threshold_uncertainty_score":0.2867327},"labels":[],"label_agreement":null},{"id":"W1997759488","doi":"10.1136/bmj.39314.620174.80","title":"Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review","year":2007,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Saskatchewan; University of Alberta Hospital; Alberta Hospital Edmonton; Institute of Health Economics","funders":"","keywords":"Medicine; Metformin; Hazard ratio; Odds ratio; Confidence interval; Diabetes mellitus; Internal medicine; Heart failure; Meta-analysis; Cohort study; Type 2 diabetes; Insulin; Endocrinology","score_opus":0.0377723300350411,"score_gpt":0.31317982448945036,"score_spread":0.27540749445440926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997759488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003919826,0.9874176,1.17776025e-7,0.00007382648,0.00003253729,0.008432828,0.000017799368,0.000013865959,0.00009163215],"genre_scores_gemma":[0.00038085497,0.99854225,0.00023798212,0.00023038001,0.000016258868,0.000309654,0.00014054879,0.000041159492,0.000100892736],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9981308,0.00008910954,0.00084796565,0.00033314267,0.00032458676,0.00027438774],"domain_scores_gemma":[0.9989412,0.00010465896,0.00041446468,0.00036990698,0.000057555193,0.00011224737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005239123,0.00036352477,0.0032093106,0.00026508697,0.0000161428,0.000013664454,0.00006596609,0.00010034714,0.000012459769],"category_scores_gemma":[0.00009449914,0.00022259535,0.00012492537,0.00030876987,0.000053055166,0.000052258503,0.0000798201,0.000110936635,0.000012025257],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022746467,0.00015047003,0.021379426,0.91620266,0.0004283801,0.0000036781514,0.0000070672336,1.35315e-8,7.1333557e-9,0.00000743412,0.0011028592,0.060715713],"study_design_scores_gemma":[0.0010521932,0.00037588138,0.013901642,0.9439605,0.007359701,0.0000016413356,0.000003283072,4.2002563e-7,5.300762e-7,9.2167676e-7,0.03312418,0.00021913231],"about_ca_topic_score_codex":0.0000019344845,"about_ca_topic_score_gemma":0.0000018386653,"teacher_disagreement_score":0.06049658,"about_ca_system_score_codex":0.00004506699,"about_ca_system_score_gemma":0.00003006656,"threshold_uncertainty_score":0.9077175},"labels":[],"label_agreement":null},{"id":"W1997883454","doi":"10.1053/j.gastro.2010.01.049","title":"Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Pancreatic Islet α-Cells and Promotes Insulin Secretion","year":2010,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Children’s Health Research Institute; University of British Columbia","funders":"Michael Smith Health Research BC; Canadian Diabetes Association; Natural Sciences and Engineering Research Council of Canada; Juvenile Diabetes Research Foundation International","keywords":"Proglucagon; Internal medicine; Endocrinology; Islet; Gastric inhibitory polypeptide; Prohormone convertase; Biology; Insulin; Enteroendocrine cell; Pancreas; Glucagon; Pancreatic islets; Glucagon-like peptide-1; Prohormone; Hormone; Diabetes mellitus; Type 2 diabetes; Endocrine system; Medicine","score_opus":0.007178361127695826,"score_gpt":0.2221052325065685,"score_spread":0.21492687137887267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997883454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967506,0.000084134736,0.000098143355,0.0018532097,0.00020389953,0.00060978555,0.000015506488,0.000057335878,0.000327395],"genre_scores_gemma":[0.9959251,0.00020837001,0.0018176754,0.0015299029,0.0000910079,0.00005816957,0.000043627686,0.000022815166,0.00030329727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875754,0.000054315587,0.0002760528,0.00037117032,0.00013545217,0.00040547812],"domain_scores_gemma":[0.9994396,0.00003099724,0.00008130142,0.00030135547,0.00002690266,0.00011986015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011879417,0.00019580772,0.00035440986,0.00019080075,0.000029282748,0.00001902049,0.00007971727,0.00010189464,0.00016424381],"category_scores_gemma":[0.000027436234,0.00017229767,0.00004804858,0.00006398166,0.00009175665,0.0000738366,0.000097934935,0.00025072382,0.000057928446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005587659,0.0005629262,0.7311995,0.00011072974,0.00013094486,0.00009505651,0.00040528036,8.455542e-7,0.26263025,0.00006694623,0.00033720012,0.0039015596],"study_design_scores_gemma":[0.013974042,0.00372828,0.9127828,0.00012459348,0.0003117931,0.000058832433,0.00015231268,0.00049001834,0.06507047,0.00032425462,0.0027914152,0.00019120351],"about_ca_topic_score_codex":0.000076020144,"about_ca_topic_score_gemma":0.00029975924,"teacher_disagreement_score":0.19755977,"about_ca_system_score_codex":0.0000324425,"about_ca_system_score_gemma":0.00001605654,"threshold_uncertainty_score":0.70260954},"labels":[],"label_agreement":null},{"id":"W1998194133","doi":"10.1007/s11154-014-9286-8","title":"Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited","year":2014,"lang":"en","type":"review","venue":"Reviews in Endocrine and Metabolic Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Novo Nordisk Fonden","keywords":"Incretin; Medicine; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Internal medicine; Stimulation; Diabetes mellitus; Carbohydrate metabolism; Endocrinology; Type 2 diabetes; Pharmacology; Cardiology","score_opus":0.025017113413646347,"score_gpt":0.3497848199108682,"score_spread":0.32476770649722186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998194133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030171947,0.9853629,0.000006544239,0.000033445933,0.00029685898,0.0044953693,0.000049524766,0.00004485829,0.009408764],"genre_scores_gemma":[0.00008160973,0.99688953,0.0002454327,0.00021470214,0.00026193264,0.00062838255,0.0004329721,0.00011933133,0.0011261071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956299,0.0005526464,0.0018076074,0.0008885841,0.00038961612,0.00073162984],"domain_scores_gemma":[0.9974444,0.00017696433,0.0008450944,0.0011975524,0.000047376416,0.00028859562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077115954,0.00112658,0.008779781,0.0010265736,0.00004133138,0.00003059854,0.00027885294,0.00014093831,0.00013759783],"category_scores_gemma":[0.0003303795,0.00072172465,0.0028199742,0.0010420867,0.00012607806,0.00010539192,0.00018933836,0.00048370313,0.00013862296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033297252,0.00047710273,0.0001372677,0.017930191,0.0014174654,0.000014392164,0.000026311962,5.6694824e-7,4.278623e-7,0.0013378252,0.0029985153,0.97562665],"study_design_scores_gemma":[0.0021373276,0.00038131035,0.00066173106,0.013531886,0.008931341,0.00001852846,0.0000055552027,0.0000020149105,7.1802845e-7,0.00004958013,0.97377425,0.000505775],"about_ca_topic_score_codex":0.00013091757,"about_ca_topic_score_gemma":0.000012537069,"teacher_disagreement_score":0.97512084,"about_ca_system_score_codex":0.0000804051,"about_ca_system_score_gemma":0.0001532552,"threshold_uncertainty_score":0.9995234},"labels":[],"label_agreement":null},{"id":"W1998778361","doi":"10.1016/s1262-3636(13)71875-5","title":"P1129 Efficacité et tolérance du lixisénatide en une injection quotidienne après échappement à la pioglitazone au cours du diabète de type 2 : étude GetGoal-P","year":2013,"lang":"fr","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Pioglitazone; Gynecology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.007991488278511665,"score_gpt":0.2315375909073046,"score_spread":0.22354610262879293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998778361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93535656,0.03208258,0.00034710643,0.01573633,0.005672821,0.002274543,0.000060302573,0.00031386752,0.008155869],"genre_scores_gemma":[0.96822166,0.0068717278,0.0019237077,0.0029259138,0.0031874755,0.00074904325,0.00025993746,0.00019960513,0.015660897],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9940561,0.000846162,0.00096549024,0.0010551644,0.0008061736,0.002270908],"domain_scores_gemma":[0.99660045,0.00076333026,0.00041770024,0.0009686749,0.00044111218,0.0008087216],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021558872,0.0010081143,0.0014459261,0.000471953,0.00033936658,0.0003231092,0.0005012381,0.00042440934,0.00092392584],"category_scores_gemma":[0.000623539,0.0009678352,0.00044096896,0.0010821841,0.00044107746,0.0007874331,0.0003826099,0.0006555752,0.0028055648],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002137674,0.008004903,0.3907379,0.001979414,0.007921136,0.00022395016,0.022279678,0.0026802348,0.019680288,0.08585255,0.05172542,0.4087008],"study_design_scores_gemma":[0.0064437836,0.000907136,0.5910888,0.0009045612,0.0033583788,0.000009307335,0.0013371827,0.00439767,0.0060228575,0.0022582447,0.382186,0.0010861187],"about_ca_topic_score_codex":0.002226107,"about_ca_topic_score_gemma":0.00026905668,"teacher_disagreement_score":0.40761465,"about_ca_system_score_codex":0.0007491851,"about_ca_system_score_gemma":0.0002658189,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W1999279907","doi":"10.1016/j.mad.2003.07.003","title":"The age-associated decline in the intestinal uptake of glucose is not accompanied by changes in the mRNA or protein abundance of SGLT1","year":2003,"lang":"en","type":"article","venue":"Mechanisms of Ageing and Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"Fonds de Recherche du Québec - Santé","keywords":"Abundance (ecology); Messenger RNA; Biology; Endocrinology; Internal medicine; Biochemistry; Ecology; Gene; Medicine","score_opus":0.02811834293826682,"score_gpt":0.2574749453764783,"score_spread":0.2293566024382115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999279907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962558,0.0003558313,0.00025587738,0.0017300709,0.000033245196,0.00097374065,0.0000038319145,0.000008813337,0.0003827915],"genre_scores_gemma":[0.9935033,0.00012370227,0.0051123016,0.00071915926,0.000003817897,0.00012352726,0.000010468168,0.00000970501,0.0003940682],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986358,0.000111824746,0.0004507792,0.00017031845,0.0003960667,0.00023517302],"domain_scores_gemma":[0.99928564,0.00019369806,0.00023121794,0.0002121526,0.000055836925,0.000021469112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017074653,0.00015593784,0.00032001367,0.00008157944,0.00007771364,0.000019028525,0.00021005406,0.00004185259,0.000013954374],"category_scores_gemma":[0.00023084048,0.000074799114,0.000031059903,0.00028817882,0.000059598395,0.000025303154,0.00006213371,0.000112772155,8.383551e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035840468,0.010744969,0.012894394,0.0024681548,0.0017729376,0.0009533911,0.09972757,0.0000239762,0.34902826,0.032572526,0.0048767934,0.48135298],"study_design_scores_gemma":[0.0067168362,0.0017066661,0.13347591,0.0018736696,0.00014420063,0.000009878792,0.01039229,0.00007679121,0.82559395,0.0034004904,0.016291667,0.00031767803],"about_ca_topic_score_codex":0.00010877709,"about_ca_topic_score_gemma":0.0008408031,"teacher_disagreement_score":0.4810353,"about_ca_system_score_codex":0.00004233772,"about_ca_system_score_gemma":0.00007258843,"threshold_uncertainty_score":0.30502194},"labels":[],"label_agreement":null},{"id":"W1999647434","doi":"10.1006/geno.2002.6762","title":"Ancient Duplications of the Human Proglucagon Gene","year":2002,"lang":"en","type":"article","venue":"Genomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Biology; Pseudogene; Gene duplication; Genetics; Gene; Tandem exon duplication; Genome; Gene family; Chromosome; Human genome; Proglucagon; Lineage (genetic); genomic DNA; Segmental duplication","score_opus":0.027790368393696526,"score_gpt":0.24352426580682793,"score_spread":0.2157338974131314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999647434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975236,0.00029774377,0.000019210122,0.00095874607,0.00006374054,0.00040932326,0.0000031217496,0.000015367967,0.018480368],"genre_scores_gemma":[0.99175185,0.000046907724,0.0007147364,0.0003134916,0.000039494254,0.000028179064,0.000008805813,0.0000071739855,0.0070893406],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99966156,0.000004204824,0.00009542084,0.00008271205,0.00006557634,0.00009049352],"domain_scores_gemma":[0.99959636,0.0000031041893,0.00004216249,0.00031053138,0.00002099229,0.000026844396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034011784,0.000044620945,0.00007164579,0.00002217341,0.000051041676,0.000004031593,0.000066111104,0.00001475059,0.00011854751],"category_scores_gemma":[0.00000388187,0.000030213278,0.000050388004,0.00007193372,0.000030631323,0.000009790468,0.000041969928,0.00002519388,0.000049325266],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016783526,0.0036616381,0.19860102,0.00021037979,0.0007349523,0.00000794502,0.0030475021,0.00017152065,0.60197043,0.026307803,0.063460544,0.10180949],"study_design_scores_gemma":[0.001847205,0.00029241134,0.44601846,0.00003318089,0.00049727474,0.0000050845097,0.000107012034,0.00067500904,0.13791332,0.00041220602,0.41203925,0.00015958553],"about_ca_topic_score_codex":0.000003645922,"about_ca_topic_score_gemma":0.0000025096817,"teacher_disagreement_score":0.46405712,"about_ca_system_score_codex":0.000056456185,"about_ca_system_score_gemma":0.0000062740974,"threshold_uncertainty_score":0.12980121},"labels":[],"label_agreement":null},{"id":"W2000026115","doi":"10.1016/j.mce.2004.10.008","title":"Structure and expression of the chicken proglucagon gene","year":2004,"lang":"en","type":"article","venue":"Molecular and Cellular Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Proglucagon; Biology; Promoter; Gene; Exon; Gene expression; Molecular biology; Genetics; Glucagon-like peptide-1; Endocrinology","score_opus":0.004987491342306676,"score_gpt":0.2069009428549708,"score_spread":0.20191345151266413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000026115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522084,0.002902714,0.00025946766,0.00063987734,0.000053127547,0.0003100368,0.0000024284461,0.00001360343,0.0005979193],"genre_scores_gemma":[0.9988208,0.00007314964,0.00071449537,0.00019799136,0.000013262318,0.000008456354,0.000012362445,0.00000919141,0.00015031786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994777,0.00001993172,0.000093147806,0.00016731725,0.000082199724,0.00015972767],"domain_scores_gemma":[0.999705,0.0000031133302,0.000035336903,0.00020222091,0.000014215898,0.00004009161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000013922198,0.00009516193,0.00015299337,0.00003699942,0.000037212885,0.000004707275,0.000043924687,0.00004108751,0.000012269737],"category_scores_gemma":[0.000006350077,0.000059642087,0.000039593935,0.000045819506,0.00010502038,0.0000140672755,0.00011332614,0.00007187316,7.3159873e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022781627,0.00005815868,0.0048438315,0.000062555955,0.000060535676,0.00009265774,0.00009811376,0.000005935234,0.9877594,0.0034838188,0.000009255561,0.0035029512],"study_design_scores_gemma":[0.0015285047,0.00018316273,0.0065197307,0.000027796668,0.00013472102,0.0000517435,0.000027608281,0.0000023231698,0.98888063,0.0016453038,0.00094592175,0.00005257018],"about_ca_topic_score_codex":0.000012187633,"about_ca_topic_score_gemma":0.0000013729386,"teacher_disagreement_score":0.0035999478,"about_ca_system_score_codex":0.000009681151,"about_ca_system_score_gemma":0.000013058367,"threshold_uncertainty_score":0.24321337},"labels":[],"label_agreement":null},{"id":"W2000290481","doi":"10.1016/s0168-8227(00)81335-2","title":"Peripheral insulin extraction is a determinant of insulin sensitivity: Studies with metformin","year":2000,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Metformin; Insulin; Insulin sensitivity; Diabetes mellitus; Internal medicine; Peripheral; Endocrinology; Insulin resistance","score_opus":0.11237309074072908,"score_gpt":0.4760048240534494,"score_spread":0.3636317333127203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000290481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98457354,0.0042709326,0.0000048241513,0.0033708657,0.000042800755,0.0006565624,0.000008489712,0.000028598171,0.007043384],"genre_scores_gemma":[0.9723134,0.019707695,0.003349652,0.0009081778,0.00014316168,0.000053893593,0.000012910595,0.00002410479,0.0034870273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730664,0.0004960407,0.00053430744,0.00045791676,0.00070820353,0.0004968991],"domain_scores_gemma":[0.99422777,0.004389772,0.00014293141,0.0003654705,0.0006195689,0.00025447115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037566589,0.00017937794,0.0005928277,0.00013395195,0.00014424355,0.000048250226,0.00005810682,0.0001097899,0.00020412393],"category_scores_gemma":[0.0029757265,0.00012272884,0.000095754905,0.0003858523,0.00061988574,0.0005457446,0.00008841953,0.0005718855,0.0000627734],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029275345,0.0027534545,0.032774027,0.0002693949,0.0015509716,0.000370477,0.00039010737,6.7160966e-7,0.00024741216,0.000072477786,0.001504305,0.9571392],"study_design_scores_gemma":[0.02079467,0.05260656,0.28061095,0.0016601031,0.003139808,0.0001476592,0.01024531,0.0032803314,0.011071378,0.0011937583,0.6142812,0.0009682728],"about_ca_topic_score_codex":0.000059474958,"about_ca_topic_score_gemma":0.000024548728,"teacher_disagreement_score":0.9561709,"about_ca_system_score_codex":0.00006228952,"about_ca_system_score_gemma":0.000097579876,"threshold_uncertainty_score":0.50047374},"labels":[],"label_agreement":null},{"id":"W2000297042","doi":"10.1111/j.1463-1326.2011.01444.x","title":"Incretin hormones and the expanding families of glucagon‐like sequences and their receptors","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Ottawa","keywords":"Biology; Proglucagon; Vertebrate; Subfamily; Receptor; Glucagon; Gene; Genetics; Lineage (genetic); Hormone; Evolutionary biology; Cell biology; Glucagon-like peptide-1; Endocrinology","score_opus":0.02292791986254658,"score_gpt":0.25544055628912127,"score_spread":0.2325126364265747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000297042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12455483,0.87325996,0.0000011302457,0.000035116227,0.00022350438,0.0010007945,0.000031965752,0.000032978944,0.0008597371],"genre_scores_gemma":[0.0077699716,0.9912419,0.00015288232,0.00009282938,0.00010796772,0.00012630287,0.00006071871,0.00003122032,0.00041626082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984113,0.00023091372,0.00045622623,0.00043273115,0.00013491052,0.00033390574],"domain_scores_gemma":[0.99880946,0.0003639198,0.00032130032,0.00032075026,0.000046426903,0.00013814752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007444706,0.00050858443,0.0024276143,0.00025590297,0.00016604552,0.00005473845,0.00013898639,0.00020212388,0.000018757171],"category_scores_gemma":[0.00007978285,0.00025950637,0.00025656185,0.00020288494,0.00088250433,0.00012579007,0.00029187457,0.00022117913,0.0000029671096],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002102685,0.00006781161,0.0017859953,0.009062817,0.0011908473,0.0000013530127,0.0013570404,3.7695718e-9,0.000007748991,0.0031550971,0.000121234894,0.98322904],"study_design_scores_gemma":[0.0014162135,0.000098922064,0.003101712,0.003935555,0.004910377,0.00000406663,0.0005452218,0.0000020980096,0.0001280395,0.0006947794,0.984828,0.00033502685],"about_ca_topic_score_codex":0.00009437586,"about_ca_topic_score_gemma":0.000005872036,"teacher_disagreement_score":0.98470676,"about_ca_system_score_codex":0.000011516974,"about_ca_system_score_gemma":0.0000385062,"threshold_uncertainty_score":0.9999857},"labels":[],"label_agreement":null},{"id":"W2000976083","doi":"10.1161/circulationaha.107.739938","title":"Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways","year":2008,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1046,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Glucagon-like peptide-1; Internal medicine; Glucagon-like peptide 1 receptor; Vasodilation; Endocrinology; Nitric oxide; Agonist; Receptor; Dipeptidyl peptidase-4; Pharmacology; Nitric oxide synthase; Incretin; Type 2 diabetes; Diabetes mellitus","score_opus":0.03600998559058563,"score_gpt":0.24457609922015353,"score_spread":0.2085661136295679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000976083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921642,0.0013693891,0.0004721364,0.000184593,0.00054089393,0.0015630819,0.000063697626,0.00013579021,0.0035062365],"genre_scores_gemma":[0.9965622,0.0013256564,0.0006709409,0.00014880252,0.00016942593,0.00017392912,0.00023810823,0.000056390978,0.000654575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977943,0.00008448255,0.0004834779,0.000653162,0.0006142151,0.00037037933],"domain_scores_gemma":[0.9986903,0.00008342262,0.00036219764,0.0004580013,0.00020116364,0.00020491428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025398607,0.00035742397,0.00060766854,0.00021474683,0.0002925964,0.000026885295,0.00007627394,0.00021525423,0.00011932877],"category_scores_gemma":[0.000074225376,0.00034522088,0.00015718018,0.000270945,0.00020280256,0.00032794953,0.000099673016,0.0002455969,0.00005141347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073587074,0.0014609541,0.82235396,0.0010287624,0.0033982543,0.00013305049,0.011673093,0.00040157235,0.13898131,0.0008914837,0.0066908374,0.012250828],"study_design_scores_gemma":[0.00433326,0.0003368238,0.9724794,0.00032651564,0.0006415369,0.000057726884,0.0023554598,0.00024437887,0.006439121,0.00016921217,0.012145394,0.0004711468],"about_ca_topic_score_codex":0.00020873324,"about_ca_topic_score_gemma":0.000043858203,"teacher_disagreement_score":0.15012544,"about_ca_system_score_codex":0.00036991667,"about_ca_system_score_gemma":0.00010352229,"threshold_uncertainty_score":0.9999},"labels":[],"label_agreement":null},{"id":"W2001281028","doi":"10.1139/y08-098","title":"Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention","year":2009,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Insulin resistance; Type 2 diabetes; Diabetes mellitus; Medicine; Insulin; Internal medicine; Endocrinology; Type 1 diabetes","score_opus":0.027717127575591593,"score_gpt":0.3213676058411903,"score_spread":0.2936504782655987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001281028","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46283996,0.53644115,9.347317e-8,0.000051609673,0.00027532663,0.00035201447,0.000003088105,9.990075e-7,0.00003574254],"genre_scores_gemma":[0.50005233,0.49975085,0.000011717206,0.0001010883,0.000053720112,0.000006071926,0.0000053478852,0.000007119491,0.000011721639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986797,0.00038150436,0.00050180015,0.00016405965,0.000043580065,0.00022935291],"domain_scores_gemma":[0.9987968,0.0003970414,0.00046948018,0.00006650438,0.000106234496,0.00016391194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033102295,0.00021487045,0.0014890581,0.00038970058,0.000031934505,0.000003875799,0.00010211969,0.00018868365,0.000060596973],"category_scores_gemma":[0.000058720783,0.00013661498,0.00013702364,0.00018214363,0.0003726259,0.000057556183,0.00003514546,0.0003650995,4.7991756e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001948128,0.00064106577,0.00096842163,0.0423743,0.005292405,0.00032602545,0.0008764332,0.00000565171,0.03639279,0.0007347411,0.0016413487,0.9087987],"study_design_scores_gemma":[0.14543462,0.1976179,0.037807968,0.08553882,0.16253017,0.0025021802,0.00060837844,0.0025179593,0.0451502,0.016368486,0.2994577,0.0044656103],"about_ca_topic_score_codex":0.00008113379,"about_ca_topic_score_gemma":0.000048047325,"teacher_disagreement_score":0.90433306,"about_ca_system_score_codex":0.000047418598,"about_ca_system_score_gemma":0.00028039824,"threshold_uncertainty_score":0.55709976},"labels":[],"label_agreement":null},{"id":"W2002444174","doi":"10.1016/s0992-5945(09)70249-1","title":"Les évolutions du diabète de type 1","year":2009,"lang":"fr","type":"article","venue":"Option/Bio","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Medicine","score_opus":0.02209918186205031,"score_gpt":0.2771161905059828,"score_spread":0.2550170086439325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002444174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4651207,0.055844735,0.0034997347,0.07084652,0.0051110853,0.0011420702,0.0000429981,0.0003886363,0.39800352],"genre_scores_gemma":[0.7675378,0.0048185927,0.0032119728,0.0011638734,0.0014280572,0.000016437267,0.00012949917,0.000020651582,0.22167315],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894834,0.00004277173,0.0001762975,0.00022128485,0.00014490177,0.00046639756],"domain_scores_gemma":[0.9993872,0.000034199846,0.00005135212,0.00027020922,0.00007566931,0.00018138638],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015739293,0.00017398047,0.00019285543,0.00009631281,0.00016167991,0.00004177655,0.00008347863,0.000111527705,0.0015044794],"category_scores_gemma":[0.00006103633,0.00017265958,0.00010527116,0.00024692222,0.00008944573,0.000121115685,0.0000286284,0.00011683741,0.0024741523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056526907,0.001621772,0.035220884,0.00009479325,0.00037828882,0.000113033675,0.00039357835,0.00021596647,0.0009133501,0.23333126,0.12157206,0.60608846],"study_design_scores_gemma":[0.0010646128,0.0007225,0.21315165,0.0002434843,0.0007385948,0.000009353664,0.00012824364,0.0011171282,0.00027296125,0.0018007176,0.7805615,0.00018924338],"about_ca_topic_score_codex":0.00013512079,"about_ca_topic_score_gemma":0.00002246144,"teacher_disagreement_score":0.6589894,"about_ca_system_score_codex":0.000413163,"about_ca_system_score_gemma":0.00007114145,"threshold_uncertainty_score":0.9994083},"labels":[],"label_agreement":null},{"id":"W2002559957","doi":"10.1038/ki.2013.406","title":"The perils of clinical trials","year":2014,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Glycemic; Diabetes mellitus; Renal function; Medicine; Kidney disease; Internal medicine; Endocrinology; Type 2 diabetes; Placebo; Population; Hemoglobin; Urology; Pathology","score_opus":0.14232728708165504,"score_gpt":0.4422700678655915,"score_spread":0.29994278078393644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002559957","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009725913,0.000064513864,0.000058405985,0.883065,0.0042316047,0.00039231768,0.000072745745,0.000022930759,0.11199523],"genre_scores_gemma":[0.0013545816,0.00026357124,0.00040228938,0.86691195,0.014107554,0.00006641933,0.001624854,0.000029048168,0.11523974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759185,0.00028170037,0.0011211458,0.00022917487,0.0006180622,0.00015807478],"domain_scores_gemma":[0.99734825,0.0013522038,0.0006541425,0.00036986894,0.00018274682,0.00009277995],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027644106,0.00015906607,0.00073167786,0.000091607944,0.00003020911,0.000037752423,0.00030524642,0.00027897872,0.0010807979],"category_scores_gemma":[0.0060704467,0.00008997397,0.0006424775,0.000032226333,0.000119378186,0.000022167369,0.00007494547,0.0005183966,0.00019747135],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061771025,0.000054234573,0.0014256941,0.000049447444,0.0020485711,0.00003076137,0.0000076222454,4.9978336e-8,0.000003984074,0.0007167959,0.9814954,0.014105662],"study_design_scores_gemma":[0.0015332593,0.00013800061,0.0008214706,0.00016269855,0.0005341775,0.000003558991,0.0000033551444,0.00006241332,0.00003443743,0.00029149768,0.99634224,0.00007291389],"about_ca_topic_score_codex":0.000007813426,"about_ca_topic_score_gemma":3.8254757e-7,"teacher_disagreement_score":0.016153049,"about_ca_system_score_codex":0.00004029221,"about_ca_system_score_gemma":0.00016072555,"threshold_uncertainty_score":0.99983233},"labels":[],"label_agreement":null},{"id":"W2002706738","doi":"10.1371/journal.pone.0024693","title":"Discovery of Dual-Action Membrane-Anchored Modulators of Incretin Receptors","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Drug Abuse; Harvard Digestive Diseases Center, Harvard University; National Institutes of Health; Canadian Institutes of Health Research; Université Laval","keywords":"Receptor; G protein-coupled receptor; Incretin; Endocytosis; Cell biology; Glucagon-like peptide 1 receptor; Biochemistry; Gastric inhibitory polypeptide; Peptide; Chemistry; Biology; Endocrinology; Agonist; Glucagon; Hormone; Type 2 diabetes","score_opus":0.06971485902262334,"score_gpt":0.23729638734460695,"score_spread":0.1675815283219836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002706738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988341,0.00006909447,0.000010923491,0.000049218845,0.00006308502,0.0003453662,0.0000054391453,0.000030259458,0.01108561],"genre_scores_gemma":[0.99524766,0.00014456607,0.0018179733,0.000022715436,0.000037422964,0.00001926374,0.00003401824,0.000015693393,0.0026607073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925834,0.000019087796,0.0002268983,0.00013364264,0.00024660706,0.00011539953],"domain_scores_gemma":[0.9995263,0.000016346214,0.0001276664,0.00023860601,0.000052485095,0.000038559083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008857943,0.00009127221,0.000314376,0.000109062006,0.000010904405,0.0000022963775,0.00003625896,0.000042041665,0.00024219275],"category_scores_gemma":[0.00003986175,0.00007725662,0.00006700907,0.000126524,0.000051210554,0.00011668184,0.00003177502,0.000044007505,0.000016791633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010062645,0.009783234,0.21539061,0.0019938769,0.0038008138,0.000010998953,0.0015507693,0.0000013510046,0.7604183,0.0016179634,0.0006814317,0.0037444208],"study_design_scores_gemma":[0.0009935407,0.0005914485,0.047869883,0.0003044324,0.00080975133,1.7014192e-7,0.00014838068,0.000035357716,0.9490128,0.00009710722,0.000063505984,0.000073611904],"about_ca_topic_score_codex":0.00009975071,"about_ca_topic_score_gemma":0.0000053014696,"teacher_disagreement_score":0.18859453,"about_ca_system_score_codex":0.00003038023,"about_ca_system_score_gemma":0.000013172599,"threshold_uncertainty_score":0.31504333},"labels":[],"label_agreement":null},{"id":"W2002764863","doi":"10.1053/gast.2000.16489","title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","year":2000,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":339,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Enteroendocrine cell; Proglucagon; Biology; Enterochromaffin cell; Internal medicine; Glucagon-like peptide-2; Ileum; Glucagon-like peptide-1; Northern blot; Small intestine; Endocrinology; Receptor; Messenger RNA; Molecular biology; Endocrine system; Gene; Medicine; Biochemistry; Peptide","score_opus":0.007436301200306188,"score_gpt":0.24156878415826924,"score_spread":0.23413248295796305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002764863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983912,0.00006340972,0.00027078832,0.00034158357,0.000050608596,0.00022221352,0.0000032111534,0.00001597261,0.00064101524],"genre_scores_gemma":[0.9979231,0.0002553315,0.0004110453,0.0004176024,0.000020261823,0.00002017373,0.00006194062,0.00000851319,0.00088205654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932665,0.000037154594,0.00019729279,0.00017118632,0.00007850609,0.00018921215],"domain_scores_gemma":[0.9997701,0.000004943156,0.000038234688,0.00012830723,0.000013029322,0.00004540079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040651637,0.00008557658,0.00020607123,0.000108010696,0.000012295183,0.0000028800905,0.00003587942,0.000021970398,0.0007197423],"category_scores_gemma":[0.00000449846,0.00007453107,0.000026071199,0.000041875723,0.000047930596,0.00004659175,0.000031842603,0.000042501415,0.000015629375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007141748,0.00035028503,0.98898584,0.00004893688,0.00003106173,0.000014817238,0.00011581669,0.00002829002,0.0020376018,0.00000928792,0.0012820427,0.0063818465],"study_design_scores_gemma":[0.013416882,0.004011169,0.9596184,0.00033831748,0.00012332635,0.000017545357,0.00010742517,0.0004086322,0.0059918654,0.00008295254,0.015787104,0.000096394746],"about_ca_topic_score_codex":0.000014011792,"about_ca_topic_score_gemma":0.00003264487,"teacher_disagreement_score":0.029367452,"about_ca_system_score_codex":0.000022433374,"about_ca_system_score_gemma":0.0000022044662,"threshold_uncertainty_score":0.7880674},"labels":[],"label_agreement":null},{"id":"W2002964620","doi":"10.1194/jlr.m012203","title":"Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation","year":2011,"lang":"en","type":"article","venue":"Journal of Lipid Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Acetylation; Adipocyte; Histone; Receptor; Gene expression; Chemistry; Gene; Peroxisome proliferator-activated receptor; Endocrinology; Biochemistry; Internal medicine; Cell biology; Biology; Adipose tissue; Medicine","score_opus":0.06086090164221299,"score_gpt":0.32287772539496973,"score_spread":0.26201682375275676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002964620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945495,0.0031059368,0.0000629293,0.0006763892,0.0002045843,0.00031782404,0.0000020605123,0.0000056516255,0.0010750907],"genre_scores_gemma":[0.9932182,0.0012928972,0.0019329117,0.000028614939,0.00023435777,0.0000054038815,0.0000044010735,0.000014344996,0.0032688642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983062,0.00019383362,0.00039106794,0.00012016172,0.0008032941,0.00018545508],"domain_scores_gemma":[0.9989693,0.00006198826,0.0002875504,0.00022607582,0.0003376106,0.00011745464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008777961,0.000087006876,0.00021984836,0.00021680794,0.0000920278,0.000013017651,0.00013334282,0.00006647357,0.00017673409],"category_scores_gemma":[0.00014349769,0.000052461484,0.000075316566,0.00018752863,0.00013201202,0.00017142443,0.00011596293,0.00026125272,0.000006837478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006550852,0.00037502675,0.032336984,0.00007933999,0.00010652585,0.0000032658636,0.0008922101,0.0000018481024,0.9390053,0.00007137601,0.012134921,0.014338123],"study_design_scores_gemma":[0.0017930649,0.0008444408,0.15034726,0.00027701506,0.00006822814,0.000007504066,0.00018745565,0.000025016974,0.8384124,0.00012788715,0.007860703,0.000049024606],"about_ca_topic_score_codex":0.000027320835,"about_ca_topic_score_gemma":0.000003173444,"teacher_disagreement_score":0.11801028,"about_ca_system_score_codex":0.0001643373,"about_ca_system_score_gemma":0.000075666125,"threshold_uncertainty_score":0.21393172},"labels":[],"label_agreement":null},{"id":"W2003316205","doi":"10.1358/dot.2010.46.2.1464700","title":"Saxagliptin in type 2 diabetes","year":2010,"lang":"en","type":"article","venue":"Drugs of today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Saxagliptin; Medicine; Glycemic; Metformin; Incretin; Type 2 diabetes; Hypoglycemia; Pharmacology; Diabetes mellitus; Internal medicine; Sitagliptin; Endocrinology","score_opus":0.006862667400269849,"score_gpt":0.24396767172015393,"score_spread":0.23710500431988407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003316205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491215,0.000115938295,2.2035707e-7,0.00082508987,0.0002811375,0.00015618121,0.0000013984287,0.000021499905,0.049477078],"genre_scores_gemma":[0.995718,0.00001809342,0.0006059244,0.00021167274,0.000050866936,0.0000069853786,0.000016795188,0.0000089104215,0.0033627339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952656,0.0000058617215,0.00012016893,0.000102176775,0.00010178771,0.00014346161],"domain_scores_gemma":[0.9996748,0.000028744804,0.00003262871,0.00019326895,0.000028111124,0.00004242786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012378037,0.00006582162,0.00016152648,0.000096950105,0.000007406645,0.0000039937263,0.00005392154,0.000036573205,0.00034847116],"category_scores_gemma":[0.000049000046,0.00005329637,0.00003745077,0.0001226354,0.000030126439,0.000034821667,0.000032002717,0.0000840691,0.000090158224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010840092,0.0013090392,0.6694132,0.0002618561,0.00022549849,0.000023929902,0.001116966,0.0000030360025,0.10048496,0.009369389,0.023649078,0.19403462],"study_design_scores_gemma":[0.0046015778,0.0007077043,0.6036561,0.000223317,0.00022621204,6.0552685e-7,0.00026026,0.00021988303,0.14024293,0.0010477203,0.2485027,0.00031096494],"about_ca_topic_score_codex":0.000021267186,"about_ca_topic_score_gemma":0.000019045163,"teacher_disagreement_score":0.22485362,"about_ca_system_score_codex":0.000010162039,"about_ca_system_score_gemma":0.000015195198,"threshold_uncertainty_score":0.38155147},"labels":[],"label_agreement":null},{"id":"W2004269133","doi":"10.1016/j.jcjd.2013.08.129","title":"Safety and Efficacy of Dulaglutide Versus Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD-5)","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Dulaglutide; Placebo; Type 2 diabetes; Internal medicine; Metformin; Nausea; Clinical endpoint; Adverse effect; Gastroenterology; Sitagliptin Phosphate; Diabetes mellitus; Endocrinology; Exenatide; Randomized controlled trial; Insulin","score_opus":0.008574828817604279,"score_gpt":0.21425008300521342,"score_spread":0.20567525418760915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004269133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99169135,0.004578964,2.916341e-7,0.0013895667,0.00040691235,0.0002848711,0.000009163117,0.0000047811477,0.0016340787],"genre_scores_gemma":[0.9989621,0.000069005495,0.00029146037,0.00021548293,0.000100502075,0.0000060947755,0.000007442171,0.00002342784,0.00032447148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986772,0.000042880805,0.00047972257,0.00014974774,0.00016567447,0.00048475974],"domain_scores_gemma":[0.9986784,0.00017781038,0.0001728516,0.00019084889,0.00018232931,0.00059774827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023610904,0.00018198673,0.0005161148,0.0005030348,0.00003181336,0.000032596625,0.00010948099,0.000078727695,0.00050444435],"category_scores_gemma":[0.00027408876,0.00015348119,0.00010791193,0.00025494627,0.00013718566,0.0001946738,0.000023830633,0.00017426259,0.000035322028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007983511,0.00008303279,0.97175086,0.00011792819,0.00043357114,0.000037513168,0.0002719597,0.000012194709,0.0005473052,0.000075024225,0.0021957115,0.024395091],"study_design_scores_gemma":[0.0050283875,0.0011767107,0.9838445,0.0004354167,0.0002920526,6.778122e-7,0.00016323676,0.000047678197,0.0009542909,0.000087689616,0.007809027,0.00016031103],"about_ca_topic_score_codex":0.00037612888,"about_ca_topic_score_gemma":0.0017831585,"teacher_disagreement_score":0.024234781,"about_ca_system_score_codex":0.00016583163,"about_ca_system_score_gemma":0.0002615297,"threshold_uncertainty_score":0.6258781},"labels":[],"label_agreement":null},{"id":"W2004322907","doi":"10.4021//jmc.v3i6.807","title":"Potential Linagliptin-Induced Renal Impairment","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Linagliptin; Medicine; Sitagliptin; Renal function; Nausea; Creatinine; Impaired renal function; Urology; Drug; Internal medicine; Diabetes mellitus; Pharmacology; Intensive care medicine; Gastroenterology; Type 2 diabetes; Endocrinology","score_opus":0.025882947791180937,"score_gpt":0.3078572396093436,"score_spread":0.28197429181816264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004322907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914707,0.0015104607,0.00012912597,0.0071480228,0.0010034695,0.00012242763,8.3394195e-7,0.000015392316,0.00092321564],"genre_scores_gemma":[0.9950395,0.0002616733,0.00053412927,0.0010543504,0.0026223937,0.000002731932,0.0000032618045,0.000011899264,0.00047005923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977611,0.000044861896,0.00041982284,0.00007003633,0.0013889198,0.0003152723],"domain_scores_gemma":[0.99876434,0.00007760957,0.00019521404,0.000117442585,0.00008814438,0.00075722375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009211489,0.00011613038,0.0003152501,0.00013519023,0.00003661701,0.000014778525,0.00010652748,0.00009322969,0.0015889389],"category_scores_gemma":[0.00039829902,0.000073774085,0.00022205387,0.00008740702,0.000037819893,0.00013453327,0.00006322673,0.00026349965,0.00005405169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002548322,0.0142391,0.07710397,0.00047846825,0.00313481,0.03766753,0.0009400165,0.0000073265705,0.0064579495,0.0012480116,0.32756862,0.5286059],"study_design_scores_gemma":[0.041804295,0.030757925,0.3023894,0.0033696322,0.0077484148,0.04487152,0.0026369265,0.0004715877,0.025259968,0.00029872457,0.53934246,0.0010491101],"about_ca_topic_score_codex":0.000009788357,"about_ca_topic_score_gemma":9.49304e-7,"teacher_disagreement_score":0.5275568,"about_ca_system_score_codex":0.00008752998,"about_ca_system_score_gemma":0.00012534583,"threshold_uncertainty_score":0.9993237},"labels":[],"label_agreement":null},{"id":"W2004409542","doi":"10.1210/en.2009-1272","title":"Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation","year":2010,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk; Amylin Pharmaceuticals","keywords":"Calcitonin; Endocrinology; Internal medicine; Liraglutide; Calcitonin receptor; Receptor; Glucagon-like peptide 1 receptor; Thyroid; Glucagon receptor; Glucagon; Medicine; Calcitonin gene-related peptide; Biology; Neuropeptide; Agonist; Diabetes mellitus; Hormone; Type 2 diabetes","score_opus":0.010023333930965456,"score_gpt":0.24874603088630842,"score_spread":0.23872269695534296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004409542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912047,0.00022322316,0.00006888443,0.0017525231,0.0011553139,0.0007151947,0.0000054716047,0.00013931129,0.0047353855],"genre_scores_gemma":[0.9816858,0.00028446177,0.0019915958,0.0006129681,0.00029941386,0.00009104584,0.00007589631,0.000036718986,0.014922076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855846,0.000046459354,0.00024689583,0.00045707996,0.00016400417,0.00052707817],"domain_scores_gemma":[0.9992356,0.000047464986,0.00010196037,0.00037452404,0.000059109527,0.00018135035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000726707,0.00024170612,0.00031747765,0.00016390068,0.00014269704,0.00004685992,0.00006290635,0.000102566824,0.00020212715],"category_scores_gemma":[0.000033157485,0.00021223121,0.000065212356,0.00009922432,0.00012534842,0.000119000244,0.00011908954,0.00034803207,0.00019556684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024299738,0.0006098741,0.01153826,0.00011383005,0.00017507492,0.00026467082,0.00042090224,0.0000056194617,0.9609138,0.00097337365,0.009331876,0.01540975],"study_design_scores_gemma":[0.004261171,0.00080576877,0.0071176803,0.00003414185,0.00026530394,0.00010780276,0.00015629399,0.00019998311,0.8293944,0.00008269561,0.1572491,0.00032564704],"about_ca_topic_score_codex":0.00011009941,"about_ca_topic_score_gemma":0.00007301766,"teacher_disagreement_score":0.14791723,"about_ca_system_score_codex":0.00006935002,"about_ca_system_score_gemma":0.00005841714,"threshold_uncertainty_score":0.8654538},"labels":[],"label_agreement":null},{"id":"W2004425702","doi":"10.1016/s1499-2671(11)80008-0","title":"Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk Canada; AstraZeneca Canada; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Liraglutide; Exenatide; Incretin; Hypoglycemia; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; Glycemic; Internal medicine; Sitagliptin; Intensive care medicine; Endocrinology","score_opus":0.015048395656596762,"score_gpt":0.2152910572020878,"score_spread":0.20024266154549103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004425702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754819,0.009360288,4.037127e-7,0.00016740018,0.00018784316,0.00026417797,0.00000866384,0.0000031166992,0.014526207],"genre_scores_gemma":[0.9989734,0.00021799134,0.0004087412,0.00014597326,0.000033634085,0.000005472804,0.0000061101177,0.00001930739,0.00018931479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986806,0.00006176619,0.00054804725,0.00009557709,0.00022811064,0.00038588714],"domain_scores_gemma":[0.99892306,0.000049715545,0.00031904376,0.00027627975,0.00015340172,0.00027850017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052834576,0.0001531811,0.0004470258,0.0006407165,0.000028856612,0.000009202231,0.00028981664,0.000053783682,0.0003336908],"category_scores_gemma":[0.00004426419,0.00010908515,0.00014121833,0.0005707807,0.0001516706,0.000090766436,0.00003417431,0.00013264701,0.000008306478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001607944,0.00013408084,0.96399015,0.00020373396,0.0009344578,0.000029098846,0.0013778725,0.000005595674,0.0002752354,0.002035414,0.0007043384,0.030293943],"study_design_scores_gemma":[0.0019175957,0.001308734,0.9466411,0.0013334609,0.0010271472,8.067922e-7,0.0040700226,0.000057370733,0.023859793,0.0023192198,0.017257918,0.00020684207],"about_ca_topic_score_codex":0.00045084316,"about_ca_topic_score_gemma":0.00044087443,"teacher_disagreement_score":0.0300871,"about_ca_system_score_codex":0.00009573468,"about_ca_system_score_gemma":0.00015370421,"threshold_uncertainty_score":0.44483632},"labels":[],"label_agreement":null},{"id":"W2004827855","doi":"10.1073/pnas.1411413111","title":"Insulin-like peptide 5 is an orexigenic gastrointestinal hormone","year":2014,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research; Wellcome Trust","keywords":"Orexigenic; Appetite; Endocrinology; Internal medicine; Enteroendocrine cell; Hormone; Glucagon-like peptide-1; Insulin; Ghrelin; Glucose homeostasis; Peptide; Biology; Peptide YY; Endocrine system; Energy homeostasis; Peptide hormone; Calorie restriction; Chemistry; Receptor; Type 2 diabetes; Neuropeptide; Diabetes mellitus; Obesity; Biochemistry; Medicine; Insulin resistance; Neuropeptide Y receptor","score_opus":0.03974494725203509,"score_gpt":0.29695519106353796,"score_spread":0.25721024381150287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004827855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973769,0.000068753056,0.0000025585693,0.00382125,0.0000093675,0.00018628864,0.0000031581772,0.000017284852,0.022122333],"genre_scores_gemma":[0.99113744,0.000016970904,0.00677554,0.0010748045,0.00008233956,0.000007387998,3.1035333e-7,0.0000039747824,0.0009012089],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99851555,0.000003396116,0.00021896162,0.00020494236,0.0009060088,0.00015113951],"domain_scores_gemma":[0.99946284,0.00003983042,0.0002256677,0.000009873734,0.00020431457,0.00005749445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000853556,0.00008646657,0.00014774087,0.00013608726,0.00010148338,0.000015594993,0.0003553853,0.00002613985,0.00002173476],"category_scores_gemma":[0.00023952196,0.000053691776,0.00006923429,0.00040333447,0.0004438177,0.00027638677,0.000094100236,0.0000892534,0.0000055752944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023576194,0.0010460325,0.1894205,0.0003366105,0.00015768428,5.166719e-8,0.0008101134,0.00004093767,0.6224074,0.14543095,0.029955974,0.010157979],"study_design_scores_gemma":[0.0013235197,0.0014758729,0.86904836,0.00028698935,0.00013872294,0.00003222921,0.00029047948,0.0039027226,0.078776345,0.041447777,0.0031210175,0.0001559434],"about_ca_topic_score_codex":0.000004097904,"about_ca_topic_score_gemma":3.1639324e-8,"teacher_disagreement_score":0.6796279,"about_ca_system_score_codex":0.000029827828,"about_ca_system_score_gemma":0.000019458308,"threshold_uncertainty_score":0.2189487},"labels":[],"label_agreement":null},{"id":"W2004914253","doi":"10.1055/s-0029-1221934","title":"Die Wirksamkeit des GLP-1 Analogons Liraglutid hinsichtlich von Blutzuckereinstellung und Gewichtsreduktion bei Patienten, die gleichzeitig mit Metformin und Rosiglitazon behandelt wurden: Eine randomisierte, doppelblinde, plazebokontrollierte Studie","year":2009,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Metformin; Medicine; Gynecology; Diabetes mellitus; Endocrinology","score_opus":0.028689868399588994,"score_gpt":0.29733394136941416,"score_spread":0.2686440729698252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004914253","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30621555,0.6694713,0.0022532402,0.002353122,0.003788122,0.006498068,0.00056915043,0.0009143665,0.00793703],"genre_scores_gemma":[0.9207112,0.0656947,0.0019343575,0.0019157487,0.0017591327,0.00055891386,0.003186196,0.00033350804,0.0039062225],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9863576,0.00091060833,0.0032035736,0.0030263886,0.0021200723,0.0043817265],"domain_scores_gemma":[0.99189734,0.0015367463,0.0015450121,0.0025178927,0.0010056327,0.0014973449],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0021775546,0.0028566944,0.004831936,0.001722874,0.0016107335,0.00060522946,0.0013730526,0.0014362546,0.00013024907],"category_scores_gemma":[0.0014969915,0.0024574785,0.0016153393,0.0016573315,0.0012786433,0.0012795051,0.00067588576,0.0016635082,0.00072527555],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010712338,0.012447458,0.04146085,0.0011806629,0.072652645,0.0030394497,0.0027042653,0.00073468476,0.001313705,0.0027734423,0.010643352,0.84033716],"study_design_scores_gemma":[0.20790967,0.04308504,0.111047216,0.0062630186,0.2965107,0.000026451142,0.0024060896,0.0156021,0.011848074,0.01603277,0.27822667,0.0110422075],"about_ca_topic_score_codex":0.0006386621,"about_ca_topic_score_gemma":0.0013864302,"teacher_disagreement_score":0.8292949,"about_ca_system_score_codex":0.0021850178,"about_ca_system_score_gemma":0.00051742996,"threshold_uncertainty_score":0.9998601},"labels":[],"label_agreement":null},{"id":"W2005561360","doi":"10.1111/dom.12474","title":"Two dose‐ranging studies with <scp>PF</scp> ‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"Pfizer","keywords":"Metformin; Glucokinase; Activator (genetics); Type 2 diabetes; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Cancer research; Receptor","score_opus":0.018849586620283482,"score_gpt":0.2627396493139453,"score_spread":0.24389006269366179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005561360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98313665,0.014227801,0.0000022665313,0.00008833074,0.00017846121,0.0014911215,0.000015289135,0.00007517254,0.00078488275],"genre_scores_gemma":[0.9973777,0.0007960697,0.00052942615,0.0005344891,0.00014172282,0.00023922652,0.000030893025,0.0000459753,0.0003045208],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979196,0.00010099599,0.00033232768,0.0005112138,0.00049883575,0.0006370371],"domain_scores_gemma":[0.9986111,0.00021636455,0.00017416704,0.00039829814,0.0002675482,0.00033254767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052497315,0.0004247161,0.0011045154,0.00041014972,0.0000730605,0.0000345326,0.00012927744,0.00007758323,0.0000053976028],"category_scores_gemma":[0.0002273333,0.0002748275,0.000072036084,0.00069699023,0.00012903694,0.0002482067,0.00009037109,0.00016165078,0.000020450816],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027741145,0.002806154,0.90587294,0.0018312794,0.0048816376,0.00014474514,0.016058905,0.00017448608,0.0076490636,0.0027114635,0.0015281852,0.053567033],"study_design_scores_gemma":[0.06574185,0.015835796,0.3819085,0.0095755225,0.0030013341,0.000011788164,0.015849125,0.00026287526,0.47513932,0.0005524386,0.031011768,0.0011096784],"about_ca_topic_score_codex":0.000060763872,"about_ca_topic_score_gemma":0.000031584717,"teacher_disagreement_score":0.5239644,"about_ca_system_score_codex":0.00006939013,"about_ca_system_score_gemma":0.00009407132,"threshold_uncertainty_score":0.9999704},"labels":[],"label_agreement":null},{"id":"W2005563324","doi":"10.1016/j.atherosclerosis.2015.03.026","title":"GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats","year":2015,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novo Nordisk Pharma; Kyushu University; Saskatoon Community Foundation","keywords":"Liraglutide; Endocrinology; Internal medicine; Steatosis; AMPK; Oxidative stress; Streptozotocin; Diabetic cardiomyopathy; Medicine; Diabetes mellitus; Chemistry; Protein kinase A; Type 2 diabetes; Kinase; Biochemistry; Heart failure; Cardiomyopathy","score_opus":0.03392711636348277,"score_gpt":0.25721937008986123,"score_spread":0.22329225372637845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005563324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391353,0.00042704475,0.00000768596,0.00040034956,0.00015217547,0.0024124759,0.000032803935,0.000117994736,0.002535914],"genre_scores_gemma":[0.99774426,0.0002490385,0.0003737967,0.00033298868,0.00007630569,0.00074436824,0.00006480345,0.00006061542,0.00035381562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997838,0.0001607001,0.00036875287,0.0006266507,0.00042673503,0.0005791548],"domain_scores_gemma":[0.9987417,0.00007394505,0.0001368463,0.0005237615,0.00012975662,0.00039398175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003440318,0.0003926701,0.00069815305,0.00023775882,0.00007616378,0.00007622111,0.00013035162,0.0001496957,0.000014217413],"category_scores_gemma":[0.0001278935,0.00034224812,0.0001201278,0.00057586184,0.000095384254,0.00020606138,0.00016548028,0.00021528447,0.00004911803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015842768,0.0012770299,0.85411876,0.00035168513,0.00090820086,0.000012466836,0.002952506,0.00003030027,0.11305744,0.0001718256,0.0013053215,0.025656022],"study_design_scores_gemma":[0.0066579827,0.0018401537,0.53741586,0.0015409051,0.0004967352,3.2533856e-7,0.0028139416,0.00014568819,0.4476466,0.0001161297,0.00058292964,0.0007427291],"about_ca_topic_score_codex":0.0002859161,"about_ca_topic_score_gemma":0.000046028494,"teacher_disagreement_score":0.33458915,"about_ca_system_score_codex":0.0002961851,"about_ca_system_score_gemma":0.00009242355,"threshold_uncertainty_score":0.99990296},"labels":[],"label_agreement":null},{"id":"W2005624604","doi":"10.1210/me.2004-0196","title":"The HeLa Cell Glucagon-Like Peptide-2 Receptor Is Coupled to Regulation of Apoptosis and ERK1/2 Activation through Divergent Signaling Pathways","year":2004,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Biology; Signal transduction; HeLa; Pertussis toxin; Cell biology; Heterotrimeric G protein; MAPK/ERK pathway; Adenylyl cyclase; Molecular biology; Receptor; G protein; Cell; Biochemistry","score_opus":0.014310798376675714,"score_gpt":0.2366955590748491,"score_spread":0.2223847606981734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005624604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883474,0.00034521817,0.0061127897,0.0029777598,0.00014749776,0.0006806952,0.000003345313,0.0000387484,0.0008592323],"genre_scores_gemma":[0.9947312,0.00025177037,0.0035208198,0.00091512204,0.000024744351,0.00007523316,0.000039145973,0.000019777248,0.00042219204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896705,0.000031516807,0.0002322548,0.0002787245,0.00019518193,0.00029524966],"domain_scores_gemma":[0.9994322,0.000036085003,0.00010296308,0.00028722535,0.00008280358,0.000058689086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055618046,0.0001519933,0.00021756733,0.00007493242,0.000108965934,0.000013599711,0.00007466171,0.000049933406,0.000045170353],"category_scores_gemma":[0.000027337172,0.00011894268,0.00007474513,0.00015385721,0.000060882063,0.00005116851,0.00010558174,0.000069303,0.000028022012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013670817,0.0001695504,0.00040065355,0.000056771187,0.00021817013,0.0000063159546,0.00074062747,0.0002998514,0.9882946,0.0053040744,0.00047631667,0.0038963777],"study_design_scores_gemma":[0.0017824221,0.000577007,0.0014266338,0.00005078855,0.00016521242,0.0000019879687,0.00026116727,0.00003661563,0.9851981,0.0010653026,0.00932599,0.00010881679],"about_ca_topic_score_codex":0.00010205141,"about_ca_topic_score_gemma":0.00000255721,"teacher_disagreement_score":0.008849674,"about_ca_system_score_codex":0.00009818514,"about_ca_system_score_gemma":0.000027250238,"threshold_uncertainty_score":0.48503417},"labels":[],"label_agreement":null},{"id":"W2005759075","doi":"10.1586/17512433.2013.842465","title":"Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus","year":2013,"lang":"en","type":"review","venue":"Expert Review of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Glycemic; Lixisenatide; Postprandial; Internal medicine; Hypoglycemia; Type 2 Diabetes Mellitus; Endocrinology; Basal (medicine); Diabetes mellitus; Insulin; Type 2 diabetes; Basal insulin","score_opus":0.0986510902370301,"score_gpt":0.47317738335092646,"score_spread":0.37452629311389635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005759075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023215107,0.9879786,0.000010186202,0.0011360969,0.0012346396,0.009298154,0.000014300032,0.0000129128575,0.00008296092],"genre_scores_gemma":[0.00006686674,0.9941226,0.0007127488,0.002243041,0.00041833648,0.0021850842,0.000110389374,0.0000410522,0.00009984893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965608,0.0005168599,0.0021009112,0.00039854922,0.00015348132,0.0002693593],"domain_scores_gemma":[0.9936833,0.0047021494,0.0010311648,0.0003097601,0.00017638842,0.00009727235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087076216,0.00039173377,0.004409742,0.00012713937,0.000024756,0.0000050648505,0.00017729065,0.00021759588,0.000181503],"category_scores_gemma":[0.0002567016,0.00020704596,0.0008215146,0.00019929095,0.00022178132,0.000041458272,0.000034443674,0.00017367784,0.000007828717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026984172,0.0017274629,0.000027735723,0.021558717,0.0017597211,0.0000024062574,0.000030446765,2.3826408e-7,0.0000031506609,0.000025336687,0.0050350265,0.9695599],"study_design_scores_gemma":[0.010491853,0.005437421,0.000028734223,0.015383128,0.0026775445,5.2307047e-7,0.000003933287,0.00017101904,0.000020412463,0.000017259883,0.96562445,0.00014369145],"about_ca_topic_score_codex":0.00000946644,"about_ca_topic_score_gemma":6.102166e-7,"teacher_disagreement_score":0.9694162,"about_ca_system_score_codex":0.000080728714,"about_ca_system_score_gemma":0.00016792066,"threshold_uncertainty_score":0.8443089},"labels":[],"label_agreement":null},{"id":"W2005841347","doi":"10.1203/01.pdr.0000098500.94041.9b","title":"The Effect of Massive Small Bowel Resection and Oral Epidermal Growth Factor Therapy on SGLT-1 Distribution in Rabbit Distal Remnant","year":2003,"lang":"en","type":"article","venue":"Pediatric Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Epidermal growth factor; Western blot; Brush border; Internal medicine; Endocrinology; Small intestine; Biology; Messenger RNA; Medicine; Receptor; Biochemistry","score_opus":0.036268279179978685,"score_gpt":0.33157304059295883,"score_spread":0.2953047614129801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005841347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567145,0.0011111688,0.000020915455,0.0006003075,0.00008924139,0.0011763894,0.000014343445,0.000012978552,0.0013031872],"genre_scores_gemma":[0.9952166,0.0037921073,0.000012151291,0.000007033916,0.000095641626,0.00011802081,0.000042079617,0.00001342419,0.0007029319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784845,0.00067427167,0.00022811006,0.0002693302,0.0005307792,0.00044903046],"domain_scores_gemma":[0.9983826,0.001121946,0.0000579859,0.0002267935,0.00010924612,0.00010137319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019191372,0.00013295359,0.00022285955,0.00021609922,0.00016043526,0.000038180402,0.00007777641,0.00006816484,0.000021686996],"category_scores_gemma":[0.0011415199,0.0000757205,0.00006529041,0.0005366504,0.000107371605,0.00005460241,0.000046083936,0.0003146734,0.000010531543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028662225,0.0003058846,0.9677631,0.00024600307,0.00008058284,0.00006720158,0.00013066459,0.0000025733966,0.00045905696,0.0018052736,0.0019551704,0.024318267],"study_design_scores_gemma":[0.0066272477,0.0073879547,0.96376586,0.00003953283,0.000054338372,0.0000028812688,0.000079426514,0.000101742306,0.018849473,0.00033354168,0.0026283509,0.00012966411],"about_ca_topic_score_codex":0.0001686272,"about_ca_topic_score_gemma":0.000039062124,"teacher_disagreement_score":0.024188602,"about_ca_system_score_codex":0.00017234971,"about_ca_system_score_gemma":0.00005090109,"threshold_uncertainty_score":0.30877924},"labels":[],"label_agreement":null},{"id":"W2006464798","doi":"10.1186/1472-6823-8-17","title":"Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system","year":2008,"lang":"en","type":"article","venue":"BMC Endocrine Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Ministère de l'Énergie et des Ressources Naturelles","keywords":"Medicine; Internal medicine; Comorbidity; Diabetes mellitus; Odds ratio; Angiotensin-converting enzyme; Confounding; Blood pressure; ACE inhibitor; Confidence interval; Body mass index; Endocrinology","score_opus":0.016459017113029523,"score_gpt":0.21799877515224353,"score_spread":0.201539758039214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006464798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667186,0.0006709629,0.0000067969168,0.0011287517,0.00013635584,0.000678912,0.000044936416,0.000055877525,0.0006055703],"genre_scores_gemma":[0.99873555,0.00045287516,0.0001742488,0.00024538493,0.000045444558,0.000039512503,0.00021913002,0.000010770072,0.00007708524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987927,0.00007641356,0.0004448031,0.00015935767,0.00026295357,0.0002637671],"domain_scores_gemma":[0.99905735,0.00034628902,0.0002641797,0.00022752151,0.00006444556,0.0000402371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023649773,0.00015277267,0.00030221653,0.00009432658,0.000072558694,0.0000146732045,0.00006219503,0.000039876115,0.0000043086366],"category_scores_gemma":[0.00028236766,0.00011088657,0.000081839054,0.0001809341,0.000046538684,0.00022587345,0.000047724167,0.000091197,0.00000692877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012049504,0.00009523003,0.99082583,0.00006811909,0.0001451303,0.0000015445003,0.0011110982,0.000024911666,0.00023407697,0.000026756677,0.002668038,0.0046787877],"study_design_scores_gemma":[0.0075362134,0.00017296456,0.98149407,0.00017077602,0.00008098971,2.6599324e-7,0.0008147073,0.002915152,0.002863095,0.000018166731,0.0038122113,0.00012141513],"about_ca_topic_score_codex":0.0006052892,"about_ca_topic_score_gemma":0.000236244,"teacher_disagreement_score":0.009331769,"about_ca_system_score_codex":0.00012681153,"about_ca_system_score_gemma":0.000028128012,"threshold_uncertainty_score":0.4521823},"labels":[],"label_agreement":null},{"id":"W2006544732","doi":"10.1586/17446651.2015.972370","title":"The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health","year":2014,"lang":"en","type":"article","venue":"Expert Review of Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Incretin; Medicine; Glycemic; Type 2 diabetes; Saxagliptin; Diabetes mellitus; Glucagon-like peptide-1; Bone mineral; Internal medicine; Sitagliptin; Cognition; Bioinformatics; Endocrinology; Osteoporosis","score_opus":0.008362640545998152,"score_gpt":0.28416641536956166,"score_spread":0.2758037748235635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006544732","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09839241,0.8957932,0.00013433443,0.0029502967,0.000432394,0.0014073926,0.000001847933,0.000024200623,0.00086393446],"genre_scores_gemma":[0.5019121,0.49321952,0.0001494977,0.00430678,0.00008299212,0.00019525652,0.000013570751,0.000015428164,0.00010480522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848443,0.000330265,0.00040204087,0.00025435508,0.0002443331,0.00028454888],"domain_scores_gemma":[0.99874616,0.00042328052,0.00022134035,0.00046214787,0.00008555873,0.00006153618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004240631,0.00020823613,0.0013377863,0.00008688981,0.000075166616,0.0000034839438,0.00007105709,0.00003383701,0.0000102331005],"category_scores_gemma":[0.00033294017,0.00011743722,0.0003422268,0.00010102584,0.00019367876,0.000029562148,0.000063963715,0.0001155071,0.000009380219],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032035046,0.00027235795,0.0021425015,0.0051872297,0.004940567,0.000008472341,0.00030684329,6.9761946e-8,0.0005133317,0.009366523,0.002334939,0.9746068],"study_design_scores_gemma":[0.009655461,0.0026516363,0.22878282,0.007509669,0.003070762,0.000020621837,0.00017661133,0.0000032204762,0.0036184755,0.00028680588,0.7439797,0.000244204],"about_ca_topic_score_codex":0.00007901711,"about_ca_topic_score_gemma":0.0000016575204,"teacher_disagreement_score":0.9743626,"about_ca_system_score_codex":0.000013747302,"about_ca_system_score_gemma":0.000022654589,"threshold_uncertainty_score":0.4788951},"labels":[],"label_agreement":null},{"id":"W2006984980","doi":"10.2337/diacare.24.5.964","title":"Glucagon-Like Peptide-1 (7-37) Augments Insulin Release in Elderly Patients With Diabetes","year":2001,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Diabetes mellitus; Insulin; Internal medicine; Glucagon-like peptide-1; Endocrinology; Glucagon; Type 2 diabetes","score_opus":0.006780083040042886,"score_gpt":0.207075407157952,"score_spread":0.20029532411790912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006984980","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664961,0.0023007605,4.3974475e-7,0.021286279,0.0007261611,0.003037925,0.00041221402,0.00026579812,0.0054743006],"genre_scores_gemma":[0.44898045,0.00036842408,0.00056490535,0.4849795,0.002526284,0.0019030044,0.0466645,0.0007788223,0.013234124],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949094,0.0001269863,0.00073813496,0.0013276497,0.0011831697,0.0017146806],"domain_scores_gemma":[0.99757516,0.00013640102,0.000369322,0.0012758428,0.00036427958,0.0002789794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010204456,0.00116178,0.0015146774,0.0007032958,0.00011339071,0.00013335698,0.0004334253,0.00083240337,0.00028882804],"category_scores_gemma":[0.000060313676,0.0009647423,0.0003531908,0.00071006885,0.00015367098,0.00025811806,0.00021967487,0.0014876853,0.0007383699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005581934,0.00035139004,0.62806493,0.0012150337,0.0005857661,0.00031063452,0.00018060622,0.000003806156,0.0000024397377,6.787343e-7,0.35032263,0.018906286],"study_design_scores_gemma":[0.009644018,0.0026062606,0.23496576,0.0027282233,0.0014212213,2.238708e-7,0.00018186054,0.000016454202,0.00014917065,0.00002463831,0.74707055,0.001191642],"about_ca_topic_score_codex":0.000029367158,"about_ca_topic_score_gemma":0.00003653272,"teacher_disagreement_score":0.51751566,"about_ca_system_score_codex":0.0007499575,"about_ca_system_score_gemma":0.00014428596,"threshold_uncertainty_score":0.99928033},"labels":[],"label_agreement":null},{"id":"W2007374852","doi":"10.1016/s2213-8587(15)00044-3","title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","year":2015,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Women's College Hospital; University of Toronto; University Health Network","funders":"Women's College Research Institute; Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Type 2 diabetes; Internal medicine; Heart failure; Diabetes mellitus; Relative risk; Meta-analysis; Randomized controlled trial; Clinical endpoint; Cochrane Library; Endocrinology; Confidence interval","score_opus":0.1464167848642998,"score_gpt":0.3674972547904398,"score_spread":0.22108046992614003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007374852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057530545,0.9302715,0.0000032223666,0.000059665428,0.00013577701,0.011435123,0.00035181807,0.00005595564,0.0001563784],"genre_scores_gemma":[0.009515215,0.9833732,0.00024345051,0.00011705014,0.00009366067,0.0055065565,0.00052189815,0.00009632706,0.000532623],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9943879,0.0014752263,0.0017471783,0.00071805186,0.0004765513,0.0011950457],"domain_scores_gemma":[0.9905394,0.0064194477,0.0013597632,0.0013269545,0.00024447887,0.000109981054],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0043739546,0.00085930695,0.033797625,0.0007505936,0.00007299516,0.000057776142,0.0003675785,0.00018565018,0.00013389072],"category_scores_gemma":[0.0016584292,0.00032689373,0.00492751,0.00073540583,0.0002230392,0.00009556963,0.00021484627,0.0002618509,0.0000046313867],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009982369,0.00024809426,0.008296592,0.0040454553,0.87407625,0.000010500112,0.000102629994,0.000031585267,1.6619428e-7,0.000034141052,0.00013108771,0.10304112],"study_design_scores_gemma":[0.09880085,0.0012226704,0.00055168197,0.00027452112,0.8024713,2.633163e-7,0.00007134441,0.000018395249,0.000004544254,0.000028017472,0.09622752,0.00032890151],"about_ca_topic_score_codex":0.00002455365,"about_ca_topic_score_gemma":0.00007104918,"teacher_disagreement_score":0.10271222,"about_ca_system_score_codex":0.00013245325,"about_ca_system_score_gemma":0.00020730283,"threshold_uncertainty_score":0.9999183},"labels":[],"label_agreement":null},{"id":"W2007703492","doi":"10.1111/j.1532-5415.2012.04055.x","title":"Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care","year":2012,"lang":"en","type":"article","venue":"Journal of the American Geriatrics Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Novo Nordisk","keywords":"Medicine; Hypoglycemia; Glycemic; Insulin; Diabetes mellitus; Polypharmacy; Intensive care medicine; Population; Life expectancy; Internal medicine; Endocrinology; Environmental health","score_opus":0.011110747386148739,"score_gpt":0.25450033791170135,"score_spread":0.24338959052555262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007703492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651927,0.0026750641,0.00016543547,0.0001729664,0.00013506979,0.00025819935,0.000018472409,0.0000036480237,0.000051889103],"genre_scores_gemma":[0.98552126,0.0028831966,0.011253057,0.00013814411,0.00015309943,0.0000046217665,0.0000014107557,0.0000114631775,0.000033765857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992326,0.000037177262,0.00030530224,0.00006619612,0.00017779742,0.00018096578],"domain_scores_gemma":[0.9987493,0.0001484758,0.00075868913,0.00013865298,0.00013404991,0.00007081896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002597304,0.00009671378,0.0003413266,0.000050733284,0.000035730354,0.000018265488,0.00008398297,0.000029439796,0.000001582549],"category_scores_gemma":[0.000099775476,0.000060226437,0.0002932735,0.00027356908,0.000105959254,0.00019544213,0.000044266682,0.00014476568,1.7129418e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007850313,0.0003318043,0.9420306,0.00028992206,0.0005403007,0.0000014572502,0.00994901,0.00005365859,0.00036716004,0.00009682314,0.0035857402,0.041968487],"study_design_scores_gemma":[0.0064419233,0.0024816787,0.92919695,0.00015053255,0.001345926,0.000011376341,0.054185003,0.00009232787,0.00030585146,0.00021960596,0.0054128338,0.0001559867],"about_ca_topic_score_codex":0.00013539138,"about_ca_topic_score_gemma":0.00000886201,"teacher_disagreement_score":0.044235993,"about_ca_system_score_codex":0.000103815204,"about_ca_system_score_gemma":0.000076911136,"threshold_uncertainty_score":0.24559627},"labels":[],"label_agreement":null},{"id":"W2008167661","doi":"10.1007/s00125-007-0873-z","title":"Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy","year":2007,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Human physiology; Medicine; Diabetes mellitus; Type 2 diabetes; Type 2 Diabetes Mellitus; Intensive care medicine; Algorithm; Internal medicine; Endocrinology; Computer science","score_opus":0.023642553790167692,"score_gpt":0.28204548835497445,"score_spread":0.2584029345648068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008167661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778932,0.019277109,0.0002520839,0.00019697931,0.00015936827,0.0013769988,0.000009349718,0.000016598113,0.0008183329],"genre_scores_gemma":[0.98775387,0.004420921,0.0074432977,0.00015991891,0.000021423408,0.00007444534,0.000030969557,0.000011219908,0.00008392644],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991668,0.0000178438,0.0003021707,0.00015921146,0.00012836826,0.00022564126],"domain_scores_gemma":[0.9992785,0.00030751282,0.0001183839,0.00019018252,0.00007450317,0.00003092963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045913018,0.00011622437,0.00029890504,0.000114261056,0.000018581139,0.0000028733295,0.00005855437,0.000054311666,0.00001269364],"category_scores_gemma":[0.000018798679,0.00007625509,0.00005113384,0.0002027509,0.000108901026,0.000018161265,0.000034172877,0.000043712236,0.0000011129063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014963576,0.00034542344,0.045799688,0.00021211554,0.0005248623,0.000008415333,0.00014642018,0.000003268636,0.00054156646,0.0018716805,0.00018727739,0.9502096],"study_design_scores_gemma":[0.0060792477,0.0015073405,0.9538024,0.00022958484,0.00042828824,6.7063e-7,0.0009373207,0.0010742069,0.032440122,0.0006729998,0.0026785934,0.00014922731],"about_ca_topic_score_codex":0.000007963855,"about_ca_topic_score_gemma":0.0000032035841,"teacher_disagreement_score":0.9500604,"about_ca_system_score_codex":0.000033693934,"about_ca_system_score_gemma":0.000011216172,"threshold_uncertainty_score":0.31095922},"labels":[],"label_agreement":null},{"id":"W2008427683","doi":"10.1016/j.pharmthera.2012.05.009","title":"Targeting the glucagon receptor family for diabetes and obesity therapy","year":2012,"lang":"en","type":"review","venue":"Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Endocrinology; Internal medicine; Glucagon; Receptor; Glucagon receptor; Insulin; Glucagon-like peptide-1; Diabetes mellitus; Medicine; Gastric inhibitory polypeptide; Type 2 diabetes","score_opus":0.11326458060631459,"score_gpt":0.3808651345988934,"score_spread":0.26760055399257876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008427683","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015254891,0.99177086,0.000020565269,0.0007686768,0.0013567733,0.004242774,0.00004151032,0.00009394947,0.00017940589],"genre_scores_gemma":[0.00012009576,0.9874002,0.0003202835,0.008806542,0.0010796784,0.0011567462,0.00023749213,0.00010369788,0.0007752605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981792,0.00023387844,0.00041138433,0.0003855142,0.0001424155,0.00064763613],"domain_scores_gemma":[0.99868375,0.00058587966,0.00028499248,0.00025636406,0.00007066899,0.00011831524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005830089,0.00052603695,0.0012836964,0.00010453741,0.00023435343,0.000032066986,0.00022478313,0.00026300034,0.000112922724],"category_scores_gemma":[0.0000029162343,0.00030431073,0.0003780837,0.00014796811,0.0001852626,0.000058102694,0.00010299642,0.00036535732,0.00005145373],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004209888,0.00039084605,0.0001884126,0.0035374332,0.0056397542,9.899213e-7,0.00014301148,6.066187e-8,0.00042997373,0.000045398156,0.0049339645,0.98464805],"study_design_scores_gemma":[0.0013032163,0.0003266426,0.00002401318,0.0003452282,0.017532194,0.0000011814925,0.000025935673,0.000016799022,0.00017445318,0.000028191904,0.97995496,0.00026716554],"about_ca_topic_score_codex":8.9435974e-7,"about_ca_topic_score_gemma":1.17505365e-7,"teacher_disagreement_score":0.9843809,"about_ca_system_score_codex":0.00010898061,"about_ca_system_score_gemma":0.00008495054,"threshold_uncertainty_score":0.9999409},"labels":[],"label_agreement":null},{"id":"W2008473687","doi":"10.1007/s00125-010-1986-3","title":"New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser","year":2010,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Metformin; Incretin; Internal medicine; Glucagon-like peptide-1; Endocrinology; Medicine; Receptor; Type 2 diabetes; Insulin; Diabetes mellitus; Pharmacology","score_opus":0.008963569399374352,"score_gpt":0.24816750242540114,"score_spread":0.2392039330260268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008473687","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86576223,0.0015606787,0.000013180032,0.08034629,0.0015606037,0.0018283097,0.00005886599,0.0002668491,0.048603006],"genre_scores_gemma":[0.08117361,0.0008034168,0.015788423,0.6621516,0.0052487403,0.00026909795,0.0037433929,0.00039872015,0.23042303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750024,0.000065096516,0.00046010013,0.00079458335,0.00047414977,0.0007058445],"domain_scores_gemma":[0.9982324,0.00014575994,0.00031874274,0.0009369808,0.00011424864,0.0002518262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020493708,0.00059992145,0.0012920711,0.00027475093,0.00005443238,0.00005072948,0.00021474723,0.0011001464,0.0007972196],"category_scores_gemma":[0.00007130073,0.0004911376,0.00021829421,0.0001949202,0.0001828768,0.00016521776,0.00018366831,0.0015653716,0.00018632514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005611562,0.00015143947,0.0014169895,0.00052956655,0.0009290306,0.0018728223,0.00023825982,1.4203897e-7,0.0017888242,0.00041209502,0.9518339,0.040770795],"study_design_scores_gemma":[0.0024703105,0.0009127543,0.004423758,0.0003922441,0.0019873567,0.000059641687,0.000058680922,0.000014777222,0.028450122,0.0013698785,0.9591865,0.00067400414],"about_ca_topic_score_codex":0.0004358075,"about_ca_topic_score_gemma":0.00012718789,"teacher_disagreement_score":0.7845886,"about_ca_system_score_codex":0.00007525378,"about_ca_system_score_gemma":0.00018794682,"threshold_uncertainty_score":0.999754},"labels":[],"label_agreement":null},{"id":"W2008486201","doi":"10.1152/ajpendo.90440.2008","title":"Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells","year":2008,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"PDX1; PAX6; Proglucagon; Incretin; Glucose homeostasis; Biology; Enteroendocrine cell; Internal medicine; Endocrinology; Cell biology; Glucagon-like peptide-1; Transcription factor; Islet; Insulin; Hormone; Biochemistry; Gene; Type 2 diabetes; Medicine; Insulin resistance; Endocrine system; Diabetes mellitus","score_opus":0.015674880198213288,"score_gpt":0.25464574363559994,"score_spread":0.23897086343738666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008486201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932904,0.005233141,0.000027429005,0.0006918652,0.00035965495,0.00035592625,0.000003432679,0.000010868071,0.000027250624],"genre_scores_gemma":[0.98994464,0.005850839,0.0036622523,0.00017687818,0.00021110488,0.000022497105,0.0000026792165,0.000014569092,0.00011456545],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987813,0.000102676066,0.00045722237,0.00024922888,0.000097275086,0.00031224766],"domain_scores_gemma":[0.99896115,0.00006325304,0.0006111354,0.00015519245,0.00012566286,0.00008361744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010851972,0.00016835413,0.0008462504,0.0002769164,0.00006837111,0.0000027963877,0.00006896088,0.00004148501,0.0000034711902],"category_scores_gemma":[0.00007453539,0.00012950804,0.00009036931,0.00012532853,0.00079652434,0.00012782168,0.000051971085,0.00018846721,6.1399896e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013199054,0.0005530725,0.023916591,0.00013547893,0.0004525624,0.000055207365,0.0008708404,0.000012915715,0.90501636,0.0002648277,0.00015769077,0.06724456],"study_design_scores_gemma":[0.004768914,0.0017089337,0.7675324,0.00013068253,0.000445039,0.00032940687,0.0014264293,0.000008156974,0.21987511,0.00049633445,0.0031263696,0.00015223303],"about_ca_topic_score_codex":0.000029040733,"about_ca_topic_score_gemma":0.0000030626613,"teacher_disagreement_score":0.7436158,"about_ca_system_score_codex":0.000020091875,"about_ca_system_score_gemma":0.000055368066,"threshold_uncertainty_score":0.5281185},"labels":[],"label_agreement":null},{"id":"W2008577165","doi":"10.2337/dc14-0666","title":"Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial","year":2015,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Dapagliflozin; Metformin; Sulfonylurea; Medicine; Placebo; Glycemic; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Insulin; Urology; Gastroenterology","score_opus":0.05880475676178025,"score_gpt":0.34162137410146826,"score_spread":0.282816617339688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008577165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776095,0.0060161203,0.0000041610397,0.0013054935,0.0015318817,0.007929941,0.000040656425,0.00014804918,0.0054141805],"genre_scores_gemma":[0.99227035,0.00045025756,0.00031227598,0.0025732087,0.0012010792,0.0015044933,0.00026108723,0.00007078256,0.0013564761],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969521,0.00023483564,0.0008292898,0.0007709719,0.00056124903,0.00065156305],"domain_scores_gemma":[0.9975536,0.0006693621,0.00023313877,0.0005773432,0.00025734957,0.00070924347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010015563,0.0005091488,0.0017920331,0.0002975925,0.000089668065,0.00012970676,0.00021576938,0.00024367997,0.000046316967],"category_scores_gemma":[0.0004759041,0.0003491733,0.00046446145,0.00024063267,0.00021074394,0.00017395789,0.00009980167,0.0002834792,0.00024229978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.946609,0.00056358735,0.0011951138,0.000050903658,0.0016551468,0.00003061059,0.001013091,0.0000015399091,0.0005232595,0.00028722262,0.008261109,0.039809372],"study_design_scores_gemma":[0.9454653,0.012917697,0.000113423215,0.00013729681,0.001255432,0.0000011504544,0.00085935945,0.00010277634,0.003965741,0.00017729808,0.03462421,0.0003802656],"about_ca_topic_score_codex":0.00003408706,"about_ca_topic_score_gemma":0.00000719541,"teacher_disagreement_score":0.039429106,"about_ca_system_score_codex":0.00016078024,"about_ca_system_score_gemma":0.00020763659,"threshold_uncertainty_score":0.99989605},"labels":[],"label_agreement":null},{"id":"W2008608749","doi":"10.1038/nrendo.2009.49","title":"Is it possible to reduce cardiovascular risk with glucose-lowering approaches?","year":2009,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Hamilton Health Sciences","funders":"","keywords":"Medicine; Diabetes mellitus; Myocardial infarction; Disease; Internal medicine; Kidney disease; Risk factor; Type 2 Diabetes Mellitus; Intensive care medicine; Cardiology; Endocrinology","score_opus":0.08256633341055405,"score_gpt":0.34781539953774077,"score_spread":0.2652490661271867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008608749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007863087,0.9695726,0.00006007611,0.0005291067,0.00034271728,0.0069405674,0.000024973831,0.00013382049,0.022388296],"genre_scores_gemma":[0.000008277507,0.9880382,0.004177801,0.0014436239,0.0005583367,0.001146152,0.0002148377,0.00013182226,0.0042809793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954163,0.0003531239,0.0010147644,0.0015712209,0.0005059625,0.0011386673],"domain_scores_gemma":[0.9965696,0.00007199996,0.0005178684,0.0024052118,0.00008336731,0.0003520004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048858154,0.0011950827,0.006851427,0.0006403474,0.00011409269,0.000047710437,0.00054797524,0.00078455394,0.000108715896],"category_scores_gemma":[0.00016823885,0.00075345114,0.0026391267,0.0010475034,0.000068943256,0.000074378324,0.00023254359,0.0022255587,0.000966231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021530168,0.00015141339,0.0000100563575,0.016224682,0.004182765,0.00030860963,0.000031942225,7.196016e-7,7.266076e-8,0.00013447613,0.017433066,0.96150064],"study_design_scores_gemma":[0.0008304574,0.0006134537,0.00001840811,0.018345317,0.020998472,0.0004211511,0.000008636853,2.5443043e-7,0.000020701254,0.00000817017,0.9581141,0.0006209005],"about_ca_topic_score_codex":0.00001399936,"about_ca_topic_score_gemma":0.0000054087664,"teacher_disagreement_score":0.96087974,"about_ca_system_score_codex":0.00042215805,"about_ca_system_score_gemma":0.00019294245,"threshold_uncertainty_score":0.99981165},"labels":[],"label_agreement":null},{"id":"W2009488954","doi":"10.1186/1472-6963-13-442","title":"Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines","year":2013,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Guideline; Medical prescription; Cohort study; Cohort; Internal medicine; Health administration; Logistic regression; Family medicine; Public health; Nursing; Endocrinology","score_opus":0.10499330300196573,"score_gpt":0.3758134518577589,"score_spread":0.27082014885579314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009488954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201375,0.0018649438,3.2680882e-7,0.0025847803,0.000036375906,0.0034489809,0.000014068739,0.000006737123,0.000030036434],"genre_scores_gemma":[0.99600226,0.0009518395,0.0008915062,0.00090626016,0.00003501535,0.0005397555,0.00013333124,0.000016327014,0.00052369776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741673,0.00036421258,0.00068784313,0.00025216356,0.0007053499,0.00057368417],"domain_scores_gemma":[0.997097,0.00090231304,0.00021654903,0.0003727562,0.0012468583,0.00016453181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012002124,0.00015774749,0.0004899377,0.0003612354,0.00008802753,0.000050713395,0.00018641051,0.00006619847,0.000015231166],"category_scores_gemma":[0.00025020872,0.00008286092,0.000035629193,0.00072583783,0.00004472514,0.00017996057,0.00004417183,0.00012026761,0.0000035717258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058930134,0.00043789478,0.977595,0.00047585525,0.000066480636,8.227661e-7,0.0024757856,0.00004000981,0.0000050161866,0.000008389028,0.0005391615,0.018296685],"study_design_scores_gemma":[0.0018208931,0.0018692954,0.9864308,0.00044569574,0.00003679271,2.519327e-8,0.0009217958,0.0031516072,0.000011520376,0.000008131211,0.005239201,0.00006418913],"about_ca_topic_score_codex":0.74800247,"about_ca_topic_score_gemma":0.80042624,"teacher_disagreement_score":0.052423794,"about_ca_system_score_codex":0.0014972799,"about_ca_system_score_gemma":0.00050234626,"threshold_uncertainty_score":0.39153346},"labels":[],"label_agreement":null},{"id":"W2009876577","doi":"10.1016/s0003-4266(04)95625-9","title":"Gastro-intestinal hormones GIP and GLP-1","year":2004,"lang":"fr","type":"review","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Glucose homeostasis; Hormone; Peptidomimetic; Gastrointestinal tract; Diabetes mellitus; Secretion; Endocrinology; Food intake; Internal medicine; Medicine; Biology; Biochemistry; Insulin resistance; Peptide","score_opus":0.0789815681016102,"score_gpt":0.33056924801677545,"score_spread":0.2515876799151653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009876577","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016020543,0.98319733,0.00006106131,0.0013764165,0.0011451298,0.0013875266,0.000050973267,0.00026888953,0.010910599],"genre_scores_gemma":[0.0037053237,0.9771765,0.0022272966,0.00024042673,0.00073299155,0.00026805938,0.00032153222,0.00008885039,0.015239027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605405,0.0001275976,0.0007769508,0.001002093,0.0003508244,0.0016884921],"domain_scores_gemma":[0.99811226,0.00031855417,0.00032364312,0.00072849204,0.00011505333,0.00040202303],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014217681,0.0010588128,0.002031864,0.0003493053,0.00022793277,0.00014852095,0.00038422595,0.00023370418,0.00046314936],"category_scores_gemma":[0.00025649078,0.0008480353,0.00054788654,0.00029393614,0.0008834337,0.00016155817,0.00058148464,0.0006522748,0.0028734333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033166736,0.00043542174,0.0038704248,0.020974943,0.0012560041,0.0025165225,0.00005391428,0.0000021742337,0.0000041416665,0.00623722,0.0036413649,0.9609747],"study_design_scores_gemma":[0.001492608,0.0018385561,0.0055321273,0.025055628,0.0046523474,0.00084732583,0.000132307,0.000005422021,0.00003393502,0.0005919659,0.95917493,0.0006428687],"about_ca_topic_score_codex":0.0001350228,"about_ca_topic_score_gemma":0.000016231485,"teacher_disagreement_score":0.96033186,"about_ca_system_score_codex":0.0004895159,"about_ca_system_score_gemma":0.0004226353,"threshold_uncertainty_score":0.99939704},"labels":[],"label_agreement":null},{"id":"W2009969219","doi":"10.1210/jc.2011-0599","title":"The Safety of Incretin-Based Therapies—Review of the Scientific Evidence","year":2011,"lang":"en","type":"review","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Medicine; Pancreatitis; Pancreatic cancer; Medullary thyroid cancer; Type 2 diabetes; Cancer; Diabetes mellitus; Internal medicine; Pharmacology; Bioinformatics; Endocrinology; Thyroid cancer","score_opus":0.16497970789209176,"score_gpt":0.43962965934369674,"score_spread":0.274649951451605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009969219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002345085,0.9911239,0.000011344774,0.0038232505,0.0026747736,0.0014564095,0.000010646646,0.00000766154,0.0006575009],"genre_scores_gemma":[0.00029436467,0.9971157,0.0001506074,0.0009951633,0.00041831486,0.000020220143,0.0000027967956,0.00003419028,0.000968681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98984015,0.003978379,0.0046527777,0.0002722359,0.0007906433,0.00046578704],"domain_scores_gemma":[0.9829732,0.007648082,0.006620851,0.0018593231,0.0007709435,0.00012757372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011507877,0.00042760515,0.0046518897,0.00016329078,0.0002154216,0.000013698217,0.0022278307,0.00018311801,0.00021125074],"category_scores_gemma":[0.005016733,0.00014626609,0.0031710016,0.00059684523,0.0027109042,0.00006515227,0.0003964617,0.0014560786,0.000025819503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030064184,0.0003003064,0.000105898325,0.012167989,0.0027023796,0.000009278556,0.000035758283,2.0511953e-7,0.000001344615,0.002605212,0.0035957831,0.9781752],"study_design_scores_gemma":[0.00094924757,0.00031107766,0.0012756513,0.061199293,0.018537551,0.00006677902,0.000014431271,5.1628854e-7,0.000016367514,0.00019901802,0.91733086,0.00009921459],"about_ca_topic_score_codex":0.00001074793,"about_ca_topic_score_gemma":0.0000033922313,"teacher_disagreement_score":0.978076,"about_ca_system_score_codex":0.000032109238,"about_ca_system_score_gemma":0.0012798976,"threshold_uncertainty_score":0.998844},"labels":[],"label_agreement":null},{"id":"W2010208232","doi":"10.1007/s00125-002-0828-3","title":"Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice","year":2002,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"Hospital for Sick Children; Simon Fraser University; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Insulin; Glucagon; Beta cell; Diabetes mellitus; Glucagon-like peptide-1; Pancreatic hormone; Medicine; C-peptide; Type 2 diabetes; Insulin resistance; Chemistry; Islet","score_opus":0.026788766921547743,"score_gpt":0.24237112756697718,"score_spread":0.21558236064542943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010208232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852138,0.0017821348,0.0000016814874,0.0017813423,0.0002648992,0.0009379376,0.000030819603,0.00008532504,0.009902031],"genre_scores_gemma":[0.9899831,0.00036712544,0.0002501015,0.00096723234,0.000050050865,0.00024979838,0.00007760251,0.0000313729,0.008023629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981278,0.00009871267,0.00046160968,0.0004182374,0.00025506166,0.00063857756],"domain_scores_gemma":[0.99872214,0.0003020811,0.00015174004,0.0006643974,0.000046703637,0.00011291959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002209767,0.00034405838,0.00068223034,0.00021651707,0.0000709622,0.000022622777,0.00023098262,0.00011458542,0.00036993698],"category_scores_gemma":[0.00007380096,0.00021583974,0.00021880666,0.0004209419,0.00019636039,0.000086457854,0.00009479969,0.00014821891,0.00027395348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043061387,0.0028353168,0.9393373,0.00012379525,0.0007195803,0.000085811604,0.00070959044,0.000022449092,0.0009157723,0.00048167014,0.018639471,0.036086187],"study_design_scores_gemma":[0.008942791,0.0050030267,0.9086742,0.0003841198,0.0015289641,0.000007367221,0.00078326603,0.0027157739,0.0251029,0.00044090708,0.045690127,0.0007266063],"about_ca_topic_score_codex":0.00013608846,"about_ca_topic_score_gemma":0.00011883393,"teacher_disagreement_score":0.03535958,"about_ca_system_score_codex":0.00020160835,"about_ca_system_score_gemma":0.000020224732,"threshold_uncertainty_score":0.8801689},"labels":[],"label_agreement":null},{"id":"W2010671489","doi":"10.1210/en.2008-0726","title":"Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell","year":2008,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Internal medicine; Endocrinology; Insulin resistance; Insulin; Protein kinase B; Glucagon-like peptide-1; Wortmannin; Biology; Insulin oscillation; Insulin receptor; Medicine; Signal transduction; Type 2 diabetes; Diabetes mellitus; Cell biology","score_opus":0.017100885472188763,"score_gpt":0.23329326511964954,"score_spread":0.21619237964746077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010671489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791349,0.0020698395,0.00005483702,0.0043388526,0.00055839913,0.00045744632,0.000011617176,0.00017323592,0.013200878],"genre_scores_gemma":[0.9794237,0.0018448869,0.0005390828,0.0019312934,0.0002968136,0.00007026213,0.0002738344,0.000026593827,0.015593545],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868923,0.00006441645,0.000246545,0.00035007048,0.00017099625,0.0004787575],"domain_scores_gemma":[0.9991604,0.00011229664,0.00007825528,0.00052511744,0.000041944535,0.00008198841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000027759384,0.00020742833,0.00029414464,0.00007729264,0.00014458991,0.000010013454,0.0001628592,0.000037894006,0.0006375375],"category_scores_gemma":[0.000024790876,0.00014164488,0.00012329458,0.000116202464,0.00017462451,0.00006298851,0.00015515006,0.00018030495,0.0006852266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012700363,0.002647055,0.5419256,0.00012339659,0.001874495,0.0053075734,0.0031600276,0.000036798465,0.025629189,0.003979809,0.37215784,0.0418882],"study_design_scores_gemma":[0.0059883757,0.0007809139,0.3341165,0.000038586146,0.00034401283,0.00023747655,0.00032016804,0.00009349943,0.029051755,0.00050688616,0.62828696,0.00023489432],"about_ca_topic_score_codex":0.00027902445,"about_ca_topic_score_gemma":0.000033244498,"teacher_disagreement_score":0.2561291,"about_ca_system_score_codex":0.000063554595,"about_ca_system_score_gemma":0.00002595208,"threshold_uncertainty_score":0.880743},"labels":[],"label_agreement":null},{"id":"W2011081855","doi":"10.1210/jc.2002-020002","title":"Elevated Glucagon-Like Peptide-1-(7–36)-Amide, but Not Glucose, Associated with Hyperinsulinemic Compensation for Fat Feeding","year":2002,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; Arcadia Fund","keywords":"Internal medicine; Endocrinology; Hyperinsulinemia; Incretin; Glucagon-like peptide-1; Insulin; Glucagon; Insulin resistance; Biology; Gastric inhibitory polypeptide; Chemistry; Diabetes mellitus; Type 2 diabetes; Medicine","score_opus":0.07391032992197769,"score_gpt":0.3306909497595229,"score_spread":0.2567806198375452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011081855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917174,0.0018453514,0.00032504112,0.0060713356,0.0011516698,0.0006978834,0.000010566554,0.00006339419,0.0006630428],"genre_scores_gemma":[0.98770916,0.0040067127,0.0015345092,0.0030728613,0.0010249582,0.000018957926,0.000020263511,0.000047326903,0.0025652538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967522,0.000324414,0.0015931999,0.00025621284,0.00046516227,0.00060878496],"domain_scores_gemma":[0.9957796,0.0017365498,0.0012981915,0.00036162595,0.00061404484,0.0002100348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012414509,0.0003105542,0.0013766219,0.00021194077,0.00016419702,0.000025361032,0.0003440771,0.00015620272,0.000115193325],"category_scores_gemma":[0.001559362,0.00018154526,0.0004381684,0.00026313422,0.0003085377,0.00017555534,0.00008017186,0.00071740407,0.000041984098],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05860477,0.020231234,0.10542527,0.00053506385,0.054898366,0.001975676,0.0030994127,0.0014862583,0.11049078,0.01657077,0.08905804,0.53762436],"study_design_scores_gemma":[0.077749476,0.008302697,0.66968346,0.0005750828,0.017241135,0.00076163275,0.0010559753,0.0045169126,0.027691226,0.0008833374,0.1906538,0.0008852983],"about_ca_topic_score_codex":0.000013465072,"about_ca_topic_score_gemma":0.000010935638,"teacher_disagreement_score":0.56425816,"about_ca_system_score_codex":0.000061349456,"about_ca_system_score_gemma":0.000052516425,"threshold_uncertainty_score":0.7403201},"labels":[],"label_agreement":null},{"id":"W2011543174","doi":"10.1371/journal.pone.0032675","title":"Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of British Columbia and Yukon; Heart and Stroke Foundation of Canada","keywords":"G protein-coupled receptor; Receptor; Gastric inhibitory polypeptide; Glucagon-like peptide 1 receptor; Biology; Cell biology; Glycosylation; N-linked glycosylation; 5-HT5A receptor; Protease-activated receptor 2; Glucagon receptor; Endoplasmic reticulum; Signal transduction; Endocrinology; Biochemistry; Insulin; Glucagon; Glycoprotein","score_opus":0.020448221491799198,"score_gpt":0.21021625703950308,"score_spread":0.18976803554770388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011543174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755013,0.0009367734,0.00016137301,0.00018623976,0.000033937748,0.00043205495,0.000009821172,0.000031840296,0.0006578469],"genre_scores_gemma":[0.99114335,0.00046283565,0.005958031,0.000025530719,0.000046958627,0.000010059857,0.00031118316,0.000014811946,0.0020272164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99939156,0.000028354247,0.00014689565,0.00012703429,0.00018761714,0.00011852011],"domain_scores_gemma":[0.99964225,0.000025946825,0.00009980847,0.00011349512,0.000038437207,0.000080045924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009717131,0.00008683733,0.00016926561,0.000041106876,0.000032148982,0.000008493005,0.000014267966,0.000052028703,0.00013055946],"category_scores_gemma":[0.000019578743,0.00007729825,0.000012921775,0.00006936413,0.00002449662,0.00021742951,0.00002590118,0.000030726747,0.000013292702],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006951196,0.0007619229,0.08690821,0.00024925562,0.00004579141,2.1619808e-8,0.00026794808,5.6222154e-7,0.90914494,0.000016964137,0.001265469,0.0012694331],"study_design_scores_gemma":[0.0011035695,0.00027546546,0.04638887,0.00023406679,0.00019528896,7.956655e-8,0.000029735249,0.00021113358,0.95047206,0.000009789502,0.0009973142,0.00008265446],"about_ca_topic_score_codex":0.0000048851766,"about_ca_topic_score_gemma":2.156469e-7,"teacher_disagreement_score":0.041327123,"about_ca_system_score_codex":0.000025179073,"about_ca_system_score_gemma":0.0000030634974,"threshold_uncertainty_score":0.31521314},"labels":[],"label_agreement":null},{"id":"W2011697063","doi":"10.2174/157016309789054951","title":"Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management","year":2009,"lang":"en","type":"review","venue":"Current Drug Discovery Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Neova Technologies Inc.","funders":"","keywords":"Glycemic; Medicine; Insulin; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Insulin glargine; Diabetes management; Insulin delivery; Insulin lispro; Type 1 diabetes; Internal medicine; Endocrinology","score_opus":0.02237956429797906,"score_gpt":0.31572750710166625,"score_spread":0.2933479428036872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011697063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008453947,0.99031544,0.00008309198,0.0012533737,0.00059299305,0.0066149007,0.00004343749,0.0006200563,0.00039215566],"genre_scores_gemma":[0.00017059076,0.992156,0.00046964636,0.000047983063,0.00018081552,0.0043517067,0.00034971652,0.000048864673,0.002224618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795294,0.000047713504,0.0004898102,0.0007360797,0.00020841419,0.0005650468],"domain_scores_gemma":[0.99886996,0.00024010283,0.00025538064,0.0005522015,0.000025738354,0.000056614273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022078323,0.00059818226,0.0014208045,0.003898127,0.00012414981,0.00010065168,0.00027224486,0.00017881281,0.0000031106592],"category_scores_gemma":[0.000036326604,0.0004474622,0.00037105984,0.0023148446,0.00012293553,0.00024074812,0.00028605352,0.00042893627,0.000008330023],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009878559,0.00031316208,0.000115777926,0.01048583,0.0007494045,0.000004852374,0.000053182455,2.231754e-7,6.4388296e-8,0.0062273755,0.0018288592,0.9802114],"study_design_scores_gemma":[0.0009708196,0.000110002744,0.00015995189,0.022206092,0.0036471433,0.0000011112592,0.0004968326,0.00000897741,0.0000065297877,0.0031045307,0.96889967,0.00038831428],"about_ca_topic_score_codex":0.0000018662813,"about_ca_topic_score_gemma":0.00002048398,"teacher_disagreement_score":0.97982305,"about_ca_system_score_codex":0.0003915507,"about_ca_system_score_gemma":0.00008263028,"threshold_uncertainty_score":0.9997977},"labels":[],"label_agreement":null},{"id":"W2011770848","doi":"10.1016/j.regpep.2013.12.006","title":"Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs","year":2013,"lang":"en","type":"article","venue":"Regulatory Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; University of Calgary; Institute of Infection and Immunity","funders":"Hospital Research Foundation; University of Calgary","keywords":"Weaning; Glucagon-like peptide-2; Medicine; Internal medicine; Glucagon; Glucagon-like peptide-1; Endocrinology; Animal science; Physiology; Biology; Peptide; Biochemistry; Hormone","score_opus":0.006473158658518769,"score_gpt":0.21707772666897393,"score_spread":0.21060456801045516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011770848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165684,0.0062311953,0.0000071269865,0.000073744915,0.00011528665,0.0010113674,5.6953184e-7,0.00008030075,0.0008235703],"genre_scores_gemma":[0.9955638,0.00032267554,0.0002655927,0.00007805385,0.00012673235,0.00013834902,0.000008606188,0.00003952171,0.0034566931],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987553,0.00003315276,0.00029132975,0.0002914728,0.0002597501,0.00036903273],"domain_scores_gemma":[0.9993535,0.0000656876,0.00010180521,0.0003384827,0.000039328555,0.000101178746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009696495,0.00021978524,0.00038345615,0.00022337948,0.0000439204,0.000018532637,0.000103354185,0.000069215675,0.00018352197],"category_scores_gemma":[0.00001546846,0.00018622767,0.0001353056,0.0001706559,0.00009216743,0.00022076578,0.00006889599,0.000104520506,0.00010905319],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020147413,0.00087787746,0.19479175,0.0029974855,0.0006657739,0.00018986367,0.0018724445,0.00012600931,0.6847088,0.0007488891,0.002215191,0.110604495],"study_design_scores_gemma":[0.004321044,0.00042471688,0.9153846,0.00090613746,0.00006016188,0.000005612624,0.00015422417,0.00014857818,0.077034146,0.000120297045,0.0012462483,0.00019423847],"about_ca_topic_score_codex":0.0000808552,"about_ca_topic_score_gemma":0.000014384583,"teacher_disagreement_score":0.72059286,"about_ca_system_score_codex":0.00022285766,"about_ca_system_score_gemma":0.000048994858,"threshold_uncertainty_score":0.7594144},"labels":[],"label_agreement":null},{"id":"W2012071311","doi":"10.1016/s0165-6147(03)00031-2","title":"GIP or not GIP? That is the question","year":2003,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Endocrinology; Internal medicine; Gastric inhibitory polypeptide; Hormone; Type 2 diabetes; Insulin; Receptor; Gastrointestinal hormone; Medicine; Diabetes mellitus; Obesity; Peptide hormone; Glucagon","score_opus":0.306496118130111,"score_gpt":0.5018778555600093,"score_spread":0.19538173742989828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012071311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013007894,0.95478797,0.0000013913639,0.0018824609,0.00063682854,0.00076300907,0.00001034606,0.00006950395,0.041718423],"genre_scores_gemma":[0.0005527933,0.97335446,0.00018540658,0.0027525125,0.000119672746,0.00030343173,0.000018405977,0.000009549447,0.02270378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772465,0.00030902718,0.00036761843,0.0005914455,0.00051941816,0.00048781253],"domain_scores_gemma":[0.9991832,0.00032631124,0.00018722902,0.00017259474,0.000013402433,0.000117300275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001127353,0.00035219113,0.0009349111,0.00029324574,0.00017349409,0.00007437294,0.0004684496,0.00015995157,0.0065706233],"category_scores_gemma":[0.00003789648,0.00013578993,0.00031025062,0.0014967031,0.0005071854,0.0000894391,0.00012636874,0.00033398895,0.00015039725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017462184,0.00024132316,0.000057742527,0.00033834213,0.000104710605,0.00007454402,0.000026470978,4.2842768e-7,4.3605252e-7,0.00040338375,0.016282449,0.9824527],"study_design_scores_gemma":[0.00044120074,0.0004653306,0.0002561029,0.0008997194,0.001740144,0.000012893796,0.000011853828,0.000016394042,0.000010893812,0.000054930704,0.99590605,0.00018446324],"about_ca_topic_score_codex":0.000015944848,"about_ca_topic_score_gemma":0.000009537935,"teacher_disagreement_score":0.9822683,"about_ca_system_score_codex":0.00017648768,"about_ca_system_score_gemma":0.00009183259,"threshold_uncertainty_score":0.9943375},"labels":[],"label_agreement":null},{"id":"W2012117258","doi":"10.2337/dc09-1727","title":"The Effect of Oral Antidiabetic Agents on A1C Levels","year":2010,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Women's College Hospital; University of Toronto; McMaster University","funders":"Heart and Stroke Foundation of Canada; AstraZeneca","keywords":"Medicine; Diabetes mellitus; Placebo; Randomized controlled trial; Meta-analysis; MEDLINE; Internal medicine; Clinical trial; Research design; Intensive care medicine; Alternative medicine; Endocrinology","score_opus":0.030229944431795483,"score_gpt":0.3273888520279542,"score_spread":0.2971589075961587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012117258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011436697,0.98012626,4.7895103e-8,0.000025252295,0.00087287585,0.0026751002,0.00015329027,0.00006646566,0.0046440284],"genre_scores_gemma":[0.00650893,0.99076855,0.000023271929,0.00006901769,0.00015385817,0.00045555894,0.0006680467,0.00012239003,0.0012303711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979051,0.00016103353,0.0004901492,0.00044381752,0.00044200453,0.0005579103],"domain_scores_gemma":[0.99801147,0.0004945936,0.00031671516,0.0009615114,0.0000753583,0.00014033815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002960906,0.00061366876,0.0021927461,0.00019394951,0.000118486576,0.000044107004,0.00035301482,0.00031908875,0.00006275477],"category_scores_gemma":[0.00013495414,0.0003214376,0.0009861644,0.00027328642,0.00014129742,0.000029844065,0.00014293513,0.00047955694,0.0005770731],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000059161894,0.000038675353,0.0065459954,0.02291206,0.00078446424,0.0000098444825,0.000023541992,6.262565e-8,0.0000015141219,0.000021394782,0.0018464803,0.96781003],"study_design_scores_gemma":[0.00083865266,0.0016438548,0.0012034184,0.011732286,0.005644259,3.1556732e-7,0.0000119462275,0.0000010843327,0.0004243786,0.0000035977735,0.9782412,0.0002550061],"about_ca_topic_score_codex":0.0000014824959,"about_ca_topic_score_gemma":0.0000017893877,"teacher_disagreement_score":0.9763947,"about_ca_system_score_codex":0.00011471,"about_ca_system_score_gemma":0.00006678795,"threshold_uncertainty_score":0.99992377},"labels":[],"label_agreement":null},{"id":"W2012275906","doi":"10.1016/j.jcjd.2012.07.360","title":"Liraglutide + Metformin Combination Therapy in Type 2 Diabetes: Clinical Benefits Associated with Early Use of Liraglutide and with Switching a Sulfonylurea for Liraglutide","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Liraglutide; Medicine; Sulfonylurea; Type 2 diabetes; Glycemic; Diabetes mellitus; Internal medicine; Endocrinology; Pharmacology","score_opus":0.047853093542986606,"score_gpt":0.26955755672212733,"score_spread":0.22170446317914072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012275906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949848,0.0035760442,0.000011901308,0.00036398717,0.00017884419,0.00076041365,0.000024555724,0.000011240639,0.000088187415],"genre_scores_gemma":[0.9977115,0.00014754996,0.001433663,0.00040262635,0.000096313015,0.000020300666,0.00003179604,0.000054639826,0.000101655336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978985,0.00010217166,0.00075270596,0.00020095948,0.00028000373,0.000765644],"domain_scores_gemma":[0.9972495,0.0006948369,0.0006158578,0.00021346127,0.00049352384,0.00073286326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012860837,0.0002869611,0.0008637859,0.00065535575,0.00008459438,0.000064040025,0.00012484145,0.00014234988,0.000010047344],"category_scores_gemma":[0.0007662104,0.00020624592,0.00013345425,0.00047454043,0.00013690702,0.0007272607,0.000014862289,0.0002937507,8.364865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011611113,0.00029769653,0.9678185,0.000057023466,0.0009135222,0.00000915937,0.0004343266,0.000017920285,0.00008819291,0.00026289668,0.00024888982,0.029735755],"study_design_scores_gemma":[0.006778977,0.006433354,0.9819671,0.001257064,0.0005553223,0.0000026019056,0.000109675195,0.00015497516,0.00090072607,0.00008354673,0.001509452,0.00024719792],"about_ca_topic_score_codex":0.00048350662,"about_ca_topic_score_gemma":0.0051652524,"teacher_disagreement_score":0.029488558,"about_ca_system_score_codex":0.00020362927,"about_ca_system_score_gemma":0.00048157625,"threshold_uncertainty_score":0.84104645},"labels":[],"label_agreement":null},{"id":"W2012282857","doi":"10.1186/1475-2840-13-102","title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)","year":2014,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Hazard ratio; Placebo; Randomized controlled trial; Internal medicine; Diabetes mellitus; Myocardial infarction; Type 2 diabetes; Clinical trial; Confidence interval; Endocrinology; Alternative medicine","score_opus":0.0208631510821815,"score_gpt":0.2518084300720267,"score_spread":0.23094527898984518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012282857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8487212,0.012214117,0.123963594,0.00035097887,0.00086897984,0.012696267,0.000023816727,0.00009343233,0.0010676066],"genre_scores_gemma":[0.9927416,0.00066505803,0.0045377836,0.00016358402,0.00031267162,0.0010271802,0.000116043346,0.000058087702,0.00037797968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99419683,0.0021833552,0.0017913834,0.0005986431,0.0007834657,0.00044631184],"domain_scores_gemma":[0.9959683,0.0016622205,0.00046628746,0.0012860982,0.00042518103,0.00019191984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009976401,0.00045569547,0.007900306,0.00042461162,0.000058532733,0.000015883195,0.00017255802,0.00025878343,0.000044384473],"category_scores_gemma":[0.004478999,0.0003527941,0.0048257825,0.0002180007,0.00044272808,0.00008063672,0.00011789392,0.00018745441,0.000013733805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7485355,0.0011674641,0.023842676,0.001822177,0.1394347,0.00011300184,0.00026015064,0.0015097177,0.0002333404,0.0025867096,0.00027613665,0.080218434],"study_design_scores_gemma":[0.9580983,0.000586999,0.0027680248,0.00006988067,0.028634645,0.000017535509,0.000026760335,0.003126206,0.0005753292,0.0001401316,0.0056303144,0.00032588956],"about_ca_topic_score_codex":0.000022330865,"about_ca_topic_score_gemma":8.508517e-7,"teacher_disagreement_score":0.2095628,"about_ca_system_score_codex":0.000055029752,"about_ca_system_score_gemma":0.00007308061,"threshold_uncertainty_score":0.9998924},"labels":[],"label_agreement":null},{"id":"W2012532988","doi":"10.3109/15563650.2014.880174","title":"The enigma of metformin-associated lactic acidosis","year":2014,"lang":"en","type":"letter","venue":"Clinical Toxicology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Metformin; Lactic acidosis; Medicine; Type 2 diabetes; Diabetes mellitus; Acidosis; Internal medicine; Pharmacology; Endocrinology","score_opus":0.0785843326733736,"score_gpt":0.3797374924921966,"score_spread":0.301153159818823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012532988","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009306845,0.0008807702,0.000015275173,0.95684665,0.0025325532,0.0010466242,0.00001296717,0.00009369376,0.029264607],"genre_scores_gemma":[0.025233619,0.0013569641,0.00017573085,0.91508424,0.0029316195,0.00015429113,0.00030803256,0.000073309355,0.05468216],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730706,0.00045224963,0.0010390632,0.00040673243,0.0002861203,0.0005087517],"domain_scores_gemma":[0.99336904,0.00500371,0.0006706651,0.00074023305,0.0001262597,0.00009006305],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012763308,0.00027145652,0.0012808978,0.00008710605,0.00008009477,0.000014271308,0.0003166045,0.0014050981,0.00024942312],"category_scores_gemma":[0.002546393,0.00016586148,0.0006636348,0.00013042243,0.00049075234,0.000019505796,0.00015976207,0.0013907376,0.00027261625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000770223,0.00033505092,0.002210454,0.000086459964,0.0018619673,0.00015017483,0.000006982776,3.5177422e-8,0.0000065546833,0.00014760312,0.9596293,0.035488382],"study_design_scores_gemma":[0.0018264258,0.002441837,0.0030650874,0.00006496098,0.0019503532,0.0000052697656,0.0000058009173,0.0000131846755,0.00006911632,0.00058085506,0.9898407,0.00013639325],"about_ca_topic_score_codex":0.0000045122024,"about_ca_topic_score_gemma":0.000012086737,"teacher_disagreement_score":0.041762393,"about_ca_system_score_codex":0.000100581376,"about_ca_system_score_gemma":0.0001069297,"threshold_uncertainty_score":0.9998913},"labels":[],"label_agreement":null},{"id":"W2012887020","doi":"10.2337/diacare.25.2.405","title":"Angioneurotic Edema as a Side Effect of Pioglitazone","year":2002,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Medicine; Pioglitazone; Edema; Diabetes mellitus; Side effect (computer science); Internal medicine; Endocrinology; Type 2 diabetes","score_opus":0.00799538180986806,"score_gpt":0.22730376504657485,"score_spread":0.2193083832367068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012887020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7821285,0.013577407,8.9311175e-7,0.12840052,0.0014221215,0.005052853,0.00030324064,0.00048186744,0.068632595],"genre_scores_gemma":[0.5351637,0.00024859773,0.00019614861,0.43015668,0.003942556,0.0008432411,0.0061690793,0.00044383717,0.022836203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997714,0.0001232988,0.00037373137,0.0005582401,0.0005968178,0.0006339421],"domain_scores_gemma":[0.99843377,0.0002965009,0.00019885565,0.000839776,0.00012663008,0.000104476916],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007746085,0.00056245486,0.0012339761,0.00038490575,0.0000421678,0.000025764393,0.0001980332,0.00048021882,0.00033706194],"category_scores_gemma":[0.00012431853,0.0004467138,0.000655412,0.00024815387,0.00009702509,0.000050931067,0.00011812786,0.00057169184,0.0012821408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021073132,0.000066541834,0.10434959,0.0075815725,0.0011202655,0.0007705721,0.00017496872,9.619669e-7,0.00013945304,0.000003895275,0.87312615,0.012644943],"study_design_scores_gemma":[0.0044640875,0.0072878017,0.010463595,0.0026988292,0.0072085364,0.0000061765422,0.000073034316,0.000027909577,0.009809552,0.000038953127,0.9571011,0.0008203979],"about_ca_topic_score_codex":0.000008872786,"about_ca_topic_score_gemma":5.3414647e-7,"teacher_disagreement_score":0.30175614,"about_ca_system_score_codex":0.00013873346,"about_ca_system_score_gemma":0.000023802524,"threshold_uncertainty_score":0.9997985},"labels":[],"label_agreement":null},{"id":"W2013212771","doi":"10.1503/cmaj.060049","title":"Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pioglitazone; Medicine; Type 2 diabetes; Macrovascular disease; Clinical trial; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.0019493744606315171,"score_gpt":0.18340858266029986,"score_spread":0.18145920819966835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013212771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925822,0.000097095246,0.0000037168281,0.0050220853,0.00044419002,0.00030952969,0.000005794551,0.000012766599,0.0015226101],"genre_scores_gemma":[0.9948672,0.000026799786,0.000100186684,0.0021165875,0.00043165352,0.000010831617,0.00008785605,0.000018805289,0.002340048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977555,0.00007590581,0.0003123699,0.00015423936,0.0012021207,0.0004998441],"domain_scores_gemma":[0.99885416,0.000028841878,0.00012486278,0.00010975346,0.00023414695,0.0006482207],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006304413,0.00012740033,0.0002480262,0.00022584602,0.0000784999,0.000022187458,0.00008745369,0.00014834116,0.0011827569],"category_scores_gemma":[0.00018829679,0.00007625959,0.000072157294,0.00027623097,0.000015647138,0.00009673634,0.000011921729,0.00033582046,0.000083381754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014002348,0.00027363794,0.982271,0.000012402496,0.0002108582,0.00008333523,0.000018521852,0.0000032987357,6.453118e-7,0.000027606426,0.0100166565,0.007068018],"study_design_scores_gemma":[0.003531776,0.00021840568,0.9412212,0.00015289443,0.00009699593,0.0000014541779,0.00001938511,0.00001873264,0.000010048507,0.00014609068,0.054478683,0.000104360784],"about_ca_topic_score_codex":0.0010351794,"about_ca_topic_score_gemma":0.013652038,"teacher_disagreement_score":0.044462025,"about_ca_system_score_codex":0.0014195885,"about_ca_system_score_gemma":0.00057981117,"threshold_uncertainty_score":0.9997303},"labels":[],"label_agreement":null},{"id":"W2013265294","doi":"10.1007/s00125-011-2365-4","title":"Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice","year":2011,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Merck","keywords":"Streptozotocin; Internal medicine; Endocrinology; Beta cell; Incretin; Islet; Sitagliptin; Insulin; Glucagon; Alpha cell; Apoptosis; Diabetes mellitus; Glucagon-like peptide-1; Medicine; Chemistry; Type 2 diabetes; Biochemistry","score_opus":0.02567337076832455,"score_gpt":0.2327589999790125,"score_spread":0.20708562921068796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013265294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960041,0.00017449465,0.000024213128,0.000037352576,0.00003232718,0.0011624087,0.000017776154,0.000026305555,0.0025210294],"genre_scores_gemma":[0.99819654,0.000037058904,0.0012263405,0.0000355477,0.000009869954,0.00015584093,0.00011675849,0.000019548641,0.0002024927],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865794,0.00006380776,0.00048260644,0.00034217918,0.00016707293,0.00028640334],"domain_scores_gemma":[0.9994161,0.00002703717,0.00022480437,0.00020127397,0.00006719267,0.00006356598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025352003,0.00020085124,0.0004713359,0.00031753725,0.000017850129,0.0000062153604,0.000045425175,0.00013184096,0.000015107175],"category_scores_gemma":[0.00001962329,0.00018590837,0.000050491697,0.00026305916,0.00006079484,0.00018874329,0.00004754888,0.00012911174,0.0000022598256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007162338,0.0014410628,0.5158679,0.0005156005,0.000029307945,0.0000028615102,0.0009500702,0.000029705943,0.4798763,0.00010700822,0.00017775463,0.0009307976],"study_design_scores_gemma":[0.0028212175,0.0008673751,0.13140072,0.00022547605,0.00012592452,2.3777224e-7,0.00023712707,0.0037537296,0.86010355,0.00030282434,0.0000015975219,0.00016025167],"about_ca_topic_score_codex":0.00013887636,"about_ca_topic_score_gemma":0.00003360799,"teacher_disagreement_score":0.38446715,"about_ca_system_score_codex":0.00007481331,"about_ca_system_score_gemma":0.000040777126,"threshold_uncertainty_score":0.7581123},"labels":[],"label_agreement":null},{"id":"W2013909000","doi":"10.1038/oby.2007.16","title":"Glucose Tolerance, Lipids, and GLP‐1 Secretion in JCR:LA‐cp Rats Fed a High Protein Fiber Diet","year":2008,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Ministry of Agriculture and Forestry; University of Alberta; University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Triglyceride; Glycemic; Proglucagon; Inulin; Glucagon-like peptide-1; Leptin; Glucose tolerance test; Incretin; Insulin; Chemistry; Type 2 diabetes; Medicine; Cholesterol; Insulin resistance; Diabetes mellitus; Obesity; Food science","score_opus":0.009177028073869602,"score_gpt":0.21726287146619966,"score_spread":0.20808584339233005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013909000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885759,0.00028322835,0.00000719301,0.0003195053,0.00004997727,0.00080710696,0.00000324795,0.000058377685,0.009895515],"genre_scores_gemma":[0.98876154,0.00014552083,0.0006635839,0.00014871894,0.00008739062,0.00008188478,0.000046167814,0.00001203308,0.010053148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923384,0.00004458674,0.00013403973,0.00023649703,0.00015124778,0.00019981294],"domain_scores_gemma":[0.9996559,0.000017673432,0.000037641366,0.00018506302,0.000023081182,0.000080662205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115819435,0.00013286159,0.0002383492,0.00007304131,0.00008247845,0.000017586604,0.000035017118,0.00006878422,0.00014410248],"category_scores_gemma":[0.000017374874,0.00011475194,0.00003702874,0.00013540892,0.000066963905,0.00009382842,0.000050101968,0.0000946315,0.000108838554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029395022,0.004114927,0.90963316,0.00091886683,0.00028852222,0.0012030228,0.0016564995,0.000009623934,0.016352154,0.0019004982,0.011425441,0.049557805],"study_design_scores_gemma":[0.0036561356,0.00069525273,0.9524105,0.00021448365,0.00006619056,0.0000060480816,0.000019503263,0.000091994116,0.0071894964,0.00024319915,0.035228677,0.0001785115],"about_ca_topic_score_codex":0.00015452004,"about_ca_topic_score_gemma":0.00005685383,"teacher_disagreement_score":0.049379297,"about_ca_system_score_codex":0.0000602526,"about_ca_system_score_gemma":0.00002668974,"threshold_uncertainty_score":0.46794483},"labels":[],"label_agreement":null},{"id":"W2014004959","doi":"10.1038/nutd.2012.30","title":"Menin and GIP are inversely regulated by food intake and diet via PI3/AKT signaling in the proximal duodenum","year":2012,"lang":"en","type":"article","venue":"Nutrition and Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Internal medicine; Endocrinology; Protein kinase B; Duodenum; MAPK/ERK pathway; Medicine; PI3K/AKT/mTOR pathway; Incretin; Downregulation and upregulation; Cancer research; Signal transduction; Biology; Cell biology; Diabetes mellitus; Type 2 diabetes; Gene; Biochemistry","score_opus":0.016751403538273958,"score_gpt":0.2234996916732658,"score_spread":0.20674828813499185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014004959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003315,0.0075104767,0.0000017889718,0.0015778773,0.000029234687,0.0005780094,0.000015877325,0.000030951556,0.00022265404],"genre_scores_gemma":[0.9984917,0.00020440728,0.00015159992,0.0008069982,0.00006668144,0.00009781453,0.000093977775,0.00001053045,0.00007631318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928635,0.00004875994,0.00013437006,0.00016295597,0.00012049297,0.00024703855],"domain_scores_gemma":[0.9996863,0.00006072327,0.000047342186,0.00008778014,0.000018772706,0.0000991041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019245429,0.00013044951,0.00019434337,0.0000824544,0.000070255795,0.000042710322,0.00002563914,0.00006241377,0.000013715686],"category_scores_gemma":[0.00001937686,0.0000944387,0.000021042784,0.00010820124,0.00007736667,0.00016716126,0.000030116078,0.00008190763,0.000001555303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017215534,0.0013465929,0.9460016,0.0007499361,0.00019528868,0.000006066652,0.0018940131,1.11552545e-7,0.0248606,0.0005425727,0.0114823785,0.012748719],"study_design_scores_gemma":[0.0225406,0.004559615,0.85362256,0.0016583735,0.00091460074,0.000012003461,0.00505198,0.00058510504,0.0715037,0.003031701,0.03572728,0.00079249404],"about_ca_topic_score_codex":0.000008304479,"about_ca_topic_score_gemma":0.000005956103,"teacher_disagreement_score":0.09237902,"about_ca_system_score_codex":0.000015932002,"about_ca_system_score_gemma":0.0000025004176,"threshold_uncertainty_score":0.38510984},"labels":[],"label_agreement":null},{"id":"W2014084450","doi":"10.1016/j.jcjd.2014.07.055","title":"Does the Increase in BMI Associated with Initiation of Insulin Therapy Among Youth Newly Diagnosed with Type 1 Diabetes Mellitus (T1DM) Predict Obesity at Age 18?","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Medicine; Obesity; Diabetes mellitus; Type 1 diabetes; Internal medicine; Insulin; Pediatrics; Endocrinology","score_opus":0.011300377911523787,"score_gpt":0.19902850871419078,"score_spread":0.18772813080266698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014084450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997251,0.0010750302,0.0000013410942,0.000223279,0.0001250217,0.0005195307,0.000037860456,0.000013044531,0.00075394387],"genre_scores_gemma":[0.9990836,0.00011083479,0.00004741023,0.00041432146,0.00009807375,0.000013991245,0.00009930623,0.000035661178,0.000096827316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982981,0.00023100866,0.00044706822,0.00018656874,0.00035506746,0.0004821865],"domain_scores_gemma":[0.99810266,0.00037037363,0.0004930272,0.00028452187,0.0002938232,0.000455566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007397057,0.000250948,0.0005921365,0.00037437977,0.00010660266,0.000047358535,0.00020589567,0.00009557402,0.00008933893],"category_scores_gemma":[0.0004697926,0.00012292963,0.00009238373,0.0004933577,0.00028778234,0.0002069434,0.0000174227,0.00023794662,0.000002104132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000647845,0.00017289084,0.9946544,0.00003774792,0.0005510561,0.00004609637,0.0012467534,0.000058916063,0.000082153696,0.000012980844,0.00025291226,0.0028192701],"study_design_scores_gemma":[0.005105242,0.0021156336,0.9892125,0.000852831,0.00043625443,2.964805e-7,0.00040462165,0.000089406225,0.0012348554,0.00007356164,0.0003077755,0.00016702937],"about_ca_topic_score_codex":0.0016474371,"about_ca_topic_score_gemma":0.04754326,"teacher_disagreement_score":0.045895826,"about_ca_system_score_codex":0.0003001328,"about_ca_system_score_gemma":0.00037713684,"threshold_uncertainty_score":0.9698366},"labels":[],"label_agreement":null},{"id":"W2014124623","doi":"10.1016/j.metabol.2014.10.032","title":"Biomarkers of vascular complications in type 2 diabetes","year":2014,"lang":"en","type":"review","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Intensive care medicine; Nephropathy; Type 2 diabetes; Stroke (engine); Disease; Diabetes mellitus; Intervention (counseling); Risk assessment; Compliance (psychology); Retinopathy; Bioinformatics; Internal medicine; Psychology; Computer science","score_opus":0.03371838990282213,"score_gpt":0.3155968054536668,"score_spread":0.2818784155508447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014124623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110309935,0.9927317,0.0000052109376,0.000036177593,0.00022742816,0.0009580287,0.000010606716,0.000027332057,0.005893201],"genre_scores_gemma":[0.000049262133,0.9983312,0.0006121208,0.00006156363,0.000065181695,0.00014359123,0.00033605847,0.000036991558,0.0003640459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881035,0.00008905747,0.00046425793,0.00026029345,0.00016707722,0.00020896558],"domain_scores_gemma":[0.99902755,0.00006758388,0.00019273473,0.0005976608,0.000050048282,0.000064426655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025924318,0.00024248635,0.0018763934,0.0004264256,0.000013637567,0.0000072365397,0.00014393317,0.000117822514,0.00007174675],"category_scores_gemma":[0.000055811466,0.00017931081,0.0004260259,0.00054258463,0.000051227675,0.000021946747,0.0000641836,0.0001027745,0.00015651727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000010911787,0.00015974964,0.00011483108,0.010149927,0.0011765411,0.0000012287021,0.000009576382,1.06440375e-7,0.0000011081834,0.0012895106,0.0011822799,0.98591405],"study_design_scores_gemma":[0.00040244343,0.00002669316,0.0020203802,0.003787059,0.0042619365,2.5614904e-7,0.0000018979289,0.0000044338467,0.000002039131,0.00004878777,0.98931545,0.00012863368],"about_ca_topic_score_codex":0.00001201279,"about_ca_topic_score_gemma":0.0000018183621,"teacher_disagreement_score":0.98813313,"about_ca_system_score_codex":0.000034162447,"about_ca_system_score_gemma":0.000057005243,"threshold_uncertainty_score":0.73120826},"labels":[],"label_agreement":null},{"id":"W2015569637","doi":"10.1007/s00125-010-1937-z","title":"Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice","year":2010,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Metformin; Internal medicine; Endocrinology; Incretin; AMPK; Peroxisome proliferator-activated receptor; Gastric inhibitory polypeptide; Type 2 diabetes; Glucagon-like peptide-1; Receptor; Gastric emptying; Biology; Glucagon; Medicine; Insulin; Diabetes mellitus; Protein kinase A; Kinase; Biochemistry; Stomach","score_opus":0.009754378819011101,"score_gpt":0.23238737551526695,"score_spread":0.22263299669625586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015569637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274,0.000115425806,0.0000025238617,0.0019114878,0.00061114435,0.001486154,0.000017277012,0.00017900598,0.0029369893],"genre_scores_gemma":[0.9956714,0.000036448717,0.00081067014,0.000873124,0.00014247235,0.00044855714,0.00015791376,0.000046043344,0.0018133642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789417,0.0001419158,0.00042613022,0.0005482159,0.00037011268,0.0006194818],"domain_scores_gemma":[0.9987273,0.00025397268,0.00015169429,0.00062771037,0.000085627726,0.00015368046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007225687,0.00036738632,0.00053926226,0.00023579506,0.000121382,0.00005218053,0.0002909644,0.00023332331,0.00060970394],"category_scores_gemma":[0.00036003662,0.00023075905,0.00012567497,0.00044197144,0.00014884981,0.00013036179,0.00013019916,0.00064794946,0.0005330123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006033363,0.0011565045,0.09158967,0.000094167204,0.00033887435,0.000050388076,0.0005768391,0.0000028048821,0.84217334,0.0015590037,0.004258881,0.05759618],"study_design_scores_gemma":[0.0027039556,0.0011003045,0.049462605,0.000121987265,0.0000943122,0.000006873971,0.00024292961,0.0000758844,0.91678494,0.00028757294,0.028712017,0.00040659067],"about_ca_topic_score_codex":0.000072384086,"about_ca_topic_score_gemma":0.00008220694,"teacher_disagreement_score":0.07461161,"about_ca_system_score_codex":0.00015810311,"about_ca_system_score_gemma":0.000063102954,"threshold_uncertainty_score":0.9410081},"labels":[],"label_agreement":null},{"id":"W2015788437","doi":"10.1038/ijo.2013.120","title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study","year":2013,"lang":"en","type":"article","venue":"International Journal of Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":820,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk; F. Hoffmann-La Roche","keywords":"Liraglutide; Weight loss; Medicine; Overweight; Randomization; Placebo; Body mass index; Internal medicine; Very low calorie diet; Randomized controlled trial; Obesity; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.004680378386743965,"score_gpt":0.2182724167707537,"score_spread":0.21359203838400975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015788437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864336,0.00020037063,0.00048993115,0.00899386,0.0007532644,0.0011449676,0.00006262346,0.000022626311,0.0018987121],"genre_scores_gemma":[0.9940126,0.00030178367,0.001038924,0.0011788291,0.0008326199,0.00018978785,0.000030499723,0.00002763428,0.0023873532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973605,0.00015743924,0.00069244514,0.00031486145,0.0011283621,0.0003463734],"domain_scores_gemma":[0.99744314,0.0003633154,0.00052310876,0.00026937094,0.0011798667,0.0002212221],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006487232,0.0003184802,0.00069695985,0.00019476806,0.000107138796,0.00012323837,0.00039176978,0.00006340297,0.0025487123],"category_scores_gemma":[0.0001521465,0.00016559173,0.0002711799,0.00013491244,0.00034166183,0.0005359193,0.0001579904,0.00038122816,0.00010417033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13100171,0.007953259,0.73260736,0.00010987929,0.010746092,0.0058132033,0.0015718078,0.000011537866,0.00018789215,0.0028902527,0.0991772,0.007929824],"study_design_scores_gemma":[0.15947296,0.0016028713,0.812201,0.001333447,0.0011053184,0.00062023214,0.0003334375,0.00024410404,0.00047938654,0.0039863056,0.018162237,0.00045867416],"about_ca_topic_score_codex":0.000048894737,"about_ca_topic_score_gemma":0.000043962766,"teacher_disagreement_score":0.08101496,"about_ca_system_score_codex":0.00023549786,"about_ca_system_score_gemma":0.00010880235,"threshold_uncertainty_score":0.9983631},"labels":[],"label_agreement":null},{"id":"W2016552617","doi":"10.1111/dme.12049","title":"Progression through diabetes therapies among new elderly users of metformin: a population‐based study","year":2012,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; McMaster University; St. Joseph’s Healthcare Hamilton; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Metformin; Diabetes mellitus; Type 2 diabetes; Internal medicine; Population; Insulin; Cohort; Combination therapy; Cohort study; Endocrinology","score_opus":0.03186685485275425,"score_gpt":0.3159310364005052,"score_spread":0.2840641815477509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016552617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914074,0.003279163,0.00008298071,0.0011505047,0.00034813606,0.0018544014,0.0000016448267,0.00010630688,0.0017694894],"genre_scores_gemma":[0.99634004,0.000024932498,0.0018477493,0.0004051548,0.00032807313,0.00012647563,0.00011274221,0.000041027542,0.00077379285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978776,0.00007623469,0.00052655913,0.0002642118,0.0007279545,0.0005274278],"domain_scores_gemma":[0.99869967,0.00016110884,0.00025154318,0.0005257722,0.00007812798,0.00028378348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004995783,0.00029867495,0.00075978803,0.0002289987,0.000066048924,0.000008513888,0.00012439892,0.00007450785,0.00060692907],"category_scores_gemma":[0.00016324232,0.00019174883,0.000106877946,0.0004351332,0.00011691018,0.00025781614,0.00004370703,0.00011463586,0.000016371707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042898566,0.0011911568,0.9561579,0.0001943386,0.00044728225,0.000003885286,0.0028076256,0.0000014954975,0.0003770527,0.00014615757,0.0015094416,0.037120737],"study_design_scores_gemma":[0.006507885,0.0039936877,0.98068255,0.0007674553,0.0014381175,2.7074273e-7,0.0017176825,0.000052455598,0.002726501,0.00021062425,0.0017049189,0.00019787492],"about_ca_topic_score_codex":0.0001761457,"about_ca_topic_score_gemma":0.000009611717,"teacher_disagreement_score":0.036922865,"about_ca_system_score_codex":0.00006445909,"about_ca_system_score_gemma":0.000035250327,"threshold_uncertainty_score":0.781929},"labels":[],"label_agreement":null},{"id":"W2016818962","doi":"10.1093/eurheartj/ehn156","title":"Diabetes, left ventricular systolic dysfunction, and chronic heart failure","year":2008,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Epidemiology; Cardiology; Intensive care medicine; Internal medicine; Diabetic cardiomyopathy; Cardiomyopathy; Endocrinology","score_opus":0.027885210673191073,"score_gpt":0.2756027977280864,"score_spread":0.2477175870548953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016818962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020812241,0.99608034,0.0000069673993,0.0004632373,0.0005627263,0.0008003366,0.0000062977488,0.00009050744,0.0017814565],"genre_scores_gemma":[0.00010799865,0.9938059,0.00027854653,0.0003196619,0.002339098,0.000008762012,0.0000883165,0.00014931819,0.0029024107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739665,0.00050001044,0.0006407108,0.0004400795,0.0004252772,0.0005972845],"domain_scores_gemma":[0.9986766,0.000056159282,0.000274129,0.00043100095,0.000076278506,0.0004858062],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000443734,0.00054005074,0.0016468104,0.00044224242,0.00033840296,0.00014489434,0.0001303754,0.00010896052,0.0003009789],"category_scores_gemma":[0.000050055005,0.0003937936,0.0007345081,0.00023007508,0.000083590865,0.00012310584,0.0001352935,0.0008779632,0.0011044249],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000052383944,0.00022312335,0.0015041698,0.010876797,0.001920273,0.0026687272,0.000027592634,0.0000012298623,0.0000027995386,0.000015605276,0.597384,0.3853705],"study_design_scores_gemma":[0.00084924616,0.0005445219,0.00088894006,0.012745332,0.0020990758,0.0107126655,0.0000043043246,0.0000016970242,0.0000010047107,0.0000015796656,0.97185004,0.00030162217],"about_ca_topic_score_codex":5.552491e-7,"about_ca_topic_score_gemma":5.510325e-7,"teacher_disagreement_score":0.38506886,"about_ca_system_score_codex":0.00035483763,"about_ca_system_score_gemma":0.00025191583,"threshold_uncertainty_score":0.9998514},"labels":[],"label_agreement":null},{"id":"W2017030986","doi":"10.1016/j.clinthera.2005.05.005","title":"Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Dartmouth General Hospital","funders":"","keywords":"Medicine; Pioglitazone; Insulin; Glycemic; Internal medicine; Type 2 diabetes; Placebo; Diabetes mellitus; Type 2 Diabetes Mellitus; Clinical endpoint; Glycated hemoglobin; Endocrinology; Randomized controlled trial; Gastroenterology","score_opus":0.031599770645512774,"score_gpt":0.31556168110491983,"score_spread":0.28396191045940705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017030986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789229,0.00429727,0.000027360813,0.00041725574,0.00007373216,0.016137263,0.000014195342,0.0000361212,0.00007387835],"genre_scores_gemma":[0.99510646,0.002342755,0.0008710103,0.000657501,0.000035795416,0.0007828396,0.00007921912,0.00006107098,0.00006337768],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958626,0.0006743346,0.0016680124,0.0006372195,0.00074452756,0.00041332777],"domain_scores_gemma":[0.99641097,0.0014554382,0.00084411504,0.0006422646,0.00046829417,0.00017893869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013953048,0.00047179076,0.002479984,0.00033533692,0.000032072385,0.000023900788,0.00019279262,0.00012858669,0.0000054635807],"category_scores_gemma":[0.00020242414,0.00027004708,0.00020286263,0.0007201716,0.00037156604,0.00018348647,0.000050508963,0.00034416415,0.0000038300054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59087723,0.033710454,0.35714433,0.00008611034,0.002581371,0.000010869673,0.00089883676,0.00008522467,0.0000050920994,0.00007759329,0.0000013540671,0.014521544],"study_design_scores_gemma":[0.6138803,0.012683656,0.3702665,0.00033698225,0.0014137886,2.298104e-8,0.00006970924,0.0008386082,0.0002122131,0.000024227436,0.000082518935,0.00019152187],"about_ca_topic_score_codex":0.000046954337,"about_ca_topic_score_gemma":0.000119812496,"teacher_disagreement_score":0.023003032,"about_ca_system_score_codex":0.000075996795,"about_ca_system_score_gemma":0.00011297304,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W2017201029","doi":"10.2337/diacare.26.10.2835","title":"Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes","year":2003,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Vedecká Grantová Agentúra MŠVVaŠ SR a SAV; Boston Area Diabetes Endocrinology Research Center; U.S. Public Health Service; University of British Columbia; National Institutes of Health","keywords":"Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Insulin; Glucagon; Glucagon-like peptide-1; Ghrelin; Area under the curve; Hormone","score_opus":0.0031961121343739196,"score_gpt":0.2000412097458465,"score_spread":0.19684509761147256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017201029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960473,0.0011575212,5.646456e-7,0.0000057658017,0.0001116007,0.0010192977,0.00002511213,0.00001708652,0.0016157153],"genre_scores_gemma":[0.99932235,0.000022270293,0.00029185033,0.00002842963,0.0000068253125,0.00003934124,0.00016890059,0.000025932384,0.000094112074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988183,0.0000504901,0.00035969247,0.00021606892,0.000284106,0.00027136112],"domain_scores_gemma":[0.9989911,0.00013728805,0.00023548128,0.00026237566,0.0003096543,0.000064157204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058252197,0.00019307435,0.000585167,0.00016418357,0.000012583763,0.0000048847705,0.00007047188,0.00007413238,0.0000169024],"category_scores_gemma":[0.00010621924,0.00015874374,0.00008219786,0.00028821887,0.00008155216,0.00006048799,0.00001719263,0.00006355884,0.0000040999066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018040107,0.00071217905,0.98589295,0.0019233745,0.00023425055,0.00001460843,0.0004710013,0.000007744702,0.004123608,0.000049866536,0.00007516681,0.0063148737],"study_design_scores_gemma":[0.005011915,0.012946873,0.6833876,0.0010103266,0.00061692705,1.7477447e-7,0.00056095404,0.0000099473655,0.29581487,0.00002698014,0.00040258124,0.00021086389],"about_ca_topic_score_codex":0.000009000357,"about_ca_topic_score_gemma":0.000023513505,"teacher_disagreement_score":0.30250534,"about_ca_system_score_codex":0.000045792094,"about_ca_system_score_gemma":0.00006299252,"threshold_uncertainty_score":0.64733815},"labels":[],"label_agreement":null},{"id":"W2017854217","doi":"10.2174/1871529x11202020092","title":"Regulation of Intestinal Chylomicron Production by Glucagon-Like Peptides","year":2012,"lang":"en","type":"review","venue":"Cardiovascular & Haematological Disorders - Drug Targets","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Postprandial; Endocrinology; Internal medicine; Chylomicron; Insulin resistance; Incretin; Glucagon-like peptide-1; Dyslipidemia; Insulin; Lipoprotein; Apolipoprotein B; LDL receptor; Biology; Medicine; Type 2 diabetes; Diabetes mellitus; Very low-density lipoprotein; Cholesterol","score_opus":0.026428657707144483,"score_gpt":0.2672017883146897,"score_spread":0.24077313060754524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017854217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004189538,0.9935473,0.00034214166,0.000089956986,0.0006681348,0.0031696814,0.00001844224,0.0001860721,0.0015593019],"genre_scores_gemma":[0.0055630254,0.9901334,0.0007456084,0.0000240584,0.0001709709,0.00047330587,0.0016076679,0.000099841585,0.0011821428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627376,0.00039437678,0.0009893414,0.0009833993,0.0006887825,0.00067033945],"domain_scores_gemma":[0.9979158,0.00008495774,0.00048762138,0.0011607929,0.00013210592,0.00021873745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007829771,0.00081892736,0.004204412,0.00027187847,0.00011315373,0.000024852028,0.00026658905,0.00039804998,0.00009902323],"category_scores_gemma":[0.00021412593,0.000594523,0.0035986078,0.0004610433,0.00031560427,0.00016169065,0.00021445706,0.00040341407,0.00015189093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030820443,0.0008162524,0.00023143968,0.02369377,0.006177986,0.000022167891,0.00006182929,0.0000052390205,0.000007445674,0.00013261093,0.01589927,0.95292115],"study_design_scores_gemma":[0.0006453181,0.00010665181,0.00021509657,0.004306695,0.0153325,0.00012311405,0.00004847935,0.000003486677,0.00008717486,0.00010678165,0.9784893,0.0005354087],"about_ca_topic_score_codex":0.000022572693,"about_ca_topic_score_gemma":0.0000024411754,"teacher_disagreement_score":0.96259004,"about_ca_system_score_codex":0.0001965046,"about_ca_system_score_gemma":0.00007589993,"threshold_uncertainty_score":0.9996506},"labels":[],"label_agreement":null},{"id":"W2017951061","doi":"10.1177/0145721706287652","title":"The Evidence for Achieving Glycemic Control With Incretin Mimetics","year":2006,"lang":"en","type":"review","venue":"The Diabetes Educator","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; Toronto General Hospital","funders":"","keywords":"Glycemic; Incretin; Medicine; Control (management); Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Computer science; Endocrinology; Artificial intelligence","score_opus":0.04977510721994906,"score_gpt":0.352582352213031,"score_spread":0.302807244993082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017951061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012828643,0.99058336,0.000012187488,0.0014793201,0.0004876813,0.0055620736,0.000039213453,0.000075746946,0.00047754333],"genre_scores_gemma":[0.0009146205,0.9889089,0.000282427,0.0005013547,0.0010325541,0.0031451536,0.00013350314,0.00014128079,0.0049402155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772024,0.00017871137,0.0005440071,0.0004613363,0.00032987603,0.0007658351],"domain_scores_gemma":[0.99365044,0.004517513,0.00046025938,0.001135373,0.00010686771,0.00012954022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083187275,0.00058874127,0.0014824382,0.00010409764,0.00039698763,0.00016149729,0.0006062805,0.00013706964,0.000017444001],"category_scores_gemma":[0.00040270993,0.00024777948,0.0005745069,0.00030191173,0.00026755323,0.000053433418,0.00008995677,0.00033659363,0.00008642371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017970677,0.00018786165,0.0007743172,0.014768456,0.0024330493,0.0000025751901,0.000049334623,4.2825624e-7,0.0000017798747,0.00047870053,0.032068733,0.9490551],"study_design_scores_gemma":[0.00090092357,0.0006518539,0.00006132058,0.015641296,0.012898119,0.0000026331093,0.00003945302,0.00000805421,0.000004672383,0.000036618603,0.96946526,0.00028981932],"about_ca_topic_score_codex":0.000011539139,"about_ca_topic_score_gemma":0.000004821624,"teacher_disagreement_score":0.9487652,"about_ca_system_score_codex":0.00024795966,"about_ca_system_score_gemma":0.0005485558,"threshold_uncertainty_score":0.99999744},"labels":[],"label_agreement":null},{"id":"W2018146332","doi":"10.1038/ki.2014.296","title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; McMaster University Medical Centre","funders":"","keywords":"Medicine; Glycemic; Kidney disease; Diabetes mellitus; Type 2 diabetes; Internal medicine; Disease; Intensive care medicine; Endocrinology; Cardiology","score_opus":0.0030424571966284624,"score_gpt":0.19324830826656045,"score_spread":0.19020585106993199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018146332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510556,0.00030237169,0.00006912233,0.0019568463,0.00030270303,0.0005679412,0.00013639723,0.00003964837,0.0015194323],"genre_scores_gemma":[0.99490166,0.000060700364,0.00010115246,0.0038541702,0.0001965857,0.000049228376,0.0006035281,0.00002043479,0.00021253755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895865,0.000047488415,0.0001550672,0.0002912924,0.00034357156,0.00020393971],"domain_scores_gemma":[0.9988899,0.000038205955,0.00006293478,0.00024454828,0.00026909763,0.0004952941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012219271,0.00016237503,0.00026279845,0.00015929752,0.000029411829,0.000026926418,0.00008078549,0.00003232052,0.00013071523],"category_scores_gemma":[0.0011498441,0.00012597923,0.00008307194,0.00008410838,0.00006795173,0.00010857938,0.000054418448,0.00010631834,0.00004284426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092686753,0.00014221703,0.9862164,0.000051545674,0.0018580273,0.000011997243,0.000026758209,0.00003197589,0.000008469063,0.000120445715,0.00602613,0.004579119],"study_design_scores_gemma":[0.022352781,0.0007688713,0.91239196,0.00031323615,0.0011301559,4.0734253e-7,0.000008390354,0.0030737363,0.000019848305,0.00011941037,0.05963805,0.00018317282],"about_ca_topic_score_codex":0.000051055264,"about_ca_topic_score_gemma":0.0000034301427,"teacher_disagreement_score":0.07382451,"about_ca_system_score_codex":0.00018084557,"about_ca_system_score_gemma":0.000115294846,"threshold_uncertainty_score":0.5137284},"labels":[],"label_agreement":null},{"id":"W2018323223","doi":"10.1001/jama.2009.2017","title":"Composite End Points in Randomized Trials","year":2010,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Surgery","score_opus":0.023226345551390526,"score_gpt":0.3027675137285484,"score_spread":0.27954116817715785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018323223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9343627,0.0000909107,0.00001866441,0.0059524174,0.00034652397,0.0009905129,0.0000021839664,0.000037466136,0.058198627],"genre_scores_gemma":[0.992529,0.000030499192,0.0019981454,0.0011174101,0.00019172962,0.000073514486,0.00003201489,0.0000089207315,0.0040188204],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920946,0.00012681066,0.00029963156,0.000115457784,0.00011824959,0.00013040604],"domain_scores_gemma":[0.9991714,0.0005156685,0.00007022633,0.00016670192,0.000020256797,0.000055794477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019711638,0.00007944731,0.00075327884,0.000111464076,0.000012020995,0.000023508243,0.000039418934,0.00005119343,0.00073954073],"category_scores_gemma":[0.00093592476,0.000052992866,0.00016689376,0.00006871864,0.000037101567,0.000048766204,0.00002404798,0.000114994014,0.00017812477],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13765872,0.001987355,0.03436701,0.00019501711,0.0016129335,0.0004239573,0.0011407176,0.0000013789664,0.0646593,0.021990143,0.033880375,0.7020831],"study_design_scores_gemma":[0.8920159,0.000104317936,0.044041894,0.000100011435,0.0005906795,0.000004227859,0.00002588043,0.00020183297,0.012159454,0.002290319,0.048329297,0.0001362093],"about_ca_topic_score_codex":0.000040399435,"about_ca_topic_score_gemma":0.000024893927,"teacher_disagreement_score":0.75435716,"about_ca_system_score_codex":0.000014153239,"about_ca_system_score_gemma":0.00001143761,"threshold_uncertainty_score":0.8097452},"labels":[],"label_agreement":null},{"id":"W2018366759","doi":"10.1111/j.1463-1326.2011.01509.x","title":"What matters in ADVANCE and ADVANCE‐ON","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Computer Research Institute of Montréal","funders":"Servier; U.S. Department of Veterans Affairs","keywords":"Medicine; Diabetes mellitus; Blood pressure; Disease; Type 2 diabetes; Internal medicine; Glycated haemoglobin; Intensive care medicine; Cardiology; Endocrinology","score_opus":0.0209471570295346,"score_gpt":0.28055525726273617,"score_spread":0.2596081002332016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018366759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058817407,0.99135476,8.3546763e-7,0.00012504174,0.0005964857,0.0012191546,0.00001721343,0.000047795053,0.00075699226],"genre_scores_gemma":[0.00006562871,0.9961401,0.0003020525,0.0014633848,0.0001134625,0.00020062919,0.00009637944,0.00005204007,0.0015663065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982669,0.00008489435,0.0003805925,0.00063722016,0.0001498888,0.0004805378],"domain_scores_gemma":[0.9990952,0.00009362421,0.00016886195,0.0004166055,0.000021386884,0.00020432244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022730105,0.0005370905,0.0020984726,0.00039573343,0.000054623113,0.00007351237,0.000106922955,0.00019865461,0.00004012083],"category_scores_gemma":[0.000025268588,0.00041471832,0.0001999558,0.00021631768,0.00011946847,0.00040461347,0.00014108852,0.00030669133,0.00006487839],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007230303,0.00022809661,0.00073119445,0.009587617,0.00022587374,0.00002090807,0.00008216769,3.0917846e-8,3.8375083e-7,0.0014405044,0.00022809274,0.9874479],"study_design_scores_gemma":[0.00089798373,0.00008611467,0.004891743,0.012987337,0.0018260407,0.0000020170849,0.000024296089,8.093233e-7,0.0000069989796,0.0003183105,0.97861016,0.0003482129],"about_ca_topic_score_codex":0.000006482776,"about_ca_topic_score_gemma":0.000005099739,"teacher_disagreement_score":0.9870997,"about_ca_system_score_codex":0.000037919242,"about_ca_system_score_gemma":0.000025610203,"threshold_uncertainty_score":0.9998305},"labels":[],"label_agreement":null},{"id":"W2018664950","doi":"10.1016/j.jcjd.2013.08.125","title":"Intensification of Basal Insulin Therapy with Step-Wise Addition of Insulin Aspart Boluses vs. Basal-Bolus Therapy: The FullSTEP™ Study","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi","keywords":"Medicine; Insulin aspart; Bolus (digestion); Insulin; Diabetes mellitus; Basal (medicine); Internal medicine; Regimen; Type 2 diabetes; Randomized controlled trial; Endocrinology; Anesthesia","score_opus":0.018427299043963164,"score_gpt":0.2243861205023053,"score_spread":0.20595882145834213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018664950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926527,0.0030717456,0.000008873061,0.0024410537,0.00017423592,0.001232151,0.000029335073,0.000007968724,0.00038193454],"genre_scores_gemma":[0.99827427,0.00021343665,0.00020816183,0.00094105786,0.00012977011,0.000055566674,0.000024831015,0.000034885674,0.000118031334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835694,0.00014230386,0.0006301799,0.00016942922,0.00037393573,0.00032718395],"domain_scores_gemma":[0.9976172,0.00015603441,0.00060978136,0.00040077599,0.00089221576,0.00032402703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004008168,0.00022537699,0.0005651066,0.0004176624,0.00007942143,0.000044279514,0.000245651,0.00006200284,0.0004507219],"category_scores_gemma":[0.000114593786,0.00013430884,0.0001376697,0.00036532688,0.00021487009,0.000251981,0.000012567859,0.00019516281,0.0000122694455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003294446,0.0014491853,0.810101,0.00009074033,0.002581355,0.000019695972,0.002944754,0.0000371212,0.002064328,0.000088278524,0.028046573,0.15224758],"study_design_scores_gemma":[0.006418702,0.0071469573,0.97086936,0.00033358103,0.0002907589,0.0000013416799,0.0030618762,0.00009566651,0.006826543,0.00012231735,0.0046579,0.000174998],"about_ca_topic_score_codex":0.0013302619,"about_ca_topic_score_gemma":0.0017018206,"teacher_disagreement_score":0.16076842,"about_ca_system_score_codex":0.00010345326,"about_ca_system_score_gemma":0.0005054136,"threshold_uncertainty_score":0.5476955},"labels":[],"label_agreement":null},{"id":"W2018799227","doi":"10.1016/j.amjmed.2010.11.003","title":"Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?","year":2010,"lang":"en","type":"review","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Amylin; Context (archaeology); Diabetes mellitus; Type 2 diabetes; Glycemic; Disease; Insulin resistance; Type 2 Diabetes Mellitus; Intensive care medicine; Incretin; Pathophysiology; Internal medicine; Endocrinology; Islet","score_opus":0.08371980857763474,"score_gpt":0.407038822832602,"score_spread":0.3233190142549673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018799227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003470921,0.9837057,0.00009420147,0.011857132,0.0007496492,0.0026114557,0.000027392422,0.000015805346,0.00059157243],"genre_scores_gemma":[0.00008407106,0.9914838,0.0006964223,0.0032404203,0.0020574094,0.00010076237,0.0002068464,0.000078173005,0.0020520752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802524,0.00011965609,0.0008989724,0.00020050898,0.000436462,0.00031913308],"domain_scores_gemma":[0.9958576,0.0010647983,0.0019638715,0.00041306944,0.0005469963,0.00015366955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015129629,0.00037611934,0.0026484902,0.00031052085,0.00007999392,0.000015556447,0.00035318438,0.0000902167,0.00016851793],"category_scores_gemma":[0.00032803704,0.00018138811,0.00048440095,0.00031734435,0.00048131967,0.000053761152,0.00002517354,0.0003891186,0.000025625104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033494295,0.00019017622,0.000002257681,0.0009164532,0.0014296459,0.0000037938166,0.00017267678,1.8474504e-8,0.000017224442,0.00008259357,0.046866816,0.9499834],"study_design_scores_gemma":[0.0037353656,0.015609081,0.0000074828095,0.005731929,0.005876309,0.000027234742,0.000078202924,0.000010059371,0.000032814707,0.00027094028,0.96846604,0.00015450826],"about_ca_topic_score_codex":0.000003413529,"about_ca_topic_score_gemma":2.0598398e-7,"teacher_disagreement_score":0.94982886,"about_ca_system_score_codex":0.000093014016,"about_ca_system_score_gemma":0.0002590202,"threshold_uncertainty_score":0.7396792},"labels":[],"label_agreement":null},{"id":"W2018800952","doi":"10.1139/y03-107","title":"Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2","year":2003,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Proglucagon; Glucagon; Glucagon-like peptide-1; Glucagon-like peptide-2; Secretion; Peptide YY; Peptide hormone; Hormone; Peptide; Biology; Endocrinology; Internal medicine; Chemistry; Biochemistry; Neuropeptide; Receptor; Medicine; Neuropeptide Y receptor; Diabetes mellitus; Type 2 diabetes","score_opus":0.02731563590993351,"score_gpt":0.2976098030777026,"score_spread":0.27029416716776905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018800952","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039618038,0.95706505,0.000008005655,0.0000868096,0.0013190112,0.0007209837,0.000044710305,0.000008561043,0.0011288081],"genre_scores_gemma":[0.019934425,0.97762245,0.0003832074,0.00055002223,0.00025194007,0.000027087168,0.00007648864,0.0000506804,0.0011037114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783623,0.0004247526,0.0007597241,0.0003952333,0.00010033518,0.0004837311],"domain_scores_gemma":[0.99796915,0.00025212852,0.000866962,0.00014858597,0.00012567244,0.00063752214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005365932,0.0004498075,0.0022288568,0.0006785429,0.00016385857,0.00001441776,0.00011510647,0.00039900103,0.00037762432],"category_scores_gemma":[0.000031508043,0.00036617764,0.00024341575,0.00020367836,0.00039928773,0.000094404095,0.000048458733,0.00047587205,0.0000027312728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048019938,0.0003583643,0.0006384666,0.054955628,0.015099803,0.0012235026,0.0014738381,0.000009020328,0.027557937,0.0015446541,0.03125452,0.86540407],"study_design_scores_gemma":[0.002625621,0.0018662506,0.0004999682,0.0035041922,0.008997956,0.0008380148,0.000095337135,0.000012066178,0.0011800837,0.0006816243,0.9792281,0.0004707791],"about_ca_topic_score_codex":0.00017426522,"about_ca_topic_score_gemma":0.00023261024,"teacher_disagreement_score":0.9479736,"about_ca_system_score_codex":0.00012862332,"about_ca_system_score_gemma":0.0007285603,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W2019091650","doi":"10.1016/s1499-2671(08)22010-1","title":"Incretin-based Therapies for Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Bundesministerium für Bildung und Forschung; Canadian Diabetes Association; Canada Foundation for Innovation; U.S. Department of Housing and Urban Development","keywords":"Incretin; Vildagliptin; Medicine; Exenatide; Sitagliptin; Liraglutide; Type 2 diabetes; Internal medicine; Endocrinology; Gastric inhibitory polypeptide; Glucagon-like peptide-1; Gastric emptying; Postprandial; Diabetes mellitus; Pharmacology; Insulin; Glucagon; Stomach","score_opus":0.025637660818081158,"score_gpt":0.24155291065233866,"score_spread":0.2159152498342575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019091650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126977,0.004776954,0.000008412862,0.0020915049,0.00040775316,0.00028974426,0.00001486962,0.000013733574,0.0011272447],"genre_scores_gemma":[0.9953988,0.000021080774,0.0016780954,0.0019482704,0.00026449937,0.00001250457,0.000024333567,0.00003154487,0.00062086544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896896,0.00002402789,0.00028511448,0.000115635856,0.00015024538,0.00045598863],"domain_scores_gemma":[0.998658,0.0001454929,0.00014994072,0.00016721322,0.00033692105,0.000542425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002236126,0.00015902321,0.00038551842,0.00038501614,0.00014591635,0.000024235824,0.00013082309,0.000061644736,0.00017760787],"category_scores_gemma":[0.00021933278,0.00012744374,0.00020029306,0.00019078843,0.00014154498,0.00008818579,0.000004762702,0.000101973885,0.000014537809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014076333,0.00005513434,0.96273017,0.00009724409,0.0005179131,0.000028799805,0.00018371579,0.000013349569,0.000803848,0.00013915448,0.029535472,0.005881121],"study_design_scores_gemma":[0.0070078596,0.005446197,0.6049547,0.000586652,0.0009961114,0.000005443357,0.00020139462,0.00039671158,0.01654358,0.0006512729,0.36267522,0.00053481926],"about_ca_topic_score_codex":0.000044259996,"about_ca_topic_score_gemma":0.00025095834,"teacher_disagreement_score":0.35777542,"about_ca_system_score_codex":0.00012129772,"about_ca_system_score_gemma":0.0008279034,"threshold_uncertainty_score":0.51970047},"labels":[],"label_agreement":null},{"id":"W2019285763","doi":"10.1097/mnh.0000000000000084","title":"Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","year":2014,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Kidney Foundation of Canada","keywords":"Tubuloglomerular feedback; Glomerular hyperfiltration; Macula densa; Medicine; Renal glucose reabsorption; Diabetic nephropathy; Internal medicine; Endocrinology; Renal function; Albuminuria; Renal sodium reabsorption; Diabetes mellitus; Dapagliflozin; Nephropathy; Type 2 diabetes; Kidney; Renin–angiotensin system; Blood pressure; Reabsorption","score_opus":0.048318743857966896,"score_gpt":0.3076721633883372,"score_spread":0.2593534195303703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019285763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043930938,0.9836401,0.0006099778,0.0009377559,0.0025324388,0.007802975,0.00001631031,0.000055446762,0.000011906755],"genre_scores_gemma":[0.003163108,0.9921127,0.000072962794,0.00025371666,0.00070931716,0.0024771877,0.0011337596,0.000058551876,0.000018680139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972019,0.00039944975,0.000956714,0.00074094685,0.00021940032,0.00048157654],"domain_scores_gemma":[0.9989193,0.00016375192,0.0003589903,0.00039141838,0.00007726518,0.0000892841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079687504,0.00051558734,0.0019860624,0.00061100855,0.000108643784,0.000028275334,0.000093784256,0.00043042516,0.000010670491],"category_scores_gemma":[0.000060304796,0.0003344631,0.00041119175,0.0003048465,0.00029693634,0.00008575878,0.000083370636,0.0006088183,0.000017005543],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007299687,0.00049167825,0.000027443939,0.015269406,0.00012276885,0.000013528035,0.00004996145,0.000003413606,0.000033070934,0.0003342891,0.0011767141,0.98174775],"study_design_scores_gemma":[0.012893723,0.0007125964,0.0005412435,0.016323537,0.001572094,0.00010685587,0.000010690421,0.0015923022,0.0000037208058,0.00050166587,0.96540177,0.00033978772],"about_ca_topic_score_codex":0.000017963488,"about_ca_topic_score_gemma":0.000010801383,"teacher_disagreement_score":0.98140794,"about_ca_system_score_codex":0.00013371553,"about_ca_system_score_gemma":0.00008979254,"threshold_uncertainty_score":0.9999107},"labels":[],"label_agreement":null},{"id":"W2019406413","doi":"10.1016/j.diabres.2003.11.018","title":"Effect of carbohydrate source on post-prandial blood glucose in subjects with type 1 diabetes treated with insulin lispro","year":2004,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Insulin lispro; Hypoglycemia; Internal medicine; Glycemic index; Insulin; Endocrinology; Glycemic; Meal; Type 1 diabetes; Diabetes mellitus; Carbohydrate; Type 2 diabetes","score_opus":0.02453509048523186,"score_gpt":0.36861430069504847,"score_spread":0.34407921020981663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019406413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320376,0.0012205187,3.5625854e-7,0.0013736389,0.000032847696,0.0014983527,0.0000069121843,0.000046040917,0.0026175985],"genre_scores_gemma":[0.99826926,0.00070666976,0.00021183111,0.00033653516,0.00009209933,0.00009637577,0.000058878668,0.000048099166,0.00018025939],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99662894,0.0007135299,0.00046976947,0.00061154686,0.0008077425,0.0007684426],"domain_scores_gemma":[0.9931064,0.0053054346,0.00016840677,0.0004670974,0.00057150435,0.00038112202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030005279,0.00029136756,0.0007486681,0.0004613766,0.00009779416,0.00007206925,0.00013838054,0.00016661634,0.000017624521],"category_scores_gemma":[0.0054499167,0.00017914586,0.00006916345,0.001344356,0.00051021634,0.00028183588,0.00009967794,0.0008456798,0.00003804974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029771162,0.008242101,0.91256666,0.0006769569,0.0020982635,0.00056888285,0.0001665777,0.00003836121,0.0035736307,0.00012565097,0.000040934825,0.04213079],"study_design_scores_gemma":[0.080342166,0.483294,0.26201224,0.003198397,0.0030411053,0.0000069672496,0.00046688644,0.00017504318,0.16424079,0.00014504044,0.0022974315,0.0007799047],"about_ca_topic_score_codex":0.00015239861,"about_ca_topic_score_gemma":0.00006070042,"teacher_disagreement_score":0.6505544,"about_ca_system_score_codex":0.000066762856,"about_ca_system_score_gemma":0.00020064546,"threshold_uncertainty_score":0.7305356},"labels":[],"label_agreement":null},{"id":"W2019442960","doi":"10.1016/s1499-2671(09)33184-6","title":"Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Blood pressure; Type 2 diabetes; Quartile; Internal medicine; Diabetes mellitus; Agonist; Endocrinology; Cardiology; Glucagon-like peptide 1 receptor; Receptor","score_opus":0.007457371771681628,"score_gpt":0.20959537339780193,"score_spread":0.2021380016261203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019442960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992575,0.0041548186,1.0015217e-7,0.0006233072,0.00021169877,0.0004451259,0.000019926156,0.000018867506,0.0019511484],"genre_scores_gemma":[0.9981649,0.000008445086,0.00018857712,0.00088969286,0.00015998894,0.000006264371,0.000057294514,0.000034573623,0.00049029215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997941,0.00006920904,0.00060381397,0.000275709,0.00037521828,0.0007350335],"domain_scores_gemma":[0.998101,0.000036541755,0.00039617333,0.00030625265,0.00034779502,0.00081222533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029291605,0.00032153484,0.0007226363,0.0008689081,0.00012336741,0.00008875844,0.00027045238,0.00011836095,0.000071851064],"category_scores_gemma":[0.00012314475,0.00024880192,0.00011872203,0.0006050308,0.00012330741,0.00029560126,0.00001273569,0.00035014123,0.000008074729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023225119,0.00036890781,0.99239534,0.000090248766,0.0009622603,0.00007812586,0.00039810376,0.00006212974,0.00029956017,0.00015538151,0.002714442,0.0024522664],"study_design_scores_gemma":[0.004603561,0.005702814,0.9834077,0.0012397789,0.0013893062,0.0000013239478,0.00010360023,0.000015161951,0.0012249392,0.00016830931,0.0018425504,0.0003009971],"about_ca_topic_score_codex":0.00022456578,"about_ca_topic_score_gemma":0.0023219432,"teacher_disagreement_score":0.008987691,"about_ca_system_score_codex":0.00012712217,"about_ca_system_score_gemma":0.0005195003,"threshold_uncertainty_score":0.9999964},"labels":[],"label_agreement":null},{"id":"W2020035790","doi":"10.1016/j.jcjd.2013.01.030","title":"Vascular Protection in People with Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Endocrinology","score_opus":0.006533416148409044,"score_gpt":0.1801009842414059,"score_spread":0.17356756809299684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020035790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565715,0.00076389784,0.0000059062754,0.0015116124,0.00010831737,0.00055685325,0.0000011964975,0.000008084763,0.0013869926],"genre_scores_gemma":[0.99886775,0.000004880227,0.00031796558,0.00036138235,0.00008742354,0.00005754652,0.0000041709563,0.000021211034,0.00027767805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990161,0.000028744522,0.00024751393,0.00011513408,0.00016913087,0.00042339152],"domain_scores_gemma":[0.9990705,0.000019762116,0.00011137561,0.00015237846,0.00016550891,0.0004804432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018011793,0.00013647169,0.00033085584,0.0005408751,0.000044600096,0.000057093774,0.00008503791,0.000050064173,0.00029844692],"category_scores_gemma":[0.000058189693,0.00009957814,0.00009020961,0.00033176036,0.00004869137,0.00026839654,0.000006009374,0.00016519643,0.000042351854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000014002857,0.000046406538,0.986368,0.00007225139,0.00022017754,0.000011053924,0.00014117874,0.000024388073,0.00039300756,0.000028203778,0.0010456565,0.011648271],"study_design_scores_gemma":[0.0015755418,0.00091112097,0.9913538,0.00036657575,0.0001608981,0.0000011522725,0.00015739487,0.00014676701,0.0010069726,0.00015916774,0.004030973,0.00012961295],"about_ca_topic_score_codex":0.0012107779,"about_ca_topic_score_gemma":0.009829157,"teacher_disagreement_score":0.011518658,"about_ca_system_score_codex":0.00021488915,"about_ca_system_score_gemma":0.0003170178,"threshold_uncertainty_score":0.54849005},"labels":[],"label_agreement":null},{"id":"W2020804579","doi":"10.1016/j.jcjd.2013.08.084","title":"Effects of Canagliflozin Added on to Basal Insulin +/– Other Antihyperglycemic Agents in Type 2 Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Internal medicine; Confidence interval; Basal insulin; Type 2 diabetes; Population; Basal (medicine); Hypoglycemia; Canagliflozin; Gastroenterology; Diabetes mellitus; Endocrinology; Insulin; Urology","score_opus":0.010950686727252742,"score_gpt":0.22650544367252645,"score_spread":0.2155547569452737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020804579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954242,0.0011962665,3.1304003e-7,0.0009675903,0.0004639246,0.00059915555,0.000008706924,0.0000061396236,0.0013336821],"genre_scores_gemma":[0.99596274,0.000016786305,0.0001770671,0.0032980298,0.00011544805,0.000018153736,0.00000521043,0.000037428774,0.00036914708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985678,0.000056512006,0.00043047246,0.00016727444,0.00022562893,0.0005523028],"domain_scores_gemma":[0.9985501,0.00012804894,0.0001601848,0.0002028145,0.0001821658,0.00077665085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001733275,0.00020683749,0.00054751977,0.0009461708,0.000028211889,0.000027005613,0.00019052978,0.000080287966,0.00035890625],"category_scores_gemma":[0.00032070992,0.00017160157,0.00011145663,0.00047904524,0.000053668828,0.00011836202,0.000016558008,0.00017175912,0.00011819961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003095756,0.00021932743,0.93926674,0.00028594752,0.00047997027,0.00006105812,0.0003259832,0.00005523702,0.0061474307,0.00006169625,0.033885214,0.019180411],"study_design_scores_gemma":[0.0032600218,0.0029035204,0.96294206,0.0014288117,0.00021477068,3.1664413e-7,0.00007337942,0.00007285422,0.021960035,0.00014180063,0.0067655207,0.0002369348],"about_ca_topic_score_codex":0.0023953514,"about_ca_topic_score_gemma":0.0038549718,"teacher_disagreement_score":0.027119692,"about_ca_system_score_codex":0.00025199456,"about_ca_system_score_gemma":0.00036281082,"threshold_uncertainty_score":0.69977087},"labels":[],"label_agreement":null},{"id":"W2021257063","doi":"10.2337/diacare.26.1.243","title":"Is Metformin Cardioprotective?","year":2003,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Diabetes mellitus; Pharmacology; Internal medicine; Endocrinology","score_opus":0.033773344971112666,"score_gpt":0.30888272766802627,"score_spread":0.2751093826969136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021257063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025132158,0.9567191,0.0000011463937,0.000010883325,0.00032792657,0.0025846532,0.00018055513,0.00011765518,0.04003295],"genre_scores_gemma":[0.000011220978,0.99223554,0.0002876329,0.00026374293,0.00017015642,0.001042571,0.00068070187,0.00012487163,0.0051835864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803424,0.00007066682,0.000393551,0.0006125254,0.00033910602,0.00054991624],"domain_scores_gemma":[0.99867064,0.000043893997,0.00017357062,0.00081658585,0.0001145214,0.00018080369],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010487119,0.00062770233,0.0025178175,0.0003137511,0.00007071562,0.000042233358,0.0001583984,0.00032497168,0.00027694076],"category_scores_gemma":[0.000026816511,0.00046841282,0.0014449655,0.0004087222,0.00004658156,0.000058195677,0.00009274045,0.0003093108,0.001907798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.3859794e-7,0.000036007128,0.00043482875,0.03621861,0.0017495024,0.000029033095,0.000084241314,1.4792901e-8,6.211032e-8,0.00003556447,0.0056144446,0.95579684],"study_design_scores_gemma":[0.0004132217,0.00020511009,0.000018234274,0.00885419,0.008893406,0.000002846825,0.00010999612,2.0020943e-7,0.000021732785,0.000015398613,0.9810679,0.00039775507],"about_ca_topic_score_codex":0.0000018430353,"about_ca_topic_score_gemma":3.8890443e-7,"teacher_disagreement_score":0.97545344,"about_ca_system_score_codex":0.00043292862,"about_ca_system_score_gemma":0.00014896748,"threshold_uncertainty_score":0.9997768},"labels":[],"label_agreement":null},{"id":"W2022389605","doi":"10.2337/dc11-0986","title":"Incretin-Based Therapy and the Quest for Sustained Improvements in β-Cell Health","year":2011,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Medicine; Type 2 diabetes; Liraglutide; Internal medicine; Insulin; Endocrinology; Vildagliptin; Glucagon-like peptide-1; Diabetes mellitus; Pharmacology","score_opus":0.013343558101556328,"score_gpt":0.24401480378708407,"score_spread":0.23067124568552774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022389605","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17659397,0.027996356,0.000010480684,0.76581454,0.0007910988,0.021468174,0.0005735449,0.00023309057,0.00651873],"genre_scores_gemma":[0.096110664,0.0004687786,0.00033586417,0.8935138,0.0007066467,0.002240119,0.004423265,0.00013673544,0.0020641172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815655,0.00012027519,0.00034385428,0.00048332327,0.00022419624,0.00067182846],"domain_scores_gemma":[0.9988619,0.00023468696,0.00021632122,0.0004996209,0.00011680002,0.00007066487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032984474,0.00040016818,0.00077132706,0.00021707067,0.0000861804,0.00004493837,0.00016804917,0.000255594,0.000026982223],"category_scores_gemma":[0.000028458173,0.0002564044,0.00019351678,0.00010813634,0.00013340259,0.000030617543,0.000057378962,0.00043541286,0.000009670965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000514637,0.00021161584,0.11381857,0.0077020335,0.0004524888,0.00003878923,0.00197145,2.9121787e-7,0.000018771487,0.000118364216,0.82655257,0.04860039],"study_design_scores_gemma":[0.030632246,0.0021929254,0.005205285,0.00055890664,0.00032023518,7.358385e-8,0.0007738725,0.00008021403,0.0005878287,0.00022165527,0.9589804,0.0004463715],"about_ca_topic_score_codex":0.00015197422,"about_ca_topic_score_gemma":0.000024913186,"teacher_disagreement_score":0.13242778,"about_ca_system_score_codex":0.00022319763,"about_ca_system_score_gemma":0.00017294816,"threshold_uncertainty_score":0.9999888},"labels":[],"label_agreement":null},{"id":"W2022788684","doi":"10.1210/en.2010-1352","title":"Essential Role for Protein Kinase Cζ in Oleic Acid-Induced Glucagon-Like Peptide-1 Secretion in Vivo in the Rat","year":2011,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Secretion; Internal medicine; Oleic acid; Protein kinase C; Endocrinology; In vivo; Glucagon-like peptide-1; Stimulation; Chemistry; Ileum; Ingestion; Gastric acid; Biology; Kinase; Medicine; Biochemistry","score_opus":0.023980171425555082,"score_gpt":0.26460778403330054,"score_spread":0.24062761260774546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022788684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114627,0.00015302107,0.000033224682,0.0008591846,0.00020686195,0.0022129882,0.0000019854979,0.000032855274,0.0053535923],"genre_scores_gemma":[0.9970452,0.00002137107,0.0002928623,0.00033399707,0.00006512857,0.0013546931,0.00002750903,0.000017254657,0.0008419423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869365,0.000108487446,0.00027427368,0.0003073376,0.000103385006,0.0005128482],"domain_scores_gemma":[0.9995685,0.000029280518,0.000059074857,0.00029058888,0.0000184568,0.000034099045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001588302,0.00016455606,0.0002779962,0.00032848242,0.000025276755,0.000008289659,0.00014530774,0.00007386227,0.00013532868],"category_scores_gemma":[0.00004599765,0.00012637899,0.000064028616,0.00021196203,0.00004288636,0.00007748384,0.00006313665,0.00017762376,0.00003446614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035327186,0.006031281,0.15199459,0.0005101724,0.0002638998,0.0029960417,0.015503058,0.000009665585,0.73011786,0.037458103,0.0021797179,0.049402915],"study_design_scores_gemma":[0.027336499,0.0038196084,0.14276358,0.00033855852,0.00022388344,0.000050033646,0.005598265,0.000461583,0.784083,0.0061841384,0.028517492,0.0006233205],"about_ca_topic_score_codex":0.00052677066,"about_ca_topic_score_gemma":0.002030521,"teacher_disagreement_score":0.05396519,"about_ca_system_score_codex":0.000099402365,"about_ca_system_score_gemma":0.00003672541,"threshold_uncertainty_score":0.5153585},"labels":[],"label_agreement":null},{"id":"W2023231007","doi":"10.1016/j.jcjd.2013.08.126","title":"Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1)","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Exenatide; Dulaglutide; Placebo; Type 2 diabetes; Incidence (geometry); Metformin; Internal medicine; Gastroenterology; Randomized controlled trial; Adverse effect; Diabetes mellitus; Endocrinology; Insulin","score_opus":0.011140817719087566,"score_gpt":0.2225710513030658,"score_spread":0.21143023358397822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023231007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176234,0.005110696,2.6737652e-7,0.0011652383,0.00023196635,0.00033678932,0.0000052236996,0.0000041777485,0.0013833146],"genre_scores_gemma":[0.99912554,0.00015095819,0.00034256108,0.00015680729,0.00005147298,0.0000046364858,0.000005504697,0.000016781445,0.00014573117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897957,0.000036575533,0.000367859,0.000126679,0.00012808407,0.00036123645],"domain_scores_gemma":[0.9988258,0.00023688396,0.0001493782,0.00012836163,0.00012763264,0.0005319517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023730361,0.00014742764,0.00043267442,0.00044140755,0.00003739433,0.000029481087,0.00007587822,0.000057616828,0.000110502726],"category_scores_gemma":[0.00031918587,0.00012364288,0.000046609417,0.00018705399,0.00014838121,0.00017105794,0.00002068802,0.00013579728,0.000005958656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008409897,0.00005349219,0.95715505,0.00016071153,0.0004174248,0.000020638092,0.0002858449,0.00001102388,0.00079853355,0.00021274078,0.0024364125,0.038364],"study_design_scores_gemma":[0.009479516,0.0011900354,0.9824502,0.0005193085,0.0002543658,0.0000012332963,0.00021694803,0.00008983117,0.0013017928,0.00017476051,0.0041707186,0.00015132512],"about_ca_topic_score_codex":0.0003987447,"about_ca_topic_score_gemma":0.0013984129,"teacher_disagreement_score":0.038212676,"about_ca_system_score_codex":0.00010168093,"about_ca_system_score_gemma":0.0002039416,"threshold_uncertainty_score":0.504201},"labels":[],"label_agreement":null},{"id":"W2023859994","doi":"10.1007/s13300-012-0013-8","title":"Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)","year":2012,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"F. Hoffmann-La Roche","keywords":"Sitagliptin; Medicine; Placebo; Metformin; Internal medicine; Sitagliptin Phosphate; Clinical endpoint; Gastroenterology; Diabetes mellitus; Type 2 diabetes; Randomized controlled trial; Endocrinology","score_opus":0.043983561132298676,"score_gpt":0.3092227144635877,"score_spread":0.265239153331289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023859994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97340167,0.022046905,0.000006574674,0.00028792914,0.0008951866,0.0021315669,0.000024531388,0.0000624089,0.0011432446],"genre_scores_gemma":[0.9947937,0.0028253603,0.0009601597,0.00026565546,0.0003658825,0.00015776427,0.00013986629,0.000050774375,0.00044085065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985336,0.000047562327,0.00035786413,0.00025179095,0.00019503753,0.0006141401],"domain_scores_gemma":[0.99874187,0.0004757889,0.00014057416,0.00036419553,0.000086911314,0.00019066704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044793397,0.000258314,0.0005708796,0.00012349442,0.000072342074,0.000013418504,0.000092521834,0.00009089933,0.00017339046],"category_scores_gemma":[0.00012251972,0.00020583412,0.00015756059,0.00020157734,0.000094621006,0.00013195621,0.00003970172,0.00006902263,0.000023870138],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11958282,0.0049767387,0.14186403,0.00064687966,0.0062407926,0.0000012964133,0.0012161137,0.0000044814137,0.031159041,0.005908486,0.0067026187,0.6816967],"study_design_scores_gemma":[0.37478453,0.017236475,0.108930305,0.00024729938,0.0016186445,1.2816184e-7,0.00019485442,0.00012534343,0.104655504,0.0003073143,0.3910507,0.00084891584],"about_ca_topic_score_codex":0.0000020854457,"about_ca_topic_score_gemma":6.0112774e-7,"teacher_disagreement_score":0.68084776,"about_ca_system_score_codex":0.000042580068,"about_ca_system_score_gemma":0.00002092542,"threshold_uncertainty_score":0.83936715},"labels":[],"label_agreement":null},{"id":"W2023984564","doi":"10.1007/s00125-014-3460-0","title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":690,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Lilly Deutschland; Servier; Université de Nantes; Intarcia Therapeutics; Uniwersytet Łódzki; School of Medicine, University of Kansas; University of Ioannina; University of Sydney; School of Medicine, Case Western Reserve University; F. Hoffmann-La Roche; Yale University; University of Toronto; Lee Kong Chian School of Medicine, Nanyang Technological University; Eli Lilly and Company; Kaiser Permanente; Massachusetts General Hospital; Case Western Reserve University; Sanofi; European Association for the Study of Diabetes; Novo Nordisk; National Institute for Health and Care Research; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb","keywords":"Position statement; Diabetes mellitus; Medicine; Association (psychology); Human physiology; Type 2 diabetes; Internal medicine; Type 1 diabetes; Statement (logic); Endocrinology; Family medicine; Psychology; Political science","score_opus":0.015050648903565018,"score_gpt":0.2439640759964109,"score_spread":0.22891342709284587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023984564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928328,0.0007798543,0.0000041592107,0.0017293317,0.00017263403,0.003901387,0.000039336795,0.000018320721,0.00052217575],"genre_scores_gemma":[0.9988418,0.00007242098,0.0002730912,0.0002731755,0.000019416877,0.00032167614,0.000054364235,0.0000224584,0.0001215457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975569,0.00058705744,0.0006355202,0.0002788533,0.0005529336,0.00038871562],"domain_scores_gemma":[0.9978258,0.00039004534,0.0010032911,0.0004333085,0.000287634,0.00005992328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001638828,0.00020273485,0.00063032034,0.000119163255,0.00006189356,0.000021721838,0.00023616826,0.000036645855,0.0000016988183],"category_scores_gemma":[0.0003307266,0.00011000279,0.00010380118,0.0006296534,0.000101280915,0.00006418012,0.00026309647,0.00010050858,0.0000020972673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020432545,0.0013303806,0.9767626,0.00017285175,0.0016763463,4.6797774e-7,0.0024757192,0.00018645613,0.00026039314,0.00021865946,0.0027234054,0.013988406],"study_design_scores_gemma":[0.008560237,0.0022081682,0.9754124,0.00015976162,0.0017969888,2.2541858e-8,0.007649128,0.00091162464,0.0020935137,0.00020684897,0.00082591403,0.00017533725],"about_ca_topic_score_codex":0.00004268709,"about_ca_topic_score_gemma":0.000019833959,"teacher_disagreement_score":0.013813069,"about_ca_system_score_codex":0.00034074998,"about_ca_system_score_gemma":0.000023296363,"threshold_uncertainty_score":0.44857833},"labels":[],"label_agreement":null},{"id":"W2024196604","doi":"10.2165/00003495-200363200-00003","title":"Dual ACE and Neutral Endopeptidase Inhibitors","year":2003,"lang":"en","type":"review","venue":"Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Blood pressure; Internal medicine; Cardiology; Heart failure; ACE inhibitor; Neprilysin; Bradykinin; Angiotensin-converting enzyme; Population; Aldosterone","score_opus":0.026725863270189346,"score_gpt":0.30546557313898653,"score_spread":0.2787397098687972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024196604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001561606,0.96861833,2.4807994e-7,0.00006719757,0.00025287137,0.00097085553,0.000012966082,0.00005491074,0.029866477],"genre_scores_gemma":[0.00002087723,0.9750918,0.00013574977,0.00017160768,0.00021943655,0.00010134806,0.00017382568,0.00004648886,0.024038857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895245,0.00004537926,0.00026463968,0.00033570913,0.00013098739,0.00027084866],"domain_scores_gemma":[0.9994095,0.00004332346,0.00009838581,0.00027188536,0.000014483052,0.00016239696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010772835,0.00033145302,0.0010146756,0.00014347766,0.000036811438,0.00003169104,0.00004052928,0.00012680788,0.00007765545],"category_scores_gemma":[0.000009747811,0.00023902151,0.00025295437,0.00014512271,0.000048795315,0.00004326305,0.00006474958,0.00017829343,0.00022328187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023520702,0.00008935616,0.00000820126,0.0077084806,0.0002962848,0.00011636943,0.00006075854,8.757241e-9,9.3706284e-8,0.00051552523,0.018222038,0.97298056],"study_design_scores_gemma":[0.000606324,0.00010150751,0.000002898805,0.0041680643,0.002337263,0.000027125983,0.00002922588,1.5022766e-7,0.000003879327,0.000009381313,0.99252576,0.00018845196],"about_ca_topic_score_codex":0.0000060642647,"about_ca_topic_score_gemma":7.8519577e-7,"teacher_disagreement_score":0.97430366,"about_ca_system_score_codex":0.00008586433,"about_ca_system_score_gemma":0.00006740256,"threshold_uncertainty_score":0.97470146},"labels":[],"label_agreement":null},{"id":"W2024585422","doi":"10.1053/jpsu.2001.22952","title":"Systemic GLP-2 levels do not limit adaptation after distal intestinal resection","year":2001,"lang":"en","type":"article","venue":"Journal of Pediatric Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cecum; Ileum; Jejunum; Medicine; Short bowel syndrome; Gastroenterology; Small intestine; Internal medicine; Weight loss; Endocrinology; Parenteral nutrition; Obesity","score_opus":0.04716794759431744,"score_gpt":0.26449260394465063,"score_spread":0.21732465635033318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024585422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948894,0.001829946,0.00094749714,0.0003645954,0.0012212602,0.00014205907,0.000002464311,0.000022456341,0.0005803373],"genre_scores_gemma":[0.99320376,0.0010197704,0.00031263175,0.000099751334,0.004422153,0.000009957653,0.0000052006444,0.000018708728,0.0009080481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846977,0.000061661005,0.0006202922,0.00013115912,0.0004942942,0.0002228451],"domain_scores_gemma":[0.9986449,0.00036196833,0.0004559265,0.00012888391,0.00026061252,0.00014774979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007269633,0.00013876487,0.00035563702,0.00059635367,0.00003740358,0.00004198269,0.000046124398,0.000057474128,0.00016210327],"category_scores_gemma":[0.00035874703,0.00010806626,0.0002729551,0.00039317226,0.000015323429,0.0002651689,0.000021745424,0.00017426028,0.00004355705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002371065,0.0004758993,0.92214364,0.00028542263,0.0002585263,0.0024742826,0.0002528825,0.000058657468,0.0002303237,0.00001549091,0.02498389,0.046449926],"study_design_scores_gemma":[0.0034043877,0.0015501324,0.97832626,0.00074711087,0.0029270244,0.0021780445,0.0009116831,0.0002855422,0.00029384063,0.000119663346,0.008805934,0.00045036193],"about_ca_topic_score_codex":0.000007666973,"about_ca_topic_score_gemma":0.0000026355804,"teacher_disagreement_score":0.05618264,"about_ca_system_score_codex":0.00020048498,"about_ca_system_score_gemma":0.00013846678,"threshold_uncertainty_score":0.44068143},"labels":[],"label_agreement":null},{"id":"W2025841294","doi":"10.1210/en.2010-1098","title":"Differential Effects of PPAR-γ Activation versus Chemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice","year":2010,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; University of Toronto","keywords":"Sitagliptin; Pioglitazone; Internal medicine; Endocrinology; Ovariectomized rat; Dipeptidyl peptidase-4; Bone mineral; Thiazolidinedione; Osteoporosis; Rosiglitazone; Bone density; Bone remodeling; Chemistry; Medicine; Diabetes mellitus; Type 2 diabetes; Estrogen","score_opus":0.02150080483153897,"score_gpt":0.31083906780632975,"score_spread":0.28933826297479076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025841294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982091,0.0000070862066,0.000027500862,0.00022449394,0.000574836,0.00036265215,0.0000011413887,0.000019227962,0.0005739184],"genre_scores_gemma":[0.99941117,0.000018691655,0.0002863932,0.000008591492,0.00008026683,0.00003553929,0.000011834286,0.000007699819,0.00013982128],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999279,0.000050664927,0.00018659492,0.0001886993,0.000116036,0.00017900183],"domain_scores_gemma":[0.9994527,0.00017702804,0.00011822528,0.00019731952,0.00002470176,0.000030015919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002377492,0.00009833932,0.000303032,0.00012950465,0.000008874403,0.0000013259857,0.00004234615,0.00007158411,0.0000720162],"category_scores_gemma":[0.00017420507,0.00008081645,0.00005060066,0.00009473767,0.00008554971,0.000028880311,0.00003733282,0.00016899363,0.0000047672193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035403643,0.001043811,0.0018841531,0.00019320156,0.00009267773,0.0000100237985,0.00006183733,7.4499536e-7,0.95849234,0.0006340981,0.000040528153,0.034006238],"study_design_scores_gemma":[0.004615922,0.0007783928,0.16538632,0.00002680477,0.00007465759,0.0000028866486,0.00001345133,0.000009403377,0.82894397,0.000035867477,0.0000641852,0.000048168626],"about_ca_topic_score_codex":0.00012275483,"about_ca_topic_score_gemma":0.000024882744,"teacher_disagreement_score":0.16350216,"about_ca_system_score_codex":0.000046636298,"about_ca_system_score_gemma":0.000020617088,"threshold_uncertainty_score":0.32955992},"labels":[],"label_agreement":null},{"id":"W2026462475","doi":"10.1016/j.regpep.2008.07.006","title":"Expression of PCSK1 (PC1/3), PCSK2 (PC2) and PCSK3 (furin) in mouse small intestine","year":2008,"lang":"en","type":"article","venue":"Regulatory Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Furin; Kexin; Cholecystokinin; Proteases; Prohormone; Biology; Prohormone convertase; Ileum; Jejunum; Serine; Proprotein Convertases; Subtilisin; Hormone; Proteolysis; Peptide hormone; Internal medicine; Molecular biology; Endocrinology; Biochemistry; Enzyme; Receptor","score_opus":0.02661325875567388,"score_gpt":0.23166801522828526,"score_spread":0.20505475647261137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026462475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570054,0.0009180124,0.0000105513545,0.00011976601,0.000034057863,0.00036577263,0.0000032308453,0.00006995291,0.002778124],"genre_scores_gemma":[0.9881741,0.000206011,0.0023212912,0.000094894094,0.00005278366,0.000027599139,0.000016807515,0.000026762275,0.009079761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895304,0.000029632209,0.0003106164,0.0002812374,0.00019039013,0.00023505594],"domain_scores_gemma":[0.9993265,0.00005353198,0.000097354234,0.00035624593,0.00004468308,0.00012163268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013626931,0.00018471702,0.00037188063,0.00021914691,0.00004224603,0.0000057509183,0.00007008277,0.000067355635,0.000051386214],"category_scores_gemma":[0.000056574707,0.00015325178,0.000068619054,0.00012727577,0.00015015375,0.000094060546,0.00010504888,0.000090949914,0.000014636775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027972722,0.0009257158,0.7430838,0.00058416155,0.000095183575,0.0002022396,0.0009850728,0.000027653914,0.2424854,0.0007936973,0.0038941316,0.006643243],"study_design_scores_gemma":[0.0031099143,0.00047400186,0.7785821,0.00062964205,0.00007557558,0.00003549434,0.0002103026,0.00009004001,0.21359016,0.00014353165,0.0028405904,0.00021866703],"about_ca_topic_score_codex":0.000032131575,"about_ca_topic_score_gemma":0.000024034376,"teacher_disagreement_score":0.03549832,"about_ca_system_score_codex":0.000056053763,"about_ca_system_score_gemma":0.000032446675,"threshold_uncertainty_score":0.62494266},"labels":[],"label_agreement":null},{"id":"W2026963340","doi":"10.2337/dc14-1850","title":"Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; University of Toronto","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Saxagliptin; Internal medicine; Renal function; Alogliptin; TIMI; Type 2 diabetes; Myocardial infarction; Hazard ratio; Diabetes mellitus; Heart failure; Glycemic; Cardiology; Endocrinology; Percutaneous coronary intervention; Sitagliptin; Confidence interval; Insulin","score_opus":0.013150647895497905,"score_gpt":0.20561426102808417,"score_spread":0.19246361313258625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026963340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997116,0.00092375197,0.0000014415837,0.0002498461,0.00011454585,0.0012970107,0.000090852605,0.000044627857,0.00016192325],"genre_scores_gemma":[0.99801075,0.00004321878,0.00041082277,0.0006809742,0.00008364113,0.00011771709,0.00051121344,0.000031902724,0.00010972623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986649,0.000098610944,0.0002158161,0.0003797937,0.00030804359,0.00033282858],"domain_scores_gemma":[0.999068,0.00021882236,0.000059260856,0.00044859026,0.00010428915,0.000100995734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015783687,0.0002552388,0.0005714247,0.00006552405,0.000119200085,0.0000815766,0.00008184429,0.0000699221,0.000024042576],"category_scores_gemma":[0.00011258015,0.00014232703,0.00009348525,0.00016778702,0.000073347685,0.00013444929,0.000098838216,0.000113310496,0.0000072710404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000907053,0.00012591672,0.9886004,0.000052320647,0.0009108532,0.0000014352878,0.00059995573,0.000041063184,0.000004816114,0.000013514757,0.00031656664,0.008426127],"study_design_scores_gemma":[0.03278018,0.0014147108,0.9623864,0.00015746822,0.0007940678,2.9668579e-8,0.00029598564,0.00027028643,0.000044681074,0.0000547305,0.00159896,0.00020244578],"about_ca_topic_score_codex":0.00003438657,"about_ca_topic_score_gemma":0.00006747437,"teacher_disagreement_score":0.031873126,"about_ca_system_score_codex":0.000048785434,"about_ca_system_score_gemma":0.000028275583,"threshold_uncertainty_score":0.5803928},"labels":[],"label_agreement":null},{"id":"W2027744617","doi":"10.1038/clpt.2010.184","title":"Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1","year":2010,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Metformin; Incretin; Glucagon-like peptide-1; In vivo; Dipeptidyl peptidase; Endocrinology; Internal medicine; Chemistry; Glucagon; Pharmacology; Dipeptidyl peptidase-4; Pharmacokinetics; Small intestine; Type 2 diabetes; Diabetes mellitus; Hormone; Medicine; Biology; Biochemistry; Enzyme","score_opus":0.05141449335925543,"score_gpt":0.39199612142172,"score_spread":0.3405816280624646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027744617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953278,0.000018251505,0.0000022173185,0.0020844333,0.00026517524,0.0014294175,0.000022593349,0.000014586072,0.00083557796],"genre_scores_gemma":[0.99482995,0.000109603105,0.00020042597,0.004389615,0.000104402694,0.00014359993,0.00016911745,0.000015370195,0.00003794019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809486,0.0004931544,0.0006585059,0.00029634152,0.00020006437,0.00025706715],"domain_scores_gemma":[0.9984033,0.0009574752,0.0002553667,0.00020300191,0.000099383105,0.000081446786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092972734,0.00017465885,0.00040641875,0.00015620442,0.000026066571,0.000009467488,0.00015181513,0.000187276,0.00005904083],"category_scores_gemma":[0.000049998587,0.000120762474,0.00005955192,0.00035338377,0.00038625265,0.00017840196,0.000031157164,0.0006861844,0.0000049016708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03152618,0.03347486,0.66699594,0.00011160778,0.0010695013,0.0006790124,0.014366735,0.000029678631,0.045400023,0.0007705381,0.0014103986,0.20416553],"study_design_scores_gemma":[0.052457437,0.010519946,0.8837592,0.00016420743,0.0011393268,0.000008980938,0.0039424086,0.003322537,0.03786656,0.00029302647,0.006180514,0.00034587947],"about_ca_topic_score_codex":0.000034763147,"about_ca_topic_score_gemma":0.0009543792,"teacher_disagreement_score":0.21676324,"about_ca_system_score_codex":0.00007537122,"about_ca_system_score_gemma":0.00013959258,"threshold_uncertainty_score":0.49245507},"labels":[],"label_agreement":null},{"id":"W2027913824","doi":"10.1111/j.1365-2982.2009.01430.x","title":"Glucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons","year":2010,"lang":"en","type":"article","venue":"Neurogastroenterology & Motility","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Nodose Ganglion; Rheobase; Depolarization; Potassium channel; Chemistry; Membrane potential; Internal medicine; Endocrinology; Biophysics; Extracellular; Patch clamp; Voltage clamp; Neuroscience; Receptor; Electrophysiology; Biology; Vagus nerve; Medicine; Biochemistry","score_opus":0.011902896218401628,"score_gpt":0.2519155427753948,"score_spread":0.24001264655699317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027913824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955172,0.00001181194,0.000030469557,0.0011910262,0.0014855488,0.0009085188,0.00004287031,0.00022984941,0.0005827026],"genre_scores_gemma":[0.9963306,0.000016102418,0.00012395527,0.0023223963,0.00009342582,0.00004991399,0.00017411921,0.00004905652,0.0008404079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972874,0.00015976731,0.0005265077,0.00085257465,0.00029828632,0.0008754985],"domain_scores_gemma":[0.9985411,0.000044230866,0.00015019727,0.000850157,0.000091479626,0.00032284603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022261911,0.00040570638,0.0005456262,0.00034982775,0.00007907156,0.00003064497,0.00024334024,0.00016587833,0.00016662636],"category_scores_gemma":[0.0001339353,0.0003866621,0.00018907095,0.00024855498,0.00023652597,0.00019829365,0.0002864186,0.0009485091,0.00015241098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018010262,0.002440578,0.9490541,0.0000600798,0.00006834463,0.0002854871,0.00009554026,0.000008607074,0.04351894,0.000014004186,0.0016915272,0.00258264],"study_design_scores_gemma":[0.005441409,0.0012373287,0.9831081,0.000021361931,0.00014357641,0.000038315204,0.000019439743,0.000457787,0.0045970865,0.000015464708,0.0048647826,0.000055343062],"about_ca_topic_score_codex":0.00006697148,"about_ca_topic_score_gemma":0.0005695567,"teacher_disagreement_score":0.038921855,"about_ca_system_score_codex":0.00006719391,"about_ca_system_score_gemma":0.000031356754,"threshold_uncertainty_score":0.99985856},"labels":[],"label_agreement":null},{"id":"W2028275376","doi":"10.1016/j.regpep.2009.04.009","title":"Molecular evolution of mammalian incretin hormone genes","year":2009,"lang":"en","type":"article","venue":"Regulatory Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs","funders":"","keywords":"Proglucagon; Biology; Incretin; Gene; Conserved sequence; Genome; Molecular evolution; Prohormone convertase; Intron; Genetics; Glucagon-like peptide-2; Lineage (genetic); Evolution of mammals; Evolutionary biology; Glucagon-like peptide-1; Hormone; Peptide sequence; Peptide; Endocrinology; Prohormone; Biochemistry","score_opus":0.0076138432862280295,"score_gpt":0.22803895116440123,"score_spread":0.2204251078781732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028275376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884624,0.0044918708,0.000098251534,0.0004003812,0.000023570954,0.0002494517,0.0000017955676,0.00006231516,0.005826127],"genre_scores_gemma":[0.99708474,0.00004172092,0.0012461842,0.00013170541,0.000053767526,0.000006437096,0.000017922599,0.000011084905,0.0014064682],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999247,0.00001928097,0.00018282488,0.00016431259,0.00021638448,0.00017020523],"domain_scores_gemma":[0.9995135,0.000005776576,0.000057446934,0.00029870748,0.00004817194,0.00007637865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001089359,0.000115865456,0.00021308246,0.00011751535,0.000025495681,0.0000058287164,0.00005360879,0.00004939082,0.000030449311],"category_scores_gemma":[0.000011397415,0.0001023913,0.000104918574,0.0001184485,0.000054901135,0.000055212015,0.000018888928,0.00003454317,0.00002834607],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020908244,0.00048498434,0.025826298,0.00013813062,0.00025369815,0.00008045802,0.00010512551,0.00011909976,0.8874097,0.029388852,0.0054604537,0.050524153],"study_design_scores_gemma":[0.0012972376,0.0008511202,0.88712436,0.000094974464,0.00028375402,0.0000058768596,0.000101300764,0.00012825106,0.10408982,0.0011686592,0.0047013727,0.00015327649],"about_ca_topic_score_codex":0.000012601013,"about_ca_topic_score_gemma":0.0000011396747,"teacher_disagreement_score":0.8612981,"about_ca_system_score_codex":0.000097802214,"about_ca_system_score_gemma":0.00002594255,"threshold_uncertainty_score":0.4175396},"labels":[],"label_agreement":null},{"id":"W2028502361","doi":"10.1038/nm.3761","title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","year":2014,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":627,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Diabetes mellitus; Obesity; Medicine; Peptide; Endocrinology; Internal medicine; Chemistry; Biochemistry","score_opus":0.006621690652211054,"score_gpt":0.24741482314629068,"score_spread":0.24079313249407963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028502361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359793,0.0019037221,0.00009736166,0.0041419636,0.0003593271,0.0006617376,0.0000011563308,0.000055805936,0.009181021],"genre_scores_gemma":[0.99321926,0.00010919418,0.00057427963,0.0028130407,0.00029426257,0.000046349425,0.000096447766,0.000017016248,0.0028301456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880046,0.00006489794,0.00024332189,0.00031424614,0.00031896232,0.00025813008],"domain_scores_gemma":[0.99929553,0.00020263396,0.000080718004,0.00021575736,0.00005821587,0.0001471137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005000365,0.00019151799,0.00047247662,0.00024307064,0.000052457246,0.000012863791,0.00007159327,0.000138391,0.00008029356],"category_scores_gemma":[0.0005329995,0.00013865637,0.00003577252,0.00028908174,0.00009811438,0.00006818439,0.000037482692,0.0002851922,0.000016027254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002810879,0.00050716335,0.9415268,0.00025693898,0.00019521633,0.000048392933,0.00029334342,0.000005416992,0.0054704486,0.0015996008,0.015368827,0.034446806],"study_design_scores_gemma":[0.010292113,0.0012545392,0.9670729,0.00044634732,0.0003068444,0.0000041372355,0.00007600619,0.001405202,0.0012190179,0.00058547367,0.017146502,0.00019091577],"about_ca_topic_score_codex":0.000026955684,"about_ca_topic_score_gemma":0.000052571133,"teacher_disagreement_score":0.034255892,"about_ca_system_score_codex":0.00008174332,"about_ca_system_score_gemma":0.000026430167,"threshold_uncertainty_score":0.56542426},"labels":[],"label_agreement":null},{"id":"W202882061","doi":"10.1161/circ.124.suppl_21.a9520","title":"Abstract 9520: Dapagliflozin, a Novel Antihyperglycemic Agent that Promotes Urinary Glucose Excretion, Reduces Systolic Blood Pressure in Patients with Type 2 Diabetes Mellitus","year":2011,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dapagliflozin; Medicine; Type 2 Diabetes Mellitus; Blood pressure; Diabetes mellitus; Excretion; Urinary system; Internal medicine; Endocrinology; Type 2 diabetes; Cardiology","score_opus":0.024058682256728345,"score_gpt":0.22013360689839834,"score_spread":0.19607492464166998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W202882061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952375,0.0021060647,0.000007637979,0.000022702576,0.00013926548,0.0012123691,0.000006930804,0.000091359245,0.0011761482],"genre_scores_gemma":[0.9990583,0.000074496136,0.00031719892,0.00003262292,0.00004512811,0.000059499678,0.00032678383,0.000034614488,0.00005137651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877393,0.000020406258,0.0002448911,0.00036845673,0.0003038364,0.00028849466],"domain_scores_gemma":[0.99930257,0.000015892176,0.00015130428,0.0003189047,0.00012192934,0.00008941081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107817774,0.00021567891,0.00027480948,0.00020031813,0.00005387838,0.000022405357,0.00007821865,0.00009124133,0.00009969229],"category_scores_gemma":[0.000023731407,0.00017458496,0.00004893045,0.0002498868,0.000045093966,0.00025117493,0.000031089407,0.00009538836,0.000029334919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003011926,0.0027978732,0.9876499,0.00036417873,0.000585196,0.000018804725,0.0007646449,0.000032138927,0.0051067765,0.00006729264,0.00002654707,0.002285409],"study_design_scores_gemma":[0.0031587125,0.00060164125,0.98840636,0.00040137928,0.000796879,0.0000020342777,0.0000405601,0.00014602915,0.0061086905,0.00004099538,0.00010390439,0.00019283475],"about_ca_topic_score_codex":0.000024290975,"about_ca_topic_score_gemma":0.0000021208493,"teacher_disagreement_score":0.0038207576,"about_ca_system_score_codex":0.000047699235,"about_ca_system_score_gemma":0.000034882676,"threshold_uncertainty_score":0.71193683},"labels":[],"label_agreement":null},{"id":"W2029071587","doi":"10.1210/er.2011-1052","title":"Cardiovascular Biology of the Incretin System","year":2012,"lang":"en","type":"review","venue":"Endocrine Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Incretin; Medicine; Diabetes mellitus; Internal medicine; Hypoglycemia; Endocrinology; Type 2 diabetes; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Type 2 Diabetes Mellitus","score_opus":0.07285654113482347,"score_gpt":0.3371539108247551,"score_spread":0.2642973696899316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029071587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.5235967e-7,0.97529954,0.000008211749,0.000019189834,0.00054922624,0.0042080674,0.00001535917,0.0000368359,0.019863032],"genre_scores_gemma":[0.000013952188,0.99630016,0.00020364809,0.000020869536,0.00043799783,0.000648942,0.00010744665,0.00004744762,0.0022195554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997502,0.00065269385,0.0009894938,0.00031400254,0.00018667046,0.0003551275],"domain_scores_gemma":[0.99766505,0.000058762056,0.0005388664,0.0016157696,0.000032802684,0.00008873271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074026006,0.00043616837,0.0047553894,0.00011483888,0.000032080156,0.000004719283,0.00030619706,0.00008676363,0.00009032853],"category_scores_gemma":[0.000082095874,0.00020191894,0.0037374925,0.0003543258,0.0000627249,0.000020048627,0.00029411173,0.00022541595,0.0004838942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[6.964409e-7,0.000035124103,0.000026824726,0.11356159,0.0014786834,0.000005563441,0.0000034068014,6.576193e-9,5.8949215e-8,0.0010193306,0.0009473285,0.8829214],"study_design_scores_gemma":[0.00021814408,0.00003971018,0.0000039424644,0.029159242,0.022742355,0.00008419138,0.00000297146,6.761523e-8,0.0000020175232,0.0000010255171,0.9476081,0.0001381978],"about_ca_topic_score_codex":0.00002808143,"about_ca_topic_score_gemma":6.023633e-7,"teacher_disagreement_score":0.9466608,"about_ca_system_score_codex":0.00015906642,"about_ca_system_score_gemma":0.00005944707,"threshold_uncertainty_score":0.8234016},"labels":[],"label_agreement":null},{"id":"W2029431018","doi":"10.1016/j.clinbiochem.2011.08.1079","title":"Intestinal dysfunction in obesity and type 2 diabetes: Role of glucagon-like peptide hormones","year":2011,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Nateglinide; Postprandial; Internal medicine; Endocrinology; Type 2 diabetes; Glucagon-like peptide-1; Glucagon; Hormone; Medicine; Diabetes mellitus","score_opus":0.030985807352395374,"score_gpt":0.2836352225618524,"score_spread":0.25264941520945705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029431018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908853,0.00079898344,0.0000021815188,0.000038866703,0.000090979185,0.00011817866,0.0000014619349,0.000025060755,0.00803897],"genre_scores_gemma":[0.99803334,0.00017893602,0.00081968924,0.0001096094,0.000059865473,0.0000070894357,0.00002606433,0.0000078213625,0.00075756526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919146,0.000014676844,0.00032470148,0.00024340444,0.00008140622,0.00014435001],"domain_scores_gemma":[0.9994691,0.00007248943,0.00008529359,0.00022081188,0.000051864972,0.00010045122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022454909,0.00010293021,0.00026084995,0.000029239352,0.0000120594195,0.0000033911704,0.00005260647,0.00010300543,0.000067980625],"category_scores_gemma":[0.00026411927,0.00008768906,0.00006146874,0.00010129635,0.00014698584,0.000027734231,0.00007854225,0.00012576784,0.000016483657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017615185,0.0008330629,0.9677082,0.00014513274,0.00006997975,0.000008067844,0.000037517908,3.2744428e-8,0.015892765,0.000015049893,0.0005566133,0.01455746],"study_design_scores_gemma":[0.0016664539,0.00091517123,0.87086195,0.0002321602,0.0002062849,0.0000017760743,0.00021655514,0.000078965495,0.12458661,0.00031619976,0.0007925364,0.00012534004],"about_ca_topic_score_codex":0.000015985586,"about_ca_topic_score_gemma":0.0000020215805,"teacher_disagreement_score":0.108693846,"about_ca_system_score_codex":0.000019260078,"about_ca_system_score_gemma":0.000029479123,"threshold_uncertainty_score":0.35758564},"labels":[],"label_agreement":null},{"id":"W2029575072","doi":"10.2337/dc07-0168","title":"Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes","year":2007,"lang":"en","type":"editorial","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"U.S. Department of Veterans Affairs","keywords":"Medicine; Metformin; Type 2 diabetes; Glycemic; Diabetes mellitus; United Kingdom Prospective Diabetes Study; Insulin; Diabetes management; Intensive care medicine; Incretin; Internal medicine; Endocrinology","score_opus":0.03086366377889338,"score_gpt":0.3668910552488264,"score_spread":0.33602739146993305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029575072","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5909681,0.013276632,0.0000023406756,0.00027622565,0.38705924,0.0053752232,0.0003539339,0.00013049337,0.002557855],"genre_scores_gemma":[0.32344773,0.05225372,0.0019368526,0.0016467146,0.58097756,0.003262357,0.03359504,0.00052285404,0.002357163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995868,0.0001360101,0.0011882719,0.00086474436,0.0010855508,0.0008574172],"domain_scores_gemma":[0.9961787,0.0010343259,0.00046613597,0.0010664589,0.0011109764,0.00014339146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016780283,0.0006264927,0.0015847145,0.00033308854,0.00008908483,0.000045105597,0.0005567447,0.0005574056,0.00004533825],"category_scores_gemma":[0.00035313406,0.0004420823,0.0004390728,0.0004270213,0.0001939185,0.00013141554,0.00024577044,0.0005297097,0.000038615675],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006003085,0.001828923,0.12137985,0.013369047,0.0060836794,0.000068393376,0.0033958321,0.000002917704,0.00003341748,0.00009884607,0.6971582,0.15598059],"study_design_scores_gemma":[0.01631314,0.014800122,0.1319287,0.006272183,0.011611382,1.9672187e-7,0.023559917,0.0000117028585,0.0034301514,0.00040258834,0.78999525,0.00167467],"about_ca_topic_score_codex":0.0000014828189,"about_ca_topic_score_gemma":0.00003030626,"teacher_disagreement_score":0.2675203,"about_ca_system_score_codex":0.00023515585,"about_ca_system_score_gemma":0.000120126,"threshold_uncertainty_score":0.99980307},"labels":[],"label_agreement":null},{"id":"W2029643007","doi":"10.3821/1913-701x(2008)141[221:tmonmf]2.0.co;2","title":"The ‘magic’ of new medications fades as we consider real world safety","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"MAGIC (telescope); Physics; Astronomy","score_opus":0.04852625902755645,"score_gpt":0.30134662958106934,"score_spread":0.25282037055351286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029643007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8398586,0.011324604,0.00008142112,0.016767027,0.004574903,0.0020102067,0.0004038264,0.000098752425,0.12488068],"genre_scores_gemma":[0.91071343,0.047932405,0.00023081189,0.0025030891,0.00064106507,0.000010511637,0.00003312867,0.00004038102,0.03789518],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997595,0.00008859611,0.0006700541,0.00026908724,0.0005736717,0.000803591],"domain_scores_gemma":[0.9963106,0.00020731817,0.00028929178,0.00033584237,0.00037762997,0.0024793472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036872688,0.00029186395,0.00041061465,0.0003590632,0.0010464605,0.000054178494,0.00039156625,0.000035979298,0.0015215111],"category_scores_gemma":[0.00013598036,0.00023121422,0.00018110225,0.0006896189,0.00046720967,0.00016878197,0.00003932277,0.00043960146,0.00003136385],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003282844,0.00012976139,0.01439811,0.00017511206,0.0020220457,0.060017347,0.0029299178,0.00014700186,0.000613656,0.001515245,0.7458216,0.17190193],"study_design_scores_gemma":[0.0040587154,0.000091408234,0.00070064294,0.000064234315,0.0007860368,0.12587889,0.000057187273,0.00026823513,0.0021184715,0.00031704438,0.8652936,0.00036554024],"about_ca_topic_score_codex":0.05715115,"about_ca_topic_score_gemma":0.22177297,"teacher_disagreement_score":0.17153639,"about_ca_system_score_codex":0.0017504132,"about_ca_system_score_gemma":0.008875433,"threshold_uncertainty_score":0.99939126},"labels":[],"label_agreement":null},{"id":"W2030872041","doi":"10.1371/journal.pone.0012734","title":"Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide 1 receptor; Agonist; Exenatide; Endocrinology; Internal medicine; Glucose homeostasis; Liraglutide; Receptor; Streptozotocin; Pharmacology; Chemistry; Insulin; Chimera (genetics); Diabetes mellitus; Type 2 diabetes; Medicine; Insulin resistance; Biochemistry","score_opus":0.03191684777274422,"score_gpt":0.24498176823490903,"score_spread":0.2130649204621648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030872041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581009,0.000095886986,0.00003395873,0.0035623605,0.00028455027,0.0006956711,0.0000070349174,0.00017414903,0.037045497],"genre_scores_gemma":[0.9663159,0.00010765291,0.011096676,0.0007518778,0.0006539871,0.00006766495,0.00014649934,0.000052091415,0.02080761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866,0.000009700491,0.00020953066,0.00032319117,0.00045167108,0.0003459032],"domain_scores_gemma":[0.9991805,0.000035110028,0.00009715899,0.00040900026,0.00007829984,0.00019994123],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014538188,0.00019495402,0.00030575218,0.00009697455,0.00014713299,0.000051900322,0.000103969534,0.00009157595,0.0011913421],"category_scores_gemma":[0.00012008563,0.0001669589,0.00008993809,0.00013289224,0.000043302985,0.000103980834,0.00012084505,0.0002898945,0.0010405588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014220474,0.006078371,0.012136098,0.00021345615,0.00079735747,0.000032501277,0.00020830691,2.2876725e-7,0.92310566,0.00030615268,0.0010389999,0.05594064],"study_design_scores_gemma":[0.008800911,0.0019252888,0.07930258,0.0013590443,0.0029733847,0.000014751809,0.0003102346,0.0004113977,0.86164343,0.00009225397,0.042317815,0.0008489304],"about_ca_topic_score_codex":0.000095676834,"about_ca_topic_score_gemma":0.000039461596,"teacher_disagreement_score":0.067166485,"about_ca_system_score_codex":0.00006510847,"about_ca_system_score_gemma":0.000035266326,"threshold_uncertainty_score":0.99973726},"labels":[],"label_agreement":null},{"id":"W2031438601","doi":"10.1016/j.metabol.2014.06.004","title":"Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"Université Laval","keywords":"Sitagliptin; Inflammation; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Cell adhesion molecule; Adhesion; Endocrinology; Immunology; Materials science; Composite material","score_opus":0.002776053944017342,"score_gpt":0.18276274623284022,"score_spread":0.17998669228882289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031438601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844384,0.00051535515,0.0000027375102,0.000023925972,0.000044696575,0.000487185,6.980173e-7,0.000008241492,0.00047334435],"genre_scores_gemma":[0.99937844,0.00012789652,0.00035144715,0.000042903455,0.000014236336,0.000011717689,0.000016170525,0.000011235632,0.0000459779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994501,0.000050805316,0.00012852071,0.00011171186,0.00015925904,0.00009961198],"domain_scores_gemma":[0.9996711,0.00006124586,0.00008759985,0.000114835304,0.00003644396,0.000028777113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085733416,0.000096262534,0.00024341217,0.00013033971,0.000007738434,0.0000031612717,0.000027060401,0.000029509501,0.000005925936],"category_scores_gemma":[0.000026610678,0.000064953536,0.000021738226,0.00010865842,0.000025865393,0.00003701454,0.000012646762,0.000032303244,0.00000197622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016881007,0.0015163018,0.7259325,0.0013832301,0.00022802886,0.0000017799185,0.0005452706,0.000029367331,0.13028409,0.00046304837,0.00011497182,0.13781333],"study_design_scores_gemma":[0.004086169,0.0008638875,0.7117555,0.00010842837,0.00006505181,3.1068135e-9,0.000004588133,0.000045990044,0.28272292,0.000029279474,0.0002745752,0.00004359871],"about_ca_topic_score_codex":0.000006624148,"about_ca_topic_score_gemma":8.4300046e-7,"teacher_disagreement_score":0.15243883,"about_ca_system_score_codex":0.000006439248,"about_ca_system_score_gemma":0.0000037199293,"threshold_uncertainty_score":0.26487282},"labels":[],"label_agreement":null},{"id":"W2031439954","doi":"10.1053/j.gastro.2011.09.014","title":"Loss of Glucagon-Like Peptide-2–Induced Proliferation Following Intestinal Epithelial Insulin-Like Growth Factor-1–Receptor Deletion","year":2011,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Crypt; Glucagon-like peptide-2; Endocrinology; Internal medicine; Cell growth; Biology; Insulin-like growth factor; Gastric inhibitory polypeptide; Paneth cell; Receptor; Growth factor; Glucagon; Small intestine; Insulin; Medicine; Biochemistry; Peptide","score_opus":0.024344001717041812,"score_gpt":0.24414113324645895,"score_spread":0.21979713152941713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031439954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949155,0.00001857677,0.0027054593,0.00022225213,0.0009311618,0.00062905473,0.00001059049,0.00008756127,0.0004798378],"genre_scores_gemma":[0.9950379,0.000016577276,0.0038059652,0.0005923704,0.00014163382,0.00008026141,0.00012701287,0.00003078938,0.00016747591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839956,0.00010082574,0.0004615922,0.00036176218,0.00022470434,0.00045153627],"domain_scores_gemma":[0.99925506,0.000022292614,0.00020260325,0.00025322326,0.00013247978,0.00013432787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016805509,0.00024840733,0.00044354974,0.00021926433,0.0000523733,0.000009032458,0.00012747674,0.000098065764,0.00017944005],"category_scores_gemma":[0.00005892497,0.00022016135,0.00020235899,0.000102158556,0.000073898955,0.00014809071,0.00008985744,0.0001586588,0.000079852885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020924904,0.0009379685,0.9628936,0.00010200385,0.000519004,0.000055971013,0.0008162559,8.0514224e-7,0.02961346,0.00021000233,0.0004307733,0.002327691],"study_design_scores_gemma":[0.012423799,0.015683852,0.9255468,0.0002518431,0.0008480961,0.00008030721,0.0002190203,0.00016128721,0.043504354,0.0002750421,0.00070480973,0.00030079528],"about_ca_topic_score_codex":0.000070778886,"about_ca_topic_score_gemma":0.000040528015,"teacher_disagreement_score":0.03734678,"about_ca_system_score_codex":0.00009428643,"about_ca_system_score_gemma":0.0000334974,"threshold_uncertainty_score":0.8977919},"labels":[],"label_agreement":null},{"id":"W2031730303","doi":"10.1111/dom.12428","title":"Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Janssen Research and Development; American Heart Association","keywords":"Canagliflozin; Medicine; Placebo; Blood pressure; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Regimen; Adverse effect; Gastroenterology","score_opus":0.004615864103886198,"score_gpt":0.20171394092333242,"score_spread":0.19709807681944622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031730303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719834,0.0014572316,0.0000014776892,0.000044378594,0.00012523745,0.0005888132,0.0000148495255,0.000029417346,0.0005402765],"genre_scores_gemma":[0.99882174,0.00028178855,0.0001636898,0.00032053105,0.00005184563,0.000012750307,0.00009085172,0.000025098714,0.00023170543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869394,0.00007603388,0.0002566157,0.00033712556,0.0002443413,0.00039196372],"domain_scores_gemma":[0.9992858,0.00008744917,0.00010564922,0.00028376427,0.000057590452,0.00017975146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027045238,0.00023353194,0.00063699466,0.00021019913,0.000049455553,0.000025461706,0.00007655792,0.00008859684,0.00003953599],"category_scores_gemma":[0.00007151297,0.00018877737,0.0000441117,0.00024479575,0.00014319606,0.00013340333,0.00009970674,0.00013320475,0.0000064395294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012792643,0.00048849505,0.9742357,0.00020104642,0.00023925214,0.000002689112,0.00019882627,0.0000015219903,0.00023873555,0.00017701554,0.00013171314,0.023957081],"study_design_scores_gemma":[0.007835066,0.00037544928,0.98835534,0.00020957379,0.0005115023,6.474124e-8,0.0000074736313,0.000022416109,0.0007274278,0.000044905908,0.0017151302,0.00019563531],"about_ca_topic_score_codex":0.000066475266,"about_ca_topic_score_gemma":0.00008993816,"teacher_disagreement_score":0.023761446,"about_ca_system_score_codex":0.000023010041,"about_ca_system_score_gemma":0.000019784988,"threshold_uncertainty_score":0.76981175},"labels":[],"label_agreement":null},{"id":"W2032322539","doi":"10.1016/j.cmet.2006.01.004","title":"The biology of incretin hormones","year":2006,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Incretin; Hormone; Biology; Glucagon-like peptide-1; Computational biology; Bioinformatics; Endocrinology; Internal medicine; Cell biology; Medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.024835614222637355,"score_gpt":0.3044147166328629,"score_spread":0.27957910241022554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032322539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022520207,0.9559385,0.000003987126,0.00003560012,0.0004091541,0.000810423,0.0000171567,0.000026603764,0.042736057],"genre_scores_gemma":[0.000020917852,0.9843807,0.0001795742,0.00002162464,0.00029343244,0.00011686688,0.00022940074,0.00003572953,0.014721757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988185,0.0001089078,0.00047468292,0.00022935019,0.00011313026,0.00025539656],"domain_scores_gemma":[0.9989074,0.00016371784,0.00033142502,0.0005093971,0.0000401686,0.000047898735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024363649,0.0002825512,0.0015538218,0.00012780154,0.000049011447,0.000010920514,0.00019793169,0.00016836404,0.000030317304],"category_scores_gemma":[0.000024947849,0.0001422953,0.0005049091,0.00019116804,0.0001220575,0.000011686245,0.00010926231,0.00014953676,0.0001181905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000317591,0.00006836351,0.0000045012184,0.0038823504,0.0002705976,0.000003853246,0.000004650757,8.8103915e-9,0.000004556613,0.0036823577,0.0074580633,0.98461753],"study_design_scores_gemma":[0.00031222746,0.000042947984,0.000026539034,0.0005768127,0.004948584,0.0000012943469,0.000003907316,2.0189437e-7,0.00004030617,0.0001356216,0.99380076,0.00011078434],"about_ca_topic_score_codex":0.000030382227,"about_ca_topic_score_gemma":0.0000012539563,"teacher_disagreement_score":0.9863427,"about_ca_system_score_codex":0.000018531084,"about_ca_system_score_gemma":0.000068019064,"threshold_uncertainty_score":0.5802634},"labels":[],"label_agreement":null},{"id":"W2032513267","doi":"10.1034/j.1399-5448.2000.010108.x","title":"Synthesis, secretion and biological actions of the glucagon-like peptides","year":2000,"lang":"en","type":"article","venue":"Pediatric Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Medical Research Council; Amylin Pharmaceuticals","keywords":"Proglucagon; Internal medicine; Endocrinology; Glucagon-like peptide-2; Glucokinase; Islet; Enteroendocrine cell; Glucagon-like peptide-1; Glucagon; Gastric emptying; Prohormone convertase; Medicine; Insulin; Biology; Prohormone; Hormone; Diabetes mellitus; Type 2 diabetes; Biochemistry; Stomach; Endocrine system; Peptide","score_opus":0.0174667313950156,"score_gpt":0.23485597164622168,"score_spread":0.2173892402512061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032513267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909779,0.0011498263,8.712365e-7,0.00042222504,0.000091738046,0.00027133562,0.00000938554,0.000045864897,0.007030881],"genre_scores_gemma":[0.9960021,0.0020131143,0.0001458774,0.00015498088,0.00015545991,0.00005583127,0.000009058561,0.000008535805,0.0014550876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932665,0.000034102915,0.00015579695,0.00016954119,0.00012747468,0.00018645308],"domain_scores_gemma":[0.99951077,0.00016144711,0.000052916406,0.00019267057,0.000022275979,0.00005990984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108443826,0.00010934366,0.00019397271,0.00006471182,0.000072840405,0.000011182962,0.00006435015,0.000054054024,0.00034330477],"category_scores_gemma":[0.00007008235,0.00006486286,0.0000904348,0.00021757612,0.00008202346,0.000051619372,0.00003780012,0.000059991304,0.000027827946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013157296,0.00021087921,0.95315355,0.000089049834,0.00008272761,6.838835e-7,0.000042558877,0.0000022724594,0.00047862972,0.00014863079,0.0018198073,0.04395804],"study_design_scores_gemma":[0.00044323498,0.00018940771,0.9817962,0.000030615625,0.0006995449,7.574821e-7,0.00005129059,0.00006122157,0.0024811507,0.00018425846,0.013954033,0.000108262066],"about_ca_topic_score_codex":0.000010321774,"about_ca_topic_score_gemma":0.0000013715363,"teacher_disagreement_score":0.043849777,"about_ca_system_score_codex":0.000017292321,"about_ca_system_score_gemma":0.00001711149,"threshold_uncertainty_score":0.37589464},"labels":[],"label_agreement":null},{"id":"W2032824509","doi":"10.1038/ki.2012.431","title":"Intensive glycemic control in type 2 diabetics at high cardiovascular risk: do the benefits justify the risks?","year":2013,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Kidney Disease Network; University of Alberta","funders":"","keywords":"Medicine; Albuminuria; Glycemic; Microalbuminuria; Kidney disease; Diabetes mellitus; Internal medicine; Renal function; Intensive care medicine; Endocrinology","score_opus":0.019674211723497505,"score_gpt":0.24509098114559477,"score_spread":0.22541676942209726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032824509","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02767567,0.003336002,0.000018760733,0.9568815,0.004940933,0.0018488944,0.00054866634,0.000057648096,0.0046918727],"genre_scores_gemma":[0.26536167,0.0023429473,0.00006515293,0.71495664,0.004590194,0.0004067104,0.0024219279,0.00009126506,0.009763501],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975446,0.00014705867,0.00040467602,0.0004954131,0.0009782215,0.00043003916],"domain_scores_gemma":[0.9977645,0.0003327784,0.00025194947,0.00090542017,0.0006428365,0.00010247126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002956711,0.00040694163,0.0005847784,0.0001979664,0.00011065632,0.00011134277,0.0006195934,0.0003664657,0.001074903],"category_scores_gemma":[0.0008539886,0.00022683728,0.0004911848,0.00015425228,0.00017518825,0.00006452574,0.000284242,0.0013565826,0.0010819485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011348258,0.000036578956,0.00479654,0.000040866034,0.0057926937,0.0001297654,0.00012066929,0.00014021287,0.0000026297462,0.00019498232,0.98508704,0.0035445387],"study_design_scores_gemma":[0.0036193817,0.00012821874,0.014064347,0.00026812006,0.002629229,0.000015265736,0.00004686539,0.00045461027,0.000016722975,0.00017456002,0.97835475,0.00022795278],"about_ca_topic_score_codex":0.00057499734,"about_ca_topic_score_gemma":0.000013732612,"teacher_disagreement_score":0.24192493,"about_ca_system_score_codex":0.00054997957,"about_ca_system_score_gemma":0.00010224653,"threshold_uncertainty_score":0.99983823},"labels":[],"label_agreement":null},{"id":"W2033160068","doi":"10.1111/j.1524-4733.2004.71249.x","title":"Modeling the Efficiency of Reaching a Target Intermediate End Point: A Case Study in Type 2 Diabetes in the United States","year":2004,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology; McGill University","funders":"","keywords":"Glycemic; Nateglinide; Medicine; Metformin; Postprandial; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.04393572366586446,"score_gpt":0.31595252541208896,"score_spread":0.2720168017462245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033160068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574625,0.00072965975,0.000029441315,0.0018907688,0.00006935591,0.0014648143,0.0000025560391,0.00001406431,0.00005308523],"genre_scores_gemma":[0.99886566,0.0001761459,0.00015358195,0.0007040665,0.000015971642,0.000048184404,0.000020789847,0.000012055053,0.0000035185315],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984229,0.00036007556,0.00048456885,0.00018536442,0.00021140168,0.00033564057],"domain_scores_gemma":[0.99935675,0.00022592256,0.00007994556,0.00027440843,0.000022730545,0.000040240455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024188051,0.00012021538,0.00027408169,0.00041953244,0.000046508285,0.000011927909,0.00012219088,0.000022347716,0.0000035813423],"category_scores_gemma":[0.00014333815,0.000068908004,0.000027441069,0.0008667923,0.00003431541,0.000045820736,0.000051573494,0.00025452027,0.000001752031],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010382913,0.003660854,0.21160936,0.00050218246,0.00005475528,0.0011118368,0.1462132,0.63352126,0.0000106287225,0.00043036346,0.000012253817,0.002769497],"study_design_scores_gemma":[0.008003802,0.004026077,0.016888715,0.0014652344,0.00007509943,0.00002815256,0.10487605,0.8612848,0.000036783335,0.003077835,0.000042324802,0.00019511656],"about_ca_topic_score_codex":0.04945579,"about_ca_topic_score_gemma":0.0022877313,"teacher_disagreement_score":0.22776358,"about_ca_system_score_codex":0.00023987562,"about_ca_system_score_gemma":0.00011114513,"threshold_uncertainty_score":0.95687395},"labels":[],"label_agreement":null},{"id":"W2033185429","doi":"10.1111/j.1463-1326.2012.01673.x","title":"Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Weight loss; Exenatide; Medicine; Placebo; Weight change; Sitagliptin; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Gastroenterology; Obesity","score_opus":0.05835125910981301,"score_gpt":0.2946800038701167,"score_spread":0.23632874476030372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033185429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96661735,0.031393886,0.000021479438,0.00033699127,0.00010398114,0.0012921904,0.00011264844,0.00006188125,0.000059592683],"genre_scores_gemma":[0.9948625,0.00069607014,0.0024639496,0.00089578616,0.0003180018,0.0003030415,0.0003725253,0.000027319686,0.00006082405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977221,0.00031614583,0.00052696915,0.00039692177,0.0003626259,0.0006752521],"domain_scores_gemma":[0.99833626,0.00039197,0.00031922356,0.0004577568,0.00009650868,0.0003982632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015890403,0.00038476978,0.0015842061,0.0002581018,0.00020149423,0.000074272495,0.00014239957,0.000093503666,0.00007404606],"category_scores_gemma":[0.00007417102,0.00021812538,0.0001728562,0.0005378749,0.00022648153,0.00040788043,0.00010455837,0.00012578229,0.0000041442786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096489384,0.0017248956,0.9228727,0.000077745164,0.009267359,0.0000013654801,0.0061377767,3.207526e-7,0.0009032628,0.0003430037,0.000086535336,0.058488514],"study_design_scores_gemma":[0.0040419376,0.00023869838,0.93244874,0.00008640413,0.012875132,1.6867016e-7,0.00058806397,0.00017359786,0.009011773,0.000042800766,0.04021072,0.00028197665],"about_ca_topic_score_codex":0.00010631803,"about_ca_topic_score_gemma":0.00007096638,"teacher_disagreement_score":0.058206536,"about_ca_system_score_codex":0.000024860235,"about_ca_system_score_gemma":0.000034967565,"threshold_uncertainty_score":0.8894895},"labels":[],"label_agreement":null},{"id":"W2033904567","doi":"10.1210/en.2006-1403","title":"Protein Kinase Cζ Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells","year":2006,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Protein kinase C; Oleic acid; Internal medicine; Secretion; Enteroendocrine cell; Endocrinology; Glucagon-like peptide-1; Chemistry; Biology; Cell biology; Kinase; Biochemistry; Medicine; Hormone; Diabetes mellitus","score_opus":0.01726937907930023,"score_gpt":0.26233783085426415,"score_spread":0.24506845177496392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033904567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949903,0.00045315293,0.0009990092,0.001964884,0.00028901704,0.0020788764,0.00004573691,0.00015005207,0.0045202235],"genre_scores_gemma":[0.9814479,0.000023803277,0.0036859936,0.00032699335,0.00015518615,0.0005252983,0.00033462208,0.00004165506,0.013458588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982088,0.000043708806,0.0004586489,0.00045397642,0.00018808692,0.0006467636],"domain_scores_gemma":[0.99911064,0.00005723088,0.00020573789,0.00041132016,0.00012932121,0.00008575688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000067394576,0.00027675976,0.00049038714,0.00020618139,0.000059033093,0.000010706164,0.00013625181,0.000066003064,0.00018462243],"category_scores_gemma":[0.00004801223,0.00025356121,0.0001702652,0.00016243765,0.00010442998,0.000078610756,0.000092371396,0.00012288927,0.000067953995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036047847,0.00068789616,0.0013534267,0.0002789562,0.00015778658,0.00010389496,0.000047337082,0.0000010828168,0.9538101,0.0030382846,0.032017253,0.008143491],"study_design_scores_gemma":[0.0047995327,0.0022320405,0.0009556246,0.000098548626,0.00025516353,0.000029633706,0.00006681671,0.00009098709,0.920934,0.00067009823,0.06967103,0.00019648604],"about_ca_topic_score_codex":0.00027285505,"about_ca_topic_score_gemma":0.00002217356,"teacher_disagreement_score":0.03765377,"about_ca_system_score_codex":0.000112706155,"about_ca_system_score_gemma":0.000048233742,"threshold_uncertainty_score":0.99999166},"labels":[],"label_agreement":null},{"id":"W2034171544","doi":"10.1111/j.1463-1326.2011.01362.x","title":"Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Sitagliptin; Postprandial; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus; Insulin","score_opus":0.010168186497145333,"score_gpt":0.21106722708303688,"score_spread":0.20089904058589156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034171544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963792,0.0010188764,3.1605836e-7,0.000017479571,0.00013075938,0.0011748606,0.000015643447,0.000034201756,0.0012286619],"genre_scores_gemma":[0.9993324,0.000083091065,0.00016226522,0.00020003419,0.00004300415,0.000045458746,0.000037702204,0.000025420855,0.00007061294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987533,0.00011923782,0.00021149509,0.00029979803,0.0002542382,0.0003619161],"domain_scores_gemma":[0.9993667,0.00007892446,0.00009694513,0.00027307752,0.000071196715,0.000113182046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003583068,0.00026723673,0.0006507103,0.00022858074,0.000040610885,0.000011676348,0.000079877515,0.00008833625,0.000086644824],"category_scores_gemma":[0.000054115328,0.00017526721,0.00007208677,0.0002430268,0.000092899754,0.00011902811,0.00004067716,0.00012551872,0.000015714164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016642535,0.0010077833,0.94389594,0.00014540757,0.00028196882,0.0000028691845,0.00032773046,2.661626e-7,0.00046774885,0.0001502006,0.000014707984,0.052041125],"study_design_scores_gemma":[0.008641825,0.00905408,0.92472774,0.00014787682,0.00022807313,2.2703173e-8,0.000004068617,0.0000034425607,0.056641743,0.000056972942,0.00033152962,0.0001626001],"about_ca_topic_score_codex":0.000036425383,"about_ca_topic_score_gemma":0.0000043932373,"teacher_disagreement_score":0.056173995,"about_ca_system_score_codex":0.000014725951,"about_ca_system_score_gemma":0.000014283915,"threshold_uncertainty_score":0.71471894},"labels":[],"label_agreement":null},{"id":"W2034718914","doi":"10.1089/jmf.2007.405","title":"Fourteen Weeks of Treatment with Viscofiber <sup>®</sup> Increased Fasting Levels of Glucagon-Like Peptide-1 and Peptide-YY","year":2007,"lang":"en","type":"article","venue":"Journal of Medicinal Food","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration","keywords":"Peptide YY; Internal medicine; Endocrinology; Medicine; Weight loss; Meal; Glucagon-like peptide-1; Overweight; Obesity; Type 2 diabetes; Diabetes mellitus; Neuropeptide Y receptor; Neuropeptide","score_opus":0.02380942421687755,"score_gpt":0.2663935614238599,"score_spread":0.24258413720698235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034718914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99155676,0.001265208,0.0007654203,0.0005871839,0.000084109706,0.00041540628,0.00001214814,0.00001151062,0.005302267],"genre_scores_gemma":[0.9936027,0.0001494211,0.005002355,0.00015714594,0.00030939604,0.0000032762036,0.0000057462803,0.000032920874,0.00073705387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975724,0.000051851668,0.0009769336,0.00020939184,0.00080479315,0.0003846363],"domain_scores_gemma":[0.9978838,0.0003003746,0.00083633926,0.0002451017,0.00034575575,0.00038860893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010198095,0.00030624092,0.0010069442,0.000471814,0.000051436724,0.000009717975,0.000116896175,0.000085715656,0.00008748651],"category_scores_gemma":[0.00009136459,0.00019013601,0.00019670319,0.00024989693,0.00019790808,0.00014742625,0.000044151846,0.00020164633,0.000001881384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014092432,0.0056792405,0.4845277,0.0025279936,0.017086776,0.002751116,0.01347231,0.0002670925,0.022884483,0.00067482697,0.003296258,0.43273976],"study_design_scores_gemma":[0.081161104,0.23003824,0.576188,0.011158595,0.015675932,0.0029653485,0.02127749,0.00064701255,0.040386885,0.0003722815,0.019158935,0.00097015087],"about_ca_topic_score_codex":0.00008701701,"about_ca_topic_score_gemma":0.0000356674,"teacher_disagreement_score":0.4317696,"about_ca_system_score_codex":0.00020015096,"about_ca_system_score_gemma":0.00023126688,"threshold_uncertainty_score":0.7753521},"labels":[],"label_agreement":null},{"id":"W2034868834","doi":"10.1210/en.2004-0853","title":"Miniglucagon (MG)-Generating Endopeptidase, which Processes Glucagon into MG, Is Composed of N-Arginine Dibasic Convertase and Aminopeptidase B","year":2004,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Glucagon; Aminopeptidase; Endopeptidase; Biology; Arginine; Biochemistry; Internal medicine; Endocrinology; Enzyme; Immunogold labelling; Hormone; Amino acid; Leucine; Antibody","score_opus":0.013446095853206379,"score_gpt":0.2627938174762724,"score_spread":0.249347721623066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034868834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920835,0.0019428916,0.00007745834,0.002111808,0.00014572886,0.0007047502,0.000022967306,0.00010466674,0.002806239],"genre_scores_gemma":[0.9929951,0.00044714802,0.0040324135,0.0010414117,0.0001106433,0.00009591885,0.00018220524,0.000037573034,0.0010576172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982126,0.000044715944,0.00046834841,0.0005240733,0.00020956021,0.0005407456],"domain_scores_gemma":[0.9989112,0.00010829967,0.00018179993,0.0004016376,0.0002196826,0.00017735678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007120564,0.0003321757,0.0006443779,0.00025535747,0.0001075454,0.000021723074,0.00012829188,0.000081685204,0.00016716124],"category_scores_gemma":[0.0001673085,0.00029032788,0.0000662694,0.00029208843,0.00022085352,0.00013128301,0.0001611862,0.00016908506,0.0000575048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015681195,0.005276356,0.102223545,0.0060704104,0.0027280557,0.0017903802,0.014122461,0.00011824637,0.76405686,0.007687887,0.0040685064,0.09028916],"study_design_scores_gemma":[0.015929379,0.0030302014,0.0081026275,0.0004040105,0.00060410093,0.00012757159,0.0010585946,0.000110216686,0.95701426,0.0003205744,0.012840655,0.0004578088],"about_ca_topic_score_codex":0.0002859393,"about_ca_topic_score_gemma":0.00025103573,"teacher_disagreement_score":0.19295739,"about_ca_system_score_codex":0.00007720475,"about_ca_system_score_gemma":0.00015544762,"threshold_uncertainty_score":0.9999549},"labels":[],"label_agreement":null},{"id":"W2035592622","doi":"10.1038/oby.2007.39","title":"GLP‐1 and Appetite Responses to a Meal in Lean and Overweight Adolescents Following Exercise","year":2008,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Overweight; Meal; Appetite; Medicine; Obesity; Lean body mass; Internal medicine; Physical therapy; Endocrinology; Body weight","score_opus":0.012791868768125979,"score_gpt":0.24309833358086125,"score_spread":0.23030646481273526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035592622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977924,0.00048928993,0.000006684429,0.00023213655,0.000042942862,0.0003819902,0.0000014767036,0.000027887607,0.0010251445],"genre_scores_gemma":[0.9963066,0.00025641994,0.00037853204,0.00027418853,0.000019093168,0.000010261272,0.0000031059076,0.000008273182,0.002743504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939585,0.000013475944,0.000089449306,0.0002033719,0.00012691616,0.00017096334],"domain_scores_gemma":[0.9997138,0.000010999717,0.000013612112,0.00012810204,0.000007674349,0.00012584719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010067092,0.00009683772,0.00019865904,0.000113043054,0.000059492075,0.00000894512,0.000025930385,0.000029667877,0.000006382433],"category_scores_gemma":[0.000023325469,0.000085528045,0.000029924373,0.000100749836,0.000019870604,0.000058739523,0.00008088756,0.00004804249,0.000019863233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025373173,0.00019730932,0.993996,0.00007164481,0.00001861782,0.00031488636,0.00041412681,8.573915e-8,0.00025414804,0.000026301102,0.00047387125,0.003979253],"study_design_scores_gemma":[0.0017058206,0.00013692236,0.9952353,0.00057486113,0.00005872687,0.0000053801814,0.000051521223,0.00000985211,0.00049118436,0.000029323994,0.0016167428,0.00008435933],"about_ca_topic_score_codex":0.00006492734,"about_ca_topic_score_gemma":0.000045604258,"teacher_disagreement_score":0.003894894,"about_ca_system_score_codex":0.00003870554,"about_ca_system_score_gemma":0.000011665249,"threshold_uncertainty_score":0.34877324},"labels":[],"label_agreement":null},{"id":"W2035868046","doi":"10.1007/s00125-015-3547-2","title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of General Medical Sciences; Mitsubishi Tanabe Pharma Corporation; European Foundation for the Study of Diabetes; National Institutes of Health; American Diabetes Association","keywords":"Canagliflozin; Weight loss; Medicine; Type 2 diabetes; Placebo; Diabetes mellitus; Internal medicine; Endocrinology; Blood pressure; Obesity","score_opus":0.008211505525380452,"score_gpt":0.2133823105011219,"score_spread":0.20517080497574147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035868046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971429,0.0010516153,2.4354145e-7,0.00030025802,0.000059739352,0.00078019744,0.000004779692,0.000022007249,0.00063822936],"genre_scores_gemma":[0.9991899,0.00001439985,0.00021313706,0.00023219154,0.000014006466,0.000050570223,0.000026869144,0.000011881319,0.00024701454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993248,0.00003751205,0.00009407437,0.00020732223,0.00014383407,0.00019247152],"domain_scores_gemma":[0.99949735,0.00012982871,0.000043477685,0.00014107183,0.000057173635,0.00013109433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009400117,0.0001264346,0.00027944217,0.00016904202,0.000015978725,0.000007777736,0.000034413944,0.00005800172,0.0000030353044],"category_scores_gemma":[0.00020199138,0.00008917601,0.00000787246,0.0001889537,0.00004231044,0.00003570907,0.000044773915,0.00006703715,0.0000034746165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115481635,0.00031656644,0.9969871,0.00022474294,0.00020832536,0.000006700647,0.00016122531,0.0000013253344,0.00006318506,0.0002692324,0.0005541286,0.0010919968],"study_design_scores_gemma":[0.0032997055,0.0035875652,0.9890072,0.00019728155,0.0006106195,5.6632704e-8,0.000013722531,0.000011573955,0.002565627,0.000060271323,0.00055280403,0.00009358897],"about_ca_topic_score_codex":0.000022269987,"about_ca_topic_score_gemma":0.00004767572,"teacher_disagreement_score":0.007979905,"about_ca_system_score_codex":0.000012545781,"about_ca_system_score_gemma":0.000013943308,"threshold_uncertainty_score":0.36364922},"labels":[],"label_agreement":null},{"id":"W2036379136","doi":"10.1111/1753-0407.12249","title":"Heart failure in <scp>SAVOR‐TIMI</scp> 53: The hindsight of diabetic retinopathySAVOR‐TIMI 53研究中的心脏衰竭：糖尿病视网膜病变的后尘","year":2014,"lang":"zh","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canada Research Chairs; Eli Lilly and Company","keywords":"Medicine; Alogliptin; Saxagliptin; TIMI; Heart failure; Myocardial infarction; Internal medicine; Type 2 diabetes; Diabetes mellitus; Cardiology; Acute coronary syndrome; Odds ratio; Dipeptidyl peptidase-4; Sitagliptin; Thrombolysis; Endocrinology","score_opus":0.007641097741245953,"score_gpt":0.21812885385937147,"score_spread":0.21048775611812554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036379136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699953,0.008754964,0.000017447415,0.008759065,0.0014731793,0.0009263256,0.000020230307,0.000030619925,0.010022861],"genre_scores_gemma":[0.9935189,0.000474968,0.0009374728,0.0014465267,0.0013080791,0.000031061714,0.000016805088,0.00011829988,0.0021478925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932854,0.0008189561,0.0023636704,0.00056548073,0.0015131652,0.0014533254],"domain_scores_gemma":[0.99293476,0.002934081,0.0019575744,0.0010847807,0.0005560193,0.00053276017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032954968,0.0008317343,0.0023040643,0.0009166821,0.0001748104,0.00015873002,0.00097899,0.00038818488,0.00023895584],"category_scores_gemma":[0.0024738705,0.00056326424,0.0009358501,0.0009812167,0.0004901927,0.00049644813,0.00031709365,0.0012914584,0.00017448742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037960934,0.0022111088,0.89410275,0.0012087357,0.0015775664,0.000045291068,0.0024377825,0.0002669757,0.009224441,0.0015712952,0.08136497,0.0059511024],"study_design_scores_gemma":[0.019748779,0.011455223,0.69901186,0.011333796,0.0070769666,0.000030766387,0.0053120754,0.0022753396,0.05425061,0.006657817,0.18195193,0.0008948509],"about_ca_topic_score_codex":0.00001863588,"about_ca_topic_score_gemma":0.000032788597,"teacher_disagreement_score":0.1950909,"about_ca_system_score_codex":0.00029167978,"about_ca_system_score_gemma":0.00021973261,"threshold_uncertainty_score":0.9996819},"labels":[],"label_agreement":null},{"id":"W2036419300","doi":"10.1016/j.molmet.2014.09.005","title":"GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance","year":2014,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; Mitacs; Heart and Stroke Foundation of Canada","keywords":"Internal medicine; Endocrinology; Insulin resistance; Very low-density lipoprotein; Lipogenesis; Dyslipidemia; Hyperinsulinemia; Apolipoprotein B; Chemistry; Lipid metabolism; Insulin; Lipoprotein; Biology; Medicine; Diabetes mellitus; Cholesterol","score_opus":0.00451397704786806,"score_gpt":0.21666368197078645,"score_spread":0.21214970492291838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036419300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870154,0.008589191,0.00055418717,0.0016600557,0.0002000516,0.00040240274,0.0000028777351,0.000056517616,0.0015192827],"genre_scores_gemma":[0.9883393,0.0009809843,0.008128378,0.000950769,0.0001449107,0.00008364023,0.000029273937,0.000034830988,0.0013079203],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988216,0.00011068771,0.00021701597,0.0003664836,0.00019869093,0.00028547904],"domain_scores_gemma":[0.99941605,0.000019864443,0.000066164765,0.0003431636,0.00004697191,0.000107766304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003364275,0.00018227623,0.00034093877,0.00019399221,0.000042126816,0.00003364605,0.000060312173,0.00005817077,0.000033760516],"category_scores_gemma":[0.00016677486,0.00016893953,0.000059110982,0.00030537526,0.00005024805,0.00007405001,0.000045995686,0.000087064866,0.000035390058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053670595,0.00091608503,0.024991408,0.0006120481,0.0005053736,0.00016656927,0.0011313682,0.000046555804,0.77541405,0.015056569,0.0014664922,0.1791568],"study_design_scores_gemma":[0.005942306,0.0001814372,0.39049855,0.00026455292,0.0008446115,0.0000098043365,0.000090588284,0.000278163,0.2864155,0.0035400703,0.31136933,0.000565115],"about_ca_topic_score_codex":0.00007229815,"about_ca_topic_score_gemma":0.00003708152,"teacher_disagreement_score":0.48899853,"about_ca_system_score_codex":0.000055974524,"about_ca_system_score_gemma":0.000027834418,"threshold_uncertainty_score":0.6889154},"labels":[],"label_agreement":null},{"id":"W2036532013","doi":"10.1016/j.jcte.2014.03.001","title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (&lt;50 years) obese patients with type 2 diabetes mellitus","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical & Translational Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Sanofi; Eli Lilly and Company","keywords":"Lixisenatide; Sitagliptin; Medicine; Internal medicine; Postprandial; Dipeptidyl peptidase-4 inhibitor; Metformin; Glucagon-like peptide 1 receptor; Hypoglycemia; Endocrinology; Type 2 Diabetes Mellitus; Glycated hemoglobin; Type 2 diabetes; Sitagliptin Phosphate; Gastroenterology; Adverse effect; Clinical endpoint; Liraglutide; Diabetes mellitus; Agonist; Randomized controlled trial; Receptor","score_opus":0.019794624662697515,"score_gpt":0.29456015853567835,"score_spread":0.27476553387298086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036532013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944548,0.00057321985,0.000012744282,0.002577895,0.00091489404,0.00045764138,0.000011550434,0.000008224059,0.00098903],"genre_scores_gemma":[0.9979813,0.00042700712,0.00089269347,0.00021265357,0.00031084364,0.000005483676,0.000022182272,0.000020745963,0.00012709503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746764,0.00031413118,0.001169014,0.00022789635,0.0005097309,0.00031159367],"domain_scores_gemma":[0.9969996,0.0018091201,0.0005611895,0.0002601285,0.00024988785,0.000120035955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006028634,0.00019337297,0.0006396161,0.000116609226,0.00007417195,0.000016088527,0.00020962964,0.00009545495,0.00006420855],"category_scores_gemma":[0.00055104756,0.00010708864,0.00022120724,0.00020889149,0.0004700758,0.00010830373,0.00005548129,0.000500469,0.000009115868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009370772,0.0014474356,0.9437062,0.00007092754,0.00089240825,0.0000088226425,0.0003064796,0.0001593176,0.00022207413,0.001460071,0.0006838511,0.041671623],"study_design_scores_gemma":[0.018819433,0.0025127348,0.9561936,0.00024679163,0.00038982532,0.0000035994185,0.000041885047,0.000049905586,0.00009132742,0.00016402129,0.021376515,0.000110335226],"about_ca_topic_score_codex":0.000008875544,"about_ca_topic_score_gemma":0.000092342445,"teacher_disagreement_score":0.041561287,"about_ca_system_score_codex":0.00003597052,"about_ca_system_score_gemma":0.0001236969,"threshold_uncertainty_score":0.4366948},"labels":[],"label_agreement":null},{"id":"W2036909990","doi":"10.1007/s00125-009-1643-x","title":"Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells","year":2010,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Lunenfeld-Tanenbaum Research Institute; SickKids Foundation; Mount Sinai Hospital","funders":"Hospital for Sick Children; Canada Research Chairs","keywords":"Internal medicine; Endocrinology; Immune system; Biology; CD8; Receptor; Splenocyte; NOD mice; Lymphocyte; Nod; Immunology; Medicine; Diabetes mellitus","score_opus":0.006841544147435217,"score_gpt":0.21595591479332207,"score_spread":0.20911437064588687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036909990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973667,0.0002644253,0.000056024088,0.00022746722,0.0003233894,0.0006323426,0.0000068310587,0.000096652926,0.0010261689],"genre_scores_gemma":[0.9903966,0.000095400406,0.005671683,0.00021662709,0.00010153195,0.000064589534,0.00004639127,0.000027849263,0.0033793263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874896,0.000033663193,0.00031149614,0.00037596838,0.00018931099,0.00034060818],"domain_scores_gemma":[0.9992531,0.000051911324,0.00016284581,0.00025673158,0.00016404792,0.00011138683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025126655,0.00022184585,0.00042576384,0.00010823072,0.00008210946,0.000025106783,0.00008138377,0.00013404027,0.000120800556],"category_scores_gemma":[0.000053824704,0.00018131355,0.00007782497,0.00015923244,0.00021257576,0.00012884899,0.00005938973,0.00015098526,0.000013703212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030490896,0.00033949755,0.09790586,0.00029724382,0.0003276747,0.000012373344,0.00037405657,0.000027424489,0.88236886,0.0014165489,0.003448916,0.01317661],"study_design_scores_gemma":[0.0033234598,0.0008303038,0.1625433,0.00016779857,0.00023805827,0.000007875696,0.00011917004,0.0015924232,0.8249359,0.0003062299,0.005609526,0.00032594646],"about_ca_topic_score_codex":0.000012026477,"about_ca_topic_score_gemma":0.000011406732,"teacher_disagreement_score":0.06463744,"about_ca_system_score_codex":0.00008102655,"about_ca_system_score_gemma":0.000071021524,"threshold_uncertainty_score":0.7393752},"labels":[],"label_agreement":null},{"id":"W2037261747","doi":"10.1517/13543780903143753","title":"Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Rosiglitazone; Metformin Hydrochloride; Metformin; Medicine; Glycemic; Type 2 diabetes; Pill; Pharmacology; Diabetes mellitus; Endocrinology","score_opus":0.03459180608237115,"score_gpt":0.337369398605298,"score_spread":0.30277759252292685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037261747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55488205,0.18548375,0.00044473197,0.12216338,0.0027435692,0.0057002916,0.00009501745,0.0008251922,0.12766202],"genre_scores_gemma":[0.7440834,0.08919315,0.04309995,0.11011967,0.002075674,0.00044382774,0.005466115,0.00013217145,0.0053860378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839044,0.00004839048,0.0004511588,0.00030640792,0.0005905755,0.00021302623],"domain_scores_gemma":[0.9991218,0.000053485855,0.0001608727,0.00034150068,0.00010148433,0.00022087105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030655312,0.0002058767,0.00037765224,0.0001641358,0.00007612314,0.000012172796,0.000114453345,0.000042319385,0.0002009533],"category_scores_gemma":[0.0000799371,0.00017458935,0.00012474893,0.00023061408,0.000084143925,0.00023903302,0.000023071827,0.00009328439,0.000052277137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078327523,0.004822213,0.00068426796,0.004705368,0.0008379428,0.00008370105,0.0042244033,0.00020105901,0.02345848,0.38111508,0.17052673,0.40855747],"study_design_scores_gemma":[0.0063843145,0.0043360367,0.016089141,0.028902082,0.00013034373,0.000052137624,0.0005579481,0.002781141,0.07677747,0.018594407,0.8443496,0.001045335],"about_ca_topic_score_codex":0.000015688065,"about_ca_topic_score_gemma":1.9438625e-7,"teacher_disagreement_score":0.67382294,"about_ca_system_score_codex":0.000096804746,"about_ca_system_score_gemma":0.00006550236,"threshold_uncertainty_score":0.7119547},"labels":[],"label_agreement":null},{"id":"W2037395799","doi":"10.1111/dom.12226","title":"Composite endpoints in trials of type‐2 diabetes","year":2013,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sitagliptin; Medicine; Saxagliptin; Type 2 diabetes; Exenatide; Linagliptin; Dapagliflozin; Liraglutide; Vildagliptin; Internal medicine; Diabetes mellitus; Clinical trial; Randomized controlled trial; Endocrinology","score_opus":0.056287142802563854,"score_gpt":0.32216846093570106,"score_spread":0.2658813181331372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037395799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07105812,0.9249426,2.9171792e-7,0.000027128111,0.00046418724,0.0023003172,0.00007880984,0.00004238865,0.001086124],"genre_scores_gemma":[0.0007044882,0.9968405,0.00048226223,0.00011320438,0.00019332446,0.0002112988,0.00044850545,0.00005796387,0.0009485032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99668354,0.0004909037,0.0014218426,0.00054056884,0.00029856927,0.0005645656],"domain_scores_gemma":[0.99793345,0.00053286034,0.000693452,0.0005258927,0.00009687257,0.0002174973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014615041,0.0006166949,0.0066670943,0.0007268054,0.000041301126,0.00004704395,0.00019321119,0.00036292372,0.00021601707],"category_scores_gemma":[0.00035635981,0.00044123182,0.00073080347,0.000515679,0.00013710312,0.00014466081,0.00021323857,0.00032577603,0.000112963055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000059021727,0.0005675863,0.0048955875,0.024046866,0.0015292114,0.000006638185,0.000047347166,7.224058e-8,0.000044904053,0.00042826825,0.00077724643,0.96765035],"study_design_scores_gemma":[0.0014822262,0.0001123682,0.007564543,0.010606727,0.008388178,5.507367e-7,0.0000072308026,0.0000066984667,0.0002649669,0.00021212899,0.9709453,0.00040906528],"about_ca_topic_score_codex":0.000018450566,"about_ca_topic_score_gemma":0.000001712264,"teacher_disagreement_score":0.97016805,"about_ca_system_score_codex":0.000044497046,"about_ca_system_score_gemma":0.00008783441,"threshold_uncertainty_score":0.99980396},"labels":[],"label_agreement":null},{"id":"W2037945604","doi":"10.1053/j.gastro.2005.02.033","title":"Mucosal Adaptation to Enteral Nutrients is Dependent on the Physiologic Actions of Glucagon-Like Peptide-2 in Mice","year":2005,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide-2; Internal medicine; Endocrinology; Endogeny; Crypt; Glucagon-like peptide-1; Small intestine; Enteral administration; Stimulation; Ileum; Biology; Medicine; Parenteral nutrition; Peptide; Biochemistry; Type 2 diabetes","score_opus":0.026772782625591993,"score_gpt":0.26975412753539824,"score_spread":0.24298134490980625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037945604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900891,0.0000100752095,0.00018466296,0.008430475,0.00016371533,0.0005241143,0.000010206781,0.000017677101,0.00056994136],"genre_scores_gemma":[0.9916685,0.000020844973,0.0004862709,0.0069272975,0.00006405151,0.000104109815,0.000028544206,0.000008702807,0.00069167477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990744,0.000061366976,0.00022324994,0.00022381832,0.00013471744,0.00028247637],"domain_scores_gemma":[0.99960995,0.00003088698,0.00007431175,0.00019864623,0.00003052371,0.000055692744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087553126,0.00012279571,0.00020442746,0.00015759654,0.000027934535,0.0000047096937,0.000100266734,0.00003423483,0.00013297971],"category_scores_gemma":[0.000014734437,0.00008624119,0.00007375549,0.00008491934,0.000033480683,0.000042746968,0.00006099488,0.000101227546,0.0001264763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0139091695,0.011735163,0.8153301,0.00015147695,0.00137621,0.00007178214,0.0075413133,0.0041256915,0.049898423,0.00137753,0.06007554,0.034407627],"study_design_scores_gemma":[0.009207962,0.009727987,0.9552356,0.00015827999,0.00026686137,0.000016579512,0.0014910082,0.0015556931,0.008493157,0.00013398504,0.013554791,0.00015808121],"about_ca_topic_score_codex":0.000049109094,"about_ca_topic_score_gemma":0.00025658376,"teacher_disagreement_score":0.13990554,"about_ca_system_score_codex":0.00010180461,"about_ca_system_score_gemma":0.000008188995,"threshold_uncertainty_score":0.35168135},"labels":[],"label_agreement":null},{"id":"W2037968247","doi":"10.2217/dmt.11.29","title":"ACCORD microvascular and Eye substudy: should the results change our practice?","year":2011,"lang":"en","type":"article","venue":"Diabetes Management","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Clinical Practice; Optometry; Ophthalmology; Internal medicine; Cardiology; Medical physics; Intensive care medicine; Family medicine","score_opus":0.08076079386900148,"score_gpt":0.29639779146796197,"score_spread":0.2156369975989605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037968247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8170902,0.005987603,0.0000343656,0.026635952,0.0011701159,0.0068405913,0.000016003063,0.00041742396,0.14180776],"genre_scores_gemma":[0.9812171,0.0016936794,0.002552683,0.007114112,0.00018615309,0.0006686134,0.000058935206,0.000052426458,0.0064563104],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99817693,0.00007634895,0.0003098303,0.00051873556,0.0003895124,0.00052865886],"domain_scores_gemma":[0.99877864,0.000038697406,0.00014417202,0.0008409125,0.00006698383,0.00013058355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078071794,0.00029678032,0.00032055605,0.00013229315,0.00015062373,0.000073172414,0.0002163449,0.000055867375,0.000027076578],"category_scores_gemma":[0.000053651383,0.00019823623,0.0001333117,0.00026499334,0.00005485246,0.00026163153,0.00041528084,0.00014199641,0.00016597677],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010220532,0.004492014,0.23296523,0.0013763878,0.0134542575,0.00083163125,0.007615641,9.468074e-7,0.00019952128,0.010599851,0.07789965,0.6495428],"study_design_scores_gemma":[0.0048734946,0.00078065763,0.5040872,0.00018523473,0.003671592,0.0000015992289,0.0049534505,0.0000604746,0.0010540419,0.00026814538,0.47965562,0.0004084768],"about_ca_topic_score_codex":0.000049659757,"about_ca_topic_score_gemma":0.000008872658,"teacher_disagreement_score":0.64913434,"about_ca_system_score_codex":0.00005735523,"about_ca_system_score_gemma":0.0000051220504,"threshold_uncertainty_score":0.8083839},"labels":[],"label_agreement":null},{"id":"W2038292924","doi":"10.1016/j.cjca.2013.09.001","title":"Important Treatment Gaps in Vascular Protection for the Elderly After Type 2 Diabetes Therapy Initiation","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Sulfonylurea; Metformin; Diabetes mellitus; Internal medicine; Psychological intervention; Population; Type 2 diabetes; Cohort study; Cohort; Logistic regression; Emergency medicine; Insulin; Environmental health; Endocrinology","score_opus":0.01648194479494449,"score_gpt":0.22957213217534833,"score_spread":0.21309018738040383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038292924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892089,0.0062765465,0.00014969379,0.0023015542,0.00041455508,0.0012426662,0.0000028380887,0.0000033008007,0.00039997767],"genre_scores_gemma":[0.9981867,0.0007733626,0.00006413314,0.00022915441,0.00037920414,0.0002746891,0.0000071024942,0.000010882715,0.00007474853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993714,0.000046737958,0.00022666046,0.00008001634,0.00005424227,0.00022092952],"domain_scores_gemma":[0.99948,0.000039874478,0.00008596714,0.00012269813,0.00014595737,0.00012549874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020508346,0.000091436064,0.0002615087,0.00018612212,0.000037516667,0.00001824776,0.00004274999,0.000058973237,0.00004967321],"category_scores_gemma":[0.000040915053,0.00005305607,0.00015787123,0.00008785897,0.000035445475,0.00006601976,0.0000018735819,0.0000653766,0.0000070489814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026353428,0.00003452042,0.45991415,0.0000430158,0.002953389,0.00011514356,0.0005222771,0.00037068527,0.0009992127,0.00012634075,0.0053699445,0.52928776],"study_design_scores_gemma":[0.0034243339,0.0061093695,0.71750075,0.000047083304,0.00032999995,0.00001635552,0.00014632908,0.00007724742,0.00034064476,0.00072072755,0.27118322,0.000103976956],"about_ca_topic_score_codex":0.0005215946,"about_ca_topic_score_gemma":0.001013155,"teacher_disagreement_score":0.5291838,"about_ca_system_score_codex":0.00022464918,"about_ca_system_score_gemma":0.00025410522,"threshold_uncertainty_score":0.21635637},"labels":[],"label_agreement":null},{"id":"W2038458770","doi":"10.1016/j.beem.2004.08.001","title":"Glucagon-like peptide-1 and glucagon-like peptide-2","year":2004,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital","funders":"","keywords":"Glucagon-like peptide-2; Enteroendocrine cell; Glucagon-like peptide-1; Gastric emptying; Glucagon; Secretion; Internal medicine; Endocrinology; Biology; Glucose homeostasis; Peptide; Insulin; Endocrine system; Diabetes mellitus; Medicine; Type 2 diabetes; Insulin resistance; Biochemistry; Hormone; Stomach","score_opus":0.19668288527101643,"score_gpt":0.5121038890396701,"score_spread":0.3154210037686537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038458770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024676384,0.9544849,0.000013289348,0.0040589473,0.0028243253,0.005315736,0.000063769265,0.00027295106,0.032719344],"genre_scores_gemma":[0.000040918156,0.9528803,0.003706616,0.0013152584,0.002226876,0.0013862121,0.00037412829,0.00031685276,0.037752822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98270136,0.0048550693,0.0034556405,0.003227947,0.0022738767,0.003486132],"domain_scores_gemma":[0.9818402,0.010837142,0.0013247557,0.0030901341,0.0012594389,0.0016483532],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.006941293,0.0015852202,0.006807531,0.001634191,0.00063763914,0.00037774962,0.0013347089,0.0014360447,0.0004914982],"category_scores_gemma":[0.014842851,0.0012533403,0.0018607432,0.0015377357,0.0027014762,0.0009300469,0.002833274,0.007838525,0.0054665254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040224593,0.005291341,0.00005999245,0.008152991,0.005341412,0.0044205384,0.00006966213,2.0099984e-7,7.771774e-7,0.008851751,0.018422088,0.948987],"study_design_scores_gemma":[0.005365444,0.0024319685,0.0001481495,0.006405428,0.015577349,0.0012431381,0.0003353218,0.0000017442641,0.0000015209421,0.00042683675,0.96720964,0.0008534864],"about_ca_topic_score_codex":0.0008370355,"about_ca_topic_score_gemma":0.00006399679,"teacher_disagreement_score":0.9487875,"about_ca_system_score_codex":0.00049983885,"about_ca_system_score_gemma":0.003210831,"threshold_uncertainty_score":0.9998603},"labels":[],"label_agreement":null},{"id":"W2038704502","doi":"10.1016/s0828-282x(10)70010-6","title":"The incretin system and cardiometabolic disease","year":2010,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Merck Canada; Physicians' Services Incorporated Foundation; Heart and Stroke Foundation of Canada","keywords":"Medicine; Incretin; Type 2 diabetes; Diabetes mellitus; Glucose homeostasis; Disease; Internal medicine; Homeostasis; Islet; Beta cell; Endocrinology; Bioinformatics; Insulin resistance","score_opus":0.01803068645800104,"score_gpt":0.2665400894545175,"score_spread":0.24850940299651647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038704502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047947182,0.98973095,0.000009563638,0.0002116881,0.001426898,0.00043952803,0.0000358774,0.0000052446417,0.008092293],"genre_scores_gemma":[0.0015842982,0.9958151,0.000018613757,0.000033554283,0.0020039123,0.000023208677,0.000018154999,0.000031409087,0.00047174076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866974,0.0002303352,0.00047496232,0.0001506911,0.000118208845,0.0003560579],"domain_scores_gemma":[0.99791527,0.00014980468,0.00030932153,0.00035878498,0.00012132112,0.0011455263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006633027,0.00024117908,0.0020092109,0.00043251493,0.00014296698,0.000049733044,0.00019455324,0.0001928373,0.0000026216676],"category_scores_gemma":[0.00018747817,0.00013357708,0.0007101386,0.00014068752,0.0002367686,0.000023096612,0.000025889922,0.0005108681,0.000016308455],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007389862,4.0606477e-7,0.00036062827,0.0021886337,0.0014229394,0.0009302987,0.000005403678,3.6208428e-7,2.0542624e-8,0.0012178192,0.005709496,0.9881566],"study_design_scores_gemma":[0.0002620152,0.00006992225,0.00055681815,0.0020244983,0.0072885095,0.0009482712,0.000025808793,2.1199973e-7,1.2297355e-8,0.000010527054,0.98871344,0.000099976605],"about_ca_topic_score_codex":0.00008996689,"about_ca_topic_score_gemma":0.0001379258,"teacher_disagreement_score":0.9880566,"about_ca_system_score_codex":0.00019593042,"about_ca_system_score_gemma":0.0020342402,"threshold_uncertainty_score":0.5447115},"labels":[],"label_agreement":null},{"id":"W2038868574","doi":"10.1074/jbc.m103023200","title":"A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Canadian Diabetes Association","keywords":"Signal transduction; Receptor; Endocrinology; Chemistry; Internal medicine; Cell biology; Biochemistry; Biology; Medicine","score_opus":0.029363988072058474,"score_gpt":0.2605471788209853,"score_spread":0.23118319074892685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038868574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386173,0.0014700867,0.0017621577,0.0009995091,0.00013245296,0.00017824836,0.0000039603296,0.000028569171,0.0015632528],"genre_scores_gemma":[0.98197114,0.00050418306,0.011953973,0.00039364715,0.001218591,0.0000071322333,0.000020881866,0.0000131022825,0.003917316],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989694,0.000011567602,0.00041855566,0.00016105828,0.0001887796,0.00025068372],"domain_scores_gemma":[0.9991819,0.00008108899,0.0002542443,0.00012215633,0.00010389484,0.0002566937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017760381,0.00015313363,0.00037098723,0.000028465305,0.00003634083,0.000020226436,0.00012871606,0.00013689417,0.00067774166],"category_scores_gemma":[0.00017992342,0.00009665419,0.00026856986,0.000077728364,0.000026062968,0.000041712206,0.000037430425,0.00017798322,0.000016429463],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085571577,0.00037106508,0.011750662,0.00006533466,0.00028503418,0.00014482359,0.000025852054,0.000004780206,0.9304359,0.000024165216,0.002624675,0.05341197],"study_design_scores_gemma":[0.004640126,0.0015226197,0.002396308,0.00017206026,0.00016778517,0.00013208266,0.00011227298,0.000009761901,0.87717867,0.0004251546,0.11307162,0.00017155823],"about_ca_topic_score_codex":0.0000023044317,"about_ca_topic_score_gemma":1.5112671e-7,"teacher_disagreement_score":0.110446945,"about_ca_system_score_codex":0.00011446923,"about_ca_system_score_gemma":0.00008212749,"threshold_uncertainty_score":0.74207956},"labels":[],"label_agreement":null},{"id":"W2038915028","doi":"10.1097/med.0b013e3280a02f65","title":"Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus","year":2007,"lang":"en","type":"review","venue":"Current Opinion in Endocrinology Diabetes and Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Novartis Pharma","keywords":"Vildagliptin; Sitagliptin; Medicine; Metformin; Glycated hemoglobin; Hypoglycemia; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Type 2 Diabetes Mellitus; Dipeptidyl peptidase; Internal medicine; Type 2 diabetes; Dipeptidyl peptidase-4; Pharmacology; Alogliptin; Insulin; Endocrinology; Islet; Biochemistry; Chemistry; Enzyme","score_opus":0.0490025913824454,"score_gpt":0.3424005473924351,"score_spread":0.2933979560099897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038915028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015214774,0.98006874,0.0000011828748,0.00006550331,0.002040799,0.0020651417,0.000020581183,0.000043135184,0.00048015168],"genre_scores_gemma":[0.001915253,0.997249,0.00009341604,0.000022862678,0.00017617362,0.00018202726,0.0002152968,0.00003788476,0.000108078835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972626,0.00018428836,0.000878079,0.0006632546,0.0002510892,0.0007606652],"domain_scores_gemma":[0.9985764,0.00034397913,0.00036691377,0.00051417225,0.000058270834,0.00014024432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046650678,0.0005833537,0.002157371,0.0004696827,0.00009411605,0.000026368316,0.00019959241,0.00019237908,0.000024262732],"category_scores_gemma":[0.00002496263,0.0003776824,0.00031420199,0.00044917504,0.0007280384,0.0000652126,0.00055965706,0.000504032,0.000016436352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023862834,0.00037426973,0.024136279,0.054162156,0.0008361095,0.0000050650806,0.00004993644,1.1684089e-7,6.677551e-8,0.004895914,0.00050766894,0.91500854],"study_design_scores_gemma":[0.003226092,0.00027754164,0.008787269,0.024966195,0.0021296588,0.0000033572633,0.00006521868,0.00001285457,0.0000055468504,0.00031566512,0.95983416,0.000376437],"about_ca_topic_score_codex":0.000005455843,"about_ca_topic_score_gemma":0.0000011331839,"teacher_disagreement_score":0.9593265,"about_ca_system_score_codex":0.00008346697,"about_ca_system_score_gemma":0.000033516302,"threshold_uncertainty_score":0.9998675},"labels":[],"label_agreement":null},{"id":"W2039571658","doi":"10.1016/s2213-8587(13)70027-5","title":"Intensive insulin for type 2 diabetes: the risk of causing harm","year":2013,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Type 2 diabetes; Scopus; Diabetes mellitus; Internal medicine; Insulin; Hazard ratio; Post-hoc analysis; MEDLINE; Endocrinology","score_opus":0.10492927098788356,"score_gpt":0.3586264788800713,"score_spread":0.25369720789218775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039571658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005842721,0.9862368,0.000004646576,0.0014403361,0.00095353567,0.0044442387,0.00015817131,0.00010585438,0.0008136925],"genre_scores_gemma":[0.0007485782,0.99375254,0.00028912784,0.0015934095,0.00090785726,0.0013517782,0.00030800272,0.000107340566,0.0009413922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653476,0.00036168608,0.0007589546,0.0005171901,0.0002008673,0.0016265607],"domain_scores_gemma":[0.9954017,0.0018247826,0.0008370385,0.0014335823,0.00042374016,0.00007920331],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005334735,0.00062546064,0.0034324948,0.00020229635,0.00016663902,0.000036914935,0.0006014713,0.00020311194,0.00010747391],"category_scores_gemma":[0.00087347836,0.00029857896,0.0007247854,0.00037927582,0.00049146864,0.000050547773,0.00041013042,0.00066924107,0.00019657308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002540819,0.000101565565,0.0009538594,0.008528018,0.0058428235,0.0000072226812,0.00012550925,0.0000012327715,0.0000092964465,0.00096061686,0.027340768,0.9561037],"study_design_scores_gemma":[0.0011457509,0.00063315284,0.00020760922,0.0029161691,0.011155783,0.0000051250004,0.00008862174,0.00003924536,0.00010179866,0.00062542205,0.9828043,0.00027700924],"about_ca_topic_score_codex":0.000023995783,"about_ca_topic_score_gemma":0.0000049937635,"teacher_disagreement_score":0.9558267,"about_ca_system_score_codex":0.000116784366,"about_ca_system_score_gemma":0.00012402519,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W2039688371","doi":"10.1016/j.drudis.2013.09.003","title":"Modulating GPR40: therapeutic promise and potential in diabetes","year":2013,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Free fatty acid receptor 1; Receptor; Insulin; Diabetes mellitus; Type 2 diabetes; Pharmacology; Diabetes treatment; Biology; Endocrinology; Medicine; Internal medicine; Agonist","score_opus":0.021972775168732056,"score_gpt":0.2843587499058552,"score_spread":0.2623859747371231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039688371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00898001,0.9859916,0.0000044060216,0.00011860785,0.00021156727,0.002541306,0.000014933749,0.000049890237,0.002087674],"genre_scores_gemma":[0.006648572,0.98078847,0.00008377876,0.00012451185,0.00016604745,0.00055261335,0.00024409036,0.00008124822,0.011310661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981956,0.000101086036,0.0004907512,0.00053513376,0.0002306172,0.00044681598],"domain_scores_gemma":[0.9992114,0.000077602956,0.0001949483,0.00039990147,0.000015875277,0.00010029604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001810534,0.00048462112,0.0015138095,0.00026865656,0.000045174154,0.00016433642,0.00011935425,0.00013841435,0.00007659839],"category_scores_gemma":[0.000016612437,0.00033324014,0.00030757216,0.00019366476,0.0000604898,0.0003084233,0.00017008549,0.00025359512,0.00007994953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041761164,0.00021154413,0.00074107945,0.011642998,0.00048169086,0.000033159387,0.00006349628,0.0000017995978,0.0000034852524,0.0002095501,0.00044800155,0.986159],"study_design_scores_gemma":[0.0020612602,0.000183325,0.0013564795,0.025711186,0.0046237567,0.0000056763265,0.000085259366,0.00033058508,0.000010503952,0.0003666941,0.9643879,0.00087739056],"about_ca_topic_score_codex":0.000028677758,"about_ca_topic_score_gemma":0.00000437945,"teacher_disagreement_score":0.98528165,"about_ca_system_score_codex":0.00012981302,"about_ca_system_score_gemma":0.0000760492,"threshold_uncertainty_score":0.99991196},"labels":[],"label_agreement":null},{"id":"W2039809855","doi":"10.1074/jbc.m311304200","title":"[Ser2]- and [Ser(P)2]Incretin Analogs","year":2004,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Incretin; Postprandial; Dipeptidyl peptidase; Chemistry; Gastric inhibitory polypeptide; Internal medicine; Endocrinology; In vivo; Receptor; Insulin; Glucagon-like peptide-1; Peptide hormone; Hormone; Biochemistry; Glucagon; Enzyme; Biology; Medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.018135537490362744,"score_gpt":0.2535954399838747,"score_spread":0.23545990249351195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039809855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029016,0.0009626395,0.000022481127,0.0014800364,0.000027254864,0.000042917258,0.000001096085,0.000010996325,0.0071623945],"genre_scores_gemma":[0.99766266,0.00043954785,0.0010184718,0.00035272658,0.00016952261,9.723677e-7,0.000005052657,0.0000036010085,0.00034741993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99946356,0.000005798095,0.0002098886,0.00009177989,0.00010405837,0.00012493455],"domain_scores_gemma":[0.9996035,0.000021727135,0.00011539341,0.00007242087,0.000047530848,0.00013943278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013921804,0.00008718421,0.00023682058,0.000017942173,0.000020326512,0.000009466281,0.00005393567,0.00008257538,0.00015978282],"category_scores_gemma":[0.00008395395,0.00005139579,0.0000912039,0.0000522994,0.00007121105,0.00002568106,0.00003551839,0.00013758193,0.000005870403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000721321,0.001056483,0.1587941,0.0002642799,0.0006918934,0.0015223151,0.000079875346,0.000012682535,0.81906176,0.0003314374,0.002108801,0.01535507],"study_design_scores_gemma":[0.012039272,0.003305597,0.24094126,0.0005196351,0.0005232843,0.001226643,0.0004427866,0.0000061294068,0.69054866,0.006122108,0.043914426,0.00041021372],"about_ca_topic_score_codex":0.0000012983373,"about_ca_topic_score_gemma":7.7884074e-8,"teacher_disagreement_score":0.1285131,"about_ca_system_score_codex":0.000047470283,"about_ca_system_score_gemma":0.000022993385,"threshold_uncertainty_score":0.20958595},"labels":[],"label_agreement":null},{"id":"W2040137868","doi":"10.1517/17425250902873804","title":"Rosiglitazone in Canada: experience in clinical practice","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Drug Metabolism & Toxicology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); University of Toronto; Diabetes Canada; University of Ottawa","funders":"","keywords":"Rosiglitazone; Medicine; Sulfonylurea; Metformin; Type 2 diabetes; Observational study; Diabetes mellitus; Family medicine; Clinical Practice; Clinical trial; Type 2 Diabetes Mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.04013011643806443,"score_gpt":0.3764027745857627,"score_spread":0.3362726581476983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040137868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92076385,0.0125265345,0.000016623444,0.044608135,0.0040909722,0.0012166423,0.0000032065423,0.00006687211,0.016707173],"genre_scores_gemma":[0.9592893,0.0048384713,0.0016294308,0.033175442,0.0004208671,0.00016313785,0.000020923533,0.000018750907,0.00044363897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973785,0.00033205698,0.0007969211,0.00057357317,0.0003673228,0.0005516142],"domain_scores_gemma":[0.9987777,0.00035878702,0.00015015378,0.00045321725,0.000050053874,0.00021012187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005662052,0.00025100666,0.00072815275,0.00025506184,0.000035180252,0.00001259199,0.00018321643,0.00011820453,0.00014236954],"category_scores_gemma":[0.00064367586,0.00022003394,0.000087679815,0.0003770296,0.00005973876,0.00019098583,0.000055595814,0.00036175436,0.000037601476],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037609832,0.013621767,0.039369464,0.000028079194,0.00023401926,0.0018292431,0.00981207,0.00014940443,0.0019695058,0.0412548,0.10413368,0.78383696],"study_design_scores_gemma":[0.004102274,0.0003674373,0.37171683,0.00005231324,0.000008855035,0.0000090641115,0.0016272576,0.00010070201,0.0006982857,0.00007285351,0.62104756,0.00019655524],"about_ca_topic_score_codex":0.083800465,"about_ca_topic_score_gemma":0.0804295,"teacher_disagreement_score":0.78364044,"about_ca_system_score_codex":0.0005458399,"about_ca_system_score_gemma":0.00056604494,"threshold_uncertainty_score":0.9363503},"labels":[],"label_agreement":null},{"id":"W2040155092","doi":"10.1007/s00125-008-1236-0","title":"Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","year":2008,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Manitoba Health; Health Sciences Centre","funders":"Novo Nordisk; Sanofi; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Diabetes mellitus; Statement (logic); Family medicine; Position statement; Association (psychology); MEDLINE; Metformin; Evidence-based medicine; Alternative medicine; Psychology; Endocrinology; Political science; Pathology; Psychotherapist; Law","score_opus":0.042305306110465866,"score_gpt":0.3195245040459098,"score_spread":0.277219197935444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040155092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6273063,0.0020324555,4.4963983e-7,0.36517102,0.00060918776,0.004257572,0.00026584906,0.00002778061,0.00032940586],"genre_scores_gemma":[0.85107005,0.003516255,0.00013984417,0.14114779,0.0010909404,0.0007967684,0.00022024664,0.00009153111,0.0019265983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99084616,0.003985276,0.002306365,0.0006331478,0.0012834467,0.00094562385],"domain_scores_gemma":[0.9659645,0.024613712,0.0069160345,0.00082316506,0.0015834316,0.00009915702],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013463948,0.00056217064,0.001963414,0.00015142583,0.00059566344,0.00013342682,0.0005267083,0.0003408588,0.0000054135403],"category_scores_gemma":[0.029218966,0.0002509468,0.00045442418,0.0004250951,0.0008361959,0.00008010882,0.00025992838,0.0010646507,0.0000022353156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043627584,0.00015646654,0.6727001,0.00007931405,0.0048069847,0.0000026073021,0.0004394288,0.000001508235,0.0000026580292,0.000024340712,0.31958643,0.0021565564],"study_design_scores_gemma":[0.0091162585,0.0009166028,0.87364453,0.00016250148,0.009248806,3.023497e-7,0.0014002782,0.0004986143,0.000025033229,0.00020081091,0.10443952,0.0003467565],"about_ca_topic_score_codex":0.0039668833,"about_ca_topic_score_gemma":0.0032815756,"teacher_disagreement_score":0.22402322,"about_ca_system_score_codex":0.0006877446,"about_ca_system_score_gemma":0.00026815335,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W2040201181","doi":"10.1016/j.ajpath.2014.09.010","title":"Tumor Necrosis Factor α Decreases Glucagon-Like Peptide-2 Expression by Up-Regulating G-Protein–Coupled Receptor 120 in Crohn Disease","year":2014,"lang":"en","type":"article","venue":"American Journal Of Pathology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Free fatty acid receptor 1; GPR120; Tumor necrosis factor alpha; Internal medicine; Inflammation; Endocrinology; Receptor; Cancer research; Chemistry; Biology; Medicine; G protein-coupled receptor; Agonist","score_opus":0.009022119203658016,"score_gpt":0.25248361086831717,"score_spread":0.24346149166465914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040201181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977917,0.0002327437,0.0007001752,0.00060960307,0.00022018513,0.0002977251,0.000010443601,0.000025862251,0.00011155573],"genre_scores_gemma":[0.99354863,0.00005092211,0.004742183,0.00083303644,0.00014743302,0.00003072759,0.000023661642,0.0000376194,0.00058580673],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981808,0.00024200114,0.00059214374,0.0002832127,0.00029368087,0.00040816155],"domain_scores_gemma":[0.9983359,0.0001412499,0.0006986988,0.00028857408,0.000106957006,0.000428593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029057858,0.0002444903,0.0007165287,0.00026397975,0.00006197913,0.000023474055,0.0001615332,0.000034703724,0.00025880075],"category_scores_gemma":[0.00044185997,0.0001886403,0.00019441309,0.00022924645,0.00024547972,0.00013910193,0.00007661519,0.00020880438,0.00002192273],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00362507,0.0016724265,0.25304502,0.00014964717,0.0002336268,0.001237109,0.0010081441,0.000031762993,0.5256189,0.00007502524,0.0074201683,0.20588306],"study_design_scores_gemma":[0.017275607,0.009977128,0.895526,0.0024651117,0.0008665163,0.00027056056,0.0025441956,0.0010676462,0.051631596,0.0004881434,0.016736513,0.0011509935],"about_ca_topic_score_codex":0.00005363004,"about_ca_topic_score_gemma":0.0000040366476,"teacher_disagreement_score":0.64248097,"about_ca_system_score_codex":0.00011572851,"about_ca_system_score_gemma":0.00007854093,"threshold_uncertainty_score":0.76925284},"labels":[],"label_agreement":null},{"id":"W2040590401","doi":"10.1053/j.gastro.2010.05.006","title":"Glucagon-Like Peptide-2 Receptor Modulates Islet Adaptation to Metabolic Stress in the ob/ob Mouse","year":2010,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Canada Research Chairs; University Health Network; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Glucose homeostasis; Glucagon; Islet; Alpha cell; Homeostasis; Hypoglycemia; Insulin; Glucose tolerance test; Biology; Insulin resistance; Beta cell; Medicine","score_opus":0.011925110373892088,"score_gpt":0.24311081236401932,"score_spread":0.23118570199012722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040590401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921965,0.00003250543,0.00021232145,0.0059663053,0.00047279897,0.0006899482,0.000019169782,0.000046761703,0.000363706],"genre_scores_gemma":[0.99144536,0.00003183092,0.0023052974,0.00457918,0.000176674,0.00019607393,0.0001436158,0.000020861733,0.0011011254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876744,0.000087302025,0.00023741733,0.00029574972,0.00017007733,0.00044201387],"domain_scores_gemma":[0.99936056,0.000031544212,0.00006249717,0.00041022582,0.00004119356,0.0000939626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022094976,0.00017744132,0.00028565043,0.00019334965,0.000040349743,0.00002317918,0.00019120208,0.000063251246,0.00017415745],"category_scores_gemma":[0.000036953694,0.00012538135,0.00007617191,0.0001220163,0.000053657783,0.0000744839,0.000071939096,0.00021994767,0.00016996964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017670826,0.0023875341,0.8635402,0.0000835525,0.0006707706,0.00008439058,0.006614203,0.00070070836,0.068014584,0.0015860396,0.032445155,0.022105824],"study_design_scores_gemma":[0.011975149,0.00581949,0.8043686,0.00008117313,0.00074996246,0.000046674948,0.0035784557,0.0019144547,0.012172959,0.0002294324,0.15866107,0.00040254844],"about_ca_topic_score_codex":0.00014628022,"about_ca_topic_score_gemma":0.0013837412,"teacher_disagreement_score":0.12621592,"about_ca_system_score_codex":0.000020791198,"about_ca_system_score_gemma":0.000010196143,"threshold_uncertainty_score":0.5112903},"labels":[],"label_agreement":null},{"id":"W2041598837","doi":"10.1586/17446651.2014.950226","title":"Dapagliflozin for the treatment of Type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Expert Review of Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dapagliflozin; Medicine; Type 2 diabetes; Urinary system; Diabetes mellitus; Blood pressure; Empagliflozin; Internal medicine; Endocrinology; Pharmacology","score_opus":0.024102298614873445,"score_gpt":0.3257284269763708,"score_spread":0.3016261283614973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041598837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032391362,0.95670944,0.0000835878,0.005197046,0.00091395626,0.0019071137,0.000008389792,0.000034867728,0.0027542256],"genre_scores_gemma":[0.07873738,0.91045904,0.0040193275,0.0035168752,0.0005590965,0.00078938954,0.000063817344,0.000035560588,0.0018194838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988584,0.00007147399,0.00041637893,0.000216853,0.00013011767,0.00030676086],"domain_scores_gemma":[0.998707,0.00029660345,0.00018126924,0.0006184375,0.00014736138,0.000049340986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013932589,0.00019603978,0.0009743019,0.00007192009,0.000037858805,0.000002314253,0.0001447828,0.000032860826,0.0001602107],"category_scores_gemma":[0.00017343063,0.00010465086,0.00034080743,0.0001363867,0.00014252648,0.00002764546,0.000030047999,0.000032696436,0.000017302975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008818187,0.0012453153,0.0017048744,0.0026769314,0.0021999127,0.0000022670474,0.00024938575,6.6925475e-7,0.00402382,0.026284244,0.02711777,0.93440664],"study_design_scores_gemma":[0.0015805294,0.0010262887,0.0028986665,0.0005144774,0.0012322186,0.0000015562721,0.000019836867,0.000024747278,0.018322648,0.00010125302,0.97420007,0.00007769804],"about_ca_topic_score_codex":0.000015329226,"about_ca_topic_score_gemma":0.0000012697398,"teacher_disagreement_score":0.9470823,"about_ca_system_score_codex":0.00001825186,"about_ca_system_score_gemma":0.000022873757,"threshold_uncertainty_score":0.42675385},"labels":[],"label_agreement":null},{"id":"W2041914009","doi":"10.1136/bmjopen-2014-006341","title":"Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review","year":2015,"lang":"en","type":"review","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Epidemiology; Insulin; Internal medicine; Endocrinology","score_opus":0.3287978981638697,"score_gpt":0.47061503956420725,"score_spread":0.14181714140033758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041914009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040482814,0.9062658,0.0000014458626,0.000010381614,0.00014210824,0.09202294,0.0000634931,0.000017011496,0.0010719995],"genre_scores_gemma":[0.00014880292,0.98120564,0.00009096072,0.00012055407,0.000044980985,0.016912982,0.0010736494,0.000043755008,0.00035865986],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99709016,0.0005262559,0.0010486684,0.0005675812,0.00045876764,0.00030853876],"domain_scores_gemma":[0.99764645,0.00011161043,0.0007842147,0.0011137723,0.00019190228,0.00015202787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019998145,0.00050079945,0.007816684,0.00011734156,0.000037854654,0.000071377945,0.0003132414,0.00012301024,0.0000101294845],"category_scores_gemma":[0.00038658836,0.0003229049,0.00055491837,0.0002567507,0.000032795935,0.00009699692,0.0005111778,0.00015132062,0.000027613094],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014641532,0.00028035336,0.0007710584,0.971587,0.004576695,0.000008494598,0.000053601623,1.1098597e-7,1.2352858e-9,0.00002025207,0.0018449074,0.020842869],"study_design_scores_gemma":[0.0021253717,0.000441678,0.0011551173,0.83382,0.028760584,9.561221e-7,0.000015974054,0.0000125677525,8.3603396e-8,0.000018131683,0.13326362,0.00038594336],"about_ca_topic_score_codex":0.000041360014,"about_ca_topic_score_gemma":0.000017328453,"teacher_disagreement_score":0.13776703,"about_ca_system_score_codex":0.00036055586,"about_ca_system_score_gemma":0.0001559733,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W2042751221","doi":"10.1007/s12325-015-0195-3","title":"Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Metformin; Linagliptin; Medicine; Type 2 diabetes; Internal medicine; Nausea; Gastroenterology; Vildagliptin; Clinical endpoint; Diabetes mellitus; Vomiting; Dipeptidyl peptidase-4 inhibitor; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.0350316925553353,"score_gpt":0.32522749050495703,"score_spread":0.29019579794962175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042751221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862337,0.0051636,0.00001048517,0.00005192726,0.0002766395,0.006577009,0.000016419544,0.000038649134,0.0016315372],"genre_scores_gemma":[0.9913602,0.0044395016,0.0028543444,0.00007248383,0.00006727915,0.00058138993,0.00028888162,0.000056724497,0.00027920387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976281,0.00016681956,0.0007132149,0.0005412802,0.00047848513,0.00047210863],"domain_scores_gemma":[0.9981003,0.000653903,0.00042568828,0.0004868991,0.00014426016,0.000188962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006210065,0.00047682415,0.0014893132,0.0003339126,0.000040440616,0.000029978313,0.00015650288,0.00009778321,0.000023568935],"category_scores_gemma":[0.00008800327,0.0002927414,0.00008365641,0.0005866386,0.00029458973,0.00056347315,0.000036070305,0.00013959369,0.000005732458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9055531,0.002535234,0.006476252,0.00005102634,0.00067630806,0.000035738078,0.001328246,0.00006168463,0.000017820128,0.000113098344,0.000005281727,0.08314624],"study_design_scores_gemma":[0.9662702,0.02628315,0.0012482399,0.0003181527,0.00037374048,6.580191e-7,0.00035114278,0.00004440994,0.0012865338,0.000059489397,0.003453435,0.00031082742],"about_ca_topic_score_codex":0.0000836109,"about_ca_topic_score_gemma":0.00016519168,"teacher_disagreement_score":0.082835406,"about_ca_system_score_codex":0.00027024784,"about_ca_system_score_gemma":0.00017232604,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W2042914433","doi":"10.1210/en.2010-1047","title":"GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms","year":2010,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; University of Toronto","keywords":"Internal medicine; Endocrinology; Incretin; Glucose homeostasis; Gastric emptying; Insulin; Glucagon; Glucagon-like peptide-1; Receptor; Gastric inhibitory polypeptide; Peptide YY; Glucagon-like peptide 1 receptor; Homeostasis; Agonist; Chemistry; Biology; Type 2 diabetes; Insulin resistance; Diabetes mellitus; Neuropeptide; Medicine; Neuropeptide Y receptor; Stomach","score_opus":0.010644546750339857,"score_gpt":0.24999025335108416,"score_spread":0.2393457066007443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042914433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827296,0.0013795835,0.000109384695,0.0036390172,0.0008430626,0.0006614206,0.000013180737,0.00023124811,0.010393491],"genre_scores_gemma":[0.98634225,0.0016826355,0.007020255,0.0006932927,0.00016361539,0.00010154039,0.000082874,0.000042293803,0.003871265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824774,0.000047859914,0.0002941459,0.0005392188,0.00025733042,0.0006136732],"domain_scores_gemma":[0.99909097,0.000070416216,0.000098459575,0.0005284975,0.00005702576,0.00015462122],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012401155,0.0002863174,0.00044767628,0.00016991534,0.00010362347,0.000030578038,0.00014143188,0.0001409145,0.0015917587],"category_scores_gemma":[0.00007160794,0.0002443198,0.00008172394,0.00011494377,0.00015380679,0.000111453075,0.00035048922,0.00038685027,0.0003014657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008963073,0.0016577812,0.02092457,0.0003578285,0.001957418,0.0015004795,0.0013852358,0.000002163172,0.3925486,0.3083983,0.008086634,0.2622847],"study_design_scores_gemma":[0.009909585,0.0020286927,0.038866952,0.000067174675,0.00063735456,0.0006118949,0.0008659398,0.000022623572,0.72095263,0.018030306,0.20731995,0.0006868971],"about_ca_topic_score_codex":0.00016614965,"about_ca_topic_score_gemma":0.00011448414,"teacher_disagreement_score":0.32840404,"about_ca_system_score_codex":0.000052511055,"about_ca_system_score_gemma":0.000028056078,"threshold_uncertainty_score":0.9993209},"labels":[],"label_agreement":null},{"id":"W2043111603","doi":"10.1016/j.jval.2012.03.993","title":"PDB72 The Impact on Utilities of Weight Loss and Weight Gain Among Canadian Patients With Type 2 Diabetes","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Weight loss; Type 2 diabetes; Weight gain; Medicine; Weight change; Body mass index; Psychosocial; Obesity; Diabetes mellitus; Demography; Body weight; Gerontology; Internal medicine; Endocrinology; Psychiatry","score_opus":0.014891815029242444,"score_gpt":0.25271789705141107,"score_spread":0.23782608202216862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043111603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507415,0.0012512088,1.673145e-7,0.0006933869,0.00011361856,0.00060420076,0.000018527777,0.000008913511,0.002235802],"genre_scores_gemma":[0.9990915,0.00017131516,0.00003360794,0.00038443308,0.000049008577,0.000013666892,0.000032798227,0.00001455771,0.0002090959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990153,0.00008400289,0.00017152813,0.00011356993,0.00016039687,0.00045522835],"domain_scores_gemma":[0.99931663,0.00010019252,0.000070536975,0.00020857375,0.000030021334,0.00027407127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033546684,0.00012529836,0.00023379871,0.00015316678,0.000053953765,0.0000062377185,0.000045015164,0.00003132721,0.000048282942],"category_scores_gemma":[0.000024787798,0.0000653042,0.000024034991,0.00016750551,0.00008773093,0.000068061076,0.0000140414695,0.00008692392,0.000006102853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045808432,0.00016405147,0.9948152,0.00012875519,0.00006538813,0.0000010874488,0.00080293504,0.000022488395,2.3363447e-7,0.000462144,0.00091949984,0.002572425],"study_design_scores_gemma":[0.00084960536,0.0009775327,0.9958471,0.00026895397,0.00002574824,1.2749446e-7,0.00008105473,0.00019821174,0.00004198766,0.00007003721,0.001578738,0.00006087554],"about_ca_topic_score_codex":0.07567701,"about_ca_topic_score_gemma":0.003508459,"teacher_disagreement_score":0.072168544,"about_ca_system_score_codex":0.0002351108,"about_ca_system_score_gemma":0.0001408877,"threshold_uncertainty_score":0.93047816},"labels":[],"label_agreement":null},{"id":"W2043529363","doi":"10.1016/s1499-2671(09)33334-1","title":"Therapeutic potential of glucagon-like peptide-1 agonists in insulin-treated diabetes mellitus","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Insulin; Internal medicine; Glucagon; Endocrinology; Diabetes mellitus; Meal; Glucagon-like peptide-1; Type 2 diabetes","score_opus":0.009627391715999528,"score_gpt":0.2239193054182524,"score_spread":0.21429191370225287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043529363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983843,0.01285997,0.0000026068872,0.0012322826,0.00030510934,0.00029397357,0.000014032609,0.00001149314,0.0014374901],"genre_scores_gemma":[0.9981854,0.00016624077,0.00020173032,0.0010105051,0.00012444226,0.000003829072,0.00002402413,0.000025441417,0.0002583828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807686,0.000066543726,0.0006996082,0.00019693018,0.00028168474,0.0006783497],"domain_scores_gemma":[0.9984972,0.00005241692,0.00032301896,0.00027279236,0.00022612861,0.00062848465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032203193,0.00026400384,0.00072966935,0.0008830837,0.000057699228,0.000045727753,0.00022658975,0.00011616154,0.00011464805],"category_scores_gemma":[0.000062323874,0.00022427454,0.00026600197,0.00046510014,0.00013131903,0.00018437467,0.000010347609,0.00023951645,0.000012307542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004082839,0.00051018095,0.868886,0.00015560025,0.0009312276,0.00027483812,0.00039737785,0.000108655,0.010764288,0.00032819956,0.0018835842,0.11571924],"study_design_scores_gemma":[0.004113279,0.0024028928,0.9713619,0.000700101,0.0007102014,0.0000042967513,0.00016042251,0.00016617384,0.013295388,0.0010731071,0.0057096113,0.00030262666],"about_ca_topic_score_codex":0.0002815408,"about_ca_topic_score_gemma":0.0009946361,"teacher_disagreement_score":0.11541661,"about_ca_system_score_codex":0.00024523286,"about_ca_system_score_gemma":0.0005017809,"threshold_uncertainty_score":0.914565},"labels":[],"label_agreement":null},{"id":"W2043539706","doi":"10.14740/cr357w","title":"Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction","year":2014,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Eptifibatide; Cardiology; Acute coronary syndrome; Internal medicine; Cirrhosis; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.047061142459467596,"score_gpt":0.33822840104677077,"score_spread":0.2911672585873032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043539706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950109,0.0005528945,0.00018439777,0.0012926584,0.00009142388,0.0009476157,0.0000031879943,0.00001486052,0.001902059],"genre_scores_gemma":[0.99872243,0.00016624425,0.00033092388,0.00011924669,0.00008634089,0.00021675481,0.00003650311,0.000011594458,0.00030996412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866647,0.00038443107,0.00017672975,0.00024163102,0.00021899863,0.000311729],"domain_scores_gemma":[0.9987803,0.00078235276,0.000037455276,0.0002500899,0.00011180743,0.00003800097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032367262,0.00008466245,0.000336581,0.00021373405,0.00010853181,0.000010799236,0.00008656618,0.00010043078,0.0000042903616],"category_scores_gemma":[0.00026013036,0.000058388217,0.00007012952,0.00018250286,0.00019225494,0.000049371265,0.00010474507,0.0002382625,0.0000057900033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005258796,0.00009563087,0.91367257,0.00063252967,0.0012633741,0.0003108456,0.0029748585,0.000022690432,0.0052699917,0.0024939205,0.009636131,0.06310161],"study_design_scores_gemma":[0.0016360707,0.0017587411,0.9909936,0.00017903486,0.0002823294,0.00019643971,0.0006418315,0.0004922551,0.00026641064,0.0020772656,0.0013978131,0.00007820144],"about_ca_topic_score_codex":0.00002928104,"about_ca_topic_score_gemma":0.000010648003,"teacher_disagreement_score":0.07732107,"about_ca_system_score_codex":0.000050416755,"about_ca_system_score_gemma":0.00002288426,"threshold_uncertainty_score":0.23810025},"labels":[],"label_agreement":null},{"id":"W2043551382","doi":"10.1111/dom.12456","title":"Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Heritage Foundation for Medical Research","keywords":"Observational study; Medicine; Adverse effect; Confounding; Intensive care medicine; Clinical trial; Diabetes mellitus; Randomized controlled trial; Internal medicine; Endocrinology","score_opus":0.01702600455774621,"score_gpt":0.2704242773177059,"score_spread":0.2533982727599597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043551382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036347922,0.9603063,0.0000052500804,0.000003919524,0.00035118233,0.0016415523,0.00031455173,0.000042153555,0.0009871651],"genre_scores_gemma":[0.0037615157,0.9944835,0.0003080658,0.000054075615,0.00023157294,0.00005271646,0.00046667352,0.00006861897,0.00057326956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974159,0.0002478274,0.0007386798,0.00055827235,0.0006118409,0.00042749802],"domain_scores_gemma":[0.9979486,0.000085956504,0.0004497351,0.000965418,0.00023168657,0.0003185968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009823544,0.0005167273,0.0055616084,0.00030952334,0.000031677027,0.000020971605,0.00020142327,0.0003481786,0.000041651034],"category_scores_gemma":[0.000105259445,0.00042528904,0.001241793,0.00027375037,0.00023956156,0.00016466364,0.00014728395,0.00023364434,0.000009194587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058065387,0.0005787691,0.0030530216,0.010359551,0.009036232,0.000018688124,0.00014805913,5.49502e-7,0.000004821761,0.0004994665,0.00039155927,0.97585124],"study_design_scores_gemma":[0.0031779106,0.00018440138,0.014039089,0.0028075196,0.02563103,0.0000020936395,0.000027552576,0.0000030063575,0.000019613724,0.000044859025,0.9537234,0.00033953367],"about_ca_topic_score_codex":0.00012067061,"about_ca_topic_score_gemma":0.0000042980823,"teacher_disagreement_score":0.97551167,"about_ca_system_score_codex":0.0000492131,"about_ca_system_score_gemma":0.0001767039,"threshold_uncertainty_score":0.9998199},"labels":[],"label_agreement":null},{"id":"W2043889992","doi":"10.1038/nrendo.2013.47","title":"Emerging combinatorial hormone therapies for the treatment of obesity and T2DM","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Orexigenic; Anorectic; Glucose homeostasis; Weight loss; Leptin; Type 2 Diabetes Mellitus; Amylin; Obesity; Agonist; Hormone; Diabetes mellitus; Endocrinology; Internal medicine; Bioinformatics; Receptor; Body weight; Insulin resistance; Islet; Neuropeptide; Neuropeptide Y receptor; Biology","score_opus":0.04301559868598773,"score_gpt":0.3577527993440645,"score_spread":0.31473720065807675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043889992","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023103035,0.9892076,0.0000075786643,0.0003308748,0.0009086475,0.009082025,0.000022629765,0.00003250199,0.0003850198],"genre_scores_gemma":[0.000015531254,0.9951982,0.00042999373,0.000082195125,0.00044280096,0.002587244,0.00012684811,0.000044083594,0.0010731339],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981789,0.0001581652,0.0006818138,0.00043961385,0.0001271647,0.00041432242],"domain_scores_gemma":[0.9982003,0.00049963966,0.0005100233,0.00064846093,0.00007528168,0.000066315915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014279918,0.00055549777,0.003434227,0.00016171644,0.000095337346,0.000014787967,0.0001800095,0.0003712483,0.000032541302],"category_scores_gemma":[0.000070072376,0.0002607713,0.00089941605,0.00016280991,0.00014052785,0.00003185924,0.00006380289,0.0003242314,0.000023227054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015164541,0.00034491377,0.000013201438,0.0092751905,0.001801879,0.000006705585,0.00004623332,2.7375595e-9,5.8929515e-7,0.0060507376,0.0046593477,0.97778606],"study_design_scores_gemma":[0.0015356935,0.0013854363,0.000029764711,0.0017111145,0.008589888,0.000029791445,0.000012019085,5.358683e-7,0.0000032989717,0.00016837007,0.9863585,0.00017553693],"about_ca_topic_score_codex":0.000015105099,"about_ca_topic_score_gemma":0.0000024222168,"teacher_disagreement_score":0.9816992,"about_ca_system_score_codex":0.00012808506,"about_ca_system_score_gemma":0.000050649945,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W2044238158","doi":"10.1097/mol.0b013e32834d68f0","title":"Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states","year":2011,"lang":"en","type":"review","venue":"Current Opinion in Lipidology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Postprandial; Dyslipidemia; Medicine; Chylomicron; Incretin; Internal medicine; Endocrinology; Type 2 diabetes; Insulin resistance; Diabetes mellitus; Lipoprotein; Very low-density lipoprotein; Cholesterol","score_opus":0.16304430010051948,"score_gpt":0.4155222382372293,"score_spread":0.2524779381367098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044238158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016198595,0.980744,0.00004083484,0.00009894369,0.014437043,0.004177642,0.00021559554,0.00003421239,0.00008972469],"genre_scores_gemma":[0.00006375445,0.9923955,0.00041676094,0.000016601201,0.0022787764,0.0019521198,0.0027773555,0.000063278516,0.000035862467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970005,0.00035662518,0.001372988,0.00061193766,0.00013420077,0.0005237426],"domain_scores_gemma":[0.9978796,0.0008815898,0.00059925404,0.00047192007,0.00007000034,0.00009761826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041611493,0.0006059328,0.003164416,0.0010196357,0.000024652112,0.000007517127,0.00018068553,0.00034164308,0.00009213384],"category_scores_gemma":[0.00011076432,0.0004394682,0.00060313405,0.00034147655,0.00016398585,0.00003414117,0.000046506095,0.00015612195,0.000017592549],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001611486,0.0022235557,0.0016574766,0.034607768,0.00041865057,4.2457353e-7,0.0003896227,0.0000017898415,5.215745e-7,0.0018039349,0.0020234166,0.95526135],"study_design_scores_gemma":[0.006887688,0.0051858025,0.00048750255,0.013322873,0.000609189,8.519299e-7,0.00003142881,0.000021471522,0.0000010245843,0.00020107314,0.9729551,0.0002959932],"about_ca_topic_score_codex":0.00006319303,"about_ca_topic_score_gemma":0.000023105065,"teacher_disagreement_score":0.9709317,"about_ca_system_score_codex":0.000453653,"about_ca_system_score_gemma":0.00039992848,"threshold_uncertainty_score":0.9998057},"labels":[],"label_agreement":null},{"id":"W2045629242","doi":"10.1139/y09-095","title":"Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts","year":2010,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Internal medicine; Endocrinology; Insulin; Medicine; Downregulation and upregulation; Diabetes mellitus; Glucagon-like peptide-1; Receptor; Endothelium; Glucagon; Glucagon-like peptide 1 receptor; Streptozotocin; Type 2 diabetes; Chemistry; Agonist","score_opus":0.008806025899455621,"score_gpt":0.25146696617518105,"score_spread":0.24266094027572543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045629242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970065,0.00044742099,3.501309e-7,0.0010003237,0.0008786386,0.00016237044,0.0000054722227,0.0000023922473,0.00049652916],"genre_scores_gemma":[0.9985596,0.00010912058,0.000092689945,0.0008287853,0.00020773552,0.0000050267436,0.000019376046,0.00000766479,0.00017001125],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992731,0.00008212295,0.00026483406,0.000116737734,0.00004614553,0.00021704765],"domain_scores_gemma":[0.9993734,0.000078313635,0.00014595398,0.00007503736,0.000075353266,0.00025196295],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018288143,0.00010017406,0.00032973423,0.00037674757,0.00003802119,0.0000027394083,0.00005889875,0.00010530219,0.0010372634],"category_scores_gemma":[0.000022592285,0.00008496139,0.00005428324,0.000109538196,0.00018756014,0.000053179378,0.00000853293,0.0002872543,0.000010357703],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024483964,0.00011124698,0.015902622,0.000047661564,0.00012774502,0.000020698606,0.0002955077,0.000031232306,0.9734694,0.00031919417,0.0049994895,0.004430356],"study_design_scores_gemma":[0.0053091696,0.0028175607,0.53253895,0.00009675342,0.0003071698,0.000028604825,0.00013665881,0.00014796329,0.39809746,0.0029470657,0.0573876,0.00018507217],"about_ca_topic_score_codex":0.00022705556,"about_ca_topic_score_gemma":0.0016843452,"teacher_disagreement_score":0.575372,"about_ca_system_score_codex":0.000037235975,"about_ca_system_score_gemma":0.00021349319,"threshold_uncertainty_score":0.9998759},"labels":[],"label_agreement":null},{"id":"W2045790951","doi":"10.1111/dom.12348","title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"American Heart Association","keywords":"Canagliflozin; Medicine; Placebo; Internal medicine; Kidney disease; Renal function; Diabetes mellitus; Empagliflozin; Urology; Type 2 diabetes; Endocrinology; Gastroenterology; Pathology","score_opus":0.003466919050973172,"score_gpt":0.19398320196770036,"score_spread":0.19051628291672718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045790951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028516,0.008497312,0.0000015601761,0.00015890982,0.0000871281,0.0006536363,0.00003814537,0.000023572255,0.00025458873],"genre_scores_gemma":[0.99797654,0.0011365133,0.0001095305,0.00044642444,0.000056445075,0.000015574667,0.00012227814,0.000021332096,0.00011536965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987628,0.000063736465,0.00022472348,0.00036538666,0.00020925891,0.00037408117],"domain_scores_gemma":[0.99907774,0.00007780388,0.000084403,0.00026242563,0.00005735213,0.00044026357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020246912,0.00024285875,0.0005730134,0.00016734443,0.000063586805,0.000025379708,0.000052658277,0.0000624087,0.000028935745],"category_scores_gemma":[0.00011565827,0.00018596888,0.000031826432,0.00018405683,0.00018333198,0.00014099226,0.00010265204,0.00010274785,0.0000020530547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020585043,0.00042342083,0.9758973,0.0004885362,0.00022019462,0.0000012625839,0.000082736915,0.0000017893774,0.00009671232,0.0007647573,0.00012390417,0.021693528],"study_design_scores_gemma":[0.0090422025,0.0003838558,0.9764097,0.0002571011,0.0007372312,2.4046589e-8,0.000004533543,0.00015420253,0.0003162583,0.00013649391,0.012363429,0.0001949736],"about_ca_topic_score_codex":0.000051209965,"about_ca_topic_score_gemma":0.000027835653,"teacher_disagreement_score":0.021498553,"about_ca_system_score_codex":0.000028253326,"about_ca_system_score_gemma":0.00004824515,"threshold_uncertainty_score":0.7583591},"labels":[],"label_agreement":null},{"id":"W2046526895","doi":"10.1210/me.2013-1029","title":"Stimulation of Proglucagon Gene Expression by Human GPR119 in Enteroendocrine L-cell Line GLUTag","year":2013,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Balliol College, University of Oxford; National Institutes of Health; University of Toronto; Bundesministerium für Bildung und Forschung; European Commission; University of Oxford; National Institute of General Medical Sciences; American Diabetes Association","keywords":"Proglucagon; Enteroendocrine cell; Prohormone convertase; Biology; Gene; Secretion; Receptor; Protein subunit; Transfection; Cell biology; Molecular biology; Glucagon-like peptide-1; Biochemistry; Endocrinology; Prohormone; Hormone; Endocrine system","score_opus":0.009652835905213783,"score_gpt":0.26060679786444857,"score_spread":0.2509539619592348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046526895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940683,0.00070867036,0.00058429147,0.00051438936,0.000062668405,0.0010818719,0.0000037187856,0.0000546793,0.0029214097],"genre_scores_gemma":[0.9957255,0.000053305168,0.00197751,0.0002293366,0.000018373386,0.00019102484,0.00025973422,0.000028283817,0.0015169105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865377,0.00005974165,0.0003709215,0.00032671465,0.00017092879,0.00041793648],"domain_scores_gemma":[0.99938315,0.000014010804,0.00011114748,0.000356601,0.00006007845,0.00007500548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028246666,0.0001907156,0.00035652248,0.00023859054,0.000021567237,0.000008013116,0.000100713725,0.000047422025,0.00027264628],"category_scores_gemma":[0.000014338704,0.000171134,0.00008053954,0.00012497716,0.00005445345,0.00006770338,0.00012349384,0.00011825377,0.000069758746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004271639,0.0009206593,0.021705214,0.000092891445,0.000049755992,0.00016013897,0.000034838085,0.000059043796,0.9720375,0.00015138746,0.0011892888,0.0035565773],"study_design_scores_gemma":[0.0046405196,0.0009853162,0.009584027,0.00004713194,0.000075769596,0.000011060029,0.000023714174,0.00017148879,0.9826216,0.00029224137,0.0014253841,0.00012174873],"about_ca_topic_score_codex":0.00012256941,"about_ca_topic_score_gemma":0.0000043056316,"teacher_disagreement_score":0.012121187,"about_ca_system_score_codex":0.00006275711,"about_ca_system_score_gemma":0.000010806355,"threshold_uncertainty_score":0.69786423},"labels":[],"label_agreement":null},{"id":"W2047071266","doi":"10.1038/ncpendmet0640","title":"Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?","year":2007,"lang":"en","type":"letter","venue":"Nature Clinical Practice Endocrinology &#38 Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; McMaster University Medical Centre","funders":"","keywords":"Medicine; Rosiglitazone; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.012574017902247037,"score_gpt":0.30212686666165806,"score_spread":0.289552848759411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047071266","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4643432,0.2915197,0.000069056434,0.20575972,0.011591541,0.0118970005,0.001103937,0.0007792265,0.012936622],"genre_scores_gemma":[0.15991831,0.12785164,0.045555696,0.6232091,0.022346932,0.00082184636,0.009815058,0.0011531275,0.009328276],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99243164,0.0014524389,0.0014296836,0.0017281262,0.0015848266,0.0013732937],"domain_scores_gemma":[0.98945934,0.004530466,0.001636331,0.0024803628,0.0015602548,0.00033322215],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009174085,0.001206346,0.0038314243,0.00055641745,0.0001359207,0.000041214284,0.0004214539,0.0023589195,0.00014603273],"category_scores_gemma":[0.0032321298,0.0005834826,0.0011882224,0.00059510994,0.0008473676,0.00035407537,0.00019887967,0.006577092,0.00008433501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016167918,0.013454005,0.3126,0.0011949262,0.20077886,0.0105888,0.00017624369,0.000010822293,0.0000031204222,0.00029213453,0.24351394,0.20121925],"study_design_scores_gemma":[0.011907589,0.0049922313,0.06820462,0.00014879703,0.051599253,0.000013163192,0.000053047606,9.025483e-7,0.00012909257,0.000039891824,0.86232597,0.0005854256],"about_ca_topic_score_codex":0.00017100961,"about_ca_topic_score_gemma":0.000016699083,"teacher_disagreement_score":0.618812,"about_ca_system_score_codex":0.0001982951,"about_ca_system_score_gemma":0.00033294645,"threshold_uncertainty_score":0.9996617},"labels":[],"label_agreement":null},{"id":"W2047199620","doi":"10.1111/dom.12391","title":"Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Placebo; Tolerability; Pioglitazone; Medicine; Type 2 diabetes; Randomized controlled trial; Clinical endpoint; Internal medicine; Diabetes mellitus; Adverse effect; Endocrinology","score_opus":0.016460300769629517,"score_gpt":0.25187791448215346,"score_spread":0.23541761371252395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047199620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977327,0.018109096,0.000047161924,0.0003834631,0.00040723546,0.0032388624,0.000023261038,0.00002964068,0.0004342978],"genre_scores_gemma":[0.9918148,0.006079913,0.0009666876,0.00018063815,0.0002550961,0.00015181323,0.000047773086,0.00002520515,0.00047807736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99847275,0.00017601538,0.00050112815,0.00031115543,0.00020240078,0.00033654424],"domain_scores_gemma":[0.9974291,0.0017514168,0.00022537833,0.00035311084,0.00012490786,0.000116137286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011031207,0.00027590882,0.0014996213,0.00013023404,0.00012558782,0.000023337885,0.00008503221,0.00009205731,0.000015929174],"category_scores_gemma":[0.00042558482,0.00016375678,0.00029502015,0.00015574499,0.00030609762,0.0000773084,0.000046889574,0.00005643979,0.0000013229832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47273666,0.0039873994,0.020324444,0.0012400163,0.008525568,0.0000011926942,0.0024891135,0.000018051682,0.0075334087,0.01666667,0.00024033172,0.46623716],"study_design_scores_gemma":[0.8883967,0.001896066,0.04271041,0.0001323895,0.0072350944,1.3877214e-7,0.00004802019,0.0016508809,0.011836838,0.0007254557,0.045140192,0.00022783493],"about_ca_topic_score_codex":0.000019401887,"about_ca_topic_score_gemma":0.0000024162484,"teacher_disagreement_score":0.46600932,"about_ca_system_score_codex":0.000013463143,"about_ca_system_score_gemma":0.000022694947,"threshold_uncertainty_score":0.66778076},"labels":[],"label_agreement":null},{"id":"W2047365661","doi":"10.1016/s0140-6736(07)61489-5","title":"Patient-important outcomes in diabetes—time for consensus","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Rosiglitazone; Medicine; Type 2 diabetes; Intensive care medicine; Pioglitazone; Diabetes mellitus; Psychological intervention; Journal club; Family medicine; Psychiatry; Endocrinology","score_opus":0.021446048335907797,"score_gpt":0.27945503455488147,"score_spread":0.25800898621897367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047365661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834385,0.0001766691,0.0000051113057,0.0066604004,0.00010445521,0.00075305137,0.000015988186,0.00004849633,0.008797344],"genre_scores_gemma":[0.9929656,0.0000094504185,0.000903807,0.0033561115,0.00013370297,0.00004580795,0.000028533834,0.0000131874185,0.0025438424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992533,0.000009084133,0.00019858884,0.00010732988,0.00009918276,0.0003325385],"domain_scores_gemma":[0.9994344,0.00018072277,0.000053680254,0.00027696084,0.000016296332,0.000037953407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039485458,0.00008644998,0.00032250088,0.00004544362,0.000024503302,0.000007826722,0.00005751878,0.00002353828,0.000039733543],"category_scores_gemma":[0.00007851914,0.000049557853,0.000056488934,0.00006941823,0.000031368752,0.000010377141,0.000024423909,0.000047931924,0.00004373283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021962433,0.00022527749,0.95058054,0.00005208489,0.00018707759,0.000034613036,0.00019973368,0.0000012470263,0.0006563004,0.0011056297,0.031348497,0.015389356],"study_design_scores_gemma":[0.008240355,0.0006916802,0.85766,0.000086924076,0.00021779924,0.0000013037844,0.00015600245,0.0002825127,0.003379782,0.0016606746,0.1274388,0.00018418801],"about_ca_topic_score_codex":0.0000069487337,"about_ca_topic_score_gemma":0.000020567477,"teacher_disagreement_score":0.0960903,"about_ca_system_score_codex":0.00003483045,"about_ca_system_score_gemma":0.000008483969,"threshold_uncertainty_score":0.20209105},"labels":[],"label_agreement":null},{"id":"W2047368543","doi":"10.1007/s00125-011-2119-3","title":"Synaptotagmin-7 as a positive regulator of glucose-induced glucagon-like peptide-1 secretion in mice","year":2011,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biomedical Research Council; Department of Medicine, University of Toronto; University of Toronto; Université de Genève; Agency for Science, Technology and Research","keywords":"Regulator; Internal medicine; Endocrinology; Secretion; Synaptotagmin 1; Human physiology; Glucagon-like peptide-1; Glucagon; Chemistry; Peptide; Biology; Medicine; Diabetes mellitus; Insulin; Biochemistry; Type 2 diabetes; Gene","score_opus":0.021069064298900396,"score_gpt":0.24985800961281832,"score_spread":0.2287889453139179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047368543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96990323,0.00017383082,0.000011530871,0.00012129954,0.00022269701,0.00070478534,0.0000067193723,0.00007148064,0.028784456],"genre_scores_gemma":[0.99780256,0.000027695995,0.0007332039,0.0003084714,0.000023733732,0.00007275274,0.000074892596,0.000023390434,0.0009332955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998658,0.00006380812,0.00035178984,0.00035815084,0.0001971487,0.00037111042],"domain_scores_gemma":[0.99930584,0.000060468967,0.00015109146,0.00028621336,0.00009038008,0.0001059998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021148396,0.00021557025,0.0004974419,0.0002564096,0.000026036325,0.0000062611152,0.00011201598,0.00013671609,0.00018319128],"category_scores_gemma":[0.00008849132,0.0001871746,0.00011925817,0.00031313405,0.00008578729,0.00010391342,0.000081854836,0.00013235536,0.00013823496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001930645,0.0047477097,0.61287993,0.0006523781,0.0018532507,0.00080590096,0.0055008736,0.000001512442,0.29050955,0.015114834,0.0020106635,0.06399275],"study_design_scores_gemma":[0.0020689107,0.0015415193,0.7399988,0.00024126745,0.00027056888,0.000006793972,0.0004138618,0.00005941071,0.2544942,0.00052828196,0.00017185911,0.00020450944],"about_ca_topic_score_codex":0.000262788,"about_ca_topic_score_gemma":0.000031171083,"teacher_disagreement_score":0.12711889,"about_ca_system_score_codex":0.00011947606,"about_ca_system_score_gemma":0.000052889434,"threshold_uncertainty_score":0.7632759},"labels":[],"label_agreement":null},{"id":"W2047650300","doi":"10.1345/aph.1k666a","title":"Comment: Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective","year":2009,"lang":"en","type":"letter","venue":"Annals of Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; Fraser Health; University of British Columbia","funders":"","keywords":"Medicine; Perspective (graphical); Type 2 diabetes; Internal medicine; Diabetes mellitus; Cardiology; Rosiglitazone; Intensive care medicine; Endocrinology; Artificial intelligence","score_opus":0.06417809731646455,"score_gpt":0.3757425626017573,"score_spread":0.31156446528529275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047650300","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007635243,0.013264244,0.0000013258972,0.9668744,0.00039380012,0.00088917726,0.000030371573,0.000059445818,0.010851971],"genre_scores_gemma":[0.012914442,0.022481749,0.000072067916,0.96076524,0.001963817,0.00005512233,0.0002349221,0.00006032199,0.0014522874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998284,0.00013659007,0.0003667046,0.00040468606,0.00028801666,0.0005200101],"domain_scores_gemma":[0.9990486,0.00011716132,0.00018866087,0.00034078563,0.0002446111,0.000060205977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001967229,0.00037310025,0.001053856,0.000500634,0.000021753205,0.000010131919,0.00018594788,0.0003168536,0.0002787447],"category_scores_gemma":[0.00001963132,0.00031889614,0.0003124693,0.00030432432,0.00008154053,0.000060587347,0.000025573514,0.00063771324,0.000040232302],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019279728,0.00021911786,0.0010973362,0.0001875689,0.001504521,0.00031541666,0.00025694256,0.0000031667869,0.0010827725,0.00012295831,0.9910541,0.0039632716],"study_design_scores_gemma":[0.002264192,0.001154834,0.00059907284,0.00027167852,0.00024327514,0.0000019984577,0.000048772534,0.000012153925,0.008147436,0.00092966267,0.9860743,0.0002525746],"about_ca_topic_score_codex":0.00003435118,"about_ca_topic_score_gemma":0.0000013786723,"teacher_disagreement_score":0.009399683,"about_ca_system_score_codex":0.00009065696,"about_ca_system_score_gemma":0.00008226484,"threshold_uncertainty_score":0.9999263},"labels":[],"label_agreement":null},{"id":"W2048210769","doi":"10.1016/j.ijcard.2015.02.034","title":"Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?","year":2015,"lang":"en","type":"review","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Boehringer Ingelheim Fonds; Takeda Pharmaceuticals U.S.A.; Novartis; Merck; AstraZeneca","keywords":"Medicine; Dipeptidyl peptidase-4; Myocardial infarction; Internal medicine; Clinical trial; Cardiology; Duration (music); Dipeptidyl peptidase; Pharmacology; Diabetes mellitus; Type 2 diabetes; Endocrinology; Enzyme","score_opus":0.05751102352327929,"score_gpt":0.38950145069566783,"score_spread":0.3319904271723885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048210769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057381086,0.9275231,0.00015954666,0.0002816268,0.0038338513,0.003971093,0.00026997842,0.000017163828,0.0065625836],"genre_scores_gemma":[0.059582017,0.9376692,0.00016409544,0.000013808534,0.0022871755,0.000043691023,0.00009072685,0.000028138114,0.00012110999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954842,0.0010036301,0.0023096902,0.00020684359,0.0008603944,0.00013527706],"domain_scores_gemma":[0.9947233,0.00033451352,0.0035106689,0.00021383922,0.0011437823,0.000073884206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032706356,0.00027470544,0.0037982862,0.0010828302,0.000008775193,0.000011133799,0.0002125381,0.00019698561,0.000026095164],"category_scores_gemma":[0.00052740553,0.00017701623,0.0010853255,0.0002052829,0.0000818625,0.000124899,0.00007101427,0.00033983742,0.000005871323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031612923,0.00090645585,0.06362345,0.0014367048,0.045970507,0.0005199291,0.00092368736,0.00012991804,0.000012370646,0.000046645793,0.008193795,0.8750752],"study_design_scores_gemma":[0.012900993,0.008982888,0.012443272,0.009828783,0.020640977,0.00045276337,0.00072688237,0.000003666815,0.000018805238,0.00011362196,0.93358856,0.00029876814],"about_ca_topic_score_codex":0.00008442191,"about_ca_topic_score_gemma":0.000010631647,"teacher_disagreement_score":0.9253948,"about_ca_system_score_codex":0.00036229912,"about_ca_system_score_gemma":0.00044055807,"threshold_uncertainty_score":0.7218513},"labels":[],"label_agreement":null},{"id":"W2048253075","doi":"10.4021/jem.v1i3.38","title":"Effects of Liraglutide, a Human Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in Patients With Type 2 Diabetes","year":2011,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Internal medicine; Endocrinology; Adiponectin; Adipokine; Type 2 diabetes; Diabetes mellitus; Insulin; Type 2 Diabetes Mellitus; Lipid profile; Insulin resistance","score_opus":0.010970304156687602,"score_gpt":0.23010420716779864,"score_spread":0.21913390301111105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048253075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887802,0.009742732,0.0000017537268,0.000043443764,0.00037060268,0.0003337794,0.0000023516359,0.00000850014,0.00071664865],"genre_scores_gemma":[0.9974235,0.00145389,0.0005502383,0.00028290562,0.000100047946,0.000008598489,0.0000044117687,0.000020147261,0.00015623866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871045,0.00009108041,0.00043905186,0.00020811046,0.00019461733,0.00035668214],"domain_scores_gemma":[0.99908257,0.00008334906,0.00035126813,0.00016466137,0.00017813816,0.00014004107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013473554,0.0002409386,0.000885441,0.00058646064,0.000042952932,0.0000070938854,0.00009120228,0.000071377464,0.000021618258],"category_scores_gemma":[0.000074801515,0.00015901032,0.00008031229,0.00019658626,0.00018769133,0.00015812837,0.00006304788,0.00024068798,0.0000018116422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027555795,0.0029636568,0.9469085,0.00049174996,0.002877609,0.00029643378,0.0010946129,0.0000014252641,0.0074153743,0.0058356198,0.00053910114,0.028820341],"study_design_scores_gemma":[0.009667487,0.0023689813,0.9576981,0.00018632956,0.001472326,0.000012122584,0.000036128684,8.7491685e-7,0.02271893,0.00029281442,0.005413032,0.00013287066],"about_ca_topic_score_codex":0.000023141183,"about_ca_topic_score_gemma":0.000009620037,"teacher_disagreement_score":0.028687472,"about_ca_system_score_codex":0.000013803944,"about_ca_system_score_gemma":0.000027580609,"threshold_uncertainty_score":0.6484253},"labels":[],"label_agreement":null},{"id":"W2048442469","doi":"10.1159/000112529","title":"Evidence for Increased Risk of Prediabetes in the Uremic Patient","year":2007,"lang":"en","type":"review","venue":"Nephron Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Medicine; Prediabetes; Intensive care medicine; Nephrology; Diabetes mellitus; Kidney disease; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.31720831690983753,"score_gpt":0.5253043884936736,"score_spread":0.20809607158383603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048442469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002703285,0.990548,0.00003731727,0.0003277984,0.00033088212,0.0054885037,0.000035235687,0.00002526417,0.0029366366],"genre_scores_gemma":[0.00017154193,0.9926085,0.004454403,0.0016666425,0.00042623785,0.00044446829,0.00009603833,0.00004103812,0.00009115397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952501,0.0012869878,0.0019936536,0.0005390257,0.0005700336,0.0003601841],"domain_scores_gemma":[0.93873155,0.05828123,0.0018228667,0.0008694037,0.00018524069,0.00010970432],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007833227,0.0003525239,0.0018396364,0.00016184131,0.000041741096,0.000023808781,0.00032977323,0.00040710586,0.00003568064],"category_scores_gemma":[0.04048331,0.0002061954,0.0009075921,0.00038709005,0.00013778472,0.0002084112,0.00010421625,0.0009211906,0.000055201934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003748404,0.0014293363,0.0005212124,0.0077540865,0.0007647803,0.000025402995,0.00004132931,1.6719116e-7,5.4307986e-8,0.00006955049,0.009232826,0.9797864],"study_design_scores_gemma":[0.0012091432,0.0023846864,0.0005146947,0.0143034505,0.015877504,0.0000052220475,0.0000712594,0.000009719477,4.9835666e-7,0.000043402888,0.9654201,0.00016031529],"about_ca_topic_score_codex":0.00007441843,"about_ca_topic_score_gemma":0.00001267032,"teacher_disagreement_score":0.9796261,"about_ca_system_score_codex":0.00013606925,"about_ca_system_score_gemma":0.00034759878,"threshold_uncertainty_score":0.9675991},"labels":[],"label_agreement":null},{"id":"W2049182490","doi":"10.1016/j.ejheart.2008.05.013","title":"The Risk of Heart Failure in Patients with Type 2 Diabetes Treated with Oral Agent Monotherapy","year":2008,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Laboratory of Public Health; University of Alberta","funders":"Institute of Circulatory and Respiratory Health; Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale; Kidney Foundation of Canada; University of Alberta; Canadian Diabetes Association; Institute of Nutrition, Metabolism and Diabetes; Heart and Stroke Foundation of Canada","keywords":"Medicine; Sulfonylurea; Metformin; Diabetes mellitus; Type 2 diabetes; Internal medicine; Heart failure; Incidence (geometry); Retrospective cohort study; Cohort; Insulin; Endocrinology","score_opus":0.008414176568481571,"score_gpt":0.2029828851529236,"score_spread":0.19456870858444203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049182490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957623,0.00038202145,0.0000042882593,0.0033048536,0.000040140243,0.00034219347,0.000003129154,0.000013620824,0.0001474688],"genre_scores_gemma":[0.99399215,0.00009951179,0.005282778,0.00018455436,0.000057106645,0.000001580324,0.0000072191046,0.000046690995,0.0003284245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984933,0.00027103888,0.00039661865,0.00014614682,0.00041766674,0.0002752219],"domain_scores_gemma":[0.9989908,0.000042442698,0.00027836338,0.00026992374,0.0002901535,0.00012832475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038301374,0.0002016436,0.00042376708,0.00019257134,0.000109250694,0.000020518359,0.00011469916,0.000020487654,0.000042074676],"category_scores_gemma":[0.000025961219,0.00009957807,0.00009801303,0.00040819062,0.00012888027,0.00011623489,0.000021940283,0.00025711305,0.000023612545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009081283,0.00038360263,0.96442,0.000013658357,0.00045893952,0.00008574211,0.00016815399,0.0000664021,0.00012276991,0.000002512652,0.032377943,0.0009921276],"study_design_scores_gemma":[0.007116842,0.006796913,0.83364284,0.0002840266,0.00018454825,0.000015025919,0.00011726607,0.0000058950895,0.0005250476,0.0000019498455,0.15119979,0.0001098328],"about_ca_topic_score_codex":0.0000049935475,"about_ca_topic_score_gemma":0.000017420332,"teacher_disagreement_score":0.13077715,"about_ca_system_score_codex":0.00004464107,"about_ca_system_score_gemma":0.000054332653,"threshold_uncertainty_score":0.40606758},"labels":[],"label_agreement":null},{"id":"W2049204477","doi":"10.3111/13696998.2014.925905","title":"Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Takeda Pharmaceuticals International; U.S. Department of Labor","keywords":"Medicine; Diabetes mellitus; Emergency medicine; Total cost; Type 2 diabetes; Multivariate analysis; Type 2 Diabetes Mellitus; Logistic regression; Retrospective cohort study; Cost driver; Internal medicine; Endocrinology","score_opus":0.014911014080041403,"score_gpt":0.25825043689007543,"score_spread":0.24333942281003404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049204477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998487,0.00020620515,0.00018776546,0.0007916803,0.000051921103,0.00009514635,0.000025516027,0.0000035503606,0.00015122723],"genre_scores_gemma":[0.9970423,0.0022946093,0.00027842593,0.00011392211,0.000044318585,6.868501e-7,0.00020247979,0.0000065240165,0.000016730242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904335,0.00004050476,0.00039853604,0.000161775,0.00021332837,0.0001425092],"domain_scores_gemma":[0.9991318,0.00007467216,0.00030562797,0.00022567739,0.000074170115,0.00018805079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072548544,0.00009865372,0.0005865407,0.00018477756,0.000013264607,0.0000124155,0.00015425487,0.00007888893,0.00007317408],"category_scores_gemma":[0.0001941415,0.00007041866,0.000056071767,0.00025024987,0.00011609516,0.00013825117,0.00007025485,0.0001552846,0.0000014000117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043329617,0.0002978624,0.96256185,0.00003222873,0.0024711753,0.000029792609,0.000048098645,0.00005227135,0.000006493497,0.00040774568,0.0007663683,0.032892838],"study_design_scores_gemma":[0.009857981,0.0027208258,0.93553525,0.00031112367,0.004379527,0.000012351783,0.00020787196,0.042410992,0.00014147449,0.0002415729,0.004021855,0.00015914458],"about_ca_topic_score_codex":0.00003955494,"about_ca_topic_score_gemma":0.00012626605,"teacher_disagreement_score":0.04235872,"about_ca_system_score_codex":0.00026455102,"about_ca_system_score_gemma":0.00007064506,"threshold_uncertainty_score":0.28715897},"labels":[],"label_agreement":null},{"id":"W204954543","doi":"","title":"Controlling blood glucose levels in patients with type 2 diabetes mellitus. An evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes; University of Toronto","funders":"","keywords":"Medicine; Glycemic; Glycated hemoglobin; Randomized controlled trial; Diabetes mellitus; Hypoglycemia; Family medicine; Clinical trial; MEDLINE; Type 2 Diabetes Mellitus; Observational study; Evidence-based medicine; Intensive care medicine; Type 2 diabetes; Internal medicine; Alternative medicine; Endocrinology; Pathology","score_opus":0.018629939211951177,"score_gpt":0.25657100007414096,"score_spread":0.2379410608621898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W204954543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945854,0.0011417,0.0000010542501,0.0025290744,0.000011425258,0.0015479908,0.000052454885,0.000033321605,0.00009761305],"genre_scores_gemma":[0.9949718,0.00050518836,0.00008528237,0.003572294,0.00004444927,0.0005912526,0.00003668703,0.00002625077,0.00016676701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820566,0.00014724246,0.00032442829,0.00029854925,0.00044377998,0.0005803678],"domain_scores_gemma":[0.9990001,0.00026831843,0.00036756098,0.00017788641,0.00006574931,0.00012042067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040850264,0.0002080129,0.0005318093,0.00013161905,0.00005330604,0.000037184498,0.00011615735,0.000024660307,0.000006154491],"category_scores_gemma":[0.00009072046,0.00014141755,0.000045250214,0.00066357706,0.00020563912,0.00019481474,0.000018746274,0.00011462316,0.0000017634429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001332896,0.0005731352,0.61572874,0.000022986294,0.00035619005,2.4975964e-7,0.00007812315,0.00003514265,0.00014088281,0.0000057613197,0.0001199402,0.3828056],"study_design_scores_gemma":[0.0035191018,0.00091367174,0.99072844,0.00008179345,0.00044644385,5.1086166e-9,0.00007943075,0.000113455004,0.0030095775,0.000018309003,0.0009404002,0.00014936227],"about_ca_topic_score_codex":0.00021330744,"about_ca_topic_score_gemma":0.000010702001,"teacher_disagreement_score":0.38265622,"about_ca_system_score_codex":0.00019654285,"about_ca_system_score_gemma":0.000032946256,"threshold_uncertainty_score":0.57668406},"labels":[],"label_agreement":null},{"id":"W2049785889","doi":"10.1016/j.jcjd.2015.02.002","title":"The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metformin; First line; Diabetes mellitus; Internal medicine; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.015505160480949428,"score_gpt":0.22159763458139853,"score_spread":0.2060924741004491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049785889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917116,0.0066779437,0.000007974858,0.00072881544,0.000100756326,0.0006617439,0.000028364659,0.0000011899632,0.000081620106],"genre_scores_gemma":[0.9994953,0.00008837687,0.00023682488,0.000015343325,0.00004944431,0.000053260264,0.000009589152,0.000011583854,0.000040222305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912983,0.0000600772,0.0002797643,0.00008596579,0.00023355962,0.0002107978],"domain_scores_gemma":[0.99901694,0.00018542787,0.00020117358,0.00019089946,0.00021186983,0.0001937052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069762004,0.00012751894,0.0003541193,0.00018140067,0.000054188546,0.0000142433155,0.00008623725,0.000038317947,0.0000018072823],"category_scores_gemma":[0.00013693396,0.00006298432,0.00017529147,0.00013925316,0.00006642451,0.000086089836,0.0000063510583,0.00006321243,1.9026193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024009589,0.0001293711,0.98188525,0.00007343129,0.002171768,0.000017969427,0.0010125655,0.00006077937,0.0000023377775,0.00012933312,0.00029097445,0.013986095],"study_design_scores_gemma":[0.05871436,0.022671519,0.8385674,0.0009973487,0.010529682,0.000013484335,0.00590522,0.00021466208,0.0033107495,0.001763609,0.056934632,0.00037738323],"about_ca_topic_score_codex":0.0011265154,"about_ca_topic_score_gemma":0.021707412,"teacher_disagreement_score":0.14331792,"about_ca_system_score_codex":0.00018007835,"about_ca_system_score_gemma":0.000240405,"threshold_uncertainty_score":0.9961439},"labels":[],"label_agreement":null},{"id":"W2050039414","doi":"10.1210/en.2011-1485","title":"Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell","year":2011,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto; European Foundation for the Study of Diabetes; Canada Research Chairs; Canadian Diabetes Association; University of Toronto; Eli Lilly and Company","keywords":"Internal medicine; Endocrinology; Metformin; Chemistry; Medicine; Insulin","score_opus":0.07700876647228853,"score_gpt":0.27565224803024624,"score_spread":0.1986434815579577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050039414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964438,0.00022227704,0.0024746498,0.00023350224,0.0003993761,0.00038834038,0.0000032712205,0.00007331817,0.031767268],"genre_scores_gemma":[0.99327046,0.00004441027,0.0051083844,0.0002969908,0.000024191977,0.000039669852,0.000039150094,0.000016506661,0.0011602431],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990957,0.00004173703,0.00021940056,0.0002168674,0.00012531532,0.0003010139],"domain_scores_gemma":[0.9993498,0.00009996296,0.000116159565,0.00033904886,0.000045011966,0.000050028684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000066299996,0.00014222442,0.00024380759,0.00007608544,0.000051338382,0.0000044358885,0.00014334718,0.00004378333,0.0004925058],"category_scores_gemma":[0.00002891581,0.00009677,0.00008930179,0.0000920175,0.000060934253,0.00005163167,0.00011283838,0.00013250303,0.000112488735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008473177,0.0019255142,0.028776422,0.0002287293,0.0017612453,0.00075286574,0.007775873,0.0000019818801,0.6698858,0.14451389,0.0027187709,0.14081156],"study_design_scores_gemma":[0.0074482113,0.0051863533,0.2123607,0.00022714931,0.0021352384,0.0001228589,0.0080111865,0.00021110995,0.7192229,0.034575526,0.009985038,0.0005137392],"about_ca_topic_score_codex":0.000601136,"about_ca_topic_score_gemma":0.000055576227,"teacher_disagreement_score":0.18358427,"about_ca_system_score_codex":0.000039891787,"about_ca_system_score_gemma":0.000029167093,"threshold_uncertainty_score":0.5392593},"labels":[],"label_agreement":null},{"id":"W2050345739","doi":"10.1371/annotation/3330720e-5520-4211-91f3-d3b3d20e9804","title":"Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Ministry of Health; University of British Columbia","funders":"Ministry of Health, British Columbia","keywords":"Rosiglitazone; Metformin; Myocardial infarction; Medicine; Internal medicine; MEDLINE; Correct name; Cardiology; Pharmacology; Biology; Receptor; Insulin","score_opus":0.015199704895564247,"score_gpt":0.2111320430795745,"score_spread":0.19593233818401026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050345739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288356,0.000076724195,0.0000025457373,0.00016372847,0.0003218994,0.0008665011,0.0000016342303,0.000056158282,0.0056272405],"genre_scores_gemma":[0.9960758,0.00008035075,0.00075851823,0.00013087015,0.00012181213,0.000108981534,0.000052354793,0.0000136543,0.0026576759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927074,0.000013927737,0.00015461101,0.00017652608,0.00021605227,0.00016816007],"domain_scores_gemma":[0.99963796,0.000021933321,0.000038635102,0.00016704376,0.000054905857,0.0000795069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011171012,0.000097350094,0.00021281483,0.00011335445,0.000029961393,0.000017491035,0.000025666086,0.00005762022,0.000064699605],"category_scores_gemma":[0.000108370245,0.00008709416,0.000036271602,0.00011068461,0.000027584254,0.00013446609,0.000038774997,0.00015194408,0.000027633394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024263415,0.0038852426,0.95929956,0.000121817175,0.00051832,0.000003637905,0.00032199672,2.7177012e-7,0.0036466864,0.00006300519,0.0013725054,0.03052429],"study_design_scores_gemma":[0.0042053214,0.0010123808,0.987142,0.00017364637,0.0006639804,8.126907e-7,0.000026647127,0.00020501278,0.0048239366,0.00005764602,0.0015632523,0.0001253527],"about_ca_topic_score_codex":0.00004780954,"about_ca_topic_score_gemma":0.00005628372,"teacher_disagreement_score":0.030398937,"about_ca_system_score_codex":0.000043528868,"about_ca_system_score_gemma":0.000011976098,"threshold_uncertainty_score":0.35515967},"labels":[],"label_agreement":null},{"id":"W2050826565","doi":"10.7326/0003-4819-146-7-200704030-00003","title":"The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes","year":2007,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":429,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Exenatide; Medicine; Metformin; Placebo; Glycated hemoglobin; Type 2 diabetes; Internal medicine; Glycemic; Adverse effect; Diabetes mellitus; Gastroenterology; Endocrinology; Insulin","score_opus":0.018409156592339895,"score_gpt":0.32739093865327823,"score_spread":0.30898178206093835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050826565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768235,0.0024640346,0.000035348217,0.0052248803,0.00029268628,0.0008083887,0.0000010414844,0.000014446293,0.014335645],"genre_scores_gemma":[0.9973633,0.0002360773,0.00011104146,0.0010646782,0.00016007943,0.000022462224,0.000004263462,0.000014170828,0.001023877],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984194,0.00004828252,0.0006519911,0.00015179413,0.00040011975,0.00032841857],"domain_scores_gemma":[0.9979503,0.0012698078,0.00020770337,0.00022633787,0.00021585252,0.0001299718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024747222,0.00016283197,0.0007860321,0.00033950282,0.000019603494,0.0000037716145,0.00016102035,0.000038414706,0.00005622767],"category_scores_gemma":[0.0020130482,0.00008334885,0.00011409594,0.00033663632,0.00010680577,0.000036961083,0.000060346934,0.00011278481,0.000009039513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054366183,0.0006070881,0.5723325,0.00094861834,0.0036489186,0.00031803397,0.0015615632,0.000050881914,0.11213324,0.0029768653,0.03977802,0.2112781],"study_design_scores_gemma":[0.04946632,0.05930745,0.266643,0.01065847,0.00091810524,0.000009298306,0.00065985427,0.0004993836,0.5928466,0.000293805,0.018319806,0.00037796458],"about_ca_topic_score_codex":0.0000858337,"about_ca_topic_score_gemma":0.00004117402,"teacher_disagreement_score":0.48071334,"about_ca_system_score_codex":0.000023296298,"about_ca_system_score_gemma":0.00001316384,"threshold_uncertainty_score":0.33988675},"labels":[],"label_agreement":null},{"id":"W2050856569","doi":"10.1016/s0167-4838(01)00181-9","title":"Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)","year":2001,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Internal medicine; Gastric inhibitory polypeptide; Endocrinology; Insulin; Receptor; In vivo; Stimulation; Glucagon; Biological activity; Hormone; Biology; Glucagon-like peptide-1; Amino acid; Chemistry; In vitro; Biochemistry; Diabetes mellitus; Medicine; Type 2 diabetes","score_opus":0.006341228393566573,"score_gpt":0.24163433515091107,"score_spread":0.2352931067573445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050856569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635684,0.000299923,0.00014281819,0.0014790471,0.00004705097,0.0014077034,0.00003467461,0.000017723485,0.00021422656],"genre_scores_gemma":[0.9985785,0.000091697766,0.00067056995,0.00038534333,0.000036441663,0.00008622261,0.00007188526,0.000023310595,0.000056029796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99836797,0.00020998348,0.00046927694,0.00040849083,0.0002722973,0.00027200472],"domain_scores_gemma":[0.99897504,0.000036621448,0.0003457801,0.00052122044,0.00006659418,0.00005472346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014451382,0.000259136,0.00046574464,0.00022726717,0.000035428813,0.000016388705,0.00021436003,0.00015612374,0.000010044613],"category_scores_gemma":[0.000033370252,0.00018645535,0.00011730843,0.00031555461,0.00027351658,0.000061486426,0.000099683864,0.00018878744,0.0000016968229],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003256413,0.0003155419,0.00010949241,0.000109938126,0.00023740674,0.00012169275,0.0008105999,6.074325e-7,0.9933058,0.0028303203,0.000016407255,0.0018165472],"study_design_scores_gemma":[0.0017226415,0.0007569618,0.028665103,0.00005985171,0.00022093911,0.000057615474,0.00019718436,0.000008960129,0.96475273,0.0033150292,0.000094023824,0.00014896016],"about_ca_topic_score_codex":0.00011483963,"about_ca_topic_score_gemma":0.00001848384,"teacher_disagreement_score":0.028555611,"about_ca_system_score_codex":0.000035780053,"about_ca_system_score_gemma":0.00005225124,"threshold_uncertainty_score":0.76034284},"labels":[],"label_agreement":null},{"id":"W2050952530","doi":"10.1155/2012/179318","title":"Sterol Lipid Metabolism in Down Syndrome Revisited: Down Syndrome Is Associated with a Selective Reduction in Serum Brassicasterol Levels","year":2012,"lang":"en","type":"article","venue":"Current Gerontology and Geriatrics Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Aging; National Institutes of Health; Pfizer","keywords":"Sterol; Lipid metabolism; Metabolism; Cholesterol; Endocrinology; Internal medicine; Blood lipids; Biochemistry; Population; Medicine; Biology","score_opus":0.08890316593769958,"score_gpt":0.37146223064988804,"score_spread":0.28255906471218845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050952530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874381,0.00878839,0.000020587968,0.0009698217,0.0003753814,0.0015920487,0.000034520366,0.00003977821,0.00074141717],"genre_scores_gemma":[0.9978094,0.0007344987,0.00005767515,0.000046026762,0.00010805538,0.00026095318,0.00006108876,0.00002858163,0.00089371507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641025,0.0006561231,0.00046109132,0.0006271589,0.00058408105,0.0012612893],"domain_scores_gemma":[0.9988115,0.0001996945,0.00013416442,0.0003509454,0.00021484136,0.00028884676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001980488,0.00030887092,0.00082366023,0.0013239478,0.00013733789,0.000055040495,0.0001461073,0.000271275,0.00016388096],"category_scores_gemma":[0.00015576527,0.00025237637,0.00006520267,0.0016350856,0.00019217526,0.00044448412,0.00017559552,0.00094264786,0.000052555828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001206362,0.0045951223,0.90345865,0.0007890785,0.0010258213,0.00053943536,0.0061733234,0.0000027121648,0.00036366197,0.00072036753,0.0043873955,0.07673807],"study_design_scores_gemma":[0.005076658,0.0009479977,0.989897,0.0002982102,0.00020329452,0.00029523586,0.00026612802,0.00005790514,0.000071613926,0.0001257001,0.002504239,0.00025602788],"about_ca_topic_score_codex":0.00006423054,"about_ca_topic_score_gemma":0.00010029095,"teacher_disagreement_score":0.086438335,"about_ca_system_score_codex":0.00044392853,"about_ca_system_score_gemma":0.00011853143,"threshold_uncertainty_score":0.99999285},"labels":[],"label_agreement":null},{"id":"W2051243940","doi":"10.1111/dom.12188","title":"Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Empagliflozin; Metformin; Pioglitazone; Placebo; Medicine; Type 2 diabetes; Tolerability; Internal medicine; Clinical endpoint; Urology; Diabetes mellitus; Adverse effect; Randomized controlled trial; Gastroenterology; Endocrinology","score_opus":0.0066711662358415694,"score_gpt":0.21346407052343266,"score_spread":0.2067929042875911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051243940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974837,0.0055330144,0.000006032947,0.00047277665,0.00051917863,0.017946012,0.000027141585,0.000100659774,0.0005581555],"genre_scores_gemma":[0.98976773,0.0008733971,0.0004703104,0.0029268204,0.0002651197,0.0032568672,0.00007533028,0.00007396014,0.002290467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99647814,0.00036658664,0.0007834418,0.00082632346,0.0005789395,0.0009665661],"domain_scores_gemma":[0.99760365,0.0008280604,0.00026072178,0.0005247347,0.00023497584,0.0005478734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009632438,0.0007344482,0.0030548621,0.0006350843,0.0001540515,0.00015838415,0.00017551589,0.00021513755,0.00024429074],"category_scores_gemma":[0.0006251048,0.0004302123,0.000237648,0.00047658524,0.00022910407,0.0004345422,0.00010042459,0.00029881526,0.000091238515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9508849,0.002592302,0.0155211445,0.00013214855,0.0028104726,0.0000106617035,0.00073870627,0.00000334299,0.0004203028,0.0003052213,0.00081577065,0.025765037],"study_design_scores_gemma":[0.93658453,0.005688675,0.052021485,0.00019798422,0.0014476231,2.8883255e-7,0.00008536812,0.00024753142,0.00060006883,0.0003489496,0.0022364338,0.0005410432],"about_ca_topic_score_codex":0.000113775444,"about_ca_topic_score_gemma":0.000022583734,"teacher_disagreement_score":0.036500342,"about_ca_system_score_codex":0.00008891771,"about_ca_system_score_gemma":0.000093078546,"threshold_uncertainty_score":0.999815},"labels":[],"label_agreement":null},{"id":"W2051821736","doi":"10.1136/bmj.e2914","title":"No better than less expensive drugs","year":2012,"lang":"en","type":"letter","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computer science; Data science; Medicine; Intensive care medicine; World Wide Web","score_opus":0.027727406773578524,"score_gpt":0.28064914394813034,"score_spread":0.2529217371745518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051821736","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003315834,0.00032902238,0.000004160237,0.75368,0.0016298883,0.001226552,0.000015001599,0.000100316574,0.23969921],"genre_scores_gemma":[0.0009741784,0.000017205977,0.00038991266,0.7218788,0.016481882,0.00023002674,0.00091935706,0.00007205175,0.25903654],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846655,0.00003741207,0.000237903,0.00032448902,0.00042127268,0.00051239715],"domain_scores_gemma":[0.99898916,0.000051029318,0.0001391314,0.0006548012,0.00008385571,0.00008201883],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009990492,0.00033205678,0.0005042887,0.00013464129,0.00003424446,0.00003579137,0.00012477355,0.00037716632,0.00088090973],"category_scores_gemma":[0.000015290652,0.0002574648,0.00022834673,0.000051090996,0.000046809044,0.00006473188,0.000116221294,0.00052789797,0.005530096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015644395,0.00005193531,0.0014191652,0.0002567079,0.0005046172,0.0005578303,0.00016069617,1.0224283e-8,0.000008598253,0.000013118163,0.9909536,0.006058078],"study_design_scores_gemma":[0.00084936165,0.00009519896,0.001221088,0.00024375471,0.0007159837,0.000007367854,0.000055388555,8.749203e-7,0.00007269057,0.000017762504,0.9964499,0.000270658],"about_ca_topic_score_codex":0.0000382187,"about_ca_topic_score_gemma":9.440874e-7,"teacher_disagreement_score":0.031801175,"about_ca_system_score_codex":0.00009680984,"about_ca_system_score_gemma":0.000028559381,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W2052140885","doi":"10.1016/j.bbr.2012.09.021","title":"The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders","year":2012,"lang":"en","type":"review","venue":"Behavioural Brain Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; University of Toronto","funders":"","keywords":"Neuroprotection; Neuroscience; Psychology; Mood disorders; Brain Structure and Function; Cognition; Medicine; Anxiety; Psychiatry","score_opus":0.11832472286198951,"score_gpt":0.4181288840396428,"score_spread":0.2998041611776533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052140885","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016101327,0.9587424,0.0000063561083,0.00022830705,0.000076866025,0.02356669,0.00014326363,0.0000293566,0.0011054516],"genre_scores_gemma":[0.026824933,0.9544201,0.0001174598,0.000013944926,0.00005506466,0.013240383,0.0004854101,0.00015511243,0.0046875887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964515,0.0006915602,0.00045059074,0.0005294136,0.00085550005,0.0010214302],"domain_scores_gemma":[0.9949315,0.0040329094,0.00022383391,0.0004234138,0.00021268764,0.00017565172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011342359,0.00045879974,0.0012579384,0.0006121845,0.00022868335,0.000058511567,0.0002784535,0.00020598613,0.000009125931],"category_scores_gemma":[0.0004891833,0.00024820172,0.00034238532,0.0009280134,0.00032713148,0.00009231053,0.0001975626,0.00060203404,0.000022076081],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016117105,0.0012451519,0.016696405,0.007008053,0.0011337071,0.000018386887,0.00019371673,2.8665976e-8,9.208373e-7,0.00012634973,0.00009473227,0.9733214],"study_design_scores_gemma":[0.04939019,0.048621885,0.45025992,0.12691945,0.041968998,0.000062004015,0.0020124281,0.0000068016884,0.00043876795,0.0007148983,0.27706957,0.002535113],"about_ca_topic_score_codex":0.00021163955,"about_ca_topic_score_gemma":0.00023143094,"teacher_disagreement_score":0.9707863,"about_ca_system_score_codex":0.00029646768,"about_ca_system_score_gemma":0.00028147415,"threshold_uncertainty_score":0.999997},"labels":[],"label_agreement":null},{"id":"W2053269167","doi":"10.1016/j.jcjd.2013.03.065","title":"Impact of Newer Type 2 Diabetes Medications on Body Weight","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Type 2 diabetes; Weight management; Incretin; Weight loss; Obesity; Type 2 Diabetes Mellitus; Insulin resistance; Insulin; Weight gain; Diabetes mellitus; Intensive care medicine; Body weight; Endocrinology","score_opus":0.008899518413209124,"score_gpt":0.24403004529832512,"score_spread":0.235130526885116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053269167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903066,0.0012474785,7.9049306e-7,0.0016269833,0.00033782065,0.00024189844,0.000012583496,0.0000072310904,0.007494584],"genre_scores_gemma":[0.9983059,0.000022221446,0.00019534743,0.00043767568,0.00020503282,0.000007841907,0.000020861153,0.00002288079,0.000782229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988072,0.000029478184,0.0003755714,0.00011039404,0.00022243994,0.00045495058],"domain_scores_gemma":[0.99803364,0.00009459487,0.00023601549,0.00026153462,0.0004145821,0.00095965463],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016645911,0.00016196852,0.0004059067,0.0005497916,0.000052243824,0.00002833513,0.00016553163,0.00006653777,0.0022955628],"category_scores_gemma":[0.00020218635,0.000113810085,0.00023314494,0.00029158255,0.00011242934,0.00016200429,0.000009139732,0.0001531859,0.00012895705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002432754,0.00012265828,0.9298846,0.000034226796,0.0011322821,0.000005868378,0.00008273217,0.0000060172674,0.0015733301,0.00023328316,0.059670236,0.007252298],"study_design_scores_gemma":[0.00095912616,0.0023084707,0.9862917,0.00029035492,0.00044436735,7.245917e-7,0.0000320207,0.00007784642,0.0011948587,0.0003651568,0.007913651,0.000121700716],"about_ca_topic_score_codex":0.00043252128,"about_ca_topic_score_gemma":0.00017516046,"teacher_disagreement_score":0.056407087,"about_ca_system_score_codex":0.00022487652,"about_ca_system_score_gemma":0.0007942988,"threshold_uncertainty_score":0.99861646},"labels":[],"label_agreement":null},{"id":"W2053800396","doi":"10.1016/j.jcjd.2013.03.016","title":"Potential Risk Factors of Double Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Glycemic; Insulin resistance; Obesity; Type 2 diabetes; Glycemic index; Hypoglycemia; Abdominal obesity; Environmental health; Internal medicine; Waist; Endocrinology","score_opus":0.008788324540522923,"score_gpt":0.20281390454177214,"score_spread":0.19402558000124923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053800396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955506,0.0011017986,0.0000030136594,0.00045314556,0.00043951394,0.0002834868,0.000019763378,0.000008389525,0.0021403017],"genre_scores_gemma":[0.99882555,0.00001772958,0.00027373733,0.00012695481,0.00014396201,0.000006128363,0.000013869642,0.000024588415,0.0005674667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986785,0.00002969519,0.00045008239,0.0001211579,0.0002278675,0.0004926991],"domain_scores_gemma":[0.9982552,0.00005047657,0.00036459876,0.0002128995,0.00030234604,0.0008145115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000179709,0.00018046457,0.0004915568,0.00049370766,0.00007300595,0.00004922166,0.00017153966,0.000075094234,0.0009837862],"category_scores_gemma":[0.00008108701,0.00013695579,0.00027275673,0.00019139698,0.00012838106,0.00025820063,0.00001521518,0.00017532578,0.00003934429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024254177,0.000059907543,0.98617715,0.00006149293,0.00062608137,0.0000064661317,0.00012504708,0.000026455924,0.0012588329,0.00006761483,0.0073001888,0.004288333],"study_design_scores_gemma":[0.0024836827,0.000954078,0.97335374,0.0001955306,0.000829716,6.6966976e-7,0.00029185688,0.00008554774,0.017480075,0.00044284997,0.0037023425,0.0001798819],"about_ca_topic_score_codex":0.001727714,"about_ca_topic_score_gemma":0.0004668054,"teacher_disagreement_score":0.016221242,"about_ca_system_score_codex":0.00010407615,"about_ca_system_score_gemma":0.0003063425,"threshold_uncertainty_score":0.9999294},"labels":[],"label_agreement":null},{"id":"W2053923626","doi":"10.1016/s0140-6736(08)60736-9","title":"Intensive insulin therapy in newly diagnosed type 2 diabetes","year":2008,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Diabetes Canada; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Type 2 diabetes; Medicine; Insulin resistance; Diabetes mellitus; Insulin; Internal medicine; Endocrinology; Pathophysiology","score_opus":0.038200497851324115,"score_gpt":0.26833081301695755,"score_spread":0.23013031516563343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053923626","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16783375,0.0043349653,2.1024628e-7,0.82087594,0.00048860593,0.0009202932,0.000021411124,0.00009659081,0.005428257],"genre_scores_gemma":[0.015781278,0.014388,0.00007169216,0.9577208,0.005664738,0.00012423536,0.0006214438,0.00006289768,0.005564896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986771,0.000081195474,0.00020982967,0.00028820246,0.00024783958,0.0004958507],"domain_scores_gemma":[0.99878794,0.0002023578,0.00009794939,0.0007744828,0.00010776227,0.00002953717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010954036,0.00029282703,0.00086328434,0.00013350131,0.00003640901,0.00002410899,0.00029474823,0.00024333755,0.0001314771],"category_scores_gemma":[0.000116873685,0.00017229476,0.00010939429,0.00024215864,0.00010171066,0.000025176181,0.0000710304,0.0009215798,0.00025244508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081537975,0.000050824092,0.011441722,0.00006409989,0.00030791745,0.00080443424,0.00037596625,9.565139e-7,0.000013462755,0.0000071111112,0.9765608,0.010291201],"study_design_scores_gemma":[0.004278905,0.00042154698,0.026739344,0.00024449523,0.00009040491,0.0000026808268,0.00003220957,0.0000097979055,0.000081485996,0.00019223896,0.9677205,0.00018637127],"about_ca_topic_score_codex":0.000047506303,"about_ca_topic_score_gemma":0.000010719834,"teacher_disagreement_score":0.15205246,"about_ca_system_score_codex":0.00008254415,"about_ca_system_score_gemma":0.000046538018,"threshold_uncertainty_score":0.7025976},"labels":[],"label_agreement":null},{"id":"W2054361323","doi":"10.1111/jgs.12881","title":"Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension","year":2014,"lang":"en","type":"article","venue":"Journal of the American Geriatrics Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; Placebo; Diabetes mellitus; Internal medicine; Clinical endpoint; Body mass index; Blood pressure; Randomization; Type 2 diabetes; Randomized controlled trial; Weight loss; Endocrinology; Obesity","score_opus":0.015510085956273878,"score_gpt":0.2558155422131154,"score_spread":0.24030545625684155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054361323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043196,0.003161268,0.00035686643,0.00045224008,0.00015502173,0.005326863,0.000005624122,0.00002985582,0.00008030678],"genre_scores_gemma":[0.99091756,0.00030311607,0.007628859,0.0005079094,0.00023599004,0.00021747035,0.000008290934,0.000070888775,0.00010989362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619704,0.0006349866,0.00072442257,0.00046476893,0.0014400154,0.0005387413],"domain_scores_gemma":[0.9966992,0.00047083476,0.0011196554,0.00073912967,0.00060360215,0.00036757026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022803526,0.00045275546,0.0023096828,0.00022006045,0.00016513615,0.00011300409,0.00033513558,0.000041015683,0.0000046103023],"category_scores_gemma":[0.00031022876,0.00022319853,0.0008219447,0.0012668937,0.00024053636,0.00014448879,0.00016832807,0.00040920428,0.00000218059],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7353731,0.0028319214,0.21628435,0.00021355221,0.01922162,0.00009748741,0.007962145,0.012141653,0.00003732901,0.000004994683,0.0005999869,0.0052319006],"study_design_scores_gemma":[0.92157364,0.013001301,0.029335134,0.0006922008,0.019125884,0.000012138044,0.013266135,0.0011250789,0.000044789118,0.000004950348,0.0013126465,0.00050607254],"about_ca_topic_score_codex":0.0001059951,"about_ca_topic_score_gemma":0.000032002958,"teacher_disagreement_score":0.18694921,"about_ca_system_score_codex":0.00031745931,"about_ca_system_score_gemma":0.000294159,"threshold_uncertainty_score":0.9101772},"labels":[],"label_agreement":null},{"id":"W2054867747","doi":"10.1371/journal.pone.0009590","title":"A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Michael Smith Health Research BC; Canadian Diabetes Association","keywords":"Agonist; Glycemic; Receptor; Diabetes mellitus; Glucagon-like peptide 1 receptor; Endocrinology; Apoptosis; Internal medicine; Medicine; Cell; Function (biology); Cell function; Pharmacology; Chemistry; Biology; Cell biology; Biochemistry","score_opus":0.02231774060382187,"score_gpt":0.21360980422976963,"score_spread":0.19129206362594775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054867747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680305,0.00017360764,0.000023234072,0.00025716244,0.00009421797,0.0010178902,0.000011425503,0.00004176219,0.0015776536],"genre_scores_gemma":[0.99794924,0.00007194436,0.00079473096,0.00009002716,0.000052702802,0.000102401034,0.000043844284,0.000025223018,0.00086986384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988683,0.00003058434,0.00034677776,0.00029510338,0.00016529426,0.00029396082],"domain_scores_gemma":[0.9993764,0.00010414365,0.00013516535,0.00024115547,0.00006003705,0.00008308993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018466341,0.00016316265,0.00042866604,0.0002498789,0.000038713002,0.000020375835,0.00004824149,0.00010138844,0.000029718673],"category_scores_gemma":[0.00007266457,0.00015411947,0.00004317405,0.0002106011,0.000055131466,0.00017106222,0.00003525738,0.00026762646,0.000010327438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034078734,0.0031071412,0.043944266,0.00042080568,0.00008172491,0.000001275294,0.00013090286,0.000020511052,0.9513221,0.000034803183,0.0000269171,0.0005687921],"study_design_scores_gemma":[0.04350685,0.0023452237,0.027443405,0.000999001,0.0013826092,2.9814933e-7,0.00032999454,0.065061346,0.85802937,0.00033188937,0.00008403031,0.00048597544],"about_ca_topic_score_codex":0.00007318689,"about_ca_topic_score_gemma":0.000113984745,"teacher_disagreement_score":0.0932927,"about_ca_system_score_codex":0.00005370861,"about_ca_system_score_gemma":0.00003251125,"threshold_uncertainty_score":0.6284809},"labels":[],"label_agreement":null},{"id":"W2055156006","doi":"10.1007/s12170-010-0141-5","title":"The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies","year":2010,"lang":"en","type":"article","venue":"Current Cardiovascular Risk Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Heart and Stroke Foundation; Canadian Heart Research Centre; University of Toronto","funders":"","keywords":"Incretin; Medicine; Glucagon-like peptide-1; Type 2 diabetes; Diabetes mellitus; Sitagliptin; Dipeptidyl peptidase-4; Bioinformatics; Pharmacology; Internal medicine; Endocrinology; Biology","score_opus":0.004050201482528309,"score_gpt":0.20661248524475895,"score_spread":0.20256228376223065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055156006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7702343,0.22460392,0.00033562045,0.000013636189,0.0021805228,0.0017847976,0.0000073540236,0.0001593838,0.00068048894],"genre_scores_gemma":[0.9793859,0.019502437,0.00033648263,0.0000038065905,0.00037572527,0.00025047912,0.000038412756,0.000064452506,0.000042308744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962257,0.0005568455,0.0007234444,0.00077201985,0.0012155136,0.0005064773],"domain_scores_gemma":[0.99612826,0.00027151554,0.00046371872,0.0026340743,0.00026605057,0.00023636589],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004152734,0.00044756552,0.0013426754,0.00015849757,0.00039947827,0.0000753878,0.00015187822,0.0001568402,0.0000058201463],"category_scores_gemma":[0.0008767656,0.00029203005,0.0024535335,0.00029614152,0.0003264014,0.000087438355,0.0002252061,0.0006258291,0.0000093788585],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084081265,0.00017243423,0.36328343,0.0021390126,0.037941318,0.0009849039,0.0004557977,0.000045513192,0.00032826728,0.00023775894,0.0007626133,0.59356487],"study_design_scores_gemma":[0.0042022127,0.0003421946,0.37432718,0.0008200145,0.028051777,0.00060293503,0.00046721633,0.00014718043,0.009183967,0.00017048686,0.5809659,0.0007189331],"about_ca_topic_score_codex":0.0003769047,"about_ca_topic_score_gemma":0.000009683838,"teacher_disagreement_score":0.592846,"about_ca_system_score_codex":0.000057388508,"about_ca_system_score_gemma":0.00007175277,"threshold_uncertainty_score":0.9999532},"labels":[],"label_agreement":null},{"id":"W2055217115","doi":"10.4021/jem.v1i1.14","title":"Diabetes in Elderly","year":2011,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Life expectancy; Diabetes mellitus; Gerontology; Intensive care medicine; Environmental health; Endocrinology; Population","score_opus":0.023291542149218233,"score_gpt":0.25721594481859933,"score_spread":0.23392440266938108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055217115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819144,0.007169455,0.0000048339534,0.0003871993,0.00029182882,0.00007280485,3.1286694e-7,0.0000056017516,0.010153548],"genre_scores_gemma":[0.9965222,0.0011922299,0.0013161602,0.00031378662,0.00008529186,0.000003060642,3.963644e-7,0.000005373063,0.0005615203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941045,0.000025732534,0.00022862069,0.000070350725,0.000062955376,0.00020189938],"domain_scores_gemma":[0.99970084,0.000020301282,0.00009723493,0.000073473464,0.000039699185,0.000068454916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009989332,0.00007596406,0.00031400385,0.00025574164,0.000013165712,0.000003033844,0.000044062883,0.000032658227,0.00009176976],"category_scores_gemma":[0.000033345837,0.000053593903,0.0000595082,0.000063855034,0.00005511961,0.00009049762,0.000023680741,0.0001405339,0.000005890171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028639773,0.00084265677,0.74558437,0.00006319792,0.0007843902,0.0011486686,0.0008771705,2.425369e-7,0.003054671,0.024723332,0.0014125796,0.22122231],"study_design_scores_gemma":[0.00360375,0.00056791794,0.9318582,0.000038232018,0.00038072257,0.00012060703,0.00012613148,0.0000019371132,0.0056825425,0.0028641375,0.054691438,0.00006440148],"about_ca_topic_score_codex":0.000006422748,"about_ca_topic_score_gemma":0.000003707576,"teacher_disagreement_score":0.22115791,"about_ca_system_score_codex":0.0000068395766,"about_ca_system_score_gemma":0.000016584732,"threshold_uncertainty_score":0.2185496},"labels":[],"label_agreement":null},{"id":"W2055891822","doi":"10.1016/j.bbrc.2015.04.100","title":"Nesfatin-1 stimulates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide secretion from STC-1 cells in vitro","year":2015,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research; Canada Foundation for Innovation; Saskatchewan Health Research Foundation","keywords":"Incretin; Gastric inhibitory polypeptide; Enteroendocrine cell; Internal medicine; Endocrinology; Secretion; Glucagon-like peptide-1; Proglucagon; Downregulation and upregulation; Biology; Glucagon; Insulin; Hormone; Endocrine system; Biochemistry; Type 2 diabetes; Diabetes mellitus; Medicine; Gene","score_opus":0.07449326220757368,"score_gpt":0.34546288184774615,"score_spread":0.27096961964017247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055891822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925423,0.0023528864,0.000015903728,0.0035650113,0.000024531726,0.00051911833,0.000043714164,0.000044052595,0.0008924451],"genre_scores_gemma":[0.99413747,0.0015657323,0.0032026675,0.00014115743,0.00007866536,0.00008526209,0.0003502156,0.000016664128,0.00042218543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840206,0.00016822646,0.0002496115,0.00035853146,0.00046344826,0.00035811242],"domain_scores_gemma":[0.9981783,0.0004295942,0.000037502767,0.0007734601,0.00017210524,0.0004090591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028794736,0.0001621643,0.00027785622,0.00013968606,0.00011505977,0.000073070165,0.00027623685,0.000104208746,0.000009048874],"category_scores_gemma":[0.00018391704,0.00013166746,0.000046854173,0.00032580696,0.0005195371,0.00009106046,0.00073033886,0.00043187354,0.000056986562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003171922,0.0010489554,0.0019076967,0.000038546845,0.00006500843,0.000007639471,0.00022115935,3.4490924e-7,0.98515385,0.0003814099,0.00095187797,0.0099063255],"study_design_scores_gemma":[0.007750849,0.0011635965,0.0437075,0.0003511601,0.00021560316,0.0000031392765,0.0012301942,0.010744586,0.9117795,0.0061414577,0.016369399,0.0005429928],"about_ca_topic_score_codex":0.0009197696,"about_ca_topic_score_gemma":0.000020442443,"teacher_disagreement_score":0.07337432,"about_ca_system_score_codex":0.00013499634,"about_ca_system_score_gemma":0.000076660916,"threshold_uncertainty_score":0.53692436},"labels":[],"label_agreement":null},{"id":"W2055909955","doi":"10.1016/s1499-2671(09)33132-9","title":"JNJ-28431754/TA-7284, an inhibitor of sodium glucose cotransporter 2, ameliorates diabetic syndrome in the ZDF rat","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Cotransporter; Sodium; Glucose transporter; Insulin; Chemistry","score_opus":0.010816353673538252,"score_gpt":0.22186905539373558,"score_spread":0.21105270172019733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055909955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269235,0.0026736953,0.0000017139898,0.0032498247,0.0002992049,0.00039140266,0.000017584734,0.000008318933,0.00066588254],"genre_scores_gemma":[0.99765825,0.000035664165,0.00014459342,0.0018363316,0.00015124459,0.000007260051,0.000029240922,0.000022478413,0.00011496207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998085,0.00009859259,0.0006838743,0.00018980107,0.00034186925,0.0006008482],"domain_scores_gemma":[0.9985115,0.00007704665,0.00027188243,0.0003621049,0.00017581636,0.00060163764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005935637,0.0002561133,0.0006671386,0.0006650473,0.000067720364,0.00006350755,0.00033137342,0.00009878586,0.00013305666],"category_scores_gemma":[0.00006333804,0.00017866287,0.0002089453,0.00048069787,0.00015572729,0.00031472836,0.000005255775,0.0002882388,0.000011596314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049459755,0.0009983188,0.9511834,0.0002606296,0.00044353845,0.0017872101,0.0026098134,0.000050067243,0.0078031104,0.00047885592,0.0064191194,0.02791647],"study_design_scores_gemma":[0.0037014496,0.004998377,0.9717242,0.00082086324,0.00072725536,0.000029507843,0.0009572085,0.000048113725,0.011249155,0.0010316762,0.004378157,0.00033404282],"about_ca_topic_score_codex":0.00017170451,"about_ca_topic_score_gemma":0.0020722954,"teacher_disagreement_score":0.02758243,"about_ca_system_score_codex":0.00013185138,"about_ca_system_score_gemma":0.00041752384,"threshold_uncertainty_score":0.72856605},"labels":[],"label_agreement":null},{"id":"W2056391616","doi":"10.1007/s00125-006-0316-2","title":"Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy","year":2006,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":419,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"American Diabetes Association","keywords":"Human physiology; Type 2 diabetes; Medicine; Diabetes mellitus; Algorithm; Computer science; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.01938760598646728,"score_gpt":0.2624880565092857,"score_spread":0.24310045052281842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056391616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98774004,0.009271569,0.00008878953,0.0002693087,0.000120863835,0.0013252154,0.00001403611,0.00001647347,0.0011536755],"genre_scores_gemma":[0.99323535,0.0013107536,0.0049114656,0.000116958574,0.000023797596,0.00016066522,0.000052123734,0.000010734449,0.00017813784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99928325,0.000020049287,0.00026049148,0.00014952359,0.000110280984,0.00017641249],"domain_scores_gemma":[0.9994746,0.00016244747,0.000108784974,0.00017560927,0.00006163909,0.000016942766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017872707,0.00010865475,0.00028025234,0.00008703313,0.000017132797,0.000003147556,0.00005071798,0.000045813074,0.000012070703],"category_scores_gemma":[0.000008974104,0.000071434704,0.000048261827,0.00017188708,0.00009368173,0.00001639237,0.000029581974,0.000034979774,0.0000010399696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013949348,0.0007103375,0.121975094,0.00034473647,0.00057616574,0.000009868599,0.0000800386,0.000025508469,0.00092071726,0.004144403,0.0012305375,0.8698431],"study_design_scores_gemma":[0.005855625,0.0010620833,0.9754341,0.0001758037,0.00035695772,4.860562e-7,0.0002786966,0.0024282276,0.011149019,0.0010003997,0.0021356477,0.00012294971],"about_ca_topic_score_codex":0.000021038728,"about_ca_topic_score_gemma":0.0000036021643,"teacher_disagreement_score":0.86972016,"about_ca_system_score_codex":0.000029084846,"about_ca_system_score_gemma":0.000011518954,"threshold_uncertainty_score":0.29130226},"labels":[],"label_agreement":null},{"id":"W2056728516","doi":"10.1136/ebn.12.1.14","title":"Benefits of early intensive glucose control in preventing diabetes-related complications were sustained for up to 10 yearsCommentary","year":2008,"lang":"en","type":"letter","venue":"Evidence-Based Nursing","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Ketonuria; Diabetes mellitus; United Kingdom Prospective Diabetes Study; Type 2 diabetes; Internal medicine; Blinding; Myocardial infarction; Pediatrics; Randomized controlled trial; Endocrinology","score_opus":0.035855520236700654,"score_gpt":0.29532063779479933,"score_spread":0.2594651175580987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056728516","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22285223,0.0038497618,0.00045199954,0.764286,0.0006051358,0.0073421067,0.00014485182,0.000116888,0.00035105247],"genre_scores_gemma":[0.5471641,0.00009576434,0.0020841314,0.44002646,0.00079590187,0.0011960112,0.0019891404,0.00021719147,0.0064313444],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973495,0.00014729168,0.0007826908,0.00061219337,0.00041158183,0.00069672026],"domain_scores_gemma":[0.9973372,0.00097303663,0.00040375875,0.0006050568,0.00056179357,0.000119125056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032838163,0.00041927097,0.0009520244,0.00077204214,0.00010200877,0.000032740973,0.0002483563,0.00031080277,0.00007900093],"category_scores_gemma":[0.0004113907,0.00042398163,0.00035389623,0.00044338213,0.00012666015,0.00017137139,0.00003699558,0.00052636914,0.000028137028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005502067,0.00035421498,0.011870375,0.0011494523,0.0005927542,0.00005256924,0.0009029459,0.0003179996,0.00035894645,0.00002453376,0.9460323,0.0377937],"study_design_scores_gemma":[0.06542131,0.020349003,0.2553515,0.33338213,0.014124574,0.000022905277,0.002830912,0.007927546,0.013472441,0.00087516365,0.2813749,0.004867601],"about_ca_topic_score_codex":0.00007835583,"about_ca_topic_score_gemma":0.0000046823243,"teacher_disagreement_score":0.6646574,"about_ca_system_score_codex":0.00074883475,"about_ca_system_score_gemma":0.00019494772,"threshold_uncertainty_score":0.9998212},"labels":[],"label_agreement":null},{"id":"W2057332288","doi":"10.1185/03007995.2013.837817","title":"Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes","year":2013,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Canadian Diabetes Association","keywords":"Medicine; Exenatide; Liraglutide; Metformin; Type 2 diabetes; Incretin; Hypoglycemia; Glucagon-like peptide 1 receptor; Diabetes mellitus; Internal medicine; Glycemic; Clinical trial; Pharmacology; Endocrinology; Agonist; Receptor","score_opus":0.22692591207380713,"score_gpt":0.45767175723437686,"score_spread":0.23074584516056973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057332288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033496348,0.99259245,0.0000015412332,0.00020063804,0.0013908911,0.0021769514,0.00002411795,0.000025729865,0.00023804804],"genre_scores_gemma":[0.00008339648,0.9968753,0.00007032239,0.000017153223,0.00040813923,0.0003235328,0.0009648315,0.000047194957,0.001210167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955902,0.00042817186,0.00078956876,0.00062163506,0.0017250647,0.00084535446],"domain_scores_gemma":[0.9971874,0.0010325509,0.00016375304,0.0004975445,0.00028272366,0.0008360584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014465932,0.00038150544,0.001650082,0.0007680125,0.00006116565,0.00008198334,0.00028663946,0.00038555695,0.00066349836],"category_scores_gemma":[0.0020975578,0.0002614882,0.00021441883,0.00082764163,0.00047310212,0.00015402233,0.0004738585,0.0012159953,0.0003718637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028373603,0.00056640554,0.00090956554,0.023341654,0.00016102708,0.000007565419,0.00003138043,3.4822494e-9,5.3905563e-7,0.00016580486,0.049828265,0.9249594],"study_design_scores_gemma":[0.0008209501,0.0010279105,0.00054396054,0.047707375,0.00009706641,9.2596673e-7,0.000007793792,0.000011951123,0.0000020856207,0.000038260125,0.9495579,0.00018381946],"about_ca_topic_score_codex":0.00007269972,"about_ca_topic_score_gemma":0.0000050581,"teacher_disagreement_score":0.9247756,"about_ca_system_score_codex":0.00019065663,"about_ca_system_score_gemma":0.00067641126,"threshold_uncertainty_score":0.9999837},"labels":[],"label_agreement":null},{"id":"W2057500160","doi":"10.1016/j.jcjd.2012.07.325","title":"Liraglutide Suppresses Postprandial Triglyceride (TG) and Apolipoprotein B48 (ApoB48) Responses to a Fat-Rich Meal in Patients with Type 2 Diabetes","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Postprandial; Medicine; Internal medicine; Gastric emptying; Placebo; Endocrinology; Triglyceride; Glycemic; Type 2 diabetes; Meal; Crossover study; Gastroenterology; Diabetes mellitus; Cholesterol; Insulin; Stomach","score_opus":0.00919383501236322,"score_gpt":0.21837673486107603,"score_spread":0.2091828998487128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057500160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560285,0.0020864692,5.4163775e-7,0.000916053,0.00031509608,0.0006293362,0.000037704263,0.000010724468,0.0004012364],"genre_scores_gemma":[0.9981703,0.000013244582,0.0005045039,0.0007864039,0.0002673845,0.000019067336,0.000020793741,0.000042341588,0.00017595766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980538,0.000096064,0.00041646895,0.00019210044,0.00031389494,0.0009276634],"domain_scores_gemma":[0.9978653,0.00014564522,0.00016502138,0.00021867077,0.00023085038,0.0013745078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037586907,0.00027433826,0.00058134546,0.000945044,0.000089393005,0.00007218123,0.00014095088,0.000084287385,0.00009922347],"category_scores_gemma":[0.0005128345,0.00020969102,0.00006510186,0.0004607025,0.00010415,0.00037921497,0.00003087469,0.00020954285,0.00001483077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004150508,0.00014544949,0.99226725,0.00007184583,0.0002685557,0.000017989332,0.00051239063,0.0000027915437,0.00017892788,0.000029788414,0.0016549913,0.0044349474],"study_design_scores_gemma":[0.0041037514,0.003959036,0.98202896,0.0003987842,0.00029958808,0.0000012601411,0.0001135143,0.0000019647418,0.0022391586,0.000028808747,0.006580791,0.00024437124],"about_ca_topic_score_codex":0.00044105723,"about_ca_topic_score_gemma":0.0022135829,"teacher_disagreement_score":0.0102383,"about_ca_system_score_codex":0.00023220392,"about_ca_system_score_gemma":0.00033745074,"threshold_uncertainty_score":0.8550952},"labels":[],"label_agreement":null},{"id":"W2057593057","doi":"10.1016/s1098-3015(10)66669-7","title":"PDB22 COST-EFFECTIVENESS OF INSULIN GLARGINE COMPARED TO INSULIN DETEMIR FOR TYPE 1 (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin detemir; Insulin glargine; Medicine; Internal medicine; Type 1 diabetes; Type 2 Diabetes Mellitus; Endocrinology; Insulin; Diabetes mellitus; Hypoglycemia","score_opus":0.06534911467961803,"score_gpt":0.31825093423238787,"score_spread":0.25290181955276986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057593057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932783,0.0015658952,0.0000035265743,0.0009928051,0.00015618809,0.0038323686,0.00003314649,0.000011578702,0.0001261436],"genre_scores_gemma":[0.99764323,0.00035276733,0.00062905025,0.0009952142,0.000027385639,0.00017426336,0.00014568452,0.000019400692,0.000013010438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850416,0.0002477532,0.00037187594,0.0002457785,0.00018563739,0.0004448018],"domain_scores_gemma":[0.9989645,0.00041896637,0.00008552202,0.00021448499,0.00012077674,0.00019577435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010639335,0.00014852303,0.0004148842,0.0002904829,0.00009535737,0.000008461786,0.00009084304,0.00005658482,0.000004196886],"category_scores_gemma":[0.00029014406,0.00011502076,0.000028094983,0.00056591915,0.00003812696,0.000041048625,0.000029032324,0.00011689544,0.000006208839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036242369,0.00041930945,0.97941804,0.0010111912,0.00004652579,0.00000952229,0.0020816748,0.000569936,0.000025297863,0.00018001664,0.0004307454,0.015445318],"study_design_scores_gemma":[0.00398435,0.0012929334,0.9829801,0.0005649682,0.000021546508,6.7159783e-7,0.000093164475,0.0014748636,0.00016932601,0.00011544729,0.009186146,0.00011649587],"about_ca_topic_score_codex":0.06722331,"about_ca_topic_score_gemma":0.025328526,"teacher_disagreement_score":0.041894782,"about_ca_system_score_codex":0.0004270742,"about_ca_system_score_gemma":0.00033679526,"threshold_uncertainty_score":0.9924567},"labels":[],"label_agreement":null},{"id":"W2057906239","doi":"10.1016/j.jval.2013.03.083","title":"Composite endpoints in treatment of type-2 diabetes","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Exenatide; Sitagliptin; Liraglutide; Metformin; Type 2 diabetes; Internal medicine; Clinical endpoint; Randomized controlled trial; Hypoglycemia; Diabetes mellitus; Insulin; Endocrinology","score_opus":0.035271391749435894,"score_gpt":0.2928516543339031,"score_spread":0.2575802625844672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057906239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930994,0.0016898536,6.226122e-7,0.0017371468,0.00009450419,0.0009458101,0.0000017976004,0.000017141938,0.0024137418],"genre_scores_gemma":[0.99750227,0.0006902442,0.000890099,0.0002798163,0.00002080065,0.000059848488,0.000022239494,0.000010671125,0.0005240304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911684,0.000058634618,0.00030731127,0.00014770316,0.00010480315,0.00026468156],"domain_scores_gemma":[0.9995932,0.00005774847,0.000063913874,0.00018407624,0.000018131763,0.00008293699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116337105,0.00009725929,0.0003423118,0.00019816877,0.0000102683425,0.0000042568754,0.00003203869,0.000027175014,0.000088817906],"category_scores_gemma":[0.000009859594,0.00007635338,0.000035427656,0.00021222135,0.000020196792,0.000039856084,0.000013555334,0.00003367455,0.00008772372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031319927,0.0016401306,0.93734103,0.0003869669,0.0000587949,0.00001071868,0.00079381734,0.00020522097,0.00062335376,0.0004812933,0.00035698846,0.058070336],"study_design_scores_gemma":[0.004527991,0.0035158717,0.9791209,0.0006095873,0.000027799259,6.754289e-7,0.00011976991,0.004489688,0.0029889233,0.0006674694,0.003815611,0.00011571011],"about_ca_topic_score_codex":0.0040047127,"about_ca_topic_score_gemma":0.00003467646,"teacher_disagreement_score":0.057954624,"about_ca_system_score_codex":0.00029781891,"about_ca_system_score_gemma":0.000055149667,"threshold_uncertainty_score":0.60539544},"labels":[],"label_agreement":null},{"id":"W2058866666","doi":"10.1007/s00125-012-2584-3","title":"Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes","year":2012,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"Abbott Laboratories","keywords":"Medicine; Overweight; Type 2 diabetes; Obesity; Diabetes mellitus; Internal medicine; Risk factor; Endocrinology","score_opus":0.03370901009472109,"score_gpt":0.25991877907901373,"score_spread":0.22620976898429263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058866666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822352,0.016662857,0.000008926317,0.000024385974,0.000034573644,0.00071155257,0.00006137114,0.000037053294,0.00022410617],"genre_scores_gemma":[0.99691767,0.002394454,0.000452304,0.000019976249,0.000031699095,0.00006455497,0.000036089954,0.000026282964,0.00005694588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820447,0.0002540058,0.00030598682,0.0004261409,0.00031337622,0.0004960495],"domain_scores_gemma":[0.99867785,0.00036021482,0.00012742118,0.00053204014,0.000047083176,0.00025541396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012890315,0.00030341063,0.001131325,0.00018568597,0.00007515987,0.000018321065,0.000051041952,0.00015214758,0.0000069781368],"category_scores_gemma":[0.00027181115,0.00022010402,0.00010560728,0.00020349098,0.00028114632,0.00027380386,0.00015545606,0.00020572884,0.0000018950125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022938339,0.00008427784,0.9783047,0.00024718983,0.017447913,0.000012303967,0.0006802756,0.000008518806,0.0000036069418,0.00013569492,0.000015802741,0.003036802],"study_design_scores_gemma":[0.0033232432,0.0003142206,0.98542565,0.000047671852,0.009602649,0.0000011838118,0.00026657915,0.000015708943,0.00009035507,0.00032054968,0.00035760007,0.00023459348],"about_ca_topic_score_codex":0.00032327935,"about_ca_topic_score_gemma":0.000016074193,"teacher_disagreement_score":0.014682518,"about_ca_system_score_codex":0.00006297069,"about_ca_system_score_gemma":0.000016333774,"threshold_uncertainty_score":0.89755815},"labels":[],"label_agreement":null},{"id":"W2059079195","doi":"10.1185/03007995.2015.1027185","title":"Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin","year":2015,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Linagliptin; Empagliflozin; Medicine; Metformin; Type 2 diabetes; Type 2 Diabetes Mellitus; Pill; Glycemic; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Internal medicine; Endocrinology","score_opus":0.36926063485675414,"score_gpt":0.5114607009127419,"score_spread":0.14220006605598773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059079195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000108334454,0.9929258,0.000022636073,0.00064420426,0.0017791253,0.003851594,0.000027451331,0.0000630602,0.000577773],"genre_scores_gemma":[0.00003363945,0.99419034,0.00005739104,0.00003705136,0.0011394417,0.0006616702,0.0031082027,0.000059386253,0.0007128696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959161,0.00033308656,0.0005620841,0.00063067116,0.0017694989,0.0007885545],"domain_scores_gemma":[0.9970094,0.0008869194,0.00013791499,0.0003894091,0.0006525339,0.00092381943],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003090975,0.00038739838,0.001429219,0.00051868457,0.0001366005,0.00009752356,0.00027090497,0.00038421596,0.00012929241],"category_scores_gemma":[0.001897369,0.0002602713,0.0002339074,0.0005526721,0.00030109263,0.000080984995,0.0002208368,0.00076435116,0.00011384989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089256384,0.000905407,0.00001531169,0.01540312,0.00021134756,0.0000034246302,0.000039122122,4.4160267e-9,1.0968589e-7,0.0007996341,0.0466337,0.93589956],"study_design_scores_gemma":[0.0029928281,0.0041660047,0.000006908806,0.019234292,0.00015891346,0.0000013525479,0.00001763863,0.00009559265,0.0000023755094,0.00070937036,0.9724023,0.00021244932],"about_ca_topic_score_codex":0.0000026887335,"about_ca_topic_score_gemma":0.0000010548808,"teacher_disagreement_score":0.9356871,"about_ca_system_score_codex":0.00041801244,"about_ca_system_score_gemma":0.001044564,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W2059165993","doi":"10.1161/01.cir.0000054611.89228.92","title":"Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure","year":2003,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute","funders":"Institut de Cardiologie de Montréal","keywords":"Enalapril; Medicine; Diabetes mellitus; Internal medicine; Hazard ratio; Heart failure; Incidence (geometry); ACE inhibitor; Placebo; Cardiology; Angiotensin-converting enzyme; Endocrinology; Confidence interval; Blood pressure; Pathology","score_opus":0.0068937374625656165,"score_gpt":0.21425800490464283,"score_spread":0.20736426744207723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059165993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873525,0.00013914553,0.000007227299,0.00023897977,0.000025047493,0.0003947015,4.783981e-7,0.000008859839,0.0004502977],"genre_scores_gemma":[0.9997437,0.0000015066344,0.00012777412,0.00005039559,0.0000113814185,0.000019569927,0.00001997774,0.0000056566364,0.000020049716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995121,0.000025319696,0.00011455625,0.000096147305,0.00015312378,0.00009878742],"domain_scores_gemma":[0.9997319,0.000021064716,0.000052067502,0.00013683703,0.00004118644,0.000016926899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103601946,0.00005648916,0.00010078163,0.000051191437,0.000020585643,0.000005607124,0.000023929742,0.00001943794,0.00003147769],"category_scores_gemma":[0.00003254843,0.000035025998,0.00002036964,0.00016596998,0.00003167217,0.00007180565,0.000005949778,0.000034656565,0.000006164865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000457952,0.00007732936,0.99786216,0.000028291357,0.000024001274,1.4544591e-7,0.000050666113,0.00016354567,0.0006049991,0.00021984547,0.00008602449,0.00087842025],"study_design_scores_gemma":[0.0009219446,0.000112392074,0.99423844,0.00010348436,0.000044371016,6.33409e-8,0.000016808293,0.000110669935,0.0038176442,0.00008000874,0.0005169853,0.00003719625],"about_ca_topic_score_codex":0.000006780468,"about_ca_topic_score_gemma":0.000017043405,"teacher_disagreement_score":0.00362372,"about_ca_system_score_codex":0.000074933225,"about_ca_system_score_gemma":0.0000301401,"threshold_uncertainty_score":0.14283186},"labels":[],"label_agreement":null},{"id":"W2059523942","doi":"10.1016/s1499-2671(09)33072-5","title":"Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Biomarker; Lipid profile; Endocrinology; Biochemistry","score_opus":0.011256721482710747,"score_gpt":0.20944921215527365,"score_spread":0.1981924906725629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059523942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631053,0.0021908868,4.916953e-7,0.00076084404,0.000025145911,0.00028518026,0.000017487746,0.0000058797923,0.00040357045],"genre_scores_gemma":[0.9990277,0.000022622711,0.0004617437,0.00020830733,0.000020846117,0.0000072101548,0.000023650888,0.000015549182,0.00021234219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987323,0.00007200042,0.00035890506,0.00020725053,0.00019833246,0.0004311741],"domain_scores_gemma":[0.998855,0.00004367626,0.0002149078,0.00020242414,0.00020623178,0.00047776697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026580252,0.0002173711,0.0008904285,0.0020026022,0.000057123198,0.00004800378,0.00007753843,0.000055022723,0.00010040666],"category_scores_gemma":[0.000077032055,0.0001419004,0.00016473935,0.0019494225,0.00009279518,0.000196997,0.000004725466,0.00020436484,0.0000014237293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036405407,0.00012881937,0.97662324,0.000010727024,0.019858293,0.000020064668,0.000084908104,0.00015372975,0.0000036916128,0.00000721446,0.00020592858,0.0028669941],"study_design_scores_gemma":[0.0022700734,0.0022802262,0.9445528,0.000066254775,0.050295282,2.98207e-7,0.00008913499,0.000041401665,0.000036938647,0.00003635089,0.00018641046,0.00014487807],"about_ca_topic_score_codex":0.00045508085,"about_ca_topic_score_gemma":0.0068283346,"teacher_disagreement_score":0.032070473,"about_ca_system_score_codex":0.00018682316,"about_ca_system_score_gemma":0.00021556621,"threshold_uncertainty_score":0.57865304},"labels":[],"label_agreement":null},{"id":"W2059667450","doi":"10.1016/j.jcjd.2012.01.005","title":"Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre; University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Incretin; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Type 2 diabetes; Glucagon-like peptide 1 receptor; Dipeptidyl peptidase; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Receptor; Internal medicine; Diabetes mellitus; Endocrinology; Biochemistry; Agonist; Enzyme; Biology","score_opus":0.01625554874450334,"score_gpt":0.2381646954383694,"score_spread":0.22190914669386608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059667450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96832013,0.028160641,0.000003615543,0.0016594214,0.0008387652,0.0007104504,0.000054333388,0.0000110861065,0.0002415501],"genre_scores_gemma":[0.99692506,0.00029730826,0.00082747167,0.000661903,0.00061978394,0.000051761326,0.00003879832,0.000048326136,0.0005296198],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984125,0.00005989968,0.00047419438,0.0001587612,0.0002178578,0.00067679567],"domain_scores_gemma":[0.9978653,0.00054329005,0.00033736828,0.00028450813,0.00028606772,0.00068347214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004594503,0.00029726778,0.0005961283,0.0003164846,0.00019396949,0.000054703774,0.00013952304,0.000092616094,0.00010917755],"category_scores_gemma":[0.00012445256,0.00018768614,0.00028197598,0.00020586331,0.0002970416,0.00015693081,0.000009611037,0.00009616126,0.0000074398713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052923493,0.00035407025,0.9402822,0.00021911823,0.001560324,0.0000022436154,0.0013948061,0.000007935842,0.003687749,0.00013345928,0.013252568,0.039052587],"study_design_scores_gemma":[0.00722501,0.009999777,0.2532463,0.000862054,0.002664241,0.0000017297883,0.0014404822,0.00018328306,0.039364442,0.00009744742,0.6843499,0.00056531007],"about_ca_topic_score_codex":0.00012205889,"about_ca_topic_score_gemma":0.00029073906,"teacher_disagreement_score":0.6870359,"about_ca_system_score_codex":0.0002313364,"about_ca_system_score_gemma":0.00039013903,"threshold_uncertainty_score":0.76536185},"labels":[],"label_agreement":null},{"id":"W2060202940","doi":"10.1139/y02-115","title":"The effect of epidermal growth factor on the distribution of SGLT-1 in rabbit jejunum","year":2002,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Epidermal growth factor; Brush border; Endocrinology; Internal medicine; Jejunum; Biology; Population; Stimulation; Ileum; Small intestine; Glucose transporter; Chemistry; Vesicle; Biochemistry; Insulin; Membrane; Medicine","score_opus":0.013130087921845916,"score_gpt":0.2548526491342074,"score_spread":0.2417225612123615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060202940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940702,0.00084416976,9.705219e-7,0.0042940867,0.00029061968,0.00018702283,0.00001588463,8.4710064e-7,0.00029621308],"genre_scores_gemma":[0.9992594,0.00026574073,0.0000010411812,0.00031098648,0.00007825523,0.0000051349266,0.0000040107416,0.000003531889,0.000071874085],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992367,0.00024305518,0.00022532925,0.00006314768,0.000043628006,0.00018816006],"domain_scores_gemma":[0.9990337,0.00059070945,0.0001615374,0.00005962878,0.000045164525,0.00010928928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024338608,0.00008078615,0.00027379318,0.00008010977,0.000064261396,0.0000016943748,0.00008611965,0.000050319602,0.0004424591],"category_scores_gemma":[0.000072730785,0.000041162642,0.00007166299,0.00008392046,0.0002761077,0.00002360348,0.0000085194415,0.00018743683,0.0000028673298],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031772065,0.0004417498,0.29417494,0.00080555986,0.0031200063,0.00046318473,0.0012719402,0.00012017875,0.53357786,0.008273228,0.123657,0.030917129],"study_design_scores_gemma":[0.0071427575,0.007902975,0.50837296,0.00011471939,0.0006058581,0.000047451784,0.00007457236,0.00024534418,0.460888,0.00085837016,0.01361302,0.00013397973],"about_ca_topic_score_codex":0.00013413529,"about_ca_topic_score_gemma":0.00013785427,"teacher_disagreement_score":0.21419801,"about_ca_system_score_codex":0.00004182557,"about_ca_system_score_gemma":0.000041534,"threshold_uncertainty_score":0.4844617},"labels":[],"label_agreement":null},{"id":"W2060420423","doi":"10.1016/j.jcjd.2014.07.011","title":"Efficacy and Safety of Once Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2)","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glimepiride; Medicine; Dulaglutide; Metformin; Type 2 diabetes; Insulin glargine; Diabetes mellitus; Internal medicine; Exenatide; Pharmacology; Insulin; Endocrinology","score_opus":0.00551360031396662,"score_gpt":0.2006108537760123,"score_spread":0.19509725346204568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060420423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725175,0.0014084647,0.0000017502435,0.00070071395,0.000074297015,0.00030665981,0.0000060845205,0.0000032183345,0.00024704987],"genre_scores_gemma":[0.9992193,0.00008996092,0.00043366864,0.00016503905,0.00002055383,0.000003123785,0.000018636421,0.0000168966,0.00003283267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998882,0.00005867151,0.00043142997,0.0001428038,0.00016507145,0.0003200397],"domain_scores_gemma":[0.9990521,0.0001508678,0.00021481667,0.0001163116,0.00014989336,0.00031602063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045472174,0.00015479662,0.0004979919,0.00061443617,0.000030782474,0.000018603178,0.00007177963,0.00005420211,0.000008925271],"category_scores_gemma":[0.00032112843,0.00012544305,0.00002703512,0.00032060297,0.00011429773,0.00019347707,0.000016785902,0.00013365858,7.3076325e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008072147,0.00012859181,0.9529241,0.00011510015,0.00009122531,0.000008274738,0.00018827087,0.000020465919,0.000074152544,0.00015020017,0.00007906408,0.046139855],"study_design_scores_gemma":[0.010243859,0.0024514685,0.9829558,0.0008108063,0.00012709225,6.609322e-7,0.000050011728,0.0002981074,0.00082243065,0.00012237765,0.0019967337,0.00012065557],"about_ca_topic_score_codex":0.00026218843,"about_ca_topic_score_gemma":0.0037681642,"teacher_disagreement_score":0.0460192,"about_ca_system_score_codex":0.00013750236,"about_ca_system_score_gemma":0.00015007978,"threshold_uncertainty_score":0.5115419},"labels":[],"label_agreement":null},{"id":"W2060773808","doi":"10.1016/j.diabet.2012.08.002","title":"Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes","year":2012,"lang":"en","type":"review","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk","keywords":"Incretin; Metformin; Type 2 diabetes; Medicine; Insulin; Internal medicine; Vildagliptin; Endocrinology; Diabetes mellitus; Liraglutide; Basal (medicine); Pharmacology","score_opus":0.04413566133729546,"score_gpt":0.30769890415242973,"score_spread":0.26356324281513427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060773808","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039180923,0.952731,0.000005655282,0.00014337091,0.00040672027,0.0073139537,0.00004135204,0.00004741867,0.00012962164],"genre_scores_gemma":[0.011065795,0.9835852,0.0007602215,0.00016878782,0.00030495442,0.0029868833,0.0007252354,0.00014498881,0.0002579454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975238,0.00021505945,0.0007108336,0.00047382433,0.00037705817,0.0006994666],"domain_scores_gemma":[0.99735147,0.0010241262,0.00060706225,0.00070521934,0.00019165238,0.00012048357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054601557,0.0007179421,0.0026188998,0.0004767273,0.00008585724,0.000048428978,0.0002112409,0.00022415101,0.00006126665],"category_scores_gemma":[0.00006962367,0.0003801534,0.00053554296,0.00073492184,0.0001284893,0.00011052293,0.000023914856,0.00017168777,0.000018048606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001154425,0.0021812653,0.0026795645,0.0050497046,0.001933566,0.000001585186,0.00015971568,0.0000016383764,0.000010230161,0.00014772394,0.00004688866,0.9876727],"study_design_scores_gemma":[0.00755083,0.0028267584,0.002694677,0.0036294644,0.01038865,1.5844518e-7,0.000018169443,0.00019490809,0.0004237592,0.000047748268,0.97181094,0.0004139483],"about_ca_topic_score_codex":0.000015950734,"about_ca_topic_score_gemma":0.0000036175645,"teacher_disagreement_score":0.98725873,"about_ca_system_score_codex":0.0002087931,"about_ca_system_score_gemma":0.00023468591,"threshold_uncertainty_score":0.99986506},"labels":[],"label_agreement":null},{"id":"W2061399167","doi":"10.1007/s00125-012-2788-6","title":"Lipotoxicity impairs incretin signalling","year":2012,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Incretin; Lipotoxicity; Internal medicine; Endocrinology; Glucagon-like peptide-1; Type 2 diabetes; Gastric inhibitory polypeptide; Medicine; Diabetes mellitus; Insulin; Glucagon; Insulin resistance","score_opus":0.021732767022557328,"score_gpt":0.2506895620417527,"score_spread":0.22895679501919536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061399167","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21450222,0.0049302806,0.00013050616,0.6923423,0.0025390752,0.0036365103,0.00011473989,0.0014626449,0.080341764],"genre_scores_gemma":[0.15100753,0.00013438782,0.0014312482,0.822942,0.00611088,0.00031433156,0.002627567,0.0001617277,0.015270304],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749553,0.000100963895,0.00039526063,0.00053215935,0.0004404696,0.0010356132],"domain_scores_gemma":[0.9987715,0.00019036111,0.0002208541,0.00059162965,0.00007215195,0.00015350811],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030977023,0.00053928135,0.000996576,0.00027217332,0.00007837202,0.00004468975,0.0002419279,0.0010166644,0.0012180919],"category_scores_gemma":[0.00008785,0.00043284832,0.00036175206,0.00018930953,0.0001220128,0.00008094839,0.000179855,0.0014426304,0.0013344102],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001598284,0.0001253181,0.029161373,0.00049937563,0.00067175616,0.0005178438,0.000038535054,3.549899e-7,0.00016804959,0.000030775842,0.965119,0.0036516378],"study_design_scores_gemma":[0.00083016476,0.00034333466,0.006920161,0.00025058573,0.0013554965,0.000008770747,0.000012867096,0.000019262536,0.0016104056,0.00010879229,0.98802453,0.000515622],"about_ca_topic_score_codex":0.000023012284,"about_ca_topic_score_gemma":9.251543e-7,"teacher_disagreement_score":0.13059977,"about_ca_system_score_codex":0.0002113405,"about_ca_system_score_gemma":0.000057367633,"threshold_uncertainty_score":0.9998123},"labels":[],"label_agreement":null},{"id":"W2061420451","doi":"10.1016/j.jcjd.2013.03.082","title":"Can a Dietary and Pharmacological Pre-Pregnancy Intervention Improve the Metabolic Health of Male Offspring of Obese Sprague-Dawley Rats?","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Offspring; Sitagliptin; Medicine; Endocrinology; Internal medicine; Obesity; Pregnancy; Type 2 diabetes; Weight gain; Diabetes mellitus; Physiology; Body weight; Biology","score_opus":0.016404586326319408,"score_gpt":0.2626714989388932,"score_spread":0.24626691261257377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061420451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676457,0.028709844,0.0000021300675,0.0026480074,0.0002478265,0.0005143746,0.000013201733,0.0000030284716,0.00021586959],"genre_scores_gemma":[0.99877614,0.00039901418,0.00017702868,0.0002819601,0.00007412423,0.00001877103,0.0000037708796,0.0000111343625,0.00025804862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988587,0.000086216816,0.00049863814,0.000107040585,0.0001395847,0.00030982943],"domain_scores_gemma":[0.9988056,0.000056241774,0.00042328844,0.00013471977,0.00015231187,0.0004278633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030844475,0.00012728413,0.00046589857,0.00020351312,0.000048905193,0.00001951468,0.00013126034,0.000035394536,0.00018320858],"category_scores_gemma":[0.00007361183,0.00008102571,0.00016857179,0.0001242219,0.00014484109,0.0001346188,0.000029270543,0.00015369015,0.0000013790267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015001798,0.00025181076,0.7102755,0.00074785715,0.0014715173,0.000017883538,0.0010196496,0.000006143253,0.014857412,0.00019252459,0.0020555786,0.26908916],"study_design_scores_gemma":[0.0024308115,0.002223136,0.9723675,0.0015622554,0.00074309285,0.0000057310353,0.0005565021,0.00016634003,0.018493861,0.00030543847,0.0010144478,0.00013087488],"about_ca_topic_score_codex":0.0031542177,"about_ca_topic_score_gemma":0.0028897966,"teacher_disagreement_score":0.2689583,"about_ca_system_score_codex":0.000064352564,"about_ca_system_score_gemma":0.00022856245,"threshold_uncertainty_score":0.47682545},"labels":[],"label_agreement":null},{"id":"W2061878267","doi":"10.1111/j.1440-1746.2007.05268.x","title":"Impaired glucose tolerance and incretins in chronic liver disease","year":2008,"lang":"en","type":"letter","venue":"Journal of Gastroenterology and Hepatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Endocrinology; Incretin; Impaired glucose tolerance; Glucose homeostasis; Type 2 diabetes; Metformin; Insulin; Diabetes mellitus; Insulin resistance","score_opus":0.011607639219954774,"score_gpt":0.23103303713889803,"score_spread":0.21942539791894325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061878267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8131211,0.008160655,0.000011471514,0.17825212,0.00020492946,0.00020821823,0.0000076125834,0.0000068151808,0.000027082651],"genre_scores_gemma":[0.72688365,0.023055006,0.00019473527,0.24857241,0.0009902406,0.000014474132,0.000041576444,0.000027424772,0.00022048174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845654,0.00018204555,0.00051765656,0.00026405544,0.00013326366,0.00044643745],"domain_scores_gemma":[0.9991811,0.00006447806,0.00037250752,0.00016236863,0.000058798054,0.00016077909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001399736,0.00027042566,0.0010335487,0.00043404716,0.00004011976,0.000007465132,0.00009180717,0.00033632392,0.00004504887],"category_scores_gemma":[0.000026523616,0.00022040354,0.00013633803,0.000039097762,0.00034864427,0.0000727657,0.000091607566,0.0010880731,0.000003614094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024071732,0.0001143955,0.81906223,0.0003540063,0.00034894428,0.029856762,0.000065962966,8.6398006e-7,0.00001314396,0.0000052460437,0.14694595,0.0008253175],"study_design_scores_gemma":[0.00921856,0.007851563,0.7626663,0.0004526438,0.0009867941,0.0069318735,0.000007412029,0.00027717694,0.000006461483,0.000083884166,0.21135163,0.00016569646],"about_ca_topic_score_codex":0.000021985217,"about_ca_topic_score_gemma":0.00010285016,"teacher_disagreement_score":0.086237445,"about_ca_system_score_codex":0.00015639799,"about_ca_system_score_gemma":0.0001336342,"threshold_uncertainty_score":0.8987796},"labels":[],"label_agreement":null},{"id":"W2061883499","doi":"10.1111/dom.12262","title":"A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk; American Diabetes Association","keywords":"Insulin degludec; Medicine; Internal medicine; Insulin aspart; Endocrinology; Lira; Metformin; Insulin; Basal insulin; Type 2 diabetes; Hypoglycemia; Diabetes mellitus; Insulin glargine","score_opus":0.021593007188927805,"score_gpt":0.2575520745690506,"score_spread":0.2359590673801228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061883499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891864,0.004386905,0.000012128319,0.000062300336,0.0003554659,0.0010117334,0.00004820399,0.00009017096,0.0048466595],"genre_scores_gemma":[0.9968256,0.00018751126,0.0018549267,0.00039530624,0.00015001888,0.00008119706,0.000110086505,0.00006515606,0.00033019864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688137,0.00019199341,0.00071030296,0.0006947279,0.0006116474,0.00090998213],"domain_scores_gemma":[0.99694794,0.0013250051,0.0003897064,0.00065365207,0.00025475534,0.00042894788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000674097,0.0005482399,0.0016924157,0.0007520513,0.00009908957,0.000054604698,0.00027282455,0.00020853241,0.000009484044],"category_scores_gemma":[0.0017963211,0.00047019953,0.00015494136,0.0011481221,0.00021306463,0.00022406445,0.0002274085,0.00032580917,0.000040719406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000420932,0.0056266906,0.9250621,0.0011510338,0.0013200535,0.000014930722,0.004893864,0.00031171882,0.026928408,0.0023608103,0.003454461,0.028454984],"study_design_scores_gemma":[0.011143639,0.0040372894,0.78751546,0.00094232545,0.0010617556,3.159918e-7,0.0006316893,0.000530759,0.14833052,0.00012690909,0.04547911,0.00020018569],"about_ca_topic_score_codex":0.00007217042,"about_ca_topic_score_gemma":0.00017229389,"teacher_disagreement_score":0.13754663,"about_ca_system_score_codex":0.00006791421,"about_ca_system_score_gemma":0.000077457626,"threshold_uncertainty_score":0.999775},"labels":[],"label_agreement":null},{"id":"W2061920925","doi":"10.1002/pdi.1427","title":"The addition of insulin to metformin and sulphonylureas: results of the 4‐T study","year":2010,"lang":"en","type":"article","venue":"Practical Diabetes International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Insulin; Diabetes mellitus; Type 2 diabetes; Regimen; Internal medicine; Basal (medicine); Incidence (geometry); Endocrinology","score_opus":0.015214444025518066,"score_gpt":0.31534846867585953,"score_spread":0.30013402465034145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061920925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835809,0.00002263471,0.00000642382,0.00872329,0.00043030235,0.0005551351,0.000046786558,0.000008214024,0.006626329],"genre_scores_gemma":[0.99821806,0.000016577495,0.00087499607,0.00018029702,0.00007296613,0.000050203325,0.000016679023,0.0000057745624,0.000564444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910885,0.000034507004,0.0002640298,0.00012960777,0.00036114277,0.000101870966],"domain_scores_gemma":[0.9987557,0.00066098804,0.00013107229,0.0002328419,0.00016755161,0.00005187428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004880948,0.000071074915,0.000119655604,0.000040735344,0.00004266165,0.000019656049,0.00012151335,0.000027123699,0.00007151324],"category_scores_gemma":[0.0029780967,0.000037441238,0.000046702815,0.00010235055,0.000102734666,0.00009346483,0.00016086175,0.0001393961,0.000008049143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00252903,0.008123573,0.4387226,0.00009000859,0.0034353123,0.000013963404,0.0014879345,0.000005202531,0.035011355,0.059124272,0.029224332,0.4222324],"study_design_scores_gemma":[0.003586932,0.0009869145,0.8608937,0.00006628988,0.00036221716,0.0000028598868,0.00043157086,0.00043229188,0.028663205,0.0016688028,0.10280746,0.00009774429],"about_ca_topic_score_codex":0.000014085111,"about_ca_topic_score_gemma":0.000036309662,"teacher_disagreement_score":0.4221711,"about_ca_system_score_codex":0.000015023407,"about_ca_system_score_gemma":0.000026241898,"threshold_uncertainty_score":0.3565275},"labels":[],"label_agreement":null},{"id":"W2062787977","doi":"10.1515/bc.2009.002","title":"Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes","year":2008,"lang":"en","type":"article","venue":"Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ulster University; Diabetes UK; University of Calgary","keywords":"Gastric inhibitory polypeptide; Internal medicine; Endocrinology; Medicine; Insulin; Diabetes mellitus; Obesity; Receptor; Glucagon","score_opus":0.020441267225087448,"score_gpt":0.22712851843100895,"score_spread":0.20668725120592152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062787977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789774,0.00032586895,0.000007482413,0.000045892477,0.00001105573,0.00029655272,0.000023009734,0.000056753368,0.0013356686],"genre_scores_gemma":[0.99892014,0.00012631623,0.0003957079,0.00016294266,0.00007291269,0.00004453131,0.00015932914,0.000009908892,0.0001081974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900955,0.000028726034,0.00027063861,0.00028507193,0.00012903269,0.00027700857],"domain_scores_gemma":[0.9994588,0.000047477533,0.00011459847,0.00022178388,0.000052000447,0.00010536516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009060228,0.00018460095,0.00036253285,0.00004461675,0.000040924217,0.000004739351,0.00010144948,0.00017144624,0.000019326239],"category_scores_gemma":[0.00006686571,0.00014246028,0.00009774161,0.00010887967,0.0001621983,0.000079037345,0.00005530871,0.00015624924,0.0000028668414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023721861,0.0012978758,0.09848765,0.00005215876,0.00007231759,0.000016724034,0.00005188632,0.000018188333,0.89854074,0.000006266935,0.0000122922875,0.0012066944],"study_design_scores_gemma":[0.0035474256,0.0007677839,0.23639806,0.00004606583,0.0000881546,0.000001875392,0.00009600423,0.0023902967,0.7564579,0.000037735725,0.000011244715,0.00015744704],"about_ca_topic_score_codex":0.0000061101077,"about_ca_topic_score_gemma":3.865706e-7,"teacher_disagreement_score":0.14208281,"about_ca_system_score_codex":0.000073434516,"about_ca_system_score_gemma":0.000051701318,"threshold_uncertainty_score":0.5809362},"labels":[],"label_agreement":null},{"id":"W2063252993","doi":"10.2165/00019053-200220001-00004","title":"Economic Evaluation of Pioglitazone Hydrochloride in the Management of Type 2 Diabetes Mellitus in Canada","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); Ottawa Hospital; University of Ottawa","funders":"Eli Lilly Canada","keywords":"Pioglitazone; Medicine; Type 2 diabetes; Metformin; Rosiglitazone; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Repaglinide; Intensive care medicine; Endocrinology","score_opus":0.030143520336680916,"score_gpt":0.2844244656490735,"score_spread":0.25428094531239254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063252993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822269,0.0018919214,2.8422113e-7,0.00044930287,0.00020432741,0.0006207691,0.000008930207,0.0000030715153,0.014594512],"genre_scores_gemma":[0.9978522,0.0017035448,0.00006039244,0.00023302087,0.00002248256,0.00004238063,0.00001870391,0.000009570913,0.000057688212],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99913955,0.000036918373,0.0003791335,0.0001484182,0.0001230835,0.00017288182],"domain_scores_gemma":[0.99959075,0.000042534542,0.0001149671,0.00020402815,0.000018819059,0.000028867846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005259121,0.00009869696,0.00024366958,0.00011008767,0.000008292965,0.0000037862148,0.00012230554,0.000013879209,0.0004842522],"category_scores_gemma":[0.0000028567265,0.00008595318,0.000036542355,0.0000883804,0.000018503673,0.000063726206,0.000030531428,0.000052966294,0.000020180014],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034423152,0.0017818508,0.4226767,0.001595135,0.002647832,0.000053514013,0.0019412395,0.05403394,0.000849761,0.003586488,0.012358562,0.49813074],"study_design_scores_gemma":[0.024346163,0.00041992858,0.27075696,0.00040645472,0.0030549723,0.0000023240207,0.0027313689,0.6442032,0.02958829,0.0013396872,0.0224974,0.0006532483],"about_ca_topic_score_codex":0.041361585,"about_ca_topic_score_gemma":0.06366743,"teacher_disagreement_score":0.59016925,"about_ca_system_score_codex":0.00085409224,"about_ca_system_score_gemma":0.000076541386,"threshold_uncertainty_score":0.9650221},"labels":[],"label_agreement":null},{"id":"W2063464815","doi":"10.14740/jocmr1983w","title":"Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Type 2 diabetes; Hypoglycemia; Internal medicine; Diabetes mellitus; Adverse effect; Sitagliptin Phosphate; Dipeptidyl peptidase-4 inhibitor; Logistic regression; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.1648137876307055,"score_gpt":0.47836000918456595,"score_spread":0.31354622155386047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063464815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99155855,0.00094969594,6.606505e-7,0.0030097058,0.00015455858,0.00037764592,5.076369e-7,0.0000028773043,0.0039457767],"genre_scores_gemma":[0.9985151,0.00045851985,0.00027376233,0.000103860504,0.00030574983,0.0000014472824,0.000004189777,0.000011828614,0.00032551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969809,0.00031123197,0.0010685261,0.00014238233,0.0012333927,0.0002635353],"domain_scores_gemma":[0.99599534,0.0017728324,0.00028219982,0.00019363554,0.0012885025,0.00046749768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067919213,0.00009607186,0.0008180831,0.00039041415,0.000014843663,0.000004597662,0.00011522978,0.00007279753,0.000049234535],"category_scores_gemma":[0.008233911,0.00005124405,0.00004356312,0.0004935393,0.00044562522,0.00007878922,0.00007882614,0.00056786113,0.0000055742817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061108894,0.0012531624,0.9542386,0.000108859815,0.00021085714,0.00006283454,0.0003606264,0.000002027483,0.000019072944,0.000024898549,0.004022468,0.03358573],"study_design_scores_gemma":[0.028877096,0.024352036,0.9397632,0.0013403206,0.00014128277,0.0000020716664,0.00053527503,0.000023112509,0.00002718087,0.000091864866,0.0047964095,0.00005017935],"about_ca_topic_score_codex":0.000014744361,"about_ca_topic_score_gemma":0.0000046863984,"teacher_disagreement_score":0.03353555,"about_ca_system_score_codex":0.000050002043,"about_ca_system_score_gemma":0.00019011307,"threshold_uncertainty_score":0.9857356},"labels":[],"label_agreement":null},{"id":"W2063476025","doi":"10.1111/dom.12465","title":"Incretin‐based medications for type 2 diabetes: an overview of reviews","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Systematic review; Checklist; Cochrane Library; Observational study; MEDLINE; Randomized controlled trial; Incretin; Internal medicine; Type 2 diabetes; Diabetes mellitus; Psychology; Endocrinology","score_opus":0.16725277773619593,"score_gpt":0.4005807717538717,"score_spread":0.23332799401767576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063476025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075317704,0.9941478,0.0000072744033,0.000063018226,0.00036794072,0.0039786035,0.00023185753,0.000066595574,0.0003837511],"genre_scores_gemma":[0.000022768076,0.9924582,0.0026152057,0.0004962209,0.00030612687,0.0007910669,0.0027607812,0.00007368982,0.00047593797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973206,0.0002990846,0.0009413208,0.0006057744,0.00033726063,0.00049598474],"domain_scores_gemma":[0.9974497,0.00021381016,0.0006591133,0.0009120428,0.0003124756,0.0004528378],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001644782,0.00059628254,0.0042534075,0.0003823193,0.00008827142,0.00003193417,0.00027941604,0.0003358235,0.00008750575],"category_scores_gemma":[0.0002800574,0.0004381587,0.00064176944,0.0005499433,0.00016686997,0.0001426011,0.000115096875,0.00021395566,0.000041463554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000053924914,0.0005570656,0.0003100029,0.06807498,0.0009840906,7.262758e-7,0.000047310572,4.9180077e-8,0.0000026459325,0.0011942938,0.0039388994,0.92488456],"study_design_scores_gemma":[0.0009410759,0.00029565816,0.0003606634,0.010767795,0.02057258,2.0185374e-7,0.0000044343788,0.000024796294,0.000013946204,0.00019014762,0.9664755,0.00035318657],"about_ca_topic_score_codex":0.000005384614,"about_ca_topic_score_gemma":0.0000024282194,"teacher_disagreement_score":0.96253663,"about_ca_system_score_codex":0.000053590487,"about_ca_system_score_gemma":0.00033589965,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W2064130493","doi":"10.1056/nejmoa1307684","title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3474,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Saxagliptin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Heart failure; Placebo; Stroke (engine); Type 2 diabetes; Unstable angina; Clinical endpoint; Diabetes mellitus; Confidence interval; Randomized controlled trial; Sitagliptin; Endocrinology","score_opus":0.006977232647670703,"score_gpt":0.20722574178692277,"score_spread":0.20024850913925207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064130493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125135,0.0054090605,0.0000083892055,0.0019702592,0.00019779889,0.00028701485,2.812988e-7,0.000006271186,0.00086959795],"genre_scores_gemma":[0.99792373,0.00048681337,0.0004872884,0.0003690014,0.00034067917,0.0000017741222,0.0000054954726,0.000012675444,0.00037254082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989723,0.000034757722,0.0002852596,0.00010447384,0.00042595455,0.00017723991],"domain_scores_gemma":[0.99931914,0.000068999405,0.00009749979,0.00015438424,0.00015269974,0.00020729355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033191912,0.00013241614,0.00062629743,0.00019969049,0.000013923452,0.000008925875,0.00004736915,0.00002964203,0.00016387293],"category_scores_gemma":[0.00012386013,0.00006732626,0.000052072068,0.00012899475,0.000052995987,0.00010565528,0.000016179356,0.00013145458,0.0000064906612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011370393,0.000098658624,0.7930367,0.000027076254,0.0006918985,0.000028253451,0.00017942766,0.000004730692,0.000013378487,0.000010888802,0.0017077464,0.20408751],"study_design_scores_gemma":[0.05794384,0.0032603345,0.9235664,0.00031367387,0.0005993749,0.000006264318,0.000067050685,0.0000059659533,0.000023995983,0.000112527356,0.014028964,0.00007162297],"about_ca_topic_score_codex":0.00007706477,"about_ca_topic_score_gemma":0.000006816652,"teacher_disagreement_score":0.2040159,"about_ca_system_score_codex":0.000027719989,"about_ca_system_score_gemma":0.000027841636,"threshold_uncertainty_score":0.27454853},"labels":[],"label_agreement":null},{"id":"W2064368942","doi":"10.1371/journal.pone.0093746","title":"A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company","keywords":"G protein-coupled receptor; Receptor; Biology; Glucagon-like peptide 1 receptor; Cell biology; Agonist; Biochemistry","score_opus":0.04738376703248379,"score_gpt":0.22256819974556522,"score_spread":0.17518443271308143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064368942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210066,0.00012245834,0.0010744354,0.001695527,0.00002605863,0.0007539677,0.000013588426,0.00005426868,0.0041590226],"genre_scores_gemma":[0.9769081,0.0001870938,0.018656483,0.00024583508,0.00007835081,0.00007599687,0.00008406762,0.000019149391,0.0037449533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992092,0.00003147434,0.0001826736,0.00018638425,0.000257509,0.00013274455],"domain_scores_gemma":[0.99939185,0.00003498433,0.000121320765,0.00031181498,0.00008839319,0.00005160679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021382152,0.00010542663,0.00023041737,0.000050036168,0.00007043249,0.000014348427,0.00007229459,0.00005233866,0.00009951903],"category_scores_gemma":[0.0001413426,0.000074668606,0.000043015643,0.000092092116,0.000048439757,0.0000662728,0.00004966738,0.00006521023,0.000018815303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021177567,0.00427802,0.003181272,0.0004960155,0.00045498187,5.954353e-8,0.0004271053,0.000011425179,0.9744341,0.00914215,0.0027618618,0.0046012485],"study_design_scores_gemma":[0.018287,0.0022445505,0.05717429,0.0019348151,0.0045190467,9.723917e-7,0.00038680158,0.07447636,0.8234656,0.0020207227,0.014649038,0.0008408031],"about_ca_topic_score_codex":0.000021322312,"about_ca_topic_score_gemma":0.00000873182,"teacher_disagreement_score":0.15096849,"about_ca_system_score_codex":0.000044865672,"about_ca_system_score_gemma":0.000016466316,"threshold_uncertainty_score":0.30448973},"labels":[],"label_agreement":null},{"id":"W2064988634","doi":"10.1136/bmj.39169.447488.94","title":"Waking up from the DREAM of preventing diabetes with drugs","year":2007,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Dream; Medicine; Diabetes mellitus; Promotion (chess); Psychology; Intensive care medicine; Psychotherapist; Political science; Law; Endocrinology","score_opus":0.04954025173037492,"score_gpt":0.35226256174923426,"score_spread":0.30272231001885935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064988634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005451003,0.9808884,0.000007688622,0.000094267336,0.00018244771,0.0019552035,0.000014250951,0.000038533126,0.016274096],"genre_scores_gemma":[0.00023374436,0.9909959,0.0008608412,0.00013809696,0.00055884646,0.00017260769,0.00027864455,0.00006174863,0.006699601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986411,0.00005712273,0.00046537907,0.00025455144,0.00031473092,0.0002671539],"domain_scores_gemma":[0.9985526,0.00036636993,0.00046769247,0.00053215784,0.000035262707,0.000045870074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004954914,0.00027336943,0.001124606,0.00008019708,0.000040192717,0.000018040886,0.00016616951,0.00009270111,0.000088844594],"category_scores_gemma":[0.000042365344,0.00013558408,0.0003198259,0.00020602008,0.00005198893,0.000030063538,0.00010329882,0.00016060779,0.000041220017],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000046138316,0.00006446008,0.0008467605,0.0056812456,0.0014101254,0.000009169378,0.000120233024,5.1717734e-8,1.4261651e-7,0.00006329369,0.004363545,0.98743635],"study_design_scores_gemma":[0.00041464652,0.0000941009,0.00022721381,0.03773765,0.005452664,8.495368e-7,0.00008625611,0.0000014198505,0.000009626936,0.000013484005,0.95582175,0.00014032879],"about_ca_topic_score_codex":0.00003068101,"about_ca_topic_score_gemma":0.0000055478213,"teacher_disagreement_score":0.98729604,"about_ca_system_score_codex":0.000052516065,"about_ca_system_score_gemma":0.00007590874,"threshold_uncertainty_score":0.5528958},"labels":[],"label_agreement":null},{"id":"W2065069677","doi":"10.1016/j.cjca.2011.07.597","title":"723 Dpp-4 Inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in experimental diabetes","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Internal medicine; Cardiology; Sitagliptin; Myocardial infarction; Cardiac function curve; Diabetes mellitus; Diastole; Heart failure; Blood pressure; Muscle hypertrophy; Diabetic cardiomyopathy; Endocrinology; Type 2 diabetes; Cardiomyopathy","score_opus":0.019593003121865876,"score_gpt":0.21859647083765033,"score_spread":0.19900346771578445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065069677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909826,0.0016127172,0.00011597215,0.00012679122,0.0011716279,0.00020385082,0.000002691974,0.00000782291,0.00577593],"genre_scores_gemma":[0.9990375,0.000090571586,0.00023205629,0.0001237925,0.00043948085,0.000010022705,0.00001583625,0.00001595258,0.0000347884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905145,0.000090459456,0.00030062223,0.00015506994,0.00009934522,0.0003030659],"domain_scores_gemma":[0.99943376,0.00002313902,0.00009894885,0.00010076414,0.00005920912,0.0002842059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037156796,0.0001349654,0.00045841772,0.00049264455,0.00006322931,0.00000964042,0.000030278221,0.00010655919,0.000010745874],"category_scores_gemma":[0.00003766886,0.00012811772,0.00028425106,0.000116079,0.000071762326,0.00021183734,0.000011578354,0.00015863191,0.000005706182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012706828,0.000012021641,0.9825086,0.000025749063,0.0011163768,0.00032577524,0.0011170564,0.0003412298,0.0062853643,0.00015356956,0.0009947899,0.006992415],"study_design_scores_gemma":[0.007763179,0.0027778633,0.95019436,0.0005275669,0.0019199683,0.0001356585,0.00445959,0.00021908025,0.01171593,0.00090302335,0.01881094,0.00057286286],"about_ca_topic_score_codex":0.0005102384,"about_ca_topic_score_gemma":0.00013186861,"teacher_disagreement_score":0.03231425,"about_ca_system_score_codex":0.0002835331,"about_ca_system_score_gemma":0.0001425861,"threshold_uncertainty_score":0.5224489},"labels":[],"label_agreement":null},{"id":"W2065283775","doi":"10.1053/meta.2000.7727","title":"Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment","year":2000,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Internal medicine; Endocrinology; Glucagon; Insulin; Hyperinsulinemia; Hypoglycemia; Basal (medicine); Glucose clamp technique; Streptozotocin; Medicine; Subcutaneous injection; Diabetes mellitus; Chemistry; Pancreatic hormone; Insulin resistance","score_opus":0.01287308001778916,"score_gpt":0.24700527113935064,"score_spread":0.23413219112156147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065283775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461496,0.0021477814,0.0000015073487,0.000655295,0.00014108473,0.00085483637,0.000013381271,0.00006471032,0.0015064535],"genre_scores_gemma":[0.9933764,0.001157713,0.0022380187,0.00010112989,0.00016493037,0.00009119405,0.000032487977,0.000024516843,0.0028136617],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900246,0.00005015913,0.00019252428,0.00032645167,0.00020673589,0.00022168626],"domain_scores_gemma":[0.99938637,0.000042462754,0.000043299344,0.0003166151,0.00004871748,0.0001625372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082294704,0.00020341676,0.00039161797,0.00015694198,0.00004923413,0.000015075213,0.00003990779,0.000044282126,0.00015048169],"category_scores_gemma":[0.00003666107,0.00014437888,0.000055965596,0.00024192128,0.00007088556,0.00006349944,0.000014939829,0.00004566497,0.000032181546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090590864,0.0015126959,0.0014414743,0.00007955213,0.0010932338,0.0002713056,0.0014561962,0.000027893313,0.042979162,0.00015943781,0.00019712231,0.86019105],"study_design_scores_gemma":[0.032949112,0.02055568,0.17011303,0.00020563442,0.0051184385,0.00023815846,0.0004954167,0.00004875543,0.44112763,0.000051726372,0.32838136,0.00071507413],"about_ca_topic_score_codex":0.0003157389,"about_ca_topic_score_gemma":0.000052674746,"teacher_disagreement_score":0.859476,"about_ca_system_score_codex":0.000068900445,"about_ca_system_score_gemma":0.000055032946,"threshold_uncertainty_score":0.58876},"labels":[],"label_agreement":null},{"id":"W2065337195","doi":"10.1007/s00125-013-2959-0","title":"Setting the record straight on TIDE: a lost opportunity for patients with diabetes","year":2013,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University","funders":"","keywords":"Context (archaeology); Medicine; Clinical trial; Diabetes mellitus; Intensive care medicine; Gynecology; Internal medicine; Endocrinology; Geography","score_opus":0.015891971772999433,"score_gpt":0.23450730071452114,"score_spread":0.2186153289415217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065337195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781314,0.000020367524,0.0000108089,0.0026088473,0.00014395444,0.0023010976,0.000032257645,0.00008024739,0.016670987],"genre_scores_gemma":[0.99240744,0.0000036631193,0.0009966282,0.0029049225,0.000065860055,0.00053268205,0.00027364618,0.000028641214,0.002786486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988459,0.000037509588,0.00019558713,0.00027740633,0.0001911217,0.00045250633],"domain_scores_gemma":[0.99893826,0.00028550325,0.000117513904,0.00037859444,0.00013748558,0.00014265731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001529895,0.0002100237,0.00028865397,0.000065341024,0.00012622119,0.000048261096,0.00012744861,0.0000619819,0.0005439561],"category_scores_gemma":[0.00017976761,0.00010917502,0.00008149147,0.000114856724,0.000086623215,0.00009939296,0.00004453927,0.00012040034,0.00022047479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004421968,0.0005517181,0.8424259,0.000085738044,0.00030255728,0.000002188129,0.00004593064,7.744383e-7,0.00002900102,0.00049608236,0.051296256,0.10471963],"study_design_scores_gemma":[0.0026600454,0.0029152187,0.9721054,0.00013112504,0.00024835314,8.409869e-8,0.0000861197,0.00013393145,0.00058207754,0.00054339855,0.020367099,0.00022714998],"about_ca_topic_score_codex":0.0000063639745,"about_ca_topic_score_gemma":0.0000046742084,"teacher_disagreement_score":0.12967949,"about_ca_system_score_codex":0.000051563933,"about_ca_system_score_gemma":0.000031538264,"threshold_uncertainty_score":0.5955938},"labels":[],"label_agreement":null},{"id":"W2065623326","doi":"10.1161/circulationaha.112.091215","title":"A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity","year":2012,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Heart and Stroke Foundation; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Endocrinology; Internal medicine; Medicine; Liraglutide; Insulin resistance; Insulin; Diabetes mellitus; Type 2 diabetes","score_opus":0.017671441939610417,"score_gpt":0.23422793250769358,"score_spread":0.21655649056808315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065623326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948974,0.00059956877,0.00333662,0.000055566834,0.000064491025,0.00030624017,0.000005076851,0.000011699811,0.00072328973],"genre_scores_gemma":[0.9993125,0.000056161796,0.00031713012,0.000050415892,0.000017699671,0.000012438418,0.000033597826,0.00000634526,0.00019371106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995554,0.00003480887,0.00012436294,0.00008628426,0.00010530392,0.00009385115],"domain_scores_gemma":[0.99964035,0.000016082608,0.00008290703,0.00018036574,0.00005062055,0.000029685736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017359536,0.00006178328,0.00015719884,0.000055075066,0.000022879893,0.0000020413097,0.000017549697,0.000039491708,0.000004664193],"category_scores_gemma":[0.000022473854,0.000046087327,0.000060254086,0.00006954655,0.00004823187,0.000073379815,0.00002133546,0.000029454115,0.0000019585382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046179648,0.00024467878,0.77102613,0.00018207775,0.00023159824,0.0000012514089,0.0007544414,0.001315067,0.21581326,0.0064943503,0.00016603062,0.0037249166],"study_design_scores_gemma":[0.00095587136,0.000102572056,0.9721238,0.000036698315,0.0010288189,0.0000021470294,0.0002461486,0.008189696,0.01660458,0.00044655966,0.00017033238,0.000092804],"about_ca_topic_score_codex":0.000020123896,"about_ca_topic_score_gemma":7.9979634e-7,"teacher_disagreement_score":0.20109764,"about_ca_system_score_codex":0.00002550848,"about_ca_system_score_gemma":0.000010076263,"threshold_uncertainty_score":0.18793866},"labels":[],"label_agreement":null},{"id":"W2066046508","doi":"10.1111/j.1463-1326.2010.01251.x","title":"A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Professional Engineers Ontario","funders":"Amylin Pharmaceuticals; Eli Lilly and Company","keywords":"Exenatide; Placebo; Metformin; Medicine; Internal medicine; Clinical endpoint; Type 2 diabetes; Nausea; Adverse effect; Gastroenterology; Diabetes mellitus; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.008773329220469896,"score_gpt":0.23759637324484778,"score_spread":0.2288230440243779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066046508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379724,0.00024962614,0.000015411675,0.00069266383,0.0002970979,0.003656404,0.000007716707,0.000044411372,0.0012394486],"genre_scores_gemma":[0.99447554,0.000102597456,0.00301597,0.00034322237,0.00012094771,0.00051584805,0.000032713036,0.000020434676,0.0013727162],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853975,0.00006260771,0.00041718144,0.00030235655,0.00034654263,0.00033158288],"domain_scores_gemma":[0.9990425,0.00021816828,0.00015978588,0.0002795734,0.00011974824,0.00018018577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007623037,0.00024064901,0.0010560685,0.00044510988,0.00005424963,0.000027240534,0.00009427275,0.00010073003,0.00006264568],"category_scores_gemma":[0.0003664884,0.00015515153,0.00009171156,0.00038614767,0.000070470254,0.00020463848,0.00006404243,0.00017305839,0.000008130482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7203039,0.016313752,0.076647125,0.001104003,0.0033537212,0.00011900325,0.004283996,0.000011538578,0.0713384,0.024985785,0.0014763477,0.08006246],"study_design_scores_gemma":[0.7944591,0.00314716,0.15559733,0.00019534072,0.0017301249,0.0000023663054,0.00022052402,0.00022394743,0.035854608,0.0006284298,0.0075339074,0.00040718485],"about_ca_topic_score_codex":0.000047108253,"about_ca_topic_score_gemma":0.00020286272,"teacher_disagreement_score":0.079655275,"about_ca_system_score_codex":0.000014040976,"about_ca_system_score_gemma":0.00005803845,"threshold_uncertainty_score":0.6326896},"labels":[],"label_agreement":null},{"id":"W2066967629","doi":"10.4021/jem.v3i4-5.197","title":"The Effect of Alogliptin and Metformin Combination Therapy in Type 2 Diabetes: A Pilot Study","year":2013,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alogliptin; Medicine; Metformin; Postprandial; Type 2 diabetes; Internal medicine; Insulin; Endocrinology; Diabetes mellitus; Pharmacology; Sitagliptin","score_opus":0.01493306898492277,"score_gpt":0.27194137130977714,"score_spread":0.2570083023248544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066967629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824631,0.015997045,5.421498e-7,0.0005297781,0.00022359237,0.00055679283,1.9296101e-7,0.0000030481895,0.0002258604],"genre_scores_gemma":[0.9944071,0.0052596205,0.000043135282,0.00006429937,0.000033144726,0.000020283192,5.1269785e-7,0.000005145384,0.00016673745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926746,0.00014091717,0.00026932015,0.000070389826,0.00009460498,0.00015728618],"domain_scores_gemma":[0.99939644,0.00023817304,0.00016181565,0.00008613897,0.00007781404,0.000039625476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034604882,0.00009097081,0.00038334477,0.00016055374,0.00003442465,0.000010420986,0.00004976705,0.00001690351,0.0000116647925],"category_scores_gemma":[0.000104595834,0.0000463283,0.000027548178,0.00008892906,0.00007922433,0.00009501349,0.00002944825,0.00012548648,0.0000014436539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009711478,0.0010843058,0.5578562,0.000044669967,0.00107477,0.00004187899,0.0004706937,5.85892e-7,0.0070135877,0.0013101562,0.00056905317,0.42956293],"study_design_scores_gemma":[0.011769359,0.020310545,0.95506865,0.000025269157,0.00032900317,0.00002564695,0.00022169693,0.000009890078,0.0051238216,0.0005861281,0.0064775134,0.000052452902],"about_ca_topic_score_codex":0.000023269415,"about_ca_topic_score_gemma":0.00000574832,"teacher_disagreement_score":0.42951047,"about_ca_system_score_codex":0.00000696603,"about_ca_system_score_gemma":0.0000093355575,"threshold_uncertainty_score":0.18892133},"labels":[],"label_agreement":null},{"id":"W2067291838","doi":"10.1016/s0828-282x(07)70806-1","title":"Improving outcomes in diabetes and chronic kidney disease: The basis for Canadian guidelines","year":2007,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Albuminuria; Guideline; Dialysis; Population; Intensive care medicine; Renal function; Type 2 diabetes; Internal medicine; Risk factor; Disease; Endocrinology; Environmental health; Pathology","score_opus":0.04829010739906749,"score_gpt":0.3266634158784715,"score_spread":0.278373308479404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067291838","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006322959,0.99402094,0.000029540564,0.003134202,0.0008125014,0.001056413,0.00023473526,0.0000031482496,0.0006452659],"genre_scores_gemma":[0.0009919449,0.9948574,0.00015443542,0.0015207356,0.0016356234,0.00008586868,0.00009675861,0.00005737438,0.0005998983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806106,0.00009269824,0.00078061846,0.00022499055,0.000099320954,0.0007413245],"domain_scores_gemma":[0.99705344,0.00027990382,0.00029521427,0.00029284548,0.00019589487,0.0018826983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092891586,0.00032773908,0.001977292,0.0011446031,0.00011092825,0.00003757178,0.00023389807,0.00020914675,0.00001567739],"category_scores_gemma":[0.0013839642,0.00020038061,0.0006657991,0.00017499519,0.00014494924,0.000046879813,0.000018311623,0.00030649523,0.000002965793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038329813,0.000001278955,0.011512718,0.0030273471,0.0011385436,0.00027952844,0.000011307822,0.0000046631435,5.4669204e-8,0.00010519059,0.024400828,0.9595147],"study_design_scores_gemma":[0.00053958513,0.00016020122,0.0017769656,0.0032159288,0.0030824644,0.000035616955,0.0000181843,0.0000055159394,8.183196e-8,0.000032447242,0.99096704,0.00016595791],"about_ca_topic_score_codex":0.014934838,"about_ca_topic_score_gemma":0.20192716,"teacher_disagreement_score":0.9665662,"about_ca_system_score_codex":0.0013760233,"about_ca_system_score_gemma":0.010759001,"threshold_uncertainty_score":0.9948491},"labels":[],"label_agreement":null},{"id":"W2067533175","doi":"10.1016/s2213-8587(14)70174-3","title":"Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk","keywords":"Insulin degludec; Liraglutide; Medicine; Metformin; Type 2 diabetes; Insulin; Pioglitazone; Clinical endpoint; Internal medicine; Diabetes mellitus; Urology; Endocrinology; Insulin glargine; Randomized controlled trial","score_opus":0.03207177693034416,"score_gpt":0.28331800456135975,"score_spread":0.25124622763101556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067533175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936795,0.00055223616,0.00001139351,0.0006143927,0.000064483094,0.0044412953,0.00012424515,0.000025994748,0.0004864282],"genre_scores_gemma":[0.9981672,0.00018822329,0.00089596177,0.00016280964,0.00003401402,0.00015777718,0.00032739813,0.000033450953,0.00003312737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746805,0.00039731635,0.0007940444,0.00043764518,0.00028576254,0.00061717466],"domain_scores_gemma":[0.99761635,0.0009194239,0.0005829977,0.00049588917,0.0002739571,0.00011136933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053737086,0.0003238427,0.001709548,0.0002730615,0.00006415637,0.000017820124,0.0002955484,0.00006726158,0.000006522226],"category_scores_gemma":[0.0004471123,0.00021252858,0.000031105268,0.0003943834,0.00034046036,0.00012866553,0.00025471367,0.0001664201,0.0000025030545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68996876,0.01294223,0.2613479,0.0005736623,0.0018017755,0.000013129063,0.0015489401,0.00013925384,0.008409169,0.0006467275,0.0002877985,0.022320626],"study_design_scores_gemma":[0.6994163,0.018966265,0.2672073,0.0005034466,0.00053159485,7.4962105e-7,0.000036509555,0.0008199645,0.011821119,0.00009239751,0.00039524076,0.00020915344],"about_ca_topic_score_codex":0.000071544455,"about_ca_topic_score_gemma":0.000039826766,"teacher_disagreement_score":0.022111474,"about_ca_system_score_codex":0.000043449712,"about_ca_system_score_gemma":0.000045525,"threshold_uncertainty_score":0.8666664},"labels":[],"label_agreement":null},{"id":"W2067766854","doi":"10.1055/s-2004-82617","title":"Extrapancreatic Effects of GIP and GLP-1","year":2004,"lang":"en","type":"review","venue":"Hormone and Metabolic Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Incretin; Internal medicine; Endocrinology; Postprandial; Glucagon-like peptide-1; Insulin; Glucagon; Carbohydrate metabolism; Hormone; Gastric inhibitory polypeptide; Medicine; Metabolism; Blood sugar regulation; Peptide hormone; Diabetes mellitus; Type 2 diabetes","score_opus":0.07819076433258783,"score_gpt":0.4109408753366707,"score_spread":0.33275011100408286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067766854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019403893,0.99209434,0.000002803256,0.00002579217,0.000028718505,0.0022650594,0.0000057859675,0.000018461438,0.003618659],"genre_scores_gemma":[0.00048906694,0.994878,0.00023480244,0.000009828267,0.00010204098,0.00032976424,0.000041432446,0.000042487038,0.0038725957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980571,0.00018985773,0.0003598052,0.0004107497,0.0005231072,0.00045937928],"domain_scores_gemma":[0.99880105,0.00033290003,0.000088502566,0.00043199855,0.00008658228,0.0002589579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070286414,0.00029566584,0.002022129,0.00065779133,0.000087439315,0.000047824415,0.00009635866,0.0001733822,0.000012815171],"category_scores_gemma":[0.00015029749,0.00019626087,0.00019451957,0.0005156303,0.0003351854,0.000051779854,0.00018710611,0.00036257814,0.000025245283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001734838,0.00016207478,0.000010478381,0.053684823,0.000743143,0.000075232456,0.00008483636,2.2636535e-9,0.000020243853,0.0024131883,0.00041693245,0.94237167],"study_design_scores_gemma":[0.0014946908,0.0006547414,0.00083818426,0.010608391,0.0035151676,0.000024732108,0.000015066787,3.6701522e-7,0.000047536316,0.00024721082,0.9824052,0.00014871458],"about_ca_topic_score_codex":0.000121514524,"about_ca_topic_score_gemma":0.0000010406301,"teacher_disagreement_score":0.98198825,"about_ca_system_score_codex":0.000035553407,"about_ca_system_score_gemma":0.00025965634,"threshold_uncertainty_score":0.80032855},"labels":[],"label_agreement":null},{"id":"W2068155499","doi":"10.1111/1753-0407.12053","title":"Potential for cardiac protection with dipeptidyl peptidase‐4 inhibitors: The stromal cell‐derived factor‐1α hypothesis (二肽基肽酶‐4抑制剂潜在的心脏保护作用：基质细胞衍生因子‐1α假说)","year":2013,"lang":"en","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Sitagliptin; Dipeptidyl peptidase-4; Diabetes mellitus; Internal medicine; Saxagliptin; Myocardial infarction; Odds ratio; Heart failure; Meta-analysis; Adverse effect; Incretin; Disease; Clinical trial; Alogliptin; Risk factor; Incidence (geometry); Type 2 diabetes; Endocrinology","score_opus":0.010526856625860814,"score_gpt":0.19962766477668717,"score_spread":0.18910080815082636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068155499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946487,0.0004853183,0.00020008304,0.001627027,0.00040947553,0.002075108,0.000019043495,0.000040176605,0.0004950827],"genre_scores_gemma":[0.9953192,0.00003816121,0.0021685578,0.00017477141,0.0010861069,0.00025678886,0.000008751069,0.000060511684,0.0008871465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805325,0.00008784235,0.0005258873,0.00024225895,0.0005727454,0.00051802985],"domain_scores_gemma":[0.9983486,0.00016211801,0.00055210665,0.00030505948,0.00041436407,0.00021775502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027356565,0.00033151073,0.0006178924,0.0001634063,0.00018997892,0.00015344801,0.00017987551,0.00010389824,0.00011959996],"category_scores_gemma":[0.00008012833,0.00018492465,0.00050283986,0.00017326114,0.00011115829,0.00043218106,0.000048332135,0.00026648032,0.00003354041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006261929,0.0020469236,0.11017761,0.0009645563,0.005118967,0.000029628061,0.00092944666,0.00012966225,0.73487586,0.0000311042,0.02165086,0.12341921],"study_design_scores_gemma":[0.011817164,0.014347563,0.464425,0.0010926262,0.0042004734,0.0000146522225,0.0030631102,0.0005007764,0.48617667,0.0003369902,0.013110965,0.00091399334],"about_ca_topic_score_codex":0.000013570263,"about_ca_topic_score_gemma":0.0000019600593,"teacher_disagreement_score":0.3542474,"about_ca_system_score_codex":0.00013737472,"about_ca_system_score_gemma":0.000073438525,"threshold_uncertainty_score":0.7541008},"labels":[],"label_agreement":null},{"id":"W2068393876","doi":"10.1007/s00125-011-2297-z","title":"Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology","year":2011,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Incretin; Psoriasis; Inflammation; Diabetes mellitus; Insulin resistance; Type 2 diabetes; Receptor; Agonist; Glucagon-like peptide 1 receptor; Beta cell; Insulin; Glucagon-like peptide-1; Immunology; Pharmacology; Internal medicine; Endocrinology; Islet","score_opus":0.01718305025746132,"score_gpt":0.22930872307602182,"score_spread":0.21212567281856048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068393876","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51955193,0.016465133,0.0000104117835,0.42823026,0.0056211436,0.0036461614,0.00024368182,0.0012899769,0.024941258],"genre_scores_gemma":[0.08795209,0.0049606464,0.004372815,0.8606655,0.0036396014,0.001404164,0.006679718,0.00048628196,0.029839184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561995,0.00024991352,0.00074585545,0.0013837971,0.00046199703,0.0015385075],"domain_scores_gemma":[0.9976218,0.00027506586,0.0004471591,0.0012048357,0.00016540036,0.0002857693],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024638668,0.0010721248,0.0021533065,0.00048175157,0.00021583989,0.00009778426,0.00045613988,0.0017865337,0.00067833916],"category_scores_gemma":[0.00014277299,0.0009117996,0.0003975955,0.00025640876,0.0005566406,0.00016485933,0.00046895767,0.0014795002,0.0009350102],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030232166,0.0002677466,0.10552511,0.0015083618,0.0016471929,0.000698891,0.000108228676,2.2801787e-8,0.00006139411,0.00014742755,0.88574827,0.004257102],"study_design_scores_gemma":[0.0018502973,0.00050577614,0.017103871,0.00037675523,0.002148295,0.000029134428,0.000034219753,0.000006484505,0.0015851104,0.00033567654,0.97514147,0.00088293926],"about_ca_topic_score_codex":0.00004740591,"about_ca_topic_score_gemma":0.00000905957,"teacher_disagreement_score":0.4324352,"about_ca_system_score_codex":0.00018719994,"about_ca_system_score_gemma":0.00011740358,"threshold_uncertainty_score":0.9998429},"labels":[],"label_agreement":null},{"id":"W2068834629","doi":"10.1055/s-2004-826164","title":"Glucose-dependent Insulinotropic Polypeptide as a Regulator of Beta Cell Function and Fate","year":2004,"lang":"en","type":"review","venue":"Hormone and Metabolic Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Endocrinology; Internal medicine; Beta cell; Receptor; Biology; Insulin; Hormone; Incretin; Nutrient sensing; Gastric inhibitory polypeptide; Signal transduction; Chemistry; Glucagon; Type 2 diabetes; Diabetes mellitus; Cell biology; Islet; Medicine","score_opus":0.06138470213977909,"score_gpt":0.36076063539354003,"score_spread":0.29937593325376094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068834629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012039647,0.9809714,0.000006907563,0.000055624292,0.00005453074,0.0018708458,0.000017022478,0.00003066034,0.0049533886],"genre_scores_gemma":[0.0067679277,0.984142,0.00016120725,0.00002094134,0.00016598818,0.00018818952,0.000090437694,0.00006259323,0.008400738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730647,0.00019653286,0.0005547354,0.00059074606,0.0008109538,0.0005405581],"domain_scores_gemma":[0.99867904,0.000086093285,0.0001772011,0.00057754654,0.00015408678,0.00032605452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073958264,0.00037391763,0.0017402045,0.00076450396,0.00010812608,0.000056178953,0.00010712774,0.00024694856,0.00003988541],"category_scores_gemma":[0.000038079976,0.00026664571,0.00023485791,0.00052091025,0.00020657611,0.00009060693,0.0003079785,0.0005014134,0.0000960298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001066547,0.00032957437,0.00003714762,0.012099453,0.00073504186,0.000051833245,0.00005384312,4.018423e-8,0.00018551531,0.0031460647,0.00028743694,0.9829674],"study_design_scores_gemma":[0.0025002607,0.0012037582,0.0021925867,0.0024740302,0.0032287815,0.000025613741,0.000061050225,8.022667e-7,0.00033576903,0.0003372428,0.98742217,0.00021792113],"about_ca_topic_score_codex":0.00029437453,"about_ca_topic_score_gemma":0.000003615386,"teacher_disagreement_score":0.98713475,"about_ca_system_score_codex":0.00007773525,"about_ca_system_score_gemma":0.00037447747,"threshold_uncertainty_score":0.9999786},"labels":[],"label_agreement":null},{"id":"W2069204114","doi":"10.1016/j.jfma.2012.02.027","title":"Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus","year":2012,"lang":"en","type":"article","venue":"Journal of the Formosan Medical Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Exenatide; Type 2 Diabetes Mellitus; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.005333797131979235,"score_gpt":0.22664137083414956,"score_spread":0.22130757370217033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069204114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996027,0.00069949427,0.000004838567,0.0019871725,0.00016382901,0.0003758908,0.0000010997463,0.0000036805322,0.0007370281],"genre_scores_gemma":[0.99913526,0.00016576675,0.00009138413,0.0002907909,0.000103636674,0.0000023071761,0.0000053785734,0.000008353195,0.00019714798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801964,0.00010796836,0.0005459655,0.000055670822,0.001043155,0.00022759063],"domain_scores_gemma":[0.9984469,0.00036295882,0.0007502784,0.000082450315,0.00020672222,0.00015071084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015111031,0.000098603516,0.00048898667,0.00008965552,0.000030087724,0.000007701999,0.0000851774,0.000095295,0.000047736557],"category_scores_gemma":[0.0019676427,0.00004950907,0.00008771179,0.00020072862,0.000034030683,0.00016849875,0.00003614895,0.00022496596,0.0000022702586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018941009,0.00086645107,0.97160465,0.000043038275,0.00052881363,0.0000020165635,0.00042857046,0.0000018500417,0.000023580491,0.00007961101,0.0006753712,0.023851966],"study_design_scores_gemma":[0.025373999,0.00090702606,0.9706814,0.00029434272,0.0004567023,9.3341174e-7,0.000065171815,0.00007078439,0.0001548218,0.00004488489,0.0018929674,0.000056918787],"about_ca_topic_score_codex":0.000005670129,"about_ca_topic_score_gemma":0.000006435493,"teacher_disagreement_score":0.023795048,"about_ca_system_score_codex":0.00026649356,"about_ca_system_score_gemma":0.00007167803,"threshold_uncertainty_score":0.23555942},"labels":[],"label_agreement":null},{"id":"W2069942402","doi":"10.2337/dc14-0893","title":"Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Placebo; Internal medicine; Glycemic; Diabetes mellitus; Randomization; Endocrinology; Urology; Gastroenterology; Clinical trial; Pathology","score_opus":0.00890448508541218,"score_gpt":0.2053620262720827,"score_spread":0.19645754118667053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069942402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919862,0.001574597,0.0000031606205,0.000512891,0.00019576294,0.001238725,0.0000032173355,0.00002749961,0.0044579394],"genre_scores_gemma":[0.99871844,0.00006755614,0.00002953984,0.00046003194,0.00012833356,0.0001416935,0.000056038403,0.000017001332,0.00038136265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906856,0.0001435273,0.00022664493,0.00017036525,0.00018620971,0.00020471512],"domain_scores_gemma":[0.99908775,0.00036562598,0.000101039346,0.00034240048,0.00006843422,0.000034745237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032644518,0.00012713407,0.0002960351,0.00007127534,0.000051772804,0.000032907144,0.00009200526,0.000052383497,0.000016104168],"category_scores_gemma":[0.00017510969,0.000068261375,0.00007086388,0.00023234959,0.000109328794,0.00012461223,0.00006395273,0.00009720454,0.000016853204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002294657,0.0001075582,0.9814079,0.00039178116,0.00014771009,2.5492324e-7,0.0015642269,0.0000127141475,0.00032889104,0.0010942253,0.0006204174,0.012029693],"study_design_scores_gemma":[0.06594677,0.0033288272,0.91155726,0.00030841058,0.001248547,3.1256683e-8,0.0010632046,0.0019750567,0.0028380072,0.001421844,0.010114985,0.00019708485],"about_ca_topic_score_codex":0.000023152865,"about_ca_topic_score_gemma":0.000009247432,"teacher_disagreement_score":0.06985064,"about_ca_system_score_codex":0.000022398208,"about_ca_system_score_gemma":0.000016613196,"threshold_uncertainty_score":0.2783618},"labels":[],"label_agreement":null},{"id":"W2070086714","doi":"10.1016/j.pnpbp.2008.08.014","title":"Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis","year":2008,"lang":"en","type":"review","venue":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto","funders":"","keywords":"Weight gain; Body mass index; Meta-analysis; Antipsychotic; Obesity; Schizophrenia (object-oriented programming); Internal medicine; Random effects model; Medicine; Psychology; Endocrinology; Body weight; Psychiatry","score_opus":0.05926221626214419,"score_gpt":0.3616995248961559,"score_spread":0.30243730863401175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070086714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03238683,0.9638216,0.00000669903,0.0008916759,0.00045288837,0.0021234623,0.000042062962,0.000056835775,0.00021795275],"genre_scores_gemma":[0.030003525,0.96760076,0.0007023146,0.0007073355,0.00013470874,0.0005703079,0.00011664994,0.000035942787,0.00012847886],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964234,0.0006431815,0.0009788738,0.00113588,0.00028525802,0.0005333935],"domain_scores_gemma":[0.9981086,0.0003549093,0.0009275476,0.0003425228,0.000069939735,0.00019647143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039614114,0.000719944,0.004198414,0.0008213642,0.000083973835,0.000020161344,0.00021032144,0.00080522045,0.00012819459],"category_scores_gemma":[0.000023735618,0.00041463028,0.0009569674,0.0012896586,0.00030962957,0.000055020293,0.00008519452,0.00082492054,0.00000439878],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008272865,0.00154244,0.8374057,0.0022942587,0.107089795,0.00016423452,0.0000112435755,3.147287e-7,0.0000017584547,0.000057537094,0.000759983,0.04984545],"study_design_scores_gemma":[0.010673212,0.0040403823,0.32906148,0.0005059498,0.5132378,0.00014755821,0.00001231045,0.000040873492,0.0000019456165,0.00026384892,0.14086935,0.0011453265],"about_ca_topic_score_codex":0.0000018816671,"about_ca_topic_score_gemma":0.000004324122,"teacher_disagreement_score":0.50834423,"about_ca_system_score_codex":0.000046452515,"about_ca_system_score_gemma":0.00008171387,"threshold_uncertainty_score":0.99983054},"labels":[],"label_agreement":null},{"id":"W2070284204","doi":"10.1210/jc.2003-032001","title":"Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes","year":2004,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; London Health Sciences Centre; Western University","funders":"","keywords":"Internal medicine; Endocrinology; Gastric emptying; Insulin; Glucagon; Medicine; Type 2 diabetes; Glycemic; Endogeny; Meal; Glucagon-like peptide-1; Diabetes mellitus; Stomach","score_opus":0.04326644956091682,"score_gpt":0.3704810955276818,"score_spread":0.327214645966765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070284204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97691846,0.0073098503,0.000014376728,0.0119844675,0.001737605,0.00025985594,0.0000016072892,0.00002186858,0.0017518876],"genre_scores_gemma":[0.9865614,0.008915709,0.00084597885,0.0026625625,0.00065141055,0.000003917242,0.000004067523,0.000019989997,0.0003349744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974039,0.00028241854,0.0013223477,0.0001596912,0.00029893592,0.0005326999],"domain_scores_gemma":[0.9982412,0.0005226896,0.00050796894,0.00036744445,0.00016585395,0.00019484824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009802782,0.00019608698,0.0010602033,0.00025593952,0.00005720592,0.000009209431,0.00034221922,0.000111374764,0.00017671271],"category_scores_gemma":[0.0007866448,0.00011403738,0.00035391582,0.00030466935,0.0003119447,0.00013028795,0.00012394376,0.0007995994,0.00011073996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050894275,0.018264703,0.43511432,0.000257514,0.01196979,0.005171341,0.0028087753,0.0012437474,0.017401708,0.08357183,0.019822445,0.35347956],"study_design_scores_gemma":[0.047081105,0.0043507335,0.77534795,0.00028512022,0.0036911913,0.00044696836,0.00037752045,0.000017770362,0.0032331601,0.010809002,0.15403385,0.00032565],"about_ca_topic_score_codex":0.000022244049,"about_ca_topic_score_gemma":0.00001015522,"teacher_disagreement_score":0.3531539,"about_ca_system_score_codex":0.000042929187,"about_ca_system_score_gemma":0.00019146474,"threshold_uncertainty_score":0.46503094},"labels":[],"label_agreement":null},{"id":"W2070309137","doi":"10.1016/j.amjmed.2013.06.012","title":"Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes","year":2013,"lang":"en","type":"review","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk; Sanofi; Merck; Eli Lilly and Company","keywords":"Medicine; Glycemic; Intensive care medicine; Type 2 diabetes; Patient education; Diabetes mellitus; Health care; Nursing","score_opus":0.013137875138110029,"score_gpt":0.28519502599688873,"score_spread":0.2720571508587787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070309137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010869327,0.98354375,0.000011722925,0.0036546167,0.00029645683,0.0011412087,0.0000033006909,0.000009553804,0.00047003257],"genre_scores_gemma":[0.013887318,0.97873753,0.00023280641,0.006509729,0.00048350092,0.000037099988,0.0000058183987,0.000047382233,0.00005878955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802977,0.0002012137,0.00080925145,0.0001993223,0.00040632207,0.00035413547],"domain_scores_gemma":[0.99766517,0.0003439369,0.0011119965,0.00031368513,0.00012315468,0.00044203206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047238238,0.00036684322,0.0028859566,0.00044845266,0.00004083078,0.000014961113,0.00022289368,0.00003761114,0.00008071249],"category_scores_gemma":[0.0002587831,0.0001766636,0.00018642111,0.0005972723,0.00039480277,0.000050504717,0.000063376705,0.0004197134,0.000016715756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022255073,0.00003577112,0.00006366243,0.0005961273,0.00078267045,0.00005377601,0.00035284352,0.0000050725057,0.000006995065,0.0000073948113,0.0033380657,0.9945351],"study_design_scores_gemma":[0.004096406,0.011997295,0.000118040894,0.032619048,0.0061386214,0.00008530056,0.0012554418,0.000028473176,0.0000011461215,0.0000305326,0.94335085,0.0002788385],"about_ca_topic_score_codex":0.000040577062,"about_ca_topic_score_gemma":9.766945e-7,"teacher_disagreement_score":0.99425626,"about_ca_system_score_codex":0.00017576152,"about_ca_system_score_gemma":0.00015201265,"threshold_uncertainty_score":0.72041327},"labels":[],"label_agreement":null},{"id":"W2070768644","doi":"10.1038/nm.3128","title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","year":2013,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Guelph; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Japan Science and Technology Agency; Canadian Institutes of Health Research; State University of New York Upstate Medical University; Novo Nordisk; Canada Research Chairs; Heart and Stroke Foundation of Canada","keywords":"Atrial natriuretic peptide; Secretion; NPR1; Blood pressure; Internal medicine; NPR2; Receptor; Endocrinology; Medicine; Natriuretic peptide; Heart failure","score_opus":0.004430149564142866,"score_gpt":0.23824454157181366,"score_spread":0.2338143920076708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070768644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90782154,0.010337039,0.00046922461,0.07054338,0.00089391536,0.0044436995,0.000017796612,0.00012939246,0.0053440295],"genre_scores_gemma":[0.99256,0.0001512305,0.00058358465,0.0017224015,0.0015274009,0.00004744268,0.00009616766,0.000021481048,0.0032902523],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873865,0.000042855925,0.00029198296,0.00028015097,0.00044012954,0.00020625844],"domain_scores_gemma":[0.9990217,0.00014796614,0.00013570295,0.00024924352,0.00025319154,0.00019219438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002454065,0.00018845803,0.00046504906,0.00022048272,0.000034663113,0.000008473166,0.00006544167,0.00026483007,0.00070180494],"category_scores_gemma":[0.00065382785,0.0001294625,0.00006977255,0.00024738934,0.0000742574,0.00009280903,0.000028208038,0.00032703317,0.000020517415],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003350233,0.00064200925,0.024575865,0.0022560742,0.0065855877,0.000020942902,0.002757586,0.000034326975,0.6392964,0.0058477065,0.16886912,0.14576417],"study_design_scores_gemma":[0.09701613,0.02057722,0.20365109,0.0049445806,0.027975503,0.000027073804,0.00090560724,0.0013746343,0.09809632,0.0018944406,0.54241925,0.0011181259],"about_ca_topic_score_codex":0.00006812205,"about_ca_topic_score_gemma":0.0000027176873,"teacher_disagreement_score":0.54120004,"about_ca_system_score_codex":0.000019658222,"about_ca_system_score_gemma":0.000023898485,"threshold_uncertainty_score":0.7684272},"labels":[],"label_agreement":null},{"id":"W2070921516","doi":"10.1007/s40273-013-0117-7","title":"Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Diabetes mellitus; Type 2 Diabetes Mellitus; Health administration; Medicine; Public health; Pharmacoeconomics; Intensive care medicine; Endocrinology; Nursing","score_opus":0.28139725041198266,"score_gpt":0.47458829889532744,"score_spread":0.19319104848334478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070921516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005756632,0.99436367,0.0000062500367,0.00004014704,0.00025510677,0.0038996367,0.00018449368,0.00001609977,0.0006589142],"genre_scores_gemma":[0.000022895996,0.9965545,0.0011061867,0.00018920684,0.00008386715,0.00028279438,0.00091766764,0.00007769227,0.0007651872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978364,0.000047183552,0.0013399571,0.00040945408,0.000053853903,0.0003131457],"domain_scores_gemma":[0.9983559,0.00014309604,0.00088031305,0.000427863,0.000042552296,0.00015026586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021914035,0.0004640698,0.0037388594,0.0003505615,0.000010458004,0.000010312243,0.0002239661,0.000113633556,0.00044202924],"category_scores_gemma":[0.000012238284,0.00038157386,0.0008547601,0.00011664103,0.000036156085,0.00016522403,0.00007140291,0.000090667556,0.00008379626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018573779,0.000231222,0.000037985465,0.1076136,0.0042955135,7.0483884e-7,0.000011591502,0.000040795137,0.000003828594,0.0000812251,0.012292061,0.8753729],"study_design_scores_gemma":[0.0025814483,0.00029063094,0.0000018489831,0.03577493,0.020147644,5.865258e-7,0.0000030972938,0.0010216943,0.00028387626,0.00019569557,0.93937945,0.00031911908],"about_ca_topic_score_codex":0.000119630546,"about_ca_topic_score_gemma":0.0000047965564,"teacher_disagreement_score":0.92708737,"about_ca_system_score_codex":0.00044117187,"about_ca_system_score_gemma":0.0003789127,"threshold_uncertainty_score":0.9998636},"labels":[],"label_agreement":null},{"id":"W2071204946","doi":"10.1503/cmaj.109-2037","title":"Primary care and type 2 diabetes mellitus","year":2009,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Primary care; Diabetes mellitus; Type 2 Diabetes Mellitus; Glycemic; Medicine; Type 2 diabetes; Disease; Intensive care medicine; Family medicine; Internal medicine; Endocrinology","score_opus":0.005209697836794821,"score_gpt":0.20543811488536326,"score_spread":0.20022841704856845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071204946","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057826866,0.016160836,6.5414775e-7,0.9372778,0.0012735287,0.00029358314,0.000031859792,0.000034513345,0.03914456],"genre_scores_gemma":[0.00088533433,0.0036577117,0.00014321976,0.97887516,0.009242377,0.000005526956,0.0007683854,0.000037170717,0.0063851033],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722886,0.000093537725,0.00034487116,0.00023508641,0.0014165938,0.0006810269],"domain_scores_gemma":[0.9980345,0.00009458144,0.000203648,0.00014304862,0.0003783997,0.0011458262],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004015439,0.00024342576,0.0005145503,0.00032644343,0.00015933857,0.00012658977,0.00012987338,0.0011961333,0.001242615],"category_scores_gemma":[0.0002987661,0.0002102546,0.00013609185,0.00015292325,0.000035587746,0.000065371765,0.000017903867,0.0023775883,0.00014969203],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001939575,0.000007927037,0.007867107,0.00012369997,0.00033306587,0.0018895053,0.000061983555,2.7396451e-8,2.6165685e-7,0.0000043065875,0.82043993,0.16927022],"study_design_scores_gemma":[0.00084204803,0.0002789021,0.011324684,0.00040886347,0.00042638092,0.000056657136,0.000038131497,0.0000029256216,0.0000013235506,0.000057637055,0.9863792,0.00018325204],"about_ca_topic_score_codex":0.00018733396,"about_ca_topic_score_gemma":0.00071639376,"teacher_disagreement_score":0.16908696,"about_ca_system_score_codex":0.0024641657,"about_ca_system_score_gemma":0.0023882994,"threshold_uncertainty_score":0.99992394},"labels":[],"label_agreement":null},{"id":"W2071432558","doi":"10.1016/s1262-3636(14)72595-9","title":"P304 Efficacité et tolérance de la canagliflozine sur une période de 52 semaines chez des patients diabétiques de type 2 présentant une insuffisance rénale chronique","year":2014,"lang":"fr","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.006041862100369337,"score_gpt":0.25538211043418657,"score_spread":0.24934024833381724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071432558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93339515,0.052915297,0.0005183899,0.003603383,0.0014914481,0.0010739727,0.00011414704,0.00025645643,0.0066317767],"genre_scores_gemma":[0.9661182,0.0125296,0.0056177233,0.005950307,0.0014264338,0.00029058536,0.0002737039,0.00019856516,0.0075948536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941497,0.0013617115,0.0007877546,0.0008536299,0.00057202164,0.0022751682],"domain_scores_gemma":[0.99668837,0.0008791492,0.00036225803,0.00082919915,0.00046397976,0.00077703747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022158506,0.0009019436,0.0013791699,0.0002607951,0.0002407692,0.00019419134,0.00049313705,0.00042335186,0.00017005528],"category_scores_gemma":[0.0015847265,0.00086855475,0.0003202401,0.0011012864,0.00078101945,0.00048024202,0.00023407597,0.00057678245,0.00014435303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027037776,0.005849058,0.70543486,0.0027863525,0.0026461792,0.00015334591,0.018562086,0.0012871778,0.012358922,0.022788119,0.023318987,0.20454451],"study_design_scores_gemma":[0.005410732,0.0007302202,0.51748586,0.001558239,0.001960516,0.0000048028046,0.00016864586,0.0032396102,0.025152292,0.0032621932,0.44019908,0.00082779495],"about_ca_topic_score_codex":0.004320996,"about_ca_topic_score_gemma":0.0010332811,"teacher_disagreement_score":0.4168801,"about_ca_system_score_codex":0.0008274223,"about_ca_system_score_gemma":0.00044457646,"threshold_uncertainty_score":0.99937654},"labels":[],"label_agreement":null},{"id":"W2071541095","doi":"10.4103/0975-7406.129179","title":"Canagliflozin - Beginning of the journey","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmacy And Bioallied Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Glycemic; Diabetes mellitus; Type 2 diabetes; Renal glucose reabsorption; Dapagliflozin; Internal medicine; Endocrinology; Glycosuria","score_opus":0.042285377182479635,"score_gpt":0.32493052614338497,"score_spread":0.2826451489609053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071541095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867163,0.00068013027,0.000031624186,0.0060695424,0.00025811413,0.00006472421,4.2284506e-7,0.0000022981646,0.006176856],"genre_scores_gemma":[0.99826276,0.00020304065,0.00050352403,0.0006452564,0.00011674247,2.9026734e-7,6.644423e-8,0.0000017797902,0.00026651195],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.999307,0.000030811734,0.00020910925,0.00005943248,0.00028784358,0.0001057989],"domain_scores_gemma":[0.99955297,0.000043842138,0.000231683,0.00004800345,0.000052594783,0.000070910915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007929198,0.00005451307,0.00014538835,0.00009084466,0.00010061392,0.000023003751,0.00013651769,0.000008118419,0.00003071174],"category_scores_gemma":[0.000049728154,0.000025825067,0.00006445707,0.00018243515,0.0002547821,0.00010379695,0.000035071145,0.00007554318,5.679783e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022029127,0.00042933578,0.7722426,0.00024425137,0.00042437896,0.000027147722,0.0011330578,0.00011018711,0.06373452,0.0067182467,0.010812026,0.14390394],"study_design_scores_gemma":[0.016711617,0.0035987522,0.25195584,0.0014549014,0.002309989,0.00041086963,0.0027745839,0.007374155,0.21720026,0.0036349392,0.49210003,0.00047406397],"about_ca_topic_score_codex":0.000022410886,"about_ca_topic_score_gemma":0.0000058260107,"teacher_disagreement_score":0.5202868,"about_ca_system_score_codex":0.0000102118975,"about_ca_system_score_gemma":0.000062240855,"threshold_uncertainty_score":0.105311565},"labels":[],"label_agreement":null},{"id":"W2072396082","doi":"10.1111/dom.12359","title":"Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; Centre hospitalier de l'Université Laval","funders":"Merck","keywords":"Sitagliptin; Internal medicine; Endocrinology; Apolipoprotein B; Very low-density lipoprotein; Triglyceride; Placebo; Crossover study; Type 2 diabetes; Chemistry; Cholesterol; Medicine; Lipoprotein; Insulin; Diabetes mellitus","score_opus":0.003847252317263479,"score_gpt":0.20169237514221577,"score_spread":0.19784512282495229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072396082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683726,0.0009879961,0.0000010329387,0.00005529915,0.00012780566,0.0010568439,0.000006413168,0.000037843834,0.0008894774],"genre_scores_gemma":[0.99909174,0.00012846489,0.00017306386,0.00025927325,0.00006885369,0.000047610847,0.000059666556,0.00002921154,0.00014209595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986142,0.00015677519,0.00023693347,0.00031835283,0.00030312547,0.0003706148],"domain_scores_gemma":[0.9991869,0.00017290188,0.000111591784,0.00033192168,0.00008185151,0.000114866736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041092513,0.0002829244,0.00073196535,0.00023456494,0.000035979196,0.000019588182,0.000084641586,0.00008972941,0.000028969205],"category_scores_gemma":[0.00012012337,0.00018712014,0.00006360334,0.0003200662,0.00008399563,0.000076850694,0.00004281115,0.00012969432,0.000013112318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005351707,0.001049164,0.89342076,0.00023569318,0.00021225124,8.3608563e-7,0.000081319886,0.000006340286,0.0013120834,0.00018156045,0.00006431094,0.10290052],"study_design_scores_gemma":[0.00883249,0.006567807,0.9197473,0.0001588658,0.00025025304,1.7090954e-8,0.0000021925562,0.0000453749,0.06094743,0.000046072466,0.0032217293,0.0001804739],"about_ca_topic_score_codex":0.000011910592,"about_ca_topic_score_gemma":0.0000031041816,"teacher_disagreement_score":0.102720045,"about_ca_system_score_codex":0.000018132396,"about_ca_system_score_gemma":0.0000081453,"threshold_uncertainty_score":0.7630538},"labels":[],"label_agreement":null},{"id":"W2072408213","doi":"10.1016/j.jcjd.2013.07.030","title":"Effects of Aerobic Exercise with or without Metformin on Plasma Incretins in Type 2 Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Metformin; Medicine; Incretin; Type 2 diabetes; Internal medicine; Aerobic exercise; Endocrinology; Crossover study; Placebo; Diabetes mellitus; Hormone; Glucagon; Postprandial","score_opus":0.006862998279342286,"score_gpt":0.20576630628412518,"score_spread":0.1989033080047829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072408213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968319,0.0011031969,2.7191484e-7,0.00021973858,0.00016240109,0.000700871,0.0000021131593,0.0000073605897,0.0009721581],"genre_scores_gemma":[0.99829745,0.000051304814,0.0006495696,0.00025514804,0.000052215848,0.0000312358,0.0000056352173,0.00003511514,0.00062233506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986925,0.0000385191,0.00038619223,0.00014884715,0.00022886679,0.0005050629],"domain_scores_gemma":[0.998602,0.00019182562,0.00023767122,0.00019118375,0.00019684926,0.00058046903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019795824,0.00022416597,0.00071432744,0.00075791444,0.00003443375,0.000031110554,0.00015803393,0.00007550404,0.00021079506],"category_scores_gemma":[0.00018271437,0.00014255254,0.00008419554,0.00042176488,0.000111529065,0.00020093475,0.000012163531,0.00019463965,0.000034610963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009537402,0.00019145367,0.9648614,0.0006005807,0.0004435241,0.00010965734,0.0003561543,0.000019594265,0.0017822657,0.000053995587,0.0027922525,0.028693734],"study_design_scores_gemma":[0.013250317,0.016148524,0.8023199,0.010497314,0.001635888,0.0000068294726,0.00051371614,0.00035789286,0.15067193,0.00017978673,0.0037519743,0.00066593155],"about_ca_topic_score_codex":0.000460147,"about_ca_topic_score_gemma":0.0024287014,"teacher_disagreement_score":0.16254152,"about_ca_system_score_codex":0.00016653391,"about_ca_system_score_gemma":0.00046406753,"threshold_uncertainty_score":0.5813124},"labels":[],"label_agreement":null},{"id":"W2072484220","doi":"10.1016/j.metabol.2014.02.012","title":"Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress","year":2014,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hokkaido University; University of Toronto","keywords":"Endoplasmic reticulum; Cell biology; Chemistry; Internal medicine; Biology; Medicine","score_opus":0.00779460499966103,"score_gpt":0.21862699083926235,"score_spread":0.21083238583960132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072484220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98536485,0.0017348913,0.00023614957,0.0061325976,0.0008855417,0.0011057958,0.000032501404,0.000100891426,0.004406757],"genre_scores_gemma":[0.99058944,0.00028562854,0.0006129446,0.0013965294,0.00052027544,0.00015623693,0.00012802695,0.00003710656,0.0062738094],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981948,0.00014343204,0.0003313104,0.00046431905,0.0004347132,0.00043138544],"domain_scores_gemma":[0.99873304,0.000040118142,0.000116638854,0.00095726614,0.00005955993,0.000093363284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049992296,0.00028099798,0.00041650614,0.00013807391,0.00008235273,0.000044217395,0.00028278286,0.00008796145,0.00010462781],"category_scores_gemma":[0.000077515135,0.00018691353,0.00013464731,0.00031773324,0.000073803356,0.00013146609,0.00010263269,0.00021305801,0.00011989374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085581036,0.009958017,0.0797122,0.0012631709,0.0012123958,0.000119431934,0.015155845,0.00014520698,0.14761677,0.0013061615,0.55261075,0.19004425],"study_design_scores_gemma":[0.008512993,0.00056920236,0.08205474,0.00012559962,0.0014158371,0.00001367485,0.0007030382,0.0013018713,0.46282643,0.001080496,0.44083723,0.0005588966],"about_ca_topic_score_codex":0.0001883233,"about_ca_topic_score_gemma":0.000057032634,"teacher_disagreement_score":0.31520966,"about_ca_system_score_codex":0.00003663943,"about_ca_system_score_gemma":0.00001771936,"threshold_uncertainty_score":0.76221126},"labels":[],"label_agreement":null},{"id":"W2072686461","doi":"10.1371/journal.pone.0040156","title":"GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC; Canadian Diabetes Association","keywords":"Endocrinology; Internal medicine; Glucose homeostasis; Steatosis; Gastric inhibitory polypeptide; Adipose tissue; Adipocyte; Energy homeostasis; Biology; Carbohydrate metabolism; Homeostasis; Insulin resistance; Insulin; Medicine; Glucagon; Obesity","score_opus":0.03955642371691417,"score_gpt":0.24027716090743337,"score_spread":0.2007207371905192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072686461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927914,0.0047431826,0.000002584651,0.00035455995,0.000036006197,0.0006050123,0.000011288369,0.000082958,0.0013730084],"genre_scores_gemma":[0.9956393,0.0008819694,0.0027605589,0.00018314828,0.00011121053,0.00003835107,0.000025162544,0.000025513045,0.0003347914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896336,0.000033802964,0.00016979768,0.00026032957,0.00018851702,0.0003841748],"domain_scores_gemma":[0.99932563,0.000048010035,0.00007593383,0.00022924921,0.000039578867,0.00028161582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001517819,0.00019282085,0.0003559275,0.00007630834,0.00011124286,0.000051983236,0.000039848837,0.00007485114,0.000028111876],"category_scores_gemma":[0.000047749763,0.00016965097,0.000033143064,0.000090597154,0.00005114613,0.00026075408,0.00010665533,0.00011158543,0.00001559863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022693996,0.0029954966,0.0693289,0.0004395081,0.0009350995,0.0000058423566,0.00037559698,5.4385287e-9,0.89803594,0.0000436639,0.000093517905,0.027519498],"study_design_scores_gemma":[0.0028977585,0.00065240706,0.228236,0.0005016817,0.002043966,0.0000028126972,0.00021841863,0.00010578946,0.76492083,0.000041970245,0.00010860246,0.0002697745],"about_ca_topic_score_codex":0.000039569422,"about_ca_topic_score_gemma":0.0000044121016,"teacher_disagreement_score":0.1589071,"about_ca_system_score_codex":0.000049729668,"about_ca_system_score_gemma":0.000016139838,"threshold_uncertainty_score":0.69181657},"labels":[],"label_agreement":null},{"id":"W2073531152","doi":"10.1016/j.jcjd.2013.01.012","title":"Screening for Type 1 and Type 2 Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Glycated hemoglobin; Diabetes mellitus; Impaired glucose tolerance; Internal medicine; Plasma glucose; Glucose tolerance test; Impaired fasting glucose; Endocrinology; Insulin resistance","score_opus":0.02642571605601093,"score_gpt":0.24636160964136966,"score_spread":0.21993589358535873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073531152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927786,0.0039524953,0.0000064381984,0.0015816115,0.00032130102,0.00032110684,0.0000045399956,0.000007456026,0.0010264684],"genre_scores_gemma":[0.99488723,0.000019685665,0.0028254476,0.0010240373,0.00020350642,0.000008579388,0.000012863422,0.000022559694,0.0009960877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923545,0.000011280387,0.00020400979,0.000097660646,0.00008428879,0.00036728528],"domain_scores_gemma":[0.9987507,0.000076880155,0.00009542125,0.000103868246,0.00037927183,0.0005938454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014768243,0.00011546243,0.000274856,0.00024984387,0.00007428994,0.00006844395,0.000070735216,0.000047896498,0.000220617],"category_scores_gemma":[0.00023370146,0.00009305104,0.000060980805,0.00016862869,0.0000625571,0.00017001454,0.000009080733,0.00008033587,0.000016231072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000405215,0.000019031932,0.89281356,0.00010461373,0.00044050516,0.0000043063524,0.0000820848,0.0000027985022,0.00094187167,0.0001896099,0.04546507,0.059932508],"study_design_scores_gemma":[0.0031573996,0.0035928467,0.84489703,0.00061141944,0.00089666137,0.0000031373315,0.00029296012,0.0005556473,0.0027178163,0.0013599168,0.14155318,0.0003619799],"about_ca_topic_score_codex":0.00009085266,"about_ca_topic_score_gemma":0.00019700383,"teacher_disagreement_score":0.09608811,"about_ca_system_score_codex":0.000043949723,"about_ca_system_score_gemma":0.00019936262,"threshold_uncertainty_score":0.37945113},"labels":[],"label_agreement":null},{"id":"W2074139183","doi":"10.1016/s0168-8227(00)81316-9","title":"Prodrugs of DP IV-inhibitors strongly improve incretin-mediated glucose tolerance","year":2000,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Incretin; Prodrug; Diabetes mellitus; Pharmacology; Internal medicine; Exenatide; Endocrinology; Type 2 diabetes","score_opus":0.03805080149548078,"score_gpt":0.40198314861001216,"score_spread":0.3639323471145314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074139183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568875,0.0027911572,3.9188293e-7,0.0050744084,0.00012045736,0.001116717,0.000022641778,0.000052967436,0.033933803],"genre_scores_gemma":[0.98715836,0.0063628294,0.00081679894,0.0005879417,0.0003732506,0.00008526153,0.000069627684,0.000032909138,0.004513003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964383,0.00050956727,0.00077788136,0.0005897011,0.00093690393,0.0007476424],"domain_scores_gemma":[0.9934346,0.004823358,0.00016893615,0.0005385282,0.000545652,0.00048893556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039528045,0.00019963871,0.00055704307,0.00013266904,0.00012198008,0.00006658941,0.00017323109,0.0001678808,0.00050831813],"category_scores_gemma":[0.006825749,0.00015980273,0.00013824314,0.0004629761,0.00060923875,0.00042004779,0.0001200598,0.00080701016,0.0003083129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004083044,0.0072763897,0.23189606,0.0007845365,0.0013147556,0.00012935372,0.00019895872,0.0000016446176,0.0034212703,0.0003832821,0.013483881,0.7370268],"study_design_scores_gemma":[0.0129203275,0.018308854,0.14047192,0.00058510574,0.00076680817,0.0000031049917,0.0010235715,0.0015401494,0.011751199,0.00041208908,0.811675,0.0005418861],"about_ca_topic_score_codex":0.00006500374,"about_ca_topic_score_gemma":0.000004968172,"teacher_disagreement_score":0.79819113,"about_ca_system_score_codex":0.000048524238,"about_ca_system_score_gemma":0.0001464428,"threshold_uncertainty_score":0.8171552},"labels":[],"label_agreement":null},{"id":"W2074352721","doi":"10.1016/j.jcjd.2013.08.093","title":"Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Glycemic; Insulin; Basal (medicine); Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes; Irbesartan; Blood pressure; Chemistry","score_opus":0.006194750994470681,"score_gpt":0.21127788603714456,"score_spread":0.2050831350426739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074352721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137443,0.0012679737,0.0000028441139,0.004368635,0.0003464174,0.0015972407,0.00005207976,0.000020670745,0.00096972357],"genre_scores_gemma":[0.99346936,0.00002138062,0.00038320068,0.0049626813,0.00030820962,0.0001440312,0.00004220091,0.00007454126,0.0005943803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777013,0.000052952877,0.00059493294,0.00033148905,0.00027498958,0.00097551366],"domain_scores_gemma":[0.997385,0.00023753094,0.00024396364,0.0003178783,0.00049530674,0.0013202783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024121709,0.00039505734,0.0008203144,0.001019257,0.00008870837,0.00010073751,0.00026262068,0.00014658978,0.00031477798],"category_scores_gemma":[0.00035780735,0.0002943984,0.00015697039,0.0005382832,0.000108243876,0.00025620655,0.000015003889,0.00029755343,0.0001601056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090863823,0.00042447183,0.9256618,0.00020566121,0.0015721143,0.00014252092,0.0004183393,0.00008235467,0.0036748212,0.00019171527,0.028136374,0.038581192],"study_design_scores_gemma":[0.04437627,0.04198933,0.84383833,0.0027209958,0.0013928373,0.0000060679345,0.0003876267,0.0006554916,0.017859621,0.00132692,0.044135552,0.0013109364],"about_ca_topic_score_codex":0.0008282878,"about_ca_topic_score_gemma":0.0035524233,"teacher_disagreement_score":0.081823446,"about_ca_system_score_codex":0.00043179502,"about_ca_system_score_gemma":0.0007222059,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W2074450286","doi":"10.1161/01.cir.0000062646.09566.cc","title":"Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats","year":2003,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; University of Toronto; Heart and Stroke Foundation of Canada","keywords":"Medicine; Sensitization; Internal medicine; Insulin; Endocrinology; Glucose uptake; Diabetes mellitus; Pharmacology; Immunology","score_opus":0.016784921049611816,"score_gpt":0.2433254193603864,"score_spread":0.22654049831077458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074450286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963238,0.00053239573,0.00009565601,0.00013177763,0.00012482064,0.0008833173,0.000003065907,0.000045923927,0.0018592367],"genre_scores_gemma":[0.99901545,0.000074286545,0.00031213087,0.0001651383,0.00013571457,0.000035121793,0.00019398339,0.000018729717,0.00004944232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903554,0.00008246551,0.00024386741,0.0002754741,0.00018551419,0.00017715],"domain_scores_gemma":[0.9995802,0.000042248616,0.00007250037,0.00015461289,0.00006374124,0.0000866833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021176177,0.0001492064,0.00021358191,0.00019680627,0.00006163574,0.000044238157,0.000015031386,0.000092546645,0.00002607244],"category_scores_gemma":[0.0001688631,0.0001419985,0.000042008665,0.0002768858,0.000033133903,0.00024445172,0.000017058175,0.0000717856,0.00002715899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011031693,0.0004637043,0.94871396,0.00013802976,0.00012260617,0.00006019447,0.00046388825,0.00014854858,0.0275378,0.0020734358,0.00012828097,0.020039223],"study_design_scores_gemma":[0.0028048253,0.00007492449,0.9883586,0.00011540799,0.0001586973,0.000009200375,0.000097532284,0.000561641,0.0064751706,0.00054411445,0.0006402517,0.00015961503],"about_ca_topic_score_codex":0.000041141033,"about_ca_topic_score_gemma":0.000023674982,"teacher_disagreement_score":0.039644647,"about_ca_system_score_codex":0.0001232078,"about_ca_system_score_gemma":0.000046156743,"threshold_uncertainty_score":0.5790531},"labels":[],"label_agreement":null},{"id":"W2075492284","doi":"10.1016/s1262-3636(15)30408-0","title":"P295 Durée de maintien d’une bithérapie par metformine-sitagliptine chez les diabétiques de type 2 – étude observationnelle ODYSSÉE","year":2015,"lang":"fr","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.03042369252191279,"score_gpt":0.2612138109013601,"score_spread":0.2307901183794473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075492284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86074245,0.12017226,0.00021606383,0.008990749,0.0030014897,0.0010361449,0.00006764989,0.00031639135,0.0054568173],"genre_scores_gemma":[0.9392053,0.0059826663,0.014268805,0.0029467465,0.003834759,0.0003033001,0.0005573398,0.0002217146,0.032679405],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99489564,0.00035515154,0.0009033138,0.00081922056,0.0007480408,0.0022786309],"domain_scores_gemma":[0.99659055,0.00031977138,0.00038772682,0.0009544661,0.0005832236,0.0011642608],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021590216,0.00088892377,0.0014064716,0.00041545753,0.00024553965,0.00019008332,0.00055816607,0.00046350856,0.00092932966],"category_scores_gemma":[0.0011086791,0.00083718234,0.00040452383,0.0012804465,0.0004155187,0.0006974109,0.00036719986,0.00049437146,0.00088193495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031893936,0.0039598136,0.61848813,0.0014900333,0.0067392616,0.00031521858,0.012696655,0.00059419824,0.021344857,0.04277114,0.15328084,0.13800092],"study_design_scores_gemma":[0.0066388687,0.00080595224,0.25688735,0.0006400525,0.0059425193,0.000004588849,0.0020673245,0.004801702,0.040801518,0.0073069385,0.67287,0.0012331918],"about_ca_topic_score_codex":0.00086883386,"about_ca_topic_score_gemma":0.00009142367,"teacher_disagreement_score":0.5195891,"about_ca_system_score_codex":0.00048200585,"about_ca_system_score_gemma":0.00037654862,"threshold_uncertainty_score":0.99998397},"labels":[],"label_agreement":null},{"id":"W2075662972","doi":"10.1016/j.neurobiolaging.2013.03.010","title":"IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults","year":2013,"lang":"en","type":"article","venue":"Neurobiology of Aging","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute on Aging; National Institutes of Health; Canada Research Chairs; Alberta Health Services","keywords":"Neurocognitive; Type 2 diabetes; Allele; Cognition; Cognitive decline; Psychology; Disease; Effects of sleep deprivation on cognitive performance; Internal medicine; Diabetes mellitus; Oncology; Medicine; Endocrinology; Biology; Genetics; Dementia; Neuroscience; Gene","score_opus":0.007040659131999416,"score_gpt":0.2101124877673109,"score_spread":0.20307182863531148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075662972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973532,0.00035932657,0.0000059504896,0.00065592665,0.0002189428,0.00041073022,0.0000010952249,0.000031906075,0.0009629286],"genre_scores_gemma":[0.9988101,0.00008392818,0.00006849291,0.00045793987,0.000030179192,0.000023716811,0.000029594106,0.000011937865,0.00048407353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993062,0.000035837154,0.00016477065,0.00023334671,0.000044445616,0.00021537264],"domain_scores_gemma":[0.999682,0.000048757705,0.00006150238,0.00012721766,0.00003738208,0.00004311358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038085484,0.00012132008,0.0002488422,0.0001585918,0.000020700176,0.000006114313,0.000037149603,0.000058792306,0.00010175208],"category_scores_gemma":[0.000013584997,0.000097887714,0.00003164294,0.000088511966,0.00007703972,0.00006744413,0.00006221063,0.00009167395,0.000018428189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001409295,0.00037694888,0.9366439,0.00021514152,0.00021252129,0.000008879967,0.00053981406,0.0000036556485,0.040969882,0.00031586047,0.0013943838,0.019178106],"study_design_scores_gemma":[0.001912637,0.00052724313,0.9915384,0.00014947183,0.0000933534,9.890098e-7,0.000076689525,0.00012467087,0.0052455086,0.00019504548,0.000056337925,0.00007963705],"about_ca_topic_score_codex":0.00007294224,"about_ca_topic_score_gemma":0.0000075215244,"teacher_disagreement_score":0.054894537,"about_ca_system_score_codex":0.00001319276,"about_ca_system_score_gemma":0.0000074490904,"threshold_uncertainty_score":0.3991745},"labels":[],"label_agreement":null},{"id":"W2075801621","doi":"10.1038/ncpendmet0026","title":"Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?","year":2005,"lang":"en","type":"article","venue":"Nature Clinical Practice Endocrinology &#38 Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital","funders":"","keywords":"Exenatide; Medicine; Type 2 diabetes; Diabetes treatment; Internal medicine; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.019925868844207984,"score_gpt":0.3561294154458551,"score_spread":0.3362035466016471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075801621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92092454,0.007431085,0.00025163824,0.052129842,0.005149538,0.006430978,0.00003921203,0.00050272536,0.007140451],"genre_scores_gemma":[0.812029,0.0029568207,0.14758323,0.014556447,0.004888017,0.00049119565,0.0005436265,0.00015420998,0.016797468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697804,0.00021114956,0.000754926,0.0008672162,0.00040896525,0.00077968865],"domain_scores_gemma":[0.9959748,0.0019159296,0.0005317943,0.00066304393,0.0005659561,0.00034849462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034953663,0.00045311812,0.0009503123,0.00018872457,0.00012809303,0.000049493752,0.00018373433,0.00042384517,0.00010786825],"category_scores_gemma":[0.0049117547,0.00024277947,0.00028486064,0.00024034365,0.00013166932,0.0006335211,0.00008429613,0.0008190763,0.00013392721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070497575,0.0092909755,0.064594276,0.00009102798,0.0055569806,0.000078809804,0.00022089212,0.00001448422,0.00006601621,0.012054217,0.023244686,0.8777379],"study_design_scores_gemma":[0.014954709,0.003709588,0.062698066,0.000040034047,0.003934601,0.0000046301748,0.00005617439,0.00003905277,0.0005343432,0.0003675805,0.91337734,0.00028388904],"about_ca_topic_score_codex":0.000013733294,"about_ca_topic_score_gemma":0.000026783497,"teacher_disagreement_score":0.89013267,"about_ca_system_score_codex":0.0001687627,"about_ca_system_score_gemma":0.00022744181,"threshold_uncertainty_score":0.99002594},"labels":[],"label_agreement":null},{"id":"W2076506641","doi":"10.2337/dc14-0315","title":"Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension","year":2015,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Biotech; National Institutes of Health; Servier; Sanofi; Halozyme; National Institute of General Medical Sciences; Novo Nordisk; Intarcia Therapeutics; MannKind Corporation; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Diabetes mellitus; Placebo; Type 2 diabetes; Internal medicine; Randomized controlled trial; Multicenter study; Endocrinology","score_opus":0.012155753045091948,"score_gpt":0.22224127321431342,"score_spread":0.21008552016922147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076506641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98189276,0.0020563467,0.0000031445225,0.000017930799,0.00041674534,0.015262905,0.000038199807,0.00014611187,0.00016587405],"genre_scores_gemma":[0.99746996,0.00010356213,0.00016631815,0.00011942196,0.00007420273,0.0014755332,0.00040912602,0.00012229657,0.00005957713],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957229,0.00070467626,0.00053153833,0.00106635,0.0011723107,0.0008022467],"domain_scores_gemma":[0.9970131,0.00069142744,0.0003185098,0.0009951517,0.00052409695,0.0004577488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080835883,0.0008069248,0.0026697153,0.0005098482,0.00013683627,0.00010862348,0.00016041544,0.00017590549,0.000007362879],"category_scores_gemma":[0.0004516513,0.00048355217,0.00033137467,0.00047717904,0.0001406439,0.00021517514,0.00013784973,0.0004731777,0.00003920925],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34204903,0.0016165203,0.64653665,0.00016641761,0.0049180854,0.000042498083,0.0018719417,0.0003082383,0.0000015965594,0.0000010872895,0.000088639536,0.0023992958],"study_design_scores_gemma":[0.822604,0.014574856,0.14971876,0.0006286084,0.008762116,7.993169e-8,0.002557361,0.0002836992,0.00022668303,0.0000045605643,0.00013368796,0.0005055734],"about_ca_topic_score_codex":0.00037315828,"about_ca_topic_score_gemma":0.00017081865,"teacher_disagreement_score":0.4968179,"about_ca_system_score_codex":0.00030108934,"about_ca_system_score_gemma":0.00008056702,"threshold_uncertainty_score":0.99976164},"labels":[],"label_agreement":null},{"id":"W2077038286","doi":"10.1111/dom.12090","title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":486,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; European Foundation for the Study of Diabetes; American Society of Nephrology; American Diabetes Association","keywords":"Canagliflozin; Medicine; Renal function; Placebo; Kidney disease; Internal medicine; Type 2 diabetes; Urology; Diabetes mellitus; Creatinine; Endocrinology; Empagliflozin; Blood urea nitrogen; Gastroenterology","score_opus":0.0051452716821656095,"score_gpt":0.20177999333681063,"score_spread":0.19663472165464502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077038286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826174,0.015535064,6.2157125e-7,0.0004709259,0.000057308767,0.00088577904,0.000016333546,0.000027159631,0.0003894564],"genre_scores_gemma":[0.9967116,0.0022142609,0.00016742134,0.00046772114,0.000050591396,0.000043813852,0.000052765165,0.000019075102,0.00027275566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989049,0.000043787844,0.00019667874,0.00032779638,0.0001515868,0.00037527474],"domain_scores_gemma":[0.9991197,0.00007019559,0.000064529544,0.00022205735,0.000058175905,0.00046536757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014157078,0.00022148105,0.000520496,0.00017640146,0.000057094083,0.000033480435,0.00004752906,0.00005430251,0.00005334604],"category_scores_gemma":[0.00008906772,0.0001665411,0.00002638247,0.00022122334,0.00020113018,0.00018753138,0.00009322254,0.00009887342,0.0000048800207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099470504,0.000317636,0.97760206,0.0007938157,0.0002814578,0.0000072800117,0.00019422238,0.0000016533239,0.0019771636,0.0006894277,0.00031488386,0.017720895],"study_design_scores_gemma":[0.0047821184,0.00023972822,0.9881596,0.00031785516,0.00055441266,2.1663514e-7,0.000025616579,0.00015921472,0.0016722345,0.00017955147,0.003728858,0.00018057029],"about_ca_topic_score_codex":0.00013509644,"about_ca_topic_score_gemma":0.000049031318,"teacher_disagreement_score":0.017540324,"about_ca_system_score_codex":0.00002410413,"about_ca_system_score_gemma":0.00007865745,"threshold_uncertainty_score":0.67913485},"labels":[],"label_agreement":null},{"id":"W2077306519","doi":"10.2337/diacare.27.3.850-a","title":"Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study","year":2004,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Diabetes Association","keywords":"Medicine; Diabetes mellitus; Retrospective cohort study; Type 2 diabetes; Cohort; Internal medicine; Cohort study; Heart failure; Endocrinology","score_opus":0.007555173988201318,"score_gpt":0.21631475153532212,"score_spread":0.2087595775471208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077306519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99021006,0.00077849644,1.2656369e-7,0.005670136,0.00011037932,0.0028587217,0.0002463989,0.00004447736,0.00008120359],"genre_scores_gemma":[0.9915038,0.00017874903,0.00038625844,0.0064694853,0.00019871141,0.00022722516,0.00079500873,0.00009519488,0.00014559743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776185,0.0001029405,0.00043332766,0.000633474,0.00061641645,0.00045199835],"domain_scores_gemma":[0.99834824,0.00014804804,0.0003273144,0.0006742379,0.00043517127,0.000067016335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001478387,0.00047435772,0.0016616882,0.00047129364,0.000035914843,0.000027413484,0.000107806336,0.00032206724,0.000029671264],"category_scores_gemma":[0.00011363106,0.00036340652,0.0001372582,0.00058690645,0.00013626381,0.00012645358,0.00011536447,0.0006813634,0.0000066312577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003909807,0.0002778602,0.96195096,0.0013866997,0.0017919947,0.000027953018,0.0012885532,0.000010250329,0.00002504024,0.0000020367097,0.03312652,0.000073005554],"study_design_scores_gemma":[0.0021480874,0.003453669,0.98234075,0.0011713298,0.0028240809,3.0747256e-7,0.0009935946,0.000004578377,0.00036590002,0.000014707015,0.006374774,0.00030822217],"about_ca_topic_score_codex":0.00027416614,"about_ca_topic_score_gemma":0.0005962147,"teacher_disagreement_score":0.026751747,"about_ca_system_score_codex":0.00025165992,"about_ca_system_score_gemma":0.00010616893,"threshold_uncertainty_score":0.9998818},"labels":[],"label_agreement":null},{"id":"W2077372959","doi":"10.1016/j.pharmthera.2009.11.001","title":"Glycaemic control in type 2 diabetes: Targets and new therapies","year":2009,"lang":"en","type":"review","venue":"Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research","keywords":"Incretin; Medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Intensive care medicine; Diabetes mellitus; Disease; Bioinformatics; Pharmacology; Internal medicine; Endocrinology","score_opus":0.06878506968200675,"score_gpt":0.37326505116626324,"score_spread":0.3044799814842565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077372959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020652413,0.99537003,0.000005081919,0.0013636017,0.0005629737,0.0018162684,0.0000067834912,0.00008305932,0.00058568595],"genre_scores_gemma":[0.00031303466,0.98365366,0.000120924175,0.014020457,0.00032699486,0.000083707244,0.0000694895,0.00006491642,0.0013468337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982971,0.00017447745,0.00044629586,0.00042383687,0.00013214763,0.0005261334],"domain_scores_gemma":[0.9992102,0.00019674,0.00018518245,0.00022234043,0.000034816843,0.00015075554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018171154,0.000518411,0.0018234967,0.0003131533,0.000038679715,0.00002105359,0.00015950167,0.00029519224,0.00022830145],"category_scores_gemma":[0.000002433095,0.0003925052,0.00020418873,0.0002811836,0.00009653647,0.00004946348,0.00004167117,0.00044840775,0.00008218451],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070991315,0.00026215918,0.00028361136,0.0015555609,0.0034533152,0.000053254927,0.00010241807,2.2346538e-7,0.000037743204,0.000022369508,0.003778432,0.9903799],"study_design_scores_gemma":[0.0034576713,0.0006075741,0.00010411379,0.0010868247,0.013128453,0.0000063734346,0.0000062679524,0.000025487587,0.000008288909,0.00012261934,0.9811622,0.0002841562],"about_ca_topic_score_codex":0.0000033752494,"about_ca_topic_score_gemma":0.0000024339377,"teacher_disagreement_score":0.9900958,"about_ca_system_score_codex":0.00015913542,"about_ca_system_score_gemma":0.00021949179,"threshold_uncertainty_score":0.99985266},"labels":[],"label_agreement":null},{"id":"W2077404015","doi":"10.2515/therapie/2013063","title":"Clinically Relevant Efficacy of Insulin Therapy in Patients with Type 2 Diabetes","year":2013,"lang":"en","type":"letter","venue":"Therapies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Type 2 diabetes; Medicine; Insulin; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.01611377797794818,"score_gpt":0.2517154360785867,"score_spread":0.23560165810063852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077404015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500097,0.0019029957,2.6488055e-7,0.04525705,0.00016935718,0.0014672931,0.000008502152,0.000053862987,0.0011309751],"genre_scores_gemma":[0.6117691,0.004771509,0.0013531906,0.37280282,0.0010020961,0.0001951477,0.0014416327,0.0002601558,0.006404351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984007,0.000075752134,0.00048072365,0.00032271544,0.0003850988,0.00033504408],"domain_scores_gemma":[0.9987677,0.00021991806,0.00026545083,0.00054696715,0.00016462001,0.000035346115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012780224,0.00032948263,0.00079357723,0.00021989246,0.00001537101,0.000017174263,0.00016755913,0.0002848714,0.00036068648],"category_scores_gemma":[0.000033502933,0.00020142677,0.00010912093,0.00019481996,0.00013696986,0.0000530325,0.00003730905,0.0004976367,0.00010217527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015085989,0.001988157,0.51456094,0.00037374202,0.002828962,0.000031886113,0.0008232926,0.0000010189691,0.00003939762,0.000011552486,0.31938168,0.15845077],"study_design_scores_gemma":[0.011666941,0.008332793,0.66148096,0.0007186917,0.00020424165,6.104821e-8,0.000018426334,0.000002049555,0.00007276388,0.0001069843,0.31706795,0.00032814464],"about_ca_topic_score_codex":0.000016592428,"about_ca_topic_score_gemma":9.710939e-7,"teacher_disagreement_score":0.33824062,"about_ca_system_score_codex":0.000042294574,"about_ca_system_score_gemma":0.00004798594,"threshold_uncertainty_score":0.8213945},"labels":[],"label_agreement":null},{"id":"W2078126254","doi":"10.2174/1381612013397401","title":"Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes","year":2001,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Glucagon-like peptide-2; Incretin; Glucagon-like peptide-1; Enteroendocrine cell; Receptor; Glucagon-like peptide 1 receptor; In vivo; Endocrinology; Pharmacology; Diabetes mellitus; Internal medicine; Medicine; Biology; Endocrine system; Type 2 diabetes; Hormone; Biochemistry; Peptide; Agonist","score_opus":0.3592725044069848,"score_gpt":0.4789353361507858,"score_spread":0.11966283174380099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078126254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000063157284,0.9808328,0.006747234,0.000093096445,0.0010424061,0.010865687,0.00007115223,0.000078205616,0.0002062552],"genre_scores_gemma":[0.00019245845,0.9920189,0.0027568347,0.00018605113,0.00020616896,0.0034276717,0.000356197,0.00013937375,0.0007163889],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954877,0.0003081914,0.0017166922,0.0007813764,0.0007530375,0.00095302885],"domain_scores_gemma":[0.9958584,0.0020936981,0.00066189934,0.0007523783,0.00020432856,0.00042933642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007262148,0.001055361,0.0029140639,0.00036557252,0.00016006648,0.000034604614,0.00048813864,0.00022733414,0.000483784],"category_scores_gemma":[0.000054864806,0.00062009576,0.0015701567,0.00062098197,0.00033435665,0.000054612072,0.00007151621,0.00027132343,0.000112700574],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020800703,0.00533862,0.000033315842,0.020871526,0.0047772345,0.0000059029962,0.00009165158,0.00000659218,0.000024803378,0.00016884856,0.000998212,0.9674753],"study_design_scores_gemma":[0.0046412926,0.0013000718,0.000010752325,0.0059931064,0.024395945,0.0000017386,0.000013636497,0.0012899842,0.0026247913,0.000029412962,0.9592221,0.00047717209],"about_ca_topic_score_codex":5.123704e-7,"about_ca_topic_score_gemma":1.342653e-7,"teacher_disagreement_score":0.9669981,"about_ca_system_score_codex":0.00052462664,"about_ca_system_score_gemma":0.0008949775,"threshold_uncertainty_score":0.999625},"labels":[],"label_agreement":null},{"id":"W2078287362","doi":"10.1016/s1499-2671(09)33070-1","title":"A strategy implementing initial therapy with a fixed- dose combination tablet of sitagliptin and metformin in patients with type 2 diabetes provides superior glycaemic control compared with a strategy using initial metformin monotherapy over 44 weeks","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Sitagliptin; Glycemic; Combination therapy; Type 2 diabetes; Fixed-dose combination; Diabetes mellitus; Internal medicine; Type 2 Diabetes Mellitus; Insulin; Endocrinology","score_opus":0.016769088937914976,"score_gpt":0.25731232061831877,"score_spread":0.24054323168040379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078287362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773246,0.0009056229,0.000009600603,0.000052789976,0.000028078415,0.0011173179,0.000044909757,0.000008714301,0.00010048768],"genre_scores_gemma":[0.9989431,0.000012714906,0.00066747225,0.00022786795,0.000044503755,0.000013466491,0.00004546244,0.00003785523,0.000007588526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980787,0.00008196472,0.000598128,0.00023035999,0.00034978363,0.0006610689],"domain_scores_gemma":[0.99853224,0.00008945691,0.0005010852,0.00015936066,0.00037442098,0.00034341883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033040243,0.00034336484,0.00082972896,0.00066350895,0.00009982651,0.00011689474,0.000116988784,0.000074432355,0.000055930388],"category_scores_gemma":[0.00002482773,0.0002351878,0.000058156435,0.0004311383,0.00015314561,0.00074546365,0.0000064328224,0.00020785807,1.7472273e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012351195,0.0004017955,0.9657036,0.00008427324,0.0008426483,0.000051759915,0.00049410656,0.00018615692,0.0020638178,0.00005223854,0.000021231801,0.028863218],"study_design_scores_gemma":[0.060756944,0.036108855,0.8916666,0.0013278426,0.00080963917,0.000007945235,0.0012320302,0.0015151313,0.005676557,0.00018927392,0.00011945672,0.000589755],"about_ca_topic_score_codex":0.00061755005,"about_ca_topic_score_gemma":0.0033996617,"teacher_disagreement_score":0.07403707,"about_ca_system_score_codex":0.0001982095,"about_ca_system_score_gemma":0.0008737605,"threshold_uncertainty_score":0.95906806},"labels":[],"label_agreement":null},{"id":"W2078466721","doi":"10.1124/jpet.109.160531","title":"Pharmacological Characterization of Human Incretin Receptor Missense Variants","year":2009,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; National Institutes of Health; American Diabetes Association","keywords":"Incretin; Receptor; Gastric inhibitory polypeptide; Internal medicine; Endocrinology; Biology; Mutant; Wild type; HEK 293 cells; Missense mutation; Phenotype; Hormone; Gene; Biochemistry; Type 2 diabetes; Glucagon; Medicine","score_opus":0.03130188207595449,"score_gpt":0.35980149687192586,"score_spread":0.3284996147959714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078466721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966567,0.0008332671,0.0000144064425,0.0015310643,0.00030719463,0.0001952674,0.0000024021144,0.000009366294,0.00045032534],"genre_scores_gemma":[0.9948178,0.0004938558,0.0003356854,0.00392681,0.00021460997,0.00000203645,0.000009735704,0.0000070283318,0.00019244285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992164,0.0000742649,0.00035504618,0.00009057279,0.00012693917,0.00013681472],"domain_scores_gemma":[0.9995232,0.00002059999,0.00027385855,0.000037176505,0.00006655047,0.00007856935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017398379,0.000117914,0.0003072583,0.00010060896,0.000052688054,0.000007848592,0.00005687769,0.00006952692,0.0005446723],"category_scores_gemma":[0.0000015656415,0.000090339934,0.00007621186,0.00006906639,0.00008263201,0.00008652306,0.000018129838,0.00013380799,0.0000027958095],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011653475,0.0013837805,0.0005085415,0.000010385947,0.00050054846,0.00006287458,0.0003681659,3.0699974e-7,0.9921456,0.00014389136,0.00052940904,0.003181172],"study_design_scores_gemma":[0.0047766203,0.0044910093,0.0064266846,0.000022452992,0.00061738584,0.00007459483,0.000120010685,0.000034295,0.9790505,0.000038708586,0.0042694006,0.00007833378],"about_ca_topic_score_codex":2.8372594e-7,"about_ca_topic_score_gemma":6.658785e-9,"teacher_disagreement_score":0.0130950725,"about_ca_system_score_codex":0.000047310084,"about_ca_system_score_gemma":0.000023346787,"threshold_uncertainty_score":0.59637797},"labels":[],"label_agreement":null},{"id":"W2078561985","doi":"10.1016/s1499-2671(09)33076-2","title":"Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alogliptin; Pioglitazone; Medicine; Tolerability; Type 2 diabetes; Combination therapy; Internal medicine; Insulin resistance; Pharmacology; Diabetes mellitus; Endocrinology; Insulin; Adverse effect","score_opus":0.007649947546106491,"score_gpt":0.2027120765146986,"score_spread":0.19506212896859212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078561985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964095,0.000920669,6.4721246e-7,0.0007427616,0.0000918465,0.001138021,0.000012054227,0.000013028798,0.00067146734],"genre_scores_gemma":[0.99894965,0.000018741635,0.00027579546,0.00032474147,0.00004522499,0.00002553092,0.00009570155,0.000019637102,0.00024495655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842894,0.00004787787,0.0004379097,0.00020006674,0.00030129746,0.0005839075],"domain_scores_gemma":[0.99853,0.00006660458,0.00028085193,0.00016136217,0.00037422858,0.0005869836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016702537,0.00030186024,0.0009186944,0.000547233,0.00007124685,0.000058997193,0.00011093253,0.00007336529,0.00005646802],"category_scores_gemma":[0.0000542351,0.000176572,0.000099956145,0.00041094108,0.000065667766,0.00023044669,0.000004484662,0.00014016923,0.00000760542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010261906,0.0006630922,0.97640115,0.000028652637,0.0004722984,0.00005596628,0.0002532896,0.00006595883,0.000031061933,0.00006113175,0.00028620134,0.020654991],"study_design_scores_gemma":[0.03936102,0.02753956,0.93013716,0.00069746946,0.00081729284,3.6120932e-7,0.00008284835,0.000106200656,0.0003025518,0.00008887401,0.0006240144,0.00024263057],"about_ca_topic_score_codex":0.00019684408,"about_ca_topic_score_gemma":0.0033573823,"teacher_disagreement_score":0.046263985,"about_ca_system_score_codex":0.00079584715,"about_ca_system_score_gemma":0.00055414287,"threshold_uncertainty_score":0.72003967},"labels":[],"label_agreement":null},{"id":"W2078860212","doi":"10.2337/dc11-s217","title":"Should A1C Targets Be Individualized for All People With Diabetes?","year":2011,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Glycemic; Medicine; Intensive care medicine; Glycated hemoglobin; Diabetes mellitus; Harm; Diabetes management; Intervention (counseling); MEDLINE; Risk analysis (engineering); Type 2 diabetes; Psychiatry; Psychology","score_opus":0.05889761143808768,"score_gpt":0.31883241852132616,"score_spread":0.25993480708323846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078860212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046373642,0.9847133,0.0000041845665,0.0000946908,0.00040892744,0.0068906285,0.0012911147,0.0003091368,0.0058242567],"genre_scores_gemma":[0.00016580953,0.96646917,0.0024467346,0.0012950405,0.00036931015,0.0066609783,0.020468611,0.00041450255,0.0017098623],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637693,0.000091990434,0.00069454254,0.0010670954,0.00047350052,0.0012959512],"domain_scores_gemma":[0.9974955,0.00025555503,0.0004860502,0.001109848,0.0002477183,0.00040533853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022098052,0.0011725567,0.00375824,0.00047746932,0.00012392181,0.0000931418,0.00043937832,0.00053366553,0.00029470032],"category_scores_gemma":[0.00007606852,0.00081444235,0.0011750137,0.00041842708,0.00009280301,0.00013745771,0.00022878674,0.00038201307,0.00022448623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024529509,0.00034665642,0.015710756,0.08969706,0.0068220827,0.000013785469,0.000911017,1.1539481e-7,4.6945541e-7,0.00024725855,0.02391532,0.86231095],"study_design_scores_gemma":[0.0023522486,0.0013022047,0.00030645813,0.009495327,0.019641213,5.3164837e-7,0.00014604031,0.0000018604887,0.000025136153,0.000026191456,0.96583766,0.00086511474],"about_ca_topic_score_codex":0.000004804959,"about_ca_topic_score_gemma":0.000026780574,"teacher_disagreement_score":0.94192237,"about_ca_system_score_codex":0.0002766715,"about_ca_system_score_gemma":0.0002165829,"threshold_uncertainty_score":0.99943066},"labels":[],"label_agreement":null},{"id":"W2079017544","doi":"10.1055/s-2006-925126","title":"Effects of an Olive Oil-enriched Diet on Glucagon-like Peptide 1 Release and Intestinal Content, Plasma Insulin Concentration, Glucose Tolerance and Pancreatic Insulin Content in an Animal Model of Type 2 Diabetes","year":2006,"lang":"en","type":"article","venue":"Hormone and Metabolic Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; Universidad CES","keywords":"Internal medicine; Endocrinology; Insulin; Type 2 diabetes; Streptozotocin; Diabetes mellitus; Medicine; Glucagon; Pancreas; Glucose tolerance test; Glucagon-like peptide-1; Meal; Pancreatic hormone; Insulin tolerance test; Insulin resistance; Insulin sensitivity","score_opus":0.047833768505403634,"score_gpt":0.2964010013717497,"score_spread":0.24856723286634605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079017544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728919,0.025893023,0.0000034767208,0.000062015664,0.000014753696,0.0007486408,0.000013202067,0.00001588236,0.0003570836],"genre_scores_gemma":[0.98318493,0.01566913,0.0005676711,0.000067498615,0.000042261054,0.00009449834,0.000056320147,0.000021370217,0.0002963209],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99810904,0.00022541948,0.00043009102,0.0004139631,0.0004022939,0.00041916664],"domain_scores_gemma":[0.9987944,0.0002714163,0.000112983675,0.00023602322,0.0003501171,0.00023506855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005647303,0.00021912149,0.0006582271,0.0002507993,0.00006498518,0.000036529564,0.00007834402,0.00007699077,0.0000024630858],"category_scores_gemma":[0.000284511,0.00017641814,0.00003183372,0.00030628414,0.00034117355,0.00020329154,0.00007996029,0.00022076804,0.0000012218026],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011128428,0.0033787433,0.07837511,0.0013807297,0.00022347897,0.000071306284,0.0012339901,0.00007177196,0.8579013,0.0039585093,0.00012426288,0.04215239],"study_design_scores_gemma":[0.013735411,0.011200387,0.8274507,0.0005074413,0.00031549655,0.000003139729,0.0005622505,0.050729495,0.094817296,0.0002849259,0.00013323915,0.00026021915],"about_ca_topic_score_codex":0.000761851,"about_ca_topic_score_gemma":0.0000681936,"teacher_disagreement_score":0.763084,"about_ca_system_score_codex":0.000027925866,"about_ca_system_score_gemma":0.00007580558,"threshold_uncertainty_score":0.71941227},"labels":[],"label_agreement":null},{"id":"W2079213767","doi":"10.1016/j.jval.2012.08.928","title":"PMD79 A Population-Based Study on the Use of Blood Glucose Monitoring Test Strips","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada); Université Laval","funders":"","keywords":"Medicine; Metformin; Insulin; Cohort; Sulfonylurea; Glucose test; Population; Diabetes mellitus; Internal medicine; Cohort study; Endocrinology; Environmental health","score_opus":0.14458997614660202,"score_gpt":0.3360439226074668,"score_spread":0.19145394646086478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079213767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975163,0.00028276845,0.0000023659059,0.0007368195,0.00013660197,0.0012501713,0.000004286861,0.000024080106,0.000046661098],"genre_scores_gemma":[0.99912107,0.000017100263,0.0004180943,0.00020098075,0.00010010047,0.000052598552,0.0000076213546,0.000012602854,0.00006981812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989951,0.00014289077,0.0002735991,0.00010928145,0.00023727663,0.00024184401],"domain_scores_gemma":[0.998853,0.0006516792,0.000105019884,0.00028732244,0.000017810724,0.00008511244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057668606,0.00009072119,0.00019026473,0.00011632083,0.000053608674,0.000007817005,0.000042733853,0.000019418634,0.000009747956],"category_scores_gemma":[0.0002144959,0.00006027502,0.000032729782,0.00020557627,0.000006657469,0.000051086754,0.00001547621,0.000103700695,0.0000075889384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022361648,0.003495284,0.9935382,0.00008062731,0.00004027585,0.0000023705848,0.00045236314,0.0005644965,0.000027226257,0.00016657438,0.000043750533,0.0015664651],"study_design_scores_gemma":[0.0014383367,0.0012080721,0.9956044,0.0002617999,0.00007274747,1.3116413e-7,0.00030648263,0.00032900632,0.00043226083,0.00000721772,0.00029516226,0.000044385422],"about_ca_topic_score_codex":0.0027937405,"about_ca_topic_score_gemma":0.000011200435,"teacher_disagreement_score":0.00278254,"about_ca_system_score_codex":0.00010864566,"about_ca_system_score_gemma":0.000045074685,"threshold_uncertainty_score":0.42233184},"labels":[],"label_agreement":null},{"id":"W2079286031","doi":"10.2337/diacare.27.3.852","title":"Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study","year":2004,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Diabetes Association","keywords":"Medicine; Retrospective cohort study; Diabetes mellitus; Type 2 diabetes; Internal medicine; Cohort; Cohort study; Heart failure; Endocrinology","score_opus":0.006899047444975343,"score_gpt":0.22021559793485673,"score_spread":0.21331655048988138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079286031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791145,0.00039798845,3.976589e-7,0.00008561557,0.000039952276,0.0014127024,0.00004223867,0.000029806792,0.000079825],"genre_scores_gemma":[0.9990568,0.00007962087,0.0006335136,0.000036788573,0.000018038547,0.00007677533,0.00005221269,0.000024860637,0.000021354326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889344,0.00003820802,0.0002327425,0.00030306197,0.00029127952,0.0002412891],"domain_scores_gemma":[0.9991836,0.000057379,0.0001166342,0.00033011974,0.00024367996,0.00006860357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012123178,0.00018739236,0.00066556904,0.00019892529,0.000028510814,0.000012743437,0.00004769548,0.000053817275,0.000011712971],"category_scores_gemma":[0.00009342488,0.0001409527,0.00005403471,0.0004833218,0.00007660798,0.0001271536,0.000059633265,0.000112146285,0.000003765546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052487227,0.00046964595,0.99575233,0.00022121263,0.00057530345,0.0000030934575,0.0023159084,0.00005242832,0.000311918,0.000026232,0.00008469653,0.00013472924],"study_design_scores_gemma":[0.0025541158,0.003066732,0.9864832,0.00028998917,0.00075326086,1.3195042e-7,0.0032766797,0.000009072707,0.0033338184,0.000026785627,0.00008085058,0.00012537389],"about_ca_topic_score_codex":0.000198024,"about_ca_topic_score_gemma":0.0010154936,"teacher_disagreement_score":0.009269156,"about_ca_system_score_codex":0.000106498665,"about_ca_system_score_gemma":0.000042225314,"threshold_uncertainty_score":0.57478845},"labels":[],"label_agreement":null},{"id":"W2079474223","doi":"10.1016/s1561-5413(09)60049-1","title":"Diabetic nephropathy in type 2 diabetes mellitus: prevention and treatment","year":2001,"lang":"en","type":"article","venue":"Hong Kong Journal of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"","keywords":"Medicine; Diabetic nephropathy; Diabetes mellitus; Type 2 Diabetes Mellitus; Nephropathy; Dialysis; Internal medicine; Disease; Mortality rate; Intensive care medicine; Endocrinology","score_opus":0.016744306385570812,"score_gpt":0.26356908758736497,"score_spread":0.24682478120179416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079474223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985237,0.0077974624,0.000021975473,0.0013594727,0.0001890718,0.00023835404,3.5891279e-7,0.000012094696,0.0005288134],"genre_scores_gemma":[0.9908276,0.007174513,0.0007755289,0.00055819575,0.00018547624,0.0000069491716,0.000005686569,0.000016050619,0.00044998052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989754,0.000087329056,0.00036892013,0.00014997806,0.00012748575,0.00029091572],"domain_scores_gemma":[0.9994386,0.00006803832,0.0001735049,0.00013689013,0.00006781956,0.000115168084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022176883,0.00015381003,0.00044951687,0.0003159307,0.000028294251,0.00001587987,0.000051641626,0.000076889184,0.000103106315],"category_scores_gemma":[0.000023842296,0.00011599521,0.00009135949,0.00020011823,0.000072372626,0.00012354937,0.00002587992,0.00011036078,0.00001607574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006869232,0.0012781738,0.6473457,0.000047288817,0.00066028,0.00095996866,0.00036621906,0.00002480784,0.004172243,0.00014743759,0.00095089123,0.34336004],"study_design_scores_gemma":[0.009215357,0.012878631,0.90922856,0.0002518774,0.0009303979,0.00024413822,0.00018650363,0.00036908253,0.0007719211,0.0013485102,0.06437162,0.00020340909],"about_ca_topic_score_codex":0.0000069502603,"about_ca_topic_score_gemma":0.00002975677,"teacher_disagreement_score":0.3431566,"about_ca_system_score_codex":0.00012125868,"about_ca_system_score_gemma":0.000047829493,"threshold_uncertainty_score":0.47301474},"labels":[],"label_agreement":null},{"id":"W2079685634","doi":"10.1016/j.jval.2011.08.1310","title":"PDB7 Prevalence, Demographics and Treatment Characteristics of Diabetes with Lantus, NPH and Premix Insulin in a Representative Canadian Cohort","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada); Lawson Health Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Population; Incidence (geometry); Internal medicine; NPH insulin; Insulin; Type 2 diabetes; Comorbidity; Cohort; Pediatrics; Endocrinology; Insulin glargine; Environmental health","score_opus":0.031495247184333934,"score_gpt":0.2588369720333785,"score_spread":0.22734172484904458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079685634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961752,0.0014816205,8.814026e-7,0.00023899603,0.00002207257,0.0013418114,0.00004468878,0.000010139457,0.0006845588],"genre_scores_gemma":[0.9920848,0.0067081973,0.00084809575,0.000120220386,0.000010135044,0.000090655194,0.000027193291,0.000012725003,0.00009797499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989333,0.000087065724,0.00030200358,0.00026306382,0.000109053966,0.0003055094],"domain_scores_gemma":[0.9993913,0.00006890642,0.00011152719,0.0001722521,0.000026386888,0.00022962654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028818904,0.00013898482,0.0003937314,0.00035712947,0.000026652711,0.0000054213965,0.00003078897,0.00004468645,0.000008865143],"category_scores_gemma":[0.000028957593,0.00010675941,0.000015679725,0.00023977789,0.000103682156,0.00004973907,0.000017683516,0.00007425149,5.58791e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006970322,0.0002404636,0.99061227,0.00056922884,0.000092348935,0.000031779942,0.0024205223,0.0000013336801,0.0000029472305,0.0004029903,0.0000129909085,0.0055434015],"study_design_scores_gemma":[0.0016532355,0.0016736405,0.9949568,0.0006923409,0.000077727804,0.0000020605764,0.00019574148,0.00041558864,0.000042988682,0.00007002102,0.0001383179,0.000081561426],"about_ca_topic_score_codex":0.09976596,"about_ca_topic_score_gemma":0.028567707,"teacher_disagreement_score":0.07119825,"about_ca_system_score_codex":0.00016931898,"about_ca_system_score_gemma":0.00021865954,"threshold_uncertainty_score":0.9891584},"labels":[],"label_agreement":null},{"id":"W2080785707","doi":"10.1073/pnas.0806720106","title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","year":2009,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":576,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Drug Abuse; National Institute on Aging; National Institutes of Health; University of Toronto","keywords":"Dopaminergic; Endocrinology; Internal medicine; Biology; Agonist; MPTP; Glial cell line-derived neurotrophic factor; Dopamine; Neurotrophic factors; Neuroscience; Medicine; Receptor","score_opus":0.03335565160767487,"score_gpt":0.2766941191750168,"score_spread":0.24333846756734193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080785707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949678,0.0005561024,0.0000011100667,0.0021951757,0.000003966707,0.00022842214,0.0000038514954,0.0000034161098,0.002040113],"genre_scores_gemma":[0.9984173,0.00020764647,0.0010932036,0.00009887908,0.000011824966,0.000003279247,3.1847185e-7,0.0000015252535,0.00016598146],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991228,0.0000045086335,0.00019397779,0.00015321698,0.00044683262,0.0000786943],"domain_scores_gemma":[0.99972713,0.00005588938,0.00012453522,0.000005882129,0.00005565429,0.000030885018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041323516,0.000059400634,0.00014299051,0.000120080644,0.000039495375,0.0000103774855,0.00007711952,0.00003245764,0.0000018634685],"category_scores_gemma":[0.00008260751,0.00003964031,0.000016727534,0.00015001584,0.00031908273,0.00026671874,0.00006597189,0.00006120453,3.187233e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015187266,0.00036678658,0.18423234,0.0003715348,0.00003674026,5.3340926e-8,0.0004614391,0.00045255545,0.7643041,0.04327532,0.00020994474,0.0061373],"study_design_scores_gemma":[0.0007078879,0.00031575098,0.9257453,0.000119170036,0.00004419222,0.0000013053976,0.00006655651,0.014042622,0.046138432,0.012731104,0.000041629046,0.000046014604],"about_ca_topic_score_codex":0.0000035449316,"about_ca_topic_score_gemma":4.562079e-8,"teacher_disagreement_score":0.741513,"about_ca_system_score_codex":0.000012149585,"about_ca_system_score_gemma":0.000008668406,"threshold_uncertainty_score":0.1616485},"labels":[],"label_agreement":null},{"id":"W2081197848","doi":"10.1177/0269881110389214","title":"Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs","year":2010,"lang":"en","type":"review","venue":"Journal of Psychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Metformin; Antipsychotic; Medicine; Schizophrenia (object-oriented programming); Weight gain; Psychiatry; Diabetes mellitus; Psychological intervention; Internal medicine; Endocrinology; Body weight","score_opus":0.014855973775141283,"score_gpt":0.33105269908968893,"score_spread":0.3161967253145476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081197848","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18296705,0.8137934,0.000020593394,0.000056620116,0.0011903493,0.001875909,0.000007873014,0.000007917181,0.00008023266],"genre_scores_gemma":[0.0021351303,0.99328583,0.00388286,0.00009517383,0.00033699354,0.000048815506,0.00003816711,0.0000482885,0.00012873893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983897,0.00008181703,0.0007916058,0.00025563498,0.00021402737,0.0002671646],"domain_scores_gemma":[0.99835044,0.0001771006,0.0009964915,0.00015268418,0.00016892451,0.00015435208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005229194,0.00031754005,0.0015671854,0.0007310157,0.000041206098,0.000019896728,0.00012254126,0.00024278059,0.00005197508],"category_scores_gemma":[0.000029968638,0.0002130751,0.00024228376,0.00025085502,0.000056449862,0.00015201041,0.000023543624,0.0005469798,0.000003778065],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021291676,0.0008314167,0.0026654406,0.0037566111,0.00069827156,0.000022306755,0.00004516917,2.5711972e-7,0.0000037346324,0.000018694236,0.00094725465,0.98888165],"study_design_scores_gemma":[0.035173282,0.0028574404,0.029101266,0.0076328684,0.008339049,0.00006367883,0.000011246674,0.000008218197,0.00000529544,0.00017044174,0.91628903,0.0003481814],"about_ca_topic_score_codex":8.145971e-7,"about_ca_topic_score_gemma":0.000003265409,"teacher_disagreement_score":0.9885335,"about_ca_system_score_codex":0.00012870115,"about_ca_system_score_gemma":0.00012467714,"threshold_uncertainty_score":0.868895},"labels":[],"label_agreement":null},{"id":"W2081199780","doi":"10.1111/dom.12271","title":"Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2‐year trial in insulin‐naïve patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Medicine; Insulin glargine; Insulin degludec; Insulin; Internal medicine; Diabetes mellitus; Metformin; Hypoglycemia; Population; Type 2 diabetes; Endocrinology","score_opus":0.007403713643261174,"score_gpt":0.22060987078041594,"score_spread":0.21320615713715477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081199780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991524,0.005640843,0.000004870565,0.00028869128,0.00032448006,0.0016869265,0.000034790908,0.00009056711,0.00040484322],"genre_scores_gemma":[0.99501765,0.0017793471,0.0018130263,0.000704693,0.00017739901,0.00008914338,0.0002857364,0.000055580942,0.00007739756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737936,0.00016473256,0.00041771546,0.0006659241,0.00045654713,0.00091573916],"domain_scores_gemma":[0.9985373,0.00017726008,0.0002101761,0.00041324474,0.0001510955,0.00051089795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004501392,0.0004655535,0.001104785,0.00035390593,0.00014935038,0.00008593757,0.00010552092,0.00014530595,0.000018215753],"category_scores_gemma":[0.00020079807,0.00034215336,0.000054349824,0.0005723289,0.00019697801,0.0002794886,0.00013002708,0.00031558098,0.00001636283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014777335,0.0015440073,0.9237951,0.0003309366,0.00047095804,0.0000037173863,0.000489776,0.000005007768,0.000016382144,0.00074779673,0.00014299864,0.05767597],"study_design_scores_gemma":[0.13623987,0.004055736,0.8463531,0.000198975,0.00039696082,1.0189461e-7,0.00005376277,0.00007652517,0.0001338949,0.0001057843,0.0120233195,0.0003619597],"about_ca_topic_score_codex":0.0001262273,"about_ca_topic_score_gemma":0.00016199767,"teacher_disagreement_score":0.12146254,"about_ca_system_score_codex":0.000082659564,"about_ca_system_score_gemma":0.00013657182,"threshold_uncertainty_score":0.999903},"labels":[],"label_agreement":null},{"id":"W2081427029","doi":"10.2337/diacare.25.8.1490-b","title":"On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors","year":2002,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Metformin; Medicine; Dipeptidyl peptidase-4; Internal medicine; Endocrinology; Diabetes mellitus; Dipeptidyl peptidase; Insulin; Gluconeogenesis; Glucagon-like peptide-1; Type 2 diabetes; Linagliptin; Glucagon; Pharmacology; Glycogenolysis; Enzyme; Metabolism; Biochemistry; Biology","score_opus":0.009647402451824473,"score_gpt":0.21216657317860652,"score_spread":0.20251917072678205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081427029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96956724,0.0038129955,3.7892625e-7,0.018881084,0.00019373767,0.0017391092,0.0001540925,0.00012423328,0.005527128],"genre_scores_gemma":[0.8231983,0.00070843,0.00031639086,0.16584231,0.00085780275,0.00056618016,0.0047119954,0.00027838972,0.0035202035],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977132,0.0000623985,0.0003734637,0.00060247805,0.00067502493,0.0005734033],"domain_scores_gemma":[0.99855,0.00022028077,0.00030290266,0.00059849134,0.00022079964,0.000107517015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008859441,0.0006272794,0.0009726997,0.0005080592,0.000077141834,0.000052145504,0.00013737284,0.00042943956,0.00010210705],"category_scores_gemma":[0.000026832131,0.00045330808,0.0002144023,0.00026003944,0.00019901774,0.00012569306,0.000061313476,0.0005965377,0.000053029988],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057008845,0.0005324262,0.3244093,0.0031406465,0.0018551231,0.000110839304,0.0009211379,0.000002068068,0.00032466897,0.00008196063,0.5971186,0.07144622],"study_design_scores_gemma":[0.021067362,0.022416504,0.053472668,0.008273153,0.002886447,0.0000016187533,0.00086384563,0.0001259239,0.041499913,0.00043085188,0.84642756,0.0025341618],"about_ca_topic_score_codex":0.0000029859466,"about_ca_topic_score_gemma":0.0000010829059,"teacher_disagreement_score":0.27093664,"about_ca_system_score_codex":0.0001372894,"about_ca_system_score_gemma":0.000026208669,"threshold_uncertainty_score":0.99979186},"labels":[],"label_agreement":null},{"id":"W2081770159","doi":"10.1016/j.clinthera.2014.07.019","title":"Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Mellitus","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Medicine; Insulin glargine; Sitagliptin; Metformin; Type 2 Diabetes Mellitus; Hypoglycemia; Internal medicine; Insulin; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.0806538993218418,"score_gpt":0.36118291305526934,"score_spread":0.28052901373342753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081770159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996126,0.00072600355,0.00007460249,0.00008544072,0.00048697993,0.0010554643,0.0000067043948,0.000034002613,0.0014047914],"genre_scores_gemma":[0.99805397,0.0005155988,0.00076371216,0.00037890233,0.00007793941,0.000032395248,0.00009555062,0.00003411946,0.00004779876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.0002837569,0.00052162405,0.00031809078,0.00026388542,0.00030099475],"domain_scores_gemma":[0.99769336,0.0013909348,0.00016471707,0.00042596128,0.00021356152,0.00011146475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008469441,0.00020863111,0.0006564984,0.000095948395,0.000020799625,0.000009809027,0.00012387766,0.00014542497,0.0000315154],"category_scores_gemma":[0.00024228918,0.00015175468,0.00010505605,0.000343264,0.0001702347,0.000052353236,0.00006298041,0.00023034347,0.0000448831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005173511,0.0027838007,0.7951092,0.00016519192,0.000651018,0.000002947423,0.000046436315,0.00003296807,0.000037346446,0.00039222682,0.000012700003,0.19559264],"study_design_scores_gemma":[0.027414368,0.00820016,0.9468776,0.0003003135,0.0005476039,4.1011134e-8,0.000021255637,0.00056164415,0.0007572529,0.00021974684,0.014892349,0.00020767403],"about_ca_topic_score_codex":0.000003333555,"about_ca_topic_score_gemma":0.0000053584063,"teacher_disagreement_score":0.19538496,"about_ca_system_score_codex":0.00006394393,"about_ca_system_score_gemma":0.000042771495,"threshold_uncertainty_score":0.6188376},"labels":[],"label_agreement":null},{"id":"W2081796610","doi":"10.1016/j.jcjd.2013.12.006","title":"Regarding “Cardiovascular Complications of Diabetes” Editorial article Can J Diabetes; 37(5); (2013), 279-281.","year":2014,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Glenrose Rehabilitation Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Disease; Intensive care medicine; Metabolic syndrome; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.013201353374366535,"score_gpt":0.20964717662083598,"score_spread":0.19644582324646945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081796610","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43623748,0.017101066,0.000039195886,0.49643743,0.040579084,0.0024982165,0.000594898,0.000121482015,0.0063911555],"genre_scores_gemma":[0.70568573,0.00010816033,0.00082095165,0.17565638,0.11502842,0.00015496,0.00082177686,0.000427964,0.0012956552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951193,0.00025598248,0.0013364943,0.00056034495,0.0011690311,0.0015588806],"domain_scores_gemma":[0.99500704,0.0003684168,0.000991714,0.001354676,0.0011116497,0.001166483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011447101,0.00069083134,0.002264848,0.0010595793,0.00022718852,0.00015044944,0.00072770996,0.0007685202,0.00015785937],"category_scores_gemma":[0.00050182745,0.0006352039,0.0016621177,0.00050329504,0.00033730877,0.00021430565,0.00006447671,0.0016452757,0.000058683076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017416556,0.0000493522,0.09151088,0.0005964985,0.0047786883,0.000044371754,0.0000625041,0.00005087471,0.00019065295,0.000024317873,0.9005687,0.002121372],"study_design_scores_gemma":[0.0023836342,0.0006554154,0.010503203,0.0014231278,0.0046217176,0.0000023677153,0.000027021864,0.00008461686,0.00090804923,0.00024872838,0.9785732,0.00056890544],"about_ca_topic_score_codex":0.00042746376,"about_ca_topic_score_gemma":0.0005075233,"teacher_disagreement_score":0.32078105,"about_ca_system_score_codex":0.00067589263,"about_ca_system_score_gemma":0.0011636617,"threshold_uncertainty_score":0.99960995},"labels":[],"label_agreement":null},{"id":"W2082073809","doi":"10.1016/s0140-6736(10)60973-7","title":"More insights on the dysglycaemia–cardiovascular connection","year":2010,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Diabetes mellitus; Medicine; Glycated hemoglobin; Scopus; Epidemiology; Incidence (geometry); Diabetic retinopathy; Internal medicine; Retinopathy; Type 2 diabetes; MEDLINE; Gerontology; Endocrinology","score_opus":0.029987851168253837,"score_gpt":0.24606928683807278,"score_spread":0.21608143566981894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082073809","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014369646,0.0007610971,0.000007397093,0.92032737,0.0009254611,0.0009677356,0.000010826709,0.00013164816,0.062498823],"genre_scores_gemma":[0.014703579,0.0003346816,0.00002853739,0.9495043,0.019360503,0.00021389042,0.00031677147,0.000057439393,0.015480271],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871415,0.000091114816,0.00012824476,0.00028173576,0.00048014105,0.0003046096],"domain_scores_gemma":[0.99789023,0.00016180507,0.00007287327,0.0018140955,0.00003732181,0.00002365142],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00025630265,0.00025822566,0.00062461384,0.000059058668,0.00013480565,0.000051162646,0.0003253716,0.00043694154,0.00016523925],"category_scores_gemma":[0.0000506098,0.00011001614,0.00037629265,0.00010314585,0.0001093155,0.000021446984,0.00006695982,0.002351571,0.00043599706],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003343663,0.000020793725,0.00003981373,0.00008217483,0.0015411051,0.00018079476,0.00010659237,0.0000023604734,0.000014466462,0.00056385965,0.99254686,0.004867772],"study_design_scores_gemma":[0.00094410405,0.00010825215,0.00073735556,0.00012987052,0.0010965223,0.000010533141,0.00003189667,0.000012964722,0.00018402276,0.00038443587,0.9962317,0.00012835687],"about_ca_topic_score_codex":0.000024370685,"about_ca_topic_score_gemma":0.000003979025,"teacher_disagreement_score":0.047018554,"about_ca_system_score_codex":0.00006077883,"about_ca_system_score_gemma":0.000019829891,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W2083122969","doi":"10.1016/j.jcjd.2014.07.025","title":"Reductions in Post-Prandial Glucagon by the GLP-1 Receptor Agonist Lixisenatide Correlate to Reductions in PPG and A1C in Patients with Type 2 Diabetes Mellitus","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lixisenatide; Medicine; Post-prandial; Internal medicine; Endocrinology; Glycated hemoglobin; Type 2 Diabetes Mellitus; Glucagon-like peptide 1 receptor; Glucagon; Glycemic; Glucagon-like peptide-1; Agonist; Type 2 diabetes; Incretin; Diabetes mellitus; Receptor; Insulin; Exenatide","score_opus":0.004282672334090492,"score_gpt":0.19324922858216936,"score_spread":0.18896655624807887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083122969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918222,0.0012194184,4.5847094e-7,0.005366431,0.00056778523,0.0004937359,0.000027616225,0.000005274357,0.0004970704],"genre_scores_gemma":[0.9987297,0.000045292043,0.00016063494,0.00053248915,0.00010522732,0.00002173962,0.000053955162,0.00002574194,0.00032522288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998616,0.00010325757,0.0004094565,0.00020845658,0.00017662256,0.00048620388],"domain_scores_gemma":[0.99893594,0.00009882461,0.00013573725,0.00019243312,0.00016512719,0.00047193986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003816738,0.00018686376,0.00037389752,0.0006957232,0.000100947254,0.00006430793,0.00012320114,0.00007004428,0.000049369868],"category_scores_gemma":[0.00033289025,0.00013603694,0.000044745768,0.00062774,0.00014149085,0.00017957728,0.0000157077,0.00031016523,0.000010174694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006809634,0.0001928508,0.96987003,0.000027800208,0.00014292082,0.000004975326,0.0009470009,0.000080291924,0.0002930515,0.00006409242,0.006509128,0.02179977],"study_design_scores_gemma":[0.0040294356,0.002227438,0.9705872,0.00055765995,0.00016361037,0.0000010545234,0.00055120426,0.000040070445,0.00037356786,0.00010026419,0.02113706,0.00023143706],"about_ca_topic_score_codex":0.0012058641,"about_ca_topic_score_gemma":0.016491424,"teacher_disagreement_score":0.021568332,"about_ca_system_score_codex":0.00034842207,"about_ca_system_score_gemma":0.0002853444,"threshold_uncertainty_score":0.9202602},"labels":[],"label_agreement":null},{"id":"W2083342497","doi":"10.1001/jama.290.4.486","title":"Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance","year":2003,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1623,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Montréal; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Bayer","keywords":"Medicine; Acarbose; Impaired glucose tolerance; Internal medicine; Hazard ratio; Postprandial; Placebo; Heart failure; Diabetes mellitus; Body mass index; Randomized controlled trial; Surgery; Type 2 diabetes; Endocrinology; Insulin; Confidence interval","score_opus":0.006003306144631211,"score_gpt":0.18127431898449473,"score_spread":0.17527101283986352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083342497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991979,0.006857526,0.0000026655869,0.00011691926,0.000015404366,0.00076846144,0.0000052965015,0.000007396884,0.00024733538],"genre_scores_gemma":[0.9979072,0.0018084749,0.00009343082,0.000068229056,0.000008634595,0.000041706062,0.000007390461,0.0000077833465,0.000057129735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994557,0.000069860005,0.00009157436,0.00015588987,0.0001260805,0.00010091234],"domain_scores_gemma":[0.9995839,0.00003331198,0.000032176627,0.00025401413,0.000028817773,0.00006779969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011687228,0.000099130135,0.00026514186,0.000034254444,0.000025174597,0.00000806647,0.00001418515,0.000017987388,0.0000021041972],"category_scores_gemma":[0.000044196895,0.000048084312,0.00006319231,0.000065834,0.000071717855,0.00004057598,0.000012615202,0.000028858278,5.87338e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016987575,0.0005071969,0.913453,0.0000435241,0.0011317974,0.000028167775,0.00021755816,0.00005962489,0.0000035687563,0.00009325544,0.000021303431,0.082742274],"study_design_scores_gemma":[0.03346744,0.0004696376,0.9627662,0.00007145405,0.0014396138,5.553779e-7,0.00004059893,0.00021868254,0.00011312068,0.000047448684,0.001310085,0.000055212236],"about_ca_topic_score_codex":0.00012157381,"about_ca_topic_score_gemma":0.0000047874228,"teacher_disagreement_score":0.082687065,"about_ca_system_score_codex":0.000027117789,"about_ca_system_score_gemma":0.000011659783,"threshold_uncertainty_score":0.19608213},"labels":[],"label_agreement":null},{"id":"W2083415436","doi":"10.1111/j.1463-1326.2011.01493.x","title":"Achieving a clinically relevant composite outcome of an HbA1c of &lt;7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Merck Sharp and Dohme; Novo Nordisk","keywords":"Liraglutide; Medicine; Sitagliptin; Glimepiride; Exenatide; Type 2 diabetes; Internal medicine; Weight loss; Rosiglitazone; Weight gain; Placebo; Diabetes mellitus; Endocrinology; Obesity","score_opus":0.16090406437223578,"score_gpt":0.39536483810216133,"score_spread":0.23446077372992555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083415436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34956607,0.6466147,0.0000018468461,0.000022269372,0.00035933204,0.003149641,0.00011691728,0.000028595472,0.00014065026],"genre_scores_gemma":[0.029115535,0.9661091,0.0034432407,0.0001760909,0.00018187355,0.00026938843,0.0002514542,0.00009559129,0.00035775764],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99137855,0.0017741219,0.004537857,0.00096443394,0.0006014268,0.0007436279],"domain_scores_gemma":[0.9933177,0.0014269059,0.0029973157,0.0016460757,0.00026994955,0.00034202376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0051385527,0.0008421239,0.013306402,0.00093865325,0.00006308634,0.00002661678,0.00074268033,0.00065795024,0.00007917055],"category_scores_gemma":[0.0012635774,0.00046033767,0.004640534,0.0020687424,0.0006310013,0.00015073482,0.00053846487,0.00078840856,0.0000035147343],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030799077,0.008197237,0.20021999,0.021302817,0.24820988,0.000013859004,0.0002623112,0.0000014826147,0.000011578055,0.00049595576,0.000023889306,0.5181811],"study_design_scores_gemma":[0.014317426,0.002049755,0.051487084,0.0031075997,0.8185086,5.8697964e-7,0.00001722103,0.00006467793,0.00003148891,0.00005480239,0.10974809,0.0006126661],"about_ca_topic_score_codex":0.00005991661,"about_ca_topic_score_gemma":0.000082196966,"teacher_disagreement_score":0.57029873,"about_ca_system_score_codex":0.000038007965,"about_ca_system_score_gemma":0.00029271463,"threshold_uncertainty_score":0.9997848},"labels":[],"label_agreement":null},{"id":"W2084048627","doi":"10.1093/ehjqcco/qcw013","title":"Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey","year":2016,"lang":"en","type":"article","venue":"European Heart Journal - Quality of Care and Clinical Outcomes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Credit Valley Hospital; St. Michael's Hospital; Canadian Heart Research Centre; University of Toronto","funders":"Merck Canada; University of Toronto; Heart and Stroke Foundation of Canada","keywords":"Medicine; Diabetes mellitus; Coronary artery disease; Guideline; Internal medicine; Aspirin; Risk factor; Disease; Blood pressure; Intensive care medicine; Cardiology; Endocrinology; Pathology","score_opus":0.028523442690551955,"score_gpt":0.2877286236382481,"score_spread":0.2592051809476961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084048627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913585,0.00746602,0.0000042859556,0.00027476353,0.00006466367,0.0005658191,0.00022285759,0.000006176587,0.00003689555],"genre_scores_gemma":[0.99679387,0.002462399,0.000064723,0.00059588574,0.00002527949,0.0000037876905,0.000019015406,0.000021598356,0.0000134177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662286,0.0015645234,0.00068112824,0.0003425849,0.00049001735,0.00029890484],"domain_scores_gemma":[0.99742055,0.001639061,0.00019858679,0.00032673543,0.00008970111,0.0003253863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008353168,0.00023150572,0.00088808633,0.0000553894,0.00006778135,0.000034957084,0.00007321598,0.000022701146,0.000006377981],"category_scores_gemma":[0.00021695139,0.000105991014,0.00012870599,0.00006318232,0.00020167936,0.000116151576,0.000073335876,0.00020864961,6.874287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088399654,0.00010516341,0.95658964,0.00006134473,0.001980665,0.000039751445,0.00011111388,0.0000010903614,2.6948464e-7,0.0000021979945,0.000028246926,0.040196493],"study_design_scores_gemma":[0.013586415,0.00072934193,0.98373073,0.00041675367,0.0005879509,2.0129562e-7,0.00029393073,0.0000017907648,5.737438e-7,0.000015590873,0.00047332828,0.00016341756],"about_ca_topic_score_codex":0.010982133,"about_ca_topic_score_gemma":0.07716836,"teacher_disagreement_score":0.06618623,"about_ca_system_score_codex":0.000079638885,"about_ca_system_score_gemma":0.00009534112,"threshold_uncertainty_score":0.9956038},"labels":[],"label_agreement":null},{"id":"W2084514272","doi":"10.1046/j.1464-5491.2000.00236.x","title":"Effect of ageing and diabetes on glucose‐dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose","year":2000,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council Canada; University of British Columbia; Canadian Diabetes Association","keywords":"Medicine; Internal medicine; Diabetes mellitus; Endocrinology; Ageing; Dipeptidyl peptidase; Insulin; Body mass index; Type 2 diabetes; Middle age; Enzyme","score_opus":0.00967409658410349,"score_gpt":0.2656267584479443,"score_spread":0.2559526618638408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084514272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904738,0.00289322,0.0000042696497,0.0019312807,0.00011319463,0.001308078,0.000013297652,0.000085311396,0.0031775585],"genre_scores_gemma":[0.9934823,0.0006845507,0.00023425742,0.0021958235,0.00016400198,0.00010314417,0.000039957005,0.0000483516,0.0030475997],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99757165,0.00023186373,0.00049823377,0.00058472133,0.000550505,0.00056305795],"domain_scores_gemma":[0.99805033,0.0007487259,0.000099200304,0.0005274493,0.00004876527,0.00052550295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007540361,0.00044137283,0.0010322079,0.00039976105,0.00009300107,0.000021269167,0.000114140734,0.00009595752,0.00043506455],"category_scores_gemma":[0.0004922951,0.00030735607,0.00007433201,0.00029992542,0.000298059,0.00007594759,0.00009173875,0.00019111985,0.00007218558],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025109216,0.00045935856,0.17288813,0.0012425159,0.0005112077,0.00032011486,0.00081447297,0.000005730625,0.043910213,0.00013918242,0.0012341158,0.775964],"study_design_scores_gemma":[0.024406867,0.04362707,0.7665042,0.0047925264,0.002385799,0.000013498528,0.00021951317,0.00035157125,0.14765903,0.00014423318,0.00914123,0.0007544441],"about_ca_topic_score_codex":0.000059731752,"about_ca_topic_score_gemma":0.0000057972356,"teacher_disagreement_score":0.7752096,"about_ca_system_score_codex":0.000066721965,"about_ca_system_score_gemma":0.000021557396,"threshold_uncertainty_score":0.99993783},"labels":[],"label_agreement":null},{"id":"W2084574308","doi":"10.1016/s0140-6736(10)62299-4","title":"Cardiovascular safety and diabetes drug development","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Scopus; Pharmacotherapy; Disease; Glycated haemoglobin; Glycated hemoglobin; Disease control; National Health and Nutrition Examination Survey; MEDLINE; Intensive care medicine; Internal medicine; Family medicine; Environmental health; Endocrinology","score_opus":0.026716374742927436,"score_gpt":0.2177986222780807,"score_spread":0.19108224753515327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084574308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9103058,0.0044619637,0.000032364293,0.0010614765,0.000089212175,0.00036726464,0.0000017408629,0.00008464938,0.0835955],"genre_scores_gemma":[0.99351174,0.00039305128,0.0022079714,0.0008049912,0.00016138525,0.000026770782,0.0000093831495,0.000010448012,0.0028742466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995165,0.000018641955,0.00007697504,0.00010698135,0.00010641595,0.00017447023],"domain_scores_gemma":[0.9995994,0.00001230711,0.000014453542,0.0003250989,0.000010914621,0.000037843718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002879094,0.000073801435,0.00025723205,0.000017380175,0.000056416084,0.0000075102307,0.00006574594,0.000011790579,0.000060917606],"category_scores_gemma":[0.000007483634,0.00004175538,0.0000480445,0.000040727515,0.00003650246,0.00002311915,0.000063033236,0.00004149711,0.000059285518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032356207,0.00027206546,0.5413184,0.00045766387,0.0071620285,0.000056468507,0.007767152,0.0000024354974,0.00009877348,0.005870196,0.051345397,0.38532585],"study_design_scores_gemma":[0.0012762775,0.000028024266,0.5481338,0.00003900805,0.00028085336,8.725951e-7,0.000068498586,0.000008312701,0.001360704,0.00016410477,0.44857177,0.000067761386],"about_ca_topic_score_codex":0.000009258098,"about_ca_topic_score_gemma":0.000002381041,"teacher_disagreement_score":0.3972264,"about_ca_system_score_codex":0.000017048673,"about_ca_system_score_gemma":0.000008466732,"threshold_uncertainty_score":0.1702735},"labels":[],"label_agreement":null},{"id":"W2084948079","doi":"10.1053/j.gastro.2007.03.054","title":"Biology of Incretins: GLP-1 and GIP","year":2007,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3573,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.045151218455141126,"score_gpt":0.3502311483063948,"score_spread":0.30507992985125365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084948079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016988587,0.9958103,0.00006566547,0.000060534523,0.00017350224,0.00063617766,0.00002632982,0.000027152868,0.0015015092],"genre_scores_gemma":[0.00030748523,0.9979533,0.0007199872,0.0002695024,0.000099029145,0.000043987573,0.00027407098,0.000027155313,0.00030549767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986725,0.00009237276,0.00048051306,0.00032360145,0.00006102471,0.0003700222],"domain_scores_gemma":[0.999267,0.00006128237,0.0002577849,0.0002911976,0.000027952794,0.00009477519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002096103,0.00027573935,0.0017862959,0.00035306127,0.00001303404,0.0000025569225,0.00009307227,0.0002277592,0.000083759114],"category_scores_gemma":[0.000024689887,0.00020296342,0.00023169156,0.00007438188,0.00021052221,0.000012253924,0.00016837312,0.00017480174,0.000025956948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000800298,0.0001174734,0.009334792,0.007958765,0.00087907125,0.000041731386,0.000011708157,3.5875067e-9,9.845235e-7,0.00032913155,0.0006530817,0.9805932],"study_design_scores_gemma":[0.0008879199,0.002099187,0.0004978749,0.0017115236,0.00203127,0.00010049776,0.000003641691,2.584709e-7,7.602086e-7,0.00002452144,0.9925815,0.00006105789],"about_ca_topic_score_codex":0.000012160304,"about_ca_topic_score_gemma":0.0000087256,"teacher_disagreement_score":0.9919284,"about_ca_system_score_codex":0.000037496913,"about_ca_system_score_gemma":0.000022905257,"threshold_uncertainty_score":0.8276608},"labels":[],"label_agreement":null},{"id":"W2086357998","doi":"10.1016/j.jcjd.2014.04.006","title":"Optimal Medication Dosing in Patients with Diabetes Mellitus and Chronic Kidney Disease","year":2014,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck","keywords":"Dosing; Medicine; Intensive care medicine; Kidney disease; Diabetes mellitus; Renal function; Population; Disease; Drug; Pharmacodynamics; Pharmacology; Pharmacokinetics; Internal medicine; Endocrinology","score_opus":0.00944786220844184,"score_gpt":0.23732345395637414,"score_spread":0.2278755917479323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086357998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03710082,0.96158415,0.0000016057911,0.00021492074,0.00022221058,0.0007154102,0.000048865764,0.0000064464075,0.00010556559],"genre_scores_gemma":[0.038960833,0.9585635,0.0003508834,0.00050230755,0.00058195,0.00006924402,0.0006946088,0.00014239637,0.00013426095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980577,0.00009850689,0.00066903775,0.00027974235,0.00030560768,0.00058938377],"domain_scores_gemma":[0.9968414,0.000095871386,0.00055736816,0.00028064442,0.000121528305,0.002103202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034043554,0.00039874445,0.0015512017,0.0009587735,0.000066875604,0.00007632982,0.00017729173,0.00013295817,0.000062717445],"category_scores_gemma":[0.00021573977,0.00028158358,0.00020860607,0.00026305308,0.0001669675,0.00016485674,0.000020918495,0.00034021452,0.000008080267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000436933,0.00007724887,0.25929865,0.012509313,0.00071370834,0.00002402291,0.00003110751,0.0000026888379,3.4842937e-8,0.000027307144,0.0013121715,0.72599936],"study_design_scores_gemma":[0.0027463557,0.0009786587,0.056376964,0.05348142,0.0047346554,4.6746544e-7,0.0000050742,0.00002318625,7.4896906e-7,0.000013446995,0.88125664,0.00038241042],"about_ca_topic_score_codex":0.000024745364,"about_ca_topic_score_gemma":0.00019435384,"teacher_disagreement_score":0.87994444,"about_ca_system_score_codex":0.00072813744,"about_ca_system_score_gemma":0.0025736468,"threshold_uncertainty_score":0.99996364},"labels":[],"label_agreement":null},{"id":"W2086667590","doi":"10.1111/j.1752-8062.2011.00284.x","title":"Association of <i>TCF7L2</i> Allelic Variations with Gastric Function, Satiation, and GLP‐1 Levels","year":2011,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"National Center for Research Resources; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Georgia Clinical and Translational Science Alliance; Mayo Clinic","keywords":"SNP; Internal medicine; Single-nucleotide polymorphism; TCF7L2; Endocrinology; Postprandial; Glucagon-like peptide-1; Proglucagon; Type 2 diabetes; Gastric emptying; Genotype; Biology; Allele; Medicine; Diabetes mellitus; Stomach; Genetics; Gene","score_opus":0.05893975403448876,"score_gpt":0.2974382468739922,"score_spread":0.23849849283950342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086667590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.947967,0.00015565935,0.0399795,0.0027320818,0.00011484977,0.00046742274,0.000013389304,0.000033728003,0.008536392],"genre_scores_gemma":[0.99110925,0.0000417731,0.008269909,0.00022158974,0.000029179322,0.000007144164,0.000007922847,0.0000026927034,0.00031056555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991605,0.000018511904,0.00024381587,0.00019535061,0.00027907666,0.00010273905],"domain_scores_gemma":[0.999441,0.0001318713,0.000099195095,0.000069072,0.00016810773,0.00009074403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060308754,0.000058379508,0.00012541206,0.00006878779,0.00012369527,0.0000150007,0.00003161083,0.000032658463,0.00007453074],"category_scores_gemma":[0.00006819353,0.000042148633,0.000024169462,0.00030470107,0.0003014268,0.00018794891,0.000009916895,0.000048023503,0.0000031310033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063182786,0.00018186698,0.97011054,0.000012563969,0.00007658281,3.7709003e-7,0.00017918818,0.000002721546,0.00007267672,0.016879361,0.000046334953,0.012374618],"study_design_scores_gemma":[0.001239247,0.0003590834,0.99168277,0.000015595459,0.0002058915,0.000001248407,0.000010616985,0.0003468877,0.00003115894,0.0053218887,0.0007406966,0.00004494256],"about_ca_topic_score_codex":0.000012839089,"about_ca_topic_score_gemma":0.00001565584,"teacher_disagreement_score":0.043142244,"about_ca_system_score_codex":0.0000072728526,"about_ca_system_score_gemma":0.000109368804,"threshold_uncertainty_score":0.17187713},"labels":[],"label_agreement":null},{"id":"W2086985270","doi":"10.1007/s00125-009-1611-5","title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","year":2009,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; SickKids Foundation; Mount Sinai Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Endocrinology; Internal medicine; Postprandial; Apolipoprotein B; Glucagon-like peptide-1; LDL receptor; Biology; Lipoprotein; Very low-density lipoprotein; Incretin; Type 2 diabetes; Cholesterol; Medicine; Diabetes mellitus","score_opus":0.008051558183132967,"score_gpt":0.240596666260362,"score_spread":0.23254510807722903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086985270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913101,0.00073691143,0.000037497248,0.0061057606,0.00016039809,0.0010366313,0.00001182568,0.00003504709,0.0005657967],"genre_scores_gemma":[0.9971091,0.00041475808,0.0007936868,0.0008607048,0.00007302556,0.00015997412,0.000030384896,0.0000107421,0.00054759614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991272,0.00003661991,0.00017848675,0.00026895633,0.000100258054,0.0002884615],"domain_scores_gemma":[0.9994909,0.00020893727,0.000058082438,0.00014791546,0.000026202442,0.00006793899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025303476,0.00014702165,0.0002515076,0.00007748148,0.000112714966,0.00005589238,0.000053503296,0.000074406315,0.000013502694],"category_scores_gemma":[0.00012883327,0.000102205435,0.000050483424,0.00008521248,0.000090155016,0.00007129906,0.000028214554,0.000069071764,0.000006271629],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038931966,0.00050910155,0.05199074,0.00032980336,0.0004915686,0.000027135375,0.001456641,9.844225e-7,0.023682155,0.0016508133,0.014399139,0.9015687],"study_design_scores_gemma":[0.014439923,0.0065322528,0.8008234,0.0008064382,0.0014208303,0.000013766237,0.0015080059,0.0012715147,0.088223845,0.002733045,0.08118446,0.0010424973],"about_ca_topic_score_codex":0.000033706572,"about_ca_topic_score_gemma":0.000031195712,"teacher_disagreement_score":0.9005262,"about_ca_system_score_codex":0.000035870842,"about_ca_system_score_gemma":0.000013738389,"threshold_uncertainty_score":0.41678166},"labels":[],"label_agreement":null},{"id":"W2087168693","doi":"10.1007/s00125-012-2464-x","title":"Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes","year":2012,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; University of Toronto; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Glucagon; Glucose homeostasis; Glucagon receptor; Insulin; Alpha cell; Homeostasis; Biology; Beta cell; Glucagon-like peptide 1 receptor; Receptor; Insulin resistance; Medicine; Islet; Agonist","score_opus":0.017768452245957377,"score_gpt":0.2508516248111067,"score_spread":0.2330831725651493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087168693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964966,0.0023926226,0.000008650327,0.00006415413,0.00008602573,0.00052054564,0.000025985957,0.000031273572,0.0003741074],"genre_scores_gemma":[0.99735594,0.00024516272,0.0020011123,0.000050578023,0.00002293481,0.00010047825,0.000052474654,0.000019953508,0.00015139037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861616,0.000056189696,0.00044699784,0.0002208818,0.00018638321,0.00047338312],"domain_scores_gemma":[0.9993052,0.00008935443,0.00016274751,0.00032029732,0.000035069315,0.00008736044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002751147,0.00019469054,0.00061917584,0.00036865828,0.000011761412,0.0000040517357,0.00011535504,0.00013187666,0.00003917817],"category_scores_gemma":[0.00012919717,0.0001565264,0.00010858407,0.00024367745,0.00009398941,0.00018352584,0.00011408892,0.00011938922,0.000007371547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028118186,0.0011460916,0.45447612,0.00033242186,0.000038192306,5.982727e-7,0.0004031642,0.000019123041,0.5159217,0.00013074838,0.000073453746,0.027430242],"study_design_scores_gemma":[0.0018417207,0.00028054134,0.17294517,0.00019424681,0.000052188632,3.0544893e-8,0.00020709267,0.0005081272,0.82368296,0.00009151458,0.00006132013,0.00013511072],"about_ca_topic_score_codex":0.000027220303,"about_ca_topic_score_gemma":0.000010748127,"teacher_disagreement_score":0.30776122,"about_ca_system_score_codex":0.00007709479,"about_ca_system_score_gemma":0.000025580868,"threshold_uncertainty_score":0.6382961},"labels":[],"label_agreement":null},{"id":"W2087609283","doi":"10.1016/j.peptides.2012.06.006","title":"Protection of exenatide for retinal ganglion cells with different glucose concentrations","year":2012,"lang":"en","type":"article","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; University of Toronto; National University of Singapore","keywords":"Exenatide; Internal medicine; Western blot; Endocrinology; Chemistry; Retina; Biology; Medicine; Diabetes mellitus; Biochemistry; Type 2 diabetes; Neuroscience","score_opus":0.020061906920612056,"score_gpt":0.24725639949951397,"score_spread":0.22719449257890192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087609283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382746,0.0001224158,0.0029612384,0.0002041267,0.00009141429,0.001154411,0.0000058652367,0.00003210856,0.0016009344],"genre_scores_gemma":[0.9965263,0.000017778182,0.0018651217,0.000032413445,0.00011569941,0.00022268343,0.000030561347,0.000009921267,0.0011795199],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995458,0.000009176748,0.00010550382,0.000079779806,0.000105927014,0.00015381118],"domain_scores_gemma":[0.9997061,0.000022525628,0.000062337895,0.00009920627,0.00005382213,0.000056047375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059850612,0.00007643468,0.00012584987,0.000041660263,0.00003398243,0.0000059362847,0.000018279528,0.000018111912,0.0000318687],"category_scores_gemma":[0.000013337581,0.000050848284,0.000041692154,0.000050610768,0.000030134523,0.00007123841,0.00000773056,0.000026146268,0.000004753943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025544434,0.005867401,0.3056541,0.0024572776,0.0011922139,0.000007932728,0.0036524197,0.000063008796,0.58725876,0.01597895,0.008857206,0.06645631],"study_design_scores_gemma":[0.0021070677,0.0014189857,0.05637079,0.00020328868,0.00041600136,0.0000019453107,0.00030110803,0.00021464634,0.9332423,0.0001082276,0.0055107963,0.00010481393],"about_ca_topic_score_codex":0.000009687961,"about_ca_topic_score_gemma":0.0000074255795,"teacher_disagreement_score":0.3459836,"about_ca_system_score_codex":0.000039018785,"about_ca_system_score_gemma":0.000008606762,"threshold_uncertainty_score":0.2073533},"labels":[],"label_agreement":null},{"id":"W2087801844","doi":"10.1007/s12349-010-0029-4","title":"Impact of the Mediterranean diet with and without weight loss on plasma cell adhesion molecule concentrations in men with the metabolic syndrome","year":2010,"lang":"en","type":"article","venue":"Mediterranean Journal of Nutrition and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Weight loss; Mediterranean diet; Medicine; Metabolic syndrome; Internal medicine; Obesity; Body weight; Endocrinology","score_opus":0.011612545469944575,"score_gpt":0.24850847360734651,"score_spread":0.23689592813740193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087801844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375075,0.001393086,0.0000125476145,0.0034792956,0.00019434573,0.0006305227,0.00001531933,0.0000063458874,0.0005177991],"genre_scores_gemma":[0.99767417,0.0015056923,0.00029382145,0.0001617918,0.00022059474,0.000019748277,0.000009411015,0.000020384616,0.000094407456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986952,0.000106830805,0.00033938294,0.00016118873,0.00048478512,0.00021261701],"domain_scores_gemma":[0.99906147,0.0000675325,0.0003279763,0.00022468522,0.00013137984,0.00018694645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030938414,0.00022006221,0.00052299496,0.0002069287,0.00008757044,0.000032084135,0.00012514109,0.0000613268,0.000044116823],"category_scores_gemma":[0.00002172775,0.00009241478,0.00010925995,0.00023513648,0.000308475,0.00017834936,0.000023116289,0.00041067833,5.9845377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038680404,0.021370033,0.45689398,0.00195771,0.0075727133,0.0021268707,0.040211182,0.000099029035,0.35513112,0.0042306194,0.023960799,0.047765527],"study_design_scores_gemma":[0.03854063,0.005279421,0.90013593,0.0011472771,0.0022721596,0.001518335,0.0009710239,0.0003366012,0.027939716,0.00013752514,0.02139089,0.000330503],"about_ca_topic_score_codex":0.000011334808,"about_ca_topic_score_gemma":0.000025696558,"teacher_disagreement_score":0.44324192,"about_ca_system_score_codex":0.000015799,"about_ca_system_score_gemma":0.00005810308,"threshold_uncertainty_score":0.37685654},"labels":[],"label_agreement":null},{"id":"W2087872951","doi":"10.4137/cmed.s20906","title":"Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review","year":2015,"lang":"en","type":"review","venue":"Clinical Medicine Insights Endocrinology and Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Novo Nordisk","keywords":"Glycemic; Medicine; Hypoglycemia; Intensive care medicine; Type 2 Diabetes Mellitus; Psychological intervention; Type 2 diabetes; Diabetes mellitus; Insulin; Health care; Cost effectiveness; Internal medicine; Endocrinology; Nursing; Risk analysis (engineering)","score_opus":0.24175528658791923,"score_gpt":0.505526802686711,"score_spread":0.2637715160987918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087872951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005367565,0.98283005,4.997082e-7,0.004515906,0.0025952281,0.003990285,0.000010669231,0.00008888049,0.0054317336],"genre_scores_gemma":[0.0001796287,0.99213386,0.00038250812,0.0050103655,0.0013173627,0.00026695867,0.00049956795,0.00007325048,0.00013652992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98857343,0.0038120644,0.004899136,0.0012509564,0.00069113664,0.00077329733],"domain_scores_gemma":[0.9880581,0.0064998697,0.0026700085,0.0012140139,0.0008264063,0.0007316039],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008620883,0.0007772027,0.009227401,0.00040306433,0.00007874871,0.000009781006,0.00032369306,0.0005824756,0.00014348212],"category_scores_gemma":[0.011638567,0.00049650075,0.00071716687,0.0003590195,0.0013943559,0.0001671271,0.00028249455,0.0010629179,0.00017036554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029132756,0.0005617929,0.0013339353,0.031420365,0.0026657255,0.000015305768,0.000018432882,5.773897e-8,1.1260984e-8,0.0006881761,0.035652764,0.92761433],"study_design_scores_gemma":[0.0039761714,0.0062287636,0.00033513713,0.060508925,0.026321765,0.0000114766835,0.000016032644,0.000028161365,2.5131385e-7,0.0004984089,0.90174866,0.00032622967],"about_ca_topic_score_codex":0.000016141983,"about_ca_topic_score_gemma":0.000007802686,"teacher_disagreement_score":0.92728806,"about_ca_system_score_codex":0.0002423341,"about_ca_system_score_gemma":0.001947903,"threshold_uncertainty_score":0.99974865},"labels":[],"label_agreement":null},{"id":"W2088104264","doi":"10.1139/cjpp-2013-0185","title":"Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Downregulation and upregulation; Internal medicine; Endothelial dysfunction; Endocrinology; Medicine; Diabetes mellitus; Insulin resistance; Risperidone; Proinflammatory cytokine; Streptozotocin; Pharmacology; Inflammation; Chemistry; Schizophrenia (object-oriented programming); Biochemistry","score_opus":0.008701701083832508,"score_gpt":0.24240496865890798,"score_spread":0.23370326757507548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088104264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773735,0.000718751,0.000036756916,0.0006240626,0.00045592934,0.00035932302,0.0000033594508,0.0000040784494,0.000060375067],"genre_scores_gemma":[0.998492,0.00040428434,0.0001396529,0.0006678489,0.00018485138,0.000012042673,0.0000114061495,0.000012905254,0.000074995536],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989221,0.00016594578,0.00035750348,0.00018618251,0.00007823732,0.00029001175],"domain_scores_gemma":[0.99921924,0.00010490528,0.00017044751,0.00008222281,0.000118692005,0.00030450197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015618923,0.000153692,0.0004361835,0.00031893555,0.00006283757,0.000007742557,0.000056853885,0.00014775737,0.00070620875],"category_scores_gemma":[0.000028281922,0.00013225147,0.0000729311,0.00012963421,0.00022539041,0.00009746664,0.000014221432,0.0002231687,0.000008860389],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010347065,0.00010640647,0.027889756,0.00010229535,0.0002985748,0.000036110436,0.00015866852,0.00003900944,0.9647044,0.000113181544,0.00069920183,0.0048176907],"study_design_scores_gemma":[0.003909208,0.0013972374,0.7855914,0.00005686466,0.00045058524,0.00004252579,0.00005804567,0.00065211207,0.20566265,0.0011812422,0.00086172094,0.00013638481],"about_ca_topic_score_codex":0.00048744437,"about_ca_topic_score_gemma":0.00030997553,"teacher_disagreement_score":0.7590417,"about_ca_system_score_codex":0.00004781636,"about_ca_system_score_gemma":0.00014152711,"threshold_uncertainty_score":0.77324903},"labels":[],"label_agreement":null},{"id":"W2088164570","doi":"10.3810/pgm.2014.10.2821","title":"Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes","year":2014,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Hôtel-Dieu de Montréal","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Exenatide; Metformin; Type 2 diabetes; Glucagon-like peptide 1 receptor; Glycemic; Sitagliptin; Liraglutide; Internal medicine; Nausea; Hypoglycemia; Clinical endpoint; Pharmacology; Diabetes mellitus; Insulin; Endocrinology; Clinical trial; Agonist; Receptor","score_opus":0.03907160391263062,"score_gpt":0.32320189569306046,"score_spread":0.2841302917804298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088164570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010922648,0.9900821,0.00008753228,0.0025437349,0.00054766156,0.004442489,0.0000597938,0.00003820779,0.0020892648],"genre_scores_gemma":[0.0003154788,0.99311644,0.0009392369,0.00014448236,0.000275633,0.00014634729,0.0005923066,0.00007890822,0.0043911524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974103,0.000088502595,0.0011539062,0.00049045583,0.0004484783,0.00040833783],"domain_scores_gemma":[0.9970939,0.0009786502,0.00077340694,0.00082164654,0.00018932317,0.00014307893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009220464,0.00053476554,0.0029228395,0.00022746135,0.00008354359,0.0000074709037,0.0002910228,0.00012422305,0.000057372068],"category_scores_gemma":[0.00017963494,0.0002883093,0.00037746647,0.00045915076,0.00044449375,0.00002626412,0.00018061399,0.0001767222,0.000014857498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017481828,0.00015819678,0.000032473014,0.061951578,0.003665783,0.000003961318,0.00006282716,2.7009813e-7,0.0000037639406,0.0016946706,0.0052474183,0.9270042],"study_design_scores_gemma":[0.0034126025,0.0018534794,0.00029066874,0.03941786,0.0173192,0.0000026503649,0.000049528364,0.00003191365,0.000010226142,0.000041552135,0.9373601,0.00021020412],"about_ca_topic_score_codex":0.000025239562,"about_ca_topic_score_gemma":0.0000015980236,"teacher_disagreement_score":0.9321127,"about_ca_system_score_codex":0.00008326984,"about_ca_system_score_gemma":0.000057983754,"threshold_uncertainty_score":0.9999569},"labels":[],"label_agreement":null},{"id":"W2088385809","doi":"10.1016/s0168-8227(00)82206-8","title":"Oral insulin metformin combination therapy for treatment of type - 2 diabetes","year":2000,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Generex Biotechnology (Canada)","funders":"","keywords":"Medicine; Metformin; Diabetes mellitus; Type 2 diabetes; Insulin; Internal medicine; Endocrinology","score_opus":0.15092566808343033,"score_gpt":0.48754500024286557,"score_spread":0.33661933215943524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088385809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98245955,0.005053458,0.0000014086191,0.0032893657,0.00008403387,0.0016059697,0.000013673029,0.00003026224,0.0074622836],"genre_scores_gemma":[0.9551637,0.034704965,0.002747113,0.0005513252,0.00015981341,0.00023254367,0.00018947103,0.000032791395,0.006218245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800134,0.0002729866,0.00048286197,0.00035558024,0.0004089582,0.00047828085],"domain_scores_gemma":[0.99446034,0.004357087,0.00009838194,0.00031825487,0.00054110034,0.0002248222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002064611,0.00015521009,0.0005093112,0.00013215814,0.000117561,0.00004769223,0.000085746186,0.000117228934,0.00031845074],"category_scores_gemma":[0.0017607635,0.00011172757,0.0001367388,0.00033662264,0.00027458958,0.00028742652,0.000026836933,0.0001239547,0.00006330742],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018402565,0.0073843016,0.043772522,0.00006958817,0.000926601,0.000004965082,0.000059593243,2.665743e-7,0.00014030305,0.0006467866,0.00225505,0.94289976],"study_design_scores_gemma":[0.015120849,0.06277362,0.053679265,0.0000705539,0.00043060604,5.4484514e-7,0.00016806509,0.001063852,0.0038879241,0.0027517763,0.85985994,0.00019299873],"about_ca_topic_score_codex":0.000021918815,"about_ca_topic_score_gemma":0.0000022752129,"teacher_disagreement_score":0.94270676,"about_ca_system_score_codex":0.000058714017,"about_ca_system_score_gemma":0.00008051087,"threshold_uncertainty_score":0.4556118},"labels":[],"label_agreement":null},{"id":"W2088954563","doi":"10.1152/physiol.00030.2005","title":"Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential","year":2005,"lang":"en","type":"review","venue":"Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Proglucagon; Hypoglycemia; Glucagon; Glucagon-like peptide-1; Receptor; Glucagon receptor; Glucagon-like peptide-2; Type 2 diabetes; Medicine; Pharmacology; Diabetes mellitus; Endocrinology; Therapeutic approach; Disease; Internal medicine; Biology; Insulin; Peptide; Biochemistry","score_opus":0.057467880332073853,"score_gpt":0.34685035970241385,"score_spread":0.28938247937034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088954563","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006793301,0.9977183,0.00005955201,0.000033434502,0.00016811932,0.0010191011,0.000005624619,0.000035921963,0.00028066392],"genre_scores_gemma":[0.0049223225,0.99371713,0.00031252817,0.00006845769,0.00016824158,0.00013760786,0.00014720984,0.00002970741,0.0004968167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991933,0.000061476974,0.0002529404,0.00023632919,0.000075780445,0.00018015048],"domain_scores_gemma":[0.9994803,0.000025597685,0.00021002302,0.00021667371,0.000024996645,0.000042403928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047800688,0.00023459854,0.0011511798,0.00011359587,0.000023209805,0.000003762469,0.000056588677,0.00015242485,0.00008574671],"category_scores_gemma":[0.0000040595505,0.00016272035,0.00022967409,0.0000653761,0.00006391545,0.000019336198,0.000057328438,0.000108408836,0.000036651854],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021716662,0.00015717048,1.5113841e-7,0.006483341,0.0007304807,0.0000020415437,0.000017187902,1.5536531e-7,0.003420715,0.0005987466,0.000046729052,0.9885216],"study_design_scores_gemma":[0.0010410299,0.0011870533,0.00015614339,0.0028753956,0.0071022036,0.000024196808,0.00005461189,0.000015277845,0.00034567202,0.001861406,0.98506176,0.0002752601],"about_ca_topic_score_codex":0.0000045889506,"about_ca_topic_score_gemma":8.610398e-7,"teacher_disagreement_score":0.9882463,"about_ca_system_score_codex":0.00004041889,"about_ca_system_score_gemma":0.000048984577,"threshold_uncertainty_score":0.6635543},"labels":[],"label_agreement":null},{"id":"W2089560299","doi":"10.3810/pgm.2010.01.2108","title":"Reaching HbA<sub>1c</sub>Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs","year":2010,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Saxagliptin; Medicine; Glycemic; Type 2 diabetes; Vildagliptin; Hypoglycemia; Postprandial; Tolerability; Diabetes mellitus; Glycated hemoglobin; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Metformin; Pharmacology; Endocrinology; Adverse effect; Sitagliptin","score_opus":0.03119454403990676,"score_gpt":0.3018268130513877,"score_spread":0.27063226901148096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089560299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02789144,0.9554837,0.00004684714,0.002875677,0.00041596006,0.005342554,0.000020780548,0.00025955657,0.0076635303],"genre_scores_gemma":[0.009847187,0.9848782,0.0006658687,0.0007229424,0.00036466445,0.00043298368,0.0011691663,0.00032365078,0.0015953475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606025,0.00024947367,0.0009813784,0.00092497567,0.0009749215,0.0008089802],"domain_scores_gemma":[0.9976757,0.00023748146,0.0006818692,0.00092068466,0.00016420019,0.0003200748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001086998,0.001040139,0.0034293698,0.0011114399,0.00009192374,0.00003966193,0.00027160184,0.00031174,0.000065515946],"category_scores_gemma":[0.00012428146,0.0005897976,0.00019780805,0.001050325,0.0003596554,0.00014678984,0.00008223651,0.0011403149,0.00012608165],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013795985,0.0006624975,0.0016007418,0.009472141,0.00071280194,0.0002933681,0.000480815,2.6626057e-7,0.00005400419,0.00023292609,0.00081237726,0.9855401],"study_design_scores_gemma":[0.011235675,0.004027471,0.0010609992,0.083181106,0.0087338565,0.00012395048,0.00015118292,0.000020653413,0.00013061441,0.00008577506,0.89026946,0.0009792402],"about_ca_topic_score_codex":0.00027917585,"about_ca_topic_score_gemma":0.00019456577,"teacher_disagreement_score":0.98456085,"about_ca_system_score_codex":0.0003269058,"about_ca_system_score_gemma":0.00023608765,"threshold_uncertainty_score":0.99965537},"labels":[],"label_agreement":null},{"id":"W2089657724","doi":"10.14740/jem.v4i5.243","title":"Significant Differences in Effects of Sitagliptin Treatment on Body Weight and Lipid Metabolism Between Obese and Non-Obese Patients With Type 2 Diabetes","year":2014,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Endocrinology; Sitagliptin; Body mass index; Blood pressure; Triglyceride; Type 2 diabetes; Obesity; Lipid profile; Weight change; Renal function; Blood lipids; Diabetes mellitus; High-density lipoprotein; Weight loss; Cholesterol","score_opus":0.007092657959354466,"score_gpt":0.22163910232423165,"score_spread":0.2145464443648772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089657724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393713,0.005024133,0.000004656162,0.0001862698,0.00023276292,0.00038333994,0.000003789969,0.000005640376,0.00022225267],"genre_scores_gemma":[0.9955806,0.0036961678,0.0003404561,0.00008013589,0.00017997205,0.000011674862,0.0000062460517,0.000013661071,0.00009110201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880934,0.00012278548,0.0003619334,0.00021897037,0.00017769555,0.00030925072],"domain_scores_gemma":[0.9990001,0.0003309548,0.00026697404,0.00014241683,0.00009300648,0.00016659877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012586135,0.0002493833,0.0010346489,0.00037484794,0.000040195002,0.000012957961,0.000057401314,0.00006667074,0.000005464049],"category_scores_gemma":[0.000091965245,0.00014326068,0.000053101492,0.000108102184,0.00016904264,0.00010195119,0.00004455496,0.00015889501,9.783039e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004082989,0.0007227768,0.9546998,0.00017184467,0.0008981522,0.000041297757,0.00028946908,2.0424187e-7,0.0018797381,0.0006096914,0.000025195834,0.0402535],"study_design_scores_gemma":[0.0097327605,0.0039184885,0.97558767,0.00021407318,0.0015292856,0.0000031929635,0.00003053405,0.000005886953,0.0057294746,0.00019611944,0.0029313785,0.00012113782],"about_ca_topic_score_codex":0.00001381105,"about_ca_topic_score_gemma":0.000003923458,"teacher_disagreement_score":0.040132362,"about_ca_system_score_codex":0.000014615363,"about_ca_system_score_gemma":0.000021560623,"threshold_uncertainty_score":0.58420014},"labels":[],"label_agreement":null},{"id":"W2089828771","doi":"10.1002/pds.1834","title":"Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case‐control study","year":2010,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Sanofi; AstraZeneca; Pfizer","keywords":"Medicine; Metformin; Sulfonylurea; Internal medicine; Combination therapy; Cohort; Type 2 diabetes; Nested case-control study; Cohort study; Relative risk; Population; Diabetes mellitus; Insulin; Endocrinology; Confidence interval","score_opus":0.01995787504680979,"score_gpt":0.32187380815476285,"score_spread":0.30191593310795306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089828771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942693,0.0021793377,0.000034085977,0.0016576279,0.000056323242,0.0015771918,0.000003080539,0.000013508163,0.00020952079],"genre_scores_gemma":[0.99802935,0.0011946678,0.00014421078,0.0004251118,0.000018471512,0.00007578959,0.00000867967,0.000007111656,0.00009660641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988125,0.0005319576,0.0002624933,0.00019476628,0.000051633782,0.00014667732],"domain_scores_gemma":[0.9985768,0.0010993256,0.000118093376,0.00011166622,0.000042111045,0.00005195486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002776601,0.00012688975,0.0004341459,0.00007926556,0.00006805136,0.000004030174,0.000026998921,0.00004158032,0.000016859341],"category_scores_gemma":[0.00014868699,0.00006880562,0.000022102859,0.00009764925,0.00018280023,0.00007781375,0.000024213165,0.00016811493,2.9602847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027373,0.0005023454,0.9395403,0.000043920212,0.00043477194,0.000036847032,0.0007133729,0.0000022397558,0.00020184075,0.0029614766,0.000026048003,0.052799486],"study_design_scores_gemma":[0.039920647,0.0010934169,0.9530047,0.000033848264,0.0007857151,0.00007862338,0.00039640703,0.002634564,0.0001451164,0.001338354,0.00046192767,0.00010663616],"about_ca_topic_score_codex":0.00012386499,"about_ca_topic_score_gemma":0.00017975603,"teacher_disagreement_score":0.05269285,"about_ca_system_score_codex":0.000006880363,"about_ca_system_score_gemma":0.000014569673,"threshold_uncertainty_score":0.28058115},"labels":[],"label_agreement":null},{"id":"W2089982846","doi":"10.1007/s11906-015-0551-3","title":"Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?","year":2015,"lang":"en","type":"review","venue":"Current Hypertension Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Diabetic nephropathy; Blood pressure; Dapagliflozin; Canagliflozin; Pharmacology; Nephrology; Urology; Renal function; Internal medicine; Intensive care medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.08265500050740061,"score_gpt":0.3309756649838896,"score_spread":0.24832066447648898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089982846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008322801,0.9919536,0.0000013306897,0.00012547705,0.0022003856,0.0033177359,0.000014866712,0.00022644654,0.0013278892],"genre_scores_gemma":[0.000169208,0.9962411,0.00012122623,0.00013865044,0.00050707685,0.0002781496,0.0003735409,0.00013976211,0.002031303],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960815,0.00011792623,0.001072868,0.0013632529,0.00079197687,0.0005725091],"domain_scores_gemma":[0.9959894,0.000061203886,0.0015288804,0.001114555,0.0007439104,0.0005620766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005247742,0.0008918538,0.0036756606,0.00048072345,0.00014895263,0.000073094336,0.0000817266,0.0003795936,0.00003076494],"category_scores_gemma":[0.0004305876,0.00061606395,0.00057062705,0.0004758229,0.00014226804,0.00013403413,0.00035722353,0.0005988652,0.00008805782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012928954,0.0003377236,0.00013342612,0.01006571,0.00044277965,0.0052972967,0.000024292593,4.134727e-8,7.841374e-7,0.0000068306954,0.07858443,0.9050937],"study_design_scores_gemma":[0.0005930168,0.00016135903,0.00010913149,0.0339769,0.0059219245,0.0030846277,0.00009061172,0.0000045018996,0.0000031306647,0.00006736572,0.95541984,0.00056757877],"about_ca_topic_score_codex":0.000023446637,"about_ca_topic_score_gemma":0.0000010130747,"teacher_disagreement_score":0.9045262,"about_ca_system_score_codex":0.00028724855,"about_ca_system_score_gemma":0.00033432385,"threshold_uncertainty_score":0.9996291},"labels":[],"label_agreement":null},{"id":"W2090096004","doi":"10.1016/j.jval.2011.08.1316","title":"PDB13 A Prospective Registry to Identify Patients' Characteristics Associated with Achieving Target Metabolic Control After Three Months Treatment with Insulin Glulisine in Type 1 And 2 Diabetes Mellitus Patients Previously Uncontrolled on Basal Insulin and/or Other Anti-Diabetic Treatment (API Registry)","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital; Sanofi (Canada); University of Toronto","funders":"","keywords":"Medicine; Diabetes mellitus; Insulin; Type 2 Diabetes Mellitus; Internal medicine; Prospective cohort study; Type 2 diabetes; Population; Type 1 diabetes; Logistic regression; Odds ratio; Endocrinology","score_opus":0.017002703349487922,"score_gpt":0.24817811634583484,"score_spread":0.23117541299634692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090096004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891046,0.0029162287,0.00000904357,0.00031039974,0.000094291376,0.007217936,0.00017024312,0.000060246017,0.000117007854],"genre_scores_gemma":[0.9961591,0.0010755971,0.00063551334,0.0006018907,0.00004481134,0.0011234246,0.00012129559,0.000090652604,0.00014775892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686784,0.00028386543,0.00077217555,0.0008497499,0.00039917225,0.0008271967],"domain_scores_gemma":[0.998238,0.00018416217,0.00048254404,0.0005169041,0.00018989432,0.00038845552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035564922,0.00063434994,0.0015378204,0.0003864714,0.00008962036,0.00005742811,0.00009121121,0.00013448218,0.00003341162],"category_scores_gemma":[0.00023074343,0.00039781124,0.00006009169,0.0005956274,0.00010434568,0.0001380086,0.00003989488,0.00018085628,0.0000073945916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009273516,0.005500644,0.9700118,0.00017726776,0.0007635004,0.000075983255,0.0019811864,0.000031097323,0.0000036176496,0.000028662676,0.000007305674,0.012145454],"study_design_scores_gemma":[0.035343997,0.027649071,0.93392664,0.0014477104,0.00042987536,3.920327e-7,0.000057996785,0.00048729693,0.000040370116,0.00003112685,0.00024190785,0.0003436393],"about_ca_topic_score_codex":0.0021326058,"about_ca_topic_score_gemma":0.0010892644,"teacher_disagreement_score":0.03608515,"about_ca_system_score_codex":0.0009770541,"about_ca_system_score_gemma":0.00026123153,"threshold_uncertainty_score":0.99984735},"labels":[],"label_agreement":null},{"id":"W2090414284","doi":"10.1503/cmaj.050748","title":"Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute of Health Economics","funders":"University of Alberta","keywords":"Medicine; Hazard ratio; Sulfonylurea; Internal medicine; Cohort; Metformin; Proportional hazards model; Confidence interval; Diabetes mellitus; Cohort study; Retrospective cohort study; Population; Type 2 diabetes; Type 2 Diabetes Mellitus; Insulin; Endocrinology; Environmental health","score_opus":0.008067022187794058,"score_gpt":0.2533730650975468,"score_spread":0.24530604290975275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090414284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936607,0.00018964487,0.0000038887133,0.004762006,0.00018043241,0.00055509084,0.000009333605,0.000020689404,0.00061820744],"genre_scores_gemma":[0.99835783,0.000015945176,0.00004122614,0.00079463463,0.0003704147,0.000016453228,0.00013698496,0.000014215432,0.00025227718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975678,0.0003288137,0.00050481927,0.00019629035,0.0010338239,0.00036846384],"domain_scores_gemma":[0.9986427,0.00030690836,0.00018139124,0.00011582763,0.00015821194,0.000594961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031968318,0.00013631444,0.00033655312,0.0003689628,0.00013461939,0.00006822984,0.00006117302,0.0002004447,0.0003527372],"category_scores_gemma":[0.0007814729,0.00012517962,0.000053723208,0.000365114,0.000019124522,0.000113914444,0.000008917746,0.00037909843,0.000021752783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028502482,0.000115401956,0.9940963,0.000007766366,0.00016514414,0.00008022723,0.00008188759,0.000013690816,0.0000013073634,0.000025667934,0.0013042904,0.0040798313],"study_design_scores_gemma":[0.0024557011,0.00017664995,0.9930786,0.000057920657,0.00023003218,0.0000010553401,0.000103433944,0.00032928988,0.000002260956,0.00014535933,0.003310494,0.00010920128],"about_ca_topic_score_codex":0.012097652,"about_ca_topic_score_gemma":0.026000371,"teacher_disagreement_score":0.013902719,"about_ca_system_score_codex":0.0014455377,"about_ca_system_score_gemma":0.0007489962,"threshold_uncertainty_score":0.99448085},"labels":[],"label_agreement":null},{"id":"W2090532872","doi":"10.1371/journal.pone.0006080","title":"Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin","year":2009,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Ministry of Health; University of British Columbia","funders":"Ministry of Health, British Columbia","keywords":"Metformin; Rosiglitazone; Myocardial infarction; Medicine; Internal medicine; Cardiology; Receptor; Insulin","score_opus":0.020391720089602633,"score_gpt":0.21589610276714563,"score_spread":0.195504382677543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090532872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402,0.00033560625,0.0000024303117,0.0003948011,0.00001934925,0.00092354533,0.0000016953848,0.00004703338,0.0042555765],"genre_scores_gemma":[0.997501,0.00020297436,0.0009699433,0.0003967024,0.00004766084,0.000039248913,0.000051956977,0.000008138657,0.0007823681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925816,0.00001581115,0.0001558226,0.0001633817,0.00022250766,0.0001843012],"domain_scores_gemma":[0.99970806,0.000010052592,0.000032394815,0.00014301643,0.000034650817,0.000071844355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008929747,0.000095656105,0.00023279234,0.00011067536,0.000019247796,0.000013651183,0.000024557663,0.00003839916,0.000018726148],"category_scores_gemma":[0.000047636917,0.00008408746,0.000035595593,0.00010286866,0.000013507293,0.00012499306,0.000021467691,0.00006203366,0.000017579281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006101495,0.011419695,0.8764577,0.00023048602,0.00093324046,0.000013016599,0.0007288244,9.697126e-7,0.002774338,0.00031973323,0.0007813905,0.105730444],"study_design_scores_gemma":[0.004673131,0.0019692506,0.9898064,0.0002364494,0.0006008398,1.9530297e-7,0.00001550969,0.000055344335,0.0019694353,0.00023156898,0.00033814018,0.00010374038],"about_ca_topic_score_codex":0.000014343805,"about_ca_topic_score_gemma":0.0000038071314,"teacher_disagreement_score":0.113348685,"about_ca_system_score_codex":0.000069806694,"about_ca_system_score_gemma":0.000007617971,"threshold_uncertainty_score":0.34289873},"labels":[],"label_agreement":null},{"id":"W2090990145","doi":"10.1016/s1262-3636(14)72692-8","title":"SGLT-2 inhibition in patients with kidney disease","year":2014,"lang":"en","type":"review","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Medicine; Albuminuria; Renal function; Kidney; Dialysis; Diabetes mellitus; Kidney disease; Intensive care medicine; Empagliflozin; Blood pressure; Pharmacology; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.009974918772914045,"score_gpt":0.25325101516372717,"score_spread":0.24327609639081313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090990145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045828843,0.99018466,0.0000022978727,0.00007439867,0.0003547601,0.002790135,0.00013435625,0.000099469005,0.0017770072],"genre_scores_gemma":[0.0006744497,0.9885983,0.00017795383,0.0010845684,0.00036310346,0.0008577432,0.0066173845,0.00015099294,0.0014755079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741316,0.00014921211,0.0006118968,0.00067682005,0.000514889,0.0006340204],"domain_scores_gemma":[0.9981964,0.000055870973,0.0003171154,0.00074120687,0.00008476709,0.00060462876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022110998,0.00068900886,0.002587132,0.00061979494,0.000043443302,0.000054371387,0.00011021442,0.00017297688,0.00018965517],"category_scores_gemma":[0.00012553237,0.00046549123,0.0004524307,0.00051577797,0.00007024168,0.00014630462,0.000109896384,0.00029945475,0.0005044147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003622163,0.0010404738,0.013923466,0.022431308,0.0007417315,0.000030025267,0.000016773305,2.1871362e-7,6.1394154e-8,0.000576963,0.0051637874,0.95603895],"study_design_scores_gemma":[0.0030087708,0.00011571394,0.018163709,0.016499437,0.007002791,7.075899e-8,8.258637e-7,0.0000022956133,9.377396e-7,0.000055389377,0.9547076,0.00044242997],"about_ca_topic_score_codex":0.0000029446742,"about_ca_topic_score_gemma":6.5819086e-7,"teacher_disagreement_score":0.95559657,"about_ca_system_score_codex":0.00012696443,"about_ca_system_score_gemma":0.00014988269,"threshold_uncertainty_score":0.9997797},"labels":[],"label_agreement":null},{"id":"W2091122818","doi":"10.1136/bmj.f2267","title":"Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study","year":2013,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Innovates; Alberta Innovates - Health Solutions; Canadian Diabetes Association","keywords":"Sitagliptin; Medicine; Hazard ratio; Retrospective cohort study; Internal medicine; Cohort; Type 2 diabetes; Population; Proportional hazards model; Cohort study; Diabetes mellitus; Confidence interval; Emergency medicine; Endocrinology; Environmental health","score_opus":0.008254085960437661,"score_gpt":0.26202706267238307,"score_spread":0.25377297671194543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091122818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940085,0.0000105805375,0.000005288893,0.000017502878,0.000028192911,0.004857045,0.0000031101592,0.000013084687,0.0010566851],"genre_scores_gemma":[0.99958736,3.944879e-7,0.00012626873,0.000016107862,0.0000067463616,0.0001249763,0.00009621606,0.0000074750187,0.000034433047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992883,0.000101397185,0.00015644275,0.00017421927,0.00017890008,0.00010074104],"domain_scores_gemma":[0.9995541,0.00006723703,0.000076528486,0.00013887782,0.00013167957,0.000031594696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023276808,0.000096364645,0.0003592877,0.00008280399,0.000017094333,0.000006155851,0.00001891675,0.000020357666,0.000019245745],"category_scores_gemma":[0.000028470284,0.000069255795,0.000013262521,0.00017452396,0.000020023548,0.000074504445,0.000017320506,0.00004000633,0.000011207732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005291317,0.00085861044,0.9980235,0.000060800718,0.00018988467,7.729021e-7,0.000093781055,0.00002730543,0.000015695961,0.000015553944,0.000034874804,0.00015009593],"study_design_scores_gemma":[0.005092343,0.0025820506,0.99161685,0.00014578534,0.00012932958,1.0611131e-8,0.000081167476,0.00019798923,0.0000667114,0.000014790462,0.0000023004122,0.00007065316],"about_ca_topic_score_codex":0.00022764203,"about_ca_topic_score_gemma":0.00003750893,"teacher_disagreement_score":0.0064066234,"about_ca_system_score_codex":0.000116243005,"about_ca_system_score_gemma":0.000009965173,"threshold_uncertainty_score":0.28241694},"labels":[],"label_agreement":null},{"id":"W2091475095","doi":"10.1186/1745-6215-10-12","title":"Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality","year":2009,"lang":"en","type":"article","venue":"Trials","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"University of Alberta","keywords":"Metformin; Medicine; Heart failure; Diabetes mellitus; Clinical equipoise; Intensive care medicine; MEDLINE; Clinical research; Clinical trial; Internal medicine; Endocrinology","score_opus":0.2059055526430975,"score_gpt":0.4526784786941658,"score_spread":0.24677292605106826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091475095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701151,0.0025005138,0.0000032556015,0.023325004,0.00013607803,0.0023055312,0.000011228967,0.000086977154,0.0015162991],"genre_scores_gemma":[0.9929976,0.001331233,0.0020997394,0.0017860061,0.0003861709,0.00013250891,0.00005840315,0.000015976533,0.0011923934],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99755263,0.00043043026,0.0010463684,0.00039439453,0.00020148928,0.0003746578],"domain_scores_gemma":[0.9985688,0.0006959752,0.00017320675,0.00032877186,0.000020060443,0.00021318412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040208893,0.00022737884,0.0013145126,0.00014693353,0.000031636388,0.000022552318,0.000063123196,0.0001776965,0.00009853693],"category_scores_gemma":[0.0007790311,0.00015468853,0.00021723214,0.000113652684,0.000055104887,0.00012143123,0.00003448026,0.00013960434,0.000042964944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011570392,0.002147689,0.24326622,0.00009518071,0.0008670269,0.000079042475,0.00058761396,0.000001615179,0.0047504636,0.0027085626,0.056563366,0.68777615],"study_design_scores_gemma":[0.03770446,0.007904835,0.4968215,0.00042867963,0.0025073108,0.000005540401,0.00014847968,0.00008572529,0.012194092,0.017169897,0.4244504,0.00057909446],"about_ca_topic_score_codex":0.000041155265,"about_ca_topic_score_gemma":0.000027909844,"teacher_disagreement_score":0.6871971,"about_ca_system_score_codex":0.00012318783,"about_ca_system_score_gemma":0.000048592105,"threshold_uncertainty_score":0.6308015},"labels":[],"label_agreement":null},{"id":"W2091942573","doi":"10.1016/j.regpep.2004.07.019","title":"GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice","year":2004,"lang":"en","type":"review","venue":"Regulatory Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital","funders":"Juvenile Diabetes Research Foundation Canada; Canadian Diabetes Association; Canada Research Chairs; Juvenile Diabetes Research Foundation International","keywords":"Incretin; Endocrinology; Internal medicine; Glucose homeostasis; Gastric inhibitory polypeptide; Gastric emptying; Glucagon-like peptide-1; Receptor; Glucagon; Glucagon receptor; Type 2 diabetes; Insulin; Diabetes mellitus; Biology; Insulin resistance; Medicine; Stomach","score_opus":0.04324344547128407,"score_gpt":0.3122055570347935,"score_spread":0.26896211156350947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091942573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04838631,0.9467019,0.0000013109023,0.00026537784,0.0001394326,0.0015350862,0.000085482585,0.00017197167,0.0027131694],"genre_scores_gemma":[0.0024057673,0.98718834,0.0014559389,0.00012577078,0.00040585184,0.00018096277,0.0008624739,0.00015250721,0.007222408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740195,0.00011199574,0.0006507184,0.0009662405,0.00037745942,0.00049162784],"domain_scores_gemma":[0.9983047,0.00020304037,0.0003844722,0.0006706765,0.000057335354,0.00037977996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002998969,0.00078194425,0.0021103397,0.00029437433,0.0001909349,0.0001689313,0.00017557401,0.0004633495,0.00022053419],"category_scores_gemma":[0.0000568849,0.0006412983,0.00032196488,0.00021276556,0.0004754422,0.00014563803,0.00032780142,0.00032913306,0.00029659952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016784681,0.00035021582,0.0001811397,0.021743052,0.0018176239,0.000098217366,0.0005893876,1.8132941e-7,0.00028640308,0.00121248,0.007467364,0.9660861],"study_design_scores_gemma":[0.0020637682,0.00037652344,0.00035800878,0.025746446,0.0037298175,0.000032626744,0.0001637908,6.510178e-7,0.00013910353,0.00018541302,0.96659845,0.00060542126],"about_ca_topic_score_codex":0.00044036092,"about_ca_topic_score_gemma":0.000032882537,"teacher_disagreement_score":0.9654807,"about_ca_system_score_codex":0.00040651657,"about_ca_system_score_gemma":0.0002855497,"threshold_uncertainty_score":0.9996038},"labels":[],"label_agreement":null},{"id":"W2091977092","doi":"10.2337/dc13-0512","title":"Personalized Management of Hyperglycemia in Type 2 Diabetes","year":2013,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Genentech; Servier; Chinese University of Hong Kong; Sanofi; Halozyme; F. Hoffmann-La Roche; Novo Nordisk; Daiichi-Sankyo; Teva Pharmaceutical Industries; Intarcia Therapeutics; MannKind Corporation; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Diabetes management; Personalized medicine; Diabetes mellitus; Type 2 diabetes; Specialty; Intensive care medicine; MEDLINE; Disease management; Prediabetes; Clinical trial; Precision medicine; Alternative medicine; Family medicine; Bioinformatics; Internal medicine; Health management system; Pathology","score_opus":0.009486422332321737,"score_gpt":0.23223795481317142,"score_spread":0.22275153248084967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091977092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97447735,0.003206771,2.951608e-7,0.00022913693,0.00014896572,0.00085707277,0.0000071228083,0.000056622055,0.021016637],"genre_scores_gemma":[0.99664396,0.00018601837,0.00096703874,0.00036675905,0.000028977991,0.00019125444,0.00016002623,0.000029757533,0.0014262273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987994,0.00002178206,0.00025345047,0.00027097698,0.00024722182,0.00040717144],"domain_scores_gemma":[0.9993514,0.000029388251,0.0000621083,0.00033505814,0.00012608482,0.00009595929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056369994,0.00019316404,0.00040312114,0.00018277773,0.000021591708,0.000017245733,0.0001129844,0.0000639484,0.0006447594],"category_scores_gemma":[0.000010970439,0.00016556265,0.000115588504,0.0003571196,0.00007064988,0.00009967796,0.000092196366,0.00007818487,0.0005168192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018711486,0.00017033757,0.9518648,0.0012062399,0.00034907582,0.000010150391,0.00040629148,0.000003969586,0.0015343642,0.0004987799,0.002476947,0.04146036],"study_design_scores_gemma":[0.0045452304,0.00064730947,0.96729803,0.00085586077,0.00046974566,1.1817435e-7,0.003874419,0.00016739107,0.008328492,0.00023832102,0.013249445,0.00032565132],"about_ca_topic_score_codex":0.000009977464,"about_ca_topic_score_gemma":0.0000017838424,"teacher_disagreement_score":0.04113471,"about_ca_system_score_codex":0.00010252417,"about_ca_system_score_gemma":0.000014665382,"threshold_uncertainty_score":0.70596635},"labels":[],"label_agreement":null},{"id":"W2092344163","doi":"10.1021/bi000497p","title":"Structural Determinants for Activity of Glucagon-like Peptide-2","year":2000,"lang":"en","type":"article","venue":"Biochemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Alanine; Peptide; Receptor; Chemistry; Amino acid; Stereochemistry; Ligand (biochemistry); Biochemistry; Glucagon-like peptide-2; Circular dichroism; Glucagon-like peptide 1 receptor; Oligopeptide; Agonist","score_opus":0.014236962502838887,"score_gpt":0.2731730360625533,"score_spread":0.2589360735597144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092344163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946877,0.000090194706,0.0000027687106,0.000056672005,0.000046659832,0.00022682155,0.000021301503,0.00002416267,0.0048437347],"genre_scores_gemma":[0.9794658,0.000014758669,0.0004985754,0.000046955094,0.000070935814,0.000025165178,0.000029587167,0.000009962206,0.01983829],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994947,0.0000023311118,0.0001000175,0.00015981498,0.00009041634,0.00015277124],"domain_scores_gemma":[0.9996478,0.0000143766665,0.000040405215,0.00021583494,0.000024531388,0.000057044846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028904078,0.00009780462,0.00017034801,0.000013372714,0.00002424001,0.000004856963,0.000053002866,0.000051980955,0.00028820412],"category_scores_gemma":[0.000010559305,0.000082275656,0.00009412706,0.00003978702,0.0000395294,0.000025448315,0.000014756417,0.000027427976,0.000008273218],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007386768,0.00032584846,0.024554854,0.0012142338,0.00027232026,0.00001747946,0.000063800675,0.0000013510944,0.5000755,0.000007471147,0.007083729,0.4656447],"study_design_scores_gemma":[0.0014524948,0.00015744564,0.018981542,0.000066364686,0.00014979151,0.0000046040605,0.0000144067335,0.00021010426,0.9750083,0.00002219314,0.0038353559,0.00009741217],"about_ca_topic_score_codex":0.000008989889,"about_ca_topic_score_gemma":7.9130785e-7,"teacher_disagreement_score":0.47493273,"about_ca_system_score_codex":0.000030549254,"about_ca_system_score_gemma":0.000025941872,"threshold_uncertainty_score":0.3355104},"labels":[],"label_agreement":null},{"id":"W2092434810","doi":"10.1177/1479164112441526","title":"GLP-1 receptor agonists: A clinical perspective on cardiovascular effects","year":2012,"lang":"en","type":"review","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Liraglutide; Exenatide; Agonist; Glucagon-like peptide-1; Incretin; Heart failure; Glucagon-like peptide 1 receptor; Type 2 diabetes; Diabetes mellitus; Myocardial infarction; Blood pressure; Internal medicine; Receptor; Pharmacology; Endocrinology","score_opus":0.13312816773917574,"score_gpt":0.4480097301496274,"score_spread":0.3148815624104517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092434810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045849773,0.9912571,0.00000220761,0.000108301574,0.0003446242,0.005126649,0.00006940136,0.00010180811,0.0025314542],"genre_scores_gemma":[0.0003326482,0.9950648,0.000060095324,0.000093860544,0.001204713,0.0016713367,0.00051492493,0.00017709332,0.00088054215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99273413,0.0019965502,0.00060782384,0.0014465603,0.0017657084,0.0014492252],"domain_scores_gemma":[0.9948122,0.0010332488,0.00010986345,0.0018777234,0.0003509713,0.001816022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003912729,0.0007639086,0.0033625276,0.0006877687,0.00031794404,0.0001781466,0.00030461568,0.00041249793,0.00012260064],"category_scores_gemma":[0.0008349101,0.00054638786,0.0043316046,0.00069693965,0.0004722289,0.00010328222,0.00048107663,0.0012483007,0.0010407132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035672238,0.0014884097,0.0008872123,0.04169178,0.018036453,0.00009984316,0.000032269476,7.645213e-8,6.151108e-8,0.0018386855,0.0022617816,0.9336278],"study_design_scores_gemma":[0.0015679224,0.0007039686,0.0013930524,0.013385269,0.018069971,5.668715e-7,0.000048985516,0.0000047843437,5.738063e-7,0.00009192077,0.96424496,0.0004880416],"about_ca_topic_score_codex":0.00001792134,"about_ca_topic_score_gemma":4.1664381e-7,"teacher_disagreement_score":0.96198314,"about_ca_system_score_codex":0.0006680663,"about_ca_system_score_gemma":0.00043831434,"threshold_uncertainty_score":0.9997371},"labels":[],"label_agreement":null},{"id":"W2092926285","doi":"10.1111/j.1749-6632.2000.tb06970.x","title":"New Developments in the Biology of the Glucagon‐Like Peptides GLP‐1 and GLP‐2","year":2000,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Proglucagon; Glucagon-like peptide-2; Enteroendocrine cell; Glucagon-like peptide-1; Islet; Gastric emptying; Biology; Receptor; Glucagon; Internal medicine; Signal transduction; Gastrointestinal hormone; Endocrinology; Glucagon receptor; Cell biology; Hormone; Diabetes mellitus; Peptide hormone; Endocrine system; Medicine; Peptide; Type 2 diabetes; Biochemistry; Stomach","score_opus":0.15389881771568414,"score_gpt":0.39401272786194536,"score_spread":0.2401139101462612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092926285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045502074,0.9828738,2.8022845e-7,0.007125082,0.00010633489,0.0009977018,0.000008380227,0.0000052647138,0.004332938],"genre_scores_gemma":[0.0053228037,0.98988867,0.00033072254,0.0013393266,0.00007227547,0.000013095519,0.0000019544505,0.000009091112,0.003022055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979801,0.00019367723,0.00068841246,0.00033268044,0.00048328156,0.0003218504],"domain_scores_gemma":[0.9987684,0.0002701036,0.0006596956,0.00022031533,0.000015371777,0.00006613529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011402264,0.00027016556,0.001030981,0.00019456047,0.00012162563,0.000019101743,0.0014830821,0.00018237003,0.000029581553],"category_scores_gemma":[0.000077432815,0.00010629445,0.0003260987,0.0010776606,0.0010557021,0.00006808928,0.0002845193,0.00025682143,0.000004532099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009195884,0.00005596152,0.0010597599,0.0010463935,0.00018603085,1.543142e-7,0.00042502367,8.85381e-7,0.000005837227,0.0014524485,0.018235764,0.97752255],"study_design_scores_gemma":[0.00024539934,0.00013913632,0.003782036,0.006878199,0.00039544582,0.0000043261634,0.00010946189,4.7677983e-7,0.0002625063,0.002312536,0.9857638,0.00010670937],"about_ca_topic_score_codex":0.00020159504,"about_ca_topic_score_gemma":0.000011311368,"teacher_disagreement_score":0.97741586,"about_ca_system_score_codex":0.00001200746,"about_ca_system_score_gemma":0.00042861508,"threshold_uncertainty_score":0.43345618},"labels":[],"label_agreement":null},{"id":"W2093652590","doi":"10.1007/s11883-014-0408-2","title":"Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors","year":2014,"lang":"en","type":"review","venue":"Current Atherosclerosis Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto; Toronto General Hospital","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Incretin; Dyslipidemia; Type 2 diabetes; Saxagliptin; Diabetes mellitus; Angiology; Bioinformatics; Dipeptidyl peptidase; Inflammation; Internal medicine; Pharmacology; Sitagliptin; Endocrinology; Enzyme","score_opus":0.03484905152691045,"score_gpt":0.3268820601098149,"score_spread":0.2920330085829045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093652590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022122818,0.99053246,0.000046768004,0.000006711941,0.002632992,0.00379448,0.000008200401,0.00018604974,0.0005800411],"genre_scores_gemma":[0.0029151465,0.9947808,0.00013018666,0.000015714624,0.00046862251,0.0005016336,0.00030199875,0.00021051882,0.00067537127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567384,0.00016160774,0.0018146836,0.0010192806,0.0007271303,0.00060343725],"domain_scores_gemma":[0.99586934,0.00020430675,0.0019525615,0.001546947,0.000114447175,0.0003124047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040502433,0.0009782057,0.004267608,0.0004267055,0.00007639471,0.000045949037,0.00018522715,0.00034058883,0.00008896244],"category_scores_gemma":[0.00020885529,0.0007268338,0.0019688786,0.0005004554,0.00018324342,0.00008926368,0.00022498112,0.00042051665,0.00013442754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028462564,0.0012103863,0.00092703174,0.116376944,0.00086948153,0.000058676233,0.00006988363,1.5578433e-7,0.000033981287,0.000028215194,0.0035662851,0.8768561],"study_design_scores_gemma":[0.0005856555,0.00043200966,0.00051990343,0.112882555,0.008143402,0.00003132251,0.0000027450617,0.0000013499811,0.00014255093,0.000016593169,0.8767089,0.00053297955],"about_ca_topic_score_codex":0.0000063258176,"about_ca_topic_score_gemma":5.474369e-7,"teacher_disagreement_score":0.8763231,"about_ca_system_score_codex":0.00023019388,"about_ca_system_score_gemma":0.00018362519,"threshold_uncertainty_score":0.9995183},"labels":[],"label_agreement":null},{"id":"W2094278085","doi":"10.1111/j.1440-1681.2008.04972.x","title":"ASSOCIATION BETWEEN µ‐OPIOID RECEPTOR‐1 102T&gt;C POLYMORPHISM AND INTERMEDIATE TYPE 2 DIABETES PHENOTYPES: RESULTS FROM THE QUEBEC FAMILY STUDY (QFS)","year":2008,"lang":"en","type":"article","venue":"Clinical and Experimental Pharmacology and Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research; Health Canada; Medical Research Council Canada","keywords":"Internal medicine; Endocrinology; Type 2 diabetes; Insulin; Glucose tolerance test; Diabetes mellitus; Impaired glucose tolerance; Medicine; Type 2 Diabetes Mellitus; Insulin resistance; Area under the curve","score_opus":0.03736234229593776,"score_gpt":0.3411612439285266,"score_spread":0.3037989016325888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094278085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933378,0.003682486,1.5958655e-7,0.0012594827,0.0009472082,0.00052497734,0.00004435392,0.000036621022,0.00016688707],"genre_scores_gemma":[0.99304795,0.0017656849,0.000022600474,0.0031885433,0.00090855,0.000039889892,0.00020942824,0.000012325012,0.0008050263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984478,0.0003194936,0.00041729887,0.0004654121,0.00008537998,0.0002646446],"domain_scores_gemma":[0.99850893,0.0010333597,0.00015031018,0.00012915596,0.000029141434,0.00014909745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027669425,0.00019909737,0.00052389404,0.000028118702,0.00021842495,0.000010144732,0.00007543463,0.000165717,0.000102592305],"category_scores_gemma":[0.00006186497,0.00013375668,0.00005580755,0.00005993532,0.00055418164,0.00006744605,0.00021837694,0.00025732093,0.00003965245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025940249,0.001609215,0.8608017,0.000014261133,0.0026282908,0.000015815236,0.0032695967,2.0364934e-7,0.07572826,0.00001844542,0.04453046,0.00878973],"study_design_scores_gemma":[0.0084445495,0.002542988,0.9747806,0.000012648519,0.0005537541,4.342644e-7,0.00068338995,0.000021927759,0.0032597552,0.000106906286,0.009440211,0.00015279997],"about_ca_topic_score_codex":0.00031709415,"about_ca_topic_score_gemma":0.000019105024,"teacher_disagreement_score":0.11397894,"about_ca_system_score_codex":0.000030790186,"about_ca_system_score_gemma":0.000023518884,"threshold_uncertainty_score":0.5454439},"labels":[],"label_agreement":null},{"id":"W2094364524","doi":"10.1185/03007995.2014.973939","title":"A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes","year":2014,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Canada","keywords":"Medicine; Liraglutide; Metformin; Type 2 diabetes; Clinical endpoint; Exenatide; Glycemic; Clinical trial; Internal medicine; Glucagon-like peptide 1 receptor; Hypoglycemia; Diabetes mellitus; Endocrinology; Insulin; Agonist; Receptor","score_opus":0.29486009570304916,"score_gpt":0.5409420813016502,"score_spread":0.24608198559860106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094364524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004053336,0.9932869,0.0000016539773,0.0002487885,0.00074223115,0.0015593346,0.000018663373,0.0000076270776,0.000081486265],"genre_scores_gemma":[0.0013414724,0.99801624,0.00006966474,0.0000092981845,0.00019901407,0.00013579073,0.00016781848,0.00001708879,0.000043616583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961236,0.00079019944,0.00076818577,0.0003572027,0.0015432421,0.00041758298],"domain_scores_gemma":[0.99727726,0.0015468063,0.0002604893,0.0003603327,0.0003387078,0.00021641525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039469535,0.00023133402,0.0016108113,0.00027518783,0.00007086419,0.000009213211,0.00026174256,0.0001506213,0.000053322197],"category_scores_gemma":[0.0058359327,0.00012550793,0.00020066982,0.0005357913,0.0006354122,0.000024514355,0.0006575783,0.0007359631,0.000009446437],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003722714,0.00040164206,0.0012604519,0.05747295,0.00024862232,5.944239e-7,0.00010394472,2.8739116e-8,0.000004630892,0.00012191371,0.0018531338,0.93849486],"study_design_scores_gemma":[0.0011915351,0.0011689799,0.0008196466,0.11221516,0.00018977202,4.1948374e-7,0.00004639499,0.00013372472,0.00004117243,0.00013577909,0.88393027,0.00012712237],"about_ca_topic_score_codex":0.000011684096,"about_ca_topic_score_gemma":0.000005153116,"teacher_disagreement_score":0.9383677,"about_ca_system_score_codex":0.000153753,"about_ca_system_score_gemma":0.00035831114,"threshold_uncertainty_score":0.6986578},"labels":[],"label_agreement":null},{"id":"W2094524041","doi":"10.1038/nrendo.2013.185","title":"Clinical inertia—a barrier to effective management of T2DM","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Intensive care medicine; Diabetes mellitus; Primary care; Type 2 Diabetes Mellitus; Family medicine; Endocrinology","score_opus":0.04980846245712591,"score_gpt":0.43009721993590144,"score_spread":0.38028875747877555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094524041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069650114,0.96443695,0.00001863091,0.00014541401,0.0011751681,0.014505087,0.000017312708,0.00006962817,0.019624844],"genre_scores_gemma":[0.0000044266944,0.9820588,0.0043407334,0.0009794532,0.0003437137,0.0038060367,0.00016651268,0.00008463637,0.008215678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953968,0.0006404578,0.001933152,0.0010222726,0.000288914,0.0007183862],"domain_scores_gemma":[0.99712557,0.00028438517,0.0007316502,0.0014180918,0.00012064764,0.00031968323],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005030703,0.0008200041,0.0066400426,0.00051609095,0.000032125532,0.000011407158,0.00047748126,0.00079847965,0.00038169313],"category_scores_gemma":[0.00022891875,0.0005169481,0.0019340834,0.0006127472,0.000113961156,0.000043456435,0.00057664985,0.0014522846,0.0025160217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013707958,0.00025321107,0.000045269855,0.05584671,0.0025458916,0.00017678675,0.000004602578,1.2082868e-8,1.2429533e-7,0.002071312,0.035132933,0.90390944],"study_design_scores_gemma":[0.0007629963,0.0006936566,0.00013811598,0.027023878,0.009710159,0.00004898395,0.0000036356955,1.0382856e-7,0.0000020756454,0.000022638114,0.96126086,0.00033289142],"about_ca_topic_score_codex":0.0000044545777,"about_ca_topic_score_gemma":0.0000013032943,"teacher_disagreement_score":0.9261279,"about_ca_system_score_codex":0.00019656448,"about_ca_system_score_gemma":0.00005745268,"threshold_uncertainty_score":0.9997282},"labels":[],"label_agreement":null},{"id":"W2094966569","doi":"10.1177/1479164109341691","title":"What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management","year":2009,"lang":"en","type":"article","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; General partnership; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Diabetes management; Control (management); Process (computing); Diabetes control; Risk analysis (engineering); Endocrinology","score_opus":0.09000592979041158,"score_gpt":0.42138970219317023,"score_spread":0.3313837724027586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094966569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8271618,0.012457249,0.00003671787,0.15210089,0.00006015355,0.007786115,0.00013505659,0.000036175163,0.00022586255],"genre_scores_gemma":[0.9874884,0.005458172,0.00036421427,0.0010007891,0.000114812006,0.0048879283,0.0006042949,0.000022759148,0.000058642458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975819,0.00043729038,0.00035428783,0.0005352631,0.00037698745,0.0007142544],"domain_scores_gemma":[0.9958354,0.0027622445,0.00011891149,0.00068650895,0.00035710298,0.00023978364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018922752,0.00022282977,0.00038181964,0.000116873896,0.00041022315,0.00024577224,0.0002186704,0.000061684004,0.00002109163],"category_scores_gemma":[0.0011110383,0.00013550701,0.00024798524,0.0006677574,0.00015423709,0.00033646365,0.00013504035,0.00015741253,0.0000028992504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017447765,0.0011301569,0.8584473,0.0004009353,0.0013909667,0.0000012545627,0.00019728999,0.0000068195613,0.00016592717,0.008599572,0.006893576,0.122591734],"study_design_scores_gemma":[0.0024123902,0.0004724799,0.94710904,0.001291535,0.0012255881,2.7418938e-8,0.0015171627,0.0017626948,0.0004893546,0.022361498,0.02117054,0.00018769984],"about_ca_topic_score_codex":0.0000054504953,"about_ca_topic_score_gemma":0.000017045357,"teacher_disagreement_score":0.16032661,"about_ca_system_score_codex":0.00019127675,"about_ca_system_score_gemma":0.00006403507,"threshold_uncertainty_score":0.55258155},"labels":[],"label_agreement":null},{"id":"W2095346349","doi":"10.1016/s1499-2671(09)33223-2","title":"Patient characteristics are associated with prescription of sitagliptin vs. other oral antihyperglycaemic agents based on an electronic medical record database from Us","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Medical prescription; Electronic medical record; Type 2 diabetes; Medical record; Diabetes mellitus; Database; Intensive care medicine; Internal medicine; Pharmacology; Emergency medicine; Endocrinology","score_opus":0.011381728184566236,"score_gpt":0.22124926975239906,"score_spread":0.20986754156783283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095346349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984936,0.00012679312,0.000009458465,0.00065345946,0.0001554906,0.0002117878,0.00019464776,0.000010333126,0.00014441037],"genre_scores_gemma":[0.9964625,0.000009563244,0.00014751586,0.0029162958,0.00009470392,0.0000026238968,0.0003056528,0.000024216019,0.000036906404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843246,0.00009899903,0.000403459,0.0001757035,0.0004522658,0.0004370905],"domain_scores_gemma":[0.9983924,0.000045440425,0.0004583412,0.00024175797,0.00018082176,0.0006812531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002489024,0.00018754372,0.0004767409,0.0002910377,0.000046396435,0.000025575668,0.00013510717,0.00009098692,0.00040749458],"category_scores_gemma":[0.00027004592,0.00014544546,0.00008511469,0.00015622491,0.00005423971,0.00014332948,0.000004838453,0.0002489686,0.0000037120237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014711701,0.00054962136,0.97974414,0.000019267747,0.00034118214,0.00015126585,0.00007933931,0.000011944437,0.0004711024,0.00001243852,0.0023876016,0.016084967],"study_design_scores_gemma":[0.0030685293,0.0069643166,0.98220795,0.0015250129,0.0005192779,8.026043e-7,0.00005034045,0.001704856,0.0008348345,0.00002290825,0.0029226737,0.00017851609],"about_ca_topic_score_codex":0.0004980026,"about_ca_topic_score_gemma":0.0058159125,"teacher_disagreement_score":0.015906451,"about_ca_system_score_codex":0.00033548733,"about_ca_system_score_gemma":0.00062380754,"threshold_uncertainty_score":0.59310937},"labels":[],"label_agreement":null},{"id":"W2095497214","doi":"10.1111/j.1463-1326.2006.00639.x","title":"A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes","year":2006,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk","keywords":"Insulin aspart; Medicine; Insulin; Diabetes mellitus; Internal medicine; Endocrinology; Type 2 diabetes; Metformin; Regular insulin; Human insulin; Hypoglycemia","score_opus":0.009411476953642984,"score_gpt":0.224953700820747,"score_spread":0.21554222386710403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095497214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97257334,0.019471066,7.160005e-7,0.00609184,0.00021742609,0.0011018438,0.00007060561,0.00004640718,0.00042676786],"genre_scores_gemma":[0.96522844,0.0007395803,0.0007850814,0.029518193,0.0005248393,0.000093017115,0.0020344614,0.00010361927,0.00097275845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753714,0.00011395738,0.0005909731,0.00063682673,0.0004962044,0.00062489486],"domain_scores_gemma":[0.99880075,0.00010714026,0.00033846675,0.00045106682,0.00018556153,0.00011698039],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002101595,0.0005517525,0.0018095252,0.00052996626,0.00006318346,0.0000511487,0.00012975367,0.00052267796,0.000024377112],"category_scores_gemma":[0.000046450023,0.00044406904,0.00009772454,0.0003962985,0.00025140814,0.00015218227,0.00013484686,0.0007177775,0.000008646345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003928622,0.00088035926,0.92938894,0.0012347917,0.00047124922,0.00001628139,0.00013027817,0.0000017155263,0.00003367738,0.000023456863,0.055642523,0.01213745],"study_design_scores_gemma":[0.0039769486,0.0006946176,0.7930215,0.000650463,0.0011514535,8.697335e-8,0.0000104545,0.00003523548,0.00056644715,0.00015181908,0.1993556,0.00038533926],"about_ca_topic_score_codex":0.00005805742,"about_ca_topic_score_gemma":0.000022609323,"teacher_disagreement_score":0.14371309,"about_ca_system_score_codex":0.000033975713,"about_ca_system_score_gemma":0.00004664266,"threshold_uncertainty_score":0.9998011},"labels":[],"label_agreement":null},{"id":"W2095717568","doi":"10.1586/14737167.4.2.135","title":"Economic benefits of pioglitazone for treating patients with Type 2 diabetes","year":2004,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Pioglitazone; Metformin; Type 2 diabetes; Medicine; Sulfonylurea; Diabetes mellitus; Insulin resistance; Intensive care medicine; Insulin; Internal medicine; Endocrinology","score_opus":0.03182937887154053,"score_gpt":0.4519257589841406,"score_spread":0.4200963801126001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095717568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95747626,0.03605825,0.0000043895716,0.0013962156,0.00015668466,0.0026092369,0.00006748912,0.000017884868,0.002213614],"genre_scores_gemma":[0.8833649,0.102469005,0.009329673,0.0023897544,0.00023585811,0.00074583007,0.00046958763,0.00013500052,0.0008603989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837375,0.00003982654,0.0006215158,0.00032489313,0.0002141473,0.00042584655],"domain_scores_gemma":[0.9986694,0.00025611982,0.00021788475,0.00038808124,0.0003280267,0.00014049711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006662687,0.00020887157,0.0009001442,0.00023067715,0.000057081194,0.000011269772,0.00020953949,0.000036714413,0.0002662328],"category_scores_gemma":[0.00009747604,0.00015326816,0.00021777199,0.00013081689,0.00010816469,0.0001424353,0.000103218816,0.0001018011,0.000039120827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009914458,0.003595717,0.6629695,0.026790613,0.0048644166,0.0000030271417,0.00081603025,0.0003112609,0.0014243592,0.0051045953,0.014861566,0.27826747],"study_design_scores_gemma":[0.12036265,0.024596682,0.2966054,0.058531553,0.003096957,0.000003161494,0.00076964195,0.00065707776,0.23198842,0.0009204916,0.2593657,0.0031022585],"about_ca_topic_score_codex":0.000043088294,"about_ca_topic_score_gemma":0.0000056278145,"teacher_disagreement_score":0.3663641,"about_ca_system_score_codex":0.00037173586,"about_ca_system_score_gemma":0.00016368303,"threshold_uncertainty_score":0.6250095},"labels":[],"label_agreement":null},{"id":"W2096303420","doi":"10.1016/j.jval.2014.03.1109","title":"The impact of alternative estimates of disutilities associated with hypoglycemia on net qalys: Canagliflozin versus sitagliptin as add-on therapy in individuals with type 2 diabetes mellitus (T2DM) inadequately controlled on a background of metformin (MET) plus sulfonylurea (SU) in the canadian setting","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Sitagliptin; Medicine; Hypoglycemia; Type 2 Diabetes Mellitus; Adverse effect; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.044760867475298415,"score_gpt":0.315457924689682,"score_spread":0.2706970572143836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096303420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948405,0.0006737438,3.3820652e-7,0.0004139964,0.000048509377,0.0021332444,0.0000624778,0.000008537786,0.001818639],"genre_scores_gemma":[0.9992512,0.00018907136,0.00007169449,0.00021003072,0.000017970468,0.00011562653,0.00008825211,0.000029807774,0.000026333606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969752,0.0007189079,0.0007337566,0.00028719413,0.00061466615,0.00067031424],"domain_scores_gemma":[0.99391335,0.004783076,0.0006571111,0.00039769968,0.00011429061,0.00013446156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028954195,0.00033140235,0.0010760115,0.00059937395,0.00008590416,0.00003159647,0.0002453491,0.00008766389,0.000014358296],"category_scores_gemma":[0.00075819547,0.0001668037,0.000089966714,0.0007798498,0.00018062277,0.000066492816,0.000017300512,0.0003195992,0.0000018722285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045767047,0.0029011548,0.77238256,0.0005760577,0.005493669,0.000072820934,0.028617727,0.095859505,0.00003653588,0.016639877,0.00042358888,0.031229481],"study_design_scores_gemma":[0.10975537,0.1144407,0.7209816,0.0070243194,0.00040574512,0.0000016097923,0.013661787,0.028596967,0.0017081341,0.0025094505,0.00022012557,0.0006941846],"about_ca_topic_score_codex":0.47005838,"about_ca_topic_score_gemma":0.23881069,"teacher_disagreement_score":0.23124768,"about_ca_system_score_codex":0.0014637805,"about_ca_system_score_gemma":0.0011720271,"threshold_uncertainty_score":0.775079},"labels":[],"label_agreement":null},{"id":"W2097008225","doi":"10.2337/db07-1202","title":"Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice","year":2007,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto","keywords":"Internal medicine; Endocrinology; Incretin; Sitagliptin; Glucose tolerance test; Medicine; Insulin; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Insulin tolerance test; Insulin resistance; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes; Diabetes mellitus","score_opus":0.010855282432589293,"score_gpt":0.25034023131759603,"score_spread":0.23948494888500674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097008225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960029,0.00017457064,0.00001608554,0.00016227285,0.000419148,0.00054172106,0.000009642133,0.00006917112,0.0026044485],"genre_scores_gemma":[0.9988564,0.000020966349,0.00028352794,0.0000877014,0.00013615853,0.000018772475,0.00027429752,0.000028179322,0.00029396842],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846625,0.000039349405,0.0004149525,0.0002988398,0.00028779462,0.0004927985],"domain_scores_gemma":[0.9992043,0.00024827363,0.00012746126,0.00025401436,0.000054962402,0.00011102462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021241554,0.00021504427,0.00046161845,0.00033198873,0.000034580476,0.00001568367,0.00006233718,0.00010286371,0.00018355377],"category_scores_gemma":[0.000121762576,0.00019839047,0.00011782717,0.000339273,0.00010235126,0.00007384634,0.00007520899,0.00012576052,0.000060131795],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020058446,0.0029855843,0.49536687,0.0007397803,0.0006362402,0.00012734138,0.000457754,0.000005676993,0.46036384,0.0017572115,0.0013787298,0.03417513],"study_design_scores_gemma":[0.010119059,0.00076745625,0.46891308,0.00026524102,0.00025022845,1.4142535e-7,0.000053774023,0.00004117172,0.5190393,0.00006254222,0.00031485982,0.00017317913],"about_ca_topic_score_codex":0.00007286808,"about_ca_topic_score_gemma":0.000021296952,"teacher_disagreement_score":0.05867544,"about_ca_system_score_codex":0.00010264216,"about_ca_system_score_gemma":0.00001668224,"threshold_uncertainty_score":0.80901283},"labels":[],"label_agreement":null},{"id":"W2097112828","doi":"10.1592/phco.2005.25.6.810","title":"Secondary Failure Rates Associated with Metformin and Sulfonylurea Therapy for Type 2 Diabetes Mellitus","year":2005,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Sulfonylurea; Metformin; Hazard ratio; Combination therapy; Internal medicine; Type 2 Diabetes Mellitus; Retrospective cohort study; Type 2 diabetes; Population; Diabetes mellitus; Cohort; Cohort study; Proportional hazards model; Confidence interval; Insulin; Endocrinology","score_opus":0.02235961912729856,"score_gpt":0.3275688447965729,"score_spread":0.30520922566927433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097112828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9199761,0.07252024,0.000012223282,0.0060499194,0.00017877445,0.0010726854,0.000008761084,0.000033598535,0.00014765296],"genre_scores_gemma":[0.92515284,0.06413978,0.00027887322,0.008935634,0.0005513481,0.00004617318,0.000015311223,0.00005830699,0.0008217239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850374,0.00024454616,0.00043418302,0.00020304725,0.0002067727,0.0004077141],"domain_scores_gemma":[0.99851567,0.0005080608,0.000425887,0.000119304175,0.00025634,0.00017474983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001261333,0.00034774005,0.00060125976,0.00020509283,0.0003486284,0.00004389968,0.00018527926,0.00007415493,0.00059923885],"category_scores_gemma":[0.0000060941434,0.000192075,0.00012455473,0.00016511886,0.0002948204,0.00030582497,0.000018428587,0.00037094962,0.0000015300257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013557029,0.002114393,0.011766102,0.00008005616,0.011838565,0.000036464364,0.006046148,0.00002898422,0.54890394,0.00014050293,0.07283931,0.3326485],"study_design_scores_gemma":[0.069967695,0.008649226,0.006449954,0.00011397417,0.0017729341,0.0001042164,0.00058377587,0.0002563202,0.5470611,0.0009143344,0.3635557,0.0005708035],"about_ca_topic_score_codex":0.0000021542814,"about_ca_topic_score_gemma":0.000005734857,"teacher_disagreement_score":0.33207768,"about_ca_system_score_codex":0.000043118198,"about_ca_system_score_gemma":0.00008290473,"threshold_uncertainty_score":0.7832591},"labels":[],"label_agreement":null},{"id":"W2097119459","doi":"10.1161/atvbaha.114.304873","title":"Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain–Gut Axis","year":2015,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Endocrinology; Internal medicine; Chylomicron; Lipoprotein; Chemistry; Very low-density lipoprotein; Medicine; Cholesterol","score_opus":0.026330043179780584,"score_gpt":0.25292961621134485,"score_spread":0.22659957303156428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097119459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949076,0.00041582796,0.0023142814,0.0008349184,0.00028081765,0.00071988796,0.000017953607,0.00009457646,0.00041413968],"genre_scores_gemma":[0.9976465,0.00017087208,0.0014204225,0.00030801806,0.000101973725,0.000084824474,0.00018758445,0.000029047871,0.000050771247],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983726,0.0001472383,0.0004299192,0.00044477155,0.00019097331,0.0004145092],"domain_scores_gemma":[0.99899864,0.00002958179,0.00018426724,0.00041211623,0.00012339636,0.0002519743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033856268,0.0002744626,0.00071075663,0.0001174604,0.0000712161,0.000026416381,0.00010158407,0.0001434766,0.00003092773],"category_scores_gemma":[0.000037759917,0.00022067873,0.00020238505,0.0001714072,0.00018416553,0.00010484133,0.00011296132,0.00008312294,0.000015011359],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006524309,0.0010119001,0.109158896,0.00057123305,0.0025606693,5.845234e-7,0.0016299103,0.000008153188,0.85015947,0.0031403014,0.010437201,0.021256443],"study_design_scores_gemma":[0.0028002625,0.0011080834,0.9808729,0.00022113339,0.0006826988,0.0000021684352,0.00037000756,0.0006270545,0.0016005225,0.00006681258,0.011415473,0.00023283534],"about_ca_topic_score_codex":0.00047589748,"about_ca_topic_score_gemma":0.00002628451,"teacher_disagreement_score":0.87171406,"about_ca_system_score_codex":0.00007946838,"about_ca_system_score_gemma":0.000031386957,"threshold_uncertainty_score":0.89990175},"labels":[],"label_agreement":null},{"id":"W2097168611","doi":"10.1111/dme.12624","title":"Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial","year":2014,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca","keywords":"Dapagliflozin; Medicine; Metformin; Placebo; Type 2 diabetes; Internal medicine; Regimen; Diabetes mellitus; Adverse effect; Gastroenterology; Urinary system; Urology; Endocrinology","score_opus":0.016511435010604456,"score_gpt":0.26604431474365453,"score_spread":0.24953287973305008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097168611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799251,0.0016357442,0.00012996315,0.0021290074,0.0002679376,0.008212939,0.0000012760555,0.000052677933,0.0076453597],"genre_scores_gemma":[0.9962467,0.0006429279,0.00034350995,0.00062558835,0.0002773235,0.0005534493,0.00007390066,0.000049578433,0.0011870298],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99734515,0.0002992499,0.00093865657,0.0004594125,0.00049821864,0.00045934142],"domain_scores_gemma":[0.997091,0.0017442424,0.00032348215,0.00049175875,0.00011397638,0.0002355681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022652668,0.00038654477,0.0029185403,0.00044894536,0.000042465497,0.000012787621,0.00011908023,0.00011205722,0.00030147246],"category_scores_gemma":[0.00072065566,0.00022921231,0.00011699151,0.00050500315,0.00038509283,0.00005945352,0.00003741681,0.0001820527,0.000010637298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9860206,0.0008094407,0.0032936851,0.0002173107,0.0011503659,0.000005755382,0.001044953,0.000018197788,0.00032728395,0.00053366396,0.00027180018,0.0063069006],"study_design_scores_gemma":[0.9850362,0.00668708,0.0024416866,0.0008298219,0.0017404475,7.2477536e-7,0.00011194519,0.0016060378,0.00023398412,0.00011906747,0.0009855081,0.00020751766],"about_ca_topic_score_codex":0.000059940656,"about_ca_topic_score_gemma":0.00003773834,"teacher_disagreement_score":0.016321598,"about_ca_system_score_codex":0.000052124487,"about_ca_system_score_gemma":0.000070700786,"threshold_uncertainty_score":0.93470067},"labels":[],"label_agreement":null},{"id":"W2097172830","doi":"10.1155/2012/671595","title":"Metformin-Associated Lactic Acidosis following Intentional Overdose Successfully Treated with Tris-Hydroxymethyl Aminomethane and Renal Replacement Therapy","year":2012,"lang":"en","type":"article","venue":"Case Reports in Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Metformin; Hydroxymethyl; Lactic acidosis; Tris; Renal replacement therapy; Medicine; Acidosis; Pharmacology; Anesthesia; Intensive care medicine; Internal medicine; Chemistry; Endocrinology; Diabetes mellitus; Biochemistry; Stereochemistry","score_opus":0.017132986788774944,"score_gpt":0.2732949026192589,"score_spread":0.2561619158304839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097172830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303734,0.0045579844,0.000035687906,0.00017648745,0.00015940514,0.0008628324,0.0000030778265,0.00007267104,0.0010945098],"genre_scores_gemma":[0.99713045,0.00040155867,0.0004608488,0.00054649654,0.000061988634,0.0002140157,0.00014594366,0.000034127286,0.0010045381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803996,0.00011628604,0.00055189955,0.00043993857,0.00026936305,0.0005825417],"domain_scores_gemma":[0.99888116,0.0001503958,0.00032980743,0.0003661802,0.000060199316,0.00021228152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009691063,0.00029114773,0.0006082251,0.00039421927,0.00008342922,0.000021050193,0.00002736825,0.00015870886,0.0001698711],"category_scores_gemma":[0.0001282987,0.00021847,0.00012789847,0.0003979011,0.000101661855,0.00026786828,0.000063076215,0.0001893756,0.0000032137318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021175062,0.0019488969,0.8716217,0.000051058796,0.0029721847,0.09113636,0.00053946156,0.0000029905862,0.003181274,0.00008822508,0.0005817575,0.025758546],"study_design_scores_gemma":[0.06741107,0.016570482,0.6395372,0.0006498128,0.008469606,0.144949,0.0017828612,0.00032923828,0.02951168,0.000656949,0.08783606,0.0022960405],"about_ca_topic_score_codex":0.0002777653,"about_ca_topic_score_gemma":0.00007992095,"teacher_disagreement_score":0.23208454,"about_ca_system_score_codex":0.00027462933,"about_ca_system_score_gemma":0.0000544742,"threshold_uncertainty_score":0.8908948},"labels":[],"label_agreement":null},{"id":"W2097225786","doi":"10.2337/dc09-0959","title":"Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes","year":2009,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":257,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; Servier; American Society of Nephrology; GW Pharmaceuticals; International Society of Hypertension; Novo Nordisk; Sanofi; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; High Blood Pressure Research Council of Australia; National Heart Foundation of Australia; Institut de Recherches Servier; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Diabetes mellitus; Blood pressure; Microalbuminuria; Type 2 diabetes; Gliclazide; Macrovascular disease; Nephropathy; Cardiology; Endocrinology","score_opus":0.0016840393403076564,"score_gpt":0.1781455557916664,"score_spread":0.17646151645135874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097225786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217784,0.0062333113,4.1792455e-7,0.000095465344,0.000058779264,0.0013402859,0.00001207359,0.000035593755,0.000046207926],"genre_scores_gemma":[0.9989725,0.0000636606,0.000060772854,0.00072994275,0.000010121961,0.000025672382,0.000087114764,0.000024818828,0.000025432697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886966,0.000034358756,0.00019950702,0.00034174067,0.00022516916,0.0003295591],"domain_scores_gemma":[0.99917275,0.00010108438,0.00007884467,0.00031307014,0.00023593078,0.000098337325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062651685,0.00027895757,0.0007315872,0.00016079622,0.000030382595,0.000020344007,0.000056520363,0.00007217464,0.0000028883371],"category_scores_gemma":[0.00012834564,0.0002044743,0.00008229867,0.00014086143,0.00006514446,0.00006737633,0.00004059582,0.00010803755,0.000001975995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016193806,0.00045675316,0.98920804,0.00076063373,0.0016725964,0.000017833907,0.00029940944,0.000008638696,0.0013649105,0.000013109684,0.0000129942,0.00602314],"study_design_scores_gemma":[0.0195744,0.0054899273,0.9376599,0.00070471066,0.0024028514,6.8405825e-8,0.00008537705,0.000018896935,0.033818472,0.000011081448,0.000043047385,0.00019122293],"about_ca_topic_score_codex":0.0000046907953,"about_ca_topic_score_gemma":0.0000017839219,"teacher_disagreement_score":0.0515481,"about_ca_system_score_codex":0.000016680588,"about_ca_system_score_gemma":0.000008552905,"threshold_uncertainty_score":0.833822},"labels":[],"label_agreement":null},{"id":"W2097275353","doi":"10.1002/cpdd.87","title":"Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase‐4 inhibitor","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitor; Pharmacokinetics; Pharmacology; Dipeptidyl peptidase; Population; Diabetes mellitus; Type 2 diabetes; Endocrinology; Biochemistry; Enzyme; Environmental health","score_opus":0.023717635637227237,"score_gpt":0.3603088754721077,"score_spread":0.3365912398348805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097275353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509066,0.00009989862,0.000020497419,0.0008747836,0.0006263619,0.001407507,0.000002882158,0.00006089499,0.0018164819],"genre_scores_gemma":[0.99329317,0.00008189209,0.002226597,0.0017081526,0.0001629921,0.0004214131,0.00016716217,0.000020667407,0.0019179605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972307,0.00021608725,0.0013506996,0.0005114532,0.00027919727,0.00041183687],"domain_scores_gemma":[0.9987306,0.00037361635,0.00031017247,0.00017657876,0.00019242596,0.00021663384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068832026,0.00025029003,0.00096035126,0.0007576739,0.00004428859,0.000009134726,0.00013642672,0.00011603817,0.0016800998],"category_scores_gemma":[0.00008475938,0.00021885797,0.00025842933,0.0011991761,0.00011969883,0.00010832213,0.00014155527,0.00030476655,0.00018910611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026933185,0.0030831846,0.92228484,0.000104023806,0.006207502,0.000039663482,0.0008870039,0.0002166396,0.0030080536,0.00001550479,0.03232425,0.03156],"study_design_scores_gemma":[0.004662582,0.00015382026,0.98042166,0.00004661791,0.0027353002,6.1504795e-7,0.00007569616,0.0018037349,0.0067105833,0.000039828537,0.0031422824,0.00020729826],"about_ca_topic_score_codex":0.00009627559,"about_ca_topic_score_gemma":0.000047526384,"teacher_disagreement_score":0.0581368,"about_ca_system_score_codex":0.00026045318,"about_ca_system_score_gemma":0.00011324322,"threshold_uncertainty_score":0.9992325},"labels":[],"label_agreement":null},{"id":"W2097382190","doi":"10.3945/jn.112.163204","title":"Sitagliptin Reduces Hyperglycemia and Increases Satiety Hormone Secretion More Effectively When Used with a Novel Polysaccharide in Obese Zucker Rats3","year":2012,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pacific Centre for Reproductive Medicine; University of British Columbia; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Sitagliptin; Internal medicine; Endocrinology; Glycated hemoglobin; Glucagon-like peptide-1; Sitagliptin Phosphate; Chemistry; Dipeptidyl peptidase-4; Type 2 diabetes; Hormone; Insulin; Incretin; Diabetes mellitus; Medicine","score_opus":0.014445872019623761,"score_gpt":0.2485222208993446,"score_spread":0.2340763488797208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097382190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957253,0.002655313,0.00011447407,0.0009703626,0.000042824537,0.00041058735,0.0000053610943,0.000011576844,0.0000642531],"genre_scores_gemma":[0.9959051,0.00044447248,0.0031730859,0.00011672603,0.00027316026,0.000023064093,0.000015034235,0.000014506233,0.000034822944],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991592,0.00003911574,0.00025253443,0.00009843515,0.0002660721,0.00018462181],"domain_scores_gemma":[0.9994171,0.00006993519,0.00020616225,0.00007014326,0.00009515106,0.00014146224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029696446,0.00013122759,0.00029944314,0.00024963025,0.00003134337,0.000022826238,0.000029648105,0.000058655954,0.000011030054],"category_scores_gemma":[0.000058980844,0.000094121075,0.000057172023,0.00013307783,0.000040303,0.000509557,0.000016889006,0.00014554226,0.0000012891715],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063277,0.0073059895,0.27652127,0.00039533127,0.0005380492,0.00010621292,0.0023031097,0.000004384919,0.6991918,0.000102988306,0.0023299328,0.004873232],"study_design_scores_gemma":[0.020718306,0.003235668,0.954144,0.0015355827,0.0006970952,0.00030143818,0.001651517,0.00008302927,0.016814502,0.00010819224,0.0005198961,0.00019078681],"about_ca_topic_score_codex":0.00005387126,"about_ca_topic_score_gemma":0.00000802452,"teacher_disagreement_score":0.6823773,"about_ca_system_score_codex":0.0001607917,"about_ca_system_score_gemma":0.000025187293,"threshold_uncertainty_score":0.3838146},"labels":[],"label_agreement":null},{"id":"W2098033708","doi":"10.1016/j.jcjd.2015.01.001","title":"The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"Ontario Ministry of Health and Long-Term Care; London Health Sciences Centre","keywords":"Glibenclamide; Medicine; Gliclazide; Diabetes mellitus; Internal medicine; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.016565623349941924,"score_gpt":0.21694636297511063,"score_spread":0.20038073962516872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098033708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163085,0.0034011928,0.0000210996,0.00085242273,0.0002355971,0.00023802514,0.000020071087,0.000008340136,0.0035924239],"genre_scores_gemma":[0.9986566,0.000037023343,0.00038152141,0.00020454553,0.00011458237,0.0000056526446,0.000006440329,0.000023711393,0.00056997564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986211,0.000067232395,0.0004302114,0.00011669595,0.00032720485,0.00043754582],"domain_scores_gemma":[0.99761933,0.00015648396,0.00042258957,0.00031720984,0.00042862215,0.0010557607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004604674,0.00017271457,0.00042355768,0.0002350485,0.00011163917,0.000038548736,0.00022020635,0.00004436221,0.000015377052],"category_scores_gemma":[0.00032501647,0.00010273289,0.00013481324,0.00022726206,0.00025242812,0.00012613481,0.000014512632,0.0002108645,0.000009042946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017912118,0.000111224814,0.95203537,0.00007152951,0.0018175477,0.0001529218,0.00062729977,0.0012957235,0.00022204581,0.0010378207,0.026680054,0.015769321],"study_design_scores_gemma":[0.036976967,0.01162121,0.7568188,0.0024243428,0.008221872,0.00006572847,0.0055809473,0.0038829192,0.01901731,0.007566247,0.1465121,0.0013116053],"about_ca_topic_score_codex":0.0011501946,"about_ca_topic_score_gemma":0.0055962596,"teacher_disagreement_score":0.19521664,"about_ca_system_score_codex":0.0002283643,"about_ca_system_score_gemma":0.001185677,"threshold_uncertainty_score":0.4189326},"labels":[],"label_agreement":null},{"id":"W2098090355","doi":"10.1111/1753-0407.12329","title":"Approaches to treatment 1: How is type 2 diabetes actually treated?","year":2015,"lang":"en","type":"editorial","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Type 2 diabetes; Thiazolidinedione; Diabetes mellitus; Internal medicine; Insulin; Endocrinology; Glucagon-like peptide-1; Medical prescription; Pharmacology","score_opus":0.061359471884578354,"score_gpt":0.2680988128371474,"score_spread":0.20673934095256907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098090355","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31935522,0.018169042,0.0000020310727,0.0070059975,0.6464745,0.002059455,0.0003284211,0.00015034915,0.006454999],"genre_scores_gemma":[0.032647505,0.0016912139,0.0025923927,0.00073325296,0.9128066,0.0001267561,0.0008520659,0.00038009175,0.048170127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961357,0.00009932888,0.0007611832,0.00053710426,0.0016208892,0.00084580947],"domain_scores_gemma":[0.99617773,0.00044701033,0.0008519261,0.00067549833,0.00097294897,0.00087486126],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005374334,0.000874978,0.0021911236,0.0008365793,0.00007030652,0.00022835535,0.00041429527,0.00068147405,0.00010644357],"category_scores_gemma":[0.00076177757,0.00059693103,0.00070578995,0.00046141868,0.00007839054,0.0002614155,0.00013031934,0.0005511809,0.00013369112],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018584801,0.0009547927,0.005298809,0.00026900106,0.0047787568,0.000057594374,0.0005182159,0.000003481857,0.00013597649,0.0000038893663,0.9645577,0.023235904],"study_design_scores_gemma":[0.0035842631,0.016807701,0.0002716644,0.0007792342,0.004721576,8.828049e-7,0.00016528883,0.000012702159,0.0034037628,0.00006155737,0.9696974,0.0004939376],"about_ca_topic_score_codex":0.0000051733755,"about_ca_topic_score_gemma":0.00000511082,"teacher_disagreement_score":0.2867077,"about_ca_system_score_codex":0.0011390955,"about_ca_system_score_gemma":0.0007433153,"threshold_uncertainty_score":0.9996482},"labels":[],"label_agreement":null},{"id":"W2098266516","doi":"10.1152/ajpendo.00270.2002","title":"Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis","year":2003,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Internal medicine; Endocrinology; Islet; Gastric inhibitory polypeptide; Pancreas; Biology; Knockout mouse; Downregulation and upregulation; Insulin; Receptor; Hormone; Glucagon; Gene; Medicine; Biochemistry","score_opus":0.009918110371438117,"score_gpt":0.2391847983694354,"score_spread":0.2292666879979973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098266516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98831517,0.008099175,0.000011670749,0.002310726,0.00044939067,0.00026330276,0.0000045021566,0.00001500758,0.00053104974],"genre_scores_gemma":[0.9885511,0.0064323493,0.0009937991,0.0036603261,0.00020488893,0.000019758094,0.000004632473,0.000017895589,0.0001152741],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980671,0.00057633786,0.0004132841,0.00027242905,0.00018229723,0.00048854545],"domain_scores_gemma":[0.99897414,0.00015251983,0.00039932548,0.00027443003,0.000083574785,0.000116023344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028225282,0.0002493685,0.0008320417,0.00029541604,0.00008133798,0.000010515288,0.00020502137,0.00004974268,0.00009250953],"category_scores_gemma":[0.00007550635,0.0001623617,0.000135578,0.00021295434,0.00053527666,0.00008143623,0.00005387905,0.00048548813,0.000024181196],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016638158,0.002533599,0.0381133,0.00012384557,0.002395611,0.00056529825,0.003920475,0.000009145395,0.7952977,0.020417063,0.0018270512,0.13313311],"study_design_scores_gemma":[0.008051795,0.0031468237,0.7295074,0.00008861658,0.00083204714,0.00087851175,0.0059627155,0.000002666077,0.03253917,0.00081416185,0.21784152,0.00033459428],"about_ca_topic_score_codex":0.000046640955,"about_ca_topic_score_gemma":0.000019543113,"teacher_disagreement_score":0.7627585,"about_ca_system_score_codex":0.000037014113,"about_ca_system_score_gemma":0.000054145712,"threshold_uncertainty_score":0.6620918},"labels":[],"label_agreement":null},{"id":"W2098519566","doi":"10.1053/j.ajkd.2013.06.020","title":"Glycated Hemoglobin and Risk of Death in Diabetic Patients Treated With Hemodialysis: A Meta-analysis","year":2013,"lang":"en","type":"review","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Public Health Agency","keywords":"Medicine; Internal medicine; Hemodialysis; Glycated hemoglobin; Meta-analysis; Observational study; Cochrane Library; Randomized controlled trial; Confounding; Population; Relative risk; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.023659501994516614,"score_gpt":0.28180864579050713,"score_spread":0.2581491437959905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098519566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050670963,0.9478347,0.0000063529815,0.000050008093,0.000011782936,0.000907203,0.0004164423,0.000011216583,0.00009138578],"genre_scores_gemma":[0.02790426,0.970882,0.00044754756,0.000117083044,0.000021050277,0.00010204517,0.00034373667,0.000043012944,0.00013928562],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971758,0.0004437744,0.0011994727,0.00035414117,0.00052827975,0.00029852916],"domain_scores_gemma":[0.99527085,0.00021615498,0.0027833187,0.00043140483,0.0002962412,0.0010020406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016600951,0.00054550485,0.007398619,0.0014846972,0.00002504786,0.000031513464,0.00018039114,0.000052554675,0.0001536407],"category_scores_gemma":[0.0003905903,0.00029593852,0.0024908574,0.00196183,0.00023179466,0.00011542939,0.000053230873,0.00019564881,0.0000044581047],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015194152,0.0014448062,0.3175198,0.0019904857,0.4115615,0.00007983745,0.00002517837,0.0000042450283,4.968654e-8,0.0000018157098,0.00034294094,0.26687738],"study_design_scores_gemma":[0.0017781754,0.0019397117,0.016257014,0.001238059,0.96325326,0.000004521519,0.00003985096,0.000006900669,0.0000010802739,0.0000037049608,0.015214897,0.00026280974],"about_ca_topic_score_codex":0.00029944113,"about_ca_topic_score_gemma":0.0000042517454,"teacher_disagreement_score":0.5516918,"about_ca_system_score_codex":0.00013796278,"about_ca_system_score_gemma":0.000370802,"threshold_uncertainty_score":0.9999493},"labels":[],"label_agreement":null},{"id":"W2098938905","doi":"10.2337/dc11-1918","title":"Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes","year":2012,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Ethnic group; Diabetes mellitus; Internal medicine; Type 2 diabetes; Demography; Plasma glucose; Endocrinology","score_opus":0.0334471876362774,"score_gpt":0.27466437883708494,"score_spread":0.24121719120080753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098938905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433094,0.0021893433,6.0591714e-7,0.00016995956,0.0001765273,0.00044060155,0.000019501309,0.000096506155,0.002576027],"genre_scores_gemma":[0.9982084,0.000018389934,0.0006317097,0.00016407244,0.0002362689,0.000053413485,0.0002978149,0.000037751674,0.00035218248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867874,0.000042727417,0.0002467676,0.00024539756,0.0001794316,0.0006069125],"domain_scores_gemma":[0.99898154,0.0004509262,0.000065251596,0.00023607943,0.00005281696,0.00021337798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016132496,0.00021571707,0.0003568475,0.00021237369,0.000080008285,0.000032288815,0.00006505842,0.000116976196,0.000049897375],"category_scores_gemma":[0.0003231975,0.00017534007,0.00004797235,0.00037034266,0.000053028547,0.00023162347,0.00010050995,0.00017929458,0.00016483336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001929651,0.000048996855,0.9774315,0.0003425677,0.00006097846,0.000003380034,0.0009035501,9.625682e-7,0.000112627975,0.000095691656,0.00027274792,0.020707736],"study_design_scores_gemma":[0.0014449192,0.00028804474,0.9920328,0.00021695279,0.00027766617,2.671852e-7,0.00076937536,0.000040346054,0.0021296558,0.000045176388,0.0025584907,0.00019626544],"about_ca_topic_score_codex":0.0000029989098,"about_ca_topic_score_gemma":0.000009248865,"teacher_disagreement_score":0.02051147,"about_ca_system_score_codex":0.00012546676,"about_ca_system_score_gemma":0.000026962105,"threshold_uncertainty_score":0.71501607},"labels":[],"label_agreement":null},{"id":"W2099578939","doi":"10.1093/gerona/56.1.m5","title":"Diabetes in Elderly Adults","year":2001,"lang":"en","type":"review","venue":"The Journals of Gerontology Series A","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia; Canadian Diabetes Association","keywords":"Diabetes mellitus; Medicine; Glycemic; Risk factor; Population; Elderly people; Intensive care medicine; Gerontology; Internal medicine; Endocrinology; Environmental health","score_opus":0.06654145894151722,"score_gpt":0.3513281156321682,"score_spread":0.28478665669065095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099578939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002768105,0.99015695,6.4993134e-7,0.0011188618,0.00021465671,0.0009012219,0.0000067528213,0.000019958254,0.0048128525],"genre_scores_gemma":[0.00016015465,0.99615675,0.00009751636,0.00009657456,0.00013218148,0.000097025775,0.000022169295,0.0000347235,0.003202903],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980577,0.00020521185,0.00087063917,0.0002228642,0.00019346419,0.00045007278],"domain_scores_gemma":[0.9985422,0.00018547632,0.0006286215,0.0005053437,0.000060483988,0.000077885394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047584102,0.00035443198,0.0024413276,0.00029834404,0.00004536704,0.000014115442,0.00030266115,0.00024919934,0.0003673259],"category_scores_gemma":[0.000078980265,0.0001969326,0.00046214633,0.00030092616,0.00019179712,0.000097492615,0.00009559154,0.00041904696,0.00003696395],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074016665,0.00017316526,0.000760019,0.00578837,0.00090072234,0.00009707495,0.00010405378,1.2612229e-7,2.5504113e-7,0.00010672351,0.0017276368,0.9902678],"study_design_scores_gemma":[0.0008030468,0.0010268188,0.0005088346,0.019360349,0.0021871342,0.00014538804,0.00015569045,6.757936e-7,0.0000018834761,0.00018116954,0.975468,0.00016101038],"about_ca_topic_score_codex":0.000038369944,"about_ca_topic_score_gemma":0.00030782082,"teacher_disagreement_score":0.9901068,"about_ca_system_score_codex":0.00009030897,"about_ca_system_score_gemma":0.00010033398,"threshold_uncertainty_score":0.8030678},"labels":[],"label_agreement":null},{"id":"W2100377339","doi":"10.1161/atvbaha.112.246207","title":"Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans","year":2012,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Exenatide; Agonist; Glucagon-like peptide-1; Endocrinology; Glucagon-like peptide-2; Internal medicine; Medicine; Receptor; Glucagon-like peptide 1 receptor; Lipoprotein; Peptide; Chemistry; Type 2 diabetes; Diabetes mellitus; Biochemistry; Cholesterol","score_opus":0.04392628542649243,"score_gpt":0.2958515256256914,"score_spread":0.251925240199199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100377339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952967,0.00037020605,0.000046144127,0.0022485356,0.00050855236,0.0010325557,0.000005750467,0.000087665874,0.00040384856],"genre_scores_gemma":[0.99346954,0.002575516,0.0020968944,0.0010132118,0.00029268448,0.0003229671,0.00013669812,0.000036060013,0.00005642369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980662,0.00014566457,0.0004349662,0.00054989825,0.00014512253,0.0006581391],"domain_scores_gemma":[0.99917626,0.0000284865,0.00012875846,0.00039065184,0.000059006823,0.00021685226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005502883,0.0003102198,0.0005771554,0.0002344566,0.00015551285,0.000032703774,0.00008228528,0.00014773117,0.00010130651],"category_scores_gemma":[0.000058005055,0.00025864554,0.00014827382,0.00027661762,0.00017823637,0.00022603967,0.00012816863,0.00018519894,0.00008173467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006626334,0.0021122475,0.8016524,0.00028441206,0.00061392464,2.0519148e-7,0.0018350587,5.5567e-7,0.17554413,0.00078037626,0.0024470359,0.014663428],"study_design_scores_gemma":[0.0018464228,0.0016175555,0.97725743,0.00027626552,0.00020402204,0.0000012382641,0.00026930607,0.000008526261,0.0020583333,0.000032893764,0.01615287,0.00027514258],"about_ca_topic_score_codex":0.00023861811,"about_ca_topic_score_gemma":0.00014706318,"teacher_disagreement_score":0.17560506,"about_ca_system_score_codex":0.00012795505,"about_ca_system_score_gemma":0.000030143106,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W2100587870","doi":"10.1210/en.2008-0182","title":"GPR119: “Double-Dipping” for Better Glycemic Control","year":2008,"lang":"en","type":"letter","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glycemic; Endocrinology; Internal medicine; Medicine; Control (management); Diabetes mellitus; Computer science; Artificial intelligence","score_opus":0.0273485876008702,"score_gpt":0.2704593686238225,"score_spread":0.24311078102295233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100587870","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029398089,0.0014758934,0.0004662719,0.9647221,0.001923966,0.0032083972,0.00008788783,0.00038063858,0.024795057],"genre_scores_gemma":[0.006619596,0.00032707438,0.0007730669,0.9254432,0.006891338,0.0014134443,0.0016883094,0.00014768055,0.056696307],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974497,0.00003351831,0.00040740805,0.0006987424,0.00022851776,0.0011821375],"domain_scores_gemma":[0.99876416,0.00018928346,0.00017908985,0.0006986873,0.00009190785,0.00007688661],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000027797323,0.0005060156,0.0010503815,0.0003763609,0.000095908865,0.000016748661,0.00023511084,0.0005280567,0.00042416176],"category_scores_gemma":[0.000023851353,0.00044357748,0.00044049273,0.000076775636,0.00017263448,0.00004329616,0.000079296165,0.0009136011,0.0005862216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070347113,0.000079885045,0.0005082997,0.00027295793,0.0015259278,0.0027809474,0.0000224762,5.3684107e-7,0.000048203947,0.00016912582,0.98941565,0.0044725165],"study_design_scores_gemma":[0.018695313,0.0011030004,0.0001510255,0.00006217644,0.0011534172,0.00029958365,0.0000036288914,0.000011580773,0.00023932032,0.00014729182,0.9777939,0.00033979886],"about_ca_topic_score_codex":0.000028010803,"about_ca_topic_score_gemma":0.000002864483,"teacher_disagreement_score":0.039278895,"about_ca_system_score_codex":0.00017307018,"about_ca_system_score_gemma":0.00007952839,"threshold_uncertainty_score":0.9998016},"labels":[],"label_agreement":null},{"id":"W2100951883","doi":"10.1186/1478-7547-2-2","title":"Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K","year":2004,"lang":"en","type":"article","venue":"Cost Effectiveness and Resource Allocation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nateglinide; Metformin; Medicine; Glycemic; United Kingdom Prospective Diabetes Study; Type 2 diabetes; Diabetes mellitus; Health economics; Quality-adjusted life year; Internal medicine; Intensive care medicine; Cost effectiveness; Public health; Endocrinology; Risk analysis (engineering)","score_opus":0.014177208242740444,"score_gpt":0.3161204027754747,"score_spread":0.30194319453273427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100951883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962047,0.0004536396,0.0006689219,0.0007899692,0.0000070710103,0.0017168471,0.000008965254,0.000003748,0.0001461654],"genre_scores_gemma":[0.9997365,0.000027189188,0.000047867277,0.00008206609,0.000004045231,0.00007687136,0.000017616152,0.0000065320187,0.0000013427639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999372,0.000118230135,0.0002182523,0.00011787826,0.00008285485,0.000090749585],"domain_scores_gemma":[0.9992668,0.00027530783,0.0001915851,0.00018510639,0.000036893678,0.000044314897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003658897,0.00008512952,0.00032928624,0.000079552185,0.000047079207,0.000005424961,0.00006493191,0.00002317446,3.4824762e-7],"category_scores_gemma":[0.000023487226,0.000045645465,0.000036610956,0.00013434619,0.00010011788,0.000027242244,0.000022985267,0.000058825008,2.62137e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00567062,0.0009484023,0.872457,0.00060666795,0.00055247906,5.0980816e-7,0.0067991093,0.04670838,0.0042427084,0.0073679886,0.00001980043,0.05462632],"study_design_scores_gemma":[0.005886298,0.0033490926,0.98644805,0.0008047306,0.00010284963,0.000003804076,0.0008684433,0.0010894726,0.0012645236,0.00008606805,0.000043374468,0.000053316315],"about_ca_topic_score_codex":0.0010086795,"about_ca_topic_score_gemma":0.00013742616,"teacher_disagreement_score":0.11399101,"about_ca_system_score_codex":0.00018181305,"about_ca_system_score_gemma":0.00010151713,"threshold_uncertainty_score":0.18613681},"labels":[],"label_agreement":null},{"id":"W2101095092","doi":"10.1161/hypertensionaha.113.02855","title":"Comparative Effectiveness of Olmesartan and Other Angiotensin Receptor Blockers in Diabetes Mellitus","year":2014,"lang":"en","type":"article","venue":"Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; Diabetes Canada; Provincial Health Services Authority","funders":"","keywords":"Olmesartan; Medicine; Hazard ratio; Internal medicine; Diabetes mellitus; Kidney disease; Cohort; Blood pressure; Confidence interval; Endocrinology","score_opus":0.01883307444717446,"score_gpt":0.246463489251935,"score_spread":0.22763041480476054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101095092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976104,0.0008191511,0.0000068389927,0.000252535,0.00006633763,0.0003928647,0.0000016282577,0.000021087264,0.00082916167],"genre_scores_gemma":[0.99842674,0.000028863904,0.0011539907,0.0002750252,0.000018963692,0.000010692363,0.0000117285335,0.000011646816,0.00006236561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993158,0.000101739664,0.0001309752,0.00019296518,0.00010657804,0.00015195142],"domain_scores_gemma":[0.9995425,0.00016361696,0.000039884937,0.00015298511,0.000047604,0.000053420743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024368637,0.00011469788,0.00045015695,0.00011003488,0.000017816454,0.0000046719197,0.000021735306,0.00004661624,0.000011427982],"category_scores_gemma":[0.000030650066,0.000085482716,0.00004189151,0.0001167494,0.000068953595,0.000030284558,0.000026169197,0.000046042886,0.000015404436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006900086,0.0010967704,0.5092573,0.0005265033,0.0004196339,0.000012492916,0.0005784087,0.000015037264,0.4633764,0.0010601989,0.0056190537,0.017348178],"study_design_scores_gemma":[0.008362904,0.0017359025,0.6687422,0.0016733126,0.0003954331,0.0000041377416,0.00019706316,0.0040898127,0.282458,0.00034112897,0.031688213,0.000311943],"about_ca_topic_score_codex":0.00004055916,"about_ca_topic_score_gemma":0.000007534436,"teacher_disagreement_score":0.18091841,"about_ca_system_score_codex":0.00002348936,"about_ca_system_score_gemma":0.0000065948634,"threshold_uncertainty_score":0.34858838},"labels":[],"label_agreement":null},{"id":"W2101382476","doi":"10.1016/s2213-8587(14)70031-2","title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","year":2014,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"University of Oxford; Medtronic; Teva Pharmaceutical Industries; Novartis; Roche; Novo Nordisk; Merck; Bayer; Servier; British Microcirculation Society; Amgen","keywords":"Medicine; Heart failure; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Internal medicine; Cardiology; Randomized controlled trial; Surrogate endpoint; Endocrinology","score_opus":0.030508690995126726,"score_gpt":0.2589968043897658,"score_spread":0.22848811339463906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101382476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663969,0.0016615647,0.00000464139,0.026789995,0.00044897333,0.00088349,0.000015940555,0.00023559814,0.0035628446],"genre_scores_gemma":[0.986567,0.000091751535,0.00050739787,0.011084629,0.0005763478,0.0004038537,0.00008123043,0.000059209135,0.00062858034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962162,0.0003153482,0.00037929817,0.0005830694,0.0003690426,0.002137035],"domain_scores_gemma":[0.9979927,0.0002581024,0.000087522414,0.0014619274,0.0000601188,0.00013964776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007514232,0.00041054198,0.0015298511,0.00022578845,0.00009899056,0.000044307322,0.00041348548,0.000111619935,0.00014103386],"category_scores_gemma":[0.00020912793,0.00028274878,0.00043471134,0.0002692707,0.000267955,0.000081741186,0.0002669389,0.00040776716,0.00027100055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021716007,0.00014375549,0.977091,0.0001546821,0.0011965882,0.000026753693,0.000108510714,0.000029368412,0.0007119666,0.0009752269,0.012450952,0.007089441],"study_design_scores_gemma":[0.006065715,0.000545435,0.55448705,0.00009478605,0.0009083655,0.000006212266,0.000121678466,0.0002721788,0.00481057,0.0006882822,0.43153602,0.0004636974],"about_ca_topic_score_codex":0.00011530553,"about_ca_topic_score_gemma":0.0001771,"teacher_disagreement_score":0.422604,"about_ca_system_score_codex":0.00012098329,"about_ca_system_score_gemma":0.000023331573,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W2101732802","doi":"10.1016/s0140-6736(14)61402-1","title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","year":2015,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Saxagliptin; Heart failure; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Placebo; Drug; Pharmacotherapy; Internal medicine; Pharmacology; Endocrinology; Sitagliptin","score_opus":0.037447383360112566,"score_gpt":0.3181448629631721,"score_spread":0.2806974796030596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101732802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064005973,0.9897111,1.0365211e-7,0.00079182425,0.00018620196,0.001844477,0.000011296273,0.00004533818,0.0010090594],"genre_scores_gemma":[0.00072615675,0.9972273,0.00008720736,0.0004093848,0.00045044205,0.00020004743,0.00008816819,0.000045398785,0.00076586363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998725,0.0001717043,0.00030485148,0.00023038927,0.00022906021,0.00033897546],"domain_scores_gemma":[0.99877036,0.00019179506,0.00015178102,0.00080539053,0.000026777065,0.00005387107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045107244,0.00030265906,0.002896547,0.00013378159,0.00001478942,0.000012306791,0.00028633227,0.0001017107,0.000020818175],"category_scores_gemma":[0.000035008925,0.00015645035,0.00026803013,0.00030176845,0.000060894956,0.000029324143,0.00007397363,0.00026440763,0.00009577629],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022748534,0.00031893922,0.0033281182,0.040008474,0.00090336316,0.000024198976,0.00018455234,4.5278927e-7,0.0000107293745,0.00009984967,0.2330232,0.72207534],"study_design_scores_gemma":[0.0018903732,0.0001388397,0.00028565383,0.013776589,0.00064666395,0.000001377589,0.000008197195,9.891071e-7,0.000021632377,0.00004667517,0.98305035,0.0001326901],"about_ca_topic_score_codex":0.000011807246,"about_ca_topic_score_gemma":0.000005598537,"teacher_disagreement_score":0.7500271,"about_ca_system_score_codex":0.00007606667,"about_ca_system_score_gemma":0.00008558426,"threshold_uncertainty_score":0.637986},"labels":[],"label_agreement":null},{"id":"W2102036241","doi":"10.1016/j.mce.2007.06.003","title":"GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion","year":2007,"lang":"en","type":"article","venue":"Molecular and Cellular Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"GLUT2; Incretin; Endocrinology; Internal medicine; Gastric inhibitory polypeptide; Secretion; Receptor; Glucagon-like peptide-1; Biology; Glucose transporter; Chemistry; Insulin; Diabetes mellitus; Glucagon; Type 2 diabetes; Medicine","score_opus":0.009060403162072045,"score_gpt":0.22809495490764345,"score_spread":0.2190345517455714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102036241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895533,0.004221812,0.0004978454,0.0018049976,0.00011644609,0.0006538864,6.871813e-7,0.000046428922,0.003104627],"genre_scores_gemma":[0.998158,0.0004289612,0.00018359644,0.0008823375,0.000038404072,0.00003924458,0.000045797937,0.00002221419,0.00020144823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859285,0.00016159663,0.00027905472,0.00035568417,0.00015202159,0.00045876714],"domain_scores_gemma":[0.9994659,0.00008352123,0.000085527456,0.0002323196,0.000030802028,0.00010194485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044646004,0.00020442327,0.00037413245,0.00020359839,0.00006817925,0.000019430556,0.000068561574,0.00010642429,0.000037315385],"category_scores_gemma":[0.00008412392,0.00015161186,0.00006723784,0.00018129531,0.00021516749,0.000031150103,0.00015042048,0.0002369696,0.000012174824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003375629,0.00047779476,0.31447303,0.00037783006,0.0007534997,0.0050785905,0.0014553291,0.000002148851,0.5495727,0.049449995,0.0003083705,0.07467508],"study_design_scores_gemma":[0.031756677,0.0010745454,0.10611545,0.00023334434,0.0007733434,0.00014595155,0.003710109,0.00039625514,0.82547694,0.002774622,0.02680387,0.00073889113],"about_ca_topic_score_codex":0.00020911776,"about_ca_topic_score_gemma":0.00010899178,"teacher_disagreement_score":0.27590424,"about_ca_system_score_codex":0.00004918594,"about_ca_system_score_gemma":0.000013398765,"threshold_uncertainty_score":0.61825526},"labels":[],"label_agreement":null},{"id":"W2102218442","doi":"10.1158/0008-5472.can-08-0029","title":"Glucagon-like Peptide-2 Does Not Modify the Growth or Survival of Murine or Human Intestinal Tumor Cells","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide-2; Cell growth; Cancer research; Biology; Intestinal epithelium; Enteroendocrine cell; Cancer cell; Internal medicine; Gastrointestinal epithelium; Cancer; Endocrinology; Epithelium; Medicine; Peptide; Endocrine system; Biochemistry","score_opus":0.13879719428475934,"score_gpt":0.3963507674668255,"score_spread":0.2575535731820662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102218442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174255,0.00014266085,0.000006321846,0.0016882273,0.00021977996,0.00090413244,0.000026938302,0.000041783114,0.0052275765],"genre_scores_gemma":[0.9200965,0.00044396071,0.0001314186,0.00019104131,0.00031280014,0.00027106013,0.000013879864,0.000033386972,0.07850594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977732,0.00012559145,0.00027895957,0.00033612794,0.0009262591,0.00055986183],"domain_scores_gemma":[0.9985734,0.00031760614,0.00006548667,0.00048279855,0.00040086728,0.00015983527],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066726445,0.00017069007,0.0003424648,0.00019429282,0.00026903933,0.000021909414,0.00034212592,0.000033815984,0.0014146687],"category_scores_gemma":[0.00014862203,0.00007728386,0.00008800439,0.0004818502,0.0005668518,0.00006672729,0.00027953568,0.00035146446,0.000064682674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017329335,0.005249706,0.13068569,0.005583192,0.0025636838,0.0061884876,0.0057665333,0.00004458057,0.5598578,0.006024643,0.2443906,0.01631578],"study_design_scores_gemma":[0.009662052,0.005518094,0.071338244,0.0010702529,0.00035298918,0.000053232397,0.0020136393,0.00017814922,0.85184455,0.0003097322,0.05713696,0.0005221035],"about_ca_topic_score_codex":0.0017484737,"about_ca_topic_score_gemma":0.000603807,"teacher_disagreement_score":0.2919868,"about_ca_system_score_codex":0.00019680544,"about_ca_system_score_gemma":0.00034973896,"threshold_uncertainty_score":0.9994982},"labels":[],"label_agreement":null},{"id":"W2102261669","doi":"10.1016/j.jcjd.2013.07.041","title":"Le diabète chez les personnes âgées","year":2013,"lang":"fr","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.010704512882161786,"score_gpt":0.19808142482574453,"score_spread":0.18737691194358275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102261669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85982984,0.0962372,0.0000049190353,0.022945045,0.0029746676,0.00035540963,0.000027514936,0.000011564556,0.017613841],"genre_scores_gemma":[0.9717593,0.00028840275,0.00042612726,0.0010461383,0.0022158832,0.000016645487,0.000012398931,0.000058190857,0.024176879],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977224,0.00010856886,0.0005479978,0.00021023922,0.00025091978,0.0011598928],"domain_scores_gemma":[0.99716413,0.00014497973,0.00030480383,0.00026027128,0.00035207949,0.001773721],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038613318,0.00033366765,0.0006522847,0.0005646835,0.00024886234,0.00022353348,0.00031290768,0.0001776865,0.0040318384],"category_scores_gemma":[0.00024173879,0.00031011688,0.00035378584,0.00026460816,0.00049002393,0.00058572297,0.000024339804,0.0003482401,0.0007031576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001955954,0.00018736767,0.6612978,0.00048508326,0.0017147769,0.00011107283,0.0021257913,0.000030563777,0.000553676,0.005611772,0.16355106,0.16432911],"study_design_scores_gemma":[0.0033445803,0.0016262993,0.4478636,0.0029452413,0.0018036718,0.000014936666,0.0073279054,0.00021160931,0.0026979055,0.0016292781,0.52983373,0.00070122146],"about_ca_topic_score_codex":0.013542435,"about_ca_topic_score_gemma":0.012905333,"teacher_disagreement_score":0.36628267,"about_ca_system_score_codex":0.00031662188,"about_ca_system_score_gemma":0.0015350847,"threshold_uncertainty_score":0.9999351},"labels":[],"label_agreement":null},{"id":"W2102279107","doi":"10.2337/dc14-1459","title":"Incretin-Based Drugs and the Risk of Congestive Heart Failure","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Heart failure; Diabetes mellitus; Incretin; Internal medicine; Cardiology; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.0030621957988526812,"score_gpt":0.20052337983921428,"score_spread":0.19746118404036161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102279107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259126,0.0005851739,0.0000053611743,0.0027740607,0.000042889467,0.00047004563,0.000031534993,0.00003570141,0.0034639582],"genre_scores_gemma":[0.99830663,0.000009407148,0.00046031308,0.00093832775,0.00004438101,0.000051078565,0.00007045266,0.0000133810845,0.000106053994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992668,0.00010649668,0.0001216876,0.00016120121,0.00017773248,0.00016604993],"domain_scores_gemma":[0.9990768,0.00039406415,0.00007045802,0.00025952872,0.00013854721,0.000060631734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000274355,0.00011938263,0.0003082644,0.00004730016,0.00005565639,0.000013939755,0.000052029452,0.000040787985,0.000024998419],"category_scores_gemma":[0.0002211787,0.00007124931,0.00009438427,0.00008141748,0.00024106425,0.000021291426,0.00004032638,0.000084548,0.000024810312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057578007,0.000025258418,0.98773515,0.00019216516,0.00017808548,2.5949586e-7,0.0007938611,0.000009040468,0.00009518093,0.00087549177,0.0031123539,0.0069255517],"study_design_scores_gemma":[0.018903714,0.0011758048,0.84689015,0.00045679408,0.0025023962,1.8455634e-7,0.004973754,0.0028597987,0.020207893,0.0006627452,0.101042934,0.0003238353],"about_ca_topic_score_codex":0.00002106145,"about_ca_topic_score_gemma":0.0000064446663,"teacher_disagreement_score":0.14084503,"about_ca_system_score_codex":0.000016928061,"about_ca_system_score_gemma":0.000014535435,"threshold_uncertainty_score":0.29054627},"labels":[],"label_agreement":null},{"id":"W2102382908","doi":"10.2337/diacare.24.6.989","title":"The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes","year":2001,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bayer Canada; Sanofi","keywords":"Metformin; Medicine; Postprandial; Type 2 diabetes; Internal medicine; Glycemic; Placebo; Endocrinology; Combination therapy; Diabetes mellitus; Gastroenterology","score_opus":0.010641323095928155,"score_gpt":0.26131721087990484,"score_spread":0.2506758877839767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102382908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548526,0.011022394,3.279887e-7,0.00020957395,0.00016747146,0.0013328601,0.0000091304055,0.000018927834,0.0017540843],"genre_scores_gemma":[0.9972409,0.0020707767,0.000011568103,0.000054660344,0.00003783887,0.00024444875,0.00013034401,0.000017201673,0.00019224903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988593,0.00014404683,0.00027217093,0.00016319784,0.00027491103,0.000286376],"domain_scores_gemma":[0.9985742,0.0007412299,0.00011677332,0.00043143335,0.00010358495,0.00003277045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024607024,0.0001960279,0.0004317446,0.00010735781,0.00006280442,0.000016253407,0.00014980332,0.00005173302,0.00001539581],"category_scores_gemma":[0.00006693621,0.00009274046,0.00015931616,0.00037831094,0.00010357309,0.00004310905,0.000014407282,0.00004744662,0.000011757475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018057278,0.00047546977,0.75422287,0.00019975397,0.00040167547,0.000008272593,0.0019750325,0.000017315471,0.0012031876,0.00034653718,0.0002332231,0.24073607],"study_design_scores_gemma":[0.025749987,0.054116126,0.5794182,0.0006394428,0.0019797673,8.229925e-7,0.0046449043,0.0016569763,0.25142437,0.00050230935,0.079315536,0.00055158423],"about_ca_topic_score_codex":0.000021053014,"about_ca_topic_score_gemma":0.000016398024,"teacher_disagreement_score":0.2502212,"about_ca_system_score_codex":0.00014072994,"about_ca_system_score_gemma":0.000023878747,"threshold_uncertainty_score":0.37818465},"labels":[],"label_agreement":null},{"id":"W2102619124","doi":"10.1016/j.diabres.2015.04.002","title":"Clinical use of insulin degludec","year":2015,"lang":"en","type":"review","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk; Novo Nordisk UK Research Foundation","keywords":"Insulin degludec; Medicine; Pharmacodynamics; Dosing; Pharmacokinetics; Insulin glargine; Diabetes mellitus; Insulin; Population; Insulin analog; Pharmacology; Internal medicine; Hypoglycemia; Endocrinology","score_opus":0.5504258919014049,"score_gpt":0.6100329504426127,"score_spread":0.05960705854120785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102619124","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062509376,0.9882523,0.000001485657,0.00042496147,0.00034331033,0.0021914693,0.00005288215,0.000044915032,0.008063623],"genre_scores_gemma":[0.000027810416,0.9915421,0.003302355,0.0003426513,0.000629143,0.0001140718,0.00025321372,0.00007823304,0.0037104185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99077284,0.0033180478,0.002685999,0.0009993127,0.0013930337,0.00083079014],"domain_scores_gemma":[0.9629242,0.032386657,0.0008274893,0.0011986564,0.0015332268,0.0011297651],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016918156,0.0004297637,0.0037570149,0.0003990261,0.0000833983,0.00014117282,0.0003408,0.0008172612,0.00007980221],"category_scores_gemma":[0.054102823,0.00030238772,0.0008605701,0.0007799266,0.0011361483,0.0004630293,0.00085157325,0.0026677444,0.00047011272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002005625,0.0033442487,0.0035143825,0.0066046035,0.0025230802,0.00010435792,0.000005252394,8.355097e-9,1.613585e-8,0.0002555207,0.031279728,0.9521682],"study_design_scores_gemma":[0.0016051274,0.005076084,0.0006643303,0.005504081,0.004269279,0.0000045275783,0.000030138031,0.000008244575,1.2634882e-7,0.00013082137,0.9824771,0.00023008931],"about_ca_topic_score_codex":0.000027646664,"about_ca_topic_score_gemma":0.000003090543,"teacher_disagreement_score":0.95193815,"about_ca_system_score_codex":0.000106739935,"about_ca_system_score_gemma":0.0010377454,"threshold_uncertainty_score":0.99994284},"labels":[],"label_agreement":null},{"id":"W2103134564","doi":"10.1016/j.ahj.2004.04.034","title":"How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry","year":2004,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; McGill University; Sunnybrook Health Science Centre; Jewish General Hospital; Canadian Heart Research Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Diabetes mellitus; Myocardial infarction; Internal medicine; Vascular disease; Disease; Angina; Stroke (engine); Coronary artery disease; Risk factor; Unstable angina; Revascularization; Type 2 diabetes; Cardiology; Endocrinology","score_opus":0.013938131921355464,"score_gpt":0.21374156422921237,"score_spread":0.1998034323078569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103134564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810109,0.0010909188,0.000067057634,0.016828187,0.00006589877,0.00083772483,0.000013695716,0.000014046707,0.000071541865],"genre_scores_gemma":[0.9985668,0.00009763553,0.00054232654,0.0005325013,0.00012874218,0.00006919255,0.000016717608,0.000020120995,0.000025975352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869573,0.00011596566,0.00018195677,0.00017906088,0.0005610757,0.00026622484],"domain_scores_gemma":[0.9988161,0.00005105624,0.0002531928,0.00044931396,0.00016377434,0.00026660075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015475326,0.00016760567,0.00039489518,0.00009626988,0.0002785938,0.00011255586,0.00016740456,0.00001951965,0.000015761032],"category_scores_gemma":[0.00005809656,0.000070794835,0.00021638763,0.00033901812,0.00050716934,0.00015031996,0.00002471306,0.0002320035,0.0000010525184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056677432,0.00023188768,0.9924848,0.00006291224,0.0015709652,0.000022533577,0.0006226076,0.00010752288,0.00037224597,0.000060252292,0.00052285654,0.0038847108],"study_design_scores_gemma":[0.0011309751,0.0005104165,0.9774014,0.0004900288,0.0010126517,0.0000039655433,0.0023125925,0.00002801177,0.0026592526,0.000245387,0.014083678,0.00012167644],"about_ca_topic_score_codex":0.043543473,"about_ca_topic_score_gemma":0.031156817,"teacher_disagreement_score":0.017555859,"about_ca_system_score_codex":0.00015282902,"about_ca_system_score_gemma":0.00034988826,"threshold_uncertainty_score":0.986522},"labels":[],"label_agreement":null},{"id":"W2103337198","doi":"10.1152/ajpendo.00116.2012","title":"Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells","year":2012,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Canadian Institutes of Health Research","keywords":"CD36; Phloretin; Oleic acid; Chemistry; Secretion; Fatty acid; Glucagon-like peptide-1; Internal medicine; Palmitic acid; Biochemistry; Endocrinology; Biology; Medicine; Diabetes mellitus; Receptor","score_opus":0.009380762938811233,"score_gpt":0.23719460115822275,"score_spread":0.2278138382194115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103337198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962193,0.0027209104,0.000045948495,0.00021237528,0.00027287874,0.00030610047,0.0000097351885,0.000016572643,0.00019618684],"genre_scores_gemma":[0.995512,0.0005068683,0.0033831147,0.00022217735,0.00026414506,0.000024946285,0.000019320714,0.000019371655,0.000048064867],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99829227,0.0001853746,0.0006096584,0.00023594906,0.00015448245,0.00052227883],"domain_scores_gemma":[0.9988346,0.0000523014,0.0005948208,0.00022091834,0.00010445283,0.00019289055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018337966,0.00026086767,0.0010682305,0.00032713872,0.000036441816,0.0000025680495,0.00014073175,0.000065577144,0.00009108],"category_scores_gemma":[0.000030813742,0.00020399372,0.00017683487,0.00021986527,0.0003918352,0.0001964001,0.000055546992,0.00044196728,0.000008100466],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007484118,0.0005783148,0.02266225,0.00003315281,0.0003843659,0.000022361277,0.00056364905,0.0000014743108,0.9413875,0.00028268414,0.000012617007,0.033323232],"study_design_scores_gemma":[0.0021735362,0.0009187482,0.6088162,0.0000780141,0.00038396212,0.00005099269,0.00093471585,0.0000045459556,0.384815,0.00030944846,0.0013938656,0.00012093512],"about_ca_topic_score_codex":0.00018906589,"about_ca_topic_score_gemma":0.000010798355,"teacher_disagreement_score":0.586154,"about_ca_system_score_codex":0.000030435074,"about_ca_system_score_gemma":0.000059694252,"threshold_uncertainty_score":0.8318623},"labels":[],"label_agreement":null},{"id":"W2103828712","doi":"10.1111/j.1463-1326.2008.00994.x","title":"Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","year":2008,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute for Health and Care Research","keywords":"Vildagliptin; Glimepiride; Medicine; Metformin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Hypoglycemia; Confidence interval; Randomized controlled trial; Gastroenterology; Endocrinology","score_opus":0.009903568371051009,"score_gpt":0.2167715782832629,"score_spread":0.2068680099122119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103828712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911106,0.0065042498,0.0000023262967,0.00013373733,0.000098312186,0.0016020327,0.000019542776,0.00004266024,0.00048653645],"genre_scores_gemma":[0.99571764,0.0027939847,0.00051577366,0.000570754,0.000045613328,0.00005000355,0.00007236044,0.000034749126,0.00019908919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813557,0.0001067239,0.0004691962,0.00043537896,0.00035081655,0.0005022909],"domain_scores_gemma":[0.99889654,0.00026887807,0.00019685911,0.00031908092,0.00012069201,0.00019796031],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003554935,0.00037397552,0.0013704302,0.00033265306,0.00011087679,0.000019155532,0.00009128613,0.00009859424,0.000031649837],"category_scores_gemma":[0.0001063525,0.00026872492,0.00008970731,0.0003312604,0.00021656799,0.00017868113,0.000055453922,0.0001735298,0.000008135734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062400317,0.0031737962,0.94437885,0.00016757654,0.0010311052,0.000014974649,0.0006380076,0.000021647737,0.0003472363,0.0007964219,0.00008603815,0.04310433],"study_design_scores_gemma":[0.050475113,0.0018982791,0.93789804,0.00018113086,0.0005193835,2.3660446e-7,0.000016649823,0.000088999994,0.005075969,0.00009590843,0.0034789867,0.00027127692],"about_ca_topic_score_codex":0.000037065376,"about_ca_topic_score_gemma":0.000009143491,"teacher_disagreement_score":0.04423508,"about_ca_system_score_codex":0.000032379245,"about_ca_system_score_gemma":0.00003824078,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W2103836214","doi":"10.1371/journal.pone.0137596","title":"Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research; Astellas Pharma; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Novo Nordisk; Academic Medical Organization of Southwestern Ontario; Sanofi; London Health Sciences Centre; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Metformin; Hypoglycemia; Diabetes mellitus; Gliclazide; Internal medicine; Comorbidity; Population; Medical prescription; Type 2 diabetes; Thiazolidinedione; Vildagliptin; Insulin; Pediatrics; Endocrinology; Pharmacology; Environmental health","score_opus":0.03617157011763101,"score_gpt":0.24580525166798975,"score_spread":0.20963368155035875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103836214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98589104,0.0014504879,0.000002662713,0.0026144183,0.0000317675,0.00035577896,0.0000036896845,0.000041920313,0.009608214],"genre_scores_gemma":[0.99054646,0.00054677145,0.00081660185,0.00021264066,0.00005389281,0.00011653247,0.000101604455,0.000013184766,0.007592301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999176,0.00001894849,0.00018533976,0.0002065363,0.00023160345,0.00018153245],"domain_scores_gemma":[0.9996087,0.000013213427,0.000034922527,0.00018832408,0.000033514363,0.00012131162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102271384,0.00009734874,0.00021142256,0.00037635423,0.000010664026,0.0000093570725,0.000041720104,0.000059891398,0.00021989328],"category_scores_gemma":[0.00004054819,0.000086802254,0.000015776415,0.00026972961,0.00003436861,0.00011809406,0.00003437786,0.00009424821,0.00005962894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012314594,0.0143345175,0.86254036,0.00047923045,0.00044222825,0.000097218195,0.0045756735,0.000004139952,0.002741239,0.00028011893,0.03212652,0.08114727],"study_design_scores_gemma":[0.021583172,0.0008717057,0.9667791,0.0018251244,0.00048371573,0.0000034665056,0.0007882301,0.0031101399,0.0008410876,0.00011907507,0.0033220146,0.00027318415],"about_ca_topic_score_codex":0.00020438684,"about_ca_topic_score_gemma":0.00025238222,"teacher_disagreement_score":0.1042387,"about_ca_system_score_codex":0.00010251346,"about_ca_system_score_gemma":0.00002012235,"threshold_uncertainty_score":0.3539693},"labels":[],"label_agreement":null},{"id":"W2104105195","doi":"10.1111/j.1464-5491.2005.01610.x","title":"Long‐term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus","year":2005,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Takeda Pharmaceuticals North America; Eli Lilly and Company","keywords":"Pioglitazone; Medicine; Metformin; Internal medicine; Quantitative insulin sensitivity check index; Type 2 Diabetes Mellitus; Type 2 diabetes; Insulin; Diabetes mellitus; Endocrinology; Insulin resistance; Gastroenterology; Insulin sensitivity","score_opus":0.00564497434058047,"score_gpt":0.22122346967046888,"score_spread":0.2155784953298884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104105195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950336,0.002510163,0.0000072263856,0.0004630667,0.00010342172,0.00096633134,0.0000022867507,0.000028772112,0.0008851035],"genre_scores_gemma":[0.9985569,0.00023971766,0.00024753562,0.00057675457,0.00008511376,0.000022751638,0.00007993865,0.000024843346,0.00016642561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859816,0.000053744552,0.00030355193,0.0003040327,0.00039936294,0.000341145],"domain_scores_gemma":[0.99902654,0.00028815557,0.00010512484,0.00031913983,0.00009002702,0.00017100933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031159635,0.00024463586,0.0006872208,0.0002996356,0.000020992797,0.0000039282304,0.000040126768,0.00006409422,0.00004499783],"category_scores_gemma":[0.00019580069,0.00015847273,0.000028234956,0.00032082424,0.0001917924,0.00006912807,0.0000382429,0.00012703636,0.000015848931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028607098,0.0010500754,0.84796107,0.0006935649,0.00020476956,0.000040836494,0.00032086787,0.0000026584867,0.00037859075,0.00009077507,0.00012373229,0.14884697],"study_design_scores_gemma":[0.010885107,0.0052342634,0.9743035,0.0015215754,0.0004113891,4.0857793e-7,0.00001456435,0.000056149584,0.007230248,0.000024248295,0.00017630293,0.00014225858],"about_ca_topic_score_codex":0.000012619596,"about_ca_topic_score_gemma":0.000017185253,"teacher_disagreement_score":0.14870471,"about_ca_system_score_codex":0.000075628384,"about_ca_system_score_gemma":0.000017593133,"threshold_uncertainty_score":0.646233},"labels":[],"label_agreement":null},{"id":"W2104243240","doi":"10.1185/03007995.2012.689956","title":"Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study","year":2012,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"American Diabetes Association","keywords":"Medicine; Canagliflozin; Sitagliptin; Metformin; Internal medicine; Placebo; Type 2 diabetes; Sitagliptin Phosphate; Urinary system; Creatinine; Gastroenterology; Glycemic; Diabetes mellitus; Renal function; Endocrinology; Urology","score_opus":0.04561111091520502,"score_gpt":0.39865473916015326,"score_spread":0.3530436282449482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104243240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952054,0.0024072656,6.642062e-7,0.000114033384,0.00026474855,0.0018032406,0.0000037680843,0.000014393469,0.00018648792],"genre_scores_gemma":[0.996981,0.002529929,0.0000019674433,0.000012843198,0.000172963,0.00017026535,0.000099215096,0.000015272906,0.00001649176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976306,0.00040436359,0.00028841733,0.0002985612,0.0008335837,0.00054448517],"domain_scores_gemma":[0.9988357,0.00043611403,0.000045393295,0.0001645803,0.000047641446,0.000470561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024095827,0.00018896692,0.0004534192,0.000558843,0.000043074186,0.000015949758,0.000048473623,0.000087120134,0.00006269911],"category_scores_gemma":[0.00033774128,0.00012415224,0.00002840684,0.00036440237,0.00016235636,0.00014064675,0.000044238626,0.00049425033,0.000004715132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005130551,0.0140515035,0.9015643,0.0009490024,0.00006101486,0.000062501815,0.0005491905,4.9406697e-8,0.00013566323,0.000006777617,0.00017292223,0.07731652],"study_design_scores_gemma":[0.026611708,0.06066542,0.9069517,0.0017128834,0.00004811657,0.0000039539855,0.000070397306,0.00006462797,0.0016985934,0.000006088991,0.0020352637,0.00013119972],"about_ca_topic_score_codex":0.00018503984,"about_ca_topic_score_gemma":0.00011323286,"teacher_disagreement_score":0.077185325,"about_ca_system_score_codex":0.000094254254,"about_ca_system_score_gemma":0.00010213824,"threshold_uncertainty_score":0.50627816},"labels":[],"label_agreement":null},{"id":"W2104521207","doi":"10.1139/cjc-2015-0039","title":"Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of Jordan","keywords":"Pharmacophore; Chemistry; Docking (animal); Dipeptidyl peptidase; Pharmacology; Combinatorial chemistry; Stereochemistry; Isostere; Dipeptidyl peptidase-4; Molecular model; Biochemistry; Glucagon-like peptide-1; Enzyme; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.02587336260101997,"score_gpt":0.2832273578712312,"score_spread":0.25735399527021124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104521207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840921,0.013413559,0.000013014674,0.0008385202,0.00017054079,0.00005191912,0.0000022026281,0.0000029748014,0.0014151363],"genre_scores_gemma":[0.9992117,0.00017245943,0.00012434847,0.00012175979,0.00021116021,9.92756e-7,0.0000026193359,0.000011121016,0.00014383442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934113,0.000006374841,0.00024081794,0.000081260565,0.00016871923,0.00016171414],"domain_scores_gemma":[0.99898714,0.0000057583948,0.00011722015,0.00007375048,0.00029267557,0.0005234285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014235725,0.00010128933,0.00025240923,0.000074604395,0.000027785578,0.000014326214,0.000057077694,0.000036081412,0.000016897611],"category_scores_gemma":[0.000100757476,0.00008693678,0.00007134013,0.00006616539,0.0000632126,0.000050663606,0.00001785688,0.00009838302,6.1382184e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005236809,0.0002206056,0.020555237,0.002706851,0.0066302503,0.013388032,0.006896647,0.015426491,0.8678406,0.000055794324,0.026915114,0.038840737],"study_design_scores_gemma":[0.0067278044,0.00038662314,0.000066053435,0.0014387675,0.0015656326,0.00074100326,0.010585939,0.0029762175,0.9691238,0.0009002261,0.0051421397,0.00034584058],"about_ca_topic_score_codex":0.00017292993,"about_ca_topic_score_gemma":0.000025225998,"teacher_disagreement_score":0.10128319,"about_ca_system_score_codex":0.0001102023,"about_ca_system_score_gemma":0.00044280256,"threshold_uncertainty_score":0.3545179},"labels":[],"label_agreement":null},{"id":"W2104578230","doi":"10.1001/jama.2011.353","title":"Use of Fibrates in the United States and Canada","year":2011,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Fibrate; Medicine; Medical prescription; Population; Fenofibrate; Pharmacoepidemiology; Confidence interval; Internal medicine; Demography; Environmental health; Statin; Pharmacology","score_opus":0.03214058158615034,"score_gpt":0.22194434796644633,"score_spread":0.189803766380296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104578230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973313,0.00003953345,5.3342524e-7,0.00090876,0.000010625537,0.00009983515,0.0000035570486,0.0000029740868,0.0016028581],"genre_scores_gemma":[0.9981544,0.00007112946,0.00013311989,0.0011347987,0.0000049166865,0.0000041446497,0.000029116267,0.0000022667346,0.0004661016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997974,0.000010972857,0.000050126804,0.000036883765,0.00005019746,0.000054396965],"domain_scores_gemma":[0.99984133,0.000044529104,0.000013887601,0.000073278294,0.000012669349,0.000014321358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000035063727,0.00002980093,0.000053442873,0.000032841264,0.000005914629,0.0000048732963,0.000018825374,0.000008012773,0.000029241179],"category_scores_gemma":[0.00001701208,0.000016946557,0.00000504178,0.000062653664,0.000014474259,0.000030430137,0.000010513439,0.000019635007,4.967988e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009683832,0.00016908004,0.9333197,0.000096405216,0.00011362264,0.0001059323,0.0029989157,0.0000036257945,0.000091199014,0.0018259692,0.048623044,0.012555653],"study_design_scores_gemma":[0.0007419869,0.00014004683,0.96146655,0.00003698386,0.000045977526,7.5422616e-7,0.0009761823,0.00016196648,0.0016930582,0.00011809863,0.0345877,0.000030666288],"about_ca_topic_score_codex":0.67298585,"about_ca_topic_score_gemma":0.29500878,"teacher_disagreement_score":0.3779771,"about_ca_system_score_codex":0.000008639588,"about_ca_system_score_gemma":0.000015049577,"threshold_uncertainty_score":0.71785545},"labels":[],"label_agreement":null},{"id":"W2104831380","doi":"10.1093/ndt/gfp180","title":"Diabetes, kidney disease and cardiovascular disease patients. Assessing care of complex patients using outpatient testing and visits: additional metrics by which to evaluate health care system functioning","year":2009,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Centre for Advancing Health Outcomes; Ministry of Health; University of British Columbia","funders":"University of British Columbia","keywords":"Medicine; Kidney disease; Diabetes mellitus; Ambulatory care; Emergency medicine; Disease; Pharmacy; Diagnosis code; Cohort; Medical diagnosis; Health care; Outpatient clinic; Intensive care medicine; Internal medicine; Family medicine; Population; Environmental health","score_opus":0.018221260664122572,"score_gpt":0.2592642287226716,"score_spread":0.241042968058549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104831380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936627,0.0016295479,0.0009610913,0.000115765484,0.00007874816,0.0011296904,0.0023061438,0.000058591482,0.00005771234],"genre_scores_gemma":[0.97712797,0.00005830668,0.0021961946,0.0009726753,0.000043104763,0.00006209699,0.01951812,0.00002028084,0.0000012694371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997899,0.00022573932,0.0004567909,0.00052047527,0.0005831133,0.00031488138],"domain_scores_gemma":[0.99830574,0.00012518805,0.00019643531,0.00022462044,0.00061737606,0.0005306264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001703948,0.0002500395,0.00055528467,0.00039678544,0.00028857694,0.000044873505,0.000043030217,0.000061055405,0.000013382066],"category_scores_gemma":[0.00019012134,0.0002452949,0.00011974321,0.0005780363,0.00003349037,0.00020249658,0.000018433375,0.00008097694,9.937227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037783917,0.0003309199,0.9398645,0.0020206075,0.0010060365,0.0000061197534,0.0012578394,0.0021817323,0.00009947878,0.000010129086,0.00046201263,0.052382752],"study_design_scores_gemma":[0.00410895,0.0008474532,0.98256195,0.00051914726,0.0066219755,3.2436273e-7,0.00030914103,0.0045156996,0.000017681044,0.0000033556175,0.00028833997,0.00020597749],"about_ca_topic_score_codex":0.000054499105,"about_ca_topic_score_gemma":0.0000053877993,"teacher_disagreement_score":0.052176777,"about_ca_system_score_codex":0.0002717453,"about_ca_system_score_gemma":0.0001352847,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W2104847526","doi":"10.1136/ebn.12.1.4","title":"To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes","year":2008,"lang":"en","type":"article","venue":"Evidence-Based Nursing","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"","keywords":"Medicine; Diabetes mellitus; United Kingdom Prospective Diabetes Study; Intensive care medicine; Clinical trial; Population; Disease; Type 2 diabetes; Randomized controlled trial; Confusion; Glycated haemoglobin; Internal medicine; Endocrinology; Environmental health","score_opus":0.12463885007552807,"score_gpt":0.38408234401580377,"score_spread":0.2594434939402757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104847526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97103465,0.00055568025,0.0002161764,0.025605762,0.0004430531,0.0016689366,0.00000453676,0.000036161193,0.00043504467],"genre_scores_gemma":[0.9925527,0.000031129824,0.00038539307,0.006194172,0.00009065506,0.000035914552,7.33405e-7,0.00002746962,0.000681823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997823,0.00021831633,0.0002451175,0.00041169702,0.0008780757,0.0004237752],"domain_scores_gemma":[0.9977574,0.0008611226,0.000046300007,0.00074004184,0.00043809385,0.00015708024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008658617,0.00019313255,0.00052321464,0.0003084839,0.00019306358,0.00002595862,0.00011814217,0.000056505152,0.000020458954],"category_scores_gemma":[0.0017330468,0.00011836534,0.00024432922,0.000521379,0.00021256067,0.0000782165,0.00005385121,0.00020137071,0.000040107378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08529117,0.0044764117,0.35868368,0.0019104335,0.007886875,0.012031397,0.021436933,0.02925995,0.03819704,0.0007973196,0.1303372,0.3096916],"study_design_scores_gemma":[0.016092172,0.015217286,0.85245365,0.060910102,0.0027143352,0.00015296627,0.0043402785,0.0016063062,0.034913216,0.00007822906,0.010443967,0.001077495],"about_ca_topic_score_codex":0.000053755994,"about_ca_topic_score_gemma":0.000006280821,"teacher_disagreement_score":0.49376997,"about_ca_system_score_codex":0.00028537455,"about_ca_system_score_gemma":0.00011687925,"threshold_uncertainty_score":0.48267984},"labels":[],"label_agreement":null},{"id":"W2105575861","doi":"10.1016/s2213-8587(13)70006-8","title":"Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis","year":2013,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":257,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Insulin resistance; Internal medicine; Insulin; Diabetes mellitus; Meta-analysis; Type 2 diabetes; Type 2 Diabetes Mellitus; Homeostatic model assessment; Endocrinology","score_opus":0.11718134704544426,"score_gpt":0.35498969325980406,"score_spread":0.2378083462143598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105575861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052247726,0.9890678,2.988921e-7,0.0017568358,0.00009618229,0.008166811,0.00004876639,0.000106794876,0.00023404235],"genre_scores_gemma":[0.00036405693,0.98802394,0.00007128285,0.005532958,0.00008834773,0.0049536023,0.0003415059,0.00008464713,0.00053964165],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99491847,0.00090029347,0.0014448167,0.0008717479,0.0002785592,0.001586128],"domain_scores_gemma":[0.9962407,0.0008938279,0.0005774444,0.0019023751,0.0002509832,0.00013468886],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00082290865,0.0010062723,0.017903863,0.00065582833,0.000063123334,0.00006997354,0.0006683196,0.00021731983,0.00037143895],"category_scores_gemma":[0.00030911935,0.00049775996,0.001895245,0.0012672673,0.00026259874,0.00008622735,0.00035628988,0.00067203003,0.000258704],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000484751,0.00013611662,0.00034889622,0.54194814,0.37131584,0.000047837144,0.00005797989,1.2830998e-7,5.265169e-7,0.00023255045,0.001211664,0.08469545],"study_design_scores_gemma":[0.00044211195,0.00033225148,0.000119574426,0.019175056,0.8980303,0.000008609704,0.000021926633,0.0000040815194,0.000003382554,0.00007817127,0.08130646,0.0004781075],"about_ca_topic_score_codex":0.000011808103,"about_ca_topic_score_gemma":0.000011229979,"teacher_disagreement_score":0.52671444,"about_ca_system_score_codex":0.00011997147,"about_ca_system_score_gemma":0.000049445975,"threshold_uncertainty_score":0.9997474},"labels":[],"label_agreement":null},{"id":"W2106512674","doi":"10.3111/13696990701438629","title":"Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Johns Hopkins University; Sanofi","keywords":"Medicine; Rimonabant; Overweight; Quality-adjusted life year; Cost effectiveness; Obesity; Internal medicine; Risk analysis (engineering)","score_opus":0.01895269973768576,"score_gpt":0.2711988113097658,"score_spread":0.25224611157208005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106512674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982004,0.00021170334,0.00079995074,0.0000487331,0.00019932058,0.00030239837,0.000036843998,0.000004448292,0.00019620922],"genre_scores_gemma":[0.9966826,0.0006236213,0.0024558946,0.000100348254,0.00007021211,0.000003391071,0.000036307338,0.000016975628,0.0000106853095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985364,0.000065389344,0.0007101918,0.00013900733,0.00033170814,0.00021726578],"domain_scores_gemma":[0.99824095,0.0007429911,0.00044675317,0.00016676809,0.000063310945,0.0003392494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018174471,0.00013925193,0.000766677,0.0003063364,0.000017593631,0.000010297356,0.00013527944,0.00012144805,0.000049317165],"category_scores_gemma":[0.00062374317,0.000109842156,0.00019076625,0.000086820575,0.00007187927,0.00013685426,0.000097973345,0.000217404,0.0000036274243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023184884,0.0007594267,0.9646004,0.000060836417,0.0006270522,0.00006636236,0.000053106985,0.0006343874,0.00003604591,0.00003572683,0.000095226074,0.030712947],"study_design_scores_gemma":[0.011590485,0.00029824988,0.97091687,0.00032683223,0.00048862223,0.000003893524,0.000023299146,0.014850814,0.0010189535,0.0001828696,0.0002093316,0.00008977365],"about_ca_topic_score_codex":0.00022982832,"about_ca_topic_score_gemma":0.00005635939,"teacher_disagreement_score":0.030623173,"about_ca_system_score_codex":0.00031695204,"about_ca_system_score_gemma":0.00011926,"threshold_uncertainty_score":0.44792333},"labels":[],"label_agreement":null},{"id":"W2106647566","doi":"10.1016/j.jcjd.2014.05.001","title":"Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies","year":2014,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Incretin; Dipeptidyl peptidase-4; Diabetes mellitus; Exenatide; Internal medicine; Endocrinology; Type 2 diabetes; Blood pressure; Pharmacology","score_opus":0.010459309792511504,"score_gpt":0.24178071895768766,"score_spread":0.23132140916517616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106647566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011012003,0.9867956,0.0000020967907,0.00007117952,0.0006389836,0.00086490833,0.00003158427,0.00001675709,0.000566908],"genre_scores_gemma":[0.06815466,0.92902845,0.0005058645,0.00041598245,0.0008525934,0.00010242969,0.00009280358,0.00024649606,0.00060074084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737203,0.00018618695,0.0010679157,0.00028280544,0.0003588815,0.0007321793],"domain_scores_gemma":[0.9963664,0.0008280185,0.0012032038,0.000518189,0.00024381065,0.00084038597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005878266,0.0005968059,0.003408905,0.0011902427,0.00007592896,0.000062785795,0.0004458669,0.0002870893,0.00010703145],"category_scores_gemma":[0.00051765866,0.0004437588,0.00116198,0.00034343172,0.00020082417,0.000084459716,0.000027427142,0.00044712765,0.000011261336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032597547,0.00021672412,0.02648929,0.1596108,0.016405161,0.00010832665,0.00010635325,0.000005041764,0.000039886912,0.00007820411,0.0024645901,0.79447234],"study_design_scores_gemma":[0.0014953787,0.0014510583,0.00073672284,0.062768675,0.030889671,0.0000018285137,0.0000058633636,0.0000058702503,0.000687958,0.000025850522,0.9015315,0.00039958724],"about_ca_topic_score_codex":0.00006876528,"about_ca_topic_score_gemma":0.00012418373,"teacher_disagreement_score":0.8990669,"about_ca_system_score_codex":0.00008830535,"about_ca_system_score_gemma":0.0013583148,"threshold_uncertainty_score":0.9998014},"labels":[],"label_agreement":null},{"id":"W2106709036","doi":"10.2337/dc12-2454","title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin","year":2013,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Lixisenatide; Medicine; Basal insulin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Basal (medicine); Endocrinology","score_opus":0.014347802948763632,"score_gpt":0.25139085058131777,"score_spread":0.23704304763255413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106709036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98148185,0.0049778814,0.000009049726,0.001271732,0.0005385175,0.0038877968,0.0001476096,0.00026626082,0.00741932],"genre_scores_gemma":[0.98939925,0.00008563501,0.0014946901,0.0024948611,0.00024430192,0.0018428218,0.0017342059,0.00009932497,0.002604885],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976601,0.000056717912,0.00048000715,0.0005421343,0.00035722175,0.0009037908],"domain_scores_gemma":[0.99805206,0.000469539,0.00017728818,0.00045072404,0.00054602925,0.0003043363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016995505,0.0004281861,0.00095621886,0.00022118153,0.00014957337,0.00019635653,0.00021183718,0.00016272592,0.00040900824],"category_scores_gemma":[0.00056489796,0.00035013419,0.00029012226,0.00033932546,0.00007856721,0.00037319292,0.000097855314,0.00016343144,0.00050850736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004226197,0.0006418411,0.42125323,0.0012548529,0.0020456894,0.000007889443,0.0010636807,0.00001542566,0.020607019,0.00034155563,0.42117402,0.13117218],"study_design_scores_gemma":[0.14684905,0.012751512,0.13304715,0.0023100795,0.006002797,4.953487e-7,0.009714268,0.01411031,0.14951813,0.002179884,0.5193471,0.0041692434],"about_ca_topic_score_codex":0.000020798889,"about_ca_topic_score_gemma":0.000005884125,"teacher_disagreement_score":0.2882061,"about_ca_system_score_codex":0.00020868656,"about_ca_system_score_gemma":0.00007596748,"threshold_uncertainty_score":0.99989504},"labels":[],"label_agreement":null},{"id":"W2106888324","doi":"10.1186/s12933-015-0294-0","title":"Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes","year":2015,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Medicine; Sitagliptin; Saxagliptin; Alogliptin; Vildagliptin; Linagliptin; Metformin; Pharmacology; Incretin; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.027318749212543743,"score_gpt":0.27995428870040395,"score_spread":0.2526355394878602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106888324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000990409,0.9892429,0.000038040933,0.00004878608,0.0004934936,0.005527199,0.00003249444,0.000246398,0.0033802586],"genre_scores_gemma":[0.0006954934,0.99554604,0.00030408488,0.00006942459,0.00027708142,0.0019651346,0.00030527113,0.00026488796,0.00057255634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948755,0.00075851986,0.00062815845,0.0017250681,0.0009443883,0.0010683606],"domain_scores_gemma":[0.9957356,0.00036259255,0.00019805286,0.002988743,0.00014143961,0.000573595],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00071678706,0.0015856783,0.011961965,0.0006601762,0.00011848917,0.000059380953,0.0002304559,0.0006789684,0.00001064911],"category_scores_gemma":[0.00009234385,0.000969551,0.006144422,0.00045188685,0.00031595954,0.00007161382,0.00017257602,0.0003990544,0.00028251315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019615516,0.00031559297,0.00057924155,0.010524581,0.10974308,0.0019148913,0.00002890893,0.0000040940395,3.1515153e-8,0.0000937603,0.00015141976,0.87662476],"study_design_scores_gemma":[0.005761292,0.0027924401,0.00026118397,0.0041070697,0.107950635,0.00024238907,0.000010288182,0.0000014119546,0.000007706466,0.000032624368,0.87805676,0.00077618676],"about_ca_topic_score_codex":0.000042931915,"about_ca_topic_score_gemma":0.000002955148,"teacher_disagreement_score":0.87790537,"about_ca_system_score_codex":0.0007370586,"about_ca_system_score_gemma":0.0003327286,"threshold_uncertainty_score":0.9996891},"labels":[],"label_agreement":null},{"id":"W2107166617","doi":"10.2337/diacare.25.12.2244","title":"Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes","year":2002,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":421,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Metformin; Sulfonylurea; Odds ratio; Internal medicine; Type 2 diabetes; Confounding; Diabetes mellitus; Combination therapy; Population; Medical prescription; Logistic regression; Insulin; Pharmacology; Endocrinology; Environmental health","score_opus":0.04170545697191242,"score_gpt":0.2464083756673805,"score_spread":0.20470291869546808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107166617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969105,0.0012237224,0.0000014256455,0.00018382663,0.000027539516,0.00090265204,0.000046339635,0.00006655264,0.0006374074],"genre_scores_gemma":[0.9985286,0.00005611474,0.00023021587,0.00051610905,0.000015179248,0.000100252444,0.0003106007,0.000039425133,0.00020350183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986508,0.00007502194,0.00023685441,0.00026876002,0.00035608196,0.0004124875],"domain_scores_gemma":[0.99883676,0.00021300597,0.00015507819,0.00048857334,0.0002112443,0.00009536317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010919815,0.00026065277,0.0005504884,0.00013139182,0.000049330705,0.000033532888,0.00012349254,0.000066578374,0.000113232214],"category_scores_gemma":[0.00005864623,0.00014792106,0.000079758596,0.0006255726,0.0001482466,0.00014819088,0.00002538105,0.00012122735,0.000012255242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077040524,0.0003658661,0.99207133,0.00008168413,0.0008845149,0.000012968236,0.00080396177,0.000110008,0.0002101187,0.000021072776,0.0011440009,0.0042174556],"study_design_scores_gemma":[0.005629256,0.0013140109,0.9796185,0.00043653915,0.0008142543,1.4259656e-7,0.00073996326,0.0020753122,0.0049411324,0.000007989335,0.0041346382,0.00028826282],"about_ca_topic_score_codex":0.00005213345,"about_ca_topic_score_gemma":0.00037531764,"teacher_disagreement_score":0.012452809,"about_ca_system_score_codex":0.00011257535,"about_ca_system_score_gemma":0.000026451655,"threshold_uncertainty_score":0.6032046},"labels":[],"label_agreement":null},{"id":"W2107421879","doi":"10.1016/s0140-6736(09)61029-1","title":"Thiazolidinediones and clinical outcomes in type 2 diabetes","year":2009,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Rosiglitazone; Medicine; Insulin resistance; Pioglitazone; Type 2 diabetes; Metformin; Diabetes mellitus; Scopus; Internal medicine; Type 2 Diabetes Mellitus; Endocrinology; Insulin; MEDLINE; Chemistry","score_opus":0.049757030322658394,"score_gpt":0.3308905987900765,"score_spread":0.2811335684674181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107421879","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.113281846,0.0011667358,1.1283288e-7,0.8785556,0.00040780017,0.00038875395,0.0000066204307,0.000057899084,0.006134653],"genre_scores_gemma":[0.01470022,0.0027100588,0.00015989173,0.96560645,0.006149408,0.00001693079,0.000161204,0.00002712767,0.010468695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990065,0.000065143824,0.00023737644,0.00022153254,0.00016257136,0.00030685202],"domain_scores_gemma":[0.9991615,0.00023789155,0.00007040066,0.00048628647,0.000017732325,0.000026217362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030582945,0.00018640068,0.00089511054,0.000068514695,0.000022018114,0.000026800933,0.00014796603,0.00022426594,0.00003816946],"category_scores_gemma":[0.00009239608,0.00009955713,0.00009035064,0.00008069178,0.00006818705,0.000023529497,0.00006466613,0.0006969637,0.000074429525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018319377,0.000036533085,0.28029275,0.000059146874,0.00018843346,0.00006707683,0.0000132527275,3.5985266e-8,3.1733146e-7,0.00002910683,0.71420723,0.005087801],"study_design_scores_gemma":[0.0011145293,0.00020505615,0.3678228,0.00010135443,0.000267831,6.8870173e-7,0.0000034098757,0.0000053962035,0.0000014551614,0.00047464008,0.6299174,0.000085499916],"about_ca_topic_score_codex":0.0000073084616,"about_ca_topic_score_gemma":0.000007028361,"teacher_disagreement_score":0.09858163,"about_ca_system_score_codex":0.000020848096,"about_ca_system_score_gemma":0.000014755251,"threshold_uncertainty_score":0.4059822},"labels":[],"label_agreement":null},{"id":"W2107562831","doi":"10.1111/j.1463-1326.2010.01233.x","title":"Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute for Health and Care Research","keywords":"Vildagliptin; Glimepiride; Medicine; Metformin; Diabetes mellitus; Internal medicine; Type 2 diabetes; Gastroenterology; Endocrinology","score_opus":0.008943048231581338,"score_gpt":0.22399462829677433,"score_spread":0.21505158006519298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107562831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994617,0.0004249631,0.0000017399014,0.00041314334,0.00038485893,0.0028100521,0.00018706547,0.0001450223,0.0010161663],"genre_scores_gemma":[0.993709,0.000117748335,0.004124341,0.0004153246,0.00070619746,0.00014468828,0.00013894048,0.0000533251,0.00059038156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740195,0.00011235716,0.00036829003,0.0010302159,0.00052558957,0.0005615705],"domain_scores_gemma":[0.99807805,0.00024431886,0.00020153272,0.0008139149,0.0001900494,0.00047214594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006075705,0.00050899497,0.0009565243,0.00026006807,0.00025401363,0.00011931469,0.00016422333,0.000104928906,0.00003180329],"category_scores_gemma":[0.00030912654,0.00033297087,0.000054650016,0.00034425975,0.00016221587,0.00019483891,0.00013821569,0.000444639,0.00005578926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026916662,0.017589815,0.7901687,0.0003503894,0.008549449,0.00026844774,0.013699234,0.00004632304,0.05365875,0.0003692288,0.01922299,0.06916004],"study_design_scores_gemma":[0.023985203,0.003201287,0.9052574,0.0002269491,0.002978949,0.0000016952557,0.0004299252,0.000060103037,0.024185263,0.00005756557,0.038992945,0.00062271976],"about_ca_topic_score_codex":0.00017911098,"about_ca_topic_score_gemma":0.00018274528,"teacher_disagreement_score":0.115088716,"about_ca_system_score_codex":0.000017617744,"about_ca_system_score_gemma":0.000047575428,"threshold_uncertainty_score":0.99991226},"labels":[],"label_agreement":null},{"id":"W2107824623","doi":"10.2337/db13-0822","title":"Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls","year":2013,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Incretin; Sitagliptin; Internal medicine; Endocrinology; Hormone; Dipeptidyl peptidase-4; Pancreas; Receptor; Glucagon-like peptide-1; Vildagliptin; Glucagon; Medicine; Diabetes mellitus; Biology; Type 2 diabetes","score_opus":0.045549648177754004,"score_gpt":0.31326212553582095,"score_spread":0.2677124773580669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107824623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06436788,0.9313038,4.919287e-7,0.00016241669,0.00010700457,0.0025317373,0.000012217623,0.000055579298,0.0014588768],"genre_scores_gemma":[0.002895464,0.99423,0.00018335927,0.00020412318,0.00022101976,0.0010969236,0.0003312327,0.000035256842,0.0008026496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827975,0.00026563028,0.00037779476,0.00043188292,0.00023788505,0.00040706503],"domain_scores_gemma":[0.9992361,0.00012978705,0.00016113446,0.00035908355,0.000027269125,0.00008659937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004229239,0.0003880655,0.001201772,0.00018054117,0.00006335994,0.00011502663,0.00015870553,0.00025540777,0.00012208488],"category_scores_gemma":[0.0000814838,0.00020585126,0.00023824957,0.00021311094,0.000093322466,0.000092088325,0.00011363187,0.0003310216,0.000108052394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000051777015,0.00022471626,0.001790212,0.006773557,0.0001855751,0.000052992786,0.000049021055,2.7661526e-8,0.000011018696,0.00009711503,0.0014429938,0.9893676],"study_design_scores_gemma":[0.0009928418,0.00057582714,0.007921812,0.0062497375,0.0028866776,0.0000206322,0.00012686255,0.000017393704,0.000009600479,0.00015473798,0.98062134,0.00042251023],"about_ca_topic_score_codex":0.00002263814,"about_ca_topic_score_gemma":0.0000017551401,"teacher_disagreement_score":0.98894507,"about_ca_system_score_codex":0.0000664854,"about_ca_system_score_gemma":0.000045557903,"threshold_uncertainty_score":0.83943707},"labels":[],"label_agreement":null},{"id":"W2108018037","doi":"10.1586/erc.10.186","title":"Wrongfully accused: metformin use in heart failure","year":2011,"lang":"en","type":"letter","venue":"Expert Review of Cardiovascular Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"","keywords":"Medicine; Metformin; Heart failure; Type 2 diabetes; Tolerability; Diabetes mellitus; Glycemic; Internal medicine; Observational study; Intensive care medicine; Cardiology; Endocrinology; Adverse effect","score_opus":0.037822860367822904,"score_gpt":0.2856028198099922,"score_spread":0.2477799594421693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108018037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017169786,0.91549164,0.000047013385,0.07915369,0.0003363363,0.0033427668,0.000010343886,0.00006723815,0.0013792756],"genre_scores_gemma":[0.000018312654,0.6260545,0.0035289759,0.36731675,0.000977098,0.00054255733,0.00036526207,0.0001171013,0.001079427],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659264,0.00034771636,0.0008020653,0.0006876131,0.0010421443,0.000527819],"domain_scores_gemma":[0.9971596,0.00006132805,0.00019980647,0.0023263958,0.00016815205,0.00008471379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000886235,0.0006580661,0.003242644,0.00034436534,0.00002396462,0.000023883493,0.00033213626,0.000474712,0.00065789785],"category_scores_gemma":[0.00006046892,0.00047422605,0.003985043,0.00035265204,0.00008214549,0.00020167335,0.00007874234,0.00071583246,0.0000947216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002521212,0.00012106121,0.00009305086,0.004850478,0.007471852,0.00046205826,0.00006765824,2.0127713e-7,0.000012930981,0.0000066094876,0.9062365,0.08065237],"study_design_scores_gemma":[0.0019724783,0.00025410275,0.0001242154,0.013027653,0.0010177555,0.000038489565,0.000007822195,2.2737433e-7,0.00048250187,0.000009283146,0.9826664,0.00039909707],"about_ca_topic_score_codex":0.00025049766,"about_ca_topic_score_gemma":0.0000031866764,"teacher_disagreement_score":0.28943714,"about_ca_system_score_codex":0.00014605855,"about_ca_system_score_gemma":0.00010304743,"threshold_uncertainty_score":0.99977094},"labels":[],"label_agreement":null},{"id":"W2108055674","doi":"10.18433/j3hg73","title":"Clinical Trial Risk in Type-2 Diabetes: Importance of Patient History","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Type 2 diabetes; Clinical trial; Drug; Diabetes mellitus; Internal medicine; Drug class; Pharmacology; Endocrinology","score_opus":0.11421847922615486,"score_gpt":0.43315321272142093,"score_spread":0.3189347334952661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108055674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890734,0.0043790503,0.000010305809,0.00067899755,0.0018874212,0.00032897273,9.3187447e-7,0.000008954481,0.0036319436],"genre_scores_gemma":[0.9954193,0.0019310323,0.00089926674,0.0012940618,0.00038922872,0.000003791472,5.83185e-7,0.00000793626,0.00005474741],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972077,0.0003027323,0.0012245936,0.00022306266,0.0007056484,0.0003362716],"domain_scores_gemma":[0.9982664,0.000427636,0.0007252227,0.00012382076,0.0001401448,0.0003167925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035328518,0.00014437278,0.0005608986,0.00022891068,0.00003477951,0.000010459249,0.000251346,0.000034822373,0.00055092503],"category_scores_gemma":[0.00068800227,0.00009870027,0.00026024837,0.0003392832,0.00047406254,0.00021906359,0.00006531121,0.0003962444,0.0000130263625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00596881,0.0017356635,0.7349581,0.000057639114,0.00014193486,0.000031564683,0.00011059338,0.000027994862,0.0007195188,0.00017413282,0.0040493333,0.25202468],"study_design_scores_gemma":[0.07826237,0.007887723,0.026683139,0.0001933501,0.00095326354,0.000007867517,0.00009038022,0.006667699,0.0044075293,0.00032461336,0.87428105,0.00024099898],"about_ca_topic_score_codex":0.0000066608436,"about_ca_topic_score_gemma":0.0000021112808,"teacher_disagreement_score":0.87023175,"about_ca_system_score_codex":0.00016786985,"about_ca_system_score_gemma":0.00023332071,"threshold_uncertainty_score":0.6032243},"labels":[],"label_agreement":null},{"id":"W2108771199","doi":"10.2337/diacare.26.10.2929","title":"Enhancing Incretin Action for the Treatment of Type 2 Diabetes","year":2003,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Diabetes Association; Juvenile Diabetes Research Foundation International","keywords":"Incretin; Medicine; Type 2 diabetes; Diabetes mellitus; Glucose homeostasis; Internal medicine; Endocrinology; Gastric emptying; Glucagon-like peptide-1; Exenatide; Dipeptidyl peptidase-4; Dipeptidyl peptidase; Gastric inhibitory polypeptide; Cytoprotection; Pharmacology; Glucagon; Insulin; Insulin resistance; Chemistry; Stomach; Biochemistry; Enzyme","score_opus":0.04169450956255244,"score_gpt":0.3262727724405492,"score_spread":0.28457826287799676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108771199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020509497,0.9926213,0.000002495668,0.000019738633,0.00075478206,0.0037671735,0.00012660977,0.000054815733,0.0006021472],"genre_scores_gemma":[0.0002723656,0.9952125,0.00028086346,0.00006041388,0.00027229934,0.0013711078,0.001335939,0.00009700526,0.0010975193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983504,0.0000748443,0.0005036856,0.0004062585,0.00020638279,0.00045844432],"domain_scores_gemma":[0.9981898,0.0005710505,0.0003329806,0.00063786516,0.00018423746,0.000084083484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001225415,0.00051120546,0.0017840879,0.00018358421,0.000104382976,0.000027737973,0.00013174982,0.00021856195,0.000074457865],"category_scores_gemma":[0.000060035913,0.00029699947,0.00091826677,0.00031876942,0.000061148596,0.000037490012,0.000025728134,0.00009233545,0.00008338447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000064747796,0.00015647816,0.0012213648,0.02536645,0.00183635,8.3876154e-7,0.00014724382,3.419707e-7,0.000008534091,0.000031663818,0.00069873,0.9705255],"study_design_scores_gemma":[0.00067576073,0.0017567839,0.0000506313,0.004820922,0.011406609,1.6052545e-7,0.0002403271,0.0000048291745,0.00072062475,0.000006367154,0.98008245,0.00023456047],"about_ca_topic_score_codex":0.0000026637433,"about_ca_topic_score_gemma":0.000005880548,"teacher_disagreement_score":0.9793837,"about_ca_system_score_codex":0.0004209202,"about_ca_system_score_gemma":0.00014060234,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W2109149515","doi":"10.1016/j.jcjd.2014.05.006","title":"Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?","year":2014,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Kidney Foundation of Canada","keywords":"Medicine; Diabetes mellitus; Internal medicine; Glomerular hyperfiltration; Diabetic nephropathy; Type 2 diabetes; Glycemic; Blood pressure; Endocrinology; Nephropathy; Kidney disease; Renin–angiotensin system","score_opus":0.017937997889920336,"score_gpt":0.24983815060085318,"score_spread":0.23190015271093284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109149515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09794579,0.9002191,0.000004605731,0.00010850194,0.0004520782,0.0010068176,0.000024944515,0.000015414467,0.00022274994],"genre_scores_gemma":[0.1341134,0.8643542,0.000110437344,0.00027516994,0.0005679341,0.000060644066,0.00013666495,0.00012743018,0.0002541546],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976813,0.00009007104,0.0009880511,0.00033426093,0.0002389555,0.00066735793],"domain_scores_gemma":[0.99807554,0.00014124214,0.0005313116,0.0002634869,0.00018461805,0.0008038068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004931456,0.00049004436,0.0019080167,0.0012506902,0.00008293284,0.00009200784,0.00010978094,0.00030350738,0.00009315836],"category_scores_gemma":[0.00021487992,0.00040559255,0.0003508207,0.00044982068,0.00012611879,0.00016138366,0.000016790274,0.00064610114,0.000025948622],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009169134,0.00009100923,0.002340838,0.012311002,0.00073141244,0.0005946154,0.000100156365,0.000012550045,0.000033336906,0.000011379178,0.00035022813,0.9834143],"study_design_scores_gemma":[0.001628085,0.0014062907,0.0004311864,0.03988842,0.0026385463,0.000029762827,0.000017437203,0.000055636632,0.00018276228,0.000065752,0.95312405,0.0005320686],"about_ca_topic_score_codex":0.000099442055,"about_ca_topic_score_gemma":0.002059586,"teacher_disagreement_score":0.98288226,"about_ca_system_score_codex":0.00050049723,"about_ca_system_score_gemma":0.00082997733,"threshold_uncertainty_score":0.9998396},"labels":[],"label_agreement":null},{"id":"W2109164644","doi":"10.1016/j.molmet.2013.11.010","title":"Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency","year":2013,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Deafness and Other Communication Disorders; Canadian Institutes of Health Research; University of Texas Southwestern Medical Center","keywords":"Glucose homeostasis; Glucagon-like peptide-1; Energy homeostasis; Endocrinology; Internal medicine; Homeostasis; Secretion; Chemistry; Receptor; Biology; Medicine; Insulin; Diabetes mellitus; Type 2 diabetes; Insulin resistance","score_opus":0.008307215883344382,"score_gpt":0.21459861848475348,"score_spread":0.2062914026014091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109164644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98389095,0.012423037,0.001997105,0.00013098832,0.000101390775,0.00067146536,0.000008365639,0.000024235944,0.000752462],"genre_scores_gemma":[0.9973899,0.0007772988,0.00068149704,0.00028816107,0.000024072962,0.00019270311,0.000031593747,0.000031712876,0.000583027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984672,0.000120669814,0.00033287838,0.0003436906,0.00043331392,0.0003022592],"domain_scores_gemma":[0.9991766,0.00008073007,0.00016060237,0.0003507462,0.000111955225,0.00011933731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013006241,0.00024058744,0.0005445654,0.00044085438,0.000021865106,0.000014875698,0.00010356188,0.000050577037,0.000033654476],"category_scores_gemma":[0.00006434832,0.0002011128,0.00013351932,0.00037964643,0.00005734157,0.00014549201,0.00011611707,0.00008314746,0.0000061584133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010578581,0.009833103,0.009422948,0.0026849608,0.0019926138,0.00033102586,0.0007647933,0.014792963,0.78701115,0.03649354,0.0044713463,0.13114369],"study_design_scores_gemma":[0.019190775,0.00082690374,0.3609283,0.00041977252,0.0015483537,0.000006352929,0.00022064404,0.0077283224,0.6028851,0.0034359305,0.0022109176,0.0005985918],"about_ca_topic_score_codex":0.000520269,"about_ca_topic_score_gemma":0.000017152006,"teacher_disagreement_score":0.35150534,"about_ca_system_score_codex":0.00003527997,"about_ca_system_score_gemma":0.000028305383,"threshold_uncertainty_score":0.8201142},"labels":[],"label_agreement":null},{"id":"W2109312821","doi":"10.2337/dc15-0347","title":"Incretin-Based Drugs and Adverse Pancreatic Events: Almost a Decade Later and Uncertainty Remains","year":2015,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Incretin; Hypoglycemia; Intensive care medicine; Population; Adverse effect; Diabetes mellitus; Pancreatitis; Narrative review; Liraglutide; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.01830731212754084,"score_gpt":0.29063178487092306,"score_spread":0.27232447274338223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109312821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017297784,0.9770994,1.9076825e-7,0.000104478706,0.00011362511,0.0020912231,0.00027042878,0.000102463935,0.0029203587],"genre_scores_gemma":[0.0033536975,0.9899339,0.00027466682,0.00052982324,0.00015692826,0.000479438,0.0038660734,0.00012566881,0.0012798074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978026,0.00015583329,0.00044753493,0.00065093796,0.00042061124,0.0005224964],"domain_scores_gemma":[0.99848014,0.00019402737,0.00021843472,0.0005376644,0.00018648342,0.00038324844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003093073,0.000641281,0.0019998997,0.00027213077,0.00007900179,0.000033873952,0.00012034858,0.00029140624,0.00004163345],"category_scores_gemma":[0.00012379268,0.0004694943,0.00028445988,0.00023263428,0.00011583379,0.000063603635,0.00017620524,0.0002577532,0.00010137538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026752432,0.00010085188,0.054081842,0.06263733,0.0013688965,0.00006489716,0.00070204097,0.0000010008366,3.6309007e-7,0.000025744575,0.003747491,0.8772428],"study_design_scores_gemma":[0.0019386796,0.00033658615,0.0008863638,0.018513307,0.007881083,0.0000018358824,0.0005001277,0.00002972359,0.0000015816086,0.00002161091,0.9694251,0.0004640043],"about_ca_topic_score_codex":0.000010857671,"about_ca_topic_score_gemma":0.000007835569,"teacher_disagreement_score":0.9656776,"about_ca_system_score_codex":0.00034218832,"about_ca_system_score_gemma":0.0002079622,"threshold_uncertainty_score":0.99977565},"labels":[],"label_agreement":null},{"id":"W2110020655","doi":"10.2337/diacare.28.3.600","title":"Clinical Inertia in Response to Inadequate Glycemic Control","year":2005,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":390,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Specialty; Confounding; Propensity score matching; Primary care; Insulin; Psychological intervention; Internal medicine; Intensive care medicine; Primary care physician; Emergency medicine; Family medicine; Endocrinology; Nursing","score_opus":0.013922105397514012,"score_gpt":0.299021268512845,"score_spread":0.285099163115331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110020655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167603,0.00056066643,0.000005562705,0.00488324,0.00013867415,0.0007347723,0.000017433003,0.00006150931,0.0019220981],"genre_scores_gemma":[0.9926193,0.000014114624,0.00048612637,0.005853202,0.0001813065,0.00012422926,0.00004352283,0.000025577017,0.0006526457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985987,0.000107724605,0.0003757404,0.0003197046,0.0001777983,0.00042035774],"domain_scores_gemma":[0.9991226,0.00019244145,0.00004255697,0.00035886775,0.000064019514,0.00021948342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032163574,0.00016812856,0.00040704617,0.00022472901,0.000023409306,0.00001785958,0.00010264028,0.000087474145,0.00010218673],"category_scores_gemma":[0.0002693991,0.00014606368,0.00012589015,0.00023631322,0.000033287288,0.0000692094,0.000057392743,0.00014740485,0.0015035175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019254445,0.0001697766,0.8117743,0.000034721397,0.00008215151,0.00002688242,0.00039752675,0.000043066968,0.00088064506,0.000023355902,0.0019055925,0.18273653],"study_design_scores_gemma":[0.010732513,0.0016535003,0.8359147,0.00018277974,0.00017142059,2.420816e-7,0.00032979506,0.0003130562,0.0006483208,0.000011764444,0.14982866,0.0002132875],"about_ca_topic_score_codex":0.0000049846067,"about_ca_topic_score_gemma":0.000038656897,"teacher_disagreement_score":0.18252324,"about_ca_system_score_codex":0.00019507873,"about_ca_system_score_gemma":0.000046541292,"threshold_uncertainty_score":0.99927396},"labels":[],"label_agreement":null},{"id":"W2110333911","doi":"10.1016/j.ahj.2013.07.012","title":"Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","year":2013,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Abbott Diabetes Care; Novartis Pharma; Abbott Vascular; St. Jude Medical; National Institutes of Health; Genentech; Saint Luke's Health System; ResMed; Novo Nordisk; Dexcom; Amylin Pharmaceuticals; Cleveland Clinic; Leona M. and Harry B. Helmsley Charitable Trust; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Halozyme; Sanofi; Park Nicollet Foundation","keywords":"Medicine; Liraglutide; Myocardial infarction; Diabetes mellitus; Internal medicine; Stroke (engine); Placebo; Clinical endpoint; Type 2 diabetes; Body mass index; Randomized controlled trial; Heart failure; Endocrinology","score_opus":0.0777163334936535,"score_gpt":0.33829375137668605,"score_spread":0.26057741788303257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110333911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972088,0.0005635758,0.000051973693,0.0005659006,0.00014143952,0.0013563909,5.2962764e-7,0.0000041998196,0.000107215725],"genre_scores_gemma":[0.9993049,0.00008657827,0.0003885573,0.00006979923,0.0000730458,0.000043655524,8.560758e-7,0.000007755054,0.000024852758],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981804,0.0006545215,0.0003730147,0.000108422064,0.00053432176,0.0001493087],"domain_scores_gemma":[0.99924207,0.00018740632,0.00019667656,0.00021084762,0.00011123869,0.000051787847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025434738,0.000087086584,0.00045248424,0.0001238563,0.00003119931,0.000010810553,0.00004133947,0.000021106893,0.000013655218],"category_scores_gemma":[0.000433149,0.000052861807,0.00018966146,0.00020876327,0.0001144833,0.000083911946,0.000019737705,0.00012838423,0.0000031009322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051504467,0.00048645932,0.40725863,0.00015933426,0.0024138142,0.000003642763,0.000696363,0.004483774,0.007850192,0.0000026328678,0.0017897751,0.56970495],"study_design_scores_gemma":[0.05794305,0.0055948207,0.9193978,0.00030191598,0.002490775,0.000014517666,0.00048571723,0.0048216395,0.008126936,0.00006343759,0.0006268335,0.00013257336],"about_ca_topic_score_codex":0.0001707059,"about_ca_topic_score_gemma":0.0000017106485,"teacher_disagreement_score":0.5695724,"about_ca_system_score_codex":0.000085991654,"about_ca_system_score_gemma":0.000050945702,"threshold_uncertainty_score":0.21556419},"labels":[],"label_agreement":null},{"id":"W2110382695","doi":"10.1210/en.2011-0286","title":"Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice","year":2011,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Sitagliptin; Endocrinology; Internal medicine; Sitagliptin Phosphate; Medicine; Dipeptidyl peptidase-4; Pharmacology; Diabetes mellitus; Chemistry; Type 2 diabetes","score_opus":0.042241340660705284,"score_gpt":0.27945292476525785,"score_spread":0.23721158410455256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110382695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842665,0.00046551292,0.000033468586,0.002281754,0.00021726571,0.00052374636,0.0000016199133,0.000092526636,0.012117607],"genre_scores_gemma":[0.9950407,0.0003147656,0.0022955118,0.0013457158,0.00009173022,0.000111237845,0.000008700762,0.000011007432,0.0007806261],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988129,0.000089836074,0.00020193617,0.00035195868,0.000087204404,0.00045616901],"domain_scores_gemma":[0.9996307,0.00007972722,0.000050108047,0.00016041755,0.00002742651,0.000051625295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064404536,0.00017772199,0.00030418116,0.000049676455,0.000060636496,0.0000069573985,0.00011649037,0.000091261405,0.00043699468],"category_scores_gemma":[0.0000454354,0.000102989594,0.000045829795,0.00014776454,0.00016747443,0.000058787748,0.00021838002,0.00023574529,0.00007963004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004416804,0.0036933504,0.023883464,0.00017776336,0.0015057129,0.0024635124,0.004784269,0.0000073781816,0.5336102,0.3803255,0.02008054,0.025051475],"study_design_scores_gemma":[0.020806078,0.007843658,0.41391262,0.00009410769,0.0011713179,0.00037618403,0.0023114858,0.00027713086,0.44235983,0.08472531,0.025216233,0.00090601644],"about_ca_topic_score_codex":0.00006101437,"about_ca_topic_score_gemma":0.000026944777,"teacher_disagreement_score":0.39002916,"about_ca_system_score_codex":0.000036737452,"about_ca_system_score_gemma":0.000012409608,"threshold_uncertainty_score":0.47847855},"labels":[],"label_agreement":null},{"id":"W2111069331","doi":"10.1161/circulationaha.114.010389","title":"Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial","year":2014,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":729,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Saxagliptin; Medicine; TIMI; Diabetes mellitus; Heart failure; Randomized controlled trial; Internal medicine; Cardiology; Type 2 diabetes; Endocrinology; Myocardial infarction; Sitagliptin; Percutaneous coronary intervention","score_opus":0.02283123168196418,"score_gpt":0.2386207703046963,"score_spread":0.21578953862273212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111069331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893192,0.00055851985,0.00073716394,0.0067309826,0.00022069484,0.0016184972,0.000004467571,0.00007265887,0.00073779374],"genre_scores_gemma":[0.99627,0.000025951918,0.0015382268,0.0012441105,0.00041636475,0.00010296911,0.00031336845,0.000012086558,0.00007692849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999065,0.00015500694,0.00024682854,0.00020668753,0.00017965966,0.00014684466],"domain_scores_gemma":[0.998817,0.0007129109,0.00008628464,0.00027527713,0.000051825366,0.000056688605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000481216,0.00012102839,0.00035362027,0.000040651285,0.00011756544,0.000062368876,0.000041459272,0.000055202276,0.00009360617],"category_scores_gemma":[0.00039586183,0.00008016667,0.00011986656,0.00010296722,0.00007460591,0.00011004566,0.00001834811,0.000061033228,0.00003196466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048204914,0.0003975594,0.88169837,0.000090016874,0.001418478,8.4786484e-7,0.0008005935,0.000292426,0.0018725645,0.014534645,0.014959963,0.035729595],"study_design_scores_gemma":[0.453616,0.00006834407,0.5107339,0.000068394176,0.0008559334,1.5162051e-7,0.000045224628,0.011227931,0.000095244235,0.0058067897,0.017357834,0.00012427049],"about_ca_topic_score_codex":0.00006430518,"about_ca_topic_score_gemma":0.000019580955,"teacher_disagreement_score":0.4054111,"about_ca_system_score_codex":0.000022759292,"about_ca_system_score_gemma":0.00001317889,"threshold_uncertainty_score":0.3269102},"labels":[],"label_agreement":null},{"id":"W2111155556","doi":"10.2337/dc13-2338","title":"Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":228,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Toronto General Hospital; University of Toronto","funders":"University Health Network","keywords":"Empagliflozin; Medicine; Glycemic; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Insulin; Hypoglycemia; Dapagliflozin; Randomized controlled trial; Excretion","score_opus":0.019216344086916578,"score_gpt":0.26174081668523314,"score_spread":0.24252447259831655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111155556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952788,0.00080092746,0.00000560382,0.00014567902,0.00018960836,0.0022697768,0.00017508278,0.000028881843,0.0011056733],"genre_scores_gemma":[0.9981361,0.00001587859,0.00022197314,0.0003528646,0.00008689561,0.00012291496,0.0009782109,0.00003125778,0.000053890075],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998331,0.000100516925,0.0005790934,0.00040648232,0.00023323209,0.00034966398],"domain_scores_gemma":[0.9989487,0.0001120283,0.00022492453,0.00040402557,0.00018232015,0.00012798139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002893359,0.00023241836,0.0007346583,0.00018390876,0.00002916713,0.000025959442,0.00013258593,0.000126507,0.00001714721],"category_scores_gemma":[0.00009978055,0.00020283449,0.000054578664,0.0002308723,0.00014327581,0.00026448417,0.00005278735,0.00011744778,0.0000043149903],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14462255,0.012200295,0.21560027,0.00425036,0.001318006,0.00004446856,0.011030313,0.00008260008,0.051727973,0.00056216965,0.0021979157,0.5563631],"study_design_scores_gemma":[0.64356625,0.043257672,0.020767879,0.0017315816,0.0012492938,2.8160335e-7,0.0010796163,0.0023646543,0.28175777,0.00045558988,0.0030855779,0.00068384904],"about_ca_topic_score_codex":0.000021329575,"about_ca_topic_score_gemma":0.000038857757,"teacher_disagreement_score":0.55567926,"about_ca_system_score_codex":0.000047825208,"about_ca_system_score_gemma":0.000049724436,"threshold_uncertainty_score":0.827135},"labels":[],"label_agreement":null},{"id":"W2111354330","doi":"10.2337/db14-1514","title":"Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture","year":2015,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Postprandial; Glucose homeostasis; Medal; Internal medicine; Endocrinology; Medicine; Hormone; Liraglutide; Diabetes mellitus; Blood sugar regulation; Insulin; Type 2 diabetes; Insulin resistance; Art","score_opus":0.026502685785217826,"score_gpt":0.2644231058234964,"score_spread":0.23792042003827854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111354330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96630853,0.019374501,0.00014371768,0.008300207,0.0003120721,0.00042860818,0.000004083741,0.000106873245,0.0050214077],"genre_scores_gemma":[0.993718,0.00012429092,0.00035718817,0.004595932,0.00044875764,0.0000737912,0.000045296143,0.000026383394,0.000610349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895394,0.00007314075,0.0001994529,0.00020786174,0.00027652716,0.00028909813],"domain_scores_gemma":[0.9990291,0.00028300672,0.00009476652,0.00044194798,0.00010736999,0.00004378621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038953245,0.00018055817,0.00024397335,0.000048021466,0.0001511092,0.00009740511,0.00017579425,0.00004541472,0.000095628595],"category_scores_gemma":[0.00013446731,0.000086150205,0.00007032189,0.00038955783,0.00008792726,0.000103473125,0.00009700897,0.00014074752,0.000074348274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020625614,0.00013270645,0.79162735,0.000023281595,0.0018352574,0.0000061665332,0.0025896868,0.00006854253,0.010028344,0.0075628133,0.02128756,0.16481768],"study_design_scores_gemma":[0.0019139656,0.00013614722,0.61298263,0.00012880721,0.001143094,6.77777e-7,0.001232295,0.0006720877,0.023640802,0.00601198,0.35184467,0.00029283512],"about_ca_topic_score_codex":0.00003146822,"about_ca_topic_score_gemma":0.000008410064,"teacher_disagreement_score":0.3305571,"about_ca_system_score_codex":0.000019302905,"about_ca_system_score_gemma":0.000033634296,"threshold_uncertainty_score":0.35131034},"labels":[],"label_agreement":null},{"id":"W2111611857","doi":"10.1053/j.gastro.2008.07.075","title":"Glucagon Receptor Signaling Is Essential for Control of Murine Hepatocyte Survival","year":2008,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Canada Research Chairs","keywords":"Glucagon receptor; Glucagon; Glucose homeostasis; Hepatocyte; Endocrinology; Internal medicine; Biology; Glucagon-like peptide 1 receptor; Protein kinase A; Receptor; Agonist; Cell biology; Kinase; Biochemistry; Insulin; In vitro; Insulin resistance; Medicine","score_opus":0.016924743826940425,"score_gpt":0.24975249555717036,"score_spread":0.23282775173022993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111611857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98437816,0.00006130498,0.01299524,0.0012444454,0.00038447036,0.00067675544,0.00004830383,0.00003745146,0.0001738424],"genre_scores_gemma":[0.99611884,0.00004375421,0.0018408196,0.00095905265,0.00021586752,0.00008709946,0.00008621841,0.000020688422,0.0006276421],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893916,0.000037603335,0.000293406,0.00023575735,0.000133004,0.0003610803],"domain_scores_gemma":[0.99946594,0.00004044443,0.00012106275,0.00019677382,0.000090206006,0.00008557196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115139366,0.00014571809,0.00046767385,0.00010117523,0.000043986867,0.0000024209583,0.000073234856,0.000051208935,0.0002644946],"category_scores_gemma":[0.00001890999,0.00013007478,0.00018949079,0.000042005613,0.000102995,0.00003417014,0.000032733682,0.000056951474,0.000019378786],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00974111,0.0010602755,0.9254331,0.0002330572,0.0015933068,0.000049249506,0.00028499286,0.000030719963,0.052288562,0.00019845554,0.007806662,0.0012805338],"study_design_scores_gemma":[0.18305929,0.053027947,0.27691612,0.00038177974,0.004909065,0.00023344734,0.00042265764,0.0052450546,0.39506936,0.0003009308,0.07957979,0.0008545569],"about_ca_topic_score_codex":0.000018753997,"about_ca_topic_score_gemma":0.000007073137,"teacher_disagreement_score":0.64851695,"about_ca_system_score_codex":0.000030437168,"about_ca_system_score_gemma":0.00001792485,"threshold_uncertainty_score":0.5304296},"labels":[],"label_agreement":null},{"id":"W2111738450","doi":"10.2337/diacare.29.02.06.dc05-1267","title":"Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1","year":2006,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Diabetes Association","keywords":"Amylin; Medicine; Glycemic; Postprandial; Gastric emptying; Type 2 diabetes; Diabetes mellitus; Insulin; Incretin; Hormone; Glucose homeostasis; Exenatide; Internal medicine; Endocrinology; Pharmacology; Bioinformatics; Insulin resistance; Biology","score_opus":0.01174669533312722,"score_gpt":0.2737117762110465,"score_spread":0.26196508087791925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111738450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007701424,0.9889702,6.126923e-7,0.000038358943,0.0003428084,0.0016173321,0.000025378531,0.00005860754,0.0012452777],"genre_scores_gemma":[0.0020205525,0.99618775,0.00009172524,0.00013667312,0.00017201575,0.00026959056,0.000384468,0.00008002925,0.0006571785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855465,0.00009255789,0.00038784684,0.00036128928,0.00023569852,0.0003679473],"domain_scores_gemma":[0.998699,0.00042402957,0.00027003762,0.00049014465,0.00006056983,0.000056199027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010210658,0.00045465273,0.0014676942,0.00019067545,0.00008956305,0.000037782953,0.00016222856,0.00013878806,0.000009346033],"category_scores_gemma":[0.000037145495,0.0002682332,0.00047590508,0.00022298246,0.00011433999,0.000041631814,0.00013831837,0.00019731991,0.000018421782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000012884565,0.00003853791,0.005197926,0.07540661,0.0009806483,0.000009731249,0.00048248764,1.2778821e-7,0.000004627323,0.000035232348,0.0017176352,0.9161251],"study_design_scores_gemma":[0.0004803155,0.00018881117,0.0008771459,0.023920206,0.0053518256,6.872199e-7,0.0002999641,0.0000017865341,0.000048625105,0.000015168846,0.9685726,0.00024286831],"about_ca_topic_score_codex":0.000012071902,"about_ca_topic_score_gemma":0.000005698779,"teacher_disagreement_score":0.966855,"about_ca_system_score_codex":0.00007529908,"about_ca_system_score_gemma":0.000044046545,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W2111824270","doi":"10.1016/s0140-6736(10)60576-4","title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1422,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Diabetes mellitus; Randomized controlled trial; Internal medicine; Type 2 diabetes; Creatinine; Renal function; Diabetic retinopathy; Dialysis; Renal replacement therapy; Kidney disease; Surgery; Endocrinology","score_opus":0.017059881797086212,"score_gpt":0.2958858045236296,"score_spread":0.2788259227265434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111824270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976554,0.000084961415,2.134517e-7,0.00041145747,0.00022732044,0.0013018172,0.000010120745,0.0000072952707,0.0003014117],"genre_scores_gemma":[0.99948525,0.00005620817,0.000021970664,0.00016028553,0.00006779191,0.00004739185,0.000022485392,0.000008368548,0.00013024923],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991379,0.00016850689,0.00026055524,0.00012883656,0.00016482036,0.0001394188],"domain_scores_gemma":[0.9984823,0.00040936534,0.0001656792,0.0008379802,0.00008267635,0.000022018283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043997267,0.00013103371,0.0012553462,0.00013260043,0.000013089929,0.0000031563086,0.00016828958,0.000042879474,0.00003480936],"category_scores_gemma":[0.00032334242,0.00005388175,0.00041049806,0.00034890074,0.000089461304,0.00001579105,0.00002603095,0.000067841094,0.0000017547512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15429568,0.0014951994,0.7617761,0.00015190645,0.012885736,0.000005488075,0.0010153583,0.00010320596,0.04618161,0.00011170775,0.00024463382,0.02173336],"study_design_scores_gemma":[0.37282634,0.009932801,0.35840574,0.000087012515,0.013391314,1.6717006e-7,0.0001320118,0.00035043305,0.24428895,0.000025476953,0.00044809,0.00011167046],"about_ca_topic_score_codex":0.00009246324,"about_ca_topic_score_gemma":0.00009863667,"teacher_disagreement_score":0.40337035,"about_ca_system_score_codex":0.000027606364,"about_ca_system_score_gemma":0.000016082604,"threshold_uncertainty_score":0.2197234},"labels":[],"label_agreement":null},{"id":"W2111876001","doi":"10.1007/s00125-012-2534-0","title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","year":2012,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3932,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Abbott Diabetes Care; Novartis Pharma; University of Illinois at Urbana-Champaign; Servier; Université de Nantes; European Association for the Study of Diabetes; Novo Nordisk; University of Melbourne; University of Southern California; University of Sydney; Health Science Center, University of Tennessee; National Institute for Health and Care Research; National Institutes of Health; School of Medicine, Case Western Reserve University; Dexcom; Leonard M. Miller School of Medicine, University of Miami; Georgetown University; Intarcia Therapeutics; American Diabetes Association; MedStar Health Research Institute; Leona M. and Harry B. Helmsley Charitable Trust; F. Hoffmann-La Roche; Wayne State University; Leonard M. Miller School of Medicine; University of Toronto; Yale University; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; School of Medicine, University of Kansas; Pfizer; University of Miami; AstraZeneca; Halozyme; Case Western Reserve University; University of Ioannina; Amylin Pharmaceuticals; Sanofi","keywords":"Diabetes mellitus; Position statement; Medicine; Association (psychology); Type 2 diabetes; Human physiology; Endocrinology; Internal medicine; Gerontology; Family medicine; Psychology","score_opus":0.013628302475869195,"score_gpt":0.23961613661557954,"score_spread":0.22598783413971035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111876001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421936,0.00087579596,0.0000062846575,0.000511767,0.00021450728,0.003300701,0.000030309357,0.000017823422,0.00082342234],"genre_scores_gemma":[0.99905825,0.00012176127,0.00014974155,0.0001577749,0.000030092084,0.00031926046,0.00004530738,0.000024286936,0.00009351065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974725,0.0006466182,0.00066190737,0.00022739063,0.00052423123,0.0004673487],"domain_scores_gemma":[0.997343,0.0007575966,0.0012714047,0.00041660725,0.00017048889,0.000040872834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022333986,0.00021158939,0.0006301705,0.000103504455,0.00009179791,0.000016963972,0.00021123588,0.000042591073,0.0000029162707],"category_scores_gemma":[0.00027387476,0.00011352585,0.00014197838,0.00048936217,0.00014494194,0.00009830307,0.00021309806,0.0001210609,9.968284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096531316,0.0017190056,0.98014975,0.0002738768,0.0018627923,1.3922052e-7,0.0014864134,0.00003980888,0.00036865028,0.00022093393,0.0002981474,0.0134839695],"study_design_scores_gemma":[0.0046376484,0.00097204425,0.98595315,0.00013525301,0.0016968822,1.4567385e-8,0.0035267142,0.0004533514,0.002255181,0.00006484767,0.00019188011,0.0001130277],"about_ca_topic_score_codex":0.000018000688,"about_ca_topic_score_gemma":0.0000062554373,"teacher_disagreement_score":0.013370941,"about_ca_system_score_codex":0.00024977024,"about_ca_system_score_gemma":0.000011639688,"threshold_uncertainty_score":0.46294495},"labels":[],"label_agreement":null},{"id":"W2111948659","doi":"10.1136/bmjopen-2014-005752","title":"Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis","year":2014,"lang":"en","type":"review","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; Ottawa Hospital; University of Ottawa; McMaster University; University of Calgary; St. Michael's Hospital","funders":"National Institute on Deafness and Other Communication Disorders; Canadian Institutes of Health Research; Ministry of Health, British Columbia; Fondation pour la Recherche Médicale; Alberta Innovates; University of Ottawa","keywords":"Medicine; Placebo; Internal medicine; Meta-analysis; Insulin; Dipeptidyl peptidase-4 inhibitor; Dipeptidyl peptidase-4; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology; Pathology; Alternative medicine","score_opus":0.10725418835895335,"score_gpt":0.40490617347274477,"score_spread":0.29765198511379143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111948659","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008440002,0.9448821,0.000032268006,0.00000760448,0.00013948296,0.053870548,0.0000871381,0.000020354237,0.00011649911],"genre_scores_gemma":[0.00238429,0.9860121,0.0016074722,0.00008914865,0.00007486865,0.007828646,0.0015898873,0.00013613926,0.00027747086],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962876,0.00092145713,0.001378563,0.00070398813,0.0003231695,0.0003852354],"domain_scores_gemma":[0.9952112,0.0021606842,0.0015631169,0.0006912968,0.0002198405,0.0001538934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033553762,0.0006691598,0.010940612,0.00023647326,0.00009606898,0.000099189485,0.00026168537,0.0001212439,0.000046021574],"category_scores_gemma":[0.0009916553,0.00036280588,0.0008023144,0.0007915127,0.00007763284,0.00018033928,0.00050994166,0.00015631062,0.000005915635],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001472994,0.00011516448,0.00068817753,0.8315277,0.1518986,0.0000043617083,0.00002178235,0.0000051399643,2.48047e-8,0.0000045333923,0.00005714501,0.014204396],"study_design_scores_gemma":[0.00504864,0.0014529323,0.000058199545,0.29334345,0.69359434,7.8751765e-7,0.000019310899,0.00003365538,4.2740527e-7,8.760852e-7,0.0060613784,0.0003860015],"about_ca_topic_score_codex":0.000015558757,"about_ca_topic_score_gemma":0.0000291856,"teacher_disagreement_score":0.5416957,"about_ca_system_score_codex":0.00012220438,"about_ca_system_score_gemma":0.00010983972,"threshold_uncertainty_score":0.9998824},"labels":[],"label_agreement":null},{"id":"W2112228502","doi":"10.1517/13543784.12.1.87","title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Incretin; Dipeptidyl peptidase; Aminopeptidase; Peptide; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Type 2 diabetes; Sitagliptin; Chemistry; Pharmacology; Biochemistry; Endocrinology; Internal medicine; Biology; Diabetes mellitus; Medicine; Enzyme; Amino acid","score_opus":0.02959327137273806,"score_gpt":0.2913622153120864,"score_spread":0.26176894393934835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112228502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728742,0.012396391,0.00015395648,0.006621084,0.0020091322,0.002811562,0.00005311198,0.00006273548,0.0030178023],"genre_scores_gemma":[0.9956123,0.0011397479,0.0011147123,0.00072214624,0.00023010373,0.00024559454,0.00017467173,0.000023274792,0.00073743047],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990109,0.000043462078,0.00028408383,0.00018945,0.0003070289,0.00016506133],"domain_scores_gemma":[0.9991738,0.00024922017,0.00013010584,0.00023950913,0.00012935809,0.00007799614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113054244,0.00016372219,0.00023826964,0.00009350189,0.00007788175,0.000008051818,0.000058878675,0.000047736034,0.000093273185],"category_scores_gemma":[0.000053027525,0.00010207802,0.00017241098,0.00014981956,0.00018859886,0.000044405664,0.000007255219,0.000030120753,0.000010054607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001957906,0.014788178,0.038770843,0.0007143906,0.0071785212,0.0000039949887,0.015425104,0.0023254815,0.12606,0.5154888,0.08388976,0.193397],"study_design_scores_gemma":[0.009369196,0.0088431295,0.016221084,0.00044873153,0.0002186479,0.000001192477,0.0013391036,0.0025281238,0.3341505,0.0066788336,0.61980194,0.0003995658],"about_ca_topic_score_codex":0.000008814109,"about_ca_topic_score_gemma":2.3245778e-7,"teacher_disagreement_score":0.53591216,"about_ca_system_score_codex":0.00007191397,"about_ca_system_score_gemma":0.000092932176,"threshold_uncertainty_score":0.41626206},"labels":[],"label_agreement":null},{"id":"W2113021949","doi":"10.1210/en.2002-0049","title":"Aberrant Regulation of Human Intestinal Proglucagon Gene Expression in the NCI-H716 Cell Line","year":2003,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"","keywords":"Proglucagon; Sodium butyrate; Biology; Endocrinology; Internal medicine; Forskolin; Butyrate; Gene expression; Enteroendocrine cell; Glucagon-like peptide-1; Molecular biology; Gene; Biochemistry; Hormone; Stimulation","score_opus":0.027147327607282692,"score_gpt":0.2832728673203699,"score_spread":0.2561255397130872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113021949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97618747,0.00037030695,0.00011525503,0.00037650313,0.00007813684,0.00049346307,5.739414e-7,0.000024097852,0.022354182],"genre_scores_gemma":[0.99598604,0.000027679238,0.0020329624,0.000112757654,0.000036789643,0.000059450424,0.000032294905,0.00000872468,0.0017033037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991765,0.00009332938,0.00022215265,0.00016602482,0.00011587923,0.000226084],"domain_scores_gemma":[0.9995686,0.000040674022,0.00008077686,0.00025808875,0.000029728182,0.000022149185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011060018,0.00009824212,0.00018268138,0.00011635203,0.000031202366,0.0000033153485,0.00007153692,0.00003121119,0.00012315494],"category_scores_gemma":[0.00003869569,0.00006414411,0.000040517414,0.00010997375,0.000055275046,0.000027703172,0.000025843356,0.00010070177,0.000016145399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120652316,0.0017426382,0.07159314,0.00016889822,0.00004226313,0.00016137306,0.0010407236,0.000031887357,0.9058256,0.0098867025,0.0017310744,0.00765505],"study_design_scores_gemma":[0.0028895098,0.0012364906,0.090804614,0.000071226954,0.00008658066,0.000041369585,0.0002613653,0.000026403808,0.8962406,0.0010300312,0.007226851,0.0000849723],"about_ca_topic_score_codex":0.000015447189,"about_ca_topic_score_gemma":0.000011080423,"teacher_disagreement_score":0.020650877,"about_ca_system_score_codex":0.000031104773,"about_ca_system_score_gemma":0.00001574813,"threshold_uncertainty_score":0.26157206},"labels":[],"label_agreement":null},{"id":"W2113411572","doi":"10.1111/j.1463-1326.2010.01254.x","title":"Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Merck Canada","keywords":"Sitagliptin; Medicine; Metformin; Internal medicine; Insulin; Placebo; Sitagliptin Phosphate; Endocrinology; Diabetes mellitus; Beta cell; Insulin resistance; Type 2 diabetes; Pharmacology; Islet","score_opus":0.0534038358896754,"score_gpt":0.3209368514847031,"score_spread":0.2675330155950277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113411572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948186,0.0008079227,0.00010815935,0.0002922385,0.0001087148,0.0035632367,0.000014387141,0.000042023865,0.00024469834],"genre_scores_gemma":[0.99792975,0.00008301696,0.00064899644,0.00037720782,0.00011432099,0.0005861319,0.000113452355,0.000027094311,0.00012000407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985914,0.00010509574,0.000292261,0.00034045856,0.00039568698,0.0002750757],"domain_scores_gemma":[0.99851173,0.0001864672,0.0001788976,0.00036822126,0.00065819384,0.000096502816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073912466,0.000236237,0.00045623578,0.0001283822,0.00019073868,0.00005273191,0.00011277767,0.00004938569,0.000030741845],"category_scores_gemma":[0.00009097204,0.00013477483,0.000046038393,0.00024799735,0.00019058758,0.0002609039,0.000043712844,0.00020629361,0.0000020411362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044304268,0.0076010725,0.8295591,0.00041805345,0.0030897425,0.0000053030594,0.0034346008,0.00003370589,0.058695726,0.001507083,0.00009693807,0.09112824],"study_design_scores_gemma":[0.008400636,0.022639232,0.9519724,0.00007243405,0.0026893965,9.360315e-7,0.001355576,0.0005101196,0.011553549,0.00037952152,0.00023067076,0.00019552119],"about_ca_topic_score_codex":0.00006873527,"about_ca_topic_score_gemma":0.00009814693,"teacher_disagreement_score":0.1224133,"about_ca_system_score_codex":0.000008235967,"about_ca_system_score_gemma":0.00010727728,"threshold_uncertainty_score":0.5495958},"labels":[],"label_agreement":null},{"id":"W2113605780","doi":"10.1210/en.2012-1549","title":"A Beautiful Cell (or Two or Three?)","year":2012,"lang":"en","type":"letter","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto; Eli Lilly and Company","keywords":"Internal medicine; Endocrinology; Medicine; Biology","score_opus":0.039326265372784074,"score_gpt":0.2923753471244129,"score_spread":0.2530490817516288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113605780","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042867684,0.0032850166,0.0000676932,0.7921904,0.0037333574,0.0021710426,0.00005128085,0.00057220086,0.19364226],"genre_scores_gemma":[0.0044921646,0.00030223688,0.0011307904,0.5891777,0.006868812,0.0003656917,0.000751486,0.00013301623,0.39677808],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754685,0.000052050273,0.00032262833,0.0005306446,0.00025763296,0.0012902116],"domain_scores_gemma":[0.99874395,0.00014870393,0.00014913097,0.0008103201,0.00003861322,0.00010930524],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004085694,0.0004814085,0.00083274674,0.00031043676,0.000056125988,0.00001794599,0.00024332931,0.0003557958,0.00705806],"category_scores_gemma":[0.000023280038,0.00030651237,0.000209241,0.00012529625,0.00012722166,0.00005189348,0.00023820315,0.0010888736,0.0036135416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001725855,0.0002081121,0.0018420677,0.00037450515,0.00057016086,0.008518954,0.000038171787,7.688139e-8,0.00002066033,0.00013229725,0.9728087,0.015313663],"study_design_scores_gemma":[0.0032985245,0.00081211375,0.00064072723,0.00005680075,0.0013035155,0.00024084673,0.000012440792,0.0000023277767,0.00035895244,0.000088675275,0.9928767,0.0003083898],"about_ca_topic_score_codex":0.000080754726,"about_ca_topic_score_gemma":0.000080189755,"teacher_disagreement_score":0.20313583,"about_ca_system_score_codex":0.00014682474,"about_ca_system_score_gemma":0.00010617327,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2113936882","doi":"10.1006/bbrc.2002.6607","title":"Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1","year":2002,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Metformin; Glucagon-like peptide-1; Surface plasmon resonance; Chemistry; Dipeptidyl peptidase; Dipeptidyl peptidase-4; Internal medicine; Endocrinology; Hydrolysis; Peptide; Vildagliptin; Glycemic; Enzyme; Pharmacology; Biochemistry; Diabetes mellitus; Type 2 diabetes; Medicine; Nanoparticle; Nanotechnology; Materials science","score_opus":0.08153660429434237,"score_gpt":0.35367529170505063,"score_spread":0.27213868741070824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113936882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98286635,0.0009936321,0.000011581157,0.0042337556,0.000015818208,0.0006509155,0.000011420593,0.000041901905,0.011174645],"genre_scores_gemma":[0.9927238,0.0015102597,0.001679271,0.00013007486,0.000050864335,0.0001286936,0.000105766914,0.000012671056,0.003658557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868995,0.00011338206,0.00020193032,0.00024002677,0.00046816317,0.00028656187],"domain_scores_gemma":[0.9977961,0.0007893325,0.000042367796,0.0009893851,0.0001661641,0.00021661229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023493453,0.00013035804,0.00023977131,0.00015798447,0.00015732856,0.000023332603,0.0002882496,0.0000723964,0.000038632414],"category_scores_gemma":[0.00030929805,0.00009682954,0.00010055856,0.0004638765,0.0004997362,0.00006325533,0.000305145,0.00029916078,0.000119102246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012474523,0.0034941917,0.0003934062,0.00032694472,0.00018523274,0.0000059777576,0.000117999094,5.3079827e-8,0.83950424,0.014978726,0.020478733,0.12038976],"study_design_scores_gemma":[0.0033138383,0.0034303071,0.0082850475,0.00087454,0.00029838915,0.0000045372544,0.0002080129,0.0034299367,0.9262207,0.0015781152,0.05198101,0.00037552288],"about_ca_topic_score_codex":0.000028784221,"about_ca_topic_score_gemma":0.0000013843495,"teacher_disagreement_score":0.120014235,"about_ca_system_score_codex":0.000061854655,"about_ca_system_score_gemma":0.000014495854,"threshold_uncertainty_score":0.39485943},"labels":[],"label_agreement":null},{"id":"W2114027444","doi":"10.2337/dc13-2855","title":"Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Sitagliptin; Type 2 diabetes; Internal medicine; Regimen; Dulaglutide; Dipeptidyl peptidase-4 inhibitor; Clinical endpoint; Adverse effect; Diabetes mellitus; Renal function; Nausea; Gastroenterology; Liraglutide; Endocrinology; Randomized controlled trial","score_opus":0.00594548738920311,"score_gpt":0.23057151787577979,"score_spread":0.22462603048657667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114027444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538726,0.00048186228,3.6458357e-7,0.00010997403,0.00015819386,0.0031820196,0.000032629505,0.000026329202,0.00062136486],"genre_scores_gemma":[0.99939543,0.00002690452,0.00009469579,0.00008735838,0.00003717167,0.000106762636,0.00014495914,0.000028117276,0.00007858061],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983571,0.0002197789,0.00037691282,0.000371893,0.0003211299,0.0003531827],"domain_scores_gemma":[0.9988269,0.00036365382,0.00018303274,0.00038093326,0.00012600365,0.00011947715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034443024,0.00027845107,0.000829684,0.00010933486,0.00010219887,0.00003123704,0.000103324215,0.000053328306,0.00002690519],"category_scores_gemma":[0.0001998213,0.00016919272,0.00007842445,0.00025621778,0.00024478827,0.00007671719,0.00014729922,0.00012333017,0.0000053000067],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055411,0.0015653245,0.9245659,0.00017309879,0.0007654494,9.047056e-7,0.0023931216,0.0000045154784,0.00015567771,0.000025139218,0.00018811418,0.014751763],"study_design_scores_gemma":[0.54063594,0.0063020093,0.4492767,0.0003541261,0.0010167371,1.5288833e-8,0.0009883062,0.000061756036,0.00054251554,0.000004967878,0.00062236824,0.00019455308],"about_ca_topic_score_codex":0.000013260988,"about_ca_topic_score_gemma":0.000025487654,"teacher_disagreement_score":0.48522496,"about_ca_system_score_codex":0.0000819217,"about_ca_system_score_gemma":0.000029223525,"threshold_uncertainty_score":0.68994784},"labels":[],"label_agreement":null},{"id":"W2114103060","doi":"10.1016/j.schres.2008.12.012","title":"Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model","year":2009,"lang":"en","type":"article","venue":"Schizophrenia Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Ziprasidone; Olanzapine; Clozapine; Antipsychotic; Haloperidol; Atypical antipsychotic; Internal medicine; Risperidone; Endocrinology; Insulin resistance; Medicine; Diabetes mellitus; Insulin; Glucose clamp technique; Pharmacology; Dopamine antagonist; Schizophrenia (object-oriented programming); Pancreatic hormone; Psychiatry; Dopamine","score_opus":0.029967637873818252,"score_gpt":0.3401721148858183,"score_spread":0.31020447701200005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114103060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970174,0.0006151603,0.000017918679,0.0006153094,0.000016972064,0.0007664155,0.0000026764085,0.000015679769,0.0009324869],"genre_scores_gemma":[0.99789214,0.00048320982,0.00119675,0.000029715238,0.000024602992,0.000024235642,0.000010358309,0.000011172914,0.0003278333],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985552,0.00012958443,0.00022481487,0.00030431233,0.00043931484,0.00034676163],"domain_scores_gemma":[0.99942964,0.00008178023,0.0000287731,0.00027802557,0.000066423,0.00011533145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042877416,0.000119700766,0.000279833,0.00054623914,0.00002954309,0.000021298121,0.00008923593,0.00007454649,0.0000068329523],"category_scores_gemma":[0.00007690967,0.00010168713,0.00002546472,0.00043879,0.00007809879,0.000103892155,0.000041311338,0.00027682804,0.0000019423212],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07248944,0.010663575,0.21616648,0.0030987721,0.000120335775,0.00066799164,0.0027700518,0.00012318678,0.5433495,0.066471845,0.0011720753,0.08290674],"study_design_scores_gemma":[0.009535973,0.0022809778,0.9464369,0.00072485703,0.000020640704,5.706755e-7,0.00005780221,0.015889797,0.01298092,0.01191898,0.00002213758,0.00013043678],"about_ca_topic_score_codex":0.000009665918,"about_ca_topic_score_gemma":0.00031168116,"teacher_disagreement_score":0.73027045,"about_ca_system_score_codex":0.000093772825,"about_ca_system_score_gemma":0.00004164326,"threshold_uncertainty_score":0.41466808},"labels":[],"label_agreement":null},{"id":"W2114506972","doi":"10.1111/dom.12444","title":"<scp>LEADER</scp> 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the <scp>L</scp> iraglutide <scp>E</scp> ffect and <scp>A</scp> ction in <scp>D</scp> iabetes: <scp>E</scp> valuation of cardiovascular outcome <scp>R</scp> esults ( <scp>LEADER</scp> ) trial: preliminary observations","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novartis Pharma; Novo Nordisk Fonden; Astellas Pharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Orexigen Therapeutics; F. Hoffmann-La Roche; Novo Nordisk; Medicines Company; Intarcia Therapeutics; GlaxoSmithKline; Osiris Therapeutics; Halozyme; Sanofi; St. Jude Medical; MannKind Corporation; Pfizer","keywords":"Medicine; Calcitonin; Gerontology; Internal medicine","score_opus":0.04427697335830322,"score_gpt":0.2587140336290045,"score_spread":0.2144370602707013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114506972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91574436,0.06050746,0.000315648,0.00031677692,0.0028579629,0.013435972,0.00077656633,0.0010013652,0.0050439057],"genre_scores_gemma":[0.9573047,0.009871259,0.003069488,0.002493029,0.0025183302,0.004576921,0.004633735,0.0010792873,0.014453217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9698626,0.0056913076,0.0060428414,0.0055427295,0.0058027767,0.0070577874],"domain_scores_gemma":[0.9498673,0.0369542,0.0034215425,0.004764414,0.0023902778,0.0026022792],"candidate_categories":["metaresearch","metaepi_narrow","sts","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.017350616,0.0048572123,0.009204896,0.005006119,0.0014296774,0.0013013334,0.0027185031,0.0028796967,0.0000105033605],"category_scores_gemma":[0.07644753,0.004303288,0.0023973472,0.009351858,0.001668585,0.0037098164,0.0016102808,0.0041757924,0.00027227154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001607626,0.0124101015,0.8021524,0.0061901663,0.010785993,0.0005243996,0.05990456,0.009575192,0.0051496136,0.0014648488,0.087287016,0.004394948],"study_design_scores_gemma":[0.073627576,0.005431276,0.62429816,0.0025072538,0.012618636,0.000054812153,0.053568546,0.011583276,0.015944598,0.0021157004,0.1977783,0.00047188636],"about_ca_topic_score_codex":0.0013932972,"about_ca_topic_score_gemma":0.0010822561,"teacher_disagreement_score":0.17785425,"about_ca_system_score_codex":0.001148869,"about_ca_system_score_gemma":0.0014350271,"threshold_uncertainty_score":0.9998703},"labels":[],"label_agreement":null},{"id":"W2114591044","doi":"10.1210/endo.142.1.7870","title":"Coregulation of Glucagon-Like Peptide-1 Synthesis with Proglucagon and Prohormone Convertase 1 Gene Expression in Enteroendocrine GLUTag Cells**This work was supported by operating grants (to P.L.B.) from the Canadian Diabetes Association and the Medical Research Council of Canada.","year":2001,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Proglucagon; Prohormone convertase; Internal medicine; Prohormone; Endocrinology; Glucagon-like peptide-1; Enteroendocrine cell; Glucagon; Gene expression; Biology; Gene; Chemistry; Endocrine system; Biochemistry; Hormone; Medicine; Diabetes mellitus","score_opus":0.020616517445529475,"score_gpt":0.24142099561951452,"score_spread":0.22080447817398505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114591044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98788923,0.00088130974,0.0000022878905,0.0096897585,0.00005969548,0.001159512,0.00005244394,0.000007911164,0.0002578605],"genre_scores_gemma":[0.99812543,0.00030484592,0.0001427249,0.0003719167,0.000027006503,0.00022465388,0.000065054635,0.000015643218,0.0007227347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974164,0.00033926746,0.00036292672,0.00029868682,0.0010169847,0.0005657542],"domain_scores_gemma":[0.9981163,0.0009861114,0.00013260423,0.00025208812,0.00032267824,0.00019023048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094056595,0.00015613645,0.00041823677,0.00010170645,0.00016737902,0.00001848999,0.0001304534,0.00006001481,0.0001102154],"category_scores_gemma":[0.0010358103,0.000091124646,0.00001941684,0.00024638153,0.00025423593,0.000047324047,0.00009740719,0.00022012815,9.4618935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009869193,0.00020366798,0.950554,0.00006680352,0.00040425945,0.00018737344,0.00213783,0.000007647853,0.015101118,0.000028365168,0.022056773,0.008265218],"study_design_scores_gemma":[0.014845369,0.0009641417,0.6266702,0.0010203985,0.0004943346,0.000022751346,0.0017619208,0.0013126519,0.32992578,0.00006094534,0.022548074,0.0003734782],"about_ca_topic_score_codex":0.61931217,"about_ca_topic_score_gemma":0.8875006,"teacher_disagreement_score":0.32388386,"about_ca_system_score_codex":0.0008578767,"about_ca_system_score_gemma":0.0011326913,"threshold_uncertainty_score":0.38322285},"labels":[],"label_agreement":null},{"id":"W2114702224","doi":"","title":"Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.","year":2011,"lang":"en","type":"review","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Randomized controlled trial; Meta-analysis; Internal medicine; Hypoglycemia; MEDLINE; Adverse effect; Diabetes mellitus; Pharmacology; Insulin; Endocrinology","score_opus":0.09803282321020572,"score_gpt":0.2929628930868581,"score_spread":0.19493006987665235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114702224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007731015,0.96456826,0.0000017514787,0.000031429827,0.000025787953,0.03421982,0.000034343375,0.00004919441,0.00029630118],"genre_scores_gemma":[0.0016244492,0.95241416,0.0001033685,0.00029666652,0.0000115458315,0.043007456,0.0005045616,0.00009618169,0.0019416272],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99624985,0.0004861313,0.0015108879,0.0007501432,0.0003798481,0.000623157],"domain_scores_gemma":[0.99708813,0.0002487177,0.0013256102,0.0009359011,0.00016301982,0.00023859147],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00083661167,0.0010688651,0.018141782,0.0007481349,0.000040674808,0.000057550184,0.00018646306,0.00015377735,0.0001561781],"category_scores_gemma":[0.000038267422,0.00046087863,0.001343372,0.0011553008,0.00006509957,0.00011220486,0.00003404321,0.00018370882,0.0000129705495],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038367158,0.0014090426,0.0014544649,0.2538361,0.54826176,0.000012030425,0.000036106958,2.1688058e-7,6.434322e-10,0.000013691778,0.000040337225,0.1945526],"study_design_scores_gemma":[0.010677654,0.002350656,0.001356263,0.0124975955,0.93627083,9.88565e-7,0.0000053713297,0.000002051114,6.9443104e-7,0.0000026704554,0.036322877,0.0005123279],"about_ca_topic_score_codex":0.000021592881,"about_ca_topic_score_gemma":0.00016622072,"teacher_disagreement_score":0.3880091,"about_ca_system_score_codex":0.00028004355,"about_ca_system_score_gemma":0.00007158015,"threshold_uncertainty_score":0.9997843},"labels":[],"label_agreement":null},{"id":"W2114762146","doi":"10.1210/endo.141.10.7750","title":"Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist<sup>1</sup>","year":2000,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage Medical Research Clinic; University of Alberta","funders":"","keywords":"Internal medicine; Endocrinology; Gastric inhibitory polypeptide; Insulin; Receptor; Glucagon; Biology; Receptor antagonist; Antagonist; Chemistry; Medicine","score_opus":0.01252096758847448,"score_gpt":0.26949360783531173,"score_spread":0.25697264024683725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114762146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900251,0.0009997598,0.00007312545,0.0032406715,0.00014068985,0.0013593418,0.000066580425,0.00020936818,0.003885385],"genre_scores_gemma":[0.9907865,0.0011318846,0.0011809095,0.0019952862,0.00011851614,0.00024075412,0.00035834737,0.00005003914,0.0041377437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740386,0.00016151514,0.00060097786,0.0006713449,0.0002786456,0.00088366383],"domain_scores_gemma":[0.99899334,0.000054337936,0.00008176402,0.0004807087,0.000050922365,0.00033891413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009109736,0.00037582358,0.00059523614,0.00033709075,0.00009124592,0.000049549973,0.00018835942,0.00013514142,0.0016211858],"category_scores_gemma":[0.000060543618,0.00036670794,0.000107364736,0.00032732493,0.00012448234,0.00018801483,0.000066885696,0.00033935782,0.0017272058],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074367323,0.005730399,0.030539973,0.000084918305,0.0005596848,0.002022967,0.0013350797,0.00016115577,0.038685374,0.0014922317,0.01458081,0.8973707],"study_design_scores_gemma":[0.07319817,0.015166446,0.022491235,0.00026978212,0.00071668485,0.00019416776,0.0014497713,0.0014142316,0.25936535,0.00024630988,0.6238647,0.0016231217],"about_ca_topic_score_codex":0.0007708021,"about_ca_topic_score_gemma":0.000105250474,"teacher_disagreement_score":0.89574754,"about_ca_system_score_codex":0.00031949882,"about_ca_system_score_gemma":0.00011715121,"threshold_uncertainty_score":0.99987847},"labels":[],"label_agreement":null},{"id":"W2115024823","doi":"10.9778/cmajo.20140060","title":"The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study","year":2015,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research; Astellas Pharma; Novo Nordisk; Sanofi; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Sitagliptin; Medicine; Acute pancreatitis; Odds ratio; Internal medicine; Population; Metformin; Insulin","score_opus":0.01571556425592623,"score_gpt":0.2791003738466118,"score_spread":0.26338480959068555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115024823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030894,0.00012912467,0.000007738726,0.00018515732,0.000027967611,0.0044042696,0.000004088966,0.000012847477,0.004919862],"genre_scores_gemma":[0.9981603,0.000034281096,0.00026149867,0.000098097895,0.00001488103,0.00045203124,0.000040712075,0.000013236502,0.00092495204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924916,0.000080337115,0.00016998073,0.00016309376,0.0002175767,0.00011986263],"domain_scores_gemma":[0.9993587,0.000067098445,0.00009524826,0.00035219028,0.0000753425,0.000051379437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004629824,0.00009375961,0.00024032455,0.000042365635,0.00003812814,0.000034735112,0.0001376243,0.000016963106,0.000042496973],"category_scores_gemma":[0.000043765405,0.000049492097,0.000022420461,0.00015795603,0.000020258458,0.00006444471,0.00004162493,0.00004634719,0.00000911773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064465136,0.00069705,0.9849687,0.000006102042,0.00021929861,0.000012584757,0.0006207206,0.000025974523,3.5074555e-7,0.000023394266,0.000516112,0.012265016],"study_design_scores_gemma":[0.010510895,0.0014456025,0.9857498,0.00009750118,0.0001291765,2.0170506e-7,0.001395286,0.0001117698,0.000025378971,0.000020795813,0.00045305755,0.00006056151],"about_ca_topic_score_codex":0.014670377,"about_ca_topic_score_gemma":0.004604767,"teacher_disagreement_score":0.012204454,"about_ca_system_score_codex":0.00005867421,"about_ca_system_score_gemma":0.000051517607,"threshold_uncertainty_score":0.991891},"labels":[],"label_agreement":null},{"id":"W2115236055","doi":"10.2337/dc09-1867","title":"Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy","year":2010,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute for Health and Care Research","keywords":"Vildagliptin; Glimepiride; Medicine; Metformin; Postprandial; Sulfonylurea; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus; Glucagon-like peptide-1; Post-prandial; Glucagon; Insulin","score_opus":0.009317937667218102,"score_gpt":0.22989329456044924,"score_spread":0.22057535689323113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115236055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514824,0.0002879341,5.601393e-7,0.00021438987,0.000095598305,0.003744606,0.000061876955,0.00007403248,0.0003727348],"genre_scores_gemma":[0.9961648,0.000036343477,0.00097311265,0.00038262655,0.00008251184,0.0016952041,0.00022326518,0.00010052139,0.00034161622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978191,0.00006153484,0.00031447073,0.0005867634,0.0004206237,0.0007974691],"domain_scores_gemma":[0.9988791,0.000121177975,0.00015613833,0.00047247665,0.0001878647,0.00018324004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013213124,0.0005650958,0.0010852154,0.00045858696,0.000046826903,0.00006454295,0.00011544958,0.00014372892,0.00019117843],"category_scores_gemma":[0.000026472844,0.0002998405,0.0000695008,0.0005575039,0.000114281655,0.00019409908,0.000029384208,0.00022392868,0.000032189964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018421864,0.00089069566,0.95089734,0.00012475859,0.00061946886,0.000079069345,0.0015677348,0.0000057606194,0.00029098356,0.000006669924,0.000009057613,0.027086584],"study_design_scores_gemma":[0.09377843,0.025632994,0.86641777,0.0005554048,0.0006101322,3.6392376e-7,0.0007297348,0.000037461887,0.009684971,0.0000058414403,0.0019808193,0.0005660547],"about_ca_topic_score_codex":0.000049069087,"about_ca_topic_score_gemma":0.008047448,"teacher_disagreement_score":0.08447956,"about_ca_system_score_codex":0.00026931273,"about_ca_system_score_gemma":0.00015182981,"threshold_uncertainty_score":0.99994534},"labels":[],"label_agreement":null},{"id":"W2115337061","doi":"10.2337/db11-0251","title":"Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes","year":2011,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Deutsche Forschungsgemeinschaft; Medical Research Council; Sundhed og Sygdom, Det Frie Forskningsråd; GlaxoSmithKline","keywords":"Internal medicine; Endocrinology; Pulsatile flow; Type 2 diabetes; Medicine; Glucagon; Diabetes mellitus; Insulin; Secretion","score_opus":0.022989280799969397,"score_gpt":0.2239480292843993,"score_spread":0.2009587484844299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115337061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978864,0.00012562216,4.687396e-7,0.000023506049,0.000035853496,0.00042766987,0.000014235431,0.00002347955,0.0014627712],"genre_scores_gemma":[0.9990816,0.0000081724675,0.0003912261,0.000054705684,0.000013038468,0.000029615427,0.0003233738,0.000017282791,0.0000809809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992196,0.00004016975,0.0001960745,0.00017863313,0.00016555875,0.00019998827],"domain_scores_gemma":[0.9995224,0.00008702144,0.000097298616,0.00017370249,0.000053205073,0.00006638717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013944002,0.00012077366,0.00024750567,0.00019864604,0.000032149976,0.0000047944645,0.00004481659,0.000047840247,0.0001221489],"category_scores_gemma":[0.000076639226,0.00010017717,0.000022703542,0.0002839156,0.00007860888,0.0001304547,0.00004951743,0.00008880848,0.000008180422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005233119,0.00024112093,0.9967979,0.00011446869,0.00007767184,7.8016893e-7,0.00042763253,6.2625867e-7,0.00003024631,0.00013835498,0.000046372475,0.00207247],"study_design_scores_gemma":[0.002085396,0.0011244911,0.9942685,0.00008705192,0.00016109658,8.558567e-9,0.000060970087,0.000019810996,0.0016108317,0.00035972483,0.00012187523,0.00010029271],"about_ca_topic_score_codex":0.000021095737,"about_ca_topic_score_gemma":0.0000048771785,"teacher_disagreement_score":0.0025294742,"about_ca_system_score_codex":0.00004161591,"about_ca_system_score_gemma":0.000015744929,"threshold_uncertainty_score":0.40851066},"labels":[],"label_agreement":null},{"id":"W2115653936","doi":"10.1136/bmj.d4169","title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","year":2011,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":809,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Microalbuminuria; Jadad scale; Meta-analysis; Relative risk; Type 2 diabetes; Confidence interval; Diabetes mellitus; Randomized controlled trial; Cochrane Library; Endocrinology; Blood pressure","score_opus":0.1672523253223639,"score_gpt":0.39763793845122797,"score_spread":0.23038561312886408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115653936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024949579,0.9583895,0.0000025939266,0.000008131113,0.00013274948,0.016222963,0.0000456402,0.000015519858,0.00023331093],"genre_scores_gemma":[0.004257639,0.9925844,0.000026319713,0.000031139825,0.000042172953,0.0024130868,0.00036734968,0.000060652303,0.00021724297],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993515,0.0025867051,0.0023999733,0.00067903084,0.00047768175,0.00034161832],"domain_scores_gemma":[0.994823,0.0021105583,0.0013303835,0.0013529867,0.00025147112,0.00013164879],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0075512403,0.0008532762,0.031345308,0.0011836867,0.000014483392,0.000007942808,0.00014052459,0.0002531752,0.00008332598],"category_scores_gemma":[0.0022988687,0.00045239474,0.020800252,0.0005389674,0.000049806447,0.000032735832,0.00008963727,0.00012345395,0.0000077985715],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002430921,0.00037438222,0.00013350313,0.00639252,0.9081955,0.00008800719,0.00005041375,0.000014363794,0.000004062405,0.00000469105,0.000021981208,0.08228966],"study_design_scores_gemma":[0.060495757,0.001921791,0.000043905562,0.0016001532,0.9172029,0.0000012650802,0.000006190038,0.000008136997,0.00041966225,0.0000021877954,0.018043466,0.00025457176],"about_ca_topic_score_codex":0.0002716206,"about_ca_topic_score_gemma":0.000023628349,"teacher_disagreement_score":0.08203509,"about_ca_system_score_codex":0.00020346082,"about_ca_system_score_gemma":0.000081471684,"threshold_uncertainty_score":0.99979275},"labels":[],"label_agreement":null},{"id":"W2115780192","doi":"10.1210/en.2008-0336","title":"The Glucagon-Like Peptide-1 Receptor Agonist Oxyntomodulin Enhances β-Cell Function but Does Not Inhibit Gastric Emptying in Mice","year":2008,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Endocrinology; Internal medicine; Gastric emptying; Agonist; Glucagon-like peptide-1; Receptor; Glucagon; Chemistry; Gastrointestinal hormone; Glucagon-like peptide 1 receptor; Function (biology); Medicine; Peptide hormone; Biology; Stomach; Diabetes mellitus; Type 2 diabetes; Insulin; Cell biology","score_opus":0.015288651350732976,"score_gpt":0.23700301848083521,"score_spread":0.22171436713010223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115780192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871805,0.0010747926,0.0000657355,0.0018791155,0.0012277568,0.00051198155,0.0000048939755,0.00011622846,0.007939051],"genre_scores_gemma":[0.95377785,0.0026091086,0.00046211688,0.0006207038,0.00024194374,0.00015319597,0.000038373182,0.000024193376,0.042072516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827254,0.0000854063,0.00036508273,0.00042200915,0.00019716739,0.0006577929],"domain_scores_gemma":[0.9992594,0.00017446646,0.00012495808,0.0003164704,0.00004724779,0.00007746852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010881671,0.00022705039,0.00031592086,0.0002005118,0.00027129054,0.00002241211,0.00014574095,0.00006677188,0.00012636482],"category_scores_gemma":[0.000056960045,0.00014611219,0.00010091975,0.00022968832,0.00019231164,0.00009823002,0.00011613656,0.00025505674,0.00048432377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031607747,0.0028160561,0.15367885,0.00037859078,0.0008628205,0.0014541375,0.0021699008,0.000044266922,0.646447,0.0018144238,0.03356343,0.15360974],"study_design_scores_gemma":[0.009096181,0.0022220677,0.076454565,0.000120450575,0.0003626488,0.00017531576,0.002627431,0.000082988256,0.55138224,0.00020866038,0.3566454,0.00062201946],"about_ca_topic_score_codex":0.00020482195,"about_ca_topic_score_gemma":0.00025845424,"teacher_disagreement_score":0.32308197,"about_ca_system_score_codex":0.00014061683,"about_ca_system_score_gemma":0.000057050627,"threshold_uncertainty_score":0.6225164},"labels":[],"label_agreement":null},{"id":"W2115826570","doi":"10.1155/2013/972034","title":"Management of Pediatric and Adolescent Type 2 Diabetes","year":2013,"lang":"en","type":"review","venue":"International Journal of Pediatrics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"","keywords":"Medicine; Type 2 diabetes; Presentation (obstetrics); Obesity; Intervention (counseling); Adolescent Obesity; Diabetes mellitus; Disease; Pediatrics; Type 1 diabetes; Diabetes management; Gerontology; Psychiatry; Surgery; Overweight; Internal medicine; Endocrinology","score_opus":0.03471299893794836,"score_gpt":0.328215833193243,"score_spread":0.2935028342552946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115826570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00091499917,0.99609363,0.00001627936,0.00007500491,0.0016415074,0.00043474147,0.000013500449,0.0000077468,0.0008025768],"genre_scores_gemma":[0.00014850688,0.9953865,0.001824143,0.000038408536,0.0017022935,0.000007414207,0.00003449107,0.000031846812,0.0008263921],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997972,0.00003276736,0.00093339576,0.00016253653,0.0007319369,0.00016733624],"domain_scores_gemma":[0.9978487,0.00008219163,0.0011965476,0.00015050385,0.0005855989,0.00013647242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002379062,0.0002585591,0.0010283351,0.00083316286,0.000011819192,0.00003655144,0.00030363462,0.000115606344,0.000085077816],"category_scores_gemma":[0.000035417062,0.00018646782,0.00037736763,0.00028050688,0.000027344244,0.00009976368,0.00019400675,0.0002418121,0.00003617701],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015615487,0.00038841722,0.0030887038,0.020373004,0.0014354659,0.0002260187,0.000009522012,4.544963e-7,8.4508024e-8,0.00016048967,0.015021475,0.9592807],"study_design_scores_gemma":[0.001100778,0.0004373716,0.0010451707,0.0041610715,0.014273521,0.00004087398,0.000018852283,0.0000019387933,0.000001056314,0.00007800809,0.97863287,0.00020851995],"about_ca_topic_score_codex":5.092737e-7,"about_ca_topic_score_gemma":2.9753993e-8,"teacher_disagreement_score":0.96361136,"about_ca_system_score_codex":0.00014984373,"about_ca_system_score_gemma":0.00011968847,"threshold_uncertainty_score":0.76039374},"labels":[],"label_agreement":null},{"id":"W2116142692","doi":"10.4021/jem.v1i4.50","title":"Which Is the Best Treatment for Diabetes Complicated With Severe Obesity, Intensive Insulin Therapy or Basal Supported Oral Therapy or Glucagon-Like Peptide-1 Analog?","year":2011,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin; Diabetes mellitus; Basal (medicine); Internal medicine; Glucagon-like peptide-1; Endocrinology; Type 2 diabetes","score_opus":0.0658209794851546,"score_gpt":0.2998162705609941,"score_spread":0.2339952910758395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116142692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98900306,0.0044974363,0.00004188145,0.004428851,0.00031830414,0.0011980061,0.000030071133,0.000024836556,0.00045755508],"genre_scores_gemma":[0.9726984,0.01668145,0.001588513,0.006138602,0.00019836333,0.00011524306,0.000027311371,0.0000410448,0.0025110943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998421,0.000104641396,0.00047391694,0.0002914358,0.00017920468,0.00052977004],"domain_scores_gemma":[0.9981243,0.00018241278,0.00039245552,0.00031661455,0.0008108113,0.00017339338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015775628,0.00036972138,0.0009385619,0.0002294188,0.00017251151,0.000027752922,0.0001923757,0.000095255156,0.00025551615],"category_scores_gemma":[0.000047848986,0.0001550048,0.00018507944,0.00025464193,0.0002223641,0.00015321873,0.000046298745,0.00021930134,0.0000076245756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07957824,0.012872581,0.44106683,0.00017630027,0.044562988,0.001468662,0.012676049,0.000004645042,0.0057717515,0.0027585563,0.029870726,0.36919266],"study_design_scores_gemma":[0.058411974,0.029767346,0.5813044,0.00016981014,0.004269068,0.0011674751,0.0035188913,0.000049891943,0.031885903,0.0012121213,0.28764698,0.00059619657],"about_ca_topic_score_codex":0.00006147306,"about_ca_topic_score_gemma":0.000116287716,"teacher_disagreement_score":0.36859646,"about_ca_system_score_codex":0.000036510777,"about_ca_system_score_gemma":0.00018564874,"threshold_uncertainty_score":0.6320913},"labels":[],"label_agreement":null},{"id":"W2116266342","doi":"10.3109/10425170109024999","title":"cDNA Cloning of Proglucagon from the Stomach and Pancreas of the Dog","year":2001,"lang":"en","type":"article","venue":"DNA sequence","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Proglucagon; Biology; Complementary DNA; Alternative splicing; Messenger RNA; Molecular biology; Biochemistry; Gene; Glucagon-like peptide-1; Endocrinology","score_opus":0.024747465343700342,"score_gpt":0.2700454796399369,"score_spread":0.24529801429623657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116266342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408245,0.0007851596,0.000009245755,0.0011033352,0.000043945136,0.00031754372,0.0000072432813,0.00001241995,0.0036386373],"genre_scores_gemma":[0.9987212,0.00015578452,0.00026537606,0.00023269688,0.000030633346,0.0000126444775,0.0000069708613,0.0000056229055,0.0005690667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999494,0.000029257231,0.00011621559,0.000110242145,0.00014793391,0.00010235687],"domain_scores_gemma":[0.9995271,0.00007070139,0.00007654594,0.00027399,0.000027417,0.000024248846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113192036,0.000066824294,0.00013237938,0.000012642906,0.000034675864,0.00000556934,0.00009506281,0.000020381302,0.000023584495],"category_scores_gemma":[0.00004372434,0.000033386652,0.00003699385,0.00010691573,0.00012824191,0.000033816694,0.00005900703,0.000048775382,0.0000021251028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005709971,0.00013495827,0.8436772,0.00006148107,0.0001987199,0.000015992813,0.0010566186,0.0000021803946,0.10971301,0.002025952,0.00036024195,0.04269655],"study_design_scores_gemma":[0.00096456445,0.00019873667,0.934919,0.00033192692,0.00032923766,0.000006237691,0.00034539323,0.00016387472,0.05674025,0.0007524082,0.0051779277,0.00007047028],"about_ca_topic_score_codex":0.00047609577,"about_ca_topic_score_gemma":0.00001998112,"teacher_disagreement_score":0.09124178,"about_ca_system_score_codex":0.000017054119,"about_ca_system_score_gemma":0.000020265079,"threshold_uncertainty_score":0.13614681},"labels":[],"label_agreement":null},{"id":"W2116285515","doi":"10.1111/j.1742-1241.2005.00675.x","title":"Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control","year":2005,"lang":"en","type":"review","venue":"International Journal of Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Guideline; Type 2 diabetes; Intervention (counseling); Intensive care medicine; Diabetes mellitus; Disease; Clinical trial; Type 1 diabetes; Randomized controlled trial; Pediatrics; Surgery; Internal medicine; Endocrinology; Pathology; Nursing","score_opus":0.08451894490346816,"score_gpt":0.49334711122506303,"score_spread":0.40882816632159485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116285515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025790075,0.98872423,0.00018564159,0.005348432,0.0015991324,0.0010236875,0.000010775301,0.000006461831,0.00052262936],"genre_scores_gemma":[0.013651716,0.982054,0.0009789057,0.0009278815,0.0017998829,0.0000268879,0.000014576916,0.000029623949,0.0005165263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996952,0.0004506029,0.0019137706,0.00019231971,0.00032487698,0.00016642301],"domain_scores_gemma":[0.98954713,0.0073959166,0.002049689,0.00015029541,0.00075644394,0.00010053185],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042043077,0.00019590073,0.001123751,0.00023611417,0.00002846984,0.00011074426,0.00023701292,0.0001686137,0.00003286027],"category_scores_gemma":[0.012071793,0.00011858465,0.0006894767,0.00009608713,0.0000640342,0.0004220659,0.00007832318,0.00078016054,0.0000108640015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008220625,0.0005162512,0.0002561675,0.0005806953,0.002643222,0.0016893288,0.000024993573,8.5319067e-7,4.2753e-8,0.000253811,0.00071869994,0.99249387],"study_design_scores_gemma":[0.004539104,0.0011623946,0.00026688218,0.0047822394,0.004629659,0.0011416263,0.0000952154,0.00005846013,2.9316187e-8,0.000051083654,0.9831779,0.00009543332],"about_ca_topic_score_codex":0.000009781499,"about_ca_topic_score_gemma":0.000007712616,"teacher_disagreement_score":0.99239844,"about_ca_system_score_codex":0.00016212699,"about_ca_system_score_gemma":0.00017439021,"threshold_uncertainty_score":0.99625},"labels":[],"label_agreement":null},{"id":"W2116478518","doi":"10.1210/en.2009-1197","title":"Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor","year":2010,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute; Heart and Stroke Foundation; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide-1; Amide; Internal medicine; Endocrinology; Nitric oxide; Chemistry; Protein kinase B; Receptor; Cytoprotection; Apoptosis; Biochemistry; Biology; Medicine; Type 2 diabetes; Diabetes mellitus","score_opus":0.010364391049258462,"score_gpt":0.2506779716964618,"score_spread":0.24031358064720332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116478518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96420914,0.0003687005,0.000030251687,0.021900069,0.003956386,0.0014346355,0.000099026096,0.00045376597,0.0075480044],"genre_scores_gemma":[0.91917235,0.0007439891,0.0004946485,0.0028245766,0.0005583495,0.0005498692,0.00031226702,0.000076459815,0.075267486],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974705,0.0000973953,0.00045553353,0.00069383864,0.00034611337,0.0009366078],"domain_scores_gemma":[0.9983893,0.00018648036,0.00020311943,0.00092555565,0.00010683811,0.00018871411],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00017934518,0.0004183781,0.00051599107,0.00017111046,0.00028293754,0.00004609319,0.0003312859,0.00022170642,0.0028448857],"category_scores_gemma":[0.00015289185,0.00026048417,0.00019480029,0.00028366325,0.0003749965,0.00017391719,0.0002226469,0.0007114914,0.0014586085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091898674,0.0009713662,0.007996679,0.00019823505,0.0015092554,0.00022477514,0.0009664293,5.629137e-7,0.62688625,0.0028013007,0.2693954,0.08813077],"study_design_scores_gemma":[0.0029911255,0.0006287574,0.0054423986,0.000044325898,0.00030102546,0.000049169314,0.0003661762,0.0000349905,0.18408026,0.00021411608,0.80554265,0.0003050151],"about_ca_topic_score_codex":0.00032323884,"about_ca_topic_score_gemma":0.00016458273,"teacher_disagreement_score":0.53614724,"about_ca_system_score_codex":0.00011847274,"about_ca_system_score_gemma":0.0000591553,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W2116831537","doi":"10.2337/db11-1824","title":"Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes","year":2012,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Eye Institute; RIKEN; National Institute of Diabetes and Digestive and Kidney Diseases; Manpei Suzuki Diabetes Foundation; Novartis Foundation; Joslin Diabetes Center; National Institutes of Health; American Diabetes Association","keywords":"Diabetes mellitus; Internal medicine; Medicine; Endocrinology; Endothelium; Protein kinase C; Biology; Cell biology; Signal transduction","score_opus":0.005971094334526042,"score_gpt":0.21895360278810672,"score_spread":0.2129825084535807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116831537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963498,0.0012888783,0.0000048214038,0.00020853097,0.0000683203,0.0013279216,0.0000074963555,0.00003758122,0.000706623],"genre_scores_gemma":[0.99910975,0.000030704843,0.000031525975,0.00026287112,0.000057181413,0.00033630387,0.000055902772,0.000021233676,0.000094555864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990716,0.000056656525,0.00016293465,0.00018686168,0.00018267594,0.00033927202],"domain_scores_gemma":[0.9995048,0.00016738099,0.00008832089,0.00012309603,0.0000328727,0.00008353124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016758272,0.00016690038,0.00029003387,0.00019381991,0.000026078804,0.000007935862,0.000024061523,0.00007059126,0.000011305731],"category_scores_gemma":[0.00015516818,0.00014153458,0.00004261185,0.0001798825,0.000032987446,0.00022939687,0.00003000205,0.00008979909,0.000013476563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032260534,0.000826294,0.18388917,0.00092209614,0.00014324838,6.795342e-7,0.00029867137,5.2880813e-7,0.8020082,0.00053314003,0.0002448736,0.011100855],"study_design_scores_gemma":[0.0016597945,0.00065897516,0.0969687,0.0005401888,0.00008346217,2.8350463e-8,0.00002985015,0.00004116379,0.8995217,0.0001779303,0.00020682834,0.000111364],"about_ca_topic_score_codex":0.0000068919885,"about_ca_topic_score_gemma":3.0290641e-7,"teacher_disagreement_score":0.09751353,"about_ca_system_score_codex":0.00007458216,"about_ca_system_score_gemma":0.000006367979,"threshold_uncertainty_score":0.57716125},"labels":[],"label_agreement":null},{"id":"W2117177982","doi":"10.1016/s1499-2671(08)24099-2","title":"Quick Release Bromocriptine (Cycloset™) Improves Glycemic Control in Patients with Diabetes Failing Metformin/Sulfonylurea Combination Therapy","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sulfonylurea; Metformin; Bromocriptine; Glycemic; Diabetes mellitus; Internal medicine; Endocrinology; Hormone; Prolactin","score_opus":0.0066671502836000126,"score_gpt":0.1890841143599206,"score_spread":0.18241696407632058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117177982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965336,0.0016743876,0.0000032744856,0.0005204893,0.00020868868,0.0006725193,0.000019500403,0.000015629876,0.00035194957],"genre_scores_gemma":[0.99842894,0.000043465345,0.00023899757,0.0008817802,0.00008724058,0.000020079433,0.00006425889,0.000044263954,0.0001909861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981553,0.000049487953,0.0005596764,0.0002155109,0.00035232145,0.00066772563],"domain_scores_gemma":[0.99831045,0.000084307925,0.00035731547,0.00024146025,0.0003573542,0.00064914057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021498378,0.00029152262,0.00064212334,0.0007730531,0.00013207423,0.0000408206,0.00017362859,0.00008928983,0.000038723592],"category_scores_gemma":[0.00013011527,0.00022160687,0.00014444042,0.0003457168,0.0001530599,0.00044963657,0.000008225525,0.00027337635,0.0000075639746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015981469,0.00030179034,0.98529357,0.000046926885,0.00042018105,0.000061427905,0.00023070267,0.000014049093,0.0005615034,0.00003691182,0.00062628416,0.012246819],"study_design_scores_gemma":[0.027635578,0.0053606345,0.96150655,0.0003997818,0.00025805086,0.0000025833638,0.00009096797,0.00017581084,0.0016352669,0.00010956561,0.002505807,0.00031937892],"about_ca_topic_score_codex":0.00022454836,"about_ca_topic_score_gemma":0.0008323535,"teacher_disagreement_score":0.027475763,"about_ca_system_score_codex":0.00034879195,"about_ca_system_score_gemma":0.00052322686,"threshold_uncertainty_score":0.9036866},"labels":[],"label_agreement":null},{"id":"W2117340025","doi":"10.1210/jc.2015-2725","title":"The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial","year":2015,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Diabetes Canada","funders":"Novo Nordisk; Novo Nordisk Canada; University of Toronto; Ontario Ministry of Research and Innovation; Heart and Stroke Foundation of Canada","keywords":"Liraglutide; Medicine; Internal medicine; Postprandial; Endocrinology; Placebo; Glucagon; Type 2 diabetes; Glycemic; Hyperglucagonemia; Insulin; Glucagon-like peptide-1; Area under the curve; Crossover study; Diabetes mellitus","score_opus":0.08988804946360275,"score_gpt":0.3954046109103621,"score_spread":0.30551656144675937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117340025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604087,0.02919903,0.0000038128642,0.007137638,0.001968215,0.0005923551,0.0000030695999,0.000010560299,0.0006766546],"genre_scores_gemma":[0.9686049,0.027874451,0.000023426088,0.0009076414,0.0024183912,0.000007894764,0.0000056634262,0.000020438723,0.00013714541],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996362,0.0013815009,0.0013174036,0.00014744091,0.00040180745,0.00038986298],"domain_scores_gemma":[0.995006,0.0031611377,0.0009114349,0.00059174286,0.00019344436,0.00013620239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024476699,0.00021079124,0.00093664567,0.00009506819,0.00006776346,0.000019694176,0.0005302565,0.00011255952,0.00006035179],"category_scores_gemma":[0.0014700295,0.000076633194,0.0005119694,0.00025187805,0.00039805705,0.000105417515,0.00009345316,0.00087514473,0.000026587482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25672576,0.0056423256,0.045151718,0.000013667214,0.00973298,0.00012390708,0.0028776443,0.0007005117,0.0016111048,0.0041599064,0.029353214,0.64390725],"study_design_scores_gemma":[0.14290206,0.024261555,0.6285465,0.00019198951,0.0014670605,0.000015931962,0.00032446967,0.00032219215,0.002320969,0.007962215,0.19147098,0.00021410013],"about_ca_topic_score_codex":0.00012988149,"about_ca_topic_score_gemma":0.000023581857,"teacher_disagreement_score":0.64369315,"about_ca_system_score_codex":0.00007403227,"about_ca_system_score_gemma":0.00048196554,"threshold_uncertainty_score":0.3802117},"labels":[],"label_agreement":null},{"id":"W2117347138","doi":"10.2337/dc12-0862","title":"Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function","year":2012,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Glycemic; Diabetes mellitus; Cohort; Renal function; Proteinuria; Type 2 diabetes; Internal medicine; Intensive care medicine; Emergency medicine; Kidney; Endocrinology","score_opus":0.003022765251055158,"score_gpt":0.19721566688642664,"score_spread":0.19419290163537148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117347138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914254,0.008190799,0.000005393435,0.00094909227,0.000078080986,0.0009217365,0.00007433099,0.00006341076,0.0005746419],"genre_scores_gemma":[0.99651855,0.00007034233,0.00006705893,0.0025887585,0.00007758978,0.00015733688,0.0004435209,0.0000307282,0.00004610302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886703,0.000051622737,0.00014015294,0.00024372371,0.00017424858,0.0005232202],"domain_scores_gemma":[0.9992845,0.00007996582,0.00011109744,0.00015661881,0.00009506689,0.00027272553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011512168,0.00021963734,0.00043102427,0.00012549368,0.00008180499,0.00003588045,0.000025897329,0.000070387076,0.000006847209],"category_scores_gemma":[0.000026876727,0.00014806891,0.000025584346,0.00017596838,0.000029800074,0.00019988584,0.000023101313,0.000114842514,0.0000052705427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014480707,0.0000567243,0.9792483,0.00045216194,0.00022568421,3.8576732e-7,0.0041511003,7.8541456e-7,0.000105861174,0.00002004478,0.00051937933,0.015074795],"study_design_scores_gemma":[0.0070931804,0.0019618112,0.97990465,0.00039184417,0.000275491,2.6768853e-7,0.006541601,0.00003960489,0.00030362443,0.000002315347,0.003295656,0.00018992493],"about_ca_topic_score_codex":0.00003659528,"about_ca_topic_score_gemma":0.00023785292,"teacher_disagreement_score":0.0148848705,"about_ca_system_score_codex":0.0005387308,"about_ca_system_score_gemma":0.000060668808,"threshold_uncertainty_score":0.6038075},"labels":[],"label_agreement":null},{"id":"W2117505171","doi":"10.1111/dom.12187","title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Astellas Pharma; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Insulin; Adverse effect; Diabetes mellitus; Type 2 diabetes; Population; Internal medicine; Urology; Endocrinology","score_opus":0.0043399929951399956,"score_gpt":0.19137911585337625,"score_spread":0.18703912285823626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117505171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648976,0.0023147846,3.4901194e-7,0.00007424539,0.00010743558,0.0007443573,0.000012085909,0.000029145736,0.0002278493],"genre_scores_gemma":[0.99841225,0.0005751522,0.00051000743,0.00023825836,0.00003776668,0.000020010215,0.000063754145,0.000021138456,0.00012166256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887437,0.000046104262,0.00024765093,0.00029377762,0.00020917902,0.00032889852],"domain_scores_gemma":[0.99936473,0.00009585668,0.00009465194,0.00022719613,0.000084153675,0.0001333876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014836412,0.00020054783,0.0005502186,0.00019248914,0.000040171268,0.000031594172,0.00006086034,0.000077471435,0.00009080605],"category_scores_gemma":[0.00007891865,0.00015617574,0.000030288966,0.0002709777,0.00012174523,0.00024180318,0.00010443032,0.00011234832,0.000010351926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006236294,0.0005148385,0.9637934,0.00013390838,0.00019642522,9.226417e-7,0.00017541587,0.0000015079615,0.0003365041,0.00018059881,0.00012605533,0.034478083],"study_design_scores_gemma":[0.0059629777,0.0002912765,0.99078035,0.00019671489,0.00027247277,2.774191e-8,0.000016876887,0.000016785089,0.0007380617,0.00012373719,0.0014353363,0.00016535188],"about_ca_topic_score_codex":0.000085293344,"about_ca_topic_score_gemma":0.0000075589196,"teacher_disagreement_score":0.03431273,"about_ca_system_score_codex":0.000016540282,"about_ca_system_score_gemma":0.000015096513,"threshold_uncertainty_score":0.6368662},"labels":[],"label_agreement":null},{"id":"W2118451434","doi":"10.1016/s0168-8227(02)00176-6","title":"Acarbose in the treatment of elderly patients with type 2 diabetes","year":2002,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Saint John Regional Hospital; University of Toronto; Université de Sherbrooke; Western University; McMaster University; McGill University; University of Calgary; University of Alberta; Université de Montréal; University of Manitoba; Calgary Laboratory Services","funders":"","keywords":"Acarbose; Medicine; Internal medicine; Glycemic; Type 2 diabetes; Placebo; Diabetes mellitus; Hypoglycemia; Endocrinology; Flatulence; Gastroenterology; Insulin","score_opus":0.10471340285040501,"score_gpt":0.42615827264056516,"score_spread":0.3214448697901602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118451434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811581,0.0023221804,9.7828405e-8,0.002551384,0.000044674638,0.0009372661,0.0000041048934,0.000011544018,0.01297069],"genre_scores_gemma":[0.9942348,0.00429253,0.0002458316,0.00043285947,0.00007262096,0.00006575449,0.000025133666,0.000014847635,0.00061560137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977758,0.00043735807,0.00036411243,0.00031156963,0.00063979026,0.0004713762],"domain_scores_gemma":[0.9946445,0.0043598246,0.00009351618,0.00041416206,0.0003367212,0.00015124652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011849047,0.00013893114,0.0003523276,0.00013030566,0.00007253829,0.000046802517,0.00011844843,0.00007754811,0.00009478167],"category_scores_gemma":[0.0015307976,0.0000741873,0.00006036399,0.00049899524,0.00032611607,0.00019966121,0.000036715923,0.0002834781,0.000053479784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026793432,0.010192677,0.8161726,0.000045224017,0.00037528397,0.000019307658,0.00022244062,1.2779479e-7,0.000006168515,0.000100006386,0.001369626,0.17122862],"study_design_scores_gemma":[0.007327521,0.05957237,0.8071793,0.00011073412,0.00038951784,2.249686e-7,0.00052164716,0.00016941599,0.00008609112,0.00016105433,0.124344684,0.00013745578],"about_ca_topic_score_codex":0.000018062698,"about_ca_topic_score_gemma":0.000009976651,"teacher_disagreement_score":0.17109117,"about_ca_system_score_codex":0.000042992426,"about_ca_system_score_gemma":0.000021691096,"threshold_uncertainty_score":0.30252704},"labels":[],"label_agreement":null},{"id":"W2118622985","doi":"10.1016/j.jcjd.2013.08.233","title":"Use of WebDR, a Web-Based Diabetes Electronic Medical Record, as a Researchable Database to Identify and Define a Cohort of Patients with Type 1 Diabetes on Insulin Pump Therapy","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cohort; Medical record; Diabetes mellitus; Type 2 diabetes; Cohort study; Family medicine; Electronic health record; Electronic medical record; Health care; Database; Pediatrics; Internal medicine","score_opus":0.017856460925834514,"score_gpt":0.25773853774630456,"score_spread":0.23988207682047005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118622985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588346,0.0015485538,7.829571e-7,0.0012720154,0.00009411166,0.0010128103,0.00007103619,0.0000092375885,0.00010801139],"genre_scores_gemma":[0.997755,0.00019112315,0.00033384544,0.0013801828,0.000044484055,0.000053328786,0.00008785942,0.000049477472,0.00010473072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732506,0.00013260638,0.00060951343,0.00028904734,0.000803002,0.0008407917],"domain_scores_gemma":[0.9967146,0.00039753137,0.00032161135,0.0004205531,0.0008348477,0.0013108777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006809506,0.0002799407,0.0007665527,0.00097447715,0.00006676814,0.00006372266,0.0002523914,0.00010402977,0.00080718164],"category_scores_gemma":[0.0011363474,0.00020450524,0.00010515731,0.0006139612,0.00024768972,0.00030959843,0.0000382379,0.00032326693,0.000022661354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010623853,0.0003515804,0.9800854,0.00015519223,0.0007821074,0.000009536582,0.000039343697,0.0000042789247,0.0015061849,0.000047476195,0.004013873,0.012898788],"study_design_scores_gemma":[0.005456317,0.011685622,0.9627827,0.0016365479,0.00030057307,2.8423213e-7,0.000028965535,0.00019012782,0.011007153,0.00011548002,0.0065312316,0.0002650115],"about_ca_topic_score_codex":0.0012008435,"about_ca_topic_score_gemma":0.0022889837,"teacher_disagreement_score":0.017302712,"about_ca_system_score_codex":0.00018567551,"about_ca_system_score_gemma":0.0016917202,"threshold_uncertainty_score":0.8838073},"labels":[],"label_agreement":null},{"id":"W2118647217","doi":"10.1139/y2012-039","title":"MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canada Research Chairs","funders":"Merck Canada","keywords":"Internal medicine; Endocrinology; Hyperinsulinemia; Dipeptidyl peptidase-4 inhibitor; Incretin; Type 2 diabetes; Insulin; Medicine; Dipeptidyl peptidase-4; Dipeptidyl peptidase; Glucagon-like peptide-1; Glucagon; Diabetes mellitus; Insulin resistance; Chemistry; Enzyme; Biochemistry","score_opus":0.012606810139202116,"score_gpt":0.26086819748996387,"score_spread":0.24826138735076175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118647217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426436,0.0012424858,0.0000017800196,0.0019953414,0.0017916624,0.00029869835,0.000037525424,0.0000051248026,0.00036302485],"genre_scores_gemma":[0.994732,0.00026565712,0.0001253472,0.0026678396,0.0011378702,0.000018229472,0.00000713041,0.000018408693,0.0010275113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872047,0.00012378357,0.0004007054,0.00014913334,0.00008213439,0.0005238005],"domain_scores_gemma":[0.99862367,0.00024064232,0.00027080128,0.00014073079,0.0001356076,0.0005885264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028512807,0.00020050467,0.0005186447,0.00018925442,0.000121412064,0.000006142183,0.00016274415,0.00013485657,0.0011662276],"category_scores_gemma":[0.000053997977,0.00010752629,0.00012855425,0.000117784264,0.00046441818,0.00012110173,0.0000409691,0.0003557899,0.00001462491],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080861774,0.00016908809,0.010039847,0.00022596138,0.00062504906,0.00006948819,0.0008180162,0.0000040677555,0.9793708,0.00010089359,0.0048465524,0.0029216239],"study_design_scores_gemma":[0.0083512785,0.0031336215,0.05741519,0.00011595949,0.0022083588,0.00021224096,0.00075036695,0.00005741803,0.87714726,0.0001649833,0.050101355,0.00034198578],"about_ca_topic_score_codex":0.00025201493,"about_ca_topic_score_gemma":0.00025748555,"teacher_disagreement_score":0.10222355,"about_ca_system_score_codex":0.00008037839,"about_ca_system_score_gemma":0.00040810605,"threshold_uncertainty_score":0.99974686},"labels":[],"label_agreement":null},{"id":"W2118929450","doi":"10.1016/j.jdiacomp.2014.05.012","title":"Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day","year":2014,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Lixisenatide; Medicine; Postprandial; Metformin; Meal; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.011670406206240802,"score_gpt":0.24099409474020872,"score_spread":0.22932368853396792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118929450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839109,0.00013197337,0.00009262187,0.013751538,0.000041996293,0.00045062535,0.00001071054,0.0000038825337,0.0016057167],"genre_scores_gemma":[0.9987116,0.000021894324,0.00024767636,0.00052321603,0.000058433794,0.000019012567,0.0000031044885,0.000008454172,0.00040660336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992112,0.000047769252,0.00030802432,0.00008497349,0.00020380605,0.00014423054],"domain_scores_gemma":[0.99920267,0.00014071491,0.000277698,0.00020823747,0.00011057282,0.00006008896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003620548,0.00009241165,0.00021512661,0.00006945302,0.000074737596,0.000017133632,0.00015332332,0.00002055068,0.000013372241],"category_scores_gemma":[0.000059519145,0.00003494655,0.00006021033,0.00016849424,0.000067641085,0.000060693816,0.00006198707,0.000115939794,0.0000010244463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003042515,0.0027886126,0.578539,0.00066778244,0.0020770417,0.0000073972383,0.0045662825,0.00020026272,0.02688291,0.07247127,0.0063778595,0.3051173],"study_design_scores_gemma":[0.0033489391,0.0026455435,0.9760169,0.0005799968,0.0004553753,0.000010297913,0.000581593,0.0017821614,0.0023815108,0.0019162096,0.010174123,0.000107344255],"about_ca_topic_score_codex":0.000003976318,"about_ca_topic_score_gemma":0.000060455666,"teacher_disagreement_score":0.39747787,"about_ca_system_score_codex":0.00004037725,"about_ca_system_score_gemma":0.000044624332,"threshold_uncertainty_score":0.1425079},"labels":[],"label_agreement":null},{"id":"W2118991613","doi":"10.2337/db14-0883","title":"Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis","year":2014,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Downregulation and upregulation; Glucagon-like peptide-1; Receptor; Cholecystokinin; Glucagon; Chemistry; Pancreatic polypeptide; Glucose homeostasis; Biology; Insulin; Diabetes mellitus; Insulin resistance; Medicine; Type 2 diabetes; Biochemistry; Gene","score_opus":0.0075782447475977914,"score_gpt":0.21279793427149113,"score_spread":0.20521968952389333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118991613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200773,0.00033257733,0.00002911568,0.00041450246,0.00012155849,0.00073168223,0.000021542155,0.00010395777,0.0062373457],"genre_scores_gemma":[0.9928194,0.000035300483,0.0018031104,0.00017552802,0.00010538208,0.00039468624,0.00014199739,0.000038625647,0.004485964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986851,0.00009804454,0.00029726702,0.00030422426,0.0002768303,0.00033848983],"domain_scores_gemma":[0.99908054,0.00012689053,0.00016110393,0.00040637888,0.000073007075,0.0001520991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003107842,0.00022069209,0.00047782203,0.00013275472,0.000056765763,0.00002186514,0.00009954209,0.000088379515,0.00022463169],"category_scores_gemma":[0.00031743114,0.00018566495,0.00012033977,0.00018838471,0.000093663526,0.000112706075,0.000038953072,0.00008289376,0.0001251345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011243609,0.00091599004,0.11224069,0.0011511714,0.0009134135,0.0000021802766,0.00011865596,0.0000012718444,0.7758214,0.0005770957,0.02178085,0.086364836],"study_design_scores_gemma":[0.0015485539,0.0008158552,0.010622547,0.0007679481,0.00086244225,2.800281e-7,0.00011971181,0.0001767446,0.93005943,0.0002824881,0.05440352,0.0003404744],"about_ca_topic_score_codex":0.000079149635,"about_ca_topic_score_gemma":0.0000012140347,"teacher_disagreement_score":0.15423803,"about_ca_system_score_codex":0.00007579581,"about_ca_system_score_gemma":0.000023792136,"threshold_uncertainty_score":0.7571197},"labels":[],"label_agreement":null},{"id":"W2119547941","doi":"10.4297/najms.2010.2556","title":"A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors","year":2010,"lang":"en","type":"article","venue":"North American Journal of Medical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Glycemic; Dapagliflozin; Internal medicine; Renal glucose reabsorption; Insulin; Adverse effect; Weight loss; Endocrinology; Pharmacology; Type 2 diabetes; Obesity","score_opus":0.026260976110108844,"score_gpt":0.30581396636318287,"score_spread":0.279552990253074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119547941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930682,0.0007153525,0.00029866444,0.0049837423,0.00041208917,0.0003302419,0.000011609732,0.0000079408,0.00017214094],"genre_scores_gemma":[0.9971301,0.0009957324,0.0011662559,0.00022732852,0.00041947237,0.000017293187,0.0000041754556,0.000007150094,0.000032477914],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99769396,0.000017064282,0.00050260435,0.00016486991,0.0012827428,0.00033874527],"domain_scores_gemma":[0.9985384,0.00038911257,0.0004393113,0.0001447996,0.0001030056,0.0003853832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008760812,0.00015028002,0.00047878473,0.00012335918,0.00012135865,0.000018935556,0.0003416168,0.0000344826,0.00010917395],"category_scores_gemma":[0.000093498835,0.000071020055,0.00025591173,0.00041144833,0.0018485638,0.00008396186,0.00000901705,0.00014991684,0.0000015818803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008686085,0.001413435,0.3175963,0.000025233705,0.0003196984,0.000017040375,0.00028292948,0.000017453121,0.00052951433,0.0001889233,0.00020470552,0.6793179],"study_design_scores_gemma":[0.010262074,0.059608415,0.78141254,0.00024192371,0.0019791876,0.0000669518,0.0027729534,0.0012533584,0.015369913,0.00017646592,0.12643418,0.00042201605],"about_ca_topic_score_codex":0.00011669455,"about_ca_topic_score_gemma":0.0003464494,"teacher_disagreement_score":0.6788959,"about_ca_system_score_codex":0.000029167943,"about_ca_system_score_gemma":0.00045970167,"threshold_uncertainty_score":0.68111104},"labels":[],"label_agreement":null},{"id":"W2119592108","doi":"10.18433/j3g883","title":"The Efficacy and Tolerability of Exenatide in Comparison to Placebo; A Systematic Review and Meta-Analysis of Randomized Clinical Trials","year":2011,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Exenatide; Tolerability; Medicine; Placebo; Type 2 diabetes; Meta-analysis; Pharmacology; Diabetes mellitus; Internal medicine; Clinical trial; Randomized controlled trial; Drug; Incretin; Adverse effect; Endocrinology; Alternative medicine","score_opus":0.5616560356679907,"score_gpt":0.601295443060551,"score_spread":0.03963940739256033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119592108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024497474,0.991551,0.000024689798,0.00092429685,0.0001018031,0.006988811,0.000011753559,0.0000033430033,0.00014934423],"genre_scores_gemma":[0.003462051,0.99567026,0.0003228725,0.0003231584,0.000027766668,0.00014126497,0.0000011510032,0.00000850093,0.00004298006],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98037004,0.009617265,0.008554839,0.00036949906,0.0008049401,0.00028342736],"domain_scores_gemma":[0.9685793,0.025482913,0.004986646,0.0002765412,0.000257993,0.0004166028],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09415334,0.0003802841,0.025565337,0.00061529805,0.00006013977,0.000045159122,0.0004892127,0.000059703474,0.00018561188],"category_scores_gemma":[0.014292736,0.00015309095,0.0042190114,0.0013903572,0.0009533051,0.00010942957,0.0001777978,0.00046079073,0.0000014680036],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006720503,0.0014167841,0.00021748769,0.49078047,0.3154255,0.000015707381,0.00017287566,0.0000036499364,0.0000013099968,0.0003060534,0.00028756473,0.18465208],"study_design_scores_gemma":[0.018918963,0.0002342333,0.000007738489,0.016337452,0.9268643,0.00001040312,0.000022204253,0.00021583114,0.0000070578694,0.00001494188,0.03724388,0.00012299007],"about_ca_topic_score_codex":0.000013294745,"about_ca_topic_score_gemma":0.0000037530983,"teacher_disagreement_score":0.6114388,"about_ca_system_score_codex":0.000046022637,"about_ca_system_score_gemma":0.00021513099,"threshold_uncertainty_score":0.99401027},"labels":[],"label_agreement":null},{"id":"W2119960290","doi":"10.2337/db05-1502","title":"Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter–Exendin-4 (MT-Exendin) Transgenic Mice","year":2006,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Transgene; Immune system; Biology; Endocrinology; Genetically modified mouse; Metallothionein; Receptor; Antibody; Internal medicine; Glucagon; T-cell receptor; Pancreas; Insulin; Immunology; T cell; Medicine; Biochemistry; Gene","score_opus":0.008067666085365237,"score_gpt":0.2205611038132086,"score_spread":0.21249343772784335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119960290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945299,0.0005328021,0.000051822626,0.0004370942,0.00009291423,0.00073992525,0.0000027117585,0.0000795734,0.0035332765],"genre_scores_gemma":[0.99777484,0.000040134186,0.00040503242,0.00013096552,0.000073023824,0.000118543234,0.00024638086,0.000024400526,0.0011866719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892455,0.000035368943,0.00029893417,0.00027177754,0.00017562613,0.00029375163],"domain_scores_gemma":[0.9996448,0.000045637356,0.00007342254,0.0001644857,0.00002446352,0.00004715062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017574496,0.0001871784,0.00029954407,0.0002595338,0.000047275687,0.000039546874,0.000048019563,0.0000739485,0.000047700763],"category_scores_gemma":[0.000018350773,0.0001688893,0.000069020076,0.00025555358,0.000042256772,0.00027864106,0.000017698434,0.00007139456,0.000019121366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008594249,0.00068201957,0.090744555,0.0004507518,0.0002735918,0.000005901046,0.00040310706,0.000032233056,0.88079476,0.0029464576,0.0002748951,0.023305804],"study_design_scores_gemma":[0.006830292,0.0005575403,0.48836508,0.00035482307,0.0004692178,0.0000013155328,0.000106469175,0.002609848,0.49652827,0.0014778232,0.0022990366,0.00040029944],"about_ca_topic_score_codex":0.0001558111,"about_ca_topic_score_gemma":0.000027496246,"teacher_disagreement_score":0.39762053,"about_ca_system_score_codex":0.00022045802,"about_ca_system_score_gemma":0.00003537239,"threshold_uncertainty_score":0.6887106},"labels":[],"label_agreement":null},{"id":"W2120069833","doi":"10.2337/db05-1145","title":"Activation of Glucagon-Like Peptide-1 Receptor Signaling Does Not Modify the Growth or Apoptosis of Human Pancreatic Cancer Cells","year":2006,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; Banting and Best Diabetes Centre, University of Toronto; Canadian Diabetes Association; Eli Lilly and Company","keywords":"Forskolin; Biology; Cell biology; Internal medicine; Endocrinology; MAPK/ERK pathway; Cancer research; Cell growth; Pancreatic cancer; Signal transduction; Stimulation; Cancer; Medicine; Biochemistry","score_opus":0.015670638971116407,"score_gpt":0.24939049707703861,"score_spread":0.23371985810592222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120069833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977575,0.00010636006,0.000009886101,0.0003802235,0.00012196468,0.000552613,0.000029592607,0.000036933736,0.0010049138],"genre_scores_gemma":[0.996285,0.000058119476,0.0003384386,0.00018923746,0.0001387888,0.00014657911,0.00006921939,0.000026426847,0.0027481432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988621,0.00004036356,0.00035883836,0.00020455044,0.0002824168,0.00025173897],"domain_scores_gemma":[0.99913055,0.00019901854,0.0002522675,0.0002532705,0.00012842979,0.000036458372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016015026,0.00017764437,0.0004008257,0.00011208179,0.00007474577,0.000014097904,0.000113520226,0.000055228964,0.00023683177],"category_scores_gemma":[0.000026385307,0.000094907344,0.00012555979,0.00021660174,0.000100958394,0.00009311854,0.000040112005,0.00006634632,0.0000052333444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051285042,0.00028850508,0.0535377,0.00052018196,0.00034502638,1.7138329e-7,0.00020028887,0.00004005089,0.9414835,0.00038491425,0.0019061124,0.001242256],"study_design_scores_gemma":[0.0008379824,0.00026717476,0.008637005,0.00038566184,0.00051418453,9.231374e-9,0.00019330793,0.00007665531,0.98851985,0.00016024307,0.0002964629,0.00011149371],"about_ca_topic_score_codex":0.00082028727,"about_ca_topic_score_gemma":0.00001463167,"teacher_disagreement_score":0.047036313,"about_ca_system_score_codex":0.000064273874,"about_ca_system_score_gemma":0.000028087832,"threshold_uncertainty_score":0.38702092},"labels":[],"label_agreement":null},{"id":"W2120614342","doi":"10.14740/jocmr2057w","title":"The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vildagliptin; Medicine; Sitagliptin; Postprandial; Insulin; Type 2 diabetes; Dipeptidyl peptidase-4; Internal medicine; Diabetes mellitus; Concomitant; Regimen; Pharmacology; Endocrinology; Dipeptidyl peptidase-4 inhibitor; Insulin lispro; Gastroenterology","score_opus":0.2531507623795033,"score_gpt":0.5073617990980388,"score_spread":0.2542110367185355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120614342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724547,0.00679011,0.0000035464411,0.014732742,0.0003638774,0.0005196992,2.1172173e-7,0.000004374005,0.005130703],"genre_scores_gemma":[0.99071664,0.007602653,0.00017363382,0.00019863763,0.00067982,0.0000043137625,0.0000010851546,0.000017171005,0.000606061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958063,0.00071021763,0.0013653429,0.00015054368,0.0016051913,0.00036242348],"domain_scores_gemma":[0.99117523,0.006173992,0.00041572592,0.00035206066,0.001452978,0.00043003808],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015136102,0.00011766388,0.00086348,0.00030822662,0.000035051762,0.00001078354,0.00028671895,0.000083157924,0.000036341142],"category_scores_gemma":[0.012098821,0.000050089624,0.00010001601,0.0007947653,0.000801081,0.00005245011,0.000060106137,0.0009617907,0.0000130258195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030033406,0.0029427668,0.56539196,0.000090918606,0.0008842926,0.000802163,0.0008645835,0.00001226992,0.00029562484,0.0006193517,0.022325477,0.3757372],"study_design_scores_gemma":[0.07678761,0.10000231,0.73630726,0.0026137116,0.00021675779,0.000045304732,0.0028788594,0.00012929368,0.000992466,0.0010725529,0.0788062,0.0001477035],"about_ca_topic_score_codex":0.000037303987,"about_ca_topic_score_gemma":0.0000207901,"teacher_disagreement_score":0.3755895,"about_ca_system_score_codex":0.00008258154,"about_ca_system_score_gemma":0.0007687077,"threshold_uncertainty_score":0.9962227},"labels":[],"label_agreement":null},{"id":"W2120771901","doi":"10.1111/j.1463-1326.2005.00541.x","title":"Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (&gt;60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rosiglitazone; Medicine; Glipizide; Tolerability; Placebo; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Gastroenterology; Insulin; Endocrinology; Adverse effect; Alternative medicine","score_opus":0.005432125892819263,"score_gpt":0.2292860588156759,"score_spread":0.22385393292285663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120771901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950159,0.0015188236,0.0000014657024,0.00013174783,0.00020451621,0.0029087192,0.00007084727,0.00003288625,0.0001151028],"genre_scores_gemma":[0.99884415,0.00020416845,0.00010157871,0.00018542036,0.00012989425,0.00018192134,0.00015019708,0.000033778022,0.00016891364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779785,0.00027618377,0.00055071886,0.00041319008,0.0005224611,0.00043959534],"domain_scores_gemma":[0.9987246,0.00022998934,0.00020905191,0.00048008887,0.00021295971,0.00014332456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008819026,0.00033205643,0.0008414181,0.00032959948,0.00006198586,0.000041183626,0.00017564013,0.00012262534,0.000057968744],"category_scores_gemma":[0.00013729329,0.0002360841,0.00013884027,0.0006296503,0.00010671586,0.00030324806,0.000091464986,0.00015866845,0.000024920544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005881042,0.0027824189,0.9119934,0.00010874832,0.00041177432,0.0000024824483,0.0040488285,0.000013168456,0.005718512,0.00006372912,0.00036696988,0.07390187],"study_design_scores_gemma":[0.0069556865,0.0046939137,0.9552936,0.00012398204,0.00041026503,4.1000945e-8,0.000045185356,0.000019114299,0.031075193,0.000021789974,0.0011672457,0.00019399301],"about_ca_topic_score_codex":0.00016821863,"about_ca_topic_score_gemma":0.00006397835,"teacher_disagreement_score":0.07370787,"about_ca_system_score_codex":0.000044585722,"about_ca_system_score_gemma":0.000025495929,"threshold_uncertainty_score":0.962723},"labels":[],"label_agreement":null},{"id":"W2120993742","doi":"10.1111/dom.12238","title":"Intensification of medication and glycaemic control among patients with type 2 diabetes – the <scp>ADVANCE</scp> trial","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Diabetes mellitus; Odds ratio; Confidence interval; Type 2 diabetes; Internal medicine; Randomized controlled trial; Insulin; Logistic regression; Endocrinology","score_opus":0.004643060273135869,"score_gpt":0.1916671397977088,"score_spread":0.18702407952457292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120993742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950168,0.0025326377,0.000015475624,0.00022293687,0.00019007406,0.0017418916,0.0000083813275,0.000032472784,0.00023931348],"genre_scores_gemma":[0.9985015,0.00038037196,0.00015374059,0.00043519353,0.000083971754,0.00014585983,0.00008684297,0.000015191605,0.0001973369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895704,0.00006193718,0.0002354178,0.0002461347,0.00024684388,0.00025263842],"domain_scores_gemma":[0.9989256,0.00021193674,0.0001972367,0.00027239,0.00027381803,0.000118999014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022847955,0.00017417672,0.00041130272,0.00008616718,0.00009029015,0.000034278102,0.00007495121,0.00006887781,0.000012610336],"category_scores_gemma":[0.00027461015,0.00010372988,0.000040334082,0.00015930922,0.00029469395,0.0002513245,0.000039939252,0.00010177671,0.0000081408725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098150136,0.00032208615,0.9819115,0.00009374858,0.00035222166,1.3984538e-7,0.00025332367,6.432973e-7,0.00088042277,0.0003917609,0.00066559704,0.015030446],"study_design_scores_gemma":[0.01641756,0.00037718983,0.9775635,0.00005980567,0.00078840455,4.530365e-8,0.00008197621,0.0001718378,0.0012701247,0.00029923982,0.0029214823,0.000048809838],"about_ca_topic_score_codex":0.00002266574,"about_ca_topic_score_gemma":0.0000029008047,"teacher_disagreement_score":0.016319409,"about_ca_system_score_codex":0.000010820745,"about_ca_system_score_gemma":0.000015622745,"threshold_uncertainty_score":0.42299816},"labels":[],"label_agreement":null},{"id":"W2121428690","doi":"10.2337/dc10-0452","title":"Variation at the <i>NFATC2</i> Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study","year":2010,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre; McMaster University; Population Health Research Institute; McGill University","funders":"Canadian Institutes of Health Research; British Heart Foundation; Heart and Stroke Foundation of Canada","keywords":"Rosiglitazone; Medicine; Thiazolidinedione; Diabetes mellitus; Ramipril; Dream; Internal medicine; Type 2 diabetes; Endocrinology; Blood pressure","score_opus":0.006726473022555151,"score_gpt":0.24676322964438419,"score_spread":0.24003675662182902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121428690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397314,0.0005189496,0.0000032755981,0.0023145638,0.00019452607,0.0024791914,0.000024853765,0.000038736955,0.00045277856],"genre_scores_gemma":[0.9985816,0.0001028127,0.0000809093,0.00020182846,0.00020537055,0.00062492763,0.00014806665,0.000024936167,0.000029574454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979894,0.00036247037,0.00034392695,0.0003598253,0.00064994424,0.00029438845],"domain_scores_gemma":[0.99819803,0.00047177266,0.00030041428,0.0007956091,0.00017342599,0.00006073598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012539105,0.00024729103,0.00033843084,0.00010630507,0.00030953065,0.000061787294,0.00021981318,0.000084649684,0.000020232113],"category_scores_gemma":[0.0001605039,0.00010943818,0.00007020016,0.00038746736,0.00018759748,0.00014462268,0.000118743046,0.00034406284,0.0000052994187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005156758,0.0006507256,0.97223157,0.00008541801,0.00038837508,0.0000014605204,0.005830318,0.000013587312,0.0117125185,0.00016155456,0.00029923866,0.008573679],"study_design_scores_gemma":[0.0025091765,0.0011043056,0.97413933,0.000080902086,0.0014126288,0.0000013500772,0.015273411,0.00016245295,0.0048070597,0.00011335326,0.00025924525,0.00013679183],"about_ca_topic_score_codex":0.00028097574,"about_ca_topic_score_gemma":0.000561836,"teacher_disagreement_score":0.009443092,"about_ca_system_score_codex":0.00009716254,"about_ca_system_score_gemma":0.00005935409,"threshold_uncertainty_score":0.44627595},"labels":[],"label_agreement":null},{"id":"W2122515552","doi":"10.1016/j.jcjd.2012.07.326","title":"Renal Impairment Does Not Affect the Glycemic Efficacy or Safety of Liraglutide Treatment in Patients with Type 2 Diabetes","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Placebo; Glycemic; Renal function; Hypoglycemia; Urology; Creatinine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Gastroenterology; Endocrinology","score_opus":0.009127803490784537,"score_gpt":0.22196538146984338,"score_spread":0.21283757797905883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122515552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728894,0.00085700746,3.3746545e-7,0.00048213804,0.00031023397,0.00075094827,0.00003135442,0.0000060733323,0.00027296803],"genre_scores_gemma":[0.9990687,0.000029554527,0.00015429154,0.00026141157,0.00015116058,0.000013332584,0.000023538605,0.00002905811,0.00026899567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983159,0.000085349064,0.0004787995,0.00013570041,0.0002849172,0.0006993505],"domain_scores_gemma":[0.99845415,0.00023389583,0.0003033126,0.00028940415,0.000145828,0.0005734125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034000893,0.0002581926,0.00057580695,0.0003601581,0.000076657634,0.000021506357,0.00015994773,0.000058348647,0.00016313566],"category_scores_gemma":[0.00011880956,0.00011510716,0.0001487894,0.00032214756,0.00013962263,0.00017159125,0.000017013426,0.00014373953,0.0000078961075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050688355,0.0005271768,0.98525244,0.000053650852,0.0007503685,0.0000092377895,0.00049478887,0.000019192436,0.00010707148,0.000018641575,0.00036601373,0.011894563],"study_design_scores_gemma":[0.0074492022,0.007299667,0.9765605,0.00048314198,0.00063852884,6.380534e-7,0.0001033874,0.000007442515,0.0036988843,0.000005884945,0.0036025888,0.00015015797],"about_ca_topic_score_codex":0.00023747988,"about_ca_topic_score_gemma":0.0022511478,"teacher_disagreement_score":0.011744405,"about_ca_system_score_codex":0.00059655297,"about_ca_system_score_gemma":0.00052104495,"threshold_uncertainty_score":0.46939337},"labels":[],"label_agreement":null},{"id":"W2122596924","doi":"10.1111/j.1464-5491.2006.01881.x","title":"A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study","year":2006,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada); Western University; McGill University; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"McMaster University; Sanofi","keywords":"Medicine; Internal medicine; Insulin glargine; Metformin; Type 2 diabetes; Insulin; Endocrinology; Diabetes mellitus; Randomized controlled trial; Gastroenterology","score_opus":0.02317300455415875,"score_gpt":0.2758955446500657,"score_spread":0.25272254009590694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122596924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025285,0.001508612,0.000021183709,0.00035114135,0.000121330675,0.0068924683,0.000039878305,0.000026492718,0.0007860586],"genre_scores_gemma":[0.9969889,0.00034389814,0.0010702013,0.000094565,0.00018011956,0.000504388,0.00019155667,0.0000691781,0.00055717735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968271,0.0001634282,0.0012072152,0.0004980992,0.00061469886,0.0006894418],"domain_scores_gemma":[0.99745595,0.0009482573,0.0006268498,0.00048349093,0.0002747558,0.00021068587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012411393,0.00055315363,0.002312508,0.0006131529,0.000108475375,0.000026459998,0.00019830307,0.000096397634,0.00017763347],"category_scores_gemma":[0.0005578353,0.000266863,0.00010630821,0.0010128001,0.00032984078,0.00014806395,0.000050940325,0.00016240685,0.000001173728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8795594,0.0036583107,0.08684286,0.0010078613,0.0027802985,0.0001030457,0.005390471,0.00015998146,0.0009840567,0.00042322974,0.00020336863,0.018887136],"study_design_scores_gemma":[0.9130742,0.035882395,0.036644947,0.0017423659,0.0025383525,0.0000033805973,0.0021960388,0.0007281047,0.005306967,0.000054722692,0.0014606799,0.00036782512],"about_ca_topic_score_codex":0.04533729,"about_ca_topic_score_gemma":0.16188318,"teacher_disagreement_score":0.116545886,"about_ca_system_score_codex":0.00021408274,"about_ca_system_score_gemma":0.00080551667,"threshold_uncertainty_score":0.99997836},"labels":[],"label_agreement":null},{"id":"W2122643907","doi":"10.1016/s0140-6736(14)61335-0","title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis","year":2014,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":382,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Ontario Ministry of Research, Innovation and Science; Heart and Stroke Foundation of Canada; Canadian Diabetes Association","keywords":"Medicine; Type 2 diabetes; Internal medicine; Insulin; Glucagon-like peptide 1 receptor; Diabetes mellitus; Hypoglycemia; Weight loss; Endocrinology; Agonist; Basal (medicine); Weight gain; Meta-analysis; Obesity; Body weight; Receptor","score_opus":0.09333612985953953,"score_gpt":0.34544360843643107,"score_spread":0.25210747857689153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122643907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000054233756,0.98821384,0.000024016263,0.0017857802,0.00005990052,0.009433733,0.000110035995,0.000023584807,0.0003437023],"genre_scores_gemma":[0.0000468786,0.9902291,0.00034029403,0.00071400916,0.00005185589,0.0031766533,0.00037800884,0.000034589262,0.0050285584],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9981706,0.0002678541,0.00073298777,0.00035643438,0.0002275248,0.00024455562],"domain_scores_gemma":[0.9975583,0.0005145499,0.00067012396,0.0011245995,0.00007911108,0.0000533431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012329916,0.00043240856,0.006977368,0.00010598505,0.000106400155,0.000052143372,0.00024172613,0.00006645592,0.00005124359],"category_scores_gemma":[0.000037863334,0.00017314755,0.001074848,0.00042011356,0.000090052854,0.000026136924,0.00010552398,0.000078243975,0.000017038063],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000991074,0.00009888391,0.0000018743383,0.7049281,0.27687654,6.4119394e-7,0.000028236005,1.826128e-7,1.5725366e-8,0.0005942801,0.002914798,0.014546544],"study_design_scores_gemma":[0.0005526176,0.0002740753,0.00000549804,0.015899796,0.6743667,4.562322e-7,0.000014986224,0.00002330107,2.1133157e-7,0.00002546851,0.30872995,0.0001069536],"about_ca_topic_score_codex":0.000007800389,"about_ca_topic_score_gemma":0.000004504918,"teacher_disagreement_score":0.68902826,"about_ca_system_score_codex":0.00008498003,"about_ca_system_score_gemma":0.00001974403,"threshold_uncertainty_score":0.70607525},"labels":[],"label_agreement":null},{"id":"W2122879720","doi":"10.1210/jcem.87.8.8743","title":"Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State","year":2002,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Research Resources; National Institute on Aging; National Institutes of Health; Massachusetts General Hospital; Howard Hughes Medical Institute","keywords":"Internal medicine; Insulin; Endocrinology; Glucagon-like peptide-1; Glucagon; Hormone; Medicine; Pancreatic hormone; Insulin resistance; Chemistry; Type 2 diabetes; Diabetes mellitus","score_opus":0.061907593506268566,"score_gpt":0.3445425281500376,"score_spread":0.28263493464376904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122879720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662892,0.014656079,0.000017195522,0.014172178,0.0014719553,0.0005299919,0.0000053577387,0.000024691453,0.0028333515],"genre_scores_gemma":[0.93817306,0.0482552,0.000356655,0.010016161,0.00077759003,0.000015892163,0.0000059273575,0.00003034207,0.0023691931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99543697,0.000995868,0.0020293924,0.00022896203,0.00063062203,0.0006781659],"domain_scores_gemma":[0.9966682,0.0014446157,0.0008497726,0.0006509297,0.00017883956,0.00020762127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025725751,0.0002919456,0.001137272,0.00025114202,0.00009379989,0.000025358262,0.00072534254,0.00010813016,0.0003368166],"category_scores_gemma":[0.0011133434,0.00014269755,0.00045185274,0.0003961636,0.00038961423,0.00016462174,0.00015033726,0.0012858341,0.00034790713],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006511263,0.01758804,0.06775388,0.0001362818,0.007906216,0.0067995233,0.007838162,0.0001534905,0.0011655578,0.0025242292,0.10699165,0.77463174],"study_design_scores_gemma":[0.015196976,0.0011662461,0.45281783,0.00008040732,0.0015779994,0.000312285,0.0005062835,0.0002015787,0.0001278868,0.0009770262,0.526864,0.00017148082],"about_ca_topic_score_codex":0.000028952461,"about_ca_topic_score_gemma":0.000024599462,"teacher_disagreement_score":0.77446026,"about_ca_system_score_codex":0.00003304942,"about_ca_system_score_gemma":0.000066836285,"threshold_uncertainty_score":0.5819037},"labels":[],"label_agreement":null},{"id":"W2122994980","doi":"10.2337/dc09-2294","title":"A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs","year":2010,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; LMC Diabetes & Endocrinology (Canada)","funders":"European Foundation for the Study of Diabetes; Novo Nordisk; Sanofi","keywords":"Medicine; Insulin glargine; Insulin detemir; Hypoglycemia; Internal medicine; Diabetes mellitus; Type 2 diabetes; Randomized controlled trial; Endocrinology; Insulin; Type 1 diabetes; Gastroenterology","score_opus":0.010673327803946,"score_gpt":0.22979904335565274,"score_spread":0.21912571555170673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122994980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908119,0.00035165637,0.000006925268,0.00010868847,0.00041998673,0.006226096,0.000043376178,0.0001286351,0.001902756],"genre_scores_gemma":[0.99675834,0.000018286728,0.0010563921,0.00035077645,0.00013408395,0.00079351827,0.00073219504,0.0001024667,0.000053964934],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664253,0.0001942825,0.0009423945,0.0006687116,0.0007804463,0.0007716269],"domain_scores_gemma":[0.99761176,0.00051973277,0.00048394472,0.00058632565,0.0005158893,0.00028236606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005263879,0.0006366231,0.0024589067,0.00071526016,0.00008873006,0.00007563604,0.000236317,0.00019549078,0.00005005239],"category_scores_gemma":[0.00049103587,0.0004495819,0.00022757206,0.00083603454,0.0001578397,0.0002659912,0.00009669319,0.00048604832,0.00005268978],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4473218,0.0016182867,0.537064,0.00027565315,0.00072065863,0.000013995307,0.0017682685,0.0001712214,0.0005448051,0.000038264792,0.000035572917,0.010427426],"study_design_scores_gemma":[0.8711089,0.010767798,0.101841256,0.0009025498,0.0009443109,1.06588665e-7,0.00042759598,0.00077571673,0.012367289,0.000020494414,0.00027395427,0.00057005876],"about_ca_topic_score_codex":0.00005102735,"about_ca_topic_score_gemma":0.00014351455,"teacher_disagreement_score":0.43522277,"about_ca_system_score_codex":0.00021741018,"about_ca_system_score_gemma":0.0001247898,"threshold_uncertainty_score":0.9997956},"labels":[],"label_agreement":null},{"id":"W2123454062","doi":"10.3945/jn.110.122721","title":"Dietary Oat β-Glucan Reduces Peak Net Glucose Flux and Insulin Production and Modulates Plasma Incretin in Portal-Vein Catheterized Grower Pigs","year":2010,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agriculture and Agri-Food Canada; University of Alberta","funders":"","keywords":"Internal medicine; Endocrinology; Insulin; Portal vein; Glucagon; Latin square; Basal (medicine); Incretin; Chemistry; Flux (metallurgy); Biology; Medicine; Fermentation; Food science; Diabetes mellitus; Type 2 diabetes","score_opus":0.010175357478594682,"score_gpt":0.23578472423829333,"score_spread":0.22560936675969864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123454062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994117,0.0011016497,6.5413536e-7,0.003971364,0.00030842505,0.0003457525,0.000003303443,0.00001174035,0.00014010776],"genre_scores_gemma":[0.99580765,0.0023069077,0.0012539383,0.00006178243,0.00036487827,0.000012752041,0.000051969684,0.000012901572,0.00012724202],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991626,0.000034215038,0.00034105606,0.00015465684,0.0001716032,0.00013583714],"domain_scores_gemma":[0.99951017,0.000023353114,0.00019649974,0.000090630245,0.00007977275,0.00009959044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031717858,0.0001236675,0.00027617073,0.00026886788,0.00003730588,0.000034143206,0.00003348048,0.00006859188,0.00003350427],"category_scores_gemma":[0.00009139169,0.00010007388,0.0000488875,0.000105831314,0.000061923405,0.0003044145,0.000024197658,0.00022839525,0.0000015499776],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018215651,0.0027031116,0.014515369,0.00039830236,0.00021532469,0.00025864033,0.00092746806,0.0000035988587,0.927078,0.000030674997,0.0039784643,0.048069492],"study_design_scores_gemma":[0.020540716,0.0054699825,0.7757546,0.0022640638,0.000833517,0.0013630687,0.0014991158,0.00075750786,0.17940702,0.002707648,0.008877262,0.0005255073],"about_ca_topic_score_codex":0.000020764614,"about_ca_topic_score_gemma":0.00003502559,"teacher_disagreement_score":0.76123923,"about_ca_system_score_codex":0.000028165623,"about_ca_system_score_gemma":0.000015735708,"threshold_uncertainty_score":0.40808943},"labels":[],"label_agreement":null},{"id":"W2123955086","doi":"10.1016/s0140-6736(14)60611-5","title":"Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; St. Michael's Hospital; Western University; McMaster University; Population Health Research Institute; St Joseph's Health Care; Hamilton Health Sciences","funders":"National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; Instituto de Astrofísica de Andalucía","keywords":"Ischaemic heart disease; Medicine; Randomized controlled trial; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.027153358174509586,"score_gpt":0.29597141456147996,"score_spread":0.26881805638697037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123955086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811376,0.0010755601,0.00027411696,0.01276141,0.00021620421,0.0037808535,0.00021197033,0.000025810456,0.0005164991],"genre_scores_gemma":[0.99175763,0.00008870636,0.000022524064,0.007020228,0.00057585334,0.00012810351,0.00024112492,0.000010051892,0.00015578863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987052,0.00033917342,0.00030625678,0.00021514735,0.00026384043,0.0001703653],"domain_scores_gemma":[0.99407727,0.0041100653,0.00023321105,0.0014272145,0.00010231723,0.000049933453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007188901,0.00013969006,0.0015472572,0.00006398564,0.00003308997,0.000010573825,0.00043717516,0.000026753467,0.00004970293],"category_scores_gemma":[0.0020678628,0.000061418694,0.00028509702,0.00018224491,0.00010379826,0.000035628353,0.00009407904,0.000095177464,0.000015011032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9219956,0.00029143077,0.004818946,0.00005603767,0.012639183,0.000004413208,0.000115404255,0.000049114224,0.0018696903,0.00031100158,0.056127615,0.001721588],"study_design_scores_gemma":[0.9195507,0.00062926934,0.03574959,0.0001659594,0.03317669,7.3458445e-8,0.000054582197,0.006802936,0.0003090679,0.00024704423,0.0032285943,0.00008548291],"about_ca_topic_score_codex":0.0000915541,"about_ca_topic_score_gemma":0.000013518313,"teacher_disagreement_score":0.05289902,"about_ca_system_score_codex":0.000013302642,"about_ca_system_score_gemma":0.000020886368,"threshold_uncertainty_score":0.25045815},"labels":[],"label_agreement":null},{"id":"W2124124929","doi":"10.1186/1758-5996-5-4","title":"Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome","year":2013,"lang":"en","type":"article","venue":"Diabetology & Metabolic Syndrome","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Canadian Institutes of Health Research; Université Laval","keywords":"Medicine; Metabolic syndrome; Internal medicine; Meth-; Endocrinology; Quartile; Diabetes mellitus; Dipeptidyl peptidase-4; Obesity; Type 2 diabetes; Confidence interval","score_opus":0.028175053315034126,"score_gpt":0.28444608543747846,"score_spread":0.25627103212244434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124124929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872984,0.007966205,0.00007023682,0.0013999316,0.00018737462,0.0022982226,0.000034775738,0.00009011807,0.00065471075],"genre_scores_gemma":[0.9968508,0.00013080535,0.00090651686,0.0003726223,0.00005607141,0.0003692201,0.000050131846,0.00006962492,0.0011942124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693394,0.00041623507,0.0007130207,0.00061022805,0.0005938906,0.0007327009],"domain_scores_gemma":[0.997744,0.00027200856,0.00048823186,0.001086164,0.00018193756,0.00022764878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005493239,0.0005264925,0.0021603813,0.00028162933,0.00025797068,0.000053369225,0.00042150693,0.00021261476,0.00019266173],"category_scores_gemma":[0.000099424244,0.00027901836,0.00022896267,0.00075704965,0.0006951422,0.00028040388,0.00026595106,0.0003976282,0.00010668408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023304576,0.0002472329,0.9881547,0.000077830446,0.0024181225,0.000011808594,0.0006545655,0.000009634515,0.0016030777,0.0009680847,0.000116888616,0.005714715],"study_design_scores_gemma":[0.0023524158,0.00042816668,0.9816976,0.00009767038,0.0033315567,0.00020906658,0.00020020282,0.000075550204,0.008858622,0.00040567596,0.0020568005,0.00028667765],"about_ca_topic_score_codex":0.0002523179,"about_ca_topic_score_gemma":0.00003150055,"teacher_disagreement_score":0.009552369,"about_ca_system_score_codex":0.000031571642,"about_ca_system_score_gemma":0.00009052678,"threshold_uncertainty_score":0.9999662},"labels":[],"label_agreement":null},{"id":"W2124182221","doi":"10.2337/diabetes.52.3.751","title":"Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate","year":2003,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; ConjuChem (Canada); University of Toronto","funders":"","keywords":"Internal medicine; Endocrinology; Glucagon-like peptide-1; In vivo; Islet; Dipeptidyl peptidase; Albumin; Glucagon; Chemistry; Basal (medicine); Proinsulin; Insulin; Medicine; Biology; Diabetes mellitus; Type 2 diabetes; Biochemistry; Enzyme","score_opus":0.011675267071389588,"score_gpt":0.21931949426831454,"score_spread":0.20764422719692496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124182221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953796,0.00014480799,0.000013525384,0.000067164096,0.000073100644,0.00027423835,0.0000025436652,0.000028345405,0.004016675],"genre_scores_gemma":[0.99503005,0.00004006386,0.0020465716,0.00031928334,0.000011287497,0.000039634593,0.00009065931,0.000013226805,0.0024092447],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938494,0.000014244586,0.0001757703,0.0001473392,0.00010651446,0.00017120365],"domain_scores_gemma":[0.9997029,0.000016141044,0.00006484477,0.0001156471,0.000034810353,0.000065705215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010842989,0.000105734216,0.00020470255,0.00007729452,0.000029494187,0.000010163147,0.00002249597,0.000028880024,0.000041104082],"category_scores_gemma":[0.000019267012,0.00009014648,0.000026141146,0.000084872365,0.000036624268,0.000058984744,0.000019143974,0.000026743628,0.000017213702],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022035609,0.00043134132,0.37573588,0.0005151861,0.00048110035,0.000007986161,0.0010070248,2.042299e-7,0.5745431,0.0035765907,0.0002642934,0.04341525],"study_design_scores_gemma":[0.0013379476,0.00014663795,0.17578283,0.00014761786,0.0001437521,4.888339e-7,0.000083295,0.000025306774,0.703911,0.000033692737,0.11825058,0.0001368528],"about_ca_topic_score_codex":0.0000010370287,"about_ca_topic_score_gemma":6.5965537e-7,"teacher_disagreement_score":0.19995303,"about_ca_system_score_codex":0.000020406549,"about_ca_system_score_gemma":0.000026835976,"threshold_uncertainty_score":0.36760667},"labels":[],"label_agreement":null},{"id":"W2124515086","doi":"10.2174/187152512803530315","title":"Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System","year":2012,"lang":"en","type":"review","venue":"Cardiovascular & Hematological Agents in Medicinal Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Dyslipidemia; Incretin; Chylomicron; Medicine; Internal medicine; Type 2 diabetes; Postprandial; Endocrinology; Glycemic; Apolipoprotein B; Diabetes mellitus; Lipoprotein; Niacin; Cholesterol; Very low-density lipoprotein","score_opus":0.0501070114409346,"score_gpt":0.30119598566907874,"score_spread":0.25108897422814414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124515086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040727516,0.99310863,0.0011000509,0.00005365572,0.00023211529,0.0038210005,0.00002932322,0.00006602561,0.0011819019],"genre_scores_gemma":[0.020874612,0.97522444,0.00037361952,0.000045897992,0.00034083636,0.0027891009,0.0001991747,0.00007181627,0.00008047819],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691427,0.00021368919,0.0008219616,0.00078089506,0.0007127562,0.00055640703],"domain_scores_gemma":[0.9969298,0.00094158103,0.00024373857,0.001545704,0.00008428239,0.00025486868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001782578,0.000660608,0.004472808,0.000101877435,0.00010717022,0.000013606932,0.00037879046,0.00061312574,0.000013059143],"category_scores_gemma":[0.0003590996,0.00037788064,0.0035251467,0.00031685148,0.00019959625,0.000022762655,0.00022294014,0.0004943737,0.0000097277625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040063358,0.00019088792,0.00006810975,0.20726582,0.017871283,0.00014052281,0.000018647512,0.0000033837862,0.00000495249,0.0013565228,0.0002785311,0.7727613],"study_design_scores_gemma":[0.0030840102,0.0002417387,0.000300467,0.029147213,0.06140415,0.0009019857,0.000109986206,0.00001806936,0.00041334282,0.00008710885,0.9037694,0.0005225592],"about_ca_topic_score_codex":0.0000054770344,"about_ca_topic_score_gemma":7.334978e-8,"teacher_disagreement_score":0.90349084,"about_ca_system_score_codex":0.00027751626,"about_ca_system_score_gemma":0.00006914846,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W2124633895","doi":"10.1016/j.abb.2008.08.001","title":"GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP","year":2008,"lang":"en","type":"article","venue":"Archives of Biochemistry and Biophysics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Diabetes UK","keywords":"Agonist; Internal medicine; Antagonist; Receptor; Glucagon-like peptide-1; Endocrinology; Chemistry; Potassium channel; Pharmacology; Medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.011430098764387142,"score_gpt":0.21995978286270537,"score_spread":0.20852968409831824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124633895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657315,0.0014638687,0.000015662516,0.000093884024,0.000019602676,0.00015968295,0.000013072193,0.000011941716,0.0016491326],"genre_scores_gemma":[0.9950426,0.003532814,0.0007691911,0.000022710083,0.000017530545,0.000004431364,0.00008629116,0.0000064694973,0.0005179486],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99942964,0.000010285558,0.00018722199,0.00018341512,0.000093762384,0.000095673255],"domain_scores_gemma":[0.99960905,0.00005711315,0.00013594178,0.00012542825,0.000021414924,0.00005102942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000024602226,0.000109597146,0.00019096714,0.0000136767185,0.000058611167,0.0000057579177,0.000024180234,0.000038686085,0.0000023856235],"category_scores_gemma":[0.000021066795,0.00009239336,0.000031583535,0.00004974947,0.00033929368,0.00007138989,0.0000493493,0.000053609238,2.2906912e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010003986,0.00018553957,0.034436118,0.0005498483,0.00022228183,0.000020871861,0.0024755239,8.6467844e-7,0.95771694,0.0013023453,0.000029383624,0.002960252],"study_design_scores_gemma":[0.0016050347,0.0002597384,0.021956353,0.00029250112,0.00018022052,0.000020989155,0.0005219884,0.00016531709,0.9729134,0.0019287015,0.00003446145,0.000121304736],"about_ca_topic_score_codex":0.000020719986,"about_ca_topic_score_gemma":8.6551876e-7,"teacher_disagreement_score":0.015196459,"about_ca_system_score_codex":0.0000051290167,"about_ca_system_score_gemma":0.000028119322,"threshold_uncertainty_score":0.37676919},"labels":[],"label_agreement":null},{"id":"W2124761817","doi":"10.1152/ajpendo.00149.2007","title":"Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators","year":2007,"lang":"en","type":"review","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon-like peptide-2; Signal transduction; Vasoactive intestinal peptide; Cell biology; Enteroendocrine cell; Biology; Receptor; Growth factor; Motility; Endocrinology; Hormone; Endocrine system; Biochemistry; Peptide; Neuropeptide","score_opus":0.027222460931977516,"score_gpt":0.3127700749387955,"score_spread":0.285547614006818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124761817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022972828,0.973585,0.00004709419,0.00010403328,0.0024861752,0.0006074873,0.000018606395,0.000031013096,0.00014776952],"genre_scores_gemma":[0.005750423,0.989286,0.0036028568,0.0003660212,0.00059106713,0.00005109518,0.00005205854,0.00006037048,0.00024010926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996847,0.00037828943,0.0012241334,0.00051261263,0.00021344617,0.0008245557],"domain_scores_gemma":[0.9972857,0.0005040039,0.0013930047,0.00039034474,0.00011584011,0.00031110735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031358597,0.00061723514,0.0044249594,0.0015995065,0.000088570894,0.000010496951,0.00028219595,0.00022341813,0.000028341941],"category_scores_gemma":[0.00021484407,0.00045124715,0.00073779566,0.0005982713,0.0008670385,0.00014615487,0.00014309549,0.0012272191,0.000018828523],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024570772,0.0003653659,0.0017926214,0.0008993066,0.0022527042,0.00018930653,0.000096141855,9.592588e-7,0.0000486496,0.00007391215,0.0021475558,0.99188775],"study_design_scores_gemma":[0.002867329,0.0005206389,0.015348075,0.00097328133,0.0035448794,0.0003790875,0.0006008549,0.0000027789067,0.000013790213,0.00006032645,0.9753627,0.0003262368],"about_ca_topic_score_codex":0.000059718546,"about_ca_topic_score_gemma":0.000013817565,"teacher_disagreement_score":0.99156153,"about_ca_system_score_codex":0.00013082224,"about_ca_system_score_gemma":0.00024879343,"threshold_uncertainty_score":0.99979395},"labels":[],"label_agreement":null},{"id":"W2124762650","doi":"10.1152/ajpregu.00424.2010","title":"Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4","year":2011,"lang":"en","type":"article","venue":"American Journal of Physiology-Regulatory, Integrative and Comparative Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Canadian Institutes of Health Research","funders":"","keywords":"Agonist; Peripheral; Receptor; Glucagon-like peptide 1 receptor; Medicine; Pharmacology; Endocrinology; Internal medicine; Neuroscience; Chemistry; Psychology","score_opus":0.030905720520329295,"score_gpt":0.2913228581928156,"score_spread":0.2604171376724863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124762650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765056,0.000099076955,0.00010405194,0.0004559817,0.00025882162,0.0003023978,0.0000066778875,0.000009705659,0.0011126957],"genre_scores_gemma":[0.99801916,0.000019695353,0.0010782859,0.0004636939,0.00013092712,0.000019841596,0.000018243449,0.000011764413,0.00023840235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984027,0.0003968011,0.0005201763,0.0002711258,0.00017843753,0.00023074952],"domain_scores_gemma":[0.9982412,0.00015150703,0.0010072291,0.0002531755,0.00025125116,0.00009562694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016309721,0.00028580532,0.0009782187,0.00011600828,0.00012727478,0.0000071636077,0.00018605385,0.000057919624,0.00011997298],"category_scores_gemma":[0.000042336917,0.0001669406,0.00036365024,0.0002543329,0.0011973538,0.00018171582,0.000059284106,0.0002748886,0.0000032111827],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002316802,0.00054848235,0.0038638692,0.000022866436,0.0012427648,0.0000015621877,0.004436836,0.0000069701023,0.9785951,0.0047772485,0.0016750981,0.0025124054],"study_design_scores_gemma":[0.0013996275,0.0077687926,0.7430999,0.00018755665,0.0002435282,0.000011428403,0.00897468,0.000040935218,0.23567712,0.0014346567,0.0009763158,0.00018543362],"about_ca_topic_score_codex":0.00004056856,"about_ca_topic_score_gemma":0.000010366389,"teacher_disagreement_score":0.74291795,"about_ca_system_score_codex":0.00009068187,"about_ca_system_score_gemma":0.00015038702,"threshold_uncertainty_score":0.680764},"labels":[],"label_agreement":null},{"id":"W2124852816","doi":"10.1038/nm919","title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","year":2003,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":844,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Marsden Fund","keywords":"Neuroprotection; Hippocampal formation; Kainate receptor; Glucagon-like peptide-1; Internal medicine; Endocrinology; Hippocampus; Receptor; Biology; Glucagon-like peptide 1 receptor; Neuroscience; Pharmacology; Glutamate receptor; Medicine; Type 2 diabetes; Agonist; Diabetes mellitus; AMPA receptor","score_opus":0.008709362958644358,"score_gpt":0.25935037413578066,"score_spread":0.2506410111771363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124852816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9599299,0.0060196896,0.000030773543,0.0063330606,0.0006991699,0.00071794546,4.7669758e-7,0.00010009986,0.026168881],"genre_scores_gemma":[0.9812868,0.0009258801,0.00044905243,0.0029398184,0.00017601156,0.000031799565,0.000025651716,0.00002588059,0.014139097],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895597,0.00006263019,0.00018929364,0.00030730903,0.00026051546,0.00022431435],"domain_scores_gemma":[0.99959356,0.000045422406,0.000058458205,0.00014384487,0.00004936357,0.00010935637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003244332,0.0001667729,0.0002938978,0.00024502567,0.000050791805,0.000007167816,0.000030370125,0.00017034778,0.00039297197],"category_scores_gemma":[0.0003659663,0.00012236745,0.000029796922,0.0003709889,0.00006645486,0.000054850443,0.000019257712,0.00071294996,0.00002509484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084012613,0.0008805323,0.6576779,0.0011873126,0.00056016824,0.00043532622,0.0045576156,0.0000059481267,0.097453445,0.0041803285,0.109787725,0.1224336],"study_design_scores_gemma":[0.006503262,0.0014517175,0.025794314,0.0005113193,0.0001840692,0.000014592965,0.000907803,0.000072495415,0.0078067766,0.00019145948,0.95637983,0.00018238384],"about_ca_topic_score_codex":0.000027564836,"about_ca_topic_score_gemma":0.000018164548,"teacher_disagreement_score":0.84659207,"about_ca_system_score_codex":0.000069086345,"about_ca_system_score_gemma":0.000018049263,"threshold_uncertainty_score":0.49899998},"labels":[],"label_agreement":null},{"id":"W2124909544","doi":"10.1056/nejmoa1407963","title":"Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":624,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; Merck Sharp and Dohme; Astellas Pharma; British Heart Foundation; Daiichi-Sankyo; National Institute for Health and Care Research; Novo Nordisk; Sanofi; Servier; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Type 2 diabetes; Medicine; Internal medicine; Blood pressure; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.007796010729728189,"score_gpt":0.23259558996070487,"score_spread":0.22479957923097668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124909544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98001796,0.015449233,0.00006471124,0.0025977194,0.00047595648,0.0001355863,5.3644027e-7,0.0000058304004,0.0012524888],"genre_scores_gemma":[0.99730265,0.0008200018,0.00013911493,0.00040339254,0.00083387166,6.3494224e-7,0.0000019085126,0.000010692624,0.00048770988],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999067,0.000039737486,0.00038830645,0.0000899518,0.00025731482,0.00015769755],"domain_scores_gemma":[0.99921125,0.00019738001,0.00019980219,0.00012053843,0.000098654426,0.0001723542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072438654,0.00011432269,0.0005891887,0.00020877596,0.000011245397,0.0000038793196,0.000061900115,0.000039935996,0.00008028793],"category_scores_gemma":[0.00043212774,0.000072096416,0.00004186905,0.00011738152,0.00005674618,0.000056519402,0.000016933072,0.00014318971,8.438635e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023239555,0.00036449157,0.49357873,0.0005811592,0.0023266885,0.00019241167,0.0012820588,0.000048478032,0.053337242,0.0003916584,0.00477325,0.44079986],"study_design_scores_gemma":[0.5780293,0.020782346,0.19794665,0.004926742,0.012672776,0.00014839976,0.00023953163,0.0008875547,0.012953302,0.0016158056,0.16946521,0.00033237564],"about_ca_topic_score_codex":0.000025554782,"about_ca_topic_score_gemma":0.000015132567,"teacher_disagreement_score":0.57570535,"about_ca_system_score_codex":0.000006125712,"about_ca_system_score_gemma":0.000027475135,"threshold_uncertainty_score":0.29400066},"labels":[],"label_agreement":null},{"id":"W2125074756","doi":"10.1016/j.jcjd.2013.08.103","title":"The Effect of Liraglutide on A1C and Body Weight is Largely Independent of Diabetes Duration","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Diabetes mellitus; Type 2 diabetes; Post-hoc analysis; Internal medicine; Placebo; Clinical endpoint; Weight loss; Obesity; Endocrinology; Clinical trial","score_opus":0.004439001506855196,"score_gpt":0.20052539606115738,"score_spread":0.19608639455430218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125074756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381727,0.002621242,6.077458e-7,0.0018244425,0.00020769985,0.00040722897,0.000012068887,0.0000033443523,0.0011060915],"genre_scores_gemma":[0.99918133,0.0000523154,0.00004150678,0.00025594077,0.0000861076,0.000013707604,0.0000050847557,0.00001661849,0.00034739223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874336,0.00007701564,0.00046204496,0.0001130988,0.00026349255,0.00034100012],"domain_scores_gemma":[0.99858093,0.0002949536,0.00036556486,0.00020404512,0.0001763425,0.00037818414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047057838,0.00016394343,0.00042988727,0.0002827601,0.000091383066,0.000041777417,0.00012907575,0.000064422544,0.00011433956],"category_scores_gemma":[0.00018439698,0.00009905383,0.00013957151,0.00012914214,0.00013790843,0.00014774376,0.000015524569,0.00014675541,0.000009945354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009106368,0.000031778196,0.9704515,0.00016256496,0.00062678615,0.000004104037,0.00012988225,0.0000011532383,0.0041600023,0.00018567797,0.007781736,0.016455757],"study_design_scores_gemma":[0.0023608645,0.0043117465,0.8791335,0.00056749076,0.00057360565,8.8933774e-7,0.00007783693,0.00016138711,0.107981294,0.00039911165,0.0042988393,0.0001334231],"about_ca_topic_score_codex":0.00018549137,"about_ca_topic_score_gemma":0.00035085264,"teacher_disagreement_score":0.10382129,"about_ca_system_score_codex":0.00008057973,"about_ca_system_score_gemma":0.00013141714,"threshold_uncertainty_score":0.4039298},"labels":[],"label_agreement":null},{"id":"W2125191390","doi":"10.2337/diacare.28.10.2345","title":"Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure","year":2005,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":421,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Metformin; Sulfonylurea; Internal medicine; Diabetes mellitus; Combination therapy; Type 2 diabetes; Hazard ratio; Lactic acidosis; Proportional hazards model; Heart failure; Insulin; Endocrinology; Confidence interval","score_opus":0.0075435766864467135,"score_gpt":0.2453331679729809,"score_spread":0.2377895912865342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125191390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978595,0.0002114344,2.9687075e-7,0.00054959196,0.000037584166,0.0009604846,0.000036572183,0.00008860694,0.00025596732],"genre_scores_gemma":[0.9967572,0.0000038049566,0.0013299348,0.0011988303,0.00003493562,0.000099317745,0.00038194028,0.00004266226,0.00015136294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845105,0.000046325848,0.0003202111,0.0004019816,0.00026862888,0.0005117996],"domain_scores_gemma":[0.99913865,0.00015672644,0.000102324964,0.00029007558,0.00013638339,0.00017581183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016256509,0.00028875005,0.0006794373,0.00014655212,0.000049983628,0.00003934898,0.0000682478,0.00011544678,0.000025250187],"category_scores_gemma":[0.000105656225,0.0001843783,0.00008873963,0.00021600416,0.00010277676,0.00020267202,0.00006205388,0.00018867952,0.000017285287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037138805,0.00041576318,0.98636484,0.000057340014,0.00044230954,0.0000016422471,0.00015195846,0.0000013452109,0.000007517253,0.0000056145154,0.00040766448,0.012106856],"study_design_scores_gemma":[0.00894621,0.0018820701,0.98555887,0.00020665005,0.0003823091,2.1865795e-8,0.00027080334,0.000056550125,0.00020414122,0.0000032005778,0.0022492493,0.00023995606],"about_ca_topic_score_codex":0.0000028262273,"about_ca_topic_score_gemma":0.00018370339,"teacher_disagreement_score":0.0118669,"about_ca_system_score_codex":0.00011791319,"about_ca_system_score_gemma":0.00003206145,"threshold_uncertainty_score":0.7518729},"labels":[],"label_agreement":null},{"id":"W2125468958","doi":"10.1056/nejmoa1006524","title":"Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1042,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Disease; Intensive care; Term (time); Internal medicine; Endocrinology","score_opus":0.021540638032590136,"score_gpt":0.2550016657156834,"score_spread":0.23346102768309326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125468958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882347,0.0057019214,0.0005257842,0.0007987271,0.0011935023,0.00027391815,2.6004446e-7,0.0000120007235,0.0032591836],"genre_scores_gemma":[0.9966704,0.00092755904,0.00019331762,0.0007367518,0.00087622576,0.0000014616844,0.0000021640144,0.000017718243,0.00057436957],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99874234,0.000036115314,0.00040658182,0.00011384905,0.00052864855,0.0001724642],"domain_scores_gemma":[0.99878913,0.00014892883,0.00022730175,0.00027938845,0.0003231417,0.00023211651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041991027,0.00017033363,0.0009097465,0.00026796025,0.000015225779,0.0000022150982,0.00009796264,0.00004106446,0.00009408151],"category_scores_gemma":[0.0006193951,0.00009661352,0.00030167628,0.00009831024,0.00006940272,0.00005459044,0.000026701566,0.0001802331,0.0000066118428],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018423748,0.00049415947,0.23802513,0.00070419785,0.008154726,0.0060956404,0.00334338,0.0000071679183,0.0022016983,0.00012667889,0.0028835859,0.73612124],"study_design_scores_gemma":[0.117953084,0.013960636,0.8116277,0.0045240787,0.0059670117,0.00038831402,0.00022514923,0.0000023723783,0.04014126,0.00018593078,0.0048398087,0.00018466503],"about_ca_topic_score_codex":0.000047933943,"about_ca_topic_score_gemma":0.0000034258585,"teacher_disagreement_score":0.7359366,"about_ca_system_score_codex":0.00004444438,"about_ca_system_score_gemma":0.00003443355,"threshold_uncertainty_score":0.3939785},"labels":[],"label_agreement":null},{"id":"W2125569652","doi":"10.1016/j.jcjd.2013.08.007","title":"Association Between Newly Diagnosed Diabetes and Dementia Diagnosis in Older Adults: A Population-Based Study","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Dementia; Diabetes mellitus; Cohort; Incidence (geometry); Vascular dementia; Population; Kidney disease; Cohort study; Internal medicine; Disease; Type 2 diabetes; Pediatrics; Endocrinology","score_opus":0.007465104016016026,"score_gpt":0.21782764167501883,"score_spread":0.2103625376590028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125569652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955529,0.0013106196,7.70669e-7,0.0017780685,0.00014216159,0.0011180718,0.000014663263,0.0000112418675,0.000071519586],"genre_scores_gemma":[0.99886644,0.000007540429,0.00017684477,0.00053338555,0.00013668308,0.00015545033,0.000042354673,0.000027613238,0.000053714924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983034,0.00010209667,0.0005702636,0.00020418191,0.0002888504,0.00053118065],"domain_scores_gemma":[0.99829227,0.00040441926,0.00033533116,0.0001585721,0.00020719314,0.0006022018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041318467,0.00021005624,0.0005310079,0.0007269547,0.00008364548,0.00012448277,0.00010990723,0.00009178466,0.00031389005],"category_scores_gemma":[0.00042629262,0.0001881077,0.00010337684,0.0003140266,0.000019570738,0.00032139584,0.000013352484,0.0001811984,0.000013436571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000012723381,0.0002123109,0.9814957,0.000063433734,0.00067585125,0.000012150125,0.0003296462,0.000008079698,0.000003035545,0.0000017954537,0.0020107108,0.015186016],"study_design_scores_gemma":[0.005107385,0.0006455889,0.9919452,0.0004915349,0.0008687744,3.0842717e-8,0.00042378937,0.00006976581,0.000052526153,0.00005654952,0.00017310133,0.00016575784],"about_ca_topic_score_codex":0.003543377,"about_ca_topic_score_gemma":0.0141798705,"teacher_disagreement_score":0.015020259,"about_ca_system_score_codex":0.00044739977,"about_ca_system_score_gemma":0.00017973453,"threshold_uncertainty_score":0.7912701},"labels":[],"label_agreement":null},{"id":"W2126278923","doi":"10.2215/cjn.03470807","title":"Rosiglitazone","year":2007,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Rosiglitazone; Internal medicine; Insulin","score_opus":0.041043935026441644,"score_gpt":0.3767334625710915,"score_spread":0.33568952754464987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126278923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98252064,0.00024098942,0.0006564469,0.015704125,0.00025074682,0.000103276536,7.0608684e-7,0.0000062048885,0.0005168389],"genre_scores_gemma":[0.9333048,0.000519179,0.0103586465,0.05493823,0.00046764297,3.8530877e-7,4.044662e-7,0.0000103378925,0.00040037424],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998592,0.000082058636,0.00079394755,0.0000952442,0.00022689615,0.00020981605],"domain_scores_gemma":[0.99787176,0.0004986176,0.0010964402,0.00025247806,0.00015747375,0.00012322956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001518162,0.00008653967,0.0006335098,0.000027473607,0.000030060537,0.0000022882587,0.00021885335,0.000053963653,0.000024599454],"category_scores_gemma":[0.00008596281,0.000050319482,0.0010601751,0.00021148026,0.0012138215,0.00002768549,0.00009703033,0.00031518406,0.000005316459],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019828803,0.0018768982,0.3895556,0.000044327553,0.0032520012,0.00004435639,0.00048178234,0.0000056080585,0.010361817,0.00021342687,0.41160098,0.18058033],"study_design_scores_gemma":[0.0024512503,0.0040628305,0.8064215,0.00003727665,0.00063073146,0.00006617267,0.00096073403,0.000015483167,0.0004427911,0.00037891074,0.18447289,0.00005941254],"about_ca_topic_score_codex":0.000008369005,"about_ca_topic_score_gemma":0.0000013620041,"teacher_disagreement_score":0.41686592,"about_ca_system_score_codex":0.00003812517,"about_ca_system_score_gemma":0.000063075466,"threshold_uncertainty_score":0.44723758},"labels":[],"label_agreement":null},{"id":"W2126774100","doi":"10.1681/asn.2004110974","title":"Oral Antihyperglycemic Agents and Renal Disease","year":2005,"lang":"en","type":"review","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Rosiglitazone; Nateglinide; Repaglinide; Pioglitazone; Hypoglycemia; Acarbose; Diabetes mellitus; Nephropathy; Type 2 diabetes; Internal medicine; Insulin; Glycemic; Endocrinology","score_opus":0.03991917862062206,"score_gpt":0.341115180776094,"score_spread":0.30119600215547193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126774100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01152629,0.98532355,0.000007089523,0.0026533843,0.000093701245,0.00031301784,0.00001180504,0.0000056028284,0.000065579],"genre_scores_gemma":[0.0004043509,0.9923925,0.0014099613,0.0048120962,0.0003686364,0.0000037954471,0.000005392446,0.00002588074,0.00057741464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867815,0.00012513656,0.0005688346,0.0001509338,0.00025898434,0.00021798628],"domain_scores_gemma":[0.99771595,0.00007605652,0.001700245,0.00028113034,0.000065737964,0.00016086843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020442753,0.00023855967,0.0018611315,0.00007304298,0.00004120367,0.0000067131386,0.00024051474,0.00006675389,0.000031281652],"category_scores_gemma":[0.000017005657,0.00013260054,0.0014617724,0.00021759172,0.0006415255,0.00003949727,0.00016494763,0.00034098243,0.0000034951274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001548631,0.0001903356,0.00037013734,0.0013803083,0.0026915534,0.000025280444,0.000041447085,8.623831e-7,0.00001019992,0.000006491423,0.10718032,0.8879482],"study_design_scores_gemma":[0.00074010435,0.00067741313,0.0041452027,0.0015049414,0.007000641,0.00013636719,0.000030565672,0.0000078703715,1.6932144e-7,0.000014731419,0.9856513,0.00009067934],"about_ca_topic_score_codex":0.0000069233997,"about_ca_topic_score_gemma":4.884432e-7,"teacher_disagreement_score":0.8878575,"about_ca_system_score_codex":0.000104672035,"about_ca_system_score_gemma":0.00021867082,"threshold_uncertainty_score":0.5407293},"labels":[],"label_agreement":null},{"id":"W2127043893","doi":"10.1136/bmj.d7282","title":"Glucagon-like peptide-1 agonists","year":2012,"lang":"en","type":"letter","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Glucagon-like peptide-1; Glucagon; Chemistry; Internal medicine; Endocrinology; Medicine; Diabetes mellitus; Insulin; Type 2 diabetes","score_opus":0.02740202189698992,"score_gpt":0.2897845146606847,"score_spread":0.2623824927636948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127043893","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044812055,0.0008882558,0.000008853335,0.7568437,0.001994763,0.0012273439,0.000016201366,0.00016877918,0.238404],"genre_scores_gemma":[0.0005488491,0.000053620784,0.00058754423,0.6100443,0.010316017,0.00018631131,0.0011952533,0.00007182591,0.37699625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838436,0.000029642688,0.00027432156,0.00032705217,0.00042238625,0.0005622681],"domain_scores_gemma":[0.99894977,0.000037336988,0.00014222362,0.00072522584,0.000042373114,0.0001030486],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014371712,0.00033344195,0.00049532595,0.00014507603,0.000044502267,0.000035702313,0.00013066774,0.00040916656,0.0010501406],"category_scores_gemma":[0.000018099194,0.00026818694,0.00024983403,0.000082593215,0.000048096997,0.00005516773,0.00010508402,0.00056105084,0.004176025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012289348,0.00008305952,0.00088730577,0.0003817456,0.00053815753,0.0008080087,0.00003554073,4.2922178e-8,0.000007175913,0.000027019843,0.9907564,0.0064632595],"study_design_scores_gemma":[0.0007554154,0.00012337643,0.0020481972,0.00020245522,0.0009715627,0.000024447474,0.0000066013,0.0000015074801,0.00003498127,0.000029622634,0.99553543,0.0002664238],"about_ca_topic_score_codex":0.000025370604,"about_ca_topic_score_gemma":0.0000020859652,"teacher_disagreement_score":0.14679936,"about_ca_system_score_codex":0.0001353987,"about_ca_system_score_gemma":0.000057774192,"threshold_uncertainty_score":0.99997705},"labels":[],"label_agreement":null},{"id":"W2127833912","doi":"10.2337/dc09-0517","title":"A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers","year":2009,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca; Bristol-Myers Squibb; American Diabetes Association","keywords":"Medicine; Dapagliflozin; Insulin; Diabetes mellitus; Type 2 diabetes; Internal medicine; Type 1 diabetes; Endocrinology","score_opus":0.007679730796582718,"score_gpt":0.22103168498361428,"score_spread":0.21335195418703157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127833912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745077,0.0005191947,1.10846386e-7,0.000045579527,0.00009713843,0.0012864015,0.000029057252,0.000048758422,0.00052298035],"genre_scores_gemma":[0.9992496,0.000023336928,0.0002589754,0.00014869538,0.000025644393,0.00002202782,0.00021739694,0.000029588431,0.000024738212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830896,0.00007277141,0.000450803,0.00035274538,0.0004330844,0.00038163035],"domain_scores_gemma":[0.998849,0.00008143844,0.00020545312,0.00044521134,0.00032856353,0.000090381545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011101392,0.00027064106,0.00077367027,0.0003666112,0.000028502222,0.0000118964435,0.00011660653,0.000075431046,0.000017676603],"category_scores_gemma":[0.0001000055,0.0002175691,0.00006277237,0.0007042114,0.000055857825,0.00010915042,0.000062006795,0.00012843644,0.000009411469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026373,0.001545842,0.9728804,0.00022971138,0.0002739194,0.000009981261,0.003301365,0.00012479872,0.000368365,0.000009551555,0.0000766581,0.020915639],"study_design_scores_gemma":[0.010219963,0.0076860194,0.97295535,0.00055579335,0.0003534069,2.055727e-8,0.0035806613,0.000022947557,0.00437615,0.000015120809,0.000033965494,0.0002005961],"about_ca_topic_score_codex":0.000031013285,"about_ca_topic_score_gemma":0.000038284055,"teacher_disagreement_score":0.020715043,"about_ca_system_score_codex":0.00013977072,"about_ca_system_score_gemma":0.000052653784,"threshold_uncertainty_score":0.88722104},"labels":[],"label_agreement":null},{"id":"W2128093058","doi":"10.1111/dom.12290","title":"Pronounced reduction of postprandial glucagon by lixisenatide: a meta‐analysis of randomized clinical trials","year":2014,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi","keywords":"Lixisenatide; Postprandial; Meta-analysis; Randomized controlled trial; Glucagon; Medicine; Internal medicine; Reduction (mathematics); Endocrinology; Diabetes mellitus; Type 2 diabetes; Insulin; Mathematics; Liraglutide","score_opus":0.0973132919649313,"score_gpt":0.40441716668855515,"score_spread":0.3071038747236239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128093058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041417093,0.9899383,0.0000589575,0.000054139527,0.0004459065,0.0047153067,0.00033316622,0.000037998263,0.000274513],"genre_scores_gemma":[0.0015762512,0.9950826,0.00048577687,0.000049222235,0.00024782834,0.0005220146,0.0014561507,0.000042357107,0.0005377976],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98914635,0.0053367335,0.0038913754,0.0007265791,0.0005321202,0.00036681344],"domain_scores_gemma":[0.9919329,0.0034481094,0.0034227245,0.00068854954,0.0002622642,0.00024542585],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.01864252,0.0006700017,0.03187109,0.0010158303,0.000053015556,0.00003084793,0.0001857655,0.0005170221,0.00013514105],"category_scores_gemma":[0.0031121995,0.00041582645,0.011791503,0.0008781713,0.00042047614,0.000101010046,0.00011191357,0.00031647753,0.0000055183036],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020006504,0.0010404151,0.000042839005,0.013375453,0.64606375,6.6000865e-7,0.00006701482,3.65303e-7,0.000009315921,0.00055127376,0.00043034003,0.33641794],"study_design_scores_gemma":[0.025240647,0.00016509694,0.00004141422,0.0006262679,0.7457498,2.8275548e-7,0.000005721564,0.000020216097,0.000087093074,0.000058609614,0.2277661,0.0002387897],"about_ca_topic_score_codex":0.000041210165,"about_ca_topic_score_gemma":0.0000020572793,"teacher_disagreement_score":0.33617914,"about_ca_system_score_codex":0.000022637467,"about_ca_system_score_gemma":0.00013519268,"threshold_uncertainty_score":0.99982935},"labels":[],"label_agreement":null},{"id":"W2128772657","doi":"10.1159/000364909","title":"Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy","year":2014,"lang":"en","type":"article","venue":"American Journal of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Canagliflozin; Medicine; Kidney disease; Internal medicine; Renal function; Placebo; Type 2 diabetes; Blood pressure; Diabetes mellitus; Diabetic nephropathy; Urology; Population; Gastroenterology; Endocrinology; Pathology","score_opus":0.0035551954082943776,"score_gpt":0.2087944862425772,"score_spread":0.20523929083428283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128772657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990525,0.00015927128,0.000013334204,0.00040009557,0.000026953594,0.0001378872,0.0000014505998,0.0000028700554,0.00020559187],"genre_scores_gemma":[0.9979858,0.00011360681,0.00077846163,0.0010576219,0.00002553449,8.2317933e-7,0.0000029665384,0.000009811616,0.000025400439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930555,0.00007108757,0.00024718113,0.000099809695,0.00011136557,0.00016499923],"domain_scores_gemma":[0.99934274,0.00010345343,0.0002776979,0.000099353536,0.00008098998,0.000095750525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016689967,0.00009596146,0.00045614273,0.00017688086,0.000013281916,0.0000035045719,0.00003996469,0.000019174002,0.000014472129],"category_scores_gemma":[0.00004121046,0.000066314395,0.000017425204,0.00015580488,0.00029840603,0.000045736568,0.000029275569,0.00009174384,5.3257423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019731908,0.00020351993,0.89769775,0.000023596196,0.00022280104,0.000010752691,0.0001972196,0.000009551243,0.00019792838,0.00007735065,0.000110706394,0.09927562],"study_design_scores_gemma":[0.0059248954,0.012956518,0.97300774,0.00004739233,0.0001625075,0.0000028695524,0.000081073405,0.000025606767,0.000026922513,0.000014977419,0.0076922434,0.000057238394],"about_ca_topic_score_codex":0.00004830536,"about_ca_topic_score_gemma":0.000030035599,"teacher_disagreement_score":0.099218376,"about_ca_system_score_codex":0.000021401376,"about_ca_system_score_gemma":0.000027350305,"threshold_uncertainty_score":0.27042225},"labels":[],"label_agreement":null},{"id":"W2129794960","doi":"10.1016/j.jcjd.2015.06.010","title":"Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Society of Endocrinology and Metabolism; Boehringer Ingelheim; Eli Lilly and Company; Society for Endocrinology; Canadian Diabetes Association; American Diabetes Association","keywords":"Linagliptin; Medicine; Post-hoc analysis; Type 2 diabetes; Post hoc; Diabetes mellitus; Safety profile; Insulin; Internal medicine; Endocrinology; Adverse effect","score_opus":0.01812911597299567,"score_gpt":0.24731097014216208,"score_spread":0.22918185416916642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129794960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99147195,0.006862358,0.0000013939131,0.00065230584,0.00014149491,0.0003923492,0.000027240614,0.0000064835453,0.00044443042],"genre_scores_gemma":[0.99839246,0.00005479389,0.00033637736,0.0010210635,0.000082811304,0.0000041764715,0.00003968669,0.000024171019,0.000044458742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983633,0.0001333515,0.0005005075,0.0002452157,0.00033318132,0.00042443906],"domain_scores_gemma":[0.9973508,0.00010127671,0.0001542605,0.00038279718,0.0006158045,0.0013950455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005194917,0.0002190975,0.0010165893,0.0015242583,0.00003623084,0.00003398255,0.00015979707,0.000109108696,0.000044205368],"category_scores_gemma":[0.00042901855,0.00019042719,0.00026519105,0.0010827837,0.00008034364,0.00012055652,0.000026309992,0.00022495083,0.00001499092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010751305,0.00065859844,0.81144816,0.00023687359,0.022159426,0.00040886953,0.0042705657,0.007086537,0.00060772116,0.00024711655,0.0016016929,0.15019931],"study_design_scores_gemma":[0.012661415,0.015709234,0.9410543,0.0008002616,0.0075582867,0.0000028116656,0.0016989807,0.0003815253,0.0008987147,0.00010777051,0.018658841,0.00046785592],"about_ca_topic_score_codex":0.0008242452,"about_ca_topic_score_gemma":0.002971152,"teacher_disagreement_score":0.14973146,"about_ca_system_score_codex":0.0002049657,"about_ca_system_score_gemma":0.000533341,"threshold_uncertainty_score":0.77653956},"labels":[],"label_agreement":null},{"id":"W2129934471","doi":"10.2337/dc09-1914","title":"DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks","year":2010,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Exenatide; Medicine; Tolerability; Glycemic; Type 2 diabetes; Internal medicine; Diabetes mellitus; Hypoglycemia; Weight loss; Nausea; Endocrinology; Gastroenterology; Adverse effect; Obesity","score_opus":0.0032663095766140723,"score_gpt":0.21758923167102232,"score_spread":0.21432292209440823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129934471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914341,0.00074656226,0.000004206145,0.0026709305,0.00035446967,0.0009408354,0.000040490242,0.00013286374,0.0036755442],"genre_scores_gemma":[0.9966762,0.000041918185,0.00025162078,0.0008134271,0.00033507074,0.00014476391,0.00019593886,0.00003528507,0.0015057948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986428,0.000021722977,0.00024198681,0.00041808744,0.00025970684,0.0004156872],"domain_scores_gemma":[0.99906725,0.000089341214,0.00009603022,0.0003934944,0.00019089931,0.00016295884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009260164,0.00024641465,0.00034851223,0.00012526278,0.00011352417,0.00006905501,0.00009627049,0.00009690253,0.00012892332],"category_scores_gemma":[0.00012502674,0.00019959248,0.00008113628,0.00014180473,0.00011850724,0.00020670227,0.000056265013,0.000196926,0.00005863758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012928777,0.0001079889,0.9639427,0.00036852382,0.00025520645,0.000033660675,0.0006268182,8.137702e-7,0.018231433,0.00082484126,0.0031420318,0.0123367],"study_design_scores_gemma":[0.017920207,0.0014387205,0.8579816,0.0002530555,0.0012727441,0.0000033154822,0.0020140817,0.0006290827,0.03223144,0.0005631441,0.08486795,0.0008246317],"about_ca_topic_score_codex":0.000010102148,"about_ca_topic_score_gemma":0.000028240467,"teacher_disagreement_score":0.105961055,"about_ca_system_score_codex":0.0000626028,"about_ca_system_score_gemma":0.000055645294,"threshold_uncertainty_score":0.81391454},"labels":[],"label_agreement":null},{"id":"W2130570549","doi":"10.1016/s0140-6736(13)60683-2","title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":724,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Mitsubishi Tanabe Pharma Corporation","keywords":"Glimepiride; Medicine; Canagliflozin; Metformin; Type 2 diabetes; Population; Internal medicine; Randomized controlled trial; Diabetes mellitus; Clinical endpoint; Endocrinology","score_opus":0.03620259462299996,"score_gpt":0.28485283862101796,"score_spread":0.248650243998018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130570549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903972,0.00012758948,0.0000040157147,0.0005895846,0.00013542412,0.007137697,0.00009689608,0.000025729169,0.0014858693],"genre_scores_gemma":[0.9985892,0.000070455055,0.0003165996,0.00010954898,0.00016256618,0.00027722205,0.0003528869,0.000021672908,0.00009985035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99845177,0.0000856242,0.000483151,0.0002913821,0.00031385742,0.00037423454],"domain_scores_gemma":[0.9983505,0.0006301339,0.0002761444,0.00051298545,0.00011591421,0.000114332135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004707372,0.00025094755,0.0012741014,0.00009474057,0.00005215714,0.000042811313,0.00015108332,0.00005317391,0.00004593947],"category_scores_gemma":[0.00015599135,0.00012911264,0.00004906903,0.00024262533,0.00012770256,0.00013927025,0.00005348169,0.00015702721,0.0000118480675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98534787,0.00092309486,0.0070291744,0.000032309876,0.001196742,0.000008990629,0.0002920475,0.000012100198,0.00003815947,0.000018083423,0.0005226444,0.0045787976],"study_design_scores_gemma":[0.9600708,0.0071817883,0.030360283,0.0001613938,0.0010341393,7.8910546e-8,0.0000676448,0.0001565808,0.00037215473,0.000014212182,0.0004255765,0.00015535246],"about_ca_topic_score_codex":0.0029474099,"about_ca_topic_score_gemma":0.00089548365,"teacher_disagreement_score":0.02527706,"about_ca_system_score_codex":0.00006974452,"about_ca_system_score_gemma":0.00009134629,"threshold_uncertainty_score":0.52650607},"labels":[],"label_agreement":null},{"id":"W2130684080","doi":"10.1016/j.clinthera.2012.09.007","title":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Memorial Hospital","funders":"","keywords":"Exenatide; Medicine; Metformin; Pioglitazone; Internal medicine; Glycemic; Sitagliptin; Type 2 diabetes; Type 2 Diabetes Mellitus; Rosiglitazone; Thiazolidinedione; Population; Diabetes mellitus; Adverse effect; Endocrinology; Insulin","score_opus":0.05035296391707674,"score_gpt":0.3298384970012453,"score_spread":0.27948553308416857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130684080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780065,0.00030289261,0.00008938517,0.00015868006,0.000045414083,0.001382947,0.000007657882,0.000021438416,0.00019095748],"genre_scores_gemma":[0.9940253,0.000291255,0.0048527825,0.00032453495,0.000025849293,0.00005344601,0.00011868566,0.0000326691,0.00027550824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987096,0.000059557446,0.00048508658,0.00019158855,0.00024728331,0.0003068637],"domain_scores_gemma":[0.9989197,0.00043246162,0.00019511768,0.00023062127,0.00014139882,0.00008067711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051977613,0.00016345899,0.00054879737,0.000121163604,0.000016279426,0.000005937235,0.000067230474,0.000085617976,0.000012160059],"category_scores_gemma":[0.000049704813,0.00009321,0.000038604354,0.00043983114,0.000108251545,0.00012925886,0.00001776358,0.00012353389,0.000002365397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008600409,0.0034410716,0.94223326,0.000068822505,0.00043825188,0.0000032192652,0.00016117387,0.000008536931,0.000007964693,0.00017880533,0.000016406735,0.04484209],"study_design_scores_gemma":[0.02630255,0.012819824,0.95628285,0.00040873076,0.0005684901,2.274309e-7,0.0001068523,0.0002157972,0.0005654759,0.000039652306,0.0025160054,0.00017354541],"about_ca_topic_score_codex":0.000008205687,"about_ca_topic_score_gemma":0.00003430703,"teacher_disagreement_score":0.044668544,"about_ca_system_score_codex":0.00007991735,"about_ca_system_score_gemma":0.00005308995,"threshold_uncertainty_score":0.38009936},"labels":[],"label_agreement":null},{"id":"W2131411448","doi":"10.1016/j.diabres.2014.02.014","title":"SGLT2 inhibitors in the treatment of type 2 diabetes","year":2014,"lang":"en","type":"review","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Renal glucose reabsorption; Medicine; Type 2 diabetes; Diabetes mellitus; Reabsorption; Glucose homeostasis; Diabetes treatment; Endocrinology; Pharmacology; Insulin; Internal medicine; Kidney; Insulin resistance","score_opus":0.21269835624007336,"score_gpt":0.5345501564562678,"score_spread":0.3218518002161944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131411448","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005052768,0.9816183,7.5311554e-8,0.00091353146,0.00023019048,0.002425584,0.000010719137,0.000017844024,0.00973103],"genre_scores_gemma":[0.00076460507,0.99698013,0.00013768353,0.0002378663,0.0005236477,0.0002819446,0.00015172175,0.00004648934,0.0008758962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942177,0.0022324042,0.0012844686,0.00065341045,0.00084618875,0.0007658318],"domain_scores_gemma":[0.97736824,0.020789031,0.00039188904,0.00088279886,0.00031855862,0.0002495072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060672495,0.00039099055,0.0022989814,0.00039470175,0.00009382512,0.000091403606,0.00029687778,0.0003654862,0.000046196383],"category_scores_gemma":[0.005986714,0.00021113602,0.00049655896,0.0009526245,0.00055102655,0.0001392335,0.00013258371,0.00087670045,0.00017237969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004968328,0.0041140546,0.0042220238,0.00530628,0.0011079435,0.000035116373,0.00005111723,1.5011926e-8,1.1607702e-7,0.0002218008,0.003706697,0.98118514],"study_design_scores_gemma":[0.0010560878,0.011417463,0.00043415822,0.00365175,0.0021319182,0.0000010520396,0.000113440125,0.000008970107,0.0000014824985,0.000112779504,0.98090833,0.00016258885],"about_ca_topic_score_codex":0.000023540988,"about_ca_topic_score_gemma":0.000007380115,"teacher_disagreement_score":0.98102254,"about_ca_system_score_codex":0.00013286548,"about_ca_system_score_gemma":0.00023606993,"threshold_uncertainty_score":0.8609877},"labels":[],"label_agreement":null},{"id":"W2131457893","doi":"10.1074/mcp.m114.040196","title":"Progesterone Receptor Membrane Component 1 Is a Functional Part of the Glucagon-like Peptide-1 (GLP-1) Receptor Complex in Pancreatic β Cells","year":2014,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide 1 receptor; Cell biology; Receptor; Signal transduction; G protein-coupled receptor; Chemistry; Chinese hamster ovary cell; Internal medicine; Endocrinology; Biology; Biochemistry; Agonist; Medicine","score_opus":0.015588650843865293,"score_gpt":0.2086035206510682,"score_spread":0.19301486980720292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131457893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206024,0.00016272589,0.0014472628,0.0016071649,0.00038857874,0.0031963063,0.000025890165,0.000049028262,0.0010627743],"genre_scores_gemma":[0.9840633,0.00005828115,0.009192507,0.0014485223,0.00012721565,0.00045030448,0.0003813472,0.00009044673,0.0041880724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759716,0.00022504739,0.0006119173,0.00051261653,0.0005973926,0.0004558597],"domain_scores_gemma":[0.9986008,0.000036159436,0.00027362493,0.0008434496,0.0001027983,0.00014317679],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044460272,0.00035894365,0.0006014685,0.0001355898,0.00007873786,0.000031008472,0.00024394148,0.00013121315,0.00051277416],"category_scores_gemma":[0.00003309181,0.0002802414,0.00028270934,0.00030586869,0.00016419998,0.000055857436,0.00019491096,0.00023825608,0.0001608577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021349828,0.0007872796,0.0040027695,0.0004330591,0.00028322492,0.0000088035185,0.00018488377,0.00011959264,0.98902106,0.00034708934,0.004014727,0.0005839834],"study_design_scores_gemma":[0.0031032255,0.00039680445,0.0019415608,0.00034338943,0.00028585343,0.0000026572395,0.000049830945,0.0013682051,0.930523,0.00006633201,0.061657343,0.00026182394],"about_ca_topic_score_codex":0.000049855105,"about_ca_topic_score_gemma":0.000005810979,"teacher_disagreement_score":0.058498114,"about_ca_system_score_codex":0.00017710651,"about_ca_system_score_gemma":0.000074397445,"threshold_uncertainty_score":0.99996495},"labels":[],"label_agreement":null},{"id":"W2131463267","doi":"10.1111/j.1464-5491.2004.01317.x","title":"Pre‐prandial vs. post‐prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet‐treated or metformin‐treated Type 2 diabetes: a randomized controlled clinical trial","year":2004,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Memorial University of Newfoundland; McMaster University Medical Centre","funders":"Novo Nordisk","keywords":"Repaglinide; Metformin; Medicine; Post-prandial; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus; Nateglinide; Dosing","score_opus":0.03569179678845695,"score_gpt":0.3263592177129459,"score_spread":0.29066742092448894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131463267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712383,0.001775687,0.000044020093,0.002051892,0.00097390986,0.022699242,0.000017442511,0.00019313832,0.0010063581],"genre_scores_gemma":[0.98949087,0.0010855697,0.000576781,0.0018107125,0.00090511824,0.0034841641,0.001865706,0.000082469014,0.0006986064],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939915,0.0005545176,0.0024466768,0.0009660673,0.001098181,0.0009430842],"domain_scores_gemma":[0.99538064,0.0020625328,0.0007522009,0.0006129823,0.00066073076,0.00053094083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0048921495,0.00076038914,0.004765757,0.00047931424,0.00014278627,0.00004624937,0.00020189067,0.0003623818,0.00040014464],"category_scores_gemma":[0.007876876,0.00039729205,0.0005985577,0.0007464994,0.0003304586,0.00020304434,0.00004796686,0.00032924212,0.000044875578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9685776,0.0025164657,0.021588113,0.00023605295,0.003440146,0.0001579483,0.0005401626,0.000015709276,0.0006122583,0.000040327555,0.0003055212,0.0019696683],"study_design_scores_gemma":[0.93491846,0.045966778,0.008537807,0.00093342434,0.0065761814,0.000004170597,0.00009073112,0.00031389404,0.0015721453,0.00017861776,0.00046482158,0.0004429464],"about_ca_topic_score_codex":0.000443934,"about_ca_topic_score_gemma":0.000905561,"teacher_disagreement_score":0.043450315,"about_ca_system_score_codex":0.0003367488,"about_ca_system_score_gemma":0.0005502763,"threshold_uncertainty_score":0.9998479},"labels":[],"label_agreement":null},{"id":"W2131520853","doi":"10.1161/circheartfailure.112.000162","title":"Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure","year":2013,"lang":"en","type":"review","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metformin; Diabetes mellitus; Internal medicine; Heart failure; Lactic acidosis; Relative risk; Endocrinology; Confidence interval","score_opus":0.018350076960639478,"score_gpt":0.27733455149221115,"score_spread":0.2589844745315717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131520853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.111420035,0.88241,0.00001295066,0.000074267635,0.000038882565,0.005905572,0.000038716487,0.000031613374,0.00006797234],"genre_scores_gemma":[0.43778884,0.55137783,0.0057319277,0.0000894958,0.0001085668,0.0011409222,0.0034683577,0.00019143583,0.00010260435],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983212,0.00024714012,0.00047043434,0.00044882577,0.000259648,0.00025275288],"domain_scores_gemma":[0.99896127,0.00031467486,0.00019574151,0.00027967492,0.00012761973,0.00012099421],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028069137,0.00039987586,0.0022254614,0.0003253514,0.000049758495,0.00002918744,0.000038780472,0.00020188185,0.00003202983],"category_scores_gemma":[0.000021120353,0.00028306394,0.00012383221,0.00034647738,0.00011771899,0.00020203796,0.00005267555,0.00019752725,0.000013326092],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001438476,0.00071075745,0.7085993,0.080482,0.001876545,0.0000029106054,0.0002674728,0.000018254152,0.000012195429,0.0005268061,0.00061967614,0.20674019],"study_design_scores_gemma":[0.0029038615,0.00048339585,0.4340795,0.016781647,0.0013511849,0.0000021974827,0.000036985268,0.000021718233,0.000012675756,0.000027329956,0.54395574,0.00034374252],"about_ca_topic_score_codex":0.000015615431,"about_ca_topic_score_gemma":0.000011395195,"teacher_disagreement_score":0.5433361,"about_ca_system_score_codex":0.00011678833,"about_ca_system_score_gemma":0.000059681937,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W2131735394","doi":"10.1161/jaha.114.001577","title":"Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta‐analysis of Randomized Controlled Trials","year":2015,"lang":"en","type":"review","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Women's College Hospital; University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"","keywords":"Medicine; Glycemic; Internal medicine; Randomized controlled trial; Hypoglycemia; Odds ratio; Diabetes mellitus; Meta-analysis; Type 2 Diabetes Mellitus; Type 2 diabetes; Intensive care; Intensive care medicine; Insulin; Endocrinology","score_opus":0.02269843157098695,"score_gpt":0.3299181985710356,"score_spread":0.30721976700004866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131735394","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019877229,0.9698843,5.748007e-7,0.00033955468,0.00009276544,0.009753178,0.00004377857,0.0000013927026,0.000007252311],"genre_scores_gemma":[0.06250132,0.9370212,0.000012004576,0.00013372372,0.000015490023,0.00023046661,0.000008922607,0.000018452134,0.000058445454],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98450875,0.011360452,0.0030175012,0.00011678436,0.000854378,0.0001421287],"domain_scores_gemma":[0.9721666,0.013092292,0.013094094,0.0003227228,0.0012765669,0.000047728707],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01389564,0.000294272,0.039627902,0.00065427733,0.000012623153,0.0000081349435,0.00013625657,0.00004614864,0.0000047287376],"category_scores_gemma":[0.020967076,0.00009856829,0.004770858,0.001370315,0.00009924969,0.000032804932,0.000035571487,0.00021167452,9.086331e-8],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048684876,0.00040179642,0.008213727,0.11263167,0.82914287,8.531043e-7,0.000072298375,0.000008131947,6.820072e-7,0.0000057919747,0.00019275512,0.00064454426],"study_design_scores_gemma":[0.11255235,0.0016612425,0.00035864685,0.04097306,0.8443082,1.2853951e-7,0.000013658919,0.000004249626,0.000004106388,0.0000027006379,0.000061304534,0.00006032219],"about_ca_topic_score_codex":0.000016548147,"about_ca_topic_score_gemma":0.000026294156,"teacher_disagreement_score":0.07165861,"about_ca_system_score_codex":0.000379333,"about_ca_system_score_gemma":0.00012880891,"threshold_uncertainty_score":0.9872797},"labels":[],"label_agreement":null},{"id":"W2131809420","doi":"10.1186/1471-2261-14-129","title":"The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies","year":2014,"lang":"en","type":"review","venue":"BMC Cardiovascular Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Relative risk; Internal medicine; Meta-analysis; Heart failure; Metformin; Rosiglitazone; Cohort study; Observational study; Type 2 Diabetes Mellitus; Cochrane Library; Diabetes mellitus; Pioglitazone; Type 2 diabetes; Intensive care medicine; Endocrinology; Insulin; Confidence interval","score_opus":0.07962582804466167,"score_gpt":0.2947098799957855,"score_spread":0.21508405195112384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131809420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009728983,0.99477005,0.00007026922,0.00018280919,0.000016145917,0.0047309026,0.00010012838,0.000015319976,0.000017083536],"genre_scores_gemma":[0.00034437,0.9981101,0.0002613792,0.00003948651,0.0000062430304,0.0008666813,0.00018507076,0.000040693885,0.00014596038],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99562234,0.0013467035,0.0013275706,0.00042630604,0.001061417,0.00021568114],"domain_scores_gemma":[0.9938299,0.0022580542,0.0016491683,0.0016939553,0.0005246666,0.00004426086],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004235345,0.0004803457,0.0120884795,0.00022394418,0.00010306791,0.00003951548,0.00025514158,0.00010060795,0.000007672217],"category_scores_gemma":[0.002447388,0.00019967451,0.010031158,0.0014607236,0.00026065775,0.00009381341,0.00014450781,0.00017657563,5.273789e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023322941,0.00006366037,0.00014154149,0.31693876,0.68193674,2.2839146e-7,0.000038811304,0.00011973402,5.2499196e-9,0.000022576374,0.00023023573,0.0005053973],"study_design_scores_gemma":[0.00046983617,0.0000677214,0.00017976717,0.02053647,0.9254536,8.3086206e-7,0.00014055311,0.000010452025,2.1078054e-7,0.0000025708691,0.052984074,0.00015391195],"about_ca_topic_score_codex":0.000060938273,"about_ca_topic_score_gemma":0.00027437552,"teacher_disagreement_score":0.29640228,"about_ca_system_score_codex":0.000042162585,"about_ca_system_score_gemma":0.000102784565,"threshold_uncertainty_score":0.9998831},"labels":[],"label_agreement":null},{"id":"W2132285082","doi":"10.1093/gerona/56.9.m575","title":"Effect of Aging and Diabetes on the Enteroinsular Axis","year":2001,"lang":"en","type":"article","venue":"The Journals of Gerontology Series A","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council Canada; University of British Columbia; Canadian Diabetes Association","keywords":"Diabetes mellitus; Medicine; Internal medicine; Young adult; Body mass index; Endocrinology; Elderly people; Type 2 diabetes; Insulin; Gerontology","score_opus":0.021588013611004576,"score_gpt":0.29022042880248533,"score_spread":0.26863241519148073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132285082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790401,0.004445093,0.0000033691254,0.013927213,0.000064863605,0.00026397695,0.0000011289716,0.000008613335,0.0022456557],"genre_scores_gemma":[0.9973499,0.0015633266,0.000022653032,0.00040857037,0.00003480042,0.000010712951,7.6257106e-7,0.000007485451,0.0006017913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992513,0.00017036828,0.00019902994,0.00008044351,0.00012372925,0.00017514624],"domain_scores_gemma":[0.99916965,0.0003684692,0.00015583512,0.00024362307,0.000030102605,0.00003233564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007099021,0.000106915446,0.0003419781,0.000053785883,0.0000717079,0.0000073425035,0.00009867309,0.000030010371,0.00011533412],"category_scores_gemma":[0.00008892146,0.000047314854,0.000078001,0.000060081155,0.00023355613,0.000051671024,0.00005198231,0.00009692226,0.000002845085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020284082,0.00036407568,0.8706986,0.00048480823,0.0029957201,0.00007430704,0.0018988918,0.000009292367,0.022051802,0.0029351984,0.0035903472,0.0928686],"study_design_scores_gemma":[0.008255089,0.029909277,0.634077,0.0019113836,0.003215723,0.0003332726,0.0021181782,0.00011843945,0.29270935,0.0025902512,0.024404354,0.00035768538],"about_ca_topic_score_codex":0.000011519246,"about_ca_topic_score_gemma":0.0000109521625,"teacher_disagreement_score":0.27065754,"about_ca_system_score_codex":0.000011073001,"about_ca_system_score_gemma":0.0000050978324,"threshold_uncertainty_score":0.19294438},"labels":[],"label_agreement":null},{"id":"W2132295069","doi":"10.1038/nchembio.209","title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","year":2009,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":634,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Agonist; Glucagon; Glucagon receptor; Endocrinology; Internal medicine; Glucagon-like peptide-1; Agonism; Receptor; Chemistry; Glucagon-like peptide 1 receptor; Diet-induced obese; Weight loss; Obesity; Insulin; Pharmacology; Diabetes mellitus; Medicine; Type 2 diabetes; Insulin resistance","score_opus":0.005858100839457447,"score_gpt":0.28445268371410243,"score_spread":0.278594582874645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132295069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98860294,0.0025348184,0.0000046859036,0.0037837964,0.000064748536,0.00020808913,0.0000034738803,0.000039588194,0.004757885],"genre_scores_gemma":[0.9961224,0.0001412927,0.00075353176,0.0021935867,0.00010298165,0.0000035460068,0.00016177792,0.0000047972817,0.0005160598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993077,0.000011586453,0.000118587195,0.0002715279,0.00005846881,0.00023212256],"domain_scores_gemma":[0.99968255,0.000033212593,0.000026794283,0.00012906286,0.000015119657,0.00011326781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054104297,0.00012845507,0.0002545087,0.00006355408,0.00001819515,0.000010475253,0.00006614102,0.0003682652,0.0000438031],"category_scores_gemma":[0.000067037065,0.0000980504,0.000038363698,0.00009531619,0.0000559908,0.0000223101,0.000033563832,0.00031480138,0.000017830933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057005236,0.00086821354,0.2521476,0.00007386209,0.00011960121,0.00010465842,0.0001381648,4.472978e-8,0.5037751,0.005336043,0.016643144,0.2202235],"study_design_scores_gemma":[0.0064906096,0.0010517242,0.39340243,0.00011270794,0.00018018961,0.000023028684,0.000029514387,0.00001807683,0.5235865,0.007916927,0.06684811,0.0003402095],"about_ca_topic_score_codex":0.000018063869,"about_ca_topic_score_gemma":0.000004226433,"teacher_disagreement_score":0.2198833,"about_ca_system_score_codex":0.000058194804,"about_ca_system_score_gemma":0.000020098516,"threshold_uncertainty_score":0.3998379},"labels":[],"label_agreement":null},{"id":"W2132593820","doi":"10.1016/j.molmet.2014.04.009","title":"Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection","year":2014,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novo Nordisk; University of Toronto; Canadian Diabetes Association; Canada Research Chairs; Banting and Best Diabetes Centre, University of Toronto; Alberta Innovates; Heart and Stroke Foundation of Canada","keywords":"Cardioprotection; Liraglutide; Internal medicine; Agonist; Medicine; Glucagon-like peptide-1; Endocrinology; Myocardial infarction; Cardiology; Ventricular remodeling; Heart failure; Chronotropic; Receptor; Type 2 diabetes; Heart rate; Diabetes mellitus; Blood pressure","score_opus":0.006019980463625694,"score_gpt":0.21067871839544067,"score_spread":0.20465873793181497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132593820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96796143,0.0020701198,0.009014022,0.00083227176,0.0026274456,0.0026230444,0.000029233033,0.00022227455,0.014620142],"genre_scores_gemma":[0.99573225,0.00015707815,0.00080560526,0.00055041304,0.00039639173,0.00027921872,0.00013258848,0.00009247602,0.0018539695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965847,0.00042511456,0.00058061857,0.0006586408,0.0012075315,0.00054341025],"domain_scores_gemma":[0.9976929,0.000047508136,0.0003535064,0.0012999829,0.00040424636,0.00020184928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007896044,0.0004692274,0.0009994749,0.0003256696,0.00016601094,0.0000494091,0.0002989094,0.00021055088,0.000048358517],"category_scores_gemma":[0.00031968104,0.0003573488,0.0008017109,0.000783705,0.00012936335,0.00016263616,0.0002381008,0.0003680807,0.0000939249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046198076,0.00042647007,0.0018527316,0.0003826568,0.0043260683,0.000041607076,0.0005647047,0.000850958,0.94022405,0.0036632284,0.0023198286,0.044885702],"study_design_scores_gemma":[0.005025804,0.00022771851,0.046409223,0.00016755413,0.0024579957,0.000020579011,0.00016388914,0.00030481644,0.5625413,0.00026003414,0.38190976,0.0005113215],"about_ca_topic_score_codex":0.00046711514,"about_ca_topic_score_gemma":0.000009733606,"teacher_disagreement_score":0.37958995,"about_ca_system_score_codex":0.00033454603,"about_ca_system_score_gemma":0.00013135979,"threshold_uncertainty_score":0.9998878},"labels":[],"label_agreement":null},{"id":"W2133027387","doi":"10.2174/1871529x14666140505125300","title":"Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States","year":2014,"lang":"en","type":"review","venue":"Cardiovascular & Haematological Disorders - Drug Targets","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Chylomicron; Endocrinology; Postprandial; Very low-density lipoprotein; Dyslipidemia; Insulin resistance; Lipid metabolism; Lipoprotein; Medicine; Biology; Insulin; Cholesterol; Diabetes mellitus","score_opus":0.012133229080845418,"score_gpt":0.2559103813778894,"score_spread":0.243777152297044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133027387","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0092772385,0.98576826,0.00007793571,0.00012339363,0.00021358952,0.0032858115,0.000022545344,0.00009084505,0.0011403939],"genre_scores_gemma":[0.008990218,0.9892342,0.0006602187,0.00007950228,0.00010420258,0.00045116135,0.00025121478,0.000092473645,0.00013679401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958197,0.0005902926,0.001104223,0.0011537632,0.0006261225,0.0007059253],"domain_scores_gemma":[0.9981758,0.00026716193,0.00037283104,0.00079737016,0.00007584186,0.00031100298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011267975,0.00089831353,0.0065814243,0.0004390545,0.000099515484,0.00005520465,0.00021659699,0.000434938,0.00003517228],"category_scores_gemma":[0.00046091253,0.0006428105,0.001955367,0.00039402273,0.00040912253,0.00010756971,0.00042347412,0.00046280652,0.000021364685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012742914,0.00032435392,0.00033054763,0.03026507,0.006497608,0.0002883424,0.0003514097,0.000006138384,3.77396e-7,0.000737864,0.0003760512,0.9606948],"study_design_scores_gemma":[0.0034517995,0.00029497498,0.0006865747,0.0077299126,0.007893804,0.00015278648,0.00016772555,0.00003183257,0.0000054625093,0.0006852258,0.97816133,0.0007385628],"about_ca_topic_score_codex":0.00016380558,"about_ca_topic_score_gemma":0.00002280579,"teacher_disagreement_score":0.9777853,"about_ca_system_score_codex":0.00005048997,"about_ca_system_score_gemma":0.00008422128,"threshold_uncertainty_score":0.9996023},"labels":[],"label_agreement":null},{"id":"W2133057488","doi":"10.1111/j.1742-1241.2008.01917.x","title":"The IMPROVE™ study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts","year":2008,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"Novo Nordisk; American Diabetes Association","keywords":"Medicine; Postprandial; Observational study; Type 2 diabetes; Diabetes mellitus; Regimen; Insulin; Internal medicine; Insulin aspart; Population; Endocrinology; Environmental health","score_opus":0.16503950883518376,"score_gpt":0.4624175452438186,"score_spread":0.29737803640863486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133057488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855954,0.00018481657,0.00004386529,0.009135188,0.0032893824,0.000706915,0.000029373092,0.000010993793,0.0010040583],"genre_scores_gemma":[0.99246067,0.00040013655,0.0019246076,0.0025130077,0.0019642198,0.00002460303,0.000091728354,0.000018689774,0.0006023128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99456334,0.0005331302,0.0021610344,0.00027282548,0.0022953823,0.00017429728],"domain_scores_gemma":[0.9850779,0.008667641,0.0014606102,0.00019625867,0.0044655195,0.00013206832],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051968964,0.00017566091,0.00050476234,0.00018130968,0.00011506196,0.000086057305,0.00040331588,0.0000684433,0.00013492914],"category_scores_gemma":[0.031157026,0.00012168486,0.000176469,0.00021014856,0.0000925538,0.0006956504,0.00013293987,0.00060151017,0.000047819096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023146805,0.014740594,0.9617408,0.0000022477159,0.0022480648,0.001013378,0.00025758476,0.000019057274,0.000015447304,0.00011667479,0.0045396634,0.012991799],"study_design_scores_gemma":[0.0067068404,0.0017278788,0.9280009,0.000042249376,0.0003117623,0.000026212163,0.0004735618,0.0010807887,0.0000046411756,0.00017193594,0.0613505,0.00010271139],"about_ca_topic_score_codex":0.000036152185,"about_ca_topic_score_gemma":0.000027227703,"teacher_disagreement_score":0.056810834,"about_ca_system_score_codex":0.00020547619,"about_ca_system_score_gemma":0.0006216898,"threshold_uncertainty_score":0.97700393},"labels":[],"label_agreement":null},{"id":"W2133508153","doi":"10.3945/jn.111.147132","title":"Prebiotic Fiber Increases Hepatic Acetyl CoA Carboxylase Phosphorylation and Suppresses Glucose-Dependent Insulinotropic Polypeptide Secretion More Effectively When Used with Metformin in Obese Rats,","year":2012,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; AMPK; Gastric inhibitory polypeptide; Glucagon-like peptide-1; Metformin; Adiponectin; Chemistry; Acetyl-CoA carboxylase; Enteroendocrine cell; Secretion; Leptin; Protein kinase A; Gut flora; Prebiotic; Insulin; Type 2 diabetes; Insulin resistance; Glucagon; Diabetes mellitus; Hormone; Pyruvate carboxylase; Biology; Medicine; Kinase; Endocrine system; Obesity; Biochemistry; Enzyme","score_opus":0.009852287544387309,"score_gpt":0.23939953643275072,"score_spread":0.22954724888836342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133508153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934056,0.005248947,0.00008962174,0.00030739864,0.000064032705,0.00080839376,0.0000064943583,0.000016482367,0.000053042775],"genre_scores_gemma":[0.99685526,0.0008533152,0.0018731663,0.00006380038,0.0001742666,0.000034014673,0.000044952776,0.000020706118,0.00008054342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888295,0.000100933554,0.0003130562,0.00012415856,0.00035906406,0.00021984876],"domain_scores_gemma":[0.99920756,0.00013420855,0.0002694047,0.00010822496,0.00011986156,0.00016073544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028443543,0.00017175826,0.00036538346,0.00029504055,0.00003818138,0.00003139814,0.0000385744,0.00007200907,0.000038459893],"category_scores_gemma":[0.00008824845,0.00012785205,0.00005536641,0.00013987342,0.00004208295,0.00054338906,0.000021736363,0.0001585707,0.0000040622144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049139773,0.008018099,0.902039,0.0021057422,0.0008166906,0.00029750477,0.0018706339,0.000055788343,0.064720936,0.00006652065,0.0005506174,0.014544512],"study_design_scores_gemma":[0.021474272,0.005697307,0.7850111,0.0032408328,0.001832036,0.0003018302,0.0008726268,0.0004396323,0.1796591,0.00022001796,0.0009272068,0.00032399734],"about_ca_topic_score_codex":0.00014336116,"about_ca_topic_score_gemma":0.00006810954,"teacher_disagreement_score":0.11702784,"about_ca_system_score_codex":0.0002617288,"about_ca_system_score_gemma":0.000035858055,"threshold_uncertainty_score":0.5213655},"labels":[],"label_agreement":null},{"id":"W2133980496","doi":"10.1177/1479164115570301","title":"Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA <sup>®</sup> )","year":2015,"lang":"en","type":"article","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Eli Lilly and Company","keywords":"Glimepiride; Medicine; Linagliptin; Type 2 diabetes; Internal medicine; Hazard ratio; Diabetes mellitus; Myocardial infarction; Regimen; Metformin; Randomized controlled trial; Confidence interval; Endocrinology","score_opus":0.09392858695292594,"score_gpt":0.333408670727387,"score_spread":0.23948008377446106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133980496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581713,0.011932142,0.000017165792,0.00024866848,0.000113442904,0.0017645352,0.000021907761,0.000013932406,0.00007108587],"genre_scores_gemma":[0.99795693,0.0014198391,0.00024259507,0.000029773511,0.00011149189,0.00010146568,0.000046004323,0.00003195571,0.00005994221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688375,0.00073879235,0.00046669945,0.0003929461,0.00099837,0.0005194652],"domain_scores_gemma":[0.9978453,0.00046096995,0.00007738162,0.00077663566,0.00042983118,0.00040989896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042620506,0.00021489215,0.0007736281,0.00027866053,0.00006333003,0.000030672807,0.00017249945,0.00008678258,0.0000103162565],"category_scores_gemma":[0.0019481747,0.00015160057,0.00030807947,0.0005489933,0.00032569573,0.0000829017,0.00032610854,0.00022999513,0.0000040933396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013274358,0.0017191102,0.9418908,0.002544622,0.0035429506,0.000039128856,0.00047203453,0.0006165398,0.0001971185,0.00024638735,0.0003536813,0.035103288],"study_design_scores_gemma":[0.21446308,0.007566577,0.68579364,0.0014546386,0.006697905,4.3600818e-7,0.0008331157,0.066056915,0.002474508,0.00080280297,0.012926374,0.00092999806],"about_ca_topic_score_codex":0.000028128235,"about_ca_topic_score_gemma":8.01227e-7,"teacher_disagreement_score":0.25609714,"about_ca_system_score_codex":0.00006578987,"about_ca_system_score_gemma":0.00018690906,"threshold_uncertainty_score":0.6182092},"labels":[],"label_agreement":null},{"id":"W2134315188","doi":"10.2337/diacare.25.10.1737","title":"A Diabetes Outcome Progression Trial (ADOPT)","year":2002,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Metformin; Rosiglitazone; Type 2 diabetes; Internal medicine; Diabetes mellitus; Glycemic; Tolerability; Randomized controlled trial; Endocrinology; Insulin; Adverse effect","score_opus":0.02622778580854675,"score_gpt":0.2841993568145309,"score_spread":0.25797157100598417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134315188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97285926,0.0027856114,6.2086957e-7,0.0007112332,0.0005670202,0.0015632204,0.000020454516,0.00031607883,0.021176485],"genre_scores_gemma":[0.9947953,0.000035937992,0.0005364239,0.00096507266,0.00036495138,0.00039864093,0.0001807845,0.000050410123,0.002672479],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819547,0.000037111804,0.00034223424,0.0003998214,0.00041073404,0.00061464467],"domain_scores_gemma":[0.99904746,0.00005709778,0.00009716585,0.0004895348,0.00009419048,0.00021454673],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000090427115,0.00029013594,0.00049724925,0.00016851076,0.00010746152,0.00006217217,0.00013202608,0.000116251744,0.0006882826],"category_scores_gemma":[0.000085153224,0.00022393579,0.00027241278,0.0002465327,0.00006725978,0.00012717982,0.00010061909,0.00014877155,0.0012390236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001899325,0.00043481038,0.8975558,0.0003489791,0.000199027,0.000017717623,0.00033934377,6.821606e-7,0.00022836463,0.00006183065,0.008659409,0.091964066],"study_design_scores_gemma":[0.22840737,0.013889208,0.27476618,0.0015354153,0.0036684303,0.0000010923516,0.0019287758,0.0017915743,0.020639384,0.00019313561,0.45101434,0.0021651061],"about_ca_topic_score_codex":5.736973e-7,"about_ca_topic_score_gemma":7.8932464e-7,"teacher_disagreement_score":0.6227897,"about_ca_system_score_codex":0.000118058604,"about_ca_system_score_gemma":0.000009137972,"threshold_uncertainty_score":0.9995386},"labels":[],"label_agreement":null},{"id":"W2134534032","doi":"10.2337/diabetes.51.9.2677","title":"Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat","year":2002,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Killam Trusts; Michael Smith Health Research BC","keywords":"Internal medicine; Endocrinology; Hyperinsulinemia; Insulin; Peripheral; Type 2 diabetes; Dipeptidyl peptidase; Medicine; Glucagon-like peptide-1; Glucose clamp technique; Diabetes mellitus; Glucagon; Gastric inhibitory polypeptide; Dipeptidyl peptidase-4; Pancreatic hormone; Insulin resistance; Chemistry; Enzyme; Biochemistry","score_opus":0.011097909098055794,"score_gpt":0.22041448521357532,"score_spread":0.20931657611551951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134534032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560153,0.0012987059,0.0000024400617,0.00094081496,0.000056452085,0.0010918884,0.000006626793,0.00005698414,0.00094453106],"genre_scores_gemma":[0.9970599,0.0002337691,0.00013764131,0.00067374785,0.00013010138,0.00021329724,0.000048710237,0.00002898575,0.001473865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869734,0.00008793972,0.0001970951,0.00036589953,0.00022488406,0.00042684493],"domain_scores_gemma":[0.99933195,0.00011866958,0.00006162219,0.00034789965,0.000028872151,0.000110999485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014965713,0.00031465304,0.000396422,0.00009597357,0.00009061654,0.000081871985,0.000046175537,0.000056649566,0.000072154624],"category_scores_gemma":[0.000016351192,0.00017578447,0.000076044125,0.00016382277,0.0001447075,0.00015902024,0.000038478265,0.00010600023,0.000027721158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005706259,0.0012492834,0.9279201,0.00013624215,0.00021466997,0.00027248435,0.0015723509,0.0000013952396,0.0041122963,0.000021270454,0.0002691461,0.06417372],"study_design_scores_gemma":[0.007935117,0.0040519047,0.9760251,0.00035492858,0.0005803967,0.000011459146,0.00037867104,0.0020309957,0.007334136,0.000016928565,0.0008725729,0.00040780622],"about_ca_topic_score_codex":0.000039104263,"about_ca_topic_score_gemma":0.00016563806,"teacher_disagreement_score":0.06376591,"about_ca_system_score_codex":0.00012448989,"about_ca_system_score_gemma":0.000011855451,"threshold_uncertainty_score":0.7168283},"labels":[],"label_agreement":null},{"id":"W2134599810","doi":"10.1016/s0140-6736(10)60746-5","title":"Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Population Health Research Institute; University Health Network; University of Toronto; Hamilton Health Sciences; Western University; Mount Sinai Hospital; McMaster University","funders":"Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Medicine; Rosiglitazone; Metformin; Placebo; Diabetes mellitus; Type 2 diabetes; Internal medicine; Randomized controlled trial; Type 2 Diabetes Mellitus; Relative risk; Endocrinology; Confidence interval; Alternative medicine","score_opus":0.03009392224643396,"score_gpt":0.2984234900865297,"score_spread":0.2683295678400957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134599810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981369,0.0005075321,0.000004809928,0.002267853,0.00022119333,0.014359312,0.0000020339705,0.000058911726,0.0012093137],"genre_scores_gemma":[0.9959049,0.00018036115,0.0001445637,0.000513246,0.0002570337,0.0014647124,0.000018683835,0.00002191219,0.0014945618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989118,0.00008999652,0.00024132324,0.00022757043,0.0002620296,0.00026728952],"domain_scores_gemma":[0.9990245,0.00018751755,0.000105082785,0.0004983408,0.00008697364,0.000097561395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010973476,0.00018994875,0.0008130882,0.00007932845,0.000084684,0.000070881746,0.00012960438,0.000036352623,0.00005683435],"category_scores_gemma":[0.000057445115,0.00009259248,0.000057887988,0.00018933702,0.000045715267,0.00006635451,0.000037476573,0.00013430376,0.000015484395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.969782,0.0038316732,0.0014199968,0.000031915668,0.0014352239,0.0000076089186,0.0010857825,0.000002532519,0.003120434,0.0005965503,0.00068800256,0.01799826],"study_design_scores_gemma":[0.9820094,0.0069837687,0.0029216444,0.000035892663,0.0005961565,6.121251e-7,0.00013457783,0.000049031365,0.00454733,0.00015817418,0.0024335275,0.00012987983],"about_ca_topic_score_codex":0.000021606631,"about_ca_topic_score_gemma":0.00007101617,"teacher_disagreement_score":0.017868381,"about_ca_system_score_codex":0.00002289138,"about_ca_system_score_gemma":0.000033147335,"threshold_uncertainty_score":0.3775812},"labels":[],"label_agreement":null},{"id":"W2134625795","doi":"10.2337/dc13-1545","title":"Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial","year":2013,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Medicine; Hypoglycemia; Hazard ratio; Diabetes mellitus; Randomized controlled trial; Randomization; Subgroup analysis; Internal medicine; Adverse effect; Relative risk; Type 2 diabetes; Pediatrics; Meta-analysis; Confidence interval; Endocrinology","score_opus":0.006345884989035507,"score_gpt":0.2288216636246319,"score_spread":0.2224757786355964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134625795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991392,0.001337583,0.0000032552198,0.00013397627,0.00025419777,0.0067703477,0.000014162951,0.000011697308,0.000082779465],"genre_scores_gemma":[0.99802095,0.00006379553,0.000006650074,0.0005835248,0.000056850477,0.0011587503,0.00008878754,0.000012526808,0.000008172637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988734,0.00016822194,0.00020810071,0.00025398986,0.0002890355,0.00020722757],"domain_scores_gemma":[0.99915165,0.0002603642,0.00004634011,0.0003162405,0.00014218834,0.00008320303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016824425,0.00015713813,0.00046333016,0.000133759,0.000016243208,0.000006977651,0.000065404296,0.00004251584,0.0000072962903],"category_scores_gemma":[0.00047220438,0.00010640616,0.00018811923,0.00017472824,0.000024226008,0.00009558277,0.000029867439,0.0000690522,0.000016168726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06202246,0.0008030294,0.89834154,0.0011815425,0.0022537191,0.000055113327,0.0036831265,0.00037367945,0.000089568755,0.00003902893,0.00028846253,0.030868737],"study_design_scores_gemma":[0.21983974,0.00063422666,0.7763751,0.00037165292,0.0010312087,1.356738e-8,0.0012688609,0.00010043329,0.00021320491,0.000009678727,0.00006410893,0.000091786984],"about_ca_topic_score_codex":0.00013379127,"about_ca_topic_score_gemma":0.000023592067,"teacher_disagreement_score":0.15781727,"about_ca_system_score_codex":0.000070660884,"about_ca_system_score_gemma":0.000015448251,"threshold_uncertainty_score":0.43391174},"labels":[],"label_agreement":null},{"id":"W2134636215","doi":"10.1053/j.gastro.2008.01.017","title":"An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis","year":2008,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Conjugate; Peripheral; Energy homeostasis; Glucose homeostasis; Homeostasis; Albumin; Endocrinology; Internal medicine; Chemistry; Medicine; Insulin; Receptor; Insulin resistance; Mathematics","score_opus":0.013116707607245082,"score_gpt":0.22897554840808576,"score_spread":0.21585884080084067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134636215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977142,0.00075597415,0.00023995829,0.0006136205,0.00011359358,0.00016724426,0.0000095853675,0.00007214573,0.00031368126],"genre_scores_gemma":[0.996623,0.0010668228,0.0005193069,0.0011688939,0.00013695269,0.000022783313,0.000088080844,0.000024697598,0.00034947303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986562,0.0000919085,0.0002095261,0.00037986186,0.000108489454,0.0005540216],"domain_scores_gemma":[0.99940133,0.000020499105,0.00006906514,0.00021621746,0.000025329786,0.00026754566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008097523,0.00020970733,0.00036350903,0.00010522292,0.00014628319,0.00001714658,0.000052249543,0.000056383284,0.00006895835],"category_scores_gemma":[0.000012336524,0.0001909327,0.000044093853,0.00003912351,0.00023065826,0.00011862326,0.00007537037,0.00008810856,9.0777576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045921837,0.00037995548,0.94234955,0.00006334109,0.00035692664,0.000427288,0.00078631885,0.000014394531,0.004503165,0.00030953583,0.00074718887,0.04960312],"study_design_scores_gemma":[0.0069380607,0.004270361,0.98157704,0.000036718615,0.00023846235,0.0007370047,0.00020029704,0.0006865766,0.001954268,0.000051359668,0.0031561316,0.00015374774],"about_ca_topic_score_codex":0.0000475919,"about_ca_topic_score_gemma":0.00006587304,"teacher_disagreement_score":0.049449373,"about_ca_system_score_codex":0.000039913397,"about_ca_system_score_gemma":0.000009623692,"threshold_uncertainty_score":0.778601},"labels":[],"label_agreement":null},{"id":"W2134860331","doi":"10.1371/journal.pone.0127221","title":"Acute Glucagon Induces Postprandial Peripheral Insulin Resistance","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Glucagon; Postprandial; Internal medicine; Endocrinology; Insulin; Insulin resistance; Glutathione; Glucose clamp technique; Pancreatic hormone; Medicine; Chemistry; Biochemistry","score_opus":0.05558824236917081,"score_gpt":0.25697550001264025,"score_spread":0.20138725764346943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134860331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527682,0.0007690409,0.0000037612876,0.002657284,0.000072365525,0.00039018417,0.000007805025,0.000101504294,0.043229822],"genre_scores_gemma":[0.9775293,0.0001335132,0.003242302,0.0006565196,0.00026301492,0.000048843496,0.00006832865,0.00002003583,0.018038169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909186,0.000018865527,0.00013448637,0.00018612207,0.00035940192,0.00020923876],"domain_scores_gemma":[0.9994708,0.000010759976,0.00004185729,0.00022236159,0.00008334284,0.00017092646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089180394,0.00011692621,0.0002505762,0.000058040903,0.000032530363,0.000025745225,0.00006596858,0.000048404512,0.00009039366],"category_scores_gemma":[0.000046323457,0.00009834352,0.000040112238,0.00011966758,0.00003311326,0.00009958115,0.000040342424,0.0000842536,0.00018323808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06486881,0.09108347,0.16878635,0.0031118006,0.04967501,0.0039226036,0.024919746,0.0000065755116,0.39082626,0.012135127,0.13689005,0.0537742],"study_design_scores_gemma":[0.10448406,0.026633425,0.1440805,0.004135862,0.021088582,0.000015484853,0.0023751995,0.00033352157,0.5532442,0.004812217,0.13584116,0.002955816],"about_ca_topic_score_codex":0.00000922341,"about_ca_topic_score_gemma":0.000017692504,"teacher_disagreement_score":0.1624179,"about_ca_system_score_codex":0.00010633204,"about_ca_system_score_gemma":0.00005207765,"threshold_uncertainty_score":0.40103322},"labels":[],"label_agreement":null},{"id":"W2134932941","doi":"10.1016/j.jdiacomp.2014.12.016","title":"Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus","year":2014,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Janssen Research and Development; Mitsubishi Tanabe Pharma Corporation","keywords":"Medicine; Canagliflozin; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Duration (music); Baseline (sea); Type 2 diabetes; Endocrinology","score_opus":0.011472528357587037,"score_gpt":0.24769147290887827,"score_spread":0.23621894455129125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134932941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98631567,0.010695418,0.000083546125,0.0021259522,0.00003770126,0.00023041009,0.000022351256,0.000005258015,0.0004837046],"genre_scores_gemma":[0.9967786,0.0021879026,0.00072376523,0.00013757475,0.000041210624,0.0000030202232,0.000031807893,0.000008707718,0.00008738394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991451,0.000041649997,0.00045787464,0.00010998079,0.00012641438,0.00011899931],"domain_scores_gemma":[0.9989133,0.00023804812,0.00033197697,0.00012567303,0.0002660373,0.00012495562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003077233,0.000101915255,0.00035220198,0.000118537595,0.000052627136,0.000012353388,0.000046017063,0.00003478185,0.000014402215],"category_scores_gemma":[0.000162762,0.000078818855,0.00003545904,0.0001256815,0.00007098553,0.00009243835,0.000032852568,0.00006374808,6.580797e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027626814,0.0022717707,0.34344608,0.0019699642,0.002317593,8.813927e-7,0.0007274421,0.000048091944,0.25884697,0.016601125,0.015290684,0.35820317],"study_design_scores_gemma":[0.0060792454,0.00307656,0.91944057,0.00079671026,0.001557403,0.0000033242459,0.00010804889,0.007963665,0.017823655,0.0006761675,0.042226378,0.0002482537],"about_ca_topic_score_codex":0.0000036089193,"about_ca_topic_score_gemma":0.0000025203467,"teacher_disagreement_score":0.5759945,"about_ca_system_score_codex":0.000012268421,"about_ca_system_score_gemma":0.000019143397,"threshold_uncertainty_score":0.32141396},"labels":[],"label_agreement":null},{"id":"W2135064706","doi":"10.2337/dc12-2462","title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine","year":2013,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Lixisenatide; Medicine; Insulin glargine; Postprandial; Type 2 diabetes; Internal medicine; Glycated hemoglobin; Placebo; Glycemic; Endocrinology; Diabetes mellitus; Hypoglycemia; Insulin; Gastroenterology; Liraglutide","score_opus":0.01919884745114034,"score_gpt":0.25095478587355485,"score_spread":0.23175593842241451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135064706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98937154,0.0028049175,0.000011316464,0.0007419224,0.0001502171,0.003520045,0.00007337874,0.00023754788,0.0030891027],"genre_scores_gemma":[0.9932712,0.00007766682,0.0021772755,0.0016438134,0.0001315298,0.00090979267,0.0010267968,0.000089484594,0.0006724645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808383,0.000055478617,0.00039911148,0.00048332792,0.00026410894,0.00071413105],"domain_scores_gemma":[0.99822557,0.0003251257,0.00017598973,0.00029451097,0.00070857746,0.00027020797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013126252,0.00042409822,0.00094775925,0.00022905829,0.00013270731,0.00016081713,0.00011206499,0.00013822412,0.00013712376],"category_scores_gemma":[0.00024114682,0.0003134414,0.00011722214,0.00036093628,0.00011672498,0.00028244636,0.000059971608,0.00015911688,0.000115095136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016210098,0.00051959965,0.9042357,0.0014188093,0.0035048646,0.000043889846,0.0013842569,0.000033989025,0.011467961,0.0004312486,0.01583373,0.059504937],"study_design_scores_gemma":[0.2738771,0.027110262,0.5419245,0.0043801526,0.007997521,0.0000027600388,0.011278342,0.02421694,0.057831373,0.0008687909,0.04656599,0.003946275],"about_ca_topic_score_codex":0.000029239147,"about_ca_topic_score_gemma":0.00003316607,"teacher_disagreement_score":0.36231124,"about_ca_system_score_codex":0.00009609108,"about_ca_system_score_gemma":0.00009147892,"threshold_uncertainty_score":0.99993175},"labels":[],"label_agreement":null},{"id":"W2135285778","doi":"10.1016/j.jcjd.2013.08.128","title":"Efficacy and Safety of Dulaglutide Versus Sitagliptin after 52 Weeks in Type 2 Diabetes (AWARD-5)","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Dulaglutide; Placebo; Metformin; Internal medicine; Nausea; Type 2 diabetes; Gastroenterology; Adverse effect; Hypoglycemia; Diabetes mellitus; Sitagliptin Phosphate; Endocrinology; Exenatide","score_opus":0.009170530534435254,"score_gpt":0.21503862251181569,"score_spread":0.20586809197738043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135285778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916132,0.0049944576,2.6714477e-7,0.0011667359,0.00038947497,0.00032042,0.000008596651,0.0000047317567,0.0015021027],"genre_scores_gemma":[0.9990382,0.00006525572,0.0003097359,0.00021222103,0.000096149706,0.00000860488,0.0000069969274,0.000023178936,0.00023966194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870104,0.000042291267,0.0004629853,0.00014746767,0.00016429006,0.00048193822],"domain_scores_gemma":[0.99871,0.0001613173,0.00016642314,0.00018762468,0.00018003875,0.0005946219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022801089,0.00018062809,0.0004972306,0.0005008834,0.00003167565,0.000032270556,0.00010824775,0.0000784081,0.00048599104],"category_scores_gemma":[0.00024066596,0.00015224151,0.00009330301,0.0002494427,0.00013590627,0.00019370079,0.000023542994,0.00017539703,0.00003423086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009048091,0.000081567356,0.9749155,0.00012674817,0.00043426055,0.000037464786,0.00026334857,0.000010137397,0.00070165435,0.00006909123,0.0024763173,0.020793403],"study_design_scores_gemma":[0.0054492964,0.0012440038,0.9856984,0.00044417937,0.00028258737,6.742248e-7,0.0001605811,0.00003818972,0.001028433,0.00010017715,0.0053932695,0.0001602189],"about_ca_topic_score_codex":0.00034338585,"about_ca_topic_score_gemma":0.0016566918,"teacher_disagreement_score":0.020633183,"about_ca_system_score_codex":0.00015401647,"about_ca_system_score_gemma":0.0002498579,"threshold_uncertainty_score":0.62082285},"labels":[],"label_agreement":null},{"id":"W2135424734","doi":"10.1016/j.orcp.2014.10.211","title":"Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial","year":2014,"lang":"en","type":"article","venue":"Obesity Research & Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Overweight; Obesity; Prediabetes; Gerontology; Family medicine; Diabetes mellitus; University hospital; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.05571496663354958,"score_gpt":0.38905799109910977,"score_spread":0.3333430244655602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135424734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97642547,0.001706811,0.000013089062,0.0019280777,0.0004035925,0.012578338,0.000021298822,0.00010030161,0.006823034],"genre_scores_gemma":[0.9869363,0.007126769,0.00045664032,0.00027533533,0.0012533953,0.0010283039,0.00003749892,0.000070259826,0.0028155018],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877879,0.006068074,0.0015823712,0.0014288033,0.0017124113,0.0014204666],"domain_scores_gemma":[0.9634491,0.033132482,0.0006593844,0.001280296,0.00055924075,0.0009194838],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.026133928,0.0006224862,0.002457396,0.0004980683,0.00070756604,0.00046229272,0.000490955,0.00045548828,0.00007262066],"category_scores_gemma":[0.037880953,0.000356762,0.0005642797,0.0007980608,0.0011049906,0.0010097724,0.0007950728,0.0023656522,0.00006428682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61668706,0.0045005865,0.36868843,0.0002067889,0.0017183891,0.000024857469,0.00031590427,6.30934e-7,0.000039873383,0.00006458163,0.0009900058,0.006762892],"study_design_scores_gemma":[0.80520403,0.0070305974,0.16452795,0.0002535369,0.0031972034,0.0000027913707,0.00071810995,0.0028892972,0.00017748066,0.00024015104,0.015311128,0.000447707],"about_ca_topic_score_codex":0.0009149992,"about_ca_topic_score_gemma":0.0003274145,"teacher_disagreement_score":0.2041605,"about_ca_system_score_codex":0.00013888367,"about_ca_system_score_gemma":0.00030946947,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W2135449636","doi":"10.1016/j.tem.2009.02.005","title":"Mining incretin hormone pathways for novel therapies","year":2009,"lang":"en","type":"review","venue":"Trends in Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Incretin; Glucagon-like peptide-1; Hormone; Diabetes mellitus; Enteroendocrine cell; Internal medicine; Endocrinology; Medicine; Gastric inhibitory polypeptide; Endocrine system; Type 2 diabetes; Bioinformatics; Glucagon; Biology","score_opus":0.07297417502411421,"score_gpt":0.3397906251032665,"score_spread":0.26681645007915233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135449636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030875308,0.99225897,0.000016260386,0.00020375261,0.0003055818,0.0006668358,0.000047616028,0.0000812587,0.0061109634],"genre_scores_gemma":[0.00013473899,0.9907869,0.0038648122,0.00020980723,0.00034349677,0.00051113265,0.00041775985,0.00004672119,0.0036845966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815613,0.00005836813,0.0005193541,0.00054152345,0.00009982752,0.000624809],"domain_scores_gemma":[0.9992009,0.00015856735,0.00019332727,0.00033716715,0.000022599193,0.00008747541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015471019,0.00050433155,0.0023402781,0.000951941,0.00006210957,0.000016082797,0.0001323289,0.0002591743,0.00003325801],"category_scores_gemma":[0.000035064626,0.00037364362,0.00036116276,0.00028472274,0.00011260204,0.000049642305,0.00008328044,0.00027483108,0.000006419074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038625036,0.0001983411,0.00000794366,0.0008509194,0.0005007866,0.000032538515,0.00014256821,2.7592638e-8,0.0000047434446,0.014215621,0.0009909872,0.9830169],"study_design_scores_gemma":[0.0033424424,0.00024736449,0.000976993,0.00085373374,0.003117759,0.00006927006,0.00004585059,0.0000014338976,0.000002808779,0.00019683572,0.9908597,0.0002858378],"about_ca_topic_score_codex":0.000007297491,"about_ca_topic_score_gemma":0.000006912644,"teacher_disagreement_score":0.9898687,"about_ca_system_score_codex":0.000036043,"about_ca_system_score_gemma":0.000041567266,"threshold_uncertainty_score":0.99987155},"labels":[],"label_agreement":null},{"id":"W2135617148","doi":"10.2337/diabetes.49.4.611","title":"Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.","year":2000,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Internal medicine; Endocrinology; Insulin; Glucagon; Basal (medicine); Saline; Somatostatin; Glucagon-like peptide-1; Type 2 diabetes; Pancreatic hormone; Diabetes mellitus; Chemistry; Medicine; Insulin resistance","score_opus":0.005573316896254305,"score_gpt":0.2396207901027833,"score_spread":0.234047473206529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135617148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956281,0.0014386642,3.4229132e-7,0.000039370367,0.00009038449,0.0009966056,0.0000045522797,0.00006389212,0.0017380702],"genre_scores_gemma":[0.9988482,0.000495588,0.000034733454,0.00012566829,0.000035104742,0.00014083624,0.000058101625,0.000037063284,0.00022472325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870574,0.00016057766,0.00019502582,0.00035512302,0.00022056425,0.00036298885],"domain_scores_gemma":[0.999074,0.00044434328,0.00006453784,0.0002836727,0.000035696343,0.00009778132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038444257,0.00026863147,0.0005848656,0.00021417288,0.000037403974,0.00001731482,0.000060421327,0.00007806226,0.000082807135],"category_scores_gemma":[0.000054061118,0.00019570919,0.000059561284,0.00043114752,0.00007544121,0.00012062831,0.000025778802,0.00013387352,0.000045718934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014882433,0.00046250827,0.6509524,0.001119551,0.00028162744,0.000010701721,0.00011239658,0.00008427564,0.009983437,0.000013979769,0.000078269295,0.33541262],"study_design_scores_gemma":[0.0048352946,0.0067874226,0.71092755,0.00073360174,0.0002834038,3.4506095e-7,0.000014758792,0.00023806434,0.27516907,0.000016043909,0.00081374956,0.0001806776],"about_ca_topic_score_codex":0.000055367338,"about_ca_topic_score_gemma":0.000029061861,"teacher_disagreement_score":0.33523193,"about_ca_system_score_codex":0.00010041649,"about_ca_system_score_gemma":0.000020736743,"threshold_uncertainty_score":0.79807895},"labels":[],"label_agreement":null},{"id":"W2135873200","doi":"10.1016/s1499-2671(11)53004-7","title":"Diabetes Clinical Practice: Same Evidence-Based Medicine, Two Different Guidelines","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Family medicine; Scopus; MEDLINE; Clinical Practice; Statement (logic); Evidence-based medicine; Alternative medicine; Gerontology; Endocrinology; Pathology; Law","score_opus":0.1664022325240789,"score_gpt":0.38070080495831643,"score_spread":0.21429857243423753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135873200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95639926,0.014777952,0.000029957275,0.021272754,0.0018754997,0.00043008037,0.000008394579,0.00003090611,0.0051752054],"genre_scores_gemma":[0.9775679,0.00021010001,0.0055798125,0.014646581,0.0014289984,0.000015588508,0.000011800061,0.00005065117,0.0004885452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967158,0.00022212374,0.0014916114,0.00030286278,0.0005257763,0.00074181653],"domain_scores_gemma":[0.9948179,0.0009384939,0.00075368054,0.00048193213,0.0012641819,0.0017437971],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018713286,0.00035458655,0.0010013293,0.00065317354,0.00011235175,0.000045028468,0.00036731156,0.00012305168,0.0009982509],"category_scores_gemma":[0.0073351124,0.00024236349,0.0004013937,0.00029108592,0.00040707522,0.00048228865,0.000025500618,0.00040125096,0.00004625593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029517178,0.00019077036,0.9066107,0.00009859149,0.00081161637,0.0001362379,0.00016685433,0.000002840643,0.00011111933,0.00031896017,0.053042814,0.038479943],"study_design_scores_gemma":[0.0077592237,0.007654007,0.8766477,0.0062928614,0.0048194565,0.000008806363,0.0006229596,0.00034661923,0.0021122359,0.0011057226,0.09201963,0.0006107364],"about_ca_topic_score_codex":0.0006509647,"about_ca_topic_score_gemma":0.0012742478,"teacher_disagreement_score":0.03897682,"about_ca_system_score_codex":0.00022051844,"about_ca_system_score_gemma":0.0010206132,"threshold_uncertainty_score":0.99991494},"labels":[],"label_agreement":null},{"id":"W2135967557","doi":"10.1152/ajpregu.2000.278.4.r1057","title":"Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease","year":2000,"lang":"en","type":"article","venue":"American Journal of Physiology-Regulatory, Integrative and Comparative Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital","funders":"","keywords":"Inflammatory bowel disease; Glucagon-like peptide-2; Medicine; Internal medicine; Glucagon-like peptide-1; Peptide; Glucagon; Disease; Endocrinology; Chemistry; Diabetes mellitus; Biochemistry; Hormone; Type 2 diabetes","score_opus":0.019582167813053598,"score_gpt":0.2802859445098354,"score_spread":0.2607037766967818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135967557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983859,0.0003601614,0.000015353096,0.00008511645,0.00004472158,0.00035205897,0.000011643724,0.000012980588,0.0007320427],"genre_scores_gemma":[0.99895674,0.000052177995,0.00035780837,0.00026583084,0.00009919347,0.00002532179,0.000017754,0.000019466634,0.00020568208],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997918,0.00037313363,0.00070930185,0.0004044967,0.0002197678,0.00037530027],"domain_scores_gemma":[0.99824834,0.00016738048,0.00078185875,0.0003033201,0.00027983246,0.0002192709],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017118249,0.00040745368,0.0014169008,0.0003013141,0.00009126388,0.000007999971,0.000171962,0.00005084655,0.00020411951],"category_scores_gemma":[0.000013215381,0.0002701398,0.00020615474,0.00029777753,0.001764575,0.00019648706,0.000043689022,0.00036220832,0.0000051613706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005934702,0.0014202348,0.075287916,0.00019783713,0.002133951,0.000099320394,0.0057678204,0.0019237504,0.89767295,0.0033524008,0.00035188044,0.0058572157],"study_design_scores_gemma":[0.0025869198,0.0049839206,0.97934484,0.0004715752,0.00022440824,0.000019867897,0.0036241447,0.00018975626,0.0071022282,0.0010497344,0.00014767807,0.00025489836],"about_ca_topic_score_codex":0.00004497973,"about_ca_topic_score_gemma":0.000030179053,"teacher_disagreement_score":0.90405697,"about_ca_system_score_codex":0.00009592728,"about_ca_system_score_gemma":0.00017428603,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W2136073859","doi":"10.1161/01.cir.0000148680.83392.50","title":"Lessons Learned From a Clinical Trial","year":2004,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Medical Association; University of Alberta","funders":"","keywords":"Medicine; Library science; Family medicine","score_opus":0.3830419703072252,"score_gpt":0.4804681453224523,"score_spread":0.0974261750152271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136073859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001251597,0.9938752,0.000117389325,0.00018687657,0.0008005329,0.0020514089,0.000014436825,0.000095406234,0.0027335912],"genre_scores_gemma":[0.00038147662,0.9953455,0.00018822729,0.00004459713,0.0010052713,0.00012331543,0.0023913456,0.000039808743,0.0004804653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850947,0.00010028555,0.0006195941,0.00042360928,0.00019861973,0.00014840878],"domain_scores_gemma":[0.9990446,0.00012558968,0.00028156696,0.0004331608,0.000024251578,0.00009082308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023447238,0.0002192557,0.0012725671,0.00010876883,0.000033158176,0.000028385844,0.000065679116,0.00031601582,0.00017539598],"category_scores_gemma":[0.0001244399,0.00017413491,0.00075862155,0.00014110451,0.000027296112,0.000038183454,0.000032430784,0.00021404524,0.00069280475],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019130943,0.00025449583,0.000040152358,0.0018269233,0.00056668307,0.00001719655,0.0000075587436,6.683374e-7,2.0872346e-8,0.0004314295,0.00016518835,0.99649835],"study_design_scores_gemma":[0.019830564,0.00012192878,0.00050319784,0.008048853,0.006281281,8.372161e-7,0.0000018720312,0.000005757064,2.4018094e-8,0.0007961202,0.9642631,0.00014646757],"about_ca_topic_score_codex":0.000017093467,"about_ca_topic_score_gemma":0.0000015726009,"teacher_disagreement_score":0.9963519,"about_ca_system_score_codex":0.00023418159,"about_ca_system_score_gemma":0.00026176518,"threshold_uncertainty_score":0.89048344},"labels":[],"label_agreement":null},{"id":"W2137204969","doi":"10.1016/j.jval.2014.03.1472","title":"Methodological challenges in calculation of daily average consumption (DACON) for GLP-1 receptor agonist injectables from claims data","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Dosing; Internal medicine; Diabetes mellitus; Pediatrics; Animal science; Urology; Endocrinology","score_opus":0.40653566832348687,"score_gpt":0.41289773706279104,"score_spread":0.006362068739304172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137204969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821524,0.0043704314,0.0055337953,0.005446102,0.00030670833,0.0016628354,0.00012445047,0.000044159075,0.00035913568],"genre_scores_gemma":[0.9439014,0.0045981263,0.04951855,0.0003019074,0.00012157209,0.000067909255,0.0014123073,0.000016132597,0.00006207216],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99830437,0.00048569945,0.0004657568,0.00036808883,0.00014642836,0.0002296408],"domain_scores_gemma":[0.99837935,0.0009291449,0.00016915836,0.00043138777,0.000022969032,0.00006797749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023663284,0.000111542315,0.0004588845,0.00013665883,0.000027887932,0.000006838248,0.0001087568,0.000087408094,0.000036544607],"category_scores_gemma":[0.00040401047,0.00009486125,0.000033164826,0.00008106564,0.000037142476,0.00008460807,0.00006829348,0.000089457346,0.00000870121],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015110425,0.0017964033,0.24541743,0.0047555096,0.00021547837,0.000006024419,0.0028598765,0.0023943696,0.0016199023,0.025944851,0.0028322507,0.71064687],"study_design_scores_gemma":[0.015040543,0.0033085528,0.76276284,0.0022596994,0.00015935871,0.0000015611263,0.0005029308,0.14004406,0.0010973605,0.013941904,0.06042893,0.00045223272],"about_ca_topic_score_codex":0.001690645,"about_ca_topic_score_gemma":0.00031895997,"teacher_disagreement_score":0.71019465,"about_ca_system_score_codex":0.00014387467,"about_ca_system_score_gemma":0.00005600754,"threshold_uncertainty_score":0.38683295},"labels":[],"label_agreement":null},{"id":"W2137289428","doi":"10.2337/dc13-0027","title":"Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes","year":2013,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"","keywords":"Medicine; Overweight; Diabetes mellitus; Type 2 diabetes; Internal medicine; Obesity; Endocrinology","score_opus":0.005196492538671451,"score_gpt":0.1940949933928509,"score_spread":0.18889850085417947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137289428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349135,0.0034949642,2.2581514e-7,0.00018556628,0.000043349748,0.0011157027,0.000013505578,0.0000453123,0.0016100431],"genre_scores_gemma":[0.9980248,0.00023886755,0.00030556612,0.00009598178,0.000022347496,0.00020830423,0.0001110843,0.000035523655,0.00095752993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867785,0.000042414355,0.00018606968,0.0003271736,0.0003685681,0.00039794808],"domain_scores_gemma":[0.9990982,0.000094575626,0.00010484022,0.00041586556,0.00018678117,0.00009976804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007305785,0.000267745,0.00074390345,0.00017469117,0.00003108048,0.000026570842,0.000047951282,0.000081494574,0.000029490779],"category_scores_gemma":[0.00002977652,0.00016825648,0.000114444425,0.00026191788,0.000047926027,0.00014389625,0.00003006618,0.00006737195,0.000028534416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030489473,0.00018110084,0.99052453,0.00022569599,0.002504398,0.000009198841,0.000576919,0.000014108395,0.00040282035,0.000010319717,0.0001246676,0.005395742],"study_design_scores_gemma":[0.00532709,0.002868395,0.98035425,0.00027534922,0.0014448594,2.6965938e-7,0.0007332848,0.000032617878,0.007190273,0.000018160235,0.0015310228,0.0002244174],"about_ca_topic_score_codex":0.00009381986,"about_ca_topic_score_gemma":0.00008768951,"teacher_disagreement_score":0.010170279,"about_ca_system_score_codex":0.00037108635,"about_ca_system_score_gemma":0.00004283257,"threshold_uncertainty_score":0.68613},"labels":[],"label_agreement":null},{"id":"W2137357413","doi":"10.3389/fnene.2013.00002","title":"Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain","year":2013,"lang":"en","type":"article","venue":"Frontiers in Neuroenergetics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Ministeriet for Fø devarer, Landbrug og Fiskeri; Sundhed og Sygdom, Det Frie Forskningsråd; Statens Naturvidenskabelige Forskningsrad; Diabetesforeningen; Aarhus Universitetshospital; Medical Research Council; Novo Nordisk; Aarhus Universitet; H. Lundbeck A/S; Lundbeckfonden; National Science Foundation","keywords":"Endocrinology; Internal medicine; Hypoglycemia; Glucose uptake; Glucose transporter; Glucagon; Carbohydrate metabolism; Hexokinase; Insulin; Chemistry; Metabolism; Medicine; Glycolysis","score_opus":0.012133629868002944,"score_gpt":0.223587346924074,"score_spread":0.21145371705607105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137357413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209964,0.00039940662,0.0002934869,0.0043075434,0.0005094461,0.0009828499,0.00001021788,0.00007818405,0.0013192357],"genre_scores_gemma":[0.9926153,0.00036497813,0.0016005602,0.002182813,0.00006829207,0.00014407025,0.000028261129,0.000058925503,0.0029368415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997965,0.00016621892,0.00037189413,0.000584331,0.00029213435,0.0006204364],"domain_scores_gemma":[0.9991327,0.0000878618,0.00004950785,0.00044485516,0.000037970793,0.00024712205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018964961,0.00037299492,0.0005865543,0.00043945282,0.000079852194,0.000059606373,0.00014598526,0.00011605588,0.000047848873],"category_scores_gemma":[0.00010460664,0.00035927736,0.000108002474,0.0003540981,0.00022210182,0.00025307364,0.00008527316,0.0003404434,0.0000057470406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034106078,0.005064078,0.64684284,0.00087789574,0.00045959672,0.001166909,0.0015470523,0.00019974977,0.14265648,0.0011089435,0.16943334,0.030302035],"study_design_scores_gemma":[0.02048665,0.0025933255,0.8298947,0.00043570073,0.00063052145,0.000030976742,0.0005509246,0.00339393,0.078794874,0.002405241,0.059444137,0.0013390162],"about_ca_topic_score_codex":0.000347399,"about_ca_topic_score_gemma":0.0002118095,"teacher_disagreement_score":0.18305185,"about_ca_system_score_codex":0.00009800389,"about_ca_system_score_gemma":0.000030351268,"threshold_uncertainty_score":0.9998859},"labels":[],"label_agreement":null},{"id":"W2137746085","doi":"10.1503/cmaj.110178","title":"Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin","year":2011,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); AstraZeneca (Canada); Nordion (Canada); University of Alberta","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Metformin; Medicine; Type 2 diabetes; Glycemic; Diabetes mellitus; Type 2 Diabetes Mellitus; Intensive care medicine; Cost effectiveness; Internal medicine; Endocrinology; Risk analysis (engineering)","score_opus":0.033067364638749014,"score_gpt":0.28949367682156796,"score_spread":0.25642631218281897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137746085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05494504,0.93836325,0.0000011542454,0.000084777705,0.00071969593,0.0037241012,0.000066541565,0.000014072036,0.0020813888],"genre_scores_gemma":[0.010688269,0.98782194,0.000020020187,0.0005234389,0.00020275844,0.00012768566,0.00028112074,0.00005873034,0.00027605056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968076,0.000547426,0.00087363285,0.0002595116,0.0009392801,0.00057254743],"domain_scores_gemma":[0.99717903,0.00057669455,0.0007828459,0.00018924307,0.00045999678,0.0008121617],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020715992,0.0003830045,0.002585048,0.0007810134,0.000056663746,0.000025892075,0.00020399744,0.00055752974,0.0014829411],"category_scores_gemma":[0.0006521898,0.00024139232,0.00032335095,0.0004978052,0.00004370013,0.00008102016,0.000012866647,0.00094609975,0.00005724935],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000710144,0.00041720807,0.013436004,0.0012503072,0.002353365,0.00010934392,0.00003248913,2.6014882e-7,4.0655912e-8,0.00006201511,0.0006221129,0.9810067],"study_design_scores_gemma":[0.0245867,0.004050584,0.010585821,0.013913566,0.0010687017,0.000006724681,0.000012696589,0.000003391745,0.0000029464313,0.00002555857,0.94542503,0.00031828482],"about_ca_topic_score_codex":0.00019840145,"about_ca_topic_score_gemma":0.0013433796,"teacher_disagreement_score":0.98068845,"about_ca_system_score_codex":0.0018622004,"about_ca_system_score_gemma":0.0027592015,"threshold_uncertainty_score":0.9994298},"labels":[],"label_agreement":null},{"id":"W2137853043","doi":"10.1016/j.orcp.2014.10.210","title":"Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: The SCALE Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial","year":2014,"lang":"en","type":"article","venue":"Obesity Research & Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Overweight; Liraglutide; Obesity; Gerontology; Family medicine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.05155899500550123,"score_gpt":0.4032814934516828,"score_spread":0.3517224984461816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137853043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96198386,0.0020680074,0.000057511523,0.004994752,0.00010388956,0.01963593,0.000010672742,0.000024237817,0.011121118],"genre_scores_gemma":[0.9778995,0.015656058,0.0028704936,0.00032514517,0.0003820522,0.0011049432,0.000024284356,0.000036769816,0.0017007473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951372,0.0016052176,0.0010748549,0.00083630206,0.00073985563,0.00060654327],"domain_scores_gemma":[0.97617453,0.02223184,0.0003263025,0.00058046996,0.00027842697,0.00040843413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017988874,0.00029005343,0.0011851856,0.00021942495,0.00032599908,0.00013400902,0.00018199018,0.00021056925,0.000019140802],"category_scores_gemma":[0.0076444387,0.00019195637,0.00013938206,0.00025016267,0.00078090746,0.00037766638,0.0005978824,0.0007050448,0.0000074348472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94033754,0.0033548092,0.018893564,0.0006134791,0.00085151574,0.000019519895,0.00021693244,3.6423074e-7,0.000006278912,0.0011810681,0.0011276177,0.033397302],"study_design_scores_gemma":[0.92557126,0.0039909496,0.04401046,0.00035812796,0.0013411618,0.0000053185013,0.0003504024,0.0017951031,0.000025690024,0.0006118259,0.02175467,0.00018501563],"about_ca_topic_score_codex":0.000088884786,"about_ca_topic_score_gemma":0.00008254781,"teacher_disagreement_score":0.033212285,"about_ca_system_score_codex":0.000055128716,"about_ca_system_score_gemma":0.00006902952,"threshold_uncertainty_score":0.91516596},"labels":[],"label_agreement":null},{"id":"W2137996684","doi":"10.1136/thoraxjnl-2014-206260.34","title":"S28 Liraglutide 3.0 Mg Reduces Severity Of Obstructive Sleep Apnoea And Body Weight In Obese Individuals With Moderate Or Severe Disease: Scale Sleep Apnoea Trial","year":2014,"lang":"en","type":"article","venue":"Thorax","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Sleep Institute","funders":"","keywords":"Liraglutide; Medicine; Placebo; Weight loss; Internal medicine; Continuous positive airway pressure; Diabetes mellitus; Blood pressure; Sleep study; Type 2 diabetes; Anesthesia; Obesity; Gastroenterology; Endocrinology; Polysomnography; Obstructive sleep apnea; Apnea","score_opus":0.011033217296714063,"score_gpt":0.253275297357078,"score_spread":0.24224208006036393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137996684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317384,0.00037035864,0.000059565104,0.00048321192,0.00016243504,0.0014951599,0.00005812412,0.00006401199,0.0041332934],"genre_scores_gemma":[0.9952806,0.00007283698,0.0021658295,0.00013193494,0.00018023858,0.00013724079,0.0000858963,0.000037238653,0.0019081726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981202,0.00016336086,0.0003818597,0.0005064696,0.0004244323,0.0004036618],"domain_scores_gemma":[0.99891675,0.00011777776,0.00018398372,0.00042729996,0.000077859666,0.00027632006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037576543,0.00032004833,0.0007018482,0.00020364513,0.00007831656,0.000041457086,0.00013237851,0.000093401264,0.000098841694],"category_scores_gemma":[0.00008953047,0.0002204296,0.00007339224,0.00030984022,0.00019331726,0.00025064993,0.00013544474,0.00016888016,0.00001228128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21555284,0.005797622,0.58356005,0.0021837917,0.0032698796,0.00038981583,0.005232409,0.00025120733,0.0014586434,0.0029414624,0.0019914843,0.1773708],"study_design_scores_gemma":[0.1324741,0.0061357506,0.8262625,0.0013949831,0.003329745,0.000024775096,0.0009683151,0.008331188,0.009469037,0.0048274086,0.0054453015,0.0013369008],"about_ca_topic_score_codex":0.000054740467,"about_ca_topic_score_gemma":0.00006046537,"teacher_disagreement_score":0.24270245,"about_ca_system_score_codex":0.00007418327,"about_ca_system_score_gemma":0.00006935038,"threshold_uncertainty_score":0.89888585},"labels":[],"label_agreement":null},{"id":"W2138077952","doi":"10.1016/s0140-6736(08)61206-4","title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1068,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk; Amylin Pharmaceuticals; Eli Lilly and Company","keywords":"Exenatide; Medicine; Type 2 diabetes; Open label; Internal medicine; Diabetes mellitus; Randomized controlled trial; Endocrinology","score_opus":0.10224088238195751,"score_gpt":0.34767239190921156,"score_spread":0.24543150952725407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138077952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98458093,0.00097541773,0.000019953002,0.0023086648,0.00038950372,0.005850304,0.000020236625,0.000036426405,0.0058185584],"genre_scores_gemma":[0.99326754,0.0012071748,0.00047810757,0.0003697975,0.00039592833,0.00084055465,0.0000220098,0.000022827817,0.0033960864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99897355,0.000059611066,0.00023355661,0.0002208354,0.00020479635,0.0003076248],"domain_scores_gemma":[0.99820524,0.0007032724,0.00011866368,0.000837224,0.00008590398,0.000049689614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003685594,0.00018736535,0.00069754035,0.000027950842,0.00020788908,0.000028732604,0.0004056486,0.00002596092,0.00003113341],"category_scores_gemma":[0.00008505661,0.00009098395,0.000074719675,0.00018015903,0.00009815815,0.00006848579,0.00008660772,0.000056166587,0.000026771224],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3033689,0.042414937,0.27883562,0.00057607517,0.02465954,0.00018178321,0.032807488,0.00013468646,0.0038599337,0.0012466285,0.17570421,0.1362102],"study_design_scores_gemma":[0.6417811,0.03995301,0.10747066,0.00014526867,0.004753331,0.0000017777791,0.0020800657,0.0015482004,0.002160736,0.00010563164,0.19958904,0.00041117886],"about_ca_topic_score_codex":0.00014776696,"about_ca_topic_score_gemma":0.000053771313,"teacher_disagreement_score":0.3384122,"about_ca_system_score_codex":0.000093745,"about_ca_system_score_gemma":0.00006037453,"threshold_uncertainty_score":0.37102178},"labels":[],"label_agreement":null},{"id":"W2138173919","doi":"10.2337/dc14-1096","title":"Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":462,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Type 2 diabetes; Blood pressure; Internal medicine; Cardiology; Intensive care medicine; Endocrinology","score_opus":0.004756568371282576,"score_gpt":0.18694331933528605,"score_spread":0.18218675096400347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138173919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955729,0.0023239488,5.0863335e-8,0.00009921471,0.000097731034,0.0004960828,0.000009851042,0.00006312559,0.0013370758],"genre_scores_gemma":[0.99885654,0.00002519289,0.00021353984,0.00040157352,0.0000518204,0.000032354757,0.0002191463,0.000031364754,0.00016843421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894255,0.00003453458,0.00014197559,0.00033407155,0.00021171935,0.00033513314],"domain_scores_gemma":[0.9994011,0.000045539862,0.00004763189,0.00026027154,0.0001355835,0.000109876135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061654464,0.00020024923,0.00034850003,0.00013279726,0.000044696168,0.000029745359,0.000058423637,0.0000695763,0.000021947648],"category_scores_gemma":[0.00005707864,0.00014364006,0.000030868436,0.00018014516,0.00005458694,0.000096932956,0.000062123516,0.0000894885,0.0000236782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031337888,0.00021784178,0.98354924,0.0002350573,0.00024892786,0.0000020247276,0.000228527,0.000003883479,0.00036909146,0.000013193121,0.00042733076,0.014673523],"study_design_scores_gemma":[0.003890586,0.0016482379,0.9844002,0.0003351526,0.0010843179,5.5975935e-8,0.00015243939,0.00006967281,0.0042513926,0.000015278849,0.0039598155,0.00019284898],"about_ca_topic_score_codex":0.0000026753305,"about_ca_topic_score_gemma":0.000004505354,"teacher_disagreement_score":0.014480674,"about_ca_system_score_codex":0.0000117108875,"about_ca_system_score_gemma":0.000011668299,"threshold_uncertainty_score":0.5857472},"labels":[],"label_agreement":null},{"id":"W2138224856","doi":"10.1111/j.1368-5031.2006.00914.x","title":"A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance","year":2006,"lang":"en","type":"review","venue":"International Journal of Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Acarbose; Medicine; Impaired glucose tolerance; Metformin; Diabetes mellitus; Placebo; Type 2 Diabetes Mellitus; Internal medicine; Disease; Type 2 diabetes; Gerontology; Endocrinology; Alternative medicine","score_opus":0.1291893999938949,"score_gpt":0.47596656460171316,"score_spread":0.34677716460781827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138224856","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007614286,0.9893766,0.0000118000835,0.0009926273,0.0002684382,0.0016152648,0.000012355804,8.9756577e-7,0.000107720036],"genre_scores_gemma":[0.006218012,0.9924651,0.0006384865,0.00036928573,0.00020438056,0.00006520216,0.000008513516,0.000011638785,0.000019384233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609214,0.0008965549,0.0021664687,0.00017575709,0.000570482,0.00009858585],"domain_scores_gemma":[0.991592,0.0047361003,0.0030893951,0.0002765626,0.00027779464,0.00002812813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008229442,0.00015815593,0.0016211394,0.0001312365,0.000008350745,0.000010060885,0.0004476584,0.00008688435,0.000003985703],"category_scores_gemma":[0.005185175,0.00007944932,0.001048636,0.000121715435,0.000066238674,0.0003178968,0.00007546377,0.00036928352,5.22174e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021286019,0.00089987426,0.01864339,0.024507264,0.0052433508,0.000017847893,0.000036040474,0.000025865205,9.3754e-8,0.000066721834,0.0006116641,0.94973505],"study_design_scores_gemma":[0.0031519365,0.00084001356,0.02099533,0.34550095,0.009310099,0.00006410327,0.000023334796,0.000013523223,0.0000014853047,0.00015817536,0.61983603,0.000105011386],"about_ca_topic_score_codex":0.000016178723,"about_ca_topic_score_gemma":0.000007912477,"teacher_disagreement_score":0.94963,"about_ca_system_score_codex":0.00010625971,"about_ca_system_score_gemma":0.000464666,"threshold_uncertainty_score":0.6207513},"labels":[],"label_agreement":null},{"id":"W2138512196","doi":"10.1091/mbc.e03-11-0825","title":"Lipid Raft-dependent Glucagon-like Peptide-2 Receptor Trafficking Occurs Independently of Agonist-induced Desensitization","year":2004,"lang":"en","type":"article","venue":"Molecular Biology of the Cell","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research","keywords":"Biology; Desensitization (medicine); Lipid raft; Raft; Agonist; Cell biology; Receptor; Peptide; Homologous desensitization; Biophysics; Endocrinology; Signal transduction; Biochemistry; Chemistry","score_opus":0.010534110329016437,"score_gpt":0.2449922056799126,"score_spread":0.23445809535089615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138512196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470866,0.00017950297,0.0009748065,0.0006317466,0.0005223149,0.0007822505,0.000008110128,0.000032267093,0.0021603252],"genre_scores_gemma":[0.9979019,0.00003789313,0.0011184411,0.00032554363,0.000043712087,0.00001764677,0.00007317786,0.000023791048,0.00045785404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988604,0.000091716334,0.00032445532,0.00027402342,0.00019677,0.0002525915],"domain_scores_gemma":[0.9991318,0.000020532192,0.00025146772,0.00044249167,0.00009224447,0.00006148449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019120236,0.00018253662,0.00033568675,0.00011241301,0.000050199993,0.000005733644,0.00019354155,0.00015285716,0.000025886597],"category_scores_gemma":[0.000036073652,0.00013537362,0.0002144356,0.00016999798,0.00012295596,0.000023062024,0.00012741565,0.00012370602,0.000020813466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090483394,0.0004431001,0.0020939421,0.00009675403,0.00022780657,0.0000119927545,0.00020364966,0.00030525867,0.9934868,0.0004131136,0.00017138422,0.0024557079],"study_design_scores_gemma":[0.002440228,0.00053333124,0.00097468845,0.000099739445,0.000272445,0.000004714749,0.0001256408,0.000014639186,0.9943867,0.00017738725,0.0008527817,0.00011773873],"about_ca_topic_score_codex":0.000050888248,"about_ca_topic_score_gemma":0.000011376428,"teacher_disagreement_score":0.0031932644,"about_ca_system_score_codex":0.00009504255,"about_ca_system_score_gemma":0.000085430016,"threshold_uncertainty_score":0.5520376},"labels":[],"label_agreement":null},{"id":"W2138923096","doi":"10.1093/ndt/gfq649","title":"Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case–control study","year":2010,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Nested case-control study; Renal function; Insulin; Population; Internal medicine; Impaired renal function; Case-control study; Endocrinology; Environmental health","score_opus":0.00872407690260027,"score_gpt":0.22783454502232978,"score_spread":0.2191104681197295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138923096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970979,0.000016489215,0.0010090653,0.00016584166,0.00013072547,0.0013795277,0.00011105767,0.000057742378,0.00003161684],"genre_scores_gemma":[0.9990585,0.000020511303,0.00017084261,0.0001756996,0.00006671773,0.0001422588,0.0003176774,0.000018234074,0.000029543991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835247,0.00031123462,0.00056840735,0.0002836325,0.00029160894,0.0001926342],"domain_scores_gemma":[0.9984747,0.0005091288,0.00042752334,0.00038140238,0.0001507703,0.00005647263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005141483,0.00020534552,0.00049796625,0.000297564,0.00012752978,0.000010632209,0.00008177193,0.00016204434,0.00007845026],"category_scores_gemma":[0.000064962216,0.00014766518,0.00022305256,0.00032929197,0.00012504401,0.00012456336,0.0000054645852,0.00021808915,0.0000035943162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004960055,0.0006401903,0.95961535,0.00009382467,0.0021927916,0.0001045106,0.0010921451,0.00987629,0.01565843,0.000029717934,0.000012139761,0.00572456],"study_design_scores_gemma":[0.009353619,0.0009519097,0.9678451,0.0000151136865,0.012999005,0.000020804368,0.0002651395,0.0064792945,0.0019154035,0.000040850093,0.000005216113,0.0001085828],"about_ca_topic_score_codex":0.0034791557,"about_ca_topic_score_gemma":0.0074159265,"teacher_disagreement_score":0.013743027,"about_ca_system_score_codex":0.00002610116,"about_ca_system_score_gemma":0.000047015725,"threshold_uncertainty_score":0.6021611},"labels":[],"label_agreement":null},{"id":"W2138969543","doi":"10.1177/193229681300700205","title":"An Overview of Canadian and U.S. Approaches to Drug Regulation and Responses to Postmarket Adverse Drug Reactions","year":2013,"lang":"en","type":"review","venue":"Journal of Diabetes Science and Technology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lockheed Martin (Canada)","funders":"","keywords":"Drug; Adverse effect; Marketing authorization; Authorization; Drug reaction; Medicine; Pharmacology; Adverse drug reaction; Business; Intensive care medicine; Risk analysis (engineering); Computer security; Bioinformatics; Computer science","score_opus":0.09460726235909048,"score_gpt":0.3171217728891006,"score_spread":0.22251451053001012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138969543","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23531173,0.75906414,3.4801823e-7,0.0044124103,0.00007668358,0.00085919263,0.000012452827,0.000013207377,0.0002498397],"genre_scores_gemma":[0.023088576,0.9733709,0.002869058,0.00015210321,0.000034104432,0.000037749305,0.0000038895396,0.00001662821,0.00042700287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862456,0.000049208684,0.00046944444,0.00029822616,0.00025580233,0.00030277943],"domain_scores_gemma":[0.9985916,0.00008308217,0.0003366905,0.0002937972,0.00022977346,0.00046506303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011405676,0.0002003222,0.00090523023,0.0050818077,0.000120329954,0.000041857733,0.00020202051,0.00011296082,0.000010373555],"category_scores_gemma":[0.0003396492,0.0001437374,0.000053823624,0.0019626538,0.00040995918,0.00031373344,0.00011351565,0.00017748124,0.000002465307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000061812657,0.000058417012,0.003327553,0.001872955,0.00010457053,0.0000057350503,0.00010359647,1.545666e-7,0.00012116722,0.0010417856,0.000927716,0.99243015],"study_design_scores_gemma":[0.00038449938,0.0011393127,0.0124351485,0.0074326596,0.0011756945,0.000067467365,0.00047846674,0.00001629874,0.00014353919,0.00045491828,0.976015,0.00025701488],"about_ca_topic_score_codex":0.00031038426,"about_ca_topic_score_gemma":0.00052395626,"teacher_disagreement_score":0.99217314,"about_ca_system_score_codex":0.0001332233,"about_ca_system_score_gemma":0.0004721198,"threshold_uncertainty_score":0.5861441},"labels":[],"label_agreement":null},{"id":"W2139019118","doi":"10.1177/1479164109336047","title":"Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients","year":2009,"lang":"en","type":"article","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Rosiglitazone; Diabetes mellitus; Stroke (engine); Internal medicine; Retrospective cohort study; Cohort; Cohort study; Logistic regression; Population; Emergency medicine; Endocrinology","score_opus":0.03994422934185823,"score_gpt":0.29336590631010595,"score_spread":0.25342167696824774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139019118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899606,0.00851115,0.0000028813884,0.00009985687,0.000011946891,0.0011728756,0.000048982263,0.00003411227,0.00015758106],"genre_scores_gemma":[0.998189,0.0013099302,0.000033053326,0.00007048868,0.000019009656,0.000083990824,0.0001395171,0.000019376052,0.0001356894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733174,0.00028386633,0.0001970821,0.0006144386,0.0009002224,0.0006726554],"domain_scores_gemma":[0.9985837,0.00013202481,0.000027050743,0.0004867207,0.00018467304,0.0005858653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010427155,0.00023466545,0.000524731,0.00026382552,0.00015058546,0.0001655063,0.00005784521,0.00007567591,0.000009855689],"category_scores_gemma":[0.00032254998,0.00018411865,0.0001336559,0.00031845897,0.0002310649,0.000251176,0.00010543549,0.0002380412,0.0000018724398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004155632,0.000765077,0.9822525,0.00015259217,0.0010804129,0.000046696103,0.000049921735,0.0000043140485,0.000028291393,0.00007903482,0.000060783488,0.015438856],"study_design_scores_gemma":[0.0045300163,0.00092601805,0.9923962,0.000271126,0.0007471149,7.583317e-8,0.000049389953,0.0004298085,0.000034471024,0.00015218297,0.0002683199,0.0001953096],"about_ca_topic_score_codex":0.000112234506,"about_ca_topic_score_gemma":0.000035852972,"teacher_disagreement_score":0.015243545,"about_ca_system_score_codex":0.00007060392,"about_ca_system_score_gemma":0.000042184027,"threshold_uncertainty_score":0.750814},"labels":[],"label_agreement":null},{"id":"W2139076767","doi":"10.1097/mpa.0000000000000229","title":"LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes","year":2014,"lang":"en","type":"article","venue":"Pancreas","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"Novartis Pharma; BERLIN-CHEMIE; Novo Nordisk; Saint Luke's Health System; Medicines Company; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company","keywords":"Liraglutide; Medicine; Placebo; Internal medicine; Lipase; Type 2 diabetes; Amylase; Gastroenterology; Endocrinology; Diabetes mellitus; Renal function; Acute pancreatitis; Enzyme; Chemistry; Pathology; Biochemistry","score_opus":0.011241889805045603,"score_gpt":0.22806511582863018,"score_spread":0.2168232260235846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139076767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877085,0.00019424853,0.0000066702246,0.00040271026,0.000031051273,0.00022223679,7.0306453e-7,0.000040414758,0.011393439],"genre_scores_gemma":[0.998076,0.000034157038,0.00020409374,0.0003393273,0.000049886065,0.000022158576,0.000008594424,0.000013765832,0.0012519729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994323,0.000028872231,0.00005563019,0.00018031878,0.00009687832,0.0002059595],"domain_scores_gemma":[0.9996427,0.00005726693,0.000022566359,0.00016578793,0.000017374192,0.000094257026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011145264,0.00010558665,0.0002034131,0.00007216418,0.000019763336,0.0000133392,0.000021704573,0.000028310144,0.000035981186],"category_scores_gemma":[0.000048426013,0.00007584081,0.000014560648,0.00012323973,0.000043853754,0.00006499231,0.000021626134,0.00006155577,0.000038449056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027899843,0.00032119922,0.95377696,0.00016227453,0.00011022181,0.00003221689,0.00011455649,0.0000014634961,0.003084787,0.00033420476,0.0005490352,0.041234087],"study_design_scores_gemma":[0.0032747716,0.00090316404,0.9783477,0.00014654231,0.00020219097,0.0000021075637,0.000039187868,0.0003718646,0.008636166,0.00009670504,0.007822912,0.00015666988],"about_ca_topic_score_codex":0.00007817538,"about_ca_topic_score_gemma":0.000082239494,"teacher_disagreement_score":0.041077416,"about_ca_system_score_codex":0.000023537343,"about_ca_system_score_gemma":0.000013391641,"threshold_uncertainty_score":0.30926988},"labels":[],"label_agreement":null},{"id":"W2139337147","doi":"10.1016/j.jcjd.2014.06.001","title":"Canada Welcomes a Novel Class of Oral Glucose-Lowering Drugs for People with Type 2 Diabetes","year":2014,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Glycemic; Sulfonylurea; Hypoglycemia; Glycated hemoglobin; Insulin; Insulin resistance; Diabetes management; Exenatide; Blood sugar; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.006055081229127336,"score_gpt":0.2090055565065253,"score_spread":0.20295047527739796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139337147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5042316,0.004518201,0.000016761816,0.0012288261,0.48665035,0.0011990801,0.0009793838,0.000020459142,0.0011553616],"genre_scores_gemma":[0.7702025,0.000082683386,0.001704431,0.0006866031,0.22325638,0.00007289249,0.00090065465,0.0003341966,0.0027596485],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721897,0.000025891204,0.00075232756,0.00031684808,0.00076360925,0.00092237414],"domain_scores_gemma":[0.99582595,0.0006490002,0.00085584034,0.0004048771,0.0012766187,0.0009877342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047461267,0.00051062484,0.0017483354,0.00059353304,0.00010771795,0.00006961282,0.00042086453,0.0003170135,0.0000606338],"category_scores_gemma":[0.00074058655,0.00040774856,0.00028571047,0.0003313147,0.00012050668,0.00012284148,0.000028918088,0.0004902426,0.0000015594879],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040860086,0.00005724834,0.029823493,0.0012920819,0.0021254036,0.000010710797,0.00009328039,0.000026334192,0.000099276454,0.000028042394,0.9642675,0.0021358025],"study_design_scores_gemma":[0.003914487,0.0022965407,0.0034461683,0.0017862954,0.0020622085,5.862031e-7,0.00010824835,0.000048099526,0.0011294571,0.000021146616,0.9847501,0.00043667867],"about_ca_topic_score_codex":0.12797362,"about_ca_topic_score_gemma":0.84395623,"teacher_disagreement_score":0.7159826,"about_ca_system_score_codex":0.0008708512,"about_ca_system_score_gemma":0.011512622,"threshold_uncertainty_score":0.99983746},"labels":[],"label_agreement":null},{"id":"W2139538720","doi":"10.1093/gerona/56.11.m681","title":"Glucagon-like Peptide-1 (7-37) Augments Insulin-Mediated Glucose Uptake in Elderly Patients With Diabetes","year":2001,"lang":"en","type":"article","venue":"The Journals of Gerontology Series A","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; University of British Columbia; Canadian Diabetes Association","keywords":"Insulin; Internal medicine; Endocrinology; Hyperinsulinemia; Diabetes mellitus; Medicine; Glucagon; Glucagon-like peptide-1; Type 2 diabetes; Pancreatic hormone; Insulin resistance","score_opus":0.02002250059930306,"score_gpt":0.2586468775408943,"score_spread":0.23862437694159128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139538720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991009,0.0030379065,0.00000607045,0.0029691723,0.00021444538,0.00070516614,0.00000963328,0.000036654543,0.00201194],"genre_scores_gemma":[0.9956501,0.0016242146,0.0003371536,0.0007206278,0.000048961272,0.000049405244,0.00004849831,0.00003143365,0.0014895779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980948,0.00010904347,0.00060165866,0.00024301508,0.00037236756,0.0005791375],"domain_scores_gemma":[0.9987727,0.00010973773,0.000373175,0.00042766734,0.00017785977,0.00013888354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036744296,0.00027951115,0.0006577638,0.00018458208,0.0000971195,0.000022551438,0.00023783294,0.0001095106,0.00028900462],"category_scores_gemma":[0.000089449655,0.0001690929,0.00009660067,0.00032473978,0.0002485338,0.0002881575,0.000085042324,0.000248009,0.00003349592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020544247,0.0013470069,0.9655918,0.0000641311,0.00092086935,0.000092643306,0.0007886294,0.000015160953,0.0004625366,0.00004649417,0.001621182,0.026995156],"study_design_scores_gemma":[0.007435275,0.0036050829,0.97377974,0.00028695376,0.0003512179,0.000013815624,0.0006034622,0.000018329752,0.00046614534,0.00019833473,0.0130545935,0.00018704626],"about_ca_topic_score_codex":0.000052707317,"about_ca_topic_score_gemma":0.0005602259,"teacher_disagreement_score":0.02680811,"about_ca_system_score_codex":0.00009342524,"about_ca_system_score_gemma":0.000059013033,"threshold_uncertainty_score":0.68954086},"labels":[],"label_agreement":null},{"id":"W2139562487","doi":"10.1007/s00125-008-1157-y","title":"Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy","year":2008,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":715,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Insulet Corporation; Novo Nordisk; Sanofi; MannKind Corporation; GlaxoSmithKline; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Algorithm; Consensus algorithm; Psychological intervention; Type 2 Diabetes Mellitus; Medicine; Human physiology; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Computer science; Internal medicine; Nursing","score_opus":0.028897584209011465,"score_gpt":0.276434298285966,"score_spread":0.24753671407695454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139562487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97723013,0.02038496,0.000080130536,0.00050933764,0.00014557331,0.0011238223,0.000009304221,0.000017774215,0.0004989927],"genre_scores_gemma":[0.97682214,0.018703444,0.0038717987,0.0002885664,0.000025505697,0.00015507317,0.00003644953,0.000011565687,0.00008542947],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990446,0.000032888827,0.00030803523,0.00017240144,0.00024012143,0.00020196888],"domain_scores_gemma":[0.9992876,0.00029481662,0.000103622864,0.00019496722,0.00007146865,0.000047538357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027788006,0.00012128417,0.00035720857,0.00009122038,0.000027473016,0.0000016894455,0.00007867959,0.00007504124,0.000039973984],"category_scores_gemma":[0.000042334883,0.000077282624,0.000057282876,0.00018402252,0.00021651441,0.000018111938,0.000046115278,0.000059059927,0.000001627445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015086107,0.0006947645,0.088703305,0.0002969632,0.0008656567,0.000034787114,0.00027764722,0.0000039109996,0.00016020442,0.0015243837,0.0010962504,0.9061913],"study_design_scores_gemma":[0.010411851,0.0020183034,0.9668822,0.00038595204,0.00043248935,0.0000053535177,0.00054567313,0.0047678864,0.01045684,0.00048857206,0.003399275,0.00020558838],"about_ca_topic_score_codex":0.000009659502,"about_ca_topic_score_gemma":0.0000019285899,"teacher_disagreement_score":0.90598565,"about_ca_system_score_codex":0.000027009997,"about_ca_system_score_gemma":0.00003317738,"threshold_uncertainty_score":0.3151494},"labels":[],"label_agreement":null},{"id":"W2139611060","doi":"10.2337/dc08-9016","title":"Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy","year":2007,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":326,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; MEDLINE; Algorithm; Endocrinology; Computer science","score_opus":0.01666272172934711,"score_gpt":0.2677987973218668,"score_spread":0.25113607559251966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139611060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980227,0.017130772,0.000036237725,0.00010781231,0.00015766542,0.0014937648,0.000031082705,0.000015144603,0.00080051296],"genre_scores_gemma":[0.99495536,0.0013658179,0.003179507,0.00021313768,0.000034450826,0.00009546532,0.00008699295,0.000017439594,0.000051836007],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991439,0.000013335054,0.00027498754,0.00016570445,0.00016203804,0.0002400153],"domain_scores_gemma":[0.9993164,0.00020028594,0.00010339156,0.00021050908,0.0001311829,0.00003820962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022000314,0.00012841854,0.00026951553,0.000121736586,0.000022008453,0.0000038801036,0.000056882796,0.00004703175,0.000010073489],"category_scores_gemma":[0.000011500525,0.000090559326,0.00006566746,0.00020566331,0.000073699084,0.000021099499,0.00003648133,0.000041835476,0.0000015764379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009098716,0.00015537186,0.15517484,0.0005195232,0.0004448054,0.0000033698109,0.0005696651,0.0000051992197,0.00054257695,0.00024613977,0.0001457979,0.84210175],"study_design_scores_gemma":[0.008124538,0.0018593118,0.94489944,0.00055237813,0.00058900757,1.6910921e-7,0.0062370123,0.00094809494,0.031906337,0.00014592396,0.0045488505,0.00018895917],"about_ca_topic_score_codex":0.0000040479367,"about_ca_topic_score_gemma":0.0000042132942,"teacher_disagreement_score":0.84191275,"about_ca_system_score_codex":0.000053853175,"about_ca_system_score_gemma":0.0000134788625,"threshold_uncertainty_score":0.3692902},"labels":[],"label_agreement":null},{"id":"W2139772567","doi":"10.2337/db07-1775","title":"Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis","year":2008,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"University of Miami","keywords":"Postprandial; Glucose homeostasis; Agonist; Receptor; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Pharmacokinetics; Pharmacology; Gastric emptying; Chemistry; Endocrinology; In vivo; Peptide; Internal medicine; Diabetes mellitus; Biology; Medicine; Type 2 diabetes; Biochemistry; Insulin resistance","score_opus":0.010600681905114637,"score_gpt":0.22089149407929437,"score_spread":0.21029081217417972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139772567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939212,0.0020709366,0.0008470082,0.00025411232,0.00013853141,0.0020980723,0.00005535785,0.00013964919,0.00047514038],"genre_scores_gemma":[0.99565375,0.000089504545,0.0019430513,0.00010440424,0.000095580035,0.0006310441,0.00010801164,0.00004460052,0.0013300321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864674,0.000016599688,0.0003290404,0.0002745771,0.00025589956,0.0004771427],"domain_scores_gemma":[0.9991922,0.00010358824,0.000114647955,0.00029846388,0.0001713231,0.000119781485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016894337,0.00024682496,0.0005178592,0.00018754217,0.000064866195,0.000020440597,0.00010469956,0.000073674775,0.000054149652],"category_scores_gemma":[0.00009498752,0.00021522213,0.00019248774,0.00015735846,0.000062715066,0.00016593571,0.0000348159,0.00007349858,0.000012922879],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011893831,0.0035194198,0.059776116,0.0065928176,0.0059958673,0.00010311646,0.0019452828,0.00087572786,0.8605418,0.015636569,0.0115253925,0.032298487],"study_design_scores_gemma":[0.023638014,0.0045026345,0.010624624,0.0007184734,0.0011827071,0.000002535701,0.0025011443,0.0032160673,0.916859,0.000409929,0.035354376,0.0009905203],"about_ca_topic_score_codex":0.00001335378,"about_ca_topic_score_gemma":0.0000014245547,"teacher_disagreement_score":0.056317154,"about_ca_system_score_codex":0.000085556196,"about_ca_system_score_gemma":0.00009381043,"threshold_uncertainty_score":0.8776503},"labels":[],"label_agreement":null},{"id":"W2139779556","doi":"10.1186/2046-4053-2-47","title":"Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis","year":2013,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; Ottawa Hospital; University of Alberta; University of Calgary; St. Michael's Hospital","funders":"Fondation pour la Recherche Médicale; Canadian Institutes of Health Research; Alberta Innovates; University of Ottawa","keywords":"Medicine; Metformin; Insulin; Type 2 diabetes; Meta-analysis; Type 2 Diabetes Mellitus; Randomized controlled trial; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.16604196196518006,"score_gpt":0.4187325981021462,"score_spread":0.25269063613696613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139779556","genre_codex":"review","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.5245325e-8,0.5357065,0.0001182347,0.000008185828,0.00006317685,0.46400186,0.000035019915,0.000019575482,0.00004735787],"genre_scores_gemma":[8.351765e-7,0.4936828,0.00054207013,0.000032483887,0.0000575617,0.505314,0.00012516053,0.000063664695,0.00018144792],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9900021,0.0027064541,0.005483755,0.0008759337,0.00038170817,0.00055002456],"domain_scores_gemma":[0.98577726,0.006030352,0.0062546525,0.0013159893,0.00038980445,0.00023191737],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009824977,0.0012248922,0.033454612,0.0003654143,0.00012229713,0.00009422169,0.0002817998,0.0002561114,0.00004305081],"category_scores_gemma":[0.0049521946,0.0006214155,0.0049083675,0.0010238498,0.00008561169,0.00014376422,0.00019332288,0.00018993691,0.000034352302],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002601974,0.00006976073,0.0000015344233,0.86590004,0.12422684,6.653131e-7,0.0000199881,1.8710834e-7,4.0816722e-8,0.000035098372,0.000744145,0.008975689],"study_design_scores_gemma":[0.0008576243,0.00039478522,2.1092966e-7,0.48303097,0.44523388,0.0000013106059,0.00000849949,0.000016664675,1.4321996e-7,0.0000054341385,0.07021195,0.00023854064],"about_ca_topic_score_codex":0.0000031471538,"about_ca_topic_score_gemma":0.0000043243285,"teacher_disagreement_score":0.38286906,"about_ca_system_score_codex":0.00021492201,"about_ca_system_score_gemma":0.000093223156,"threshold_uncertainty_score":0.9996237},"labels":[],"label_agreement":null},{"id":"W2140137473","doi":"10.1210/endo.142.2.7983","title":"Minireview: The Glucagon-Like Peptides","year":2001,"lang":"en","type":"review","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Glucagon-like peptide-2; Enteroendocrine cell; Endocrinology; Internal medicine; Glucose homeostasis; Gastric emptying; Proglucagon; Biology; Glucagon-like peptide-1; Nutrient sensing; Glucagon; Islet; Stimulation; Insulin; Diabetes mellitus; Signal transduction; Endocrine system; Insulin resistance; Type 2 diabetes; Stomach; Hormone; Cell biology; Medicine; Biochemistry; Peptide","score_opus":0.06782294264918169,"score_gpt":0.35605956857182786,"score_spread":0.28823662592264615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140137473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004688056,0.9555706,0.000002635064,0.0006313053,0.00076354144,0.0016574138,0.0000061741,0.00011680931,0.041246857],"genre_scores_gemma":[0.0000018134336,0.9405133,0.00009541659,0.0007664443,0.00042198825,0.0006034016,0.0001771531,0.000058419053,0.057362046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803823,0.00015076868,0.00051982945,0.00047341187,0.00016257544,0.0006551693],"domain_scores_gemma":[0.9985131,0.0002018482,0.00022661839,0.00093931594,0.00003008005,0.00008906163],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009262265,0.0004857599,0.0019823168,0.0001877218,0.00008684021,0.000020276719,0.0003372998,0.00013868525,0.00054875726],"category_scores_gemma":[0.00004909188,0.00025715303,0.000747543,0.00031096058,0.00016345418,0.0000263422,0.00023048541,0.00037545772,0.0027755247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002758118,0.00010060967,0.000017028897,0.005201356,0.0008737265,0.00041235756,0.0000106544385,1.0751414e-8,2.4594994e-8,0.0011963483,0.055338647,0.9368465],"study_design_scores_gemma":[0.000357656,0.00019247546,0.000016332535,0.0035327058,0.005210932,0.0004890159,0.000015292491,1.3876704e-7,4.1418105e-7,0.000031151492,0.9899564,0.00019749769],"about_ca_topic_score_codex":0.0000144321875,"about_ca_topic_score_gemma":0.000007457925,"teacher_disagreement_score":0.93664896,"about_ca_system_score_codex":0.00011925212,"about_ca_system_score_gemma":0.00010606572,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W2140551754","doi":"10.3109/07853890108998750","title":"Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2","year":2001,"lang":"en","type":"review","venue":"Annals of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon-like peptide-2; Short bowel syndrome; Intestinal epithelium; Gastrointestinal hormone; Hormone; Therapeutic approach; Enterocyte; Medicine; Internal medicine; Intestinal Disorder; Intestinal mucosa; Atrophy; Endocrinology; Biology; Peptide hormone; Epithelium; Parenteral nutrition; Peptide; Pathology; Small intestine; Disease; Biochemistry","score_opus":0.10775445692397316,"score_gpt":0.3707721072918744,"score_spread":0.2630176503679012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140551754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014780049,0.98855746,0.000023663384,0.0023502803,0.00047955723,0.0012914394,0.000010027921,0.000028685852,0.007111117],"genre_scores_gemma":[0.0013058262,0.98993593,0.0000378939,0.0010259832,0.00042164858,0.00004700205,0.00008955345,0.000053614178,0.007082545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975208,0.00012239955,0.0010094682,0.00032868903,0.00066650525,0.0003521608],"domain_scores_gemma":[0.99777246,0.00013412168,0.0008262653,0.00092159305,0.00022474279,0.000120836194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003642133,0.00045116962,0.0024131394,0.0002764234,0.00003715461,0.0000035898604,0.00041328557,0.00017664624,0.00022379933],"category_scores_gemma":[0.00013306076,0.00022487529,0.00074326055,0.000645312,0.0004842789,0.000033013002,0.00015597408,0.00030396218,0.000025005316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003306669,0.0002710875,0.000042242344,0.0087428335,0.0014678565,0.00003608724,0.000046454486,2.807675e-7,0.000012983961,0.0003013294,0.035349205,0.95369655],"study_design_scores_gemma":[0.0012213065,0.001352729,0.00066985964,0.024164427,0.0065304795,0.00004471683,0.00003511451,0.0000032026674,0.000012619086,0.00021593641,0.96559626,0.00015335508],"about_ca_topic_score_codex":0.00006831831,"about_ca_topic_score_gemma":0.000002305151,"teacher_disagreement_score":0.95354325,"about_ca_system_score_codex":0.000027774531,"about_ca_system_score_gemma":0.00015219527,"threshold_uncertainty_score":0.9170148},"labels":[],"label_agreement":null},{"id":"W2141264129","doi":"10.2337/diabetes.51.4.943","title":"Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (<i>fa/fa</i>) Zucker Rats","year":2002,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research; Killam Trusts; Diabetes Canada; Michael Smith Health Research BC; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Insulin; Hyperinsulinemia; Basal (medicine); Pancreatic hormone; Gastric inhibitory polypeptide; Glucagon; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Diabetes mellitus; Biology; Type 2 diabetes; Medicine; Insulin resistance","score_opus":0.009696976774214107,"score_gpt":0.22229203419190857,"score_spread":0.21259505741769447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141264129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133927,0.004352843,0.0000019928248,0.0010005339,0.00010308892,0.002548261,0.00003785024,0.00008974138,0.00052641134],"genre_scores_gemma":[0.99387914,0.0012947669,0.00009957609,0.00085300417,0.00014391106,0.00052340754,0.00010203339,0.000082162405,0.0030220018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708855,0.00023752631,0.00050457235,0.0008128348,0.00041702873,0.00093951204],"domain_scores_gemma":[0.99844104,0.00034728984,0.00017577114,0.00066693494,0.00012585809,0.00024309657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035263182,0.0006593272,0.0008675653,0.00042810637,0.00014297418,0.00011313663,0.000120806784,0.00014318936,0.000050138155],"category_scores_gemma":[0.000055782515,0.0004452036,0.000115604635,0.0006558724,0.0002331916,0.00030439324,0.00018702484,0.00025440645,0.000036960046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010870442,0.0045026713,0.8320602,0.00050515676,0.0003027044,0.0018688302,0.0018777056,0.00003994444,0.12285166,0.000016757764,0.00026230584,0.034624994],"study_design_scores_gemma":[0.030465664,0.0045180176,0.65128744,0.001037456,0.0005768376,0.000009027946,0.0013073855,0.0014734198,0.30632684,0.000014725041,0.0019659468,0.0010172374],"about_ca_topic_score_codex":0.00019289408,"about_ca_topic_score_gemma":0.0009065569,"teacher_disagreement_score":0.18347517,"about_ca_system_score_codex":0.00042189957,"about_ca_system_score_gemma":0.00007203009,"threshold_uncertainty_score":0.99979997},"labels":[],"label_agreement":null},{"id":"W2141451572","doi":"10.1677/jme.0.0250321","title":"Characterization of glucagon-like peptide-1 receptor-binding determinants","year":2000,"lang":"en","type":"article","venue":"Journal of Molecular Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"Medical Research Council; Canadian Diabetes Association","keywords":"Receptor; Chemistry; Peptide; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Sf9; Biochemistry; Binding site; Amino acid; Cell biology; Biology; Endocrinology; Agonist; Recombinant DNA; Type 2 diabetes; Gene; Diabetes mellitus","score_opus":0.010648959936487146,"score_gpt":0.25577525015162594,"score_spread":0.2451262902151388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141451572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718785,0.00016940043,0.000102480706,0.00034617106,0.0002558954,0.00014484952,0.0000029861603,0.0000094886245,0.0017808474],"genre_scores_gemma":[0.99598074,0.0007485228,0.00087578746,0.00022959938,0.00006671165,0.0000033266274,0.000017057244,0.000017672535,0.002060555],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989652,0.00004657233,0.0004460848,0.00010948406,0.0001936507,0.00023898133],"domain_scores_gemma":[0.99935967,0.000013468602,0.00029660604,0.00015937026,0.00009604823,0.00007483537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007666697,0.00011573604,0.0003819006,0.00022928335,0.000020737452,0.0000063857087,0.00009850446,0.00004706518,0.00057728315],"category_scores_gemma":[0.000020804295,0.00009737609,0.00015817714,0.000112070986,0.00004573958,0.000085026804,0.000023922867,0.000114754796,0.00006685896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023782256,0.00027343116,0.009900936,0.000054281005,0.00033308085,0.00077985367,0.00008059937,0.000003851986,0.87371737,0.00007794865,0.00021684704,0.11432399],"study_design_scores_gemma":[0.004236786,0.0023193674,0.032632537,0.00027572399,0.0006095699,0.0008224862,0.00006046254,0.000020245938,0.8861381,0.00004331277,0.07267268,0.0001687268],"about_ca_topic_score_codex":0.0000023846958,"about_ca_topic_score_gemma":4.0217316e-7,"teacher_disagreement_score":0.11415526,"about_ca_system_score_codex":0.000048575093,"about_ca_system_score_gemma":0.00003753213,"threshold_uncertainty_score":0.6320846},"labels":[],"label_agreement":null},{"id":"W2142593697","doi":"10.1177/1479164114559852","title":"SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials","year":2015,"lang":"en","type":"review","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Empagliflozin; Renal glucose reabsorption; Type 2 Diabetes Mellitus; Albuminuria; Diabetes mellitus; Internal medicine; Endocrinology; Arterial stiffness; Type 2 diabetes; Blood pressure; Bioinformatics; Cardiology","score_opus":0.2176713554852567,"score_gpt":0.4260384978853561,"score_spread":0.20836714240009938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142593697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021854525,0.9904804,0.0000015095219,0.000051292835,0.00006352707,0.0067533,0.00018714427,0.000038753653,0.00023860535],"genre_scores_gemma":[0.00029212885,0.99841535,0.00008358442,0.000030752246,0.00017761358,0.0004865184,0.00033282605,0.00009444261,0.00008677214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99286383,0.0024708507,0.001289498,0.0010057064,0.0016429694,0.00072712],"domain_scores_gemma":[0.9963054,0.0006389424,0.00034443015,0.0011767856,0.00043185655,0.0011025551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.017127011,0.00061221456,0.0058006113,0.0006134557,0.00017808027,0.00010974134,0.00016386168,0.0002129856,0.000025696452],"category_scores_gemma":[0.0032995667,0.00040392307,0.0018709528,0.0005841282,0.00039212548,0.00011147021,0.0006163323,0.0005538924,0.000011330853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008379742,0.00013600584,0.0034263202,0.31680602,0.004824245,0.00003278371,0.000019032099,3.300206e-8,2.3119249e-7,0.000060394894,0.0005692248,0.6741173],"study_design_scores_gemma":[0.0019226435,0.00032704434,0.00071194273,0.12773266,0.027250152,0.0000014210848,0.000040783743,0.000011283657,0.00000160067,0.00010777084,0.8414858,0.0004069188],"about_ca_topic_score_codex":0.000023590846,"about_ca_topic_score_gemma":5.670365e-7,"teacher_disagreement_score":0.8409166,"about_ca_system_score_codex":0.00011141529,"about_ca_system_score_gemma":0.00047195665,"threshold_uncertainty_score":0.9998413},"labels":[],"label_agreement":null},{"id":"W2142628001","doi":"10.2337/dc14-1636","title":"Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076–1082","year":2014,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Glucagon; Internal medicine; Diabetes mellitus; Endocrinology; Insulin response; Type 2 diabetes; Insulin; Plasma glucose","score_opus":0.029654120845583734,"score_gpt":0.3206584022804947,"score_spread":0.29100428143491097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142628001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73373777,0.0029948393,3.4153254e-7,0.25768,0.00050911034,0.0030438502,0.001366279,0.000117424555,0.00055036845],"genre_scores_gemma":[0.52368665,0.00019760986,0.00028848177,0.4715094,0.00023922398,0.00054217374,0.0028987015,0.00032483257,0.00031293771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99182767,0.0016785826,0.0014260908,0.0016176366,0.0014740106,0.0019759955],"domain_scores_gemma":[0.993199,0.001966282,0.000636193,0.002706295,0.00089708605,0.00059516093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014992221,0.0015646858,0.003184833,0.0019762595,0.000079369354,0.00007851374,0.0008947433,0.00093964237,0.00030370295],"category_scores_gemma":[0.0010664408,0.0013680415,0.000999045,0.0009039331,0.00020199013,0.00014403994,0.0006010327,0.0014758732,0.0011943526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00731909,0.0005685237,0.0834108,0.0020485686,0.0012022811,0.00009910888,0.0046775276,0.00012696076,0.0047157207,0.0000037801194,0.89060247,0.005225164],"study_design_scores_gemma":[0.0057615493,0.02422834,0.034619935,0.005093297,0.0008169948,2.006689e-7,0.0009790452,0.000023212007,0.014288401,0.000018665647,0.91284704,0.0013233153],"about_ca_topic_score_codex":0.00008497196,"about_ca_topic_score_gemma":0.00003533388,"teacher_disagreement_score":0.21382938,"about_ca_system_score_codex":0.001744431,"about_ca_system_score_gemma":0.00043124278,"threshold_uncertainty_score":0.99971014},"labels":[],"label_agreement":null},{"id":"W2142830692","doi":"10.1056/nejmoa1501352","title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2590,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian VIGOUR Centre; St. Michael's Hospital; University of Alberta","funders":"South Australian Health and Medical Research Institute","keywords":"Sitagliptin; Medicine; Semaglutide; Placebo; Hazard ratio; Sitagliptin Phosphate; Myocardial infarction; Internal medicine; Glycated hemoglobin; Alogliptin; Glycemic; Type 2 diabetes; Relative risk; Confidence interval; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Heart failure; Endocrinology; Insulin; Liraglutide","score_opus":0.017622879837444753,"score_gpt":0.2752469197992141,"score_spread":0.25762403996176936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142830692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883387,0.005359448,0.0000066439575,0.0019234897,0.00064191094,0.00019877608,3.283985e-7,0.0000064935393,0.0035242217],"genre_scores_gemma":[0.998283,0.00019605871,0.00009578887,0.00018925095,0.0007490491,0.0000010369512,0.0000034218888,0.000011943324,0.00047044648],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986256,0.00013212195,0.0003801941,0.00008901383,0.0006171462,0.00015594714],"domain_scores_gemma":[0.99904233,0.00026759683,0.00014688345,0.0002017714,0.000115684554,0.00022570336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020930143,0.00013743254,0.0009770698,0.00030408148,0.000006035498,0.0000023746027,0.00007528443,0.000038827315,0.000036525722],"category_scores_gemma":[0.0009930956,0.00007270588,0.00015379644,0.00018134568,0.000040775456,0.000041995187,0.000015896634,0.00015931422,0.0000074737145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002090315,0.00022669669,0.5847603,0.00018832597,0.0019165542,0.00046343694,0.0006118033,0.00021759943,0.00039824602,0.000056960373,0.009565106,0.39950466],"study_design_scores_gemma":[0.4822668,0.12093764,0.20323421,0.0038987785,0.006563797,0.00010679516,0.00034665674,0.0000988092,0.0122557115,0.0005027934,0.16941662,0.00037137765],"about_ca_topic_score_codex":0.000031175532,"about_ca_topic_score_gemma":0.0000033382216,"teacher_disagreement_score":0.4801765,"about_ca_system_score_codex":0.000063925145,"about_ca_system_score_gemma":0.000054121065,"threshold_uncertainty_score":0.29648596},"labels":[],"label_agreement":null},{"id":"W2142877036","doi":"10.2337/diacare.26.3.837","title":"Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes","year":2003,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; University of British Columbia; National Institutes of Health; Boston Area Diabetes Endocrinology Research Center; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Medicine; Insulin; Glucagon; Glucose clamp technique; Type 2 diabetes; Diabetes mellitus; Glucagon-like peptide-1; Pancreatic hormone; C-peptide; Insulin resistance","score_opus":0.004374582294198575,"score_gpt":0.21155947193195151,"score_spread":0.20718488963775294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142877036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932336,0.0010525393,1.03563515e-7,0.000018323599,0.000299067,0.0014103368,0.000052280593,0.000085863176,0.003847873],"genre_scores_gemma":[0.99825764,0.00004469296,0.000095183874,0.0003636712,0.000024526991,0.00011279942,0.0008909958,0.00007025227,0.00014025292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979115,0.00014309882,0.00037889436,0.0004669966,0.00047746388,0.0006220585],"domain_scores_gemma":[0.998648,0.0002676546,0.00015200507,0.00055199116,0.00020551206,0.00017484398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021506702,0.00041803316,0.0007473747,0.00034284822,0.000042818167,0.000019505575,0.00012743863,0.00012501678,0.00007877614],"category_scores_gemma":[0.00031060763,0.00030461952,0.0001251423,0.00066445087,0.00008795711,0.00010012545,0.000043378597,0.000194287,0.00020976928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004034248,0.000524977,0.98305035,0.000619727,0.00029075338,0.000008933095,0.00023720457,0.00002450715,0.0003470826,0.000022766639,0.00042191317,0.014048358],"study_design_scores_gemma":[0.010802016,0.011382068,0.92658854,0.0007584284,0.0004275757,3.0917437e-8,0.0001354674,0.00002344291,0.04419709,0.000007347297,0.005337092,0.00034091066],"about_ca_topic_score_codex":0.00000477872,"about_ca_topic_score_gemma":0.000009786519,"teacher_disagreement_score":0.056461822,"about_ca_system_score_codex":0.000188324,"about_ca_system_score_gemma":0.00005131093,"threshold_uncertainty_score":0.9999406},"labels":[],"label_agreement":null},{"id":"W2143161390","doi":"10.1016/j.diabres.2012.08.005","title":"Balancing the risks and benefits for pioglitazone in type 2 diabetes","year":2012,"lang":"en","type":"letter","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pioglitazone; Medicine; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.21641014449699675,"score_gpt":0.4717970703928954,"score_spread":0.2553869258958987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143161390","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3192857,0.040467273,8.8040116e-7,0.6323628,0.0005632385,0.002850802,0.000054006796,0.00004247035,0.004372835],"genre_scores_gemma":[0.2208729,0.04183845,0.002233194,0.710965,0.012763887,0.0013060364,0.0011757973,0.0002974591,0.008547312],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579805,0.000709913,0.0006696101,0.00070940144,0.00073957804,0.0013734187],"domain_scores_gemma":[0.974344,0.024070585,0.00020241532,0.0006046706,0.0005038669,0.000274461],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007745644,0.00032706498,0.00080037117,0.0002534641,0.00023495156,0.00019861189,0.00022197398,0.000646816,0.00004347772],"category_scores_gemma":[0.013137316,0.00021546424,0.0001347275,0.00037137995,0.0005258881,0.00032926307,0.0003978063,0.0031885654,0.000060017068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026759505,0.00067822763,0.22255978,0.0010058316,0.0011437127,0.00004687835,0.00007019254,1.4387761e-7,0.0000059595313,0.00019350238,0.641671,0.13235721],"study_design_scores_gemma":[0.0018538802,0.0024299119,0.07717093,0.00038192922,0.00072252244,0.0000011766999,0.00013454414,0.0001044432,0.000015885116,0.0006042668,0.9163467,0.0002337599],"about_ca_topic_score_codex":0.000054956632,"about_ca_topic_score_gemma":0.000014723878,"teacher_disagreement_score":0.2746758,"about_ca_system_score_codex":0.000082296116,"about_ca_system_score_gemma":0.00009946281,"threshold_uncertainty_score":0.9991111},"labels":[],"label_agreement":null},{"id":"W2143199902","doi":"10.1186/1743-7075-10-33","title":"Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men","year":2013,"lang":"en","type":"article","venue":"Nutrition & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Overweight; Internal medicine; Endocrinology; Medicine; Glucose homeostasis; Calorie; Obesity; Glucagon-like peptide-1; Incretin; Insulin; Insulin resistance; Energy homeostasis; Anthropometry; Glucagon; Diabetes mellitus; Peptide YY; Type 2 diabetes","score_opus":0.019122084525289327,"score_gpt":0.27395363117258115,"score_spread":0.2548315466472918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143199902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932644,0.00075253873,0.0000131226225,0.0011976693,0.00010370085,0.0015988385,0.000005425183,0.000073783376,0.0029905671],"genre_scores_gemma":[0.9961409,0.00017759071,0.0014088133,0.00068119686,0.00018590798,0.00072960096,0.000050075036,0.000028814635,0.00059711735],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984331,0.00011368288,0.00040374193,0.00035142194,0.00029726955,0.00040077767],"domain_scores_gemma":[0.99934244,0.00011043224,0.000045325243,0.00025504566,0.00006644855,0.0001802894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045507273,0.00019893957,0.0004247,0.0007165124,0.000041011433,0.000060992454,0.00008484553,0.00007651491,0.00024378077],"category_scores_gemma":[0.00013582301,0.00019413639,0.00008566219,0.00057125476,0.000020873144,0.0003270434,0.000060886665,0.00013284266,0.00013410818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002670455,0.0062161153,0.32868615,0.00067842327,0.00029885976,0.0007337613,0.0029343946,0.000044229742,0.5809587,0.0014219558,0.018276537,0.057080396],"study_design_scores_gemma":[0.004507547,0.000107414126,0.98131317,0.0005737001,0.00008938334,0.000008296262,0.0006235401,0.0001858311,0.0017059797,0.00027192532,0.010405126,0.00020809211],"about_ca_topic_score_codex":0.00052655925,"about_ca_topic_score_gemma":0.000035670782,"teacher_disagreement_score":0.652627,"about_ca_system_score_codex":0.00017581163,"about_ca_system_score_gemma":0.000022739929,"threshold_uncertainty_score":0.7916652},"labels":[],"label_agreement":null},{"id":"W2143280048","doi":"10.1016/s1499-2671(06)03005-x","title":"Is Clinical Inertia the Biggest Challenge to Diabetes Care?","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Type 2 diabetes; Diabetes management; Family medicine; Glycated hemoglobin; MEDLINE; Gerontology; Endocrinology","score_opus":0.023730341764733515,"score_gpt":0.2721430294396705,"score_spread":0.248412687674937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143280048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639813,0.006210343,0.0000010337241,0.019828793,0.0006735301,0.00031243687,0.000026165779,0.000012529495,0.008953877],"genre_scores_gemma":[0.99286884,0.000028037392,0.00019532374,0.005184758,0.0010234386,0.000012292795,0.000011926715,0.000032708707,0.00064265216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998283,0.00006103555,0.000602919,0.00019350479,0.00025232378,0.0006072074],"domain_scores_gemma":[0.9982312,0.00013725295,0.00018210226,0.00035126944,0.00027954744,0.0008186502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004186346,0.00020816913,0.00047744016,0.00034592132,0.00013551638,0.00007624411,0.0002832588,0.00009129471,0.00017370793],"category_scores_gemma":[0.00014460944,0.00013616786,0.00031642275,0.00027105532,0.00013837432,0.0000985822,0.000026833315,0.00025717085,0.00021214294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000029647335,0.0000715493,0.8791163,0.000046504785,0.00028558326,0.00003107085,0.00029434444,0.00000744535,0.000050992847,0.00018618024,0.09783928,0.022067813],"study_design_scores_gemma":[0.0011744807,0.0011452684,0.6483577,0.00023409772,0.00049983244,9.250489e-7,0.0003285315,0.000013162457,0.00094161805,0.00014561394,0.34697798,0.00018080047],"about_ca_topic_score_codex":0.00035147992,"about_ca_topic_score_gemma":0.0059119724,"teacher_disagreement_score":0.2491387,"about_ca_system_score_codex":0.0001627333,"about_ca_system_score_gemma":0.00043039056,"threshold_uncertainty_score":0.5552764},"labels":[],"label_agreement":null},{"id":"W2143462158","doi":"10.1016/s0149-2918(03)80122-4","title":"Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Indirect costs; Emergency medicine; Intensive care medicine; Cost database; Microalbuminuria; Macrovascular disease; Complication; Type 2 diabetes; Health care; Surgery; Endocrinology; Database","score_opus":0.06930654272877787,"score_gpt":0.37471949241252256,"score_spread":0.30541294968374466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143462158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875876,0.009383669,0.00014797982,0.001661775,0.000067046276,0.00078744366,0.000014811098,0.00001766676,0.00033205052],"genre_scores_gemma":[0.9793381,0.010029321,0.0065040383,0.0035528527,0.000031424708,0.0000687858,0.00042559495,0.000026057556,0.000023823673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855524,0.00023942099,0.000558844,0.00023918088,0.00018993477,0.00021738175],"domain_scores_gemma":[0.9964035,0.0030269774,0.00008689476,0.0003427779,0.00007703315,0.00006280818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016370233,0.00012575579,0.00041113605,0.00008589532,0.000032826076,0.000014999384,0.000120292425,0.00010964428,0.000014181949],"category_scores_gemma":[0.00070229644,0.000085048836,0.00010692373,0.00032807013,0.0001958103,0.000021438726,0.000024753544,0.0001621988,0.000002325505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022476575,0.0028560113,0.8645623,0.0001814489,0.0018899104,0.000017213657,0.0010780463,0.00007031817,0.00031053316,0.0015918427,0.00039275194,0.12682489],"study_design_scores_gemma":[0.023298653,0.0019776337,0.57975787,0.0014345425,0.0025658673,0.0000028403238,0.0017060605,0.04900862,0.005485476,0.011661277,0.32246238,0.000638804],"about_ca_topic_score_codex":0.00009576013,"about_ca_topic_score_gemma":0.000045414552,"teacher_disagreement_score":0.32206962,"about_ca_system_score_codex":0.000031677835,"about_ca_system_score_gemma":0.000049182094,"threshold_uncertainty_score":0.3468191},"labels":[],"label_agreement":null},{"id":"W2144278955","doi":"10.1152/ajpendo.90887.2008","title":"Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes","year":2008,"lang":"en","type":"review","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Glucagon receptor; Glucagon; Glucose homeostasis; Endocrinology; Internal medicine; Receptor; Homeostasis; Type 2 diabetes; Action (physics); Diabetes mellitus; Medicine; Insulin; Insulin resistance","score_opus":0.07724597128129786,"score_gpt":0.32806674492891275,"score_spread":0.2508207736476149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144278955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14879514,0.8502762,0.0000021363062,0.0001106222,0.00033037234,0.0004448144,0.000015548236,0.0000042223774,0.00002095549],"genre_scores_gemma":[0.015542469,0.98344076,0.0006389238,0.000028282413,0.0002204606,0.000043161628,0.000019721656,0.000018750574,0.000047502912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883896,0.00011793188,0.0005599701,0.00018581597,0.0000702295,0.00022709239],"domain_scores_gemma":[0.9973464,0.0010696739,0.0011504054,0.00019337953,0.0001788473,0.00006130257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057520832,0.0002480038,0.0020955233,0.0002719739,0.000077358374,0.0000024511382,0.00007752448,0.00006365926,0.0000029250734],"category_scores_gemma":[0.00009820817,0.00013857584,0.00037526508,0.00017843429,0.0006353211,0.00004445874,0.000024159703,0.00013303917,4.3103165e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010146081,0.00025732527,0.000021758413,0.0005617656,0.0029768427,0.0000011102532,0.00017984753,0.0000052920363,0.00031443266,0.00035395703,0.000071058836,0.99515516],"study_design_scores_gemma":[0.0015823916,0.0062656594,0.008070999,0.00092227623,0.011790206,0.00012879775,0.00033440135,0.000004492532,0.00041638027,0.00007540383,0.9702673,0.00014170886],"about_ca_topic_score_codex":0.000014455495,"about_ca_topic_score_gemma":0.0000011016393,"teacher_disagreement_score":0.9950134,"about_ca_system_score_codex":0.000023197303,"about_ca_system_score_gemma":0.00010343896,"threshold_uncertainty_score":0.56509584},"labels":[],"label_agreement":null},{"id":"W2145089546","doi":"10.2337/db05-1360","title":"Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor","year":2006,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":403,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Centre National de la Recherche Scientifique; Canada Research Chairs","keywords":"Internal medicine; Endocrinology; Glucagon-like peptide-1; Glucose homeostasis; Insulin; Receptor; Insulin receptor substrate; Glucagon; Type 2 diabetes; Glucagon-like peptide 1 receptor; Insulin receptor; Insulin resistance; Chemistry; Diabetes mellitus; Biology; Medicine; Agonist","score_opus":0.0062355630849229475,"score_gpt":0.20442319228135006,"score_spread":0.1981876291964271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145089546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955144,0.0023932878,0.000025023419,0.0003326817,0.00018088376,0.00050556916,0.0000627964,0.00006564966,0.00091970945],"genre_scores_gemma":[0.99652874,0.00016824139,0.0006415797,0.0004684934,0.000120577846,0.000071973605,0.0002870979,0.000023617298,0.0016896472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872506,0.000030932857,0.00032069258,0.00032919314,0.00027372007,0.00032043262],"domain_scores_gemma":[0.9993476,0.00010418767,0.00013359627,0.00024277697,0.00008114667,0.000090670605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019923982,0.00021696174,0.00039005437,0.000090922076,0.00005862439,0.00001995884,0.000033233922,0.000057077985,0.00006058824],"category_scores_gemma":[0.00003643016,0.00018942406,0.00008651116,0.00014168366,0.00012405681,0.00012517213,0.000067165354,0.00007099355,0.000018339704],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113120754,0.0009630715,0.17784964,0.0004420448,0.00027739778,0.0000067980645,0.00006584592,0.000010014169,0.7531655,0.00025016707,0.01900499,0.047851417],"study_design_scores_gemma":[0.0039968663,0.0010227287,0.2395127,0.00029079753,0.00036811622,9.318479e-7,0.000070893526,0.0008262226,0.73623943,0.0003190871,0.017005516,0.00034668672],"about_ca_topic_score_codex":0.00020976113,"about_ca_topic_score_gemma":0.000021683298,"teacher_disagreement_score":0.061663065,"about_ca_system_score_codex":0.00006658957,"about_ca_system_score_gemma":0.000025874813,"threshold_uncertainty_score":0.7724489},"labels":[],"label_agreement":null},{"id":"W2145173022","doi":"10.1053/j.gastro.2014.08.037","title":"Glucagon-Like Peptide-2 Regulates Release of Chylomicrons From the Intestine","year":2014,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Diabetes Canada; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Chylomicron; Apolipoprotein B; Internal medicine; Endocrinology; Lipoprotein; Triglyceride; Retinyl palmitate; Cholesterol; Chemistry; Gastric emptying; Postprandial; Very low-density lipoprotein; Biology; Stomach; Medicine; Insulin; Vitamin; Retinol","score_opus":0.008090764951429057,"score_gpt":0.2158141166538767,"score_spread":0.20772335170244766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145173022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297845,0.00007800483,0.00050917524,0.0050297696,0.00019261213,0.00023153312,0.0000115805815,0.000041514602,0.00092738],"genre_scores_gemma":[0.9944228,0.000022443372,0.0015288643,0.0028532157,0.00012903639,0.00002066435,0.000103101935,0.0000160652,0.00090384507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911076,0.00007389358,0.00023906522,0.00021447479,0.000089646725,0.0002721506],"domain_scores_gemma":[0.9992132,0.00010824897,0.00011282925,0.00045279186,0.000041959076,0.000070966664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001327234,0.00013472182,0.00029606617,0.000046419365,0.000032677297,0.000005727653,0.00014006764,0.000036458125,0.00014445126],"category_scores_gemma":[0.000079457895,0.00008794046,0.00010023737,0.000047733116,0.00016799734,0.000024451956,0.000118079224,0.000093930044,0.000062208725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083027047,0.0003828487,0.9432213,0.00002935807,0.0004523157,0.000011815168,0.00016961835,0.000015232612,0.012373346,0.0003508154,0.033990994,0.008172133],"study_design_scores_gemma":[0.005066464,0.0029415812,0.95242643,0.000119785305,0.0006576146,0.00002170496,0.00011326387,0.0005071948,0.0047459137,0.0005986373,0.03271673,0.00008468139],"about_ca_topic_score_codex":0.00012198431,"about_ca_topic_score_gemma":0.00008894017,"teacher_disagreement_score":0.009205179,"about_ca_system_score_codex":0.00002168147,"about_ca_system_score_gemma":0.000008144936,"threshold_uncertainty_score":0.3586108},"labels":[],"label_agreement":null},{"id":"W2145219684","doi":"10.1016/j.jcjd.2013.05.002","title":"Assessment of Serum Creatinine and Kidney Function among Incident Metformin Users","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Metformin; Medicine; Renal function; Kidney disease; Diabetes mellitus; Creatinine; Medical prescription; Internal medicine; Type 2 diabetes; Urology; Endocrinology; Pharmacology","score_opus":0.008188151605702968,"score_gpt":0.2252812375075005,"score_spread":0.21709308590179754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145219684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499017,0.0004402224,0.000014526449,0.0005802107,0.00019814812,0.00026920286,0.000010384474,0.0000047143917,0.0034924422],"genre_scores_gemma":[0.99755317,0.000021643857,0.0010431259,0.0005834864,0.000070784605,0.0000097035945,0.000009287695,0.000014547129,0.0006942809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907225,0.000024324407,0.000359259,0.0000971049,0.00018253436,0.00026450606],"domain_scores_gemma":[0.9984372,0.000038504884,0.00026044302,0.00012940915,0.0002115182,0.00092288374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024987585,0.000125895,0.0003490497,0.00039135548,0.00004759301,0.000039319464,0.000064407104,0.000047675614,0.00074237055],"category_scores_gemma":[0.0001036488,0.000099177654,0.00008885271,0.00013281402,0.00009460392,0.0003025175,0.000013740239,0.0001105145,0.0000032611824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000010771917,0.000028451987,0.983639,0.000083374915,0.0004032551,0.000007803862,0.00006270926,0.0000040404316,0.0003626672,0.00014972377,0.00467151,0.01058636],"study_design_scores_gemma":[0.0011203242,0.00091861875,0.9936495,0.00026558433,0.00048012965,0.0000018795931,0.0003564941,0.0001552316,0.00066471385,0.00010808163,0.0021977434,0.00008173686],"about_ca_topic_score_codex":0.001104095,"about_ca_topic_score_gemma":0.00088866346,"teacher_disagreement_score":0.010504623,"about_ca_system_score_codex":0.00013719023,"about_ca_system_score_gemma":0.00040525745,"threshold_uncertainty_score":0.81284374},"labels":[],"label_agreement":null},{"id":"W2145821992","doi":"10.1002/pds.1802","title":"Trends in the prescription of anti‐diabetic medications in the United Kingdom: a population‐based analysis","year":2009,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"McGill University Health Centre","keywords":"Medicine; Medical prescription; Cohort; Metformin; Type 2 diabetes; Diabetes mellitus; Glycemic; Cohort study; Population; Pharmacoepidemiology; Internal medicine; Pediatrics; Emergency medicine; Endocrinology; Pharmacology; Environmental health","score_opus":0.050011325208388635,"score_gpt":0.3714214237948782,"score_spread":0.32141009858648956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145821992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484218,0.0003430766,0.00038200736,0.049307786,0.00003286957,0.00032927576,0.000007480751,0.000015601327,0.0011601009],"genre_scores_gemma":[0.9906135,0.00014060928,0.00019734679,0.008348147,0.000026200907,0.00003221833,0.00059930776,0.00000259005,0.000040060517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806094,0.0010367222,0.00042616602,0.00017850379,0.00011673809,0.0001809166],"domain_scores_gemma":[0.9986818,0.0009116059,0.00013031244,0.00022536943,0.000019448697,0.00003147455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027142093,0.00010626831,0.00035803727,0.0007798037,0.000060996044,0.000003283536,0.00011688385,0.000044471595,0.000068960195],"category_scores_gemma":[0.00015435349,0.000058935486,0.000099670404,0.0016827115,0.00006624139,0.000045400415,0.000010024423,0.00016540982,0.0000011346806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010643486,0.0004030106,0.9794819,0.0000200604,0.0002435605,0.0000059259605,0.00069440855,0.001647241,0.000067958295,0.0053465962,0.0015339057,0.010449047],"study_design_scores_gemma":[0.0014606152,0.000050743634,0.9798511,0.000019081885,0.0013256653,8.187002e-7,0.00009235629,0.014637706,0.000011662093,0.00054386223,0.0019565462,0.000049830152],"about_ca_topic_score_codex":0.0006190051,"about_ca_topic_score_gemma":0.00011374833,"teacher_disagreement_score":0.042191718,"about_ca_system_score_codex":0.000024876472,"about_ca_system_score_gemma":0.000009115744,"threshold_uncertainty_score":0.24033195},"labels":[],"label_agreement":null},{"id":"W2146108171","doi":"10.1093/eurheartj/ehr437","title":"Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?","year":2012,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Association de Recherche et d'Information en Cardiologie; Institut National de la Santé et de la Recherche Médicale; National Institute for Health and Care Research; American Research Institute of the South Caucasus","keywords":"Medicine; Intensive care medicine; Clinical trial; Diabetes mellitus; Albuminuria; Risk analysis (engineering); Diabetic retinopathy; Risk assessment; Type 2 diabetes; Internal medicine","score_opus":0.46307683860248244,"score_gpt":0.49790158486200853,"score_spread":0.034824746259526085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146108171","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026570377,0.99254495,0.00000538163,0.0005963527,0.0028340723,0.0018345166,0.000021816099,0.000047033685,0.0018501462],"genre_scores_gemma":[0.0002968997,0.99270034,0.0000657085,0.00046936315,0.0038647118,0.000038621478,0.00012061926,0.0001480259,0.0022957164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98580754,0.009192321,0.0030170623,0.000471792,0.0006958642,0.0008153954],"domain_scores_gemma":[0.9961689,0.0011728875,0.0013065404,0.0007726625,0.000045184286,0.0005338202],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025013104,0.00061313604,0.0032782753,0.00029829724,0.00017980694,0.00018457293,0.00043535797,0.00012197467,0.0006305817],"category_scores_gemma":[0.0010774523,0.00030099903,0.0015704868,0.00028611807,0.00013482351,0.00017306634,0.0002609308,0.0020183679,0.0007993044],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041393338,0.00054767233,0.0017625936,0.0017122943,0.00070716767,0.000066177025,0.000035937544,1.969156e-8,1.3148929e-7,0.0000077392815,0.12595537,0.8691635],"study_design_scores_gemma":[0.0021848043,0.00039021624,0.0039840713,0.012924908,0.003937902,0.000039756058,0.000010434235,7.8078733e-7,2.1075078e-7,0.000010701336,0.9762293,0.00028690335],"about_ca_topic_score_codex":5.9006885e-7,"about_ca_topic_score_gemma":0.0000015172287,"teacher_disagreement_score":0.8688766,"about_ca_system_score_codex":0.0002858606,"about_ca_system_score_gemma":0.00032251424,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W2146264128","doi":"10.1056/nejmoa1504720","title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12000,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Placebo; Confidence interval; Relative risk; Diabetes mellitus; Stroke (engine); Angina; Type 2 diabetes; Cardiology; Endocrinology","score_opus":0.03667286996223124,"score_gpt":0.28962934826844844,"score_spread":0.2529564783062172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146264128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711436,0.023785489,0.000014487456,0.0026348094,0.00055513805,0.0001368483,3.8610716e-7,0.000007956599,0.0017212615],"genre_scores_gemma":[0.9970699,0.0008811075,0.0002459254,0.0005255445,0.0009053759,0.0000012495217,0.000003770881,0.000010533011,0.0003566234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988003,0.000058356964,0.00035846946,0.00010654062,0.0005067202,0.00016963175],"domain_scores_gemma":[0.99915123,0.00005332831,0.000093334536,0.00019048307,0.00013519861,0.00037640514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013612175,0.00012717332,0.000715279,0.00020049025,0.000008393732,0.000006139442,0.00005126102,0.000038621005,0.00003948493],"category_scores_gemma":[0.00042666667,0.00007527038,0.000081143124,0.0001668377,0.000058525955,0.00007830213,0.000024949271,0.00015943089,0.0000035153248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017874851,0.00006794824,0.91801804,0.00003954982,0.0008957813,0.000502502,0.00043642745,0.000012654539,0.00001684682,0.000030765725,0.0035202932,0.07628046],"study_design_scores_gemma":[0.058333818,0.0018077426,0.85526615,0.00029435876,0.0013615959,0.00006198569,0.00017943133,0.000021208081,0.000033074837,0.000682053,0.08187098,0.0000876256],"about_ca_topic_score_codex":0.00009606587,"about_ca_topic_score_gemma":0.00003169207,"teacher_disagreement_score":0.078350686,"about_ca_system_score_codex":0.000055907232,"about_ca_system_score_gemma":0.000089350666,"threshold_uncertainty_score":0.30694368},"labels":[],"label_agreement":null},{"id":"W2146400000","doi":"10.1152/ajpendo.00315.2002","title":"Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes","year":2003,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Research Resources","keywords":"Medicine; Internal medicine; Endocrinology; Bolus (digestion); Type 2 diabetes; Hemoglobin; Diabetes mellitus; Glucose homeostasis; Glucagon-like peptide-1; Insulin; Agonist; Hypoglycemia; Insulin resistance; Receptor","score_opus":0.005362749000354293,"score_gpt":0.2419848633039627,"score_spread":0.2366221143036084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146400000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300903,0.0061545405,0.000004098292,0.00010158967,0.00025990882,0.0001553491,0.0000014009431,0.000004870327,0.0003091956],"genre_scores_gemma":[0.99620444,0.002877505,0.00067725877,0.00013898865,0.0000402552,0.000004188224,0.0000020510308,0.000009061345,0.00004626159],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99888986,0.00018714313,0.00042915254,0.0001413181,0.0000916756,0.00026081954],"domain_scores_gemma":[0.999012,0.0001993127,0.0005042194,0.00010845865,0.00010545792,0.000070551636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001083786,0.00014029768,0.0008821843,0.00027293,0.000016844015,0.0000015377386,0.00006803931,0.000039437422,0.000017323438],"category_scores_gemma":[0.00014893545,0.000109236746,0.000099495206,0.00022362727,0.00042405396,0.000052807278,0.0000209214,0.00017150924,0.0000013789447],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017790465,0.0012207307,0.019999877,0.00034227525,0.0011580375,0.00021970489,0.00034845585,0.000008381802,0.87831306,0.010094571,0.00012656613,0.08638928],"study_design_scores_gemma":[0.003736465,0.006667671,0.7397739,0.000105667,0.00091017055,0.00024816385,0.00036243093,0.0000039832985,0.24298242,0.0019364682,0.003130108,0.0001425587],"about_ca_topic_score_codex":0.00000833407,"about_ca_topic_score_gemma":0.000001185838,"teacher_disagreement_score":0.719774,"about_ca_system_score_codex":0.000012089951,"about_ca_system_score_gemma":0.00006569498,"threshold_uncertainty_score":0.4454545},"labels":[],"label_agreement":null},{"id":"W2146468024","doi":"10.1093/ndtplus/4.s2.31","title":"General &amp; clinical epidemiology CKD 1-5 (1)","year":2011,"lang":"en","type":"article","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Epidemiology; Clinical epidemiology; Data science; Intensive care medicine; Internal medicine; Computer science","score_opus":0.3540145266919351,"score_gpt":0.47412967746807877,"score_spread":0.12011515077614365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146468024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8371071,0.0010131241,0.004428453,0.019519113,0.011042651,0.000698214,0.0000131608185,0.0002104886,0.12596768],"genre_scores_gemma":[0.330696,0.013921969,0.31276467,0.21884413,0.02308732,0.0000508244,0.00020044524,0.00020597877,0.10022866],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952368,0.00096957217,0.0025131397,0.00045113932,0.00020569828,0.00062364363],"domain_scores_gemma":[0.9953563,0.00094852573,0.000610749,0.00058315176,0.00015584182,0.0023454214],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007523613,0.00023753066,0.001228552,0.00010993561,0.000119002485,0.000015994601,0.00026807355,0.00034275142,0.003520394],"category_scores_gemma":[0.011910235,0.00016554962,0.0010720645,0.00010955794,0.00041101957,0.00010315764,0.00015304027,0.0011924644,0.001827438],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028982322,0.0010939697,0.63054013,0.000010863473,0.000573547,0.00015242324,0.000024213738,9.180948e-8,0.0000028921982,0.0013478413,0.32196206,0.04400215],"study_design_scores_gemma":[0.004056613,0.0014873152,0.46703437,0.0000810712,0.0005691336,0.00017057217,0.000010501567,0.000032930344,0.000004902001,0.006030549,0.5203705,0.00015159095],"about_ca_topic_score_codex":0.0000074276713,"about_ca_topic_score_gemma":0.0000020934158,"teacher_disagreement_score":0.50641114,"about_ca_system_score_codex":0.000048543683,"about_ca_system_score_gemma":0.00028734226,"threshold_uncertainty_score":0.99894977},"labels":[],"label_agreement":null},{"id":"W2146539382","doi":"10.1016/j.bmc.2009.12.032","title":"Design, synthesis and in vitro characterization of Glucagon-Like Peptide-1 derivatives for pancreatic beta cell imaging by SPECT","year":2009,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lawson Health Research Institute","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Chemistry; DOTA; Chinese hamster ovary cell; Peptide; Linker; In vitro; In vivo; Insulinoma; Alpha cell; Beta cell; Receptor; Biochemistry; Islet; Chelation; Pancreas; Insulin; Internal medicine","score_opus":0.009328616978725229,"score_gpt":0.2207022946865611,"score_spread":0.21137367770783588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146539382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995138,0.00097403285,0.0016354518,0.001205291,0.000025025502,0.00049799326,0.000014180079,0.000032107004,0.00047794593],"genre_scores_gemma":[0.9978347,0.00023864913,0.00094027945,0.0002319924,0.00006758785,0.00003123131,0.00014444876,0.000019197869,0.00049191795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990325,0.000014478506,0.00028218928,0.00027427694,0.0001652976,0.00023123474],"domain_scores_gemma":[0.999501,0.000085260064,0.00013862703,0.00017409828,0.0000315387,0.000069468086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016819422,0.00018817364,0.00039437518,0.00005100368,0.000028767046,0.000009746832,0.00006994837,0.000044528228,0.00006177953],"category_scores_gemma":[0.000066377324,0.0001636014,0.000041623578,0.00014157091,0.000085587875,0.000061869534,0.000018393248,0.00006353317,0.0000013557373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025871536,0.0002244468,0.0017351222,0.00044841075,0.00004646567,0.000011537221,0.0001234317,2.9124065e-8,0.9891891,9.671136e-7,0.0003236202,0.007638147],"study_design_scores_gemma":[0.0014730139,0.00011487833,0.009504974,0.0002865585,0.00035275976,0.0000074246527,0.00028598984,0.0001211117,0.98746836,0.000017973896,0.00023995042,0.00012698809],"about_ca_topic_score_codex":0.0000056580748,"about_ca_topic_score_gemma":8.1304776e-8,"teacher_disagreement_score":0.007769852,"about_ca_system_score_codex":0.000081169914,"about_ca_system_score_gemma":0.000039635255,"threshold_uncertainty_score":0.66714716},"labels":[],"label_agreement":null},{"id":"W2146723462","doi":"10.2337/dc09-2227","title":"Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database","year":2010,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"","keywords":"Medicine; Nested case-control study; Diabetes mellitus; Heart failure; Type 2 diabetes; Research design; Internal medicine; Case-control study; Database; Intensive care medicine; Endocrinology; Statistics","score_opus":0.017501435219133936,"score_gpt":0.31114093879010374,"score_spread":0.2936395035709698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146723462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954408,0.0004130332,5.5227154e-8,0.00097103347,0.00009828519,0.0027065421,0.0002922091,0.00002339649,0.00005466845],"genre_scores_gemma":[0.99860936,0.00000647561,0.0005816317,0.00020877941,0.000058917336,0.00022046168,0.00024834578,0.000029412613,0.000036584806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983051,0.0002521581,0.00023144428,0.000384175,0.00042964824,0.00039751493],"domain_scores_gemma":[0.997824,0.00092946587,0.00007248132,0.0006887046,0.00037125926,0.000114051676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002477552,0.00022754207,0.00048366282,0.00013974689,0.00010583041,0.000050146347,0.000086998545,0.000054609125,0.00003219106],"category_scores_gemma":[0.00028777594,0.00012620832,0.000044768218,0.00031520578,0.00012250857,0.00017328045,0.000074583775,0.00019928349,0.000012784339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015687359,0.0018700275,0.9915335,0.000029107632,0.00059280556,0.000062610365,0.0016009915,0.0000010124355,0.00020949129,0.00000882859,0.0001739322,0.0037607881],"study_design_scores_gemma":[0.009868858,0.004610971,0.97778946,0.000035057335,0.00074636174,5.0622896e-7,0.0047491086,0.00003816032,0.00024470204,0.0000030945932,0.0017911075,0.00012258855],"about_ca_topic_score_codex":0.00038295554,"about_ca_topic_score_gemma":0.0010721437,"teacher_disagreement_score":0.013744048,"about_ca_system_score_codex":0.00006887741,"about_ca_system_score_gemma":0.000049548977,"threshold_uncertainty_score":0.5146626},"labels":[],"label_agreement":null},{"id":"W2146901298","doi":"10.2337/dc08-9025","title":"Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy","year":2008,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3837,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Insulet Corporation; Novo Nordisk; Sanofi; GlaxoSmithKline; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psychological intervention; Algorithm; Consensus algorithm; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; MEDLINE; Diabetes management; Computer science; Nursing","score_opus":0.02024918920528253,"score_gpt":0.2630219083756123,"score_spread":0.24277271917032975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146901298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97958195,0.018219423,0.000012234488,0.00028046564,0.00014462399,0.001222908,0.000030206085,0.000016213917,0.0004919632],"genre_scores_gemma":[0.99179256,0.0057543064,0.0016763967,0.0003751445,0.000040115316,0.00019273754,0.0000989967,0.000017539585,0.00005222517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990073,0.000024304529,0.00027919083,0.00017788875,0.00029769106,0.00021366787],"domain_scores_gemma":[0.99932146,0.00019313396,0.000090200076,0.00021373211,0.00012361242,0.000057854508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013556208,0.00013269669,0.0003199386,0.00009666251,0.000031965214,0.0000022645831,0.00007556229,0.00006444739,0.00003110029],"category_scores_gemma":[0.000025741807,0.00009072897,0.00007255365,0.00018551291,0.00014556207,0.000020779162,0.000048602917,0.000055980974,0.000002247339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085167725,0.00028897356,0.2626185,0.0006551089,0.0006727704,0.000012772469,0.00096267,0.0000055932887,0.0001501007,0.00019228607,0.00077076716,0.73358524],"study_design_scores_gemma":[0.013857099,0.0024916818,0.9577616,0.0009140084,0.00059611624,0.0000013438136,0.0035777548,0.0041623362,0.010517592,0.000110457826,0.005750967,0.0002590614],"about_ca_topic_score_codex":0.0000049083674,"about_ca_topic_score_gemma":0.0000025239528,"teacher_disagreement_score":0.7333262,"about_ca_system_score_codex":0.00004265031,"about_ca_system_score_gemma":0.00003881021,"threshold_uncertainty_score":0.369982},"labels":[],"label_agreement":null},{"id":"W2147076608","doi":"10.1016/j.jcjd.2013.08.081","title":"Canagliflozin Demonstrates Durable Glycemic Improvements Over 104 Weeks Compared with Glimepiride in Subjects with Type 2 Diabetes Mellitus on Metformin","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glimepiride; Medicine; Canagliflozin; Metformin; Glycemic; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.008738853057500107,"score_gpt":0.20726640736907675,"score_spread":0.19852755431157665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147076608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932069,0.0019099669,6.4527967e-7,0.00051987893,0.0001737199,0.00080189295,0.0000130603985,0.000016208423,0.0033576833],"genre_scores_gemma":[0.9979514,0.000032706066,0.0004239997,0.0009278879,0.000079291225,0.000041238865,0.000031841588,0.00005631022,0.0004553105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977546,0.00004533614,0.0005147041,0.0002920786,0.00037747962,0.0010158037],"domain_scores_gemma":[0.9979808,0.00011522404,0.00030499636,0.0003202384,0.00029256332,0.0009861885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021955556,0.0003883734,0.0007647815,0.0007887073,0.00009739844,0.00012871719,0.00022716577,0.000090220325,0.0003003117],"category_scores_gemma":[0.00006107215,0.0002685758,0.00008818717,0.0005963408,0.00016235771,0.00042594242,0.000014011835,0.0003304496,0.000045930185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001430466,0.00017950659,0.9860486,0.00015492259,0.00101533,0.00018907143,0.00015655803,0.00011595196,0.0019750162,0.00007118615,0.0035099587,0.006440887],"study_design_scores_gemma":[0.015684754,0.013880188,0.933522,0.0030897188,0.00113696,0.00001247945,0.0010125537,0.00060992973,0.025850419,0.0003974568,0.0038455757,0.00095796684],"about_ca_topic_score_codex":0.008115898,"about_ca_topic_score_gemma":0.05018211,"teacher_disagreement_score":0.052526567,"about_ca_system_score_codex":0.00055201526,"about_ca_system_score_gemma":0.001030564,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W2147189355","doi":"10.1161/circulationaha.113.004652","title":"Rosiglitazone and Cardiovascular Outcomes","year":2013,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Gerontology; Epidemiology; Population; Disease; Demography; Family medicine; Internal medicine; Environmental health; Endocrinology","score_opus":0.019669885432068743,"score_gpt":0.22765214110673204,"score_spread":0.2079822556746633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147189355","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15124929,0.012233709,0.0009159426,0.7996024,0.0012535572,0.0047857985,0.000018482348,0.0004885508,0.029452292],"genre_scores_gemma":[0.43501413,0.00025023264,0.00063581945,0.5455669,0.0026801487,0.0003213366,0.0022803585,0.00013460046,0.0131164575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904203,0.000022697706,0.00015228822,0.00029555918,0.0003138724,0.00017354444],"domain_scores_gemma":[0.9993975,0.000021896902,0.000045847046,0.00045114418,0.00004700365,0.00003658802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074189324,0.00018682721,0.00045797785,0.00012469132,0.000033516968,0.000039031427,0.000029479137,0.00026580677,0.000108333035],"category_scores_gemma":[0.000017681326,0.00015236021,0.0002646733,0.000051324507,0.000027194174,0.000070552225,0.000027548327,0.00020575518,0.00017582679],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016527556,0.000026246555,0.12777762,0.0005112065,0.0028941764,0.00012119316,0.0000455666,0.000010828155,0.000018165105,0.00005505727,0.8410138,0.027524486],"study_design_scores_gemma":[0.0006833885,0.000019334268,0.38995534,0.000060069215,0.0015140533,0.000005428852,0.0000050637855,0.00009203852,0.0000043082814,0.00015787286,0.60735846,0.00014464132],"about_ca_topic_score_codex":0.00003898351,"about_ca_topic_score_gemma":2.1959765e-7,"teacher_disagreement_score":0.28376484,"about_ca_system_score_codex":0.00006403592,"about_ca_system_score_gemma":0.000010706599,"threshold_uncertainty_score":0.6213069},"labels":[],"label_agreement":null},{"id":"W2147618898","doi":"10.1007/s00223-015-9993-5","title":"Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis","year":2015,"lang":"en","type":"article","venue":"Calcified Tissue International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Population; Hazard ratio; Osteoporosis; Cohort; Proportional hazards model; Bone fracture; Endocrinology; Confidence interval; Environmental health","score_opus":0.0349381426331615,"score_gpt":0.2886355376951096,"score_spread":0.2536973950619481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147618898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688525,0.00007832007,0.003404248,0.0073347483,0.0002743466,0.00068346044,0.0003224269,0.00007341539,0.0009438013],"genre_scores_gemma":[0.98264295,0.000010071319,0.0010437465,0.0019358799,0.000091400274,0.00006110989,0.002501614,0.000022140808,0.011691092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838775,0.00006244735,0.000310404,0.00028780068,0.0007811136,0.0001705037],"domain_scores_gemma":[0.9984737,0.00020117214,0.0003615452,0.00035333147,0.0004911832,0.00011908944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024738934,0.0001833846,0.0003712463,0.00024269818,0.000058905276,0.00006175359,0.00014066933,0.00009016469,0.00056404015],"category_scores_gemma":[0.0002744426,0.00012023772,0.00015555386,0.00043500445,0.000068733774,0.00011469723,0.00003367348,0.00014697314,0.000037993294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005184718,0.00047696763,0.9158839,0.000009665641,0.008201881,0.00002427328,0.0003574376,0.0038353375,0.00009526473,0.00014224982,0.06869704,0.0017575327],"study_design_scores_gemma":[0.0030665542,0.00031619173,0.77282536,0.000079996404,0.004376837,0.0000012774225,0.00009602758,0.007211058,0.0017413393,0.00002607567,0.21003915,0.00022011194],"about_ca_topic_score_codex":0.0010568555,"about_ca_topic_score_gemma":0.00017923968,"teacher_disagreement_score":0.1430585,"about_ca_system_score_codex":0.00030131143,"about_ca_system_score_gemma":0.000072112365,"threshold_uncertainty_score":0.6175844},"labels":[],"label_agreement":null},{"id":"W2147679298","doi":"10.2337/diabetes.51.2007.s434","title":"The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion","year":2002,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto","funders":"","keywords":"Proglucagon; Endocrinology; Internal medicine; Exocytosis; Insulin; Secretion; Glucose homeostasis; Glucagon-like peptide-1; Biology; Intracellular; Enteroendocrine cell; Glucagon; Chemistry; Cell biology; Insulin resistance; Diabetes mellitus; Type 2 diabetes; Medicine; Hormone; Endocrine system","score_opus":0.05160646268758857,"score_gpt":0.31443110046365597,"score_spread":0.2628246377760674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147679298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011656219,0.98294467,8.5217255e-7,0.00013886324,0.00014781932,0.002010765,0.000059991806,0.00004410515,0.0029966866],"genre_scores_gemma":[0.030004885,0.9685025,0.000011492251,0.000038112317,0.000064844426,0.00032613837,0.00022724306,0.000040038827,0.0007847436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986354,0.000098576515,0.0005047486,0.00022083272,0.00029927003,0.00024116875],"domain_scores_gemma":[0.99785244,0.00096626126,0.00047173048,0.0005405182,0.00012290185,0.00004614426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023189491,0.00028484303,0.0009344409,0.00013023017,0.00010811635,0.000014226099,0.00021294005,0.00013814845,0.000078586236],"category_scores_gemma":[0.00033127595,0.00013409652,0.00038638109,0.00043684407,0.00013165445,0.000030514911,0.00004326168,0.00021605243,0.000046022175],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012092026,0.00046674378,0.00022805748,0.009517004,0.0012640952,9.712812e-7,0.00008246108,0.000007681527,0.000016656315,0.00030633,0.00088466925,0.98721325],"study_design_scores_gemma":[0.0006531687,0.0004738579,0.00015264223,0.011830662,0.0030144558,2.3994082e-7,0.00006421801,0.00052036135,0.00092447276,0.000055467088,0.9821356,0.00017486127],"about_ca_topic_score_codex":0.0000053277354,"about_ca_topic_score_gemma":0.000001733077,"teacher_disagreement_score":0.9870384,"about_ca_system_score_codex":0.000058899703,"about_ca_system_score_gemma":0.00004659027,"threshold_uncertainty_score":0.54682976},"labels":[],"label_agreement":null},{"id":"W2147734798","doi":"10.1146/annurev-physiol-021113-170315","title":"Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond","year":2013,"lang":"en","type":"review","venue":"Annual Review of Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Foundation of Korea; Japan Society for the Promotion of Science; National Research Foundation","keywords":"Glucose homeostasis; Incretin; Glucagon-like peptide-1; Endogeny; Exenatide; Homeostasis; Receptor; Secretion; Pharmacology; Endocrinology; Chemistry; Diabetes mellitus; Type 2 diabetes; Internal medicine; Biology; Medicine; Insulin resistance","score_opus":0.022967393265536835,"score_gpt":0.32587008643112886,"score_spread":0.30290269316559204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147734798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002538282,0.99376136,3.9767656e-7,0.00013931417,0.00020974473,0.0025274728,0.00012346669,0.000031973035,0.003180861],"genre_scores_gemma":[0.000002637384,0.99494946,0.00026807925,0.0016017528,0.00014232434,0.00041936405,0.00088817935,0.000056463767,0.0016717592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777645,0.00018036943,0.000879378,0.000582539,0.00019192466,0.0003893624],"domain_scores_gemma":[0.9981672,0.00017686877,0.000597337,0.00071865256,0.00016761506,0.00017230495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022347308,0.00056554284,0.0043503945,0.00017900973,0.000033440338,0.0000061854084,0.00020346731,0.00021370602,0.00057857105],"category_scores_gemma":[0.000098991164,0.00036724473,0.00073838414,0.00028140718,0.00020041509,0.000092842376,0.0003023912,0.00023261787,0.00047320756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000027460198,0.00012212069,2.444647e-7,0.26633897,0.0006268872,0.000005383742,0.000013150239,1.1668205e-9,0.0000030685756,0.00019776956,0.037906185,0.69478345],"study_design_scores_gemma":[0.0002649135,0.00057811686,0.00002155717,0.08349456,0.005255595,0.000014698846,0.000020122292,9.365999e-8,0.0000032387347,0.000058488276,0.9100462,0.0002424067],"about_ca_topic_score_codex":0.0000151871245,"about_ca_topic_score_gemma":6.571945e-7,"teacher_disagreement_score":0.87214005,"about_ca_system_score_codex":0.000051532326,"about_ca_system_score_gemma":0.00012457365,"threshold_uncertainty_score":0.9998779},"labels":[],"label_agreement":null},{"id":"W2147764623","doi":"10.1177/1479164112475102","title":"Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial","year":2013,"lang":"en","type":"review","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Observational study; Randomized controlled trial; Population; Type 2 diabetes; Metformin; Clinical trial; Diabetes mellitus; Incidence (geometry); Internal medicine; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.20307089588001462,"score_gpt":0.4293408538119436,"score_spread":0.22626995793192897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147764623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007410502,0.96729714,0.0000038375124,0.00050996797,0.00026992988,0.024273686,0.00015210557,0.00002233981,0.000060517068],"genre_scores_gemma":[0.003050057,0.9838206,0.000019060952,0.000103042556,0.0006431378,0.011469164,0.0004560481,0.000076649994,0.00036224548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936223,0.0026305749,0.0010252349,0.00079008675,0.0010516832,0.00088011945],"domain_scores_gemma":[0.9881441,0.009794606,0.00022821671,0.001104757,0.00033844012,0.00038988312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011873923,0.0005609035,0.004412143,0.00038570512,0.00039957403,0.00032102867,0.00032739333,0.00020990241,0.000048312584],"category_scores_gemma":[0.004564955,0.0002674741,0.0025990692,0.00052029797,0.0005584729,0.00012832612,0.00028861267,0.0005566951,0.000026909269],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043625333,0.00054750347,0.0018914483,0.024531959,0.0308895,0.000011792158,0.00018647262,0.0000058116957,5.193893e-7,0.0023183837,0.0045087743,0.9307453],"study_design_scores_gemma":[0.05467013,0.0003102,0.0009260755,0.001653895,0.016147733,2.088859e-7,0.0001656142,0.00037441857,0.0000010819149,0.00033411782,0.9250813,0.0003351885],"about_ca_topic_score_codex":0.00003852947,"about_ca_topic_score_gemma":0.0000044414046,"teacher_disagreement_score":0.9304101,"about_ca_system_score_codex":0.00015518606,"about_ca_system_score_gemma":0.0004055299,"threshold_uncertainty_score":0.99997777},"labels":[],"label_agreement":null},{"id":"W2147767541","doi":"10.1177/1479164115579001","title":"Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease","year":2015,"lang":"en","type":"article","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; Sanofi; Eli Lilly and Company","keywords":"Linagliptin; Medicine; Internal medicine; Diabetes mellitus; Kidney disease; Placebo; Type 2 diabetes; Insulin; Dipeptidyl peptidase-4 inhibitor; Gastroenterology; Type 2 Diabetes Mellitus; Endocrinology; Pathology","score_opus":0.026080909726013672,"score_gpt":0.2849093727592314,"score_spread":0.2588284630332177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147767541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546463,0.010846227,0.0000013427891,0.0020244154,0.00004732482,0.0013936802,0.000030266141,0.000027091683,0.00016501],"genre_scores_gemma":[0.99874306,0.00039835877,0.000044445253,0.0001915899,0.00006261053,0.00017493976,0.00014494419,0.000037067795,0.00020296853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759406,0.00028032062,0.00023356426,0.00045200504,0.0008818673,0.0005582137],"domain_scores_gemma":[0.9978368,0.00012474536,0.000065583146,0.0005906751,0.00035877962,0.001023393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090846006,0.00022388736,0.00034620924,0.00031440012,0.000118655546,0.000065143584,0.00013022406,0.000056668214,0.00001773543],"category_scores_gemma":[0.0005553944,0.00014749865,0.000096174466,0.00071231823,0.000458201,0.00012028362,0.00020910123,0.00023451057,0.0000067614246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002866389,0.0011095951,0.9916853,0.0015554042,0.00022513495,0.0000191128,0.0001371293,0.000042528387,0.0003807353,0.0004952137,0.0011161221,0.0029471286],"study_design_scores_gemma":[0.010893823,0.0015336169,0.9700118,0.0021351832,0.0005135746,6.8511625e-8,0.00017999113,0.00860257,0.0013767718,0.00056688435,0.0038955002,0.000290265],"about_ca_topic_score_codex":0.000015147143,"about_ca_topic_score_gemma":0.00000841788,"teacher_disagreement_score":0.021673504,"about_ca_system_score_codex":0.00016976646,"about_ca_system_score_gemma":0.0006854329,"threshold_uncertainty_score":0.60148203},"labels":[],"label_agreement":null},{"id":"W2148162269","doi":"10.1016/j.ahj.2015.02.002","title":"Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo","year":2015,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Lixisenatide; Medicine; Placebo; Internal medicine; Acute coronary syndrome; Cardiology; End point; Type 2 diabetes; Diabetes mellitus; Myocardial infarction; Endocrinology; Pathology; Alternative medicine","score_opus":0.06478109415188663,"score_gpt":0.3256364134488027,"score_spread":0.2608553192969161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148162269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672955,0.00065214135,0.00046993338,0.00037299973,0.0001932258,0.0014936458,0.000004981566,0.0000054995157,0.00007801116],"genre_scores_gemma":[0.99546194,0.00044751138,0.0038307041,0.000062429324,0.000062189065,0.000060075246,0.000029437799,0.00001593052,0.00002977669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975211,0.00055478263,0.0006324742,0.00018006112,0.00091790844,0.00019366125],"domain_scores_gemma":[0.9987606,0.0002882921,0.00027903216,0.00019655889,0.0003160005,0.00015955236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035803437,0.000147573,0.0007340738,0.0003993719,0.000018659826,0.0000131438,0.000052562635,0.000031876425,0.000034369998],"category_scores_gemma":[0.00059397536,0.00013182638,0.00013901999,0.00028000647,0.00013306194,0.00014357858,0.00003746023,0.0001598709,0.0000017661221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12909573,0.0029618188,0.6640122,0.0001819719,0.005224629,0.0020903873,0.0015822417,0.0020770396,0.0014545112,0.000025114856,0.0010607461,0.19023359],"study_design_scores_gemma":[0.13256805,0.0064687775,0.8530742,0.0003573815,0.0017047332,0.0004926013,0.00041731313,0.0040407614,0.00055280403,0.00004402103,0.000087038374,0.00019232807],"about_ca_topic_score_codex":0.00006060912,"about_ca_topic_score_gemma":0.000013011205,"teacher_disagreement_score":0.19004127,"about_ca_system_score_codex":0.0002745858,"about_ca_system_score_gemma":0.0004165149,"threshold_uncertainty_score":0.5375724},"labels":[],"label_agreement":null},{"id":"W2148288005","doi":"10.1503/cmaj.121771","title":"Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study","year":2013,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Hospital; University of Toronto; St. Michael's Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; F. Hoffmann-La Roche; Novo Nordisk; Sanofi; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Telmisartan; Medicine; Irbesartan; Internal medicine; Valsartan; Myocardial infarction; Hazard ratio; Diabetes mellitus; Stroke (engine); Population; Heart failure; Cardiology; Type 2 diabetes; Confidence interval; Endocrinology; Blood pressure","score_opus":0.004235041393288549,"score_gpt":0.22381679886747824,"score_spread":0.2195817574741897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148288005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960269,0.000023815097,0.000024341089,0.000797593,0.00010942444,0.002974367,0.000016917402,0.0000072704024,0.000019399144],"genre_scores_gemma":[0.99895847,4.5494727e-7,0.00028183372,0.0003003186,0.00006388659,0.00018240487,0.00016709483,0.00001351281,0.000032043627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981161,0.00021284312,0.0003285362,0.00016720784,0.0008491277,0.00032622402],"domain_scores_gemma":[0.99824864,0.00022787631,0.0002066993,0.00009765186,0.00052496645,0.0006941489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010208373,0.0001261177,0.00043121964,0.00023138242,0.0000840216,0.000030391408,0.00006342047,0.00006968149,0.00026782847],"category_scores_gemma":[0.00044576603,0.000100189885,0.00011023519,0.00021534177,0.00001732016,0.00009222411,0.000006364902,0.00015976667,0.000008048341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006352858,0.0005655102,0.99641323,0.000054655382,0.0007316598,0.000006006963,0.00006396011,0.00006883501,0.0000010791538,0.0000024090994,0.0013092259,0.0007198998],"study_design_scores_gemma":[0.0072167227,0.00043103105,0.99027896,0.00036768714,0.00031330026,4.8361287e-8,0.00007175568,0.000988347,0.000008661399,0.00001185986,0.00021490021,0.00009670393],"about_ca_topic_score_codex":0.0018431653,"about_ca_topic_score_gemma":0.0020691657,"teacher_disagreement_score":0.007153194,"about_ca_system_score_codex":0.0009958744,"about_ca_system_score_gemma":0.00062046066,"threshold_uncertainty_score":0.4085625},"labels":[],"label_agreement":null},{"id":"W2148606668","doi":"10.2337/diabetes.53.suppl_3.s205","title":"Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R–Dependent Glucose Homeostasis In Vivo","year":2004,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canada Research Chairs; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Ex vivo; Glucagon-like peptide 1 receptor; Glucagon; Glucose homeostasis; Insulin; Receptor; Glucagon-like peptide-1; Biology; Chemistry; Type 2 diabetes; Medicine; Agonist; Insulin resistance; Diabetes mellitus; In vitro; Biochemistry","score_opus":0.009064261146641871,"score_gpt":0.23273774172395992,"score_spread":0.22367348057731803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148606668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072605,0.002000858,0.000022345926,0.0040945667,0.00041905142,0.0020977105,0.0001611304,0.00019586766,0.00028240783],"genre_scores_gemma":[0.9953433,0.00040442738,0.0011989201,0.00084675994,0.00026320282,0.00045388492,0.00033573934,0.00008629742,0.0010674258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968314,0.00011356777,0.0006349466,0.00084144744,0.00052469934,0.0010539328],"domain_scores_gemma":[0.99869233,0.00010497606,0.00016066554,0.0006097993,0.00014954305,0.0002826699],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042180796,0.0005166868,0.00081319746,0.00064475636,0.000101260965,0.00010014598,0.00022239551,0.0002125011,0.00011720566],"category_scores_gemma":[0.00024571855,0.00042780163,0.00015354842,0.00066397217,0.00010286444,0.00024974742,0.00019224515,0.00025651735,0.00022397062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028604636,0.0011572186,0.025710894,0.00046745982,0.00028225104,0.00034625956,0.0010337406,0.00028997916,0.88293266,0.000103936014,0.00015987124,0.08722971],"study_design_scores_gemma":[0.005147234,0.0012702873,0.017058974,0.00051169755,0.00016213724,0.0000026435068,0.0002464097,0.00006187279,0.9739396,0.00023033745,0.0008687072,0.00050008454],"about_ca_topic_score_codex":0.00039517722,"about_ca_topic_score_gemma":0.00062600983,"teacher_disagreement_score":0.09100698,"about_ca_system_score_codex":0.0015738023,"about_ca_system_score_gemma":0.00018769961,"threshold_uncertainty_score":0.9998174},"labels":[],"label_agreement":null},{"id":"W2149341824","doi":"10.2337/db07-0697","title":"Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice","year":2007,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Vildagliptin; Incretin; Glucagon-like peptide-1; Internal medicine; Receptor; Endocrinology; Glucagon; Chemistry; Diabetes mellitus; Medicine; Insulin; Type 2 diabetes","score_opus":0.012460428607932736,"score_gpt":0.26626339477436334,"score_spread":0.2538029661664306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149341824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267864,0.0029413046,0.0004707569,0.0011147828,0.00038487412,0.0021109555,0.00003854142,0.000046906236,0.00021320746],"genre_scores_gemma":[0.9943882,0.00031454014,0.0028296446,0.00032049353,0.0002131773,0.00034464832,0.000076894365,0.00004180541,0.0014705816],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854463,0.000029147775,0.0004203375,0.00030966103,0.00018604983,0.0005101539],"domain_scores_gemma":[0.998618,0.0006338924,0.00020404755,0.00031181716,0.00013484184,0.00009741187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057261257,0.00021887895,0.00044954097,0.0002557171,0.000112874724,0.000024215236,0.00015271887,0.000084763946,0.000018695584],"category_scores_gemma":[0.00038680746,0.00016432081,0.00015600443,0.00024581442,0.0001065171,0.000090567206,0.000098708806,0.000103914586,0.0000024330427],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022436792,0.002096402,0.7086765,0.0021316854,0.003022551,0.00001288044,0.0026213734,0.000047286023,0.16865656,0.008347218,0.009692101,0.092451766],"study_design_scores_gemma":[0.01424881,0.0010683686,0.346467,0.00034078633,0.0022460388,0.0000012962548,0.010219528,0.00083465734,0.51132345,0.00058503466,0.112110786,0.00055427436],"about_ca_topic_score_codex":0.0001232586,"about_ca_topic_score_gemma":0.00026699758,"teacher_disagreement_score":0.36220953,"about_ca_system_score_codex":0.00006932712,"about_ca_system_score_gemma":0.000040610517,"threshold_uncertainty_score":0.67008084},"labels":[],"label_agreement":null},{"id":"W2149379354","doi":"10.1016/j.amjmed.2010.04.002","title":"Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies","year":2010,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Incretin; Type 2 diabetes; Intensive care medicine; Diabetes mellitus; MEDLINE; Endocrinology","score_opus":0.008812078602495674,"score_gpt":0.26882489118417274,"score_spread":0.2600128125816771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149379354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9183858,0.003877304,0.000028258639,0.0760154,0.00028866823,0.00019412485,5.315393e-7,0.000009613451,0.0012003134],"genre_scores_gemma":[0.99456346,0.00026522993,0.00032041132,0.0040293783,0.0006720903,0.0000038263147,0.0000013886648,0.000017867013,0.00012633392],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998584,0.00019651475,0.000473186,0.00008234735,0.0004342116,0.00022977657],"domain_scores_gemma":[0.9972449,0.0010748077,0.0009710674,0.00040915838,0.0002311186,0.000068930705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026564654,0.0001440686,0.00053584925,0.00008942054,0.00012150846,0.000007539614,0.00039970412,0.00001569864,0.0001601974],"category_scores_gemma":[0.00063849567,0.00004938289,0.00012068615,0.00032572975,0.0014201468,0.000031017706,0.000041192012,0.00045629617,0.0000035552682],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085690216,0.00017763166,0.20844325,0.000053520635,0.0020388379,0.000015872636,0.0074964957,0.00005712756,0.19505759,0.0016370608,0.010958074,0.5732076],"study_design_scores_gemma":[0.012113151,0.017213639,0.4690223,0.0022087272,0.007530471,0.00015120371,0.09350674,0.0047812127,0.025551613,0.00548259,0.36184758,0.00059078354],"about_ca_topic_score_codex":0.000083526225,"about_ca_topic_score_gemma":0.000006708985,"teacher_disagreement_score":0.5726168,"about_ca_system_score_codex":0.000014527674,"about_ca_system_score_gemma":0.00006156702,"threshold_uncertainty_score":0.523259},"labels":[],"label_agreement":null},{"id":"W2149545030","doi":"10.1172/jci7456","title":"Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"American Diabetes Association; Medical Research Council; Medical Research Council Canada; Cedars-Sinai Medical Center; National Institute on Drug Abuse; Canadian Diabetes Association","keywords":"Proglucagon; Glucagon; Internal medicine; Endocrinology; Proinsulin; Insulin; Streptozotocin; Prohormone; Pancreas; Glucagon-like peptide-1; Pancreatic polypeptide; Islet; Prohormone convertase; Pancreatic hormone; Biology; Chemistry; Diabetes mellitus; Medicine; Hormone; Type 2 diabetes; Insulin resistance","score_opus":0.03856143132473881,"score_gpt":0.3108096892421192,"score_spread":0.2722482579173804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149545030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983422,0.000145503,0.0000065714726,0.0006028262,0.000045416447,0.00023663625,9.589405e-7,0.000007732755,0.00061213796],"genre_scores_gemma":[0.9977008,0.0002021148,0.0011522986,0.0003750322,0.00006994062,0.0000034974323,0.000022553344,0.000010691852,0.00046304442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821794,0.00020573054,0.0010394241,0.000116878335,0.00030507508,0.00011495274],"domain_scores_gemma":[0.99847734,0.0004571455,0.00064432604,0.000111547066,0.00014478067,0.00016487016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010788483,0.00010183336,0.00054881343,0.00013739537,0.00001750025,0.000012216652,0.000038780952,0.000088465735,0.00007054904],"category_scores_gemma":[0.0006168214,0.00007314985,0.00007792643,0.00023719446,0.00015885496,0.0001849776,0.0000075696666,0.00017059116,0.0000028760637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051292527,0.00044045958,0.98029333,0.00007862168,0.00029951253,0.000022221286,0.00013922536,0.00008892067,0.0017713581,0.000054605058,0.00045835233,0.015840465],"study_design_scores_gemma":[0.0046116826,0.0015429995,0.98868537,0.0010836152,0.0005434663,0.000004169334,0.000031039795,0.001048715,0.0010022171,0.0011932425,0.0001877003,0.00006575703],"about_ca_topic_score_codex":0.000025342777,"about_ca_topic_score_gemma":0.000019778636,"teacher_disagreement_score":0.015774708,"about_ca_system_score_codex":0.000048247053,"about_ca_system_score_gemma":0.000112077636,"threshold_uncertainty_score":0.29829645},"labels":[],"label_agreement":null},{"id":"W2149717292","doi":"10.1126/scitranslmed.3007218","title":"Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans","year":2013,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":675,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Agonist; Exenatide; Glucagon-like peptide-1; Pharmacology; PEGylation; Internal medicine; Endocrinology; Diabetes mellitus; Receptor; Hormone; Type 2 diabetes; Medicine; Chemistry; Biochemistry","score_opus":0.018041354036384537,"score_gpt":0.26491631168276314,"score_spread":0.2468749576463786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149717292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752799,0.0022891888,0.000103346894,0.013425828,0.00010312452,0.0006740866,0.0000029791331,0.00003339692,0.008088098],"genre_scores_gemma":[0.9967864,0.00028602013,0.0015508154,0.000847468,0.000076225246,0.00004968074,0.000032759905,0.000009805788,0.00036079157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982811,0.000018918567,0.00026458022,0.00036017084,0.0007583079,0.00031690457],"domain_scores_gemma":[0.9994288,0.000043552896,0.000039818024,0.0001813871,0.00010458135,0.00020184813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037967978,0.00014854402,0.0002727227,0.00045362065,0.000100511956,0.000022594595,0.00010391915,0.000027742142,0.000470427],"category_scores_gemma":[0.00006811399,0.00011008501,0.00002615376,0.00070639665,0.000615377,0.00030280687,0.00002837204,0.00009857942,0.000034559707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012985099,0.00065838324,0.6273574,0.00016949163,0.00019649991,0.00009942601,0.004286871,0.00028901876,0.049774185,0.1685712,0.00083360675,0.14763406],"study_design_scores_gemma":[0.0033787917,0.00018297293,0.98984325,0.00015064194,0.0001122156,0.000007731937,0.00019475135,0.0011846272,0.00068675564,0.0023797627,0.0017560179,0.00012247813],"about_ca_topic_score_codex":0.00034560947,"about_ca_topic_score_gemma":0.00004569712,"teacher_disagreement_score":0.36248583,"about_ca_system_score_codex":0.00002562913,"about_ca_system_score_gemma":0.00007076513,"threshold_uncertainty_score":0.5150846},"labels":[],"label_agreement":null},{"id":"W2150012656","doi":"10.1161/circresaha.114.301958","title":"Cardiovascular Actions of Incretin-Based Therapies","year":2014,"lang":"en","type":"review","venue":"Circulation Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":348,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Incretin; Glucagon-like peptide-1; Medicine; Dipeptidyl peptidase; Receptor; Pharmacology; Diabetes mellitus; Dipeptidyl peptidase-4; Metabolite; Type 2 Diabetes Mellitus; Sitagliptin; Type 2 diabetes; Bioinformatics; Internal medicine; Endocrinology; Biology; Enzyme; Biochemistry","score_opus":0.2355942376598043,"score_gpt":0.45161451570871286,"score_spread":0.21602027804890855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150012656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000080558435,0.98795545,0.00026903258,0.000060569488,0.00006556415,0.0016903075,0.0000067277965,0.000040088245,0.009831703],"genre_scores_gemma":[0.0056322534,0.9926252,0.00012072653,0.000010547007,0.0001544734,0.00032515437,0.0003587276,0.000046576897,0.0007263888],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761164,0.0005108208,0.0003671794,0.00031603922,0.000932689,0.00026165426],"domain_scores_gemma":[0.99826217,0.0003634234,0.00010381576,0.0008487846,0.00033564516,0.00008616873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016236033,0.00017976071,0.0012637425,0.000778694,0.00009345943,0.000026478976,0.00012777097,0.00017862809,0.0002267995],"category_scores_gemma":[0.00017651073,0.00013926627,0.0010071744,0.00068625156,0.00013196448,0.000027740547,0.000045926052,0.0003067703,0.00017746112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000047458916,0.000094473966,0.00017892804,0.021206453,0.0020270539,0.0000053143513,0.000016721624,0.00004117013,0.0000010428528,0.00046820837,0.00055396196,0.97540194],"study_design_scores_gemma":[0.00040336474,0.000079083424,0.00050171674,0.004558166,0.0015646305,0.0000014255462,0.000012365382,0.00011448115,0.0000020029456,0.000032553366,0.99263316,0.00009703541],"about_ca_topic_score_codex":0.000048604285,"about_ca_topic_score_gemma":0.0000015385698,"teacher_disagreement_score":0.9920792,"about_ca_system_score_codex":0.0001942568,"about_ca_system_score_gemma":0.00029029185,"threshold_uncertainty_score":0.5679113},"labels":[],"label_agreement":null},{"id":"W2150022402","doi":"10.2215/cjn.09291010","title":"Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy","year":2011,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"GlaxoSmithKline","keywords":"Rosiglitazone; Medicine; Metformin; Albuminuria; Internal medicine; Type 2 diabetes; Renal function; Endocrinology; Diabetes mellitus; Glycemic; Creatinine; Urology","score_opus":0.03970256684085736,"score_gpt":0.308035580202508,"score_spread":0.2683330133616506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150022402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732405,0.0005252822,0.00007391574,0.0017646399,0.00007878763,0.0001305014,4.5096905e-7,0.00000433827,0.000098012344],"genre_scores_gemma":[0.97322863,0.002609622,0.007692062,0.016211847,0.0001119055,0.0000023875698,4.5169406e-7,0.000012792557,0.000130306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999036,0.00009259187,0.00047722255,0.00010930759,0.00012776164,0.00015711735],"domain_scores_gemma":[0.9988335,0.00019849217,0.0006378832,0.0001637996,0.00009581991,0.00007053042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051579,0.000095829426,0.00056045747,0.000037432867,0.000020368805,0.0000025282807,0.00010591328,0.000046582107,0.00002891236],"category_scores_gemma":[0.000030192738,0.000047656315,0.00021674535,0.0002238047,0.00080489024,0.00005766964,0.00004205018,0.00022671203,8.0322513e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011603892,0.00091334636,0.85805696,0.000033382577,0.0023006867,0.000018793928,0.00055442145,0.0000038113533,0.002594287,0.000055074594,0.015333239,0.10853209],"study_design_scores_gemma":[0.0041316855,0.018760443,0.95639527,0.000078572855,0.0006029891,0.000028607139,0.00050364574,0.000052422885,0.00036088345,0.00053289864,0.018477134,0.000075447526],"about_ca_topic_score_codex":0.000022119708,"about_ca_topic_score_gemma":0.00000889062,"teacher_disagreement_score":0.10845665,"about_ca_system_score_codex":0.000021803118,"about_ca_system_score_gemma":0.000067548775,"threshold_uncertainty_score":0.29656518},"labels":[],"label_agreement":null},{"id":"W2150339979","doi":"10.2165/11595370-000000000-00000","title":"Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus","year":2011,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; McGill University","keywords":"Medicine; Type 2 Diabetes Mellitus; Pharmacotherapy; Diabetes mellitus; Secretion; Internal medicine; Type 2 diabetes; Gastroenterology; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.2086526985467771,"score_gpt":0.3294358003476996,"score_spread":0.1207831018009225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150339979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07622526,0.9146059,0.00017818212,0.00038544682,0.0009907542,0.006200132,0.000012338475,0.00020549307,0.0011964638],"genre_scores_gemma":[0.005474056,0.9708376,0.01475011,0.0007083677,0.00096274714,0.00032314207,0.004946135,0.00019825897,0.0017995659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724036,0.0002579979,0.0010919916,0.0007261922,0.00031215622,0.00037130993],"domain_scores_gemma":[0.9983826,0.00015880991,0.0004334006,0.00044948873,0.00007338245,0.0005022886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006008581,0.0004473092,0.001424907,0.00032965792,0.00004105998,0.000043233493,0.00017732783,0.0002647122,0.000042730517],"category_scores_gemma":[0.0004187662,0.00032789077,0.00024261701,0.00059192604,0.00013570416,0.00014138829,0.00012859445,0.00050679,0.00024218785],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008339657,0.00036928937,0.036106456,0.003868436,0.00024916814,0.0000049811674,0.00009518626,0.000005812239,3.1020843e-8,0.0003418414,0.0009605674,0.9579148],"study_design_scores_gemma":[0.007969528,0.005568857,0.13805194,0.0779773,0.011025966,0.0000021296476,0.000041162006,0.0005397152,0.000006541132,0.0030787792,0.7537782,0.0019598608],"about_ca_topic_score_codex":0.000037268568,"about_ca_topic_score_gemma":0.000011674029,"teacher_disagreement_score":0.95595497,"about_ca_system_score_codex":0.00018578276,"about_ca_system_score_gemma":0.0003389219,"threshold_uncertainty_score":0.9999173},"labels":[],"label_agreement":null},{"id":"W2150556712","doi":"10.1185/030079906x104786","title":"Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial","year":2006,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Glimepiride; Pioglitazone; Medicine; Metformin; Type 2 diabetes; Rosiglitazone; Hypoglycemia; Internal medicine; Diabetes mellitus; Randomized controlled trial; Clinical endpoint; Urology; Endocrinology","score_opus":0.1340628565789854,"score_gpt":0.4469974842120171,"score_spread":0.3129346276330317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150556712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866168,0.0055558165,0.000016573476,0.0016471293,0.0006834366,0.004034543,0.0000035436847,0.00002229435,0.0014198432],"genre_scores_gemma":[0.98242617,0.01650951,0.000039785366,0.000032388547,0.00032147215,0.00031229327,0.00020601833,0.000015744412,0.00013659433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957876,0.0010483862,0.0009140378,0.00036733717,0.00145561,0.00042698928],"domain_scores_gemma":[0.9929871,0.0060927253,0.00018036392,0.00023135818,0.00027080104,0.00023767547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010221426,0.00017648842,0.0011973615,0.00044856453,0.000049345414,0.00002461601,0.000108029024,0.00013450618,0.000031266976],"category_scores_gemma":[0.0058485987,0.00010338757,0.00014036208,0.00046115267,0.00051156443,0.000066663,0.000038029364,0.00045394053,0.000006843212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81657785,0.003364052,0.0009082096,0.000058964033,0.0002142732,0.000008634271,0.000039464674,3.6210383e-7,0.000009324618,0.002359101,0.0008345419,0.17562525],"study_design_scores_gemma":[0.9650999,0.02571044,0.0022942242,0.00063565344,0.00003848541,1.695541e-7,0.000024910829,0.0010025355,0.00032583333,0.0010487672,0.0037230065,0.00009607787],"about_ca_topic_score_codex":0.000102378435,"about_ca_topic_score_gemma":0.00003106735,"teacher_disagreement_score":0.17552917,"about_ca_system_score_codex":0.000074329495,"about_ca_system_score_gemma":0.00026604428,"threshold_uncertainty_score":0.70017415},"labels":[],"label_agreement":null},{"id":"W2150855258","doi":"10.2337/dc08-1863","title":"Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":696,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"European Foundation for the Study of Diabetes; Bristol-Myers Squibb; American Diabetes Association","keywords":"Dapagliflozin; Medicine; Metformin; Type 2 diabetes; Internal medicine; Renal glucose reabsorption; Endocrinology; Diabetes mellitus; Placebo; Glycemic; Renal function; Uric acid; Urinary system; Weight loss; Creatinine; Adverse effect; Urology; Obesity","score_opus":0.010638883833744136,"score_gpt":0.2136145807987445,"score_spread":0.20297569696500037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150855258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069726,0.0020379503,9.991852e-7,0.00020805892,0.00012471319,0.0006682578,0.000023120732,0.00015216254,0.006087449],"genre_scores_gemma":[0.99721724,0.00022979424,0.000339259,0.00072538474,0.000084550884,0.00010651399,0.000924765,0.00004850603,0.00032401175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998537,0.00002340631,0.00023913408,0.00037698066,0.00031008,0.0005133685],"domain_scores_gemma":[0.99929166,0.000029293127,0.00005663758,0.00034089564,0.00013750837,0.0001439877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006384902,0.0002644933,0.0004201984,0.00024017069,0.000075532305,0.000014564245,0.0000655794,0.00009228154,0.00011040857],"category_scores_gemma":[0.000015050841,0.0002159427,0.000083237595,0.00048082115,0.00011625114,0.00016026638,0.000026996491,0.00015445305,0.00023300057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006369258,0.00022919165,0.9907535,0.00025755144,0.00011357722,0.00016934362,0.0008036774,0.000012512108,0.0028115504,0.000042206,0.0010935112,0.003649715],"study_design_scores_gemma":[0.0047102044,0.0013892849,0.88928336,0.00050649454,0.0002923471,0.0000018424818,0.0006330191,0.0000516974,0.0929243,0.000030549112,0.009778326,0.0003985735],"about_ca_topic_score_codex":0.00000926157,"about_ca_topic_score_gemma":0.000046049197,"teacher_disagreement_score":0.10147011,"about_ca_system_score_codex":0.00013884829,"about_ca_system_score_gemma":0.00007163207,"threshold_uncertainty_score":0.88058877},"labels":[],"label_agreement":null},{"id":"W2150913805","doi":"10.2337/db08-1193","title":"GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice","year":2009,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":572,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Hospital for Sick Children; University of Toronto; Toronto General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Liraglutide; Medicine; Cardioprotection; Myocardial infarction; Agonist; Internal medicine; Endocrinology; Type 2 diabetes; Glucagon-like peptide-1; Metformin; Diabetes mellitus; Cardiac function curve; Cardiology; Pharmacology; Receptor; Heart failure","score_opus":0.007874935338447417,"score_gpt":0.23392181588786326,"score_spread":0.22604688054941585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150913805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953037,0.0011510142,0.0000015915664,0.00067194365,0.00013357612,0.0007731353,0.000007759851,0.00008931144,0.0018679542],"genre_scores_gemma":[0.99794656,0.00003502111,0.00025936303,0.0011798105,0.000085787455,0.0002448036,0.000021929378,0.000018784458,0.00020791932],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998876,0.00003154491,0.00020311339,0.00035026472,0.00016797343,0.00037111988],"domain_scores_gemma":[0.99960434,0.000042858625,0.000056758778,0.0001690293,0.000027726766,0.00009929048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097109645,0.00024922108,0.0003779516,0.00017401569,0.00006103023,0.000053677573,0.00004720536,0.00008043709,0.00001688352],"category_scores_gemma":[0.000044411852,0.00020535284,0.00012589758,0.0001271075,0.00006926558,0.0002477032,0.00005400878,0.00012749177,0.0000137219],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025349282,0.00075442466,0.41154662,0.00005464487,0.00037552568,0.000031061823,0.0010947348,8.237875e-7,0.51486444,0.0001932653,0.00007924324,0.0707517],"study_design_scores_gemma":[0.0018879724,0.0007041524,0.7359775,0.00007963119,0.00009479035,7.786376e-7,0.0003397052,0.00004293788,0.26004195,0.00027644378,0.00036155226,0.00019264789],"about_ca_topic_score_codex":0.000049277012,"about_ca_topic_score_gemma":0.000004773286,"teacher_disagreement_score":0.32443082,"about_ca_system_score_codex":0.00016166129,"about_ca_system_score_gemma":0.000018801731,"threshold_uncertainty_score":0.8374046},"labels":[],"label_agreement":null},{"id":"W2151062846","doi":"10.1093/jn/132.5.990","title":"Exendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats","year":2002,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Endocrinology; Chemistry; Internal medicine; Agonist; Corn oil; Food intake; Carbohydrate; Receptor; Food science; Biology; Biochemistry; Medicine","score_opus":0.012062052496010948,"score_gpt":0.23761848837509505,"score_spread":0.2255564358790841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151062846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929952,0.0023942653,0.000013096295,0.0025767225,0.0002771148,0.00052696734,0.000017008468,0.000009156717,0.0011904364],"genre_scores_gemma":[0.99785256,0.0011197762,0.00012341091,0.00012260387,0.00020386094,0.000014262932,0.000019781486,0.000012640807,0.00053110026],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990516,0.00007151057,0.00031566716,0.000088081164,0.00033449387,0.00013865552],"domain_scores_gemma":[0.99934226,0.00010065548,0.00028531987,0.00013426479,0.00006755671,0.00006993516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021697581,0.000120393466,0.00029586875,0.00012665505,0.00004443802,0.000018206445,0.00008116868,0.00004009106,0.00015566964],"category_scores_gemma":[0.000042860906,0.000070818955,0.00018451641,0.00013532437,0.000037374324,0.00008653622,0.000013287322,0.00013681084,0.00002732023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003255597,0.007240937,0.008366454,0.0009978429,0.0015574959,0.00007927824,0.00031423118,0.000008420711,0.06764082,0.00018368669,0.83237815,0.07797707],"study_design_scores_gemma":[0.02713568,0.06121293,0.004106607,0.002751587,0.0013444894,0.00008534832,0.00017225355,0.00015560286,0.688143,0.00042466988,0.2142123,0.00025550587],"about_ca_topic_score_codex":0.0000012015685,"about_ca_topic_score_gemma":2.4705756e-7,"teacher_disagreement_score":0.62050223,"about_ca_system_score_codex":0.000100172925,"about_ca_system_score_gemma":0.0000030903504,"threshold_uncertainty_score":0.2887913},"labels":[],"label_agreement":null},{"id":"W2151307778","doi":"10.1177/1715163513506547","title":"Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; University of British Columbia; Alberta Health Services","funders":"","keywords":"Medicine; Type 2 diabetes; Glycemic; Metformin; Family medicine; Diabetes mellitus; Hypoglycemia; Nursing; Health professionals; Health care","score_opus":0.02962029722761858,"score_gpt":0.30864400587137947,"score_spread":0.2790237086437609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151307778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894034,0.008627979,0.0000014424512,0.00019527822,0.00045001777,0.0010458058,0.0000662444,0.0000073824276,0.000202415],"genre_scores_gemma":[0.9966304,0.0016067399,0.00034321292,0.00073486235,0.000099006545,0.00009925241,0.000040342093,0.000023072676,0.00042311216],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99866676,0.00005589494,0.00032155623,0.0002548824,0.00019801279,0.0005028734],"domain_scores_gemma":[0.9982074,0.000052237887,0.00019260793,0.000091920716,0.00054667547,0.00090919726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001383253,0.00020476223,0.00037651722,0.00021199769,0.0004454609,0.000058794885,0.00008491627,0.000025443589,0.00012939346],"category_scores_gemma":[0.00007573931,0.00017122929,0.0000544027,0.00015929525,0.00012911962,0.00023405738,0.000025434072,0.00009831263,5.071755e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019522528,0.0003803275,0.1470173,0.0021419192,0.002080648,0.0007216448,0.15467629,0.000006028013,0.0005183892,0.000056955076,0.045156583,0.6470487],"study_design_scores_gemma":[0.20474847,0.025984451,0.08229233,0.0055348068,0.013907672,0.051556673,0.37097523,0.0066110403,0.043146223,0.0010371016,0.18221535,0.011990668],"about_ca_topic_score_codex":0.0028447388,"about_ca_topic_score_gemma":0.0015557233,"teacher_disagreement_score":0.63505805,"about_ca_system_score_codex":0.00091415737,"about_ca_system_score_gemma":0.0009538962,"threshold_uncertainty_score":0.6982528},"labels":[],"label_agreement":null},{"id":"W2151753166","doi":"10.1172/jci18784","title":"Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Medical Research Council; National Institutes of Health; Ipsen; Vlaamse regering; Wellcome Trust","keywords":"Endocrinology; Internal medicine; Missense mutation; Nonsense mutation; Allele; Biology; Medicine; Phenotype; Genetics; Gene","score_opus":0.16691108186061038,"score_gpt":0.3650470267147205,"score_spread":0.19813594485411012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151753166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556875,0.00012840386,0.00038569415,0.0011245492,0.00026199227,0.00039673783,7.7636525e-7,0.000011676327,0.0021214015],"genre_scores_gemma":[0.9956851,0.000022052736,0.0033948144,0.00047797375,0.00015596596,0.0000064378346,0.000007991601,0.000008992657,0.00024069572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786353,0.0002568005,0.0012717022,0.00012023687,0.00034865653,0.00013908303],"domain_scores_gemma":[0.99795187,0.0002708772,0.0010630819,0.0001887582,0.00038864312,0.00013680218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001467925,0.00011485951,0.00041935695,0.00009490399,0.000081770275,0.000020824109,0.00010457844,0.000044449152,0.00008699825],"category_scores_gemma":[0.0016904124,0.00006821451,0.0002142073,0.00014042864,0.00032036472,0.00011012117,0.00001926368,0.0002718969,0.00000955512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004381687,0.0018582775,0.9050736,0.00036134679,0.00037820483,0.00008144328,0.0003927657,0.000061952596,0.032906797,0.02997913,0.0041472306,0.024321124],"study_design_scores_gemma":[0.006611973,0.0075456183,0.92059904,0.0005350628,0.001154758,0.00015018732,0.00059138733,0.0003669845,0.045907617,0.012598868,0.003761558,0.00017695448],"about_ca_topic_score_codex":0.000016511285,"about_ca_topic_score_gemma":0.0000068320446,"teacher_disagreement_score":0.024144169,"about_ca_system_score_codex":0.00003288813,"about_ca_system_score_gemma":0.00014769027,"threshold_uncertainty_score":0.2781707},"labels":[],"label_agreement":null},{"id":"W2151847420","doi":"10.1152/ajpendo.90419.2008","title":"Epac is involved in cAMP-stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic α- and intestinal L-cell lines","year":2008,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Diabetes Association","keywords":"Proglucagon; Forskolin; Glucagon; Enteroendocrine cell; Secretion; Cell culture; Internal medicine; Hormone; Chemistry; Endocrinology; Alpha cell; Stimulation; Cell biology; Biology; Glucagon-like peptide-1; Beta cell; Endocrine system; Insulin; Islet; Medicine","score_opus":0.014116174726139531,"score_gpt":0.24602174756822281,"score_spread":0.2319055728420833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151847420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888542,0.009834102,0.000007408785,0.0008455802,0.00008751901,0.0003328921,0.000001905102,0.00001548569,0.00002087774],"genre_scores_gemma":[0.9750088,0.023066452,0.0014080035,0.00025608318,0.00012535567,0.000020633212,0.000009097381,0.000013696331,0.00009186982],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99861413,0.00017259008,0.00045884258,0.0003241401,0.00010513111,0.0003251776],"domain_scores_gemma":[0.9992227,0.00007743311,0.00035985644,0.00013139081,0.00009272665,0.00011587468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014632677,0.00022324409,0.00083410396,0.00043660088,0.00006812469,0.000005288805,0.000048687423,0.000060516915,0.000004307201],"category_scores_gemma":[0.00009823987,0.00016928492,0.000044718425,0.00022968055,0.00063372724,0.00017550917,0.00007052713,0.00037114264,0.000001167057],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019230277,0.0003939678,0.043456115,0.000052645908,0.00010024135,0.00012756916,0.00116058,0.000008667167,0.9401419,0.000020034257,0.00010706579,0.012508185],"study_design_scores_gemma":[0.0048156995,0.0018961239,0.95655334,0.00011339169,0.0002541086,0.0004895149,0.0008935188,0.00012077571,0.034241334,0.00023459017,0.00023371205,0.00015387019],"about_ca_topic_score_codex":0.00012462652,"about_ca_topic_score_gemma":0.0000057695715,"teacher_disagreement_score":0.91309726,"about_ca_system_score_codex":0.000025811254,"about_ca_system_score_gemma":0.000041353516,"threshold_uncertainty_score":0.6903239},"labels":[],"label_agreement":null},{"id":"W2151947272","doi":"10.1016/s2213-8587(14)70213-x","title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","year":2014,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Killam Trusts; Canadian Diabetes Association","keywords":"Medicine; Gliclazide; Glibenclamide; Glimepiride; Glipizide; Tolbutamide; Internal medicine; Chlorpropamide; Relative risk; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Myocardial infarction; Stroke (engine); Confidence interval; Cardiology; Endocrinology; Insulin","score_opus":0.09578919385841846,"score_gpt":0.3540050939430012,"score_spread":0.2582159000845828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151947272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000418693,0.99223757,0.000009400888,0.00046912406,0.00009668397,0.005717266,0.00009202205,0.00017364441,0.0011624361],"genre_scores_gemma":[0.0001540286,0.99190456,0.000091259404,0.0022360897,0.00033488518,0.0037356552,0.00034733978,0.00007081525,0.0011253484],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99343044,0.002240225,0.0014496213,0.00087194936,0.00032394708,0.0016838418],"domain_scores_gemma":[0.9942246,0.0011999569,0.0015269076,0.0027969847,0.000077958866,0.00017358833],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002514048,0.00093597383,0.023405876,0.00023765,0.00015842616,0.000060351307,0.000631167,0.00019608582,0.00022791463],"category_scores_gemma":[0.00039296536,0.0004594862,0.0039647394,0.00092742563,0.00032623,0.000049298425,0.00040735633,0.000688583,0.0001443323],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.8525826e-7,0.000036741563,0.0016953535,0.53587687,0.45521176,0.000017874803,0.0000048254337,9.2622713e-7,1.4123492e-9,0.00051588356,0.0023898885,0.0042490037],"study_design_scores_gemma":[0.00020732515,0.00007807248,0.00034486325,0.021976452,0.7905114,0.0000067158317,0.0000017316279,0.0000071016957,3.9174626e-8,0.00015771358,0.18641493,0.00029361297],"about_ca_topic_score_codex":0.000056450375,"about_ca_topic_score_gemma":0.000072983974,"teacher_disagreement_score":0.5139004,"about_ca_system_score_codex":0.00007354311,"about_ca_system_score_gemma":0.0000363018,"threshold_uncertainty_score":0.99978566},"labels":[],"label_agreement":null},{"id":"W2152096085","doi":"10.1038/ki.2012.401","title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","year":2013,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Center for Theoretical Sciences","keywords":"Medicine; Albuminuria; Microalbuminuria; Type 2 diabetes; Internal medicine; Kidney disease; Dialysis; Urology; Diabetes mellitus; Glycated hemoglobin; Type 1 diabetes; Creatinine; Renal function; Endocrinology","score_opus":0.004460990555300714,"score_gpt":0.2165610818668057,"score_spread":0.21210009131150498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152096085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792453,0.000014611879,0.000007894993,0.012542683,0.0006583486,0.0008434732,0.000044831224,0.000049740782,0.006593086],"genre_scores_gemma":[0.97338384,0.0000049461623,0.0003820358,0.02084327,0.000058604768,0.00011254609,0.00040467255,0.000020034648,0.004790047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901396,0.000012944444,0.00020519644,0.00022357985,0.00031054148,0.0002337938],"domain_scores_gemma":[0.99891436,0.00003594647,0.00007559139,0.00016979365,0.00053450227,0.00026978107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043036784,0.00016718516,0.0002542269,0.00018735266,0.00001826087,0.000044556138,0.00011667083,0.000041427324,0.0009009741],"category_scores_gemma":[0.0006269851,0.000114432434,0.000054472603,0.00008981679,0.00004551203,0.00022094774,0.000048580838,0.00009285225,0.00037351178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097965894,0.00044487923,0.956625,0.000016302456,0.00070246344,0.000004193563,0.00005618384,7.395078e-7,0.00031372564,0.00015878945,0.038297415,0.0032823505],"study_design_scores_gemma":[0.0090920655,0.0005512082,0.97498536,0.000110588546,0.00010459165,1.7034282e-7,0.00003885259,0.00034838193,0.00037575973,0.00011475247,0.014140297,0.00013794654],"about_ca_topic_score_codex":0.000063665146,"about_ca_topic_score_gemma":0.0000029285284,"teacher_disagreement_score":0.024157118,"about_ca_system_score_codex":0.00012440598,"about_ca_system_score_gemma":0.000068704074,"threshold_uncertainty_score":0.9865035},"labels":[],"label_agreement":null},{"id":"W2152151074","doi":"10.1210/jc.2011-1074","title":"Weight Beneficial Treatments for Type 2 Diabetes","year":2011,"lang":"en","type":"review","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Type 2 diabetes; Weight loss; Context (archaeology); Weight gain; Diabetes mellitus; Medicine; Body weight; Obesity; Internal medicine; Endocrinology; Biology","score_opus":0.18638852766381642,"score_gpt":0.4474934652758752,"score_spread":0.2611049376120588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152151074","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011452297,0.99130017,0.000008887705,0.00035986578,0.0044903643,0.0013202366,0.000020545924,0.00002503177,0.0013296588],"genre_scores_gemma":[0.000046310877,0.99189097,0.0008074355,0.00048112482,0.0039490163,0.000048924147,0.00004007039,0.00008081576,0.002655333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99552166,0.0005720993,0.0026824304,0.00029979958,0.00025846335,0.00066556636],"domain_scores_gemma":[0.99484515,0.0016497893,0.002273464,0.0006470847,0.00033845392,0.0002460723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001228762,0.0005548279,0.005344563,0.00031382166,0.00009618044,0.000012860413,0.00062702544,0.0003774847,0.00020800608],"category_scores_gemma":[0.00067541853,0.00027019263,0.0024469958,0.0002119476,0.00027654823,0.00007646469,0.00015334209,0.000879784,0.00014367075],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003378404,0.0007631625,0.00010210731,0.00087990187,0.010495364,0.000039733648,0.00001922649,6.2600314e-8,2.0019932e-7,0.0018875616,0.0052625113,0.98021233],"study_design_scores_gemma":[0.0031822568,0.0017135411,0.00052845606,0.0012449449,0.06643424,0.0000852349,0.000005863283,5.2748055e-7,0.0000051952475,0.0007506533,0.9258707,0.00017838359],"about_ca_topic_score_codex":0.000003181982,"about_ca_topic_score_gemma":0.0000010730188,"teacher_disagreement_score":0.98003393,"about_ca_system_score_codex":0.000043993157,"about_ca_system_score_gemma":0.000397166,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2152549678","doi":"10.1007/s11886-015-0608-6","title":"Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications","year":2015,"lang":"en","type":"review","venue":"Current Cardiology Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Disease; Intensive care medicine; Obesity; Internal medicine; Endocrinology","score_opus":0.031078020753401107,"score_gpt":0.30677667678727355,"score_spread":0.27569865603387245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152549678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070342876,0.99374497,0.00012945691,0.000007813578,0.0016617572,0.0026146336,0.00003529828,0.00018275918,0.000919891],"genre_scores_gemma":[0.0013338124,0.99509114,0.00001803674,0.000006722053,0.0005623203,0.0010047287,0.0017579268,0.00007755103,0.0001477642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970828,0.00034910446,0.0006038513,0.0010097094,0.00050996186,0.00044453787],"domain_scores_gemma":[0.9971388,0.00017273623,0.00054400513,0.0013808594,0.00015667723,0.0006069073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011425117,0.0005905994,0.003563633,0.00024226874,0.000103339524,0.00002177862,0.00008227572,0.00024069437,0.000004605839],"category_scores_gemma":[0.00069038465,0.0004032584,0.0010894251,0.00027577282,0.0002111121,0.00005030622,0.00017533256,0.00047946547,0.0000142099425],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007422405,0.00009803569,0.010830734,0.008298719,0.02015635,0.0035078686,0.000014541609,0.000005925286,9.2706e-9,0.0000032550531,0.0024570748,0.95462006],"study_design_scores_gemma":[0.0006173895,0.00015121736,0.0027474042,0.0102157695,0.079911925,0.00042642755,0.000002813337,0.0000019558736,8.313831e-8,0.000023900944,0.90555835,0.00034277118],"about_ca_topic_score_codex":0.000004459787,"about_ca_topic_score_gemma":5.0476655e-7,"teacher_disagreement_score":0.9542773,"about_ca_system_score_codex":0.0002500125,"about_ca_system_score_gemma":0.0004913556,"threshold_uncertainty_score":0.9998419},"labels":[],"label_agreement":null},{"id":"W2152777465","doi":"10.1210/en.2007-1142","title":"Cross Talk between the Insulin and Wnt Signaling Pathways: Evidence from Intestinal Endocrine L Cells","year":2008,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Proglucagon; Internal medicine; Endocrinology; Wnt signaling pathway; Enteroendocrine cell; Insulin; Biology; Glucagon-like peptide-1; Chromatin immunoprecipitation; Signal transduction; Incretin; Transcription factor; Insulin receptor; Cell biology; Hormone; Gene expression; Insulin resistance; Endocrine system; Biochemistry; Promoter; Gene; Diabetes mellitus; Type 2 diabetes; Medicine","score_opus":0.05970379390083393,"score_gpt":0.2861140112597829,"score_spread":0.22641021735894898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152777465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936278,0.003599875,0.00014060673,0.0012631349,0.00017371593,0.00039073362,0.000011734145,0.00011205924,0.00068034127],"genre_scores_gemma":[0.9959514,0.001004685,0.0013079235,0.00039298474,0.00034187193,0.00005421739,0.000028501549,0.000019785886,0.0008986397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998602,0.000070003545,0.00028889967,0.00038884903,0.00017609705,0.00047414808],"domain_scores_gemma":[0.99878585,0.0006300111,0.00008787983,0.00033254418,0.00005486296,0.000108859495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007136593,0.0002088377,0.00034958488,0.00007925008,0.0001810018,0.00002336003,0.00016871376,0.000036660982,0.00023537835],"category_scores_gemma":[0.00015731392,0.00014283619,0.00007114062,0.0001100658,0.00037003288,0.00009801472,0.00026074753,0.00024701835,0.00012470235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019538486,0.00020644684,0.9134698,0.0000657847,0.0004951771,0.0033509461,0.0010123792,0.000019905307,0.033092026,0.0003674609,0.00082909316,0.046895623],"study_design_scores_gemma":[0.0031268592,0.0011012921,0.7702541,0.00021237905,0.00040000325,0.00036410717,0.00018486052,0.00006359669,0.20949076,0.0006395863,0.013875661,0.0002867981],"about_ca_topic_score_codex":0.0003738582,"about_ca_topic_score_gemma":0.000009277871,"teacher_disagreement_score":0.17639874,"about_ca_system_score_codex":0.000047409856,"about_ca_system_score_gemma":0.000037483187,"threshold_uncertainty_score":0.58246905},"labels":[],"label_agreement":null},{"id":"W2153152770","doi":"10.1210/en.2007-1292","title":"The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption","year":2007,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Endocrinology; Internal medicine; Bone resorption; Deoxypyridinoline; Bone remodeling; Osteoclast; Calcitonin; Resorption; Chemistry; Calcitonin receptor; Bone mineral; Calcitonin gene-related peptide; Osteoporosis; Receptor; Medicine; Osteocalcin; Neuropeptide","score_opus":0.010678562095568538,"score_gpt":0.275089574164608,"score_spread":0.26441101206903944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153152770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96468717,0.0020904858,0.01183627,0.010239069,0.0016751265,0.0020855851,0.000030278345,0.00011643393,0.0072395694],"genre_scores_gemma":[0.9832257,0.00032461737,0.00092963333,0.0006232789,0.00029455012,0.000087026005,0.000042536638,0.000017929258,0.014454698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989274,0.000019456307,0.00030829117,0.00019164354,0.00012205721,0.00043112572],"domain_scores_gemma":[0.99924624,0.00021136396,0.00012172863,0.00028036028,0.0000880129,0.00005231959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019200782,0.00011478136,0.00026740498,0.000103498234,0.00007887989,0.0000057419415,0.0000689942,0.000044256463,0.000130962],"category_scores_gemma":[0.000063463616,0.00008022262,0.00013239888,0.00007683911,0.0001281149,0.000027422106,0.00003780203,0.00007007206,0.000053200973],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011460059,0.0019880661,0.03611673,0.00051618175,0.0034356595,0.00015932928,0.0007482709,0.000005070565,0.18461184,0.07290144,0.21200773,0.47604963],"study_design_scores_gemma":[0.009319141,0.0013656922,0.015618574,0.000027794431,0.00039915013,0.000017131924,0.00019322666,0.000048225167,0.11107813,0.0004203577,0.8613966,0.000115946685],"about_ca_topic_score_codex":0.000029711015,"about_ca_topic_score_gemma":0.00003383746,"teacher_disagreement_score":0.6493889,"about_ca_system_score_codex":0.000041402196,"about_ca_system_score_gemma":0.000017713433,"threshold_uncertainty_score":0.32713836},"labels":[],"label_agreement":null},{"id":"W2153248040","doi":"10.1111/j.2040-1124.2012.00196.x","title":"Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes","year":2012,"lang":"en","type":"review","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.0377607288756329,"score_gpt":0.2777966269264184,"score_spread":0.24003589805078548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153248040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.124056146,0.87481165,0.000003154126,0.00004671013,0.0003326061,0.0006065874,0.000004046664,0.000012755164,0.00012635915],"genre_scores_gemma":[0.0166969,0.9800242,0.002334514,0.00014161169,0.0004964794,0.000031862703,0.00004530491,0.000054884535,0.00017424901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762803,0.00019245718,0.0011943238,0.00021213113,0.00040191016,0.000371146],"domain_scores_gemma":[0.997991,0.0002684843,0.0011394966,0.00020661537,0.000088147746,0.00030620664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006543783,0.0003931661,0.0017985819,0.0007244999,0.0000353478,0.00005714085,0.00012463445,0.00021381244,0.000025013867],"category_scores_gemma":[0.000112347,0.00029287045,0.00028522155,0.00030171606,0.000091841444,0.00029515513,0.00006219443,0.00046801692,0.000023303463],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007729918,0.0002097636,0.023710893,0.018163955,0.001132961,0.000039302202,0.00019599657,0.0000031827212,0.00046467327,0.0000835826,0.00013255817,0.9558554],"study_design_scores_gemma":[0.008799479,0.0036859522,0.01941243,0.20325218,0.059904628,0.00012542018,0.00024282576,0.00007701375,0.006960532,0.0020897558,0.69337344,0.0020763134],"about_ca_topic_score_codex":0.0000047583517,"about_ca_topic_score_gemma":0.0000017437449,"teacher_disagreement_score":0.9537791,"about_ca_system_score_codex":0.00033068308,"about_ca_system_score_gemma":0.00019797283,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W2153449155","doi":"10.2337/dc06-9912","title":"Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy","year":2006,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; MEDLINE; Algorithm; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.012887757416934856,"score_gpt":0.24700480699927038,"score_spread":0.23411704958233553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153449155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770662,0.020224283,0.0000122704705,0.0001488548,0.000121458594,0.0014462038,0.000050636656,0.000015995103,0.0009140722],"genre_scores_gemma":[0.99600744,0.0009922371,0.0023633891,0.00013164019,0.00004026975,0.0001998425,0.0001621715,0.000017468174,0.00008552192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992152,0.000017225158,0.00025327396,0.00016600813,0.00014847555,0.0001998581],"domain_scores_gemma":[0.9994334,0.00012552625,0.00010029741,0.0002021752,0.00011607551,0.000022544615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095523545,0.000129026,0.0002712911,0.00009751476,0.000021927443,0.000004963039,0.000052657426,0.00004190992,0.000010049239],"category_scores_gemma":[0.0000057375755,0.000090924805,0.000066526554,0.00017758593,0.00007045778,0.00002120531,0.000032638214,0.000034753288,0.0000015860147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007299653,0.00027519398,0.2507315,0.0007787924,0.000461122,0.0000031198479,0.00030055805,0.000033051576,0.0007589779,0.00061421096,0.0006188847,0.7453516],"study_design_scores_gemma":[0.008630288,0.0014991647,0.9570247,0.00052956777,0.00065275014,1.383998e-7,0.002503157,0.0022924773,0.021177659,0.00037345002,0.005117398,0.00019925955],"about_ca_topic_score_codex":0.000011994855,"about_ca_topic_score_gemma":0.0000048875986,"teacher_disagreement_score":0.74515235,"about_ca_system_score_codex":0.00004654006,"about_ca_system_score_gemma":0.000013717813,"threshold_uncertainty_score":0.37078062},"labels":[],"label_agreement":null},{"id":"W2153567889","doi":"10.1053/j.gastro.2010.03.006","title":"ErbB Activity Links the Glucagon-Like Peptide-2 Receptor to Refeeding-Induced Adaptation in the Murine Small Bowel","year":2010,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Glucagon-like peptide-2; Endocrinology; Internal medicine; Crypt; Biology; Refeeding syndrome; Epidermal growth factor; Cell growth; ErbB; Protein kinase B; Small intestine; Receptor; Signal transduction; Cell biology; Medicine; Biochemistry; Peptide","score_opus":0.027130080238229957,"score_gpt":0.26105713887785553,"score_spread":0.23392705863962557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153567889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665312,0.0000044462445,0.00015199075,0.030550495,0.00077837997,0.00086289423,0.0000037910233,0.00004134265,0.0010754522],"genre_scores_gemma":[0.99102604,0.000008823692,0.0010645451,0.0067561837,0.00027024504,0.00015533825,0.000026187094,0.00001805329,0.00067455793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878687,0.00011076638,0.00019897465,0.000301031,0.00016279609,0.00043954805],"domain_scores_gemma":[0.9992596,0.00006969933,0.00008280753,0.00045964573,0.000044236385,0.00008399474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050090934,0.00017718869,0.0002224276,0.00012607328,0.000075632764,0.000025159274,0.00024396824,0.00011629319,0.00007696706],"category_scores_gemma":[0.000071426395,0.00010421358,0.00008168633,0.00012777664,0.000053573654,0.000053912467,0.00011000622,0.0006285089,0.00010959732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007003404,0.003713439,0.59833896,0.00014358356,0.00083043973,0.00016968107,0.012643393,0.000087664914,0.22210146,0.0010717058,0.039438974,0.11445728],"study_design_scores_gemma":[0.0042286813,0.004655949,0.94608265,0.00004329273,0.00022170084,0.000037929924,0.0010215977,0.00037320203,0.0017686479,0.000063231324,0.04136962,0.00013346881],"about_ca_topic_score_codex":0.00014457383,"about_ca_topic_score_gemma":0.004378969,"teacher_disagreement_score":0.34774372,"about_ca_system_score_codex":0.000047496284,"about_ca_system_score_gemma":0.000016264754,"threshold_uncertainty_score":0.42497063},"labels":[],"label_agreement":null},{"id":"W2153950991","doi":"10.2337/diabetes.53.9.2492","title":"A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis","year":2004,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":379,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Toronto General Hospital","funders":"Canadian Diabetes Association","keywords":"Internal medicine; Glucose homeostasis; Endocrinology; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Receptor; Chemistry; Peptide YY; Glucagon-like peptide-2; Agonist; Biology; Peptide; Neuropeptide; Biochemistry; Neuropeptide Y receptor; Insulin; Medicine; Type 2 diabetes; Insulin resistance; Diabetes mellitus","score_opus":0.014361414817790661,"score_gpt":0.22276974090829127,"score_spread":0.2084083260905006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153950991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654174,0.00029563572,0.00008261267,0.0005178496,0.00006215505,0.001999562,0.00002500931,0.00013688787,0.0003385306],"genre_scores_gemma":[0.9926494,0.000070670416,0.0060820053,0.00012245808,0.000050236056,0.00025810453,0.00029933875,0.00007011139,0.00039769532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750334,0.00006057598,0.00057330553,0.00064895896,0.0005786723,0.0006351494],"domain_scores_gemma":[0.9985002,0.00007806805,0.00038907662,0.0005430266,0.00023455858,0.00025506198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037066347,0.00048311238,0.00072619616,0.00025576816,0.00016975624,0.000059954837,0.00015442041,0.000088929715,0.0000651126],"category_scores_gemma":[0.00010534578,0.00039882475,0.00013981495,0.0003176183,0.00024090419,0.00023028806,0.00016007623,0.00024011175,0.000015609658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067763147,0.005012824,0.29333016,0.0023626399,0.0009534459,0.00007115325,0.0013171246,0.00016890641,0.6799061,0.001654639,0.00032621215,0.014219226],"study_design_scores_gemma":[0.018418288,0.011995911,0.25407493,0.0056606987,0.00089608296,0.000024182687,0.0016152597,0.00058747624,0.7033525,0.0021542069,0.00027560987,0.0009448557],"about_ca_topic_score_codex":0.00025338898,"about_ca_topic_score_gemma":0.00006186942,"teacher_disagreement_score":0.039255235,"about_ca_system_score_codex":0.00032319687,"about_ca_system_score_gemma":0.00012974546,"threshold_uncertainty_score":0.99984634},"labels":[],"label_agreement":null},{"id":"W2154268206","doi":"10.1111/j.1463-1326.2012.01576.x","title":"Liraglutide: from clinical trials to clinical practice","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk; Eli Lilly and Company","keywords":"Liraglutide; Exenatide; Medicine; Tolerability; Sitagliptin; Regimen; Nausea; Clinical trial; Type 2 diabetes; Internal medicine; Pharmacology; Diabetes mellitus; Adverse effect; Endocrinology","score_opus":0.270250484376392,"score_gpt":0.4984562156673189,"score_spread":0.22820573129092692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154268206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019873667,0.98713505,0.000018422346,0.00041058034,0.004368925,0.0034445068,0.00023920563,0.00014333248,0.0022525804],"genre_scores_gemma":[0.000050097417,0.9803993,0.006170622,0.003707052,0.0070236106,0.00025696593,0.0006273374,0.00010054731,0.0016644681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899658,0.003982468,0.0034713654,0.0011789541,0.0005408984,0.00086049683],"domain_scores_gemma":[0.9876777,0.00823548,0.0013226364,0.0011714476,0.00017472586,0.00141803],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01647908,0.0008542657,0.009489798,0.00030394166,0.00012475281,0.00013959312,0.00031930875,0.0009911102,0.0002610523],"category_scores_gemma":[0.011313876,0.0006014957,0.0023403715,0.00037577932,0.00016680625,0.00030607026,0.0005546319,0.001073124,0.0015083418],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033050033,0.001547516,0.0035300774,0.002225723,0.0047569172,0.000024006618,0.00002905446,5.191586e-9,8.654537e-8,0.00042141593,0.007828992,0.9796032],"study_design_scores_gemma":[0.0016532311,0.00018621248,0.013689552,0.0028561987,0.06516739,0.0000019142235,0.00001211593,6.482934e-7,9.838155e-7,0.00007042259,0.91585183,0.00050947885],"about_ca_topic_score_codex":0.000032390646,"about_ca_topic_score_gemma":0.0000025828551,"teacher_disagreement_score":0.9790937,"about_ca_system_score_codex":0.000047625344,"about_ca_system_score_gemma":0.00022305224,"threshold_uncertainty_score":0.9996436},"labels":[],"label_agreement":null},{"id":"W2154383633","doi":"10.2337/db06-s020","title":"Glucagon-Like Peptide 1 Secretion by the L-Cell","year":2006,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto; University of Toronto; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Canadian Diabetes Association","keywords":"Glucagon-like peptide-1; Gastrin; Endocrinology; Glucose homeostasis; Internal medicine; Secretion; Enteroendocrine cell; Gastric emptying; Hormone; Peptide YY; Gastrointestinal hormone; Biology; Leptin; Intracellular; Peptide hormone; Glucagon; Insulin; Type 2 diabetes; Neuropeptide; Diabetes mellitus; Receptor; Cell biology; Neuropeptide Y receptor; Insulin resistance; Medicine; Endocrine system; Stomach","score_opus":0.005792314675708471,"score_gpt":0.20611324013672716,"score_spread":0.20032092546101868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154383633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215928,0.0014455062,0.000015912417,0.0011605005,0.00014255189,0.0003398984,0.0000075630733,0.00009578795,0.07519948],"genre_scores_gemma":[0.9537418,0.00002820136,0.00011678584,0.0012235055,0.0001446775,0.00007039628,0.00032079473,0.000019880606,0.044333972],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992211,0.000019360952,0.00013000134,0.00017524466,0.00017676814,0.0002775471],"domain_scores_gemma":[0.9995832,0.000048104488,0.000045393008,0.00025307975,0.000026036247,0.000044190067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001043225,0.00012906278,0.00014402931,0.000037945276,0.00007770548,0.00003192935,0.00007319042,0.000037297064,0.00012879625],"category_scores_gemma":[0.000006541431,0.00008237997,0.00008373535,0.0001121295,0.000051023788,0.000055034816,0.00003358372,0.00006389762,0.00022447204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013923657,0.0006233061,0.16102432,0.00011461429,0.00014202051,0.00000652966,0.00006764846,0.000010735641,0.04824727,0.0008742717,0.7787141,0.010161263],"study_design_scores_gemma":[0.0022036112,0.00036755198,0.045206774,0.00006317878,0.0004940079,4.98437e-7,0.00012256904,0.0005958928,0.130507,0.00065590633,0.8195232,0.0002597578],"about_ca_topic_score_codex":0.00006065766,"about_ca_topic_score_gemma":0.000004185615,"teacher_disagreement_score":0.11581754,"about_ca_system_score_codex":0.00004013269,"about_ca_system_score_gemma":0.000009414936,"threshold_uncertainty_score":0.33593577},"labels":[],"label_agreement":null},{"id":"W2154654985","doi":"10.2337/db11-0464","title":"Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC-δ","year":2011,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Endocrinology; Internal medicine; Protein kinase C; Insulin; Insulin receptor; Signal transduction; Biology; Agonist; Type 2 diabetes; Vascular smooth muscle; Insulin resistance; Diabetes mellitus; Receptor; Medicine; Cell biology","score_opus":0.021879872641621292,"score_gpt":0.21901361040029685,"score_spread":0.19713373775867554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154654985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941111,0.0012124085,0.000022450724,0.00047139707,0.00012228891,0.0004117654,0.000014042404,0.00017245318,0.0034620445],"genre_scores_gemma":[0.9911453,0.00005930333,0.00677371,0.001180739,0.0001335134,0.000027389044,0.00006884381,0.00003858943,0.00057260296],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867773,0.0000712195,0.0002263568,0.0003967641,0.00017544026,0.00045247976],"domain_scores_gemma":[0.99930143,0.00015366457,0.000074827614,0.0003100498,0.0000454716,0.00011457044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026555808,0.0002661053,0.00042590682,0.00009403096,0.00008768053,0.000035669116,0.000048677502,0.00009097166,0.00008887841],"category_scores_gemma":[0.00007238617,0.0002295297,0.000102725186,0.00014109873,0.00013330692,0.00021843034,0.00008921888,0.0001151134,0.000045626773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012814334,0.0019083285,0.7200145,0.0006338655,0.0023196407,0.00061701966,0.004113463,0.000008986191,0.18122436,0.001085676,0.002544518,0.08540148],"study_design_scores_gemma":[0.005456034,0.0011270692,0.36771253,0.00045232888,0.0014278396,0.000019443398,0.00034202036,0.0019636115,0.6156598,0.0041918815,0.000984199,0.0006632632],"about_ca_topic_score_codex":0.000029776404,"about_ca_topic_score_gemma":0.000006393974,"teacher_disagreement_score":0.4344354,"about_ca_system_score_codex":0.00002226085,"about_ca_system_score_gemma":0.00001660003,"threshold_uncertainty_score":0.935995},"labels":[],"label_agreement":null},{"id":"W2156374993","doi":"10.2337/diacare.24.11.1951","title":"Effect of Glucagon-Like Peptide 1 on Non–Insulin-Mediated Glucose Uptake in the Elderly Patient With Diabetes","year":2001,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Medical Research Council Canada; University of British Columbia; Canadian Diabetes Association","keywords":"Internal medicine; Endocrinology; Medicine; Insulin; Diabetes mellitus; Glucagon; Glucagon-like peptide-1; Glucose uptake; Type 2 diabetes; Hormone; Glucose clamp technique; Clamp; Carbohydrate metabolism; Pancreatic hormone; Insulin resistance","score_opus":0.005026712320205257,"score_gpt":0.21786935510246644,"score_spread":0.21284264278226117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156374993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384314,0.00083011435,2.6256646e-7,0.00019532655,0.00013176785,0.0017818856,0.00028342498,0.00005985859,0.0028742426],"genre_scores_gemma":[0.9963762,0.00007138115,0.00003663516,0.00083629834,0.000050864986,0.00041169548,0.0021331315,0.00004054193,0.000043258042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791485,0.00013686757,0.00036443237,0.0004121534,0.00054897927,0.00062272366],"domain_scores_gemma":[0.9985093,0.00044797533,0.00014804014,0.00067063735,0.00010267606,0.00012137649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025173105,0.00039769587,0.0006118857,0.00025638967,0.00006454333,0.000031577456,0.00021542644,0.00009778319,0.000042594223],"category_scores_gemma":[0.00008819047,0.0002281048,0.00017382285,0.00061002467,0.0000990463,0.00008277719,0.000050125615,0.00021991372,0.00011427665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045337505,0.0007138952,0.8330608,0.0006764217,0.0003797875,0.00016216288,0.0017280572,0.0000636014,0.0012661603,0.000008369307,0.0040970133,0.15739034],"study_design_scores_gemma":[0.018899687,0.0796003,0.7482849,0.0024846138,0.0017577758,0.0000023988136,0.0040010847,0.0003201929,0.07394591,0.000016541806,0.06972326,0.0009633645],"about_ca_topic_score_codex":0.000017641027,"about_ca_topic_score_gemma":0.0000398453,"teacher_disagreement_score":0.15642698,"about_ca_system_score_codex":0.000108191656,"about_ca_system_score_gemma":0.000033195305,"threshold_uncertainty_score":0.93018436},"labels":[],"label_agreement":null},{"id":"W2156756013","doi":"10.1186/1753-6561-6-s4-o46","title":"Association between kidney function and mortality among incident metformin users: a retrospective cohort study","year":2012,"lang":"en","type":"article","venue":"BMC Proceedings","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Metformin; Renal function; Lactic acidosis; Kidney disease; Retrospective cohort study; Internal medicine; Type 2 diabetes; Diabetes mellitus; Cohort; Cohort study; Intensive care medicine; Endocrinology","score_opus":0.02268788021415208,"score_gpt":0.27514923720949375,"score_spread":0.25246135699534167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156756013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269176,0.000034128872,0.00003094195,0.000041356037,0.00013638481,0.0017972471,0.0000037300115,0.00012040155,0.0051440513],"genre_scores_gemma":[0.99712527,0.000008640223,0.00016231788,0.00009951636,0.00034814843,0.00021580569,0.000029605591,0.000018230385,0.0019924606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987008,0.000009782598,0.00022083927,0.00026476415,0.0005009003,0.00030290795],"domain_scores_gemma":[0.9992992,0.000018764858,0.00020287542,0.000087998,0.0001491038,0.00024204796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011389907,0.00015872739,0.0003307676,0.00010836288,0.0000866684,0.000056737845,0.00003577728,0.00007652835,0.00003431059],"category_scores_gemma":[0.00032718733,0.0001356894,0.000054175474,0.00020173003,0.000020101957,0.00066346483,0.00007754455,0.00010939677,0.000019091984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026366564,0.00033895244,0.9953757,0.00007092692,0.000995796,3.5318658e-7,0.00061712356,7.2996253e-9,0.00003225371,0.00015712925,0.0022500881,0.00013529524],"study_design_scores_gemma":[0.001416336,0.00046187823,0.992857,0.000033581455,0.0032191114,3.6813833e-7,0.0012513804,0.000008265827,0.00015092046,0.0001434938,0.00033370795,0.0001239745],"about_ca_topic_score_codex":0.00016121387,"about_ca_topic_score_gemma":0.000018497747,"teacher_disagreement_score":0.004433517,"about_ca_system_score_codex":0.0006569972,"about_ca_system_score_gemma":0.000017394788,"threshold_uncertainty_score":0.55332536},"labels":[],"label_agreement":null},{"id":"W2157068658","doi":"10.2337/diabetes.50.5.1004","title":"Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats","year":2001,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Endocrinology; Internal medicine; Receptor; Chemistry; Diabetes mellitus; Biology; Medicine","score_opus":0.011391039611602444,"score_gpt":0.24076631940807955,"score_spread":0.2293752797964771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157068658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092215,0.0018002241,0.00002686115,0.00037219212,0.0002926358,0.00086714735,0.000007321644,0.00016409218,0.005547373],"genre_scores_gemma":[0.99588335,0.00036448086,0.000975468,0.0006642457,0.00015861227,0.00025400962,0.00009095452,0.000051608105,0.0015572702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998059,0.00009121582,0.00034138907,0.0005012537,0.0003471236,0.0006600533],"domain_scores_gemma":[0.9991059,0.00011199133,0.000093254734,0.00043195646,0.000058965677,0.00019798311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016660674,0.00031050734,0.00048277905,0.0002821953,0.00006909666,0.000036893027,0.00013058449,0.0001214922,0.00037847357],"category_scores_gemma":[0.00010282539,0.0002578694,0.00013840573,0.00035669343,0.00006506391,0.00018687302,0.00012456259,0.00021194309,0.00050625036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069928494,0.00071458693,0.8437906,0.00007020767,0.000115406256,0.000047856567,0.00021080098,0.000007735982,0.13016415,0.000057109177,0.00088813243,0.023863519],"study_design_scores_gemma":[0.0034454388,0.0005190156,0.5445003,0.0004310387,0.00014681989,7.610893e-7,0.00017039476,0.000100911675,0.44318932,0.0002492384,0.006910101,0.00033670192],"about_ca_topic_score_codex":0.000027352196,"about_ca_topic_score_gemma":0.000016843449,"teacher_disagreement_score":0.31302518,"about_ca_system_score_codex":0.00024991395,"about_ca_system_score_gemma":0.000032954347,"threshold_uncertainty_score":0.99998736},"labels":[],"label_agreement":null},{"id":"W2157094207","doi":"10.1152/ajpgi.00275.2012","title":"Intestinal adaptation and Reg gene expression induced by antidiabetic duodenal-jejunal bypass surgery in Zucker fatty rats","year":2013,"lang":"en","type":"article","venue":"American Journal of Physiology-Gastrointestinal and Liver Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Duodenum; Jejunum; Ileum; Internal medicine; Biology; Intestinal mucosa; Immunohistochemistry; Small intestine; Endocrinology; Medicine","score_opus":0.01480854415142874,"score_gpt":0.22468006283665506,"score_spread":0.20987151868522633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157094207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987041,0.0003449124,0.0001537342,0.00047919972,0.00006936577,0.00019956626,0.0000027656654,0.000017238728,0.00002913887],"genre_scores_gemma":[0.9920801,0.0002110101,0.0070177964,0.0004241769,0.0001546843,0.00002201112,0.000028355245,0.000022698228,0.00003917915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980627,0.00028085997,0.0006014172,0.00040848998,0.00016951015,0.0004770281],"domain_scores_gemma":[0.9982392,0.0004616189,0.00064537267,0.00016725712,0.00022872038,0.0002578272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021670519,0.00032430826,0.0009614231,0.00030126792,0.00006993375,0.000019242261,0.00010506938,0.000047278587,0.00006929561],"category_scores_gemma":[0.0001445556,0.00024303532,0.00012385735,0.0002271784,0.0005860735,0.00026041456,0.00011855699,0.00040550515,0.000011335022],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005762564,0.00034289804,0.0382696,0.000059040824,0.00007894617,0.000039403625,0.000117735144,0.000013520778,0.9474259,0.000012174517,0.00078641874,0.012278093],"study_design_scores_gemma":[0.0013880309,0.0048722047,0.9703745,0.00058054936,0.00012881517,0.00069158577,0.00058122113,0.00060719723,0.020138804,0.00037016426,0.00003275071,0.00023418092],"about_ca_topic_score_codex":0.00026315928,"about_ca_topic_score_gemma":0.0000031143475,"teacher_disagreement_score":0.9321049,"about_ca_system_score_codex":0.000051461895,"about_ca_system_score_gemma":0.00007618909,"threshold_uncertainty_score":0.99106926},"labels":[],"label_agreement":null},{"id":"W2157292050","doi":"10.1016/j.jcjd.2015.01.183","title":"Liraglutide 3.0 mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity: The SCALE Obesity and Prediabetes Randomised Trial","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Liraglutide; Medicine; Prediabetes; Overweight; Placebo; Internal medicine; Body mass index; Endocrinology; Waist; Weight loss; Obesity; Diabetes mellitus; Type 2 diabetes","score_opus":0.006901810554957756,"score_gpt":0.19806417522333336,"score_spread":0.1911623646683756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157292050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903789,0.007238395,6.117134e-7,0.00039450827,0.00033456666,0.0011188744,0.000033247405,0.000010649796,0.00049022713],"genre_scores_gemma":[0.99897975,0.00028213844,0.00012389992,0.00008746619,0.00034429165,0.000025095918,0.0000099122935,0.000026723885,0.00012069729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824184,0.00018282289,0.00044672543,0.00026365233,0.0003190759,0.00054587435],"domain_scores_gemma":[0.99799347,0.00023185345,0.00032397246,0.00023098441,0.00016736906,0.0010523364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086928165,0.00029803428,0.0008526493,0.0005266604,0.00015016488,0.00012319785,0.00015396948,0.000094611125,0.00000875821],"category_scores_gemma":[0.00035386762,0.00017189911,0.00012902943,0.0003127906,0.00031897414,0.00031673757,0.00003277489,0.00030427045,0.0000010157923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018150841,0.00009955451,0.9916457,0.000058462465,0.00066302024,0.000023387767,0.0014695951,0.0000019753995,0.000106229505,0.000014354596,0.00067156716,0.0034311032],"study_design_scores_gemma":[0.12969756,0.0024052865,0.86020076,0.0004153886,0.0014683198,0.0000042744978,0.0013268029,0.00009498742,0.0020502084,0.00023321174,0.0018250706,0.00027811408],"about_ca_topic_score_codex":0.0015306199,"about_ca_topic_score_gemma":0.0039023294,"teacher_disagreement_score":0.13144489,"about_ca_system_score_codex":0.00013535802,"about_ca_system_score_gemma":0.000548617,"threshold_uncertainty_score":0.70098424},"labels":[],"label_agreement":null},{"id":"W2157648117","doi":"10.1152/ajpendo.00140.2015","title":"Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses","year":2015,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Biotechnology and Biological Sciences Research Council; Directorate for Biological Sciences; Government of Canada; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Glucagon; Internal medicine; Endocrinology; Neurotransmission; Medicine; Term (time); Insulin; Receptor","score_opus":0.017232737666778353,"score_gpt":0.2698068700352388,"score_spread":0.25257413236846044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157648117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920464,0.004873117,0.000026090309,0.0019732886,0.0004862885,0.00022112593,0.000008684519,0.000055151173,0.00030986188],"genre_scores_gemma":[0.9950607,0.0029311231,0.00062878,0.00090753543,0.0002583324,0.000015311718,0.000009843048,0.00003609949,0.00015228386],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997807,0.00043088474,0.0005585712,0.00034299283,0.00024411824,0.00061639823],"domain_scores_gemma":[0.998313,0.00029393198,0.00028644083,0.00032401737,0.00027124034,0.00051137264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025803913,0.00033185366,0.001099801,0.00031492056,0.000083570354,0.000016349502,0.00022003075,0.00007668325,0.000045825378],"category_scores_gemma":[0.00027222416,0.00023061143,0.00020385852,0.00021883968,0.00085981004,0.00014573103,0.00010929719,0.00044718973,0.000016485734],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007601233,0.0013874638,0.05547246,0.00013521883,0.002284,0.0009426149,0.0023327745,0.000020213278,0.77560246,0.001092762,0.00212167,0.15100713],"study_design_scores_gemma":[0.0059824223,0.0048747933,0.93347985,0.00014526231,0.001980588,0.0005291414,0.0016545072,0.000024141887,0.03277469,0.0014090565,0.016713627,0.00043194008],"about_ca_topic_score_codex":0.000010694211,"about_ca_topic_score_gemma":6.552642e-7,"teacher_disagreement_score":0.87800735,"about_ca_system_score_codex":0.00002903951,"about_ca_system_score_gemma":0.00013983693,"threshold_uncertainty_score":0.9404061},"labels":[],"label_agreement":null},{"id":"W2157936156","doi":"10.1152/ajpendo.00429.2006","title":"Role of phosphatidylinositol-3 kinase-γ in the actions of glucagon-like peptide-2 on the murine small intestine","year":2007,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs","funders":"","keywords":"Crypt; Phosphatidylinositol; Internal medicine; Endocrinology; Glucagon-like peptide-2; Basal (medicine); Small intestine; Kinase; Biology; Receptor; Motility; Intestinal epithelium; Knockout mouse; Epithelium; Cell biology; Peptide; Medicine; Biochemistry; Insulin","score_opus":0.015450649412067514,"score_gpt":0.26331152533528623,"score_spread":0.24786087592321873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157936156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463403,0.0018101995,0.000014251901,0.0016527554,0.00015113752,0.00020827424,0.0000036833237,0.0000054905563,0.0015201975],"genre_scores_gemma":[0.99721277,0.0010898226,0.0005591701,0.0009308583,0.00012221855,0.000007699279,0.0000025386062,0.000008809719,0.00006612826],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987747,0.00016420167,0.0005010751,0.00014031926,0.00012534717,0.00029436892],"domain_scores_gemma":[0.99836314,0.00060937525,0.0005911228,0.00025874394,0.00012330365,0.000054328593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003869283,0.00015864728,0.00062944356,0.00024673206,0.000052127394,0.000002468316,0.0002071684,0.00002934441,0.00002462259],"category_scores_gemma":[0.00012024862,0.00008311766,0.00014736259,0.00030498038,0.00074751215,0.00003877068,0.00005648417,0.0003730416,0.000001949914],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003237406,0.0031025864,0.03351616,0.00007509095,0.0018322655,0.0001040409,0.002920237,0.00004952842,0.6361372,0.066480726,0.0007381575,0.2518066],"study_design_scores_gemma":[0.0017351541,0.0020241856,0.92966473,0.000072179115,0.00048504077,0.000120385266,0.0052793124,0.0000063295197,0.04775995,0.0015554492,0.01121711,0.000080202066],"about_ca_topic_score_codex":0.0001022227,"about_ca_topic_score_gemma":0.000025016183,"teacher_disagreement_score":0.89614856,"about_ca_system_score_codex":0.000012423396,"about_ca_system_score_gemma":0.00003659434,"threshold_uncertainty_score":0.33894396},"labels":[],"label_agreement":null},{"id":"W2157951358","doi":"10.1139/h2012-068","title":"Alterations in energy balance following exenatide administration","year":2012,"lang":"en","type":"article","venue":"Applied Physiology Nutrition and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; NIH Clinical Center; National Center for Research Resources; National Heart, Lung, and Blood Institute","keywords":"Exenatide; Internal medicine; Medicine; Endocrinology; Weight loss; Body mass index; Energy expenditure; Animal science; Obesity; Type 2 diabetes; Diabetes mellitus; Biology","score_opus":0.011616258267959081,"score_gpt":0.256178393874269,"score_spread":0.2445621356063099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157951358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004203,0.0027833881,0.0001229057,0.0004851844,0.00019587058,0.00030514935,0.000003157094,0.000039460007,0.0060228505],"genre_scores_gemma":[0.9962068,0.00065646955,0.0010039818,0.0011080878,0.00022974762,0.00033943396,0.00024103657,0.000007815573,0.0002066246],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.999446,0.000019440738,0.00013732945,0.000142641,0.000059103048,0.00019548663],"domain_scores_gemma":[0.99976474,0.000022394572,0.000032586093,0.000096915624,0.000009219063,0.00007417215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062691506,0.0000962803,0.00020593838,0.000091945956,0.000045388482,0.0000074094446,0.000019239802,0.00005199587,0.000025609954],"category_scores_gemma":[0.000004386486,0.00008757508,0.00004045895,0.00010011013,0.000024343615,0.00010009029,0.000014563171,0.00004976341,0.000010074902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019293228,0.0027063433,0.0024529917,0.00011978308,0.00023545517,0.000006820228,0.00044475365,0.0000019717982,0.3915377,0.5706068,0.0027180284,0.02897642],"study_design_scores_gemma":[0.008734008,0.000041565705,0.60293245,0.000058524252,0.00028148777,0.0000054480784,0.00027943472,0.00010932011,0.029410709,0.007536465,0.3503546,0.00025595384],"about_ca_topic_score_codex":0.000005776186,"about_ca_topic_score_gemma":0.0000030428307,"teacher_disagreement_score":0.6004795,"about_ca_system_score_codex":0.000012561389,"about_ca_system_score_gemma":0.000008660351,"threshold_uncertainty_score":0.35712078},"labels":[],"label_agreement":null},{"id":"W2158388227","doi":"10.2337/diacare.27.6.1330","title":"Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes","year":2004,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Internal medicine; ACE inhibitor; Endocrinology; Angiotensin-converting enzyme","score_opus":0.015414143284171365,"score_gpt":0.22334882057994657,"score_spread":0.2079346772957752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158388227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846613,0.00013487042,1.358403e-7,0.00022765034,0.000062846775,0.0008561437,0.000035077628,0.00004641465,0.00017075038],"genre_scores_gemma":[0.99906874,0.0000037740708,0.0001055511,0.00025349576,0.00001618419,0.000045975554,0.00042011304,0.000031082433,0.0000551036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988171,0.000038718594,0.00018661523,0.0002442347,0.000371387,0.00034198695],"domain_scores_gemma":[0.99910754,0.000061968094,0.00013358174,0.00036803045,0.00026103688,0.00006785713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007059582,0.00020155423,0.0003486455,0.0000944742,0.000041817908,0.000022731725,0.00008433878,0.00006239651,0.000009512384],"category_scores_gemma":[0.00008643401,0.00011491216,0.000052760297,0.0005303092,0.00011903664,0.00013872123,0.000046308305,0.000117331256,0.0000073959077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044827055,0.00036093037,0.9968055,0.00007666521,0.0004083083,0.0000028895083,0.0005981279,0.00018127971,0.00013418244,0.000012769368,0.00037002287,0.0010045],"study_design_scores_gemma":[0.0035567787,0.0012721708,0.9875286,0.0005124051,0.00038903527,6.519563e-9,0.0002569733,0.000004971748,0.005942899,0.000007116493,0.00038408823,0.00014495813],"about_ca_topic_score_codex":0.000024206289,"about_ca_topic_score_gemma":0.00011018718,"teacher_disagreement_score":0.0092769,"about_ca_system_score_codex":0.00018920528,"about_ca_system_score_gemma":0.000060314702,"threshold_uncertainty_score":0.4685982},"labels":[],"label_agreement":null},{"id":"W2158717881","doi":"10.1159/000177502","title":"Structure and Function of Small Arteries of Essential Hypertensive Patients Following Chronic Treatment with Once-a-Day Nifedipine","year":2008,"lang":"en","type":"review","venue":"Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Myograph; Nifedipine; Atenolol; Medicine; Essential hypertension; Blood pressure; Cardiology; Internal medicine; Nebivolol; Anesthesia; Artery; Calcium","score_opus":0.0172955771547234,"score_gpt":0.2442007328055702,"score_spread":0.2269051556508468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158717881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041371852,0.95658123,0.00003957017,0.0000056121003,0.0004574249,0.0011633337,0.00006408172,0.000016113197,0.00030078774],"genre_scores_gemma":[0.025691146,0.9727571,0.00007879233,0.00001089036,0.00024329928,0.0000656646,0.0009222196,0.000032756467,0.00019811942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988972,0.00008585998,0.00035928548,0.00034361798,0.00011121232,0.00020280495],"domain_scores_gemma":[0.9992128,0.000055878903,0.00028639956,0.0002936463,0.00009583843,0.000055430635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023658939,0.00035710566,0.0026939588,0.00015317298,0.000030425985,0.000002467761,0.000041558942,0.00020261417,0.000008150028],"category_scores_gemma":[0.00001187391,0.00021621266,0.0004352855,0.00009740491,0.00017380505,0.000023681423,0.000040686562,0.000080249425,0.0000013844551],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069044545,0.00007110916,0.0036839398,0.004217534,0.0077316468,0.0001266088,0.00005922809,0.000002173987,0.000010565455,0.00001946633,0.00012899184,0.9838797],"study_design_scores_gemma":[0.0051448653,0.013235362,0.0051152864,0.0044596954,0.022347338,0.000119734126,0.000038797443,0.000001448703,0.000043817792,0.0000066265884,0.9491621,0.00032488053],"about_ca_topic_score_codex":0.000010357859,"about_ca_topic_score_gemma":0.000006104375,"teacher_disagreement_score":0.98355484,"about_ca_system_score_codex":0.00015273156,"about_ca_system_score_gemma":0.00015968493,"threshold_uncertainty_score":0.8816896},"labels":[],"label_agreement":null},{"id":"W2158770486","doi":"10.2337/dc06-0845","title":"Adequacy of Glycemic Control in Hemodialysis Patients With Diabetes","year":2006,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Diabetes mellitus; Glycemic; Internal medicine; Type 2 diabetes; Odds ratio; Hemodialysis; Dialysis; Endocrinology","score_opus":0.002791067732334729,"score_gpt":0.18626304953287798,"score_spread":0.18347198180054325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158770486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953189,0.00065305724,0.0000032345247,0.000084613406,0.000047320988,0.0007319393,0.00007974823,0.000048327172,0.0030328683],"genre_scores_gemma":[0.9986579,0.0000029011899,0.00018201537,0.00025226557,0.00004410928,0.0001091217,0.00063546846,0.000031402433,0.0000848337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986572,0.000027783457,0.0003047489,0.00028532042,0.00030798384,0.0004169531],"domain_scores_gemma":[0.99925715,0.00007006255,0.00011865644,0.0003275369,0.00016096229,0.000065611304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047094607,0.00021903646,0.0005534536,0.00026447547,0.000024634921,0.000013402201,0.00008941597,0.00006578784,0.000049512175],"category_scores_gemma":[0.000019493735,0.0001702541,0.0001249739,0.00035240946,0.00007072299,0.000097910255,0.00002916729,0.00007845755,0.000034341738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117269985,0.00038777784,0.99245524,0.00025324515,0.00017893822,0.000002992168,0.00009412107,0.000055924167,0.0004023715,0.00004294693,0.00025833305,0.0057508303],"study_design_scores_gemma":[0.012032983,0.0008504053,0.98158616,0.00022589865,0.00055318326,9.252415e-9,0.0001321698,0.00013025229,0.0034949596,0.000052703195,0.0007483841,0.00019289949],"about_ca_topic_score_codex":0.000024171912,"about_ca_topic_score_gemma":0.000031849948,"teacher_disagreement_score":0.011915714,"about_ca_system_score_codex":0.00011301844,"about_ca_system_score_gemma":0.000025354428,"threshold_uncertainty_score":0.6942761},"labels":[],"label_agreement":null},{"id":"W2159175156","doi":"10.1503/cmaj.080547","title":"Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Insulin; Internal medicine; Metformin; Diabetes mellitus; Cohort; Type 2 diabetes; Population; Drug; Cohort study; Endocrinology; Pharmacology","score_opus":0.010123200838020263,"score_gpt":0.2480213635442766,"score_spread":0.23789816270625633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159175156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867493,0.00019049371,0.0000043985046,0.0073757013,0.00020699028,0.00018602067,0.000004780671,0.000008905448,0.005273445],"genre_scores_gemma":[0.9936232,0.00029239495,0.00010800206,0.0056742704,0.00018206636,0.0000026099788,0.000033400007,0.0000071526038,0.00007691667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824125,0.00008507372,0.00041431733,0.000100494406,0.0008359503,0.00032294437],"domain_scores_gemma":[0.99887145,0.000053226075,0.00029941514,0.000063829735,0.00025346357,0.00045864392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007836345,0.00009490407,0.00024992847,0.00035649605,0.000055376728,0.000027400247,0.00007880181,0.00016509184,0.00069582433],"category_scores_gemma":[0.00063202926,0.00008351124,0.00007242175,0.00029202105,0.000013339702,0.00013904713,0.0000040192213,0.00031284508,0.000017318842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013099808,0.00015906856,0.51986307,0.0000039427423,0.00005569192,0.000032361597,0.00029495894,8.947575e-7,0.000009487614,0.000079758385,0.0032735788,0.47621408],"study_design_scores_gemma":[0.004778049,0.000721714,0.9794435,0.00014975047,0.000025378364,0.0000018433337,0.00011511018,0.00007369054,0.00010394249,0.00027511446,0.014227964,0.00008393595],"about_ca_topic_score_codex":0.00048239695,"about_ca_topic_score_gemma":0.0013129446,"teacher_disagreement_score":0.47613013,"about_ca_system_score_codex":0.00061911804,"about_ca_system_score_gemma":0.00059904903,"threshold_uncertainty_score":0.76187885},"labels":[],"label_agreement":null},{"id":"W2159205789","doi":"10.1016/s0140-6736(06)69705-5","title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","year":2006,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3875,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Deutsche Diabetes Gesellschaft; Canada Research Chairs; Juvenile Diabetes Research Foundation Canada; Canadian Diabetes Association; Deutsche Forschungsgemeinschaft; Eli Lilly and Company","keywords":"Vildagliptin; Incretin; Exenatide; Liraglutide; Sitagliptin; Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Pharmacology; Glucagon-like peptide 1 receptor; Gastric emptying; Diabetes mellitus; Receptor; Agonist","score_opus":0.026999477159742994,"score_gpt":0.28659426343957495,"score_spread":0.25959478627983196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159205789","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026752804,0.9809056,1.6588722e-7,0.0006495366,0.00076197385,0.0021593266,0.000046187914,0.0001435742,0.012658349],"genre_scores_gemma":[0.00075295573,0.98908085,0.000071750765,0.0002172944,0.0016890095,0.00040014883,0.00041665253,0.000097445874,0.007273902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733347,0.00034900106,0.0007050188,0.0005049995,0.00035920623,0.00074831897],"domain_scores_gemma":[0.99787176,0.0005101066,0.00037208616,0.0010924938,0.000050613085,0.00010294297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001119229,0.0005882277,0.002253867,0.00014529121,0.00023599788,0.0001798939,0.00045467122,0.00022179837,0.000015458098],"category_scores_gemma":[0.00008658117,0.00029052372,0.00026408053,0.00049303024,0.00024081916,0.000054222226,0.00029698206,0.00053691096,0.000298363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064741515,0.00010786781,0.0014002704,0.024880031,0.00071611535,0.000038552116,0.00009428817,3.9862908e-7,0.0000030861263,0.0008452157,0.3068169,0.6650325],"study_design_scores_gemma":[0.00084471476,0.00016112941,0.00027014565,0.01683661,0.0011397082,0.000005144388,0.00007999168,0.000006436247,0.0000030771387,0.000017052496,0.98034406,0.00029192987],"about_ca_topic_score_codex":0.00006915364,"about_ca_topic_score_gemma":0.000058369533,"teacher_disagreement_score":0.6735271,"about_ca_system_score_codex":0.00031809715,"about_ca_system_score_gemma":0.000108675194,"threshold_uncertainty_score":0.9999547},"labels":[],"label_agreement":null},{"id":"W2160001758","doi":"10.2337/dc08-2124","title":"Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)","year":2009,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":838,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Liraglutide; Medicine; Placebo; Metformin; Type 2 diabetes; Internal medicine; Endocrinology; Postprandial; Thiazolidinedione; Diabetes mellitus; Rosiglitazone; Pioglitazone; Urology","score_opus":0.005774949752751799,"score_gpt":0.21593961548802468,"score_spread":0.21016466573527287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160001758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718463,0.0007784452,3.56882e-7,0.00013450162,0.000033477347,0.0011105082,0.000010619986,0.000022484395,0.0007249959],"genre_scores_gemma":[0.99924105,0.000041995892,0.00020281946,0.00021878426,0.00001059136,0.000021283586,0.00018516048,0.000019545818,0.00005876967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987737,0.000049055543,0.0002753784,0.00030079138,0.0002850616,0.00031602502],"domain_scores_gemma":[0.9993232,0.00006504156,0.00012659121,0.00028705565,0.00013074932,0.00006739921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014441808,0.00023235951,0.00045843594,0.00024430745,0.00006585869,0.000019900204,0.000087022556,0.000065263375,0.000004771658],"category_scores_gemma":[0.000038201575,0.0001433064,0.000030912735,0.00053075934,0.00011385673,0.00015210824,0.00005952918,0.00013971444,0.0000012257069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015710793,0.0003843043,0.98263085,0.0001485338,0.00010019782,0.0000021189908,0.0006782196,0.000010102592,0.00025424125,0.00021982778,0.000037912236,0.015376573],"study_design_scores_gemma":[0.009684795,0.002924182,0.98370457,0.0006426665,0.00024630444,8.957426e-8,0.00035199666,0.000027296397,0.0020347158,0.00007926596,0.0001381636,0.00016598302],"about_ca_topic_score_codex":0.000012596608,"about_ca_topic_score_gemma":0.000072672636,"teacher_disagreement_score":0.01521059,"about_ca_system_score_codex":0.000088450644,"about_ca_system_score_gemma":0.00002343134,"threshold_uncertainty_score":0.5843865},"labels":[],"label_agreement":null},{"id":"W2160080698","doi":"10.1210/en.2003-0309","title":"Glucagon-Like Peptide-2 Receptor Activation in the Rat Intestinal Mucosa","year":2003,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research; University of Toronto; Canada Research Chairs; Canadian Diabetes Association","keywords":"Endocrinology; Internal medicine; Biology; Enteroendocrine cell; Receptor; Protein kinase A; MAPK/ERK pathway; Chromogranin A; Intestinal mucosa; Kinase; Glucagon; Signal transduction; Glucagon-like peptide-2; Cell biology; Peptide; Biochemistry; Hormone; Medicine; Endocrine system","score_opus":0.02243284426387987,"score_gpt":0.2711033319241066,"score_spread":0.24867048766022676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160080698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9214311,0.00010267456,0.0001244076,0.0041018855,0.00040094243,0.00050570694,3.2800637e-7,0.000056865214,0.07327604],"genre_scores_gemma":[0.9926295,0.00004806739,0.00096702,0.0017488172,0.000059609356,0.00010829903,0.000029762701,0.000010129545,0.0043987436],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914896,0.000103391954,0.00014626633,0.00018768763,0.00010260066,0.00031111622],"domain_scores_gemma":[0.9995617,0.000113094924,0.000039916016,0.00023397202,0.000022573524,0.00002872078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009843225,0.00011135816,0.00015253486,0.0001178819,0.00003952244,0.0000099991385,0.00007831541,0.000029056047,0.00032476272],"category_scores_gemma":[0.00015569192,0.00007554824,0.00004209423,0.00017203734,0.000053076412,0.000052858897,0.000022912993,0.00015365922,0.0002405013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055783667,0.0033336645,0.27048302,0.00019093178,0.0005005683,0.00049870234,0.0034102278,0.000016597474,0.034450367,0.33232582,0.20407844,0.15015385],"study_design_scores_gemma":[0.0037512719,0.000878643,0.03776141,0.00006124076,0.00009739856,0.00007668043,0.0015027852,0.0000109357825,0.033004,0.0011924792,0.92148304,0.00018011936],"about_ca_topic_score_codex":0.000026688043,"about_ca_topic_score_gemma":0.000017476379,"teacher_disagreement_score":0.7174046,"about_ca_system_score_codex":0.000077901,"about_ca_system_score_gemma":0.000030040357,"threshold_uncertainty_score":0.3555924},"labels":[],"label_agreement":null},{"id":"W2160286139","doi":"10.1016/j.jash.2009.04.001","title":"Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies","year":2009,"lang":"en","type":"article","venue":"Journal of the American Society of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Diabetes Canada; Toronto General Hospital; University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Incretin; Sitagliptin; Glucagon-like peptide-1; Exenatide; Type 2 diabetes; Diabetes mellitus; Liraglutide; Pharmacology; Dipeptidyl peptidase-4; Internal medicine; Endocrinology","score_opus":0.020863537846023295,"score_gpt":0.24752333668650447,"score_spread":0.22665979884048118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160286139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98865455,0.0047888053,0.00011517897,0.005733976,0.00006575032,0.0006191054,0.00001054117,0.0000037020015,0.000008397312],"genre_scores_gemma":[0.99358857,0.0016132338,0.004268534,0.00043313674,0.000052720512,0.0000053328895,0.0000018711154,0.000010365309,0.000026263753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986074,0.00008875707,0.00052268704,0.00010097291,0.00053503114,0.00014517434],"domain_scores_gemma":[0.9977358,0.00022805635,0.0012088977,0.00037327,0.0004154968,0.00003845185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004598758,0.00014574325,0.0010247013,0.00004554695,0.0000517765,0.0000034556672,0.00017214003,0.000029470202,0.00000400561],"category_scores_gemma":[0.000032886557,0.00006737361,0.0020579922,0.0001905795,0.000731553,0.000035914112,0.0000146541015,0.000052923482,6.3426654e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001087282,0.0023413978,0.011385163,0.00030006733,0.011388948,0.0000038117046,0.002627973,0.0008077299,0.8892603,0.000011706738,0.0024307535,0.078354895],"study_design_scores_gemma":[0.01721543,0.024429476,0.10192021,0.0011756698,0.014725774,0.000015478434,0.011846948,0.0029066156,0.8208625,0.00028306028,0.0043642097,0.00025463774],"about_ca_topic_score_codex":0.00007192849,"about_ca_topic_score_gemma":2.8156904e-7,"teacher_disagreement_score":0.09053505,"about_ca_system_score_codex":0.000048866325,"about_ca_system_score_gemma":0.00011184892,"threshold_uncertainty_score":0.27474162},"labels":[],"label_agreement":null},{"id":"W2160488115","doi":"","title":"Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.","year":2012,"lang":"en","type":"review","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Internal medicine; Hypoglycemia; Meta-analysis; Adverse effect; Randomized controlled trial; Diabetes mellitus; MEDLINE; Cochrane Library; Glycated hemoglobin; Type 2 Diabetes Mellitus; Insulin; Endocrinology","score_opus":0.09875895686175265,"score_gpt":0.303926196849103,"score_spread":0.20516723998735034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160488115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024083054,0.9730424,4.5508543e-7,0.000028191153,0.000015143332,0.024372285,0.000023111686,0.000017486269,0.00009258533],"genre_scores_gemma":[0.013344044,0.9655462,0.0000683682,0.00006829486,0.000008457271,0.020301837,0.00025824024,0.000047569676,0.00035698566],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99713695,0.0003639919,0.0011727217,0.00046478552,0.00039186465,0.00046966854],"domain_scores_gemma":[0.9974044,0.00044795306,0.0012136559,0.00058836816,0.00013817908,0.00020744979],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00075221364,0.0007173186,0.015032896,0.0005398607,0.00002525777,0.00002980479,0.00009914351,0.000110122164,0.000014893753],"category_scores_gemma":[0.0000752783,0.00030705286,0.0006957746,0.00095263805,0.00007618208,0.00010124292,0.00003996927,0.00011688216,0.0000017873838],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001455971,0.0010826691,0.014598165,0.41255653,0.40892515,0.0000033316142,0.00003294374,1.0724714e-7,1.1302079e-9,0.000007899618,0.000011154825,0.16263644],"study_design_scores_gemma":[0.0071379715,0.0010422838,0.011016797,0.013272245,0.95772094,7.1281886e-7,0.000006740344,7.8496726e-7,4.3283538e-7,6.3916013e-7,0.009506074,0.00029436202],"about_ca_topic_score_codex":0.000051663672,"about_ca_topic_score_gemma":0.00012160892,"teacher_disagreement_score":0.5487958,"about_ca_system_score_codex":0.00015130667,"about_ca_system_score_gemma":0.000041068142,"threshold_uncertainty_score":0.99993813},"labels":[],"label_agreement":null},{"id":"W2160658586","doi":"10.1136/eb-2013-101248","title":"Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride","year":2013,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Exenatide; Glimepiride; Medicine; Internal medicine; Gastroenterology; Metformin; Web of science; Type 2 diabetes; Endocrinology; Insulin; Diabetes mellitus","score_opus":0.01819912133871854,"score_gpt":0.2422558173079865,"score_spread":0.22405669596926797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160658586","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24673392,0.00835117,0.0013640013,0.72783303,0.0011794433,0.011964013,0.00010411118,0.00045653724,0.0020137404],"genre_scores_gemma":[0.3409171,0.0008268866,0.010718234,0.5692751,0.0063571464,0.0030009134,0.0021078254,0.0007098283,0.066087015],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99334747,0.0002221026,0.0011331239,0.001492622,0.0024131094,0.0013915923],"domain_scores_gemma":[0.99379283,0.0014192717,0.0012946324,0.002038611,0.00093339,0.0005212758],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005818969,0.0014544479,0.003014093,0.00076756394,0.00010871313,0.00003299439,0.0006963916,0.0005550748,0.0003696419],"category_scores_gemma":[0.0004863824,0.000868087,0.00030465494,0.0005432828,0.0014908377,0.00045380375,0.00013246984,0.0017035286,0.000110876594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044089565,0.00046782455,0.014099608,0.015483195,0.0024419338,0.010146705,0.0006249721,0.000052691175,0.0022639276,0.00001776256,0.9433878,0.0066045956],"study_design_scores_gemma":[0.10850817,0.052200023,0.08313542,0.35694957,0.027950164,0.00019952988,0.0018527558,0.0011846765,0.04416017,0.00017998947,0.3182659,0.0054136547],"about_ca_topic_score_codex":0.0027621177,"about_ca_topic_score_gemma":0.00005815624,"teacher_disagreement_score":0.62512195,"about_ca_system_score_codex":0.0006250818,"about_ca_system_score_gemma":0.0007152587,"threshold_uncertainty_score":0.99982053},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2160940672","doi":"10.1053/j.gastro.2009.05.051","title":"Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36","year":2009,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Hospital for Sick Children; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Chylomicron; Lipoprotein; Endocrinology; CD36; Internal medicine; Chemistry; Very low-density lipoprotein; Biology; Biochemistry; Cholesterol; Medicine; Receptor","score_opus":0.008401844126862198,"score_gpt":0.228982388320247,"score_spread":0.2205805441933848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160940672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505013,0.00007991159,0.00038785764,0.0034187355,0.00023552302,0.00037028154,0.0000011998153,0.00009515164,0.00036123456],"genre_scores_gemma":[0.9955444,0.000083366765,0.0013119607,0.0018040783,0.00030977017,0.000022063145,0.00007783814,0.000010967737,0.00083558756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905086,0.0000388909,0.00018773458,0.00032616864,0.00008722751,0.00030912494],"domain_scores_gemma":[0.9995804,0.000007932011,0.00007655558,0.00019339102,0.000041483578,0.00010026222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011065693,0.00015978288,0.00023428639,0.0001398173,0.00004785173,0.000012048056,0.00004219594,0.00004227174,0.00004472964],"category_scores_gemma":[0.000028157458,0.0001415599,0.00004859512,0.000052371808,0.00007515781,0.00009226332,0.000038729617,0.00009653465,0.00004283771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031825954,0.0016730927,0.78895247,0.000107579406,0.000254088,0.000075117,0.00015404669,0.000010558172,0.10050043,0.000092622366,0.012632337,0.092365064],"study_design_scores_gemma":[0.0024971308,0.006121689,0.9848645,0.000077212666,0.00030451134,0.00045553633,0.000040218092,0.00008996739,0.0018101572,0.0001583648,0.003488892,0.00009187378],"about_ca_topic_score_codex":0.000030432582,"about_ca_topic_score_gemma":0.000030050265,"teacher_disagreement_score":0.19591197,"about_ca_system_score_codex":0.00006060221,"about_ca_system_score_gemma":0.0000072371568,"threshold_uncertainty_score":0.57726455},"labels":[],"label_agreement":null},{"id":"W2161216860","doi":"10.1152/ajpendo.00529.2012","title":"Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance","year":2013,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canada Research Chairs","keywords":"Endocrinology; Internal medicine; Medicine; Glucocorticoid; Hypothalamic–pituitary–adrenal axis; Adrenal gland; Agonist; Receptor; Hormone","score_opus":0.005224791574582386,"score_gpt":0.2272917844044184,"score_spread":0.22206699282983602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161216860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747276,0.0007564823,0.000011034269,0.0011058074,0.0001799336,0.0003308121,0.0000020067403,0.000010831138,0.00013033525],"genre_scores_gemma":[0.9979876,0.0009978206,0.00042466508,0.00032899372,0.00012524934,0.000027036354,0.0000033478132,0.0000103427665,0.00009493794],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989608,0.0001536573,0.00025703004,0.00020965635,0.00010407352,0.00031478822],"domain_scores_gemma":[0.99924994,0.00013583618,0.00028555593,0.00013512223,0.000082765604,0.00011078424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007693034,0.00018549449,0.00073823385,0.00017497063,0.000050079343,0.000005895568,0.000067654066,0.00004259855,0.00003294879],"category_scores_gemma":[0.000038241986,0.00011548369,0.0000897359,0.00006156426,0.0005400517,0.00014337251,0.000047815465,0.0002413943,0.0000066840344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086242706,0.00049557094,0.0034596615,0.000106170985,0.0006775913,0.00004212382,0.00021114774,7.901666e-7,0.8712382,0.00052168133,0.00011631876,0.122268364],"study_design_scores_gemma":[0.0020810028,0.0031501632,0.7191495,0.000034320656,0.0003604406,0.00012007168,0.00007133347,0.0000068647937,0.27398694,0.0005736504,0.00038122866,0.00008452883],"about_ca_topic_score_codex":0.00002752328,"about_ca_topic_score_gemma":9.092062e-7,"teacher_disagreement_score":0.7156898,"about_ca_system_score_codex":0.000011026161,"about_ca_system_score_gemma":0.000023418155,"threshold_uncertainty_score":0.47092882},"labels":[],"label_agreement":null},{"id":"W2162417507","doi":"10.1016/s0016-5085(14)62382-9","title":"Mo1766 Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes","year":2014,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Sitagliptin; Medicine; Exenatide; Inflammation; Incretin; Type 2 diabetes; Liraglutide; Internal medicine; Glucagon-like peptide-2; Glucagon-like peptide-1; Pharmacology; Diabetes mellitus; Endocrinology; Chemistry; Peptide; Biochemistry","score_opus":0.006473647964689926,"score_gpt":0.2044528206126397,"score_spread":0.19797917264794976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162417507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839544,0.000035646943,0.000023120274,0.0003337254,0.0001841131,0.000482086,0.0000045570637,0.000014655911,0.0005266535],"genre_scores_gemma":[0.9991172,0.000007994372,0.00016350826,0.00046951967,0.000036007783,0.00004356198,0.000008820601,0.000017571034,0.00013581029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893165,0.0001125569,0.00026104957,0.00021356445,0.000163898,0.0003172566],"domain_scores_gemma":[0.99939245,0.00007327661,0.00012513176,0.00030533958,0.000051908584,0.000051873554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013292652,0.00015668973,0.00043501199,0.00014694368,0.00001657882,0.0000019510678,0.000120485965,0.000063803636,0.000008704043],"category_scores_gemma":[0.00009409221,0.0001091854,0.00012310475,0.00011961883,0.00012340842,0.000021560636,0.00008469676,0.00009353088,0.0000057531424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055912527,0.0005773025,0.91233504,0.00026650206,0.00012543221,0.000002311933,0.0001433305,0.00077296223,0.084000066,0.00013540493,0.000458805,0.0006237125],"study_design_scores_gemma":[0.005220279,0.008318365,0.83091253,0.00034560633,0.0003175693,0.0000010789798,0.000025813975,0.00898219,0.14561534,0.0001409827,0.00003569481,0.000084532985],"about_ca_topic_score_codex":0.000011210253,"about_ca_topic_score_gemma":0.00004400761,"teacher_disagreement_score":0.08142249,"about_ca_system_score_codex":0.0000445339,"about_ca_system_score_gemma":0.00001422115,"threshold_uncertainty_score":0.44524515},"labels":[],"label_agreement":null},{"id":"W2162860082","doi":"10.1161/circulationaha.115.015511","title":"Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”","year":2015,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Saxagliptin; TIMI; Diabetes mellitus; Randomized controlled trial; Internal medicine; Family medicine; Gerontology; Myocardial infarction; Metformin; Endocrinology","score_opus":0.03875004111077762,"score_gpt":0.2567863375601015,"score_spread":0.21803629644932387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162860082","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42895523,0.0004797768,0.00012158562,0.56685,0.00032833297,0.0030173205,0.000023460865,0.00007925523,0.00014505007],"genre_scores_gemma":[0.228992,0.000020716252,0.0031197183,0.7599947,0.004160641,0.0006735561,0.001689363,0.000089573696,0.0012597289],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972521,0.00077000743,0.0005446149,0.00052099954,0.0005479274,0.0003643423],"domain_scores_gemma":[0.9968536,0.0019517369,0.00020818574,0.000704801,0.00017081389,0.00011085654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016688424,0.00033821943,0.00088504207,0.00018760709,0.00014016026,0.00019811153,0.00011248136,0.00031995843,0.00009717709],"category_scores_gemma":[0.0014383765,0.00023788524,0.0002571369,0.00025400784,0.00009434554,0.00016430655,0.0000619362,0.00041693123,0.00011845312],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04124166,0.00003006422,0.0076164007,0.00003170134,0.0005460727,0.000010608872,0.00025538486,0.000032500033,0.00048066955,0.00001574707,0.9490453,0.00069386075],"study_design_scores_gemma":[0.24636811,0.00007609881,0.025896894,0.0002904877,0.0015987305,5.8139955e-7,0.000030547773,0.00046400118,0.000058499038,0.0007941276,0.724153,0.00026894544],"about_ca_topic_score_codex":0.00006364606,"about_ca_topic_score_gemma":0.000009733815,"teacher_disagreement_score":0.22489236,"about_ca_system_score_codex":0.00016185248,"about_ca_system_score_gemma":0.00006619793,"threshold_uncertainty_score":0.97006786},"labels":[],"label_agreement":null},{"id":"W2162913302","doi":"10.2337/db08-1237","title":"GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell","year":2009,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto; University of Toronto; European Foundation for the Study of Diabetes; Canada Research Chairs; Canadian Diabetes Association; Deutsche Forschungsgemeinschaft; Eli Lilly and Company","keywords":"Internal medicine; Endocrinology; Incretin; Glucagon-like peptide-1; Secretion; Enteroendocrine cell; Chemistry; Biology; Hormone; Diabetes mellitus; Type 2 diabetes; Medicine; Endocrine system","score_opus":0.013479377435606257,"score_gpt":0.25501014690791446,"score_spread":0.2415307694723082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162913302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892822,0.00045953572,0.00017750375,0.005846134,0.00043210984,0.0011119465,0.00003811126,0.00014733605,0.002505118],"genre_scores_gemma":[0.98941904,0.000044868135,0.0008809922,0.0059265755,0.0005593906,0.00013235598,0.00056059,0.000031736174,0.002444426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984234,0.000034990284,0.0003042504,0.00043619447,0.000276329,0.00052484946],"domain_scores_gemma":[0.99899393,0.00019395053,0.00012475661,0.00046580672,0.00010358531,0.0001179906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012391403,0.00029386222,0.00035430232,0.00008045531,0.00012846329,0.000075649536,0.00019771315,0.000052458447,0.00018730349],"category_scores_gemma":[0.0000672476,0.00020986544,0.0002469491,0.00014720282,0.000044348973,0.0001264704,0.00006322137,0.00014405334,0.00009241346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000501324,0.0024419401,0.14075173,0.0002898028,0.0010875359,0.000052696752,0.0013378134,0.000005773539,0.62745,0.00075875904,0.12159628,0.10372639],"study_design_scores_gemma":[0.009354904,0.0033031642,0.103087634,0.0005279163,0.0017547344,0.000002401546,0.00033610757,0.0023327272,0.8211478,0.0021823733,0.055373944,0.00059631],"about_ca_topic_score_codex":0.00004739984,"about_ca_topic_score_gemma":0.0000060997604,"teacher_disagreement_score":0.19369781,"about_ca_system_score_codex":0.00006802778,"about_ca_system_score_gemma":0.00002944478,"threshold_uncertainty_score":0.8558064},"labels":[],"label_agreement":null},{"id":"W2163316193","doi":"10.2337/db07-1639","title":"Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice","year":2008,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"TRIUMF; Washington State University","keywords":"Sitagliptin; Islet; Incretin; Internal medicine; Endocrinology; Streptozotocin; Dipeptidyl peptidase; Sitagliptin Phosphate; Dipeptidyl peptidase-4; Diabetes mellitus; Glycemic; Medicine; Type 2 diabetes; Glucagon-like peptide-1; Hormone; Insulin; Chemistry; Enzyme; Biochemistry","score_opus":0.014692191302034642,"score_gpt":0.2253512479056937,"score_spread":0.21065905660365905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163316193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467933,0.00014604609,0.0000036259075,0.0003258341,0.0000795416,0.0014782569,0.000015986168,0.000105860585,0.003165495],"genre_scores_gemma":[0.9980325,0.000017098802,0.00042008885,0.00021269437,0.00008134888,0.00028181553,0.00016293887,0.000053917367,0.00073757936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790335,0.00008338277,0.00045488632,0.00048630073,0.00047141916,0.00060063717],"domain_scores_gemma":[0.99896175,0.000110958375,0.00019357484,0.00041578975,0.00016034747,0.0001576025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024687903,0.00034840818,0.00068234396,0.00033113724,0.00006666837,0.000014164935,0.00009917204,0.0001111118,0.00008193281],"category_scores_gemma":[0.00008279337,0.00028447053,0.00011900754,0.00061271276,0.00016739177,0.00020245322,0.000072348215,0.00020214634,0.00004811034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001578356,0.0013770915,0.8858157,0.00047990418,0.0002676667,0.00016045447,0.00095724047,0.000014075237,0.10860773,0.000092623275,0.0005600695,0.0015096426],"study_design_scores_gemma":[0.009830676,0.0033245517,0.6162041,0.0012037858,0.00044498622,0.0000042081756,0.0006155049,0.00023645115,0.3671097,0.000090950176,0.00031712253,0.0006179905],"about_ca_topic_score_codex":0.00008399535,"about_ca_topic_score_gemma":0.00004386099,"teacher_disagreement_score":0.2696116,"about_ca_system_score_codex":0.00010478543,"about_ca_system_score_gemma":0.000076066375,"threshold_uncertainty_score":0.9999607},"labels":[],"label_agreement":null},{"id":"W2163317532","doi":"10.2337/db12-0202","title":"GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production","year":2012,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Diabetes Canada; American Diabetes Association","keywords":"Postprandial; Endocrinology; Glucagon-like peptide-2; Glucagon-like peptide-1; Internal medicine; Proglucagon; Chemistry; Lipoprotein; Triglyceride; Chylomicron; Insulin; Biology; Type 2 diabetes; Medicine; Diabetes mellitus; Biochemistry; Cholesterol; Very low-density lipoprotein; Peptide","score_opus":0.01241215784630915,"score_gpt":0.2428146349779617,"score_spread":0.23040247713165257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163317532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312437,0.003105058,0.0000019092186,0.000602903,0.000093920135,0.00036762844,0.0000010996688,0.000034134264,0.002668985],"genre_scores_gemma":[0.9976029,0.000055392415,0.0010140024,0.00009307286,0.0001533523,0.000038410915,0.000011998134,0.000010986568,0.0010199076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994343,0.000014714969,0.00011233959,0.00013688195,0.0001037758,0.00019802348],"domain_scores_gemma":[0.9996779,0.000026234198,0.00004905544,0.00012420582,0.000031066946,0.00009155939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017176422,0.00009692569,0.00017408107,0.000074920266,0.00003387905,0.000011350812,0.000019219677,0.000027311618,0.0000304384],"category_scores_gemma":[0.00014541253,0.00007787499,0.000021023207,0.000075870405,0.000095780066,0.00012707173,0.00004833156,0.000045115594,0.000012018121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024386076,0.00024636165,0.80312854,0.00039550144,0.00012367676,0.0000013059529,0.00044661414,9.602558e-8,0.038986117,0.00068243925,0.0006653823,0.15529959],"study_design_scores_gemma":[0.001215845,0.0009499277,0.5951127,0.0004413522,0.00045248627,0.000006672437,0.00039573218,0.000037584407,0.39195716,0.00048048334,0.008752534,0.00019756408],"about_ca_topic_score_codex":0.00003651178,"about_ca_topic_score_gemma":0.0000016167211,"teacher_disagreement_score":0.35297105,"about_ca_system_score_codex":0.000013437224,"about_ca_system_score_gemma":0.00000742373,"threshold_uncertainty_score":0.317565},"labels":[],"label_agreement":null},{"id":"W2163498104","doi":"10.1007/s00125-005-1751-1","title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","year":2005,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Eli Lilly and Company","keywords":"Pioglitazone; Gliclazide; Metformin; Medicine; Internal medicine; Tolerability; Type 2 diabetes; Diabetes mellitus; Endocrinology; Combination therapy; Adverse effect","score_opus":0.01846969852170322,"score_gpt":0.26504796646947704,"score_spread":0.24657826794777382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163498104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817234,0.00018486248,0.000011575851,0.00008059598,0.00001891671,0.0013584432,0.00002077374,0.000031095584,0.00012137904],"genre_scores_gemma":[0.9977702,0.0000382914,0.0017415158,0.00020061395,0.000014568591,0.00006017129,0.00012126611,0.000019889503,0.000033510893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988463,0.000041440708,0.000330529,0.00030086932,0.00022119458,0.00025965922],"domain_scores_gemma":[0.99918616,0.0001535099,0.00014355544,0.0003141059,0.0001227364,0.00007992365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014367065,0.00020821416,0.00063381996,0.00019579362,0.000020890273,0.000008059606,0.00007516922,0.000055654935,0.00011189273],"category_scores_gemma":[0.00003758751,0.00012419773,0.000029084878,0.00034255863,0.00010218795,0.00009836257,0.000021025984,0.00007497784,0.0000034213276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006387402,0.0017965534,0.9024463,0.000083569,0.00023613189,0.000002338569,0.00027871892,0.000077175544,0.00035695801,0.000016141395,0.000045296685,0.088273354],"study_design_scores_gemma":[0.010112024,0.008610117,0.96118414,0.0003141054,0.00006606942,9.905282e-8,0.000034287656,0.000040585215,0.019417496,0.00000555667,0.00007654816,0.00013899228],"about_ca_topic_score_codex":0.0000089489795,"about_ca_topic_score_gemma":0.000047160047,"teacher_disagreement_score":0.08813436,"about_ca_system_score_codex":0.000067138775,"about_ca_system_score_gemma":0.000024891164,"threshold_uncertainty_score":0.50646365},"labels":[],"label_agreement":null},{"id":"W2163672431","doi":"10.9778/cmajo.20130073","title":"Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis","year":2014,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Randomized controlled trial; Medicine; Meta-analysis; Type 2 diabetes; Sulfonylurea; Internal medicine; Diabetes mellitus; Cochrane collaboration; Systematic review; Clinical trial; MEDLINE; Cochrane Library; Insulin; Endocrinology","score_opus":0.13240623652641115,"score_gpt":0.42798157759845107,"score_spread":0.2955753410720399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163672431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8878924,0.065330066,0.00042798265,0.0006957619,0.00016973056,0.044244967,0.000069543596,0.00003252213,0.001136989],"genre_scores_gemma":[0.98898035,0.0064067305,0.0011866175,0.00086029654,0.000027751092,0.0014355893,0.0004495661,0.000032037646,0.0006210544],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99432015,0.002822303,0.0019642094,0.00038653478,0.00033668426,0.00017008763],"domain_scores_gemma":[0.9951684,0.0029566952,0.0010297489,0.00056774326,0.00016164825,0.00011578199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018042363,0.00024233463,0.013864698,0.00046974706,0.000023490147,0.000061769,0.00015424972,0.00007156769,0.00027093894],"category_scores_gemma":[0.0034647414,0.00012720445,0.0013110855,0.0011352315,0.00010709711,0.0001211594,0.00008788684,0.000070989496,0.0000021983967],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20107639,0.0004539418,0.00475208,0.008898087,0.784341,0.0000013277547,0.000059067956,0.000004442127,5.475214e-7,0.00007868035,0.00004075944,0.00029370608],"study_design_scores_gemma":[0.33500937,0.0009011842,0.000639504,0.00034931998,0.6627425,1.5062604e-8,0.000007864188,0.00023925748,0.0000040447453,0.000007779607,0.000011179482,0.00008796919],"about_ca_topic_score_codex":0.00011945271,"about_ca_topic_score_gemma":0.00014833744,"teacher_disagreement_score":0.13393298,"about_ca_system_score_codex":0.000022567023,"about_ca_system_score_gemma":0.000028256844,"threshold_uncertainty_score":0.947763},"labels":[],"label_agreement":null},{"id":"W2165403578","doi":"10.2337/db12-0601","title":"Activation of Enteroendocrine Membrane Progesterone Receptors Promotes Incretin Secretion and Improves Glucose Tolerance in Mice","year":2012,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Incretin; Glucose homeostasis; Receptor; Enteroendocrine cell; Secretion; Glucagon-like peptide-1; Biology; Protein kinase A; Hormone; Chemistry; Kinase; Insulin; Cell biology; Insulin resistance; Endocrine system; Type 2 diabetes; Medicine; Diabetes mellitus","score_opus":0.008638927647010507,"score_gpt":0.2320932659266619,"score_spread":0.2234543382796514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165403578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997633,0.0008196751,0.0000029598862,0.00037261442,0.00010019025,0.00074360723,0.0000022724041,0.000035973284,0.00028973917],"genre_scores_gemma":[0.9986701,0.00010867996,0.0006476446,0.000099785386,0.00006218738,0.00010517749,0.00008535128,0.00001653081,0.00020455323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991417,0.000038224214,0.00022862962,0.00016809964,0.00013351647,0.00028986178],"domain_scores_gemma":[0.99962205,0.0000463897,0.00010311151,0.00012072462,0.000034250294,0.00007348614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016961376,0.00014014533,0.00027181846,0.00013725608,0.00001727412,0.000009389498,0.000035893932,0.0000349881,0.000022327597],"category_scores_gemma":[0.000067667286,0.000119885364,0.000030146091,0.00014704984,0.00005049215,0.00028695498,0.000044757424,0.00006684222,0.0000037018078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056432244,0.0003375004,0.48677042,0.00045500777,0.00005073346,3.9339614e-7,0.00036259316,2.568945e-7,0.49550387,0.000055615397,0.00003558193,0.016371585],"study_design_scores_gemma":[0.0013702177,0.00030820866,0.21502435,0.00031522493,0.00006212895,3.9975717e-7,0.000089969704,0.00014293853,0.78186613,0.000015133055,0.00071662996,0.000088683395],"about_ca_topic_score_codex":0.00002542182,"about_ca_topic_score_gemma":0.0000023837538,"teacher_disagreement_score":0.28636223,"about_ca_system_score_codex":0.00004233602,"about_ca_system_score_gemma":0.0000069636953,"threshold_uncertainty_score":0.48887834},"labels":[],"label_agreement":null},{"id":"W2165466849","doi":"10.1210/en.2012-1781","title":"P21-Activated Protein Kinase 1 (Pak1) Mediates the Cross Talk between Insulin and β-Catenin on Proglucagon Gene Expression and Its Ablation Affects Glucose Homeostasis in Male C57BL/6 Mice","year":2012,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Glucose homeostasis; Internal medicine; Endocrinology; Proglucagon; Insulin; PAK1; Biology; Homeostasis; Glucagon; Wnt signaling pathway; Signal transduction; Glucagon-like peptide-1; Cell biology; Insulin resistance; Diabetes mellitus; Type 2 diabetes; Medicine","score_opus":0.022364514917578033,"score_gpt":0.27824140927901864,"score_spread":0.2558768943614406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165466849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894971,0.0074406625,0.0000043942914,0.00092782767,0.00008822053,0.0017396731,0.00001323646,0.000061463616,0.00022741855],"genre_scores_gemma":[0.9981539,0.00052307406,0.00024750346,0.000094881885,0.00014375849,0.00036968378,0.00010512424,0.000025986394,0.00033604432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864584,0.00014447131,0.00020287519,0.00032182684,0.00014586266,0.00053910527],"domain_scores_gemma":[0.9993972,0.00015668166,0.00010885855,0.00018568571,0.000027115222,0.00012442106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016746485,0.00022603644,0.00031060624,0.0002073045,0.00010024415,0.00002452898,0.000069446134,0.0000996808,0.000037686234],"category_scores_gemma":[0.00012131689,0.00015554341,0.000027814012,0.0001775579,0.000097328186,0.00019437014,0.00014381573,0.00020093934,0.000026647083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005510117,0.00064097584,0.26589552,0.00023617482,0.00015848063,0.0001284852,0.001247009,0.0000028240695,0.6488378,0.00022144394,0.00010742106,0.08197284],"study_design_scores_gemma":[0.0023961745,0.0004109235,0.3504408,0.00008040034,0.000049159335,0.000012765413,0.00007215527,0.000014533728,0.6450323,0.000029114008,0.0013524212,0.00010926452],"about_ca_topic_score_codex":0.00004298645,"about_ca_topic_score_gemma":0.000007741654,"teacher_disagreement_score":0.08454527,"about_ca_system_score_codex":0.00006746112,"about_ca_system_score_gemma":0.000013514158,"threshold_uncertainty_score":0.63428766},"labels":[],"label_agreement":null},{"id":"W2165556241","doi":"10.1016/s0140-6736(15)60936-9","title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Dulaglutide; Medicine; Insulin glargine; Type 2 diabetes; Internal medicine; Metformin; Bedtime; Lixisenatide; Exenatide; Glycemic; Insulin; Regimen; Diabetes mellitus; Randomized controlled trial; Endocrinology","score_opus":0.03752558679091073,"score_gpt":0.3086463844184889,"score_spread":0.2711207976275782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165556241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079096,0.00012263165,0.000008490225,0.0010960796,0.00019320074,0.0054516015,0.000021212783,0.000048910773,0.0022669274],"genre_scores_gemma":[0.9986055,0.00003132137,0.0003466934,0.00021103764,0.00012212584,0.00034375928,0.0001487451,0.0000348509,0.00015596494],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981927,0.00018518696,0.0003334529,0.00036874745,0.00046812766,0.00045174317],"domain_scores_gemma":[0.9989056,0.00012044536,0.00016196705,0.00054372574,0.00014366902,0.00012458579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008766151,0.00028002405,0.0008507363,0.00015343315,0.000055366898,0.00008318691,0.00032883996,0.000053780186,0.00001642315],"category_scores_gemma":[0.00016501163,0.00015718202,0.000018219476,0.0005822208,0.00007916444,0.00031498153,0.00015654266,0.00021536383,0.00003334284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20671661,0.013314927,0.76647633,0.000050142087,0.0004328661,0.000064666434,0.0014209053,0.000017271437,0.00001734322,0.000048274065,0.001140205,0.010300466],"study_design_scores_gemma":[0.5867567,0.015686128,0.3957041,0.00019614013,0.00021176334,1.5294398e-7,0.00016836957,0.00020739538,0.00003832606,0.000035975394,0.00080048875,0.00019445494],"about_ca_topic_score_codex":0.00020239504,"about_ca_topic_score_gemma":0.00048659724,"teacher_disagreement_score":0.38004008,"about_ca_system_score_codex":0.00025376963,"about_ca_system_score_gemma":0.00016427143,"threshold_uncertainty_score":0.6409697},"labels":[],"label_agreement":null},{"id":"W2165688201","doi":"10.14740/jem.v4i1-2.205","title":"Outpatient Diabetic Care in a Public Central Hospital: Patient Characteristics, Therapeutic Regimens and Results","year":2014,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycated hemoglobin; Internal medicine; Dyslipidemia; Type 2 diabetes; Blood pressure; Diabetes mellitus; Disease; Outpatient clinic; Referral; Endocrinology","score_opus":0.010797811773092,"score_gpt":0.23140198846960097,"score_spread":0.22060417669650897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165688201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862606,0.008850852,0.000009633055,0.0031001368,0.000655683,0.00024126607,0.00000556485,0.000008871087,0.0008674169],"genre_scores_gemma":[0.9966997,0.0023053603,0.00023385383,0.0005166761,0.00012763111,0.000007472521,0.000009174318,0.000010796128,0.000089369394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987432,0.00009675876,0.00048488437,0.00016686333,0.00013409014,0.00037421327],"domain_scores_gemma":[0.99922925,0.00005808166,0.0002935527,0.0001414637,0.00011374932,0.0001638934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012242045,0.00014748964,0.00047413827,0.00024707694,0.000037872367,0.000020682075,0.000049932492,0.000055824334,0.0000055680266],"category_scores_gemma":[0.00016149798,0.00010714112,0.00006207495,0.000063884836,0.00009900995,0.00009199204,0.000054243643,0.00021721105,0.0000014572314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007747685,0.0010447277,0.21515557,0.00015865844,0.00066384004,0.00030582317,0.0074966988,9.063904e-7,0.0002733949,0.010957734,0.00054002914,0.76262784],"study_design_scores_gemma":[0.005944788,0.001991021,0.78722644,0.000074594165,0.00036690035,0.00005342173,0.0006044908,0.000011510603,0.00024401331,0.00028468654,0.20308416,0.000113993345],"about_ca_topic_score_codex":0.0000058794076,"about_ca_topic_score_gemma":0.0000043205782,"teacher_disagreement_score":0.7625139,"about_ca_system_score_codex":0.00003467376,"about_ca_system_score_gemma":0.00002895889,"threshold_uncertainty_score":0.4369088},"labels":[],"label_agreement":null},{"id":"W2165736145","doi":"10.1074/jbc.m005119200","title":"Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital","funders":"","keywords":"Endocrinology; Internal medicine; Glucose homeostasis; Ex vivo; Homeostasis; Insulin; Receptor; Biology; Metallothionein; Glucose tolerance test; Chemistry; In vivo; Insulin resistance; Medicine; Biochemistry","score_opus":0.02128862812922886,"score_gpt":0.25463048367559693,"score_spread":0.23334185554636808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165736145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467176,0.0022855392,0.000016244521,0.00045701722,0.000053402575,0.00023429109,0.000018801938,0.000017534601,0.0022454006],"genre_scores_gemma":[0.9924764,0.0037141666,0.0012659928,0.00011987328,0.00012965272,0.000010495929,0.000020342284,0.000013520805,0.0022495694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99836123,0.00005243181,0.0007410788,0.0002615565,0.00028593707,0.00029779493],"domain_scores_gemma":[0.9991267,0.00012332827,0.00029152725,0.00021384448,0.00007303937,0.00017157568],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034428234,0.00023342406,0.0006649926,0.00007823464,0.0000258624,0.000012745146,0.00021718541,0.00020606251,0.002664505],"category_scores_gemma":[0.00010637739,0.00011774768,0.00031506218,0.00017675146,0.000086953594,0.000080045276,0.0000429006,0.00030471376,0.000004159499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035361035,0.0012220872,0.0013979404,0.0003423256,0.00014231709,0.0001560116,0.000106392545,0.0000050517974,0.98198086,0.0000031400405,0.00015442289,0.010953329],"study_design_scores_gemma":[0.004479159,0.0013681534,0.0013313033,0.00026126608,0.00018521668,0.000028365468,0.00066130375,0.0000054469097,0.9889509,0.00013615297,0.0024427047,0.00015001991],"about_ca_topic_score_codex":0.0000019720421,"about_ca_topic_score_gemma":8.4407816e-7,"teacher_disagreement_score":0.010803308,"about_ca_system_score_codex":0.00011559988,"about_ca_system_score_gemma":0.00006365565,"threshold_uncertainty_score":0.9982472},"labels":[],"label_agreement":null},{"id":"W2165816400","doi":"10.2337/db08-0553","title":"The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat Feeding","year":2008,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; National Institutes of Health; Canadian Diabetes Association; Amgen","keywords":"Free fatty acid receptor 1; Internal medicine; Endocrinology; Fatty acid; Insulin; Steatosis; Type 2 diabetes; Free fatty acid receptor; Insulinoma; Fatty liver; Glucose tolerance test; Biology; Insulin receptor; Diabetes mellitus; Receptor; Insulin resistance; Medicine; Polyunsaturated fatty acid; Biochemistry; Agonist","score_opus":0.008381699867449039,"score_gpt":0.21004634361717223,"score_spread":0.20166464374972318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165816400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438655,0.0016727247,0.0000020652112,0.00079865166,0.00017395006,0.00049874786,0.000007949345,0.00005452485,0.002404854],"genre_scores_gemma":[0.9976649,0.00036166256,0.00027879592,0.00036035437,0.00013979107,0.00033095598,0.00003908976,0.000023536952,0.0008008878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878937,0.000043222684,0.0002594527,0.00025994008,0.00021475686,0.00043328188],"domain_scores_gemma":[0.99953365,0.00008727201,0.000053590247,0.00022651901,0.000026307674,0.00007264835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020651668,0.00017652071,0.00026689406,0.00017935543,0.00007694327,0.000024128929,0.000091653004,0.00008078238,0.00019938042],"category_scores_gemma":[0.000071212184,0.00012705132,0.00006488232,0.00030791824,0.00007033251,0.00013340997,0.00006945176,0.00015243505,0.00012306926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001450656,0.00027371262,0.95030415,0.0000483276,0.00007336048,0.00003416714,0.0010391029,0.000006981298,0.037983254,0.00019259016,0.0022913257,0.0076079625],"study_design_scores_gemma":[0.0043689846,0.00049124187,0.8118002,0.00040803524,0.00007091475,7.044987e-7,0.00050186156,0.00055778114,0.16298813,0.00040037007,0.018081611,0.00033019177],"about_ca_topic_score_codex":0.000047813177,"about_ca_topic_score_gemma":0.00006730194,"teacher_disagreement_score":0.13850397,"about_ca_system_score_codex":0.00016525174,"about_ca_system_score_gemma":0.000016158334,"threshold_uncertainty_score":0.5181002},"labels":[],"label_agreement":null},{"id":"W2166438249","doi":"10.2337/diaclin.24.2.66","title":"Commentary on the Results and Clinical Implications of the PROactive Study","year":2006,"lang":"en","type":"article","venue":"Clinical Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Medicine; Pioglitazone; Macrovascular disease; Type 2 diabetes; Insulin resistance; Diabetes mellitus; Blood pressure; Internal medicine; Disease; Type 2 Diabetes Mellitus; Clinical trial; Endocrinology","score_opus":0.06231102106237414,"score_gpt":0.3794726780393778,"score_spread":0.31716165697700366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166438249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9297722,0.00004614259,4.6189783e-7,0.06213399,0.00014274221,0.0015721329,0.000027175562,0.000021214551,0.006283924],"genre_scores_gemma":[0.9920174,0.000024615456,0.000041647323,0.0071003335,0.0002203859,0.00007764492,0.000019197814,0.0000099202225,0.00048887363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983906,0.00030343301,0.0007084231,0.00028473596,0.00015407162,0.00015873442],"domain_scores_gemma":[0.99639255,0.0026537539,0.0001960458,0.00064969214,0.000052434774,0.000055533827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011286098,0.00011331867,0.00031916404,0.000021045811,0.00010390504,0.000011869558,0.00015299537,0.00005337882,0.0000074947343],"category_scores_gemma":[0.00053177273,0.000052835083,0.00018968295,0.00012637029,0.00039957926,0.000024043908,0.00016165168,0.00022387675,0.000009065586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007235393,0.003938486,0.91820747,0.000005932988,0.0003741792,4.2081143e-7,0.000019659841,2.8936296e-7,0.000005789578,0.00091231405,0.0661341,0.010329031],"study_design_scores_gemma":[0.0025072224,0.001801381,0.98784584,0.000039078877,0.0005513344,3.8380332e-8,0.00010229151,0.000022431195,0.00010791504,0.0011841652,0.0057854755,0.00005280533],"about_ca_topic_score_codex":0.000024497138,"about_ca_topic_score_gemma":0.000026694395,"teacher_disagreement_score":0.06963842,"about_ca_system_score_codex":0.000016361484,"about_ca_system_score_gemma":0.000016114227,"threshold_uncertainty_score":0.21545522},"labels":[],"label_agreement":null},{"id":"W2166823746","doi":"10.2337/dc13-2762","title":"Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Glimepiride; Canagliflozin; Medicine; Metformin; Type 2 diabetes; Dapagliflozin; Hypoglycemia; Glycemic; Diabetes mellitus; Urology; Empagliflozin; Adverse effect; Internal medicine; Endocrinology; Gastroenterology","score_opus":0.009782681608392617,"score_gpt":0.2566497003829425,"score_spread":0.24686701877454986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166823746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163216,0.00034691454,4.0341345e-7,0.00006762636,0.0005210292,0.0060798917,0.000020703552,0.00008698375,0.0012442879],"genre_scores_gemma":[0.99800664,0.00002603037,0.000064318345,0.00013849871,0.00011731807,0.00084531633,0.0005202256,0.0000669931,0.00021468122],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755955,0.00010632954,0.00046000228,0.0006907195,0.0005348457,0.0006485346],"domain_scores_gemma":[0.9987246,0.0001357943,0.0002100665,0.0005192351,0.00020333726,0.00020701221],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003145495,0.00047202274,0.00097096746,0.00042372584,0.000120436256,0.00008549541,0.00012170814,0.00009984693,0.000040219347],"category_scores_gemma":[0.00009173213,0.0003444159,0.00009998835,0.00040000989,0.000110376444,0.00031659985,0.0000907002,0.00020443772,0.00003213041],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34868345,0.0026866586,0.6289636,0.00040513184,0.0016555545,0.000007821095,0.00080867246,0.000008412041,0.00031606562,0.000052230975,0.00033407827,0.016078355],"study_design_scores_gemma":[0.94455147,0.01896273,0.027551595,0.00036616248,0.0020743553,7.266532e-8,0.00091430324,0.00028211,0.0038945375,0.000027066828,0.0008693555,0.0005062157],"about_ca_topic_score_codex":0.0001679871,"about_ca_topic_score_gemma":0.00010771163,"teacher_disagreement_score":0.601412,"about_ca_system_score_codex":0.0003255893,"about_ca_system_score_gemma":0.000056062338,"threshold_uncertainty_score":0.99990076},"labels":[],"label_agreement":null},{"id":"W2166848153","doi":"10.2337/db09-1618","title":"Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4+ T-Cell Migration Through Incretin-Dependent and -Independent Pathways","year":2010,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Sitagliptin; NOD mice; Nod; Internal medicine; Endocrinology; Lymph node; Incretin; T cell; Medicine; Immunology; Diabetes mellitus; Immune system; Type 2 diabetes","score_opus":0.00886193002856656,"score_gpt":0.2141700445322981,"score_spread":0.20530811450373154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166848153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465656,0.00043791323,0.000027440334,0.0002607602,0.00015620727,0.0010274865,0.00006753423,0.00014461404,0.0032214632],"genre_scores_gemma":[0.9963241,0.00017389165,0.0015942998,0.00031220692,0.00014527785,0.00017390055,0.00040490986,0.00006032376,0.00081108854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977638,0.00007303673,0.00053677714,0.0005666139,0.0005292641,0.0005304999],"domain_scores_gemma":[0.99854267,0.0001898065,0.00027397546,0.0005521578,0.00017296837,0.000268451],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003489516,0.00040475407,0.00057335285,0.00022225078,0.00011921316,0.000070524766,0.00010924048,0.00018643512,0.00021306697],"category_scores_gemma":[0.00017021113,0.0003532143,0.00017162884,0.00020099433,0.00018010342,0.00035512174,0.00017380717,0.00028426063,0.00007066952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058574395,0.0012302421,0.21723726,0.00043182005,0.00013175557,0.000023250363,0.0006315018,0.0000034440748,0.7766268,0.00050052186,0.00063494314,0.0024898618],"study_design_scores_gemma":[0.0039157034,0.0009725762,0.038092915,0.00021961132,0.0005966169,0.0000023633374,0.00054907915,0.00034467742,0.95361805,0.0005214833,0.0007351642,0.00043176382],"about_ca_topic_score_codex":0.00014702082,"about_ca_topic_score_gemma":0.0001291451,"teacher_disagreement_score":0.17914434,"about_ca_system_score_codex":0.00006132895,"about_ca_system_score_gemma":0.000054996468,"threshold_uncertainty_score":0.999892},"labels":[],"label_agreement":null},{"id":"W2166886145","doi":"10.1111/dom.12527","title":"Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the <scp>AWARD</scp> ‐1 and <scp>AWARD</scp> ‐3 clinical trials","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Type 2 Diabetes Mellitus; Liraglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.07220703135005108,"score_gpt":0.3189510850167525,"score_spread":0.24674405366670144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166886145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753067,0.020969074,0.000013649103,0.0004817088,0.0003751798,0.0019782977,0.00027297405,0.00014485982,0.0004575836],"genre_scores_gemma":[0.9871543,0.008156943,0.0009618803,0.0005349086,0.00050867355,0.00015736566,0.0013032698,0.000075630625,0.0011470012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955396,0.00095697376,0.00087985327,0.001177557,0.0005961343,0.0008498853],"domain_scores_gemma":[0.99450153,0.0029477982,0.00045025212,0.0012809709,0.0001915207,0.00062793173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024641769,0.0006958208,0.002133883,0.00020294101,0.00022228863,0.00022448054,0.00027827217,0.00028081832,0.000010677551],"category_scores_gemma":[0.0017130387,0.00039476983,0.00013805198,0.0006055941,0.0003507747,0.00052615925,0.00026930452,0.00035619905,0.000045292403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007398009,0.00077688653,0.96842235,0.000051838088,0.0019067058,0.00002900545,0.0008698733,0.0000074848294,0.00010959727,0.00009235994,0.00374057,0.02391934],"study_design_scores_gemma":[0.011547561,0.0015358125,0.92332006,0.00017579738,0.004590128,0.000002446443,0.0010239369,0.0005054612,0.0008852076,0.00021936593,0.056062933,0.00013131139],"about_ca_topic_score_codex":0.0016883139,"about_ca_topic_score_gemma":0.0018294222,"teacher_disagreement_score":0.052322365,"about_ca_system_score_codex":0.00012198042,"about_ca_system_score_gemma":0.00023022873,"threshold_uncertainty_score":0.9998504},"labels":[],"label_agreement":null},{"id":"W2167373984","doi":"10.2337/db09-0281","title":"Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats","year":2009,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Glenmark Pharmaceuticals; MannKind Corporation; GlaxoSmithKline; Amylin Pharmaceuticals; Eli Lilly and Company; American Diabetes Association","keywords":"Anorectic; Glucagon-like peptide-1; Agonist; Internal medicine; Antagonism; Endocrinology; Food intake; Central nervous system; Medicine; Pharmacology; Receptor; Diabetes mellitus; Type 2 diabetes","score_opus":0.008005905320842529,"score_gpt":0.22358657291336348,"score_spread":0.21558066759252095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167373984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562854,0.0015395308,4.226413e-7,0.00041077618,0.000082633895,0.0004979312,7.020939e-7,0.000012713402,0.0018267801],"genre_scores_gemma":[0.9991293,0.00016831158,0.000040800485,0.00044554734,0.00002283939,0.000028677849,0.0000074467575,0.000004612238,0.0001524651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992213,0.000052745414,0.00015008355,0.00015596366,0.00013147612,0.00028840112],"domain_scores_gemma":[0.99958163,0.00019326081,0.000037941576,0.00013988251,0.000007835964,0.000039421662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011700552,0.00011819393,0.00027270505,0.0001325349,0.000015863443,0.000014753152,0.00006842297,0.000032378633,0.0000061504843],"category_scores_gemma":[0.00004751565,0.00007388894,0.000036642406,0.00019916907,0.000046684607,0.00005749698,0.00001616494,0.000069573995,0.0000017914285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001519163,0.00040119377,0.977495,0.0001714862,0.000032197488,0.000023331459,0.0009350823,3.0301806e-7,0.0028919524,0.00027261674,0.00026706335,0.017494591],"study_design_scores_gemma":[0.0011633725,0.00062154926,0.9870322,0.00026047332,0.000071938004,2.4130156e-7,0.00015630489,0.000050930437,0.010076828,0.0003756557,0.00012022124,0.00007029605],"about_ca_topic_score_codex":0.00002762176,"about_ca_topic_score_gemma":0.000023169687,"teacher_disagreement_score":0.017424297,"about_ca_system_score_codex":0.000022501357,"about_ca_system_score_gemma":0.000009080887,"threshold_uncertainty_score":0.30131036},"labels":[],"label_agreement":null},{"id":"W2167522349","doi":"10.2337/db09-0955","title":"Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice","year":2010,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Heart and Stroke Foundation; SickKids Foundation; University of Toronto; Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Myocardial infarction; Dipeptidyl peptidase-4; Dipeptidyl peptidase; Pharmacology; Medicine; Internal medicine; Cardiology; Peptidyl-Dipeptidase A; Enzyme; Endocrinology; Biology; Diabetes mellitus; Biochemistry; Type 2 diabetes; Renin–angiotensin system","score_opus":0.008845632447334382,"score_gpt":0.24174773197415347,"score_spread":0.2329020995268191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167522349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979697,0.00030438357,0.0000096529775,0.00016890389,0.0003560009,0.00075476535,0.000009219072,0.000055710698,0.00037170574],"genre_scores_gemma":[0.998043,0.000072980896,0.0008244391,0.0003574107,0.00016422852,0.00033330786,0.000044761287,0.000020354368,0.00013949953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875677,0.000052460648,0.00031096864,0.00029126497,0.0002902221,0.00029834217],"domain_scores_gemma":[0.9995181,0.000054851203,0.000068008856,0.00021528314,0.00006084284,0.00008293441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023346877,0.00019239973,0.00046831663,0.00020927656,0.000025156436,0.00001459131,0.000046481113,0.00012424194,0.00014231089],"category_scores_gemma":[0.00007545557,0.00014076865,0.00039066118,0.00019352813,0.00008862142,0.000120739925,0.000055262142,0.00018240146,0.000024508245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013839558,0.00041705245,0.6808699,0.00013961286,0.0008936894,0.000027520538,0.0000825343,0.000011530793,0.29173592,0.0000136023355,0.00016401494,0.025506286],"study_design_scores_gemma":[0.0027226435,0.0003326608,0.94891155,0.000054723616,0.0009030641,0.0000010058951,0.00003299032,0.00012243129,0.045141146,0.000049253442,0.0015705833,0.00015793732],"about_ca_topic_score_codex":0.00003653775,"about_ca_topic_score_gemma":0.00002158843,"teacher_disagreement_score":0.2680417,"about_ca_system_score_codex":0.00004865371,"about_ca_system_score_gemma":0.000023716133,"threshold_uncertainty_score":0.5740379},"labels":[],"label_agreement":null},{"id":"W2167613041","doi":"10.2337/db13-1654","title":"Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans","year":2014,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; Canadian Institutes of Health Research; Merck Canada; University of Toronto; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Heart and Stroke Foundation of Canada","keywords":"Sitagliptin; Postprandial; Internal medicine; Endocrinology; Lipoprotein; Hormone; Triglyceride; Chemistry; Insulin; Diabetes mellitus; Medicine; Type 2 diabetes; Cholesterol","score_opus":0.015372021567266702,"score_gpt":0.25448305992777603,"score_spread":0.23911103836050934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167613041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269134,0.0002736207,0.000060637354,0.0018334218,0.00013964275,0.00072695065,0.0000024665028,0.00017479582,0.0040971166],"genre_scores_gemma":[0.996414,0.000014253779,0.0007846927,0.0015923441,0.00025144062,0.00020101173,0.000064037726,0.000034061402,0.0006441424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982815,0.00008433267,0.00037618395,0.00039550225,0.00027917576,0.0005833066],"domain_scores_gemma":[0.9992341,0.00008813057,0.00009563218,0.0003165412,0.00006922644,0.000196404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004535084,0.00022909413,0.00037322505,0.000169609,0.00007250562,0.000041313666,0.000083711304,0.00007987595,0.00008176278],"category_scores_gemma":[0.00022025623,0.00020560903,0.00008800916,0.0003380487,0.000088838744,0.00016587427,0.00008365532,0.00018519528,0.00020304203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032391335,0.001340105,0.80313385,0.0005443784,0.00013693035,0.00002866904,0.0007637544,0.000017129843,0.058259025,0.005307152,0.002417909,0.12772718],"study_design_scores_gemma":[0.019760283,0.01383945,0.5018301,0.0024502208,0.000560037,0.000005188314,0.00048306162,0.012009281,0.40561563,0.003504283,0.038529284,0.0014131728],"about_ca_topic_score_codex":0.00007185124,"about_ca_topic_score_gemma":0.000069016474,"teacher_disagreement_score":0.34735662,"about_ca_system_score_codex":0.00012469868,"about_ca_system_score_gemma":0.0000302366,"threshold_uncertainty_score":0.8384493},"labels":[],"label_agreement":null},{"id":"W2167687273","doi":"10.2337/db07-0704","title":"Insulin Action in the Double Incretin Receptor Knockout Mouse","year":2007,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Vanderbilt University","keywords":"Internal medicine; Endocrinology; Incretin; Insulin; Hyperinsulinemia; Type 2 diabetes; Insulin receptor; Skeletal muscle; Glucose homeostasis; Biology; Glucagon-like peptide-1; Wild type; Protein kinase B; Knockout mouse; Glucose uptake; Insulin resistance; Receptor; Diabetes mellitus; Medicine; Phosphorylation","score_opus":0.02354695355677798,"score_gpt":0.2803903360407844,"score_spread":0.2568433824840064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167687273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98319685,0.00046086457,0.0000049327937,0.0009558775,0.00012515554,0.0005028891,0.0000018135111,0.00006736822,0.014684256],"genre_scores_gemma":[0.99610543,0.00009269435,0.00026565875,0.001078475,0.0001523975,0.000054748754,0.000081335995,0.000015264504,0.002153991],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911857,0.00002586573,0.00018110595,0.00016565842,0.00019369842,0.0003150788],"domain_scores_gemma":[0.99954563,0.000096949945,0.000044406257,0.00023728049,0.00002411521,0.000051588904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000629497,0.00011580779,0.00015966373,0.00014166452,0.000042989395,0.0000236902,0.00008976317,0.000056845478,0.00012439414],"category_scores_gemma":[0.000036732592,0.000077366836,0.00005550561,0.00025539746,0.00003201614,0.00008002807,0.000029971789,0.00012466627,0.00022983032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005916047,0.0017362476,0.5747828,0.0002710272,0.00031113284,0.00003447061,0.0024580422,0.0000063690923,0.06960189,0.002945327,0.030210681,0.3170504],"study_design_scores_gemma":[0.008150131,0.0007557416,0.32175067,0.00014252328,0.0002015429,7.08596e-7,0.0019176648,0.00006310697,0.35383862,0.00016875396,0.31266347,0.0003470449],"about_ca_topic_score_codex":0.000049990544,"about_ca_topic_score_gemma":0.000036906386,"teacher_disagreement_score":0.31670338,"about_ca_system_score_codex":0.000076542216,"about_ca_system_score_gemma":0.000011054835,"threshold_uncertainty_score":0.31549278},"labels":[],"label_agreement":null},{"id":"W2167872811","doi":"10.2337/dc13-2334","title":"Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Medicine; Internal medicine; Simvastatin; Type 2 diabetes; Hazard ratio; Diabetes mellitus; Blood pressure; Randomized controlled trial; Fenofibrate; Myocardial infarction; Stroke (engine); Endocrinology; Confidence interval","score_opus":0.010536816672806908,"score_gpt":0.24055808778841326,"score_spread":0.23002127111560636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167872811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698753,0.002458353,0.000012461774,0.00012659052,0.0006024787,0.00352374,0.000026858392,0.000076124124,0.006185851],"genre_scores_gemma":[0.9984812,0.0004160644,0.00016701821,0.00017118259,0.000071021816,0.00040350514,0.00009391739,0.000035942783,0.00016016308],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977886,0.0003932753,0.00052812323,0.000353602,0.00049550104,0.00044086273],"domain_scores_gemma":[0.99827355,0.00046944988,0.00018399733,0.0008807379,0.00011912474,0.00007316564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007228141,0.00032148467,0.0015338063,0.00021216908,0.000062411644,0.000053358737,0.0002474294,0.000086083324,0.00006122298],"category_scores_gemma":[0.00023173224,0.00019298529,0.0008277686,0.00031749805,0.00015637618,0.00010270884,0.0001328367,0.00015861492,0.00004907875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05046952,0.00047408897,0.83142596,0.0011471065,0.0115452735,0.0000072320877,0.0013855887,0.00018677916,0.000018695797,0.002395705,0.00029589614,0.10064814],"study_design_scores_gemma":[0.7345181,0.001008413,0.25215885,0.00017758382,0.0033548519,1.778053e-8,0.0024926635,0.00022187342,0.00038028293,0.00074597815,0.0046365536,0.0003048314],"about_ca_topic_score_codex":0.000024148825,"about_ca_topic_score_gemma":0.000011589905,"teacher_disagreement_score":0.6840486,"about_ca_system_score_codex":0.00007015404,"about_ca_system_score_gemma":0.000025739766,"threshold_uncertainty_score":0.78697115},"labels":[],"label_agreement":null},{"id":"W2168174885","doi":"10.1136/jmedgenet-2015-103065","title":"Contribution of the low-frequency, loss-of-function p.R270H mutation in <i>FFAR4</i> (<i>GPR120</i>) to increased fasting plasma glucose levels","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Genetics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Internal medicine; Endocrinology; Insulin resistance; Type 2 diabetes; Glucose homeostasis; Body mass index; Diabetes mellitus; Insulin; Obesity; Glucose tolerance test; Medicine; Biology","score_opus":0.025341703073773994,"score_gpt":0.2823497109163082,"score_spread":0.25700800784253425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168174885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932137,0.0005559254,0.0026724755,0.0024840576,0.00052394514,0.00031196966,0.000004890141,0.0000046519003,0.0002283786],"genre_scores_gemma":[0.9979254,0.00008839026,0.0012707193,0.0004912302,0.0001809013,0.0000034237535,0.000005778532,0.0000097393795,0.000024433055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974149,0.000113574184,0.0007906716,0.00009853204,0.001404363,0.0001779435],"domain_scores_gemma":[0.9983879,0.00012618043,0.00048448707,0.00015614777,0.0005379151,0.00030742612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015095249,0.00010996457,0.00035927008,0.00014268671,0.000017701126,0.000007785921,0.00017697619,0.00011422094,0.000032646156],"category_scores_gemma":[0.00214866,0.00007274673,0.00010525492,0.00036076148,0.0000831375,0.00005240578,0.00006771486,0.0002134406,0.0000039372653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027095773,0.0034742765,0.69484496,0.0006242646,0.0009847691,0.00061961834,0.0021945515,0.0029650573,0.07254791,0.0017022198,0.0052593667,0.21207343],"study_design_scores_gemma":[0.04354363,0.009270595,0.6679403,0.005163324,0.0018871271,0.0004408107,0.0013244426,0.007374099,0.2524504,0.004113446,0.00604074,0.00045105442],"about_ca_topic_score_codex":0.000025927662,"about_ca_topic_score_gemma":0.000027179552,"teacher_disagreement_score":0.21162237,"about_ca_system_score_codex":0.00014784216,"about_ca_system_score_gemma":0.000417788,"threshold_uncertainty_score":0.29665256},"labels":[],"label_agreement":null},{"id":"W2168278105","doi":"10.1016/j.diabres.2009.12.020","title":"Lack of preservation of insulin gene expression by a Glucagon-Like Peptide 1 agonist or a Dipeptidyl Peptidase 4 inhibitor in an in vivo model of glucolipotoxicity","year":2010,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Exenatide; Sitagliptin; Internal medicine; Endocrinology; Insulin; Medicine; Incretin; Dipeptidyl peptidase-4; Agonist; Glucagon-like peptide-1; In vivo; Dipeptidyl peptidase; Glucagon; Vildagliptin; Type 2 diabetes; Diabetes mellitus; Chemistry; Biology; Receptor; Enzyme; Biochemistry","score_opus":0.12787605426982598,"score_gpt":0.4439569533108236,"score_spread":0.31608089904099756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168278105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970858,0.00016094657,0.000012965367,0.00051528827,0.00004427723,0.0011836414,0.00007659827,0.000011130849,0.0009093153],"genre_scores_gemma":[0.99269605,0.00063260697,0.0057503716,0.00013957157,0.000057126075,0.000104048355,0.000059111055,0.000023940154,0.00053720194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99654716,0.0004938685,0.0012043,0.0004919228,0.0007986027,0.00046411814],"domain_scores_gemma":[0.9954496,0.0026842633,0.0004113334,0.0005882216,0.0005754255,0.00029117637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041639623,0.00018025724,0.0006834598,0.00031385483,0.00004246424,0.000026487563,0.00022548308,0.0002437472,0.00006432475],"category_scores_gemma":[0.007555715,0.00014142567,0.00008707883,0.00056624465,0.00052819453,0.0008066349,0.00030146376,0.0008357818,0.0000023896005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047801184,0.010919177,0.22800997,0.00064050604,0.00009005564,0.000013910003,0.00032971048,0.000018301202,0.7489882,0.00008935105,0.0014290772,0.0046915878],"study_design_scores_gemma":[0.016036863,0.012786165,0.07497682,0.001167095,0.00019881452,8.4846073e-7,0.0012272722,0.03294431,0.85662836,0.00089763204,0.0027430197,0.00039279577],"about_ca_topic_score_codex":0.00032411586,"about_ca_topic_score_gemma":0.00045171665,"teacher_disagreement_score":0.15303315,"about_ca_system_score_codex":0.000040498075,"about_ca_system_score_gemma":0.00026431814,"threshold_uncertainty_score":0.90454423},"labels":[],"label_agreement":null},{"id":"W2168722029","doi":"10.1016/j.jcjd.2013.08.088","title":"Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D)","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Internal medicine; Type 2 diabetes; Placebo; Myocardial infarction; Diabetes mellitus; Endocrinology; Confidence interval","score_opus":0.026541666841119384,"score_gpt":0.23413469653366287,"score_spread":0.20759302969254348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168722029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891074,0.007858375,0.0000066855055,0.0008026945,0.0009168513,0.0010371294,0.0000037315635,0.0000043822774,0.00026277435],"genre_scores_gemma":[0.99888486,0.000026283102,0.00022792321,0.00034622545,0.00016459114,0.000036382036,0.0000020328216,0.000025326655,0.0002863718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981851,0.00016510327,0.000668835,0.00014306261,0.0003465313,0.0004913893],"domain_scores_gemma":[0.99862987,0.00010084049,0.00022831566,0.00040821635,0.00023036849,0.0004023977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007477963,0.00019059016,0.00071440235,0.00039973893,0.00004277612,0.000033929795,0.0002628211,0.00008483276,0.00027416565],"category_scores_gemma":[0.00035458096,0.00012590915,0.00048436763,0.00039962455,0.00010867247,0.00014586962,0.000025600748,0.00021893716,0.000026581241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094505434,0.00012345123,0.98483473,0.00012161843,0.0015201173,0.00002181072,0.00019454517,0.000603815,0.00024306148,0.000025326819,0.0032432142,0.008973832],"study_design_scores_gemma":[0.02479552,0.0018527331,0.962897,0.0006735377,0.0014448449,0.0000013936807,0.00017545452,0.00023480343,0.0020033796,0.00043173457,0.0052005975,0.00028900342],"about_ca_topic_score_codex":0.00044989822,"about_ca_topic_score_gemma":0.0003879807,"teacher_disagreement_score":0.024701012,"about_ca_system_score_codex":0.00023617333,"about_ca_system_score_gemma":0.00054566545,"threshold_uncertainty_score":0.51344264},"labels":[],"label_agreement":null},{"id":"W2169224435","doi":"10.2310/7290.2014.00057","title":"Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging","year":2015,"lang":"en","type":"article","venue":"Molecular Imaging","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Peptide; Glucagon-like peptide-1; Chemistry; Optical imaging; Biophysics; Biochemistry; Medicine; Biology; Endocrinology; Physics; Optics","score_opus":0.026433498345738753,"score_gpt":0.3024435961521724,"score_spread":0.27601009780643365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169224435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851633,0.002680748,0.003740069,0.00253153,0.000042315798,0.0006081481,0.000004955141,0.000030474226,0.005198515],"genre_scores_gemma":[0.9897671,0.000015194811,0.009791466,0.00025105604,0.000022684058,0.00006696356,0.000026088937,0.00001819352,0.000041279167],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99912447,0.00003653367,0.00015175492,0.00021813855,0.00029906537,0.00017004392],"domain_scores_gemma":[0.99941975,0.000054441058,0.00005072146,0.00015325438,0.00020874353,0.000113103735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006898995,0.000111677255,0.00021116258,0.00011295187,0.000027811713,0.00003252089,0.000030577874,0.00000970206,0.000004971277],"category_scores_gemma":[0.00040700342,0.00010066642,0.000044841305,0.000058257658,0.00007757512,0.0000939241,0.000056011988,0.00003114646,0.00000148405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029368544,0.00046204875,0.16535704,0.00075941696,0.00086438074,0.00032645048,0.00090435427,0.000076091215,0.0903157,0.0046889093,0.004410047,0.7315419],"study_design_scores_gemma":[0.024174549,0.0007130561,0.13181262,0.0015326318,0.016001325,0.00028256138,0.0043863617,0.47293183,0.3241004,0.012876923,0.0099365935,0.0012511592],"about_ca_topic_score_codex":0.000026137259,"about_ca_topic_score_gemma":0.0000019332574,"teacher_disagreement_score":0.7302907,"about_ca_system_score_codex":0.00005678873,"about_ca_system_score_gemma":0.000042902986,"threshold_uncertainty_score":0.4105057},"labels":[],"label_agreement":null},{"id":"W2170016962","doi":"10.1093/jn/133.11.3703","title":"Glucagon-Like Peptide-2 and Intestinal Adaptation: An Historical and Clinical Perspective","year":2003,"lang":"en","type":"review","venue":"Journal of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Glucagon-like peptide-2; Hormone; Internal medicine; Peptide hormone; Glucagon; Endocrinology; Adaptation (eye); Biology; Medicine; Peptide; Biochemistry; Neuroscience","score_opus":0.11088790413649022,"score_gpt":0.38953515237053216,"score_spread":0.27864724823404197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170016962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019258649,0.9979238,0.0001225821,0.0002753662,0.00041775635,0.0004397276,0.000001946635,0.000008494616,0.0006177544],"genre_scores_gemma":[0.000042600626,0.9917133,0.0068217837,0.00007119863,0.0007157323,0.000010880397,0.000016540216,0.00002025052,0.00058771414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856406,0.00016562424,0.00072341476,0.00020808757,0.00022275426,0.00011604346],"domain_scores_gemma":[0.9986607,0.00015169458,0.0005800954,0.000103796636,0.00027803375,0.00022567982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004350183,0.00020196821,0.0011643084,0.00026250133,0.00004130049,0.000033009317,0.000042276955,0.00014735093,0.000015301464],"category_scores_gemma":[0.00013355592,0.0001507335,0.00029514366,0.00011578886,0.0000556134,0.00016537729,0.000017747045,0.00039802503,0.0000028189027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010802409,0.0021381818,0.00010651231,0.0046330956,0.00057456567,0.0003273496,0.00007724962,2.3213481e-8,1.2215149e-7,0.00043872907,0.009960504,0.98163563],"study_design_scores_gemma":[0.0020242855,0.004008479,0.00017385015,0.009523871,0.0047477214,0.0013772042,0.00029372875,0.0000069070857,4.3165702e-8,0.00032441833,0.9773925,0.000126994],"about_ca_topic_score_codex":0.000005561987,"about_ca_topic_score_gemma":0.0000022225177,"teacher_disagreement_score":0.9815087,"about_ca_system_score_codex":0.0007039168,"about_ca_system_score_gemma":0.00012565468,"threshold_uncertainty_score":0.6146733},"labels":[],"label_agreement":null},{"id":"W2170048668","doi":"10.1124/pr.55.1.6","title":"International Union of Pharmacology. XXXV. The Glucagon Receptor Family","year":2003,"lang":"en","type":"review","venue":"Pharmacological Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":504,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Secretin; Secretin family; Receptor; Biology; Glucagon; Glucagon receptor; Peptide hormone; Hormone; Endocrinology; Internal medicine; Pharmacology; Biochemistry; Pancreas; Neuropeptide; Medicine; Vasoactive intestinal peptide","score_opus":0.15227125565561606,"score_gpt":0.4387284690109331,"score_spread":0.28645721335531704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170048668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007857933,0.9639355,0.000024394054,0.00058818667,0.0025631874,0.0050243,0.000032142012,0.000047529495,0.027776916],"genre_scores_gemma":[0.0000037742725,0.98943704,0.0004305585,0.0027191655,0.00053276913,0.0013079115,0.0002757947,0.00003726943,0.0052556903],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637496,0.0010958365,0.0012746822,0.0005243125,0.00035221534,0.00037801347],"domain_scores_gemma":[0.99830157,0.00031134792,0.00086251274,0.0002884121,0.00009331914,0.00014283654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014999565,0.0005627507,0.0026471016,0.00015429397,0.00006576511,0.00001781261,0.00057833415,0.00022764674,0.005763105],"category_scores_gemma":[0.00011647945,0.00027069866,0.0012653195,0.00045792176,0.00017605575,0.000056155957,0.0002192088,0.0006002683,0.0010071865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016680055,0.0004748289,0.0000017566412,0.004612996,0.0009774554,0.000012642674,0.000005200564,6.8160915e-8,0.00011301811,0.00016854689,0.21214864,0.78146815],"study_design_scores_gemma":[0.0008202176,0.0002475604,0.0000025277518,0.0029870018,0.009618692,0.000008326256,0.0000036228903,0.000002094518,0.000046397534,0.000011161453,0.98603547,0.00021693119],"about_ca_topic_score_codex":0.000001636423,"about_ca_topic_score_gemma":6.938836e-8,"teacher_disagreement_score":0.78125125,"about_ca_system_score_codex":0.00026716277,"about_ca_system_score_gemma":0.00010752195,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W2170644619","doi":"10.1177/0145721706287651","title":"Incretin-Based Therapies","year":2006,"lang":"en","type":"article","venue":"The Diabetes Educator","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Incretin; Medicine; Pharmacology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.007126006918977337,"score_gpt":0.23235080422208107,"score_spread":0.22522479730310374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170644619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97226906,0.0013826343,0.0000027926594,0.009049439,0.00025838288,0.00040207675,0.000003636752,0.0001199791,0.016511982],"genre_scores_gemma":[0.9902416,0.0000055239702,0.0003418369,0.002951536,0.00040428425,0.00012688688,0.000052919964,0.000026048723,0.00584937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991842,0.00003437001,0.00013554774,0.00016217097,0.00016897032,0.00031477018],"domain_scores_gemma":[0.9993515,0.00011622432,0.00004676767,0.00039644988,0.000033281223,0.000055749308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016932601,0.00014772126,0.00018377257,0.000069519236,0.00009820986,0.000035850113,0.00011905737,0.000030622996,0.0004192111],"category_scores_gemma":[0.000017735514,0.00008673314,0.00010544266,0.00015541763,0.00010563374,0.00002811444,0.000023672084,0.00007093454,0.00029153432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004882533,0.001143128,0.8299272,0.00014123374,0.00038824935,0.0000053592294,0.00026452212,0.00000870734,0.0067093796,0.0059350613,0.14038171,0.015046641],"study_design_scores_gemma":[0.0023943565,0.00045661168,0.6017869,0.00012409952,0.00069487526,6.023169e-7,0.00043224375,0.00018906714,0.04682243,0.0028059846,0.34392416,0.00036863566],"about_ca_topic_score_codex":0.000044353135,"about_ca_topic_score_gemma":0.0000034736427,"teacher_disagreement_score":0.22814026,"about_ca_system_score_codex":0.00004964,"about_ca_system_score_gemma":0.000069372574,"threshold_uncertainty_score":0.45900676},"labels":[],"label_agreement":null},{"id":"W2170738901","doi":"10.2337/db12-1498","title":"Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency","year":2013,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Center for Advancing Translational Sciences; Ethicon Endo-Surgery; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Glucagon-like peptide-1; Postprandial; Endocrinology; Internal medicine; Glucose homeostasis; Glucagon-like peptide-2; Sleeve gastrectomy; Receptor; Weight loss; Ingestion; Biology; Glucagon; Glucagon-like peptide 1 receptor; Insulin; Type 2 diabetes; Medicine; Diabetes mellitus; Obesity; Insulin resistance; Peptide; Biochemistry; Gastric bypass","score_opus":0.008845603393893703,"score_gpt":0.24058466202934525,"score_spread":0.23173905863545155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170738901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428743,0.0005239967,0.000044479984,0.00021205939,0.00009553416,0.0013020287,0.000008002751,0.00005253763,0.0034739135],"genre_scores_gemma":[0.99650586,0.0000419628,0.0019080192,0.00040210085,0.00003219263,0.0004163451,0.000023623816,0.000031162923,0.00063875323],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985207,0.000052777454,0.00031099032,0.0003534193,0.00025661406,0.0005055454],"domain_scores_gemma":[0.99924743,0.00013076463,0.0000473705,0.00033855592,0.0000916952,0.00014417245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010317571,0.00022456133,0.00043182357,0.00020488373,0.00002488744,0.000018286846,0.00011444518,0.000049516373,0.00030624622],"category_scores_gemma":[0.000045818855,0.0001863128,0.00012403502,0.00026528188,0.00009880657,0.00015753883,0.000084679545,0.000107702894,0.00025984176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007161525,0.0020902085,0.82843226,0.00048689643,0.00042287234,0.0000092575165,0.0015363849,0.00037519264,0.10861996,0.00050393166,0.0066457163,0.050805695],"study_design_scores_gemma":[0.010073415,0.0023224985,0.36401618,0.00062234356,0.0006477614,8.7120645e-7,0.0005313603,0.030049186,0.5877855,0.0026725035,0.0005371218,0.0007412832],"about_ca_topic_score_codex":0.0002146687,"about_ca_topic_score_gemma":0.000008358095,"teacher_disagreement_score":0.47916552,"about_ca_system_score_codex":0.00010820143,"about_ca_system_score_gemma":0.000026157304,"threshold_uncertainty_score":0.7597616},"labels":[],"label_agreement":null},{"id":"W2170748529","doi":"10.1530/joe-12-0468","title":"The sorting of proglucagon to secretory granules is mediated by carboxypeptidase E and intrinsic sorting signals","year":2013,"lang":"en","type":"article","venue":"Journal of Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Ontario Ministry of Research and Innovation; Natural Sciences and Engineering Research Council of Canada; Lawson Health Research Institute","keywords":"Proglucagon; Glucagon; Alpha cell; Enteroendocrine cell; Prohormone convertase; Carboxypeptidase; Cell biology; Internal medicine; Secretion; Glucagon-like peptide-1; Biology; Endocrinology; Prohormone; Chemistry; Biochemistry; Hormone; Beta cell; Enzyme; Islet; Endocrine system","score_opus":0.012345380477639572,"score_gpt":0.2591304131340757,"score_spread":0.24678503265643612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170748529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991612,0.0024082928,0.000020021813,0.004558867,0.00011398117,0.00037034627,0.0000016050249,0.000010852097,0.00090399367],"genre_scores_gemma":[0.9979722,0.00045619,0.0004317411,0.00064255483,0.000092799564,0.000016876098,0.0000021537603,0.0000127419735,0.0003727397],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987048,0.000053264208,0.0006134228,0.00011338807,0.00018964444,0.00032551528],"domain_scores_gemma":[0.998786,0.00022446294,0.0005061184,0.00012874714,0.00021554294,0.00013913798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020155925,0.00012085693,0.00037414633,0.00014953395,0.00006166954,0.000018592033,0.00009714813,0.00003533668,0.000064744265],"category_scores_gemma":[0.00031468942,0.000074000745,0.00008044623,0.000099431716,0.00009654468,0.00008133255,0.00007705706,0.00016401883,0.000011720133],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040928498,0.0004926911,0.17888586,0.00028208588,0.0019784414,0.00022952522,0.0022670813,0.000004860945,0.3172596,0.00075140403,0.04079628,0.45664287],"study_design_scores_gemma":[0.020961873,0.017137062,0.21684502,0.0014812513,0.002877352,0.0009027719,0.01224974,0.0004968879,0.61051327,0.005108863,0.110356934,0.0010689611],"about_ca_topic_score_codex":0.00004665897,"about_ca_topic_score_gemma":0.000005419637,"teacher_disagreement_score":0.45557392,"about_ca_system_score_codex":0.00003610632,"about_ca_system_score_gemma":0.000037684873,"threshold_uncertainty_score":0.30176628},"labels":[],"label_agreement":null},{"id":"W2171174384","doi":"10.1093/jn/133.7.2326","title":"Exendin-4, a GLP-1 Receptor Agonist, Interacts with Proteins and Their Products of Digestion to Suppress Food Intake in Rats","year":2003,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Digestion (alchemy); Hydrolysate; Ingestion; Chemistry; Internal medicine; Glucagon-like peptide-1; Endocrinology; Receptor; Casein; Agonist; Food intake; G protein; Food science; Biochemistry; Biology; Medicine; Diabetes mellitus; Chromatography; Hydrolysis","score_opus":0.015448194720483768,"score_gpt":0.23726126247500814,"score_spread":0.22181306775452436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171174384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962267,0.00042179882,0.000061377854,0.00201509,0.00008644817,0.0008795412,0.0000041827707,0.0000045743213,0.00030028168],"genre_scores_gemma":[0.9957736,0.00014299306,0.0038432872,0.00005069655,0.0000709126,0.000033409826,0.000008796262,0.000009401839,0.00006686157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993541,0.00004382475,0.0002563653,0.00010081699,0.00013815086,0.00010674334],"domain_scores_gemma":[0.9994865,0.00002013506,0.00017587587,0.00008425339,0.0001614352,0.0000718214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018870404,0.00009293603,0.00024032708,0.0002508247,0.000014777111,0.000016303584,0.00002893671,0.00002770477,0.000009981741],"category_scores_gemma":[0.00009645037,0.00006230454,0.000027907117,0.00018594431,0.000019439747,0.00017462112,0.000008923494,0.00009456882,8.548898e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008968669,0.016255802,0.020423545,0.0035949394,0.00091877335,0.00018276226,0.0056435945,0.000022749104,0.8901141,0.0014836568,0.008325564,0.044065792],"study_design_scores_gemma":[0.007979739,0.014613435,0.02853936,0.004732625,0.00016174163,0.00013453867,0.0011200607,0.000003673992,0.92301404,0.00036560776,0.019188045,0.00014710294],"about_ca_topic_score_codex":0.000002454145,"about_ca_topic_score_gemma":0.000009529158,"teacher_disagreement_score":0.043918688,"about_ca_system_score_codex":0.00007364369,"about_ca_system_score_gemma":0.000030711624,"threshold_uncertainty_score":0.25407055},"labels":[],"label_agreement":null},{"id":"W2171197390","doi":"10.1016/s1262-3636(10)70452-3","title":"PP2 Les adultes atteints de diabète de type 1 suivent-ils les recommandations nutritionnelles ? Quel impact sur le contrôle glycémique ?","year":2010,"lang":"fr","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Gynecology; Medicine","score_opus":0.015812770940846453,"score_gpt":0.272937678614291,"score_spread":0.2571249076734446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171197390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91917276,0.068363264,0.00017086386,0.0061786,0.0022863043,0.001107051,0.0004178953,0.00019094342,0.0021123395],"genre_scores_gemma":[0.9664064,0.008137245,0.0036501444,0.00067802815,0.002243592,0.00030181286,0.00081875775,0.00014026284,0.017623773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99586254,0.0004447251,0.000681376,0.00066355837,0.00033612092,0.0020116612],"domain_scores_gemma":[0.9968892,0.00072599726,0.0003053209,0.0007790591,0.0005045643,0.0007958857],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010952699,0.0007128203,0.0010811187,0.00037053876,0.00048972375,0.00025745097,0.0004201879,0.0004899421,0.0030736036],"category_scores_gemma":[0.0011302585,0.00068160787,0.0005650833,0.00049100776,0.0004328023,0.00058040395,0.00016973016,0.0007898459,0.000551603],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018990834,0.0048737056,0.29700395,0.0008136913,0.0036085977,0.00007377494,0.0013134974,0.00009260903,0.11114817,0.038875643,0.06002773,0.4819787],"study_design_scores_gemma":[0.009485999,0.00052911404,0.21132503,0.0013235301,0.0034779701,0.000008947969,0.0010076808,0.0021108778,0.08584372,0.007583734,0.6760784,0.0012250342],"about_ca_topic_score_codex":0.0045317053,"about_ca_topic_score_gemma":0.0016764803,"teacher_disagreement_score":0.6160506,"about_ca_system_score_codex":0.00025053238,"about_ca_system_score_gemma":0.00042036336,"threshold_uncertainty_score":0.9995635},"labels":[],"label_agreement":null},{"id":"W2171441059","doi":"10.1136/ebmed-2011-100035","title":"Intensive glucose lowering (HbA1c target&lt;6.0%) for people with type 2 diabetes increases mortality","year":2011,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.050119805825547044,"score_gpt":0.2846489121697051,"score_spread":0.23452910634415808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171441059","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19052723,0.03735902,0.0011114863,0.75243616,0.003193468,0.010397271,0.00014115857,0.00089454517,0.0039396696],"genre_scores_gemma":[0.1203186,0.0016242308,0.0025732752,0.8509451,0.010306649,0.0015454736,0.004491619,0.00037745512,0.0078176055],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958218,0.00009989439,0.00075839506,0.0011520917,0.001081499,0.0010863392],"domain_scores_gemma":[0.994952,0.0012910947,0.0005467297,0.0013584335,0.0014878662,0.00036382885],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007055768,0.0009911894,0.0021271019,0.00056294154,0.00013949549,0.000034985194,0.0003912009,0.0004971506,0.0011772639],"category_scores_gemma":[0.0025651776,0.0006581712,0.00031435935,0.00057919597,0.0004645072,0.0002626076,0.000109681714,0.00089094613,0.0000915243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093956006,0.00022984242,0.037921995,0.005095249,0.0018698379,0.00082330755,0.00018356161,0.0000042764923,0.00032185944,0.000015782307,0.9507106,0.0018841535],"study_design_scores_gemma":[0.010800137,0.019404951,0.026850382,0.04320921,0.016223708,0.000020261157,0.00025927677,0.00020750679,0.008637821,0.00037236503,0.87226254,0.001751873],"about_ca_topic_score_codex":0.00072496105,"about_ca_topic_score_gemma":0.00009501758,"teacher_disagreement_score":0.09850895,"about_ca_system_score_codex":0.00034861526,"about_ca_system_score_gemma":0.00052935915,"threshold_uncertainty_score":0.9997358},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2171779326","doi":"10.2337/diabetes.53.5.1326","title":"Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors","year":2004,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Incretin; Internal medicine; Endocrinology; Glucose homeostasis; Receptor; Insulin; Glucagon; Glucagon-like peptide-1; Gastric inhibitory polypeptide; Chemistry; Biology; Type 2 diabetes; Diabetes mellitus; Medicine; Insulin resistance","score_opus":0.01217094794031287,"score_gpt":0.25054997407134155,"score_spread":0.23837902613102868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171779326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951242,0.0011684992,0.00003543289,0.00163056,0.00029262193,0.0013710465,0.000024658966,0.00004784307,0.00030511772],"genre_scores_gemma":[0.9983728,0.000044909528,0.0003731949,0.00019718021,0.0002604145,0.0002877621,0.000092771865,0.00003378096,0.00033722114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987413,0.000045146848,0.00034654472,0.00028583896,0.0002225845,0.00035855788],"domain_scores_gemma":[0.99921024,0.00013758814,0.00010955482,0.0004096246,0.00006164178,0.00007136073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043095072,0.0001923871,0.00030035828,0.00012399933,0.00015165447,0.000028356866,0.00018723132,0.00007414759,0.000041737214],"category_scores_gemma":[0.00003119552,0.00012242566,0.00018695155,0.00023891892,0.00013680317,0.00015608543,0.00004139037,0.00013907293,0.000007805856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089633616,0.002136954,0.075628236,0.00060130074,0.0012239064,0.000003779818,0.009159266,0.0008710361,0.8681774,0.0026023942,0.0016918014,0.03700755],"study_design_scores_gemma":[0.009583843,0.00087310094,0.04056298,0.000477555,0.0007735409,7.4070846e-7,0.0026666226,0.00037389938,0.9281177,0.0004564406,0.015823098,0.00029051045],"about_ca_topic_score_codex":0.00029709513,"about_ca_topic_score_gemma":0.00012642973,"teacher_disagreement_score":0.05994023,"about_ca_system_score_codex":0.00010765491,"about_ca_system_score_gemma":0.000054741125,"threshold_uncertainty_score":0.49923733},"labels":[],"label_agreement":null},{"id":"W2171780887","doi":"10.1210/endo.141.11.7773","title":"Ontogeny of the Glucagon-Like Peptide-2 Receptor Axis in the Developing Rat Intestine**This work was supported in part by operating grants from the Medical Research Council (to D.J.D. and P.L.B.), the Crohn’s and Colitis Foundation of Canada (to P.L.B.), and the Ontario Research and Development Challenge Fund (to D.J.D.). GLP-2 is the subject of a licensing agreement between Toronto General Hospital, the University of Toronto, D.J.D., and NPS Allelix Corp.","year":2000,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Internal medicine; Enteroendocrine cell; Ileum; Endocrinology; Jejunum; Small intestine; Biology; Glucagon-like peptide-2; Receptor; Glucagon-like peptide-1; Fetus; Stomach; Medicine; Endocrine system; Peptide; Biochemistry; Hormone; Pregnancy","score_opus":0.07579648995719201,"score_gpt":0.2936788329446829,"score_spread":0.21788234298749087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171780887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959283,0.004460491,0.000003975898,0.032709304,0.000075324955,0.002633417,0.000020820604,0.0000031727718,0.00081047136],"genre_scores_gemma":[0.9940081,0.003978749,0.00027530245,0.00070989854,0.00004498468,0.00007927335,0.000012551915,0.000012865702,0.00087824534],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9960975,0.0011335775,0.00057752756,0.00043338854,0.0011958217,0.0005621614],"domain_scores_gemma":[0.9962431,0.0025468946,0.00013593337,0.0005061989,0.00045781038,0.00011002397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004380823,0.00022250587,0.0005301144,0.000036243815,0.00059018,0.000042446667,0.0004872366,0.00007161308,0.00027816414],"category_scores_gemma":[0.0007084891,0.00010099099,0.00003024534,0.0002458577,0.0013331724,0.000073551484,0.0007182561,0.0003766389,6.176637e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005166169,0.00037220065,0.32188243,0.00021749585,0.0013224457,0.000052337775,0.44774148,0.0000068390773,0.00019731878,0.0013596717,0.055352345,0.16632926],"study_design_scores_gemma":[0.005444999,0.0006140926,0.8166455,0.0005933011,0.000105554594,0.000009107759,0.02731066,0.000036711554,0.00038937308,0.00007719553,0.14860421,0.0001692549],"about_ca_topic_score_codex":0.8367687,"about_ca_topic_score_gemma":0.97567546,"teacher_disagreement_score":0.4947631,"about_ca_system_score_codex":0.000933676,"about_ca_system_score_gemma":0.0012066014,"threshold_uncertainty_score":0.49121293},"labels":[],"label_agreement":null},{"id":"W2172193326","doi":"10.2337/dc12-0413","title":"Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach","year":2012,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3218,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leonard M. Miller School of Medicine, University of Miami; Leonard M. Miller School of Medicine; Health Science Center, University of Tennessee; University of Illinois at Urbana-Champaign; University of Melbourne; European Association for the Study of Diabetes; National Institute for Health and Care Research; MedStar Health Research Institute; School of Medicine, University of Kansas; University of Ioannina; University of Sydney; School of Medicine, Case Western Reserve University; Université de Nantes; Georgetown University; University of Toronto; Case Western Reserve University; Yale University; Wayne State University; University of Miami; University of Southern California","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; MEDLINE; Intensive care medicine; Diabetes management; Internal medicine; Endocrinology","score_opus":0.036511422786637666,"score_gpt":0.27670548052893157,"score_spread":0.2401940577422939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172193326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060360404,0.9745248,2.441679e-7,0.00000433638,0.0004565674,0.00287352,0.000103209306,0.000072398725,0.015928905],"genre_scores_gemma":[0.009398214,0.98499703,0.0008546707,0.00006119749,0.000090786765,0.00070120645,0.0034497601,0.00014313539,0.00030398575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970734,0.000103266524,0.00087631395,0.000632071,0.00044248736,0.00087243284],"domain_scores_gemma":[0.9983296,0.000047125955,0.00038901286,0.0009337922,0.000101521975,0.00019896806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012104057,0.0007064256,0.0025399497,0.00056572596,0.000028802913,0.000021280763,0.00029169203,0.00031346406,0.00008398157],"category_scores_gemma":[0.000009862175,0.00056854374,0.00064910983,0.00083015935,0.00007107386,0.000091512135,0.00033766453,0.0002982373,0.0002618065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010412357,0.0005642365,0.015368216,0.114394724,0.0014144621,0.000017662256,0.00022757363,4.3148677e-7,2.8897782e-7,0.000055428478,0.0003089642,0.8676376],"study_design_scores_gemma":[0.0012597595,0.0004414214,0.0007513694,0.026820008,0.0072524054,4.6341773e-7,0.00059017184,0.0000046709815,0.00000946728,0.0000036580977,0.962352,0.0005146556],"about_ca_topic_score_codex":0.0000017477585,"about_ca_topic_score_gemma":5.898778e-7,"teacher_disagreement_score":0.962043,"about_ca_system_score_codex":0.0004137335,"about_ca_system_score_gemma":0.00006054366,"threshold_uncertainty_score":0.9996766},"labels":[],"label_agreement":null},{"id":"W2172438155","doi":"10.1007/s13300-015-0142-y","title":"IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy","year":2015,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk Fonden; Novo Nordisk","keywords":"Medicine; Liraglutide; Insulin glargine; Insulin degludec; Type 2 diabetes; Insulin aspart; Hypoglycemia; Internal medicine; Insulin; Glycated hemoglobin; Lixisenatide; Diabetes mellitus; Glucagon-like peptide 1 receptor; Endocrinology; Agonist","score_opus":0.04309277245387194,"score_gpt":0.2779275746307542,"score_spread":0.23483480217688224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172438155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270725,0.0010413488,0.0000027686388,0.0004783363,0.00045722933,0.0018793617,0.000006624244,0.000097775905,0.0033292836],"genre_scores_gemma":[0.99756444,0.0003317936,0.00011459622,0.0012560501,0.00010222713,0.00024304433,0.00022714648,0.000056393656,0.00010430269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812394,0.00013106894,0.00034616212,0.00042354196,0.000499684,0.00047557504],"domain_scores_gemma":[0.9986268,0.0001951119,0.00018328839,0.00040321448,0.00043332754,0.00015825691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030723767,0.0003721329,0.0006674857,0.00031072574,0.000041164185,0.00008717973,0.00015997158,0.00009046396,0.000051687388],"category_scores_gemma":[0.00009933657,0.00024810844,0.00008298128,0.00040210603,0.00010159175,0.00027987082,0.000021162825,0.00018556864,0.00007857943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060999207,0.0050668493,0.78327554,0.000033731892,0.0029429279,0.000015319261,0.0021674146,0.00026041493,0.0008051876,0.0017621568,0.0012463033,0.14142497],"study_design_scores_gemma":[0.21962912,0.03477958,0.728529,0.00025095738,0.00011939907,2.4549834e-8,0.0008884807,0.00088633044,0.009328059,0.001579569,0.0033074308,0.0007020453],"about_ca_topic_score_codex":0.000017554665,"about_ca_topic_score_gemma":0.0000071815753,"teacher_disagreement_score":0.15862992,"about_ca_system_score_codex":0.00020302155,"about_ca_system_score_gemma":0.000108010645,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W2175831347","doi":"10.1152/ajpheart.2001.280.4.h1480","title":"Platelet hyperactivity and abnormal Ca<sup>2+</sup>homeostasis in diabetes mellitus","year":2001,"lang":"en","type":"article","venue":"American Journal of Physiology-Heart and Circulatory Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Platelet; Homeostasis; Chemistry; Internal medicine; Endocrinology; Thrombin; Platelet activation; Diabetes mellitus; Calcium; Calcium metabolism; Fura-2; Cytosol; Biochemistry; Enzyme; Medicine","score_opus":0.010261477757324047,"score_gpt":0.24129536316008618,"score_spread":0.23103388540276212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2175831347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970865,0.0019821562,3.900582e-7,0.0005472936,0.00008699653,0.00017919025,0.0000046511445,0.000015206408,0.00009761856],"genre_scores_gemma":[0.9967314,0.0015087612,0.00013835028,0.0013339537,0.00022491698,0.000010202219,0.000013005168,0.00002204706,0.000017378019],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983495,0.00019704436,0.00042592257,0.00038348124,0.00013837674,0.0005056771],"domain_scores_gemma":[0.9990018,0.0001892231,0.00025908387,0.00024439042,0.00007536775,0.00023010826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002543114,0.00027734946,0.0011000845,0.00028776174,0.00008341258,0.000010745959,0.00008478474,0.000090242094,0.00008891659],"category_scores_gemma":[0.000031920128,0.00022421758,0.00015168934,0.00024764988,0.0006707299,0.00021323039,0.000075153315,0.0003669577,0.000013072436],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005953136,0.00060151384,0.11336525,0.00008891516,0.00066032674,0.000019014919,0.00049391174,0.0003362145,0.86041045,0.000054771343,0.00031279898,0.023061538],"study_design_scores_gemma":[0.0020612865,0.0019019707,0.98863655,0.00005871383,0.00015770942,0.00014897436,0.0006832312,0.00051430025,0.00047714048,0.0004153459,0.004734041,0.00021070501],"about_ca_topic_score_codex":0.00005695987,"about_ca_topic_score_gemma":0.0000027009933,"teacher_disagreement_score":0.8752713,"about_ca_system_score_codex":0.00005996785,"about_ca_system_score_gemma":0.000059564605,"threshold_uncertainty_score":0.9143328},"labels":[],"label_agreement":null},{"id":"W2176459589","doi":"10.1016/j.diabet.2015.10.003","title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Mitsubishi Tanabe Pharma Corporation; American Diabetes Association","keywords":"Canagliflozin; Internal medicine; Endocrinology; Liver function; Bilirubin; Sitagliptin; Alkaline phosphatase; Medicine; Liver function tests; Type 2 diabetes; Chemistry; Diabetes mellitus; Biochemistry; Enzyme","score_opus":0.006894431358910349,"score_gpt":0.21803860513254783,"score_spread":0.21114417377363748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176459589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994267,0.0013428385,3.6766062e-7,0.00003812132,0.00041865872,0.0008946305,0.000008084617,0.00004888922,0.0029814332],"genre_scores_gemma":[0.9988073,0.0000139117365,0.00007391551,0.00031748015,0.00008585802,0.00006883222,0.0001387741,0.00003615963,0.00045778422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845564,0.00011757337,0.00023774501,0.00030943577,0.00046297113,0.00041663836],"domain_scores_gemma":[0.99904895,0.000119167955,0.00011110329,0.00036729066,0.00016937405,0.00018408787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003835266,0.00027286934,0.00062039273,0.00032737997,0.000019707286,0.000014259428,0.00008571978,0.00007425381,0.00005455444],"category_scores_gemma":[0.00017437458,0.00018488448,0.000068538226,0.0004888666,0.000056285724,0.00013276112,0.00004416384,0.00012318738,0.00012836802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000583585,0.00053355156,0.95572585,0.00014927259,0.00030605786,0.0000037118843,0.00007178079,0.000021573844,0.00015038633,0.00011951761,0.0017401163,0.040594608],"study_design_scores_gemma":[0.008140733,0.006334064,0.970767,0.00019241218,0.000844248,1.6911628e-8,0.000008242102,0.000078655146,0.0072425655,0.000033063854,0.0061691245,0.0001898321],"about_ca_topic_score_codex":0.000040597908,"about_ca_topic_score_gemma":0.000014818369,"teacher_disagreement_score":0.040404774,"about_ca_system_score_codex":0.00008044511,"about_ca_system_score_gemma":0.00003467057,"threshold_uncertainty_score":0.75393707},"labels":[],"label_agreement":null},{"id":"W2176915168","doi":"10.1586/17446651.2016.1113129","title":"Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Expert Review of Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk","keywords":"Liraglutide; Insulin degludec; Medicine; Type 2 diabetes; Hypoglycemia; Glycemic; Insulin; Glucagon-like peptide 1 receptor; Combination therapy; Diabetes mellitus; Internal medicine; Endocrinology; Insulin glargine; Receptor; Agonist","score_opus":0.04876117986645024,"score_gpt":0.3449064192195603,"score_spread":0.29614523935311005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176915168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052874677,0.93823653,0.000037580176,0.003913106,0.0009451577,0.00209128,0.000014292197,0.000040927338,0.0018464188],"genre_scores_gemma":[0.07141501,0.9165905,0.0058226073,0.0030795017,0.00051051483,0.0009570547,0.00008871719,0.00004589381,0.0014902122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984089,0.00008636839,0.00059248065,0.0002791225,0.00022262866,0.00041051547],"domain_scores_gemma":[0.99833465,0.00023961377,0.0002566956,0.0007137865,0.00034124742,0.00011402356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020008658,0.0002669146,0.001201134,0.00010840571,0.000037280864,0.0000037046893,0.0002015613,0.000048667767,0.00008439049],"category_scores_gemma":[0.0003400476,0.00014931902,0.00038042644,0.00023285874,0.00018840528,0.000051375366,0.000055437118,0.00005102482,0.000027684711],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042357258,0.0029513373,0.0044014193,0.0028943093,0.0042850263,0.000024448875,0.0010253991,0.0000031833754,0.0028472848,0.014859654,0.07722036,0.889064],"study_design_scores_gemma":[0.0032979785,0.0013637998,0.0028247454,0.0005952595,0.0014327625,0.000004902259,0.000088588116,0.00001615055,0.019045645,0.00016840892,0.971043,0.000118764416],"about_ca_topic_score_codex":0.000043199645,"about_ca_topic_score_gemma":0.000003147158,"teacher_disagreement_score":0.8938226,"about_ca_system_score_codex":0.00005373414,"about_ca_system_score_gemma":0.0000959961,"threshold_uncertainty_score":0.6089053},"labels":[],"label_agreement":null},{"id":"W2178262235","doi":"10.1152/ajpendo.2000.278.1.e134","title":"Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats","year":2000,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Internal medicine; Endocrinology; In vivo; Dipeptidyl peptidase; Kidney; Glucagon-like peptide-1; Glucagon-like peptide-2; Catabolism; Chemistry; Dipeptidyl peptidase-4; Glucagon; Enzyme; Hormone; In vitro; Medicine; Peptide; Biology; Metabolism; Diabetes mellitus; Type 2 diabetes; Biochemistry","score_opus":0.007128402170650444,"score_gpt":0.23310509121426412,"score_spread":0.22597668904361368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178262235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904531,0.0076930374,0.0000037928369,0.0010833852,0.000168156,0.00020971893,0.000004172421,0.000008201407,0.00037643922],"genre_scores_gemma":[0.98980784,0.008202843,0.000701816,0.0006951057,0.00010844325,0.000010091046,0.0000019167674,0.000012538079,0.00045942713],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985573,0.0002053954,0.0005327216,0.00021642476,0.00014086463,0.00034729042],"domain_scores_gemma":[0.99903727,0.00011292789,0.0004050441,0.0002608526,0.0000789032,0.00010503489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013623436,0.00020363294,0.00087799534,0.00019403269,0.000056451656,0.0000056504705,0.00016291074,0.000040860337,0.000049274655],"category_scores_gemma":[0.00005488421,0.00012678257,0.00010937007,0.00021753351,0.00087471155,0.00009577844,0.00009763568,0.00036767626,0.0000037613975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015826705,0.00094306876,0.019565372,0.000102766426,0.0013119106,0.00013426327,0.0026365872,0.00005009687,0.48100784,0.0028819493,0.0011766828,0.4886068],"study_design_scores_gemma":[0.0034180272,0.0007888846,0.97919685,0.000086593245,0.00055235816,0.00034003748,0.00047808356,0.000012803219,0.0059866607,0.0011512976,0.007859907,0.00012850153],"about_ca_topic_score_codex":0.00012217314,"about_ca_topic_score_gemma":0.000010760933,"teacher_disagreement_score":0.9596315,"about_ca_system_score_codex":0.000016755403,"about_ca_system_score_gemma":0.000057513207,"threshold_uncertainty_score":0.5170043},"labels":[],"label_agreement":null},{"id":"W2178569306","doi":"10.1007/s12325-015-0261-x","title":"Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease","year":2015,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Metformin; Liraglutide; Kidney disease; Intensive care medicine; Glycemic; Diabetes mellitus; Guideline; Alogliptin; Type 2 Diabetes Mellitus; Type 2 diabetes; Saxagliptin; Internal medicine; Pharmacology; Sitagliptin; Endocrinology; Pathology","score_opus":0.1538682301300158,"score_gpt":0.41104867924444327,"score_spread":0.2571804491144275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178569306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003213781,0.99813986,0.0000017654587,0.000113230184,0.000121163954,0.0010330018,0.0001386513,0.0000075838566,0.0001233943],"genre_scores_gemma":[0.00042395177,0.99826777,0.000172425,0.000112383386,0.000046870795,0.00006499967,0.00082022813,0.000024083489,0.00006728647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867046,0.00012914558,0.0005027639,0.00030622323,0.00021429769,0.0001771321],"domain_scores_gemma":[0.99832404,0.00029911287,0.00033189383,0.0009028754,0.000043779783,0.000098326076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003483098,0.00021410949,0.0010789551,0.00014204672,0.000013829257,0.000006824667,0.00032754874,0.000056441102,0.000038360246],"category_scores_gemma":[0.0001246748,0.00012739243,0.00006318002,0.00041736077,0.00022055846,0.00027672015,0.00014465018,0.00014137432,0.0000026244372],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030579056,0.00011261556,0.0017989507,0.0071819252,0.00020844664,0.0000034041998,0.00004323611,0.0000019207384,6.120425e-7,0.00022702124,0.00016768597,0.9902236],"study_design_scores_gemma":[0.0009679142,0.00015076027,0.00019913002,0.015432301,0.0005466361,3.3693755e-7,0.000009381396,0.000045131615,9.909238e-7,0.00011739532,0.98242754,0.00010248026],"about_ca_topic_score_codex":0.000016298403,"about_ca_topic_score_gemma":0.00001692597,"teacher_disagreement_score":0.9901211,"about_ca_system_score_codex":0.000089897134,"about_ca_system_score_gemma":0.00046005068,"threshold_uncertainty_score":0.5194912},"labels":[],"label_agreement":null},{"id":"W2180280557","doi":"10.1515/jpem.2004.17.11.1561","title":"Short-term Insulin Therapy in Adolescents with Type 2 Diabetes Mellitus","year":2004,"lang":"en","type":"article","venue":"Journal of Pediatric Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Heilongjiang Bayi Agricultural University","keywords":"Medicine; Hypoglycemia; Glycemic; Insulin; Diabetes mellitus; Body mass index; Type 2 Diabetes Mellitus; Type 1 diabetes; Internal medicine; Type 2 diabetes; Endocrinology; Pediatrics","score_opus":0.014093842955900153,"score_gpt":0.25670118680300036,"score_spread":0.2426073438471002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180280557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92367333,0.07533482,0.0000080088175,0.00032262912,0.0003350429,0.00018472841,5.7731995e-7,0.0000104798155,0.00013038487],"genre_scores_gemma":[0.9235929,0.075235814,0.00038683895,0.00023911803,0.0004964607,0.000004206023,0.0000014098208,0.00001263034,0.000030593263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900186,0.000033335262,0.0003264475,0.00014404977,0.0001683383,0.00032599233],"domain_scores_gemma":[0.999523,0.000013312375,0.00013120464,0.000115636234,0.00009705351,0.00011979798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011070392,0.00015934894,0.00045670904,0.00042398018,0.000027954933,0.0000103776065,0.000076952434,0.000059252663,0.000008542255],"category_scores_gemma":[0.000021564383,0.00010398751,0.00006208507,0.00025366235,0.00005593172,0.00011861591,0.000026907805,0.0002687193,0.000005008284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048783046,0.0007937518,0.9335641,0.00007054022,0.00024630263,0.00062083465,0.0001810161,0.000012211594,0.00034015026,0.00038232235,0.00004532508,0.0632556],"study_design_scores_gemma":[0.008940181,0.0009983367,0.98632425,0.00006301132,0.00051827094,0.00008406435,0.000040444032,3.8061918e-7,0.0010233019,0.00029993014,0.0015987847,0.00010902085],"about_ca_topic_score_codex":0.000004172358,"about_ca_topic_score_gemma":0.0000039300503,"teacher_disagreement_score":0.063146584,"about_ca_system_score_codex":0.000029483903,"about_ca_system_score_gemma":0.00007519808,"threshold_uncertainty_score":0.42404875},"labels":[],"label_agreement":null},{"id":"W2183923108","doi":"10.14740/jocmr2385w","title":"Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Cotransporter; Pharmacology; Sodium; Internal medicine; Chemistry","score_opus":0.23055801237155135,"score_gpt":0.5171979662395405,"score_spread":0.28663995386798913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183923108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043747965,0.98385984,0.000020266241,0.001292625,0.0030663796,0.0025539016,0.0000056722884,0.000038112605,0.004788406],"genre_scores_gemma":[0.0012918139,0.9875835,0.0002401359,0.00021257433,0.008367725,0.000049098442,0.00004822085,0.00016281859,0.002044075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879535,0.0012713243,0.0049433196,0.0007132981,0.0039691045,0.0011494551],"domain_scores_gemma":[0.98935235,0.004311533,0.0017282192,0.001015368,0.0016762238,0.0019162862],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.020724522,0.00074454217,0.007883825,0.0016392563,0.00011763119,0.00006928822,0.00080063124,0.00080436404,0.00026600767],"category_scores_gemma":[0.005004645,0.00043125672,0.0017962046,0.0012969995,0.0009248316,0.00023439706,0.00026128558,0.004567219,0.00029278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002620858,0.0016406293,0.0008826679,0.02627509,0.0020517902,0.0033874593,0.00008509776,1.7421696e-7,0.000009598296,0.000022419703,0.03436174,0.9310213],"study_design_scores_gemma":[0.008204869,0.010593083,0.00052241416,0.100185595,0.0054718186,0.00018577934,0.0000596839,0.0000030234562,0.000047881083,0.00019499377,0.87422186,0.00030899802],"about_ca_topic_score_codex":0.00001484446,"about_ca_topic_score_gemma":0.000002237673,"teacher_disagreement_score":0.9307122,"about_ca_system_score_codex":0.0004471565,"about_ca_system_score_gemma":0.0020456086,"threshold_uncertainty_score":0.9998139},"labels":[],"label_agreement":null},{"id":"W2195293762","doi":"10.2337/db14-1706","title":"Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism","year":2015,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Postprandial; Hyperlipidemia; Incretin; Lipoprotein; Glucagon-like peptide-1; Endocrinology; Internal medicine; Secretion; Glucagon-like peptide-2; Diabetes mellitus; Type 2 diabetes; Medicine; Biology; Cholesterol; Biochemistry; Peptide","score_opus":0.06782462679350769,"score_gpt":0.33366551191618526,"score_spread":0.26584088512267756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2195293762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.089766316,0.9072952,0.000007938904,0.00002034472,0.00013682518,0.0021141728,0.000043124008,0.000052950272,0.000563119],"genre_scores_gemma":[0.18555231,0.8037731,0.0062162555,0.00006683878,0.0007747876,0.0013365763,0.0009999993,0.00017367497,0.0011064443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795955,0.00008692786,0.00077223073,0.00044865592,0.00044391924,0.00028872615],"domain_scores_gemma":[0.9984821,0.00007211897,0.0008037001,0.0002993485,0.00016963585,0.00017309055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035909165,0.00047946235,0.00218972,0.00030151688,0.00003352907,0.000016697606,0.00013840341,0.00022416399,0.000094223426],"category_scores_gemma":[0.00009376674,0.00035899386,0.00034963066,0.0002733938,0.00021719169,0.00010440588,0.0002004291,0.00018969382,0.000006900209],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000666763,0.0013967059,0.0009152303,0.025260916,0.001971074,0.000015554917,0.00013265283,0.0000013385596,0.0061845947,0.0011206641,0.000595444,0.96233916],"study_design_scores_gemma":[0.008828647,0.003620257,0.009034086,0.06343672,0.024956992,0.000035129768,0.00059004134,0.0003154319,0.042183127,0.00033245445,0.8446663,0.0020008117],"about_ca_topic_score_codex":0.000022981858,"about_ca_topic_score_gemma":5.8706416e-7,"teacher_disagreement_score":0.96033835,"about_ca_system_score_codex":0.00010193752,"about_ca_system_score_gemma":0.00007408517,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W2200208573","doi":"10.1016/j.ahj.2015.12.009","title":"Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial","year":2015,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"British Microcirculation Society; Novartis; Novo Nordisk; Merck; Bayer; AstraZeneca","keywords":"Exenatide; Medicine; Glycemic; Clinical endpoint; Placebo; Myocardial infarction; Stroke (engine); Type 2 diabetes; Internal medicine; Semaglutide; Liraglutide; Randomized controlled trial; Diabetes mellitus; Insulin; Endocrinology; Alternative medicine","score_opus":0.05568336115756114,"score_gpt":0.2985380026289485,"score_spread":0.24285464147138733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200208573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974057,0.0005910918,0.00065463514,0.00022540109,0.00013760569,0.0008713088,4.3978298e-7,0.0000035823223,0.00011022886],"genre_scores_gemma":[0.9989108,0.000053796804,0.0007657353,0.000050017068,0.0000925238,0.000014421187,2.4569545e-7,0.000006726853,0.000105758714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990568,0.00012410751,0.0002260449,0.000077767865,0.00042441947,0.00009082559],"domain_scores_gemma":[0.99949247,0.00004482963,0.0001172892,0.00017055891,0.00009222108,0.000082646024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006214803,0.00006386342,0.00032207815,0.00005548296,0.000036036574,0.0000075108405,0.00004446133,0.000007070415,0.000007482195],"category_scores_gemma":[0.000084297106,0.000039869963,0.00012945732,0.000122060286,0.000074121,0.000036221383,0.000037327074,0.00006941781,7.415396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041324195,0.018390594,0.5567526,0.00025377978,0.031906597,0.0003110744,0.025487034,0.0580502,0.00617441,0.00011505208,0.034419045,0.2268154],"study_design_scores_gemma":[0.36889297,0.0961596,0.38446328,0.0008460214,0.012049512,0.0006710792,0.05400542,0.002124586,0.013528167,0.0005495056,0.06578558,0.0009242895],"about_ca_topic_score_codex":0.00008185608,"about_ca_topic_score_gemma":0.0000017817817,"teacher_disagreement_score":0.32756877,"about_ca_system_score_codex":0.000037890542,"about_ca_system_score_gemma":0.000084018815,"threshold_uncertainty_score":0.16258499},"labels":[],"label_agreement":null},{"id":"W2207883647","doi":"10.1177/1932296815610124","title":"IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test","year":2015,"lang":"en","type":"article","venue":"Journal of Diabetes Science and Technology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk","keywords":"Postprandial; Meal; Medicine; Continuous glucose monitoring; Blood Glucose Self-Monitoring; Glucose test; Diabetes mellitus; Internal medicine; Endocrinology; Glycemic","score_opus":0.013213471722966504,"score_gpt":0.2676616137754726,"score_spread":0.2544481420525061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2207883647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930193,0.0053785946,0.000030563235,0.0009406297,0.00016272908,0.00028279726,0.000003377184,0.000041477902,0.00014056193],"genre_scores_gemma":[0.99705744,0.0001955651,0.0025733213,0.0000650799,0.00008606501,0.0000035440362,2.3244495e-7,0.00001093777,0.000007811473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985054,0.000019334897,0.00037095184,0.0002491951,0.00041927784,0.00043584165],"domain_scores_gemma":[0.9985689,0.00012440984,0.00031016683,0.00011747794,0.00057305134,0.00030598007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011600197,0.000178209,0.0005435939,0.00063894375,0.00018897423,0.00014908904,0.00011411185,0.00010277139,0.0000010135113],"category_scores_gemma":[0.0015993669,0.00013350848,0.00003017389,0.0005497514,0.000975164,0.00044067347,0.00011722496,0.00022061485,3.7806325e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014171642,0.00009299867,0.45018563,0.000029140992,0.000108450375,0.00008218475,0.0001116758,7.3964105e-7,0.48480314,0.00007587632,0.000006302847,0.06436215],"study_design_scores_gemma":[0.07098286,0.04403044,0.17241691,0.0022031097,0.0032320241,0.0016689419,0.010786946,0.007619317,0.6782776,0.006605667,0.00094848225,0.00122768],"about_ca_topic_score_codex":0.000007873233,"about_ca_topic_score_gemma":9.160474e-7,"teacher_disagreement_score":0.27776873,"about_ca_system_score_codex":0.00010637072,"about_ca_system_score_gemma":0.00034644778,"threshold_uncertainty_score":0.54443175},"labels":[],"label_agreement":null},{"id":"W2207970920","doi":"10.1111/dom.12624","title":"Patient‐reported outcome results in patients with type 2 diabetes treated with once‐weekly dulaglutide: data from the <scp>AWARD</scp> phase <scp>III</scp> clinical trial programme","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Exenatide; Medicine; Checklist; Type 2 diabetes; Diabetes mellitus; Internal medicine; Quality of life (healthcare); Physical therapy; Psychology; Endocrinology; Nursing","score_opus":0.08649019103364348,"score_gpt":0.31850987965368993,"score_spread":0.23201968862004646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2207970920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922343,0.001925292,0.0000027963802,0.00021295901,0.0006296862,0.0037607527,0.0004435934,0.00019988135,0.0005907447],"genre_scores_gemma":[0.99156,0.000115422634,0.00076552265,0.0006984436,0.00038489883,0.00015374727,0.00555107,0.00008065298,0.0006902656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99467486,0.00040213726,0.0013812752,0.0013387639,0.001033023,0.0011699196],"domain_scores_gemma":[0.9951032,0.0010373762,0.0007483539,0.0018604017,0.00049634103,0.00075436314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016222786,0.0006994904,0.0016177926,0.00025827173,0.0001831731,0.00020847954,0.0004958384,0.0002809568,0.000004047366],"category_scores_gemma":[0.0034175522,0.00041329174,0.00013804995,0.0010822745,0.00042658034,0.0005645283,0.0004757082,0.00054566766,0.00003447886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017837881,0.005781343,0.9678286,0.000032288328,0.0014999987,0.00005221808,0.00051228376,0.0000022327104,0.0000066545426,0.000016323298,0.005799074,0.016685229],"study_design_scores_gemma":[0.15631826,0.004677024,0.77846146,0.00017987777,0.002757406,3.0517378e-7,0.00047594978,0.00014585641,0.00021481716,0.000058054153,0.05656619,0.00014482006],"about_ca_topic_score_codex":0.00022024983,"about_ca_topic_score_gemma":0.00009438411,"teacher_disagreement_score":0.18936713,"about_ca_system_score_codex":0.00007333697,"about_ca_system_score_gemma":0.00022363312,"threshold_uncertainty_score":0.9998319},"labels":[],"label_agreement":null},{"id":"W2208361839","doi":"10.14740/jem.v5i6.315","title":"Observational Study of the Use of Insulin Glargine as Basal Therapy in Patients With Type 2 Diabetes Mellitus in Morocco","year":2015,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin glargine; Hypoglycemia; Glycated hemoglobin; Type 2 Diabetes Mellitus; Internal medicine; Glycemic; Regimen; Insulin; Diabetes mellitus; Adverse effect; Observational study; Type 2 diabetes; Endocrinology","score_opus":0.0703901315541837,"score_gpt":0.2856403257867934,"score_spread":0.2152501942326097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208361839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962219,0.0029553762,3.4819251e-7,0.00025058462,0.00021685702,0.0003178561,0.0000016152245,0.0000013336435,0.000034158656],"genre_scores_gemma":[0.99897027,0.0005103815,0.00022791063,0.00019255438,0.000024793873,0.0000037256127,0.0000022787121,0.000005740989,0.0000623164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912167,0.000091829075,0.00035687943,0.00007664332,0.00022065768,0.00013234437],"domain_scores_gemma":[0.9992874,0.000057366306,0.00024586148,0.00011648745,0.00025150555,0.00004135323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013259889,0.00008877806,0.00039981952,0.0001954197,0.000008523318,0.0000029923808,0.00006823529,0.000027080252,0.000008846151],"category_scores_gemma":[0.00009945088,0.00004844547,0.00002906472,0.00021533332,0.000058850736,0.00012502873,0.000036401278,0.00013480229,2.980213e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010657036,0.0019823797,0.9901395,0.000008261313,0.00031632307,0.000012760629,0.00047953037,0.00007018085,0.00006691129,0.00021802277,0.00008026059,0.0055601974],"study_design_scores_gemma":[0.015143594,0.0021139528,0.97869927,0.000038629147,0.00014685588,0.0000014256077,0.00015169251,0.0000063858947,0.00045533726,0.00016801966,0.0030369887,0.00003782632],"about_ca_topic_score_codex":0.00005010215,"about_ca_topic_score_gemma":0.000024606914,"teacher_disagreement_score":0.014077891,"about_ca_system_score_codex":0.000014374072,"about_ca_system_score_gemma":0.00006908795,"threshold_uncertainty_score":0.19755489},"labels":[],"label_agreement":null},{"id":"W2209332382","doi":"10.1177/1932296815593295","title":"Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience","year":2015,"lang":"en","type":"article","venue":"Journal of Diabetes Science and Technology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Liraglutide; Overweight; Usability; Medicine; Diabetes mellitus; Obesity; Internal medicine; Family medicine; Type 2 diabetes; Endocrinology; Computer science","score_opus":0.01356746085719108,"score_gpt":0.25476280986948296,"score_spread":0.2411953490122919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209332382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987862,0.00004708431,0.000012774445,0.0003737078,0.00018013039,0.0004445738,0.0000019737367,0.000018813109,0.00013475106],"genre_scores_gemma":[0.9983749,0.000007409846,0.001318001,0.00013142353,0.00002321375,0.000013749946,2.1989018e-7,0.000007344756,0.00012377343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840087,0.000015734724,0.0003607509,0.00022607276,0.0007039959,0.0002925822],"domain_scores_gemma":[0.99783367,0.000039944433,0.00044817908,0.00032440908,0.0012138643,0.00013990424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047148173,0.00013979946,0.00036727713,0.000375587,0.00011481407,0.00002890865,0.0003430948,0.00007501092,0.000010355277],"category_scores_gemma":[0.001432981,0.00006179845,0.0000362149,0.0014293789,0.001700846,0.00052139093,0.00020267926,0.00017883873,6.734343e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016951066,0.00044498438,0.9908257,0.000033014458,0.000040011782,0.0000017050111,0.0004406697,0.0000012273197,0.0021892088,0.00005852973,0.000044509918,0.0057508936],"study_design_scores_gemma":[0.0046059215,0.007570025,0.9565266,0.00041214927,0.0001883621,0.000016090948,0.001967189,0.0002288038,0.027874509,0.00013598717,0.00033401468,0.00014039502],"about_ca_topic_score_codex":0.000016284397,"about_ca_topic_score_gemma":0.000053080465,"teacher_disagreement_score":0.03429918,"about_ca_system_score_codex":0.00017359486,"about_ca_system_score_gemma":0.00045385366,"threshold_uncertainty_score":0.6266838},"labels":[],"label_agreement":null},{"id":"W2214416180","doi":"10.2337/db15-1224","title":"Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat–Fed Diabetic Mice","year":2015,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Internal medicine; Fibrosis; Dipeptidyl peptidase; Endocrinology; Dipeptidyl peptidase-4; Cardiac function curve; Medicine; Diabetes mellitus; Cardiac fibrosis; Ventricular function; Cardiology; Biology; Type 2 diabetes; Heart failure; Enzyme; Biochemistry","score_opus":0.009318231846163242,"score_gpt":0.20941922081031453,"score_spread":0.2001009889641513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214416180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694914,0.0013812326,0.00000588911,0.00019949787,0.00015279917,0.0007675083,0.000021038644,0.00006308148,0.00045983962],"genre_scores_gemma":[0.99894756,0.000023337021,0.0002569761,0.00007171928,0.000079099664,0.00012336226,0.00024095394,0.00002482358,0.00023215354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987532,0.000067445006,0.00028626088,0.00029628797,0.0002700085,0.00032682955],"domain_scores_gemma":[0.9993766,0.00005923383,0.00010579174,0.0002076633,0.00009106898,0.0001596696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025905986,0.00020092672,0.0004602836,0.00025744896,0.000027012393,0.000021869151,0.000034601027,0.00008674867,0.000020992455],"category_scores_gemma":[0.000090311696,0.00017533897,0.00009827544,0.00033653618,0.000074217554,0.000170043,0.0000639163,0.00008382788,0.000022858649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008321085,0.0005283583,0.94122434,0.00046728828,0.0002476584,0.000011445025,0.00025114193,0.000006848503,0.051230613,0.00017291933,0.0014498042,0.004326359],"study_design_scores_gemma":[0.0057847635,0.0029455048,0.7212869,0.00082495617,0.00095301913,3.846352e-7,0.00058475346,0.00027419414,0.26476482,0.0015449815,0.00066348416,0.00037225752],"about_ca_topic_score_codex":0.00006962112,"about_ca_topic_score_gemma":0.0000025448232,"teacher_disagreement_score":0.21993747,"about_ca_system_score_codex":0.00010021451,"about_ca_system_score_gemma":0.000022057477,"threshold_uncertainty_score":0.7150116},"labels":[],"label_agreement":null},{"id":"W2216866389","doi":"10.14740/jocmr2417w","title":"Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma","keywords":"Medicine; Glycemic; Interim analysis; Internal medicine; Type 2 diabetes; Diabetes mellitus; Blood pressure; Confidence interval; Hemoglobin; Weight loss; Type 2 Diabetes Mellitus; Gastroenterology; Insulin; Surgery; Randomized controlled trial; Endocrinology; Obesity","score_opus":0.2746439977644976,"score_gpt":0.5244041043851908,"score_spread":0.2497601066206932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216866389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951015,0.00029996576,8.2095573e-7,0.0022265029,0.0002676883,0.0008813116,8.241471e-7,0.0000019559811,0.0012194045],"genre_scores_gemma":[0.9993786,0.00007692787,0.000060433227,0.000080689606,0.00015010187,0.00000281452,0.0000011302483,0.000012331498,0.00023696614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956051,0.0007407805,0.0016789193,0.00015312087,0.0015909808,0.00023111534],"domain_scores_gemma":[0.99572617,0.0018499155,0.0005486116,0.00034480623,0.001240089,0.00029043457],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009437236,0.00011378279,0.0010511486,0.00031859925,0.000017812383,0.000004240172,0.0002465546,0.000063415886,0.00003578855],"category_scores_gemma":[0.010475042,0.00005019985,0.00007141516,0.0006147143,0.0005506109,0.00006867319,0.00019375453,0.0007053692,0.0000017941196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046496606,0.0034120088,0.9785378,0.00010463757,0.00034085434,0.000024336452,0.0008823325,0.0000021391477,0.000014516016,0.000006552971,0.00089231797,0.0111328345],"study_design_scores_gemma":[0.025933579,0.030777792,0.93921185,0.0011171631,0.00022384977,9.931929e-7,0.0020244836,0.000012557444,0.000021206693,0.000026293448,0.000611224,0.000039042447],"about_ca_topic_score_codex":0.000035582405,"about_ca_topic_score_gemma":0.000019540314,"teacher_disagreement_score":0.039325994,"about_ca_system_score_codex":0.000060885763,"about_ca_system_score_gemma":0.00017552808,"threshold_uncertainty_score":0.99786013},"labels":[],"label_agreement":null},{"id":"W2218085405","doi":"10.14740/jocmr2418w","title":"Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alogliptin; Medicine; Type 2 diabetes; Diabetes mellitus; Pharmacology; Internal medicine; Endocrinology; Dipeptidyl peptidase-4","score_opus":0.20135046828785982,"score_gpt":0.5038410302549573,"score_spread":0.30249056196709745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2218085405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996571,0.00028349017,0.000001108057,0.0016686661,0.000110379,0.00061112165,0.000001168316,0.0000013017659,0.0007517455],"genre_scores_gemma":[0.9995199,0.000112743386,0.00006680818,0.000059536666,0.00009817342,0.0000015012863,0.0000026829582,0.0000076073025,0.00013106412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960935,0.0006332759,0.0013364577,0.00014547276,0.0015927451,0.00019851614],"domain_scores_gemma":[0.99591196,0.00164383,0.0005030047,0.00033749867,0.0013606591,0.0002430247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007967499,0.00008940005,0.0011428401,0.00063074654,0.000017239654,0.0000029957168,0.00019143222,0.000051739724,0.000035812354],"category_scores_gemma":[0.00654736,0.00003989667,0.00009769767,0.0018192815,0.00045976893,0.00004285386,0.00012527591,0.00049631373,7.4161284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037661642,0.0029324035,0.9766823,0.000040537492,0.0022189303,0.000011142369,0.0004368321,0.000018350329,0.000004307269,0.000007264725,0.00088810973,0.01299363],"study_design_scores_gemma":[0.016586086,0.021204503,0.9586031,0.00045471906,0.0018314782,1.4823753e-7,0.00071900646,0.000040558723,0.000012020982,0.000016964577,0.0005013443,0.000030106745],"about_ca_topic_score_codex":0.000033874003,"about_ca_topic_score_gemma":0.000039114566,"teacher_disagreement_score":0.0182721,"about_ca_system_score_codex":0.000046008216,"about_ca_system_score_gemma":0.00018733578,"threshold_uncertainty_score":0.7838275},"labels":[],"label_agreement":null},{"id":"W2218171412","doi":"10.1016/j.jcjd.2015.09.090","title":"Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes","year":2015,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Calgary; Libin Cardiovascular Institute of Alberta","funders":"","keywords":"Medicine; Type 2 diabetes; Glycemic; Hypoglycemia; Incretin; Metformin; Weight loss; Diabetes mellitus; Exenatide; Liraglutide; Insulin; Type 2 Diabetes Mellitus; Internal medicine; Pharmacology; Endocrinology; Obesity","score_opus":0.02951312816637098,"score_gpt":0.32251777097525836,"score_spread":0.2930046428088874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2218171412","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18346646,0.8149286,5.4536535e-8,0.000023586179,0.00059735595,0.0003763717,0.000031561853,0.0000046588184,0.000571329],"genre_scores_gemma":[0.05095251,0.94848216,0.000026625692,0.000022038284,0.00030235221,0.000010960845,0.00005805465,0.00007382095,0.00007149168],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978698,0.00007547172,0.0008801247,0.00024569695,0.0002931896,0.0006357131],"domain_scores_gemma":[0.99776924,0.00012230076,0.0006416434,0.00028351852,0.00021270491,0.0009706087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005708267,0.00046702064,0.002273221,0.0017128292,0.00003479678,0.000041055133,0.00021175183,0.00014418141,0.00008291767],"category_scores_gemma":[0.00017521894,0.0003377946,0.00051691785,0.00052429846,0.00008912923,0.00012738282,0.000034057557,0.00050193333,0.000008824286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000039783426,0.00009623204,0.053355303,0.0048406627,0.0011013127,0.000035346562,0.00013460321,0.0000015397721,0.0000021303613,0.00002160601,0.0025878574,0.9378194],"study_design_scores_gemma":[0.0015994933,0.0023516146,0.0076347496,0.05450543,0.0030515895,0.0000031595723,0.000032545257,0.000014272368,0.000016294953,0.00007655684,0.93021744,0.0004968238],"about_ca_topic_score_codex":0.00009593776,"about_ca_topic_score_gemma":0.00015033217,"teacher_disagreement_score":0.9373226,"about_ca_system_score_codex":0.00085747306,"about_ca_system_score_gemma":0.001936928,"threshold_uncertainty_score":0.99990743},"labels":[],"label_agreement":null},{"id":"W2219086221","doi":"10.1016/j.jcjd.2015.09.083","title":"Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Glycemic; Metformin; Diabetes mellitus; Disease; Intensive care medicine; Insulin glargine; Harm; Insulin; Comorbidity; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.02065578813335361,"score_gpt":0.23837792403056687,"score_spread":0.21772213589721326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219086221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89495516,0.103327684,0.000027022132,0.0002586859,0.0003560859,0.00010658376,0.0000043785913,0.0000039897773,0.0009603932],"genre_scores_gemma":[0.999266,0.00031774398,0.00019139974,0.00004657907,0.00012181519,0.0000015162549,0.000002613995,0.00001265265,0.000039637198],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992086,0.000021052987,0.0002610994,0.00008289866,0.00019463968,0.00023169881],"domain_scores_gemma":[0.9989974,0.000020067931,0.00010460056,0.00014475385,0.00017356472,0.0005596523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042545534,0.00010538339,0.0003926685,0.00026463307,0.000034683282,0.000017096518,0.0000678714,0.000024596588,0.000020811682],"category_scores_gemma":[0.000080546,0.0000850945,0.00017898099,0.00011122777,0.00007181813,0.00010545604,0.00001264268,0.000091228765,0.0000011912203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011373899,0.000038501978,0.6758121,0.00018113657,0.0024348614,0.000036757483,0.0015136155,0.00006539024,0.00023904191,0.00020298123,0.0015007522,0.31796342],"study_design_scores_gemma":[0.008745422,0.0016338538,0.34752136,0.002025186,0.0030114364,0.000018785831,0.0026617248,0.00010530684,0.008694341,0.0008879943,0.624193,0.00050156884],"about_ca_topic_score_codex":0.00011423573,"about_ca_topic_score_gemma":0.00021099421,"teacher_disagreement_score":0.6226922,"about_ca_system_score_codex":0.00010102006,"about_ca_system_score_gemma":0.00029433114,"threshold_uncertainty_score":0.3470053},"labels":[],"label_agreement":null},{"id":"W2219424825","doi":"10.1139/cjpp-2015-0242","title":"Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pioglitazone; Insulin resistance; Internal medicine; Microglia; Exenatide; Endocrinology; Amylin; Hippocampal formation; Insulin; Medicine; Insulin receptor; Agonist; Hippocampus; Amyloid beta; Neuroprotection; Diabetes mellitus; Receptor; Type 2 diabetes; Inflammation; Islet","score_opus":0.01531459866032607,"score_gpt":0.27164536787944604,"score_spread":0.25633076921911996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219424825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877265,0.010662383,0.0000021981261,0.001059399,0.00019932666,0.000193835,0.000012299119,0.000002793191,0.00014127708],"genre_scores_gemma":[0.9972765,0.001399216,0.00020552448,0.00088728697,0.00011137973,0.000006994801,0.000011578648,0.0000080307545,0.00009352573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991903,0.000107212814,0.00023244396,0.000180686,0.00004457797,0.00024479502],"domain_scores_gemma":[0.9991542,0.000053694697,0.00011561768,0.00004626068,0.000091622715,0.00053859706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022320583,0.00013406572,0.00034782183,0.00024835358,0.00006334483,0.000010200193,0.00003298635,0.00009184424,0.00006283079],"category_scores_gemma":[0.000017613691,0.000110229965,0.000016747566,0.00007374949,0.0003099853,0.00010767196,0.000026548629,0.00017815488,0.0000012198061],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007136611,0.00004955072,0.0045956704,0.000116455914,0.00014030682,0.00023972256,0.0007134908,0.0000017649683,0.9876505,0.0000459293,0.0017542547,0.003978674],"study_design_scores_gemma":[0.018205438,0.0030811734,0.3157841,0.000366113,0.00088572875,0.00030252998,0.00067146565,0.00008150121,0.6454857,0.0051835827,0.009545485,0.00040716695],"about_ca_topic_score_codex":0.00016169515,"about_ca_topic_score_gemma":0.00052279077,"teacher_disagreement_score":0.34216478,"about_ca_system_score_codex":0.00004140409,"about_ca_system_score_gemma":0.00015252297,"threshold_uncertainty_score":0.44950476},"labels":[],"label_agreement":null},{"id":"W2222194911","doi":"10.1016/j.jcjd.2015.09.006","title":"Diabetes, Dementia and Hypoglycemia","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"VGH and UBC Hospital Foundation","keywords":"Dementia; Medicine; Hypoglycemia; Diabetes mellitus; Pediatrics; Internal medicine; Disease; Endocrinology","score_opus":0.019608813687067045,"score_gpt":0.255761877034259,"score_spread":0.23615306334719197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222194911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014667986,0.99504805,7.6350983e-7,0.00020662983,0.0005909741,0.00047447486,0.000065831286,0.000010872666,0.0021356142],"genre_scores_gemma":[0.0007562075,0.9970011,0.00019053111,0.0002594607,0.00051267474,0.000022374945,0.00003803709,0.00008505091,0.0011345233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789023,0.000073292766,0.00079797005,0.00027156554,0.0002239059,0.00074303796],"domain_scores_gemma":[0.99737036,0.00015921975,0.0006016026,0.00032701463,0.00014151927,0.001400304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035046804,0.0004738312,0.0020588967,0.0009687833,0.00009292868,0.00009192234,0.00024008562,0.00024154787,0.00032970338],"category_scores_gemma":[0.00014618626,0.0003096169,0.00057475106,0.00021342903,0.00017174902,0.00015119975,0.000038050148,0.00031606283,0.00007521305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[5.566864e-7,0.000018115334,0.011569543,0.0052936496,0.002774259,0.000065195265,0.000010817555,8.703628e-9,6.40162e-7,0.00009993665,0.013157178,0.9670101],"study_design_scores_gemma":[0.0007562727,0.00039226035,0.000640342,0.025906844,0.0067530065,0.000008794517,0.000004876726,2.662234e-7,0.0000031911343,0.0000828609,0.96516955,0.00028172575],"about_ca_topic_score_codex":0.000021120532,"about_ca_topic_score_gemma":0.00018053803,"teacher_disagreement_score":0.9667284,"about_ca_system_score_codex":0.00031764386,"about_ca_system_score_gemma":0.0015065259,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W2226908594","doi":"10.1152/ajpregu.00003.2015","title":"Glucose-dependent insulinotropic polypeptide directly induces glucose transport in rat skeletal muscle","year":2015,"lang":"en","type":"article","venue":"American Journal of Physiology-Regulatory, Integrative and Comparative Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Internal medicine; Endocrinology; GLUT4; Skeletal muscle; Glucose transporter; Wortmannin; Glucose uptake; Insulin; Insulin receptor; Soleus muscle; Protein kinase B; Snf3; Biology; Chemistry; Phosphorylation; Insulin resistance; Biochemistry; Medicine","score_opus":0.02620229725336124,"score_gpt":0.28424298754058525,"score_spread":0.258040690287224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226908594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965688,0.0017402063,0.000035003148,0.00028739573,0.00031437055,0.00038247748,0.000009939478,0.000026353657,0.00063548435],"genre_scores_gemma":[0.9979875,0.00027334486,0.0007329559,0.0005180067,0.00025052417,0.000036977264,0.00003469277,0.000023117125,0.00014284976],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99743,0.0004912585,0.0007810489,0.00051097036,0.00029939835,0.00048731652],"domain_scores_gemma":[0.9980846,0.0001647154,0.0007204713,0.00029964713,0.00038605958,0.0003444824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026372616,0.0005008491,0.0018219934,0.0003835753,0.0000697542,0.000011460227,0.00024107551,0.00009587186,0.000047359925],"category_scores_gemma":[0.000032220443,0.00034319834,0.00026639152,0.00040418902,0.0013012178,0.00026638492,0.00007138627,0.00057983224,0.000022108155],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021859817,0.0016076941,0.008306363,0.000034674238,0.0011516146,0.00006407163,0.0061259093,0.00016208745,0.96400005,0.0017344509,0.00052201754,0.014105069],"study_design_scores_gemma":[0.0050769015,0.010330943,0.8836076,0.00018159249,0.00028354063,0.000038147526,0.01397144,0.000083260784,0.08229215,0.0015307552,0.0021866327,0.00041702975],"about_ca_topic_score_codex":0.00019554835,"about_ca_topic_score_gemma":0.000119364064,"teacher_disagreement_score":0.8817079,"about_ca_system_score_codex":0.00022317532,"about_ca_system_score_gemma":0.00028287305,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W2229147493","doi":"10.1016/j.jcjd.2015.12.003","title":"Diabetes in the Elderly: A Silent Global Tsunami","year":2016,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Diabetes mellitus; Endocrinology","score_opus":0.006964871507053544,"score_gpt":0.24000129065508508,"score_spread":0.23303641914803153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229147493","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29842442,0.012807615,0.0000010603667,0.005451473,0.67215043,0.0009483247,0.00055770786,0.000020035322,0.00963892],"genre_scores_gemma":[0.3136559,0.0002417776,0.000086058884,0.0011102067,0.68274736,0.000079011304,0.00021439242,0.000106165084,0.001759126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678147,0.00017132168,0.0007770667,0.00031291056,0.00089247635,0.0010647302],"domain_scores_gemma":[0.9971973,0.0006437751,0.00050603907,0.0005195512,0.00037288215,0.000760454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010301864,0.00048076594,0.0010239634,0.0005669429,0.00009748682,0.00016660936,0.0007271405,0.00049407635,0.00017780719],"category_scores_gemma":[0.0010852489,0.0002838836,0.00046893794,0.0003766257,0.00019529072,0.00017071937,0.00003215183,0.00073805964,0.000057607678],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005169876,0.00007054272,0.103739604,0.00016976621,0.0005408586,0.00017610603,0.000077549215,6.397403e-7,0.0000044953435,0.00007009416,0.8784451,0.016700106],"study_design_scores_gemma":[0.0023391098,0.001768388,0.013686774,0.0021160718,0.0008731042,0.0000012293975,0.00010520626,0.0000027494275,0.000016062493,0.0007078697,0.9780716,0.0003118521],"about_ca_topic_score_codex":0.00047814,"about_ca_topic_score_gemma":0.011916914,"teacher_disagreement_score":0.09962652,"about_ca_system_score_codex":0.0011794558,"about_ca_system_score_gemma":0.0028086274,"threshold_uncertainty_score":0.9999613},"labels":[],"label_agreement":null},{"id":"W2231922283","doi":"10.1371/journal.pone.0144640","title":"Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs; TD Bank; Eli Lilly and Company","keywords":"Dapagliflozin; Tubuloglomerular feedback; Glycosuria; Endocrinology; Internal medicine; Medicine; Kidney disease; Nephron; Glomerulosclerosis; Kidney; Renal function; Proteinuria; Diabetes mellitus; Type 2 diabetes","score_opus":0.030165709026586097,"score_gpt":0.24779875157308381,"score_spread":0.2176330425464977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231922283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655385,0.00027080716,0.00010847708,0.031751677,0.00004921548,0.0017906692,0.00027543688,0.00007289944,0.00014232479],"genre_scores_gemma":[0.9949285,0.000750029,0.00018921889,0.001975617,0.00011926969,0.00037714504,0.00038567276,0.000030750904,0.0012438257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827075,0.000060700364,0.00036799794,0.00035459967,0.00061068434,0.00033526128],"domain_scores_gemma":[0.998622,0.000033646276,0.00013594396,0.00056171714,0.00007829697,0.00056842074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002116295,0.0002181414,0.00033100808,0.0001274488,0.000052153984,0.000014893035,0.00011448887,0.000047100726,0.000075455726],"category_scores_gemma":[0.00012069788,0.000101199315,0.000119964476,0.000127527,0.00012320514,0.00017939454,0.000044530312,0.00009262933,0.00003583598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074224886,0.03331865,0.18807814,0.0061924136,0.0007909362,0.0006257278,0.0007418441,0.000009738093,0.73703325,0.0010703162,0.003662617,0.021053893],"study_design_scores_gemma":[0.05563328,0.0025721642,0.17120017,0.052550748,0.012054531,8.829922e-7,0.00010208682,0.043638855,0.6545863,0.0044757924,0.0016151803,0.0015699873],"about_ca_topic_score_codex":0.0000042050265,"about_ca_topic_score_gemma":0.0000058934215,"teacher_disagreement_score":0.08244692,"about_ca_system_score_codex":0.00013806512,"about_ca_system_score_gemma":0.00027586985,"threshold_uncertainty_score":0.4126788},"labels":[],"label_agreement":null},{"id":"W2233074121","doi":"10.1371/journal.pone.0145890","title":"Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Novo Nordisk Fonden; Sahlgrenska Universitetssjukhuset; Vetenskapsrådet; Novo Nordisk; Sanofi; Helsingin ja Uudenmaan Sairaanhoitopiiri; European Foundation for the Study of Diabetes; AstraZeneca; Diabetestutkimussäätiö; Eli Lilly and Company; Amgen","keywords":"Postprandial; Internal medicine; Medicine; Obesity; Endocrinology; Glucagon-like peptide-1; Type 2 diabetes; Diabetes mellitus; Insulin","score_opus":0.030722212964559847,"score_gpt":0.22342880277295402,"score_spread":0.19270658980839417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233074121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352074,0.00033429806,0.0000072822972,0.0015985717,0.000014470567,0.00075903727,0.000016562262,0.00001942763,0.0037296056],"genre_scores_gemma":[0.99845266,0.0001569034,0.00028515083,0.0001264824,0.000055719152,0.000050228056,0.000015286565,0.000008111737,0.0008494396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933714,0.00001674455,0.00015472829,0.00014287642,0.00016779675,0.00018072978],"domain_scores_gemma":[0.99963,0.00005039118,0.000035893405,0.00013787921,0.000052890733,0.000092993156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010491943,0.00008125662,0.00026711184,0.00010307867,0.000014889064,0.000005507084,0.00003183127,0.000036162302,0.0000711121],"category_scores_gemma":[0.00011436424,0.000055490065,0.000021999796,0.00007860577,0.000029214343,0.00004238924,0.000040073006,0.00002416597,0.000044855013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015990778,0.0025242642,0.24018352,0.00016438669,0.00046841722,0.00005479026,0.00043818002,4.4157506e-8,0.7395898,0.00040262638,0.00022721045,0.014347694],"study_design_scores_gemma":[0.021038081,0.0058190394,0.26645926,0.0015985331,0.0010805972,0.0000036680133,0.00007329595,0.00001604041,0.70209944,0.00025826713,0.0013052074,0.0002485559],"about_ca_topic_score_codex":0.00006169257,"about_ca_topic_score_gemma":0.000047560774,"teacher_disagreement_score":0.037490338,"about_ca_system_score_codex":0.00007733622,"about_ca_system_score_gemma":0.000019828665,"threshold_uncertainty_score":0.22628193},"labels":[],"label_agreement":null},{"id":"W2233805588","doi":"10.1007/s00125-015-3842-y","title":"Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice","year":2015,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Japan Society for the Promotion of Science; Novo Nordisk Pharma; Japan Diabetes Foundation; Novo Nordisk; Pfizer; Eli Lilly and Company","keywords":"Internal medicine; Endocrinology; Gastric inhibitory polypeptide; Streptozotocin; Diabetes mellitus; Islet; Glucagon-like peptide-1; Insulin; Medicine; Pancreatic islets; Dipeptidyl peptidase-4; Glucagon; Downregulation and upregulation; Chemistry; Type 2 diabetes; Biochemistry","score_opus":0.018875982638303652,"score_gpt":0.2611174809152568,"score_spread":0.24224149827695318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233805588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947865,0.002041956,8.1198306e-7,0.00066939485,0.00019729514,0.0017147975,0.000018975059,0.00011005209,0.00046023872],"genre_scores_gemma":[0.99870425,0.00013057566,0.00024975304,0.00029277257,0.000040001913,0.00023664928,0.00009798492,0.000054279953,0.00019375257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969655,0.0002907653,0.000763593,0.0006655571,0.00054268155,0.00077187014],"domain_scores_gemma":[0.99844986,0.0002041783,0.00029586756,0.0006562893,0.00013434695,0.0002594502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046078,0.00046725225,0.00097419636,0.00034990523,0.00006598293,0.000043941647,0.00031766735,0.00028772998,0.000069494774],"category_scores_gemma":[0.0002756681,0.0003128756,0.00008953401,0.000547676,0.00018909757,0.00015376971,0.00032659486,0.0003996637,0.000024679126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031098118,0.0009491232,0.7842805,0.000408207,0.00019190497,0.00012241512,0.0027060977,0.000024752295,0.19776969,0.00003394747,0.00041114146,0.012791239],"study_design_scores_gemma":[0.00731285,0.0008668955,0.62323236,0.0013223969,0.00022435567,0.000002855983,0.00054256816,0.001310294,0.3646171,0.00015651165,0.00007158102,0.0003402293],"about_ca_topic_score_codex":0.00031730437,"about_ca_topic_score_gemma":0.00006682938,"teacher_disagreement_score":0.16684744,"about_ca_system_score_codex":0.0001911396,"about_ca_system_score_gemma":0.00012154044,"threshold_uncertainty_score":0.99993235},"labels":[],"label_agreement":null},{"id":"W2236719092","doi":"10.1056/nejmc1510995","title":"Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Sitagliptin; Type 2 diabetes; Diabetes mellitus; Sitagliptin Phosphate; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.03142146972555031,"score_gpt":0.2219890536083011,"score_spread":0.1905675838827508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236719092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783614,0.003983343,9.764846e-7,0.00059675873,0.00017241572,0.0006778614,6.572584e-7,0.00004137455,0.016165175],"genre_scores_gemma":[0.9965809,0.000060572864,0.00009468668,0.00029039243,0.000034720593,0.00034959486,0.0000067527626,0.000010256213,0.0025721407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993427,0.000016337883,0.000089192,0.00015016971,0.00016420908,0.00023741263],"domain_scores_gemma":[0.99959993,0.0000130791595,0.000011149662,0.00020441193,0.000024200675,0.00014721748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032751038,0.00008032915,0.00026561838,0.000085786,0.000007236458,0.000012760875,0.000028153156,0.00002808051,0.0000045806087],"category_scores_gemma":[0.00011484425,0.00006199731,0.000055903296,0.00011305508,0.000019935136,0.00004973824,0.000045885008,0.00003995797,0.000019696661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012230059,0.00007693263,0.81625545,0.000021131284,0.00038566045,0.00002714731,0.000048725276,0.0000027974288,6.666477e-7,0.000051357183,0.0015424156,0.18157548],"study_design_scores_gemma":[0.0019949174,0.000042377753,0.95714825,0.000004915891,0.000192037,4.602039e-7,0.000048731672,0.000012241967,0.00004796535,0.00008482148,0.0403554,0.00006790022],"about_ca_topic_score_codex":0.000017489636,"about_ca_topic_score_gemma":0.000005562351,"teacher_disagreement_score":0.18150757,"about_ca_system_score_codex":0.00004709666,"about_ca_system_score_gemma":0.000008363985,"threshold_uncertainty_score":0.2528177},"labels":[],"label_agreement":null},{"id":"W2237443673","doi":"10.1016/j.jcjd.2015.09.001","title":"The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes","year":2015,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University of Manitoba; St. Boniface Hospital","funders":"","keywords":"Medicine; Renal glucose reabsorption; Type 2 diabetes; Metformin; Glycemic; Hypoglycemia; Diabetes mellitus; Internal medicine; Renal function; Urinary system; Endocrinology; Insulin; Insulin resistance","score_opus":0.01613698765001694,"score_gpt":0.2505515429314681,"score_spread":0.23441455528145114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2237443673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01013479,0.9865074,3.268184e-9,0.0003877142,0.00067938335,0.0004939986,0.00002428909,0.0000023679547,0.0017700511],"genre_scores_gemma":[0.010464862,0.9883812,0.000018916295,0.00020542205,0.00030359294,0.00001595815,0.000014907034,0.000053478616,0.00054164615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998365,0.0001379987,0.0006736913,0.00013891076,0.00024675622,0.00043765915],"domain_scores_gemma":[0.99804664,0.00016612059,0.00055303617,0.00032465096,0.00019602582,0.00071350276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007291095,0.00027110218,0.0011871998,0.00037534782,0.00007917817,0.00005208278,0.00032960245,0.00014445161,0.000015565285],"category_scores_gemma":[0.00058701343,0.000136005,0.00030157637,0.0004634175,0.00024126442,0.00006833338,0.000052311854,0.00038840913,0.00000485438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000010332043,0.000021839087,0.063321024,0.0016829084,0.00056095596,0.000006245236,0.00008876989,1.8522022e-7,0.0000011202249,0.00012511275,0.01177794,0.9224129],"study_design_scores_gemma":[0.00033808948,0.00021987189,0.0011739243,0.0110606635,0.0012630108,0.0000017214028,0.000076966724,0.0000017872371,0.000014815772,0.00028925957,0.98544085,0.0001190366],"about_ca_topic_score_codex":0.00011539417,"about_ca_topic_score_gemma":0.0011089697,"teacher_disagreement_score":0.9736629,"about_ca_system_score_codex":0.0002714568,"about_ca_system_score_gemma":0.0026729486,"threshold_uncertainty_score":0.5546122},"labels":[],"label_agreement":null},{"id":"W2253559447","doi":"10.71781/28065","title":"Caractérisation de la région promotrice du gène codant pour le récepteur du peptide insulinotrope dépendant du glucose humain","year":2006,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Université de Montréal; Canadian Institutes of Health Research; Conselho Nacional de Desenvolvimento Científico e Tecnológico","keywords":"Chemistry; Molecular biology; Biology","score_opus":0.004076857220594166,"score_gpt":0.17610661321226326,"score_spread":0.1720297559916691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253559447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9008616,0.013483406,0.000975209,0.0012795749,0.0013882072,0.0013254008,0.00007896998,0.00021538991,0.08039221],"genre_scores_gemma":[0.9288419,0.002672592,0.0013719049,0.0001609835,0.0011974879,0.00010319591,0.002832436,0.00009262749,0.06272688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582016,0.000535337,0.0007979014,0.0009795466,0.0009820333,0.0008850465],"domain_scores_gemma":[0.99732244,0.00031991446,0.0008202412,0.0005221423,0.000505525,0.00050973735],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00069356425,0.00085313997,0.00081217894,0.00064770214,0.0051338887,0.00015288916,0.00042963005,0.00063496653,0.00007122315],"category_scores_gemma":[0.00022164508,0.0009527767,0.00055838487,0.0005339522,0.0003600135,0.00058672915,0.00021534778,0.0006198349,0.00023196649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055872947,0.01114311,0.5404507,0.0022396126,0.0047074216,0.048759174,0.052470103,0.015226233,0.15478635,0.11148404,0.023231106,0.029914856],"study_design_scores_gemma":[0.009288023,0.0006702405,0.801586,0.0012471608,0.003416473,0.0013779784,0.018882655,0.009712011,0.024538556,0.00037976296,0.12767226,0.0012289112],"about_ca_topic_score_codex":0.11268066,"about_ca_topic_score_gemma":0.0049757287,"teacher_disagreement_score":0.26113528,"about_ca_system_score_codex":0.012785147,"about_ca_system_score_gemma":0.003768445,"threshold_uncertainty_score":0.99929225},"labels":[],"label_agreement":null},{"id":"W2255492660","doi":"10.1016/j.jcjd.2015.10.005","title":"Diabetes Management in Long-Term Care: An Exploratory Study of the Current Practices and Processes to Managing Frail Elderly Persons with Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Research Institute for Aging; Hamilton Health Sciences; McMaster University; University of Waterloo","funders":"Hamilton Health Sciences","keywords":"Medicine; Diabetes management; Glycated hemoglobin; Glycemic; Blood glucose monitoring; Gerontology; Diabetes mellitus; Long-term care; Life expectancy; Exploratory research; Population; Type 2 diabetes; Family medicine; Nursing; Environmental health","score_opus":0.019966605728096477,"score_gpt":0.2676756576619947,"score_spread":0.24770905193389822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255492660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043894,0.007128013,0.000001026535,0.0009921369,0.00024097509,0.0009818362,0.00000872606,0.000009831436,0.00019848777],"genre_scores_gemma":[0.99940056,0.00010279918,0.00008481194,0.00016957428,0.000076490884,0.000055054996,0.0000026993805,0.00003601577,0.00007201587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829715,0.000108276436,0.00039337232,0.0003059334,0.00035750875,0.00053777365],"domain_scores_gemma":[0.99820143,0.000105869025,0.0004643453,0.00036955808,0.00031480612,0.00054397096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031619344,0.00026428732,0.0004622781,0.00064938125,0.000113062386,0.000080802005,0.00030820648,0.00003362914,0.000019119583],"category_scores_gemma":[0.00014488037,0.00014982632,0.000048926344,0.000599835,0.00012635035,0.00051751017,0.0000612738,0.00016735861,0.0000021861515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015271175,0.00026543788,0.8894655,0.00068649615,0.00044737622,0.000027874734,0.00385981,0.000004553033,0.00011208964,0.00000808981,0.00017599021,0.10493151],"study_design_scores_gemma":[0.002847827,0.0051344438,0.97790897,0.0030287106,0.0009697866,5.7106524e-7,0.0076424335,0.00000209842,0.0009138236,0.000032173073,0.0012522422,0.00026694793],"about_ca_topic_score_codex":0.000041698415,"about_ca_topic_score_gemma":0.017805465,"teacher_disagreement_score":0.104664564,"about_ca_system_score_codex":0.00019785245,"about_ca_system_score_gemma":0.0004039358,"threshold_uncertainty_score":0.9935868},"labels":[],"label_agreement":null},{"id":"W2256494709","doi":"","title":"Fenofibrate benefits in cardiovascular risk reduction : Heartwire discussion endorses use in type 2 diabetes : drug trends","year":2011,"lang":"en","type":"article","venue":"˜The œSouth African journal of diabetes & vascular disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fenofibrate; Medicine; Type 2 diabetes; Diabetes mellitus; Drug; Triglyceride; Statin; Internal medicine; Intensive care medicine; Pharmacology; Cholesterol; Endocrinology","score_opus":0.016828657659616615,"score_gpt":0.2064988719451697,"score_spread":0.18967021428555308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256494709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778829,0.020792412,0.0000044200683,0.00022267165,0.0003818148,0.00048111225,0.000031953485,0.000035622503,0.0001670577],"genre_scores_gemma":[0.9985239,0.0005766145,0.00026620823,0.000066666755,0.00019578225,0.000044104952,0.000029856687,0.00006771265,0.00022913395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966289,0.0005761904,0.0007903976,0.00046424055,0.0008041632,0.00073611795],"domain_scores_gemma":[0.9978634,0.00007082982,0.00041250617,0.00088712975,0.0001763734,0.00058977713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012252316,0.00042836528,0.00095793314,0.00093381316,0.0001217181,0.00008005709,0.00030156734,0.00007110503,0.000110210465],"category_scores_gemma":[0.00017493182,0.00025171347,0.0011294116,0.0012429354,0.00015639602,0.0005041109,0.00012298871,0.00041622884,0.000020454545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028700376,0.00088762917,0.91421366,0.000098827535,0.0019272597,0.0001163732,0.0036169353,0.0009245418,0.000048521364,0.000015888776,0.000194701,0.07766869],"study_design_scores_gemma":[0.003993365,0.0005189911,0.98576033,0.0006567768,0.0037257883,0.0000017186527,0.0019194802,0.00023131522,0.0002366944,0.00022856632,0.002348795,0.00037815407],"about_ca_topic_score_codex":0.00005627101,"about_ca_topic_score_gemma":0.000033016957,"teacher_disagreement_score":0.077290535,"about_ca_system_score_codex":0.00017381618,"about_ca_system_score_gemma":0.00012864567,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W2257723432","doi":"10.1016/j.kint.2015.12.038","title":"Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","year":2016,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Natriuresis; Cotransporter; Type 2 diabetes; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Reduction (mathematics); Sodium; Chemistry; Blood pressure","score_opus":0.003138303510324793,"score_gpt":0.1856595038347485,"score_spread":0.1825212003244237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257723432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975496,0.00020381417,0.000023623537,0.0008351842,0.0001399192,0.00025380804,0.000030775573,0.000011688396,0.00095158396],"genre_scores_gemma":[0.99931353,0.00019894335,0.00011407611,0.00007270381,0.0000562012,0.00001837523,0.00008457159,0.000008751985,0.00013281475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993338,0.000020333478,0.00013518831,0.00014380168,0.00027652408,0.00009036765],"domain_scores_gemma":[0.9996507,0.0000123005975,0.000057565412,0.00012702408,0.00010813175,0.00004424886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012852812,0.00007507732,0.00011814523,0.00011263143,0.000020950134,0.000006350796,0.00003411313,0.00002481085,0.00008397656],"category_scores_gemma":[0.00004361749,0.00004042135,0.000054372438,0.0000823552,0.000046715995,0.00010728759,0.000015320129,0.00004084555,0.000004698853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021359388,0.0001850234,0.96122175,0.000019633795,0.0010208309,0.0000015138677,0.00019153873,0.0000053685276,0.001448272,0.00012397282,0.00075581716,0.034812666],"study_design_scores_gemma":[0.0049009994,0.0002371975,0.97230655,0.00027801094,0.00041762166,4.888529e-7,0.00007935039,0.000033946333,0.009952323,0.00023473678,0.011474528,0.00008422402],"about_ca_topic_score_codex":0.000026321097,"about_ca_topic_score_gemma":0.0000029863584,"teacher_disagreement_score":0.03472844,"about_ca_system_score_codex":0.00004482134,"about_ca_system_score_gemma":0.000018319803,"threshold_uncertainty_score":0.16483349},"labels":[],"label_agreement":null},{"id":"W2258044149","doi":"10.71781/4568","title":"L'accélération de la rigidité vasculaire associée au diabète de type 1 : implication de la protéine Gla de la matrice","year":2013,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Endocrinology","score_opus":0.003355730838202254,"score_gpt":0.2021236093337267,"score_spread":0.19876787849552444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258044149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91532034,0.008480436,0.0012621428,0.0004083718,0.0005620086,0.001419764,0.00003456161,0.00020802602,0.072304375],"genre_scores_gemma":[0.9267048,0.0024419175,0.003501491,0.00015593608,0.00069373805,0.00033816707,0.0013970856,0.00008275541,0.06468408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964097,0.0009492085,0.0004583934,0.0006679381,0.00063383614,0.00088088354],"domain_scores_gemma":[0.9974035,0.00065883505,0.0005276445,0.0005068155,0.00034530694,0.0005578776],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0012246752,0.0005855683,0.0005308335,0.00038371954,0.0031006704,0.00019200152,0.00036909623,0.001030274,0.000088989356],"category_scores_gemma":[0.00033660748,0.0006646258,0.0003874709,0.0004955376,0.00036731575,0.00047755978,0.00013066606,0.0006678404,0.0001450608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002425891,0.0039671734,0.46573734,0.0029525096,0.0064291377,0.0051272633,0.06762693,0.009635925,0.18938796,0.17360424,0.0136959925,0.05940963],"study_design_scores_gemma":[0.004267909,0.0003960884,0.80889463,0.0010281975,0.004594307,0.00082235143,0.010695596,0.007089932,0.020977542,0.001607992,0.13866101,0.0009644258],"about_ca_topic_score_codex":0.03795848,"about_ca_topic_score_gemma":0.0012139202,"teacher_disagreement_score":0.3431573,"about_ca_system_score_codex":0.023449793,"about_ca_system_score_gemma":0.005090163,"threshold_uncertainty_score":0.9995805},"labels":[],"label_agreement":null},{"id":"W2261401807","doi":"10.14740/jocmr2467w","title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Internal medicine; Endocrinology; Renal function; Type 2 diabetes; Diabetes mellitus; Triglyceride; Blood pressure; Hematocrit; Cholesterol; Gastroenterology","score_opus":0.054539617116312965,"score_gpt":0.40289702817374795,"score_spread":0.348357411057435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261401807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954845,0.00046394256,0.000024062938,0.0030155247,0.00021819361,0.00060980505,0.0000019372583,0.0000056534877,0.00017638435],"genre_scores_gemma":[0.99858546,0.00048070998,0.0002221953,0.00036635756,0.00020343375,0.000011078081,0.000006446999,0.000020474039,0.00010383476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954828,0.0005079348,0.0014417728,0.00026624394,0.0018636704,0.00043758855],"domain_scores_gemma":[0.99404025,0.003836598,0.00050809915,0.00034370556,0.00085206743,0.00041928014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041728406,0.00018194881,0.0015696426,0.001690609,0.000021037731,0.000005069583,0.00018357778,0.00011180382,0.00008936898],"category_scores_gemma":[0.0027960367,0.00008162023,0.00033315714,0.0015890715,0.000484603,0.00008396412,0.000021750735,0.00052834523,0.000012009318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048616873,0.002673433,0.94102484,0.00019175111,0.0022656897,0.000108047185,0.000048253674,0.0000048647157,0.00024902038,0.0000144446985,0.00083314895,0.047724802],"study_design_scores_gemma":[0.024212021,0.022551686,0.93917257,0.0024560343,0.0021352964,1.133249e-7,0.000020853102,0.000020403495,0.008228632,0.00003150675,0.001086986,0.000083921994],"about_ca_topic_score_codex":0.000012316951,"about_ca_topic_score_gemma":0.0000072290195,"teacher_disagreement_score":0.04764088,"about_ca_system_score_codex":0.00006721665,"about_ca_system_score_gemma":0.00016621669,"threshold_uncertainty_score":0.3347319},"labels":[],"label_agreement":null},{"id":"W2262101396","doi":"10.1161/circ.126.suppl_21.a9654","title":"Abstract 9654: Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Meta-analyses Oof Randomized Controlled Trials","year":2012,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Type 2 diabetes; Meta-analysis; Randomized controlled trial; Adverse effect; Dipeptidyl peptidase-4; Internal medicine; Diabetes mellitus; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.08683563299346389,"score_gpt":0.3315228606246526,"score_spread":0.2446872276311887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262101396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914687,0.0033677688,0.000018677292,0.0000341892,0.00012240712,0.0047073625,0.000015031227,0.00001854326,0.00024730814],"genre_scores_gemma":[0.99921894,0.00013704403,0.00006214104,0.000028319502,0.00007067822,0.00027841137,0.00015210806,0.00002127638,0.00003105263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673754,0.001108937,0.0010180586,0.00025406087,0.00062830077,0.00025308115],"domain_scores_gemma":[0.9977244,0.0007386706,0.0007917138,0.00049064297,0.00015840001,0.0000961541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006509945,0.0002666517,0.0030493278,0.00018299003,0.00004738557,0.000012431441,0.000052374377,0.00007713184,0.00008886551],"category_scores_gemma":[0.0015291878,0.0001286033,0.0013349263,0.00021311005,0.00008728406,0.00023285688,0.000025866519,0.00010124921,0.0000063521243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009153686,0.00048309125,0.8381685,0.00008073582,0.15050809,0.0000010388267,0.00020908768,0.0005820562,0.00016482575,0.00001506321,0.000027610966,0.0006062217],"study_design_scores_gemma":[0.134578,0.00003977594,0.72222656,0.000046902554,0.14259757,6.065616e-8,0.000051593404,0.00006276551,0.00024928033,0.000029120592,0.000020741592,0.000097599695],"about_ca_topic_score_codex":0.00013327698,"about_ca_topic_score_gemma":0.000007705326,"teacher_disagreement_score":0.12542433,"about_ca_system_score_codex":0.00006802119,"about_ca_system_score_gemma":0.000023131843,"threshold_uncertainty_score":0.524429},"labels":[],"label_agreement":null},{"id":"W2267726385","doi":"10.1161/circulationaha.115.015744","title":"Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia","year":2015,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Hazard ratio; Myocardial infarction; Biomarker; Cause of death; Stroke (engine); Clinical trial; Confidence interval; Disease","score_opus":0.06645191247257648,"score_gpt":0.292589424133953,"score_spread":0.22613751166137652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267726385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9298428,0.00019575442,0.06762953,0.00008056083,0.00012002744,0.0012105067,0.0000018970703,0.000042808497,0.00087607175],"genre_scores_gemma":[0.9942338,0.0000044519247,0.0052587087,0.00003518833,0.00004057303,0.00013097233,0.00013069727,0.000018118613,0.00014751445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928945,0.0000090887415,0.00012403856,0.00019446628,0.0002276972,0.00015528112],"domain_scores_gemma":[0.9996199,0.000015123787,0.000036145568,0.0001962757,0.00006364754,0.00006887712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019958669,0.00008996288,0.00019067815,0.00012892993,0.000023898025,0.000012904222,0.000029668156,0.000037085196,0.0000053370304],"category_scores_gemma":[0.000041798943,0.00006901303,0.00010112498,0.00020924407,0.0000061066216,0.00012014057,0.000012979147,0.00002391336,0.0000085172405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041325658,0.00014204976,0.992536,0.00014108089,0.0008771553,0.000010768768,0.00032766757,0.00076789816,0.00018527951,0.00027268,0.00007455345,0.004251574],"study_design_scores_gemma":[0.009899369,0.00014009236,0.98261094,0.0001537767,0.0007158237,0.0000088280685,0.00021809762,0.0041774875,0.00014574669,0.00017714272,0.0016269685,0.0001257124],"about_ca_topic_score_codex":0.000071704,"about_ca_topic_score_gemma":0.000057349687,"teacher_disagreement_score":0.064390935,"about_ca_system_score_codex":0.00024757444,"about_ca_system_score_gemma":0.000060084156,"threshold_uncertainty_score":0.28142697},"labels":[],"label_agreement":null},{"id":"W2268853406","doi":"10.1161/atvb.34.suppl_1.247","title":"Abstract 247: Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans","year":2014,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sitagliptin; Internal medicine; Endocrinology; Postprandial; Hormone; Triglyceride; Lipoprotein; Incretin; Sitagliptin Phosphate; Chemistry; Medicine; Insulin; Diabetes mellitus; Type 2 diabetes; Cholesterol","score_opus":0.028172474933073767,"score_gpt":0.26874417153509483,"score_spread":0.24057169660202107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268853406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969289,0.000035008852,0.0004196403,0.0013285712,0.000042104566,0.00069030514,0.0000050416534,0.00008461917,0.00046585742],"genre_scores_gemma":[0.99741066,0.0003081187,0.0009311346,0.00091446145,0.00008779986,0.00016949265,0.00014200567,0.000030012112,0.0000063340367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835914,0.00011179402,0.0003760017,0.00054304895,0.00014913945,0.00046086728],"domain_scores_gemma":[0.99929386,0.00004726726,0.00012362517,0.0003108176,0.00005664257,0.00016775983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043536705,0.0002757409,0.0004904592,0.00013442883,0.00012860907,0.000046765246,0.00005036967,0.00012750798,0.0000883966],"category_scores_gemma":[0.000030918985,0.00021540772,0.000097754346,0.00020161753,0.00017192842,0.00015519184,0.00006650248,0.0001665825,0.000043182885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012082656,0.0011549685,0.62450117,0.00025406174,0.0002902557,9.855153e-7,0.0006888545,0.0000057087473,0.36211318,0.0022974084,0.000113826936,0.008458724],"study_design_scores_gemma":[0.0039957883,0.0036207307,0.9882402,0.00047527225,0.00014365646,8.5986113e-7,0.0001497329,0.00020526939,0.0021839296,0.000102038626,0.0006440167,0.00023851558],"about_ca_topic_score_codex":0.00022573561,"about_ca_topic_score_gemma":0.00046720056,"teacher_disagreement_score":0.363739,"about_ca_system_score_codex":0.00007071156,"about_ca_system_score_gemma":0.000019546429,"threshold_uncertainty_score":0.87840724},"labels":[],"label_agreement":null},{"id":"W2268864767","doi":"","title":"[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.026377750334401068,"score_gpt":0.26913873861024784,"score_spread":0.24276098827584677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268864767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911608,0.0006968832,0.000006844693,0.0045742225,0.00029468263,0.0029749079,0.00007962097,0.000027573371,0.00018445053],"genre_scores_gemma":[0.99761105,0.00011607169,0.00016434872,0.000982845,0.000106397696,0.000733116,0.000055115634,0.000021113518,0.00020993757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733764,0.00058958534,0.0007819436,0.00024206078,0.00063401955,0.00041472435],"domain_scores_gemma":[0.9960061,0.0017295625,0.0013844646,0.0005461324,0.0002577827,0.000076009615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002218177,0.0001867632,0.0007991025,0.000037228252,0.00009455601,0.00002979022,0.00030525756,0.000046582845,0.000012420935],"category_scores_gemma":[0.0017973016,0.000074662195,0.00025247282,0.0005087269,0.0002949693,0.000055501445,0.00010303036,0.00016559183,0.000002165897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010108022,0.000590609,0.9629467,0.000022163224,0.0026245154,2.2863064e-7,0.00015045133,0.00006840761,0.000008249604,0.000039919396,0.0016630088,0.03178468],"study_design_scores_gemma":[0.0042833276,0.00019373684,0.9899067,0.000086407956,0.001715444,4.730609e-9,0.0001138669,0.000011461072,0.002300784,0.000112801135,0.0011890436,0.00008638132],"about_ca_topic_score_codex":0.00006374864,"about_ca_topic_score_gemma":0.000040098854,"teacher_disagreement_score":0.031698298,"about_ca_system_score_codex":0.00018036232,"about_ca_system_score_gemma":0.000052488595,"threshold_uncertainty_score":0.3044636},"labels":[],"label_agreement":null},{"id":"W2273304042","doi":"10.1093/eurheartj/ehv728","title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial","year":2016,"lang":"en","type":"erratum","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":902,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Empagliflozin; Medicine; Heart failure; Hazard ratio; Internal medicine; Discontinuation; Cardiology; Diabetes mellitus; Type 2 diabetes; Placebo; Adverse effect; Confidence interval; Endocrinology","score_opus":0.014832496204504124,"score_gpt":0.2332985587299601,"score_spread":0.21846606252545597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273304042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670846,0.00094508135,0.0000010077507,0.0018691373,0.0038395273,0.002063784,0.0001705093,0.000054968474,0.0043475446],"genre_scores_gemma":[0.8492145,0.0002978261,0.00069653476,0.0008254217,0.0036365539,0.00002763119,0.000399594,0.00051165174,0.14439031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99435705,0.0012312889,0.0011249807,0.0006759251,0.001800308,0.0008104439],"domain_scores_gemma":[0.99690527,0.00014139223,0.0007477216,0.0015277792,0.0003581554,0.0003196585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017194854,0.00076049624,0.002004336,0.0004341566,0.00025573577,0.00008358275,0.00043835703,0.0001881579,0.00011945272],"category_scores_gemma":[0.00042136226,0.00035211636,0.00094397477,0.00042807817,0.00021243472,0.00016544743,0.00032763535,0.001492759,0.00016022817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00559575,0.00030158155,0.59400225,0.0000790123,0.0025724012,0.00006710199,0.000107832886,0.00008162169,3.8691363e-7,6.0076604e-7,0.3968639,0.00032754787],"study_design_scores_gemma":[0.05521041,0.0026742083,0.54408944,0.0011971008,0.0014748005,0.000007751943,0.000024159875,0.0000014559714,0.0000065728404,0.0000016742118,0.39501846,0.00029398128],"about_ca_topic_score_codex":0.000029033105,"about_ca_topic_score_gemma":0.00003337163,"teacher_disagreement_score":0.14004277,"about_ca_system_score_codex":0.0003870255,"about_ca_system_score_gemma":0.00022299564,"threshold_uncertainty_score":0.99989307},"labels":[],"label_agreement":null},{"id":"W2274300369","doi":"10.18553/jmcp.2007.13.9-c.1","title":"The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes","year":2007,"lang":"en","type":"review","venue":"Journal of Managed Care Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; McGill University; U.S. Department of Veterans Affairs; University of Southern California; Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Incretin; Intensive care medicine; Exenatide; Type 2 Diabetes Mellitus; Disease; Diabetes mellitus; Type 2 diabetes; Postprandial; Sitagliptin; Bioinformatics; Internal medicine; Endocrinology","score_opus":0.030240095817671963,"score_gpt":0.34629571035188284,"score_spread":0.3160556145342109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274300369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006201219,0.9888512,0.0000021572398,0.00021380496,0.0004034214,0.0011751744,0.00001289901,0.000013939999,0.0031261842],"genre_scores_gemma":[0.11158165,0.88767415,0.00007173323,0.00017562011,0.00017564026,0.00002709732,0.00004023102,0.000064664244,0.00018918232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970887,0.00037529945,0.0011913535,0.00019588452,0.000699956,0.00044885013],"domain_scores_gemma":[0.9967271,0.0008675345,0.0014449595,0.00050073577,0.0003776194,0.00008206421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014739792,0.00043721884,0.00186269,0.0009929185,0.00011429689,0.000037188962,0.0006642865,0.00008511435,0.000046326764],"category_scores_gemma":[0.00010244754,0.00021475083,0.00097038195,0.00085609156,0.00010563852,0.0000706092,0.00014443988,0.0006833042,0.0000044388066],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012464925,0.00008784166,0.0100718755,0.012206207,0.0022104308,0.00007878405,0.0018427891,0.000011865512,0.0000025843697,0.000047055037,0.00023375265,0.9730822],"study_design_scores_gemma":[0.002576104,0.00028232168,0.00065814715,0.009045274,0.0053569633,0.0000033465603,0.012764999,0.000021089527,0.00008946166,0.000016208704,0.9689697,0.00021635686],"about_ca_topic_score_codex":0.000015549755,"about_ca_topic_score_gemma":0.000017375572,"teacher_disagreement_score":0.9728658,"about_ca_system_score_codex":0.00019341249,"about_ca_system_score_gemma":0.00017356506,"threshold_uncertainty_score":0.8757285},"labels":[],"label_agreement":null},{"id":"W2276028032","doi":"10.1007/s13300-016-0155-1","title":"A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus","year":2016,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sheridan College; Public Health Ontario","funders":"AstraZeneca","keywords":"Exenatide; Medicine; Lixisenatide; Tolerability; Dulaglutide; Metformin; Liraglutide; Internal medicine; Type 2 diabetes; Glycated hemoglobin; Glucagon-like peptide 1 receptor; Discontinuation; Type 2 Diabetes Mellitus; Pharmacology; Diabetes mellitus; Adverse effect; Endocrinology; Agonist; Insulin; Receptor","score_opus":0.1266099849112865,"score_gpt":0.3423086737592977,"score_spread":0.2156986888480112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276028032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004982382,0.9933073,0.00006741416,0.00031177863,0.0002174646,0.004975562,0.00017450785,0.000087596,0.00036016374],"genre_scores_gemma":[0.000261106,0.98986655,0.0013002082,0.00027887736,0.0004175616,0.0032579356,0.0004515538,0.00018418685,0.0039820075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967387,0.0002268794,0.0009062012,0.00080264994,0.00044721912,0.0008783922],"domain_scores_gemma":[0.9954019,0.0018954598,0.000917087,0.001423662,0.00020704039,0.00015485795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048273872,0.0010277865,0.006902353,0.00029745506,0.00016810991,0.00007770387,0.00041650777,0.00019574136,0.00054011046],"category_scores_gemma":[0.000019630468,0.00042824866,0.0038268056,0.0010562277,0.00020831425,0.000070985065,0.00003605945,0.00011205261,0.000050918043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008178982,0.00052756455,0.0010125285,0.0011494345,0.4135447,8.480332e-7,0.00006660178,0.000016620505,0.0000022001125,0.00012555785,0.0009406808,0.58253145],"study_design_scores_gemma":[0.0011579037,0.0020119406,0.00003259459,0.0010073386,0.2780427,6.641645e-8,0.000006473443,0.000023828148,0.000054159387,0.0000349348,0.71728945,0.00033859874],"about_ca_topic_score_codex":0.000015287333,"about_ca_topic_score_gemma":0.000014868014,"teacher_disagreement_score":0.71634877,"about_ca_system_score_codex":0.00025256048,"about_ca_system_score_gemma":0.00012234451,"threshold_uncertainty_score":0.99981695},"labels":[],"label_agreement":null},{"id":"W2276127276","doi":"10.1007/0-306-46881-6_90","title":"DP IV-inhibitors: Potential antidiabetic drugs","year":2006,"lang":"en","type":"book-chapter","venue":"Kluwer Academic Publishers eBooks","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacology; Medicine; Traditional medicine","score_opus":0.009876142031840122,"score_gpt":0.22322261521679926,"score_spread":0.21334647318495914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276127276","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014334653,0.0017924624,0.00002546463,0.0015049387,0.002093291,0.0018056729,0.00005074119,0.00062502926,0.99066895],"genre_scores_gemma":[0.0315043,0.000059739523,0.00016086704,0.0020337033,0.0028698593,0.000096330936,0.0008971268,0.00033409917,0.962044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99509007,0.000032136773,0.0010933684,0.0012686889,0.0014098107,0.0011059123],"domain_scores_gemma":[0.99764794,0.000055828128,0.0005456541,0.0010068417,0.00021378028,0.00052996597],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004681464,0.0011062621,0.0013181849,0.0009137907,0.00015495776,0.00033388185,0.0005748958,0.0018491538,0.0008699195],"category_scores_gemma":[0.00003261885,0.0010311279,0.0008080474,0.0000578652,0.00038542395,0.0005103316,0.00041515706,0.002339239,0.00066930236],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007234327,0.000056436547,0.00014005096,0.00029669623,0.00096922106,0.0002476234,0.000109374516,0.000001963871,0.00019719223,0.0050210566,0.9603159,0.03257216],"study_design_scores_gemma":[0.0029246248,0.00023802358,0.00011442529,0.00092561706,0.0023264848,0.000023146951,0.00003588586,0.00002506675,0.00034839704,0.0073945476,0.9846902,0.0009535719],"about_ca_topic_score_codex":0.00004616966,"about_ca_topic_score_gemma":0.0000017233199,"teacher_disagreement_score":0.03161859,"about_ca_system_score_codex":0.0005334883,"about_ca_system_score_gemma":0.00030072653,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W2279162094","doi":"10.1186/s12933-016-0341-5","title":"LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial","year":2016,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Universitat de les Illes Balears; Novo Nordisk; Sanofi; AstraZeneca","keywords":"Medicine; Overweight; Internal medicine; Body mass index; Obesity; Type 2 Diabetes Mellitus; Liraglutide; Diabetes mellitus; Waist; Metabolic syndrome; Type 2 diabetes; Endocrinology","score_opus":0.018832387675454077,"score_gpt":0.24746095024550352,"score_spread":0.22862856257004943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279162094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90051854,0.09633572,0.00023556234,0.000091841895,0.00032055832,0.0016517285,0.00076191593,0.00004047085,0.00004366326],"genre_scores_gemma":[0.9929829,0.005940792,0.00022709629,0.000047841382,0.00028021602,0.00006835875,0.00039558034,0.000039665993,0.00001752011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960702,0.0009690054,0.0004800741,0.0010597683,0.0007542222,0.00066673994],"domain_scores_gemma":[0.9958284,0.00037136138,0.00015224701,0.0032384212,0.00023772188,0.00017182954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016422067,0.00044585593,0.0021044537,0.00012776173,0.000067609435,0.000021267411,0.0004927051,0.00020553965,0.000053247128],"category_scores_gemma":[0.0006243806,0.00023099825,0.0009450585,0.0005788966,0.00051251886,0.00024662097,0.00041772556,0.0001845094,0.00002693786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013578464,0.00029967376,0.8970037,0.00008908762,0.025643881,0.000019159232,0.000036329875,0.00007331291,0.0000063036764,0.000012187963,0.00026928936,0.075189196],"study_design_scores_gemma":[0.044506032,0.0006967414,0.9403914,0.00016759952,0.010769541,0.0000015532163,0.00002214908,0.000028588753,0.00006505069,0.00005939367,0.003013308,0.00027863946],"about_ca_topic_score_codex":0.00093625643,"about_ca_topic_score_gemma":0.000049075017,"teacher_disagreement_score":0.09246438,"about_ca_system_score_codex":0.00016808252,"about_ca_system_score_gemma":0.00013401305,"threshold_uncertainty_score":0.9419836},"labels":[],"label_agreement":null},{"id":"W2281351730","doi":"10.1136/bmj.h2650","title":"Scant evidence on the effectiveness of metformin in type 2 diabetes","year":2015,"lang":"en","type":"letter","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Metformin; Type 2 diabetes; Medicine; Diabetes mellitus; Endocrinology","score_opus":0.05378713099625686,"score_gpt":0.32029005965067503,"score_spread":0.26650292865441816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281351730","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33280253,0.005953526,0.0000018050414,0.60632646,0.0013610909,0.0068719652,0.000017462371,0.00006304747,0.046602096],"genre_scores_gemma":[0.5029995,0.0005424473,0.0002380329,0.47330022,0.0031017796,0.001523282,0.00040449778,0.00016731136,0.017722989],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987367,0.000254124,0.00020258188,0.00020499952,0.00038478637,0.00021681868],"domain_scores_gemma":[0.99809295,0.0011869806,0.000108981774,0.0005022004,0.00008505155,0.000023822866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016368278,0.00017758721,0.0004560089,0.00014924305,0.00000977506,0.000008356856,0.00014796628,0.0001511736,0.0000552156],"category_scores_gemma":[0.0007058557,0.00009876698,0.00008219433,0.00020196213,0.00005206102,0.000033942608,0.000067194895,0.00033256534,0.00010731383],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015423015,0.00006504183,0.005803556,0.001027965,0.00023527858,0.00014386183,0.000022194981,0.0000015821797,0.000079962825,0.000096110976,0.9894657,0.0029045164],"study_design_scores_gemma":[0.0017102212,0.0025878213,0.038437545,0.016899271,0.0009313908,0.0000023033845,0.00002800556,0.00003342213,0.007987842,0.0011066761,0.9298923,0.00038319605],"about_ca_topic_score_codex":0.000034049557,"about_ca_topic_score_gemma":0.0000030098843,"teacher_disagreement_score":0.17019692,"about_ca_system_score_codex":0.00015024276,"about_ca_system_score_gemma":0.000093212315,"threshold_uncertainty_score":0.40276006},"labels":[],"label_agreement":null},{"id":"W2281697559","doi":"10.18553/jmcp.2013.19.9.740","title":"Comparative Effectiveness of Hypoglycemic Medications Among Veterans","year":2013,"lang":"en","type":"article","venue":"Journal of Managed Care Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of South Florida; McGill University; Florida Department of Health; U.S. Department of Veterans Affairs","keywords":"Medicine; Internal medicine; Odds ratio; Repaglinide; Rosiglitazone; Metformin; Diabetes mellitus; Type 2 diabetes; Logistic regression; Polypharmacy; Insulin; Endocrinology","score_opus":0.02348004923849426,"score_gpt":0.32931035817338683,"score_spread":0.30583030893489255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281697559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869882,0.001253273,0.00035275897,0.00026254845,0.0002310546,0.00064183224,0.0000027269639,0.000014128683,0.010253487],"genre_scores_gemma":[0.9988911,0.00018932355,0.00052326167,0.00008670577,0.00008461143,0.00002930398,0.000012288969,0.000011681385,0.00017171275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989095,0.00014742058,0.00036267957,0.000099832505,0.0003353762,0.00014519219],"domain_scores_gemma":[0.9987937,0.0001932831,0.00031047006,0.000157374,0.000405435,0.00013973375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002641386,0.00012520564,0.00046288143,0.000248235,0.00003843799,0.000014748799,0.0001415355,0.000019013482,0.0002167271],"category_scores_gemma":[0.000019540088,0.000094244955,0.00019195178,0.0001794704,0.000084439765,0.00025950003,0.000033841618,0.0001895551,0.000029868836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038034618,0.0037637288,0.488424,0.0078104367,0.01947954,0.0007340834,0.019743066,0.0006933837,0.14093259,0.0009994732,0.034533337,0.2790829],"study_design_scores_gemma":[0.022460338,0.0015506305,0.87878764,0.0017643138,0.0047821635,0.000056261568,0.00627595,0.0005405314,0.07384253,0.00033236798,0.009280558,0.00032673415],"about_ca_topic_score_codex":0.00006850792,"about_ca_topic_score_gemma":0.0000022242389,"teacher_disagreement_score":0.39036363,"about_ca_system_score_codex":0.00010723708,"about_ca_system_score_gemma":0.00004751734,"threshold_uncertainty_score":0.38431978},"labels":[],"label_agreement":null},{"id":"W2282542030","doi":"10.14288/1.0166186","title":"Dietary proteins as precursors of dipeptidyl-peptidase IV inhibitors — allies to complement pharmacotherapy in the management of type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Dipeptidyl peptidase; Pharmacotherapy; Complement (music); Type 2 diabetes; Dipeptidyl peptidase-4; Medicine; Diabetes mellitus; Pharmacology; Sitagliptin; Chemistry; Endocrinology; Internal medicine; Biochemistry; Enzyme","score_opus":0.021170052155078927,"score_gpt":0.23447404317752527,"score_spread":0.21330399102244635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282542030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935787,0.00033927546,0.0000050749263,0.0005012831,0.000071324495,0.0017592222,0.000045712393,0.000021165628,0.0036782932],"genre_scores_gemma":[0.9976812,0.00022748974,0.0010983055,0.00013960844,0.00001552315,0.000008023099,0.000042024894,0.000012628279,0.0007751915],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99880093,0.00006401782,0.00020686023,0.0002486712,0.00044548672,0.00023402506],"domain_scores_gemma":[0.9992936,0.000022310736,0.00013615568,0.00028876067,0.00014470016,0.00011446395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003246745,0.00006970467,0.00035525637,0.000094410054,0.00004042647,0.00001592331,0.0002567544,0.00003422206,0.00009413529],"category_scores_gemma":[0.000006764833,0.00014447622,0.0001042999,0.00043371794,0.00015154731,0.00011740864,0.0001420455,0.0000662104,0.000013260509],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004553566,0.004216201,0.19481483,0.0019324578,0.0018327436,0.0003724138,0.0063003222,0.00009640248,0.003324577,0.000028230228,0.035585567,0.7510409],"study_design_scores_gemma":[0.0046743727,0.0019564424,0.9770889,0.0010766153,0.00035488867,0.0000017239958,0.010165731,0.000050910417,0.00019205247,0.0001447425,0.0041205287,0.00017307894],"about_ca_topic_score_codex":0.010389789,"about_ca_topic_score_gemma":0.009317403,"teacher_disagreement_score":0.78227407,"about_ca_system_score_codex":0.00007838557,"about_ca_system_score_gemma":0.000036604608,"threshold_uncertainty_score":0.9962001},"labels":[],"label_agreement":null},{"id":"W2282578582","doi":"10.1056/nejmoa1509225","title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2338,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; McMaster University","funders":"","keywords":"Lixisenatide; Acute coronary syndrome; Type 2 diabetes; Medicine; Internal medicine; Cardiology; Diabetes mellitus; Myocardial infarction; Endocrinology","score_opus":0.011952365187007236,"score_gpt":0.23544450911502637,"score_spread":0.22349214392801914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282578582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516714,0.0012517245,0.000004022524,0.0023164016,0.00023421423,0.00016496897,5.5866826e-7,0.0000064688156,0.0008544763],"genre_scores_gemma":[0.99806476,0.00014958685,0.00047074966,0.00047826907,0.0001980465,6.834067e-7,0.000012979878,0.000011861556,0.00061307685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911296,0.000026175787,0.00024852954,0.000086889966,0.00037525923,0.00015019412],"domain_scores_gemma":[0.99926454,0.000049333084,0.00012725848,0.00008976673,0.0001484551,0.0003206658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047607,0.000113467315,0.00039735835,0.00020873628,0.000009869111,0.0000048823167,0.000045664598,0.000026553615,0.00003709123],"category_scores_gemma":[0.00009064702,0.00006208635,0.0000144925525,0.00015060062,0.000056400895,0.000102362064,0.000019820965,0.00013258662,0.000002890903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010813293,0.00014377711,0.95276195,0.00002198184,0.00032801813,0.0007010677,0.00039615238,0.0000030521333,0.000017028791,0.000016622313,0.005538503,0.0389905],"study_design_scores_gemma":[0.09334512,0.013748494,0.8855426,0.0005532715,0.0005159183,0.00015463564,0.00008745285,0.000009629537,0.000015265974,0.00019386904,0.0057632066,0.000070538925],"about_ca_topic_score_codex":0.000008673207,"about_ca_topic_score_gemma":0.0000056008394,"teacher_disagreement_score":0.09226379,"about_ca_system_score_codex":0.00005310738,"about_ca_system_score_gemma":0.000070942915,"threshold_uncertainty_score":0.25318077},"labels":[],"label_agreement":null},{"id":"W2282623102","doi":"10.1136/bmj.i610","title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","year":2016,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Hospital for Sick Children; University of British Columbia; McMaster University; University of Toronto","funders":"Canadian Institutes of Health Research; National Natural Science Foundation of China","keywords":"Medicine; Observational study; Meta-analysis; Odds ratio; Type 2 diabetes; Internal medicine; Randomized controlled trial; Heart failure; Relative risk; Placebo; Sitagliptin; Confidence interval; Cohort study; Diabetes mellitus; Pathology; Endocrinology; Alternative medicine","score_opus":0.11537497083997934,"score_gpt":0.3734791008510779,"score_spread":0.25810413001109855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282623102","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000493957,0.9935883,2.7348418e-7,0.00045736542,0.000014364193,0.0053153043,0.000095513366,0.000006739265,0.000028132938],"genre_scores_gemma":[0.00012125988,0.99820673,0.0002699074,0.00008710335,0.000014594766,0.00070156844,0.00006652702,0.000017843946,0.0005144839],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975038,0.00041660297,0.001364615,0.00032148088,0.00025481326,0.00013866369],"domain_scores_gemma":[0.9973391,0.0010788619,0.0010023534,0.00036599117,0.00015147307,0.00006216509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016036824,0.00033998632,0.0097341705,0.0004054916,0.000019484576,0.000007658242,0.00004733118,0.00008700973,0.00004131011],"category_scores_gemma":[0.0010263944,0.00017344093,0.0008131197,0.0005374802,0.00011793601,0.000054920358,0.00009504274,0.000078907775,0.000002018694],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011824668,0.000043035347,0.0010775323,0.7597137,0.235923,0.0000014254288,0.000033639422,5.048482e-8,2.1445682e-7,0.000021962713,0.0021743677,0.0009992415],"study_design_scores_gemma":[0.0015731893,0.00009839357,0.00021537585,0.119372614,0.86565065,7.788468e-7,0.000028389073,0.0000012408831,4.7210034e-7,0.000009495036,0.012910589,0.00013880052],"about_ca_topic_score_codex":0.000004854075,"about_ca_topic_score_gemma":0.000017174301,"teacher_disagreement_score":0.6403411,"about_ca_system_score_codex":0.000030558836,"about_ca_system_score_gemma":0.00003875174,"threshold_uncertainty_score":0.70727164},"labels":[],"label_agreement":null},{"id":"W2283517602","doi":"10.1016/j.jval.2015.03.355","title":"The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian setting","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Sitagliptin; Medicine; Metformin; Internal medicine; Population; Placebo; Type 2 Diabetes Mellitus; Sulfonylurea; Surgery; Diabetes mellitus; Endocrinology; Insulin; Environmental health","score_opus":0.06972131726292441,"score_gpt":0.33978473491633193,"score_spread":0.2700634176534075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283517602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824332,0.010110736,3.387202e-7,0.002752625,0.00046013444,0.0019701037,0.000006696874,0.000014262586,0.0022518889],"genre_scores_gemma":[0.9977816,0.001493095,0.00007271137,0.000379232,0.000040582752,0.00011908353,0.000028355467,0.000021646258,0.000063737374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786717,0.0005264565,0.00041791293,0.00024254055,0.0002382589,0.00070764765],"domain_scores_gemma":[0.9985585,0.0006636996,0.000101709826,0.00028785318,0.00007227595,0.0003159683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003564785,0.00015885835,0.00040739923,0.000368877,0.000041568062,0.000013310834,0.00012335446,0.00006752744,0.0000073980855],"category_scores_gemma":[0.0004997199,0.00012099876,0.000034930305,0.0007229198,0.000046583646,0.000050827526,0.000027975522,0.00020589626,0.000017186272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025298225,0.00058142625,0.85595226,0.0006723174,0.00018225053,0.00013926375,0.0035282243,0.006813253,0.000055259643,0.004195224,0.00069647713,0.124654226],"study_design_scores_gemma":[0.047710784,0.012772983,0.81383455,0.004488808,0.0000779926,0.0000027401609,0.004871065,0.022092905,0.0020854624,0.0034380397,0.08781372,0.0008109375],"about_ca_topic_score_codex":0.69116014,"about_ca_topic_score_gemma":0.4702225,"teacher_disagreement_score":0.22093762,"about_ca_system_score_codex":0.0017923793,"about_ca_system_score_gemma":0.0017335007,"threshold_uncertainty_score":0.53944457},"labels":[],"label_agreement":null},{"id":"W2289925905","doi":"10.1161/atvb.34.suppl_1.411","title":"Abstract 411: Effect of Sitagliptin Therapy on Triglyceride-Rich Lipoprotein Kinetics in Patients With Type 2 Diabetes","year":2014,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Sitagliptin; Internal medicine; Endocrinology; Postprandial; Medicine; Type 2 diabetes; Apolipoprotein B; Incretin; Triglyceride; Placebo; Sitagliptin Phosphate; Insulin; Very low-density lipoprotein; Crossover study; Cholesterol; Diabetes mellitus; Lipoprotein","score_opus":0.012390088845765226,"score_gpt":0.2384584385638453,"score_spread":0.22606834971808007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289925905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987366,0.000054115186,0.0000028679253,0.00008625382,0.00007014751,0.0007275929,0.000003904626,0.000022143035,0.0002963607],"genre_scores_gemma":[0.99909306,0.00042593534,0.000119554614,0.00018948721,0.0000286495,0.000050348535,0.00006658189,0.000024199448,0.0000022155423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989302,0.00010290055,0.0002437565,0.00032206648,0.00012978862,0.00027129037],"domain_scores_gemma":[0.9993679,0.00009731635,0.000100520214,0.00032242606,0.000046935995,0.00006491648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024964553,0.00023303182,0.0006262137,0.00013399786,0.000029879531,0.0000125476745,0.00006582156,0.00010373303,0.000058444686],"category_scores_gemma":[0.000032344356,0.00014647614,0.00008103684,0.00016042103,0.00010051,0.000034342454,0.00003182484,0.00007968631,0.000011044159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009026643,0.00065738935,0.9528791,0.00007920734,0.00037702263,2.326539e-8,0.000057727688,0.0000020784219,0.03206412,0.000041530417,0.000035889945,0.01371566],"study_design_scores_gemma":[0.006589867,0.016353888,0.9712807,0.00017119909,0.000118058524,5.0447175e-9,0.0000044114336,0.000013099233,0.004806315,0.000008117437,0.0005110983,0.00014326542],"about_ca_topic_score_codex":0.000026599944,"about_ca_topic_score_gemma":0.000010600226,"teacher_disagreement_score":0.027257806,"about_ca_system_score_codex":0.000018794895,"about_ca_system_score_gemma":0.0000046932623,"threshold_uncertainty_score":0.5973124},"labels":[],"label_agreement":null},{"id":"W2291499225","doi":"10.1111/dom.12658","title":"Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Seven Oaks General Hospital; Manitoba Health; University of Manitoba; Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research; Western University; Institute for Clinical Evaluative Sciences; London Health Sciences Centre; Lawson Health Research Institute","keywords":"Medicine; Gliclazide; Kidney disease; Metformin; Internal medicine; Diabetes mellitus; Sitagliptin; Rosiglitazone; Thiazolidinedione; Medical prescription; Type 2 diabetes; Glibenclamide; Pioglitazone; Dialysis; Renal function; Population; Saxagliptin; Nephrology; Endocrinology; Pharmacology","score_opus":0.00432910448264221,"score_gpt":0.20576289492310285,"score_spread":0.20143379044046064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291499225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760706,0.019602675,0.000008253532,0.003410214,0.00009142675,0.0005519626,0.000044037915,0.000052779236,0.00016806982],"genre_scores_gemma":[0.9948549,0.0030282964,0.000098766184,0.00044604734,0.00009030033,0.00019661731,0.00019041914,0.000024315303,0.0010703402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849415,0.00006198783,0.0002402384,0.00048970064,0.00022916525,0.00048477575],"domain_scores_gemma":[0.9991475,0.00003605705,0.000067867804,0.00031286242,0.000036354693,0.0003993756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019441091,0.00025601956,0.00044557406,0.0004936523,0.000057007896,0.000027179993,0.00007450132,0.00008688506,0.00013055542],"category_scores_gemma":[0.000047022535,0.0001669797,0.000049573016,0.0003315729,0.00017440319,0.00031949766,0.00006772611,0.000106637286,0.00000921739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055279186,0.0005729514,0.9339832,0.00033177706,0.00013433099,0.000015466287,0.00026406403,8.767825e-7,0.0018593529,0.00024903868,0.0020027286,0.060530953],"study_design_scores_gemma":[0.007662501,0.000097790755,0.9786819,0.0011802248,0.00037266727,4.0867258e-7,0.00003063079,0.00022927918,0.0007067028,0.00011806475,0.010693568,0.00022624356],"about_ca_topic_score_codex":0.00005080212,"about_ca_topic_score_gemma":0.0001200999,"teacher_disagreement_score":0.06030471,"about_ca_system_score_codex":0.000067020126,"about_ca_system_score_gemma":0.00004599455,"threshold_uncertainty_score":0.6809235},"labels":[],"label_agreement":null},{"id":"W2291621546","doi":"10.1096/fasebj.22.1_supplement.1053.2","title":"Quantification of myo‐inositol cotransporter expression in control and streptozotocin‐treated rats.","year":2008,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Kidney; Endocrinology; Internal medicine; Cotransporter; Streptozotocin; Brush border; Diabetes mellitus; Urinary system; Messenger RNA; Small intestine; Chemistry; Apical membrane; Excretion; Epithelial polarity; Biology; Medicine; Sodium; Biochemistry; Cell; Membrane; Gene","score_opus":0.019456633120134854,"score_gpt":0.24795245683681189,"score_spread":0.22849582371667704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291621546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980354,0.0003639705,0.00021415608,0.0005437672,0.0000381541,0.00037247466,0.0000035797696,0.000008682859,0.00041983082],"genre_scores_gemma":[0.9990813,0.000290684,0.00010918024,0.00008655474,0.000034876175,0.000009785532,0.000009497133,0.000006672343,0.00037144826],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993712,0.00004595867,0.00022983742,0.00008266605,0.00015550217,0.000114883645],"domain_scores_gemma":[0.99962956,0.000031804688,0.00011184033,0.00012945563,0.00004201025,0.0000553272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001587004,0.00007859793,0.00018100349,0.00008333551,0.00007103833,0.0000071922377,0.000044699103,0.000028747527,0.00005248938],"category_scores_gemma":[0.000006877742,0.000045409273,0.00004620094,0.000071240545,0.00006761794,0.00006489793,0.000005484991,0.000107277956,0.000003850937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031858793,0.00020417897,0.45595407,0.00001946531,0.00007881131,0.00010023831,0.0004396702,0.000014208697,0.54044425,0.000025179652,0.000714979,0.001686381],"study_design_scores_gemma":[0.0044971616,0.00026161736,0.5892129,0.00018745587,0.00017607438,0.000073023184,0.00018965176,0.00021596941,0.40491682,0.000034000877,0.00017631514,0.00005902018],"about_ca_topic_score_codex":0.000013496298,"about_ca_topic_score_gemma":0.0000031515294,"teacher_disagreement_score":0.13552739,"about_ca_system_score_codex":0.000021710823,"about_ca_system_score_gemma":0.000018969378,"threshold_uncertainty_score":0.18517363},"labels":[],"label_agreement":null},{"id":"W2292183787","doi":"10.14740/jem.v6i1.333","title":"Plasma B-Type Natriuretic Peptide Levels May Increase Because of Fat Mass Loss by Metformin or Sodium-Glucose Transporter 2 Inhibitors Treatment","year":2016,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Glycemic; Diabetes mellitus; Natriuretic peptide; Pharmacology; Heart failure","score_opus":0.020329637866798644,"score_gpt":0.26741453179254765,"score_spread":0.247084893925749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292183787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059725,0.0067397044,0.00006476061,0.0013100313,0.0005335096,0.00032745735,0.00005960147,0.000015948885,0.00035171333],"genre_scores_gemma":[0.9815049,0.009375231,0.0010861811,0.0001539381,0.00024474118,0.000011247013,0.000008426693,0.000025696825,0.0075896294],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982736,0.00008113176,0.00072627695,0.00022692056,0.0002547344,0.00043735452],"domain_scores_gemma":[0.9987403,0.00017267141,0.0004202394,0.00022612643,0.00017055855,0.0002700673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016309023,0.0003048196,0.0009496101,0.0003646698,0.000047776295,0.000008270795,0.000109178174,0.000113331604,0.00031251894],"category_scores_gemma":[0.00008479518,0.00015508571,0.00024202635,0.00013518562,0.00023030757,0.00022799142,0.000026730457,0.00014033073,0.000012164294],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017195433,0.004683275,0.0959085,0.0004708274,0.01232832,0.009879055,0.0015526993,0.0000026688467,0.40242583,0.005401233,0.015757337,0.43439484],"study_design_scores_gemma":[0.031808272,0.004138257,0.027044058,0.00027014827,0.0056440625,0.0011965384,0.00023242447,0.0000018853012,0.5577972,0.0005281139,0.37099093,0.000348104],"about_ca_topic_score_codex":0.000026868884,"about_ca_topic_score_gemma":0.000011791005,"teacher_disagreement_score":0.43404672,"about_ca_system_score_codex":0.000071616465,"about_ca_system_score_gemma":0.000111007386,"threshold_uncertainty_score":0.6324212},"labels":[],"label_agreement":null},{"id":"W2292799020","doi":"10.1093/ijnp/pyw014","title":"Central Agonism of GPR120 Acutely Inhibits Food Intake and Food Reward and Chronically Suppresses Anxiety-Like Behavior in Mice","year":2016,"lang":"en","type":"article","venue":"The International Journal of Neuropsychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Université de Montréal; Canadian Diabetes Association","keywords":"GPR120; Anorectic; Polyunsaturated fatty acid; Anxiolytic; Receptor; Internal medicine; Food intake; Endocrinology; Anxiety; Psychology; Chemistry; Neuroscience; Medicine; Fatty acid; G protein-coupled receptor; Biochemistry; Psychiatry","score_opus":0.017794718630928297,"score_gpt":0.29398983953860774,"score_spread":0.27619512090767945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292799020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654246,0.00063775014,0.00001710297,0.011294947,0.0010514006,0.00025413837,0.000019802212,0.0000061419983,0.00017627391],"genre_scores_gemma":[0.99451846,0.0035954453,0.000118437805,0.0014321026,0.00020436702,0.000009408526,0.0000014572643,0.000014290863,0.0001060211],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99886966,0.00007652356,0.00044145636,0.00015478331,0.00027006748,0.00018748551],"domain_scores_gemma":[0.99920714,0.00017374138,0.00027711192,0.000076598175,0.00016490833,0.000100509955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017550237,0.00012792113,0.00025313772,0.00018098528,0.000017520395,0.000014861146,0.00023485621,0.00004292141,0.00006983851],"category_scores_gemma":[0.000043952004,0.000074284726,0.000074226286,0.000060909944,0.00016728476,0.00012711823,0.00012625351,0.00017445665,0.000001317281],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037885513,0.0012454244,0.074781224,0.000049369148,0.0013647781,0.00034693338,0.0004421934,0.000004762224,0.8553139,0.00042293812,0.004236469,0.058003463],"study_design_scores_gemma":[0.025414368,0.0085829245,0.8865741,0.00028330876,0.0009532258,0.0017412776,0.00009369199,0.000013733261,0.051320713,0.00048360613,0.024331281,0.00020775781],"about_ca_topic_score_codex":0.0000032712016,"about_ca_topic_score_gemma":0.0000140098755,"teacher_disagreement_score":0.8117929,"about_ca_system_score_codex":0.000056781464,"about_ca_system_score_gemma":0.000058388345,"threshold_uncertainty_score":0.30292434},"labels":[],"label_agreement":null},{"id":"W2297859446","doi":"10.1111/tan.12777","title":"Discovery of <i><scp>HLA</scp>‐B*58:77</i>, a novel <i><scp>HLA</scp>‐B*58</i> variant, in a Taiwanese blood donor","year":2016,"lang":"en","type":"article","venue":"HLA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Buddhist Compassion Relief Tzu Chi Foundation","keywords":"Blood donor; Medicine; Immunology","score_opus":0.011331184601716324,"score_gpt":0.2260759694277894,"score_spread":0.21474478482607307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297859446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94351286,0.0014508542,0.00078217965,0.0008557877,0.00060864823,0.0016653631,0.00025348327,0.00021485751,0.050655972],"genre_scores_gemma":[0.9356299,0.0006990865,0.0014074661,0.0012919767,0.00042496083,0.00029067183,0.00011423962,0.00014232122,0.059999388],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960141,0.00008901532,0.00095013843,0.0009806042,0.0007757444,0.0011903854],"domain_scores_gemma":[0.99707574,0.00077282434,0.00042047747,0.0012448966,0.00014412876,0.00034196026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005851623,0.0006860433,0.0011462984,0.0005414421,0.0000855855,0.00009471309,0.00046704532,0.00027614384,0.00007213747],"category_scores_gemma":[0.00068483525,0.00048739318,0.00041416584,0.0007923585,0.00026838158,0.00063686306,0.0003919751,0.0002784093,0.00030590373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006529717,0.02214097,0.19045216,0.0027971903,0.004437707,0.0040735137,0.005429199,0.000027075954,0.54270726,0.021784438,0.18741027,0.018087255],"study_design_scores_gemma":[0.08531434,0.0055815857,0.16706021,0.005853611,0.0063066017,0.0004467598,0.003241313,0.00021556047,0.20761704,0.0035188054,0.51377475,0.001069378],"about_ca_topic_score_codex":0.00022713727,"about_ca_topic_score_gemma":0.00015518376,"teacher_disagreement_score":0.33509022,"about_ca_system_score_codex":0.00019652447,"about_ca_system_score_gemma":0.00023810146,"threshold_uncertainty_score":0.99975777},"labels":[],"label_agreement":null},{"id":"W2297966562","doi":"10.14740/jocmr2492w","title":"Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Interim; Type 2 diabetes; Hemoglobin; Diabetes mellitus; Interim analysis; Internal medicine; Endocrinology; Clinical trial","score_opus":0.16510460107998812,"score_gpt":0.4693324237366741,"score_spread":0.304227822656686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297966562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519986,0.00067882374,0.000001183393,0.003348511,0.00010928566,0.0005008423,0.0000018982944,0.0000029222572,0.00015669412],"genre_scores_gemma":[0.9982562,0.0012413368,0.000027296372,0.000019435398,0.00015983086,0.0000065971867,6.4659986e-7,0.000011999469,0.0002766404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684906,0.0004942831,0.0011282488,0.00021140954,0.0010287379,0.00028824128],"domain_scores_gemma":[0.9965712,0.0018119237,0.00055103283,0.00035750607,0.00050894206,0.00019938847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027254187,0.00015902813,0.0014189236,0.0009865654,0.000034190885,0.0000054863485,0.00017741909,0.00006447638,0.000101766804],"category_scores_gemma":[0.0013523619,0.00005658553,0.0001577015,0.0012432688,0.00046262878,0.00007288319,0.000106757,0.00023761102,4.167693e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082758814,0.0014879053,0.9769456,0.00007849442,0.0037168597,0.000049693383,0.0008247417,0.0000010155727,0.0052842163,0.0000058152223,0.000033138906,0.010744966],"study_design_scores_gemma":[0.007483896,0.022699635,0.95915294,0.0012363052,0.001991555,0.0000011852333,0.0017602135,0.000019611081,0.005403631,0.000015663276,0.00018445986,0.00005090259],"about_ca_topic_score_codex":0.000055266264,"about_ca_topic_score_gemma":0.00016146434,"teacher_disagreement_score":0.02121173,"about_ca_system_score_codex":0.00015072618,"about_ca_system_score_gemma":0.00012465652,"threshold_uncertainty_score":0.23074909},"labels":[],"label_agreement":null},{"id":"W2299322097","doi":"10.18553/jmcp.2005.11.s1-b.1","title":"Trends in the Management of Type 2 Diabetes: An Emerging Role for Insulin","year":2005,"lang":"en","type":"review","venue":"Journal of Managed Care Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, New York University; National Institutes of Health; York University; University of Pennsylvania; GlaxoSmithKline; Washington State University; AstraZeneca; Bristol-Myers Squibb; Pfizer; Novo Nordisk; American Diabetes Association","keywords":"Medicine; Glycemic; Insulin; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Basal insulin; Pharmacy; Diabetes management; Internal medicine; Endocrinology; Family medicine","score_opus":0.07207173885985754,"score_gpt":0.4106241114465462,"score_spread":0.3385523725866887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299322097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046129126,0.99231964,0.0000064723604,0.00020388298,0.00034772753,0.0010951759,0.000015240618,0.00001247063,0.005538093],"genre_scores_gemma":[0.0027463946,0.99465454,0.0010243469,0.0001921623,0.0005054839,0.00007818663,0.00016580729,0.000062890205,0.00057017815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976262,0.0001772997,0.0010969717,0.00024370258,0.00050222746,0.0003535922],"domain_scores_gemma":[0.998338,0.00008250527,0.0009017093,0.00040857427,0.00016464369,0.000104575665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009024103,0.0003864748,0.0015255131,0.0011149319,0.000047119902,0.000035955585,0.00056897156,0.00006332986,0.00009836285],"category_scores_gemma":[0.000008538933,0.00024379104,0.00085469685,0.0007847903,0.000027033151,0.00018525864,0.00008377844,0.0004194515,0.000005789429],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007896081,0.00039479815,0.000026188103,0.015211418,0.0019677365,0.00012493227,0.00047583343,0.000013991385,3.914045e-7,0.00008298433,0.0017892371,0.97983354],"study_design_scores_gemma":[0.003010533,0.0005157333,0.00006596615,0.0073568886,0.01121702,0.000009315983,0.0012958254,0.00003220051,0.000002972652,0.000017330878,0.9762864,0.00018977966],"about_ca_topic_score_codex":0.0000031455234,"about_ca_topic_score_gemma":0.0000033348608,"teacher_disagreement_score":0.97964376,"about_ca_system_score_codex":0.00024096966,"about_ca_system_score_gemma":0.00005635935,"threshold_uncertainty_score":0.99415106},"labels":[],"label_agreement":null},{"id":"W2299595115","doi":"10.1007/s13300-016-0163-1","title":"Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin","year":2016,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Janssen Research and Development","keywords":"Canagliflozin; Glimepiride; Medicine; Metformin; Glycemic; Hypoglycemia; Type 2 diabetes; Diabetes mellitus; Adverse effect; Internal medicine; Urology; Weight loss; Endocrinology; Gastroenterology; Obesity","score_opus":0.006691807101830577,"score_gpt":0.21757832562927343,"score_spread":0.21088651852744286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299595115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973843,0.00058051076,6.3822984e-7,0.00033867708,0.00014862203,0.0009389088,0.0000076604765,0.000053306954,0.0005473394],"genre_scores_gemma":[0.998644,0.00039841747,0.00019462043,0.00020663899,0.000052174753,0.0000838575,0.000045110115,0.000050706007,0.00032445646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985205,0.000046405134,0.0002142944,0.00042557134,0.00028643728,0.0005068241],"domain_scores_gemma":[0.99922913,0.0001949535,0.000083921834,0.00031539044,0.000059590566,0.00011703124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013644443,0.00029726216,0.0004184084,0.0003204492,0.000036697442,0.000021390659,0.0000742106,0.00007080156,0.00005240702],"category_scores_gemma":[0.000033892306,0.00016389914,0.000027231215,0.00036523087,0.00009782721,0.00016806676,0.000018717235,0.00009895336,0.000014697627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00411349,0.0008010287,0.8742461,0.00003215421,0.00042476406,0.000026802067,0.00013269219,0.000012818891,0.0015656048,0.00006463026,0.00014424617,0.11843564],"study_design_scores_gemma":[0.0518069,0.02176671,0.89747566,0.0010003123,0.00021153443,3.3835775e-7,0.000074795964,0.00015005823,0.01872161,0.000110391906,0.007985676,0.00069601],"about_ca_topic_score_codex":0.000046144305,"about_ca_topic_score_gemma":0.000119049604,"teacher_disagreement_score":0.11773963,"about_ca_system_score_codex":0.00022017406,"about_ca_system_score_gemma":0.000038255854,"threshold_uncertainty_score":0.6683613},"labels":[],"label_agreement":null},{"id":"W2301357986","doi":"10.1111/dom.12661","title":"Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( <scp>BEGIN</scp> : <scp>ADD TO GLP</scp> ‐1 <scp>S</scp> tudy)","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Placebo; Metformin; Insulin degludec; Type 2 diabetes; Internal medicine; Diabetes mellitus; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.0085891965301117,"score_gpt":0.23521407583377166,"score_spread":0.22662487930365996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301357986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965433,0.0053492966,0.000026134156,0.00007986185,0.00037728963,0.02735892,0.00007281908,0.00012828542,0.0011744123],"genre_scores_gemma":[0.99026597,0.00066217914,0.000653979,0.00029236788,0.00021231812,0.0050030667,0.000102520666,0.00012206377,0.002685518],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938281,0.0009151107,0.00145266,0.001255244,0.0009877755,0.0015610765],"domain_scores_gemma":[0.9867974,0.01026246,0.0007885063,0.0007351491,0.00044994833,0.0009665389],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002934568,0.0013104309,0.007229191,0.0013628701,0.00021771871,0.00017710461,0.00028840452,0.00032819502,0.000011980564],"category_scores_gemma":[0.0059033707,0.00069331547,0.00054056244,0.0010994809,0.0003200713,0.00047972167,0.00024360865,0.00025924837,0.000032237567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7367414,0.005704085,0.2064125,0.0006761537,0.013992057,0.00006059951,0.0035956053,0.00003197199,0.0015935412,0.00059088756,0.0007405898,0.029860592],"study_design_scores_gemma":[0.92962164,0.012341154,0.029817985,0.00073675555,0.0075408802,6.5981084e-7,0.00016847317,0.000057251604,0.014592452,0.000056075838,0.0048837606,0.00018292008],"about_ca_topic_score_codex":0.00008763938,"about_ca_topic_score_gemma":0.00008808345,"teacher_disagreement_score":0.19288021,"about_ca_system_score_codex":0.00018978193,"about_ca_system_score_gemma":0.00018465068,"threshold_uncertainty_score":0.9999647},"labels":[],"label_agreement":null},{"id":"W2307058739","doi":"10.1016/j.jcjd.2015.11.005","title":"Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; Canada Research Chairs; Janssen Research and Development; American Diabetes Association","keywords":"Canagliflozin; Medicine; Placebo; Glycated hemoglobin; Glycemic; Body mass index; Renal function; Internal medicine; Adverse effect; Diabetes mellitus; Type 2 diabetes; Blood pressure; Endocrinology","score_opus":0.0435796171113577,"score_gpt":0.33837318066583527,"score_spread":0.29479356355447756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307058739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968246,0.0020775276,0.0000027166639,0.00070955575,0.000044122276,0.00018807457,0.00006448995,0.0000017026445,0.00008719619],"genre_scores_gemma":[0.99943113,0.00038134877,0.00005257845,0.00006565014,0.000021660931,0.0000013253122,0.0000055396413,0.000007419345,0.000033322616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878234,0.000110995796,0.0006908717,0.00010800213,0.00013087211,0.00017692473],"domain_scores_gemma":[0.9979881,0.00079257524,0.00054433313,0.00017742021,0.00023526452,0.0002623164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000687205,0.00012376574,0.0008500557,0.00045149453,0.00003353515,0.0000068093796,0.00007023638,0.00004377286,0.000039241597],"category_scores_gemma":[0.0010722661,0.000061801584,0.00022501142,0.0003439734,0.00032784097,0.00005831158,0.000011305889,0.00006782056,2.4701592e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028085583,0.000087344815,0.9564574,0.00008497184,0.019218655,0.000024293317,0.0003032074,0.00006488371,0.003148584,0.0001449193,0.00048318016,0.019701717],"study_design_scores_gemma":[0.0029077989,0.002190214,0.98744154,0.0006085836,0.005747348,4.119487e-7,0.00010202318,0.00011921176,0.00073291536,0.00005593149,0.000034919012,0.00005908483],"about_ca_topic_score_codex":0.0005805417,"about_ca_topic_score_gemma":0.002238978,"teacher_disagreement_score":0.03098417,"about_ca_system_score_codex":0.00007322559,"about_ca_system_score_gemma":0.00026816997,"threshold_uncertainty_score":0.25201955},"labels":[],"label_agreement":null},{"id":"W2307508267","doi":"10.1038/ijo.2016.52","title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","year":2016,"lang":"en","type":"article","venue":"International Journal of Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":530,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Sleep Institute; University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Obstructive sleep apnea; Liraglutide; Sleep apnea; Randomized controlled trial; Obesity; Apnea; Sleep (system call); Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.014491998755731388,"score_gpt":0.30543669124622985,"score_spread":0.2909446924904985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307508267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542785,0.00011418128,0.00132138,0.0012335096,0.00051689934,0.0009763883,0.000015434096,0.0000074754175,0.0003868687],"genre_scores_gemma":[0.9984271,0.00010768257,0.000777321,0.00011962079,0.00030575466,0.00001783661,0.000003149789,0.000011337144,0.00023021456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742013,0.0007169288,0.00084419193,0.00019641804,0.00065410335,0.00016821963],"domain_scores_gemma":[0.9962797,0.0024312248,0.0007128771,0.00015700876,0.00031113546,0.00010805203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035792496,0.00018932576,0.0009840224,0.00018111184,0.00003950725,0.000033501237,0.0002501372,0.00008122841,0.000058296006],"category_scores_gemma":[0.0009469161,0.000077821,0.0002726799,0.000090061374,0.0002949692,0.0002444433,0.00012420984,0.00022759807,0.00000410413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5112682,0.00079441484,0.42667645,0.00003031624,0.0024603505,0.00013771419,0.00023081491,0.000019058753,0.000038566694,0.0001222916,0.000082922146,0.058138926],"study_design_scores_gemma":[0.77130544,0.0037856393,0.21942686,0.0004174028,0.001175602,0.00014532052,0.00006272988,0.0006268895,0.0019868873,0.000801042,0.00011530552,0.00015091241],"about_ca_topic_score_codex":0.000020821331,"about_ca_topic_score_gemma":0.000024133851,"teacher_disagreement_score":0.2600372,"about_ca_system_score_codex":0.00010423762,"about_ca_system_score_gemma":0.00006357165,"threshold_uncertainty_score":0.31734484},"labels":[],"label_agreement":null},{"id":"W2308305952","doi":"10.2337/db15-1141","title":"Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis","year":2016,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Heart and Stroke Foundation; Canadian Blood Services; University of Toronto; University Health Network; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Merck Canada; Heart and Stroke Foundation of Canada; Merck","keywords":"Exenatide; Internal medicine; Endocrinology; Medicine; Platelet; Agonist; Bone marrow; Thrombus; In vivo; Thrombin; Ex vivo; Receptor; Biology; Type 2 diabetes; Diabetes mellitus","score_opus":0.016005988821578013,"score_gpt":0.2434756642068601,"score_spread":0.22746967538528207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308305952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946759,0.000119524135,0.000024550678,0.0031672725,0.00012202551,0.00033740955,0.000007817113,0.000107778986,0.0014377715],"genre_scores_gemma":[0.9957369,0.0002515215,0.00055884547,0.00054923084,0.000103493825,0.000070015354,0.00007549027,0.000022093684,0.0026324003],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921525,0.000018266808,0.0001406706,0.00024224653,0.00014828752,0.0002352771],"domain_scores_gemma":[0.9995061,0.00011999277,0.00006921066,0.00017522988,0.000048784943,0.00008066936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095907926,0.00014320973,0.00019929469,0.000096706935,0.000060076865,0.00002465352,0.000037227794,0.000054563134,0.0001629926],"category_scores_gemma":[0.00006936466,0.00009158649,0.000045198973,0.00009920799,0.000059664242,0.00024360348,0.000037397767,0.00003334661,0.00014268918],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026577572,0.00015048149,0.384412,0.00010521954,0.00036709753,7.002244e-7,0.00014803311,1.9752314e-7,0.21347144,0.00037262536,0.016457405,0.38448822],"study_design_scores_gemma":[0.002252859,0.00039103066,0.15018976,0.00058863463,0.00015976955,1.738002e-7,0.00007495478,0.000031362,0.8042836,0.00037325502,0.04143568,0.00021888061],"about_ca_topic_score_codex":0.000008110933,"about_ca_topic_score_gemma":0.0000011404923,"teacher_disagreement_score":0.5908122,"about_ca_system_score_codex":0.00006343228,"about_ca_system_score_gemma":0.000010319739,"threshold_uncertainty_score":0.37347886},"labels":[],"label_agreement":null},{"id":"W2309242694","doi":"10.2337/dc15-2322","title":"Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON","year":2016,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Kidney disease; Diabetes mellitus; Dialysis; Hazard ratio; Internal medicine; Intensive care medicine; Type 2 diabetes; Randomized controlled trial; Cause of death; Disease; Endocrinology; Confidence interval","score_opus":0.010517971650343308,"score_gpt":0.2551768059825687,"score_spread":0.2446588343322254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309242694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921386,0.0026800064,0.000087572684,0.0008898292,0.0002853824,0.0017071592,0.001680782,0.00007391496,0.00045673898],"genre_scores_gemma":[0.99490863,0.0000964005,0.0001122837,0.0018158649,0.00014678095,0.0003519074,0.00047845978,0.00004229601,0.0020473609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877805,0.000019420346,0.00024570565,0.00033892272,0.00021168884,0.0004062303],"domain_scores_gemma":[0.9984922,0.00018525131,0.0001492918,0.00039382448,0.0005069046,0.00027257332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006370456,0.00021982427,0.00040713884,0.00010913476,0.000045352725,0.000010297094,0.00010025947,0.00004445548,0.00012204047],"category_scores_gemma":[0.000536533,0.00014858533,0.00024572015,0.00006924227,0.000060960367,0.00010264613,0.00004980113,0.000038824975,0.000037972226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028555666,0.00015910005,0.82479125,0.0012436782,0.00039583148,0.000008151091,0.00012545168,0.0000051836982,0.0032806613,0.00064103806,0.001213371,0.16785075],"study_design_scores_gemma":[0.018867264,0.0020904995,0.84723294,0.0054126275,0.0018171899,1.4845403e-7,0.00038530445,0.000039863546,0.107900634,0.00011174349,0.01565512,0.00048668502],"about_ca_topic_score_codex":6.2304053e-7,"about_ca_topic_score_gemma":0.0000018452484,"teacher_disagreement_score":0.16736406,"about_ca_system_score_codex":0.0000943159,"about_ca_system_score_gemma":0.00004292796,"threshold_uncertainty_score":0.6059134},"labels":[],"label_agreement":null},{"id":"W2309442115","doi":"10.1111/jdi.12480","title":"Discovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflections","year":2016,"lang":"en","type":"review","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Gastric inhibitory polypeptide; Incretin; Dipeptidyl peptidase; Islet; Gastric acid; Medicine; Internal medicine; Endocrinology; Somatostatin; Glucagon-like peptide-1; Secretion; Dipeptidyl peptidase-4; Diabetes mellitus; Type 2 diabetes; Insulin; Glucagon; Enzyme; Biochemistry; Chemistry","score_opus":0.05200852060653297,"score_gpt":0.317076692176275,"score_spread":0.265068171569742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309442115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035580423,0.96307087,0.000010120735,0.00017393012,0.00038870607,0.00045593316,0.000030118053,0.000011287209,0.0002785866],"genre_scores_gemma":[0.006781689,0.9911255,0.00037136892,0.000068163754,0.00056486914,0.000021497837,0.000042710286,0.000040257873,0.000983898],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980891,0.00012198246,0.00094765984,0.00019505761,0.0004175996,0.00022859946],"domain_scores_gemma":[0.9979171,0.00015827714,0.0014075226,0.00013610831,0.00020160415,0.00017935704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039802404,0.00029862075,0.001266559,0.000719364,0.00004762747,0.000035151843,0.000086746295,0.00015718339,0.000016471056],"category_scores_gemma":[0.00020191741,0.0001921679,0.00044141212,0.00031928,0.00013543713,0.00043102767,0.00005200287,0.0002705141,0.000009257974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031254505,0.00040781815,0.0050674025,0.03784218,0.0041361107,0.00004108329,0.0003106456,5.6574777e-7,0.0059706173,0.00083578867,0.0045852624,0.9407713],"study_design_scores_gemma":[0.0049622077,0.0053538173,0.0041018017,0.24066378,0.023676569,0.00022683856,0.0001722532,0.00002329202,0.0067479834,0.0013457544,0.7115515,0.0011742334],"about_ca_topic_score_codex":9.066108e-7,"about_ca_topic_score_gemma":5.08253e-7,"teacher_disagreement_score":0.939597,"about_ca_system_score_codex":0.00030617634,"about_ca_system_score_gemma":0.00040658624,"threshold_uncertainty_score":0.783638},"labels":[],"label_agreement":null},{"id":"W2310500953","doi":"10.1111/jgs.14028","title":"Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis","year":2016,"lang":"en","type":"article","venue":"Journal of the American Geriatrics Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Janssen Research and Development; Mitsubishi Tanabe Pharma Corporation; Sanofi","keywords":"Canagliflozin; Medicine; Placebo; Internal medicine; Diabetes mellitus; Incidence (geometry); Adverse effect; Type 2 diabetes; Randomized controlled trial; Blood pressure; Type 2 Diabetes Mellitus; Gastroenterology; Endocrinology","score_opus":0.005767148805116744,"score_gpt":0.23408521606308827,"score_spread":0.22831806725797152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2310500953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542946,0.0021749581,0.00004711084,0.0020655624,0.000030837455,0.00020993453,0.0000063100633,0.000004131177,0.00003171807],"genre_scores_gemma":[0.99205685,0.0052774497,0.0021663525,0.00032117666,0.000041967727,0.0000017106522,9.928577e-7,0.000011532138,0.00012196969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989147,0.00008575891,0.0003661431,0.00013502245,0.0003063355,0.00019199373],"domain_scores_gemma":[0.9986968,0.00021385493,0.0006898507,0.00019896116,0.00010332221,0.0000972076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005587939,0.00013138149,0.00064607704,0.00016256276,0.000040947845,0.000014616085,0.00010502961,0.000028263543,0.0000118754215],"category_scores_gemma":[0.00008336758,0.00006235899,0.00018976218,0.0012921796,0.0002493231,0.00006711528,0.00008030856,0.00010797012,2.0470742e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001764933,0.00017853115,0.97694665,0.000042825228,0.005026901,0.0000036902163,0.00085970835,0.000017626777,0.0013526606,0.000010956634,0.0010041056,0.014379858],"study_design_scores_gemma":[0.0037319867,0.0005891061,0.98956835,0.00011006906,0.0047675935,0.0000024114988,0.00043578204,0.000016089409,0.00025442414,0.000028121776,0.00041048677,0.00008556814],"about_ca_topic_score_codex":0.00008268568,"about_ca_topic_score_gemma":0.000017748796,"teacher_disagreement_score":0.01429429,"about_ca_system_score_codex":0.00009312978,"about_ca_system_score_gemma":0.0000689601,"threshold_uncertainty_score":0.25429258},"labels":[],"label_agreement":null},{"id":"W2311186584","doi":"10.1111/dom.12666","title":"Long‐term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; AstraZeneca (Canada); St. Michael's Hospital","funders":"National Institutes of Health; Servier; National Institute of General Medical Sciences; Intarcia Therapeutics; Sanofi; MannKind Corporation; AstraZeneca","keywords":"Dapagliflozin; Medicine; Type 2 Diabetes Mellitus; Disease; Diabetes mellitus; Term (time); Internal medicine; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.005550549728598769,"score_gpt":0.19105456191078776,"score_spread":0.18550401218218898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311186584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816356,0.017554795,0.0000061873834,0.000045207344,0.00006783291,0.0005636128,0.000032456224,0.00001501259,0.00007932011],"genre_scores_gemma":[0.9977124,0.0019430413,0.00013017481,0.00004783981,0.00002346374,0.0000145342265,0.000023793573,0.000017108396,0.00008765522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998811,0.000050624843,0.00023640419,0.00032283456,0.00027016088,0.0003089682],"domain_scores_gemma":[0.9991444,0.00006967538,0.000084591615,0.00040371495,0.00011701277,0.00018062723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021314697,0.00019477883,0.0006883311,0.00015580669,0.000022902594,0.000007603722,0.00006662637,0.00004612686,0.00001439768],"category_scores_gemma":[0.00009622805,0.00011742147,0.00010531327,0.00018397708,0.00022323945,0.00013262757,0.00008279321,0.00004744641,0.0000020107786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015418125,0.000583426,0.9443132,0.00035863748,0.00079042814,0.0000037775462,0.000058923608,0.000001061607,0.00020411206,0.00019384843,0.000015388094,0.053322986],"study_design_scores_gemma":[0.006894741,0.00020922265,0.9879102,0.00053534744,0.0012373729,3.0450533e-8,0.0000044433214,0.000003706983,0.0024333005,0.00007076576,0.00055959687,0.00014123513],"about_ca_topic_score_codex":0.00000827602,"about_ca_topic_score_gemma":0.0000019682714,"teacher_disagreement_score":0.053181753,"about_ca_system_score_codex":0.0000133731755,"about_ca_system_score_gemma":0.000021705766,"threshold_uncertainty_score":0.47883087},"labels":[],"label_agreement":null},{"id":"W2311523609","doi":"10.1016/s2213-8587(16)00049-8","title":"Heart failure event definitions in drug trials in patients with type 2 diabetes","year":2016,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Saxagliptin; Heart failure; Diabetes mellitus; Myocardial infarction; Type 2 diabetes; Type 2 Diabetes Mellitus; Internal medicine; Intensive care medicine; Stroke (engine); Sitagliptin; Endocrinology","score_opus":0.03372443033758165,"score_gpt":0.2737029513498433,"score_spread":0.23997852101226164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311523609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97954553,0.0004188093,9.552474e-7,0.017842947,0.00016629315,0.00095707143,0.00002621919,0.0000750754,0.0009670873],"genre_scores_gemma":[0.99702895,0.00013843922,0.00026691883,0.0018327493,0.00012606978,0.00028206847,0.000059688202,0.000027605414,0.00023748641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974423,0.0003825204,0.000459877,0.00032695621,0.00018547791,0.0012028464],"domain_scores_gemma":[0.9984199,0.0008089371,0.00012366314,0.00052638043,0.000056288878,0.000064863554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007208455,0.00023368663,0.0010588248,0.00025009,0.00004325206,0.0000145033355,0.00018332204,0.000049504015,0.00018850503],"category_scores_gemma":[0.0003674168,0.000115069946,0.00009178325,0.0003212243,0.00014935594,0.00009147091,0.00010343656,0.00017331098,0.00018605845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014160719,0.00038185448,0.9843984,0.000034042216,0.00019775766,0.0000069296393,0.00005350268,0.0000039817055,0.0003062168,0.0019296724,0.007404915,0.0051410687],"study_design_scores_gemma":[0.01065674,0.0006947689,0.9569046,0.000326211,0.00018706579,3.7898758e-7,0.00003908513,0.0000041146263,0.0017735495,0.0021037967,0.027117632,0.00019204263],"about_ca_topic_score_codex":0.000018015075,"about_ca_topic_score_gemma":0.00018174133,"teacher_disagreement_score":0.027493836,"about_ca_system_score_codex":0.000116021874,"about_ca_system_score_gemma":0.00003511875,"threshold_uncertainty_score":0.46924162},"labels":[],"label_agreement":null},{"id":"W2311957294","doi":"10.1016/j.jval.2015.03.366","title":"Evaluating the Cost of Bringing People with type 2 Diabetes mellitus to multiple targets of Treatment In Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Exenatide; Sitagliptin; Pioglitazone; Glycemic; Type 2 diabetes; Insulin glargine; Insulin detemir; Internal medicine; Sulfonylurea; Hypoglycemia; Diabetes mellitus; Endocrinology; Insulin","score_opus":0.07310793442859402,"score_gpt":0.32670698901806644,"score_spread":0.2535990545894724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311957294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566346,0.0016999925,0.00000506449,0.0009341523,0.000086868575,0.0013918887,0.0000056301733,0.0000054216007,0.00020752897],"genre_scores_gemma":[0.9982185,0.000069709014,0.001377415,0.0001694379,0.000013483455,0.00006599642,0.000011997564,0.000011597954,0.00006187054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890244,0.00009591142,0.00031415772,0.00014764552,0.00025318033,0.0002866389],"domain_scores_gemma":[0.9992998,0.00018774557,0.00011139655,0.00021613917,0.00006222466,0.00012267962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005830662,0.00009926774,0.00035064388,0.000100400845,0.000016271913,0.0000024470646,0.00005417674,0.000011467765,0.0000059167855],"category_scores_gemma":[0.00013462082,0.000062942585,0.000015966056,0.00037430774,0.000011208019,0.000019811692,0.0000251172,0.000043306114,0.0000013278307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012988839,0.00017033628,0.90931433,0.00022984754,0.0000521469,0.000004041159,0.0026884093,0.06849351,0.000057337264,0.00003347145,0.0001095343,0.018717157],"study_design_scores_gemma":[0.00958252,0.011867617,0.7976474,0.0018271906,0.00012395169,0.0000014222434,0.0046887775,0.16807708,0.0034323575,0.00005604232,0.0024487844,0.00024685217],"about_ca_topic_score_codex":0.90777874,"about_ca_topic_score_gemma":0.76376206,"teacher_disagreement_score":0.14401665,"about_ca_system_score_codex":0.0016134725,"about_ca_system_score_gemma":0.0019232351,"threshold_uncertainty_score":0.42191747},"labels":[],"label_agreement":null},{"id":"W2312302971","doi":"10.1097/00024382-200403001-00444","title":"ADJUNCTIVE THERAPY AND RECOMBINANT HUMAN ACTIVATED PROTEIN C.","year":2004,"lang":"en","type":"article","venue":"Shock","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services","funders":"","keywords":"Recombinant DNA; Adjunctive treatment; Medicine; Chemistry; Internal medicine; Biochemistry","score_opus":0.023569095385875077,"score_gpt":0.2637043156397645,"score_spread":0.24013522025388942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312302971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879291,0.00022180194,0.000011902289,0.0009680117,0.000042781223,0.00079135096,6.1939187e-7,0.000067296714,0.009967157],"genre_scores_gemma":[0.9940115,0.000038952945,0.00043280664,0.00023053495,0.00002831745,0.00004278082,0.000020210886,0.000013275469,0.0051816055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995472,0.000007945584,0.00007110277,0.00015447765,0.000082288745,0.000137004],"domain_scores_gemma":[0.9997665,0.0000032537082,0.000023797567,0.00013191163,0.000019488043,0.00005499847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003773781,0.00009280149,0.00013130723,0.000047327307,0.00005287276,0.000010991732,0.00002339154,0.00002978814,0.0000651252],"category_scores_gemma":[0.0000045691113,0.000066297776,0.00002853979,0.00006951455,0.000027128695,0.00004618673,0.000019494726,0.000053277192,0.000021033067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010376031,0.0028794957,0.008745157,0.00018802537,0.0015244983,0.00024974725,0.0021184292,0.0000034085997,0.54961836,0.03290191,0.0033430923,0.39739025],"study_design_scores_gemma":[0.035590425,0.008222844,0.19991131,0.00061309827,0.0002296711,0.000010013259,0.00036861096,0.000007975773,0.6423007,0.032928556,0.079240635,0.00057616143],"about_ca_topic_score_codex":0.000056312634,"about_ca_topic_score_gemma":0.0000072493744,"teacher_disagreement_score":0.39681408,"about_ca_system_score_codex":0.000063112,"about_ca_system_score_gemma":0.000015630587,"threshold_uncertainty_score":0.27035448},"labels":[],"label_agreement":null},{"id":"W2312319918","doi":"10.1055/s-0035-1549743","title":"IDegLira bei Patienten mit Typ 2 Diabetes: Wirksamkeit und Sicherheit nach 1 Jahr","year":2015,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Gynecology; Insulin degludec; Type 2 diabetes; Diabetes mellitus; Insulin glargine; Endocrinology","score_opus":0.052298573659798016,"score_gpt":0.30482477281447395,"score_spread":0.25252619915467595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312319918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4852663,0.43138203,0.0002009233,0.0052600284,0.013821386,0.0042272927,0.00044083296,0.0012452264,0.05815599],"genre_scores_gemma":[0.94446105,0.007022672,0.0039314856,0.008874505,0.0042903074,0.0010029138,0.0036109297,0.0006618649,0.026144287],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913754,0.00051007804,0.0015410163,0.001959107,0.0015802525,0.0030341889],"domain_scores_gemma":[0.9940076,0.0007120299,0.0007323871,0.00226697,0.0007179632,0.0015630559],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001390907,0.0015993292,0.002354137,0.0007386288,0.00035005034,0.0003353574,0.001180949,0.0010063887,0.00041147476],"category_scores_gemma":[0.0015268436,0.0014380983,0.00070543564,0.0012576657,0.00075060694,0.0005886266,0.00096520217,0.0010876121,0.007986879],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052324944,0.005670549,0.51331806,0.0010948307,0.026342856,0.000703372,0.0022093828,0.00013447032,0.00014950629,0.004415758,0.28938776,0.15605019],"study_design_scores_gemma":[0.0119835185,0.00548162,0.019001577,0.00094207696,0.018997682,6.1622484e-7,0.0012358616,0.0018629003,0.001804891,0.0027124872,0.9337156,0.0022611716],"about_ca_topic_score_codex":0.0001870917,"about_ca_topic_score_gemma":0.000039772072,"teacher_disagreement_score":0.6443278,"about_ca_system_score_codex":0.0012878445,"about_ca_system_score_gemma":0.0006303047,"threshold_uncertainty_score":0.99967545},"labels":[],"label_agreement":null},{"id":"W2312778649","doi":"10.1016/s1499-2671(08)24117-1","title":"Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-Daily Human GLP- 1 Analog, Compared With Glimepiride: All as Monotherapy In Type 2 Diabetes.","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glimepiride; Medicine; Lira; Liraglutide; Nausea; Glycemic; Hypoglycemia; Internal medicine; Weight loss; Type 2 diabetes; Adverse effect; Vomiting; Diabetes mellitus; Endocrinology; Gastroenterology; Obesity","score_opus":0.013509296136836418,"score_gpt":0.22269187767107995,"score_spread":0.20918258153424354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312778649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379796,0.0029963376,0.0000029898167,0.0018899179,0.00010392017,0.0004827537,0.000009516639,0.000016216361,0.00070039596],"genre_scores_gemma":[0.9968888,0.00008958606,0.00032566898,0.002207961,0.00018298799,0.000017167207,0.000026419679,0.000050239832,0.00021117779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982861,0.00006712568,0.00045092808,0.00028831736,0.00027290196,0.00063457375],"domain_scores_gemma":[0.998499,0.00005051322,0.00028221178,0.00024030304,0.00022036636,0.00070761144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001819716,0.00031151867,0.00071918225,0.00066447625,0.00013545436,0.000050154977,0.00013751604,0.00008661494,0.00007018404],"category_scores_gemma":[0.00001723913,0.00023012269,0.00007254495,0.0003789643,0.00034203645,0.00026090012,0.0000061250375,0.00030283947,0.000007740335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045252478,0.00014137325,0.9853569,0.000053406613,0.0012901779,0.0004996388,0.00063946354,0.00006486805,0.0042585684,0.00003280486,0.004500567,0.0027096546],"study_design_scores_gemma":[0.03324856,0.0140687125,0.92609006,0.0011976575,0.0013052119,0.00012138059,0.00040961883,0.00021727663,0.0035812596,0.00025373008,0.018663794,0.0008427128],"about_ca_topic_score_codex":0.000676787,"about_ca_topic_score_gemma":0.0032270928,"teacher_disagreement_score":0.05926687,"about_ca_system_score_codex":0.0002873943,"about_ca_system_score_gemma":0.0005492218,"threshold_uncertainty_score":0.9384131},"labels":[],"label_agreement":null},{"id":"W2312861434","doi":"10.1016/j.jcjd.2015.01.182","title":"Additional Analyses of the Weight-lowering Efficacy of Liraglutide 3.0 mg in Adults with Overweight and Obesity: The SCALE Obesity and Prediabetes Randomized Trial","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prediabetes; Liraglutide; Overweight; Obesity; Randomized controlled trial; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.01252833753107599,"score_gpt":0.22689312993497873,"score_spread":0.21436479240390274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312861434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959178,0.0021192748,9.992609e-7,0.00043695862,0.0001112546,0.00070695055,0.00018451946,0.000002572062,0.0005196544],"genre_scores_gemma":[0.99943364,0.00003517596,0.00020351988,0.00008269342,0.0001197117,0.000017343491,0.00002295019,0.0000113480455,0.00007363066],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99868715,0.0001415851,0.00048122954,0.0001346807,0.00030455357,0.000250774],"domain_scores_gemma":[0.9981234,0.0007518209,0.00040318927,0.00018680021,0.00019729804,0.00033748447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064060313,0.0001619387,0.0007500948,0.00026230974,0.000062456835,0.000023345929,0.00013909662,0.000051531497,0.00013931966],"category_scores_gemma":[0.00068509544,0.00008203367,0.00015398774,0.0002543897,0.00051827176,0.00013203421,0.000033856526,0.00015886518,3.1070184e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025680488,0.00041609604,0.9601135,0.00031110007,0.0016752848,0.000020234831,0.0016577339,0.000028423978,0.000116608935,0.000122017685,0.0073016607,0.0025568495],"study_design_scores_gemma":[0.49960208,0.0013704591,0.48888615,0.002919187,0.0015725249,0.0000052227415,0.00041067842,0.00020910027,0.0034695459,0.0005406291,0.0008266722,0.00018774947],"about_ca_topic_score_codex":0.0003666635,"about_ca_topic_score_gemma":0.0026957486,"teacher_disagreement_score":0.4739216,"about_ca_system_score_codex":0.00007616824,"about_ca_system_score_gemma":0.00049098564,"threshold_uncertainty_score":0.33452362},"labels":[],"label_agreement":null},{"id":"W2313109089","doi":"10.1016/j.cjca.2016.07.182","title":"EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Type 2 diabetes; Placebo; Diabetes mellitus; Internal medicine; Adverse effect; Benzhydryl compounds; Endocrinology; Alternative medicine","score_opus":0.008367515142909622,"score_gpt":0.21583415092349947,"score_spread":0.20746663578058985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313109089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985343,0.0007056971,0.0000038779417,0.000024338036,0.00013950937,0.00020924609,0.000032307013,0.0000013605669,0.00034933316],"genre_scores_gemma":[0.9997457,0.00013326047,0.000015247463,0.000013998757,0.00005700161,0.0000023218406,0.000004283676,0.00000995091,0.000018226821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999104,0.00021442841,0.00023046481,0.00011181476,0.00014226465,0.00019700002],"domain_scores_gemma":[0.9991766,0.00014259444,0.00014964775,0.0002110851,0.00012389809,0.00019617126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004694576,0.00011235915,0.0007832614,0.000244558,0.000015577229,0.0000015919388,0.00004989421,0.00005791172,0.000008198464],"category_scores_gemma":[0.00018800421,0.00006139495,0.00014364083,0.000078361976,0.0001237513,0.000031513213,0.000011071614,0.000062738276,0.0000011706884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002717932,0.000005637503,0.9919508,0.00005530796,0.0020953454,0.000050482868,0.000017053817,0.00007598668,0.000023014443,0.000013908184,0.00016278372,0.0052778698],"study_design_scores_gemma":[0.004028025,0.0061285347,0.9858322,0.00018601997,0.0012038638,0.0000022460401,0.0000029713292,2.3658694e-7,0.001447477,0.000017343473,0.0010949105,0.000056166733],"about_ca_topic_score_codex":0.000693934,"about_ca_topic_score_gemma":0.0006655449,"teacher_disagreement_score":0.0061228974,"about_ca_system_score_codex":0.00015245497,"about_ca_system_score_gemma":0.000106583444,"threshold_uncertainty_score":0.25036135},"labels":[],"label_agreement":null},{"id":"W2313139583","doi":"10.1055/s-0032-1325427","title":"Glucagon-like Peptide-1 (GLP-1): 25 Jahre Ansporn für die Diabetesforschung","year":2012,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemistry; Molecular biology; Stereochemistry; Biology","score_opus":0.027539984448387407,"score_gpt":0.30093008661188997,"score_spread":0.27339010216350257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313139583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58908844,0.34528786,0.0002605494,0.0023580072,0.016660752,0.0036587133,0.00039296725,0.0012759309,0.041016787],"genre_scores_gemma":[0.9475981,0.015571622,0.0020057028,0.003629097,0.003673064,0.0005558998,0.0018668183,0.00037292758,0.024726793],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.990096,0.00038858675,0.0016214056,0.0016591793,0.0013051914,0.004929641],"domain_scores_gemma":[0.9940556,0.0008344223,0.0007640368,0.0023876273,0.0002890771,0.0016692184],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016367269,0.0018293434,0.0025677327,0.0008146613,0.00065859046,0.00024218891,0.001092182,0.0010611071,0.00087423634],"category_scores_gemma":[0.00056131533,0.0016343326,0.0010058959,0.0009893297,0.00072501076,0.001086482,0.00084275607,0.0012326853,0.009015992],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023904834,0.0050820904,0.7488417,0.0014724621,0.00955737,0.00040031117,0.0015674974,0.000016991651,0.00048255286,0.005147772,0.09440122,0.13279097],"study_design_scores_gemma":[0.005391475,0.0013461623,0.15688485,0.0007545196,0.010467276,0.0000019647841,0.0008921614,0.00024362207,0.0031163045,0.000519007,0.8184396,0.0019430723],"about_ca_topic_score_codex":0.00014320061,"about_ca_topic_score_gemma":0.000033459248,"teacher_disagreement_score":0.72403836,"about_ca_system_score_codex":0.0009897273,"about_ca_system_score_gemma":0.00031639825,"threshold_uncertainty_score":0.99944514},"labels":[],"label_agreement":null},{"id":"W2314177323","doi":"10.1016/s1499-2671(09)33130-5","title":"Incidence of urinary tract infections and of genital infections in two T2DM populations cotreated with dapagliflozin and oral antidiabetics +/− insulin","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Urinary system; Incidence (geometry); Glycemic; Insulin; Population; Epidemiology; Sex organ; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Biology; Environmental health","score_opus":0.014309855839465825,"score_gpt":0.2610773889856762,"score_spread":0.24676753314621036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314177323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997926,0.0010925488,0.000007443401,0.00034054788,0.00004396091,0.00021034486,0.000025971302,0.0000043353175,0.00034883837],"genre_scores_gemma":[0.9991771,0.00006402009,0.00063486863,0.000053885884,0.000020770007,0.000002316381,0.000010793885,0.0000091186985,0.000027145805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916965,0.00003733854,0.0003765468,0.00010064383,0.00010735971,0.00020844703],"domain_scores_gemma":[0.9991655,0.00006101972,0.00019946438,0.000106800835,0.00016786323,0.00029934832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014973672,0.00012651515,0.000373871,0.0007646972,0.000057727335,0.000016607462,0.000040353145,0.000039835882,0.000016396156],"category_scores_gemma":[0.00010637472,0.00010791897,0.00004594071,0.00043356055,0.00015803264,0.0002189862,0.000007466408,0.00014516391,3.2442966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006345463,0.00048379114,0.99475616,0.000034731343,0.00009632191,0.000031655345,0.00022159769,0.00012334913,0.00036092385,0.00018674403,0.000044390064,0.003654013],"study_design_scores_gemma":[0.0020362402,0.004009683,0.9921505,0.00034023362,0.0003414088,0.00003959181,0.00010522123,0.00015332778,0.00042760358,0.00022129752,0.00008262082,0.000092265334],"about_ca_topic_score_codex":0.0010851702,"about_ca_topic_score_gemma":0.010461284,"teacher_disagreement_score":0.009376113,"about_ca_system_score_codex":0.00007002732,"about_ca_system_score_gemma":0.00027147427,"threshold_uncertainty_score":0.5837642},"labels":[],"label_agreement":null},{"id":"W2314298979","doi":"10.1016/s1262-3636(16)30128-8","title":"CAD-32: Évaluation de Lixisenatide dans le syndrome coronarien aigu (ELIXA : Evaluation of LIXisenatide in Acute Coronary Syndrome)","year":2016,"lang":"fr","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université de Montréal","funders":"","keywords":"Medicine; Gynecology","score_opus":0.01944442493101066,"score_gpt":0.27199899391074095,"score_spread":0.2525545689797303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314298979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94873244,0.038625408,0.00019098089,0.004244911,0.0025545552,0.0027935,0.00022347366,0.00009709985,0.0025376554],"genre_scores_gemma":[0.9821747,0.0026878011,0.001596405,0.00036264557,0.00018655637,0.0007345674,0.00027234625,0.00013992305,0.011845079],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9923047,0.0015040806,0.0014634351,0.0010320042,0.0020172868,0.001678521],"domain_scores_gemma":[0.99650496,0.0006737399,0.0006726084,0.0010887755,0.00060259807,0.0004572867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00531637,0.0007990574,0.0016204666,0.0008944142,0.00014489813,0.000056189285,0.00050623383,0.0004275769,0.0011353793],"category_scores_gemma":[0.0007911326,0.0006901191,0.00042605205,0.00093568076,0.00054244505,0.0010122262,0.00028985325,0.0003190235,0.0004217899],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018040881,0.003229833,0.4480483,0.0007106018,0.0047473735,0.0006580394,0.004683196,0.0005252948,0.061794702,0.010965442,0.001980566,0.46247625],"study_design_scores_gemma":[0.012072707,0.00062872947,0.94099486,0.0022051157,0.007447144,0.000062530184,0.00067095755,0.004731092,0.021083295,0.006339949,0.003042008,0.000721616],"about_ca_topic_score_codex":0.00048244934,"about_ca_topic_score_gemma":0.00010472652,"teacher_disagreement_score":0.49294657,"about_ca_system_score_codex":0.0014180129,"about_ca_system_score_gemma":0.0009987203,"threshold_uncertainty_score":0.99977773},"labels":[],"label_agreement":null},{"id":"W2314453111","doi":"10.1016/j.jcjd.2014.07.138","title":"Adjunctive Lixisenatide Treatment Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus Irrespective of β-cell Function","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lixisenatide; Glycemic; Type 2 Diabetes Mellitus; Islet; Diabetes mellitus; Internal medicine; Type 2 diabetes; Islet cell transplantation; Agonist; Mirabegron; Endocrinology; Receptor; Exenatide","score_opus":0.003936129222373601,"score_gpt":0.17940287764548443,"score_spread":0.17546674842311083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314453111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959145,0.0014092072,0.000008688752,0.00009320722,0.0002685737,0.0005300755,0.000020859086,0.000006775668,0.001748075],"genre_scores_gemma":[0.99934816,0.000014477219,0.00012698342,0.00023252188,0.000087336826,0.000013093777,0.000027314318,0.000029538194,0.00012054335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986569,0.000071342954,0.0004081852,0.00019626081,0.00022758475,0.00043969287],"domain_scores_gemma":[0.99844307,0.00014578296,0.00036207482,0.00020321082,0.00042656763,0.00041929077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015918066,0.00024453911,0.0006412695,0.0006086217,0.00004241958,0.000020561733,0.00008996634,0.000069993104,0.00004347862],"category_scores_gemma":[0.00009735437,0.00017342079,0.00012457641,0.00029100303,0.00010981236,0.00017067416,0.000006024886,0.00013004144,0.000006215241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045388917,0.00039674694,0.98161244,0.000064302694,0.0007367225,0.0000047957524,0.00020436569,0.00003849952,0.00091135304,0.000071041184,0.00022388625,0.015281941],"study_design_scores_gemma":[0.0181482,0.021662224,0.9525166,0.00030735743,0.0009633537,1.3603913e-7,0.0001245112,0.00013239012,0.004047258,0.00025830188,0.001636855,0.00020280175],"about_ca_topic_score_codex":0.00027147608,"about_ca_topic_score_gemma":0.0015428262,"teacher_disagreement_score":0.029095845,"about_ca_system_score_codex":0.00054223696,"about_ca_system_score_gemma":0.00040061877,"threshold_uncertainty_score":0.7071895},"labels":[],"label_agreement":null},{"id":"W2314925473","doi":"10.1016/j.jval.2014.08.139","title":"Incretin Therapy and Risk of Pancreatitis in Type 2 Diabetes Mellitus: Systematic Review of Randomized and Non-Randomized Studies","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University","funders":"","keywords":"Medicine; Exenatide; Sitagliptin; Internal medicine; Randomized controlled trial; Pancreatitis; Incretin; Type 2 diabetes; Hazard ratio; Type 2 Diabetes Mellitus; Diabetes mellitus; Cohort study; Endocrinology; Confidence interval","score_opus":0.02188000461485413,"score_gpt":0.2939801133482795,"score_spread":0.2721001087334254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314925473","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5430347,0.4527206,0.0000047062863,0.00030778695,0.000030135288,0.0037900116,0.0000017432504,0.000005348359,0.0001049907],"genre_scores_gemma":[0.39671078,0.60217416,0.0006816767,0.00021602275,0.0000068127997,0.00018292452,0.0000036996764,0.0000071763266,0.000016735372],"study_design_codex":"systematic_review","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99648255,0.0018386638,0.0011688861,0.00017117203,0.0001706542,0.00016804533],"domain_scores_gemma":[0.9956201,0.0034509434,0.00058852,0.00021234572,0.00007568787,0.000052403426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009871208,0.00014691637,0.0040630633,0.00017857942,0.000015450503,0.0000031218296,0.00003620394,0.000030681844,0.0000049684563],"category_scores_gemma":[0.0035936374,0.000089804984,0.00009882881,0.0001638875,0.00020926715,0.000027901737,0.00002834554,0.000066629924,7.459114e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028490223,0.00018520394,0.027844362,0.9352242,0.0015767096,0.0000018291743,0.0027689375,0.0000057132415,0.000007880046,0.0011629558,0.00005829515,0.0026736946],"study_design_scores_gemma":[0.6252979,0.00069793157,0.0020206266,0.36680788,0.0013002382,6.7238625e-7,0.00023368838,0.0022153866,0.0000783865,0.0012090881,0.000017790602,0.00012043284],"about_ca_topic_score_codex":0.0011303258,"about_ca_topic_score_gemma":0.000014695928,"teacher_disagreement_score":0.59680766,"about_ca_system_score_codex":0.000035901983,"about_ca_system_score_gemma":0.000032321983,"threshold_uncertainty_score":0.43021792},"labels":[],"label_agreement":null},{"id":"W2315156665","doi":"10.5414/cp201603","title":"Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses","year":2012,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacology and Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Nifedipine; Medicine; Pharmacokinetics; Angina; Pharmacology; Clinical trial; Regimen; Bioequivalence; Internal medicine","score_opus":0.0635210436057631,"score_gpt":0.43724859029219487,"score_spread":0.37372754668643177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315156665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9181002,0.0070135533,0.00023720243,0.07063003,0.0033559082,0.0003445588,0.0000044531184,0.0000085717365,0.00030556272],"genre_scores_gemma":[0.9602606,0.012580032,0.00005488338,0.024623597,0.002186757,0.00000923178,0.000002739994,0.000009963681,0.00027215187],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983889,0.00042476706,0.00064747606,0.00008230644,0.0002907306,0.000165853],"domain_scores_gemma":[0.996078,0.0030547788,0.0004802279,0.00008851556,0.0002219282,0.00007651377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022841946,0.00012400119,0.00027501426,0.000047688864,0.00013918047,0.00004449881,0.0002351118,0.000056184414,0.000059262526],"category_scores_gemma":[0.00011131091,0.000050293962,0.00013702053,0.000051895582,0.0005610248,0.00013713285,0.00008265317,0.0004354316,0.0000041918975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019760393,0.0011435187,0.46932155,0.000029622433,0.011130032,0.00004423446,0.0028462673,0.000009374822,0.0015030279,0.012639172,0.0025960037,0.4789768],"study_design_scores_gemma":[0.012333791,0.0005023609,0.73129654,0.000039289098,0.0033656808,0.00024380659,0.00026217502,0.0019987738,0.000378542,0.0024997606,0.24697275,0.000106510604],"about_ca_topic_score_codex":0.000001222796,"about_ca_topic_score_gemma":2.62186e-7,"teacher_disagreement_score":0.47887027,"about_ca_system_score_codex":0.000016685832,"about_ca_system_score_gemma":0.0000424198,"threshold_uncertainty_score":0.20671193},"labels":[],"label_agreement":null},{"id":"W2315708179","doi":"10.1016/j.jcjd.2014.07.127","title":"Effectiveness of Switching from a DPP-4 Inhibitor to the Human GLP-1 Analogue Liraglutide in Patients with Type 2 Diabetes","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Sitagliptin; McNemar's test; Glycemic; Internal medicine; Observational study; Diabetes mellitus; Endocrinology","score_opus":0.0053975852264380175,"score_gpt":0.2027511960044727,"score_spread":0.19735361077803468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315708179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984164,0.0003244421,0.0000067705146,0.00021321033,0.00022438067,0.0003992013,0.000015880529,0.0000045961438,0.0003950945],"genre_scores_gemma":[0.99938124,9.4594606e-7,0.00013300913,0.00028653245,0.00012050884,0.000008023208,0.000028609313,0.000025540698,0.000015572148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987269,0.0001502158,0.00034328667,0.00015986287,0.00023722633,0.00038251863],"domain_scores_gemma":[0.9986912,0.00022771615,0.00019375047,0.00025119717,0.00022957467,0.0004065533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058659323,0.00017616765,0.00049957045,0.00044010312,0.000072587056,0.000033093555,0.0001958015,0.000049364673,0.00002028925],"category_scores_gemma":[0.00020038868,0.00011242833,0.00008251909,0.00037152442,0.000052342904,0.0001355646,0.000022639606,0.00018256709,0.0000054495727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023381286,0.00007277444,0.993466,0.000085151485,0.00028701092,0.0000038988237,0.00021801698,0.00009941056,0.00076771766,0.00009078241,0.0002961997,0.0045896466],"study_design_scores_gemma":[0.0023270133,0.001850474,0.99036723,0.0014512849,0.00022779366,5.221987e-8,0.000044576584,0.000024980745,0.0024484138,0.00030232183,0.0008324561,0.00012337042],"about_ca_topic_score_codex":0.001465262,"about_ca_topic_score_gemma":0.008647338,"teacher_disagreement_score":0.0071820756,"about_ca_system_score_codex":0.00017927353,"about_ca_system_score_gemma":0.00017276897,"threshold_uncertainty_score":0.48254174},"labels":[],"label_agreement":null},{"id":"W2317381170","doi":"10.1016/j.cjca.2014.07.070","title":"GLYCEMIC CONTROL AND CARDIOVASCULAR RISK FACTOR MANAGEMENT IN PATIENTS WITH DIABETES WITH AND WITHOUT CORONARY ARTERY DISEASE: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Coronary artery disease; Hypoglycemia; Risk factor; Intensive care medicine; Internal medicine; Emergency medicine; Endocrinology","score_opus":0.004453284034630852,"score_gpt":0.16377065525642542,"score_spread":0.15931737122179457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317381170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052167,0.008250132,0.000035489313,0.0000969988,0.00012710333,0.00061579375,0.0002361549,0.000002629603,0.00011401752],"genre_scores_gemma":[0.9991564,0.0003578145,0.000030371526,0.00028572755,0.00006538949,0.000019578963,0.000056446806,0.00002365498,0.000004584589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816406,0.00046932665,0.00030566778,0.00028433892,0.00025922677,0.00051739044],"domain_scores_gemma":[0.9985689,0.0002349148,0.00013613664,0.0003196272,0.000095658834,0.00064475846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024903164,0.00024731105,0.0008522564,0.0002062685,0.00006411681,0.000027547172,0.00010399974,0.00004426943,0.0000037343123],"category_scores_gemma":[0.000056680878,0.00014971594,0.00006306368,0.00012791659,0.00018110435,0.00009066475,0.000019137862,0.0002281906,3.79369e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057287276,0.0000064765227,0.9802373,0.000023252467,0.0028605973,0.00014192198,0.000063182844,0.0006412388,2.7911378e-7,0.0000048270663,0.000103614,0.015344453],"study_design_scores_gemma":[0.010313326,0.0005775292,0.9844728,0.0001485043,0.0009115366,0.0000015102651,0.00010633901,0.000074150834,6.530996e-7,0.000037370202,0.0031846159,0.00017167065],"about_ca_topic_score_codex":0.24040979,"about_ca_topic_score_gemma":0.85267353,"teacher_disagreement_score":0.61226374,"about_ca_system_score_codex":0.00041994272,"about_ca_system_score_gemma":0.0006931925,"threshold_uncertainty_score":0.7646484},"labels":[],"label_agreement":null},{"id":"W2317657515","doi":"10.1016/j.jcjd.2014.07.117","title":"Glycemic Improvement with Fixed-Dose Combination of DPP-4 Inhibitor + Metformin in Patients with Type 2 DM (GIFT Study)","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Metformin; Glycemic; Fixed-dose combination; Type 2 diabetes; Pharmacology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.004605479313388534,"score_gpt":0.1928659971093089,"score_spread":0.18826051779592037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317657515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852866,0.000086364555,0.0000024280744,0.00008364762,0.00015123472,0.00059651624,0.0000040758,0.0000037073335,0.00054334954],"genre_scores_gemma":[0.9994993,0.000001097059,0.00016896772,0.00011345403,0.000039162558,0.000008088799,0.000015310961,0.000020439751,0.00013418189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889904,0.0000290347,0.00036133156,0.00012472647,0.00029836505,0.00028749683],"domain_scores_gemma":[0.9988697,0.000034022112,0.00028400111,0.00017468995,0.00033698182,0.00030058864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022225697,0.00015294892,0.0003903533,0.0005012664,0.00003226864,0.000019177694,0.0000972378,0.0000340824,0.000030662904],"category_scores_gemma":[0.0000630512,0.00010470662,0.000038849026,0.00030470794,0.000057754412,0.00016281237,0.0000106802745,0.00011956314,0.0000026422147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015733222,0.0004651953,0.9835035,0.000060606253,0.0002671006,0.000008498115,0.00022986076,0.000012910334,0.000074584044,0.000029524723,0.00024868193,0.014942194],"study_design_scores_gemma":[0.015978836,0.030129042,0.9503953,0.00038015418,0.00037750235,2.788545e-7,0.00033111603,0.000026990963,0.0012618334,0.00003437401,0.0009322133,0.00015240238],"about_ca_topic_score_codex":0.00032792226,"about_ca_topic_score_gemma":0.00502886,"teacher_disagreement_score":0.033108253,"about_ca_system_score_codex":0.00021861448,"about_ca_system_score_gemma":0.00029171593,"threshold_uncertainty_score":0.42698118},"labels":[],"label_agreement":null},{"id":"W2317733955","doi":"10.1097/mnh.0000000000000214","title":"New and old agents in the management of diabetic nephropathy","year":2016,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Medicine; Diabetic nephropathy; Nephropathy; Diabetes mellitus; Tubuloglomerular feedback; Pharmacology; Bioinformatics; Internal medicine; Kidney; Endocrinology","score_opus":0.10013000304509678,"score_gpt":0.35955952861631185,"score_spread":0.25942952557121507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317733955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011269129,0.99409294,0.000010662983,0.0004689091,0.0017184454,0.0023363032,0.000007384964,0.00002014195,0.0002182899],"genre_scores_gemma":[0.00019475257,0.998682,0.0001184777,0.00024826656,0.000208859,0.00020357837,0.00014991887,0.000036285648,0.00015785579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997654,0.0002382186,0.0007899626,0.0005951914,0.00029349112,0.00042912405],"domain_scores_gemma":[0.99882466,0.00014643693,0.00027593336,0.00063097477,0.000027013852,0.00009499617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037437328,0.00045214954,0.0015733051,0.00054714293,0.00003124099,0.000011578412,0.00024601887,0.00023245547,0.000063741536],"category_scores_gemma":[0.000011178863,0.00025317929,0.0002376925,0.00040818384,0.000110585504,0.00005695785,0.00027369664,0.00032004798,0.00006282935],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031462077,0.00035230356,0.00045230793,0.013642919,0.00022737212,0.0000463619,0.00004865574,7.690786e-8,5.7881e-7,0.000706996,0.01063675,0.97385424],"study_design_scores_gemma":[0.0024832797,0.00029730253,0.0059918957,0.038164344,0.0009975332,0.000034802666,0.000018522232,0.0000071932564,1.6277079e-7,0.00016713576,0.95163983,0.00019800416],"about_ca_topic_score_codex":0.0000111104855,"about_ca_topic_score_gemma":0.0000012744221,"teacher_disagreement_score":0.97365624,"about_ca_system_score_codex":0.00009357717,"about_ca_system_score_gemma":0.000057342244,"threshold_uncertainty_score":0.9999921},"labels":[],"label_agreement":null},{"id":"W2318586790","doi":"10.1016/j.jcjd.2014.07.124","title":"Glycemic Efficacy of Canagliflozin (CANA) by Baseline A1C and Known Duration of Type 2 Diabetes Mellitus (T2DM)","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Glycemic; Type 2 Diabetes Mellitus; Internal medicine; Empagliflozin; Diabetes mellitus; Endocrinology","score_opus":0.007450228047958615,"score_gpt":0.21324000946536617,"score_spread":0.20578978141740756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318586790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933065,0.008512831,0.000010751183,0.0009312089,0.0002535585,0.0002005646,0.000038845963,0.0000056592935,0.00071593723],"genre_scores_gemma":[0.99885064,0.00014881328,0.00031539967,0.00027505567,0.00013037065,0.0000021797307,0.00005226484,0.000024276167,0.0002010132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858195,0.00007289934,0.00060134334,0.000154172,0.00021907328,0.000370567],"domain_scores_gemma":[0.9982036,0.00021620073,0.00041166108,0.00022194684,0.0003368067,0.0006098157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048464345,0.00018466068,0.0005981558,0.0004219804,0.00004638037,0.000018536084,0.00012720765,0.0000791364,0.00011606844],"category_scores_gemma":[0.0004939067,0.00015853609,0.00010763867,0.00027400546,0.00016398825,0.00011659517,0.000013788529,0.00012652244,0.0000032305045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014656926,0.00031492143,0.7679318,0.00094574975,0.0017833767,0.000014279685,0.00048066562,0.000063552456,0.021781126,0.0008484566,0.051572252,0.15411726],"study_design_scores_gemma":[0.027882377,0.019330252,0.45540974,0.0046687988,0.006767113,0.0000097585535,0.0006782835,0.005621387,0.200196,0.0013931039,0.27640656,0.0016366204],"about_ca_topic_score_codex":0.00095762644,"about_ca_topic_score_gemma":0.0032728207,"teacher_disagreement_score":0.31252205,"about_ca_system_score_codex":0.00010958644,"about_ca_system_score_gemma":0.00037465658,"threshold_uncertainty_score":0.6464914},"labels":[],"label_agreement":null},{"id":"W2318884656","doi":"10.1016/s1262-3636(15)30444-4","title":"P331 Efficacité et tolérance cardiovasculaire de la linagliptine associée à l’insuline chez des patients atteints de diabète de type 2: analyse post-hoc de données poolées","year":2015,"lang":"fr","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Gynecology","score_opus":0.014385028284285806,"score_gpt":0.26864996869034896,"score_spread":0.2542649404060632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318884656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85824686,0.13587505,0.00012477227,0.0013345183,0.0012321899,0.00077909394,0.00018936141,0.00022015879,0.001997977],"genre_scores_gemma":[0.97036046,0.010008596,0.0074067973,0.0030357956,0.0017483841,0.00017216876,0.0005015484,0.00020823764,0.0065580187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930173,0.0017518845,0.0008220665,0.0008951996,0.0009081253,0.002605381],"domain_scores_gemma":[0.9957949,0.0005191381,0.00038495337,0.0010143043,0.00086153357,0.0014251992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045927404,0.0009493139,0.0018188683,0.0003819886,0.00024213656,0.00025719046,0.00058306556,0.00059161894,0.00016733404],"category_scores_gemma":[0.0030737252,0.00091401604,0.0008798844,0.0010118921,0.00062416104,0.00049938366,0.00036156515,0.0007156987,0.00038689995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003446003,0.002818658,0.67796516,0.0008273781,0.0074982475,0.00022638252,0.007773465,0.0013514947,0.002791825,0.0007610542,0.004437397,0.29320434],"study_design_scores_gemma":[0.01170238,0.00089959434,0.8257685,0.0011496674,0.010604064,0.000007631339,0.0007535036,0.0021430785,0.009339641,0.001179237,0.13544899,0.0010037313],"about_ca_topic_score_codex":0.00058054354,"about_ca_topic_score_gemma":0.00009457271,"teacher_disagreement_score":0.29220062,"about_ca_system_score_codex":0.0013076565,"about_ca_system_score_gemma":0.0007106033,"threshold_uncertainty_score":0.99933106},"labels":[],"label_agreement":null},{"id":"W2319034355","doi":"10.1016/j.jcjd.2012.07.406","title":"In vivo Efficacy the Sodium/glucose Co-transporter 2 (SGLT2)Iinhibitor SBM-TFC-039 on Glucose Excretion and tTlerance in Normal Sprague-Dawley and Zucker Diabetic Fatty (ZDF) Rats","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"QLT (Canada)","funders":"","keywords":"Medicine; Internal medicine; Fructosamine; Endocrinology; Renal glucose reabsorption; Excretion; Type 2 diabetes; Diabetes mellitus; Oral administration; Glycosuria; Insulin","score_opus":0.010077573567485575,"score_gpt":0.2297213518825578,"score_spread":0.21964377831507223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319034355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894929,0.0066765444,0.0000016720666,0.0022373872,0.00043886912,0.00051687955,0.000019338439,0.000006881869,0.00060956],"genre_scores_gemma":[0.9977873,0.00020998121,0.000053225842,0.0013706204,0.00038966868,0.000018664752,0.000009133648,0.00003318641,0.00012821415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981306,0.000108779655,0.0005084649,0.00021863586,0.00025473395,0.0007787647],"domain_scores_gemma":[0.99861497,0.00015599196,0.0001789566,0.00022231958,0.000059495407,0.00076828257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069590524,0.0002880924,0.00049980526,0.00051282597,0.00009507234,0.00006924913,0.00011929035,0.00011447481,0.00012852997],"category_scores_gemma":[0.0000880556,0.00021063373,0.00009624537,0.00023535815,0.00021232745,0.0004505711,0.000012874474,0.00039377963,0.00001346852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057099478,0.00021215249,0.9850995,0.000110640976,0.00011096355,0.00008909341,0.0013934458,0.000009043308,0.0035014576,0.00008681653,0.0015485676,0.007781218],"study_design_scores_gemma":[0.0042909305,0.00055627734,0.95758706,0.0007255217,0.00019804054,0.0000070204383,0.00021004294,0.000049625876,0.027117996,0.00004696857,0.008960238,0.00025026803],"about_ca_topic_score_codex":0.00025562412,"about_ca_topic_score_gemma":0.0030901555,"teacher_disagreement_score":0.02751243,"about_ca_system_score_codex":0.00019894406,"about_ca_system_score_gemma":0.00015261781,"threshold_uncertainty_score":0.8589394},"labels":[],"label_agreement":null},{"id":"W2319309398","doi":"10.1055/s-0033-1341734","title":"Langzeitwirkung von Dapagliflozin über einen Zeitraum von 104 Wochen bei Patienten mit Typ-2-Diabetes und unzureichender Blutzuckerkontrolle durch Insulin","year":2013,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Dapagliflozin; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.019394867977840374,"score_gpt":0.26288059449510465,"score_spread":0.24348572651726427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319309398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6592925,0.30153733,0.0001348456,0.009427396,0.0051478217,0.006267116,0.0003616032,0.0010115484,0.016819792],"genre_scores_gemma":[0.96121067,0.0041939546,0.0030815874,0.0044672918,0.0025999534,0.0014230642,0.003035801,0.0004791893,0.01950849],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903381,0.00060864835,0.0018521099,0.002215768,0.0014351364,0.0035502345],"domain_scores_gemma":[0.994432,0.00090390525,0.0007947147,0.0021451558,0.0006753561,0.0010488698],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0009551857,0.0018887485,0.0027589784,0.0009958644,0.00053550146,0.00048960047,0.0012270488,0.0012837751,0.0016937727],"category_scores_gemma":[0.00067798444,0.001616988,0.0008581954,0.0012133609,0.0006514798,0.0007685675,0.0008994385,0.0013818153,0.011174796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059096894,0.0071883635,0.4847126,0.0018966149,0.04451836,0.00039025545,0.0023341356,0.00023298235,0.0026337225,0.0028199707,0.26645327,0.18622875],"study_design_scores_gemma":[0.034181062,0.006495833,0.23654214,0.0019809867,0.043996498,0.0000019534768,0.0020708991,0.00942221,0.013511973,0.0069257678,0.6389784,0.0058922363],"about_ca_topic_score_codex":0.00084737275,"about_ca_topic_score_gemma":0.000086762804,"teacher_disagreement_score":0.37252516,"about_ca_system_score_codex":0.0008641757,"about_ca_system_score_gemma":0.00034521497,"threshold_uncertainty_score":0.99938565},"labels":[],"label_agreement":null},{"id":"W2319528073","doi":"10.1155/2001/793658","title":"Glucagon‐Like Peptide‐2: New Insights‐New Questions","year":2001,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology and Hepatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Glucagon-like peptide-1; Glucagon; Peptide; Chemistry; Computer science; Endocrinology; Biochemistry; Medicine; Hormone; Diabetes mellitus","score_opus":0.014176919846901665,"score_gpt":0.23322949130430068,"score_spread":0.219052571457399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319528073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790697,0.0018341771,0.0006541807,0.016220648,0.00062529295,0.00010819861,0.0000015319662,0.00000884161,0.0014773929],"genre_scores_gemma":[0.98803055,0.0006030407,0.0010333679,0.006433138,0.0002829317,0.00000150413,0.000008176298,0.00001247828,0.0035948148],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902314,0.000054163425,0.0003105647,0.0001448019,0.000058916663,0.00040842712],"domain_scores_gemma":[0.9984293,0.000021282038,0.00013105744,0.00013505717,0.000071322545,0.0012119714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007703599,0.00014168026,0.00042594012,0.0004519641,0.00008712401,0.000014215544,0.00009159513,0.00010851338,0.00038608682],"category_scores_gemma":[0.000035237186,0.000120637604,0.0000935319,0.00007741594,0.00016224047,0.00009043832,0.000014730649,0.00022923625,0.000024724868],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031500784,0.000035881912,0.92560714,0.000007236262,0.00031426604,0.0019479542,0.000205812,0.0000018442784,0.000023412658,0.0009568004,0.06711388,0.00347074],"study_design_scores_gemma":[0.0047030365,0.0046026604,0.42251807,0.00006921367,0.00059559266,0.007918744,0.00011508005,0.00002317057,0.000010767894,0.001856754,0.5574909,0.00009601034],"about_ca_topic_score_codex":0.002970138,"about_ca_topic_score_gemma":0.091512,"teacher_disagreement_score":0.5030891,"about_ca_system_score_codex":0.000088259294,"about_ca_system_score_gemma":0.0007098955,"threshold_uncertainty_score":0.9250655},"labels":[],"label_agreement":null},{"id":"W2319689835","doi":"10.1056/nejmp1011042","title":"Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Toronto Western Hospital; University of Toronto","funders":"","keywords":"Rosiglitazone; Medicine; Drug; Diabetes mellitus; Warning system; Emergency medicine; Environmental health; Pharmacology; Endocrinology","score_opus":0.03265365165257035,"score_gpt":0.28985652155156666,"score_spread":0.2572028698989963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319689835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98972386,0.000108722044,0.00053991604,0.0087621175,0.00038385275,0.00019928973,4.527069e-7,0.0000052713476,0.00027651014],"genre_scores_gemma":[0.9949281,0.000059291826,0.0028284318,0.00074819487,0.0011796728,0.0000016271596,0.000004233577,0.000008623347,0.00024179256],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998831,0.00010037485,0.0004151248,0.0000864624,0.00042855096,0.00013848796],"domain_scores_gemma":[0.9990331,0.0002914474,0.00021525395,0.00019450959,0.000111662215,0.00015403522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018811839,0.00009129161,0.00030034606,0.0009247343,0.000025680281,0.000011410174,0.00010885486,0.000037920054,0.00007091099],"category_scores_gemma":[0.0007599731,0.000048474023,0.000043353324,0.00055045023,0.000032862325,0.00016700484,0.000013442394,0.0003064867,0.0000010123621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032655608,0.0007108584,0.3772062,0.00009427198,0.0003463887,0.00047795166,0.026751373,0.00034073234,0.19345026,0.0041955747,0.004197929,0.3889629],"study_design_scores_gemma":[0.035763107,0.0062953844,0.843102,0.00073179114,0.0005543744,0.0001811714,0.0005707114,0.00021030894,0.00038441562,0.0004965168,0.111610785,0.000099468925],"about_ca_topic_score_codex":0.00016209086,"about_ca_topic_score_gemma":0.00011778713,"teacher_disagreement_score":0.46589574,"about_ca_system_score_codex":0.00001643441,"about_ca_system_score_gemma":0.000037916052,"threshold_uncertainty_score":0.19767132},"labels":[],"label_agreement":null},{"id":"W2319804203","doi":"10.1016/s1499-2671(09)33186-x","title":"Improvement in glycaemic control β-cell function over 2 years with sitagliptin as monotherapy or add-on therapy to metformin in patients with type 2 diabetes","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sitagliptin; Metformin; Glycemic; Type 2 diabetes; Internal medicine; Diabetes mellitus; Sitagliptin Phosphate; Endocrinology; Oncology; Insulin","score_opus":0.004877285530310808,"score_gpt":0.19862288082327037,"score_spread":0.19374559529295957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319804203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789697,0.0004294864,0.0000014157487,0.00029773274,0.00010775427,0.00089027366,0.000007475316,0.000007101319,0.0003617875],"genre_scores_gemma":[0.99429667,0.00001736189,0.00012240147,0.005195164,0.000058448146,0.000017268401,0.000011896182,0.00003053976,0.00025025252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864745,0.000029833927,0.0003276156,0.00020274014,0.0002798134,0.0005125274],"domain_scores_gemma":[0.999066,0.00004446296,0.00016201053,0.00018777327,0.000114645714,0.00042512408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019805491,0.00023181924,0.0004438339,0.00076733436,0.00002698618,0.000040849452,0.00010915551,0.00006094135,0.00019343721],"category_scores_gemma":[0.00002441021,0.00015117043,0.000053005624,0.00045464045,0.000025274227,0.00016801369,0.000002775129,0.00017966694,0.000012497447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018650068,0.00041803357,0.9092987,0.000012488714,0.00021271784,0.0000478382,0.00021951481,0.0001355274,0.00067586475,0.000012317592,0.0009302288,0.08617177],"study_design_scores_gemma":[0.020285433,0.0388326,0.9351149,0.00034360713,0.00009348342,1.6789089e-7,0.00008048605,0.000016836597,0.0012759431,0.00004095079,0.003700318,0.0002152506],"about_ca_topic_score_codex":0.00018797588,"about_ca_topic_score_gemma":0.0026471892,"teacher_disagreement_score":0.08595652,"about_ca_system_score_codex":0.00040594497,"about_ca_system_score_gemma":0.00035171796,"threshold_uncertainty_score":0.61645514},"labels":[],"label_agreement":null},{"id":"W2320041514","doi":"10.1016/j.clinthera.2016.03.024","title":"Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Metformin; Medicine; Concomitant; Internal medicine; Retrospective cohort study; Hazard ratio; Proportional hazards model; Cohort study; Confounding; Cohort; Proton-pump inhibitor; Confidence interval; Insulin","score_opus":0.06983626572215627,"score_gpt":0.3746050386675284,"score_spread":0.30476877294537214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320041514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955931,0.00006318109,0.000098868135,0.00032142646,0.00014974592,0.0033506372,0.000010007939,0.000035715435,0.00037735217],"genre_scores_gemma":[0.99803996,0.0004671908,0.0003223943,0.00019195794,0.00008472211,0.00007245107,0.000007077844,0.00001682821,0.00079739594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986703,0.00009793324,0.000592002,0.00026616806,0.00023517323,0.00013843212],"domain_scores_gemma":[0.999001,0.00033063546,0.0001867454,0.00030285405,0.000105096326,0.0000736427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008125709,0.0001245538,0.0005073571,0.00004343022,0.000030651838,0.000009934652,0.000040753966,0.000083055216,0.000027386035],"category_scores_gemma":[0.00016553067,0.000070906004,0.00009117577,0.000085860236,0.00011488071,0.00009398377,0.00005516194,0.00008307441,0.000004738612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005526471,0.0009176709,0.955791,0.000017502374,0.0007507066,0.000005096805,0.000051880044,3.285583e-8,0.00012670761,0.0004297664,0.000013036371,0.041343972],"study_design_scores_gemma":[0.0050914166,0.0031009188,0.9871508,0.00008733138,0.0007278186,8.160022e-7,0.000052425374,0.00002478864,0.0004261255,0.00040708572,0.0028447828,0.00008570249],"about_ca_topic_score_codex":0.000012119203,"about_ca_topic_score_gemma":0.0000066083794,"teacher_disagreement_score":0.04125827,"about_ca_system_score_codex":0.00008844149,"about_ca_system_score_gemma":0.000017673943,"threshold_uncertainty_score":0.2891463},"labels":[],"label_agreement":null},{"id":"W2320346965","doi":"10.1016/j.jcjd.2015.01.140","title":"Weight Loss with Liraglutide 3.0 mg is Associated with Improved Health-related Quality of Life (HRQoL) and Treatment Satisfaction in Adults with Overweight/Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"College of Physicians and Surgeons of Ontario","funders":"","keywords":"Liraglutide; Medicine; Overweight; Type 2 diabetes; Weight loss; Placebo; Obesity; Quality of life (healthcare); Diabetes mellitus; Health related quality of life; Gerontology; Internal medicine; Physical therapy; Endocrinology; Alternative medicine; Nursing","score_opus":0.019866225766959903,"score_gpt":0.24095117253195883,"score_spread":0.22108494676499893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320346965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873511,0.005791525,0.0000011030312,0.0022949753,0.00016260559,0.0041811373,0.00004149436,0.000017435366,0.00015860474],"genre_scores_gemma":[0.9988849,0.00017871986,0.00012006494,0.0003261826,0.00009907899,0.00015060008,0.00004078641,0.00004797152,0.00015168093],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965451,0.000587019,0.001230671,0.000391461,0.00048576648,0.0007600243],"domain_scores_gemma":[0.99574256,0.00080865243,0.0014570951,0.00031595075,0.0005084399,0.0011673186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002287765,0.00050210854,0.00261523,0.0004893277,0.00017419858,0.00009241763,0.000120111275,0.00016390119,0.000025640787],"category_scores_gemma":[0.00036683047,0.00026345844,0.00019681729,0.0005097591,0.0005865303,0.00031798767,0.000019916673,0.00032492212,0.0000010096157],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34021738,0.000350208,0.6528031,0.00010160924,0.003688552,0.0000112062535,0.0014045526,0.000013061733,0.000011277731,0.0000269184,0.00014012471,0.0012319902],"study_design_scores_gemma":[0.85574865,0.011519616,0.12867849,0.0010261812,0.0016067588,0.0000017662348,0.00048123713,0.0003005841,0.00022003158,0.00007833312,0.000036993264,0.00030138015],"about_ca_topic_score_codex":0.0060136598,"about_ca_topic_score_gemma":0.062158555,"teacher_disagreement_score":0.5241246,"about_ca_system_score_codex":0.00060524925,"about_ca_system_score_gemma":0.0017366783,"threshold_uncertainty_score":0.99998176},"labels":[],"label_agreement":null},{"id":"W2320350442","doi":"10.1016/s1499-2671(09)33264-5","title":"safety of vildagliptin in patients with mild renal impairment patients with normal renal function: GALIANT study","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vildagliptin; Medicine; Renal function; Metformin; Type 2 diabetes; Diabetes mellitus; Urology; Internal medicine; Endocrinology","score_opus":0.004868643527591991,"score_gpt":0.18634828421655508,"score_spread":0.18147964068896308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320350442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981274,0.000103922175,0.0000034814434,0.0002192592,0.00010470116,0.000793553,0.00002374281,0.0000051653683,0.00061878975],"genre_scores_gemma":[0.9992693,9.840228e-7,0.00021472748,0.0002784429,0.000062799416,0.0000055366895,0.000042164742,0.00001800298,0.00010805193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817693,0.000053433487,0.0005810865,0.0001868325,0.000524457,0.0004772484],"domain_scores_gemma":[0.9984817,0.000019227558,0.0003573041,0.00022297447,0.000365788,0.0005530188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002554945,0.0002348333,0.0005160423,0.00055005646,0.00006819028,0.000023310507,0.00012377922,0.000044368895,0.00013234896],"category_scores_gemma":[0.000020589487,0.00015834127,0.00008304931,0.00035890026,0.000063110594,0.0002184462,0.000009358544,0.00019536554,0.0000027032524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066753716,0.0015007028,0.99056065,0.000021525695,0.00048746017,0.00003109579,0.0002816574,0.000091067224,0.0000035668556,0.000008937081,0.0008642383,0.0054815584],"study_design_scores_gemma":[0.015812987,0.026134128,0.9560348,0.00052585936,0.00047234065,2.5890947e-7,0.00015412722,0.0000038487306,0.000049670824,0.000007289749,0.00064670236,0.00015799835],"about_ca_topic_score_codex":0.0001513754,"about_ca_topic_score_gemma":0.0030175694,"teacher_disagreement_score":0.034525864,"about_ca_system_score_codex":0.0003253312,"about_ca_system_score_gemma":0.00038177377,"threshold_uncertainty_score":0.64569694},"labels":[],"label_agreement":null},{"id":"W2320714655","doi":"10.1016/s1499-2671(09)33225-6","title":"Improvement of glycaemic control via reducing insulin resistance with pioglitazone and metformin fixed-dose combination therapy","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pioglitazone; Medicine; Metformin; Biguanide; Thiazolidinedione; Glycemic; Insulin resistance; Internal medicine; Type 2 Diabetes Mellitus; Fixed-dose combination; Type 2 diabetes; Combination therapy; Pharmacology; Insulin; Diabetes mellitus; Endocrinology","score_opus":0.005792202818057883,"score_gpt":0.2042389281046479,"score_spread":0.19844672528659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320714655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905732,0.0067545637,0.000042634056,0.0016066744,0.00006340147,0.00037936066,0.000008122674,0.00000502055,0.0005669863],"genre_scores_gemma":[0.99843097,0.00011167334,0.00061301596,0.0005304122,0.000045281144,0.000004814041,0.0000061092355,0.000011761472,0.00024599492],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990575,0.00001989481,0.00035444697,0.000117623604,0.00018320249,0.00026734525],"domain_scores_gemma":[0.99896824,0.000043614993,0.00029724045,0.00014559264,0.0002131024,0.00033220043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003094736,0.0001405225,0.00039135484,0.00032093909,0.000055553817,0.000021952277,0.00007454265,0.000039637624,0.000019059396],"category_scores_gemma":[0.000041725558,0.0001042635,0.00006169279,0.00016439611,0.000075829805,0.00016219307,0.0000026731216,0.000104285966,5.2164035e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006361133,0.00067790534,0.18444894,0.0003016125,0.0019266517,0.00014363287,0.0015776132,0.00003330935,0.08504935,0.001637901,0.002108296,0.7214587],"study_design_scores_gemma":[0.03898502,0.021415463,0.8546202,0.0019620687,0.0011006955,0.0000136759045,0.000559602,0.00024056796,0.07161519,0.0031886685,0.0057587004,0.00054014934],"about_ca_topic_score_codex":0.00013110839,"about_ca_topic_score_gemma":0.00045710237,"teacher_disagreement_score":0.72091854,"about_ca_system_score_codex":0.00015143168,"about_ca_system_score_gemma":0.00023778739,"threshold_uncertainty_score":0.4251742},"labels":[],"label_agreement":null},{"id":"W2321173821","doi":"10.1056/nejmoa1506115","title":"A Multicenter Observational Study of Incretin-based Drugs and Heart Failure","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McMaster University; Saskatchewan Health Quality Council; Women's College Hospital; Western University; University of Toronto; University Health Network; University of Manitoba; University of British Columbia; Jewish General Hospital; Manitoba Health; Institute for Clinical Evaluative Sciences; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Heart failure; Incretin; Internal medicine; Diabetes mellitus; Confidence interval; Cohort study; Cohort; Type 2 diabetes; Dipeptidyl peptidase-4; Endocrinology","score_opus":0.030481031128098385,"score_gpt":0.28779912954045805,"score_spread":0.25731809841235964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321173821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95701945,0.00020324763,0.00010171886,0.04212117,0.00012354735,0.00024050278,0.0000011483763,0.000005450118,0.00018373725],"genre_scores_gemma":[0.99684995,0.000021731303,0.0011371523,0.00073476427,0.00069654215,0.0000016701418,0.0000025651557,0.000008599861,0.0005470237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988102,0.000054526383,0.00040055322,0.000091239475,0.0005353029,0.000108187895],"domain_scores_gemma":[0.99897265,0.00028332142,0.00021087061,0.000112057554,0.0002458222,0.00017524934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006290765,0.00010272388,0.00039258384,0.00016434926,0.000017819442,0.0000030861663,0.000049093353,0.00002422129,0.00019947391],"category_scores_gemma":[0.00029671256,0.000049078808,0.000038606468,0.00008099916,0.00006117449,0.0000601729,0.0000164954,0.00007813353,0.0000015730807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017213726,0.00075070246,0.8976401,0.000079829144,0.00044304898,0.00007156474,0.0016361794,0.0000029985924,0.010107425,0.000067765635,0.028381707,0.05909732],"study_design_scores_gemma":[0.24865003,0.010704003,0.6425206,0.0014155665,0.0008907958,0.00004152129,0.0011721937,0.000033633307,0.00082684174,0.00011383093,0.09353476,0.00009623884],"about_ca_topic_score_codex":0.00004090995,"about_ca_topic_score_gemma":0.000017596485,"teacher_disagreement_score":0.2551195,"about_ca_system_score_codex":0.000027011152,"about_ca_system_score_gemma":0.00006143063,"threshold_uncertainty_score":0.21840996},"labels":[],"label_agreement":null},{"id":"W2321418675","doi":"10.1016/j.jcjd.2013.08.115","title":"Effectiveness and Tolerability of Liraglutide Among Type 2 Diabetes Patients in Routine Clinical Practice: 1-Year Data from EVIDENCE®","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Discontinuation; Tolerability; Observational study; Type 2 diabetes; Internal medicine; Weight loss; Diabetes mellitus; Clinical trial; Randomized controlled trial; Adverse effect; Obesity; Endocrinology","score_opus":0.03849599005103947,"score_gpt":0.31744483323363554,"score_spread":0.27894884318259605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321418675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590206,0.0025783288,6.4391605e-7,0.00043146775,0.00034522195,0.0005178472,0.000034168403,0.00000393889,0.00018632015],"genre_scores_gemma":[0.9988812,0.00009599737,0.0006893231,0.0001636062,0.00009357336,0.0000054989937,0.000042932967,0.00001617803,0.000011676403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809754,0.00031448458,0.00075588113,0.000268577,0.00022739955,0.00033611336],"domain_scores_gemma":[0.9965489,0.0015187976,0.0004088247,0.0004796118,0.0004943308,0.00054957136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015506512,0.00015846216,0.00067541166,0.00021559221,0.000031903473,0.000046270863,0.00025868375,0.000095385694,0.00013603881],"category_scores_gemma":[0.006376143,0.00012878412,0.000070962786,0.000219579,0.0002208321,0.00088712864,0.0000860811,0.00023188525,0.000010059278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021627391,0.00019025234,0.9821827,0.00012166583,0.0003028518,0.0000062031054,0.00005860889,0.0000016040129,0.00003562803,0.000005210966,0.001323805,0.015749872],"study_design_scores_gemma":[0.0018880675,0.0009963684,0.99447787,0.001247192,0.000367575,9.385446e-8,0.000094183066,0.00013130266,0.000178374,0.00015433229,0.00035821908,0.00010641037],"about_ca_topic_score_codex":0.0037646478,"about_ca_topic_score_gemma":0.0024668714,"teacher_disagreement_score":0.01564346,"about_ca_system_score_codex":0.00012468881,"about_ca_system_score_gemma":0.00035234317,"threshold_uncertainty_score":0.7633299},"labels":[],"label_agreement":null},{"id":"W2321989483","doi":"10.17925/ee.2016.12.01.31","title":"Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy","year":2016,"lang":"en","type":"editorial","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Clinical endpoint; Diabetes mellitus; Incidence (geometry); Endpoint Determination; Internal medicine; Pharmacology; Clinical trial; Endocrinology","score_opus":0.032188216426415395,"score_gpt":0.3249771707485819,"score_spread":0.2927889543221665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321989483","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003418991,0.26726392,0.00005194185,0.0016919223,0.7119772,0.0088392375,0.00012662863,0.00026123316,0.0063689556],"genre_scores_gemma":[0.0004901532,0.39859015,0.002731901,0.0013039417,0.5681852,0.00597781,0.0014367481,0.00041302474,0.020871041],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967405,0.0001549115,0.0006689031,0.0009089852,0.0004968932,0.0010297782],"domain_scores_gemma":[0.99734586,0.0006518839,0.00023543372,0.0014225384,0.00023057278,0.000113710026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029178592,0.0007188044,0.0030711656,0.0003740271,0.000044959266,0.000021423224,0.00035085986,0.000406848,0.00016152624],"category_scores_gemma":[0.0005105793,0.0004072655,0.0007969307,0.00021373526,0.00014074374,0.000070397946,0.00010821993,0.00039665643,0.00018579408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019748003,0.00018717987,0.006545165,0.0006424351,0.0036542707,0.00008257249,0.000016422371,5.551009e-7,0.0000043768096,0.00008595712,0.7235117,0.2650719],"study_design_scores_gemma":[0.00769679,0.0017132164,0.0006679998,0.0006724327,0.0013502368,0.000001862703,0.0000073475776,3.524993e-7,0.00006756779,0.00010510057,0.98729086,0.00042623995],"about_ca_topic_score_codex":0.00004298065,"about_ca_topic_score_gemma":0.00008249728,"teacher_disagreement_score":0.26464567,"about_ca_system_score_codex":0.00024099776,"about_ca_system_score_gemma":0.00021902772,"threshold_uncertainty_score":0.99983793},"labels":[],"label_agreement":null},{"id":"W2322029653","doi":"10.1093/ndt/gfs252","title":"Clinical epidemiology and CKD 1-5","year":2012,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Epidemiology; Intensive care medicine; Kidney disease; MEDLINE; Internal medicine","score_opus":0.0454762387528759,"score_gpt":0.3476105998091748,"score_spread":0.3021343610562989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322029653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926634,0.0006929612,0.0019126115,0.0014290626,0.00018446139,0.00020968304,0.0000036993831,0.00006127655,0.002842855],"genre_scores_gemma":[0.9888978,0.002402398,0.0028674516,0.0049660937,0.00028412265,0.0000346664,0.00022068525,0.000008946196,0.00031784977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998823,0.00026409555,0.00036880624,0.00019344226,0.000057178488,0.00029349327],"domain_scores_gemma":[0.99907947,0.00053062476,0.00008074896,0.00013451846,0.00001796492,0.00015669878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097586896,0.00010541353,0.0004603127,0.000103388455,0.000054035587,0.0000015875735,0.000025263997,0.00014812879,0.00012081421],"category_scores_gemma":[0.00005831881,0.000085786836,0.00011415211,0.00007681889,0.0001538499,0.00009424118,0.00000715297,0.00009800073,0.00009235798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002206667,0.0001987889,0.9798847,0.000044412347,0.0004033762,0.000012002016,0.00024061419,0.0000011172532,0.00019372583,0.0020029072,0.000566592,0.01623109],"study_design_scores_gemma":[0.0018207589,0.0002421514,0.987189,0.000006132699,0.0021467314,0.000039122453,0.0000120269715,0.00004844761,0.0000634345,0.00022830191,0.0081348745,0.000069044734],"about_ca_topic_score_codex":0.000014230514,"about_ca_topic_score_gemma":0.000011029434,"teacher_disagreement_score":0.016162045,"about_ca_system_score_codex":0.000011360881,"about_ca_system_score_gemma":0.0000093561275,"threshold_uncertainty_score":0.34982857},"labels":[],"label_agreement":null},{"id":"W2322518529","doi":"10.1016/j.cjca.2013.07.552","title":"Characteristics of Non-Diabetic Middle-Aged Adults With Chronic Kidney Disease (CKD) - Insight From the Paradigm Registry","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Cohort; Internal medicine; Disease; Endocrinology","score_opus":0.009039527097945026,"score_gpt":0.19216092976951457,"score_spread":0.18312140267156954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322518529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906275,0.0016145608,0.00014281047,0.0044878297,0.000439951,0.00046017952,0.00011130831,0.0000043721343,0.0021114484],"genre_scores_gemma":[0.99757487,0.00019249674,0.00006940115,0.00088895607,0.00088955974,0.00001891308,0.00009932643,0.000020619103,0.00024586005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989407,0.00008028153,0.00035585818,0.00014644973,0.00014091295,0.0003357791],"domain_scores_gemma":[0.99798685,0.000082983024,0.00029285596,0.00042331082,0.00014689013,0.0010671027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010547605,0.00016669942,0.0005788267,0.00011657871,0.00006184422,0.000022033584,0.00021212794,0.0000718003,0.00013717197],"category_scores_gemma":[0.00013704132,0.00010126333,0.00016828066,0.00010048114,0.00028365225,0.00007512133,0.000013937972,0.00022642789,0.000024975097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042072407,0.000023881741,0.9089667,0.00024412981,0.0023204365,0.0012136565,0.0006310356,0.00004643385,0.00020309901,0.00013413113,0.077082224,0.008713517],"study_design_scores_gemma":[0.00254901,0.00067057647,0.93432343,0.0006286498,0.00088436855,0.000032911004,0.000072039984,0.000026994676,0.00003800647,0.00009983002,0.060561445,0.00011272499],"about_ca_topic_score_codex":0.0015796757,"about_ca_topic_score_gemma":0.0006664906,"teacher_disagreement_score":0.025356716,"about_ca_system_score_codex":0.00019031156,"about_ca_system_score_gemma":0.0015979744,"threshold_uncertainty_score":0.41293988},"labels":[],"label_agreement":null},{"id":"W2323936422","doi":"10.1016/s1499-2671(09)33187-1","title":"Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes receiving metformin","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pioglitazone; Alogliptin; Medicine; Metformin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Pharmacology; Endocrinology","score_opus":0.008645561299528112,"score_gpt":0.2098133839698058,"score_spread":0.2011678226702777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323936422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664205,0.00076022453,9.476188e-7,0.00058042374,0.00017125891,0.00044065743,0.000006976767,0.0000107265805,0.0013867177],"genre_scores_gemma":[0.9984812,0.000013029088,0.0006423846,0.0003684409,0.00006460433,0.0000060271277,0.00005621579,0.000020117115,0.00034795963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866724,0.00003990956,0.00038552872,0.00016218431,0.00022919221,0.0005159659],"domain_scores_gemma":[0.99885005,0.000052426163,0.0002040397,0.0001564318,0.00025617357,0.00048085247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019760121,0.00022045228,0.0005112259,0.00071270386,0.0000632757,0.00004548504,0.00010244883,0.000066048146,0.00008066624],"category_scores_gemma":[0.00010347171,0.00016185701,0.00008783951,0.00041062798,0.000047105037,0.00026457294,0.0000048550773,0.00012425345,0.000010623611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024784713,0.00028275113,0.9555729,0.00001940928,0.00021145058,0.00002135875,0.0002468472,0.000029830424,0.00004399787,0.000103510545,0.00050557783,0.042937562],"study_design_scores_gemma":[0.006430306,0.0075587668,0.98221904,0.00034809645,0.00029054208,4.624217e-7,0.00007215673,0.00006715973,0.0006173118,0.0001889398,0.0020320439,0.00017514816],"about_ca_topic_score_codex":0.00016572776,"about_ca_topic_score_gemma":0.0021245214,"teacher_disagreement_score":0.042762414,"about_ca_system_score_codex":0.0010287501,"about_ca_system_score_gemma":0.0004905015,"threshold_uncertainty_score":0.6600337},"labels":[],"label_agreement":null},{"id":"W2324385605","doi":"10.1053/j.ajkd.2016.03.410","title":"No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?","year":2016,"lang":"en","type":"letter","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Johnson and Johnson; Sanofi Pasteur; Medtronic","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Glycemic; Diabetes mellitus; Internal medicine; Dapagliflozin; Endocrinology","score_opus":0.0048743295245235714,"score_gpt":0.22314987538919753,"score_spread":0.21827554586467396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324385605","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036413547,0.0025900316,0.00015323842,0.95584244,0.0013861484,0.001218428,0.0010658603,0.00007019224,0.0012601317],"genre_scores_gemma":[0.06706334,0.002553363,0.0007287058,0.9085155,0.011608703,0.000117162694,0.0006406154,0.00021104637,0.008561542],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967606,0.00040771888,0.00067267014,0.00046812362,0.0012364085,0.0004544584],"domain_scores_gemma":[0.9966855,0.0001503382,0.0007689572,0.00085355673,0.00047593564,0.0010657291],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030117558,0.0004481868,0.0011486434,0.0005243537,0.00013553913,0.00008083206,0.00027364513,0.000132531,0.00045380378],"category_scores_gemma":[0.0010157534,0.00026511474,0.001381932,0.0005442381,0.00018768485,0.00015730967,0.000105351806,0.0007118479,0.00032970763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040845282,0.000084448766,0.0009266274,0.00004154832,0.006288729,0.0005479274,0.00018664112,0.0000066066023,0.00012641762,0.0000011524866,0.95548034,0.035901137],"study_design_scores_gemma":[0.0017596487,0.0012405879,0.002459436,0.0011237094,0.011134665,0.000032346106,0.00025034393,9.236858e-7,0.00020271311,0.00015124331,0.9813197,0.0003246864],"about_ca_topic_score_codex":0.00028484128,"about_ca_topic_score_gemma":2.6834272e-7,"teacher_disagreement_score":0.047326904,"about_ca_system_score_codex":0.00036231763,"about_ca_system_score_gemma":0.0003501946,"threshold_uncertainty_score":0.9999801},"labels":[],"label_agreement":null},{"id":"W2325198396","doi":"10.1016/s1499-2671(08)24118-3","title":"Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycem1c Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin.","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glimepiride; Metformin; Lira; Liraglutide; Hypoglycemia; Internal medicine; Placebo; Endocrinology; Adverse effect; Gastroenterology; Type 2 diabetes; Diabetes mellitus; Insulin","score_opus":0.015187614518996695,"score_gpt":0.22509217668655374,"score_spread":0.20990456216755704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325198396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285454,0.0020741166,0.0000051352845,0.0021785125,0.00013504968,0.0010905986,0.000033999804,0.00003147688,0.001596596],"genre_scores_gemma":[0.99546504,0.000018420467,0.0016196131,0.0019027852,0.00022200531,0.000054296444,0.000047334925,0.00007752935,0.000592998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971238,0.00009496654,0.0007435318,0.00040123455,0.0005009477,0.0011355219],"domain_scores_gemma":[0.99697345,0.0001263142,0.0003880742,0.00045165507,0.00052174187,0.0015387391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035378634,0.00048934354,0.0012598084,0.0012042784,0.00023179363,0.00007749526,0.00035830372,0.00010510905,0.00016406144],"category_scores_gemma":[0.00015662597,0.00035215993,0.00015403473,0.0007472043,0.00028719357,0.00040176982,0.000021621136,0.00036742163,0.000020472322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039810158,0.0002767475,0.9709008,0.00013061125,0.0018013603,0.0012282518,0.0011183949,0.0001476559,0.0047947783,0.000080771526,0.017894415,0.0012281386],"study_design_scores_gemma":[0.027442833,0.020295981,0.89209217,0.0033238037,0.0026506314,0.0000708439,0.0007445534,0.0003985049,0.013757457,0.00027451137,0.03750722,0.0014415147],"about_ca_topic_score_codex":0.0007523415,"about_ca_topic_score_gemma":0.0148675665,"teacher_disagreement_score":0.07880863,"about_ca_system_score_codex":0.0005523769,"about_ca_system_score_gemma":0.0015106902,"threshold_uncertainty_score":0.999893},"labels":[],"label_agreement":null},{"id":"W2326452566","doi":"10.1016/j.jcjd.2015.01.141","title":"Effects of Liraglutide 3.0 mg and 1.8 mg on Body Weight and Cardiometabolic Risk Factors in Adults with Overweight or Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Overweight; Type 2 diabetes; Obesity; Diabetes mellitus; Internal medicine; Endocrinology; Randomized controlled trial","score_opus":0.009760329519533489,"score_gpt":0.2171183833087616,"score_spread":0.20735805378922811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326452566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820023,0.01356644,5.574107e-7,0.00029691268,0.00042076226,0.003318296,0.000022766271,0.000010672754,0.00036128284],"genre_scores_gemma":[0.99852675,0.00069344055,0.000078175995,0.00013313619,0.00027935658,0.000096070304,0.000010064812,0.000044345696,0.00013864545],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973508,0.00044985043,0.0007114824,0.00035451615,0.00043828526,0.000695072],"domain_scores_gemma":[0.99608284,0.0017658469,0.00058348756,0.00027764987,0.00025429056,0.0010358938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016307266,0.00047184952,0.00222842,0.0008703139,0.00014352844,0.00011816979,0.00016889551,0.00015021916,0.000011280601],"category_scores_gemma":[0.0009589788,0.0002484777,0.00023797093,0.00045458134,0.0005609204,0.0002748698,0.000045914534,0.0003928703,0.0000014116381],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27852798,0.00029087163,0.7142534,0.00034666044,0.0028377261,0.000037254475,0.0010574707,0.000007667174,0.000050681476,0.000056282028,0.0004041743,0.002129849],"study_design_scores_gemma":[0.89153737,0.0056848857,0.09475622,0.001024234,0.003889791,0.0000016796612,0.00032071184,0.00020328158,0.0016654558,0.00013956513,0.0004516819,0.0003251265],"about_ca_topic_score_codex":0.00073868607,"about_ca_topic_score_gemma":0.0027639538,"teacher_disagreement_score":0.6194972,"about_ca_system_score_codex":0.00012482196,"about_ca_system_score_gemma":0.00045546843,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W2326873139","doi":"10.1016/j.jcjd.2013.08.116","title":"Effect of Type 2 Diabetes Disease Stage on Liraglutide Response in Clinical Practice: Data from the EVIDENCE® Study","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Diabetes mellitus; Type 2 diabetes; Insulin; Observational study; Internal medicine; Endocrinology","score_opus":0.06133131373255559,"score_gpt":0.3735799798490254,"score_spread":0.31224866611646984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326873139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886951,0.004760142,1.6986782e-7,0.004828811,0.00044923497,0.0010900963,0.000059289494,0.0000053231856,0.00011181909],"genre_scores_gemma":[0.99825567,0.000037895876,0.000057847195,0.0012113602,0.00020529132,0.0000159513,0.000022220178,0.00002389571,0.00016986101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966423,0.0014977923,0.00078132574,0.00027705933,0.00040165032,0.0003998993],"domain_scores_gemma":[0.9884506,0.009051165,0.00043347725,0.0010713168,0.00022762704,0.0007658146],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051634046,0.0002045732,0.0006037691,0.0002610061,0.000060029946,0.00007663603,0.0006211556,0.00005459021,0.0002882323],"category_scores_gemma":[0.022951609,0.0001237127,0.00012612961,0.0003066278,0.0001503403,0.0005245414,0.000086279455,0.0003886699,0.00007179175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064362015,0.0003302798,0.9754014,0.00004238922,0.00056343095,0.00012907792,0.00014566003,0.000011619662,0.00004707257,0.0000040152295,0.012193044,0.010488376],"study_design_scores_gemma":[0.002180619,0.009346873,0.9815781,0.0009677309,0.0010048699,9.925701e-8,0.0003679226,0.00016615853,0.000085258274,0.000019204277,0.0041748076,0.00010837019],"about_ca_topic_score_codex":0.0011051885,"about_ca_topic_score_gemma":0.001027046,"teacher_disagreement_score":0.017788203,"about_ca_system_score_codex":0.00013893236,"about_ca_system_score_gemma":0.0008625513,"threshold_uncertainty_score":0.9852785},"labels":[],"label_agreement":null},{"id":"W2326938831","doi":"10.1177/155989771111009","title":"Combined Intensive BP and Glycemic Control Has No Benefit in Reducing CV Risk in Patients with T2DM","year":2011,"lang":"en","type":"article","venue":"MD Conference Express","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Glycemic; Medicine; Regimen; Diabetes mellitus; Randomized controlled trial; Internal medicine; Clinical trial; Intensive care medicine; Endocrinology","score_opus":0.01849125873581971,"score_gpt":0.20189685296393173,"score_spread":0.183405594228112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326938831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490196,0.00006057919,0.000061521816,0.00007833183,0.000078263794,0.00082961924,0.0000121829835,0.00002816912,0.0039494038],"genre_scores_gemma":[0.99901664,0.000044744615,0.00027204683,0.00022407691,0.000011261076,0.00009291782,0.000028960294,0.000015493877,0.00029383245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990153,0.000026838374,0.00021444961,0.00031809122,0.00014696964,0.00027838195],"domain_scores_gemma":[0.99929225,0.000037261147,0.00009714326,0.0002604412,0.00022479334,0.00008809829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065574495,0.00018110496,0.00036178617,0.00014834992,0.000030883108,0.000028518652,0.00008273105,0.00005527978,0.000108019696],"category_scores_gemma":[0.000055635344,0.00014161263,0.000020987627,0.00008764423,0.000095915275,0.0001258021,0.00005920318,0.00015380107,0.000020770625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005111135,0.00047681574,0.9826891,0.00004999266,0.000118503405,0.00004148344,0.0032322335,0.0000049822356,0.00020064054,0.00039458388,0.0002769347,0.0074036405],"study_design_scores_gemma":[0.030964488,0.0026560521,0.9626192,0.0008290534,0.00016518006,4.5005703e-7,0.0007239327,0.000618642,0.0005930333,0.00034373635,0.00022878665,0.00025745155],"about_ca_topic_score_codex":0.000991778,"about_ca_topic_score_gemma":0.00010070763,"teacher_disagreement_score":0.025853353,"about_ca_system_score_codex":0.000052185234,"about_ca_system_score_gemma":0.00002865306,"threshold_uncertainty_score":0.57747954},"labels":[],"label_agreement":null},{"id":"W2327248072","doi":"10.5414/cpp48400","title":"Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports","year":2010,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacology and Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Nifedipine; Blood pressure; Medicine; Bioequivalence; Pharmacology; Anesthesia; Pharmacokinetics; Internal medicine; Calcium","score_opus":0.06302953436985198,"score_gpt":0.3879503145838778,"score_spread":0.3249207802140258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327248072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917589,0.0018951222,0.0015856565,0.0011803792,0.0031421366,0.00031378242,0.0000037916209,0.000013101647,0.00010716982],"genre_scores_gemma":[0.9955608,0.0011033253,0.0016316428,0.0007152163,0.00086618843,0.0000060639254,0.0000016566015,0.000016070955,0.00009903369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980417,0.00012970969,0.0010803267,0.00019003949,0.00039386135,0.0001644031],"domain_scores_gemma":[0.9974294,0.00087311585,0.00082970905,0.0001282089,0.0005890851,0.0001504982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008796465,0.0001732562,0.00059115555,0.00011922288,0.00004063365,0.000027498292,0.00013716726,0.00012054252,0.000071815455],"category_scores_gemma":[0.000050249295,0.00010729265,0.00014216073,0.000047869085,0.00030699786,0.0000994409,0.000057342488,0.00057940854,6.740253e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009311212,0.006051513,0.77323425,0.00022557055,0.053013973,0.06635068,0.00032011024,0.00032745762,0.045116,0.0010394722,0.00014933421,0.04486045],"study_design_scores_gemma":[0.0711885,0.027805999,0.638841,0.0014374328,0.07197239,0.12625542,0.00035387216,0.027120963,0.012112861,0.0058086086,0.015898284,0.0012046669],"about_ca_topic_score_codex":0.000009643789,"about_ca_topic_score_gemma":0.000009506497,"teacher_disagreement_score":0.13439323,"about_ca_system_score_codex":0.0000064627193,"about_ca_system_score_gemma":0.00011485006,"threshold_uncertainty_score":0.43752676},"labels":[],"label_agreement":null},{"id":"W2327416432","doi":"10.1016/j.jcjd.2014.07.159","title":"Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Overweight; Placebo; Obesity; Internal medicine; Type 2 diabetes; Body mass index; Diabetes mellitus; Post-hoc analysis; Endocrinology; Alternative medicine","score_opus":0.004812209489320978,"score_gpt":0.18866752554049046,"score_spread":0.18385531605116948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327416432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686533,0.001128137,0.0000011562086,0.0002230012,0.000102788435,0.0003551725,0.000012475759,0.000005972555,0.0013059478],"genre_scores_gemma":[0.99905443,0.000027571348,0.00039085664,0.00030429184,0.000064877146,0.000003860122,0.000023795257,0.00003367767,0.0000966677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858594,0.000055868193,0.0004050438,0.00018803783,0.00028651895,0.00047859093],"domain_scores_gemma":[0.99848497,0.00012664917,0.00026546014,0.00023245598,0.00028063607,0.0006098178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002818462,0.00023184984,0.00062035886,0.00053736975,0.00005098775,0.000028592694,0.00012327953,0.00006667918,0.000065355256],"category_scores_gemma":[0.00014635644,0.00015756304,0.00005116534,0.00036827827,0.00018369347,0.00023219945,0.000015830043,0.00018093243,0.000003474373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001182966,0.00017339166,0.98883283,0.00014073745,0.0004144871,0.000011559528,0.00019924223,0.000018729137,0.00005802152,0.000102198836,0.0003649296,0.0095656],"study_design_scores_gemma":[0.007849057,0.0041459855,0.98245317,0.0011418861,0.0003967226,6.0633425e-7,0.000057187965,0.000029164901,0.00044056465,0.00007381913,0.003225049,0.00018680346],"about_ca_topic_score_codex":0.00012269794,"about_ca_topic_score_gemma":0.0018496198,"teacher_disagreement_score":0.009378797,"about_ca_system_score_codex":0.00013301837,"about_ca_system_score_gemma":0.00029303256,"threshold_uncertainty_score":0.6425234},"labels":[],"label_agreement":null},{"id":"W2327867802","doi":"10.15562/diabesity.2015.8","title":"Canagliflozin in the treatment of diabetes: Perspectives","year":2015,"lang":"en","type":"article","venue":"Diabesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Hypoglycemia; Adverse effect; Intensive care medicine; Diabetes mellitus; Glucose homeostasis; Type 2 diabetes; Pharmacotherapy; Type 2 Diabetes Mellitus; Glycemic; Blood sugar; Pharmacology; Internal medicine; Endocrinology; Insulin resistance","score_opus":0.030151904701550825,"score_gpt":0.27299383877300903,"score_spread":0.2428419340714582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327867802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98169285,0.0016253906,0.0000016402621,0.00093966164,0.000053086125,0.00053438405,0.0000052281175,0.000018991372,0.015128796],"genre_scores_gemma":[0.99894685,0.00009925489,0.00010577306,0.00014895837,0.000051649564,0.00005946097,0.000015756465,0.000006710012,0.0005656133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928963,0.000050328978,0.00012182638,0.00015192053,0.00019307743,0.00019320592],"domain_scores_gemma":[0.9995089,0.000044851146,0.000035240075,0.00029305584,0.000046424626,0.00007148899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001764778,0.00010745015,0.0002588287,0.000085545245,0.000017358347,0.000007633717,0.00007129404,0.000027316983,0.00002006812],"category_scores_gemma":[0.000030957697,0.00006412594,0.00007636847,0.00019372159,0.000056432906,0.00004007116,0.000011536603,0.000030900566,0.000023763336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003280384,0.0033486688,0.9736324,0.00003264989,0.00018646028,0.000024399977,0.012659079,0.0000058208566,0.00005421026,0.0011626469,0.0019857066,0.006875185],"study_design_scores_gemma":[0.004527958,0.0027198948,0.95619047,0.00004618983,0.0003360062,3.920702e-7,0.011270165,0.00010392023,0.0018110675,0.00047295974,0.022386573,0.0001344138],"about_ca_topic_score_codex":0.0003428652,"about_ca_topic_score_gemma":0.00025724107,"teacher_disagreement_score":0.020400867,"about_ca_system_score_codex":0.0002185839,"about_ca_system_score_gemma":0.000045851877,"threshold_uncertainty_score":0.261498},"labels":[],"label_agreement":null},{"id":"W2329842120","doi":"10.1016/j.jcjd.2013.08.114","title":"Effectiveness of Liraglutide in Type 2 Diabetes Patients Switched from a DPP-4 Inhibitor: 1-Year Data from EVIDENCE®","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Glycemic; Internal medicine; Weight loss; Sitagliptin; Diabetes mellitus; Gastroenterology; Endocrinology; Obesity","score_opus":0.023621574344599862,"score_gpt":0.24366448371330085,"score_spread":0.220042909368701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329842120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938869,0.0044649397,7.926309e-7,0.00020162096,0.0005692592,0.000530937,0.00013425977,0.00000690087,0.00020439991],"genre_scores_gemma":[0.99895227,0.00004173529,0.00042027133,0.00013713972,0.00015378316,0.000011035707,0.00022495739,0.00003107231,0.000027740596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982261,0.00016048647,0.00056880683,0.0002850302,0.0003021519,0.00045740188],"domain_scores_gemma":[0.9975522,0.0006595707,0.00030026684,0.0005821578,0.00035394312,0.0005518615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045109662,0.00022058157,0.0007030499,0.00043511108,0.000032340813,0.000053350406,0.0004465894,0.00010403084,0.00041551492],"category_scores_gemma":[0.0010075353,0.00018542487,0.00010025262,0.00033331872,0.00009691005,0.0006297502,0.000085779415,0.00019663274,0.000063616375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022015263,0.00011388215,0.9854446,0.00012287908,0.00043643767,0.000009024991,0.000106924555,0.0000033194433,0.0037158949,0.0000041278777,0.0034464975,0.0065744002],"study_design_scores_gemma":[0.002428498,0.00067437685,0.9844408,0.0032336072,0.0003416582,3.8672834e-8,0.0000840649,0.0000900079,0.0075548952,0.00048764262,0.00050008047,0.00016432731],"about_ca_topic_score_codex":0.00896731,"about_ca_topic_score_gemma":0.0044662007,"teacher_disagreement_score":0.006410073,"about_ca_system_score_codex":0.00025467272,"about_ca_system_score_gemma":0.0005000752,"threshold_uncertainty_score":0.9976321},"labels":[],"label_agreement":null},{"id":"W2330240636","doi":"10.1111/1753-0407.12328","title":"Diabetes News","year":2015,"lang":"sv","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.024524716864343408,"score_gpt":0.26474355534684557,"score_spread":0.24021883848250217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330240636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94388586,0.032962333,0.0000057042585,0.004762924,0.0037424099,0.00036752052,0.00001145942,0.000033363267,0.014228444],"genre_scores_gemma":[0.9868492,0.00060416723,0.0011127526,0.0019457254,0.0029053187,0.00000828374,0.000013823519,0.00007788677,0.006482859],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99634945,0.00017241246,0.0011999842,0.00027818856,0.0010646961,0.00093525654],"domain_scores_gemma":[0.99647754,0.0002455278,0.0010541092,0.00046757847,0.0006941273,0.0010611251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012572439,0.00047546593,0.00128927,0.00055744266,0.00006466778,0.00015072306,0.0004164779,0.00019046286,0.00027470055],"category_scores_gemma":[0.0007136549,0.00036320483,0.00056987215,0.00044077987,0.00015817673,0.00056415936,0.00016292027,0.0004617961,0.00045012365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053425207,0.0011672991,0.7533244,0.00030773683,0.0027279872,0.00010124163,0.0005329683,0.000031069598,0.0015063571,0.00019228469,0.19910231,0.04095294],"study_design_scores_gemma":[0.029723175,0.023225922,0.17020828,0.0054777004,0.014023305,0.000012262994,0.005531272,0.0008466961,0.026594985,0.0035404668,0.71910435,0.0017115758],"about_ca_topic_score_codex":0.0000069527423,"about_ca_topic_score_gemma":0.000003905056,"teacher_disagreement_score":0.5831161,"about_ca_system_score_codex":0.00035484007,"about_ca_system_score_gemma":0.00037822963,"threshold_uncertainty_score":0.999882},"labels":[],"label_agreement":null},{"id":"W2330397425","doi":"10.1016/j.jcjd.2014.07.150","title":"Glycemic Efficacy of Canagliflozin (CANA) is Largely Independent of Baseline Beta-Cell Function or Insulin Sensitivity","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Canagliflozin; Internal medicine; Endocrinology; Insulin sensitivity; Diabetes mellitus; Insulin; Urinary system; Type 2 diabetes; Insulin resistance","score_opus":0.012314976044779064,"score_gpt":0.21633960051235226,"score_spread":0.2040246244675732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330397425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996421,0.0007324033,0.000105706415,0.0008351907,0.0003352048,0.00024414307,0.000073960466,0.0000064099095,0.0012460055],"genre_scores_gemma":[0.9982166,0.00002256432,0.00029625554,0.00075226754,0.00018331541,0.0000020031905,0.000027653627,0.000027149152,0.00047214204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982998,0.00012671297,0.0006372428,0.00017840831,0.00035422057,0.00040362592],"domain_scores_gemma":[0.9978593,0.0002356734,0.00053911115,0.000292239,0.00040472273,0.00066897407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008790171,0.0002062026,0.00069899566,0.00059280463,0.000048773454,0.000013949851,0.00011345702,0.00010247541,0.00032649105],"category_scores_gemma":[0.00032294833,0.00016479053,0.000232078,0.0003110685,0.00009767997,0.00011009874,0.000018357461,0.00020965244,0.000009643646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010657227,0.001068883,0.83812153,0.0012933991,0.0027989675,0.00017806739,0.0007922922,0.00035845552,0.014755488,0.0003492031,0.032784197,0.10643377],"study_design_scores_gemma":[0.02517077,0.010342257,0.7815235,0.0016108542,0.0051603485,0.000015965064,0.00059821014,0.0019785538,0.11446965,0.00018466944,0.05820488,0.00074033655],"about_ca_topic_score_codex":0.0036121125,"about_ca_topic_score_gemma":0.024174709,"teacher_disagreement_score":0.10569344,"about_ca_system_score_codex":0.00019361087,"about_ca_system_score_gemma":0.00088642957,"threshold_uncertainty_score":0.99363154},"labels":[],"label_agreement":null},{"id":"W2330448517","doi":"10.1016/s1499-2671(09)33161-5","title":"a meta-analysis of the effect of oral antidiabetic agents on A1c levels at 12 weeks","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Meta-analysis; Diabetes mellitus; Pharmacology; Internal medicine; Traditional medicine; Endocrinology","score_opus":0.05147612150567074,"score_gpt":0.2729464043922039,"score_spread":0.22147028288653317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330448517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995084,0.0014548108,6.129532e-7,0.0012733568,0.00012695049,0.00029471697,0.00005298656,0.0000029778423,0.0017096205],"genre_scores_gemma":[0.99816346,0.0000042852685,0.00004498559,0.0006445015,0.000022646758,0.0000029671744,0.0000068435434,0.000012631904,0.0010976807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984098,0.00013737101,0.0005434623,0.00014535719,0.0003976502,0.00036633317],"domain_scores_gemma":[0.99847984,0.00013333265,0.0004916406,0.00038484138,0.00011698363,0.0003933633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058147765,0.00021503255,0.0015002318,0.0007652713,0.00006343963,0.000013577373,0.00025306834,0.000063048836,0.00057756994],"category_scores_gemma":[0.00012681686,0.00012128664,0.0017012128,0.0006129151,0.00010725955,0.00006240089,0.00001628562,0.00013194238,0.000005397939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026326705,0.00011885544,0.83027947,0.00009888632,0.15786974,0.00003113521,0.00019190511,0.00031930016,0.0016380582,0.00006107837,0.0044226726,0.0049425624],"study_design_scores_gemma":[0.0012761032,0.002708434,0.7218688,0.00007356829,0.23668112,5.819732e-7,0.000011370826,0.000054984535,0.036225755,0.00003913729,0.0009569086,0.000103240316],"about_ca_topic_score_codex":0.0001531375,"about_ca_topic_score_gemma":0.0011240852,"teacher_disagreement_score":0.10841068,"about_ca_system_score_codex":0.00016393125,"about_ca_system_score_gemma":0.00013486437,"threshold_uncertainty_score":0.6323986},"labels":[],"label_agreement":null},{"id":"W2330711757","doi":"10.4172/2155-6156.1000353","title":"Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery","year":2014,"lang":"en","type":"article","venue":"Journal of Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Princess Nourah Bint Abdulrahman University","keywords":"Medicine; Metformin; Diabetes mellitus; Gastric bypass; Gastric bypass surgery; Internal medicine; Gastroenterology; Pharmacology; Endocrinology; Obesity; Weight loss","score_opus":0.00990777671652507,"score_gpt":0.20349813781378354,"score_spread":0.19359036109725847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330711757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966931,0.0012218498,0.00081546704,0.00034430609,0.00028596996,0.00016124982,0.000003935947,0.000007234902,0.0004669274],"genre_scores_gemma":[0.99702144,0.00014564916,0.0020562352,0.0003115311,0.00024322596,0.000005843778,0.000012042399,0.000021615224,0.00018244523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984181,0.000077551034,0.0005612274,0.00010720032,0.00056698004,0.00026894486],"domain_scores_gemma":[0.9980563,0.00023778365,0.0007157234,0.00022243924,0.00065691257,0.00011085293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008489168,0.00016720312,0.0006364807,0.0003339865,0.000045521032,0.00002262932,0.00012023793,0.000040756342,0.000030859723],"category_scores_gemma":[0.00013008078,0.0000869388,0.00025760866,0.00027487724,0.000053302818,0.00024332757,0.000027604989,0.00015260195,0.0000075962616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008308953,0.0033672557,0.64642465,0.00064449955,0.005360909,0.000015399186,0.0008172547,0.013853645,0.004442911,0.0015692642,0.0065847547,0.31608856],"study_design_scores_gemma":[0.016326226,0.004489812,0.8423083,0.0016300906,0.013664762,0.000022503658,0.00046833797,0.014792756,0.027578808,0.0012656584,0.07660169,0.00085105054],"about_ca_topic_score_codex":0.000007175128,"about_ca_topic_score_gemma":5.076767e-7,"teacher_disagreement_score":0.31523752,"about_ca_system_score_codex":0.000027182097,"about_ca_system_score_gemma":0.000039206534,"threshold_uncertainty_score":0.35452613},"labels":[],"label_agreement":null},{"id":"W2330961795","doi":"10.1016/s1499-2671(09)33335-3","title":"Initial combination therapy with sitagliptin and pioglitazone: complementary effects on postprandial glucose and islet cell function","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Postprandial; Sitagliptin; Pioglitazone; Internal medicine; Endocrinology; Placebo; Insulin; Alogliptin; Type 2 diabetes; Islet; Diabetes mellitus","score_opus":0.007020235986694477,"score_gpt":0.21243389805959592,"score_spread":0.20541366207290143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330961795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497736,0.0016186208,0.0000051501197,0.001700163,0.00012359762,0.00034365838,0.000007858411,0.0000069534644,0.0012166692],"genre_scores_gemma":[0.99681926,0.000050123745,0.00011585268,0.002775774,0.00016321625,0.0000028454701,0.000033098848,0.000011488651,0.000028348113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928546,0.00004359964,0.00016693346,0.000119316144,0.00014937129,0.00023529306],"domain_scores_gemma":[0.99930394,0.00007265687,0.000104513594,0.00007757381,0.00007491448,0.00036642974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001547942,0.0001457093,0.0002463398,0.00030152831,0.000100613324,0.00005201979,0.00003446083,0.00003616523,0.00003004692],"category_scores_gemma":[0.000012988991,0.00010963302,0.000036895068,0.000086814085,0.000049418697,0.00014221366,0.0000033194358,0.00011665986,0.0000018015648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017484354,0.00069626805,0.59516406,0.0002294836,0.0008851263,0.00031057806,0.0011441953,0.0000065947015,0.0056489594,0.0014317892,0.005223215,0.38751128],"study_design_scores_gemma":[0.0177943,0.058631256,0.9077556,0.00034754083,0.000472452,0.000008374688,0.00019017866,0.000025146892,0.009760344,0.0008754475,0.003913234,0.00022610188],"about_ca_topic_score_codex":0.00006505523,"about_ca_topic_score_gemma":0.00018721644,"teacher_disagreement_score":0.38728517,"about_ca_system_score_codex":0.00007405268,"about_ca_system_score_gemma":0.00008870907,"threshold_uncertainty_score":0.4470705},"labels":[],"label_agreement":null},{"id":"W2331252176","doi":"10.1016/j.jcjd.2012.07.359","title":"Patients Treated with Liraglutide Are More Likely to Reach Target HbA1c Compared with Sitagliptin or Exenatide BID","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Exenatide; Medicine; Sitagliptin; Type 2 diabetes; Post-hoc analysis; Internal medicine; Hazard ratio; Proportional hazards model; Incidence (geometry); Cumulative incidence; Urology; Diabetes mellitus; Endocrinology; Confidence interval; Cohort","score_opus":0.014597045257797654,"score_gpt":0.22015041958429651,"score_spread":0.20555337432649887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331252176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965056,0.00039698626,0.0000067003966,0.0009919761,0.000117619056,0.00054478,0.00005599934,0.000021770016,0.0013585296],"genre_scores_gemma":[0.9947576,0.0000025605411,0.0024367191,0.0011411252,0.00019306177,0.000021965514,0.00006892269,0.0000584494,0.0013196158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818933,0.000041321244,0.0003671145,0.00018606737,0.0003765937,0.00083955406],"domain_scores_gemma":[0.99702626,0.000053402255,0.00029952632,0.0002712183,0.00040966563,0.0019399044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017783255,0.00030808273,0.0006202884,0.0005939849,0.0001106356,0.000055302164,0.00017004121,0.000057710924,0.00016022511],"category_scores_gemma":[0.00010611246,0.00018655931,0.00008430295,0.0004809287,0.000085503285,0.00029561672,0.000015609206,0.00018070069,0.00002834745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012639926,0.00022312699,0.9840124,0.000062324216,0.00064054993,0.00010687863,0.0005250027,0.000029042842,0.000038023267,0.000009875991,0.012817916,0.0014084104],"study_design_scores_gemma":[0.00357298,0.0025676263,0.9766542,0.000824344,0.0006189957,0.0000066970874,0.00053007464,0.000012518477,0.001366828,0.0000031379593,0.013560199,0.00028240914],"about_ca_topic_score_codex":0.00038821794,"about_ca_topic_score_gemma":0.003646527,"teacher_disagreement_score":0.0073582595,"about_ca_system_score_codex":0.0003546029,"about_ca_system_score_gemma":0.0003578914,"threshold_uncertainty_score":0.7607668},"labels":[],"label_agreement":null},{"id":"W2331765932","doi":"10.1016/s1499-2671(09)33280-3","title":"Why does diabetes therapy often fails?","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Diabetes mellitus; Intensive care medicine; Disease; Insulin; Type 2 diabetes; Endocrinology; Internal medicine","score_opus":0.00970887328503822,"score_gpt":0.21892979978444116,"score_spread":0.20922092649940294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331765932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714451,0.005286188,0.0000022335169,0.018418282,0.00041365525,0.00023456843,0.0000078385265,0.000020694386,0.0041714604],"genre_scores_gemma":[0.97741306,0.000073144576,0.00035316971,0.021098686,0.00038590556,0.0000041946537,0.00001146466,0.000023000062,0.00063735584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985463,0.000036212936,0.00038392414,0.00016381488,0.0002394532,0.00063027977],"domain_scores_gemma":[0.9983898,0.000053008018,0.00018924923,0.00025773482,0.00020022702,0.0009100064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025275277,0.00022628027,0.00049129035,0.00051815197,0.00009973821,0.00013495197,0.00021126423,0.00007993238,0.00043153443],"category_scores_gemma":[0.000088507375,0.0001477557,0.0002560077,0.00023780654,0.00008695465,0.00036718787,0.000006094175,0.00018572409,0.000017840328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012065948,0.00019641958,0.6501329,0.000045810084,0.0008935026,0.00010818619,0.00031625511,0.00000538775,0.0035204247,0.00031894838,0.13633536,0.20811477],"study_design_scores_gemma":[0.003872487,0.003303271,0.58917177,0.00045968825,0.00044524987,0.0000028697762,0.00025474856,0.000021963795,0.015840732,0.0030775075,0.38312984,0.00041988541],"about_ca_topic_score_codex":0.00008179218,"about_ca_topic_score_gemma":0.00060534506,"teacher_disagreement_score":0.24679448,"about_ca_system_score_codex":0.00014686157,"about_ca_system_score_gemma":0.0002930807,"threshold_uncertainty_score":0.60253024},"labels":[],"label_agreement":null},{"id":"W2331971860","doi":"10.1016/s1499-2671(09)33272-4","title":"A time course analysis of glycaemic improvements with albiglutide, a long-acting GLP-1-receptor agonist for the treatment of type 2 diabetes","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Dosing; Metformin; Placebo; Exenatide; Type 2 diabetes; Agonist; Dulaglutide; Pharmacokinetics; Internal medicine; Diabetes mellitus; Insulin; Endocrinology; Receptor","score_opus":0.010825132333888099,"score_gpt":0.24402872382676524,"score_spread":0.23320359149287714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331971860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940158,0.0040560514,0.0000101456835,0.000850389,0.00012708746,0.00061657187,0.000096125426,0.000006153192,0.00022167686],"genre_scores_gemma":[0.9984617,0.00007416603,0.00045044645,0.00022279761,0.00009852051,0.00001458289,0.000069225505,0.000022419605,0.00058612175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998552,0.000025876812,0.0005318452,0.00017048,0.00024047217,0.00047928607],"domain_scores_gemma":[0.9980675,0.00020684699,0.0006094742,0.00031477015,0.0004254106,0.00037599052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023664125,0.00024098586,0.00086701504,0.0005002362,0.000103691185,0.000030158253,0.0001780933,0.000055885776,0.00014223103],"category_scores_gemma":[0.00006494342,0.00014795261,0.00041810237,0.000704936,0.00017004047,0.00010084311,0.0000048024444,0.00006749793,0.0000027105368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019932588,0.0010346143,0.80875295,0.0001449451,0.029214378,0.000016091217,0.00093737687,0.0004236379,0.0070847236,0.00004536871,0.0024402284,0.14970635],"study_design_scores_gemma":[0.0147813335,0.052260883,0.77937645,0.001228808,0.07628063,0.0000019110048,0.0013334043,0.0058338563,0.046426278,0.000080510086,0.021579942,0.00081601535],"about_ca_topic_score_codex":0.00020819245,"about_ca_topic_score_gemma":0.00126848,"teacher_disagreement_score":0.14889033,"about_ca_system_score_codex":0.000258369,"about_ca_system_score_gemma":0.00053719175,"threshold_uncertainty_score":0.60333323},"labels":[],"label_agreement":null},{"id":"W2332662154","doi":"10.1016/j.jcjd.2013.08.209","title":"The Association Between Adherence to a Mediterranean-Style Diet and the Cardiometabolic Profile Among Adult Patients with Type 1 Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer","funders":"","keywords":"Medicine; Waist; Blood pressure; Mediterranean diet; Diabetes mellitus; Internal medicine; Lipid profile; Type 2 diabetes; Circumference; Endocrinology; Body mass index","score_opus":0.007438978302872142,"score_gpt":0.2002395171914376,"score_spread":0.19280053888856546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332662154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509925,0.0008317548,3.5145413e-7,0.0019061051,0.0002484432,0.00088122353,0.000018647082,0.0000067406977,0.0010074973],"genre_scores_gemma":[0.998519,0.000021656379,0.000056890265,0.0004969998,0.00023136336,0.00006772209,0.000017093005,0.000019325791,0.0005699415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998686,0.000089736815,0.000285764,0.0001246794,0.00034627444,0.00046755248],"domain_scores_gemma":[0.9980034,0.00031397076,0.00025953312,0.000191034,0.00069432816,0.0005377355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004376526,0.00015714495,0.00040101894,0.00016642828,0.00022034529,0.00018055015,0.00017368582,0.000050746123,0.00004403898],"category_scores_gemma":[0.00061128626,0.00007655209,0.00007712864,0.00032560673,0.00015815572,0.00020089353,0.000018734905,0.00017008522,0.000026936606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011718635,0.000009596321,0.9722996,0.000017720584,0.00074529817,6.2104715e-7,0.00037930527,6.428927e-7,0.0000041908565,0.000023123672,0.0073702508,0.019137962],"study_design_scores_gemma":[0.002125641,0.0012156264,0.99116594,0.00015056411,0.0005694159,4.7201723e-8,0.00018166323,0.000016327485,0.000069727306,0.000058882735,0.004346304,0.00009987891],"about_ca_topic_score_codex":0.00059493433,"about_ca_topic_score_gemma":0.0017271319,"teacher_disagreement_score":0.019038083,"about_ca_system_score_codex":0.00014089883,"about_ca_system_score_gemma":0.00014616114,"threshold_uncertainty_score":0.31217036},"labels":[],"label_agreement":null},{"id":"W2333300554","doi":"10.1016/j.jcjd.2014.07.149","title":"Lixisenatide Reduces BeAM Value (Difference Between Bedtime (Be) and Next-Day Pre-Breakfast (AM) Glucose): A Clinical Indicator for Initiation of Prandial Therapy","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Lixisenatide; Bedtime; Medicine; Post-prandial; Placebo; Basal insulin; Internal medicine; Endocrinology; Basal (medicine); Agonist; Type 2 diabetes; Diabetes mellitus; Insulin; Receptor","score_opus":0.037139693616494614,"score_gpt":0.29603051136746406,"score_spread":0.25889081775096945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333300554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573606,0.001363141,0.00006239472,0.001772878,0.00022702268,0.0005595213,0.00005553415,0.000007721183,0.00021574028],"genre_scores_gemma":[0.99777025,0.00011132046,0.0006902011,0.0006255941,0.0006384317,0.00001782907,0.000046547128,0.000025610367,0.00007420779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998491,0.00011776775,0.0006376829,0.00019369117,0.0002135096,0.0003463399],"domain_scores_gemma":[0.99774414,0.0007007817,0.000542873,0.00016404217,0.00016819114,0.0006799787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010671427,0.00018435942,0.00066226703,0.00037994536,0.00008331218,0.000053881136,0.00015623002,0.00012426167,0.00003011328],"category_scores_gemma":[0.0005872629,0.00014694016,0.00018898121,0.000114872404,0.00020398828,0.00017464478,0.000013622087,0.00016789704,0.0000013465008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054127057,0.00012185142,0.8399517,0.00010376603,0.0008016085,0.000002675507,0.00066855346,0.0000015315053,0.0014488406,0.00022859713,0.0012039101,0.15541284],"study_design_scores_gemma":[0.005215298,0.004027218,0.96145034,0.00035128513,0.0005919001,0.0000011628097,0.000060484494,0.00006819309,0.0131535,0.0005126364,0.014386913,0.00018104492],"about_ca_topic_score_codex":0.00007118748,"about_ca_topic_score_gemma":0.000107382046,"teacher_disagreement_score":0.15523179,"about_ca_system_score_codex":0.00006415602,"about_ca_system_score_gemma":0.000472126,"threshold_uncertainty_score":0.5992046},"labels":[],"label_agreement":null},{"id":"W2333798893","doi":"10.1016/j.jcjd.2014.07.114","title":"Least Glucose Variability Is Observed with the Combination of a GLP-1 Receptor Agonist and Basal Insulin Among Four Commonly Used Insulin Regimen in Type 2 Diabetes (VARIATION Study)","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital; Etobicoke General Hospital","funders":"","keywords":"Medicine; Insulin; Internal medicine; Endocrinology; Basal (medicine); Type 2 diabetes; Regimen; Basal insulin; Diabetes mellitus; Agonist; Glucagon-like peptide 1 receptor; Receptor","score_opus":0.017353935448842932,"score_gpt":0.211291247062554,"score_spread":0.19393731161371108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333798893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954318,0.00034417302,0.000005175883,0.0031059347,0.00013883667,0.00073533907,0.000013206251,0.0000071657937,0.00021839066],"genre_scores_gemma":[0.9993235,0.000010715812,0.00019058182,0.0003017251,0.0000614044,0.000016687858,0.000018593924,0.00002443333,0.00005239063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983154,0.00035407173,0.0005050147,0.00020670748,0.0002905907,0.00032822505],"domain_scores_gemma":[0.9982557,0.00031232816,0.00045237204,0.00031388638,0.00035478096,0.0003109025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016406177,0.00020592897,0.00054504845,0.00031011313,0.00010696091,0.000072304945,0.00018325761,0.00008031337,0.00004228998],"category_scores_gemma":[0.00046758933,0.00014501264,0.00006252504,0.0004693748,0.00019726089,0.00023440075,0.000026479094,0.00024510565,0.0000021945177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004828201,0.00032546092,0.9923543,0.000087155204,0.00031685448,0.000003521605,0.001903452,0.000012186129,0.0004086976,0.00011545643,0.00045804007,0.003966623],"study_design_scores_gemma":[0.0046837116,0.0026918536,0.98922026,0.00025603824,0.00032574753,2.0764622e-7,0.0005169564,0.0005890625,0.00076410524,0.00023656293,0.0005748734,0.00014063365],"about_ca_topic_score_codex":0.0008836904,"about_ca_topic_score_gemma":0.011314134,"teacher_disagreement_score":0.010430443,"about_ca_system_score_codex":0.00021043622,"about_ca_system_score_gemma":0.00033766197,"threshold_uncertainty_score":0.6313552},"labels":[],"label_agreement":null},{"id":"W2333810203","doi":"10.1055/s-0035-1549682","title":"Wirksamkeit und Verträglichkeit von Dapagliflozin über 2 Jahre bei T2DM-Patienten mit kardiovaskulärer Vorerkrankung","year":2015,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Dapagliflozin; Gynecology; Type 2 Diabetes Mellitus; Endocrinology; Diabetes mellitus","score_opus":0.04387474780275619,"score_gpt":0.2946987693157108,"score_spread":0.25082402151295463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333810203","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3172328,0.5804753,0.00065464305,0.0061488533,0.016364837,0.0054460205,0.0005645542,0.0014338358,0.07167921],"genre_scores_gemma":[0.9452604,0.00685804,0.004117,0.0055616098,0.0038164656,0.00070626213,0.0034767664,0.0006607696,0.029542675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907216,0.00056151365,0.0016040272,0.0022033544,0.0019868438,0.0029226665],"domain_scores_gemma":[0.99381185,0.0005498009,0.00063227536,0.0026728543,0.00076599687,0.0015672345],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015102518,0.0017441442,0.0026602151,0.0008859705,0.00040392557,0.00035536973,0.0011902908,0.0010983839,0.00037353762],"category_scores_gemma":[0.0012114907,0.0015635208,0.0010269401,0.0012995173,0.00076397514,0.00067003217,0.0010147328,0.0011512828,0.008505154],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016934301,0.0059038326,0.28201815,0.0012494732,0.0664866,0.0025061357,0.0034817837,0.0004452267,0.00014056933,0.005437358,0.3605533,0.27008414],"study_design_scores_gemma":[0.0136245,0.0029791724,0.021820253,0.0008412544,0.036176383,0.0000036956105,0.0006371,0.0013847109,0.0014141813,0.0015871241,0.917433,0.002098592],"about_ca_topic_score_codex":0.0005731466,"about_ca_topic_score_gemma":0.00010431888,"teacher_disagreement_score":0.6280276,"about_ca_system_score_codex":0.0014308828,"about_ca_system_score_gemma":0.00066695444,"threshold_uncertainty_score":0.99953043},"labels":[],"label_agreement":null},{"id":"W2334389758","doi":"10.1055/s-0034-1374990","title":"Dapagliflozin bei Patienten mit Typ-2-Diabetes und bestehender kardiovaskulärer Erkrankung: Hypotonie und Verträglichkeit in Bezug auf Volumenverlust","year":2014,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; Gynecology; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.021090220888890905,"score_gpt":0.26597844305660123,"score_spread":0.24488822216771033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334389758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6464702,0.31167358,0.00028594097,0.003604073,0.0071770167,0.0050179134,0.0004429829,0.00082403456,0.024504282],"genre_scores_gemma":[0.97990257,0.0037585814,0.0018339653,0.0036919347,0.0013074989,0.0007069385,0.0016733006,0.0004320442,0.006693158],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893258,0.0008714994,0.0019878263,0.002584552,0.0015650814,0.003665213],"domain_scores_gemma":[0.9939506,0.0013001224,0.00067945983,0.0027253716,0.00037773445,0.0009667043],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018233631,0.0019262674,0.0031358278,0.0013815957,0.00047247,0.0003531523,0.001328242,0.0012214049,0.00043299963],"category_scores_gemma":[0.0011369553,0.0018359744,0.0009625999,0.0015638783,0.0008808614,0.0006071255,0.0009928104,0.0014141399,0.0049699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045979526,0.0053225495,0.7150761,0.0016887592,0.036111586,0.0004266314,0.0010784505,0.0004972624,0.000283553,0.0031599004,0.034158446,0.20173699],"study_design_scores_gemma":[0.017713921,0.0038549732,0.1488,0.0014667009,0.03692365,9.634351e-7,0.00034408568,0.0069760075,0.0029105244,0.0026592412,0.7751661,0.003183822],"about_ca_topic_score_codex":0.0004714389,"about_ca_topic_score_gemma":0.0002946738,"teacher_disagreement_score":0.7410077,"about_ca_system_score_codex":0.0013807232,"about_ca_system_score_gemma":0.00038781716,"threshold_uncertainty_score":0.9993481},"labels":[],"label_agreement":null},{"id":"W2334786722","doi":"10.1111/j.1753-0407.2010.00097.x","title":"<i>Journal of Diabetes</i> NEWS","year":2010,"lang":"fr","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Internal medicine; Family medicine; Endocrinology","score_opus":0.008737442499982566,"score_gpt":0.24283361630021497,"score_spread":0.2340961738002324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334786722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9242348,0.041393448,0.00002099322,0.008368673,0.020542098,0.00024672828,0.000015608493,0.000010725675,0.005166904],"genre_scores_gemma":[0.9722128,0.0020615,0.0049378965,0.0020870639,0.011173987,0.0000035384364,0.0000051963552,0.00009506531,0.0074229515],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957154,0.00015986762,0.001905132,0.00019842568,0.0010094274,0.0010117444],"domain_scores_gemma":[0.99481505,0.00051248155,0.0024252352,0.0004340756,0.0009945788,0.000818598],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020040793,0.0004593001,0.0014669816,0.00066070445,0.00008423098,0.00013162955,0.00058836985,0.00030676034,0.0011813138],"category_scores_gemma":[0.00084258645,0.00035703497,0.0010049073,0.00043174456,0.0003264368,0.0008413329,0.0001218824,0.0014821348,0.00011856164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048760776,0.0020964348,0.5827923,0.0006510743,0.0033795263,0.00021290817,0.00032336297,0.000023419872,0.055771243,0.0007618169,0.13345858,0.22048059],"study_design_scores_gemma":[0.011388504,0.008906184,0.08667492,0.004105407,0.00822427,0.000074275,0.00064201996,0.00016009985,0.061331894,0.0023769024,0.8154479,0.0006675801],"about_ca_topic_score_codex":0.0000044811063,"about_ca_topic_score_gemma":0.000011600454,"teacher_disagreement_score":0.6819894,"about_ca_system_score_codex":0.00016994018,"about_ca_system_score_gemma":0.00040368398,"threshold_uncertainty_score":0.9998882},"labels":[],"label_agreement":null},{"id":"W2334834910","doi":"10.1177/171516350714000122","title":"Novel Approaches to Diabetes Treatment","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Diabetes treatment; Medicine; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.12001712873599593,"score_gpt":0.27730526313681125,"score_spread":0.15728813440081532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334834910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98388475,0.0007164064,0.00038081684,0.0007132269,0.0016195109,0.0010294451,0.00018691905,0.000053619504,0.011415281],"genre_scores_gemma":[0.98753375,0.00046958975,0.0016309833,0.004828613,0.0011018262,0.00003843138,0.000062725274,0.000073673094,0.004260381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969535,0.000030531948,0.0005371558,0.0004613427,0.00044237266,0.0015750858],"domain_scores_gemma":[0.99475884,0.00007474066,0.00013532437,0.00030800363,0.00019338653,0.0045297104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056533836,0.00046837397,0.00050845044,0.0006857935,0.0005356899,0.00014208912,0.00029648838,0.000056599893,0.0004695333],"category_scores_gemma":[0.00006434054,0.00042698655,0.0002152042,0.0006839361,0.000096667565,0.00019212964,0.000037666334,0.00027930818,0.000045371697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036265925,0.00074123155,0.02911263,0.0003160136,0.0023405503,0.08557088,0.0019102638,0.0006757529,0.012970478,0.00032784248,0.034487132,0.83118457],"study_design_scores_gemma":[0.013296775,0.0011175827,0.0018344856,0.00009900587,0.0020195162,0.17262368,0.00007272346,0.0017907331,0.048947655,0.00005273722,0.75641835,0.0017267835],"about_ca_topic_score_codex":0.011212596,"about_ca_topic_score_gemma":0.1076882,"teacher_disagreement_score":0.82945776,"about_ca_system_score_codex":0.0062335534,"about_ca_system_score_gemma":0.0019683996,"threshold_uncertainty_score":0.9998182},"labels":[],"label_agreement":null},{"id":"W2335484376","doi":"10.1016/s1499-2671(09)33270-0","title":"Safet and tolerability, pharmacokinetic and spharmacodynamics of albiglutide in Japanese subjects with type 2 diabetes: a comparison with an ethnically mixed population","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Glycemic; Pharmacokinetics; Ethnically diverse; Type 2 diabetes; Population; Pharmacodynamics; Pharmacology; Diabetes mellitus; Internal medicine; Endocrinology; Adverse effect; Environmental health","score_opus":0.014015527687432769,"score_gpt":0.26856389251315577,"score_spread":0.254548364825723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335484376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972347,0.0017067653,0.000001160202,0.00052318687,0.00004782978,0.00031431857,0.000005912171,0.000005852745,0.00016027155],"genre_scores_gemma":[0.9988322,0.000034831053,0.0006992193,0.00034545813,0.000032296764,0.000002089704,0.000023428169,0.000015639982,0.000014803089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883676,0.00006971579,0.00041369512,0.00017334952,0.00017920231,0.00032726466],"domain_scores_gemma":[0.99886763,0.00006704793,0.00022094366,0.00013091258,0.00015362864,0.000559836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029836653,0.00017975281,0.0005633324,0.0003508591,0.000034439076,0.000026443253,0.000074824835,0.000049883813,0.000014093644],"category_scores_gemma":[0.00004666583,0.00013421982,0.000027353548,0.00029205673,0.00011895712,0.00019908088,0.000007417344,0.00018081201,2.1029072e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012058861,0.00014703629,0.9792759,0.0001280725,0.00013545688,0.000025871375,0.0004402846,0.00023335486,0.000973101,0.000015832027,0.00003486596,0.01846965],"study_design_scores_gemma":[0.0032591159,0.00453337,0.9882286,0.00044407527,0.00041874117,0.0000043998,0.00019153801,0.0021936717,0.0004515908,0.00006716642,0.00006113821,0.00014659906],"about_ca_topic_score_codex":0.00039760242,"about_ca_topic_score_gemma":0.011542717,"teacher_disagreement_score":0.01832305,"about_ca_system_score_codex":0.0000981802,"about_ca_system_score_gemma":0.0001664435,"threshold_uncertainty_score":0.6441107},"labels":[],"label_agreement":null},{"id":"W2339892644","doi":"10.1007/s00508-016-0988-7","title":"Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz","year":2016,"lang":"de","type":"review","venue":"Wiener klinische Wochenschrift","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lockheed Martin (Canada)","funders":"","keywords":"Medicine; Cardiology; Internal medicine","score_opus":0.02707166540166534,"score_gpt":0.30499869113002326,"score_spread":0.2779270257283579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339892644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035030022,0.9442106,0.000045324017,0.0016592134,0.004902398,0.0043067005,0.0005517121,0.00057330227,0.04340045],"genre_scores_gemma":[0.0018716368,0.9513332,0.0009553716,0.0016740134,0.00568078,0.0010795128,0.002389303,0.0007288979,0.034287274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98724985,0.000862817,0.0031034632,0.0033305709,0.0019327839,0.003520492],"domain_scores_gemma":[0.99127525,0.0011246585,0.0016041645,0.0039200312,0.0004822145,0.001593704],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0017229429,0.0033238141,0.00647191,0.0009294028,0.00053397036,0.0003744436,0.0016122669,0.0019476308,0.005363093],"category_scores_gemma":[0.00047433827,0.0023284762,0.0030055002,0.0012009607,0.0008778247,0.00051901373,0.0010567415,0.0016199825,0.041663576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009862199,0.0018857676,0.0009985308,0.019089881,0.019444268,0.00043120742,0.00028031008,0.0000013039219,0.000024269144,0.005713845,0.025382759,0.9266492],"study_design_scores_gemma":[0.0043314006,0.0011640382,0.00013917011,0.039098002,0.025186654,0.0000050473504,0.00006249426,0.000011781227,0.00021600071,0.00012023756,0.92728996,0.00237523],"about_ca_topic_score_codex":0.000029844285,"about_ca_topic_score_gemma":0.000014251226,"teacher_disagreement_score":0.924274,"about_ca_system_score_codex":0.00039872577,"about_ca_system_score_gemma":0.0010630185,"threshold_uncertainty_score":0.99934804},"labels":[],"label_agreement":null},{"id":"W2340143475","doi":"10.2337/dci15-0036","title":"DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty","year":2016,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Saxagliptin; Medicine; Metformin; Internal medicine; Diabetes mellitus; Sitagliptin; Type 2 diabetes; Heart failure; Myocardial infarction; Alogliptin; Hypoglycemia; Endocrinology","score_opus":0.0060262379325466435,"score_gpt":0.21833500442889284,"score_spread":0.2123087664963462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340143475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976296,0.0027097547,5.007493e-7,0.005768252,0.0002727259,0.00048427278,0.000056405675,0.00016221822,0.0007829054],"genre_scores_gemma":[0.9967574,0.00012217215,0.00018329638,0.0014988323,0.00036727125,0.000092302995,0.000065423104,0.000034159584,0.0008791767],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987206,0.00002684018,0.00018709384,0.00037841024,0.00024007792,0.00044696886],"domain_scores_gemma":[0.9992503,0.00007275337,0.000047569767,0.00034800975,0.00007518117,0.0002061875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007710258,0.00022805839,0.00036316382,0.00012580717,0.000074223935,0.00003136373,0.00006272228,0.0000853198,0.00005721216],"category_scores_gemma":[0.000045090525,0.00014524744,0.00011514389,0.00011162357,0.00011618273,0.0002767507,0.00008208224,0.00006695408,0.0002661339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023089218,0.0000780569,0.90097713,0.00028907543,0.0002132495,0.000011127616,0.00017749396,7.6769726e-7,0.010970456,0.0013983393,0.038649034,0.04721218],"study_design_scores_gemma":[0.0064024585,0.00090939854,0.45464426,0.0010585238,0.0004758994,0.0000015854392,0.0007429915,0.000011980332,0.029960115,0.0015743751,0.50360477,0.00061362],"about_ca_topic_score_codex":0.0000063744787,"about_ca_topic_score_gemma":0.0000060343696,"teacher_disagreement_score":0.46495578,"about_ca_system_score_codex":0.00010928088,"about_ca_system_score_gemma":0.000027668011,"threshold_uncertainty_score":0.5923019},"labels":[],"label_agreement":null},{"id":"W2340355954","doi":"10.1056/jw200909010000001","title":"Pioglitazone vs. Rosiglitazone in Older Patients with Type 2 Diabetes","year":2009,"lang":"en","type":"article","venue":"Journal watch","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pioglitazone; Rosiglitazone; Medicine; Type 2 diabetes; Myocardial infarction; Internal medicine; Retrospective cohort study; Diabetes mellitus; Heart failure; Cohort; Cardiology; Endocrinology; Insulin","score_opus":0.005194855292031074,"score_gpt":0.22362310052417664,"score_spread":0.21842824523214557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340355954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933756,0.00026512647,0.0000072573434,0.007976806,0.00015409934,0.00031841244,0.0000010070396,0.000027022757,0.001912709],"genre_scores_gemma":[0.9945657,0.00016662366,0.00078854465,0.0012999077,0.0001312987,0.000004143727,0.000022672588,0.000017069971,0.0030040364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988515,0.000023068687,0.0002472628,0.00016011139,0.00035023614,0.00036783164],"domain_scores_gemma":[0.9994383,0.000016712054,0.00008143702,0.00017279472,0.00012841198,0.00016232891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016064459,0.00015894385,0.00030300033,0.00013087109,0.000055981956,0.000041807685,0.00007245216,0.00004870477,0.00015801801],"category_scores_gemma":[0.00002423654,0.00010190794,0.00005761805,0.00026841153,0.00001914444,0.00017569131,0.000016367972,0.00021996185,0.000059549617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029063752,0.0016174411,0.95987004,0.000023491682,0.00012247695,0.00009278173,0.0002440462,0.000007425795,0.0001447151,0.000034271627,0.016973894,0.02057875],"study_design_scores_gemma":[0.005632578,0.0027954658,0.984076,0.000238633,0.00013480253,0.000003480956,0.000036647125,0.000014939579,0.0002848164,0.0003011491,0.0063445647,0.00013689122],"about_ca_topic_score_codex":0.0000034239094,"about_ca_topic_score_gemma":0.0000038126618,"teacher_disagreement_score":0.024205962,"about_ca_system_score_codex":0.00019369299,"about_ca_system_score_gemma":0.000026990687,"threshold_uncertainty_score":0.41556853},"labels":[],"label_agreement":null},{"id":"W2341277771","doi":"10.1111/dom.12679","title":"Gastrointestinal safety across the albiglutide development programme","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Liraglutide; Placebo; Tolerability; Medicine; Nausea; Vomiting; Internal medicine; Gastroenterology; Adverse effect; Type 2 diabetes; Endocrinology; Diabetes mellitus","score_opus":0.013575770224160314,"score_gpt":0.23616941183591605,"score_spread":0.22259364161175574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341277771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405223,0.0010891021,0.00017460423,0.002717787,0.00011720174,0.00057928433,0.000011959376,0.00010920952,0.0011486312],"genre_scores_gemma":[0.9895292,0.00016095635,0.00434456,0.0009026946,0.00015192058,0.000101016376,0.000020451082,0.000021024272,0.0047681546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984408,0.0000424461,0.00024423632,0.00031757503,0.00024402588,0.0007109281],"domain_scores_gemma":[0.99923253,0.00010310041,0.00007232253,0.00030021032,0.0000719169,0.00021994054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052834465,0.00022671832,0.00033389239,0.000041401803,0.0002960044,0.000052293184,0.0001193431,0.000030226342,0.000056240453],"category_scores_gemma":[0.0001128679,0.00010995037,0.000091799884,0.00012269121,0.0002111432,0.00012027364,0.00018598951,0.00008889306,0.00009865356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051920822,0.00039144908,0.5042367,0.00007980842,0.00027617687,0.00001841723,0.00034746266,1.138385e-7,0.0016463812,0.0031342076,0.00062671315,0.4891906],"study_design_scores_gemma":[0.0016712066,0.00006521131,0.7420104,0.00014431427,0.00015920562,0.000007931834,0.000066312976,0.0000039768174,0.00432939,0.0001844005,0.25122544,0.00013220923],"about_ca_topic_score_codex":0.000008835825,"about_ca_topic_score_gemma":0.000015810054,"teacher_disagreement_score":0.4890584,"about_ca_system_score_codex":0.000043296244,"about_ca_system_score_gemma":0.00004598174,"threshold_uncertainty_score":0.4483646},"labels":[],"label_agreement":null},{"id":"W2341759996","doi":"10.25011/cim.v39i2.26481","title":"Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"Clinical and investigative medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Sulfonylurea; Metformin; Glycemic; Internal medicine; Meta-analysis; Type 2 diabetes; Diabetes mellitus; Type 2 Diabetes Mellitus; Randomized controlled trial; Relative risk; Cochrane Library; Endocrinology; Insulin; Confidence interval","score_opus":0.21382155069592904,"score_gpt":0.403985373605832,"score_spread":0.19016382290990294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341759996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002600787,0.9884477,0.000014844287,0.0039008714,0.00005569139,0.00718613,0.000059117436,0.000019075982,0.00005647244],"genre_scores_gemma":[0.0005286697,0.9963404,0.00024063079,0.0014168606,0.00005683718,0.00047459954,0.00044437748,0.000036006146,0.0004616454],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955236,0.0005489824,0.0026560074,0.00069681543,0.00030891542,0.0002657227],"domain_scores_gemma":[0.9942762,0.003399975,0.0012781034,0.00046874522,0.0002530912,0.00032383256],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0032305124,0.0006114416,0.011735038,0.0004794769,0.000049060283,0.000010153969,0.000113212205,0.00023622157,0.000062214545],"category_scores_gemma":[0.0034520978,0.0002855569,0.00096243434,0.00079140847,0.0028293193,0.00008643433,0.00006246815,0.0002364142,0.000002225428],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008759248,0.0004742384,0.0005605592,0.83142316,0.09606859,0.000004849217,0.000075662836,3.9018374e-8,7.6708716e-7,0.0018367296,0.0004569941,0.069010824],"study_design_scores_gemma":[0.0056963377,0.003816475,0.00038731293,0.1693829,0.7719743,8.773306e-7,0.000017518492,0.000017661981,0.000006232835,0.00066663563,0.047674973,0.00035877337],"about_ca_topic_score_codex":0.000007693449,"about_ca_topic_score_gemma":0.0000040502205,"teacher_disagreement_score":0.6759057,"about_ca_system_score_codex":0.00003889653,"about_ca_system_score_gemma":0.00010170321,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W2341978310","doi":"10.1055/s-0036-1580780","title":"Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin: Pooled analysis of phase III trials","year":2016,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Renal function; Medicine; Blood pressure; Internal medicine; Urology; Kidney disease; Endocrinology; Cardiology; Diabetes mellitus; Type 2 diabetes","score_opus":0.04145010487802439,"score_gpt":0.32553483769684793,"score_spread":0.2840847328188235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341978310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556476,0.0018000106,0.0005852327,0.00039666024,0.00007448711,0.0006100396,0.00008772806,0.000062038554,0.00081902574],"genre_scores_gemma":[0.99876314,0.00014443525,0.00034986576,0.00005382742,0.000039668903,0.00005649121,0.000038902515,0.000010807604,0.00054288504],"study_design_codex":"bench_or_experimental","study_design_gemma":"meta_analysis","domain_scores_codex":[0.998419,0.00013168277,0.0005857918,0.00034967775,0.00027228773,0.0002415832],"domain_scores_gemma":[0.9982717,0.0006443996,0.0005024764,0.00032362132,0.00016816068,0.00008966513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006107168,0.00020124555,0.0011639607,0.0005421881,0.00006255212,0.0000111048075,0.00007063328,0.000094673305,0.00007873762],"category_scores_gemma":[0.0005646876,0.000110592744,0.00017625511,0.0005830964,0.00023977601,0.00011069784,0.00002855073,0.00006929469,0.0000010413634],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009597208,0.0058005066,0.16225019,0.0004308171,0.282555,0.00004113732,0.0005232166,0.00047181585,0.29311374,0.0045871576,0.0009789057,0.2396503],"study_design_scores_gemma":[0.05431273,0.016030263,0.18986431,0.0011160399,0.5946624,0.000003123592,0.00067633454,0.0005094061,0.13972013,0.0005834514,0.0019454538,0.0005763563],"about_ca_topic_score_codex":0.000029839197,"about_ca_topic_score_gemma":0.00001304051,"teacher_disagreement_score":0.31210738,"about_ca_system_score_codex":0.000013019529,"about_ca_system_score_gemma":0.000052712956,"threshold_uncertainty_score":0.45098412},"labels":[],"label_agreement":null},{"id":"W2342441589","doi":"10.1016/j.jval.2015.03.318","title":"Ideglira Versus other Intensification Strategies In Patients With Type 2 Diabetes Inadequately Controlled on Basal Insulin – An Indirect Statistical Comparison","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Insulin aspart; Liraglutide; Insulin degludec; Insulin glargine; Type 2 diabetes; Hypoglycemia; Basal (medicine); Insulin; Internal medicine; Basal insulin; Diabetes mellitus; Endocrinology","score_opus":0.09327190028223893,"score_gpt":0.33845534585790626,"score_spread":0.24518344557566735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342441589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649835,0.00015481946,0.000027238644,0.00043851734,0.00022474279,0.0013126035,0.000009476606,0.00004384941,0.0012904058],"genre_scores_gemma":[0.9983179,0.000010360303,0.0009091539,0.0004507178,0.000031729596,0.00005325557,0.0001833092,0.000024284845,0.000019294317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983271,0.00027963065,0.00043673877,0.0002764887,0.00034040702,0.0003396575],"domain_scores_gemma":[0.99913317,0.00020155185,0.00014419573,0.0002192021,0.00011012506,0.00019173196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005866153,0.00016828904,0.00056631555,0.0002664412,0.000022432238,0.000030133904,0.000060405095,0.000056310208,0.000016495169],"category_scores_gemma":[0.00024439307,0.00012557651,0.00001532663,0.0002841627,0.00004674666,0.00011788971,0.000013503199,0.00017839968,0.000035683177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022740286,0.0035805558,0.9463678,0.00016380774,0.00014243026,0.000009732571,0.0020316255,0.0032311913,0.0000030877059,0.006303355,0.00069694914,0.0147291925],"study_design_scores_gemma":[0.054327797,0.020415602,0.9053404,0.00035654995,0.000052010266,3.5201275e-8,0.0014784584,0.016754705,0.000026918307,0.0005534274,0.00048585323,0.00020828746],"about_ca_topic_score_codex":0.0009770327,"about_ca_topic_score_gemma":0.0002459161,"teacher_disagreement_score":0.04102743,"about_ca_system_score_codex":0.00043369073,"about_ca_system_score_gemma":0.00030179534,"threshold_uncertainty_score":0.5120861},"labels":[],"label_agreement":null},{"id":"W2342644148","doi":"10.1016/j.numecd.2016.04.010","title":"Interaction between GPR120 p.R270H loss-of-function variant and dietary fat intake on incident type 2 diabetes risk in the D.E.S.I.R. study","year":2016,"lang":"en","type":"article","venue":"Nutrition Metabolism and Cardiovascular Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novartis Pharma; Association Diabète Risque Vasculaire; Topcon Europe Medical; Ministère de l'Enseignement Supérieur et de la Recherche; Fédération Française de Cardiologie; Fondation de France; Institut National de la Santé et de la Recherche Médicale; French Dairy Interbranch Organization; Les Laboratories Pierre Fabre","keywords":"Overweight; GPR120; Calorie; Internal medicine; Type 2 diabetes; Endocrinology; Medicine; Diabetes mellitus; Obesity; Weight loss; Incidence (geometry); Saturated fat; Receptor; Cholesterol","score_opus":0.015305713256017116,"score_gpt":0.2451423842494288,"score_spread":0.22983667099341168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342644148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763215,0.021910839,0.00006416772,0.00021692364,0.0001821674,0.0011348843,0.00005987134,0.000028415434,0.00008124043],"genre_scores_gemma":[0.99072284,0.008570437,0.000020173084,0.00010641764,0.00031405303,0.00017385796,0.0000667785,0.0000137317675,0.000011689263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984879,0.0003481226,0.00024717374,0.0003397532,0.00041241702,0.00016464265],"domain_scores_gemma":[0.9992219,0.00014864381,0.000074955875,0.0003886677,0.00006346495,0.000102347054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042147897,0.00018271463,0.0005039854,0.00020699407,0.00008121861,0.000032897675,0.000057173966,0.00004410772,0.00002104293],"category_scores_gemma":[0.00011632295,0.000103702754,0.00024767665,0.00020309429,0.00007417218,0.00018982716,0.000047095764,0.00008317047,0.0000058372734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004990083,0.0017253339,0.73985416,0.00021863126,0.002890649,0.000047304235,0.00022735397,0.000003956584,0.000070766735,0.0001557967,0.00028465452,0.2540224],"study_design_scores_gemma":[0.00511351,0.00070934265,0.978687,0.00016116125,0.0060260254,0.0000022252189,0.0008938094,0.000003540433,0.00011157268,0.00066325406,0.007506906,0.00012166202],"about_ca_topic_score_codex":0.000058878646,"about_ca_topic_score_gemma":0.0000061806054,"teacher_disagreement_score":0.25390074,"about_ca_system_score_codex":0.000023860517,"about_ca_system_score_gemma":0.000008833941,"threshold_uncertainty_score":0.42288756},"labels":[],"label_agreement":null},{"id":"W2343419019","doi":"10.14740/jocmr2547w","title":"An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Renal function; Cotransporter; Sodium; Urology; Internal medicine; Endocrinology; Metallurgy; Materials science","score_opus":0.093703660183376,"score_gpt":0.45363925276564604,"score_spread":0.35993559258227004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343419019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547983,0.00031411843,0.00002465355,0.013190837,0.00023170098,0.00060833147,0.0000042003317,0.000005399527,0.00014091474],"genre_scores_gemma":[0.9970771,0.0018375412,0.00011341771,0.0006015206,0.0001860722,0.000012815285,0.0000034373456,0.000014483137,0.00015363401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579626,0.000593512,0.0017073707,0.0002265033,0.0013369711,0.0003393651],"domain_scores_gemma":[0.996956,0.0012707916,0.0005259323,0.00042739592,0.0005141951,0.0003056876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008004992,0.00014516519,0.0007423849,0.00034273826,0.000036177087,0.000008270275,0.000282796,0.00010427445,0.00006387719],"category_scores_gemma":[0.0026864652,0.00006208649,0.00016923896,0.00049389654,0.00057080033,0.0001864394,0.000029234048,0.0005722997,0.000006767131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038075822,0.0031416474,0.39401606,0.00016501934,0.0005240131,0.00014098662,0.0002481867,0.00007943209,0.3116588,0.00019511099,0.0058647585,0.2801584],"study_design_scores_gemma":[0.015636059,0.019396631,0.7894716,0.0032981208,0.00031127397,0.0000044082776,0.0001622327,0.00012151343,0.16783078,0.00057375734,0.0030762288,0.00011735682],"about_ca_topic_score_codex":0.00006885837,"about_ca_topic_score_gemma":0.000009954152,"teacher_disagreement_score":0.39545557,"about_ca_system_score_codex":0.000074061936,"about_ca_system_score_gemma":0.0001967322,"threshold_uncertainty_score":0.32161438},"labels":[],"label_agreement":null},{"id":"W2343465675","doi":"10.1016/j.jval.2015.03.361","title":"Impact Of Weight-Related Utilities On The Cost-Effectiveness Of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Third-Line Therapy In Type 2 Diabetes Mellitus (T2dm) In A Canadian Setting","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Sitagliptin; Metformin; Weight loss; Type 2 Diabetes Mellitus; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Weight gain; Diabetes mellitus; Endocrinology; Obesity; Body weight","score_opus":0.07152820302960439,"score_gpt":0.3415893340382168,"score_spread":0.2700611310086124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343465675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898778,0.0038007111,8.837918e-8,0.0013971044,0.00024800765,0.001991879,0.000028953848,0.000013037984,0.002642408],"genre_scores_gemma":[0.999093,0.0005360948,0.000020052608,0.0001539579,0.000019261188,0.00006644898,0.000045212382,0.000024493544,0.000041477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975943,0.0006930568,0.0005174071,0.00025389323,0.00028943658,0.0006518932],"domain_scores_gemma":[0.9982507,0.0008623388,0.00016806004,0.000339331,0.00009796299,0.00028156347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027659342,0.00021171055,0.00059971464,0.0006279924,0.000027924207,0.0000071720083,0.0001317203,0.000094003495,0.000036748424],"category_scores_gemma":[0.00048121138,0.00014981366,0.000077868455,0.0008819279,0.00007056473,0.00005486507,0.000023754625,0.00025414655,0.000008895777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003363482,0.00076987984,0.95801795,0.0005527007,0.0004487118,0.00006321237,0.004918951,0.011588825,0.000067287525,0.0040715775,0.00043070488,0.015706707],"study_design_scores_gemma":[0.016984256,0.013179005,0.94681364,0.003157871,0.000057755908,9.225734e-7,0.0023207108,0.013070622,0.001520155,0.0015463505,0.001007451,0.00034123164],"about_ca_topic_score_codex":0.7874521,"about_ca_topic_score_gemma":0.2255078,"teacher_disagreement_score":0.5619443,"about_ca_system_score_codex":0.0023565635,"about_ca_system_score_gemma":0.0021526834,"threshold_uncertainty_score":0.78862464},"labels":[],"label_agreement":null},{"id":"W2344104450","doi":"10.1016/j.jval.2015.03.334","title":"Glycated Hemoglobin (Hba1c) Control In Patients with Type 2 Diabetes Mellitus (T2dm) Treated with Canagliflozin In a real-world setting","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Canagliflozin; Glycemic; Glycated hemoglobin; Internal medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology; Insulin","score_opus":0.020484828497267325,"score_gpt":0.25867420052536416,"score_spread":0.23818937202809684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344104450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941305,0.00050809747,0.0000015918885,0.0012080288,0.000064389504,0.0022392522,0.000012636739,0.00007789394,0.0017576363],"genre_scores_gemma":[0.9979331,0.00005755685,0.00043296523,0.0009250248,0.000025342144,0.000104096005,0.00018974484,0.00004670638,0.0002855034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975571,0.00024718227,0.0005586349,0.00044481995,0.00039803126,0.0007942186],"domain_scores_gemma":[0.9989509,0.00009906339,0.00018592067,0.0003373425,0.000111066765,0.00031572173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000710668,0.00028639208,0.0007048649,0.0006806687,0.000028018429,0.000019592264,0.00009079684,0.00006146481,0.000011131929],"category_scores_gemma":[0.000062408304,0.00021195371,0.000022733777,0.0015772808,0.00004603051,0.000107854066,0.000025380732,0.00022782423,0.000015989062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012894681,0.00077569473,0.99106467,0.00020782916,0.00008270286,0.00008149877,0.00047259932,0.0018187743,0.0000020954635,0.000073717616,0.00046288897,0.0036680405],"study_design_scores_gemma":[0.029617159,0.0038216803,0.9575824,0.0015864994,0.00007254155,4.428736e-7,0.00020183217,0.005573559,0.00003784652,0.00004972459,0.0011733142,0.0002830091],"about_ca_topic_score_codex":0.052167647,"about_ca_topic_score_gemma":0.01680039,"teacher_disagreement_score":0.035367258,"about_ca_system_score_codex":0.0015511017,"about_ca_system_score_gemma":0.0005061409,"threshold_uncertainty_score":0.95414406},"labels":[],"label_agreement":null},{"id":"W2344311719","doi":"10.1002/pds.4014","title":"Dose‐response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes","year":2016,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Laboratory of Public Health; Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research; Government of Canada; Diabetes Canada; Canadian Diabetes Association","keywords":"Medicine; Gliclazide; Mace; Hazard ratio; Confidence interval; Internal medicine; Proportional hazards model; Type 2 diabetes; Pharmacoepidemiology; Diabetes mellitus; Retrospective cohort study; Adverse effect; Myocardial infarction; Endocrinology; Conventional PCI; Pharmacology; Insulin; Medical prescription","score_opus":0.020523849693562857,"score_gpt":0.281765151571705,"score_spread":0.26124130187814215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344311719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949898,0.0014797669,0.000035021494,0.002554833,0.00008092415,0.00063959206,0.00002081816,0.000039321145,0.00015993424],"genre_scores_gemma":[0.9984318,0.00028701584,0.00024374829,0.00037447066,0.000049756713,0.00003758648,0.00006221569,0.000017725146,0.0004956582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799114,0.00083022594,0.00031742972,0.00038957468,0.00012028968,0.00035135096],"domain_scores_gemma":[0.99703866,0.0024382402,0.00008101873,0.00021690039,0.000046767844,0.00017843426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019713661,0.0002081337,0.0005489825,0.00015271577,0.00008726014,0.0000015420085,0.000050119503,0.000085813466,0.000033831813],"category_scores_gemma":[0.00071475655,0.00012656272,0.00007708682,0.00014476954,0.0001336436,0.00014814903,0.00006451545,0.00013839001,0.000024961118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020018888,0.00008428114,0.9771039,0.00004955209,0.00057331077,0.0000082153165,0.00006196763,0.00000457731,0.000012136061,0.000058000125,0.0002800998,0.019762103],"study_design_scores_gemma":[0.010288048,0.0002980148,0.9813246,0.00012378363,0.0006972759,8.8781724e-7,0.000013575076,0.0000067014043,0.000022439863,0.00023914788,0.00683094,0.00015458725],"about_ca_topic_score_codex":0.000020701282,"about_ca_topic_score_gemma":0.0000065608883,"teacher_disagreement_score":0.019607514,"about_ca_system_score_codex":0.0000633003,"about_ca_system_score_gemma":0.000028401717,"threshold_uncertainty_score":0.51610786},"labels":[],"label_agreement":null},{"id":"W2344377042","doi":"10.1016/j.diabres.2016.04.031","title":"Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?","year":2016,"lang":"en","type":"letter","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Medicine; Acute pancreatitis; Pancreatitis; Diabetes mellitus; Disease; Internal medicine; Meta-analysis; Incretin; Type 2 diabetes; Randomized controlled trial; Intensive care medicine; Clinical trial; Endocrinology","score_opus":0.05559122916541765,"score_gpt":0.3810542133293744,"score_spread":0.32546298416395675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344377042","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040579293,0.035469517,0.000015281614,0.91252583,0.00019549255,0.0026572426,0.00084682344,0.000053905544,0.0076566036],"genre_scores_gemma":[0.050481007,0.1979826,0.0005203623,0.72931767,0.0058406177,0.00083953043,0.0012256214,0.0002487458,0.013543871],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99252284,0.0029726229,0.0006959965,0.0008719137,0.0020682814,0.00086833886],"domain_scores_gemma":[0.97633284,0.020479174,0.0003593179,0.0017346273,0.00075132283,0.000342727],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060344944,0.0003614341,0.0010552107,0.00015087581,0.00023806874,0.00010937936,0.00042133898,0.00047390864,0.00032898132],"category_scores_gemma":[0.008328859,0.00019509485,0.00092252146,0.00027327205,0.00128119,0.00014900751,0.0002453814,0.0025492145,0.00013280059],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034717735,0.00033198774,0.08773687,0.00025121027,0.009975248,0.0001522673,0.000010923172,9.733935e-8,0.000003995314,0.000007555533,0.8316807,0.06950195],"study_design_scores_gemma":[0.0026688015,0.0017726854,0.009604419,0.0003515365,0.0031739278,3.9113684e-7,0.000020186615,0.000054388056,0.00006573536,0.00023396534,0.9818485,0.00020551016],"about_ca_topic_score_codex":0.00017179394,"about_ca_topic_score_gemma":6.351694e-7,"teacher_disagreement_score":0.1832082,"about_ca_system_score_codex":0.00006664058,"about_ca_system_score_gemma":0.0002665388,"threshold_uncertainty_score":0.9997519},"labels":[],"label_agreement":null},{"id":"W2345057135","doi":"10.14740/jocmr2540w","title":"Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sitagliptin; Type 2 diabetes; Hemoglobin; Internal medicine; Diabetes mellitus; Endocrinology; Urology; Gastroenterology","score_opus":0.10517294544638256,"score_gpt":0.44170124866435834,"score_spread":0.3365283032179758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345057135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951188,0.0007351822,0.0000017940383,0.0033533128,0.000085158135,0.000383932,0.0000054629113,0.0000019183212,0.00031441456],"genre_scores_gemma":[0.9976251,0.0018066408,0.000099720775,0.00010027259,0.00013153192,0.0000072722537,0.000003160176,0.000012461662,0.0002138483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660766,0.00035719256,0.0012469701,0.00018162122,0.0012818947,0.00032465704],"domain_scores_gemma":[0.9964431,0.0018049208,0.00045219,0.00028656138,0.0008205931,0.00019265905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00338392,0.00012449882,0.0013562653,0.0015823514,0.0000069543544,0.0000025787906,0.00017021674,0.0000951331,0.00055579306],"category_scores_gemma":[0.0020483986,0.00005597672,0.00014943643,0.001263085,0.0003363552,0.00007619801,0.000053622178,0.00032941138,0.0000021817634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004490511,0.0013530838,0.9032479,0.00005745359,0.0012285904,0.000031959753,0.00015577565,8.205993e-7,0.00032467966,0.00000354149,0.0002490087,0.08885669],"study_design_scores_gemma":[0.0118087055,0.01617462,0.9691498,0.0012718565,0.00028445967,7.334489e-8,0.000094077936,0.000012083639,0.00065249664,0.000029958692,0.00047106913,0.000050763876],"about_ca_topic_score_codex":0.000032695498,"about_ca_topic_score_gemma":0.00016002999,"teacher_disagreement_score":0.08880592,"about_ca_system_score_codex":0.00007759686,"about_ca_system_score_gemma":0.00010637709,"threshold_uncertainty_score":0.6085544},"labels":[],"label_agreement":null},{"id":"W2345950256","doi":"10.1016/j.tem.2016.04.009","title":"Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?","year":2016,"lang":"en","type":"review","venue":"Trends in Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide 1 receptor; Beta cell; Agonist; Glucagon-like peptide-1; Receptor; Endocrinology; Internal medicine; Islet; BETA (programming language); Alpha cell; Secretion; Insulin; Peptide; Chemistry; Biology; Medicine; Diabetes mellitus; Type 2 diabetes; Biochemistry","score_opus":0.05344280187717194,"score_gpt":0.3348550670529008,"score_spread":0.28141226517572887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345950256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010335895,0.98555857,0.0000151129125,0.0004311235,0.0014741835,0.0011486165,0.00005275044,0.00015531066,0.0110610025],"genre_scores_gemma":[0.000062392384,0.8786165,0.0004079667,0.000085632666,0.0005187306,0.0011330456,0.00025326302,0.000068409296,0.118854046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721426,0.000206624,0.00074815215,0.0008695488,0.00019052149,0.00077086966],"domain_scores_gemma":[0.998788,0.00008100794,0.00033671095,0.00058698317,0.00004157874,0.00016572546],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016973588,0.0006937119,0.0024114791,0.0012744566,0.00010625981,0.000025739057,0.00017274998,0.0004111938,0.0012662783],"category_scores_gemma":[0.00002845111,0.000419408,0.00039774211,0.0005116616,0.00021268577,0.00012058381,0.00017427164,0.0005487196,0.00038400188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008959369,0.00025309058,0.000012941673,0.0027893533,0.0005428009,0.0001282062,0.000035839123,2.4865356e-8,0.000003937419,0.0012950997,0.0031742845,0.99167484],"study_design_scores_gemma":[0.00295507,0.0002419152,0.00020646398,0.0024456175,0.0030406583,0.00012501676,0.0000197115,2.7106407e-7,0.000027288006,0.000043324577,0.99050033,0.00039435652],"about_ca_topic_score_codex":0.000031289273,"about_ca_topic_score_gemma":0.000022025039,"teacher_disagreement_score":0.9912805,"about_ca_system_score_codex":0.00014886998,"about_ca_system_score_gemma":0.00010894068,"threshold_uncertainty_score":0.9998258},"labels":[],"label_agreement":null},{"id":"W2346578725","doi":"10.1371/journal.pone.0154589","title":"The Human Sodium-Glucose Cotransporter (hSGLT1) Is a Disulfide-Bridged Homodimer with a Re-Entrant C-Terminal Loop","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Cysteine; Cotransporter; Chemistry; Förster resonance energy transfer; Biophysics; Xenopus; Transmembrane protein; Transmembrane domain; Membrane potential; Fluorescence; Biochemistry; Fluorophore; Membrane; Sodium; Biology; Enzyme","score_opus":0.030888110241240736,"score_gpt":0.23590835332389767,"score_spread":0.20502024308265693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346578725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865927,0.0003172019,0.000058340924,0.00717686,0.00002865941,0.00095781375,0.000022296159,0.000109656154,0.0047364845],"genre_scores_gemma":[0.97106194,0.00028625556,0.00021560563,0.00076945033,0.00012676563,0.00018695885,0.000029631814,0.000046084522,0.02727731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982826,0.000026880485,0.00027229806,0.00036625538,0.00056419784,0.00048778392],"domain_scores_gemma":[0.9989533,0.000059268423,0.000089904,0.00062730565,0.00008989764,0.00018033851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013891856,0.00025062842,0.00037043114,0.000065923225,0.00020634,0.00004481165,0.0001534802,0.000050873867,0.00047530438],"category_scores_gemma":[0.000009488642,0.00011705991,0.000108184555,0.00010815898,0.00019658208,0.00011473687,0.00003049642,0.00010819546,0.0002639711],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004737247,0.025911149,0.37874135,0.0011888703,0.015423993,0.002633431,0.0035223574,1.6271281e-7,0.45369536,0.0022180157,0.02427919,0.08764885],"study_design_scores_gemma":[0.029377053,0.0058371807,0.3226284,0.0049461867,0.012077427,0.000022224152,0.00031600858,0.000041481147,0.60271746,0.0006657597,0.020146811,0.0012239928],"about_ca_topic_score_codex":0.000024378929,"about_ca_topic_score_gemma":0.000057917212,"teacher_disagreement_score":0.1490221,"about_ca_system_score_codex":0.000073798656,"about_ca_system_score_gemma":0.00003444271,"threshold_uncertainty_score":0.52042496},"labels":[],"label_agreement":null},{"id":"W2346955125","doi":"10.1093/eurheartj/ehw158","title":"Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead","year":2016,"lang":"en","type":"letter","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Empagliflozin; Type 2 Diabetes Mellitus; Canagliflozin; Diabetes mellitus; Mace; Myocardial infarction; Internal medicine; Type 2 diabetes; Dapagliflozin; Stroke (engine); Endocrinology; Conventional PCI","score_opus":0.0154567835218368,"score_gpt":0.23703809493644012,"score_spread":0.22158131141460333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346955125","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6306009,0.00315452,0.0000038802687,0.34088832,0.002040281,0.0017524358,0.000047820828,0.00013012982,0.021381684],"genre_scores_gemma":[0.2786819,0.0014873691,0.00028977534,0.68094575,0.019947276,0.000028985338,0.0009120677,0.00069663586,0.01701027],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682105,0.00043828506,0.00059240166,0.0004349456,0.0008619941,0.0008513408],"domain_scores_gemma":[0.9986926,0.00007419277,0.00029467538,0.00059700216,0.00015380845,0.0001877209],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007214176,0.00052067207,0.00064333406,0.00034766688,0.00017220131,0.00014136985,0.00029745,0.00014476021,0.0004009341],"category_scores_gemma":[0.000023985638,0.0002623229,0.00023864768,0.00020813166,0.00016241969,0.00017345397,0.000052264553,0.001773029,0.0008702334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012162293,0.00015259118,0.24131657,0.00008283728,0.0003499063,0.0009018844,0.00012433127,3.259217e-7,0.000012829111,6.500361e-7,0.73904526,0.017891156],"study_design_scores_gemma":[0.0027606692,0.0010383129,0.27432942,0.0011745506,0.00026147073,0.000011506617,0.000009865955,3.5994879e-7,0.00005804846,0.00000509983,0.7201006,0.0002501122],"about_ca_topic_score_codex":0.000003450246,"about_ca_topic_score_gemma":0.0000022505649,"teacher_disagreement_score":0.35191903,"about_ca_system_score_codex":0.00018248319,"about_ca_system_score_gemma":0.00009342724,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W2347028544","doi":"10.1371/journal.pone.0154206","title":"Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Specialized Research Fund for the Doctoral Program of Higher Education of China; Zhongnan Hospital of Wuhan University; Peking University; National Natural Science Foundation of China; McMaster University","keywords":"Dulaglutide; Liraglutide; Medicine; Exenatide; Sitagliptin; Placebo; Hypoglycemia; Internal medicine; Type 2 diabetes; Cochrane Library; Lixisenatide; Glycemic; Discontinuation; Insulin glargine; Randomized controlled trial; Pharmacology; Endocrinology; Diabetes mellitus; Insulin","score_opus":0.08547644141615994,"score_gpt":0.29949287174555395,"score_spread":0.214016430329394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2347028544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006356184,0.99069566,0.0000048229226,0.00005551341,0.000025463247,0.008266542,0.00011425516,0.0000328752,0.00016927731],"genre_scores_gemma":[0.002447556,0.99514115,0.0003351357,0.00009321619,0.00004174575,0.0007918635,0.00014950291,0.000053296848,0.00094652694],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99617326,0.0005241742,0.0018125359,0.0006377531,0.0004860064,0.000366243],"domain_scores_gemma":[0.99563706,0.0009553315,0.0017094044,0.0012372816,0.000263258,0.0001976556],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0010756889,0.0006042818,0.016263096,0.00023802891,0.000036432135,0.0000193238,0.00020743265,0.0001919616,0.0007382574],"category_scores_gemma":[0.00060593296,0.00034582464,0.0015989518,0.0007920808,0.00023365684,0.00007201658,0.00014528813,0.00016413683,0.000024232602],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025227286,0.00052331446,0.0002468147,0.65561754,0.34014636,9.0897925e-7,0.000009246988,3.4774857e-8,7.8118245e-7,0.0000073546253,0.00008379405,0.0033386166],"study_design_scores_gemma":[0.0008323441,0.00040939372,0.00006632439,0.16577111,0.8297647,2.47858e-7,0.0000021688645,0.0000029582623,0.0000020377074,0.000003760029,0.0029231233,0.00022181508],"about_ca_topic_score_codex":0.000007038582,"about_ca_topic_score_gemma":0.0000036416602,"teacher_disagreement_score":0.48984644,"about_ca_system_score_codex":0.000081231956,"about_ca_system_score_gemma":0.00006805426,"threshold_uncertainty_score":0.9998994},"labels":[],"label_agreement":null},{"id":"W2347202413","doi":"10.1139/bcb-2016-0016","title":"Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats","year":2016,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Liraglutide; Endocrinology; Internal medicine; Creatine kinase; Creatine; Hypothalamus; Medicine; Hippocampus; Striatum; Prefrontal cortex; Chemistry; Diabetes mellitus; Type 2 diabetes; Dopamine","score_opus":0.009874513559063396,"score_gpt":0.23016669399401893,"score_spread":0.22029218043495552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2347202413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274397,0.0015445244,0.000005263207,0.0005474286,0.000012709572,0.00006404514,0.000017048882,0.0000036624833,0.005061351],"genre_scores_gemma":[0.9982683,0.0007134542,0.00007294328,0.00011372265,0.000021128173,0.000008449166,0.000031863856,0.000002578214,0.00076755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995885,0.000022249773,0.00013871206,0.00013931244,0.00002601192,0.00008520318],"domain_scores_gemma":[0.9997242,0.00004788315,0.000057141933,0.00011758331,0.000023599407,0.000029591996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006076832,0.00007050427,0.00014447144,0.000021513739,0.000014529559,0.0000026491712,0.00002624429,0.000060961458,0.0000096161875],"category_scores_gemma":[0.000026594145,0.000038326078,0.000017138778,0.000038236536,0.00017188789,0.000012604635,0.000025973755,0.000019035715,9.8199635e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060112365,0.0001338826,0.0073641976,0.000057485235,0.000032891883,0.0000036161466,0.000090813715,4.5161324e-9,0.98391944,0.0006958648,0.0000951047,0.007546574],"study_design_scores_gemma":[0.0012152501,0.00024336272,0.010346053,0.000034373454,0.00008465391,0.000007327261,0.00016109592,0.0000026648781,0.9856087,0.00014792955,0.0020985492,0.000050025785],"about_ca_topic_score_codex":0.00003023753,"about_ca_topic_score_gemma":0.000012855216,"teacher_disagreement_score":0.0074965484,"about_ca_system_score_codex":0.0000032800099,"about_ca_system_score_gemma":0.000013248625,"threshold_uncertainty_score":0.1562892},"labels":[],"label_agreement":null},{"id":"W2351420769","doi":"10.1016/j.jcjd.2015.12.004","title":"Metformin-Associated Lactic Acidosis in a Patient with Normal Renal Function","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Metformin; Lactic acidosis; Medicine; Renal function; Diabetes mellitus; Acidosis; Internal medicine; Metabolic acidosis; Endocrinology; Gastroenterology; Intensive care medicine","score_opus":0.00715822903390739,"score_gpt":0.1852358241091889,"score_spread":0.1780775950752815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2351420769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959993,0.00054984353,0.000008036679,0.0009284761,0.000121826386,0.00014113092,0.0000068815843,0.0000059373187,0.0022386184],"genre_scores_gemma":[0.9990862,0.000008988289,0.00008395326,0.00034965525,0.000047129473,0.000008213719,0.0000043166847,0.000014615352,0.00039692482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999057,0.000027672533,0.00026470397,0.000094541625,0.00018272045,0.00037334603],"domain_scores_gemma":[0.99910295,0.000050910272,0.00018383928,0.00009947683,0.00013412038,0.0004286796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018260966,0.000118417694,0.00026087847,0.00047258413,0.000038880447,0.000019438678,0.000054294513,0.00004634104,0.0001974655],"category_scores_gemma":[0.00011050202,0.00006842951,0.00007583594,0.00023255474,0.00004457217,0.0002495487,0.0000056312074,0.00009246374,0.000013520541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005727048,0.00010965836,0.8691989,0.000019516336,0.0006037988,0.00026685922,0.00017070578,0.0000033925382,0.0006445031,0.00007451077,0.001781426,0.12706943],"study_design_scores_gemma":[0.009352545,0.008384546,0.94870776,0.0018691114,0.0011482583,0.000024489827,0.00030216225,0.000016565078,0.0063106124,0.0002860463,0.023264898,0.0003329954],"about_ca_topic_score_codex":0.00019144104,"about_ca_topic_score_gemma":0.008671532,"teacher_disagreement_score":0.12673645,"about_ca_system_score_codex":0.00045460564,"about_ca_system_score_gemma":0.00038912275,"threshold_uncertainty_score":0.48389187},"labels":[],"label_agreement":null},{"id":"W2358863574","doi":"10.1186/s12872-016-0260-0","title":"Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","year":2016,"lang":"en","type":"review","venue":"BMC Cardiovascular Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Canada Research Chairs; University of British Columbia; University of Toronto; McMaster University","funders":"Canadian Institutes of Health Research; Mitacs; National Natural Science Foundation of China; Sichuan University; Canadian Diabetes Association","keywords":"Medicine; Heart failure; Observational study; Randomized controlled trial; Internal medicine; Lixisenatide; Odds ratio; Meta-analysis; Type 2 diabetes; Placebo; Exenatide; Angiology; Diabetes mellitus; Endocrinology; Pathology","score_opus":0.07908583304290631,"score_gpt":0.3264886231892626,"score_spread":0.24740279014635627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2358863574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047459984,0.9922306,0.000011685757,0.00022388359,0.00004498989,0.00734097,0.00004838433,0.000019565434,0.00003248199],"genre_scores_gemma":[0.0000319178,0.9967304,0.00054475584,0.0001390915,0.000011606473,0.0018915875,0.00019867023,0.00004338703,0.00040858774],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960948,0.001158329,0.0012986597,0.000682829,0.0005032955,0.00026208448],"domain_scores_gemma":[0.9975014,0.0010103122,0.00045153737,0.0007785492,0.0001617567,0.0000964539],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0030614904,0.00059982674,0.02146723,0.00051888486,0.00004508938,0.000028221322,0.00008893643,0.00014201978,0.000035449048],"category_scores_gemma":[0.0009937547,0.00033694378,0.0063679474,0.0006721494,0.00027303677,0.00008679032,0.00015409991,0.00011033129,0.0000056405743],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028952447,0.000026195334,0.00006668592,0.5100909,0.48787883,6.5185e-7,0.00002714697,5.810879e-7,1.4528462e-8,0.000030073135,0.00025963565,0.0015903277],"study_design_scores_gemma":[0.0068061803,0.000034324315,0.000032150205,0.041580964,0.84541464,0.000001593809,0.00004778548,0.0000019006333,2.7757086e-8,0.000015044739,0.10580296,0.00026241288],"about_ca_topic_score_codex":0.000013416977,"about_ca_topic_score_gemma":0.00006278064,"teacher_disagreement_score":0.46850994,"about_ca_system_score_codex":0.00006595155,"about_ca_system_score_gemma":0.000074573385,"threshold_uncertainty_score":0.99990827},"labels":[],"label_agreement":null},{"id":"W2377396108","doi":"","title":"Pharmacokinetic and pharmacodynamic studies on repaglinide in 20 healthy Chinese volunteers","year":2002,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Repaglinide; Pharmacokinetics; Medicine; Cmax; Insulin; Internal medicine; Endocrinology; Radioimmunoassay; Pharmacodynamics; Diabetes mellitus; Pharmacology; Type 2 diabetes","score_opus":0.03316438810717884,"score_gpt":0.3496085828618356,"score_spread":0.3164441947546568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2377396108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95143723,0.0033238162,0.0000012917525,0.0059511834,0.00023348331,0.00053022447,0.0000016470716,0.00008660073,0.03843449],"genre_scores_gemma":[0.97129804,0.0040670345,0.00016556,0.0048167896,0.0000682635,0.000050976672,0.0000062411127,0.000015774742,0.019511336],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990986,0.00002358995,0.00023492085,0.0002666952,0.00014420562,0.0002319948],"domain_scores_gemma":[0.99964446,0.00006150173,0.000032658143,0.00013778993,0.00002014351,0.00010344914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012204462,0.00016533179,0.00028610334,0.00020157553,0.000030435356,0.000006521462,0.00003433561,0.00002037665,0.00037153496],"category_scores_gemma":[0.000034596433,0.00011497303,0.000040585674,0.00019487012,0.000045478173,0.000050857692,0.000039438368,0.00009910174,0.00013472237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019755256,0.0064167166,0.5004318,0.002005685,0.003100416,0.0014517166,0.005993795,0.0006783437,0.0050354702,0.0010625077,0.18858494,0.28326312],"study_design_scores_gemma":[0.10785056,0.013503893,0.3193812,0.0013790863,0.0025387253,0.00007992782,0.003765105,0.4351787,0.002253222,0.0008539992,0.11093622,0.00227936],"about_ca_topic_score_codex":0.000019853474,"about_ca_topic_score_gemma":0.000057598907,"teacher_disagreement_score":0.43450034,"about_ca_system_score_codex":0.00009073587,"about_ca_system_score_gemma":0.0000039890965,"threshold_uncertainty_score":0.4688464},"labels":[],"label_agreement":null},{"id":"W2387599933","doi":"10.1111/dom.12684","title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"Janssen Research and Development; Roche; Novartis; Novo Nordisk; Sanofi; GlaxoSmithKline; Merck; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Amgen; Pfizer","keywords":"Canagliflozin; Sitagliptin; Metformin; Medicine; Sitagliptin Phosphate; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Pharmacology","score_opus":0.006258163269643421,"score_gpt":0.20136252006855904,"score_spread":0.1951043567989156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2387599933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944307,0.0036974654,0.0000011684749,0.00017452426,0.00006078594,0.0011152914,0.000028106933,0.000025214582,0.000466695],"genre_scores_gemma":[0.99816555,0.001181995,0.00015680777,0.00018639452,0.000020894655,0.000025960491,0.000030364155,0.000019341509,0.00021269453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868435,0.00007514192,0.0003120402,0.00034174338,0.00021583101,0.00037090966],"domain_scores_gemma":[0.9991551,0.00024361935,0.00012268034,0.0001993774,0.00009878946,0.00018044339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031840024,0.0002609128,0.0009051968,0.00024336594,0.000053122996,0.000019239475,0.000049101673,0.00008639819,0.000024766476],"category_scores_gemma":[0.0001513195,0.00015105652,0.00003520433,0.00021382293,0.00016335378,0.00014539313,0.000056131965,0.000083459105,0.000003734107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023294764,0.0008249041,0.91418236,0.00017973907,0.0006910596,0.0000049397418,0.00016238772,7.64137e-7,0.0011040437,0.0015756424,0.0000486834,0.07889598],"study_design_scores_gemma":[0.033966165,0.00090235035,0.95896894,0.00031245372,0.00061085215,7.403663e-8,0.000016589373,0.00001933514,0.0033537277,0.000119849894,0.0015379867,0.00019167615],"about_ca_topic_score_codex":0.00004052009,"about_ca_topic_score_gemma":0.00004169342,"teacher_disagreement_score":0.078704305,"about_ca_system_score_codex":0.000026119302,"about_ca_system_score_gemma":0.000026760554,"threshold_uncertainty_score":0.61599064},"labels":[],"label_agreement":null},{"id":"W2392111475","doi":"","title":"Cardiovascular Endocrinology: a challenge confronted by clinical endocrinologists","year":2005,"lang":"en","type":"article","venue":"Zhonghua neifenmi daixie zazhi","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Endocrine system; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Hormone","score_opus":0.038251321639149724,"score_gpt":0.3094104753854373,"score_spread":0.2711591537462876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2392111475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68545187,0.06981209,0.0010010148,0.028220847,0.0025019974,0.0041554803,0.00013150714,0.0021155414,0.20660965],"genre_scores_gemma":[0.9713973,0.006331093,0.001657816,0.0024661839,0.0010227507,0.00020525389,0.00025896923,0.00008623566,0.016574405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964904,0.00016893673,0.000758683,0.0009678583,0.0005221543,0.0010919602],"domain_scores_gemma":[0.99790317,0.000121826815,0.0001448502,0.0013316658,0.00010937967,0.0003891084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032864654,0.00048275988,0.0011673882,0.0001736941,0.00013038632,0.000041260755,0.0003231623,0.00022146374,0.00056664244],"category_scores_gemma":[0.00016101364,0.00042111558,0.00093514676,0.00018437275,0.00034024878,0.00017921889,0.00026843147,0.00049087295,0.001708236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034423423,0.0029734639,0.022624625,0.00013011739,0.0072933356,0.0009900053,0.00016164286,0.000015784926,0.000417649,0.0025111826,0.22397558,0.73856235],"study_design_scores_gemma":[0.007684367,0.00093973795,0.013251204,0.000050608523,0.0011624981,0.00007167478,0.000100954836,0.00015374454,0.0015642593,0.000053602107,0.97456276,0.00040460544],"about_ca_topic_score_codex":0.000056968212,"about_ca_topic_score_gemma":0.000017697526,"teacher_disagreement_score":0.75058717,"about_ca_system_score_codex":0.00017412705,"about_ca_system_score_gemma":0.00006584704,"threshold_uncertainty_score":0.99982405},"labels":[],"label_agreement":null},{"id":"W2397268769","doi":"10.1016/j.jdiacomp.2016.05.018","title":"Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials","year":2016,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Postprandial; Internal medicine; Type 2 diabetes; Post-hoc analysis; Glycated hemoglobin; Quartile; Glycemic; Diabetes mellitus; Glucagon-like peptide 1 receptor; Endocrinology; Insulin; Gastroenterology; Agonist; Exenatide; Confidence interval; Receptor","score_opus":0.014939113582577148,"score_gpt":0.240734361207701,"score_spread":0.22579524762512385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397268769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985077,0.0004216408,0.000007881005,0.00032183566,0.000018634099,0.00058894674,0.000039649505,0.000002467323,0.00009126407],"genre_scores_gemma":[0.99958265,0.00010202308,0.00012707489,0.000105028164,0.000009970667,0.000009697986,0.00003813288,0.000008073885,0.000017345898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878705,0.00009894856,0.0005506918,0.00013716571,0.00028141486,0.00014476333],"domain_scores_gemma":[0.9982105,0.0004565898,0.00063715474,0.00018279035,0.00044891686,0.00006406923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003681772,0.00012520226,0.00058621116,0.00055714994,0.000032243563,0.000012406526,0.00008179238,0.000031274234,0.00001492963],"category_scores_gemma":[0.00013248288,0.000058539776,0.00007930818,0.0006109618,0.0000641297,0.00015847763,0.000029015187,0.00006446211,5.3889937e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048226808,0.0014354147,0.9900216,0.000051164556,0.0008190612,2.4094481e-7,0.00020735277,0.0000148187455,0.00031628687,0.0000534435,0.000048920163,0.006549417],"study_design_scores_gemma":[0.009099287,0.0036547338,0.98437035,0.0002496511,0.0022342822,2.454804e-8,0.00010416258,0.000033115135,0.00007739205,0.00001675379,0.00009060202,0.00006961752],"about_ca_topic_score_codex":0.0000026805674,"about_ca_topic_score_gemma":0.000011109658,"teacher_disagreement_score":0.008617018,"about_ca_system_score_codex":0.000030748946,"about_ca_system_score_gemma":0.00002612556,"threshold_uncertainty_score":0.23871829},"labels":[],"label_agreement":null},{"id":"W2398537854","doi":"10.1136/bmj.i2927","title":"Authors’ reply to Patel and colleagues","year":2016,"lang":"en","type":"letter","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Heart failure; Psychology; Medicine; Internal medicine","score_opus":0.029368528529768023,"score_gpt":0.29781283037227213,"score_spread":0.2684443018425041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398537854","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006985284,0.00017545094,0.000010008469,0.9463464,0.00048034877,0.0012014678,0.00002843334,0.00008107574,0.05097827],"genre_scores_gemma":[0.00008138339,0.000045424404,0.00047866759,0.62450534,0.0035314462,0.00012560099,0.00008043872,0.000029032051,0.3711227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894583,0.000023229179,0.00019069316,0.0003458671,0.0002278032,0.00026658067],"domain_scores_gemma":[0.9993401,0.000047078847,0.000065116474,0.00042111453,0.00003569722,0.00009088009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001545828,0.00019002725,0.00034346856,0.00014358984,0.000028963119,0.000025447545,0.00005715597,0.00018743031,0.00021028187],"category_scores_gemma":[0.000056329965,0.00012273801,0.00006662204,0.000055866214,0.000026047566,0.000021157923,0.00009234048,0.0001716731,0.0005993339],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023119572,0.000010815723,0.0005704628,0.00012265566,0.00020136585,0.000681642,0.000042263844,4.042103e-9,0.000012349041,0.00001839213,0.97840136,0.019915588],"study_design_scores_gemma":[0.00062856294,0.00026682616,0.0017499111,0.00042332115,0.00025181982,0.0000073023048,0.000005754608,3.6558168e-7,0.00005141669,0.000100600744,0.99635756,0.00015653971],"about_ca_topic_score_codex":0.000020334242,"about_ca_topic_score_gemma":0.0000012259889,"teacher_disagreement_score":0.3218411,"about_ca_system_score_codex":0.00005519273,"about_ca_system_score_gemma":0.00002669896,"threshold_uncertainty_score":0.77034247},"labels":[],"label_agreement":null},{"id":"W2399436709","doi":"10.1016/j.jval.2016.03.1315","title":"CHARACTERISTICS OF PATIENTS INITIATING TREATMENT WITH DULAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Dulaglutide; Exenatide; Medicine; Liraglutide; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Diabetes mellitus; Endocrinology; Agonist; Receptor","score_opus":0.03022752582593738,"score_gpt":0.27330634948259236,"score_spread":0.24307882365665498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399436709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997789,0.0001228571,0.00001765328,0.00080966786,0.00005409805,0.0005676437,0.00004969815,0.000016683702,0.000572654],"genre_scores_gemma":[0.99760145,0.00042599405,0.0012739463,0.0003212503,0.000031749176,0.000028882636,0.000017795563,0.000017411174,0.00028152528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992093,0.00004626895,0.0002648383,0.00015899345,0.0001204469,0.00020019515],"domain_scores_gemma":[0.9995237,0.00006530118,0.00015369584,0.00014058159,0.000025767187,0.00009096619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011631475,0.000106790605,0.00027781818,0.000078662844,0.000024185147,0.000003974055,0.00001975063,0.000023069408,0.000029841614],"category_scores_gemma":[0.00002380201,0.00005972056,0.000018271086,0.00006679485,0.000038096812,0.00003160506,0.000014238413,0.000021414739,0.000007755918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014122935,0.0004259539,0.89020413,0.00020945002,0.000051008887,0.0000033233691,0.00040885626,2.9253795e-7,0.000041334126,0.00031408056,0.00003672162,0.108163625],"study_design_scores_gemma":[0.007667455,0.0062300772,0.9652483,0.0016290974,0.00005681228,0.0000010268805,0.00006137311,0.000045063014,0.00056105334,0.000050692965,0.018316403,0.00013268366],"about_ca_topic_score_codex":0.0004792668,"about_ca_topic_score_gemma":0.000015794349,"teacher_disagreement_score":0.108030945,"about_ca_system_score_codex":0.00022263727,"about_ca_system_score_gemma":0.0000688644,"threshold_uncertainty_score":0.24353339},"labels":[],"label_agreement":null},{"id":"W2408187559","doi":"10.2337/diaspect.22.1.6","title":"Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy","year":2009,"lang":"en","type":"article","venue":"Diabetes Spectrum","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Diabetes management; Algorithm; Dyslipidemia; Psychological intervention; Insulin resistance; Endocrinology; Nursing","score_opus":0.014341905013084931,"score_gpt":0.2638669190625858,"score_spread":0.24952501404950087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408187559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827501,0.010732725,0.000050895796,0.0035519188,0.00016547683,0.0015197893,0.000011760705,0.000024958012,0.0011923355],"genre_scores_gemma":[0.9931751,0.003895562,0.0018036113,0.0008415973,0.00005960458,0.00007635907,0.00003680399,0.000014109706,0.00009725828],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99884224,0.000024096493,0.00033731194,0.00020388236,0.00030151717,0.00029094852],"domain_scores_gemma":[0.99936324,0.00017737602,0.00011393684,0.00023861857,0.000041039395,0.00006578505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030320513,0.00015240865,0.00036220768,0.00012720577,0.00002346111,0.0000053091803,0.00008987723,0.00006369605,0.000060091224],"category_scores_gemma":[0.000024323144,0.00010423868,0.000075049415,0.0002402906,0.00009460741,0.00002566622,0.00003157289,0.00006929514,0.0000016927222],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014748907,0.00079138455,0.021448616,0.00022368738,0.000660577,0.000008767807,0.00014916326,0.000005208986,0.00046893614,0.0037620005,0.0005972043,0.97173697],"study_design_scores_gemma":[0.017391788,0.00714921,0.91518223,0.0010191561,0.0008136631,0.000001297708,0.0004948517,0.01778605,0.030648116,0.005344456,0.0037984569,0.0003707044],"about_ca_topic_score_codex":0.0000051432326,"about_ca_topic_score_gemma":0.000003071059,"teacher_disagreement_score":0.9713663,"about_ca_system_score_codex":0.0000458396,"about_ca_system_score_gemma":0.000032159896,"threshold_uncertainty_score":0.425073},"labels":[],"label_agreement":null},{"id":"W2409172672","doi":"10.1111/1753-0407.12439","title":"The incretin hormone GLP‐1 and mechanisms underlying its secretion","year":2016,"lang":"en","type":"review","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; University Health Network","funders":"","keywords":"Proglucagon; Incretin; Enteroendocrine cell; Glucose homeostasis; Secretion; Glucagon-like peptide-1; Prohormone convertase; Hormone; Islet; Endocrinology; Homeostasis; Medicine; Alpha cell; Internal medicine; Biology; Insulin; Type 2 diabetes; Endocrine system; Diabetes mellitus; Beta cell; Insulin resistance; Prohormone","score_opus":0.0434244877586062,"score_gpt":0.3165189818888984,"score_spread":0.2730944941302922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409172672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042949323,0.9975643,0.00005711006,0.00042381664,0.00028170898,0.0005057357,0.0000057091247,0.000014281589,0.00071784365],"genre_scores_gemma":[0.00058978813,0.9977297,0.00022103144,0.0000673439,0.00020286183,0.000020482377,0.000008519905,0.00004185397,0.0011183767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998373,0.0001225428,0.0006729494,0.0001576402,0.00036737754,0.00030649322],"domain_scores_gemma":[0.9981598,0.0004733364,0.00088664494,0.00019480806,0.00012675206,0.00015865493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090401707,0.00029722063,0.0012257529,0.00021251822,0.00012480865,0.000083999956,0.00015691327,0.00015011297,0.000021663287],"category_scores_gemma":[0.00017759192,0.00013576512,0.0004055231,0.0001241019,0.000051521838,0.00011967336,0.00009213756,0.00027261124,0.000028475917],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000075899734,0.000031906977,0.00001347516,0.0025020326,0.0011303001,0.00001566893,0.000009922232,7.868347e-9,0.00007884853,0.0017217208,0.0012397429,0.99324876],"study_design_scores_gemma":[0.0008297841,0.0009287291,0.00010597524,0.01932408,0.0035337457,0.000020829968,0.000027362225,0.000002743179,0.000017314384,0.0013788489,0.9736608,0.0001697747],"about_ca_topic_score_codex":2.3493206e-7,"about_ca_topic_score_gemma":2.532882e-7,"teacher_disagreement_score":0.993079,"about_ca_system_score_codex":0.00014116615,"about_ca_system_score_gemma":0.000102288126,"threshold_uncertainty_score":0.5536341},"labels":[],"label_agreement":null},{"id":"W2409275980","doi":"","title":"Diabetes mellitus related morbidity, risk of hospitalization and disability.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Diabetes mellitus; Stroke (engine); Population; Heart failure; Disease; Cataracts; Comorbidity; Internal medicine; Pediatrics; Ophthalmology","score_opus":0.010294594485574477,"score_gpt":0.20916252984537637,"score_spread":0.19886793535980188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409275980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866722,0.0013048401,0.000008868129,0.00018116983,0.000094335526,0.0008503811,0.0000044356784,0.000039419672,0.010844355],"genre_scores_gemma":[0.99832815,0.00049086293,0.00010692498,0.000025275924,0.000009165802,0.0002600161,0.000018928988,0.000009915651,0.00075077784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993262,0.00004645428,0.000167162,0.00015898996,0.000118072734,0.00018306648],"domain_scores_gemma":[0.9995881,0.00004259158,0.00007211423,0.00018761645,0.000026428455,0.00008315858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027737548,0.000082852974,0.00017934719,0.000035270103,0.000023350345,0.000008347109,0.000022198054,0.00003919645,0.00002704416],"category_scores_gemma":[0.0002463961,0.00006705676,0.000044036355,0.00013811664,0.00009977363,0.00006133786,0.00001913599,0.0000374476,0.000002953396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005527513,0.00023853852,0.9399207,0.000080348,0.00018530959,8.425787e-7,0.000045021723,0.000002155682,0.0000063622033,0.0019866668,0.00018171148,0.057346806],"study_design_scores_gemma":[0.00096256245,0.00006631069,0.9919339,0.000009748487,0.00038796663,2.2823883e-7,0.000024216972,0.00003174772,0.0020864622,0.002197559,0.00223674,0.00006258513],"about_ca_topic_score_codex":0.000015050122,"about_ca_topic_score_gemma":0.000003023091,"teacher_disagreement_score":0.05728422,"about_ca_system_score_codex":0.000034297835,"about_ca_system_score_gemma":0.0000036506478,"threshold_uncertainty_score":0.27344954},"labels":[],"label_agreement":null},{"id":"W2410032344","doi":"10.7326/acpjc-2008-148-2-039","title":"Review: Thiazolidinediones increase congestive heart failure but not cardiovascular deaths in prediabetes or type 2 diabetes","year":2008,"lang":"en","type":"article","venue":"ACP Journal Club","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prediabetes; Medicine; Heart failure; Type 2 diabetes; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.024728924011874563,"score_gpt":0.25927874787543703,"score_spread":0.23454982386356246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410032344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89404446,0.10000971,0.0000034160828,0.0041605206,0.0003271009,0.0008099048,0.00000891505,0.00006771443,0.0005682508],"genre_scores_gemma":[0.9192083,0.07139883,0.0013430717,0.0058017387,0.0006837043,0.00007205288,0.000042188523,0.000054285236,0.0013958602],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793524,0.00017323298,0.00049557356,0.0003307501,0.0005187458,0.0005464902],"domain_scores_gemma":[0.9986302,0.0001808463,0.00012668807,0.00043260917,0.00029170836,0.00033793072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007655942,0.0003156794,0.00097441894,0.0002347495,0.00016879651,0.00003123021,0.00016426013,0.00010740856,0.00023121665],"category_scores_gemma":[0.00083899376,0.00021738336,0.000408173,0.00044600043,0.00010044361,0.00028527016,0.000100017816,0.0004417696,0.00014636516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007711285,0.0011283986,0.4954083,0.0022413787,0.005374392,0.0034477229,0.0003833939,0.000072809584,0.0016654867,0.00006920268,0.47384733,0.015590453],"study_design_scores_gemma":[0.010230585,0.0041995286,0.20644806,0.009580747,0.0044394312,0.0014048994,0.0002940029,0.00012533752,0.009241456,0.00018056389,0.75285167,0.001003723],"about_ca_topic_score_codex":0.000027414017,"about_ca_topic_score_gemma":0.000010281086,"teacher_disagreement_score":0.28896025,"about_ca_system_score_codex":0.00015201348,"about_ca_system_score_gemma":0.000190944,"threshold_uncertainty_score":0.8864636},"labels":[],"label_agreement":null},{"id":"W2410715964","doi":"10.1111/1753-0407.12377","title":"Diabetes News","year":2016,"lang":"sv","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mace; Diabetes mellitus; Hazard ratio; Myocardial infarction; Randomized controlled trial; Confidence interval; Family medicine; Accordion; Gerontology; Internal medicine","score_opus":0.012111268086890043,"score_gpt":0.24362813160799918,"score_spread":0.23151686352110915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410715964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632366,0.015896684,0.000016387967,0.011981092,0.0026842176,0.00034187405,0.00002230197,0.0000328671,0.00578802],"genre_scores_gemma":[0.98189014,0.0021174075,0.0005265258,0.0014312017,0.002367279,0.000009001052,0.000003240492,0.00007469155,0.0115804905],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965413,0.00014569056,0.0012057363,0.00030759996,0.0007936273,0.0010060034],"domain_scores_gemma":[0.99685365,0.00060927,0.0010802483,0.0004990235,0.0003921856,0.0005656119],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007802083,0.0004744092,0.0011943264,0.00054066064,0.000083674284,0.00008806864,0.00041236638,0.00018343079,0.0012605466],"category_scores_gemma":[0.00054992706,0.00026632386,0.00070374005,0.0003095619,0.00020662196,0.0005980904,0.00014404413,0.00025243778,0.0005918465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037126312,0.0007420824,0.7028545,0.00025810592,0.002610229,0.000056890978,0.00010171926,8.738836e-7,0.031627063,0.0002645452,0.06464171,0.19680513],"study_design_scores_gemma":[0.021049917,0.01204489,0.40778142,0.011725556,0.008598652,0.0000060556963,0.00057792006,0.000041595275,0.102653705,0.0024300928,0.4318232,0.001267008],"about_ca_topic_score_codex":0.0000022322026,"about_ca_topic_score_gemma":0.0000027442534,"teacher_disagreement_score":0.36718148,"about_ca_system_score_codex":0.00028900217,"about_ca_system_score_gemma":0.00017117838,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2411043285","doi":"","title":"Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Blockade; Blood pressure; Internal medicine; Cardiology; Angiotensin II; Angiotensin Receptor Blockers; Disease; Kidney disease; Renin–angiotensin system; Risk factor; Endocrinology; Receptor","score_opus":0.038670017766279,"score_gpt":0.23668001535228908,"score_spread":0.19800999758601007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411043285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8708421,0.09313026,0.0000024983522,0.03133117,0.00025307512,0.0018622979,0.0000014493071,0.000055546665,0.002521605],"genre_scores_gemma":[0.98166645,0.009561771,0.00015185146,0.0020314534,0.000157107,0.00033357163,0.000007133109,0.000014633237,0.006076035],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991647,0.000033820463,0.00014282904,0.00020967901,0.00014828547,0.00030068753],"domain_scores_gemma":[0.9993595,0.00012495184,0.000038467682,0.00032344006,0.000030564912,0.00012306834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018110836,0.00010785593,0.00018835897,0.0000742884,0.000041975287,0.00008651181,0.000075613156,0.000035966965,0.000026527277],"category_scores_gemma":[0.000095863776,0.000074003554,0.000042564152,0.00026328993,0.00006283735,0.0001791421,0.00005223008,0.00007999745,0.00005101481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015790223,0.00009904145,0.14751552,0.000027252587,0.00016693395,0.000007683376,0.00025640576,0.00000593103,0.000106586755,0.00008172053,0.04831483,0.8034023],"study_design_scores_gemma":[0.00041193524,0.000033932178,0.9089784,0.00012914324,0.0001616048,6.784358e-7,0.000026117561,0.00010511417,0.00028630553,0.000046211306,0.08974232,0.00007821219],"about_ca_topic_score_codex":0.000029235882,"about_ca_topic_score_gemma":0.000008876518,"teacher_disagreement_score":0.8033241,"about_ca_system_score_codex":0.000054864868,"about_ca_system_score_gemma":0.000007915232,"threshold_uncertainty_score":0.30177772},"labels":[],"label_agreement":null},{"id":"W2413843295","doi":"","title":"Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Sitagliptin; Internal medicine; Endocrinology; Gluconeogenesis; Postprandial; Glycerol; Chemistry; Glycemic; Dipeptidyl peptidase-4 inhibitor; Adipose tissue; Type 2 diabetes; Diabetes mellitus; Medicine; Metabolism; Biochemistry","score_opus":0.014598723996332021,"score_gpt":0.22220387428703892,"score_spread":0.2076051502907069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413843295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899613,0.0014340988,0.0000037454113,0.0009311606,0.00048044237,0.0024146044,0.000004545885,0.00012668231,0.0046433774],"genre_scores_gemma":[0.98846215,0.00007686331,0.00014546898,0.00027307475,0.00049533683,0.0029015779,0.00012528132,0.000034977358,0.0074852956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832755,0.00006144758,0.0002814066,0.0003077535,0.0003000792,0.0007217355],"domain_scores_gemma":[0.99912953,0.000034731183,0.0000804003,0.0003472139,0.000038532307,0.00036958331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047770562,0.00021493902,0.00029101424,0.00018820589,0.000044098713,0.00002517095,0.00006395408,0.00006780739,0.00005733118],"category_scores_gemma":[0.00027162928,0.00018362899,0.00007889604,0.00031668614,0.00004303223,0.00033607258,0.000051479827,0.00011752206,0.00012786298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038501428,0.0049291635,0.679759,0.00035919534,0.00024244493,0.00003262281,0.0005379321,0.0000016018457,0.008323097,0.00006502384,0.0480931,0.2572718],"study_design_scores_gemma":[0.00333624,0.00011814845,0.87178075,0.00010474145,0.0003197415,0.0000046328764,0.0001718472,0.00002461884,0.09899937,0.000038154438,0.024785258,0.00031650104],"about_ca_topic_score_codex":0.00005049031,"about_ca_topic_score_gemma":0.000028016515,"teacher_disagreement_score":0.2569553,"about_ca_system_score_codex":0.00027301718,"about_ca_system_score_gemma":0.000016785485,"threshold_uncertainty_score":0.74881727},"labels":[],"label_agreement":null},{"id":"W2416445012","doi":"10.1016/s1701-2163(16)30676-4","title":"The “Glitazones”: Rosiglitazone and Pioglitazone","year":2003,"lang":"en","type":"review","venue":"Journal of Obstetrics and Gynaecology Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Rosiglitazone; Pioglitazone; Metformin; Gynecology; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; Diabetes mellitus; Insulin; Endocrinology","score_opus":0.0200253763128297,"score_gpt":0.2621970083117474,"score_spread":0.24217163199891772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416445012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023621476,0.9903863,0.0000025044305,0.00020691345,0.0069178008,0.0004581817,0.000013884508,0.0000033695528,0.0017748142],"genre_scores_gemma":[0.00029826097,0.9965362,0.00016574976,0.00019617681,0.000045661105,0.000013329754,0.0000074978007,0.00003208632,0.0027050364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979879,0.00012979266,0.0009119149,0.00021839835,0.00036724342,0.00038474755],"domain_scores_gemma":[0.9951793,0.003229192,0.00078850647,0.000251042,0.00022457847,0.00032737028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005325759,0.00034510996,0.0016801747,0.00028666237,0.00020424825,0.000057447593,0.0001483139,0.00021760976,0.000040535357],"category_scores_gemma":[0.0016454634,0.00019347177,0.0002238066,0.00039104896,0.00013745498,0.000048619342,0.00008303429,0.00052405027,0.0000010760699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001364978,0.000052915868,0.0003712227,0.0018195508,0.0009647989,0.0013678515,0.0000093695135,6.547289e-8,9.553271e-9,0.00053666416,0.005460689,0.9894155],"study_design_scores_gemma":[0.0011251476,0.0005214509,0.0010505026,0.0002587422,0.0029550865,0.00020712703,0.00008228024,7.331597e-7,7.1445115e-8,0.00008054301,0.9935564,0.00016193604],"about_ca_topic_score_codex":0.00092912954,"about_ca_topic_score_gemma":0.00295533,"teacher_disagreement_score":0.9892536,"about_ca_system_score_codex":0.0011498361,"about_ca_system_score_gemma":0.0019387609,"threshold_uncertainty_score":0.78895503},"labels":[],"label_agreement":null},{"id":"W2416488997","doi":"10.1016/j.molmet.2016.05.014","title":"Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival","year":2016,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Natural Sciences and Engineering Research Council of Canada","keywords":"Glucagon; Endocrinology; Internal medicine; Glucagon receptor; Insulin; Diabetes mellitus; Knockout mouse; Receptor; Medicine; Biology; Chemistry","score_opus":0.009401615512820784,"score_gpt":0.2306908801321935,"score_spread":0.2212892646193727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416488997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906071,0.005326884,0.0003359027,0.0022338186,0.0003451098,0.0007580064,0.000032479937,0.000083564104,0.00027712394],"genre_scores_gemma":[0.991079,0.0023670373,0.004072877,0.00026828947,0.0001516555,0.000109404784,0.000038770228,0.0000490018,0.0018639724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982864,0.00013201624,0.0003336083,0.00053093606,0.00033136804,0.00038566368],"domain_scores_gemma":[0.9993026,0.000029896006,0.00010049373,0.00032791903,0.00008153945,0.00015751584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033647023,0.00028871806,0.000480121,0.00022981029,0.000045876877,0.00003447188,0.000108285196,0.00009811653,0.000036829268],"category_scores_gemma":[0.00011162186,0.00017919064,0.00009853744,0.00017373354,0.000094523915,0.00014730537,0.00010867713,0.00009426465,0.000040706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019448831,0.00039350163,0.00032173964,0.000045127596,0.00022560026,0.00008249479,0.00016187264,0.0000011686864,0.9287826,0.0007166049,0.000010440329,0.069064364],"study_design_scores_gemma":[0.0047509847,0.00012592625,0.009843756,0.00011976612,0.0005418807,0.0000057896636,0.000043957913,0.000025307487,0.97918993,0.0003718628,0.004733875,0.0002469569],"about_ca_topic_score_codex":0.00012725877,"about_ca_topic_score_gemma":0.000018073075,"teacher_disagreement_score":0.06881741,"about_ca_system_score_codex":0.000036300815,"about_ca_system_score_gemma":0.000040566218,"threshold_uncertainty_score":0.73071826},"labels":[],"label_agreement":null},{"id":"W2416547215","doi":"10.1177/1715163515600674","title":"Individualizing drug therapy in patients with diabetes and chronic kidney disease","year":2015,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"","keywords":"Medicine; Linagliptin; Alogliptin; Saxagliptin; Sitagliptin; Renal function; Kidney disease; Dialysis; Diabetes mellitus; Ramipril; Urology; Dosing; Pharmacology; Metformin; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.022345758425713326,"score_gpt":0.24452762414992424,"score_spread":0.22218186572421092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416547215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958285,0.002069172,0.0000011495221,0.00031043825,0.00046858852,0.00062113674,0.00017619,0.000017381144,0.00050746126],"genre_scores_gemma":[0.9939196,0.0010871113,0.000065290806,0.0040042694,0.0002812258,0.000029200994,0.000120432946,0.000049608563,0.00044322084],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979678,0.000082439765,0.00031240907,0.00032575626,0.00046338007,0.0008482173],"domain_scores_gemma":[0.99446326,0.000025748324,0.00012442924,0.00018078445,0.00025351145,0.0049522356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003273224,0.0003181227,0.00034419785,0.00043791835,0.0002197402,0.0001361345,0.00018537375,0.000024046238,0.00014556981],"category_scores_gemma":[0.00007462212,0.00027183612,0.000050664858,0.0003924846,0.00012828005,0.00033820848,0.00003342021,0.0003157707,0.000003906883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026935464,0.00014537996,0.89673805,0.0001746392,0.00034410378,0.012619427,0.0008173605,0.00008532544,0.000026431939,0.000011957349,0.021621495,0.06714649],"study_design_scores_gemma":[0.20281957,0.0031770759,0.15219173,0.0013420726,0.0029327564,0.015039205,0.00014069775,0.0056686844,0.0029632708,0.00039167854,0.6079299,0.0054033473],"about_ca_topic_score_codex":0.0032540204,"about_ca_topic_score_gemma":0.017109875,"teacher_disagreement_score":0.7445463,"about_ca_system_score_codex":0.002838386,"about_ca_system_score_gemma":0.004606901,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W2419285181","doi":"10.1111/1753-0407.12094","title":"Journal of Diabetes News","year":2013,"lang":"fr","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.011311012495103981,"score_gpt":0.2396497407918532,"score_spread":0.22833872829674923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419285181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696853,0.10792842,0.000022720302,0.010950732,0.0072916024,0.00035200416,0.0000068442964,0.000009243822,0.0037531247],"genre_scores_gemma":[0.9725048,0.0039479067,0.0037979377,0.0018232787,0.0065921578,0.000008300918,0.0000041480703,0.000085975,0.0112355165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956397,0.00022856529,0.001977302,0.00017959723,0.0009555323,0.0010193496],"domain_scores_gemma":[0.99472386,0.0005249493,0.0023659123,0.00034131645,0.0012823625,0.00076160615],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012223291,0.0004480035,0.0014956305,0.0007110618,0.00007614014,0.0001951024,0.0005054096,0.00021691076,0.0027760689],"category_scores_gemma":[0.00065492466,0.00033422202,0.00093476014,0.00040850084,0.00025593117,0.0013309936,0.00011819064,0.00070393004,0.00038391098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016733127,0.0014033063,0.53867215,0.00065561064,0.0037242013,0.00007564982,0.00032493725,0.00004291201,0.0074209664,0.00028484853,0.21123566,0.23614302],"study_design_scores_gemma":[0.017614547,0.020526512,0.4450693,0.013660902,0.012687108,0.00006651044,0.0032024728,0.0006561117,0.040226635,0.007889247,0.43720224,0.0011984201],"about_ca_topic_score_codex":0.000012666705,"about_ca_topic_score_gemma":0.000002516485,"teacher_disagreement_score":0.2349446,"about_ca_system_score_codex":0.00032353817,"about_ca_system_score_gemma":0.00028111186,"threshold_uncertainty_score":0.999911},"labels":[],"label_agreement":null},{"id":"W2419494614","doi":"10.1016/j.jcjd.2016.04.008","title":"WITHDRAWN: Targets for Glycemic Control","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":true,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Control (management); Internal medicine; Artificial intelligence; Insulin; Computer science","score_opus":0.007744575099900559,"score_gpt":0.21287332728235805,"score_spread":0.2051287521824575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419494614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824147,0.0029777153,0.0005368614,0.010352104,0.000668195,0.00054535107,0.00006503853,0.000012877746,0.0024271202],"genre_scores_gemma":[0.99646926,0.000007703485,0.00048442365,0.0011860845,0.00029021475,0.000013882454,0.000003057497,0.000020024621,0.0015253365],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916273,0.00001122457,0.00023900885,0.000093786766,0.000100937374,0.00039231576],"domain_scores_gemma":[0.9988116,0.00010405668,0.00013285984,0.00012486932,0.00019333477,0.00063326355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015681145,0.00011297261,0.00030455602,0.00023995321,0.00005479365,0.000019863386,0.00009471444,0.000043235086,0.000165556],"category_scores_gemma":[0.00018057156,0.0000680015,0.00016370331,0.000060451308,0.00007186899,0.000117275384,0.0000029914224,0.000045053195,0.000020135638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015564427,0.00008356653,0.80287546,0.00012997178,0.0016400791,0.00007333954,0.00012382006,0.0000028298327,0.0068884906,0.0017674038,0.08776708,0.09849232],"study_design_scores_gemma":[0.042527325,0.0081912745,0.17516296,0.0015033432,0.0021154329,0.000015990143,0.00012236852,0.000056479363,0.010893869,0.003980293,0.7548608,0.0005698857],"about_ca_topic_score_codex":0.00002865247,"about_ca_topic_score_gemma":0.00049087126,"teacher_disagreement_score":0.6670937,"about_ca_system_score_codex":0.00016787616,"about_ca_system_score_gemma":0.00044526474,"threshold_uncertainty_score":0.27730206},"labels":[],"label_agreement":null},{"id":"W2424539745","doi":"10.1056/nejmoa1515920","title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3629,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Placebo; Hazard ratio; Internal medicine; Diabetes mellitus; Albuminuria; Renal function; Type 2 diabetes; Diabetic nephropathy; Creatinine; Kidney disease; Urology; Surgery; Confidence interval; Endocrinology; Pathology","score_opus":0.012078441125996937,"score_gpt":0.278069689627907,"score_spread":0.2659912485019101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2424539745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96958727,0.00455693,0.000014909307,0.024928695,0.0002534427,0.00014100096,0.0000011777178,0.0000048392717,0.0005117552],"genre_scores_gemma":[0.99664456,0.0014838647,0.00024286243,0.00041462053,0.0006129575,8.5470805e-7,0.0000025843694,0.000008117016,0.0005895528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991751,0.00003383621,0.00032047278,0.00007924057,0.00026439314,0.00012697061],"domain_scores_gemma":[0.9990196,0.00009442979,0.00016732283,0.00009810317,0.0000826162,0.0005379295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003967784,0.00008957966,0.0003448829,0.00021249152,0.000007953054,0.000001938814,0.00004356347,0.000022551672,0.00014806529],"category_scores_gemma":[0.00087249104,0.000040335817,0.000028097405,0.000115489216,0.00008104275,0.00006745246,0.00001987137,0.00006272017,0.0000014810054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009160674,0.00012394266,0.5755192,0.00011533227,0.00009006257,0.00012871946,0.000176248,2.408909e-7,0.005074875,0.00007951885,0.011439448,0.40633634],"study_design_scores_gemma":[0.16190319,0.009851316,0.65808296,0.0145283695,0.0011325113,0.00003136157,0.0000804178,0.00003167509,0.003476411,0.0023225646,0.14837837,0.0001808385],"about_ca_topic_score_codex":0.0000048632487,"about_ca_topic_score_gemma":0.0000016674849,"teacher_disagreement_score":0.4061555,"about_ca_system_score_codex":0.00002337937,"about_ca_system_score_gemma":0.00011526147,"threshold_uncertainty_score":0.1644847},"labels":[],"label_agreement":null},{"id":"W2425017047","doi":"10.1007/s00125-016-4008-2","title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","year":2016,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Toronto General Hospital","funders":"Kidney Foundation of Canada; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Microalbuminuria; Medicine; Type 2 diabetes; Albuminuria; Internal medicine; Diabetes mellitus; Urology; Endocrinology; Placebo; Blood pressure; Renal function; Metformin; Pathology","score_opus":0.002741215341084006,"score_gpt":0.18922291446512146,"score_spread":0.18648169912403745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2425017047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980986,0.00017903275,0.0000012876966,0.000276874,0.00007033773,0.00096260844,0.00001185252,0.000030774536,0.00036862784],"genre_scores_gemma":[0.99946725,0.000034896108,0.000048057977,0.000091321206,0.00001508293,0.000068991874,0.00004269031,0.000024710747,0.00020696905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988822,0.0000720562,0.00021076265,0.00028772748,0.00020301987,0.0003442528],"domain_scores_gemma":[0.99922997,0.0002503464,0.00010677999,0.00028645445,0.000058651465,0.00006780478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019995293,0.00023302615,0.00039621964,0.00010098769,0.000044695906,0.000014010443,0.000057209592,0.000074039956,0.000020026786],"category_scores_gemma":[0.000032458625,0.000094015246,0.000033618882,0.00017427145,0.00025512083,0.00007169996,0.000020376841,0.00008013438,0.000015582067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002572442,0.00019518216,0.9779177,0.00009156686,0.00017276716,0.0000130915105,0.000040716797,1.328145e-7,0.0019657088,0.000033779565,0.0002873822,0.016709562],"study_design_scores_gemma":[0.009335577,0.010176903,0.8755131,0.00048075547,0.00021389716,2.2818216e-7,0.0000086186565,0.0000012652719,0.103814945,0.000018127666,0.0003029656,0.00013364296],"about_ca_topic_score_codex":0.0000041250523,"about_ca_topic_score_gemma":0.000024323363,"teacher_disagreement_score":0.102404594,"about_ca_system_score_codex":0.0000504196,"about_ca_system_score_gemma":0.000014885782,"threshold_uncertainty_score":0.38338307},"labels":[],"label_agreement":null},{"id":"W2425644022","doi":"10.1056/nejmoa1603827","title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7350,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Center for Advancing Translational Sciences; Relypsa; National Institutes of Health; ResMed; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Orexigen Therapeutics; Massachusetts Medical Society; Novo Nordisk; Intarcia Therapeutics; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Amgen; Pfizer; Celgene","keywords":"Liraglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.014279907717171853,"score_gpt":0.24628451141808885,"score_spread":0.232004603700917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2425644022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723498,0.0117545035,0.000047968206,0.01375819,0.00039516226,0.000116912954,3.4388e-7,0.000007936817,0.0015691712],"genre_scores_gemma":[0.99399173,0.0031315163,0.00025891955,0.00043471224,0.00079500966,7.3330744e-7,6.708083e-7,0.000010332459,0.0013763896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990858,0.000038040493,0.00029687237,0.000097585704,0.00031627985,0.00016546523],"domain_scores_gemma":[0.99935937,0.00015525719,0.00007796252,0.00015280406,0.00006742621,0.00018718894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006895917,0.00010994732,0.0006025514,0.00022444237,0.000010942578,0.000003491054,0.000048750913,0.00003048071,0.000110386085],"category_scores_gemma":[0.00040701937,0.00004917575,0.00008082971,0.00010432308,0.000059876245,0.00007303841,0.000020162805,0.000083614985,0.0000049691307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012159813,0.00004329258,0.50474364,0.000025155805,0.0006776187,0.00021324876,0.00012846071,9.502967e-7,0.00075822556,0.00007682592,0.002927558,0.49028346],"study_design_scores_gemma":[0.11217512,0.003528185,0.64865553,0.0014125833,0.0012652301,0.00012297087,0.00009892961,0.000004624247,0.000592148,0.0011510358,0.23085485,0.00013876123],"about_ca_topic_score_codex":0.000019216945,"about_ca_topic_score_gemma":0.000007994039,"teacher_disagreement_score":0.49014467,"about_ca_system_score_codex":0.000033073535,"about_ca_system_score_gemma":0.000036876,"threshold_uncertainty_score":0.20053288},"labels":[],"label_agreement":null},{"id":"W2427532542","doi":"10.1016/j.kint.2016.05.002","title":"Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?","year":2016,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Glycemic; Medicine; Kidney disease; Diabetes mellitus; End stage renal disease; Intensive care medicine; Stage (stratigraphy); Disease; Randomized controlled trial; Intensive care; Internal medicine; Endocrinology","score_opus":0.0067550993474169855,"score_gpt":0.24597782085371642,"score_spread":0.23922272150629942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2427532542","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025322005,0.00082735677,0.00016479008,0.9602461,0.00064000644,0.002146144,0.002704867,0.000020932406,0.007927812],"genre_scores_gemma":[0.44126883,0.0017391643,0.0003046375,0.54553354,0.0011513865,0.00049782376,0.0013943927,0.000049101272,0.008061146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998352,0.00014125954,0.0003911019,0.0002976323,0.00060323614,0.00021475762],"domain_scores_gemma":[0.99859565,0.00026864788,0.0004105226,0.0004717346,0.00018644334,0.00006699919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035107177,0.00022414335,0.00039656906,0.00016309664,0.000023910214,0.000017228169,0.00039421802,0.000077372584,0.00021502144],"category_scores_gemma":[0.00015010506,0.000110312045,0.00016209387,0.00006452228,0.0003500842,0.00010054672,0.00010354505,0.00033308435,0.000006545789],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041948985,0.0003686346,0.048833728,0.0014386789,0.010733758,0.00055840984,0.0006924615,0.00001241232,0.00007509721,0.01382552,0.9049895,0.014276895],"study_design_scores_gemma":[0.01796063,0.00025904662,0.028814722,0.0016854495,0.0020619226,0.0000016853916,0.0001571116,0.0004779072,0.000030631883,0.0015813594,0.9467803,0.00018918386],"about_ca_topic_score_codex":0.000016947663,"about_ca_topic_score_gemma":0.0000021393048,"teacher_disagreement_score":0.4159468,"about_ca_system_score_codex":0.0000697314,"about_ca_system_score_gemma":0.00004012555,"threshold_uncertainty_score":0.44983947},"labels":[],"label_agreement":null},{"id":"W2429776344","doi":"10.1016/j.jdiacomp.2016.06.015","title":"Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials","year":2016,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Linagliptin; Medicine; Placebo; Internal medicine; Coronary artery disease; Diabetes mellitus; Adverse effect; Clinical trial; Incidence (geometry); Type 2 diabetes; Endocrinology; Pathology","score_opus":0.034617282275087945,"score_gpt":0.3211522579258667,"score_spread":0.2865349756507788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2429776344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994184,0.0045458027,0.000017049391,0.00069692923,0.000032742166,0.000368067,0.00013436434,0.0000032587795,0.000017755428],"genre_scores_gemma":[0.9977377,0.0018172914,0.0002566203,0.000075424505,0.000023917299,0.0000036734439,0.000055651784,0.000007876183,0.000021853702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983701,0.00016818783,0.0009786547,0.00017360333,0.00018400594,0.00012544364],"domain_scores_gemma":[0.9974319,0.0012634373,0.00069421413,0.00018314722,0.00021394205,0.00021340513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062533136,0.00011939659,0.00091331924,0.00027973833,0.00002741851,0.0000070146525,0.000060550865,0.000039592447,0.000024390365],"category_scores_gemma":[0.00047387983,0.00006921307,0.00012408935,0.00025020924,0.000087315646,0.00010249342,0.00004845988,0.000060938066,4.896222e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004688062,0.0008837565,0.96005803,0.000040226347,0.0029548532,5.868663e-7,0.00003407964,0.0000029122277,0.00028268428,0.000066276756,0.000032075757,0.035175737],"study_design_scores_gemma":[0.0068986905,0.0009523339,0.9860397,0.0004103865,0.0051539927,5.3894624e-8,0.000013653417,0.00014754182,0.00003540643,0.00014343901,0.00013364873,0.0000711737],"about_ca_topic_score_codex":0.000001139294,"about_ca_topic_score_gemma":0.0000016246361,"teacher_disagreement_score":0.03510456,"about_ca_system_score_codex":0.000017800574,"about_ca_system_score_gemma":0.000033803793,"threshold_uncertainty_score":0.28224272},"labels":[],"label_agreement":null},{"id":"W2430195644","doi":"10.1016/j.ahj.2016.06.004","title":"Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1","year":2016,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Insulin degludec; Insulin glargine; Clinical endpoint; Myocardial infarction; Internal medicine; Type 2 diabetes; Population; Randomization; Stroke (engine); Randomized controlled trial; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.012172645416848467,"score_gpt":0.2189745249790762,"score_spread":0.20680187956222776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430195644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946429,0.0022156052,0.0019914887,0.0000403858,0.00014192594,0.00091403467,0.0000165765,0.000012415893,0.00002463173],"genre_scores_gemma":[0.99193364,0.0017995954,0.006087553,0.000020607158,0.00007741718,0.000011882637,0.000012470841,0.000040219584,0.000016627635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693054,0.0004919886,0.0008548862,0.00030431637,0.0009936707,0.00042459046],"domain_scores_gemma":[0.9980883,0.00018229299,0.0005428606,0.00061956135,0.00038798468,0.00017900123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012508497,0.00027141176,0.0018318635,0.00035163146,0.000058017835,0.0000046212344,0.00016092576,0.000054991313,0.00003776944],"category_scores_gemma":[0.00020656637,0.00017755714,0.00059367064,0.0006120908,0.00024928653,0.00012077345,0.00011576533,0.00018625039,0.000008072056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020309467,0.0006861188,0.9268462,0.00007390987,0.009248279,0.000012426305,0.00008431847,0.0049335742,0.00022572347,0.0000029005978,0.000052602038,0.037524465],"study_design_scores_gemma":[0.063338205,0.006111691,0.9214508,0.0007089545,0.0026407854,0.000004678608,0.00002820402,0.00008763141,0.0036708806,0.00001653535,0.0017077368,0.00023393301],"about_ca_topic_score_codex":0.0004479925,"about_ca_topic_score_gemma":0.000010562813,"teacher_disagreement_score":0.043028735,"about_ca_system_score_codex":0.00026516098,"about_ca_system_score_gemma":0.0001369448,"threshold_uncertainty_score":0.724057},"labels":[],"label_agreement":null},{"id":"W243411354","doi":"10.1096/fasebj.20.5.a1053-b","title":"Expression of the sodium‐glucose cotransporter SGLT1 gene along the jejunal crypt‐villus axis measured by quantitative real time RT‐PCR in the formula‐fed neonatal pig","year":2006,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agriculture and Agri-Food Canada; University of Guelph","funders":"","keywords":"Crypt; Jejunum; Andrology; Biology; Real-time polymerase chain reaction; Messenger RNA; Cotransporter; Trypan blue; Molecular biology; Internal medicine; Cell; Endocrinology; Chemistry; Gene; Sodium; Medicine; Biochemistry","score_opus":0.01453277729997134,"score_gpt":0.23731671634220652,"score_spread":0.22278393904223517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W243411354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121886,0.0015232083,0.00027822691,0.0034494426,0.00017216637,0.0008335657,0.00004263217,0.000017841348,0.0024640756],"genre_scores_gemma":[0.99785817,0.00019216722,0.00023015104,0.0004090698,0.00018223595,0.000027986758,0.000051673193,0.000026845519,0.0010217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753,0.0003863479,0.00054968626,0.00019188879,0.00092093233,0.00042116572],"domain_scores_gemma":[0.99871963,0.0002391877,0.00034585415,0.0005188865,0.00011005725,0.000066396184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013636291,0.00026170863,0.00033683868,0.00007798784,0.00041582828,0.000064539054,0.0005736747,0.00007101215,0.00018847614],"category_scores_gemma":[0.000034857138,0.00009907208,0.00030142334,0.00026158534,0.00026960205,0.00015962527,0.00006522611,0.00047297907,0.00002291289],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027197648,0.0011585065,0.021279534,0.00006964025,0.00067138724,0.0002660811,0.009917514,0.00022165156,0.92650574,0.0011307914,0.029572906,0.006486506],"study_design_scores_gemma":[0.013979847,0.0016118595,0.23132046,0.00086245703,0.001781029,0.00035634014,0.0051950864,0.0011902782,0.73462874,0.0028592471,0.0056669605,0.0005476956],"about_ca_topic_score_codex":0.00035222105,"about_ca_topic_score_gemma":0.00017753817,"teacher_disagreement_score":0.21004091,"about_ca_system_score_codex":0.00009984369,"about_ca_system_score_gemma":0.00007879727,"threshold_uncertainty_score":0.40400422},"labels":[],"label_agreement":null},{"id":"W2461842986","doi":"10.1016/j.molmet.2016.06.006","title":"Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice","year":2016,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Directorate for Biological Sciences; Novo Nordisk Fonden; Sahlgrenska Universitetssjukhuset; Västra Götalandsregionen; Vetenskapsrådet; Knut och Alice Wallenbergs Stiftelse; Stiftelsen för Strategisk Forskning; IngaBritt och Arne Lundbergs Forskningsstiftelse; European Research Council; Torsten Söderbergs Stiftelse; Biotechnology and Biological Sciences Research Council; Svenska Forskningsrådet Formas","keywords":"Glucagon-like peptide-1; Glucagon; Peptide; Glucagon-like peptide-2; Internal medicine; Endocrinology; Chemistry; Diabetes mellitus; Biology; Biochemistry; Medicine; Insulin; Type 2 diabetes","score_opus":0.006171070613708712,"score_gpt":0.2233760585971283,"score_spread":0.21720498798341958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461842986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946667,0.0041882354,0.0002509109,0.0023996213,0.00047041452,0.0009296242,0.000006036245,0.00009355103,0.0021949413],"genre_scores_gemma":[0.9868534,0.00029135778,0.0028394957,0.0024009226,0.00013838077,0.0001317324,0.000017138882,0.0000557506,0.0072718253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834764,0.000057604026,0.0003166263,0.0005473062,0.00024308634,0.0004877273],"domain_scores_gemma":[0.9991609,0.000017793167,0.00008407879,0.00053399266,0.00007359766,0.00012962434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020167716,0.00027248764,0.00044770213,0.00020140689,0.000029941408,0.000027233844,0.00016701681,0.000060554496,0.0000485049],"category_scores_gemma":[0.000075444266,0.00018865835,0.00015701777,0.0002666726,0.000058053414,0.00013113327,0.00010054207,0.000089285015,0.00019999572],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014129098,0.00029481648,0.00043172235,0.000049764887,0.00012932444,0.00017754135,0.000095717725,0.0000014781102,0.9556822,0.0006022155,0.00092523143,0.04146867],"study_design_scores_gemma":[0.0047946996,0.00007648688,0.032015767,0.00016309874,0.00024971706,0.000007279148,0.000014547698,0.000007955572,0.83399564,0.00014587677,0.12826605,0.00026289534],"about_ca_topic_score_codex":0.00006444531,"about_ca_topic_score_gemma":0.000022610557,"teacher_disagreement_score":0.12734082,"about_ca_system_score_codex":0.000067710214,"about_ca_system_score_gemma":0.00007459208,"threshold_uncertainty_score":0.7693264},"labels":[],"label_agreement":null},{"id":"W2463959854","doi":"10.1111/dom.12736","title":"Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes ( <scp>LIRA‐SWITCH</scp> ): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novo Nordisk","keywords":"Liraglutide; Sitagliptin; Medicine; Clinical endpoint; Metformin; Type 2 diabetes; Sitagliptin Phosphate; Internal medicine; Weight loss; Randomized controlled trial; Urology; Endocrinology; Gastroenterology; Diabetes mellitus; Obesity","score_opus":0.014695607301590724,"score_gpt":0.2412439360185757,"score_spread":0.22654832871698496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463959854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875314,0.003929154,0.000038103954,0.000398737,0.00034767497,0.0066578477,0.000029376672,0.000118165226,0.0009495404],"genre_scores_gemma":[0.9966462,0.0009519903,0.0007389001,0.0003185185,0.00029572757,0.0004057955,0.000038312734,0.00007333353,0.0005311714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966221,0.00027212908,0.0008739014,0.0008625114,0.00049961795,0.0008697541],"domain_scores_gemma":[0.9963986,0.002037008,0.0004008594,0.0005191916,0.00018438199,0.00045993342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013605565,0.0006261665,0.003007867,0.00058926834,0.00014467831,0.0000909564,0.00019688878,0.00021702562,0.000029008548],"category_scores_gemma":[0.0006645652,0.00038199138,0.00025209106,0.0005328601,0.00020110597,0.0004024231,0.00023687408,0.00025406483,0.000024409594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91364974,0.001988318,0.035506748,0.00020083446,0.0035073305,0.000023904393,0.0018166204,0.000008082551,0.023742769,0.0011702009,0.000086060485,0.01829938],"study_design_scores_gemma":[0.89146954,0.0008838964,0.076574646,0.0006318928,0.0026363975,3.5610813e-7,0.00012849766,0.00003064684,0.025666596,0.00036357468,0.0013531501,0.00026083316],"about_ca_topic_score_codex":0.00024223997,"about_ca_topic_score_gemma":0.00013804283,"teacher_disagreement_score":0.041067902,"about_ca_system_score_codex":0.00005932291,"about_ca_system_score_gemma":0.000099497774,"threshold_uncertainty_score":0.9998632},"labels":[],"label_agreement":null},{"id":"W2463982285","doi":"10.14740/jocmr2611w","title":"The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Pioglitazone; Medicine; Observational study; Type 2 diabetes; Diabetes mellitus; Reduction (mathematics); Retrospective cohort study; Internal medicine; Longitudinal study; Endocrinology; Pathology","score_opus":0.19333711860095146,"score_gpt":0.46753700116231856,"score_spread":0.27419988256136707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463982285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960486,0.00038463203,0.0000010076574,0.0026889262,0.00016785531,0.00060315203,0.0000013728612,0.0000017881594,0.000102631166],"genre_scores_gemma":[0.9990584,0.0005433351,0.00013022225,0.000020108353,0.00014911531,0.000008119081,8.650015e-7,0.000008052147,0.000081751634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644154,0.00042250069,0.0011237897,0.00018727688,0.0016078682,0.00021703685],"domain_scores_gemma":[0.9954458,0.0021206539,0.00056989794,0.00022998001,0.0014943094,0.00013934923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059217247,0.00010501281,0.0007351945,0.00034243424,0.000045301484,0.00000611647,0.0001358708,0.000045379587,0.000011485018],"category_scores_gemma":[0.005394044,0.000041258914,0.000057945854,0.0005965654,0.0009442252,0.00013341226,0.000049662638,0.00037439328,8.283661e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005665481,0.0016530292,0.9704357,0.000026737522,0.0006280512,0.0000080662985,0.00018817594,0.0000017310874,0.0000618794,0.00012719631,0.0002117904,0.020992154],"study_design_scores_gemma":[0.010638695,0.03827426,0.94883955,0.00090806093,0.0001944008,7.2948166e-7,0.0005440797,0.0000025913807,0.00009302702,0.00040296506,0.0000652291,0.000036417543],"about_ca_topic_score_codex":0.000028582224,"about_ca_topic_score_gemma":0.000012745976,"teacher_disagreement_score":0.036621228,"about_ca_system_score_codex":0.00005845386,"about_ca_system_score_gemma":0.00016570545,"threshold_uncertainty_score":0.6457564},"labels":[],"label_agreement":null},{"id":"W2464585615","doi":"10.1002/ejhf.633","title":"Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes","year":2016,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Toronto General Hospital; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Saxagliptin; Empagliflozin; Heart failure; Liraglutide; Metformin; Diabetes mellitus; Internal medicine; Population; Incretin; Type 2 diabetes; Cardiology; Sitagliptin; Intensive care medicine; Endocrinology","score_opus":0.07656538118847907,"score_gpt":0.3724456152186598,"score_spread":0.29588023403018077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464585615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14546809,0.8467256,0.0000059769404,0.0031623142,0.00092679,0.0033326994,0.00007605431,0.00003165501,0.00027083058],"genre_scores_gemma":[0.03710876,0.9497147,0.009642233,0.0007168227,0.0012019275,0.00003445385,0.00014300586,0.0005499648,0.0008881243],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99143016,0.0025751418,0.0044268076,0.0003931204,0.00068625994,0.0004884775],"domain_scores_gemma":[0.9961681,0.00075280585,0.0021110654,0.00051553943,0.00017251118,0.0002799963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0075377044,0.0005687752,0.0060716486,0.000911746,0.000023831846,0.00003573524,0.00031360835,0.00013646527,0.00017006566],"category_scores_gemma":[0.001147349,0.00030562925,0.0014650348,0.00034882245,0.00009474611,0.00019401168,0.00015185591,0.00081425044,0.00010049752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019696294,0.0014829221,0.66559255,0.0045504645,0.0017529381,0.00026507897,0.00003578657,9.5210146e-7,0.0000015447919,0.0000034610632,0.027376167,0.2987412],"study_design_scores_gemma":[0.0076168436,0.0019385722,0.10655772,0.04518404,0.0009969764,0.0000050092135,0.0000127127205,1.03444236e-7,0.000003197266,0.0000015901612,0.8374436,0.00023966562],"about_ca_topic_score_codex":8.5037664e-7,"about_ca_topic_score_gemma":0.0000047302665,"teacher_disagreement_score":0.8100674,"about_ca_system_score_codex":0.00014547797,"about_ca_system_score_gemma":0.00018413129,"threshold_uncertainty_score":0.99993956},"labels":[],"label_agreement":null},{"id":"W2464600010","doi":"","title":"[Pharmacologic treatment of diabetes].","year":2007,"lang":"fr","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Diabetes mellitus; Diabetes treatment; Medicine; Type 2 diabetes; Endocrinology","score_opus":0.03299503693387176,"score_gpt":0.2699418165816913,"score_spread":0.23694677964781954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464600010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81066626,0.069421306,0.000033592034,0.0025217708,0.005216564,0.0033888088,0.000028444265,0.0000840971,0.10863915],"genre_scores_gemma":[0.89744073,0.0020095299,0.0001866393,0.0003687792,0.00092008524,0.0009843893,0.000030322683,0.000028058086,0.09803146],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977512,0.000043275435,0.0004326181,0.00030408145,0.00024458664,0.0012242493],"domain_scores_gemma":[0.9989139,0.00019026984,0.00015137026,0.0002959926,0.00005472492,0.00039373297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056673295,0.00027694175,0.00051354914,0.0002011054,0.00003817344,0.000011633232,0.00009240948,0.00012348867,0.00051971956],"category_scores_gemma":[0.000036632184,0.00023005638,0.00023914932,0.00030942244,0.00017444308,0.00008177106,0.00004239847,0.000056081306,0.00018566533],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072900475,0.0031094898,0.12539731,0.00023602243,0.0012768173,0.00011557008,0.00011426432,0.0000034810985,0.00013131496,0.0010301748,0.003942497,0.86457014],"study_design_scores_gemma":[0.004299945,0.0008998994,0.62369794,0.000038212187,0.0019380968,8.2924464e-7,0.000079020465,0.00002114365,0.023524962,0.000102943544,0.34523505,0.00016197818],"about_ca_topic_score_codex":0.000030524727,"about_ca_topic_score_gemma":0.000010954206,"teacher_disagreement_score":0.8644082,"about_ca_system_score_codex":0.00068633305,"about_ca_system_score_gemma":0.000025295594,"threshold_uncertainty_score":0.9381427},"labels":[],"label_agreement":null},{"id":"W2466620119","doi":"10.1111/dom.12687","title":"Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and &lt;65 years","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Gerontology; Exenatide; Endocrinology","score_opus":0.005353490245852348,"score_gpt":0.19682980196859595,"score_spread":0.1914763117227436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466620119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960153,0.0028068905,0.0000015707446,0.00019925678,0.00007700464,0.0006187294,0.00003131733,0.000029684037,0.0002202297],"genre_scores_gemma":[0.9978869,0.0011511669,0.00039211696,0.00019861119,0.00003280696,0.000011434089,0.000029989087,0.000022602686,0.00027440238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872446,0.000063013664,0.00025090517,0.0003634309,0.000223411,0.00037475768],"domain_scores_gemma":[0.9992717,0.00014222506,0.00009943509,0.0002463006,0.000064775464,0.00017557539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002477979,0.00023168635,0.0006149285,0.00018304966,0.000053445394,0.000019049488,0.000059976304,0.00008514533,0.000024651074],"category_scores_gemma":[0.000101246595,0.00015372144,0.000034924265,0.00019365877,0.00023119949,0.0001821036,0.000115457304,0.000084738866,0.000004012449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017184058,0.00039828563,0.9421974,0.00012699321,0.00023736335,0.000003506285,0.00017616569,3.0188457e-7,0.0014691413,0.00022517545,0.00010069072,0.054893177],"study_design_scores_gemma":[0.009491073,0.00042711743,0.9825702,0.0003163881,0.0004260821,8.050593e-8,0.000014885774,0.000005419926,0.0018356093,0.00012375902,0.0046004616,0.00018896737],"about_ca_topic_score_codex":0.000009309336,"about_ca_topic_score_gemma":0.000010821448,"teacher_disagreement_score":0.054704208,"about_ca_system_score_codex":0.000018035527,"about_ca_system_score_gemma":0.000018653687,"threshold_uncertainty_score":0.6268579},"labels":[],"label_agreement":null},{"id":"W2467635050","doi":"10.4212/cjhp.v69i3.1564","title":"DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics","year":2016,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Native Mental Health Association of Canada; University of British Columbia","funders":"","keywords":"Chemistry; Information retrieval; Computer science","score_opus":0.017979566917466095,"score_gpt":0.2654001242442268,"score_spread":0.24742055732676072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467635050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502796,0.0009409109,0.000012967476,0.044754494,0.00084133126,0.00024469415,0.000010730119,0.000004835844,0.0029104387],"genre_scores_gemma":[0.99767905,0.00015921776,0.00005283623,0.0007911227,0.0003150575,0.0000019115134,8.923297e-7,0.000015081752,0.0009848328],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991384,0.000031234358,0.0002938634,0.00006670102,0.00021899461,0.00025077187],"domain_scores_gemma":[0.99908143,0.000056413643,0.00020980378,0.0001960439,0.00017460845,0.00028168256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003184473,0.00011175766,0.00020465294,0.00010602022,0.00010037904,0.000024177501,0.0002473634,0.000018650351,0.00020588958],"category_scores_gemma":[0.00007107726,0.000044862063,0.00016362433,0.0001330937,0.00022846194,0.00014642932,0.000021879203,0.00013597314,0.00002603386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004975256,0.00043531068,0.4126306,0.00009890794,0.0030166123,0.0010450025,0.00314548,0.000018113153,0.0059355632,0.004594247,0.3020189,0.26656374],"study_design_scores_gemma":[0.010655108,0.0028363625,0.03374168,0.0006475406,0.0016211716,0.00015746582,0.0006031851,0.000024409528,0.03877062,0.0016343647,0.9089682,0.00033985838],"about_ca_topic_score_codex":0.0021970375,"about_ca_topic_score_gemma":0.001540176,"teacher_disagreement_score":0.6069493,"about_ca_system_score_codex":0.00012787324,"about_ca_system_score_gemma":0.00047399514,"threshold_uncertainty_score":0.33212778},"labels":[],"label_agreement":null},{"id":"W2468732910","doi":"10.1097/md.0000000000003995","title":"Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users","year":2016,"lang":"en","type":"article","venue":"Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Memorial University of Newfoundland","funders":"University of Alberta; Canadian Diabetes Association","keywords":"Medicine; Metformin; Mace; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Discontinuation; Hazard ratio; Glycated hemoglobin; Cohort; Incretin; Proportional hazards model; Retrospective cohort study; Diabetes mellitus; Type 2 diabetes; Insulin; Endocrinology; Percutaneous coronary intervention; Myocardial infarction","score_opus":0.015168648963171593,"score_gpt":0.2654994642088632,"score_spread":0.2503308152456916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468732910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644227,0.011320098,0.00050341967,0.0004125517,0.000027236061,0.00094208395,0.000003726448,0.0000071787795,0.00034141116],"genre_scores_gemma":[0.9972637,0.0024505057,0.00012799828,0.000038746013,0.0000152087505,0.000059294634,0.0000029766886,0.000008461538,0.000033051223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895006,0.00035191295,0.00020561984,0.00015978926,0.00022303184,0.00010957911],"domain_scores_gemma":[0.99870443,0.0008817764,0.00009415086,0.00023752083,0.000045844045,0.000036301397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001651123,0.00013043171,0.00079189066,0.00012818076,0.000019250201,7.706824e-7,0.00004617684,0.000029013303,0.000015652528],"category_scores_gemma":[0.0000846534,0.00005378334,0.00007979302,0.00011752405,0.0003843099,0.000029245944,0.000018268378,0.000043728774,3.3909842e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034719226,0.0001335914,0.9655024,0.00039500976,0.0031975764,0.0000059470894,0.0022948876,0.000009266285,0.0028110007,0.00061943574,0.000017737762,0.021541253],"study_design_scores_gemma":[0.041952174,0.0011237789,0.93858355,0.0014728323,0.00097266975,0.0000013866338,0.00060048426,0.0001204759,0.013763567,0.00084156817,0.00048707196,0.00008042796],"about_ca_topic_score_codex":0.00047352808,"about_ca_topic_score_gemma":0.000012933976,"teacher_disagreement_score":0.038480252,"about_ca_system_score_codex":0.00002336115,"about_ca_system_score_gemma":0.000014125598,"threshold_uncertainty_score":0.21932209},"labels":[],"label_agreement":null},{"id":"W2469620169","doi":"10.1093/ehjqcco/qcw033","title":"Improving cardiovascular risk in type 2 diabetes: time to get personal","year":2016,"lang":"en","type":"letter","venue":"European Heart Journal - Quality of Care and Clinical Outcomes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Blood pressure; Disease; Population; Type 2 Diabetes Mellitus; Coronary artery disease; Insulin resistance; Psychological intervention; Intensive care medicine; Internal medicine; Environmental health; Endocrinology; Nursing","score_opus":0.061911808488367276,"score_gpt":0.3635230903516746,"score_spread":0.3016112818633073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469620169","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70524514,0.012473396,0.000019523424,0.27058154,0.0013954353,0.0011510724,0.00015447225,0.00007581005,0.008903615],"genre_scores_gemma":[0.06357868,0.005261877,0.0025183402,0.8913053,0.014020798,0.000009377561,0.00021109424,0.00035184747,0.022742659],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99508727,0.0017656784,0.0014202613,0.00049492915,0.0007531219,0.00047874806],"domain_scores_gemma":[0.99733734,0.0012288423,0.0004061792,0.00050126965,0.00024244357,0.00028394503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041691475,0.00035694437,0.0019501826,0.0002215442,0.00007583447,0.000058889,0.00017737072,0.00022451687,0.00023868127],"category_scores_gemma":[0.0016438459,0.00023708765,0.0020118875,0.00009903076,0.00012382334,0.000077524746,0.00019910304,0.0014561252,0.00046298336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001284889,0.00007788433,0.5350243,0.0005869751,0.0030598787,0.00044338446,0.00025707827,3.062612e-7,0.0000041609214,6.044975e-7,0.2956148,0.16480212],"study_design_scores_gemma":[0.00182085,0.0012700082,0.3415807,0.00053980737,0.0009307695,0.000004968918,0.00006028656,8.690345e-7,0.000001399293,0.0000066153348,0.6535552,0.00022853236],"about_ca_topic_score_codex":0.000027480979,"about_ca_topic_score_gemma":0.0000030426297,"teacher_disagreement_score":0.6416665,"about_ca_system_score_codex":0.00009398368,"about_ca_system_score_gemma":0.00009146929,"threshold_uncertainty_score":0.9668154},"labels":[],"label_agreement":null},{"id":"W2470220408","doi":"10.2174/1570161112999140305095250","title":"Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)","year":2014,"lang":"en","type":"editorial","venue":"Current Vascular Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Receptor; Computational biology; Medicine; Disease; Thematic map; MEDLINE; Neuroscience; Bioinformatics; Data science; Biology; Pathology; Internal medicine; Biochemistry; Computer science; Geography","score_opus":0.011715558569280728,"score_gpt":0.3369493292585035,"score_spread":0.32523377068922277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470220408","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006129245,0.019262813,0.0001016801,0.0008154872,0.96920294,0.0043479325,0.000025887393,0.00009120206,0.000022812264],"genre_scores_gemma":[0.0008831394,0.015071204,0.000092943046,0.00013577427,0.977908,0.0018801517,0.0038257632,0.00009332872,0.000109654524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959643,0.00064734987,0.0009484035,0.0010748174,0.0005920342,0.0007730884],"domain_scores_gemma":[0.9979947,0.0002703541,0.00042296544,0.0005402003,0.00014633255,0.0006254079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015698246,0.00059648976,0.0015157082,0.0006948736,0.00006963209,0.000026301883,0.00026516317,0.0005720949,0.00020294917],"category_scores_gemma":[0.00068713614,0.0005571854,0.00029083015,0.0003713753,0.00015833003,0.00007665036,0.00020793689,0.0010769299,0.00010322887],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017551612,0.0009030644,0.00056447973,0.0038120414,0.00047616556,0.0000035525186,0.00011606937,0.000006295425,0.0001271822,0.00006201306,0.98322874,0.0105248485],"study_design_scores_gemma":[0.010315718,0.0004369627,0.00013800616,0.00093590724,0.0006605306,8.613076e-8,0.000014993183,0.00041575302,0.0000094924135,0.00037804735,0.98630136,0.0003931561],"about_ca_topic_score_codex":0.00010450171,"about_ca_topic_score_gemma":0.000013011806,"teacher_disagreement_score":0.010140202,"about_ca_system_score_codex":0.00074182637,"about_ca_system_score_gemma":0.0007763164,"threshold_uncertainty_score":0.99968797},"labels":[],"label_agreement":null},{"id":"W2474359312","doi":"10.1371/journal.pone.0158796","title":"Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Korea Health Industry Development Institute; Ministry of Health and Welfare; University of Toronto","keywords":"Insulin; Internal medicine; Endocrinology; In vivo; Secretion; Type 2 diabetes; Glucose homeostasis; Chemistry; Diabetes mellitus; In vitro; Glucagon-like peptide-1; Glucagon; Glucose tolerance test; Free fatty acid receptor 1; Receptor; Pharmacology; Medicine; Biology; Insulin resistance; Biochemistry; Agonist","score_opus":0.0394037484679987,"score_gpt":0.2471922400754764,"score_spread":0.2077884916074777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474359312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706265,0.00028033226,0.0001433424,0.008125527,0.000032195498,0.0006474288,0.0000071811387,0.000048833226,0.020088699],"genre_scores_gemma":[0.99246466,0.00026895004,0.001185917,0.00054535666,0.00012390071,0.00007104318,0.000006888492,0.000013069119,0.0053201984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99929196,0.000014456209,0.00014216707,0.00014845979,0.00025351642,0.00014941502],"domain_scores_gemma":[0.9993717,0.00009069126,0.000092077746,0.0003474482,0.00006661858,0.00003145821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059342885,0.00008721221,0.00018026566,0.000023450897,0.000029740844,0.0000057925395,0.00007193658,0.000030523726,0.0001246447],"category_scores_gemma":[0.000076493816,0.000043732096,0.000042932967,0.00009449662,0.000047012094,0.00013824881,0.000033743898,0.00004069706,0.00006768097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018833025,0.0033064757,0.0021664086,0.000170278,0.0006045223,0.0000034384357,0.0003418879,2.2672846e-7,0.9283597,0.0012299125,0.0018776202,0.061751205],"study_design_scores_gemma":[0.0017832834,0.00047803618,0.019766131,0.00048323045,0.00039126992,1.8567195e-7,0.000033571887,0.000020791202,0.9665827,0.0005284396,0.009850328,0.00008200369],"about_ca_topic_score_codex":0.00001554626,"about_ca_topic_score_gemma":0.0000014950574,"teacher_disagreement_score":0.0616692,"about_ca_system_score_codex":0.000042755,"about_ca_system_score_gemma":0.000015182387,"threshold_uncertainty_score":0.17833431},"labels":[],"label_agreement":null},{"id":"W2475233216","doi":"10.1016/j.cmet.2016.06.009","title":"The Cardiovascular Biology of Glucagon-like Peptide-1","year":2016,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":629,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canada Research Chairs","keywords":"Biology; Glucagon-like peptide-1; Glucagon; Computational biology; Internal medicine; Bioinformatics; Endocrinology; Medicine; Diabetes mellitus; Hormone; Type 2 diabetes","score_opus":0.026557724676159394,"score_gpt":0.2875782455091884,"score_spread":0.261020520833029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475233216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006947842,0.9723097,0.00003204137,0.00002646773,0.001458787,0.0012174771,0.000026769181,0.000036209323,0.024885608],"genre_scores_gemma":[0.000010724376,0.9765387,0.00012606887,0.000031138014,0.00047782244,0.000210503,0.00007305475,0.000061709405,0.022470249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982038,0.00019631702,0.00055395096,0.00041142956,0.00023313124,0.00040134258],"domain_scores_gemma":[0.99799657,0.00018271753,0.00029611666,0.0013432006,0.000076605436,0.00010481582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000512308,0.00041231856,0.002633736,0.00015547543,0.00006893788,0.000012925486,0.00032660735,0.00022219517,0.00007294375],"category_scores_gemma":[0.000039786002,0.00018534713,0.0022742925,0.00019255544,0.00017339112,0.000023718188,0.00018303329,0.00016256118,0.0004558418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000031988384,0.000052905525,0.0000015331581,0.00492911,0.003534091,0.000008270461,0.000008670314,1.6547013e-8,0.0000023116097,0.0014143784,0.0032380873,0.9868074],"study_design_scores_gemma":[0.00063169084,0.00004299948,0.0000069819803,0.001984608,0.012962951,0.0000036136043,0.000005843389,6.087311e-8,0.000034543133,0.00009181925,0.9840626,0.00017229182],"about_ca_topic_score_codex":0.000010807922,"about_ca_topic_score_gemma":3.8115834e-7,"teacher_disagreement_score":0.98663515,"about_ca_system_score_codex":0.000041390045,"about_ca_system_score_gemma":0.00013598912,"threshold_uncertainty_score":0.7558237},"labels":[],"label_agreement":null},{"id":"W2475633253","doi":"10.1016/b0-12-443710-9/00732-8","title":"Glucagon Family of Peptides and their Receptors","year":2004,"lang":"en","type":"book-chapter","venue":"Encyclopedia of Biological Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Receptor; Glucagon; Glucagon-like peptide-1; Chemistry; Internal medicine; Biology; Biochemistry; Endocrinology; Medicine; Diabetes mellitus; Hormone","score_opus":0.01779466231308939,"score_gpt":0.2227360617728337,"score_spread":0.20494139945974432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475633253","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20679154,0.003437527,0.0000016243617,0.00005191529,0.000060580627,0.00022421981,0.000042873213,0.00003281582,0.7893569],"genre_scores_gemma":[0.45893693,0.043759566,0.0008565867,0.00012346562,0.00040438856,0.000026259719,0.0006767359,0.000058196867,0.49515787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989753,0.0000040719465,0.0003836579,0.00034558182,0.00012566398,0.0001657418],"domain_scores_gemma":[0.9992601,0.00007101643,0.00024395614,0.00026303684,0.000055419958,0.00010642268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007343201,0.00032831868,0.0007279652,0.000033083998,0.000015178093,0.0000026089272,0.00010184514,0.00044101937,0.00066115474],"category_scores_gemma":[0.000046111654,0.00021030569,0.00020798571,0.000021289967,0.00034614454,0.000013722156,0.00012390324,0.00019637274,0.000008121448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020845032,0.0030108267,0.025720295,0.017173048,0.007398521,0.00031385897,0.0012187228,0.0000045913876,0.34880856,0.030623391,0.021454472,0.54218924],"study_design_scores_gemma":[0.0036192515,0.0023307211,0.0061481646,0.002997397,0.0008922449,0.000013760571,0.0003480593,0.0000010234264,0.14141591,0.02643614,0.81465954,0.0011378158],"about_ca_topic_score_codex":0.0000049756204,"about_ca_topic_score_gemma":1.7454688e-7,"teacher_disagreement_score":0.793205,"about_ca_system_score_codex":0.000047783768,"about_ca_system_score_gemma":0.00005196976,"threshold_uncertainty_score":0.8576017},"labels":[],"label_agreement":null},{"id":"W2476278189","doi":"10.1002/dmrr.2825","title":"Why China guidelines for type 2 diabetes represent an opportunity for treating this disease","year":2016,"lang":"en","type":"article","venue":"Diabetes/Metabolism Research and Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Medicine; Diabetes mellitus; Quarter (Canadian coin); Ethnic group; Type 2 diabetes; Disease; Incidence (geometry); Chinese people; Face (sociological concept); Gerontology; Political science; Geography; Internal medicine; Sociology; Endocrinology","score_opus":0.2616391648523144,"score_gpt":0.4531035042494724,"score_spread":0.19146433939715796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2476278189","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80157024,0.14803414,0.00018910454,0.03368997,0.0005761183,0.0128632905,0.00037619623,0.00017846585,0.002522513],"genre_scores_gemma":[0.28181207,0.36881357,0.053583175,0.032363188,0.014291607,0.03571616,0.0049269544,0.0009584639,0.2075348],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653894,0.0003050296,0.0007175431,0.0008182653,0.00047652665,0.0011437269],"domain_scores_gemma":[0.99603105,0.0004921282,0.00017003923,0.00097101025,0.0010799591,0.0012558384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035169593,0.00037304894,0.001008135,0.00032707897,0.00039403097,0.000113018534,0.0002550269,0.00009392887,0.0003115822],"category_scores_gemma":[0.007208195,0.00020343577,0.00031056095,0.0003668064,0.000244586,0.00033919193,0.0001890653,0.00013401586,0.000036891168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026202144,0.0006557151,0.016418686,0.0018822529,0.0002866608,0.00000449734,0.00007006798,1.1740552e-7,0.008038933,0.0013270759,0.38902768,0.5820263],"study_design_scores_gemma":[0.0030845671,0.0012572414,0.008957951,0.0010598826,0.00044035853,2.0958959e-7,0.000030404366,0.00032331244,0.004178975,0.004374159,0.97595686,0.0003360881],"about_ca_topic_score_codex":0.000017905519,"about_ca_topic_score_gemma":0.0000054312864,"teacher_disagreement_score":0.58692914,"about_ca_system_score_codex":0.000052509076,"about_ca_system_score_gemma":0.0001268169,"threshold_uncertainty_score":0.8629404},"labels":[],"label_agreement":null},{"id":"W2480832378","doi":"10.17925/ee.2014.10.02.98","title":"The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?","year":2014,"lang":"en","type":"editorial","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Receptor; Diabetes mellitus; Agonist; Endocrinology; Pharmacology; Internal medicine","score_opus":0.00987615569664187,"score_gpt":0.2814787907792313,"score_spread":0.27160263508258947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480832378","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.118654095,0.3437665,0.000004566986,0.006165212,0.51968616,0.0061333613,0.0001082168,0.00007994154,0.00540192],"genre_scores_gemma":[0.04046332,0.84631336,0.0011663468,0.0008290108,0.10049136,0.0010710324,0.0013621899,0.00020838801,0.0080949925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972666,0.00029816956,0.0009892975,0.00047099264,0.00044217787,0.00053275505],"domain_scores_gemma":[0.9974898,0.00062857877,0.0007618707,0.00078836334,0.00028704279,0.000044346198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004316103,0.00044336158,0.0016540855,0.00034830676,0.000037489026,0.000011522104,0.00039313466,0.0003184836,0.0001272112],"category_scores_gemma":[0.00025571548,0.00027542977,0.00015781597,0.00043472234,0.00031075638,0.000055023942,0.00013615904,0.0006011341,0.000040004543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055358,0.00057835114,0.0077276872,0.002496866,0.00054399425,0.000020729258,0.00068138476,0.0000010236341,0.000052871736,0.0006667319,0.8133815,0.17329526],"study_design_scores_gemma":[0.0032881566,0.001994294,0.0012786957,0.0015237469,0.00025397618,0.0000010089717,0.0002274348,0.0000040687605,0.00027522957,0.0001324394,0.9908065,0.00021444625],"about_ca_topic_score_codex":0.000053087602,"about_ca_topic_score_gemma":0.00034535272,"teacher_disagreement_score":0.50254685,"about_ca_system_score_codex":0.00015564768,"about_ca_system_score_gemma":0.00017309279,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W2482910821","doi":"10.1016/j.kint.2016.06.012","title":"Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy","year":2016,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Diabetic nephropathy; Endocrinology; Internal medicine; Dipeptidyl peptidase-4; Medicine; Albuminuria; Glomerulosclerosis; Linagliptin; Glomerular hyperfiltration; Diabetes mellitus; Dipeptidyl peptidase; Nephropathy; Incretin; Kidney; Type 2 diabetes; Chemistry; Proteinuria","score_opus":0.008768478034887721,"score_gpt":0.2266389297368573,"score_spread":0.21787045170196956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482910821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775136,0.00010307983,0.00016094846,0.009157807,0.000093854556,0.0008995319,0.00027510873,0.00006279287,0.0014955166],"genre_scores_gemma":[0.99679375,0.000020528627,0.00027506004,0.00061509083,0.00007554992,0.00023859755,0.00021471473,0.000022211718,0.001744478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884635,0.000033591157,0.00021978978,0.00035440043,0.00031043417,0.0002354218],"domain_scores_gemma":[0.9994534,0.000028291486,0.000110080364,0.00012737334,0.00009738827,0.00018345562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005259413,0.00019474809,0.0001941706,0.00016865434,0.000045821915,0.00005825963,0.00006412865,0.000076100165,0.0007382012],"category_scores_gemma":[0.00006820392,0.0001391025,0.000055778077,0.00007715437,0.00013671428,0.00023369401,0.00008158666,0.00008473053,0.00004872497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043484502,0.0013000485,0.12285622,0.000098394594,0.00052497094,0.00011744213,0.0017029756,4.3680262e-7,0.8203202,0.00016192725,0.02456912,0.027913446],"study_design_scores_gemma":[0.016367242,0.001257402,0.3039775,0.0016703869,0.00016332387,0.000012200884,0.00024032593,0.0003803171,0.66497195,0.00096638314,0.009488405,0.0005045895],"about_ca_topic_score_codex":0.000017957305,"about_ca_topic_score_gemma":0.0000032093974,"teacher_disagreement_score":0.18112126,"about_ca_system_score_codex":0.00020182623,"about_ca_system_score_gemma":0.000058251022,"threshold_uncertainty_score":0.80827856},"labels":[],"label_agreement":null},{"id":"W2485875310","doi":"10.1001/jamainternmed.2016.1531","title":"Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus","year":2016,"lang":"en","type":"article","venue":"JAMA Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Incretin; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Exenatide; Bile duct; Gallbladder; Gallbladder disease; Gastroenterology; Type 2 diabetes; General surgery; Endocrinology","score_opus":0.007217444047666791,"score_gpt":0.2110213764003582,"score_spread":0.2038039323526914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485875310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928613,0.00019882838,0.000011353491,0.0063224696,0.00004545273,0.00035438684,0.000013640775,0.000008847364,0.00018377659],"genre_scores_gemma":[0.9984194,0.000042097854,0.00007730954,0.00041653914,0.000044965072,0.0000137091365,0.000022220254,0.0000120937075,0.0009516689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990206,0.000046608748,0.00019901455,0.00013429459,0.0004618319,0.0001376604],"domain_scores_gemma":[0.99878925,0.00049411115,0.00021994858,0.00016535365,0.00027368957,0.000057621834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016370324,0.0001115822,0.00029091284,0.00011520932,0.000009755521,0.000005248968,0.000052889725,0.000027964854,0.00010641553],"category_scores_gemma":[0.00041225733,0.00004276521,0.000019505555,0.00014391799,0.00014936799,0.00008189561,0.00002290271,0.000052620228,0.0000013876003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011715868,0.00020500466,0.98327947,0.00008612954,0.00029891086,0.000002584624,0.00014852786,0.0000015262553,0.00018514083,0.000014442456,0.0041229734,0.010483711],"study_design_scores_gemma":[0.008885105,0.0031949806,0.98162335,0.0017837179,0.00043092546,7.348779e-8,0.00005189291,0.000028462664,0.0011238261,0.0000090327485,0.0028112775,0.000057381945],"about_ca_topic_score_codex":0.00012752092,"about_ca_topic_score_gemma":0.000026796088,"teacher_disagreement_score":0.010426329,"about_ca_system_score_codex":0.000067660425,"about_ca_system_score_gemma":0.000021872014,"threshold_uncertainty_score":0.17439146},"labels":[],"label_agreement":null},{"id":"W2490438497","doi":"10.1097/01.hjh.0000491466.50734.fe","title":"[OP.4C.10] CLINICALLY IMPORTANT DIFFERENCES IN SYSTOLIC AMBULATORY BLOOD PRESSURE IN PATIENTS SWITCHED BETWEEN ALTERNATE NIFEDIPINE OSMOTIC DELIVERY FORMULATIONS","year":2016,"lang":"en","type":"article","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Nifedipine; Blood pressure; Ambulatory; Ambulatory blood pressure; Population; Morning; Internal medicine; Cardiology; Anesthesia; Calcium","score_opus":0.03238424617807928,"score_gpt":0.2530282865860282,"score_spread":0.22064404040794894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2490438497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981056,0.0006471328,0.000011479457,0.00063273666,0.00019239787,0.0003344421,0.000004522231,0.000011241015,0.00006046452],"genre_scores_gemma":[0.9987843,0.0003627325,0.00024776068,0.00015546603,0.00014952756,0.000003476744,0.000008014933,0.000017173226,0.00027153007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780357,0.000056360583,0.0012555886,0.0001869354,0.00044086028,0.00025670198],"domain_scores_gemma":[0.99867463,0.00016251174,0.00056963315,0.00020589845,0.00023498129,0.00015232677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004377758,0.00017149183,0.0006705632,0.00038365263,0.000026694435,0.000012438435,0.00011675927,0.00009581848,0.000051772582],"category_scores_gemma":[0.000241089,0.0000961016,0.00014686317,0.00013399612,0.000028922166,0.00021854807,0.00006167114,0.00016528495,0.0000107431215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002985802,0.0008873155,0.990893,0.000048682607,0.00038749445,0.00024238219,0.00003508537,0.000002682872,0.0012387707,0.000007106733,0.0002139133,0.0057449853],"study_design_scores_gemma":[0.01075484,0.0017091235,0.9844719,0.0011835262,0.001164526,0.000015684294,0.000012536842,0.00010683678,0.00014429963,0.00015407913,0.00017112013,0.00011153044],"about_ca_topic_score_codex":0.000024981555,"about_ca_topic_score_gemma":0.000011076116,"teacher_disagreement_score":0.01045626,"about_ca_system_score_codex":0.000053714393,"about_ca_system_score_gemma":0.000062735104,"threshold_uncertainty_score":0.39189094},"labels":[],"label_agreement":null},{"id":"W2490560905","doi":"10.1136/ebm.14.6.167","title":"Review: intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes","year":2009,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.09375141006748999,"score_gpt":0.33291636011027087,"score_spread":0.23916495004278088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2490560905","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021224052,0.23087552,0.0000025590773,0.7411358,0.0015363828,0.0049010827,0.000036509893,0.00014751154,0.00014058281],"genre_scores_gemma":[0.027091574,0.08565294,0.000035421024,0.87452245,0.007949291,0.0007707845,0.0015065636,0.0001038332,0.0023671673],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940515,0.00046689794,0.0014093202,0.0012985546,0.0015530924,0.0012205992],"domain_scores_gemma":[0.9956065,0.0008273961,0.00075987366,0.0016225365,0.0008331715,0.00035052252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015918931,0.0010727523,0.0031841183,0.0008004636,0.00006559796,0.000016572654,0.00049666053,0.0006331221,0.00054975203],"category_scores_gemma":[0.004194382,0.0007928279,0.00041743714,0.00077720865,0.0002904725,0.00038020982,0.00008432668,0.0017868147,0.00025883122],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035947646,0.00023039251,0.006270129,0.008728179,0.00063268334,0.0018773897,0.000063450134,5.458868e-7,0.0008230885,0.000004612272,0.96131516,0.019694919],"study_design_scores_gemma":[0.012554033,0.006142586,0.07710844,0.27059522,0.0089820875,0.000008874291,0.000035417204,0.00010722969,0.0013229689,0.00015931833,0.6217326,0.0012512014],"about_ca_topic_score_codex":0.00040916752,"about_ca_topic_score_gemma":0.000013988359,"teacher_disagreement_score":0.33958253,"about_ca_system_score_codex":0.00076724123,"about_ca_system_score_gemma":0.00032555911,"threshold_uncertainty_score":0.9994523},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2491908576","doi":"10.1530/joe-16-0056","title":"Targeting the gastrointestinal tract to treat type 2 diabetes","year":2016,"lang":"en","type":"review","venue":"Journal of Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto","keywords":"Type 2 diabetes; Gut flora; Metformin; Glucose homeostasis; Medicine; Gastrointestinal tract; Diabetes mellitus; Glucagon-like peptide-1; Obesity; Bioinformatics; Internal medicine; Endocrinology; Biology; Insulin resistance; Immunology","score_opus":0.039733172528759,"score_gpt":0.3328840383790932,"score_spread":0.2931508658503342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491908576","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037355543,0.99490786,0.000018556562,0.0012885752,0.0005474798,0.00048449708,0.000004972009,0.000017302245,0.0023572089],"genre_scores_gemma":[0.000108179185,0.995066,0.00079886726,0.00022965521,0.0010244739,0.000017341836,0.000007968164,0.00004254285,0.0027049766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981827,0.00013205351,0.00075025886,0.0001891737,0.00020584096,0.0005399788],"domain_scores_gemma":[0.9983211,0.000438042,0.00063455617,0.0002712985,0.00017266578,0.00016231382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020698775,0.00032729498,0.0015926177,0.0003541382,0.000049668328,0.000020270765,0.00029415966,0.00005566841,0.00028902927],"category_scores_gemma":[0.0004356447,0.00014325703,0.00053448544,0.00018007755,0.00006384171,0.00004880651,0.00010289202,0.00040814982,0.00031890132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031541273,0.00015850393,0.0006455617,0.0015562242,0.000290633,0.0008170875,0.000010410005,3.261755e-7,0.000016054644,0.00012678179,0.021208309,0.97513855],"study_design_scores_gemma":[0.0005256718,0.0021140333,0.00010759684,0.009096971,0.0022645933,0.0018523268,0.000013239191,1.6695685e-7,0.0000069121925,0.000024406694,0.9838802,0.00011384958],"about_ca_topic_score_codex":7.111795e-7,"about_ca_topic_score_gemma":1.9701805e-7,"teacher_disagreement_score":0.9750247,"about_ca_system_score_codex":0.00017683918,"about_ca_system_score_gemma":0.00017428138,"threshold_uncertainty_score":0.58418524},"labels":[],"label_agreement":null},{"id":"W2492672367","doi":"10.1161/circulationaha.116.021887","title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","year":2016,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1346,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; Toronto General Hospital; St. Michael's Hospital; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Medicine; Internal medicine; Renal function; Diabetes mellitus; Tubuloglomerular feedback; Endocrinology; Kidney disease; Canagliflozin; Dapagliflozin; Cardiology; Blood pressure; Heart failure; Myocardial infarction; Type 2 diabetes; Urology","score_opus":0.0317982732403083,"score_gpt":0.2908156015844842,"score_spread":0.2590173283441759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492672367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038989782,0.9924999,0.000006339162,0.00006711505,0.00017691018,0.002096021,0.00001721013,0.00002063149,0.0012169243],"genre_scores_gemma":[0.019516775,0.9793608,0.000013980105,0.000021836286,0.0001798537,0.00029733687,0.00047959067,0.000027368977,0.00010246944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874026,0.000073931464,0.00050707546,0.00025453788,0.00022051597,0.00020367201],"domain_scores_gemma":[0.99920386,0.00010448265,0.00022168267,0.00040839906,0.000025456442,0.00003609278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013548946,0.00027409827,0.0009665041,0.00022302486,0.000019964735,0.000010149792,0.00007066855,0.00013969663,0.000052218136],"category_scores_gemma":[0.000005270803,0.00013634993,0.00044594746,0.0002098717,0.000043591295,0.000047004203,0.000004570692,0.00004703851,0.000060818336],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000030848923,0.00048304704,0.003805905,0.00355147,0.00030058224,0.000009247933,0.0001772703,2.1641087e-7,0.000002729866,0.00012483152,0.000059848186,0.9914818],"study_design_scores_gemma":[0.0009948628,0.0002058195,0.005860493,0.0069812816,0.0025189542,7.3100506e-7,0.000010449172,0.0000026405735,0.000024993216,0.00006632054,0.9831973,0.00013620674],"about_ca_topic_score_codex":0.0000059745953,"about_ca_topic_score_gemma":0.000003898404,"teacher_disagreement_score":0.9913456,"about_ca_system_score_codex":0.00024895582,"about_ca_system_score_gemma":0.000052889314,"threshold_uncertainty_score":0.5560189},"labels":[],"label_agreement":null},{"id":"W2492974594","doi":"10.1001/jama.2016.9400","title":"Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta; Université de Montréal; University of Calgary; Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Metformin; Type 2 diabetes; Adverse effect; Sulfonylurea; Odds ratio; Hypoglycemia; Diabetes mellitus; Randomized controlled trial; Insulin; Endocrinology","score_opus":0.019228730397049393,"score_gpt":0.3074528950895887,"score_spread":0.2882241646925393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492974594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891305,0.000023255361,0.0000013116912,0.00015126844,0.000060234823,0.0003033332,0.0000040458976,0.00001994976,0.0005235596],"genre_scores_gemma":[0.9993459,0.000008763712,0.00011947034,0.00007465838,0.000009445916,0.0000068682307,0.000018337369,0.000012725713,0.00040386012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916816,0.000026306427,0.0002712001,0.00016076102,0.00020966513,0.00016393821],"domain_scores_gemma":[0.9994206,0.00015604259,0.0001467375,0.00013924137,0.000073426796,0.000063960804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016452464,0.00010489162,0.0004332139,0.000063108775,0.000011892222,0.000002323495,0.000036527654,0.00004933236,0.000020714204],"category_scores_gemma":[0.0001647699,0.000053314172,0.000030322422,0.00010216011,0.000047175865,0.00008823374,0.000037835023,0.00005593813,0.0000063572625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035132584,0.0007665139,0.97158694,0.000021077947,0.00032152463,0.0000014444156,0.000085075786,3.887456e-7,0.000006333255,0.0000057602256,0.00007645568,0.026777154],"study_design_scores_gemma":[0.014651141,0.0014102408,0.9828941,0.00045677836,0.00014823349,8.522639e-9,0.00004217431,0.000010075961,0.00018846765,0.0000061616097,0.00011859537,0.000073975454],"about_ca_topic_score_codex":0.0000064043884,"about_ca_topic_score_gemma":0.000020243779,"teacher_disagreement_score":0.026703179,"about_ca_system_score_codex":0.000036879617,"about_ca_system_score_gemma":0.000015710664,"threshold_uncertainty_score":0.21740888},"labels":[],"label_agreement":null},{"id":"W2493756352","doi":"10.1136/bmjdrc-2016-000270","title":"Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes","year":2016,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk; Novo Nordisk Canada; University of Toronto; Ontario Ministry of Research and Innovation; Heart and Stroke Foundation of Canada","keywords":"Medicine; Diabetes mellitus; Insulin; Type 2 diabetes; Drug; Internal medicine; Term (time); Intensive care medicine; Endocrinology; Pharmacology","score_opus":0.04425397384925764,"score_gpt":0.37965019184853316,"score_spread":0.33539621799927555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493756352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364574,0.0036360337,2.0621631e-7,0.0016253534,0.0004017563,0.0070486176,0.00007016547,0.00008358985,0.003488543],"genre_scores_gemma":[0.9944125,0.00056728115,0.000111225,0.00022558909,0.0002004738,0.0010690014,0.0001730026,0.00013022231,0.0031107091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941231,0.0005891206,0.0008779996,0.0009965058,0.0016677893,0.0017454758],"domain_scores_gemma":[0.994924,0.00089049194,0.00017290248,0.001791419,0.0017292331,0.000491932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00217959,0.00052911235,0.001249293,0.00084108947,0.00017995396,0.00020152013,0.001445198,0.0002494815,0.000279892],"category_scores_gemma":[0.003103985,0.0003566878,0.00034740465,0.0013476524,0.00035466885,0.0007410923,0.0021622372,0.0004790709,0.000053632604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038195684,0.00030848573,0.91211003,0.0004245425,0.0008054394,0.00006891342,0.0014259339,5.92167e-7,0.029438332,0.000039661754,0.013438091,0.041558046],"study_design_scores_gemma":[0.009703099,0.0031588823,0.88571966,0.0048331446,0.0001725571,1.1348554e-7,0.003445806,0.000038540806,0.08834323,0.00042218965,0.0035486387,0.0006141166],"about_ca_topic_score_codex":0.0001034802,"about_ca_topic_score_gemma":0.000058620382,"teacher_disagreement_score":0.0589049,"about_ca_system_score_codex":0.0006545209,"about_ca_system_score_gemma":0.00044324514,"threshold_uncertainty_score":0.99988854},"labels":[],"label_agreement":null},{"id":"W2494432242","doi":"10.1111/dom.12741","title":"One‐year efficacy and safety of saxagliptin add‐on in patients receiving dapagliflozin and metformin","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Saxagliptin; Dapagliflozin; Placebo; Metformin; Medicine; Internal medicine; Adverse effect; Glycated haemoglobin; Type 2 diabetes; Diabetes mellitus; Endocrinology; Sitagliptin; Insulin","score_opus":0.009020959823222884,"score_gpt":0.21245615479370644,"score_spread":0.20343519497048357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494432242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965214,0.0013816686,0.0000026979537,0.00019712867,0.00007589185,0.00054373953,0.000024859935,0.00002201688,0.0012306131],"genre_scores_gemma":[0.99732304,0.0016166454,0.0005325651,0.00015049068,0.00003888238,0.000014075427,0.000014142593,0.000015645312,0.00029452526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886006,0.000055767152,0.00026946375,0.0003176064,0.0002057281,0.0002913626],"domain_scores_gemma":[0.99934614,0.00017031947,0.000090820344,0.00020215545,0.00004495507,0.00014560689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003639281,0.00018081626,0.00052965037,0.00021510528,0.00004885773,0.000014568993,0.000046061043,0.000085215586,0.000029701063],"category_scores_gemma":[0.000199459,0.00012989204,0.00003744466,0.00012566372,0.000117804906,0.00015322935,0.000112383656,0.00008164793,0.000005716906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019076535,0.0006025818,0.7042328,0.00014392374,0.00015095434,9.3765146e-7,0.00025735,8.451382e-8,0.0010025564,0.0019457752,0.000072774725,0.2913995],"study_design_scores_gemma":[0.008444503,0.00030192555,0.9821463,0.0004362907,0.00025687148,6.8014884e-8,0.000025869267,0.0000036631668,0.0042567905,0.00024799202,0.0037370329,0.00014264257],"about_ca_topic_score_codex":0.000012874672,"about_ca_topic_score_gemma":0.000008638354,"teacher_disagreement_score":0.29125687,"about_ca_system_score_codex":0.0000199215,"about_ca_system_score_gemma":0.000010884143,"threshold_uncertainty_score":0.52968436},"labels":[],"label_agreement":null},{"id":"W2498901811","doi":"10.1016/j.cmet.2016.07.018","title":"Empagliflozin’s Fuel Hypothesis: Not so Soon","year":2016,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Alberta","funders":"","keywords":"Empagliflozin; Computational biology; Aeronautics; Medicine; Biology; Engineering; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.022965895704101208,"score_gpt":0.22506404688785586,"score_spread":0.20209815118375465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498901811","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029236253,0.015215428,0.000028231607,0.80734074,0.004058624,0.0017717989,0.00012901457,0.0004493411,0.1680832],"genre_scores_gemma":[0.0014648869,0.0019884137,0.00069920276,0.6425296,0.013352535,0.00022535623,0.00019617348,0.00019631542,0.3393475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970077,0.00008712049,0.00046237616,0.00081725797,0.0006993414,0.0009262012],"domain_scores_gemma":[0.9981148,0.00011827796,0.00026455833,0.0012270093,0.00009704628,0.00017826357],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019133493,0.00070831086,0.0012151075,0.0005764569,0.000085873915,0.00010046673,0.00034674778,0.0007289752,0.0016179729],"category_scores_gemma":[0.00003894012,0.00048320508,0.00058063824,0.00017423622,0.00013392561,0.00010212896,0.00015589643,0.00077008764,0.0059525464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025753265,0.00009243471,0.000049507194,0.00066832895,0.0005819965,0.0005539282,0.00008360946,2.8424973e-8,0.00059648906,0.000077292294,0.9715862,0.025684385],"study_design_scores_gemma":[0.0023710865,0.000071143586,0.00057660026,0.00020545162,0.0032180012,0.000004611665,0.000014153178,9.3147435e-7,0.0037894102,0.00042043,0.98881155,0.00051663525],"about_ca_topic_score_codex":0.000017063752,"about_ca_topic_score_gemma":0.0000011338085,"teacher_disagreement_score":0.1712643,"about_ca_system_score_codex":0.000103046965,"about_ca_system_score_gemma":0.00012880878,"threshold_uncertainty_score":0.99976194},"labels":[],"label_agreement":null},{"id":"W2500205677","doi":"10.1016/j.cjca.2016.07.512","title":"Diabetes for Cardiologists: Practical Issues in Diagnosis and Management","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary; Libin Cardiovascular Institute of Alberta; Université Laval; Population Health Research Institute; St. Michael's Hospital; McMaster University; LMC Diabetes & Endocrinology (Canada); McGill University Health Centre; North York General Hospital; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Glycemic; Intensive care medicine; Life expectancy; Disease; Macrovascular disease; Population; Adverse effect; Diabetes mellitus; Natural history; Type 2 diabetes; Internal medicine; Endocrinology; Environmental health","score_opus":0.05721912056924105,"score_gpt":0.356771565449529,"score_spread":0.2995524448802879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500205677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026506641,0.9926224,0.000069565096,0.0016376261,0.00057709793,0.0012809283,0.000062612125,0.000004887747,0.0037183948],"genre_scores_gemma":[0.0001782305,0.99716437,0.0007123583,0.000115615905,0.0009865187,0.00034666844,0.000028284436,0.0000375164,0.00043042077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982353,0.00019421539,0.0006546084,0.00028146108,0.00009445321,0.0005399838],"domain_scores_gemma":[0.9984357,0.0004638443,0.0002971326,0.00024976156,0.000094056486,0.0004595194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070425443,0.0003128727,0.0028160803,0.00085231184,0.000037769285,0.000025023524,0.00013081121,0.0002905592,0.000012549539],"category_scores_gemma":[0.00034015873,0.00020360248,0.0006456118,0.000116611445,0.00019262075,0.00006409611,0.000034235945,0.00022178644,0.000011054904],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011073069,0.000004826529,0.0052006165,0.0059815105,0.0030254147,0.0009833818,0.0000085522715,5.7032634e-7,1.743692e-8,0.001096338,0.057450626,0.92623705],"study_design_scores_gemma":[0.00087471056,0.0005221604,0.00071408646,0.008286546,0.0034130723,0.0001528864,0.000020034837,1.0926039e-7,1.9903811e-7,0.00024257235,0.9855967,0.00017692213],"about_ca_topic_score_codex":0.00003136938,"about_ca_topic_score_gemma":0.00012155229,"teacher_disagreement_score":0.92814606,"about_ca_system_score_codex":0.0004497324,"about_ca_system_score_gemma":0.0005088777,"threshold_uncertainty_score":0.83026683},"labels":[],"label_agreement":null},{"id":"W2504850179","doi":"10.1111/hdi.12438","title":"A systematic review of the benefits and harms of dipeptidyl peptidase‐4 inhibitor for chronic kidney disease","year":2016,"lang":"en","type":"review","venue":"Hemodialysis International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Medicine; Internal medicine; Placebo; Kidney disease; Diabetes mellitus; Glycemic; Odds ratio; Hypoglycemia; Adverse effect; Dipeptidyl peptidase-4 inhibitor; Sitagliptin; Meta-analysis; Randomized controlled trial; Dipeptidyl peptidase-4; Gastroenterology; Type 2 diabetes; Endocrinology; Insulin; Pathology","score_opus":0.021755263268817892,"score_gpt":0.2992754298550444,"score_spread":0.2775201665862265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504850179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007108344,0.9941269,0.000032004904,0.00049318967,0.00025856728,0.0038001654,0.0009212371,0.000010320929,0.00035048896],"genre_scores_gemma":[0.000084012696,0.9955274,0.00008499314,0.00023415989,0.00024622423,0.0011123337,0.00047902958,0.000031761418,0.0022000961],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99796563,0.000072709234,0.0010371703,0.0003045121,0.0004790695,0.00014089806],"domain_scores_gemma":[0.99785817,0.00021932775,0.0010089352,0.00053487846,0.00023791849,0.00014074585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034357604,0.00028616973,0.002004483,0.00019037382,0.000025499905,0.000011523627,0.00028028837,0.00006572946,0.00016958918],"category_scores_gemma":[0.0008676788,0.00014381498,0.0012920968,0.00014448861,0.000079497215,0.000050245453,0.00017232336,0.000059559654,0.000012760963],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009577626,0.00012052388,0.000021171947,0.9068045,0.002694085,9.1405326e-7,0.0000062924173,5.5008396e-8,9.3943004e-7,0.0007815068,0.0028828692,0.08667755],"study_design_scores_gemma":[0.00062207377,0.00004406491,0.000008766546,0.79578805,0.015833296,0.0000019360398,0.0000010075452,0.00001219659,0.000009489159,0.000019462672,0.187553,0.000106625295],"about_ca_topic_score_codex":0.0000011110749,"about_ca_topic_score_gemma":5.263155e-7,"teacher_disagreement_score":0.18467014,"about_ca_system_score_codex":0.00023083712,"about_ca_system_score_gemma":0.00030516143,"threshold_uncertainty_score":0.5864605},"labels":[],"label_agreement":null},{"id":"W2506770244","doi":"10.2196/resprot.5073","title":"Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study","year":2016,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prediabetes; Sitagliptin; Metformin; Medicine; Type 2 diabetes; Sitagliptin Phosphate; Diabetes mellitus; Randomized controlled trial; Clinical trial; Protocol (science); Internal medicine; Endocrinology; Alternative medicine","score_opus":0.2663964826492966,"score_gpt":0.5824015883056879,"score_spread":0.3160051056563913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2506770244","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36292502,0.000017412729,0.0000034396967,0.00032947617,0.000018829263,0.636505,0.00000983473,0.00005456482,0.0001363841],"genre_scores_gemma":[0.078832194,0.000004315446,0.0005210027,0.000033204506,0.00023149422,0.9196618,0.0000074166974,0.000082838436,0.00062569196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928907,0.0018301525,0.0016205591,0.0011576237,0.0012808205,0.0012201443],"domain_scores_gemma":[0.9868681,0.01089337,0.00040946814,0.00091088447,0.00047337834,0.0004448043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.02101667,0.00058792863,0.0018692384,0.00072924345,0.00020744176,0.0001921234,0.00047151878,0.00026097434,0.000052435753],"category_scores_gemma":[0.0028040526,0.00027100195,0.00030047056,0.00068652426,0.0006248555,0.00034957615,0.00072447385,0.0005079142,0.000020546458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.811031,0.0057229465,0.056391213,0.0020043673,0.00057869,0.0000073403908,0.00031646434,7.057685e-7,0.0005750263,0.000081678205,0.0009984599,0.1222921],"study_design_scores_gemma":[0.86298084,0.09238645,0.0012387802,0.004964607,0.00019580493,2.931051e-7,0.00010843864,0.000227628,0.027670106,0.00008921205,0.009858492,0.0002793563],"about_ca_topic_score_codex":0.00001016347,"about_ca_topic_score_gemma":0.000013058601,"teacher_disagreement_score":0.28409284,"about_ca_system_score_codex":0.00012752743,"about_ca_system_score_gemma":0.00012096138,"threshold_uncertainty_score":0.9999742},"labels":[],"label_agreement":null},{"id":"W2507202841","doi":"10.1016/j.ando.2016.07.098","title":"Efficacité et sécurité du traitement du diabète de type 2 (DT2) par pompe à insuline : l’étude OPT2MISE à 1 an","year":2016,"lang":"fr","type":"article","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Gynecology","score_opus":0.04124601018526316,"score_gpt":0.29787322999310367,"score_spread":0.25662721980784053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507202841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8783594,0.046713572,0.00020407882,0.06656954,0.002146361,0.0010053972,0.00012076587,0.00049421214,0.004386717],"genre_scores_gemma":[0.89959496,0.08004601,0.0008706989,0.0056443335,0.0012658724,0.0001394868,0.00015409851,0.00009196006,0.0121925995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598765,0.00029655598,0.00063647056,0.00085569086,0.0004049979,0.0018186516],"domain_scores_gemma":[0.9977601,0.00035330467,0.00019157179,0.00090465747,0.0002020323,0.00058833463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037689588,0.0006635352,0.0007318313,0.00023758903,0.0001663957,0.00007563827,0.0005168831,0.00019357898,0.0014530042],"category_scores_gemma":[0.0004616907,0.00048787112,0.0002609817,0.000314734,0.00041306732,0.00042474663,0.00037167303,0.0002764315,0.0014900863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007957119,0.0059757954,0.10800013,0.00042425393,0.0020933882,0.0034600082,0.00070856244,0.000128372,0.005238865,0.024176037,0.08724124,0.7617576],"study_design_scores_gemma":[0.0075173564,0.0035543898,0.15057883,0.0006425256,0.00085446215,0.000073351766,0.00016837982,0.00019957004,0.009154522,0.00066163985,0.82595396,0.0006410031],"about_ca_topic_score_codex":0.000093024326,"about_ca_topic_score_gemma":0.00009220049,"teacher_disagreement_score":0.7611166,"about_ca_system_score_codex":0.00028066715,"about_ca_system_score_gemma":0.00018390905,"threshold_uncertainty_score":0.9997573},"labels":[],"label_agreement":null},{"id":"W2508631163","doi":"10.14740/jocmr2610w","title":"Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Polypharmacy; Type 2 diabetes; Medical prescription; Insulin; Diabetes mellitus; Internal medicine; Type 2 Diabetes Mellitus; Drug; Endocrinology; Pharmacology","score_opus":0.14549306449871163,"score_gpt":0.4716470172857532,"score_spread":0.32615395278704157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508631163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828521,0.00031350675,0.000005479288,0.015160989,0.00017742721,0.00026664598,0.0000048132956,0.00000253963,0.0012164748],"genre_scores_gemma":[0.9958293,0.002248878,0.0001508687,0.0002091896,0.0009103015,0.0000025923457,0.000010870755,0.000013271261,0.0006247186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956465,0.00075663766,0.0017173161,0.00020004321,0.0013561323,0.00032339527],"domain_scores_gemma":[0.9933946,0.004623648,0.00050700275,0.00034268128,0.0008125214,0.00031953532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008375697,0.00013074276,0.0010773907,0.00038839018,0.000030028363,0.0000071786676,0.00023788949,0.00013812132,0.00015832967],"category_scores_gemma":[0.0038176826,0.000050378647,0.00011933606,0.00048468652,0.0008079748,0.00008001329,0.000083829436,0.00078999455,0.000009262926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010202923,0.00047300625,0.72377086,0.00004037512,0.00021693231,0.000070268674,0.000041773517,1.5631025e-8,0.0000029678624,0.000019332174,0.012026362,0.2623178],"study_design_scores_gemma":[0.011557094,0.0150506245,0.95430505,0.0010257754,0.0003074445,0.00000768711,0.00006308431,0.0000023585972,0.00000282333,0.00011463018,0.017507859,0.000055594424],"about_ca_topic_score_codex":0.000012885506,"about_ca_topic_score_gemma":0.0000036058154,"teacher_disagreement_score":0.2622622,"about_ca_system_score_codex":0.000032408618,"about_ca_system_score_gemma":0.000116703886,"threshold_uncertainty_score":0.45703983},"labels":[],"label_agreement":null},{"id":"W2509255910","doi":"10.1055/s-0042-110988","title":"Typ-1-Diabetes: Lipidsenkende Therapie reduziert kardiovaskuläres Risiko","year":2016,"lang":"de","type":"article","venue":"DMW - Deutsche Medizinische Wochenschrift","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Gynecology; Diabetes mellitus; Endocrinology","score_opus":0.017790594880248898,"score_gpt":0.25323669494166406,"score_spread":0.23544610006141517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509255910","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28610307,0.46665147,0.0011032309,0.043168336,0.02736111,0.0076880343,0.00085433153,0.002592519,0.1644779],"genre_scores_gemma":[0.900727,0.029371543,0.004707474,0.007083444,0.014695427,0.0008066632,0.00056106865,0.0007975262,0.041249868],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98858154,0.0008302367,0.0020399631,0.002597531,0.002443101,0.0035076488],"domain_scores_gemma":[0.9913989,0.0017669371,0.00082649593,0.0036365082,0.00055137236,0.0018198359],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0028206005,0.0021448964,0.0028009007,0.00092768524,0.00051703065,0.0003046355,0.0013858528,0.0012911343,0.0044072834],"category_scores_gemma":[0.0017958153,0.001445524,0.0017075161,0.0011783636,0.0011960424,0.00072563894,0.00079111,0.0012207846,0.021900425],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017413237,0.0042909244,0.066977024,0.0017888932,0.061172616,0.0012319349,0.0035340001,0.0000064272313,0.050336517,0.0079354,0.4524395,0.34854546],"study_design_scores_gemma":[0.012391462,0.0017212637,0.0068347347,0.0026101833,0.010513808,0.000008312231,0.00047733553,0.00006972103,0.039030362,0.00030824693,0.9241851,0.0018494677],"about_ca_topic_score_codex":0.000032912303,"about_ca_topic_score_gemma":0.000011939005,"teacher_disagreement_score":0.6146239,"about_ca_system_score_codex":0.0002719411,"about_ca_system_score_gemma":0.00068849383,"threshold_uncertainty_score":0.9991292},"labels":[],"label_agreement":null},{"id":"W2514658869","doi":"10.2337/dc16-0691","title":"Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Placebo; Type 2 diabetes; Glycemic; Insulin; Internal medicine; Diabetes mellitus; Endocrinology; Urology; Gastroenterology","score_opus":0.014027237228094772,"score_gpt":0.2495618072164118,"score_spread":0.23553456998831704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514658869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859652,0.0023741382,0.000005770569,0.0028124368,0.000220794,0.0069538737,0.00012393232,0.000053983254,0.0014898636],"genre_scores_gemma":[0.99637014,0.00039100036,0.0005828009,0.0006184118,0.00016034492,0.0008423487,0.00013138045,0.000045678244,0.00085792725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99786,0.00023161646,0.00058528525,0.00048270304,0.00029726242,0.00054312666],"domain_scores_gemma":[0.997873,0.0010193526,0.00011973725,0.00060512475,0.00012726372,0.00025554284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004004731,0.0003683248,0.0013387605,0.000297543,0.00005763722,0.000020035228,0.00014615658,0.00009358994,0.000114437695],"category_scores_gemma":[0.00070627057,0.0001881707,0.00022413701,0.0004630147,0.00012433644,0.00006106408,0.00011812695,0.00006480858,0.00013838509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55387855,0.0016730593,0.073367275,0.00024835562,0.0017914468,0.000017719312,0.004348398,0.000018270543,0.0042315116,0.00023762709,0.0012865965,0.35890123],"study_design_scores_gemma":[0.92223644,0.0061921277,0.035784524,0.000819031,0.0011292319,1.1691565e-7,0.00027648621,0.000018767334,0.017968653,0.00009414705,0.015149121,0.00033135654],"about_ca_topic_score_codex":0.00003407,"about_ca_topic_score_gemma":0.000039343184,"teacher_disagreement_score":0.36835793,"about_ca_system_score_codex":0.00026901934,"about_ca_system_score_gemma":0.000079749574,"threshold_uncertainty_score":0.7673378},"labels":[],"label_agreement":null},{"id":"W2514766623","doi":"10.2337/dc16-0917","title":"Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Insulin glargine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Endocrinology; Basal insulin","score_opus":0.022696378881757177,"score_gpt":0.26154900023256145,"score_spread":0.23885262135080426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514766623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987633,0.0047304635,0.000004255959,0.0010251675,0.0005538625,0.00501073,0.00013073861,0.00005379197,0.0008580152],"genre_scores_gemma":[0.997107,0.0011567752,0.00013922498,0.00020160367,0.00009515428,0.0005683628,0.0004354738,0.000051149822,0.00024525466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969218,0.00037775197,0.0010808374,0.00047839375,0.0006209621,0.0005202589],"domain_scores_gemma":[0.9967534,0.0015965796,0.0005678426,0.00052147446,0.0004211772,0.00013953808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000825312,0.000456265,0.0019258548,0.0004909741,0.00007412975,0.00003992872,0.00024050938,0.0001794749,0.000058995414],"category_scores_gemma":[0.0014075161,0.00027186464,0.0002743537,0.00051695626,0.00022719923,0.0002244732,0.00013893613,0.00018374907,0.00002329177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89545226,0.0025998196,0.042594064,0.0008941166,0.0031879914,0.000014449373,0.0023369147,0.0003329984,0.0035770203,0.0038578606,0.0012046996,0.04394781],"study_design_scores_gemma":[0.9589036,0.003519852,0.01742749,0.0009388697,0.0007934782,1.1207532e-7,0.00031033892,0.0021746587,0.015018909,0.00017098647,0.00042393472,0.00031773586],"about_ca_topic_score_codex":0.00006974161,"about_ca_topic_score_gemma":0.000074346186,"teacher_disagreement_score":0.06345138,"about_ca_system_score_codex":0.00022101542,"about_ca_system_score_gemma":0.00010669841,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W2515214902","doi":"10.1053/j.ajkd.2016.06.014","title":"Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis","year":2016,"lang":"en","type":"review","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Newfoundland and Labrador Centre for Applied Health Research","keywords":"Medicine; Incretin; Internal medicine; Sitagliptin; Placebo; Hypoglycemia; Linagliptin; Diabetes mellitus; Vildagliptin; Type 2 diabetes; Context (archaeology); Relative risk; Kidney disease; Renal function; Glycated hemoglobin; Endocrinology; Confidence interval; Pathology","score_opus":0.013335948976680303,"score_gpt":0.27757127641252977,"score_spread":0.2642353274358495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515214902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083098793,0.9974039,0.0000027623907,0.00027445727,0.0000068167524,0.0013040078,0.00016174001,0.0000044431763,0.000010848792],"genre_scores_gemma":[0.0033751614,0.99568236,0.00014241405,0.00065894047,0.000007735494,0.000028876653,0.000053506006,0.000026236501,0.00002476329],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9978124,0.0004303291,0.0010152566,0.00023640305,0.00033313874,0.00017250853],"domain_scores_gemma":[0.9966009,0.0006085637,0.0018119179,0.00030000726,0.00017917166,0.00049943995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003376443,0.00037314094,0.007609963,0.00049598946,0.000021323493,0.000018856485,0.00009412852,0.000026757882,0.00005587442],"category_scores_gemma":[0.0007252169,0.00016898711,0.00066148763,0.0006041344,0.00031025696,0.000060679926,0.000037288515,0.00008555337,6.051207e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002443266,0.0005178698,0.015261066,0.6349886,0.2649309,0.000017425798,0.00003453184,1.2196843e-7,2.37322e-8,0.000006958601,0.0000965166,0.08390166],"study_design_scores_gemma":[0.0013324673,0.0014892046,0.0034923125,0.09403499,0.89381725,0.0000012888534,0.000015562091,3.5387652e-7,6.430009e-8,0.0000019267763,0.005632699,0.00018186803],"about_ca_topic_score_codex":0.0000050252434,"about_ca_topic_score_gemma":3.538802e-7,"teacher_disagreement_score":0.62888634,"about_ca_system_score_codex":0.00004168227,"about_ca_system_score_gemma":0.00020383108,"threshold_uncertainty_score":0.6891095},"labels":[],"label_agreement":null},{"id":"W2515629008","doi":"10.1139/cjpp-2016-0026","title":"Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Research Foundation of Korea; Korea Health Industry Development Institute; National Research Foundation","keywords":"Endocrinology; Internal medicine; Insulin resistance; Lipogenesis; Metabolic syndrome; Adipocyte; Oxidative stress; Glucose homeostasis; Adipose tissue; Triglyceride; Dipeptidyl peptidase-4; Inflammation; Glucose uptake; Diabetes mellitus; Insulin; Type 2 diabetes; Chemistry; Medicine; Cholesterol","score_opus":0.017948872701667003,"score_gpt":0.27741847394775015,"score_spread":0.25946960124608315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515629008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339473,0.0016204483,0.0000013867794,0.0040553557,0.00058454426,0.00014304806,0.0000055761057,0.000003986095,0.00019091016],"genre_scores_gemma":[0.99729514,0.0003917904,0.00003732404,0.0016973122,0.00015634077,0.000007924664,0.0000019357933,0.000010129987,0.00040211662],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991302,0.000095374155,0.0002576416,0.00014056546,0.000038780836,0.00033747457],"domain_scores_gemma":[0.9992919,0.00008566665,0.00012627679,0.000059919388,0.000060678612,0.00037553682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016850454,0.00012500405,0.00043231942,0.00037946354,0.000037747017,0.0000040620043,0.000088785564,0.00009029655,0.00079069805],"category_scores_gemma":[0.000016713415,0.000082562125,0.00005697123,0.000114409406,0.00012843085,0.00009469513,0.000014560195,0.00015260535,0.000031843425],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028273225,0.00007294416,0.04427592,0.000050975937,0.00045150524,0.0011782915,0.00017123853,0.0000013941104,0.94647616,0.00019585296,0.0021220713,0.0047208946],"study_design_scores_gemma":[0.009473957,0.003274876,0.80194646,0.00016453471,0.0007641559,0.0005962402,0.000097077595,0.000005088405,0.14364801,0.0011850025,0.038565595,0.0002789712],"about_ca_topic_score_codex":0.0002901726,"about_ca_topic_score_gemma":0.0011708743,"teacher_disagreement_score":0.80282813,"about_ca_system_score_codex":0.000056259934,"about_ca_system_score_gemma":0.00025295003,"threshold_uncertainty_score":0.8657589},"labels":[],"label_agreement":null},{"id":"W2516820342","doi":"10.1111/dme.13256","title":"Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the <scp>DUAL IV</scp> trial","year":2016,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Metformin; Placebo; Internal medicine; Type 2 diabetes; Diabetes mellitus; Insulin; Endocrinology; Gastroenterology; Odds ratio","score_opus":0.015786945300784384,"score_gpt":0.2547060729086166,"score_spread":0.23891912760783218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516820342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871843,0.0025403067,0.00010825683,0.0033725891,0.00041751386,0.004822489,0.000062054634,0.0001022037,0.0013902821],"genre_scores_gemma":[0.9911938,0.0015019095,0.0009854042,0.0023410807,0.00049955636,0.0003344945,0.00013568389,0.00011340749,0.0028947105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99530333,0.00021532271,0.001290259,0.0009768236,0.001049553,0.0011647127],"domain_scores_gemma":[0.992719,0.004694423,0.00036958486,0.0010274032,0.00028289837,0.00090672314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017645573,0.0007515469,0.0019833294,0.00073473295,0.00013258767,0.00003481171,0.00033763642,0.00022854203,0.0000830686],"category_scores_gemma":[0.0075251968,0.0003753701,0.00009194346,0.001771545,0.0004981203,0.00016809315,0.00035602797,0.00031359153,0.00005976771],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042708665,0.0065898327,0.24262755,0.0024806736,0.0065435246,0.00080723333,0.05713003,0.00007419176,0.027498722,0.0016621795,0.081498794,0.53037864],"study_design_scores_gemma":[0.2498667,0.031009417,0.6162806,0.0043386035,0.0029912863,0.000036126337,0.0051049166,0.00010359325,0.011815943,0.000212986,0.07780708,0.00043274064],"about_ca_topic_score_codex":0.00023680151,"about_ca_topic_score_gemma":0.0005817279,"teacher_disagreement_score":0.52994585,"about_ca_system_score_codex":0.00017370965,"about_ca_system_score_gemma":0.0002453431,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2518446169","doi":"10.1016/j.ando.2016.07.227","title":"L’insuline asparte ultra-rapide vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude onset® 2","year":2016,"lang":"fr","type":"article","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gynecology; Medicine","score_opus":0.021509959203693925,"score_gpt":0.27462593358977305,"score_spread":0.25311597438607913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518446169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9450478,0.012830471,0.00020867566,0.019858874,0.002343038,0.0022520511,0.0006648489,0.00065932615,0.016134892],"genre_scores_gemma":[0.9355151,0.04435779,0.00087466603,0.0013566448,0.00091897574,0.0002147001,0.0007111611,0.00020377696,0.015847193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922025,0.0007939007,0.0015035999,0.0015564966,0.0009235494,0.0030199152],"domain_scores_gemma":[0.9949263,0.0017665909,0.0005423082,0.0014666494,0.00044615654,0.00085199863],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00069018774,0.001434188,0.0017370302,0.00050088984,0.0004238822,0.00015640206,0.0010498762,0.0005428987,0.0009537371],"category_scores_gemma":[0.0008287812,0.0011054643,0.0006357654,0.0008048986,0.0014826186,0.00082956883,0.00064741424,0.00073443685,0.0026087495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010374701,0.0111863185,0.58228236,0.001222407,0.005933097,0.0045531825,0.0053105587,0.00029434747,0.0056911977,0.0032372298,0.041354544,0.32856005],"study_design_scores_gemma":[0.05427644,0.006436343,0.7137525,0.0021050302,0.0026564659,0.00009671496,0.0008923489,0.000087004286,0.036733687,0.0014743215,0.17970833,0.0017807914],"about_ca_topic_score_codex":0.00095629663,"about_ca_topic_score_gemma":0.0014298587,"teacher_disagreement_score":0.32677925,"about_ca_system_score_codex":0.0010175043,"about_ca_system_score_gemma":0.0003243952,"threshold_uncertainty_score":0.9999595},"labels":[],"label_agreement":null},{"id":"W2518492470","doi":"","title":"Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Sitagliptin; Metformin; Medicine; Sulfonylurea; Type 2 diabetes; Glycemic; Type 2 Diabetes Mellitus; Diabetes mellitus; Pharmacology; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Endocrinology; Hypoglycemia","score_opus":0.034074361019488415,"score_gpt":0.24141917421757292,"score_spread":0.2073448131980845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518492470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500513,0.00031816843,0.000001418493,0.0005829755,0.00019313814,0.0020725045,0.000016138401,0.000008439312,0.0018021057],"genre_scores_gemma":[0.9980545,0.00003639812,0.00006188541,0.00008116522,0.000014804248,0.0012730209,0.00000916529,0.000013041535,0.00045604457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989771,0.000055499626,0.00018981416,0.00021272346,0.00016127563,0.0004035395],"domain_scores_gemma":[0.9992688,0.00031475208,0.00003797273,0.00017561253,0.00003971393,0.00016315201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039845126,0.00012533554,0.00034190022,0.0002139756,0.000007667122,0.0000046086134,0.00006379547,0.0000316779,0.000025468733],"category_scores_gemma":[0.0003022667,0.00008947393,0.000017945405,0.00025922086,0.000021557575,0.00006840035,0.00006235601,0.000039347116,0.000002978288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010997772,0.00009568803,0.6010957,0.00015669866,0.00015503286,0.00004412686,0.00006819197,0.000003862521,0.0003100659,0.00015096234,0.0011545942,0.39566532],"study_design_scores_gemma":[0.0059123146,0.00011172048,0.98048884,0.00013374237,0.000070930284,1.7864079e-7,0.00007822469,0.000007356789,0.0068335477,0.00004679799,0.006198352,0.00011797005],"about_ca_topic_score_codex":0.24067952,"about_ca_topic_score_gemma":0.85106933,"teacher_disagreement_score":0.6103898,"about_ca_system_score_codex":0.00081840006,"about_ca_system_score_gemma":0.0001772823,"threshold_uncertainty_score":0.7643769},"labels":[],"label_agreement":null},{"id":"W2519510391","doi":"10.1056/nejmoa1607141","title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2016,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6603,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto; St. Michael's Hospital","funders":"Servier; Novo Nordisk Fonden; Medicines Company; Novo Nordisk; Intarcia Therapeutics; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Mylan; MannKind Corporation; GlaxoSmithKline","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology; Liraglutide","score_opus":0.008063027747281284,"score_gpt":0.21135040011135772,"score_spread":0.20328737236407643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519510391","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48308316,0.0083664255,0.000009889119,0.5055591,0.0009909298,0.0005933032,0.000005591276,0.000016017131,0.0013755965],"genre_scores_gemma":[0.3292003,0.0042395014,0.0012917378,0.60076797,0.043408014,0.000014488974,0.00025163457,0.00031801057,0.02050837],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980605,0.00007389581,0.0004601929,0.00020817037,0.0008770467,0.00032015462],"domain_scores_gemma":[0.99885976,0.00022013158,0.0002539412,0.00030524924,0.00019574084,0.00016516879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004970062,0.00030793578,0.0014693934,0.0004660959,0.000016570404,0.000008448258,0.00009727086,0.00016235487,0.000106906475],"category_scores_gemma":[0.00021105209,0.0001402609,0.00012948512,0.00012152913,0.00009953059,0.000057341906,0.000030740324,0.0006238,0.0000047356407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019315205,0.00003451279,0.5619485,0.00015252942,0.0024709587,0.0007461012,0.00006443955,4.8435277e-7,0.0000018032363,0.0000011672063,0.33288386,0.10150251],"study_design_scores_gemma":[0.068329096,0.003321993,0.19379728,0.0020219227,0.0021722894,0.000019603602,0.000007115811,2.6905107e-7,0.000004214843,0.000056909692,0.73012877,0.00014056485],"about_ca_topic_score_codex":0.00001915334,"about_ca_topic_score_gemma":0.0000038603716,"teacher_disagreement_score":0.39724487,"about_ca_system_score_codex":0.000073499985,"about_ca_system_score_gemma":0.00008107373,"threshold_uncertainty_score":0.57196736},"labels":[],"label_agreement":null},{"id":"W2519976593","doi":"10.2337/dc15-2780","title":"Pancreatic Safety of Sitagliptin in the TECOS Study","year":2016,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Liver Centre; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute for Health and Care Research","keywords":"Sitagliptin; Medicine; Acute pancreatitis; Sitagliptin Phosphate; Pancreatitis; Pancreatic cancer; Hazard ratio; Internal medicine; Gastroenterology; Placebo; Diabetes mellitus; Cancer; Type 2 diabetes; Dipeptidyl peptidase-4 inhibitor; Surgery; Endocrinology; Confidence interval; Pathology","score_opus":0.009697606270542575,"score_gpt":0.2403971435162653,"score_spread":0.2306995372457227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519976593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083394,0.00036195168,0.0000011963618,0.00042355116,0.000035908794,0.0010438205,0.000017206527,0.000022728274,0.007259721],"genre_scores_gemma":[0.9993245,0.000019644607,0.000039829232,0.00017338122,0.000030142535,0.000118085525,0.000017602853,0.000011026284,0.00026578183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991881,0.0000602418,0.00019479278,0.0001562241,0.0001992545,0.00020136542],"domain_scores_gemma":[0.9993665,0.00014116333,0.000046332763,0.0003727817,0.00004416664,0.000029034847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016955836,0.000107686195,0.0002535444,0.00008360502,0.000021405549,0.0000056957406,0.00011058407,0.00002395981,0.000083517756],"category_scores_gemma":[0.00005925632,0.000050801256,0.00006712636,0.0001614102,0.000033252953,0.000039735714,0.000041241845,0.000037507616,0.000080879414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002192541,0.00032116967,0.9648081,0.00008183604,0.000106995474,0.000009169139,0.0019207961,2.5557767e-7,0.0005008503,0.000070291026,0.00041601018,0.031742565],"study_design_scores_gemma":[0.0027794645,0.00085524394,0.9825088,0.00017243599,0.00027399266,8.707272e-8,0.009132239,0.0000019602946,0.0011591949,0.000038616792,0.003003954,0.00007400654],"about_ca_topic_score_codex":0.0000067465303,"about_ca_topic_score_gemma":0.000025734575,"teacher_disagreement_score":0.03166856,"about_ca_system_score_codex":0.000057577825,"about_ca_system_score_gemma":0.0000127033745,"threshold_uncertainty_score":0.2071615},"labels":[],"label_agreement":null},{"id":"W2520168785","doi":"","title":"[L'acidocétose diabétique euglycémique due à la canagliflozine: Une complication « acide » mais évitable de l'utilisation des inhibiteurs du cotransporteur sodium-glucose de type 2].","year":2016,"lang":"fr","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Medical Association; University of British Columbia","funders":"","keywords":"Medicine; Chemistry","score_opus":0.01649862935300593,"score_gpt":0.22521894819132132,"score_spread":0.20872031883831538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520168785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525888,0.0054659704,0.0053927437,0.01822421,0.0008607322,0.0026766045,0.00010708937,0.00028408016,0.014399748],"genre_scores_gemma":[0.97076905,0.0056109778,0.0007477045,0.00087531743,0.00059370324,0.002042348,0.00020480687,0.00010527869,0.01905084],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966446,0.00034226466,0.000557272,0.0006045559,0.00031077326,0.0015404945],"domain_scores_gemma":[0.9978517,0.0003732404,0.00022145425,0.00059119577,0.00024103548,0.0007213735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013726997,0.00047103502,0.0005271359,0.00025805034,0.00017816249,0.000091031136,0.000246528,0.0003145489,0.00016234952],"category_scores_gemma":[0.0004609544,0.0004062374,0.00016540749,0.0006830039,0.00043543515,0.0005337525,0.00007258241,0.0002221431,0.00019528196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048593947,0.0011581163,0.293448,0.00075596524,0.0006867242,0.0005326632,0.001069237,0.000060275095,0.008906156,0.021211514,0.010844595,0.6608408],"study_design_scores_gemma":[0.0039275913,0.00017210521,0.83399487,0.0005017056,0.0010751447,0.000083464474,0.00027186115,0.00015199251,0.04601021,0.0045934743,0.108721755,0.0004958311],"about_ca_topic_score_codex":0.0032971287,"about_ca_topic_score_gemma":0.0026717656,"teacher_disagreement_score":0.660345,"about_ca_system_score_codex":0.001586972,"about_ca_system_score_gemma":0.0003178131,"threshold_uncertainty_score":0.99983895},"labels":[],"label_agreement":null},{"id":"W2521015329","doi":"","title":"Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto East General Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"Diabetic ketoacidosis; Medicine; Diabetes mellitus; Type 2 diabetes; Ketoacidosis; Food and drug administration; Type 2 Diabetes Mellitus; Sodium; Endocrinology; Internal medicine; Type 1 diabetes; Pharmacology; Chemistry","score_opus":0.011836299669964603,"score_gpt":0.19514001253775937,"score_spread":0.18330371286779476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521015329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283683,0.0005513086,0.0000026340977,0.0015107656,0.00010539147,0.0014692779,0.0000088351235,0.00015885165,0.0033560786],"genre_scores_gemma":[0.9944605,0.00020308736,0.0000642839,0.00026364016,0.00007749299,0.0017415705,0.00003323501,0.000046613513,0.0031095385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834985,0.000023994624,0.0002649209,0.00039709982,0.00025266895,0.00071149884],"domain_scores_gemma":[0.9992422,0.000045203233,0.0000667933,0.0003542917,0.00006426268,0.00022724652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014025628,0.00025870194,0.0004133338,0.0003595131,0.00002849712,0.000020767035,0.00009017381,0.0000800031,0.00007587596],"category_scores_gemma":[0.000029731318,0.00015166111,0.00006531265,0.0006498772,0.00009882434,0.0001454221,0.00002464367,0.000075400305,0.00007790935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037669324,0.00040085946,0.80672306,0.00006846769,0.00022346435,0.00007701601,0.00003685763,1.9572713e-7,0.0013815043,0.000023742261,0.00040010185,0.190288],"study_design_scores_gemma":[0.0077609024,0.00045191258,0.9420619,0.0002676069,0.00040473233,0.0000013902218,0.00001961265,0.000004383969,0.043502126,0.00005159258,0.005207657,0.00026617752],"about_ca_topic_score_codex":0.00001116022,"about_ca_topic_score_gemma":0.000027379941,"teacher_disagreement_score":0.19002183,"about_ca_system_score_codex":0.0001945035,"about_ca_system_score_gemma":0.000027709291,"threshold_uncertainty_score":0.61845607},"labels":[],"label_agreement":null},{"id":"W2522752051","doi":"10.1016/j.tcm.2016.08.005","title":"Editorial commentary: Anti-glycemic drugs and heart failure—A new era","year":2016,"lang":"en","type":"review","venue":"Trends in Cardiovascular Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Glycemic; Medicine; Heart failure; Intensive care medicine; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.02046661840172139,"score_gpt":0.3052387174296595,"score_spread":0.28477209902793815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522752051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000051400175,0.9720748,0.000011507133,0.00405942,0.0204098,0.000979463,0.000021863334,0.000115507035,0.0023225008],"genre_scores_gemma":[0.000016718777,0.9057343,0.00022939088,0.00045649448,0.09153231,0.000114325856,0.0006540577,0.00012104695,0.0011413359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959664,0.00023539095,0.0008857406,0.0010128974,0.0012230346,0.0006765527],"domain_scores_gemma":[0.99769974,0.0001829252,0.00017149803,0.0014298141,0.000047835427,0.00046818308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095096347,0.0008913979,0.005755516,0.0012333285,0.000059883954,0.000022496724,0.0002347562,0.00046283347,0.00040395505],"category_scores_gemma":[0.00006142091,0.00055741344,0.001683899,0.0007746815,0.00023838649,0.00010322333,0.0002210094,0.0006681371,0.00008762554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020177147,0.000036273348,0.000020407306,0.0017342448,0.0030837758,0.000049572867,0.000041788746,5.675309e-8,1.8133667e-7,0.000010941801,0.4586209,0.53638166],"study_design_scores_gemma":[0.010125511,0.00049191096,0.000049852315,0.024381874,0.012470655,0.00006077377,0.000030007232,2.780005e-7,4.3453312e-7,0.0000208355,0.95192695,0.00044091925],"about_ca_topic_score_codex":0.00031440725,"about_ca_topic_score_gemma":0.000010379233,"teacher_disagreement_score":0.53594077,"about_ca_system_score_codex":0.0004263737,"about_ca_system_score_gemma":0.00013871658,"threshold_uncertainty_score":0.99968773},"labels":[],"label_agreement":null},{"id":"W2523321497","doi":"10.1080/00325481.2016.1238280","title":"Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia","year":2016,"lang":"en","type":"article","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Linagliptin; Metformin; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Population; Dipeptidyl peptidase-4 inhibitor; Body mass index; Gastroenterology; Endocrinology; Insulin","score_opus":0.010234711397371936,"score_gpt":0.2236963286372605,"score_spread":0.21346161723988855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523321497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894479,0.00066207803,0.0000068372005,0.0069088824,0.00015879406,0.0008590098,0.000005187255,0.00006695836,0.0018843383],"genre_scores_gemma":[0.9942446,0.00045096118,0.00047833455,0.00088048226,0.00009403896,0.000047334717,0.00007719939,0.000040108356,0.003686961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848884,0.00003624081,0.00030217055,0.00037046053,0.00036498986,0.00043731078],"domain_scores_gemma":[0.9990644,0.00019211449,0.00009289055,0.000313786,0.000120971556,0.00021586836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019188771,0.00027655234,0.00055431575,0.00027812566,0.000034160792,0.000008088219,0.00007777308,0.000058530044,0.0001209542],"category_scores_gemma":[0.00028740749,0.00013819827,0.000027579359,0.0003370833,0.00019143753,0.000101061014,0.000064829124,0.000090675145,0.0000362055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010613184,0.00021695669,0.85220486,0.00010083477,0.00017744399,0.00008354562,0.00022654701,2.4443344e-7,0.00033452242,0.00008637388,0.002180172,0.14332718],"study_design_scores_gemma":[0.03771365,0.004676691,0.94943714,0.0012465371,0.00043392103,0.0000017540431,0.00008991775,0.000031832365,0.0003784699,0.00014269356,0.0055900905,0.00025730077],"about_ca_topic_score_codex":0.000053711832,"about_ca_topic_score_gemma":0.000037804406,"teacher_disagreement_score":0.14306988,"about_ca_system_score_codex":0.00013923275,"about_ca_system_score_gemma":0.000036911413,"threshold_uncertainty_score":0.5635562},"labels":[],"label_agreement":null},{"id":"W2523634442","doi":"10.1016/s2213-8587(16)30237-6","title":"SGLT2 inhibitors: β blockers for the kidney?","year":2016,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Renal function; Nephron; Kidney disease; Tubuloglomerular feedback; Diabetes mellitus; Kidney; Type 2 diabetes; Urology; Internal medicine; Endocrinology","score_opus":0.028122738169641774,"score_gpt":0.2737894242405104,"score_spread":0.2456666860708686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523634442","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012772202,0.003293178,0.000015960664,0.9854675,0.0022687558,0.0024883118,0.00023997274,0.00027968464,0.0046694246],"genre_scores_gemma":[0.001641181,0.0012049518,0.00021860871,0.93629825,0.029853223,0.0021015361,0.00048884377,0.00014050514,0.028052919],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995784,0.00012889088,0.0004097857,0.0006297057,0.0003244048,0.0027232552],"domain_scores_gemma":[0.99640983,0.0014469709,0.0002602719,0.0016906303,0.0000983712,0.00009390096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035668176,0.0005855207,0.0011602172,0.00015432914,0.00025210012,0.00005665502,0.000859484,0.00036006892,0.0002733402],"category_scores_gemma":[0.00022778062,0.0002625774,0.0004794368,0.00013246742,0.00054568914,0.000046886296,0.00032251983,0.0010438286,0.0004260866],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004915409,0.00002859555,0.0018800322,0.00029894066,0.0022394902,0.000074178264,0.00003663422,1.2541616e-7,0.00012636665,0.0004991214,0.96739554,0.027371837],"study_design_scores_gemma":[0.0030312168,0.00040623528,0.00025849917,0.0002600198,0.0020704414,0.000010855556,0.000016801961,0.00001090852,0.0014213368,0.0015816883,0.9906225,0.0003094638],"about_ca_topic_score_codex":0.000012376874,"about_ca_topic_score_gemma":0.000002955424,"teacher_disagreement_score":0.04916926,"about_ca_system_score_codex":0.00014299274,"about_ca_system_score_gemma":0.00010006009,"threshold_uncertainty_score":0.99998266},"labels":[],"label_agreement":null},{"id":"W2523705911","doi":"10.2147/ceor.s113559","title":"Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand","year":2016,"lang":"en","type":"article","venue":"ClinicoEconomics and Outcomes Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4 inhibitor; Cost effectiveness; Type 2 diabetes; Tolerability; Hypoglycemia; Metformin; Type 2 Diabetes Mellitus; Incremental cost-effectiveness ratio; Population; Internal medicine; Diabetes mellitus; Cost-effectiveness analysis; Insulin; Endocrinology; Adverse effect; Environmental health","score_opus":0.0753620826860664,"score_gpt":0.40364102088506476,"score_spread":0.32827893819899834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523705911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972833,0.00015217028,9.084947e-7,0.00033459743,0.00011598954,0.001234089,0.000013989867,0.0000070205588,0.0008579651],"genre_scores_gemma":[0.9978951,0.001198415,0.000043223612,0.00006476018,0.000021951717,0.000098047014,0.000015324353,0.000020874915,0.00064226065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986121,0.00016235988,0.00040919142,0.00032017133,0.00012876572,0.00036741543],"domain_scores_gemma":[0.99805826,0.0014286812,0.00006327723,0.00026277662,0.00008843459,0.00009855108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014475388,0.00013209575,0.00051412417,0.00041178343,0.000022012346,0.000018975214,0.0000936349,0.00009058519,0.000049643964],"category_scores_gemma":[0.00022008453,0.000087146145,0.00006585499,0.00014791086,0.00014131538,0.00010789871,0.000099961886,0.00012328695,0.000025261113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042766065,0.00045585053,0.8862847,0.000108835746,0.000060766382,0.0000028942957,0.00006757942,7.3906705e-7,0.00018049651,0.000137585,0.0000827119,0.11219015],"study_design_scores_gemma":[0.010287083,0.0012868684,0.98501927,0.00031455653,0.000008699039,3.7392017e-8,0.000050634957,0.00003279942,0.00092872104,0.00051846704,0.0014566798,0.000096214826],"about_ca_topic_score_codex":0.00004676778,"about_ca_topic_score_gemma":0.00015314565,"teacher_disagreement_score":0.11209393,"about_ca_system_score_codex":0.00015862069,"about_ca_system_score_gemma":0.00005653541,"threshold_uncertainty_score":0.35537165},"labels":[],"label_agreement":null},{"id":"W2524173913","doi":"10.1016/j.jcjd.2016.08.131","title":"A Systematic Review on Hypoglycemia Rate Attributable to Sulfonylureas Utilization in Randomized Controlled Trials of SGLT2 Inhibitors","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Randomized controlled trial; Intensive care medicine; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.05286929996904083,"score_gpt":0.3245531960452185,"score_spread":0.27168389607617766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524173913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000106478125,0.9831249,0.0000048219317,0.00045016414,0.0005135167,0.015219749,0.00009210512,0.0000062935774,0.00048194907],"genre_scores_gemma":[0.00035700735,0.997043,0.000028961505,0.00045843323,0.00018668224,0.0007695996,0.00006465102,0.00006172962,0.001029933],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98831487,0.0035803048,0.0068566822,0.00027332176,0.00042494244,0.00054991],"domain_scores_gemma":[0.98678017,0.0058762636,0.0055956603,0.0004567416,0.00047982077,0.0008113644],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01919924,0.0006190614,0.032741137,0.0023955223,0.0000346222,0.000046038356,0.00028285867,0.00022409776,0.000196561],"category_scores_gemma":[0.041668925,0.0003097038,0.0039318986,0.0007309264,0.00007330331,0.00009716442,0.000017140388,0.00025324593,0.000047458772],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014041116,0.00010493484,0.000039055838,0.93979067,0.009237151,0.00006990447,0.000032233802,0.0000012501804,0.000001458468,0.00025981403,0.0065224655,0.042536948],"study_design_scores_gemma":[0.08452282,0.00036092568,0.0000015541369,0.8355307,0.028180787,0.0000026592213,0.000006119953,0.0000010948344,0.000008303979,0.000037050253,0.05113436,0.00021360144],"about_ca_topic_score_codex":0.000058928752,"about_ca_topic_score_gemma":0.0001784982,"teacher_disagreement_score":0.104259945,"about_ca_system_score_codex":0.00078738277,"about_ca_system_score_gemma":0.0023577523,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W2524233347","doi":"10.1016/j.jcjd.2016.08.097","title":"Early Weight Loss Responders to Liraglutide 3.0 mg had Greater Weight Loss, Regression to Normoglycemia and Reduced T2D Development at 3 Years vs. Early Non-Responders: SCALE Obesity and Prediabetes","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Liraglutide; Medicine; Prediabetes; Overweight; Weight loss; Dyslipidemia; Placebo; Obesity; Internal medicine; Post-hoc analysis; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.008248974173083784,"score_gpt":0.21057962937369948,"score_spread":0.2023306552006157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524233347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294037,0.00064900046,0.000008977557,0.0051271413,0.0003643106,0.0006378707,0.000039755447,0.000022591219,0.00020996906],"genre_scores_gemma":[0.9917558,0.00005470067,0.0018835221,0.0009438228,0.0002181716,0.000027731612,0.000007433315,0.00006549772,0.005043361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972621,0.000083708335,0.00061390403,0.00054032804,0.0004699192,0.001029991],"domain_scores_gemma":[0.99640507,0.00012972362,0.0002241665,0.00039757486,0.00023465525,0.0026087887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050529337,0.00044243273,0.0007301708,0.0010818576,0.00024705834,0.00012262863,0.00026576727,0.00018323491,0.00013408916],"category_scores_gemma":[0.00015119037,0.00031079137,0.00012469034,0.00035182235,0.0002355868,0.0004045596,0.00015264082,0.00019405928,0.000095025345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037655432,0.00004358226,0.96137786,0.00007527487,0.00037288605,0.00025848785,0.002018553,4.1270079e-7,0.0071579656,0.000009845242,0.01291843,0.015390124],"study_design_scores_gemma":[0.003330738,0.0012980403,0.94424856,0.0017398304,0.00023368077,0.000010989578,0.000050923223,0.0000013818403,0.026653618,0.00006893191,0.021961847,0.00040148557],"about_ca_topic_score_codex":0.00015298602,"about_ca_topic_score_gemma":0.0011365245,"teacher_disagreement_score":0.019495651,"about_ca_system_score_codex":0.00078817224,"about_ca_system_score_gemma":0.00055027223,"threshold_uncertainty_score":0.99993443},"labels":[],"label_agreement":null},{"id":"W2524239142","doi":"10.1016/j.jcjd.2016.08.028","title":"Exercise Reduces Insulin and Glucagon, but not Incretin, Responses to Oral Glucose in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Incretin; Glucagon; Internal medicine; Glycemic; Endocrinology; Type 2 diabetes; Insulin; Diabetes mellitus; Hormone; Glucagon-like peptide-1; Insulin sensitivity; Insulin resistance","score_opus":0.015099783552319555,"score_gpt":0.24234913401475028,"score_spread":0.22724935046243072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524239142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865995,0.00691563,3.1610352e-7,0.005607667,0.00031659595,0.00030292606,0.000027536918,0.000011368221,0.00021848035],"genre_scores_gemma":[0.9969765,0.00037677638,0.0004942708,0.001106021,0.00012262606,0.000011954066,0.0000037390269,0.000031296422,0.0008768441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984385,0.00007734398,0.00045544704,0.000225786,0.00019930389,0.0006036127],"domain_scores_gemma":[0.99815774,0.00019715149,0.0001409026,0.00020886994,0.00022071131,0.0010746067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006047292,0.00022087427,0.0005486208,0.0009486408,0.00006171682,0.000059265974,0.00017038501,0.0000865473,0.00012953387],"category_scores_gemma":[0.00095048023,0.00015321291,0.00007651208,0.00036767387,0.00013839874,0.00022289404,0.00003823705,0.0001288308,0.0000420092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021143662,0.00007774174,0.73554,0.00007489792,0.000196719,0.00013822838,0.0003898093,8.6385575e-7,0.03865575,0.00006374311,0.0056589115,0.2189919],"study_design_scores_gemma":[0.0035227227,0.0020090733,0.8135462,0.0025159847,0.00029788422,0.0000031880218,0.0002532855,0.0000053262734,0.15501618,0.00022119064,0.02225309,0.00035589733],"about_ca_topic_score_codex":0.00027122692,"about_ca_topic_score_gemma":0.0016285785,"teacher_disagreement_score":0.218636,"about_ca_system_score_codex":0.00021891561,"about_ca_system_score_gemma":0.0005411268,"threshold_uncertainty_score":0.6247841},"labels":[],"label_agreement":null},{"id":"W2524357241","doi":"10.1016/j.jcjd.2016.08.108","title":"SGLT2-Inhibitor Use Associated with Euglycemic Ketoacidosis: A Case Series","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Diabetic ketoacidosis; Medicine; Ketoacidosis; Type 2 diabetes; Diabetes mellitus; Type 1 diabetes; Series (stratigraphy); Pediatrics; Endocrinology; Intensive care medicine","score_opus":0.013061888607145064,"score_gpt":0.20108948369872642,"score_spread":0.18802759509158135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524357241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963637,0.0004847644,0.000003830557,0.0021916458,0.00022694931,0.00018656914,0.00004921417,0.000018904075,0.00047442238],"genre_scores_gemma":[0.9960283,0.000012247968,0.00021809878,0.00045557498,0.00015936926,0.000008249047,0.0000057763423,0.00003413105,0.003078276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988301,0.00003920206,0.0003006911,0.00014302788,0.00018704243,0.0004999705],"domain_scores_gemma":[0.99833924,0.00010788347,0.00021438206,0.00019265705,0.0002822742,0.00086356193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018182285,0.00019164746,0.00038358124,0.0003612783,0.000099359706,0.00007162442,0.00008142352,0.00006973307,0.00015896466],"category_scores_gemma":[0.00036908418,0.00011147677,0.00012439922,0.00020561072,0.00014340147,0.0004966158,0.00000917842,0.00010644785,0.00001671372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039411076,0.000076065604,0.9686652,0.00003267708,0.001283612,0.0059991484,0.00019395398,0.0000010424496,0.0010077663,0.00010683061,0.013637946,0.008956354],"study_design_scores_gemma":[0.039969917,0.021433266,0.72163254,0.015516132,0.008843873,0.0045434847,0.0020094544,0.00002537236,0.030802535,0.0006200604,0.15229343,0.0023099652],"about_ca_topic_score_codex":0.00016812037,"about_ca_topic_score_gemma":0.010093032,"teacher_disagreement_score":0.24703267,"about_ca_system_score_codex":0.0003696142,"about_ca_system_score_gemma":0.0005667694,"threshold_uncertainty_score":0.5632149},"labels":[],"label_agreement":null},{"id":"W2524832544","doi":"10.1016/j.cjca.2016.07.272","title":"EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Adjudication; Heart failure; Proxy (statistics); Internal medicine; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.009771633988470014,"score_gpt":0.24071258255972494,"score_spread":0.23094094857125494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524832544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783785,0.00026930048,0.000042297914,0.008694426,0.00035436027,0.00021401026,0.0000054055063,0.000003319315,0.0025790292],"genre_scores_gemma":[0.99826765,0.000022660257,0.00009905032,0.00045584992,0.00039965817,0.0000037438126,0.0000011938041,0.000012605658,0.0007375869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990506,0.00009632468,0.00033049803,0.000109095105,0.000111032175,0.00030245213],"domain_scores_gemma":[0.9991538,0.0001536292,0.000108644155,0.00016130868,0.00007149511,0.00035113038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023563033,0.000119174816,0.00065787346,0.00048795086,0.0000140516395,0.0000037142008,0.00009485028,0.00009288288,0.000032084354],"category_scores_gemma":[0.0002154877,0.00007515725,0.00021482207,0.00007606158,0.00007587237,0.000046841193,0.00000891403,0.00012217266,0.000026130705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018481868,0.000013040825,0.92886716,0.00011622316,0.0006236463,0.0013681821,0.00013894451,0.000117244555,0.0040583936,0.0006884737,0.056059204,0.007764652],"study_design_scores_gemma":[0.0056752837,0.0021518678,0.73861396,0.0004952365,0.00026390562,0.00009531792,0.00004504681,8.253038e-7,0.0015280693,0.00031414334,0.2506901,0.00012625926],"about_ca_topic_score_codex":0.00033345385,"about_ca_topic_score_gemma":0.00077740307,"teacher_disagreement_score":0.19463089,"about_ca_system_score_codex":0.00025442507,"about_ca_system_score_gemma":0.0002583273,"threshold_uncertainty_score":0.30648237},"labels":[],"label_agreement":null},{"id":"W2524916276","doi":"10.1016/j.jcjd.2016.08.117","title":"Heart Failure Hospitalization or Cardiovascular Death with Empagliflozin in Patients with Type 2 Diabetes and High Cardiovascular Risk: Analysis Over Time in EMPA-REG OUTCOME","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Type 2 diabetes; Diabetes mellitus; Heart failure; Internal medicine; Cardiology; Endocrinology","score_opus":0.00455510125738001,"score_gpt":0.18381145500927257,"score_spread":0.17925635375189256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524916276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698997,0.002243368,0.000012285391,0.00019910067,0.0000467174,0.00044400958,0.000030837997,0.000008972202,0.000024719177],"genre_scores_gemma":[0.999264,0.000027592123,0.00037905364,0.00009692211,0.00004578164,0.000011013119,0.000030257188,0.000040452054,0.0001049381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811316,0.00012792199,0.00042693634,0.00031967435,0.00047306297,0.00053924345],"domain_scores_gemma":[0.9986164,0.00006213658,0.00016282979,0.00042821778,0.00024513408,0.00048526758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005153123,0.00028951446,0.0011930405,0.0012398032,0.000053931228,0.000049868253,0.00010897941,0.000094906194,0.000104409344],"category_scores_gemma":[0.00014298594,0.00016095629,0.00032912387,0.0010765704,0.00009040101,0.00032743622,0.000016829454,0.00014272312,0.000005917161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033598488,0.00006055007,0.98766637,0.000041485288,0.009247252,0.000049049224,0.000079002115,0.000532805,0.000002471321,0.0000035243547,0.00017203364,0.0021118594],"study_design_scores_gemma":[0.0058749295,0.0012062035,0.9851882,0.0003814035,0.0055846707,4.6007105e-7,0.000028835942,0.000029814704,0.00004709829,0.000010614634,0.0014019775,0.00024582952],"about_ca_topic_score_codex":0.0008908508,"about_ca_topic_score_gemma":0.007353615,"teacher_disagreement_score":0.0064627645,"about_ca_system_score_codex":0.0003582835,"about_ca_system_score_gemma":0.00024392235,"threshold_uncertainty_score":0.65636075},"labels":[],"label_agreement":null},{"id":"W2525452711","doi":"10.1016/j.jcjd.2016.08.018","title":"Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Sitagliptin; Medicine; Metformin; Type 2 diabetes; Glycated hemoglobin; Clinical endpoint; Internal medicine; Sitagliptin Phosphate; Pharmacology; Endocrinology; Diabetes mellitus; Randomized controlled trial; Insulin; Liraglutide","score_opus":0.008054181259289151,"score_gpt":0.22381989267670974,"score_spread":0.2157657114174206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525452711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935221,0.0014584553,0.0000010646302,0.0037743712,0.00010058313,0.000490236,0.000019898172,0.000007707007,0.0006255715],"genre_scores_gemma":[0.9974206,0.00008467484,0.00043139988,0.00089209544,0.000111841015,0.000014273194,0.000002767241,0.000033313725,0.0010089993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984779,0.00005404282,0.0004350812,0.00023445456,0.00023620945,0.0005623182],"domain_scores_gemma":[0.9982827,0.00033472574,0.00017672,0.00020794377,0.000190272,0.0008076511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041410315,0.00025791881,0.0006373339,0.00075386866,0.00004682979,0.000029244922,0.00010998836,0.00007983737,0.00014008247],"category_scores_gemma":[0.00049677043,0.00014852648,0.000066107634,0.0003629303,0.00014851513,0.00016009837,0.00003014433,0.00013172644,0.000008462551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019675517,0.00016890392,0.9132905,0.00029349077,0.00069001253,0.00033862892,0.00085229386,0.000008757996,0.001516954,0.0002868952,0.0030440993,0.077541895],"study_design_scores_gemma":[0.013046891,0.017485507,0.9314126,0.00489875,0.0007450781,0.000012797381,0.0007075243,0.000012390785,0.012403429,0.00023837763,0.018506816,0.00052988355],"about_ca_topic_score_codex":0.00015535277,"about_ca_topic_score_gemma":0.0042785998,"teacher_disagreement_score":0.07701201,"about_ca_system_score_codex":0.00021850795,"about_ca_system_score_gemma":0.00053522934,"threshold_uncertainty_score":0.60567343},"labels":[],"label_agreement":null},{"id":"W2525964128","doi":"10.1016/j.jcjd.2016.08.100","title":"Reduction in the Risk of Developing Type 2 Diabetes (T2D) with Liraglutide 3.0 mg in People with Prediabetes from the SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled Trial","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Prediabetes; Medicine; Liraglutide; Type 2 diabetes; Overweight; Placebo; Obesity; Randomized controlled trial; Clinical endpoint; Diabetes mellitus; Internal medicine; Weight loss; Physical therapy; Endocrinology; Alternative medicine","score_opus":0.009906781794180607,"score_gpt":0.21113122512839877,"score_spread":0.20122444333421816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525964128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99000186,0.0031074912,0.000006152986,0.002520355,0.00026713044,0.0038551562,0.000025360938,0.0000095014475,0.0002070061],"genre_scores_gemma":[0.99854565,0.0002325681,0.00044087647,0.00012488071,0.0002850301,0.00025896908,0.0000126929635,0.00003340468,0.000065907116],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99718183,0.0005661515,0.00087000924,0.00031026412,0.000428087,0.00064368325],"domain_scores_gemma":[0.9961859,0.0021775283,0.00072851044,0.00036935127,0.00027374944,0.00026493962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025696235,0.0003557587,0.0014763095,0.0004941593,0.00013860803,0.00008734156,0.00031906384,0.000119975804,0.000029742856],"category_scores_gemma":[0.0006182918,0.00015003738,0.00017962017,0.0006084392,0.00050612766,0.00034604178,0.00002801814,0.00033386494,0.0000018476387],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1740995,0.000114883085,0.82151085,0.000048296017,0.0010923613,0.0000059070912,0.0012516831,0.000025329353,0.00009444251,0.000055847613,0.00015884673,0.0015420517],"study_design_scores_gemma":[0.8079584,0.0014651396,0.1846871,0.001391912,0.0016772618,0.0000015637509,0.00068768667,0.000058791007,0.001275738,0.00049202086,0.00008075877,0.00022362819],"about_ca_topic_score_codex":0.0011833747,"about_ca_topic_score_gemma":0.021771086,"teacher_disagreement_score":0.6368238,"about_ca_system_score_codex":0.00020813798,"about_ca_system_score_gemma":0.00085643557,"threshold_uncertainty_score":0.996079},"labels":[],"label_agreement":null},{"id":"W2526090031","doi":"10.1016/j.jcjd.2016.08.114","title":"Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Exenatide; Sulfonylurea; Type 2 diabetes; Glycated hemoglobin; Metformin; Dulaglutide; Clinical endpoint; Internal medicine; Glucagon-like peptide-1; Diabetes mellitus; Pharmacology; Endocrinology; Randomized controlled trial; Liraglutide","score_opus":0.0059244680355755915,"score_gpt":0.20474143807205414,"score_spread":0.19881697003647855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526090031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351376,0.0026116772,0.0000018386993,0.002423791,0.000113918424,0.00034960263,0.000015803449,0.0000069527086,0.0009626734],"genre_scores_gemma":[0.99818826,0.000065360015,0.00034603782,0.00038460246,0.00009415582,0.000008588097,0.0000034971201,0.000034176963,0.0008753496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844956,0.00006212129,0.00046511437,0.00019990501,0.0002294774,0.00059382693],"domain_scores_gemma":[0.99846804,0.00022184853,0.00022466866,0.00022783253,0.00023413905,0.00062347355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036917697,0.00023006409,0.000598483,0.00062444265,0.000036983063,0.000023984969,0.000123622,0.000076595876,0.00014544892],"category_scores_gemma":[0.0002568689,0.00014345582,0.00009011021,0.00032464962,0.00023838808,0.00017306299,0.000022268356,0.00014693222,0.0000060182397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001949797,0.00008032099,0.9726805,0.00015403994,0.00042973703,0.00014054304,0.00024426155,0.000004682277,0.0007782641,0.00007641985,0.0013416754,0.023874594],"study_design_scores_gemma":[0.006783557,0.0024257381,0.9772197,0.002235368,0.0003899647,0.000002646078,0.00014233435,0.00000831609,0.003582177,0.00014510003,0.0068371003,0.0002280212],"about_ca_topic_score_codex":0.00016457109,"about_ca_topic_score_gemma":0.0041187927,"teacher_disagreement_score":0.023646573,"about_ca_system_score_codex":0.00026346886,"about_ca_system_score_gemma":0.00059566624,"threshold_uncertainty_score":0.58499587},"labels":[],"label_agreement":null},{"id":"W2526499309","doi":"10.1016/j.jcjd.2016.08.162","title":"Double-Blind Mealtime Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Improves Glycemic Control in T1D: The Onset® 1 Trial","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Insulin aspart; Medicine; Postprandial; Glycemic; Internal medicine; Crossover study; Insulin detemir; Type 1 diabetes; Endocrinology; Type 2 diabetes; Clinical endpoint; Insulin; Diabetes mellitus; Randomized controlled trial; Basal insulin; Placebo","score_opus":0.025167269401236706,"score_gpt":0.25595335764006716,"score_spread":0.23078608823883046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526499309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836984,0.001637817,0.0000063994466,0.011160152,0.00088692084,0.0013105103,0.00002436055,0.000011778239,0.0012636613],"genre_scores_gemma":[0.9969134,0.00005506954,0.000060255,0.0018236153,0.00055075804,0.00007304242,0.00000738442,0.000044531815,0.00047196448],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972108,0.0001719142,0.0010404274,0.00029554366,0.00033842746,0.0009429129],"domain_scores_gemma":[0.9978021,0.0005054362,0.00048320802,0.00036498267,0.00014728445,0.00069698074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012212796,0.00032807994,0.0008359053,0.0009039235,0.00009786333,0.00009808294,0.0003470439,0.00016038408,0.00018305557],"category_scores_gemma":[0.00046624025,0.0002019381,0.0002141438,0.0004356172,0.00016050575,0.00035575245,0.00003041259,0.00045557783,0.000053246917],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091538034,0.0011386683,0.6167501,0.00026399197,0.0021984205,0.00084419455,0.0027947954,0.000087583176,0.0046451604,0.00025171528,0.012454387,0.2670329],"study_design_scores_gemma":[0.7788927,0.007616233,0.16536619,0.002719505,0.00083129323,0.000014488661,0.0008039391,0.00038010147,0.0030461797,0.00049488986,0.03896206,0.00087241764],"about_ca_topic_score_codex":0.0014098773,"about_ca_topic_score_gemma":0.01777763,"teacher_disagreement_score":0.6873547,"about_ca_system_score_codex":0.00067652593,"about_ca_system_score_gemma":0.0012973465,"threshold_uncertainty_score":0.9920334},"labels":[],"label_agreement":null},{"id":"W2526933571","doi":"10.1016/j.cjca.2016.07.124","title":"EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Mace; EMPA; Heart failure; Internal medicine; Placebo; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology; Myocardial infarction; Alternative medicine","score_opus":0.023073895117317427,"score_gpt":0.27623021943294573,"score_spread":0.2531563243156283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526933571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938195,0.0010499504,0.00008267164,0.003083256,0.00059661793,0.0009430635,0.000013669052,0.0000032377977,0.00040804586],"genre_scores_gemma":[0.998713,0.00008448527,0.000022022845,0.0004450224,0.0004755267,0.000029676763,0.0000027325998,0.000012983506,0.00021450412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810046,0.0005294046,0.0005251743,0.00016585366,0.00033724355,0.0003418382],"domain_scores_gemma":[0.99877936,0.00028864163,0.00015830845,0.00039926867,0.000085714564,0.0002887252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013288342,0.00016699734,0.000989092,0.0002619164,0.000030568597,0.0000083323575,0.0002033316,0.000108953645,0.000021071679],"category_scores_gemma":[0.00050725404,0.00007973727,0.0006828204,0.00012785601,0.00012188588,0.000051058076,0.000013503701,0.00017360818,0.0000087630415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00625869,0.00011809587,0.79115534,0.00039203884,0.007184346,0.0028269968,0.00044551614,0.00015885818,0.00057674566,0.00018064046,0.18123011,0.009472641],"study_design_scores_gemma":[0.053451017,0.006425981,0.5904337,0.00040506784,0.0025818262,0.00016936596,0.0001787218,5.167365e-7,0.00088437955,0.00008767271,0.34517458,0.00020716549],"about_ca_topic_score_codex":0.0004762537,"about_ca_topic_score_gemma":0.0012995712,"teacher_disagreement_score":0.2007216,"about_ca_system_score_codex":0.00030647742,"about_ca_system_score_gemma":0.0003767201,"threshold_uncertainty_score":0.32515916},"labels":[],"label_agreement":null},{"id":"W2527123743","doi":"10.3747/pdi.2015.00309","title":"The Phantom of Metformin-Induced Lactic Acidosis in End-Stage Renal Disease Patients: Time to Reconsider with Peritoneal Dialysis Treatment","year":2016,"lang":"en","type":"article","venue":"Peritoneal Dialysis International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"U.S. Food and Drug Administration","keywords":"Peritoneal dialysis; Medicine; Metformin; Lactic acidosis; End stage renal disease; Dialysis; End-stage kidney disease; Kidney disease; Renal replacement therapy; Urology; Acidosis; Internal medicine; Intensive care medicine; Disease; Insulin","score_opus":0.01416678218759003,"score_gpt":0.2650555502654587,"score_spread":0.25088876807786864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527123743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064064,0.00007872264,0.00003368548,0.004738819,0.00017702697,0.0006943328,0.00020356028,0.000035634515,0.0033976068],"genre_scores_gemma":[0.98565555,0.0001247043,0.00034921637,0.00015120806,0.00017208153,0.00046615987,0.00019721866,0.000033327546,0.012850528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99771786,0.0000816641,0.00059042295,0.00048479525,0.0007518294,0.00037344533],"domain_scores_gemma":[0.998497,0.00029110446,0.00022439742,0.0004638704,0.00024905344,0.00027455844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002275255,0.00030680807,0.0005137054,0.00042655534,0.00009738567,0.000062003666,0.0002221539,0.00004953452,0.002199744],"category_scores_gemma":[0.00023332995,0.00016278298,0.0002997369,0.00034634222,0.000107323795,0.0002465605,0.00010245208,0.00005958801,0.00019801345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058269585,0.004213472,0.40900537,0.000037638285,0.0063202716,0.00017075698,0.0012678024,0.00003426409,0.011289135,0.00034654472,0.00071124453,0.56077653],"study_design_scores_gemma":[0.026984422,0.0050788363,0.71876603,0.00072927773,0.0057843663,0.000008458704,0.00047047,0.0013088728,0.061943803,0.00015670864,0.1773587,0.0014100369],"about_ca_topic_score_codex":0.00024459106,"about_ca_topic_score_gemma":0.0004679888,"teacher_disagreement_score":0.5593665,"about_ca_system_score_codex":0.0007120871,"about_ca_system_score_gemma":0.00012844332,"threshold_uncertainty_score":0.99871236},"labels":[],"label_agreement":null},{"id":"W2527237307","doi":"10.14740/jocmr2741w","title":"Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Insulin; Internal medicine; Insulin glargine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Adverse effect; Body mass index; Gastroenterology; Hypoglycemia; Urology","score_opus":0.14350632870562371,"score_gpt":0.49299935502777775,"score_spread":0.34949302632215407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527237307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600805,0.007953011,0.000009980731,0.030074237,0.0002513701,0.0009333392,0.0000033570072,0.000009332275,0.0006848418],"genre_scores_gemma":[0.9872495,0.010742682,0.00050212553,0.00055610016,0.00056752376,0.0000151389,0.0000029399043,0.000024768558,0.00033924117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951544,0.00076922134,0.0021278437,0.00032741763,0.0011249261,0.00049621944],"domain_scores_gemma":[0.9921633,0.00524113,0.0004548903,0.00034860466,0.0010000763,0.00079201435],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008724472,0.000223169,0.0020273882,0.00089981407,0.000043577744,0.000014988389,0.00021763194,0.00016793945,0.00014917045],"category_scores_gemma":[0.0125213275,0.00011712716,0.000121080404,0.000744307,0.0005184033,0.00011856767,0.00016018045,0.00063438795,0.000009935645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014354257,0.0016341805,0.6153595,0.00011854482,0.00046389617,0.000098673525,0.00023296525,6.4700146e-7,0.0039812475,0.00018135893,0.0065693757,0.3570054],"study_design_scores_gemma":[0.0844509,0.05008181,0.84539175,0.0028264595,0.00021870834,0.0000064115716,0.00039402986,0.00021857335,0.0018749436,0.001187362,0.013160439,0.00018862453],"about_ca_topic_score_codex":0.00006460096,"about_ca_topic_score_gemma":0.000035177876,"teacher_disagreement_score":0.35681674,"about_ca_system_score_codex":0.00006629899,"about_ca_system_score_gemma":0.00026378006,"threshold_uncertainty_score":0.9957966},"labels":[],"label_agreement":null},{"id":"W2527292102","doi":"10.1016/j.jcjd.2016.08.143","title":"A Canadian Needs Assessment of Endocrinologist's use of Mealtime Insulin in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Insulin; Diabetes mellitus; Endocrinology; Type 1 diabetes; Internal medicine","score_opus":0.024794476043404918,"score_gpt":0.25534212640882653,"score_spread":0.2305476503654216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527292102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433935,0.0017764282,0.0000018256025,0.0020374837,0.00028786826,0.00026195182,0.0000665098,0.0000045889547,0.001223995],"genre_scores_gemma":[0.99827784,0.000105210915,0.00072045956,0.0003314719,0.000053124666,0.0000057661114,0.000008745271,0.000023965653,0.00047338908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981514,0.0000726383,0.0007000364,0.00013585523,0.00022788053,0.0007121443],"domain_scores_gemma":[0.99787164,0.00019807304,0.0003591943,0.00029115283,0.00037569928,0.00090426265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031342596,0.00019560175,0.00069248775,0.0019346931,0.000030252282,0.000018545217,0.00020817897,0.00009090788,0.00028024882],"category_scores_gemma":[0.0004154134,0.00013957465,0.00015132247,0.00057174184,0.0001763848,0.00023477965,0.000018936964,0.00015086395,0.000005998898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005746134,0.000068595546,0.9732454,0.000086614265,0.00034941285,0.00004889014,0.000093672745,0.000018517012,0.0016609649,0.0004789116,0.0020160219,0.021927288],"study_design_scores_gemma":[0.0023889432,0.001489726,0.97059876,0.0010444387,0.00027843012,0.0000017064182,0.00011735355,0.00006098494,0.0045730365,0.00018788599,0.019068934,0.00018979885],"about_ca_topic_score_codex":0.049201265,"about_ca_topic_score_gemma":0.26813146,"teacher_disagreement_score":0.21893021,"about_ca_system_score_codex":0.0007790659,"about_ca_system_score_gemma":0.0027142165,"threshold_uncertainty_score":0.9571302},"labels":[],"label_agreement":null},{"id":"W2527370459","doi":"10.1016/j.jcjd.2016.08.020","title":"Achievement of Composite Endpoint of HbA1c, Weight and Blood Pressure Reduction with Titrated Canagliflozin Added to Metformin+Sitagliptin in Patients with Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Canagliflozin; Medicine; Sitagliptin; Metformin; Blood pressure; Type 2 Diabetes Mellitus; Weight loss; Type 2 diabetes; Internal medicine; Post-hoc analysis; Overweight; Diabetes mellitus; Endocrinology; Urology; Obesity","score_opus":0.0043269713592368345,"score_gpt":0.17737186558751064,"score_spread":0.1730448942282738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527370459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781483,0.0009895307,0.0000012232404,0.000384373,0.00007670198,0.00046243568,0.000054298365,0.0000038163957,0.00021277393],"genre_scores_gemma":[0.9989537,0.000013077104,0.000738945,0.0000731372,0.000029252255,0.00000683693,0.000015919446,0.000021565116,0.00014758068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988065,0.000036512196,0.00041025353,0.00016068501,0.00025011113,0.0003359518],"domain_scores_gemma":[0.99867606,0.000033289973,0.00029542024,0.00017687936,0.0003777627,0.00044059224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018598753,0.000180065,0.0005008799,0.0005591555,0.000026936294,0.000011012623,0.000094218594,0.000046664103,0.00004717613],"category_scores_gemma":[0.000033367774,0.000106652726,0.000039358438,0.00032597626,0.00010387978,0.00015901508,0.000014633961,0.000080009166,8.104347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016224965,0.00022793477,0.98673934,0.00016290878,0.0015283512,0.000009057243,0.00021426164,0.00001400369,0.0061215106,0.000042080857,0.00036679124,0.004411486],"study_design_scores_gemma":[0.0061351373,0.006462629,0.9199472,0.0016150157,0.0017884651,7.412776e-7,0.000093260634,0.0000039689826,0.06251827,0.000021012496,0.0012299119,0.00018438432],"about_ca_topic_score_codex":0.00031703472,"about_ca_topic_score_gemma":0.0024113061,"teacher_disagreement_score":0.06679216,"about_ca_system_score_codex":0.00007309577,"about_ca_system_score_gemma":0.00027320205,"threshold_uncertainty_score":0.43491718},"labels":[],"label_agreement":null},{"id":"W2527668864","doi":"10.1016/j.jcjd.2016.08.127","title":"Lixisenatide Therapy in Older Patients with Type 2 Diabetes Inadequately Controlled on Their Current Anti-Diabetic Treatment: The GetGoal-O Study (NCT01798706)","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lixisenatide; Medicine; Placebo; Internal medicine; Glycated hemoglobin; Type 2 diabetes; Postprandial; Diabetes mellitus; Liraglutide; Endocrinology; Insulin","score_opus":0.015451818249242529,"score_gpt":0.23484828430662127,"score_spread":0.21939646605737875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527668864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275607,0.0026807648,4.1520525e-7,0.001438229,0.0004723031,0.0022701665,0.000021295571,0.000013813955,0.00034693626],"genre_scores_gemma":[0.9989218,0.00014374507,0.0000069856947,0.0004249641,0.0001464158,0.00009670248,0.000010385224,0.000055075318,0.0001939013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977084,0.0002225099,0.0005988574,0.00030200512,0.00038191932,0.0007863535],"domain_scores_gemma":[0.99785733,0.00045780322,0.00036830298,0.00044858,0.00033608687,0.0005319203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040561942,0.00044739095,0.0009980539,0.00069272827,0.00014053786,0.0000816479,0.00027672018,0.000060964314,0.00012802522],"category_scores_gemma":[0.00015998994,0.00018228414,0.00020774997,0.0004029929,0.000159193,0.00018515468,0.000013863435,0.00019553842,0.000026725671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013161798,0.0013639557,0.89545697,0.000012860832,0.0010215176,0.000022424814,0.00052941,0.0000060767175,0.000046751844,0.000026895184,0.0004074484,0.100974075],"study_design_scores_gemma":[0.037909295,0.011411534,0.9456539,0.0006495059,0.0003454584,2.2394254e-7,0.00020440426,0.000009527682,0.00062992075,0.00008487289,0.002858903,0.00024241187],"about_ca_topic_score_codex":0.000082120045,"about_ca_topic_score_gemma":0.0014432961,"teacher_disagreement_score":0.10073166,"about_ca_system_score_codex":0.0005094521,"about_ca_system_score_gemma":0.0005364905,"threshold_uncertainty_score":0.74333316},"labels":[],"label_agreement":null},{"id":"W2528138059","doi":"10.1111/dom.12805","title":"Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: <scp>a</scp> systematic review and meta‐analysis","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Boehringer Ingelheim; Amgen","keywords":"Dulaglutide; Exenatide; Medicine; Liraglutide; Internal medicine; Type 2 diabetes; Basal (medicine); Sitagliptin; Meta-analysis; Lixisenatide; Randomized controlled trial; Glucagon-like peptide 1 receptor; Diabetes mellitus; Endocrinology; Insulin; Receptor; Agonist","score_opus":0.03299279135512655,"score_gpt":0.2840780141662557,"score_spread":0.25108522281112916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528138059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012308393,0.98803216,0.000012662788,0.00013646219,0.00014968203,0.009568711,0.0007339651,0.0000613353,0.00007419926],"genre_scores_gemma":[0.00014054164,0.99253404,0.00050723244,0.000390251,0.00010372362,0.0028323578,0.0006290057,0.00008999,0.0027728432],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964088,0.000395464,0.001187218,0.0008814124,0.00042752383,0.0006995457],"domain_scores_gemma":[0.994898,0.0022066878,0.0010651948,0.001180219,0.00032682266,0.00032306297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007795937,0.0011120776,0.0121187605,0.0004186264,0.00022816635,0.00009523713,0.00029173787,0.00023283239,0.000046576693],"category_scores_gemma":[0.000196874,0.000495762,0.0021364682,0.0008745973,0.0003196942,0.00012908729,0.000099731405,0.00013863404,0.000023525046],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066211524,0.0007210476,0.00012041763,0.60200655,0.38601038,0.0000019968932,0.00015286492,1.8424768e-7,8.7719343e-7,0.00017253541,0.0006484476,0.010158086],"study_design_scores_gemma":[0.0007236694,0.00036441433,0.00007980431,0.016514486,0.58638054,4.5219156e-7,0.000022734424,0.0000050156677,0.00001732446,0.000013205624,0.395704,0.00017434104],"about_ca_topic_score_codex":0.000013204644,"about_ca_topic_score_gemma":0.000011691872,"teacher_disagreement_score":0.5854921,"about_ca_system_score_codex":0.000078497396,"about_ca_system_score_gemma":0.00012114117,"threshold_uncertainty_score":0.9997494},"labels":[],"label_agreement":null},{"id":"W2530418367","doi":"10.1016/j.jcjd.2016.08.220","title":"Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Empagliflozin; Liraglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Clinical trial; Internal medicine; Disease; Endocrinology","score_opus":0.13166227061621077,"score_gpt":0.36881280799427346,"score_spread":0.2371505373780627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530418367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97641665,0.0148281595,0.0000037645862,0.0067916214,0.00084004237,0.0009643765,0.00003168468,0.000010938487,0.000112787886],"genre_scores_gemma":[0.9965868,0.00060802524,0.0001445497,0.0019738397,0.00035723927,0.000034210385,0.0000040567893,0.000045217144,0.00024606803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926029,0.0017888095,0.0036989246,0.00041414605,0.0005072284,0.0009879923],"domain_scores_gemma":[0.98951113,0.007670466,0.0008541588,0.000714223,0.0002756519,0.00097436755],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02295103,0.00039893415,0.003623767,0.0010464097,0.00009609663,0.00010244911,0.00043283566,0.00024907663,0.000119153716],"category_scores_gemma":[0.04338205,0.00020745327,0.0011642394,0.0006316224,0.0004014185,0.00046668295,0.000063633364,0.00049426634,0.000027312582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001860725,0.00006398074,0.9418489,0.00003449278,0.0011097325,0.000057417034,0.00008883737,0.00002388325,0.000093682,0.00004588277,0.0010169292,0.055597693],"study_design_scores_gemma":[0.007286085,0.00061024673,0.9637334,0.0010935289,0.0012675289,0.0000013123399,0.0001354763,0.000011844676,0.000117611424,0.0004796324,0.024984602,0.00027875951],"about_ca_topic_score_codex":0.00013681212,"about_ca_topic_score_gemma":0.002152117,"teacher_disagreement_score":0.055318933,"about_ca_system_score_codex":0.0003438193,"about_ca_system_score_gemma":0.0005941369,"threshold_uncertainty_score":0.96467596},"labels":[],"label_agreement":null},{"id":"W2532735232","doi":"10.14740/jocmr2760w","title":"Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Hematocrit; Internal medicine; Renal glucose reabsorption; Endocrinology; Hemoconcentration; Erythropoietin; Diabetes mellitus; Hypoxia (environmental); Renal function; Type 2 diabetes","score_opus":0.15056723300419414,"score_gpt":0.47042669331854975,"score_spread":0.31985946031435564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532735232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036044184,0.9584389,0.000013469192,0.0014886507,0.0012055993,0.0017171965,0.000015763277,0.000013937353,0.001062316],"genre_scores_gemma":[0.014421437,0.9814635,0.00004846954,0.00009909372,0.00329794,0.00005646855,0.000039803337,0.00007730053,0.00049600034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99060446,0.0012799398,0.004957259,0.00048826702,0.0020022008,0.0006678663],"domain_scores_gemma":[0.99244815,0.0038832526,0.0017518558,0.00052749325,0.0006650067,0.00072423054],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009778394,0.0004568683,0.00511225,0.002374797,0.000047941634,0.000016552704,0.00043522404,0.0005241397,0.0009763203],"category_scores_gemma":[0.0036027594,0.00024732304,0.001265812,0.00078261015,0.00074888417,0.0001808313,0.00010441749,0.0022103158,0.000059913196],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043723416,0.0020249335,0.0050947694,0.019413652,0.0021813035,0.00096547627,0.000047834055,3.0509888e-8,0.00009783137,0.000019049841,0.0061551244,0.9596276],"study_design_scores_gemma":[0.027690614,0.0216785,0.008207882,0.28990844,0.0025152802,0.00013117972,0.00010576137,0.0000011178747,0.0003760104,0.00043690627,0.6485496,0.0003986907],"about_ca_topic_score_codex":0.000029410323,"about_ca_topic_score_gemma":0.0000038403273,"teacher_disagreement_score":0.95922893,"about_ca_system_score_codex":0.00030287987,"about_ca_system_score_gemma":0.0011766937,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W2534210051","doi":"10.1016/j.jcjd.2016.08.218","title":"Mortality and Cardiovascular Risk of Sulfonylureas in South Asian, Chinese and Other Canadians with Diabetes","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; University of Toronto","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Diabetes mellitus; Internal medicine; Traditional medicine; Endocrinology","score_opus":0.00856813139714123,"score_gpt":0.20429535788302922,"score_spread":0.19572722648588797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534210051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993503,0.004813587,0.0000032812993,0.00034132093,0.000051069183,0.00022411156,0.00009929259,0.0000037479458,0.0009605946],"genre_scores_gemma":[0.9995022,0.000032300748,0.00013501353,0.00014733641,0.00006610831,0.0000061768724,0.0000014021559,0.000025354433,0.000084147265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884397,0.00006847063,0.00030616665,0.00018488668,0.00018862211,0.0004078893],"domain_scores_gemma":[0.9986907,0.00006211175,0.00016566919,0.0002546003,0.00009636763,0.0007305041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000485974,0.0001937459,0.000626611,0.00044991946,0.000040861032,0.000020886355,0.000079808604,0.00006282357,0.000037692203],"category_scores_gemma":[0.00016983102,0.00011241254,0.00012682368,0.00019566249,0.00025441783,0.00012267863,0.00001099022,0.00010695544,8.406939e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048312118,0.000017445733,0.9883747,0.00007846086,0.0015349203,0.0000418279,0.00051040464,0.0000028456834,0.000046982073,0.00004718621,0.0000637058,0.009276685],"study_design_scores_gemma":[0.002451005,0.0003821601,0.9937052,0.000457859,0.0008082487,0.0000021821982,0.00025706476,0.0000057405246,0.00014353718,0.00017768684,0.0014701685,0.00013913139],"about_ca_topic_score_codex":0.008734191,"about_ca_topic_score_gemma":0.13838133,"teacher_disagreement_score":0.12964714,"about_ca_system_score_codex":0.0000931255,"about_ca_system_score_gemma":0.00037164905,"threshold_uncertainty_score":0.99786675},"labels":[],"label_agreement":null},{"id":"W2539439489","doi":"10.2147/ceor.s116570","title":"Bringing patient centricity to diabetes medication access in Canada","year":2016,"lang":"en","type":"review","venue":"ClinicoEconomics and Outcomes Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; Alberta Health; University of Alberta; Alberta Health Services","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Diabetes mellitus; Public health; Health care; Gerontology; Rehabilitation; Family medicine; Business; Nursing; Economic growth; Physical therapy","score_opus":0.13138048648490971,"score_gpt":0.4679964293457163,"score_spread":0.33661594286080654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539439489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034025285,0.9592507,0.000001079257,0.0017344243,0.0004868596,0.0025782369,0.00006361331,0.000019861045,0.0018399749],"genre_scores_gemma":[0.0027743243,0.9955899,0.000028509565,0.00052881095,0.000079679456,0.00026027596,0.000051024705,0.000049923554,0.0006375236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975073,0.00012566746,0.0008475725,0.0005815908,0.0002726572,0.00066521566],"domain_scores_gemma":[0.9975717,0.0013307381,0.00016774333,0.0004816869,0.000058804155,0.00038930622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000964948,0.000260918,0.0015143955,0.0006552761,0.000064017666,0.000087008455,0.0003092335,0.000112366244,0.00009036872],"category_scores_gemma":[0.00038764902,0.00017961679,0.00015297037,0.00022506794,0.000045221022,0.00007677498,0.00070852,0.00035638883,0.0000854927],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000040547206,0.000043972846,0.07636881,0.0025104417,0.00015888391,0.000014067566,0.000011840793,1.814925e-7,6.7393384e-9,0.00005194265,0.0019116168,0.9189242],"study_design_scores_gemma":[0.00052528066,0.000082019826,0.019219605,0.00484715,0.00010238102,4.3405595e-7,0.000025240792,0.00002545063,7.008084e-7,0.000036649646,0.97494704,0.00018807966],"about_ca_topic_score_codex":0.055896387,"about_ca_topic_score_gemma":0.122864656,"teacher_disagreement_score":0.9730354,"about_ca_system_score_codex":0.0021319047,"about_ca_system_score_gemma":0.0016815081,"threshold_uncertainty_score":0.95039046},"labels":[],"label_agreement":null},{"id":"W2540798315","doi":"10.1016/j.jval.2016.09.1882","title":"Cost Effectiveness of Empagliflozin in Patients with T2DM and High CV Risk in Canada","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Boehringer Ingelheim (Canada)","funders":"","keywords":"Empagliflozin; Medicine; Cost–benefit analysis; Quality-adjusted life year; Hazard ratio; Demography; Emergency medicine; Cost effectiveness; Confidence interval; Internal medicine; Type 2 diabetes; Diabetes mellitus; Risk analysis (engineering); Endocrinology","score_opus":0.013972489305047619,"score_gpt":0.24531437140533663,"score_spread":0.231341882100289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540798315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983863,0.0001267143,0.000006302452,0.00022902415,0.00005769119,0.0011070868,0.000022595152,0.000003668557,0.000060578488],"genre_scores_gemma":[0.99962366,0.00013168041,0.00009783119,0.000067416404,0.000004594695,0.000040834195,0.000008610447,0.000008724626,0.000016655233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990517,0.00019427967,0.00021590998,0.00016450159,0.000155391,0.00021824354],"domain_scores_gemma":[0.9994821,0.00021884414,0.00007783962,0.00013010924,0.000017301933,0.00007378334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041061122,0.00008420462,0.0002968436,0.0001431919,0.000008680193,0.0000013705439,0.000027184218,0.000017938306,0.0000057919888],"category_scores_gemma":[0.0000444258,0.000052760057,0.0000067691035,0.0001793905,0.000019397457,0.00003449246,0.000018849398,0.0000555155,8.002438e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035844414,0.0001918966,0.97746104,0.00037421708,0.000015747808,0.000009890953,0.00007454406,0.00010274547,0.000001929429,0.00007712136,0.000025002963,0.021307401],"study_design_scores_gemma":[0.0089384215,0.00062159356,0.98857635,0.0015297354,0.000009073133,8.705607e-8,0.000031749707,0.000049694987,0.000058556565,0.00006829354,0.00006531999,0.000051140887],"about_ca_topic_score_codex":0.91473013,"about_ca_topic_score_gemma":0.62222075,"teacher_disagreement_score":0.29250935,"about_ca_system_score_codex":0.0010077133,"about_ca_system_score_gemma":0.00041940334,"threshold_uncertainty_score":0.38467273},"labels":[],"label_agreement":null},{"id":"W2541955529","doi":"10.1136/bmj.i5340","title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink","year":2016,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Hazard ratio; Breast cancer; Confidence interval; Cohort; Population; Proportional hazards model; Internal medicine; Cohort study; Incidence (geometry); Cumulative incidence; Type 2 diabetes; Cancer; Diabetes mellitus; Oncology; Endocrinology; Environmental health","score_opus":0.0710230084317841,"score_gpt":0.42630143584337465,"score_spread":0.35527842741159055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2541955529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723184,0.000101379876,0.0000065505096,0.0008861681,0.00007792022,0.0014914138,0.000028350894,0.000008916109,0.00016743426],"genre_scores_gemma":[0.9989645,0.00020944141,0.00029154934,0.00011196717,0.0000952169,0.0001017458,0.000013893195,0.000012532237,0.00019914174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984288,0.00041656647,0.00029739048,0.00024851726,0.00038709276,0.00022158444],"domain_scores_gemma":[0.9986184,0.00058040256,0.00015878571,0.0003894918,0.0001919987,0.00006092656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035815248,0.00008716576,0.00024495882,0.00010687223,0.000053445885,0.00001583253,0.00006590527,0.00003290106,0.00004584772],"category_scores_gemma":[0.00038884365,0.000042279753,0.000014411925,0.0002920973,0.00009550129,0.000121425204,0.00007172989,0.00011106498,0.0000028925458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008455273,0.00041814608,0.98539054,0.000023074852,0.00046729908,0.0000106731195,0.00014289706,0.000010325485,0.000027804394,0.0000032835346,0.0005848407,0.012075579],"study_design_scores_gemma":[0.0021438315,0.0008131627,0.9947317,0.00022983887,0.00038706022,7.461572e-7,0.00080029014,0.00024412913,0.0000063881284,0.000007713295,0.0005768197,0.000058281683],"about_ca_topic_score_codex":0.002117909,"about_ca_topic_score_gemma":0.00077686005,"teacher_disagreement_score":0.012017298,"about_ca_system_score_codex":0.00013584082,"about_ca_system_score_gemma":0.000095746946,"threshold_uncertainty_score":0.3201659},"labels":[],"label_agreement":null},{"id":"W2542456927","doi":"10.1002/ejhf.657","title":"Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial","year":2016,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"Sanofi France; Pfizer; Daiichi-Sankyo; Novo Nordisk; Steno Diabetes Center Copenhagen; Bayer; Novartis","keywords":"Medicine; Liraglutide; Heart failure; Placebo; Diabetes mellitus; Internal medicine; Glucagon-like peptide-1; Cardiology; Glucagon; Double blind; Endocrinology; Insulin; Type 2 diabetes","score_opus":0.006214557916760957,"score_gpt":0.22044858257250555,"score_spread":0.2142340246557446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2542456927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328285,0.0005532868,0.000028165614,0.0011403546,0.0002534183,0.0046151415,0.0000052369373,0.000022273165,0.00009928592],"genre_scores_gemma":[0.9987835,0.000032965236,0.0003576156,0.000099583835,0.00025724326,0.000033515986,0.000017514963,0.00006172897,0.00035631182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99669665,0.0009281502,0.00087840785,0.00035849796,0.00064142403,0.0004968708],"domain_scores_gemma":[0.9982464,0.0003703391,0.00058175006,0.00031204245,0.00022261296,0.00026690622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018507296,0.0004115015,0.0013495634,0.00051685906,0.000080237936,0.000048269412,0.00011199688,0.00006243124,0.00011496123],"category_scores_gemma":[0.00016669605,0.00021943892,0.00033309005,0.00020308238,0.00009422629,0.00030582907,0.0000538176,0.0003072923,0.000045528228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7737974,0.0007166746,0.2174011,0.00018060746,0.0009958685,0.00006208983,0.000053804608,0.00007110687,0.00073584856,0.0000023080229,0.0050752326,0.00090796605],"study_design_scores_gemma":[0.93618625,0.023980951,0.020288019,0.0017232988,0.0013476094,0.000011098774,0.000034309902,0.000027736929,0.0014068143,9.984984e-7,0.014771049,0.00022183763],"about_ca_topic_score_codex":0.0000045851884,"about_ca_topic_score_gemma":0.000025758041,"teacher_disagreement_score":0.1971131,"about_ca_system_score_codex":0.00016951669,"about_ca_system_score_gemma":0.00008962599,"threshold_uncertainty_score":0.89484596},"labels":[],"label_agreement":null},{"id":"W2544948603","doi":"10.1016/j.jcjd.2016.10.004","title":"Are Diabetes Care Providers Too Glucocentric?","year":2016,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Diabetes mellitus; Endocrinology","score_opus":0.006544139145563532,"score_gpt":0.2220515862416012,"score_spread":0.21550744709603767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544948603","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06902312,0.03405296,8.992214e-7,0.002335892,0.8870785,0.0009940028,0.0011213488,0.000050804978,0.0053424537],"genre_scores_gemma":[0.08167269,0.0002770608,0.00018374505,0.0011301696,0.90992695,0.00005717209,0.00045418355,0.0002865136,0.006011499],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646735,0.00007902667,0.00082287093,0.0004364763,0.00090974674,0.0012845132],"domain_scores_gemma":[0.9944547,0.00042651623,0.001354024,0.00054309494,0.001410489,0.0018111984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030812473,0.0006364756,0.001437621,0.0012235431,0.00016716553,0.0002089443,0.0005304685,0.0006973489,0.00030265216],"category_scores_gemma":[0.0019413829,0.00047412995,0.00066442444,0.00028531993,0.00021829565,0.000303239,0.000045577217,0.00078569155,0.00021620623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000064343863,0.000031413987,0.14943014,0.00079983246,0.0011057958,0.0002028532,0.00011633822,5.669661e-7,0.0000103543325,0.0000043330715,0.8391452,0.009146761],"study_design_scores_gemma":[0.0026411796,0.00075294776,0.0071532177,0.0032788021,0.001859541,5.25404e-7,0.00034337182,6.282346e-7,0.0003019315,0.00006146479,0.98312956,0.00047682988],"about_ca_topic_score_codex":0.00010191452,"about_ca_topic_score_gemma":0.0019525213,"teacher_disagreement_score":0.14398438,"about_ca_system_score_codex":0.0015227245,"about_ca_system_score_gemma":0.0038093904,"threshold_uncertainty_score":0.99977106},"labels":[],"label_agreement":null},{"id":"W2544950685","doi":"10.1111/dom.12816","title":"Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase <scp>II</scp> and <scp>III</scp> clinical trials","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Merck Sharp and Dohme; European Association for the Study of Diabetes; Novo Nordisk; Amgen","keywords":"Dulaglutide; Medicine; Insulin glargine; Renal function; Internal medicine; Placebo; Type 2 diabetes; Urology; Endocrinology; Exenatide; Gastroenterology; Diabetes mellitus","score_opus":0.01698268501004133,"score_gpt":0.2805988584911671,"score_spread":0.26361617348112576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544950685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521697,0.0020713047,0.000004911375,0.000096210664,0.00050631794,0.0017124936,0.0000384711,0.000047892703,0.00030542436],"genre_scores_gemma":[0.99682444,0.0010816423,0.0001012606,0.00094465894,0.00015438654,0.000084482606,0.00008686619,0.000037403825,0.0006848328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969326,0.0005270618,0.0008691868,0.0006475171,0.00039462285,0.0006289823],"domain_scores_gemma":[0.9961018,0.002610753,0.000396965,0.00034533523,0.00012262848,0.00042254798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019405159,0.00041258286,0.0016792327,0.0004747414,0.000079372956,0.000028072991,0.00010265014,0.00023520383,0.0000046864516],"category_scores_gemma":[0.0043974076,0.00026270453,0.00014606306,0.00041489344,0.00022327538,0.00028545794,0.00012987368,0.000228578,0.000012112782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001824228,0.003856134,0.94490856,0.00035395366,0.00049603754,0.0000070929013,0.0001901105,4.2329012e-7,0.0032234117,0.00031175616,0.0017222579,0.044747844],"study_design_scores_gemma":[0.035706695,0.0034371426,0.9238827,0.00088585785,0.001073814,5.5073954e-8,0.000037336464,0.000024761124,0.024003275,0.00030716023,0.010552486,0.00008871921],"about_ca_topic_score_codex":0.000020543368,"about_ca_topic_score_gemma":0.000012613225,"teacher_disagreement_score":0.044659123,"about_ca_system_score_codex":0.000040909094,"about_ca_system_score_gemma":0.00006292554,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W2547968424","doi":"10.1210/en.2016-1667","title":"The Endocrine Society Centennial: Cleavage Matters","year":2016,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Centennial; Endocrine system; Endocrinology; Internal medicine; Cleavage (geology); Medicine; Biology; Hormone; Pathology","score_opus":0.012228110964998939,"score_gpt":0.2531965233064185,"score_spread":0.24096841234141958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547968424","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28675854,0.0021886544,0.000794356,0.6095096,0.0028977355,0.0017507441,0.000022060216,0.00091047725,0.09516781],"genre_scores_gemma":[0.9280157,0.0026084757,0.0005013461,0.009141295,0.00030162337,0.00011612826,0.00001013803,0.00003743407,0.05926784],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886096,0.00002766285,0.00016487524,0.00022935327,0.00012192444,0.00059524743],"domain_scores_gemma":[0.99932796,0.00013785613,0.000045463476,0.000388094,0.000024658018,0.00007596577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047322043,0.0001365671,0.00017900077,0.00002994877,0.0001262855,0.000012526686,0.00012753645,0.000023164113,0.00018854084],"category_scores_gemma":[0.000024128016,0.000064539665,0.0001577044,0.00005936335,0.00020703771,0.000044064655,0.00013115483,0.000072058276,0.00068962877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015378011,0.00020416794,0.026796937,0.00002852791,0.0007993277,0.00025461536,0.00008277067,6.723416e-8,0.008287024,0.029919267,0.65662366,0.27684984],"study_design_scores_gemma":[0.0026102108,0.00023584817,0.017926048,0.00001940493,0.000104523315,0.000056441037,0.00009852705,0.0000021852923,0.0071766386,0.00041493727,0.9712679,0.00008735284],"about_ca_topic_score_codex":0.000013176065,"about_ca_topic_score_gemma":0.000007935602,"teacher_disagreement_score":0.64125717,"about_ca_system_score_codex":0.00007941042,"about_ca_system_score_gemma":0.000015093213,"threshold_uncertainty_score":0.88640124},"labels":[],"label_agreement":null},{"id":"W2548768578","doi":"10.1002/oby.21629","title":"Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers","year":2016,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk","keywords":"Liraglutide; Weight loss; Medicine; Prediabetes; Type 2 diabetes; Diabetes mellitus; Internal medicine; Obesity; Weight change; Endocrinology","score_opus":0.008235601882070488,"score_gpt":0.2346548625170301,"score_spread":0.22641926063495962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548768578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937795,0.00004849879,0.000032924356,0.0010604681,0.000082609724,0.00070043415,0.000023381403,0.000070148606,0.0042020543],"genre_scores_gemma":[0.99006855,0.00025834356,0.0002531941,0.00045252382,0.00007044018,0.000030770283,0.000018762095,0.000030834595,0.008816575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982836,0.000073540454,0.0003125795,0.0004980333,0.00038583117,0.0004463972],"domain_scores_gemma":[0.99907815,0.000106556974,0.00014509243,0.00035661,0.000074771146,0.00023883166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044016153,0.00024403297,0.00044892094,0.0000958858,0.00005634334,0.000021763375,0.00009671561,0.00012546932,0.0001656214],"category_scores_gemma":[0.000055018656,0.00013596701,0.00005823568,0.0001870344,0.00021775195,0.00019006037,0.00010095193,0.0001501353,0.00006793927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090233586,0.0007749295,0.98881924,0.000038287984,0.0006216254,0.0003312795,0.000069117894,1.8768073e-8,0.000027089929,0.000076546145,0.0018260598,0.006513458],"study_design_scores_gemma":[0.013934154,0.0019009885,0.98031676,0.00058700726,0.0003420564,0.000002589362,0.000011348749,0.000008939561,0.0003054569,0.000086428314,0.0023120814,0.00019217866],"about_ca_topic_score_codex":0.0000805953,"about_ca_topic_score_gemma":0.00013501503,"teacher_disagreement_score":0.013031818,"about_ca_system_score_codex":0.00015866641,"about_ca_system_score_gemma":0.00006432267,"threshold_uncertainty_score":0.5544574},"labels":[],"label_agreement":null},{"id":"W2549354005","doi":"10.1053/j.ajkd.2016.10.013","title":"Digging Deeper: Hidden Messages Beyond the Overall Prevalence of Diabetic Kidney Disease","year":2016,"lang":"en","type":"letter","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Digging; Kidney disease; Disease; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.00660948677359722,"score_gpt":0.23844900663302626,"score_spread":0.23183951985942905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549354005","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015630988,0.007093769,0.000040013216,0.9728636,0.0006681347,0.0007861495,0.0015552647,0.00004854501,0.0013135255],"genre_scores_gemma":[0.07572342,0.004568663,0.00026683457,0.9069735,0.0042902534,0.0000649647,0.00021760305,0.00015116372,0.007743628],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965634,0.00027088175,0.00085474196,0.00040742112,0.0012679155,0.00063566986],"domain_scores_gemma":[0.99475914,0.00046043113,0.0016852441,0.00088672305,0.00030712053,0.0019013121],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020188373,0.0005518024,0.0012315378,0.00036864617,0.000098396275,0.00006153275,0.0007188116,0.00007844181,0.0007925721],"category_scores_gemma":[0.0016299869,0.00030453235,0.0009450892,0.00021889951,0.0009558703,0.00024302036,0.00018541032,0.00056789484,0.000024856436],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028382783,0.00023951477,0.06046908,0.0016579798,0.0017050024,0.00088515365,0.000069822454,4.581829e-7,0.000034897548,0.00002224397,0.91559315,0.01903885],"study_design_scores_gemma":[0.0028398016,0.0017484117,0.044337455,0.0070172553,0.01799477,0.000035173176,0.00009267225,0.0000055639257,0.00011278494,0.0015651188,0.9235713,0.0006797083],"about_ca_topic_score_codex":0.000009168044,"about_ca_topic_score_gemma":5.0318473e-8,"teacher_disagreement_score":0.06589013,"about_ca_system_score_codex":0.0001795556,"about_ca_system_score_gemma":0.0013360002,"threshold_uncertainty_score":0.9999407},"labels":[],"label_agreement":null},{"id":"W2550203760","doi":"10.1016/s2213-8587(16)30373-4","title":"Cardiovascular effects of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Incretin; Type 2 diabetes; Metformin; Placebo; Internal medicine; Meta-analysis; Alogliptin; Diabetes mellitus; Stroke (engine); Cochrane Library; Myocardial infarction; Linagliptin; Saxagliptin; Exenatide; Adverse effect; Odds ratio; Sitagliptin; Insulin; Endocrinology","score_opus":0.030809290791371076,"score_gpt":0.27701789372438546,"score_spread":0.2462086029330144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550203760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006793174,0.9925873,0.0000021041874,0.0001662781,0.000057395395,0.006351265,0.00002809501,0.000048946742,0.00007924341],"genre_scores_gemma":[0.0015327964,0.9950432,0.00009089992,0.00092277245,0.000058542882,0.0020698786,0.00014343509,0.00006569787,0.00007275993],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99551225,0.0014997025,0.0009014519,0.00058401335,0.00036986987,0.0011327259],"domain_scores_gemma":[0.9957146,0.0015540792,0.0006922645,0.0018394303,0.00012820533,0.00007140658],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0010279422,0.00069919176,0.016826447,0.00035529162,0.000043031854,0.000015572481,0.00040396958,0.00012644407,0.000047933652],"category_scores_gemma":[0.00022086705,0.00029524454,0.0021404212,0.0010798723,0.00023314309,0.000034170058,0.00015542084,0.00026696644,0.000020246209],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008688021,0.00007775313,0.0048943493,0.58259463,0.4035855,0.000009313407,0.0000074230957,0.0000016468173,2.0464741e-8,0.000046125766,0.00010702291,0.008667505],"study_design_scores_gemma":[0.0013126591,0.0005290022,0.0008172651,0.09421347,0.87015665,3.5239268e-7,9.916598e-7,0.0000011462674,0.0000011508606,0.000019488143,0.032656863,0.00029094936],"about_ca_topic_score_codex":0.0000054247357,"about_ca_topic_score_gemma":0.000003725209,"teacher_disagreement_score":0.48838118,"about_ca_system_score_codex":0.00007481937,"about_ca_system_score_gemma":0.000053153697,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W2550794647","doi":"10.1111/dom.12821","title":"Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: <scp>A B</scp> ayesian meta‐analysis of survival data","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Simon Fraser University; MD Precision (Canada); Precision Nanosystems (Canada); University of British Columbia","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Hazard ratio; Observational study; Placebo; Randomized controlled trial; Relative risk; Myocardial infarction; Stroke (engine); Confidence interval; Sitagliptin; Type 2 diabetes; Diabetes mellitus; Pharmacology; Insulin; Endocrinology; Metformin","score_opus":0.07167600119653196,"score_gpt":0.3062117333737652,"score_spread":0.23453573217723328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550794647","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0821276,0.91351146,0.000026478381,0.0000125827455,0.00007601527,0.0015451759,0.0022319844,0.00007698981,0.00039170886],"genre_scores_gemma":[0.00870005,0.9865076,0.00020046256,0.00006862027,0.00007694172,0.00012714743,0.00351383,0.00011697976,0.00068837684],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99556184,0.00064086355,0.00073559023,0.0013475886,0.0009961383,0.00071796356],"domain_scores_gemma":[0.995959,0.00051603734,0.0007062772,0.002236164,0.00019101625,0.0003915313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015392507,0.0010081382,0.009429945,0.0006425189,0.00011183061,0.00006198437,0.00047213215,0.0003201504,0.000030369434],"category_scores_gemma":[0.00012587676,0.00057043676,0.0014528069,0.0010447041,0.00031733565,0.00028487088,0.00041676406,0.0002750584,0.000005090497],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009090304,0.00055725937,0.02020744,0.003777977,0.9626876,0.000024511362,0.00010899604,0.0000010622969,8.3375676e-7,0.000089169036,0.00007950828,0.012456564],"study_design_scores_gemma":[0.0016217205,0.000057682766,0.02646089,0.0013828295,0.6926346,0.0000011572935,0.00003622818,0.000009601746,0.000004612343,0.000009359825,0.27752417,0.00025718028],"about_ca_topic_score_codex":0.00023792432,"about_ca_topic_score_gemma":0.00014598003,"teacher_disagreement_score":0.27744466,"about_ca_system_score_codex":0.000045436173,"about_ca_system_score_gemma":0.00013246242,"threshold_uncertainty_score":0.99967474},"labels":[],"label_agreement":null},{"id":"W2552060437","doi":"10.1016/j.kint.2016.09.010","title":"Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference","year":2016,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Vancouver Hospital and Health Sciences Centre; Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"UCB Celltech; Akebia Therapeutics; Servier; Kidney Research UK; British Heart Foundation; Daiichi Sankyo Europe; Bayer HealthCare; Sanofi; GlaxoSmithKline; Fresenius Medical Care North America; Medical Research Council; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; National Heart, Lung, and Blood Institute; Pfizer; National Institute for Health and Care Research; U.S. Department of Veterans Affairs","keywords":"Medicine; Kidney disease; Diabetes mellitus; Glycemic; Intensive care medicine; Disease; Population; Renal function; Type 2 diabetes; Cause of death; Internal medicine; Endocrinology; Environmental health","score_opus":0.005556902747931545,"score_gpt":0.22680388034110424,"score_spread":0.2212469775931727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552060437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96913755,0.000045665114,0.0007255417,0.016720008,0.00040232873,0.00066465605,0.0035518338,0.000057235655,0.008695167],"genre_scores_gemma":[0.99415976,0.0000233122,0.0012631711,0.0019819564,0.000027175674,0.000039914583,0.0005127871,0.000009626921,0.0019822717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894464,0.000011565071,0.00019163391,0.00026645945,0.0004085561,0.00017715593],"domain_scores_gemma":[0.99909204,0.00006604128,0.00011888738,0.00018855365,0.00015040029,0.00038405834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003690019,0.00016004372,0.00022827186,0.000053017477,0.00003923645,0.000025865078,0.0001216078,0.000024637326,0.0005598168],"category_scores_gemma":[0.00015683175,0.00009666834,0.00005771111,0.00004298333,0.000115501716,0.00016174717,0.00022876587,0.000026071213,0.000014229247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021221254,0.0003008585,0.97528577,0.000053021733,0.0014176564,0.000013501487,0.000029055618,8.63837e-8,0.000066216206,0.007884591,0.0051784324,0.009558609],"study_design_scores_gemma":[0.009506383,0.00015477106,0.9739896,0.0005746367,0.00055863964,5.504278e-8,0.000048901067,0.00006886774,0.000084435706,0.0006996235,0.014180356,0.00013374048],"about_ca_topic_score_codex":0.000021103926,"about_ca_topic_score_gemma":0.0000019921229,"teacher_disagreement_score":0.02502222,"about_ca_system_score_codex":0.00012846469,"about_ca_system_score_gemma":0.0000684512,"threshold_uncertainty_score":0.61296016},"labels":[],"label_agreement":null},{"id":"W2552168025","doi":"10.1016/j.jcjd.2016.08.001","title":"Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre; Lunenfeld-Tanenbaum Research Institute; Health Sciences Centre; Mount Sinai Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"Merck; AstraZeneca; Boehringer Ingelheim","keywords":"Incretin; Medicine; Glucose homeostasis; Glucagon; Endocrinology; Internal medicine; Type 2 diabetes; Glucagon receptor; Diabetes mellitus; Dipeptidyl peptidase-4; Insulin; Insulin resistance","score_opus":0.02074184690218539,"score_gpt":0.2522277475255255,"score_spread":0.23148590062334012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552168025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1712064,0.8262653,1.919927e-7,0.0011441091,0.00023917563,0.00064308697,0.00011080384,0.000002044854,0.00038892846],"genre_scores_gemma":[0.2346316,0.76464176,0.000014794672,0.00018564724,0.00013423241,0.000017087215,0.00003419905,0.00003600138,0.0003046675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848694,0.00014008622,0.00074663537,0.0001416126,0.00021540007,0.00026934862],"domain_scores_gemma":[0.9981581,0.00026360573,0.00086944347,0.00023508725,0.00016770141,0.00030605536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072992686,0.00024876886,0.001072009,0.0003279812,0.00007998915,0.000025425845,0.0001859621,0.00011800229,0.0000693358],"category_scores_gemma":[0.000110480076,0.00012100942,0.00024660816,0.000156122,0.0003518605,0.00006673989,0.000020447753,0.00021604683,0.000001183582],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004846927,0.00004282834,0.03331534,0.005342832,0.0014339401,0.000018474819,0.00062494795,4.7443788e-8,0.000010369574,0.0001880572,0.0049069333,0.9541114],"study_design_scores_gemma":[0.001972237,0.0008545404,0.017684896,0.028401585,0.0050334753,0.000013134824,0.00031411543,0.0000019649708,0.00024463073,0.00021973571,0.94499,0.00026973066],"about_ca_topic_score_codex":0.00041544597,"about_ca_topic_score_gemma":0.0017758787,"teacher_disagreement_score":0.9538416,"about_ca_system_score_codex":0.00012673094,"about_ca_system_score_gemma":0.00060697465,"threshold_uncertainty_score":0.49346212},"labels":[],"label_agreement":null},{"id":"W2556857110","doi":"10.1016/j.cmet.2016.10.007","title":"Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis","year":2016,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk; University of Toronto; Alberta Innovates - Health Solutions; Canadian Institutes of Health Research; Sunnybrook Research Institute; Canadian Diabetes Association","keywords":"Incretin; Glucose homeostasis; Homeostasis; Dipeptidyl peptidase-4; Dipeptidyl peptidase; Hormone; Endocrinology; Chemistry; Internal medicine; Biology; Diabetes mellitus; Medicine; Biochemistry; Enzyme; Type 2 diabetes; Insulin resistance","score_opus":0.012925447945547326,"score_gpt":0.23025417926197161,"score_spread":0.2173287313164243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556857110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713386,0.003765024,0.007900568,0.0003083767,0.000089214176,0.0005751785,0.000020259813,0.000027766546,0.00017975188],"genre_scores_gemma":[0.9961163,0.0016058717,0.001771193,0.00002967713,0.00007714236,0.000026027705,0.000007518236,0.000019280224,0.00034698093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990981,0.000056727953,0.00020585733,0.00026445568,0.00019538648,0.00017944722],"domain_scores_gemma":[0.9993495,0.00005923681,0.00016987608,0.00021966656,0.000078249235,0.00012351174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027408035,0.00015987203,0.00044344412,0.00020434034,0.00003925415,0.000009551659,0.00003711824,0.000072698254,0.00002254874],"category_scores_gemma":[0.000036839545,0.00011442199,0.000062478975,0.00012934528,0.00006500568,0.00013558744,0.00005976406,0.000051834828,0.0000047368117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003120639,0.00015023454,0.00025045782,0.0001317959,0.00010634942,0.0000019213192,0.00016080948,3.5863576e-7,0.9017843,0.0004772414,0.000044228258,0.096580245],"study_design_scores_gemma":[0.003321715,0.0003976469,0.019828465,0.00009508882,0.0006814051,0.000001529518,0.00013574625,0.000022398333,0.97398746,0.0004943119,0.00092127983,0.00011297458],"about_ca_topic_score_codex":0.000030047479,"about_ca_topic_score_gemma":0.0000014708537,"teacher_disagreement_score":0.09646727,"about_ca_system_score_codex":0.000022808928,"about_ca_system_score_gemma":0.000012030647,"threshold_uncertainty_score":0.46659935},"labels":[],"label_agreement":null},{"id":"W2558369602","doi":"10.1016/j.jcjd.2016.09.003","title":"Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Interim; Type 2 diabetes; Diabetes mellitus; Interim analysis; Internal medicine; Clinical trial; Endocrinology; Law","score_opus":0.018143760467450778,"score_gpt":0.2597050012906354,"score_spread":0.24156124082318461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558369602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877792,0.0031991415,0.00000950782,0.0022483976,0.00083651446,0.00024153435,0.000019345918,0.000011563565,0.0056547727],"genre_scores_gemma":[0.9961333,0.00034074858,0.000538474,0.0007544704,0.000119664575,0.0000062936906,0.0000050457124,0.000023783907,0.0020781718],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868727,0.000037022397,0.0004554647,0.00014949995,0.00018353018,0.0004872367],"domain_scores_gemma":[0.99865144,0.00004706204,0.00027454883,0.0002199751,0.00022770291,0.00057927566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030162823,0.00017983302,0.0004397228,0.00041666906,0.000038304912,0.000016761738,0.00023421738,0.00005320473,0.0012556462],"category_scores_gemma":[0.00003639833,0.000110985566,0.0001723841,0.00022042108,0.00014505172,0.00016594504,0.00003369663,0.00008207713,0.00012197015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050474588,0.00030182238,0.5792077,0.0006477655,0.0049004653,0.00028269025,0.000114038805,0.000003910566,0.015010326,0.0013178046,0.12868448,0.2694785],"study_design_scores_gemma":[0.015353772,0.0069425446,0.3174945,0.00832298,0.005004121,0.0000070638453,0.00042143758,0.000037818398,0.07718902,0.0022439351,0.56601,0.0009727756],"about_ca_topic_score_codex":0.00001229329,"about_ca_topic_score_gemma":0.000039330127,"teacher_disagreement_score":0.43732554,"about_ca_system_score_codex":0.00020286572,"about_ca_system_score_gemma":0.00024161454,"threshold_uncertainty_score":0.99965733},"labels":[],"label_agreement":null},{"id":"W2559840873","doi":"10.1186/s12986-016-0153-3","title":"Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review","year":2016,"lang":"en","type":"review","venue":"Nutrition & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut du Savoir Montfort; Montfort Hospital; University of Ottawa","funders":"","keywords":"Glucose homeostasis; Nutrient sensing; Appetite; Glucagon-like peptide-1; Peptide YY; Type 2 diabetes; Secretion; Enteroendocrine cell; Context (archaeology); Endocrinology; Polyunsaturated fatty acid; Medicine; Diabetes mellitus; Internal medicine; Biology; Receptor; Hormone; Fatty acid; Biochemistry; Endocrine system; Insulin resistance; Signal transduction; Neuropeptide Y receptor; Neuropeptide","score_opus":0.06089317840435768,"score_gpt":0.31605668664298686,"score_spread":0.2551635082386292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559840873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000038810604,0.98997235,0.00013391087,0.00037851612,0.00054468965,0.004686929,0.00044888392,0.00011006815,0.0037207496],"genre_scores_gemma":[0.000017926232,0.98969924,0.0011820601,0.000359438,0.0011046813,0.0017477339,0.0043123737,0.00008396642,0.0014925608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967692,0.0002167859,0.0013005468,0.0006024371,0.00073603814,0.00037498816],"domain_scores_gemma":[0.9978217,0.00011355341,0.0007965515,0.00069110206,0.00038614348,0.00019094531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038555745,0.0005827482,0.0031745958,0.00051909004,0.00007530376,0.000018838908,0.00018403534,0.0003042029,0.0011763154],"category_scores_gemma":[0.000065803404,0.00043160637,0.0014168202,0.0005575653,0.0000947981,0.00017705122,0.000071371585,0.00021797557,0.00039737506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027037919,0.0011488434,9.201081e-7,0.19961506,0.00070344633,0.00003157949,0.0000073520446,1.9101805e-8,0.000049277965,0.0031016385,0.016840415,0.7784744],"study_design_scores_gemma":[0.0020007521,0.000094054994,0.00001326416,0.16849467,0.0060598613,0.000100328674,0.0000024305377,6.928984e-7,0.000013201016,0.0003957,0.82254136,0.00028368278],"about_ca_topic_score_codex":0.000004702846,"about_ca_topic_score_gemma":3.881678e-7,"teacher_disagreement_score":0.80570096,"about_ca_system_score_codex":0.00018159473,"about_ca_system_score_gemma":0.0001944587,"threshold_uncertainty_score":0.99981356},"labels":[],"label_agreement":null},{"id":"W2560321248","doi":"10.1007/s00125-016-4172-4","title":"Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels","year":2016,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; University of Toronto; Diabetes Research Center, University of Washington; University of Washington; U.S. Department of Veterans Affairs","keywords":"Neprilysin; Internal medicine; Endocrinology; Glucagon-like peptide-1; Insulin; Incretin; Dipeptidyl peptidase; Chemistry; Type 2 diabetes; Insulin resistance; Downregulation and upregulation; Dipeptidyl peptidase-4; Diabetes mellitus; Beta cell; Biology; Medicine; Islet; Enzyme; Biochemistry","score_opus":0.014213551057888739,"score_gpt":0.2410891071060947,"score_spread":0.22687555604820597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560321248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959268,0.000054896627,0.000027611219,0.0015657727,0.00009368163,0.0009846255,0.000085079475,0.00013699071,0.0011245434],"genre_scores_gemma":[0.997851,0.00001648954,0.0002301315,0.0005050148,0.000031530344,0.00013299541,0.000040988,0.00003445699,0.0011573771],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980707,0.00012707415,0.00024918598,0.00067206234,0.00025885456,0.00062211143],"domain_scores_gemma":[0.99878824,0.00029140912,0.00021893917,0.0004090432,0.00010934563,0.00018299575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024914317,0.000355545,0.00073972804,0.00022340572,0.000075825876,0.000029025525,0.00011952708,0.0002028135,0.000118106684],"category_scores_gemma":[0.00030627253,0.00022210345,0.000072197,0.00040776742,0.00018569802,0.00018777323,0.0001264256,0.00017736082,0.000028811619],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019400684,0.0013755168,0.15298454,0.000063688734,0.001062855,0.00011185955,0.00040063408,2.3788729e-7,0.78508514,0.00018683677,0.0007565547,0.05603203],"study_design_scores_gemma":[0.008945825,0.0010059327,0.7656956,0.00025516687,0.00035800485,0.0000017997518,0.00007140493,0.000062546045,0.22305289,0.00015037127,0.00009172098,0.00030879103],"about_ca_topic_score_codex":0.0003202069,"about_ca_topic_score_gemma":0.000103307764,"teacher_disagreement_score":0.612711,"about_ca_system_score_codex":0.0004959853,"about_ca_system_score_gemma":0.000090096415,"threshold_uncertainty_score":0.9057116},"labels":[],"label_agreement":null},{"id":"W2560424376","doi":"10.1111/dom.12815","title":"Predictors of outcomes in patients with type 2 diabetes in the lixisenatide <scp>GetGoal</scp> clinical trials","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Boehringer Ingelheim; Novo Nordisk; Merck; Sanofi; Roche; GlaxoSmithKline; Janssen Pharmaceuticals; AstraZeneca","keywords":"Medicine; Lixisenatide; Type 2 diabetes; Internal medicine; Placebo; Basal insulin; Basal (medicine); Clinical endpoint; Diabetes mellitus; Insulin; Randomized controlled trial; Glycated hemoglobin; Endocrinology","score_opus":0.02459821376528614,"score_gpt":0.2894897659217755,"score_spread":0.26489155215648935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560424376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671024,0.0010369864,8.2687643e-7,0.00027125547,0.00030587832,0.0011398694,0.00003360683,0.000024830304,0.00047652292],"genre_scores_gemma":[0.9984275,0.0004160222,0.0001110453,0.0005111366,0.000083512816,0.00005422882,0.000029142113,0.000018638644,0.00034878217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747497,0.00057405373,0.0007927366,0.00034229178,0.0003909322,0.00042499226],"domain_scores_gemma":[0.996925,0.002196576,0.0002754404,0.00038595512,0.00009565554,0.00012135099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028908334,0.00025085278,0.0012850697,0.00026134972,0.000032583368,0.000019989864,0.00016532838,0.00012129946,0.000012874397],"category_scores_gemma":[0.0027167357,0.00011370584,0.00015604068,0.00034449447,0.0001848555,0.00017872902,0.00008127907,0.000149224,0.00000963654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028457187,0.001277271,0.9884448,0.000060776463,0.00038600093,0.0000021622545,0.00019501577,2.1925334e-7,0.00005459626,0.00023298823,0.00045068757,0.008867034],"study_design_scores_gemma":[0.007740492,0.00046996927,0.98623466,0.00017492194,0.00053512084,2.0709923e-8,0.000061378596,0.0000038934086,0.0006732502,0.00023183708,0.0038044082,0.00007006864],"about_ca_topic_score_codex":0.000010675585,"about_ca_topic_score_gemma":0.000023804729,"teacher_disagreement_score":0.008796965,"about_ca_system_score_codex":0.000018366736,"about_ca_system_score_gemma":0.000034510034,"threshold_uncertainty_score":0.463679},"labels":[],"label_agreement":null},{"id":"W2561108792","doi":"10.71781/28231","title":"Le glucagon-like peptide-I : un facteur de croissance et une hormone anti-apoptotique pour la cellule pancréatique[bêta] : étude de la transduction du signal","year":2003,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Cancer Research Society; Medical Research Council Canada; McGill University; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Molecular biology; Biology","score_opus":0.003664364228784683,"score_gpt":0.18101475781614726,"score_spread":0.17735039358736257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561108792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9147037,0.019439694,0.0070336666,0.0022864807,0.0007261277,0.00088543224,0.00005552389,0.0002074191,0.05466193],"genre_scores_gemma":[0.91913843,0.006586296,0.0023865337,0.00027373966,0.0002449187,0.000090360605,0.00080638874,0.00009647764,0.07037683],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960061,0.00089320476,0.0005980797,0.0009117045,0.00067941373,0.00091149844],"domain_scores_gemma":[0.9978964,0.00030984485,0.00050143513,0.00042865888,0.0002940825,0.0005695854],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0007704841,0.00082016614,0.00078770245,0.00039394587,0.003228826,0.0001274124,0.00035823433,0.00082796224,0.00010704698],"category_scores_gemma":[0.000063173306,0.0009853063,0.0005538106,0.000508596,0.0004287907,0.0005480955,0.00007834295,0.0008688896,0.000058292964],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022830658,0.005320632,0.057196077,0.0012621263,0.00448178,0.013889465,0.067046426,0.017738676,0.55959934,0.25755948,0.004939858,0.008683076],"study_design_scores_gemma":[0.0122564025,0.0008055889,0.5157125,0.0016784774,0.0048818104,0.0023042718,0.052937735,0.003390325,0.20919128,0.0011871998,0.19348352,0.0021708712],"about_ca_topic_score_codex":0.03284463,"about_ca_topic_score_gemma":0.0037667465,"teacher_disagreement_score":0.45851645,"about_ca_system_score_codex":0.004793139,"about_ca_system_score_gemma":0.0039905384,"threshold_uncertainty_score":0.9992597},"labels":[],"label_agreement":null},{"id":"W2562700584","doi":"10.1161/circulationaha.116.024764","title":"Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists","year":2016,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital","funders":"University of Toronto; AstraZeneca; Amgen; Ontario Ministry of Research and Innovation; National Heart, Lung, and Blood Institute; Heart and Stroke Foundation of Canada","keywords":"Medicine; Excellence; Emergency department; Diabetes mellitus; Family medicine; Internal medicine; Gerontology; Endocrinology; Nursing; Law","score_opus":0.0350089726621563,"score_gpt":0.25065217501689235,"score_spread":0.21564320235473605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562700584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986169,0.000061724335,0.00017883246,0.00024772956,0.000040651747,0.00024064418,0.0000024157273,0.000006257931,0.00060485443],"genre_scores_gemma":[0.99981296,0.000025601645,0.000025188107,0.000038298556,0.000023610706,0.000008948248,0.000019017725,0.0000032436697,0.000043144475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999602,0.000019578463,0.00014690401,0.00006842927,0.00010277705,0.000060262548],"domain_scores_gemma":[0.9997236,0.000039846393,0.000052078114,0.00014652548,0.00002796409,0.000009996959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011164782,0.000041854477,0.00011625276,0.000055982586,0.000005548761,0.0000017229962,0.000021655625,0.000027911097,0.000010122201],"category_scores_gemma":[0.000018876182,0.000021414375,0.00005159255,0.00007333881,0.00004085021,0.000057287096,0.000003853687,0.000014140073,0.0000023586829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033942197,0.00007139647,0.96535456,0.000035098357,0.000037519356,0.0000037713999,0.00021651175,0.000012047849,0.018047255,0.0003206425,0.00015207377,0.01571516],"study_design_scores_gemma":[0.0009998607,0.00006202681,0.9853361,0.00008499322,0.00007559389,4.6251006e-7,0.000017773233,0.000019511623,0.012575748,0.00009489665,0.0007081695,0.000024855306],"about_ca_topic_score_codex":0.000024140734,"about_ca_topic_score_gemma":0.000006873562,"teacher_disagreement_score":0.019981526,"about_ca_system_score_codex":0.000020127742,"about_ca_system_score_gemma":0.000007697416,"threshold_uncertainty_score":0.08732528},"labels":[],"label_agreement":null},{"id":"W2563172289","doi":"10.2337/dbi16-0056","title":"Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney","year":2016,"lang":"en","type":"letter","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Sciences; Providence Health Care","keywords":"Medicine; Glomerular hyperfiltration; Clinical trial; Mechanism (biology); Kidney; Disease; Diabetic nephropathy; Internal medicine; Intensive care medicine; Pharmacology","score_opus":0.00673220986257943,"score_gpt":0.20743081174651978,"score_spread":0.20069860188394034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563172289","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075635365,0.0036116268,0.000007781257,0.9781742,0.0009657264,0.0018666284,0.000060036546,0.000045914046,0.0077045616],"genre_scores_gemma":[0.001838039,0.0004895615,0.0001494466,0.96030647,0.0083648395,0.00045784793,0.00038573678,0.00007145232,0.0279366],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998226,0.00013812278,0.00025366357,0.00044052143,0.00038871405,0.0005529621],"domain_scores_gemma":[0.9986251,0.00025484685,0.00010388409,0.0008171752,0.000062965504,0.00013605584],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032555952,0.00038409414,0.00053709163,0.0001045479,0.00014926778,0.0001176144,0.000251269,0.00024853263,0.00038883358],"category_scores_gemma":[0.00007913496,0.00015873672,0.00018249766,0.00016873336,0.00021772928,0.00006431328,0.00013139703,0.00041188372,0.0011005556],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015464113,0.000014388676,0.0018357221,0.0002214993,0.00048413116,0.000007807857,0.00008147593,9.0383075e-8,0.0000785406,0.0001948498,0.98206407,0.015001977],"study_design_scores_gemma":[0.0017797309,0.00014472881,0.0006452532,0.00026913866,0.00089507404,8.1573376e-7,0.000017959423,0.000015710304,0.00040780928,0.00020696636,0.9954019,0.00021490785],"about_ca_topic_score_codex":0.0000046996047,"about_ca_topic_score_gemma":0.0000010602133,"teacher_disagreement_score":0.020232039,"about_ca_system_score_codex":0.000054401182,"about_ca_system_score_gemma":0.000039758317,"threshold_uncertainty_score":0.9996772},"labels":[],"label_agreement":null},{"id":"W2564748425","doi":"10.1016/j.ahj.2016.12.011","title":"Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial","year":2016,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Impaired glucose tolerance; Nateglinide; Valsartan; Disease; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology; Type 2 diabetes; Blood pressure","score_opus":0.024141969236856003,"score_gpt":0.28800051482039685,"score_spread":0.2638585455835408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564748425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94857943,0.047440484,0.000040579664,0.0003231633,0.0002443583,0.0031920238,0.000109353896,0.000060889306,0.000009712808],"genre_scores_gemma":[0.9900617,0.008844675,0.00021751615,0.00013470194,0.0003577483,0.00020800711,0.00003390412,0.00012888573,0.000012849663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99083376,0.0025387164,0.0009878376,0.0013165709,0.0031040646,0.0012190797],"domain_scores_gemma":[0.99522656,0.0008433424,0.00026953936,0.002323644,0.00036987558,0.0009670605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028018653,0.0008603519,0.0035533756,0.0004978354,0.00056999293,0.00022511926,0.00040215466,0.00016030528,0.000008892843],"category_scores_gemma":[0.0006386598,0.00043768532,0.0024677226,0.0010598064,0.00093117054,0.0005391077,0.00029445128,0.0010285347,0.000006128806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009443123,0.000553176,0.9431294,0.00005100501,0.013849277,0.0012608629,0.0011181781,0.00051388564,0.000005612162,0.0000016934712,0.00004544942,0.030028323],"study_design_scores_gemma":[0.054375257,0.0013123312,0.93471664,0.0009587967,0.0033849191,0.000026893213,0.0016591673,0.000084805055,0.00007816582,0.000056546487,0.0027682486,0.0005782404],"about_ca_topic_score_codex":0.006211627,"about_ca_topic_score_gemma":0.00035400095,"teacher_disagreement_score":0.044932134,"about_ca_system_score_codex":0.0005917331,"about_ca_system_score_gemma":0.0003200683,"threshold_uncertainty_score":0.9998075},"labels":[],"label_agreement":null},{"id":"W2564814356","doi":"10.1016/s0735-1097(16)31870-8","title":"EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK","year":2016,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Placebo; Type 2 diabetes; Internal medicine; Diabetes mellitus; Benzhydryl compounds; Adverse effect; Cardiology; Endocrinology; Alternative medicine","score_opus":0.007026060051899098,"score_gpt":0.23490681573658093,"score_spread":0.22788075568468183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564814356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999064,0.00030608822,0.0000026833318,0.000050072533,0.00010159108,0.00029547172,0.000056237837,0.0000016337152,0.0001221917],"genre_scores_gemma":[0.9995481,0.00031121552,0.00005185429,0.000016556194,0.000033932734,0.0000028122845,6.935091e-7,0.000009846517,0.000024985737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867773,0.00045366216,0.00032906525,0.000108443295,0.0002957682,0.00013535518],"domain_scores_gemma":[0.99849755,0.00035134028,0.00063062843,0.00032685092,0.00014900172,0.0000446065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058505556,0.000121088415,0.0012863284,0.00013633126,0.00001371501,5.270346e-7,0.00009385097,0.00002687572,0.0000024981596],"category_scores_gemma":[0.0002283455,0.000052897627,0.0002846764,0.00018329103,0.0003256791,0.000025063973,0.00006700175,0.00006482268,2.7138333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019502863,0.000058196543,0.9919135,0.000062942396,0.0036720866,0.00001831398,0.0000071730037,0.00009594524,0.00028156233,0.000010149927,0.00015378588,0.0017760425],"study_design_scores_gemma":[0.0041300603,0.012869525,0.97330755,0.00020015442,0.0019229286,0.0000036326826,0.000009762573,6.929847e-7,0.0073130205,0.000017365905,0.00017669468,0.00004860146],"about_ca_topic_score_codex":0.000033398166,"about_ca_topic_score_gemma":0.000004873854,"teacher_disagreement_score":0.018605955,"about_ca_system_score_codex":0.00008268142,"about_ca_system_score_gemma":0.000034205113,"threshold_uncertainty_score":0.21571025},"labels":[],"label_agreement":null},{"id":"W2565209491","doi":"10.1016/j.molmet.2016.12.009","title":"Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects","year":2017,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Japan Society for the Promotion of Science; Japan Diabetes Foundation; Japan Diabetes Society; Eli Lilly and Company","keywords":"Incretin; Dipeptidyl peptidase; Bioassay; Glucagon-like peptide-1; Gastric inhibitory polypeptide; Internal medicine; Endocrinology; Receptor; Dipeptidyl peptidase-4; Luciferase; Biological activity; Chemistry; Dipeptidyl peptidase-4 inhibitor; Transfection; Glucagon; In vitro; Medicine; Type 2 diabetes; Diabetes mellitus; Biology; Insulin; Biochemistry; Enzyme; Gene","score_opus":0.01938139833921708,"score_gpt":0.26389274527100276,"score_spread":0.24451134693178567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565209491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99326247,0.0004356267,0.0000062065405,0.00028574315,0.00017428384,0.0013638728,0.00004862941,0.000024873645,0.004398281],"genre_scores_gemma":[0.9982634,0.00006253902,0.00049470144,0.00010924584,0.0000778338,0.00028180805,0.00003241529,0.0000536444,0.0006244103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979389,0.0001141819,0.00044938384,0.00056824036,0.0003717484,0.0005575701],"domain_scores_gemma":[0.9984863,0.000034628018,0.00025876253,0.0009517025,0.00006497118,0.00020366583],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023991788,0.00044008196,0.0009445341,0.00063385785,0.000072693016,0.00006298779,0.00023784523,0.00013443819,0.00005448097],"category_scores_gemma":[0.000109159766,0.00035515384,0.00023175587,0.00022065609,0.00016928722,0.00022193957,0.00017247985,0.0001589262,0.000041798306],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00145714,0.0056342147,0.3023608,0.00045371466,0.0019595507,0.0045294287,0.007737951,0.000028513728,0.60120606,0.0008315362,0.00007456118,0.07372649],"study_design_scores_gemma":[0.008086305,0.0003127971,0.62623185,0.00030027085,0.00035460544,0.000002839345,0.00012916813,0.00005023587,0.36403933,0.00008583484,0.00018050909,0.00022624483],"about_ca_topic_score_codex":0.0019792877,"about_ca_topic_score_gemma":0.00033852554,"teacher_disagreement_score":0.32387105,"about_ca_system_score_codex":0.00018767659,"about_ca_system_score_gemma":0.00009841581,"threshold_uncertainty_score":0.99989},"labels":[],"label_agreement":null},{"id":"W2565444732","doi":"10.14740/jocmr2857w","title":"A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Erythropoietin; Cotransporter; Mechanism (biology); Pharmacology; Sodium; Endocrinology; Internal medicine; Chemistry","score_opus":0.10325333019671964,"score_gpt":0.4689832083058901,"score_spread":0.36572987810917046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565444732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97819424,0.00026633329,0.0017647443,0.016822083,0.00068067404,0.0018050497,0.0000040417817,0.0000080971695,0.0004547166],"genre_scores_gemma":[0.9956427,0.0009395577,0.0008558043,0.000032900996,0.0015296248,0.000039901908,0.0000033363858,0.000021225986,0.00093489664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99607784,0.0004301033,0.0016911202,0.00023291807,0.0012893819,0.0002786603],"domain_scores_gemma":[0.99409485,0.0021997783,0.0008504468,0.00028578498,0.0023765347,0.00019260633],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0127824135,0.00013288924,0.0010527173,0.00050442846,0.0000399852,0.0000027576484,0.00012832037,0.00014061463,0.00008670429],"category_scores_gemma":[0.010141792,0.0000645462,0.0003013409,0.00034212193,0.00048526903,0.0001258242,0.000028596842,0.00037292068,0.0000036771848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03424789,0.002430377,0.048863314,0.0031529546,0.001804696,0.00005815568,0.00047350556,5.235246e-7,0.48223028,0.0023118323,0.015272194,0.4091543],"study_design_scores_gemma":[0.022267498,0.07884951,0.01706457,0.0055015697,0.000776744,0.000018416225,0.00020726767,0.000018941386,0.8661213,0.0074668955,0.0016152817,0.0000919905],"about_ca_topic_score_codex":0.00001678194,"about_ca_topic_score_gemma":0.0000039289866,"teacher_disagreement_score":0.4090623,"about_ca_system_score_codex":0.00008832301,"about_ca_system_score_gemma":0.00020440655,"threshold_uncertainty_score":0.9981962},"labels":[],"label_agreement":null},{"id":"W2565483524","doi":"10.1016/j.jcjd.2016.08.225","title":"Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Canadian Institute for Health Information; St. Michael's Hospital; McMaster University; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Boehringer Ingelheim; Institute for Clinical Evaluative Sciences; Bayer; Pfizer; Bristol-Myers Squibb","keywords":"Formulary; Medicine; Reimbursement; Medical prescription; Population; Environmental health; Nova scotia; Public health; Fiscal year; Demography; Family medicine; Geography; Health care; Economic growth; Finance; Business","score_opus":0.013597319015289693,"score_gpt":0.2522256310517695,"score_spread":0.2386283120364798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565483524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976816,0.0009199901,3.0758068e-7,0.00047568095,0.00028679174,0.00023319913,0.000103580845,0.0000043696773,0.0002944536],"genre_scores_gemma":[0.99963486,0.00003156673,0.00009094608,0.000030472751,0.0001227818,0.0000037836346,0.0000030690717,0.00001816749,0.00006433584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984437,0.000040234638,0.00050816406,0.00012182599,0.00031810353,0.00056796597],"domain_scores_gemma":[0.99831355,0.00014564651,0.00046356276,0.00019668348,0.00030533076,0.0005752107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037027505,0.00017383938,0.0005188054,0.00026387497,0.000052374617,0.000025414856,0.00018848343,0.000055347165,0.00002397775],"category_scores_gemma":[0.00049915054,0.00011581384,0.00016268122,0.00024391332,0.00007738295,0.0002472563,0.000015456795,0.00012823282,7.54629e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017247816,0.00014670986,0.98632175,0.000116635754,0.0005908763,0.000068071255,0.00019507382,0.0000019183826,0.001239896,0.0001447353,0.0003621667,0.010794905],"study_design_scores_gemma":[0.0030266792,0.0011487637,0.94905037,0.0008735269,0.00019945779,0.0000021514186,0.00016275713,0.0000025928841,0.044719655,0.000022411296,0.00066147506,0.00013018491],"about_ca_topic_score_codex":0.21527934,"about_ca_topic_score_gemma":0.86998135,"teacher_disagreement_score":0.654702,"about_ca_system_score_codex":0.0010414644,"about_ca_system_score_gemma":0.0036498127,"threshold_uncertainty_score":0.7899462},"labels":[],"label_agreement":null},{"id":"W2566774342","doi":"10.14740/jocmr2875w","title":"Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Renal function; Diabetic nephropathy; Type 2 diabetes; Urology; Diabetes mellitus; Glycated hemoglobin; Internal medicine; Blood pressure; Creatinine; Endocrinology; Nephropathy; Gastroenterology","score_opus":0.09663928386458767,"score_gpt":0.4616215208010465,"score_spread":0.3649822369364588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566774342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995438,0.00081312266,8.104058e-7,0.001474961,0.00016772177,0.0017440717,0.0000011357349,0.000004410988,0.0003557875],"genre_scores_gemma":[0.9986805,0.00041322093,0.0001097724,0.00017183827,0.00026242874,0.000017327367,0.0000012299273,0.000025667507,0.00031802457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958217,0.0009839693,0.0010755226,0.00031214405,0.001428794,0.0003778348],"domain_scores_gemma":[0.9945549,0.0034378015,0.00037263954,0.00038765604,0.00079816394,0.00044889128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005893084,0.00016766848,0.0011489742,0.0004694125,0.00003503679,0.00001574652,0.00034626215,0.00008802027,0.000043162803],"category_scores_gemma":[0.0052688564,0.00007579522,0.00002900728,0.00045016443,0.00039620508,0.00020401747,0.00020118861,0.00055876723,0.0000043806276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045593465,0.024313096,0.8983125,0.0002627002,0.00095249515,0.00017176414,0.0001596674,1.4972213e-7,0.00032501327,0.000024823155,0.0006784694,0.07023998],"study_design_scores_gemma":[0.066594556,0.1763421,0.75240713,0.002798347,0.0009190928,5.4353603e-7,0.00008398772,0.000004376596,0.00026308614,0.00008453418,0.00043654555,0.00006568207],"about_ca_topic_score_codex":0.000011623241,"about_ca_topic_score_gemma":0.000006846443,"teacher_disagreement_score":0.152029,"about_ca_system_score_codex":0.000021928296,"about_ca_system_score_gemma":0.00014422803,"threshold_uncertainty_score":0.6307694},"labels":[],"label_agreement":null},{"id":"W2567557402","doi":"10.1007/s13300-016-0220-9","title":"Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Waterloo; Women's College Hospital; University of Toronto; Ottawa Hospital; University of Ottawa; Bruyère","funders":"Canadian Institutes of Health Research","keywords":"Deprescribing; Medicine; MEDLINE; Type 2 diabetes; Glycemic; Cochrane Library; Hypoglycemia; CINAHL; Glycated hemoglobin; Polypharmacy; Adverse effect; Intensive care medicine; Systematic review; Diabetes mellitus; Meta-analysis; Nursing; Internal medicine; Psychological intervention","score_opus":0.23377379864574205,"score_gpt":0.4214522913955017,"score_spread":0.18767849274975967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567557402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007403831,0.99198765,0.000009436907,0.00012030177,0.0001191738,0.0070925453,0.000034297434,0.00004462588,0.00051794923],"genre_scores_gemma":[0.0000223364,0.9964542,0.0003352052,0.0007669455,0.000058228907,0.0007357086,0.000029679875,0.00008417594,0.0015135644],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966861,0.00023683763,0.0017481382,0.00046507618,0.00047480807,0.00038904924],"domain_scores_gemma":[0.9965932,0.0006224626,0.0010204526,0.0013904377,0.00023242108,0.00014106251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089691323,0.00052255596,0.0059077363,0.00032704385,0.000018384368,0.000010523295,0.0004710613,0.00013621115,0.00010772277],"category_scores_gemma":[0.0006152964,0.00026574038,0.0010304828,0.00050058524,0.000060760074,0.00008491188,0.00012188755,0.0000981795,0.000113690454],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005763683,0.00008132037,0.00005689526,0.6755111,0.0013358116,0.0000028464256,0.000016702455,1.4465465e-8,0.000033006472,0.000023421373,0.0011930076,0.32174012],"study_design_scores_gemma":[0.00028234773,0.0003832141,0.000002291674,0.73164284,0.0038803697,9.858455e-7,0.0000022845031,2.7898645e-7,0.0000946083,0.000006052077,0.26351553,0.00018920808],"about_ca_topic_score_codex":0.0000038859566,"about_ca_topic_score_gemma":2.6116817e-7,"teacher_disagreement_score":0.3215509,"about_ca_system_score_codex":0.00013638442,"about_ca_system_score_gemma":0.00015008547,"threshold_uncertainty_score":0.9999795},"labels":[],"label_agreement":null},{"id":"W2569761099","doi":"","title":"The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides","year":2012,"lang":"en","type":"dissertation","venue":"TSpace","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; University of Toronto","keywords":"Chylomicron; Secretion; Glucagon; Glucagon-like peptide-1; Glucagon-like peptide-2; Internal medicine; Chemistry; Endocrinology; Medicine; Biochemistry; Peptide; Lipoprotein; Hormone; Very low-density lipoprotein; Diabetes mellitus; Cholesterol","score_opus":0.010826059548410844,"score_gpt":0.29936664387173123,"score_spread":0.2885405843233204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569761099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626787,0.0027950734,0.000045180248,0.00045383733,0.00068120076,0.00081233366,0.0000060400844,0.000063984786,0.032463674],"genre_scores_gemma":[0.67826223,0.0004859764,0.00028551428,0.000032131014,0.00013979318,0.00006371332,0.004712035,0.000043646894,0.31597495],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990872,0.000025423331,0.00022566301,0.0001846656,0.00025399454,0.00022301529],"domain_scores_gemma":[0.9991653,0.00005065281,0.00031308472,0.00029656777,0.00011345408,0.000060968352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016267928,0.00020930966,0.00026674176,0.000073386596,0.000085266554,0.000021113936,0.0000834088,0.00012468926,0.00010838349],"category_scores_gemma":[0.000025680181,0.00014822609,0.00011056316,0.00010472684,0.000040113337,0.000056970006,0.000018762154,0.0001311244,0.000055739496],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023270624,0.00066657277,0.0043345853,0.0014799302,0.002361015,0.000006338115,0.0076560634,0.0000035062658,0.6580443,0.0020568245,0.19596985,0.12509395],"study_design_scores_gemma":[0.004461993,0.0018894802,0.35628268,0.0026029549,0.009270176,0.000015731352,0.010795789,0.00035966656,0.283988,0.00044178686,0.32890013,0.000991596],"about_ca_topic_score_codex":0.00009508503,"about_ca_topic_score_gemma":0.000056797366,"teacher_disagreement_score":0.37405628,"about_ca_system_score_codex":0.000106637264,"about_ca_system_score_gemma":0.000040413306,"threshold_uncertainty_score":0.60444844},"labels":[],"label_agreement":null},{"id":"W2570182724","doi":"10.2337/dc16-1135","title":"Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Merck","keywords":"Medicine; Sitagliptin; Internal medicine; Hypoglycemia; Myocardial infarction; Hazard ratio; Diabetes mellitus; Type 2 diabetes; Unstable angina; Sitagliptin Phosphate; Cohort; Stroke (engine); Heart failure; Physical therapy; Insulin; Confidence interval; Endocrinology","score_opus":0.0625424219001235,"score_gpt":0.3587561390561757,"score_spread":0.2962137171560522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570182724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933396,0.0009018861,0.0000028289437,0.00065571466,0.00014287652,0.001972408,0.0000074712802,0.000017455164,0.0029597883],"genre_scores_gemma":[0.9991478,0.000013198024,0.00018858195,0.00019279921,0.000078613455,0.00028782274,0.000026606824,0.000024511593,0.000040101342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780834,0.0002825409,0.00041692972,0.00031519568,0.0006750565,0.00050196674],"domain_scores_gemma":[0.99801594,0.0003252954,0.00022091571,0.0012979251,0.0000954573,0.000044491495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018493383,0.00022640251,0.00068319583,0.0000962784,0.0002216396,0.00015735808,0.00037101156,0.000064380845,0.000019205336],"category_scores_gemma":[0.0005541488,0.000114217284,0.00027633534,0.00014848988,0.00013040725,0.00022952413,0.00012648966,0.00020600646,0.000010150132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003295373,0.00016948591,0.96317625,0.00013897911,0.00048516484,0.000023230663,0.00309566,0.00013953848,0.000037671856,0.000026158737,0.000026711923,0.03235159],"study_design_scores_gemma":[0.028308779,0.00043318653,0.95904845,0.00041572077,0.00086005195,1.6021838e-7,0.00991044,0.00032568097,0.0002914913,0.000018426725,0.00024665732,0.0001409317],"about_ca_topic_score_codex":0.000070713584,"about_ca_topic_score_gemma":0.00015382057,"teacher_disagreement_score":0.03221066,"about_ca_system_score_codex":0.00010004616,"about_ca_system_score_gemma":0.00006889813,"threshold_uncertainty_score":0.46576455},"labels":[],"label_agreement":null},{"id":"W2572398654","doi":"10.1016/s2213-8587(17)30013-x","title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":707,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Semaglutide; Medicine; Placebo; Tolerability; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Dulaglutide; Internal medicine; Clinical trial; Adverse effect; Physical therapy; Exenatide; Liraglutide; Endocrinology; Alternative medicine","score_opus":0.03132321637257893,"score_gpt":0.3149938320151195,"score_spread":0.2836706156425406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572398654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858009,0.0007097809,0.0000039807114,0.0020842263,0.00033592072,0.009780827,0.000022635704,0.00006503685,0.0011966537],"genre_scores_gemma":[0.99728686,0.00037506997,0.0005177815,0.0002203607,0.00024060496,0.00086213334,0.0001367599,0.000047651956,0.00031280745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970189,0.00025717137,0.00063064793,0.0005262088,0.000346841,0.001220246],"domain_scores_gemma":[0.99682045,0.0013820691,0.0005982825,0.000917996,0.00015648332,0.00012469052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006263967,0.000441895,0.0015882629,0.00021476603,0.00025812464,0.00006645465,0.00043423942,0.00010985866,0.000055836255],"category_scores_gemma":[0.00045086688,0.0002848584,0.00013938312,0.00012557254,0.0004689309,0.00015240254,0.00017702868,0.00030699678,0.0000121706935],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8965141,0.0019302273,0.08367867,0.00008319526,0.0019137866,0.000014539278,0.00022550469,0.00009544276,0.0000839971,0.00052106817,0.00019988939,0.014739579],"study_design_scores_gemma":[0.9532591,0.0044803335,0.038266316,0.00012352256,0.00081520475,2.3512413e-7,0.000091899194,0.00073472457,0.00024509872,0.00005016307,0.0016640167,0.0002693881],"about_ca_topic_score_codex":0.000038074228,"about_ca_topic_score_gemma":0.00007629458,"teacher_disagreement_score":0.056744996,"about_ca_system_score_codex":0.00012181588,"about_ca_system_score_gemma":0.00006588145,"threshold_uncertainty_score":0.99996036},"labels":[],"label_agreement":null},{"id":"W2574678721","doi":"10.1111/dom.12832","title":"Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 ( <scp>DPP</scp> ‐4) inhibitor omarigliptin or the once‐daily <scp>DPP</scp> ‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Sitagliptin; Medicine; Sitagliptin Phosphate; Metformin; Internal medicine; Randomized controlled trial; Dipeptidyl peptidase-4 inhibitor; Confidence interval; Dipeptidyl peptidase-4; Adverse effect; Type 2 diabetes; Gastroenterology; Saxagliptin; Diabetes mellitus; Pharmacology; Endocrinology; Insulin","score_opus":0.02663838770768699,"score_gpt":0.2781004863912154,"score_spread":0.25146209868352837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574678721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860342,0.0020799614,0.0000047665008,0.0005875176,0.0004403856,0.0098365275,0.000042185024,0.00006228322,0.0009121353],"genre_scores_gemma":[0.99504465,0.001256312,0.00019085094,0.0005598527,0.000553525,0.00070295803,0.00007611958,0.00007987304,0.0015358523],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99482876,0.0012404639,0.0013023118,0.00088113244,0.0007866375,0.000960704],"domain_scores_gemma":[0.98847073,0.008303623,0.0013598329,0.0013041884,0.00025751966,0.00030411052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037392504,0.0009033512,0.003439342,0.00021610426,0.0009459894,0.0003702116,0.00054515054,0.00025391398,0.000009211879],"category_scores_gemma":[0.0021897731,0.00034077364,0.00043179115,0.0003176722,0.0014985438,0.00035588793,0.0002575305,0.0005968962,0.000010370356],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35915446,0.008398068,0.55629295,0.00022544061,0.008938799,0.00002450418,0.005335597,0.000051962204,0.00019440932,0.0009570899,0.0011576968,0.05926903],"study_design_scores_gemma":[0.63878626,0.0065586604,0.3393784,0.0004178834,0.0029420282,3.7703327e-7,0.00055656955,0.00036194807,0.0009797218,0.000052558215,0.009793146,0.00017245897],"about_ca_topic_score_codex":0.00013414944,"about_ca_topic_score_gemma":0.00018409213,"teacher_disagreement_score":0.2796318,"about_ca_system_score_codex":0.000108876455,"about_ca_system_score_gemma":0.00018973692,"threshold_uncertainty_score":0.99990445},"labels":[],"label_agreement":null},{"id":"W2577260237","doi":"10.1007/s11695-017-2549-1","title":"Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids","year":2017,"lang":"en","type":"review","venue":"Obesity Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ottawa Hospital Research Institute","keywords":"Farnesoid X receptor; FGF19; G protein-coupled bile acid receptor; Bile acid; Medicine; Weight loss; Glucose homeostasis; Internal medicine; Receptor; Endocrinology; Obesity; Gastroenterology; Insulin resistance; Biochemistry; Fibroblast growth factor; Biology; Nuclear receptor","score_opus":0.058415996572801464,"score_gpt":0.3379570939662151,"score_spread":0.27954109739341365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577260237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004103275,0.99202585,0.000022710656,0.000048072023,0.0007880205,0.0011725847,0.00019859188,0.000034265853,0.0016065987],"genre_scores_gemma":[0.050138585,0.947368,0.000011707045,0.0000024873461,0.000054113123,0.000057590918,0.00053095835,0.0000275991,0.0018089592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982109,0.00019210015,0.0008142863,0.0002446033,0.00036557004,0.00017253579],"domain_scores_gemma":[0.9976845,0.0002863651,0.0011212621,0.0007495293,0.000084516854,0.00007384927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043635428,0.00025230984,0.0018850045,0.00032972594,0.00006936162,0.000009544377,0.0001811752,0.00018866532,0.00039325576],"category_scores_gemma":[0.00006645606,0.00015529267,0.0026253504,0.00016380819,0.000119540986,0.000057323734,0.00011902311,0.00016328695,0.000028003133],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009051463,0.0030473054,0.00061547017,0.026143342,0.002757378,0.000055375225,0.0000131999195,8.1664825e-7,0.000010636714,0.002186251,0.0014922892,0.9635874],"study_design_scores_gemma":[0.0012366965,0.0006718741,0.0043151,0.07272597,0.025921913,0.000022276292,0.000074244475,0.000018569363,0.00048488178,0.0017641833,0.892326,0.0004382777],"about_ca_topic_score_codex":0.000032535554,"about_ca_topic_score_gemma":0.000002563112,"teacher_disagreement_score":0.96314913,"about_ca_system_score_codex":0.0000557729,"about_ca_system_score_gemma":0.0001239587,"threshold_uncertainty_score":0.63326514},"labels":[],"label_agreement":null},{"id":"W2579358365","doi":"10.1096/fasebj.30.1_supplement.740.22","title":"Renal effects of glucagon‐like peptide‐1 receptor knockout in Akita‐diabetic mice","year":2016,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institutes of Health","keywords":"Endocrinology; Internal medicine; Albuminuria; Diabetes mellitus; Glucagon; Chemistry; Glucagon-like peptide-1; Creatinine; Kidney; Type 2 diabetes; Medicine; Insulin","score_opus":0.008519949423413678,"score_gpt":0.23122269501954199,"score_spread":0.2227027455961283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579358365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935886,0.00081028417,0.00007734193,0.0020173297,0.00041830377,0.00034690724,0.0000027199733,0.000016685277,0.0027217746],"genre_scores_gemma":[0.99056065,0.00032620796,0.0003346058,0.00031776636,0.00022424052,0.000014769063,0.000002241043,0.000019656247,0.008199885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988202,0.00011566021,0.000310238,0.00013418347,0.00029126302,0.00032846225],"domain_scores_gemma":[0.9991434,0.0002609698,0.000162472,0.00024515844,0.00005649943,0.00013147948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004449991,0.00014931231,0.00029432264,0.00016571906,0.000056163542,0.000015805364,0.00016702407,0.000044269593,0.00031257127],"category_scores_gemma":[0.00011425236,0.00007198643,0.00014008342,0.00015204368,0.000092134746,0.000092765775,0.000056722893,0.00016913575,0.0001840866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003730957,0.0004835387,0.019457085,0.00016027552,0.0004959881,0.00015076598,0.00056631997,0.000003041383,0.8900794,0.00021230262,0.015331605,0.072686605],"study_design_scores_gemma":[0.012906255,0.0020271468,0.05998382,0.0030917546,0.00078255794,0.00009515567,0.00023384698,0.000017714843,0.9048217,0.00074058754,0.015019644,0.0002797941],"about_ca_topic_score_codex":0.00000927426,"about_ca_topic_score_gemma":0.000006257142,"teacher_disagreement_score":0.07240681,"about_ca_system_score_codex":0.00013542041,"about_ca_system_score_gemma":0.000058785892,"threshold_uncertainty_score":0.34224364},"labels":[],"label_agreement":null},{"id":"W2581298240","doi":"10.1161/cir.0000000000000334","title":"Late-Breaking Clinical Trial Abstracts","year":2015,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.15534167241973068,"score_gpt":0.3829892457523486,"score_spread":0.22764757333261793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581298240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611527,0.0000366627,0.00012660539,0.0003111713,0.0005872646,0.0004120325,2.410318e-7,0.000068248286,0.037305128],"genre_scores_gemma":[0.9985286,0.0000027042015,0.00024855766,0.00019309827,0.00050064543,0.000009782789,0.000055729142,0.000008045936,0.0004528591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993717,0.000019665362,0.00023312702,0.00012541939,0.00015518122,0.00009489617],"domain_scores_gemma":[0.9996175,0.000025294601,0.00006991335,0.00014048544,0.000045427983,0.00010133802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037764685,0.00005396425,0.00012575227,0.00004067721,0.000016605572,0.000015789077,0.00002003417,0.000052663698,0.000027295991],"category_scores_gemma":[0.00013062419,0.000046720386,0.00006248494,0.00005793185,0.000013380039,0.00007324493,0.0000115361145,0.000048566435,0.0002468747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008007594,0.0013025609,0.7218534,0.00005053414,0.0003694055,0.00008644049,0.00032666718,0.00078334846,0.00015709334,0.0018738481,0.0074016126,0.25778753],"study_design_scores_gemma":[0.05070725,0.00029340357,0.92813295,0.000028491864,0.00021805728,0.0000014518263,0.000024063178,0.0010314834,0.00003667119,0.0007521923,0.018696148,0.000077847995],"about_ca_topic_score_codex":0.0000086695245,"about_ca_topic_score_gemma":0.0000014711765,"teacher_disagreement_score":0.25770968,"about_ca_system_score_codex":0.000053512576,"about_ca_system_score_gemma":0.000035453828,"threshold_uncertainty_score":0.31731573},"labels":[],"label_agreement":null},{"id":"W2581368499","doi":"10.1016/j.tcm.2017.01.009","title":"The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors","year":2017,"lang":"en","type":"review","venue":"Trends in Cardiovascular Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University Health Network; University of Toronto; Women's College Hospital; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Alogliptin; Medicine; Empagliflozin; Semaglutide; Saxagliptin; Sitagliptin; Heart failure; Lixisenatide; Type 2 diabetes; Dulaglutide; Liraglutide; Internal medicine; Dapagliflozin; Dipeptidyl peptidase-4; Population; Pharmacology; Diabetes mellitus; Endocrinology","score_opus":0.11545070404918288,"score_gpt":0.3786707929696252,"score_spread":0.2632200889204423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581368499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000075187827,0.9824222,0.00001650541,0.00039605846,0.0018818876,0.0024557665,0.00006444956,0.00007357513,0.012682064],"genre_scores_gemma":[0.00021788318,0.9934512,0.000083444924,0.000024829276,0.0024339478,0.00038876117,0.0006747555,0.00016360253,0.0025616009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99055904,0.0016832871,0.0034426409,0.001312853,0.0021481817,0.00085401564],"domain_scores_gemma":[0.9926192,0.00089530036,0.0012823502,0.004664666,0.00017293429,0.00036555092],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.017987857,0.0012530554,0.015700182,0.0012868901,0.00035360848,0.000065056425,0.0006361595,0.0006644761,0.00006019505],"category_scores_gemma":[0.0019191833,0.0007007038,0.010142415,0.0008904163,0.0011782101,0.00011431222,0.00046468497,0.00087670994,0.000014202556],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061126884,0.00008223757,0.000042545413,0.009300684,0.037272204,0.0003830755,0.000096214564,0.0000025122076,1.9608706e-7,0.0001127747,0.0055108354,0.94713557],"study_design_scores_gemma":[0.005697266,0.00035368215,0.00025398875,0.02496994,0.055209488,0.00012932203,0.000076811535,0.0000016814561,0.000003857139,0.00002442191,0.9127949,0.0004846577],"about_ca_topic_score_codex":0.00041386898,"about_ca_topic_score_gemma":0.000034297715,"teacher_disagreement_score":0.9466509,"about_ca_system_score_codex":0.00044704697,"about_ca_system_score_gemma":0.00025772964,"threshold_uncertainty_score":0.99977076},"labels":[],"label_agreement":null},{"id":"W2582426955","doi":"10.1111/dom.12892","title":"Safety and efficacy of <scp>IDegLira</scp> titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: <scp>DUAL VI</scp> randomized clinical trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk; European Foundation for the Study of Diabetes; American Diabetes Association","keywords":"Medicine; Type 2 diabetes; Metformin; Pioglitazone; Liraglutide; Internal medicine; Adverse effect; Diabetes mellitus; Randomized controlled trial; Gastroenterology; Insulin; Urology; Endocrinology","score_opus":0.01647658566892487,"score_gpt":0.2755543898933128,"score_spread":0.259077804224388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582426955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99058384,0.001817692,0.0000018011348,0.00012256305,0.0011869953,0.0035522955,0.00005168607,0.00007757293,0.0026055612],"genre_scores_gemma":[0.9972768,0.00091163674,0.00026843586,0.00027367944,0.00026045972,0.00006874166,0.00016701386,0.00006053131,0.00071271334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955838,0.00076186575,0.0011781256,0.0008959954,0.0006750616,0.0009051527],"domain_scores_gemma":[0.99298954,0.0045389384,0.0008620887,0.00087275315,0.00030738136,0.0004293182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027384125,0.00064860866,0.0032072524,0.0003445883,0.00033388863,0.00017424488,0.0002920411,0.0003225541,0.000009053234],"category_scores_gemma":[0.00654163,0.00048190157,0.00034066552,0.00029982146,0.0008428763,0.00040021582,0.00023164558,0.00048449484,0.000021908258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20362072,0.008149672,0.7509609,0.00046475022,0.005783052,0.000027573526,0.00091467635,0.000015480418,0.00020998623,0.0010901567,0.0009413094,0.027821725],"study_design_scores_gemma":[0.4927921,0.002488068,0.49974743,0.00023687525,0.0021373825,4.0260396e-8,0.00007476576,0.0001404695,0.0005233582,0.00006460893,0.001687258,0.000107636],"about_ca_topic_score_codex":0.000060963728,"about_ca_topic_score_gemma":0.0000203559,"teacher_disagreement_score":0.28917137,"about_ca_system_score_codex":0.00004533161,"about_ca_system_score_gemma":0.00012458485,"threshold_uncertainty_score":0.99976325},"labels":[],"label_agreement":null},{"id":"W2582457104","doi":"10.14740/jocmr2820w","title":"Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kidney Foundation, Japan","keywords":"Medicine; Evening; Morning; Blood pressure; Sitagliptin; Internal medicine; Type 2 diabetes; Endocrinology; Lipid profile; Diabetes mellitus","score_opus":0.06933935821974552,"score_gpt":0.4067061203919644,"score_spread":0.3373667621722189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582457104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947508,0.0007124622,1.3849144e-7,0.002281364,0.00020930529,0.00068379455,0.0000018493297,0.0000016614072,0.0013586095],"genre_scores_gemma":[0.99941975,0.00006253284,0.00006310931,0.00015472477,0.00019765484,0.0000044816984,0.000005709966,0.000011803837,0.00008025039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996935,0.0005682778,0.0007824731,0.00014169983,0.0013797204,0.00019282306],"domain_scores_gemma":[0.99482745,0.0024022355,0.00080323074,0.00051693793,0.0013075199,0.00014265031],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0033026552,0.00010727137,0.00086664525,0.0002286675,0.000055465134,0.0000062003387,0.0002981643,0.0000863161,0.000013714147],"category_scores_gemma":[0.008516083,0.000047063462,0.000117239404,0.0001883914,0.0007569222,0.000059501817,0.000077102435,0.00062130525,0.0000010217501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002413336,0.00032061228,0.9856128,0.0008378356,0.00043147252,0.000018708848,0.00007359777,0.000009825454,0.00051739265,0.0000050824165,0.0006853394,0.009073986],"study_design_scores_gemma":[0.014513181,0.03812946,0.93287987,0.0045445077,0.0009144092,2.6642283e-7,0.00003202918,0.000017498327,0.008733207,0.000020690468,0.00018011229,0.000034757537],"about_ca_topic_score_codex":0.000019280737,"about_ca_topic_score_gemma":0.000005213586,"teacher_disagreement_score":0.05273293,"about_ca_system_score_codex":0.000025707943,"about_ca_system_score_gemma":0.0002460472,"threshold_uncertainty_score":0.9998356},"labels":[],"label_agreement":null},{"id":"W2582569357","doi":"10.14740/jocmr2874w","title":"Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vildagliptin; Medicine; Hypoglycemia; Glycemic; Diabetes mellitus; Type 2 diabetes; Internal medicine; Insulin; Basal (medicine); Gastroenterology; Endocrinology","score_opus":0.1502789973004076,"score_gpt":0.4845620811863991,"score_spread":0.3342830838859915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582569357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99023414,0.00044180788,3.5685372e-7,0.0041714096,0.00012063143,0.0010452236,0.0000013153413,0.0000046677405,0.0039804713],"genre_scores_gemma":[0.9955238,0.0034695738,0.00007046989,0.00025836518,0.00036731537,0.000007629388,0.0000076158053,0.000021868404,0.0002733683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618375,0.0006316996,0.0013690337,0.0002482143,0.0012128003,0.00035450677],"domain_scores_gemma":[0.9947766,0.002537662,0.0007743099,0.00046904443,0.0010114792,0.00043087197],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0063307006,0.00017636555,0.0014919658,0.00047268416,0.00009806014,0.000024598967,0.00027946042,0.00013034134,0.00013660407],"category_scores_gemma":[0.009991685,0.00009053354,0.00008978276,0.00021518207,0.00068922475,0.0001484935,0.00006310641,0.0007211815,0.000005605365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08835307,0.0030939379,0.7092363,0.000043872213,0.00051910186,0.00012532691,0.000114971255,0.0000010911506,0.00008906763,0.00006648959,0.0005979951,0.19775875],"study_design_scores_gemma":[0.12543124,0.0855371,0.78588355,0.0013241412,0.00011436916,0.0000010510075,0.00007618551,0.00006529878,0.00024742488,0.0001250916,0.0011286694,0.00006587175],"about_ca_topic_score_codex":0.00006260285,"about_ca_topic_score_gemma":0.000018774008,"teacher_disagreement_score":0.19769287,"about_ca_system_score_codex":0.00004960838,"about_ca_system_score_gemma":0.0002060313,"threshold_uncertainty_score":0.9983476},"labels":[],"label_agreement":null},{"id":"W2583060653","doi":"10.3389/fphys.2017.00015","title":"Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies","year":2017,"lang":"en","type":"review","venue":"Frontiers in Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Natural Science Foundation of China; Juvenile Diabetes Research Foundation International; Canadian Diabetes Association; National Science Foundation","keywords":"Medicine; Pharmacology; Glucagon-like peptide-1; Diabetes mellitus; Chemistry; Intensive care medicine; Internal medicine; Bioinformatics; Type 2 diabetes; Endocrinology; Biology","score_opus":0.06490725132722103,"score_gpt":0.3420220802241444,"score_spread":0.27711482889692335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583060653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013726769,0.99491525,0.000031136675,0.0000078617195,0.00056088174,0.0026089929,0.00017515765,0.000020115036,0.00030791175],"genre_scores_gemma":[0.00046727926,0.9964925,0.0012985438,0.000024101359,0.00021014373,0.0007363944,0.0005630473,0.00005233887,0.00015562779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998308,0.00015057801,0.0004350206,0.00061437977,0.00014711263,0.00034488612],"domain_scores_gemma":[0.99871176,0.000054639746,0.0004108056,0.0006590963,0.00007232882,0.000091340604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028168564,0.00042969594,0.0036609054,0.0004342785,0.00005854887,0.000017776769,0.00027571,0.00032173595,0.000007357021],"category_scores_gemma":[0.00004283234,0.00032209072,0.00067928876,0.00009995166,0.00017943821,0.00015660914,0.00007524762,0.00016811765,0.0000017657179],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008190439,0.00020230869,0.000027954142,0.008988992,0.0064467276,0.0000035692622,0.00015393383,0.0000021744631,0.000003321809,0.0012353457,0.0005728175,0.98228097],"study_design_scores_gemma":[0.0020763825,0.00080165104,0.00077691243,0.0019113439,0.0030492074,0.0000016649212,0.00015189745,0.0000106907955,0.000022813292,0.00089281093,0.99002427,0.00028037038],"about_ca_topic_score_codex":0.000011568498,"about_ca_topic_score_gemma":0.0000016429037,"teacher_disagreement_score":0.9894514,"about_ca_system_score_codex":0.00006287465,"about_ca_system_score_gemma":0.00019065264,"threshold_uncertainty_score":0.9999231},"labels":[],"label_agreement":null},{"id":"W2586052899","doi":"10.2337/dc16-2143","title":"Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Placebo; Postprandial; Glycemic; Internal medicine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Hypoglycemia; Endocrinology; Liraglutide","score_opus":0.01578729879775819,"score_gpt":0.26362159334163426,"score_spread":0.24783429454387607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586052899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182225,0.0037004952,2.1020284e-7,0.0006292202,0.0007916557,0.010685027,0.00003944314,0.000076643715,0.0022550442],"genre_scores_gemma":[0.99597305,0.0008307375,0.000013470366,0.00039726292,0.00021359259,0.0019528219,0.00034047107,0.00007307035,0.00020550773],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973929,0.00031451692,0.00051822816,0.00056779926,0.00047098348,0.0007355759],"domain_scores_gemma":[0.997268,0.00070365693,0.00042909963,0.0012055467,0.00024537282,0.00014830167],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035959933,0.0006137111,0.0017797871,0.00023386428,0.00037144567,0.00022629564,0.00035599756,0.00010389318,0.00006308634],"category_scores_gemma":[0.00032025235,0.00028424794,0.00045511697,0.00015445921,0.0003098272,0.00016424562,0.00007064637,0.00021737989,0.00008317859],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25501022,0.0021390016,0.59768295,0.0000826177,0.0016203289,0.0000065652325,0.0012856805,0.0000074607833,0.000018993092,0.000074764204,0.00021279616,0.14185864],"study_design_scores_gemma":[0.80138284,0.00445782,0.18965285,0.0003852338,0.00055723474,1.6238724e-8,0.00012909493,0.00011789071,0.0013289967,0.000075804426,0.0016141039,0.00029809613],"about_ca_topic_score_codex":0.0000157162,"about_ca_topic_score_gemma":0.00001937068,"teacher_disagreement_score":0.54637265,"about_ca_system_score_codex":0.00022477334,"about_ca_system_score_gemma":0.00009035861,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W2586129535","doi":"10.1111/dom.12902","title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: <scp>H</scp> igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Exenatide; Liraglutide; Medicine; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Gastroenterology; Endocrinology; Insulin glargine; Diabetes mellitus; Urology; Agonist; Receptor","score_opus":0.013362450733565802,"score_gpt":0.2128715142048029,"score_spread":0.19950906347123712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586129535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411213,0.0031294564,0.000003608835,0.00012905501,0.000060981267,0.0016427324,0.00009198084,0.000087332715,0.00074269524],"genre_scores_gemma":[0.9949468,0.0013087922,0.0014443614,0.00018593518,0.000048449296,0.00017950911,0.00023551224,0.00007213759,0.0015785495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971614,0.00009291639,0.00032819083,0.0010338561,0.0004916932,0.0008919282],"domain_scores_gemma":[0.99795854,0.00015274722,0.00036183203,0.00078958407,0.0002500774,0.00048719553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014908549,0.0007780949,0.0012534007,0.0002249999,0.0005046076,0.00033665646,0.00019576278,0.0001232352,0.000015891224],"category_scores_gemma":[0.000043902222,0.00047155836,0.000053425694,0.0002310724,0.00070385257,0.000601462,0.00012775257,0.00021675858,0.000006864015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039565965,0.0009568383,0.9909485,0.0002436296,0.0010647401,0.000047372883,0.00082300254,0.0000041233125,0.00010162435,0.000045959612,0.000056758094,0.0053117755],"study_design_scores_gemma":[0.013594157,0.0049239346,0.9723275,0.0009425675,0.0016453259,0.0000027613492,0.0005439754,0.000062270636,0.0021502562,0.000011269139,0.003412828,0.00038317798],"about_ca_topic_score_codex":0.0005946967,"about_ca_topic_score_gemma":0.000801183,"teacher_disagreement_score":0.01862104,"about_ca_system_score_codex":0.00012317578,"about_ca_system_score_gemma":0.00008864522,"threshold_uncertainty_score":0.9997736},"labels":[],"label_agreement":null},{"id":"W2586360876","doi":"10.1111/dom.12858","title":"Chronic liraglutide therapy induces an enhanced endogenous glucagon‐like peptide‐1 secretory response in early type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Incretin; Medicine; Internal medicine; Endocrinology; Glucagon-like peptide-1; Endogeny; Type 2 diabetes; Context (archaeology); Placebo; Glucagon; Diabetes mellitus; Hormone; Area under the curve; Glucagon-like peptide 1 receptor; Receptor; Agonist; Biology","score_opus":0.025454983720309386,"score_gpt":0.25834506315053946,"score_spread":0.23289007943023007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586360876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98061806,0.016238527,0.0000011591717,0.0002446302,0.0005841817,0.0008797513,0.00001634146,0.00011586837,0.0013014629],"genre_scores_gemma":[0.9950135,0.00259661,0.00016789688,0.0005668512,0.00042516846,0.00010883178,0.000052313164,0.00005457419,0.0010142792],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975709,0.00023764552,0.00034485036,0.00066569535,0.0003244332,0.00085651566],"domain_scores_gemma":[0.9981216,0.00012023813,0.00021897956,0.001087083,0.000111608664,0.00034046997],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008781017,0.00043429426,0.0008227553,0.00031725707,0.0004609665,0.00023623522,0.00037337426,0.00020235912,0.0000811589],"category_scores_gemma":[0.00018308595,0.00037902762,0.00013666472,0.00016224,0.00028610078,0.0007062661,0.0001898741,0.00030804359,0.00006097888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084959564,0.0011052393,0.34816688,0.0001957626,0.00064592395,0.00007465577,0.0026244696,0.0000037755794,0.56470704,0.0003019411,0.00010477459,0.08121994],"study_design_scores_gemma":[0.003592033,0.0011089453,0.84886336,0.00012419814,0.00021078397,5.647847e-7,0.00006081671,0.000024187495,0.13532227,0.0002325468,0.010099105,0.00036119233],"about_ca_topic_score_codex":0.0001390604,"about_ca_topic_score_gemma":0.000054718097,"teacher_disagreement_score":0.5006965,"about_ca_system_score_codex":0.00009914591,"about_ca_system_score_gemma":0.00015604445,"threshold_uncertainty_score":0.9998662},"labels":[],"label_agreement":null},{"id":"W2588151434","doi":"10.1111/dom.12904","title":"Treatment with the glucagon receptor antagonist <scp>LY2409021</scp> increases ambulatory blood pressure in patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Internal medicine; Placebo; Blood pressure; Ambulatory blood pressure; Endocrinology; Type 2 diabetes; Glycemic; Glycated hemoglobin; Crossover study; Lipid profile; Mean arterial pressure; Ambulatory; Diabetes mellitus; Gastroenterology; Insulin; Heart rate","score_opus":0.00583972582482539,"score_gpt":0.20114962719925142,"score_spread":0.19530990137442603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588151434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999107,0.007050048,1.905452e-7,0.00021458759,0.00013766582,0.0012146105,0.000065759676,0.00006839134,0.0012576611],"genre_scores_gemma":[0.99665266,0.0006325056,0.0001812275,0.00029825035,0.00015075158,0.00012946135,0.00016945135,0.000046386147,0.0017392829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981781,0.00008531524,0.00020784813,0.00053954765,0.00036669878,0.0006224787],"domain_scores_gemma":[0.9983875,0.00012323717,0.00023271683,0.0008872377,0.00013496223,0.00023430781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017887497,0.00045154706,0.0007232915,0.00012784153,0.0005516142,0.00023069249,0.00023206357,0.00011081399,0.000023725033],"category_scores_gemma":[0.00008106616,0.0002486725,0.00008083547,0.00013996221,0.00038506635,0.00033767702,0.000138383,0.00016465802,0.000018908038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072467585,0.0019991372,0.98944443,0.00012080549,0.0016115707,0.000009053914,0.00021291133,0.0000014275665,0.00031554417,0.00012838036,0.00031340052,0.005770863],"study_design_scores_gemma":[0.0076263375,0.001314003,0.93967754,0.00014214353,0.003801634,2.8607457e-7,0.00007618334,0.000011653728,0.006774561,0.000019605488,0.04040045,0.00015559193],"about_ca_topic_score_codex":0.00016277684,"about_ca_topic_score_gemma":0.00005796997,"teacher_disagreement_score":0.049766887,"about_ca_system_score_codex":0.000026829332,"about_ca_system_score_gemma":0.00006555839,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W2588615098","doi":"10.1016/j.ahj.2017.02.005","title":"Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","year":2017,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Medicine; Internal medicine; Myocardial infarction; Placebo; Exenatide; Stroke (engine); Heart failure; Sitagliptin; Diabetes mellitus; Dulaglutide; Coronary artery disease; Randomized controlled trial; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology","score_opus":0.017382529602164937,"score_gpt":0.2890095629359575,"score_spread":0.27162703333379257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588615098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988592,0.00009098303,0.0000357238,0.00019425486,0.00011281693,0.00047146648,0.0000029353514,0.0000028318989,0.0002297398],"genre_scores_gemma":[0.9995028,0.00013280942,0.00013862932,0.000088852605,0.00007754021,0.000012006232,0.000002853139,0.000010348215,0.00003418324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986868,0.00011952147,0.00042014403,0.0001089569,0.00050077576,0.00016383818],"domain_scores_gemma":[0.9988672,0.000055745208,0.0003596559,0.00053144625,0.00012809742,0.00005781855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008926103,0.00010248036,0.0005871863,0.000109792905,0.00009640091,0.000022805998,0.00016997785,0.00001033762,0.000020530288],"category_scores_gemma":[0.00022040629,0.00006608674,0.00022631619,0.000079215926,0.00008487955,0.00006019875,0.00006059417,0.00014043658,0.0000020351267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001435217,0.0021158922,0.9427617,0.000026091911,0.0007379683,0.00006588971,0.0009019825,0.000025966872,0.000047902868,9.786246e-7,0.0001630984,0.053009],"study_design_scores_gemma":[0.0028971434,0.0019728292,0.9911406,0.00008745674,0.00040841356,0.000005429352,0.0011464608,0.00004200703,0.00010593895,0.0000026824985,0.0021351324,0.000055924233],"about_ca_topic_score_codex":0.00026049008,"about_ca_topic_score_gemma":0.000009840024,"teacher_disagreement_score":0.052953076,"about_ca_system_score_codex":0.00003831336,"about_ca_system_score_gemma":0.000028109973,"threshold_uncertainty_score":0.2694939},"labels":[],"label_agreement":null},{"id":"W2588739214","doi":"10.1159/000454683","title":"Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials","year":2017,"lang":"en","type":"review","venue":"˜The œNephron journals/Nephron journals","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital; University of Manitoba; Orthopaedic Innovation Centre","funders":"","keywords":"Medicine; Internal medicine; Kidney disease; Renal function; Adverse effect; Placebo; Diabetes mellitus; Population; Relative risk; Dialysis; Hypoglycemia; Randomized controlled trial; Type 2 diabetes; Gastroenterology; Endocrinology; Insulin; Confidence interval; Pathology","score_opus":0.17021662540779944,"score_gpt":0.47110205789977466,"score_spread":0.3008854324919752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588739214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000052852174,0.96923053,0.00009175669,0.0025912975,0.0015679981,0.025102928,0.00018569456,0.00007358465,0.0011509323],"genre_scores_gemma":[0.000065624794,0.98612577,0.000098914126,0.0020715026,0.0035475118,0.002307628,0.00021879646,0.0003183223,0.005245916],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.94420654,0.027490675,0.022121,0.0013155859,0.003215779,0.001650401],"domain_scores_gemma":[0.95569384,0.00885533,0.028037146,0.0041008405,0.00082735904,0.0024854746],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.11626755,0.0022499918,0.038929824,0.0018815286,0.0005057405,0.00064053497,0.0023462814,0.0008796675,0.0031090744],"category_scores_gemma":[0.03089646,0.0012038033,0.01686448,0.0010369611,0.00095618854,0.00060014887,0.0005874755,0.0036081735,0.0004757083],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019546854,0.00070176553,0.000016865795,0.7550532,0.011014127,0.0005678433,0.000047599046,0.000001054474,0.0000014402672,0.00003096652,0.04904857,0.18156186],"study_design_scores_gemma":[0.034305897,0.00023450388,0.000009567918,0.5448202,0.05418883,0.00020480083,0.000020235206,0.000020696716,4.166248e-7,0.00007914574,0.36555025,0.0005654477],"about_ca_topic_score_codex":0.000017036316,"about_ca_topic_score_gemma":0.00001430293,"teacher_disagreement_score":0.31650168,"about_ca_system_score_codex":0.002019351,"about_ca_system_score_gemma":0.005731179,"threshold_uncertainty_score":0.9999054},"labels":[],"label_agreement":null},{"id":"W2588781544","doi":"10.22374/1710-6222.24.1.2","title":"Lack of Health-Related Quality of Life and Patient-Centered Outcome Measures in RCTs Conducted for Diabetes Pharmacotherapy: SGLT-2 receptor inhibitors as an example","year":2017,"lang":"en","type":"review","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Quality of life (healthcare); Pharmacotherapy; Hypoglycemia; Diabetes mellitus; MEDLINE; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.5840562822708415,"score_gpt":0.5592030692017719,"score_spread":0.024853213069069624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588781544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4442508,0.55288213,0.0000019741176,0.0006624892,0.00097377965,0.0011879686,0.000030670137,0.000005240236,0.0000049551672],"genre_scores_gemma":[0.20273921,0.79574525,0.00017620479,0.0010272807,0.00015150131,0.000014650821,0.00008937487,0.000034543016,0.000021992804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99375314,0.0011654112,0.004350742,0.00026651568,0.00023829415,0.00022591178],"domain_scores_gemma":[0.9927783,0.00071314716,0.0058571054,0.00017316056,0.00026058248,0.00021770074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028207903,0.00027859551,0.0033616095,0.0002860468,0.000054215147,0.000013982245,0.00012889133,0.00028506966,0.000045739485],"category_scores_gemma":[0.00018123527,0.00020320882,0.00046518716,0.000090981724,0.00016971855,0.00011171777,0.00003858105,0.0003744107,3.8966135e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008158565,0.0015746874,0.06768027,0.0044751163,0.0031258042,0.0000013766207,0.00015447217,9.021008e-7,0.0001244177,0.000050609415,0.00021249839,0.921784],"study_design_scores_gemma":[0.035447475,0.013070203,0.04286243,0.0046767527,0.0070647774,0.000006153843,0.00015907643,0.000088883826,0.000082573824,0.0007870289,0.8951537,0.0006009446],"about_ca_topic_score_codex":0.00010132084,"about_ca_topic_score_gemma":0.00001235521,"teacher_disagreement_score":0.92118305,"about_ca_system_score_codex":0.0000687266,"about_ca_system_score_gemma":0.0001852517,"threshold_uncertainty_score":0.8286615},"labels":[],"label_agreement":null},{"id":"W2589079421","doi":"10.1093/ndt/gfw168.01","title":"SP374CANAGLIFLOZIN, A SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT-2) BLOCKER, NORMALIZES BLOOD GLUCOSE WITHOUT AFFECTING SYSTEMIC BLOOD PRESSURE, OXIDATIVE STRESS, INTRARENAL ANGIOTENSINOGEN GENE EXPRESSION AND KIDNEY INJURY IN TYPE 1 DIABETIC MICE","year":2016,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oxidative stress; Blood pressure; Internal medicine; Endocrinology; Type 2 diabetes; Transporter; Diabetes mellitus; Kidney; Gene; Biochemistry","score_opus":0.006329337626800737,"score_gpt":0.22830970658838967,"score_spread":0.22198036896158893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589079421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532926,0.0022388932,0.00030067755,0.00030380956,0.00013305967,0.0011655842,0.00030548853,0.000139172,0.00008406543],"genre_scores_gemma":[0.9921308,0.004828511,0.0011266643,0.00052673614,0.00016725236,0.00012072213,0.00095605507,0.00005589182,0.00008732796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99733204,0.00030679657,0.0006314805,0.0007838465,0.00034241984,0.00060339575],"domain_scores_gemma":[0.99880505,0.00014798663,0.00026790463,0.0003661208,0.0001352851,0.00027762703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032923828,0.00046564455,0.0008166622,0.0005279408,0.00012099818,0.000034299494,0.00013716971,0.00031148584,0.00009096014],"category_scores_gemma":[0.00004773186,0.00034954256,0.00014325124,0.00035566656,0.00018587134,0.00032636058,0.000023600205,0.00019585618,0.000016491847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016299288,0.00050277694,0.3398111,0.0004779694,0.0018443387,0.00022917046,0.0011766783,0.000007601026,0.6524967,0.000008477502,0.00008022798,0.0017350641],"study_design_scores_gemma":[0.011635084,0.00091624114,0.12795262,0.001066646,0.015624926,0.00009670975,0.000057840007,0.000065526656,0.84196544,0.000022632434,0.00017013312,0.00042622318],"about_ca_topic_score_codex":0.00015298216,"about_ca_topic_score_gemma":0.00015671102,"teacher_disagreement_score":0.21185847,"about_ca_system_score_codex":0.000034588043,"about_ca_system_score_gemma":0.00009173953,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W2589800818","doi":"10.9778/cmajo.20160058","title":"Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); University Health Network","funders":"St. Jude Medical; Servier; Eisai; Regado Biosciences; Novo Nordisk; Medicines Company; Amarin Corporation; Boston Scientific Corporation; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Meta-analysis; Dipeptidyl peptidase-4; Heart failure; Medicine; Dipeptidyl peptidase; Systematic review; Internal medicine; MEDLINE; Diabetes mellitus; Type 2 diabetes; Endocrinology; Chemistry; Biochemistry; Enzyme","score_opus":0.1004140709211837,"score_gpt":0.3733832861008448,"score_spread":0.2729692151796611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589800818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.8826705e-7,0.98376065,0.0000016749017,0.0010398724,0.0000144631085,0.013751524,0.00007374997,0.0000097493175,0.0013476328],"genre_scores_gemma":[0.000029919882,0.9884248,0.00024010033,0.00027879656,0.000018571329,0.0021011352,0.00007829159,0.00003145354,0.008796968],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973544,0.00069050584,0.0010197486,0.00047085393,0.00027781213,0.00018666152],"domain_scores_gemma":[0.99625015,0.0003724073,0.0014688739,0.0017180546,0.00007146577,0.00011904344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025844374,0.00046905,0.013409587,0.00017548694,0.00014547043,0.00020594553,0.00046536422,0.000101660524,0.00017365426],"category_scores_gemma":[0.00043100474,0.00019728557,0.0024712335,0.0002826774,0.0002335356,0.00011523213,0.00072599796,0.00019370398,0.00003732776],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003031026,0.000035153662,0.000017818837,0.7108447,0.2809006,0.0000037716575,0.000027884567,7.478742e-9,2.9551204e-9,0.00011397242,0.00521555,0.0028375422],"study_design_scores_gemma":[0.0003761249,0.000038732178,0.0000045299375,0.0488417,0.6665282,0.0000057260563,0.00001214267,3.1000388e-7,6.846344e-8,0.000011580466,0.28406584,0.00011503383],"about_ca_topic_score_codex":0.00029840972,"about_ca_topic_score_gemma":0.000085956504,"teacher_disagreement_score":0.662003,"about_ca_system_score_codex":0.00002803111,"about_ca_system_score_gemma":0.000055288423,"threshold_uncertainty_score":0.9166525},"labels":[],"label_agreement":null},{"id":"W2590240054","doi":"10.1016/s1957-2557(17)30015-9","title":"Comparaison d’une intensification de l’insulinothérapie par l’ajout progressif de bolus prandiaux d’insuline asparte par rapport au schéma basal-bolus : résultats de l’étude FullSTEP, un essai clinique randomisé de phase IV en titration forcée","year":2017,"lang":"fr","type":"article","venue":"Médecine des Maladies Métaboliques","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bolus (digestion); Gynecology; Internal medicine","score_opus":0.03241511333846984,"score_gpt":0.34050184791268717,"score_spread":0.3080867345742173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590240054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9208247,0.017914673,0.03346421,0.016628224,0.0011364575,0.004077164,0.00019013604,0.0005323788,0.005232052],"genre_scores_gemma":[0.9479696,0.021025479,0.021487981,0.00162607,0.0027040532,0.0012251312,0.00068891933,0.00022552838,0.0030472307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924018,0.0011173068,0.001867599,0.001256471,0.0006356835,0.0027211853],"domain_scores_gemma":[0.99406,0.00066552527,0.0015596703,0.0016905759,0.0008413684,0.0011828743],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0048980727,0.0012604722,0.0021136801,0.00045500317,0.0014957144,0.0005999252,0.000891247,0.0007485871,0.00025146344],"category_scores_gemma":[0.002333411,0.0012367243,0.00059156836,0.00036425175,0.0013981723,0.0010595956,0.0002892542,0.0009022189,0.000099724195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019673865,0.01188206,0.5942421,0.0031372518,0.004333945,0.001410703,0.016010048,0.00030347696,0.010610725,0.005905602,0.016664712,0.31582555],"study_design_scores_gemma":[0.079295404,0.0028204846,0.7953778,0.0037830488,0.004784996,0.00016927581,0.0013191799,0.037338883,0.03927007,0.0067146732,0.027657771,0.0014683878],"about_ca_topic_score_codex":0.001215064,"about_ca_topic_score_gemma":0.00088787073,"teacher_disagreement_score":0.31435716,"about_ca_system_score_codex":0.0014107014,"about_ca_system_score_gemma":0.0016154811,"threshold_uncertainty_score":0.9998042},"labels":[],"label_agreement":null},{"id":"W2590664415","doi":"10.1016/s0140-6736(17)30069-7","title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":844,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prediabetes; Liraglutide; Medicine; Placebo; Type 2 diabetes; Diabetes mellitus; Internal medicine; Weight loss; Weight management; Endocrinology; Obesity; Alternative medicine","score_opus":0.05654559697299896,"score_gpt":0.31622443820126966,"score_spread":0.2596788412282707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590664415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082065,0.0003181627,0.0000030370231,0.0006722333,0.00032689876,0.0041003255,0.000016475133,0.000019776711,0.0037224684],"genre_scores_gemma":[0.9960564,0.00073423324,0.0014059197,0.000025297437,0.00048002225,0.0005671068,0.000032513144,0.00001834354,0.00068017445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992014,0.000034169127,0.00017739882,0.0001925216,0.00015824828,0.00023622712],"domain_scores_gemma":[0.9990557,0.00012775969,0.00021971989,0.0005346963,0.00002549714,0.000036646896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006604422,0.000115050505,0.0004315064,0.00008350017,0.00008613847,0.000047375583,0.00016229738,0.00003889039,0.000009456358],"category_scores_gemma":[0.00006681567,0.00007474696,0.000043554373,0.00006308732,0.00011779687,0.000085725624,0.000073352996,0.0000776904,0.0000030468952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92726153,0.0002650083,0.029004809,0.00027134188,0.0021323934,0.000004293755,0.00047077428,0.000018992403,0.000030200921,0.0005222804,0.004239675,0.03577872],"study_design_scores_gemma":[0.95961165,0.0016196552,0.029164333,0.00017883291,0.0013620293,2.3247571e-7,0.00010975512,0.00008052817,0.0006164749,0.00034602257,0.0068018814,0.00010862691],"about_ca_topic_score_codex":0.000014822962,"about_ca_topic_score_gemma":0.000011453127,"teacher_disagreement_score":0.03567009,"about_ca_system_score_codex":0.000025868274,"about_ca_system_score_gemma":0.000014684173,"threshold_uncertainty_score":0.30480924},"labels":[],"label_agreement":null},{"id":"W2591702989","doi":"10.1177/1479164116679775","title":"Gaps and barriers in the control of blood glucose in people with type 2 diabetes","year":2017,"lang":"en","type":"review","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"McGill University; AstraZeneca","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Type 1 diabetes; Internal medicine; Gerontology; Endocrinology","score_opus":0.042019083935074183,"score_gpt":0.35085096771521795,"score_spread":0.30883188378014376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591702989","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12876016,0.86852026,8.2663256e-8,0.00008872509,0.000015579926,0.0023728034,0.000039598723,0.0000069161465,0.0001958658],"genre_scores_gemma":[0.1083942,0.8907829,0.0000066701073,0.00003274549,0.000035876572,0.000536013,0.00011536425,0.000039278522,0.00005697128],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972154,0.0005577687,0.00034718323,0.00052579143,0.00066974154,0.0006841006],"domain_scores_gemma":[0.9980404,0.00047860638,0.00011234257,0.0008780174,0.00011244473,0.00037818454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020068313,0.0003400511,0.001538707,0.000560165,0.00013051699,0.00012066416,0.00028114603,0.000121268815,0.000025047164],"category_scores_gemma":[0.00046433118,0.00019333899,0.00022289433,0.0004965164,0.00036516768,0.00008662081,0.00016060697,0.0004379803,0.0000041557514],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073951705,0.0008232912,0.4605441,0.065292716,0.0031155823,0.00016431307,0.00026575493,6.0456733e-7,0.0000024104827,0.0003228336,0.00011903732,0.4692754],"study_design_scores_gemma":[0.01276548,0.002304393,0.20091538,0.054191496,0.016423956,0.0000017059215,0.0004633411,0.00020059686,0.0000068135196,0.00027368646,0.7115254,0.0009277862],"about_ca_topic_score_codex":0.00003849523,"about_ca_topic_score_gemma":0.00004379356,"teacher_disagreement_score":0.71140635,"about_ca_system_score_codex":0.0000379047,"about_ca_system_score_gemma":0.00035494924,"threshold_uncertainty_score":0.78841347},"labels":[],"label_agreement":null},{"id":"W2591734061","doi":"","title":"Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs","year":2016,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Glucagon; Internal medicine; Endocrinology; Insulin; Medicine; Chemistry","score_opus":0.013817410005409744,"score_gpt":0.24093271262324586,"score_spread":0.22711530261783613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591734061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745864,0.0003324859,0.01900828,0.0019440594,0.00008068534,0.0007713364,0.000037732618,0.000039067025,0.0031999222],"genre_scores_gemma":[0.9966743,0.00046234278,0.0012096233,0.00019109664,0.00004072481,0.00006985555,0.00004711831,0.000024055078,0.0012808632],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99864525,0.000033807497,0.00040612885,0.0003554705,0.00026747305,0.0002918808],"domain_scores_gemma":[0.999206,0.00017161762,0.0001280814,0.00030877488,0.00009813083,0.00008738277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023924526,0.00023328776,0.0003366329,0.00018261911,0.000038790753,0.000022850798,0.00008805438,0.00009899113,0.000045280583],"category_scores_gemma":[0.00003372741,0.0001275948,0.000081445316,0.00022579379,0.0001274916,0.00014167324,0.00006517998,0.000098423145,0.000008965058],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042119574,0.016549604,0.10666415,0.0026445661,0.0048330035,0.0024018122,0.013642597,0.005151872,0.07722614,0.22811761,0.00043745604,0.5002116],"study_design_scores_gemma":[0.034958,0.014026374,0.047485795,0.003068203,0.0025283776,0.00036284982,0.005307258,0.75044566,0.1265851,0.009622851,0.0034126046,0.002196936],"about_ca_topic_score_codex":0.00035627853,"about_ca_topic_score_gemma":0.0012242105,"teacher_disagreement_score":0.7452938,"about_ca_system_score_codex":0.00019469553,"about_ca_system_score_gemma":0.00006776938,"threshold_uncertainty_score":0.5203165},"labels":[],"label_agreement":null},{"id":"W2591840752","doi":"10.1016/j.jcjd.2017.08.241","title":"The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Glycated hemoglobin; Hypoglycemia; Type 2 diabetes; Insulin; Internal medicine; Blood pressure; Endocrinology; Diabetes mellitus","score_opus":0.025672901371429295,"score_gpt":0.27387586620683024,"score_spread":0.24820296483540094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591840752","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014523014,0.9791823,3.6247343e-8,0.00017088676,0.00049583195,0.00087919435,0.00003503304,0.000002456962,0.004711247],"genre_scores_gemma":[0.056792986,0.9424931,0.000044391832,0.00005621273,0.00017796841,0.0000329806,0.000039200328,0.000047216196,0.00031595796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975901,0.00012132527,0.0011644923,0.0001795627,0.00039524233,0.00054923154],"domain_scores_gemma":[0.9973619,0.00018817837,0.0012625417,0.0007340941,0.00018418588,0.0002691048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010884332,0.00035953414,0.0016281434,0.00051098346,0.00012547227,0.00006212061,0.00089218887,0.00015081151,0.00003435889],"category_scores_gemma":[0.00005015011,0.00019163515,0.00068481517,0.0003066495,0.00031842635,0.000097177355,0.00003057014,0.00038820214,0.000007655789],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035114297,0.00008159397,0.016614314,0.0065496936,0.0021698894,0.000058172194,0.00015943892,3.348589e-7,0.0000012050159,0.00037619768,0.0012726188,0.97271305],"study_design_scores_gemma":[0.0005409834,0.000388525,0.0036812224,0.019238725,0.004046372,0.0000014099038,0.00024692077,0.0000012415575,0.00004879821,0.00020013783,0.9714422,0.00016345081],"about_ca_topic_score_codex":0.00011236819,"about_ca_topic_score_gemma":0.0009177126,"teacher_disagreement_score":0.97254956,"about_ca_system_score_codex":0.0001513584,"about_ca_system_score_gemma":0.00068835786,"threshold_uncertainty_score":0.7814655},"labels":[],"label_agreement":null},{"id":"W2591971201","doi":"10.1016/j.ejcb.2017.03.004","title":"Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors","year":2017,"lang":"en","type":"article","venue":"European Journal of Cell Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Institutes of Health; Crohn's and Colitis Canada; Natural Sciences and Engineering Research Council of Canada; University of British Columbia","keywords":"Microglia; Incretin; Internal medicine; Endocrinology; Neurotrophic factors; Neurotrophin; Biology; Glial cell line-derived neurotrophic factor; Growth factor; Downregulation and upregulation; Nerve growth factor; Hormone; Receptor; Gastric inhibitory polypeptide; Brain-derived neurotrophic factor; Cell biology; Glucagon; Inflammation; Diabetes mellitus; Medicine; Type 2 diabetes; Biochemistry","score_opus":0.01859420031906367,"score_gpt":0.24794689918238974,"score_spread":0.22935269886332607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591971201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901742,0.00073290546,0.00002363584,0.0001693281,0.00018232041,0.000077394514,0.000008167387,0.0000041845938,0.008627868],"genre_scores_gemma":[0.9981268,0.0005896048,0.00060801965,0.000011377678,0.00009647669,1.4002266e-7,0.000009464267,0.000013189344,0.00054494484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915737,0.00023454808,0.00029673713,0.00011037319,0.0000731595,0.00012783163],"domain_scores_gemma":[0.9989101,0.00004245935,0.0006666597,0.00021447412,0.0000808903,0.00008540705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035202337,0.00011548083,0.00033322515,0.00008434087,0.00006997278,0.000015215495,0.00015689388,0.000025512662,0.000032464148],"category_scores_gemma":[0.00006867643,0.000072950905,0.00007580561,0.000015023126,0.00019836288,0.00006296405,0.00013216742,0.00010708909,0.0000044208923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030059883,0.000102101076,0.088333145,0.00004181991,0.00010332898,0.00011343018,0.00020177217,4.555472e-7,0.9068639,0.000032681135,0.00021981027,0.0036869075],"study_design_scores_gemma":[0.0024158065,0.0019109265,0.4218447,0.00013990352,0.0001626618,0.0000053200756,0.0002216731,0.0000015885547,0.5696294,0.00004176047,0.003545358,0.000080937556],"about_ca_topic_score_codex":0.0000045335996,"about_ca_topic_score_gemma":5.2731343e-7,"teacher_disagreement_score":0.33723456,"about_ca_system_score_codex":0.000008786299,"about_ca_system_score_gemma":0.000011473613,"threshold_uncertainty_score":0.29748514},"labels":[],"label_agreement":null},{"id":"W2594469475","doi":"10.5430/jha.v6n2p59","title":"Factors associated with physician prescribing behavior of dipeptidyl peptidase-4 inhibitors for type 2 diabetes in the US outpatient population","year":2017,"lang":"en","type":"article","venue":"Journal of Hospital Administration","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Medicaid; Logistic regression; Family medicine; Odds; Odds ratio; Ambulatory care; Population; Context (archaeology); Multivariate analysis; Ambulatory; Medical prescription; Cross-sectional study; Diabetes mellitus; Primary care physician; Health care; Internal medicine; Primary care; Nursing; Endocrinology; Environmental health","score_opus":0.04088609055223072,"score_gpt":0.2966518794380136,"score_spread":0.25576578888578283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594469475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986686,0.000020507885,0.0000032165985,0.0002247472,0.0002217629,0.000670488,0.000008944513,0.000003963167,0.00017773805],"genre_scores_gemma":[0.9996806,0.0000019489048,0.0000567695,0.000017349048,0.00008855506,0.000015900137,0.00008866429,0.000010247365,0.00003998415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913853,0.000021731237,0.00033855657,0.000082949045,0.00029627394,0.00012194837],"domain_scores_gemma":[0.99873114,0.000045536402,0.0008497744,0.00014887357,0.0001898685,0.00003483492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020739442,0.00010883737,0.00023518801,0.00006942902,0.00008807477,0.000058246525,0.000093844996,0.00004280181,0.0000020849245],"category_scores_gemma":[0.00018490641,0.00006384795,0.000100268226,0.000052406096,0.000035198136,0.00031705562,0.000010198463,0.00008516765,2.2662508e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008398387,0.0014867253,0.9965195,0.000029446812,0.00009545036,0.0000054521806,0.00030362906,0.000006759361,0.0003196243,0.000056603672,0.000101662125,0.0009911368],"study_design_scores_gemma":[0.0012033461,0.017452605,0.9749147,0.00030733203,0.00038291485,1.5878855e-7,0.0004635131,0.000037257236,0.0051128357,0.00003913842,0.000017109498,0.00006907839],"about_ca_topic_score_codex":0.00000848568,"about_ca_topic_score_gemma":0.00004086053,"teacher_disagreement_score":0.021604815,"about_ca_system_score_codex":0.000075412216,"about_ca_system_score_gemma":0.00003819292,"threshold_uncertainty_score":0.26036435},"labels":[],"label_agreement":null},{"id":"W2594728560","doi":"10.2337/dc16-0984","title":"Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Sitagliptin; Exenatide; Placebo; Internal medicine; Gastroenterology; Acute pancreatitis; Insulin glargine; Type 2 diabetes; Metformin; Diabetes mellitus; Hypoglycemia; Endocrinology; Insulin","score_opus":0.017764906383187562,"score_gpt":0.3043594013106409,"score_spread":0.2865944949274533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594728560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96670634,0.00027601517,0.0000020847456,0.00051484245,0.00012933,0.0013846782,0.000037331283,0.000029069195,0.030920297],"genre_scores_gemma":[0.99250007,0.000050714894,0.006486311,0.00008038553,0.00004185165,0.00027912203,0.00029288125,0.000018227314,0.00025042208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850386,0.000055530716,0.0004353755,0.0002509622,0.00042337982,0.00033090173],"domain_scores_gemma":[0.99863344,0.000065178,0.00030117258,0.0007937158,0.00014185366,0.00006464871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003564345,0.00019216743,0.00047699362,0.00008457636,0.00014571565,0.00004032048,0.00035847435,0.00006220608,0.000044455795],"category_scores_gemma":[0.000072516865,0.00013169208,0.00013010124,0.00010014229,0.00016292236,0.00008016491,0.00014260192,0.00011223095,0.000013821051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021131737,0.00059430447,0.83449227,0.000503539,0.00019206817,0.000003922816,0.000994035,0.0000016633198,0.00050222006,0.00040904118,0.00034263337,0.16194315],"study_design_scores_gemma":[0.001631053,0.00053721084,0.9527013,0.00046645134,0.00016117905,9.224435e-8,0.0019317215,0.000026348214,0.0061417776,0.000014333806,0.036264893,0.00012365996],"about_ca_topic_score_codex":0.00003694118,"about_ca_topic_score_gemma":0.00007769999,"teacher_disagreement_score":0.1618195,"about_ca_system_score_codex":0.00016644796,"about_ca_system_score_gemma":0.00017594431,"threshold_uncertainty_score":0.53702474},"labels":[],"label_agreement":null},{"id":"W2595010755","doi":"10.1016/s2213-8587(17)30087-6","title":"Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute","keywords":"Enalapril; Sacubitril, Valsartan; Sacubitril; Medicine; Valsartan; Internal medicine; Diabetes mellitus; Type 2 diabetes; Heart failure; Post-hoc analysis; Endocrinology; Ejection fraction; ACE inhibitor; Cardiology; Angiotensin-converting enzyme; Blood pressure","score_opus":0.01004263881300927,"score_gpt":0.261315251005856,"score_spread":0.25127261219284674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595010755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902784,0.00056779437,5.081441e-7,0.006841592,0.0002079747,0.0017696251,0.000120009776,0.000037189973,0.00017688735],"genre_scores_gemma":[0.99815786,0.000049462134,0.000023987015,0.0011532682,0.00022391664,0.00023177112,0.0001130161,0.000024947522,0.000021794776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975603,0.00043016832,0.00032356672,0.00044209877,0.00029584963,0.0009479751],"domain_scores_gemma":[0.99614763,0.0020497944,0.00030298243,0.0013753197,0.000047016692,0.00007723471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046972727,0.00034316588,0.0017566311,0.00015746173,0.0001924635,0.000060288647,0.00044374057,0.00008161497,0.000039162882],"category_scores_gemma":[0.00028754107,0.00017104653,0.00020263913,0.00017566427,0.00043460852,0.00008490878,0.0001310629,0.00030270763,0.000015673568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04860182,0.00020803293,0.9439948,0.000034448913,0.0032560136,0.000006370903,0.000056437722,0.0000092925775,0.00015497916,0.00013496575,0.00049380265,0.0030490411],"study_design_scores_gemma":[0.15883753,0.016302789,0.81637055,0.00010744611,0.005188469,1.08779034e-7,0.000024019719,0.00009577925,0.001027087,0.00006573517,0.001787992,0.0001925192],"about_ca_topic_score_codex":0.00010323736,"about_ca_topic_score_gemma":0.00020127543,"teacher_disagreement_score":0.12762426,"about_ca_system_score_codex":0.000058786805,"about_ca_system_score_gemma":0.000023951998,"threshold_uncertainty_score":0.6975075},"labels":[],"label_agreement":null},{"id":"W2595853302","doi":"10.1016/j.cmet.2017.02.008","title":"The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice","year":2017,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Ethicon Endo-Surgery; Canadian Institutes of Health Research; Canada Research Chairs; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi","keywords":"Glucose homeostasis; Internal medicine; Endocrinology; Enteroendocrine cell; Islet; Homeostasis; Glucagon-like peptide-1; Biology; Glucagon; Pancreatic islets; Glucose tolerance test; Blood sugar regulation; Antagonist; Type 2 diabetes; Endocrine system; Insulin; Diabetes mellitus; Medicine; Receptor; Insulin resistance; Hormone","score_opus":0.00913281535809707,"score_gpt":0.24393790961351686,"score_spread":0.2348050942554198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595853302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9350901,0.031182293,6.7174994e-7,0.00023732426,0.00011526149,0.00050927774,0.0000019644203,0.0000095793885,0.03285353],"genre_scores_gemma":[0.9942436,0.0035316572,0.0002146276,0.000034547,0.000039706847,0.00007399858,0.0000042328093,0.000012586235,0.0018450232],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991945,0.000037130103,0.0002213659,0.00018031205,0.00013942205,0.00022726599],"domain_scores_gemma":[0.9991095,0.000050981336,0.00013485091,0.000636258,0.000023362296,0.000045040073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033089123,0.0001070435,0.000302081,0.00009001637,0.000065201166,0.000032193566,0.00020189957,0.00003819827,0.000018407523],"category_scores_gemma":[0.000095188225,0.00007187463,0.00006368841,0.00007430979,0.000070566144,0.000081297665,0.00010000432,0.000080788646,0.000031471518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003718836,0.0014467726,0.20373851,0.00024861397,0.00020439868,0.000053580003,0.0018735549,0.0000062223335,0.0439388,0.003802837,0.00026845842,0.7440464],"study_design_scores_gemma":[0.003146886,0.000061325634,0.67278606,0.00009540508,0.0002817378,4.5225988e-7,0.0005695401,0.000107281325,0.24956806,0.0016165113,0.071660705,0.00010604335],"about_ca_topic_score_codex":0.00037328727,"about_ca_topic_score_gemma":0.00012280206,"teacher_disagreement_score":0.7439403,"about_ca_system_score_codex":0.000024696697,"about_ca_system_score_gemma":0.000024734223,"threshold_uncertainty_score":0.29309624},"labels":[],"label_agreement":null},{"id":"W2598091122","doi":"10.14740/jocmr3004w","title":"What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hemoglobin; Cotransporter; Body weight; Sodium; Endocrinology; Pharmacology; Diabetes mellitus; Internal medicine; Chemistry","score_opus":0.15077457553046103,"score_gpt":0.4497246248034717,"score_spread":0.29895004927301067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598091122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95087606,0.00462284,0.0000017879368,0.042372186,0.0007362819,0.00066062814,4.957839e-7,0.0000028209995,0.0007269106],"genre_scores_gemma":[0.98016214,0.017404268,0.0000601923,0.00030114048,0.0010524781,0.000012731019,9.293477e-7,0.000014699966,0.0009913996],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99628985,0.00020616512,0.0016651704,0.00021135592,0.0012678612,0.00035956982],"domain_scores_gemma":[0.99745744,0.0005321195,0.00064019323,0.00056460145,0.00051989267,0.00028572962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008679513,0.00015021738,0.00091286405,0.00028291627,0.00012392645,0.00005860748,0.00037896863,0.00010192622,0.000058228175],"category_scores_gemma":[0.0016957836,0.00006901068,0.00016281045,0.00011186103,0.0013881307,0.00036038714,0.0001725699,0.00084944913,0.0000031926575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045884517,0.0021589645,0.4208848,0.0009854169,0.00076445844,0.0009532587,0.0011499976,2.0293402e-7,0.030946575,0.00013882507,0.0062349904,0.5311941],"study_design_scores_gemma":[0.040124085,0.029145446,0.8003953,0.017682074,0.00089796056,0.00008308599,0.0043788683,0.0003680946,0.074551694,0.0013697926,0.030722944,0.00028065138],"about_ca_topic_score_codex":0.00008151873,"about_ca_topic_score_gemma":0.000045711004,"teacher_disagreement_score":0.5309134,"about_ca_system_score_codex":0.000050920695,"about_ca_system_score_gemma":0.00018553965,"threshold_uncertainty_score":0.5114625},"labels":[],"label_agreement":null},{"id":"W2598553007","doi":"10.2337/dc16-1771","title":"Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Insulin aspart; Medicine; Postprandial; Glycemic; Insulin detemir; Clinical endpoint; Internal medicine; Type 2 diabetes; Randomized controlled trial; Crossover study; Diabetes mellitus; Type 1 diabetes; Endocrinology; Insulin; Gastroenterology; Placebo; Insulin glargine","score_opus":0.024347347289387374,"score_gpt":0.2938112519996245,"score_spread":0.2694639047102371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598553007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97624606,0.0016825615,0.000045660734,0.0007219775,0.0008846858,0.018000167,0.00075856555,0.00012887444,0.0015314278],"genre_scores_gemma":[0.99011886,0.00017361788,0.0020321563,0.00037409528,0.0003389086,0.0055978326,0.0006365526,0.00012234374,0.00060561486],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959784,0.0002720115,0.0013149318,0.00094172807,0.00038684165,0.001106098],"domain_scores_gemma":[0.9955201,0.0016691396,0.000969305,0.0011771385,0.00032640368,0.00033791948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066879415,0.00074772065,0.0032787826,0.00043656072,0.00027027054,0.00013488666,0.00037234626,0.00023327685,0.000021233338],"category_scores_gemma":[0.0025268537,0.00057108223,0.0009932332,0.00015867194,0.000191206,0.0002859701,0.000117878895,0.00018129837,0.000050532784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92790663,0.0021799053,0.010083058,0.00035597084,0.0023633917,0.00002349164,0.0017238021,0.00008206512,0.0022568328,0.000012580126,0.00033221644,0.052680068],"study_design_scores_gemma":[0.9691045,0.0113305785,0.004333015,0.0005414885,0.0021908234,1.4856509e-7,0.0009966993,0.005357968,0.0036189794,0.00004669264,0.001991178,0.00048787062],"about_ca_topic_score_codex":0.0001670377,"about_ca_topic_score_gemma":0.00011747846,"teacher_disagreement_score":0.052192196,"about_ca_system_score_codex":0.00048646453,"about_ca_system_score_gemma":0.00014199877,"threshold_uncertainty_score":0.9996741},"labels":[],"label_agreement":null},{"id":"W2600127085","doi":"10.1111/dom.12958","title":"Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Sitagliptin; Medicine; Internal medicine; Endocrinology; Placebo; Metformin; Glycated hemoglobin; Type 2 diabetes; Glucagon receptor; Blood pressure; Lipid profile; Glucagon-like peptide 1 receptor; Glucagon; Diabetes mellitus; Insulin; Receptor","score_opus":0.008540022634781116,"score_gpt":0.21006093675243936,"score_spread":0.20152091411765824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600127085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341387,0.0030658655,7.725684e-7,0.00009204006,0.0001621533,0.0011901142,0.000065165776,0.00008054614,0.0019294994],"genre_scores_gemma":[0.9952893,0.001382416,0.0006829353,0.00026212868,0.00015873942,0.00012183919,0.00030647815,0.000052899566,0.0017432387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979747,0.00006896356,0.0002458905,0.0006244835,0.00036224214,0.0007237143],"domain_scores_gemma":[0.9984287,0.00010284889,0.00022564332,0.00076012634,0.0001530239,0.0003296662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001278757,0.0005045653,0.000885938,0.00022078115,0.0003861523,0.00021393165,0.0001842476,0.00012348237,0.000037657952],"category_scores_gemma":[0.00009984486,0.0003317222,0.00008875435,0.00016669252,0.00028636437,0.00046943268,0.00013986429,0.00013997733,0.00005319862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011957338,0.0021769397,0.9805034,0.00013733347,0.0006474002,0.000022954533,0.00023917032,5.4268e-7,0.00022510135,0.0001429048,0.0003100025,0.015474695],"study_design_scores_gemma":[0.009203386,0.0020883027,0.94902384,0.00023513727,0.0010885245,3.1808463e-7,0.000059816462,0.00002579867,0.0065849996,0.00002738112,0.031460643,0.00020187067],"about_ca_topic_score_codex":0.0002763,"about_ca_topic_score_gemma":0.00010316787,"teacher_disagreement_score":0.03147956,"about_ca_system_score_codex":0.00009506092,"about_ca_system_score_gemma":0.00005399038,"threshold_uncertainty_score":0.99991345},"labels":[],"label_agreement":null},{"id":"W2601172948","doi":"10.1016/j.molmet.2017.03.006","title":"Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway","year":2017,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; National Institutes of Health; Shire","keywords":"Internal medicine; Endocrinology; Cholecystokinin; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; G protein-coupled bile acid receptor; Agonist; Glucose homeostasis; Enteroendocrine cell; Receptor; Bile acid; Biology; Type 2 diabetes; Medicine; Diabetes mellitus; Hormone; Insulin resistance; Endocrine system","score_opus":0.0152310483048753,"score_gpt":0.25782567013046104,"score_spread":0.24259462182558575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601172948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9043623,0.0065342947,0.0050923624,0.0024494203,0.00249746,0.0025355641,0.000028759183,0.00043346558,0.07606634],"genre_scores_gemma":[0.9811994,0.00016853359,0.0028443402,0.0011723574,0.0004041889,0.00019492349,0.00008170196,0.00012770267,0.013806841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968177,0.000084470106,0.00047518007,0.0008633885,0.0009440872,0.00081514963],"domain_scores_gemma":[0.9971156,0.000017890616,0.0003476657,0.00196166,0.00018086167,0.0003763252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047836255,0.0005320875,0.00076548086,0.00023210552,0.00045331335,0.00032453096,0.00054717745,0.0001628386,0.0002592032],"category_scores_gemma":[0.00013480449,0.00045474884,0.0004253659,0.00010201097,0.00012364781,0.0002951889,0.00045815692,0.00032745054,0.00048769367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066508,0.003256985,0.0063945483,0.000660187,0.006340598,0.0077653816,0.0012377199,0.00004640808,0.78374106,0.014795577,0.0038040737,0.1712924],"study_design_scores_gemma":[0.014026388,0.0004972122,0.09240053,0.0004554429,0.0038923027,0.0001533213,0.00019329283,0.0005261593,0.5430663,0.0053512724,0.33762345,0.0018143281],"about_ca_topic_score_codex":0.00020841285,"about_ca_topic_score_gemma":0.00003896721,"teacher_disagreement_score":0.33381936,"about_ca_system_score_codex":0.000083791834,"about_ca_system_score_gemma":0.000091259404,"threshold_uncertainty_score":0.99979043},"labels":[],"label_agreement":null},{"id":"W2603117483","doi":"10.14740/jocmr2806w","title":"The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Postprandial; Medicine; Type 2 diabetes; Lipid metabolism; Endocrinology; Internal medicine; Carbohydrate metabolism; Diabetes mellitus","score_opus":0.12920597076435028,"score_gpt":0.4869549509606337,"score_spread":0.35774898019628343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603117483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560673,0.0017442036,1.02795006e-7,0.0063560223,0.0002778743,0.0014698034,7.9842425e-7,0.0000035822623,0.0045408756],"genre_scores_gemma":[0.9950559,0.0033396443,0.000013823958,0.000038977894,0.0010117653,0.000029865925,0.0000013181319,0.000019183952,0.0004895052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591535,0.0011189564,0.0010333754,0.00024407398,0.0012887683,0.00039945391],"domain_scores_gemma":[0.9924126,0.0056845406,0.00052823755,0.00066583866,0.00036539533,0.00034334135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012241342,0.00020076724,0.0013750974,0.00031955756,0.00019780043,0.000042716703,0.00031618288,0.000051449348,0.000023731127],"category_scores_gemma":[0.0069879545,0.000078731755,0.00009435837,0.00019445576,0.00074982253,0.000090805486,0.0001131236,0.0006368835,0.0000056667454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08512577,0.004167776,0.7596506,0.000112477836,0.0019147635,0.00054742227,0.0007005342,0.0000011390943,0.0003385749,0.000027922999,0.00076322805,0.1466498],"study_design_scores_gemma":[0.0331086,0.41916054,0.5432855,0.0006370943,0.00060154777,0.000005548917,0.0005226928,0.000021576132,0.0003266956,0.000022979724,0.0022532938,0.000053918557],"about_ca_topic_score_codex":0.00018273084,"about_ca_topic_score_gemma":0.000117528514,"teacher_disagreement_score":0.41499278,"about_ca_system_score_codex":0.00007310274,"about_ca_system_score_gemma":0.00014402489,"threshold_uncertainty_score":0.8365739},"labels":[],"label_agreement":null},{"id":"W2604277961","doi":"10.1161/strokeaha.116.015756","title":"Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk","year":2017,"lang":"en","type":"article","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Placebo; Internal medicine; Stroke (engine); Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Confidence interval; Myocardial infarction; Cardiology; Surgery; Endocrinology","score_opus":0.005760050851273726,"score_gpt":0.20087524813638216,"score_spread":0.19511519728510843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604277961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966459,0.0013331654,0.0000021193473,0.00004368492,0.00015288718,0.0006099603,0.000018579205,0.000025298095,0.0011683722],"genre_scores_gemma":[0.9979977,0.0004336298,0.00025245562,0.000030929557,0.00004442361,0.000025879684,0.00006171086,0.000025092899,0.0011281724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988307,0.000037075406,0.00013069293,0.00033222607,0.00036219714,0.00030713395],"domain_scores_gemma":[0.9988869,0.000012345394,0.00008116414,0.0008550777,0.00005385764,0.00011065834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017268541,0.00018138754,0.00040417234,0.00008374627,0.00015978552,0.00002358906,0.00010107784,0.00005383846,0.000041073556],"category_scores_gemma":[0.00004688688,0.00013441496,0.00011986392,0.000042851443,0.00006558612,0.00011171669,0.0001511713,0.00009032401,0.00004667313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007451529,0.00014292411,0.9861461,0.000052050746,0.001700829,0.000005625841,0.000034711098,0.000007747355,0.0000037231719,0.000012905197,0.00009252105,0.011726353],"study_design_scores_gemma":[0.006904719,0.00051099795,0.98560554,0.000084417385,0.0009523091,1.300885e-7,0.000009935509,0.000009571068,0.0002875225,0.000029024428,0.005466437,0.00013939023],"about_ca_topic_score_codex":0.00019869907,"about_ca_topic_score_gemma":0.00006295988,"teacher_disagreement_score":0.011586963,"about_ca_system_score_codex":0.00009263699,"about_ca_system_score_gemma":0.000012065497,"threshold_uncertainty_score":0.5481283},"labels":[],"label_agreement":null},{"id":"W2604623769","doi":"10.1016/j.jcjd.2017.08.242","title":"Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Type 2 diabetes; Semaglutide; Liraglutide; Lixisenatide; Incretin; Exenatide; Hypoglycemia; Drug class; Diabetes mellitus; Intensive care medicine; Endocrinology; Pharmacology; Drug","score_opus":0.05117790030075134,"score_gpt":0.3166139700665522,"score_spread":0.2654360697658008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604623769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017811612,0.9911262,0.0000011279657,0.00040861408,0.0024842166,0.0014195913,0.0002763982,0.000024949386,0.00247778],"genre_scores_gemma":[0.000384054,0.98734057,0.00138848,0.0004547254,0.001766499,0.0001510526,0.00079470355,0.00024492195,0.00747499],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966786,0.00010051078,0.0012513571,0.00046464725,0.00029945132,0.0012054599],"domain_scores_gemma":[0.99517274,0.00029884293,0.0017907296,0.00080409937,0.0005351227,0.0013984906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071352534,0.0007722949,0.0034336236,0.0010113739,0.00042449604,0.0003685396,0.00071179133,0.00039780937,0.000233364],"category_scores_gemma":[0.0007821023,0.000603117,0.0014657455,0.00026348562,0.0002179001,0.00027189733,0.000049400554,0.0005256505,0.00013633283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004819012,0.00007134032,0.0018055954,0.011034388,0.0035853807,0.00003759677,0.0000450144,3.2383215e-7,0.0000019908646,0.000106340514,0.08849044,0.89481676],"study_design_scores_gemma":[0.0010484678,0.0011393698,0.00005309568,0.023585664,0.0067980937,0.0000042916367,0.000029036257,0.0000059831086,0.0000117095105,0.00005429804,0.96677303,0.00049694034],"about_ca_topic_score_codex":0.000067794186,"about_ca_topic_score_gemma":0.0007312942,"teacher_disagreement_score":0.89431983,"about_ca_system_score_codex":0.00090260466,"about_ca_system_score_gemma":0.003463322,"threshold_uncertainty_score":0.999642},"labels":[],"label_agreement":null},{"id":"W2604761574","doi":"10.1016/s2213-8587(17)30102-x","title":"Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure","year":2017,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Canadian VIGOUR Centre","funders":"","keywords":"Medicine; Guideline; Statement (logic); Heart failure; MEDLINE; Intensive care medicine; Cardiology; Epistemology; Pathology; Law","score_opus":0.034596081187273496,"score_gpt":0.30894695214025825,"score_spread":0.27435087095298477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604761574","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050283846,0.00063134276,0.00000700686,0.94175047,0.0020378954,0.001569929,0.00012405717,0.00020719628,0.003388268],"genre_scores_gemma":[0.008718145,0.00016567709,0.0011414982,0.93072736,0.0051366105,0.00048808986,0.0010999768,0.00008885285,0.052433763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963071,0.00013395188,0.0004793735,0.00084908993,0.00037969003,0.0018508431],"domain_scores_gemma":[0.99738187,0.00018582559,0.00023284095,0.0019180216,0.00014370384,0.0001377379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044915755,0.0005196804,0.0011478739,0.00041726494,0.0005428788,0.00026312526,0.0005174288,0.00021434863,0.00020160191],"category_scores_gemma":[0.00014129856,0.00034437948,0.000162838,0.00013869155,0.00038186964,0.0000679646,0.0003435099,0.0009743825,0.00073033327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036732647,0.00007842614,0.00100056,0.00008073366,0.0004807368,0.00009693574,0.000053263517,0.000003569148,0.00042435594,0.00010452741,0.98932403,0.00831612],"study_design_scores_gemma":[0.0015638927,0.00095345546,0.0011388821,0.00026049,0.00056547014,0.000009469481,0.000045595458,0.000016892145,0.0010666364,0.00039216212,0.9936784,0.00030863823],"about_ca_topic_score_codex":0.000078968056,"about_ca_topic_score_gemma":0.000045413402,"teacher_disagreement_score":0.049045492,"about_ca_system_score_codex":0.00016271207,"about_ca_system_score_gemma":0.000088506116,"threshold_uncertainty_score":0.9999008},"labels":[],"label_agreement":null},{"id":"W2604893317","doi":"","title":"L’acidocétose diabétique euglycémique due à la canagliflozine","year":2016,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Medical Association; University of British Columbia","funders":"","keywords":"Medicine; Gynecology","score_opus":0.012377969381078359,"score_gpt":0.2204315863186533,"score_spread":0.20805361693757496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604893317","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05101199,0.01917484,0.00015522866,0.033143707,0.0043546474,0.0013814827,0.0008645722,0.00016347312,0.88975006],"genre_scores_gemma":[0.6994526,0.0022352363,0.00018741506,0.13381803,0.003642022,0.00021794156,0.00015796069,0.00023447625,0.16005434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962468,0.00021812832,0.00043872994,0.00076480804,0.00031916477,0.0020123455],"domain_scores_gemma":[0.9963252,0.00022107556,0.0001280501,0.0009532099,0.0001480904,0.0022243697],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031372142,0.0006550506,0.0007487749,0.00049343257,0.00019202038,0.00009772245,0.00037023742,0.00034164812,0.00014025296],"category_scores_gemma":[0.000053246597,0.00054978736,0.0003035569,0.00056401093,0.00044336228,0.00037748073,0.00007960398,0.0002917169,0.004025047],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026125728,0.00023899342,0.00058449595,0.00019469637,0.0007895828,0.002561499,0.00011453761,0.000004505651,0.0035442896,0.07993281,0.28913364,0.62287486],"study_design_scores_gemma":[0.002319133,0.00032796117,0.016767694,0.0017219237,0.00062866346,0.0000041700096,0.00031233486,0.00003497258,0.0014238687,0.0017291926,0.9740417,0.00068839546],"about_ca_topic_score_codex":0.075978294,"about_ca_topic_score_gemma":0.11743089,"teacher_disagreement_score":0.72969574,"about_ca_system_score_codex":0.0024390658,"about_ca_system_score_gemma":0.0019010254,"threshold_uncertainty_score":0.99969536},"labels":[],"label_agreement":null},{"id":"W2606453842","doi":"10.2337/dc17-0237","title":"Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series","year":2017,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Canagliflozin; Medicine; Diabetes mellitus; Type 2 diabetes; Kidney transplant; Series (stratigraphy); Internal medicine; Kidney disease; Intensive care medicine; Kidney; Urology; Kidney transplantation; Endocrinology","score_opus":0.03333465728755388,"score_gpt":0.261627339539279,"score_spread":0.22829268225172514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606453842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9407992,0.0049444265,5.566632e-7,0.04008507,0.001489851,0.0050304555,0.007327986,0.00004545719,0.00027702822],"genre_scores_gemma":[0.88385546,0.0047493083,0.00086301565,0.072267875,0.0021132259,0.0035550601,0.020345096,0.00045535297,0.011795597],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980427,0.000057092824,0.00051915064,0.00046789326,0.00030111388,0.00061205274],"domain_scores_gemma":[0.9977206,0.0003657529,0.00036232307,0.0011848506,0.00025994936,0.00010652676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008176915,0.0005086848,0.0011963667,0.00029611748,0.000098225406,0.000040571304,0.00022988253,0.00037535565,0.000033999182],"category_scores_gemma":[0.00011071828,0.00033637488,0.00044168235,0.00014351968,0.00019923864,0.000116149175,0.000033218308,0.00021414043,0.0000065430186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023802526,0.00046937537,0.62530804,0.0055954014,0.0035705476,0.0015881995,0.0035524226,0.000010392802,0.00009461601,0.000007782861,0.34096044,0.018604783],"study_design_scores_gemma":[0.0034107582,0.0040000603,0.007114238,0.0029137006,0.00479464,0.000006865753,0.00026837076,0.00007678445,0.0035060467,0.000012866805,0.9734672,0.0004284745],"about_ca_topic_score_codex":0.00040011152,"about_ca_topic_score_gemma":0.00041323013,"teacher_disagreement_score":0.6325068,"about_ca_system_score_codex":0.00028764046,"about_ca_system_score_gemma":0.00017912456,"threshold_uncertainty_score":0.9999088},"labels":[],"label_agreement":null},{"id":"W2606759177","doi":"10.1161/circoutcomes.116.003514","title":"Treatment Deintensification Is Uncommon in Adults With Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Glycemic; Metformin; Diabetes mellitus; Discontinuation; Internal medicine; Retrospective cohort study; Type 2 Diabetes Mellitus; Type 2 diabetes; Cohort; Endocrinology","score_opus":0.05012309001472828,"score_gpt":0.3056344755884695,"score_spread":0.2555113855737412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606759177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294466,0.0030890375,0.000070304864,0.0015681718,0.00009072235,0.0006391332,0.0000038652825,0.000039993753,0.0015541391],"genre_scores_gemma":[0.9986073,0.00068144285,0.00016443875,0.00023735446,0.000033953907,0.00004177124,0.00007585032,0.00001446578,0.00014346938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888045,0.00006743271,0.00023969928,0.00034724304,0.00027849522,0.0001866564],"domain_scores_gemma":[0.9987302,0.00003955616,0.0001054453,0.0009401437,0.00010537619,0.00007929918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030910588,0.00017920663,0.00056785875,0.00008835033,0.00016194243,0.00007189235,0.00005564692,0.00006758348,0.0000114890545],"category_scores_gemma":[0.000075244425,0.00012840757,0.00026306885,0.000067137946,0.000077970326,0.00016630781,0.000025403073,0.000048723534,0.000015724447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006838977,0.00010388065,0.91966957,0.0001280483,0.0013923708,0.000012956146,0.00037254952,0.00003114893,0.000014415434,0.00048296835,0.000006920286,0.077716805],"study_design_scores_gemma":[0.004070099,0.00013418135,0.9918833,0.000095964584,0.00057181803,0.0000018434891,0.00014855759,0.00028341627,0.00020740966,0.00013167312,0.0023214736,0.00015030669],"about_ca_topic_score_codex":0.00035816067,"about_ca_topic_score_gemma":0.00006274496,"teacher_disagreement_score":0.0775665,"about_ca_system_score_codex":0.00012652457,"about_ca_system_score_gemma":0.000022546817,"threshold_uncertainty_score":0.52363086},"labels":[],"label_agreement":null},{"id":"W2607405121","doi":"10.1111/dom.12983","title":"Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from <scp>TECOS</scp>","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Merck","keywords":"Medicine; Sitagliptin; Kidney disease; Sitagliptin Phosphate; Internal medicine; Diabetes mellitus; Cohort; Adverse effect; Type 2 diabetes; Population; Surgery; Endocrinology","score_opus":0.006523128332024438,"score_gpt":0.21133195236320448,"score_spread":0.20480882403118006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607405121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933602,0.004818948,8.5596e-7,0.000193642,0.00018593266,0.00062308816,0.00019305992,0.00003095517,0.00059329305],"genre_scores_gemma":[0.998007,0.0006252405,0.00023891244,0.00032267475,0.00006441879,0.00002273274,0.00026995625,0.000025670151,0.00042340814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860984,0.00004183057,0.0002625616,0.00040620504,0.00026163334,0.00041794157],"domain_scores_gemma":[0.9986344,0.00011676885,0.0002042646,0.0005855797,0.00008463951,0.0003743415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017137268,0.00028581423,0.0007628295,0.00013701273,0.00016488029,0.0000675487,0.00014894748,0.00007941237,0.000032885517],"category_scores_gemma":[0.00041147723,0.00021323399,0.00006882167,0.00008030473,0.00022233052,0.00029114282,0.00021698963,0.00012263499,0.000008354631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003287229,0.0004531475,0.9914636,0.0002107884,0.0004157107,0.0000031386317,0.00010068901,5.6453695e-7,0.00012817138,0.00016950084,0.00025556146,0.00676628],"study_design_scores_gemma":[0.0062116277,0.0001768144,0.9844892,0.00025978903,0.0008215444,8.763548e-9,0.000015002961,0.00003881077,0.00093274424,0.000239587,0.006705012,0.00010983651],"about_ca_topic_score_codex":0.0000381396,"about_ca_topic_score_gemma":0.000019824707,"teacher_disagreement_score":0.006974353,"about_ca_system_score_codex":0.00003120449,"about_ca_system_score_gemma":0.000056070996,"threshold_uncertainty_score":0.86954296},"labels":[],"label_agreement":null},{"id":"W2607457744","doi":"10.2337/dc16-1943","title":"Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies","year":2017,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Observational study; Metformin; Meta-analysis; Relative risk; Internal medicine; Randomized controlled trial; Type 2 diabetes; Cohort study; Diabetes mellitus; Confidence interval; Endocrinology; Insulin","score_opus":0.691527844453416,"score_gpt":0.5019872687906131,"score_spread":0.1895405756628029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607457744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008201047,0.99016315,0.000002175624,0.00007159102,0.000075175776,0.0012098823,0.00016609373,0.0000071980817,0.000103704915],"genre_scores_gemma":[0.009573228,0.9894628,0.0003110775,0.000028547698,0.000031360116,0.00030247448,0.00017540148,0.00001557701,0.0000995567],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976502,0.00086293387,0.00048726238,0.0003641646,0.00046774675,0.00016771436],"domain_scores_gemma":[0.9968434,0.0013028312,0.0006233086,0.0009518507,0.00023492982,0.000043700275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013056257,0.00036873244,0.005332978,0.00016601654,0.00014095084,0.000012922688,0.00023796757,0.00014630026,0.0000075479493],"category_scores_gemma":[0.0010360823,0.00012865206,0.0034619498,0.00028544373,0.0003408256,0.00003441927,0.0004583096,0.00015314545,4.680572e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013269908,0.000039736253,0.075325415,0.013873605,0.35816503,0.0000020538077,0.00026135525,0.0000078009625,1.316809e-7,0.00032302036,0.000052354128,0.5519362],"study_design_scores_gemma":[0.0009574341,0.000066027496,0.06804301,0.004015312,0.6891161,4.463153e-7,0.00017812016,0.000011127792,0.000005412425,0.00015017083,0.23730738,0.00014941668],"about_ca_topic_score_codex":0.000021127638,"about_ca_topic_score_gemma":0.0000040083746,"teacher_disagreement_score":0.5517868,"about_ca_system_score_codex":0.000036986206,"about_ca_system_score_gemma":0.000040883755,"threshold_uncertainty_score":0.52462786},"labels":[],"label_agreement":null},{"id":"W2607581455","doi":"10.1111/dom.12986","title":"Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Medicine; Lixisenatide; Type 2 diabetes; Internal medicine; Diabetes mellitus; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.017480152213805566,"score_gpt":0.2692898192023451,"score_spread":0.25180966698853957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607581455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40035275,0.59812295,7.561675e-8,0.00001181628,0.00006167667,0.0012083125,0.000029850808,0.000012926105,0.00019964838],"genre_scores_gemma":[0.014648022,0.98446125,0.00022572477,0.00004479915,0.0000581436,0.000051678046,0.00022694665,0.000041564446,0.00024187806],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822366,0.00009359769,0.00048172136,0.0005234411,0.00025983274,0.00041772885],"domain_scores_gemma":[0.9987352,0.00013253334,0.00038613647,0.0004511062,0.00007881045,0.00021622785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033803852,0.0004951226,0.0024364481,0.00034143572,0.00010392329,0.00005411162,0.00011055986,0.00018750883,0.000010388087],"category_scores_gemma":[0.00008496057,0.00033573926,0.00010707151,0.00015245352,0.00024952003,0.00014212824,0.0002423343,0.00022683185,0.0000023791606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072300245,0.0006761014,0.17496708,0.01049387,0.001024825,0.0000050569715,0.00008348792,5.538798e-8,7.247557e-7,0.00011301867,0.00006562449,0.81249785],"study_design_scores_gemma":[0.0046991254,0.00050049677,0.62650955,0.008621903,0.0036462226,2.5587295e-7,0.0000034672178,0.0000014743389,0.000008289939,0.000025131198,0.35568178,0.00030234168],"about_ca_topic_score_codex":0.000009067,"about_ca_topic_score_gemma":0.000003913052,"teacher_disagreement_score":0.8121955,"about_ca_system_score_codex":0.000031985495,"about_ca_system_score_gemma":0.00006339775,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W2608794164","doi":"10.14740/jocmr3011w","title":"Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ejection fraction; Diabetes mellitus; Cardiology; Internal medicine; Dapagliflozin; Heart failure; Glycemic; Coronary artery disease; Hemodynamics; Diabetic cardiomyopathy; Type 2 Diabetes Mellitus; Renal glucose reabsorption; Type 2 diabetes; Cardiomyopathy; Endocrinology","score_opus":0.34295457968735993,"score_gpt":0.5923258221642471,"score_spread":0.2493712424768872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608794164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007538668,0.9888,0.000012040561,0.0011365225,0.0021765158,0.0017170317,0.000003867635,0.000009733243,0.005390449],"genre_scores_gemma":[0.0011685942,0.9912318,0.0001663007,0.00005565984,0.0041892673,0.000024613291,0.000028247705,0.00007567544,0.0030598594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906256,0.0009780055,0.0046451977,0.00042492652,0.0027021437,0.00062413263],"domain_scores_gemma":[0.9878166,0.0060178777,0.003068832,0.0011090896,0.0011607665,0.00082685397],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012269498,0.0004536436,0.007675596,0.0013518115,0.000090779235,0.000020150477,0.0008331147,0.00062024046,0.00014786184],"category_scores_gemma":[0.008462781,0.00024906814,0.0021224355,0.00040146295,0.0013269517,0.0001166157,0.00017429885,0.003245115,0.000057913796],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002396274,0.00096342806,0.00044713123,0.054415505,0.0021336796,0.0019693442,0.000028743952,1.28804185e-8,0.0000021704855,0.000043417993,0.01399039,0.9257665],"study_design_scores_gemma":[0.005134822,0.0076966975,0.0005920306,0.13639164,0.005747173,0.00008284503,0.000016844186,0.0000022812292,0.000014090341,0.00012554355,0.8440554,0.0001406358],"about_ca_topic_score_codex":0.000018287159,"about_ca_topic_score_gemma":0.0000029125176,"teacher_disagreement_score":0.9256259,"about_ca_system_score_codex":0.00017266133,"about_ca_system_score_gemma":0.001402085,"threshold_uncertainty_score":0.9999962},"labels":[],"label_agreement":null},{"id":"W2609324502","doi":"10.1016/j.molmet.2017.04.007","title":"The endogenous preproglucagon system is not essential for gut growth homeostasis in mice","year":2017,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; Novo Nordisk Fonden; Canada Research Chairs; Sanofi; Novo Nordisk; National Institute of Diabetes and Digestive and Kidney Diseases; Innovationsfonden","keywords":"Endogeny; Homeostasis; Biology; Cell biology; Endocrinology","score_opus":0.019106675610186582,"score_gpt":0.2625368785857931,"score_spread":0.24343020297560652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609324502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774615,0.006762753,0.000788852,0.0034473168,0.00083564786,0.0027565195,0.000038479284,0.00008171297,0.007827173],"genre_scores_gemma":[0.9969554,0.00022278447,0.0007476984,0.00043683956,0.00014132625,0.00045822293,0.000019196901,0.00003958502,0.0009789459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986356,0.000043983502,0.00025318676,0.00037370663,0.00028151151,0.00041201548],"domain_scores_gemma":[0.9987672,0.000033757835,0.00015955843,0.00085302093,0.000099662786,0.00008682578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036082856,0.0001972769,0.0003642744,0.0000861534,0.00036077105,0.00017724733,0.00032891234,0.000055297496,0.0000060655725],"category_scores_gemma":[0.00012507747,0.0001406928,0.00022384031,0.00005953002,0.00007140009,0.00007959874,0.00014365364,0.00007980494,0.000037133454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021494431,0.0015679682,0.003978427,0.0023587309,0.00490355,0.0015773518,0.0030756139,0.000006208272,0.622096,0.10759823,0.004523722,0.24616472],"study_design_scores_gemma":[0.0068957442,0.00012716517,0.02037368,0.00013100043,0.0016942761,0.000022478675,0.0002601496,0.00026543255,0.9079224,0.00042313343,0.06156831,0.00031623317],"about_ca_topic_score_codex":0.00022645426,"about_ca_topic_score_gemma":0.00001661738,"teacher_disagreement_score":0.28582639,"about_ca_system_score_codex":0.00005542582,"about_ca_system_score_gemma":0.000039531275,"threshold_uncertainty_score":0.5737286},"labels":[],"label_agreement":null},{"id":"W2609479444","doi":"10.14740/jocmr2976w","title":"Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycated hemoglobin; Lipid profile; Internal medicine; Type 2 diabetes; Creatinine; Cohort; Diabetes mellitus; Population; Hemoglobin; Cholesterol; Endocrinology; Weight loss; Blood pressure; Gastroenterology; Urology; Pharmacology; Obesity","score_opus":0.08490409268839673,"score_gpt":0.44637375162752574,"score_spread":0.361469658939129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609479444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260294,0.0009924328,3.8356904e-7,0.004349142,0.0001549084,0.0004649324,5.923881e-7,0.0000020819691,0.0014325576],"genre_scores_gemma":[0.99765736,0.0017271435,0.00019484418,0.000046219702,0.00023375454,0.0000019954625,0.0000031054544,0.000012066681,0.00012352446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738383,0.0002265638,0.0011651109,0.00020223878,0.0007380801,0.00028415493],"domain_scores_gemma":[0.99735844,0.0011696218,0.00047690852,0.00028075906,0.00045469802,0.00025959188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046965876,0.000115100534,0.0008561564,0.000449458,0.000059695358,0.000015832906,0.00014326735,0.000095022966,0.000026729604],"category_scores_gemma":[0.0063804435,0.00006662117,0.000032802585,0.00026356048,0.0006956667,0.00014568112,0.00013701308,0.00069524493,8.858806e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029821757,0.0006447091,0.91821545,0.00014855081,0.00011529986,0.00007284135,0.0001588172,8.7722265e-7,0.00011835031,0.000015887674,0.0007555536,0.07677148],"study_design_scores_gemma":[0.0226758,0.007536062,0.9642907,0.004058826,0.00007636983,0.000001785529,0.000093727875,0.000051043808,0.00022618285,0.00008137613,0.00085305184,0.000055067514],"about_ca_topic_score_codex":0.000054836855,"about_ca_topic_score_gemma":0.000021217747,"teacher_disagreement_score":0.076716416,"about_ca_system_score_codex":0.00005259284,"about_ca_system_score_gemma":0.00013423253,"threshold_uncertainty_score":0.7638447},"labels":[],"label_agreement":null},{"id":"W2610697451","doi":"10.1210/jc.2017-00928","title":"Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion","year":2017,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Liraglutide; Glucagon; Placebo; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Glucagon-like peptide-1; Area under the curve; Type 2 diabetes; Insulin","score_opus":0.048304897131600806,"score_gpt":0.42594921863710183,"score_spread":0.37764432150550103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610697451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860464,0.0043906574,0.000046209618,0.005944937,0.001459073,0.00059045025,0.0000029861067,0.000008896304,0.001510403],"genre_scores_gemma":[0.9938589,0.004427474,0.00003956843,0.00029012316,0.0010907231,0.0000058737105,0.0000013111858,0.00002394844,0.0002621265],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99557877,0.0020736735,0.0012540647,0.00016812765,0.0005328355,0.00039251026],"domain_scores_gemma":[0.9930781,0.002496732,0.0028099709,0.001327478,0.00019478292,0.00009295078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004562708,0.00026981003,0.0012900718,0.00009846835,0.0002827714,0.000035226734,0.0010246534,0.0001286135,0.00008746541],"category_scores_gemma":[0.0020036106,0.0000952721,0.0012713178,0.00007869081,0.000885423,0.000170419,0.00019629356,0.0009798319,0.000007749023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006274042,0.0014859814,0.24607782,0.000100300625,0.008451127,0.00005035959,0.00053507456,0.00024669728,0.020533962,0.0013592188,0.002668489,0.7122169],"study_design_scores_gemma":[0.008298224,0.005536683,0.95104903,0.00024825218,0.0021500504,0.000057768524,0.000026488124,0.00009634662,0.02543976,0.00067202095,0.0063419314,0.00008342264],"about_ca_topic_score_codex":0.00012245134,"about_ca_topic_score_gemma":0.0000076115975,"teacher_disagreement_score":0.71213347,"about_ca_system_score_codex":0.00006627648,"about_ca_system_score_gemma":0.00023760361,"threshold_uncertainty_score":0.42569366},"labels":[],"label_agreement":null},{"id":"W2610858877","doi":"10.1055/s-0037-1601751","title":"Kombination von DPP-4-/SGLT-2-Inhibitoren als Add-on zu Metformin bei Patienten mit Typ-2-Diabetes: Vergleich mit OAD, GLP-1RA und Basalinsulin","year":2017,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Metformin; Diabetes mellitus; Endocrinology","score_opus":0.03313681190464309,"score_gpt":0.3109621525272162,"score_spread":0.27782534062257314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610858877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8579267,0.08894223,0.000071982075,0.0056354785,0.013884955,0.005625911,0.00092705,0.0008539194,0.026131773],"genre_scores_gemma":[0.9727137,0.0059881737,0.0012251514,0.0018608046,0.0020205523,0.0007333806,0.0033107267,0.00038463666,0.011762858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99051684,0.0004866906,0.0018773763,0.0024156205,0.0018075135,0.002895938],"domain_scores_gemma":[0.99160767,0.0009867527,0.0018522391,0.0039711255,0.0006744234,0.00090776465],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016718091,0.0018692056,0.0025807335,0.0010488628,0.0014968914,0.00084616384,0.0019868927,0.0012979794,0.0005064826],"category_scores_gemma":[0.0025383006,0.0016972864,0.0009566232,0.00058297743,0.0008354056,0.0010767324,0.0010771293,0.0011437557,0.0054883827],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012818757,0.008953393,0.34288108,0.0017619358,0.023848835,0.0006978263,0.0010247699,0.00008701244,0.0010163018,0.00676215,0.12293265,0.4887522],"study_design_scores_gemma":[0.031002719,0.013941252,0.13448663,0.004498554,0.033702187,0.0000011293068,0.0005627056,0.004064757,0.06405941,0.006954945,0.70183146,0.004894276],"about_ca_topic_score_codex":0.00029114625,"about_ca_topic_score_gemma":0.00009185839,"teacher_disagreement_score":0.5788988,"about_ca_system_score_codex":0.0013307333,"about_ca_system_score_gemma":0.00038256936,"threshold_uncertainty_score":0.99999857},"labels":[],"label_agreement":null},{"id":"W2611213499","doi":"10.1210/jc.2016-3373","title":"Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial","year":2017,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"McMaster University; Hamilton Health Sciences; Canadian Diabetes Association","keywords":"Medicine; Type 2 diabetes; Randomized controlled trial; Relative risk; Diabetes mellitus; Internal medicine; Glycemic; Confidence interval; Insulin glargine; Metformin; Insulin; Endocrinology","score_opus":0.07295735699025833,"score_gpt":0.4045118595144266,"score_spread":0.33155450252416824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611213499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980484,0.0039978866,0.000005391942,0.0047654165,0.0015439562,0.0017291224,9.814778e-7,0.00000815782,0.0074651036],"genre_scores_gemma":[0.99130124,0.0062439605,0.00019948071,0.00025180992,0.0008870947,0.00001500031,0.0000012703738,0.000013056711,0.0010871105],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939391,0.0016256983,0.0035666716,0.00015816196,0.00036126102,0.00034908188],"domain_scores_gemma":[0.99083275,0.004092649,0.0040191635,0.0006049643,0.00032591392,0.00012456514],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010611687,0.00018546477,0.0043572565,0.00019017655,0.00008332314,0.000019116484,0.00044463633,0.00011378057,0.000039232662],"category_scores_gemma":[0.026041698,0.00008875086,0.00092515204,0.00007168103,0.0005182171,0.000111227855,0.00012188806,0.000640398,0.0000062520003],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97820103,0.00074741006,0.00068899663,0.000015176538,0.0015864255,0.00006095142,0.00006465047,0.00001484383,0.00023558541,0.0006208418,0.00043606688,0.017328026],"study_design_scores_gemma":[0.97923577,0.0017496247,0.011286349,0.00019739321,0.0032384463,0.000009412964,0.000054590662,0.00015184753,0.00031977374,0.001229701,0.0024594618,0.00006762311],"about_ca_topic_score_codex":0.000027723165,"about_ca_topic_score_gemma":0.0000050415338,"teacher_disagreement_score":0.017260402,"about_ca_system_score_codex":0.000012113165,"about_ca_system_score_gemma":0.0001962368,"threshold_uncertainty_score":0.98216236},"labels":[],"label_agreement":null},{"id":"W2611388262","doi":"10.1016/j.psyneuen.2017.05.005","title":"Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia","year":2017,"lang":"en","type":"article","venue":"Psychoneuroendocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Olanzapine; Internal medicine; Endocrinology; Glucagon; Glucose homeostasis; Glucagon receptor; Insulin resistance; Insulin; Chemistry; Biology; Medicine; Schizophrenia (object-oriented programming)","score_opus":0.031386082642608275,"score_gpt":0.30608544896689865,"score_spread":0.2746993663242904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611388262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577617,0.00013369368,0.0000116418305,0.014852162,0.0022278957,0.0013510189,0.000018556426,0.00036274144,0.023280572],"genre_scores_gemma":[0.9818202,0.0007236769,0.0008512712,0.0025675253,0.00044030516,0.0003499386,0.000079841586,0.0000868818,0.013080309],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773866,0.00006900103,0.00034906447,0.00079330336,0.00023299195,0.00081696565],"domain_scores_gemma":[0.9976976,0.000028833278,0.00036870464,0.0015576761,0.000118043004,0.00022917046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000032544893,0.00039150944,0.0006021146,0.00022389028,0.0003880426,0.00007659973,0.00049878744,0.00009378602,0.0001944915],"category_scores_gemma":[0.00015988108,0.00034848432,0.00018323137,0.000106905485,0.00016978309,0.00015732787,0.00023119333,0.00041076692,0.0016729294],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004357814,0.0023106595,0.050666086,0.00037103248,0.003192994,0.004883479,0.00026719546,0.0000012566048,0.6964028,0.0007676166,0.0895169,0.14726217],"study_design_scores_gemma":[0.023984198,0.0029836933,0.3498483,0.00033605343,0.0012305895,0.00050150946,0.0001955752,0.00007498211,0.10962168,0.00016091771,0.5099854,0.0010771005],"about_ca_topic_score_codex":0.000034352528,"about_ca_topic_score_gemma":0.000020503829,"teacher_disagreement_score":0.58678114,"about_ca_system_score_codex":0.00008309527,"about_ca_system_score_gemma":0.000037435413,"threshold_uncertainty_score":0.9998967},"labels":[],"label_agreement":null},{"id":"W2611973976","doi":"10.1111/dom.12963","title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; Novo Nordisk","keywords":"Medicine; Liraglutide; Randomized controlled trial; Phase (matter); Weight management; Internal medicine; Weight loss; Type 2 diabetes; Endocrinology; Diabetes mellitus; Obesity","score_opus":0.014177553145384573,"score_gpt":0.27153404159708555,"score_spread":0.257356488451701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611973976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724301,0.0089677945,0.00032123647,0.0020908772,0.0006109298,0.008195249,0.00044871328,0.00009081514,0.0068442547],"genre_scores_gemma":[0.9772545,0.009392445,0.006004785,0.00091420475,0.0006760972,0.0007308977,0.00042712118,0.000052787385,0.0045471727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743545,0.00031206422,0.0008587009,0.00066284015,0.00027126874,0.00045965813],"domain_scores_gemma":[0.9969304,0.0012233446,0.0007553718,0.000732859,0.00009181254,0.00026620078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028511425,0.00042215403,0.0034950331,0.00022244707,0.00059105916,0.0002578102,0.00016843995,0.00009549159,0.000025460247],"category_scores_gemma":[0.0011246637,0.00025787417,0.00044005262,0.00007179976,0.00025120613,0.0002592457,0.00013365195,0.000114362025,0.0000057490115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8039005,0.0025170427,0.0064444207,0.0006195848,0.017918423,0.00009418904,0.0004917106,0.000001749221,0.00044987327,0.021399634,0.003037221,0.14312567],"study_design_scores_gemma":[0.89625347,0.0002445887,0.042971604,0.00015127708,0.016697047,6.316963e-7,0.000029930005,0.000510049,0.00034542056,0.002121356,0.04036409,0.00031053522],"about_ca_topic_score_codex":0.000037891066,"about_ca_topic_score_gemma":0.000008889847,"teacher_disagreement_score":0.14281513,"about_ca_system_score_codex":0.00001127819,"about_ca_system_score_gemma":0.000020186897,"threshold_uncertainty_score":0.99998736},"labels":[],"label_agreement":null},{"id":"W2612230287","doi":"10.2337/dc16-1770","title":"Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Sanofi","keywords":"Insulin aspart; Medicine; Postprandial; Hypoglycemia; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Clinical endpoint; Insulin; Gastroenterology; Randomized controlled trial","score_opus":0.03297408587882984,"score_gpt":0.29130348169407383,"score_spread":0.258329395815244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612230287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97025985,0.00162842,1.1039907e-7,0.00205757,0.0015994244,0.0028189407,0.000045224817,0.000049020706,0.021541463],"genre_scores_gemma":[0.9963507,0.00012746398,0.000030396195,0.0007100417,0.0003139734,0.0005366328,0.00019412122,0.000050304963,0.0016863483],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975504,0.00017459488,0.0006068836,0.00047182842,0.0005010283,0.0006952591],"domain_scores_gemma":[0.9973474,0.0004170143,0.00043515518,0.0014182902,0.00021775092,0.0001643991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051041046,0.0003793509,0.0011179638,0.00018332516,0.00019947188,0.00012392641,0.00048179406,0.00017414034,0.0002198535],"category_scores_gemma":[0.0011034163,0.00026352404,0.00026513028,0.0001843266,0.00024566485,0.0001901778,0.0002502031,0.00026043694,0.00039129728],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13637002,0.0022283352,0.7268262,0.0009672798,0.0055896738,0.00016136715,0.004472776,0.000042555293,0.0005758469,0.0007979464,0.05440762,0.06756041],"study_design_scores_gemma":[0.64855146,0.016095607,0.18878536,0.0014925991,0.0033014815,3.8308482e-7,0.0033361479,0.00048982183,0.010038809,0.00043850634,0.12634583,0.0011240133],"about_ca_topic_score_codex":0.000041640204,"about_ca_topic_score_gemma":0.00008467814,"teacher_disagreement_score":0.5380408,"about_ca_system_score_codex":0.00014560395,"about_ca_system_score_gemma":0.00017114783,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W2613203965","doi":"10.1016/j.cjca.2017.04.012","title":"A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary; University of British Columbia; McMaster University; LMC Diabetes & Endocrinology (Canada); McGill University Health Centre; North York General Hospital; Université Laval; Population Health Research Institute; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Intensive care medicine; Liraglutide; Type 2 diabetes; Diabetes mellitus; Adverse effect; Residual risk; Risk analysis (engineering); Pharmacology; Internal medicine; Endocrinology","score_opus":0.06126338434389308,"score_gpt":0.29879936388796047,"score_spread":0.23753597954406738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613203965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8973476,0.0016085535,0.02060714,0.037979458,0.0022855077,0.002912594,0.000095913376,0.000018547877,0.037144627],"genre_scores_gemma":[0.99472034,0.00012898498,0.0029063364,0.0005224723,0.00048594928,0.000009194014,0.0000028787085,0.00002022856,0.0012036389],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999022,0.00004474477,0.0002907642,0.00013224686,0.00020897764,0.0003012859],"domain_scores_gemma":[0.99831384,0.000059958686,0.00019851087,0.0007162267,0.00025294514,0.00045850535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004764815,0.00012056416,0.0006047473,0.00013168459,0.0001583698,0.00004613327,0.00021187292,0.00004994389,0.000023541941],"category_scores_gemma":[0.0006576361,0.00006612665,0.00029424572,0.00005352551,0.00012551552,0.00013755159,0.00003983896,0.00014565616,0.0000065003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047197756,0.000054677555,0.2570872,0.00026652764,0.04556954,0.021305831,0.00093907904,0.025930556,0.00021923792,0.0011578887,0.38277438,0.25997528],"study_design_scores_gemma":[0.0012683448,0.00081024197,0.11576647,0.00011676477,0.0011276222,0.0005585687,0.00005811051,0.000012122861,0.00012657263,0.0000051094203,0.8800809,0.000069209214],"about_ca_topic_score_codex":0.0013998878,"about_ca_topic_score_gemma":0.0039268895,"teacher_disagreement_score":0.49730647,"about_ca_system_score_codex":0.00017628096,"about_ca_system_score_gemma":0.00069999316,"threshold_uncertainty_score":0.26965666},"labels":[],"label_agreement":null},{"id":"W2617014272","doi":"10.1016/j.jdiacomp.2017.05.010","title":"Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks","year":2017,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; Insulin glargine; Liraglutide; Internal medicine; Insulin lispro; Endocrinology; Glycemic; Insulin; Hypoglycemia; Diabetes mellitus; Dulaglutide; Type 2 Diabetes Mellitus; Agonist; Basal (medicine); Glucagon-like peptide 1 receptor; Type 2 diabetes; Receptor","score_opus":0.015160282120070548,"score_gpt":0.2590254035204728,"score_spread":0.24386512140040228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617014272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908883,0.0008867785,0.000005012992,0.0057035657,0.00029125818,0.00083182676,0.000106375395,0.000019366918,0.0012675339],"genre_scores_gemma":[0.9961598,0.00037361242,0.0016485701,0.0010015883,0.00019575912,0.000035731347,0.00012570422,0.000036442565,0.00042280616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979545,0.00005719621,0.0007459,0.00036894932,0.00041921635,0.0004542549],"domain_scores_gemma":[0.99767876,0.00015187381,0.00070612616,0.00057897205,0.0005085243,0.00037575018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036089274,0.00028944018,0.0006133622,0.00030176438,0.00034018717,0.00019983217,0.00033985573,0.00008863408,0.000035220815],"category_scores_gemma":[0.00041391468,0.00022264716,0.00010123395,0.00024364656,0.000106062915,0.00045040724,0.00015614078,0.0002798674,0.000047270925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024493476,0.0033090357,0.92613775,0.0002256356,0.0010270484,0.000007988241,0.00082779914,0.00006025853,0.0019388342,0.00039768402,0.02875522,0.034863397],"study_design_scores_gemma":[0.008704479,0.0032374654,0.95740557,0.00066158385,0.00024020996,2.708801e-7,0.00004545528,0.00014030123,0.00052749645,0.00007125265,0.028713992,0.00025189936],"about_ca_topic_score_codex":0.000014324117,"about_ca_topic_score_gemma":0.000030593572,"teacher_disagreement_score":0.034611497,"about_ca_system_score_codex":0.00013125796,"about_ca_system_score_gemma":0.000119804325,"threshold_uncertainty_score":0.90792876},"labels":[],"label_agreement":null},{"id":"W2617258928","doi":"10.2337/dc17-0061","title":"Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Merck Sharp and Dohme","keywords":"Sitagliptin; Natriuresis; Medicine; Internal medicine; Endocrinology; Sitagliptin Phosphate; Type 2 diabetes; Hemodynamics; Renal function; Diabetes mellitus","score_opus":0.00581109705125962,"score_gpt":0.21920600823563904,"score_spread":0.21339491118437942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617258928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977043,0.00076673727,1.6311297e-7,0.000052393727,0.000045011646,0.0008352109,0.000059941794,0.000052228403,0.00048400022],"genre_scores_gemma":[0.9987924,0.000018001403,0.00013482897,0.00010894631,0.00004698288,0.00006419183,0.00075926486,0.000044925815,0.000030458328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984191,0.000043905515,0.00027716896,0.00046107927,0.00030373977,0.00049497135],"domain_scores_gemma":[0.99901634,0.000085371685,0.00014769347,0.00047221791,0.00013459829,0.00014375069],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011305586,0.00030614654,0.00046299957,0.00027438943,0.00018388357,0.00014451974,0.0000939264,0.00009954671,0.000028442886],"category_scores_gemma":[0.00024898397,0.0002567361,0.00005932629,0.00017520016,0.00013439331,0.00037633677,0.00016572632,0.00015460448,0.000016477667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008736849,0.00030150864,0.99234664,0.00041230355,0.00009181696,0.000041849104,0.00026865234,0.000019417046,0.00040386646,0.000014408376,0.000037123595,0.0059750536],"study_design_scores_gemma":[0.005331303,0.00063723826,0.99058384,0.001145709,0.00018396715,9.242688e-8,0.00033220174,0.00020232864,0.0011984142,0.00004109733,0.000052020812,0.00029179754],"about_ca_topic_score_codex":0.00010264187,"about_ca_topic_score_gemma":0.00013182021,"teacher_disagreement_score":0.0056832563,"about_ca_system_score_codex":0.00015752351,"about_ca_system_score_gemma":0.000029441322,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W2617745588","doi":"10.1503/cmaj.161455","title":"Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Renal glucose reabsorption; Diabetes mellitus; Medicine; Glycemic; Cotransporter; Endocrinology; Type 2 Diabetes Mellitus; Internal medicine; Dapagliflozin; Urinary system; Insulin; Reabsorption; Renal sodium reabsorption; Sodium; Pharmacology; Chemistry; Kidney","score_opus":0.008975608949581526,"score_gpt":0.24330306705499327,"score_spread":0.23432745810541175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617745588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9166913,0.00065332407,0.00007160968,0.06576985,0.0017114398,0.00056984526,0.00004512037,0.000037936046,0.014449552],"genre_scores_gemma":[0.98736066,0.0002145783,0.0003978158,0.005793759,0.0025464166,0.00003865391,0.000053176336,0.00002810435,0.0035668423],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811244,0.0000276364,0.00036074928,0.00016629371,0.0007367812,0.0005961126],"domain_scores_gemma":[0.9977269,0.000095663665,0.0003065977,0.00019081983,0.00024439345,0.0014356263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010099662,0.0001427405,0.0003020729,0.00014089757,0.00075228204,0.00021931503,0.00017907661,0.00023300745,0.0008933504],"category_scores_gemma":[0.001075592,0.00012065017,0.00020958981,0.000041161842,0.000046992896,0.00018358165,0.000010624421,0.00032069747,0.00006274255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020763177,0.00010030434,0.5633231,0.000054839296,0.0007016716,0.00027969776,0.00021520878,4.4905988e-7,0.000064995394,0.00029284158,0.112246044,0.32270008],"study_design_scores_gemma":[0.0061297775,0.00032526877,0.17989425,0.0003518895,0.0005082384,0.000018872513,0.00019079151,0.00036030723,0.0011524672,0.00040802275,0.81040066,0.00025942517],"about_ca_topic_score_codex":0.0005112409,"about_ca_topic_score_gemma":0.0062200683,"teacher_disagreement_score":0.6981546,"about_ca_system_score_codex":0.00073137245,"about_ca_system_score_gemma":0.0008188446,"threshold_uncertainty_score":0.9781561},"labels":[],"label_agreement":null},{"id":"W2617778100","doi":"10.14740/jocmr3012w","title":"A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alogliptin; Vildagliptin; Sitagliptin; Medicine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Sitagliptin Phosphate; Internal medicine; Pharmacology; Endocrinology","score_opus":0.09679463444513695,"score_gpt":0.4721060148704849,"score_spread":0.37531138042534795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617778100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98372555,0.00042470676,0.000003279415,0.0026751552,0.0017419579,0.005435355,0.000002219436,0.0000058826427,0.0059858942],"genre_scores_gemma":[0.99724334,0.00039952202,0.00028292637,0.00005992416,0.0016291102,0.000088583,0.000010387977,0.00002595888,0.00026021834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926349,0.0018604747,0.002604787,0.00031225124,0.0021210054,0.00046660777],"domain_scores_gemma":[0.9754002,0.019466516,0.002099947,0.0006846777,0.0019716176,0.00037701352],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018189892,0.00024028299,0.0048367893,0.00044245285,0.00009260349,0.000030622028,0.00044602054,0.00018903488,0.00020102572],"category_scores_gemma":[0.06889925,0.000121391786,0.0005425865,0.00023495452,0.0011455474,0.00016116425,0.00015332871,0.0011515904,0.000013222646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81339115,0.0021218108,0.16702099,0.00004870439,0.0025392596,0.000063761174,0.00009668647,8.279662e-7,0.0000233226,0.00003347016,0.00080333394,0.013856703],"study_design_scores_gemma":[0.8219235,0.032934774,0.14194582,0.0012707184,0.0011485823,1.4243358e-7,0.000082765204,0.00005591838,0.000060516963,0.00022456597,0.00027237597,0.000080340054],"about_ca_topic_score_codex":0.00011200271,"about_ca_topic_score_gemma":0.000025334422,"teacher_disagreement_score":0.05070936,"about_ca_system_score_codex":0.00009623733,"about_ca_system_score_gemma":0.0003005943,"threshold_uncertainty_score":0.9389438},"labels":[],"label_agreement":null},{"id":"W2618447273","doi":"10.14740/jocmr3046w","title":"Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Internal medicine; Uric acid; Endocrinology; Renal glucose reabsorption; Canagliflozin; Triglyceride; Type 2 diabetes; Diabetes mellitus; Renal function; Blood pressure; Cholesterol; Hyperuricemia","score_opus":0.13403446376879438,"score_gpt":0.468145908505153,"score_spread":0.33411144473635856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618447273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083346,0.0033877194,0.000035147263,0.00420976,0.0002363729,0.000832027,0.000010058779,0.0000036368613,0.00045182768],"genre_scores_gemma":[0.9933147,0.0055822055,0.00041697704,0.00008098131,0.00038434277,0.000005668501,0.000018651115,0.000017628972,0.00017886265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662054,0.00054165977,0.0011443594,0.00027392962,0.0011703274,0.00024920123],"domain_scores_gemma":[0.9899219,0.0077215456,0.0008078785,0.00065747584,0.0004867429,0.00040440145],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009501226,0.00016628459,0.0014022352,0.0003935901,0.00009559889,0.000015184592,0.00030367204,0.000115437804,0.000021049853],"category_scores_gemma":[0.0108490735,0.000089056135,0.000097139404,0.00015050889,0.0008648256,0.00019026813,0.0001516974,0.0007575156,0.000001374009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018191557,0.002402078,0.76391554,0.0027925177,0.0031539632,0.0007920755,0.00022404348,0.0000019998793,0.0043467204,0.00035400552,0.0053227465,0.19850275],"study_design_scores_gemma":[0.0487365,0.037785053,0.8783481,0.0072419704,0.004013426,0.00003275182,0.0000700633,0.0009462581,0.018267091,0.000104402854,0.004301052,0.00015328731],"about_ca_topic_score_codex":0.00004355322,"about_ca_topic_score_gemma":0.000012260093,"teacher_disagreement_score":0.19834946,"about_ca_system_score_codex":0.000010145346,"about_ca_system_score_gemma":0.00012833992,"threshold_uncertainty_score":0.99748296},"labels":[],"label_agreement":null},{"id":"W2618480968","doi":"10.1093/ndt/gfx103","title":"SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL","year":2017,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Outcome (game theory); Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.025990210161373862,"score_gpt":0.3032182854693702,"score_spread":0.2772280753079963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618480968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994859,0.00010626525,0.0002728627,0.0014782036,0.0005392314,0.0013102557,0.0005334496,0.000063852545,0.0008368756],"genre_scores_gemma":[0.9971048,0.0006460896,0.00011334862,0.00054697273,0.00028688187,0.00013253254,0.0009071507,0.000025806094,0.00023638667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760807,0.0003406888,0.00064915675,0.0005222366,0.0005175673,0.00036226885],"domain_scores_gemma":[0.9966989,0.0010076673,0.0005077112,0.0016262172,0.00007974754,0.000079767466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010854829,0.00030765787,0.0010624694,0.00008977895,0.0004914575,0.000060922073,0.000337438,0.00021229294,0.000020880287],"category_scores_gemma":[0.00043398855,0.000195364,0.00090834894,0.00009899846,0.00027093382,0.00014730448,0.000032221848,0.00022687535,0.00006294617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09568559,0.0009768909,0.83510166,0.00013588561,0.020357313,0.00020456254,0.010411676,0.0008405185,0.00038270804,0.00019507243,0.00081706926,0.034891076],"study_design_scores_gemma":[0.08951037,0.0010748449,0.89376754,0.00003340969,0.011423251,0.0000011099081,0.00017544109,0.00006583927,0.0017547677,0.00016356524,0.0018448633,0.00018499307],"about_ca_topic_score_codex":0.0026811073,"about_ca_topic_score_gemma":0.0013230171,"teacher_disagreement_score":0.058665905,"about_ca_system_score_codex":0.000048903366,"about_ca_system_score_gemma":0.000032366457,"threshold_uncertainty_score":0.7966713},"labels":[],"label_agreement":null},{"id":"W2619446181","doi":"10.1007/s10557-017-6729-y","title":"The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease","year":2017,"lang":"en","type":"review","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Heart and Stroke Foundation","funders":"","keywords":"Medicine; Mace; Empagliflozin; Coronary artery disease; Diabetes mellitus; Intensive care medicine; Clinical trial; Revascularization; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Disease; Cardiology; Population; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.01138825684342383,"score_gpt":0.2428716451420452,"score_spread":0.23148338829862136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619446181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28847626,0.7096068,3.6150257e-7,0.000012283684,0.00007731608,0.001732008,0.000013670748,0.000008690134,0.000072553165],"genre_scores_gemma":[0.08712349,0.912355,0.000011813343,0.00001680585,0.00006159433,0.00028392553,0.00006353094,0.000060487007,0.000023328192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971063,0.0002814918,0.0006380027,0.00056226394,0.0010288196,0.00038312163],"domain_scores_gemma":[0.9980456,0.0001421225,0.00025586385,0.0012753333,0.000074871416,0.0002061778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012488331,0.0005148971,0.0032050111,0.00021770233,0.00008911835,0.00004168997,0.00023426571,0.00019014001,0.0000047899757],"category_scores_gemma":[0.000057496745,0.00028074594,0.0017030641,0.00012714826,0.0003857236,0.00010484604,0.00013197032,0.00026093514,6.624741e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011715116,0.00024626104,0.104779124,0.0011813461,0.012666299,0.00004561399,0.00009250441,0.000001507485,4.2590283e-8,0.000011450352,0.0000022596855,0.88085645],"study_design_scores_gemma":[0.015021869,0.0011040074,0.119388096,0.009384952,0.00454679,0.0000043876266,0.00016286415,0.000013037934,0.000008211223,0.00004606097,0.8496811,0.0006386194],"about_ca_topic_score_codex":0.000046473895,"about_ca_topic_score_gemma":0.0000018704019,"teacher_disagreement_score":0.88021785,"about_ca_system_score_codex":0.00004636444,"about_ca_system_score_gemma":0.00020449335,"threshold_uncertainty_score":0.9999645},"labels":[],"label_agreement":null},{"id":"W2619815194","doi":"10.14740/jocmr3038w","title":"Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Postprandial; Internal medicine; Endocrinology; Diabetes mellitus; Triglyceride; Waist; Type 2 Diabetes Mellitus; Bioelectrical impedance analysis; Body mass index; Cholesterol","score_opus":0.06922723574647471,"score_gpt":0.4467596698508529,"score_spread":0.3775324341043782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619815194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894777,0.0024140917,0.0000029218113,0.005655879,0.00027800442,0.00053792144,9.958172e-7,0.0000051505203,0.0016273693],"genre_scores_gemma":[0.99621814,0.0023153846,0.00015108757,0.00028992238,0.0007436645,0.0000057919283,0.0000038242742,0.00001858774,0.0002535642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970203,0.00024612987,0.0009511512,0.00023558513,0.0011107469,0.00043608787],"domain_scores_gemma":[0.995908,0.0017397703,0.000495324,0.00044964228,0.0008715082,0.00053572434],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035260501,0.00015224141,0.0009866492,0.00034526445,0.000119183635,0.000047781166,0.00026265255,0.00010312226,0.000056661895],"category_scores_gemma":[0.010229195,0.0000824852,0.000079249214,0.00013361665,0.0008121336,0.00021270264,0.0001027549,0.00077601464,0.000008517988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007424135,0.0007779181,0.9085603,0.00009495083,0.00039079835,0.00013543574,0.000025735919,1.207431e-7,0.000107160544,0.00005061413,0.0022493207,0.08018356],"study_design_scores_gemma":[0.03346344,0.023947433,0.93601644,0.0012620842,0.00030019364,0.0000027790359,0.00007075293,0.000058673584,0.00006101054,0.00032566595,0.00441376,0.000077769044],"about_ca_topic_score_codex":0.000044581553,"about_ca_topic_score_gemma":0.000012244899,"teacher_disagreement_score":0.08010579,"about_ca_system_score_codex":0.000053583357,"about_ca_system_score_gemma":0.00015975838,"threshold_uncertainty_score":0.9981081},"labels":[],"label_agreement":null},{"id":"W2619881304","doi":"10.1016/j.jacc.2017.04.014","title":"Novel Diabetes Drugs and the Cardiovascular Specialist","year":2017,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.03325384510560778,"score_gpt":0.3028036520213695,"score_spread":0.2695498069157617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619881304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039072626,0.99159694,0.000013385453,0.00088096526,0.00077956734,0.0008360011,0.00008416991,0.0000035533114,0.0054146694],"genre_scores_gemma":[0.0014041667,0.99595976,0.00020633594,0.0001233637,0.0013883908,0.000020981322,0.0000024549615,0.00003374473,0.00086077576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786836,0.00049756625,0.0007651229,0.0001940997,0.00042289498,0.00025195262],"domain_scores_gemma":[0.99586004,0.0004516749,0.002345102,0.0010854648,0.00017413717,0.00008359333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015261903,0.00031938602,0.006268193,0.0001787362,0.0001301568,0.000015008104,0.00066292315,0.00008552721,0.0000025700206],"category_scores_gemma":[0.00035956086,0.0001375116,0.0042119343,0.00018958846,0.0020170116,0.000035975874,0.00033174324,0.00039350425,0.0000018635143],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019495965,0.000050264014,0.00034775556,0.0033944675,0.04274638,0.00015811922,0.000025534824,0.0000072172784,0.000001585426,0.0008579532,0.012834426,0.93938136],"study_design_scores_gemma":[0.0019328474,0.00028128712,0.00041476265,0.0022415724,0.022454103,0.0005512207,0.000063915315,6.8777524e-7,0.0000011828123,0.000056330355,0.97188777,0.00011434557],"about_ca_topic_score_codex":0.000009155598,"about_ca_topic_score_gemma":5.623105e-7,"teacher_disagreement_score":0.95905334,"about_ca_system_score_codex":0.00011037896,"about_ca_system_score_gemma":0.00029092235,"threshold_uncertainty_score":0.7431763},"labels":[],"label_agreement":null},{"id":"W2620677458","doi":"10.1016/j.jcjd.2017.01.009","title":"Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; Winnipeg Regional Health Authority; Montreal Clinical Research Institute; Health Sciences Centre; Mount Sinai Hospital; Alberta Health Services; LMC Diabetes & Endocrinology (Canada); Alberta Health; University of Manitoba","funders":"Regeneron Pharmaceuticals; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Transporter; Insulin; Type 2 diabetes; Sodium; Diabetes mellitus; Internal medicine; Endocrinology; Pharmacology; Biochemistry","score_opus":0.07830772161440945,"score_gpt":0.3219295847188609,"score_spread":0.24362186310445144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620677458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056560576,0.94054484,0.0000013707689,0.00009447514,0.0005064731,0.0016631335,0.00020383179,0.000009751989,0.0004155511],"genre_scores_gemma":[0.13468404,0.8548631,0.0060484954,0.00079232675,0.002049739,0.0002486506,0.00075648044,0.0003763695,0.00018081098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977089,0.000068477006,0.0010248735,0.00029730995,0.00020267704,0.0006977251],"domain_scores_gemma":[0.9972749,0.00032228098,0.0010249409,0.00035032502,0.0003908255,0.00063676375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004375064,0.00047331885,0.0021020651,0.0010848521,0.00022843093,0.00016361549,0.00018091545,0.00024290291,0.00007095878],"category_scores_gemma":[0.0004788505,0.000364468,0.00040465678,0.00019630641,0.00015836078,0.0002828339,0.000009587527,0.0004380512,0.0000064500296],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004472906,0.0003384617,0.08100265,0.04641735,0.0044264654,0.00082315534,0.0010671164,0.0000116965775,0.000008214621,0.00011417721,0.0034547937,0.86229116],"study_design_scores_gemma":[0.0072215693,0.0026165824,0.0019863544,0.17017008,0.00799671,0.00002242255,0.00016700238,0.00007321109,0.0000746626,0.0001605076,0.80844295,0.0010679421],"about_ca_topic_score_codex":0.00012627679,"about_ca_topic_score_gemma":0.005404898,"teacher_disagreement_score":0.8612232,"about_ca_system_score_codex":0.00043668243,"about_ca_system_score_gemma":0.004643117,"threshold_uncertainty_score":0.99988073},"labels":[],"label_agreement":null},{"id":"W2621101635","doi":"10.1111/dom.13028","title":"Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"Regeneron Pharmaceuticals; Novo Nordisk; Sanofi; Servier; Amgen; Pfizer; AstraZeneca; Duke Clinical Research Institute; Eli Lilly and Company; Mylan; GlaxoSmithKline","keywords":"Medicine","score_opus":0.02342545171499733,"score_gpt":0.2439605460816667,"score_spread":0.22053509436666938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621101635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563463,0.03253399,0.0002557303,0.00008462059,0.00086483004,0.008166528,0.00020211635,0.00015149459,0.0013944301],"genre_scores_gemma":[0.98815835,0.0066929194,0.0007309672,0.00049000187,0.0008514436,0.0013675217,0.00023758975,0.00030285094,0.0011683417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9834953,0.004302934,0.0023365146,0.002480443,0.0034163783,0.003968461],"domain_scores_gemma":[0.96824116,0.024658557,0.0015136687,0.003987082,0.0005734558,0.0010260583],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.014583191,0.0020781856,0.0056080665,0.0015403661,0.0009955913,0.00072339433,0.0019672767,0.00089377543,0.000002978238],"category_scores_gemma":[0.04681424,0.0015306331,0.0017128023,0.0015664313,0.0014262379,0.0010049734,0.0011194262,0.0021146773,0.00004367131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032567972,0.0138634145,0.835164,0.011348385,0.032121412,0.0027225334,0.050023746,0.0025990906,0.012704688,0.0020413613,0.009693734,0.027391968],"study_design_scores_gemma":[0.047567107,0.0024255987,0.83556193,0.0035933366,0.009688823,0.000015733618,0.00699544,0.0025481693,0.04575433,0.000804141,0.044826496,0.00021892272],"about_ca_topic_score_codex":0.0005764492,"about_ca_topic_score_gemma":0.00008367435,"teacher_disagreement_score":0.047241427,"about_ca_system_score_codex":0.00022370186,"about_ca_system_score_gemma":0.0004274642,"threshold_uncertainty_score":0.999196},"labels":[],"label_agreement":null},{"id":"W2621109607","doi":"10.1016/j.jcjd.2017.03.003","title":"Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Merck Canada Inc. (Canada); University of Alberta; Diabetes Canada; University of Toronto; Canadian Heart Research Centre; University of Manitoba; Health Sciences Centre; St. Michael's Hospital; Winnipeg Regional Health Authority; University of British Columbia Hospital","funders":"Merck Canada; Sanofi","keywords":"Medicine; Type 2 diabetes; Glycated hemoglobin; Glycemic; Diabetes mellitus; Depression (economics); Blood pressure; Diabetes management; Population; Internal medicine; Diabetic foot; Insulin; Physical therapy; Gerontology; Endocrinology","score_opus":0.007746375901171522,"score_gpt":0.2153878549091219,"score_spread":0.20764147900795038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621109607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98229957,0.010094207,3.1254575e-7,0.00079025456,0.00030668656,0.00053817534,0.0000016901183,0.0000026321297,0.0059665046],"genre_scores_gemma":[0.999229,0.0000650159,0.0001756558,0.0002948056,0.000084496576,0.00001734693,0.000016981612,0.000016107444,0.00010056511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883324,0.000046220128,0.0003263684,0.00014644451,0.00030774585,0.0003399883],"domain_scores_gemma":[0.9986664,0.00005098074,0.00036468694,0.00052634574,0.00020291211,0.00018867526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023826392,0.0001786729,0.00031839276,0.00019964173,0.0002547136,0.00009508217,0.00051475305,0.00003158806,0.000018880837],"category_scores_gemma":[0.000021787871,0.00009137691,0.000097098105,0.00011684367,0.00017457141,0.00017365368,0.00004322153,0.00029598776,0.000003126643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012567451,0.000058126312,0.85683894,0.0005715431,0.00034521832,0.00005799269,0.014923354,0.000006000745,0.0000059642766,0.00009743325,0.0006103504,0.12647249],"study_design_scores_gemma":[0.0016812684,0.00045397517,0.97990066,0.0034120493,0.0004424267,4.177239e-7,0.0025832674,0.0000062579643,0.0001254388,0.000084759056,0.011199506,0.0001099525],"about_ca_topic_score_codex":0.0031144046,"about_ca_topic_score_gemma":0.18637064,"teacher_disagreement_score":0.18325622,"about_ca_system_score_codex":0.00037239614,"about_ca_system_score_gemma":0.0004770118,"threshold_uncertainty_score":0.82847595},"labels":[],"label_agreement":null},{"id":"W2621207536","doi":"10.1097/mnh.0000000000000343","title":"Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?","year":2017,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Diabetes mellitus; Medicine; Cotransporter; Disease; Kidney disease; Sodium; Internal medicine; Endocrinology; Pharmacology; Chemistry","score_opus":0.029495224509051354,"score_gpt":0.2906572691400907,"score_spread":0.26116204463103937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621207536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2870334,0.70470965,0.0000018715846,0.00007598894,0.0033950934,0.004709405,0.000039379313,0.000027669164,0.0000075315065],"genre_scores_gemma":[0.12505534,0.87054646,0.000044385775,0.00013682754,0.00020608661,0.00062691106,0.003265515,0.00010833744,0.000010103467],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99600244,0.00031759767,0.0012850212,0.0011238883,0.00051310065,0.0007579658],"domain_scores_gemma":[0.99748033,0.00020480741,0.0007326127,0.0010371392,0.00015169596,0.00039339892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023140099,0.0008986854,0.003305022,0.0016977573,0.00006708541,0.000037100435,0.00032487998,0.0004942042,0.00001220742],"category_scores_gemma":[0.0001850587,0.00067150785,0.0004138677,0.0004874822,0.00034124395,0.00032096225,0.00023016422,0.0007709056,0.000021121386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006068007,0.005514005,0.4336564,0.06250421,0.0004383952,0.00020164583,0.00020035559,0.0000033647268,0.000012385482,0.00001136933,0.0013705062,0.49548057],"study_design_scores_gemma":[0.016815808,0.0016709684,0.51597303,0.14058693,0.002381016,0.0000011555583,0.000004699327,0.00006488684,0.000011254864,0.0000322187,0.3216043,0.00085372105],"about_ca_topic_score_codex":0.00003606566,"about_ca_topic_score_gemma":0.000016242584,"teacher_disagreement_score":0.49462682,"about_ca_system_score_codex":0.00028567854,"about_ca_system_score_gemma":0.00032994105,"threshold_uncertainty_score":0.9995736},"labels":[],"label_agreement":null},{"id":"W2621355506","doi":"10.1210/en.2017-00393","title":"Peptide Therapeutics for Weight Loss: Preventing Plasma Pancreatic Polypeptide Proteolysis","year":2017,"lang":"en","type":"letter","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Proteolysis; Endocrinology; Internal medicine; Peptide; Pancreatic polypeptide; Chemistry; Medicine; Biology; Biochemistry; Insulin; Enzyme","score_opus":0.029144017115986198,"score_gpt":0.28754503735630077,"score_spread":0.2584010202403146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621355506","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036148705,0.0022822474,0.00029753245,0.9083977,0.0018724349,0.008344849,0.00013369843,0.00053886505,0.041984],"genre_scores_gemma":[0.018144833,0.0014614324,0.012150489,0.3375349,0.011872636,0.005443192,0.0026610584,0.00045637164,0.6102751],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972044,0.000075975164,0.0004761777,0.00076174847,0.00028068534,0.0012010026],"domain_scores_gemma":[0.99783623,0.00023724086,0.0004966775,0.001263103,0.00009821872,0.00006852077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008917745,0.0005838484,0.0011446201,0.00032680313,0.0002454588,0.00006363649,0.00043243752,0.00045894127,0.0002022415],"category_scores_gemma":[0.00008476258,0.00048688296,0.00053803425,0.000055750064,0.00021133073,0.00007812613,0.000190726,0.00085343287,0.00025277905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016470149,0.00021133646,0.00938616,0.0016078546,0.0065971618,0.002903954,0.000101068756,4.5540165e-7,0.00016847262,0.00030278746,0.94487417,0.033681866],"study_design_scores_gemma":[0.0030559185,0.00061526964,0.00086640083,0.00032928807,0.004526237,0.00014668661,0.000012515132,0.00003835473,0.0015300129,0.0005265075,0.9879503,0.00040249532],"about_ca_topic_score_codex":0.000038876944,"about_ca_topic_score_gemma":0.000010041571,"teacher_disagreement_score":0.57086277,"about_ca_system_score_codex":0.00016508643,"about_ca_system_score_gemma":0.00010637337,"threshold_uncertainty_score":0.9997583},"labels":[],"label_agreement":null},{"id":"W2621379028","doi":"10.1016/j.ypmed.2017.05.025","title":"Healthy lifestyle and glucagon-like peptide-1 in young and healthy adults: A population-based study","year":2017,"lang":"en","type":"article","venue":"Preventive Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Hamilton Health Sciences","funders":"","keywords":"Medicine; Glycated hemoglobin; Body mass index; Internal medicine; Diabetes mellitus; Glycemic; Confidence interval; Population; Blood pressure; Endocrinology; Type 2 diabetes; Environmental health","score_opus":0.01782996877090406,"score_gpt":0.323504545632061,"score_spread":0.30567457686115695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621379028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885229,0.0013204193,0.00002696635,0.006433157,0.0002508079,0.002196493,0.000003698376,0.00003592021,0.0012096333],"genre_scores_gemma":[0.9974917,0.00020217276,0.00020468958,0.0008513838,0.00014424043,0.00015721869,0.000053936557,0.000021533277,0.0008731042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984878,0.00009555918,0.0003774342,0.00045012092,0.00028602264,0.00030308648],"domain_scores_gemma":[0.998949,0.0000928072,0.00022083928,0.00045047046,0.000056178545,0.00023068505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059732195,0.00021467503,0.00052958925,0.00022127907,0.00023170417,0.000025631864,0.000084352105,0.000043413384,0.000043257],"category_scores_gemma":[0.00025133358,0.00016526072,0.000029344059,0.00008579093,0.00010692074,0.0001294243,0.00009466148,0.00014354223,0.00000490287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009304426,0.0007566014,0.9844243,0.00031734092,0.00008924293,0.000050459275,0.0013081005,3.0714145e-7,0.0000046062105,0.00005504242,0.00021138601,0.011852201],"study_design_scores_gemma":[0.016618408,0.005090536,0.9750361,0.0008194324,0.00022989734,0.0000029745433,0.0014025127,0.00023913992,0.0000022284814,0.00009589574,0.00034357104,0.00011932385],"about_ca_topic_score_codex":0.0041983197,"about_ca_topic_score_gemma":0.004077478,"teacher_disagreement_score":0.015687967,"about_ca_system_score_codex":0.00011559883,"about_ca_system_score_gemma":0.000042127576,"threshold_uncertainty_score":0.67391366},"labels":[],"label_agreement":null},{"id":"W2621490931","doi":"10.1016/j.jcjd.2017.03.006","title":"Effects on Diabetes Medications, Weight and Glycated Hemoglobin Among Adult Patients With Obesity and Type 2 Diabetes: 6-Month Observations From a Full Meal Replacement, Low-Calorie Diet Weight Management Program","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Glycated hemoglobin; Glycemic; Diabetes mellitus; Type 2 diabetes; Weight loss; Metformin; Internal medicine; Obesity; Meal; Diabetes management; Endocrinology; Gastroenterology","score_opus":0.005952261996620297,"score_gpt":0.2045996044889879,"score_spread":0.1986473424923676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621490931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949309,0.00093776785,0.00000164986,0.0014772584,0.00038717594,0.0015886638,0.00006952836,0.00003713109,0.0005698964],"genre_scores_gemma":[0.9973177,0.00009866651,0.0012219802,0.00056548446,0.00018502136,0.00013295707,0.0002667363,0.000049685263,0.00016182016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977672,0.00007513324,0.00048494418,0.00046366712,0.00046148087,0.0007475587],"domain_scores_gemma":[0.99703485,0.00015679134,0.0005901583,0.0006106153,0.00040304472,0.001204544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025904,0.0004116033,0.0006549015,0.00035248828,0.000585998,0.0002746265,0.00030992093,0.00012593492,0.00003532888],"category_scores_gemma":[0.00024616506,0.00031635136,0.0000877567,0.00020079479,0.00036964833,0.00047030163,0.00007888691,0.00026739272,0.000007094847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096026015,0.00033562776,0.9805896,0.00029423024,0.0017077925,0.00003216836,0.00010397842,5.2350913e-7,0.000022912118,0.00009308997,0.0024650618,0.01425895],"study_design_scores_gemma":[0.006212677,0.0046657934,0.9819881,0.0017004502,0.0016236827,1.0095682e-7,0.000044904795,0.000113963,0.00050193677,0.00020064514,0.0026330783,0.0003146962],"about_ca_topic_score_codex":0.0002342068,"about_ca_topic_score_gemma":0.0022264796,"teacher_disagreement_score":0.013944254,"about_ca_system_score_codex":0.00025648565,"about_ca_system_score_gemma":0.0001565045,"threshold_uncertainty_score":0.99992883},"labels":[],"label_agreement":null},{"id":"W2622984285","doi":"10.1186/s12902-017-0180-8","title":"Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors","year":2017,"lang":"en","type":"article","venue":"BMC Endocrine Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Johnson and Johnson; Janssen Scientific Affairs; American Diabetes Association","keywords":"Medicine; Canagliflozin; Glycated hemoglobin; Internal medicine; Diabetes mellitus; Hazard ratio; Blood pressure; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology","score_opus":0.013282908318683019,"score_gpt":0.27567462487704025,"score_spread":0.26239171655835725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622984285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934223,0.00021559803,0.000008297297,0.000438599,0.00006499614,0.0012975374,0.000018526202,0.00006811227,0.004465998],"genre_scores_gemma":[0.9975598,0.00015945642,0.00070146495,0.000076264616,0.000031929085,0.00012656978,0.00017975824,0.00005144213,0.0011133091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980478,0.00007296206,0.00030465567,0.0005377667,0.00048634442,0.0005504329],"domain_scores_gemma":[0.9987091,0.00006221351,0.00020570128,0.00070474367,0.000120449244,0.00019779352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014219726,0.00038717594,0.00055228744,0.0001646311,0.00019146284,0.00008714368,0.00014671423,0.00004264267,0.00007171151],"category_scores_gemma":[0.000077041164,0.00023789247,0.000051483225,0.00018475993,0.00021705587,0.00025335184,0.00009848397,0.00016755449,0.0000067089336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011360496,0.00091489055,0.9866682,0.00024345277,0.00031517082,0.000034778386,0.00006155996,0.000007844617,0.000007184694,0.00009338646,0.00029366862,0.010223803],"study_design_scores_gemma":[0.014761404,0.0016997302,0.98001564,0.00031639545,0.0002709389,5.225735e-7,0.0001629834,0.00003178999,0.0001162487,0.000022765624,0.00226107,0.00034052378],"about_ca_topic_score_codex":0.0013427713,"about_ca_topic_score_gemma":0.015305606,"teacher_disagreement_score":0.013962834,"about_ca_system_score_codex":0.00014899106,"about_ca_system_score_gemma":0.00013183315,"threshold_uncertainty_score":0.97009736},"labels":[],"label_agreement":null},{"id":"W2623048124","doi":"10.1016/j.jcjd.2017.04.001","title":"So Many Antihyperglycemics: How to Choose? A Practical Approach","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Metformin; Glycemic; Hypoglycemia; Intensive care medicine; Disease; Type 2 diabetes; Diabetes mellitus; Mechanism (biology); Internal medicine; Endocrinology","score_opus":0.027188071699876908,"score_gpt":0.2688695495236257,"score_spread":0.24168147782374877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623048124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96338505,0.0004429627,0.00006623315,0.023915438,0.0004423996,0.00028383176,0.000010084305,0.000008670872,0.011445354],"genre_scores_gemma":[0.98933786,0.000011305123,0.006200855,0.0015149962,0.00045832538,0.0000073238057,0.0000054161483,0.000026141872,0.0024377613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988885,0.000020590129,0.00020752827,0.00016644811,0.00021374303,0.0005031958],"domain_scores_gemma":[0.99773806,0.000031341995,0.00022968928,0.00046533835,0.00017981722,0.0013557432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028832097,0.00016153521,0.00039584827,0.00031851605,0.0003062184,0.0004309047,0.00026958276,0.00007143865,0.00006515595],"category_scores_gemma":[0.0006719732,0.0001309658,0.00015691208,0.000067166155,0.00013489918,0.00033292524,0.000033501896,0.00021270219,0.00003991802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037320024,0.00019160577,0.83468854,0.00014616626,0.0010095335,0.00046984188,0.00045484694,0.000004329728,0.0006436737,0.0020462524,0.11264563,0.04766226],"study_design_scores_gemma":[0.0027369368,0.00101837,0.6518315,0.0003292174,0.00072346046,0.0000392105,0.00044746627,0.00013617998,0.001021892,0.00020183499,0.34120324,0.00031070918],"about_ca_topic_score_codex":0.00017845826,"about_ca_topic_score_gemma":0.00052340666,"teacher_disagreement_score":0.2285576,"about_ca_system_score_codex":0.00016776058,"about_ca_system_score_gemma":0.00070189446,"threshold_uncertainty_score":0.53406304},"labels":[],"label_agreement":null},{"id":"W2624023817","doi":"10.1038/s41598-017-03310-x","title":"Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts","year":2017,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Dipeptidyl peptidase; Endocrinology; Internal medicine; Incretin; Medicine; Dipeptidyl peptidase-4; Insulin; Glucagon-like peptide-1; Diabetes mellitus; Biology; Type 2 diabetes","score_opus":0.017244268531207276,"score_gpt":0.2685495080596555,"score_spread":0.25130523952844824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624023817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105185,0.0009978837,0.000008542764,0.0004486264,0.0018139108,0.0006782002,3.8485015e-7,0.000046804194,0.0049538002],"genre_scores_gemma":[0.9952677,0.000026567252,0.0001257439,0.00006609102,0.000063642336,0.000051978932,0.000006621244,0.000014718889,0.004376974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818045,0.00002234686,0.00035415436,0.00069238193,0.00042542105,0.0003252529],"domain_scores_gemma":[0.9981897,0.0000030198462,0.0002749264,0.0012863163,0.00006024127,0.00018578922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093018194,0.00015743912,0.00026924093,0.00022750953,0.00040646936,0.0004166619,0.00009537442,0.000058587382,0.000021983375],"category_scores_gemma":[0.00016382032,0.0001254351,0.00006446192,0.00009718561,0.0002525393,0.00027920085,0.00024982303,0.000106002815,0.000027323062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057187655,0.00057695486,0.90012765,0.00051234564,0.000025685777,0.0032737437,0.00035977748,0.0000024047083,0.06915875,0.00002869438,0.009692246,0.016184578],"study_design_scores_gemma":[0.001363887,0.00014729382,0.9242528,0.0063877907,0.000088209315,0.000105008316,0.00012652329,0.00006467236,0.05623404,0.0008795885,0.010115895,0.00023428755],"about_ca_topic_score_codex":0.00001022404,"about_ca_topic_score_gemma":0.000027869404,"teacher_disagreement_score":0.02412517,"about_ca_system_score_codex":0.0000654425,"about_ca_system_score_gemma":0.000059506146,"threshold_uncertainty_score":0.5115095},"labels":[],"label_agreement":null},{"id":"W2624162283","doi":"10.1136/bmj.j2499","title":"Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Canadian Institutes of Health Research; Sichuan University; National Natural Science Foundation of China","keywords":"Medicine; Meta-analysis; Confidence interval; Odds ratio; Internal medicine; Type 2 diabetes; Incretin; Placebo; Relative risk; Publication bias; Randomized controlled trial; MEDLINE; Diabetes mellitus; Endocrinology; Alternative medicine; Pathology","score_opus":0.12004933015755356,"score_gpt":0.3874918884318709,"score_spread":0.2674425582743173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624162283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019489745,0.99017036,2.6562861e-7,0.000055931607,0.000011606961,0.008981604,0.000063038424,0.00001605499,0.0005062474],"genre_scores_gemma":[0.00019762528,0.9957515,0.0001213616,0.00026580147,0.0000071767286,0.001473324,0.00076005183,0.00003313161,0.0013900357],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99792075,0.00029222044,0.0007654438,0.0004904938,0.00031182155,0.00021927475],"domain_scores_gemma":[0.9978251,0.00009594438,0.0007988753,0.0010925068,0.00006833966,0.00011926577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000686797,0.0004862824,0.008378344,0.0002826926,0.00004270323,0.000047615667,0.00010427203,0.000098477096,0.00009003516],"category_scores_gemma":[0.00015787342,0.0002504936,0.0006379697,0.00032003215,0.00005114068,0.000056804387,0.00006965667,0.00009350408,0.00001733233],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000033940084,0.00016546888,0.016015856,0.74447674,0.23663698,0.00001708172,0.0000030092174,2.051741e-8,2.1145863e-10,0.0000018105161,0.00012664094,0.002552999],"study_design_scores_gemma":[0.0006243633,0.00023065714,0.006066869,0.05875163,0.9257584,2.2468609e-7,7.152471e-7,0.0000018918387,9.070393e-9,8.1815176e-7,0.008358963,0.00020541721],"about_ca_topic_score_codex":0.000023321136,"about_ca_topic_score_gemma":0.000020388994,"teacher_disagreement_score":0.6891215,"about_ca_system_score_codex":0.00008521275,"about_ca_system_score_gemma":0.00005709793,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W2669035283","doi":"10.1111/dom.13040","title":"Glycemic Improvement with a Fixed‐dose combination of <scp>DPP</scp> ‐4 inhibitor + metformin in patients with Type 2 diabetes ( <scp>GIFT</scp> study)","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"","keywords":"Metformin; Medicine; Fixed-dose combination; Type 2 diabetes; Pill; Glycemic; Formulary; Diabetes mellitus; Internal medicine; Pharmacology; Endocrinology","score_opus":0.006730278868638191,"score_gpt":0.21396269146593078,"score_spread":0.20723241259729258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2669035283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952011,0.00096722925,0.0000018191399,0.000028089295,0.00025161656,0.0025445006,0.00003376709,0.000056575802,0.0009152813],"genre_scores_gemma":[0.99813837,0.00012314189,0.00036757503,0.00013863093,0.00006852165,0.00017236671,0.00014565974,0.000051824074,0.00079393975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749947,0.000065442204,0.00046754937,0.00060901954,0.0006606046,0.0006979335],"domain_scores_gemma":[0.99793863,0.00016226931,0.0005171499,0.00081114564,0.0003295574,0.00024122818],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041198957,0.00047985883,0.0010334096,0.00040034417,0.0002525767,0.00012995106,0.000267784,0.00012916065,0.00000602417],"category_scores_gemma":[0.00034744787,0.00035068882,0.0000869577,0.00030792435,0.00023035586,0.0006120858,0.0002729207,0.00023667526,0.000011359258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007242953,0.0043211426,0.9819737,0.0002992983,0.00071139453,0.000008299191,0.0007965949,0.0000015533964,0.00086537347,0.00013137392,0.00023107819,0.010587783],"study_design_scores_gemma":[0.017564366,0.0048402813,0.9591427,0.00026134762,0.0011596337,1.0984261e-7,0.00046219703,0.000044831373,0.014391603,0.00011471701,0.0019080584,0.00011018306],"about_ca_topic_score_codex":0.00007582659,"about_ca_topic_score_gemma":0.00006240741,"teacher_disagreement_score":0.022831008,"about_ca_system_score_codex":0.000066927176,"about_ca_system_score_gemma":0.000066133456,"threshold_uncertainty_score":0.9998945},"labels":[],"label_agreement":null},{"id":"W2679991926","doi":"10.1080/03007995.2017.1345730","title":"Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients","year":2017,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Liraglutide; Dipeptidyl peptidase-4; Type 2 diabetes; Dipeptidyl peptidase-4 inhibitor; Saxagliptin; Sitagliptin; Internal medicine; Diabetes mellitus; Dipeptidyl peptidase; Pharmacology; Glucagon-like peptide-1; Meta-analysis; Endocrinology; Enzyme; Biochemistry","score_opus":0.4695309847121052,"score_gpt":0.513261358917863,"score_spread":0.04373037420575776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2679991926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007148478,0.9952501,7.341523e-7,0.00012612472,0.0007518936,0.0029358917,0.000104278915,0.000006038016,0.00011009483],"genre_scores_gemma":[0.0012832124,0.99597496,0.000013417204,0.000003391339,0.0003264314,0.0007732127,0.001417044,0.000024252424,0.00018406485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649227,0.00029891988,0.00084113807,0.00047526887,0.0012986624,0.0005937242],"domain_scores_gemma":[0.99478316,0.0034717505,0.0003862526,0.00073055545,0.0003085103,0.0003197407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017147749,0.00034946552,0.003400159,0.0006327666,0.00012396692,0.000026074978,0.00031964108,0.00020884362,0.000115792616],"category_scores_gemma":[0.0015378655,0.00017393191,0.0014025589,0.00084618555,0.0004674548,0.000042670108,0.00017619111,0.00029908196,0.000004875734],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018956295,0.001498792,0.0010019139,0.006716226,0.048433397,0.000001409864,0.00007599434,6.0113547e-7,7.937258e-9,0.00005332356,0.0024802806,0.9395485],"study_design_scores_gemma":[0.0020758535,0.0038581933,0.00042152053,0.003072236,0.086559184,3.6936942e-8,0.00001912524,0.00014305783,4.395573e-7,0.000019312929,0.90370864,0.0001223754],"about_ca_topic_score_codex":0.00006449267,"about_ca_topic_score_gemma":0.00005746383,"teacher_disagreement_score":0.9394261,"about_ca_system_score_codex":0.0001577879,"about_ca_system_score_gemma":0.00028821162,"threshold_uncertainty_score":0.70927376},"labels":[],"label_agreement":null},{"id":"W2698787928","doi":"10.14740/jem.v7i3.426","title":"Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure","year":2017,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Cotransporter; Internal medicine; Cardiology; Pharmacology; Sodium; Metallurgy","score_opus":0.016040725887744252,"score_gpt":0.27869793194568426,"score_spread":0.26265720605794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2698787928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780673,0.004667823,0.000088782785,0.014862056,0.0010831174,0.00028604324,0.0000056680947,0.000010402049,0.0009288398],"genre_scores_gemma":[0.9928481,0.00074184797,0.0037109454,0.000696054,0.00067930395,0.000010439763,0.0000032524692,0.000011887066,0.0012982003],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926615,0.000012673905,0.00026607755,0.0001120366,0.00009620586,0.00024684437],"domain_scores_gemma":[0.99929726,0.000028272065,0.00024076815,0.00020145926,0.00011289487,0.000119323195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012418986,0.00011704787,0.00044405813,0.0001265619,0.00016212356,0.000028503799,0.00008987045,0.0000568723,0.000033162083],"category_scores_gemma":[0.0000603768,0.00008260055,0.00018239039,0.000014011996,0.00012803318,0.00018338067,0.000027197739,0.00014544402,0.0000041357375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038421783,0.0021772548,0.3471589,0.00069440337,0.0066367034,0.0014908155,0.0010847708,0.0000025498193,0.07847313,0.0547407,0.24729493,0.25640363],"study_design_scores_gemma":[0.0058534043,0.00031744904,0.19164076,0.000040722953,0.00088962005,0.0002214949,0.00005777868,0.0000012673376,0.019651437,0.0008111068,0.7804404,0.00007452947],"about_ca_topic_score_codex":0.0000041935923,"about_ca_topic_score_gemma":0.000005501771,"teacher_disagreement_score":0.5331455,"about_ca_system_score_codex":0.000007748265,"about_ca_system_score_gemma":0.000032177224,"threshold_uncertainty_score":0.33683527},"labels":[],"label_agreement":null},{"id":"W2715646815","doi":"10.1111/dom.13043","title":"Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the <scp>DUAL V</scp> randomized trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Insulin degludec; Type 2 diabetes; Insulin glargine; Internal medicine; Weight loss; Insulin; Body mass index; Post-hoc analysis; Basal (medicine); Diabetes mellitus; Endocrinology; Gastroenterology; Obesity","score_opus":0.00983911403288233,"score_gpt":0.2613156423722514,"score_spread":0.25147652833936907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2715646815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873763,0.0067677638,0.000018811043,0.00021902748,0.00035930544,0.0038246955,0.000040725838,0.000033738925,0.0013596469],"genre_scores_gemma":[0.9972613,0.0011960951,0.00011550939,0.00025229473,0.00024941223,0.00052186544,0.000028959323,0.000024133575,0.00035042738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764884,0.0004201858,0.00048813305,0.00045274917,0.00040173586,0.0005883464],"domain_scores_gemma":[0.9975575,0.0011940447,0.00037679504,0.0006241029,0.00009861382,0.00014892142],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025473752,0.00037827622,0.0016196318,0.00016141358,0.00038634296,0.00020826531,0.0002460246,0.00019504153,0.0000037263123],"category_scores_gemma":[0.0019205159,0.0002477126,0.00023847289,0.00014425813,0.0008313617,0.00034225063,0.00024307902,0.0003076446,0.00000399442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04991274,0.0014122921,0.9016668,0.000799505,0.0021020947,0.00010328427,0.009725532,0.0000019988536,0.0013994306,0.0057044784,0.00037739988,0.026794435],"study_design_scores_gemma":[0.3843557,0.00018940638,0.6079562,0.00007925634,0.00095202704,0.0000012012621,0.0005575351,0.000072191026,0.0023718518,0.0021582008,0.001219599,0.0000868371],"about_ca_topic_score_codex":0.00031158162,"about_ca_topic_score_gemma":0.00006784392,"teacher_disagreement_score":0.33444294,"about_ca_system_score_codex":0.000024031408,"about_ca_system_score_gemma":0.000038976592,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W2724585937","doi":"10.14740/jocmr3067w","title":"Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Medicine; Glycemic; Regimen; Fixed-dose combination; Type 2 diabetes; Pharmacology; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.0968579961831598,"score_gpt":0.47116307243285016,"score_spread":0.37430507624969034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724585937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991222,0.00012543087,0.0000068418826,0.0026804947,0.00040625842,0.0053610043,0.000007225133,0.000009817633,0.0001808975],"genre_scores_gemma":[0.99920464,0.000045342094,0.000040787912,0.00017984127,0.0002593677,0.00010056642,0.000033559398,0.00004057113,0.000095355645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99441886,0.001216596,0.0014970403,0.00043993702,0.0019218797,0.0005056854],"domain_scores_gemma":[0.991304,0.005226362,0.0010354328,0.00082575576,0.0011059976,0.00050246704],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010520951,0.00026840382,0.0016315293,0.0007012684,0.00017899777,0.000044598644,0.00048497407,0.000094627096,0.000033394197],"category_scores_gemma":[0.009791412,0.00016317346,0.0001202379,0.000278227,0.00020184797,0.00025815924,0.0001541147,0.0006654381,0.000008900913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082326286,0.0148819545,0.86002076,0.00028894996,0.00070002046,0.00010664679,0.0007874076,0.000014989063,0.0013505077,0.000008959789,0.0004436259,0.039069917],"study_design_scores_gemma":[0.09457956,0.29863778,0.6034253,0.0017932412,0.0004611979,3.0418298e-7,0.00012881811,0.00058389746,0.00018884316,0.000080291094,0.00002861738,0.00009209186],"about_ca_topic_score_codex":0.00014485743,"about_ca_topic_score_gemma":0.00007161351,"teacher_disagreement_score":0.28375584,"about_ca_system_score_codex":0.0003037018,"about_ca_system_score_gemma":0.00011088212,"threshold_uncertainty_score":0.9985495},"labels":[],"label_agreement":null},{"id":"W2725639197","doi":"10.1097/hco.0000000000000435","title":"Antihyperglycemic agents and cardiovascular outcomes","year":2017,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Empagliflozin; Medicine; Liraglutide; Hazard ratio; Type 2 diabetes; Confidence interval; Internal medicine; EMPA; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.27776080177513,"score_gpt":0.4566119345396774,"score_spread":0.1788511327645474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725639197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020584574,0.9882544,0.000009955341,0.000028213182,0.0083423685,0.0013966444,0.000031494284,0.000039826948,0.0018764902],"genre_scores_gemma":[0.0000649906,0.9981951,0.000019720099,0.000008873138,0.0006454213,0.0003002468,0.00052676484,0.000043517666,0.0001953616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980189,0.00018782268,0.00049839396,0.0006965733,0.00020806259,0.00039022238],"domain_scores_gemma":[0.99847347,0.0000708584,0.00017610421,0.0011352681,0.00002793068,0.00011634742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036623832,0.00047378172,0.004300955,0.0003952331,0.000063223364,0.000026772026,0.00020511702,0.0002990509,0.000012228627],"category_scores_gemma":[0.00008874309,0.0003479355,0.0014270263,0.00008157291,0.00013550224,0.000047997564,0.0002979991,0.0003704937,0.0000938339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005107875,0.00003672608,0.014751064,0.017381076,0.0025709036,0.000030703577,0.0000073446745,4.6002805e-7,1.2591533e-9,0.00007099567,0.0049826456,0.960163],"study_design_scores_gemma":[0.0012059999,0.0000874768,0.005178275,0.009470754,0.0023840852,0.00007346842,0.000004155551,0.0000011739298,3.1791194e-9,0.000015629214,0.9813176,0.0002614233],"about_ca_topic_score_codex":0.0000064325186,"about_ca_topic_score_gemma":1.772966e-7,"teacher_disagreement_score":0.9763349,"about_ca_system_score_codex":0.00011841569,"about_ca_system_score_gemma":0.000100454,"threshold_uncertainty_score":0.99989724},"labels":[],"label_agreement":null},{"id":"W2733849831","doi":"10.1016/s2213-8587(17)30182-1","title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Toronto General Hospital","funders":"Sanofi","keywords":"Empagliflozin; Medicine; Albuminuria; Microalbuminuria; Type 2 diabetes; Placebo; Internal medicine; Diabetes mellitus; Creatinine; Renal function; Endocrinology","score_opus":0.016893468684284544,"score_gpt":0.25567587485054005,"score_spread":0.2387824061662555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2733849831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906919,0.0013281488,0.0000034266595,0.0014928343,0.00020543886,0.006031941,0.00002500873,0.000040267976,0.00018101367],"genre_scores_gemma":[0.9972658,0.000103432496,0.000034997556,0.00093857525,0.0002714014,0.0011764339,0.000093267045,0.00003365734,0.00008242691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697125,0.0008226014,0.00045386393,0.00050381554,0.00044279272,0.0008056889],"domain_scores_gemma":[0.9948871,0.0024491798,0.00030106067,0.0021179672,0.000100881465,0.0001437729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011809157,0.0003770037,0.0018570697,0.00020214339,0.0002776385,0.00008532364,0.00060810597,0.00005619669,0.000029284345],"category_scores_gemma":[0.0012699617,0.00016815691,0.00033009527,0.00027626895,0.0003526722,0.0001425078,0.00023936987,0.00025255638,0.000008609802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18119979,0.0006039678,0.80548525,0.000044668956,0.00997489,0.000028787294,0.00038266156,0.000088034416,0.000045353412,0.00007877057,0.00018205818,0.0018857481],"study_design_scores_gemma":[0.31206465,0.0018885648,0.6768412,0.000066893765,0.008106375,3.716352e-8,0.00007889896,0.00013895945,0.00040399667,0.000049252598,0.00020206854,0.00015909655],"about_ca_topic_score_codex":0.000049107424,"about_ca_topic_score_gemma":0.00004849812,"teacher_disagreement_score":0.13086487,"about_ca_system_score_codex":0.00004487362,"about_ca_system_score_gemma":0.00003588038,"threshold_uncertainty_score":0.68572396},"labels":[],"label_agreement":null},{"id":"W2735160054","doi":"10.3389/fendo.2017.00154","title":"Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Frontiers in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia; University of Alberta","funders":"","keywords":"Internal medicine; Medicine; Endocrinology; Incretin; Glycemic; Type 2 diabetes; Glucagon; Crossover study; Postprandial; Hormone; Insulin; Diabetes mellitus; Placebo","score_opus":0.0077638315042695425,"score_gpt":0.24505032283331254,"score_spread":0.237286491329043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735160054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917539,0.006598225,0.00006410918,0.00007461832,0.0002715837,0.00057313155,0.0000017783912,0.000012464354,0.00065020967],"genre_scores_gemma":[0.9950095,0.002433599,0.0021489908,0.00003558978,0.000013844688,0.000039342533,0.000005741813,0.000013739923,0.00029969093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990536,0.000025939868,0.00021481697,0.00024360714,0.00009476093,0.00036729185],"domain_scores_gemma":[0.9993402,0.00002562741,0.0001445808,0.00038465453,0.000055315526,0.00004965452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049235347,0.00015939944,0.0008225888,0.0002188999,0.000031428397,0.0000075295775,0.0001265031,0.000043576227,0.000004492155],"category_scores_gemma":[0.0000535293,0.00011944895,0.000028486009,0.000085890504,0.00026767055,0.00012131242,0.00011823816,0.00011218081,9.026052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004991368,0.0002456702,0.9674442,0.00044236745,0.00021665284,0.00031748172,0.00029168857,0.000038555994,0.0006533613,0.00009119426,0.00018406387,0.025083434],"study_design_scores_gemma":[0.015019201,0.00106233,0.86362135,0.00064019783,0.00038946027,0.000007991228,0.00011249164,0.0020116766,0.11668,0.00019340201,0.00009325717,0.0001686113],"about_ca_topic_score_codex":0.00020397258,"about_ca_topic_score_gemma":0.00011342908,"teacher_disagreement_score":0.11602664,"about_ca_system_score_codex":0.000028361435,"about_ca_system_score_gemma":0.00003152048,"threshold_uncertainty_score":0.4870987},"labels":[],"label_agreement":null},{"id":"W2735464518","doi":"10.22374/1710-6222.24.2.6","title":"Non-Severe Hypoglycemia Risk Difference Between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (Sglt2-I) as an Add-On to Metformin in Randomized Controlled Trials","year":2017,"lang":"en","type":"review","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Medicine; Hypoglycemia; Sulfonylurea; Metformin; Randomized controlled trial; Canagliflozin; Glimepiride; Empagliflozin; Dapagliflozin; Diabetes mellitus; Type 2 diabetes; Internal medicine; Anesthesia; Insulin; Endocrinology","score_opus":0.17401052912437157,"score_gpt":0.500247011863442,"score_spread":0.32623648273907047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735464518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3377578,0.65306824,0.00003055045,0.00050893147,0.0017093461,0.0067497063,0.000047317164,0.000013184745,0.00011489958],"genre_scores_gemma":[0.09214468,0.90550363,0.00014849477,0.00059281103,0.0012210842,0.0000789685,0.00008341893,0.000038160862,0.0001887707],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991999,0.0019927358,0.004957571,0.00040376457,0.00034943604,0.00029752209],"domain_scores_gemma":[0.9888289,0.005153134,0.005197097,0.00024450407,0.00014283574,0.00043356026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010644273,0.0005337347,0.013189409,0.00059725763,0.000100488,0.000072469666,0.00020319398,0.00055339764,0.0000616185],"category_scores_gemma":[0.00083852647,0.00030339116,0.0017469418,0.00009651557,0.00014573375,0.00011034835,0.000045813395,0.00096273626,0.000004740591],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06745249,0.000541202,0.0050531947,0.0004951601,0.0065891217,0.000066175584,0.000054093507,9.789704e-7,0.0000022716133,0.00002713711,0.000059960137,0.9196582],"study_design_scores_gemma":[0.6467621,0.006785926,0.014410415,0.004880562,0.09798858,0.000038738915,0.000025110261,0.000100043,0.000006131184,0.0011750814,0.22722664,0.0006006967],"about_ca_topic_score_codex":0.00003695447,"about_ca_topic_score_gemma":0.000017456065,"teacher_disagreement_score":0.9190575,"about_ca_system_score_codex":0.00009373957,"about_ca_system_score_gemma":0.00016743304,"threshold_uncertainty_score":0.9999418},"labels":[],"label_agreement":null},{"id":"W2735695101","doi":"","title":"Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Sitagliptin; Internal medicine; Endocrinology; Medicine; Placebo; Metformin; Glycated hemoglobin; Type 2 diabetes; Glucagon receptor; Blood pressure; Lipid profile; Glucagon; Diabetes mellitus; Insulin","score_opus":0.012636163900260403,"score_gpt":0.21571259437037038,"score_spread":0.20307643047010998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735695101","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22711486,0.0012203567,9.4337105e-7,0.00011217382,0.00014264557,0.0028986926,0.00009257134,0.00014838342,0.76826936],"genre_scores_gemma":[0.15909936,0.0015520604,0.0007659247,0.0002135712,0.0001810648,0.00011552446,0.0021886572,0.00016791408,0.83571595],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981236,0.000013148546,0.0002795245,0.0006852089,0.00044966274,0.00044886747],"domain_scores_gemma":[0.99841326,0.000042289634,0.00026812256,0.0008933004,0.00016441382,0.00021861629],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000037559712,0.00074252166,0.0009796674,0.00028932723,0.00010266454,0.00007248453,0.00014242453,0.00020942463,0.0012942816],"category_scores_gemma":[0.000007904688,0.00043146993,0.000118844466,0.000029543475,0.00018249395,0.00014074953,0.0000835071,0.00014811342,0.00034729962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005396939,0.004180594,0.820685,0.00059084664,0.0061001414,0.0005913623,0.00016882263,7.9607173e-7,0.000014375208,0.004128685,0.008948846,0.14919357],"study_design_scores_gemma":[0.028580891,0.042720996,0.06676354,0.0037671314,0.004858127,0.0000031126394,0.0000330161,0.000012524569,0.00068820635,0.00009581304,0.850711,0.0017656444],"about_ca_topic_score_codex":0.00037502366,"about_ca_topic_score_gemma":0.00051540206,"teacher_disagreement_score":0.8417621,"about_ca_system_score_codex":0.0005408216,"about_ca_system_score_gemma":0.00012329513,"threshold_uncertainty_score":0.99981374},"labels":[],"label_agreement":null},{"id":"W2735973581","doi":"10.1161/strokeaha.117.018125","title":"Response by Zinman et al to Letter Regarding Article, “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk”","year":2017,"lang":"en","type":"letter","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Empagliflozin; Diabetes mellitus; Internal medicine; Cardiology; Type 2 Diabetes Mellitus; Type 2 diabetes; Stroke (engine); Endocrinology","score_opus":0.0063382613075365435,"score_gpt":0.2126432551624394,"score_spread":0.20630499385490286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735973581","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8813118,0.00091770495,0.0000044758012,0.115738966,0.0002788588,0.0013745121,0.00013829164,0.000047767368,0.0001876507],"genre_scores_gemma":[0.48416287,0.0003206291,0.0006397204,0.50184405,0.00038259002,0.00026308213,0.0014139934,0.0002645682,0.0107084755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966897,0.00039470894,0.00031158037,0.00090340397,0.00095352833,0.0007470765],"domain_scores_gemma":[0.9980287,0.00009377625,0.00016681288,0.0014395332,0.00009602905,0.0001751511],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007471129,0.00053244043,0.0010003351,0.00031155525,0.00014030572,0.00006533547,0.00020868919,0.00026522827,0.000040892097],"category_scores_gemma":[0.00013901276,0.0004240567,0.00029168517,0.00011453713,0.00007451028,0.00014089543,0.00028270896,0.00070426916,0.000108273045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050553604,0.00007308277,0.38317183,0.00006371148,0.0026528572,0.000085726846,0.000049016755,0.0000062491263,0.000027229013,2.9378828e-7,0.6124122,0.00095223985],"study_design_scores_gemma":[0.0051431563,0.00071662856,0.27384028,0.00031904518,0.0010925316,5.951593e-7,0.0000033023034,0.0000019022573,0.0002865701,0.0000033089686,0.7182475,0.0003451825],"about_ca_topic_score_codex":0.00014665785,"about_ca_topic_score_gemma":0.000019344874,"teacher_disagreement_score":0.3971489,"about_ca_system_score_codex":0.000332358,"about_ca_system_score_gemma":0.000030892425,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W2736458946","doi":"10.14740/jocmr3116w","title":"Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Interim; Type 2 diabetes; Hemoglobin; Duration (music); Diabetes mellitus; Hemoglobin A; Interim analysis; Internal medicine; Endocrinology; Clinical trial","score_opus":0.1556934353405462,"score_gpt":0.5147115159928488,"score_spread":0.3590180806523026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736458946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952559,0.000075336306,0.000017011673,0.0017881644,0.0005067199,0.0017172876,0.0000010536106,0.0000016649881,0.00063684763],"genre_scores_gemma":[0.99935347,0.000019209896,0.00016248082,0.000015592277,0.00024636197,0.000020879994,0.0000028104566,0.00001382829,0.00016536257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962232,0.0006245956,0.0015680571,0.0002004828,0.0011619062,0.0002217194],"domain_scores_gemma":[0.9943297,0.0019518186,0.0011832189,0.00065946265,0.0017577657,0.00011805189],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015135745,0.00010963851,0.0009885351,0.00022508082,0.00007371499,0.000012762397,0.00033743837,0.000065590095,0.000022847815],"category_scores_gemma":[0.014213913,0.000052458243,0.00013973187,0.00021883268,0.0004593072,0.0001255806,0.00014975022,0.0004671312,4.0735296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004368975,0.002477321,0.980269,0.0004217348,0.0005561868,0.00006540326,0.00012600329,0.0000020791983,0.00029128883,0.000011531019,0.000657153,0.010753326],"study_design_scores_gemma":[0.011909075,0.024349991,0.95751166,0.0040586693,0.0002779177,0.0000031027669,0.00022784102,0.000025164452,0.0013542252,0.00008741533,0.00015310635,0.000041797866],"about_ca_topic_score_codex":0.00002765226,"about_ca_topic_score_gemma":0.000009787062,"teacher_disagreement_score":0.022757305,"about_ca_system_score_codex":0.00007306156,"about_ca_system_score_gemma":0.00026636393,"threshold_uncertainty_score":0.9940898},"labels":[],"label_agreement":null},{"id":"W2736785714","doi":"10.3389/fnagi.2017.00247","title":"Strong Association between Plasma Dipeptidyl Peptidase-4 Activity and Impaired Cognitive Function in Elderly Population with Normal Glucose Tolerance","year":2017,"lang":"en","type":"article","venue":"Frontiers in Aging Neuroscience","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Guilin Medical University; Science and Technology Department of Guangxi Zhuang Autonomous; Natural Science Foundation of Guangxi Province; National Natural Science Foundation of China","keywords":"Impaired glucose tolerance; Dipeptidyl peptidase; Association (psychology); Cognition; Population; Medicine; Function (biology); Dipeptidyl peptidase-4; Internal medicine; Endocrinology; Diabetes mellitus; Gerontology; Clinical psychology; Psychology; Type 2 diabetes; Psychiatry; Biology; Enzyme; Biochemistry; Cell biology; Psychotherapist; Environmental health","score_opus":0.015202045094340559,"score_gpt":0.25137497663187186,"score_spread":0.2361729315375313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736785714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966673,0.000021214892,0.0019330984,0.0002320867,0.00032089234,0.0004318564,0.00000597609,0.0000312217,0.0003563524],"genre_scores_gemma":[0.9991218,0.000017580955,0.0003579508,0.000054909153,0.000040352395,0.000024972922,0.000011092804,0.000009651095,0.0003617179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998888,0.000043071297,0.00012658343,0.00036682925,0.0002796601,0.00029585738],"domain_scores_gemma":[0.9995183,0.00003260844,0.00019706457,0.00016288957,0.000024270568,0.00006490748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025666642,0.00013036972,0.00022011543,0.00017933248,0.00021934656,0.00012524973,0.00007832709,0.000042545966,8.3842707e-7],"category_scores_gemma":[0.00013732612,0.00012067609,0.00002059182,0.00014827175,0.00007932801,0.0008476332,0.000049949274,0.00015889134,6.761896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013362394,0.00006860663,0.94713855,0.000023278091,0.000009828822,0.000015932745,0.00011862891,0.000042483316,0.0004622831,0.000003059463,0.000028262048,0.05195548],"study_design_scores_gemma":[0.0023367924,0.000436379,0.9893625,0.00021341647,0.00007988574,7.1178374e-7,0.00007892828,0.006654025,0.000680921,0.000018680297,0.000025991303,0.00011180096],"about_ca_topic_score_codex":0.00021223038,"about_ca_topic_score_gemma":0.000168082,"teacher_disagreement_score":0.05184368,"about_ca_system_score_codex":0.00019801676,"about_ca_system_score_gemma":0.00002208224,"threshold_uncertainty_score":0.49210283},"labels":[],"label_agreement":null},{"id":"W2737015170","doi":"10.2147/dmso.s117982","title":"Emerging use of combination therapies for the management of type 2 diabetes &amp;ndash; focus on saxagliptin and dapagliflozin","year":2017,"lang":"en","type":"review","venue":"Diabetes Metabolic Syndrome and Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"","keywords":"Saxagliptin; Dapagliflozin; Type 2 diabetes; Medicine; Diabetes mellitus; Endocrinology; Sitagliptin","score_opus":0.07047307259858364,"score_gpt":0.3239700210056702,"score_spread":0.25349694840708653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737015170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17618692,0.82096565,0.0000040010173,0.000076239914,0.00024170903,0.0023140449,0.00007331911,0.000024708157,0.000113408925],"genre_scores_gemma":[0.019921025,0.9779342,0.0005575511,0.00003594372,0.000038743518,0.00025419716,0.00014940904,0.00005716773,0.0010517709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981388,0.00009029829,0.00059667346,0.00047530603,0.00031138828,0.00038752248],"domain_scores_gemma":[0.99780023,0.00044417215,0.00068188383,0.0008639143,0.00011773022,0.00009204037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006456695,0.00049909175,0.002372609,0.00031514585,0.00021428442,0.000074796466,0.0002366586,0.00015884849,0.000019256797],"category_scores_gemma":[0.00007014641,0.00031827326,0.0003873268,0.00020804255,0.00023093456,0.00013965085,0.00022604608,0.00014629164,0.0000056656554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013328517,0.00039654665,0.00996195,0.02060146,0.005754091,0.0000021144124,0.00008661014,1.8088124e-7,0.0000023228963,0.0030254691,0.00017828906,0.9599776],"study_design_scores_gemma":[0.0012253835,0.0005666707,0.058431674,0.009273975,0.013835803,0.0000013512602,0.000028932483,0.000020747393,0.00003878988,0.00044643763,0.9157918,0.0003384479],"about_ca_topic_score_codex":0.000014841882,"about_ca_topic_score_gemma":0.0000027875867,"teacher_disagreement_score":0.9596392,"about_ca_system_score_codex":0.00002321415,"about_ca_system_score_gemma":0.000027549338,"threshold_uncertainty_score":0.9999269},"labels":[],"label_agreement":null},{"id":"W2738463628","doi":"10.1111/ijcp.12973","title":"Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully","year":2017,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; Western University; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Jewish General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Eli Lilly and Company","keywords":"Medicine; Insulin; Discontinuation; Diabetes mellitus; Type 2 diabetes; Type 1 diabetes; Intensive care medicine; Basal insulin; Internal medicine; Endocrinology","score_opus":0.05100988702093786,"score_gpt":0.404871406203345,"score_spread":0.35386151918240716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738463628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9282037,0.00029061487,0.00014134008,0.063531175,0.0011402518,0.0001819715,0.000004434252,0.000009408424,0.00649713],"genre_scores_gemma":[0.9819183,0.0006740948,0.011714958,0.0041116076,0.0011624753,0.000003239404,0.000005099915,0.000015626465,0.000394605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983433,0.000090717236,0.0006051592,0.00017506976,0.00063613645,0.00014961083],"domain_scores_gemma":[0.9952518,0.0013705161,0.0013258862,0.00021660626,0.0016003089,0.00023489285],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014714987,0.00012209953,0.00042242944,0.00010657117,0.000089807516,0.00037906156,0.00030501944,0.000059874983,0.00003932958],"category_scores_gemma":[0.019826125,0.00008803154,0.00008265813,0.00004871507,0.000075288495,0.0010918216,0.0001737108,0.00035919898,0.000021971522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004239647,0.0009956447,0.826889,0.000034690718,0.0023220389,0.0008744025,0.00027484683,0.000006977746,0.00009863871,0.00036752087,0.005903271,0.15799333],"study_design_scores_gemma":[0.0065878835,0.0038311172,0.7664471,0.000470627,0.0006119448,0.000112050126,0.00041293597,0.00010056951,0.00021524416,0.00014844668,0.22090638,0.00015567536],"about_ca_topic_score_codex":0.000015619507,"about_ca_topic_score_gemma":0.000034304056,"teacher_disagreement_score":0.21500312,"about_ca_system_score_codex":0.000034113153,"about_ca_system_score_gemma":0.00013993922,"threshold_uncertainty_score":0.9884303},"labels":[],"label_agreement":null},{"id":"W2738470483","doi":"10.1111/dom.13063","title":"Beyond glycaemic control: A cross‐over, double‐blinded, 24‐week intervention with liraglutide in type 1 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Novo Nordisk","keywords":"Medicine; Liraglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.016842916185050797,"score_gpt":0.27087693168449756,"score_spread":0.25403401549944676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738470483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867196,0.0066026733,0.0000081604,0.00038901728,0.00060024625,0.0008998694,0.00002189972,0.000080456244,0.0027256913],"genre_scores_gemma":[0.9965746,0.00050034106,0.00023694799,0.00059162313,0.00018576048,0.00009086758,0.00006324821,0.000038907026,0.0017177257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980956,0.000052059266,0.0003548294,0.00053837296,0.00030664008,0.00065253564],"domain_scores_gemma":[0.9986295,0.000056292334,0.00025933547,0.00070330687,0.00012517876,0.00022638982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051141786,0.0003614371,0.0007954046,0.00026226928,0.0003002664,0.0003321502,0.00024268676,0.00015089952,0.00007610989],"category_scores_gemma":[0.000097523785,0.0002884792,0.00015426542,0.00015439896,0.0002950655,0.00062902196,0.00017484435,0.00026759182,0.000039254806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007176323,0.0009302559,0.9804415,0.00027264134,0.00053405255,0.000031767908,0.000111406014,0.000004572489,0.00083597563,0.0017632907,0.00026657,0.014090307],"study_design_scores_gemma":[0.025368912,0.0004627329,0.96063167,0.000303366,0.00079187605,8.9492823e-7,0.000023674553,0.00019685121,0.0033743854,0.0009930306,0.0075330683,0.00031955665],"about_ca_topic_score_codex":0.00015305096,"about_ca_topic_score_gemma":0.00016911217,"teacher_disagreement_score":0.02465128,"about_ca_system_score_codex":0.000048236907,"about_ca_system_score_gemma":0.00003735837,"threshold_uncertainty_score":0.9999567},"labels":[],"label_agreement":null},{"id":"W2738559477","doi":"10.2337/dbi17-0020","title":"Species-Dependent Mechanisms Regulating Glucose-Dependent GLP-1 Secretion?","year":2017,"lang":"en","type":"letter","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Secretion; Endocrinology; Internal medicine; Biology; Cell biology; Chemistry; Medicine","score_opus":0.019721146560419095,"score_gpt":0.24597227149766607,"score_spread":0.22625112493724697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738559477","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.091262095,0.0039089937,0.0003508841,0.6763775,0.0076864804,0.006510581,0.00055786816,0.0017907418,0.21155486],"genre_scores_gemma":[0.091964886,0.00035191217,0.0026111256,0.42187718,0.013334107,0.00085284817,0.00757326,0.0006559938,0.46077868],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955839,0.000098351135,0.0006103128,0.0011320905,0.0013744447,0.0012009263],"domain_scores_gemma":[0.996905,0.00013690954,0.0006285937,0.0019567376,0.00017093885,0.00020176658],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00044536745,0.0008650135,0.0012668165,0.0003939066,0.00038549263,0.00035203228,0.000610121,0.00084324705,0.0013533871],"category_scores_gemma":[0.00013754632,0.00076285354,0.0005321951,0.00008997426,0.00013470816,0.00020369234,0.00043451786,0.0012624954,0.00080803764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021353175,0.00020493966,0.0030929826,0.0011507138,0.0019716364,0.0012716484,0.00008496936,0.0000024594056,0.0059838737,0.0006250021,0.9767001,0.008890319],"study_design_scores_gemma":[0.0030931921,0.0007038453,0.0025064957,0.0014237838,0.0025892223,0.000012110659,0.00006909559,0.00014902928,0.037335537,0.003257948,0.9475933,0.0012664737],"about_ca_topic_score_codex":0.00004305462,"about_ca_topic_score_gemma":0.0000068648937,"teacher_disagreement_score":0.2545003,"about_ca_system_score_codex":0.00045637062,"about_ca_system_score_gemma":0.00009895795,"threshold_uncertainty_score":0.99996996},"labels":[],"label_agreement":null},{"id":"W2738689849","doi":"10.1111/dom.13069","title":"Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Canadian Diabetes Association","keywords":"Glucagon; Internal medicine; Endocrinology; Crossover study; Nasal administration; Chemistry; Glucose clamp technique; Triglyceride; Medicine; Placebo; Insulin; Pancreatic hormone; Cholesterol; Pharmacology; Insulin resistance","score_opus":0.014209217674613837,"score_gpt":0.25399865322804516,"score_spread":0.23978943555343132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738689849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939689,0.0035584632,9.376699e-7,0.0004515051,0.00028130395,0.0013902994,0.000002106467,0.000007578996,0.0003389267],"genre_scores_gemma":[0.99757224,0.0021703336,0.00003366686,0.000029277058,0.00010740629,0.00004605569,0.0000071987483,0.0000071720847,0.000026660451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989079,0.00015986401,0.00020587501,0.00021898093,0.00034750762,0.00015982901],"domain_scores_gemma":[0.9992773,0.000039506816,0.00020669738,0.00033666028,0.0000922536,0.00004757788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007538711,0.000116142444,0.00033445258,0.000070448885,0.00013018874,0.000020290487,0.00005584434,0.00004819107,0.000003393905],"category_scores_gemma":[0.0002983696,0.000084219035,0.00003924531,0.00006808726,0.00012706165,0.00014431293,0.000040106115,0.00007846596,4.694114e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004764322,0.0012719239,0.7169937,0.0022975951,0.0003835274,0.0000014708928,0.0019773603,0.00002348128,0.1876194,0.001866578,0.00003620307,0.08705233],"study_design_scores_gemma":[0.0026498297,0.00014143673,0.767453,0.0003493597,0.00051417755,1.6339811e-7,0.000029687806,0.00018708901,0.22835562,0.00021642155,0.000052969626,0.000050203475],"about_ca_topic_score_codex":0.000035315814,"about_ca_topic_score_gemma":0.000020924343,"teacher_disagreement_score":0.08700213,"about_ca_system_score_codex":0.000043232187,"about_ca_system_score_gemma":0.00003094262,"threshold_uncertainty_score":0.34343526},"labels":[],"label_agreement":null},{"id":"W2738794532","doi":"10.1055/s-0043-103969","title":"Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"review","venue":"Experimental and Clinical Endocrinology & Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Discontinuation; Medicine; Type 2 Diabetes Mellitus; Context (archaeology); Type 2 diabetes; Adverse effect; Glucagon-like peptide 1 receptor; Diabetes mellitus; Hypoglycemia; Internal medicine; Insulin; Endocrinology; Receptor; Agonist; Biology","score_opus":0.06746239107097732,"score_gpt":0.4169249024850672,"score_spread":0.3494625114140899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738794532","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14055023,0.8566982,5.5722303e-8,0.00018876605,0.0006082274,0.0011309116,0.000071198614,0.0000297863,0.00072258344],"genre_scores_gemma":[0.040857792,0.9579642,0.00006616639,0.00009551271,0.00022429661,0.000079379075,0.00014348,0.00004611205,0.00052306626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969034,0.00023585072,0.0012964961,0.00068064634,0.0002008764,0.00068269065],"domain_scores_gemma":[0.9970677,0.0010316239,0.00082752696,0.0008420697,0.000043029388,0.00018806403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000367715,0.00053794694,0.0032058936,0.000073048905,0.0002020021,0.000031190943,0.00036319383,0.0003010598,0.0001104401],"category_scores_gemma":[0.00023533197,0.0003278834,0.0005674928,0.00009807985,0.002273745,0.000060711416,0.00073745166,0.00043687696,0.00002680946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014695557,0.0010961724,0.010191901,0.003101415,0.0033127775,0.000009888406,0.000092300084,1.0466818e-8,0.000039148337,0.0006610948,0.0004244503,0.9809239],"study_design_scores_gemma":[0.0034417438,0.0033325125,0.0055157966,0.0037965646,0.0023701414,0.000004484032,0.000108037624,0.0000016893933,0.0015198353,0.00004037784,0.9795179,0.00035092633],"about_ca_topic_score_codex":0.000014728219,"about_ca_topic_score_gemma":0.0000020557984,"teacher_disagreement_score":0.98057294,"about_ca_system_score_codex":0.000043661537,"about_ca_system_score_gemma":0.00007103556,"threshold_uncertainty_score":0.9999173},"labels":[],"label_agreement":null},{"id":"W2739456155","doi":"10.14740/jocmr3112w","title":"Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Renal glucose reabsorption; Medicine; Canagliflozin; Internal medicine; Endocrinology; Incretin; Type 2 Diabetes Mellitus; Glucagon-like peptide-1; Hypoglycemia; Glycemic; Dipeptidyl peptidase-4; Diabetes mellitus; Type 2 diabetes; Pharmacology","score_opus":0.2218592515214993,"score_gpt":0.5220486934782061,"score_spread":0.3001894419567068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739456155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13711786,0.85655093,0.0000027750991,0.0004755246,0.001104464,0.0024087029,0.000007331632,0.000014399008,0.0023180344],"genre_scores_gemma":[0.11482939,0.8823955,0.00006525983,0.000050118793,0.0020203101,0.000037208378,0.000029337967,0.000101443446,0.00047141875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895083,0.0024124102,0.0036571217,0.00066815485,0.002815149,0.00093891006],"domain_scores_gemma":[0.9845372,0.01029135,0.002525319,0.0009872295,0.0009997503,0.00065918907],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024739103,0.00066047575,0.0074276575,0.0014938157,0.000112881455,0.00003442857,0.0006304744,0.0005712855,0.000105850224],"category_scores_gemma":[0.007946236,0.00035109665,0.0010063498,0.00094716175,0.00094114715,0.00016271065,0.00011941507,0.004071748,0.000028328783],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013690768,0.0010362485,0.015681386,0.028942097,0.001855502,0.0012323313,0.00005598942,0.0000013431651,0.000008848262,0.000007342734,0.0014056473,0.9484042],"study_design_scores_gemma":[0.017127136,0.08138871,0.013082763,0.3507167,0.0067267185,0.00008280799,0.00004009448,0.00003225581,0.00040424036,0.000045617126,0.52976817,0.0005847686],"about_ca_topic_score_codex":0.000041784086,"about_ca_topic_score_gemma":0.000020698037,"teacher_disagreement_score":0.9478194,"about_ca_system_score_codex":0.00036146978,"about_ca_system_score_gemma":0.0013608772,"threshold_uncertainty_score":0.9998941},"labels":[],"label_agreement":null},{"id":"W2740627130","doi":"10.2337/dc17-0744","title":"When Insulin Therapy Fails: The Impact of SGLT2 Inhibitors in Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Centre for Family Medicine; Western University","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Insulin; Type 1 diabetes; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.010171442467341975,"score_gpt":0.23936339213615257,"score_spread":0.2291919496688106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740627130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804772,0.0041266703,2.0461338e-8,0.0112572145,0.00030517316,0.0019387767,0.00017682598,0.000049176655,0.0016689431],"genre_scores_gemma":[0.9716191,0.00014866472,0.000035555604,0.023078077,0.0007901346,0.00017423081,0.0036170545,0.0001476651,0.00038949706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767303,0.000096546224,0.0004004738,0.0005135516,0.00059906376,0.0007173023],"domain_scores_gemma":[0.99765396,0.00012383107,0.00044967452,0.0013275665,0.0003695243,0.000075472104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012001641,0.0006185422,0.0010180621,0.0003310897,0.00008990462,0.000114130315,0.0004795991,0.00042949832,0.0001267931],"category_scores_gemma":[0.0000673433,0.00033154114,0.00035650854,0.00019575786,0.0002237096,0.00019108242,0.00013227138,0.00080128113,0.000066792745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000535159,0.00013469714,0.7157895,0.000268062,0.0009219681,0.000013680227,0.0005641425,0.0000023678992,0.0000071024947,2.9618815e-7,0.26481068,0.017434007],"study_design_scores_gemma":[0.0050715534,0.003714637,0.8798109,0.0013531852,0.00042892617,4.080868e-8,0.00012971264,0.000005187905,0.00040394976,0.00004169324,0.10855062,0.000489534],"about_ca_topic_score_codex":0.00007438493,"about_ca_topic_score_gemma":0.000008497662,"teacher_disagreement_score":0.16402149,"about_ca_system_score_codex":0.00027731748,"about_ca_system_score_gemma":0.00014795046,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W2741645104","doi":"10.14740/jocmr3118w","title":"Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alogliptin; Medicine; Glycemic; Type 2 diabetes; Pioglitazone; Internal medicine; Diabetes mellitus; Repaglinide; Observational study; Gastroenterology; Endocrinology; Dipeptidyl peptidase-4","score_opus":0.19828962308858636,"score_gpt":0.5103893357678566,"score_spread":0.3120997126792703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741645104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995277,0.0000830498,5.0868874e-7,0.001959765,0.00032409042,0.0013352599,0.0000019373736,0.000003605236,0.0010147772],"genre_scores_gemma":[0.99895144,0.00006656699,0.000019428806,0.00014837192,0.0005501972,0.000015234854,0.000008353755,0.000019126928,0.00022131148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956168,0.00064281194,0.0012270366,0.00023247018,0.0019328942,0.00034801097],"domain_scores_gemma":[0.9937196,0.0036356032,0.000738706,0.0005679665,0.0010595944,0.00027856726],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0070574097,0.00016330663,0.0012693473,0.00041265917,0.000072739196,0.000017712387,0.00038561554,0.00009352105,0.000115098155],"category_scores_gemma":[0.011440147,0.0000855139,0.00012383639,0.00021771707,0.00045426085,0.00012289651,0.000080796104,0.0009071092,0.000017329328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023337308,0.0029933404,0.9627919,0.00016116654,0.0005797923,0.00019643935,0.00010822007,0.0000018112098,0.000029376175,0.000005803524,0.00078655186,0.009008259],"study_design_scores_gemma":[0.051756743,0.10285647,0.843308,0.0015888656,0.00026793889,7.1931066e-7,0.000061166655,0.00001660006,0.000018489207,0.000011885361,0.00006070515,0.0000524458],"about_ca_topic_score_codex":0.000024870484,"about_ca_topic_score_gemma":0.000020581432,"teacher_disagreement_score":0.11948396,"about_ca_system_score_codex":0.00008288369,"about_ca_system_score_gemma":0.00016154314,"threshold_uncertainty_score":0.9968869},"labels":[],"label_agreement":null},{"id":"W2742198484","doi":"10.1016/j.diabres.2017.07.033","title":"Renal glucose metabolism in normal physiological conditions and in diabetes","year":2017,"lang":"en","type":"review","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Renal glucose reabsorption; Internal medicine; Endocrinology; Gluconeogenesis; Medicine; Postprandial; Diabetes mellitus; Kidney; Carbohydrate metabolism; Hypoglycemia; Glycosuria; Renal physiology; Glucose homeostasis; Metabolism; Type 2 diabetes; Insulin resistance","score_opus":0.30264114466129516,"score_gpt":0.5510799041388322,"score_spread":0.24843875947753707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742198484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037269004,0.9547715,7.5599296e-8,0.0008387832,0.000117428644,0.0017895807,0.000051617833,0.000024138759,0.00513788],"genre_scores_gemma":[0.0035485043,0.9940536,0.00024324204,0.00028076736,0.00034040186,0.000498767,0.00031130973,0.000038761395,0.0006846146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99457353,0.001638582,0.0011714183,0.0009694396,0.00057221425,0.0010748217],"domain_scores_gemma":[0.9896035,0.008624623,0.00037289053,0.0007055348,0.00018493482,0.00050851604],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005871331,0.00042217973,0.0025845494,0.000472498,0.00021144227,0.0002356771,0.0003090777,0.00054433703,0.0000882845],"category_scores_gemma":[0.014069979,0.0003034764,0.00029532786,0.00039800783,0.0010535133,0.000558675,0.0007313415,0.002521138,0.00011035338],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009914871,0.0023161725,0.0065654106,0.004004559,0.00078639755,0.00029098545,0.000012560242,3.3966128e-8,0.0000028438312,0.0004261969,0.0017784617,0.9837172],"study_design_scores_gemma":[0.0020944679,0.0011093683,0.042194,0.0051276414,0.0010335903,0.0000027252254,0.000036272082,0.000027753038,0.0000016251914,0.0005381594,0.94754624,0.00028816945],"about_ca_topic_score_codex":0.000029293207,"about_ca_topic_score_gemma":0.000027979437,"teacher_disagreement_score":0.9834291,"about_ca_system_score_codex":0.00008461142,"about_ca_system_score_gemma":0.0002483449,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W2743269164","doi":"10.1016/j.jcjd.2017.07.001","title":"Regarding Insulin Initiation in Type 2 Diabetes Mellitus and the Risk for Hypoglycemia","year":2017,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin; Hypoglycemia; Diabetes mellitus; Glycemic; Type 2 diabetes; Intensive care medicine; Type 1 diabetes; Insulin resistance; Type 2 Diabetes Mellitus; Internal medicine; Endocrinology","score_opus":0.01736577275592976,"score_gpt":0.2348560615740124,"score_spread":0.21749028881808263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743269164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63247234,0.054195948,0.00000285899,0.3070615,0.001968546,0.0016222531,0.00016906964,0.000012062223,0.0024954153],"genre_scores_gemma":[0.845494,0.002433125,0.0005662858,0.14381188,0.005605356,0.00010134897,0.00037101205,0.00014814505,0.0014688916],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835265,0.00012081909,0.0005162256,0.000220677,0.00020543682,0.0005842168],"domain_scores_gemma":[0.99773073,0.00061476574,0.00077707646,0.0003653983,0.00026750853,0.00024450204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095469685,0.00028968853,0.0008664643,0.000641384,0.00021886198,0.00019550424,0.00027227326,0.00034129657,0.000023638588],"category_scores_gemma":[0.0015079268,0.0001968979,0.00023975903,0.000109206274,0.00027028788,0.00018003842,0.000022950477,0.0009738242,0.000006305318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006342231,0.000017100429,0.20495082,0.0006221444,0.0013886258,0.00016752383,0.00036146704,0.00000603538,0.00000480824,0.00008388126,0.75498325,0.03735092],"study_design_scores_gemma":[0.0096042985,0.0006771722,0.034611348,0.0016618723,0.0022748078,0.0000034645986,0.000053353902,0.00015234282,0.00007171578,0.0026738523,0.9478739,0.00034186512],"about_ca_topic_score_codex":0.00028765545,"about_ca_topic_score_gemma":0.0013004703,"teacher_disagreement_score":0.2130216,"about_ca_system_score_codex":0.00026666257,"about_ca_system_score_gemma":0.00061216083,"threshold_uncertainty_score":0.80292636},"labels":[],"label_agreement":null},{"id":"W2744247868","doi":"10.1016/j.jcjd.2017.05.004","title":"Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Empagliflozin; Medicine; Diabetic ketoacidosis; Type 2 diabetes; Diabetes mellitus; Canagliflozin; Glycemic; Ketoacidosis; Internal medicine; Intensive care medicine; Type 1 diabetes; Endocrinology","score_opus":0.028562885088618085,"score_gpt":0.24043446441766222,"score_spread":0.21187157932904413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744247868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890805,0.0021074114,0.0000014030173,0.0053341025,0.00048180213,0.00042354263,0.000016088332,0.000008991314,0.0027186237],"genre_scores_gemma":[0.9978434,0.0006093637,0.00016767306,0.0008119732,0.00014510097,0.000024645635,0.000020880265,0.000030909057,0.00034609466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840987,0.00006754774,0.0005497212,0.00021755113,0.00032892686,0.00042639283],"domain_scores_gemma":[0.99796975,0.000080443475,0.00068254804,0.00046633455,0.00027716625,0.00052376935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039360055,0.00024771516,0.00053046126,0.0003639744,0.00046008895,0.00016065995,0.0003358172,0.00010515984,0.000050653332],"category_scores_gemma":[0.00018817312,0.00018048713,0.00019606261,0.00014402294,0.0003405234,0.00030271555,0.00006412899,0.00021365067,0.00001608053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011691816,0.00056200544,0.6921146,0.0019091934,0.009126789,0.00033152482,0.006580934,0.000007929114,0.0051566833,0.0005260843,0.023108793,0.26045856],"study_design_scores_gemma":[0.006821562,0.0016538606,0.9460011,0.005282027,0.005091421,0.0000034283662,0.002546314,0.000092750655,0.019997543,0.0014989233,0.010486154,0.00052492466],"about_ca_topic_score_codex":0.0005032386,"about_ca_topic_score_gemma":0.003054981,"teacher_disagreement_score":0.25993362,"about_ca_system_score_codex":0.00024356597,"about_ca_system_score_gemma":0.00017384632,"threshold_uncertainty_score":0.7360051},"labels":[],"label_agreement":null},{"id":"W2744253559","doi":"10.1016/s2213-8587(17)30259-0","title":"SGLT2 inhibitors in the real world: too good to be true?","year":2017,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Disease; Internal medicine; Incidence (geometry); Endocrinology","score_opus":0.04354202120162847,"score_gpt":0.307080378171915,"score_spread":0.26353835697028655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744253559","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08855051,0.0006250155,1.9453446e-7,0.80636567,0.0010861743,0.0016913433,0.000056339042,0.00013864292,0.10148613],"genre_scores_gemma":[0.06082345,0.00046336162,0.000110192464,0.89324963,0.010106417,0.0011668279,0.00051056955,0.00010742593,0.033462122],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953441,0.00035307877,0.00048406303,0.00073402084,0.00049693894,0.0025877745],"domain_scores_gemma":[0.9962971,0.0005829563,0.0002709163,0.0027267167,0.00004703594,0.000075252894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005766922,0.00062487694,0.0014616225,0.00049286574,0.00021901191,0.00013558575,0.0016211368,0.00028281278,0.00012583694],"category_scores_gemma":[0.0001301668,0.00035343654,0.00028005108,0.00030216758,0.00033141422,0.000075086864,0.00050478044,0.0019848994,0.0003857417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039058872,0.00009329036,0.030527832,0.00014503306,0.0005075146,0.0011167296,0.00033995984,8.2879154e-7,0.000035935886,0.0011955632,0.95445675,0.0115414895],"study_design_scores_gemma":[0.0018110032,0.00041848153,0.030263383,0.00016737191,0.0006148755,0.000009864751,0.000055941047,0.0000020703037,0.00022316512,0.0007096956,0.9653848,0.00033934115],"about_ca_topic_score_codex":0.000266665,"about_ca_topic_score_gemma":0.00047768615,"teacher_disagreement_score":0.086883985,"about_ca_system_score_codex":0.00019578334,"about_ca_system_score_gemma":0.000067252004,"threshold_uncertainty_score":0.99989176},"labels":[],"label_agreement":null},{"id":"W2745294544","doi":"10.1016/j.jacbts.2017.07.003","title":"Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure","year":2017,"lang":"en","type":"review","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Libin Cardiovascular Institute of Alberta; St. Michael's Hospital; University of Calgary; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Innovates - Health Solutions; AstraZeneca; Eli Lilly and Company; Alberta Innovates; Heart and Stroke Foundation of Canada; Amgen","keywords":"Empagliflozin; Medicine; Cardiac function curve; Heart failure; Diabetes mellitus; Cardiology; Internal medicine; Type 2 Diabetes Mellitus; Ex vivo; Type 2 diabetes; Diastole; In vivo; Blood pressure; Endocrinology; Biology","score_opus":0.09415707814941483,"score_gpt":0.3762072484118737,"score_spread":0.2820501702624589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745294544","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.074628286,0.9170976,0.00011916099,0.0001963444,0.00052486063,0.0052004443,0.00020562542,0.000045991317,0.0019816838],"genre_scores_gemma":[0.94163513,0.047830023,0.008429236,0.00005870768,0.00021923285,0.000477628,0.00023681026,0.00007100425,0.001042208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978192,0.000052823623,0.0005093304,0.00052365725,0.0008301073,0.0002649242],"domain_scores_gemma":[0.99901676,0.000033126467,0.00024435247,0.00047636594,0.00007901875,0.00015036364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052712095,0.00025451125,0.0010344785,0.00044644758,0.00008563586,0.000022745071,0.00028696124,0.00011731193,0.00003975318],"category_scores_gemma":[0.000021571992,0.00021526679,0.00028565607,0.0004144748,0.000108835324,0.0004713142,0.000052529387,0.00013923373,0.0000051462757],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017598085,0.0015744645,0.004470938,0.0076991394,0.0004923408,0.0000022398895,0.0014115203,0.0016281161,0.020771129,0.0013255713,0.0002884945,0.9601601],"study_design_scores_gemma":[0.0049217124,0.0032029992,0.039028227,0.050013352,0.0075945375,0.0000063795137,0.00031668128,0.0068231733,0.009360643,0.00033493267,0.8762254,0.0021719353],"about_ca_topic_score_codex":0.000028339498,"about_ca_topic_score_gemma":0.000014766595,"teacher_disagreement_score":0.95798814,"about_ca_system_score_codex":0.0000789867,"about_ca_system_score_gemma":0.000526642,"threshold_uncertainty_score":0.8778325},"labels":[],"label_agreement":null},{"id":"W2745858008","doi":"10.1161/hypertensionaha.117.09482","title":"Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events","year":2017,"lang":"en","type":"article","venue":"Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Hazard ratio; Internal medicine; Diabetes mellitus; Blood pressure; Proportional hazards model; Sitagliptin; Kidney disease; Confidence interval; Cardiology; Renal function; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.014860511377566898,"score_gpt":0.21182491810167894,"score_spread":0.19696440672411206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745858008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892121,0.008196647,0.0000114600725,0.0009269295,0.00017232356,0.0008428684,0.0000027545427,0.000039767925,0.000595168],"genre_scores_gemma":[0.99759096,0.0014237274,0.00024966814,0.00048221293,0.00006032078,0.000047819936,0.000022843502,0.000025570991,0.000096864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998724,0.000035958165,0.0001712694,0.00042558397,0.00032410782,0.0003190807],"domain_scores_gemma":[0.9989193,0.00002810228,0.00007239987,0.0007473305,0.000095287585,0.00013754821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020219793,0.00021108038,0.0005796951,0.000106935724,0.00016365136,0.00003060532,0.00007602521,0.0000723581,0.000006028214],"category_scores_gemma":[0.00006734912,0.00013972499,0.00011612559,0.000044878627,0.00006826149,0.00014404434,0.000074522126,0.000107048225,0.00002252318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014032876,0.0010453498,0.63586694,0.00049367483,0.0013096408,0.0010281042,0.0001283007,0.000013112729,0.0017256166,0.000055702123,0.0013826932,0.35554758],"study_design_scores_gemma":[0.019354103,0.0011278606,0.9646188,0.0020876676,0.0010737735,0.000034264085,0.000064934124,0.0027938373,0.00043865558,0.00004300541,0.008084565,0.000278538],"about_ca_topic_score_codex":0.00008267641,"about_ca_topic_score_gemma":0.000026893065,"teacher_disagreement_score":0.35526904,"about_ca_system_score_codex":0.000039997733,"about_ca_system_score_gemma":0.000014759517,"threshold_uncertainty_score":0.56978196},"labels":[],"label_agreement":null},{"id":"W2746628081","doi":"10.1111/dom.13086","title":"Effect of once‐weekly dulaglutide on glycated haemoglobin ( <scp>HbA1c</scp> ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline <scp>HbA1c</scp>","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Internal medicine; Diabetes mellitus; Confidence interval; Glycated hemoglobin; Type 2 diabetes; Gastroenterology; Glycated haemoglobin; Adverse effect; Endocrinology; Liraglutide","score_opus":0.01035491514470968,"score_gpt":0.23737268121278995,"score_spread":0.22701776606808027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746628081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032784,0.007513498,0.000009783482,0.00008890743,0.00015653638,0.0012765336,0.00016036544,0.00004922085,0.00041729066],"genre_scores_gemma":[0.9978452,0.001025726,0.0003064149,0.00010594198,0.00006177183,0.00007914719,0.00036389608,0.0000380782,0.00017382846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974332,0.0002738356,0.0006975914,0.00061377365,0.0003981944,0.0005834457],"domain_scores_gemma":[0.9975178,0.00091685116,0.0006194171,0.0005484473,0.00013379127,0.00026366638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009680193,0.0004660407,0.0011287729,0.0003507146,0.00032843216,0.000094721014,0.00014203964,0.00019326556,0.0000037131965],"category_scores_gemma":[0.0020249977,0.00040343046,0.0001220067,0.00021301192,0.00030370193,0.00037858367,0.00021696337,0.00022379876,0.0000021725623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020265015,0.00097442506,0.9021555,0.0010351698,0.00050297385,0.000010321432,0.0007431882,0.000014656352,0.06584504,0.00031618794,0.00032618764,0.028056072],"study_design_scores_gemma":[0.0053984323,0.0009317142,0.7133101,0.00039302558,0.0014008951,9.197664e-7,0.00012473056,0.0016028974,0.27591616,0.00016860847,0.00065124803,0.000101259975],"about_ca_topic_score_codex":0.00015630554,"about_ca_topic_score_gemma":0.000039026734,"teacher_disagreement_score":0.2100711,"about_ca_system_score_codex":0.00002688602,"about_ca_system_score_gemma":0.000026345026,"threshold_uncertainty_score":0.99984175},"labels":[],"label_agreement":null},{"id":"W2746874591","doi":"10.1161/circulationaha.117.028136","title":"Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","year":2017,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Banting and Best Diabetes Centre, University of Toronto; Medicines Company; Novo Nordisk; Intarcia Therapeutics; Sanofi; GlaxoSmithKline; Servier; Pfizer; Canada Research Chairs; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Semaglutide; Lixisenatide; Alogliptin; Saxagliptin; Liraglutide; Glucagon-like peptide 1 receptor; Internal medicine; Diabetes mellitus; Exenatide; Sitagliptin; Dipeptidyl peptidase-4; Type 2 diabetes; Myocardial infarction; Pharmacology; Endocrinology; Agonist; Receptor","score_opus":0.10379896922383484,"score_gpt":0.3727103154527517,"score_spread":0.2689113462289168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746874591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004737767,0.9896239,0.00005199469,0.00007660378,0.0005738623,0.002418913,0.000022582855,0.00011622284,0.0023781313],"genre_scores_gemma":[0.0046882704,0.9921079,0.00036870493,0.0000469869,0.00039989085,0.00017382547,0.0005966637,0.0000864912,0.0015312401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783605,0.0001240899,0.00061175204,0.0007695201,0.00037537687,0.0002831896],"domain_scores_gemma":[0.9981381,0.00013504046,0.00042798836,0.00096917327,0.000082415005,0.00024725057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046330897,0.00050397095,0.0021851102,0.00022565604,0.00029611168,0.00015934804,0.00008577881,0.00033908233,0.00001596337],"category_scores_gemma":[0.0000977942,0.00036038688,0.00089308864,0.00010847144,0.00023180974,0.00020827941,0.00010208015,0.00031735367,0.000060651255],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009889033,0.00011965291,0.042663313,0.0043188394,0.0050791707,0.00002553363,0.000025706695,6.32325e-7,1.2348704e-7,0.000041290936,0.0006196842,0.94709617],"study_design_scores_gemma":[0.0012568744,0.00012769486,0.06297916,0.005296916,0.012030295,0.000027885291,0.000019929988,0.000005745072,1.2694453e-7,0.0000062537233,0.91790164,0.00034748376],"about_ca_topic_score_codex":0.000029650777,"about_ca_topic_score_gemma":0.000011808368,"teacher_disagreement_score":0.9467487,"about_ca_system_score_codex":0.0001624196,"about_ca_system_score_gemma":0.00013389261,"threshold_uncertainty_score":0.9998848},"labels":[],"label_agreement":null},{"id":"W2746903407","doi":"10.1002/ejhf.933","title":"Moderated ePoster Session 2","year":2014,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute on Aging; Medical Research Council; Sundhedsvidenskabelige Fakultet, Aarhus Universitet; National Institutes of Health; H. Lundbeck A/S; Hjartavernd; Lundbeckfonden; Institut National de la Santé et de la Recherche Médicale; Aarhus Universitet; Université de Lille; Wellcome Trust; Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease; Centre hospitalier régional universitaire de Lille; Danmarks Frie Forskningsfond; Erasmus Medisch Centrum; Novo Nordisk; Bundesministerium für Bildung und Forschung; National Heart, Lung, and Blood Institute; Villum Fonden","keywords":"Empagliflozin; Medicine; Heart failure; Canagliflozin; Diabetes mellitus; Internal medicine; Intensive care medicine; Clinical trial; Disease; Type 2 Diabetes Mellitus; Cardiology; Endocrinology","score_opus":0.03160162829318401,"score_gpt":0.30447044304439363,"score_spread":0.2728688147512096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746903407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021316688,0.99377406,0.00008816607,0.0014022257,0.00033913675,0.00036057844,0.0000024339877,0.000025481286,0.003986594],"genre_scores_gemma":[0.000097106036,0.9893108,0.0046864985,0.0004172174,0.0009058252,0.0000016110766,0.000045415592,0.00011490784,0.004420631],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978329,0.00059093576,0.00084546435,0.0001857148,0.00031995558,0.00022506075],"domain_scores_gemma":[0.99870783,0.00004014899,0.0005720428,0.0003129771,0.0001438392,0.00022313655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007210885,0.00033297174,0.0016927235,0.0002971511,0.0000498019,0.000061257844,0.00014888417,0.000061690844,0.00020940001],"category_scores_gemma":[0.000042715503,0.00019780289,0.00075637473,0.00014382222,0.0000253884,0.0000812503,0.00007902056,0.00052683963,0.0007592953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001721163,0.00009478941,0.000009408622,0.004888464,0.0004767789,0.00055514876,0.000016242924,7.077471e-7,0.0000024369997,0.0000074613995,0.30839667,0.68553466],"study_design_scores_gemma":[0.00082821003,0.0007113458,0.000015134866,0.027317524,0.002154578,0.00073878496,0.0000051039874,0.0000016268037,0.0000017592131,0.0000022987024,0.968072,0.00015166444],"about_ca_topic_score_codex":1.16059674e-7,"about_ca_topic_score_gemma":1.07576994e-7,"teacher_disagreement_score":0.685383,"about_ca_system_score_codex":0.00006437869,"about_ca_system_score_gemma":0.0000985577,"threshold_uncertainty_score":0.97594583},"labels":[],"label_agreement":null},{"id":"W2747409868","doi":"","title":"GLP-1受容体作動薬の作用機序と血糖改善プロファイルの違い：Prandial GLP-1受容体作動薬とFasting GLP-1受容体作動薬","year":2014,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glucagon-like peptide-1; Internal medicine; Medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus","score_opus":0.02194927514689466,"score_gpt":0.29080140246761144,"score_spread":0.2688521273207168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747409868","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30525205,0.03402212,0.00455155,0.0415164,0.036245428,0.008810815,0.00035306654,0.0030769648,0.5661716],"genre_scores_gemma":[0.95598114,0.0035510678,0.0011850107,0.0070464406,0.011610439,0.00031207295,0.00055112754,0.0003405812,0.01942213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895609,0.0006910547,0.0019076723,0.0020402607,0.002768926,0.0030312098],"domain_scores_gemma":[0.9937373,0.0010162941,0.0008582948,0.00171223,0.00031949478,0.0023564287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00292578,0.001621231,0.002214299,0.0007524522,0.00074655603,0.00029485504,0.0011873846,0.0005797315,0.010865765],"category_scores_gemma":[0.001585894,0.0014772307,0.0008587726,0.0011085316,0.0007621389,0.0005999196,0.00082570617,0.0014634812,0.0074108276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016671611,0.004172772,0.009631081,0.0031097566,0.0049574743,0.0012254599,0.00508018,0.00004175036,0.00620525,0.0028829032,0.22360618,0.73742],"study_design_scores_gemma":[0.026357587,0.0022269008,0.0032513216,0.002264822,0.0057563367,0.00007734199,0.0009314265,0.012070628,0.0066487393,0.0003199935,0.9382663,0.001828613],"about_ca_topic_score_codex":0.0002202581,"about_ca_topic_score_gemma":0.000022975362,"teacher_disagreement_score":0.7355914,"about_ca_system_score_codex":0.0005589578,"about_ca_system_score_gemma":0.0004070709,"threshold_uncertainty_score":0.9996535},"labels":[],"label_agreement":null},{"id":"W2747870241","doi":"10.1016/j.jcjd.2017.08.002","title":"Choosing the Best Therapy for Your Patients in Today's Diabetes World","year":2017,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"McGill University Health Centre; McGill University; Yale University","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.018219164247599177,"score_gpt":0.26715786336806424,"score_spread":0.24893869912046507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747870241","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3944033,0.0105237495,4.2910494e-7,0.0021514618,0.5879264,0.0018815185,0.00036783156,0.000010783689,0.0027345056],"genre_scores_gemma":[0.26654547,0.000627719,0.00023839026,0.0010754846,0.7193581,0.00023712413,0.00076928944,0.0002947439,0.010853676],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974734,0.00006466205,0.0006909425,0.00029967882,0.00053239247,0.0009389298],"domain_scores_gemma":[0.99672806,0.00059932825,0.00086223864,0.0005666883,0.0006482411,0.00059543236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075715425,0.00045504508,0.0010189431,0.0009833869,0.0003159934,0.00032665033,0.00071136694,0.00031386534,0.000047663983],"category_scores_gemma":[0.0013440893,0.00031020268,0.00045869476,0.00017528412,0.00018035325,0.00023715849,0.000029701767,0.000774126,0.000010675682],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001265463,0.00009974729,0.313083,0.00011213399,0.00050181296,0.000008795371,0.000093312454,0.0000014311024,0.000003085807,0.00000589161,0.6615633,0.024514861],"study_design_scores_gemma":[0.004748371,0.0011282524,0.046523884,0.00197163,0.00054492726,5.149209e-8,0.000051979314,0.0000065964114,0.00008532551,0.00018816318,0.94445306,0.0002977821],"about_ca_topic_score_codex":0.0005601521,"about_ca_topic_score_gemma":0.01626606,"teacher_disagreement_score":0.28288978,"about_ca_system_score_codex":0.00059619936,"about_ca_system_score_gemma":0.0018104116,"threshold_uncertainty_score":0.99993503},"labels":[],"label_agreement":null},{"id":"W2747878664","doi":"10.1016/j.amjmed.2017.05.047","title":"Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study","year":2017,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; St. Michael's Hospital; Population Health Research Institute; McMaster University; University of Toronto","funders":"Sanofi","keywords":"Medicine; Kidney disease; Internal medicine; Hazard ratio; Diabetes mellitus; Myocardial infarction; Type 2 diabetes; Stroke (engine); Macrovascular disease; Cardiology; Confidence interval; Endocrinology","score_opus":0.018596780302576867,"score_gpt":0.32463709143840813,"score_spread":0.30604031113583124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747878664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7437262,0.00088647247,0.00002680442,0.2545535,0.00010285156,0.0005243747,0.000001618118,0.000005690709,0.00017248279],"genre_scores_gemma":[0.99309176,0.00090272777,0.00006153308,0.0051756226,0.00040518978,0.000013701996,0.000001961691,0.000016961361,0.00033052653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862653,0.00011036645,0.00037014968,0.00013802647,0.00049570255,0.00025923102],"domain_scores_gemma":[0.99813807,0.00010662875,0.00076730165,0.00057863287,0.000060811,0.00034857288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010812373,0.00017503853,0.0007619014,0.00012324663,0.00020549161,0.000025050665,0.0003227613,0.000007454437,0.00002771228],"category_scores_gemma":[0.00019302947,0.000065605,0.000042736887,0.00016414974,0.000659569,0.00008385014,0.00007667895,0.00030421538,0.0000022207582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008607924,0.0002804881,0.96197265,0.000032343887,0.00037533138,0.00016238455,0.0012521286,0.0000046791047,0.000003833475,0.000055251636,0.0028443472,0.03215579],"study_design_scores_gemma":[0.010965871,0.0101333875,0.97269845,0.00038379116,0.00045634597,0.000029168446,0.0027067156,0.000032067743,0.0000010857686,0.00005114888,0.0024785288,0.000063458225],"about_ca_topic_score_codex":0.00086458784,"about_ca_topic_score_gemma":0.00038829382,"teacher_disagreement_score":0.24937786,"about_ca_system_score_codex":0.00015860003,"about_ca_system_score_gemma":0.00038089996,"threshold_uncertainty_score":0.26752946},"labels":[],"label_agreement":null},{"id":"W2748386152","doi":"10.1089/dia.2017.0134","title":"Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis","year":2017,"lang":"en","type":"article","venue":"Diabetes Technology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Diabetes Canada","funders":"Novo Nordisk; Eli Lilly and Company","keywords":"Medicine; Dapagliflozin; Glycemic; Blood pressure; Type 2 diabetes; Internal medicine; Diabetes mellitus; Body mass index; Glycated hemoglobin; Endocrinology","score_opus":0.003797282530182528,"score_gpt":0.23199106008326786,"score_spread":0.22819377755308534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748386152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957454,0.0014254027,4.2314994e-7,0.0008577075,0.00008883171,0.0011524594,0.000033526656,0.00003886502,0.00065739115],"genre_scores_gemma":[0.99921036,0.00021965166,0.00006240022,0.0003080474,0.00001747958,0.000094469964,0.000033492113,0.000029770757,0.000024326037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981664,0.00010934703,0.00033659776,0.000517255,0.0002875702,0.0005828616],"domain_scores_gemma":[0.99825275,0.0003428556,0.00040192026,0.0008110643,0.0001404854,0.000050904182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023349642,0.00032317347,0.0011508309,0.00076004973,0.00009099506,0.000021711568,0.00025580288,0.00017393572,0.000010665058],"category_scores_gemma":[0.00022181797,0.00025214328,0.000055842833,0.00059352064,0.00033921568,0.00011139817,0.00010670702,0.00038871536,0.0000011141618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009482238,0.00039204877,0.9824569,0.0000631814,0.010586889,0.000040478008,0.00003013851,0.000007399457,0.00023364837,0.000281289,0.0000070468136,0.004952746],"study_design_scores_gemma":[0.009486785,0.0049586315,0.96483886,0.0001243004,0.015013059,3.8412276e-7,0.00002611135,0.00015933481,0.0047424473,0.000052636213,0.0003963172,0.00020110578],"about_ca_topic_score_codex":0.0069123227,"about_ca_topic_score_gemma":0.02897319,"teacher_disagreement_score":0.022060867,"about_ca_system_score_codex":0.00023487315,"about_ca_system_score_gemma":0.000099396624,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W2748536545","doi":"10.1016/j.clinthera.2017.07.036","title":"Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Natural Science Foundation of China","keywords":"Saxagliptin; Vildagliptin; Alogliptin; Medicine; Sitagliptin; Linagliptin; Internal medicine; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes; Adverse effect; Sitagliptin Phosphate; Placebo; Dipeptidyl peptidase-4; Gastroenterology; Pharmacology; Diabetes mellitus; Randomized controlled trial; Endocrinology; Pathology","score_opus":0.3313066883383314,"score_gpt":0.46532881768452417,"score_spread":0.1340221293461928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748536545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016476713,0.9957038,0.000005559825,0.000075657816,0.000100405494,0.0038535462,0.000023540448,0.000022084474,0.00019892062],"genre_scores_gemma":[0.00008774848,0.99686533,0.0007347708,0.00060097117,0.000090447626,0.00023258077,0.00013032439,0.000053985186,0.0012038365],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99482155,0.0008370346,0.002974329,0.0006028051,0.00034751958,0.0004167577],"domain_scores_gemma":[0.9948285,0.0011042561,0.0022346247,0.001485443,0.00014828173,0.0001988956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028134456,0.00061141275,0.014145874,0.00024112387,0.000044660293,0.000012222839,0.00033935628,0.00018261815,0.00008143632],"category_scores_gemma":[0.0006136833,0.00037539005,0.004510362,0.0006508168,0.00019010558,0.00005221457,0.00021303417,0.0005061666,0.000037607446],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011284958,0.00050828315,0.002254699,0.7585156,0.21933296,0.000040202318,0.0000051990473,0.0000010484858,4.9797095e-9,0.00001580295,0.00011846259,0.01919648],"study_design_scores_gemma":[0.00033280978,0.00045458451,0.00007714605,0.2079492,0.75486565,0.0000042117176,0.000003191237,0.0000147595465,8.98917e-9,0.000017561275,0.036074966,0.00020591696],"about_ca_topic_score_codex":0.0000020133612,"about_ca_topic_score_gemma":0.000005703983,"teacher_disagreement_score":0.5505664,"about_ca_system_score_codex":0.00006404764,"about_ca_system_score_gemma":0.0001297673,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2749114690","doi":"10.1016/j.jcjd.2017.06.008","title":"Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; St. Michael's Hospital; Toronto General Hospital; University of Toronto; University Health Network; Humber River Regional Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"Janssen Canada; Boehringer Ingelheim; AstraZeneca Canada; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Incretin; Diabetes mellitus; Type 2 diabetes; Kidney; Kidney disease; Dipeptidyl peptidase-4; Blood pressure; Disease; Renin–angiotensin system; Internal medicine; Endocrinology","score_opus":0.024628160296387105,"score_gpt":0.2757740103592968,"score_spread":0.2511458500629097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749114690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040851696,0.97709733,5.124737e-7,0.016275804,0.0005151054,0.0013236748,0.00018434037,0.0000043054306,0.00051377865],"genre_scores_gemma":[0.015917154,0.9731779,0.00006299173,0.006606262,0.00151043,0.00007277577,0.00017840027,0.00013906992,0.0023349891],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811786,0.0001479558,0.00060351036,0.00024199649,0.0003239499,0.00056471],"domain_scores_gemma":[0.996035,0.00035280047,0.00074583717,0.0011211688,0.00015353344,0.0015916713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054715323,0.0004072371,0.0012950355,0.00024610382,0.00018283301,0.00013355697,0.0011766747,0.000079568075,0.000098374396],"category_scores_gemma":[0.00065822696,0.00016267877,0.0003865793,0.00035687818,0.00019846333,0.000099268036,0.00006285901,0.0005004775,0.00002319182],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017634506,0.000047171245,0.047572687,0.002213111,0.0016801686,0.00008057028,0.0006462888,0.000009633781,6.510294e-8,0.00005442155,0.12639947,0.82127875],"study_design_scores_gemma":[0.0007027694,0.0002679964,0.009165273,0.05010453,0.0040597855,5.398139e-7,0.00013250444,0.000008052962,7.460031e-7,0.00007814808,0.9352974,0.00018219776],"about_ca_topic_score_codex":0.0016860105,"about_ca_topic_score_gemma":0.009780149,"teacher_disagreement_score":0.8210966,"about_ca_system_score_codex":0.00019905463,"about_ca_system_score_gemma":0.0044802953,"threshold_uncertainty_score":0.79478514},"labels":[],"label_agreement":null},{"id":"W2750589886","doi":"10.1016/j.kint.2017.06.017","title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","year":2017,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Renal function; Blood pressure; Medicine; Body weight; Internal medicine; Urology; Cardiology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.02681947564398948,"score_gpt":0.32663226571035003,"score_spread":0.2998127900663606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750589886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903397,0.000095920754,0.00022617112,0.0013821587,0.00020252651,0.00033867487,0.00019324198,0.000017495033,0.0072041326],"genre_scores_gemma":[0.99794453,0.000039775223,0.00031547487,0.00008653382,0.00012589224,0.000031652267,0.00023489296,0.0000063061307,0.0012149268],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99890137,0.00003739099,0.00041611682,0.00020531438,0.00034538534,0.00009442564],"domain_scores_gemma":[0.9986837,0.000083420295,0.00073737296,0.00022518882,0.00016476278,0.00010554228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039138232,0.00011085777,0.0004668872,0.00044858828,0.000090800444,0.00003628192,0.000106696876,0.000037728278,0.0002808277],"category_scores_gemma":[0.000614764,0.000078994715,0.00011212997,0.00010894486,0.00013737383,0.00015091903,0.00003335353,0.000062261766,0.0000010470405],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116793625,0.006473756,0.23610659,0.00022135687,0.55053955,0.000051509887,0.0007915642,0.00026263428,0.15274304,0.013035094,0.0065356167,0.021559894],"study_design_scores_gemma":[0.05141165,0.0039701224,0.58756524,0.00094037125,0.28964153,0.000008240794,0.0001899501,0.0054636514,0.052839234,0.0003897258,0.0072611384,0.00031910883],"about_ca_topic_score_codex":0.00007600149,"about_ca_topic_score_gemma":0.0000060715884,"teacher_disagreement_score":0.35145867,"about_ca_system_score_codex":0.000010113368,"about_ca_system_score_gemma":0.000058281923,"threshold_uncertainty_score":0.3221311},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2752932668","doi":"10.1016/j.molmet.2017.08.010","title":"The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice","year":2017,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk; Sanofi; Pfizer","keywords":"Autonomic nervous system; Receptor; Heart rate; Medicine; Neuroscience; Sympathetic nervous system; Biology; Internal medicine; Cardiology; Endocrinology; Blood pressure","score_opus":0.005283393623815065,"score_gpt":0.22324218038113672,"score_spread":0.21795878675732167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752932668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977995,0.012338936,0.000039555624,0.0034873008,0.0010179309,0.00091914454,0.000005263337,0.00004881983,0.004148085],"genre_scores_gemma":[0.9975627,0.00022452378,0.00011201759,0.0003460683,0.000093202776,0.00010350818,0.000005053771,0.000024029947,0.0015289104],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99903136,0.00012794501,0.00018743148,0.0002480589,0.00011938297,0.0002858132],"domain_scores_gemma":[0.99918944,0.000035107656,0.00009077283,0.0005592195,0.00002773407,0.000097708864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005252737,0.00015885473,0.0004130177,0.000057629808,0.00022473054,0.00014925565,0.00013285551,0.000041831947,0.0000030990564],"category_scores_gemma":[0.00006143588,0.000110005545,0.00011479333,0.0000347008,0.00008622163,0.000066001005,0.00007633002,0.00009450535,0.00004247985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012446193,0.000586893,0.10871488,0.00077596563,0.0067485785,0.0012222411,0.0013560854,0.00015589152,0.43762738,0.1600036,0.016618636,0.26494524],"study_design_scores_gemma":[0.0044004316,0.0000545111,0.65599346,0.00009099356,0.0008095975,0.0000030487613,0.00014945601,0.00041607572,0.0068625566,0.0000843924,0.33092478,0.0002106773],"about_ca_topic_score_codex":0.00021561925,"about_ca_topic_score_gemma":0.000009095732,"teacher_disagreement_score":0.5472786,"about_ca_system_score_codex":0.00005201917,"about_ca_system_score_gemma":0.000028754215,"threshold_uncertainty_score":0.4485896},"labels":[],"label_agreement":null},{"id":"W2753333999","doi":"10.1111/dom.13104","title":"Metformin extended‐release versus immediate‐release: <scp>A</scp> n international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Metformin; Medicine; Type 2 diabetes; Randomized controlled trial; Placebo; Clinical endpoint; Internal medicine; Adverse effect; Diabetes mellitus; Pharmacotherapy; Gastroenterology; Endocrinology; Pharmacology","score_opus":0.023221334526631464,"score_gpt":0.3015745698871178,"score_spread":0.27835323536048634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753333999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872312,0.0033902207,0.000005027869,0.00038610073,0.0024916376,0.0039255763,0.00005603665,0.00008261179,0.002431598],"genre_scores_gemma":[0.9936295,0.0019816163,0.00046084746,0.00076915545,0.00061737903,0.0005843573,0.00033791637,0.000069137684,0.0015500967],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970682,0.00013102904,0.0005633752,0.0007229501,0.0006843923,0.00083002186],"domain_scores_gemma":[0.9977283,0.00041548823,0.00037160417,0.0006892695,0.00026837797,0.0005269948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008442802,0.00055174244,0.0014189568,0.000538117,0.00028339608,0.00027400555,0.00042793385,0.00016513836,0.00009447043],"category_scores_gemma":[0.0007018603,0.0004211661,0.00024825035,0.0002499955,0.00026295305,0.0006646766,0.00022379989,0.00031131116,0.00009925149],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68343794,0.006972454,0.21176194,0.0003062579,0.005521867,0.00006891297,0.0010820846,0.000017853725,0.00058862666,0.001341195,0.0028108861,0.08608995],"study_design_scores_gemma":[0.8566434,0.0007308195,0.10538952,0.0001650243,0.0014628196,1.5065775e-7,0.000052838182,0.00013868336,0.0037524607,0.0001464469,0.031252597,0.00026524934],"about_ca_topic_score_codex":0.00010780378,"about_ca_topic_score_gemma":0.000056540393,"teacher_disagreement_score":0.17320542,"about_ca_system_score_codex":0.00008352778,"about_ca_system_score_gemma":0.00008256665,"threshold_uncertainty_score":0.999824},"labels":[],"label_agreement":null},{"id":"W2753755248","doi":"10.1007/s10557-017-6750-1","title":"Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"review","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto","funders":"","keywords":"Medicine; Diabetes mellitus; Dyslipidemia; Blood pressure; Glycated hemoglobin; Internal medicine; Type 2 diabetes; PCSK9; Type 2 Diabetes Mellitus; Statin; Myocardial infarction; Stroke (engine); Endocrinology; Cardiology; Cholesterol; Lipoprotein","score_opus":0.04689214265877351,"score_gpt":0.31346270388519376,"score_spread":0.26657056122642026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753755248","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002573334,0.9917917,0.000002986536,0.000022286804,0.0012468619,0.002901966,0.000004362279,0.00008683644,0.001369651],"genre_scores_gemma":[0.0006515265,0.99761456,0.00007429212,0.0000316129,0.00065157854,0.00046117418,0.00021396288,0.00010622331,0.00019509427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966737,0.00062138337,0.0005610387,0.0010603995,0.0005862403,0.0004972447],"domain_scores_gemma":[0.99757296,0.00004349389,0.00025800403,0.0017829246,0.00013715652,0.00020543547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001318192,0.0007476576,0.0041279844,0.00045327513,0.0002447127,0.000111395944,0.00025775726,0.0004071316,0.00003338567],"category_scores_gemma":[0.00004274965,0.0005333862,0.0035571528,0.00039205904,0.00016643737,0.00013888083,0.0001288108,0.0005367059,0.000056691457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025024396,0.0001413918,0.000015314059,0.0023920196,0.03214483,0.00009290075,0.00019092149,0.000010058056,3.8402962e-7,0.000010303622,0.00017193123,0.96480495],"study_design_scores_gemma":[0.0027014813,0.00022178204,0.00004637161,0.0024583011,0.01375455,0.000011038189,0.00003401143,0.00000606903,0.00001692652,0.00011476259,0.9801297,0.0005050163],"about_ca_topic_score_codex":0.0000657028,"about_ca_topic_score_gemma":8.953489e-7,"teacher_disagreement_score":0.97995776,"about_ca_system_score_codex":0.00029178703,"about_ca_system_score_gemma":0.00015584774,"threshold_uncertainty_score":0.99971175},"labels":[],"label_agreement":null},{"id":"W2753975261","doi":"10.2337/dci17-0042","title":"Diabetes Research and Care Through the Ages","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Presentation (obstetrics); Narrative; Event (particle physics); Gerontology; Medical education; Family medicine; Library science; Surgery","score_opus":0.051906823817335676,"score_gpt":0.34512223295655664,"score_spread":0.29321540913922095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753975261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940692,0.011018775,1.7839312e-7,0.003001837,0.0001941508,0.0007331923,0.000034671077,0.000065412845,0.044259757],"genre_scores_gemma":[0.9970832,0.00027466763,0.00012635549,0.00037990185,0.00023937067,0.00018470855,0.00011705322,0.00003387711,0.0015609028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844503,0.000049398117,0.00013182254,0.00037361053,0.00040120512,0.00059892755],"domain_scores_gemma":[0.99824953,0.0001424352,0.00006181668,0.0011529641,0.00028996056,0.00010329393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016068103,0.00019187487,0.0002814567,0.000065864595,0.0011036417,0.00033251342,0.00033743822,0.00007919165,0.0000413713],"category_scores_gemma":[0.00015684382,0.000121319645,0.00008624875,0.000078031124,0.00055657147,0.00020284971,0.00044980322,0.0002294555,0.00014887028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067815017,0.000039986055,0.94665223,0.00045364353,0.0001854226,0.000011320209,0.004729912,3.6089955e-7,0.00027004848,0.0007968572,0.0067495033,0.04010395],"study_design_scores_gemma":[0.0015265523,0.0008107673,0.8083213,0.00038547002,0.00029178025,2.0002585e-7,0.015682006,0.000010894767,0.010144567,0.0010758027,0.1615113,0.00023934754],"about_ca_topic_score_codex":0.000029161092,"about_ca_topic_score_gemma":0.000029779734,"teacher_disagreement_score":0.15476179,"about_ca_system_score_codex":0.00007546251,"about_ca_system_score_gemma":0.000024920966,"threshold_uncertainty_score":0.84884316},"labels":[],"label_agreement":null},{"id":"W2754041380","doi":"10.1056/nejmoa1612917","title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Duke Clinical Research Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Exenatide; Hazard ratio; Myocardial infarction; Placebo; Interquartile range; Internal medicine; Stroke (engine); Diabetes mellitus; Type 2 diabetes; Heart failure; Confidence interval; Endocrinology","score_opus":0.01492942373253294,"score_gpt":0.26970778221583236,"score_spread":0.25477835848329944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754041380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857139,0.0042507034,0.000009663212,0.004948367,0.0008574887,0.0002458807,3.221338e-7,0.000005563974,0.003968119],"genre_scores_gemma":[0.9965016,0.0010694016,0.0001864966,0.00025266348,0.00083546096,0.0000015887689,0.0000016229122,0.00001359722,0.001137562],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998692,0.00005235796,0.00038599572,0.00011016888,0.0005783365,0.0001811766],"domain_scores_gemma":[0.9987625,0.0002635098,0.00032403064,0.00037964885,0.00010792698,0.0001623899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007453165,0.00014805172,0.00097479834,0.00025829967,0.000032733264,0.0000078191715,0.00017231474,0.0000432266,0.00003104145],"category_scores_gemma":[0.0012831353,0.00008557183,0.00018184764,0.00006615783,0.00008535244,0.00008140564,0.000030014851,0.00018661862,0.0000046148048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000643008,0.00045570274,0.4117888,0.00041291318,0.0026913823,0.0010338263,0.0004956142,0.000042572166,0.0017918176,0.00020158074,0.0050989985,0.5753438],"study_design_scores_gemma":[0.09500932,0.007094293,0.8521058,0.0026894552,0.0016987545,0.000015655281,0.00004993496,0.000019815487,0.0065258527,0.0004175005,0.034255695,0.00011792658],"about_ca_topic_score_codex":0.00007411666,"about_ca_topic_score_gemma":0.000009536194,"teacher_disagreement_score":0.5752259,"about_ca_system_score_codex":0.00005136251,"about_ca_system_score_gemma":0.000053047235,"threshold_uncertainty_score":0.3489518},"labels":[],"label_agreement":null},{"id":"W2754095176","doi":"10.1016/j.ando.2017.07.021","title":"Expression surrénalienne du glucose-dependent insulinotropic peptide receptor (GIPR) et microduplications de la région 19q13 dans le syndrome de Cushing dépendant de l’alimentation","year":2017,"lang":"fr","type":"article","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Fish <Actinopterygii>; Molecular biology; Biology","score_opus":0.028923510943535215,"score_gpt":0.3114201176697324,"score_spread":0.28249660672619714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754095176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96127015,0.009046248,0.0040092166,0.019644042,0.00078638736,0.0007411769,0.000072464434,0.0002432453,0.0041870936],"genre_scores_gemma":[0.9614444,0.02059515,0.0068753054,0.00061185984,0.0003308882,0.00028053467,0.00024039803,0.0000755414,0.009545929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965414,0.00059496466,0.0005137534,0.0006937835,0.00029853082,0.0013575767],"domain_scores_gemma":[0.9976754,0.00035173306,0.00044520712,0.0010970477,0.00009867578,0.00033190308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007667605,0.00045372843,0.00047686536,0.00018795527,0.00093253533,0.00037706594,0.0006901814,0.00021414546,0.00013636614],"category_scores_gemma":[0.00055697985,0.00045701154,0.00023485383,0.00009294597,0.0004850036,0.0006650749,0.00052486337,0.00048716812,0.00038398887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020956715,0.0030205173,0.47008795,0.0005447817,0.0009353023,0.0018733258,0.002935063,0.00057853357,0.43715099,0.018353235,0.015856905,0.04845385],"study_design_scores_gemma":[0.0036874213,0.0005932046,0.5833504,0.001119619,0.0006505802,0.00049792195,0.0020061864,0.00031172368,0.35086194,0.0016616152,0.054735836,0.0005235419],"about_ca_topic_score_codex":0.0025393348,"about_ca_topic_score_gemma":0.00022172662,"teacher_disagreement_score":0.11326247,"about_ca_system_score_codex":0.0011968416,"about_ca_system_score_gemma":0.00038573937,"threshold_uncertainty_score":0.99978817},"labels":[],"label_agreement":null},{"id":"W2755269925","doi":"10.1016/j.ando.2017.07.590","title":"Méta-analyse des études SUSTAIN 1-5 : Perte de poids sous semaglutide dans le diabète de type 2","year":2017,"lang":"fr","type":"article","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.07485256292496362,"score_gpt":0.3380477526033197,"score_spread":0.2631951896783561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755269925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8969806,0.046009462,0.00039533447,0.012543427,0.000743735,0.0005060839,0.00003323623,0.00024775323,0.042540412],"genre_scores_gemma":[0.8779617,0.013552486,0.0026919814,0.0006952069,0.00046500695,0.00005863127,0.000036282785,0.00006656628,0.10447213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962757,0.00023028311,0.00041211213,0.00062211487,0.0002649128,0.0021948244],"domain_scores_gemma":[0.99750894,0.00019481874,0.00023732516,0.0014498418,0.00019460804,0.00041444774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044466121,0.00052071415,0.0007307213,0.00019748916,0.00095421885,0.0002798726,0.0008327982,0.00017042397,0.00024325738],"category_scores_gemma":[0.0012419587,0.0004806194,0.0004090065,0.00015178717,0.0012919407,0.00031336633,0.0006302724,0.00036639,0.0005441936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020991168,0.0013513388,0.62009233,0.00075804506,0.004832444,0.0073262635,0.0013565273,0.0003345381,0.0031799087,0.025925068,0.028694961,0.30593863],"study_design_scores_gemma":[0.0043435427,0.0021956998,0.60790896,0.0006492904,0.006855264,0.0002731096,0.011835853,0.001468061,0.027716925,0.01383255,0.32169977,0.0012209498],"about_ca_topic_score_codex":0.003511427,"about_ca_topic_score_gemma":0.0015597071,"teacher_disagreement_score":0.3047177,"about_ca_system_score_codex":0.0009510698,"about_ca_system_score_gemma":0.0007288956,"threshold_uncertainty_score":0.99976456},"labels":[],"label_agreement":null},{"id":"W2756152366","doi":"10.1016/s2213-8587(17)30309-1","title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute; Centre Hospitalier de l’Université de Montréal","funders":"National Institute for Health and Care Research; Bayer","keywords":"Acarbose; Medicine; Diabetes mellitus; Placebo; Impaired glucose tolerance; Internal medicine; Coronary heart disease; Double blind; Type 2 diabetes; Cardiology; Impaired fasting glucose; Randomized controlled trial; Clinical trial; Endocrinology; Alternative medicine","score_opus":0.013756135652715646,"score_gpt":0.25266708870099563,"score_spread":0.23891095304828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756152366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853075,0.0037115165,2.1615354e-7,0.0013789788,0.00020328774,0.00920263,0.000011033507,0.000046388213,0.0001384154],"genre_scores_gemma":[0.99696124,0.00029699365,0.000033753702,0.0005012715,0.00011139144,0.001966745,0.000017711776,0.000032074906,0.00007881575],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99777937,0.00022770894,0.00034209914,0.00046788104,0.00029736728,0.00088556437],"domain_scores_gemma":[0.9979148,0.0006887176,0.00021189735,0.000989172,0.00004487167,0.00015056373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039601658,0.00037193974,0.0020934592,0.00014071072,0.00015615589,0.000044679993,0.00022868555,0.00006335925,0.0000043330674],"category_scores_gemma":[0.00023712458,0.00021714489,0.00023916589,0.000051253868,0.00040582105,0.00011724264,0.00019445272,0.00020418847,0.00000312318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44643757,0.00049395417,0.5486923,0.00019021558,0.0018560127,0.000027615915,0.00003794864,0.000007581889,0.000038832204,0.00005554641,0.000029039951,0.002133437],"study_design_scores_gemma":[0.5138395,0.0013929307,0.48278117,0.000119453056,0.0011972833,1.8156092e-7,0.0000037804946,0.000029409086,0.00040906842,0.00005564919,0.00005463288,0.0001169482],"about_ca_topic_score_codex":0.000018587118,"about_ca_topic_score_gemma":0.00000513058,"teacher_disagreement_score":0.06740192,"about_ca_system_score_codex":0.00003760421,"about_ca_system_score_gemma":0.000028947563,"threshold_uncertainty_score":0.88549113},"labels":[],"label_agreement":null},{"id":"W2756174617","doi":"10.1111/dom.13114","title":"Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Medicine; Internal medicine; Type 2 diabetes; Endocrinology; Placebo; Type 1 diabetes; Cholesterol; Insulin; Diabetes mellitus; PCSK9; Population; Apolipoprotein B; Lipoprotein; Apolipoprotein A1; LDL receptor","score_opus":0.010753474393634945,"score_gpt":0.23046606069594383,"score_spread":0.2197125863023089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756174617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690209,0.027395189,0.0000024213857,0.000108184286,0.00021572363,0.0028324684,0.000044163236,0.000040618554,0.00034029936],"genre_scores_gemma":[0.97863215,0.020306978,0.00036099806,0.00010399744,0.00015039467,0.00008933132,0.000070101385,0.00003555019,0.00025050077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976918,0.00041130974,0.0004889267,0.00053275976,0.00039615048,0.00047906986],"domain_scores_gemma":[0.9975565,0.0009025131,0.00038463643,0.000816306,0.00015108584,0.00018897033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018366093,0.00041079771,0.001976135,0.00020025147,0.00037719004,0.00015105642,0.0002024847,0.00018075934,0.000011361253],"category_scores_gemma":[0.00190476,0.00022938104,0.00016421231,0.00025401532,0.0006729702,0.00022699288,0.00026259696,0.00026045565,0.0000035708022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09400989,0.0016470168,0.81401926,0.0007088202,0.016949078,0.000042905776,0.002430718,0.00002461643,0.00023210798,0.0010231986,0.0002637467,0.06864861],"study_design_scores_gemma":[0.39325434,0.00046156635,0.5947263,0.00016732849,0.004884203,7.5530096e-7,0.00005745972,0.000048593327,0.0008965408,0.00020744136,0.005183242,0.000112230744],"about_ca_topic_score_codex":0.00027200763,"about_ca_topic_score_gemma":0.000030061743,"teacher_disagreement_score":0.29924443,"about_ca_system_score_codex":0.000015083306,"about_ca_system_score_gemma":0.000057282607,"threshold_uncertainty_score":0.93538874},"labels":[],"label_agreement":null},{"id":"W2756191633","doi":"10.1161/circulationaha.117.028268","title":"Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":471,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Disease; Diabetes mellitus; Kidney disease; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.014934625505703871,"score_gpt":0.2627652329903545,"score_spread":0.2478306074846506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756191633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968887,0.0018638595,0.000008298205,0.0002553691,0.0001194502,0.00071125425,0.000009664186,0.000023904076,0.000119474935],"genre_scores_gemma":[0.9992563,0.00024801466,0.000040550327,0.000099865436,0.000056168425,0.000019691797,0.00021679388,0.000016139193,0.00004644305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990836,0.00003491615,0.00017031573,0.00031886628,0.00022332123,0.00016902534],"domain_scores_gemma":[0.99893796,0.000024840698,0.00006911217,0.0005668926,0.00005272154,0.00034846738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016445595,0.00013035619,0.00030368543,0.000068049994,0.00009770814,0.00008773576,0.00004528845,0.000034970257,0.00001120087],"category_scores_gemma":[0.00030194235,0.0000995167,0.00007652273,0.00004297809,0.000099565004,0.00026288946,0.000055406024,0.00005630932,0.000004730892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097691125,0.00019256919,0.98263806,0.00012281656,0.00062695215,0.000009324493,0.000011237606,0.000016332528,5.0016456e-7,0.0000382333,0.000050820745,0.016195478],"study_design_scores_gemma":[0.004683562,0.000101061116,0.9920501,0.00013536963,0.0013007863,1.9708976e-8,0.000002224927,0.0006751775,6.7695555e-7,0.000089499066,0.00084729475,0.000114199174],"about_ca_topic_score_codex":0.000015656111,"about_ca_topic_score_gemma":0.000005897908,"teacher_disagreement_score":0.01608128,"about_ca_system_score_codex":0.00006220984,"about_ca_system_score_gemma":0.000062057705,"threshold_uncertainty_score":0.4058173},"labels":[],"label_agreement":null},{"id":"W2756246648","doi":"10.1111/jdi.12746","title":"Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial","year":2017,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Merck; Bayer; AstraZeneca; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Linagliptin; Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Randomized controlled trial; Subgroup analysis; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitor; Type 2 Diabetes Mellitus; Pharmacology; Endocrinology; Meta-analysis","score_opus":0.025764637751822715,"score_gpt":0.30177114402945776,"score_spread":0.27600650627763507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756246648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99753046,0.000296364,0.000011378608,0.00028499696,0.00011005144,0.0016417932,0.000008255534,0.000012623842,0.0001040583],"genre_scores_gemma":[0.9946999,0.00018541809,0.004720785,0.00008614474,0.00009733878,0.000060955314,0.00008785462,0.00003234732,0.000029268504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734604,0.00029673154,0.0011702757,0.00034244085,0.0005171849,0.00032733122],"domain_scores_gemma":[0.9965068,0.00065942015,0.0017842479,0.00036362308,0.0003672898,0.0003186333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013471885,0.00036535767,0.0023629102,0.0006493701,0.00011135453,0.00012969217,0.00012799802,0.00012820456,0.000010852099],"category_scores_gemma":[0.0010038797,0.0002191235,0.00019789823,0.00040242955,0.0006984104,0.00044717127,0.000058644186,0.00022794181,4.5801485e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1368713,0.0009429667,0.83963764,0.000085001935,0.005504199,0.000053114323,0.00047856514,0.00004366854,0.00006452204,0.000010152502,0.000006183091,0.016302671],"study_design_scores_gemma":[0.459808,0.013533484,0.51303667,0.00065092597,0.0103426315,0.0000011944877,0.00014726509,0.0010350882,0.0011617194,0.00006283641,0.000012262863,0.00020792543],"about_ca_topic_score_codex":0.00006289918,"about_ca_topic_score_gemma":0.00025508183,"teacher_disagreement_score":0.326601,"about_ca_system_score_codex":0.00011298476,"about_ca_system_score_gemma":0.0001706307,"threshold_uncertainty_score":0.8935597},"labels":[],"label_agreement":null},{"id":"W2757046241","doi":"10.1016/j.cjca.2017.07.075","title":"SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Semaglutide; Medicine; Post-hoc analysis; Type 2 diabetes; Post hoc; Diabetes mellitus; Internal medicine; Endocrinology; Liraglutide","score_opus":0.004687958188300004,"score_gpt":0.21964963331781612,"score_spread":0.2149616751295161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757046241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960025,0.0007699832,0.0000014133387,0.0003558944,0.00012936724,0.0002478739,0.000013305809,0.0000013494674,0.0024783122],"genre_scores_gemma":[0.99962425,0.000015151818,0.000011203268,0.00007258299,0.0000491235,0.0000025800612,0.0000043023792,0.000011320566,0.00020949083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989432,0.00020806362,0.00026017768,0.0001180613,0.00020346316,0.0002670348],"domain_scores_gemma":[0.99859744,0.00013936011,0.00027199302,0.00065915775,0.00017452422,0.00015754838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007133375,0.00013838454,0.0013562335,0.00062885316,0.00004983761,0.000009444286,0.00022746155,0.00006893605,0.000015676895],"category_scores_gemma":[0.00042214696,0.00007600839,0.00077710336,0.00025137243,0.0002021584,0.00003486275,0.000022112197,0.00013411819,0.0000015657007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022857219,0.0000036893139,0.97844696,0.00004455465,0.015325869,0.00019358048,0.000050003066,0.0030799394,0.000086921624,0.00001971708,0.00030087607,0.0022192907],"study_design_scores_gemma":[0.0021112652,0.0027200277,0.9857592,0.0001032072,0.0069237812,0.0000054929583,0.000023048557,0.000021999544,0.00044338292,0.0000072095318,0.0018152971,0.000066061024],"about_ca_topic_score_codex":0.0010637,"about_ca_topic_score_gemma":0.0023689675,"teacher_disagreement_score":0.008402089,"about_ca_system_score_codex":0.00015701042,"about_ca_system_score_gemma":0.00030626875,"threshold_uncertainty_score":0.30995324},"labels":[],"label_agreement":null},{"id":"W2757605863","doi":"10.1016/j.cjca.2017.07.338","title":"DIFFERENCES IN 24-H AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN PATIENTS SWITCHED BETWEEN DIFFERING EXTENDED-RELEASE FORMULATIONS OF NIFEDIPINE: DOSE SCALING BETWEEN 30-MG VS. 60-MG DOSES","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Nifedipine; Medicine; Blood pressure; Morning; Evening; Pharmacology; Urology; Anesthesia; Internal medicine; Calcium","score_opus":0.028301997774135577,"score_gpt":0.26374758810554766,"score_spread":0.23544559033141207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757605863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997772,0.0006989763,0.000031414755,0.00016500337,0.00045199852,0.0003330454,0.000033453023,0.0000058528244,0.0005082613],"genre_scores_gemma":[0.998876,0.00006012733,0.00012973331,0.000009995037,0.0008335599,0.000009035385,0.000014719204,0.000022069906,0.000044790075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982711,0.00008489583,0.00071626686,0.0002165096,0.0002265352,0.00048468466],"domain_scores_gemma":[0.9984051,0.000119605385,0.00047616038,0.00037859625,0.0001514906,0.00046907293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031984033,0.000222527,0.0010711973,0.00065543706,0.0001379974,0.00003835628,0.0003156717,0.00017389744,0.00000916571],"category_scores_gemma":[0.0003191043,0.0001958128,0.00019266554,0.00009587288,0.00013571867,0.00021869762,0.000058585032,0.00035482462,0.0000014925404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048854494,0.000020870486,0.9912467,0.000087145796,0.0008511012,0.00011718571,0.00020058392,0.00011365727,0.00006875551,0.000018790955,0.000029072382,0.0071972646],"study_design_scores_gemma":[0.004388733,0.00048635155,0.9926086,0.00050031615,0.0011187558,0.0000024954882,0.00007318248,0.00001133561,0.0002474143,0.00015012793,0.0002639857,0.00014869071],"about_ca_topic_score_codex":0.0013157565,"about_ca_topic_score_gemma":0.00042180787,"teacher_disagreement_score":0.007048574,"about_ca_system_score_codex":0.00012594817,"about_ca_system_score_gemma":0.00025097196,"threshold_uncertainty_score":0.79850143},"labels":[],"label_agreement":null},{"id":"W2757732796","doi":"10.1016/j.cjca.2017.07.266","title":"EMPAGLIFLOZIN REDUCES LV MASS AND IMPROVES DIASTOLIC FUNCTION IN AN EXPERIMENTAL MODEL OF HEART FAILURE WITH PRESERVED EF","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Empagliflozin; Heart failure; Internal medicine; Cardiology; Volume overload; Heart failure with preserved ejection fraction; Diastole; Blood pressure; Pressure overload; Diuresis; Ejection fraction; Saline; Cardiac function curve; Renal function; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.022870262029100353,"score_gpt":0.25453056062148266,"score_spread":0.2316602985923823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757732796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738026,0.0004936748,0.00005745851,0.0008672141,0.000102400176,0.00015824114,0.0000050200065,0.000001915961,0.0009338442],"genre_scores_gemma":[0.99910116,0.000011447058,0.0005731462,0.000054214248,0.00014942062,0.0000067987935,0.000003704483,0.000010127813,0.00009000505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940723,0.00003930586,0.00017681885,0.00011319784,0.000072476825,0.00019096614],"domain_scores_gemma":[0.99928844,0.000008627641,0.00013660229,0.0002062803,0.00006830098,0.00029174742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015360641,0.000093999624,0.00039229094,0.00020130521,0.00006163444,0.000024544433,0.00009015427,0.000060998198,0.000005527794],"category_scores_gemma":[0.000024441199,0.000071761446,0.00005518071,0.000022797862,0.0001644304,0.00021171848,0.000011198111,0.00009990681,4.2675597e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008657669,0.000033704287,0.8496482,0.000072281975,0.00079002883,0.00019680432,0.0007735568,0.0024541584,0.1359511,0.00024093174,0.005082409,0.0038910503],"study_design_scores_gemma":[0.0074820076,0.0065785428,0.9583702,0.0002386938,0.0005614446,0.00013338328,0.002368189,0.00087209285,0.016590424,0.0003177916,0.00622424,0.00026297994],"about_ca_topic_score_codex":0.0004951133,"about_ca_topic_score_gemma":0.0028986149,"teacher_disagreement_score":0.11936068,"about_ca_system_score_codex":0.00006672803,"about_ca_system_score_gemma":0.0002608878,"threshold_uncertainty_score":0.2926347},"labels":[],"label_agreement":null},{"id":"W2758323603","doi":"10.1016/j.cjca.2017.07.359","title":"EMPAGLIFLOZIN (EMPA) REDUCES MORTALITY IN ANALYSES ADJUSTED FOR CONTROL OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C OVER TIME","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Diabetes mellitus; Blood pressure; Placebo; Type 2 diabetes; Cholesterol; Endocrinology; Cardiology","score_opus":0.032444676750315385,"score_gpt":0.3000378857760638,"score_spread":0.2675932090257484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758323603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962664,0.001845058,0.00006189663,0.00053725863,0.00013733425,0.00054518104,0.00007075513,0.0000028653326,0.0005332108],"genre_scores_gemma":[0.99919677,0.00003959679,0.000064260785,0.0001239981,0.00030369847,0.000011877008,0.000008490808,0.000012423164,0.00023890821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891263,0.00009901152,0.00039912324,0.00017668777,0.00011484944,0.0002977202],"domain_scores_gemma":[0.99863267,0.000056899287,0.00041215026,0.00034371938,0.0002012809,0.00035328415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049110356,0.00015207542,0.0009475341,0.00026972053,0.00008102749,0.000028762886,0.00016275066,0.00013244213,0.000015344449],"category_scores_gemma":[0.00032702752,0.00012636531,0.00020778227,0.000041111653,0.00022987147,0.00012217752,0.00001773622,0.0001409839,8.1951396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004529929,0.000044654927,0.96623003,0.00027694763,0.009891206,0.00048662355,0.0001986731,0.0005114658,0.007921054,0.000035997575,0.0025477067,0.0114026405],"study_design_scores_gemma":[0.006135946,0.00062868453,0.9823542,0.00017160583,0.004889616,0.000048117796,0.00003214763,0.00012098643,0.0035946139,0.00007309984,0.0018481014,0.000102829814],"about_ca_topic_score_codex":0.0041499096,"about_ca_topic_score_gemma":0.008206249,"teacher_disagreement_score":0.016124215,"about_ca_system_score_codex":0.000031783762,"about_ca_system_score_gemma":0.00030549598,"threshold_uncertainty_score":0.6273449},"labels":[],"label_agreement":null},{"id":"W2759780526","doi":"10.1016/j.cjca.2017.07.333","title":"CARDIAC EFFECTS OF COMBINED SGLT 1/2 INHIBITION FOLLOWING EXPERIMENTAL MYOCARDIAL INFARCTION IN THE RAT","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Dapagliflozin; Myocardial infarction; Internal medicine; Cardiology; Glucose transporter; GLUT4; Cardiac function curve; GLUT1; Endocrinology; Glucose uptake; Diabetes mellitus; Type 2 diabetes; Insulin; Heart failure","score_opus":0.0102810414434854,"score_gpt":0.25014023277985725,"score_spread":0.23985919133637185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759780526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709226,0.0009368187,0.000022701915,0.00085151725,0.0022385041,0.00034113467,0.0000018534407,0.0000020532818,0.008513182],"genre_scores_gemma":[0.999311,0.000035237947,0.000023881024,0.00016488387,0.0004007963,0.000013220254,0.000007962357,0.0000084653475,0.000034601653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917144,0.00015234362,0.00024222794,0.00008631756,0.00013661596,0.00021106005],"domain_scores_gemma":[0.9993052,0.00006518449,0.00018066386,0.00025532887,0.00005126487,0.00014236092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044055478,0.000099310695,0.0004879775,0.00022457854,0.000118643824,0.00002667145,0.00011534484,0.000073838804,0.0000026736463],"category_scores_gemma":[0.00015985103,0.00007327542,0.00044384488,0.000048657388,0.00011270451,0.000121328645,0.000014201964,0.00014631444,0.0000026600228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046516812,0.00006161536,0.9069442,0.00016400381,0.004142638,0.0033898447,0.0025935653,0.00018352021,0.03402067,0.0020929591,0.030404678,0.015537112],"study_design_scores_gemma":[0.0076053403,0.0024340202,0.942767,0.00031643416,0.0010537335,0.000085544234,0.00089579873,0.0000040764567,0.009240902,0.00023302568,0.0352,0.0001641303],"about_ca_topic_score_codex":0.00055303925,"about_ca_topic_score_gemma":0.00014523773,"teacher_disagreement_score":0.035822768,"about_ca_system_score_codex":0.0001672895,"about_ca_system_score_gemma":0.00020722531,"threshold_uncertainty_score":0.2988085},"labels":[],"label_agreement":null},{"id":"W2760749285","doi":"10.1016/j.cjca.2017.07.248","title":"DETAILED DESCRIPTION OF MYOCARDIAL INFARCTIONS AND THE VARIOUS SUBTYPES IN THE LEADER TRIAL","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Liraglutide; Placebo; Myocardial infarction; Internal medicine; Cardiology; Coronary artery disease; Type 2 diabetes; Stroke (engine); Diabetes mellitus; Percutaneous coronary intervention; Surgery; Endocrinology; Pathology","score_opus":0.03252811013419905,"score_gpt":0.2538506571746042,"score_spread":0.22132254704040516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760749285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734645,0.00075247354,0.00010184572,0.009466942,0.000801583,0.0003946563,0.000002760624,0.0000010013762,0.015014242],"genre_scores_gemma":[0.9989378,0.00011375317,0.00002081278,0.00024484022,0.00054005184,0.000007933892,0.000001242658,0.0000035858027,0.0001299654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993929,0.00015662359,0.00019603234,0.00005188446,0.000070968905,0.00013154317],"domain_scores_gemma":[0.99942255,0.00008146407,0.00015048982,0.00020488496,0.000064990614,0.000075609096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007573994,0.000056185927,0.00032140088,0.00012649073,0.0001274851,0.00003088147,0.00012750861,0.00004923255,0.0000043867635],"category_scores_gemma":[0.00029579274,0.000029358527,0.00013109103,0.000030711803,0.00040043742,0.00005867327,0.000008662381,0.00014278377,0.00000155643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012677048,0.000022475848,0.92781377,0.000037417267,0.0026465552,0.00043282146,0.0034629155,0.00023563817,0.000065732456,0.012072035,0.016651599,0.023881964],"study_design_scores_gemma":[0.0377524,0.0006339484,0.9071213,0.000027095386,0.0007453426,0.00016990156,0.00055938517,0.000008565947,0.000004861314,0.0013894206,0.051541764,0.000046029552],"about_ca_topic_score_codex":0.0011271323,"about_ca_topic_score_gemma":0.004869831,"teacher_disagreement_score":0.034890167,"about_ca_system_score_codex":0.00004142101,"about_ca_system_score_gemma":0.00023314795,"threshold_uncertainty_score":0.271748},"labels":[],"label_agreement":null},{"id":"W2760952310","doi":"10.1093/eurheartj/ehx511","title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial","year":2017,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Hazard ratio; Internal medicine; Heart failure; EMPA; Confidence interval; Population; Placebo; Diabetes mellitus; Type 2 diabetes; Cardiology; Lower risk; Endocrinology","score_opus":0.02208451585615833,"score_gpt":0.29906976628526377,"score_spread":0.27698525042910543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760952310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992406,0.0006597203,0.00015853894,0.004466818,0.00027785267,0.0018703014,0.000018945537,0.000011669422,0.00013016042],"genre_scores_gemma":[0.9982407,0.0001774782,0.00065812527,0.00021049475,0.0005644364,0.00001682708,0.000004665834,0.0000385035,0.00008874667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769616,0.00081032066,0.00043912852,0.0002416661,0.00047662613,0.00033612287],"domain_scores_gemma":[0.99845713,0.00029039633,0.00036181364,0.0007333197,0.00006441671,0.00009290114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035254655,0.0002185684,0.00060346717,0.00009044666,0.0005730334,0.00015600144,0.00023866759,0.000045399112,0.00000630685],"category_scores_gemma":[0.0007369332,0.00011991201,0.00068193773,0.000081968254,0.00012806071,0.00013395966,0.00008890923,0.00038539432,0.000008359666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002343978,0.0004954697,0.97636545,0.00021799492,0.001192598,0.000052330586,0.0016781086,0.00012403606,0.00012766717,0.000114194525,0.01575358,0.0015346105],"study_design_scores_gemma":[0.025057184,0.0030496398,0.9218216,0.0002451041,0.00091321656,0.00003707962,0.0003632072,0.000033920012,0.00072720944,0.00010122867,0.047527242,0.00012335104],"about_ca_topic_score_codex":0.000053617536,"about_ca_topic_score_gemma":0.000032689248,"teacher_disagreement_score":0.054543816,"about_ca_system_score_codex":0.000036069785,"about_ca_system_score_gemma":0.000023957578,"threshold_uncertainty_score":0.488987},"labels":[],"label_agreement":null},{"id":"W2761179810","doi":"10.1016/j.amjmed.2017.09.044","title":"Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia","year":2017,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Diabetes UK; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Metformin; Sulfonylurea; Hypoglycemia; Hazard ratio; Type 2 diabetes; Internal medicine; Diabetes mellitus; Proportional hazards model; Cohort; Incidence (geometry); Cohort study; Confidence interval; Insulin; Endocrinology","score_opus":0.026041675864132828,"score_gpt":0.3263215074762468,"score_spread":0.30027983161211397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761179810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729801,0.0016200546,0.000013457062,0.02236391,0.0002064232,0.0004358257,0.0000047661983,0.0000043172918,0.0023711342],"genre_scores_gemma":[0.99489826,0.0029331697,0.00024805762,0.0007136697,0.0006096394,0.000009772863,0.0000025700099,0.000013912818,0.00057096285],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906725,0.00009354156,0.0003258847,0.000090186935,0.00025505404,0.00016806253],"domain_scores_gemma":[0.99747765,0.00063287985,0.0011810379,0.00042592257,0.00018133105,0.00010116119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082431786,0.00014433567,0.0007295013,0.0000656355,0.00018790748,0.000013338717,0.00021452738,0.000015456833,0.000032288586],"category_scores_gemma":[0.0008031339,0.00005440919,0.00013525615,0.0000616483,0.0018509411,0.000049455826,0.00004230908,0.00010626736,0.0000020453597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021833744,0.0003667223,0.066372395,0.00008954736,0.0065369937,0.00005873704,0.0036788464,0.000011513506,0.0006014147,0.0018568413,0.007890827,0.8907024],"study_design_scores_gemma":[0.17881465,0.13659476,0.53829724,0.0022771508,0.036505315,0.00064500084,0.011640429,0.0004371217,0.0042070393,0.022031687,0.067974046,0.00057555205],"about_ca_topic_score_codex":0.00017758251,"about_ca_topic_score_gemma":0.0000045452,"teacher_disagreement_score":0.8901269,"about_ca_system_score_codex":0.000037113034,"about_ca_system_score_gemma":0.000068105146,"threshold_uncertainty_score":0.681987},"labels":[],"label_agreement":null},{"id":"W2761721053","doi":"10.1016/j.jcjo.2017.07.028","title":"Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors","year":2017,"lang":"en","type":"editorial","venue":"Canadian Journal of Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Novo Nordisk; Merck; Diabetes Canada; AstraZeneca","keywords":"Empagliflozin; Liraglutide; Medicine; Semaglutide; Type 2 diabetes; Metformin; Diabetes mellitus; Canagliflozin; Dulaglutide; Internal medicine; Glycemic; Pharmacology; Endocrinology","score_opus":0.027945868732204115,"score_gpt":0.30159979680322097,"score_spread":0.27365392807101685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761721053","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3495785,0.0111978715,0.000004420297,0.003102858,0.6154488,0.001907763,0.0010752581,0.000017536397,0.01766704],"genre_scores_gemma":[0.823061,0.00014874586,0.0020327338,0.000033991306,0.17124401,0.000046988156,0.0002922084,0.00009501774,0.0030453189],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695265,0.00014087827,0.0012207825,0.00049688615,0.00043270196,0.0007561103],"domain_scores_gemma":[0.994109,0.0016111307,0.0014419704,0.0005426066,0.0013259457,0.00096935173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006593549,0.00055527803,0.0018586708,0.00086905865,0.00037625112,0.00016163316,0.0003178105,0.0011654535,0.00039310547],"category_scores_gemma":[0.004870768,0.00047806127,0.0004978002,0.00010043834,0.0009481063,0.00020300873,0.000077966244,0.0007843472,0.0000052585824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015609086,0.00018092677,0.007651878,0.0006309255,0.0012870989,0.015973253,0.00017764946,0.0000019081206,0.00010588802,0.00047578392,0.9728289,0.00052968424],"study_design_scores_gemma":[0.009644207,0.01315813,0.0051392796,0.003023069,0.0047172904,0.034102302,0.00061046926,0.000011696104,0.0021451248,0.013332792,0.912622,0.0014936888],"about_ca_topic_score_codex":0.0009172245,"about_ca_topic_score_gemma":0.000104329876,"teacher_disagreement_score":0.4734825,"about_ca_system_score_codex":0.00032603132,"about_ca_system_score_gemma":0.004740199,"threshold_uncertainty_score":0.9997671},"labels":[],"label_agreement":null},{"id":"W2762499399","doi":"10.1093/eurheartj/ehx493.p4903","title":"P4903Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c","year":2017,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cardiology; Heart failure; Internal medicine; Blood pressure; Cholesterol","score_opus":0.01728977452687389,"score_gpt":0.2668593880378243,"score_spread":0.2495696135109504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762499399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375355,0.0012060655,0.000022824428,0.0021412466,0.00012562386,0.00046542133,0.000010423589,0.000016608601,0.0022582153],"genre_scores_gemma":[0.9978177,0.00005445455,0.00089889154,0.0001585806,0.0003116508,0.000002238844,0.0000012029037,0.000027683805,0.0007276105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870944,0.00020701392,0.00033284945,0.00021308316,0.00030768965,0.00022989389],"domain_scores_gemma":[0.9988044,0.000036405007,0.00036120712,0.00042784942,0.00016943926,0.0002007289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070129335,0.00016958849,0.000492968,0.00011457706,0.00021838599,0.00009508983,0.00014440123,0.00003297142,0.000047516543],"category_scores_gemma":[0.00018715794,0.00013406627,0.00014568777,0.00003369539,0.00020483173,0.00019359143,0.0001076478,0.00025584438,0.000012364662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016187301,0.0024669878,0.6604435,0.00077450357,0.0070950785,0.0005926845,0.0013995866,0.000024430712,0.27793837,0.00017726191,0.023614792,0.023854125],"study_design_scores_gemma":[0.005802059,0.00118659,0.92229253,0.0006309603,0.0013684125,0.00022149744,0.000082349565,0.000014995013,0.061076548,0.00003825075,0.007167698,0.00011809829],"about_ca_topic_score_codex":0.00003333042,"about_ca_topic_score_gemma":0.000009211852,"teacher_disagreement_score":0.26184908,"about_ca_system_score_codex":0.000007848109,"about_ca_system_score_gemma":0.000034525565,"threshold_uncertainty_score":0.5467064},"labels":[],"label_agreement":null},{"id":"W2762708459","doi":"10.1093/eurheartj/ehx493.5935","title":"5935Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome","year":2017,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Hjerteforeningen","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Cardiology; Hemodynamics; Diabetes mellitus; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.010319967830340376,"score_gpt":0.22945869934324953,"score_spread":0.21913873151290916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762708459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876285,0.00026490347,0.0000033864187,0.00009970428,0.000066826855,0.00033603824,0.000010063146,0.0000059381114,0.00045028116],"genre_scores_gemma":[0.99906814,0.0003850353,0.0002550449,0.000060303177,0.000024059342,8.496739e-7,0.000008944388,0.000027489963,0.00017013999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998919,0.0002227927,0.00022844398,0.00019712273,0.00025615492,0.00017646689],"domain_scores_gemma":[0.99928945,0.000054026408,0.00020060412,0.00027137922,0.00003830873,0.0001462475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006385101,0.00016146651,0.00047482055,0.00012858155,0.00011644702,0.000038899216,0.000049532497,0.000024278366,0.0000038879857],"category_scores_gemma":[0.00007208158,0.000111637986,0.000054983724,0.00003239975,0.00012264306,0.000101665006,0.00008251598,0.00017779747,0.0000013354407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002761172,0.00017062711,0.9907006,0.00009247565,0.00020331194,0.000070180555,0.00008455819,0.000001949689,0.00029032663,0.0000020211583,0.00056425796,0.007543597],"study_design_scores_gemma":[0.0058742594,0.0019334656,0.9910155,0.00035339952,0.00026955712,0.0000064074316,0.000036037614,0.000040685736,0.00007419792,0.0000042961888,0.00029275307,0.000099455145],"about_ca_topic_score_codex":0.000046025838,"about_ca_topic_score_gemma":0.000003556759,"teacher_disagreement_score":0.0074441414,"about_ca_system_score_codex":0.000023383862,"about_ca_system_score_gemma":0.000006200495,"threshold_uncertainty_score":0.45524648},"labels":[],"label_agreement":null},{"id":"W2763339077","doi":"10.1093/eurheartj/ehx504.3910","title":"3910SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Semaglutide; Medicine; Post-hoc analysis; Type 2 diabetes; Post hoc; Diabetes mellitus; Internal medicine; Endocrinology; Liraglutide","score_opus":0.00941158742249015,"score_gpt":0.2546135269140696,"score_spread":0.24520193949157942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763339077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940802,0.00037561695,4.2398767e-7,0.0002961327,0.00006422747,0.00026210758,0.0000027741235,0.000006516002,0.0049120146],"genre_scores_gemma":[0.9984773,0.000015178769,0.00004374085,0.00012178868,0.000036875037,0.000001056898,0.0000020996101,0.000024575886,0.0012774013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986401,0.000384913,0.00021334073,0.0001424667,0.00041185424,0.00020730021],"domain_scores_gemma":[0.9988443,0.00007896371,0.0001909033,0.00074296794,0.000073811105,0.000069031965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012338165,0.00014342775,0.00067668216,0.00028082568,0.000082433064,0.00003286303,0.00016899107,0.000016148033,0.000057658526],"category_scores_gemma":[0.00024511732,0.00007285016,0.00056203257,0.00023436362,0.00007912668,0.00005072636,0.000083535044,0.0001604799,0.000024146017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030984994,0.00007567383,0.99048156,0.00005436844,0.00589641,0.00012419718,0.00008541912,0.00028362457,0.00048256936,0.000003264555,0.0004563971,0.0017466631],"study_design_scores_gemma":[0.0023251467,0.0025240108,0.9892964,0.00023942692,0.0033198942,0.0000038580433,0.000012283383,0.00005752074,0.0011020533,0.0000012464418,0.0010500058,0.00006816901],"about_ca_topic_score_codex":0.000014402414,"about_ca_topic_score_gemma":0.0000067533424,"teacher_disagreement_score":0.004397096,"about_ca_system_score_codex":0.000046632817,"about_ca_system_score_gemma":0.000022006927,"threshold_uncertainty_score":0.29707432},"labels":[],"label_agreement":null},{"id":"W2763514769","doi":"10.1038/s41598-017-14010-x","title":"Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents","year":2017,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Institute for Nanotechnology; University of Alberta","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; APC Microbiome Institute; Teagasc; Science Foundation Ireland; Ireland Canada University Foundation","keywords":"Lactobacillus paracasei; Incretin; Lipid metabolism; Endocrinology; Internal medicine; Cholesterol; Insulin; Glucagon-like peptide-1; Carbohydrate metabolism; Biology; Triglyceride; Type 2 diabetes; Pharmacology; Diabetes mellitus; Medicine; Biochemistry; Lactobacillus","score_opus":0.013271486738461983,"score_gpt":0.25306627803862536,"score_spread":0.23979479130016337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763514769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97944623,0.0002945177,0.000011559228,0.0005157177,0.01269987,0.0008007553,8.989335e-7,0.00007577641,0.006154695],"genre_scores_gemma":[0.9619665,0.000029432073,0.0005055374,0.000056444867,0.000115050985,0.00006640151,0.00014916381,0.00002538276,0.037086044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755055,0.000038864942,0.0005713516,0.0008917182,0.00045988208,0.00048765482],"domain_scores_gemma":[0.99755085,0.000015546791,0.0005937312,0.0015812349,0.00011406268,0.00014455637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016132889,0.00021815163,0.0004271488,0.00029651646,0.0006134412,0.00060720823,0.00016847387,0.00007901757,0.00013199865],"category_scores_gemma":[0.00038797624,0.00017904775,0.00012939106,0.00019233074,0.00019170188,0.00036400955,0.00029374086,0.00013706333,0.0000979262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035841012,0.00087978796,0.7016026,0.00024714717,0.00028708234,0.0023275663,0.0004449322,0.0000038403955,0.21179914,0.00038947663,0.029533282,0.052126776],"study_design_scores_gemma":[0.0031863898,0.00046315973,0.79568404,0.0005357292,0.00046034917,0.000062653955,0.00017865811,0.00014664039,0.067729376,0.004318425,0.12674697,0.00048759455],"about_ca_topic_score_codex":0.00056178705,"about_ca_topic_score_gemma":0.00015091151,"teacher_disagreement_score":0.14406978,"about_ca_system_score_codex":0.00011063069,"about_ca_system_score_gemma":0.00005824957,"threshold_uncertainty_score":0.73013556},"labels":[],"label_agreement":null},{"id":"W2763914808","doi":"10.1093/eurheartj/ehx493.4881","title":"4881Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time","year":2017,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Blood pressure; Internal medicine; Cardiology; Cholesterol; Ldl cholesterol","score_opus":0.06343172822427626,"score_gpt":0.3441992975105389,"score_spread":0.2807675692862627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763914808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970531,0.0008271375,0.000029075109,0.00033861364,0.000072998686,0.00061664294,0.00001555724,0.000014020585,0.001032863],"genre_scores_gemma":[0.99816173,0.000051135583,0.00031932414,0.00015968281,0.00022713008,0.0000053112744,0.0000047070007,0.000023317645,0.0010476564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988334,0.00016733225,0.00034142938,0.00020842877,0.0002167416,0.00023262111],"domain_scores_gemma":[0.9990645,0.00003893755,0.00029025483,0.00035922864,0.00008963258,0.00015745508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008477511,0.00015273246,0.0004531061,0.000120669334,0.00015383249,0.00011142318,0.00011942143,0.000029952069,0.000047492194],"category_scores_gemma":[0.00020465012,0.00012039666,0.00013234004,0.000034677447,0.00009629912,0.00019358506,0.00006649941,0.00015656663,0.0000071345503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072619884,0.0011568577,0.9042506,0.0003685942,0.0036530234,0.0003364882,0.00021759987,0.00004280002,0.07242299,0.0000141433375,0.002579842,0.014230833],"study_design_scores_gemma":[0.007051107,0.00049303356,0.9773707,0.0003377378,0.0019771005,0.000035841666,0.000010843527,0.00034623718,0.011440923,0.00001685502,0.0008201879,0.00009945461],"about_ca_topic_score_codex":0.0000743248,"about_ca_topic_score_gemma":0.000025286952,"teacher_disagreement_score":0.07312005,"about_ca_system_score_codex":0.000008756653,"about_ca_system_score_gemma":0.000024894656,"threshold_uncertainty_score":0.4909633},"labels":[],"label_agreement":null},{"id":"W2763921543","doi":"10.2337/dc17-1091","title":"Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck","keywords":"Medicine; Diabetes mellitus; Atherosclerotic cardiovascular disease; Type 2 diabetes; Disease; Cohort; Internal medicine; Cohort study; Endocrinology","score_opus":0.02093008020251412,"score_gpt":0.22767018310115147,"score_spread":0.20674010289863737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763921543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98784703,0.009797208,1.5196687e-7,0.000025829917,0.00009242778,0.0018010668,0.00012776967,0.0000132966115,0.00029519803],"genre_scores_gemma":[0.9993709,0.0000942965,0.000022979786,0.000042831944,0.000040592742,0.00010171751,0.00028947226,0.00002345496,0.000013797786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895656,0.000054935776,0.00022456063,0.00026689805,0.00033022574,0.00016680706],"domain_scores_gemma":[0.9986714,0.0000770051,0.00016245709,0.00086240337,0.00014599443,0.00008071826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072314506,0.00017789488,0.00058085547,0.00005634231,0.00007252158,0.000026316893,0.00015227908,0.00004546469,0.000007123116],"category_scores_gemma":[0.00012350835,0.00010662411,0.00012816307,0.00006308602,0.0001723908,0.00011110321,0.00010544727,0.00006464426,0.0000021604585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075614505,0.00018604878,0.9957326,0.00017680426,0.0014837659,0.000003684262,0.00030078818,0.0000028587344,0.000025726487,0.000013029286,0.00005952082,0.0012589986],"study_design_scores_gemma":[0.018084597,0.0006377189,0.9783445,0.00042775483,0.0010728234,2.4213926e-9,0.00012833222,0.000011068242,0.000602269,0.000035474008,0.0005450314,0.000110399385],"about_ca_topic_score_codex":0.0000900441,"about_ca_topic_score_gemma":0.0000193483,"teacher_disagreement_score":0.0173881,"about_ca_system_score_codex":0.000029999752,"about_ca_system_score_gemma":0.00005478225,"threshold_uncertainty_score":0.4348005},"labels":[],"label_agreement":null},{"id":"W2765113122","doi":"10.1111/dom.13134","title":"Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: <scp>A</scp> randomized clinical trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); GDI Integrated Facility Services (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Nasal congestion; Decongestant; Concomitant; Nasal decongestant; Pharmacodynamics; Common cold; Pseudoephedrine; Anesthesia; Adverse effect; rhinorrhea; Mucous membrane of nose; Nausea; Pharmacokinetics; Nose; Internal medicine; Surgery; Pathology; Immunology","score_opus":0.031824790788710894,"score_gpt":0.3455311865108615,"score_spread":0.31370639572215064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765113122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309903,0.0037526647,0.000003886108,0.00031023347,0.00030662506,0.0023464374,0.000038320002,0.000008625835,0.00013418437],"genre_scores_gemma":[0.99279934,0.006613916,0.00008127325,0.00030460244,0.00007302829,0.000076718134,0.000008047603,0.00001470098,0.00002835068],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792725,0.0005269293,0.0007967525,0.0002548763,0.00021924695,0.00027494124],"domain_scores_gemma":[0.9955646,0.0032472129,0.00068727665,0.0002716651,0.000065600914,0.00016366302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023539069,0.00021233503,0.0014041954,0.000094756135,0.00008467728,0.00002706957,0.0001117932,0.00010529397,0.0000022951074],"category_scores_gemma":[0.0012265075,0.00014571947,0.00012794415,0.000055776913,0.0007194626,0.00010385098,0.00009150086,0.0001803928,2.6005551e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37852675,0.019098002,0.43235284,0.0074308277,0.005814918,0.000088221714,0.0038210838,0.000009041616,0.066900626,0.032859996,0.00039421284,0.052703485],"study_design_scores_gemma":[0.5813365,0.0024298101,0.2675173,0.000423209,0.0030286976,4.706003e-7,0.00014179577,0.0028625282,0.14116238,0.00041308522,0.0005647958,0.00011946588],"about_ca_topic_score_codex":0.000034131674,"about_ca_topic_score_gemma":0.000023113867,"teacher_disagreement_score":0.2028097,"about_ca_system_score_codex":0.000010039654,"about_ca_system_score_gemma":0.000056627832,"threshold_uncertainty_score":0.5942268},"labels":[],"label_agreement":null},{"id":"W2765130763","doi":"10.1016/j.jcjd.2017.08.130","title":"Changes in Treatment Patterns at Six Months of the CANadian CAnagliflozin REgistry (CanCARE)","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Canagliflozin; Medicine; Regimen; Cohort; Prospective cohort study; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.019417464560397543,"score_gpt":0.23745648640073322,"score_spread":0.2180390218403357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765130763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98253435,0.00078331534,3.8810146e-8,0.009678212,0.0005307656,0.00035198266,0.00013260364,0.0000021865833,0.0059865643],"genre_scores_gemma":[0.996702,0.000045552268,0.00001915053,0.00046009535,0.00015532848,0.000014107898,0.000009715819,0.000022672351,0.0025713744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998737,0.000035637113,0.00030423584,0.00015292848,0.00020196632,0.0005682345],"domain_scores_gemma":[0.9978416,0.000028397162,0.00040872925,0.00068499177,0.00012313444,0.00091316266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018019517,0.00019610582,0.00045330692,0.00038766023,0.00032303986,0.000066394816,0.00041496873,0.000091644724,0.00014643699],"category_scores_gemma":[0.00014358318,0.00013605104,0.00017180054,0.00008416362,0.00016873062,0.00008523507,0.000028622264,0.00013298179,0.0000039446977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038002995,0.000024574685,0.9886524,0.000048248126,0.00024479438,0.00014341927,0.00031070065,0.000006351322,0.000058087746,0.00005035961,0.0022763496,0.008180926],"study_design_scores_gemma":[0.0014369838,0.00035144275,0.96630305,0.00051500124,0.00025220957,0.0000035041494,0.00016164657,0.0000133306885,0.0026587157,0.000027841781,0.02815965,0.000116649135],"about_ca_topic_score_codex":0.7856913,"about_ca_topic_score_gemma":0.99950707,"teacher_disagreement_score":0.21381578,"about_ca_system_score_codex":0.0024762992,"about_ca_system_score_gemma":0.0020412125,"threshold_uncertainty_score":0.6475436},"labels":[],"label_agreement":null},{"id":"W2765183832","doi":"10.1371/journal.pone.0186910","title":"The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Sanofi; FP7 Health; AstraZeneca; Eli Lilly and Company","keywords":"Cotransporter; Sodium; Proteome; Chemistry; Urinary system; Medicine; Biochemistry; Pharmacology; Endocrinology","score_opus":0.02715155097547186,"score_gpt":0.23688251203342456,"score_spread":0.2097309610579527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765183832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97830665,0.000089664805,0.0000010229244,0.0056886114,0.000030620908,0.0017434399,0.0000044354115,0.000027159844,0.014108408],"genre_scores_gemma":[0.9962669,0.00008732508,0.000026855654,0.00013563833,0.000084436535,0.0002868476,0.000014603199,0.0000132165915,0.0030841501],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992757,0.000037355247,0.0001222295,0.00012301558,0.0002903347,0.00015139444],"domain_scores_gemma":[0.9990813,0.000099971745,0.00010959588,0.00064676505,0.000027368604,0.000035003904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000285752,0.00010504192,0.00018845056,0.000024326935,0.0002618795,0.000029370012,0.00010917086,0.000030303445,0.000054818775],"category_scores_gemma":[0.00006355953,0.000047882066,0.000073372066,0.00002304953,0.00012272566,0.00005172608,0.000033832377,0.000095144256,0.00008953912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01151283,0.023104051,0.37799668,0.005377622,0.01078357,0.0006421573,0.0013291752,0.000001223537,0.5011343,0.008289222,0.009206779,0.05062243],"study_design_scores_gemma":[0.0025383583,0.0051000994,0.12384815,0.00084300333,0.00089581904,6.820291e-7,0.00001290135,0.000027960059,0.86569047,0.00021469877,0.00074743934,0.000080396116],"about_ca_topic_score_codex":0.00000789519,"about_ca_topic_score_gemma":0.0000025482316,"teacher_disagreement_score":0.36455622,"about_ca_system_score_codex":0.000022161645,"about_ca_system_score_gemma":0.0000068673553,"threshold_uncertainty_score":0.20141919},"labels":[],"label_agreement":null},{"id":"W2765245125","doi":"10.1016/j.jcjo.2017.09.019","title":"Les « nouvelles » classes d’antidiabétiques: Considérations ophtalmologiques relatives aux agonistes du GLP-1R, aux inhibiteurs de la DPP-4 et aux inhibiteurs du SGLT2","year":2017,"lang":"fr","type":"editorial","venue":"Canadian Journal of Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.036795256519557056,"score_gpt":0.3431082145877234,"score_spread":0.30631295806816633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765245125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5882777,0.026868947,0.00005599762,0.017506374,0.17984013,0.0013820184,0.0008681488,0.0000688326,0.18513188],"genre_scores_gemma":[0.8818228,0.005468737,0.0015877727,0.00024502075,0.0843048,0.00008505189,0.00059880904,0.000255475,0.025631487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99172163,0.0026261786,0.0020464468,0.0009856244,0.00070609886,0.0019140193],"domain_scores_gemma":[0.9864128,0.005684853,0.0025870588,0.00094750896,0.0022146103,0.0021531486],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.003080133,0.0014134947,0.0025794045,0.0017846855,0.0019699906,0.0007907445,0.0012822455,0.00274568,0.0021720757],"category_scores_gemma":[0.016626498,0.0013432776,0.0009763388,0.0003265828,0.004746092,0.0008642943,0.00025216182,0.0032123446,0.00010044426],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039309193,0.0008522676,0.15183027,0.00074537005,0.0041256794,0.1903909,0.00526609,0.00012440953,0.0002652565,0.055602573,0.58886516,0.0015389094],"study_design_scores_gemma":[0.005954662,0.0076941852,0.038812354,0.0055050584,0.0038121874,0.06553613,0.0057120454,0.000044004984,0.0008054048,0.008393307,0.85584277,0.0018878998],"about_ca_topic_score_codex":0.020415615,"about_ca_topic_score_gemma":0.004064517,"teacher_disagreement_score":0.29354516,"about_ca_system_score_codex":0.002117943,"about_ca_system_score_gemma":0.038478427,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W2765324362","doi":"10.1016/j.jcjd.2017.08.017","title":"Are the Cardiovascular (CV) Risk Reductions Seen with Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional CV Risk Factors?","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Cardiology; Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.029888743192072326,"score_gpt":0.2538668440667618,"score_spread":0.22397810087468947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765324362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928683,0.001838098,0.000006647544,0.003368378,0.0005460283,0.0007122093,0.00017070015,0.0000067151745,0.0004829274],"genre_scores_gemma":[0.99853414,0.00004909436,0.000034727247,0.00018099311,0.0004639426,0.000036920028,0.000026298241,0.000024777994,0.0006491025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998172,0.000270369,0.0004415425,0.00019622399,0.00046924656,0.00045064828],"domain_scores_gemma":[0.9977689,0.00015537105,0.00079708034,0.0007530227,0.00014841084,0.0003772201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012623192,0.00023627901,0.00057598413,0.00023106002,0.0007993179,0.00021484206,0.00050439575,0.00007484925,0.000085932224],"category_scores_gemma":[0.0006881875,0.00012229389,0.00054808444,0.00013330686,0.00028949362,0.00024536584,0.000019463445,0.00049431925,0.000008794562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010351198,0.0000826147,0.98421025,0.00001565066,0.00248326,0.000049149516,0.00043992483,0.00006097972,0.0000031191055,0.000028735332,0.011643372,0.00087941793],"study_design_scores_gemma":[0.01785271,0.0005936093,0.9491119,0.00014268939,0.0025374407,0.0000052725572,0.0032616989,0.000013762985,0.00005223342,0.00012631077,0.026131092,0.00017127105],"about_ca_topic_score_codex":0.0032784864,"about_ca_topic_score_gemma":0.00812918,"teacher_disagreement_score":0.035098355,"about_ca_system_score_codex":0.00020327487,"about_ca_system_score_gemma":0.00028944164,"threshold_uncertainty_score":0.6147788},"labels":[],"label_agreement":null},{"id":"W2765424888","doi":"10.1016/j.celrep.2017.10.008","title":"Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion","year":2017,"lang":"en","type":"article","venue":"Cell Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"European Regional Development Fund; Canadian Institutes of Health Research; Novo Nordisk; Agence Nationale de la Recherche; Canada Research Chairs; Institut National de la Santé et de la Recherche Médicale","keywords":"Enteroendocrine cell; Secretion; Inflammation; TLR4; Lipopolysaccharide; Glucagon-like peptide-1; Incretin; Internal medicine; Endocrinology; Receptor; Hormone; Proinflammatory cytokine; Biology; Medicine; Endocrine system; Type 2 diabetes","score_opus":0.00615010394375903,"score_gpt":0.2677313336545945,"score_spread":0.2615812297108355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765424888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498716,0.00010775007,0.00008574708,0.0005333588,0.0010257642,0.00069561414,0.0000050477297,0.00006656136,0.04760853],"genre_scores_gemma":[0.8938958,0.00006111097,0.00047996198,0.00082946656,0.00020715709,0.000103244514,0.00002652322,0.00002871468,0.10436803],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986013,0.0000142093995,0.00031294432,0.00045933368,0.00027012482,0.00034206966],"domain_scores_gemma":[0.9981478,0.000007828474,0.00021374387,0.001277653,0.00007356123,0.00027940064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013175719,0.00020069553,0.00026841936,0.00008643611,0.00011331145,0.00008367151,0.000058456553,0.00004016136,0.0006900272],"category_scores_gemma":[0.000050507522,0.00017410606,0.00011797355,0.000034870307,0.0000423665,0.00012852266,0.0001785168,0.00008244141,0.00034554212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009606569,0.0010596857,0.099744774,0.00065552845,0.00034688585,0.04994584,0.0009856994,0.000004792558,0.646279,0.000014358742,0.15559983,0.04440297],"study_design_scores_gemma":[0.0003646734,0.00038634802,0.024712771,0.0001524935,0.00022399159,0.00006287323,0.000032807486,0.000008195316,0.5831401,0.000056869867,0.3906385,0.00022039343],"about_ca_topic_score_codex":0.000035700414,"about_ca_topic_score_gemma":0.000011022437,"teacher_disagreement_score":0.23503868,"about_ca_system_score_codex":0.00008060681,"about_ca_system_score_gemma":0.000027300559,"threshold_uncertainty_score":0.75553143},"labels":[],"label_agreement":null},{"id":"W2765427898","doi":"10.1016/j.jval.2017.08.435","title":"Prevalence of Cardiovascular Disease In Type 2 Diabetes: A Global Systematic Review","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Myocardial infarction; Angina; Internal medicine; Coronary artery disease; Stroke (engine); Diabetes mellitus; Heart failure; Cardiology; Disease; Type 2 diabetes; Cause of death; Checklist","score_opus":0.04519239517489385,"score_gpt":0.3158561704397169,"score_spread":0.27066377526482305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765427898","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.303821,0.6897745,0.0000038401627,0.0013776977,0.00017561052,0.0041594137,0.000014572097,0.00001956941,0.00065377564],"genre_scores_gemma":[0.92447245,0.07480627,0.00010927818,0.00035550783,0.00001571129,0.00010937053,0.00000453143,0.0000076156516,0.000119267],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99866086,0.00017339489,0.00044680838,0.00020211037,0.0002859744,0.00023086308],"domain_scores_gemma":[0.9985585,0.000026369777,0.00018837008,0.0010648274,0.000032579086,0.00012934681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011670769,0.0001001248,0.00075405044,0.000046787973,0.00002781955,0.0000075451353,0.00015488778,0.000018572733,0.000008667495],"category_scores_gemma":[0.0006413236,0.00007939021,0.00013826744,0.0001212821,0.00003214783,0.000057185953,0.000056557787,0.000047329147,0.000018235105],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009931199,0.00014889598,0.23512463,0.7634618,0.00016073394,0.000027162816,0.0000235166,0.00014784407,7.3595785e-8,0.00023556717,0.00007031278,0.0005894803],"study_design_scores_gemma":[0.001328742,0.0003156207,0.37122288,0.6235345,0.0014052228,5.889081e-7,0.000009773563,0.0016234624,0.0000018369577,0.00021244747,0.00022486808,0.00012007295],"about_ca_topic_score_codex":0.0007990567,"about_ca_topic_score_gemma":0.000004122001,"teacher_disagreement_score":0.6206514,"about_ca_system_score_codex":0.0002388172,"about_ca_system_score_gemma":0.00015580555,"threshold_uncertainty_score":0.32374388},"labels":[],"label_agreement":null},{"id":"W2765431642","doi":"10.1016/j.jcjd.2017.08.013","title":"Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Pharmacokinetics; Pharmacodynamics; Metformin; Type 2 Diabetes Mellitus; Internal medicine; Excretion; Endocrinology; Diabetes mellitus; Urology","score_opus":0.008731920476707648,"score_gpt":0.23162049444688507,"score_spread":0.22288857397017742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765431642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397177,0.00388804,5.033827e-7,0.0003974592,0.0003898145,0.00030134685,0.000042674004,0.0000039865668,0.0010044395],"genre_scores_gemma":[0.99888957,0.00038972436,0.00023550009,0.00020712728,0.00013538555,0.000003742237,0.000018162236,0.000032565706,0.000088223416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986092,0.00003116957,0.00041301645,0.00017558943,0.00026239635,0.00050862937],"domain_scores_gemma":[0.99813896,0.000055433316,0.00048293322,0.00027210932,0.00034607897,0.0007045028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002335931,0.00022129691,0.00052492094,0.00061700755,0.00010588667,0.000062842846,0.00025309733,0.00006114994,0.000044804325],"category_scores_gemma":[0.00013332514,0.00018182893,0.000066281944,0.00019769087,0.00017762944,0.0002253782,0.00003190583,0.00020981583,0.000001879697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023127624,0.00009468621,0.9892618,0.0002116145,0.00028340673,0.000036358437,0.000090295194,0.000027891323,0.000045157478,0.00002490749,0.0009047081,0.008996029],"study_design_scores_gemma":[0.0045002485,0.00089872396,0.9902984,0.00022299777,0.00091885915,3.9041092e-7,0.000029680728,0.00021726982,0.00079297135,0.000048681122,0.0018746081,0.00019719364],"about_ca_topic_score_codex":0.00066518225,"about_ca_topic_score_gemma":0.008118614,"teacher_disagreement_score":0.008798836,"about_ca_system_score_codex":0.00016408654,"about_ca_system_score_gemma":0.00051568984,"threshold_uncertainty_score":0.7414769},"labels":[],"label_agreement":null},{"id":"W2765477536","doi":"10.1016/j.clinthera.2017.10.003","title":"Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec; McGill University","funders":"","keywords":"Medicine; Canagliflozin; Sulfonylurea; Glycemic; Type 2 Diabetes Mellitus; Randomized controlled trial; Diabetes mellitus; Weight loss; Internal medicine; Endocrinology; Obesity","score_opus":0.016708703572632867,"score_gpt":0.2982125618759192,"score_spread":0.28150385830328634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765477536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909016,0.00055492995,0.000029324756,0.00082814734,0.0004338884,0.006327387,0.000005863671,0.000025453714,0.00089340424],"genre_scores_gemma":[0.99688697,0.000907353,0.00008646886,0.0013813515,0.00015122686,0.0002508594,0.000028729473,0.000034132845,0.0002728932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977697,0.000305514,0.0008206964,0.0004047464,0.00030094243,0.00039839116],"domain_scores_gemma":[0.9977955,0.0009797647,0.0004420423,0.0005208274,0.00012137773,0.0001404636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011667091,0.0003021422,0.0019646122,0.0001312304,0.00007783267,0.00007176481,0.0001244856,0.00018224402,0.000032080876],"category_scores_gemma":[0.00028881725,0.00017323559,0.00016033358,0.000092108596,0.0005423353,0.00012144908,0.00003668817,0.00031510566,0.0000055564146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58355314,0.00078491075,0.41075435,0.00001612925,0.0011370019,0.00001843259,0.00002460965,0.0000024639232,6.276215e-7,0.00018889901,0.000012059993,0.0035073732],"study_design_scores_gemma":[0.8337185,0.004641116,0.15788887,0.0001594363,0.0014928257,1.9518791e-7,0.000013156114,0.00070454564,0.0000017779721,0.0002251721,0.0009737079,0.00018070833],"about_ca_topic_score_codex":0.00008576165,"about_ca_topic_score_gemma":0.0003655337,"teacher_disagreement_score":0.2528655,"about_ca_system_score_codex":0.00009822058,"about_ca_system_score_gemma":0.00011404809,"threshold_uncertainty_score":0.70643425},"labels":[],"label_agreement":null},{"id":"W2765509755","doi":"10.1016/j.jcjd.2017.08.018","title":"Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Placebo; Type 2 diabetes; Diabetes mellitus; Randomized controlled trial; Internal medicine; Alternative medicine; Endocrinology","score_opus":0.030085068760997268,"score_gpt":0.26424415736387763,"score_spread":0.23415908860288037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765509755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909964,0.00088948966,5.20622e-8,0.0048944997,0.00062277366,0.00026858144,0.000014847016,0.0000018804973,0.002311435],"genre_scores_gemma":[0.99844587,0.000019312483,0.000061541126,0.00031164457,0.00012577143,0.0000024708195,0.0000018524413,0.000011781666,0.0010197794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989375,0.00004033693,0.00042717587,0.00011046151,0.00017018152,0.00031434477],"domain_scores_gemma":[0.99873126,0.00009122292,0.00040781524,0.0003823812,0.00010720074,0.00028012076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044973614,0.000124536,0.00044340588,0.00022593532,0.000113864764,0.00005393212,0.00025344407,0.000060543523,0.000018959634],"category_scores_gemma":[0.0011472844,0.00007790267,0.00012517658,0.00007818003,0.00023562308,0.0001405711,0.000033429846,0.00017294376,0.0000020769155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018787976,0.000050753068,0.9900515,0.000036837417,0.00025545617,0.00001453821,0.00019387859,0.0000026660039,0.00018534632,0.00006265586,0.0029422152,0.006016241],"study_design_scores_gemma":[0.02461226,0.0008776612,0.96531934,0.00045253482,0.00023584825,4.4809784e-7,0.0000747772,0.000012660539,0.0014075057,0.0002001832,0.0067151426,0.00009164346],"about_ca_topic_score_codex":0.00037632624,"about_ca_topic_score_gemma":0.005845519,"teacher_disagreement_score":0.024732197,"about_ca_system_score_codex":0.000077008284,"about_ca_system_score_gemma":0.00037924072,"threshold_uncertainty_score":0.3261937},"labels":[],"label_agreement":null},{"id":"W2765554536","doi":"10.1016/j.jcjd.2017.08.154","title":"Day-to-day Variability of Fasting Self-Measured Blood Glucose (SMBG) Associates with Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D)","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin glargine; Hypoglycemia; Type 2 diabetes; Internal medicine; Insulin degludec; Crossover study; Endocrinology; Post-hoc analysis; Insulin; Diabetes mellitus; Placebo","score_opus":0.009599760177356366,"score_gpt":0.21494307602712523,"score_spread":0.20534331584976886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765554536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965025,0.00060292304,0.0000018828716,0.0003532622,0.00027251404,0.000586562,0.000042288935,0.00002045481,0.001617583],"genre_scores_gemma":[0.997131,0.000046264155,0.0022601646,0.00013026503,0.00015908612,0.000012140727,0.000014201098,0.00005649892,0.00019037478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975934,0.00017340101,0.0006167712,0.0003518669,0.00044174906,0.0008227976],"domain_scores_gemma":[0.9961866,0.00044179423,0.00093799515,0.0006608859,0.0008564276,0.000916261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016324386,0.00036043095,0.00094532024,0.00045952533,0.00023712107,0.00011572477,0.00044052882,0.00013982413,0.00011828348],"category_scores_gemma":[0.0039263484,0.00024589436,0.000105248466,0.0004661348,0.00017118017,0.00031036412,0.00004547539,0.00039962123,0.000009413762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001911677,0.00027627533,0.98982435,0.00025904024,0.0013687488,0.00010131519,0.00083192566,0.00003735864,0.0002776192,0.000011653026,0.00026075236,0.0065597645],"study_design_scores_gemma":[0.0060914,0.005290285,0.9799856,0.0027435094,0.0015839456,0.0000023414925,0.00021366258,0.00009304726,0.0028989348,0.000068810106,0.0006861069,0.00034238375],"about_ca_topic_score_codex":0.00084260385,"about_ca_topic_score_gemma":0.02153878,"teacher_disagreement_score":0.020696176,"about_ca_system_score_codex":0.00033263923,"about_ca_system_score_gemma":0.001640902,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W2765723298","doi":"10.1016/j.ihj.2017.09.015","title":"Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus","year":2017,"lang":"en","type":"article","venue":"Indian Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Glimepiride; Canagliflozin; Adipokine; Medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Internal medicine; Inflammation; Linagliptin; Chemokine; Endocrinology; Insulin resistance","score_opus":0.007952204311307446,"score_gpt":0.23746581328006058,"score_spread":0.22951360896875314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765723298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781984,0.0007363802,7.242141e-8,0.00032839223,0.00036024075,0.00036488756,0.000002355177,0.000008482623,0.0003793253],"genre_scores_gemma":[0.99948865,0.00011847724,0.000114098235,0.00010169362,0.000095095864,0.000006057718,0.0000062355184,0.000018499777,0.00005116056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910194,0.00002883416,0.00019752477,0.00015009372,0.00024943132,0.0002721569],"domain_scores_gemma":[0.9992594,0.00008452857,0.00016632311,0.0002392143,0.00006914885,0.00018138379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015594026,0.00015428415,0.0003039242,0.00024413409,0.00011867413,0.00005277253,0.00008361858,0.000055323766,0.00001679715],"category_scores_gemma":[0.00014473447,0.00011352999,0.000040385035,0.000067740264,0.000102997285,0.0001402514,0.00003687998,0.0001455162,0.0000069585303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010834202,0.0002019343,0.983268,0.00019920338,0.00041126896,0.00014253032,0.00008910085,8.3420514e-7,0.00019081937,0.000008925545,0.00083987747,0.013564088],"study_design_scores_gemma":[0.009151443,0.0017946729,0.97984546,0.00065581815,0.00016482905,0.0000023802252,0.000011716987,0.0000026101013,0.0057584033,0.000013545616,0.002490919,0.00010818372],"about_ca_topic_score_codex":0.000050607854,"about_ca_topic_score_gemma":0.000073381314,"teacher_disagreement_score":0.013455905,"about_ca_system_score_codex":0.000084238854,"about_ca_system_score_gemma":0.000069904796,"threshold_uncertainty_score":0.46296188},"labels":[],"label_agreement":null},{"id":"W2765902909","doi":"10.1161/atvbaha.117.310251","title":"GLP-1 Elicits an Intrinsic Gut–Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance","year":2017,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Food and Agriculture; Natural Sciences and Engineering Research Council of Canada; Heart and Stroke Foundation of Canada; U.S. Department of Agriculture","keywords":"Endocrinology; Internal medicine; Very low-density lipoprotein; Insulin resistance; Lipogenesis; Hyperlipidemia; Microsomal triglyceride transfer protein; Lipid metabolism; Insulin; Biology; Chemistry; Lipoprotein; Medicine; Diabetes mellitus; Cholesterol","score_opus":0.04703942451355801,"score_gpt":0.2990474105668805,"score_spread":0.2520079860533225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765902909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961489,0.00059953163,0.000048285186,0.0019742055,0.00018516231,0.00063899445,0.000012882875,0.000056260065,0.0003357686],"genre_scores_gemma":[0.988529,0.009388185,0.0007794212,0.00085654797,0.00026015379,0.00008854799,0.000037103488,0.000028372562,0.00003266391],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984161,0.000098989316,0.0002588985,0.0007256122,0.00012721424,0.0003731566],"domain_scores_gemma":[0.9987269,0.000015458043,0.00014218282,0.0007812743,0.00008673143,0.00024742106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029455964,0.00028574138,0.0006039865,0.00014110624,0.0004542646,0.00015325902,0.00014020091,0.00012914758,0.000053114843],"category_scores_gemma":[0.000042596635,0.00023635407,0.00009616362,0.00009489985,0.00017066118,0.0002782276,0.00021453915,0.00010227608,0.00003064267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017062663,0.0007691935,0.17639463,0.00014852299,0.0016230756,0.0000013516371,0.0009118115,5.7167335e-7,0.7206647,0.0044366377,0.0006558508,0.09422308],"study_design_scores_gemma":[0.0016342994,0.0012620463,0.9813198,0.0000805952,0.00039609586,2.567452e-7,0.00005617304,0.000023885088,0.0015183088,0.000093843315,0.013361965,0.00025273033],"about_ca_topic_score_codex":0.0002086015,"about_ca_topic_score_gemma":0.00027305496,"teacher_disagreement_score":0.8049252,"about_ca_system_score_codex":0.000027571044,"about_ca_system_score_gemma":0.00001619253,"threshold_uncertainty_score":0.9638239},"labels":[],"label_agreement":null},{"id":"W2765923679","doi":"10.1016/j.clinthera.2017.10.002","title":"Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Dulaglutide; Insulin glargine; Placebo; Diabetes mellitus; Type 2 diabetes; Internal medicine; Repeated measures design; Urology; Exenatide; Endocrinology","score_opus":0.04830368495985739,"score_gpt":0.3371819936526016,"score_spread":0.2888783086927442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765923679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961338,0.00005518626,0.000005135748,0.0011448644,0.00017224766,0.00127445,0.000011269736,0.0000993496,0.0011036688],"genre_scores_gemma":[0.99579597,0.000039700215,0.001154048,0.0019426274,0.00003458011,0.000039947943,0.00012310654,0.000057208057,0.0008128436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803674,0.000056914057,0.00064010476,0.00046402862,0.0003644127,0.00043779906],"domain_scores_gemma":[0.9979885,0.00010066992,0.00032504482,0.0010249582,0.0003245147,0.00023631133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001932363,0.00031696862,0.00075802277,0.0001574837,0.00011149088,0.00006852559,0.00017712075,0.00013368212,0.000043630193],"category_scores_gemma":[0.00017349143,0.00019371657,0.00008588277,0.00030794888,0.0001588057,0.00010874469,0.0000846353,0.00022480161,0.00005863742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015839991,0.0022025418,0.9620193,0.000015003303,0.0013470587,0.000056096014,0.0000374641,0.000006616181,0.000016958475,0.000013487845,0.000080481506,0.03262096],"study_design_scores_gemma":[0.012561535,0.006531598,0.97453344,0.0001938464,0.00064119237,2.0982516e-7,0.00001967318,0.00006749608,0.000337156,0.000021321615,0.0048333476,0.0002591594],"about_ca_topic_score_codex":0.0000144959695,"about_ca_topic_score_gemma":0.000032385484,"teacher_disagreement_score":0.032361798,"about_ca_system_score_codex":0.00006745768,"about_ca_system_score_gemma":0.00007334518,"threshold_uncertainty_score":0.78995323},"labels":[],"label_agreement":null},{"id":"W2765966284","doi":"10.1016/j.jcjd.2017.08.023","title":"DISCOVER: A Prospective Investigation of Disease Management and Clinical Evolution of Second Line Treatments in T2DM: A First Look at the Enrolled Cohort in Canada","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Cohort; Prospective cohort study; Type 2 Diabetes Mellitus; Disease; Baseline (sea); Cohort study; Disease management; Diabetes mellitus; Family medicine; Internal medicine","score_opus":0.01041741249146064,"score_gpt":0.23572749980250293,"score_spread":0.2253100873110423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765966284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965558,0.0011796602,3.3055363e-7,0.0008252855,0.000111502355,0.00074195146,0.000046953894,6.652564e-7,0.0005378319],"genre_scores_gemma":[0.9992879,0.00007341414,0.000028680819,0.00006495926,0.000026173968,0.000020754955,0.000009495474,0.000008473086,0.00048017225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988767,0.000047985868,0.0005382412,0.00014370409,0.00018447738,0.00020888016],"domain_scores_gemma":[0.99879044,0.00007690889,0.00045439013,0.0002650425,0.00006926426,0.000343971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003546999,0.00011926895,0.00041652523,0.00020934941,0.00007826524,0.000015779247,0.0001215511,0.000027647226,0.000036734302],"category_scores_gemma":[0.00015876145,0.0000843979,0.00007593619,0.00008742392,0.00021462324,0.00013009024,0.00003761696,0.000093451614,3.8593154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006589385,0.000058305406,0.99792165,0.0001263562,0.00048105617,0.000066594104,0.00009487792,0.000018473425,0.000006020999,0.00006461542,0.00037043585,0.0007257306],"study_design_scores_gemma":[0.0040692664,0.0003362342,0.993811,0.00053369685,0.00045805261,4.2546762e-7,0.00014687887,0.00010511755,0.00009915293,0.00029195088,0.000085239,0.00006298032],"about_ca_topic_score_codex":0.23104618,"about_ca_topic_score_gemma":0.98123336,"teacher_disagreement_score":0.75018716,"about_ca_system_score_codex":0.0014824021,"about_ca_system_score_gemma":0.0013718554,"threshold_uncertainty_score":0.7740744},"labels":[],"label_agreement":null},{"id":"W2766142749","doi":"10.1016/j.jcjd.2017.08.152","title":"Efficacy and Safety of Fast-acting Insulin Aspart Are Maintained over 52 weeks: Comparison with Insulin Aspart in Onset 1","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Postprandial; Insulin aspart; Medicine; Internal medicine; Insulin detemir; Insulin; Endocrinology; Meal; Type 2 diabetes; Confidence interval; Diabetes mellitus; Basal insulin","score_opus":0.01834149820867056,"score_gpt":0.25786031534062054,"score_spread":0.23951881713194997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766142749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953368,0.0010823722,0.0000056491494,0.0014790633,0.00012550081,0.00032859723,0.000028466575,0.0000055893747,0.0016079877],"genre_scores_gemma":[0.9990553,0.00003675848,0.00041470266,0.00020807472,0.00008934199,0.0000046763003,0.000013042665,0.000025687654,0.00015236359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985485,0.000052741823,0.0005498575,0.00018270306,0.00021576814,0.00045042607],"domain_scores_gemma":[0.99807334,0.00012265428,0.0007455864,0.0003365122,0.00013272952,0.0005891504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043591476,0.00021897904,0.00075875095,0.0004095614,0.0001629341,0.00008387147,0.00019602316,0.00008021114,0.0000780347],"category_scores_gemma":[0.00039166602,0.00017305186,0.000074238145,0.00011835013,0.00021348093,0.00023409257,0.000034607347,0.00029130123,0.0000035660944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014978947,0.0001279458,0.9786105,0.00010002364,0.00034405146,0.000108811924,0.00040389673,0.000038022285,0.000058656362,0.000050784645,0.0007706962,0.019236794],"study_design_scores_gemma":[0.007261878,0.0010388165,0.9840125,0.001485985,0.00024106675,0.0000037082045,0.0006561315,0.000135621,0.00049064093,0.000034639714,0.0044738026,0.00016525373],"about_ca_topic_score_codex":0.0009136274,"about_ca_topic_score_gemma":0.01553923,"teacher_disagreement_score":0.01907154,"about_ca_system_score_codex":0.00019286867,"about_ca_system_score_gemma":0.00038810665,"threshold_uncertainty_score":0.8671255},"labels":[],"label_agreement":null},{"id":"W2766166596","doi":"10.1016/j.jval.2017.12.019","title":"Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Type 2 Diabetes Mellitus; Indirect costs; Disease burden; Population; Coronary artery disease; MEDLINE; Type 2 diabetes; Disease; Intensive care medicine; Diabetes mellitus; Emergency medicine; Comorbidity; Environmental health; Internal medicine","score_opus":0.06739378503097723,"score_gpt":0.33144060148306953,"score_spread":0.26404681645209227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766166596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003806782,0.9910074,3.095551e-7,0.00009081877,0.00024515035,0.008400212,0.000022022574,0.000019278265,0.00017677965],"genre_scores_gemma":[0.000024641511,0.99877024,0.00004902742,0.000111661284,0.00011501315,0.00057305815,0.00013543917,0.000051575567,0.00016934257],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965743,0.00068469794,0.0016600009,0.00045077383,0.00024715785,0.00038305882],"domain_scores_gemma":[0.9978979,0.00013676724,0.0005262232,0.0012081305,0.00002766849,0.00020329743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002144309,0.00034136052,0.005701586,0.00041069055,0.000012273545,0.0000064202864,0.00019234426,0.00008646247,0.000031896237],"category_scores_gemma":[0.00023023313,0.000256354,0.00085495185,0.00038229334,0.000034644858,0.00003201108,0.00007391327,0.00015553256,0.00024115296],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002221874,0.00006566185,0.000027122487,0.9756233,0.0010849629,0.000020861953,0.000025002542,0.000054236956,1.7709505e-10,0.000045452758,0.00035305627,0.022698106],"study_design_scores_gemma":[0.000244705,0.00014294763,0.0000034163304,0.7087605,0.0051652393,6.582615e-7,0.0000030589517,0.00010701739,4.695427e-9,0.000010856427,0.28544548,0.000116109455],"about_ca_topic_score_codex":0.0008961181,"about_ca_topic_score_gemma":0.000004092767,"teacher_disagreement_score":0.2850924,"about_ca_system_score_codex":0.0010385294,"about_ca_system_score_gemma":0.0009420442,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W2766174279","doi":"10.14740/jocmr3220w","title":"The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cotransporter; Kidney disease; Sodium; Pharmacology; Disease; Endocrinology; Internal medicine","score_opus":0.12603549602737676,"score_gpt":0.508389879809768,"score_spread":0.3823543837823913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766174279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7382711,0.0025606893,0.0007003846,0.246172,0.0013313937,0.0019823182,0.00001275959,0.000013586512,0.008955722],"genre_scores_gemma":[0.9910184,0.0023092348,0.00010990148,0.0004930515,0.0026359023,0.00002295561,0.0000059671415,0.000017973509,0.0033866018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610645,0.00018855288,0.0014002189,0.00020110948,0.0017432458,0.00036042673],"domain_scores_gemma":[0.9952078,0.0009743821,0.0006962164,0.00094913045,0.00089383696,0.0012786207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009214685,0.000117573676,0.0006220216,0.00020570861,0.0002671688,0.000033387496,0.00062290684,0.00006817262,0.00010360805],"category_scores_gemma":[0.007691487,0.000060312846,0.00025038954,0.00015119866,0.0008776305,0.000109076595,0.00013205995,0.00067260984,0.000034453482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054890793,0.0012836884,0.36350602,0.00062206207,0.0007056392,0.0003292696,0.0001544196,0.000002735386,0.0022360925,0.0020293782,0.11495007,0.50869155],"study_design_scores_gemma":[0.0068287356,0.0054885396,0.40843138,0.0011710874,0.0003315778,0.0000022306867,0.0001262054,0.00012786184,0.0013890682,0.0005168857,0.57551515,0.00007124754],"about_ca_topic_score_codex":0.000040431896,"about_ca_topic_score_gemma":0.00001557131,"teacher_disagreement_score":0.5086203,"about_ca_system_score_codex":0.00010062123,"about_ca_system_score_gemma":0.0007172309,"threshold_uncertainty_score":0.9207984},"labels":[],"label_agreement":null},{"id":"W2766303877","doi":"10.1016/j.jcjd.2017.08.156","title":"Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Glycemic; Metformin; Type 2 diabetes; Pioglitazone; Urology; Hypoglycemia; Internal medicine; Insulin; Gastroenterology; Diabetes mellitus; Endocrinology","score_opus":0.012063451455519137,"score_gpt":0.2397180373763442,"score_spread":0.22765458592082508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766303877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593693,0.00039105126,4.970922e-7,0.0005150877,0.00033571388,0.0010085439,0.000035114168,0.000008865814,0.0017682082],"genre_scores_gemma":[0.99945277,0.000010730029,0.00011341992,0.00013657549,0.00006913542,0.000007148543,0.000018542378,0.00003949606,0.00015218202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776334,0.00013593058,0.000727825,0.00031174519,0.00046661048,0.0005945719],"domain_scores_gemma":[0.9975506,0.00026275558,0.0006800464,0.00050306896,0.00032990417,0.00067363586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006006281,0.00034020533,0.0010264099,0.00058403116,0.00021538939,0.0001023517,0.00028236597,0.000087087785,0.00003173493],"category_scores_gemma":[0.00058061036,0.000266462,0.0001106294,0.00022509096,0.0002407257,0.00029264542,0.00003940542,0.0003271116,0.0000069846847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021036498,0.0009283352,0.98286027,0.000052896008,0.0010482246,0.00010888236,0.00044863936,0.000049241997,0.000029820087,0.00003685554,0.00023385396,0.012099328],"study_design_scores_gemma":[0.060753506,0.010899112,0.9257596,0.0006634718,0.0007250854,2.907605e-7,0.00048268965,0.00003684186,0.00016249645,0.0000126229115,0.0002740219,0.00023027782],"about_ca_topic_score_codex":0.0013479451,"about_ca_topic_score_gemma":0.009725307,"teacher_disagreement_score":0.058649857,"about_ca_system_score_codex":0.00031171623,"about_ca_system_score_gemma":0.00063592126,"threshold_uncertainty_score":0.9999788},"labels":[],"label_agreement":null},{"id":"W2766384958","doi":"10.1016/j.jcjd.2017.08.137","title":"Semaglutide Reduces HbA1c and Body Weight Across Multiple Background OAD Treatment Categories","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Sitagliptin; Exenatide; Medicine; Internal medicine; Willmore energy; Urology; Gastroenterology; Pharmacology; Type 2 diabetes; Endocrinology; Diabetes mellitus; Liraglutide; Mathematics","score_opus":0.024449286400466914,"score_gpt":0.2762277312292887,"score_spread":0.2517784448288218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766384958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99060225,0.0040948414,8.019786e-7,0.0025053623,0.00053914735,0.0002296356,0.0000392609,0.000009249128,0.001979432],"genre_scores_gemma":[0.9954313,0.00014100276,0.00033715233,0.00016470454,0.00037207684,0.000010660269,0.000012964613,0.000026470572,0.0035036597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987361,0.000018500976,0.0003155317,0.00019515787,0.00015285678,0.00058187294],"domain_scores_gemma":[0.99818826,0.00008187452,0.0003109814,0.00037312237,0.00014281303,0.0009029421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019383048,0.00023959212,0.00049848267,0.00016077477,0.0006179754,0.00033386634,0.00019266698,0.00007195273,0.00006533148],"category_scores_gemma":[0.00014291597,0.00017882886,0.00014648646,0.000045902103,0.0003491453,0.00029536054,0.000029455181,0.00010793742,0.000015723434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013120111,0.000078289624,0.9679338,0.000051351406,0.0008864925,0.00018997911,0.00066591584,7.179138e-7,0.0009838903,0.00018878268,0.0022119759,0.026795724],"study_design_scores_gemma":[0.004062613,0.0013051294,0.91316086,0.00025156862,0.0006519365,0.000016491094,0.0008661705,0.000042654276,0.009145979,0.00033169257,0.06991261,0.00025228295],"about_ca_topic_score_codex":0.00205892,"about_ca_topic_score_gemma":0.014079058,"teacher_disagreement_score":0.06770063,"about_ca_system_score_codex":0.00028629892,"about_ca_system_score_gemma":0.0003446929,"threshold_uncertainty_score":0.7856445},"labels":[],"label_agreement":null},{"id":"W2766490052","doi":"10.1016/j.jcjd.2017.08.016","title":"CANadian CAnagliflozin REgistry (CanCARE) – A Prospective, Observational, Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus (T2DM); Six Month Results","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Canagliflozin; Medicine; Glycemic; Observational study; Type 2 Diabetes Mellitus; Internal medicine; Type 2 diabetes; Diabetes mellitus; Surgery; Endocrinology; Insulin","score_opus":0.030556280132394822,"score_gpt":0.2846181710753628,"score_spread":0.254061890942968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766490052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97606593,0.0032468864,3.5968398e-7,0.0052846298,0.00075910403,0.00086726475,0.0004005422,0.000009495736,0.013365774],"genre_scores_gemma":[0.9966328,0.00018704038,0.00069216976,0.0003420107,0.00023142056,0.000046875317,0.00013870394,0.000052395284,0.0016765757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698395,0.00008178687,0.0009971792,0.00042271303,0.0004510713,0.001063312],"domain_scores_gemma":[0.9955934,0.00012303908,0.0009027503,0.0009856154,0.00069667486,0.0016984923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006113587,0.00042760314,0.001055662,0.0010508479,0.00032447098,0.00016764044,0.0005526861,0.00017672905,0.000104931816],"category_scores_gemma":[0.0006844049,0.00038045485,0.00025137456,0.00036910587,0.00023905073,0.0003725022,0.00003117416,0.0002989222,0.00000555076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000025873225,0.0001377288,0.9854242,0.000107277934,0.0008329339,0.0002564719,0.0002532691,0.000119859025,0.000086276246,0.0005369363,0.006444247,0.005774924],"study_design_scores_gemma":[0.004180274,0.0014482703,0.962098,0.0007169228,0.00044795155,0.0000018531902,0.00023250528,0.00026737942,0.0006038336,0.0002194881,0.02946798,0.00031555517],"about_ca_topic_score_codex":0.6213603,"about_ca_topic_score_gemma":0.974864,"teacher_disagreement_score":0.3535037,"about_ca_system_score_codex":0.005035835,"about_ca_system_score_gemma":0.010662257,"threshold_uncertainty_score":0.99986476},"labels":[],"label_agreement":null},{"id":"W2766527970","doi":"10.1016/j.jcjd.2017.08.019","title":"Responder Analysis of Subjects Achieving HbA1c ≥1% and Weight Loss ≥5% Across SUSTAIN 1–5 Clinical Trials","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Weight loss; Exenatide; Sitagliptin; Placebo; Hypoglycemia; Clinical endpoint; Internal medicine; Type 2 diabetes; Insulin glargine; Clinical trial; Dulaglutide; Diabetes mellitus; Pharmacology; Gastroenterology; Insulin; Obesity; Endocrinology; Liraglutide","score_opus":0.06972482064087465,"score_gpt":0.39839416618360685,"score_spread":0.3286693455427322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766527970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441516,0.002171744,0.0000075626817,0.0021224127,0.0003196588,0.00020365698,0.00004373861,0.0000036606298,0.00071238796],"genre_scores_gemma":[0.998418,0.00013354146,0.00018918682,0.00026604361,0.00024213633,0.0000022238994,0.000008985222,0.000017021743,0.0007228601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977057,0.0002995783,0.0010973869,0.00019462404,0.00022799465,0.00047472585],"domain_scores_gemma":[0.9964034,0.0007137259,0.0011991365,0.0004970944,0.00029713937,0.00088952563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006038933,0.00017320891,0.0014953862,0.0006675706,0.000250263,0.00014546333,0.0002674278,0.00012148504,0.0001051262],"category_scores_gemma":[0.0050374023,0.00013134972,0.00061117526,0.00022859912,0.00038835587,0.00023788417,0.000047053563,0.0002169915,0.00000181503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044451477,0.00004850758,0.96926624,0.00006532865,0.005731991,0.00012486793,0.00025346252,0.0000037325337,0.00009836593,0.00015057856,0.0011110889,0.023101373],"study_design_scores_gemma":[0.0025804646,0.00047623366,0.98453134,0.00019382552,0.005714553,0.0000013690037,0.00026214818,0.000057394995,0.0003385526,0.00009984181,0.005625988,0.00011831095],"about_ca_topic_score_codex":0.00034635246,"about_ca_topic_score_gemma":0.005346119,"teacher_disagreement_score":0.022983061,"about_ca_system_score_codex":0.0000970855,"about_ca_system_score_gemma":0.00050615246,"threshold_uncertainty_score":0.6030605},"labels":[],"label_agreement":null},{"id":"W2766611920","doi":"10.1016/j.jcjd.2017.08.163","title":"HbA1c Levels, Persistence, Treatment Progression, and Durability of HbA1c Control in Patients with T2DM Initiated on Canagliflozin or a GLP-1 in a Real-world Setting","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Canagliflozin; Discontinuation; Hazard ratio; Persistence (discontinuity); Internal medicine; Type 2 Diabetes Mellitus; Confidence interval; Proportional hazards model; Diabetes mellitus; Endocrinology","score_opus":0.035502273309608534,"score_gpt":0.27638978612453874,"score_spread":0.2408875128149302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766611920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965411,0.00015595091,1.2197296e-7,0.001108975,0.00006439959,0.00074478623,0.000064624626,0.0000036526706,0.0013164349],"genre_scores_gemma":[0.999479,0.000009222522,0.0001497505,0.00016276863,0.000025816547,0.000022596523,0.000010424095,0.000017393213,0.00012302933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859583,0.0000777076,0.00047549928,0.00020723933,0.0002194063,0.00042430195],"domain_scores_gemma":[0.9984884,0.00010584766,0.00046430822,0.00029556072,0.00018471618,0.0004611333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033936708,0.00021182203,0.0006238462,0.0006284577,0.0001119366,0.0000491003,0.00012984607,0.000052192016,0.00003453192],"category_scores_gemma":[0.0002718415,0.00013539367,0.00006509884,0.00016897423,0.00018618186,0.00017718767,0.000011730918,0.00013927932,5.876876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022027094,0.0002929813,0.9807215,0.00009531857,0.00026945458,0.00013272201,0.00036559635,0.000007119708,0.000008835051,0.000015757309,0.00008608797,0.017784405],"study_design_scores_gemma":[0.011289934,0.003368285,0.9826908,0.0017149355,0.0002311151,5.5535986e-7,0.00017836908,0.000052665444,0.000109481625,0.00001876137,0.00021972296,0.00012538763],"about_ca_topic_score_codex":0.0050220033,"about_ca_topic_score_gemma":0.2331934,"teacher_disagreement_score":0.2281714,"about_ca_system_score_codex":0.00064576964,"about_ca_system_score_gemma":0.00079194194,"threshold_uncertainty_score":0.78079885},"labels":[],"label_agreement":null},{"id":"W2766617433","doi":"10.1161/circulationaha.117.030012","title":"Sodium Glucose Cotransporter-2 Inhibition in Heart Failure","year":2017,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":462,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"National Institutes of Health; Canadian Institutes of Health Research; Diabetes Action Research and Education Foundation; International Society for Pediatric and Adolescent Diabetes; University of Toronto; Ontario Ministry of Research and Innovation; Women's College Hospital; National Institute of Diabetes and Digestive and Kidney Diseases; Heart and Stroke Foundation of Canada","keywords":"Empagliflozin; Medicine; Canagliflozin; Heart failure; Natriuresis; Preload; Internal medicine; Type 2 diabetes; Diabetes mellitus; Cardiology; Blood pressure; Type 2 Diabetes Mellitus; Afterload; Dapagliflozin; Pharmacology; Endocrinology; Hemodynamics","score_opus":0.06322076151064368,"score_gpt":0.33157537166781037,"score_spread":0.26835461015716666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766617433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074253714,0.99529415,0.00003725188,0.00020438588,0.0001791356,0.0017504946,0.000010272898,0.000061905914,0.0017198635],"genre_scores_gemma":[0.013474986,0.98295486,0.00012999983,0.0000535576,0.00019829688,0.00017182657,0.002716391,0.000042014148,0.00025806561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988629,0.000032724212,0.0004221393,0.00031538607,0.00017942724,0.00018738669],"domain_scores_gemma":[0.99923086,0.000014402654,0.00022567825,0.0004403864,0.0000283467,0.00006029685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015938621,0.00024022353,0.0009403259,0.00028567397,0.000050848284,0.000039972343,0.000037065398,0.00022707816,0.000070301845],"category_scores_gemma":[0.000015337511,0.00021174214,0.00030127264,0.00010901386,0.00002579135,0.00012810795,0.000014364855,0.00016423054,0.00022317574],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000056801896,0.00018376192,0.0026522118,0.014222506,0.00013472205,0.00010541274,0.000031263193,0.0000012756174,0.000005166743,0.00017992641,0.0010796901,0.9813984],"study_design_scores_gemma":[0.00070375524,0.000026894191,0.0066127838,0.012728332,0.0010713695,0.000014753574,0.0000029503267,0.00000854412,0.0000035421363,0.000057631984,0.9785996,0.00016982362],"about_ca_topic_score_codex":0.000014047805,"about_ca_topic_score_gemma":0.000028841634,"teacher_disagreement_score":0.98122853,"about_ca_system_score_codex":0.00022689402,"about_ca_system_score_gemma":0.00008403007,"threshold_uncertainty_score":0.86345935},"labels":[],"label_agreement":null},{"id":"W2766695480","doi":"10.1016/j.jcjd.2017.08.037","title":"Reduced Health Care Costs with Automated Basal Insulin Titration in Patients with Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Glycemic; Insulin glargine; Basal (medicine); Basal insulin; Randomized controlled trial; Insulin; Type 2 diabetes; Diabetes mellitus; Titration; Health care; Internal medicine; Endocrinology","score_opus":0.00774507296449647,"score_gpt":0.2358938700274838,"score_spread":0.22814879706298732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766695480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996452,0.00071569945,1.93726e-7,0.0010897891,0.00019456536,0.00041223888,0.000016025111,0.00001790629,0.0011016048],"genre_scores_gemma":[0.99882954,0.000006375647,0.00038528498,0.0005502028,0.000063477746,0.0000056490762,0.00008262837,0.000028065386,0.000048753613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988634,0.000035573572,0.00028182092,0.00015091483,0.00022742896,0.00044086046],"domain_scores_gemma":[0.9983954,0.000017184288,0.00037429397,0.0002888253,0.0003712054,0.0005531313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014877,0.0001702357,0.00039475533,0.00034772308,0.00018542378,0.000109952634,0.00015593432,0.00005141913,0.000027839082],"category_scores_gemma":[0.00009272441,0.00012209015,0.000036783753,0.0001421231,0.000094810275,0.00028691787,0.000009306766,0.00015691867,0.0000068115064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036847665,0.000065177104,0.987889,0.000072905765,0.0001780382,0.00001710065,0.00028829687,0.000010357137,0.000015515683,0.000012622426,0.0020102195,0.009403901],"study_design_scores_gemma":[0.004184419,0.0033344005,0.9903128,0.00082554127,0.00010020324,1.7986481e-7,0.000120776975,0.000045122477,0.00028215488,0.000004684634,0.00065762666,0.00013209925],"about_ca_topic_score_codex":0.00055056036,"about_ca_topic_score_gemma":0.014792615,"teacher_disagreement_score":0.014242054,"about_ca_system_score_codex":0.0005987404,"about_ca_system_score_gemma":0.0012948603,"threshold_uncertainty_score":0.82546264},"labels":[],"label_agreement":null},{"id":"W2766703029","doi":"10.1016/j.jcjd.2017.08.155","title":"Risk Reductions across Hypoglycemia Definitions with Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in SWITCH 1 and 2","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Insulin degludec; Medicine; Insulin glargine; Hypoglycemia; Crossover study; Insulin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Pediatrics; Placebo","score_opus":0.019333060622890873,"score_gpt":0.24702130958436536,"score_spread":0.2276882489614745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766703029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919424,0.0023952702,0.000006549542,0.003296197,0.00021999521,0.00026926288,0.00009476932,0.000010277638,0.0017652436],"genre_scores_gemma":[0.9973301,0.00049469783,0.001397116,0.0002640689,0.00019143183,0.000019684694,0.000020980715,0.0000320985,0.00024979986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998569,0.000037125163,0.00041522327,0.0002185939,0.00018736547,0.0005726971],"domain_scores_gemma":[0.9981017,0.000069187554,0.00039582237,0.0004265828,0.00020215672,0.000804568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037845512,0.00022055733,0.00047844776,0.0004046002,0.00055238267,0.00021513706,0.0002152003,0.00009819417,0.000059183843],"category_scores_gemma":[0.0004554697,0.00018132776,0.00009109056,0.00018548453,0.00032985862,0.00039469148,0.00003419915,0.00041521736,0.000014013416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004856905,0.00010548057,0.9802041,0.00004647663,0.00034743376,0.00018109477,0.00052858563,0.000022511518,0.00008005971,0.00024312874,0.0012364314,0.01695613],"study_design_scores_gemma":[0.005628226,0.0008502539,0.981437,0.0005191081,0.00041307788,0.00003250264,0.00042413108,0.000036556077,0.00039853808,0.0007360817,0.009310743,0.00021373104],"about_ca_topic_score_codex":0.002574919,"about_ca_topic_score_gemma":0.04471991,"teacher_disagreement_score":0.04214499,"about_ca_system_score_codex":0.0002239029,"about_ca_system_score_gemma":0.0006096874,"threshold_uncertainty_score":0.97271144},"labels":[],"label_agreement":null},{"id":"W2766979007","doi":"10.1016/j.jcjd.2017.08.020","title":"Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Sitagliptin; Placebo; Weight loss; Tolerability; Exenatide; Internal medicine; Obesity; Type 2 diabetes; Endocrinology; Diabetes mellitus; Adverse effect; Liraglutide","score_opus":0.013790601760852951,"score_gpt":0.2837582146950227,"score_spread":0.26996761293416977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766979007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883197,0.0021117702,0.000005651169,0.0061915885,0.00086547417,0.0002624733,0.00009419123,0.000016378537,0.002132772],"genre_scores_gemma":[0.9914181,0.000041058374,0.00036489923,0.0006945275,0.00085814646,0.000008303043,0.000025220024,0.000045587214,0.006544155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976991,0.00004258024,0.0005383954,0.00025146818,0.0003075435,0.0011609055],"domain_scores_gemma":[0.9969607,0.00010596909,0.00053243537,0.00064251083,0.0004006817,0.0013576963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011274752,0.0002863551,0.0006200469,0.00018537256,0.0008354347,0.00040503617,0.00053872523,0.000114529146,0.00020181216],"category_scores_gemma":[0.0008196834,0.00023527932,0.00029309356,0.00010929921,0.00037580772,0.00038342312,0.00006776927,0.00029739842,0.00004204493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002094429,0.00011036724,0.94041294,0.00012926586,0.00076130946,0.0006768598,0.0006894593,0.000003848646,0.0013492544,0.00023973853,0.023971356,0.03163466],"study_design_scores_gemma":[0.004496633,0.0008629878,0.82492995,0.00068954943,0.0005362879,0.000021420325,0.0015689718,0.00012973625,0.012293972,0.00046806215,0.15353253,0.0004699095],"about_ca_topic_score_codex":0.0008759107,"about_ca_topic_score_gemma":0.008746216,"teacher_disagreement_score":0.12956119,"about_ca_system_score_codex":0.00032724155,"about_ca_system_score_gemma":0.0005520366,"threshold_uncertainty_score":0.95944124},"labels":[],"label_agreement":null},{"id":"W2766992315","doi":"10.1016/j.jcjd.2017.08.148","title":"The Impact of Baseline BMI and HbA1c on Glycemic Control After Treatment with Fast-Acting Insulin Aspart in Individuals with Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin aspart; Glycemic; Type 2 diabetes; Metformin; Internal medicine; Insulin; Post-hoc analysis; Regimen; Diabetes mellitus; Randomized controlled trial; Endocrinology","score_opus":0.010897186923050025,"score_gpt":0.24583751098209158,"score_spread":0.23494032405904156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766992315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961754,0.0020323682,6.6968875e-7,0.0007613635,0.000057487912,0.00038344337,0.000037218997,0.0000031698291,0.0005488418],"genre_scores_gemma":[0.9994812,0.00007830101,0.00008495958,0.00012165813,0.00008395523,0.000019682138,0.0000058930013,0.000025721136,0.00009861617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988384,0.0000542794,0.00031574423,0.00015249054,0.00017976417,0.00045931878],"domain_scores_gemma":[0.9984363,0.00022477834,0.0004251044,0.0003350318,0.00015009618,0.0004287063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036002553,0.00023592326,0.0005333953,0.00027018602,0.0001612673,0.00011700351,0.0001291508,0.00004971649,0.000032309028],"category_scores_gemma":[0.00015952019,0.0001179279,0.000085793035,0.00009535642,0.0002214363,0.00016499797,0.000009994596,0.00015140405,0.0000021816793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027996444,0.00008724002,0.96729445,0.00002145942,0.0010908423,0.000048714373,0.00018290746,0.000047358564,0.00006863712,0.0000058251767,0.000098192446,0.030774407],"study_design_scores_gemma":[0.008911666,0.013320008,0.9745704,0.0008433222,0.00048568327,0.0000025660352,0.00015538369,0.00014057993,0.0005017662,0.000023730328,0.0008957113,0.0001491762],"about_ca_topic_score_codex":0.00071832846,"about_ca_topic_score_gemma":0.0056106136,"teacher_disagreement_score":0.030625232,"about_ca_system_score_codex":0.00024628313,"about_ca_system_score_gemma":0.00055416033,"threshold_uncertainty_score":0.48089603},"labels":[],"label_agreement":null},{"id":"W2768451744","doi":"10.1161/circulationaha.117.031227","title":"Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Stroke (engine); Heart failure; Proportional hazards model; Adverse effect; Population; Diabetes mellitus; Lower risk; Propensity score matching; Confidence interval; Endocrinology","score_opus":0.03018973052340542,"score_gpt":0.27423326913038676,"score_spread":0.24404353860698133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768451744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718356,0.0004573976,0.00033475214,0.00016156257,0.00010284187,0.0003368226,0.00000386451,0.000016824973,0.001402345],"genre_scores_gemma":[0.9996166,0.00004306499,0.00012296964,0.00005291357,0.00005267483,0.000028365848,0.000038168,0.000008358262,0.000036879388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994983,0.000009043372,0.00013005415,0.00012675881,0.00016104958,0.00007481396],"domain_scores_gemma":[0.9994941,0.0000065302884,0.000075151576,0.00034376065,0.00004671795,0.000033752505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010435906,0.00007185365,0.0001998805,0.000053563195,0.00005190295,0.000021269449,0.000021781361,0.00004206926,0.000020263511],"category_scores_gemma":[0.000020490239,0.000061470186,0.0001181061,0.000015957878,0.000039458686,0.0001579007,0.000013207856,0.000026127833,0.0000066802104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032020558,0.000049361755,0.98159575,0.000095207535,0.00032145847,0.000010684815,0.000141267,0.000004257878,0.00038975684,0.000072061244,0.000008675304,0.01727951],"study_design_scores_gemma":[0.0016856419,0.000026347889,0.995278,0.000048036116,0.0006385788,7.901657e-7,0.000011694396,0.00011650298,0.0015180162,0.00012348135,0.0004969926,0.000055922013],"about_ca_topic_score_codex":0.00003880994,"about_ca_topic_score_gemma":0.000005281769,"teacher_disagreement_score":0.017223587,"about_ca_system_score_codex":0.00002006187,"about_ca_system_score_gemma":0.000007932433,"threshold_uncertainty_score":0.25066814},"labels":[],"label_agreement":null},{"id":"W2768891003","doi":"10.71781/4869","title":"La prise de médicaments antiasthmatiques pendant la grossesse et le risque de diabète gestationnel","year":2016,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Gynecology; Medicine","score_opus":0.020676465216381633,"score_gpt":0.3385659135687547,"score_spread":0.3178894483523731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768891003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78438634,0.00092368637,0.0011176347,0.0013867023,0.00032171386,0.0017921546,0.00015530047,0.00001105723,0.20990543],"genre_scores_gemma":[0.87388813,0.0022720578,0.017499574,0.00021421035,0.00018133904,0.00041660815,0.0020093767,0.00012225215,0.10339644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972131,0.00063399965,0.0005261298,0.0006193258,0.00034236955,0.00066504587],"domain_scores_gemma":[0.99818736,0.0004988636,0.00044198733,0.0004366741,0.00012262615,0.0003124855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015105958,0.0004906427,0.000623866,0.00019766233,0.00019747681,0.0005282251,0.00047838106,0.000375971,0.0020638534],"category_scores_gemma":[0.00024262957,0.00042498077,0.00015642997,0.00014441457,0.00013393878,0.0006023802,0.00019426158,0.0003242549,0.0008840304],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006268507,0.0044983253,0.025304426,0.001335801,0.0022805422,0.002460477,0.027884264,0.00003836767,0.01257251,0.008789335,0.0064784354,0.90773064],"study_design_scores_gemma":[0.016715646,0.0011744446,0.24440911,0.016404154,0.0040022917,0.00011738412,0.019274771,0.00100546,0.08006072,0.002118919,0.61277795,0.0019391703],"about_ca_topic_score_codex":0.001476065,"about_ca_topic_score_gemma":0.00047521485,"teacher_disagreement_score":0.9057915,"about_ca_system_score_codex":0.00039257066,"about_ca_system_score_gemma":0.0011425494,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W2769141179","doi":"10.1007/s12630-017-1019-5","title":"Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting","year":2017,"lang":"en","type":"letter","venue":"Canadian Journal of Anesthesia/Journal canadien d anesthésie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Cotransporter; Perioperative; Medicine; Sodium; Chemistry; Internal medicine; Anesthesia; Organic chemistry","score_opus":0.013160657687938483,"score_gpt":0.22846216337642855,"score_spread":0.21530150568849007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769141179","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3240515,0.0029825405,0.000001258337,0.66743743,0.0008555467,0.00079503807,0.000019857289,0.000010641951,0.003846191],"genre_scores_gemma":[0.77089894,0.0006402334,0.00042555347,0.19555716,0.020834116,0.000053832428,0.00030854033,0.00043665344,0.010844958],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.994513,0.0003842191,0.0015904658,0.0004839003,0.0012338299,0.0017946148],"domain_scores_gemma":[0.9950104,0.00014960214,0.0017566963,0.0008349632,0.0007091389,0.0015392407],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002367954,0.0009171191,0.0016220948,0.0018600904,0.001039903,0.0010528421,0.0016159866,0.0008414581,0.00028446649],"category_scores_gemma":[0.00020572876,0.0006474386,0.00089336705,0.0003588135,0.000524521,0.00061097945,0.000013800477,0.0054965843,0.000035378365],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047311507,0.000031631767,0.0031167096,0.00011244891,0.0002757981,0.63338435,0.0024217211,0.000007591745,0.0000031761251,0.000018900584,0.35874385,0.0018364879],"study_design_scores_gemma":[0.0014042702,0.00092583516,0.0029448818,0.0009752622,0.00067199726,0.5008901,0.0007194759,0.000002948308,0.000018351646,0.00004767708,0.49100867,0.00039053612],"about_ca_topic_score_codex":0.008127932,"about_ca_topic_score_gemma":0.023070646,"teacher_disagreement_score":0.4718803,"about_ca_system_score_codex":0.0019121615,"about_ca_system_score_gemma":0.007882445,"threshold_uncertainty_score":0.99998415},"labels":[],"label_agreement":null},{"id":"W2769176372","doi":"10.1016/j.clinthera.2017.10.016","title":"Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Metformin; Dipeptidyl peptidase-4; Pharmacology; Cotransporter; Internal medicine; Sodium; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.08102948794696149,"score_gpt":0.373015477501862,"score_spread":0.2919859895549005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769176372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987589,0.0003284146,0.00028772143,0.004332797,0.0029575373,0.0019643898,0.00020990461,0.00023215113,0.002098097],"genre_scores_gemma":[0.97889555,0.0009872782,0.0024452487,0.010596919,0.0029587673,0.00009935607,0.00026490085,0.00013438793,0.0036176231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959019,0.00012561165,0.0016510062,0.00083999144,0.0006855167,0.0007959835],"domain_scores_gemma":[0.9961091,0.00035462462,0.00085506943,0.0016184876,0.00027974535,0.0007829297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087349373,0.0005986625,0.0012222828,0.00016113899,0.0005737274,0.00028404497,0.0004481764,0.00037919258,0.0004342766],"category_scores_gemma":[0.00062315626,0.00045885766,0.0005767283,0.0001576951,0.00034585586,0.00027008553,0.00027405223,0.0005925907,0.00040692938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004034665,0.0055566956,0.14712341,0.00025770487,0.0015563887,0.0011112012,0.00078869594,0.0000016680428,0.0018278188,0.00013826492,0.013118563,0.82448494],"study_design_scores_gemma":[0.0090541355,0.006605882,0.097039916,0.001902827,0.00276502,0.000025406789,0.0004674697,0.00023456532,0.012805956,0.00014498866,0.8677527,0.0012011741],"about_ca_topic_score_codex":0.000019428677,"about_ca_topic_score_gemma":0.000051475905,"teacher_disagreement_score":0.8546341,"about_ca_system_score_codex":0.00015422206,"about_ca_system_score_gemma":0.00021553821,"threshold_uncertainty_score":0.9997863},"labels":[],"label_agreement":null},{"id":"W2769268568","doi":"10.1152/ajpendo.00374.2017","title":"Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"Novo Nordisk","keywords":"Liraglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.008405542865724435,"score_gpt":0.26754997171333345,"score_spread":0.259144428847609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769268568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98433745,0.013566631,9.452812e-8,0.0012930767,0.0001659245,0.00027072956,0.000002597218,0.0000060445564,0.00035744277],"genre_scores_gemma":[0.9902129,0.009104657,0.000037584203,0.00033687026,0.00016385497,0.000008952674,0.000001667493,0.000014362467,0.00011916229],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998894,0.00019330195,0.0002635241,0.00021710155,0.00008958892,0.00034253136],"domain_scores_gemma":[0.9989814,0.00019173826,0.00037664888,0.00025550567,0.00006954405,0.0001251494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002039116,0.00020252618,0.000981243,0.00025055802,0.000075000244,0.0000073280744,0.00015501368,0.000039438142,0.000048751637],"category_scores_gemma":[0.0001369875,0.00013633053,0.00008010029,0.000070564005,0.00037406533,0.00009119602,0.00009676618,0.00023272251,0.00002007204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003692915,0.0004021579,0.005457367,0.000083648425,0.0009862115,0.000057783196,0.00025055237,0.0000064232304,0.38576317,0.00052601483,0.0001369556,0.6026368],"study_design_scores_gemma":[0.0062056375,0.026474271,0.9083146,0.00015532106,0.000311,0.000036260462,0.00004116839,0.000022076134,0.05277968,0.00009182662,0.0054085315,0.00015964317],"about_ca_topic_score_codex":0.00001364515,"about_ca_topic_score_gemma":0.0000023868563,"teacher_disagreement_score":0.90285724,"about_ca_system_score_codex":0.000019917667,"about_ca_system_score_gemma":0.000036561607,"threshold_uncertainty_score":0.55593973},"labels":[],"label_agreement":null},{"id":"W2769439127","doi":"10.1007/s12630-017-1018-6","title":"Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Anesthesia/Journal canadien d anesthésie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Vomiting; Ketoacidosis; Metabolic acidosis; Diabetes mellitus; Perioperative; Anion gap; Nausea; Complication; Surgery; Anesthesia; Internal medicine; Endocrinology; Type 1 diabetes","score_opus":0.012466769076744943,"score_gpt":0.2180382719635514,"score_spread":0.20557150288680648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769439127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550146,0.0011818722,0.0000013165223,0.0022853054,0.00024275256,0.00042097323,0.00006645355,0.000003357832,0.0002965066],"genre_scores_gemma":[0.9992497,0.00018362937,0.00015244648,0.00003855632,0.00018406822,0.000020895926,0.000017258026,0.000047270965,0.00010618869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973298,0.00009038018,0.0012938908,0.00023237827,0.0003732422,0.0006803121],"domain_scores_gemma":[0.9959706,0.00007017209,0.0012117262,0.00053671474,0.0009102442,0.0013005607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007641348,0.00035045107,0.001236741,0.0010898266,0.00032980813,0.0001245303,0.0003361317,0.00015814154,0.000109583125],"category_scores_gemma":[0.00016694864,0.00030921676,0.00054671266,0.00026397587,0.0004906855,0.00068795617,0.000013260415,0.0004090399,0.0000024228966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029878874,0.00013595367,0.7979595,0.00013614248,0.00029106584,0.19439013,0.0014582293,0.00000458789,0.000053756845,0.000044443776,0.00034536517,0.0048820293],"study_design_scores_gemma":[0.0016914528,0.0013283142,0.79711074,0.0010597317,0.0007233474,0.19483356,0.0006950169,0.0000025937204,0.0009316584,0.0001013732,0.0011992889,0.00032294734],"about_ca_topic_score_codex":0.0106369555,"about_ca_topic_score_gemma":0.05278304,"teacher_disagreement_score":0.042146083,"about_ca_system_score_codex":0.00062651903,"about_ca_system_score_gemma":0.0024957904,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W2769531501","doi":"10.1016/j.ecl.2017.10.003","title":"Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes","year":2017,"lang":"en","type":"review","venue":"Endocrinology and Metabolism Clinics of North America","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Eli Lilly Canada; Novo Nordisk; Sanofi; Merck; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Intensive care medicine; Clinical trial; MEDLINE; Internal medicine; Endocrinology","score_opus":0.10205316089838802,"score_gpt":0.39787453905467945,"score_spread":0.29582137815629145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769531501","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01326436,0.9839677,0.0000034313891,0.000025532976,0.00081767904,0.00118471,0.00007605379,0.000026937563,0.00063359225],"genre_scores_gemma":[0.0024829688,0.9962463,0.0005131898,0.00003863874,0.000108568645,0.000108745604,0.00014427182,0.000042674823,0.0003146491],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639493,0.00036132216,0.0019631477,0.0005284744,0.0002536169,0.00049849594],"domain_scores_gemma":[0.9959838,0.0011006625,0.0016124947,0.0010966808,0.000102695005,0.00010367894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007660485,0.0005215229,0.010315307,0.0005342022,0.000047201072,0.000015922496,0.0003222516,0.000188205,0.000039832572],"category_scores_gemma":[0.0015381995,0.00033835252,0.0016254478,0.00024564148,0.00047746205,0.00010951762,0.0002551027,0.00038835627,0.000009679216],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006577791,0.00019297295,0.0034421515,0.006086198,0.0072667445,0.000058688478,0.000055485212,0.0000018880639,7.327903e-8,0.0000968165,0.000030176778,0.98270303],"study_design_scores_gemma":[0.001846126,0.00029590825,0.008385478,0.0014989772,0.012707692,0.0000031350369,0.0000664291,5.526976e-7,0.0000038093904,0.000036914134,0.9749065,0.0002484722],"about_ca_topic_score_codex":0.000060997016,"about_ca_topic_score_gemma":0.000017692348,"teacher_disagreement_score":0.98245454,"about_ca_system_score_codex":0.000015593705,"about_ca_system_score_gemma":0.00038792647,"threshold_uncertainty_score":0.99990684},"labels":[],"label_agreement":null},{"id":"W2769714327","doi":"","title":"Erratum to “Poster Presentation Abstracts.”: Canadian Journal of Diabetes 2017;41:S78","year":2017,"lang":"en","type":"erratum","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Presentation (obstetrics); Family medicine; Surgery","score_opus":0.0205935417434008,"score_gpt":0.26171075264228477,"score_spread":0.24111721089888397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769714327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6076433,0.03423537,0.0000047954168,0.019418135,0.10667205,0.0023135561,0.0009147873,0.000028532933,0.22876944],"genre_scores_gemma":[0.7759059,0.00018084997,0.00043805243,0.0029123412,0.009089572,0.000026158463,0.0004920577,0.00027022496,0.21068485],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952801,0.00011704511,0.001705663,0.00040545873,0.0008373756,0.0016543773],"domain_scores_gemma":[0.9893515,0.000114720584,0.0024710684,0.0008850348,0.0017122934,0.0054653734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010794447,0.0007601899,0.0018389651,0.003340699,0.0004689109,0.0007557432,0.001215789,0.0006924595,0.00054229173],"category_scores_gemma":[0.0013002018,0.00066921575,0.00080769556,0.00028885354,0.00031038077,0.0007365333,0.00004475464,0.0017243234,0.00011847855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007675087,0.00004904983,0.09876608,0.00037771915,0.0016557284,0.00056739483,0.00048876816,0.00001646098,0.00004963266,0.000012866977,0.8919338,0.0060748197],"study_design_scores_gemma":[0.0016335512,0.0016516765,0.24610262,0.0039311545,0.0021751649,0.000024412459,0.00019798228,0.0000059119725,0.00034382046,0.00030156027,0.7430379,0.00059426494],"about_ca_topic_score_codex":0.012079741,"about_ca_topic_score_gemma":0.29375592,"teacher_disagreement_score":0.28167617,"about_ca_system_score_codex":0.001222705,"about_ca_system_score_gemma":0.013375642,"threshold_uncertainty_score":0.9995759},"labels":[],"label_agreement":null},{"id":"W2769932926","doi":"10.1152/ajprenal.00445.2017","title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","year":2017,"lang":"en","type":"article","venue":"American Journal of Physiology-Renal Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Manitoba; St. Michael's Hospital; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Kidney Foundation of Canada; Canadian Diabetes Association","keywords":"Renal function; Medicine; Proteinuria; Urology; Internal medicine; Endocrinology; Kidney disease; Glomerulosclerosis; Effective renal plasma flow; Focal segmental glomerulosclerosis; Albuminuria; Kidney; Nephropathy; Renal blood flow; Excretion; Diabetes mellitus","score_opus":0.02976761704707564,"score_gpt":0.30855355248598554,"score_spread":0.2787859354389099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769932926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980534,0.00006763996,0.0000033154363,0.00055801636,0.000346407,0.00056291604,0.0000061096616,0.000021853879,0.00038035595],"genre_scores_gemma":[0.9985621,0.000058950493,0.00019716,0.00056732225,0.00039849788,0.000044647706,0.000018897123,0.000035995545,0.00011645887],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997473,0.00029797864,0.00083451095,0.0004795143,0.00031119084,0.0006037972],"domain_scores_gemma":[0.9974988,0.0000840582,0.001268811,0.0007779445,0.00013622387,0.00023414884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034931823,0.00038691427,0.0015284125,0.00034163598,0.0002588305,0.000031686155,0.0006233529,0.000044407167,0.00012395026],"category_scores_gemma":[0.000049402868,0.00029862393,0.00026044887,0.00016482404,0.00097457925,0.00021579735,0.00033793575,0.00048265225,0.000043712997],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041357228,0.009174866,0.04010463,0.000032931046,0.0014496698,0.00010793591,0.00032143568,0.000052364234,0.9392952,0.00015123984,0.00076607574,0.004407927],"study_design_scores_gemma":[0.009310769,0.061529167,0.9243375,0.00013383107,0.00038166397,0.000011790968,0.0012272085,0.000024889223,0.0021034374,0.00062372105,0.00007997043,0.0002360288],"about_ca_topic_score_codex":0.0005647266,"about_ca_topic_score_gemma":0.00013144256,"teacher_disagreement_score":0.9371918,"about_ca_system_score_codex":0.00019622582,"about_ca_system_score_gemma":0.00008426695,"threshold_uncertainty_score":0.9999466},"labels":[],"label_agreement":null},{"id":"W2770618453","doi":"10.1016/j.jemermed.2017.10.001","title":"Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report","year":2017,"lang":"en","type":"article","venue":"Journal of Emergency Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Diabetic ketoacidosis; Medicine; Vomiting; Emergency department; Nausea; Abdominal pain; Diabetes mellitus; Anion gap; Metabolic acidosis; Dapagliflozin; Pediatrics; Internal medicine; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.06553727425708623,"score_gpt":0.3557694635220118,"score_spread":0.29023218926492556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770618453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663304,0.0012387126,0.00016575024,0.011809772,0.005282644,0.00043743505,0.0000045207516,0.00002189177,0.014708892],"genre_scores_gemma":[0.9772754,0.0006825288,0.0009012527,0.00049431226,0.0017738449,0.000012789723,0.000008975795,0.000039448554,0.018811448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974984,0.00003283829,0.0012353844,0.00026030943,0.0006072571,0.00036581737],"domain_scores_gemma":[0.9969061,0.000045188597,0.0010245395,0.0009597036,0.00045286797,0.0006116233],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087963673,0.0002574317,0.0007731865,0.0003911314,0.00022849563,0.00001958952,0.00025689925,0.000072348244,0.0034525287],"category_scores_gemma":[0.0019004811,0.00017807868,0.000246364,0.00016247424,0.00008148723,0.00036960465,0.00011623224,0.00030655236,0.000045811812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006584702,0.00066783646,0.15864201,0.00038664477,0.0020262974,0.23783554,0.0010689975,0.0000072593307,0.006899648,0.000105486164,0.56404585,0.027655944],"study_design_scores_gemma":[0.014147066,0.010394811,0.3118835,0.0026936291,0.0068753357,0.05625571,0.0011521878,0.00007261905,0.002200975,0.00047076578,0.5930882,0.0007651707],"about_ca_topic_score_codex":0.0001527993,"about_ca_topic_score_gemma":0.00004504244,"teacher_disagreement_score":0.18157984,"about_ca_system_score_codex":0.00011310285,"about_ca_system_score_gemma":0.00012105192,"threshold_uncertainty_score":0.99745846},"labels":[],"label_agreement":null},{"id":"W2770623194","doi":"10.1016/j.clinthera.2017.11.001","title":"Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Basal (medicine); Diabetes mellitus; Logistic regression; Type 2 diabetes; Insulin; Exenatide; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.06292542923687601,"score_gpt":0.3321202038179004,"score_spread":0.2691947745810244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770623194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971031,0.000100911086,0.000003570484,0.00055505487,0.0001812181,0.000614014,0.000011606962,0.000032637792,0.0013978824],"genre_scores_gemma":[0.9973909,0.00038647445,0.00005442513,0.001065768,0.00009425804,0.000016927299,0.00005652379,0.00003626714,0.00089840835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988704,0.000056688426,0.0003099697,0.00021498659,0.0002833011,0.0002646933],"domain_scores_gemma":[0.9977915,0.0004932743,0.0005358075,0.0007937053,0.0003114372,0.000074239004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030517834,0.00018531729,0.00046177633,0.000023331957,0.00023959739,0.000063572836,0.00027214395,0.00010402516,0.000035966423],"category_scores_gemma":[0.00019264055,0.00009165371,0.000084125,0.000089947614,0.00052338716,0.000087432716,0.00006114436,0.00020498053,0.0000058893966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028069926,0.0010643022,0.98597175,0.000015403097,0.0014174818,0.0000016841901,0.000045799618,6.4817107e-7,0.0000034262762,0.000010957486,0.00017036899,0.011017468],"study_design_scores_gemma":[0.00411362,0.0032707413,0.97607654,0.0001491004,0.0005838023,2.3158426e-8,0.000008939468,0.00010696393,0.000072307776,0.000010362523,0.01548651,0.000121076584],"about_ca_topic_score_codex":0.0000112258285,"about_ca_topic_score_gemma":0.000048562328,"teacher_disagreement_score":0.01531614,"about_ca_system_score_codex":0.000025492653,"about_ca_system_score_gemma":0.000035123423,"threshold_uncertainty_score":0.37375298},"labels":[],"label_agreement":null},{"id":"W2770790027","doi":"10.2337/dc17-1638","title":"Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute; University of Calgary","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health; Hearst Foundations","keywords":"Medicine; Glycemic; Diabetes mellitus; Internal medicine; Biomarker; Glucagon-like peptide-1; Genome-wide association study; Randomized controlled trial; Oncology; Endocrinology; Genotype; Type 2 diabetes; Single-nucleotide polymorphism","score_opus":0.009584108685810413,"score_gpt":0.22136216004997086,"score_spread":0.21177805136416045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770790027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912605,0.0069033094,0.00004750389,0.00022291907,0.00016237388,0.001187079,0.000038535418,0.000012819466,0.00016494644],"genre_scores_gemma":[0.9994324,0.00007566126,0.00007147074,0.00020825722,0.000032234628,0.000091252165,0.00003830312,0.000019945444,0.000030518244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990218,0.000057216745,0.00020903937,0.000223513,0.0002623976,0.00022599037],"domain_scores_gemma":[0.9984915,0.00011762272,0.00019447065,0.00088685314,0.0002699309,0.000039603216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103797865,0.00016292608,0.00056468026,0.00007671911,0.000055237193,0.000019310675,0.00018929064,0.0000706465,0.000005236175],"category_scores_gemma":[0.00023316788,0.00011252614,0.00026130845,0.000057902864,0.00012347063,0.00007438162,0.00007925556,0.000068871865,0.0000042919874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001507729,0.00009688881,0.8898377,0.0014368705,0.0023774805,0.000034181507,0.0014453686,0.00022396761,0.03020929,0.00003174298,0.00058067846,0.073575094],"study_design_scores_gemma":[0.005489866,0.00041591076,0.9376691,0.00055021205,0.0010976515,4.868872e-7,0.00049639255,0.001098775,0.052652642,0.000120884884,0.00029090393,0.00011720012],"about_ca_topic_score_codex":0.000070755465,"about_ca_topic_score_gemma":0.000007228815,"teacher_disagreement_score":0.07345789,"about_ca_system_score_codex":0.000056479144,"about_ca_system_score_gemma":0.000019740932,"threshold_uncertainty_score":0.4588683},"labels":[],"label_agreement":null},{"id":"W2770821084","doi":"10.1161/circulationaha.117.032031","title":"Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease","year":2017,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Internal medicine; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.009474951038159759,"score_gpt":0.21253140559390324,"score_spread":0.20305645455574348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770821084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991573,0.0023890408,0.0000068995755,0.0048783515,0.0001058697,0.0008262146,0.000018720379,0.000013888628,0.00018800944],"genre_scores_gemma":[0.99451834,0.000103994935,0.00004656584,0.0041928613,0.00011313097,0.000019963121,0.0008668767,0.00002695622,0.00011128791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906373,0.00003401292,0.00017680536,0.00028197755,0.00028386636,0.00015958319],"domain_scores_gemma":[0.9993245,0.000019888204,0.00010437023,0.00043753913,0.00006120497,0.000052510146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008090278,0.00019011465,0.00053227274,0.00011498671,0.00003700669,0.00002619705,0.000034582667,0.000116893956,0.000011381169],"category_scores_gemma":[0.000026938238,0.00014617037,0.0000870359,0.000035134846,0.00007439187,0.00009906874,0.000028780507,0.00013491523,0.0000011740244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000649879,0.000045899193,0.9886708,0.0005280644,0.0009029733,0.00003566953,0.00005074156,0.000016476517,4.2722837e-7,0.0000026774273,0.0012650484,0.008416201],"study_design_scores_gemma":[0.0026165973,0.0000755499,0.9848618,0.00028511687,0.0011237882,1.3908004e-7,0.0000027434432,0.00007154678,5.568544e-7,0.000031293865,0.010791567,0.0001392888],"about_ca_topic_score_codex":0.00001010962,"about_ca_topic_score_gemma":0.0000013282591,"teacher_disagreement_score":0.009526518,"about_ca_system_score_codex":0.000059650658,"about_ca_system_score_gemma":0.000022806245,"threshold_uncertainty_score":0.59606546},"labels":[],"label_agreement":null},{"id":"W2771082072","doi":"10.1016/j.diabres.2017.12.008","title":"The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study","year":2017,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Waterloo; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; University of Alberta; Diabetes Canada","keywords":"Medicine; Diabetes mellitus; Osteoporosis; Hazard ratio; Internal medicine; Dipeptidyl peptidase-4; Proportional hazards model; Cohort; Type 2 diabetes; Cohort study; Endocrinology; Confidence interval","score_opus":0.06169304245225413,"score_gpt":0.45266953965956624,"score_spread":0.3909764972073121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771082072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156886,0.00066107133,0.000001043533,0.0023989216,0.00007341654,0.0023260573,0.00001580088,0.0000112074695,0.00294359],"genre_scores_gemma":[0.99837476,0.00068426837,0.0002237152,0.00019554049,0.00009189929,0.00005015424,0.0000034943155,0.000020572548,0.00035559208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996316,0.00095857517,0.00080055575,0.0005379984,0.0008620771,0.0005248037],"domain_scores_gemma":[0.98958343,0.008095696,0.00044015693,0.0010904993,0.00034310127,0.0004470867],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008944173,0.00019454348,0.00075333216,0.00015812977,0.00033943378,0.00015733468,0.00032157137,0.00010605446,0.000025730873],"category_scores_gemma":[0.02039214,0.00012708646,0.00010203372,0.00021258034,0.0009107736,0.0002569208,0.00049206096,0.000699012,0.000009322353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000703624,0.0023427883,0.97640914,0.00007384929,0.00083741645,0.000008737257,0.00049059273,0.0000010627267,0.00005236608,0.000039375416,0.0016622193,0.017378818],"study_design_scores_gemma":[0.0034325279,0.0023211557,0.9831548,0.000178136,0.00032872235,1.4095012e-7,0.00261302,0.00006134404,0.00030900317,0.00027778777,0.007215299,0.0001080777],"about_ca_topic_score_codex":0.002315808,"about_ca_topic_score_gemma":0.0005342428,"teacher_disagreement_score":0.017270742,"about_ca_system_score_codex":0.000034598757,"about_ca_system_score_gemma":0.00013544566,"threshold_uncertainty_score":0.9878595},"labels":[],"label_agreement":null},{"id":"W2772059359","doi":"10.1172/jci97233","title":"Discovery, characterization, and clinical development of the glucagon-like peptides","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":399,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canada Research Chairs","keywords":"Glucagon-like peptide-2; Translational science; Short bowel syndrome; Relevance (law); Computational biology; Medicine; Data science; Bioinformatics; Biology; Computer science; Internal medicine; Political science; Pathology; Biochemistry; Peptide","score_opus":0.2527332337757946,"score_gpt":0.4628754719202606,"score_spread":0.21014223814446598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772059359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07978496,0.9125865,0.0002541597,0.0010771379,0.0043226546,0.0016166031,0.00001536308,0.000012909592,0.00032972769],"genre_scores_gemma":[0.00061310333,0.993948,0.001902768,0.00022670308,0.0007771305,0.0000067837645,0.00006484203,0.000024979414,0.0024357068],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99492526,0.0003422398,0.0039645396,0.00021886079,0.00042406793,0.0001250523],"domain_scores_gemma":[0.9922528,0.0005017747,0.006379417,0.00042266093,0.00025122816,0.00019211229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029863722,0.00023614985,0.0022696655,0.00010936317,0.00009776572,0.000073470415,0.00028244834,0.00029359446,0.0000052973774],"category_scores_gemma":[0.0021402477,0.00012508084,0.00089751673,0.000092586466,0.00045280397,0.00028137988,0.00016540698,0.00053689326,0.0000062347453],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022657887,0.00020480783,0.018379396,0.0028704621,0.0010152232,0.0000052213695,0.00003308534,2.106242e-8,0.0000014650924,0.00007038649,0.00048250082,0.97691476],"study_design_scores_gemma":[0.00085283926,0.00029872585,0.113932915,0.01906028,0.003584321,0.0000141012515,0.000005734617,0.0000031295504,0.0000072799703,0.000071672366,0.86206174,0.000107236214],"about_ca_topic_score_codex":8.326673e-7,"about_ca_topic_score_gemma":0.00000251673,"teacher_disagreement_score":0.97680753,"about_ca_system_score_codex":0.000047857666,"about_ca_system_score_gemma":0.001315657,"threshold_uncertainty_score":0.51006484},"labels":[],"label_agreement":null},{"id":"W2772204795","doi":"10.2337/dc17-1096","title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":747,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eisai; AstraZeneca","keywords":"Empagliflozin; Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Placebo; Diabetes mellitus; Type 2 diabetes; Uric acid; Post-hoc analysis; Confidence interval; Endocrinology","score_opus":0.02700654752745105,"score_gpt":0.2818045509879635,"score_spread":0.2547980034605124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772204795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504316,0.0015972712,0.000003126951,0.00062879536,0.0009126985,0.0009526488,0.00014129498,0.00004012725,0.0006808522],"genre_scores_gemma":[0.99852735,0.0000364517,0.00004337552,0.0000971946,0.00034263424,0.00010825123,0.0004397674,0.000020998801,0.00038400706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825704,0.00009669391,0.00031409966,0.00040102255,0.0006944815,0.00023663478],"domain_scores_gemma":[0.99718976,0.000059773494,0.00032447596,0.0021578544,0.0001712587,0.000096863565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013284992,0.00023054946,0.000956567,0.0001942045,0.00020530754,0.00012963367,0.0003813024,0.00011086558,0.00002143475],"category_scores_gemma":[0.00034548223,0.00012818546,0.0014036424,0.00026568552,0.00012810205,0.00020435272,0.00017823794,0.0001039108,0.0000073010733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011422677,0.00008890605,0.975551,0.000082766186,0.018570473,0.000005482069,0.0009785518,0.000022322267,0.0003363673,0.000041350428,0.00011453497,0.004094033],"study_design_scores_gemma":[0.010269479,0.000102877915,0.95562977,0.00004999712,0.022842377,8.666681e-9,0.0010728149,0.000110938556,0.0072762724,0.00008094142,0.0024003726,0.0001641541],"about_ca_topic_score_codex":0.00017504087,"about_ca_topic_score_gemma":0.00029867698,"teacher_disagreement_score":0.019921219,"about_ca_system_score_codex":0.00010150446,"about_ca_system_score_gemma":0.00003538134,"threshold_uncertainty_score":0.52272516},"labels":[],"label_agreement":null},{"id":"W2772364154","doi":"10.14740/jocmr3225w","title":"Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"MSD K.K.; Japan Diabetes Foundation; Tokyo Women's Medical University","keywords":"Medicine; Sitagliptin; Renal function; Internal medicine; Creatinine; Diabetes mellitus; Urology; Prospective cohort study; Population; Type 2 diabetes; Observational study; Gastroenterology; Endocrinology","score_opus":0.2886818592571634,"score_gpt":0.5079410532815252,"score_spread":0.21925919402436178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772364154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640125,0.000022266573,0.0000050681797,0.0008864741,0.0001968693,0.0020746507,0.0000027616131,0.0000022423335,0.00040839988],"genre_scores_gemma":[0.99908334,0.000009780587,0.00010235137,0.00005395127,0.00054906606,0.00002624464,0.0000067427286,0.000012244085,0.00015627802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99443924,0.00088124134,0.0018275154,0.00026047262,0.002333414,0.0002580876],"domain_scores_gemma":[0.9948126,0.0010156882,0.0009696062,0.00044567263,0.002582272,0.00017417556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009846983,0.00012339016,0.0012189873,0.000742813,0.00007343971,0.000012632438,0.00041086163,0.00006912058,0.00009858009],"category_scores_gemma":[0.0041603344,0.0000613559,0.00012021853,0.002187841,0.0005338259,0.00022591672,0.00020935963,0.0005987314,0.0000010209377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075759076,0.012981189,0.9048182,0.000032730873,0.003487921,0.0000058600626,0.00031906637,0.0000048376883,0.00019861826,0.00003242505,0.00014723698,0.0022128592],"study_design_scores_gemma":[0.12479207,0.07654081,0.7955749,0.00037530778,0.001974105,9.0283265e-8,0.00040072302,0.000074131734,0.00011853352,0.0000903493,0.000018870267,0.000040122908],"about_ca_topic_score_codex":0.000040116698,"about_ca_topic_score_gemma":0.00015623176,"teacher_disagreement_score":0.1092433,"about_ca_system_score_codex":0.000118112046,"about_ca_system_score_gemma":0.0002950047,"threshold_uncertainty_score":0.49806094},"labels":[],"label_agreement":null},{"id":"W2772844083","doi":"10.1159/000484633","title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics","year":2017,"lang":"en","type":"article","venue":"American Journal of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Albuminuria; Canagliflozin; Kidney disease; Internal medicine; Renal function; Empagliflozin; Diabetes mellitus; Endocrinology; Type 2 diabetes; Diabetic nephropathy; Creatinine; Urology; Nephropathy; Kidney","score_opus":0.030887919665192207,"score_gpt":0.3256573267011754,"score_spread":0.2947694070359832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772844083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943618,0.00020107493,0.00029531878,0.004338828,0.00007887179,0.0006811301,0.0000012754087,0.0000031200373,0.000038573522],"genre_scores_gemma":[0.9964604,0.00042891514,0.0019131752,0.0009552917,0.00017051585,0.000025106132,0.0000034105908,0.00001009916,0.000033094857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982214,0.00060048176,0.0005089151,0.00017929933,0.00028890098,0.00020099095],"domain_scores_gemma":[0.99791086,0.00067706953,0.0007645974,0.0002544682,0.0002681301,0.00012487295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003564783,0.00012640252,0.00046662826,0.00011444039,0.00018637542,0.00009333454,0.00012379861,0.0000255828,0.000011570265],"category_scores_gemma":[0.000809897,0.00007503549,0.00002877106,0.00006889137,0.0006631195,0.00017551736,0.00005988633,0.00020033366,6.831311e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014676789,0.00031098883,0.686455,0.0000039644638,0.00034860472,0.00013310646,0.00023544909,0.0000069932594,0.0001682001,0.000012196603,0.00041100342,0.31044683],"study_design_scores_gemma":[0.004274662,0.0087779425,0.9809821,0.000040131115,0.0005719871,0.000039412185,0.0005124601,0.003028099,0.000011626013,0.00008121058,0.001607313,0.000073060066],"about_ca_topic_score_codex":0.00006355265,"about_ca_topic_score_gemma":0.00028610736,"teacher_disagreement_score":0.31037375,"about_ca_system_score_codex":0.000041268177,"about_ca_system_score_gemma":0.00017801655,"threshold_uncertainty_score":0.30598584},"labels":[],"label_agreement":null},{"id":"W2773969925","doi":"10.1016/s2213-8587(17)30412-6","title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":592,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"AstraZeneca; National Heart, Lung, and Blood Institute; Amylin Pharmaceuticals","keywords":"Medicine; Semaglutide; Liraglutide; Lixisenatide; Exenatide; Glucagon-like peptide 1 receptor; Internal medicine; Type 2 diabetes; Placebo; Myocardial infarction; Dulaglutide; Meta-analysis; Adverse effect; Odds ratio; Stroke (engine); Hazard ratio; Diabetes mellitus; Agonist; Endocrinology; Receptor; Confidence interval","score_opus":0.09996280311863774,"score_gpt":0.32910575817358245,"score_spread":0.2291429550549447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773969925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009185346,0.9849399,0.0000011536468,0.0003984383,0.00028305073,0.003407278,0.00014089675,0.00015485699,0.0014891132],"genre_scores_gemma":[0.0034904212,0.9874777,0.00047692005,0.00081692595,0.0002222298,0.0021381082,0.0017693733,0.00021821311,0.0033901085],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941767,0.0005680486,0.0008390433,0.0012782553,0.0007786137,0.0023593665],"domain_scores_gemma":[0.9940426,0.00037125478,0.0007800676,0.004420499,0.00020835472,0.00017724858],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007120169,0.0012829925,0.014118143,0.0007729171,0.00020780711,0.00012897258,0.0011531537,0.00025166955,0.00023377221],"category_scores_gemma":[0.00011027114,0.000605634,0.0035931387,0.0009584652,0.0004623303,0.0001360484,0.00040821862,0.00079095125,0.00027189488],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006294604,0.00039169833,0.14898717,0.0031592443,0.6926251,0.00006996507,0.00003652316,0.000011076072,2.7117878e-8,0.000053985677,0.0011241052,0.15347818],"study_design_scores_gemma":[0.0017909735,0.000556257,0.011175849,0.00038436765,0.40110138,7.259871e-7,0.0000049331425,8.570919e-7,8.1713324e-7,0.0000063251327,0.584545,0.00043253612],"about_ca_topic_score_codex":0.000056287954,"about_ca_topic_score_gemma":0.00010198876,"teacher_disagreement_score":0.5834209,"about_ca_system_score_codex":0.00026026982,"about_ca_system_score_gemma":0.00017320873,"threshold_uncertainty_score":0.9999922},"labels":[],"label_agreement":null},{"id":"W2775794168","doi":"10.1016/j.cjca.2017.12.005","title":"Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1838,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"British Heart Foundation; Wellcome Trust","keywords":"Medicine; Diabetes mellitus; Disease; Vascular disease; Cardiology; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.0782121040416241,"score_gpt":0.3063625545832741,"score_spread":0.22815045054165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775794168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019027384,0.9972016,0.00008020006,0.0000926856,0.0010871285,0.0005670483,0.000020040652,0.0000060628763,0.00075493765],"genre_scores_gemma":[0.0014702528,0.99683213,0.00015045314,0.00012595234,0.0011794021,0.000015750415,0.000040570365,0.000051200972,0.00013429661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997782,0.0003984038,0.00076036685,0.0004310288,0.0002124547,0.00041575325],"domain_scores_gemma":[0.99664605,0.00011776158,0.0003639006,0.00085251266,0.00019497324,0.0018248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010135111,0.00039678972,0.0045711296,0.00049073936,0.00016944193,0.000061284154,0.00021019552,0.00039520604,0.0000058418864],"category_scores_gemma":[0.00044246748,0.00027809961,0.0020083622,0.0000599616,0.00036957953,0.00007572099,0.00006860074,0.0004819819,0.000008634578],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004432362,0.000003919655,0.00084955926,0.0023089875,0.015647927,0.0024488403,0.000004449798,0.000001366358,2.5738128e-8,0.00024758957,0.004409173,0.9740737],"study_design_scores_gemma":[0.0009583001,0.00029048955,0.002755315,0.0036873093,0.028444378,0.00028478054,0.0000060030507,0.0000014482076,2.1286962e-8,0.00027072386,0.9630741,0.00022712376],"about_ca_topic_score_codex":0.00005625403,"about_ca_topic_score_gemma":0.000035200133,"teacher_disagreement_score":0.9738466,"about_ca_system_score_codex":0.0000913862,"about_ca_system_score_gemma":0.001446866,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2776650529","doi":"10.1016/j.jcjd.2017.02.003","title":"WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Type 2 diabetes; Class (philosophy); Accidental; Glucagon; Pharmacology; Internal medicine; Endocrinology; Diabetes mellitus; Insulin; Artificial intelligence; Computer science","score_opus":0.015314715657301848,"score_gpt":0.25191476246152916,"score_spread":0.2366000468042273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776650529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866473,0.00201656,0.0000056254225,0.0042765182,0.0014826179,0.00049897074,0.00005556244,0.000020065872,0.00499679],"genre_scores_gemma":[0.99149966,0.000053101434,0.002496717,0.001126267,0.0007294935,0.00002967311,0.00006844461,0.000068967216,0.003927653],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981867,0.000029752684,0.00049399066,0.00025787822,0.00021787526,0.00081381045],"domain_scores_gemma":[0.99727917,0.00009872549,0.0006249945,0.0005691397,0.00046250608,0.00096549344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004290178,0.000297158,0.0006724887,0.0003444447,0.0006453022,0.00037631087,0.0004243147,0.00011319856,0.00019943887],"category_scores_gemma":[0.000607391,0.00024900315,0.0002983829,0.00010768785,0.00023572618,0.00040574925,0.00003343139,0.00019964493,0.00005403086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000503946,0.00016087078,0.80974084,0.0003881017,0.0021226464,0.000049630038,0.00033957488,0.000009129655,0.0025404408,0.00079597044,0.1346359,0.049166515],"study_design_scores_gemma":[0.0075063366,0.0044933967,0.10568278,0.0018897771,0.0020459103,0.0000048335082,0.00045902064,0.00034338192,0.010986455,0.0008395489,0.8649507,0.00079781754],"about_ca_topic_score_codex":0.00016051788,"about_ca_topic_score_gemma":0.0019301851,"teacher_disagreement_score":0.73031485,"about_ca_system_score_codex":0.00032150545,"about_ca_system_score_gemma":0.00080558896,"threshold_uncertainty_score":0.99999624},"labels":[],"label_agreement":null},{"id":"W2777075846","doi":"10.1016/j.jcjd.2017.11.006","title":"Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Diabetes mellitus; Angiotensin-converting enzyme; Angiotensin receptor; Internal medicine; Mineralocorticoid receptor; Angiotensin II; Kidney disease; Endocrinology; Pharmacology; Angioedema; Receptor; Blood pressure","score_opus":0.03974046080204955,"score_gpt":0.2601889160471822,"score_spread":0.22044845524513265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777075846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047236364,0.93940264,6.371566e-7,0.008018608,0.0018379947,0.0032929888,0.00016810825,0.00002453568,0.000018128025],"genre_scores_gemma":[0.0072135567,0.98532605,0.0036321166,0.00068848726,0.0016354616,0.000109761764,0.0003590686,0.00036366342,0.0006718363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99536806,0.00018483774,0.0017404226,0.00072863745,0.0005387213,0.0014393425],"domain_scores_gemma":[0.9939748,0.0006616335,0.0022048238,0.0010825471,0.0010622893,0.0010138991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006551784,0.0011579137,0.0042337,0.0015732347,0.00034128965,0.00012944316,0.00054740044,0.0005830808,0.000055280107],"category_scores_gemma":[0.00050044403,0.00071246823,0.0016610976,0.0007311374,0.00047665965,0.00022253016,0.000039349157,0.0004987146,0.000019883571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020360996,0.00044265363,0.009072504,0.0035893566,0.0062165125,0.00017480504,0.00081358117,0.000007740207,0.000051599985,0.000004645974,0.18729472,0.79212826],"study_design_scores_gemma":[0.004445443,0.0052917707,0.00037301285,0.047425933,0.006678621,0.000015655196,0.00022040402,0.00007067037,0.0004383644,0.000004812815,0.93435913,0.0006761555],"about_ca_topic_score_codex":0.0008766645,"about_ca_topic_score_gemma":0.0032103225,"teacher_disagreement_score":0.7914521,"about_ca_system_score_codex":0.001388849,"about_ca_system_score_gemma":0.002553873,"threshold_uncertainty_score":0.99953264},"labels":[],"label_agreement":null},{"id":"W2777592053","doi":"10.1016/j.cmet.2017.11.003","title":"Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction","year":2017,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; University of Alberta; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Scheme for Promotion of Academic and Research Collaboration; Ono Pharmaceutical; Banting and Best Diabetes Centre, University of Toronto; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma; Eli Lilly and Company; Alberta Innovates - Health Solutions; Sanofi; Meso Scale Diagnostics; Kowa Company; Canada Research Chairs; Canadian Diabetes Association; Novo Nordisk; Merck; Heart and Stroke Foundation of Canada; Takeda Pharmaceutical Company","keywords":"Internal medicine; Incretin; Endocrinology; Myocardial infarction; Receptor; Hormone-sensitive lipase; Hormone; Beta oxidation; Medicine; Biology; Adipose tissue; Metabolism; Diabetes mellitus; Lipolysis; Type 2 diabetes","score_opus":0.011806323141793272,"score_gpt":0.2581829700198258,"score_spread":0.24637664687803254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777592053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893797,0.0008488821,0.000015579431,0.00040990656,0.0024175758,0.0006027582,0.000003010389,0.000035035588,0.0062875235],"genre_scores_gemma":[0.99605143,0.000054008196,0.00045173732,0.00019792884,0.00018809305,0.000055299297,0.000007861045,0.000022920849,0.002970702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989931,0.000035830646,0.00023537489,0.00021180822,0.00033295222,0.0001909063],"domain_scores_gemma":[0.9989694,0.00001739228,0.0002646726,0.00065449555,0.000035625915,0.000058419617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010799179,0.00016710437,0.0003419457,0.00006648799,0.00023853187,0.000049950206,0.00019331404,0.00006292478,0.000029225379],"category_scores_gemma":[0.000077682475,0.000110397705,0.00030302018,0.00004575689,0.00005934581,0.0002564618,0.00017777907,0.000101779005,0.000026139503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053341133,0.0003693014,0.08836352,0.000027980932,0.00041713737,0.0000015322082,0.00037900792,0.0000010630326,0.88753456,0.00038615288,0.00014829008,0.022318106],"study_design_scores_gemma":[0.0018423789,0.00005010167,0.4906669,0.000018980923,0.00025311956,1.6536688e-7,0.00015059323,0.000005537369,0.5020954,0.000024946192,0.0048227203,0.0000691662],"about_ca_topic_score_codex":0.00019485703,"about_ca_topic_score_gemma":0.0000026124826,"teacher_disagreement_score":0.40230337,"about_ca_system_score_codex":0.000078172925,"about_ca_system_score_gemma":0.0000330247,"threshold_uncertainty_score":0.4501888},"labels":[],"label_agreement":null},{"id":"W2778176386","doi":"10.7326/acpjc-2017-167-12-067","title":"Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes","year":2017,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Exenatide; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.055908302500220705,"score_gpt":0.3339820803387313,"score_spread":0.27807377783851056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778176386","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11423759,0.013372427,0.0000032772211,0.8458245,0.002346552,0.00096452906,0.000033799406,0.00005596953,0.023161374],"genre_scores_gemma":[0.22219591,0.0032511603,0.00014621248,0.7083847,0.005555586,0.0001174928,0.00043675984,0.00017096984,0.05974123],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967338,0.000084329076,0.00083216,0.0005915817,0.0011447315,0.00061341136],"domain_scores_gemma":[0.99733156,0.00020846465,0.00048950454,0.0014946074,0.00034595848,0.0001298846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007503798,0.00054250564,0.0024826077,0.00069257105,0.00003453941,0.000019381378,0.0005896366,0.00036698603,0.0003208224],"category_scores_gemma":[0.0010803348,0.0003724616,0.0006924009,0.00012251348,0.00031415696,0.00010460975,0.00019537423,0.0009791438,0.0000808182],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012659038,0.00012630105,0.019390749,0.0009791433,0.0062307985,0.0024791206,0.00010064061,6.032416e-7,0.0001400197,0.000013052052,0.954106,0.016307006],"study_design_scores_gemma":[0.0031610127,0.0017139043,0.033670723,0.0068497346,0.0016643222,0.000012728955,0.000026064841,0.000007574372,0.0050321496,0.00017252946,0.9473247,0.00036453805],"about_ca_topic_score_codex":0.0008286857,"about_ca_topic_score_gemma":0.000011597961,"teacher_disagreement_score":0.1374398,"about_ca_system_score_codex":0.00006379822,"about_ca_system_score_gemma":0.000057437785,"threshold_uncertainty_score":0.99987274},"labels":[],"label_agreement":null},{"id":"W2778234808","doi":"10.1080/03007995.2017.1421146","title":"Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment","year":2017,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Dulaglutide; Persistence (discontinuity); Internal medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Physical therapy; Exenatide; Endocrinology","score_opus":0.09947148768741258,"score_gpt":0.39894085193484075,"score_spread":0.29946936424742815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778234808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358535,0.0029595473,0.0000036400959,0.00021302918,0.00025906874,0.00082817033,0.000005448784,0.000024028903,0.0021217137],"genre_scores_gemma":[0.9867982,0.012703267,0.00004747179,0.000008117138,0.0001225708,0.000096162374,0.00010055184,0.000013101134,0.00011053037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979756,0.00013056627,0.00015162979,0.00041617735,0.0008488377,0.00047721318],"domain_scores_gemma":[0.9984245,0.0003986685,0.000071503375,0.0003350789,0.00021109176,0.00055916706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006714763,0.00016997692,0.00029827125,0.00013546867,0.0004978398,0.00012227694,0.00012225888,0.000052979398,0.00005011695],"category_scores_gemma":[0.000801801,0.00010852442,0.000029639139,0.00011838955,0.0007263644,0.00018387838,0.00020746417,0.00023473403,0.0000106573425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015441157,0.00034060772,0.72202384,0.00033255396,0.0000749376,0.000008472353,0.000057716505,2.5007092e-8,0.0000038788057,0.00018240897,0.000096698015,0.27672446],"study_design_scores_gemma":[0.0033423917,0.003726336,0.9863745,0.0025219063,0.000045070094,2.568558e-7,0.000034620647,0.00019605715,0.00013474519,0.00014008474,0.0033726254,0.000111429654],"about_ca_topic_score_codex":0.00018840028,"about_ca_topic_score_gemma":0.000093687515,"teacher_disagreement_score":0.27661303,"about_ca_system_score_codex":0.00012316112,"about_ca_system_score_gemma":0.00013051639,"threshold_uncertainty_score":0.44254974},"labels":[],"label_agreement":null},{"id":"W2778907143","doi":"10.1002/jcph.1051","title":"Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus","year":2017,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Empagliflozin; Medicine; Pharmacodynamics; Renal glucose reabsorption; Placebo; Internal medicine; Diabetes mellitus; Population; Endocrinology; Renal function; Type 2 Diabetes Mellitus; Pharmacokinetics; Type 2 diabetes; Pharmacology; Urology","score_opus":0.026713679420603053,"score_gpt":0.3810745709882775,"score_spread":0.3543608915676745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778907143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955603,0.00011082031,0.0000043140194,0.002362441,0.00094022683,0.0008379739,0.0000074342074,0.0000060937227,0.00017038386],"genre_scores_gemma":[0.9977677,0.0003208555,0.000025380124,0.0013998395,0.00038227974,0.000009733898,0.000016490716,0.000017509314,0.00006023305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749637,0.0006257972,0.000992468,0.00017130557,0.00043423977,0.00027982303],"domain_scores_gemma":[0.99708575,0.0009941598,0.0011813429,0.00037434828,0.00020146777,0.00016290238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027926986,0.0002061448,0.0009977522,0.0002619961,0.000104272214,0.000017574517,0.0004957145,0.00006195633,0.00019084055],"category_scores_gemma":[0.00026148258,0.00009367582,0.000260375,0.00034436368,0.00017411084,0.000107745385,0.00010834649,0.00049905706,0.000013040397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021879531,0.00084118225,0.94172966,0.000032932752,0.00462409,0.00002134676,0.000051518666,0.0011264116,0.0031748884,0.0000024948163,0.0010657782,0.025450172],"study_design_scores_gemma":[0.011890995,0.009371518,0.9616001,0.00006767859,0.010064579,5.371684e-7,0.000002574458,0.0012010925,0.005206288,0.00000865142,0.0004979081,0.00008804712],"about_ca_topic_score_codex":0.000012011039,"about_ca_topic_score_gemma":0.0000074300237,"teacher_disagreement_score":0.025362125,"about_ca_system_score_codex":0.000054261167,"about_ca_system_score_gemma":0.000030589898,"threshold_uncertainty_score":0.3819989},"labels":[],"label_agreement":null},{"id":"W2779223875","doi":"10.2337/dci17-0057","title":"Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a<i>Diabetes Care</i>Editors’ Expert Forum","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":369,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Hamilton Health Sciences; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Scope (computer science); Clinical trial; Food and drug administration; Intensive care medicine; Alternative medicine; Clinical endpoint; Placebo; MEDLINE; Research design; Family medicine; Medical emergency; Internal medicine; Pathology","score_opus":0.037296795244393686,"score_gpt":0.31311574313286056,"score_spread":0.2758189478884669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779223875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8321864,0.15090111,0.0000019641298,0.002478538,0.007575151,0.0017568271,0.0009174386,0.0003026117,0.0038799774],"genre_scores_gemma":[0.9887942,0.0032657406,0.0010265204,0.00067288603,0.003728447,0.00079729955,0.001051211,0.00019748512,0.0004661793],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99509823,0.00039363324,0.0010371611,0.0012697905,0.0009092506,0.0012919264],"domain_scores_gemma":[0.9949909,0.0007245491,0.0004526083,0.003075926,0.0003666201,0.00038939065],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005345692,0.0008552071,0.0030169548,0.00034370934,0.0005340705,0.0004988403,0.0007429731,0.00047628928,0.00045165478],"category_scores_gemma":[0.0011104421,0.0007187017,0.0016301244,0.00027395497,0.0001942824,0.0005397631,0.00044661516,0.0004410481,0.00092561025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003242978,0.00017309135,0.9061766,0.00022084422,0.00406521,0.000028321672,0.002150957,0.000015892829,0.00090306747,0.000008673652,0.029679777,0.056545135],"study_design_scores_gemma":[0.0073258253,0.0005657756,0.23657255,0.0017609784,0.0028771474,4.3927596e-8,0.013448787,0.00003223317,0.011461896,0.0004394719,0.7244596,0.0010556949],"about_ca_topic_score_codex":0.00058325345,"about_ca_topic_score_gemma":0.00085346296,"teacher_disagreement_score":0.6947798,"about_ca_system_score_codex":0.00056355976,"about_ca_system_score_gemma":0.00012501207,"threshold_uncertainty_score":0.9998523},"labels":[],"label_agreement":null},{"id":"W2779587939","doi":"10.1111/1753-0407.12628","title":"Diabetes Canada 2017","year":2017,"lang":"en","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Health care; Family medicine; Gerontology; Political science; Endocrinology","score_opus":0.014588645283324363,"score_gpt":0.25237701496241205,"score_spread":0.23778836967908767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779587939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793292,0.0010825052,8.518501e-7,0.004260706,0.0007962302,0.00011322637,0.0000045722027,0.000007758197,0.014404936],"genre_scores_gemma":[0.9959407,0.00006204997,0.00036835685,0.00073262764,0.000409629,0.0000031502457,0.0000028517982,0.000015242727,0.0024654183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988757,0.000014113708,0.00030799964,0.00010208867,0.0003820914,0.00031805597],"domain_scores_gemma":[0.9985722,0.00005695489,0.0005437816,0.00043809527,0.00017305872,0.00021592979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024430835,0.00014015917,0.00042476208,0.00008677003,0.00018521557,0.00009195493,0.0002901193,0.000036887548,0.000079787496],"category_scores_gemma":[0.00027075983,0.00010119422,0.00015021439,0.000026939259,0.000065326545,0.00025189065,0.0000730346,0.00013874429,0.00001024839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000826991,0.000112508336,0.8877433,0.000072362964,0.0005779139,0.000079500875,0.000014373832,0.000001569114,0.001463759,0.00006829359,0.09599537,0.013862806],"study_design_scores_gemma":[0.0020392376,0.0005495673,0.89543915,0.00031750242,0.0005615998,0.0000025504037,0.000038273785,0.000043813863,0.0124894,0.00020466675,0.08816549,0.00014876862],"about_ca_topic_score_codex":0.0019965644,"about_ca_topic_score_gemma":0.0058784876,"teacher_disagreement_score":0.016611459,"about_ca_system_score_codex":0.0001242718,"about_ca_system_score_gemma":0.0002666272,"threshold_uncertainty_score":0.41265807},"labels":[],"label_agreement":null},{"id":"W2780039859","doi":"10.1097/ede.0000000000000793","title":"Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Colorectal cancer; Incretin; Type 2 diabetes; Internal medicine; Confidence interval; Incidence (geometry); Proportional hazards model; Oncology; Population; Diabetes mellitus; Sitagliptin; Dipeptidyl peptidase-4; Cancer; Endocrinology","score_opus":0.013465312965783412,"score_gpt":0.28917029723410276,"score_spread":0.27570498426831935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780039859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941588,0.00032414886,0.0000014416376,0.0040412666,0.000070053065,0.00036767035,0.000003312541,0.000005949897,0.0010273784],"genre_scores_gemma":[0.9987432,0.00004514953,0.00024896834,0.00079477916,0.000015187049,0.000045340577,0.000010188451,0.0000055598816,0.000091652284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932694,0.00012930372,0.00017101299,0.00014064935,0.00006514942,0.00016694023],"domain_scores_gemma":[0.9987366,0.00075487763,0.00019282466,0.00021868644,0.00006508202,0.00003192003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007953982,0.00007783733,0.00039633687,0.000036329115,0.000051191237,0.000002721067,0.00008774929,0.000039754916,0.000032182463],"category_scores_gemma":[0.0015739562,0.000040609226,0.000021146232,0.000033044318,0.000505674,0.000027787251,0.000059825874,0.000070008995,0.0000023611633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006639341,0.000046595123,0.99486285,0.000027594017,0.00006005133,7.204104e-7,0.0000644555,0.000011742971,0.000009153817,0.00047674135,0.00026454535,0.0035116272],"study_design_scores_gemma":[0.0045579537,0.00049344223,0.9935575,0.00008975673,0.00007486377,2.7231962e-8,0.000008604776,0.00054968795,0.00011305703,0.0002949913,0.00021899567,0.00004110185],"about_ca_topic_score_codex":0.00044100854,"about_ca_topic_score_gemma":0.00012720606,"teacher_disagreement_score":0.0045843963,"about_ca_system_score_codex":0.00002509417,"about_ca_system_score_gemma":0.000029729817,"threshold_uncertainty_score":0.18842863},"labels":[],"label_agreement":null},{"id":"W2780645176","doi":"10.2337/dc17-1223","title":"Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?","year":2017,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Empagliflozin; Observational study; Diabetes mellitus; Type 2 diabetes; Internal medicine; Randomized controlled trial; Medical prescription; Canagliflozin; Pharmacology; Endocrinology","score_opus":0.0778401094154545,"score_gpt":0.3191970094529683,"score_spread":0.2413569000375138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780645176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939194,0.0005064504,2.7412378e-7,0.00023248742,0.00015820234,0.00044183029,0.000048036276,0.000026517831,0.004666856],"genre_scores_gemma":[0.9980457,0.0003244806,0.0005545393,0.00010010249,0.0000898276,0.00008040464,0.0000774676,0.0000200594,0.00070743193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906063,0.000021749778,0.00019227272,0.00023098281,0.00025962092,0.00023476036],"domain_scores_gemma":[0.99895406,0.00011012632,0.00020864262,0.0004762289,0.00019199085,0.00005896945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012545436,0.00016101653,0.00038971315,0.00009750703,0.00009651954,0.000021960246,0.000113001624,0.000046635934,0.00002732684],"category_scores_gemma":[0.0002599048,0.000101659134,0.000071713424,0.00008568551,0.00010264276,0.00013853631,0.00009227623,0.00007981745,0.000016321648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010603434,0.00012559319,0.9910262,0.0002984001,0.00042259315,0.000030871368,0.00072904624,0.00000939975,0.0000307412,0.000115965304,0.0009972716,0.006107884],"study_design_scores_gemma":[0.0024010101,0.00089170993,0.990528,0.00071439723,0.00034737127,9.028386e-8,0.001659,0.000021543285,0.0012798171,0.000043968696,0.0019908028,0.00012227241],"about_ca_topic_score_codex":0.000057250134,"about_ca_topic_score_gemma":0.00031676955,"teacher_disagreement_score":0.0059856116,"about_ca_system_score_codex":0.00011075372,"about_ca_system_score_gemma":0.000058673068,"threshold_uncertainty_score":0.4145539},"labels":[],"label_agreement":null},{"id":"W2780866398","doi":"10.1016/j.kisu.2017.10.005","title":"Novel therapies for diabetic kidney disease","year":2017,"lang":"en","type":"review","venue":"Kidney International Supplements","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; University of Toronto; Bayer","keywords":"Medicine; Canagliflozin; Diabetic nephropathy; Diabetes mellitus; Internal medicine; Nephropathy; Glycemic; Mineralocorticoid receptor; Pharmacology; Endothelin receptor; Endocrinology; Type 2 diabetes; Aldosterone; Receptor","score_opus":0.09018120787172312,"score_gpt":0.39659813985445486,"score_spread":0.30641693198273173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780866398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.5982526e-7,0.9622969,0.00035674128,0.0058743404,0.0031511982,0.0048351046,0.017082963,0.000094102616,0.006307775],"genre_scores_gemma":[0.00001139384,0.91491234,0.0018083683,0.0019910503,0.0008353292,0.0023039575,0.042089153,0.00010049752,0.035947926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780446,0.00001930249,0.00059085124,0.00059274246,0.0005654761,0.00042716262],"domain_scores_gemma":[0.99775016,0.00006416664,0.00045771335,0.0007048225,0.00014741863,0.0008757358],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018239534,0.00052920036,0.0011171699,0.00031920418,0.00015954179,0.00013313083,0.0006604575,0.00011032665,0.0024202936],"category_scores_gemma":[0.00059752044,0.00041276697,0.00089222076,0.000049340815,0.00006479019,0.0001521856,0.0002481516,0.00013161478,0.00024141825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004851966,0.0007268687,0.0003821907,0.009192578,0.0045279106,0.00002021751,0.000020011725,2.0901734e-8,0.0000014932955,0.001295161,0.49266076,0.49112427],"study_design_scores_gemma":[0.002995791,0.00010390778,0.000046391106,0.009237518,0.004219055,0.0000024528529,0.0000034956697,0.0000106287,0.0000021963424,0.00018212086,0.9828637,0.00033274223],"about_ca_topic_score_codex":0.000011916484,"about_ca_topic_score_gemma":0.0000011714695,"teacher_disagreement_score":0.49079153,"about_ca_system_score_codex":0.0003468868,"about_ca_system_score_gemma":0.00062069116,"threshold_uncertainty_score":0.9998324},"labels":[],"label_agreement":null},{"id":"W2780874826","doi":"10.1161/circulationaha.117.030924","title":"Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization","year":2017,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Population; Heart failure; Gerontology; Demography; Humanities; Family medicine; Internal medicine; Sociology; Art; Environmental health","score_opus":0.009114954028323585,"score_gpt":0.2524240227256111,"score_spread":0.24330906869728752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780874826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8494144,0.0010597615,0.00013413545,0.14549108,0.0005032961,0.0023394497,0.000047038928,0.000045845925,0.0009649873],"genre_scores_gemma":[0.995072,0.000059573045,0.00007691243,0.0026604151,0.00040899814,0.000035155965,0.0015710895,0.00002790459,0.00008792671],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99910766,0.000049581748,0.00022915658,0.00023563119,0.000264363,0.0001136375],"domain_scores_gemma":[0.9991814,0.000084792984,0.00028850924,0.00035329082,0.00006776962,0.00002425497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015863539,0.00018622569,0.00045885667,0.00017685312,0.000048351383,0.00001372436,0.000045327575,0.00023519956,0.000023631806],"category_scores_gemma":[0.00010887242,0.00015462683,0.000099363795,0.000052306772,0.000054327997,0.000061200226,0.000023532362,0.00015590311,0.00000636861],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002938243,0.00025499376,0.4010951,0.011875323,0.00065686554,0.00003356618,0.00016895996,0.00008308269,0.00023874371,0.00013342705,0.5599581,0.025208056],"study_design_scores_gemma":[0.0059483,0.0040658913,0.68511444,0.004666522,0.0018092052,0.0000034224292,0.000004104504,0.0012881316,0.004065819,0.00014509558,0.2924885,0.00040059374],"about_ca_topic_score_codex":0.000015131958,"about_ca_topic_score_gemma":0.0000029031928,"teacher_disagreement_score":0.28401932,"about_ca_system_score_codex":0.000055013406,"about_ca_system_score_gemma":0.00001028989,"threshold_uncertainty_score":0.63054997},"labels":[],"label_agreement":null},{"id":"W2782103987","doi":"10.1186/s12933-017-0654-z","title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","year":2018,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca Canada; Bristol-Myers Squibb","keywords":"Dapagliflozin; Medicine; Postprandial; Placebo; Ambulatory blood pressure; Blood pressure; Diabetes mellitus; Urology; Angiology; Type 2 diabetes; Internal medicine; Sodium; Endocrinology; Chemistry; Pathology","score_opus":0.019888394648504486,"score_gpt":0.24182933607736162,"score_spread":0.22194094142885715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782103987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440858,0.004176839,0.0009972859,0.00059321907,0.001093556,0.008808726,0.000004486475,0.00022631243,0.040013786],"genre_scores_gemma":[0.9936769,0.00012682643,0.00047890595,0.00045048347,0.0012344276,0.0017910631,0.000115799296,0.000054876007,0.0020706924],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975292,0.00033524088,0.0004602359,0.0006297664,0.0004571988,0.0005883376],"domain_scores_gemma":[0.9984342,0.00012230342,0.00013996889,0.000785081,0.00031392448,0.0002045348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007952738,0.00035837942,0.0020650325,0.000227011,0.00013684235,0.000038486116,0.00010182038,0.00018808573,0.00018637427],"category_scores_gemma":[0.00021187903,0.00025052892,0.0009707044,0.00022366067,0.00043282978,0.00010591599,0.00005608086,0.00014354792,0.00024167133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8823689,0.0012636299,0.00059694133,0.00016083414,0.043246023,0.00088664755,0.0003794667,0.000005427369,0.008333365,0.0013077051,0.004836617,0.056614444],"study_design_scores_gemma":[0.917485,0.0032797349,0.00031459218,0.000082417464,0.0072391653,0.000049879727,0.00009821253,0.000026357257,0.032801222,0.000055538803,0.03827664,0.00029126895],"about_ca_topic_score_codex":0.000014191263,"about_ca_topic_score_gemma":0.0000041159306,"teacher_disagreement_score":0.056323174,"about_ca_system_score_codex":0.00008893508,"about_ca_system_score_gemma":0.000083914834,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W2782548982","doi":"10.2337/dc17-1778","title":"Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype","year":2018,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"National Institute for Health and Care Research; Merck","keywords":"Medicine; Sitagliptin; Internal medicine; Myocardial infarction; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Microalbuminuria; Stroke (engine); Unstable angina; Heart failure; Cardiology; Angina; Endocrinology; Confidence interval","score_opus":0.0045229897993177256,"score_gpt":0.20889427300520236,"score_spread":0.20437128320588463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782548982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455565,0.0036191463,2.3140117e-7,0.000018323844,0.00020318756,0.00097179855,0.00032751914,0.00006675447,0.00023736736],"genre_scores_gemma":[0.9987274,0.00017623947,0.00028256144,0.00016083098,0.000078625126,0.00013479404,0.00032956075,0.00006147247,0.00004853368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792516,0.00015781855,0.00038192462,0.00055289344,0.0004432642,0.0005389553],"domain_scores_gemma":[0.99845386,0.00008771531,0.00016676508,0.00083616714,0.00023766118,0.00021782814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019664447,0.00037225155,0.00085370895,0.00024663852,0.000084531435,0.000014959062,0.0001242711,0.00015778086,0.00009938831],"category_scores_gemma":[0.00021309982,0.00030241802,0.000262697,0.0002813495,0.00014031674,0.00014894911,0.00022120812,0.00016414947,0.00008181807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001555975,0.00020803144,0.94168264,0.00025844877,0.001241152,0.000008641169,0.0013434782,0.0000061670476,0.00007294211,0.0000011468095,0.00006804275,0.054953694],"study_design_scores_gemma":[0.0031326285,0.002307865,0.9891544,0.00021513521,0.0014278364,2.2265633e-7,0.00037669006,0.00007628081,0.0014287635,0.00009023631,0.0015048004,0.00028513634],"about_ca_topic_score_codex":0.00014372861,"about_ca_topic_score_gemma":0.00072979584,"teacher_disagreement_score":0.054668557,"about_ca_system_score_codex":0.00019474902,"about_ca_system_score_gemma":0.000037306145,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W2782868584","doi":"10.1186/s12883-018-1014-7","title":"Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus","year":2018,"lang":"en","type":"article","venue":"BMC Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company","keywords":"Linagliptin; Medicine; Cognitive decline; Glimepiride; Dementia; Internal medicine; Type 2 diabetes; Type 2 Diabetes Mellitus; Cognition; Randomized controlled trial; Diabetes mellitus; Physical therapy; Psychiatry; Endocrinology; Disease","score_opus":0.02628531293959732,"score_gpt":0.25890534582294755,"score_spread":0.23262003288335023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782868584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335885,0.000044213455,0.000014634948,0.0000983227,0.00023894722,0.006003885,0.0000057860148,0.0000071542554,0.00022822208],"genre_scores_gemma":[0.99937546,0.000009844417,0.000054812757,0.00025693348,0.000028809352,0.00021840484,0.000017197519,0.000009571935,0.000028982895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990055,0.00027591994,0.00025508128,0.00017139278,0.00016111942,0.00013099417],"domain_scores_gemma":[0.9980542,0.0014422027,0.00018486487,0.00011393372,0.00018019583,0.000024586994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019631513,0.0001148753,0.0004930004,0.00009352515,0.000025655236,0.0000023712819,0.000037438636,0.00004649637,0.000016103037],"category_scores_gemma":[0.0006350669,0.000067279434,0.00005181457,0.00010877859,0.0001893975,0.00002270822,0.000022523838,0.00005817728,0.0000026897715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74296856,0.0006344125,0.2556941,0.000019572753,0.00028605503,0.0000011254731,0.0000797597,0.0000075137946,0.000047840982,0.000027667524,0.000012169741,0.00022123575],"study_design_scores_gemma":[0.5996837,0.013867925,0.38487232,0.000020783367,0.0005574535,4.375453e-8,0.000007911337,0.000062910876,0.0008450847,0.000040645544,0.0000036758458,0.000037524904],"about_ca_topic_score_codex":0.0000032146265,"about_ca_topic_score_gemma":0.000025248028,"teacher_disagreement_score":0.14328481,"about_ca_system_score_codex":0.000006878032,"about_ca_system_score_gemma":0.000043919892,"threshold_uncertainty_score":0.27435756},"labels":[],"label_agreement":null},{"id":"W2782920834","doi":"10.1111/dom.13217","title":"<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Medicine; TIMI; Baseline (sea); Internal medicine; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.01928314700339614,"score_gpt":0.2485237473738867,"score_spread":0.22924060037049054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782920834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188215,0.0017513889,0.0000872513,0.00034460786,0.0005669515,0.00046336325,0.000055935125,0.00016430757,0.0046840776],"genre_scores_gemma":[0.98743325,0.0006050386,0.0011694154,0.0030369328,0.0010081778,0.00005480465,0.00016950046,0.000038643837,0.0064842077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980564,0.000078435325,0.00033885034,0.00045464287,0.00028738388,0.00078430184],"domain_scores_gemma":[0.99864864,0.00014880257,0.00011874432,0.0004523864,0.0001936873,0.00043774373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055649615,0.0003173366,0.0006707963,0.00016550442,0.00020879401,0.00008920599,0.000116934534,0.00012800998,0.00017285762],"category_scores_gemma":[0.00052698114,0.00026342724,0.0001258277,0.00023574448,0.000244912,0.00019557084,0.00015869856,0.00015614177,0.0003475588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049666105,0.0020784547,0.8845383,0.00048773107,0.0013600953,0.000064188185,0.0014038667,2.916219e-7,0.0071671815,0.00445772,0.0323397,0.06605283],"study_design_scores_gemma":[0.0013687036,0.00018032316,0.6508459,0.0000661419,0.0010714378,9.618046e-7,0.00005797672,0.0003644561,0.010194162,0.0002662794,0.33548033,0.00010336762],"about_ca_topic_score_codex":0.000009122701,"about_ca_topic_score_gemma":0.0000045512465,"teacher_disagreement_score":0.30314064,"about_ca_system_score_codex":0.00002295946,"about_ca_system_score_gemma":0.00003817133,"threshold_uncertainty_score":0.9999818},"labels":[],"label_agreement":null},{"id":"W2783777683","doi":"10.7326/acpjc-2018-168-2-008","title":"Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas","year":2018,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Glycemic; Type 2 diabetes; Internal medicine; Psychosocial; Family medicine; Gerontology; Endocrinology; Psychiatry","score_opus":0.04642740869211852,"score_gpt":0.367924298332931,"score_spread":0.32149688964081247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783777683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79645073,0.046877697,0.0003589103,0.12661865,0.0016992724,0.010414287,0.0001883681,0.00016084113,0.017231204],"genre_scores_gemma":[0.8903725,0.0030071728,0.00017266901,0.09415803,0.0018854734,0.0007515194,0.00012563611,0.00005648803,0.00947049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982272,0.000032502678,0.00056446955,0.00037681757,0.00036641565,0.00043258924],"domain_scores_gemma":[0.9977156,0.00027677335,0.00039553962,0.0004458041,0.0009211849,0.0002450817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006607923,0.00031231367,0.0009857066,0.00020451509,0.000043262993,0.000006185457,0.0002053242,0.00007070857,0.0007795262],"category_scores_gemma":[0.0007577725,0.00020825854,0.0002623339,0.00019269729,0.0003654065,0.00010238187,0.00008361824,0.00013726373,0.00004823671],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011156874,0.00048009708,0.013931884,0.00403762,0.0016592963,0.000022017173,0.0005484831,1.5914766e-7,0.002568539,0.00021896562,0.8929555,0.082461745],"study_design_scores_gemma":[0.006815881,0.0109185865,0.035740178,0.03293365,0.0012819952,0.000007694831,0.0003167991,0.0001496956,0.12785485,0.0003378116,0.78330237,0.00034051004],"about_ca_topic_score_codex":0.000051036848,"about_ca_topic_score_gemma":0.00002120107,"teacher_disagreement_score":0.12528633,"about_ca_system_score_codex":0.000034417568,"about_ca_system_score_gemma":0.00002248086,"threshold_uncertainty_score":0.85352653},"labels":[],"label_agreement":null},{"id":"W2785139619","doi":"10.1111/dom.13172","title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; Novo Nordisk Fonden; Steno Diabetes Center Copenhagen","keywords":"Medicine; Semaglutide; Glycated haemoglobin; Diabetic retinopathy; Glycated hemoglobin; Ophthalmology; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.007429259347866054,"score_gpt":0.2222728373629661,"score_spread":0.21484357801510004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785139619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918615,0.005041068,0.000001368302,0.00095812266,0.00019953185,0.00065062265,0.000011967461,0.0000212646,0.0012545224],"genre_scores_gemma":[0.99679,0.0023001016,0.0001995573,0.00007797187,0.000064921565,0.00003890612,0.000009591913,0.000011232757,0.00050771516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989784,0.00012099624,0.00023953641,0.00025897397,0.00015042824,0.0002517016],"domain_scores_gemma":[0.9990594,0.000081474,0.00023244994,0.0004937247,0.00005037875,0.00008259383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078845484,0.00016298275,0.0005432042,0.00011170386,0.0002326379,0.000054996755,0.000108202694,0.000070613394,0.000011446752],"category_scores_gemma":[0.00038576708,0.00010696038,0.00007650228,0.00008373943,0.00057124277,0.00011988855,0.00014948781,0.00014778349,0.0000039077986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015072212,0.00025689765,0.9610153,0.00019381898,0.00028003706,0.0000051207035,0.00062511803,0.0000012805009,0.001877324,0.0032330805,0.00013839558,0.03222291],"study_design_scores_gemma":[0.0055779936,0.000053893997,0.98067325,0.00010971795,0.0008777162,0.0000012067553,0.0000737934,0.00019182914,0.008686784,0.0026626003,0.0009873831,0.00010384983],"about_ca_topic_score_codex":0.0002740734,"about_ca_topic_score_gemma":0.0000179777,"teacher_disagreement_score":0.03211906,"about_ca_system_score_codex":0.000011306179,"about_ca_system_score_gemma":0.000013443569,"threshold_uncertainty_score":0.43617177},"labels":[],"label_agreement":null},{"id":"W2785618541","doi":"10.1016/j.cjca.2018.01.091","title":"Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles","year":2018,"lang":"en","type":"editorial","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University; St. Michael's Hospital; St. Boniface Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Myocardial infarction; Internal medicine; Dyslipidemia; Type 2 diabetes; Cardiology; Stroke (engine); Disease; Endocrinology","score_opus":0.007078544680373891,"score_gpt":0.21710370068755613,"score_spread":0.21002515600718225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785618541","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15361947,0.1490838,0.000037277106,0.0032904355,0.68705535,0.0012652033,0.000058272824,0.000008736872,0.00558144],"genre_scores_gemma":[0.57990575,0.010394306,0.000014737202,0.00003630693,0.4093366,0.000010481354,0.000016356411,0.0000284846,0.00025697768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982974,0.0006151167,0.00040119654,0.00015592472,0.00026501305,0.0002653406],"domain_scores_gemma":[0.9978725,0.00067356694,0.00051990594,0.00037901252,0.0004049553,0.00015011417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030295188,0.00018868121,0.0010991148,0.00014119294,0.00020717153,0.00003768062,0.00019553071,0.00024638933,0.0000038462754],"category_scores_gemma":[0.0019298346,0.000079803736,0.0004907688,0.000074625306,0.0017263143,0.000035358284,0.00003954417,0.0005821924,0.0000011670039],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039092632,0.0000015843642,0.0032641285,0.000084457635,0.016757222,0.000020418107,0.0016340085,0.0000950715,0.0000023973319,0.00014073747,0.9595086,0.018100455],"study_design_scores_gemma":[0.0034696842,0.00028777678,0.0011224844,0.00012573665,0.008398982,0.000023675351,0.00067902246,0.0000060784873,0.000012647657,0.0005052372,0.98528516,0.00008350277],"about_ca_topic_score_codex":0.00064633205,"about_ca_topic_score_gemma":0.00048112147,"teacher_disagreement_score":0.42628628,"about_ca_system_score_codex":0.0000757649,"about_ca_system_score_gemma":0.0005205317,"threshold_uncertainty_score":0.6360677},"labels":[],"label_agreement":null},{"id":"W2789044349","doi":"10.1016/s2213-8587(18)30025-1","title":"Do sulphonylureas still have a place in clinical practice?","year":2018,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Janssen Pharmaceuticals; Collaboration for Leadership in Applied Health Research and Care - Greater Manchester; Merck Sharp and Dohme; National Institutes of Health; University of Leicester; Novo Nordisk; National Institute for Health and Care Research; Amgen; Boehringer Ingelheim; Merck; Sanofi; Loughborough University; AstraZeneca; Eli Lilly and Company; University Hospitals of Leicester NHS Trust","keywords":"Medicine; Observational study; Diabetes mellitus; Incidence (geometry); Internal medicine; Linagliptin; Clinical trial; Hypoglycemia; Type 2 diabetes; Intensive care medicine; Insulin; Endocrinology","score_opus":0.10339826261121242,"score_gpt":0.42102339555231955,"score_spread":0.3176251329411071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789044349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009128291,0.97250926,8.455746e-7,0.00259995,0.0009855592,0.0022899706,0.00004262771,0.00016489523,0.02049407],"genre_scores_gemma":[0.00017915767,0.99071383,0.0006149423,0.0025536993,0.0023594482,0.00064442854,0.00020817234,0.00010397646,0.0026223515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942459,0.0010178105,0.0013119142,0.00096303236,0.0003260292,0.0021353278],"domain_scores_gemma":[0.9944536,0.0027357393,0.0006977777,0.0018403119,0.00010759406,0.00016496118],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001784994,0.0007171341,0.0043464242,0.00032330654,0.00006000585,0.00005919095,0.0007711885,0.00040241648,0.00020312925],"category_scores_gemma":[0.0015170675,0.00043354806,0.00069327146,0.00034758408,0.0005318142,0.000097257005,0.00058036204,0.0013202403,0.0013424827],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010076526,0.00059189403,0.003561248,0.0039362176,0.0024783956,0.0004920682,0.000081458114,1.3875719e-7,6.450585e-8,0.0014924626,0.047214966,0.9400503],"study_design_scores_gemma":[0.0023677873,0.00071732764,0.0006737153,0.0042555765,0.004841279,0.00007164378,0.00004644514,0.0000050248777,0.0000010598925,0.00020924237,0.9864488,0.000362064],"about_ca_topic_score_codex":0.000028409413,"about_ca_topic_score_gemma":0.00004062568,"teacher_disagreement_score":0.93968827,"about_ca_system_score_codex":0.00023857366,"about_ca_system_score_gemma":0.00024769243,"threshold_uncertainty_score":0.99981165},"labels":[],"label_agreement":null},{"id":"W2789332567","doi":"10.1016/j.peptides.2017.11.023","title":"Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism","year":2018,"lang":"en","type":"review","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Postprandial; Incretin; Type 2 diabetes; Endocrinology; Dipeptidyl peptidase-4; Internal medicine; Medicine; Dipeptidyl peptidase; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Metabolism; Lipid metabolism; Carbohydrate metabolism; Glucagon-like peptide-1; Chemistry; Biochemistry; Enzyme","score_opus":0.01789752583645868,"score_gpt":0.27087618941925884,"score_spread":0.25297866358280013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789332567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22434564,0.7735983,6.31643e-7,0.00004784903,0.00016558405,0.0015896499,0.00004018786,0.000012136542,0.00020001696],"genre_scores_gemma":[0.13070051,0.86851066,0.00009581525,0.000053723794,0.00028838377,0.00007013799,0.00007309044,0.000037816877,0.00016982123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833286,0.00021102844,0.00064436905,0.000336078,0.00024743043,0.00022824401],"domain_scores_gemma":[0.99867916,0.00025018258,0.0004779595,0.00040451682,0.00011565754,0.00007250061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004827812,0.00035179945,0.001621666,0.00024858516,0.000037450445,0.000018465757,0.000108326036,0.0001777039,0.00003836204],"category_scores_gemma":[0.0001812813,0.00020903768,0.00023307496,0.00031578777,0.00032068187,0.000077021905,0.000101550446,0.00014737518,0.0000041528433],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006206892,0.0003961165,0.009036413,0.013835751,0.0012084215,0.0000026071502,0.0005442305,1.8710733e-7,0.00082421117,0.00021938432,0.00045106767,0.97286093],"study_design_scores_gemma":[0.008840538,0.0027254764,0.043981913,0.027724307,0.004158528,0.0000041914964,0.00006502634,0.00002797065,0.00097109826,0.00015378492,0.91079485,0.0005523277],"about_ca_topic_score_codex":0.000034184424,"about_ca_topic_score_gemma":0.000018344117,"teacher_disagreement_score":0.9723086,"about_ca_system_score_codex":0.00003265977,"about_ca_system_score_gemma":0.000087957655,"threshold_uncertainty_score":0.85243094},"labels":[],"label_agreement":null},{"id":"W2789566251","doi":"10.1017/cem.2017.439","title":"Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Emergency Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Liraglutide; Medicine; Hypoglycemia; Diabetes mellitus; Intensive care medicine; Emergency medicine; Type 2 diabetes; Endocrinology","score_opus":0.036219255117845475,"score_gpt":0.29535333627710364,"score_spread":0.2591340811592582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789566251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784001,0.001785095,0.00005697503,0.0014458639,0.0035740947,0.0002535012,0.000006615521,0.0000030371623,0.014474699],"genre_scores_gemma":[0.99780655,0.00019988584,0.0002458685,0.0002613854,0.0006001104,0.0000028759134,0.00001075064,0.000018329765,0.0008542481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823916,0.000029098435,0.0008976439,0.00014050986,0.00033823273,0.00035537244],"domain_scores_gemma":[0.99833834,0.000022990494,0.00035431972,0.00019036603,0.00051403337,0.00057997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030937328,0.00016184195,0.00046608003,0.0007658133,0.000045694447,0.000002079632,0.000093877,0.000058444413,0.004089235],"category_scores_gemma":[0.0002716601,0.0001275797,0.00012248757,0.0005053461,0.00017473302,0.00009962437,0.000016410977,0.00017571614,0.000011972437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064050895,0.0005283146,0.6098354,0.00063250377,0.0012663077,0.0019937477,0.008260355,0.000050266543,0.010390168,0.0008966612,0.33191445,0.033591297],"study_design_scores_gemma":[0.022766596,0.023405256,0.76429343,0.012761967,0.0026619388,0.00037571657,0.00614694,0.00074279605,0.004837475,0.0028909398,0.15808743,0.0010295153],"about_ca_topic_score_codex":0.0034393151,"about_ca_topic_score_gemma":0.0088445395,"teacher_disagreement_score":0.17382702,"about_ca_system_score_codex":0.00030074097,"about_ca_system_score_gemma":0.00053283974,"threshold_uncertainty_score":0.99682117},"labels":[],"label_agreement":null},{"id":"W2789621478","doi":"10.1080/00325481.2018.1450058","title":"Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations","year":2018,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Medicine; Liraglutide; Insulin glargine; Type 2 diabetes; Insulin degludec; Lixisenatide; Glycemic; Hypoglycemia; Insulin; Glucagon-like peptide 1 receptor; Combination therapy; Diabetes mellitus; Adverse effect; Pharmacology; Internal medicine; Agonist; Endocrinology; Receptor","score_opus":0.06877619568524193,"score_gpt":0.347579191084556,"score_spread":0.2788029953993141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789621478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052669237,0.9725359,0.000051884024,0.016191734,0.0018865226,0.0069103003,0.00008587181,0.000182908,0.0016281798],"genre_scores_gemma":[0.00022617327,0.97308636,0.00030456326,0.00259298,0.0007871034,0.00095091184,0.005746577,0.00015155229,0.016153783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968137,0.0001893746,0.0009887354,0.00078943156,0.0006203944,0.0005983311],"domain_scores_gemma":[0.996927,0.00068394636,0.00063198246,0.00087143143,0.0006544165,0.00023117564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011758682,0.00081298273,0.0019930447,0.00041978928,0.0005004449,0.0001154321,0.00038848363,0.00031611632,0.000119867334],"category_scores_gemma":[0.0005592661,0.000458431,0.00033947433,0.0007200826,0.000603209,0.00019142381,0.00013261756,0.00044990852,0.00009751234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007798839,0.00061968435,0.00012629216,0.005189946,0.0015543435,0.0000031089178,0.00077132165,3.5394738e-8,0.000009264845,0.0027995897,0.10006119,0.8887872],"study_design_scores_gemma":[0.0047759386,0.0032877524,0.00030972765,0.009840563,0.0034979284,0.000003987908,0.0000939593,0.00007543466,0.000011115579,0.00041130913,0.9772707,0.00042158022],"about_ca_topic_score_codex":0.000050512375,"about_ca_topic_score_gemma":0.0000073038595,"teacher_disagreement_score":0.8883656,"about_ca_system_score_codex":0.00023042677,"about_ca_system_score_gemma":0.00023053034,"threshold_uncertainty_score":0.99978673},"labels":[],"label_agreement":null},{"id":"W2789737616","doi":"10.1155/2018/4817178","title":"Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy","year":2018,"lang":"en","type":"article","venue":"Journal of Diabetes Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Discontinuation; Medicine; Type 2 diabetes; Dipeptidyl peptidase-4; Insulin; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Diabetes mellitus; NPH insulin; Dipeptidyl peptidase; Endocrinology; Pharmacology; Insulin glargine; Chemistry; Enzyme; Biochemistry","score_opus":0.064342256966848,"score_gpt":0.39196632052575675,"score_spread":0.3276240635589087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789737616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967354,0.0007490218,2.6874116e-7,0.0006788954,0.00013452818,0.0011044549,0.000005047515,0.000016258431,0.0005761204],"genre_scores_gemma":[0.9954614,0.0018722713,0.00019486013,0.00010076949,0.00046250576,0.00003273541,0.00003843823,0.00004341584,0.0017935856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679965,0.00042040224,0.0008402351,0.00035432214,0.0009526367,0.0006327371],"domain_scores_gemma":[0.9975703,0.0004969656,0.00030981321,0.00029205903,0.0009916289,0.00033925133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013499651,0.00028242596,0.00072603393,0.00071406015,0.000114460105,0.000055733744,0.00014937141,0.00013298684,0.00011686937],"category_scores_gemma":[0.0005398282,0.00015399819,0.00012735769,0.00081527646,0.00031954751,0.00031493066,0.000081350336,0.00034627426,0.000051326693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018791317,0.003768701,0.8847075,0.00002303496,0.0006400661,0.000028912718,0.00021011126,4.4779037e-7,0.00034611733,0.000004151532,0.00047101232,0.107920796],"study_design_scores_gemma":[0.016475758,0.07609079,0.898124,0.0006748905,0.00015551622,0.0000011737397,0.00015387157,0.00010514495,0.005531725,0.000049967322,0.0024684381,0.00016874702],"about_ca_topic_score_codex":0.000022938893,"about_ca_topic_score_gemma":0.000054975124,"teacher_disagreement_score":0.10775205,"about_ca_system_score_codex":0.00030853628,"about_ca_system_score_gemma":0.00022704246,"threshold_uncertainty_score":0.62798643},"labels":[],"label_agreement":null},{"id":"W2789918798","doi":"10.1016/j.neuropharm.2018.01.048","title":"Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?","year":2018,"lang":"en","type":"review","venue":"Neuropharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Liraglutide; Neuroprotection; Mood; Type 2 diabetes; Medicine; Mood disorders; Psychology; Bioinformatics; Neuroscience; Diabetes mellitus; Psychiatry; Endocrinology; Biology","score_opus":0.071026885676487,"score_gpt":0.3645970708126922,"score_spread":0.2935701851362052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789918798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004024626,0.9853212,0.000017412765,0.00017748078,0.0021904658,0.005313506,0.00014634505,0.000111570276,0.0026973481],"genre_scores_gemma":[0.0004414229,0.9930882,0.00011618011,0.00073319516,0.00047575412,0.001652445,0.00069988985,0.00010410457,0.0026888337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976804,0.0003713699,0.0005917858,0.0007337845,0.00013927318,0.0004833574],"domain_scores_gemma":[0.9985562,0.0005600258,0.00036835895,0.00021082387,0.0000955874,0.00020898042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002873859,0.0005196934,0.0017573263,0.0004627284,0.00012967092,0.000037584017,0.00010395546,0.00021962945,0.00021699574],"category_scores_gemma":[0.000218287,0.00045422046,0.00031021718,0.00026080827,0.00025852973,0.00010511223,0.00015681458,0.00036655058,0.000046618417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037720293,0.00066848734,0.00008485453,0.011173691,0.0011964813,0.000051882274,0.00012189011,5.9174507e-8,0.000019255405,0.000081410966,0.01005986,0.97616494],"study_design_scores_gemma":[0.0036053632,0.0013012075,0.000115353556,0.00200437,0.0061217914,0.000028974986,0.00007145987,0.000013062495,0.000020944835,0.000029351437,0.9863815,0.00030662058],"about_ca_topic_score_codex":0.000023849705,"about_ca_topic_score_gemma":0.00003703395,"teacher_disagreement_score":0.97632164,"about_ca_system_score_codex":0.00010208922,"about_ca_system_score_gemma":0.00023882954,"threshold_uncertainty_score":0.99979097},"labels":[],"label_agreement":null},{"id":"W2790160447","doi":"10.1111/dom.13251","title":"Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Merck","keywords":"Extension (predicate logic); Term (time); Medicine; Physical therapy; Internal medicine; Computer science; Physics","score_opus":0.007645441871384784,"score_gpt":0.22841082766575554,"score_spread":0.22076538579437077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790160447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264497,0.0045024306,0.000007726301,0.000069924135,0.00006742434,0.0026261904,0.000008976334,0.00002610665,0.00004626947],"genre_scores_gemma":[0.9977874,0.0016811594,0.0001680703,0.00015128903,0.000038100847,0.00005848526,0.000020303803,0.000023298346,0.00007189044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861103,0.000081078004,0.00033984642,0.00042205316,0.00023331965,0.0003126741],"domain_scores_gemma":[0.9992415,0.00008014123,0.00012537985,0.00027361207,0.000117572024,0.00016184032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030143923,0.00027738928,0.0009949548,0.00022085053,0.00009686142,0.000032874847,0.00005507139,0.000072019124,0.00001297287],"category_scores_gemma":[0.000040110648,0.00019593364,0.00003930323,0.00017581861,0.00019817242,0.00017307619,0.00009141029,0.00009018411,0.0000017695255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007484014,0.0017058146,0.911736,0.00008068094,0.00037084668,0.000006036204,0.0010035085,2.9151923e-7,0.00016094618,0.000025406931,0.000009819276,0.07741664],"study_design_scores_gemma":[0.05620108,0.0029303443,0.93894416,0.0002527557,0.0007427443,1.04522414e-7,0.000043654007,0.000048447746,0.0005084682,0.00003087911,0.00011408265,0.00018327622],"about_ca_topic_score_codex":0.00004517657,"about_ca_topic_score_gemma":0.000035202607,"teacher_disagreement_score":0.07723337,"about_ca_system_score_codex":0.000015646274,"about_ca_system_score_gemma":0.00001298228,"threshold_uncertainty_score":0.7989942},"labels":[],"label_agreement":null},{"id":"W2790166173","doi":"10.1136/bmj.k872","title":"Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study","year":2018,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Jewish General Hospital; Deutsche Forschungsgemeinschaft; McGill University","keywords":"Medicine; Hazard ratio; Inflammatory bowel disease; Dipeptidyl peptidase-4; Internal medicine; Confidence interval; Cohort; Population; Incidence (geometry); Proportional hazards model; Cohort study; Cumulative incidence; Dipeptidyl peptidase; Diabetes mellitus; Rate ratio; Type 2 diabetes; Gastroenterology; Disease; Endocrinology; Environmental health; Biology","score_opus":0.00605161670656375,"score_gpt":0.23966015884241346,"score_spread":0.2336085421358497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790166173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971986,0.000017499937,0.0000024378637,0.000035566267,0.00008209997,0.0022322696,0.000004276987,0.000039595114,0.0003876863],"genre_scores_gemma":[0.999351,9.64993e-7,0.000110687884,0.00008096146,0.000084814084,0.00008856606,0.0000917847,0.000018555917,0.00017264426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898463,0.00003570458,0.00023329299,0.0002308903,0.00036328187,0.00015217402],"domain_scores_gemma":[0.99922836,0.00002466088,0.00014345083,0.0003008467,0.00016185023,0.00014085104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017759537,0.00013541391,0.00019077305,0.000109311375,0.000050094193,0.0000126760415,0.00003928708,0.000025461228,0.000039474893],"category_scores_gemma":[0.00008471187,0.00010177279,0.000024682226,0.00012718598,0.00009432005,0.00013730834,0.000046397105,0.00003806515,0.00000968181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020772268,0.0005132538,0.997741,0.00010569848,0.00011790257,0.000007344495,0.00009049211,0.0000049967853,0.000010813448,0.0000044935377,0.0006806269,0.00051565614],"study_design_scores_gemma":[0.0019267012,0.001357382,0.995526,0.00028244223,0.00037100873,1.6111379e-8,0.00004468651,0.00026741324,0.00006843859,0.0000066736234,0.00003816593,0.00011103522],"about_ca_topic_score_codex":0.000046791884,"about_ca_topic_score_gemma":0.000050518014,"teacher_disagreement_score":0.0022149624,"about_ca_system_score_codex":0.000047014,"about_ca_system_score_gemma":0.000033000273,"threshold_uncertainty_score":0.4150174},"labels":[],"label_agreement":null},{"id":"W2790193266","doi":"10.1016/j.ahj.2018.01.012","title":"The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial","year":2018,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Hadassah Medical Organization; AstraZeneca","keywords":"Medicine; TIMI; Dapagliflozin; Internal medicine; Cardiology; Intensive care medicine; Myocardial infarction; Diabetes mellitus; Endocrinology; Type 2 diabetes; Percutaneous coronary intervention","score_opus":0.034157788605698326,"score_gpt":0.30517257187148833,"score_spread":0.27101478326579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790193266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94112134,0.0041052205,0.025304692,0.018629124,0.0018912043,0.008012604,0.0000050576155,0.00005321513,0.0008775482],"genre_scores_gemma":[0.99011755,0.0005823506,0.0029338857,0.0022990103,0.0025757067,0.0003217502,0.0000038297894,0.000034201756,0.0011316958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886805,0.00024642557,0.00016118461,0.00014378589,0.00034386592,0.00023667827],"domain_scores_gemma":[0.998407,0.0010987028,0.000067188885,0.00025585786,0.000073259,0.00009801477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015574045,0.00011824832,0.00027029606,0.000041431034,0.0006447444,0.000066086206,0.000078761776,0.000016333346,0.000020703903],"category_scores_gemma":[0.00022822905,0.000055560646,0.00028393228,0.000097025695,0.00021227359,0.000040488736,0.000022159944,0.00011956476,0.000023743743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030759748,0.00025854088,0.0027463103,0.000019114143,0.0061827805,0.000019106938,0.0003026731,0.00014654515,0.00022283086,0.00019611952,0.112951584,0.8461946],"study_design_scores_gemma":[0.037742298,0.029004823,0.010336008,0.00008487586,0.002009233,0.00012301259,0.00027028765,0.0012469655,0.0010665295,0.00043683595,0.9174878,0.00019132579],"about_ca_topic_score_codex":0.000010656935,"about_ca_topic_score_gemma":0.00000147454,"teacher_disagreement_score":0.8460033,"about_ca_system_score_codex":0.000051545292,"about_ca_system_score_gemma":0.000053037696,"threshold_uncertainty_score":0.49589178},"labels":[],"label_agreement":null},{"id":"W2790252631","doi":"10.1210/en.2018-00004","title":"GLP-1 Receptor Expression Within the Human Heart","year":2018,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Health Canada; University of Pennsylvania","keywords":"Endocrinology; Internal medicine; Human heart; Receptor; Medicine; Biology","score_opus":0.023740841647590688,"score_gpt":0.30118568661593115,"score_spread":0.27744484496834043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790252631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94537175,0.0001544417,0.000016098465,0.006506686,0.0006008987,0.000334645,0.0000010927342,0.0001237143,0.04689069],"genre_scores_gemma":[0.98099256,0.000009486921,0.0007692154,0.0019243014,0.0004727306,0.000051704636,0.000015655934,0.0000129668315,0.015751405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930114,0.00004150275,0.0001228335,0.00018416629,0.00009378328,0.0002565682],"domain_scores_gemma":[0.9995175,0.000023559884,0.000036695394,0.00034548526,0.000030352207,0.000046389458],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000053265947,0.00009396232,0.00014576454,0.000050399318,0.00015016373,0.000008707075,0.00008726547,0.00002995517,0.0010163549],"category_scores_gemma":[0.000023802962,0.000054955784,0.00004544237,0.00006167431,0.00019472167,0.000028714681,0.00009737632,0.00009439671,0.0010994999],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016149455,0.0005269358,0.07749741,0.000041431656,0.00030212395,0.000065615764,0.0012207675,4.5470713e-7,0.28588578,0.045083664,0.57923406,0.009980295],"study_design_scores_gemma":[0.0014763685,0.0011006806,0.028152524,0.000037250426,0.000079887075,0.000024945237,0.00023417777,0.000004628181,0.21253213,0.00063511374,0.75562423,0.00009806935],"about_ca_topic_score_codex":0.000020981253,"about_ca_topic_score_gemma":0.000010790304,"teacher_disagreement_score":0.17639019,"about_ca_system_score_codex":0.000026495049,"about_ca_system_score_gemma":0.000010927684,"threshold_uncertainty_score":0.9998968},"labels":[],"label_agreement":null},{"id":"W2790286202","doi":"10.1016/j.metabol.2018.02.002","title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","year":2018,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; Janssen Scientific Affairs","keywords":"Glimepiride; Canagliflozin; Medicine; Adipokine; Adiponectin; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Metformin; Leptin; Insulin resistance; Obesity","score_opus":0.008005100947638746,"score_gpt":0.2397679669925269,"score_spread":0.23176286604488816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790286202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901014,0.0043363264,3.244362e-7,0.0001380851,0.00069014984,0.0003709077,0.0000014651243,0.00002806578,0.004333288],"genre_scores_gemma":[0.9989974,0.00021364745,0.00016855323,0.00020065629,0.00015212923,0.000022089373,0.000005753516,0.000016130434,0.00022363417],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99929,0.00003335237,0.00015255212,0.00017975736,0.0001362696,0.00020805898],"domain_scores_gemma":[0.9995503,0.00010749502,0.00004962137,0.00017509273,0.00004304839,0.00007445502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012587247,0.00013120627,0.00029326603,0.00024201848,0.000019040073,0.000006628942,0.00004682868,0.00004459601,0.00002567393],"category_scores_gemma":[0.00013725752,0.00010551637,0.00003471856,0.00021585858,0.00011288549,0.000046233166,0.000040496154,0.000043868873,0.000027326329],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008366322,0.0018410017,0.37110677,0.0032758915,0.008648267,0.00032931357,0.0020510457,0.0000049689393,0.17688623,0.016526187,0.019074753,0.39188924],"study_design_scores_gemma":[0.007014538,0.0007913508,0.8129527,0.00020700594,0.0006749731,1.8644769e-7,0.000027885639,0.000046966226,0.13140312,0.00009999832,0.046627767,0.00015350648],"about_ca_topic_score_codex":0.00008822583,"about_ca_topic_score_gemma":0.0000848222,"teacher_disagreement_score":0.44184595,"about_ca_system_score_codex":0.00002326964,"about_ca_system_score_gemma":0.00002245232,"threshold_uncertainty_score":0.43028325},"labels":[],"label_agreement":null},{"id":"W2790579026","doi":"10.1007/s00592-018-1116-0","title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","year":2018,"lang":"en","type":"review","venue":"Acta Diabetologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital; University of Toronto","funders":"McGill University","keywords":"Meta-analysis; Randomized controlled trial; Medicine; Systematic review; Intensive care medicine; Diabetes mellitus; MEDLINE; Internal medicine; Biology; Endocrinology","score_opus":0.07448642640280867,"score_gpt":0.35378149063950887,"score_spread":0.2792950642367002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790579026","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027810633,0.9707829,0.000004324144,0.00027045622,0.000041135743,0.028179964,0.00008355344,0.00002236039,0.0005875415],"genre_scores_gemma":[0.0008444161,0.9905694,0.000060726077,0.00016755839,0.000019400271,0.007826942,0.00006421737,0.000017871813,0.000429452],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.983775,0.01059405,0.004680943,0.0004169628,0.0003361469,0.00019687464],"domain_scores_gemma":[0.9657244,0.025467673,0.0076750806,0.0008366323,0.00022080303,0.00007537757],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.02469364,0.00059436035,0.08806462,0.0006118881,0.00006687267,0.00002974722,0.00016058332,0.00021709198,0.00023846963],"category_scores_gemma":[0.03453251,0.00019118638,0.01502893,0.0008072338,0.0007052694,0.000039187613,0.00014217355,0.00017365295,0.000003552448],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081789156,0.00010753544,0.000003404968,0.35287642,0.645289,7.350662e-7,0.000017137014,1.4384177e-8,1.5403456e-8,0.00021666504,0.00024272976,0.0004284505],"study_design_scores_gemma":[0.058305193,0.00014462096,7.5197744e-7,0.024614025,0.91262317,0.0000018011169,0.000008923185,0.000004614737,2.3678676e-7,0.00009129719,0.00407736,0.000128036],"about_ca_topic_score_codex":0.00002343998,"about_ca_topic_score_gemma":0.0000034753139,"teacher_disagreement_score":0.3282624,"about_ca_system_score_codex":0.000022267031,"about_ca_system_score_gemma":0.00004384424,"threshold_uncertainty_score":0.9948353},"labels":[],"label_agreement":null},{"id":"W2790895069","doi":"10.1002/dmrr.3004","title":"Risk of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on site‐specific cancer: A systematic review and meta‐analysis","year":2018,"lang":"en","type":"review","venue":"Diabetes/Metabolism Research and Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Observational study; Internal medicine; Meta-analysis; Randomized controlled trial; Cancer; Thyroid cancer; Dipeptidyl peptidase-4; Oncology; Pancreatic cancer; Placebo; Breast cancer; Endocrinology; Pathology; Type 2 diabetes; Diabetes mellitus","score_opus":0.11646977040179068,"score_gpt":0.4010385081206752,"score_spread":0.2845687377188845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790895069","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008902367,0.9828587,6.111077e-7,0.0001414822,0.0000826884,0.015436936,0.0005605519,0.0000376433,0.0007923746],"genre_scores_gemma":[0.00001116176,0.9866559,0.00013829595,0.00024639146,0.0002598163,0.0063218446,0.00033389783,0.000108944456,0.005923752],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9900669,0.0031702907,0.002749952,0.0015516713,0.0012997045,0.0011615229],"domain_scores_gemma":[0.993838,0.0009906858,0.0017101578,0.0021609997,0.00054968626,0.0007504735],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.007575407,0.0012548408,0.0216818,0.001970097,0.00027921362,0.00014100346,0.0004602631,0.0003548879,0.0006231016],"category_scores_gemma":[0.000794268,0.00068067445,0.00411465,0.0034554692,0.00069113675,0.00011698394,0.0004818207,0.0010567929,0.00040566284],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005627964,0.000287067,0.0000310569,0.85187864,0.10565717,0.000008608111,0.000035604702,1.3761764e-8,6.822403e-7,0.00008945611,0.013839093,0.028166965],"study_design_scores_gemma":[0.00021088695,0.00024419234,0.000008448556,0.12755042,0.45510456,9.616011e-7,0.000005003007,5.818409e-7,0.000004329867,0.000013113218,0.41657102,0.0002864834],"about_ca_topic_score_codex":0.000047801874,"about_ca_topic_score_gemma":0.000015691772,"teacher_disagreement_score":0.7243282,"about_ca_system_score_codex":0.00012052148,"about_ca_system_score_gemma":0.00012006816,"threshold_uncertainty_score":0.99956447},"labels":[],"label_agreement":null},{"id":"W2790964190","doi":"10.1186/s12933-018-0673-4","title":"Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent therapy choices: a comparison across health states","year":2018,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"University of Alberta","keywords":"Medicine; Glycemic; Diabetes mellitus; Blood pressure; Angiology; Medical record; Internal medicine; Retrospective cohort study; Diabetes management; Cohort; Electronic medical record; Physical therapy; Emergency medicine; Type 2 diabetes; Endocrinology","score_opus":0.008257134507125017,"score_gpt":0.24704602638327217,"score_spread":0.23878889187614716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790964190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7714275,0.22725943,0.00004985281,0.00013695694,0.000046182693,0.0009837653,0.00003439613,0.00003008346,0.000031798136],"genre_scores_gemma":[0.99160624,0.0076252487,0.00020429667,0.00027751114,0.000058050842,0.00013042087,0.000054779095,0.000027970722,0.000015456593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815303,0.00017040504,0.0003549353,0.0005134861,0.00023135378,0.00057678355],"domain_scores_gemma":[0.999093,0.000081460676,0.0001257963,0.0004134854,0.00012206875,0.0001642161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004530926,0.00022109332,0.0014301847,0.000080975165,0.00006776792,0.0000307821,0.00007558884,0.00010931524,0.000007980616],"category_scores_gemma":[0.00002201894,0.00019786492,0.00014845606,0.00016046264,0.00057481346,0.00007425354,0.000049625192,0.00012509844,0.000001063153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003592566,0.00039844084,0.8752367,0.0007864624,0.009416033,0.000049165963,0.0013224039,0.0000252324,0.00005705251,0.000030296327,0.00003651179,0.11228247],"study_design_scores_gemma":[0.0491385,0.005884019,0.9166848,0.0009998555,0.0026315714,0.00004214791,0.0007625102,0.0007684437,0.0027114102,0.0000605138,0.019894958,0.00042124593],"about_ca_topic_score_codex":0.0007293394,"about_ca_topic_score_gemma":0.00078359793,"teacher_disagreement_score":0.22017872,"about_ca_system_score_codex":0.000019283012,"about_ca_system_score_gemma":0.00004207892,"threshold_uncertainty_score":0.80686975},"labels":[],"label_agreement":null},{"id":"W2791027285","doi":"10.1016/j.peptides.2017.12.005","title":"Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism","year":2018,"lang":"en","type":"review","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada; Canadian Diabetes Association","keywords":"Liraglutide; Semaglutide; Cardioprotection; Glucagon-like peptide 1 receptor; Agonist; Endocrinology; Internal medicine; Medicine; Type 2 diabetes; Exenatide; Glucagon-like peptide-1; Insulin; Receptor; Diabetes mellitus; Pharmacology; Myocardial infarction","score_opus":0.022932237160327423,"score_gpt":0.281701790476836,"score_spread":0.2587695533165086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791027285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023831773,0.9868706,0.000019669733,0.000041060837,0.0014849207,0.0011747396,0.0003268042,0.00014003726,0.009918329],"genre_scores_gemma":[0.00005398199,0.9773082,0.00046137342,0.00018086948,0.0011002519,0.0004783724,0.0014744733,0.00013913414,0.018803347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99702275,0.00021658435,0.0010072561,0.00065687473,0.0005365987,0.00055994943],"domain_scores_gemma":[0.9975567,0.0003439809,0.0006793342,0.0009094433,0.0002376086,0.00027296264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003965101,0.0007439103,0.004222872,0.00044358653,0.000056440455,0.000029270113,0.000297478,0.00035255097,0.00046540378],"category_scores_gemma":[0.00016390874,0.0005358779,0.0015659875,0.00044543247,0.00022657009,0.00008683808,0.00013240217,0.00019246565,0.0006639391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049836584,0.0003277276,0.000033268556,0.012516926,0.008115405,0.000012190127,0.000055401768,5.7716356e-8,0.000018157827,0.0005867261,0.104912646,0.87337166],"study_design_scores_gemma":[0.0008457209,0.000251162,0.000020729714,0.0068683648,0.010862086,0.0000017750282,0.000018834628,0.000001893058,0.000042022235,0.000018797316,0.9806744,0.00039423624],"about_ca_topic_score_codex":0.00007844528,"about_ca_topic_score_gemma":0.000007948117,"teacher_disagreement_score":0.87576175,"about_ca_system_score_codex":0.0001406824,"about_ca_system_score_gemma":0.00026163342,"threshold_uncertainty_score":0.99970925},"labels":[],"label_agreement":null},{"id":"W2791162071","doi":"10.1111/dom.13301","title":"Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; University of Toronto; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"Dapagliflozin; Albuminuria; Urology; Medicine; Internal medicine; Excretion; Endocrinology; Urinary system; Placebo; Renal function; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.0032171069287916525,"score_gpt":0.20101722841888417,"score_spread":0.19780012149009252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791162071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941313,0.0030153508,0.0000017616061,0.00033308507,0.0004212576,0.00067516294,0.000009527595,0.00003135521,0.0013811807],"genre_scores_gemma":[0.9974994,0.00038102447,0.00015887077,0.0011232992,0.00022958902,0.000024631072,0.000004921039,0.00001717454,0.00056105695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989659,0.00007727098,0.00016622688,0.0002795213,0.0002345784,0.0002764808],"domain_scores_gemma":[0.9993629,0.00007611519,0.000074076845,0.00030420488,0.000052684558,0.00013004165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022407967,0.00019880474,0.00040244634,0.000107605476,0.0001247972,0.000021999007,0.00007952019,0.00008094781,0.0000178495],"category_scores_gemma":[0.00010595091,0.00013025802,0.00009193091,0.00018306256,0.00032591444,0.00007826638,0.00015064249,0.00010459437,0.000012564926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005620351,0.0024383971,0.6151953,0.0031976937,0.0025940484,0.000023718263,0.001127934,2.9345088e-7,0.19648175,0.0152184,0.010603559,0.1525569],"study_design_scores_gemma":[0.0016160576,0.00039414552,0.6944866,0.00023371351,0.00082588854,3.221743e-7,0.000015908347,0.000018356652,0.27001944,0.00039580482,0.031862993,0.00013076926],"about_ca_topic_score_codex":0.000010998813,"about_ca_topic_score_gemma":0.0000013953697,"teacher_disagreement_score":0.15242612,"about_ca_system_score_codex":0.000012361116,"about_ca_system_score_gemma":0.000014789864,"threshold_uncertainty_score":0.53117675},"labels":[],"label_agreement":null},{"id":"W2791595183","doi":"10.1016/j.jcjd.2018.01.006","title":"Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, Improves Trabecular Bone Mineral Density and Microstructure in Obese, Insulin-Resistant, Pre-diabetic Rats","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Thailand Research Fund; Mahidol University; National Science and Technology Development Agency; Cricket Island Foundation","keywords":"Vildagliptin; Medicine; Bone mineral; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Dipeptidyl peptidase-4; Endocrinology; Diabetes mellitus; Insulin; Insulin resistance; Type 2 diabetes; Osteoporosis","score_opus":0.005657929539884949,"score_gpt":0.20808513380245022,"score_spread":0.20242720426256527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791595183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254626,0.0055931606,0.0000010961137,0.00066921697,0.0003811812,0.00041571946,0.00002284286,0.000012852312,0.00035764228],"genre_scores_gemma":[0.9974356,0.000034973815,0.00068320596,0.0008092492,0.0005277183,0.000007003527,0.000017973804,0.000042495863,0.00044174542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980302,0.00006768923,0.0006004834,0.00031530752,0.0002462537,0.0007400863],"domain_scores_gemma":[0.9981551,0.000050940835,0.00025224642,0.00028175325,0.00029439214,0.0009655505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003418945,0.00033474716,0.00068979396,0.0006636777,0.00013726576,0.000114141614,0.00014718939,0.000163181,0.00006424056],"category_scores_gemma":[0.00020980311,0.00028689756,0.00015741911,0.00033956603,0.00041313816,0.00024081497,0.000035756155,0.00033309762,0.00000731526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101625,0.00014938018,0.64429134,0.00033596111,0.00042079148,0.00042941028,0.0013865794,0.0000018311755,0.33488032,0.00007497979,0.0062959553,0.011631823],"study_design_scores_gemma":[0.0043763444,0.002118023,0.9397162,0.0009003741,0.00043228825,0.000022817307,0.00026102562,0.000051506875,0.045150835,0.00033087237,0.0062404936,0.00039917105],"about_ca_topic_score_codex":0.00040013567,"about_ca_topic_score_gemma":0.013669305,"teacher_disagreement_score":0.2954249,"about_ca_system_score_codex":0.00024582518,"about_ca_system_score_gemma":0.0004802414,"threshold_uncertainty_score":0.99995834},"labels":[],"label_agreement":null},{"id":"W2791609812","doi":"10.1093/jcag/gwy008.150","title":"A149 DEVELOPING, EVALUATING, AND DISSEMINATING KNOWLEDGE TRANSLATION RESOURCES TO ANSWER PATIENT QUESTIONS ABOUT IBD AND ITS MANAGEMENT","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Medicine; Family medicine; Knowledge translation; Web resource; Medical education; Knowledge management; Computer science; World Wide Web","score_opus":0.019815677031586574,"score_gpt":0.2920245050840149,"score_spread":0.2722088280524283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791609812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924375,0.00016772868,0.00003675392,0.008403346,0.00027315438,0.00031187825,0.000005917304,0.0000032421365,0.0015542508],"genre_scores_gemma":[0.9955669,0.000035582478,0.002397422,0.0010326932,0.00008059034,0.0000066166353,0.0000017825164,0.0000077051,0.00087068614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990613,0.00012585481,0.00032923243,0.00009642606,0.0001886968,0.00019847641],"domain_scores_gemma":[0.9989802,0.000036979003,0.00039439017,0.00007002251,0.00035480197,0.00016357812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005873595,0.00008418484,0.0001981552,0.00027358741,0.0001272664,0.000018990577,0.00006485902,0.00004536126,0.000013476722],"category_scores_gemma":[0.00017440096,0.00006544823,0.0000463904,0.000100660334,0.000030375917,0.000054390704,0.00003207649,0.000080693775,0.0000016119617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002611225,0.00013461617,0.9108745,0.00013394305,0.00079863064,0.0000062438176,0.0058795484,0.0000115359535,0.00039211375,0.00082534924,0.007926176,0.07275624],"study_design_scores_gemma":[0.0015223543,0.0024240925,0.9719266,0.0005671505,0.0004686631,0.000019773623,0.00036883375,0.00016014383,0.00013088407,0.00011348147,0.022237143,0.000060860362],"about_ca_topic_score_codex":0.00015943378,"about_ca_topic_score_gemma":0.039966907,"teacher_disagreement_score":0.072695374,"about_ca_system_score_codex":0.00047244734,"about_ca_system_score_gemma":0.000085929954,"threshold_uncertainty_score":0.9775512},"labels":[],"label_agreement":null},{"id":"W2791740462","doi":"10.1111/dom.13137","title":"Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Medicine; Glucagon-like peptide 1 receptor; Agonist; Exenatide; Type 2 diabetes; Dipeptidyl peptidase; Internal medicine; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Adverse effect; Weight loss; Diabetes mellitus; Liraglutide; Alogliptin; Meta-analysis; Endocrinology; Receptor; Chemistry; Obesity; Biochemistry; Enzyme","score_opus":0.12533389312906065,"score_gpt":0.40361008164803713,"score_spread":0.2782761885189765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791740462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024151405,0.9605386,0.0000648982,0.00007719437,0.0009318998,0.013328249,0.0007035823,0.000043346547,0.00016078522],"genre_scores_gemma":[0.003398812,0.9886506,0.0037163752,0.0001646988,0.0003665776,0.0015920746,0.0010155996,0.000095336,0.0009999229],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99006385,0.0024254543,0.0050019096,0.0010433568,0.0007775917,0.00068783306],"domain_scores_gemma":[0.9842121,0.009771766,0.0034675007,0.0015188089,0.0006527391,0.00037707406],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.017061055,0.0009958101,0.024411112,0.0011351531,0.00012893623,0.000048242462,0.00061770395,0.00040980513,0.00018881826],"category_scores_gemma":[0.001797985,0.0005747511,0.012419429,0.0019435957,0.0007836811,0.00008414525,0.0004747314,0.00027402176,0.00001732808],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003450466,0.0019478339,0.00016324995,0.028947966,0.815229,0.0000010704206,0.000236597,0.0000053971307,0.000008482448,0.0005870202,0.0032634167,0.14615948],"study_design_scores_gemma":[0.022161143,0.0002454254,0.00039984478,0.002615602,0.64112216,4.3795417e-8,0.000044778037,0.00004437441,0.00010920054,0.000022626598,0.3329,0.00033484548],"about_ca_topic_score_codex":0.000020546813,"about_ca_topic_score_gemma":0.0000056318877,"teacher_disagreement_score":0.32963657,"about_ca_system_score_codex":0.000039576877,"about_ca_system_score_gemma":0.00012868564,"threshold_uncertainty_score":0.9996704},"labels":[],"label_agreement":null},{"id":"W2791751914","doi":"10.1155/2018/5284963","title":"Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling","year":2018,"lang":"en","type":"article","venue":"Stem Cells International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk; Else Kröner-Fresenius-Stiftung; Canada Research Chairs","keywords":"Sitagliptin; Endothelial progenitor cell; Endothelial stem cell; Regeneration (biology); Progenitor cell; Signal transduction; Medicine; Receptor; Internal medicine; Endocrinology; Pharmacology; Cell biology; Biology; Type 2 diabetes; Diabetes mellitus; Stem cell; Biochemistry","score_opus":0.012627290029900422,"score_gpt":0.243169553081131,"score_spread":0.23054226305123057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791751914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899188,0.00016347974,0.0007571351,0.00039938698,0.0024314895,0.0003698903,0.00012630472,0.00007685048,0.0057566143],"genre_scores_gemma":[0.98487204,0.000052445892,0.0020425704,0.00058014464,0.0023406616,0.00008024622,0.00025369343,0.000028161743,0.009750042],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998646,0.000035460045,0.00027862669,0.00035303595,0.00049820775,0.00018866792],"domain_scores_gemma":[0.9993867,0.000027283877,0.00009231105,0.00021620977,0.0001952733,0.000082185215],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014166141,0.00017382615,0.00017555754,0.00012636013,0.00005626435,0.0001005375,0.00013882507,0.00007809252,0.0051176418],"category_scores_gemma":[0.0000063332122,0.00015302563,0.00012053834,0.000064208245,0.000042900723,0.00016840707,0.00009529982,0.00008991163,0.0011720319],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010982674,0.0006409452,0.020615093,0.000036890266,0.0020203975,0.000046756955,0.001101639,0.000031689215,0.9092338,0.00070363196,0.022068227,0.042402666],"study_design_scores_gemma":[0.0016229765,0.00030119828,0.0019017755,0.000105892024,0.00015943576,4.8837836e-7,0.00009875332,0.00063385855,0.9026142,0.00013354982,0.0922335,0.00019440425],"about_ca_topic_score_codex":0.000043433447,"about_ca_topic_score_gemma":0.000015069431,"teacher_disagreement_score":0.07016528,"about_ca_system_score_codex":0.00017565973,"about_ca_system_score_gemma":0.000033465334,"threshold_uncertainty_score":0.99960566},"labels":[],"label_agreement":null},{"id":"W2792260658","doi":"10.1097/mol.0000000000000495","title":"Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Lipidology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Proglucagon; Glucagon-like peptide-1; Glucagon-like peptide-2; Endocrinology; Receptor; Internal medicine; Glucagon; Lipoprotein; LDL receptor; Secretion; Agonist; Chemistry; Biology; Peptide; Biochemistry; Hormone; Cholesterol; Medicine; Type 2 diabetes; Diabetes mellitus","score_opus":0.0637798830453021,"score_gpt":0.34566497407249286,"score_spread":0.2818850910271907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792260658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024648453,0.97904557,0.000049802456,0.00030887828,0.0136278,0.004079286,0.000052948413,0.00008403358,0.0002868364],"genre_scores_gemma":[0.00017084142,0.9895753,0.0008244996,0.000052492956,0.006391083,0.0009538444,0.0010490945,0.000104376435,0.00087844796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956353,0.00063372916,0.0014911538,0.001140514,0.00040870704,0.00069062196],"domain_scores_gemma":[0.99716145,0.00048083003,0.0011026997,0.00083568733,0.00019341442,0.00022590465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009579518,0.0009142271,0.0025433514,0.0006143903,0.00014327734,0.0000649093,0.00034517644,0.0004341323,0.000065564556],"category_scores_gemma":[0.000335578,0.00063658087,0.0003616375,0.00051437493,0.00092027005,0.00019187182,0.0005434742,0.0007205895,0.00003611926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017501718,0.0005874039,0.00035686357,0.028418096,0.0004935365,3.4908618e-7,0.0005275382,2.707802e-7,0.00008219864,0.0006016155,0.08141488,0.8873422],"study_design_scores_gemma":[0.001676166,0.0008819776,0.0017947152,0.01833424,0.0013021979,0.00007951006,0.000107485794,0.000031386717,0.000024240646,0.00016436914,0.97511965,0.00048408099],"about_ca_topic_score_codex":0.00008373075,"about_ca_topic_score_gemma":0.000018672634,"teacher_disagreement_score":0.8937048,"about_ca_system_score_codex":0.00014871552,"about_ca_system_score_gemma":0.00023174385,"threshold_uncertainty_score":0.9996086},"labels":[],"label_agreement":null},{"id":"W2792873317","doi":"10.14740/jem.v8i1.489","title":"Impaired Crosstalk Between Insulin and Glucagon Secretion in Patients With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Crosstalk; Internal medicine; Endocrinology; Glucagon; Secretion; Insulin; Glucagon-like peptide-1; Diabetes mellitus; Optics","score_opus":0.010600275822952119,"score_gpt":0.2488553142461161,"score_spread":0.23825503842316398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792873317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668527,0.0024805441,0.0000041315448,0.00025559744,0.00017671532,0.00014609192,0.00000217566,0.0000064843157,0.00024296653],"genre_scores_gemma":[0.9987118,0.0004221413,0.00042057896,0.00014630375,0.00019350131,0.0000015890406,0.00000771889,0.0000079146575,0.000088400324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993315,0.000033978667,0.00021865942,0.00010638875,0.000099387784,0.000210131],"domain_scores_gemma":[0.9995352,0.000028162167,0.00013548987,0.00007361728,0.00014291737,0.0000846068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009881304,0.000103158294,0.000348461,0.00021086892,0.000038212715,0.000011617759,0.000031442392,0.00004521927,0.000019082645],"category_scores_gemma":[0.000043776417,0.00006832682,0.000023107666,0.00010592376,0.00015998931,0.00012893009,0.00003461502,0.00012468467,0.0000023537245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039245162,0.00012906824,0.9601196,0.000020829717,0.0002462696,0.000016756054,0.00017391215,8.3794866e-8,0.00022770847,0.0001475721,0.00008979208,0.038435977],"study_design_scores_gemma":[0.0062760315,0.0017670005,0.9797594,0.00005027156,0.0003408783,0.0000066301727,0.000034092922,0.0000018249028,0.0010646028,0.00023169878,0.010405561,0.00006200493],"about_ca_topic_score_codex":0.00000454977,"about_ca_topic_score_gemma":0.0000039223573,"teacher_disagreement_score":0.038373973,"about_ca_system_score_codex":0.000013534592,"about_ca_system_score_gemma":0.000022532196,"threshold_uncertainty_score":0.2786287},"labels":[],"label_agreement":null},{"id":"W2792911949","doi":"10.2337/dc17-1059","title":"Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect","year":2018,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Empagliflozin; Liraglutide; Medicine; Diabetes mellitus; Glycemic; Type 2 diabetes; Internal medicine; EMPA; Lixisenatide; Mortality rate; Endocrinology","score_opus":0.02227712426713496,"score_gpt":0.2992500991323044,"score_spread":0.2769729748651694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792911949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9162199,0.0016568211,1.0057438e-7,0.070177406,0.0028050232,0.004412129,0.00012596564,0.00020976637,0.0043928837],"genre_scores_gemma":[0.74350935,0.00009673059,0.00004852937,0.22891198,0.012581749,0.0018689643,0.0075036054,0.00030129633,0.005177807],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962075,0.0003741955,0.00073736074,0.00091633596,0.00077038415,0.0009942265],"domain_scores_gemma":[0.99764943,0.00027036722,0.00032968298,0.0015007737,0.00015581335,0.00009395893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006224629,0.0007727099,0.0014417587,0.00041926195,0.00014279786,0.000117327094,0.00039879492,0.00076489017,0.00016236327],"category_scores_gemma":[0.00016689276,0.00050303113,0.00065688055,0.00047195147,0.00028769384,0.00013691136,0.00018464965,0.001260241,0.0004965473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018462924,0.00007006124,0.45822102,0.0013377486,0.00068526546,0.000071793525,0.00023904374,4.26221e-7,0.000036815527,0.000002958048,0.5358736,0.0032766187],"study_design_scores_gemma":[0.038745746,0.004580854,0.16444558,0.0010722707,0.0059107305,0.0000017297839,0.00038234468,0.000013333386,0.00474007,0.00019272038,0.778592,0.0013226405],"about_ca_topic_score_codex":0.00004149993,"about_ca_topic_score_gemma":0.000018933564,"teacher_disagreement_score":0.29377544,"about_ca_system_score_codex":0.00041996784,"about_ca_system_score_gemma":0.00006597898,"threshold_uncertainty_score":0.99974215},"labels":[],"label_agreement":null},{"id":"W2793156972","doi":"10.2337/dci17-0051","title":"Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943–950. Comment on Bowering et al. Diabetes Care 2017;40:951–957","year":2018,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Postprandial; Medicine; Glycemic; Insulin aspart; Diabetes mellitus; Dosing; Hypoglycemia; Gastric emptying; Gastroparesis; Insulin; Type 1 diabetes; Type 2 diabetes; Intensive care medicine; Internal medicine; Endocrinology; Stomach","score_opus":0.018526583880574137,"score_gpt":0.28052762155058314,"score_spread":0.262001037670009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793156972","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18555568,0.0062801153,0.0000015467941,0.7824812,0.0041841376,0.006308973,0.005716455,0.000907852,0.008564049],"genre_scores_gemma":[0.06711681,0.0005340916,0.00053741806,0.90221816,0.0013764056,0.002969587,0.023205463,0.00079329434,0.0012487746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9864253,0.0013848133,0.0016916464,0.0035800394,0.0029783857,0.003939837],"domain_scores_gemma":[0.9902261,0.001908123,0.00089562964,0.004724389,0.0011696641,0.0010761142],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0011526555,0.0033703053,0.003563209,0.0018637497,0.0008296072,0.0007648758,0.0018006127,0.001318945,0.00048912806],"category_scores_gemma":[0.00043474665,0.0030731286,0.0014791578,0.0006635191,0.0004260365,0.00040159075,0.0015584887,0.0031885924,0.007139831],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066294434,0.00053215685,0.0344035,0.0024668307,0.0021900681,0.00038678994,0.0073384815,0.000046497098,0.0004345459,0.000019525774,0.94717157,0.004347089],"study_design_scores_gemma":[0.004827478,0.007814666,0.0076034004,0.0076076286,0.0017608792,8.7806774e-7,0.0053081946,0.000022161697,0.008743011,0.000025187946,0.95345443,0.0028320805],"about_ca_topic_score_codex":0.0000776259,"about_ca_topic_score_gemma":0.000056890927,"teacher_disagreement_score":0.11973698,"about_ca_system_score_codex":0.0028235817,"about_ca_system_score_gemma":0.00032672205,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W2793465758","doi":"10.1016/s0735-1097(18)32260-5","title":"EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE","year":2018,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Myocardial infarction; Stroke (engine); Baseline (sea); Internal medicine; Heart failure; Cardiology; Emergency medicine; Diabetes mellitus","score_opus":0.013552786077513857,"score_gpt":0.2633401180801453,"score_spread":0.24978733200263142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793465758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984334,0.000054583354,0.000105744504,0.0005165978,0.00025093684,0.0005035231,0.000047863115,0.0000020352118,0.00008527912],"genre_scores_gemma":[0.9978752,0.000028081842,0.0013335984,0.00012356641,0.00017680506,0.000008626265,0.0000041345616,0.00000981428,0.00044016476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991168,0.00012822589,0.00035027452,0.00010247669,0.00019261427,0.00010961339],"domain_scores_gemma":[0.99882954,0.000069084774,0.00059129123,0.00014607963,0.00032165597,0.00004234893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032835608,0.00009450322,0.0007090374,0.00013948475,0.000019641137,9.885943e-7,0.000056572793,0.000028803448,0.0000087661865],"category_scores_gemma":[0.0001646638,0.00004969481,0.00011484099,0.00014248237,0.00043261817,0.000054432516,0.000036693727,0.000049150913,1.10836105e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008136667,0.00008428537,0.976539,0.000033796143,0.0007481768,0.0000029226119,0.00007775607,0.000028519122,0.00053706847,0.0000038783414,0.013434008,0.00037390154],"study_design_scores_gemma":[0.005101253,0.01136662,0.96358275,0.00009927406,0.0007838518,0.000024317536,0.00032006623,0.00005070999,0.00040974608,0.000006359089,0.01818547,0.00006955959],"about_ca_topic_score_codex":0.00001539219,"about_ca_topic_score_gemma":0.00007478564,"teacher_disagreement_score":0.012956248,"about_ca_system_score_codex":0.00025141973,"about_ca_system_score_gemma":0.00019285067,"threshold_uncertainty_score":0.20264955},"labels":[],"label_agreement":null},{"id":"W2793469097","doi":"10.1210/en.2018-00186","title":"The Cardiac Glucagonlike Peptide-1 Receptor: Whither Art Thou?","year":2018,"lang":"en","type":"letter","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Thou; Internal medicine; Endocrinology; Medicine; Receptor; Theology; Philosophy","score_opus":0.014553664592437409,"score_gpt":0.25582530529871544,"score_spread":0.24127164070627805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793469097","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010454655,0.002389201,0.0000051813004,0.74121845,0.005578441,0.00102612,0.00004111973,0.00026722508,0.2484288],"genre_scores_gemma":[0.00011158211,0.0014603452,0.00028217395,0.3511631,0.010999503,0.00033606763,0.00081290555,0.00012208184,0.6347123],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974004,0.00017361151,0.0003424464,0.000618859,0.00034571436,0.0011189596],"domain_scores_gemma":[0.9982005,0.00022607508,0.00016454968,0.0012359535,0.00009958811,0.00007333125],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011468443,0.0004717763,0.0007242026,0.00015830573,0.00019710169,0.00005172837,0.00035463285,0.0004063326,0.0012916259],"category_scores_gemma":[0.000056331133,0.0003010915,0.00039380998,0.000113490685,0.0004243326,0.00003643514,0.00024745878,0.0010948566,0.011802824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003528398,0.00003744237,0.0010724086,0.0000548555,0.0013946983,0.0002746875,0.000041887422,2.123177e-8,0.000021072612,0.0002136849,0.9865583,0.010295623],"study_design_scores_gemma":[0.0006497274,0.0004888289,0.00061735825,0.00005377751,0.00066017377,0.00002293807,0.00003221785,4.7969655e-7,0.00020694996,0.00013732021,0.9968674,0.0002627982],"about_ca_topic_score_codex":0.000016040385,"about_ca_topic_score_gemma":0.000009814712,"teacher_disagreement_score":0.39005536,"about_ca_system_score_codex":0.00017074913,"about_ca_system_score_gemma":0.00007807446,"threshold_uncertainty_score":0.9999441},"labels":[],"label_agreement":null},{"id":"W2793793620","doi":"10.1111/dom.13252","title":"Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"European Foundation for the Study of Diabetes; Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Dulaglutide; Subgroup analysis; Diabetes mellitus; Glycated haemoglobin; Internal medicine; Type 2 diabetes; Endocrinology; Meta-analysis; Liraglutide","score_opus":0.007338434889576477,"score_gpt":0.23898001209343775,"score_spread":0.23164157720386128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793793620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970799,0.0005983632,0.00013597595,0.00016262101,0.00015469763,0.0014658974,0.00019583845,0.0000548269,0.00015188388],"genre_scores_gemma":[0.99505615,0.00020048265,0.00042838714,0.0008122747,0.00014267654,0.00010668178,0.0030684439,0.000020560365,0.0001643432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829227,0.00013803858,0.00044854893,0.00048630085,0.00029365515,0.00034118467],"domain_scores_gemma":[0.99883986,0.00014335963,0.0002637679,0.00027881964,0.00027884683,0.00019533053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046615108,0.00028467216,0.00074860535,0.00025503436,0.00017460604,0.000058893504,0.000061832245,0.00013067794,0.000029451658],"category_scores_gemma":[0.00026303594,0.00023927857,0.00013556848,0.00038049853,0.00014971655,0.00026408362,0.000026782105,0.00007150831,0.0000051312077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027837346,0.007940829,0.79899335,0.000519945,0.005720684,0.0000029268278,0.0009721362,0.000035596404,0.055066686,0.0075351563,0.0020074095,0.11842154],"study_design_scores_gemma":[0.018190194,0.0046670623,0.8784622,0.00011896644,0.006062183,4.5477496e-8,0.000046786176,0.014009846,0.07414949,0.0010003708,0.002883908,0.00040897698],"about_ca_topic_score_codex":0.000024734729,"about_ca_topic_score_gemma":0.00002768795,"teacher_disagreement_score":0.11801256,"about_ca_system_score_codex":0.00003571789,"about_ca_system_score_gemma":0.000017158469,"threshold_uncertainty_score":0.9757497},"labels":[],"label_agreement":null},{"id":"W2793965691","doi":"10.1139/cjpp-2017-0680","title":"Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pioglitazone; Internal medicine; Vildagliptin; Medicine; Endocrinology; Insulin; Hypoglycemia; Streptozotocin; Diabetes mellitus; Glycemic; Type 2 diabetes; Gliclazide; Pancreas; Type 1 diabetes","score_opus":0.009483156702398611,"score_gpt":0.2610381783118234,"score_spread":0.2515550216094248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793965691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935873,0.00088944566,0.000004423231,0.003772409,0.0010720915,0.00025976697,0.000003010308,0.0000029866146,0.00040853384],"genre_scores_gemma":[0.9938622,0.000092945396,0.000016675112,0.0055014924,0.00034523412,0.0000060133534,0.000004855219,0.0000073021133,0.00016327493],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99926853,0.00011302522,0.00021013746,0.00010453551,0.00003505629,0.00026873135],"domain_scores_gemma":[0.99938434,0.00009286622,0.00011596928,0.00007067475,0.00014415257,0.00019199593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001984866,0.00009693818,0.00026255703,0.00017533105,0.00008282455,0.0000058799246,0.000085218955,0.00007307977,0.0006357433],"category_scores_gemma":[0.000024712866,0.000066727094,0.000040217517,0.00010272411,0.00030667952,0.0000543969,0.000009713496,0.00020622117,0.000014097361],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017539974,0.00014043068,0.010579614,0.000057201807,0.0005460252,0.00010256438,0.0005785731,0.000006965269,0.9710346,0.0007831923,0.011226779,0.0031900553],"study_design_scores_gemma":[0.07378832,0.03174403,0.6442626,0.00021245237,0.0030582598,0.00028301295,0.00040811315,0.0055529187,0.12101732,0.018124018,0.10076083,0.00078810845],"about_ca_topic_score_codex":0.00027734117,"about_ca_topic_score_gemma":0.0007556567,"teacher_disagreement_score":0.85001725,"about_ca_system_score_codex":0.000081823906,"about_ca_system_score_gemma":0.0002587861,"threshold_uncertainty_score":0.69609433},"labels":[],"label_agreement":null},{"id":"W2794058777","doi":"10.14740/jem.v8i1.491","title":"Steroid-Induced Hyperglycemia Successfully Treated With Once-Weekly Dulaglutide in an Old Patient With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dulaglutide; Hyperglucagonemia; Internal medicine; Glycemic; Endocrinology; Postprandial; Type 2 diabetes; Prednisolone; Diabetes mellitus; Insulin; Glucagon-like peptide 1 receptor; Glucagon; Exenatide; Receptor; Agonist","score_opus":0.014348569451187662,"score_gpt":0.2524941076810681,"score_spread":0.23814553822988044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794058777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967743,0.0012308067,0.0000027075096,0.00044644973,0.00018588126,0.00023955673,0.0000013885317,0.000018212997,0.0011007035],"genre_scores_gemma":[0.99788034,0.00022621705,0.00078092393,0.0005696745,0.00018856487,0.000008115021,0.000005125858,0.000021155915,0.00031989755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987464,0.00007796958,0.00034864675,0.0002168339,0.00019894789,0.00041121335],"domain_scores_gemma":[0.9990485,0.000034799137,0.00025036692,0.00020580154,0.0002860659,0.00017450454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087484244,0.00021429993,0.0006044653,0.0003451251,0.000056221776,0.000021754227,0.00009006675,0.00006331923,0.000040376166],"category_scores_gemma":[0.000025446965,0.00012715266,0.00003957923,0.00023788301,0.00015910616,0.00026723617,0.000034279394,0.00022909923,0.0000050992376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055703335,0.0011866882,0.9040663,0.000055577926,0.0012279368,0.0017230168,0.00076869206,0.0000065922327,0.02679725,0.00079845847,0.000287305,0.057511844],"study_design_scores_gemma":[0.013765763,0.019062322,0.9151135,0.00023007627,0.0011112373,0.00044520802,0.00048750607,0.00002051373,0.038016956,0.00008060863,0.011388299,0.00027801652],"about_ca_topic_score_codex":0.000034640187,"about_ca_topic_score_gemma":0.00011172662,"teacher_disagreement_score":0.05723383,"about_ca_system_score_codex":0.000034741905,"about_ca_system_score_gemma":0.00006919535,"threshold_uncertainty_score":0.5185135},"labels":[],"label_agreement":null},{"id":"W2794167054","doi":"10.1371/journal.pone.0190579","title":"The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3","year":2018,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Insulin glargine; Medicine; Concomitant; Internal medicine; Adverse effect; Type 2 diabetes; Insulin; Hypoglycemia; Diabetes mellitus; Gastroenterology; Basal insulin; Endocrinology","score_opus":0.06493390092065401,"score_gpt":0.2709747200712747,"score_spread":0.2060408191506207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794167054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38866183,0.6058358,0.000005712507,0.00010820513,0.000069032,0.0044649593,0.0007033241,0.000040730905,0.00011040366],"genre_scores_gemma":[0.21426362,0.78196245,0.00046473922,0.00010603457,0.00014040132,0.0010712681,0.0015204074,0.00016946383,0.00030161047],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957751,0.0005318318,0.0011881214,0.00088404154,0.0010348995,0.00058601086],"domain_scores_gemma":[0.99436593,0.002759038,0.0012399307,0.0010345998,0.0003822152,0.00021829102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008228751,0.0009555565,0.006787062,0.0009046941,0.00009925711,0.00006192016,0.00022452947,0.00029950473,0.000065002896],"category_scores_gemma":[0.0005708793,0.0005133884,0.0005762716,0.001824181,0.0003837389,0.0001693552,0.00013057068,0.00045819732,0.000009927453],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023055347,0.005980654,0.014732128,0.029629365,0.83786017,0.00014495112,0.0005732139,0.000019856996,0.00010006747,0.00010502816,0.0005463027,0.0872529],"study_design_scores_gemma":[0.027723884,0.03514571,0.0042658816,0.009107931,0.9041609,0.0000036364206,0.0000557955,0.0005369496,0.00033823386,0.00000472967,0.01774586,0.00091049913],"about_ca_topic_score_codex":0.0001501162,"about_ca_topic_score_gemma":0.000546531,"teacher_disagreement_score":0.17612666,"about_ca_system_score_codex":0.00025256985,"about_ca_system_score_gemma":0.00016884634,"threshold_uncertainty_score":0.9997318},"labels":[],"label_agreement":null},{"id":"W2794193682","doi":"10.14740/jem.v8i1.486","title":"Improved Glycemic Control due to Reduction in Glucagon Levels by the Administration of Once-Weekly Dulaglutide in a Non-Obese Patient With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dulaglutide; Hyperglucagonemia; Medicine; Glycemic; Postprandial; Type 2 diabetes; Internal medicine; Glucagon; Endocrinology; Diabetes mellitus; Insulin; Liraglutide","score_opus":0.009233962460068879,"score_gpt":0.2531080958761106,"score_spread":0.24387413341604172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794193682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599326,0.0013132666,0.000036717283,0.001784691,0.00028328723,0.00039433237,0.0000034217562,0.000002818382,0.00018823448],"genre_scores_gemma":[0.99908644,0.00012700206,0.0003105979,0.00024585286,0.000109005785,0.000014476054,0.0000019626634,0.0000069588855,0.00009772235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991347,0.000057849044,0.0003666239,0.000116807154,0.000106507134,0.0002174918],"domain_scores_gemma":[0.9994144,0.00003773196,0.00022811035,0.000113360635,0.00014688178,0.00005953153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014009254,0.000108371925,0.00038679823,0.0002037832,0.000024000252,0.000006392845,0.000055629866,0.000040922292,0.000010902613],"category_scores_gemma":[0.00006849786,0.00006512533,0.00003326581,0.00017967279,0.00010818471,0.00009458309,0.00001791389,0.00015204314,0.0000011775439],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029485399,0.0022207447,0.023079745,0.00014090592,0.001298878,0.00039646958,0.00404135,0.000029813276,0.70347434,0.00074697187,0.00190864,0.23317672],"study_design_scores_gemma":[0.027296325,0.022592492,0.6203732,0.00044588977,0.0010465059,0.00070949574,0.0016925252,0.00021347943,0.31338346,0.00037066467,0.011594097,0.00028188401],"about_ca_topic_score_codex":0.0000332151,"about_ca_topic_score_gemma":0.000052853124,"teacher_disagreement_score":0.59729344,"about_ca_system_score_codex":0.000030050052,"about_ca_system_score_gemma":0.000066352266,"threshold_uncertainty_score":0.26557338},"labels":[],"label_agreement":null},{"id":"W2794447083","doi":"10.1002/14651858.cd012990.pub2","title":"GLP-1 receptor agonists for Parkinson's disease","year":2020,"lang":"en","type":"review","venue":"Cochrane Database of Systematic Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Exenatide; Medicine; Dulaglutide; Placebo; Internal medicine; Cochrane Library; Clinical trial; Glucagon-like peptide 1 receptor; Oncology; Type 2 diabetes; Pharmacology; Diabetes mellitus; Agonist; Receptor; Endocrinology; Randomized controlled trial; Pathology; Alternative medicine","score_opus":0.11202421064881017,"score_gpt":0.3802424003379355,"score_spread":0.2682181896891253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794447083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.358422e-8,0.96088576,0.00033560148,0.00010845148,0.0005347303,0.035871644,0.0018507072,0.00006152225,0.00035149575],"genre_scores_gemma":[2.0158573e-7,0.9700236,0.003666202,0.00012613532,0.00034153246,0.011732787,0.012127939,0.00011988807,0.0018617151],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943823,0.0005661818,0.0032451942,0.0008371022,0.0005767569,0.00039242872],"domain_scores_gemma":[0.9938565,0.0006705949,0.0024852469,0.0022738213,0.00015180188,0.0005620262],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016913102,0.0009009777,0.011782054,0.00021803606,0.00006002161,0.000045565717,0.00051409,0.00012562983,0.00022866283],"category_scores_gemma":[0.0031034313,0.00055425655,0.0025766697,0.00042348012,0.00007106844,0.00010649607,0.00018466591,0.00017195618,0.0011673315],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002363452,0.00018409632,6.8993876e-7,0.8152655,0.0008159465,0.00004412654,0.000013777811,4.536009e-9,4.3105703e-7,0.00026201826,0.054068714,0.12932111],"study_design_scores_gemma":[0.00037248907,0.00008979394,9.525054e-8,0.47482824,0.016194066,0.000005637399,0.0000052494183,0.0000038940793,3.7099488e-7,0.0000016520664,0.5082916,0.00020690428],"about_ca_topic_score_codex":0.0000021687447,"about_ca_topic_score_gemma":5.9664745e-7,"teacher_disagreement_score":0.4542229,"about_ca_system_score_codex":0.0001779225,"about_ca_system_score_gemma":0.00030306418,"threshold_uncertainty_score":0.9996909},"labels":[],"label_agreement":null},{"id":"W2795481136","doi":"10.1016/j.cmet.2018.03.001","title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","year":2018,"lang":"en","type":"review","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1922,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Gastric emptying; Glucagon-like peptide-1; Enteroendocrine cell; Appetite; Glycemic; Medicine; Type 2 diabetes; Glucagon-like peptide-2; Glucagon-like peptide 1 receptor; Pharmacology; Receptor; Diabetes mellitus; Endocrinology; Bioinformatics; Internal medicine; Biology; Endocrine system; Agonist; Peptide; Hormone; Biochemistry; Stomach","score_opus":0.04118604965361883,"score_gpt":0.31564131698150255,"score_spread":0.2744552673278837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795481136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012485881,0.9944745,0.0013335422,0.0000065617382,0.00028527304,0.0013116377,0.000010229587,0.000022689712,0.0024307508],"genre_scores_gemma":[0.0009102285,0.9952984,0.0010339584,0.000031123644,0.00009391309,0.00014040616,0.00009499936,0.00003999475,0.0023569956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892426,0.000048283553,0.0004173934,0.00028461457,0.00018578625,0.00013968443],"domain_scores_gemma":[0.99890035,0.00003466554,0.0004999036,0.0004358673,0.00007203565,0.00005717124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018202874,0.0002497263,0.001291875,0.00020365612,0.00001985782,0.00000547584,0.00008945016,0.0001570966,0.000033888675],"category_scores_gemma":[0.0000044188105,0.00018218264,0.0002563059,0.00018577736,0.000065425505,0.000027231441,0.000054222237,0.00008330726,0.000034466007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008331085,0.00016576196,0.0000011778975,0.017339306,0.0004071113,4.1594714e-7,0.000033197335,2.1618199e-8,0.00048519782,0.0023326396,0.0001472434,0.9790796],"study_design_scores_gemma":[0.00046095575,0.00011395589,0.000042936532,0.001087306,0.008207015,0.0000018554315,0.000020343263,0.0000064464407,0.0018470584,0.00063379394,0.98745614,0.00012220065],"about_ca_topic_score_codex":0.000013186494,"about_ca_topic_score_gemma":8.937063e-7,"teacher_disagreement_score":0.9873089,"about_ca_system_score_codex":0.000021930637,"about_ca_system_score_gemma":0.00004666127,"threshold_uncertainty_score":0.74291927},"labels":[],"label_agreement":null},{"id":"W2795827343","doi":"10.21037/atm.2018.03.29","title":"The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials","year":2018,"lang":"en","type":"letter","venue":"Annals of Translational Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Type 2 Diabetes Mellitus; Disease; Diabetes mellitus; Clinical trial; Type 2 diabetes; Glucagon-like peptide-1; Internal medicine; Bioinformatics; Endocrinology; Biology","score_opus":0.15657080761368106,"score_gpt":0.3990244554205581,"score_spread":0.24245364780687703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795827343","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03296169,0.32525912,0.000013783632,0.6377961,0.0011313073,0.0024568834,0.00013028714,0.000014827297,0.00023599711],"genre_scores_gemma":[0.17177872,0.64171827,0.0006917812,0.15451656,0.017925106,0.0007207807,0.010803795,0.00021555649,0.0016294068],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99387443,0.0017034762,0.0021560877,0.00053618144,0.0013674358,0.00036240352],"domain_scores_gemma":[0.991975,0.005786604,0.00066528656,0.0009073818,0.0005603115,0.00010543496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008827367,0.00034073033,0.0016696302,0.00017632933,0.00005386342,0.000012669437,0.00038240026,0.00029882113,0.0002839204],"category_scores_gemma":[0.004271809,0.00018853298,0.0006197009,0.0005383852,0.00056822307,0.00010287927,0.000041181116,0.0006130907,0.00001538104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023692953,0.00051115535,0.052006643,0.0005441052,0.006255794,0.00003158074,0.0005047512,0.00004660832,0.00008377811,0.000053350548,0.61323357,0.3243594],"study_design_scores_gemma":[0.002445754,0.00078184454,0.06622571,0.00759149,0.0021626938,1.514983e-7,0.000068690315,0.00011372584,0.00019072233,0.003100299,0.91714245,0.0001764651],"about_ca_topic_score_codex":0.0002720044,"about_ca_topic_score_gemma":0.000076816956,"teacher_disagreement_score":0.48327953,"about_ca_system_score_codex":0.0000333715,"about_ca_system_score_gemma":0.0003470473,"threshold_uncertainty_score":0.76881516},"labels":[],"label_agreement":null},{"id":"W2796063363","doi":"10.1161/circulationaha.117.032799","title":"Reduced Mortality With Sodium-Glucose Cotransporter–2 Inhibitors in Observational Studies","year":2018,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"McGill University; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Empagliflozin; Hazard ratio; Observational study; Canagliflozin; Randomized controlled trial; Internal medicine; Diabetes mellitus; Epidemiology; Type 2 Diabetes Mellitus; Confidence interval; Surgery; Endocrinology","score_opus":0.09935385431621913,"score_gpt":0.3318332872121939,"score_spread":0.23247943289597478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796063363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968887,0.00011320623,0.000053935273,0.00047843144,0.00012429946,0.00041872056,0.0000014377173,0.00004543942,0.0018758108],"genre_scores_gemma":[0.99907935,0.000013425879,0.00025832633,0.00020475284,0.00016261745,0.00003895036,0.00013618861,0.000009172583,0.000097202654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993146,0.000012497331,0.00017619951,0.00018050856,0.00019696334,0.00011920758],"domain_scores_gemma":[0.99963725,0.000013442374,0.000053518826,0.00014467728,0.000117705844,0.00003339424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012153554,0.00008868066,0.00015560248,0.00008007793,0.000039352282,0.00000752597,0.00002041293,0.000029592913,0.000029613615],"category_scores_gemma":[0.000017149421,0.00007130688,0.000027336566,0.00020387243,0.00007510565,0.00012811109,0.000006759142,0.00003580134,0.000018587432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005415146,0.00013656502,0.99245864,0.00005351177,0.00015999164,0.000012612472,0.00055628794,0.000018460754,0.0031644143,0.0006896858,0.00018096204,0.00251474],"study_design_scores_gemma":[0.0012683506,0.000103338985,0.9938656,0.00011512028,0.00013677341,8.1593504e-7,0.00012102684,0.00025994628,0.0033163687,0.00037260124,0.0003646569,0.000075391574],"about_ca_topic_score_codex":0.000018582743,"about_ca_topic_score_gemma":0.00010536559,"teacher_disagreement_score":0.0024393485,"about_ca_system_score_codex":0.00011564848,"about_ca_system_score_gemma":0.00003398855,"threshold_uncertainty_score":0.29078102},"labels":[],"label_agreement":null},{"id":"W2796587260","doi":"10.14740/jocmr3392w","title":"Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Insulin; Postprandial; Hypoglycemia; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Glycemic","score_opus":0.11214405489370739,"score_gpt":0.4401502499260218,"score_spread":0.32800619503231443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796587260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766607,0.0015046687,0.0000018758393,0.018554464,0.0005322395,0.0010022371,0.0000015644813,0.000010987974,0.0017312114],"genre_scores_gemma":[0.990719,0.0050099352,0.00005281629,0.0014189574,0.0023451063,0.00001463662,0.000013995268,0.000029492816,0.00039604455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955187,0.00067563937,0.0014340277,0.00030573286,0.0015465727,0.00051933475],"domain_scores_gemma":[0.9934898,0.0016467128,0.00044798982,0.0003764661,0.0036573478,0.00038170538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047970153,0.00022581151,0.0009830187,0.0005439094,0.000097731776,0.000021932672,0.00029588066,0.00016025032,0.00023686755],"category_scores_gemma":[0.0034169317,0.0001008187,0.00014594922,0.0011380794,0.0015365438,0.0001275698,0.000052025807,0.0013422051,0.000045733428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033863503,0.0027867812,0.7275488,0.000062145744,0.0007829468,0.00049784704,0.0016644698,5.6090585e-7,0.0003598194,0.00002453727,0.03003894,0.20236966],"study_design_scores_gemma":[0.039017327,0.05861846,0.85786927,0.0015383823,0.00024987894,0.000013474813,0.0010799068,0.00001859197,0.0025544877,0.00008759665,0.03880596,0.00014665368],"about_ca_topic_score_codex":0.00007866254,"about_ca_topic_score_gemma":0.00004522383,"teacher_disagreement_score":0.202223,"about_ca_system_score_codex":0.00010163998,"about_ca_system_score_gemma":0.00037291468,"threshold_uncertainty_score":0.5831288},"labels":[],"label_agreement":null},{"id":"W2797054241","doi":"10.1152/physiol.00004.2018","title":"Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms","year":2018,"lang":"en","type":"review","venue":"Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"","keywords":"Type 2 diabetes; Pathophysiology; Medicine; Diabetes mellitus; Bioinformatics; Neuroscience; Intensive care medicine; Biology; Internal medicine; Endocrinology","score_opus":0.05885520276195418,"score_gpt":0.33026402518744064,"score_spread":0.2714088224254865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797054241","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023299758,0.99511087,0.0001539964,0.000013178322,0.00096513797,0.0022389605,0.00013744824,0.00015374536,0.0009936647],"genre_scores_gemma":[0.00015252571,0.99424314,0.0012803043,0.0001365043,0.000955995,0.0014418912,0.001377045,0.00007522808,0.0003373672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981147,0.00006623577,0.00042223083,0.0007394477,0.00010677836,0.0005506218],"domain_scores_gemma":[0.99885094,0.00017326734,0.00022171272,0.00056598656,0.000076974575,0.00011109477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012424389,0.0005488302,0.0026036846,0.00012302217,0.000084483916,0.000024520956,0.00020186733,0.00038009943,0.000078134704],"category_scores_gemma":[0.000028038772,0.0003678232,0.0010979195,0.00013029603,0.000105572115,0.000055779405,0.00019750578,0.00017071684,0.00025768855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008032367,0.00029262912,9.3490996e-8,0.01851068,0.0016644053,0.000009169878,0.000018650771,9.602282e-7,0.00062951935,0.020225449,0.002747982,0.95582014],"study_design_scores_gemma":[0.00043903285,0.0018628981,0.000015482829,0.0029132024,0.0029823682,0.0000020532286,0.000030954827,0.0000040106956,0.00005402672,0.008129039,0.983192,0.00037492547],"about_ca_topic_score_codex":0.0000034865775,"about_ca_topic_score_gemma":5.3087956e-7,"teacher_disagreement_score":0.980444,"about_ca_system_score_codex":0.000097286975,"about_ca_system_score_gemma":0.00013534805,"threshold_uncertainty_score":0.9998774},"labels":[],"label_agreement":null},{"id":"W2797097396","doi":"10.1016/j.jcjd.2017.10.021","title":"Diabetes in Older People","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Diabetes mellitus; Glycated hemoglobin; Hypoglycemia; Dementia; Older people; Gerontology; Elderly people; Intensive care medicine; Diabetes management; Type 2 diabetes; Internal medicine; Endocrinology; Disease","score_opus":0.008472724915272279,"score_gpt":0.2207973979712194,"score_spread":0.2123246730559471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797097396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970187,0.0009948038,0.0000012545938,0.0016548976,0.00044673652,0.00017083854,0.00000425169,0.000007253658,0.007018122],"genre_scores_gemma":[0.99760574,0.0000060312927,0.00022969201,0.001096229,0.00036838523,0.000005431426,0.0000055014266,0.000021186697,0.0006617835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884474,0.000025721041,0.00032258616,0.00012383203,0.00015206246,0.0005310417],"domain_scores_gemma":[0.99888825,0.00004472899,0.00011490334,0.00017530264,0.00017493339,0.00060189667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026947397,0.00013892104,0.00036982962,0.000645682,0.00005513368,0.00003925149,0.00013364649,0.00005957528,0.00059660454],"category_scores_gemma":[0.00012464833,0.00011672429,0.00011354655,0.00035642402,0.000110173394,0.00015567029,0.000011806005,0.00013676113,0.00007016303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016435879,0.00004974525,0.98251873,0.000037473837,0.00011666234,0.00002198409,0.00033031317,8.170141e-7,0.00020616553,0.00010397328,0.010427937,0.006184538],"study_design_scores_gemma":[0.0015454022,0.00071140175,0.97964823,0.0003219963,0.00013780415,0.0000012262169,0.00013697431,0.00006267799,0.0020682614,0.00023489696,0.015004649,0.00012650243],"about_ca_topic_score_codex":0.00027362996,"about_ca_topic_score_gemma":0.020902695,"teacher_disagreement_score":0.020629065,"about_ca_system_score_codex":0.00017926419,"about_ca_system_score_gemma":0.00040244623,"threshold_uncertainty_score":0.99696326},"labels":[],"label_agreement":null},{"id":"W2797218304","doi":"10.1016/j.jcjd.2017.10.024","title":"Cardiovascular Protection in People With Diabetes","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Myocardial infarction; Stroke (engine); Disease; Amputation; Psychological intervention; Intensive care medicine; Cause of death; Type 2 diabetes; Internal medicine; Cardiology; Surgery; Endocrinology; Psychiatry","score_opus":0.00856001661505409,"score_gpt":0.1906321146812952,"score_spread":0.1820720980662411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797218304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994847,0.0014592827,0.000014102466,0.0006313072,0.00019943267,0.000342401,0.0000022021384,0.000008387881,0.002495905],"genre_scores_gemma":[0.9989466,0.000004392936,0.00027849767,0.00023714971,0.00029090064,0.00001865927,0.0000030147992,0.00002182496,0.00019896965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897563,0.000035267803,0.00022784446,0.00013459136,0.00020719139,0.0004194626],"domain_scores_gemma":[0.999071,0.000014447433,0.00008893089,0.0002076039,0.00021263433,0.00040538414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033696668,0.00013489347,0.0004038786,0.0005480834,0.00006355193,0.000036089517,0.00008743061,0.00005105624,0.00009057496],"category_scores_gemma":[0.000068853704,0.00010168326,0.0001553305,0.00040945737,0.00010620329,0.00015939419,0.0000067780047,0.00014159692,0.000020552878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000064659116,0.000036333895,0.97998196,0.00006554015,0.0007326869,0.00003167265,0.00023627412,0.000017622817,0.00016439876,0.000028118098,0.00060979935,0.01808911],"study_design_scores_gemma":[0.0024896332,0.002494041,0.9609555,0.000555468,0.000567905,0.000004557036,0.00016873429,0.00010319368,0.0038267758,0.000097998505,0.028548177,0.00018801898],"about_ca_topic_score_codex":0.0005348946,"about_ca_topic_score_gemma":0.015027184,"teacher_disagreement_score":0.027938379,"about_ca_system_score_codex":0.00023558877,"about_ca_system_score_gemma":0.0004088909,"threshold_uncertainty_score":0.8385522},"labels":[],"label_agreement":null},{"id":"W2797320481","doi":"10.14740/jocmr3419w","title":"Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Urology; Bioelectrical impedance analysis; Type 2 Diabetes Mellitus; Diabetes mellitus; Creatinine; Type 2 diabetes; Internal medicine; Glycemic; Body mass index; Endocrinology; Gastroenterology","score_opus":0.11150351843836746,"score_gpt":0.4691259284646911,"score_spread":0.3576224100263236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797320481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952612,0.0003998143,0.000005700843,0.0027508184,0.00016852518,0.00074083655,0.0000010716951,0.0000033116082,0.00066871254],"genre_scores_gemma":[0.99803686,0.0008893015,0.000118054115,0.00020255195,0.00062320894,0.0000063968623,0.0000035144037,0.000013549606,0.00010657428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728316,0.000490861,0.0008958819,0.00018114732,0.0008510027,0.00029796464],"domain_scores_gemma":[0.99720275,0.0007307389,0.0003578866,0.00020968364,0.0011500223,0.0003489087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044844435,0.0001222279,0.00087847386,0.0005873292,0.000030618645,0.000005481533,0.00009657307,0.00010347793,0.00021150919],"category_scores_gemma":[0.003926399,0.00005848912,0.00009496212,0.00047106936,0.0006223877,0.000060200935,0.000028649902,0.00063109363,0.0000048029565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026824435,0.0016632488,0.86820227,0.00003599542,0.0007571572,0.000030511736,0.000090982234,0.000001268607,0.0005974304,0.000013754873,0.0034164216,0.09836653],"study_design_scores_gemma":[0.03047082,0.14601041,0.82119906,0.0007485467,0.00007164595,0.000001772527,0.000014358977,0.000053789914,0.00024758372,0.00013904189,0.0010001512,0.00004282502],"about_ca_topic_score_codex":0.00005204875,"about_ca_topic_score_gemma":0.0000039159654,"teacher_disagreement_score":0.14434716,"about_ca_system_score_codex":0.00007906745,"about_ca_system_score_gemma":0.00027261607,"threshold_uncertainty_score":0.470055},"labels":[],"label_agreement":null},{"id":"W2797619061","doi":"","title":"Sulfonylurea treatment in type 2 diabetes.","year":2018,"lang":"fr","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Medical Association; University of Alberta","funders":"","keywords":"Sulfonylurea; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Harm; Intensive care medicine; Endocrinology","score_opus":0.025464796779132284,"score_gpt":0.24091944150417813,"score_spread":0.21545464472504583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797619061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7329349,0.04519686,0.0000028190846,0.008372349,0.009751439,0.003847691,0.00001944435,0.00011947571,0.19975504],"genre_scores_gemma":[0.81977373,0.0019702937,0.000092769194,0.0007235452,0.0019673216,0.0017556027,0.00005339319,0.00004282753,0.17362049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976595,0.00006973208,0.00031669272,0.00043211278,0.00020857021,0.0013134127],"domain_scores_gemma":[0.9989974,0.00006883399,0.00006772397,0.0004663247,0.00007050306,0.0003292206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031574527,0.0003182976,0.0004738633,0.00024398383,0.00004915528,0.000044376287,0.000113148846,0.00014501957,0.00077316904],"category_scores_gemma":[0.0000864664,0.00027754586,0.00010919854,0.00057226705,0.00023943918,0.00014049019,0.000071641196,0.00008956881,0.0019129481],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007762209,0.0012211753,0.13241428,0.00008961543,0.0004988245,0.00010021944,0.00023977213,0.0000010657576,0.0000071306536,0.0009701261,0.013684789,0.8506954],"study_design_scores_gemma":[0.0026590838,0.00072415546,0.46344185,0.00007596503,0.00044786348,8.5944646e-7,0.000043175223,0.00007149598,0.0012265436,0.00016637024,0.53096384,0.00017882398],"about_ca_topic_score_codex":0.00018747298,"about_ca_topic_score_gemma":0.00032066283,"teacher_disagreement_score":0.85051656,"about_ca_system_score_codex":0.001053082,"about_ca_system_score_gemma":0.00006792243,"threshold_uncertainty_score":0.9999677},"labels":[],"label_agreement":null},{"id":"W2797859454","doi":"10.1016/j.jcjd.2017.10.026","title":"Treatment of Diabetes in People With Heart Failure","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Dyslipidemia; Diabetes mellitus; Cardiology; Internal medicine; Type 2 diabetes; Peripheral edema; Depression (economics); Disease; Endothelial dysfunction; Obesity; Anemia; Pulmonary edema; Lung","score_opus":0.007837827551225657,"score_gpt":0.21320454544027506,"score_spread":0.2053667178890494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797859454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523044,0.0008315312,6.7488065e-7,0.0023600708,0.0001237556,0.00025786748,0.000011101649,0.0000053723793,0.0011791772],"genre_scores_gemma":[0.99844027,0.000006771783,0.0008217465,0.00021425413,0.00018379734,0.000010189749,0.000007960398,0.000022749538,0.0002922564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887043,0.000028740911,0.0003366042,0.0001357785,0.00016980228,0.00045865998],"domain_scores_gemma":[0.9988869,0.00005203237,0.00015626493,0.00020984192,0.00020218629,0.0004928007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010960377,0.00017912364,0.00057537126,0.00056622125,0.000043428874,0.000021461194,0.00008957938,0.000054544787,0.00019736073],"category_scores_gemma":[0.000035163277,0.00012513819,0.000121912046,0.0003530407,0.00016583125,0.00012330606,0.0000056137146,0.00006766548,0.0000140458105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000077607065,0.00013991227,0.99436015,0.00004604876,0.00026254676,0.000011975839,0.0003515409,0.0000032237197,0.00050810527,0.000048259553,0.0021768746,0.0020836133],"study_design_scores_gemma":[0.003674044,0.009001896,0.94282717,0.00042209387,0.00037170268,0.0000031268971,0.00034119483,0.000039174956,0.011613705,0.00006455885,0.031479053,0.00016229521],"about_ca_topic_score_codex":0.000590871,"about_ca_topic_score_gemma":0.045730643,"teacher_disagreement_score":0.051532984,"about_ca_system_score_codex":0.0002781462,"about_ca_system_score_gemma":0.00056549825,"threshold_uncertainty_score":0.9716823},"labels":[],"label_agreement":null},{"id":"W2798096448","doi":"","title":"Signaling pathways of the endogenous glucagon-like peptide-2 (GLP-2) receptor","year":2001,"lang":"en","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Endogeny; Receptor; Chemistry; Signal transduction; Cell biology; Endocrinology; Biology; Biochemistry; Type 2 diabetes; Diabetes mellitus; Agonist","score_opus":0.022449804259982286,"score_gpt":0.225940112335454,"score_spread":0.20349030807547172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798096448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6723343,0.0017027636,0.000011762141,0.00012665037,0.0005069624,0.0006895445,0.000025573883,0.00004482348,0.3245576],"genre_scores_gemma":[0.8257065,0.0013750534,0.00066951115,0.000025269828,0.00005341888,0.0000010962211,0.00039269277,0.000030943447,0.17174552],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9988738,0.00004145697,0.00014849854,0.00028649153,0.00040430075,0.0002454985],"domain_scores_gemma":[0.998806,0.000033352662,0.0004224272,0.00048088108,0.00016731762,0.000090046975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010165204,0.00024294802,0.00053667073,0.000059118498,0.00013603066,0.000005460931,0.00030322693,0.00019205424,0.009179587],"category_scores_gemma":[0.000013591515,0.00022877955,0.0003970832,0.00009332297,0.00006842156,0.00012133106,0.000075738135,0.00013013593,0.000027815964],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005826191,0.004836104,0.013671114,0.008514719,0.009447466,0.00044208675,0.18453003,0.00007658892,0.26289126,0.0029357541,0.035655245,0.47117344],"study_design_scores_gemma":[0.016272984,0.004505188,0.32108626,0.0068495683,0.015612663,0.000022055612,0.4601624,0.0001376887,0.06181832,0.00014079419,0.1110999,0.0022921802],"about_ca_topic_score_codex":0.024669826,"about_ca_topic_score_gemma":0.014239747,"teacher_disagreement_score":0.46888125,"about_ca_system_score_codex":0.00036859274,"about_ca_system_score_gemma":0.0001504148,"threshold_uncertainty_score":0.99172616},"labels":[],"label_agreement":null},{"id":"W2799590338","doi":"10.1186/s13098-018-0331-8","title":"Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial","year":2018,"lang":"en","type":"article","venue":"Diabetology & Metabolic Syndrome","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Institut de Recherches Servier; Servier","keywords":"Medicine; Gliclazide; Diabetes mellitus; Hypoglycemia; Body mass index; Type 2 diabetes; Internal medicine; Observational study; Regimen; Post-hoc analysis; Dosing; Endocrinology","score_opus":0.03090361195092886,"score_gpt":0.32281119450277035,"score_spread":0.29190758255184146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799590338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902342,0.0048666596,0.00001067081,0.000262514,0.00062951096,0.0017187583,0.000021939528,0.000026100459,0.0022296454],"genre_scores_gemma":[0.99866873,0.00027526246,0.0002470216,0.0002866241,0.00009531011,0.00023673427,0.00007547582,0.000024132285,0.00009068629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974495,0.0007386699,0.00057359244,0.00040517095,0.0003822101,0.0004508327],"domain_scores_gemma":[0.9978049,0.00080639945,0.00024606992,0.0009807587,0.00010739082,0.000054475433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013513648,0.0002774489,0.0013283676,0.0002178223,0.00006011772,0.000012002521,0.000502717,0.00011772866,0.00016527456],"category_scores_gemma":[0.00009890091,0.00015615462,0.0002553639,0.0009945732,0.000514451,0.000069558904,0.0001572275,0.00015154325,0.00006867666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016378123,0.007442679,0.8401841,0.0018760964,0.039354056,0.00073496334,0.003477469,0.000036247344,0.023537993,0.024230931,0.0016900476,0.041057304],"study_design_scores_gemma":[0.018458823,0.0013190445,0.965781,0.00030951618,0.00341529,0.0000031787872,0.0003241406,0.000033773413,0.006311539,0.0011978581,0.002692859,0.00015298472],"about_ca_topic_score_codex":0.00019982655,"about_ca_topic_score_gemma":0.000018551716,"teacher_disagreement_score":0.12559691,"about_ca_system_score_codex":0.00002699351,"about_ca_system_score_gemma":0.00003780326,"threshold_uncertainty_score":0.6367801},"labels":[],"label_agreement":null},{"id":"W2799682709","doi":"10.1016/j.domaniend.2018.04.003","title":"Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus","year":2018,"lang":"en","type":"article","venue":"Domestic Animal Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Saskatchewan","funders":"","keywords":"Exenatide; Medicine; Insulin glargine; Internal medicine; Insulin; Endocrinology; Placebo; Diabetes mellitus; Weight loss; Incretin; Glucagon; Type 2 Diabetes Mellitus; CATS; Type 2 diabetes; Hypoglycemia; Obesity","score_opus":0.018730890911604542,"score_gpt":0.3243188167607632,"score_spread":0.3055879258491586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799682709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936953,0.0018230851,0.00088186807,0.0009269874,0.00010389795,0.0012913247,0.00004626305,0.000038625283,0.0011926142],"genre_scores_gemma":[0.9923076,0.0010050529,0.006085222,0.000052627453,0.00007948541,0.00007663414,0.00013692313,0.000018797968,0.00023766978],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987556,0.00003769182,0.0004443274,0.0002911354,0.00012903244,0.0003422462],"domain_scores_gemma":[0.9989791,0.0003349863,0.00018399961,0.00022924591,0.0001910031,0.00008164916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084561165,0.00019972249,0.0007012134,0.00020032475,0.000045565535,0.0000045292654,0.000056222245,0.000054966058,0.000059355683],"category_scores_gemma":[0.000106087864,0.00015823149,0.00009750164,0.00013968235,0.0003303114,0.000033021348,0.000049063085,0.000028691295,0.000003976911],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007870677,0.01902636,0.15403163,0.0016241272,0.0049136174,0.00009798407,0.0008760019,0.000011406645,0.062070794,0.16347028,0.00028117083,0.58572596],"study_design_scores_gemma":[0.038076416,0.06157971,0.85198075,0.00012565208,0.0020901177,0.000022893772,0.00009573095,0.0038017882,0.024865733,0.0006642047,0.0164418,0.00025520573],"about_ca_topic_score_codex":0.000025008627,"about_ca_topic_score_gemma":0.00000414397,"teacher_disagreement_score":0.6979491,"about_ca_system_score_codex":0.00009061737,"about_ca_system_score_gemma":0.00005229144,"threshold_uncertainty_score":0.6452493},"labels":[],"label_agreement":null},{"id":"W2800126263","doi":"10.1161/circulationaha.117.033238","title":"Response by Lytvyn et al to Letter Regarding Article, “Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials”","year":2018,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto; Health Sciences Centre; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Clinical trial; Internal medicine; Family medicine; Gerontology","score_opus":0.051130846231079066,"score_gpt":0.36406261693751424,"score_spread":0.3129317707064352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800126263","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27242637,0.00012632586,0.015594048,0.7085702,0.00035896507,0.002738195,0.00007941391,0.000060451384,0.00004604331],"genre_scores_gemma":[0.31344765,0.00009888206,0.003996122,0.6779101,0.0011695062,0.00029111476,0.0028448359,0.000072028386,0.00016977235],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948463,0.0015099503,0.0021038358,0.0007554368,0.00049170404,0.00029277842],"domain_scores_gemma":[0.9980272,0.0006718446,0.00053505815,0.00050205126,0.00012997905,0.00013386266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008027489,0.00028270765,0.0011859385,0.00032427834,0.000044526096,0.00004266693,0.000058621725,0.0006407434,0.00004563385],"category_scores_gemma":[0.0004193785,0.00027178566,0.0003581128,0.00021624494,0.00011126298,0.00014797992,0.000050323135,0.00066736585,0.00004058966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014841747,0.00027912183,0.009001459,0.00009846632,0.00017515801,0.000058050333,0.000020775491,0.000002714759,0.008849552,0.000033743956,0.97671515,0.0032816406],"study_design_scores_gemma":[0.005527296,0.00044136343,0.054090444,0.0004227326,0.0005955079,0.000008526727,0.000012851453,0.00016304564,0.001246609,0.00033409277,0.9368779,0.00027960952],"about_ca_topic_score_codex":0.00001859786,"about_ca_topic_score_gemma":0.000008694053,"teacher_disagreement_score":0.045088984,"about_ca_system_score_codex":0.000083550236,"about_ca_system_score_gemma":0.00008508917,"threshold_uncertainty_score":0.9999734},"labels":[],"label_agreement":null},{"id":"W2800283810","doi":"10.1016/s2213-8587(18)30052-4","title":"Precision medicine in the management of type 2 diabetes","year":2018,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Wellcome Trust","keywords":"Medicine; Type 2 diabetes; MEDLINE; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.06677750395896741,"score_gpt":0.3539323562698343,"score_spread":0.2871548523108669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800283810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030227469,0.97236294,5.6859926e-7,0.001728769,0.00066632184,0.0024471832,0.000013685756,0.000064528314,0.019693257],"genre_scores_gemma":[0.0011070978,0.9953525,0.00016160106,0.0008842972,0.0007699946,0.00048945687,0.00020660112,0.000058001988,0.0009704144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626553,0.00046107196,0.0008766406,0.0005505956,0.00042854663,0.0014175932],"domain_scores_gemma":[0.99692434,0.00073249073,0.0004372266,0.0017793128,0.00007358128,0.000053062427],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012249893,0.00055978016,0.002980343,0.00034385835,0.00007085183,0.000015160622,0.0011890582,0.00016137704,0.00021523739],"category_scores_gemma":[0.00007368938,0.00025264287,0.00031358123,0.00085601374,0.0005830916,0.000039102,0.00044776473,0.00048200553,0.00024189721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026879648,0.00023263862,0.001130529,0.016544849,0.002457944,0.00006580243,0.00013738,2.3352983e-7,0.000001227847,0.0039948914,0.028158335,0.9472493],"study_design_scores_gemma":[0.0012557334,0.00093921367,0.0012613296,0.013181922,0.005027286,0.000005921689,0.00007274782,0.000004939483,0.000008462194,0.0008872648,0.9771479,0.00020728513],"about_ca_topic_score_codex":0.000007871946,"about_ca_topic_score_gemma":0.000004549363,"teacher_disagreement_score":0.94898957,"about_ca_system_score_codex":0.000096554126,"about_ca_system_score_gemma":0.00003675663,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W2800723402","doi":"10.1016/j.kint.2017.12.027","title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","year":2018,"lang":"en","type":"review","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cotransporter; Medicine; Sodium; Pharmacology; Endocrinology; Internal medicine; Chemistry","score_opus":0.01694389127939786,"score_gpt":0.30013745291288163,"score_spread":0.28319356163348375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800723402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005756939,0.972754,0.00006807214,0.00020971935,0.0027195313,0.0021792427,0.00016719555,0.00007614457,0.02176854],"genre_scores_gemma":[0.00013416515,0.9908071,0.000531859,0.00018700949,0.0008219345,0.00029970866,0.0013605721,0.00005382323,0.0058038183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984346,0.000036540852,0.0005220548,0.0003761738,0.00044255523,0.0001880765],"domain_scores_gemma":[0.99889636,0.0000696638,0.00037186485,0.00030680175,0.0001620445,0.00019326086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011232043,0.00033783776,0.00104035,0.00037494148,0.00002273222,0.000014866969,0.0002174603,0.00018826565,0.00034535243],"category_scores_gemma":[0.00018089668,0.00026065097,0.0005776263,0.00015468411,0.00010254863,0.00006265745,0.00006987254,0.00018725499,0.00023700659],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054750122,0.0008065219,0.000071019545,0.037362557,0.00634233,0.00015223034,0.000120895245,1.01045075e-8,0.000018125305,0.00064720074,0.06127236,0.893152],"study_design_scores_gemma":[0.0010753627,0.00037792974,0.00003652254,0.027079022,0.0027108393,0.000009660531,0.0000026240857,0.0000016002225,0.0007748332,0.000070637085,0.96768254,0.0001784542],"about_ca_topic_score_codex":0.000016406388,"about_ca_topic_score_gemma":0.0000011362375,"teacher_disagreement_score":0.90641016,"about_ca_system_score_codex":0.00023509319,"about_ca_system_score_gemma":0.0002569707,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W2800843957","doi":"10.1038/s41467-018-03941-2","title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"FP7 Health; Precursory Research for Embryonic Science and Technology; Biotechnology and Biological Sciences Research Council; Medical Research Council; Japan Society for the Promotion of Science; Academy of Medical Sciences; East China Institute of Technology; Université de Genève; Rosetrees Trust; Royal Society; Diabetes Research and Wellness Foundation; National Institute for Health and Care Research; Diabetes UK; University of Alberta; Wellcome Trust; Japan Agency for Medical Research and Development","keywords":"Agonist; Endocytosis; Internalization; Endocytic cycle; Glucagon-like peptide 1 receptor; Receptor; G protein-coupled receptor; Pharmacology; Incretin; Chemistry; Cell biology; Type 2 diabetes; Endocrinology; Medicine; Biology; Diabetes mellitus; Biochemistry","score_opus":0.017915648530523073,"score_gpt":0.31591461310984564,"score_spread":0.29799896457932257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800843957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54290223,0.013064822,0.0007632705,0.15097141,0.0043870695,0.006232394,0.00009100299,0.0017380831,0.27984974],"genre_scores_gemma":[0.9600428,0.00013498779,0.034531686,0.0024726358,0.00045054045,0.00007472304,0.00024070244,0.000025991892,0.0020259563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991833,0.00003972162,0.00018567851,0.00021074593,0.00015102673,0.00022952956],"domain_scores_gemma":[0.9980914,0.00011520309,0.000059362286,0.0014242457,0.00018095842,0.00012882592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018425735,0.00012808104,0.00016752373,0.00010642315,0.00035469307,0.00004559189,0.00046989374,0.0001282352,0.00009657325],"category_scores_gemma":[0.00028794794,0.000112915586,0.00007266586,0.00034078496,0.00010398316,0.000057578058,0.00032469156,0.0004024932,0.00048438663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021344685,0.0025039155,0.0060463795,0.00007777185,0.00077157415,0.000004764035,0.0034531686,0.0000063716493,0.07531015,0.028800283,0.64674467,0.2360675],"study_design_scores_gemma":[0.00080944115,0.00029527422,0.0055728266,0.000073922536,0.00013844963,6.764567e-7,0.00016922386,0.00017939239,0.0027851001,0.000013016625,0.98982203,0.000140653],"about_ca_topic_score_codex":0.0000081353355,"about_ca_topic_score_gemma":0.00003978788,"teacher_disagreement_score":0.41714057,"about_ca_system_score_codex":0.00010647319,"about_ca_system_score_gemma":0.000036992034,"threshold_uncertainty_score":0.62259716},"labels":[],"label_agreement":null},{"id":"W2800927426","doi":"10.7326/acpjc-2018-168-10-052","title":"In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization","year":2018,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Kidney disease; Disease; Internal medicine; EMPA; Type 2 Diabetes Mellitus; Benzhydryl compounds; Intensive care medicine; Endocrinology","score_opus":0.03503530630174901,"score_gpt":0.322942579953373,"score_spread":0.287907273651624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800927426","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62829196,0.0028166224,0.0000036641625,0.36675537,0.00030304224,0.00045564584,0.00002365546,0.000017304827,0.0013327341],"genre_scores_gemma":[0.3176199,0.0028359543,0.000075084536,0.6716749,0.0026623826,0.00004090644,0.0006522141,0.00006867609,0.004369978],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99847364,0.00004324224,0.00039581044,0.00039783103,0.0004093492,0.00028012926],"domain_scores_gemma":[0.9989254,0.00005472619,0.00023434925,0.00031100842,0.00023938344,0.00023516326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020824427,0.0003052774,0.0007026201,0.00032593208,0.000016198514,0.000012252564,0.00008925061,0.0001437929,0.00019626052],"category_scores_gemma":[0.0003266272,0.00020191747,0.00003799388,0.0001749845,0.0004120074,0.00010436648,0.000070375165,0.0002712977,0.000003517388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021331068,0.00006929306,0.18060209,0.0011351126,0.0006376067,0.000312551,0.00014509787,4.407265e-8,0.00006515638,0.00001898213,0.8162874,0.0005133641],"study_design_scores_gemma":[0.0049269544,0.008704001,0.5038694,0.01868563,0.0022017402,0.000010458741,0.000066182874,0.00010786579,0.0014271814,0.000800352,0.45862174,0.0005784833],"about_ca_topic_score_codex":0.00021877562,"about_ca_topic_score_gemma":0.000009826576,"teacher_disagreement_score":0.35766566,"about_ca_system_score_codex":0.00002037508,"about_ca_system_score_gemma":0.00005278004,"threshold_uncertainty_score":0.82339555},"labels":[],"label_agreement":null},{"id":"W2801057607","doi":"10.1007/s11695-018-3249-1","title":"Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery","year":2018,"lang":"en","type":"article","venue":"Obesity Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Calgary; University of Alberta","funders":"","keywords":"Liraglutide; Medicine; Weight loss; Gastric emptying; Gold standard (test); Context (archaeology); Surgery; Glucagon-like peptide-1; Obesity; Candidacy; General surgery; Type 2 diabetes; Diabetes mellitus; Internal medicine; Stomach; Endocrinology","score_opus":0.022124599582319212,"score_gpt":0.25514942270043856,"score_spread":0.23302482311811934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801057607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98790866,0.000046594992,0.00036347273,0.0065653226,0.00034170906,0.00074208196,0.000006955432,0.00022788985,0.0037973332],"genre_scores_gemma":[0.9869535,0.000015094398,0.0048535136,0.0050007896,0.0006916743,0.00018355993,0.0000943452,0.000036594127,0.0021709371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984913,0.00007315985,0.00031560808,0.00041476352,0.0002503034,0.00045486933],"domain_scores_gemma":[0.99731743,0.0014818158,0.00009282318,0.00056665484,0.00014979714,0.00039149445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004485727,0.0002222804,0.0004189832,0.00058808515,0.00022144352,0.000044771215,0.000074805415,0.000043858414,0.00013386189],"category_scores_gemma":[0.0014321526,0.00020158105,0.0002321652,0.00071451755,0.000068590045,0.000101198,0.00007134693,0.00010198453,0.0017965412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045874935,0.000361663,0.8530183,0.00009616211,0.00005965768,0.000028899085,0.000027758713,5.5573133e-7,0.0005568313,0.00050210324,0.1273571,0.017945107],"study_design_scores_gemma":[0.00019477407,0.00021369362,0.98251075,0.00046105674,0.00016755116,0.000021602571,0.000007714715,0.000011640399,0.003735892,0.00026496022,0.012231123,0.00017924543],"about_ca_topic_score_codex":0.000040934683,"about_ca_topic_score_gemma":0.000012216128,"teacher_disagreement_score":0.12949246,"about_ca_system_score_codex":0.0001542596,"about_ca_system_score_gemma":0.00018707942,"threshold_uncertainty_score":0.9989807},"labels":[],"label_agreement":null},{"id":"W2801318333","doi":"10.1111/dom.13337","title":"A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; Credit Valley Hospital; Health Sciences Centre; McGill University; University of Toronto; Jewish General Hospital; McGill University Health Centre; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Sanofi; Merck; Boehringer Ingelheim; AstraZeneca","keywords":"Basal insulin; Type 2 diabetes; Basal (medicine); Insulin; Diabetes mellitus; Medicine; Intensive care medicine; Computer science; Process (computing); Risk analysis (engineering); Algorithm; Endocrinology","score_opus":0.049416641570814795,"score_gpt":0.32308235014969566,"score_spread":0.27366570857888084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801318333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052467,0.99090743,0.00008678798,0.000092041766,0.00045140152,0.0025986175,0.000077865116,0.00006245701,0.00047672732],"genre_scores_gemma":[0.00008282547,0.9618256,0.035586912,0.0005058444,0.0005413026,0.00042119887,0.00058530417,0.00008522612,0.0003657481],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740607,0.00014916545,0.0005919756,0.00087726186,0.0002330679,0.0007424376],"domain_scores_gemma":[0.99855,0.00037873414,0.00023856183,0.00038408214,0.00015819601,0.00029043926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000843279,0.00064501906,0.002786046,0.0005014396,0.000118340715,0.00011415456,0.00011159016,0.00045222227,0.000012415515],"category_scores_gemma":[0.00039492932,0.00050376425,0.00028841832,0.00042377505,0.00024641215,0.00021174234,0.00028254432,0.00043112203,0.000017430219],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009288315,0.0005097139,0.00051382784,0.012472906,0.0008262653,0.000008103135,0.00007918811,8.789524e-9,7.1096207e-7,0.00045568057,0.0016583825,0.9834659],"study_design_scores_gemma":[0.0018396294,0.0002858894,0.0012565933,0.0031654346,0.0060951044,0.0000037761306,0.00003838074,0.00082938006,0.000011514946,0.00040759557,0.9855189,0.000547846],"about_ca_topic_score_codex":0.000006575677,"about_ca_topic_score_gemma":0.0000020505386,"teacher_disagreement_score":0.9838605,"about_ca_system_score_codex":0.000054537693,"about_ca_system_score_gemma":0.00013285443,"threshold_uncertainty_score":0.9997414},"labels":[],"label_agreement":null},{"id":"W2801426064","doi":"10.1097/mol.0000000000000521","title":"Unexplained reciprocal regulation of diabetes and lipoproteins","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Lipidology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Diabetes mellitus; Dyslipidemia; Type 2 diabetes; Medicine; Internal medicine; Endocrinology; Cholesterol; Insulin resistance; Very low-density lipoprotein; Disease; Incretin; Bioinformatics; Lipoprotein; Biology","score_opus":0.10734097100212939,"score_gpt":0.38662847895476593,"score_spread":0.27928750795263657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801426064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000782141,0.98219436,0.000018587061,0.00006254666,0.015791079,0.0015505757,0.000013871435,0.00003213697,0.0002586176],"genre_scores_gemma":[0.000020003527,0.99330705,0.00025870718,0.000006824979,0.0052304487,0.00030239046,0.0007025281,0.000031243482,0.00014077568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822676,0.0001685782,0.000719779,0.0004547475,0.00014632675,0.00028378068],"domain_scores_gemma":[0.99897796,0.00015591283,0.0003759591,0.0003551439,0.00005685664,0.00007819607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032256005,0.00031501308,0.0015720158,0.0005245549,0.000023258963,0.000007015221,0.00009537477,0.00027511816,0.000071107854],"category_scores_gemma":[0.00014620618,0.00024860923,0.00018751479,0.00030554523,0.00020603705,0.0000504678,0.00014307332,0.0002108706,0.000034386474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014050686,0.00023311189,0.0007450058,0.044306956,0.00013803187,2.4520363e-8,0.000042298423,5.1044644e-8,6.135477e-7,0.001153852,0.013468769,0.93989724],"study_design_scores_gemma":[0.00082602375,0.00060635025,0.00070787285,0.02597709,0.00037768387,0.0000020144507,0.000004998072,0.000016147962,0.0000010265134,0.00023596724,0.9710766,0.00016821262],"about_ca_topic_score_codex":0.00000196591,"about_ca_topic_score_gemma":0.0000010619019,"teacher_disagreement_score":0.95760787,"about_ca_system_score_codex":0.000089649046,"about_ca_system_score_gemma":0.00008638002,"threshold_uncertainty_score":0.9999966},"labels":[],"label_agreement":null},{"id":"W2802498945","doi":"10.1111/dom.13346","title":"Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Foundation; Medical Research Council; National Institute for Health and Care Research; Medical Research Council Canada; Wellcome Trust","keywords":"Medicine; Metformin; Medical prescription; Diabetes mellitus; Drug; Type 2 diabetes; Drug class; Clinical trial; Pharmacology; Internal medicine; Endocrinology","score_opus":0.008734570265024708,"score_gpt":0.22983335037809052,"score_spread":0.22109878011306583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802498945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975075,0.0011077836,0.000008760027,0.00043457857,0.00009400351,0.00046963847,0.000066279885,0.00001938158,0.00029207524],"genre_scores_gemma":[0.9979342,0.000082945066,0.0011961864,0.0002785308,0.00015112592,0.00007216239,0.00008565542,0.0000123444715,0.00018681481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989395,0.000044129793,0.00024848583,0.00033007975,0.00012708656,0.00031071244],"domain_scores_gemma":[0.99946433,0.00014305602,0.00006145054,0.00017690947,0.000036433466,0.00011783928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039086267,0.00015954372,0.00050103804,0.00048420712,0.000042821826,0.000024532703,0.000058493057,0.00009221188,0.000016221735],"category_scores_gemma":[0.00006332738,0.0001413437,0.000052733045,0.00027523568,0.00009636723,0.0001376237,0.000080729274,0.00006647319,0.000004007301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010597071,0.0004719559,0.9368724,0.00012400979,0.00020038223,0.0000010937357,0.0027969552,0.0000012148992,0.013320456,0.00040854965,0.00021922574,0.04547775],"study_design_scores_gemma":[0.003824889,0.00021816186,0.9777307,0.00013741874,0.00026995683,3.1677306e-8,0.000018071487,0.0010233726,0.004703825,0.0005808762,0.01135694,0.00013574903],"about_ca_topic_score_codex":0.00013085583,"about_ca_topic_score_gemma":0.00009417523,"teacher_disagreement_score":0.045342002,"about_ca_system_score_codex":0.000011235896,"about_ca_system_score_gemma":0.000008626258,"threshold_uncertainty_score":0.5763829},"labels":[],"label_agreement":null},{"id":"W2802681724","doi":"10.1016/j.jcjd.2018.04.004","title":"Safe Use of Metformin in Adults With Type 2 Diabetes and Chronic Kidney Disease: Lower Dosages and Sick-Day Education Are Essential","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; Toronto General Hospital","funders":"","keywords":"Medicine; Metformin; Dose; Type 2 diabetes; Diabetes mellitus; Kidney disease; Disease; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.012353452377959932,"score_gpt":0.2532200840199862,"score_spread":0.24086663164202626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802681724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13800533,0.8606831,1.4184201e-7,0.00013315414,0.00038441678,0.0006249572,0.00008863047,0.0000034756044,0.000076807744],"genre_scores_gemma":[0.0312962,0.9668868,0.00023996877,0.00016962481,0.00056845555,0.000035481928,0.00018880327,0.00007880393,0.0005358177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843234,0.00008784341,0.0005841503,0.00027671814,0.00019716454,0.00042176223],"domain_scores_gemma":[0.9974362,0.00013075663,0.00066557626,0.00033578725,0.0002468301,0.0011848412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002490388,0.00037549037,0.0013771409,0.00087477,0.0000476037,0.00006832032,0.0001508546,0.0001292376,0.00008539563],"category_scores_gemma":[0.00044670072,0.00026747317,0.00015279293,0.00034252545,0.0002752555,0.0002635445,0.000036139805,0.0002209353,0.000003207615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029170824,0.00024118958,0.116836384,0.040253524,0.0017309214,0.00009698633,0.00017594862,5.836092e-7,0.0000017806466,0.000052308897,0.011880036,0.82870114],"study_design_scores_gemma":[0.0015736339,0.0013943287,0.019468049,0.12810273,0.00534739,0.000004888746,0.00005568617,0.000008762446,0.000014028286,0.000040877305,0.84354657,0.0004430264],"about_ca_topic_score_codex":0.000099069046,"about_ca_topic_score_gemma":0.0018311052,"teacher_disagreement_score":0.8316665,"about_ca_system_score_codex":0.00028839544,"about_ca_system_score_gemma":0.0038354176,"threshold_uncertainty_score":0.99997777},"labels":[],"label_agreement":null},{"id":"W2802967288","doi":"10.1007/s00125-018-4630-2","title":"Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®","year":2018,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Type 2 diabetes; Diabetes mellitus; Population; EMPA; Placebo; Clinical endpoint; Clinical trial; Endocrinology","score_opus":0.015663728292194364,"score_gpt":0.2602037235414586,"score_spread":0.24453999524926423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802967288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980169,0.0009929405,0.000006480102,0.00006267696,0.000039138056,0.0003171225,0.000011027071,0.000045668177,0.0005080253],"genre_scores_gemma":[0.9992128,0.000049345905,0.0002219921,0.0002450077,0.00002732054,0.000051358566,0.00005362534,0.000016451562,0.00012208524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986967,0.00006198841,0.00023995187,0.0003882788,0.00023617184,0.00037689472],"domain_scores_gemma":[0.9989526,0.00003396889,0.00005840097,0.00063640415,0.00009388737,0.00022473153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003273955,0.00018495442,0.0008333145,0.0004854422,0.000029943145,0.0000144197065,0.00008938123,0.000053352018,0.00011573888],"category_scores_gemma":[0.00006944556,0.00013176925,0.00010666093,0.0009810244,0.00022591985,0.00009871125,0.00006021117,0.000061419436,0.00000889183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019902263,0.00026498243,0.98388743,0.00007368239,0.0058133057,0.000033302807,0.0003502859,0.000049044353,0.000058544425,0.000045690886,0.000036970192,0.009187727],"study_design_scores_gemma":[0.0012222516,0.0010766285,0.99103314,0.00003223023,0.0047014616,9.483179e-8,0.00032915294,0.00071016315,0.00024203416,0.00003254356,0.00047055553,0.00014976008],"about_ca_topic_score_codex":0.00003202853,"about_ca_topic_score_gemma":0.00003362678,"teacher_disagreement_score":0.009037968,"about_ca_system_score_codex":0.00005931573,"about_ca_system_score_gemma":0.000027616215,"threshold_uncertainty_score":0.5373394},"labels":[],"label_agreement":null},{"id":"W2803026933","doi":"10.1161/circulationaha.117.032985","title":"Letter by Grocott Regarding Article, “Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials”","year":2018,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Manitoba","funders":"","keywords":"Medicine; Perioperative; Diabetic ketoacidosis; Clinical trial; Empagliflozin; Anesthesiology; Intensive care medicine; Ketoacidosis; Cotransporter; Diabetes mellitus; Internal medicine; Endocrinology; Surgery; Anesthesia; Type 2 diabetes; Sodium; Type 1 diabetes","score_opus":0.04717362657083893,"score_gpt":0.3389030121596277,"score_spread":0.2917293855887888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803026933","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35142735,0.0012305344,0.048131347,0.58723736,0.0015173529,0.009534023,0.0001944505,0.00023503492,0.0004925213],"genre_scores_gemma":[0.7602417,0.00043434845,0.004440921,0.21703474,0.008378986,0.00046808427,0.008581549,0.00012247666,0.0002971893],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99568874,0.00061452825,0.0022786902,0.0006934164,0.000440088,0.00028456468],"domain_scores_gemma":[0.99829096,0.00032197745,0.0007257457,0.00044340896,0.00012045122,0.000097475044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033466949,0.00028275303,0.0013051227,0.0002378432,0.00004892177,0.000035982444,0.000054051226,0.0009172581,0.000060929437],"category_scores_gemma":[0.00014310326,0.00026661548,0.00042214213,0.00017607663,0.00015916699,0.00016135786,0.000037696074,0.0007275491,0.000030327059],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020391044,0.00037248287,0.02728075,0.0004514436,0.00029668133,0.000054370692,0.000012517983,0.0000011875372,0.0027337484,0.00007643632,0.95972586,0.008790595],"study_design_scores_gemma":[0.010805815,0.00042980077,0.08287731,0.0007906398,0.0023293952,0.000015842732,0.000018358149,0.00051676884,0.0019454675,0.0020242296,0.8977355,0.00051092263],"about_ca_topic_score_codex":0.000020094874,"about_ca_topic_score_gemma":0.0000072640564,"teacher_disagreement_score":0.40881434,"about_ca_system_score_codex":0.000065822554,"about_ca_system_score_gemma":0.000053472548,"threshold_uncertainty_score":0.9999786},"labels":[],"label_agreement":null},{"id":"W2803668751","doi":"10.2337/dci18-0015","title":"Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10","year":2018,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Observational study; Diabetes mellitus; Medical prescription; Propensity score matching; Cohort study; MEDLINE; Internal medicine; Intensive care medicine; Pharmacology; Endocrinology","score_opus":0.056243310354401166,"score_gpt":0.2999294099415197,"score_spread":0.2436860995871185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803668751","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.872047,0.0011857649,1.854167e-7,0.12038328,0.0006954536,0.0027597358,0.0017896468,0.00011954729,0.0010193953],"genre_scores_gemma":[0.2897538,0.0005135737,0.0025562665,0.6777437,0.0042375717,0.003073565,0.0122279255,0.00064981787,0.009243788],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995173,0.00044845627,0.0008166629,0.0011395268,0.0013251393,0.0010972207],"domain_scores_gemma":[0.9953649,0.001565791,0.0005313745,0.0013172543,0.0010026833,0.00021796962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005298418,0.0010117079,0.0017646265,0.0009332338,0.000141328,0.000055648274,0.00039632092,0.0005580657,0.00023719468],"category_scores_gemma":[0.00068938604,0.00070979784,0.00034197114,0.0006033466,0.0002380924,0.00011614187,0.0003204131,0.0007918513,0.00039924178],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001160989,0.00015981567,0.42155665,0.0012884722,0.0011159695,0.00013485296,0.002345161,0.000009077364,0.000018347717,0.0000018782539,0.57143927,0.0007695292],"study_design_scores_gemma":[0.003964328,0.011698962,0.11657347,0.006406662,0.0014945467,1.826426e-7,0.00363698,0.0000042188094,0.0016581796,0.000014150403,0.85371095,0.0008373847],"about_ca_topic_score_codex":0.000060664202,"about_ca_topic_score_gemma":0.00017087837,"teacher_disagreement_score":0.5822932,"about_ca_system_score_codex":0.0014451079,"about_ca_system_score_gemma":0.00028265416,"threshold_uncertainty_score":0.9995353},"labels":[],"label_agreement":null},{"id":"W2803712877","doi":"10.1016/j.diabres.2018.05.028","title":"The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents","year":2018,"lang":"en","type":"review","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Servier","keywords":"Gliclazide; Medicine; Hypoglycemia; Glipizide; Diabetes mellitus; Type 2 diabetes; Dipeptidyl peptidase-4; Pharmacology; Pharmacokinetics; Oral administration; Internal medicine; Drug; Sulfonylurea; Endocrinology","score_opus":0.1764242921680565,"score_gpt":0.5019427865216034,"score_spread":0.3255184943535469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803712877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059549753,0.9327986,2.6573497e-7,0.0009675738,0.00009956288,0.0017839118,0.0000112098,0.000015306021,0.004773793],"genre_scores_gemma":[0.01104897,0.98707396,0.00023211345,0.00034137483,0.0002301596,0.00011392236,0.00004918664,0.000055992954,0.00085430895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949729,0.0018866446,0.00089957775,0.000601106,0.00086320424,0.00077656953],"domain_scores_gemma":[0.9815699,0.01660891,0.00043527284,0.0007419251,0.00043428567,0.00020971269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00779487,0.0003541492,0.0014494241,0.00018476274,0.00023648058,0.000238859,0.00040413372,0.0002572979,0.00004155415],"category_scores_gemma":[0.0062526218,0.0001635907,0.00015012668,0.0007889253,0.000962067,0.0002189059,0.00032922605,0.0012916607,0.000043310287],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011869881,0.002368199,0.28162584,0.0073215663,0.0036705262,0.000051631556,0.0002627804,1.214962e-7,7.2932767e-7,0.0002599545,0.049789242,0.6534624],"study_design_scores_gemma":[0.0015014282,0.004055673,0.004807278,0.004307025,0.0015019996,0.0000035131504,0.0005129689,0.0001262372,6.496785e-7,0.000038027847,0.9829612,0.00018401712],"about_ca_topic_score_codex":0.000056188957,"about_ca_topic_score_gemma":0.00008895766,"teacher_disagreement_score":0.9331719,"about_ca_system_score_codex":0.000045651308,"about_ca_system_score_gemma":0.00024102468,"threshold_uncertainty_score":0.7485424},"labels":[],"label_agreement":null},{"id":"W2803721928","doi":"10.1111/dom.13351","title":"Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim Japan; Eli Lilly and Company","keywords":"Empagliflozin; Placebo; Medicine; Pharmacodynamics; Insulin; Internal medicine; Randomized controlled trial; Diabetes mellitus; Pharmacokinetics; Type 2 diabetes; Endocrinology","score_opus":0.03184946405653108,"score_gpt":0.3047898708028425,"score_spread":0.27294040674631137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803721928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763657,0.0017048466,0.0000024754238,0.00044687674,0.00044990354,0.0072899517,0.00002863928,0.000059608697,0.0023811492],"genre_scores_gemma":[0.9962322,0.00021578057,0.00030923996,0.0007141277,0.00039112696,0.0007881459,0.00008064182,0.00004046613,0.0012282737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662954,0.00032516776,0.001001628,0.00066710095,0.0005090928,0.000867465],"domain_scores_gemma":[0.9978431,0.00046351092,0.000325308,0.0005808375,0.00029851365,0.0004887524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023482994,0.0004761675,0.0026674261,0.00059780636,0.00009207305,0.000057991332,0.00017524304,0.0001656556,0.00008442261],"category_scores_gemma":[0.0012117635,0.00032438032,0.00023260464,0.0008205042,0.00035938175,0.0002143711,0.00013161861,0.00019540808,0.00010333826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9869826,0.0035155413,0.0014025504,0.00011884401,0.0013993646,0.0000171809,0.0025145132,0.000005408565,0.0008703177,0.00019310607,0.00028922452,0.0026913425],"study_design_scores_gemma":[0.97754705,0.0044297567,0.0023309248,0.00029815428,0.0026489645,3.4351163e-7,0.00018038874,0.00031523395,0.009709613,0.00011855778,0.0020762181,0.00034478048],"about_ca_topic_score_codex":0.00017458622,"about_ca_topic_score_gemma":0.00014218835,"teacher_disagreement_score":0.009435543,"about_ca_system_score_codex":0.00003492562,"about_ca_system_score_gemma":0.00013324906,"threshold_uncertainty_score":0.99992085},"labels":[],"label_agreement":null},{"id":"W2803763849","doi":"10.1093/ndt/gfy104.sp415","title":"SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL","year":2018,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Proteinuria; EMPA; Kidney disease; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology; Kidney","score_opus":0.013995470072231418,"score_gpt":0.2724111468541314,"score_spread":0.25841567678190003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803763849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939607,0.0014473323,0.00004668321,0.0019512471,0.00012677023,0.002261055,0.00007113279,0.00005050611,0.00008459442],"genre_scores_gemma":[0.99651617,0.00039548695,0.00010986494,0.0010725782,0.00023501784,0.000258936,0.0013557364,0.000020361662,0.00003584216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984703,0.00021529949,0.00045941153,0.00037861944,0.00022542129,0.00025091358],"domain_scores_gemma":[0.9991386,0.00015269923,0.00017102652,0.00031557295,0.000074700794,0.00014739574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001473856,0.00021701491,0.00048252038,0.00014339694,0.000084979496,0.000016659786,0.00011385083,0.00012931692,0.00010162912],"category_scores_gemma":[0.00004835704,0.0001444258,0.00008447412,0.00036404008,0.00032051472,0.00011042493,0.000020423618,0.00012302061,0.000021268714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054427844,0.0024139788,0.8575466,0.00053705665,0.0016539174,0.000055997185,0.0029505682,0.000010484204,0.0582642,0.00019387643,0.0031885249,0.018756919],"study_design_scores_gemma":[0.08738896,0.0047278297,0.88133186,0.00041688685,0.0057139145,7.72297e-7,0.00004495144,0.002012571,0.010590613,0.0005637888,0.0068217735,0.00038605876],"about_ca_topic_score_codex":0.000150085,"about_ca_topic_score_gemma":0.00032394534,"teacher_disagreement_score":0.047673587,"about_ca_system_score_codex":0.00005590574,"about_ca_system_score_gemma":0.00006979571,"threshold_uncertainty_score":0.5889513},"labels":[],"label_agreement":null},{"id":"W2803869903","doi":"10.2337/dci18-0018","title":"A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks","year":2018,"lang":"en","type":"editorial","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Hamilton Health Sciences; University of Toronto; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Life expectancy; Intensive care medicine; Glycated hemoglobin; Disease; MEDLINE; Odds; Type 2 diabetes; Family medicine; Gerontology; Internal medicine; Population","score_opus":0.04669432698759163,"score_gpt":0.299745464074764,"score_spread":0.25305113708717236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803869903","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052737534,0.016822824,0.000004322509,0.0015431463,0.88707143,0.003532835,0.003554285,0.0007833893,0.03395024],"genre_scores_gemma":[0.0154218525,0.0005350689,0.0023318492,0.0024573416,0.9447286,0.0010883171,0.021050835,0.00047046904,0.011915666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954631,0.00007030522,0.0005363865,0.0012244104,0.0014972414,0.0012086002],"domain_scores_gemma":[0.9968696,0.0004161947,0.0002617217,0.0009693025,0.00092791795,0.0005552328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002687245,0.000898898,0.0014342007,0.00040993412,0.0002342278,0.00017368792,0.0004334424,0.0009545061,0.00073703163],"category_scores_gemma":[0.00086559425,0.00082417397,0.00057780143,0.000332232,0.000111729954,0.00011443723,0.00044674092,0.0006654357,0.0010269114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009480075,0.00012536455,0.009160245,0.0010231619,0.0009036638,0.000031325068,0.0011268067,0.0000035294474,0.000042491338,0.00003803959,0.9757301,0.01172045],"study_design_scores_gemma":[0.0029928677,0.001118241,0.0011855582,0.0014090096,0.0019509963,1.3476183e-7,0.0007828243,0.000010811591,0.0006373709,0.000016399901,0.9891215,0.00077427254],"about_ca_topic_score_codex":0.000037141705,"about_ca_topic_score_gemma":0.000040608236,"teacher_disagreement_score":0.057657175,"about_ca_system_score_codex":0.00054689584,"about_ca_system_score_gemma":0.00020801583,"threshold_uncertainty_score":0.9997509},"labels":[],"label_agreement":null},{"id":"W2804712568","doi":"10.1186/s12933-018-0682-3","title":"Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk","year":2018,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Eli Lilly and Company","keywords":"Linagliptin; Medicine; Kidney disease; Placebo; Randomized controlled trial; Internal medicine; Hazard ratio; Renal function; Population; Type 2 diabetes; Clinical trial; Diabetes mellitus; Confidence interval; Endocrinology; Pathology","score_opus":0.019645550840140417,"score_gpt":0.25746196483608325,"score_spread":0.23781641399594283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804712568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97645396,0.0050163902,0.0018072943,0.000059116694,0.00033905808,0.016245091,0.000020369136,0.0000307387,0.000027971268],"genre_scores_gemma":[0.9964443,0.0008383655,0.0014725144,0.000068253044,0.00033153742,0.0006480834,0.000096695,0.00006352351,0.00003671421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929212,0.0033369935,0.0013858393,0.0010171711,0.00081037736,0.0005284659],"domain_scores_gemma":[0.9965549,0.0009126968,0.0004442884,0.0012105552,0.0006744681,0.00020305083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009364064,0.00057413743,0.005062974,0.00028026119,0.00019698126,0.000050296887,0.00016962682,0.00025925104,0.0000085972515],"category_scores_gemma":[0.0008359764,0.0003349115,0.0010427581,0.00038891277,0.0012161373,0.000110848865,0.00024909218,0.00043333045,0.0000024200006],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5899559,0.00054586324,0.36558872,0.00008110827,0.03567559,0.00002618181,0.000110461384,0.00013160123,0.0000019600513,0.000013965396,0.0000071415257,0.007861487],"study_design_scores_gemma":[0.77177364,0.0037780756,0.19889711,0.00009302281,0.024223594,0.000006117152,0.000042492633,0.00028109716,0.000037315713,0.0000092672335,0.0005518709,0.00030638344],"about_ca_topic_score_codex":0.00006756398,"about_ca_topic_score_gemma":0.00002302472,"teacher_disagreement_score":0.18181774,"about_ca_system_score_codex":0.000060000268,"about_ca_system_score_gemma":0.00013001767,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W2804805813","doi":"10.1007/s00125-018-4644-9","title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial","year":2018,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Placebo; Type 2 diabetes; Internal medicine; Diabetes mellitus; Coronary artery disease; Cardiology; Surgery; Endocrinology","score_opus":0.04423228974231568,"score_gpt":0.2872711728142736,"score_spread":0.24303888307195792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804805813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690366,0.0010527365,0.00000192271,0.00016658622,0.00030421157,0.0014508957,0.000013385429,0.000028819835,0.00007776454],"genre_scores_gemma":[0.9991489,0.00006153144,0.00003395629,0.00013770709,0.00009198646,0.0002881229,0.000039473645,0.000023277655,0.00017501858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732643,0.00041803284,0.0006795759,0.00048716576,0.00051628257,0.0005725204],"domain_scores_gemma":[0.9985677,0.00022143543,0.00022892274,0.0007354326,0.00011272755,0.00013380939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012790421,0.0003122788,0.001395157,0.00019953195,0.00006415789,0.0000105398085,0.00014891004,0.000117729294,0.00008446334],"category_scores_gemma":[0.00028885953,0.00018543794,0.0004751076,0.00055412727,0.00030437607,0.00011339562,0.00011540556,0.00013617876,0.000010565931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011610562,0.00042467102,0.9809473,0.00007043625,0.00543797,0.00003398389,0.00011479975,0.000004545308,0.00012221663,0.0000015615855,0.00015605886,0.0010758889],"study_design_scores_gemma":[0.04082388,0.0004720034,0.95116353,0.00015735274,0.0039892006,9.84785e-7,0.000055012293,0.00004063947,0.002985048,0.000044670323,0.000070507376,0.00019715953],"about_ca_topic_score_codex":0.000051717914,"about_ca_topic_score_gemma":0.00014398745,"teacher_disagreement_score":0.029783763,"about_ca_system_score_codex":0.000070144946,"about_ca_system_score_gemma":0.000081320984,"threshold_uncertainty_score":0.756194},"labels":[],"label_agreement":null},{"id":"W2804985391","doi":"10.1111/dme.13693","title":"The effect of basal–bolus therapy varies with baseline 1,5‐anhydroglucitol level in people with Type 2 diabetes: a <i>post hoc</i> analysis","year":2018,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Novo Nordisk","keywords":"Medicine; Post-hoc analysis; Type 2 diabetes; Insulin aspart; Internal medicine; Basal (medicine); Diabetes mellitus; Post hoc; Randomized controlled trial; Bolus (digestion); Insulin; Gastroenterology; Endocrinology; Urology","score_opus":0.009481020102675491,"score_gpt":0.24515417075745327,"score_spread":0.23567315065477779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804985391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909713,0.0025676435,0.00015460735,0.0027679252,0.00013950003,0.0012690733,0.000009898332,0.000049790196,0.002070234],"genre_scores_gemma":[0.99680084,0.00039785667,0.0002599326,0.0010579446,0.0002179569,0.00015400584,0.0001497451,0.000047546215,0.00091417885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975858,0.00020977849,0.00047627575,0.00045350485,0.0006979302,0.00057675265],"domain_scores_gemma":[0.9974738,0.00095595815,0.0002139028,0.0008468534,0.00032803824,0.00018147311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012394005,0.00039835312,0.0012069476,0.00044050324,0.00012196174,0.000019211242,0.00021671382,0.00007231508,0.00026796423],"category_scores_gemma":[0.00025775595,0.00017856501,0.000098019285,0.0024745534,0.0007694465,0.00006776283,0.000046992147,0.00016671336,0.00002082093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006281431,0.00043306313,0.9395191,0.00034410242,0.006274827,0.000049518418,0.0016695987,0.000037657548,0.0015128113,0.000074927826,0.0025161908,0.04128674],"study_design_scores_gemma":[0.052403342,0.13196455,0.741101,0.0022543508,0.015356028,0.000005698147,0.0013114238,0.006099965,0.035977505,0.00005381839,0.0125126345,0.00095963926],"about_ca_topic_score_codex":0.00016882447,"about_ca_topic_score_gemma":0.00086711557,"teacher_disagreement_score":0.19841808,"about_ca_system_score_codex":0.00006539179,"about_ca_system_score_gemma":0.0000918957,"threshold_uncertainty_score":0.728167},"labels":[],"label_agreement":null},{"id":"W2805241084","doi":"10.1016/j.molmet.2018.06.006","title":"GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy","year":2018,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Daiichi Sankyo Europe; Pfizer; Ethicon Endo-Surgery; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Canada Research Chairs; National Institutes of Health; Shire; Novo Nordisk; University of Michigan; University of Toronto","keywords":"Glucose homeostasis; Sleeve gastrectomy; Homeostasis; Endocrinology; Bile acid; Receptor; Internal medicine; Medicine; Diabetes mellitus; Obesity; Insulin resistance; Gastric bypass","score_opus":0.019291343664530763,"score_gpt":0.25620898897099575,"score_spread":0.236917645306465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805241084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624266,0.031637795,0.0024694125,0.0013823782,0.00026605953,0.0015786948,0.00008829837,0.000048820093,0.0001019419],"genre_scores_gemma":[0.99065465,0.00030984962,0.005083399,0.0029794497,0.00028466503,0.00048689236,0.000023200262,0.00007093083,0.00010696701],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775106,0.00009533017,0.00044998084,0.0006008845,0.0003807118,0.00072205946],"domain_scores_gemma":[0.99891865,0.00019506161,0.00008529054,0.00043864973,0.00017155353,0.00019076643],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052174047,0.0003698735,0.0007097921,0.000194098,0.00015893637,0.00012298867,0.00014606662,0.000095861666,0.00015147639],"category_scores_gemma":[0.00027558426,0.0002738474,0.00023620493,0.0003272701,0.00013892731,0.00015641421,0.00014294282,0.00016785914,0.000037276655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074937794,0.0002597779,0.0021354556,0.00010540158,0.0012692355,0.000056463767,0.0013096685,0.0000261692,0.8021928,0.0019333516,0.00008163313,0.18988067],"study_design_scores_gemma":[0.0065178582,0.00014964295,0.035907384,0.00018504528,0.0019847315,0.000009105215,0.00022389731,0.0021587026,0.9373057,0.00015533579,0.01501594,0.00038667538],"about_ca_topic_score_codex":0.00008887448,"about_ca_topic_score_gemma":0.000018510333,"teacher_disagreement_score":0.18949398,"about_ca_system_score_codex":0.000045988203,"about_ca_system_score_gemma":0.000037745725,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W2805363895","doi":"10.1186/s12883-018-1086-4","title":"Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy","year":2018,"lang":"en","type":"article","venue":"BMC Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of Alberta","funders":"","keywords":"Dapagliflozin; Pentylenetetrazol; Epilepsy; Medicine; Placebo; Anesthesia; Pharmacology; Diabetes mellitus; Internal medicine; Endocrinology; Anticonvulsant; Type 2 diabetes","score_opus":0.030751238959605975,"score_gpt":0.27437210788701516,"score_spread":0.2436208689274092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805363895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229866,0.000031079377,0.00005075192,0.0005991994,0.00030933708,0.00067133305,0.000007849873,0.00006544802,0.005966358],"genre_scores_gemma":[0.9980249,0.000017865032,0.0005482204,0.00051574886,0.00024208489,0.00006174854,0.000010776518,0.000031661955,0.0005470351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984942,0.00011568579,0.0002826734,0.00050436513,0.000195501,0.0004075889],"domain_scores_gemma":[0.9992159,0.00009657417,0.0001385734,0.0003554353,0.00009593392,0.00009760474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015678846,0.00022764353,0.00049065234,0.0003105161,0.000035683817,0.0000055498294,0.00012471665,0.00015245448,0.000036665057],"category_scores_gemma":[0.00007748269,0.00020558274,0.0000920088,0.0003080526,0.00013218903,0.000097665594,0.00011527408,0.00023336241,0.00003151801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005243554,0.0028501218,0.20488504,0.0002340527,0.00029762724,0.00011381496,0.0006711125,0.00020539532,0.77031916,0.000848048,0.0024769648,0.011855088],"study_design_scores_gemma":[0.005822186,0.0073603233,0.3537961,0.00004733561,0.00024125953,0.000014880709,0.000020913603,0.009857685,0.62160695,0.0005057215,0.00044513546,0.00028154385],"about_ca_topic_score_codex":0.00005169788,"about_ca_topic_score_gemma":0.00015226896,"teacher_disagreement_score":0.14891106,"about_ca_system_score_codex":0.00004553502,"about_ca_system_score_gemma":0.00009426245,"threshold_uncertainty_score":0.8383421},"labels":[],"label_agreement":null},{"id":"W2805417982","doi":"10.1016/j.jacc.2018.01.085","title":"SGLT-2 Inhibitors and Cardiovascular Risk","year":2018,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Steno Diabetes Center Copenhagen; AstraZeneca","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.007450837801744007,"score_gpt":0.23397110429185933,"score_spread":0.2265202664901153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805417982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927684,0.0013575396,0.00012894208,0.0007871835,0.00044275343,0.00016083953,0.000011929308,0.0000043270725,0.0043380586],"genre_scores_gemma":[0.99742836,0.0007178682,0.00075711496,0.00016245605,0.0007310707,0.0000015479977,1.6631184e-7,0.000009782198,0.00019162646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990773,0.0001813313,0.00027903076,0.00009806681,0.0002241342,0.00014011745],"domain_scores_gemma":[0.9989616,0.00006451021,0.0004067713,0.0003092186,0.00018831337,0.0000695489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005097724,0.0000943188,0.0008031888,0.00011536226,0.000049914266,0.000002118992,0.00011193137,0.000024903653,0.0000043154078],"category_scores_gemma":[0.0001406448,0.000054456556,0.00056617084,0.00022199801,0.0007251906,0.000029290619,0.000093840725,0.00011748445,0.0000021039943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011257505,0.00009155614,0.85003793,0.000058665206,0.017291328,0.00041183303,0.00011564006,0.00012178273,0.0016675993,0.00033434085,0.07753988,0.051203668],"study_design_scores_gemma":[0.0040791207,0.006904872,0.59989023,0.00013495589,0.006071304,0.0015095568,0.0011443928,0.000023208393,0.0040271142,0.00057685166,0.37545875,0.00017962382],"about_ca_topic_score_codex":0.000012055448,"about_ca_topic_score_gemma":0.0000013086055,"teacher_disagreement_score":0.2979189,"about_ca_system_score_codex":0.000034193923,"about_ca_system_score_gemma":0.000056815283,"threshold_uncertainty_score":0.2671995},"labels":[],"label_agreement":null},{"id":"W2805564415","doi":"10.1016/j.jacc.2018.02.078","title":"Prevention of Heart Failure With SGLT-2 Inhibition","year":2018,"lang":"en","type":"letter","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto; Toronto General Hospital; St. Michael's Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Heart failure; Cardiology; Internal medicine; Intensive care medicine","score_opus":0.009211657270333235,"score_gpt":0.24537775673956833,"score_spread":0.23616609946923509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805564415","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43619585,0.00024087176,0.00026174402,0.558716,0.00060112274,0.00089512824,0.00010296174,0.0000094732395,0.002976858],"genre_scores_gemma":[0.8766074,0.00020656156,0.008782397,0.099757686,0.0079131415,0.000024679608,0.000056542445,0.000100142184,0.0065514315],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850327,0.00026284097,0.00051202695,0.0001328036,0.00041125395,0.0001777815],"domain_scores_gemma":[0.9973575,0.00007875069,0.001752824,0.00036927685,0.0004087441,0.00003292224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028520907,0.00017857995,0.0014231921,0.00025802682,0.00002410803,0.000002105822,0.00014737566,0.00012656636,0.000020695836],"category_scores_gemma":[0.00004338068,0.00010071723,0.0006209907,0.00027305944,0.00061197364,0.000039327562,0.00006368713,0.00045097515,0.0000027381232],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039044648,0.000035339606,0.0049341456,0.00015268342,0.001879561,0.00020543262,0.000007674788,0.000011478541,0.000592499,0.000010096608,0.99159324,0.00018741742],"study_design_scores_gemma":[0.0018990178,0.008684479,0.009336619,0.000944431,0.0028989767,0.0012982824,0.00014547762,0.0000010407078,0.001689218,0.00020445052,0.972774,0.00012395476],"about_ca_topic_score_codex":0.00000429403,"about_ca_topic_score_gemma":0.0000023803052,"teacher_disagreement_score":0.4589583,"about_ca_system_score_codex":0.000095956944,"about_ca_system_score_gemma":0.00020542914,"threshold_uncertainty_score":0.41071296},"labels":[],"label_agreement":null},{"id":"W2805664121","doi":"10.1016/j.atherosclerosissup.2018.04.341","title":"Cardioprotective Benefits of Combined Treatment With Glucagon-Like Peptide-1 Receptor Agonist &amp; Sodium Glucose Transporter-2 Inhibitor In Mice","year":2018,"lang":"en","type":"article","venue":"Atherosclerosis Supplements","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Glucagon-like peptide 1 receptor; Agonist; Transporter; Glucagon-like peptide-1; Chemistry; Pharmacology; Endocrinology; Internal medicine; Glucagon; Sodium; Glucose transporter; Receptor; Medicine; Diabetes mellitus; Biochemistry; Type 2 diabetes; Insulin","score_opus":0.022786782033017813,"score_gpt":0.24746815099184638,"score_spread":0.22468136895882856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805664121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952131,0.00011831603,0.000049253318,0.00035436376,0.00031027765,0.002664082,0.00032131837,0.00007711902,0.0008921495],"genre_scores_gemma":[0.9935899,0.00030677934,0.002643621,0.00017226124,0.0001565399,0.0006632037,0.00066265883,0.00008842616,0.0017166426],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974441,0.000052854786,0.00062408304,0.0006949382,0.00052380626,0.00066024094],"domain_scores_gemma":[0.9987445,0.00002865727,0.00023631351,0.0006123674,0.0001813838,0.00019678235],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018637514,0.0005085709,0.0008219763,0.0002263303,0.00012687685,0.000032539334,0.00016827525,0.000114601826,0.00049760495],"category_scores_gemma":[0.0000051537504,0.00040034106,0.00021845914,0.0004426821,0.0002284436,0.00016235387,0.000056701763,0.00010698894,0.00013514135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063188784,0.010689568,0.74918705,0.00038413715,0.0039059771,0.000015474003,0.009245777,0.000012883535,0.19104828,0.00016501642,0.004449039,0.024577918],"study_design_scores_gemma":[0.038902316,0.02202822,0.33975062,0.0011742245,0.0013867693,0.0000025275444,0.0009883877,0.00001570741,0.5405693,0.000024420551,0.054321382,0.0008361402],"about_ca_topic_score_codex":0.001554559,"about_ca_topic_score_gemma":0.002833371,"teacher_disagreement_score":0.40943643,"about_ca_system_score_codex":0.00049673236,"about_ca_system_score_gemma":0.00009773504,"threshold_uncertainty_score":0.99984485},"labels":[],"label_agreement":null},{"id":"W2806248366","doi":"10.1007/s11892-018-1011-7","title":"Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA","year":2018,"lang":"en","type":"review","venue":"Current Diabetes Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Toronto General Hospital; University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"","keywords":"Medicine; Endothelial dysfunction; Diabetes mellitus; Internal medicine; Natriuresis; Endocrinology; Bioinformatics; Pharmacology; Blood pressure; Biology","score_opus":0.07405202301916616,"score_gpt":0.32643606282928506,"score_spread":0.2523840398101189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806248366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023829078,0.99334234,0.0000617434,0.0000171801,0.0010971559,0.0023973892,0.000016235259,0.000069965696,0.0006150693],"genre_scores_gemma":[0.0021302162,0.9967782,0.00015491442,0.000026618063,0.00009701932,0.0003468008,0.00028027882,0.00009922885,0.0000867153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678206,0.00012220509,0.0010015729,0.0008350057,0.0007347013,0.00052446604],"domain_scores_gemma":[0.99723,0.00008763186,0.00073423143,0.0016111947,0.00015330504,0.000183633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008090623,0.00064229436,0.002555771,0.00025176146,0.00012592538,0.00007387256,0.00017179357,0.00020133264,0.000024418654],"category_scores_gemma":[0.00011800574,0.00040425156,0.00156935,0.00035799958,0.00022232762,0.00006433393,0.00033588038,0.00027637574,0.00001324521],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.1845513e-7,0.00014593171,0.000082343744,0.024657486,0.004156241,0.00009033572,0.000026004926,0.0000015951906,0.000001744103,0.00047491296,0.00040978583,0.9699528],"study_design_scores_gemma":[0.00024916395,0.00019630369,0.00013547472,0.020635923,0.018560037,0.00005324724,0.000009564311,0.0000063808097,0.00005371978,0.0005524452,0.9591665,0.00038120462],"about_ca_topic_score_codex":0.0000036843846,"about_ca_topic_score_gemma":3.9936123e-7,"teacher_disagreement_score":0.9695716,"about_ca_system_score_codex":0.000101104815,"about_ca_system_score_gemma":0.00016190595,"threshold_uncertainty_score":0.9998409},"labels":[],"label_agreement":null},{"id":"W2806521060","doi":"10.1186/s12933-018-0728-6","title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017","year":2018,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2348,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group; University of Toronto","funders":"Novo Nordisk; American Diabetes Association","keywords":"Medicine; Angiology; Type 2 diabetes; Disease; Diabetes mellitus; Systematic review; MEDLINE; Scientific literature; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.03919924751054406,"score_gpt":0.3184236154855464,"score_spread":0.27922436797500233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806521060","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017132785,0.9895488,0.0000038698468,0.000025370393,0.0011713378,0.00725179,0.00018054526,0.000024909808,0.000080074096],"genre_scores_gemma":[0.0006724623,0.9970511,0.00006410291,0.000047537775,0.00017116121,0.0012277939,0.00026942464,0.00007260642,0.00042378556],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920321,0.002487388,0.0020010835,0.0014312882,0.0012256666,0.0008224524],"domain_scores_gemma":[0.99195236,0.0008098617,0.0007342192,0.0057806014,0.00053104985,0.0001919095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0068278685,0.0007799471,0.009105277,0.0006787749,0.0000652685,0.00005478259,0.0011477441,0.00032334952,0.000046373996],"category_scores_gemma":[0.0023436681,0.00050224457,0.005853877,0.0030703319,0.00083579845,0.00017924845,0.00050930004,0.0005628225,0.000074972246],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012284418,0.00014596527,0.0018115176,0.94937104,0.014610081,0.00028894155,0.00012250917,0.0000116449,1.3536551e-7,0.000006552506,0.0006934877,0.03292583],"study_design_scores_gemma":[0.00044977988,0.0000569144,0.0008451314,0.761313,0.036949232,0.000005494099,0.000006427585,0.000011333953,0.0000028715485,0.000009246717,0.20005219,0.00029836927],"about_ca_topic_score_codex":0.00002364313,"about_ca_topic_score_gemma":0.000013336984,"teacher_disagreement_score":0.1993587,"about_ca_system_score_codex":0.00028902543,"about_ca_system_score_gemma":0.0004240759,"threshold_uncertainty_score":0.9997429},"labels":[],"label_agreement":null},{"id":"W2806700450","doi":"10.1016/j.atherosclerosissup.2018.04.354","title":"Canagliflozin Directly Reduces Macrophage Inflammation via AMPK in a Mouse Model of Atherosclerosis","year":2018,"lang":"en","type":"article","venue":"Atherosclerosis Supplements","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Canagliflozin; Inflammation; AMPK; Macrophage; Medicine; Chemistry; Immunology; Endocrinology; Diabetes mellitus; Biochemistry; Type 2 diabetes; Protein kinase A","score_opus":0.026429712191632673,"score_gpt":0.26611465408116824,"score_spread":0.23968494188953557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806700450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630356,0.000035985347,0.00043744268,0.00033445185,0.00012920953,0.0011919508,0.00013538112,0.000091434864,0.0013405886],"genre_scores_gemma":[0.99323446,0.00021020361,0.0037953581,0.0002695831,0.00011656762,0.00025229892,0.00014738337,0.00007594985,0.0018982288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975718,0.00005302011,0.0007251007,0.00051582535,0.0005369006,0.00059731095],"domain_scores_gemma":[0.9988424,0.000027063554,0.00026602027,0.0005722582,0.00015057033,0.00014164335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034026266,0.00035332303,0.0005315458,0.00033791072,0.000096602984,0.00003876218,0.0002387774,0.000119729586,0.0005024467],"category_scores_gemma":[0.000035254125,0.0003295298,0.00015989988,0.00043454487,0.0001712211,0.00029082494,0.00016590802,0.00011569296,0.00010781316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012683343,0.0006413691,0.0858868,0.000099799654,0.0002184352,7.7975e-7,0.0012413117,0.000047933783,0.9011561,0.00012312071,0.001045625,0.009411883],"study_design_scores_gemma":[0.005266644,0.0007401233,0.041746847,0.00028702727,0.00022507747,2.93094e-7,0.00018113847,0.006999196,0.94303364,0.00018044731,0.0009766637,0.00036293518],"about_ca_topic_score_codex":0.0012549362,"about_ca_topic_score_gemma":0.001201801,"teacher_disagreement_score":0.044139955,"about_ca_system_score_codex":0.00028042722,"about_ca_system_score_gemma":0.00005728861,"threshold_uncertainty_score":0.99991566},"labels":[],"label_agreement":null},{"id":"W2807279220","doi":"10.1016/j.jcjd.2018.05.008","title":"Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Gilead Sciences; Sanofi; Pfizer","keywords":"Semaglutide; Medicine; Dulaglutide; Sitagliptin; Type 2 diabetes; Exenatide; Metformin; Glycated hemoglobin; Glycemic; Clinical trial; Placebo; Internal medicine; Weight loss; Insulin glargine; Diabetes mellitus; Pharmacology; Insulin; Endocrinology; Liraglutide; Obesity","score_opus":0.024381469849103936,"score_gpt":0.2820044215583799,"score_spread":0.25762295170927596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807279220","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056142984,0.99155325,8.768127e-8,0.00033006433,0.00018086408,0.00207963,0.00004416365,0.0000062076692,0.00019141864],"genre_scores_gemma":[0.00017601279,0.99772334,0.00031221827,0.00090651057,0.0002240964,0.00009124178,0.000068151254,0.000074964606,0.00042348768],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828506,0.00007055137,0.0006558908,0.00027701753,0.00014341612,0.00056808646],"domain_scores_gemma":[0.99808484,0.00023883388,0.0005089889,0.00027059083,0.00028887804,0.0006078466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005203615,0.00042161817,0.0023074406,0.000593339,0.000051916853,0.000040940282,0.00018726205,0.0001461898,0.00007369226],"category_scores_gemma":[0.00024290649,0.0002703952,0.00026532338,0.00041252424,0.00013397011,0.00008092956,0.000012206569,0.00024800608,0.000008276867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012331456,0.000057317655,0.0076747825,0.07914837,0.0015550136,0.00003087854,0.00007131504,7.594941e-8,6.846431e-8,0.00001187118,0.033585448,0.87785256],"study_design_scores_gemma":[0.0013680933,0.002111576,0.00035654986,0.13013545,0.0029468369,0.000005318717,0.000012303334,0.000001072578,0.0000010673534,0.000008670013,0.86281145,0.00024159538],"about_ca_topic_score_codex":0.000030451605,"about_ca_topic_score_gemma":0.0013655396,"teacher_disagreement_score":0.8776109,"about_ca_system_score_codex":0.00022954885,"about_ca_system_score_gemma":0.0014384716,"threshold_uncertainty_score":0.99997485},"labels":[],"label_agreement":null},{"id":"W2807310966","doi":"10.1111/ctr.13302","title":"Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data","year":2018,"lang":"en","type":"article","venue":"Clinical Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Medicine; Metformin; Internal medicine; Diabetes mellitus; Hazard ratio; Retrospective cohort study; Proportional hazards model; Intensive care medicine; Insulin; Endocrinology; Confidence interval","score_opus":0.05841071051614581,"score_gpt":0.3538913074038677,"score_spread":0.2954805968877219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807310966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970445,0.00007292292,0.00018820267,0.00046973387,0.00009490699,0.00057059753,0.0014475633,0.000018094823,0.0000934459],"genre_scores_gemma":[0.99318135,0.003407949,0.00018376512,0.0005354254,0.000014235963,0.000033028908,0.0025784508,0.0000122686015,0.000053527678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982193,0.00017115755,0.0007225509,0.00045222326,0.0002231055,0.00021164959],"domain_scores_gemma":[0.9987764,0.0005761192,0.00014244978,0.00035442002,0.00005786384,0.00009278265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009883967,0.00018588644,0.000653152,0.00029444954,0.000034885456,0.00002826147,0.0001437978,0.000119980694,0.000039091523],"category_scores_gemma":[0.00017105335,0.00012595784,0.000098431636,0.0007105695,0.00025732227,0.00024946124,0.000012471976,0.00026877504,0.0000020700047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013312766,0.0006022299,0.9940748,0.00006872064,0.001328061,0.00010444752,0.0016453783,6.689172e-7,0.000009448008,0.000032218515,0.000056191777,0.0007465484],"study_design_scores_gemma":[0.006037592,0.00037881438,0.98348945,0.00050113833,0.0065985816,0.0000028369632,0.000099941906,0.0025969413,0.000024283052,0.000045745488,0.00010127708,0.00012339385],"about_ca_topic_score_codex":0.00026963121,"about_ca_topic_score_gemma":0.0034305216,"teacher_disagreement_score":0.0105853565,"about_ca_system_score_codex":0.000042865107,"about_ca_system_score_gemma":0.000030922576,"threshold_uncertainty_score":0.5136411},"labels":[],"label_agreement":null},{"id":"W2807363782","doi":"10.1111/dom.13396","title":"Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical endpoint; Sitagliptin; Placebo; Exenatide; Internal medicine; Adverse effect; Weight gain; Weight loss; Dulaglutide; Hypoglycemia; Gastroenterology; Diabetes mellitus; Clinical trial; Insulin; Endocrinology; Obesity; Liraglutide; Body weight","score_opus":0.02843823787394919,"score_gpt":0.3032648852547078,"score_spread":0.2748266473807586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807363782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467367,0.0008353067,0.000012213344,0.0007224063,0.0004733378,0.0027545323,0.000007456029,0.00006741618,0.00045367374],"genre_scores_gemma":[0.99568427,0.00018050736,0.0008988849,0.0016363331,0.000879488,0.00019391063,0.000043455067,0.000033482538,0.00044969804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659586,0.0005774044,0.0007611044,0.0006056287,0.00039532885,0.0010646608],"domain_scores_gemma":[0.99840534,0.00052460097,0.00021260255,0.0004781348,0.0001370438,0.00024229377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027394642,0.00039672275,0.0010060312,0.00028844495,0.00013285587,0.00003213688,0.00028007198,0.00014365067,0.000063385065],"category_scores_gemma":[0.0013013139,0.00025344803,0.00018914239,0.0005709778,0.00034215627,0.00022546724,0.00013039708,0.0004970008,0.00004180332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005601107,0.0016193305,0.9793972,0.00010252037,0.00014997428,0.000047355534,0.00020327454,7.2423825e-7,0.00010557469,0.00022143242,0.00022346602,0.012328037],"study_design_scores_gemma":[0.07092995,0.0025895673,0.9164817,0.00037840146,0.00070805417,0.000004624012,0.0002961723,0.00050784094,0.00007702169,0.0002375321,0.007478159,0.00031099157],"about_ca_topic_score_codex":0.000043566146,"about_ca_topic_score_gemma":0.00013363581,"teacher_disagreement_score":0.065328844,"about_ca_system_score_codex":0.000067908884,"about_ca_system_score_gemma":0.0001390266,"threshold_uncertainty_score":0.9999918},"labels":[],"label_agreement":null},{"id":"W2807732548","doi":"10.1111/dom.13413","title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Renal function; Kidney disease; Type 2 diabetes; Internal medicine; Urology; Clinical endpoint; Adverse effect; Randomization; Diabetes mellitus; Gastroenterology; Randomized controlled trial; Endocrinology","score_opus":0.005970261016607593,"score_gpt":0.21811641055821412,"score_spread":0.21214614954160654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807732548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995755,0.0020728766,0.0000023243226,0.0001473662,0.00006806071,0.0018051161,0.000052235104,0.000021605652,0.000075380005],"genre_scores_gemma":[0.9990483,0.00026021877,0.000078330864,0.00030305452,0.00006161848,0.000041819363,0.00005677603,0.000019598707,0.00013031969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986299,0.00011379253,0.0002497642,0.00038788776,0.00025115183,0.00036750102],"domain_scores_gemma":[0.99912065,0.000058995334,0.00010131823,0.00031739136,0.000102801285,0.0002988137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029850015,0.00025627192,0.0005030337,0.00012244057,0.0001572216,0.000043488784,0.00007240355,0.00003892935,0.000031763364],"category_scores_gemma":[0.000056815094,0.00015843392,0.000028405086,0.00018153193,0.00033686374,0.000149905,0.00018313066,0.00010793418,0.0000024358671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008000066,0.0015689777,0.99080765,0.00017110199,0.0004895279,0.0000031742302,0.0008948505,0.0000038564913,0.00011622173,0.0001289306,0.00007098275,0.004944706],"study_design_scores_gemma":[0.01118509,0.0018221333,0.98387694,0.00015522272,0.00086983776,3.1034954e-8,0.00008428143,0.00028835752,0.0004976361,0.00005186409,0.0009986965,0.00016992966],"about_ca_topic_score_codex":0.000020285912,"about_ca_topic_score_gemma":0.00001844926,"teacher_disagreement_score":0.010385083,"about_ca_system_score_codex":0.000029395338,"about_ca_system_score_gemma":0.00006350319,"threshold_uncertainty_score":0.6460748},"labels":[],"label_agreement":null},{"id":"W2808220657","doi":"10.1016/s2213-8587(18)30125-6","title":"Dulaglutide and renal protection in type 2 diabetes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; Toronto General Hospital","funders":"Canadian Institutes of Health Research; University of Toronto; Juvenile Diabetes Research Foundation Canada","keywords":"Medicine; Dulaglutide; Type 2 diabetes; Insulin glargine; Kidney disease; Internal medicine; Diabetes mellitus; Renal function; Metformin; Insulin; Exenatide; Endocrinology","score_opus":0.030730179965765016,"score_gpt":0.2625737284194719,"score_spread":0.2318435484537069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808220657","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50004214,0.0030619514,9.4501206e-7,0.491327,0.0006870994,0.0013097244,0.000016104506,0.0001789003,0.00337612],"genre_scores_gemma":[0.17639436,0.0021849247,0.0003760642,0.7964851,0.014211326,0.0010610657,0.000671509,0.00020062338,0.008415002],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677515,0.0002091902,0.00034723617,0.0006055421,0.00022918024,0.0018337043],"domain_scores_gemma":[0.99874663,0.00016499982,0.00017000145,0.0007960374,0.00007191168,0.00005043311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030181452,0.0004429295,0.0010662894,0.00032599337,0.00009233776,0.00004428512,0.00027954887,0.0003609813,0.00014099285],"category_scores_gemma":[0.000115261755,0.0003031925,0.00009748173,0.00027293194,0.00042691766,0.00006192589,0.00026908,0.0013112706,0.00021627251],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007699617,0.00007601451,0.048234396,0.00057332707,0.0008682201,0.00027113926,0.000077275945,7.358243e-7,0.0010364758,0.00012931738,0.9270428,0.021613337],"study_design_scores_gemma":[0.001894995,0.0009879132,0.029606165,0.00031969306,0.00052222796,0.000011405337,0.000008600531,0.00007491935,0.0020117904,0.0016470911,0.96258885,0.00032633997],"about_ca_topic_score_codex":0.00003318858,"about_ca_topic_score_gemma":0.0000276546,"teacher_disagreement_score":0.3236478,"about_ca_system_score_codex":0.00012265625,"about_ca_system_score_gemma":0.00003984497,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W2808271763","doi":"10.1111/dom.13353","title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"ExxonMobil Research and Engineering Company; Novo Nordisk","keywords":"Semaglutide; Nausea; Weight loss; Vomiting; Medicine; Sitagliptin; Type 2 diabetes; Placebo; Internal medicine; Dulaglutide; Adverse effect; Gastroenterology; Exenatide; Liraglutide; Diabetes mellitus; Obesity; Endocrinology","score_opus":0.019855582552365737,"score_gpt":0.2665220678581215,"score_spread":0.24666648530575574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808271763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997003,0.0006632667,0.000009709606,0.00034521046,0.00012875433,0.0014375736,0.00002370604,0.000028733655,0.00036003697],"genre_scores_gemma":[0.99667984,0.0001131324,0.0013916269,0.0007877707,0.00024090291,0.00008964956,0.000042813168,0.00002727047,0.0006270159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972872,0.0005444849,0.0005901256,0.00045555973,0.00042387712,0.00069871533],"domain_scores_gemma":[0.99778664,0.0011420546,0.00023096478,0.00042148703,0.00022783331,0.00019100809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030944042,0.00034895024,0.0011094776,0.00049503805,0.00007354693,0.00001404786,0.00022940905,0.00007734519,0.000031931457],"category_scores_gemma":[0.0027145522,0.00020269227,0.00009442833,0.0010360522,0.00018571016,0.0001517625,0.00012648966,0.00020710615,0.000016088927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027428678,0.00095549197,0.9917781,0.00030758991,0.00017971412,0.00006272293,0.0011541208,0.000005895244,0.0023143818,0.00025831495,0.00057494256,0.002134463],"study_design_scores_gemma":[0.0049879686,0.001151854,0.96886545,0.00085164275,0.0005538309,0.0000038150083,0.0009874279,0.000050459515,0.018668486,0.000215476,0.0035263898,0.00013718323],"about_ca_topic_score_codex":0.000076529504,"about_ca_topic_score_gemma":0.0003503428,"teacher_disagreement_score":0.022912608,"about_ca_system_score_codex":0.00004202226,"about_ca_system_score_gemma":0.00012065409,"threshold_uncertainty_score":0.8265551},"labels":[],"label_agreement":null},{"id":"W2808284219","doi":"10.1016/j.ahj.2018.03.030","title":"Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics","year":2018,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Placebo; Double blind; Type 2 Diabetes Mellitus; Randomized controlled trial; Harmony (color); Diabetes mellitus; Internal medicine; Physical therapy; Traditional medicine; Alternative medicine; Endocrinology","score_opus":0.0133052421642988,"score_gpt":0.25852340406817875,"score_spread":0.24521816190387996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808284219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936257,0.00014662767,0.000108116736,0.00025236583,0.00020985237,0.005611562,0.000003065334,0.0000049007626,0.00003779143],"genre_scores_gemma":[0.9988744,0.00006418776,0.00052153476,0.0001887866,0.00010763098,0.00014807514,0.000008044596,0.000018468605,0.000068820875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977043,0.00079680677,0.0005529166,0.00016622996,0.0005703206,0.00020940795],"domain_scores_gemma":[0.99821675,0.00084775104,0.00038699745,0.00025853427,0.0002005218,0.000089442925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002137077,0.00019852455,0.0016221101,0.0001773554,0.000059640406,0.000009994448,0.00007320897,0.000027752747,0.000020816791],"category_scores_gemma":[0.0004982038,0.00009775715,0.0003694683,0.00022963359,0.00026961835,0.000052933217,0.000027880704,0.00014337806,0.0000032781124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7745761,0.00029750908,0.2207811,0.000025236794,0.0023134202,0.0000013902512,0.00004020254,0.000016959455,0.00001612815,0.0000019477993,0.000063882995,0.0018660916],"study_design_scores_gemma":[0.9174709,0.00818525,0.07137331,0.0001931316,0.0018472633,0.0000011748459,0.000007670254,0.00013918395,0.0005897311,0.0000045490324,0.0001024074,0.000085421794],"about_ca_topic_score_codex":0.000023450517,"about_ca_topic_score_gemma":0.000001728248,"teacher_disagreement_score":0.14940777,"about_ca_system_score_codex":0.00004867378,"about_ca_system_score_gemma":0.00006536041,"threshold_uncertainty_score":0.39864206},"labels":[],"label_agreement":null},{"id":"W2808400246","doi":"10.1016/j.vph.2018.06.006","title":"Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress","year":2018,"lang":"en","type":"article","venue":"Vascular Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"NADPH oxidase; Endothelial dysfunction; Vasodilation; Endocrinology; Internal medicine; Oxidative stress; Protein kinase C; Biology; Pharmacology; Kinase; Chemistry; Medicine; Biochemistry","score_opus":0.012005947329470803,"score_gpt":0.28047054032237556,"score_spread":0.26846459299290476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808400246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973878,0.0005638126,0.00037521883,0.00014373526,0.00016190208,0.0009340083,0.00007511315,0.00003373457,0.00032464103],"genre_scores_gemma":[0.9980189,0.00073935575,0.00034263535,0.00013026378,0.000109837085,0.00007643569,0.0004644828,0.000017892771,0.000100194964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881196,0.0000956664,0.0003991495,0.0002627327,0.00021355311,0.00021692213],"domain_scores_gemma":[0.9994095,0.000047112022,0.00021889708,0.00012986972,0.0001106946,0.000083954605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020266294,0.00016201446,0.0003738908,0.00015249918,0.000041173495,0.0000036192587,0.00004256625,0.00008138111,0.00042963563],"category_scores_gemma":[0.000007751828,0.00014932023,0.000121992525,0.00013567001,0.00021390554,0.00009400724,0.000024958394,0.0000691542,0.0000116340825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036075432,0.0012431126,0.015142862,0.0003449751,0.0012487435,0.000010091062,0.00082213426,0.0000016604436,0.9738303,0.000016599211,0.0010082592,0.005970497],"study_design_scores_gemma":[0.008239642,0.0018693134,0.016064232,0.000120936165,0.0012860015,0.0000023558925,0.0001738699,0.00030961828,0.9699581,0.000043158005,0.0018101116,0.00012262791],"about_ca_topic_score_codex":0.00002506673,"about_ca_topic_score_gemma":0.000004704997,"teacher_disagreement_score":0.0078788875,"about_ca_system_score_codex":0.000050090068,"about_ca_system_score_gemma":0.000043268265,"threshold_uncertainty_score":0.6089102},"labels":[],"label_agreement":null},{"id":"W2808467887","doi":"10.1016/j.jacc.2018.03.009","title":"Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs","year":2018,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":466,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"Saint Luke's Health System; AstraZeneca","keywords":"Empagliflozin; Dapagliflozin; Medicine; Canagliflozin; Hazard ratio; Internal medicine; Confidence interval; Heart failure; Diabetes mellitus; Propensity score matching; Type 2 diabetes; Relative risk; Endocrinology","score_opus":0.010406503439718185,"score_gpt":0.2422334085107746,"score_spread":0.2318269050710564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808467887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178916,0.00039838182,0.000083748906,0.00046816407,0.0008353985,0.00023860608,0.000013070559,0.0000106034095,0.0061628353],"genre_scores_gemma":[0.9986429,0.00006672644,0.00021766596,0.00015151752,0.00056395243,0.0000039292036,7.0258227e-7,0.000026052981,0.00032654358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986331,0.00017498509,0.0003432339,0.00013588724,0.00046570826,0.0002470808],"domain_scores_gemma":[0.9985315,0.00010468845,0.0005999436,0.00038148582,0.00030032164,0.000082030754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005340024,0.0001558974,0.0010081226,0.00014270129,0.000058878733,0.0000025973384,0.00020534305,0.00003948884,0.000008549166],"category_scores_gemma":[0.00015014235,0.00009122966,0.0007243068,0.00042581887,0.00045074488,0.00004777044,0.000085582535,0.00014679522,0.0000038440603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025713278,0.00096024567,0.6897417,0.0001622738,0.17632034,0.0014023039,0.0008839769,0.0020738626,0.008397705,0.00035392997,0.05245762,0.04153281],"study_design_scores_gemma":[0.050676208,0.038789906,0.5123346,0.0016969123,0.021894284,0.0007293915,0.005036227,0.0000612012,0.035051405,0.0002589168,0.33245173,0.0010192582],"about_ca_topic_score_codex":0.000013633723,"about_ca_topic_score_gemma":0.0000044499625,"teacher_disagreement_score":0.2799941,"about_ca_system_score_codex":0.00019803258,"about_ca_system_score_gemma":0.000116377,"threshold_uncertainty_score":0.37202376},"labels":[],"label_agreement":null},{"id":"W2808793740","doi":"10.2337/db18-124-lb","title":"Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 Inhibitors—Analysis from the CVD-REAL 2 Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hazard ratio; Medicine; Dapagliflozin; Stroke (engine); Internal medicine; Cohort study; Clinical trial; Cohort; Diabetes mellitus; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.010417826648635114,"score_gpt":0.24195340758209838,"score_spread":0.23153558093346327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808793740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986376,0.00009593581,0.0000050241983,0.00006131417,0.00004915217,0.0004743739,0.000068414665,0.000020257277,0.0005879261],"genre_scores_gemma":[0.9995093,0.000031997213,0.000051523606,0.000059631995,0.000060476385,0.000023808429,0.00014293035,0.000012603937,0.00010773276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901766,0.00010463655,0.0002223083,0.00019613026,0.00030294465,0.00015630017],"domain_scores_gemma":[0.99901557,0.00023770811,0.00027367848,0.00026620782,0.00016274568,0.00004406823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002921302,0.00013257265,0.00040504997,0.00011365762,0.000055795124,0.000008847229,0.000063969244,0.00003998735,0.0000516958],"category_scores_gemma":[0.00012282109,0.00007885344,0.00008322667,0.00040262853,0.00006903747,0.0000650105,0.00005414813,0.00005319251,0.0000033243157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006093016,0.00083803094,0.9903547,0.00000846671,0.006731152,0.0000010312025,0.00078864093,0.0000022152744,0.00020918694,0.000010534414,0.00015789848,0.000837189],"study_design_scores_gemma":[0.0020376367,0.0018451478,0.9827426,0.00008325264,0.008995054,6.720695e-9,0.0002910119,0.0001823577,0.0036620984,0.00006842864,0.000019270503,0.00007314873],"about_ca_topic_score_codex":0.00046188277,"about_ca_topic_score_gemma":0.00028603265,"teacher_disagreement_score":0.0076121376,"about_ca_system_score_codex":0.000029568439,"about_ca_system_score_gemma":0.000015162904,"threshold_uncertainty_score":0.321555},"labels":[],"label_agreement":null},{"id":"W2808801699","doi":"10.2337/db18-1029-p","title":"Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin glargine; Insulin degludec; Hypoglycemia; Metformin; Insulin; Clinical endpoint; Internal medicine; Diabetes mellitus; Randomized controlled trial; Incidence (geometry); Endocrinology","score_opus":0.01649256160347659,"score_gpt":0.2783276440155871,"score_spread":0.2618350824121105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808801699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901076,0.003005557,0.000010223785,0.0006198885,0.0002672884,0.004551665,0.00009790541,0.00013660832,0.0012032742],"genre_scores_gemma":[0.9962158,0.0010792793,0.0002414027,0.0008885529,0.00042885708,0.0003897878,0.00032484173,0.00012439626,0.0003070598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957851,0.0005442758,0.001029606,0.0009011722,0.00084987655,0.0008899364],"domain_scores_gemma":[0.99632096,0.0013768963,0.00048331972,0.001281829,0.00031240366,0.00022461229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011308772,0.00079976075,0.0022354866,0.0004438024,0.00017062035,0.000109257315,0.00053685386,0.00018765347,0.0006023514],"category_scores_gemma":[0.00023733753,0.00044089794,0.00046472362,0.0012058512,0.00045936255,0.0002588227,0.0001629159,0.00041720836,0.00016638104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08753231,0.0077969683,0.87283826,0.000052648127,0.004774562,0.000052762007,0.0056310133,0.000035489684,0.001684169,0.00009849827,0.0015996196,0.017903674],"study_design_scores_gemma":[0.23580036,0.008681996,0.7486011,0.0003819349,0.00066729187,9.790889e-7,0.0005208452,0.00049059896,0.0034744097,0.00016377453,0.0007350728,0.0004816653],"about_ca_topic_score_codex":0.0038715533,"about_ca_topic_score_gemma":0.00086140534,"teacher_disagreement_score":0.14826804,"about_ca_system_score_codex":0.00027461877,"about_ca_system_score_gemma":0.00021951432,"threshold_uncertainty_score":0.99980426},"labels":[],"label_agreement":null},{"id":"W2808825425","doi":"10.2337/db18-136-lb","title":"Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Dulaglutide; Medicine; Type 2 diabetes; Exenatide; Cohort; Internal medicine; Metformin; Diabetes mellitus; Endocrinology; Insulin; Liraglutide","score_opus":0.02483835922337897,"score_gpt":0.2848306507766425,"score_spread":0.25999229155326353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808825425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937427,0.00051253027,3.4660792e-7,0.00030740688,0.0002101049,0.002247239,0.00003696884,0.000015325832,0.0029273722],"genre_scores_gemma":[0.9986034,0.000067971814,0.000106099054,0.0004989028,0.00005751727,0.0003838914,0.000057605223,0.000029276542,0.00019532372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799985,0.00019794823,0.0004388145,0.0003631152,0.00041746872,0.00058281544],"domain_scores_gemma":[0.9983219,0.0007563876,0.00012551589,0.0005568061,0.00012138517,0.000118009426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004908004,0.00030839661,0.00079748314,0.00031825365,0.00003393441,0.000009378059,0.00021016794,0.00005808851,0.00007272395],"category_scores_gemma":[0.0001892636,0.00020813089,0.000102438455,0.0007915231,0.00010286972,0.000054288266,0.000043611562,0.000076546305,0.000032710584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005320579,0.0015900229,0.9264917,0.0003257942,0.00040076807,0.00004013371,0.000812727,0.00008898788,0.0079420395,0.0003968786,0.0009362947,0.060442634],"study_design_scores_gemma":[0.004250796,0.010579154,0.6529583,0.0008970411,0.00026863135,3.0926694e-7,0.0004997589,0.00037567984,0.32024145,0.00021004089,0.009453651,0.00026520205],"about_ca_topic_score_codex":0.10874814,"about_ca_topic_score_gemma":0.18882276,"teacher_disagreement_score":0.31229943,"about_ca_system_score_codex":0.00083170214,"about_ca_system_score_gemma":0.00034961323,"threshold_uncertainty_score":0.89718676},"labels":[],"label_agreement":null},{"id":"W2808886095","doi":"10.2337/db18-1032-p","title":"Lower Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM on Oral Antihyperglycemic Therapy ± GLP-1RA—The BRIGHT Randomized Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hypoglycemia; Medicine; Insulin glargine; Glycemic; Insulin; Internal medicine; Insulin degludec; Endocrinology; Confidence interval","score_opus":0.010868552001967473,"score_gpt":0.25086397759343404,"score_spread":0.23999542559146655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808886095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858999,0.0024701653,0.000011466522,0.0015810108,0.00043813032,0.007150107,0.00003274791,0.00032932853,0.002087095],"genre_scores_gemma":[0.99208736,0.0009837333,0.00054997345,0.003011918,0.0004917997,0.0011221342,0.00023992872,0.00021723988,0.001295925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942939,0.0005639724,0.0011371262,0.0014199646,0.0011734156,0.0014115779],"domain_scores_gemma":[0.99636817,0.0008195099,0.0005015666,0.0014485345,0.00050681055,0.0003554279],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012954717,0.0012076354,0.0023981745,0.0006876597,0.0003269651,0.00020356129,0.0006460381,0.00025967296,0.00036076145],"category_scores_gemma":[0.0002703771,0.00066635746,0.0003047508,0.001633499,0.0009109812,0.00038539112,0.00018301143,0.00068416365,0.00033450205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5372915,0.013577814,0.3741091,0.00021767685,0.0051276237,0.00063720666,0.005591274,0.00007095266,0.00083444157,0.0002498032,0.0032961934,0.05899642],"study_design_scores_gemma":[0.74150586,0.034048665,0.18677513,0.00194586,0.0015596648,0.0000119914375,0.0014485241,0.0016389347,0.016648423,0.00018258109,0.01237284,0.0018615176],"about_ca_topic_score_codex":0.0005326854,"about_ca_topic_score_gemma":0.0005212391,"teacher_disagreement_score":0.20421436,"about_ca_system_score_codex":0.000278794,"about_ca_system_score_gemma":0.00024713652,"threshold_uncertainty_score":0.9995788},"labels":[],"label_agreement":null},{"id":"W2808981859","doi":"10.2337/db18-301-or","title":"Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin degludec; Hypoglycemia; Glycemic; Insulin glargine; Insulin; Internal medicine; Endocrinology; Clinical endpoint; Adverse effect; Randomized controlled trial","score_opus":0.013203639710603721,"score_gpt":0.25181041253336245,"score_spread":0.23860677282275872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808981859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866874,0.0022451102,0.000023457531,0.0019486914,0.0003427359,0.0064332974,0.000050823284,0.00024501438,0.0020234382],"genre_scores_gemma":[0.9932607,0.00049004395,0.00025086853,0.0032033669,0.0003835604,0.0007997613,0.00012605415,0.00014273914,0.0013429356],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99492526,0.000539691,0.0011245159,0.0012136025,0.00091207924,0.0012848672],"domain_scores_gemma":[0.9961752,0.001592517,0.0004385505,0.0011330498,0.00029453926,0.00036610797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013539911,0.0009798537,0.0027331149,0.0005790865,0.0003722905,0.00019270435,0.0004994235,0.00022770077,0.00017642928],"category_scores_gemma":[0.00032536453,0.00057768275,0.00023696976,0.0009902708,0.00081873615,0.00029610464,0.00019889785,0.0005881581,0.00015300508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63889444,0.008065702,0.31087273,0.00053230015,0.005856483,0.00054006506,0.0055766,0.00021016633,0.0017635358,0.00040977664,0.006018774,0.021259429],"study_design_scores_gemma":[0.8895235,0.014190151,0.06003575,0.001412873,0.0037719132,0.000015855532,0.0023660485,0.011232387,0.00463366,0.00024066727,0.011001848,0.0015753111],"about_ca_topic_score_codex":0.0004576842,"about_ca_topic_score_gemma":0.0003768223,"teacher_disagreement_score":0.250837,"about_ca_system_score_codex":0.0002769569,"about_ca_system_score_gemma":0.0002014825,"threshold_uncertainty_score":0.99966747},"labels":[],"label_agreement":null},{"id":"W2809055720","doi":"10.2337/db18-1184-p","title":"CANadian CAnagliflozin REgistry (CanCARE)—A Prospective, Observational Assessment of Canagliflozin (CANA) Treatment in Type 2 Diabetes Mellitus (T2DM)—Twelve-Month Results","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Canagliflozin; Prospective cohort study; Adverse effect; Internal medicine; Regimen; Polyuria; Type 2 Diabetes Mellitus; Surgery; Weight loss; Hypoglycemia; Diabetes mellitus; Obesity; Endocrinology; Insulin","score_opus":0.023523160872887448,"score_gpt":0.2851653549676845,"score_spread":0.26164219409479705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809055720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96144867,0.0012864862,0.0000010982011,0.0025292607,0.00054938864,0.0015770486,0.000425728,0.00007623735,0.032106087],"genre_scores_gemma":[0.9928386,0.0001841728,0.0012123202,0.0007216533,0.00030806084,0.0002997024,0.0010149317,0.00006474473,0.0033557727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664396,0.00009451523,0.0007632958,0.0008079184,0.0005629305,0.0011273503],"domain_scores_gemma":[0.9976189,0.0001569806,0.00028130395,0.00089911494,0.000479999,0.0005637176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004154915,0.0005077648,0.00090378197,0.0006361088,0.00014479298,0.000051067786,0.00026633005,0.00018285398,0.00017909051],"category_scores_gemma":[0.0002120776,0.0004554186,0.00017013299,0.0010535833,0.00023809049,0.0002155421,0.00007011919,0.00017996845,0.000028447375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011302952,0.00048703296,0.97958356,0.00013583952,0.0008067554,0.000048999853,0.00024207996,0.000033470376,0.0005010508,0.0016851319,0.007968858,0.008394203],"study_design_scores_gemma":[0.0042317067,0.0024048863,0.9348445,0.00035846248,0.00040396827,4.08086e-7,0.00019794234,0.001179029,0.010729443,0.0002777768,0.044916917,0.0004549473],"about_ca_topic_score_codex":0.24123552,"about_ca_topic_score_gemma":0.5924805,"teacher_disagreement_score":0.35124493,"about_ca_system_score_codex":0.0036142932,"about_ca_system_score_gemma":0.0020001405,"threshold_uncertainty_score":0.9997898},"labels":[],"label_agreement":null},{"id":"W2809076088","doi":"10.2337/db18-25-lb","title":"Risk Factors for Adverse Kidney Disease Outcomes in Type 1 Diabetes (T1D)","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Albuminuria; Adverse effect; Kidney disease; Renal function; Internal medicine; Glycemic; Diabetes mellitus; Logistic regression; Endocrinology","score_opus":0.0144038277509038,"score_gpt":0.26453712978829313,"score_spread":0.2501333020373893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809076088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962301,0.00020441096,0.0000031650563,0.0005481956,0.00058918516,0.0009908355,0.00014301689,0.00012874571,0.001162314],"genre_scores_gemma":[0.99534667,0.000036487803,0.00038850098,0.0012817242,0.00015737713,0.000153411,0.0003514543,0.00004463542,0.002239771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985674,0.00003111431,0.00025333263,0.0003726858,0.00018939134,0.0005860603],"domain_scores_gemma":[0.99877965,0.00022151743,0.000089581925,0.0004024221,0.00009795713,0.00040887587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016315638,0.00026919364,0.0004438232,0.00022443027,0.00008697213,0.000019981695,0.00011819817,0.000062922874,0.00023614845],"category_scores_gemma":[0.0010555133,0.00020404646,0.00019125426,0.00023785417,0.00011849208,0.00013937823,0.00006775552,0.00007831814,0.00014917541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000478182,0.0003844484,0.9894233,0.00011576672,0.00031204964,0.0000022570907,0.00013538345,0.00000109367,0.00022453218,0.00013814974,0.0069623515,0.002252887],"study_design_scores_gemma":[0.00265278,0.0007725813,0.9625638,0.00012092802,0.00061899127,6.3045937e-9,0.000096913725,0.00051978894,0.0054862495,0.00060439954,0.02628708,0.00027648467],"about_ca_topic_score_codex":0.000017139655,"about_ca_topic_score_gemma":0.000007437369,"teacher_disagreement_score":0.026859466,"about_ca_system_score_codex":0.00007937819,"about_ca_system_score_gemma":0.000056519464,"threshold_uncertainty_score":0.8320773},"labels":[],"label_agreement":null},{"id":"W2809142589","doi":"10.2337/db18-821-p","title":"Relationship between Weight Change Patterns and Health Satisfaction in the CANadian Canagliflozin Registry (CanCARE) Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Weight loss; Medicine; Weight change; Weight gain; Observational study; Patient satisfaction; Diabetes mellitus; Physical therapy; Demography; Internal medicine; Type 2 diabetes; Body weight; Obesity; Surgery; Endocrinology","score_opus":0.0800645804339732,"score_gpt":0.3177382784960646,"score_spread":0.23767369806209143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809142589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881054,0.00021964546,5.8005156e-7,0.008637688,0.00009811132,0.0011298461,0.000025848385,0.000022690108,0.001055035],"genre_scores_gemma":[0.9972994,0.000008692255,0.000019792506,0.001945443,0.00035668796,0.00016037484,0.000084972155,0.000012998218,0.00011168697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904203,0.00008544992,0.00016294976,0.00021003206,0.00017090549,0.00032864235],"domain_scores_gemma":[0.99942064,0.00006722177,0.00005670925,0.00027530704,0.000025513067,0.00015460445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044018432,0.000117120144,0.00018845995,0.00019615817,0.00020771264,0.00004013251,0.000059452825,0.000042708092,0.000019383426],"category_scores_gemma":[0.000028678356,0.00008670808,0.000019901063,0.00020519056,0.00004333445,0.00008282437,0.000018403052,0.00012244009,0.000013436719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000013197727,0.00003237475,0.98423576,0.00004192303,0.00003739815,0.0000055417854,0.002101126,1.1519628e-8,2.5528152e-7,0.00013464608,0.0013235332,0.012086102],"study_design_scores_gemma":[0.0006450668,0.00047952225,0.99566233,0.00006536996,0.00008052468,2.2021915e-7,0.00084242993,0.0000057221923,0.000007395206,0.00007925246,0.0020559118,0.00007626024],"about_ca_topic_score_codex":0.50906694,"about_ca_topic_score_gemma":0.9189778,"teacher_disagreement_score":0.40991083,"about_ca_system_score_codex":0.00031114044,"about_ca_system_score_gemma":0.00008735139,"threshold_uncertainty_score":0.4942022},"labels":[],"label_agreement":null},{"id":"W2809166521","doi":"10.2337/db18-1052-p","title":"Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry—The REALITY Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Internal medicine; Insulin glargine; Insulin; Endocrinology; Type 2 diabetes; Insulin detemir; Basal (medicine); Diabetes mellitus; Type 1 diabetes; Cohort; Weight loss; Obesity","score_opus":0.016442584237971628,"score_gpt":0.26917789238853684,"score_spread":0.2527353081505652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809166521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881333,0.00097116403,1.0623985e-7,0.0052668685,0.0003293806,0.003727049,0.0001329147,0.00007045572,0.0013687361],"genre_scores_gemma":[0.99539393,0.00015856867,0.00012836576,0.0031039068,0.00012316518,0.00022447182,0.0005372375,0.000089528156,0.00024080067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994979,0.0005538176,0.0011686442,0.0008991619,0.00096433604,0.001434991],"domain_scores_gemma":[0.9966353,0.00044609685,0.0005650406,0.0014659191,0.0004679156,0.00041973233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016539126,0.00071213744,0.0014551262,0.00076367246,0.0003357462,0.00011394048,0.0005466657,0.00015927569,0.00008497225],"category_scores_gemma":[0.00047761778,0.00044352934,0.00010787503,0.0022150269,0.0005311138,0.00022700553,0.00023977381,0.0005156155,0.00002591459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021570626,0.0022213932,0.98249114,0.00022322031,0.00047803455,0.000011281504,0.0023170402,0.000006647823,0.000011261294,0.00015848338,0.0024911528,0.009374637],"study_design_scores_gemma":[0.005852349,0.006447548,0.9791373,0.00035641607,0.0002648759,9.731459e-8,0.0005792838,0.00012974205,0.00019168871,0.0001202747,0.0064909975,0.0004294151],"about_ca_topic_score_codex":0.045434568,"about_ca_topic_score_gemma":0.20699161,"teacher_disagreement_score":0.16155705,"about_ca_system_score_codex":0.00058307516,"about_ca_system_score_gemma":0.0004595664,"threshold_uncertainty_score":0.99980164},"labels":[],"label_agreement":null},{"id":"W2809241860","doi":"10.1503/cmaj.171319","title":"Euglycemic diabetic ketoacidosis associated with the use of a sodium–glucose cotransporter-2 inhibitor","year":2018,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Diabetic ketoacidosis; Medicine; Vomiting; Nausea; Emergency department; Regimen; Diabetes mellitus; Type 2 Diabetes Mellitus; Dyslipidemia; Internal medicine; Ketoacidosis; Pediatrics; Intensive care medicine; Endocrinology; Type 1 diabetes; Psychiatry","score_opus":0.01335134722140336,"score_gpt":0.21246736936915275,"score_spread":0.1991160221477494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809241860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97352624,0.00008510697,0.00004519228,0.024598023,0.0003310326,0.0002836644,0.000031176874,0.000022369899,0.0010771787],"genre_scores_gemma":[0.9886367,0.000061550374,0.000090682304,0.008985601,0.0006745828,0.000011865471,0.00003279031,0.000022988685,0.001483276],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975634,0.00011272267,0.00038151856,0.00015104354,0.0012852434,0.00050606334],"domain_scores_gemma":[0.99779135,0.00019743647,0.00031516867,0.00015922353,0.00059598003,0.00094084354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079197437,0.00015390741,0.0003249515,0.00018163974,0.00022031761,0.00006555664,0.00014025615,0.0002166862,0.001401247],"category_scores_gemma":[0.00074808614,0.00009733076,0.00012367281,0.00038756666,0.00017298231,0.0001315784,0.000010685683,0.00046062583,0.000054540295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018613492,0.00041331697,0.6013671,0.00003321805,0.0028863407,0.0005795467,0.0013500077,0.000001735963,0.00022983618,0.00013571083,0.34651574,0.046301298],"study_design_scores_gemma":[0.007902343,0.0018517957,0.42822593,0.00083940016,0.0014509234,0.00007609229,0.00041773776,0.000437435,0.0011956362,0.000041609306,0.5572157,0.00034540778],"about_ca_topic_score_codex":0.00069289515,"about_ca_topic_score_gemma":0.020009747,"teacher_disagreement_score":0.21069995,"about_ca_system_score_codex":0.0008017749,"about_ca_system_score_gemma":0.0012490826,"threshold_uncertainty_score":0.9995116},"labels":[],"label_agreement":null},{"id":"W2809343280","doi":"10.2337/db18-1094-p","title":"Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quartile; Duration (music); Medicine; Lixisenatide; Type 2 diabetes; Internal medicine; Hypoglycemia; Insulin glargine; Insulin; Endocrinology; Animal science; Basal insulin; Diabetes mellitus; Confidence interval; Biology","score_opus":0.012471510341874747,"score_gpt":0.2860320893763274,"score_spread":0.27356057903445263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809343280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704427,0.00015117844,0.000004097187,0.00039589475,0.000117189105,0.0004374067,0.00002925015,0.000047897363,0.0017728097],"genre_scores_gemma":[0.99832934,0.000016196762,0.00033489938,0.0003070902,0.0001141818,0.000027480452,0.00008746723,0.000030860298,0.00075250503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984314,0.00010246773,0.00042547702,0.00030887136,0.00035643342,0.00037537524],"domain_scores_gemma":[0.998461,0.000234788,0.00018618416,0.0006005318,0.00035250967,0.000164958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004968851,0.00023056945,0.00060790824,0.00054261414,0.00004446781,0.000017163822,0.00013603354,0.0000824999,0.00044143604],"category_scores_gemma":[0.0005866463,0.00017731855,0.00027569634,0.00076267304,0.00010509515,0.000093073155,0.00006141542,0.00006415363,0.00021884673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001432192,0.00065885985,0.7961239,0.00009997975,0.0014181887,0.0000027809776,0.00043738025,0.000021760323,0.18688835,0.00006582235,0.0058509912,0.0069997814],"study_design_scores_gemma":[0.0010891263,0.008868481,0.6998122,0.00018753677,0.00059537747,6.137638e-8,0.000034246812,0.0004115035,0.2876042,0.000046426805,0.0011822497,0.00016858891],"about_ca_topic_score_codex":0.00004299765,"about_ca_topic_score_gemma":0.000006945307,"teacher_disagreement_score":0.10071585,"about_ca_system_score_codex":0.000109692526,"about_ca_system_score_gemma":0.000060513386,"threshold_uncertainty_score":0.72308403},"labels":[],"label_agreement":null},{"id":"W2809439593","doi":"10.2337/db18-1036-p","title":"Similar Variability of Fasting and 24-h Self-Measured Plasma Glucose (SMPG) with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM—The Randomized BRIGHT Trial","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin degludec; Insulin glargine; Internal medicine; Medicine; Endocrinology; Insulin; Hypoglycemia","score_opus":0.00892508957815301,"score_gpt":0.21917643985107035,"score_spread":0.21025135027291733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809439593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896405,0.0010866846,0.0000714993,0.0010699042,0.0003079913,0.005973603,0.000055680037,0.00023762572,0.0015565628],"genre_scores_gemma":[0.9932635,0.00029730852,0.0045492463,0.00043290382,0.000419787,0.0006134711,0.00014945067,0.00010732202,0.0001670287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994793,0.0007610181,0.001360773,0.001105205,0.0009811687,0.0009988346],"domain_scores_gemma":[0.9954522,0.001877928,0.0007134976,0.001006779,0.0006141408,0.00033543786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033264349,0.0008197922,0.0023349926,0.00042559233,0.0002278698,0.00009919761,0.00036997965,0.00028688385,0.000120731995],"category_scores_gemma":[0.0018795866,0.0005005975,0.00024068439,0.0011345517,0.0009168907,0.00032157503,0.00022244228,0.00050438073,0.00002057346],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76409554,0.0064675524,0.16790603,0.001530136,0.0045449133,0.0001182933,0.0067664343,0.00007800879,0.0009701251,0.0004598748,0.0004659907,0.04659707],"study_design_scores_gemma":[0.9064822,0.0068698893,0.051468913,0.0017359632,0.0024929156,0.0000066167427,0.00036469687,0.00974166,0.016796196,0.00029499148,0.0028129406,0.00093297305],"about_ca_topic_score_codex":0.00022588717,"about_ca_topic_score_gemma":0.00028143858,"teacher_disagreement_score":0.14238667,"about_ca_system_score_codex":0.000208909,"about_ca_system_score_gemma":0.00030331616,"threshold_uncertainty_score":0.9997446},"labels":[],"label_agreement":null},{"id":"W2809484473","doi":"10.1007/s00018-018-2857-1","title":"Histones and heart failure in diabetes","year":2018,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Diabetes Canada; Heart and Stroke Foundation of Canada","keywords":"Diabetes mellitus; Histone; Heart failure; Medicine; Epigenetics; Bioinformatics; Intensive care medicine; Cardiology; Biology; Endocrinology; Genetics; Gene","score_opus":0.02364723873088905,"score_gpt":0.28580899316705627,"score_spread":0.26216175443616724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809484473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006027962,0.99182457,0.000006499145,0.00030700286,0.00010820013,0.00060213695,0.0000024828696,0.000021890162,0.001099243],"genre_scores_gemma":[0.0011427989,0.9971817,0.00079903204,0.00037292353,0.000066510474,0.000053918095,0.000028519873,0.000019736204,0.00033485037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985781,0.000066813016,0.00025936402,0.0005525444,0.00022453378,0.00031866966],"domain_scores_gemma":[0.9994872,0.000035054854,0.00007775374,0.00019982642,0.000017205035,0.00018296741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037009263,0.00028024043,0.00091448496,0.00032234626,0.00009213243,0.00005733822,0.00010579402,0.00012305877,0.000020681402],"category_scores_gemma":[0.00005503889,0.0001975154,0.00014155805,0.0003309394,0.0005644316,0.0000616921,0.00013532756,0.000105067964,0.000019863388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010026932,0.00062265317,0.006940251,0.062995575,0.0010186778,0.00044382614,0.00037545737,3.7576362e-7,0.0007706417,0.0037593488,0.022916833,0.9001463],"study_design_scores_gemma":[0.00023031096,0.00024629076,0.000036982325,0.0034583837,0.000596537,0.0000046319747,0.000031268497,0.00000856442,0.00008419486,0.00007204953,0.995021,0.00020979173],"about_ca_topic_score_codex":0.000008017351,"about_ca_topic_score_gemma":0.00000421267,"teacher_disagreement_score":0.97210413,"about_ca_system_score_codex":0.000023740651,"about_ca_system_score_gemma":0.00012342528,"threshold_uncertainty_score":0.8054444},"labels":[],"label_agreement":null},{"id":"W2809573217","doi":"10.2337/db18-1096-p","title":"Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP–1RA) in PatientS with Type 2 Diabetes—PROGRESS-DIABETES Study","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Type 2 diabetes; Internal medicine; Diabetes mellitus; Weight loss; Dulaglutide; Glucagon-like peptide 1 receptor; Interim analysis; Clinical trial; Physical therapy; Obesity; Endocrinology; Agonist","score_opus":0.011364599851427527,"score_gpt":0.2566469624209649,"score_spread":0.2452823625695374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809573217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955309,0.00024454747,3.4339678e-7,0.000088179775,0.00083599455,0.0023616473,0.000016323811,0.00015559382,0.0007664542],"genre_scores_gemma":[0.99808955,0.00000349912,0.00053598324,0.00035096952,0.000059017824,0.00023833787,0.00045742546,0.000089149056,0.00017609162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660563,0.00012136336,0.0008841479,0.00068553496,0.00086088566,0.00084241887],"domain_scores_gemma":[0.997953,0.00014099444,0.0005070646,0.0007484618,0.00046487842,0.00018563282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037086423,0.0005092612,0.0010363228,0.000512009,0.00012296253,0.000059132417,0.00018086977,0.00012618583,0.000102255435],"category_scores_gemma":[0.00023313242,0.00039984394,0.00018938983,0.00092607556,0.0001994804,0.0003856194,0.00016194863,0.00016778708,0.000060878792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008978857,0.0034144623,0.98405606,0.00012708259,0.0016448271,0.0000074960353,0.0007433838,0.0000011796374,0.00040290522,0.000006600063,0.0004538539,0.0090523455],"study_design_scores_gemma":[0.0069981907,0.007428429,0.9753521,0.0004156927,0.00077274436,1.456887e-8,0.0003021941,0.0000336475,0.0077590826,0.000019928057,0.00050951645,0.00040843943],"about_ca_topic_score_codex":0.00001506694,"about_ca_topic_score_gemma":0.00001904239,"teacher_disagreement_score":0.008703955,"about_ca_system_score_codex":0.0001641721,"about_ca_system_score_gemma":0.00007705555,"threshold_uncertainty_score":0.9998453},"labels":[],"label_agreement":null},{"id":"W2809681611","doi":"10.1111/dom.13377","title":"Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Canadian VIGOUR Centre; University of Alberta","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research","keywords":"Medicine; Type 2 diabetes; Hazard ratio; Sitagliptin; Internal medicine; Aspirin; Diabetes mellitus; Myocardial infarction; Stroke (engine); Angina; Disease; Proportional hazards model; Confidence interval; Endocrinology","score_opus":0.007154820336780577,"score_gpt":0.19809272029479205,"score_spread":0.19093789995801147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809681611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903294,0.008566588,0.0000031986617,0.00004316033,0.00008377158,0.000620875,0.00003061153,0.0000242021,0.00029822488],"genre_scores_gemma":[0.9980736,0.00086902594,0.000515185,0.00009044524,0.000031339394,0.00003623195,0.00007150291,0.000014079211,0.00029860227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876845,0.000038916678,0.00021713797,0.00043122188,0.0002874327,0.0002568624],"domain_scores_gemma":[0.99930257,0.000040541312,0.00007042373,0.00036145395,0.00006472912,0.00016026675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017816773,0.00021622243,0.00071984873,0.00015460228,0.000056223937,0.000028488419,0.000050153907,0.00004372728,0.000020466188],"category_scores_gemma":[0.00003317702,0.00015080745,0.00005849329,0.00014413627,0.00022344304,0.00011507372,0.00014437118,0.000054736403,0.0000015954383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028954595,0.00028008706,0.9834855,0.00020137221,0.0017996774,0.000018029785,0.00013199895,8.780735e-8,0.00000805322,0.000060906463,0.000035156743,0.013950133],"study_design_scores_gemma":[0.0023320888,0.00011949403,0.9928231,0.0001203674,0.001921147,6.9479356e-8,0.00005123206,0.000024619696,0.00019773017,0.00031772736,0.0019287363,0.000163654],"about_ca_topic_score_codex":0.00004149308,"about_ca_topic_score_gemma":0.0000069235757,"teacher_disagreement_score":0.013786479,"about_ca_system_score_codex":0.000007515617,"about_ca_system_score_gemma":0.000008484304,"threshold_uncertainty_score":0.6149749},"labels":[],"label_agreement":null},{"id":"W2809777901","doi":"10.14740/jocmr3456w","title":"Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Regimen; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Dipeptidyl peptidase; Internal medicine; Endocrinology; Enzyme; Biochemistry; Chemistry; Diabetes mellitus; Type 2 diabetes","score_opus":0.09519118258978237,"score_gpt":0.4500221399080783,"score_spread":0.35483095731829595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809777901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809688,0.00076771126,0.00006398516,0.014498885,0.0008510648,0.0007785335,0.0000048496217,0.000013868693,0.0020523395],"genre_scores_gemma":[0.99128336,0.00045013143,0.00177371,0.00072163035,0.0051730354,0.000016385065,0.0000026108773,0.000034135006,0.000544978],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99455786,0.00046496378,0.0020310858,0.00041839824,0.0020455508,0.0004821539],"domain_scores_gemma":[0.9945736,0.0022689397,0.0006127085,0.00045494913,0.0011750463,0.00091479224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036246027,0.00023147758,0.0011581159,0.00059181644,0.000096482065,0.000029190753,0.00015360325,0.0001787546,0.0003489128],"category_scores_gemma":[0.00465865,0.00015074105,0.00018904168,0.00046892965,0.00055753085,0.0002045744,0.0002494512,0.0010202569,0.000061919694],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01256722,0.0011319654,0.16278128,0.00015447156,0.00072741945,0.0003102487,0.00269779,8.035599e-7,0.009811473,0.000032691267,0.058421787,0.75136286],"study_design_scores_gemma":[0.016137742,0.0496674,0.8604513,0.0070967367,0.00050183636,0.000019697809,0.0018417046,0.000037638132,0.0052708164,0.0004396322,0.058316614,0.00021888375],"about_ca_topic_score_codex":0.00026500312,"about_ca_topic_score_gemma":0.000052323092,"teacher_disagreement_score":0.751144,"about_ca_system_score_codex":0.00015519602,"about_ca_system_score_gemma":0.00023460765,"threshold_uncertainty_score":0.61470413},"labels":[],"label_agreement":null},{"id":"W2809840320","doi":"10.14740/jocmr3467w","title":"SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacology; Clinical trial; Outcome (game theory); Intensive care medicine; Internal medicine","score_opus":0.6068964028826357,"score_gpt":0.5605697643811668,"score_spread":0.0463266385014689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809840320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007865495,0.98537076,0.000037826998,0.003156895,0.0006462809,0.0026124606,0.0000048963093,0.000006914228,0.00029845224],"genre_scores_gemma":[0.033047292,0.96484804,0.00006474859,0.000016653752,0.0018729832,0.000049476403,0.0000045476663,0.000045307977,0.000050946695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911331,0.0021528054,0.0037737796,0.00051758904,0.0019456933,0.00047702386],"domain_scores_gemma":[0.99206877,0.004933625,0.0015684201,0.0004714876,0.00048453282,0.00047318972],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.04127866,0.0004108069,0.0059431354,0.0011296567,0.00019108532,0.000066267676,0.00020692182,0.00028182208,0.000009535622],"category_scores_gemma":[0.0071195127,0.00019275049,0.0006236429,0.00088922307,0.0016340655,0.00012502336,0.00029823216,0.0024735,9.132827e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043457682,0.00025847025,0.0073941527,0.013437229,0.0025412622,0.00010245118,0.00023835726,5.629604e-7,2.714579e-7,0.0002265812,0.00075870147,0.9746074],"study_design_scores_gemma":[0.026733981,0.02230131,0.00702656,0.32859296,0.01550023,0.0007013023,0.0025347525,0.000021410087,0.000007780144,0.0014410297,0.5945308,0.0006078915],"about_ca_topic_score_codex":0.00004067696,"about_ca_topic_score_gemma":0.000022654873,"teacher_disagreement_score":0.9739995,"about_ca_system_score_codex":0.00020131134,"about_ca_system_score_gemma":0.00053624186,"threshold_uncertainty_score":0.99982786},"labels":[],"label_agreement":null},{"id":"W2809913281","doi":"10.1016/j.jval.2018.04.1668","title":"Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Weight loss; Prediabetes; Cohort; Weight management; Weight change; Body weight; Internal medicine; Weight gain; Type 2 diabetes; Diabetes mellitus; Obesity; Gastroenterology; Endocrinology","score_opus":0.047210574591376675,"score_gpt":0.3647974245499249,"score_spread":0.31758684995854825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809913281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842224,0.00018882644,0.000069733396,0.0010504733,0.0006936694,0.0029087774,0.000010240801,0.000016704853,0.010839158],"genre_scores_gemma":[0.9953859,0.0004675127,0.0028546364,0.00044878665,0.000107559055,0.00014528514,0.000022051254,0.000018269631,0.00054999813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982834,0.0002319398,0.000635233,0.00028588128,0.0001898471,0.00037371804],"domain_scores_gemma":[0.9989897,0.00043802388,0.00012889341,0.0002889685,0.000036105623,0.00011830041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017615266,0.000116491974,0.000503914,0.00022764996,0.000023544388,0.0000024398898,0.00008158983,0.000026017815,0.000015043055],"category_scores_gemma":[0.000040923005,0.00010237225,0.000058285263,0.00034020236,0.000041663287,0.000025149871,0.000047590165,0.00008034443,0.0000044132225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000979827,0.0007204378,0.92073435,0.004451496,0.00020982052,0.000071369686,0.000081162245,0.000096780066,0.000006049145,0.016669117,0.0036033918,0.052376222],"study_design_scores_gemma":[0.0057719266,0.0010604567,0.97294605,0.0014162718,0.000053497108,3.828532e-7,0.000066308006,0.0022894528,0.00019330392,0.0009557905,0.015143885,0.00010268498],"about_ca_topic_score_codex":0.82083684,"about_ca_topic_score_gemma":0.7177119,"teacher_disagreement_score":0.10312491,"about_ca_system_score_codex":0.0012193038,"about_ca_system_score_gemma":0.0006894789,"threshold_uncertainty_score":0.41746193},"labels":[],"label_agreement":null},{"id":"W2810191405","doi":"10.1016/j.jval.2018.04.520","title":"Real-World Comparison of Healthcare Costs Among Patients with Type 2 Diabetes Treated with Dulaglutide Vs. Liraglutide in the United States","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Liraglutide; Dulaglutide; Medicine; Exenatide; Type 2 diabetes; Propensity score matching; Pharmacy; Health care; Internal medicine; Demography; Diabetes mellitus; Emergency medicine; Family medicine; Endocrinology; Economics","score_opus":0.028896201102718882,"score_gpt":0.3041923772416751,"score_spread":0.2752961761389562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810191405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477947,0.00018028112,0.0000011050868,0.0026945146,0.00004551466,0.0017682498,0.000016412745,0.000045993722,0.00046846454],"genre_scores_gemma":[0.9979838,0.00014310367,0.0003379918,0.00080421777,0.00002795508,0.000048938087,0.00051264674,0.00003372275,0.00010758714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783206,0.0003072227,0.00056140864,0.00030809108,0.00042951663,0.00056172936],"domain_scores_gemma":[0.99870455,0.00017445128,0.0003005504,0.00043239025,0.00024253066,0.00014553932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045566933,0.00023136883,0.00059858605,0.00073772995,0.00008157184,0.000014827273,0.00013241003,0.000044441702,0.000011083756],"category_scores_gemma":[0.000032534645,0.00013660581,0.000023682998,0.0024991587,0.00017709834,0.000070341724,0.000030095332,0.0002032017,0.000006295256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005872287,0.0008375691,0.9938733,0.0003724881,0.00007137703,0.000007631645,0.0017246718,0.00037057363,8.8878727e-7,0.00024752688,0.0005514487,0.0013552736],"study_design_scores_gemma":[0.0034377128,0.0073272414,0.98248357,0.0019484942,0.000054701934,1.349878e-7,0.00066914374,0.0028943832,0.00012540797,0.00003063124,0.0008980186,0.00013056028],"about_ca_topic_score_codex":0.07034776,"about_ca_topic_score_gemma":0.01923965,"teacher_disagreement_score":0.05110811,"about_ca_system_score_codex":0.00055233703,"about_ca_system_score_gemma":0.0001605287,"threshold_uncertainty_score":0.9986567},"labels":[],"label_agreement":null},{"id":"W2810327986","doi":"10.14740/jocmr3464w","title":"Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Internal medicine; Diabetes mellitus; Endocrinology; Lipid profile; Cholesterol; Type 2 Diabetes Mellitus","score_opus":0.059014763627178744,"score_gpt":0.45747166160771185,"score_spread":0.39845689798053313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810327986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381125,0.00044391552,7.283496e-7,0.0011377685,0.00024687775,0.000556133,6.788746e-7,0.0000035582545,0.0037990708],"genre_scores_gemma":[0.9983147,0.00045853117,0.00012137677,0.00010605595,0.0007724785,0.000003954982,0.0000048678007,0.000014349438,0.000203691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712497,0.0004738638,0.0008442021,0.00018142923,0.0010709726,0.0003045917],"domain_scores_gemma":[0.9961007,0.0024111262,0.00027884697,0.0002255621,0.00072403013,0.00025971181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006005941,0.00011846251,0.00085936126,0.0004827448,0.00002557255,0.000005294235,0.00011712135,0.000082512735,0.00014614532],"category_scores_gemma":[0.00441675,0.000059220023,0.00005696494,0.00049359875,0.00067666924,0.00005603243,0.000058267353,0.00059578236,0.000016387714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017654216,0.0006559959,0.81631684,0.00028017754,0.00020520503,0.00002590658,0.000058398182,1.4195354e-7,0.000063018924,0.000022084649,0.0029352582,0.16178274],"study_design_scores_gemma":[0.023535958,0.29135624,0.6759197,0.0029805582,0.00020097174,0.0000011188049,0.000040607138,0.0000424839,0.0013679975,0.00004473612,0.0044447724,0.00006483231],"about_ca_topic_score_codex":0.0000072028565,"about_ca_topic_score_gemma":0.0000024576898,"teacher_disagreement_score":0.29070026,"about_ca_system_score_codex":0.0000435786,"about_ca_system_score_gemma":0.00008803502,"threshold_uncertainty_score":0.5287581},"labels":[],"label_agreement":null},{"id":"W2810590812","doi":"10.1152/ajpendo.00164.2018","title":"Antipsychotics and glucose metabolism: how brain and body collide","year":2018,"lang":"en","type":"review","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; Centre for Addiction and Mental Health","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Schizophrenia (object-oriented programming); Type 2 diabetes; Antipsychotic; Insulin resistance; Medicine; Diabetes mellitus; Disease; Glucose homeostasis; Clozapine; Bioinformatics; Neuroscience; Psychiatry; Psychology; Endocrinology; Internal medicine; Biology","score_opus":0.020002386825638725,"score_gpt":0.3062027351974144,"score_spread":0.2862003483717757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810590812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058985177,0.9384583,0.000009286019,0.0012085642,0.00068116793,0.000513951,0.000025736868,0.000024130928,0.000093686154],"genre_scores_gemma":[0.0052987314,0.99089086,0.0014399814,0.000929988,0.0008846544,0.000023186292,0.000021450103,0.00005914902,0.0004520257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730754,0.0005072125,0.0007379313,0.0006045311,0.00017553629,0.0006672665],"domain_scores_gemma":[0.9973143,0.00039677162,0.001334622,0.0003963547,0.00017844392,0.00037955737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031179623,0.00067666743,0.0046126423,0.0006555817,0.00014582327,0.000042900225,0.00020545414,0.00018912517,0.000019626244],"category_scores_gemma":[0.0001703815,0.00046420548,0.0004002416,0.00032095573,0.0021346186,0.00015798915,0.00023415047,0.0007345512,0.0000068061777],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003094128,0.00023684811,0.000057142886,0.0018805183,0.0048569306,0.0001566171,0.00012778213,2.0275762e-8,0.00041968317,0.00262603,0.0036865033,0.9856425],"study_design_scores_gemma":[0.002194944,0.0012539853,0.010776083,0.0009779836,0.009884132,0.0019454575,0.00018907258,8.1170583e-7,0.000032714514,0.0005005197,0.9718873,0.00035701125],"about_ca_topic_score_codex":0.000007153611,"about_ca_topic_score_gemma":0.0000012794656,"teacher_disagreement_score":0.9852855,"about_ca_system_score_codex":0.0000217123,"about_ca_system_score_gemma":0.00014702622,"threshold_uncertainty_score":0.99978095},"labels":[],"label_agreement":null},{"id":"W2810651762","doi":"10.1111/dom.13448","title":"Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; McGill University; University of Alberta; McGill University Health Centre","funders":"Government of Canada","keywords":"Metformin; Medicine; Exacerbation; Hazard ratio; Confidence interval; Diabetes mellitus; Proportional hazards model; Internal medicine; Heart failure; Type 2 diabetes; Population; Cumulative dose; Endocrinology; Environmental health","score_opus":0.009007983188584895,"score_gpt":0.21779254340710125,"score_spread":0.20878456021851635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810651762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814427,0.00096414814,6.326212e-7,0.00008614211,0.00007414555,0.00057123555,0.000038651484,0.00002440762,0.00009638221],"genre_scores_gemma":[0.99713695,0.00011123863,0.0020906606,0.00036123558,0.00004513915,0.000014677428,0.000073401105,0.000019414485,0.00014728383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988974,0.000034032095,0.00020681122,0.00030583757,0.00021234753,0.00034362084],"domain_scores_gemma":[0.99930334,0.000063644875,0.00008477395,0.00022109944,0.00019222854,0.0001349363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014372962,0.00022123098,0.0006003384,0.00021899858,0.00006137375,0.000030157395,0.000048131827,0.000079703685,0.000023672575],"category_scores_gemma":[0.000050383573,0.00016252145,0.00003847725,0.00030321215,0.00020665138,0.00037927748,0.00009931454,0.0000891055,0.000005976705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010410298,0.00033261205,0.9949073,0.00007530914,0.00037659754,6.354229e-7,0.0002705593,5.987858e-7,0.0002235608,0.00045869162,0.0001994406,0.003050589],"study_design_scores_gemma":[0.0033911862,0.00086357107,0.9821106,0.00014951061,0.00067862106,9.9978145e-8,0.000021406639,0.000032218475,0.008605692,0.000096309486,0.0038842775,0.00016647267],"about_ca_topic_score_codex":0.000018596458,"about_ca_topic_score_gemma":0.000035420115,"teacher_disagreement_score":0.012796668,"about_ca_system_score_codex":0.000012524699,"about_ca_system_score_gemma":0.000014699208,"threshold_uncertainty_score":0.6627433},"labels":[],"label_agreement":null},{"id":"W2810705424","doi":"10.2337/dc18-0394","title":"Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes","year":2018,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Type 2 diabetes; Excretion; Internal medicine; Endocrinology","score_opus":0.0069691722907066055,"score_gpt":0.23073800688539767,"score_spread":0.22376883459469107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810705424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923961,0.00050623424,2.3331003e-7,0.0039594914,0.00026397742,0.0008769036,0.0003309201,0.000032534048,0.0016335945],"genre_scores_gemma":[0.9768526,0.00007442973,0.000088994966,0.016214857,0.0006861051,0.00008225786,0.0055779577,0.000085011714,0.0003377914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983431,0.00009169142,0.00029927594,0.00043200306,0.00046438706,0.00036952845],"domain_scores_gemma":[0.998913,0.00020684747,0.0002504198,0.0003892923,0.00018674547,0.000053723346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000118855634,0.0003996516,0.0009314017,0.0004425138,0.00002493792,0.000014307471,0.00009637857,0.00037076743,0.00006303856],"category_scores_gemma":[0.000039213362,0.00028931996,0.000121979494,0.00023965622,0.00018618422,0.0000652772,0.000058295453,0.00043420706,0.000027338576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054716354,0.000104471364,0.9040252,0.0039530783,0.0015485109,0.000044274468,0.0007305867,0.000001321915,0.00053369586,0.000003427691,0.08602385,0.0024844185],"study_design_scores_gemma":[0.032913227,0.10538695,0.4800215,0.02354217,0.02430163,0.0000025196987,0.0013665167,0.00018057007,0.21669044,0.00010532628,0.11248939,0.0029997649],"about_ca_topic_score_codex":0.000007638812,"about_ca_topic_score_gemma":0.00000388406,"teacher_disagreement_score":0.4240037,"about_ca_system_score_codex":0.00011453606,"about_ca_system_score_gemma":0.000042130137,"threshold_uncertainty_score":0.9999559},"labels":[],"label_agreement":null},{"id":"W2810977826","doi":"10.1016/j.jval.2018.04.469","title":"Characteristics &amp; Glycemic Response of Patients With Uncontrolled Type 2 Diabetes Initiating Dulaglutide Alone or In Combination with Insulin In US Real World Practice","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Dulaglutide; Type 2 diabetes; Internal medicine; Glycemic; Medical prescription; Diabetes mellitus; Retrospective cohort study; Glucagon-like peptide 1 receptor; Insulin; Exenatide; Agonist; Endocrinology; Pharmacology","score_opus":0.024793714633708025,"score_gpt":0.29655450761118235,"score_spread":0.27176079297747435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810977826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719274,0.00005544148,0.000005215612,0.0009172142,0.000081382896,0.0014383957,0.00000870343,0.00002165746,0.00027924965],"genre_scores_gemma":[0.9962213,0.00011077854,0.0026834018,0.00067721313,0.000027552995,0.000048851372,0.000118678414,0.000026964104,0.00008528193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788207,0.0005049755,0.00067671906,0.00025264546,0.00032240438,0.0003611683],"domain_scores_gemma":[0.99820375,0.0008589691,0.0003918893,0.00024674274,0.00021759444,0.000081037404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013191362,0.00016390937,0.00055359636,0.0006010327,0.00003181584,0.000010604025,0.000059276128,0.000044969438,0.000014729753],"category_scores_gemma":[0.0013193935,0.00012075132,0.0000135335895,0.0011081763,0.000065884815,0.00016148151,0.00003074818,0.00018016773,0.000007993967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06666436,0.0016131466,0.9285194,0.00027438407,0.0000487706,0.000027365628,0.0010794046,0.00006550343,0.000019811214,0.00006604991,0.000018434657,0.0016033305],"study_design_scores_gemma":[0.021936616,0.009072194,0.96573937,0.0014964645,0.000046499492,4.5719685e-7,0.000096977434,0.001073849,0.00003459047,0.000020097457,0.00036551498,0.00011734151],"about_ca_topic_score_codex":0.0026012736,"about_ca_topic_score_gemma":0.0036897918,"teacher_disagreement_score":0.044727746,"about_ca_system_score_codex":0.00053866697,"about_ca_system_score_gemma":0.00042570994,"threshold_uncertainty_score":0.4924096},"labels":[],"label_agreement":null},{"id":"W2811425937","doi":"10.1161/circulationaha.118.034986","title":"Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus","year":2018,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"University of Glasgow; University of Oxford; Wellcome Trust; Novo Nordisk; Cytokinetics; Sanofi; Defense Acquisition Program Administration; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Case fatality rate; Incidence (geometry); Heart failure; Type 2 Diabetes Mellitus; Population; Epidemiology; Poisson regression; Internal medicine; Pediatrics; Demography; Endocrinology; Environmental health","score_opus":0.00875566002669636,"score_gpt":0.24307189294827555,"score_spread":0.2343162329215792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811425937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556994,0.00022608746,0.0031723913,0.00014887349,0.00002336016,0.0007863289,0.0000046492864,0.000022832075,0.00004555918],"genre_scores_gemma":[0.9980712,0.00000972443,0.0017136211,0.000031114672,0.0000395342,0.00003726502,0.00007426174,0.000009921805,0.000013363112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995013,0.000012641129,0.00011785796,0.00017554227,0.00009587832,0.000096781405],"domain_scores_gemma":[0.9996134,0.000021225966,0.00007359497,0.00012057834,0.00012640544,0.000044820503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114466144,0.00007994564,0.00015785846,0.000058847138,0.000066483015,0.000016896805,0.000010746961,0.000038052887,0.0000045965708],"category_scores_gemma":[0.000029719286,0.000065291555,0.000016035861,0.000106019994,0.00009776986,0.00017660516,0.000013295901,0.000015810816,4.7650184e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017778913,0.000029016699,0.99714017,0.00021954234,0.000048877417,8.125727e-7,0.00032844156,0.0000047119884,0.0007730133,0.00023807352,0.000052790318,0.0011468009],"study_design_scores_gemma":[0.00093541376,0.0003326722,0.9908035,0.0001266835,0.0002582648,0.000009573215,0.0001240121,0.004708393,0.0023120497,0.0002042256,0.00011195628,0.00007325784],"about_ca_topic_score_codex":0.000061195155,"about_ca_topic_score_gemma":0.00021253688,"teacher_disagreement_score":0.006336643,"about_ca_system_score_codex":0.00002038907,"about_ca_system_score_gemma":0.0000086764885,"threshold_uncertainty_score":0.26625124},"labels":[],"label_agreement":null},{"id":"W2811431920","doi":"10.1007/s00422-018-0765-y","title":"Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases","year":2018,"lang":"en","type":"article","venue":"Biological Cybernetics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Nephron; Tubuloglomerular feedback; Renal glucose reabsorption; Kidney; Endocrinology; Renal function; Internal medicine; Kidney disease; Diabetes mellitus; Natriuresis; Reabsorption; Medicine; Excretion; Population; Type 2 diabetes; Renal sodium reabsorption; Tubular fluid; Glomerular hyperfiltration; Diabetic nephropathy","score_opus":0.028413961320929795,"score_gpt":0.26690096180565037,"score_spread":0.23848700048472057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811431920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998165,0.0015373655,0.00031156576,0.0014751796,0.00023031494,0.0019166301,0.00009768205,0.0002524915,0.0041971174],"genre_scores_gemma":[0.98748094,0.00022807084,0.007492075,0.0009841007,0.0010029245,0.00034409898,0.00029719874,0.000025440342,0.0021451558],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891585,0.00001837943,0.00016528134,0.00036163026,0.000108975146,0.00042987216],"domain_scores_gemma":[0.9992443,0.00007882887,0.00005704233,0.00024538333,0.00007754569,0.00029694207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000385886,0.00023889469,0.00032930815,0.000044193283,0.00009120551,0.000029407744,0.00007002142,0.000085606924,0.00014723194],"category_scores_gemma":[0.00006545348,0.000129224,0.00012064412,0.00009125297,0.00025242913,0.00002670565,0.00004844046,0.000033654083,0.000061398685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032763674,0.007848777,0.67923236,0.000561495,0.003888866,0.00010961037,0.00047573505,0.000026751479,0.019758059,0.008127968,0.046739977,0.22995406],"study_design_scores_gemma":[0.014959223,0.08088502,0.05841155,0.0005017287,0.0018821955,0.0000031808886,0.00006165243,0.0011666394,0.04296543,0.00050629355,0.7978564,0.00080071855],"about_ca_topic_score_codex":0.0000035883993,"about_ca_topic_score_gemma":0.0000054936827,"teacher_disagreement_score":0.7511164,"about_ca_system_score_codex":0.00020282422,"about_ca_system_score_gemma":0.00006875647,"threshold_uncertainty_score":0.5269602},"labels":[],"label_agreement":null},{"id":"W2815605547","doi":"10.1055/s-0038-1641913","title":"Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c","year":2018,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Blood pressure; Internal medicine; Heart failure; Cardiology; Type 2 diabetes; Diabetes mellitus; Placebo; Cholesterol; Lipoprotein; Endocrinology","score_opus":0.010821793697958137,"score_gpt":0.26195185400338594,"score_spread":0.2511300603054278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2815605547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427724,0.0025816462,0.00009025522,0.00076784595,0.000119737524,0.001197567,0.000047861646,0.000083736915,0.0008341148],"genre_scores_gemma":[0.9976256,0.000039280843,0.0015915701,0.00021511772,0.00009573807,0.000056410485,0.0000127416815,0.000023176026,0.00034035795],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838734,0.00009880723,0.00039336146,0.00044894914,0.00029313285,0.00037839016],"domain_scores_gemma":[0.99873674,0.00014289138,0.00023110236,0.00047756435,0.0002798969,0.00013182881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029054523,0.00026817535,0.00085716177,0.00020024712,0.00006817246,0.000017709337,0.00014172401,0.00017010237,0.0000366111],"category_scores_gemma":[0.00024132903,0.00021826767,0.00012852589,0.00021072815,0.0005825653,0.00011477406,0.000110998735,0.00015143777,0.000009763857],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002202267,0.006219091,0.58823264,0.0021841764,0.018597517,0.00006997409,0.0018806016,0.000012522576,0.30708304,0.0028609147,0.009670864,0.060986403],"study_design_scores_gemma":[0.006905745,0.0033327497,0.34115154,0.00035088536,0.0047742506,0.000005820522,0.0002550809,0.00008403068,0.63959336,0.0007046356,0.002565622,0.00027628575],"about_ca_topic_score_codex":0.00015857848,"about_ca_topic_score_gemma":0.00006995995,"teacher_disagreement_score":0.33251032,"about_ca_system_score_codex":0.00001647306,"about_ca_system_score_gemma":0.00006023524,"threshold_uncertainty_score":0.8900697},"labels":[],"label_agreement":null},{"id":"W2828900474","doi":"10.1213/xaa.0000000000000734","title":"When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium–Glucose Cotransporter-2 Inhibitor: A Case Report","year":2018,"lang":"en","type":"article","venue":"A&A Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Canagliflozin; Medicine; Diabetic ketoacidosis; Perioperative; Ketoacidosis; Diabetes mellitus; Cotransporter; Type 2 diabetes; Surgery; Type 2 Diabetes Mellitus; Intensive care medicine; Anesthesia; Endocrinology; Sodium; Type 1 diabetes","score_opus":0.031383415959890505,"score_gpt":0.2977714465636361,"score_spread":0.26638803060374555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2828900474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98745626,0.0018489847,0.0001130209,0.005206935,0.00073379424,0.0010042058,0.000008377641,0.00014598174,0.0034824135],"genre_scores_gemma":[0.99011153,0.00023831532,0.004480259,0.0037320293,0.0005426009,0.0003519355,0.00005743784,0.00006679327,0.00041907333],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968892,0.00014024887,0.0011491141,0.000689665,0.0005239727,0.0006078501],"domain_scores_gemma":[0.9974145,0.00048365933,0.0006582978,0.0007637713,0.0004615004,0.00021824343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010373167,0.00036307087,0.0005808159,0.00050228345,0.00009202712,0.000084345826,0.000074648065,0.00014199104,0.00034951998],"category_scores_gemma":[0.001697974,0.00032495012,0.00020631407,0.0005582796,0.000086413354,0.0007345531,0.00009775126,0.00024730133,0.0001892494],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020186375,0.0017774248,0.07552641,0.0003471822,0.00074945454,0.79910475,0.0046206126,0.0000021836179,0.0003385202,0.000025775827,0.027035868,0.08845319],"study_design_scores_gemma":[0.01001715,0.0030923248,0.017775403,0.0021748547,0.00870873,0.1242261,0.005612434,0.0007086828,0.007993883,0.00024092013,0.81723386,0.002215628],"about_ca_topic_score_codex":0.0012524424,"about_ca_topic_score_gemma":0.0003781131,"teacher_disagreement_score":0.790198,"about_ca_system_score_codex":0.00023551781,"about_ca_system_score_gemma":0.00018519552,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W2867826920","doi":"10.1055/s-0038-1641875","title":"SUSTAIN 6: Effekt von Semaglutid auf kardiovaskuläre Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung)","year":2018,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Hazard ratio; Gynecology; Internal medicine; Confidence interval","score_opus":0.013710115928422821,"score_gpt":0.2636822321365893,"score_spread":0.24997211620816648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2867826920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76853806,0.18948044,0.00014517698,0.004878706,0.009477392,0.0054704356,0.0007711875,0.0014362091,0.019802405],"genre_scores_gemma":[0.96660787,0.0047586295,0.0014628229,0.004630757,0.0037005637,0.00067156286,0.0028124913,0.0004788242,0.014876476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891635,0.0008035148,0.0017203637,0.0025603424,0.0015790379,0.0041732364],"domain_scores_gemma":[0.9927471,0.0010942536,0.0007825066,0.0030230654,0.0012156335,0.0011374109],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0016332734,0.0020374598,0.0029196995,0.0010745189,0.0009369479,0.00038391261,0.0014819234,0.001199715,0.00093774823],"category_scores_gemma":[0.0014480819,0.0018079375,0.0012615543,0.0013260759,0.0016678331,0.000635633,0.0014351588,0.0011382807,0.008073164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022935662,0.005476866,0.28892896,0.0032100743,0.05184828,0.0012518544,0.0031642835,0.000024392051,0.0017624322,0.0036835189,0.18719922,0.45115656],"study_design_scores_gemma":[0.013847883,0.018626142,0.057999935,0.0015429029,0.030954162,0.0000024189226,0.0013340348,0.001348352,0.011764849,0.00097519124,0.85817456,0.0034295965],"about_ca_topic_score_codex":0.0002020715,"about_ca_topic_score_gemma":0.00007758627,"teacher_disagreement_score":0.6709753,"about_ca_system_score_codex":0.0012417921,"about_ca_system_score_gemma":0.00054573925,"threshold_uncertainty_score":0.9999755},"labels":[],"label_agreement":null},{"id":"W2876707141","doi":"10.1186/s12933-018-0741-9","title":"Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction","year":2018,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"St. Michael's Hospital Foundation; AstraZeneca Canada","keywords":"Medicine; Internal medicine; Cardiology; Dapagliflozin; Myocardial infarction; Diastole; Cardiac function curve; Endocrinology; Ventricle; Incretin; Type 2 diabetes; Blood pressure; Heart failure; Diabetes mellitus","score_opus":0.010239193582079992,"score_gpt":0.22678149763013455,"score_spread":0.21654230404805455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2876707141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879801,0.007955561,0.00031647473,0.00009242641,0.0014354044,0.0007197474,0.000008171315,0.00010180939,0.0013902921],"genre_scores_gemma":[0.998387,0.00030564598,0.0003183808,0.00010308606,0.0004741453,0.000107706845,0.00021513834,0.000034787576,0.00005412749],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984116,0.00012771999,0.00032208764,0.00046050016,0.00033352018,0.00034455225],"domain_scores_gemma":[0.9992571,0.000030387375,0.00007621083,0.0004114014,0.0000988339,0.00012606883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039352817,0.0002458272,0.0008932468,0.00021883343,0.00010631685,0.000014820526,0.000030630647,0.00019114451,0.000029609118],"category_scores_gemma":[0.000025015315,0.00024059997,0.00093060953,0.00019111266,0.00029864447,0.00016610627,0.000051612125,0.000108500324,0.000022304383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001155116,0.0009833944,0.33452547,0.000569114,0.052692544,0.00030765848,0.003280019,0.000033183907,0.44692305,0.00093052705,0.0018273714,0.15677255],"study_design_scores_gemma":[0.016056016,0.0032404175,0.3816795,0.00024954678,0.012607488,0.00005366749,0.0015866773,0.0001432574,0.5407032,0.00013783875,0.042714354,0.0008280233],"about_ca_topic_score_codex":0.000047597892,"about_ca_topic_score_gemma":0.0000017776124,"teacher_disagreement_score":0.15594453,"about_ca_system_score_codex":0.00010845129,"about_ca_system_score_gemma":0.00003386676,"threshold_uncertainty_score":0.9811382},"labels":[],"label_agreement":null},{"id":"W2883091608","doi":"10.1136/bmj.k2693","title":"Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study","year":2018,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Metformin; Hazard ratio; Type 2 diabetes; Internal medicine; Confidence interval; Cohort; Population; Cohort study; Proportional hazards model; Myocardial infarction; Stroke (engine); Diabetes mellitus; Cardiology; Endocrinology; Insulin","score_opus":0.00810118431094352,"score_gpt":0.2551826101602795,"score_spread":0.24708142584933596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883091608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955654,0.0014205892,0.0000020755356,0.00017724966,0.00007095729,0.0018395828,0.0000029100909,0.000011966049,0.00090924674],"genre_scores_gemma":[0.9992385,0.000098926306,0.00007978549,0.00008337263,0.00007974218,0.00006154255,0.000023957406,0.000010122733,0.00032407974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991971,0.00012924502,0.00019372794,0.00017932607,0.00019175783,0.0001088288],"domain_scores_gemma":[0.999471,0.00007794967,0.00007061974,0.00029494186,0.00005216057,0.000033297372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010102728,0.00009573109,0.0003297699,0.00007840583,0.00003297674,0.0000067108203,0.0000320039,0.000029532699,0.000043674754],"category_scores_gemma":[0.00013720225,0.0000613428,0.00005670011,0.00012936354,0.00006061783,0.00003795788,0.00003876317,0.000050467905,0.000005687902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018813813,0.00014018938,0.9932315,0.00004065988,0.0009667805,0.0000019208626,0.00023585759,0.000006853249,0.000006969202,0.000020169626,0.00015886953,0.005002146],"study_design_scores_gemma":[0.006281659,0.0005425576,0.9900559,0.000052517185,0.0012865397,4.3499168e-7,0.00016965116,0.00057279854,0.00010566785,0.00019188809,0.0006781777,0.00006217309],"about_ca_topic_score_codex":0.00049190887,"about_ca_topic_score_gemma":0.00008840114,"teacher_disagreement_score":0.006093521,"about_ca_system_score_codex":0.000022588485,"about_ca_system_score_gemma":0.000013571041,"threshold_uncertainty_score":0.25014868},"labels":[],"label_agreement":null},{"id":"W2883419804","doi":"10.1007/s00125-018-4669-0","title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","year":2018,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Health and Medical Research Council; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Servier; Diabetes Canada; University of Toronto; Institute of Nutrition, Metabolism and Diabetes; Juvenile Diabetes Research Foundation Canada; Mylan; University Health Network; Eli Lilly and Company; AstraZeneca; Canadian Diabetes Association; Sanofi","keywords":"Endocrinology; Internal medicine; Nephron; Renal function; Tubuloglomerular feedback; Natriuresis; Type 2 diabetes; Renal glucose reabsorption; Carbohydrate metabolism; Kidney; Diabetes mellitus; Glucose homeostasis; Medicine; Blood pressure; Chemistry; Insulin resistance","score_opus":0.03718076875149322,"score_gpt":0.3020023220138079,"score_spread":0.26482155326231466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883419804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028729453,0.9924853,0.000001390614,0.00005416131,0.0005531759,0.0010015726,0.00003316984,0.0000554828,0.0055284603],"genre_scores_gemma":[0.0007854116,0.9952147,0.000038700797,0.000040961233,0.00033038692,0.00020534484,0.00011997078,0.000029397763,0.00323512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987535,0.00009946124,0.00037297985,0.00033127054,0.00019919536,0.00024357827],"domain_scores_gemma":[0.99888664,0.0002011779,0.0003148516,0.00046607238,0.00006113592,0.00007010787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022892578,0.00029829843,0.0010581387,0.0001528061,0.00012900268,0.000026410466,0.00010070544,0.00022431543,0.000036308906],"category_scores_gemma":[0.00009832021,0.00015844741,0.00028885013,0.0002109416,0.00019392988,0.00003686891,0.00008420347,0.00022818515,0.00003835736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003875905,0.00037292487,0.00017395995,0.0049232882,0.007274048,0.0000048967804,0.000015016018,7.979579e-8,0.000003523975,0.004934574,0.019004008,0.9632549],"study_design_scores_gemma":[0.00043681543,0.00052508595,0.00061821245,0.0022462243,0.0272652,0.0000024239232,0.0000071323475,5.492451e-7,0.000037898135,0.00010779808,0.9686333,0.000119390286],"about_ca_topic_score_codex":0.0000038137025,"about_ca_topic_score_gemma":0.0000018041718,"teacher_disagreement_score":0.96313554,"about_ca_system_score_codex":0.00001221633,"about_ca_system_score_gemma":0.000051516432,"threshold_uncertainty_score":0.6461298},"labels":[],"label_agreement":null},{"id":"W2883434295","doi":"10.1016/j.ando.2018.06.226","title":"L’insuline faster aspart en schéma basal-bolus permet d’obtenir une glycémie post-prandiale dans la cible","year":2018,"lang":"fr","type":"article","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Gynecology; Insulin aspart; Insulin; Internal medicine; Hypoglycemia","score_opus":0.025501412291359802,"score_gpt":0.2928219169265812,"score_spread":0.2673205046352214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883434295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6783922,0.02318038,0.00025372475,0.04387409,0.005950976,0.0014370672,0.0003040699,0.00059972145,0.2460078],"genre_scores_gemma":[0.83163965,0.011952012,0.0016201169,0.003686784,0.003083926,0.00015365344,0.00042823463,0.00013341916,0.14730223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519753,0.00036392844,0.00072047266,0.0010549666,0.00053485896,0.0021282404],"domain_scores_gemma":[0.9973036,0.00047422253,0.00020515612,0.0011893132,0.00037822736,0.00044948573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003451922,0.00080597337,0.0009625837,0.0004134599,0.00032171447,0.00015242143,0.00060390326,0.00033521507,0.0025024624],"category_scores_gemma":[0.00047753184,0.0007209092,0.00036340547,0.00065229007,0.001443941,0.0004659142,0.00066057104,0.00053620985,0.008871666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023699452,0.005506605,0.043460056,0.0013538232,0.005773667,0.008651481,0.004670418,0.00007113979,0.010563129,0.025047196,0.35582608,0.53670645],"study_design_scores_gemma":[0.0067469645,0.005393053,0.072198614,0.0005862062,0.0015511907,0.00019235024,0.0026175054,0.0003454338,0.01557718,0.0008705312,0.8930807,0.00084023847],"about_ca_topic_score_codex":0.00060760137,"about_ca_topic_score_gemma":0.0003897095,"teacher_disagreement_score":0.53725463,"about_ca_system_score_codex":0.00036104143,"about_ca_system_score_gemma":0.00029025975,"threshold_uncertainty_score":0.9995242},"labels":[],"label_agreement":null},{"id":"W2883666482","doi":"10.1017/s1463423618000476","title":"Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects","year":2018,"lang":"en","type":"article","venue":"Primary Health Care Research & Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Adverse effect; Type 2 diabetes; Medicine; Cotransporter; Diabetes mellitus; Drug class; Pharmacology; Internal medicine; Sodium; Endocrinology; Chemistry; Drug","score_opus":0.016437254288842407,"score_gpt":0.32232656418630146,"score_spread":0.30588930989745905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883666482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98617464,0.00627492,0.00001232754,0.0024734975,0.000115230294,0.0016853348,0.000001738986,0.00003255109,0.0032297769],"genre_scores_gemma":[0.99267733,0.0009601972,0.004117166,0.0014810234,0.00011111361,0.00028596667,0.00013510157,0.000022369453,0.00020974234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99770963,0.00010487537,0.00035647646,0.0003796184,0.0008300506,0.0006193504],"domain_scores_gemma":[0.9988697,0.00010110925,0.00008314649,0.00025844047,0.0002719164,0.0004156566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058414886,0.00016503003,0.00039077253,0.0003666275,0.0001490661,0.000010005692,0.00010863975,0.00005146319,0.000026671607],"category_scores_gemma":[0.0000277855,0.0001264686,0.000021705262,0.0006740868,0.0003275631,0.00010412066,0.00008943321,0.00019461867,0.000018137263],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079101045,0.0009930184,0.08204831,0.005789241,0.00042548717,0.00007256005,0.14649524,2.2872638e-7,0.00082380977,0.00014952288,0.028405622,0.7340059],"study_design_scores_gemma":[0.0080368705,0.0069873137,0.7559322,0.0037131049,0.00008826192,0.0000019600561,0.01995467,0.0000113131155,0.032624144,0.00004105251,0.17213498,0.00047413912],"about_ca_topic_score_codex":0.00012494046,"about_ca_topic_score_gemma":0.00036248437,"teacher_disagreement_score":0.73353183,"about_ca_system_score_codex":0.00064577133,"about_ca_system_score_gemma":0.0029582628,"threshold_uncertainty_score":0.52478313},"labels":[],"label_agreement":null},{"id":"W2883769056","doi":"10.1016/j.cjca.2018.07.011","title":"Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Regina; Genome Prairie; University of Toronto; St. Michael's Hospital; University of Saskatchewan","funders":"","keywords":"Medicine; Formulary; Diabetes mellitus; Disease; Intensive care medicine; Internal medicine; Family medicine; Endocrinology","score_opus":0.0417358123139904,"score_gpt":0.28561509460407614,"score_spread":0.24387928229008574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883769056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074603005,0.9973014,0.00007180619,0.000113257825,0.0004385956,0.0012981831,0.00011750382,0.0000054049624,0.000579267],"genre_scores_gemma":[0.00059048174,0.9974008,0.00008772763,0.00032652702,0.0013501443,0.000040398896,0.00012055368,0.000046212997,0.000037106136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974054,0.00054007047,0.000929234,0.00034465076,0.00033100776,0.0004496146],"domain_scores_gemma":[0.99695295,0.00015428904,0.0005367171,0.0007474293,0.00040581435,0.0012028059],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015024892,0.00039778536,0.004199486,0.00052693166,0.000058563408,0.00001951864,0.00026838787,0.0002134395,0.000032938595],"category_scores_gemma":[0.0006291548,0.00029185222,0.002130373,0.0002042545,0.00029828638,0.00016363298,0.000029121416,0.00027785462,0.0000057431293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001842909,0.00000670113,0.0006782438,0.12886596,0.005295579,0.00063361,0.0000045538864,0.000004284522,5.4225996e-8,0.00003730745,0.0060151224,0.85844016],"study_design_scores_gemma":[0.00040084304,0.000792801,0.00022335623,0.13964511,0.022273079,0.000061253806,0.0000017450838,0.0000010249132,4.5601456e-7,0.000023376018,0.83639103,0.0001859002],"about_ca_topic_score_codex":0.00010296207,"about_ca_topic_score_gemma":0.000039082173,"teacher_disagreement_score":0.85825425,"about_ca_system_score_codex":0.00027743436,"about_ca_system_score_gemma":0.0049697016,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W2883802895","doi":"10.7202/1048941ar","title":"Particularités du traitement du diabète de type 2 chez la personne âgée","year":2018,"lang":"fr","type":"article","venue":"Nutrition, science en évolution","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.01302499764544226,"score_gpt":0.26827564761608,"score_spread":0.2552506499706378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883802895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95971245,0.0048694317,0.0022029958,0.01730726,0.0037506367,0.0010679847,0.00001785544,0.0001466334,0.010924759],"genre_scores_gemma":[0.9871833,0.0018045948,0.0028150347,0.00051590364,0.0036392438,0.00010302662,0.000045133733,0.000020279906,0.0038735147],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739224,0.00019426673,0.00029879683,0.0005461212,0.0006529404,0.00091563654],"domain_scores_gemma":[0.99868375,0.00008773207,0.00009431193,0.0003129127,0.00045761312,0.0003636509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023243248,0.00023531093,0.0002400632,0.00025680597,0.00056617433,0.00015239208,0.00024269748,0.00014036307,0.0007255223],"category_scores_gemma":[0.00045472817,0.00023594392,0.00010404086,0.0012085891,0.0018499448,0.00065738213,0.00008989288,0.0001433828,0.0006862979],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056378735,0.018163353,0.18159671,0.002018609,0.0007047563,0.00041268326,0.026075806,0.000105060935,0.14189422,0.24785492,0.20646363,0.17414647],"study_design_scores_gemma":[0.006529174,0.003123589,0.45780882,0.0017247386,0.0011144959,0.00014432079,0.0034346273,0.01949214,0.023989795,0.0030171934,0.4789485,0.0006726022],"about_ca_topic_score_codex":0.0002940477,"about_ca_topic_score_gemma":0.0000712726,"teacher_disagreement_score":0.27621213,"about_ca_system_score_codex":0.0013353487,"about_ca_system_score_gemma":0.0003209932,"threshold_uncertainty_score":0.9621514},"labels":[],"label_agreement":null},{"id":"W2884339835","doi":"10.1007/s10238-018-0519-0","title":"Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes","year":2018,"lang":"en","type":"review","venue":"Clinical and Experimental Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"National Science and Technology Infrastructure Program; National Key Research and Development Program of China; Xiangya Hospital, Central South University; Central South University; National Natural Science Foundation of China","keywords":"Medicine; Diabetes mellitus; Dipeptidyl peptidase-4; Dipeptidyl peptidase; Alogliptin; Pharmacology; Type 1 diabetes; Clinical trial; Hematology; In vivo; Autoimmune diabetes; Type 2 diabetes; Immunology; Internal medicine; Endocrinology; Biology; Enzyme; Biochemistry","score_opus":0.14448117536185545,"score_gpt":0.4463483027305552,"score_spread":0.30186712736869975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884339835","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016063175,0.9895227,0.000008498983,0.00060088193,0.002137981,0.004066564,0.000017360055,0.00015378778,0.001885896],"genre_scores_gemma":[0.00032013483,0.97193503,0.0010318755,0.0009666167,0.006594042,0.00052353577,0.00080452586,0.00015475764,0.017669497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958527,0.00010942823,0.0018936439,0.0010907192,0.00038900258,0.00066449697],"domain_scores_gemma":[0.9975255,0.0004896649,0.0005352058,0.00063337304,0.000062196,0.00075403374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072237325,0.0008345408,0.0037636054,0.00022162565,0.00017398747,0.000044392615,0.00021784796,0.00047493246,0.0004255532],"category_scores_gemma":[0.00038830677,0.0005352428,0.0008490167,0.00021732347,0.00086868345,0.000103231374,0.0003075087,0.00036513168,0.0001383866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011293467,0.0009144822,0.00025373825,0.00930393,0.0014391859,0.000025204221,0.00017424488,4.0438835e-9,0.00001908222,0.00008203169,0.1528995,0.8347757],"study_design_scores_gemma":[0.0061454847,0.005781982,0.000072656294,0.040956166,0.0037533352,0.000008607128,0.000112583024,0.00001019904,0.00006909338,0.00006715535,0.9425688,0.0004539799],"about_ca_topic_score_codex":0.000014028631,"about_ca_topic_score_gemma":6.2214866e-7,"teacher_disagreement_score":0.8343217,"about_ca_system_score_codex":0.0001268576,"about_ca_system_score_gemma":0.00016320465,"threshold_uncertainty_score":0.9997099},"labels":[],"label_agreement":null},{"id":"W2884466498","doi":"10.1007/s00125-018-4670-7","title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","year":2018,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":964,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"University of Glasgow; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Natriuresis; Afterload; Heart failure; Medicine; Adipokine; Context (archaeology); Diuresis; Diabetes mellitus; Pharmacology; Type 2 diabetes; Internal medicine; Endocrinology; Kidney; Blood pressure; Biology","score_opus":0.024855646136996354,"score_gpt":0.27649914059021957,"score_spread":0.2516434944532232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884466498","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006692722,0.9958741,0.000029448902,0.000039204813,0.00033260704,0.0025128,0.00004816279,0.000028935745,0.0010678315],"genre_scores_gemma":[0.000039985047,0.99825746,0.00035029856,0.0001367494,0.000037959177,0.00018852156,0.00009007037,0.00004351732,0.00085541955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997982,0.00011848283,0.00077747257,0.00043571653,0.00039330148,0.00029299606],"domain_scores_gemma":[0.99817646,0.00007323136,0.0005088582,0.0010353235,0.00012042921,0.000085723754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005874218,0.00041325035,0.0035732153,0.00014157718,0.00003165165,0.0000062975073,0.00022353468,0.00014276347,0.000040402483],"category_scores_gemma":[0.00012103561,0.00024184036,0.0014819492,0.00040826926,0.00019551828,0.00003190684,0.00030338753,0.00016545026,0.000038977378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000019798038,0.000086902655,0.000046021934,0.13776971,0.0038347775,0.000009149229,0.000006638267,5.8979722e-8,3.817514e-7,0.00039150738,0.005228553,0.8526243],"study_design_scores_gemma":[0.0002878722,0.00026543465,0.000032164895,0.08480082,0.015624121,0.0000064491064,0.0000017384046,3.4099378e-7,0.000086857646,0.00040329437,0.8983076,0.00018326633],"about_ca_topic_score_codex":0.0000058300834,"about_ca_topic_score_gemma":0.000001105971,"teacher_disagreement_score":0.8930791,"about_ca_system_score_codex":0.000056236593,"about_ca_system_score_gemma":0.00008323258,"threshold_uncertainty_score":0.98619634},"labels":[],"label_agreement":null},{"id":"W2884582164","doi":"10.71781/30806","title":"Étude des voies de signalisation en aval du récepteur FFA1/GPR40 dans la cellule bêta pancréatique","year":2017,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Alberta Innovates; National Institutes of Health; University of Alberta; Diabète Québec; Amgen","keywords":"Free fatty acid receptor 1; Chemistry; Receptor","score_opus":0.02386285747937721,"score_gpt":0.30558223416117014,"score_spread":0.2817193766817929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884582164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8046272,0.0009327216,0.0002998829,0.0002558344,0.0006461987,0.0015677277,0.000063074935,0.0000073990536,0.19159997],"genre_scores_gemma":[0.7777335,0.00084943924,0.004156013,0.00004293497,0.0005550842,0.00024875998,0.0031841886,0.00008191344,0.21314816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751586,0.00036424107,0.000488979,0.0006551425,0.0003707302,0.0006050541],"domain_scores_gemma":[0.99823505,0.00027276945,0.00047788586,0.0006319981,0.0001434708,0.00023883404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010979177,0.00054927275,0.0006924372,0.00014497466,0.00049872015,0.0006792743,0.0008075103,0.00043435182,0.005621643],"category_scores_gemma":[0.00029670855,0.00052992906,0.00019676483,0.000083096835,0.00022675666,0.00057190564,0.00017900247,0.00030180978,0.0019530912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000676197,0.0020464235,0.13355106,0.001310716,0.0026514714,0.0010559977,0.1923834,0.00020904532,0.04029448,0.0017411945,0.003634427,0.6204456],"study_design_scores_gemma":[0.0061970577,0.0014745543,0.5144633,0.005025168,0.0065118563,0.000029051696,0.044489864,0.0012434449,0.18470511,0.0010072656,0.23331782,0.0015354677],"about_ca_topic_score_codex":0.0034316478,"about_ca_topic_score_gemma":0.0068037426,"teacher_disagreement_score":0.61891013,"about_ca_system_score_codex":0.00048730327,"about_ca_system_score_gemma":0.00042111252,"threshold_uncertainty_score":0.9997152},"labels":[],"label_agreement":null},{"id":"W2884635364","doi":"10.1111/1753-0407.12831","title":"Talks and tweets from the ADA","year":2018,"lang":"en","type":"editorial","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Hyperinsulinemia; Dyslipidemia; Insulin resistance; Disease; Gerontology; Family medicine; Internal medicine; Endocrinology","score_opus":0.006765618051076398,"score_gpt":0.24389629986033953,"score_spread":0.23713068180926314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884635364","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21462588,0.015321597,0.0000010887937,0.0012893009,0.7661746,0.0002701576,0.00008815746,0.000016028409,0.0022131521],"genre_scores_gemma":[0.010058106,0.0013284254,0.00030874263,0.00035396207,0.9854485,0.0000055607998,0.000103534105,0.000044686938,0.0023485022],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984611,0.00004629604,0.00040542972,0.00016531385,0.0006907092,0.00023109664],"domain_scores_gemma":[0.9978389,0.00094551244,0.00052347744,0.00026407844,0.00029278308,0.00013523114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038686753,0.00023593337,0.00063701323,0.00007100807,0.000059909526,0.000080588645,0.0001996568,0.00025345365,0.00012625505],"category_scores_gemma":[0.0005705151,0.00012820312,0.00020039368,0.00006489898,0.000121724755,0.000093993774,0.00010308021,0.0004956384,0.000021201851],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002852169,0.00007873711,0.010904048,0.00005711341,0.001314294,0.00002175739,0.000071971874,3.903522e-8,0.000048774953,0.0000020050236,0.98079884,0.0066738753],"study_design_scores_gemma":[0.0016431672,0.0010403187,0.0066093407,0.00084509415,0.002020685,4.792673e-7,0.000044986173,0.000002231428,0.0001845665,0.00026147513,0.9872301,0.00011750371],"about_ca_topic_score_codex":0.0000135355685,"about_ca_topic_score_gemma":0.000008248084,"teacher_disagreement_score":0.21927385,"about_ca_system_score_codex":0.00006619859,"about_ca_system_score_gemma":0.00013186417,"threshold_uncertainty_score":0.5227971},"labels":[],"label_agreement":null},{"id":"W2884640639","doi":"10.1007/s11892-018-1035-z","title":"Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach","year":2018,"lang":"en","type":"review","venue":"Current Diabetes Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Metformin; Medicine; Tolerability; Type 2 Diabetes Mellitus; Type 2 diabetes; Atherosclerotic cardiovascular disease; Diabetes mellitus; Internal medicine; First line; Disease; Clinical trial; Intensive care medicine; Adverse effect; Endocrinology","score_opus":0.0752495858083535,"score_gpt":0.3271841103223085,"score_spread":0.251934524513955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884640639","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02069711,0.96982116,0.00008132585,0.000012921105,0.0009977428,0.008087515,0.00009464885,0.00013353488,0.0000740637],"genre_scores_gemma":[0.0014955698,0.98876756,0.0004596233,0.000052723302,0.000814482,0.0022877746,0.005802021,0.00023361595,0.000086627086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945715,0.00017832131,0.0011070352,0.0016942589,0.0015148002,0.0009340676],"domain_scores_gemma":[0.9960799,0.00021080782,0.0006972439,0.0016486833,0.00040841405,0.00095494936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011762241,0.0011056293,0.0032407555,0.00032475046,0.00018652267,0.00010792528,0.00027049868,0.000302155,0.000049755592],"category_scores_gemma":[0.00040071135,0.0006973935,0.001028935,0.00039788295,0.00033388467,0.00022289302,0.00018601886,0.00035961793,0.0000069277103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046186473,0.0020371669,0.01481477,0.018502094,0.0068436847,0.00004045967,0.000043417105,0.0000020438697,1.2159086e-8,0.000015437246,0.00048286162,0.95717186],"study_design_scores_gemma":[0.002193902,0.0022125805,0.0009024289,0.013622907,0.011359921,0.0000034711288,0.0000037522595,0.0002654431,0.000002725896,0.00015729041,0.9684226,0.0008529941],"about_ca_topic_score_codex":0.0000027086,"about_ca_topic_score_gemma":9.2998425e-7,"teacher_disagreement_score":0.96793973,"about_ca_system_score_codex":0.00021253635,"about_ca_system_score_gemma":0.00030221848,"threshold_uncertainty_score":0.9995477},"labels":[],"label_agreement":null},{"id":"W2885394528","doi":"10.14740/jocmr3491w","title":"Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetic nephropathy; Glycemic; Diabetes mellitus; Type 2 diabetes; Blood pressure; Renal function; Urology; Nephropathy; Discontinuation; Internal medicine; Creatinine; Gastroenterology; Endocrinology","score_opus":0.09903282844611432,"score_gpt":0.45414490760945875,"score_spread":0.3551120791633444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885394528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960313,0.00084484415,7.7730317e-7,0.00035122223,0.00036101832,0.0020393133,0.0000017158213,0.0000042591932,0.00036556067],"genre_scores_gemma":[0.9988364,0.0002119467,0.00013260513,0.000124185,0.000382926,0.000014634318,0.000005160097,0.000031834363,0.00026029797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951207,0.00096798444,0.001424767,0.00035248586,0.0017122519,0.00042179332],"domain_scores_gemma":[0.9947877,0.0021896102,0.0006066017,0.0005457808,0.0014220254,0.00044827443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005785226,0.00020707716,0.0015222688,0.0005828461,0.000046539077,0.000018301842,0.00045109948,0.000113288595,0.000056017736],"category_scores_gemma":[0.004508461,0.00011989762,0.000047499394,0.00066646014,0.00075072865,0.00019567311,0.00026844122,0.0007226502,0.0000034276075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077716,0.029500779,0.9220624,0.0006552069,0.0015027703,0.00017433573,0.00044902728,1.9238306e-7,0.00019119531,0.000008905406,0.00040013797,0.037283443],"study_design_scores_gemma":[0.061187748,0.25365838,0.6802922,0.0028074987,0.0012748097,7.478111e-7,0.00009958385,0.0000124171975,0.0005159326,0.000033366796,0.00004977024,0.00006758021],"about_ca_topic_score_codex":0.000022848355,"about_ca_topic_score_gemma":0.00003106951,"teacher_disagreement_score":0.24177024,"about_ca_system_score_codex":0.000020670881,"about_ca_system_score_gemma":0.00018893728,"threshold_uncertainty_score":0.53973746},"labels":[],"label_agreement":null},{"id":"W2885588864","doi":"10.1016/s0140-6736(18)31773-2","title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":804,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Liraglutide; Placebo; Clinical endpoint; Dose-ranging study; Weight loss; Randomized controlled trial; Intention-to-treat analysis; Internal medicine; Body mass index; Obesity; Type 2 diabetes; Diabetes mellitus; Double blind; Endocrinology","score_opus":0.021263887155415547,"score_gpt":0.28493406600659904,"score_spread":0.2636701788511835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885588864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878654,0.0001443355,0.00006737979,0.00051843334,0.000039987834,0.010381838,0.000049614926,0.000022554554,0.00091044034],"genre_scores_gemma":[0.9985808,0.000058518624,0.00048948865,0.00012755167,0.00019412441,0.00032865812,0.00004453946,0.000019712763,0.00015660281],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99893117,0.000070649425,0.00025667195,0.00026863863,0.00018149316,0.0002913595],"domain_scores_gemma":[0.99897,0.00042944582,0.00018501391,0.00025297923,0.00007790435,0.00008468727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045348608,0.00021644146,0.0010441121,0.00009740555,0.00009849451,0.000023991288,0.0000679633,0.00004090343,0.000009793297],"category_scores_gemma":[0.00004089408,0.00011394526,0.00003347251,0.00010824829,0.00031977458,0.00006621606,0.00004609479,0.000088540124,0.000001160178],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97625667,0.0007187219,0.018594733,0.00010996327,0.0008374966,0.0000050631847,0.00077587186,0.0000025732875,0.000013049165,0.00011178314,0.00029607405,0.0022779969],"study_design_scores_gemma":[0.970802,0.005465918,0.020589981,0.00027936682,0.0009815039,0.0000021164437,0.000085267566,0.00025706086,0.00022773199,0.000029218803,0.0011423512,0.00013749751],"about_ca_topic_score_codex":0.000021808595,"about_ca_topic_score_gemma":0.00008797148,"teacher_disagreement_score":0.010715388,"about_ca_system_score_codex":0.000030662395,"about_ca_system_score_gemma":0.00003184112,"threshold_uncertainty_score":0.46465525},"labels":[],"label_agreement":null},{"id":"W2886292959","doi":"10.1161/circulationaha.117.032759","title":"Use of GLP-1 RAs in Cardiovascular Disease Prevention","year":2018,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Disease; Intensive care medicine; Internal medicine; Cardiology","score_opus":0.04264410841260188,"score_gpt":0.2733653089102442,"score_spread":0.2307212004976423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886292959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971429,0.00029250083,0.0013262142,0.0000468668,0.00006584896,0.0003931307,8.6339435e-7,0.000017338376,0.000714309],"genre_scores_gemma":[0.9994273,0.000015358886,0.00021615854,0.000022840873,0.00006031411,0.000014452431,0.00005914147,0.0000059637805,0.00017846822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995509,0.000021388674,0.00010908089,0.00011093699,0.00014074761,0.00006696107],"domain_scores_gemma":[0.9996684,0.000006346114,0.000027520082,0.00021967558,0.000043494543,0.00003453997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009266396,0.000044261502,0.0001116713,0.000086860215,0.000010982862,0.000005114212,0.000012820148,0.000018419358,0.000039759285],"category_scores_gemma":[0.000036300768,0.00004208941,0.00010080114,0.00011937817,0.000021959262,0.00010766462,0.000009719849,0.00001444918,0.000021182506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006976028,0.0002252509,0.9348492,0.00009919836,0.0003104175,0.000008609263,0.00009223068,0.00045399132,0.0007154552,0.00066326716,0.00012551501,0.06238711],"study_design_scores_gemma":[0.00072198187,0.00003985421,0.99273443,0.000083592575,0.000336882,1.9283469e-7,0.000006120604,0.0021364659,0.00032469878,0.00032811012,0.0032509512,0.000036706773],"about_ca_topic_score_codex":0.000027663516,"about_ca_topic_score_gemma":0.0000038505445,"teacher_disagreement_score":0.0623504,"about_ca_system_score_codex":0.00004639536,"about_ca_system_score_gemma":0.000014628205,"threshold_uncertainty_score":0.17163564},"labels":[],"label_agreement":null},{"id":"W2886392580","doi":"10.1016/j.jchf.2018.05.020","title":"Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus","year":2018,"lang":"nl","type":"review","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health; European Commission; ResMed; Luitpold Pharmaceuticals; Bayer Fund; HeartWare; Novartis; GlaxoSmithKline; Merck; AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; Amgen; Janssen Pharmaceuticals; Gilead Sciences","keywords":"Medicine; Diabetes mellitus; Heart failure; Glycemic; Intensive care medicine; Clinical trial; Disease; Harm; Randomized controlled trial; Internal medicine; Endocrinology","score_opus":0.011602057552320551,"score_gpt":0.2518180514144868,"score_spread":0.24021599386216627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886392580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23516005,0.7436365,0.0000036028744,0.011092454,0.0006194963,0.008252538,0.0003317312,0.00028530107,0.0006183452],"genre_scores_gemma":[0.055438187,0.8746169,0.0216538,0.009266389,0.00458313,0.0024397362,0.003799495,0.0013273907,0.026874963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939172,0.00034197583,0.0010406268,0.0019124523,0.0010365774,0.0017511225],"domain_scores_gemma":[0.9963601,0.00030786937,0.00032724286,0.0016121181,0.00039848543,0.0009941681],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00041364034,0.0018422252,0.0039089876,0.00067475886,0.00042878845,0.0003722171,0.00037818842,0.00072169804,0.0015185096],"category_scores_gemma":[0.000082934464,0.0012374104,0.00059906003,0.00096898683,0.00038685102,0.0003701415,0.000380487,0.00065308396,0.0057498906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027390363,0.0013074744,0.23301628,0.017986955,0.0027386902,0.000025806912,0.000433668,4.0636218e-7,0.000029838455,0.000056616995,0.6836172,0.060513176],"study_design_scores_gemma":[0.0036901138,0.0051887752,0.009073985,0.015618754,0.0041073356,0.0000072340817,0.00023013778,0.0000014869828,0.000042600383,0.000011967114,0.960813,0.0012146516],"about_ca_topic_score_codex":0.000058607162,"about_ca_topic_score_gemma":0.000055073182,"teacher_disagreement_score":0.27719578,"about_ca_system_score_codex":0.0003129842,"about_ca_system_score_gemma":0.00024408674,"threshold_uncertainty_score":0.99943227},"labels":[],"label_agreement":null},{"id":"W2886431944","doi":"10.1152/ajprenal.00384.2017","title":"Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease","year":2018,"lang":"en","type":"review","venue":"American Journal of Physiology-Renal Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Tubuloglomerular feedback; Natriuresis; Medicine; Internal medicine; Endocrinology; Thiazide; Diabetes mellitus; Diuretic; Kidney","score_opus":0.02315055892644207,"score_gpt":0.31754972260703845,"score_spread":0.2943991636805964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886431944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12638247,0.8711457,0.0000034264826,0.00030035878,0.00090549525,0.00094633194,0.00007138133,0.00003581634,0.00020897416],"genre_scores_gemma":[0.057249323,0.9388868,0.00025317754,0.0017671073,0.0011647763,0.00006979942,0.00025415162,0.00011563016,0.00023923835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961619,0.00047368224,0.0014127977,0.00075054256,0.00034784197,0.00085324433],"domain_scores_gemma":[0.99614125,0.0003008398,0.001978289,0.0007096277,0.00021463414,0.00065534003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002705966,0.0008689665,0.0047177346,0.00095509226,0.0000688413,0.000015836353,0.0006645734,0.00021487704,0.00035725674],"category_scores_gemma":[0.00023263202,0.000590253,0.001420143,0.00080056296,0.0014386479,0.000112998336,0.00023171143,0.0008674359,0.00026482265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007705123,0.009143809,0.00040845873,0.025039786,0.021895252,0.0008092226,0.0006821242,0.000030448458,0.036362994,0.00063897046,0.024570955,0.87271285],"study_design_scores_gemma":[0.005199506,0.012205151,0.010465043,0.020493874,0.007715138,0.00018224312,0.00012329426,0.000016710215,0.000025719073,0.0015301221,0.94091725,0.0011259394],"about_ca_topic_score_codex":0.000027002157,"about_ca_topic_score_gemma":8.462308e-7,"teacher_disagreement_score":0.9163463,"about_ca_system_score_codex":0.00028102114,"about_ca_system_score_gemma":0.0009701274,"threshold_uncertainty_score":0.9996549},"labels":[],"label_agreement":null},{"id":"W2886598107","doi":"10.1002/ehf2.12334","title":"Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial","year":2018,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biosense Webster; Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; Sanofi; GlaxoSmithKline; Amgen","keywords":"Liraglutide; Ejection fraction; Medicine; Placebo; Heart failure; Weight loss; Internal medicine; Cardiology; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology; Obesity","score_opus":0.005572750377313055,"score_gpt":0.219792490226861,"score_spread":0.21421973984954795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886598107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880942,0.00018691788,0.000017232678,0.00928755,0.00030645012,0.0017001966,0.000009733313,0.00008849171,0.00030919735],"genre_scores_gemma":[0.9951286,0.000020011475,0.0023225418,0.0010022497,0.00084244343,0.00013798935,0.00009958871,0.00003042626,0.00041619377],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868697,0.00007623478,0.00021016729,0.0004582014,0.0003127489,0.0002556791],"domain_scores_gemma":[0.99918365,0.000089715875,0.000081648155,0.00036067903,0.000120788194,0.00016354366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006800169,0.00024877675,0.00034232048,0.000075190816,0.00032306576,0.00007772337,0.000046036337,0.000119000164,0.00015646403],"category_scores_gemma":[0.0000403931,0.00014910773,0.00005411872,0.00020909437,0.00020314725,0.00036177176,0.000057616842,0.0002167431,0.000042479875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013568088,0.0008714936,0.7476306,0.00007400071,0.00083094795,0.000025486934,0.0009216005,0.000001152982,0.0018166618,0.00014010906,0.22929117,0.004828673],"study_design_scores_gemma":[0.025511274,0.0021288479,0.40512034,0.00021334308,0.0002518448,0.000003415908,0.0001919587,0.000020765192,0.0014915903,0.000088802866,0.56478167,0.00019616073],"about_ca_topic_score_codex":0.00008786858,"about_ca_topic_score_gemma":0.0003111829,"teacher_disagreement_score":0.34251028,"about_ca_system_score_codex":0.000056574423,"about_ca_system_score_gemma":0.000032823555,"threshold_uncertainty_score":0.6080437},"labels":[],"label_agreement":null},{"id":"W2887066969","doi":"10.30867/action.v3i1.96","title":"Hubungan lama terdiagnosa diabetes dan kadar glukosa darah dengan fungsi kognitif penderita diabetes tipe 2 di Jawa Timur","year":2018,"lang":"id","type":"article","venue":"AcTion Aceh Nutrition Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cognitive impairment; Internal medicine; Disease","score_opus":0.023484580956750555,"score_gpt":0.2792648318175091,"score_spread":0.25578025086075856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887066969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724441,0.0046651145,0.00010222827,0.008951717,0.006035134,0.0016218473,0.000114784,0.0003350792,0.0057299505],"genre_scores_gemma":[0.97571623,0.0058522075,0.0004959682,0.0021573303,0.009264824,0.00020110726,0.00066112546,0.00018621728,0.0054649934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99389184,0.0006456215,0.0013476147,0.0009864647,0.0013460201,0.0017824142],"domain_scores_gemma":[0.9956615,0.00047132507,0.0009787893,0.00079260534,0.0009558911,0.0011398946],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010970661,0.0010088476,0.0011561136,0.00096428755,0.0016660873,0.0010192868,0.00049338985,0.0005410123,0.002615094],"category_scores_gemma":[0.00044704298,0.0009911828,0.0006881625,0.0008031506,0.00053204433,0.0017882785,0.0002476263,0.0014324663,0.0016200166],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009449819,0.011652753,0.26508582,0.0026667456,0.0068328553,0.0006717234,0.00153098,0.0000023288376,0.08656579,0.00032219768,0.4593233,0.16440053],"study_design_scores_gemma":[0.022908898,0.010995583,0.1833488,0.00672342,0.0057193167,0.0002829531,0.009544132,0.0005558124,0.18145628,0.0008125607,0.5754104,0.002241822],"about_ca_topic_score_codex":0.000009314126,"about_ca_topic_score_gemma":0.00006960626,"teacher_disagreement_score":0.16215871,"about_ca_system_score_codex":0.0008073261,"about_ca_system_score_gemma":0.00023603669,"threshold_uncertainty_score":0.9996336},"labels":[],"label_agreement":null},{"id":"W2887140680","doi":"10.1001/jamainternmed.2018.3025","title":"Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation","year":2018,"lang":"en","type":"letter","venue":"JAMA Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; Neurology; Psychiatry","score_opus":0.008380500830973721,"score_gpt":0.23990874493265035,"score_spread":0.23152824410167663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887140680","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11746806,0.0022910498,0.00028457656,0.8630561,0.0018424899,0.0013613593,0.0000384648,0.000057723206,0.013600158],"genre_scores_gemma":[0.26764095,0.0028809747,0.0003957903,0.6861236,0.021977866,0.00011183278,0.00073438016,0.00011209171,0.020022525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980468,0.00010635624,0.00062424067,0.0003415817,0.00063379656,0.00024719816],"domain_scores_gemma":[0.9984396,0.00037167396,0.0005411923,0.0003832946,0.00019149078,0.00007275698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005616356,0.00033132918,0.00083535386,0.00025101306,0.000040363284,0.000017717277,0.00015875015,0.00030436693,0.00036255646],"category_scores_gemma":[0.00023824949,0.0001664978,0.00018311144,0.00010881704,0.00103336,0.000063778054,0.000056224784,0.00091938785,0.000032261738],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078144274,0.000041998745,0.0055790073,0.0005346119,0.0013299739,0.0002748203,0.0009526413,1.320788e-7,0.00004906703,0.00002328313,0.9752436,0.015189396],"study_design_scores_gemma":[0.017984964,0.001991618,0.01395864,0.0037293166,0.00527931,0.000050066195,0.00015019388,0.00014051999,0.00082207425,0.0007654659,0.9549144,0.00021344783],"about_ca_topic_score_codex":0.0006852183,"about_ca_topic_score_gemma":0.000016207512,"teacher_disagreement_score":0.17693254,"about_ca_system_score_codex":0.000054154352,"about_ca_system_score_gemma":0.00002270492,"threshold_uncertainty_score":0.67895836},"labels":[],"label_agreement":null},{"id":"W2887229381","doi":"10.1139/cjpp-2018-0123","title":"Effect of a nonsystemic, orally administered hydrogel, GS100, on metformin pharmacokinetics","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"Bristol-Myers Squibb","keywords":"Pharmacokinetics; Pharmacology; Metformin; Chemistry; Orally active; Oral administration; Medicine; Endocrinology; Diabetes mellitus","score_opus":0.01371060234556419,"score_gpt":0.3052900276885916,"score_spread":0.2915794253430274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887229381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959858,0.00068802625,0.0000024445399,0.0003981322,0.00097386027,0.00030108116,0.000014644376,0.0000043239434,0.0016316547],"genre_scores_gemma":[0.9977866,0.00010313854,0.000058159185,0.0012850775,0.0004652288,0.000007144806,0.0000069978346,0.000012979652,0.00027467054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999012,0.00014900838,0.00033604397,0.00014007755,0.0000678363,0.00029501374],"domain_scores_gemma":[0.99891543,0.00017339704,0.00024929392,0.000095947915,0.00013007148,0.00043584846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034399013,0.0001627102,0.0005709456,0.0003178079,0.00006781441,0.000003174742,0.000112909125,0.00009482131,0.0011613896],"category_scores_gemma":[0.00002564253,0.000120072815,0.00010573985,0.000105876716,0.00037836138,0.00003938879,0.0000161235,0.0001813932,0.00002306032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031917004,0.00014129361,0.003893014,0.000678767,0.0017125963,0.0005222485,0.00034424095,0.000005929107,0.9518949,0.00023167704,0.023164382,0.014219273],"study_design_scores_gemma":[0.007831609,0.026526637,0.0018145146,0.00013555029,0.0016631071,0.00029306216,0.00002209543,0.00009820492,0.92468315,0.00013425197,0.03665417,0.00014364447],"about_ca_topic_score_codex":0.000058264992,"about_ca_topic_score_gemma":0.00007277573,"teacher_disagreement_score":0.027211728,"about_ca_system_score_codex":0.00005576121,"about_ca_system_score_gemma":0.00026963511,"threshold_uncertainty_score":0.9997517},"labels":[],"label_agreement":null},{"id":"W2887818584","doi":"10.1016/j.bbr.2018.08.006","title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease","year":2018,"lang":"en","type":"article","venue":"Behavioural Brain Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Liraglutide; Default mode network; Placebo; Neuroprotection; Medicine; Psychology; Internal medicine; Type 2 diabetes; Endocrinology; Neuroscience; Diabetes mellitus; Cognition; Pathology","score_opus":0.1018187233708148,"score_gpt":0.3941589827032007,"score_spread":0.29234025933238594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887818584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940733,0.00087878644,0.000005684751,0.0020876045,0.00012067569,0.0022397481,0.00005339037,0.000032277057,0.00050857395],"genre_scores_gemma":[0.9943057,0.000015619617,0.00029674638,0.00008869126,0.000076600845,0.00032137305,0.00009125305,0.000029423643,0.004774638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982137,0.00017927625,0.00020961129,0.0003311134,0.00046118867,0.000605102],"domain_scores_gemma":[0.99837095,0.00079494197,0.00005176026,0.00035089892,0.0001594268,0.00027204052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075839116,0.00014383912,0.00026269536,0.00033500453,0.00015738644,0.000016820737,0.00014199987,0.000060562717,0.00011416624],"category_scores_gemma":[0.0006458141,0.0001164152,0.00014843629,0.0003216808,0.000354622,0.00006831167,0.00018906311,0.00020538199,0.000060789822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009990663,0.00042570796,0.9664382,0.000093616196,0.00008718744,0.00008607028,0.00030193944,0.0000010168834,0.00070172665,0.00020732966,0.015752962,0.014905185],"study_design_scores_gemma":[0.0034544365,0.0019816726,0.98862207,0.00014761041,0.0003316686,0.0000014419146,0.00010382913,0.0020698686,0.002243233,0.00016285686,0.00076909934,0.000112202935],"about_ca_topic_score_codex":0.00038131032,"about_ca_topic_score_gemma":0.00019139163,"teacher_disagreement_score":0.02218389,"about_ca_system_score_codex":0.00013505455,"about_ca_system_score_gemma":0.000059248992,"threshold_uncertainty_score":0.47472742},"labels":[],"label_agreement":null},{"id":"W2887998354","doi":"10.1097/hco.0000000000000562","title":"Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Incretin; Type 2 diabetes; Diabetes mellitus; Glucagon-like peptide-1; Bioinformatics; Cardioprotection; Clinical trial; Inflammation; Pharmacology; Internal medicine; Endocrinology; Ischemia","score_opus":0.09395279051898911,"score_gpt":0.3536907162774309,"score_spread":0.2597379257584418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887998354","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029943904,0.98467547,0.000011081346,0.000024889789,0.011692254,0.002801648,0.000016488284,0.00005359886,0.00042516057],"genre_scores_gemma":[0.00009829443,0.996506,0.00004855798,0.0000072278117,0.0014717431,0.0009917957,0.000725361,0.00005538266,0.00009564653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730635,0.00046005685,0.00064308784,0.0008779946,0.00020620888,0.00050629757],"domain_scores_gemma":[0.9989689,0.00006709502,0.00015683786,0.0006282984,0.00007214887,0.00010673953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007228775,0.0004949538,0.0027933347,0.00063487695,0.000040165974,0.00002235101,0.00012928499,0.00041538134,0.00002151398],"category_scores_gemma":[0.000114349736,0.00040956892,0.0006636032,0.00053009135,0.00016334529,0.000058346268,0.00019559677,0.00049865973,0.00016507735],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018286953,0.00007613264,0.0016944603,0.023563955,0.0011176097,0.0000052959354,0.000028356055,0.0000015748681,1.7155888e-7,0.000027732096,0.007532292,0.96593416],"study_design_scores_gemma":[0.00091210817,0.00039182004,0.00063857954,0.014748507,0.0007327582,0.000016016918,0.000010524024,0.000005792468,3.2269466e-7,0.000021637867,0.9822034,0.00031848255],"about_ca_topic_score_codex":0.000011783455,"about_ca_topic_score_gemma":0.000001450284,"teacher_disagreement_score":0.9746712,"about_ca_system_score_codex":0.000333221,"about_ca_system_score_gemma":0.00015057213,"threshold_uncertainty_score":0.9998356},"labels":[],"label_agreement":null},{"id":"W2888098196","doi":"10.1016/j.kint.2018.05.026","title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials","year":2018,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cotransporter; Renal ischemia; Medicine; Clinical trial; Ischemia; Sodium; Internal medicine; Pharmacology; Urology; Endocrinology; Intensive care medicine; Chemistry; Reperfusion injury","score_opus":0.07166125386261482,"score_gpt":0.388287184159287,"score_spread":0.3166259302966722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888098196","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002112731,0.00012069519,0.0010271631,0.98434186,0.002599315,0.001454527,0.0022402827,0.00007905093,0.0060243784],"genre_scores_gemma":[0.0014312546,0.0005485197,0.0050208583,0.86638683,0.055630084,0.0007481246,0.049687266,0.00007622102,0.020470867],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794734,0.000068486515,0.0009077696,0.0005534626,0.0002789036,0.00024403773],"domain_scores_gemma":[0.9984937,0.00026366065,0.00041371863,0.00030662934,0.00032579238,0.0001965242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086849113,0.0002877263,0.00065520353,0.00018740089,0.00006801603,0.00007121664,0.00012617759,0.00069007126,0.0006078628],"category_scores_gemma":[0.00044851095,0.00023463278,0.00046534202,0.000049139617,0.00012856559,0.00010097807,0.00004601201,0.00054047944,0.000056222707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016849645,0.0001416008,0.0014591144,0.00013271558,0.0013668581,0.00002086808,0.00002377301,7.4815345e-9,0.00034077413,0.000433722,0.9913072,0.004604842],"study_design_scores_gemma":[0.0044612857,0.0002611852,0.0029078133,0.00022522997,0.0013956752,0.000015868096,0.000005821661,0.000014130804,0.0007764854,0.000997232,0.9887369,0.00020236023],"about_ca_topic_score_codex":0.000002808508,"about_ca_topic_score_gemma":0.0000016656845,"teacher_disagreement_score":0.11795505,"about_ca_system_score_codex":0.000096675736,"about_ca_system_score_gemma":0.0001685503,"threshold_uncertainty_score":0.9568047},"labels":[],"label_agreement":null},{"id":"W2888195583","doi":"10.1186/s12933-018-0759-z","title":"Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data","year":2018,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Mace; Myocardial infarction; Diabetes mellitus; Internal medicine; Disease; Stroke (engine); Type 2 Diabetes Mellitus; Heart failure; Emergency medicine; Angina; Medical record; Population; Intensive care medicine; Environmental health; Conventional PCI","score_opus":0.0272730602433564,"score_gpt":0.25198581974812123,"score_spread":0.22471275950476483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888195583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619563,0.010864105,0.023231352,0.000008289873,0.00048964884,0.0029782772,0.00029208462,0.00007471093,0.000105196676],"genre_scores_gemma":[0.96391475,0.00040255822,0.03405917,0.000054870772,0.00014975322,0.00016031472,0.0011556697,0.00008709415,0.000015813815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648815,0.00024951296,0.000640771,0.0010402898,0.00075606775,0.00082519953],"domain_scores_gemma":[0.9964252,0.00005747592,0.00032133074,0.002270547,0.00067534135,0.0002501139],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012672598,0.00042874095,0.0018262325,0.00024082855,0.0002603496,0.000008071617,0.00039017102,0.00017448513,0.000007875553],"category_scores_gemma":[0.00008444418,0.00035817246,0.00068145856,0.00041572482,0.0003419191,0.00032724676,0.00033098814,0.00015623677,0.0000085682195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004762905,0.0006636228,0.8218656,0.0008723815,0.06578444,0.000007379908,0.00070758164,0.0034577942,0.000010816798,0.000025702439,0.00016814,0.10596021],"study_design_scores_gemma":[0.016473133,0.0018429526,0.9454005,0.000689005,0.009723491,0.0000022805448,0.00019160355,0.00953542,0.0010883142,0.00018819027,0.014103608,0.0007615476],"about_ca_topic_score_codex":0.000058951144,"about_ca_topic_score_gemma":0.000022514316,"teacher_disagreement_score":0.12353481,"about_ca_system_score_codex":0.00027398847,"about_ca_system_score_gemma":0.00033794693,"threshold_uncertainty_score":0.99988705},"labels":[],"label_agreement":null},{"id":"W2888486432","doi":"10.22374/1710-6222.25.1.4","title":"IMPACT OF DRUG EXPOSURE DEFINITIONS ON OBSERVED ASSOCIATIONS IN PHARMACOEPIDEMIOLOGY RESEARCH","year":2018,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Pharmacoepidemiology; Metformin; Observational study; Cohort study; Logistic regression; Proportional hazards model; Comorbidity; Demography; Cohort; Internal medicine; Pharmacology; Medical prescription","score_opus":0.43908957803362364,"score_gpt":0.5636646127701987,"score_spread":0.12457503473657511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888486432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947817,0.00030806733,0.000009379303,0.003829221,0.00050444354,0.00021482614,0.0000069203916,0.000004275165,0.00034119864],"genre_scores_gemma":[0.99655354,0.0013787327,0.00022430382,0.0012381296,0.00051504327,0.000003394022,0.000016088723,0.000008931303,0.00006181732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775636,0.00078109937,0.00096491387,0.00011935307,0.00018082243,0.00019743995],"domain_scores_gemma":[0.99740547,0.0015231087,0.00047037035,0.00007941851,0.0004159532,0.000105669096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024785674,0.00008615323,0.0004634689,0.0003038245,0.00005882455,0.0000050844374,0.00006890833,0.0001037187,0.00017163268],"category_scores_gemma":[0.0002301991,0.000062706495,0.0002107939,0.00022869775,0.0001657195,0.00005533466,0.000026033093,0.00044007652,0.0000055404375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079701,0.0015941064,0.984735,0.000009286383,0.000887572,0.000009439366,0.00011339178,0.000040196886,0.0010213235,0.000758187,0.0027730952,0.007261385],"study_design_scores_gemma":[0.004771294,0.0046218713,0.9853512,0.00003018393,0.00040265068,0.000003365804,0.000035424422,0.00053331925,0.00010094278,0.0032269403,0.0008770374,0.00004574357],"about_ca_topic_score_codex":0.000049865313,"about_ca_topic_score_gemma":0.00002541047,"teacher_disagreement_score":0.007215642,"about_ca_system_score_codex":0.000119980345,"about_ca_system_score_gemma":0.0000727357,"threshold_uncertainty_score":0.25570968},"labels":[],"label_agreement":null},{"id":"W2888544493","doi":"10.1016/j.jacbts.2018.07.006","title":"Empagliflozin Increases Cardiac Energy Production in Diabetes","year":2018,"lang":"en","type":"article","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":376,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim; Servier; Sanofi","keywords":"Empagliflozin; Internal medicine; Endocrinology; Ketone bodies; Medicine; Heart failure; Beta oxidation; Cardiac output; Diabetes mellitus; Glycolysis; Glucose uptake; Insulin; Metabolism; Type 2 diabetes; Hemodynamics","score_opus":0.012298788564100134,"score_gpt":0.25888804619176997,"score_spread":0.24658925762766984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888544493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441285,0.00009081109,0.000072938376,0.0041811704,0.00029303195,0.0003019182,0.0000051961274,0.000044878914,0.010597199],"genre_scores_gemma":[0.99641705,0.0000065245154,0.0016858075,0.0006114817,0.00033619552,0.000061105035,0.00001396766,0.0000068842965,0.0008609908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986856,0.000018742647,0.00015362517,0.000379095,0.0004715174,0.0002914048],"domain_scores_gemma":[0.9995165,0.000030123194,0.000022064209,0.00018473463,0.00010849667,0.00013810192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040376227,0.000099334284,0.00014344626,0.00032853812,0.000111199,0.000029328565,0.0001019721,0.000021736914,0.00011538652],"category_scores_gemma":[0.000080250495,0.000084637955,0.00004200544,0.0011287207,0.0002376914,0.00028757646,0.000022608801,0.000033562374,0.00006548251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011435922,0.0006079257,0.7223679,0.00003218666,0.000057116555,0.000004607149,0.00066569174,0.00008990696,0.05455819,0.008562349,0.0037344443,0.20920533],"study_design_scores_gemma":[0.0003920537,0.00023682407,0.9448457,0.00006669758,0.000040872343,4.6093342e-7,0.00002924331,0.00023654877,0.032501582,0.00073192053,0.020791655,0.00012645415],"about_ca_topic_score_codex":0.00012670095,"about_ca_topic_score_gemma":0.00012435991,"teacher_disagreement_score":0.2224778,"about_ca_system_score_codex":0.00007966593,"about_ca_system_score_gemma":0.0001349814,"threshold_uncertainty_score":0.34514356},"labels":[],"label_agreement":null},{"id":"W2888680621","doi":"10.2337/dbi18-0008","title":"The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications","year":2018,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Incretin; Diabetes mellitus; Glucagon-like peptide-1; Type 2 diabetes; Myocardial infarction; Glucose homeostasis; Gastric emptying; Liraglutide; Glucagon-like peptide 1 receptor; Stroke (engine); Internal medicine; Endocrinology; Bioinformatics; Receptor; Insulin resistance; Agonist; Biology","score_opus":0.07877540267301654,"score_gpt":0.37425768857692004,"score_spread":0.2954822859039035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888680621","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044761162,0.9934483,0.000026441096,0.00014042416,0.0008099634,0.0017020208,0.00008922128,0.000055573873,0.0032804117],"genre_scores_gemma":[0.00013910157,0.99698055,0.00059516786,0.000038495546,0.00080142124,0.00026265313,0.00065449445,0.000044780594,0.0004833233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978574,0.00021002528,0.00086102827,0.00047988037,0.0003034932,0.00028819463],"domain_scores_gemma":[0.99786127,0.00031348923,0.00027622833,0.0012926194,0.00011598408,0.0001403854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081890664,0.0002811046,0.0017330109,0.000111023226,0.00014739076,0.000027567394,0.00026519148,0.00016108027,0.000023809887],"category_scores_gemma":[0.00020400473,0.00017736065,0.0015459942,0.00029696315,0.0001519364,0.000032060096,0.0001559821,0.00017554469,0.0002717968],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048862034,0.00009690537,0.00012961334,0.0010543527,0.00606569,5.23711e-7,0.000013976684,3.2054223e-7,4.9208273e-7,0.00009054711,0.005773757,0.98676896],"study_design_scores_gemma":[0.00025433037,0.0001486731,0.0011298379,0.005392031,0.008685312,3.1170197e-7,0.000015439486,0.0000038555454,0.0000090733265,0.000029886776,0.9841842,0.0001470311],"about_ca_topic_score_codex":0.000036563655,"about_ca_topic_score_gemma":0.0000012724006,"teacher_disagreement_score":0.9866219,"about_ca_system_score_codex":0.00013566144,"about_ca_system_score_gemma":0.00007267054,"threshold_uncertainty_score":0.72325575},"labels":[],"label_agreement":null},{"id":"W2888722616","doi":"10.1016/j.diabet.2018.08.001","title":"SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes","year":2018,"lang":"en","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"Merck; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Canagliflozin; Dapagliflozin; Sitagliptin; Medicine; Type 2 diabetes; Liraglutide; Internal medicine; Incretin; Diabetes mellitus; Gastroenterology; Endocrinology","score_opus":0.01094801847148189,"score_gpt":0.24587769936939502,"score_spread":0.23492968089791313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888722616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947612,0.0010220485,0.0000024226117,0.0008752933,0.00030210635,0.0006388002,0.000024383318,0.00009329736,0.002280426],"genre_scores_gemma":[0.99730617,0.00015841036,0.00043803902,0.00085531716,0.0003211495,0.000076867276,0.00011184913,0.000041277057,0.00069092435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983574,0.00009280656,0.00024712094,0.0004210236,0.0003092174,0.00057239237],"domain_scores_gemma":[0.9991915,0.00010199237,0.000086793705,0.00029988203,0.00013545225,0.00018436903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033186143,0.00029696643,0.0005814646,0.0002780085,0.0001024469,0.00005597487,0.0000812136,0.00010399722,0.00018779241],"category_scores_gemma":[0.00011483037,0.00023680003,0.000061408326,0.0005855293,0.00017787663,0.00024726204,0.00006726319,0.00017856885,0.00007886063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081353806,0.0005861367,0.95103484,0.00008329549,0.0005739602,0.000013372992,0.0005582664,8.840539e-7,0.015388602,0.00039387675,0.0022202411,0.02906517],"study_design_scores_gemma":[0.002996155,0.0005066775,0.94475126,0.00011990795,0.00059585826,1.884373e-7,0.00004167171,0.00018275592,0.038780157,0.00009470729,0.011660356,0.00027028366],"about_ca_topic_score_codex":0.000058500496,"about_ca_topic_score_gemma":0.00007990419,"teacher_disagreement_score":0.028794887,"about_ca_system_score_codex":0.00006981197,"about_ca_system_score_gemma":0.000035084482,"threshold_uncertainty_score":0.9656425},"labels":[],"label_agreement":null},{"id":"W2888778641","doi":"10.1097/hco.0000000000000561","title":"SGLT2 inhibitors","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); St. Michael's Hospital; Diabetes Canada; University of Toronto","funders":"Valeant Pharmaceuticals International; Sanofi; AstraZeneca","keywords":"Medicine; Canagliflozin; Empagliflozin; Glycemic; Intensive care medicine; Dapagliflozin; Renal function; Adverse effect; Type 2 Diabetes Mellitus; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.14062028408324612,"score_gpt":0.42397249575295226,"score_spread":0.28335221166970614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888778641","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022315571,0.9734479,0.000012562059,0.00003184451,0.020420581,0.0012966958,0.000021011027,0.000063186395,0.004703978],"genre_scores_gemma":[0.0000036315741,0.99356776,0.000031007403,0.000009777223,0.004547229,0.0004126733,0.0011312306,0.000043077936,0.00025361098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806213,0.00019005066,0.0006145755,0.00057807605,0.00015209644,0.00040305944],"domain_scores_gemma":[0.99906385,0.00008724819,0.00018463466,0.0005175034,0.000040823452,0.000105959494],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002753443,0.00040570225,0.002300194,0.0004970146,0.00002531333,0.000010246761,0.00014719696,0.00031634024,0.000051908282],"category_scores_gemma":[0.00005676614,0.00030535847,0.0007414155,0.00030788375,0.00012527498,0.000028477645,0.00018483722,0.00036884786,0.00078727084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004607071,0.00006054438,0.0003928386,0.0195423,0.00030041422,0.000007385148,0.000008808085,8.8738126e-8,4.2797668e-9,0.00020970395,0.11228702,0.8671863],"study_design_scores_gemma":[0.0005408482,0.00020739638,0.00007563307,0.020698149,0.0006352273,0.00003269094,0.000004126662,6.0648284e-7,3.8988016e-8,0.000037792015,0.9775447,0.0002227882],"about_ca_topic_score_codex":0.0000015006592,"about_ca_topic_score_gemma":1.9162565e-7,"teacher_disagreement_score":0.8669635,"about_ca_system_score_codex":0.00027596267,"about_ca_system_score_gemma":0.00015888196,"threshold_uncertainty_score":0.99999076},"labels":[],"label_agreement":null},{"id":"W2889037229","doi":"10.2337/db18-0410","title":"The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca2+ Flux and Phosphoinositide 3-Kinase γ","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim","keywords":"Phospholamban; Internal medicine; Endocrinology; Dipeptidyl peptidase-4; Dipeptidyl peptidase; Contractility; Population; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Phosphoinositide 3-kinase; Glucagon-like peptide-1; Protein kinase A; Medicine; Type 2 diabetes; Phosphorylation; Chemistry; Heart failure; Biology; Protein kinase B; Cell biology; Enzyme; Biochemistry","score_opus":0.007154482609745246,"score_gpt":0.21667917996533856,"score_spread":0.20952469735559331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889037229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863307,0.0102283135,0.0000018799769,0.0005961584,0.00031077472,0.0011421763,0.000036987734,0.000095537216,0.0012575104],"genre_scores_gemma":[0.99770856,0.0003787687,0.0001588247,0.00041101838,0.00012755484,0.00017093586,0.00019465091,0.00005520644,0.00079451024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978459,0.00017775357,0.0003391788,0.0005521258,0.00027684186,0.0008081977],"domain_scores_gemma":[0.99832904,0.0008449532,0.00011291799,0.00034455513,0.00007032671,0.00029819654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053291325,0.00040267635,0.0005584077,0.0001299925,0.00040214323,0.00025261578,0.00012290399,0.00011426814,0.000012013804],"category_scores_gemma":[0.00021566454,0.00030564418,0.00008434541,0.00029869197,0.00059571274,0.00020692077,0.00013223827,0.00021626556,0.000035116092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008462621,0.00019671916,0.6808395,0.0003491871,0.00042857148,0.000048775553,0.0010736049,2.2240123e-7,0.30329186,0.0000533563,0.006461451,0.0071721715],"study_design_scores_gemma":[0.0045189885,0.00088330975,0.6097141,0.0007369433,0.0007624393,0.0000018023667,0.00043561967,0.00042014394,0.37977776,0.00011392658,0.0020937514,0.0005412449],"about_ca_topic_score_codex":0.00026111264,"about_ca_topic_score_gemma":0.00017841501,"teacher_disagreement_score":0.076485895,"about_ca_system_score_codex":0.00010555286,"about_ca_system_score_gemma":0.000036401412,"threshold_uncertainty_score":0.99993956},"labels":[],"label_agreement":null},{"id":"W2889059090","doi":"10.2337/dc17-2280","title":"Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy","year":2018,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; Women's College Hospital; Toronto General Hospital; University of Toronto; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University; Heart and Stroke Foundation of Canada","keywords":"Medicine; Diabetic retinopathy; Diabetes mellitus; Internal medicine; Retinopathy; Hazard ratio; Insulin; Type 2 diabetes; Cohort; Glucagon-like peptide-1; Cohort study; Glucagon-like peptide 1 receptor; Population; Endocrinology; Proportional hazards model; Receptor; Confidence interval; Agonist","score_opus":0.0056900284504641805,"score_gpt":0.22055834979372593,"score_spread":0.21486832134326175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889059090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905205,0.0026097042,0.0000022240495,0.00040763206,0.0004131245,0.00078593375,0.00004918324,0.000059382677,0.005152337],"genre_scores_gemma":[0.99750084,0.0003787775,0.00038540622,0.0005392171,0.00021321216,0.000103670645,0.00008590024,0.000031822397,0.0007611733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863315,0.000114020695,0.00029019653,0.00031586702,0.0002927477,0.00035401114],"domain_scores_gemma":[0.9987643,0.00016785727,0.00018799552,0.0005414368,0.00021744298,0.00012098722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030867322,0.00021935967,0.00045769877,0.00009025819,0.00014595616,0.000034209603,0.00013849155,0.00006774069,0.00010568743],"category_scores_gemma":[0.00019271421,0.00013864391,0.00015595778,0.00018319387,0.00064816023,0.000057822526,0.00018085122,0.00012121059,0.00017784045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013055612,0.00007897787,0.970035,0.00029230997,0.00041321685,0.000002485625,0.00347349,3.9086254e-7,0.0008875563,0.0002576038,0.0044980315,0.019930346],"study_design_scores_gemma":[0.009773685,0.0020602264,0.8806067,0.00061060354,0.0025430357,9.671489e-7,0.0041965246,0.00016882044,0.045362514,0.0004633276,0.053780302,0.00043327067],"about_ca_topic_score_codex":0.00003072291,"about_ca_topic_score_gemma":0.000018192335,"teacher_disagreement_score":0.08942831,"about_ca_system_score_codex":0.000064182685,"about_ca_system_score_gemma":0.000029695299,"threshold_uncertainty_score":0.5653735},"labels":[],"label_agreement":null},{"id":"W2889408384","doi":"10.2337/db18-0068","title":"Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents","year":2018,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"University of Cincinnati; Canadian Institutes of Health Research; Canada Research Chairs; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; American Diabetes Association","keywords":"Glucagon receptor; Internal medicine; Endocrinology; Glucagon; Insulin; Glucose homeostasis; Agonist; Glucagon-like peptide 1 receptor; Protein kinase B; Receptor; Glucagon-like peptide-1; Biology; Diabetes mellitus; Phosphorylation; Type 2 diabetes; Insulin resistance; Medicine; Biochemistry","score_opus":0.010998928952632112,"score_gpt":0.25905811767025744,"score_spread":0.24805918871762533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889408384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964459,0.000811008,0.000015420797,0.00018725432,0.00040296646,0.0005255015,0.0000062645627,0.00012496536,0.0014807013],"genre_scores_gemma":[0.9977413,0.00007753634,0.0007284567,0.00044587272,0.0002479824,0.00006373646,0.00013332069,0.000032148622,0.000529653],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854374,0.000046702928,0.00032248627,0.00035368223,0.00025794414,0.00047542067],"domain_scores_gemma":[0.9993672,0.00008687918,0.00008266167,0.00026335788,0.00007497089,0.00012497487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020505497,0.00022131545,0.00037206555,0.00021013549,0.000062952,0.000037309164,0.00011831758,0.00007819248,0.00034405672],"category_scores_gemma":[0.00011137884,0.00018731625,0.00007923124,0.00037994143,0.000095517404,0.00015198013,0.00007112437,0.00010265886,0.00052960217],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016515721,0.0010572444,0.63688445,0.00020805423,0.00034533412,0.000019325467,0.0007192675,0.000014560553,0.31794637,0.000108626526,0.00065519987,0.041876398],"study_design_scores_gemma":[0.0034520207,0.0012368627,0.08195583,0.0006739597,0.00021816637,1.4780102e-7,0.000088538356,0.003190884,0.90549684,0.00027681974,0.0030805462,0.00032941622],"about_ca_topic_score_codex":0.00004087841,"about_ca_topic_score_gemma":0.00002050158,"teacher_disagreement_score":0.58755046,"about_ca_system_score_codex":0.00010233334,"about_ca_system_score_gemma":0.000028225684,"threshold_uncertainty_score":0.7638535},"labels":[],"label_agreement":null},{"id":"W2889742409","doi":"10.1016/j.atherosclerosissup.2018.07.033","title":"Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes","year":2018,"lang":"en","type":"article","venue":"Atherosclerosis Supplements","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"COPD; Medicine; Internal medicine; Nicotine; Allele; Serotonin; Genotyping; Serotonin transporter; Endocrinology; Genotype; Gastroenterology; Receptor; Genetics; Biology","score_opus":0.005960088836770865,"score_gpt":0.23526705525586536,"score_spread":0.22930696641909448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889742409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998329,0.00007820521,9.497783e-7,0.00010097713,0.000050737206,0.0010594762,0.00006120312,0.000016922431,0.0003025276],"genre_scores_gemma":[0.9991236,0.000014050399,0.00006773216,0.00017893367,0.000013922699,0.000052397583,0.00007359268,0.000030642543,0.00044515135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821675,0.00015853395,0.00032473035,0.00031605776,0.0006233057,0.0003605999],"domain_scores_gemma":[0.9987087,0.00013008591,0.00014673252,0.00084836106,0.00011173629,0.000054337183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046761637,0.0002510146,0.0009318935,0.0003440227,0.000041880994,0.000009696504,0.0001752061,0.000051251733,0.00040615784],"category_scores_gemma":[0.00006339842,0.00013994891,0.0005052289,0.0012422585,0.00013351606,0.000042465406,0.00011004171,0.00006596708,0.000017897268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035036606,0.00024655176,0.9826626,0.000083454164,0.010144353,0.0000012779707,0.00020557715,0.00004858769,0.004992076,0.00000987056,0.00026883587,0.0009864226],"study_design_scores_gemma":[0.0045939633,0.006002687,0.9434079,0.00017796758,0.006041803,3.9705863e-8,0.000039374787,0.000125166,0.039128665,0.0000023665236,0.00035640947,0.00012368656],"about_ca_topic_score_codex":0.00026375937,"about_ca_topic_score_gemma":0.0001922242,"teacher_disagreement_score":0.039254755,"about_ca_system_score_codex":0.00011604602,"about_ca_system_score_gemma":0.000025225216,"threshold_uncertainty_score":0.5706951},"labels":[],"label_agreement":null},{"id":"W2890033749","doi":"10.1016/j.jchf.2018.05.021","title":"Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes","year":2018,"lang":"en","type":"review","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Takeda Canada; Canadian Diabetes Association; Novo Nordisk; Sanofi; Merck; Heart and Stroke Foundation of Canada; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Medicine; Placebo; Relative risk; Type 2 diabetes; Internal medicine; Randomized controlled trial; Diabetes mellitus; Alogliptin; Type 2 Diabetes Mellitus; Meta-analysis; Cochrane Library; Pharmacology; Sitagliptin; Confidence interval; Endocrinology","score_opus":0.03524503057917103,"score_gpt":0.3405572229931854,"score_spread":0.3053121924140144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890033749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020175777,0.9757237,0.0000013362861,0.0008392702,0.00041506012,0.0021203011,0.000040165545,0.00007761624,0.0006067932],"genre_scores_gemma":[0.0103935655,0.97935957,0.006907815,0.00018882564,0.00074941013,0.00010268237,0.00041729028,0.00020890366,0.001671915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970234,0.0001518856,0.0011457001,0.0006041106,0.00052656,0.00054836523],"domain_scores_gemma":[0.9979314,0.00025615015,0.00053355383,0.0009397322,0.00011453221,0.00022463426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004459766,0.000611189,0.0037501932,0.0006045728,0.00004131725,0.000022390526,0.00023019164,0.0004525304,0.00033543655],"category_scores_gemma":[0.00016744388,0.00047913587,0.00070534664,0.00083006773,0.00009601164,0.00008061552,0.00015937274,0.0006100628,0.00034723635],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082858896,0.0012426693,0.040432937,0.03327087,0.0016059197,0.000006357561,0.0005005122,0.000005313691,0.00003771419,0.00006771157,0.5771427,0.3456044],"study_design_scores_gemma":[0.0009566782,0.0012364162,0.00077297667,0.023127683,0.0015955816,9.645099e-7,0.00009587895,0.0000071000263,0.00047621652,0.00001609049,0.9714009,0.00031350553],"about_ca_topic_score_codex":0.0001051563,"about_ca_topic_score_gemma":0.000105344225,"teacher_disagreement_score":0.39425817,"about_ca_system_score_codex":0.00016803596,"about_ca_system_score_gemma":0.00029124581,"threshold_uncertainty_score":0.99976605},"labels":[],"label_agreement":null},{"id":"W2890415448","doi":"10.1111/dom.13522","title":"Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research; Lundbeckfonden; Steno Diabetes Center Copenhagen","keywords":"Medicine; Glucagon-like peptide-1; Antipsychotic; Glucagon-like peptide 1 receptor; Meta-analysis; Pharmacology; Internal medicine; Diabetes mellitus; Endocrinology; Receptor; Schizophrenia (object-oriented programming); Type 2 diabetes; Agonist; Psychiatry","score_opus":0.14773646459709897,"score_gpt":0.3460003284333762,"score_spread":0.19826386383627723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890415448","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001090993,0.9805498,0.000012799871,0.000049747916,0.00035724125,0.009278816,0.008488541,0.00014422463,0.000027842098],"genre_scores_gemma":[0.00023135357,0.9851732,0.00055206724,0.00041338115,0.00021027187,0.0016352799,0.010808255,0.00012667092,0.0008495047],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993228,0.00126068,0.001841249,0.0018374162,0.00069013686,0.0011425175],"domain_scores_gemma":[0.99395233,0.0008470851,0.001751189,0.0025392626,0.00027573013,0.00063440413],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004035076,0.001424759,0.018367091,0.0007248296,0.00041086314,0.0003170418,0.0007654252,0.00048426838,0.00008099491],"category_scores_gemma":[0.0013197855,0.00094020367,0.0033830127,0.0013339213,0.0002755847,0.00035130844,0.00070281944,0.00043745193,0.000042910633],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003662938,0.0003792785,0.00032161147,0.41818503,0.5761231,0.0000022573195,0.00011506181,2.9900384e-8,7.881482e-8,0.000047556507,0.002381364,0.0024409648],"study_design_scores_gemma":[0.0005570688,0.00007762052,0.0007270044,0.021275392,0.66861606,9.0994837e-7,0.00001946545,0.000007730682,0.0000010578021,0.00001464423,0.3081373,0.0005657745],"about_ca_topic_score_codex":0.00006301151,"about_ca_topic_score_gemma":0.0000295817,"teacher_disagreement_score":0.39690962,"about_ca_system_score_codex":0.000029437597,"about_ca_system_score_gemma":0.00013904346,"threshold_uncertainty_score":0.9998502},"labels":[],"label_agreement":null},{"id":"W2890444735","doi":"10.17925/ee.2018.14.2.40","title":"Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice","year":2018,"lang":"en","type":"review","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Canagliflozin; Dapagliflozin; Hazard ratio; Internal medicine; Type 2 diabetes; Myocardial infarction; Diabetes mellitus; Clinical endpoint; Cardiology; Heart failure; Confidence interval; Randomized controlled trial; Endocrinology","score_opus":0.0800416988838515,"score_gpt":0.40256980813250554,"score_spread":0.32252810924865405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890444735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020676586,0.9918471,0.0000051570632,0.00018744318,0.0001786135,0.0053405054,0.00005687819,0.000024568319,0.00029205033],"genre_scores_gemma":[0.000115611234,0.99611056,0.0014846333,0.00024525533,0.000114845076,0.0014739841,0.00031040533,0.000050642793,0.00009409184],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971912,0.0003979151,0.00093983987,0.00083025213,0.00013917407,0.0005016138],"domain_scores_gemma":[0.997889,0.00065543153,0.00025569618,0.00089124835,0.00012825547,0.00018036578],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053373474,0.00045187047,0.0034301335,0.0002834681,0.00003988074,0.000018684907,0.00013246588,0.00013467348,0.0000071452755],"category_scores_gemma":[0.0010850723,0.00029948587,0.00047224513,0.0002438045,0.00021995255,0.000093773386,0.00018362606,0.0002626351,0.000016192133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043594508,0.00032479232,0.2197979,0.0056389803,0.002327745,0.000016326416,0.0000065990585,7.758531e-8,9.616049e-10,0.00013162711,0.00070867245,0.77100366],"study_design_scores_gemma":[0.002324999,0.0006042294,0.12150342,0.002745886,0.00968557,0.0000042881434,0.0000030933036,4.2708746e-7,9.6512185e-9,0.000027857739,0.8628683,0.00023191673],"about_ca_topic_score_codex":0.000007168898,"about_ca_topic_score_gemma":0.0000072851735,"teacher_disagreement_score":0.8621596,"about_ca_system_score_codex":0.000083173865,"about_ca_system_score_gemma":0.00012339179,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W2890562667","doi":"10.4212/cjhp.v71i4.2831","title":"Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?","year":2018,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Native Mental Health Association of Canada; University of British Columbia","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Disease; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.019320348418158592,"score_gpt":0.2529191744428336,"score_spread":0.23359882602467502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890562667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228287,0.0045327656,0.0000010498529,0.0015983441,0.00053370907,0.0003762945,0.000012305621,0.000007832637,0.00065483066],"genre_scores_gemma":[0.99825037,0.00020269216,0.00006735391,0.0008482163,0.0005029566,0.000003333347,0.000017098007,0.000025757741,0.00008220206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990082,0.0000467425,0.00016910255,0.00014791435,0.0003158513,0.0003122175],"domain_scores_gemma":[0.9982486,0.000013815948,0.00008216269,0.0002560006,0.00035926362,0.0010401824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022459382,0.0001563753,0.00023966437,0.00011658691,0.0001482411,0.000073854826,0.00013089307,0.000017427212,0.00008116791],"category_scores_gemma":[0.000036920097,0.00009304339,0.00010074152,0.00012523215,0.00023708041,0.00025784285,0.000017046455,0.00014809307,0.000014108309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000563758,0.00039812457,0.8847387,0.00007203896,0.006360758,0.0005246122,0.0019775387,0.000023100805,0.00001975012,0.0000918058,0.016080987,0.08914886],"study_design_scores_gemma":[0.011337483,0.010554393,0.56825924,0.00036275477,0.007835942,0.0000097043885,0.0002885486,0.000115366616,0.0010013891,0.0004460271,0.39919263,0.0005964908],"about_ca_topic_score_codex":0.00082608184,"about_ca_topic_score_gemma":0.0006746314,"teacher_disagreement_score":0.38311166,"about_ca_system_score_codex":0.00010374572,"about_ca_system_score_gemma":0.00029197993,"threshold_uncertainty_score":0.37941995},"labels":[],"label_agreement":null},{"id":"W2890741038","doi":"10.1161/jaha.118.009304","title":"Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial","year":2018,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"","keywords":"Medicine; Mace; Exenatide; Interquartile range; Internal medicine; Glycated hemoglobin; Population; Body mass index; Diabetes mellitus; Type 2 diabetes; Myocardial infarction; Endocrinology; Percutaneous coronary intervention","score_opus":0.013601092601675644,"score_gpt":0.31499872310312554,"score_spread":0.3013976305014499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890741038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972399,0.000022797625,0.000003348898,0.0014538442,0.0005999547,0.00062015775,0.000005580945,0.000005258791,0.00004914459],"genre_scores_gemma":[0.9980038,0.000027626056,0.00024080319,0.001220399,0.00043213074,0.000004759378,0.0000030894296,0.000012189643,0.000055207405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976356,0.0009589997,0.00054944877,0.00011765776,0.0005879605,0.00015032521],"domain_scores_gemma":[0.9953974,0.0030638482,0.0010244552,0.00022471059,0.00022937765,0.00006019059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018852988,0.00011940073,0.0007286054,0.000091094764,0.00005625528,0.000016149155,0.00012997966,0.00003078488,0.000006118561],"category_scores_gemma":[0.0038730977,0.000052555028,0.00022161417,0.00036480845,0.00005367903,0.000066303604,0.000040469473,0.00022191812,0.000011702842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00936547,0.00035081443,0.97355163,0.0000024889,0.00050506834,3.7469303e-7,0.00011811342,0.000011107809,0.000023368286,8.2811664e-7,0.0022099437,0.013860794],"study_design_scores_gemma":[0.0148285655,0.018735908,0.9643707,0.00016015154,0.00051512907,1.9212033e-8,0.00006499824,0.00003357013,0.0004367453,0.000015803702,0.0007853265,0.00005303581],"about_ca_topic_score_codex":0.00011945209,"about_ca_topic_score_gemma":0.0000379939,"teacher_disagreement_score":0.018385094,"about_ca_system_score_codex":0.00026828016,"about_ca_system_score_gemma":0.000045143886,"threshold_uncertainty_score":0.46367395},"labels":[],"label_agreement":null},{"id":"W2891376948","doi":"10.14740/jocmr3587w","title":"Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacology; Clinical trial; Glucagon-like peptide 1 receptor; Weight loss; Receptor; Internal medicine; Bioinformatics; Obesity; Agonist; Biology","score_opus":0.25731040358279994,"score_gpt":0.5305960439764572,"score_spread":0.27328564039365727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891376948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847962,0.005373876,0.000019259127,0.0070521114,0.0015906597,0.00081547204,0.0000061921637,0.000004625464,0.00034158368],"genre_scores_gemma":[0.95214593,0.04041157,0.00045021196,0.000015862784,0.00673119,0.000005690122,0.000016814587,0.000019293122,0.00020345325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98771167,0.004464685,0.00497838,0.0003456802,0.0021552907,0.00034432558],"domain_scores_gemma":[0.99102104,0.0048015625,0.0019880356,0.0003165246,0.0014339697,0.00043884822],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.084107764,0.00016651023,0.0026317947,0.000624381,0.000055598408,0.000006916177,0.00012876398,0.0003746162,0.00008623822],"category_scores_gemma":[0.03493883,0.000108012966,0.0004589345,0.0005006069,0.0006367453,0.00016142183,0.00015901354,0.0010818429,0.000002208222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016976007,0.0006348649,0.6970346,0.00024975874,0.0020276753,0.000009186119,0.00015987315,3.047735e-7,0.0006440489,0.000013361258,0.017326836,0.28020188],"study_design_scores_gemma":[0.031758998,0.022065764,0.8170792,0.008410968,0.0028867791,0.00001136422,0.0009676691,0.000027904438,0.011108649,0.00061122404,0.104878485,0.00019300963],"about_ca_topic_score_codex":0.00006644422,"about_ca_topic_score_gemma":0.0000034046093,"teacher_disagreement_score":0.28000888,"about_ca_system_score_codex":0.00018709575,"about_ca_system_score_gemma":0.00027370855,"threshold_uncertainty_score":0.9731903},"labels":[],"label_agreement":null},{"id":"W2892054198","doi":"10.1016/j.jcjd.2018.09.001","title":"Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; AstraZeneca España; Boehringer Ingelheim España; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Body mass index; Glycated hemoglobin; Internal medicine; Blood pressure; Diabetes mellitus; Weight loss; Endocrinology; Gastroenterology; Type 2 diabetes; Obesity","score_opus":0.012573089982114689,"score_gpt":0.23655649651272323,"score_spread":0.22398340653060855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892054198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719894,0.00075720047,4.2061487e-7,0.000356642,0.0002999576,0.0010842655,0.0000056054646,0.000011965595,0.00028503122],"genre_scores_gemma":[0.99881613,0.000067983914,0.0001306119,0.00045744452,0.00011319537,0.00002388903,0.000023073944,0.000043629,0.00032402857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835294,0.000074009346,0.00042641044,0.00028223643,0.00036828517,0.00049611705],"domain_scores_gemma":[0.99833167,0.00007220139,0.00026896468,0.00023898242,0.0005547222,0.0005334859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034936593,0.00027833958,0.00049357855,0.00068513147,0.00011489322,0.000087234774,0.00012920606,0.00005272591,0.000100015306],"category_scores_gemma":[0.000033222466,0.00019327532,0.00004561033,0.0006003287,0.00024555586,0.00042709705,0.000009543211,0.00019373048,0.0000074180302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012969828,0.0005581114,0.9894062,0.000050662507,0.0003505166,0.00002408676,0.0015574924,7.087664e-7,0.00007736904,0.000006397709,0.0011278321,0.0067108893],"study_design_scores_gemma":[0.007115549,0.010542056,0.97768146,0.0014204164,0.00023362742,2.4621207e-7,0.00028714896,0.000006260346,0.00080755394,0.000010246141,0.0016693255,0.00022613742],"about_ca_topic_score_codex":0.00062655413,"about_ca_topic_score_gemma":0.030877924,"teacher_disagreement_score":0.030251369,"about_ca_system_score_codex":0.00027473504,"about_ca_system_score_gemma":0.0004613174,"threshold_uncertainty_score":0.98680604},"labels":[],"label_agreement":null},{"id":"W2892158645","doi":"","title":"Patients with type 2 diabetes on the maximum dose of insulin degludec/liraglutide (IDegLira) achieve glycaemic target: analyses from the DUAL programme","year":2018,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Liraglutide; Insulin degludec; Type 2 diabetes; Medicine; Dual (grammatical number); Diabetes mellitus; Insulin; Internal medicine; Insulin glargine; Endocrinology","score_opus":0.03263154427199412,"score_gpt":0.2697037954206432,"score_spread":0.2370722511486491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892158645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881694,0.00022365183,0.000022471637,0.0017258737,0.00012782516,0.001134762,0.000024318086,0.00007195756,0.008499773],"genre_scores_gemma":[0.99564624,0.000020777554,0.0012266074,0.0019885,0.00015674275,0.000053677402,0.00018108607,0.00003123028,0.00069512165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984615,0.00007889626,0.00027456105,0.00031037713,0.0004766675,0.0003979867],"domain_scores_gemma":[0.9985968,0.00027679035,0.00015489529,0.0006642173,0.00021739118,0.00008993558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018791936,0.000254696,0.00034234728,0.00006764822,0.00011803631,0.00003554816,0.00020741987,0.00005456175,0.00050524453],"category_scores_gemma":[0.0001376509,0.00010370362,0.0001037159,0.00041451442,0.00030123405,0.00006715078,0.00011462298,0.00012803992,0.00016591122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024817772,0.0027440644,0.9174872,0.000042011005,0.003670831,0.000010738587,0.00083506986,0.000008849839,0.0015059686,0.0011567618,0.017157512,0.05289923],"study_design_scores_gemma":[0.007900972,0.012108574,0.9239515,0.00031005178,0.0018428211,2.7733995e-7,0.000792958,0.00026969978,0.03148927,0.0021598442,0.018745204,0.00042879078],"about_ca_topic_score_codex":0.00021675564,"about_ca_topic_score_gemma":0.000101601516,"teacher_disagreement_score":0.05247044,"about_ca_system_score_codex":0.0000468421,"about_ca_system_score_gemma":0.00004534831,"threshold_uncertainty_score":0.55320734},"labels":[],"label_agreement":null},{"id":"W2892247024","doi":"10.1016/j.peptides.2018.09.002","title":"Glucagon-like peptide-1 receptor action in the vasculature","year":2018,"lang":"en","type":"review","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Liraglutide; Medicine; Cardioprotection; Glucagon-like peptide 1 receptor; Vascular smooth muscle; Glucagon-like peptide-1; Agonist; Internal medicine; Endothelium; Endocrinology; Type 2 diabetes; Nitric oxide; Semaglutide; Receptor; Pharmacology; Diabetes mellitus; Myocardial infarction; Smooth muscle","score_opus":0.07720015587120768,"score_gpt":0.35677587765518737,"score_spread":0.2795757217839797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892247024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011618993,0.9828044,0.0000020070443,0.0001651498,0.000735354,0.0017711218,0.000009760468,0.00007609479,0.01431988],"genre_scores_gemma":[0.000025808838,0.9849027,0.00033033214,0.00031541876,0.0009879376,0.0004091969,0.00051198655,0.00005817075,0.012458443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826616,0.00015013579,0.00041040973,0.0004579581,0.0003571045,0.00035821355],"domain_scores_gemma":[0.99882907,0.00012901693,0.00019463962,0.00073332427,0.000046871686,0.00006708004],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004594587,0.00043328313,0.0011076953,0.0002480496,0.000072885276,0.00007479823,0.00026048988,0.00026495734,0.0002548323],"category_scores_gemma":[0.0000624052,0.00023956712,0.0006567511,0.0004527745,0.000082361184,0.00009959254,0.00007582259,0.00040225382,0.0013904774],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000093428625,0.00019703295,0.000031276017,0.0091035655,0.00050767884,0.00002184013,0.00016119651,5.453646e-8,3.0059732e-7,0.000110760644,0.13488805,0.8549689],"study_design_scores_gemma":[0.00034253407,0.00017579799,0.00010647812,0.009806928,0.0020674306,0.000011806747,0.000106360865,7.3511734e-7,9.558221e-7,0.000031942953,0.98713464,0.00021442215],"about_ca_topic_score_codex":0.00003060394,"about_ca_topic_score_gemma":0.0000532946,"teacher_disagreement_score":0.8547545,"about_ca_system_score_codex":0.0002208226,"about_ca_system_score_gemma":0.00008978087,"threshold_uncertainty_score":0.999387},"labels":[],"label_agreement":null},{"id":"W2892394127","doi":"10.1016/j.cjca.2018.07.221","title":"SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL PROGRAM","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Semaglutide; Post-hoc analysis; Type 2 diabetes; Baseline (sea); Diabetes mellitus; Post hoc; Internal medicine; Physical therapy; Endocrinology; Liraglutide","score_opus":0.022932090882486027,"score_gpt":0.25487030854234155,"score_spread":0.23193821765985553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892394127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910115,0.006570443,0.000029236358,0.00008282254,0.00053559546,0.0011557128,0.00012175377,0.000005637237,0.00048727464],"genre_scores_gemma":[0.9987972,0.00021272564,0.00042201174,0.00002989197,0.00043409763,0.000012584183,0.000024844829,0.000029211276,0.000037433736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969978,0.0010030192,0.00074888987,0.0002690845,0.00049914996,0.00048205454],"domain_scores_gemma":[0.9964799,0.00014130956,0.0005827488,0.00075244834,0.001744119,0.00029943755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001964401,0.0002496845,0.0016932895,0.000552463,0.00008725726,0.0000132126015,0.00027008555,0.00013724495,0.000009628269],"category_scores_gemma":[0.0013447927,0.00015643056,0.001371632,0.0006251172,0.00072866376,0.000058839523,0.00003869545,0.00029072686,0.0000013014221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005457677,0.00009514631,0.89061594,0.000119835364,0.0316842,0.0001039257,0.00020273792,0.0030992485,0.000024271341,0.000009919555,0.0013483644,0.0672387],"study_design_scores_gemma":[0.042544898,0.0107740415,0.8930259,0.00039109174,0.015904633,0.000015094248,0.0005889469,0.0000182894,0.0013704012,0.000035130404,0.035041936,0.0002896762],"about_ca_topic_score_codex":0.0029730413,"about_ca_topic_score_gemma":0.0015543512,"teacher_disagreement_score":0.066949025,"about_ca_system_score_codex":0.00022545412,"about_ca_system_score_gemma":0.0012075193,"threshold_uncertainty_score":0.6379053},"labels":[],"label_agreement":null},{"id":"W2892488831","doi":"10.1016/j.cjca.2018.07.353","title":"EMPAGLIFLOZIN REDUCES MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND A HISTORY OF LEFT VENTRICULAR HYPERTROPHY: A SUB-ANALYSIS OF THE EMPA-REG OUTCOME TRIAL","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Internal medicine; Mace; Cardiology; Hazard ratio; Left ventricular hypertrophy; Type 2 diabetes; Placebo; EMPA; Diabetes mellitus; Myocardial infarction; Blood pressure; Endocrinology; Confidence interval; Conventional PCI","score_opus":0.018069658756171267,"score_gpt":0.23272076905470931,"score_spread":0.21465111029853806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892488831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791694,0.0009381633,0.0000013727652,0.00008376592,0.00040224747,0.00021830753,0.000009292869,9.388523e-7,0.00042897783],"genre_scores_gemma":[0.9997292,0.00001021492,0.000014983683,0.00006942092,0.00010481763,0.0000012379095,0.000005770632,0.000006410428,0.00005794789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990603,0.00011970382,0.0003876308,0.00010376776,0.00015032405,0.00017828992],"domain_scores_gemma":[0.99908507,0.000031114163,0.00028773813,0.00019993467,0.00024638698,0.00014977092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027974427,0.00009517501,0.000792948,0.0004790656,0.000016103762,0.0000022584911,0.000095528754,0.000054942877,0.00001989167],"category_scores_gemma":[0.00014007134,0.00005750683,0.00020731875,0.0002601303,0.00032093812,0.00003380707,0.000012981326,0.000087846165,3.3356932e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000628253,0.000017116243,0.99458754,0.0000143346215,0.0035049536,0.000023615501,0.00015440396,0.000042113632,0.000048620765,0.0000066638754,0.0006186343,0.00035373116],"study_design_scores_gemma":[0.006688435,0.0015421339,0.98457175,0.00003132943,0.004438821,0.0000015452717,0.0000364435,0.0000056096724,0.00010107356,0.000008963623,0.0025223624,0.000051552262],"about_ca_topic_score_codex":0.00043402804,"about_ca_topic_score_gemma":0.0015675961,"teacher_disagreement_score":0.0100158295,"about_ca_system_score_codex":0.0002769468,"about_ca_system_score_gemma":0.00045621078,"threshold_uncertainty_score":0.23450606},"labels":[],"label_agreement":null},{"id":"W2892591934","doi":"10.1016/j.cjca.2018.07.130","title":"DELINEATING THE MECHANISMS THAT CONTRIBUTE TO REDUCED HEART FAILURE WITH EMPAGLIFLOZIN IN THE EXPERIMENTAL SETTING","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Preload; Afterload; Cardiac function curve; Cardiology; Heart failure; Diuresis; Myocardial infarction; Internal medicine; Canagliflozin; Hemodynamics; Renal function; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.01509614252072851,"score_gpt":0.25667349938527645,"score_spread":0.24157735686454793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892591934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96377176,0.0002675874,0.0013961957,0.03129276,0.00029847966,0.0004987625,0.000005650678,0.0000046559153,0.002464128],"genre_scores_gemma":[0.9933258,0.0000012085774,0.0014739183,0.0044125887,0.00070823624,0.00001557366,0.0000036895474,0.000011033343,0.000047950693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990562,0.00015189117,0.000198376,0.00010890632,0.00014054099,0.00034408408],"domain_scores_gemma":[0.99936086,0.000072508024,0.00007912003,0.0001869506,0.0001150246,0.00018553877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077596185,0.00010950918,0.00030211135,0.00014927701,0.00013783791,0.000032851396,0.0001626536,0.000044193323,0.000021401716],"category_scores_gemma":[0.00008844407,0.00005517613,0.00008455456,0.00014691659,0.00009137581,0.000043372555,0.0000133996355,0.00017216032,0.000011920883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010808228,0.00006069203,0.21820627,0.000054318978,0.0040584384,0.0037820106,0.026310323,0.0017858698,0.037912402,0.009471411,0.67794067,0.01933675],"study_design_scores_gemma":[0.008677871,0.009300507,0.10674699,0.0006369401,0.0009701999,0.003992748,0.05476686,0.0001054221,0.034990538,0.00054689543,0.77873206,0.00053298974],"about_ca_topic_score_codex":0.00028437405,"about_ca_topic_score_gemma":0.0025948035,"teacher_disagreement_score":0.11145929,"about_ca_system_score_codex":0.00014855893,"about_ca_system_score_gemma":0.0002832706,"threshold_uncertainty_score":0.22500174},"labels":[],"label_agreement":null},{"id":"W2892664258","doi":"10.1016/j.cjca.2018.07.219","title":"NOVEL GLUCOSE LOWERING AGENTS ARE ASSOCIATED WITH A LOWER RISK OF CARDIOVASCULAR AND ADVERSE EVENTS IN TYPE 2 DIABETES: A POPULATION BASED ANALYSIS","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Type 2 diabetes; Metformin; Myocardial infarction; Population; Adverse effect; Diabetes mellitus; Cohort; Stroke (engine); Coronary artery disease; Cardiology; Insulin; Endocrinology","score_opus":0.012077344862687314,"score_gpt":0.21953891684749044,"score_spread":0.20746157198480314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892664258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99836195,0.0005225441,0.000583284,0.000033846976,0.00015355561,0.0001502008,0.000016846629,0.0000025943991,0.00017518555],"genre_scores_gemma":[0.9996625,0.000040041927,0.00011878359,0.000046222693,0.0000785423,0.0000020763555,0.000023869106,0.000011308191,0.000016627457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991558,0.00008404592,0.00024044835,0.00013624631,0.0001504321,0.00023301499],"domain_scores_gemma":[0.9990667,0.000029448274,0.0002478724,0.00018210072,0.00024904424,0.00022484171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047239254,0.00011255813,0.0007267669,0.0007074624,0.00003207732,0.0000022700865,0.000053864856,0.00007752659,0.000013765625],"category_scores_gemma":[0.00023873319,0.00009202175,0.00027816521,0.0005450929,0.00006236851,0.00005358921,0.000007969678,0.000100591176,8.2453727e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008435124,0.000012596464,0.9796281,0.000014121636,0.009566385,0.00008535401,0.000037060196,0.009864692,0.000012393932,6.958765e-7,0.000034782744,0.00065949716],"study_design_scores_gemma":[0.0025665783,0.00064414355,0.9892229,0.00017419439,0.005887054,0.0000034744883,0.00004167689,0.0005990984,0.000023374974,0.0000050581825,0.00075480394,0.000077684876],"about_ca_topic_score_codex":0.0011775743,"about_ca_topic_score_gemma":0.006969961,"teacher_disagreement_score":0.009594789,"about_ca_system_score_codex":0.00023940153,"about_ca_system_score_gemma":0.00016346294,"threshold_uncertainty_score":0.3889402},"labels":[],"label_agreement":null},{"id":"W2893062539","doi":"10.1016/j.cjca.2018.07.288","title":"EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Stroke (engine); Myocardial infarction; Heart failure; Disease; Ethnic group; Telephone survey; Cohort; Heart disease; Emergency medicine; Physical therapy; Internal medicine","score_opus":0.017141347716602758,"score_gpt":0.2475587902715369,"score_spread":0.23041744255493415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893062539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826586,0.00012294773,0.00020627711,0.0003197546,0.00039367971,0.0004025884,0.000030030527,0.0000019452657,0.0002568854],"genre_scores_gemma":[0.99849075,0.000011479556,0.00053143554,0.00013034824,0.00035369728,0.000008546228,0.000030186477,0.000010748425,0.00043280565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993031,0.0000603791,0.0002607223,0.0001122243,0.000096891854,0.00016666828],"domain_scores_gemma":[0.9992407,0.00002735143,0.00015119668,0.00009605235,0.00029460865,0.00019012326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002675842,0.00009231142,0.00044249644,0.00025735152,0.000024627934,0.000003385594,0.000031821648,0.00006532393,0.00003310487],"category_scores_gemma":[0.000138904,0.0000615311,0.000059320704,0.000064449414,0.00018021888,0.00007592691,0.000006645953,0.00005017554,4.9660053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001269979,0.000009059135,0.9772743,0.000028464041,0.00039468025,0.0000072678167,0.0002031197,0.000020656125,0.000048284364,0.00000477214,0.019789943,0.0009494488],"study_design_scores_gemma":[0.0045736404,0.004788434,0.8622313,0.00008078879,0.00043425185,0.000016426175,0.000112838425,0.000022815246,0.000061001123,0.000005511297,0.12759568,0.00007731251],"about_ca_topic_score_codex":0.00030606717,"about_ca_topic_score_gemma":0.011418491,"teacher_disagreement_score":0.11504303,"about_ca_system_score_codex":0.00052021735,"about_ca_system_score_gemma":0.0006902926,"threshold_uncertainty_score":0.63717854},"labels":[],"label_agreement":null},{"id":"W2893079853","doi":"10.1016/j.jaac.2018.08.005","title":"Dr. Handen et al. Reply","year":2018,"lang":"en","type":"letter","venue":"Journal of the American Academy of Child & Adolescent Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Holland Bloorview Kids Rehabilitation Hospital","funders":"","keywords":"Metformin; Autism spectrum disorder; Randomized controlled trial; Medicine; Overweight; Antipsychotic; Autism; Psychiatry; Pediatrics; Psychology; Body mass index; Internal medicine; Schizophrenia (object-oriented programming)","score_opus":0.013205301094267777,"score_gpt":0.2912030013435583,"score_spread":0.27799770024929055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893079853","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060072816,0.002562109,0.000020514246,0.9861768,0.0019157551,0.0005506158,0.000019790421,0.000025313673,0.0027218063],"genre_scores_gemma":[0.004305311,0.0023117913,0.0009193744,0.9825928,0.0071615907,0.0000034704344,0.0000103455595,0.0001029909,0.0025923199],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618703,0.00024595342,0.0012619443,0.00040120375,0.001396524,0.0005073446],"domain_scores_gemma":[0.99458236,0.00004599789,0.004484427,0.0005998201,0.000119635995,0.00016775227],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00063794083,0.00052640977,0.001481022,0.0004408791,0.00009527356,0.00003298404,0.0010182594,0.00018009427,0.00006669756],"category_scores_gemma":[0.00005464949,0.00032781225,0.0013505624,0.0004216108,0.00064118986,0.00011811402,0.00024307979,0.0041646264,0.000030160769],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036303984,0.0004282526,0.016448531,0.000316661,0.0015280937,0.000017693847,0.000026221522,0.0000014105908,0.000021576958,0.000018272995,0.97933185,0.0014983972],"study_design_scores_gemma":[0.0017434112,0.00079140294,0.0820243,0.005059071,0.0017630325,0.00021876823,0.000031442516,0.0000015435012,0.00012384556,0.00018553146,0.9077992,0.00025849216],"about_ca_topic_score_codex":0.0000049337195,"about_ca_topic_score_gemma":4.3630897e-7,"teacher_disagreement_score":0.07153269,"about_ca_system_score_codex":0.00015302098,"about_ca_system_score_gemma":0.00022711366,"threshold_uncertainty_score":0.9999174},"labels":[],"label_agreement":null},{"id":"W2893097539","doi":"10.1111/dom.13547","title":"Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Placebo; Quality of life (healthcare); EQ-5D; Visual analogue scale; Confidence interval; Physical therapy; Clinical trial; Type 2 diabetes; Internal medicine; Diabetes mellitus; Gerontology; Health related quality of life; Alternative medicine; Nursing; Endocrinology","score_opus":0.03952394011067687,"score_gpt":0.3006571993597987,"score_spread":0.2611332592491218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893097539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939979,0.0029751258,7.806815e-7,0.0014161364,0.00014028091,0.0009019535,0.0000042783563,0.000021604397,0.00054195215],"genre_scores_gemma":[0.9983136,0.000093280185,0.00013746505,0.0011272434,0.00009627165,0.00012711913,0.000021837526,0.0000120642435,0.0000710964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982046,0.00031383915,0.0005375822,0.00025149554,0.00025332923,0.00043918737],"domain_scores_gemma":[0.99917316,0.0001970372,0.00019424489,0.00026912248,0.000064972075,0.0001014332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015255967,0.00016470949,0.00079333683,0.00014952183,0.000068444424,0.00001980373,0.000089756366,0.00006698471,0.00004800856],"category_scores_gemma":[0.00029424045,0.00010496516,0.000050897288,0.00059296686,0.00016767238,0.00010729342,0.000044823617,0.000156795,0.000008154507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074021146,0.00079306256,0.98964024,0.0002271402,0.00013101356,9.03805e-7,0.0037233126,0.0000018981696,0.00009768575,0.00090660434,0.00014393292,0.0035939969],"study_design_scores_gemma":[0.01804115,0.0007388691,0.97923416,0.00011645255,0.000117821655,6.650523e-8,0.00043758252,0.00010139136,0.0003277199,0.00020060419,0.0005712817,0.000112921414],"about_ca_topic_score_codex":0.00045865536,"about_ca_topic_score_gemma":0.0008351889,"teacher_disagreement_score":0.01730094,"about_ca_system_score_codex":0.000018473685,"about_ca_system_score_gemma":0.00007448521,"threshold_uncertainty_score":0.4280355},"labels":[],"label_agreement":null},{"id":"W2893423621","doi":"10.1139/cjpp-2018-0359","title":"Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Cardiorespiratory fitness; Medicine; Type 2 diabetes; Heart failure; Cardiology; Internal medicine; Diabetes mellitus; Heart rate; Blood pressure; Endocrinology","score_opus":0.019306516533105958,"score_gpt":0.2945132241474032,"score_spread":0.2752067076142973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893423621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505895,0.0014959009,0.0000030694769,0.0019893053,0.000605114,0.00013422311,0.000008321794,0.0000030198028,0.0007020889],"genre_scores_gemma":[0.9970675,0.00006135654,0.00006522359,0.002263205,0.0004551201,0.0000068169293,0.0000094602965,0.0000067914443,0.00006451719],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99938494,0.000057674984,0.0001963446,0.00010728187,0.000028865008,0.0002248908],"domain_scores_gemma":[0.9994438,0.000047626945,0.0000679018,0.00005948813,0.00013738134,0.00024377531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013393942,0.00008217065,0.00023788089,0.00025838817,0.00006662767,0.000003590355,0.000062538755,0.00007147708,0.0006448845],"category_scores_gemma":[0.000011733183,0.00007121719,0.00004463162,0.00014086826,0.00027963365,0.000059648533,0.00000594838,0.00013509749,0.000009977972],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021890987,0.000108246604,0.17491944,0.00011120909,0.0007483354,0.00005949969,0.00065827125,0.000015870242,0.78884774,0.00077499554,0.017937416,0.015600044],"study_design_scores_gemma":[0.002537869,0.0012903773,0.91654056,0.000025138108,0.0003344012,0.000019108062,0.000038903174,0.00004642008,0.021721365,0.0018423459,0.055485684,0.0001178098],"about_ca_topic_score_codex":0.000053048767,"about_ca_topic_score_gemma":0.0005718237,"teacher_disagreement_score":0.7671264,"about_ca_system_score_codex":0.00004085106,"about_ca_system_score_gemma":0.00046092406,"threshold_uncertainty_score":0.70610327},"labels":[],"label_agreement":null},{"id":"W2893676915","doi":"10.1016/j.cjca.2018.07.289","title":"EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A SUB-ANALYSIS OF THE EMPA-REG OUTCOME TRIAL","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Diabetes mellitus; Type 2 diabetes; Heart failure; Myocardial infarction; Placebo; Coronary artery disease; Type 2 Diabetes Mellitus; Cardiology; Surgery; Endocrinology; Pathology","score_opus":0.014403845631609288,"score_gpt":0.2553788531811609,"score_spread":0.2409750075495516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893676915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99861073,0.00019506451,0.000013106422,0.00056331663,0.00017470279,0.0003915547,0.000027034537,0.0000011308234,0.00002336407],"genre_scores_gemma":[0.9996602,0.000004267492,0.000032344633,0.00011068781,0.00014436989,0.0000058249907,0.000019258301,0.0000061256383,0.000016955935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937,0.00006115307,0.0002346141,0.000102037295,0.000082812316,0.0001493985],"domain_scores_gemma":[0.99938405,0.00002412366,0.00012051244,0.000115127594,0.00017677844,0.00017942223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018070421,0.000081165745,0.00046411925,0.00020663971,0.00003830841,0.000011410988,0.000040582796,0.00003763889,0.0000054654847],"category_scores_gemma":[0.000113163434,0.0000500826,0.0001074119,0.00019043095,0.0001890881,0.000054360306,0.0000073262395,0.00004251258,5.979172e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006670772,0.000007690983,0.9968255,0.000015798601,0.0014660184,0.0000019554952,0.000094066665,0.000036037665,0.0000075064568,0.0000130807,0.0006596223,0.00020563774],"study_design_scores_gemma":[0.0063734055,0.0011794849,0.9887773,0.000027025791,0.0025681397,3.99101e-7,0.000054178643,0.000024724643,0.000012805131,0.000027598033,0.000906005,0.00004896039],"about_ca_topic_score_codex":0.000051881183,"about_ca_topic_score_gemma":0.0019843085,"teacher_disagreement_score":0.0080482345,"about_ca_system_score_codex":0.000056823443,"about_ca_system_score_gemma":0.00015846694,"threshold_uncertainty_score":0.2042309},"labels":[],"label_agreement":null},{"id":"W2893827367","doi":"10.1146/annurev-med-042017-094221","title":"Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes","year":2018,"lang":"en","type":"review","venue":"Annual Review of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Diabetes Canada","keywords":"Medicine; Type 2 diabetes; Adverse effect; Diabetes mellitus; Blood pressure; Canagliflozin; Weight loss; Disease; Clinical trial; Empagliflozin; Internal medicine; Pharmacology; Endocrinology; Intensive care medicine; Obesity","score_opus":0.023982821148138014,"score_gpt":0.32517397358816114,"score_spread":0.30119115244002315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893827367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073500625,0.99211377,3.757961e-7,0.0013879229,0.000416543,0.0036609098,0.000056367408,0.000022260363,0.0022683262],"genre_scores_gemma":[0.000031002277,0.9967458,0.000042876836,0.0006851109,0.00058788573,0.00016757906,0.00046352457,0.00005096228,0.0012252496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970739,0.00019461251,0.0014963808,0.00041530564,0.0005161336,0.00030370243],"domain_scores_gemma":[0.99738765,0.0003998925,0.00093171035,0.0008079346,0.00030908015,0.00016373642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089254964,0.000596331,0.0054216417,0.00019302318,0.000036382462,0.000002713092,0.00018971485,0.00014719079,0.00022154838],"category_scores_gemma":[0.00022101398,0.00025572703,0.00066053437,0.00049586414,0.0013421453,0.000043105345,0.000041763204,0.00012171714,0.000028073697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042141713,0.00026413298,0.000025685506,0.19784169,0.0013797277,0.000011199479,0.0002297823,7.4056306e-10,1.919334e-7,0.00016204476,0.014648346,0.7853951],"study_design_scores_gemma":[0.002625511,0.0035681122,0.000011915856,0.24507108,0.017971093,0.0000055373007,0.000036796133,2.3123354e-7,0.0000072335897,0.000017529108,0.73055947,0.0001254681],"about_ca_topic_score_codex":0.000029754698,"about_ca_topic_score_gemma":0.0000025211748,"teacher_disagreement_score":0.7852696,"about_ca_system_score_codex":0.000068005844,"about_ca_system_score_gemma":0.0001353996,"threshold_uncertainty_score":0.9999895},"labels":[],"label_agreement":null},{"id":"W2894644761","doi":"10.1111/dom.13553","title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University Health Network; University of Toronto; Toronto General Hospital; LMC Diabetes & Endocrinology (Canada); Heart and Stroke Foundation","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Type 2 diabetes; Baseline (sea); Diabetes mellitus; Internal medicine; Endocrinology; Liraglutide","score_opus":0.011917956048650204,"score_gpt":0.20899184292867204,"score_spread":0.19707388688002184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894644761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393,0.0021282455,0.00067067816,0.00011559562,0.000231205,0.0028434496,0.000046879526,0.000013472279,0.000020476722],"genre_scores_gemma":[0.9955474,0.00023281947,0.0034047898,0.0003849076,0.000113869224,0.00012629516,0.000119068056,0.000018880883,0.000051971656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988774,0.00009493771,0.00028137432,0.0002457277,0.00025179968,0.0002487609],"domain_scores_gemma":[0.9990687,0.00021329916,0.000095684976,0.00025197785,0.00029454587,0.00007583921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062176713,0.00017658444,0.00054051395,0.00009405966,0.00010203664,0.000020139329,0.00004942123,0.000055123626,0.000013826116],"category_scores_gemma":[0.00020735695,0.000110381014,0.00008302386,0.00016778067,0.00015870278,0.000080343714,0.00004979576,0.000062393745,0.000001534373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017806703,0.0025386466,0.7045637,0.00051878963,0.0046905912,0.0000022849324,0.0010466574,0.000063329164,0.00018283467,0.000723855,0.0011156668,0.266747],"study_design_scores_gemma":[0.03235404,0.0016560261,0.92726386,0.00009151121,0.0017918124,5.75224e-8,0.000025996316,0.0011923059,0.00094115234,0.00006767435,0.034438867,0.00017672895],"about_ca_topic_score_codex":0.000006615203,"about_ca_topic_score_gemma":0.0000025024885,"teacher_disagreement_score":0.26657027,"about_ca_system_score_codex":0.000015692121,"about_ca_system_score_gemma":0.000032674285,"threshold_uncertainty_score":0.4501207},"labels":[],"label_agreement":null},{"id":"W2894659872","doi":"10.1016/j.jcjd.2018.08.050","title":"Relationship between Weight Change Patterns and Health Satisfaction in the Canadian Canagliflozin Registry (CanCARE) Study","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Canagliflozin; Medicine; Weight gain; Observational study; Weight change; Type 2 diabetes; Weight loss; Demography; Pediatrics; Diabetes mellitus; Internal medicine; Obesity; Body weight; Endocrinology","score_opus":0.07531894602557206,"score_gpt":0.3019745681231601,"score_spread":0.22665562209758805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894659872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983564,0.0006632082,6.528938e-7,0.014338622,0.00022524067,0.0005999741,0.00003635595,0.0000036806262,0.00056824804],"genre_scores_gemma":[0.99719024,0.0000050169183,0.000026907197,0.0020414202,0.00062550145,0.000018279516,0.000017604252,0.000015277352,0.00005972916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987676,0.00011712934,0.00032589617,0.00014033564,0.0001958408,0.0004531796],"domain_scores_gemma":[0.9986285,0.00006916157,0.00017209082,0.00021584496,0.00009394983,0.00082047377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008068307,0.00013435626,0.00028302814,0.00063964294,0.00028609647,0.00007578972,0.00011574691,0.000057006117,0.00003592427],"category_scores_gemma":[0.00007831076,0.00010195657,0.000041135412,0.00027652588,0.00007838492,0.00015044343,0.0000064450583,0.0002564112,0.00000481767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.6649095e-7,0.0000119565975,0.98559487,0.000030769672,0.00006775446,0.000036230256,0.0025553664,6.979518e-8,1.0465345e-7,0.00008384062,0.0027687699,0.008849412],"study_design_scores_gemma":[0.0008051516,0.0008633375,0.9925934,0.00016560392,0.00013101251,0.000002655231,0.0014129683,0.0000022607496,0.0000018355345,0.00009544214,0.0038422807,0.00008401834],"about_ca_topic_score_codex":0.768682,"about_ca_topic_score_gemma":0.9978698,"teacher_disagreement_score":0.2291878,"about_ca_system_score_codex":0.0008963474,"about_ca_system_score_gemma":0.0012470471,"threshold_uncertainty_score":0.41576684},"labels":[],"label_agreement":null},{"id":"W2894726433","doi":"10.1038/s41598-018-33483-y","title":"Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Waterloo; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Government of Canada; Diabetes Canada","keywords":"Medicine; Acute pancreatitis; Metformin; Acute kidney injury; Dipeptidyl peptidase-4; Hazard ratio; Internal medicine; Type 2 diabetes; Diabetes mellitus; Gastroenterology; Insulin; Pharmacology; Confidence interval; Endocrinology","score_opus":0.03496465912522025,"score_gpt":0.3098318971030407,"score_spread":0.2748672379778205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894726433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897684,0.0002524458,0.00021102694,0.00018626505,0.0030345353,0.0011108142,0.000012359352,0.000057847978,0.0061578415],"genre_scores_gemma":[0.99505264,0.0000036973831,0.0011452066,0.00003427588,0.00009111612,0.00004959084,0.00003497948,0.000018181092,0.0035703192],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851245,0.00000994018,0.00040246535,0.00048844336,0.00032032098,0.00026636495],"domain_scores_gemma":[0.9988848,0.00006848745,0.00025016663,0.0005210747,0.00017857541,0.000096885335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005146123,0.0001849507,0.00042878516,0.0001515615,0.00020430404,0.00006887591,0.000055619716,0.00004391131,0.00008596826],"category_scores_gemma":[0.000038688373,0.0001325125,0.00013785712,0.00019162263,0.00057219714,0.00011869942,0.00007376674,0.000039812057,0.000008094127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035865726,0.001450325,0.7832963,0.00045720313,0.007908394,0.00023176325,0.013348619,0.0000071385907,0.11031228,0.0024257693,0.038653295,0.038322367],"study_design_scores_gemma":[0.012372005,0.0035029573,0.20162612,0.00065363484,0.002450417,0.000051033487,0.0024499393,0.00025745053,0.3877164,0.0057909237,0.38220096,0.0009281555],"about_ca_topic_score_codex":0.000020467112,"about_ca_topic_score_gemma":0.00013830567,"teacher_disagreement_score":0.58167017,"about_ca_system_score_codex":0.000043623288,"about_ca_system_score_gemma":0.00004563997,"threshold_uncertainty_score":0.5403703},"labels":[],"label_agreement":null},{"id":"W2894731212","doi":"10.5114/pg.2018.78291","title":"Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?","year":2018,"lang":"en","type":"article","venue":"Gastroenterology Review","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Concomitant; Medicine; Gluten free; Diabetes mellitus; Internal medicine; Gastroenterology; Disease; Type 2 Diabetes Mellitus; Type 1 diabetes; Endocrinology","score_opus":0.00792730333063135,"score_gpt":0.23202704483648398,"score_spread":0.22409974150585263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894731212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785164,0.017670672,0.0000019187864,0.002451174,0.00011412065,0.0011715967,0.000016223403,0.000013590853,0.000044324963],"genre_scores_gemma":[0.984505,0.012070603,0.00023763861,0.002957827,0.000047187663,0.0000657753,0.000043090084,0.000016726253,0.000056151228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998913,0.000097950484,0.00030674427,0.00024738748,0.00013463343,0.0003002646],"domain_scores_gemma":[0.9990906,0.0000610249,0.00013664372,0.00052321184,0.000088746645,0.00009977079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017640414,0.00017581621,0.00054423243,0.000048434445,0.000027787495,0.000005171762,0.00014336027,0.0000217582,0.000046877143],"category_scores_gemma":[0.00011462221,0.00007573222,0.000058598074,0.000104390034,0.000330491,0.00003865439,0.00014156726,0.00007112703,0.000008607381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013383965,0.00032787217,0.9895727,0.000875714,0.0001863354,0.0000066367015,0.000021355883,4.818638e-8,0.0000045107877,0.000009903909,0.0010864666,0.006570056],"study_design_scores_gemma":[0.004750942,0.005258502,0.98119295,0.002248234,0.000843107,3.8664962e-7,0.0000033844824,0.000008292746,0.000010790569,0.000023983228,0.0056028366,0.000056580513],"about_ca_topic_score_codex":0.0000028345598,"about_ca_topic_score_gemma":0.00003204426,"teacher_disagreement_score":0.008379743,"about_ca_system_score_codex":0.000019280957,"about_ca_system_score_gemma":0.000012498431,"threshold_uncertainty_score":0.30882704},"labels":[],"label_agreement":null},{"id":"W2894746763","doi":"10.1016/s0140-6736(18)32261-x","title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1791,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health; Sirtex Medical; Servier; Novo Nordisk; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Placebo; Type 2 diabetes; Double blind; Disease; Internal medicine; Diabetes mellitus; Physical therapy; Alternative medicine; Endocrinology","score_opus":0.02157833320229071,"score_gpt":0.24939891981256984,"score_spread":0.22782058661027912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894746763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880286,0.0028629925,0.0000046784407,0.0006529001,0.00020925209,0.007124015,0.000008055459,0.000055240605,0.0010543014],"genre_scores_gemma":[0.99787116,0.00019346911,0.00007322595,0.00051027857,0.00029397022,0.0006188718,0.000028461327,0.000032098134,0.00037847378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982366,0.00015977307,0.0002750496,0.00040664838,0.0005040962,0.00041785178],"domain_scores_gemma":[0.998556,0.00014737812,0.00006118879,0.0010003682,0.000074014104,0.00016105926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009551155,0.00029494887,0.0018800021,0.000108153996,0.00009712986,0.000059820726,0.00012532856,0.000048258597,0.000021976382],"category_scores_gemma":[0.00013984763,0.0001511081,0.000389487,0.00014876995,0.00016874977,0.00008635391,0.00009755218,0.00011698587,0.000013469513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55727893,0.00017687891,0.43072364,0.000044793334,0.00979421,0.000011494593,0.00009403462,0.000009170917,5.4338597e-7,0.000018568282,0.0003341665,0.001513538],"study_design_scores_gemma":[0.7641599,0.0005075965,0.22901423,0.000042662603,0.004231625,1.406595e-7,0.000017952452,0.00004603002,0.000006657043,0.0000274663,0.0017916991,0.0001540351],"about_ca_topic_score_codex":0.000036206384,"about_ca_topic_score_gemma":0.0000096581425,"teacher_disagreement_score":0.20688094,"about_ca_system_score_codex":0.000029346535,"about_ca_system_score_gemma":0.000030932424,"threshold_uncertainty_score":0.616201},"labels":[],"label_agreement":null},{"id":"W2894773867","doi":"10.1016/j.jcjd.2018.08.128","title":"iGlarLixi Effectively Reduces Residual Hyperglycemia in Patients with Type 2 Diabetes on Basal Insulin: A Post-Hoc Analysis From the LixiLan-L Study","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lixisenatide; Postprandial; Glycemic; Metformin; Type 2 diabetes; Insulin glargine; Internal medicine; Basal insulin; Glycated hemoglobin; Endocrinology; Post-hoc analysis; Insulin; Diabetes mellitus; Gastroenterology","score_opus":0.007477750739624903,"score_gpt":0.21659058116851243,"score_spread":0.20911283042888754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894773867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972531,0.0006265885,1.0809575e-7,0.0007898848,0.00028647363,0.0006094684,0.000053594093,0.000009396154,0.00037137442],"genre_scores_gemma":[0.9981351,0.0000034641293,0.000076954704,0.0012602941,0.00036123788,0.000013002378,0.000061626226,0.000032972803,0.000055371278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812216,0.00019771191,0.00041131373,0.00029847817,0.00044346423,0.00052686816],"domain_scores_gemma":[0.9980822,0.00031526704,0.00025316485,0.00036045388,0.0005410057,0.0004479094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004161655,0.00027833402,0.0006429467,0.0007900535,0.00015501131,0.000096415606,0.00028874236,0.000075287404,0.00013973699],"category_scores_gemma":[0.00032742516,0.00016839737,0.00013041521,0.0010808539,0.00018379888,0.00016678912,0.00002660179,0.00029827273,0.000027616921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036690934,0.00041793464,0.98862827,0.0000063051116,0.0032752906,0.00002925812,0.0011310816,0.000014912106,0.000030010558,0.0000034697691,0.0015027841,0.0045937477],"study_design_scores_gemma":[0.0046595437,0.018688763,0.9728442,0.00020683413,0.002024626,4.439975e-8,0.0006456331,0.000016174048,0.00035529005,0.000022422611,0.00035816632,0.0001783383],"about_ca_topic_score_codex":0.00092496315,"about_ca_topic_score_gemma":0.019482726,"teacher_disagreement_score":0.018557763,"about_ca_system_score_codex":0.00027792683,"about_ca_system_score_gemma":0.00044016502,"threshold_uncertainty_score":0.99840915},"labels":[],"label_agreement":null},{"id":"W2894938458","doi":"10.1016/j.jcjd.2018.08.133","title":"Empagloflozin Use in a Community Heart Failure Clinic—Renal Safety and Tolerance","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Heart failure; Type 2 diabetes; Intensive care medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology","score_opus":0.021529109988328615,"score_gpt":0.2572807823670888,"score_spread":0.23575167237876019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894938458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617624,0.00063252234,0.0000026042612,0.0021435507,0.00014683591,0.00015259387,0.000014145895,0.0000050860963,0.00072642905],"genre_scores_gemma":[0.99664545,0.000013721244,0.0009835534,0.0017919035,0.00015593813,0.0000017421121,0.0000060862267,0.00001352564,0.00038808063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989655,0.00011698764,0.00036839547,0.000091131216,0.00010923796,0.00034871825],"domain_scores_gemma":[0.99885005,0.00013466703,0.00010640252,0.00020815982,0.0001356712,0.00056506036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005541436,0.00012772714,0.00038743677,0.0003279217,0.00013002528,0.000056833727,0.00010373389,0.000062811036,0.00018516472],"category_scores_gemma":[0.00021467557,0.00010946582,0.0000757703,0.00019254575,0.00022248644,0.00022810047,0.000019638732,0.00034556378,0.00001781448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002128638,0.000052340558,0.9840382,0.00003218427,0.000100621604,0.000020088411,0.00050043705,0.0000013018519,0.00013323661,0.000031740186,0.012288865,0.0027797131],"study_design_scores_gemma":[0.0020345661,0.001029872,0.90204734,0.00050424325,0.00009626834,0.0000057176053,0.0001992532,0.000028248578,0.00030061047,0.00009087784,0.09355614,0.000106842046],"about_ca_topic_score_codex":0.0015572351,"about_ca_topic_score_gemma":0.08890128,"teacher_disagreement_score":0.08734404,"about_ca_system_score_codex":0.00012340993,"about_ca_system_score_gemma":0.00028372067,"threshold_uncertainty_score":0.9277239},"labels":[],"label_agreement":null},{"id":"W2895025776","doi":"10.1016/j.jcjd.2018.08.150","title":"Canadian Canagliflozin Registry: Prospective, Observational Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus; 12 Month Results","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Observational study; Regimen; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Clinical Practice; Type 2 diabetes; Endocrinology; Physical therapy","score_opus":0.025777620179668767,"score_gpt":0.2688830024564726,"score_spread":0.24310538227680384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895025776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97628176,0.0018268764,8.283151e-7,0.0034345356,0.0007032584,0.0007630363,0.00028075324,0.00001055814,0.016698416],"genre_scores_gemma":[0.9960078,0.000074789335,0.0011052946,0.0005013496,0.00037197347,0.000029391076,0.0001558839,0.00004553088,0.0017080083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971329,0.00009434258,0.00096951425,0.00037239192,0.00042044173,0.0010104289],"domain_scores_gemma":[0.99660647,0.00011965583,0.00048597314,0.00050307746,0.00074228697,0.0015425597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005991132,0.00037392828,0.0008676583,0.0012604875,0.00014375092,0.00006172019,0.0003000264,0.00015168087,0.00020676311],"category_scores_gemma":[0.00035267207,0.00032713072,0.00018824065,0.0007653734,0.00025557508,0.00023199948,0.000017789216,0.0002300016,0.00000955408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000029527964,0.00013975281,0.98269266,0.00006247558,0.0007153454,0.000100395126,0.00035383567,0.000053636297,0.00012250779,0.0006741876,0.010591832,0.0044638403],"study_design_scores_gemma":[0.0035323568,0.0030890382,0.93924177,0.0004993243,0.00039589952,0.0000018718443,0.00023797112,0.00036513695,0.0011530885,0.00026585732,0.050928056,0.0002896194],"about_ca_topic_score_codex":0.416095,"about_ca_topic_score_gemma":0.96818507,"teacher_disagreement_score":0.5520901,"about_ca_system_score_codex":0.004477701,"about_ca_system_score_gemma":0.009780674,"threshold_uncertainty_score":0.9999181},"labels":[],"label_agreement":null},{"id":"W2895073602","doi":"10.1016/j.jcjd.2018.08.015","title":"Empagliflozin Reduces Mortality in Patients with Type 2 Diabetes and a History of Left Ventricular Hypertrophy: A Sub-Analysis of the EMPA-REG OUTCOME Trial","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Mace; Cardiology; Type 2 diabetes; Diabetes mellitus; Placebo; Left ventricular hypertrophy; Endocrinology; Blood pressure; Myocardial infarction","score_opus":0.016623932093686757,"score_gpt":0.22733439551458784,"score_spread":0.21071046342090108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895073602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973354,0.001740758,1.0206261e-7,0.000097086355,0.0003281783,0.00033293202,0.00001726106,0.0000020684524,0.00014623311],"genre_scores_gemma":[0.99966544,0.00000496958,0.000030540174,0.00012515749,0.000058506546,0.0000022588572,0.000008920921,0.00001312217,0.00009110182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861604,0.000082804516,0.0005616562,0.0001458191,0.00031064803,0.00028301153],"domain_scores_gemma":[0.99860996,0.000051612136,0.00047434095,0.00026761656,0.00033929618,0.00025718778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032607093,0.00015560114,0.0007805702,0.0007187506,0.000029528994,0.000008617802,0.00015364375,0.00005538872,0.00007719098],"category_scores_gemma":[0.00021481437,0.00009688781,0.00021627726,0.00052429613,0.00034056994,0.000094065974,0.000019466917,0.000113002556,5.7682524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015351821,0.00014867383,0.995658,0.0000454689,0.0026711656,0.0000058404385,0.00030755083,0.0000068549543,0.00013629362,0.000005749848,0.0003672458,0.0004936565],"study_design_scores_gemma":[0.0074506123,0.001720883,0.9845368,0.00014115279,0.0046087718,9.717396e-8,0.00005188531,0.000024530063,0.0009412363,0.0000119370725,0.000419086,0.000093004564],"about_ca_topic_score_codex":0.0004118038,"about_ca_topic_score_gemma":0.0035795735,"teacher_disagreement_score":0.011121177,"about_ca_system_score_codex":0.00034197414,"about_ca_system_score_gemma":0.0005212176,"threshold_uncertainty_score":0.39509702},"labels":[],"label_agreement":null},{"id":"W2895300564","doi":"10.1016/j.jcjd.2018.08.151","title":"Canadian Canagliflozin Registry: A Prospective, 12-Month Observational Study of Canagliflozin Treatment in Type 2 Diabetes Mellitus: Achievement of the Triple Composite Endpoint and Low Incidence of Severe Hypoglycemia","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Canagliflozin; Medicine; Hypoglycemia; Type 2 diabetes; Type 2 Diabetes Mellitus; Clinical endpoint; Incidence (geometry); Internal medicine; Regimen; Diabetes mellitus; Post-hoc analysis; Weight loss; Blood pressure; Surgery; Clinical trial; Endocrinology; Obesity","score_opus":0.01968628417626557,"score_gpt":0.23854265268307737,"score_spread":0.21885636850681178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895300564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560034,0.0015550076,1.8077804e-7,0.00073891925,0.00025843488,0.0012203312,0.00016347335,0.0000028379245,0.00046048284],"genre_scores_gemma":[0.9992462,0.00003747286,0.0001647192,0.00016003144,0.000069382855,0.000023448236,0.000017856006,0.000023790168,0.0002571144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783295,0.00012145865,0.0008667855,0.00025817569,0.0004005911,0.0005200325],"domain_scores_gemma":[0.9976923,0.000105809115,0.0006346073,0.00043584488,0.00052089104,0.0006105359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004112578,0.00027935256,0.0008266896,0.0006108746,0.00010526301,0.000021336025,0.00029928397,0.00008139457,0.000048657927],"category_scores_gemma":[0.00020098087,0.00020896744,0.00012167789,0.0006105996,0.00029632103,0.00013760738,0.000040123527,0.00016137537,6.2346624e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070705704,0.000359007,0.9939951,0.00013927608,0.0007432068,0.000021469856,0.0017471836,0.00006252583,0.00056297524,0.000092833514,0.00055714906,0.0016486124],"study_design_scores_gemma":[0.003685547,0.0042538336,0.9843035,0.00067151827,0.00049245404,0.0000015047931,0.0011226519,0.00011006685,0.0042045587,0.00012908856,0.0008590129,0.00016630221],"about_ca_topic_score_codex":0.37926388,"about_ca_topic_score_gemma":0.94989514,"teacher_disagreement_score":0.57063127,"about_ca_system_score_codex":0.0014559511,"about_ca_system_score_gemma":0.0032212927,"threshold_uncertainty_score":0.8521445},"labels":[],"label_agreement":null},{"id":"W2895313197","doi":"10.1016/j.jcjd.2018.08.126","title":"Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Renal function; Type 2 diabetes; Internal medicine; Urology; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.015089894322357484,"score_gpt":0.236319382600357,"score_spread":0.22122948827799951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895313197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938221,0.0008394368,0.0000019648392,0.002411912,0.00022724971,0.00033156783,0.0000023696668,0.0000026424361,0.0023607407],"genre_scores_gemma":[0.9981735,0.000010149843,0.000053062293,0.0006742966,0.0005527114,0.000008963568,0.0000033814242,0.0000074857294,0.0005164634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993012,0.0000547525,0.00020698711,0.000082652215,0.00009340342,0.00026102463],"domain_scores_gemma":[0.9994332,0.0000733355,0.00007943358,0.00011133814,0.000070007314,0.00023265333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035592102,0.00009681535,0.00019738846,0.00028107315,0.00007400627,0.00004108793,0.00005470437,0.000033465967,0.00006590429],"category_scores_gemma":[0.000084423235,0.00005746101,0.00006548071,0.00014534875,0.000104631166,0.00005917306,0.0000037244563,0.00007035071,0.000005604994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016054458,0.0003499666,0.8065937,0.000053298285,0.0009515389,0.00023067476,0.0029414506,0.000003419705,0.0003677208,0.0016925723,0.02262183,0.16258836],"study_design_scores_gemma":[0.07710935,0.02912741,0.6218125,0.00028864734,0.0013902141,0.00001740244,0.0022752977,0.00005540362,0.00079937134,0.0016322614,0.26523498,0.00025712204],"about_ca_topic_score_codex":0.00043587343,"about_ca_topic_score_gemma":0.01090068,"teacher_disagreement_score":0.24261315,"about_ca_system_score_codex":0.00019453517,"about_ca_system_score_gemma":0.00032177716,"threshold_uncertainty_score":0.6082835},"labels":[],"label_agreement":null},{"id":"W2895618708","doi":"10.1016/j.jcjd.2018.08.021","title":"Rates of Major Adverse Cardiovascular Events and Mortality with Basal Insulin by Liraglutide Use: A DEVOTE Subanalysis","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Liraglutide; Medicine; Insulin glargine; Insulin degludec; Mace; Basal insulin; Adverse effect; Internal medicine; Type 2 diabetes; Placebo; Insulin; Diabetes mellitus; Insulin detemir; Glucagon-like peptide-1; Endocrinology; Alternative medicine; Myocardial infarction","score_opus":0.012809236287515655,"score_gpt":0.22827923140503342,"score_spread":0.21546999511751777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895618708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956543,0.003670827,0.000028753659,0.00018723129,0.000068697256,0.00017861811,0.000046861864,0.000003853575,0.00016086792],"genre_scores_gemma":[0.99883866,0.000047045753,0.00059239316,0.00021105024,0.00008610173,0.0000035433518,0.0000169271,0.000020173222,0.00018408634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987999,0.000058811274,0.00035263307,0.00016775497,0.0002862831,0.0003346187],"domain_scores_gemma":[0.99853873,0.000039702652,0.00020677169,0.0002695269,0.00033366698,0.0006116093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038103486,0.0001727816,0.00060585036,0.0003283651,0.000069565955,0.00002012899,0.00009802142,0.000052947922,0.000072008064],"category_scores_gemma":[0.00012046526,0.00013064306,0.00023857443,0.00029398382,0.00022091575,0.0002192279,0.00001412523,0.00009990519,0.0000026333737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001503071,0.00004082304,0.9905144,0.00006931964,0.005587516,0.00004205489,0.000099857534,0.000007705246,0.00017324612,0.00001004336,0.0012464116,0.0021936076],"study_design_scores_gemma":[0.0026899625,0.0009660828,0.98147243,0.00030733878,0.0046528936,0.0000034221757,0.00013443668,0.00007221652,0.0053543295,0.000047752037,0.0041277166,0.00017143053],"about_ca_topic_score_codex":0.002630249,"about_ca_topic_score_gemma":0.0075571924,"teacher_disagreement_score":0.009041966,"about_ca_system_score_codex":0.0001045744,"about_ca_system_score_gemma":0.0003471825,"threshold_uncertainty_score":0.5327469},"labels":[],"label_agreement":null},{"id":"W2895710807","doi":"10.2147/ppa.s177624","title":"Categorizing factors of adherence to parenteral treatment in growth hormone deficiencies and hemophilia: What should be the targets for future research?","year":2018,"lang":"en","type":"review","venue":"Patient Preference and Adherence","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Context (archaeology); Regimen; Categorization; Clinical trial; Internal medicine","score_opus":0.29456463344110506,"score_gpt":0.3940321134388061,"score_spread":0.09946747999770106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895710807","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08504383,0.90926194,0.0000065171425,0.00018599212,0.00022127293,0.0050090724,0.00010324122,0.00002017707,0.00014793428],"genre_scores_gemma":[0.07435521,0.92340034,0.00018153289,0.000062947925,0.0000773017,0.0014534732,0.00016746977,0.000028483573,0.00027326396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731183,0.00014860534,0.0006472519,0.00080226065,0.00046353717,0.0006265275],"domain_scores_gemma":[0.9984274,0.00040014586,0.00025781116,0.00045984844,0.00024287053,0.00021192043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003275188,0.0005490029,0.001302843,0.0003307472,0.00018829267,0.00014579471,0.0002714011,0.00018817178,0.000015684149],"category_scores_gemma":[0.00011436774,0.00030065113,0.00017634878,0.00047556087,0.00028178853,0.0002781978,0.00030027752,0.0002567442,0.000005842281],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012469488,0.0005059693,0.0015581939,0.0061203702,0.0002229588,0.000007506456,0.0072032423,1.1390673e-7,0.0000102036865,0.00065631216,0.00063301047,0.9829574],"study_design_scores_gemma":[0.0027652872,0.04529328,0.0034808852,0.03239523,0.0020044553,0.000011887077,0.018983273,0.000025308736,0.0004122794,0.0010910715,0.8922253,0.0013117001],"about_ca_topic_score_codex":0.00027022164,"about_ca_topic_score_gemma":0.00018364534,"teacher_disagreement_score":0.9816457,"about_ca_system_score_codex":0.00017544106,"about_ca_system_score_gemma":0.00018521323,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W2896549191","doi":"10.1136/bmjopen-2018-023830","title":"Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink","year":2018,"lang":"en","type":"article","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Waterloo; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Diabetes Canada","keywords":"Medicine; Cohort; Depression (economics); Population; Incretin; Type 2 diabetes; Cohort study; Internal medicine; Incidence (geometry); Psychiatry; Diabetes mellitus; Endocrinology; Environmental health","score_opus":0.19772930049745746,"score_gpt":0.4719114694836111,"score_spread":0.27418216898615366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896549191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98074716,0.000011447829,0.0000061168366,0.00017738595,0.000059760514,0.017861031,0.000008700437,0.000021105812,0.001107266],"genre_scores_gemma":[0.99700034,0.0000034772065,0.0016361953,0.0004346226,0.000050216844,0.0005969419,0.00004383223,0.000037404716,0.00019694692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606895,0.00172858,0.0004364866,0.00044069684,0.0009831941,0.00034208177],"domain_scores_gemma":[0.9958707,0.0020697983,0.0003666013,0.001070956,0.00054643996,0.00007548686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010045025,0.00017782273,0.0004567742,0.00011864801,0.00024731003,0.000120575154,0.0005652792,0.00005611425,0.00005495452],"category_scores_gemma":[0.0026027628,0.00007451999,0.000021381884,0.0009588739,0.00016842644,0.00016677282,0.00064495957,0.00030898102,0.000010504697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059847743,0.0015991498,0.98710823,0.000018368897,0.0013898157,0.000022547856,0.002206066,0.000013698909,0.000005792513,9.294896e-7,0.00044260157,0.0012080373],"study_design_scores_gemma":[0.0074503478,0.007843169,0.9785038,0.000635318,0.00092078984,1.5827521e-7,0.0034608573,0.00048905297,0.00004447222,0.0000011356332,0.0005293609,0.00012151694],"about_ca_topic_score_codex":0.00062127167,"about_ca_topic_score_gemma":0.0008228468,"teacher_disagreement_score":0.017264089,"about_ca_system_score_codex":0.0001184632,"about_ca_system_score_gemma":0.00019412072,"threshold_uncertainty_score":0.3481425},"labels":[],"label_agreement":null},{"id":"W2897161991","doi":"10.1161/circulationaha.118.033810","title":"Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease","year":2018,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Alere; Novo Nordisk; Sanofi; Merck","keywords":"Medicine; Empagliflozin; Disease; Life expectancy; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Term (time); Benzhydryl compounds; Intensive care medicine; Internal medicine; Endocrinology; Population","score_opus":0.011037859876354793,"score_gpt":0.209128624553053,"score_spread":0.1980907646766982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897161991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484015,0.0018007625,0.0000058500364,0.0017053082,0.00017827087,0.0011191663,0.00001747815,0.000028832073,0.0003041985],"genre_scores_gemma":[0.99009037,0.0000855419,0.000030730156,0.006746861,0.0004564201,0.00005279306,0.0023910233,0.000055649954,0.00009058976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984148,0.000041299147,0.00026348716,0.0004756779,0.00055544183,0.00024928345],"domain_scores_gemma":[0.9989286,0.000035666446,0.00013485076,0.0006400846,0.00015982841,0.00010097294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008557026,0.000271145,0.0005671437,0.0003218992,0.000026123415,0.000027707709,0.00005994792,0.0001793597,0.0000688858],"category_scores_gemma":[0.000058510366,0.00022471615,0.0001277052,0.00021691075,0.00005929472,0.00010665815,0.000029472392,0.00017789137,0.000017756805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015590552,0.00021460476,0.98859084,0.0007564109,0.0009841607,0.000042328902,0.000061441504,0.00003674402,9.915275e-7,0.000004312577,0.0054015764,0.0037506905],"study_design_scores_gemma":[0.0024767157,0.00034242848,0.99240464,0.00082339067,0.001525756,5.6702305e-8,0.000002209872,0.000042944182,0.0000082705465,0.000029003357,0.0021360125,0.00020857583],"about_ca_topic_score_codex":0.000007385236,"about_ca_topic_score_gemma":0.0000017824644,"teacher_disagreement_score":0.0050415527,"about_ca_system_score_codex":0.00011830279,"about_ca_system_score_gemma":0.000039637252,"threshold_uncertainty_score":0.91636586},"labels":[],"label_agreement":null},{"id":"W2897347858","doi":"10.1111/dom.13412","title":"Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"Personalized medicine; Medicine; Precision medicine; Intensive care medicine; Disease; Alternative medicine; Health care; Clinical Practice; Diabetes mellitus; MEDLINE; Family medicine; Bioinformatics; Pathology","score_opus":0.04989399605290109,"score_gpt":0.3150990897770885,"score_spread":0.26520509372418744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897347858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00580959,0.98889667,0.000002977621,0.00042961328,0.00032532233,0.0022119116,0.00015102387,0.00011435573,0.0020585405],"genre_scores_gemma":[0.00061026955,0.9934886,0.00017358239,0.00049524277,0.0008097748,0.00036518805,0.0008500228,0.00010109799,0.003106239],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959985,0.00028384055,0.0008169196,0.0011423526,0.0005267713,0.0012316251],"domain_scores_gemma":[0.9978259,0.000174976,0.00035829254,0.0006607009,0.00011776669,0.00086236704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010423358,0.00088929903,0.003485061,0.0008717305,0.00021831243,0.00007462729,0.00024087795,0.00022783101,0.00072630093],"category_scores_gemma":[0.0004671279,0.0006678816,0.0005651589,0.000656019,0.00058743666,0.00018519883,0.00033842665,0.00041527755,0.00006210261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051541596,0.0017573384,0.017112149,0.081234805,0.0045315456,0.00018534332,0.0032313976,2.5262413e-8,0.0000049137902,0.010002237,0.015400389,0.86648834],"study_design_scores_gemma":[0.0027438523,0.000102440565,0.0072644595,0.015880637,0.01002247,0.0000012865637,0.00039481645,0.0000062914824,0.0000014575877,0.00023321455,0.9627931,0.00055594457],"about_ca_topic_score_codex":0.00003462716,"about_ca_topic_score_gemma":0.000006984794,"teacher_disagreement_score":0.94739276,"about_ca_system_score_codex":0.0001579215,"about_ca_system_score_gemma":0.00025701473,"threshold_uncertainty_score":0.9995772},"labels":[],"label_agreement":null},{"id":"W2897613436","doi":"10.1161/circulationaha.118.035759","title":"Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control","year":2018,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Glycemic; Diabetes mellitus; Type 2 diabetes; Internal medicine; Cardiology; Intensive care medicine; Insulin; Endocrinology","score_opus":0.011243096252827225,"score_gpt":0.22675872720071297,"score_spread":0.21551563094788573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897613436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8811204,0.0015674992,0.0016706871,0.10406936,0.00066436845,0.006568585,0.000076146716,0.00011802203,0.004144968],"genre_scores_gemma":[0.92317885,0.000014389381,0.000070276365,0.07529926,0.00043081044,0.00013923962,0.0003662661,0.0000478109,0.0004530676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980705,0.000033786695,0.00040025084,0.00042976995,0.0007886888,0.00027703616],"domain_scores_gemma":[0.9988948,0.000024776351,0.00020727197,0.0007115618,0.00012611493,0.000035435685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017970259,0.00028845388,0.0009021417,0.00034182437,0.000018416253,0.00001470656,0.00008574588,0.00031378775,0.00010667753],"category_scores_gemma":[0.000011935833,0.00022299994,0.00034412416,0.00014807415,0.000050664377,0.00006158586,0.000026180634,0.00029761525,0.00003485151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041758793,0.00031152356,0.8795807,0.0015707618,0.012492361,0.00043282614,0.0004409646,0.00018254212,0.0002195802,0.000015530211,0.0905412,0.013794434],"study_design_scores_gemma":[0.02482545,0.001226718,0.8173552,0.00084849127,0.007035645,0.000008955526,0.000060605646,0.00044520994,0.0004472264,0.00014558488,0.1469471,0.0006537782],"about_ca_topic_score_codex":0.00015297724,"about_ca_topic_score_gemma":0.0000110374085,"teacher_disagreement_score":0.06222546,"about_ca_system_score_codex":0.00032132957,"about_ca_system_score_gemma":0.00006665711,"threshold_uncertainty_score":0.9093673},"labels":[],"label_agreement":null},{"id":"W2897993744","doi":"10.1681/asn.2018010103","title":"Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial","year":2018,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"American Society of Nephrology","keywords":"Empagliflozin; EMPA; Medicine; Type 2 diabetes; Renal function; Internal medicine; Diabetes mellitus; Endocrinology; Chemistry","score_opus":0.013672446195729923,"score_gpt":0.26646606393923694,"score_spread":0.252793617743507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897993744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960775,0.00008243823,0.00004660828,0.009860901,0.00012068861,0.000246598,0.0000060842444,0.0000037829345,0.000025161138],"genre_scores_gemma":[0.9700417,0.000057757858,0.0009388221,0.028614672,0.00026551686,0.000002336441,0.000007767311,0.000009247704,0.000062182764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989227,0.00012265437,0.00039706362,0.00012343432,0.0002657606,0.00016837665],"domain_scores_gemma":[0.99858713,0.00014033601,0.00076004583,0.00025424742,0.000184076,0.000074163756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003483157,0.00011831151,0.0006165397,0.000068622365,0.00005230227,0.000008588218,0.00015403694,0.00003665516,0.000054983917],"category_scores_gemma":[0.00007534978,0.00005571058,0.00028059733,0.0007115836,0.00055879704,0.000053060354,0.000095081385,0.00016604783,0.0000014401878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010986806,0.00029585868,0.9623139,0.0000048219113,0.0043581724,5.381911e-7,0.00035775476,0.0000057364105,0.00020810125,0.0000012485823,0.018440852,0.0030262256],"study_design_scores_gemma":[0.016923837,0.006370127,0.9605046,0.000020071164,0.0035139506,2.813713e-7,0.00025707547,0.000098391305,0.00001352881,0.000037174937,0.0122092115,0.000051735686],"about_ca_topic_score_codex":0.0001280113,"about_ca_topic_score_gemma":0.00006366599,"teacher_disagreement_score":0.01956604,"about_ca_system_score_codex":0.000052359646,"about_ca_system_score_gemma":0.000057470847,"threshold_uncertainty_score":0.22718117},"labels":[],"label_agreement":null},{"id":"W2898504124","doi":"10.1093/eurheartj/ehy565.p1876","title":"P1876Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial","year":2018,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; EMPA; Empagliflozin; Left ventricular hypertrophy; Internal medicine; Diabetes mellitus; Cardiology; Outcome (game theory); Type 2 diabetes; Endocrinology; Blood pressure","score_opus":0.034542887997192157,"score_gpt":0.26788464240246995,"score_spread":0.2333417544052778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898504124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981999,0.00048606383,5.3734703e-7,0.00007778014,0.00024626523,0.00027620947,0.0000026381415,0.000005258593,0.0007053377],"genre_scores_gemma":[0.99941534,0.000013992208,0.000059278296,0.00012350823,0.00009370896,6.233049e-7,0.0000045295274,0.000014230357,0.00027477616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872416,0.00024349542,0.00038239826,0.00014314083,0.00034228762,0.00016448872],"domain_scores_gemma":[0.99928075,0.000025011697,0.0002363946,0.0002418641,0.00013601819,0.00007993594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005184541,0.000114887654,0.00045440678,0.00026052076,0.00003402755,0.0000084409685,0.00008397598,0.000016521855,0.00008667254],"category_scores_gemma":[0.00009104431,0.00006548461,0.00016311565,0.00029894966,0.00016437714,0.000058961232,0.00005502069,0.00011981576,0.000003610128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009935334,0.0003776916,0.99567187,0.000017725573,0.0012654009,0.000015187226,0.00025251272,0.000004734412,0.00030077482,0.000001719253,0.00079829775,0.0003005495],"study_design_scores_gemma":[0.008546474,0.0015347096,0.98550826,0.00007097129,0.0022304135,0.0000012301781,0.000021665579,0.000019947885,0.0003048192,0.000001687194,0.001696701,0.00006312852],"about_ca_topic_score_codex":0.000009078694,"about_ca_topic_score_gemma":0.000008086169,"teacher_disagreement_score":0.010163621,"about_ca_system_score_codex":0.00011167284,"about_ca_system_score_gemma":0.000053409065,"threshold_uncertainty_score":0.2670385},"labels":[],"label_agreement":null},{"id":"W2898602921","doi":"10.2215/cjn.06200518","title":"Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes","year":2018,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Fenofibrate; Glycemic; Blood pressure; Intensive care medicine; Internal medicine; Cardiology; Insulin","score_opus":0.020072517758711012,"score_gpt":0.32297457532985824,"score_spread":0.30290205757114724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898602921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852246,0.00036622703,0.000034682,0.013906176,0.0001776733,0.00026955467,0.0000055030227,0.000004369439,0.000011185677],"genre_scores_gemma":[0.9009681,0.00086745847,0.00055287447,0.09734995,0.00014482524,0.0000012731398,4.957545e-7,0.000010404286,0.00010464611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988135,0.000181039,0.0005362634,0.00015094831,0.00015421724,0.00016399828],"domain_scores_gemma":[0.99681574,0.0013419186,0.0010857767,0.00023748032,0.00035501245,0.0001640885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002617373,0.00013572934,0.0009899479,0.00003092712,0.000033084056,0.0000061735755,0.00012759738,0.00007136949,0.00000495159],"category_scores_gemma":[0.0005850254,0.000077338926,0.00040994122,0.00007482348,0.0024443523,0.000047841633,0.00011221319,0.00023008113,6.6294274e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035729548,0.0005241721,0.9437925,0.00016612098,0.0078213345,0.000020382184,0.0002551429,3.726247e-7,0.0083502345,0.00002109165,0.030490993,0.0049846917],"study_design_scores_gemma":[0.010109969,0.016084133,0.96620196,0.00021380244,0.004713212,0.000043800563,0.000083572915,0.000027618107,0.0006479631,0.000067528585,0.0017423009,0.00006410937],"about_ca_topic_score_codex":0.000009529476,"about_ca_topic_score_gemma":7.5199415e-7,"teacher_disagreement_score":0.08425655,"about_ca_system_score_codex":0.0000056167314,"about_ca_system_score_gemma":0.000049122547,"threshold_uncertainty_score":0.9006318},"labels":[],"label_agreement":null},{"id":"W2898711440","doi":"10.14740/jem.v8i5.531","title":"Effects of SGLT2 Inhibition on eGFR and Glomerular and Tubular Damage Markers in Japanese Patients With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Renal function; Internal medicine; Endocrinology; Urinary system; Diabetes mellitus; Excretion; Urology","score_opus":0.004103295353995121,"score_gpt":0.21697571349124484,"score_spread":0.21287241813724972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898711440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995448,0.003759076,5.647745e-7,0.00015644445,0.00013233414,0.00020585684,0.0000010229063,0.0000032303608,0.00029346073],"genre_scores_gemma":[0.9984289,0.0010447124,0.00019501962,0.00020536181,0.00005414908,0.0000024463807,0.0000025410513,0.0000075541193,0.000059332047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937826,0.000054611573,0.00018302456,0.00011066536,0.00010631698,0.00016714142],"domain_scores_gemma":[0.99957204,0.000066209235,0.00012960966,0.00006758759,0.00009341633,0.00007116651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009485163,0.00010884757,0.0003583178,0.00025333455,0.000026416077,0.0000055795304,0.00001974804,0.00003923697,0.000007882945],"category_scores_gemma":[0.00006760948,0.00007254716,0.000019958406,0.00008901698,0.00019429483,0.00009702731,0.000030414769,0.00010701549,7.2514496e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002926291,0.0011679331,0.93021756,0.00068878237,0.001195324,0.0003891575,0.0010134138,6.2926193e-7,0.017306596,0.0012404902,0.00039566206,0.043458126],"study_design_scores_gemma":[0.007737322,0.0027172277,0.9763502,0.0002272764,0.00048690743,0.000012739403,0.000064935564,0.0000029644239,0.010427484,0.00013248756,0.0017748132,0.00006567224],"about_ca_topic_score_codex":0.0000050795247,"about_ca_topic_score_gemma":0.0000021111418,"teacher_disagreement_score":0.046132576,"about_ca_system_score_codex":0.000008635844,"about_ca_system_score_gemma":0.000009386702,"threshold_uncertainty_score":0.29583874},"labels":[],"label_agreement":null},{"id":"W2898735507","doi":"10.1016/j.jdiacomp.2018.10.016","title":"An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records","year":2018,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Glycemic; Sitagliptin; Canagliflozin; Medical prescription; Diabetes mellitus; Weight loss; Type 2 diabetes; Internal medicine; Electronic medical record; Medical record; Emergency medicine; Obesity; Endocrinology; Pharmacology","score_opus":0.015763633076186095,"score_gpt":0.28021791277569535,"score_spread":0.26445427969950924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898735507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978788,0.00008655271,0.0000037749544,0.0014781536,0.000024437335,0.00036158966,0.000011724147,0.000006130247,0.00014884844],"genre_scores_gemma":[0.9993133,0.00004165831,0.00008517869,0.00044168055,0.000030139652,0.000013043849,0.000049637896,0.000008770263,0.000016585831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986361,0.00010864261,0.0005733359,0.00014969982,0.00034363358,0.00018856119],"domain_scores_gemma":[0.9982077,0.00023755772,0.0004814113,0.00026200362,0.00067767286,0.00013365346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004442888,0.00011848831,0.00047458272,0.00047861668,0.0000784484,0.000008864757,0.00014197029,0.000042090982,0.00006987936],"category_scores_gemma":[0.00019477162,0.000067299006,0.00006395186,0.0012455601,0.00017598082,0.00011259773,0.000022776663,0.0001462232,5.289016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044093234,0.0006866046,0.99387944,0.000038756472,0.0012667187,2.0057861e-7,0.0004263174,0.000029921377,0.0005937415,0.00041255596,0.00006859496,0.0021562465],"study_design_scores_gemma":[0.0024351263,0.007450548,0.9825416,0.00018990689,0.0014464551,6.266982e-8,0.00006458368,0.005232074,0.00036280975,0.00016365868,0.000046894755,0.00006625474],"about_ca_topic_score_codex":0.00008909463,"about_ca_topic_score_gemma":0.001977873,"teacher_disagreement_score":0.011337784,"about_ca_system_score_codex":0.00010162513,"about_ca_system_score_gemma":0.00019196812,"threshold_uncertainty_score":0.2744374},"labels":[],"label_agreement":null},{"id":"W2898783072","doi":"10.1016/s2213-8587(18)30311-5","title":"The perils of polyvascular disease in type 2 diabetes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Belvoir Media Group; Regado Biosciences; Bayer Fund; Duke Clinical Research Institute; Novo Nordisk; Daiichi-Sankyo; Medicines Company; Amarin Corporation; Boston Scientific Corporation; Amgen; Boehringer Ingelheim; Biotronik; American College of Cardiology Foundation; Cleveland Clinic; AstraZeneca; Bristol-Myers Squibb; Icahn School of Medicine at Mount Sinai; Mayo Clinic; Merck; Abbott Laboratories","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Coronary artery disease; Scopus; Disease; MEDLINE; Endocrinology","score_opus":0.02155852450604999,"score_gpt":0.2663066225748478,"score_spread":0.24474809806879777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898783072","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43268862,0.02113705,2.6310155e-7,0.5409843,0.0011452492,0.0011766712,0.000048854563,0.00010632596,0.0027126803],"genre_scores_gemma":[0.36314863,0.008797282,0.00011152664,0.6060724,0.011017859,0.0008020591,0.0008671845,0.00023744027,0.0089456],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604607,0.00031775166,0.0005040167,0.00052226504,0.0004123004,0.0021975816],"domain_scores_gemma":[0.9970596,0.00061710423,0.00025808896,0.0018596163,0.00012528212,0.000080312435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045128702,0.0004785594,0.0012626841,0.00021565583,0.00013293879,0.000040776995,0.00084725604,0.00022601344,0.00016865412],"category_scores_gemma":[0.00026909914,0.00026360073,0.0003147986,0.00033903623,0.0009218818,0.00004449958,0.00038159557,0.0009910944,0.00020076784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010793147,0.000106733896,0.15029787,0.0005438906,0.0016157175,0.00020555934,0.00006873838,0.0000017167691,0.00011142641,0.00044597933,0.8388474,0.0076470277],"study_design_scores_gemma":[0.0013817059,0.00044225893,0.052693155,0.00025461626,0.0010106699,0.0000010290235,0.0000156251,0.00004527022,0.0006432961,0.001389676,0.9418593,0.00026337046],"about_ca_topic_score_codex":0.000025783587,"about_ca_topic_score_gemma":0.00001435784,"teacher_disagreement_score":0.10301191,"about_ca_system_score_codex":0.00010096952,"about_ca_system_score_gemma":0.000100096164,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W2898846041","doi":"10.1016/j.cmet.2018.10.001","title":"Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition","year":2018,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Merck Canada; Diabetes Canada; Shire; Agence Nationale de la Recherche; Canadian Diabetes Association; Novo Nordisk; Meso Scale Diagnostics; Merck","keywords":"Incretin; Glucose homeostasis; Dipeptidyl peptidase-4; Inflammation; Dipeptidyl peptidase; Internal medicine; Endocrinology; Glucagon-like peptide-1; Homeostasis; Adipose tissue; Proinflammatory cytokine; Adipocyte; Downregulation and upregulation; Chemistry; Biology; Enzyme; Diabetes mellitus; Insulin resistance; Biochemistry; Type 2 diabetes; Medicine","score_opus":0.020585533088351787,"score_gpt":0.24130490991297968,"score_spread":0.2207193768246279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898846041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593633,0.00046882426,0.000108055436,0.00015442209,0.0001524879,0.00044668277,0.0000307379,0.000057197794,0.0026452448],"genre_scores_gemma":[0.9982373,0.000021009539,0.00055893906,0.0000756348,0.00020823561,0.000023405155,0.00016588722,0.00002298641,0.0006866072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897444,0.000048283844,0.00032290412,0.0002274742,0.00022786813,0.00019900294],"domain_scores_gemma":[0.9992573,0.000046147183,0.00029708806,0.00020160545,0.00011129314,0.00008651141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015658756,0.00016030739,0.00036952543,0.000095248724,0.000079874764,0.000027729686,0.000035686055,0.000089807145,0.00015926066],"category_scores_gemma":[0.0000685208,0.0001443732,0.000056379766,0.00015907211,0.00005570579,0.00017374985,0.000053525255,0.00007507593,0.00003500719],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019097466,0.00014339943,0.0033210416,0.00014834745,0.00014873462,0.0000037648342,0.0015006667,4.4125835e-7,0.9854714,0.00012433868,0.0008250384,0.008293685],"study_design_scores_gemma":[0.0036551699,0.00012256694,0.21990377,0.00035443268,0.0007295451,4.988019e-7,0.00064138125,0.00046176868,0.7718357,0.00096302386,0.0011115288,0.00022064682],"about_ca_topic_score_codex":0.00008143458,"about_ca_topic_score_gemma":0.000011282396,"teacher_disagreement_score":0.21658273,"about_ca_system_score_codex":0.00003321773,"about_ca_system_score_gemma":0.000015335032,"threshold_uncertainty_score":0.58873683},"labels":[],"label_agreement":null},{"id":"W2899078909","doi":"10.1007/s00213-018-5089-z","title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","year":2018,"lang":"en","type":"article","venue":"Psychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute on Alcohol Abuse and Alcoholism","keywords":"Alcohol; Alcohol intake; Endocrinology; Glucagon; Ethanol; Internal medicine; Psychology; Alcohol tolerance; Pharmacology; Medicine; Chemistry; Biochemistry; Hormone","score_opus":0.025848134038912042,"score_gpt":0.3414933574906477,"score_spread":0.3156452234517356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899078909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708463,0.0002051721,0.000014071754,0.0006069351,0.0015586846,0.0009995719,0.0000033573224,0.00006399717,0.025701905],"genre_scores_gemma":[0.99468434,0.00018617346,0.00028996004,0.0031674413,0.00027758745,0.00011827592,0.000020369771,0.000028531042,0.0012273111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984595,0.00009148649,0.00035802164,0.00043857907,0.00019683872,0.0004555504],"domain_scores_gemma":[0.9992338,0.0001542231,0.00012198243,0.00029025436,0.000056979574,0.00014278475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016003048,0.0002452914,0.00047535377,0.000449621,0.00003682352,0.0000062775925,0.00017116884,0.00011239587,0.0005474628],"category_scores_gemma":[0.000030568448,0.00022164907,0.0001216511,0.00035485797,0.00014382858,0.0000622512,0.00006215136,0.00020256091,0.00035311858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011137742,0.008361356,0.39100128,0.0018623035,0.003904467,0.0012602468,0.0018266842,0.00009926928,0.32921547,0.0009884605,0.094916075,0.15542664],"study_design_scores_gemma":[0.03455614,0.0052367197,0.8112805,0.00036823633,0.0009050228,0.000008226994,0.0000619629,0.0004931865,0.120499745,0.00045338302,0.025733417,0.00040350488],"about_ca_topic_score_codex":0.00009696129,"about_ca_topic_score_gemma":0.000057357738,"teacher_disagreement_score":0.42027918,"about_ca_system_score_codex":0.000099232966,"about_ca_system_score_gemma":0.000025486013,"threshold_uncertainty_score":0.90385866},"labels":[],"label_agreement":null},{"id":"W2899455575","doi":"10.1016/j.jcjd.2018.10.005","title":"Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; University of Alberta; Merck Canada Inc. (Canada); Canadian Heart Research Centre; St. Michael's Hospital; Western University; Alberta Health Services; LMC Diabetes & Endocrinology (Canada); Centre Hospitalier de l’Université de Montréal; University of Toronto","funders":"Janssen Pharmaceuticals; Takeda Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; Merck Canada; Bayer; Servier; Novo Nordisk; Abbott Laboratories; National Institute for Health and Care Research; Mylan; Boehringer Ingelheim; AstraZeneca Canada; Canadian Diabetes Association; Medtronic; Mount Sylvia Diatomite; Roche; Diabetes Canada; Unilever; Novartis; Merck; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Janssen Biotech; Meso Scale Diagnostics; Sanofi","keywords":"Medicine; Glycated hemoglobin; Type 2 diabetes; Hemoglobin; Glycated haemoglobin; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.01141920673287887,"score_gpt":0.20981338681138287,"score_spread":0.198394180078504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899455575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964791,0.0006017378,0.0000023047728,0.0013664399,0.00040912538,0.0008474304,0.00006799366,0.0000047697235,0.0002210963],"genre_scores_gemma":[0.9978623,0.000006530398,0.00047549407,0.0011556784,0.00016378406,0.000039665712,0.0000476138,0.000035087654,0.00021385685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805427,0.000019148381,0.0005563002,0.00024454304,0.00026757337,0.000858198],"domain_scores_gemma":[0.9985441,0.000060598624,0.00021906136,0.00021085136,0.0003494862,0.00061589316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003022091,0.00025703266,0.0005328778,0.0005158192,0.000048455626,0.000029297351,0.0001930147,0.000057687797,0.00007352239],"category_scores_gemma":[0.000101149264,0.0002056619,0.000063293286,0.0004294385,0.000070005706,0.0001332309,0.000018275387,0.00016966164,0.0000036580343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012166332,0.00012914621,0.978908,0.00016587487,0.000288315,0.000056776636,0.00021750531,0.000026745878,0.00059553445,0.000029799166,0.0041059516,0.0153546985],"study_design_scores_gemma":[0.0106911985,0.006792493,0.9602536,0.0015985402,0.0002219002,0.000001090469,0.00067177304,0.00053701014,0.010363982,0.00008160742,0.008404902,0.0003819162],"about_ca_topic_score_codex":0.3398729,"about_ca_topic_score_gemma":0.9894731,"teacher_disagreement_score":0.6496002,"about_ca_system_score_codex":0.002180355,"about_ca_system_score_gemma":0.0042188102,"threshold_uncertainty_score":0.8386649},"labels":[],"label_agreement":null},{"id":"W2899457817","doi":"10.1007/s13300-018-0524-z","title":"Liraglutide and Glycaemic Outcomes in the LEADER Trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Diabetes mellitus; Intensive care medicine; Empagliflozin; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.031761159776296614,"score_gpt":0.2979267338069327,"score_spread":0.26616557403063607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899457817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053025,0.0008653353,0.0000011604261,0.00388916,0.00018259749,0.0009066134,0.0000014307428,0.000038426337,0.0035850033],"genre_scores_gemma":[0.9920018,0.00021583131,0.00007804623,0.006272835,0.00024534314,0.00011107558,0.000008644144,0.000015066623,0.0010514077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991868,0.000048893267,0.0001507486,0.0001842624,0.00015758834,0.00027167838],"domain_scores_gemma":[0.99952495,0.00011235374,0.00003347538,0.00027313564,0.000018321312,0.00003777347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025821765,0.00013778146,0.00024816176,0.00008703854,0.00005070081,0.0000335411,0.000094663155,0.00004300754,0.000093167066],"category_scores_gemma":[0.000024675108,0.000075827105,0.00006368321,0.00012840964,0.00013148984,0.00005853167,0.000019537865,0.00007762419,0.00005315642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003015542,0.0009346011,0.83348584,0.000024191011,0.00045006178,0.000012435,0.0023028504,7.910523e-8,0.0014301923,0.00088162854,0.0048044017,0.15265816],"study_design_scores_gemma":[0.10815044,0.0057859737,0.7875007,0.00006608874,0.00013754309,9.555135e-7,0.00041858558,0.00004996944,0.004022895,0.0013923178,0.09217886,0.00029567367],"about_ca_topic_score_codex":0.000008391126,"about_ca_topic_score_gemma":0.000008986557,"teacher_disagreement_score":0.1523625,"about_ca_system_score_codex":0.000018444816,"about_ca_system_score_gemma":0.000010850319,"threshold_uncertainty_score":0.30921397},"labels":[],"label_agreement":null},{"id":"W2899521789","doi":"10.1161/circulationaha.118.036862","title":"Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use","year":2018,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Liraglutide; Statin; Internal medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Baseline (sea); Type 2 diabetes; Cardiology; Cholesterol; Endocrinology","score_opus":0.03474697305137356,"score_gpt":0.26109356991459665,"score_spread":0.2263465968632231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899521789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947115,0.0017700014,0.0000499743,0.0019931549,0.000169007,0.0012093973,0.000046854115,0.000026818547,0.000023267416],"genre_scores_gemma":[0.9934966,0.00020079807,0.00021555286,0.004837913,0.0004031072,0.000031001993,0.0006918721,0.0000394266,0.00008373683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979718,0.0002094503,0.00045680563,0.0005513368,0.00053680164,0.00027382647],"domain_scores_gemma":[0.99896675,0.000067247056,0.00022399124,0.00050486124,0.00017171679,0.00006543359],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000673815,0.00029530068,0.0007444398,0.00026325005,0.00003588963,0.00003563124,0.000057595676,0.0003454001,0.000017646773],"category_scores_gemma":[0.00012531727,0.00028321633,0.0001242509,0.00017067502,0.00009736488,0.000208377,0.000081807826,0.00031924047,0.000005216491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005062379,0.00019149792,0.9474719,0.0024252767,0.0024672505,0.00011555856,0.0002972041,0.000034599365,0.0009406905,0.000003905574,0.0028821332,0.04311932],"study_design_scores_gemma":[0.0014105168,0.00009387906,0.99201065,0.0007145218,0.0010183293,0.000002110266,0.0000115951325,0.0002855028,0.0019819632,0.00015581155,0.0020905475,0.00022459793],"about_ca_topic_score_codex":0.00058147276,"about_ca_topic_score_gemma":0.00005972828,"teacher_disagreement_score":0.044538684,"about_ca_system_score_codex":0.00010330252,"about_ca_system_score_gemma":0.00004192776,"threshold_uncertainty_score":0.999962},"labels":[],"label_agreement":null},{"id":"W2899764361","doi":"10.1016/s0140-6736(18)32590-x","title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","year":2018,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2818,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Heart failure; Hazard ratio; Meta-analysis; Diabetes mellitus; Stroke (engine); Myocardial infarction; Adverse effect; Renal function; Disease; Cardiology; Placebo; Type 2 diabetes; Proportional hazards model; Clinical trial; Intensive care medicine; Confidence interval; Endocrinology; Pathology","score_opus":0.14956593113232605,"score_gpt":0.3679194309269754,"score_spread":0.21835349979464933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899764361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002071653,0.991816,0.000012201764,0.000070754155,0.00003733304,0.0076010874,0.00018105126,0.0000098660075,0.000064583175],"genre_scores_gemma":[0.000078611876,0.9983039,0.00024796775,0.00009916896,0.000053795244,0.0007789378,0.0001637093,0.00002770914,0.0002461802],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962637,0.0010804944,0.0017125878,0.0003957714,0.0003452551,0.0002021881],"domain_scores_gemma":[0.9972117,0.00061363186,0.0008619397,0.0011723901,0.00009294005,0.000047426744],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008989348,0.00038216147,0.02612298,0.00033500354,0.000024196823,0.00001655641,0.00013816619,0.000118122094,0.000013280958],"category_scores_gemma":[0.00062374846,0.0001866152,0.0057394593,0.00044389442,0.00010558608,0.00005091364,0.00012809352,0.00011487068,6.112402e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000061919936,0.000024228571,0.000048463557,0.5372134,0.45513391,0.0000010218358,0.000016316928,3.674354e-7,3.6394184e-8,0.000009347206,0.00009941961,0.007447306],"study_design_scores_gemma":[0.0009944296,0.00016153509,0.00010377368,0.025674399,0.92225546,0.0000014495697,0.000006385977,0.0000014532013,7.385416e-7,0.000020352603,0.050641388,0.00013860984],"about_ca_topic_score_codex":0.000012814911,"about_ca_topic_score_gemma":0.0000034782652,"teacher_disagreement_score":0.511539,"about_ca_system_score_codex":0.00004047129,"about_ca_system_score_gemma":0.000044888606,"threshold_uncertainty_score":0.98833525},"labels":[],"label_agreement":null},{"id":"W2899847838","doi":"10.1016/s0140-6736(18)32824-1","title":"Pump, pipes, and filter: do SGLT2 inhibitors cover it all?","year":2018,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca; Biotronik; Medicines Company; St. Jude Medical; Biosensors International Group; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Disease; Internal medicine; Intensive care medicine; Heart failure; Scopus; Prospective cohort study; Meta-analysis; MEDLINE; Endocrinology","score_opus":0.031104987070085466,"score_gpt":0.26577044562462665,"score_spread":0.23466545855454118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899847838","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005176566,0.0008690991,0.0000028705635,0.9300336,0.0006462391,0.0006453089,0.00007016319,0.000093958406,0.06246219],"genre_scores_gemma":[0.0023515427,0.0007744693,0.000107484746,0.8897028,0.020441113,0.00006064732,0.0004960209,0.000052072442,0.08601383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872404,0.0000447486,0.00017786269,0.00032370898,0.0003061666,0.0004234753],"domain_scores_gemma":[0.9989476,0.00007505378,0.000102621445,0.0007983892,0.000029049346,0.00004728764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019013397,0.00027871973,0.0006073729,0.00006576373,0.000054417433,0.00009056674,0.00021310778,0.00022856778,0.00075539213],"category_scores_gemma":[0.0000213181,0.00015881714,0.00009199235,0.000060359424,0.00014250846,0.000045023637,0.00016832005,0.0005113706,0.00078115077],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042041807,0.000021671558,0.0008061536,0.0002392929,0.0004771496,0.00015957755,0.00014656015,5.050688e-8,0.000009983555,0.000025476253,0.9965554,0.0015166759],"study_design_scores_gemma":[0.001486442,0.0002002798,0.00075599935,0.00026601253,0.00064346194,0.000010066664,0.0000091267075,0.0000043411815,0.00007636655,0.0002514978,0.9961212,0.00017517713],"about_ca_topic_score_codex":0.000023365801,"about_ca_topic_score_gemma":0.0000034103118,"teacher_disagreement_score":0.04033079,"about_ca_system_score_codex":0.000053911415,"about_ca_system_score_gemma":0.000017691475,"threshold_uncertainty_score":0.99999684},"labels":[],"label_agreement":null},{"id":"W2900102850","doi":"10.1161/circulationaha.118.038352","title":"Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Linagliptin; Internal medicine; Diabetes mellitus; Ejection fraction; Heart failure; Dipeptidyl peptidase-4 inhibitor; Type 2 Diabetes Mellitus; Type 2 diabetes; Kidney disease; Cardiology; Placebo; Endocrinology; Pathology","score_opus":0.004401096870742705,"score_gpt":0.20210134913996877,"score_spread":0.19770025226922608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900102850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967233,0.001850097,7.086573e-7,0.00022758084,0.000059958136,0.0009598984,0.0000018147098,0.000025996691,0.0001506796],"genre_scores_gemma":[0.9994932,0.00009786658,0.00015760977,0.00005425459,0.000013768641,0.000024300378,0.00006632317,0.000016735288,0.00007595499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909407,0.00008567582,0.00015054815,0.00029485955,0.0002000612,0.00017475687],"domain_scores_gemma":[0.9995688,0.00009836925,0.000046598623,0.0002186922,0.000019619412,0.00004792721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027864607,0.00014005527,0.00038773436,0.00019820365,0.00002569749,0.000014937163,0.000017501017,0.00008737411,0.000010218865],"category_scores_gemma":[0.000038593796,0.00010837498,0.000042513973,0.00019614946,0.00002022277,0.00007146432,0.000028450546,0.00011169499,0.000025497138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025350297,0.000046205994,0.99432266,0.00011735194,0.00034250334,0.000011507134,0.00017320586,0.00067471346,0.00026125184,0.000047957143,0.000016431804,0.003960854],"study_design_scores_gemma":[0.004469754,0.00031327052,0.99312896,0.00026192877,0.00030730452,0.0000013644432,0.00002040164,0.0002587312,0.0005108111,0.00012706737,0.00048602093,0.00011437294],"about_ca_topic_score_codex":0.00005606068,"about_ca_topic_score_gemma":0.000025773134,"teacher_disagreement_score":0.004444404,"about_ca_system_score_codex":0.00009705839,"about_ca_system_score_gemma":0.000008724501,"threshold_uncertainty_score":0.44194034},"labels":[],"label_agreement":null},{"id":"W2900324617","doi":"10.1016/j.jval.2018.07.277","title":"Non-Severe Hypoglycemia Episodes (Nshes) Clinical And Economic Outcomes: A Comparison Between Sulfonylurea (Su) And Sodium-Glucose Co-Transporter 2 Inhibitor (Sglt2i) As Add On To Metformin From A Canadian Perspective","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Hypoglycemia; Metformin; Sulfonylurea; Type 2 Diabetes Mellitus; Adverse effect; Reimbursement; Health economics; Environmental health; Demography; Diabetes mellitus; Internal medicine; Health care; Insulin; Economics; Endocrinology; Public health","score_opus":0.04709727888063146,"score_gpt":0.3620011550741379,"score_spread":0.3149038761935064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900324617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898109,0.00028523704,0.0000068922577,0.0053444756,0.00024671873,0.0015859868,0.00019529952,0.00003488029,0.0024896166],"genre_scores_gemma":[0.99466264,0.00015947717,0.0010638698,0.0032689322,0.0004522463,0.000049162816,0.00011503325,0.000037714206,0.00019091512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976986,0.000092676986,0.0007607422,0.0006806859,0.00017330126,0.0005940066],"domain_scores_gemma":[0.9981061,0.0003205305,0.00014205888,0.00036235826,0.00003854862,0.0010303726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065543765,0.0003124107,0.0010102406,0.00037742438,0.00012695545,0.000047063502,0.000100657555,0.00016603564,0.00010046266],"category_scores_gemma":[0.000067825364,0.00027061612,0.00008835169,0.0001082574,0.0001704566,0.00010371897,0.000036095065,0.00029217338,0.00024143283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046396448,0.00016282119,0.9798344,0.0000609858,0.00023209346,0.000033510572,0.0036141726,0.000005009948,0.0000015792649,0.00050677266,0.004178211,0.010906472],"study_design_scores_gemma":[0.0065761334,0.003944584,0.9697505,0.00037712153,0.00016768422,0.0000024517217,0.0019337329,0.00030030488,0.00011722828,0.0007645512,0.01574261,0.00032305505],"about_ca_topic_score_codex":0.46261388,"about_ca_topic_score_gemma":0.14713849,"teacher_disagreement_score":0.3154754,"about_ca_system_score_codex":0.00092596945,"about_ca_system_score_gemma":0.0005934377,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W2900413769","doi":"10.1056/nejmoa1812389","title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6310,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Dapagliflozin; Mace; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Type 2 diabetes; Diabetes mellitus; Stroke (engine); Placebo; Cardiology; Heart failure; Confidence interval; Endocrinology; Percutaneous coronary intervention","score_opus":0.016431805722801892,"score_gpt":0.2611640940270873,"score_spread":0.2447322883042854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900413769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98070097,0.009559094,0.00002533358,0.0054957094,0.000611858,0.00012720846,2.3565876e-7,0.000008018539,0.0034715594],"genre_scores_gemma":[0.99499273,0.0010075107,0.00047455294,0.0006706534,0.0019813748,5.9633106e-7,0.0000017498901,0.000010951058,0.0008598602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990562,0.00003903163,0.00030044967,0.00010325599,0.00033387178,0.0001671607],"domain_scores_gemma":[0.999385,0.00007805706,0.00007718846,0.00016360813,0.00011114142,0.00018498162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007641376,0.000113990776,0.00061574345,0.0002475762,0.00001776244,0.0000057437514,0.00005423137,0.000033917688,0.00013920043],"category_scores_gemma":[0.00029778,0.00006604449,0.0000702874,0.00015944151,0.00010590348,0.000063305175,0.000022667362,0.00012358357,0.000006925768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024142543,0.00008917798,0.59734625,0.000047718986,0.0012553236,0.0002411742,0.00066180696,0.0000020474888,0.00044517958,0.00010338089,0.0095506655,0.39001587],"study_design_scores_gemma":[0.096754156,0.008233279,0.5423305,0.00083573814,0.0018298479,0.00014064583,0.00028634453,0.000048973583,0.0006248947,0.00090689125,0.34784004,0.00016867075],"about_ca_topic_score_codex":0.00003225719,"about_ca_topic_score_gemma":0.000017701966,"teacher_disagreement_score":0.3898472,"about_ca_system_score_codex":0.000024736277,"about_ca_system_score_gemma":0.00003903855,"threshold_uncertainty_score":0.26932165},"labels":[],"label_agreement":null},{"id":"W2900437800","doi":"10.1016/j.molmet.2018.10.012","title":"The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones","year":2018,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Novo Nordisk; Novo Nordisk Foundation Center for Basic Metabolic Research; Danish Diabetes Academy; Novo Nordisk Fonden; Medical Research Council Canada; Copenhagen Graduate School for Nanoscience and Nanotechnology; Wellcome Trust","keywords":"Hormone; Metabolism; Chemistry; Endocrinology; Internal medicine; Biochemistry; Biology; Medicine","score_opus":0.0081726132542687,"score_gpt":0.23839261280412635,"score_spread":0.23021999954985764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900437800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97309846,0.018435007,0.0013227033,0.0010699013,0.00024045007,0.0010579616,0.000006819062,0.000065459964,0.004703236],"genre_scores_gemma":[0.99277145,0.000653727,0.00460026,0.00058374397,0.00017044849,0.00009086438,0.00002362111,0.000034615034,0.0010713014],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998427,0.0001261025,0.00041435953,0.00029919515,0.0003930881,0.00034026007],"domain_scores_gemma":[0.9989035,0.00007280483,0.00021929003,0.00060543575,0.00011270038,0.00008623109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026244004,0.00025511108,0.00067982945,0.000078902856,0.00014280071,0.00004786556,0.000110757064,0.000063193744,0.000023458735],"category_scores_gemma":[0.00013422419,0.00016499976,0.00014736669,0.0002180822,0.0003043535,0.00011966903,0.00006915394,0.00007371953,0.000029005514],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002487903,0.00015147864,0.00066780456,0.00010129393,0.0014414028,0.00002061426,0.00070309127,0.0000019870618,0.950482,0.024631407,0.00043151798,0.021118594],"study_design_scores_gemma":[0.0074878368,0.00031022378,0.5122137,0.00014294007,0.0054433304,0.000022750097,0.00030684387,0.0006739058,0.40558362,0.015423739,0.052000817,0.00039026793],"about_ca_topic_score_codex":0.000034828445,"about_ca_topic_score_gemma":0.0000036096635,"teacher_disagreement_score":0.5448984,"about_ca_system_score_codex":0.000014679242,"about_ca_system_score_gemma":0.000021569575,"threshold_uncertainty_score":0.6728495},"labels":[],"label_agreement":null},{"id":"W2900447792","doi":"10.1111/dom.13573","title":"CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital; University of Waterloo; McGill University Health Centre; University of British Columbia; Diabetes Canada; University of Toronto; University of Manitoba","funders":"Mitsubishi Tanabe Pharma Corporation; European Foundation for the Study of Diabetes; Diabetes Canada; Janssen Research and Development; American Diabetes Association","keywords":"Canagliflozin; Medicine; Glycated hemoglobin; Clinical endpoint; Type 2 Diabetes Mellitus; Regimen; Internal medicine; Weight loss; Diabetes mellitus; Adverse effect; Type 2 diabetes; Body mass index; Blood pressure; Renal function; Weight change; Surgery; Endocrinology; Clinical trial; Obesity","score_opus":0.012931836768372841,"score_gpt":0.2841871140611043,"score_spread":0.27125527729273147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900447792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824577,0.012045362,2.1765365e-7,0.0011346597,0.0002642086,0.0010717993,0.00008161999,0.00000693225,0.0029374838],"genre_scores_gemma":[0.9940614,0.0048706173,0.0001800175,0.00061043154,0.00010964946,0.000040971107,0.000048207872,0.000017005339,0.000061659695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977872,0.00044352066,0.0005007587,0.00039347642,0.00020190381,0.0006731734],"domain_scores_gemma":[0.9982034,0.0005591703,0.00014367378,0.00044647534,0.000165358,0.00048193472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001632579,0.0002568551,0.00085635216,0.00046191073,0.00009097597,0.00002294679,0.00013582232,0.000162274,0.000018607234],"category_scores_gemma":[0.00047658978,0.00019177499,0.00007822045,0.0005914261,0.00033672783,0.00012735353,0.000025573618,0.00014034855,0.0000032849584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010865579,0.0005038819,0.9618491,0.00016980406,0.00035874476,0.000042002706,0.0009373037,0.000001393554,0.00003961297,0.0017916255,0.0001430426,0.034054838],"study_design_scores_gemma":[0.002295808,0.00068451697,0.8737331,0.00014942946,0.00056159863,9.562567e-7,0.00026297878,0.000066671426,0.00051661074,0.00013225069,0.12144841,0.00014765834],"about_ca_topic_score_codex":0.89615417,"about_ca_topic_score_gemma":0.9636694,"teacher_disagreement_score":0.12130537,"about_ca_system_score_codex":0.00030275105,"about_ca_system_score_gemma":0.0007197115,"threshold_uncertainty_score":0.7820357},"labels":[],"label_agreement":null},{"id":"W2900584187","doi":"10.1016/s2213-8587(18)30312-7","title":"Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care","year":2018,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Boehringer Ingelheim; AstraZeneca; Eli Lilly and Company; Sanofi; Abbott Laboratories; Merck; Amgen","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Scopus; Population; Disease; Gerontology; MEDLINE; Environmental health; Internal medicine; Endocrinology","score_opus":0.08561460110873703,"score_gpt":0.296513251782073,"score_spread":0.21089865067333596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900584187","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38239262,0.06613394,0.000012632605,0.5444791,0.0011797833,0.0018224516,0.00029588345,0.0002463429,0.0034373053],"genre_scores_gemma":[0.65238345,0.026568456,0.0020213341,0.2946245,0.018080784,0.0014060863,0.0015064384,0.00036975485,0.003039207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971956,0.0001504866,0.00040688872,0.00055404747,0.00023294403,0.0014600564],"domain_scores_gemma":[0.99734014,0.0010316543,0.00031161838,0.0010499876,0.00022300286,0.000043581207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026508168,0.00045778241,0.0011833358,0.00022239723,0.00016741574,0.000039789098,0.00043943356,0.00031620456,0.00001831818],"category_scores_gemma":[0.00011364964,0.00026278952,0.00019404091,0.0001602037,0.00049174565,0.00006975744,0.00027765814,0.00073738565,0.000008198644],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029069764,0.00015386127,0.03893623,0.0055354564,0.0068838657,0.000051634866,0.0039022944,0.00008997544,0.00011924091,0.002303471,0.79227895,0.14945431],"study_design_scores_gemma":[0.00263169,0.0019269442,0.003856398,0.00056823855,0.0027444304,0.0000034935904,0.00030830858,0.0017445697,0.000574906,0.00093292835,0.984328,0.0003801311],"about_ca_topic_score_codex":0.000013912686,"about_ca_topic_score_gemma":0.000012057564,"teacher_disagreement_score":0.26999083,"about_ca_system_score_codex":0.000056176046,"about_ca_system_score_gemma":0.00003327679,"threshold_uncertainty_score":0.9999824},"labels":[],"label_agreement":null},{"id":"W2900724835","doi":"10.1136/bmjdrc-2018-000563","title":"Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis","year":2018,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Hypertension Canada; Government of Alberta","keywords":"Medicine; Dementia; Relative risk; Internal medicine; Diabetes mellitus; Meta-analysis; Randomized controlled trial; Hypoglycemia; Cohort study; Insulin; Disease; Endocrinology; Confidence interval","score_opus":0.1868345746067692,"score_gpt":0.5030276208767853,"score_spread":0.3161930462700161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900724835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7866521,0.19321679,5.7878873e-7,0.00033489286,0.00001687058,0.016594833,0.0003578249,0.000020817548,0.0028052893],"genre_scores_gemma":[0.98787373,0.0077489056,0.00021558821,0.00011468459,0.000027865724,0.0032867866,0.00013589588,0.000027047949,0.0005695134],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957354,0.001163073,0.00086248707,0.0006026995,0.0009480343,0.0006883025],"domain_scores_gemma":[0.9965683,0.0006445628,0.00044326985,0.0010453714,0.0009886315,0.00030982099],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019880682,0.0003731697,0.003839718,0.00045071266,0.00014631808,0.0000786358,0.000445509,0.00007804013,0.0020009172],"category_scores_gemma":[0.00043539001,0.00020404505,0.001426594,0.0011961226,0.0003774671,0.00012655028,0.00041750536,0.0001249141,0.00005210882],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011157782,0.0017311975,0.17995742,0.063303806,0.7509705,0.000011638831,0.00039260474,0.0000062452273,0.0003623789,0.000049098486,0.0018811583,0.0012223846],"study_design_scores_gemma":[0.0017669032,0.014653099,0.04901591,0.0019916785,0.9234064,1.4527522e-7,0.00021195669,0.00009107167,0.008512978,0.000033987362,0.000075621225,0.00024021948],"about_ca_topic_score_codex":0.00016109362,"about_ca_topic_score_gemma":0.000029991657,"teacher_disagreement_score":0.20122162,"about_ca_system_score_codex":0.00025305635,"about_ca_system_score_gemma":0.000113634815,"threshold_uncertainty_score":0.9989114},"labels":[],"label_agreement":null},{"id":"W2900819383","doi":"10.1139/cjpp-2018-0466","title":"A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn<sup>2+</sup>-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Türkiye Bilimsel ve Teknolojik Araştırma Kurumu","keywords":"Dapagliflozin; Cotransporter; Insulin; Internal medicine; Transporter; Chemistry; Endocrinology; Glucose transporter; Diabetes mellitus; Oxidative phosphorylation; Oxidative stress; Metabolic syndrome; Glucose uptake; Sodium; Biochemistry; Biology; Type 2 diabetes; Medicine","score_opus":0.01149010032593305,"score_gpt":0.2524678716376063,"score_spread":0.24097777131167325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900819383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474066,0.0035311275,0.000016351347,0.0003498337,0.00036519588,0.0006608211,0.00025560232,0.000008306166,0.00007212047],"genre_scores_gemma":[0.9978203,0.00035545844,0.00024784447,0.0009953261,0.0003516655,0.000029259794,0.00016222471,0.00002777566,0.00001010028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979721,0.00023734065,0.0007788197,0.00036470933,0.00016900111,0.00047806185],"domain_scores_gemma":[0.9986209,0.00016822267,0.0004622369,0.000165793,0.00018110241,0.00040172692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020944758,0.0003468915,0.0012713426,0.00046039422,0.000090567904,0.000008636907,0.00011851321,0.00018947243,0.00029215],"category_scores_gemma":[0.000011854666,0.00026892326,0.0001383789,0.00027019175,0.00057820656,0.0001790703,0.000011336283,0.00043829213,0.0000037884213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010605846,0.0010125042,0.09535751,0.0005873314,0.0045579495,0.004835497,0.007876999,0.00047308055,0.8713075,0.0002587502,0.0012516795,0.0018753555],"study_design_scores_gemma":[0.011010357,0.0067002713,0.12581615,0.0005734526,0.0017339329,0.000032437852,0.0005990871,0.000109238885,0.85181886,0.0002777362,0.0010299868,0.0002985185],"about_ca_topic_score_codex":0.0018467347,"about_ca_topic_score_gemma":0.0046140417,"teacher_disagreement_score":0.030458646,"about_ca_system_score_codex":0.000110168185,"about_ca_system_score_gemma":0.00044300972,"threshold_uncertainty_score":0.9999763},"labels":[],"label_agreement":null},{"id":"W2900977796","doi":"10.1155/2018/4696182","title":"A Unique Case of Metformin-Associated Lactic Acidosis","year":2018,"lang":"en","type":"article","venue":"Case Reports in Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Ottawa Hospital Research Institute; University of Ottawa","keywords":"Metformin; Medicine; Lactic acidosis; Hyperkalemia; Metabolic acidosis; Intensive care medicine; Diabetes mellitus; Context (archaeology); Type 2 diabetes; Acute kidney injury; Hemodialysis; Acidosis; Type 2 Diabetes Mellitus; Internal medicine; Endocrinology","score_opus":0.017292081099822755,"score_gpt":0.29544680563803216,"score_spread":0.2781547245382094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900977796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902019,0.00024727036,0.000017605895,0.00025563574,0.00018608735,0.00044653128,0.0000022888794,0.000046785717,0.008595907],"genre_scores_gemma":[0.99797,0.000029859975,0.00041534216,0.0006384614,0.000054759268,0.00005359341,0.0000167441,0.000017179618,0.00080410356],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9988316,0.000057738787,0.00047601428,0.00026615156,0.00008155825,0.0002869113],"domain_scores_gemma":[0.9990108,0.00008346244,0.0002702956,0.0004251631,0.00012314941,0.00008713933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004509794,0.00013721378,0.0004202558,0.00025530215,0.000038680235,0.000003923242,0.000018424276,0.00014667802,0.00025431818],"category_scores_gemma":[0.00025797114,0.00011870609,0.00008114056,0.00029926017,0.00018512666,0.000058893485,0.00006255093,0.00010491262,0.000009084358],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010173626,0.000506719,0.014603553,0.0000536826,0.00037559477,0.9691676,0.00040971243,5.184205e-7,0.00064206886,0.00030934918,0.0013490174,0.012480455],"study_design_scores_gemma":[0.0031720644,0.003031113,0.005044837,0.000100070545,0.0013878194,0.9416175,0.0005348051,0.00026618972,0.010764752,0.0014836227,0.032313615,0.00028359622],"about_ca_topic_score_codex":0.00057880953,"about_ca_topic_score_gemma":0.0012661251,"teacher_disagreement_score":0.030964598,"about_ca_system_score_codex":0.00012999048,"about_ca_system_score_gemma":0.00007422087,"threshold_uncertainty_score":0.4840694},"labels":[],"label_agreement":null},{"id":"W2901198742","doi":"10.1111/dme.13866","title":"Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes","year":2018,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Novo Nordisk","keywords":"Insulin aspart; Medicine; Postprandial; Insulin; Internal medicine; Type 2 diabetes; Endocrinology; Insulin lispro; Diabetes mellitus; Bolus (digestion)","score_opus":0.020150423656705503,"score_gpt":0.26742162351084375,"score_spread":0.24727119985413826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901198742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810726,0.002984576,0.00016221254,0.003969048,0.0014484375,0.0025658673,0.000023550876,0.00018335582,0.0075903446],"genre_scores_gemma":[0.99362475,0.00029089377,0.0017598743,0.0014101118,0.0016114531,0.00032694679,0.0003691642,0.00011446872,0.0004923683],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996236,0.00010847305,0.00091417925,0.0008271259,0.00072945154,0.0011847358],"domain_scores_gemma":[0.9971139,0.0009743737,0.00033421247,0.00064531475,0.0004772555,0.00045498103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001054466,0.0005962561,0.0015015616,0.0005218272,0.00021137147,0.00004080439,0.00024327202,0.00020915034,0.00036447454],"category_scores_gemma":[0.0014498343,0.00044172895,0.00012172215,0.000981153,0.00037329056,0.00016195362,0.00008728993,0.0003493037,0.00013243359],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18223163,0.0062258407,0.43062493,0.0044942554,0.008466368,0.0005546733,0.017713364,0.00027373104,0.03704842,0.0030439263,0.016581021,0.29274184],"study_design_scores_gemma":[0.38826677,0.14860268,0.26790968,0.0099444585,0.009322765,0.000015537062,0.005474079,0.02526087,0.017258182,0.0007421475,0.1235249,0.0036779623],"about_ca_topic_score_codex":0.00015261518,"about_ca_topic_score_gemma":0.00038675676,"teacher_disagreement_score":0.28906387,"about_ca_system_score_codex":0.00030341867,"about_ca_system_score_gemma":0.00024302822,"threshold_uncertainty_score":0.9998034},"labels":[],"label_agreement":null},{"id":"W2902125755","doi":"10.1016/j.cmet.2018.11.010","title":"Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?","year":2018,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Victory; Diabetes mellitus; Disease; Medicine; Intensive care medicine; Bioinformatics; Internal medicine; Endocrinology; Biology; Political science","score_opus":0.010806075276567465,"score_gpt":0.21658656500940246,"score_spread":0.205780489732835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902125755","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25765824,0.07059745,0.000005490945,0.60609573,0.006238439,0.0048120203,0.0008231915,0.0005269582,0.053242512],"genre_scores_gemma":[0.06243442,0.003142661,0.00039287994,0.84271747,0.019559754,0.0009091007,0.004595427,0.00042084634,0.065827444],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680346,0.00015671094,0.0004658068,0.0008798961,0.00068652816,0.0010076115],"domain_scores_gemma":[0.99814916,0.000054007884,0.0001903518,0.001131358,0.000098457094,0.0003766912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018280534,0.0007158276,0.0012542406,0.0006425097,0.00006957924,0.00006593322,0.00032528004,0.0004963231,0.00022717516],"category_scores_gemma":[0.000036715297,0.0006167944,0.00054142973,0.00031298716,0.00015208434,0.00007533585,0.00020295229,0.0010432093,0.0003997321],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028609915,0.00017199083,0.0052241143,0.0009882133,0.00050738297,0.0020323084,0.00015880298,0.000002866733,0.000115482835,0.0000063676744,0.9868685,0.0038953715],"study_design_scores_gemma":[0.0023358855,0.000048425492,0.010176625,0.00049549626,0.0021617238,2.9991324e-7,0.000011132408,0.000023107441,0.00036441482,0.0001157074,0.98371774,0.00054943614],"about_ca_topic_score_codex":0.000029539984,"about_ca_topic_score_gemma":0.00001532281,"teacher_disagreement_score":0.23662175,"about_ca_system_score_codex":0.00023377081,"about_ca_system_score_gemma":0.0002456056,"threshold_uncertainty_score":0.99962837},"labels":[],"label_agreement":null},{"id":"W2902232281","doi":"10.1007/s40263-018-0593-6","title":"Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Weston Brain Institute","keywords":"Neuroprotection; Neuroscience; Parkinson's disease; Disease; Medicine; Clinical trial; Neurology; Bioinformatics; Psychology; Internal medicine; Biology","score_opus":0.0666686767453187,"score_gpt":0.3375970176882603,"score_spread":0.2709283409429416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902232281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060205127,0.99310684,0.000002423836,0.000048355738,0.00023987604,0.0017000488,0.00010139101,0.000052581876,0.00414642],"genre_scores_gemma":[0.0014734687,0.99652344,0.00008800368,0.000060471666,0.00016225739,0.0003710999,0.0002489946,0.000053506097,0.0010187583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850607,0.000101100544,0.00043344536,0.00049265707,0.00019509789,0.00027165056],"domain_scores_gemma":[0.99897194,0.00011168761,0.00026008254,0.000454833,0.000056622564,0.00014482526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010206658,0.00037402165,0.0013573663,0.0004436081,0.00004943453,0.000019949246,0.00011531339,0.00012317396,0.00004995548],"category_scores_gemma":[0.000048789523,0.00028879638,0.0003192173,0.00037271014,0.00019494252,0.00007757836,0.00013876356,0.00018851888,0.000060351067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025651978,0.0004431623,0.00036838543,0.006417763,0.001838506,0.000045062006,0.00023049241,8.6138854e-8,3.635331e-7,0.000089246816,0.005097541,0.9854437],"study_design_scores_gemma":[0.0005141194,0.0002534317,0.0016657519,0.006203181,0.007983217,0.000005000732,0.00009679598,0.000003007186,0.0000029332757,0.00004167804,0.98301846,0.00021241924],"about_ca_topic_score_codex":0.00008884598,"about_ca_topic_score_gemma":0.000029162678,"teacher_disagreement_score":0.98523134,"about_ca_system_score_codex":0.00009331868,"about_ca_system_score_gemma":0.0001358003,"threshold_uncertainty_score":0.9999564},"labels":[],"label_agreement":null},{"id":"W2902708442","doi":"","title":"Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Ottawa Hospital; Research Institute for Aging; Women's College Hospital; University of Ottawa; Bruyère","funders":"","keywords":"Deprescribing; Guideline; Medicine; MEDLINE; Grading (engineering); Systematic review; Family medicine; Nursing; Polypharmacy; Intensive care medicine","score_opus":0.2054136735846258,"score_gpt":0.3998887457093624,"score_spread":0.19447507212473658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902708442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9141388,0.0022848598,0.00020000958,0.031190038,0.0013147913,0.003777349,0.0000037532586,0.00014310727,0.046947274],"genre_scores_gemma":[0.98550636,0.0004152735,0.003084972,0.0075185727,0.00027358794,0.00073587545,0.000013012952,0.000025060943,0.0024272618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981779,0.0000877683,0.0005101288,0.00042290986,0.00034058563,0.00046072764],"domain_scores_gemma":[0.9983378,0.00026398752,0.00025877322,0.00084972667,0.00009412236,0.00019560111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015233437,0.00016068398,0.00032852215,0.00012382561,0.00012109271,0.00012229891,0.00025227532,0.00009120342,0.00004560038],"category_scores_gemma":[0.0057448773,0.00013589299,0.0001455052,0.00007148207,0.000082529645,0.00061056495,0.00012961707,0.000187212,0.00005764571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000455472,0.00063470576,0.6081102,0.000050592193,0.00014868115,0.00035839976,0.000031013526,0.000005078252,0.0000041047456,0.000025438178,0.03500508,0.3551712],"study_design_scores_gemma":[0.004720432,0.0000827733,0.9161319,0.000267011,0.000387626,0.000003819218,0.00007893958,0.000563107,0.000054874443,0.000008826587,0.07756103,0.00013963567],"about_ca_topic_score_codex":0.00017445743,"about_ca_topic_score_gemma":0.000018728999,"teacher_disagreement_score":0.35503158,"about_ca_system_score_codex":0.00012437509,"about_ca_system_score_gemma":0.00006004389,"threshold_uncertainty_score":0.687757},"labels":[],"label_agreement":null},{"id":"W2902882391","doi":"10.1016/j.coph.2018.11.002","title":"Impact of currently used anti-diabetic drugs on myoendothelial communication","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Qatar National Research Fund; National Research Foundation","keywords":"Metformin; Medicine; Diabetes mellitus; Endothelium; Vasodilation; Type 2 diabetes; Drug; Endothelial dysfunction; Disease; Pharmacology; Intensive care medicine; Internal medicine; Bioinformatics; Endocrinology; Biology","score_opus":0.12218057223945589,"score_gpt":0.48069874772860655,"score_spread":0.35851817548915066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902882391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022977616,0.98653716,0.0000018034527,0.000050251576,0.007837982,0.0026087298,0.00013502201,0.000052195766,0.00047906968],"genre_scores_gemma":[0.001679781,0.9955912,0.000019700496,0.00001316166,0.0007027244,0.00041907333,0.0014439687,0.00005974658,0.000070616516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730426,0.00048765558,0.00096882455,0.0005013918,0.00027704216,0.00046082918],"domain_scores_gemma":[0.99816257,0.00030253144,0.0006806586,0.0006138244,0.000094022405,0.0001463897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003425287,0.0005358567,0.002050241,0.0008862603,0.000042512373,0.000012154371,0.00040605408,0.00019906381,0.00060052716],"category_scores_gemma":[0.000028558114,0.00041380324,0.00078355457,0.0004922025,0.00022122564,0.000061904255,0.00020549865,0.0005699947,0.00031204292],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009135701,0.00339986,0.0009629224,0.026020637,0.0010888585,0.0000015795312,0.00015871724,0.0000021194785,0.0000046596865,0.00013472658,0.067850985,0.9002836],"study_design_scores_gemma":[0.003852291,0.0010413385,0.00041350155,0.019624779,0.0015021868,0.000002551414,0.000004626984,0.000032408414,0.000010375981,0.000021804908,0.9732039,0.00029025105],"about_ca_topic_score_codex":0.000008429688,"about_ca_topic_score_gemma":1.9025025e-7,"teacher_disagreement_score":0.9053529,"about_ca_system_score_codex":0.0005384626,"about_ca_system_score_gemma":0.00034892082,"threshold_uncertainty_score":0.9998314},"labels":[],"label_agreement":null},{"id":"W2903137231","doi":"10.14740/jocmr3650","title":"Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Washout; Waist; Internal medicine; Endocrinology; Adiponectin; Type 2 diabetes; Uric acid; Diabetes mellitus; Weight loss; Body mass index; Obesity; Insulin resistance","score_opus":0.04637227443248755,"score_gpt":0.4274484325567197,"score_spread":0.3810761581242322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903137231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810334,0.0009597615,5.924778e-7,0.0056946254,0.0004245271,0.0006847284,0.0000018222792,0.000009272916,0.011191285],"genre_scores_gemma":[0.99406916,0.00066443614,0.0000889217,0.00033288036,0.0032837165,0.00001782892,0.000007315029,0.000037242826,0.0014984848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99463856,0.00074395526,0.0016202391,0.00033262582,0.0020649624,0.000599629],"domain_scores_gemma":[0.9951541,0.002524917,0.00035974075,0.00047203305,0.0010124635,0.00047677744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00941481,0.00025042036,0.0014906281,0.0007865658,0.000037915986,0.000010875069,0.00025074105,0.00019102178,0.0005259092],"category_scores_gemma":[0.0021133095,0.00012784445,0.00017116424,0.00068709295,0.0010888248,0.00011993065,0.00006682961,0.001168093,0.000056667377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043173496,0.0018603229,0.8957464,0.00060912786,0.0009475367,0.0014303917,0.0006335766,2.835557e-7,0.0028206953,0.000021679147,0.038600408,0.014156075],"study_design_scores_gemma":[0.03815653,0.22425573,0.66953176,0.008211335,0.0010367254,0.0000208974,0.00033942272,0.0000722905,0.04139955,0.00011922121,0.01658984,0.00026669735],"about_ca_topic_score_codex":0.000025232255,"about_ca_topic_score_gemma":0.000022897208,"teacher_disagreement_score":0.22621465,"about_ca_system_score_codex":0.00009020261,"about_ca_system_score_gemma":0.00022116148,"threshold_uncertainty_score":0.5758337},"labels":[],"label_agreement":null},{"id":"W2903310752","doi":"10.14740/jocmr3676","title":"An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin; Cotransporter; Pharmacology; Sodium; Internal medicine","score_opus":0.09564360173727451,"score_gpt":0.48484612879438566,"score_spread":0.3892025270571111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903310752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987717,0.0004153102,0.00006183119,0.0075782416,0.00033147002,0.0008860669,3.8966266e-7,0.00001021376,0.002999522],"genre_scores_gemma":[0.9956145,0.0014708686,0.00029373553,0.00048481024,0.0019431355,0.0000164829,0.0000062013655,0.000021236721,0.00014898232],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963574,0.00063834124,0.0010839703,0.00023140735,0.0013514314,0.000337445],"domain_scores_gemma":[0.99670714,0.0010659926,0.0002781764,0.0002704704,0.0012886068,0.00038958268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009158749,0.00013735513,0.00074587774,0.00068324397,0.00005368691,0.000013580367,0.00017225297,0.00012321425,0.00018612809],"category_scores_gemma":[0.0008172101,0.000074385534,0.00009651054,0.000660226,0.00083105837,0.00020190391,0.000016820617,0.0009776324,0.000021055163],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010283604,0.003988911,0.43946403,0.000055530032,0.0002986347,0.0005461902,0.00081436394,4.390866e-7,0.000839786,0.00014117558,0.002676996,0.54089034],"study_design_scores_gemma":[0.03267134,0.11337386,0.8377469,0.00116353,0.00008884916,0.000020789374,0.00048057197,0.000099454104,0.003819741,0.0006826528,0.009765056,0.00008724138],"about_ca_topic_score_codex":0.000044741864,"about_ca_topic_score_gemma":0.000043890504,"teacher_disagreement_score":0.5408031,"about_ca_system_score_codex":0.00009656956,"about_ca_system_score_gemma":0.00018633624,"threshold_uncertainty_score":0.42473805},"labels":[],"label_agreement":null},{"id":"W2903431537","doi":"10.1161/circulationaha.118.037778","title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Mace; Empagliflozin; TIMI; Myocardial infarction; Internal medicine; Cardiology; Heart failure; Diabetes mellitus; Placebo; Stroke (engine); Hazard ratio; Type 2 diabetes; Conventional PCI; Confidence interval","score_opus":0.028269585738965552,"score_gpt":0.3074572870481937,"score_spread":0.27918770130922815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903431537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526346,0.00024146325,0.0003127757,0.00080894673,0.00014861314,0.0031199749,0.000009391259,0.000013230884,0.00008216874],"genre_scores_gemma":[0.9996102,0.0000127487265,0.000036489186,0.000056100325,0.000098667624,0.00008361888,0.00006910709,0.000009389469,0.000023686938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991473,0.000082815845,0.00023319124,0.00017705224,0.00022844167,0.00013121203],"domain_scores_gemma":[0.9993965,0.0000595915,0.00009167112,0.00040453882,0.000031257397,0.000016463246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008976996,0.00008797712,0.0002501292,0.0000338251,0.000055610668,0.00002338517,0.00004964974,0.00004857372,0.0000062507893],"category_scores_gemma":[0.00008417981,0.000052656735,0.00018859743,0.00014990171,0.000030741503,0.00007912442,0.000015524534,0.000053008243,0.0000029645237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028867883,0.00008781609,0.99586034,0.00008716206,0.00036866762,3.9035612e-7,0.0010511101,0.000926583,0.00009887041,0.00039179387,0.000087679175,0.00075092603],"study_design_scores_gemma":[0.012033816,0.00015064634,0.98404247,0.000020654383,0.0004987079,5.402468e-7,0.00053810934,0.0009533908,0.00017181688,0.00042194498,0.0011092691,0.000058661622],"about_ca_topic_score_codex":0.00013854845,"about_ca_topic_score_gemma":0.000040032563,"teacher_disagreement_score":0.01181788,"about_ca_system_score_codex":0.00004195769,"about_ca_system_score_gemma":0.000011987709,"threshold_uncertainty_score":0.21472792},"labels":[],"label_agreement":null},{"id":"W2903516054","doi":"10.14740/jocmr3632","title":"Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glimepiride; Sitagliptin; Medicine; Glycemic; Type 2 diabetes; Internal medicine; Sulfonylurea; Prospective cohort study; Diabetes mellitus; Randomized controlled trial; Sitagliptin Phosphate; Gastroenterology; Type 2 Diabetes Mellitus; Hypoglycemia; Endocrinology; Insulin","score_opus":0.07957162068891334,"score_gpt":0.45834521074917606,"score_spread":0.37877359006026273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903516054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904383,0.00078647485,0.0000038879916,0.0018420509,0.00026642688,0.003624804,5.32383e-7,0.000008377774,0.0044236393],"genre_scores_gemma":[0.99678296,0.0008576186,0.00022547808,0.00008554581,0.00092697935,0.00006958781,0.0000013949307,0.000027409844,0.0010230228],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99456537,0.0015756813,0.0016232613,0.00031329034,0.0014738435,0.0004485748],"domain_scores_gemma":[0.986552,0.010989193,0.00057364977,0.0003563629,0.00120708,0.00032169835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009299143,0.0002393634,0.002810867,0.0007989746,0.00004485398,0.000010587621,0.00018023151,0.00009548074,0.00009931814],"category_scores_gemma":[0.005816207,0.00011313332,0.00023985523,0.0008914402,0.0014177226,0.000069718146,0.00004832648,0.00061885023,0.000028878372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3028148,0.019079244,0.6399892,0.0004711416,0.0060364753,0.0011297414,0.002346622,0.000002589417,0.0007541879,0.00025433852,0.001437816,0.025683828],"study_design_scores_gemma":[0.5142597,0.24991524,0.21891847,0.0034527704,0.0026264365,0.000004619083,0.0011602837,0.00007544476,0.008709999,0.0003211365,0.0004276624,0.00012822617],"about_ca_topic_score_codex":0.000078528436,"about_ca_topic_score_gemma":0.00003796712,"teacher_disagreement_score":0.42107072,"about_ca_system_score_codex":0.00017114765,"about_ca_system_score_gemma":0.0002855948,"threshold_uncertainty_score":0.6962963},"labels":[],"label_agreement":null},{"id":"W2903730689","doi":"10.1016/j.jcjd.2018.12.001","title":"Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; Alliance for Canadian Health Outcomes Research in Diabetes","funders":"Government of Canada; Diabetes Canada","keywords":"Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.011411286302440623,"score_gpt":0.2504388782668682,"score_spread":0.2390275919644276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903730689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983673,0.0005410265,0.0000013832082,0.00018863069,0.000118081734,0.00046656022,0.0000046247733,0.0000032210412,0.00030913466],"genre_scores_gemma":[0.9987741,0.000007640172,0.00056667975,0.00054819504,0.00004782163,0.000008704058,0.000011142202,0.000020604939,0.000015110801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987958,0.00008129946,0.00025787117,0.00012551274,0.00045806606,0.0002814217],"domain_scores_gemma":[0.99834436,0.00005256526,0.00023746875,0.00013376886,0.0009061194,0.00032573758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063182233,0.00013108568,0.0003269423,0.00042615426,0.000037219495,0.0000139183685,0.000063380656,0.0000514975,0.000043683325],"category_scores_gemma":[0.00021958521,0.000086841304,0.000022549311,0.00029566608,0.00017354761,0.00017776412,0.000005470982,0.00008541359,0.0000021461458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058698428,0.00006783648,0.97937983,0.000100007885,0.00027966825,0.0000016895866,0.0002481854,0.000003179574,0.00004795036,0.00002793789,0.0002939655,0.019491065],"study_design_scores_gemma":[0.007250651,0.0057548927,0.9827086,0.0008157566,0.00085916853,4.3960281e-7,0.000088372435,0.00017246923,0.001543192,0.000037134654,0.0006594573,0.00010989683],"about_ca_topic_score_codex":0.00031976507,"about_ca_topic_score_gemma":0.0091886055,"teacher_disagreement_score":0.01938117,"about_ca_system_score_codex":0.00019391094,"about_ca_system_score_gemma":0.0006212211,"threshold_uncertainty_score":0.51274574},"labels":[],"label_agreement":null},{"id":"W2904003910","doi":"10.1093/eurheartj/ehy565.p1879","title":"P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline","year":2018,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Heart failure; Baseline (sea); Internal medicine; Cardiology; Framingham Risk Score; Disease","score_opus":0.04614071553906284,"score_gpt":0.2991836529491928,"score_spread":0.25304293741012995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904003910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518985,0.0015835899,0.00056207733,0.00079867337,0.00023542855,0.0005015583,0.000027189008,0.000026577969,0.0010750325],"genre_scores_gemma":[0.99406785,0.00018925815,0.004058056,0.00013735966,0.0011881847,0.0000048211864,0.000017901126,0.000032014872,0.0003045715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864304,0.0003271841,0.00027901056,0.00024084233,0.0003005277,0.0002094035],"domain_scores_gemma":[0.9991478,0.00006213377,0.0001289747,0.00025890485,0.00023756683,0.00016462101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020772358,0.00014514376,0.00034937964,0.00010809734,0.00021878506,0.000035566278,0.000048484377,0.000024101151,0.00008641823],"category_scores_gemma":[0.00028163817,0.00011462924,0.00030156862,0.00009627743,0.00014360256,0.00011935446,0.00006124845,0.00011831892,0.000026970472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005410534,0.00042906989,0.79945016,0.00017586866,0.0049383403,0.00007257152,0.0014922018,0.000051090814,0.0043387427,0.00007405585,0.17443842,0.013998439],"study_design_scores_gemma":[0.0027287053,0.0017780847,0.80349576,0.00020645122,0.0014313039,0.00008889497,0.00025047775,0.00013104243,0.009649578,0.00008314498,0.17999455,0.00016197773],"about_ca_topic_score_codex":0.000016794718,"about_ca_topic_score_gemma":0.000008810403,"teacher_disagreement_score":0.01383646,"about_ca_system_score_codex":0.00007337222,"about_ca_system_score_gemma":0.000027867229,"threshold_uncertainty_score":0.46744448},"labels":[],"label_agreement":null},{"id":"W2904032201","doi":"10.1093/eurheartj/ehy565.p1267","title":"P1267Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition","year":2018,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Cardiology; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.017780561741426067,"score_gpt":0.25193562674176134,"score_spread":0.23415506500033528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904032201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757683,0.0000835989,0.000018755934,0.0009818933,0.00010518284,0.0003227499,0.000001957762,0.000020526044,0.00088851544],"genre_scores_gemma":[0.9961952,0.00001128654,0.0022794614,0.00046306473,0.00019727432,0.000013605975,0.00003630524,0.000032767945,0.0007710315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832803,0.0002968969,0.00042831973,0.00026357605,0.0003491486,0.00033401704],"domain_scores_gemma":[0.99938184,0.0000126116465,0.000151159,0.00019571025,0.000135787,0.00012287375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012653843,0.00016349203,0.0003530693,0.0003233439,0.00006391432,0.000033637552,0.00006159184,0.000029540019,0.000086226995],"category_scores_gemma":[0.00003573249,0.00013159082,0.00006905784,0.00030092234,0.00004648306,0.00019229973,0.000039941573,0.00015129904,0.000015316002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021235767,0.0016807967,0.9418228,0.00006945018,0.00042708314,0.000047622252,0.0019162899,0.000008788066,0.01931221,0.000024648298,0.013921474,0.020556439],"study_design_scores_gemma":[0.0028756051,0.004312894,0.9142093,0.0010800442,0.00008175152,0.0000050794324,0.00022585136,0.000036052377,0.0457821,0.000029287565,0.031172886,0.00018915479],"about_ca_topic_score_codex":0.000010926012,"about_ca_topic_score_gemma":0.00011615321,"teacher_disagreement_score":0.027613549,"about_ca_system_score_codex":0.00021994172,"about_ca_system_score_gemma":0.00010560081,"threshold_uncertainty_score":0.5366118},"labels":[],"label_agreement":null},{"id":"W2904088434","doi":"10.1111/dom.13603","title":"Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Exenatide; Dulaglutide; Liraglutide; Medicine; Discontinuation; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.014719400181179777,"score_gpt":0.22701795383515339,"score_spread":0.2122985536539736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904088434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647385,0.00048471545,0.0000017610437,0.00019788717,0.00008765151,0.0016030562,0.00004325606,0.000062074236,0.0010457485],"genre_scores_gemma":[0.99710387,0.00020098157,0.00042781938,0.0013173352,0.000056270856,0.00013023044,0.00030424455,0.000036989575,0.0004222858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975015,0.000265481,0.0004378186,0.0005638744,0.0004383502,0.0007930018],"domain_scores_gemma":[0.99842113,0.0005601779,0.00026933113,0.00034018623,0.0002200275,0.00018913907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005933013,0.00043439894,0.00081734307,0.00052431144,0.0002922588,0.00011316527,0.00017620334,0.00007616942,0.000017763601],"category_scores_gemma":[0.00016901443,0.00026376394,0.00004633494,0.0010843936,0.00042188895,0.00035737694,0.0001222991,0.00027112727,0.0000039785054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006546648,0.00029120446,0.99416935,0.0001242183,0.00026392034,0.00002565983,0.0023418004,0.000011660668,0.00006661721,0.00004476531,0.00019600215,0.001810131],"study_design_scores_gemma":[0.012137591,0.001019836,0.9802919,0.0011261554,0.00058898696,5.0133036e-7,0.0011881134,0.002185128,0.00022818992,0.000028043176,0.0008499583,0.0003556209],"about_ca_topic_score_codex":0.0010545213,"about_ca_topic_score_gemma":0.011758856,"teacher_disagreement_score":0.013877479,"about_ca_system_score_codex":0.00015634595,"about_ca_system_score_gemma":0.000059728773,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W2904119291","doi":"10.9778/cmajo.20180111","title":"Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials","year":2018,"lang":"en","type":"review","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Waterloo; Memorial University of Newfoundland","funders":"","keywords":"Dapagliflozin; Empagliflozin; Medicine; Placebo; Confidence interval; Meta-analysis; Randomized controlled trial; Internal medicine; Diabetes mellitus; Type 2 diabetes; Odds ratio; Urinary system; Endocrinology; Pathology","score_opus":0.11214542629828925,"score_gpt":0.39350369192733253,"score_spread":0.2813582656290433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904119291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012120482,0.9363902,0.000019924306,0.00012947676,0.00007378881,0.062886655,0.000046109602,0.0000123985665,0.00032021006],"genre_scores_gemma":[0.00060412195,0.985721,0.00021008351,0.00012870455,0.000031785392,0.011789234,0.00022538504,0.00003452187,0.0012551938],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9833111,0.009052642,0.006582299,0.00048288816,0.00035843346,0.00021259482],"domain_scores_gemma":[0.9866382,0.007767847,0.004416029,0.00086273474,0.00019288881,0.000122284],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.041898213,0.0005361257,0.05983032,0.0012667393,0.000033127373,0.000040642746,0.00023075646,0.00020011779,0.00026865755],"category_scores_gemma":[0.006805464,0.0002866654,0.007961089,0.0017927556,0.0000780322,0.00012859308,0.00011174535,0.00014255062,0.000011721189],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03708363,0.0011685803,0.00001145788,0.47882664,0.48147246,0.000026350084,0.00011389153,0.0000036856354,1.7564471e-7,0.000046016517,0.0003355284,0.0009115759],"study_design_scores_gemma":[0.057109173,0.00060419587,0.000018406598,0.15178818,0.78561044,0.0000037410189,0.000006475181,0.000004646072,3.1159533e-7,0.000009666198,0.00468401,0.00016076257],"about_ca_topic_score_codex":0.000101634236,"about_ca_topic_score_gemma":0.000024414732,"teacher_disagreement_score":0.32703847,"about_ca_system_score_codex":0.00010609259,"about_ca_system_score_gemma":0.00018972016,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W2904301413","doi":"10.1093/eurheartj/ehy565.p1877","title":"P1877LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS","year":2018,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Diabetes treatment; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.01703931218675195,"score_gpt":0.24144921196378563,"score_spread":0.22440989977703368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904301413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981079,0.00016932137,7.444492e-7,0.00021932634,0.00011778153,0.00023253747,0.0000079624415,0.000022120246,0.0011222702],"genre_scores_gemma":[0.9987189,0.000084437954,0.00015716051,0.00043647626,0.00010629257,0.0000015765987,0.000031167783,0.000027503898,0.00043644288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917275,0.00010812482,0.00016939218,0.00018350739,0.00016005927,0.00020615032],"domain_scores_gemma":[0.9995592,0.000039483904,0.00006995329,0.00011870394,0.00005801274,0.0001546268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081648024,0.00016278756,0.00028033234,0.00012139283,0.000092064416,0.00006675999,0.000029650826,0.00002021721,0.000071835595],"category_scores_gemma":[0.000026796328,0.00009936316,0.00002663509,0.000070699185,0.000046592257,0.00010028441,0.000040863295,0.00009511823,0.000042407606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005798432,0.0003816273,0.9930861,0.000003662558,0.0002967001,0.00004943816,0.00035351422,8.3070404e-8,0.00003503942,0.0000013895697,0.00036885656,0.00536563],"study_design_scores_gemma":[0.0046843924,0.003593595,0.9883879,0.00015433252,0.00014649458,0.0000013811299,0.00003858926,0.000009317508,0.00009222352,0.000012878535,0.0027743003,0.00010462053],"about_ca_topic_score_codex":0.000018473185,"about_ca_topic_score_gemma":0.000060250655,"teacher_disagreement_score":0.0052610096,"about_ca_system_score_codex":0.00007999756,"about_ca_system_score_gemma":0.000012191876,"threshold_uncertainty_score":0.4051912},"labels":[],"label_agreement":null},{"id":"W2904833368","doi":"10.1126/scitranslmed.aat3392","title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","year":2018,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"Amgen; Howard Hughes Medical Institute","keywords":"Medicine; Obesity; Pharmacology; Internal medicine; Endocrinology; Bioinformatics; Biology","score_opus":0.024498920671132796,"score_gpt":0.3185768657134429,"score_spread":0.2940779450423101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904833368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930376,0.00025098692,0.00072837784,0.0035079473,0.000091748334,0.00066209683,0.0000012396055,0.00001341188,0.0017066236],"genre_scores_gemma":[0.9981364,0.00006183283,0.0015329502,0.00014884792,0.000038347775,0.000013358409,0.0000149818525,0.0000055086866,0.000047772166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855834,0.000027910457,0.00028996886,0.00031660352,0.0005996315,0.0002075521],"domain_scores_gemma":[0.9994132,0.0001526786,0.00006486342,0.00014013879,0.00013176973,0.00009737648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073481805,0.00011074196,0.00033743063,0.00035934596,0.000052880543,0.0000063017205,0.000081657505,0.000032060718,0.000014003015],"category_scores_gemma":[0.00008567015,0.000078383026,0.000014306612,0.00075427507,0.0015177962,0.0002618054,0.000015276337,0.00008315555,0.000001579546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079510437,0.001790554,0.94005567,0.0005669033,0.000047006546,0.00006945334,0.0026846288,0.00010067255,0.022026552,0.01196823,0.000030167832,0.019865032],"study_design_scores_gemma":[0.008322434,0.0015137203,0.9716746,0.0007636933,0.00005867615,0.000005322835,0.000033285673,0.008450571,0.0050880183,0.0039852015,0.00002336329,0.000081075494],"about_ca_topic_score_codex":0.000088861,"about_ca_topic_score_gemma":0.00016922294,"teacher_disagreement_score":0.031618945,"about_ca_system_score_codex":0.000043702654,"about_ca_system_score_gemma":0.00013302526,"threshold_uncertainty_score":0.5592383},"labels":[],"label_agreement":null},{"id":"W2904888518","doi":"10.1093/eurheartj/ehy566.p5334","title":"P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial","year":2018,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.11960218718688803,"score_gpt":0.3676031125616314,"score_spread":0.2480009253747434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904888518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900042,0.00028695274,0.00002230291,0.0005641481,0.0010459463,0.0008360311,0.0000015704089,0.000016329519,0.0072225444],"genre_scores_gemma":[0.99770176,0.000059576443,0.00010009075,0.000453865,0.0013074053,0.0000068333793,0.000004328127,0.000031650445,0.0003344704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969559,0.0012372393,0.00050649757,0.0002146493,0.00075906486,0.00032668686],"domain_scores_gemma":[0.9991357,0.0000983574,0.00014417038,0.00044629094,0.000059290884,0.000116205716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042611775,0.00019290186,0.00047660703,0.00025612875,0.00014151761,0.000016379403,0.00021412522,0.000025436811,0.00007087608],"category_scores_gemma":[0.0002505441,0.000118493,0.0005638497,0.00023805643,0.000040005794,0.00007541714,0.00009669761,0.00036432082,0.00024780416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017902747,0.003590908,0.8854998,0.00020986877,0.002849126,0.00084341405,0.0029244437,0.00004507142,0.0002772373,0.0000845922,0.021852031,0.0639208],"study_design_scores_gemma":[0.043573625,0.008437506,0.88444066,0.00081482367,0.00058914913,0.00010082079,0.00015296695,0.000021446118,0.00021318399,0.000049819257,0.061413534,0.00019248699],"about_ca_topic_score_codex":0.000004471119,"about_ca_topic_score_gemma":0.0000020114921,"teacher_disagreement_score":0.06372832,"about_ca_system_score_codex":0.000118023425,"about_ca_system_score_gemma":0.000027094347,"threshold_uncertainty_score":0.48320043},"labels":[],"label_agreement":null},{"id":"W2905361067","doi":"10.1111/dom.13613","title":"The effects of incretin‐based therapies on β‐cell function and insulin resistance in type 2 diabetes: A systematic review and network meta‐analysis combining 360 trials","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"China Scholarship Council; Cambridge Trust; National Natural Science Foundation of China; National Institute for Health and Care Research","keywords":"Medicine; Incretin; Insulin resistance; Type 2 diabetes; Internal medicine; Placebo; Meta-analysis; Subgroup analysis; Cochrane Library; Lixisenatide; Insulin; Randomized controlled trial; Diabetes mellitus; Confidence interval; Sitagliptin; Exenatide; Gastroenterology; Endocrinology; Pathology","score_opus":0.034934140937823266,"score_gpt":0.2901301820123201,"score_spread":0.25519604107449684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905361067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031630856,0.9914487,0.0000019412457,0.00005811861,0.00016929331,0.0050249933,0.000018406952,0.000027868216,0.00008758189],"genre_scores_gemma":[0.002256942,0.99589634,0.000117229865,0.0005498655,0.000069726804,0.00074798375,0.0000890426,0.000038427097,0.00023445586],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950722,0.0023407824,0.0012902198,0.0005679109,0.00030851946,0.00042037218],"domain_scores_gemma":[0.99322516,0.004700337,0.0011907445,0.00064445205,0.000112030175,0.00012727648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0051994184,0.0006171634,0.010003415,0.00036662634,0.00017499876,0.0000809426,0.00014431887,0.00021294631,0.0000098477485],"category_scores_gemma":[0.0011641433,0.00033779972,0.0008972006,0.0010865126,0.00019584465,0.00006812313,0.00010127406,0.00025864187,0.0000037848436],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032820397,0.00018320291,0.00029585787,0.91848004,0.07412792,0.0000018705799,0.000058766178,1.1686104e-7,6.9028334e-7,0.00035953187,0.00021031855,0.0062488485],"study_design_scores_gemma":[0.0012353753,0.0003549896,0.001249029,0.13107122,0.82105815,6.547768e-8,0.000009654721,0.000007263774,0.0000064320666,0.00025034795,0.04442321,0.0003342804],"about_ca_topic_score_codex":0.00000502254,"about_ca_topic_score_gemma":0.000018277451,"teacher_disagreement_score":0.7874088,"about_ca_system_score_codex":0.000023818564,"about_ca_system_score_gemma":0.000047533846,"threshold_uncertainty_score":0.9999074},"labels":[],"label_agreement":null},{"id":"W2905642444","doi":"10.1002/edm2.53","title":"Progression of glucose‐lowering diabetes therapy in TECOS","year":2018,"lang":"en","type":"article","venue":"Endocrinology Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; St. Michael's Hospital","funders":"Merck Sharp and Dohme; Duke Clinical Research Institute; National Institute for Health and Care Research","keywords":"Diabetes mellitus; Medicine; Internal medicine; Diabetes treatment; Endocrinology; Type 2 diabetes","score_opus":0.013698149717029259,"score_gpt":0.2843375697840944,"score_spread":0.27063942006706515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905642444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98175365,0.011248817,0.00000430885,0.00051681383,0.0006462084,0.0008689991,0.0000065848944,0.00013418117,0.004820446],"genre_scores_gemma":[0.9961593,0.0009658495,0.0012613949,0.0005260578,0.00031942767,0.00025796107,0.000025304971,0.000044617285,0.00044004215],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976616,0.00007967672,0.00050487235,0.0004888486,0.00027022834,0.0009947761],"domain_scores_gemma":[0.99892414,0.000094559706,0.00017614034,0.00056883116,0.00011865016,0.00011765761],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021378946,0.00033371776,0.0008567715,0.00055550376,0.00006377698,0.000014512555,0.00022892532,0.00011519626,0.00043011302],"category_scores_gemma":[0.00009258392,0.0002658717,0.00016986756,0.0004503383,0.00039375946,0.000153049,0.00017523256,0.00021116297,0.0001324989],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008247081,0.00080323464,0.5045899,0.0000945054,0.000437444,0.000023012339,0.00021509238,6.114262e-7,0.13037938,0.0009427546,0.00041745865,0.36201409],"study_design_scores_gemma":[0.0033131528,0.00081911974,0.37655225,0.0001188838,0.000110115274,8.7426224e-7,0.000030836956,0.000034376884,0.5897943,0.00044774258,0.028596967,0.00018139828],"about_ca_topic_score_codex":0.000007184906,"about_ca_topic_score_gemma":0.000006220436,"teacher_disagreement_score":0.4594149,"about_ca_system_score_codex":0.000040609735,"about_ca_system_score_gemma":0.000032397344,"threshold_uncertainty_score":0.9999794},"labels":[],"label_agreement":null},{"id":"W2906235082","doi":"10.1016/j.jval.2018.09.721","title":"PDB15 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Saxagliptin; Empagliflozin; Sitagliptin; Medicine; Sitagliptin Phosphate; Internal medicine; Hazard ratio; Myocardial infarction; Type 2 diabetes; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Diabetes mellitus; Endocrinology; Confidence interval","score_opus":0.03487364832103898,"score_gpt":0.295668107964375,"score_spread":0.26079445964333603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906235082","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12457314,0.86304605,0.00003688182,0.0021397506,0.00061399664,0.0067890217,0.00005042281,0.00010503873,0.0026456676],"genre_scores_gemma":[0.8966347,0.09926003,0.0020736838,0.0009928665,0.00031751537,0.00017639459,0.00011369836,0.000051911662,0.0003792068],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99771917,0.00043913335,0.0008033405,0.00033647078,0.00036541666,0.00033647896],"domain_scores_gemma":[0.9987236,0.00014755463,0.00023377131,0.00060389284,0.000094733434,0.00019644883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016586012,0.00022368316,0.001495214,0.00022950463,0.00006959858,0.000017204893,0.00008032548,0.00007306136,0.000016476648],"category_scores_gemma":[0.00022043366,0.00017287668,0.00021768389,0.0005904028,0.000090314024,0.0000803383,0.000069412104,0.0001725317,0.000021773103],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052515283,0.00081873836,0.013861407,0.950929,0.0031850033,0.00011039926,0.0038463445,0.00004585973,0.000017131006,0.0008239381,0.021908892,0.00392812],"study_design_scores_gemma":[0.017586196,0.00629448,0.02272096,0.91151834,0.005888988,0.00006142481,0.00092730747,0.0009318296,0.00026130254,0.000046660723,0.03299108,0.0007714259],"about_ca_topic_score_codex":0.00022427629,"about_ca_topic_score_gemma":0.000022906961,"teacher_disagreement_score":0.7720615,"about_ca_system_score_codex":0.00022056131,"about_ca_system_score_gemma":0.000104230516,"threshold_uncertainty_score":0.70497066},"labels":[],"label_agreement":null},{"id":"W2906546777","doi":"10.1016/j.jval.2018.09.718","title":"PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Empagliflozin; Semaglutide; Lixisenatide; Liraglutide; Medicine; Dulaglutide; Exenatide; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Hazard ratio; Myocardial infarction; Diabetes mellitus; Cardiology; Pharmacology; Endocrinology; Confidence interval; Agonist; Receptor","score_opus":0.03565310845774038,"score_gpt":0.2958013506025581,"score_spread":0.2601482421448177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906546777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04239016,0.9441875,0.000052471012,0.0026140327,0.0011378708,0.0061611603,0.00006650629,0.00010906714,0.003281228],"genre_scores_gemma":[0.34847638,0.63546664,0.009245972,0.0032201104,0.0005288245,0.00045427162,0.0004259913,0.00012813554,0.002053688],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9975117,0.00048131778,0.00085217314,0.00038571577,0.000384326,0.00038477834],"domain_scores_gemma":[0.99855417,0.00015647462,0.00026832527,0.00070207345,0.000113427195,0.00020555595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014655422,0.00024782334,0.0016591548,0.00020768854,0.00008892044,0.0000209033,0.00011069254,0.000084022126,0.000033676974],"category_scores_gemma":[0.00019748269,0.00019637668,0.00023105677,0.0006211911,0.000103671555,0.000077240955,0.0000719425,0.0001860914,0.00004083206],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069163763,0.0008267109,0.007490894,0.91746825,0.0048615644,0.00006053798,0.003824444,0.000036450565,0.000018574923,0.0013630365,0.058079608,0.005278306],"study_design_scores_gemma":[0.016651632,0.006551019,0.015711552,0.67319715,0.0068252957,0.00006053112,0.0011360412,0.0007319847,0.00020320856,0.000044585777,0.27793792,0.0009490771],"about_ca_topic_score_codex":0.0002820442,"about_ca_topic_score_gemma":0.000027526583,"teacher_disagreement_score":0.3087209,"about_ca_system_score_codex":0.00031825632,"about_ca_system_score_gemma":0.0001476391,"threshold_uncertainty_score":0.80080086},"labels":[],"label_agreement":null},{"id":"W2906946509","doi":"10.1161/circulationaha.118.034516","title":"Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke","year":2018,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Liraglutide; Stroke (engine); Myocardial infarction; Internal medicine; Diabetes mellitus; Cardiology; Type 2 diabetes; Incidence (geometry); Adverse effect; Surgery; Endocrinology","score_opus":0.009596486082514623,"score_gpt":0.21306020249053187,"score_spread":0.20346371640801725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906946509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978673,0.00019937058,0.00005604604,0.0000071037452,0.00020589695,0.0009652064,0.0000015566983,0.000017804949,0.0006797402],"genre_scores_gemma":[0.99937284,0.000012172876,0.00022248316,0.00003840021,0.000040362273,0.000026052207,0.000031680727,0.000019834522,0.00023616965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990363,0.000044858796,0.0001859802,0.00019166368,0.00040069027,0.00014046827],"domain_scores_gemma":[0.9993558,0.000049288494,0.000118466414,0.00027327653,0.00016553277,0.000037624086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104333216,0.00013534422,0.0004674455,0.00020137875,0.000013050858,0.000002557154,0.0000309056,0.000048859118,0.000021207246],"category_scores_gemma":[0.000058465565,0.000080863574,0.00007541719,0.00016388301,0.00008452035,0.00008558073,0.000010714724,0.00004516045,0.000006039635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016107955,0.00036285893,0.9852677,0.00022637645,0.0012155649,0.0000022659724,0.0002369482,0.00012038629,0.00020380774,0.000009347859,0.000025897405,0.01071803],"study_design_scores_gemma":[0.0058599985,0.0030895104,0.9878331,0.00025168524,0.00083913637,1.0871365e-7,0.000012453767,0.000123926,0.0012034234,0.000002773698,0.0006899071,0.00009399657],"about_ca_topic_score_codex":0.000034543576,"about_ca_topic_score_gemma":0.00001755325,"teacher_disagreement_score":0.010624033,"about_ca_system_score_codex":0.00031029794,"about_ca_system_score_gemma":0.00007710236,"threshold_uncertainty_score":0.3297521},"labels":[],"label_agreement":null},{"id":"W2907458346","doi":"10.7326/m18-0567","title":"Fracture Risk After Initiation of Use of Canagliflozin","year":2018,"lang":"en","type":"review","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"National Institute on Aging","keywords":"Medicine; Canagliflozin; Hip fracture; Hazard ratio; Internal medicine; N-terminal telopeptide; Population; Surgery; Type 2 diabetes; Endocrinology; Osteoporosis; Diabetes mellitus; Confidence interval","score_opus":0.1043510563436493,"score_gpt":0.3933590847716739,"score_spread":0.28900802842802464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907458346","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016597939,0.99505,0.00006198268,0.00026332802,0.0002990481,0.00068633433,0.0001511664,0.0000102150725,0.0018180914],"genre_scores_gemma":[0.006270654,0.9911944,0.0001441844,0.0007262236,0.0004197199,0.00003186472,0.00015610084,0.00003668821,0.0010201379],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977655,0.00009743857,0.0012184643,0.00024674705,0.00048052354,0.00019134904],"domain_scores_gemma":[0.99699783,0.0002650501,0.0016128547,0.00049474987,0.0005122987,0.0001172271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037026027,0.0003294851,0.002295678,0.0005397719,0.000007449871,0.0000026234034,0.00016134507,0.00018410479,0.0006760759],"category_scores_gemma":[0.00063389377,0.00020111569,0.00046905133,0.00022596298,0.00024711122,0.00007859657,0.00007401098,0.00022448285,0.000013466418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050659414,0.00048512744,0.0042789346,0.046480242,0.005973301,0.00010423255,0.00040650307,3.033459e-7,0.0000026847993,0.00006531462,0.12879932,0.81289744],"study_design_scores_gemma":[0.0005892472,0.0020307603,0.0011369307,0.084795274,0.004494943,0.000007298445,0.000017659342,0.000002326354,0.00012322479,0.0000419186,0.90664816,0.000112268244],"about_ca_topic_score_codex":0.0013855203,"about_ca_topic_score_gemma":0.000051521693,"teacher_disagreement_score":0.81278515,"about_ca_system_score_codex":0.00002770409,"about_ca_system_score_gemma":0.00008398828,"threshold_uncertainty_score":0.820126},"labels":[],"label_agreement":null},{"id":"W2907603064","doi":"10.14740/jocmr3558","title":"Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Alogliptin; Dipeptidyl peptidase-4 inhibitor; Glycemic; Internal medicine; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; Gastroenterology; Insulin resistance; Thiazolidinedione; Endocrinology; Insulin; Pioglitazone; Dipeptidyl peptidase-4","score_opus":0.04231622901205359,"score_gpt":0.35953615783121906,"score_spread":0.3172199288191655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907603064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993211,0.00026079617,0.000015010662,0.00419531,0.00022026115,0.0019242663,0.000005333373,0.0000075614794,0.0001605061],"genre_scores_gemma":[0.9985909,0.00014668197,0.00048878486,0.000268471,0.00025923038,0.000026313903,0.00004444445,0.000024219142,0.00015097327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657035,0.00022113441,0.0011261286,0.0002474693,0.0015251435,0.0003097875],"domain_scores_gemma":[0.99448675,0.0017758063,0.0007375913,0.00020471007,0.0024411976,0.00035395453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022943849,0.00017271862,0.00093240786,0.00035551892,0.0000521486,0.000012923269,0.000095868716,0.000082409635,0.000028185601],"category_scores_gemma":[0.0012243618,0.00009102065,0.00008665709,0.00034199475,0.0003974313,0.00015355676,0.00004375043,0.00042615592,0.000003089035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014761613,0.0011873096,0.9680527,0.0005660005,0.0006661212,0.0000073047954,0.0003845212,0.0000052402293,0.0013610899,0.00011590317,0.004427917,0.008464312],"study_design_scores_gemma":[0.09215562,0.15442331,0.74246055,0.00464381,0.00082009897,0.0000038224052,0.0008182499,0.0004683435,0.0021981024,0.00034139582,0.0014715035,0.0001951709],"about_ca_topic_score_codex":0.0000061444002,"about_ca_topic_score_gemma":0.0000022525633,"teacher_disagreement_score":0.2255921,"about_ca_system_score_codex":0.00008541,"about_ca_system_score_gemma":0.00018379519,"threshold_uncertainty_score":0.37117144},"labels":[],"label_agreement":null},{"id":"W2908397509","doi":"10.1016/j.diabet.2018.12.001","title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials","year":2019,"lang":"en","type":"review","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Exenatide; Diabetes mellitus; Glycemic; Internal medicine; Weight loss; Clinical trial; Endocrinology; Liraglutide; Obesity","score_opus":0.06618877307589104,"score_gpt":0.3278524107480341,"score_spread":0.26166363767214307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908397509","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07729567,0.91348594,9.410503e-7,0.00016355682,0.00033486562,0.00787134,0.00019995085,0.000036582733,0.00061116886],"genre_scores_gemma":[0.010555152,0.9869188,0.000101434925,0.00020315063,0.00028527982,0.00044135682,0.0007541306,0.0000904827,0.0006501798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939371,0.002147259,0.0014519518,0.0009058371,0.00086312083,0.00069475797],"domain_scores_gemma":[0.99143404,0.005641439,0.0007338325,0.0019127904,0.00014694272,0.0001309729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011564461,0.0011557314,0.010773247,0.0003130145,0.00011851095,0.000099658755,0.0005011634,0.00027196578,0.000040208284],"category_scores_gemma":[0.00020077018,0.00047035248,0.0017994664,0.00079527363,0.0003157713,0.0000731131,0.00011097381,0.00034412747,0.000060010385],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026248753,0.001784253,0.003129505,0.0034591334,0.04619703,0.00014687695,0.004459366,0.00003524049,0.0000022052736,0.00058989896,0.00050872465,0.9394253],"study_design_scores_gemma":[0.00478152,0.0012446461,0.0060641123,0.0029238877,0.0466236,0.0000018874233,0.00057671446,0.000011963628,0.000013590556,0.000055335215,0.937221,0.00048177163],"about_ca_topic_score_codex":0.0001449794,"about_ca_topic_score_gemma":0.00003728926,"teacher_disagreement_score":0.9389435,"about_ca_system_score_codex":0.0001770931,"about_ca_system_score_gemma":0.00024011849,"threshold_uncertainty_score":0.9997748},"labels":[],"label_agreement":null},{"id":"W2908438315","doi":"10.14740/jocmr3706","title":"Does Metformin Assist New Anti-Diabetic Drugs to Succeed?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Diabetes mellitus; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.13907623761459068,"score_gpt":0.5185912547183124,"score_spread":0.3795150171037217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908438315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88795835,0.00060619076,0.00004289698,0.08098626,0.0019015594,0.00083161,8.676501e-7,0.000016698621,0.027655592],"genre_scores_gemma":[0.9390103,0.00090838474,0.0016398806,0.0019008062,0.0039997012,0.0000054079105,0.0000036129422,0.00003627017,0.052495632],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945101,0.00031880394,0.0017614422,0.00032861627,0.0024349387,0.0006460815],"domain_scores_gemma":[0.9941327,0.0026228572,0.00035420983,0.000546363,0.00087780936,0.0014660549],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011483058,0.0001903614,0.0014651386,0.0008241512,0.00005412465,0.000032680873,0.0004212788,0.00014283224,0.0022652282],"category_scores_gemma":[0.0054301736,0.00008689744,0.00035129202,0.00079592207,0.00023106796,0.00015722746,0.00019320883,0.0011894149,0.00073183875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010950754,0.0009253948,0.43905982,0.0002906391,0.00086677406,0.00039485242,0.00034000602,0.000002409897,0.0007354794,0.00067052,0.20620674,0.3494123],"study_design_scores_gemma":[0.015702566,0.01874217,0.31357387,0.0027528384,0.00060475664,0.00003388502,0.0015525648,0.000043136435,0.001551969,0.0019038185,0.6433225,0.00021587378],"about_ca_topic_score_codex":0.000062776344,"about_ca_topic_score_gemma":0.0000045637644,"teacher_disagreement_score":0.43711582,"about_ca_system_score_codex":0.00012681357,"about_ca_system_score_gemma":0.00054623024,"threshold_uncertainty_score":0.99864686},"labels":[],"label_agreement":null},{"id":"W2908676513","doi":"10.1002/ejhf.1419","title":"Empagliflozin Reduces the Risk of a Broad Spectrum of Heart Failure Outcomes Regardless of Heart Failure Status at Baseline","year":2019,"lang":"en","type":"letter","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Relypsa; Astellas Pharma; University of Toronto; Universität des Saarlandes; Universität Heidelberg; Servier; Institut National de la Santé et de la Recherche Médicale; University of Glasgow; Pfizer; Université de Lorraine; Boston Scientific Corporation; Massachusetts General Hospital; Daiichi Sankyo Europe; Sanofi; Cedars-Sinai Medical Center; Amgen; Eli Lilly and Company; AstraZeneca; ResMed","keywords":"Empagliflozin; Medicine; Heart failure; Canagliflozin; Hazard ratio; Internal medicine; Cardiology; Myocardial infarction; Population; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.011497445123190276,"score_gpt":0.23836473681677234,"score_spread":0.22686729169358205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908676513","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27264977,0.002508376,0.000017328128,0.72187895,0.0007733,0.0012816524,0.00041249717,0.000039090242,0.00043904939],"genre_scores_gemma":[0.7576388,0.0014418557,0.050157737,0.14396882,0.009713523,0.000025831248,0.0009172802,0.0012169218,0.03491921],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99154323,0.0021259144,0.0026392047,0.00068314804,0.0019869732,0.0010215242],"domain_scores_gemma":[0.99371696,0.00071052945,0.0028671992,0.0016946944,0.0007190578,0.00029154183],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027998944,0.0009936657,0.0032989273,0.0008727099,0.00014622281,0.00006564883,0.00076485134,0.00033475662,0.00086564827],"category_scores_gemma":[0.0004708097,0.00062622014,0.0019781152,0.00052909605,0.00047915717,0.00023969145,0.00043086382,0.0027752484,0.00018750838],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003869628,0.00032663558,0.058521263,0.0009726889,0.0025793102,0.00028883287,0.00039393007,0.000052522988,0.0025540143,0.000005493833,0.93375355,0.00016479407],"study_design_scores_gemma":[0.0044153356,0.0026341623,0.02027112,0.0024426202,0.0025895194,0.00026708966,0.0006279257,0.000006569224,0.0063870735,0.000013314139,0.95988154,0.0004637187],"about_ca_topic_score_codex":0.00007772652,"about_ca_topic_score_gemma":0.000055478005,"teacher_disagreement_score":0.5779101,"about_ca_system_score_codex":0.00019753611,"about_ca_system_score_gemma":0.00036997945,"threshold_uncertainty_score":0.9996189},"labels":[],"label_agreement":null},{"id":"W2909021772","doi":"10.1016/j.jchf.2018.10.002","title":"Reply","year":2018,"lang":"en","type":"letter","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novo Nordisk; Boehringer Ingelheim; Canadian Diabetes Association","keywords":"Medicine; Type 2 diabetes; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Randomized controlled trial; Internal medicine; Placebo; Clinical trial; Diabetes mellitus; Pharmacology; Meta-analysis; Endocrinology; Alternative medicine; Pathology","score_opus":0.01449649665373301,"score_gpt":0.25482324581787097,"score_spread":0.24032674916413796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909021772","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047555479,0.00014019547,0.000004083707,0.9773105,0.0005302488,0.0007131657,0.00001466513,0.00022200882,0.020589577],"genre_scores_gemma":[0.0001087932,0.0000096111535,0.0035835814,0.8510911,0.010056853,0.00007443146,0.00068562926,0.000073314724,0.13431668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832994,0.000034475986,0.0002371041,0.0005094061,0.00041316875,0.00047592248],"domain_scores_gemma":[0.99881375,0.00003775692,0.00007062577,0.00089447276,0.00009133204,0.000092090864],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000111278045,0.0003227322,0.0005463205,0.00017887371,0.0000619485,0.000052081545,0.00011052738,0.0004877648,0.0023464202],"category_scores_gemma":[0.000035467005,0.0002568273,0.00026622528,0.00013698389,0.00006714396,0.000054428525,0.000089028414,0.0007791193,0.0051142187],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008549876,0.000037798698,0.00080010894,0.00025771244,0.00025946388,0.00038715758,0.00002088666,1.00338235e-8,0.000016748128,0.000007557303,0.99766815,0.0005358793],"study_design_scores_gemma":[0.0006472703,0.0003697939,0.0005529468,0.00024821443,0.00041672593,0.000028815039,0.000008566682,0.0000016556857,0.00011070169,0.00005555922,0.9973354,0.0002243532],"about_ca_topic_score_codex":0.00003166359,"about_ca_topic_score_gemma":0.0000040992722,"teacher_disagreement_score":0.12621939,"about_ca_system_score_codex":0.00010042234,"about_ca_system_score_gemma":0.000073301475,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W2909261189","doi":"10.1097/hco.0000000000000599","title":"Treatment of diabetes and heart failure","year":2019,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"","keywords":"Medicine; Metformin; Diabetes mellitus; Heart failure; Type 2 diabetes; Disease; Intensive care medicine; Liraglutide; Dipeptidyl peptidase-4; Internal medicine; Bioinformatics; Endocrinology","score_opus":0.10340345813929588,"score_gpt":0.39054383108749585,"score_spread":0.28714037294819994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909261189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013199203,0.99508613,0.0000012984732,0.00006137651,0.0027307984,0.0016465721,0.00004822006,0.000018702041,0.00027493498],"genre_scores_gemma":[0.000089879104,0.99835503,0.000051779778,0.000003122976,0.00040110992,0.00031028295,0.00069299305,0.000026926482,0.00006887266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985893,0.00013807967,0.00046411206,0.00043295237,0.000095148134,0.00028042146],"domain_scores_gemma":[0.9992036,0.00015528758,0.00015263123,0.00039653757,0.000024162246,0.00006775221],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008092428,0.00035365307,0.0030841674,0.00034347817,0.000011032852,0.000005190171,0.000056968216,0.0002130375,0.000014331577],"category_scores_gemma":[0.000015143082,0.00024571564,0.00051541935,0.00014766911,0.00008420592,0.000021733867,0.0000679565,0.00011910058,0.00004881561],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003544548,0.00014488681,0.015034987,0.03744682,0.0006078728,0.000001036559,0.00001901719,3.8797134e-7,1.6580204e-7,0.00017517734,0.0035894269,0.94297665],"study_design_scores_gemma":[0.0011080736,0.0008551426,0.0010841578,0.008019145,0.0010916055,0.000009690337,0.000008156316,0.0000016438627,2.6929126e-7,0.000011860022,0.987654,0.00015629028],"about_ca_topic_score_codex":0.0000012944342,"about_ca_topic_score_gemma":1.5444503e-7,"teacher_disagreement_score":0.9840645,"about_ca_system_score_codex":0.00015711214,"about_ca_system_score_gemma":0.000094960764,"threshold_uncertainty_score":0.9999995},"labels":[],"label_agreement":null},{"id":"W2909377024","doi":"10.14740/jem.v8i6.540","title":"Add-On Sitagliptin Therapy for Insulin-Treated Type 2 Diabetes: An Analysis of Hemoglobin A1c and Other Variables Using ASSIST-K Follow-Up Data","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Type 2 diabetes; Internal medicine; Dipeptidyl peptidase-4 inhibitor; Insulin; Diabetes mellitus; Postprandial; Hypoglycemia; Adverse effect; Endocrinology; Gastroenterology","score_opus":0.05998681957741112,"score_gpt":0.3309976549759638,"score_spread":0.27101083539855264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909377024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331224,0.0056251767,0.00011593955,0.0001241886,0.00033047373,0.00021540526,0.000062305175,0.000009165264,0.00020510047],"genre_scores_gemma":[0.99422216,0.0009353901,0.0036706696,0.0006296809,0.00028034474,0.000002784158,0.00004214563,0.000018099405,0.00019869964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892807,0.00007902545,0.0003781939,0.00023655748,0.00012266752,0.00025547628],"domain_scores_gemma":[0.9988612,0.00011127347,0.00032677577,0.00035533065,0.00024077995,0.00010464165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003005899,0.00016674647,0.0007661926,0.000488309,0.000070279304,0.000016993612,0.00013847643,0.00007320871,0.00007757764],"category_scores_gemma":[0.000103411236,0.00011555603,0.00009611502,0.00028998122,0.00015162375,0.0001543227,0.00006193574,0.00009032548,5.7889e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009582294,0.0029389092,0.6428484,0.00018067675,0.051515482,0.00008362813,0.0011814295,0.00003796702,0.07028156,0.008873522,0.0029314759,0.20954467],"study_design_scores_gemma":[0.03391253,0.008017543,0.6741371,0.00023035871,0.040442288,0.00006117931,0.00064017024,0.0054451595,0.037590746,0.0012545598,0.19769351,0.00057484256],"about_ca_topic_score_codex":0.000024730985,"about_ca_topic_score_gemma":0.000016578779,"teacher_disagreement_score":0.20896983,"about_ca_system_score_codex":0.000013125595,"about_ca_system_score_gemma":0.000040343035,"threshold_uncertainty_score":0.47122383},"labels":[],"label_agreement":null},{"id":"W2909436531","doi":"10.2217/cer-2018-0073","title":"A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Insulin glargine; Dulaglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Insulin; Exenatide; Endocrinology","score_opus":0.16141366002993843,"score_gpt":0.457361692122425,"score_spread":0.29594803209248655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909436531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995166,0.0018707525,0.00004689035,0.00014950246,0.00021675018,0.0018048381,0.000015442998,0.0000027891756,0.0007270483],"genre_scores_gemma":[0.99949354,0.00020259478,0.000086043816,0.000018178833,0.000037215155,0.000051321735,0.000025137224,0.000010400745,0.00007557518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974133,0.00069775316,0.000472781,0.0002114965,0.0008348213,0.00036987892],"domain_scores_gemma":[0.9946025,0.0032700375,0.00022632496,0.00025771905,0.0015130496,0.0001303787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026721396,0.0001590423,0.0012180329,0.0008987249,0.00003710423,0.000014460518,0.00018622709,0.0000445351,0.00012660444],"category_scores_gemma":[0.00030828398,0.00011577021,0.00021943101,0.0019123158,0.00007911252,0.000111171044,0.000052124495,0.00033655573,0.0000056280614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03967309,0.0013030457,0.93119174,0.0003393936,0.009177423,0.000036918813,0.0003287312,0.0034675181,0.006445391,0.00028076512,0.0003222367,0.007433753],"study_design_scores_gemma":[0.013436121,0.0063765342,0.9311091,0.00024476845,0.00040975065,4.2953562e-7,0.00046508145,0.010738807,0.03534467,0.00014025785,0.0016323916,0.000102102465],"about_ca_topic_score_codex":0.024260057,"about_ca_topic_score_gemma":0.048290927,"teacher_disagreement_score":0.02889928,"about_ca_system_score_codex":0.0008712355,"about_ca_system_score_gemma":0.0014184725,"threshold_uncertainty_score":0.98223746},"labels":[],"label_agreement":null},{"id":"W2909633566","doi":"10.1016/s0140-6736(18)32840-x","title":"Real-world studies no substitute for RCTs in establishing efficacy","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Johnson and Johnson; Novo Nordisk; Amgen; Boehringer Ingelheim; Novartis; Merck; GlaxoSmithKline; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Abbott Laboratories","keywords":"Real world data; Scopus; Randomized controlled trial; Real world evidence; Medicine; MEDLINE; Library science; Computer science; Political science; Data science; Internal medicine","score_opus":0.06536129345364257,"score_gpt":0.34373913953039126,"score_spread":0.2783778460767487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909633566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9306627,0.00037456458,0.0000022505535,0.0045671067,0.00037730488,0.0009765188,0.000003785784,0.00005694324,0.06297886],"genre_scores_gemma":[0.9648798,0.0005492207,0.0008607689,0.0011161059,0.00065469416,0.000086233566,0.000029152907,0.000015274207,0.03180876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943274,0.000014195493,0.0001039215,0.00013058333,0.00009102286,0.00022751176],"domain_scores_gemma":[0.9993657,0.00021891877,0.0000338227,0.00033051975,0.000030976662,0.00002004553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031762413,0.00008209266,0.0003367884,0.00005314886,0.000026907044,0.000021675321,0.00010579499,0.000012931301,0.000023378196],"category_scores_gemma":[0.00010661855,0.000047684483,0.00003899728,0.00012552028,0.000021745862,0.00007086642,0.00004949731,0.000060596794,0.00016575605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018374798,0.0004780397,0.5719843,0.001583667,0.0013089525,0.000051037787,0.0029018638,0.00017262388,0.0013859814,0.055653132,0.343934,0.018708939],"study_design_scores_gemma":[0.013792284,0.00035314713,0.5418852,0.0006971731,0.00029580144,5.537887e-7,0.00025948815,0.0002985201,0.00077815563,0.0012452551,0.44019356,0.00020088456],"about_ca_topic_score_codex":0.000051585546,"about_ca_topic_score_gemma":0.00017892069,"teacher_disagreement_score":0.09625958,"about_ca_system_score_codex":0.00005913036,"about_ca_system_score_gemma":0.000010630418,"threshold_uncertainty_score":0.2130514},"labels":[],"label_agreement":null},{"id":"W2911139899","doi":"10.3949/ccjm.86a.18039","title":"Should metformin be used in every patient with type 2 diabetes?","year":2019,"lang":"en","type":"article","venue":"Cleveland Clinic Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage College","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.05274907847218869,"score_gpt":0.3188956963858648,"score_spread":0.2661466179136761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911139899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874974,0.0014599521,0.00000961215,0.0042597763,0.00067559694,0.00038121117,0.0000010605571,0.000009502035,0.005705895],"genre_scores_gemma":[0.99352133,0.00046754626,0.00032749897,0.0026444641,0.00021552916,0.0000032775376,0.000012617636,0.000023158742,0.0027845923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981162,0.000047750975,0.00076617935,0.00016722092,0.00061520893,0.00028745818],"domain_scores_gemma":[0.99872035,0.00025524094,0.0004118432,0.00024856944,0.00017139151,0.00019260743],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009495879,0.00018198315,0.0007956416,0.0002981769,0.000014832546,0.0000058935857,0.000108294014,0.00008335304,0.0012665959],"category_scores_gemma":[0.00018449783,0.000099164296,0.00008701748,0.00031274284,0.00008144367,0.00012232682,0.000029927818,0.00035664943,0.000055543755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018817498,0.0007867309,0.91739696,0.00021478564,0.0008985181,0.00086339156,0.00091443915,0.0000096892745,0.0004972018,0.000060538223,0.019101735,0.057374258],"study_design_scores_gemma":[0.08001867,0.07086322,0.65328044,0.0073990542,0.0027682136,0.00038400755,0.0054504713,0.00013814487,0.0014634648,0.000670542,0.17691144,0.0006523223],"about_ca_topic_score_codex":0.000005248737,"about_ca_topic_score_gemma":0.00000842244,"teacher_disagreement_score":0.26411653,"about_ca_system_score_codex":0.00009105381,"about_ca_system_score_gemma":0.00012997481,"threshold_uncertainty_score":0.99964637},"labels":[],"label_agreement":null},{"id":"W29111421","doi":"10.1016/j.jtbi.2017.10.028","title":"Abstract 10606: Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease","year":2013,"lang":"en","type":"article","venue":"Journal of Theoretical Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Manitoba","funders":"","keywords":"Medicine; Dapagliflozin; Type 2 diabetes; Blood pressure; Diabetes mellitus; Disease; Internal medicine; Cardiology; Endocrinology","score_opus":0.0033900763632678387,"score_gpt":0.1935259400915767,"score_spread":0.19013586372830885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W29111421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996938,0.0018552081,0.0000041992926,0.0003524844,0.000059914233,0.00028182328,0.0000017197348,0.0000051686507,0.0005015165],"genre_scores_gemma":[0.9994143,0.00008321995,0.0003325904,0.000062309344,0.00006533695,0.0000055291034,0.000009003475,0.000009019257,0.000018683346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999366,0.000044433255,0.00016804386,0.00012891057,0.00012953402,0.00016311127],"domain_scores_gemma":[0.999476,0.000030771473,0.00006886536,0.00014610447,0.00013018626,0.00014807712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014838587,0.00010169324,0.000297744,0.00008592875,0.000014240897,0.0000120699215,0.000043442524,0.00004680859,0.00012588459],"category_scores_gemma":[0.000052810326,0.000052946158,0.00005414937,0.00006995967,0.00026476834,0.00007224055,0.000020164156,0.0001245612,0.0000039892525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001581283,0.001077678,0.9692139,0.00012996093,0.0053181364,0.000046036985,0.000041029503,0.00004248768,0.00036834416,0.0071211373,0.00021415438,0.014845844],"study_design_scores_gemma":[0.005707077,0.0046240673,0.98099256,0.00020971008,0.0037572854,0.0000065525264,0.000038310372,0.000018322553,0.00033840482,0.0035902888,0.0005941672,0.00012326133],"about_ca_topic_score_codex":0.0000017071955,"about_ca_topic_score_gemma":6.8593025e-8,"teacher_disagreement_score":0.014722583,"about_ca_system_score_codex":0.000007688236,"about_ca_system_score_gemma":0.000020112138,"threshold_uncertainty_score":0.21590815},"labels":[],"label_agreement":null},{"id":"W2911280731","doi":"10.2337/dc18-1959","title":"Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial","year":2019,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Libin Cardiovascular Institute of Alberta; University of Toronto; University of Calgary; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Diabetes mellitus; Internal medicine; Type 2 diabetes; Cardiology; Left ventricular hypertrophy; Endocrinology; Blood pressure","score_opus":0.0072493088525143225,"score_gpt":0.20209358822571816,"score_spread":0.19484427937320384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911280731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872002,0.0050966,6.8668e-8,0.0047056316,0.00032267554,0.0024368356,0.0001222968,0.00002589447,0.00008979396],"genre_scores_gemma":[0.97793293,0.0000591001,0.00003797262,0.020372916,0.00021067154,0.00006225186,0.00079074525,0.00010003552,0.00043335586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717754,0.00016330215,0.00051553885,0.00069498975,0.0008862876,0.00056234346],"domain_scores_gemma":[0.99816406,0.00014735288,0.00023662439,0.0011693538,0.00021448302,0.000068121066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015560082,0.0005856084,0.0021767511,0.00041717032,0.00005589626,0.000047369034,0.00021638894,0.0003774659,0.000024877565],"category_scores_gemma":[0.00011745659,0.00034380145,0.00067050726,0.00035720065,0.00014988451,0.000082660474,0.00022916259,0.000547906,0.000010832547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019271561,0.00010273019,0.987573,0.0011605687,0.0053234673,0.000031051073,0.0001457475,0.000008704854,0.0000012785024,3.919591e-7,0.004530809,0.0009295168],"study_design_scores_gemma":[0.028101955,0.0012035277,0.9379223,0.00040962454,0.009277854,1.7444886e-7,0.000116873576,0.000010005162,0.00005911251,0.0000041538315,0.02242991,0.0004645038],"about_ca_topic_score_codex":0.000023949016,"about_ca_topic_score_gemma":0.000007752269,"teacher_disagreement_score":0.049650714,"about_ca_system_score_codex":0.00012749733,"about_ca_system_score_gemma":0.000050844064,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W2911802341","doi":"10.1186/s12933-019-0806-4","title":"Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction","year":2019,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Internal medicine; Medicine; Endocrinology; Insulin; Cardiac function curve; Myocardial infarction; Ejection fraction; Glucagon; Heart failure; Cardiology","score_opus":0.005062391012950612,"score_gpt":0.20212988281338223,"score_spread":0.19706749180043162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911802341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97972614,0.014511128,0.0003071081,0.0003830718,0.002789057,0.0011323236,0.0000034624986,0.00010843713,0.0010392885],"genre_scores_gemma":[0.9978506,0.00083762687,0.00016001373,0.00027141502,0.00048243444,0.00011224231,0.00008924722,0.000030454297,0.00016598903],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818546,0.00038073494,0.0002198477,0.00051145797,0.00030329375,0.00039918473],"domain_scores_gemma":[0.99913454,0.0001419875,0.000067896006,0.00050601276,0.0000659383,0.00008361369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012313823,0.00023868009,0.0008085237,0.00010065695,0.00015122889,0.000039963114,0.000045176275,0.0001550544,0.000014240647],"category_scores_gemma":[0.00012267887,0.00017659248,0.0008979241,0.00019362231,0.000088021035,0.00016185775,0.00011221156,0.00020925682,0.00011732362],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034882117,0.000167439,0.22672999,0.00037084514,0.037626192,0.000031609983,0.0006093924,0.00020304747,0.3755671,0.00055447145,0.0013603177,0.35643077],"study_design_scores_gemma":[0.007292314,0.0011377445,0.658188,0.00015571176,0.011654954,0.000020296158,0.0016332907,0.00077129994,0.016813532,0.00027358322,0.3011528,0.0009065219],"about_ca_topic_score_codex":0.000054411248,"about_ca_topic_score_gemma":0.0000013029781,"teacher_disagreement_score":0.43145797,"about_ca_system_score_codex":0.00008258344,"about_ca_system_score_gemma":0.00003497935,"threshold_uncertainty_score":0.72012323},"labels":[],"label_agreement":null},{"id":"W2911886982","doi":"10.1111/dom.13666","title":"Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk","keywords":"Medicine; Insulin glargine; Type 2 diabetes; Liraglutide; Insulin; Clinical endpoint; Internal medicine; Adverse effect; Diabetes mellitus; Gastroenterology; Hazard ratio; Randomized controlled trial; Confidence interval; Endocrinology","score_opus":0.014451675164902306,"score_gpt":0.2782371434809578,"score_spread":0.2637854683160555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911886982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863709,0.004552842,0.0000021079256,0.00034855184,0.0011477462,0.0069044945,0.000038087892,0.00008440463,0.00055086403],"genre_scores_gemma":[0.9956104,0.0019377978,0.00031253102,0.0009708724,0.00037386856,0.00029721623,0.00017891549,0.00006298648,0.00025539537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962554,0.0005077132,0.0011486245,0.000792939,0.0005799261,0.0007153841],"domain_scores_gemma":[0.9969969,0.001498791,0.00028315876,0.00064016954,0.00017761298,0.00040336477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020687648,0.00056885846,0.0032103136,0.00048479013,0.000066119355,0.000053029948,0.00021282818,0.0002527576,0.0002230908],"category_scores_gemma":[0.0007498544,0.00040318177,0.00046533323,0.00066678907,0.0002006001,0.00017785894,0.000066907276,0.00037588185,0.00011975893],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8383845,0.004700161,0.1294372,0.00016064837,0.001848461,0.000017786351,0.0007244141,0.000016709313,0.0018044501,0.00029368847,0.00009394722,0.02251802],"study_design_scores_gemma":[0.7504256,0.0056513734,0.22937538,0.00024810687,0.0009965806,1.4177563e-7,0.000055914206,0.000093332936,0.00759255,0.0000315913,0.005146799,0.00038263967],"about_ca_topic_score_codex":0.00008570497,"about_ca_topic_score_gemma":0.00006942727,"teacher_disagreement_score":0.09993819,"about_ca_system_score_codex":0.000048440736,"about_ca_system_score_gemma":0.00020222056,"threshold_uncertainty_score":0.999842},"labels":[],"label_agreement":null},{"id":"W2912265551","doi":"10.1016/j.expneurol.2019.01.016","title":"Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression","year":2019,"lang":"en","type":"review","venue":"Experimental Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Anhedonia; Insulin resistance; Depression (economics); Major depressive disorder; Type 2 Diabetes Mellitus; Mood; Glycemic; Comorbidity; Medicine; Insulin; Cognition; Disease; Psychiatry; Bipolar disorder; Psychology; Bioinformatics; Diabetes mellitus; Schizophrenia (object-oriented programming); Internal medicine; Endocrinology; Biology","score_opus":0.03452853236935606,"score_gpt":0.3537314053645556,"score_spread":0.31920287299519956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912265551","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006203658,0.9851354,0.000003028171,0.00016948127,0.00027248144,0.0070390543,0.00008732345,0.000045804125,0.001043807],"genre_scores_gemma":[0.0029583732,0.9885898,0.00028245655,0.000756366,0.00012193592,0.0036276304,0.00071987434,0.00010064923,0.0028429083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979164,0.0001302083,0.00048655435,0.0008715452,0.00013098017,0.00046430985],"domain_scores_gemma":[0.99908113,0.0002864749,0.00020098287,0.0002861302,0.000015849553,0.00012945471],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010241538,0.000562067,0.001794396,0.00030757056,0.0000492577,0.000018725323,0.000076220844,0.00028282945,0.000064925356],"category_scores_gemma":[0.00001815005,0.00042431342,0.00030768328,0.0001229582,0.0000822897,0.000047789177,0.00013106693,0.00016414668,0.000043117783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00499974,0.006373138,0.0016241473,0.014121595,0.0015374492,0.0010703434,0.00084554456,4.418711e-7,0.000041025003,0.0002265117,0.0060831355,0.96307695],"study_design_scores_gemma":[0.0093147475,0.00816536,0.00024513633,0.0023715491,0.00051494234,0.000040705283,0.000047413534,0.00000854189,0.00013735518,0.00001770976,0.9788313,0.0003052729],"about_ca_topic_score_codex":0.0000149860425,"about_ca_topic_score_gemma":0.000012667347,"teacher_disagreement_score":0.97274816,"about_ca_system_score_codex":0.00022807656,"about_ca_system_score_gemma":0.000102737285,"threshold_uncertainty_score":0.9998209},"labels":[],"label_agreement":null},{"id":"W2912530494","doi":"10.1016/j.orcp.2016.10.078","title":"Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes","year":2019,"lang":"en","type":"article","venue":"Obesity Research & Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Liraglutide; Prediabetes; Medicine; Internal medicine; Weight loss; Endocrinology; Type 2 diabetes; Obesity; Diabetes mellitus","score_opus":0.04604866068584114,"score_gpt":0.3813287754634923,"score_spread":0.3352801147776512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912530494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97749674,0.0002624106,0.000016156748,0.012900806,0.00030090674,0.0032368365,0.000016665284,0.00010345059,0.005666043],"genre_scores_gemma":[0.94429743,0.0006566509,0.00856924,0.0015473043,0.00030805633,0.0001332316,0.00003696338,0.00008191265,0.044369232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924196,0.0011978779,0.0010234632,0.0018113755,0.0020584683,0.0014892397],"domain_scores_gemma":[0.99265337,0.0032782017,0.00024869866,0.0013091005,0.0006743038,0.0018363236],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073456494,0.000534372,0.0010552254,0.0006563309,0.0005061664,0.00030788584,0.00049423514,0.00046569016,0.00027017965],"category_scores_gemma":[0.0035900772,0.00044699965,0.0001741443,0.00087392627,0.00047320814,0.0009855788,0.002098634,0.0013261416,0.0028046453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014825632,0.0014489098,0.93569785,0.00025942983,0.0005255788,0.0006800656,0.0018331379,5.1228824e-7,0.0021284001,0.00004088891,0.031495426,0.011064173],"study_design_scores_gemma":[0.004553532,0.0033282186,0.86815673,0.00066449906,0.00022818931,0.000018286428,0.00021396969,0.000022196395,0.0031801364,0.000067234774,0.119111165,0.00045581922],"about_ca_topic_score_codex":0.00024757086,"about_ca_topic_score_gemma":0.000064657506,"teacher_disagreement_score":0.08761574,"about_ca_system_score_codex":0.0006052773,"about_ca_system_score_gemma":0.0003918,"threshold_uncertainty_score":0.9997982},"labels":[],"label_agreement":null},{"id":"W2912647253","doi":"10.1080/03007995.2019.1576479","title":"The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes","year":2019,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Heart Research Centre; University of Toronto; St. Michael's Hospital; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Heart failure; Kidney disease; Canagliflozin; Cotransporter; Disease; Internal medicine; Sodium; Empagliflozin; Endocrinology","score_opus":0.05041699803246688,"score_gpt":0.391567039502338,"score_spread":0.34115004146987116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912647253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002438032,0.9940983,1.15801804e-7,0.0012360679,0.00043052807,0.0017135448,0.000024872335,0.000008687173,0.000049870538],"genre_scores_gemma":[0.0039664414,0.99501055,0.0000029132968,0.000013497152,0.00026363521,0.0001533919,0.00051835005,0.000023178534,0.000048015438],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716413,0.0002547906,0.00052721275,0.0004370044,0.0010019297,0.00061494554],"domain_scores_gemma":[0.9982055,0.0005045291,0.00007467646,0.00032879057,0.00006938014,0.0008171437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013841324,0.0002500635,0.0009413192,0.00039507874,0.000054061995,0.000032828564,0.00017619271,0.00018238813,0.00005091418],"category_scores_gemma":[0.00075505127,0.00014893239,0.00011399303,0.00049368804,0.00042822817,0.00005665697,0.00020698264,0.0009176929,0.000020246673],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054330965,0.0003261996,0.01346254,0.02724094,0.000052351028,0.00000789745,0.000021307505,7.8078255e-9,7.250625e-7,0.00020189711,0.0038162097,0.95481557],"study_design_scores_gemma":[0.0011151654,0.00051812956,0.0010984248,0.047329634,0.00007736266,4.302859e-7,0.000018202738,0.00004942029,0.000004445401,0.00013887035,0.949537,0.00011293903],"about_ca_topic_score_codex":0.000021528693,"about_ca_topic_score_gemma":0.000033848748,"teacher_disagreement_score":0.9547027,"about_ca_system_score_codex":0.00015761961,"about_ca_system_score_gemma":0.001349543,"threshold_uncertainty_score":0.60732865},"labels":[],"label_agreement":null},{"id":"W2912733453","doi":"10.1111/dom.13649","title":"Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Eli Lilly and Company","keywords":"Population; Medicine; Generalizability theory; Clinical trial; Type 2 diabetes; Internal medicine; Myocardial infarction; Population study; Diabetes mellitus; Demography; Endocrinology; Statistics; Environmental health","score_opus":0.027593446234962127,"score_gpt":0.2704935831468206,"score_spread":0.24290013691185847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912733453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917515,0.004194018,0.000003991698,0.0012880006,0.0005444404,0.0020046895,0.00005081532,0.000031421587,0.00013112758],"genre_scores_gemma":[0.995248,0.00058177084,0.00024881764,0.0026834824,0.00013624295,0.000080415484,0.00059424416,0.000020982598,0.0004059985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738425,0.0007703838,0.0006174622,0.00037673858,0.0004536699,0.00039751935],"domain_scores_gemma":[0.9984778,0.00033867845,0.00016020917,0.00079820555,0.00012763505,0.00009743818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039677266,0.00026501442,0.0011524685,0.00021481716,0.00009722075,0.00006684496,0.00021407985,0.00009020975,0.000075573385],"category_scores_gemma":[0.0003853293,0.00014831818,0.00037306247,0.00057438127,0.000065092834,0.00011848066,0.00011402508,0.00015486215,0.00003901664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054088912,0.000307178,0.9910158,0.00027234704,0.0008704139,7.600185e-7,0.0008485022,0.00049244746,0.00070573424,0.0008795477,0.0013304228,0.0032227407],"study_design_scores_gemma":[0.001629813,0.00014468138,0.85279506,0.000045950324,0.0009733665,9.681021e-8,0.00015483082,0.00022793343,0.0009765828,0.00028702253,0.142598,0.00016665814],"about_ca_topic_score_codex":0.0007101541,"about_ca_topic_score_gemma":0.000029355459,"teacher_disagreement_score":0.14126758,"about_ca_system_score_codex":0.00004150237,"about_ca_system_score_gemma":0.000017725746,"threshold_uncertainty_score":0.604824},"labels":[],"label_agreement":null},{"id":"W2913092931","doi":"10.1136/bmj.l547","title":"Hydration must be maintained in patients taking sodium glucose cotransporter 2 inhibitors","year":2019,"lang":"en","type":"letter","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eagle Ridge Hospital","funders":"","keywords":"Cotransporter; Sodium; Medicine; Computer science; Chemistry; Endocrinology; Internal medicine","score_opus":0.015665244005301567,"score_gpt":0.2537657115270232,"score_spread":0.23810046752172165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913092931","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2561422,0.00006255925,0.000018404628,0.70875585,0.0023182202,0.0055095763,0.000051288163,0.00013618081,0.027005736],"genre_scores_gemma":[0.29231197,0.000015974236,0.00020916651,0.67477226,0.0034875188,0.00025065648,0.010265213,0.00011859088,0.01856863],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814093,0.000039756393,0.0004825637,0.00042171034,0.00050386577,0.00041115875],"domain_scores_gemma":[0.9991431,0.000031698226,0.00029368573,0.00043630594,0.000057182144,0.000037979375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015414756,0.00032557387,0.0004808819,0.0003413789,0.000024651663,0.000030837266,0.00009056696,0.0004131283,0.0002642577],"category_scores_gemma":[0.000026625907,0.00028696645,0.00015504715,0.00013657367,0.000029286673,0.00009956941,0.00003745843,0.0005219922,0.00020156546],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008166199,0.00018454078,0.060277097,0.0003829199,0.00015101793,0.00039203448,0.00013279832,0.0000022925306,0.000013830723,0.00000802986,0.9360368,0.0023369754],"study_design_scores_gemma":[0.0052427854,0.00046664345,0.07538395,0.0006619501,0.00041745216,8.630843e-7,0.000024102908,0.00003943331,0.00018928769,0.000019022462,0.9171751,0.00037941476],"about_ca_topic_score_codex":0.000064383494,"about_ca_topic_score_gemma":0.00002606652,"teacher_disagreement_score":0.036169786,"about_ca_system_score_codex":0.00029141526,"about_ca_system_score_gemma":0.000055011602,"threshold_uncertainty_score":0.9999583},"labels":[],"label_agreement":null},{"id":"W2913306188","doi":"10.1136/bmjopen-2018-022577","title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Memorial University of Newfoundland","funders":"Newfoundland and Labrador Centre for Applied Health Research; Canadian Diabetes Association","keywords":"Dapagliflozin; Medicine; Canagliflozin; Empagliflozin; Relative risk; Internal medicine; Placebo; Meta-analysis; Diabetic ketoacidosis; Acute kidney injury; Randomized controlled trial; Subgroup analysis; Diabetes mellitus; Type 2 diabetes; Confidence interval; Endocrinology; Insulin","score_opus":0.23023346335146838,"score_gpt":0.4550057655896495,"score_spread":0.22477230223818112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913306188","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.942398e-7,0.92298865,0.0000028439354,0.00031240177,0.000033189663,0.06862005,0.00019093024,0.00000874151,0.007842868],"genre_scores_gemma":[0.000015543304,0.97671014,0.00006892029,0.00065455877,0.000016263815,0.005462502,0.0003664458,0.000028175597,0.016677454],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99661624,0.0005910994,0.0016747451,0.00046693385,0.00045612967,0.00019487036],"domain_scores_gemma":[0.9964354,0.00017506402,0.001567092,0.0016430274,0.000096581534,0.000082860824],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0015439552,0.00051069324,0.015726747,0.00015028592,0.000044943,0.000052392574,0.00056339346,0.00010676397,0.00056296523],"category_scores_gemma":[0.000034237288,0.00022283816,0.0033155773,0.0006427867,0.00007266233,0.00009280342,0.00030488454,0.00016334251,0.00013223842],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008040407,0.00008598477,0.000004628452,0.72949,0.26759818,0.000004870457,0.00005713668,6.4809335e-8,1.24191315e-8,0.00005368095,0.0023883912,0.00030902537],"study_design_scores_gemma":[0.0002689705,0.000056713925,0.0000066640496,0.117287084,0.72018707,0.00000416396,0.000019537641,5.2610267e-7,9.678547e-7,0.0000016866684,0.16200346,0.00016314119],"about_ca_topic_score_codex":0.000033861477,"about_ca_topic_score_gemma":0.000025981884,"teacher_disagreement_score":0.6122029,"about_ca_system_score_codex":0.000072108356,"about_ca_system_score_gemma":0.00017148542,"threshold_uncertainty_score":0.9988858},"labels":[],"label_agreement":null},{"id":"W2913716876","doi":"10.1016/j.jcjd.2019.01.005","title":"Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; Alberta Health; University of Calgary","funders":"Canadian Institutes of Health Research; Minnesota Department of Health","keywords":"Medicine; Endothelial dysfunction; Oxidative stress; Metformin; Diabetes mellitus; Type 2 diabetes; Endothelium; Pharmacology; Cotransporter; Endocrinology; Internal medicine; Bioinformatics; Sodium; Biology","score_opus":0.01201620998760196,"score_gpt":0.22322287352951725,"score_spread":0.21120666354191528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913716876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690175,0.0009218176,0.000025704743,0.00050724676,0.00016470514,0.0008244903,0.0002889768,0.000018241386,0.00034704892],"genre_scores_gemma":[0.99712163,0.000021013415,0.0018949647,0.00033044716,0.00023144207,0.0000457976,0.00018893844,0.00005853322,0.000107209635],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840224,0.00004350232,0.00047923697,0.0002986435,0.00019460931,0.00058177346],"domain_scores_gemma":[0.9983199,0.00032784118,0.0004208702,0.00017184668,0.0003118881,0.00044764433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003256697,0.00028010245,0.0005487069,0.00033809047,0.00021357225,0.00010659575,0.000104397644,0.00009786883,0.00004089244],"category_scores_gemma":[0.00018974407,0.00023107383,0.00013438304,0.00020484533,0.00007144799,0.0003293354,0.000011577895,0.00019654585,0.000003722305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000196637,0.00005117647,0.8166578,0.0001563583,0.00079440116,0.0000021426724,0.00046658271,0.000010413429,0.17039041,0.000049662794,0.000190794,0.011210613],"study_design_scores_gemma":[0.02589142,0.009226645,0.35865062,0.0039979485,0.0048089535,0.000012174352,0.0043990132,0.0003828822,0.5848047,0.0002556892,0.0062414785,0.0013284631],"about_ca_topic_score_codex":0.00011109334,"about_ca_topic_score_gemma":0.00033651348,"teacher_disagreement_score":0.45800716,"about_ca_system_score_codex":0.0001621279,"about_ca_system_score_gemma":0.00035112345,"threshold_uncertainty_score":0.94229174},"labels":[],"label_agreement":null},{"id":"W2913881125","doi":"10.14740/jocmr3647","title":"Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Glycemic; Weight loss; Internal medicine; Urology; Endocrinology; Diabetes mellitus; Gastroenterology; Nuclear medicine; Obesity","score_opus":0.05681298702019752,"score_gpt":0.4129391828731296,"score_spread":0.35612619585293204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913881125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958585,0.00043721969,0.0000016247557,0.0015646478,0.00019140926,0.0010207642,0.0000020504715,0.0000051456973,0.00091866835],"genre_scores_gemma":[0.9981466,0.0006193885,0.000504962,0.000059179463,0.00025467435,0.000009531684,0.0000030052065,0.000021705055,0.00038095115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674493,0.00035551065,0.0011657199,0.00026580293,0.0010817137,0.00038629334],"domain_scores_gemma":[0.9969288,0.0009994454,0.00040974043,0.0002491969,0.0010841439,0.0003286384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032399367,0.00016278448,0.0011028167,0.0004439726,0.00003183112,0.000013636942,0.00012195143,0.000087773,0.000105845436],"category_scores_gemma":[0.0023605432,0.00009068947,0.000070647955,0.00053492776,0.0007030555,0.00019726565,0.000074305724,0.0007744921,0.0000058033274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028161348,0.000897032,0.98159665,0.00041966687,0.00032574803,0.0010152785,0.00047717377,0.000002243241,0.00039146518,0.00003465763,0.00023330863,0.011790649],"study_design_scores_gemma":[0.015219875,0.03908718,0.93819964,0.0037131114,0.0002664324,0.000051202256,0.001697424,0.000106941065,0.00064289477,0.00062873325,0.00026144047,0.00012514614],"about_ca_topic_score_codex":0.00004182082,"about_ca_topic_score_gemma":0.000025639183,"teacher_disagreement_score":0.04339702,"about_ca_system_score_codex":0.00009481833,"about_ca_system_score_gemma":0.0002008298,"threshold_uncertainty_score":0.36982095},"labels":[],"label_agreement":null},{"id":"W2914902752","doi":"10.1111/dom.13642","title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre","funders":"Amgen","keywords":"Medicine; Metformin; Type 2 diabetes; Kidney disease; Internal medicine; Diabetes mellitus; Disease; Endocrinology","score_opus":0.005217562185070648,"score_gpt":0.18397353790726192,"score_spread":0.17875597572219126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914902752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98386407,0.014816544,5.5363387e-7,0.00004506616,0.00012138505,0.0010298378,0.000024974388,0.000029916704,0.000067626104],"genre_scores_gemma":[0.9976116,0.0013563465,0.00013738444,0.00035765313,0.00003823602,0.000032348576,0.0001338955,0.000025619891,0.00030692676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867606,0.000052319854,0.00015818187,0.00044514396,0.0002663918,0.0004019271],"domain_scores_gemma":[0.99909973,0.000037013204,0.000042806536,0.00035064755,0.00006167251,0.0004081177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020705361,0.00025629852,0.0006062634,0.00017705749,0.000054907116,0.000039832954,0.000046633766,0.00006126721,0.000025991256],"category_scores_gemma":[0.00007009993,0.00019349476,0.00007075723,0.00018225909,0.00007296963,0.00043067322,0.00012637323,0.000105105486,0.000011158714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005281549,0.00023978838,0.99097246,0.0003890421,0.00066532893,0.000003301419,0.00005418067,0.0000017768753,0.000037895443,0.000111797235,0.000045053213,0.0074265697],"study_design_scores_gemma":[0.0058984226,0.00023647735,0.98198646,0.0002173003,0.0012170137,8.988098e-8,0.000009238848,0.000075059164,0.00018916588,0.00008172848,0.009863688,0.00022533035],"about_ca_topic_score_codex":0.000015748858,"about_ca_topic_score_gemma":0.000002919613,"teacher_disagreement_score":0.013747493,"about_ca_system_score_codex":0.000027485316,"about_ca_system_score_gemma":0.000040382223,"threshold_uncertainty_score":0.78904873},"labels":[],"label_agreement":null},{"id":"W2915555967","doi":"10.1111/dom.13677","title":"Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; Novo Nordisk","keywords":"Liraglutide; Medicine; Mace; Insulin glargine; Hazard ratio; Insulin degludec; Internal medicine; Type 2 diabetes; Diabetes mellitus; Insulin; Proportional hazards model; Endocrinology; Myocardial infarction; Confidence interval; Percutaneous coronary intervention","score_opus":0.009402614858056152,"score_gpt":0.20513423684962048,"score_spread":0.19573162199156433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915555967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739194,0.0015120842,0.0000030301026,0.000014855615,0.00003088645,0.00086513354,0.000050564417,0.000028247803,0.000103265214],"genre_scores_gemma":[0.99885166,0.0002591778,0.0001260029,0.00008916484,0.000011399182,0.000026930016,0.0002325564,0.000028097389,0.00037498714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819976,0.0001401168,0.0003130375,0.00049144856,0.00046009614,0.0003955463],"domain_scores_gemma":[0.9989647,0.000071120434,0.00016124862,0.0004315145,0.00021282348,0.00015859118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037510024,0.0003251057,0.001170397,0.000265796,0.000047735175,0.0000309774,0.00006638727,0.00010976044,0.000029642926],"category_scores_gemma":[0.000085957196,0.00023000083,0.00016247432,0.0005453483,0.000099236866,0.0003156265,0.0000732638,0.00012347188,0.0000044971853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020997929,0.00094451086,0.9920303,0.00011860638,0.0056291013,0.000012586922,0.0000734958,0.000036074845,0.00003450012,0.000013168207,0.000008833591,0.00088884565],"study_design_scores_gemma":[0.00862613,0.00047324348,0.9841616,0.00024844642,0.0046433215,1.0707736e-7,0.000015842166,0.00021317785,0.0011300786,0.000017026283,0.00022019228,0.00025081294],"about_ca_topic_score_codex":0.000514754,"about_ca_topic_score_gemma":0.00016644406,"teacher_disagreement_score":0.008416151,"about_ca_system_score_codex":0.0000427992,"about_ca_system_score_gemma":0.000031039523,"threshold_uncertainty_score":0.9379162},"labels":[],"label_agreement":null},{"id":"W2916296804","doi":"10.1161/circulationaha.118.038868","title":"Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus","year":2019,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":781,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Mace; Internal medicine; Hazard ratio; Diabetes mellitus; Myocardial infarction; Type 2 diabetes; Heart failure; Adverse effect; Stroke (engine); Type 2 Diabetes Mellitus; Endocrinology; Confidence interval; Percutaneous coronary intervention","score_opus":0.0252476773952434,"score_gpt":0.2997879082580648,"score_spread":0.27454023086282137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916296804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31613904,0.6805728,0.000016879761,0.0000041133717,0.00028433572,0.0029492131,0.000012897647,0.0000050959775,0.000015633614],"genre_scores_gemma":[0.45992994,0.5392696,0.00016514376,0.0000037773202,0.000030603136,0.000108038825,0.0003740729,0.000032570082,0.00008620408],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99864066,0.00009568203,0.00064045476,0.00025865348,0.00023137237,0.00013318338],"domain_scores_gemma":[0.99891305,0.00015363356,0.0004956072,0.0003307004,0.00007552655,0.00003150489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002461034,0.00022238548,0.0017220669,0.00016956191,0.000018108507,0.0000036879846,0.00005270968,0.0001564597,0.0000026161217],"category_scores_gemma":[0.000053785952,0.00015594695,0.00058394944,0.00016829683,0.00007424159,0.000056971192,0.000028299199,0.00007805553,6.966515e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057528396,0.0004291411,0.2031314,0.14935154,0.0037253117,6.439941e-7,0.00031631126,0.000016961489,0.0005622267,0.00005472312,0.00005732925,0.6422969],"study_design_scores_gemma":[0.014441354,0.0017559023,0.6086962,0.09420987,0.06203105,0.0000016827681,0.00012037814,0.00019533315,0.010338263,0.00013684589,0.20714255,0.00093054073],"about_ca_topic_score_codex":0.000012476344,"about_ca_topic_score_gemma":0.0000056991785,"teacher_disagreement_score":0.64136636,"about_ca_system_score_codex":0.00006208758,"about_ca_system_score_gemma":0.00004919165,"threshold_uncertainty_score":0.63593316},"labels":[],"label_agreement":null},{"id":"W2916549936","doi":"10.1111/dom.13675","title":"Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Cilag; Esperion Therapeutics; Servier; Sanofi; Kowa Company; Novo Nordisk; Medicines Company; European Foundation for the Study of Diabetes; AstraZeneca; Eli Lilly and Company; Amgen; Pfizer; Steno Diabetes Center Copenhagen; American Diabetes Association","keywords":"Medicine; Insulin degludec; Liraglutide; Basal insulin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Basal (medicine); Insulin; Endocrinology","score_opus":0.003049679341641157,"score_gpt":0.17336434118006108,"score_spread":0.17031466183841992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916549936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235874,0.0053133327,0.000003196331,0.000047620186,0.00019004483,0.001577563,0.000027843911,0.000032420645,0.00044922662],"genre_scores_gemma":[0.9983239,0.0008004075,0.00031974103,0.0002223405,0.000030438843,0.000043128683,0.000116321666,0.000029193556,0.000114536015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982382,0.0001630412,0.00035110512,0.00045889095,0.00041829122,0.0003704424],"domain_scores_gemma":[0.9989679,0.00015021401,0.0001819528,0.00039669508,0.00017057669,0.00013265824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005669933,0.000308676,0.0009866371,0.00032581037,0.00006260333,0.000035570876,0.00007835152,0.00012200587,0.000013688215],"category_scores_gemma":[0.00018025705,0.00023979253,0.00013165928,0.00032638776,0.0001007199,0.00022764613,0.00008043847,0.00019375025,0.000009263559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048628755,0.00077930465,0.9661684,0.0002331884,0.001179697,0.0000013743194,0.00012134273,0.000031829415,0.00033523695,0.00021549824,0.00003109973,0.030416736],"study_design_scores_gemma":[0.018199189,0.0012866437,0.97551656,0.00017045604,0.0009958863,2.675225e-8,0.000035333516,0.000482419,0.0022987386,0.00018949845,0.0005883174,0.00023691816],"about_ca_topic_score_codex":0.00007018397,"about_ca_topic_score_gemma":0.000012449782,"teacher_disagreement_score":0.030179817,"about_ca_system_score_codex":0.00003898588,"about_ca_system_score_gemma":0.000036456186,"threshold_uncertainty_score":0.97784555},"labels":[],"label_agreement":null},{"id":"W2916824239","doi":"10.1016/j.jacbts.2018.11.010","title":"Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction","year":2019,"lang":"en","type":"article","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Cardiology; Heart failure; Ejection fraction; Preload; Afterload; Internal medicine; Ranolazine; Heart failure with preserved ejection fraction; Rodent model; Diastole; Glycemic; Hemodynamics; Diabetes mellitus; Type 2 diabetes; Blood pressure; Insulin; Endocrinology","score_opus":0.012117758835187868,"score_gpt":0.242214085202484,"score_spread":0.23009632636729613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916824239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922289,0.000018083783,0.0037210414,0.0018267496,0.00007405559,0.0009803118,0.000003912454,0.000026764319,0.0011201288],"genre_scores_gemma":[0.99479485,0.0000012961443,0.0045551895,0.00018784382,0.000023724613,0.00007002826,0.000012280188,0.000008977959,0.0003457996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986133,0.0000142196095,0.00019760134,0.0003506706,0.00059923396,0.00022496798],"domain_scores_gemma":[0.9995239,0.000028597418,0.000053648622,0.00019916538,0.00010195125,0.000092782866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029110312,0.00011202779,0.00018605945,0.00038143998,0.000047173293,0.000022919088,0.0000768636,0.00003584875,0.0000849075],"category_scores_gemma":[0.00001327892,0.00008998231,0.00004451147,0.0008338735,0.000060192873,0.000523952,0.000014723292,0.00008257528,0.000042936175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005522095,0.0005123602,0.65745014,0.00012815229,0.000035237743,5.819573e-7,0.0003290893,0.049176503,0.28649044,0.0008326108,0.00012604939,0.0043666544],"study_design_scores_gemma":[0.0015080806,0.00065275375,0.93557733,0.00010870583,0.00006203819,6.769381e-7,0.0000975075,0.05418978,0.00702519,0.0002627002,0.00040380188,0.000111412206],"about_ca_topic_score_codex":0.00008639449,"about_ca_topic_score_gemma":0.00017311543,"teacher_disagreement_score":0.27946526,"about_ca_system_score_codex":0.00010740064,"about_ca_system_score_gemma":0.00015895134,"threshold_uncertainty_score":0.36693725},"labels":[],"label_agreement":null},{"id":"W2917774200","doi":"10.1186/s12933-019-0812-6","title":"Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible","year":2019,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Medicine; Myocardial infarction; Angiology; Internal medicine; Incidence (geometry); Cardiology; Diabetes mellitus; Endocrinology","score_opus":0.008372521100008998,"score_gpt":0.2161852685534618,"score_spread":0.2078127474534528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917774200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947337,0.002895449,0.000052196625,0.00022360725,0.00022233216,0.0011909084,0.0000014339071,0.000023629858,0.00065675273],"genre_scores_gemma":[0.99895406,0.00055302185,0.00012191544,0.000080718186,0.00010232217,0.00010688093,0.00003112462,0.000014661742,0.0000353214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986962,0.00014173117,0.00025554522,0.00032913365,0.00034417902,0.00023320914],"domain_scores_gemma":[0.9993173,0.000040613166,0.00007579588,0.00044905528,0.000070127506,0.00004710039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006280905,0.00015879546,0.00061065133,0.00018553862,0.000026955258,0.000011523531,0.00007392652,0.00011373945,0.000013842774],"category_scores_gemma":[0.000016549671,0.000108925844,0.0002447535,0.0002692855,0.00016771065,0.00014221777,0.00002904685,0.00016353367,0.000010489462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022768741,0.00016630992,0.97730976,0.0003052963,0.002335113,0.000051809096,0.0012001023,0.0002561733,0.002487609,0.00020470886,0.000089333415,0.01536607],"study_design_scores_gemma":[0.0041389577,0.00067558204,0.9855728,0.00025679893,0.0016184506,0.00009634559,0.0007617215,0.00007340566,0.0031417354,0.000066893685,0.0034320091,0.00016528161],"about_ca_topic_score_codex":0.0001691599,"about_ca_topic_score_gemma":0.000025381152,"teacher_disagreement_score":0.015200789,"about_ca_system_score_codex":0.000057249887,"about_ca_system_score_gemma":0.00004353696,"threshold_uncertainty_score":0.4441867},"labels":[],"label_agreement":null},{"id":"W2918407168","doi":"10.1016/s2213-8587(19)30066-x","title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Placebo; Dulaglutide; Internal medicine; Diabetes mellitus; Randomized controlled trial; Concomitant; Clinical trial; Exenatide; Liraglutide; Endocrinology","score_opus":0.0164886080544158,"score_gpt":0.2803438125386376,"score_spread":0.2638552044842218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918407168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630746,0.0013413014,4.0845396e-7,0.011454756,0.0011725813,0.01084994,0.0000066872267,0.00019780063,0.0119019],"genre_scores_gemma":[0.97990197,0.00032923103,0.00009725868,0.0104471175,0.0009593444,0.0020841989,0.000031598556,0.00006976811,0.0060795164],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958256,0.00046965084,0.0006064998,0.0006705877,0.0003703593,0.0020573158],"domain_scores_gemma":[0.9969357,0.0015911616,0.00018809573,0.0010335725,0.00008702567,0.00016440554],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009386988,0.00049657,0.0019042997,0.00038561947,0.00008385979,0.00005251369,0.0004627237,0.00012440821,0.0005126961],"category_scores_gemma":[0.0006475138,0.0003198491,0.0002783139,0.00046612075,0.00011161976,0.00007002243,0.00018136557,0.00045710878,0.0014168224],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87602067,0.0012005686,0.050915,0.00012192849,0.0017383607,0.0001107223,0.0005276418,0.00015080818,0.009858521,0.0028346928,0.017728532,0.03879254],"study_design_scores_gemma":[0.92367977,0.01015401,0.0048416965,0.00020181407,0.00026082498,0.000001795885,0.0002017285,0.00014690771,0.0095445365,0.00076623145,0.049758945,0.0004417213],"about_ca_topic_score_codex":0.000025963162,"about_ca_topic_score_gemma":0.000020383206,"teacher_disagreement_score":0.047659107,"about_ca_system_score_codex":0.00020308973,"about_ca_system_score_gemma":0.000111176254,"threshold_uncertainty_score":0.9999254},"labels":[],"label_agreement":null},{"id":"W2918530247","doi":"10.1161/circulationaha.118.038339","title":"Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality","year":2019,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Heart failure; George (robot); Internal medicine; Diabetes mellitus; Art history","score_opus":0.008844088568384749,"score_gpt":0.23239800178057266,"score_spread":0.2235539132121879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918530247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9442486,0.00009407649,0.0000926776,0.053720538,0.00016074517,0.0010935852,0.00014155677,0.000055665154,0.00039255846],"genre_scores_gemma":[0.94182235,0.000024560954,0.00010967658,0.051480263,0.00022249656,0.00002698559,0.005297019,0.000054749682,0.000961927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882996,0.000054959022,0.00021924169,0.00034035605,0.00038629578,0.00016915823],"domain_scores_gemma":[0.9989967,0.00003957684,0.00034123712,0.00036344928,0.00023173347,0.000027331465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114963375,0.0002192282,0.00046236903,0.00014022039,0.000033365242,0.00002504981,0.000033025124,0.00034730972,0.00009783674],"category_scores_gemma":[0.00005483842,0.00018186602,0.00010248522,0.00016731443,0.000044412696,0.000112446214,0.000020693164,0.00023805829,0.000014987311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022908182,0.00006581637,0.71224797,0.0002267728,0.0019735305,0.000025798117,0.00013543553,0.000011189574,0.000069736474,0.0000053019153,0.28513062,0.00008491151],"study_design_scores_gemma":[0.0015504225,0.0004107717,0.96110404,0.00044465993,0.0042451355,0.0000028523887,0.000013393764,0.00044195264,0.000045176286,0.000038630238,0.0314769,0.00022604998],"about_ca_topic_score_codex":0.000051139465,"about_ca_topic_score_gemma":0.000010227264,"teacher_disagreement_score":0.25365373,"about_ca_system_score_codex":0.00010581842,"about_ca_system_score_gemma":0.0000425385,"threshold_uncertainty_score":0.7416281},"labels":[],"label_agreement":null},{"id":"W2919368874","doi":"10.1161/circulationaha.119.039996","title":"Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Deutsche Forschungsgemeinschaft; Fundação Lemann; Foundation for Cardiovascular Research; Harvard University","keywords":"Medicine; Dapagliflozin; Myocardial infarction; Internal medicine; Cardiology; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology","score_opus":0.005917200605202615,"score_gpt":0.19798099814340805,"score_spread":0.19206379753820543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919368874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738705,0.0011427336,0.0000061966316,0.000034555094,0.00009218453,0.00079593837,8.0948007e-7,0.000021849652,0.00051869155],"genre_scores_gemma":[0.99966836,0.00008016199,0.000059158585,0.000058010915,0.000016191394,0.000012864638,0.00006158268,0.0000106562775,0.000033016546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999417,0.000021286463,0.00009559518,0.00018905646,0.00016820146,0.00010882543],"domain_scores_gemma":[0.9997199,0.00001371393,0.000024590485,0.00016933883,0.0000367972,0.000035642952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092695205,0.00008955032,0.00023763707,0.00009128055,0.000016820273,0.00001652254,0.0000110551055,0.000037303893,0.00000896181],"category_scores_gemma":[0.0000132171535,0.00007004663,0.000033318607,0.00009438444,0.000016357024,0.000115029026,0.000016261936,0.000036902486,0.000010388654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027143607,0.000049278136,0.97500914,0.00005820741,0.0004075572,5.238e-7,0.00007007129,0.000089607674,0.000019178062,0.00003281709,0.000006021211,0.024230449],"study_design_scores_gemma":[0.0027965,0.00016920624,0.99580026,0.00004162655,0.00029520103,1.5781616e-7,0.000012919646,0.00020769757,0.000010050065,0.000033206677,0.00055600045,0.00007719258],"about_ca_topic_score_codex":0.000012320878,"about_ca_topic_score_gemma":0.000001550032,"teacher_disagreement_score":0.024153257,"about_ca_system_score_codex":0.000036685367,"about_ca_system_score_gemma":0.0000067075625,"threshold_uncertainty_score":0.28564188},"labels":[],"label_agreement":null},{"id":"W2919371810","doi":"10.1111/dom.13687","title":"Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Exeter Clinical Research Facility; Medical Research Council; National Institute for Health and Care Research; Medical Research Council Canada; Department of Health and Social Care; Wellcome Trust","keywords":"Medicine; Discontinuation; Type 2 diabetes; Metformin; Medical prescription; Blood pressure; Weight loss; Diabetes mellitus; Population; Internal medicine; Confidence interval; Endocrinology; Pharmacology; Obesity","score_opus":0.012478294501780693,"score_gpt":0.23634766540505767,"score_spread":0.22386937090327697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919371810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838645,0.009913473,2.829948e-7,0.000021663369,0.00010215254,0.00036105126,0.00058745284,0.000024508661,0.00060294376],"genre_scores_gemma":[0.9970527,0.0009274164,0.00016769918,0.000025499636,0.000019627452,0.00000588762,0.0010598684,0.000017876933,0.0007233969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983327,0.00017640393,0.0003522648,0.0005340542,0.0002786126,0.00032597064],"domain_scores_gemma":[0.99851286,0.00020569278,0.0002591375,0.00079875306,0.0001152513,0.00010831775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061136665,0.00025097525,0.0012919063,0.0010118616,0.000041954638,0.000019199706,0.00017180211,0.00011661106,0.00007158546],"category_scores_gemma":[0.00010208471,0.00021111882,0.00013006951,0.0009067806,0.00015751536,0.00028638556,0.00031748426,0.00016000734,0.0000041062453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019695963,0.00021276814,0.9849832,0.00023145489,0.0022582335,0.0000012853537,0.0018919243,0.00000602067,0.0059678596,0.00002244157,0.00012283257,0.0041049905],"study_design_scores_gemma":[0.0017474025,0.00023638087,0.9867385,0.0001324006,0.006075317,3.8560618e-8,0.0003056094,0.0006468715,0.003454622,0.000017946337,0.00046728746,0.00017762509],"about_ca_topic_score_codex":0.00018523994,"about_ca_topic_score_gemma":0.000017898305,"teacher_disagreement_score":0.008986057,"about_ca_system_score_codex":0.000054335917,"about_ca_system_score_gemma":0.000036246187,"threshold_uncertainty_score":0.86091757},"labels":[],"label_agreement":null},{"id":"W2919557056","doi":"10.1016/s0735-1097(19)32386-1","title":"CARDIOVASCULAR OUTCOMES AND MORTALITY AFTER INITIATION OF CANAGLIFLOZIN VERSUS NON-SGLT2I ANTIHYPERGLYCEMIC AGENTS: ADDITIONAL ANALYSES FROM THE EASEL POPULATION-BASED COHORT STUDY","year":2019,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Canagliflozin; Myocardial infarction; Internal medicine; Diabetes mellitus; Cohort; Stroke (engine); Type 2 diabetes; Heart failure; Population; Cardiology; Endocrinology; Environmental health","score_opus":0.023656000883314193,"score_gpt":0.302125563444178,"score_spread":0.2784695625608638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919557056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774444,0.00021355324,0.000029112547,0.0002110056,0.00032057252,0.00060331763,0.00066510204,0.0000026759992,0.00021020809],"genre_scores_gemma":[0.99943274,0.000041098454,0.00011059346,0.00019903242,0.00011110532,0.000018306979,0.00005549676,0.000009799546,0.000021827622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844754,0.0003110674,0.0004633318,0.0001470699,0.00051616185,0.000114810246],"domain_scores_gemma":[0.99824417,0.00043081352,0.00061158335,0.00045880117,0.00020930565,0.0000453009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003985271,0.00013389789,0.0010935132,0.00011048513,0.0000342026,0.0000036406366,0.00014240587,0.000027313761,0.00007852662],"category_scores_gemma":[0.00014812028,0.00007451648,0.0006109663,0.00023253658,0.00014775312,0.000052275125,0.000054405282,0.000101984064,9.949771e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008790374,0.000083241765,0.9851821,0.000012224848,0.011050207,0.000039536597,0.000016686072,0.0014230058,0.000037321715,0.0000028607271,0.001164834,0.000108960805],"study_design_scores_gemma":[0.0031993322,0.00076383783,0.990257,0.000039734565,0.004741947,0.000005370162,0.00051887386,0.00007863378,0.00002606995,0.000013466916,0.00029277804,0.00006290976],"about_ca_topic_score_codex":0.00091750117,"about_ca_topic_score_gemma":0.00008205899,"teacher_disagreement_score":0.00630826,"about_ca_system_score_codex":0.00009536308,"about_ca_system_score_gemma":0.00012048547,"threshold_uncertainty_score":0.3038694},"labels":[],"label_agreement":null},{"id":"W2919787870","doi":"10.1111/dom.13682","title":"Trial design and baseline data for LIRA‐PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GRi Simulations (Canada); Surrey Memorial Hospital","funders":"Novo Nordisk; American Diabetes Association","keywords":"Medicine; Liraglutide; Clinical endpoint; Randomized controlled trial; Type 2 diabetes; Metformin; Overweight; Internal medicine; Diabetes mellitus; Glycated hemoglobin; Pediatrics; Insulin; Obesity; Endocrinology","score_opus":0.02199204367663652,"score_gpt":0.26251990096163225,"score_spread":0.24052785728499573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919787870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97561544,0.014104849,0.000025781645,0.00021869935,0.0002771355,0.009655585,0.000028316497,0.000020136711,0.000054025404],"genre_scores_gemma":[0.9942483,0.00042553328,0.004094172,0.00039662156,0.00018957803,0.00028016965,0.00031102673,0.000026952215,0.000027658922],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973188,0.0006735543,0.0008067834,0.0005186021,0.00021857496,0.0004636989],"domain_scores_gemma":[0.99517184,0.003945939,0.00024189045,0.00048604477,0.000068026566,0.00008628119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005343049,0.0002750575,0.0016074756,0.0003012673,0.000051602605,0.000045087967,0.00019890274,0.0001291421,0.0000038680605],"category_scores_gemma":[0.003215324,0.00019644338,0.00010651715,0.00034340174,0.00014610992,0.00019666235,0.00022698875,0.00024922017,8.704265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82166684,0.0010282886,0.12553734,0.0017086599,0.00059013977,0.0000056724543,0.0023016615,0.00024325833,0.00517934,0.000315808,0.00004634356,0.041376635],"study_design_scores_gemma":[0.94820416,0.0004201592,0.019203467,0.0006952749,0.0007245733,8.087613e-8,0.0001566019,0.028688366,0.0012693666,0.0002785851,0.00015482226,0.00020456042],"about_ca_topic_score_codex":0.000076744276,"about_ca_topic_score_gemma":0.000028233791,"teacher_disagreement_score":0.1265373,"about_ca_system_score_codex":0.00004472197,"about_ca_system_score_gemma":0.00014520834,"threshold_uncertainty_score":0.80107284},"labels":[],"label_agreement":null},{"id":"W2920089634","doi":"10.1016/s0735-1097(19)32643-9","title":"THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME","year":2019,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; EMPA; Type 2 diabetes; Disease; Post-hoc analysis; Internal medicine; Diabetes mellitus; Macrovascular disease; Post hoc; Cardiology; Endocrinology","score_opus":0.006862023867410504,"score_gpt":0.24802530054440797,"score_spread":0.24116327667699747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920089634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966521,0.0021600875,0.000002132546,0.00053018826,0.00014531224,0.00037947868,0.000030822826,0.0000018361142,0.000098003795],"genre_scores_gemma":[0.9990046,0.00062463124,0.000037638252,0.00017548147,0.000027784146,0.0000038066796,0.0000022235465,0.000011631684,0.00011218453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998061,0.00037694565,0.0007046505,0.00014778158,0.0004967446,0.00021286619],"domain_scores_gemma":[0.997582,0.00025409885,0.000866041,0.0008448827,0.00037798865,0.00007495126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009036184,0.00014995449,0.0017919492,0.00043298063,0.000021883126,0.000001232618,0.0003836915,0.000027351993,0.0000036617544],"category_scores_gemma":[0.00031131716,0.00008128909,0.0019775466,0.0012154061,0.0002876593,0.000036277906,0.000109228415,0.00014593765,0.000001914771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012504334,0.000098867655,0.9408373,0.000071450224,0.021528479,0.00004112585,0.000022705935,0.034063496,0.0013381637,0.00003576749,0.00008155178,0.0006306443],"study_design_scores_gemma":[0.0014823144,0.0016609535,0.9869063,0.00013165861,0.0075044637,0.0000052249416,0.00023211938,0.000039336403,0.00024293347,0.000020845777,0.0017038392,0.00006999711],"about_ca_topic_score_codex":0.000021491296,"about_ca_topic_score_gemma":0.000004503739,"teacher_disagreement_score":0.046069,"about_ca_system_score_codex":0.00010303397,"about_ca_system_score_gemma":0.00013255191,"threshold_uncertainty_score":0.3314873},"labels":[],"label_agreement":null},{"id":"W2920491590","doi":"10.1177/2235042x19831918","title":"Nonconventional diabetes-related care strategies for patients with chronic kidney disease: A scoping review of the literature","year":2019,"lang":"en","type":"review","venue":"Journal of Comorbidity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Lawson Health Research Institute; Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research; Sanofi; Diabetes Canada; AstraZeneca","keywords":"Medicine; Diabetes mellitus; Observational study; Intensive care medicine; Glycemic; Kidney disease; Randomized controlled trial; Dialysis; Internal medicine","score_opus":0.024403852751168038,"score_gpt":0.32349441508467364,"score_spread":0.2990905623335056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920491590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016836105,0.9946645,0.0000035316837,0.00012116122,0.0006577668,0.003926879,0.00027360284,0.0000058657392,0.00017831755],"genre_scores_gemma":[0.00026639795,0.9983071,0.000061973966,0.00012970652,0.00018215527,0.00006166563,0.000750688,0.000034894107,0.00020540938],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980132,0.00012582162,0.0009054467,0.00017935476,0.0005722835,0.00020389564],"domain_scores_gemma":[0.996774,0.00009978908,0.0018186123,0.00040495372,0.00073255034,0.00017006963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024780733,0.00032528435,0.0018886542,0.00012612766,0.000048511363,0.000037552265,0.0002615257,0.000103765626,0.00009052443],"category_scores_gemma":[0.000117294825,0.0001606345,0.001333143,0.00028538195,0.00005863416,0.00016711734,0.00006661758,0.00035979433,0.0000032420128],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003430783,0.00025977686,0.0010076114,0.9282187,0.0013934474,0.000007356656,0.000023180757,8.06783e-7,3.543629e-8,0.00006979528,0.004662847,0.06432212],"study_design_scores_gemma":[0.0015117198,0.0006216567,0.00047434674,0.72826046,0.008166877,0.0000023216833,0.000003072421,5.126658e-7,2.2462967e-7,0.000020034779,0.26082554,0.00011327455],"about_ca_topic_score_codex":2.9491466e-7,"about_ca_topic_score_gemma":6.2676355e-7,"teacher_disagreement_score":0.25616267,"about_ca_system_score_codex":0.000311772,"about_ca_system_score_gemma":0.0031105694,"threshold_uncertainty_score":0.6550485},"labels":[],"label_agreement":null},{"id":"W2920867884","doi":"10.14740/jocmr3761","title":"Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Disease; Type 2 diabetes; Kidney disease; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.029200310453615052,"score_gpt":0.37664525482750394,"score_spread":0.3474449443738889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920867884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936514,0.002643757,1.04097275e-7,0.0009130639,0.00042308302,0.0016326382,0.00010379142,0.000007753035,0.00062443205],"genre_scores_gemma":[0.9962233,0.0015513647,0.00008801607,0.00012464527,0.0011841439,0.00003496677,0.00044123264,0.000032800763,0.00031954568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575084,0.00054054224,0.0012009421,0.0003930899,0.0016818319,0.00043277378],"domain_scores_gemma":[0.9941694,0.0029678163,0.00059931166,0.0003852502,0.001187679,0.0006905335],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014626225,0.00022969613,0.0012497017,0.00058987224,0.000037999136,0.000016293303,0.00015025292,0.000092922295,0.0009842428],"category_scores_gemma":[0.0039215195,0.00013250795,0.00014890938,0.0005276104,0.00047306044,0.00015187537,0.000097441574,0.0007631298,0.000009944175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005418103,0.0013338088,0.97493213,0.00060419686,0.0007210997,0.00024651655,0.00033881725,3.5115272e-7,0.00017120001,0.0000044888443,0.006307739,0.00992153],"study_design_scores_gemma":[0.02572145,0.015954524,0.94560605,0.00632822,0.00018476158,3.0833948e-7,0.00019051491,0.0000061103165,0.00049816683,0.00012811658,0.0052671153,0.00011468188],"about_ca_topic_score_codex":0.00005015366,"about_ca_topic_score_gemma":0.000024905987,"teacher_disagreement_score":0.029326119,"about_ca_system_score_codex":0.00022348508,"about_ca_system_score_gemma":0.0005721198,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W2921059178","doi":"10.1161/atvb.38.suppl_1.257","title":"Abstract 257: Apabetalone (RVX-208) Reduces Pathologic Cell-Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and Mouse Aorta","year":2018,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Resverlogix (Canada)","funders":"","keywords":"Inflammation; Cell adhesion molecule; Medicine; Endothelium; Tumor necrosis factor alpha; Proinflammatory cytokine; Endothelial activation; Monocyte; Immunology; Endothelial stem cell; Cell adhesion; Umbilical vein; Internal medicine; Endocrinology; Biology; Cell; In vitro; Biochemistry","score_opus":0.020651395501688104,"score_gpt":0.24884949509842505,"score_spread":0.22819809959673695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921059178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983847,0.0005231265,0.000020785883,0.00007781832,0.00008195285,0.00062156783,0.000020297495,0.00002971065,0.00024004748],"genre_scores_gemma":[0.9837204,0.014546733,0.0014666185,0.00007034792,0.000059587986,0.000039013732,0.00006136463,0.000023309156,0.000012609013],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984762,0.00012336412,0.00042457116,0.0005372128,0.0001266406,0.00031200453],"domain_scores_gemma":[0.999276,0.000056512185,0.00018767605,0.00031766598,0.000046235335,0.00011594538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038008537,0.00027982227,0.0005869278,0.00019053821,0.000092110626,0.000030814837,0.00007308587,0.00021004911,0.00004850852],"category_scores_gemma":[0.000014522873,0.00021964162,0.00010669647,0.00009883596,0.00031940316,0.00013787263,0.00014908065,0.00009623313,0.000008188756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025277917,0.00024824837,0.059699826,0.00018320933,0.00008424816,4.1107606e-7,0.00045217882,4.6783074e-7,0.93697464,0.000012998353,0.000050921448,0.0022675525],"study_design_scores_gemma":[0.002650072,0.00090585777,0.6142846,0.00014936615,0.00018260666,1.9075932e-7,0.00022128885,0.000045798428,0.3809761,0.000024164829,0.00039355023,0.00016640121],"about_ca_topic_score_codex":0.000117543364,"about_ca_topic_score_gemma":0.000027395101,"teacher_disagreement_score":0.55599856,"about_ca_system_score_codex":0.000023543367,"about_ca_system_score_gemma":0.000010948197,"threshold_uncertainty_score":0.89567256},"labels":[],"label_agreement":null},{"id":"W2921093011","doi":"10.1038/s41598-019-41061-z","title":"HNF4α is a novel regulator of intestinal glucose-dependent insulinotropic polypeptide","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Université de Sherbrooke; Natural Sciences and Engineering Research Council of Canada; Government of Canada; GlaxoSmithKline","keywords":"Incretin; Endocrinology; Internal medicine; Glucose homeostasis; Diabetes mellitus; Insulin; Type 2 diabetes; Carbohydrate metabolism; Hormone; Biology; Medicine; Insulin resistance","score_opus":0.013092018742791192,"score_gpt":0.2426435073762791,"score_spread":0.2295514886334879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921093011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987195,0.00020770483,0.000083055595,0.00026766854,0.0031763976,0.0006740695,0.0000025257616,0.00006912195,0.008324446],"genre_scores_gemma":[0.9452773,0.0000030779859,0.002442971,0.00011927134,0.000046676614,0.000014080159,0.00003644289,0.00001906911,0.05204113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783266,0.0000089861505,0.0005232528,0.0006373989,0.00070051296,0.00029721588],"domain_scores_gemma":[0.99823684,0.0000166726,0.0003219038,0.0011067557,0.00017723798,0.00014061213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044932935,0.00016031264,0.0003309334,0.0002283664,0.000054089513,0.000058096615,0.00009380453,0.00004785029,0.0006686419],"category_scores_gemma":[0.0000701182,0.0001295428,0.00014841728,0.00032328727,0.0001335437,0.00011110758,0.00012759434,0.00008124015,0.0002108108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009920723,0.0014243891,0.4580266,0.00044245628,0.0003350463,0.00045111866,0.0005357553,0.000012012204,0.50553286,0.0008361748,0.019721758,0.012582647],"study_design_scores_gemma":[0.0029058366,0.00079640414,0.22251797,0.000690112,0.0004923566,0.0004297736,0.00028075973,0.00037536223,0.6491561,0.0017853619,0.12014044,0.00042952356],"about_ca_topic_score_codex":0.000044538574,"about_ca_topic_score_gemma":0.0000048077422,"teacher_disagreement_score":0.23550862,"about_ca_system_score_codex":0.00008654201,"about_ca_system_score_gemma":0.00014659585,"threshold_uncertainty_score":0.732116},"labels":[],"label_agreement":null},{"id":"W2921562138","doi":"10.1111/dom.13698","title":"Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Liraglutide; Medicine; Diabetes mellitus; Mace; Internal medicine; Type 2 diabetes; Post-hoc analysis; Lixisenatide; Diabetic nephropathy; Endocrinology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.0253702906421352,"score_gpt":0.3092381997192483,"score_spread":0.2838679090771131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921562138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98725635,0.011367609,0.000002713471,0.0002951675,0.000085833846,0.00082531106,0.00007382721,0.000009346322,0.00008384117],"genre_scores_gemma":[0.9982096,0.0011993119,0.00020158748,0.00014141481,0.0000450202,0.00000812544,0.00003065458,0.000010681363,0.00015361857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997932,0.00042446575,0.0008285778,0.0003329613,0.00024956468,0.00023244311],"domain_scores_gemma":[0.99798286,0.00091832795,0.00048145937,0.0003304366,0.00016546626,0.000121432124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024168533,0.0002014109,0.0017816349,0.00028902205,0.000049616137,0.000019367331,0.00006382836,0.00012109563,0.000014187749],"category_scores_gemma":[0.00086031435,0.00013104212,0.00032330482,0.00039063313,0.00040172174,0.000096545366,0.00016423351,0.000114478265,3.2717134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009640308,0.00024498897,0.9653987,0.0005397273,0.003910949,4.1497773e-7,0.0004922354,0.000003442475,0.008027407,0.0006422102,0.000030987394,0.0206125],"study_design_scores_gemma":[0.003655626,0.00029732252,0.97610235,0.00011634866,0.011671758,1.7219311e-7,0.00029711364,0.0004206444,0.006940181,0.00009376303,0.00029084217,0.00011384999],"about_ca_topic_score_codex":0.000026594293,"about_ca_topic_score_gemma":0.000011154325,"teacher_disagreement_score":0.020498652,"about_ca_system_score_codex":0.0000064151427,"about_ca_system_score_gemma":0.000033838376,"threshold_uncertainty_score":0.53437424},"labels":[],"label_agreement":null},{"id":"W2921595130","doi":"10.1111/dom.13692","title":"Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Colorado Clinical and Translational Sciences Institute; Canadian Institutes of Health Research; National Institutes of Health; Novo Nordisk Fonden; University of Toronto; National Institute of Diabetes and Digestive and Kidney Diseases; University of Colorado; ZonMw; Fondation Leducq; University Health Network; Horizon Pharmaceuticals; Diabetes Canada; Eli Lilly and Company; AstraZeneca; Canadian Diabetes Association; International Society for Pediatric and Adolescent Diabetes; Novo Nordisk; Thrasher Research Fund; Sanofi","keywords":"Cotransporter; Medicine; Internal medicine; Endocrinology; Sodium; Chemistry","score_opus":0.044988646982151256,"score_gpt":0.28159246317917935,"score_spread":0.23660381619702808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921595130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051919427,0.97844124,0.00028943192,0.00012115441,0.0016631186,0.013459764,0.00045435646,0.00018816383,0.00019084896],"genre_scores_gemma":[0.0006724336,0.9877948,0.00088293984,0.00013521888,0.0016221902,0.0042788577,0.0008342858,0.00018184901,0.0035974316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684966,0.00006618303,0.0008101865,0.0010103626,0.0003638532,0.0008997668],"domain_scores_gemma":[0.9982609,0.00017760294,0.0004483724,0.00066133257,0.00015863888,0.00029314889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058471406,0.00096058095,0.0036105986,0.00036256746,0.00021424145,0.00015470771,0.0002139901,0.0005871513,0.000061656385],"category_scores_gemma":[0.00006244854,0.00066375436,0.0015405506,0.00026268818,0.00009070783,0.00022963484,0.00009210177,0.00034319342,0.000054946857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017608295,0.00045495338,0.00011548314,0.0600845,0.0026187813,0.000006835221,0.00011457693,1.846856e-7,0.000045091674,0.00026872443,0.0017172769,0.9343975],"study_design_scores_gemma":[0.004023696,0.0004491545,0.00016013882,0.007718786,0.017058251,0.0000050047443,0.00002822793,0.000012534274,0.0011471249,0.0001682529,0.9685252,0.00070365635],"about_ca_topic_score_codex":0.000010932692,"about_ca_topic_score_gemma":0.0000037926916,"teacher_disagreement_score":0.9668079,"about_ca_system_score_codex":0.000106137864,"about_ca_system_score_gemma":0.00020160327,"threshold_uncertainty_score":0.9995814},"labels":[],"label_agreement":null},{"id":"W2921752535","doi":"10.14740/jocmr3785","title":"Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Lean body mass; Internal medicine; Endocrinology; Diabetes mellitus; Body mass index; Subgroup analysis; Weight loss; Type 2 diabetes; Confidence interval; Body weight; Obesity","score_opus":0.06695667014037328,"score_gpt":0.4088872719661845,"score_spread":0.34193060182581125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921752535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424404,0.00017207736,0.00000896889,0.0026549802,0.00027734783,0.0018569345,0.0000023574053,0.0000036533777,0.000779618],"genre_scores_gemma":[0.99836713,0.00047224836,0.00007729716,0.00028475255,0.000283245,0.000015330987,0.0000025866414,0.000029304758,0.0004681127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503946,0.00072231295,0.0014243047,0.00021678672,0.0022253878,0.00037176345],"domain_scores_gemma":[0.9939878,0.00410089,0.0006241701,0.00057316385,0.0004414373,0.0002725701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007615325,0.0002135467,0.0013441638,0.0003273026,0.00003734746,0.000007135656,0.00040383244,0.00010704694,0.00030110928],"category_scores_gemma":[0.0021018803,0.0000701939,0.0002636344,0.0005027018,0.0005165464,0.00008250173,0.000048214748,0.001112029,0.0000057545194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03507795,0.00091501,0.946367,0.00026128982,0.0004657735,0.00004569627,0.00015800634,0.000003470464,0.0010193859,0.00002679623,0.0005914122,0.015068167],"study_design_scores_gemma":[0.05178018,0.07125055,0.84190404,0.0058931205,0.0003649367,0.0000031421287,0.00031738263,0.000113292954,0.026784869,0.00010371696,0.001358408,0.0001263615],"about_ca_topic_score_codex":0.000028928705,"about_ca_topic_score_gemma":0.000009953611,"teacher_disagreement_score":0.104462996,"about_ca_system_score_codex":0.00007494975,"about_ca_system_score_gemma":0.00018105794,"threshold_uncertainty_score":0.48312744},"labels":[],"label_agreement":null},{"id":"W2921866736","doi":"10.1161/circulationaha.119.040130","title":"Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":563,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; Internal medicine; Heart failure; Ejection fraction; TIMI; Hazard ratio; Cardiology; Myocardial infarction; Diabetes mellitus; Type 2 diabetes; Population; Thrombolysis; Endocrinology; Confidence interval","score_opus":0.009531047502136108,"score_gpt":0.260885370543757,"score_spread":0.25135432304162086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921866736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793744,0.0002906717,8.8347645e-7,0.00008850397,0.00006973027,0.00049938937,6.5449814e-7,0.000013367392,0.0010993497],"genre_scores_gemma":[0.9998299,0.000008905752,0.00002308766,0.000047675116,0.000014565557,0.00000653613,0.000035248082,0.00000575864,0.000028361217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995718,0.000034400706,0.000093705676,0.00012112842,0.00009860804,0.00008037125],"domain_scores_gemma":[0.9997451,0.000050581144,0.000026308595,0.00014188854,0.000013364813,0.000022805798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017713652,0.00006209482,0.00017601614,0.000070728485,0.000005971587,0.00000421576,0.000011795173,0.000033632547,0.00003810161],"category_scores_gemma":[0.000021946442,0.000050174316,0.000024155477,0.00009999237,0.000011595186,0.000040013176,0.0000084689,0.000033022905,0.00003506028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027358496,0.00004067939,0.9904442,0.00022552305,0.00003969194,6.2813285e-7,0.00002269362,0.000058419402,0.0048952275,0.0002232266,0.000053396016,0.003968985],"study_design_scores_gemma":[0.001033633,0.00044362515,0.9898974,0.00010324475,0.00008120954,9.6536986e-8,0.000004765794,0.00071618747,0.007200983,0.000061816325,0.00041688475,0.00004017759],"about_ca_topic_score_codex":0.0000091108695,"about_ca_topic_score_gemma":0.0000034080292,"teacher_disagreement_score":0.003928807,"about_ca_system_score_codex":0.000027048458,"about_ca_system_score_gemma":0.000004744073,"threshold_uncertainty_score":0.20460492},"labels":[],"label_agreement":null},{"id":"W2921878115","doi":"10.1111/dom.13695","title":"Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"OPKO Health (Canada)","funders":"Eli Lilly and Company","keywords":"Placebo; Medicine; Tolerability; Gastrin; Nausea; Agonist; Internal medicine; Adverse effect; Vomiting; Insulin; Endocrinology; Gastroenterology; Receptor","score_opus":0.009621001642796896,"score_gpt":0.23406959652495235,"score_spread":0.22444859488215546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921878115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564934,0.00080004585,0.000016893457,0.00030729623,0.0004370941,0.0012529931,0.00031047533,0.00007625841,0.0011495928],"genre_scores_gemma":[0.98748535,0.00041593643,0.002228246,0.001037449,0.00020321688,0.00014474476,0.0005487154,0.000038629336,0.007897742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786085,0.000053497763,0.0004954621,0.00061153714,0.0003890878,0.00058955536],"domain_scores_gemma":[0.9986448,0.00007733818,0.00017675608,0.00052886177,0.00017650549,0.00039569134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003169443,0.00039696353,0.0009175067,0.00030065468,0.000073405165,0.000072766634,0.00016333156,0.00014427316,0.0005623931],"category_scores_gemma":[0.00006275305,0.0003106728,0.00020479049,0.00037233616,0.00010090635,0.0002268177,0.00013549635,0.0001561662,0.00032263008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036034533,0.002665274,0.87184167,0.0016288782,0.002193658,0.00006998533,0.0011220719,0.000009960455,0.08365975,0.001678961,0.0092148855,0.022311421],"study_design_scores_gemma":[0.0032698351,0.002150038,0.8692387,0.00038148064,0.0013775202,0.0000022036957,0.00017985822,0.00006643828,0.02532846,0.000068639725,0.097400285,0.000536564],"about_ca_topic_score_codex":0.0000728715,"about_ca_topic_score_gemma":0.00008099167,"teacher_disagreement_score":0.08818541,"about_ca_system_score_codex":0.00005307134,"about_ca_system_score_gemma":0.00010344,"threshold_uncertainty_score":0.99993455},"labels":[],"label_agreement":null},{"id":"W2922787184","doi":"10.1016/j.kint.2019.02.033","title":"Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","year":2019,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; University of Toronto; University Health Network; Juvenile Diabetes Research Foundation Canada; AstraZeneca; Canadian Diabetes Association; Novo Nordisk; AbbVie; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Kidney disease; Diabetes mellitus; Placebo; Diabetic nephropathy; Nephropathy; Type 2 diabetes; Cardiology; Endocrinology; Pathology","score_opus":0.008964440251845096,"score_gpt":0.2819541485866346,"score_spread":0.27298970833478947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922787184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936376,0.00006724393,0.000018934963,0.0043018335,0.0002431116,0.0011377621,0.00022670544,0.000009377619,0.00035742248],"genre_scores_gemma":[0.9973783,0.000009234415,0.00011062136,0.00026497318,0.00006715816,0.00009345164,0.0018928834,0.000012632617,0.00017078323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983891,0.00009605402,0.00043723348,0.00025977517,0.0006467889,0.0001710024],"domain_scores_gemma":[0.99885756,0.00019314572,0.00039469963,0.00032086662,0.00011290527,0.00012080735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029217423,0.0001495102,0.00032645717,0.00030721992,0.000027347778,0.000019808585,0.00031055626,0.000041734264,0.00043380214],"category_scores_gemma":[0.00036286347,0.000080427795,0.00012656987,0.0005141441,0.00012136975,0.00011608624,0.000120543176,0.00015916918,0.0000066033563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001754019,0.0010488045,0.993453,0.00003296785,0.0018852444,0.0000010985577,0.00029578875,0.00006712477,0.000014996569,0.0001234011,0.0002277563,0.0010957657],"study_design_scores_gemma":[0.013260363,0.0002632928,0.98059183,0.00042412122,0.0009106918,1.6812534e-8,0.00006748751,0.00397004,0.00016020161,0.00008827313,0.00018447066,0.000079238074],"about_ca_topic_score_codex":0.00009477947,"about_ca_topic_score_gemma":0.00007893303,"teacher_disagreement_score":0.012861229,"about_ca_system_score_codex":0.0001940317,"about_ca_system_score_gemma":0.00025347498,"threshold_uncertainty_score":0.47498292},"labels":[],"label_agreement":null},{"id":"W2923237035","doi":"10.1016/j.acvdsp.2019.02.121","title":"SMIT1 is a novel cardiac sodium glucose co-transporter with potential implication in cardiac fibrosis","year":2019,"lang":"en","type":"article","venue":"Archives of Cardiovascular Diseases Supplements","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Internal medicine; Cardiology; Heart failure; Fibrosis; Ventricle; Cardiac fibrosis; Myocardial infarction; Cardiomyopathy; Glucose transporter; Insulin","score_opus":0.0045821049172673645,"score_gpt":0.21903136331869152,"score_spread":0.21444925840142415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923237035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986387,0.004893494,0.0008408388,0.00015767066,0.00014101286,0.0032025317,0.0019202763,0.000052718973,0.00240445],"genre_scores_gemma":[0.9944374,0.001141713,0.0011715788,0.000075748365,0.00007551945,0.00032235254,0.002468375,0.000054567245,0.0002527252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976423,0.000069114336,0.00039178843,0.0006192466,0.0007970366,0.00048050677],"domain_scores_gemma":[0.99851376,0.00003415094,0.00009633762,0.0010992916,0.000045934787,0.00021051375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012090504,0.00032362962,0.0009923966,0.00028321394,0.000039726165,0.00002333602,0.0001711211,0.000042456584,0.00015449447],"category_scores_gemma":[0.0000038083328,0.0002784888,0.0015754217,0.0001965786,0.00009636895,0.00016435988,0.00007461221,0.00008737286,0.00003622863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010340676,0.0009834608,0.95662796,0.00081728614,0.014644372,0.0000236518,0.0003721291,0.0002079712,0.006118813,0.00008617761,0.000615407,0.018468697],"study_design_scores_gemma":[0.008610133,0.00052079523,0.930406,0.0002563976,0.0058062063,0.0000014001279,0.00022101038,0.00007208041,0.011527419,0.00004765089,0.04217158,0.00035934497],"about_ca_topic_score_codex":0.00019933711,"about_ca_topic_score_gemma":0.0000018727359,"teacher_disagreement_score":0.041556172,"about_ca_system_score_codex":0.00005189962,"about_ca_system_score_gemma":0.000085703265,"threshold_uncertainty_score":0.99996674},"labels":[],"label_agreement":null},{"id":"W2928277836","doi":"10.1016/j.neuropharm.2019.03.035","title":"GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice","year":2019,"lang":"en","type":"article","venue":"Neuropharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Novo Nordisk Fonden; Helmholtz Association; Fonds de Recherche du Québec-Société et Culture; European Research Council; Lundbeckfonden; Alexander von Humboldt-Stiftung","keywords":"Mood; Dexamethasone; Psychology; Neuroscience; Pharmacology; Internal medicine; Medicine; Clinical psychology","score_opus":0.01713346979998678,"score_gpt":0.2722566363995134,"score_spread":0.25512316659952666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928277836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869701,0.0004557919,0.0000016966486,0.0009218815,0.00050520524,0.0009959425,0.000002504298,0.00007372071,0.010073111],"genre_scores_gemma":[0.99493015,0.00015914711,0.00023212803,0.002699889,0.0000785275,0.000044906763,0.000006570372,0.000037731927,0.0018109424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986638,0.00011346072,0.00024014738,0.0004651227,0.00014290967,0.0003746037],"domain_scores_gemma":[0.999463,0.00013865558,0.00007517257,0.00016879001,0.000032764256,0.00012159517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016718802,0.00019734335,0.00040749586,0.00025663964,0.000026144073,0.000011780137,0.00007237402,0.00008827656,0.00020843177],"category_scores_gemma":[0.000050106013,0.00018386949,0.00004074839,0.00023601188,0.000047100344,0.000088483896,0.0001461018,0.0002886172,0.00015063226],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083329174,0.0008249219,0.27464777,0.0004682333,0.00031922845,0.0002955518,0.0007145877,0.000059297152,0.6924648,0.00018444564,0.00076738716,0.028420454],"study_design_scores_gemma":[0.058360294,0.011874894,0.5979854,0.0003851153,0.0015717101,0.00023676298,0.00048686028,0.0011281264,0.31014195,0.00012214186,0.016624577,0.0010821716],"about_ca_topic_score_codex":0.000017550827,"about_ca_topic_score_gemma":0.00001449954,"teacher_disagreement_score":0.38232288,"about_ca_system_score_codex":0.000056466917,"about_ca_system_score_gemma":0.00003710469,"threshold_uncertainty_score":0.749798},"labels":[],"label_agreement":null},{"id":"W2929253275","doi":"10.1159/000499598","title":"Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease","year":2019,"lang":"en","type":"letter","venue":"American Journal of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cotransporter; Endocrinology; Kidney disease; Internal medicine; Diabetes mellitus; Sodium; Kidney; Disease; Urology; Chemistry","score_opus":0.008440035936552013,"score_gpt":0.2244422172976455,"score_spread":0.21600218136109348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929253275","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74031746,0.003607206,0.000023803093,0.25506204,0.00037520172,0.0003519756,0.000074448755,0.000020193831,0.00016765205],"genre_scores_gemma":[0.3727476,0.00032602454,0.00046579758,0.6229361,0.0026141421,0.000010027124,0.00059140933,0.000058968046,0.00024990112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797237,0.00015077529,0.00061263965,0.00042735972,0.000425259,0.00041161198],"domain_scores_gemma":[0.9982194,0.00011375401,0.00073333125,0.00038546236,0.00012156647,0.00042651428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000052861415,0.00044277863,0.0012723217,0.00039911692,0.000049213973,0.00003055463,0.00012835176,0.0002087266,0.00025135622],"category_scores_gemma":[0.000014415085,0.00035581377,0.00035740127,0.00013244884,0.000642053,0.00012161429,0.0000631002,0.0008221171,0.00004556218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015287878,0.00040223653,0.0033997993,0.00007983951,0.002648672,0.017463507,0.0004226553,9.411458e-7,0.014222248,0.000008889772,0.9563757,0.003446712],"study_design_scores_gemma":[0.00536419,0.0056872074,0.023090165,0.0004417515,0.0034647505,0.00025891903,0.00009251362,0.000013377444,0.0014829839,0.00018453445,0.95946586,0.000453771],"about_ca_topic_score_codex":0.00004507566,"about_ca_topic_score_gemma":0.0000012062482,"teacher_disagreement_score":0.36787412,"about_ca_system_score_codex":0.00012124034,"about_ca_system_score_gemma":0.00023517785,"threshold_uncertainty_score":0.9998894},"labels":[],"label_agreement":null},{"id":"W2929465767","doi":"10.1002/cphy.c170055","title":"Glucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function","year":2018,"lang":"en","type":"review","venue":"Comprehensive physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Glucagon-like peptide-2; Function (biology); Glucagon; Chemistry; Glucagon-like peptide-1; Proglucagon; Internal medicine; Peptide; Endocrinology; Cell biology; Biology; Biochemistry; Medicine; Diabetes mellitus; Hormone","score_opus":0.040865285450510644,"score_gpt":0.2942242925851652,"score_spread":0.25335900713465453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929465767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035153043,0.994357,0.000022840552,0.00006128689,0.00028383703,0.0009892436,0.0000034339475,0.00002229294,0.00074478664],"genre_scores_gemma":[0.0030507506,0.99574846,0.00013527436,0.00019955251,0.00023504587,0.00007156445,0.00017670725,0.00002061157,0.00036203215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902534,0.00015755392,0.00029405346,0.0003132962,0.00007370724,0.00013606381],"domain_scores_gemma":[0.9988573,0.00040530053,0.00028464882,0.000258785,0.00015396788,0.000039999904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056372955,0.0002421099,0.001186611,0.00010454835,0.000053594602,0.0000065255786,0.000054774282,0.00010069528,0.00002104677],"category_scores_gemma":[0.00004814929,0.00013773299,0.00015176185,0.00010407776,0.00068371237,0.000027833474,0.00017029434,0.00012015916,0.000014229608],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011273851,0.00020801715,0.00007252904,0.051631115,0.0032998926,0.0000040763334,0.0002578905,2.6345063e-7,0.00066930795,0.012791781,0.01293565,0.9170021],"study_design_scores_gemma":[0.0024836413,0.0012272844,0.013006709,0.00523641,0.005632787,0.00004366279,0.000054525768,0.000038004622,0.000010236377,0.0030225897,0.9690415,0.00020263984],"about_ca_topic_score_codex":0.000012842449,"about_ca_topic_score_gemma":7.297597e-7,"teacher_disagreement_score":0.9561059,"about_ca_system_score_codex":0.00001630093,"about_ca_system_score_gemma":0.000029164006,"threshold_uncertainty_score":0.5616588},"labels":[],"label_agreement":null},{"id":"W2933161660","doi":"10.29169/1927-5951.2019.09.02.10","title":"Diagnosis and Treatment of Chronic Heart Failure in Diabetes of the 2nd Type","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmacy and Nutrition Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Diabetes mellitus; Life expectancy; Type 2 diabetes; Incidence (geometry); Population; Type 2 Diabetes Mellitus; Intensive care medicine; Internal medicine; Environmental health; Endocrinology","score_opus":0.03133718335108624,"score_gpt":0.32652883793916165,"score_spread":0.2951916545880754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933161660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844045,0.007862495,8.860681e-8,0.0033350666,0.00008653472,0.0002074839,0.0000016596646,7.9615404e-7,0.00006543275],"genre_scores_gemma":[0.9942599,0.0055044573,0.00011334834,0.000050869858,0.0000362256,0.0000035213056,2.4467298e-7,0.0000013135583,0.000030098412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995278,0.000023641445,0.00017294794,0.000059192163,0.00014661005,0.00006981657],"domain_scores_gemma":[0.99970967,0.0000637523,0.00011936146,0.000036087677,0.00004168029,0.000029424215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001724328,0.00004599842,0.00017919831,0.0001099946,0.00002129636,0.00000790644,0.000035377696,0.000008890837,0.00005416165],"category_scores_gemma":[0.000009083418,0.000024744562,0.000042221578,0.00019360996,0.00011773455,0.00012732702,0.000011924921,0.000025663941,3.878598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054915887,0.00058037095,0.9765624,0.0001549036,0.00003652373,9.89622e-7,0.00010543236,0.000002449872,0.014910879,0.000034736295,0.00040580277,0.0071505876],"study_design_scores_gemma":[0.016880864,0.009876919,0.5245265,0.0016419961,0.00040279567,0.00001933151,0.0007526903,0.00041230174,0.36367548,0.00045751053,0.08123464,0.000118997894],"about_ca_topic_score_codex":0.000008720412,"about_ca_topic_score_gemma":0.0000068895743,"teacher_disagreement_score":0.45203593,"about_ca_system_score_codex":0.000022792661,"about_ca_system_score_gemma":0.00003347663,"threshold_uncertainty_score":0.100905396},"labels":[],"label_agreement":null},{"id":"W2933306415","doi":"10.1007/s41669-019-0131-6","title":"Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Dulaglutide; Semaglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Endocrinology; Exenatide; Liraglutide","score_opus":0.04761554358127133,"score_gpt":0.33630039552377733,"score_spread":0.288684851942506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933306415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848267,0.00040018235,1.7906572e-7,0.00048479292,0.00053571747,0.0035860194,0.00005169331,0.000005126071,0.010109579],"genre_scores_gemma":[0.998567,0.00039814741,0.000060265967,0.00024239022,0.000027470769,0.000210202,0.000083858424,0.000025138446,0.00038552214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985499,0.00016906505,0.0004585477,0.0003332014,0.00013145203,0.00035786378],"domain_scores_gemma":[0.9986256,0.0006414104,0.0001907397,0.00042578334,0.000039941533,0.00007654055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004997685,0.00023670113,0.0007645194,0.00012645744,0.000019076082,0.000020671192,0.00041615678,0.000033968307,0.00019579739],"category_scores_gemma":[0.000016781793,0.00018428282,0.00008244944,0.00021696257,0.000041337356,0.00013421457,0.000109286215,0.00008901675,0.000037153004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003993364,0.0018290867,0.9604909,0.0004431704,0.0010069987,0.000048338767,0.0006910863,0.003424759,0.002665512,0.000408862,0.00097349787,0.024024451],"study_design_scores_gemma":[0.06983942,0.005240975,0.7620916,0.00069528614,0.00097111106,0.0000017561716,0.0020639012,0.009664017,0.09033593,0.00015031324,0.058222957,0.0007227757],"about_ca_topic_score_codex":0.38022348,"about_ca_topic_score_gemma":0.25352907,"teacher_disagreement_score":0.1983993,"about_ca_system_score_codex":0.0020471294,"about_ca_system_score_gemma":0.0009412865,"threshold_uncertainty_score":0.7600921},"labels":[],"label_agreement":null},{"id":"W2936407881","doi":"10.1016/j.jcjd.2019.04.003","title":"Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Internal medicine; Odds ratio; Meta-analysis; Stroke (engine); Adverse effect; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Sitagliptin; Lixisenatide; Myocardial infarction; Liraglutide; Endocrinology; Alternative medicine; Pathology","score_opus":0.09336447834570852,"score_gpt":0.30649574546862823,"score_spread":0.21313126712291972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936407881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010239098,0.98670614,0.0000035151088,0.0000549654,0.00020102767,0.0021685453,0.00041220128,0.0000065094596,0.00020798953],"genre_scores_gemma":[0.03436989,0.9644249,0.000267776,0.0001765814,0.000100580175,0.00007460949,0.00041118645,0.00012931466,0.00004517002],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9928588,0.0015178818,0.0032009734,0.0005715581,0.0011381173,0.00071266014],"domain_scores_gemma":[0.9938536,0.0009676026,0.002242819,0.0016772742,0.00069235463,0.0005663171],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.006508744,0.0008655786,0.02248743,0.0042223386,0.000036511334,0.000032505737,0.00056070933,0.00034690744,0.0003258694],"category_scores_gemma":[0.00061780715,0.0005213623,0.019994779,0.0024779818,0.00017875781,0.00009166299,0.00002174283,0.000518713,0.000010100495],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075001364,0.0001180891,0.006829531,0.008695786,0.79094785,0.000059713773,0.000045989447,0.001960809,1.710794e-7,0.000017949322,0.000069062,0.19118007],"study_design_scores_gemma":[0.0029605813,0.0014074263,0.0006349307,0.00487062,0.6403158,4.1888802e-7,0.000019837815,0.000014113244,0.000024938843,0.00000268083,0.3493906,0.0003581076],"about_ca_topic_score_codex":0.0006893817,"about_ca_topic_score_gemma":0.0005437785,"teacher_disagreement_score":0.34932154,"about_ca_system_score_codex":0.00042118036,"about_ca_system_score_gemma":0.0018811473,"threshold_uncertainty_score":0.9997238},"labels":[],"label_agreement":null},{"id":"W2937074030","doi":"10.14740/jocmr3677","title":"Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kidney Foundation, Japan","keywords":"Sitagliptin; Medicine; Dipeptidyl peptidase-4 inhibitor; Insulin; Internal medicine; Adverse effect; Type 2 diabetes; Diabetes mellitus; Sitagliptin Phosphate; Concomitant; Type 2 Diabetes Mellitus; Clinical endpoint; Endocrinology; Clinical trial","score_opus":0.21428140698804266,"score_gpt":0.490888469743686,"score_spread":0.27660706275564334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937074030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917274,0.00030638315,1.308063e-7,0.0020375813,0.00018416805,0.001143213,8.759723e-7,0.0000021412595,0.004598074],"genre_scores_gemma":[0.9990923,0.00032188033,0.000055182278,0.000121491474,0.00019092286,0.0000040499426,0.000007872349,0.00001044102,0.00019589339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956968,0.00090112386,0.0015258945,0.0001995253,0.0014019574,0.00027469094],"domain_scores_gemma":[0.99408585,0.0048607886,0.00035510032,0.00028309366,0.0002767194,0.00013846999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009590493,0.000111811576,0.0009805517,0.00042198203,0.000028980998,0.000009606444,0.00020284254,0.000080628,0.00009603655],"category_scores_gemma":[0.0041434737,0.00006217774,0.00006292186,0.0005271641,0.00018633195,0.000045736837,0.00011015392,0.00090701575,0.000016088086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004697055,0.005613995,0.9653522,0.00010254455,0.00016674855,0.000041788146,0.00087346206,0.000005375406,0.000053026182,0.00005375574,0.0010180451,0.022022052],"study_design_scores_gemma":[0.020774065,0.024848122,0.95021325,0.0013562675,0.00008535235,2.1339623e-7,0.0014975169,0.000034439487,0.000025241954,0.000033701574,0.0010868785,0.000044976652],"about_ca_topic_score_codex":0.000014800871,"about_ca_topic_score_gemma":0.000046968336,"teacher_disagreement_score":0.021977076,"about_ca_system_score_codex":0.00008823009,"about_ca_system_score_gemma":0.00006547764,"threshold_uncertainty_score":0.49604243},"labels":[],"label_agreement":null},{"id":"W2937111213","doi":"10.1016/j.jcjd.2019.04.004","title":"CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); University of Waterloo; McGill University Health Centre; University of British Columbia; Diabetes Canada; University of Toronto; University of Manitoba","funders":"Janssen Pharmaceuticals; Janssen Research and Development; Takeda Canada; Mitsubishi Tanabe Pharma Corporation; Novo Nordisk; Valeant Pharmaceuticals International; Novartis; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Sanofi; Merck; Janssen Biotech; American Diabetes Association; Abbott Laboratories; Boehringer Ingelheim","keywords":"Canagliflozin; Medicine; Clinical Practice; Diabetes mellitus; Type 2 Diabetes Mellitus; Family medicine; Pediatrics; Intensive care medicine; Endocrinology","score_opus":0.020653272002533887,"score_gpt":0.28951797065604873,"score_spread":0.26886469865351487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937111213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981158,0.005246186,3.1349323e-8,0.0054744547,0.0008862676,0.0010183674,0.000098736346,0.0000034665559,0.0061144913],"genre_scores_gemma":[0.9975561,0.00026017873,0.0001717477,0.0015470844,0.000072076524,0.000016509162,0.000057005687,0.00003930517,0.00028000615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960019,0.00029686143,0.0016914397,0.00032711402,0.0004532139,0.0012294665],"domain_scores_gemma":[0.9954707,0.00057967356,0.000848604,0.0007596167,0.0005393308,0.0018020446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013073436,0.00036602936,0.0013151114,0.0018026779,0.000057571902,0.00004338377,0.00040856964,0.00021745072,0.00016702074],"category_scores_gemma":[0.0013462718,0.00027151802,0.00031184807,0.0010287017,0.00016604309,0.00023065753,0.000009648841,0.0003403925,0.0000126667155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001890468,0.00026761266,0.98352474,0.0000666254,0.0009155025,0.00048361934,0.0010995766,0.000055527846,0.000010466722,0.00017163492,0.0022649702,0.011120832],"study_design_scores_gemma":[0.0027136675,0.0028057331,0.8458918,0.00033652468,0.000681378,0.0000061233204,0.0018248151,0.0000618159,0.00011874111,0.000055877863,0.14525291,0.0002506293],"about_ca_topic_score_codex":0.9781924,"about_ca_topic_score_gemma":0.998483,"teacher_disagreement_score":0.14298794,"about_ca_system_score_codex":0.0025139833,"about_ca_system_score_gemma":0.011605388,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W2938218719","doi":"10.1007/s00125-019-4871-8","title":"Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus","year":2019,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Juvenile Diabetes Research Foundation Canada; Canadian Diabetes Association","keywords":"Renin–angiotensin system; Endocrinology; Internal medicine; Cotransporter; Diabetes mellitus; Human physiology; Type 2 Diabetes Mellitus; Medicine; Sodium; Chemistry; Blood pressure","score_opus":0.007967251188109915,"score_gpt":0.20333997361032655,"score_spread":0.19537272242221662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938218719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9162579,0.004021922,0.00001127473,0.07486716,0.00094966555,0.0020380255,0.000090126414,0.00010884542,0.0016550799],"genre_scores_gemma":[0.93821555,0.000074324824,0.00008413437,0.05679289,0.00017974683,0.00006475258,0.0031558052,0.00007597274,0.0013568411],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977313,0.0001653165,0.0005936796,0.0005226598,0.0004853759,0.00050163496],"domain_scores_gemma":[0.99850833,0.000083570994,0.00038614258,0.00084244634,0.00014658622,0.00003289144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021970377,0.0004088758,0.0009456224,0.00024668637,0.000028237064,0.000019444677,0.0001417509,0.0007939421,0.000039538063],"category_scores_gemma":[0.000033730485,0.00029318858,0.0002856601,0.00041998332,0.00013041617,0.00006463289,0.000061841376,0.0006205068,0.00006786658],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005842978,0.00017181184,0.045901958,0.0014727219,0.0005705494,0.00018897238,0.00006760635,0.000023111103,0.023253923,0.00014078121,0.9267494,0.0014007367],"study_design_scores_gemma":[0.0060715284,0.0011208619,0.16578405,0.0067830933,0.0037241066,0.00000889334,0.000038906324,0.000656084,0.43209034,0.00026875566,0.38205898,0.0013944024],"about_ca_topic_score_codex":0.00003068802,"about_ca_topic_score_gemma":0.0000031297345,"teacher_disagreement_score":0.54469043,"about_ca_system_score_codex":0.00024692083,"about_ca_system_score_gemma":0.000059768136,"threshold_uncertainty_score":0.999952},"labels":[],"label_agreement":null},{"id":"W2939222610","doi":"10.1056/nejmoa1811744","title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5996,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Diabetic nephropathy; Nephropathy; Dapagliflozin; Internal medicine; Clinical trial; Type 2 Diabetes Mellitus; Endocrinology; Intensive care medicine; Pharmacology; Urology","score_opus":0.009162856530291195,"score_gpt":0.24423987491276192,"score_spread":0.23507701838247072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939222610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851967,0.0047970377,0.0000025303814,0.007912701,0.00031541454,0.00015476548,3.6552328e-7,0.0000048746533,0.0016155895],"genre_scores_gemma":[0.9955014,0.001121332,0.00024194845,0.0009866284,0.00043841175,4.8021764e-7,0.0000024907788,0.000009419118,0.0016978724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992234,0.00002814392,0.00027808096,0.000098757424,0.00021715136,0.00015442682],"domain_scores_gemma":[0.9994446,0.00011423692,0.000107053515,0.000090715046,0.00004787401,0.00019551783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042198465,0.0001122323,0.00048214133,0.00023329249,0.000010829892,0.000007010987,0.000036467303,0.000031208572,0.000119992],"category_scores_gemma":[0.000120635086,0.00006550516,0.0000212293,0.00010653862,0.000047294237,0.000070582806,0.0000235351,0.00014547828,0.0000033927265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022655576,0.00004483818,0.86977535,0.000064958214,0.00016127616,0.00014269965,0.00048467756,0.0000019264419,0.0015275772,0.00011725396,0.0026131272,0.12483973],"study_design_scores_gemma":[0.07211217,0.005100267,0.8583611,0.0008543032,0.0004451522,0.00009955551,0.00029040026,0.0000740603,0.00017684292,0.0005757191,0.06178724,0.00012316859],"about_ca_topic_score_codex":0.000081049904,"about_ca_topic_score_gemma":0.00006590661,"teacher_disagreement_score":0.124716565,"about_ca_system_score_codex":0.000028022187,"about_ca_system_score_gemma":0.000044060645,"threshold_uncertainty_score":0.2671223},"labels":[],"label_agreement":null},{"id":"W2939379608","doi":"10.1210/en.2019-00215","title":"Immunometabolism Sentinels: Gut Surface T-Cells Regulate GLP-1 Availability","year":2019,"lang":"en","type":"letter","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Endocrinology; Internal medicine; Glucagon-like peptide-1; Biology; Cell biology; Medicine; Type 2 diabetes; Diabetes mellitus","score_opus":0.017450590156251392,"score_gpt":0.24799782734911202,"score_spread":0.23054723719286063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939379608","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1584728,0.007114186,0.000013544019,0.7474896,0.008101338,0.0031890038,0.00015383259,0.00062773505,0.07483797],"genre_scores_gemma":[0.009589196,0.0014541139,0.000787412,0.4162784,0.0028845468,0.00008613731,0.0016919557,0.0001933955,0.56703484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964456,0.0001889368,0.000608658,0.0010715042,0.00038729154,0.0012980091],"domain_scores_gemma":[0.99746895,0.00018265386,0.00028678135,0.0018722037,0.000120917386,0.00006848438],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000132032,0.00066713843,0.0014260741,0.00026996693,0.000064745225,0.00004015115,0.00038177767,0.0006037526,0.0024341277],"category_scores_gemma":[0.00003923558,0.0005843507,0.00046076562,0.00018885567,0.00023750981,0.00007753335,0.00040307318,0.001496925,0.007429453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050510207,0.00016297454,0.0013776519,0.0005218166,0.0011870523,0.0012081917,0.000036915615,0.000004440338,0.0017170941,0.00009303464,0.9906857,0.0029545904],"study_design_scores_gemma":[0.0023351407,0.0002159142,0.0033386345,0.00006722503,0.0009971744,0.00005721688,0.000011356851,0.0000133813655,0.0015560616,0.00011388964,0.9908586,0.0004353986],"about_ca_topic_score_codex":0.00010402274,"about_ca_topic_score_gemma":0.0000017153133,"teacher_disagreement_score":0.4921969,"about_ca_system_score_codex":0.00018704035,"about_ca_system_score_gemma":0.00010537362,"threshold_uncertainty_score":0.9996608},"labels":[],"label_agreement":null},{"id":"W2940709362","doi":"10.1016/j.jcjd.2019.04.008","title":"Exploring Clinical Care Among Adults With Diabetes Mellitus: Alignment With Recommended Statin and Sulfonylureas Treatment","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"University of Manitoba","keywords":"Medicine; Diabetes mellitus; Statin; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.032075075423359294,"score_gpt":0.24390729327119223,"score_spread":0.21183221784783293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940709362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487996,0.002393651,0.0000012127305,0.00072138896,0.00021564787,0.0007837257,0.000023766883,0.000015725767,0.00096492155],"genre_scores_gemma":[0.9979563,0.00024441892,0.0010115724,0.00025617753,0.00013281709,0.000053737247,0.000042092837,0.00005059041,0.00025231479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981737,0.000080640115,0.0005111449,0.00032978182,0.0002726834,0.00063203],"domain_scores_gemma":[0.997848,0.00015817737,0.00030455145,0.00031068848,0.00021645335,0.0011621253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024092643,0.00033883692,0.0007705865,0.00033358004,0.000087193024,0.00007923317,0.00010626336,0.000061893756,0.000090515314],"category_scores_gemma":[0.000027066944,0.00021722773,0.0001352208,0.00016472301,0.00013532971,0.00034940324,0.000014264165,0.00018097924,0.000010212775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007971814,0.00009882965,0.94681793,0.00017035652,0.0011549687,0.00007570469,0.0013822311,0.00001112659,0.000008562048,0.000029338375,0.00019825497,0.049972996],"study_design_scores_gemma":[0.013555415,0.018657722,0.9396501,0.002519603,0.0014514793,0.000004139128,0.008249618,0.000039218543,0.0017854258,0.000017272809,0.013605038,0.00046492714],"about_ca_topic_score_codex":0.00036929574,"about_ca_topic_score_gemma":0.006859536,"teacher_disagreement_score":0.04950807,"about_ca_system_score_codex":0.00040571764,"about_ca_system_score_gemma":0.00046674765,"threshold_uncertainty_score":0.88582903},"labels":[],"label_agreement":null},{"id":"W2942132427","doi":"10.1007/s13300-019-0615-5","title":"GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data","year":2019,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Discontinuation; Exenatide; Type 2 diabetes; Liraglutide; Dulaglutide; Internal medicine; Retrospective cohort study; Dosing; Lira; Pharmacy; Diabetes mellitus; Family medicine; Endocrinology","score_opus":0.01924185101910407,"score_gpt":0.28805187489398093,"score_spread":0.26881002387487685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942132427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968725,0.0012894694,7.6081716e-7,0.000063357904,0.00015056084,0.0011596404,0.00022006086,0.00003748647,0.00020619945],"genre_scores_gemma":[0.9942459,0.003907828,0.00003527272,0.00022937528,0.000031972806,0.000042049778,0.001330721,0.00003389147,0.00014300182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983281,0.000060077964,0.0003625784,0.0005699912,0.00026731673,0.00041194112],"domain_scores_gemma":[0.99872327,0.00011994043,0.00018272948,0.00077255594,0.000104453,0.00009703264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019521713,0.0002971935,0.0008616305,0.00048532514,0.000034746747,0.000042614713,0.00017235414,0.000056783116,0.0003116853],"category_scores_gemma":[0.0000124378075,0.0002308688,0.00011484459,0.0007182014,0.00007822416,0.00027202143,0.000081178565,0.0000707691,0.00001029017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011695962,0.0009436613,0.97901726,0.00006742062,0.0040298323,0.0000017911166,0.00058456766,0.0000075312273,0.00041645326,0.000011175548,0.000045443838,0.014757892],"study_design_scores_gemma":[0.0073962435,0.0014576721,0.98148036,0.000108396096,0.0013820443,8.9392005e-9,0.00006605699,0.0030206614,0.00317504,0.000014686316,0.001696768,0.00020209019],"about_ca_topic_score_codex":0.00015655691,"about_ca_topic_score_gemma":0.00011835082,"teacher_disagreement_score":0.014555802,"about_ca_system_score_codex":0.0002081419,"about_ca_system_score_gemma":0.00002467389,"threshold_uncertainty_score":0.94145566},"labels":[],"label_agreement":null},{"id":"W2942434264","doi":"10.1016/j.dsx.2019.04.041","title":"Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?","year":2019,"lang":"en","type":"review","venue":"Diabetes & Metabolic Syndrome Clinical Research & Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Contraindication; Postprandial; Diabetes mellitus; Type 2 Diabetes Mellitus; Intensive care medicine; Type 2 diabetes; Heart failure; Pharmacology; Internal medicine; Endocrinology; Alternative medicine","score_opus":0.40757654680519867,"score_gpt":0.5215565424663463,"score_spread":0.11397999566114764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942434264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032261005,0.9708366,6.470174e-7,0.00071840844,0.0020485725,0.02219549,0.00013597209,0.00013106088,0.00070715044],"genre_scores_gemma":[0.00005796305,0.9803113,0.00029686256,0.0022276826,0.0016382968,0.0070830267,0.000801001,0.00038297498,0.0072009414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9843701,0.004539209,0.004291527,0.002231184,0.001721568,0.0028464112],"domain_scores_gemma":[0.98262036,0.009584584,0.0022715987,0.0038340185,0.0007851354,0.0009042785],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.023904609,0.0015420425,0.012330214,0.0009427385,0.00047126808,0.00036261856,0.0017893713,0.00095502083,0.00047519623],"category_scores_gemma":[0.014008295,0.00082714716,0.005545967,0.0028470117,0.00080113526,0.0002190299,0.0008728324,0.0028324528,0.003434189],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024953435,0.0007528473,0.006169922,0.020921737,0.0029564502,0.000020219442,0.000012792207,4.85314e-8,5.435334e-7,0.00010975781,0.057886247,0.9111445],"study_design_scores_gemma":[0.0016085976,0.0017913464,0.0018970207,0.034522254,0.0049626795,0.0000046933756,0.000019552741,0.000008758241,0.0000024080161,0.00011772633,0.9543622,0.0007027641],"about_ca_topic_score_codex":0.000003858908,"about_ca_topic_score_gemma":0.000002563398,"teacher_disagreement_score":0.9104417,"about_ca_system_score_codex":0.00022674998,"about_ca_system_score_gemma":0.00082374515,"threshold_uncertainty_score":0.9997328},"labels":[],"label_agreement":null},{"id":"W2942519534","doi":"10.1111/dom.13754","title":"Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Acute kidney injury; Kidney disease; Hazard ratio; Internal medicine; Placebo; Randomized controlled trial; Meta-analysis; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Adverse effect; Relative risk; Confidence interval; Endocrinology; Pathology","score_opus":0.0784109921710881,"score_gpt":0.33839555872688576,"score_spread":0.25998456655579766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942519534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033949171,0.9894518,0.0000216966,0.000035153793,0.00027758186,0.0036697036,0.0027384881,0.00008880954,0.00032180262],"genre_scores_gemma":[0.0006752567,0.99387985,0.00037305173,0.00030028453,0.00019544731,0.0004542937,0.003151862,0.00010463467,0.0008653309],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99471873,0.00063719647,0.0019070168,0.0011123121,0.00093340274,0.000691352],"domain_scores_gemma":[0.99636114,0.00023196901,0.0010842918,0.0016105582,0.00017717599,0.00053489546],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.002628972,0.0011812423,0.023900313,0.001662019,0.00008446395,0.000074837466,0.0003003883,0.0004975978,0.00019518864],"category_scores_gemma":[0.00009932601,0.0007201964,0.012833336,0.0014478633,0.00018953612,0.0002214717,0.00011486359,0.00042866607,0.000038148788],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040407464,0.00045514575,0.0009952196,0.020880103,0.87686443,0.000035115525,0.00006376463,5.782574e-7,0.0000029793491,0.00009449849,0.00029382313,0.10027394],"study_design_scores_gemma":[0.001011578,0.00010436194,0.00028714436,0.0006263435,0.5252005,7.0146785e-7,0.0000036105391,0.0000012032816,0.000096952244,0.0000041035883,0.47231105,0.00035244582],"about_ca_topic_score_codex":0.000040400737,"about_ca_topic_score_gemma":0.0000017299958,"teacher_disagreement_score":0.47201723,"about_ca_system_score_codex":0.000048181188,"about_ca_system_score_gemma":0.00023479035,"threshold_uncertainty_score":0.9995249},"labels":[],"label_agreement":null},{"id":"W2944044014","doi":"10.1210/js.2019-sun-lb015","title":"SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA","year":2019,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Linagliptin; Placebo; Medicine; Baseline (sea); Urology; Internal medicine; Diabetes mellitus; Endocrinology; Alternative medicine; Type 2 diabetes","score_opus":0.008170114294834042,"score_gpt":0.26797973194997876,"score_spread":0.2598096176551447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944044014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221385,0.00020392952,0.000004972041,0.0064371433,0.0005331936,0.00040307327,0.000009022203,0.000009089498,0.00018574277],"genre_scores_gemma":[0.9946153,0.0004351867,0.00051013037,0.0014653191,0.0001755192,0.000005708349,0.0000058300693,0.000019803269,0.0027671875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999045,0.000047909292,0.00024929742,0.00013872588,0.00026956454,0.00024947364],"domain_scores_gemma":[0.99911493,0.00028403208,0.00020599042,0.00018335464,0.00007955678,0.00013211608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003415916,0.00018216863,0.00044305355,0.000030043775,0.000058175974,0.000038017242,0.00007928277,0.000031583022,0.000009422899],"category_scores_gemma":[0.00019156408,0.000098285076,0.00012873732,0.000099168385,0.00006753407,0.00008894564,0.00010490973,0.00029124357,0.0000024711512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023301,0.00025795074,0.9827053,0.0005601752,0.00081419875,0.00012537719,0.0016794751,0.000009733257,0.00047535007,0.00008932462,0.0056937267,0.005259271],"study_design_scores_gemma":[0.045116898,0.0037707868,0.91579235,0.00086183567,0.00086282654,0.00010163465,0.0020129725,0.00029146727,0.0029740166,0.000035009878,0.027885001,0.00029518738],"about_ca_topic_score_codex":0.000018049192,"about_ca_topic_score_gemma":0.0000073299198,"teacher_disagreement_score":0.06691296,"about_ca_system_score_codex":0.00009653591,"about_ca_system_score_gemma":0.000052992098,"threshold_uncertainty_score":0.4007949},"labels":[],"label_agreement":null},{"id":"W2944049182","doi":"10.1016/j.cmet.2019.04.011","title":"A Big Win for Diabetic Kidney Disease: CREDENCE","year":2019,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"Janssen Pharmaceuticals; Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Novo Nordisk; University of Toronto; Sanofi; Bayer HealthCare; Diabetes Canada; Novartis; Merck; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Boehringer Ingelheim; Amgen; Heart and Stroke Foundation of Canada","keywords":"Credence; Disease; Kidney; Diabetes mellitus; Medicine; Kidney disease; Intensive care medicine; Internal medicine; Computer science; Endocrinology","score_opus":0.018465073512479953,"score_gpt":0.23939428759645381,"score_spread":0.22092921408397387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944049182","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018598068,0.026709061,0.0005459179,0.9180287,0.010631253,0.008452274,0.00093053485,0.00038508335,0.032457355],"genre_scores_gemma":[0.00087579153,0.00046462438,0.00072870107,0.6758969,0.007892131,0.00074819644,0.002865088,0.00015851083,0.3103701],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976409,0.00004863898,0.00033049125,0.00075353467,0.00049035146,0.0007360881],"domain_scores_gemma":[0.9981736,0.00013671628,0.00018490192,0.0010907145,0.00010275542,0.00031132618],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013283873,0.0005358691,0.0009632076,0.0002813238,0.00006138089,0.0000736733,0.000295461,0.0003571998,0.00035021335],"category_scores_gemma":[0.00013424149,0.0004415081,0.00053704873,0.00015635155,0.000071321294,0.000057678804,0.00011800395,0.0005259293,0.00082771084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043491353,0.00013552926,0.00013909322,0.0026932026,0.00031228666,0.0001370492,0.000027834683,3.8878215e-7,0.00015948394,0.00008335869,0.992978,0.003290318],"study_design_scores_gemma":[0.002690612,0.00008933828,0.00088708755,0.00032536482,0.00456551,5.6332215e-7,0.000004142466,0.000030390931,0.00048562663,0.0004160041,0.99008054,0.0004247963],"about_ca_topic_score_codex":0.000007275043,"about_ca_topic_score_gemma":1.3690531e-7,"teacher_disagreement_score":0.27791274,"about_ca_system_score_codex":0.00006730406,"about_ca_system_score_gemma":0.00027609072,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W2944210149","doi":"10.1210/js.2019-mon-lb029","title":"MON-LB029 The Influence of SGLT-2 Inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients with Newly Treated Type 2 Diabetes: A Population-Based Cohort Study","year":2019,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Population; Cohort study; Retrospective cohort study; Cause of death; Cohort; Disease; Endocrinology","score_opus":0.008771957526894443,"score_gpt":0.2498038841943707,"score_spread":0.24103192666747625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944210149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835855,0.00030345505,5.901294e-7,0.000106009225,0.00006533355,0.0011418681,0.000004155775,0.0000066811444,0.000013388744],"genre_scores_gemma":[0.9996058,0.00009706109,0.000039483115,0.00018485793,0.000015777436,0.000009711493,0.0000013589233,0.000017293636,0.000028676859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988403,0.000093393304,0.00030250754,0.00014546933,0.00047182126,0.00014654703],"domain_scores_gemma":[0.9991606,0.00009988035,0.00026009302,0.00034729092,0.00009329546,0.000038863964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037531546,0.00016209725,0.00045446018,0.000042528998,0.000046025543,0.000018650711,0.00008450164,0.000020811769,0.0000054229804],"category_scores_gemma":[0.0000425992,0.000074185955,0.00020866953,0.00015608782,0.000049469963,0.00008228506,0.000043884174,0.0001683246,2.7834616e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007300963,0.0004603491,0.9905197,0.000035980007,0.005863111,0.0000021864096,0.00058851653,0.0021029867,0.000020803642,9.359322e-7,0.000020005551,0.00031243835],"study_design_scores_gemma":[0.0054822285,0.00066531263,0.99133754,0.00014430474,0.0016155707,3.957784e-7,0.00042397302,0.00006308599,0.00013363273,0.0000062366967,0.000054099917,0.000073643045],"about_ca_topic_score_codex":0.00036384433,"about_ca_topic_score_gemma":0.000028166414,"teacher_disagreement_score":0.005409219,"about_ca_system_score_codex":0.00005881305,"about_ca_system_score_gemma":0.000016168,"threshold_uncertainty_score":0.30252156},"labels":[],"label_agreement":null},{"id":"W2944619570","doi":"10.1002/oby.22462","title":"Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada","year":2019,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Canadian Institutes of Health Research; Mitacs; Novo Nordisk; AstraZeneca; Obesity Canada; Eli Lilly and Company","keywords":"Liraglutide; Medicine; Weight loss; Weight change; Cohort; Persistence (discontinuity); Body weight; Weight management; Internal medicine; Weight gain; Cohort study; Obesity; Gastroenterology; Animal science; Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.012705730307036225,"score_gpt":0.2857696282770774,"score_spread":0.2730638979700412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944619570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556379,0.000036949557,0.000022698887,0.000079282974,0.00033640972,0.0016201988,0.000006752183,0.000012158335,0.04224765],"genre_scores_gemma":[0.9939381,0.00007936117,0.0007546624,0.00009304017,0.000027592412,0.000058523765,0.00003268745,0.000011203912,0.0050048428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990634,0.00006341337,0.00026321327,0.00024062271,0.00016117108,0.00020822824],"domain_scores_gemma":[0.99930644,0.00022973197,0.000066338696,0.00030240833,0.000030429528,0.00006464219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052638946,0.00010405737,0.0004044736,0.00008450362,0.000012598039,0.0000026392377,0.00007692138,0.000024742034,0.000060072452],"category_scores_gemma":[0.000012217078,0.00008884993,0.000091164045,0.00014459017,0.000015093009,0.00002982735,0.00006566994,0.000058536367,0.000018670768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030832895,0.00035414472,0.98651046,0.00093477115,0.00023398973,0.000034334276,0.000004608232,0.0000053764034,0.000035304296,0.0035041517,0.0012487513,0.0068258047],"study_design_scores_gemma":[0.003867728,0.00018814899,0.985699,0.00023265052,0.00017232775,1.4528108e-7,0.000020428834,0.00013245082,0.0009365818,0.00022432125,0.008444748,0.00008144193],"about_ca_topic_score_codex":0.19796194,"about_ca_topic_score_gemma":0.41196862,"teacher_disagreement_score":0.21400668,"about_ca_system_score_codex":0.0004059355,"about_ca_system_score_gemma":0.00013584642,"threshold_uncertainty_score":0.8073789},"labels":[],"label_agreement":null},{"id":"W2945082808","doi":"10.1016/j.jcjd.2019.05.005","title":"Fixed-Dose and Fixed-Ratio Combination Therapies in Type 2 Diabetes","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Sanofi; Eli Lilly and Company","keywords":"Medicine; Gynecology","score_opus":0.03036640105549063,"score_gpt":0.2775498168553043,"score_spread":0.24718341579981365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945082808","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02844216,0.96905,1.5964868e-7,0.00026140784,0.00068960583,0.00072513317,0.00002109578,0.0000076148294,0.0008028521],"genre_scores_gemma":[0.015045322,0.983219,0.00009252992,0.0002756807,0.00017984287,0.000021884443,0.00013416755,0.00007042471,0.0009611129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982545,0.00011777603,0.00069533166,0.00023564803,0.00020378329,0.00049298594],"domain_scores_gemma":[0.99844307,0.00020852282,0.00047168272,0.0002615382,0.00017134137,0.0004438628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042131424,0.00038626857,0.0017582586,0.0011902828,0.000054863183,0.000109086766,0.00018572187,0.00022327907,0.000107836655],"category_scores_gemma":[0.00017073397,0.00030009917,0.00027286238,0.00041569848,0.00009860583,0.00020553326,0.000023231201,0.00039153756,0.000034641365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000018958104,0.00007572791,0.06412165,0.008051106,0.0010291872,0.00003806125,0.00017747092,6.5269165e-7,0.0000020371708,0.00031136404,0.0040070065,0.9221839],"study_design_scores_gemma":[0.0013560001,0.001012623,0.015772738,0.015962744,0.0020913505,0.000003375114,0.00006048,0.00001311019,0.0000040007844,0.00014144347,0.9632295,0.00035265306],"about_ca_topic_score_codex":0.00006502152,"about_ca_topic_score_gemma":0.00083210773,"teacher_disagreement_score":0.9592225,"about_ca_system_score_codex":0.00035247832,"about_ca_system_score_gemma":0.0011619414,"threshold_uncertainty_score":0.9999451},"labels":[],"label_agreement":null},{"id":"W2945166916","doi":"10.1111/dom.13611","title":"A safety update on sodium glucose co‐transporter 2 inhibitors","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Canagliflozin; Medicine; Empagliflozin; Dapagliflozin; Randomized controlled trial; Incidence (geometry); Internal medicine; Adverse effect; Diabetes mellitus; Observational study; Acute kidney injury; Placebo; Amputation; Surgery; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.020074418725650908,"score_gpt":0.27450870267141614,"score_spread":0.2544342839457652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945166916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054208287,0.98582757,0.0000019061013,0.00011316746,0.00091730914,0.002372652,0.0002764237,0.00014123757,0.0049288934],"genre_scores_gemma":[0.00031933546,0.99237275,0.00008846089,0.0010737398,0.0005249018,0.00013478904,0.0019261992,0.000104187304,0.0034556254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997126,0.00012341866,0.0007062845,0.00088099315,0.00043474082,0.0007286008],"domain_scores_gemma":[0.9984019,0.00010188539,0.00030130954,0.00079467235,0.00005174206,0.00034853388],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040403823,0.0008752049,0.0034689414,0.0004621414,0.00012835926,0.00007621978,0.00019514073,0.00044878141,0.00021263096],"category_scores_gemma":[0.000021303505,0.00064007053,0.0009001477,0.00028031194,0.0001199132,0.00014315899,0.00009473944,0.0005321187,0.0011155319],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028729179,0.0006218547,0.0006575271,0.019680947,0.0017551493,0.000040484916,0.000045021803,7.2609055e-8,0.0000016597717,0.0012312876,0.0032880658,0.9726492],"study_design_scores_gemma":[0.0016502531,0.00013899765,0.002359013,0.006189189,0.011000312,0.0000018455257,0.000004628119,0.0000013454421,0.00006890018,0.000043185482,0.9779763,0.0005660278],"about_ca_topic_score_codex":0.0000055874843,"about_ca_topic_score_gemma":0.0000013062895,"teacher_disagreement_score":0.97468823,"about_ca_system_score_codex":0.00007703426,"about_ca_system_score_gemma":0.00011490011,"threshold_uncertainty_score":0.9996622},"labels":[],"label_agreement":null},{"id":"W2945457198","doi":"10.1111/1753-0407.12952","title":"Efficacy and safety of lixisenatide as add‐on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal‐O Study","year":2019,"lang":"en","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi","keywords":"Medicine; Lixisenatide; Basal insulin; Diabetes mellitus; Type 2 diabetes; Internal medicine; Insulin; Basal (medicine); Endocrinology","score_opus":0.007177949371179551,"score_gpt":0.25085223643478083,"score_spread":0.24367428706360128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945457198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602085,0.0008946842,9.932838e-8,0.00076199,0.000079005935,0.0015300771,0.0000012663548,0.0000045695615,0.0007074759],"genre_scores_gemma":[0.99866605,0.0001318924,0.00008265205,0.00095953967,0.00005122082,0.00001494547,0.0000021274245,0.000018897916,0.00007269547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860954,0.000115424344,0.00043914357,0.00017008177,0.0004221624,0.00024366948],"domain_scores_gemma":[0.99900216,0.00038028133,0.0002013055,0.0002301171,0.00010721705,0.000078924124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006428272,0.00017682672,0.00051657733,0.00036171812,0.000015798783,0.000019551071,0.00014837188,0.000038100574,0.000049371665],"category_scores_gemma":[0.000110108405,0.000094844836,0.000048513502,0.0004051692,0.000028999491,0.000099509525,0.000032339372,0.00020759617,0.000009315008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018465783,0.0026505997,0.9732649,0.00006034399,0.00027201936,0.000022823453,0.0029573652,0.000052450338,0.00039746024,0.00002036141,0.0002423532,0.018212778],"study_design_scores_gemma":[0.017941374,0.01526229,0.96206033,0.0010542151,0.00007331077,4.4215057e-7,0.0016932942,0.000023419245,0.0014853406,0.000026677055,0.00027736774,0.00010191262],"about_ca_topic_score_codex":0.000010710418,"about_ca_topic_score_gemma":0.000022727016,"teacher_disagreement_score":0.018110866,"about_ca_system_score_codex":0.000042718344,"about_ca_system_score_gemma":0.000043704924,"threshold_uncertainty_score":0.38676602},"labels":[],"label_agreement":null},{"id":"W2946015735","doi":"10.1016/j.jcjd.2019.05.003","title":"A Personalized Care Plan Is Positively Associated With Better Clinical Outcomes in the Care of Patients With Type 2 Diabetes: A Cross-Sectional Real-Life Study","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Terveyden ja hyvinvoinnin laitos; Canadian Diabetes Association","keywords":"Medicine; Confidence interval; Odds ratio; Diabetes mellitus; Type 2 diabetes; Health care; Veterans Affairs; Internal medicine; Cross-sectional study; Medical record","score_opus":0.020588711103800828,"score_gpt":0.28415490291872403,"score_spread":0.2635661918149232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946015735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979151,0.00026001883,5.1603553e-8,0.00015147988,0.00015876867,0.0008793751,0.00015292778,0.0000047948547,0.000477465],"genre_scores_gemma":[0.99844867,0.0000017602277,0.000022503002,0.0012395292,0.00004451051,0.000011924338,0.00010850189,0.000026894275,0.00009571073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981678,0.00016076713,0.00053205417,0.00021545052,0.0005376325,0.00038630128],"domain_scores_gemma":[0.99804,0.00025088602,0.0003905126,0.00021612988,0.0007939032,0.00030852435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000339807,0.00021687215,0.0006767453,0.00029256713,0.00006965172,0.00005643651,0.0002016758,0.00008479899,0.00011355618],"category_scores_gemma":[0.00014266798,0.00012376881,0.00016268482,0.00028379253,0.0001485632,0.00012790949,0.000013093906,0.0002833872,0.000005164411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009836117,0.00032894505,0.9923802,0.000051355186,0.0015804435,0.000023041754,0.0051661152,0.0000032299683,0.0000011442893,0.0000036265517,0.00015843456,0.00020512156],"study_design_scores_gemma":[0.008837157,0.006653954,0.9788884,0.00024500143,0.00046286738,1.2328908e-7,0.0046465667,0.0000020752714,0.000005838651,0.000001890528,0.00011848811,0.00013763267],"about_ca_topic_score_codex":0.0003020273,"about_ca_topic_score_gemma":0.0041228305,"teacher_disagreement_score":0.013491776,"about_ca_system_score_codex":0.00026193954,"about_ca_system_score_gemma":0.00071213464,"threshold_uncertainty_score":0.50471455},"labels":[],"label_agreement":null},{"id":"W2946078715","doi":"10.1139/cjpp-2018-0670","title":"Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenesis: role of IGF-1 and VEGF","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Angiogenesis; Internal medicine; Endocrinology; Vascular endothelial growth factor; Myocardial infarction; Diabetes mellitus; Cardiac function curve; Heart failure; Type 2 diabetes; VEGF receptors","score_opus":0.007276059409464835,"score_gpt":0.23324425529364876,"score_spread":0.22596819588418393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946078715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765927,0.0012275927,0.0000019503225,0.00031044378,0.00025592005,0.00032654533,0.000006677845,0.0000020614245,0.00020951597],"genre_scores_gemma":[0.9993086,0.00019045455,0.000113034475,0.0002155314,0.00011373188,0.000007935019,0.0000055081227,0.0000075903513,0.000037646838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994257,0.00006897279,0.00018575114,0.00010735995,0.00004854441,0.00016368197],"domain_scores_gemma":[0.9994693,0.000026585556,0.0002072953,0.000057294565,0.000107719585,0.00013184361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088144436,0.00009500928,0.00036098296,0.00016639178,0.000031767027,0.000001930034,0.00003572506,0.000079761005,0.00013940387],"category_scores_gemma":[0.0000039621787,0.00007355666,0.000047532147,0.00009392206,0.00017514137,0.00009170071,0.000010285536,0.00011134248,0.0000014288399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005287953,0.00004543102,0.020540439,0.00013950813,0.0014891683,0.00001866943,0.0005267397,0.00002622244,0.97461784,0.00008932939,0.00021434193,0.0017635322],"study_design_scores_gemma":[0.0055378154,0.0067725526,0.29429498,0.00011445331,0.002170945,0.00016088507,0.00042097864,0.000029545554,0.6867813,0.0010301922,0.002529276,0.00015709679],"about_ca_topic_score_codex":0.00022084048,"about_ca_topic_score_gemma":0.00006947287,"teacher_disagreement_score":0.28783655,"about_ca_system_score_codex":0.00002913968,"about_ca_system_score_gemma":0.00023134917,"threshold_uncertainty_score":0.29995534},"labels":[],"label_agreement":null},{"id":"W2946129806","doi":"10.2337/cd18-0102","title":"Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"","keywords":"Medicine; Hypoglycemia; Glycemic; Insulin; Type 2 diabetes; Endocrinology; Internal medicine; Glucagon-like peptide 1 receptor; Agonist; Postprandial; Basal (medicine); Diabetes mellitus; Receptor","score_opus":0.04460807814621742,"score_gpt":0.34904313357106914,"score_spread":0.3044350554248517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946129806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905235,0.00036723603,0.00007128718,0.0051264153,0.00057809654,0.0023555192,0.00011716288,0.00014876197,0.0007120124],"genre_scores_gemma":[0.9865546,0.000090758534,0.00068966777,0.010412299,0.000096407646,0.00014413621,0.0016333946,0.00003577165,0.00034291347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806523,0.00019029038,0.00060784986,0.00049030397,0.00026565953,0.00038069184],"domain_scores_gemma":[0.99863416,0.0003573172,0.00016002479,0.0003861843,0.00020028878,0.0002620386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025996155,0.0002293027,0.0005609317,0.00010546003,0.00011899613,0.00006024766,0.0001110686,0.000115834395,0.00009712199],"category_scores_gemma":[0.00014922756,0.000183836,0.00021093458,0.00017633592,0.00005674017,0.00018357384,0.000036855916,0.00019903103,0.00016145631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007847034,0.001175024,0.92336875,0.000088269444,0.0003868082,0.0000010565943,0.0023008122,0.000027473183,0.00016172198,0.0003213899,0.0020346798,0.07005552],"study_design_scores_gemma":[0.0059857504,0.004507667,0.9816898,0.00047668014,0.00014135851,1.4089962e-8,0.00064224255,0.00046862414,0.0007310644,0.00034529125,0.004753918,0.00025758767],"about_ca_topic_score_codex":0.00011888433,"about_ca_topic_score_gemma":0.0000389866,"teacher_disagreement_score":0.06979793,"about_ca_system_score_codex":0.0001360742,"about_ca_system_score_gemma":0.0000989647,"threshold_uncertainty_score":0.74966145},"labels":[],"label_agreement":null},{"id":"W2946251777","doi":"10.1016/j.jtcvs.2019.04.080","title":"Commentary: Leading the way to better surgical outcomes","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic and Cardiovascular Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital; Dalhousie University","funders":"","keywords":"Medicine; Canagliflozin; Type 2 diabetes; Exenatide; Perioperative; Empagliflozin; Glycemic; Diabetes mellitus; Disease; Intensive care medicine; Adverse effect; Mace; Liraglutide; Semaglutide; Scopus; Internal medicine; MEDLINE; Surgery; Endocrinology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.022871100222127183,"score_gpt":0.27973438476847984,"score_spread":0.25686328454635265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946251777","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066698566,0.017692314,0.00011680132,0.91202486,0.002012471,0.00056225096,0.0000100820325,0.000019211035,0.0008634506],"genre_scores_gemma":[0.021711688,0.0023205574,0.00018910656,0.96468467,0.006688004,0.000020707683,0.00006871943,0.00010294474,0.0042135804],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971772,0.0003261144,0.0006293896,0.00028902845,0.0011524085,0.0004258524],"domain_scores_gemma":[0.99804395,0.000732948,0.00025776777,0.0007151805,0.00012739841,0.00012276747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023001854,0.00038597896,0.002136705,0.00040778532,0.00008686209,0.00010299636,0.00018295275,0.00026942333,0.00006504804],"category_scores_gemma":[0.000061415085,0.00021263729,0.0035467504,0.00016598006,0.00006434527,0.00011164076,0.00014388432,0.001117985,0.00006546338],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061029794,0.000029303297,0.021166751,0.00030492904,0.011824761,0.0048234714,0.000042185566,0.0000040022946,4.9539625e-7,6.722626e-7,0.8651938,0.09654865],"study_design_scores_gemma":[0.00035711515,0.000097890144,0.004988507,0.00055176124,0.005488344,0.0006421127,0.000039283703,0.0000010933719,0.000019374926,0.000015570276,0.987571,0.0002279509],"about_ca_topic_score_codex":0.00001260431,"about_ca_topic_score_gemma":2.842156e-7,"teacher_disagreement_score":0.12237724,"about_ca_system_score_codex":0.00010053888,"about_ca_system_score_gemma":0.000040431743,"threshold_uncertainty_score":0.86710966},"labels":[],"label_agreement":null},{"id":"W2946777418","doi":"10.1007/s11010-019-03555-2","title":"Empagliflozin restores the integrity of the endothelial glycocalyx in vitro","year":2019,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; University of Toronto; St. Michael's Hospital; McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Excellence Research Chairs, Government of Canada","keywords":"Empagliflozin; Glycocalyx; Endothelium; Medicine; Endothelial dysfunction; Pharmacology; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 Diabetes Mellitus; Immunology","score_opus":0.004565909652975116,"score_gpt":0.20632747941814514,"score_spread":0.20176156976517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946777418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924311,0.0011855824,0.000018760937,0.00073818926,0.000056915025,0.00027170268,0.0000057023794,0.0000073295396,0.005284692],"genre_scores_gemma":[0.99821603,0.00000714766,0.000053843785,0.00026031383,0.000020164276,0.000010743496,0.000015561014,0.000009063698,0.0014071096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993488,0.000029296423,0.00012938514,0.0001713102,0.00016822745,0.00015293376],"domain_scores_gemma":[0.99947137,0.000016527572,0.000041880132,0.00041501553,0.000017412578,0.000037809896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012597437,0.00010398244,0.00015108146,0.000018353265,0.000019404968,0.00000910108,0.000117318516,0.00006368512,0.000026058842],"category_scores_gemma":[0.000029212502,0.000057572433,0.00010098473,0.00009709451,0.00009191304,0.000008461978,0.000100729034,0.00015749266,0.0000051257384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009234355,0.000086022286,0.009703071,0.00010594015,0.000057170055,0.000017205306,0.000039385333,6.43362e-7,0.98899424,0.00015444968,0.000094677685,0.0006548385],"study_design_scores_gemma":[0.0008790183,0.000034826186,0.0012332196,0.000057554695,0.00008009984,0.0000035984856,0.0001351904,0.0000318402,0.9966593,0.000104048864,0.0007226229,0.000058701895],"about_ca_topic_score_codex":0.00003782189,"about_ca_topic_score_gemma":7.7225775e-7,"teacher_disagreement_score":0.008469851,"about_ca_system_score_codex":0.000029878553,"about_ca_system_score_gemma":0.000031576626,"threshold_uncertainty_score":0.23477356},"labels":[],"label_agreement":null},{"id":"W2948204413","doi":"10.2337/db19-1679-p","title":"1679-P: Current State of Type 1 Diabetes in Adults: Data from the Canadian LMC Diabetes Registry","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Diabetes mellitus; Type 1 diabetes; Population; Internal medicine; Cohort; Type 2 diabetes; Pediatrics; Endocrinology","score_opus":0.020708824110257866,"score_gpt":0.255136558689564,"score_spread":0.2344277345793061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948204413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98571366,0.008773218,9.2998796e-8,0.0010207721,0.0007085814,0.0010045235,0.00069919595,0.000048689177,0.002031291],"genre_scores_gemma":[0.99550164,0.00031485222,0.00009211227,0.0007030576,0.00012787526,0.000047780144,0.0027306098,0.000047826314,0.00043422746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997581,0.00008475001,0.0004769568,0.000631162,0.0003996499,0.0008264595],"domain_scores_gemma":[0.9971681,0.00036090036,0.00018975511,0.0019160977,0.000119963326,0.00024517768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042993613,0.00032656128,0.000618722,0.00020593207,0.000065037035,0.000059453527,0.0007700827,0.00007574197,0.00027187867],"category_scores_gemma":[0.00026454945,0.00023656365,0.00009217882,0.00048827237,0.00014978593,0.00023964114,0.0003248602,0.00029496898,0.00031630474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018854158,0.00018066764,0.94845665,0.00028034148,0.00027959314,0.000003045749,0.00013908633,0.0000071669147,0.00045889252,0.000037230275,0.010962669,0.039175805],"study_design_scores_gemma":[0.0024591312,0.00038187855,0.9288636,0.002044841,0.000321691,3.528965e-8,0.00010876928,0.0040288996,0.0046746675,0.00055348844,0.05613467,0.00042834427],"about_ca_topic_score_codex":0.009439443,"about_ca_topic_score_gemma":0.03838637,"teacher_disagreement_score":0.045172002,"about_ca_system_score_codex":0.00017424596,"about_ca_system_score_gemma":0.0002686292,"threshold_uncertainty_score":0.9971568},"labels":[],"label_agreement":null},{"id":"W2948249999","doi":"10.2337/db19-1665-p","title":"1665-P: Fracture Risk in Patients Using Sodium-Glucose Cotransporter 2 Inhibitors: A Real-World Study","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Dapagliflozin; Hazard ratio; Canagliflozin; Type 2 diabetes; Cohort; Cohort study; Population; Proportional hazards model; Internal medicine; Diabetes mellitus; Confidence interval; Environmental health; Endocrinology","score_opus":0.008410303604791567,"score_gpt":0.2448580309804993,"score_spread":0.23644772737570774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948249999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504846,0.00009773915,6.0534427e-7,0.000052060812,0.00027734085,0.002045676,0.000013753715,0.00007710815,0.0023872352],"genre_scores_gemma":[0.9983814,0.000017837667,0.0001134168,0.00038201027,0.00009908894,0.000047634934,0.00012885717,0.00004395059,0.00078583567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983485,0.000058191214,0.0003628519,0.00042185304,0.00035648808,0.00045216357],"domain_scores_gemma":[0.99920106,0.000050861665,0.00013693621,0.00044258812,0.000057455152,0.00011109974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019896953,0.00027026582,0.00049425033,0.00034720747,0.00004190817,0.000030128693,0.000090496535,0.000068943096,0.00022112286],"category_scores_gemma":[0.000015520876,0.00022032062,0.000113639115,0.00035594957,0.000025487396,0.00017989671,0.000045958528,0.00021280411,0.0001266683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066144654,0.002215721,0.9938667,0.00007774606,0.0002374476,0.000012399859,0.0006330478,0.000025429235,0.00017831448,0.0000042658958,0.00041601254,0.0022667674],"study_design_scores_gemma":[0.006619594,0.00084212516,0.98696184,0.00018990501,0.00039452006,1.9512504e-8,0.00017873205,0.00017071549,0.002355894,0.000028515255,0.0020332215,0.00022493902],"about_ca_topic_score_codex":0.00042023466,"about_ca_topic_score_gemma":0.0001350927,"teacher_disagreement_score":0.0069048847,"about_ca_system_score_codex":0.00015205558,"about_ca_system_score_gemma":0.000024259223,"threshold_uncertainty_score":0.89844143},"labels":[],"label_agreement":null},{"id":"W2948262001","doi":"10.2337/db19-1199-p","title":"1199-P: Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adjunct; Hypoglycemia; Insulin; Glycemic; Internal medicine; Intensive care medicine","score_opus":0.015557971919077854,"score_gpt":0.2569686137107615,"score_spread":0.24141064179168367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948262001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967352,0.0004918748,0.0000036685838,0.00017509847,0.00007186318,0.0011198533,0.000020670755,0.000014624421,0.0013671072],"genre_scores_gemma":[0.9984284,0.000050714083,0.0004145793,0.0004689546,0.000010538683,0.0001894894,0.000109504006,0.000009178877,0.00031860883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992146,0.000015256324,0.00021625744,0.00020615997,0.0001458182,0.00020189343],"domain_scores_gemma":[0.9995091,0.00009534248,0.00006044383,0.00023067524,0.000052265543,0.000052154806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010444862,0.00010799491,0.00042712945,0.00044184347,0.00000784095,0.000006901355,0.00006512947,0.000031963606,0.00012402772],"category_scores_gemma":[0.000029313227,0.000078788755,0.00013994066,0.00062049506,0.000011414121,0.000038648297,0.00002589401,0.000026138816,0.000021119758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008131355,0.00038990137,0.9183888,0.000060021128,0.001222677,2.8592837e-7,0.0004893756,0.00012866262,0.0024713126,0.00015206968,0.00024827578,0.07636733],"study_design_scores_gemma":[0.0027690523,0.002966025,0.92857414,0.000116462026,0.00078084064,5.587175e-9,0.00026319706,0.0010058059,0.053595882,0.00024441883,0.009509855,0.00017430211],"about_ca_topic_score_codex":0.000040930667,"about_ca_topic_score_gemma":0.00002862696,"teacher_disagreement_score":0.076193035,"about_ca_system_score_codex":0.00002781981,"about_ca_system_score_gemma":0.00001443131,"threshold_uncertainty_score":0.32129124},"labels":[],"label_agreement":null},{"id":"W2948285959","doi":"10.2337/db19-2355-pub","title":"2355-PUB: Discontinuation of Dapagliflozin in DEPICT-1 and DEPICT-2 Led to Clinically Meaningful Increases in HbA1c and Body Weight","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Discontinuation; Dapagliflozin; Medicine; Insulin; Weight loss; Adverse effect; Diabetes mellitus; Body weight; Weight gain; Internal medicine; Endocrinology; Type 2 diabetes; Obesity","score_opus":0.0072929483344178715,"score_gpt":0.2532337385531129,"score_spread":0.245940790218695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948285959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564654,0.00059576763,0.0000037965667,0.00033434137,0.000048542242,0.00082791207,0.0000055424216,0.000022141641,0.0025154278],"genre_scores_gemma":[0.998248,0.00011403552,0.0007448846,0.0003538523,0.000030155124,0.000056043657,0.000041187006,0.000017608292,0.00039424826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987371,0.00006565673,0.00044358452,0.000324318,0.0001619213,0.00026742538],"domain_scores_gemma":[0.99924994,0.0002915024,0.00009290643,0.00022068179,0.000033644523,0.0001113342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044092766,0.00016301614,0.0005100163,0.00028512356,0.000012445315,0.000019800205,0.000060371916,0.000066979825,0.000039453924],"category_scores_gemma":[0.00028679596,0.00013761708,0.000039787985,0.00022504994,0.000042722306,0.00014071702,0.000113037415,0.00008334669,0.00001478265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008503678,0.00035937602,0.9812005,0.00011272532,0.00007607547,0.000006048455,0.0002129793,0.000001576795,0.005146058,0.00037212926,0.00011991063,0.0123075815],"study_design_scores_gemma":[0.0036414398,0.0008193985,0.99013305,0.00043218653,0.00011078818,2.0771341e-7,0.00014995153,0.0005889483,0.0032056693,0.00019043336,0.00058379635,0.00014415446],"about_ca_topic_score_codex":0.00011750571,"about_ca_topic_score_gemma":0.000119541284,"teacher_disagreement_score":0.012163427,"about_ca_system_score_codex":0.000032605472,"about_ca_system_score_gemma":0.000018943165,"threshold_uncertainty_score":0.5611862},"labels":[],"label_agreement":null},{"id":"W2948326753","doi":"10.1016/s0140-6736(19)31267-x","title":"Is it time to REWIND the cardiorenal clock in diabetes?","year":2019,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Janssen Pharmaceuticals; AbbVie Canada; Gilead Sciences; Sanofi; Astellas Pharma US; Roche; GlaxoSmithKline; National Health and Medical Research Council; Servier; Pfizer; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Renal function; Scopus; Internal medicine; Empagliflozin; Intensive care medicine; Heart failure; Cardiorenal syndrome; Randomized controlled trial; MEDLINE; Endocrinology","score_opus":0.030444657675544846,"score_gpt":0.2669733648421195,"score_spread":0.23652870716657462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948326753","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009371619,0.00038370487,4.7573099e-7,0.90419817,0.00024491677,0.0011772878,0.000068113455,0.00003237251,0.084523365],"genre_scores_gemma":[0.001217402,0.000037498747,0.00002689166,0.77908874,0.0061442535,0.000099174016,0.00016467499,0.000038609476,0.21318278],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998426,0.00009016802,0.0001974509,0.00031883153,0.00039395507,0.00057359895],"domain_scores_gemma":[0.9983011,0.0001635609,0.00007161414,0.0014102925,0.000025253714,0.000028178969],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038894603,0.00026708608,0.00081289525,0.00008858244,0.00003943238,0.000052369774,0.0005045531,0.00018702411,0.0009773391],"category_scores_gemma":[0.000030741186,0.00013052412,0.00017359354,0.0001850278,0.00004476929,0.000023182258,0.00019069925,0.0008251566,0.0098292045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026152455,0.000013516545,0.0022739992,0.000114222756,0.00039691923,0.00005827292,0.00024341683,0.0000031208285,0.000011638279,0.000006018115,0.9954631,0.001389654],"study_design_scores_gemma":[0.001042028,0.00012661818,0.0050988444,0.00030821824,0.00037905207,0.0000013315122,0.000011065103,0.000027737351,0.000042699485,0.00003714585,0.9927702,0.00015504537],"about_ca_topic_score_codex":0.000019894143,"about_ca_topic_score_gemma":0.0000024623687,"teacher_disagreement_score":0.12865941,"about_ca_system_score_codex":0.00010770296,"about_ca_system_score_gemma":0.00003203949,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W2948367127","doi":"10.2337/db19-256-or","title":"256-OR: Costarting Sitagliptin with Metformin Is Associated with a Lower Likelihood of Disease Progression in Newly Treated Patients with Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Metformin; Confounding; Internal medicine; Type 2 diabetes; Odds ratio; Diabetes mellitus; Endocrinology; Insulin","score_opus":0.005996598281582403,"score_gpt":0.22242492024551594,"score_spread":0.21642832196393352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948367127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968228,0.00022852795,3.7336034e-7,0.00007851422,0.00003669761,0.0018514565,0.000033021224,0.00008903308,0.0008596313],"genre_scores_gemma":[0.99802566,0.000007849285,0.0003720986,0.00021836403,0.0000122646325,0.00010874389,0.00042755264,0.000068200745,0.0007592625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979724,0.000048694274,0.00033138774,0.00044795722,0.0005506595,0.0006488476],"domain_scores_gemma":[0.9986919,0.00011176031,0.0002992085,0.00039495557,0.0002794097,0.0002227648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016499883,0.00036342652,0.0006673961,0.00023973046,0.000040058632,0.000030073414,0.0001011176,0.00007236835,0.00017500992],"category_scores_gemma":[0.00008739046,0.00019920667,0.00005815031,0.0008021887,0.00008046805,0.0002550907,0.00005482452,0.00012962942,0.000023232456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020995762,0.0019099821,0.9879963,0.00023675755,0.0006599866,0.000025180478,0.00020038786,0.000009483583,0.00029626157,0.0000034215457,0.00018819128,0.0063745123],"study_design_scores_gemma":[0.017480403,0.014576653,0.94984084,0.004718123,0.0011540094,6.148155e-8,0.00014921177,0.0006748105,0.010616923,0.000013738457,0.0002717747,0.0005034716],"about_ca_topic_score_codex":0.000013809578,"about_ca_topic_score_gemma":0.000030995732,"teacher_disagreement_score":0.03815544,"about_ca_system_score_codex":0.00012512674,"about_ca_system_score_gemma":0.00010447847,"threshold_uncertainty_score":0.8123413},"labels":[],"label_agreement":null},{"id":"W2948374001","doi":"10.2337/db19-254-or","title":"254-OR: Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Albuminuria; Creatinine; Internal medicine; Diabetes mellitus; Renal function; Body mass index; Biomarker; Endocrinology; Biology","score_opus":0.014357645812403234,"score_gpt":0.2422391875471868,"score_spread":0.22788154173478356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948374001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909118,0.000039234477,0.000008757495,0.00051207974,0.00024243836,0.0015475204,0.0000037141049,0.00004644711,0.0066880113],"genre_scores_gemma":[0.9982488,0.000007946702,0.00021734304,0.00032563767,0.000110782436,0.00020004739,0.00007023543,0.000018586901,0.00080062076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882483,0.000038051177,0.00022986472,0.00027404807,0.00028572208,0.00034750698],"domain_scores_gemma":[0.99939895,0.00019263274,0.00007304495,0.0002769103,0.000018714756,0.000039778868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039396153,0.00016172866,0.0002774245,0.00021626623,0.0000281587,0.000032980948,0.00009588429,0.000060725924,0.00008975245],"category_scores_gemma":[0.00005762078,0.00009018456,0.000048261543,0.00055569323,0.000027008997,0.00013302502,0.00002827212,0.00014413791,0.00003583462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006480639,0.00043416777,0.9871338,0.00008087247,0.00015055064,0.000009879657,0.00043346704,0.000026929474,0.0012795954,0.00010560223,0.00048845337,0.003376055],"study_design_scores_gemma":[0.1724858,0.005783614,0.8052759,0.00075009145,0.0003737057,0.0000027776366,0.0019386294,0.0034920708,0.002017517,0.00003865746,0.007473527,0.00036769136],"about_ca_topic_score_codex":0.00014704974,"about_ca_topic_score_gemma":0.00037023748,"teacher_disagreement_score":0.18185787,"about_ca_system_score_codex":0.00012490734,"about_ca_system_score_gemma":0.000058977672,"threshold_uncertainty_score":0.36776197},"labels":[],"label_agreement":null},{"id":"W2948423825","doi":"10.2337/db19-1455-p","title":"1455-P: Evaluating Opportunities for Deprescribing in the Elderly and Extreme Elderly with Diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Polypharmacy; Overweight; Internal medicine; Discontinuation; Diabetes mellitus; Adverse effect; Insulin; Metformin; Hypoglycemia; Retrospective cohort study; Body mass index; Endocrinology","score_opus":0.08919190973284218,"score_gpt":0.2806726142960594,"score_spread":0.1914807045632172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948423825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078846,0.0011815312,0.0000075934936,0.0013787169,0.0000648832,0.0016686254,0.0000072957287,0.00005408079,0.0048488015],"genre_scores_gemma":[0.9960435,0.000024932135,0.0011382992,0.00084908877,0.00006223383,0.0004359315,0.000064017215,0.000033618853,0.0013483936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986291,0.000060188308,0.00022042709,0.0003230823,0.00028270003,0.00048448704],"domain_scores_gemma":[0.9990133,0.00044602054,0.00007984806,0.00032744816,0.00006657524,0.00006680447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006155407,0.00022058439,0.0003471118,0.00014808634,0.000082783205,0.00009630387,0.00011555171,0.00005048617,0.000036402744],"category_scores_gemma":[0.00006814192,0.00013826782,0.000062975785,0.00012820076,0.00006678999,0.000200726,0.000040676787,0.0001019034,0.0000064048986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004780128,0.00016765836,0.75122225,0.0005096071,0.00025712093,0.0000078806415,0.00075746485,0.000009019829,0.0047874465,0.0008880927,0.00066632224,0.24067935],"study_design_scores_gemma":[0.047632977,0.065450095,0.70825034,0.007116305,0.0052047255,0.000008031364,0.046792574,0.027534164,0.037246842,0.006254118,0.045136034,0.0033737747],"about_ca_topic_score_codex":0.000009195648,"about_ca_topic_score_gemma":0.0000121837975,"teacher_disagreement_score":0.23730558,"about_ca_system_score_codex":0.000028419488,"about_ca_system_score_gemma":0.00003468369,"threshold_uncertainty_score":0.5638398},"labels":[],"label_agreement":null},{"id":"W2948519518","doi":"10.1016/s0140-6736(19)31150-x","title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":629,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"","keywords":"Medicine; Dulaglutide; Placebo; Renal function; Internal medicine; Myocardial infarction; Type 2 diabetes; Diabetes mellitus; Kidney disease; Stroke (engine); Albuminuria; Exenatide; Endocrinology; Pathology","score_opus":0.021672760705753316,"score_gpt":0.2688715661060254,"score_spread":0.24719880540027211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948519518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436176,0.0002613743,4.8423846e-7,0.0010305655,0.00016175596,0.0021474909,0.0000044865146,0.000013775334,0.0020183027],"genre_scores_gemma":[0.9979741,0.000054036784,0.000022384347,0.00052393164,0.00009111961,0.00008694174,0.0000105030185,0.000007994318,0.001228973],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990625,0.00019488457,0.0002425872,0.00014668846,0.00017625807,0.00017712798],"domain_scores_gemma":[0.99899775,0.0002464209,0.00011591413,0.000586511,0.000022422184,0.000030995998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083306094,0.00010793154,0.0010225818,0.00011409168,0.000024167164,0.000013257345,0.00014250352,0.000032419495,0.0000791473],"category_scores_gemma":[0.00012169172,0.00004855678,0.0001542983,0.0003176889,0.000047284204,0.000051694835,0.000053237494,0.00008343783,0.0000075997937],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4574056,0.00032606497,0.53266686,0.000044766297,0.005304491,0.0000028644129,0.0010605234,0.00016413485,0.0010482747,0.00023715702,0.0007943635,0.00094488915],"study_design_scores_gemma":[0.8490934,0.0004096157,0.14477974,0.000043183867,0.003400709,5.2358224e-8,0.00018796622,0.0010780095,0.00024033674,0.000096956945,0.00058805145,0.000082007355],"about_ca_topic_score_codex":0.000009277939,"about_ca_topic_score_gemma":0.00006965,"teacher_disagreement_score":0.39168778,"about_ca_system_score_codex":0.000021762737,"about_ca_system_score_gemma":0.000022046625,"threshold_uncertainty_score":0.19800879},"labels":[],"label_agreement":null},{"id":"W2948563418","doi":"10.1155/2019/8639629","title":"A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"Case Reports in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Canagliflozin; Medicine; Acute kidney injury; Type 2 diabetes; Diabetes mellitus; Renal injury; Intensive care medicine; Pediatrics; Internal medicine; Kidney; Endocrinology","score_opus":0.006226290804853983,"score_gpt":0.23935375857009547,"score_spread":0.2331274677652415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948563418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430203,0.0002703111,3.8101658e-7,0.00013339092,0.00023468703,0.0009535389,0.00003045063,0.00003624743,0.0040389416],"genre_scores_gemma":[0.99823874,0.00006538114,0.00016649975,0.00033390464,0.000008055497,0.00008282349,0.00011236218,0.00002645581,0.0009657524],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9984257,0.000048607893,0.00049948477,0.00041826747,0.00011378175,0.0004941145],"domain_scores_gemma":[0.9990241,0.000032562508,0.00020990071,0.00052243436,0.000072237,0.00013875496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007423241,0.00020707055,0.0005429221,0.00032600752,0.000013808228,0.0000046042705,0.000026585383,0.00007553564,0.00018433356],"category_scores_gemma":[0.00007097198,0.00016759132,0.00004049358,0.00039082413,0.00007542505,0.0000614135,0.000087058244,0.00017105443,0.000008764427],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017088732,0.00036162985,0.2501029,0.00011784481,0.00026652572,0.7390784,0.0002121605,0.00001204482,0.000818735,0.00003491811,0.0034053894,0.005418588],"study_design_scores_gemma":[0.008896861,0.008562039,0.006799825,0.00070262444,0.0010502245,0.91166824,0.0013531406,0.00026316717,0.023184085,0.00011329724,0.03653172,0.0008748018],"about_ca_topic_score_codex":0.0014786338,"about_ca_topic_score_gemma":0.0003654175,"teacher_disagreement_score":0.24330308,"about_ca_system_score_codex":0.00019351124,"about_ca_system_score_gemma":0.00014818368,"threshold_uncertainty_score":0.6834176},"labels":[],"label_agreement":null},{"id":"W2948579396","doi":"10.1186/s12933-019-0871-8","title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","year":2019,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Post-hoc analysis; Angiology; Type 2 diabetes; Internal medicine; Diabetes mellitus; Baseline (sea); Post hoc; Physical therapy; Endocrinology; Liraglutide","score_opus":0.009565328861979023,"score_gpt":0.22169767755394706,"score_spread":0.21213234869196804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948579396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97651887,0.019275317,0.00009310233,0.00006181963,0.0001223444,0.0032443008,0.000030070885,0.000036099726,0.00061806623],"genre_scores_gemma":[0.99683493,0.001793065,0.00053869095,0.00006311996,0.00008403472,0.00027376687,0.00028606493,0.000046117948,0.00008018156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585396,0.0014617492,0.00049090775,0.00085958844,0.000696421,0.0006373555],"domain_scores_gemma":[0.9976915,0.00021999169,0.0002093779,0.0015382849,0.00024056704,0.000100273995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003295852,0.00039467058,0.0022404734,0.0009938519,0.000059194193,0.000025461191,0.0001777216,0.00019084038,0.000021244836],"category_scores_gemma":[0.00020391152,0.00025615667,0.0009634626,0.0024723904,0.00024984658,0.00010027058,0.00007257558,0.00041273443,0.0000078260755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015584773,0.0011664813,0.7791149,0.00081287714,0.1280766,0.0010413317,0.0020819865,0.020466974,0.00011678881,0.00009044167,0.00012602855,0.051320795],"study_design_scores_gemma":[0.09429091,0.0075775133,0.80534047,0.00021831435,0.07983897,0.000032514043,0.005462889,0.0018271867,0.0003283927,0.000051148498,0.0042427303,0.000788964],"about_ca_topic_score_codex":0.0005074902,"about_ca_topic_score_gemma":0.000217268,"teacher_disagreement_score":0.07870614,"about_ca_system_score_codex":0.0001566079,"about_ca_system_score_gemma":0.00014946944,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W2948612418","doi":"10.1016/s0140-6736(19)31149-3","title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3040,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Placebo; Population; Myocardial infarction; Diabetes mellitus; Stroke (engine); Adverse effect; Semaglutide; Randomized controlled trial; Physical therapy; Exenatide; Liraglutide; Endocrinology","score_opus":0.026432493149684228,"score_gpt":0.2691027811706797,"score_spread":0.24267028802099547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948612418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776249,0.0023667156,8.9245816e-7,0.0015612104,0.0003804817,0.0069340374,0.0000014427814,0.000047633843,0.01108269],"genre_scores_gemma":[0.9952622,0.00023913418,0.000047521648,0.00052341464,0.00030139604,0.0004194035,0.000012854788,0.000017904356,0.0031761895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988876,0.00010100069,0.00022991521,0.00022244077,0.00024061852,0.0003183973],"domain_scores_gemma":[0.9990351,0.0002213358,0.00005112677,0.0006217998,0.00002170488,0.00004888946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010176272,0.00016727441,0.001419335,0.00008391367,0.000029246468,0.000032736505,0.00011583702,0.000052308205,0.000089475165],"category_scores_gemma":[0.00007917617,0.00009100845,0.00025584188,0.00012087873,0.000032508025,0.000049104576,0.000059016907,0.000120351106,0.000099580495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9380876,0.00013831384,0.05607112,0.000062894345,0.0028412635,0.000011393468,0.00013410309,0.000033962955,0.000054171272,0.00020293001,0.000859996,0.001502289],"study_design_scores_gemma":[0.9857284,0.00031755143,0.008115361,0.000042831925,0.00083110906,4.6327574e-7,0.000038384955,0.00013133492,0.00008424298,0.00008498526,0.0045192363,0.00010609188],"about_ca_topic_score_codex":0.000021489346,"about_ca_topic_score_gemma":0.000008406089,"teacher_disagreement_score":0.04795576,"about_ca_system_score_codex":0.00002716719,"about_ca_system_score_gemma":0.000022627992,"threshold_uncertainty_score":0.37112167},"labels":[],"label_agreement":null},{"id":"W2949024755","doi":"10.2337/db19-1198-p","title":"1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Type 1 diabetes; Usability; Diabetes mellitus; Diabetic ketoacidosis; Insulin; Type 2 diabetes; Clinical trial; Internal medicine; Endocrinology; Computer science; Chemistry","score_opus":0.03263738746091734,"score_gpt":0.28712808404809637,"score_spread":0.25449069658717904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949024755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929129,0.002425906,0.0000057997327,0.0013252966,0.0001286164,0.0028683394,0.000007855749,0.00003305795,0.00029225033],"genre_scores_gemma":[0.9967753,0.00015561395,0.00012296872,0.0024255235,0.00007611363,0.00021462307,0.00003270485,0.000035722405,0.00016142751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985988,0.0001023795,0.00031067908,0.0003757651,0.0002609866,0.00035134758],"domain_scores_gemma":[0.9986652,0.0005054704,0.00008103006,0.00047675832,0.00017754764,0.00009399971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004632652,0.00025252515,0.0004809326,0.00016569634,0.000053025025,0.000030528212,0.00015630877,0.000053052372,0.000017405157],"category_scores_gemma":[0.00037253057,0.00013834082,0.000071171045,0.0005728204,0.00005482509,0.00010070086,0.00013945789,0.0001212569,0.000056350218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032071937,0.0045217616,0.53412503,0.0009929008,0.004286577,0.000005051435,0.07284236,0.13150805,0.04156563,0.0004430753,0.00040575746,0.2060966],"study_design_scores_gemma":[0.014254349,0.0049897204,0.7200875,0.0013282653,0.0005629284,2.0422661e-7,0.0077043627,0.24037407,0.0074352995,0.0006200573,0.0017503351,0.0008928696],"about_ca_topic_score_codex":0.000021559861,"about_ca_topic_score_gemma":0.0000027904287,"teacher_disagreement_score":0.20520373,"about_ca_system_score_codex":0.000053998236,"about_ca_system_score_gemma":0.000031272506,"threshold_uncertainty_score":0.5641375},"labels":[],"label_agreement":null},{"id":"W2949232422","doi":"10.1093/ndt/gfz101.sao010","title":"SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS","year":2019,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Semaglutide; Liraglutide; Medicine; Glucagon-like peptide-1; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes; Urology","score_opus":0.014088555430312025,"score_gpt":0.26589664891129117,"score_spread":0.25180809348097916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949232422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963637,0.00021670507,0.000061421444,0.0018629419,0.000089122695,0.0010240384,0.0000487997,0.000016715592,0.00031656417],"genre_scores_gemma":[0.99768925,0.00027850893,0.00007107588,0.0012291196,0.000018221715,0.000033587337,0.00010127501,0.000012130132,0.0005668425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979761,0.00058953924,0.00057473424,0.00032936528,0.00031098776,0.00021923428],"domain_scores_gemma":[0.9980493,0.0010056323,0.00040354405,0.00042420946,0.00006917598,0.000048148082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087119936,0.00021853206,0.001149187,0.00044787434,0.000069884714,0.000011049418,0.00011164501,0.00012508678,0.00003566403],"category_scores_gemma":[0.00011600517,0.00011669877,0.0005045408,0.0007233783,0.00021781548,0.000052080242,0.000029298526,0.00011975065,0.0000021708152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012733159,0.0002596309,0.9391179,0.00038500293,0.016202586,0.000007004742,0.0018804348,0.0010016995,0.035877496,0.00083676423,0.00015714728,0.003001017],"study_design_scores_gemma":[0.003652419,0.0003503552,0.9477021,0.00007282227,0.039624594,0.0000019828221,0.00017805073,0.0005390134,0.007542626,0.00010854878,0.00012945928,0.00009803926],"about_ca_topic_score_codex":0.00018609481,"about_ca_topic_score_gemma":0.00063018774,"teacher_disagreement_score":0.02833487,"about_ca_system_score_codex":0.000028596476,"about_ca_system_score_gemma":0.000036719262,"threshold_uncertainty_score":0.47588378},"labels":[],"label_agreement":null},{"id":"W2949285476","doi":"10.1055/s-0039-1688248","title":"Vergleich der kardiovaskulären Sicherheit und des Auftretens schwerer Hypoglykämien mit Insulin degludec vs. Insulin glargin 100 E/ml bei älteren Patienten (≥65 Jahre) mit Typ 2 Diabetes: Beobachtungen aus DEVOTE","year":2019,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.025696990869097464,"score_gpt":0.2712751501141682,"score_spread":0.24557815924507073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949285476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7469721,0.23397315,0.00010876513,0.0011437568,0.00368633,0.004423266,0.0006350147,0.00076820224,0.00828941],"genre_scores_gemma":[0.9638322,0.009848199,0.005797335,0.0028359424,0.0012626766,0.0007444057,0.0033099265,0.0006781807,0.0116911195],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98618263,0.00096688425,0.0024893882,0.003503951,0.0020753122,0.0047818124],"domain_scores_gemma":[0.9913845,0.0012787654,0.0011045429,0.0037936098,0.00096458156,0.0014740158],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.001590643,0.0027534456,0.004098121,0.0014755793,0.0007110183,0.0005838352,0.002184426,0.0018020382,0.0012066996],"category_scores_gemma":[0.0011455119,0.0025413975,0.0015466221,0.0022128092,0.0011760497,0.0010739012,0.0018195573,0.0018154121,0.014451344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010755535,0.003817843,0.70028377,0.001655194,0.045951482,0.00052465266,0.001791545,0.0001854176,0.00050452835,0.0005433756,0.012318201,0.23134845],"study_design_scores_gemma":[0.024853064,0.0072380267,0.38984877,0.0025295801,0.041370563,0.0000037724828,0.00050925545,0.0024993964,0.004884664,0.0019656827,0.51950556,0.0047916593],"about_ca_topic_score_codex":0.0006143938,"about_ca_topic_score_gemma":0.00030167628,"teacher_disagreement_score":0.50718737,"about_ca_system_score_codex":0.0021549785,"about_ca_system_score_gemma":0.00078158866,"threshold_uncertainty_score":0.9997063},"labels":[],"label_agreement":null},{"id":"W2949340818","doi":"10.1093/ndt/gfz106.fp330","title":"FP330APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE PATIENTS","year":2019,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Resverlogix (Canada); University of Calgary","funders":"","keywords":"Medicine; Bromodomain; Disease; BET inhibitor; Kidney disease; Internal medicine; Biochemistry; Epigenetics; Gene","score_opus":0.004625176706435028,"score_gpt":0.20624008992478488,"score_spread":0.20161491321834984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949340818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960524,0.0013330014,0.000033490458,0.00032400386,0.000054147007,0.0019547082,0.00008387681,0.00004522187,0.000119160555],"genre_scores_gemma":[0.99771166,0.0005762788,0.00008616132,0.00026347846,0.00007365718,0.0003243552,0.00080977334,0.000025163436,0.0001294544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830794,0.00018285216,0.00027339262,0.00061393355,0.0002824757,0.000339376],"domain_scores_gemma":[0.9992613,0.00003624357,0.0000693047,0.00024152397,0.000044056087,0.00034755163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017945502,0.00025686293,0.00049110677,0.00030438008,0.00006473991,0.00002688646,0.00004731716,0.00009433154,0.000029209454],"category_scores_gemma":[0.000019500489,0.00023899083,0.00015623069,0.00023127861,0.00011123399,0.0002077366,0.00001858863,0.00012914467,0.00001390904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038267628,0.0009019658,0.9558949,0.0016585864,0.0026110667,0.00046658856,0.0010527938,0.00013044818,0.009133957,0.00010364758,0.000053946238,0.024165366],"study_design_scores_gemma":[0.010415764,0.00062912586,0.98160666,0.0002565107,0.0044263666,0.0000042582083,0.000019837144,0.00060761755,0.0012587177,0.00016850945,0.00035195838,0.00025468398],"about_ca_topic_score_codex":0.000045499557,"about_ca_topic_score_gemma":0.000050196042,"teacher_disagreement_score":0.02571178,"about_ca_system_score_codex":0.0001152681,"about_ca_system_score_gemma":0.0001164237,"threshold_uncertainty_score":0.97457635},"labels":[],"label_agreement":null},{"id":"W2949656920","doi":"10.1016/j.jtcvs.2019.03.134","title":"A LEADER in the management of type 2 diabetes and cardiorenal disease","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic and Cardiovascular Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Ethicon; Janssen Biotech; Idorsia Pharmaceuticals; Eisai; Novo Nordisk; Daiichi-Sankyo; AstraZeneca; Amarin Corporation; Valeant Pharmaceuticals International; Ironwood Pharmaceuticals, Incorporated; Medtronic; Bayer HealthCare; Sanofi; Roche; Novartis; St. Jude Medical; Chiesi España; Merck; GlaxoSmithKline; Servier; Bayer; Chiesi Farmaceutici; Forest Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Amgen; Pfizer; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Medicine; Cardiorenal syndrome; Type 2 diabetes; Diabetes mellitus; Disease; Intensive care medicine; Disease management; Cardiology; Internal medicine; Kidney disease; Endocrinology","score_opus":0.021675836846124,"score_gpt":0.2559574588093977,"score_spread":0.23428162196327368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949656920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5169623,0.4073166,0.00003920206,0.07127771,0.0012833623,0.0011878039,0.000018111652,0.000012357652,0.0019025435],"genre_scores_gemma":[0.8072647,0.08610753,0.00045020154,0.09915471,0.0038607153,0.000052915464,0.00015777782,0.00015895089,0.0027924909],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793774,0.00023851318,0.00047606352,0.00022483512,0.0008594689,0.0002633743],"domain_scores_gemma":[0.99892503,0.00018545613,0.00022997937,0.000490026,0.000106225,0.00006330613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017602198,0.00025193027,0.001331534,0.0003721816,0.000023058832,0.000036152476,0.00010599801,0.00014521874,0.000008814432],"category_scores_gemma":[0.000025957224,0.00015441258,0.0012693945,0.00020832264,0.000092516464,0.000084199324,0.00007070738,0.000526285,0.0000026395242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037236486,0.00016921894,0.081641704,0.015276705,0.03881242,0.013931503,0.00023582664,0.00003898564,0.0000021473945,0.000009926219,0.6139555,0.23555371],"study_design_scores_gemma":[0.00092108897,0.0002074081,0.10450544,0.00491109,0.023505524,0.00017533786,0.0004108133,0.000014322328,0.000014217377,0.000089150155,0.8648707,0.0003748998],"about_ca_topic_score_codex":0.000002811907,"about_ca_topic_score_gemma":5.6699374e-8,"teacher_disagreement_score":0.32120907,"about_ca_system_score_codex":0.000029540019,"about_ca_system_score_gemma":0.00006156969,"threshold_uncertainty_score":0.6296762},"labels":[],"label_agreement":null},{"id":"W2949665037","doi":"10.1016/s2213-8587(19)30180-9","title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":675,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Research and Development; St. Jude Medical; Duke Clinical Research Institute; Eisai; Daiichi-Sankyo; Deutsche Forschungsgemeinschaft; Regado Biosciences; Medicines Company; Bristol-Myers Squibb; Cleveland Clinic; Society for Academic Continuing Medical Education; Biotronik; AstraZeneca; Amarin Corporation; Boston VA Research Institute; Boston Scientific Corporation; MyoKardia; Bayer; Gilead Sciences; Takeda Pharmaceutical Company; American College of Cardiology Foundation; Novartis; Mayo Clinic; Merck; GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Eli Lilly and Company; Boehringer Ingelheim; Amgen; MedImmune; Sanofi; Abbott Laboratories","keywords":"Medicine; Dapagliflozin; Renal function; Type 2 diabetes; Internal medicine; Kidney disease; TIMI; Dialysis; Diabetes mellitus; Creatinine; Albuminuria; Urology; Endocrinology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.00957636408848811,"score_gpt":0.24791610790429294,"score_spread":0.23833974381580483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949665037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632466,0.0004478884,7.291971e-7,0.0004233532,0.000117379364,0.0025336808,0.000017697355,0.000023200322,0.00011138374],"genre_scores_gemma":[0.99842894,0.000042843305,0.00019641791,0.00077978335,0.000047932554,0.00018689856,0.000265391,0.000017542481,0.000034276654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982929,0.00026317476,0.00032116933,0.00032284373,0.0002731766,0.00052672235],"domain_scores_gemma":[0.99841934,0.00060370425,0.00020951625,0.00057697535,0.00005842707,0.00013206017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024148048,0.00021486937,0.0008994177,0.00015718785,0.000036875703,0.000010312334,0.0002127208,0.000041790823,0.000038397164],"category_scores_gemma":[0.00023214392,0.00010551477,0.00007568079,0.00032317056,0.0001367916,0.000048696376,0.00010141615,0.00012895884,0.0000059600266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03553611,0.0008377712,0.94996077,0.00014577723,0.0017668593,0.0000035990438,0.0002504359,0.000023079967,0.0002219425,0.000049018436,0.00008442142,0.011120232],"study_design_scores_gemma":[0.1341856,0.002168505,0.8542124,0.00026710788,0.0018611444,7.3088375e-9,0.00001967794,0.00016299584,0.0063788285,0.000041000927,0.000586167,0.000116549665],"about_ca_topic_score_codex":0.000009967247,"about_ca_topic_score_gemma":0.000009599512,"teacher_disagreement_score":0.09864948,"about_ca_system_score_codex":0.000036392583,"about_ca_system_score_gemma":0.000067568864,"threshold_uncertainty_score":0.43027675},"labels":[],"label_agreement":null},{"id":"W2949841198","doi":"10.1093/ndt/gfz106.fp485","title":"FP485EFFECTS OF ERTUGLIFLOZIN TREATMENT OVER 2 YEARS ON MEASURES OF RENAL FUNCTION","year":2019,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Renal function; Internal medicine; Intensive care medicine","score_opus":0.012447323499591994,"score_gpt":0.23800037466685278,"score_spread":0.2255530511672608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949841198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648774,0.00008179956,0.00023892355,0.000065000284,0.0001117899,0.00052084285,0.000014712439,0.00002610479,0.0024530787],"genre_scores_gemma":[0.99873745,0.00030639133,0.00008098213,0.00020776245,0.000036810783,0.000035197372,0.00028056744,0.000011573392,0.00030326174],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991398,0.00007123881,0.000236674,0.00020335922,0.00021863362,0.00013031568],"domain_scores_gemma":[0.99950427,0.000102254715,0.00011947404,0.00020178138,0.000037294885,0.00003492969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010496357,0.00012536906,0.0003839676,0.00026386222,0.000011553286,0.0000022365125,0.00003136744,0.00009154341,0.00019379501],"category_scores_gemma":[0.000004357346,0.000101991325,0.00017488193,0.00015675162,0.000037246726,0.000047420657,0.000002550137,0.000039542,0.000048051967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015183872,0.0023820784,0.23382843,0.00055878196,0.0062454175,0.000051517243,0.0017245908,0.0025504944,0.621095,0.0021559205,0.0004526323,0.11377129],"study_design_scores_gemma":[0.0102537805,0.0078085545,0.8863627,0.00009801868,0.0054234834,0.0000023282,0.000022254268,0.00024250073,0.08730345,0.00011048798,0.0022480688,0.00012442621],"about_ca_topic_score_codex":0.000068821406,"about_ca_topic_score_gemma":0.000053846386,"teacher_disagreement_score":0.6525342,"about_ca_system_score_codex":0.000047240617,"about_ca_system_score_gemma":0.000022600776,"threshold_uncertainty_score":0.41590855},"labels":[],"label_agreement":null},{"id":"W2950048237","doi":"10.1177/0954411919853394","title":"A Markov decision process for modeling adverse drug reactions in medication treatment of type 2 diabetes","year":2019,"lang":"en","type":"article","venue":"Proceedings of the Institution of Mechanical Engineers Part H Journal of Engineering in Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kwantlen Polytechnic University; Simon Fraser University","funders":"Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences; Medical Center, University of Pittsburgh","keywords":"Medicine; Adverse effect; Intensive care medicine; Drug; Diabetes mellitus; Type 2 diabetes; Disease; Markov model; Risk analysis (engineering); Markov decision process; Quality of life (healthcare); Pharmacology; Markov process; Markov chain; Computer science; Internal medicine; Machine learning; Mathematics","score_opus":0.01771803535789541,"score_gpt":0.2704567725844237,"score_spread":0.2527387372265283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950048237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643934,0.00045619314,0.0013432335,0.0004335562,0.0005554343,0.00066092104,0.0000014605906,0.0000087934195,0.00010105175],"genre_scores_gemma":[0.9968779,0.0004470249,0.002515147,0.00001000538,0.00007971395,0.000018821629,0.000002945345,0.00001339191,0.000035025827],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99834156,0.000003650365,0.00094934495,0.00012499827,0.00041806675,0.00016239799],"domain_scores_gemma":[0.9989064,0.000122001584,0.00039932766,0.00009981086,0.00040071947,0.00007174262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072934973,0.0001493907,0.0006296469,0.00050817616,0.00000971081,0.0000012606989,0.0001449389,0.00007400185,0.000010780109],"category_scores_gemma":[0.00091230485,0.000098540455,0.00013090497,0.0004994802,0.000035989822,0.00015235876,0.00001712959,0.00013379651,2.503093e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021112126,0.0019641786,0.014445568,0.005580333,0.0007730248,0.0000041620106,0.0015898817,0.84009546,0.11813441,0.009502015,0.00028908343,0.005510651],"study_design_scores_gemma":[0.017925493,0.0046898117,0.002637119,0.01767251,0.0008543331,0.000017298324,0.0010747155,0.8798845,0.072746284,0.000720261,0.0015313163,0.00024639873],"about_ca_topic_score_codex":0.000006559517,"about_ca_topic_score_gemma":7.603174e-7,"teacher_disagreement_score":0.045388125,"about_ca_system_score_codex":0.00019710547,"about_ca_system_score_gemma":0.000069253576,"threshold_uncertainty_score":0.4018363},"labels":[],"label_agreement":null},{"id":"W2950136952","doi":"10.1111/dom.13811","title":"Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health; Lunenfeld-Tanenbaum Research Institute; Health Sciences Centre; St Joseph's Health Care; University of Toronto; Western University; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi; AstraZeneca","keywords":"Medicine; Empagliflozin; Diabetic ketoacidosis; Dapagliflozin; Diabetes mellitus; Type 2 diabetes; Type 1 diabetes; Insulin; Canagliflozin; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.026315365111541193,"score_gpt":0.2924846575457922,"score_spread":0.266169292434251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950136952","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21613047,0.7125768,9.274593e-7,0.000030848503,0.00014269703,0.07075869,0.00021512675,0.000056597954,0.000087816756],"genre_scores_gemma":[0.010296124,0.9043425,0.000100356265,0.00007102667,0.0003477388,0.08347059,0.0007834717,0.000114556744,0.00047364802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968748,0.00034936232,0.0008425834,0.0008866929,0.00022678764,0.0008197637],"domain_scores_gemma":[0.998194,0.00037528397,0.000555223,0.00059006724,0.0000854615,0.00019999863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008303476,0.00090131763,0.0025527633,0.00033530247,0.00023115432,0.00017507336,0.00017470775,0.00037913542,0.000019889068],"category_scores_gemma":[0.0000533274,0.0005453233,0.0005432427,0.00033450953,0.00016165237,0.00023091948,0.000077377284,0.00036198506,0.000014234293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030774005,0.0007381808,0.042975076,0.016025424,0.0016474952,0.0000017888943,0.00039713085,9.2759075e-7,0.000024063753,0.000075963646,0.00007598935,0.9380072],"study_design_scores_gemma":[0.0054710153,0.0009759724,0.036077153,0.0080536725,0.013581984,9.519915e-7,0.00014732599,0.0001254458,0.0010943371,0.00043530585,0.9331916,0.0008452379],"about_ca_topic_score_codex":0.000029818124,"about_ca_topic_score_gemma":0.000025405,"teacher_disagreement_score":0.9371619,"about_ca_system_score_codex":0.000110786,"about_ca_system_score_gemma":0.00016937812,"threshold_uncertainty_score":0.99969983},"labels":[],"label_agreement":null},{"id":"W2950290700","doi":"10.1161/circulationaha.119.040921","title":"Empagliflozin and Heart Failure","year":2019,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Heart failure; Cardiology; Internal medicine; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.01480430498117388,"score_gpt":0.23879675360136415,"score_spread":0.22399244862019027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950290700","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057826668,0.00047325852,0.000055584358,0.9338732,0.000369276,0.0011428102,0.000007671001,0.000108514345,0.006143058],"genre_scores_gemma":[0.20209055,0.000015515901,0.00050246913,0.78587425,0.002316078,0.000038446036,0.00211803,0.00005915418,0.006985504],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993015,0.000015255977,0.00012311514,0.00024001703,0.00017617697,0.00014393925],"domain_scores_gemma":[0.99963194,0.000023796998,0.000051717554,0.00024375644,0.000027934566,0.000020823869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004572224,0.00013929093,0.00023972064,0.00011660647,0.000022163535,0.000028556486,0.000020963824,0.00026257706,0.0001243767],"category_scores_gemma":[0.000010640976,0.00012483331,0.00006469882,0.00005290659,0.000016098411,0.000049145754,0.000019407584,0.00024338819,0.00031113336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000019980237,0.000009538292,0.045874126,0.00029752284,0.00010735982,0.00002255379,0.000019985668,0.0000015870895,0.0000829116,0.00001760918,0.9526582,0.0009066196],"study_design_scores_gemma":[0.00049530546,0.00003134761,0.11923206,0.00010796471,0.0003038934,0.000007720495,0.0000042010665,0.00007100288,0.000011168036,0.00006651424,0.87956613,0.000102685575],"about_ca_topic_score_codex":0.0000051318916,"about_ca_topic_score_gemma":6.583863e-7,"teacher_disagreement_score":0.14799891,"about_ca_system_score_codex":0.00005931384,"about_ca_system_score_gemma":0.000018232753,"threshold_uncertainty_score":0.50905544},"labels":[],"label_agreement":null},{"id":"W2950785405","doi":"10.1016/j.celrep.2019.05.055","title":"Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action","year":2019,"lang":"en","type":"article","venue":"Cell Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research; Merck Canada; Zafgen; Novo Nordisk; Intarcia Therapeutics; Diabetes Canada; Ironwood Pharmaceuticals, Incorporated; GlaxoSmithKline; Canadian Diabetes Association; Pfizer","keywords":"Incretin; Glucagon-like peptide-1; Action (physics); Neuroscience; Control (management); Biology; Cell biology; Pharmacology; Bioinformatics; Chemistry; Endocrinology; Computer science; Diabetes mellitus; Type 2 diabetes","score_opus":0.030614274195140286,"score_gpt":0.2960075053151362,"score_spread":0.2653932311199959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950785405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306464,0.00019390938,0.000008763965,0.000043638778,0.0004573528,0.0005368933,0.0000021537232,0.000037707832,0.0056549106],"genre_scores_gemma":[0.9991141,0.000040149458,0.00007252703,0.0000373246,0.00007377351,0.000020159141,0.00006769557,0.0000070755154,0.00056720653],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989405,0.000048363374,0.0003513614,0.00024158083,0.00025491632,0.00016325682],"domain_scores_gemma":[0.99917454,0.00011981463,0.00035823495,0.00020121063,0.00006977294,0.00007641405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013134682,0.00012482029,0.00038372926,0.000042508487,0.000015760625,0.0000029824853,0.00003938182,0.00007756624,0.0006634776],"category_scores_gemma":[0.000088672474,0.00008158423,0.00012815911,0.00006503358,0.000060281563,0.00004415401,0.000057812566,0.00009261363,0.000014426859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010894192,0.00043230684,0.060389515,0.0001620724,0.0000696798,0.00015755415,0.000020365738,0.000021411879,0.9358911,0.000004877012,0.0007113819,0.0010503342],"study_design_scores_gemma":[0.006417779,0.002397405,0.23456241,0.000073239644,0.0005887276,0.0000071777026,0.000070999595,0.0007026528,0.7535646,0.000038232192,0.0014313782,0.00014540575],"about_ca_topic_score_codex":0.000005751389,"about_ca_topic_score_gemma":2.683377e-7,"teacher_disagreement_score":0.1823265,"about_ca_system_score_codex":0.000031048585,"about_ca_system_score_gemma":0.000017240322,"threshold_uncertainty_score":0.7264614},"labels":[],"label_agreement":null},{"id":"W2951059146","doi":"10.1002/ejhf.1486","title":"Rationale and Design of The Emperial-Preserved and Emperial-Reduced Trials of Empagliflozin in Patients with Chronic Heart Failure","year":2019,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Heart failure; Internal medicine; Cardiology; Clinical trial; Intensive care medicine; Diabetes mellitus","score_opus":0.018822421577959415,"score_gpt":0.234219809688949,"score_spread":0.2153973881109896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951059146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940285,0.0003687954,0.000011420505,0.004220254,0.00013191887,0.0011954866,0.0000093938,0.0000036720019,0.000030531304],"genre_scores_gemma":[0.99549294,0.000019520805,0.0040776986,0.00008386234,0.00011271027,0.0000025992103,0.000005953803,0.000024738407,0.00017997334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775875,0.0008368122,0.00074238883,0.00015215679,0.0003550419,0.00015484422],"domain_scores_gemma":[0.99891543,0.0001366918,0.0004517987,0.00023918111,0.00017341951,0.00008349409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016514874,0.00015691307,0.0007145635,0.0001481582,0.000031968622,0.000025560279,0.000098597426,0.000028753666,0.00014741116],"category_scores_gemma":[0.00021309752,0.000090176945,0.00010694236,0.00014847997,0.00010284611,0.00015874258,0.0000721605,0.00014607118,0.000003971229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004109224,0.00073508086,0.7450037,0.0004884374,0.0008449593,0.000016959719,0.0011088998,0.00039043382,0.20047912,0.00007638278,0.046186093,0.0005607037],"study_design_scores_gemma":[0.02598954,0.0060513197,0.9218074,0.0014016113,0.0003862924,0.000018469811,0.00029852812,0.000020889218,0.013749148,0.000017475719,0.030080777,0.0001785365],"about_ca_topic_score_codex":0.0000036407523,"about_ca_topic_score_gemma":0.000005750403,"teacher_disagreement_score":0.18672997,"about_ca_system_score_codex":0.000033390603,"about_ca_system_score_gemma":0.00013308681,"threshold_uncertainty_score":0.36773092},"labels":[],"label_agreement":null},{"id":"W2951281859","doi":"10.1055/s-0039-1688341","title":"Wirksamkeit und Verträglichkeit von Dapagliflozin bei Patienten mit Typ-2-Diabetes und moderater Niereninsuffizienz (Chronische Nierenerkrankung Stadium 3A): Die DERIVE-Studie","year":2019,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Dapagliflozin; Gynecology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.021285674216614398,"score_gpt":0.27092358913471976,"score_spread":0.24963791491810536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951281859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6717123,0.305018,0.00012734585,0.0015745986,0.0059157414,0.003693472,0.00066324807,0.0006178737,0.010677453],"genre_scores_gemma":[0.96939594,0.010031432,0.0015561223,0.0029412657,0.001249764,0.0004936564,0.0031047417,0.00053406,0.010693029],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98837614,0.00061506924,0.0020129483,0.003108219,0.0016435041,0.0042440915],"domain_scores_gemma":[0.99350625,0.0009074883,0.00095025933,0.0029121875,0.0006527576,0.0010710441],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009207206,0.0024788852,0.003429832,0.0009753205,0.00073623663,0.0005952849,0.0014122314,0.0012866771,0.00089303544],"category_scores_gemma":[0.00041811037,0.0021855924,0.0009694814,0.0010148532,0.00089638075,0.0008454033,0.0014680338,0.0014939628,0.008054048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017304759,0.009068388,0.7086616,0.0037043889,0.09236572,0.00079356966,0.0026185387,0.0013979872,0.0029657434,0.0032619846,0.052521523,0.12091008],"study_design_scores_gemma":[0.029503725,0.011650963,0.055493657,0.0029627588,0.06492714,0.0000013502682,0.0012200417,0.017653253,0.025640791,0.0017638277,0.7826102,0.006572335],"about_ca_topic_score_codex":0.00032033477,"about_ca_topic_score_gemma":0.00020233687,"teacher_disagreement_score":0.73008865,"about_ca_system_score_codex":0.0014331988,"about_ca_system_score_gemma":0.0006238059,"threshold_uncertainty_score":0.9987948},"labels":[],"label_agreement":null},{"id":"W2951328534","doi":"10.1093/ndt/gfz106.fp483","title":"FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER","year":2019,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Semaglutide; Medicine; Liraglutide; Creatinine; Urology; Urinary system; Albumin; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.006503014633065569,"score_gpt":0.24627805214097365,"score_spread":0.23977503750790807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951328534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970514,0.00016190435,0.0005577987,0.000544767,0.000022465996,0.0007488734,0.00002338171,0.000023038236,0.00086636725],"genre_scores_gemma":[0.9977243,0.00018365507,0.00061795936,0.00074191176,0.000017124095,0.000028660386,0.00030291217,0.000013744554,0.0003697533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987572,0.000100745434,0.0003761626,0.00034591765,0.00020605138,0.00021391807],"domain_scores_gemma":[0.99905586,0.000387045,0.00015153944,0.00023548247,0.00007725912,0.000092801674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031553349,0.0001847309,0.00076028926,0.0010612,0.000027482492,0.0000055559503,0.00004190655,0.00010515515,0.00006540823],"category_scores_gemma":[0.000025355432,0.00016123759,0.00013516295,0.0007315269,0.0000914531,0.000052774012,0.0000142350245,0.00007136791,0.0000066059415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008051356,0.0011514472,0.73699456,0.0017360561,0.018996555,0.00013654925,0.0063269204,0.0024258452,0.20841499,0.0022044985,0.00012179267,0.013439418],"study_design_scores_gemma":[0.004383447,0.0030717405,0.942526,0.000088103894,0.02649655,0.0000069519874,0.00027203988,0.0022729044,0.020608101,0.000035692246,0.0000842363,0.00015426833],"about_ca_topic_score_codex":0.00009029429,"about_ca_topic_score_gemma":0.00009880667,"teacher_disagreement_score":0.20553139,"about_ca_system_score_codex":0.000022390901,"about_ca_system_score_gemma":0.000019929834,"threshold_uncertainty_score":0.65750784},"labels":[],"label_agreement":null},{"id":"W2951565188","doi":"10.1177/2054358119854113","title":"Characteristics of Adults With Type 2 Diabetes Mellitus by Category of Chronic Kidney Disease and Presence of Cardiovascular Disease in Alberta Canada: A Cross-Sectional Study","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada); University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Albuminuria; Internal medicine; Cross-sectional study; Renal function; Type 2 diabetes; Disease; Population; Myocardial infarction; Type 2 Diabetes Mellitus; Environmental health; Endocrinology; Pathology","score_opus":0.00628147905107961,"score_gpt":0.22387694784538334,"score_spread":0.21759546879430372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951565188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763259,0.020429617,0.000001059416,0.0014990788,0.00015254968,0.00081842707,0.000754152,0.0000012012958,0.000017991717],"genre_scores_gemma":[0.9976959,0.0008810789,0.0000059333665,0.0011059877,0.000040364364,0.000009637574,0.00015780033,0.00001553099,0.00008773838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984065,0.00007478141,0.0005616535,0.00022751192,0.0003929828,0.00033652838],"domain_scores_gemma":[0.9825093,0.000049796094,0.00031528505,0.00029308518,0.00024376377,0.016588757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022487146,0.00016919468,0.0005843938,0.00020371396,0.000043122476,0.0000128549345,0.00009001853,0.00002277979,0.00004515844],"category_scores_gemma":[0.002133934,0.000139104,0.0000831172,0.00017045675,0.00014511551,0.000103934646,0.000018240342,0.00010484336,2.709177e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00149238,0.00030988397,0.98861945,0.0038626043,0.000502129,0.00013572932,0.00017044443,0.000028205575,0.0000018315841,0.000019433339,0.0042455085,0.00061238604],"study_design_scores_gemma":[0.004588288,0.0012901393,0.9881154,0.0009955231,0.00055813004,0.0000011467276,0.00009464229,0.00019740297,0.0000039873094,0.000015339607,0.0040186136,0.00012142521],"about_ca_topic_score_codex":0.35840923,"about_ca_topic_score_gemma":0.053055,"teacher_disagreement_score":0.30535424,"about_ca_system_score_codex":0.0002620638,"about_ca_system_score_gemma":0.053935725,"threshold_uncertainty_score":0.9642243},"labels":[],"label_agreement":null},{"id":"W2951959817","doi":"10.14740/jem.v9i3.570","title":"Efficacy and Safety of Ipragliflozin in Patients With Type 2 Diabetes: ASSIGN-K Study","year":2019,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Postprandial; Type 2 diabetes; Internal medicine; Body mass index; Diabetes mellitus; Blood pressure; Gastroenterology; Hemoglobin; Insulin; Urology; Endocrinology","score_opus":0.008245402593199789,"score_gpt":0.2445335419761845,"score_spread":0.2362881393829847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951959817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638885,0.002283517,9.568821e-7,0.00009959142,0.0001991101,0.0004547925,0.0000010031041,0.0000031170796,0.0005690408],"genre_scores_gemma":[0.99918026,0.0003393756,0.0001759287,0.00008080575,0.000027106422,0.0000016485654,0.0000016799412,0.0000074705285,0.00018569801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922186,0.00005761333,0.00029913275,0.00011144291,0.00013636444,0.00017357402],"domain_scores_gemma":[0.9994717,0.000065448025,0.00018773822,0.00011200828,0.00010280436,0.00006028986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013767532,0.00010452629,0.0005230082,0.00022944769,0.000013162033,0.0000040814125,0.000042560638,0.000029571447,0.000035045567],"category_scores_gemma":[0.00004152713,0.000066144195,0.000024589732,0.00010894513,0.000051351075,0.00008984933,0.000041161533,0.00014731586,0.0000022312242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001416284,0.001082369,0.9822705,0.000032584867,0.0005563604,0.000024993595,0.00021662125,0.00000272241,0.0001279318,0.00020651551,0.00004907164,0.014014088],"study_design_scores_gemma":[0.020924823,0.0031079468,0.9707476,0.00006523304,0.0004967659,0.000004181523,0.00014625498,0.000001277428,0.00013888106,0.000022403905,0.0042891717,0.000055475666],"about_ca_topic_score_codex":0.000002768726,"about_ca_topic_score_gemma":0.000001727211,"teacher_disagreement_score":0.01950854,"about_ca_system_score_codex":0.000009627802,"about_ca_system_score_gemma":0.000023679228,"threshold_uncertainty_score":0.2697282},"labels":[],"label_agreement":null},{"id":"W2952159329","doi":"10.1097/hco.0000000000000647","title":"Predictors of heart failure development in type 2 diabetes","year":2019,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; St. Michael's Hospital; University of Toronto","funders":"National Institute of General Medical Sciences; AstraZeneca","keywords":"Medicine; Heart failure; Type 2 diabetes; Diabetes mellitus; Heart disease; Population; Intensive care medicine; Disease; Internal medicine; Cardiology; Endocrinology; Environmental health","score_opus":0.08659533526426667,"score_gpt":0.3675689438903298,"score_spread":0.28097360862606313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952159329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047892978,0.9899369,0.0000012209341,0.000032470383,0.0076779686,0.001576117,0.00001369264,0.000021192765,0.0002615271],"genre_scores_gemma":[0.00019569772,0.99790245,0.00010610662,0.0000057133857,0.00032821388,0.00024186344,0.001128522,0.00003231521,0.000059125246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980096,0.00018462956,0.000799972,0.00045287504,0.00017442669,0.00037848274],"domain_scores_gemma":[0.99917877,0.00012989335,0.00019313804,0.00038894833,0.000047115114,0.00006215311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032497296,0.00034960193,0.0027701326,0.00066740456,0.000008608114,0.0000039612787,0.00014314876,0.00028667194,0.000027500657],"category_scores_gemma":[0.00006132169,0.0002755478,0.00032102087,0.00043364422,0.000057297624,0.000028420458,0.00016010556,0.00035313563,0.00012591676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012921719,0.00019891348,0.16195261,0.073585905,0.00073206716,0.000002283327,0.00005228578,0.0000065076656,2.0600066e-7,0.000102230646,0.026567502,0.73678654],"study_design_scores_gemma":[0.0006528534,0.00017962989,0.0050733727,0.021187762,0.0002732671,0.0000023363252,0.0000072589023,9.149673e-7,6.2959344e-7,0.00000382451,0.97243327,0.00018485631],"about_ca_topic_score_codex":0.0000011254533,"about_ca_topic_score_gemma":8.2317456e-7,"teacher_disagreement_score":0.9458658,"about_ca_system_score_codex":0.00028086765,"about_ca_system_score_gemma":0.00038052505,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W2952833925","doi":"10.2337/db19-995-p","title":"995-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Spare part; Type 2 diabetes; Medicine; Diabetes mellitus; Pediatrics; Endocrinology; Engineering; Operations management","score_opus":0.008926568494204824,"score_gpt":0.23070728575765487,"score_spread":0.22178071726345006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952833925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864879,0.00018474256,2.206956e-8,0.0010276411,0.000121834266,0.0027274888,0.000027290482,0.000042271415,0.009380781],"genre_scores_gemma":[0.99644613,0.000008215248,0.000022435599,0.0014965951,0.00004860437,0.00024922812,0.00034360454,0.000044947894,0.0013402269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970221,0.00025110028,0.0004322179,0.0006040107,0.0006679175,0.0010226555],"domain_scores_gemma":[0.99788755,0.00029433504,0.00016373562,0.0013550933,0.00012013567,0.00017913291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083302386,0.00040468146,0.0007733839,0.0009222631,0.00014693328,0.00013810235,0.0005032302,0.00007593839,0.0001656595],"category_scores_gemma":[0.00009389728,0.00022389987,0.00013792973,0.0035320937,0.00011131539,0.00012442787,0.000088823705,0.0003465496,0.00010083522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000229562,0.00068362936,0.995234,0.000056697398,0.0011987957,0.000011313304,0.0006999886,0.00015011302,0.000004295564,0.000055897843,0.0010771902,0.00080508477],"study_design_scores_gemma":[0.0023055808,0.00086196617,0.99134016,0.00012938233,0.0013409359,9.382545e-9,0.000869232,0.0003481879,0.00004062747,0.000030703424,0.0024575375,0.00027570018],"about_ca_topic_score_codex":0.021049954,"about_ca_topic_score_gemma":0.43236172,"teacher_disagreement_score":0.41131178,"about_ca_system_score_codex":0.00042167347,"about_ca_system_score_gemma":0.0001429544,"threshold_uncertainty_score":0.985469},"labels":[],"label_agreement":null},{"id":"W2953701845","doi":"10.26596/wn.201910264-75","title":"Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition","year":2019,"lang":"en","type":"article","venue":"World Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrition International","funders":"","keywords":"Gastric emptying; Incretin; Diabetes mellitus; Glucose homeostasis; Nutrient sensing; Insulin; Medicine; Type 2 diabetes; Endocrinology; Glucagon-like peptide-1; Internal medicine; Insulin resistance; Biology; Stomach; Biochemistry","score_opus":0.019547409056560824,"score_gpt":0.24722025566939074,"score_spread":0.2276728466128299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953701845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97540206,0.015581585,0.000009273435,0.0025422955,0.00030614418,0.0015136586,0.0000037356488,0.00011489454,0.0045263423],"genre_scores_gemma":[0.9845249,0.003720176,0.0010690333,0.00053200126,0.00034684277,0.000201682,0.00011335545,0.000021950069,0.009470026],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99896127,0.000029145638,0.00018766092,0.00034407686,0.00022127008,0.00025655885],"domain_scores_gemma":[0.99942935,0.000095735995,0.00006279765,0.00026309508,0.000050448754,0.00009858082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012958853,0.00016103993,0.00024818358,0.00027028844,0.000056559365,0.00006835151,0.00004643576,0.000042153464,0.00019364158],"category_scores_gemma":[0.000009390553,0.00015457763,0.000075023105,0.0002786624,0.000043612064,0.00033046506,0.00003640116,0.00009917579,0.00036545552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012805457,0.00703226,0.5930342,0.011158865,0.0004902149,0.00009219168,0.0002693966,0.0000024024125,0.13923657,0.0055799796,0.1960549,0.045768462],"study_design_scores_gemma":[0.009958123,0.0017362194,0.19455187,0.009841123,0.00042543557,0.000009029143,0.00035057007,0.00026891378,0.02300978,0.0027771986,0.75652426,0.000547473],"about_ca_topic_score_codex":0.000006570331,"about_ca_topic_score_gemma":0.000012432605,"teacher_disagreement_score":0.5604693,"about_ca_system_score_codex":0.00012057382,"about_ca_system_score_gemma":0.000007238743,"threshold_uncertainty_score":0.6303493},"labels":[],"label_agreement":null},{"id":"W2954063001","doi":"10.1016/j.jcjd.2019.06.004","title":"Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Impact; Hamilton Health Sciences; Population Health Research Institute; McMaster University; McMaster University Medical Centre; Health Sciences Centre; HalTech","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Glycemic; Diabetes mellitus; Type 2 diabetes; Feeling; Weight loss; Quality of life (healthcare); Gerontology; Internal medicine; Endocrinology; Obesity; Nursing; Social psychology; Psychology","score_opus":0.01673576586374282,"score_gpt":0.19997961626706817,"score_spread":0.18324385040332536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954063001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963383,0.00088069955,1.3742677e-7,0.00040877314,0.0008358599,0.0002943599,0.0000029665935,0.000006291572,0.0012325897],"genre_scores_gemma":[0.99922395,0.00002899076,0.000050115905,0.00035746617,0.00014262818,0.00001721001,0.0000057140155,0.000021711192,0.00015224218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887234,0.000023336006,0.0003140835,0.00013626575,0.0002794654,0.00037448588],"domain_scores_gemma":[0.9989709,0.000075636606,0.00019777643,0.00023604902,0.00018256016,0.00033706435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017706613,0.00016817998,0.00036378996,0.0002686505,0.000054805463,0.000025542742,0.00016935123,0.000030152169,0.00016739583],"category_scores_gemma":[0.00003075076,0.000095768206,0.00011206369,0.00025457478,0.00013957814,0.00021906235,0.0000061691944,0.00015247671,0.000018361612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008233945,0.000103193765,0.9705741,0.00020839047,0.0005633454,0.000031906053,0.015364609,0.00003102456,0.0009409066,0.00009383341,0.0011313803,0.010874969],"study_design_scores_gemma":[0.006792828,0.015825313,0.6782852,0.00575284,0.00097561575,0.00000357609,0.042460732,0.000058210397,0.23300546,0.000052603173,0.016139437,0.0006481896],"about_ca_topic_score_codex":0.00006788158,"about_ca_topic_score_gemma":0.00039598605,"teacher_disagreement_score":0.2922889,"about_ca_system_score_codex":0.00006705352,"about_ca_system_score_gemma":0.0002636524,"threshold_uncertainty_score":0.39053142},"labels":[],"label_agreement":null},{"id":"W2954115740","doi":"10.1111/dom.13820","title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Ontario Drug Policy Research Network; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Dapagliflozin; Hazard ratio; Diabetes mellitus; Internal medicine; Cohort study; Population; Incidence (geometry); Urinary system; Cohort; Retrospective cohort study; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.0042578219873595285,"score_gpt":0.1978892058495821,"score_spread":0.1936313838622226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954115740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963212,0.0022803103,0.0000010647428,0.000022510247,0.00004783842,0.0011924072,0.000025488855,0.000025984224,0.00008317933],"genre_scores_gemma":[0.99934906,0.00028904228,0.00009299748,0.000037186328,0.00003071181,0.000047507412,0.000029703517,0.000019667435,0.00010415417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988435,0.00006823125,0.00027581854,0.00034024977,0.00021267617,0.0002595439],"domain_scores_gemma":[0.9993377,0.00007785973,0.00016799576,0.00020119583,0.000057662357,0.00015759155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025156696,0.00024031108,0.0006742923,0.00022512044,0.00007198699,0.000024235609,0.000026999824,0.00007017745,0.000024163008],"category_scores_gemma":[0.0000109332805,0.00018358216,0.000038853857,0.00015171159,0.000093500115,0.00022654941,0.00004461545,0.00010581611,5.8318557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008103254,0.0018895157,0.9923081,0.0006775555,0.00059836195,0.000003640824,0.0017163384,0.0000028629456,0.00050406915,0.00001440234,0.0000040654986,0.0022000943],"study_design_scores_gemma":[0.0069513577,0.0019455475,0.9872481,0.000103617516,0.0015132511,8.788373e-7,0.0003506399,0.000129543,0.0014594237,0.000058287576,0.00005837974,0.00018092262],"about_ca_topic_score_codex":0.000104048886,"about_ca_topic_score_gemma":0.0000117259015,"teacher_disagreement_score":0.006870325,"about_ca_system_score_codex":0.000013225687,"about_ca_system_score_gemma":0.000013198252,"threshold_uncertainty_score":0.7486263},"labels":[],"label_agreement":null},{"id":"W2954426845","doi":"10.1016/j.jval.2019.04.663","title":"PDB116 REAL-WORLD ADHERENCE AND PERSISTENCE AMONG ELDERLY PATIENTS WITH T2DM INITIATING DULAGLUTIDE VS. LIRAGLUTIDE OR EXENATIDE ONCE-WEEKLY IN THE US","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Liraglutide; Medicine; Dulaglutide; Discontinuation; Lira; Exenatide; Internal medicine; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Endocrinology; Confidence interval","score_opus":0.03829917965234857,"score_gpt":0.2758031372049166,"score_spread":0.23750395755256803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954426845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99034137,0.00015758259,0.000002989444,0.0012757259,0.00009346583,0.0021053748,0.000006265381,0.00003642067,0.0059808395],"genre_scores_gemma":[0.9959974,0.0002575925,0.0010264447,0.001522544,0.000030010486,0.00009255685,0.000026467602,0.00002489938,0.0010220697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978128,0.00022669646,0.00049590616,0.00044823764,0.00045642772,0.0005599139],"domain_scores_gemma":[0.998812,0.00035897002,0.00023784561,0.00040320173,0.000051589,0.00013637503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073654874,0.00023097747,0.0004460138,0.00026842425,0.00009207709,0.000042031417,0.00016053006,0.00004414223,0.000035839792],"category_scores_gemma":[0.0001018792,0.00014295774,0.00003739933,0.00062324695,0.00008604361,0.00021471767,0.00006244207,0.00028422082,0.000018485835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022706247,0.0002837587,0.98879,0.00046027647,0.000026441527,0.00005088671,0.0021951173,0.00019010782,0.0000012097662,0.0002781472,0.00014324885,0.0073537845],"study_design_scores_gemma":[0.0034880063,0.003402127,0.9879665,0.0020805846,0.00003293049,0.0000018711333,0.0011135628,0.001220781,0.000007387791,0.000062600724,0.00046048788,0.00016315616],"about_ca_topic_score_codex":0.015013693,"about_ca_topic_score_gemma":0.0051360014,"teacher_disagreement_score":0.009877692,"about_ca_system_score_codex":0.0003218838,"about_ca_system_score_gemma":0.00022367093,"threshold_uncertainty_score":0.99154544},"labels":[],"label_agreement":null},{"id":"W2954462466","doi":"10.1111/dom.13824","title":"Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Novo Nordisk; Sanofi; Pfizer; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Weight management; Type 2 diabetes; Randomized controlled trial; Internal medicine; Body mass index; Overweight; Endocrinology","score_opus":0.003699516871405874,"score_gpt":0.22044988878038713,"score_spread":0.21675037190898125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954462466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560727,0.0035139685,0.00000700534,0.00023638972,0.00014831685,0.006421016,0.0000132663645,0.0000912331,0.003961524],"genre_scores_gemma":[0.99445236,0.0011042755,0.0007611071,0.00048536205,0.000056347762,0.00044926206,0.000060529754,0.000041387837,0.002589365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749535,0.0001988697,0.00049152016,0.0007591029,0.00042595188,0.00062919816],"domain_scores_gemma":[0.99892807,0.00012564693,0.0001502774,0.00048815215,0.00006254078,0.00024531246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090591004,0.000468918,0.0016441399,0.0004365285,0.00014575123,0.000057245015,0.00011557733,0.0000807572,0.00007766631],"category_scores_gemma":[0.00003014996,0.0003269677,0.00011209069,0.00033462778,0.00016047679,0.00028091465,0.00026474404,0.00020315242,0.000020696938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01622398,0.006495199,0.9551837,0.0009415852,0.0024624802,0.000066481276,0.0019787308,0.0000015201466,0.00011820507,0.0017841794,0.00007358997,0.0146703655],"study_design_scores_gemma":[0.4674903,0.0015316462,0.521309,0.00071733055,0.0024453434,8.495695e-7,0.00050460617,0.00084736786,0.00029881988,0.00019140319,0.004208162,0.00045515996],"about_ca_topic_score_codex":0.000031744356,"about_ca_topic_score_gemma":0.0000226025,"teacher_disagreement_score":0.45126632,"about_ca_system_score_codex":0.000037648362,"about_ca_system_score_gemma":0.000017771545,"threshold_uncertainty_score":0.9999182},"labels":[],"label_agreement":null},{"id":"W2954546034","doi":"10.1111/dom.13826","title":"Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Term (time); Insulin; Glucagon-like peptide-1; Internal medicine; Intensive care medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.02133313376193959,"score_gpt":0.2495910649470088,"score_spread":0.2282579311850692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954546034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586148,0.038541913,0.0000031446875,0.00078031694,0.00028932752,0.001593745,0.000020007923,0.000029986833,0.00012671622],"genre_scores_gemma":[0.98598456,0.012360548,0.00010552961,0.0007809321,0.00014364326,0.000024725798,0.00003783842,0.000017172215,0.00054504606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987411,0.000111411086,0.0002809736,0.00037221427,0.00022913433,0.0002651492],"domain_scores_gemma":[0.99878544,0.00052675145,0.00012310676,0.0003861555,0.000051723582,0.00012679992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003959887,0.00023604972,0.0006386095,0.00006143244,0.000096212476,0.000053632073,0.00010703924,0.00009208728,0.00008043258],"category_scores_gemma":[0.000083014915,0.00015072167,0.00007932331,0.00011506989,0.00021637787,0.00019079517,0.00014779471,0.00014589907,0.000011605637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007134684,0.000699139,0.91772175,0.00019067498,0.00079149235,0.0000032848322,0.0017487003,4.4936604e-7,0.004311029,0.000351473,0.000247355,0.0668],"study_design_scores_gemma":[0.043295942,0.0005553603,0.94980633,0.0002613801,0.0005926978,2.6749984e-7,0.00006470426,0.000020297308,0.0020890825,0.00010999728,0.00305295,0.00015096091],"about_ca_topic_score_codex":0.00006635174,"about_ca_topic_score_gemma":0.0000078735775,"teacher_disagreement_score":0.066649035,"about_ca_system_score_codex":0.000008365834,"about_ca_system_score_gemma":0.000024529918,"threshold_uncertainty_score":0.6146251},"labels":[],"label_agreement":null},{"id":"W2954634225","doi":"10.1161/circheartfailure.118.005875","title":"Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure","year":2019,"lang":"en","type":"article","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of General Medical Sciences","keywords":"Medicine; Empagliflozin; Heart failure; Cardiology; Intensive care medicine; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.007768669535013249,"score_gpt":0.23950561696508885,"score_spread":0.23173694743007558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954634225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98895335,0.000011999392,0.000015155758,0.008211695,0.00013925669,0.0021755253,0.000009635364,0.00012026614,0.0003631262],"genre_scores_gemma":[0.991567,4.3725015e-7,0.0030045295,0.0022056622,0.000047072666,0.000072645795,0.00023408105,0.000045847093,0.0028226937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983998,0.00003973043,0.00030677582,0.00044168296,0.00044268474,0.00036932653],"domain_scores_gemma":[0.9990676,0.00003427136,0.00007716655,0.00049218046,0.00011161626,0.00021716606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110644745,0.00027079313,0.0005622682,0.0002512091,0.00005177899,0.000051090203,0.000063064945,0.00011944336,0.00055114116],"category_scores_gemma":[0.00005245393,0.00018483291,0.000099778066,0.00033339867,0.000033662258,0.00031349156,0.000038054615,0.00016378626,0.00044562045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016034952,0.00034523755,0.98962253,0.00013018107,0.00012409165,0.0000019075446,0.000122776,0.000023778093,0.00041026462,0.00005151345,0.008753714,0.00025362842],"study_design_scores_gemma":[0.006739055,0.00053201005,0.92821515,0.00018802795,0.000104270235,0.0000015233035,0.00012535813,0.00017077471,0.00009318893,0.000014079784,0.06359162,0.00022496466],"about_ca_topic_score_codex":0.000044706172,"about_ca_topic_score_gemma":0.00008579918,"teacher_disagreement_score":0.061407432,"about_ca_system_score_codex":0.00013194553,"about_ca_system_score_gemma":0.00011081627,"threshold_uncertainty_score":0.7537268},"labels":[],"label_agreement":null},{"id":"W2954659053","doi":"10.1053/j.ajkd.2019.03.432","title":"Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial","year":2019,"lang":"en","type":"letter","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Janssen Biotech; Servier; Daiichi-Sankyo; Novo Nordisk; Eisai; Intarcia Therapeutics; Sanofi; Merck; Boehringer Ingelheim; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Empagliflozin; Diabetes mellitus; Kidney disease; Internal medicine; Diabetic nephropathy; Type 2 diabetes; Glycemic; Disease; Nephropathy; Kidney; Population; Endocrinology","score_opus":0.007286943888473314,"score_gpt":0.2702711140901823,"score_spread":0.26298417020170894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954659053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7525634,0.00067997293,0.0000025373831,0.2442846,0.00047690512,0.001327803,0.0006017867,0.000011869874,0.00005112664],"genre_scores_gemma":[0.602981,0.00015111521,0.0000129056425,0.3953974,0.0008911559,0.000034012464,0.0003169327,0.00004379551,0.00017172704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958177,0.0014777508,0.0010468744,0.00037291972,0.0008808104,0.00040393462],"domain_scores_gemma":[0.99276376,0.004101276,0.0015615692,0.00090113765,0.000119146156,0.00055314286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007569922,0.0005469304,0.0033946733,0.00056768826,0.00005256068,0.00007151458,0.00051070284,0.000116848445,0.00010838693],"category_scores_gemma":[0.004086462,0.00024110623,0.0012725276,0.00059310556,0.00062857557,0.000109635286,0.00006512295,0.0007853041,0.00001023489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02938072,0.00030952966,0.79254174,0.00009289963,0.011780681,0.00013031754,0.00011254272,0.000011978972,0.0000035845915,0.0000015689288,0.16263427,0.0030001528],"study_design_scores_gemma":[0.25816885,0.037499018,0.49931398,0.0011929928,0.12675656,0.0000026078083,0.00041121044,0.00034466933,0.00003796466,0.00005365685,0.07538646,0.0008320249],"about_ca_topic_score_codex":0.0002637779,"about_ca_topic_score_gemma":0.000004929428,"teacher_disagreement_score":0.29322776,"about_ca_system_score_codex":0.000119352575,"about_ca_system_score_gemma":0.00030238737,"threshold_uncertainty_score":0.9832027},"labels":[],"label_agreement":null},{"id":"W2954711526","doi":"10.1016/j.hlc.2019.06.091","title":"Heart Failure Outcomes in Patients with Diabetes With and Without Atrial Fibrillation – Data From the EMPA-REG OUTCOME Study","year":2019,"lang":"en","type":"article","venue":"Heart Lung and Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Internal medicine; Atrial fibrillation; Cardiology; Heart failure; Placebo; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.017572829587435727,"score_gpt":0.2726762443320135,"score_spread":0.25510341474457776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954711526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706054,0.0001034548,0.00000393251,0.0009617847,0.000042236137,0.0017664825,0.0000144243795,0.000027419339,0.00001974676],"genre_scores_gemma":[0.9992457,0.0000010626546,0.00013803049,0.00013462892,0.00005490347,0.0000064324536,0.00034013408,0.000015055345,0.00006407785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990574,0.000050333125,0.00016540465,0.0003258508,0.00026026063,0.00014076257],"domain_scores_gemma":[0.99938774,0.000073939336,0.000052677668,0.00041317818,0.000029588551,0.000042861728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015809711,0.00013765479,0.00029641407,0.000051445426,0.000063495965,0.000053797954,0.000033222135,0.000034058372,0.000014482249],"category_scores_gemma":[0.000015474172,0.000076648765,0.000019052572,0.00009461377,0.000023577304,0.0002390557,0.00005055584,0.00006381688,0.0000071799627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001312218,0.000059727616,0.99891543,0.000022722303,0.00017417216,2.0431553e-7,0.0002310538,0.00006880321,0.0000060727875,0.0000039812912,0.000065106186,0.00032148793],"study_design_scores_gemma":[0.0061445297,0.00043359317,0.9905415,0.0000708703,0.00032054877,1.8020981e-7,0.0001976723,0.0017667691,8.883843e-7,0.000008622987,0.0004136435,0.00010115511],"about_ca_topic_score_codex":0.00011852296,"about_ca_topic_score_gemma":0.00020209122,"teacher_disagreement_score":0.00837392,"about_ca_system_score_codex":0.000025903479,"about_ca_system_score_gemma":0.000012464167,"threshold_uncertainty_score":0.31256458},"labels":[],"label_agreement":null},{"id":"W2954774129","doi":"10.1111/bcp.14056","title":"Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study","year":2019,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Metformin; Type 2 diabetes; Hazard ratio; Internal medicine; Sulfonylurea; Stroke (engine); Myocardial infarction; Cohort; Diabetes mellitus; Population; Proportional hazards model; Cohort study; Adverse effect; Confidence interval; Insulin; Endocrinology","score_opus":0.038933279126811784,"score_gpt":0.3978859644411691,"score_spread":0.3589526853143573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954774129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937713,0.0018806574,0.000010060379,0.00022595,0.00123176,0.002664027,0.000015100163,0.000006986058,0.00019416468],"genre_scores_gemma":[0.99714947,0.0015192805,0.00018338287,0.00043799297,0.00045096164,0.00005291212,0.000017498629,0.000016097914,0.00017242234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778146,0.00063324126,0.0009372067,0.0001954139,0.00027812546,0.00017454395],"domain_scores_gemma":[0.99777144,0.0011081004,0.00055433536,0.00015030558,0.00029112145,0.00012471867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024783367,0.00012588366,0.0011822097,0.000072692324,0.00005056459,0.0000056562976,0.00009164901,0.000071722345,0.00018084723],"category_scores_gemma":[0.00053608,0.00008911939,0.00078145566,0.00008746333,0.000098683624,0.000065155706,0.000032816744,0.00017888127,0.000006373684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033010945,0.0020402854,0.95423555,0.000042132822,0.011554841,0.00008755961,0.000024988072,0.00017858864,0.0000040369764,0.0000071492923,0.00056860026,0.027955143],"study_design_scores_gemma":[0.06337736,0.0071853837,0.9123619,0.000073642266,0.013008123,0.000030140587,0.00006771552,0.00024790503,0.000038328748,0.00014078949,0.0033902032,0.00007846516],"about_ca_topic_score_codex":0.00014596748,"about_ca_topic_score_gemma":0.000008775379,"teacher_disagreement_score":0.060076263,"about_ca_system_score_codex":0.00004689809,"about_ca_system_score_gemma":0.00011783511,"threshold_uncertainty_score":0.36341834},"labels":[],"label_agreement":null},{"id":"W2954897982","doi":"10.1016/j.jval.2019.04.606","title":"PDB57 REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPELTM STUDY","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Type 2 diabetes; Pharmacy; Diabetes mellitus; Basal (medicine); Basal insulin; Dulaglutide; Propensity score matching; Internal medicine; Retrospective cohort study; Exenatide; Insulin; Surgery; Endocrinology; Family medicine","score_opus":0.013326857875443965,"score_gpt":0.2506861155821586,"score_spread":0.23735925770671462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954897982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921282,0.000059496757,1.3477437e-7,0.0015469795,0.00012739561,0.004333911,0.000009518006,0.000040454135,0.0017539385],"genre_scores_gemma":[0.9979688,0.00007469027,0.00003948831,0.0011323452,0.00003725141,0.00013171311,0.00007110446,0.00004190239,0.00050273695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794066,0.00034445862,0.00046902947,0.00040675135,0.00031870272,0.0005204029],"domain_scores_gemma":[0.9987,0.0002967899,0.00020524909,0.000672623,0.00003220708,0.00009311648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075866195,0.00028748726,0.0005862574,0.00024437095,0.000079452504,0.000043079774,0.0002266634,0.00003339698,0.00004998788],"category_scores_gemma":[0.00002137736,0.00013345493,0.000044572298,0.00047522128,0.000072929426,0.0001276079,0.000059373142,0.00022772474,0.000090739464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031707552,0.0013026946,0.99481523,0.000078235214,0.0001692351,0.000012268783,0.0011715844,0.0011174344,9.80883e-8,0.00013713709,0.0002957746,0.0005832287],"study_design_scores_gemma":[0.007142324,0.0031322865,0.9872849,0.00022333418,0.00009258053,1.0854597e-7,0.0006111658,0.0009351524,0.0000024630358,0.000022663702,0.00040479816,0.0001482027],"about_ca_topic_score_codex":0.02036538,"about_ca_topic_score_gemma":0.01278695,"teacher_disagreement_score":0.007578429,"about_ca_system_score_codex":0.000458187,"about_ca_system_score_gemma":0.00014321518,"threshold_uncertainty_score":0.9861581},"labels":[],"label_agreement":null},{"id":"W2955204395","doi":"10.2337/db19-985-p","title":"985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Discontinuation; Semaglutide; Insulin; Placebo; Metformin; Internal medicine; Randomized controlled trial; Hypoglycemia; Gastroenterology; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.009527174840467379,"score_gpt":0.253410627597525,"score_spread":0.24388345275705758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955204395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96533495,0.00013690947,6.187248e-7,0.0019209821,0.00022503444,0.00080511277,0.000005149124,0.00008127986,0.031489957],"genre_scores_gemma":[0.98093945,0.000008467691,0.00034098822,0.0057867845,0.00006125139,0.00008482985,0.000049677943,0.000028531502,0.012700051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988438,0.000022993165,0.00018405452,0.0003085892,0.0002370419,0.00040352624],"domain_scores_gemma":[0.99938875,0.00006411745,0.00002953428,0.00034720747,0.0000280999,0.00014230175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015112899,0.00017810099,0.00032471117,0.0002673591,0.00001673736,0.000019602208,0.000088041445,0.00005694798,0.00061660603],"category_scores_gemma":[0.00007494535,0.00014747411,0.00007155669,0.00029237857,0.000014354524,0.000052943673,0.000069871305,0.00010432855,0.006317188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016497126,0.0009421787,0.90476763,0.00017704954,0.0002324189,0.000051877505,0.00040207923,0.0001621699,0.007291883,0.0029471915,0.022771202,0.06008935],"study_design_scores_gemma":[0.009150625,0.004113542,0.64340746,0.0008869855,0.00020923109,6.354029e-7,0.00020044448,0.0006207802,0.05945361,0.0010206553,0.28023234,0.00070370216],"about_ca_topic_score_codex":0.000046653015,"about_ca_topic_score_gemma":0.000014649396,"teacher_disagreement_score":0.26136017,"about_ca_system_score_codex":0.00009498243,"about_ca_system_score_gemma":0.000021540955,"threshold_uncertainty_score":0.9944565},"labels":[],"label_agreement":null},{"id":"W2955242889","doi":"10.1210/en.2019-00398","title":"Localization of Glucagon-Like Peptide-2 Receptor Expression in the Mouse","year":2019,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Glucagon-like peptide-1; Glucagon; Receptor; Glucagon-like peptide 1 receptor; Glucagon-like peptide-2; Biology; Peptide; Chemistry; Medicine; Diabetes mellitus; Insulin; Biochemistry; Type 2 diabetes; Agonist","score_opus":0.012991378892899065,"score_gpt":0.256791037204903,"score_spread":0.24379965831200393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955242889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98497117,0.00021607967,0.00014401892,0.00063048495,0.0001822194,0.00051969313,0.0000013786675,0.000025918813,0.01330904],"genre_scores_gemma":[0.9928225,0.00014526169,0.00025211266,0.00053762214,0.000025425905,0.00003397227,0.00005475036,0.000008370285,0.006119941],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939793,0.00004901866,0.00014454612,0.00013348652,0.00010049457,0.00017451387],"domain_scores_gemma":[0.9996186,0.000038501337,0.000047451424,0.0002616963,0.000018536453,0.000015252087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051425515,0.00007052853,0.0001570597,0.00009402948,0.000011508846,0.0000027087192,0.000079053716,0.000029785826,0.00034312383],"category_scores_gemma":[0.000016305366,0.000045088585,0.000034810342,0.000099434554,0.00003133661,0.000035106517,0.00004255608,0.00006225614,0.00020278992],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005721011,0.0019609714,0.7692795,0.00045225574,0.00022139572,0.00007943029,0.0033897995,0.0003126263,0.0972536,0.012594646,0.079778045,0.03410564],"study_design_scores_gemma":[0.0074824556,0.0016786292,0.040635422,0.00015495146,0.00012007545,0.0000150958995,0.002323348,0.00035140797,0.21551149,0.00027128536,0.73123556,0.00022029282],"about_ca_topic_score_codex":0.000022426471,"about_ca_topic_score_gemma":0.0000067783835,"teacher_disagreement_score":0.7286441,"about_ca_system_score_codex":0.000023953091,"about_ca_system_score_gemma":0.000009888964,"threshold_uncertainty_score":0.37569654},"labels":[],"label_agreement":null},{"id":"W2955351256","doi":"10.3390/ijms20133257","title":"A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum","year":2019,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Research Committee, Aristotle University of Thessaloniki; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Enzyme; Transporter; Duodenum; Drug; Biochemistry; Chemistry; Diabetes mellitus; Pharmacology; Drug metabolism; Biology; Medicine; Endocrinology; Internal medicine; Gene","score_opus":0.02507041317205435,"score_gpt":0.31153462977986873,"score_spread":0.2864642166078144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955351256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827516,0.000834465,0.0000022853028,0.0003638108,0.00007691557,0.00014428288,0.0000010654995,8.1519966e-7,0.00030117724],"genre_scores_gemma":[0.9998414,0.000059990507,0.000027208453,0.000038772232,0.000011341985,0.0000012517775,2.1463467e-7,0.0000022310503,0.00001759376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992627,0.00004847149,0.00016348557,0.00006501332,0.00040209366,0.000058218822],"domain_scores_gemma":[0.9996461,0.00007198292,0.00015712925,0.00005230141,0.000056128807,0.000016307677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005264222,0.000055909608,0.00014453052,0.00015073009,0.000019977608,0.000022259568,0.00015301864,0.0000044247404,0.000012766366],"category_scores_gemma":[0.00002145114,0.00002487406,0.00004188827,0.00007631067,0.00012015245,0.000097762335,0.000027998216,0.000053851687,5.70107e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002337372,0.0007062085,0.50967765,0.0000163831,0.00054898835,0.000021308742,0.004136829,0.00036102728,0.4806775,0.0008986362,0.000034045966,0.002687686],"study_design_scores_gemma":[0.0021148587,0.0068191374,0.6833377,0.0005263721,0.00012964432,0.000004814398,0.008741295,0.00017505353,0.29746836,0.00060188374,0.000008652588,0.000072242416],"about_ca_topic_score_codex":0.00006883321,"about_ca_topic_score_gemma":0.000005074343,"teacher_disagreement_score":0.18320914,"about_ca_system_score_codex":0.000012431063,"about_ca_system_score_gemma":0.000031484655,"threshold_uncertainty_score":0.10143347},"labels":[],"label_agreement":null},{"id":"W2955795061","doi":"10.7326/l19-0320","title":"Fracture Risk After Initiation of Use of Canagliflozin","year":2019,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; General hospital; Internal medicine; Gerontology; Family medicine","score_opus":0.043572872108592946,"score_gpt":0.3132918929829001,"score_spread":0.26971902087430716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955795061","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27154648,0.0051811244,0.00026320375,0.7098912,0.0015197719,0.0016848604,0.0006237725,0.000034712913,0.009254842],"genre_scores_gemma":[0.4371089,0.0015155685,0.00014909504,0.5517615,0.0016121741,0.000021733062,0.0005055222,0.000056265035,0.0072692214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997803,0.00007400494,0.0008776539,0.00026739654,0.0007345307,0.00024341847],"domain_scores_gemma":[0.99726146,0.00034252772,0.001202903,0.00056694186,0.0005702833,0.000055871882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023751009,0.0003096829,0.0012192337,0.0005500809,0.0000057936204,0.0000032043035,0.00016451385,0.00033906422,0.0009523107],"category_scores_gemma":[0.00044557394,0.00021159451,0.00027432552,0.00013553521,0.00017914805,0.00009603113,0.000065481305,0.0006533248,0.000015241911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004938693,0.00010508195,0.042871643,0.0017131767,0.0016712461,0.00020165085,0.00025398374,0.0000029931105,0.00008850892,0.0000061922315,0.9503599,0.0022317665],"study_design_scores_gemma":[0.0019363922,0.0031464014,0.041143004,0.008846862,0.0018524865,0.0000074804343,0.00003928591,0.00002364894,0.004549077,0.00010386684,0.93816465,0.00018686788],"about_ca_topic_score_codex":0.003486088,"about_ca_topic_score_gemma":0.000034966688,"teacher_disagreement_score":0.16556242,"about_ca_system_score_codex":0.000026510259,"about_ca_system_score_gemma":0.00005510814,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W2956532717","doi":"10.1161/circulationaha.119.042007","title":"Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of British Columbia","funders":"Merck Sharp and Dohme; University of California, San Francisco; Astellas Pharma; Eisai; NxStage; Medical Research Council; Verily Life Sciences; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Pfizer; Innovent Biologics; Janssen Pharmaceuticals; Ablynx; University of Washington; Ironwood Pharmaceuticals, Incorporated; Relypsa; University of Chicago; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; George Institute for Global Health; Kidney Foundation of Canada; Kowa Company; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; GlaxoSmithKline; Amgen; Celgene; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Medicine; Canagliflozin; Diabetes mellitus; Kidney disease; Internal medicine; Hazard ratio; Myocardial infarction; Stroke (engine); Type 2 diabetes; Heart failure; Type 2 Diabetes Mellitus; Endocrinology; Confidence interval","score_opus":0.0070233602331930475,"score_gpt":0.20752962664874106,"score_spread":0.200506266415548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956532717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92461187,0.07406812,0.000013846422,0.00009760482,0.00006434221,0.00090218324,0.000004444021,0.00001643489,0.00022114582],"genre_scores_gemma":[0.9969753,0.0026257755,0.00004860256,0.000077778604,0.00003027035,0.0000323564,0.00014117596,0.000015775342,0.000052939402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900496,0.00006945648,0.00017785917,0.00038013747,0.00018447757,0.00018313197],"domain_scores_gemma":[0.9995316,0.000022289089,0.000029076136,0.00024999207,0.00001814531,0.00014888469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003321957,0.00014855152,0.00043181767,0.00018479311,0.000027119659,0.00002965713,0.000017862372,0.00005820852,0.000010941281],"category_scores_gemma":[0.000027890028,0.00014003136,0.000085382846,0.00011862311,0.000043277763,0.00020527866,0.000055257435,0.000082118604,0.0000017453692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026538166,0.000041275816,0.93774325,0.0008494699,0.0006599669,0.000019849485,0.00009287379,0.00011382373,0.00018324774,0.00007484741,0.000009389757,0.06018549],"study_design_scores_gemma":[0.0037115028,0.000077549426,0.9923407,0.00024559005,0.0006271456,0.0000017081455,0.000020422769,0.0014239744,0.000018493694,0.0002602072,0.0011343249,0.0001384217],"about_ca_topic_score_codex":0.000109503635,"about_ca_topic_score_gemma":0.00003732295,"teacher_disagreement_score":0.07236345,"about_ca_system_score_codex":0.00013470341,"about_ca_system_score_gemma":0.0000678192,"threshold_uncertainty_score":0.57103133},"labels":[],"label_agreement":null},{"id":"W2957331709","doi":"10.1016/j.metabol.2019.07.009","title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?","year":2019,"lang":"en","type":"letter","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Boehringer Ingelheim; Mylan; Novo Nordisk; Meso Scale Diagnostics; Sanofi; Servier; Amgen","keywords":"Dapagliflozin; Steatosis; Steatohepatitis; Internal medicine; Fatty liver; Endocrinology; Alcoholic liver disease; Alcoholic fatty liver; Triglyceride; Type 2 diabetes; Diabetes mellitus; Chemistry; Medicine; Cholesterol; Cirrhosis; Disease","score_opus":0.01053630059898954,"score_gpt":0.24858749743134348,"score_spread":0.23805119683235393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957331709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9047451,0.0137028415,0.00010460347,0.045412615,0.0071175154,0.013416031,0.0011776127,0.00055448443,0.013769206],"genre_scores_gemma":[0.5556087,0.0074111037,0.0003511615,0.39732665,0.0080594905,0.0012265887,0.0068536317,0.0007908756,0.02237183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99373347,0.00031823225,0.0011677974,0.0016096361,0.001772102,0.0013987687],"domain_scores_gemma":[0.9961475,0.00040802624,0.00078653876,0.0019815539,0.000203115,0.00047326201],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00041384887,0.0016028706,0.002938224,0.0012488198,0.000110377834,0.000106192165,0.00063333154,0.0009855598,0.00033196958],"category_scores_gemma":[0.00007012499,0.0013560667,0.0014031837,0.00050469575,0.0002606939,0.00031738097,0.00016334803,0.0017654286,0.0015443553],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005194702,0.0020585505,0.014794757,0.010593544,0.0040999595,0.0043223724,0.0012035124,0.0000090264775,0.0013728051,0.00017060859,0.9513094,0.00954604],"study_design_scores_gemma":[0.008500566,0.0005997579,0.26444152,0.0024614355,0.007907853,0.000004722652,0.000013487838,0.000038607843,0.011285509,0.000047049074,0.70351034,0.0011891236],"about_ca_topic_score_codex":0.00068646914,"about_ca_topic_score_gemma":0.000023917935,"teacher_disagreement_score":0.35191402,"about_ca_system_score_codex":0.0002180937,"about_ca_system_score_gemma":0.00029434325,"threshold_uncertainty_score":0.9996719},"labels":[],"label_agreement":null},{"id":"W2959089350","doi":"10.2337/dc19-0849","title":"Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes","year":2019,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; American Diabetes Association","keywords":"Medicine; Canagliflozin; Metformin; Internal medicine; Cohort; Type 2 diabetes; Cohort study; Hazard ratio; Population; Diabetes mellitus; Endocrinology; Insulin; Confidence interval; Environmental health","score_opus":0.002875795106184517,"score_gpt":0.18449390016430242,"score_spread":0.1816181050581179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959089350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851953,0.0035539537,1.38299e-7,0.0071556894,0.0004618684,0.0020639773,0.00035758896,0.000056575594,0.0011549253],"genre_scores_gemma":[0.92146987,0.0002405232,0.000039730316,0.07243407,0.00057889003,0.000106728105,0.004399702,0.00012351433,0.00060695363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783796,0.000105179824,0.00038167796,0.00052672834,0.0006153161,0.00053311494],"domain_scores_gemma":[0.99811286,0.00030781125,0.00043924703,0.00074990717,0.0003238148,0.000066362525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011115735,0.0005633933,0.0010803784,0.00019752182,0.00007897613,0.000049394457,0.00018815152,0.00044252354,0.00008391824],"category_scores_gemma":[0.000045120527,0.00030370656,0.0002605577,0.00017853433,0.0005039024,0.000102736674,0.00008098284,0.00085799047,0.00003869443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008000099,0.00004804703,0.808109,0.001167732,0.0014099898,0.0000072513158,0.000453193,0.0000017184371,0.0000028947782,0.0000010831315,0.18676892,0.0019501714],"study_design_scores_gemma":[0.006825165,0.0008922131,0.82845247,0.0009895043,0.0050402987,3.3860733e-8,0.00012944058,0.000008323791,0.0011409812,0.000021506501,0.15606953,0.00043055209],"about_ca_topic_score_codex":0.000027068552,"about_ca_topic_score_gemma":0.000010780843,"teacher_disagreement_score":0.06527838,"about_ca_system_score_codex":0.000053737254,"about_ca_system_score_gemma":0.000041390926,"threshold_uncertainty_score":0.9999415},"labels":[],"label_agreement":null},{"id":"W2960786387","doi":"10.1515/biol-2019-0029","title":"Insulin resistance is a risk factor for mild cognitive impairment in elderly adults with T2DM","year":2019,"lang":"en","type":"article","venue":"Open Life Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin resistance; Internal medicine; Montreal Cognitive Assessment; Islet; Endocrinology; Cognitive impairment; Gastroenterology; Type 2 Diabetes Mellitus; Diabetes mellitus; Medicine; Insulin; Disease","score_opus":0.023079606311620936,"score_gpt":0.29964941066734174,"score_spread":0.2765698043557208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960786387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771962,0.00034983258,0.000014954138,0.0015443314,0.00007590615,0.0036535563,0.00012816544,0.000013827031,0.017023183],"genre_scores_gemma":[0.9887895,0.00011491961,0.002824582,0.0009803668,0.000022466696,0.00021683697,0.0000070477745,0.000007956005,0.007036327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987816,0.000023852977,0.00016698032,0.00044282773,0.00029405893,0.00029063865],"domain_scores_gemma":[0.9994622,0.000107970125,0.00010940805,0.00015209528,0.000064049054,0.000104289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032913222,0.00012944607,0.00025046887,0.00010098712,0.00009903125,0.00009049358,0.00024101092,0.000026118016,0.0003373213],"category_scores_gemma":[0.000054115982,0.00008308089,0.000037070033,0.00035468463,0.00010919622,0.0003126433,0.00008150929,0.0000538253,0.00008630698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008626776,0.0016686078,0.8823087,0.00048012892,0.00040355074,0.000022867453,0.010856683,0.000009606335,0.000034233763,0.0005700619,0.009788459,0.085230336],"study_design_scores_gemma":[0.025986698,0.013074067,0.9294524,0.0026771121,0.00018626622,6.205755e-7,0.011153246,0.00040291157,0.0013732759,0.0003393104,0.014883188,0.0004708725],"about_ca_topic_score_codex":0.000210645,"about_ca_topic_score_gemma":0.0006788879,"teacher_disagreement_score":0.08475946,"about_ca_system_score_codex":0.000043563592,"about_ca_system_score_gemma":0.00016857963,"threshold_uncertainty_score":0.36934316},"labels":[],"label_agreement":null},{"id":"W2960838833","doi":"10.1161/atvbaha.119.313011","title":"Glucose and GLP-2 (Glucagon-Like Peptide-2) Mobilize Intestinal Triglyceride by Distinct Mechanisms","year":2019,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Chylomicron; Triglyceride; Lymph; Internal medicine; Endocrinology; Chemistry; Lipoprotein; Cholesterol; Medicine; Very low-density lipoprotein; Pathology","score_opus":0.016561147459208825,"score_gpt":0.25333419876175534,"score_spread":0.2367730513025465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960838833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969642,0.00037316408,0.00047987534,0.00047947108,0.0002254055,0.0007811892,0.000021187718,0.00009099886,0.0005844866],"genre_scores_gemma":[0.99492306,0.002416823,0.00128759,0.0009020626,0.000035523044,0.0001023462,0.00015704268,0.00003707059,0.00013847921],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998347,0.00007952262,0.0003169348,0.00068496127,0.00012918616,0.0004424006],"domain_scores_gemma":[0.99914056,0.00007425723,0.000098566845,0.00043524825,0.00004270134,0.00020864405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002458763,0.0003418783,0.0006774771,0.00009083567,0.00013736672,0.00007424779,0.00009579164,0.00013809103,0.00027781219],"category_scores_gemma":[0.0000204759,0.0002667351,0.00016699689,0.00011840094,0.00022333354,0.00010076411,0.00020183981,0.0001179637,0.000084232866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035858564,0.0006629107,0.3603298,0.00021470904,0.0011275889,5.117421e-7,0.00025101012,2.0085805e-7,0.62635905,0.0021467635,0.0016333008,0.0072382903],"study_design_scores_gemma":[0.004381553,0.0027380544,0.9621766,0.0001772596,0.00063209183,0.0000025949455,0.00020979796,0.00018453089,0.0022127738,0.0002930644,0.026592614,0.00039907242],"about_ca_topic_score_codex":0.00011549881,"about_ca_topic_score_gemma":0.000019932924,"teacher_disagreement_score":0.6241463,"about_ca_system_score_codex":0.000043211156,"about_ca_system_score_gemma":0.000019450854,"threshold_uncertainty_score":0.9999785},"labels":[],"label_agreement":null},{"id":"W2960904779","doi":"10.1007/s00125-019-4948-4","title":"The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study","year":2019,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Japan Society for the Promotion of Science; National Health and Medical Research Council; Medical Research Council; Servier; National Institute for Health and Care Research","keywords":"Medicine; Internal medicine; Interquartile range; Kidney disease; Diabetes mellitus; Renal function; Proportional hazards model; Type 2 diabetes; Quartile; Creatinine; Diuretic; Hazard ratio; Cohort study; Surgery; Endocrinology; Confidence interval","score_opus":0.051672432915257895,"score_gpt":0.3222061101981451,"score_spread":0.2705336772828872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960904779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960184,0.0013995355,6.1078634e-7,0.00038791177,0.00008879018,0.0015152638,0.000006677429,0.000022626684,0.0005601802],"genre_scores_gemma":[0.9991624,0.0004312934,0.000023701377,0.0001132483,0.000011279002,0.00006115211,0.000018725128,0.0000122596375,0.00016594917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875146,0.00022044737,0.00028788013,0.00026656207,0.00022276235,0.00025088544],"domain_scores_gemma":[0.99788463,0.0013326822,0.00012872802,0.00056953717,0.000034347893,0.000050048035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093295024,0.00016590238,0.00040343625,0.000065442175,0.00007947512,0.00002191261,0.000110251865,0.000055987908,0.0000067711153],"category_scores_gemma":[0.0004745542,0.000083661005,0.00005178799,0.00018034664,0.00013293912,0.000062235275,0.000102996346,0.00019386229,0.0000135243035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001759541,0.00016546393,0.9949318,0.000036926747,0.0013262379,0.0000026285613,0.00019935494,0.0000060484467,0.0000043367927,0.001038845,0.000030577092,0.002240175],"study_design_scores_gemma":[0.001543632,0.00066746166,0.9950897,0.000033666583,0.0010543758,4.2389594e-8,0.00052169256,0.000017879533,0.000030348127,0.00060573354,0.00034948488,0.00008597681],"about_ca_topic_score_codex":0.00003607098,"about_ca_topic_score_gemma":0.000059806534,"teacher_disagreement_score":0.0031439883,"about_ca_system_score_codex":0.00004000701,"about_ca_system_score_gemma":0.000012752272,"threshold_uncertainty_score":0.3411597},"labels":[],"label_agreement":null},{"id":"W2961256602","doi":"10.2147/tcrm.s207515","title":"&lt;p&gt;SGLT2 inhibitors and the changing landscape for treatment of diabetes&lt;/p&gt;","year":2019,"lang":"en","type":"review","venue":"Therapeutics and Clinical Risk Management","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; St. Michael's Hospital","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Disease; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Clinical trial; Broad spectrum; Intensive care medicine; Pharmacology; Endocrinology","score_opus":0.06351696608587948,"score_gpt":0.3638520455124743,"score_spread":0.3003350794265948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961256602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012640839,0.98812604,0.000047550584,0.00026732506,0.0004953276,0.0064807944,0.00007082654,0.000044523586,0.0032035103],"genre_scores_gemma":[0.00083321007,0.99219096,0.00036472187,0.0002661886,0.00033036867,0.0005751838,0.00015113543,0.00008807296,0.005200149],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969877,0.00022288,0.001220428,0.00070898613,0.00031197493,0.0005480165],"domain_scores_gemma":[0.9970117,0.0012197259,0.0007687512,0.0008029309,0.000054106917,0.0001427382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013870641,0.00063710107,0.0029226425,0.00027532948,0.00014401934,0.000068704016,0.00018118136,0.00025166036,0.000019806675],"category_scores_gemma":[0.000020050255,0.0003450234,0.0011044196,0.00024302816,0.00028594528,0.000033110453,0.00025613606,0.00012856937,0.000018341736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014040986,0.00061847985,0.00045420357,0.0072251335,0.00923333,0.0000034197876,0.000103399136,3.1840761e-7,5.57195e-8,0.005385735,0.00026593814,0.9765696],"study_design_scores_gemma":[0.008638513,0.0020954022,0.000207485,0.002620611,0.0417551,6.2377336e-7,0.000060731312,0.00033888643,5.298108e-7,0.00043908355,0.9435319,0.0003111776],"about_ca_topic_score_codex":0.0000014818771,"about_ca_topic_score_gemma":0.0000038128505,"teacher_disagreement_score":0.9762584,"about_ca_system_score_codex":0.00006721609,"about_ca_system_score_gemma":0.000033051696,"threshold_uncertainty_score":0.99990016},"labels":[],"label_agreement":null},{"id":"W2963090082","doi":"10.1136/bmjopen-2018-023458","title":"Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis","year":2019,"lang":"en","type":"review","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"Novo Nordisk","keywords":"Medicine; Canagliflozin; Semaglutide; Dapagliflozin; Meta-analysis; Postprandial; Empagliflozin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Insulin; Endocrinology; Liraglutide","score_opus":0.1863984732110037,"score_gpt":0.4337060424743386,"score_spread":0.2473075692633349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963090082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015151738,0.9049038,0.0000015576198,0.00013947485,0.00007018489,0.09341254,0.000051014795,0.000014021811,0.0012558558],"genre_scores_gemma":[0.0021181898,0.9804781,0.0012024503,0.00041211033,0.000051381663,0.01224952,0.00088135817,0.0000845805,0.002522326],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944119,0.0013843694,0.0021611948,0.0008367472,0.0007316629,0.00047413984],"domain_scores_gemma":[0.99560416,0.0008251311,0.0018285244,0.0012309777,0.00029206948,0.00021914359],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020494862,0.00084892154,0.023953203,0.0005968933,0.00004158667,0.00015239722,0.00045012558,0.00013405607,0.00004917211],"category_scores_gemma":[0.00021836058,0.00048091984,0.0015013673,0.0029355728,0.00005442453,0.00013940621,0.0004959931,0.00029577554,0.000060627688],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018159063,0.0009289216,0.00012860587,0.6475605,0.34075555,0.000035577898,0.00036475042,0.00004787442,7.88705e-9,0.000048096113,0.0014715244,0.0068426793],"study_design_scores_gemma":[0.01523448,0.0014450832,0.00007124655,0.33443007,0.6433741,7.5003993e-7,0.000026400294,0.000012066138,1.3553458e-7,9.232935e-7,0.005009665,0.00039512743],"about_ca_topic_score_codex":0.00005318905,"about_ca_topic_score_gemma":0.000087627275,"teacher_disagreement_score":0.31313044,"about_ca_system_score_codex":0.00020628283,"about_ca_system_score_gemma":0.0002198522,"threshold_uncertainty_score":0.99976426},"labels":[],"label_agreement":null},{"id":"W2963201941","doi":"","title":"Diabetes is associated with unique pathological mechanisms in heart failure.","year":2019,"lang":"en","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Heart failure; Diabetes mellitus; Pathological; Cardiology; Internal medicine; MEDLINE; Intensive care medicine; Endocrinology","score_opus":0.01075507576361701,"score_gpt":0.22473543409653388,"score_spread":0.21398035833291687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963201941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720144,0.000100878715,0.000101436795,0.00081858604,0.000044817978,0.0004851882,0.00007928523,0.00009884275,0.0010695365],"genre_scores_gemma":[0.9934482,0.00005093609,0.0026417528,0.001819054,0.000033436612,0.000023834438,0.0015995684,0.000025489137,0.00035774888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853814,0.000106022206,0.00018979688,0.00053851336,0.00019522208,0.0004322795],"domain_scores_gemma":[0.99900115,0.00014239791,0.000067608875,0.0006602125,0.000014481082,0.00011415931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041200683,0.00021994389,0.00040853757,0.00009208389,0.00006119903,0.000053293857,0.00028417885,0.000069808666,0.000047072946],"category_scores_gemma":[0.000006544158,0.00015223281,0.000028751558,0.00022635488,0.00004003741,0.00017567359,0.00041337297,0.0001901904,0.000023155333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008937364,0.00024228916,0.9938528,0.00021510082,0.00022921381,0.000055380086,0.0008609829,0.00004278268,0.0015598243,0.00025760802,0.00081601326,0.0017786236],"study_design_scores_gemma":[0.0030804677,0.0010380208,0.93880206,0.0019111185,0.00029449695,0.000007946772,0.00082028087,0.047609843,0.0003302562,0.0010081732,0.0046669045,0.00043043893],"about_ca_topic_score_codex":0.000057718044,"about_ca_topic_score_gemma":0.0004978579,"teacher_disagreement_score":0.055050757,"about_ca_system_score_codex":0.00002481786,"about_ca_system_score_gemma":0.000014273023,"threshold_uncertainty_score":0.6207874},"labels":[],"label_agreement":null},{"id":"W2964008112","doi":"10.2337/db19-522-p","title":"522-P: Long-Term Renal Outcomes in Young Onset Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal replacement therapy; Internal medicine; Proportional hazards model; Population; Type 2 diabetes; Dialysis; Hazard ratio; Cohort; Diabetes mellitus; End stage renal disease; Disease; Endocrinology; Confidence interval","score_opus":0.010694082686299757,"score_gpt":0.2550865814748212,"score_spread":0.24439249878852146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964008112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925453,0.0005933434,3.0725639e-7,0.000426397,0.0005356548,0.000702488,0.000010120368,0.0001178832,0.008359283],"genre_scores_gemma":[0.9889571,0.000042830874,0.000118782504,0.0006493941,0.00005737972,0.000054622098,0.00021622355,0.00004005051,0.009863616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984025,0.00003594195,0.0002899912,0.00038159324,0.00027911912,0.0006108771],"domain_scores_gemma":[0.99916303,0.00011113752,0.000072650764,0.00048032156,0.00004917648,0.00012366338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018662597,0.0002689872,0.0005675866,0.00026949667,0.000029735003,0.000042408523,0.0001436923,0.00009173828,0.0006717823],"category_scores_gemma":[0.000065182634,0.00021569656,0.0001362032,0.00028712634,0.00004816187,0.00015612681,0.00010436823,0.00015010852,0.0008287851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017620296,0.0003416687,0.99217063,0.00014767803,0.00029138871,0.000016736145,0.000066730754,0.0000020785212,0.0028751248,0.00007766466,0.0008847472,0.0031079224],"study_design_scores_gemma":[0.0019847522,0.00046040185,0.98796386,0.00022357982,0.00015553672,2.8970834e-7,0.000019174646,0.00007016974,0.008297153,0.000070586975,0.00052147295,0.00023303162],"about_ca_topic_score_codex":0.000011999471,"about_ca_topic_score_gemma":0.000022990933,"teacher_disagreement_score":0.005422028,"about_ca_system_score_codex":0.00010042524,"about_ca_system_score_gemma":0.000030704756,"threshold_uncertainty_score":0.99994916},"labels":[],"label_agreement":null},{"id":"W2964087648","doi":"10.2337/dc18-2648","title":"Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide","year":2019,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Liraglutide; Metformin; Glycemic; Diabetes mellitus; Type 2 diabetes; Drug-naïve; Drug; Internal medicine; Pharmacology; Endocrinology","score_opus":0.004364002364641239,"score_gpt":0.21095754818298268,"score_spread":0.20659354581834144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964087648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932159,0.0004150108,1.3642914e-7,0.0002661738,0.0002715164,0.0031651186,0.000057939244,0.000091932816,0.0025162243],"genre_scores_gemma":[0.9957111,0.000031514042,0.00015300467,0.0027421282,0.00005924427,0.00026384045,0.0002503982,0.00006743933,0.0007213603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780715,0.000075452044,0.0002791953,0.00065228756,0.0004970242,0.0006889019],"domain_scores_gemma":[0.99855316,0.00040362132,0.00010387912,0.000531619,0.00015673121,0.00025101332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000098488585,0.0004580217,0.00080031285,0.0004164687,0.000056756766,0.000044303044,0.00015671655,0.0001013516,0.000056712106],"category_scores_gemma":[0.00011485174,0.00030142636,0.00006972768,0.00042818298,0.000037377427,0.00014280372,0.00007131117,0.00022773753,0.00048342848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002864075,0.0003207701,0.97265875,0.00058679265,0.00029371819,0.00001842825,0.00043182386,0.000005963993,0.00038345178,0.00006944679,0.0010104136,0.02135635],"study_design_scores_gemma":[0.021677505,0.015020498,0.9508431,0.0021076184,0.00036102906,5.6425073e-8,0.00017162687,0.000059295868,0.005320771,0.000021500698,0.0039309966,0.00048598036],"about_ca_topic_score_codex":0.000011648252,"about_ca_topic_score_gemma":0.00002817492,"teacher_disagreement_score":0.021815645,"about_ca_system_score_codex":0.0002845922,"about_ca_system_score_gemma":0.000047557063,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W2965202731","doi":"10.1111/dom.13852","title":"Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Dapagliflozin; Medicine; Propensity score matching; Population; Observational study; Type 2 diabetes; TIMI; Internal medicine; Diabetes mellitus; Inclusion and exclusion criteria; Emergency medicine; Endocrinology; Environmental health; Myocardial infarction; Alternative medicine","score_opus":0.04937953159987543,"score_gpt":0.29813904196884766,"score_spread":0.24875951036897223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965202731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112296,0.00041361802,1.7655138e-7,0.0021280346,0.00030559747,0.005817413,0.000054348322,0.00003275431,0.0001250678],"genre_scores_gemma":[0.9936608,0.00007998388,0.000050482635,0.0049538636,0.000051445728,0.00060085754,0.00027623208,0.00003122229,0.00029511485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973855,0.0002790567,0.00046515648,0.00055533095,0.0006082212,0.00070673844],"domain_scores_gemma":[0.9987548,0.00025994546,0.00014413465,0.00042079456,0.00021990617,0.00020039668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073823566,0.00036134492,0.0008443983,0.00030058922,0.000104269406,0.000074473835,0.0001547173,0.00010969976,0.00005303186],"category_scores_gemma":[0.000244799,0.00024206129,0.000077837525,0.00083906,0.000034106455,0.00021590391,0.00007566528,0.00014960376,0.00003473207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011523401,0.005890877,0.98820573,0.00003596722,0.00038969915,0.000010671869,0.0024112242,0.0000140965085,0.000017816255,0.000045203597,0.00031573363,0.0015106571],"study_design_scores_gemma":[0.035941504,0.004128502,0.956259,0.00017687524,0.00043846434,2.4767896e-8,0.0003650625,0.00022547592,0.00011924345,0.00004199188,0.0020648164,0.00023904149],"about_ca_topic_score_codex":0.00015817954,"about_ca_topic_score_gemma":0.0011641819,"teacher_disagreement_score":0.034789167,"about_ca_system_score_codex":0.00026625546,"about_ca_system_score_gemma":0.00011226314,"threshold_uncertainty_score":0.98709726},"labels":[],"label_agreement":null},{"id":"W2965229115","doi":"10.1111/dom.13839","title":"Glucagon‐like peptide‐2 mobilizes lipids from the intestine by a systemic nitric oxide‐independent mechanism","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Chylomicron; Internal medicine; Endocrinology; Nitric oxide; Triglyceride; Omega-N-Methylarginine; Medicine; Chemistry; Lipoprotein; Nitric oxide synthase; Very low-density lipoprotein; Cholesterol","score_opus":0.006032439116310421,"score_gpt":0.19833749693419228,"score_spread":0.19230505781788185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965229115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813553,0.01487769,0.000036506524,0.00035400744,0.0005842302,0.0014593184,0.00007669945,0.00016461937,0.0010916328],"genre_scores_gemma":[0.98923326,0.0010631757,0.00028506524,0.0017693199,0.00024084795,0.00014058585,0.0002036691,0.0000447858,0.0070193005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783975,0.0001262848,0.00038337984,0.00062404847,0.00046497298,0.0005615681],"domain_scores_gemma":[0.9985073,0.00028480554,0.00015996555,0.00070604135,0.00010079837,0.00024105003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004828305,0.0004103876,0.0007838046,0.00012353026,0.000152463,0.00011109645,0.00026554332,0.00014804743,0.00023472076],"category_scores_gemma":[0.00008756566,0.00027404676,0.00020133694,0.00027366608,0.00008056285,0.00019336543,0.00027735403,0.00028942683,0.00039623887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013707297,0.0016803448,0.73944116,0.0007028512,0.0026550498,0.00002657363,0.00084665715,0.0000058064857,0.21577735,0.008612248,0.019118957,0.010995912],"study_design_scores_gemma":[0.010244249,0.00041936085,0.8557158,0.0008764971,0.0045469888,0.000013005167,0.0013369198,0.0008093156,0.0364101,0.0050989375,0.08341721,0.001111634],"about_ca_topic_score_codex":0.0002514913,"about_ca_topic_score_gemma":0.000006580225,"teacher_disagreement_score":0.17936726,"about_ca_system_score_codex":0.00005546293,"about_ca_system_score_gemma":0.000038752572,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W2965440006","doi":"10.2337/dc19-0937","title":"The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Steno Diabetes Center Copenhagen; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi","keywords":"Medicine; Renal function; Albuminuria; Hematocrit; Blood pressure; Internal medicine; Type 2 diabetes; Diabetes mellitus; Placebo; Kidney disease; Endocrinology; Creatinine; Urology; Gastroenterology; Pathology","score_opus":0.00387798462343064,"score_gpt":0.2125875821903885,"score_spread":0.20870959756695787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965440006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894558,0.006985927,3.6294924e-8,0.00005890165,0.00007863211,0.0008973851,0.000022247998,0.00002947908,0.002471595],"genre_scores_gemma":[0.9990513,0.00007288132,0.00002291735,0.0000663977,0.000039814135,0.00006142451,0.0000771352,0.000028134447,0.0005800016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989415,0.00003240639,0.00019024532,0.00027769036,0.00021769581,0.00034048155],"domain_scores_gemma":[0.99918395,0.00012942556,0.000083978244,0.00038858355,0.00013456229,0.00007946986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088838424,0.00020605537,0.00034669056,0.0001034378,0.000039957726,0.000025267746,0.00007695268,0.000058632737,0.000058536392],"category_scores_gemma":[0.00003403445,0.00011630201,0.00007768926,0.00021548747,0.00006701195,0.00007151337,0.00004189134,0.00011076638,0.00003751226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003756996,0.00018319502,0.9914354,0.00046938856,0.0011192792,0.0000029403172,0.00036776104,0.00003801725,0.00074945897,0.000094089555,0.0009399105,0.00422486],"study_design_scores_gemma":[0.0063085537,0.008535195,0.9695442,0.0015101187,0.0012524225,3.5670624e-7,0.0007340794,0.00015424458,0.009921186,0.00007755273,0.0017259109,0.00023619554],"about_ca_topic_score_codex":0.000020121877,"about_ca_topic_score_gemma":0.00002037814,"teacher_disagreement_score":0.021891216,"about_ca_system_score_codex":0.000021058215,"about_ca_system_score_gemma":0.000038826074,"threshold_uncertainty_score":0.47426584},"labels":[],"label_agreement":null},{"id":"W2965609155","doi":"10.1111/dme.14094","title":"Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a <i>post hoc</i> analysis of the LixiLan‐O and LixiLan‐L trials","year":2019,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Medicine; Lixisenatide; Insulin glargine; Postprandial; Internal medicine; Post-hoc analysis; Type 2 diabetes; Diabetes mellitus; Plasma glucose; Insulin; Endocrinology; Basal insulin","score_opus":0.009277785208124667,"score_gpt":0.23656042488710607,"score_spread":0.2272826396789814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965609155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929995,0.0022497422,0.000012288386,0.004718168,0.00009295656,0.0020157453,0.000021486636,0.000037145717,0.0015524923],"genre_scores_gemma":[0.9964824,0.00022776944,0.0002544247,0.00084804895,0.000044248354,0.000119654884,0.00045544258,0.000034230783,0.0015338337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754864,0.00019667661,0.00071308017,0.0004655785,0.0006922987,0.0003837149],"domain_scores_gemma":[0.9980798,0.00045087005,0.00041348618,0.0006338646,0.00026921768,0.00015278929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086131005,0.00036041494,0.0017530515,0.00073662546,0.00004982972,0.000017995577,0.00015369852,0.00008701548,0.00036308204],"category_scores_gemma":[0.0002618378,0.00018537322,0.00010236498,0.002921936,0.00020494616,0.00008338893,0.00006798036,0.00016345746,0.000008432185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007196101,0.00047354324,0.9905292,0.00027356294,0.0026442169,0.000013078527,0.0009689087,0.00013769466,0.0025227298,0.00024608927,0.00043779553,0.0010335757],"study_design_scores_gemma":[0.026781887,0.009295079,0.9393321,0.0016737623,0.009331901,0.0000028287009,0.0012822486,0.0046150144,0.005721938,0.000056594537,0.0014895903,0.00041705344],"about_ca_topic_score_codex":0.00009221575,"about_ca_topic_score_gemma":0.00014081603,"teacher_disagreement_score":0.051197093,"about_ca_system_score_codex":0.00012595215,"about_ca_system_score_gemma":0.00010319936,"threshold_uncertainty_score":0.75593007},"labels":[],"label_agreement":null},{"id":"W2965687553","doi":"10.1016/j.pcad.2019.07.005","title":"Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes","year":2019,"lang":"en","type":"review","venue":"Progress in Cardiovascular Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Disease; Type 2 diabetes; Type 2 Diabetes Mellitus; Adverse effect; Pharmacology; Internal medicine; Bioinformatics; Endocrinology","score_opus":0.014955144823778686,"score_gpt":0.2595186607692399,"score_spread":0.24456351594546122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965687553","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024420633,0.99178207,0.0000012676119,0.00001811767,0.0002867135,0.004872679,0.00009165622,0.00006538668,0.00044005987],"genre_scores_gemma":[0.107779495,0.8897351,0.000021355223,0.0000168912,0.00021920375,0.0017716945,0.00028968017,0.00013205376,0.00003452366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952232,0.00066218205,0.00084399537,0.0012310476,0.0013973557,0.00064216607],"domain_scores_gemma":[0.99678403,0.00026507213,0.00024089086,0.0023222028,0.0000790132,0.0003087732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007190343,0.00086251274,0.004401128,0.0007193986,0.000094523864,0.000104075814,0.0003706977,0.00021124154,0.0000057337897],"category_scores_gemma":[0.00016343826,0.00057062466,0.0047797714,0.00074983254,0.00031873194,0.00011665106,0.00040943926,0.0004012988,0.000018604236],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005066672,0.00046434425,0.011513683,0.030491102,0.016452497,0.00026104713,0.00006891445,0.0000631268,2.3165345e-8,0.0003881215,0.000017394352,0.94022906],"study_design_scores_gemma":[0.0025239987,0.00021098058,0.0026005385,0.03855261,0.06870678,0.0000032858686,0.00014296282,0.00013929006,0.000008575733,0.00042588921,0.88583827,0.00084683765],"about_ca_topic_score_codex":0.000030376395,"about_ca_topic_score_gemma":0.0000016922194,"teacher_disagreement_score":0.93938226,"about_ca_system_score_codex":0.00032207396,"about_ca_system_score_gemma":0.00022565045,"threshold_uncertainty_score":0.9996745},"labels":[],"label_agreement":null},{"id":"W2966237581","doi":"10.4155/bio-2018-0097","title":"Pharmacokinetic Interaction Between Linagliptin and Tadalafil in Healthy Egyptian Males Using a Novel LC–MS Method","year":2019,"lang":"en","type":"article","venue":"Bioanalysis","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Pharmacokinetics; Tadalafil; Dosing; Pharmacodynamics; Medicine; Pharmacology; Oral administration; Plasma concentration; Bioavailability; Anesthesia; Internal medicine","score_opus":0.045507351462032594,"score_gpt":0.3645854293275377,"score_spread":0.31907807786550507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966237581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940658,0.00079651,0.0019578985,0.00095611997,0.00009159329,0.00040160478,0.0000071658137,0.000030712003,0.001692547],"genre_scores_gemma":[0.97464174,0.00009974107,0.02398439,0.0002800381,0.000090945534,0.000011534059,0.00004458512,0.00001743799,0.000829566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989474,0.000051654362,0.00028385414,0.00032998505,0.00016667489,0.00022042851],"domain_scores_gemma":[0.99948126,0.000070799666,0.00010918932,0.00020068475,0.000030221627,0.000107871565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028470464,0.00015431725,0.00042625162,0.00051985355,0.00002785013,0.000028478018,0.00004827571,0.00005112315,0.00022969517],"category_scores_gemma":[0.000015684676,0.00013358609,0.00010521532,0.00048766154,0.000019260395,0.0001016863,0.000055749002,0.00010540471,0.000035059493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000191144,0.00031762582,0.871791,0.00025531228,0.001278165,0.000014217273,0.00019556124,0.00017194907,0.0068508377,0.00006944115,0.000021613374,0.118843116],"study_design_scores_gemma":[0.014681572,0.0014576925,0.7401475,0.00059691793,0.010646248,0.000017793074,0.00125279,0.18316229,0.0030097968,0.00007710852,0.044106323,0.00084397907],"about_ca_topic_score_codex":0.00065654743,"about_ca_topic_score_gemma":0.0000642156,"teacher_disagreement_score":0.18299034,"about_ca_system_score_codex":0.00015332327,"about_ca_system_score_gemma":0.000020266047,"threshold_uncertainty_score":0.54474825},"labels":[],"label_agreement":null},{"id":"W2967668820","doi":"10.1172/jci130755","title":"Antiobesogenic effects of central GIPR antagonism","year":2019,"lang":"en","type":"letter","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; University Health Network; Toronto General Hospital; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; University of Alberta; Toronto General Hospital Research Institute, University Health Network; Canadian Institutes of Health Research; University of Toronto; Diabetes Canada","keywords":"Overnutrition; Leptin; Endocrinology; Internal medicine; Hormone; Obesity; Appetite; Antagonism; Biology; Medicine; Receptor","score_opus":0.046430447532636566,"score_gpt":0.3436032822189328,"score_spread":0.29717283468629624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967668820","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5954828,0.0012763579,0.00011726821,0.39257327,0.008258662,0.0011206983,0.000010564534,0.00002435043,0.0011359622],"genre_scores_gemma":[0.13386178,0.0023933114,0.0041702874,0.8275412,0.022352071,0.000007877226,0.0004525977,0.0001257796,0.009095105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965798,0.00024303142,0.001976942,0.00021238768,0.0007169948,0.00027083518],"domain_scores_gemma":[0.99586105,0.0008820388,0.0024824075,0.00032034182,0.00029819814,0.0001559849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076435023,0.00023727719,0.0013790114,0.00024335063,0.00001672417,0.000019948582,0.00017151047,0.000668099,0.000038493592],"category_scores_gemma":[0.00107904,0.00017602433,0.00089670456,0.00013135778,0.00019082798,0.00014526218,0.000040229483,0.0014735584,0.000042265856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009949477,0.00022236574,0.044760823,0.001989807,0.0013572163,0.00053542154,0.00003653207,0.000003191563,0.0007842801,0.000040349565,0.9448046,0.0053659324],"study_design_scores_gemma":[0.010190604,0.006845746,0.18634278,0.004452463,0.007020176,0.00007001061,0.0000095200385,0.00009692828,0.014326036,0.0019316865,0.7683275,0.00038654797],"about_ca_topic_score_codex":0.0000042320607,"about_ca_topic_score_gemma":1.8415406e-7,"teacher_disagreement_score":0.46162108,"about_ca_system_score_codex":0.000070272145,"about_ca_system_score_gemma":0.00040221584,"threshold_uncertainty_score":0.7178064},"labels":[],"label_agreement":null},{"id":"W2968525400","doi":"10.2337/dc19-0783","title":"Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Linagliptin; Medicine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Cardiorenal syndrome; Internal medicine; Heart failure; Endocrinology","score_opus":0.003514305080108636,"score_gpt":0.21278627990022186,"score_spread":0.20927197482011323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968525400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244016,0.00061008864,3.3505565e-8,0.000014345256,0.00023300157,0.0041377936,0.000029965346,0.000019480112,0.0025151314],"genre_scores_gemma":[0.9992225,0.00006462989,0.00000537317,0.0001019138,0.000052566502,0.00021698356,0.00023179654,0.000023632356,0.00008059081],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99874395,0.00020937831,0.00022428177,0.00024175434,0.00030676494,0.0002738879],"domain_scores_gemma":[0.99864143,0.0008382634,0.000109070046,0.0002212282,0.00014284534,0.000047171863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038034443,0.0002280131,0.00087087497,0.00012043593,0.0000356797,0.000015977357,0.00006449284,0.000056399305,0.000021037446],"category_scores_gemma":[0.0001267683,0.00012042835,0.00011306403,0.00016768725,0.00016100827,0.000058160538,0.000048132573,0.00014036093,0.000029302571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16873045,0.00008101305,0.82135,0.0007651532,0.00035651107,7.274763e-7,0.0005967796,0.000007951228,0.000004270843,0.0000061886167,0.000022647977,0.008078325],"study_design_scores_gemma":[0.76396126,0.017034275,0.21243685,0.0013988201,0.0009541365,2.2215566e-8,0.00039153895,0.00010733021,0.003459972,0.0000020803202,0.00008052245,0.00017318905],"about_ca_topic_score_codex":0.0000030992874,"about_ca_topic_score_gemma":9.687999e-7,"teacher_disagreement_score":0.6089131,"about_ca_system_score_codex":0.00004766129,"about_ca_system_score_gemma":0.0000243437,"threshold_uncertainty_score":0.49109256},"labels":[],"label_agreement":null},{"id":"W2968581900","doi":"10.2215/cjn.00370119","title":"The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial","year":2019,"lang":"en","type":"letter","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Medicine; Fibrate; Fenofibrate; Creatinine; Internal medicine; Renal function; Diabetes mellitus; Placebo; Randomized controlled trial; Acute kidney injury; Type 2 diabetes; Kidney disease; Discontinuation; Statin; Endocrinology","score_opus":0.039319592370957675,"score_gpt":0.3462639335524613,"score_spread":0.30694434118150365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968581900","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64543444,0.00006170616,0.0000028165248,0.35364047,0.00024201893,0.0005566913,0.000009712916,0.000001385368,0.000050736344],"genre_scores_gemma":[0.38016295,0.0015065793,0.00031453048,0.61659324,0.0010654819,0.000017020531,0.000009022062,0.000029178276,0.0003020009],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99552107,0.0014305473,0.0017924776,0.0001842266,0.00067763746,0.00039403088],"domain_scores_gemma":[0.99056816,0.0031353869,0.005506643,0.0005507594,0.00019525716,0.000043784345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039273174,0.00020487736,0.001711088,0.00006606095,0.000028175305,0.000008452698,0.0007068525,0.00030196406,0.000007846979],"category_scores_gemma":[0.0005927818,0.00009146898,0.0010002974,0.00042384412,0.0010779474,0.000044481836,0.00013444887,0.0016195676,0.0000014029388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015707107,0.0006466396,0.15410967,0.0001007365,0.0024346418,0.000019362209,0.00040301066,0.0000042627366,0.00021680778,0.000008428501,0.8241368,0.0022125544],"study_design_scores_gemma":[0.051930632,0.027318329,0.30472207,0.00076924916,0.0038263428,0.0000102576605,0.0011166778,0.000069235444,0.00009363192,0.0005442711,0.6093452,0.0002541006],"about_ca_topic_score_codex":0.00007060983,"about_ca_topic_score_gemma":0.000011854628,"teacher_disagreement_score":0.26527148,"about_ca_system_score_codex":0.000118145676,"about_ca_system_score_gemma":0.00044527987,"threshold_uncertainty_score":0.70363057},"labels":[],"label_agreement":null},{"id":"W2969024986","doi":"10.1007/s12020-019-02055-z","title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","year":2019,"lang":"en","type":"review","venue":"Endocrine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Medicine; Odds ratio; Internal medicine; Pancreatic cancer; Type 2 diabetes; Subgroup analysis; Cancer; Randomized controlled trial; Oncology; Thyroid cancer; Type 2 Diabetes Mellitus; Meta-analysis; Confidence interval; Diabetes mellitus; Endocrinology","score_opus":0.09177717741771318,"score_gpt":0.4024102593560004,"score_spread":0.3106330819382872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969024986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014647995,0.9901298,0.0000011809617,0.000044170825,0.00019330686,0.007172311,0.0005624822,0.000018012313,0.00041388217],"genre_scores_gemma":[0.0005598058,0.99256957,0.00016377718,0.000020758363,0.000048156086,0.0009963879,0.0017185736,0.000041405983,0.0038815597],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993276,0.0026106667,0.002996044,0.00048004527,0.00035480762,0.00028241603],"domain_scores_gemma":[0.99381816,0.0022921183,0.002934938,0.0006669523,0.00018780904,0.000100024765],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042629563,0.00053835986,0.046023097,0.0012741194,0.000012393015,0.000015570758,0.00014024465,0.000105940824,0.004385911],"category_scores_gemma":[0.0016031842,0.00027827328,0.006761392,0.0010137352,0.000096521915,0.000050293977,0.00006959275,0.00017778378,0.000009854505],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011579229,0.0003214088,0.00019735795,0.0041499846,0.86816967,0.000005155437,0.000024865081,0.0000070585147,0.0000044835274,0.000051272484,0.0003044569,0.11518505],"study_design_scores_gemma":[0.114722304,0.00016254411,0.000012587896,0.00044132685,0.73572445,8.204016e-8,0.0000045708466,0.00004846619,0.000018885325,0.000004986235,0.14871357,0.00014622336],"about_ca_topic_score_codex":0.0003738845,"about_ca_topic_score_gemma":0.0001185479,"teacher_disagreement_score":0.14840911,"about_ca_system_score_codex":0.00006751704,"about_ca_system_score_gemma":0.00013604014,"threshold_uncertainty_score":0.9999669},"labels":[],"label_agreement":null},{"id":"W2969169943","doi":"10.14740/jem.v9i4.564","title":"Dapagliflozin Add-On Therapy Improves Body Composition and Metabolic Parameters in Overweight Type 2 Diabetic Patients: A Pilot Study","year":2019,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Overweight; Internal medicine; Body mass index; Metformin; Endocrinology; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; Weight loss; Body water; Obesity; Body weight","score_opus":0.015119072170726814,"score_gpt":0.2606104893906222,"score_spread":0.2454914172198954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969169943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904125,0.0076448265,6.8996735e-7,0.00022018804,0.0005641135,0.00070762786,0.0000019167592,0.000008444856,0.00043971802],"genre_scores_gemma":[0.9956256,0.0033581743,0.00014758392,0.0006126503,0.00006145234,0.000011271475,0.000004823958,0.000012166826,0.00016623538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889636,0.00012562588,0.00035285787,0.00019539741,0.00017095826,0.00025882263],"domain_scores_gemma":[0.99939317,0.00008582829,0.00019324906,0.00015273727,0.00008368573,0.00009135325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014537439,0.00018076447,0.0006202789,0.00039419855,0.00003041073,0.00001857633,0.000060383827,0.00003134754,0.000025160365],"category_scores_gemma":[0.000027535465,0.0001245491,0.00004735704,0.00012712122,0.000054399836,0.00015131036,0.000039091552,0.00022867156,0.000007937248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006767886,0.013090097,0.86242265,0.00007089874,0.002710489,0.00021737021,0.00091304316,0.000007884557,0.027715102,0.00523275,0.0004689904,0.08038283],"study_design_scores_gemma":[0.015514774,0.011002749,0.9624237,0.00004206178,0.00046232637,0.000019682277,0.00014197092,0.000007145031,0.0026926536,0.00016082337,0.0074157533,0.000116383766],"about_ca_topic_score_codex":0.000015330126,"about_ca_topic_score_gemma":0.0000023685207,"teacher_disagreement_score":0.10000102,"about_ca_system_score_codex":0.00001598098,"about_ca_system_score_gemma":0.00001859689,"threshold_uncertainty_score":0.5078965},"labels":[],"label_agreement":null},{"id":"W2969368237","doi":"10.1016/j.jcjd.2019.08.011","title":"Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Lunenfeld-Tanenbaum Research Institute; Health Sciences Centre; Sunnybrook Health Science Centre; Diabetes Canada; University of Toronto","funders":"Canadian Institutes of Health Research; Diabetes Canada; Novo Nordisk; Sanofi; Merck","keywords":"Medicine; Type 2 diabetes; Intensive care medicine; Glycemic; Glucagon-like peptide-1; Diabetes mellitus; Clinical trial; Internal medicine; Endocrinology","score_opus":0.048504311537571565,"score_gpt":0.29830738422405917,"score_spread":0.2498030726864876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969368237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00529498,0.98975885,1.8619542e-7,0.00006549788,0.0013105891,0.0028220068,0.00017540381,0.00000755309,0.0005649344],"genre_scores_gemma":[0.00021407925,0.9976965,0.00029217804,0.0005217141,0.00021225117,0.00005699175,0.00046933,0.00012796967,0.00040895955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945051,0.0005342713,0.0029432783,0.00043700065,0.00077055075,0.00080981414],"domain_scores_gemma":[0.99470335,0.00032512782,0.002225023,0.00092082046,0.0010211017,0.0008045924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024220936,0.0007378245,0.009409102,0.0012097962,0.000039565813,0.00004298367,0.00049092196,0.00029132207,0.0002676271],"category_scores_gemma":[0.0017275502,0.00048785564,0.0025390731,0.0009368848,0.00012000065,0.00017539479,0.000038555798,0.0005787008,0.00008585952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009422542,0.00018634295,0.07017155,0.24674514,0.013102222,0.000038316808,0.000037576763,0.000001913658,1.4401256e-7,0.000013427911,0.011983105,0.65771085],"study_design_scores_gemma":[0.0018770345,0.00080086093,0.0009421451,0.23005216,0.015249189,7.006914e-7,0.000009206827,1.8817829e-7,0.0000012247133,0.0000011978001,0.7507225,0.000343554],"about_ca_topic_score_codex":0.00012883339,"about_ca_topic_score_gemma":0.00023315514,"teacher_disagreement_score":0.73873943,"about_ca_system_score_codex":0.00080355146,"about_ca_system_score_gemma":0.0025537834,"threshold_uncertainty_score":0.9997573},"labels":[],"label_agreement":null},{"id":"W2969552970","doi":"10.1016/j.diabres.2019.107820","title":"Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study","year":2019,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Internal medicine; Endocrinology; Type 2 diabetes; Glucagon-like peptide-1","score_opus":0.04280496340586374,"score_gpt":0.3937703315506618,"score_spread":0.35096536814479806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969552970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889219,0.0006931948,2.9389621e-8,0.0031918858,0.00048586162,0.0045252894,0.000012761193,0.000022971597,0.002146114],"genre_scores_gemma":[0.9985131,0.00010436686,0.0002473181,0.0005503266,0.000046872592,0.00024175581,0.00006620311,0.000045485485,0.0001845817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928792,0.0021406577,0.0016094381,0.00079470087,0.0015703911,0.0010055861],"domain_scores_gemma":[0.9869178,0.00936996,0.0012120124,0.0012525457,0.0010853825,0.00016228443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047886157,0.00034882687,0.0010895372,0.0003170848,0.00014525151,0.00009931556,0.00040107794,0.00016761046,0.00003251166],"category_scores_gemma":[0.020764872,0.00020545439,0.00018523597,0.0014156785,0.0007099275,0.0006931937,0.0005770164,0.0010918443,0.000014661118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000676435,0.008221321,0.9829362,0.00020921082,0.0013602838,0.000016138161,0.00042751216,0.0000017366305,0.000057792597,0.00007220416,0.00030760132,0.0057135457],"study_design_scores_gemma":[0.006212985,0.009461956,0.97530437,0.0004095061,0.0005372326,1.329273e-7,0.0025982806,0.000034528894,0.00035649742,0.00007260707,0.00480642,0.00020546107],"about_ca_topic_score_codex":0.00009065497,"about_ca_topic_score_gemma":0.000058844485,"teacher_disagreement_score":0.015976256,"about_ca_system_score_codex":0.00016076995,"about_ca_system_score_gemma":0.00026275683,"threshold_uncertainty_score":0.9874836},"labels":[],"label_agreement":null},{"id":"W2969743301","doi":"10.1016/j.jcjd.2019.08.012","title":"Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta; McGill University","funders":"Alberta Innovates - Health Solutions","keywords":"Medicine; Diabetes mellitus; Heart failure; Internal medicine; Clinical trial; Type 2 Diabetes Mellitus; Disease; Empagliflozin; Type 2 diabetes; Population; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.014206020337429914,"score_gpt":0.23674469560629152,"score_spread":0.22253867526886162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969743301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17353855,0.8248423,1.4194848e-7,0.00014720927,0.000057165817,0.0010778564,0.000097434124,0.0000018662538,0.00023751415],"genre_scores_gemma":[0.19390368,0.80524963,0.00018761936,0.000084400366,0.00014203509,0.000054560336,0.00024728177,0.000056195284,0.000074616895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842393,0.00008166315,0.0007530583,0.00016003028,0.0002565137,0.00032482285],"domain_scores_gemma":[0.9985979,0.00009300932,0.0006225229,0.0003171379,0.00013625191,0.00023315164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001854628,0.00031566303,0.0018282336,0.00066889747,0.000020506246,0.000013860682,0.00011480204,0.00013305564,0.000052426505],"category_scores_gemma":[0.000009252545,0.0001728219,0.000518141,0.00032139604,0.00009916079,0.00007814886,0.0000024986155,0.00016954368,0.000005498083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000626051,0.0014843702,0.07802894,0.030804573,0.0030807324,0.00020351898,0.0030863995,0.000005372019,0.000029898456,0.00012379907,0.0016942462,0.8813955],"study_design_scores_gemma":[0.0033904265,0.0069275685,0.004555693,0.04259043,0.0055986,0.000019368528,0.0007105304,0.0000012195723,0.00030861289,0.000018512324,0.9356462,0.00023284183],"about_ca_topic_score_codex":0.00045693127,"about_ca_topic_score_gemma":0.008516826,"teacher_disagreement_score":0.933952,"about_ca_system_score_codex":0.00025404498,"about_ca_system_score_gemma":0.0010618871,"threshold_uncertainty_score":0.70474726},"labels":[],"label_agreement":null},{"id":"W2969856835","doi":"10.7326/acpj201908200-016","title":"In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA<sub>1c</sub> and body weight vs sitagliptin","year":2019,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Semaglutide; Medicine; Sitagliptin; Glycated hemoglobin; Metformin; Type 2 diabetes; Sulfonylurea; Internal medicine; Diabetes mellitus; Sitagliptin Phosphate; Endocrinology","score_opus":0.017554269024178372,"score_gpt":0.27612931426762577,"score_spread":0.2585750452434474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969856835","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4674641,0.008541956,0.0000029368132,0.50997263,0.0018311506,0.0016005541,0.000038466565,0.00005015395,0.010498084],"genre_scores_gemma":[0.2868945,0.002548958,0.000049964103,0.68962204,0.004920695,0.000093361916,0.000566458,0.00014971828,0.0151543105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963798,0.00016206122,0.0010736596,0.00078242423,0.0008195033,0.0007825475],"domain_scores_gemma":[0.9975709,0.00048686418,0.0006385169,0.0006671871,0.00046097537,0.00017555682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062503706,0.0007207171,0.0023721384,0.0009425131,0.000025258567,0.000015175933,0.00028520043,0.0005025359,0.000390852],"category_scores_gemma":[0.00061829045,0.0005199617,0.00025118052,0.00034793455,0.00028029768,0.0001182774,0.00018535253,0.0012705628,0.00011383638],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014358178,0.00018405626,0.0051065786,0.0009873896,0.002083433,0.0010562751,0.00015944723,4.5014693e-7,0.01280489,0.000026205249,0.9739612,0.002194305],"study_design_scores_gemma":[0.020203602,0.012691658,0.017779564,0.013005563,0.0024463132,0.000033260745,0.000089101435,0.00023609804,0.034821793,0.0006263386,0.89711374,0.00095295464],"about_ca_topic_score_codex":0.00020959067,"about_ca_topic_score_gemma":0.000017857568,"teacher_disagreement_score":0.18056959,"about_ca_system_score_codex":0.00011151643,"about_ca_system_score_gemma":0.00010191294,"threshold_uncertainty_score":0.9997252},"labels":[],"label_agreement":null},{"id":"W2970346174","doi":"10.1161/circulationaha.119.042685","title":"Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Dapagliflozin; Internal medicine; Type 2 Diabetes Mellitus; Myocardial infarction; TIMI; Diabetes mellitus; Heart failure; Framingham Risk Score; Cardiology; Thrombolysis; Endocrinology; Disease","score_opus":0.00536301289335988,"score_gpt":0.20358590679920505,"score_spread":0.19822289390584516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970346174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987372,0.00017134826,0.000008398392,0.000054369517,0.00004619188,0.00083595363,0.0000030978638,0.000017091626,0.00012630605],"genre_scores_gemma":[0.9994406,0.000011216904,0.00021780052,0.000015105858,0.000011915699,0.0000063739167,0.0002772509,0.0000100140105,0.000009736931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939334,0.000017936762,0.00017181975,0.00016858055,0.00014991678,0.00009838031],"domain_scores_gemma":[0.999634,0.000021853135,0.00008715029,0.00016052501,0.00006279118,0.00003364878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007303895,0.000083571445,0.00016387615,0.0000976951,0.000013944738,0.000008192515,0.000015851607,0.00004238356,0.00002345765],"category_scores_gemma":[0.000008526735,0.00006907052,0.0000203074,0.00016095639,0.000022661701,0.00010670007,0.0000040564837,0.00004764838,0.000011885551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007647865,0.00024490914,0.9914826,0.00008556995,0.00004595967,1.3951114e-7,0.00013697622,0.000077725286,0.001591198,0.00005640485,0.000018251218,0.006183759],"study_design_scores_gemma":[0.0030792153,0.00028340824,0.9935829,0.00010572322,0.000126307,2.9259505e-8,0.0000261882,0.00022988109,0.0023113831,0.000034063694,0.0001540498,0.000066836605],"about_ca_topic_score_codex":0.000012941309,"about_ca_topic_score_gemma":0.000009821834,"teacher_disagreement_score":0.0061169225,"about_ca_system_score_codex":0.00003103484,"about_ca_system_score_gemma":0.0000137388,"threshold_uncertainty_score":0.2816614},"labels":[],"label_agreement":null},{"id":"W2970825172","doi":"10.1093/eurheartj/ehz621","title":"Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; AstraZeneca","keywords":"Empagliflozin; Medicine; Hazard ratio; Internal medicine; Type 2 diabetes; Myocardial infarction; Diabetes mellitus; Confidence interval; Placebo; Cardiology; Proportional hazards model; Endocrinology","score_opus":0.10540858813961813,"score_gpt":0.3287896711658907,"score_spread":0.22338108302627258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970825172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838105,0.0008871447,0.000007849343,0.0027568212,0.00026245022,0.0011365075,0.0000028864913,0.000027240569,0.011108609],"genre_scores_gemma":[0.9933574,0.000041176336,0.00021965065,0.00050742255,0.00049702846,0.00000963369,0.0000138437545,0.00003406252,0.005319778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789876,0.00065234286,0.00044056715,0.00024346767,0.00045058923,0.00031426083],"domain_scores_gemma":[0.99892986,0.00030901097,0.00008384736,0.00050119706,0.000022101678,0.00015399764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019249348,0.00021943239,0.0005738199,0.00020208051,0.00013442815,0.00010319038,0.00011246191,0.000037245834,0.00006548057],"category_scores_gemma":[0.00012518492,0.00012659132,0.00044728594,0.00015900137,0.000033174783,0.00011864124,0.00004541015,0.00034748996,0.0004737044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000324729,0.0001437058,0.99323213,0.000014121433,0.00038553862,0.00021998044,0.0004139123,0.0000085905,0.0000015877675,0.000045141576,0.0012158344,0.00399473],"study_design_scores_gemma":[0.03203622,0.0010127914,0.8803867,0.000031966832,0.00055032154,0.00008345503,0.00019333963,0.0000019706933,0.000003117025,0.000029222356,0.08556167,0.000109219334],"about_ca_topic_score_codex":0.000017665256,"about_ca_topic_score_gemma":0.0000033947367,"teacher_disagreement_score":0.11284541,"about_ca_system_score_codex":0.00015059253,"about_ca_system_score_gemma":0.00003646288,"threshold_uncertainty_score":0.60886693},"labels":[],"label_agreement":null},{"id":"W2970927649","doi":"10.1016/j.cmet.2019.08.015","title":"SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus","year":2019,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Robarts Clinical Trials; Western University; St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Janssen Pharmaceuticals; Duke Clinical Research Institute; Canadian Institutes of Health Research; St. Jude Medical; Schulich School of Medicine and Dentistry, Western University; Servier; Ontario Ministry of Research, Innovation and Science; Ontario Ministry of Research and Innovation; Bayer Fund; Novo Nordisk; Daiichi-Sankyo; Medicines Company; Mayo Clinic; Merck; GlaxoSmithKline; Abbott Laboratories; CSL Behring; Chiesi Farmaceutici; Icahn School of Medicine at Mount Sinai; Cleveland Clinic; Bristol-Myers Squibb; Boehringer Ingelheim España; Eli Lilly and Company; AstraZeneca; University of Toronto; American College of Cardiology Foundation; Boehringer Ingelheim; Amgen; Sanofi","keywords":"Empagliflozin; Mace; Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; EMPA; Myocardial infarction; Endocrinology; Conventional PCI","score_opus":0.006811304763485843,"score_gpt":0.19422293392520582,"score_spread":0.18741162916171997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970927649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97673625,0.009242629,0.000010291172,0.00615694,0.0004632749,0.00456524,0.000031555253,0.00017784428,0.0026159764],"genre_scores_gemma":[0.76225185,0.0016081877,0.008107672,0.18673916,0.0095410645,0.0023880703,0.008212698,0.0012002249,0.019951044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967323,0.00016411506,0.00046449713,0.000938733,0.0008365994,0.0008637791],"domain_scores_gemma":[0.998362,0.0000984993,0.00033177462,0.0008814838,0.00021137303,0.000114890536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002510239,0.0007504969,0.0013798614,0.00052838394,0.000064491614,0.00010543722,0.0001513712,0.00044754345,0.00013139247],"category_scores_gemma":[0.000021709146,0.0005326608,0.00020545656,0.0007028088,0.0000808419,0.00019261053,0.00009094177,0.000915937,0.0002411744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011933451,0.005814269,0.18372211,0.033091914,0.010844175,0.008580009,0.00275646,0.00042636847,0.03244538,0.00006417401,0.7066714,0.01439041],"study_design_scores_gemma":[0.01282964,0.0015020487,0.017289925,0.0029221075,0.009707206,0.000026494572,0.00021444073,0.00015390209,0.06810164,0.000036406665,0.8851834,0.0020327703],"about_ca_topic_score_codex":0.00019102535,"about_ca_topic_score_gemma":0.000032188622,"teacher_disagreement_score":0.21448436,"about_ca_system_score_codex":0.00015926949,"about_ca_system_score_gemma":0.0002613374,"threshold_uncertainty_score":0.99971247},"labels":[],"label_agreement":null},{"id":"W2971135507","doi":"10.1002/pds.4878","title":"A population‐based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns","year":2019,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Manitoba; Saskatchewan Health Quality Council; Centre hospitalier universitaire de Québec; Western University; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Manitoba Health; University of Calgary; Institute for Clinical Evaluative Sciences; McGill University; Lawson Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Pharmacoepidemiology; Secular variation; Demography; Population; Traditional medicine; Medical prescription; Environmental health; Pharmacology","score_opus":0.017987991191883775,"score_gpt":0.30063952075807054,"score_spread":0.2826515295661868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971135507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992679,0.0006357687,0.000089836,0.0050759604,0.000056631907,0.00032200446,0.00005757564,0.000015277006,0.0010679587],"genre_scores_gemma":[0.9976079,0.00029513214,0.00025055057,0.0011864306,0.0000125875085,0.000025314528,0.00037555821,0.000007005189,0.00023955556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987988,0.00023819006,0.0003617284,0.0002821519,0.000073691874,0.00024546028],"domain_scores_gemma":[0.99911344,0.00041026296,0.00010886537,0.00016946989,0.000022421478,0.00017552548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008873424,0.000121504614,0.0005469396,0.00084304274,0.000042884047,0.0000027588778,0.00004745632,0.000054944256,0.0002583182],"category_scores_gemma":[0.000096312564,0.000102986094,0.00007550249,0.00044380903,0.00004255823,0.000059508984,0.00002540185,0.000100928904,0.0000016669329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034868794,0.00004205877,0.9898152,0.00012115617,0.00070406497,0.000006253098,0.00012615521,0.00021390419,0.00005961071,0.00025486923,0.000097952674,0.008523942],"study_design_scores_gemma":[0.0014068716,0.000039921237,0.96560645,0.00006410217,0.0017647843,8.0981613e-7,0.000039285726,0.030236475,0.000029546938,0.00003470763,0.00069336564,0.00008365903],"about_ca_topic_score_codex":0.038044773,"about_ca_topic_score_gemma":0.03331361,"teacher_disagreement_score":0.03002257,"about_ca_system_score_codex":0.000073474876,"about_ca_system_score_gemma":0.000055233493,"threshold_uncertainty_score":0.9843259},"labels":[],"label_agreement":null},{"id":"W2971332512","doi":"10.14740/jocmr3953","title":"Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Diabetes Foundation","keywords":"Alogliptin; Medicine; Diabetes mellitus; Renal function; Age groups; Internal medicine; Diabetic nephropathy; Hemoglobin; Population; Type 2 diabetes; Endocrinology; Demography","score_opus":0.07698853922667974,"score_gpt":0.4414095688314326,"score_spread":0.36442102960475287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971332512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919573,0.0014006018,0.0000011719138,0.0023619717,0.00020576763,0.00058038137,6.9881685e-7,0.000002765842,0.0034893511],"genre_scores_gemma":[0.99708134,0.0018918588,0.00028559458,0.000109470435,0.00021276945,0.000001336587,0.0000053200424,0.000013012106,0.00039926937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704456,0.00027399234,0.0011430127,0.00017296265,0.0010688115,0.00029665756],"domain_scores_gemma":[0.9960398,0.0023815124,0.00031290765,0.00023192566,0.0007739625,0.0002598832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042589633,0.00010402182,0.00092231645,0.000401002,0.000015361713,0.0000049092755,0.00012535823,0.00008507292,0.00019658796],"category_scores_gemma":[0.0025047166,0.000056533958,0.00005855614,0.000441684,0.00033053476,0.000073661016,0.0000641322,0.0006715842,0.000013957446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041645067,0.0009292572,0.8760527,0.00018956533,0.00024394601,0.000028769517,0.000088310204,0.0000014659493,0.0000614241,0.00006619776,0.0011352565,0.11703863],"study_design_scores_gemma":[0.023526683,0.031895693,0.93330765,0.00183117,0.000122037294,0.0000012446671,0.000114663904,0.000017637472,0.00007125456,0.00010678838,0.008953874,0.000051279872],"about_ca_topic_score_codex":0.000011289742,"about_ca_topic_score_gemma":0.0000039744227,"teacher_disagreement_score":0.116987355,"about_ca_system_score_codex":0.000036579055,"about_ca_system_score_gemma":0.00013934945,"threshold_uncertainty_score":0.29985607},"labels":[],"label_agreement":null},{"id":"W2971414122","doi":"10.1016/s2213-8587(19)30256-6","title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":870,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca; National Health and Medical Research Council; Verily Life Sciences; Medical Research Council; Bristol-Myers Squibb; Akebia Therapeutics; Gilead Sciences; Servier; Relypsa; Astellas Pharma; University of New South Wales; University of Oxford; MyoKardia; Novo Nordisk; ZOLL Medical Corporation; Janssen Pharmaceuticals; Ablynx; Sanofi; GlaxoSmithKline; Eli Lilly and Company; Boehringer Ingelheim; Amgen; Pfizer; Brigham and Women's Hospital","keywords":"Medicine; Empagliflozin; Albuminuria; Meta-analysis; Kidney disease; Dialysis; Kidney transplantation; Internal medicine; Renal function; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Transplantation; Endocrinology","score_opus":0.058367977203398036,"score_gpt":0.3210231811762127,"score_spread":0.26265520397281467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971414122","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019263376,0.9862279,0.0000016766535,0.0012684594,0.00006483131,0.0120413555,0.00012051221,0.00002587602,0.000056755125],"genre_scores_gemma":[0.0005129876,0.9931445,0.00009734902,0.0014949435,0.0000433324,0.0033420164,0.0005412941,0.0000541837,0.0007693791],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970893,0.00045807404,0.000948095,0.00047247607,0.0002498251,0.00078223285],"domain_scores_gemma":[0.9967399,0.0008092285,0.0009503659,0.0012840035,0.00014280259,0.00007366936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007579093,0.00052183867,0.0091846185,0.0003067122,0.000046503912,0.000020507981,0.00039666187,0.00011139586,0.00006190788],"category_scores_gemma":[0.0003963373,0.00021240076,0.0012418319,0.00084776885,0.00013699928,0.000053747477,0.00016477457,0.0002695412,0.00001617194],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011389909,0.00015075019,0.0019643551,0.7619165,0.22940308,7.407088e-7,0.00001937771,6.417939e-7,5.489358e-8,0.0001459172,0.0022508618,0.0041363323],"study_design_scores_gemma":[0.0009292076,0.0005956668,0.00012270396,0.026782213,0.8899377,3.698372e-7,0.000008287091,0.0000033188608,0.0000010999678,0.000025973819,0.08139663,0.00019683425],"about_ca_topic_score_codex":0.0000035856403,"about_ca_topic_score_gemma":0.000012936726,"teacher_disagreement_score":0.7351343,"about_ca_system_score_codex":0.00006426695,"about_ca_system_score_gemma":0.00008979784,"threshold_uncertainty_score":0.86614513},"labels":[],"label_agreement":null},{"id":"W2971557086","doi":"10.2337/cd19-0001","title":"Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?","year":2019,"lang":"en","type":"article","venue":"Clinical Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Type 2 diabetes; Clinical trial; Clinical Practice; Outcome (game theory); Diabetes mellitus; Internal medicine; Intensive care medicine; Physical therapy; Endocrinology","score_opus":0.16827954489606553,"score_gpt":0.45488234097005964,"score_spread":0.2866027960739941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971557086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964888,0.02060368,0.0000065978707,0.0021785605,0.005140852,0.004178006,0.0000129334285,0.0001286736,0.0028627],"genre_scores_gemma":[0.9716575,0.013618069,0.0035205283,0.007690707,0.0014819959,0.0003280156,0.00017034872,0.00011991174,0.0014129042],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927594,0.0014783861,0.0033308722,0.0010480058,0.0005625537,0.0008207494],"domain_scores_gemma":[0.98015845,0.017138645,0.000587619,0.0014411095,0.00031101337,0.000363177],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.026415484,0.00041147633,0.0037662075,0.00018872075,0.00004515155,0.00017833871,0.00031510185,0.0004492053,0.00014580207],"category_scores_gemma":[0.028200444,0.00030349247,0.002849777,0.0002654241,0.00013786257,0.00061197556,0.00019448635,0.00051798456,0.00078567205],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002744076,0.0012750964,0.7958907,0.000259079,0.0034933025,0.000010952932,0.0000446796,0.000007162366,0.000009259752,0.00035396774,0.0030181028,0.19536327],"study_design_scores_gemma":[0.021692906,0.0058763083,0.32065576,0.0011154086,0.0065902523,4.6324712e-7,0.00071755645,0.00031404846,0.0000998942,0.0018164194,0.64037055,0.00075044855],"about_ca_topic_score_codex":0.000004818494,"about_ca_topic_score_gemma":0.000004246222,"teacher_disagreement_score":0.6373524,"about_ca_system_score_codex":0.00008638523,"about_ca_system_score_gemma":0.00010590861,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W2971769159","doi":"10.1111/dom.13874","title":"Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Pediatrics; Gerontology; Endocrinology","score_opus":0.011434455576190002,"score_gpt":0.24030736058747618,"score_spread":0.22887290501128618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971769159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857494,0.008521557,0.0000012687457,0.0003887525,0.00049977616,0.0018358533,0.000019421339,0.00009017006,0.0028937727],"genre_scores_gemma":[0.9930037,0.00040821484,0.0004330015,0.0014218495,0.00014032784,0.000093865296,0.0000828115,0.000039176393,0.0043770485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976453,0.00023992751,0.00052600505,0.00055396254,0.0004304226,0.00060436974],"domain_scores_gemma":[0.9987106,0.00020706472,0.000092239345,0.0006349072,0.000089021,0.0002661746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021252993,0.00033999528,0.0021549289,0.00040011946,0.00005356889,0.000057053443,0.00014138337,0.00013457511,0.00036301732],"category_scores_gemma":[0.0005889989,0.00026782512,0.00046297457,0.00043635917,0.00003399856,0.0001876007,0.0002157235,0.0001523727,0.0014557758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007155698,0.00039887498,0.9657881,0.00028021232,0.0018232217,0.000010902816,0.00036629662,0.000014832068,0.001158696,0.00013395945,0.00086798694,0.029085347],"study_design_scores_gemma":[0.0043899943,0.00018307561,0.92537606,0.00020711782,0.0011184963,2.3127775e-7,0.00003704682,0.000091326576,0.0017847485,0.00008912715,0.06640793,0.00031485295],"about_ca_topic_score_codex":0.000048699,"about_ca_topic_score_gemma":0.0000068680188,"teacher_disagreement_score":0.06553994,"about_ca_system_score_codex":0.000049940583,"about_ca_system_score_gemma":0.000030180228,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W2972107819","doi":"10.1111/dom.13876","title":"Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Empagliflozin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Dapagliflozin; Adverse effect; Canagliflozin; Placebo; Endocrinology","score_opus":0.004777926649296908,"score_gpt":0.21199667970781733,"score_spread":0.20721875305852042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972107819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899805,0.006501722,9.495045e-8,0.00006878465,0.00043109467,0.0010023495,0.0000065945223,0.000034697754,0.001974171],"genre_scores_gemma":[0.99811596,0.0011848712,0.000053280648,0.00018406361,0.000054027347,0.000071998285,0.00003830086,0.000024126017,0.00027337926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998405,0.00006628933,0.00034199265,0.00036373115,0.00024110096,0.0005818807],"domain_scores_gemma":[0.9993033,0.00016083155,0.00009117583,0.0002537186,0.00003687533,0.00015409772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003684855,0.0002577329,0.00083136704,0.00040351102,0.000020220199,0.000015795582,0.000097554555,0.00012684918,0.000058230165],"category_scores_gemma":[0.00004754303,0.00023120629,0.00008011794,0.0004103766,0.000077683355,0.00019276995,0.00005410602,0.00016908195,0.00003987596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031411607,0.00095556624,0.9613387,0.0012166529,0.00027111932,0.00001723777,0.0010584996,0.0000019300358,0.021140378,0.00027574133,0.00011462379,0.013295432],"study_design_scores_gemma":[0.009851614,0.0004134838,0.89158213,0.00026877373,0.00019722627,3.9287226e-8,0.00012793473,0.000053887583,0.09328603,0.00015781568,0.00385025,0.00021078275],"about_ca_topic_score_codex":0.00004038003,"about_ca_topic_score_gemma":0.000011353382,"teacher_disagreement_score":0.072145656,"about_ca_system_score_codex":0.00006817087,"about_ca_system_score_gemma":0.00003451965,"threshold_uncertainty_score":0.9428319},"labels":[],"label_agreement":null},{"id":"W2972217240","doi":"10.1016/j.cmet.2019.08.009","title":"Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice","year":2019,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Novo Nordisk Canada; Canadian Institutes of Health Research; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk","keywords":"Proglucagon; Glucose homeostasis; Homeostasis; Glucagon-like peptide-1; Incretin; Biology; Endocrinology; Internal medicine; Cell biology; Diabetes mellitus; Medicine; Type 2 diabetes; Insulin resistance","score_opus":0.01641888606622817,"score_gpt":0.24651707178151966,"score_spread":0.2300981857152915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972217240","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57368815,0.051558957,0.00015013712,0.34484994,0.0069015687,0.012149356,0.00042818987,0.00042478548,0.009848904],"genre_scores_gemma":[0.112695575,0.004732295,0.032322396,0.6661245,0.02616542,0.0029822118,0.010490412,0.0012103675,0.14327681],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997056,0.00008755996,0.0006121407,0.00091722084,0.0004533112,0.0008737427],"domain_scores_gemma":[0.9980579,0.00019905435,0.000502295,0.0010099597,0.00014904389,0.000081748076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025028636,0.00065346336,0.0014427225,0.00053305004,0.00007550958,0.00009512001,0.0003811684,0.0006263921,0.00012493662],"category_scores_gemma":[0.00012521619,0.0005897508,0.00051723997,0.0002564283,0.000070368544,0.00013170263,0.00023965779,0.0007182333,0.00019511065],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013837278,0.00027483705,0.00020036135,0.0034645845,0.0005276188,0.00022508085,0.00030068116,0.0000061212277,0.0152048245,0.000024429693,0.9654926,0.014140503],"study_design_scores_gemma":[0.0057047657,0.0000979044,0.0028697052,0.00055705314,0.002068042,0.0000027335473,0.00018708954,0.000058515216,0.027532952,0.0001815313,0.9601288,0.0006108943],"about_ca_topic_score_codex":0.00004876581,"about_ca_topic_score_gemma":0.000009926279,"teacher_disagreement_score":0.46099257,"about_ca_system_score_codex":0.00012752597,"about_ca_system_score_gemma":0.00009747344,"threshold_uncertainty_score":0.99965537},"labels":[],"label_agreement":null},{"id":"W2972257966","doi":"10.1016/s2213-8587(19)30253-0","title":"Diabetic kidney disease 2.0: the treatment paradigm shifts","year":2019,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Albuminuria; Renal function; Dialysis; Kidney disease; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Acute kidney injury; Kidney; Kidney transplantation; Disease; Internal medicine; Urology; Diabetic nephropathy; Endocrinology","score_opus":0.02738031076867474,"score_gpt":0.26593630356204073,"score_spread":0.23855599279336598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972257966","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03548054,0.0066212765,0.0000014532752,0.9441144,0.00185696,0.0031579956,0.0003074437,0.00033997488,0.008119947],"genre_scores_gemma":[0.028988801,0.0035600085,0.00003040203,0.92741877,0.009308547,0.0017598437,0.002215825,0.00018351008,0.026534323],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99439186,0.00041047216,0.00049857626,0.0009581821,0.0005068786,0.0032340589],"domain_scores_gemma":[0.9952666,0.0009192158,0.0002924155,0.0032553533,0.000045078126,0.00022134472],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021822902,0.00096528704,0.0017778499,0.00019827911,0.00025173498,0.00011529904,0.0010347534,0.00031283472,0.00054733525],"category_scores_gemma":[0.000106517175,0.00047870964,0.0006522806,0.00023037092,0.00056794076,0.00006303638,0.00027247934,0.0013758236,0.0023672725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078445446,0.000250458,0.023990873,0.00038476835,0.0028227784,0.00060907175,0.00011016655,0.0000033743413,0.000010607126,0.00088636985,0.9635878,0.007265259],"study_design_scores_gemma":[0.0031811583,0.0008644095,0.013542951,0.00019290307,0.004151201,0.00000524436,0.000009868809,0.000047938887,0.00009357995,0.0022113435,0.9752382,0.00046122112],"about_ca_topic_score_codex":0.00004095037,"about_ca_topic_score_gemma":0.0000058148853,"teacher_disagreement_score":0.018414374,"about_ca_system_score_codex":0.00037214402,"about_ca_system_score_gemma":0.00022516403,"threshold_uncertainty_score":0.99976647},"labels":[],"label_agreement":null},{"id":"W2972754170","doi":"10.3949/ccjm.86a.18031","title":"Diabetes management: Beyond hemoglobin A<sub>1c</sub>","year":2019,"lang":"en","type":"review","venue":"Cleveland Clinic Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage College","funders":"","keywords":"Medicine; Glycemic; Hypoglycemia; Intensive care medicine; Diabetes mellitus; Diabetes management; Disease management; Disease; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.057996881473791784,"score_gpt":0.35172417215510615,"score_spread":0.29372729068131437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972754170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000501731,0.97202575,0.000023035773,0.0009930524,0.0029233017,0.0014673346,0.000017151044,0.000034615816,0.022014005],"genre_scores_gemma":[0.0001433079,0.98634017,0.00021232605,0.0010959697,0.0020471304,0.000028607936,0.00017509585,0.0001231891,0.0098342355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946871,0.00019977262,0.002800505,0.0005364765,0.0010811677,0.0006949813],"domain_scores_gemma":[0.9955211,0.00059151597,0.0023281449,0.00081876444,0.0002365508,0.0005038974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002154245,0.0008219687,0.005448634,0.0009667587,0.000065600085,0.00002812272,0.00055424107,0.0004260084,0.0006927058],"category_scores_gemma":[0.00022689643,0.0004944967,0.0013282293,0.0005805423,0.00025938873,0.00013240369,0.00019784138,0.0010756243,0.00084401923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006330959,0.00032695945,0.00018068113,0.025522077,0.0048936075,0.0006493004,0.00003180807,7.3946204e-8,0.0000017438258,0.00009772351,0.075250626,0.89298207],"study_design_scores_gemma":[0.007999679,0.0025538367,0.00021754789,0.063781336,0.028134415,0.00018845533,0.00009126624,0.0000010787363,0.0000058441933,0.0003320297,0.89632076,0.00037374505],"about_ca_topic_score_codex":4.9802475e-7,"about_ca_topic_score_gemma":4.1698738e-7,"teacher_disagreement_score":0.89260834,"about_ca_system_score_codex":0.00026789907,"about_ca_system_score_gemma":0.00027139808,"threshold_uncertainty_score":0.99993396},"labels":[],"label_agreement":null},{"id":"W2973258158","doi":"10.1111/dme.14140","title":"Treatment of heart failure with sodium glucose co‐transporter‐2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions","year":2019,"lang":"en","type":"review","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Manitoba; St. Boniface Hospital; St. Michael's Hospital; McGill University Health Centre","funders":"National Institute of General Medical Sciences","keywords":"Medicine; Heart failure; Diabetes mellitus; Type 2 diabetes; Internal medicine; Type 2 Diabetes Mellitus; Cardiology; Endocrinology","score_opus":0.026556306248953145,"score_gpt":0.30103266004288826,"score_spread":0.2744763537939351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973258158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015756398,0.9788844,9.1927916e-7,0.0010509202,0.00045215708,0.003612134,0.000025471014,0.000054034823,0.0001635617],"genre_scores_gemma":[0.0026066497,0.9953591,0.0001513218,0.000041066236,0.00052746583,0.0004291685,0.0005679552,0.00008767433,0.00022957959],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971907,0.000117097385,0.00078684656,0.0007909114,0.0005729282,0.0005415235],"domain_scores_gemma":[0.99813944,0.00032621514,0.000366227,0.00074643653,0.00013354093,0.00028814812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020760002,0.00081264885,0.0036912982,0.000625275,0.000046482386,0.000014707841,0.00011210849,0.00019788138,0.00015827002],"category_scores_gemma":[0.000023978446,0.00043676473,0.00018380722,0.0010145495,0.00028643172,0.000101513004,0.000021500404,0.00028886413,0.000028076118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009961249,0.0010943947,0.05313846,0.043653782,0.0011341692,0.000037742117,0.0009080369,2.297024e-7,0.0000042341994,0.000025867312,0.0010524393,0.89885104],"study_design_scores_gemma":[0.0030141075,0.006567682,0.0041491436,0.06236812,0.008476742,0.00001359007,0.00018495195,0.000002951372,0.000029543991,0.000002254247,0.9148203,0.00037062727],"about_ca_topic_score_codex":0.000054495165,"about_ca_topic_score_gemma":0.00012061666,"teacher_disagreement_score":0.9137679,"about_ca_system_score_codex":0.00027823768,"about_ca_system_score_gemma":0.0003355796,"threshold_uncertainty_score":0.99980843},"labels":[],"label_agreement":null},{"id":"W2973278422","doi":"10.1016/j.jcjd.2019.07.096","title":"87 - Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dulaglutide; Semaglutide; Medicine; Glycemic; Tolerability; Type 2 diabetes; Discontinuation; Weight loss; Internal medicine; Adverse effect; Diabetes mellitus; Nausea; Gastroenterology; Exenatide; Endocrinology; Liraglutide; Obesity","score_opus":0.006599695597157515,"score_gpt":0.22545043731555153,"score_spread":0.21885074171839403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973278422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396074,0.0036554825,0.0000011941344,0.00086153153,0.00015301707,0.00038171228,0.000040623843,0.0000052271735,0.0009404461],"genre_scores_gemma":[0.99881226,0.000094896764,0.00029282214,0.00027599235,0.000036525536,0.0000017795032,0.000029114392,0.000026177857,0.00043046006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979459,0.000099659635,0.0008524803,0.00023096536,0.00029079895,0.00058017386],"domain_scores_gemma":[0.99796903,0.00029642,0.00049038266,0.0003569691,0.0003421302,0.0005450814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007346137,0.00023553795,0.0012333733,0.0017929923,0.000037227677,0.000020662947,0.00020132112,0.00009995164,0.00021600476],"category_scores_gemma":[0.00036511882,0.00020835729,0.00024823874,0.0013817898,0.00015962248,0.00014206769,0.00003576681,0.0002124101,0.000005307715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068449925,0.00010237876,0.98800355,0.00028669697,0.0022556058,0.000031261534,0.00038082423,0.0003199253,0.0023285013,0.00020335606,0.00033021043,0.0056892578],"study_design_scores_gemma":[0.0032394924,0.0016342583,0.98733985,0.0007931155,0.0024902865,7.3595044e-7,0.00048351497,0.0005875865,0.0012282138,0.00006319912,0.001943631,0.00019609778],"about_ca_topic_score_codex":0.00069391343,"about_ca_topic_score_gemma":0.003763288,"teacher_disagreement_score":0.0054931603,"about_ca_system_score_codex":0.000269474,"about_ca_system_score_gemma":0.00060304994,"threshold_uncertainty_score":0.84965634},"labels":[],"label_agreement":null},{"id":"W2973451910","doi":"10.1016/j.jcjd.2019.07.095","title":"86 - Clinical Response (HbA1C ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1C and Body Weight in the SUSTAIN Program","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Semaglutide; Dulaglutide; Medicine; Exenatide; Sitagliptin; Insulin glargine; Glycated hemoglobin; Type 2 diabetes; Weight loss; Placebo; Internal medicine; Pharmacology; Diabetes mellitus; Liraglutide; Endocrinology; Obesity","score_opus":0.010556240197648269,"score_gpt":0.28391946709986804,"score_spread":0.27336322690221976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973451910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713038,0.0021488697,0.0000018545718,0.024763187,0.00034505804,0.0010872325,0.000020853535,0.0000123244645,0.00031679045],"genre_scores_gemma":[0.9930295,0.000119104145,0.0008933919,0.0022964745,0.0003292114,0.00003048044,0.000019045683,0.00003124414,0.0032515505],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779475,0.00040866344,0.00065621507,0.0002887318,0.0002619135,0.00058974454],"domain_scores_gemma":[0.9979564,0.0004716701,0.0001783562,0.00030983836,0.00014513746,0.00093858596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002824165,0.00023144457,0.0005383633,0.00049058086,0.00009293192,0.00010429457,0.00018309054,0.000104760904,0.00016615198],"category_scores_gemma":[0.000686957,0.00014768203,0.00011006967,0.00037468254,0.00015355993,0.00015647065,0.000029964378,0.00036090173,0.000018985282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066212995,0.00049739075,0.80220586,0.00016559845,0.0005521149,0.00036589848,0.00077979814,0.000001338321,0.0009148954,0.00021866208,0.14928237,0.04435394],"study_design_scores_gemma":[0.005061214,0.00643059,0.4571387,0.0005257972,0.000555593,0.000051874606,0.0016117044,0.00021910766,0.0002614716,0.00014811869,0.52766746,0.00032836624],"about_ca_topic_score_codex":0.00020198332,"about_ca_topic_score_gemma":0.0008684677,"teacher_disagreement_score":0.3783851,"about_ca_system_score_codex":0.00016665368,"about_ca_system_score_gemma":0.00059566705,"threshold_uncertainty_score":0.60222983},"labels":[],"label_agreement":null},{"id":"W2973476146","doi":"10.1016/j.jcjd.2019.07.101","title":"92 - Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter-2 Inhibitor: A Posthoc Analysis of SUSTAIN 9","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Semaglutide; Empagliflozin; Medicine; Dapagliflozin; Placebo; Canagliflozin; Type 2 diabetes; Internal medicine; Glycated hemoglobin; Pharmacology; Metformin; Diabetes mellitus; Weight loss; Liraglutide; Endocrinology; Insulin","score_opus":0.007919358850637997,"score_gpt":0.2267099764755473,"score_spread":0.2187906176249093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973476146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487835,0.002745753,0.0000068644026,0.00043818564,0.00016438574,0.00031374156,0.00012563747,0.0000054634465,0.0013216373],"genre_scores_gemma":[0.998691,0.00002473684,0.00017473249,0.00021853579,0.000049121172,0.0000018221899,0.00009547452,0.000025682315,0.00071885344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981941,0.00004914554,0.000775957,0.00018139233,0.00033470753,0.0004646747],"domain_scores_gemma":[0.99804544,0.00013241058,0.00051941926,0.00033918678,0.00033572153,0.000627811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003945697,0.00021211068,0.0010290558,0.0012202143,0.000030230263,0.000020524994,0.00019401076,0.00008931114,0.00049463514],"category_scores_gemma":[0.00005036688,0.00018403659,0.00054991565,0.0008277823,0.0001349313,0.00012374247,0.000010993012,0.00015727841,0.000008402644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044289874,0.000269833,0.97447467,0.00029776467,0.0061047655,0.000043343,0.00039300494,0.00009133734,0.009817682,0.00013096485,0.004467444,0.0038648974],"study_design_scores_gemma":[0.008901738,0.0030660264,0.9101626,0.0008683844,0.01648647,0.0000028277047,0.001640568,0.00025769346,0.0393665,0.00007554554,0.01868192,0.00048970926],"about_ca_topic_score_codex":0.0007876354,"about_ca_topic_score_gemma":0.0021516744,"teacher_disagreement_score":0.06431205,"about_ca_system_score_codex":0.0002219648,"about_ca_system_score_gemma":0.0005988139,"threshold_uncertainty_score":0.7504794},"labels":[],"label_agreement":null},{"id":"W2973483379","doi":"10.1016/j.jcjd.2019.07.029","title":"22 - Remission and Regression Following a Short-Term Intensive Metabolic Intervention With Insulin Glargine, Metformin and Dapagliflozin: The REMIT-DAPA Trial","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Insulin glargine; Dapagliflozin; Term (time); Internal medicine; Insulin; Type 2 diabetes; Endocrinology; Diabetes mellitus; Hypoglycemia","score_opus":0.012163601345133071,"score_gpt":0.24566795933640084,"score_spread":0.23350435799126779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973483379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858401,0.011826833,0.0000045510264,0.00082571694,0.00039900505,0.00060628454,0.000003320183,0.000006469898,0.0004877257],"genre_scores_gemma":[0.9986453,0.0001579055,0.00022742564,0.00027493466,0.00014043081,0.0000085519905,0.000011612124,0.000022321412,0.00051148504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988901,0.00006567965,0.00035467386,0.00018048463,0.00021589597,0.0002931552],"domain_scores_gemma":[0.9989138,0.000080937716,0.00019626942,0.0001994662,0.00016645905,0.00044306286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005529875,0.00019106184,0.0004926358,0.0003148385,0.000102921345,0.000081435195,0.000097864766,0.00006758049,0.000040731717],"category_scores_gemma":[0.00020946987,0.00010312189,0.00015200097,0.00016636886,0.00007273737,0.00026913048,0.00003153442,0.00023031968,0.0000015360467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014686597,0.00008409365,0.80926436,0.00020411714,0.001720439,0.00021744342,0.0011311339,0.0000015700093,0.002211399,0.00021345002,0.0019837667,0.18149954],"study_design_scores_gemma":[0.14077985,0.014300266,0.72377527,0.014332923,0.00814049,0.00020769514,0.008091513,0.00057821936,0.009841265,0.00061779434,0.078202,0.0011326866],"about_ca_topic_score_codex":0.00008430897,"about_ca_topic_score_gemma":0.00036613204,"teacher_disagreement_score":0.18036686,"about_ca_system_score_codex":0.00006948715,"about_ca_system_score_gemma":0.0001540603,"threshold_uncertainty_score":0.42051888},"labels":[],"label_agreement":null},{"id":"W2973969622","doi":"10.2218/gtopdb/f29/2019.4","title":"Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database","year":2019,"lang":"en","type":"article","venue":"IUPHAR/BPS Guide to Pharmacology CITE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon; Secretin family; Secretin; Receptor; Endocrinology; Hormone; Glucagon-like peptide-1; Internal medicine; Peptide; Chemistry; Peptide hormone; Pharmacology; Medicine; Secretion; Vasoactive intestinal peptide; Biochemistry; Neuropeptide; Diabetes mellitus; Type 2 diabetes","score_opus":0.014905435570447987,"score_gpt":0.3495873460665793,"score_spread":0.33468191049613133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973969622","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9333809,0.0011086323,0.0001367594,0.02638314,0.0069864094,0.008526005,0.0036864139,0.0003378014,0.019453933],"genre_scores_gemma":[0.2832809,0.0035081436,0.007934678,0.5446461,0.004689431,0.004186325,0.02440033,0.00044493107,0.12690917],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943201,0.00057680375,0.001196931,0.001469704,0.0007814977,0.0016549914],"domain_scores_gemma":[0.9972723,0.0004672215,0.00026773222,0.0010153884,0.00021896369,0.0007583713],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017714278,0.0008159925,0.0010791201,0.0010682557,0.00020412826,0.000070078226,0.0012047627,0.00026591434,0.011984511],"category_scores_gemma":[0.000076885226,0.000666191,0.00030516763,0.0012989093,0.00013746723,0.0004304895,0.00082524,0.0007212987,0.021300297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012256143,0.0009245051,0.0019123489,0.00008873068,0.0004183115,0.00032523027,0.00026710518,0.0001066112,0.3305346,0.00004900395,0.6620576,0.0020903575],"study_design_scores_gemma":[0.01231728,0.001533552,0.0033039534,0.000099027566,0.0010572531,0.000026581918,0.00030120567,0.00012402055,0.047928855,0.0000072699845,0.9326817,0.00061933737],"about_ca_topic_score_codex":0.00038733348,"about_ca_topic_score_gemma":0.000040612846,"teacher_disagreement_score":0.6501,"about_ca_system_score_codex":0.0007593304,"about_ca_system_score_gemma":0.00025385225,"threshold_uncertainty_score":0.99957895},"labels":[],"label_agreement":null},{"id":"W2974001637","doi":"10.7326/acpj201909170-029","title":"In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA<sub>1c</sub>","year":2019,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Liraglutide; Semaglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.035419320459355176,"score_gpt":0.322916450006435,"score_spread":0.2874971295470798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974001637","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2996429,0.003097145,0.0000604361,0.6854161,0.0029950126,0.0046330127,0.00006604396,0.00006799684,0.004021342],"genre_scores_gemma":[0.103681654,0.00044430414,0.00045507043,0.86838937,0.005437315,0.00041946946,0.00043906635,0.00021447081,0.020519257],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954436,0.00011679385,0.0015776114,0.00085796893,0.0008545681,0.0011494743],"domain_scores_gemma":[0.9966491,0.00077901094,0.0006953842,0.0008349376,0.0007961643,0.0002454345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011160821,0.0007988983,0.0033517524,0.0013150354,0.00003437037,0.000027742979,0.00047015861,0.00047716114,0.00024864828],"category_scores_gemma":[0.0018593424,0.0005963482,0.0005407633,0.0004351621,0.0001547239,0.00012278123,0.00018371356,0.0009873206,0.00017836814],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026231585,0.00019706979,0.0014937693,0.0014545079,0.0018406863,0.0004896516,0.00021147628,0.0000123963955,0.009801324,0.000024578985,0.97391725,0.007934141],"study_design_scores_gemma":[0.0255839,0.013654434,0.0019273158,0.017317517,0.0018767215,0.000019865196,0.0000683624,0.00031052768,0.03747932,0.00025200375,0.90067905,0.0008309743],"about_ca_topic_score_codex":0.0004449516,"about_ca_topic_score_gemma":0.00004105513,"teacher_disagreement_score":0.19596124,"about_ca_system_score_codex":0.00018945002,"about_ca_system_score_gemma":0.00020158365,"threshold_uncertainty_score":0.9996488},"labels":[],"label_agreement":null},{"id":"W2974094757","doi":"10.17756/jocd.2019-027","title":"Use of Liraglutide in a Tertiary Bariatric Clinic: A Case Series","year":2019,"lang":"en","type":"article","venue":"Journal of Obesity and Chronic Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Liraglutide; Tertiary care; Series (stratigraphy); Medicine; Family medicine; Diabetes mellitus; Endocrinology; Geology; Paleontology; Type 2 diabetes","score_opus":0.013732723443192962,"score_gpt":0.2541123303695329,"score_spread":0.24037960692633994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974094757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400353,0.0053221807,0.0000036960855,0.00022045367,0.00012422907,0.00018800092,0.000009045478,0.000004554895,0.00012432052],"genre_scores_gemma":[0.99740356,0.0013068399,0.00015786724,0.00009084602,0.00006998561,0.0000013830794,0.0000026854689,0.000006040327,0.0009607656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928284,0.00003237736,0.00033252154,0.00008830491,0.00013826518,0.00012570464],"domain_scores_gemma":[0.9994539,0.00007480526,0.00018410696,0.00012309731,0.000047443104,0.00011662014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010250257,0.00008866866,0.00032203447,0.00016313164,0.000016355403,0.00001641394,0.000035896304,0.000030820156,0.0001945105],"category_scores_gemma":[0.00004756212,0.00006573319,0.00012643333,0.0000949697,0.000040317624,0.0003235188,0.000044698994,0.000082428145,0.000006884764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003813523,0.0010311923,0.98711365,0.0005833499,0.00022369776,0.0032372698,0.00007398114,0.000012634468,0.00007167943,0.000060654795,0.0009294922,0.006281048],"study_design_scores_gemma":[0.0042543686,0.0021338314,0.98719406,0.000580455,0.0010589191,0.000999563,0.00024086806,0.00010832732,0.00017481165,0.00014764938,0.0029991365,0.000108025044],"about_ca_topic_score_codex":0.000024028446,"about_ca_topic_score_gemma":0.000028358681,"teacher_disagreement_score":0.006173023,"about_ca_system_score_codex":0.000073034105,"about_ca_system_score_gemma":0.000136623,"threshold_uncertainty_score":0.2680522},"labels":[],"label_agreement":null},{"id":"W2974254482","doi":"10.1016/j.jcjd.2019.07.028","title":"21 - Effect and Safety of Flexible Dose Adjustment With Oral Semaglutide vs Sitagliptin in Type 2 Diabetes: PIONEER 7","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Sitagliptin; Medicine; Discontinuation; Tolerability; Adverse effect; Type 2 diabetes; Dulaglutide; Internal medicine; Pharmacology; Diabetes mellitus; Liraglutide; Endocrinology","score_opus":0.006493766427540219,"score_gpt":0.21405854053585674,"score_spread":0.20756477410831653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974254482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923751,0.004551936,5.649646e-7,0.00038179845,0.00028583064,0.00054240803,0.000009848783,0.000006695593,0.0018458596],"genre_scores_gemma":[0.99828506,0.00003169414,0.0003275636,0.00030932907,0.00005392795,0.0000066638695,0.000012278472,0.000027451835,0.00094603864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869007,0.000061129416,0.00038219403,0.0001760862,0.00021570169,0.00047479832],"domain_scores_gemma":[0.9988487,0.0001151026,0.00018882158,0.00021960557,0.00013333997,0.00049443013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043829237,0.00020926513,0.0006688741,0.00051141676,0.000026903264,0.000019316196,0.00009779254,0.000066537876,0.00029215193],"category_scores_gemma":[0.0000607477,0.00015163902,0.00008204413,0.0003321466,0.00008850236,0.00012864008,0.000018900488,0.00017360058,0.000018609297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012531327,0.00006572476,0.9837671,0.00029314592,0.00046727492,0.000042370582,0.00020742847,0.00006948533,0.0003834637,0.000099837125,0.0010178006,0.013461078],"study_design_scores_gemma":[0.006356863,0.0065017007,0.97722065,0.0013480708,0.00050968013,0.0000030368324,0.00017954511,0.0000779554,0.0020573447,0.000034596145,0.0055003446,0.00021023584],"about_ca_topic_score_codex":0.00022642328,"about_ca_topic_score_gemma":0.0011413811,"teacher_disagreement_score":0.013250842,"about_ca_system_score_codex":0.00021216368,"about_ca_system_score_gemma":0.00033563285,"threshold_uncertainty_score":0.61836594},"labels":[],"label_agreement":null},{"id":"W2974260792","doi":"10.1056/nejmoa1911303","title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6873,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Montreal Heart Institute; Libin Cardiovascular Institute of Alberta; St. Michael's Hospital; University of Calgary","funders":"AstraZeneca","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Fraction (chemistry); Medicine; Chemistry; Diabetes mellitus; Endocrinology; Chromatography","score_opus":0.005921450203652242,"score_gpt":0.2270162747503756,"score_spread":0.22109482454672338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974260792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926656,0.00015203668,0.000024876315,0.0057943747,0.00024321004,0.00023820403,1.7686553e-7,0.00000591843,0.0008755872],"genre_scores_gemma":[0.99814194,0.00003940918,0.0004855732,0.00030039603,0.0005241556,6.7806843e-7,0.000007283367,0.000008825229,0.0004917534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992715,0.00002615849,0.00021872231,0.00009126908,0.00028878846,0.00010355797],"domain_scores_gemma":[0.9995565,0.000037371843,0.00012815854,0.00008190188,0.00007872829,0.00011737245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024945824,0.000088982124,0.00030414492,0.00023206868,0.000011822142,0.0000052699866,0.000020549589,0.00003232395,0.00012006074],"category_scores_gemma":[0.00004253081,0.000051410418,0.000017961473,0.00012529905,0.000019266043,0.00013028194,0.000006662105,0.00016875833,0.0000048597635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013114548,0.00012231196,0.970643,0.00003564942,0.000080246835,0.0000131788065,0.00011241745,0.0000067077526,0.00088564516,0.000014289238,0.0055374773,0.021237629],"study_design_scores_gemma":[0.079973765,0.0059489068,0.87155414,0.00061412057,0.0001892712,0.000035242276,0.00018812482,0.000012559722,0.00014106288,0.000051961255,0.04123404,0.000056814515],"about_ca_topic_score_codex":0.00003033779,"about_ca_topic_score_gemma":0.000013856401,"teacher_disagreement_score":0.09908886,"about_ca_system_score_codex":0.000058594436,"about_ca_system_score_gemma":0.000029538034,"threshold_uncertainty_score":0.2096456},"labels":[],"label_agreement":null},{"id":"W2974506947","doi":"10.1016/j.jcjd.2019.07.100","title":"91 - Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Dulaglutide; Internal medicine; Diabetes mellitus; Gerontology; Endocrinology; Exenatide","score_opus":0.005557140227353718,"score_gpt":0.21292447101322895,"score_spread":0.20736733078587524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974506947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961059,0.002298503,6.7862715e-7,0.00026174594,0.000058366077,0.00031149507,0.000017007042,0.0000029481096,0.0009433434],"genre_scores_gemma":[0.99936056,0.000032610144,0.00021290018,0.00011623765,0.000016602406,0.0000012175639,0.000018037532,0.00001787941,0.00022396646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869734,0.00005384233,0.0004939227,0.00015464495,0.00020943281,0.00039081357],"domain_scores_gemma":[0.9985997,0.00017711097,0.0003257915,0.00023666228,0.00028151067,0.00037924486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004027352,0.0001650306,0.0008714294,0.0014706473,0.000019943445,0.000013877173,0.000112719754,0.00006238529,0.00012532827],"category_scores_gemma":[0.0001296401,0.0001283281,0.00012189017,0.0011750935,0.00011468636,0.00009457255,0.000013310563,0.00013661856,0.0000016614533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006272217,0.00007466866,0.9909757,0.00022213724,0.002322059,0.000026282569,0.0003579654,0.00017405713,0.00091174047,0.000089557994,0.0000971744,0.0046859668],"study_design_scores_gemma":[0.0032417858,0.003019902,0.9880126,0.0006240751,0.0024138242,6.5372325e-7,0.00046894368,0.00013786175,0.0013515744,0.000026140135,0.0005676771,0.00013495707],"about_ca_topic_score_codex":0.00044303125,"about_ca_topic_score_gemma":0.00591998,"teacher_disagreement_score":0.005476949,"about_ca_system_score_codex":0.00013581442,"about_ca_system_score_gemma":0.0005245737,"threshold_uncertainty_score":0.5233068},"labels":[],"label_agreement":null},{"id":"W2974714926","doi":"10.2337/dc19-0898","title":"Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Western University; Mount Sinai Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Semaglutide; Medicine; Tolerability; Placebo; Type 2 diabetes; Metformin; Internal medicine; Adverse effect; Discontinuation; Randomized controlled trial; Diabetes mellitus; Insulin; Gastroenterology; Endocrinology; Liraglutide","score_opus":0.011576203174250213,"score_gpt":0.24656627201956569,"score_spread":0.23499006884531548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974714926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413323,0.00011131034,5.86222e-7,0.00013240214,0.00017881386,0.0047693877,0.000037641843,0.00003584094,0.0006007665],"genre_scores_gemma":[0.9988179,0.0000058577957,0.0005034269,0.00017385601,0.000023851822,0.00010718719,0.00015465287,0.0000363498,0.0001768697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983971,0.00007299006,0.0003306577,0.00039418603,0.000405413,0.00039965438],"domain_scores_gemma":[0.99877423,0.0002545484,0.00011400899,0.0005307178,0.00019638642,0.00013011118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023052373,0.0002789939,0.00072333385,0.00013375316,0.00004014876,0.000022027041,0.00012903166,0.000069591326,0.000075218675],"category_scores_gemma":[0.00013674784,0.00014488026,0.000049835653,0.00047742605,0.00009418094,0.000085703716,0.000114261726,0.0001375679,0.000034846424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11510369,0.00036633515,0.8684937,0.00019817638,0.0003160049,0.0000012188532,0.0009675619,0.000052945477,0.000012523615,0.000009645175,0.00006946209,0.014408769],"study_design_scores_gemma":[0.20727243,0.020908361,0.7654857,0.00045409476,0.00060314965,4.8986614e-8,0.0010818535,0.000099418125,0.00075339904,0.0000029329528,0.0030130104,0.00032561543],"about_ca_topic_score_codex":0.000021635886,"about_ca_topic_score_gemma":0.00016521028,"teacher_disagreement_score":0.10300797,"about_ca_system_score_codex":0.00013065843,"about_ca_system_score_gemma":0.00009025558,"threshold_uncertainty_score":0.5908045},"labels":[],"label_agreement":null},{"id":"W2975114707","doi":"10.1016/j.jcjd.2019.09.002","title":"Time to Treatment Intensification in Newly Treated Adult Type 2 Diabetes Patients: Comparison of Canada and the United States","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Medicine; Hazard ratio; Confidence interval; Glycated hemoglobin; Metformin; Demography; Proportional hazards model; Cohort; Type 2 diabetes; Diabetes mellitus; Internal medicine; Retrospective cohort study; Endocrinology","score_opus":0.00773642762770777,"score_gpt":0.20813944756112387,"score_spread":0.2004030199334161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975114707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965416,0.0003883026,9.097596e-8,0.002087894,0.00010163814,0.0005246306,0.000022257886,0.0000029385362,0.00033065456],"genre_scores_gemma":[0.9983912,0.000015221997,0.000033289576,0.00078335806,0.000016083673,0.0000065164495,0.00011063677,0.000014268823,0.00062940875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895215,0.000060901526,0.00041848296,0.000114620816,0.00015499911,0.00029886194],"domain_scores_gemma":[0.99862057,0.00015479862,0.00020318391,0.0001691829,0.00050625484,0.00034602548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013391672,0.0001491918,0.0005122688,0.0004091698,0.00003256831,0.000019077042,0.000088005254,0.000033979944,0.00008741205],"category_scores_gemma":[0.00017791831,0.000094963674,0.000047087502,0.0004052551,0.00007831053,0.000055817894,0.000009009143,0.00006696615,0.0000087728695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004955403,0.00007673196,0.99024725,0.000031583215,0.0002725897,0.0000018599782,0.00074173353,0.00023155316,0.000069154965,0.000024624034,0.004106083,0.0041472823],"study_design_scores_gemma":[0.009313927,0.0032050966,0.9663829,0.000526022,0.00044974868,2.4452325e-7,0.0012123086,0.0036868544,0.0021213272,0.000036169564,0.012860449,0.00020495003],"about_ca_topic_score_codex":0.14536455,"about_ca_topic_score_gemma":0.4199326,"teacher_disagreement_score":0.27456802,"about_ca_system_score_codex":0.00043857473,"about_ca_system_score_gemma":0.00043859563,"threshold_uncertainty_score":0.8603265},"labels":[],"label_agreement":null},{"id":"W2975219544","doi":"10.1016/j.jcjd.2019.09.004","title":"Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Myocardial infarction; Dapagliflozin; Type 2 diabetes; Internal medicine; Hypoglycemia; Disease; Stroke (engine); Type 2 Diabetes Mellitus; Clinical trial; Adverse effect; Cardiology; Clinical endpoint; Intensive care medicine; Endocrinology","score_opus":0.010121869561719017,"score_gpt":0.21877353862374083,"score_spread":0.20865166906202182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975219544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10133477,0.89612913,2.261665e-7,0.000015560183,0.00072482805,0.0013943007,0.000024906125,0.0000071060513,0.00036917801],"genre_scores_gemma":[0.054557342,0.9445732,0.00009944235,0.00006391491,0.00027338075,0.000037813694,0.00012589867,0.00013166935,0.00013730853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733675,0.0001280052,0.0010112107,0.00034377942,0.0004535008,0.0007267648],"domain_scores_gemma":[0.9976181,0.00018924515,0.00065441726,0.0005779235,0.00027189884,0.0006884391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040822625,0.00057621184,0.003936896,0.0014569657,0.000028612707,0.00002733937,0.00030182963,0.00029059136,0.000033093078],"category_scores_gemma":[0.000102464204,0.00041127004,0.0012562318,0.0007525686,0.00014598266,0.00014508447,0.000015507643,0.00051719986,0.000020787313],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001333685,0.00015157183,0.06392559,0.11061446,0.00813487,0.0005333058,0.00018805095,0.0000053248477,0.0000023949588,0.000011156362,0.0007883907,0.81563157],"study_design_scores_gemma":[0.0044275555,0.0032355506,0.005120224,0.20386745,0.01782813,0.0000074490413,0.000042659434,0.0000020871576,0.00024024241,0.00000769142,0.7645813,0.00063965865],"about_ca_topic_score_codex":0.00022622813,"about_ca_topic_score_gemma":0.0009853671,"teacher_disagreement_score":0.8149919,"about_ca_system_score_codex":0.00039123054,"about_ca_system_score_gemma":0.0020314592,"threshold_uncertainty_score":0.99983394},"labels":[],"label_agreement":null},{"id":"W2976193287","doi":"10.1002/oby.22630","title":"Response to “Liraglutide Effectiveness: Is There a Real‐World Clinical Benefit?”","year":2019,"lang":"en","type":"letter","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Library science","score_opus":0.027955579852527182,"score_gpt":0.32411662808259956,"score_spread":0.2961610482300724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976193287","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58143187,0.00021576934,0.000013502023,0.3824199,0.0010616258,0.0027831823,0.000101193276,0.0002040213,0.031768903],"genre_scores_gemma":[0.023356533,0.00016368981,0.00034958727,0.7238981,0.0020062986,0.00015271647,0.00029020908,0.0001279679,0.24965487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969524,0.00050936156,0.00045673572,0.0009528135,0.00053956045,0.0005890964],"domain_scores_gemma":[0.99681413,0.0012869078,0.00016989034,0.0014506672,0.000119006196,0.00015941812],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014239078,0.0005024178,0.0012281715,0.00033382847,0.000072919276,0.000046983216,0.00028961033,0.0005823853,0.0005970455],"category_scores_gemma":[0.00017447828,0.00040979934,0.0005697404,0.00030077394,0.000058477406,0.000053070136,0.0002931346,0.0010627605,0.0046392423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013518081,0.00025336168,0.21571176,0.00046851402,0.0006366259,0.00075634575,0.00002979771,3.8502807e-7,0.000015731748,0.000021243977,0.77834976,0.0024046616],"study_design_scores_gemma":[0.001220339,0.00068611046,0.4186106,0.00058930286,0.0005311193,0.0000013720918,0.0000025894947,0.0000017077077,0.00008197469,0.00006908454,0.5779752,0.00023057191],"about_ca_topic_score_codex":0.00021857611,"about_ca_topic_score_gemma":0.00004853813,"teacher_disagreement_score":0.55807537,"about_ca_system_score_codex":0.0003959045,"about_ca_system_score_gemma":0.00013010121,"threshold_uncertainty_score":0.9998354},"labels":[],"label_agreement":null},{"id":"W2976236713","doi":"10.1152/ajprenal.00370.2019","title":"Renal SGLT mRNA expression in human health and disease: a study in two cohorts","year":2019,"lang":"en","type":"article","venue":"American Journal of Physiology-Renal Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; Toronto General Hospital; University Health Network","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Diabetic nephropathy; Nephropathy; Internal medicine; Endocrinology; Renal function; Minimal change disease; Nephrotic syndrome; Kidney disease; Glomerulosclerosis; Kidney; Glycated hemoglobin; Diabetes mellitus; Fold change; Focal segmental glomerulosclerosis; Glomerulonephritis; Gene expression; Proteinuria; Biology; Type 2 diabetes; Biochemistry","score_opus":0.010310134919652074,"score_gpt":0.3137160187062089,"score_spread":0.30340588378655686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976236713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99810916,0.00041486745,0.0000019647043,0.00059076154,0.00011164215,0.0006749892,0.0000028584057,0.000011322699,0.00008240307],"genre_scores_gemma":[0.9983163,0.00011940253,0.00016890805,0.0010957447,0.00015755549,0.000024469633,0.000024857138,0.000021985985,0.00007076534],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99773186,0.00045328148,0.00070147164,0.00042966855,0.00020593555,0.00047774983],"domain_scores_gemma":[0.9984831,0.0001060062,0.000650026,0.00031628812,0.000058799495,0.00038575588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032998537,0.00026518587,0.0013115205,0.0004544093,0.000044560413,0.000006809684,0.0001602653,0.000027148639,0.000080753765],"category_scores_gemma":[0.00003690138,0.00019616772,0.00012631336,0.00030440604,0.00028172665,0.000120353645,0.00014204963,0.00040550984,0.000010169591],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003180967,0.002673224,0.27548006,0.000090945665,0.0002761232,0.00011862003,0.00071332965,0.00027820384,0.7107011,0.00009872554,0.0006372558,0.0057514543],"study_design_scores_gemma":[0.0068482864,0.010100549,0.9797126,0.00039758233,0.00006320279,0.000011975951,0.00094898156,0.000043242715,0.00033520153,0.0011263445,0.00024138388,0.00017063279],"about_ca_topic_score_codex":0.00013557739,"about_ca_topic_score_gemma":0.000045809928,"teacher_disagreement_score":0.7103659,"about_ca_system_score_codex":0.00013569799,"about_ca_system_score_gemma":0.00020383633,"threshold_uncertainty_score":0.79994875},"labels":[],"label_agreement":null},{"id":"W2976645875","doi":"10.1016/j.jcjd.2019.09.003","title":"Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Alberta Innovates - Health Solutions","keywords":"Medicine; Incretin; Type 2 Diabetes Mellitus; Diabetes mellitus; Adverse effect; Glucagon-like peptide 1 receptor; Type 2 diabetes; Internal medicine; Glucagon-like peptide-1; Cardiac fibrosis; Endocrinology; Pharmacology; Receptor; Bioinformatics; Cardiology; Fibrosis; Agonist","score_opus":0.011142186313514093,"score_gpt":0.222069525246665,"score_spread":0.2109273389331509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976645875","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09085113,0.90591615,0.0000016697504,0.000067786576,0.0010762623,0.0016059522,0.00022790373,0.000019062645,0.00023410312],"genre_scores_gemma":[0.020915834,0.97722346,0.00041740036,0.00009736571,0.00023483681,0.000064193504,0.000530238,0.00019862091,0.00031806182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99593097,0.00027159264,0.0012618053,0.00075519766,0.0006098897,0.0011705633],"domain_scores_gemma":[0.99640733,0.00015179235,0.00090196315,0.00075577333,0.00041354253,0.0013695755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000956049,0.0009483445,0.0038987708,0.0011088749,0.00012352093,0.00013921244,0.0003811972,0.00049251836,0.00007783049],"category_scores_gemma":[0.00012455377,0.00072465284,0.0008145897,0.0009617601,0.0001751991,0.00027212457,0.000030931977,0.0009972248,0.00004646324],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004581016,0.00021471416,0.012649958,0.024461288,0.011289617,0.00021029747,0.00040521525,0.000006948647,0.000017057988,0.000024204966,0.0093310485,0.94134384],"study_design_scores_gemma":[0.0033300018,0.0021252283,0.000609057,0.048195034,0.011569119,0.000011455524,0.00013812953,0.0000042029446,0.00020364994,0.00002425984,0.9328703,0.00091954257],"about_ca_topic_score_codex":0.00074056286,"about_ca_topic_score_gemma":0.002733282,"teacher_disagreement_score":0.9404243,"about_ca_system_score_codex":0.00068436324,"about_ca_system_score_gemma":0.0021112575,"threshold_uncertainty_score":0.9995205},"labels":[],"label_agreement":null},{"id":"W2977318672","doi":"10.1093/ageing/afz096","title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial","year":2019,"lang":"en","type":"article","venue":"Age and Ageing","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Mace; Hazard ratio; Internal medicine; Myocardial infarction; Placebo; Type 2 diabetes; Confidence interval; Diabetes mellitus; Adverse effect; Endocrinology; Conventional PCI","score_opus":0.014970642107802704,"score_gpt":0.26962630457779485,"score_spread":0.25465566246999216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977318672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958706,0.000093688825,8.001632e-7,0.0001751464,0.000048122474,0.00092841516,7.601883e-7,0.0000045805773,0.0028778985],"genre_scores_gemma":[0.9991629,0.000055560045,0.000022629916,0.00025379693,0.000018284238,0.000008380764,0.00001125191,0.0000049016885,0.0004622622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944216,0.000031276733,0.00019249212,0.000119827804,0.00009960927,0.000114639755],"domain_scores_gemma":[0.9997384,0.00008253205,0.000037768335,0.000116263065,0.000005347721,0.000019688263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017892763,0.00007264149,0.00020411801,0.00007524016,0.000013226397,0.000009754619,0.000032753003,0.00002580689,0.000017345448],"category_scores_gemma":[0.000028634759,0.000044710978,0.000023204046,0.00009031372,0.000016734293,0.00004833971,0.000037135163,0.00006302962,0.0000034939017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021837293,0.0005849144,0.9377742,0.00013281319,0.00004660597,0.00045257097,0.0030978564,0.0000019733989,0.000057244422,0.00012757989,0.00010024218,0.05544027],"study_design_scores_gemma":[0.04862663,0.00032052136,0.94981533,0.00013217525,0.00004191329,1.6333107e-7,0.0002489629,0.0000123693735,0.00001273508,0.000020213225,0.00072411,0.000044851535],"about_ca_topic_score_codex":0.00008186397,"about_ca_topic_score_gemma":0.000050830145,"teacher_disagreement_score":0.055395417,"about_ca_system_score_codex":0.000010648773,"about_ca_system_score_gemma":0.0000033831216,"threshold_uncertainty_score":0.18232608},"labels":[],"label_agreement":null},{"id":"W2978840913","doi":"10.1016/j.molmet.2019.09.010","title":"Glucagon-like peptide 1 (GLP-1)","year":2019,"lang":"en","type":"review","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1738,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"European Research Council; BERLIN-CHEMIE; Canadian Institutes of Health Research; Merck Sharp and Dohme; Medical Research Council; Johnson and Johnson; Servier; Novo Nordisk; National Institute for Health and Care Research; Novo Nordisk Fonden; Deutsche Forschungsgemeinschaft; Zafgen; Indiana University; Banting and Best Diabetes Centre, University of Toronto; Wellcome Trust; Alexander von Humboldt-Stiftung; Novartis Pharma; Helmholtz Association; Novartis; Merck KGaA; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Glucagon-like peptide-1; Glucagon-like peptide-2; Glucagon; Proglucagon; Incretin; Peptide; Chemistry; Internal medicine; Diabetes mellitus; Endocrinology; Medicine; Insulin; Biochemistry; Type 2 diabetes","score_opus":0.03531689130424301,"score_gpt":0.31856511928723424,"score_spread":0.2832482279829912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978840913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011363677,0.95656407,0.00008625213,0.000047857884,0.0012538406,0.002321816,0.000023128914,0.00013951522,0.039552134],"genre_scores_gemma":[0.0000031995453,0.94669247,0.00096445146,0.00082675496,0.00025211903,0.00028975995,0.00065991,0.0001832246,0.05012809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974346,0.00012351135,0.0005782652,0.0007584304,0.00052714604,0.00057803775],"domain_scores_gemma":[0.9980612,0.000033134136,0.00026960776,0.0013414877,0.00006353128,0.00023105097],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019494638,0.00074499083,0.003087469,0.00041957755,0.000039274564,0.00006074815,0.00030576103,0.00025121513,0.00029925504],"category_scores_gemma":[0.000034917033,0.00056101405,0.0015630855,0.00041199249,0.000045952656,0.000056505414,0.00024216704,0.00037626963,0.0038172565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000052999735,0.00017308137,0.0000010339082,0.013756231,0.002284678,0.00039356726,0.000011341828,2.4438376e-7,0.000007834992,0.0025992014,0.006460624,0.9743069],"study_design_scores_gemma":[0.000823611,0.00005012619,0.000011096284,0.0042161257,0.019861016,0.000026372163,0.0000032772593,0.0000013507395,0.000018683748,0.00003180304,0.97450507,0.00045144738],"about_ca_topic_score_codex":0.000012929754,"about_ca_topic_score_gemma":5.126182e-7,"teacher_disagreement_score":0.97385544,"about_ca_system_score_codex":0.000100887504,"about_ca_system_score_gemma":0.0002274015,"threshold_uncertainty_score":0.99968415},"labels":[],"label_agreement":null},{"id":"W2979434640","doi":"10.1503/cmaj.190047","title":"Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering","year":2019,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Medical Research Council; Canadian Institutes of Health Research; National Health and Medical Research Council; George Institute for Global Health; University of New South Wales; University of Oxford; Diabetes Canada; University of Toronto; University Health Network; Canadian Diabetes Association","keywords":"Metformin; Type 2 Diabetes Mellitus; Type 2 diabetes; Dipeptidyl peptidase-4; Medicine; Glucagon-like peptide-1; Diabetes mellitus; Pharmacology; Endocrinology; Cotransporter; Internal medicine; Sodium; Chemistry","score_opus":0.014972789331065162,"score_gpt":0.26447341445088174,"score_spread":0.24950062511981658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979434640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016922347,0.9868252,0.0000017338153,0.0017903333,0.0035030225,0.00085716107,0.000025810687,0.000034540604,0.005269951],"genre_scores_gemma":[0.00043996013,0.9921683,0.000041869076,0.0037201839,0.0017815045,0.000026834601,0.00027750805,0.00008956865,0.001454236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99547535,0.00015363253,0.0011974989,0.00039930042,0.0017343586,0.001039836],"domain_scores_gemma":[0.99713916,0.00020037043,0.0005806475,0.00026248192,0.00020815515,0.0016091646],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020168526,0.00047473336,0.0018322429,0.00095224613,0.0001367617,0.00015340502,0.00033868002,0.0010677397,0.0022221548],"category_scores_gemma":[0.00052053825,0.0003978096,0.000568146,0.00066942524,0.00003383164,0.000175013,0.000038016966,0.002169654,0.0007313162],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004381289,0.00008992425,0.006325072,0.0025255487,0.0008645159,0.0013971003,0.00015004324,3.8244164e-7,1.490396e-7,0.000030409461,0.023109075,0.9655034],"study_design_scores_gemma":[0.0011962942,0.00012787615,0.0004059769,0.014453773,0.0012204013,0.000042632542,0.000042609205,0.000008085741,0.0000013517771,0.000037069924,0.98212504,0.00033890316],"about_ca_topic_score_codex":0.00030415374,"about_ca_topic_score_gemma":0.005079511,"teacher_disagreement_score":0.9651645,"about_ca_system_score_codex":0.0042197793,"about_ca_system_score_gemma":0.0049666436,"threshold_uncertainty_score":0.99984735},"labels":[],"label_agreement":null},{"id":"W2979521390","doi":"10.1111/dom.13893","title":"Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population‐based cohort study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim Stiftung","keywords":"Glimepiride; Medicine; Hazard ratio; Incidence (geometry); Type 2 diabetes; Internal medicine; Myocardial infarction; Stroke (engine); Gliclazide; Diabetes mellitus; Proportional hazards model; Population; Confidence interval; Cohort study; Cardiology; Endocrinology; Insulin","score_opus":0.011605204755857614,"score_gpt":0.23999813862626526,"score_spread":0.22839293387040766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979521390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888518,0.008263598,0.0000016366988,0.000034737903,0.00014110765,0.002112383,0.0000126996065,0.00003087363,0.00055118604],"genre_scores_gemma":[0.99913573,0.00022251606,0.0002020624,0.00013512229,0.000027919414,0.0000452842,0.000082706254,0.000015351787,0.0001333339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985202,0.00013587104,0.00033004352,0.00041336138,0.0003049062,0.00029564052],"domain_scores_gemma":[0.99921334,0.000097906996,0.000089360285,0.00040947628,0.000081807695,0.00010808902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059838314,0.00023016968,0.0012273351,0.0002566308,0.000044583663,0.000017320563,0.00006457232,0.0000694117,0.000034850207],"category_scores_gemma":[0.00003727479,0.00019958592,0.0001272928,0.0003385625,0.000057657795,0.00013089724,0.000080786114,0.00012001726,0.000012310437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005677709,0.00055801217,0.9958968,0.00018462606,0.0011135172,0.0000027763476,0.00025970404,0.00006192821,0.00028999374,0.0000842112,0.000015728721,0.0014759],"study_design_scores_gemma":[0.0042675743,0.00026164076,0.9910983,0.000100089754,0.0013459843,1.2734401e-7,0.00013890637,0.0004713395,0.0008942399,0.000058165122,0.001184826,0.00017882536],"about_ca_topic_score_codex":0.00014519905,"about_ca_topic_score_gemma":0.000022074651,"teacher_disagreement_score":0.0102839265,"about_ca_system_score_codex":0.00003526263,"about_ca_system_score_gemma":0.000025485982,"threshold_uncertainty_score":0.8138878},"labels":[],"label_agreement":null},{"id":"W2979534848","doi":"10.1016/j.cjca.2019.07.547","title":"QUALIFYING EVENT PROXIMITY, CARDIOVASCULAR RISK, AND BENEFIT OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND STABLE ATHEROSCLEROSIS IN THE EMPA-REG OUTCOME TRIAL","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Internal medicine; Placebo; Cardiology; Type 2 diabetes; Myocardial infarction; Hazard ratio; Population; Adverse effect; Stroke (engine); Diabetes mellitus; Confidence interval; Endocrinology","score_opus":0.017810910219514257,"score_gpt":0.2277168585795092,"score_spread":0.20990594835999496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979534848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975041,0.0013252259,0.000004049997,0.0000862677,0.00014250577,0.00069444,0.000009970786,0.0000011262424,0.00023230199],"genre_scores_gemma":[0.9996802,0.00011494911,0.000043986558,0.000057647376,0.000055377066,0.000006768342,0.0000045334787,0.000010820435,0.000025681922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894977,0.00015014442,0.0003442241,0.00013292588,0.00016886213,0.0002540705],"domain_scores_gemma":[0.99935484,0.000077781464,0.00015009248,0.0002010387,0.00008559755,0.00013064299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010115792,0.000117186915,0.000727947,0.0002722232,0.000025057703,0.000012337838,0.0000810365,0.00006496344,0.000004948988],"category_scores_gemma":[0.00007874705,0.0000735951,0.00011539968,0.00015703609,0.00006892607,0.000077063196,0.000016573047,0.00017737804,7.268441e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005113131,0.000013836962,0.99530876,0.000047511927,0.0005577977,0.000008181266,0.0003772121,0.00042226602,0.0000032469684,0.000022625438,0.00003082094,0.0026964217],"study_design_scores_gemma":[0.020364277,0.0018392075,0.9755038,0.00010918305,0.00040263595,0.000002021588,0.0003228898,0.000005413929,0.000008055158,0.000057780006,0.0013112886,0.00007343993],"about_ca_topic_score_codex":0.0009462478,"about_ca_topic_score_gemma":0.0015472115,"teacher_disagreement_score":0.019852964,"about_ca_system_score_codex":0.00009521795,"about_ca_system_score_gemma":0.00010274028,"threshold_uncertainty_score":0.30011213},"labels":[],"label_agreement":null},{"id":"W2979543968","doi":"10.1016/j.cjca.2019.07.568","title":"IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN 6 CLINICAL TRIALS","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Semaglutide; Medicine; Mace; Liraglutide; Type 2 diabetes; Internal medicine; Nephropathy; Myocardial infarction; Diabetic nephropathy; Clinical endpoint; Diabetes mellitus; Cardiology; Surgery; Endocrinology; Clinical trial; Percutaneous coronary intervention","score_opus":0.04910922127992327,"score_gpt":0.36392702000606697,"score_spread":0.3148177987261437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979543968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675095,0.0018683043,0.000011415327,0.0006746566,0.00023920489,0.00027082805,0.00004589154,0.0000014195107,0.00013734908],"genre_scores_gemma":[0.9992371,0.00013375541,0.000019888968,0.00025689343,0.00025665533,0.0000015696633,0.000036915524,0.000009451339,0.000047753958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979023,0.0009296004,0.00062994583,0.00016469456,0.00012131238,0.0002521747],"domain_scores_gemma":[0.99813175,0.0006494606,0.00022625353,0.0003564095,0.00012585308,0.00051028444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024251316,0.00013197053,0.0016370497,0.0003987944,0.000017590926,0.000014026033,0.000119344804,0.00007428521,0.000048451413],"category_scores_gemma":[0.0009464365,0.000072895025,0.0011307275,0.0002078157,0.00012905488,0.00004521041,0.000010969789,0.00019555679,0.0000037820018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022389427,0.0000130289,0.9834825,0.0000064505857,0.010430798,0.00012474804,0.000057990717,0.0014689561,0.000014839587,0.000018527122,0.00066521845,0.0034930408],"study_design_scores_gemma":[0.0022299155,0.0010414474,0.99019736,0.000029144756,0.004431416,0.0000014469591,0.00019490007,0.0000428959,0.0000038239573,0.00005692065,0.0017058735,0.00006483295],"about_ca_topic_score_codex":0.0013932539,"about_ca_topic_score_gemma":0.0008050119,"teacher_disagreement_score":0.0067148744,"about_ca_system_score_codex":0.00013919854,"about_ca_system_score_gemma":0.000620484,"threshold_uncertainty_score":0.29725727},"labels":[],"label_agreement":null},{"id":"W2979591360","doi":"10.1016/j.cjca.2019.07.619","title":"HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Internal medicine; Empagliflozin; Heart failure; Atrial fibrillation; Diabetes mellitus; Cardiology; Type 2 diabetes; EMPA; Population; Nephropathy; Diabetic nephropathy; Endocrinology","score_opus":0.01835187563249335,"score_gpt":0.253097556695036,"score_spread":0.23474568106254262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979591360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723583,0.00015155433,0.0000035951189,0.0016119707,0.00016214619,0.00070245384,0.000043946508,0.0000029171106,0.00008558568],"genre_scores_gemma":[0.99933946,0.0000013788101,0.000114409486,0.00017369578,0.00024057728,0.0000010546958,0.0000614065,0.000013385557,0.00005465129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910593,0.00009987903,0.00024007866,0.000177956,0.00015858689,0.00021757527],"domain_scores_gemma":[0.9991377,0.000098668344,0.00012092286,0.0003988834,0.00007296033,0.00017087955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025808124,0.0001316895,0.00061599136,0.00013218363,0.00003682998,0.000026135443,0.00013271786,0.000042885673,0.000013133907],"category_scores_gemma":[0.00005769039,0.000066730456,0.000049221104,0.000080476646,0.00006502445,0.00014046684,0.000030434812,0.00013809062,0.000005610045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015878041,0.000003886502,0.99754053,0.000004450695,0.0008787766,0.000009460536,0.00011501994,0.00017419229,4.5506016e-7,0.0000026046214,0.00069243537,0.0004193947],"study_design_scores_gemma":[0.006869698,0.0016706903,0.979907,0.000040558472,0.00049828715,0.000002404855,0.00032349775,0.000009389824,2.9446716e-7,0.0000079440215,0.010593928,0.000076352466],"about_ca_topic_score_codex":0.00072499877,"about_ca_topic_score_gemma":0.009817743,"teacher_disagreement_score":0.017633589,"about_ca_system_score_codex":0.0000695761,"about_ca_system_score_gemma":0.0001799203,"threshold_uncertainty_score":0.54785305},"labels":[],"label_agreement":null},{"id":"W2979652434","doi":"10.14740/jem.v9i5.609","title":"Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes; Dipeptidyl peptidase; Internal medicine; Diabetes mellitus; Endocrinology; Pharmacology; Biochemistry; Enzyme","score_opus":0.014334937097526408,"score_gpt":0.25524150717445326,"score_spread":0.24090657007692687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979652434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867359,0.0073063467,0.0000013882986,0.0008027098,0.001237556,0.00038945294,0.0000030677093,0.0000070267142,0.0035165907],"genre_scores_gemma":[0.9955348,0.0030114497,0.0004607952,0.00027771541,0.00019384116,0.000007873443,0.000006334425,0.000012284046,0.000494941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872166,0.000062797495,0.00048474505,0.00015601199,0.00025449588,0.0003203059],"domain_scores_gemma":[0.9992895,0.00008175017,0.00024379928,0.000227209,0.00009011896,0.00006758107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026474276,0.0001711615,0.00054571015,0.0002623103,0.000025390827,0.000009978458,0.00014188392,0.000059354643,0.0000818221],"category_scores_gemma":[0.000011216832,0.00010834773,0.00013846571,0.00019320766,0.0001007719,0.00012974201,0.000047494523,0.00025350682,0.000016835198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0140659055,0.007891292,0.60254186,0.003806155,0.0135566145,0.0040703667,0.005789309,0.000042553107,0.060646947,0.068379045,0.011532527,0.20767741],"study_design_scores_gemma":[0.028117457,0.0028930781,0.763336,0.00056141714,0.002801396,0.00006872347,0.0021929028,0.0000100395955,0.019044548,0.00045257958,0.18024369,0.00027817613],"about_ca_topic_score_codex":0.0000041612916,"about_ca_topic_score_gemma":0.0000024580434,"teacher_disagreement_score":0.20739923,"about_ca_system_score_codex":0.000018656217,"about_ca_system_score_gemma":0.000029139004,"threshold_uncertainty_score":0.4418292},"labels":[],"label_agreement":null},{"id":"W2979716772","doi":"10.1016/j.cjca.2019.07.532","title":"SCARF: SAXAGLIPTIN AND CARDIAC STRUCTURE AND FUNCTION","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Saxagliptin; Medicine; Ejection fraction; Internal medicine; Heart failure; Cardiology; Cardiac function curve; Metformin; Angiology; Sitagliptin; Insulin","score_opus":0.005201404696442222,"score_gpt":0.1921109728052055,"score_spread":0.18690956810876327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979716772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881427,0.0035043804,0.00002132926,0.0005602758,0.0008072293,0.00012992257,0.000008658753,0.000002509665,0.00682298],"genre_scores_gemma":[0.99856275,0.00011059848,0.00007442421,0.00018353139,0.00041610803,5.6117335e-7,0.000005609532,0.0000073577235,0.00063905364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995578,0.00003231557,0.00011399349,0.00008830246,0.000050447707,0.00015716234],"domain_scores_gemma":[0.99948156,0.000018262208,0.000052184118,0.00008614445,0.0000610381,0.00030083454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010998603,0.000074476,0.00033073063,0.0001668727,0.000026596796,0.000013117798,0.000022893651,0.00006696808,0.0000337071],"category_scores_gemma":[0.000018426153,0.00005866292,0.00006221174,0.000041174593,0.000056506706,0.000047617254,0.0000072520006,0.00010413198,0.0000046742634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004890819,5.237982e-7,0.95204294,0.000035669025,0.0006018892,0.00005635794,0.00006738144,0.000026592243,0.0006419849,0.00080019305,0.008649379,0.037028186],"study_design_scores_gemma":[0.0008864393,0.0005618452,0.68137753,0.000025676429,0.00037551223,0.000121200974,0.00013319997,0.000002718606,0.000037549,0.00026493988,0.31615624,0.000057140525],"about_ca_topic_score_codex":0.00010391572,"about_ca_topic_score_gemma":0.000085364314,"teacher_disagreement_score":0.30750686,"about_ca_system_score_codex":0.000051855575,"about_ca_system_score_gemma":0.0001486739,"threshold_uncertainty_score":0.23922044},"labels":[],"label_agreement":null},{"id":"W2979886169","doi":"10.1016/j.cjca.2019.07.522","title":"THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS LIRAGLUTIDE AND SEMAGLUTIDE IMPROVE CARDIOVASCULAR AND RENAL OUTCOMES ACROSS BASELINE BLOOD PRESSURE CATEGORIES: ANALYSIS OF LEADER AND SUSTAIN 6","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Semaglutide; Medicine; Liraglutide; Mace; Internal medicine; Blood pressure; Cardiology; Placebo; Clinical endpoint; Dulaglutide; Diabetic nephropathy; Myocardial infarction; Type 2 diabetes; Diabetes mellitus; Randomized controlled trial; Endocrinology; Kidney; Percutaneous coronary intervention","score_opus":0.006945901322285288,"score_gpt":0.22839154878188633,"score_spread":0.22144564745960105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979886169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625445,0.03463018,0.000110067886,0.00149655,0.00032073847,0.00040116883,0.000094608185,0.0000052725286,0.00039689784],"genre_scores_gemma":[0.9958968,0.0014130003,0.00013127056,0.00015949328,0.00016473273,0.0000064774213,0.00001797566,0.000019355935,0.0021908956],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983799,0.00018672168,0.00047358568,0.00027887663,0.00019720999,0.00048371285],"domain_scores_gemma":[0.9983483,0.00025665894,0.00022539603,0.00040435712,0.00030187747,0.00046338516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013349279,0.00022501174,0.0012921699,0.0002897789,0.00015120742,0.000051829775,0.00011539985,0.00012932663,0.00000927867],"category_scores_gemma":[0.00024041216,0.0001494434,0.00044758077,0.00023540428,0.0004566854,0.000073911746,0.0000542496,0.00022531595,8.523668e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020519846,0.000011805793,0.8852616,0.0002857149,0.08992823,0.00027323118,0.0013159639,0.0011879723,0.0006963972,0.00029326734,0.0027367028,0.01780392],"study_design_scores_gemma":[0.0058821496,0.0012246995,0.45968193,0.000089518086,0.044497017,0.00025146198,0.0049865954,0.00020134331,0.0004387445,0.0000907972,0.48227793,0.00037778998],"about_ca_topic_score_codex":0.001507259,"about_ca_topic_score_gemma":0.001989707,"teacher_disagreement_score":0.47954124,"about_ca_system_score_codex":0.000046124682,"about_ca_system_score_gemma":0.00031391022,"threshold_uncertainty_score":0.6094125},"labels":[],"label_agreement":null},{"id":"W2980072629","doi":"10.1161/jaha.119.013389","title":"SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects","year":2019,"lang":"en","type":"review","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Medicine; Heart failure; Intensive care medicine; Management of heart failure; Disease management; Cardiology; Internal medicine; Disease","score_opus":0.023435451360219194,"score_gpt":0.32073560395009565,"score_spread":0.29730015258987647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980072629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041480595,0.9906148,0.0000012254001,0.0026279015,0.00077432214,0.0016414461,0.000004575359,0.000012660213,0.0001750156],"genre_scores_gemma":[0.002768843,0.9952812,0.00021871054,0.0004324695,0.0003223627,0.00002725973,0.0000053302565,0.000041578318,0.0009022285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979513,0.0003066893,0.00069301855,0.00017364483,0.00058779237,0.00028754838],"domain_scores_gemma":[0.9980879,0.00016177591,0.0013526863,0.00025042042,0.000071132046,0.000076091186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008681623,0.0002740053,0.0019465999,0.00054381846,0.000043157645,0.000056255078,0.00012713065,0.00006674195,0.0000060432635],"category_scores_gemma":[0.00006594196,0.00017049575,0.0006404347,0.0009298015,0.000038828206,0.0000799054,0.00009998744,0.0005105069,0.000026528553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002619451,0.0003704306,0.144758,0.0045527043,0.0016434152,0.0000058433952,0.00009937737,0.0000014490843,0.000002802215,0.00008221113,0.04039452,0.80806303],"study_design_scores_gemma":[0.00067383685,0.00030752446,0.020178728,0.006536575,0.0028904746,0.000017346949,0.00007570503,0.0000018542306,0.0000011833707,0.000042285246,0.96912944,0.00014505847],"about_ca_topic_score_codex":0.000008930676,"about_ca_topic_score_gemma":0.000004521209,"teacher_disagreement_score":0.9287349,"about_ca_system_score_codex":0.0011992633,"about_ca_system_score_gemma":0.000116249874,"threshold_uncertainty_score":0.69526154},"labels":[],"label_agreement":null},{"id":"W2980268988","doi":"10.1016/j.kint.2019.09.013","title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","year":2019,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Filtration fraction; Dapagliflozin; Renal function; Medicine; Effective renal plasma flow; Type 2 diabetes; Internal medicine; Endocrinology; Renal blood flow; Vascular resistance; Metformin; Diabetes mellitus; Vasoconstriction; Gliclazide; Urology; Hemodynamics","score_opus":0.004835931823850845,"score_gpt":0.22328388578173125,"score_spread":0.21844795395788041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980268988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087167,0.00012706264,0.0000055713194,0.0012951429,0.0007795313,0.006297826,0.00004338486,0.000017420947,0.000562401],"genre_scores_gemma":[0.99764293,0.0000449333,0.000019934263,0.0002364296,0.00007099073,0.00043506693,0.00087360415,0.0000229021,0.0006531827],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99804056,0.0002438154,0.00047516363,0.00027726215,0.0007263518,0.00023687285],"domain_scores_gemma":[0.9985785,0.00040507232,0.00038867226,0.00034877428,0.00022450485,0.000054462358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005988287,0.00022782011,0.00040186616,0.00020786407,0.000063199324,0.000057159014,0.00026753754,0.000087771055,0.00003579515],"category_scores_gemma":[0.0003517818,0.000108795495,0.00015029803,0.00045967076,0.0001110469,0.00019811814,0.000055353867,0.0001991153,0.000010525845],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35482466,0.0023817155,0.6292854,0.00017805051,0.0028907096,0.000010608098,0.0009391193,0.000101250065,0.004071738,0.00049471675,0.0025817929,0.0022402173],"study_design_scores_gemma":[0.91129076,0.0008918726,0.07566228,0.0006529472,0.00070361025,5.7853066e-7,0.00016154049,0.0016201148,0.006881559,0.00009472217,0.0018193454,0.00022068952],"about_ca_topic_score_codex":0.000103152684,"about_ca_topic_score_gemma":0.00007041904,"teacher_disagreement_score":0.5564661,"about_ca_system_score_codex":0.00019596629,"about_ca_system_score_gemma":0.00007783104,"threshold_uncertainty_score":0.44365516},"labels":[],"label_agreement":null},{"id":"W2980298370","doi":"10.14336/ad.2019.0303","title":"Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Aging and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Natural Science Foundation of China","keywords":"Medicine; Incretin; Metformin; Placebo; Type 2 diabetes; Internal medicine; Linagliptin; Sitagliptin; Saxagliptin; Diabetes mellitus; Odds ratio; Type 2 Diabetes Mellitus; Pharmacology; Insulin; Endocrinology","score_opus":0.04359775138969233,"score_gpt":0.29330793316818055,"score_spread":0.24971018177848822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980298370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013258171,0.9963175,0.0000015291029,0.00006305963,0.0000075017297,0.0022376212,0.000015403682,0.000011986474,0.000019556977],"genre_scores_gemma":[0.007932846,0.99048615,0.00004819875,0.00085014955,0.0000049897135,0.00020139282,0.00039980686,0.000016211765,0.000060247366],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99880236,0.0002544238,0.0003784869,0.00027211217,0.000159594,0.00013301971],"domain_scores_gemma":[0.9990666,0.00019433662,0.000297921,0.00028926987,0.000044207056,0.00010765116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025117456,0.0002330315,0.0031775846,0.0001490368,0.000015521175,0.000014793164,0.000040477214,0.000030770832,0.000023245704],"category_scores_gemma":[0.00007891006,0.00011994164,0.00033830345,0.00039145193,0.00002931598,0.000023595867,0.000025231695,0.00006109661,0.000002113073],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019379488,0.00011938548,0.034114677,0.93004555,0.033003796,0.000009643372,0.000006770711,0.0000046492078,2.4902744e-10,0.000012873302,0.00003061599,0.0026326363],"study_design_scores_gemma":[0.00039387366,0.00024058085,0.0074336524,0.05390277,0.9371075,5.4225556e-8,0.000001627848,0.000045374214,7.704992e-10,0.0000069661783,0.00073932216,0.00012828347],"about_ca_topic_score_codex":0.0000024795877,"about_ca_topic_score_gemma":6.621355e-7,"teacher_disagreement_score":0.9041037,"about_ca_system_score_codex":0.000009213837,"about_ca_system_score_gemma":0.000036580364,"threshold_uncertainty_score":0.48910782},"labels":[],"label_agreement":null},{"id":"W2980307850","doi":"10.1016/j.cjca.2019.07.415","title":"THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES MORTALITY IN EXPERIMENTAL PULMONARY HYPERTENSION","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Heart failure; Pulmonary hypertension; Diabetes mellitus; Internal medicine; Endocrinology; Type 2 diabetes; Pharmacology; Anesthesia; Cardiology","score_opus":0.020090591347416392,"score_gpt":0.2519076264752579,"score_spread":0.2318170351278415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980307850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777145,0.0030406967,0.0000010219302,0.0011465069,0.0011920535,0.00021152473,0.0000017371412,0.000002955477,0.016689006],"genre_scores_gemma":[0.9986929,0.00007862098,0.00001822417,0.00023396293,0.0004700254,0.0000045611246,0.0000044957897,0.000009934182,0.00048723808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913156,0.00008192702,0.0002771628,0.000112919246,0.00011271189,0.00028372015],"domain_scores_gemma":[0.99936914,0.00004477841,0.000084916705,0.0001777909,0.00006382409,0.0002595574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034064733,0.00009839103,0.00036171684,0.00016857247,0.000051607905,0.000014675848,0.00010225227,0.000065488326,0.000025111414],"category_scores_gemma":[0.000039509912,0.00006373252,0.00014405386,0.000088137844,0.00009576805,0.00006367298,0.000014977357,0.00016052715,0.000028641043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022030964,0.000029036219,0.9409975,0.000019800842,0.000691798,0.0030567432,0.0002228873,0.00019178353,0.018503988,0.00032964288,0.020626526,0.015109993],"study_design_scores_gemma":[0.001974093,0.00091106055,0.8002414,0.00012254536,0.00017717159,0.00062135456,0.0018452442,0.000034724057,0.0050312057,0.00013297894,0.18875237,0.00015583326],"about_ca_topic_score_codex":0.00037343154,"about_ca_topic_score_gemma":0.0003955799,"teacher_disagreement_score":0.16812585,"about_ca_system_score_codex":0.00021229987,"about_ca_system_score_gemma":0.00033975297,"threshold_uncertainty_score":0.25989366},"labels":[],"label_agreement":null},{"id":"W2980395930","doi":"10.1016/j.ahj.2019.09.013","title":"Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease","year":2019,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Saskatchewan; Canadian VIGOUR Centre","funders":"Novo Nordisk Canada; Pfizer Canada; Boehringer Ingelheim; ZonMw; Takeda Pharmaceutical Company; Merck Sharp and Dohme; Eisai; GlaxoSmithKline; Merck; Janssen Canada; Amgen Canada; Sanofi; Genentech; AstraZeneca Canada; Novartis; Bayer","keywords":"Medicine; Hazard ratio; Internal medicine; Heart failure; Myocardial infarction; Cardiology; Type 2 diabetes; Proportional hazards model; Stroke (engine); Diabetes mellitus; Beta blocker; Confidence interval; Endocrinology","score_opus":0.01009591453789751,"score_gpt":0.22746839506772254,"score_spread":0.21737248052982502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980395930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966669,0.00219082,0.000004265308,0.00043656246,0.000039605195,0.00054895977,0.000015335172,0.000016351954,0.00008116855],"genre_scores_gemma":[0.9988107,0.0002776809,0.00042651017,0.00030930983,0.000050886712,0.000012413318,0.000024454304,0.000023379946,0.0000646289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986708,0.000099168814,0.00018732384,0.00024474788,0.0005064743,0.00029145827],"domain_scores_gemma":[0.99924165,0.000067949455,0.00005923241,0.0003074383,0.000071297596,0.0002524521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035057298,0.00016413722,0.0008233527,0.0001646448,0.00007212405,0.000070128066,0.000036994,0.00002002979,0.000015467127],"category_scores_gemma":[0.0000368452,0.000113339454,0.00025823739,0.00019147857,0.00008563751,0.00016997954,0.00003248641,0.00015365287,0.0000050298017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027249473,0.00011008369,0.97054,0.000007996635,0.004308195,0.00000770524,0.00006714538,0.000013342801,8.724054e-7,0.0000016731963,0.00008496759,0.024830768],"study_design_scores_gemma":[0.003789295,0.0005175483,0.9910915,0.000039566276,0.00077302085,5.702788e-7,0.00006411323,0.000008260252,0.000003332814,0.000011535191,0.0035684363,0.00013285447],"about_ca_topic_score_codex":0.00007021027,"about_ca_topic_score_gemma":0.0000011054814,"teacher_disagreement_score":0.024697915,"about_ca_system_score_codex":0.000058836653,"about_ca_system_score_gemma":0.000036308,"threshold_uncertainty_score":0.46218488},"labels":[],"label_agreement":null},{"id":"W2980470785","doi":"10.1016/j.cjca.2019.10.017","title":"It’s Not All About the Cardiomyocyte: Fibroblasts, Empagliflozin, and Cardiac Remodelling","year":2019,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Servier; Novartis; Novo Nordisk; Merck; Boehringer Ingelheim; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Scopus; Empagliflozin; Diabetes mellitus; Heart failure; Internal medicine; Type 2 diabetes; Cardiology; Gerontology; MEDLINE; Endocrinology","score_opus":0.026479744515896592,"score_gpt":0.24025323567279883,"score_spread":0.21377349115690222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980470785","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020216953,0.015313498,0.00027360793,0.94505453,0.005022893,0.00095410383,0.00016493865,0.000015134637,0.031179613],"genre_scores_gemma":[0.079025805,0.0041914913,0.0003048949,0.87071234,0.028445326,0.000025263873,0.00029177006,0.00019185158,0.01681128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755734,0.00029510414,0.00061198924,0.000369816,0.00034689886,0.00081882835],"domain_scores_gemma":[0.9979771,0.00027703156,0.00037122035,0.00067433895,0.00030514857,0.00039516657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007118338,0.00044349424,0.0017715783,0.0005358934,0.00011212317,0.000087242035,0.0003481459,0.0007208379,0.000023624507],"category_scores_gemma":[0.00009797941,0.0003066374,0.0008698724,0.0001101516,0.00028649188,0.00007724321,0.00005001512,0.0017961998,0.000055365763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028875407,5.7880544e-7,0.0023250817,0.00016380759,0.003964887,0.0017069546,0.00016306648,0.00046050208,0.000009383457,0.000024871466,0.9890614,0.0020905605],"study_design_scores_gemma":[0.00077481207,0.0004262494,0.0018789904,0.0003002945,0.002902423,0.0004667679,0.00006747691,0.000012902037,0.000008337771,0.000039239778,0.9928603,0.00026217508],"about_ca_topic_score_codex":0.00049598364,"about_ca_topic_score_gemma":0.000084031606,"teacher_disagreement_score":0.07700411,"about_ca_system_score_codex":0.00041180057,"about_ca_system_score_gemma":0.0012679182,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W2980745407","doi":"10.1111/dme.14154","title":"Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study","year":2019,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Sitagliptin; Medicine; Metformin; Type 2 diabetes; Internal medicine; Odds ratio; Cohort; Cohort study; Diabetes mellitus; Endocrinology; Insulin","score_opus":0.007285851313208367,"score_gpt":0.2464713990502309,"score_spread":0.23918554773702255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980745407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921578,0.00036237141,0.0000036843808,0.0004339955,0.00005463355,0.0050833537,0.000006567804,0.00008829191,0.0018093064],"genre_scores_gemma":[0.99795616,0.00001767216,0.00014281122,0.00029146107,0.000029669896,0.00029545816,0.0002093818,0.000072056224,0.0009853285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971249,0.000094378105,0.0005176654,0.00060898,0.0010105825,0.00064351177],"domain_scores_gemma":[0.99817896,0.0001550649,0.00035592236,0.0006325031,0.00032232443,0.0003552553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006251225,0.0004290245,0.0012411637,0.0003512559,0.000040809246,0.000013416484,0.00012199547,0.000063216205,0.00045011743],"category_scores_gemma":[0.00016712218,0.00023162713,0.000043567612,0.0013957757,0.00012939758,0.00012259,0.00005115108,0.00019741162,0.000020958905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002159075,0.0030004256,0.989364,0.00026722532,0.0011308203,0.0001901349,0.0015614065,0.0000109712855,0.00020592789,0.0000029140126,0.00023708832,0.0018700102],"study_design_scores_gemma":[0.022690998,0.027974764,0.9380179,0.0053198957,0.002840954,9.413703e-7,0.0015831548,0.00077493995,0.00040596968,0.0000069774446,0.00006706798,0.00031643597],"about_ca_topic_score_codex":0.00010851531,"about_ca_topic_score_gemma":0.0002199277,"teacher_disagreement_score":0.0513461,"about_ca_system_score_codex":0.00016204346,"about_ca_system_score_gemma":0.00015421594,"threshold_uncertainty_score":0.944548},"labels":[],"label_agreement":null},{"id":"W2981101186","doi":"10.1002/edm2.96","title":"Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study","year":2019,"lang":"en","type":"article","venue":"Endocrinology Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Hazard ratio; Propensity score matching; Mace; Internal medicine; Proportional hazards model; Amputation; Lower risk; Confidence interval; Diabetes mellitus; Cohort study; Type 2 diabetes; Surgery; Myocardial infarction; Percutaneous coronary intervention; Endocrinology","score_opus":0.027761137584222186,"score_gpt":0.299605482250769,"score_spread":0.27184434466654683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981101186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813107,0.016240988,0.0000035133194,0.00024694283,0.00036316641,0.0010628111,0.000046955494,0.00003936031,0.00068550993],"genre_scores_gemma":[0.998505,0.00021212811,0.00009304756,0.00062770484,0.000091183545,0.00017104957,0.000049112317,0.000018025217,0.00023274288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983431,0.00022007735,0.00033569307,0.00039897498,0.00033973108,0.00036242345],"domain_scores_gemma":[0.9986692,0.00018485553,0.000105005165,0.0008958608,0.00007559774,0.00006948926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020252667,0.00023800436,0.00097184384,0.00012449587,0.000041633823,0.000017248249,0.00012748955,0.000046866655,0.00019720926],"category_scores_gemma":[0.000076810225,0.0001500806,0.00030570637,0.00016176065,0.00011247318,0.00010706457,0.00016153282,0.00012931657,0.000043854932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019419444,0.00026129454,0.98655194,0.00002482731,0.0087045245,0.000022469414,0.00030032994,0.000007025462,0.00023839819,0.0001426146,0.00007119654,0.0036559629],"study_design_scores_gemma":[0.002714866,0.00010922123,0.98544085,0.000012805883,0.0064611062,3.4678422e-7,0.00046918198,0.000014929016,0.0015068292,0.00016467409,0.0029811668,0.00012404754],"about_ca_topic_score_codex":0.0010599415,"about_ca_topic_score_gemma":0.000103236925,"teacher_disagreement_score":0.017194252,"about_ca_system_score_codex":0.000018243827,"about_ca_system_score_gemma":0.000021211454,"threshold_uncertainty_score":0.6120109},"labels":[],"label_agreement":null},{"id":"W2981371482","doi":"10.1093/eurheartj/ehz747.0053","title":"193Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Placebo; Mace; Type 2 diabetes; Population; Hazard ratio; Cardiology; Myocardial infarction; Diabetes mellitus; Confidence interval; Endocrinology; Conventional PCI","score_opus":0.03148104337685086,"score_gpt":0.25683082165145565,"score_spread":0.22534977827460478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981371482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979102,0.0006955962,0.0000014788646,0.00007511426,0.00008292491,0.0008732627,0.0000029953753,0.0000056041263,0.00035281113],"genre_scores_gemma":[0.99938685,0.0001631683,0.00015703397,0.000100893994,0.00004869337,0.000003499731,0.0000035226672,0.000022592498,0.00011377274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986462,0.00028330652,0.00031393592,0.00017360394,0.0003556836,0.00022727941],"domain_scores_gemma":[0.9994948,0.0000578185,0.00011145697,0.00022647374,0.000041990144,0.000067441084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001767632,0.00013420077,0.0004003426,0.00013669525,0.000051342875,0.000045590165,0.00006590306,0.000018936142,0.000018267767],"category_scores_gemma":[0.000045095443,0.000079529265,0.00008506373,0.0001627308,0.00003094196,0.00012547929,0.00006534031,0.00023532874,0.0000070651067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006986527,0.00025483815,0.9955236,0.000056177283,0.00019556067,0.0000052085143,0.0006095214,0.000049478444,0.000015047754,0.000004858017,0.000035995974,0.0025511086],"study_design_scores_gemma":[0.02547807,0.001750914,0.9711045,0.00024522157,0.00019014267,0.0000015585599,0.000191314,0.000016210308,0.00002070922,0.000011113541,0.00090553757,0.00008470745],"about_ca_topic_score_codex":0.00001935369,"about_ca_topic_score_gemma":0.0000079864785,"teacher_disagreement_score":0.024779417,"about_ca_system_score_codex":0.000035374513,"about_ca_system_score_gemma":0.0000110540295,"threshold_uncertainty_score":0.32431093},"labels":[],"label_agreement":null},{"id":"W2981385176","doi":"10.1093/eurheartj/ehz748.0952","title":"P2629Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Type 2 diabetes; Adverse effect; Heart failure; Placebo; Diabetes mellitus; Clinical trial; Hazard ratio; Clinical endpoint; Proportional hazards model; Confidence interval; Endocrinology; Alternative medicine","score_opus":0.01751661167758685,"score_gpt":0.23411831015807932,"score_spread":0.2166016984804925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981385176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646646,0.000070569695,3.675551e-7,0.0017819429,0.00019021155,0.0009968033,0.00018258639,0.000022389522,0.00028864175],"genre_scores_gemma":[0.99751824,0.000007346276,0.00035765994,0.0011364847,0.00018271524,0.000003253539,0.00022442872,0.000054724638,0.00051512517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977232,0.00037470518,0.0005587865,0.0003096464,0.0006712206,0.00036242418],"domain_scores_gemma":[0.998639,0.0001585805,0.00035618574,0.0004765304,0.0001769348,0.00019275656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007004894,0.0002629987,0.00054250425,0.00013000926,0.00007785344,0.000027886195,0.00017708533,0.000039844606,0.00013486123],"category_scores_gemma":[0.00014343775,0.00014660765,0.000110219466,0.00027262323,0.000047334328,0.00020953843,0.00006904858,0.0003916071,0.0001832501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018371532,0.00059644796,0.9632029,0.000014120352,0.00023204777,0.000010191486,0.00016115989,0.00004292593,0.00006480468,9.0709705e-7,0.017163375,0.00013957694],"study_design_scores_gemma":[0.07142391,0.0038286233,0.9141043,0.0006644477,0.00019108845,0.0000015604214,0.00017172655,0.0000068168824,0.00010624696,8.736971e-7,0.009340622,0.00015982859],"about_ca_topic_score_codex":0.000053008127,"about_ca_topic_score_gemma":0.00004043939,"teacher_disagreement_score":0.053052377,"about_ca_system_score_codex":0.00007540064,"about_ca_system_score_gemma":0.000054717315,"threshold_uncertainty_score":0.59784865},"labels":[],"label_agreement":null},{"id":"W2981450937","doi":"10.1093/eurheartj/ehz747.0009","title":"56The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Heart failure; Canagliflozin; Internal medicine; Cardiology; Type 2 diabetes; Endocrinology","score_opus":0.04856269250268562,"score_gpt":0.30021809601223226,"score_spread":0.2516554035095466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981450937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604382,0.0011353758,5.6784006e-7,0.00072415895,0.0006618799,0.00031400437,8.320465e-7,0.000039750776,0.03668527],"genre_scores_gemma":[0.9952176,0.00006372919,0.00024902786,0.00085689675,0.00054215756,0.000002422235,0.000009111126,0.000038868315,0.0030201378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998607,0.00020003539,0.00031185322,0.0002476476,0.00032796335,0.00030554392],"domain_scores_gemma":[0.9994512,0.000019062363,0.00007204978,0.00023958951,0.000031117193,0.00018696893],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005919128,0.00016694875,0.00027631735,0.0001628294,0.0000694085,0.000054979468,0.00008340189,0.000025198184,0.00045571988],"category_scores_gemma":[0.000018391149,0.00012697854,0.00014019654,0.0001225528,0.000032116273,0.00018397407,0.00009435947,0.00028118546,0.0009744323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026637627,0.0017727731,0.7052418,0.00004328706,0.00017628603,0.00372149,0.00046925418,0.00001655199,0.26032937,0.000026858208,0.023988953,0.0039470275],"study_design_scores_gemma":[0.0022709505,0.00072710187,0.9432267,0.00037337086,0.00006399709,0.0006553433,0.0007048902,0.00011162978,0.021781769,0.000010147255,0.029874854,0.00019927643],"about_ca_topic_score_codex":0.000005831219,"about_ca_topic_score_gemma":5.47333e-7,"teacher_disagreement_score":0.2385476,"about_ca_system_score_codex":0.00010239142,"about_ca_system_score_gemma":0.00003005905,"threshold_uncertainty_score":0.9998034},"labels":[],"label_agreement":null},{"id":"W2981454313","doi":"10.1093/eurheartj/ehz746.0946","title":"P6350Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the spironolactone for heart failure with preserved ejection fraction (TOPCAT) trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Heart Institute","funders":"","keywords":"Medicine; Ejection fraction; Internal medicine; Heart failure; Heart failure with preserved ejection fraction; Cardiology; Diabetes mellitus; Biomarker; Spironolactone; Valsartan; Endocrinology; Blood pressure","score_opus":0.02340939361626741,"score_gpt":0.26116535143428243,"score_spread":0.23775595781801503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981454313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894085,0.00013927477,0.00009506571,0.0062149293,0.0004429053,0.002740488,0.000013659822,0.00006858052,0.0008765945],"genre_scores_gemma":[0.99653506,0.00001562882,0.0013953563,0.0004560698,0.0009835612,0.00004548534,0.00007448532,0.000093330054,0.00040099653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972227,0.0006381938,0.0005446042,0.0004957395,0.00064240786,0.00045631587],"domain_scores_gemma":[0.9982751,0.0003582103,0.00040488096,0.0005857344,0.00017817842,0.00019791164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081286114,0.00038163102,0.00063334504,0.00034509148,0.00025963603,0.00017447757,0.00014702494,0.00010805685,0.00031151262],"category_scores_gemma":[0.000106197316,0.00023233947,0.00025789972,0.00038634206,0.00006866803,0.0007810991,0.000045691333,0.0006806182,0.00008749276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02242002,0.00096559944,0.9270887,0.00010797378,0.0011574714,0.00001009512,0.00011343524,0.00039430687,0.013327126,0.0000062075783,0.034161992,0.00024708622],"study_design_scores_gemma":[0.038566165,0.0103243785,0.829152,0.0009499664,0.00037910725,0.000014277718,0.0009642964,0.0003326926,0.0075584385,0.00002821806,0.11143183,0.0002986482],"about_ca_topic_score_codex":0.000102594604,"about_ca_topic_score_gemma":0.00018566073,"teacher_disagreement_score":0.097936705,"about_ca_system_score_codex":0.00029523033,"about_ca_system_score_gemma":0.00010594628,"threshold_uncertainty_score":0.94745284},"labels":[],"label_agreement":null},{"id":"W2981486948","doi":"10.1093/eurheartj/ehz747.0105","title":"410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Internal medicine; Type 2 Diabetes Mellitus; Framingham Risk Score; TIMI; Diabetes mellitus; Heart failure; Renal function; Atrial fibrillation; Proportional hazards model; Placebo; Cardiology; Disease; Myocardial infarction; Endocrinology; Percutaneous coronary intervention; Pathology","score_opus":0.010647766244073755,"score_gpt":0.22958614654505594,"score_spread":0.21893838030098217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981486948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705696,0.00030325548,0.0000021823525,0.00016241646,0.0000720061,0.00032495975,0.0000018042557,0.000010272845,0.0020661154],"genre_scores_gemma":[0.998664,0.000075376614,0.0008890697,0.00006052648,0.00004524506,4.7737717e-7,0.000015196028,0.000019049967,0.00023102498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991806,0.0001271506,0.00020082814,0.00013889035,0.0001949731,0.0001575385],"domain_scores_gemma":[0.99952507,0.00003612183,0.00010622802,0.00016885935,0.00007363244,0.00009006016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003295211,0.000097092314,0.00019538782,0.00011907069,0.000030776802,0.000028236562,0.000037523827,0.000015271964,0.00009921574],"category_scores_gemma":[0.000032621163,0.00006865288,0.000029058978,0.00013224017,0.000028955366,0.000099119155,0.000020135769,0.00017025464,0.00008300811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012419588,0.00025931065,0.9910988,0.000030374018,0.00007760339,0.000004122228,0.00012392539,0.000015574215,0.0003113354,0.000018988107,0.0008385679,0.0070971595],"study_design_scores_gemma":[0.0035182834,0.0014555103,0.98870534,0.00017484174,0.00007969607,0.0000018037392,0.00003949756,0.000022288797,0.00019310314,0.0000067629167,0.0057358653,0.00006698517],"about_ca_topic_score_codex":0.0000014888266,"about_ca_topic_score_gemma":0.0000014403217,"teacher_disagreement_score":0.0070301746,"about_ca_system_score_codex":0.000021186015,"about_ca_system_score_gemma":0.000018570598,"threshold_uncertainty_score":0.27995834},"labels":[],"label_agreement":null},{"id":"W2981496710","doi":"10.1210/endrev/bnz010","title":"The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications","year":2019,"lang":"en","type":"review","venue":"Endocrine Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Colorado Clinical and Translational Sciences Institute; Center for Women’s Health Research, University of Colorado; International Society for Pediatric and Adolescent Diabetes; Juvenile Diabetes Research Foundation United States of America; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Thrasher Research Fund","keywords":"Diabetes mellitus; Medicine; Kidney disease; Disease; Intensive care medicine; Kidney; Pathogenesis; Stroke (engine); Type 2 diabetes; Myocardial infarction; Internal medicine; Endocrinology","score_opus":0.06944350645638162,"score_gpt":0.37277730564683387,"score_spread":0.3033337991904522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981496710","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7698375e-7,0.9919186,0.00009746074,0.0015614224,0.00018039042,0.004286882,0.00003625655,0.00002433599,0.0018944668],"genre_scores_gemma":[0.0000029643077,0.98846567,0.00030359792,0.00034818286,0.00010262123,0.00059241947,0.0002769788,0.00004134864,0.009866231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836165,0.0001696819,0.00071052584,0.00037024167,0.000082130515,0.00030575687],"domain_scores_gemma":[0.99804366,0.00020769835,0.0004300586,0.0010036584,0.000024581363,0.000290372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019207012,0.0003716408,0.0019980303,0.000100323145,0.00005639866,0.00001722117,0.00022193951,0.0000459101,0.000116351795],"category_scores_gemma":[0.00014726708,0.000186209,0.0005765953,0.0002149903,0.00007006942,0.000016354516,0.00014947561,0.00014725796,0.00024169045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000021636038,0.00004353569,0.00001569314,0.01618387,0.0003306201,8.855184e-7,0.0000026616995,2.4865123e-9,0.000001163567,0.01968398,0.0061802156,0.95755523],"study_design_scores_gemma":[0.0002961127,0.00012967743,0.000024884243,0.006857527,0.0066839517,0.000006079705,0.0000010105884,5.537217e-7,8.505286e-7,0.0017821763,0.9840748,0.0001424149],"about_ca_topic_score_codex":0.0000054163966,"about_ca_topic_score_gemma":7.109668e-7,"teacher_disagreement_score":0.97789454,"about_ca_system_score_codex":0.000046630383,"about_ca_system_score_gemma":0.00023788822,"threshold_uncertainty_score":0.75933826},"labels":[],"label_agreement":null},{"id":"W2981519727","doi":"10.1093/eurheartj/ehz745.0605","title":"P3753Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter sub-study of the EMPA-Heart CardioLink-6 Randomised Trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; Southlake Regional Health Center; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Cardiology; Heart rate variability; Internal medicine; Coronary artery disease; Placebo; Type 2 diabetes; Diabetes mellitus; Heart rate; Blood pressure; Endocrinology","score_opus":0.010682828322690439,"score_gpt":0.20199899986816694,"score_spread":0.1913161715454765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981519727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516743,0.00047079963,4.3178648e-7,0.00022833452,0.00080686796,0.0029169037,0.000008642268,0.000024611072,0.00037594797],"genre_scores_gemma":[0.999032,0.000015967507,0.000005209227,0.00027773797,0.00040604084,0.000012573413,0.000009981124,0.000043850065,0.00019663537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977513,0.0009716634,0.0003884826,0.0002516683,0.00040419336,0.0002326982],"domain_scores_gemma":[0.99877006,0.00020110985,0.00021092474,0.00059575756,0.00007828688,0.00014385166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048125707,0.00022727689,0.0004604424,0.000049472426,0.0002715503,0.00010341832,0.0001977062,0.000019992269,0.000018617746],"category_scores_gemma":[0.000028179795,0.00008864166,0.00018151972,0.000099932506,0.0001150385,0.00012550857,0.00014252208,0.00027896668,0.000039236886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00995265,0.00027261797,0.98612064,0.000017433395,0.000973892,0.000021836244,0.0008935601,0.00011647025,0.00009378408,0.0000016640178,0.0013608042,0.00017464964],"study_design_scores_gemma":[0.070883505,0.0011178888,0.9255981,0.0002738036,0.0008563828,0.0000035131075,0.00042082943,0.00017904128,0.000020293955,0.0000035487535,0.0005391142,0.00010401474],"about_ca_topic_score_codex":0.0000062977847,"about_ca_topic_score_gemma":0.0000034146133,"teacher_disagreement_score":0.06093085,"about_ca_system_score_codex":0.00004993043,"about_ca_system_score_gemma":0.000045150227,"threshold_uncertainty_score":0.3614702},"labels":[],"label_agreement":null},{"id":"W2981553020","doi":"10.1093/eurheartj/ehz745.0117","title":"4113Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; St. Michael's Hospital; Western University","funders":"","keywords":"Mace; Medicine; Internal medicine; Heart failure; Adverse effect; Relative risk; Weight loss; Meta-analysis; Diabetes mellitus; Cardiology; Clinical trial; Lower risk; Obesity; Confidence interval; Myocardial infarction; Endocrinology; Percutaneous coronary intervention","score_opus":0.043839783810450825,"score_gpt":0.2984634818735077,"score_spread":0.25462369806305685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981553020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981154,0.0075096823,0.00021867189,0.000772024,0.00015665038,0.00085214595,0.000044093635,0.000034907436,0.0006002923],"genre_scores_gemma":[0.9959165,0.00035116437,0.0012742792,0.00026332826,0.00010257387,0.0000072949338,0.000027155873,0.00005456351,0.0020031573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962763,0.0009483925,0.0008101234,0.00041889402,0.0011316262,0.0004146312],"domain_scores_gemma":[0.99844503,0.00017381576,0.0003616995,0.00060341746,0.00016078124,0.0002552812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00784547,0.00034288436,0.0034094197,0.00042184727,0.00012246639,0.000086239634,0.000089419314,0.00006221892,0.0004003899],"category_scores_gemma":[0.00013822454,0.00020316587,0.0033199715,0.00039873357,0.00002641689,0.00034993293,0.0001053233,0.00029944314,0.000032474014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013304685,0.00012025671,0.5840619,0.000109427165,0.4144232,0.00017405688,0.00016613529,0.00020267243,0.000036070658,0.000014700336,0.00040861068,0.00014986924],"study_design_scores_gemma":[0.007393026,0.00034542358,0.5640029,0.00004104865,0.34600464,0.00007471017,0.00038347903,0.000016326885,0.00005972404,0.000003459932,0.08143213,0.00024314801],"about_ca_topic_score_codex":0.000024896712,"about_ca_topic_score_gemma":0.000010516428,"teacher_disagreement_score":0.08102352,"about_ca_system_score_codex":0.00011883871,"about_ca_system_score_gemma":0.000058762384,"threshold_uncertainty_score":0.8284863},"labels":[],"label_agreement":null},{"id":"W2981583721","doi":"10.1093/eurheartj/ehz746.0869","title":"P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Placebo; Mace; Proportional hazards model; Internal medicine; Myocardial infarction; Type 2 diabetes; Diabetes mellitus; Stroke (engine); Cardiology; Confidence interval; Endocrinology","score_opus":0.010154234987034959,"score_gpt":0.20992234024481504,"score_spread":0.19976810525778008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981583721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550575,0.002798961,2.739484e-7,0.0005571015,0.0001222163,0.00036332035,0.0000034180775,0.0000062297745,0.00064270356],"genre_scores_gemma":[0.9994274,0.00018429235,0.00006216224,0.000030482019,0.00007425065,0.0000017686043,0.000009943532,0.000014820634,0.00019492538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992712,0.00009456509,0.00013926334,0.00013275792,0.00022615111,0.00013605495],"domain_scores_gemma":[0.9995659,0.000028376911,0.000047663787,0.00018059263,0.00006231628,0.00011516158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031265305,0.000092273745,0.00018425928,0.00007716493,0.000059306152,0.00005005996,0.000037694637,0.000007524033,0.00003494599],"category_scores_gemma":[0.000047609105,0.000054278848,0.00005201727,0.000107043554,0.000055195225,0.00014872501,0.00005174015,0.0001022966,0.0000064463397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091986294,0.00010926092,0.99440444,0.000049071437,0.0003176094,0.000010582604,0.00038263257,0.00011911164,0.000009912991,0.000007728949,0.0007627896,0.0037348494],"study_design_scores_gemma":[0.0017781492,0.00067950186,0.9919774,0.0002622824,0.00024241956,0.0000022630238,0.00012708658,0.00007009921,0.000010675701,0.0000039812753,0.0047806357,0.000065502274],"about_ca_topic_score_codex":0.0000035610974,"about_ca_topic_score_gemma":2.8479846e-7,"teacher_disagreement_score":0.004017846,"about_ca_system_score_codex":0.000016727838,"about_ca_system_score_gemma":0.000015797617,"threshold_uncertainty_score":0.22134271},"labels":[],"label_agreement":null},{"id":"W2981743123","doi":"10.1007/s12325-019-01126-x","title":"Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Insulin glargine; Type 2 diabetes; Population; Insulin; Diabetes mellitus; Basal insulin; Glucagon-like peptide 1 receptor; Intensive care medicine; Internal medicine; Endocrinology; Receptor","score_opus":0.016104954431143098,"score_gpt":0.2998611474260131,"score_spread":0.28375619299487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981743123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022156043,0.97396606,8.515589e-7,0.00010508504,0.00023065423,0.0023619854,0.0000135426135,0.000036230434,0.0011295638],"genre_scores_gemma":[0.0045195846,0.9938711,0.00049881754,0.0002909933,0.00007359827,0.00024970027,0.00017950404,0.000084852,0.0002318641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981788,0.00010234749,0.0004556525,0.00064823986,0.0002297671,0.0003852044],"domain_scores_gemma":[0.99900323,0.00027303305,0.00023538372,0.0003582781,0.000035946003,0.00009409905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020266564,0.0005275751,0.00161239,0.0003862716,0.00002865998,0.00003207253,0.0001150513,0.00017083419,0.00003457944],"category_scores_gemma":[0.000034204964,0.00035871848,0.00006445202,0.0004627812,0.000094268886,0.00017798622,0.000053469183,0.00037767805,0.000023651955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046895456,0.00037958237,0.001951185,0.0044874204,0.00016617964,0.00003169608,0.00026074934,0.0000012823486,4.322244e-7,0.00008225882,0.000038875252,0.9921314],"study_design_scores_gemma":[0.013480519,0.0034546598,0.0012009755,0.04686084,0.00017905093,0.0000025317552,0.000076715594,0.000021988082,0.000018901334,0.000117050324,0.9340319,0.0005548786],"about_ca_topic_score_codex":0.000011596663,"about_ca_topic_score_gemma":0.000043219166,"teacher_disagreement_score":0.9915765,"about_ca_system_score_codex":0.0001297683,"about_ca_system_score_gemma":0.000069438494,"threshold_uncertainty_score":0.99988645},"labels":[],"label_agreement":null},{"id":"W2981799436","doi":"10.4212/cjhp.v72i5.2932","title":"Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad","year":2019,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Native Mental Health Association of Canada; University of British Columbia","funders":"","keywords":"Medicine; Information retrieval; Computer science","score_opus":0.014211588717827378,"score_gpt":0.26883785683871686,"score_spread":0.2546262681208895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981799436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732293,0.00049648184,0.000009373688,0.014032325,0.001549611,0.00035413116,0.000014007841,0.000008709081,0.010306046],"genre_scores_gemma":[0.9928117,0.000020170326,0.00028392806,0.00461045,0.00043773575,0.0000018338667,0.0000072353423,0.000024253548,0.0018027269],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990677,0.00002087193,0.00024225136,0.000117966076,0.00022045897,0.00033069946],"domain_scores_gemma":[0.99889475,0.00003160253,0.0001128629,0.00021348274,0.0001293591,0.00061792217],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016958,0.00014099968,0.0002623635,0.00016568681,0.0000813725,0.0000832307,0.00024163576,0.000021934828,0.0012076322],"category_scores_gemma":[0.000030365034,0.0000942011,0.00013953347,0.00015247802,0.000034620065,0.00018028692,0.000028060778,0.00021348201,0.00045076272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043318985,0.0002064925,0.7790956,0.000036064066,0.0020494487,0.0016991178,0.0037811848,0.00025714817,0.0018983547,0.000727545,0.14675298,0.06306289],"study_design_scores_gemma":[0.007984377,0.001931112,0.11158895,0.00038524938,0.001029238,0.00007118538,0.000527571,0.00023879106,0.0027105627,0.0005737764,0.8725229,0.00043630454],"about_ca_topic_score_codex":0.01639715,"about_ca_topic_score_gemma":0.0039037704,"teacher_disagreement_score":0.7257699,"about_ca_system_score_codex":0.00021310686,"about_ca_system_score_gemma":0.00041388112,"threshold_uncertainty_score":0.9997054},"labels":[],"label_agreement":null},{"id":"W2981806884","doi":"10.1093/eurheartj/ehz746.0718","title":"P5997GLP-1(28-36) prevents progression of ischemic heart failure in mice","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Heart failure; Mace; Glucagon-like peptide-1; Internal medicine; Metabolite; Cardiology; Endocrinology; Pharmacology; Animal studies; Adverse effect; Neprilysin; Myocardial infarction; Type 2 diabetes; Diabetes mellitus; Biochemistry; Enzyme","score_opus":0.016834352248934686,"score_gpt":0.2875240939225548,"score_spread":0.2706897416736201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981806884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97550386,0.0004108525,0.000003894877,0.0017672016,0.00019862026,0.00042369548,0.0000011293159,0.000022139686,0.021668592],"genre_scores_gemma":[0.9908754,0.0000424114,0.003053562,0.0003669069,0.00016889296,0.000002100491,0.000007930814,0.000034775763,0.0054479702],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874467,0.0001540075,0.0003299566,0.00018154473,0.00031378568,0.00027605068],"domain_scores_gemma":[0.99947244,0.0000216227,0.00011837833,0.00020225452,0.000042990472,0.00014233659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005806416,0.00013837154,0.00029329615,0.00017151149,0.000031617266,0.000023819779,0.00009561617,0.000028043181,0.00041376153],"category_scores_gemma":[0.000025893936,0.00010664962,0.0001299154,0.0001498186,0.000023703285,0.00013584824,0.000083715924,0.000296424,0.0005188335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002459408,0.0006950367,0.71052516,0.00022752327,0.00011954065,0.00014912122,0.00028262212,0.000009727159,0.112094626,0.000012010362,0.1698377,0.005801015],"study_design_scores_gemma":[0.004561907,0.0012322996,0.43903145,0.0020241174,0.000088540895,0.00026031936,0.00014947531,0.000033405064,0.014742516,0.000009147906,0.5376888,0.0001780261],"about_ca_topic_score_codex":0.0000014868854,"about_ca_topic_score_gemma":7.913896e-7,"teacher_disagreement_score":0.3678511,"about_ca_system_score_codex":0.00005247228,"about_ca_system_score_gemma":0.000038104994,"threshold_uncertainty_score":0.6668728},"labels":[],"label_agreement":null},{"id":"W2981837612","doi":"10.1093/eurheartj/ehz746.0166","title":"P4988Beta-blockers in diabetes with stable coronary heart disease - a cause for concern?","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mace; Internal medicine; Meta-analysis; Diabetes mellitus; Observational study; Odds ratio; Randomized controlled trial; Hazard ratio; Cardiology; Myocardial infarction; Confidence interval; Percutaneous coronary intervention; Endocrinology","score_opus":0.036423923033219036,"score_gpt":0.2791437540665084,"score_spread":0.24271983103328934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981837612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909532,0.00069686887,0.000009644874,0.004703764,0.00019708142,0.0009591317,0.000012281179,0.0000427114,0.002425314],"genre_scores_gemma":[0.9869867,0.000029880155,0.0016179642,0.0027747427,0.0002074218,0.000017765535,0.000027574793,0.00006711233,0.008270867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986582,0.00011008455,0.00023925265,0.0002523779,0.00026347648,0.00047663244],"domain_scores_gemma":[0.99917287,0.00006715808,0.000069552465,0.00026238686,0.0000599578,0.00036808677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004503577,0.00018795018,0.00033379236,0.00014304262,0.00008326679,0.00007242203,0.000077893535,0.000014927465,0.00032589972],"category_scores_gemma":[0.000026814212,0.00013824762,0.00011346233,0.00011812235,0.000044791712,0.00018566666,0.00004589547,0.00019834058,0.00028629304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005376703,0.0002626256,0.9486321,0.00009484203,0.00018342011,0.00032616867,0.000089692905,0.000049892744,0.00038345938,0.000032563355,0.048941486,0.00046608225],"study_design_scores_gemma":[0.005698445,0.0015512189,0.769331,0.00039649574,0.00023573189,0.000042803156,0.00011539263,0.00015461475,0.00010565668,0.000023399482,0.22216193,0.00018333066],"about_ca_topic_score_codex":0.0000024019032,"about_ca_topic_score_gemma":0.000002196762,"teacher_disagreement_score":0.17930111,"about_ca_system_score_codex":0.00010349062,"about_ca_system_score_gemma":0.00010015795,"threshold_uncertainty_score":0.5637574},"labels":[],"label_agreement":null},{"id":"W2981890377","doi":"10.1093/eurheartj/ehz746.0871","title":"P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Linagliptin; Medicine; Renal function; Placebo; Population; Internal medicine; Type 2 diabetes; Diabetes mellitus; Concomitant; Heart failure; Creatinine; Kidney disease; Endocrinology; Pathology","score_opus":0.011150429599180722,"score_gpt":0.22682055569792764,"score_spread":0.21567012609874692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981890377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958273,0.0026408646,0.0000045215065,0.00014159974,0.000072961855,0.0012217165,0.0000016148342,0.000008123351,0.0000812792],"genre_scores_gemma":[0.9994887,0.00018021913,0.00008350727,0.00009551283,0.00006092209,0.0000069460625,0.00001622798,0.000029011266,0.000038924416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842966,0.00036546265,0.00022009165,0.00029763553,0.00044736126,0.00023977444],"domain_scores_gemma":[0.9994527,0.000020949368,0.00006223311,0.00025478323,0.00006565677,0.00014368683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093342864,0.0001948131,0.0003782701,0.00016286629,0.000079436206,0.00006345421,0.000058032263,0.000014764578,0.000003569384],"category_scores_gemma":[0.000025910715,0.00011282899,0.00006140578,0.00018850612,0.000041986055,0.0001305613,0.00007515151,0.00021832286,0.000004206072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003605316,0.0002923223,0.99619734,0.00007681709,0.0003932022,0.00012463515,0.0006409351,0.00008191805,0.0000018835975,0.0000013688598,0.0000341044,0.0017949217],"study_design_scores_gemma":[0.009176973,0.0027044343,0.9857977,0.00034470324,0.00051791815,0.0000124938615,0.00032359763,0.00004519984,0.0000010782339,0.000001982977,0.0009322133,0.00014167899],"about_ca_topic_score_codex":0.000005161839,"about_ca_topic_score_gemma":0.000005371674,"teacher_disagreement_score":0.010399634,"about_ca_system_score_codex":0.00005241712,"about_ca_system_score_gemma":0.000022536236,"threshold_uncertainty_score":0.46010327},"labels":[],"label_agreement":null},{"id":"W2982089035","doi":"10.1093/eurheartj/ehz748.0263","title":"P1500Effects of empagliflozin on cardiac function in patients with type 2 diabetes mellitus: echocardiographic substudy of the EMPA-HEART cardiolink-6 trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Ejection fraction; Placebo; Internal medicine; Cardiology; Ventricle; Diastole; Heart failure; Diabetes mellitus; Blood pressure; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.011466484284918211,"score_gpt":0.22573687589144392,"score_spread":0.21427039160652572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982089035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432176,0.00044051942,4.4383447e-7,0.000054895256,0.0011679798,0.0013475263,0.0000038695007,0.000013889549,0.0026491242],"genre_scores_gemma":[0.9994076,0.000069002635,0.000027392718,0.00012173411,0.00019965012,0.0000035907428,0.0000080842665,0.00003821776,0.00012476293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785817,0.0007018325,0.00036211303,0.00020899181,0.0006007763,0.00026812416],"domain_scores_gemma":[0.999053,0.000087223074,0.00017674686,0.00044638396,0.00014343859,0.00009320231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001047796,0.00018677284,0.0006172953,0.00028826192,0.00004956188,0.000016699432,0.0001007624,0.000034116147,0.000027090515],"category_scores_gemma":[0.0000522807,0.000111454996,0.00037629582,0.00050550775,0.000050922405,0.00007718544,0.00004706451,0.00031290483,0.000049714647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057484335,0.00043415837,0.9905815,0.000054291875,0.0005636538,0.0000026339123,0.00008635478,0.00010028649,0.00025556204,0.000004717712,0.0014939895,0.00067437853],"study_design_scores_gemma":[0.020417824,0.009226611,0.96579,0.00042825588,0.00040207186,6.2258334e-7,0.000039248847,0.0000032964858,0.00040592437,0.0000045413385,0.003183747,0.00009789633],"about_ca_topic_score_codex":0.00000261001,"about_ca_topic_score_gemma":5.6867356e-7,"teacher_disagreement_score":0.02479158,"about_ca_system_score_codex":0.00005024632,"about_ca_system_score_gemma":0.00004114412,"threshold_uncertainty_score":0.4545003},"labels":[],"label_agreement":null},{"id":"W2982125719","doi":"10.1093/eurheartj/ehz747.0052","title":"192Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Albuminuria; Dapagliflozin; Renal function; Internal medicine; Creatinine; Urology; Type 2 diabetes; Hazard ratio; Diabetes mellitus; TIMI; Cardiology; Endocrinology; Myocardial infarction; Confidence interval; Percutaneous coronary intervention","score_opus":0.011338867157342062,"score_gpt":0.2203877616806398,"score_spread":0.20904889452329775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982125719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979262,0.00044594935,0.000023111894,0.00006592897,0.00028363947,0.0004794662,0.0000050650456,0.000015687181,0.0007549643],"genre_scores_gemma":[0.9986467,0.000026462847,0.00062134914,0.00040753093,0.00010549797,0.0000017705818,0.000037879458,0.000036856996,0.000115983385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985907,0.00028004515,0.0002495652,0.0002444746,0.00039900537,0.000236217],"domain_scores_gemma":[0.9992957,0.00009739674,0.000074087184,0.0002749134,0.00008130166,0.000176578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040434202,0.00017712344,0.00048206965,0.00026046846,0.000039381972,0.00003552643,0.000047764654,0.00002204698,0.00005890505],"category_scores_gemma":[0.000084551684,0.00011834341,0.00010631149,0.00017153785,0.000015056525,0.00012241291,0.000052636595,0.00018292172,0.00008342124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063236867,0.00022100842,0.9890861,0.000024954501,0.00078921835,0.00002197496,0.00009060047,0.00020006768,0.0006217377,0.000002625636,0.0004985823,0.007810798],"study_design_scores_gemma":[0.0053666118,0.0033938107,0.9826442,0.00048651802,0.00030847947,6.0924714e-7,0.00005473884,0.000030116707,0.00033287634,0.0000054842926,0.0072527407,0.00012382538],"about_ca_topic_score_codex":0.000011602794,"about_ca_topic_score_gemma":0.0000034395189,"teacher_disagreement_score":0.0076869726,"about_ca_system_score_codex":0.00006480475,"about_ca_system_score_gemma":0.000019477126,"threshold_uncertainty_score":0.4825904},"labels":[],"label_agreement":null},{"id":"W2982635212","doi":"","title":"Diabetes-Related Complication in Canada; Prevalence of Complication, Their Association with Determinants and Future Potential Cost-Effectiveness of Pharmacy-Based Intervention","year":2019,"lang":"en","type":"dissertation","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Complication; Intervention (counseling); Diabetes mellitus; Association (psychology); Family medicine; Environmental health; Surgery; Psychiatry; Psychology; Endocrinology","score_opus":0.008679736345203179,"score_gpt":0.2703003818180622,"score_spread":0.261620645472859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982635212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589276,0.00033273554,0.00004304885,0.00006107585,0.00016885811,0.0029214965,0.00008058985,0.000013750868,0.00048566196],"genre_scores_gemma":[0.99656945,0.00009902511,0.000046379242,0.00001659619,0.000010640639,0.00022751879,0.0024676204,0.000023463874,0.0005392759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860096,0.00013416295,0.0004790525,0.00031176655,0.00031166413,0.00016239441],"domain_scores_gemma":[0.9984692,0.00010880452,0.00079035386,0.0002324823,0.00035788736,0.000041284515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030798468,0.00022153503,0.0005429362,0.00019366198,0.000019461519,0.000006951206,0.000085690444,0.00009977494,0.000048032627],"category_scores_gemma":[0.0000133314,0.0001786925,0.00007069194,0.00021248925,0.000015922336,0.00007802621,0.000012002984,0.00012449973,0.0000010696831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006492854,0.00037688378,0.95833755,0.010046025,0.00030570963,9.3842687e-7,0.00005860678,0.00005390833,0.005047815,0.000029214749,0.000024933073,0.025069151],"study_design_scores_gemma":[0.0049240794,0.00025295035,0.9343378,0.0018440428,0.00064546877,3.096255e-7,0.00017766107,0.0051418836,0.05247511,0.00001101885,0.00004680511,0.00014288595],"about_ca_topic_score_codex":0.033250656,"about_ca_topic_score_gemma":0.06342343,"teacher_disagreement_score":0.047427297,"about_ca_system_score_codex":0.0006465812,"about_ca_system_score_gemma":0.00034743836,"threshold_uncertainty_score":0.973187},"labels":[],"label_agreement":null},{"id":"W2982683311","doi":"10.14740/jocmr4019","title":"The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Cotransporter; Sodium; Pharmacology; Function (biology); Cell biology; Chemistry","score_opus":0.10358775226229533,"score_gpt":0.4439250558108091,"score_spread":0.34033730354851377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982683311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688742,0.00097152335,0.0028900455,0.020387849,0.0021067313,0.0026010287,0.000003467679,0.000009502051,0.0021556127],"genre_scores_gemma":[0.99203026,0.0009293744,0.0008226149,0.0006140989,0.0012495011,0.000032496955,0.000004845758,0.000023184322,0.0042936266],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962015,0.0001257452,0.0015709836,0.00021085938,0.0014874422,0.00040346774],"domain_scores_gemma":[0.9954404,0.002071795,0.00043047214,0.0003593455,0.0012993029,0.00039867646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01100179,0.0001279289,0.0007743753,0.0003159884,0.00008426553,0.000013936736,0.00023422246,0.00010200345,0.0001834115],"category_scores_gemma":[0.0012848718,0.00006544354,0.00032356457,0.0003271967,0.00017433545,0.0000804234,0.0000650379,0.00051897694,0.00003509902],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017905511,0.0022607169,0.014319215,0.0010361711,0.0018541767,0.00016343148,0.0003835167,0.0000068661416,0.051822748,0.005903115,0.06674465,0.8375999],"study_design_scores_gemma":[0.05359285,0.3158659,0.19135001,0.005297112,0.0023902804,0.000051692026,0.004411692,0.00060960423,0.09825718,0.018154722,0.30958948,0.00042947166],"about_ca_topic_score_codex":0.00002834007,"about_ca_topic_score_gemma":0.0000139626645,"teacher_disagreement_score":0.8371704,"about_ca_system_score_codex":0.00007728916,"about_ca_system_score_gemma":0.00024429776,"threshold_uncertainty_score":0.38130227},"labels":[],"label_agreement":null},{"id":"W2982909299","doi":"10.1002/edm2.100","title":"Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis","year":2019,"lang":"en","type":"review","venue":"Endocrinology Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; St. Michael's Hospital; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Internal medicine; Placebo; Relative risk; Sulfonylurea; Number needed to harm; Diabetes mellitus; Concomitant; Meta-analysis; Sitagliptin; Randomized controlled trial; Cochrane Library; Confidence interval; Pharmacology; Insulin; Endocrinology; Number needed to treat","score_opus":0.02744843115298321,"score_gpt":0.2868843925310731,"score_spread":0.2594359613780899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982909299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014873633,0.9766263,7.3613603e-7,0.000029611203,0.000110613095,0.0079023605,0.0001960641,0.00006076809,0.00019995582],"genre_scores_gemma":[0.0019079959,0.994348,0.00035001567,0.00043423337,0.000023027902,0.0010682472,0.0006022657,0.0001420316,0.0011241904],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945255,0.0008268514,0.0016211316,0.0012452824,0.0006022276,0.0011790339],"domain_scores_gemma":[0.9955092,0.00040222894,0.0017664365,0.0017925897,0.00030581813,0.00022373525],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00043248708,0.0013111498,0.018263154,0.0015829757,0.000052824344,0.00002950109,0.00044490714,0.00028250128,0.00024743844],"category_scores_gemma":[0.00019039365,0.0007371899,0.0013815655,0.0023545516,0.00025822828,0.000177483,0.0002643119,0.00065610715,0.00011009914],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022741791,0.00044755515,0.043866497,0.57269377,0.37993354,0.00002186523,0.0000222463,0.0000015218725,6.80039e-8,0.00003712966,0.00013929671,0.0028137676],"study_design_scores_gemma":[0.0021302449,0.00056073855,0.009972844,0.03450735,0.9324099,0.0000020231244,0.0000063637945,0.0000021955545,0.0000019017699,0.00000424462,0.019777078,0.0006251137],"about_ca_topic_score_codex":0.000019320381,"about_ca_topic_score_gemma":0.000009853446,"teacher_disagreement_score":0.55247635,"about_ca_system_score_codex":0.000097443575,"about_ca_system_score_gemma":0.00012863554,"threshold_uncertainty_score":0.999964},"labels":[],"label_agreement":null},{"id":"W2983971116","doi":"10.1016/j.cmet.2019.10.008","title":"The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure","year":2019,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Duke Clinical Research Institute; St. Jude Medical; Belvoir Media Group; Novo Nordisk; MyoKardia; Bayer Fund; Daiichi-Sankyo; Medicines Company; Bristol-Myers Squibb; Cleveland Clinic; American College of Cardiology Foundation; Ferring Pharmaceuticals; Novartis; Mayo Clinic; Merck; GlaxoSmithKline; Abbott Laboratories; CSL Behring; Chiesi Farmaceutici; Icahn School of Medicine at Mount Sinai; Eli Lilly and Company; AstraZeneca; Boehringer Ingelheim; Amgen; Sanofi","keywords":"Victory; Heart failure; Medicine; Internal medicine; Cardiology; Gerontology; Political science; Law","score_opus":0.008027815614147322,"score_gpt":0.22753147673768354,"score_spread":0.21950366112353623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983971116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9395692,0.005934391,0.0000015582095,0.0051484993,0.0009734267,0.0023778016,0.0000020713817,0.000051137493,0.04594192],"genre_scores_gemma":[0.97288185,0.0007368922,0.000113083515,0.0034557786,0.00037081924,0.00022131889,0.000020682417,0.000031750234,0.02216784],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986781,0.00012294464,0.00023694696,0.0002461022,0.00034843938,0.00036746878],"domain_scores_gemma":[0.99904835,0.00012626233,0.00006512764,0.00066977507,0.000026166452,0.000064304244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058740046,0.00018009369,0.00031848342,0.000086206914,0.00008619,0.000046451627,0.00023363164,0.00005696741,0.00008919496],"category_scores_gemma":[0.000023184082,0.00009073131,0.00015323167,0.00022577899,0.00004485768,0.00006904127,0.00006544929,0.00018865867,0.0005351096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009045734,0.0058681434,0.013275381,0.0005850808,0.0013868759,0.00020626838,0.015490593,0.000077405304,0.038384985,0.015248293,0.84725136,0.053179886],"study_design_scores_gemma":[0.018831717,0.00014256193,0.005930876,0.000019147139,0.00016513007,6.411949e-7,0.0012189884,0.000025572288,0.0009550898,0.00010746268,0.9724988,0.00010405285],"about_ca_topic_score_codex":0.000016233042,"about_ca_topic_score_gemma":0.000013900087,"teacher_disagreement_score":0.1252474,"about_ca_system_score_codex":0.000036846624,"about_ca_system_score_gemma":0.000037400747,"threshold_uncertainty_score":0.687793},"labels":[],"label_agreement":null},{"id":"W2984034820","doi":"10.1016/j.amjcard.2019.10.028","title":"Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits","year":2019,"lang":"en","type":"review","venue":"The American Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Natriuresis; Heart failure; Internal medicine; Dapagliflozin; Cardiology; Diabetes mellitus; Canagliflozin; Blood pressure; Empagliflozin; Type 2 diabetes; Endocrinology","score_opus":0.01973280291558417,"score_gpt":0.27211815846220344,"score_spread":0.2523853555466193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984034820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021622046,0.9940867,0.00067811966,0.00007547929,0.0010865652,0.0008299614,0.000038519644,0.000015113519,0.0010273405],"genre_scores_gemma":[0.020396627,0.97848,0.00015897003,0.000074544514,0.0005943922,0.000013889899,0.00006593741,0.000074170894,0.00014147845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687535,0.0005850051,0.0012713402,0.000290795,0.00058391056,0.000393625],"domain_scores_gemma":[0.99689955,0.00011889437,0.0017828485,0.0008365391,0.00022491979,0.00013725903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011504602,0.00046704654,0.006694432,0.00039478487,0.000037021,0.0000085210395,0.00042730867,0.00017973746,0.000027257787],"category_scores_gemma":[0.000020349276,0.00026475178,0.00512868,0.0003272858,0.00040773506,0.000045333552,0.00006625652,0.00061207596,0.000053983982],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017392654,0.000047383877,0.000020236075,0.0017084861,0.031173635,0.00044176303,0.00003299166,0.00016644633,0.000015910246,0.00017795224,0.00048063073,0.9655606],"study_design_scores_gemma":[0.002158922,0.0039056856,0.0002466317,0.004305782,0.069007896,0.002364397,0.00012038626,0.0000015406549,0.000054977885,0.0001326472,0.91733813,0.0003629893],"about_ca_topic_score_codex":0.0000074211875,"about_ca_topic_score_gemma":8.846226e-8,"teacher_disagreement_score":0.9651976,"about_ca_system_score_codex":0.00011536686,"about_ca_system_score_gemma":0.0002733292,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W2984471300","doi":"10.1016/j.jacc.2019.09.022","title":"Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection","year":2019,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Alberta; LMC Diabetes & Endocrinology (Canada); St. Michael's Hospital; University of Toronto; Toronto General Hospital; Diabetes Canada","funders":"","keywords":"Medicine; Canagliflozin; Glycemic; Diabetes mellitus; Nephropathy; Clinical trial; Empagliflozin; Intensive care medicine; Kidney disease; Diabetic nephropathy; Renal function; Internal medicine; Type 2 diabetes; Pharmacology; Endocrinology","score_opus":0.028052614183463047,"score_gpt":0.2844506100953442,"score_spread":0.25639799591188117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984471300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075277803,0.98882675,0.00011653399,0.00030032606,0.00068141025,0.0014552634,0.00010308222,0.0000071656023,0.0009816779],"genre_scores_gemma":[0.0148000335,0.98415416,0.00012663148,0.00005276829,0.00047031848,0.000021769594,0.000008186884,0.000028368977,0.00033777798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984112,0.0002782547,0.00070150895,0.00016964211,0.00026433662,0.00017510643],"domain_scores_gemma":[0.9977872,0.00006498491,0.0016201796,0.00030388028,0.00015410368,0.000069649985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037562448,0.00024774906,0.0032762378,0.00028319086,0.00003171825,0.0000038048925,0.00011395782,0.00010311524,0.000003366738],"category_scores_gemma":[0.00003032967,0.00014045603,0.0012769235,0.00026215543,0.00031459337,0.000040301886,0.00005815585,0.00035745028,0.00000357776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058830145,0.000092542425,0.00065950176,0.012254192,0.008311815,0.00057936343,0.00001769265,0.000012281799,0.00009492322,0.00009755162,0.0049234326,0.9723684],"study_design_scores_gemma":[0.0010786271,0.002040363,0.0009112457,0.00438953,0.010902758,0.0028399085,0.000048451242,0.0000010699933,0.000035944195,0.000030223822,0.9775855,0.0001363881],"about_ca_topic_score_codex":0.000004186367,"about_ca_topic_score_gemma":6.222536e-7,"teacher_disagreement_score":0.97266203,"about_ca_system_score_codex":0.00015024803,"about_ca_system_score_gemma":0.00027884557,"threshold_uncertainty_score":0.5727631},"labels":[],"label_agreement":null},{"id":"W2984683166","doi":"10.1161/circulationaha.119.044138","title":"Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Servier; Eisai; British Heart Foundation; Sanofi; Kowa Company; Amarin Corporation; Alnylam Pharmaceuticals; Novo Nordisk; Daiichi-Sankyo; Intarcia Therapeutics; GlaxoSmithKline; National Institute of Diabetes and Digestive and Kidney Diseases; Defense Acquisition Program Administration; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ejection fraction; Heart failure; Dapagliflozin; Cardiology; Internal medicine; Quality of life (healthcare); Endocrinology; Diabetes mellitus; Nursing","score_opus":0.007439656837970032,"score_gpt":0.22678349482418964,"score_spread":0.2193438379862196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984683166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999017,0.000033673026,0.00005033814,0.00004611992,0.000053275482,0.00068539183,5.690234e-7,0.000010724841,0.00010288605],"genre_scores_gemma":[0.9998506,0.0000023605942,0.00003353559,0.000038623966,0.00001088634,0.000008929642,0.00003757147,0.0000059077556,0.000011640407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994854,0.0000362495,0.00015044834,0.00013409463,0.0001417608,0.00005209528],"domain_scores_gemma":[0.99968636,0.00004407276,0.00010409099,0.00008820739,0.000051527826,0.000025722062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008929184,0.000061502935,0.00017861553,0.00011626027,0.000011007678,0.000003477151,0.0000056758063,0.000041755004,0.0000057672733],"category_scores_gemma":[0.000034458484,0.000051730905,0.000013569128,0.00010485987,0.000013968133,0.000098882556,0.000005050136,0.000036706675,0.0000017012259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041076096,0.00020686894,0.98954386,0.0004045047,0.000047874102,2.2651681e-8,0.000025009724,0.000037575744,0.008321129,0.00017395831,0.000013800613,0.0008146506],"study_design_scores_gemma":[0.004065492,0.00060111954,0.993868,0.00016010014,0.00007145122,3.0809264e-8,0.00002643732,0.000079774676,0.0010258211,0.000037453603,0.000021214586,0.000043085274],"about_ca_topic_score_codex":0.000036053654,"about_ca_topic_score_gemma":0.0000046758973,"teacher_disagreement_score":0.007295308,"about_ca_system_score_codex":0.000037400798,"about_ca_system_score_gemma":0.000008279874,"threshold_uncertainty_score":0.2109525},"labels":[],"label_agreement":null},{"id":"W2986608611","doi":"10.1161/strokeaha.119.026099","title":"Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease","year":2019,"lang":"en","type":"article","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute","funders":"","keywords":"Medicine; Coronary artery disease; Internal medicine; Diabetes mellitus; Myocardial infarction; Stroke (engine); Cardiology; Incidence (geometry); Cohort; Endocrinology","score_opus":0.0038779704174604322,"score_gpt":0.19227760318688683,"score_spread":0.1883996327694264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986608611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964495,0.00021722667,9.881943e-7,0.000030872274,0.000021243224,0.0008772279,0.00039210366,0.000029136807,0.0019817315],"genre_scores_gemma":[0.99817187,0.000034301465,0.00011356623,0.000121978526,0.000007777986,0.00003103795,0.0002672807,0.000025876188,0.0012263175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988991,0.000036479625,0.00017871211,0.00028661452,0.00032402092,0.00027509104],"domain_scores_gemma":[0.99929243,0.000048104863,0.00015079157,0.0002871881,0.00006473027,0.00015677176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088889115,0.00019763503,0.00040084214,0.00012113408,0.000019727402,0.000010354045,0.00005004568,0.000041691786,0.00006606315],"category_scores_gemma":[0.000023727109,0.00013688781,0.000041426167,0.00009976169,0.00007908342,0.00010715503,0.000038274862,0.00010698642,0.000008827871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010193302,0.00072059175,0.99570185,0.00009029675,0.0007860917,0.000007683336,0.00007209875,0.0000017032951,0.00013160058,0.0000030199071,0.00015912282,0.0013066009],"study_design_scores_gemma":[0.013674358,0.0014124026,0.9830219,0.00033993818,0.0006455784,1.14871554e-7,0.000050277133,0.000096391086,0.00046481224,0.0000035959933,0.00014447208,0.00014611514],"about_ca_topic_score_codex":0.000027325681,"about_ca_topic_score_gemma":0.000017661632,"teacher_disagreement_score":0.012679916,"about_ca_system_score_codex":0.00005769603,"about_ca_system_score_gemma":0.00004275209,"threshold_uncertainty_score":0.5582123},"labels":[],"label_agreement":null},{"id":"W2988030531","doi":"10.1016/s0167-8140(19)33327-4","title":"40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"Université de Montréal; McGill University; Canadian Institutes of Health Research; Hamilton Health Sciences","keywords":"Canagliflozin; Medicine; Oncology; Radiation therapy; Cancer research; Internal medicine; Lung cancer; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.010046118031974957,"score_gpt":0.2780758700415093,"score_spread":0.26802975200953433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988030531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9316549,0.06181462,0.00055893697,0.0034814202,0.0006148321,0.0014506222,0.000010034392,0.000025243004,0.00038941865],"genre_scores_gemma":[0.9702363,0.019219311,0.0032284027,0.0022089162,0.00038924225,0.00009313835,0.000007713079,0.000056336296,0.004560657],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836457,0.00026143086,0.0003329241,0.00042693285,0.00018132417,0.0004328342],"domain_scores_gemma":[0.9988474,0.00041252107,0.00015731087,0.0003143001,0.000051924384,0.00021651704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062545127,0.00027869554,0.0008210525,0.00016076212,0.00008551133,0.000030755018,0.00015496906,0.00011806305,0.00035239136],"category_scores_gemma":[0.000018133262,0.0001912214,0.00009652784,0.00020965158,0.00010684203,0.00005901182,0.000045265133,0.00013123767,0.0000024131748],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032321573,0.00029524395,0.040147025,0.00036610995,0.0010711583,0.00003698273,0.0068020714,0.00014842695,0.9214732,0.00009142727,0.006461961,0.019874245],"study_design_scores_gemma":[0.01730083,0.004346503,0.1434355,0.0003038824,0.0012018427,0.000009191898,0.0017579696,0.0021202106,0.2846594,0.000022124634,0.5441179,0.00072464085],"about_ca_topic_score_codex":0.0009941839,"about_ca_topic_score_gemma":0.00016123241,"teacher_disagreement_score":0.6368138,"about_ca_system_score_codex":0.00018113322,"about_ca_system_score_gemma":0.00029461648,"threshold_uncertainty_score":0.77977824},"labels":[],"label_agreement":null},{"id":"W2989060738","doi":"10.1161/circulationaha.119.042929","title":"Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Dapagliflozin; Medicine; Ejection fraction; Heart failure; Internal medicine; Placebo; Cardiology; Diabetes mellitus; Natriuretic peptide; Cardiomyopathy; Clinical endpoint; Randomized controlled trial; Diabetic cardiomyopathy; Endocrinology; Type 2 diabetes; Pathology","score_opus":0.004515661148322795,"score_gpt":0.1995319622610541,"score_spread":0.1950163011127313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989060738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99797165,0.000013815681,0.00006757098,0.00014336455,0.00010699478,0.0010699446,0.00000116359,0.000042878106,0.00058261486],"genre_scores_gemma":[0.99926656,0.0000012630691,0.00015399388,0.000105616746,0.000034417055,0.00003474773,0.00033554187,0.000016082015,0.00005176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921936,0.000028359987,0.000091213726,0.0002534617,0.0002638589,0.00014376044],"domain_scores_gemma":[0.9996752,0.000032352415,0.000053429114,0.00013502759,0.00005217953,0.000051770123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058863934,0.000114767936,0.00013859938,0.00020072053,0.000034639434,0.00001931904,0.000006652917,0.000056530713,0.00003397737],"category_scores_gemma":[0.00000890596,0.00008745156,0.00001557529,0.00019720655,0.000012265911,0.00018650475,0.000005321904,0.000074818294,0.000036326932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007791933,0.00016989298,0.9932227,0.0000638944,0.00010672621,7.5587093e-7,0.000017315027,0.00014403615,0.001183246,0.00004220123,0.0001962599,0.004073769],"study_design_scores_gemma":[0.0057857297,0.00090010546,0.991649,0.0002066395,0.00009449905,6.4917504e-7,0.000028107012,0.00025787333,0.00036778583,0.00001092381,0.0006013386,0.000097376105],"about_ca_topic_score_codex":0.000021278398,"about_ca_topic_score_gemma":0.000008689158,"teacher_disagreement_score":0.0050065364,"about_ca_system_score_codex":0.00021605894,"about_ca_system_score_gemma":0.00002091648,"threshold_uncertainty_score":0.3566171},"labels":[],"label_agreement":null},{"id":"W2989579906","doi":"10.1161/circulationaha.119.042375","title":"Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":578,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; LMC Diabetes & Endocrinology (Canada); Canadian Heart Research Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Canadian VIGOUR Centre; Heart and Stroke Foundation; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Cardiology; Ejection fraction; Internal medicine; Body surface area; Coronary artery disease; Type 2 Diabetes Mellitus; Diabetes mellitus; Glycated hemoglobin; Type 2 diabetes; Body mass index; Hematocrit; Heart failure; Endocrinology","score_opus":0.0036971234966079436,"score_gpt":0.20040592044241584,"score_spread":0.1967087969458079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989579906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873334,0.0001839874,0.0000024193623,0.000021304997,0.000063813175,0.000819822,0.0000021347187,0.000011738436,0.00016146172],"genre_scores_gemma":[0.99970967,0.000004883617,0.0000109466155,0.000035972178,0.000008314531,0.0000065805843,0.00018381495,0.000009110415,0.000030688025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948335,0.000034637374,0.00009070916,0.00014229397,0.00015235954,0.00009667905],"domain_scores_gemma":[0.99970764,0.000040986695,0.00003951717,0.00014212905,0.00002202103,0.00004768926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007276384,0.00008279387,0.00015756581,0.00009284491,0.000008221535,0.0000047309723,0.000014731128,0.000021624632,0.000031269436],"category_scores_gemma":[0.000013017409,0.000060544517,0.000021091995,0.00007593169,0.000012556751,0.0000539072,0.00000744542,0.000028539898,0.000020896086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047594175,0.00014100052,0.9932372,0.00022444478,0.00005985649,0.000010691243,0.00001688274,0.00014383877,0.00008799629,0.000016605327,0.000009703047,0.0055758674],"study_design_scores_gemma":[0.0030869378,0.0012964555,0.9942206,0.00018246801,0.00017136079,7.086998e-8,0.0000020487546,0.0006987225,0.00022974978,0.000022513323,0.000031748485,0.0000573234],"about_ca_topic_score_codex":6.5345665e-7,"about_ca_topic_score_gemma":1.8145627e-7,"teacher_disagreement_score":0.005518544,"about_ca_system_score_codex":0.00004271354,"about_ca_system_score_gemma":0.000006887217,"threshold_uncertainty_score":0.24689338},"labels":[],"label_agreement":null},{"id":"W2989595227","doi":"10.2337/dc19-1065","title":"Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute for Health and Care Research","keywords":"Medicine; Exenatide; Renal function; Diabetes mellitus; Internal medicine; Intensive care medicine; Urology; Type 2 diabetes; Endocrinology","score_opus":0.007254784475980854,"score_gpt":0.1958200466034902,"score_spread":0.18856526212750935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989595227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995469,0.0012616313,0.0000029493256,0.000088305496,0.00019559835,0.0024103061,0.000014749004,0.00004881986,0.00050869555],"genre_scores_gemma":[0.99867564,0.000016139185,0.00008003061,0.00048092846,0.000073692136,0.0001621203,0.0003496779,0.000033675442,0.00012810167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985508,0.0000737143,0.00021276533,0.00046691543,0.00041662957,0.0002791786],"domain_scores_gemma":[0.99910337,0.00008263132,0.000048168054,0.0005767299,0.000097192555,0.00009190116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008482959,0.00025524263,0.00059022865,0.000138252,0.0000611438,0.000057629342,0.000093253424,0.00007115627,0.000016209093],"category_scores_gemma":[0.000032364933,0.00015000883,0.00021411479,0.00026154102,0.000025140649,0.00012395649,0.00008321735,0.00011265068,0.00006608968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011772936,0.000105415056,0.9805207,0.000037781396,0.0015138756,0.0000050283256,0.0004927449,0.000027218719,0.0001221508,0.000005630673,0.00014412706,0.015847987],"study_design_scores_gemma":[0.043980364,0.0015971301,0.9464196,0.00023201681,0.001056145,3.5582882e-8,0.0014503592,0.000011094983,0.0008658955,0.0000078770845,0.0041752695,0.00020419278],"about_ca_topic_score_codex":0.00014209111,"about_ca_topic_score_gemma":0.000042128187,"teacher_disagreement_score":0.04280307,"about_ca_system_score_codex":0.000116606476,"about_ca_system_score_gemma":0.000019640123,"threshold_uncertainty_score":0.61171824},"labels":[],"label_agreement":null},{"id":"W2989883260","doi":"10.1016/s2213-8587(19)30382-1","title":"Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis","year":2019,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health","keywords":"Medicine; Pharmacovigilance; Anaphylactic reactions; Pharmacology; Glucagon; Anaphylaxis; Allergy; Drug; Internal medicine; Immunology; Insulin","score_opus":0.026838217049605005,"score_gpt":0.28738247348020185,"score_spread":0.26054425643059687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989883260","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14555159,0.007394124,0.000024514404,0.83291036,0.0021384375,0.0025060815,0.0003215497,0.00061421545,0.008539119],"genre_scores_gemma":[0.10445556,0.0036613962,0.0006905898,0.85770184,0.00479854,0.0009497491,0.0033466103,0.00018999017,0.024205752],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538034,0.00033528608,0.0005672136,0.0010825589,0.0004407129,0.0021938987],"domain_scores_gemma":[0.9966552,0.0009454679,0.0005037447,0.0016853143,0.00010717562,0.0001030988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034766906,0.0007615072,0.0021263012,0.0007923002,0.00020019666,0.00011030401,0.0005245788,0.0003695618,0.0005961437],"category_scores_gemma":[0.0000849015,0.00055716664,0.00054370007,0.00079197076,0.00040588278,0.00010185193,0.00020246168,0.0017442325,0.00049197464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014229637,0.00014013173,0.06050199,0.0010718191,0.010524271,0.00025329218,0.00003937688,0.000023718227,0.00065264397,0.00006201243,0.92250943,0.00407899],"study_design_scores_gemma":[0.0027735345,0.00038761654,0.008072834,0.00015135821,0.008851527,0.000009229933,0.000017534361,0.00032361335,0.00083901733,0.00006825078,0.9779874,0.00051807717],"about_ca_topic_score_codex":0.00007345807,"about_ca_topic_score_gemma":0.000014849232,"teacher_disagreement_score":0.055477947,"about_ca_system_score_codex":0.0002515982,"about_ca_system_score_gemma":0.00010657277,"threshold_uncertainty_score":0.99968797},"labels":[],"label_agreement":null},{"id":"W2990420098","doi":"10.1038/s41598-019-53388-8","title":"Contribution of rare coding mutations in CD36 to type 2 diabetes and cardio-metabolic complications","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Canada Research Chairs; Agence Nationale de la Recherche","keywords":"Type 2 diabetes; Bioinformatics; Diabetes mellitus; Medicine; CD36; Coding (social sciences); Computational biology; Genetics; Biology; Gene; Endocrinology","score_opus":0.012529333620610993,"score_gpt":0.2643987279812926,"score_spread":0.2518693943606816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990420098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948791,0.0003874147,0.000019430698,0.0003013765,0.0008072892,0.0007851375,0.000003174033,0.000020143467,0.0027969067],"genre_scores_gemma":[0.99821454,0.000006712186,0.00023914408,0.000038993046,0.000008867544,0.000029802492,0.00018289448,0.0000048893667,0.0012741395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991676,0.000013664055,0.00023678903,0.0002718307,0.00016785909,0.0001422302],"domain_scores_gemma":[0.9992925,0.00002313217,0.000083878134,0.0003484391,0.00018626532,0.0000657643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038146603,0.000060271268,0.00020100965,0.00023475569,0.00004890332,0.000033530334,0.00002411423,0.000019929244,0.00003274367],"category_scores_gemma":[0.00011935659,0.00005390317,0.000032432337,0.0005210959,0.000051470586,0.00006694452,0.00003747771,0.000028269647,0.000028177537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005742959,0.000110639216,0.94032615,0.000055160315,0.000066037035,0.000016843456,0.00032736198,0.000069372276,0.052166477,0.0017931123,0.0017259796,0.003337145],"study_design_scores_gemma":[0.00049799477,0.0000772258,0.9485385,0.00015003802,0.00012724246,0.0000075369494,0.00015736885,0.0001982909,0.015891302,0.0011154546,0.033145074,0.00009400091],"about_ca_topic_score_codex":0.000009182403,"about_ca_topic_score_gemma":0.000008106056,"teacher_disagreement_score":0.036275174,"about_ca_system_score_codex":0.000028219874,"about_ca_system_score_gemma":0.00003548732,"threshold_uncertainty_score":0.21981075},"labels":[],"label_agreement":null},{"id":"W2990472799","doi":"10.1002/ehf2.12528","title":"Eligibility of Sodium–glucose Co-Transporter-2 Inhibitors Among Patients with Diabetes Mellitus Admitted for Heart Failure","year":2019,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University Health Network; University of Toronto; Canadian VIGOUR Centre; University of Alberta; McGill University","funders":"American Heart Association","keywords":"Medicine; Heart failure; Diabetes mellitus; Internal medicine; Transporter; Cardiology; Intensive care medicine; Endocrinology; Biochemistry","score_opus":0.005380239438958435,"score_gpt":0.23307413940891225,"score_spread":0.22769389996995382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990472799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993507,0.00013921123,0.000014230182,0.0020812738,0.00015908196,0.0037037386,0.0001133722,0.000132494,0.00014957461],"genre_scores_gemma":[0.99339974,0.000003424788,0.0047710068,0.00043084624,0.00009192651,0.00016495332,0.00067391485,0.00006574263,0.00039846983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976286,0.000047399164,0.0005192295,0.00063088373,0.00054283225,0.00063102704],"domain_scores_gemma":[0.9984598,0.0001016736,0.00014899757,0.00073805754,0.00026747602,0.00028396037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026845603,0.00039368824,0.0008566746,0.00018057541,0.00007400104,0.0000294384,0.00011170106,0.00018618276,0.00025540125],"category_scores_gemma":[0.000030275502,0.00030239022,0.00030480672,0.00028257072,0.00014663844,0.00025864402,0.00003129926,0.00019926687,0.00009670931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024073909,0.00089136517,0.97414416,0.0006978668,0.00030463532,0.0000013516006,0.00012884816,0.0000029881164,0.0028222282,0.000029370767,0.02029614,0.00044031744],"study_design_scores_gemma":[0.0073111695,0.0022930505,0.8015061,0.00044990363,0.0003686416,2.6036344e-7,0.00014202333,0.000027215114,0.05065282,0.00003433737,0.13687743,0.00033705882],"about_ca_topic_score_codex":0.000038401624,"about_ca_topic_score_gemma":0.00008105186,"teacher_disagreement_score":0.17263807,"about_ca_system_score_codex":0.00008290065,"about_ca_system_score_gemma":0.000087324624,"threshold_uncertainty_score":0.99994284},"labels":[],"label_agreement":null},{"id":"W2990541661","doi":"10.1161/atv.0000615456.97862.30","title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension","year":2019,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden","keywords":"Liraglutide; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Medicine; Internal medicine; Receptor; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.019736650874997368,"score_gpt":0.2269563649948158,"score_spread":0.20721971411981843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990541661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968717,0.0005388174,0.00004952175,0.00028027812,0.0004771124,0.0015318459,0.000021185799,0.00007288798,0.0001566388],"genre_scores_gemma":[0.9967256,0.0017616986,0.00041431608,0.00039456217,0.00013118605,0.00031102233,0.00017905202,0.000048375525,0.00003419039],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980939,0.00014788665,0.00032448545,0.0007461944,0.00022175536,0.00046577668],"domain_scores_gemma":[0.9992945,0.000024550603,0.000085602405,0.00041876553,0.000044296074,0.00013228695],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025537692,0.00036148497,0.00082672207,0.00014570162,0.00008839233,0.00004314643,0.00008834846,0.00018652143,0.00015000244],"category_scores_gemma":[0.00000889369,0.0002719546,0.00026556486,0.0001615156,0.00013924782,0.00015222328,0.00009271202,0.00013626613,0.0000999645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007755586,0.0005548205,0.04062767,0.00005941567,0.0011556655,4.2983194e-7,0.00026749357,0.0000020214004,0.95589244,0.000023168208,0.00035024792,0.0009890731],"study_design_scores_gemma":[0.02205263,0.0067313146,0.82899004,0.0005475118,0.0010451507,0.0000060821285,0.001153719,0.000226108,0.07264287,0.000011042189,0.065578826,0.0010147038],"about_ca_topic_score_codex":0.00045180751,"about_ca_topic_score_gemma":0.0000295717,"teacher_disagreement_score":0.8832496,"about_ca_system_score_codex":0.00010042363,"about_ca_system_score_gemma":0.00002369844,"threshold_uncertainty_score":0.99997324},"labels":[],"label_agreement":null},{"id":"W2990704247","doi":"10.1016/j.cardfail.2019.11.005","title":"Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Ejection fraction; Heart failure; Dapagliflozin; Internal medicine; Placebo; Clinical endpoint; Randomized controlled trial; Diabetes mellitus; Cardiology; Clinical trial; Type 2 diabetes; Endocrinology","score_opus":0.003277849841856716,"score_gpt":0.19871897645154105,"score_spread":0.19544112660968432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990704247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976483,0.00021315707,0.000006088246,0.00050190045,0.00017753118,0.001329733,0.0000042322094,0.000008243265,0.00011080996],"genre_scores_gemma":[0.99932176,0.000025976737,0.00037816292,0.00006707769,0.00010681677,0.000022938859,0.00001572081,0.000023643139,0.000037884765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868226,0.00010758936,0.00024564797,0.00019701445,0.00056027976,0.00020719117],"domain_scores_gemma":[0.99911064,0.00015084735,0.0003157513,0.00015339619,0.00016962204,0.000099721794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024616075,0.00020512339,0.00054397446,0.0002489914,0.00004460444,0.000036343732,0.00002363688,0.00007001504,0.0000070645783],"category_scores_gemma":[0.000029715215,0.00010259765,0.000072369985,0.00023072763,0.00007935058,0.0002486769,0.000014598761,0.00023557621,0.000001288949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028858012,0.00027262702,0.966277,0.00013207902,0.0012743078,0.0000015431566,0.000048548034,0.000031486223,0.0010925187,0.000013171257,0.0009490695,0.0010496577],"study_design_scores_gemma":[0.045328453,0.0130210575,0.9357007,0.0007273217,0.00095215393,0.0000039500474,0.00021366503,0.0000074236223,0.0013839346,0.0000049572413,0.0025323487,0.00012400957],"about_ca_topic_score_codex":0.000009918141,"about_ca_topic_score_gemma":0.000008358931,"teacher_disagreement_score":0.030576255,"about_ca_system_score_codex":0.00009209329,"about_ca_system_score_gemma":0.00007475347,"threshold_uncertainty_score":0.4183811},"labels":[],"label_agreement":null},{"id":"W2990946575","doi":"10.1016/j.ajpath.2019.10.008","title":"Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation","year":2019,"lang":"en","type":"article","venue":"American Journal Of Pathology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Medizinische Universität Graz; Novo Nordisk Fonden; Karl-Franzens-Universität Graz; Oesterreichische Nationalbank; AstraZeneca; Austrian Science Fund; Novo Nordisk; Intarcia Therapeutics; Sanofi; Pfizer","keywords":"Endocrinology; Internal medicine; Liraglutide; Glucagon-like peptide-1; Medicine; Chemistry; Type 2 diabetes; Diabetes mellitus","score_opus":0.004691486131850022,"score_gpt":0.2257109241004548,"score_spread":0.22101943796860476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990946575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945335,0.00036832973,0.00018849796,0.0015354302,0.00039317305,0.0005128448,0.000008166743,0.00002727837,0.0024328246],"genre_scores_gemma":[0.98915195,0.00023387306,0.004326034,0.0026700436,0.00024711687,0.000018628598,0.000025723795,0.000035748733,0.0032908893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985157,0.00011863918,0.000520298,0.0002335384,0.00024425233,0.0003675453],"domain_scores_gemma":[0.998786,0.000052227468,0.00067443476,0.00018265801,0.00014208378,0.00016263971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032907058,0.00019817638,0.00057258544,0.00020183601,0.00005061892,0.00003052124,0.000109165434,0.000060918643,0.00016174604],"category_scores_gemma":[0.00003253992,0.00016662687,0.00016205333,0.00020274188,0.00014856551,0.00018932864,0.00005257663,0.00027377447,0.00014051935],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002570339,0.00044405615,0.020464085,0.00007785553,0.00017293106,0.00032072392,0.0006960335,0.000004287575,0.792193,0.000057314843,0.0117781665,0.17353448],"study_design_scores_gemma":[0.035684813,0.08933602,0.045248494,0.0012393093,0.002027554,0.004787236,0.016148878,0.0004175685,0.55738217,0.0005700322,0.24503596,0.0021219966],"about_ca_topic_score_codex":0.000008834506,"about_ca_topic_score_gemma":0.0000012212356,"teacher_disagreement_score":0.23481089,"about_ca_system_score_codex":0.00009854969,"about_ca_system_score_gemma":0.00009419119,"threshold_uncertainty_score":0.6794846},"labels":[],"label_agreement":null},{"id":"W2991226328","doi":"10.1016/j.peptides.2019.170206","title":"Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion","year":2019,"lang":"en","type":"review","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Medical Research Council Canada; Wellcome Trust","keywords":"Incretin; Nutrient sensing; Enteroendocrine cell; Internal medicine; Endocrinology; Glucose homeostasis; Receptor; Biology; Secretion; Postprandial; Carbohydrate metabolism; Biochemistry; Chemistry; Insulin; Hormone; Signal transduction; Endocrine system; Type 2 diabetes; Insulin resistance; Diabetes mellitus","score_opus":0.041523301352326174,"score_gpt":0.29367002837900036,"score_spread":0.2521467270266742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991226328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116212046,0.9836357,0.0007885423,0.00003225191,0.00075362343,0.002044181,0.000045198263,0.00024237773,0.012341869],"genre_scores_gemma":[0.0002774493,0.97151697,0.0017479596,0.00013011612,0.00039313769,0.00019366962,0.0011451365,0.00015888298,0.024436703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738353,0.0000963874,0.00064882607,0.00072304375,0.00061310566,0.0005350843],"domain_scores_gemma":[0.998432,0.00008830682,0.00045195388,0.0007894597,0.00005397118,0.00018434944],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022120349,0.00067312055,0.0020165374,0.0002708784,0.00008003148,0.000081750106,0.00024049278,0.00032134287,0.00044103898],"category_scores_gemma":[0.00004946722,0.00053077016,0.0007949932,0.00022053342,0.000033161457,0.000109391454,0.00022579811,0.0004143603,0.005502881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014256708,0.00019650582,0.000025448891,0.02688199,0.0011306659,0.00015578957,0.000037623235,7.7011697e-7,0.00009700409,0.0023528198,0.00087256235,0.96823454],"study_design_scores_gemma":[0.0007305975,0.0003787905,0.000015649608,0.0122674,0.0057585025,0.000013376634,0.000037650672,0.00001655732,0.00010829233,0.00010987607,0.9801063,0.00045700037],"about_ca_topic_score_codex":0.000046269608,"about_ca_topic_score_gemma":0.0000058535206,"teacher_disagreement_score":0.97923374,"about_ca_system_score_codex":0.0005555264,"about_ca_system_score_gemma":0.00018042195,"threshold_uncertainty_score":0.9997144},"labels":[],"label_agreement":null},{"id":"W2992060748","doi":"10.1097/hco.0000000000000704","title":"Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge","year":2019,"lang":"en","type":"article","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada); Humber River Regional Hospital; Queen's University; Health Sciences Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Intensive care medicine; Type 2 diabetes; Cotransporter; Diabetes mellitus; Adverse effect; Internal medicine; Sodium; Endocrinology","score_opus":0.024687526014195233,"score_gpt":0.32299611214918544,"score_spread":0.29830858613499023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992060748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98512995,0.005234545,0.000013345347,0.00064320775,0.0062852437,0.0020693678,0.00002069212,0.000022426208,0.0005812276],"genre_scores_gemma":[0.99221385,0.006690131,0.00008697506,0.00006477416,0.0003151541,0.00017018318,0.00038990105,0.000021778482,0.000047254944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983646,0.00007067324,0.0005551513,0.00052641047,0.00010425527,0.0003788654],"domain_scores_gemma":[0.99946105,0.000113017355,0.0000899431,0.00020514285,0.00004406655,0.00008679505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004247624,0.00020491653,0.0006041452,0.0003118347,0.000017709124,0.000014725275,0.00006219624,0.00013677338,0.000013353419],"category_scores_gemma":[0.00003844831,0.00019006895,0.00009343425,0.00017607295,0.00009528125,0.00013677536,0.00008409393,0.00020192972,0.000020983867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104406456,0.00038785528,0.9871977,0.00057512533,0.00009589991,0.0000063969605,0.00021632461,0.0000022563427,0.0000038787293,0.00088224927,0.0022437342,0.008284184],"study_design_scores_gemma":[0.007582452,0.0016878393,0.9468303,0.00041117967,0.00005796366,7.9071606e-7,0.00020095272,0.00007018188,0.0000067246597,0.0003036275,0.042636182,0.00021183351],"about_ca_topic_score_codex":0.0000026699186,"about_ca_topic_score_gemma":0.0000022410377,"teacher_disagreement_score":0.040392447,"about_ca_system_score_codex":0.000057556317,"about_ca_system_score_gemma":0.000023144321,"threshold_uncertainty_score":0.7750787},"labels":[],"label_agreement":null},{"id":"W2993236582","doi":"10.1016/j.revmed.2019.11.004","title":"Chez les patients atteints de diabète type 2 et ayant une néphropathie diabétique avec albuminurie, quel est l’effet de la canagliflozine, un inhibiteur des SGLT2, sur le pronostic rénal et cardiovasculaire ?","year":2019,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine; Vasculitis; Pathology; Disease","score_opus":0.007747661442906299,"score_gpt":0.2297115632127499,"score_spread":0.2219639017698436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993236582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547135,0.0041217436,0.0016148111,0.029942969,0.0012135806,0.0024154808,0.00030882607,0.00020851173,0.0054605436],"genre_scores_gemma":[0.9427283,0.0020246126,0.0015663048,0.021230135,0.0022978745,0.00042877955,0.002486348,0.000528711,0.026708953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99253154,0.0022167603,0.0012053945,0.0014343876,0.0007024163,0.0019094836],"domain_scores_gemma":[0.99550104,0.001535629,0.00059111236,0.0014237515,0.00043192838,0.0005165463],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002380794,0.0014864842,0.0021477905,0.0005105388,0.0001483147,0.00025903012,0.000782215,0.0012116376,0.00023414264],"category_scores_gemma":[0.0015400834,0.00143461,0.0009100245,0.0006231267,0.0006746403,0.000300468,0.000640607,0.0024677147,0.00037896636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005127215,0.0032699557,0.8743909,0.006627992,0.0057445546,0.008494674,0.0050768033,0.00071670377,0.00077567465,0.0013583242,0.057951216,0.035080504],"study_design_scores_gemma":[0.014389979,0.0016999217,0.694668,0.015008486,0.004488262,0.00048785927,0.00017892082,0.0011643355,0.0025991718,0.0005475022,0.26300913,0.0017584286],"about_ca_topic_score_codex":0.0248487,"about_ca_topic_score_gemma":0.0069015427,"teacher_disagreement_score":0.20505792,"about_ca_system_score_codex":0.0020976365,"about_ca_system_score_gemma":0.0010705768,"threshold_uncertainty_score":0.99983364},"labels":[],"label_agreement":null},{"id":"W2993457594","doi":"10.1016/j.xkme.2019.09.006","title":"Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy","year":2019,"lang":"en","type":"article","venue":"Kidney Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Janssen Pharmaceuticals; Merck; Boehringer Ingelheim; AstraZeneca; Eli Lilly and Company","keywords":"Tubuloglomerular feedback; Term (time); Medicine; Urology; Internal medicine; Renal function; Physics","score_opus":0.016639319934732055,"score_gpt":0.2683315307099756,"score_spread":0.25169221077524356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993457594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96795833,0.002347831,0.000017576729,0.011395841,0.0010410751,0.0013293263,0.0000037335674,0.00011454232,0.015791748],"genre_scores_gemma":[0.9800781,0.001048073,0.00020534878,0.0074346554,0.0009370654,0.00005688479,0.00029958543,0.00006162623,0.0098786475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978975,0.000057123645,0.0004805469,0.0005035295,0.0005281141,0.0005331752],"domain_scores_gemma":[0.99874926,0.00006590468,0.00011659699,0.0005834596,0.00006280935,0.00042195647],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046293365,0.00032923877,0.0007039877,0.00039330465,0.000035172776,0.000014052677,0.00015641261,0.00012582997,0.0022239168],"category_scores_gemma":[0.00013438454,0.0002360115,0.00010758435,0.00042803603,0.00011422629,0.00012080046,0.000070655864,0.00025929842,0.00048555544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007060172,0.0007181598,0.8718318,0.0004294701,0.0004918909,0.0005590042,0.0007869977,0.0000024996798,0.054839328,0.00021316507,0.0386451,0.030776571],"study_design_scores_gemma":[0.04903094,0.003656852,0.79359144,0.004290652,0.00041870793,0.0000530125,0.00022755955,0.00011389696,0.017391695,0.00015475684,0.13042663,0.0006438432],"about_ca_topic_score_codex":0.000059383983,"about_ca_topic_score_gemma":0.000009083378,"teacher_disagreement_score":0.091781534,"about_ca_system_score_codex":0.00017642214,"about_ca_system_score_gemma":0.000102529375,"threshold_uncertainty_score":0.99868816},"labels":[],"label_agreement":null},{"id":"W2993540759","doi":"10.1111/dom.13938","title":"Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Manitoba; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Baseline (sea); Internal medicine; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.00789071885382023,"score_gpt":0.20363925178007017,"score_spread":0.19574853292624994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993540759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919058,0.07953996,0.000004571287,0.0003399247,0.00013429021,0.00062472833,0.00004772934,0.000032708318,0.00021806771],"genre_scores_gemma":[0.9896763,0.0081321,0.0001018587,0.0016706819,0.000068244226,0.000029572706,0.00003493615,0.000019456582,0.00026687243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988846,0.00005719513,0.00020218798,0.00030713793,0.00026998075,0.00027885672],"domain_scores_gemma":[0.9991484,0.00006210153,0.00010730583,0.0004411106,0.000074745534,0.00016631812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051053456,0.00021186355,0.00062122574,0.00007815413,0.000077406665,0.000030090714,0.000091902664,0.000071215734,0.000035861325],"category_scores_gemma":[0.00008309016,0.00013950714,0.00016993277,0.00015566322,0.00009246443,0.00012682866,0.00010182655,0.00010726863,0.000007639127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049745107,0.0003364631,0.90668637,0.00047335646,0.0026345449,0.000002848227,0.00036868232,0.000026514088,0.017983373,0.00028478823,0.0009539251,0.07019938],"study_design_scores_gemma":[0.0035750456,0.00009591983,0.8384235,0.00018568808,0.00094608316,7.8533884e-7,0.00011250853,0.00009618122,0.058363724,0.000050214752,0.09793904,0.00021129289],"about_ca_topic_score_codex":0.000036278805,"about_ca_topic_score_gemma":0.0000011167945,"teacher_disagreement_score":0.09698511,"about_ca_system_score_codex":0.000007690649,"about_ca_system_score_gemma":0.000013593027,"threshold_uncertainty_score":0.5688936},"labels":[],"label_agreement":null},{"id":"W2994385868","doi":"10.1016/j.peptides.2019.170228","title":"Cardiovascular biology of the GIP receptor","year":2019,"lang":"en","type":"review","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Adipose tissue; Gastric inhibitory polypeptide; Obesity; Biology; Receptor; Type 2 diabetes; Diabetes mellitus; White adipose tissue; Insulin; Medicine; Glucagon","score_opus":0.06058993151663128,"score_gpt":0.3179373208452649,"score_spread":0.2573473893286336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994385868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025432884,0.98683244,0.0000020763646,0.000028262413,0.0005351329,0.0011585995,0.000021728682,0.000020035563,0.011376313],"genre_scores_gemma":[0.000037035068,0.9899974,0.0001390436,0.00002949758,0.00015661702,0.00007797584,0.00009700408,0.000028553453,0.009436893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991188,0.00008656135,0.0002639036,0.0002338789,0.00013475289,0.00016209194],"domain_scores_gemma":[0.99889475,0.000059939266,0.00014386438,0.00084071123,0.000031140346,0.000029580166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001727407,0.00020892866,0.0016067878,0.00007465557,0.000017182478,0.000004442282,0.00017749815,0.00012847145,0.00011723014],"category_scores_gemma":[0.000047477974,0.00010464017,0.001737675,0.00015078721,0.00007002826,0.000011822675,0.00013214155,0.00011415741,0.00039535554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000012166222,0.000037365586,0.00010287613,0.016245635,0.0033507717,8.4511333e-7,0.000010623255,1.1246441e-7,6.5704984e-7,0.00033234025,0.0040451507,0.9758724],"study_design_scores_gemma":[0.00019088289,0.00007440537,0.000025184023,0.0063511534,0.007149851,0.0000015420017,0.000003826545,9.066637e-8,0.0000074943164,0.000014779199,0.986093,0.000087794026],"about_ca_topic_score_codex":0.000020719795,"about_ca_topic_score_gemma":6.701536e-7,"teacher_disagreement_score":0.98204786,"about_ca_system_score_codex":0.00006003105,"about_ca_system_score_gemma":0.000079975405,"threshold_uncertainty_score":0.50816274},"labels":[],"label_agreement":null},{"id":"W2994806186","doi":"","title":"Sodium-Glucose Cotransporter-2 Inhibitor Use and the Risk of Acute Kidney Injury in Older Adults in Routine Clinical Practice: A Population-Based Cohort Study","year":2019,"lang":"en","type":"article","venue":"Scholarship@Western (Western University)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Lawson Health Research Institute; Canadian Institutes of Health Research; Schulich School of Medicine and Dentistry, Western University; Ontario Ministry of Health and Long-Term Care; Schulich School of Medicine and Dentistry; Academic Medical Organization of Southwestern Ontario","keywords":"Medicine; Acute kidney injury; Cohort; Population; Kidney disease; Cohort study; Intensive care medicine; Internal medicine; Emergency medicine; Environmental health","score_opus":0.03020975672762915,"score_gpt":0.32357714198059656,"score_spread":0.2933673852529674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994806186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564004,0.000020053962,0.000008523406,0.00033485383,0.00017195713,0.0036787943,0.00006326878,0.00004086601,0.00004163495],"genre_scores_gemma":[0.9985365,0.00012987711,0.000049810144,0.0005376887,0.000028106191,0.0000089149935,0.00013001233,0.00002996836,0.00054910104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997225,0.0007412499,0.0006574578,0.0006083044,0.00045539858,0.0003126173],"domain_scores_gemma":[0.99819833,0.00037284987,0.0004254042,0.0006516744,0.00014617226,0.00020555581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015539938,0.00028937293,0.0007444994,0.0005294572,0.00005142475,0.000074761905,0.00022018104,0.00016293813,0.000017013348],"category_scores_gemma":[0.00022119675,0.00023516073,0.0001560363,0.0005178575,0.00010903703,0.0011334593,0.00014049707,0.00060292677,0.000020114447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068188286,0.002309508,0.9889652,0.000090142574,0.0005515325,0.0003143201,0.00053525995,0.0000030975643,0.000008300773,0.000010984087,6.951105e-7,0.00039212158],"study_design_scores_gemma":[0.032628767,0.0008118443,0.9636522,0.0005561098,0.0016210603,0.0000021967523,0.00036007696,0.0000062624886,0.0000729987,0.0000047940407,0.00007954455,0.0002041321],"about_ca_topic_score_codex":0.00024855568,"about_ca_topic_score_gemma":0.001080953,"teacher_disagreement_score":0.025809936,"about_ca_system_score_codex":0.00016079326,"about_ca_system_score_gemma":0.000104258346,"threshold_uncertainty_score":0.9589576},"labels":[],"label_agreement":null},{"id":"W2995051978","doi":"10.1111/dom.13943","title":"Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near‐normoglycaemia","year":2019,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research","keywords":"Mount; Medicine; Exenatide; Diabetes mellitus; Metformin; Family medicine; Gerontology; Library science; History; Type 2 diabetes; Engineering; Endocrinology","score_opus":0.012862102025733136,"score_gpt":0.24962455513296092,"score_spread":0.2367624531072278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995051978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996485,0.0050511807,0.000010429057,0.012304686,0.0001503781,0.0021608842,0.000025098247,0.000017232083,0.00031524722],"genre_scores_gemma":[0.97203255,0.0018173102,0.00028506777,0.024418807,0.00015898197,0.00014976933,0.00083807186,0.000027261707,0.0002721967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821377,0.00025604924,0.0004429682,0.0003671275,0.00045172567,0.0002683363],"domain_scores_gemma":[0.99813646,0.0008362444,0.00045096586,0.00039826374,0.00014774116,0.000030353667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006108508,0.00033710874,0.0010555807,0.00033484664,0.000072175324,0.00003741602,0.0001455093,0.0002680767,0.0000048665133],"category_scores_gemma":[0.000102821905,0.0002370296,0.000100652825,0.00030339777,0.00014375758,0.00018752395,0.00004461231,0.00047448333,0.0000039913452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010180383,0.008796736,0.45196518,0.031700216,0.008139756,0.00009926467,0.071797304,0.00015146035,0.038825933,0.017722731,0.22172238,0.148061],"study_design_scores_gemma":[0.0077978694,0.00078811747,0.9228035,0.00087436405,0.0011418583,0.0000015683946,0.00012706085,0.0013241624,0.025033562,0.0008342881,0.038885266,0.0003883536],"about_ca_topic_score_codex":0.00005505416,"about_ca_topic_score_gemma":0.0000029712012,"teacher_disagreement_score":0.47083837,"about_ca_system_score_codex":0.000029888313,"about_ca_system_score_gemma":0.00004266226,"threshold_uncertainty_score":0.96657866},"labels":[],"label_agreement":null},{"id":"W2995061256","doi":"10.1002/ejhf.1663","title":"Efficacy of Empagliflozin on Heart Failure and Renal Outcomes in Patients with Atrial Fibrillation: Data from the EMPA-REG OUTCOME Trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Internal medicine; Hazard ratio; Atrial fibrillation; Heart failure; Cardiology; Confidence interval; Diabetes mellitus; Clinical endpoint; Adverse effect; Randomized controlled trial; Type 2 diabetes; Endocrinology","score_opus":0.025114661905414865,"score_gpt":0.2705442719564672,"score_spread":0.24542961005105232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995061256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494214,0.00008117702,0.0000027615247,0.013755177,0.00024280434,0.00084451045,0.000039651542,0.000009205468,0.00008256908],"genre_scores_gemma":[0.99657595,0.000004121333,0.002209394,0.0003158741,0.00059857045,2.0850382e-7,0.0000800319,0.00003177713,0.000184058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979191,0.00035814382,0.00069211243,0.00025511472,0.00058187573,0.00019365312],"domain_scores_gemma":[0.9984655,0.00034532676,0.00034255564,0.0006514191,0.00008525221,0.00010998661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007798239,0.00020983636,0.0006636454,0.0001364313,0.000041723233,0.000044011438,0.00022429334,0.000031645563,0.00012540935],"category_scores_gemma":[0.000190396,0.00011251125,0.00017028609,0.00013912702,0.000054247692,0.00020752894,0.00014468785,0.00028686065,0.000063670064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016137363,0.00015264974,0.9613866,0.000013838714,0.00034487853,0.000022693564,0.00011425148,0.000061369596,0.000022485408,0.0000070578685,0.02126857,0.00046823145],"study_design_scores_gemma":[0.07994057,0.0044218944,0.8228875,0.000290295,0.00026825062,0.0000038255116,0.00007941633,0.000009178669,0.000012360247,0.0000023058328,0.09198154,0.00010286803],"about_ca_topic_score_codex":0.000008003161,"about_ca_topic_score_gemma":0.000014600424,"teacher_disagreement_score":0.13849911,"about_ca_system_score_codex":0.000029997118,"about_ca_system_score_gemma":0.000046636804,"threshold_uncertainty_score":0.45880753},"labels":[],"label_agreement":null},{"id":"W2995152480","doi":"10.2337/dc19-1476","title":"Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study","year":2019,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; Hazard ratio; Hypoglycemia; Placebo; Diabetes mellitus; Internal medicine; TIMI; Adverse effect; Type 2 diabetes; Renal function; Endocrinology; Myocardial infarction; Confidence interval","score_opus":0.009779830887110683,"score_gpt":0.2461932095256478,"score_spread":0.23641337863853712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995152480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994671,0.0016017671,9.642606e-7,0.0004785839,0.000046672965,0.0014235879,0.000042636617,0.000016024005,0.0017187962],"genre_scores_gemma":[0.9991851,0.00003814753,0.00003785145,0.00037939375,0.000028705232,0.00004612396,0.00019685345,0.000011300143,0.00007653314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890393,0.00012690354,0.0002271942,0.00026520976,0.00027476187,0.00020199477],"domain_scores_gemma":[0.9987588,0.000438745,0.000067740075,0.0006548052,0.000045029017,0.00003489565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022915343,0.00014886854,0.000411108,0.000110616005,0.00004342206,0.000028356484,0.00018898949,0.00003936861,0.0001125455],"category_scores_gemma":[0.000039704537,0.00007865698,0.00011750637,0.0005486977,0.000042702548,0.00004180917,0.000090795176,0.000109803885,0.00003083003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004902654,0.00026846628,0.9754541,0.000029288596,0.0014465126,0.0000036961726,0.006234617,0.00003106759,0.00005033373,0.00002531764,0.00021842963,0.016189156],"study_design_scores_gemma":[0.003230128,0.000715261,0.9731361,0.000050856383,0.0028469907,2.1191328e-8,0.017785555,0.00008497566,0.00009720202,0.000015384187,0.0019558927,0.00008160322],"about_ca_topic_score_codex":0.0001089051,"about_ca_topic_score_gemma":0.00025000205,"teacher_disagreement_score":0.016107554,"about_ca_system_score_codex":0.000029958546,"about_ca_system_score_gemma":0.00001288246,"threshold_uncertainty_score":0.32075387},"labels":[],"label_agreement":null},{"id":"W2995255548","doi":"10.1093/cvr/cvz328","title":"The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction","year":2019,"lang":"en","type":"article","venue":"Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Ejection fraction; Heart failure; Cardiology; Internal medicine; Medicine","score_opus":0.04444521316683675,"score_gpt":0.3313884357896185,"score_spread":0.28694322262278177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995255548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623973,0.002873184,0.000026580634,0.0030864433,0.00010400291,0.0037618405,6.5703006e-7,0.000009280754,0.0038982993],"genre_scores_gemma":[0.99736065,0.0006245663,0.000088913184,0.00001530544,0.00022342573,0.00022309695,0.000010983864,0.000016365902,0.0014366778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766535,0.00054422405,0.00018981016,0.00023050363,0.0010899116,0.0002802057],"domain_scores_gemma":[0.99843335,0.00032338986,0.000045578705,0.0010200823,0.0001396119,0.000037985345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025442925,0.000112348236,0.0003635107,0.00014148289,0.00013162348,0.00003982193,0.00014635935,0.00005326796,0.000023381532],"category_scores_gemma":[0.00006781379,0.00004644832,0.00043572136,0.0005911383,0.00012083569,0.00005981775,0.000028741384,0.00024125887,0.000016124404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08740699,0.005066994,0.069642276,0.0007884824,0.03803129,0.00016283161,0.01312968,0.0022005693,0.0091665825,0.0023656513,0.05513418,0.71690446],"study_design_scores_gemma":[0.06695064,0.010833907,0.060798664,0.0003319534,0.0013675807,0.000026562204,0.01611496,0.00021009233,0.0074394164,0.00013627284,0.83561397,0.00017597996],"about_ca_topic_score_codex":0.0006619644,"about_ca_topic_score_gemma":0.00003814804,"teacher_disagreement_score":0.7804798,"about_ca_system_score_codex":0.00018487178,"about_ca_system_score_gemma":0.00014899184,"threshold_uncertainty_score":0.18941075},"labels":[],"label_agreement":null},{"id":"W2995378877","doi":"10.14740/jem.v9i6.627","title":"Mitochondrial Diabetes Treated With a Sodium-Glucose Co-Transporter 2 Inhibitor","year":2019,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Transporter; Oxidative stress; Mitochondrion; Glucose transporter; Pharmacology; Autophagy; Type 2 diabetes; Internal medicine; Endocrinology; Biochemistry; Insulin; Apoptosis; Chemistry","score_opus":0.007754131242042849,"score_gpt":0.23436801650107797,"score_spread":0.2266138852590351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995378877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99261194,0.0032940432,0.0000055497603,0.0008208608,0.0005847426,0.00030916024,0.0000041903713,0.000018691775,0.0023508382],"genre_scores_gemma":[0.99523073,0.00058209617,0.00086000573,0.00042235942,0.0005014613,0.000008763155,0.000009108633,0.000018929755,0.0023665435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998977,0.000030860938,0.00031484597,0.00016532339,0.00017997468,0.00033201094],"domain_scores_gemma":[0.9993529,0.000033320528,0.0001943959,0.00015325095,0.00012182526,0.0001443156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057834717,0.000182639,0.0006167035,0.00032759798,0.00003442253,0.000015218351,0.00006169407,0.00006586547,0.00017125944],"category_scores_gemma":[0.000010385616,0.00011289343,0.00011534621,0.00011765743,0.00009703752,0.00016039191,0.000013946842,0.00021600485,0.000029864726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030843068,0.0010853191,0.84525275,0.00018982362,0.0037576293,0.0011813918,0.00035519656,0.0000021942526,0.11428132,0.0021414552,0.0038786216,0.024789989],"study_design_scores_gemma":[0.032088473,0.003246533,0.41177642,0.00025185203,0.0034717785,0.0003678232,0.00022340278,0.000005614163,0.14707296,0.00021254823,0.40095136,0.00033123253],"about_ca_topic_score_codex":0.0000020384903,"about_ca_topic_score_gemma":0.0000011269541,"teacher_disagreement_score":0.43347633,"about_ca_system_score_codex":0.000014205072,"about_ca_system_score_gemma":0.000045684446,"threshold_uncertainty_score":0.46036604},"labels":[],"label_agreement":null},{"id":"W2996266725","doi":"10.1038/s41573-019-0053-0","title":"Advances in oral peptide therapeutics","year":2019,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":625,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden","keywords":"Medicine; Exenatide; Calcitonin; Pharmacology; Clinical trial; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.04136762818510996,"score_gpt":0.38035474860624024,"score_spread":0.3389871204211303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996266725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014102787,0.9704995,0.0000033973868,0.0000953043,0.0008246092,0.0046023643,0.000026681135,0.000039032537,0.023907688],"genre_scores_gemma":[0.0000027318597,0.9749622,0.0002224214,0.00094654167,0.00025987322,0.00034009924,0.00060461246,0.00009248194,0.022569075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972253,0.00024920178,0.0009611677,0.0007157344,0.00037452736,0.00047410696],"domain_scores_gemma":[0.99827594,0.00014851628,0.00051774323,0.00095271517,0.000026912297,0.00007820559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053291285,0.00078049116,0.0044580447,0.0003483236,0.000024857174,0.00007594138,0.000327821,0.0005009945,0.00005489297],"category_scores_gemma":[0.00005509862,0.00046584045,0.0013808325,0.0006388934,0.000044356428,0.00049165974,0.0001387513,0.0014263466,0.00071403297],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008117378,0.00018649768,0.000056528646,0.071978234,0.00018751278,0.000035762114,0.000012442512,1.199987e-7,2.8479755e-8,0.0004421485,0.0049602115,0.9221324],"study_design_scores_gemma":[0.0004654459,0.000055433273,0.00000841017,0.06791563,0.0042746714,0.000007942048,0.000007914972,5.7324553e-7,2.0210244e-7,0.00003850165,0.9268382,0.00038705018],"about_ca_topic_score_codex":0.0000023948544,"about_ca_topic_score_gemma":0.000027976912,"teacher_disagreement_score":0.921878,"about_ca_system_score_codex":0.00036544784,"about_ca_system_score_gemma":0.00021241533,"threshold_uncertainty_score":0.99977934},"labels":[],"label_agreement":null},{"id":"W2996401508","doi":"10.1210/clinem/dgz261","title":"Postprandial Dyslipidemia, Hyperinsulinemia, and Impaired Gut Peptides/Bile Acids in Adolescents with Obesity","year":2019,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Dyslipidemia; Postprandial; Hyperinsulinemia; Internal medicine; Endocrinology; Obesity; Medicine; Insulin resistance; Insulin","score_opus":0.02166279664166299,"score_gpt":0.314925528713223,"score_spread":0.29326273207156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996401508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338704,0.0025142194,0.000011560649,0.0023903456,0.0006429764,0.00050757546,0.0000016347861,0.000017332422,0.00052733335],"genre_scores_gemma":[0.99505913,0.0019677347,0.00042754976,0.0016086169,0.0005752121,0.0000039923207,0.0000014981895,0.000021510727,0.0003347762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997478,0.00040285074,0.0011279553,0.00022530263,0.0003147718,0.0004510972],"domain_scores_gemma":[0.9984383,0.00029905065,0.0005306361,0.00038062967,0.00013868937,0.00021270056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013367238,0.00023055203,0.001268716,0.0001744224,0.00004168878,0.0000119156175,0.00024229345,0.0001243907,0.000052160383],"category_scores_gemma":[0.00032964433,0.00012567885,0.00022115486,0.00015760773,0.0002774353,0.00014457901,0.00013921323,0.0008782053,0.00004857123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062978957,0.00075411133,0.97946143,0.00006184512,0.00037670173,0.00018871139,0.00016114063,0.00001431382,0.00032328317,0.0001668986,0.0001637064,0.012029984],"study_design_scores_gemma":[0.017003706,0.0022990687,0.9733183,0.0002559914,0.0008436777,0.000263594,0.00020484377,0.000031144453,0.0000998363,0.0001411289,0.0054191705,0.00011958973],"about_ca_topic_score_codex":0.000034742443,"about_ca_topic_score_gemma":0.000025234158,"teacher_disagreement_score":0.011910395,"about_ca_system_score_codex":0.000027126247,"about_ca_system_score_gemma":0.00012661387,"threshold_uncertainty_score":0.5125035},"labels":[],"label_agreement":null},{"id":"W2996500186","doi":"10.1002/ejhf.1673","title":"European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure","year":2019,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Relypsa; Pfizer; Servier; Boston Scientific Corporation; Sanofi; AstraZeneca","keywords":"Dapagliflozin; Empagliflozin; Medicine; Heart failure; Saxagliptin; Canagliflozin; Ejection fraction; Internal medicine; Cardiology; Liraglutide; Type 2 diabetes; Benzhydryl compounds; Diabetes mellitus; Intensive care medicine; Sitagliptin; Endocrinology","score_opus":0.0038454431696052565,"score_gpt":0.186350849677464,"score_spread":0.18250540650785874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996500186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758358,0.0001406578,0.000015664897,0.022238996,0.00007638377,0.00049896195,0.000008877704,0.000013201588,0.0011714764],"genre_scores_gemma":[0.9959434,0.00002493872,0.0027239507,0.0007919426,0.00016605564,6.954544e-7,0.000018906756,0.000046585807,0.00028349928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796206,0.00046917357,0.0005635548,0.000217707,0.0005194985,0.00026798926],"domain_scores_gemma":[0.9988858,0.00009877402,0.00040826696,0.0002803491,0.0002089279,0.00011784908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012929422,0.00022145969,0.00057519536,0.00011476381,0.00006072563,0.000026297394,0.00011216259,0.00004938205,0.00006273672],"category_scores_gemma":[0.000039657083,0.00014452304,0.00024398141,0.00019041295,0.000054344055,0.0002177363,0.0000747176,0.00042280758,0.000037597725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053975574,0.00016945552,0.90164906,0.00008101103,0.00047535868,0.000005736559,0.0008372921,0.00015116489,0.00965548,0.000042464115,0.08571533,0.0006779133],"study_design_scores_gemma":[0.0049472116,0.0020553072,0.78220564,0.0007477004,0.00017647212,0.000010580305,0.00090936804,0.000004517989,0.0010652151,0.000009375139,0.20773645,0.00013218843],"about_ca_topic_score_codex":0.0000051194843,"about_ca_topic_score_gemma":0.0000030807062,"teacher_disagreement_score":0.12202111,"about_ca_system_score_codex":0.000121805155,"about_ca_system_score_gemma":0.00004826279,"threshold_uncertainty_score":0.58934784},"labels":[],"label_agreement":null},{"id":"W2996648211","doi":"10.1136/bmjdrc-2019-000884","title":"Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study","year":2019,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Propensity score matching; Basal insulin; Exenatide; Basal (medicine); Insulin; Endocrinology","score_opus":0.05430770626494246,"score_gpt":0.413608602435735,"score_spread":0.3593008961707925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996648211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816482,0.00006779724,3.496049e-8,0.00024072693,0.00011506864,0.01188553,0.00002858492,0.000034948793,0.0059790798],"genre_scores_gemma":[0.99788,0.000015238029,0.00014409254,0.00020704704,0.000064785905,0.0008630319,0.00017906408,0.00006717993,0.0005796019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627084,0.0007301457,0.00065725023,0.00078522414,0.00071960944,0.00083692325],"domain_scores_gemma":[0.99717844,0.0011322207,0.00021334388,0.00086148287,0.0003815862,0.00023290656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020912657,0.0003374533,0.000901724,0.00033471803,0.00024184679,0.0003956453,0.00048032872,0.000067818764,0.00008932341],"category_scores_gemma":[0.00030604232,0.00020145992,0.00006419374,0.00062683853,0.00034156267,0.00043436605,0.001022509,0.00062043837,0.00007689438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041914673,0.0006234561,0.9934997,0.00015786743,0.0006411834,0.000015488153,0.0010496068,0.00009276866,9.0567437e-7,0.000016490552,0.0003744623,0.0031089203],"study_design_scores_gemma":[0.009070614,0.00371949,0.97915035,0.0005565073,0.00013908034,6.395458e-8,0.0062265233,0.0007162063,0.0000138250325,0.000017272752,0.000116380914,0.00027367653],"about_ca_topic_score_codex":0.0018781561,"about_ca_topic_score_gemma":0.014762177,"teacher_disagreement_score":0.01623173,"about_ca_system_score_codex":0.0003268975,"about_ca_system_score_gemma":0.00030371107,"threshold_uncertainty_score":0.82376415},"labels":[],"label_agreement":null},{"id":"W2996892147","doi":"","title":"The weight-lowering effects of glucagon-like peptide-1 receptor agonists and the risk of breast cancer among patients with type 2 diabetes","year":2019,"lang":"en","type":"article","venue":"Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Breast cancer; Medicine; Type 2 diabetes; Glucagon-like peptide 1 receptor; Internal medicine; Endocrinology; Glucagon-like peptide-1; Receptor; Diabetes mellitus; Oncology; Cancer; Agonist","score_opus":0.0044370727466468635,"score_gpt":0.22651838325979118,"score_spread":0.2220813105131443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996892147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952449,0.0022424976,0.0000036660872,0.0006205907,0.0005071361,0.0008356751,0.000009121252,0.0000124397575,0.00052394875],"genre_scores_gemma":[0.9971071,0.0017680295,0.00009090117,0.00020484946,0.000046011217,0.00005941282,0.000013870657,0.000015530582,0.00069429475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888974,0.00025961985,0.00028848252,0.00020202888,0.0000908946,0.00026921794],"domain_scores_gemma":[0.99672705,0.002455087,0.0003439866,0.00033493683,0.00008793427,0.00005097663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006627788,0.00014340493,0.00058852683,0.000033480956,0.00006096288,0.0000026843593,0.000095131276,0.000056383902,0.000037009744],"category_scores_gemma":[0.00036062312,0.000061099665,0.00007151197,0.0000958526,0.00044580433,0.00003514125,0.00008191574,0.000111458605,0.000009087821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044743574,0.00006926882,0.99023604,0.00017882895,0.0007683326,2.3335649e-7,0.00011322787,0.000009645774,0.00007440642,0.00028607892,0.0011854025,0.0066311057],"study_design_scores_gemma":[0.0032786352,0.0006063945,0.99249554,0.00022811696,0.00040521668,1.5271038e-7,0.000016413322,0.000090626345,0.00039326315,0.00012343134,0.0022958987,0.00006634075],"about_ca_topic_score_codex":0.00024296026,"about_ca_topic_score_gemma":0.000036603247,"teacher_disagreement_score":0.006564765,"about_ca_system_score_codex":0.00002664018,"about_ca_system_score_gemma":0.000018044613,"threshold_uncertainty_score":0.2491572},"labels":[],"label_agreement":null},{"id":"W2998054194","doi":"10.1056/nejmc1913157","title":"Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes","year":2019,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Liraglutide","score_opus":0.0179894320149499,"score_gpt":0.2519230647323942,"score_spread":0.23393363271744427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998054194","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18379213,0.040445052,0.00001014937,0.7696925,0.0026361444,0.00061157264,0.0000034635268,0.000019428475,0.0027895442],"genre_scores_gemma":[0.104327366,0.010707528,0.0013436791,0.81398076,0.03416,0.000007681206,0.0001936832,0.00021425921,0.035065062],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979063,0.00011251748,0.0005962837,0.00023213304,0.00080527546,0.0003474424],"domain_scores_gemma":[0.99884224,0.0002753241,0.00025039125,0.0003647891,0.0001306869,0.00013659004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095819624,0.00033465432,0.0020134868,0.00059166475,0.000014443246,0.000012782772,0.00012685852,0.00024494817,0.00015877931],"category_scores_gemma":[0.000337836,0.00019776808,0.0002486509,0.00016948306,0.00008137356,0.000055180215,0.000047035617,0.0011262626,0.0000146007715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094752315,0.000035020003,0.114526145,0.000378953,0.0029202686,0.002544518,0.00013825762,0.000006463074,0.000015580958,0.000003156079,0.79253656,0.08680033],"study_design_scores_gemma":[0.040336944,0.001956229,0.019847628,0.0013280464,0.0028244813,0.00014223046,0.00002742591,0.000007933625,0.000009842926,0.00012699045,0.9332283,0.00016395166],"about_ca_topic_score_codex":0.000075469645,"about_ca_topic_score_gemma":0.000008651194,"teacher_disagreement_score":0.14069174,"about_ca_system_score_codex":0.0000783417,"about_ca_system_score_gemma":0.00012254743,"threshold_uncertainty_score":0.8064748},"labels":[],"label_agreement":null},{"id":"W2998114686","doi":"10.1016/j.mayocp.2019.07.017","title":"A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study","year":2020,"lang":"en","type":"article","venue":"Mayo Clinic Proceedings","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; St Joseph's Health Care; Institute for Clinical Evaluative Sciences; Seven Oaks General Hospital; Western University; University of Manitoba","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Sulfonylurea; Metformin; Retrospective cohort study; Type 2 diabetes; Kidney disease; Diabetes mellitus; Internal medicine; Cohort; Cohort study; Endocrinology","score_opus":0.015820410306356086,"score_gpt":0.27860605900678914,"score_spread":0.2627856487004331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998114686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957688,0.00014474474,0.0000013546136,0.000412666,0.00003634587,0.0022751568,0.0000145349995,0.00004625134,0.0013001339],"genre_scores_gemma":[0.99923456,0.000041310956,0.00008522394,0.00031642438,0.000043374363,0.00007725428,0.00010717834,0.000021363248,0.00007330025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986042,0.000010053688,0.00043417033,0.00037900344,0.0003595422,0.00021307397],"domain_scores_gemma":[0.99921155,0.000029713521,0.00022914886,0.00009357045,0.00020996027,0.00022606416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024870774,0.00017871466,0.0006176105,0.00010346504,0.0000339383,0.00001791315,0.00006530332,0.000042396074,0.00007661417],"category_scores_gemma":[0.00041585136,0.00014108972,0.000035426696,0.0004433048,0.000061514016,0.00017837211,0.000084954445,0.00014502041,0.000008950136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001549669,0.0011419015,0.993814,0.0003238797,0.00029997446,0.0000018429557,0.0011104869,2.4127138e-7,0.000009348312,0.00003860211,0.0008329773,0.0008770783],"study_design_scores_gemma":[0.007599393,0.007815745,0.9824353,0.00021191868,0.0006788606,2.5564454e-8,0.00033459795,0.0002862168,0.000069981914,0.000024468958,0.00041157988,0.0001319538],"about_ca_topic_score_codex":0.0000053484437,"about_ca_topic_score_gemma":0.0000032002338,"teacher_disagreement_score":0.01137874,"about_ca_system_score_codex":0.00017452806,"about_ca_system_score_gemma":0.00008361184,"threshold_uncertainty_score":0.5753472},"labels":[],"label_agreement":null},{"id":"W2998214503","doi":"10.1016/j.jns.2019.10.1195","title":"Utilization of monotherapy and combination therapies in advanced Parkinson's disease patients during levodopa-carbidopa intestinal gel treatment from the cosmos study","year":2019,"lang":"en","type":"article","venue":"Journal of the Neurological Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Parkinson's disease; Physical therapy; Internal medicine; Disease","score_opus":0.030025855752420068,"score_gpt":0.2764949379360462,"score_spread":0.24646908218362612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998214503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740124,0.00030122456,0.0000014408967,0.0015335942,0.000121641,0.0005957835,0.0000011567573,0.0000033049905,0.000040617808],"genre_scores_gemma":[0.9995401,0.0001879847,0.00003463341,0.00019148576,0.000013250693,0.0000056875188,3.8928255e-7,0.000002427905,0.000024074072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991354,0.00014538951,0.00020468002,0.00012437988,0.00029976547,0.000090412585],"domain_scores_gemma":[0.99942917,0.00017046843,0.00023158782,0.00009428915,0.000040372557,0.000034099154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020268971,0.00007961609,0.00016752045,0.000042288306,0.00006606125,0.000020707821,0.00014693264,0.000010873489,0.000013935502],"category_scores_gemma":[0.00008233697,0.000031615717,0.000050432656,0.00016004636,0.000109219574,0.00010259672,0.000040825173,0.00006085559,4.0488788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005216092,0.0010060284,0.98848754,0.0000027362357,0.000022355294,0.0000047421345,0.00029131072,0.00015409429,0.00020803168,0.00001898084,0.0000025160048,0.009280068],"study_design_scores_gemma":[0.003193774,0.004954759,0.9903075,0.000035853238,0.000052971714,7.62736e-7,0.00024366524,0.00045688392,0.00013675875,0.00049260457,0.00009576887,0.000028698814],"about_ca_topic_score_codex":0.000013936401,"about_ca_topic_score_gemma":0.000007353831,"teacher_disagreement_score":0.009251369,"about_ca_system_score_codex":0.000025086203,"about_ca_system_score_gemma":0.00001733173,"threshold_uncertainty_score":0.12892514},"labels":[],"label_agreement":null},{"id":"W2998275298","doi":"10.1111/dom.13955","title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Cardiology; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.01189550944405662,"score_gpt":0.22508104765261885,"score_spread":0.21318553820856223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998275298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8826075,0.11582862,0.000011203789,0.0003461684,0.00018490884,0.0007533319,0.000025429106,0.00009759483,0.0001452065],"genre_scores_gemma":[0.98991245,0.008626434,0.0004680508,0.0005279449,0.00024337893,0.000056216635,0.000048649857,0.000043851076,0.000073019066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747556,0.00021972015,0.0003385422,0.00074156537,0.00046634107,0.00075826043],"domain_scores_gemma":[0.99890834,0.00008880705,0.00007789529,0.00044590296,0.000090278445,0.0003887594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009692151,0.00038775755,0.0012659399,0.00013607845,0.00020525507,0.000053420194,0.00012312061,0.00014546883,0.000011303938],"category_scores_gemma":[0.00038773174,0.00035042164,0.00046126483,0.0005150799,0.00011978248,0.00021953456,0.00029560548,0.0003025892,0.000018120985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051518346,0.00025964936,0.89157605,0.00079770386,0.0068245707,0.000059598606,0.0020453306,0.0002581471,0.00083753385,0.000076406126,0.00015332353,0.09706018],"study_design_scores_gemma":[0.004480548,0.00016017622,0.9425772,0.00016451892,0.003679534,0.0000011537039,0.00039280707,0.0006269977,0.005569321,0.0002487963,0.041596044,0.0005029184],"about_ca_topic_score_codex":0.000085757056,"about_ca_topic_score_gemma":0.0000027731337,"teacher_disagreement_score":0.107304916,"about_ca_system_score_codex":0.000037488986,"about_ca_system_score_gemma":0.000030404422,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W2998713219","doi":"10.1161/jaha.119.012940","title":"Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus","year":2020,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metformin; Hazard ratio; Internal medicine; Diabetes mellitus; Type 2 diabetes; Type 2 Diabetes Mellitus; Dipeptidyl peptidase-4; Myocardial infarction; Proportional hazards model; Dipeptidyl peptidase-4 inhibitor; Heart failure; Unstable angina; Stroke (engine); Endocrinology; Confidence interval","score_opus":0.011070701661843747,"score_gpt":0.2465971729009189,"score_spread":0.23552647123907516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998713219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977001,0.000909844,0.00001240573,0.0008868202,0.0001274138,0.00027662492,9.850182e-7,0.0000043927166,0.00008144759],"genre_scores_gemma":[0.9992794,0.00014667594,0.00018288696,0.00029290695,0.000064786174,0.0000054416205,6.083921e-7,0.000008397471,0.000018928939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874884,0.0002730676,0.00030217753,0.00009490994,0.00041832522,0.00016270125],"domain_scores_gemma":[0.9992267,0.00027575085,0.000234084,0.000106497355,0.00009253303,0.00006444181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001207119,0.00008700506,0.0008270302,0.0001272358,0.000013401854,0.000009412704,0.00008525164,0.000021750637,0.000004125647],"category_scores_gemma":[0.0005693574,0.000060148755,0.0002650886,0.00068613025,0.000015480351,0.00007313309,0.00004376494,0.00012750739,0.000002812066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013374678,0.00009879294,0.9812461,0.00006147925,0.0006350704,0.0000032923551,0.0007335948,0.0002468273,0.0055735875,0.0000022702823,0.00010748095,0.0111577315],"study_design_scores_gemma":[0.001016221,0.0006881556,0.9755812,0.0002362356,0.00023893706,3.538353e-7,0.00036774913,0.00009219006,0.021100413,0.000026529693,0.00059068785,0.000061286315],"about_ca_topic_score_codex":0.00009372185,"about_ca_topic_score_gemma":0.0000054068587,"teacher_disagreement_score":0.015526826,"about_ca_system_score_codex":0.00037715072,"about_ca_system_score_gemma":0.000045879573,"threshold_uncertainty_score":0.2452795},"labels":[],"label_agreement":null},{"id":"W2998838100","doi":"10.1093/aje/kwz272","title":"Adaptive Treatment Strategies With Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database","year":2019,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de recherche du Québec – Nature et technologies; Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada","keywords":"Observational study; Censoring (clinical trials); Medicine; Personalized medicine; Survival analysis; Outcome (game theory); Disease; Intensive care medicine; Bioinformatics; Internal medicine","score_opus":0.10130524150680803,"score_gpt":0.37442803274611575,"score_spread":0.2731227912393077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998838100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933479,0.00024967108,0.004185996,0.0014192021,0.000102451595,0.0005533127,0.00002946975,0.000007110361,0.00010487665],"genre_scores_gemma":[0.9824448,0.00016961689,0.016536845,0.0005640373,0.00009746715,0.000022262557,0.000077997254,0.0000152192815,0.00007173997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986246,0.00029229058,0.00047414328,0.00019809784,0.00014015443,0.00027068876],"domain_scores_gemma":[0.997944,0.00074201135,0.0006260142,0.00036579266,0.00019139564,0.00013076111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005526448,0.00018326983,0.00095027825,0.00011386098,0.000035716315,0.0000043018304,0.000099000375,0.000021916827,0.000034012108],"category_scores_gemma":[0.000064940075,0.00008838419,0.00011707894,0.00023111295,0.00011416608,0.00012207463,0.000014088494,0.00004832607,0.000009423904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083812815,0.0013850991,0.96996635,0.000009262693,0.0014052105,0.00000637281,0.00044375364,0.0035879794,0.0004931802,0.0033983986,0.000029325127,0.018436935],"study_design_scores_gemma":[0.0053142854,0.10993902,0.8460355,0.00011420768,0.0016995346,0.000017853365,0.008177426,0.007765406,0.00021967119,0.00032001358,0.020128848,0.00026827064],"about_ca_topic_score_codex":0.00029748972,"about_ca_topic_score_gemma":0.00010018556,"teacher_disagreement_score":0.123930894,"about_ca_system_score_codex":0.00022636214,"about_ca_system_score_gemma":0.00017194093,"threshold_uncertainty_score":0.3604203},"labels":[],"label_agreement":null},{"id":"W2998893353","doi":"10.3390/ijms21020383","title":"Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue “The Biology and Pharmacology of Glucagon”","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Glucagon; Value (mathematics); Insulin; Isolation (microbiology); Pharmacology; Medicine; Endocrinology; Biology; Bioinformatics; Computer science","score_opus":0.0274933598906333,"score_gpt":0.3716048834573664,"score_spread":0.34411152356673314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998893353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8773278,0.0015238884,0.001406113,0.100387484,0.018330464,0.00042783047,0.000010289305,0.0000038124888,0.00058229157],"genre_scores_gemma":[0.94193065,0.0002561177,0.00069835025,0.0021967865,0.054900013,0.0000052340197,0.0000012057378,0.0000030572023,0.000008594737],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990152,0.00010275209,0.00030019856,0.00010242188,0.0003810541,0.00009835208],"domain_scores_gemma":[0.9989488,0.000358016,0.00033079533,0.00003937596,0.00027773198,0.000045267163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091747515,0.00006666694,0.00016463034,0.000043233384,0.00007510821,0.000023189355,0.0005112347,0.00002599383,0.000097419164],"category_scores_gemma":[0.00019639662,0.000029012368,0.000104483435,0.00009712774,0.00048831763,0.00006681316,0.00009414548,0.0001048112,5.4216787e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027025328,0.0003702281,0.0035673399,0.000058884296,0.003036653,0.0000808324,0.0022621492,0.0010618588,0.73927724,0.023100082,0.035053954,0.18942824],"study_design_scores_gemma":[0.006351595,0.00665476,0.0024517076,0.000088121276,0.0017603728,0.000079590216,0.002288678,0.005506868,0.32906887,0.0020425017,0.643551,0.00015595533],"about_ca_topic_score_codex":0.0000055497812,"about_ca_topic_score_gemma":2.2594027e-7,"teacher_disagreement_score":0.608497,"about_ca_system_score_codex":0.000013734267,"about_ca_system_score_gemma":0.000080370446,"threshold_uncertainty_score":0.17992266},"labels":[],"label_agreement":null},{"id":"W2998998206","doi":"10.1002/ejhf.1708","title":"Use of Sodium–Glucose Co-Transporter-2 Inhibitors in Patients with and without Type 2 Diabetes: Implications for Incident and Prevalent Heart Failure","year":2020,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of General Medical Sciences; AstraZeneca","keywords":"Medicine; Heart failure; Ejection fraction; Type 2 diabetes; Internal medicine; Cardiology; Diabetes mellitus; Heart failure with preserved ejection fraction; Endocrinology","score_opus":0.028997952413673055,"score_gpt":0.2814480441105888,"score_spread":0.2524500916969158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998998206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13451722,0.8571138,0.00002250795,0.0039429665,0.00011773559,0.004076418,0.00016718394,0.000025976875,0.000016219034],"genre_scores_gemma":[0.05377991,0.9241991,0.020188892,0.00050310005,0.00039108467,0.00005284313,0.0004348205,0.00030808145,0.00014218429],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997991,0.00020593066,0.00096313126,0.0003197537,0.00026468295,0.00025549697],"domain_scores_gemma":[0.99852633,0.00007909091,0.0006188855,0.00026569323,0.00023376392,0.00027621118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037693357,0.00038268554,0.0016001686,0.00032187413,0.000045503555,0.000051182447,0.000097639095,0.00006382454,0.000008567423],"category_scores_gemma":[0.00005892641,0.0002621405,0.00023447962,0.0002249523,0.000112961876,0.00019427235,0.000051585714,0.00034519949,0.000004165801],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038266738,0.00083307544,0.75517225,0.02011901,0.0015261013,0.00003203753,0.00032183097,0.0000011472825,0.000027894994,0.000020753381,0.041757286,0.17980593],"study_design_scores_gemma":[0.0024023275,0.0028749409,0.07232366,0.011818355,0.0019226781,0.000019720686,0.000019238236,3.9198835e-7,0.000009065639,0.0000015886844,0.9084106,0.00019745356],"about_ca_topic_score_codex":8.57708e-7,"about_ca_topic_score_gemma":0.000004368729,"teacher_disagreement_score":0.8666533,"about_ca_system_score_codex":0.00006717757,"about_ca_system_score_gemma":0.00013046566,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W3000040775","doi":"10.1016/s2213-8587(19)30423-1","title":"The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University; Population Health Research Institute; Hamilton Health Sciences","funders":"","keywords":"Dulaglutide; Medicine; Placebo; Stroke (engine); Modified Rankin Scale; Randomized controlled trial; Internal medicine; Diabetes mellitus; Clinical trial; Type 2 diabetes; Physical therapy; Exenatide; Ischemic stroke; Endocrinology; Alternative medicine","score_opus":0.029892093681518128,"score_gpt":0.28478468934896,"score_spread":0.2548925956674419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000040775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891767,0.0005695094,0.0000012631266,0.0074543487,0.00023801344,0.0008751657,0.000037397942,0.000039650313,0.0016079734],"genre_scores_gemma":[0.9980205,0.00012060457,0.000009172749,0.0012747735,0.00027973892,0.00010374393,0.000022855964,0.000015610316,0.0001529914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979975,0.00056827354,0.00032227347,0.00024303953,0.00026829966,0.00060061645],"domain_scores_gemma":[0.997891,0.000801585,0.00022804918,0.0009839921,0.00003539492,0.000059983013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048231063,0.00018557403,0.0008766823,0.0000804582,0.000106777516,0.000010641868,0.0005153961,0.000041308853,0.00004342878],"category_scores_gemma":[0.0002791565,0.00007873415,0.00034009205,0.00048507343,0.0003221543,0.00003395161,0.00017765672,0.00021629171,0.00001180364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031250935,0.00055759307,0.83883494,0.00029152984,0.026701199,0.00002732807,0.0016557763,0.00057936285,0.024950825,0.009155882,0.01118853,0.054806076],"study_design_scores_gemma":[0.09779402,0.032041766,0.40102446,0.00013161972,0.0315986,9.957997e-7,0.0008375093,0.0020692935,0.37641916,0.00040996567,0.05716437,0.00050823967],"about_ca_topic_score_codex":0.000009290389,"about_ca_topic_score_gemma":0.000033844557,"teacher_disagreement_score":0.43781048,"about_ca_system_score_codex":0.00002618835,"about_ca_system_score_gemma":0.000020908179,"threshold_uncertainty_score":0.32106853},"labels":[],"label_agreement":null},{"id":"W3001438287","doi":"10.1007/s40265-019-01245-3","title":"Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; Western University","funders":"Novo Nordisk; Novo Nordisk Fonden; Steno Diabetes Center Copenhagen","keywords":"Liraglutide; Medicine; Insulin degludec; Hypoglycemia; Type 2 diabetes; Regimen; Glycemic; Insulin; Glucagon-like peptide 1 receptor; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology; Insulin glargine; Agonist","score_opus":0.057567502740075806,"score_gpt":0.34438592346030833,"score_spread":0.2868184207202325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001438287","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030613306,0.98684967,0.0000038211874,0.00040312318,0.00011842562,0.0014710256,0.000015143344,0.00009516896,0.007982274],"genre_scores_gemma":[0.0033629532,0.9895079,0.0052341423,0.0009324902,0.00024014083,0.00015998779,0.0002874791,0.00007388638,0.00020100044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979713,0.00017193268,0.00082456996,0.00051529694,0.00020587686,0.00031101218],"domain_scores_gemma":[0.9983731,0.0008333829,0.00029167676,0.00026874722,0.000061324106,0.00017176614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037756024,0.00036727858,0.0017706295,0.00017346974,0.00007594443,0.00007967576,0.00006591872,0.00016958141,0.00007639779],"category_scores_gemma":[0.00053637126,0.00027801684,0.00014978112,0.00031691897,0.00007203664,0.0000972423,0.00012450088,0.00048613304,0.00007152415],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011145398,0.0001676831,0.018441994,0.0071960622,0.00065563316,0.00014020916,0.0007317177,3.6636044e-7,2.0325776e-7,0.0005189767,0.001465634,0.9706704],"study_design_scores_gemma":[0.0026361507,0.0008777524,0.002642819,0.0214937,0.0039122347,0.000017771616,0.00026755754,0.00015668587,0.0000017770395,0.00026047605,0.9670709,0.00066218135],"about_ca_topic_score_codex":0.000020439877,"about_ca_topic_score_gemma":0.00010195666,"teacher_disagreement_score":0.9700082,"about_ca_system_score_codex":0.00008429029,"about_ca_system_score_gemma":0.000390608,"threshold_uncertainty_score":0.9999672},"labels":[],"label_agreement":null},{"id":"W3002400028","doi":"10.1161/circheartfailure.119.006277","title":"Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure","year":2020,"lang":"en","type":"article","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; York University; University of Alberta Hospital; Women and Children’s Health Research Institute; University of Alberta; Juvenile Diabetes Research Foundation","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Inflammasome; Medicine; Ejection fraction; Heart failure; Internal medicine; Inflammation; Cardiac function curve; Endocrinology; Pharmacology; Cardiology; Diabetes mellitus; Type 2 diabetes","score_opus":0.01466514547113107,"score_gpt":0.22509693053166976,"score_spread":0.2104317850605387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002400028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730867,0.000018122484,0.00016260977,0.023493849,0.00014658568,0.002584716,0.0000072422363,0.00031980692,0.0001803631],"genre_scores_gemma":[0.9944258,8.610696e-7,0.003345988,0.00052561116,0.00029545501,0.00024518353,0.0007516942,0.00007820258,0.00033122342],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975008,0.00020056461,0.00049968815,0.000664852,0.00063374906,0.0005003498],"domain_scores_gemma":[0.99898016,0.000065493434,0.00022254112,0.00030822857,0.00017030786,0.00025325315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037586896,0.00036077178,0.0006031374,0.0003411194,0.0001994574,0.00010549585,0.00006529005,0.00023915787,0.00020523889],"category_scores_gemma":[0.00021547568,0.000349333,0.00016022882,0.0012387638,0.00004708688,0.00062066293,0.000045548673,0.00041255855,0.00017437867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038491568,0.00021962583,0.35767442,0.00020572123,0.00049222686,0.000010383176,0.0016317831,0.0011738513,0.62285197,0.0001540509,0.014354574,0.00084647164],"study_design_scores_gemma":[0.01476814,0.001474065,0.7732383,0.0035893607,0.0006310483,0.0000053271337,0.004377102,0.0020213155,0.047095757,0.000119404256,0.15104517,0.0016350325],"about_ca_topic_score_codex":0.000028887167,"about_ca_topic_score_gemma":0.000036322996,"teacher_disagreement_score":0.5757562,"about_ca_system_score_codex":0.0005901974,"about_ca_system_score_gemma":0.00012265317,"threshold_uncertainty_score":0.9998959},"labels":[],"label_agreement":null},{"id":"W3003004415","doi":"10.1172/jci99934","title":"Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Heart and Stroke Foundation; University Health Network; Toronto General Hospital; University of Toronto; Ted Rogers Centre for Heart Research","funders":"Canadian Institutes of Health Research; Novo Nordisk; University of Toronto; Toronto General Hospital Research Institute, University Health Network; Heart and Stroke Foundation of Canada","keywords":"Glycolysis; Chemistry; Glucagon-like peptide-1; Biochemistry; Internal medicine; Pharmacology; Endocrinology; Cell biology; Biology; Metabolism; Medicine","score_opus":0.045910617349171255,"score_gpt":0.3288346081097357,"score_spread":0.28292399076056446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003004415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99145216,0.0005340062,0.00055601046,0.004540874,0.0007830729,0.0009677249,0.000022114362,0.000030111603,0.0011139023],"genre_scores_gemma":[0.98639345,0.00007365061,0.0063333916,0.0019006418,0.0045253458,0.000044880027,0.00006253864,0.000029221228,0.00063690107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997377,0.00021853512,0.001335534,0.00024645007,0.000643765,0.00017872457],"domain_scores_gemma":[0.99804705,0.000107273896,0.0009633659,0.00010507941,0.00030241234,0.00047483132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008775602,0.0001717554,0.0007832048,0.000071297436,0.00005196456,0.00003324034,0.00008304312,0.00015181038,0.00003027023],"category_scores_gemma":[0.001887476,0.0001376943,0.00057855126,0.0002357158,0.00011017244,0.00032708113,0.00004589416,0.00058479555,0.000024988065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004826716,0.0006605646,0.058092657,0.0003702051,0.004657713,0.000050365856,0.000648058,0.000026915213,0.71417975,0.00027449918,0.14774211,0.068470426],"study_design_scores_gemma":[0.018348627,0.008517925,0.03534412,0.0011134384,0.0045853388,0.000015132696,0.00040433469,0.00039612583,0.72224915,0.002452466,0.20590983,0.0006635079],"about_ca_topic_score_codex":0.0000043203095,"about_ca_topic_score_gemma":4.1503885e-8,"teacher_disagreement_score":0.067806914,"about_ca_system_score_codex":0.000062886116,"about_ca_system_score_gemma":0.00024003272,"threshold_uncertainty_score":0.561501},"labels":[],"label_agreement":null},{"id":"W3003420651","doi":"10.1093/ndt/gfz230","title":"Renal physiology of glucose handling and therapeutic implications","year":2019,"lang":"en","type":"review","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"Canadian Institutes of Health Research; Department of Medicine, University of Toronto; University of Toronto; Diabetes Canada; Heart and Stroke Foundation of Canada","keywords":"Medicine; Empagliflozin; Glycemic; Renal function; Type 2 diabetes; Diabetes mellitus; Canagliflozin; Kidney disease; Albuminuria; Internal medicine; Clinical trial; Dapagliflozin; Intensive care medicine; Endocrinology; Urology; Pharmacology","score_opus":0.03682037251775153,"score_gpt":0.31488906252777776,"score_spread":0.2780686900100262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003420651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043969187,0.9937633,0.00025843238,0.00008450616,0.00005993794,0.001016589,0.000055900207,0.00003479084,0.00032962076],"genre_scores_gemma":[0.004314454,0.9931469,0.0001925978,0.0001930743,0.00006331609,0.00017555336,0.00177898,0.000025622732,0.000109524924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987911,0.00012239428,0.00045325924,0.00036700646,0.0000808939,0.00018534667],"domain_scores_gemma":[0.99909276,0.00024124155,0.00028044413,0.00029960411,0.0000425657,0.000043374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001102214,0.00024951083,0.0014681033,0.0003342757,0.000038854134,0.000005686244,0.000072945455,0.00026957574,0.000044271477],"category_scores_gemma":[0.000003999106,0.0001927439,0.00033156946,0.00021376359,0.00009868873,0.000029599832,0.000011538158,0.00013467764,0.000030380203],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009705204,0.00015551024,0.000108361804,0.01432288,0.0029547624,0.0000038578005,0.00017696535,0.000004067847,0.0012623582,0.00057791243,0.000023079232,0.9803132],"study_design_scores_gemma":[0.00426792,0.0010523915,0.015349328,0.0039073336,0.13024579,0.000093482624,0.000013676642,0.00005589379,0.00022296517,0.0005166738,0.84372085,0.0005537117],"about_ca_topic_score_codex":0.000011001899,"about_ca_topic_score_gemma":0.000011724272,"teacher_disagreement_score":0.97975945,"about_ca_system_score_codex":0.000028580449,"about_ca_system_score_gemma":0.00007313079,"threshold_uncertainty_score":0.78598684},"labels":[],"label_agreement":null},{"id":"W3003497764","doi":"10.1016/j.jcjd.2019.10.010","title":"Time to Rethink Reducing Cardiovascular Risk: Are We Ready?","year":2020,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Prediabetes; Scopus; Disease; Internal medicine; Intensive care medicine; Gerontology; MEDLINE; Endocrinology","score_opus":0.011875561800549956,"score_gpt":0.2199202202443505,"score_spread":0.20804465844380055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003497764","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015845839,0.056035448,0.000006056,0.013384993,0.9020112,0.0016251241,0.0013518349,0.00009675364,0.009642763],"genre_scores_gemma":[0.0037714385,0.00068575155,0.0009677387,0.00073802,0.98102045,0.000028484286,0.00037264367,0.00027073832,0.012144706],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996886,0.00015059522,0.0007148356,0.0004671844,0.0010096896,0.0007716663],"domain_scores_gemma":[0.99523944,0.00031334837,0.00062424585,0.0006645579,0.00069360796,0.00246481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087603077,0.0004975286,0.0017860063,0.0008006691,0.0001542796,0.00013553062,0.0004482152,0.0005372445,0.00040233124],"category_scores_gemma":[0.0034477657,0.00044607752,0.0009978221,0.00038659477,0.00009518487,0.00012709464,0.00005012983,0.0013960178,0.0005320928],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010190323,0.000018177278,0.0010674547,0.00032086752,0.004883355,0.00048198586,0.0003103561,0.00007350325,0.000008882175,0.000001126358,0.9823537,0.0104704285],"study_design_scores_gemma":[0.0008960296,0.00085353554,0.0006360744,0.0031391226,0.0048661134,0.0000014884346,0.000078335535,0.00001030357,0.000054574488,0.000024415995,0.98906827,0.0003717234],"about_ca_topic_score_codex":0.00070202374,"about_ca_topic_score_gemma":0.00044545217,"teacher_disagreement_score":0.07900929,"about_ca_system_score_codex":0.00086486025,"about_ca_system_score_gemma":0.0025258795,"threshold_uncertainty_score":0.9997991},"labels":[],"label_agreement":null},{"id":"W3003790882","doi":"10.14740/jocmr4084","title":"Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Pharmacology; Biomedical engineering; Endocrinology","score_opus":0.12766229353050176,"score_gpt":0.4945049228359713,"score_spread":0.3668426293054695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003790882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944684,0.0010796391,0.000011549487,0.0022602354,0.00026772276,0.0014650899,3.5362135e-7,0.0000030929825,0.00044393746],"genre_scores_gemma":[0.99867207,0.00037364548,0.00027215862,0.00010046613,0.000535699,0.000007103213,0.0000021335043,0.000012619467,0.000024118703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958749,0.00063824485,0.0018945562,0.00016527355,0.001188877,0.00023818805],"domain_scores_gemma":[0.99212354,0.006060431,0.0006838765,0.00014920911,0.0006473018,0.0003356236],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0053490777,0.00011786331,0.0024554657,0.0003345237,0.000013700959,0.0000044325125,0.00012727258,0.000081750295,0.000035330137],"category_scores_gemma":[0.018826993,0.00006494156,0.0001462778,0.000523596,0.000520527,0.0000584145,0.00007841519,0.00063382956,9.888973e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5161053,0.0013212246,0.46536213,0.00092891976,0.00051492907,0.00002222294,0.00040702696,0.0000017977387,0.00008555876,0.000010523568,0.000940141,0.014300221],"study_design_scores_gemma":[0.85195065,0.05083469,0.09247529,0.0027702218,0.00043474414,1.6639879e-7,0.00017058311,0.00024182055,0.00061595277,0.000026407048,0.0004253992,0.00005406845],"about_ca_topic_score_codex":0.000007403852,"about_ca_topic_score_gemma":0.0000010808029,"teacher_disagreement_score":0.37288684,"about_ca_system_score_codex":0.00002197774,"about_ca_system_score_gemma":0.00012267781,"threshold_uncertainty_score":0.9894378},"labels":[],"label_agreement":null},{"id":"W3003885000","doi":"10.14740/jocmr4078","title":"Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Glimepiride; Glycemic; Endocrinology; Internal medicine; Type 2 diabetes; Insulin resistance; Diabetes mellitus","score_opus":0.0529982194401512,"score_gpt":0.39386449148769287,"score_spread":0.34086627204754166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003885000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97481817,0.00029504107,0.000001409287,0.02265163,0.00019410143,0.000980462,0.0000010716627,0.0000038507055,0.0010542426],"genre_scores_gemma":[0.9980671,0.00017622493,0.000032143857,0.00082067813,0.0007628258,0.000008258424,0.000002020215,0.000016979811,0.000113794464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584514,0.001304605,0.0009189134,0.00019399796,0.0014597874,0.000277567],"domain_scores_gemma":[0.993454,0.0052395533,0.00035568597,0.0002758772,0.0004192056,0.00025572797],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006400521,0.00014564207,0.00085802906,0.00014111376,0.0000598751,0.000013207578,0.0002282007,0.000073766154,0.00006129361],"category_scores_gemma":[0.009410434,0.000053133932,0.00013614312,0.0005588224,0.00081693305,0.00006525815,0.00011568802,0.0010341506,0.0000066576454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010504599,0.0005280818,0.91753864,0.00038631647,0.00031689164,0.000032632346,0.00044950462,0.000008498944,0.00044386456,0.00009195998,0.00855516,0.06114387],"study_design_scores_gemma":[0.039500754,0.04816693,0.9055171,0.0021418731,0.00033979944,3.1390204e-7,0.0002270713,0.00020588556,0.0009113156,0.000069993825,0.0028441944,0.00007474401],"about_ca_topic_score_codex":0.0000056046742,"about_ca_topic_score_gemma":0.0000023166217,"teacher_disagreement_score":0.061069127,"about_ca_system_score_codex":0.00003835057,"about_ca_system_score_gemma":0.00007630843,"threshold_uncertainty_score":0.99893373},"labels":[],"label_agreement":null},{"id":"W3003924888","doi":"10.1039/d0ra00104j","title":"Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1","year":2020,"lang":"en","type":"article","venue":"RSC Advances","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Agriculture","funders":"","keywords":"Semaglutide; In vivo; Chemistry; PEGylation; Pharmacology; Glucagon-like peptide-1; Internal medicine; Albumin; Receptor; Endocrinology; Liraglutide; Medicine; Diabetes mellitus; Biochemistry; Type 2 diabetes; Biology","score_opus":0.04613948047465876,"score_gpt":0.30363272240641764,"score_spread":0.2574932419317589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003924888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8700623,0.00448284,0.11812444,0.0024007151,0.000038233826,0.004541967,0.000017116714,0.000022980004,0.00030942634],"genre_scores_gemma":[0.98299706,0.00010038757,0.016421247,0.00017461994,0.000023497607,0.00021892312,0.000019973213,0.000011680934,0.00003260125],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99914485,0.000045878725,0.00020106707,0.00016851118,0.00032120457,0.000118471755],"domain_scores_gemma":[0.99902254,0.00047049116,0.0002046171,0.000121615274,0.00013173842,0.000049021066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051920925,0.00011051461,0.0003557699,0.000048575468,0.000046994388,0.0000059680174,0.00004912709,0.00001975191,0.000016400365],"category_scores_gemma":[0.0001378201,0.000062680796,0.00005550617,0.00014417837,0.00009976868,0.000067075365,0.000009849606,0.00002958868,5.245216e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05992457,0.0044488898,0.031142479,0.004851068,0.007163976,0.000022837121,0.0049383296,0.073395215,0.6000999,0.00794053,0.002367721,0.20370448],"study_design_scores_gemma":[0.26879367,0.017017432,0.009893418,0.0012820215,0.012702454,0.0000034460018,0.0045415685,0.48604578,0.19504838,0.0012585393,0.0028134617,0.00059981324],"about_ca_topic_score_codex":0.000005070308,"about_ca_topic_score_gemma":0.0000049307105,"teacher_disagreement_score":0.4126506,"about_ca_system_score_codex":0.000025543939,"about_ca_system_score_gemma":0.0000743705,"threshold_uncertainty_score":0.25560486},"labels":[],"label_agreement":null},{"id":"W3003995118","doi":"10.1002/ehf2.12555","title":"Highlights in Heart Failure","year":2019,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Hazard ratio; Ejection fraction; Clinical endpoint; Sacubitril; Dapagliflozin; Enalapril; Cardiology; Decompensation; Valsartan; Ranolazine; Placebo; Confidence interval; Hyperkalemia; Adverse effect; Randomized controlled trial; Blood pressure; Type 2 diabetes; Diabetes mellitus; Endocrinology; Angiotensin-converting enzyme","score_opus":0.030302811380362997,"score_gpt":0.30882808361247616,"score_spread":0.27852527223211315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003995118","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025846743,0.9792113,0.0000011568815,0.014583786,0.00047955793,0.003345758,0.000024966388,0.00016985791,0.0021578087],"genre_scores_gemma":[0.000031652384,0.97246426,0.0035380584,0.0007507222,0.0005656681,0.0003405153,0.0006489107,0.00015496758,0.021505248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706227,0.00014951797,0.0007130229,0.0008547171,0.00047669036,0.00074378867],"domain_scores_gemma":[0.9983648,0.00011198209,0.00013982298,0.0010770719,0.000048774953,0.00025751354],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026709403,0.0007461022,0.0031770752,0.0006105524,0.000053485597,0.000069014306,0.00020593712,0.0005978457,0.00088106823],"category_scores_gemma":[0.000032410844,0.0005491307,0.00087478384,0.00063631654,0.000048381473,0.00013064436,0.00016283315,0.00067802996,0.008181564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009774594,0.00039512562,0.0003221917,0.03009651,0.0005400674,0.00013198645,0.00004331531,3.3350437e-7,0.0000023722137,0.0011681222,0.8736736,0.09361657],"study_design_scores_gemma":[0.0009616805,0.00024258888,0.00007424236,0.017989919,0.0013081881,0.00004320496,0.000018717254,9.713525e-7,0.000003501919,0.000011509528,0.9788918,0.00045369376],"about_ca_topic_score_codex":0.000036041158,"about_ca_topic_score_gemma":0.00009832754,"teacher_disagreement_score":0.10521815,"about_ca_system_score_codex":0.00033088325,"about_ca_system_score_gemma":0.00033045918,"threshold_uncertainty_score":0.999696},"labels":[],"label_agreement":null},{"id":"W3004095885","doi":"10.1161/circulationaha.119.041022","title":"Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; McGill University Health Centre","funders":"National Institutes of Health; Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; National Institute for Health and Care Research; U.S. Department of Health and Human Services","keywords":"Medicine; Clinical trial; Intensive care medicine; Glycated hemoglobin; Diabetes mellitus; Adverse effect; Type 2 Diabetes Mellitus; Myocardial infarction; Type 2 diabetes; Internal medicine","score_opus":0.03826599917969691,"score_gpt":0.2974279295548862,"score_spread":0.25916193037518925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004095885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99136007,0.007170778,0.00029692377,0.00006751481,0.000048781458,0.00048386588,0.0000033569036,0.000036847603,0.00053186517],"genre_scores_gemma":[0.9990815,0.00011489085,0.0005982385,0.000040945164,0.000101410675,0.000006486469,0.000016417325,0.000019788293,0.000020316544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990583,0.000042102736,0.00022908571,0.0002070416,0.00032963822,0.00013383426],"domain_scores_gemma":[0.9993177,0.00003659457,0.00011524976,0.000330852,0.0000997858,0.000099838646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021662684,0.00012489813,0.00035848084,0.00007591808,0.000023582796,0.0000064058663,0.000047225734,0.000036146885,0.00004284778],"category_scores_gemma":[0.00017322172,0.000103523125,0.00029784997,0.00026483583,0.000015172895,0.000055329554,0.000018533166,0.00003927656,0.000013866281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020355913,0.000089133755,0.53668594,0.00023063368,0.0023137599,0.0000016120193,0.0018783167,0.052458685,0.07143484,0.00004672875,0.00021435416,0.3344424],"study_design_scores_gemma":[0.001175601,0.0009694794,0.96562856,0.00016528167,0.0008681565,8.4763585e-8,0.000035594014,0.0020704705,0.028776858,0.00007284713,0.00014429342,0.00009276484],"about_ca_topic_score_codex":0.00005336179,"about_ca_topic_score_gemma":3.4211487e-7,"teacher_disagreement_score":0.4289426,"about_ca_system_score_codex":0.00010045826,"about_ca_system_score_gemma":0.000044676948,"threshold_uncertainty_score":0.42215505},"labels":[],"label_agreement":null},{"id":"W3004319546","doi":"10.1161/circulationaha.119.044183","title":"Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":452,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Harvard University; Deutsche Forschungsgemeinschaft; AstraZeneca","keywords":"Dapagliflozin; Medicine; Atrial fibrillation; Internal medicine; Cardiology; Type 2 Diabetes Mellitus; Diabetes mellitus; Myocardial infarction; Heart failure; Hazard ratio; Type 2 diabetes; Atrial flutter; Endocrinology","score_opus":0.00942147224222568,"score_gpt":0.2300643068026778,"score_spread":0.22064283456045214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004319546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854267,0.0000988693,0.000008859426,0.000084927415,0.000058597907,0.0006574862,0.0000012710135,0.000021445483,0.0005259057],"genre_scores_gemma":[0.9996423,0.000004254743,0.00002914332,0.000042180534,0.00008272508,0.0000018294179,0.00018458495,0.000009325439,0.000003670419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994639,0.000036011374,0.00012151154,0.000127974,0.00016986042,0.000080734135],"domain_scores_gemma":[0.9997386,0.00005013259,0.000057809455,0.000086945794,0.00003206409,0.000034455035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006758822,0.00007435093,0.0001707404,0.000062051724,0.00000941512,0.000004398324,0.000014996057,0.000029922092,0.00002069014],"category_scores_gemma":[0.00006543716,0.00005584494,0.000038308466,0.00020504117,0.00000967665,0.000050187078,0.000006586539,0.000028152455,0.000021621043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008154919,0.000018291641,0.9628479,0.00011109791,0.00006546352,5.01069e-7,0.00005867184,0.0029064028,0.00012095833,0.000044155488,0.000023121474,0.03298793],"study_design_scores_gemma":[0.004405539,0.002555346,0.9885194,0.00007922917,0.00016643651,7.679418e-9,0.0000015627667,0.0028061904,0.0012416345,0.000008361557,0.00016401811,0.000052322415],"about_ca_topic_score_codex":0.0000019365168,"about_ca_topic_score_gemma":3.5957572e-7,"teacher_disagreement_score":0.03293561,"about_ca_system_score_codex":0.000041321742,"about_ca_system_score_gemma":0.000007631128,"threshold_uncertainty_score":0.22772905},"labels":[],"label_agreement":null},{"id":"W3004582921","doi":"10.2215/cjn.08540719","title":"SONAR","year":2020,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Impact; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Nephrology; Internal medicine; Type 2 diabetes; Diabetes mellitus; Clinical trial; Intensive care medicine; Endocrinology","score_opus":0.06422102297407473,"score_gpt":0.3622558352249629,"score_spread":0.2980348122508882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004582921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84663004,0.0001982109,0.00024022798,0.15249483,0.00009243058,0.000089274436,0.0000011737487,0.0000063354523,0.00024748553],"genre_scores_gemma":[0.7620604,0.000773614,0.008483422,0.22803473,0.00051904505,5.7389315e-7,4.0828976e-7,0.000009433381,0.0001183808],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988959,0.000108478365,0.0005765853,0.0000966436,0.00018551288,0.00013690049],"domain_scores_gemma":[0.9984822,0.00023545157,0.00088268874,0.00015149447,0.00009987011,0.00014827687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032617932,0.00007743095,0.00063136773,0.000009381676,0.000022930155,0.0000023486455,0.00022807908,0.00003876363,0.000043585544],"category_scores_gemma":[0.00006826525,0.00004549123,0.001015893,0.00017257113,0.0008780955,0.000024358915,0.00011524228,0.00029661148,0.000009663541],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008009785,0.00047335424,0.1393718,0.000036939364,0.001923155,0.00002002691,0.00029153176,0.000007800834,0.0033316526,0.00007760359,0.75145346,0.102211714],"study_design_scores_gemma":[0.002871274,0.0067855604,0.32372206,0.000031148535,0.0008556306,0.000036064135,0.00059902505,0.0001389933,0.00021653908,0.0002474932,0.6644287,0.000067479006],"about_ca_topic_score_codex":0.0000030027145,"about_ca_topic_score_gemma":1.5472496e-7,"teacher_disagreement_score":0.18435027,"about_ca_system_score_codex":0.000015345326,"about_ca_system_score_gemma":0.000078010904,"threshold_uncertainty_score":0.32353795},"labels":[],"label_agreement":null},{"id":"W3004904344","doi":"10.3967/bes2020.005","title":"Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cochrane Library; Internal medicine; Meta-analysis; Placebo; Type 2 diabetes; Confidence interval; Body mass index; Subgroup analysis; Randomized controlled trial; Incretin; Diabetes mellitus; Endocrinology","score_opus":0.013486001565688535,"score_gpt":0.19321887851150607,"score_spread":0.17973287694581752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004904344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949941,0.0009226892,0.000006886015,0.0005276746,0.0000473948,0.0020101261,0.0000040760033,0.00008396252,0.0014030801],"genre_scores_gemma":[0.9971176,0.000007930339,0.000088969246,0.0015884774,0.000026893005,0.000846991,0.000115571,0.000028578772,0.00017898277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985726,0.00010642192,0.0002616753,0.00030564776,0.00039933732,0.0003543002],"domain_scores_gemma":[0.99906206,0.00019305083,0.00023205607,0.0002479199,0.00005624753,0.0002086722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016593019,0.0002254417,0.00093898264,0.00022799202,0.000033774053,0.000012722429,0.000101151105,0.00006285729,0.00013930364],"category_scores_gemma":[0.00007120596,0.0001357545,0.00038865834,0.0015761566,0.00007977469,0.00003902797,0.000028167577,0.0001062282,0.000010545303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027009935,0.00038945273,0.8366062,0.00013246821,0.15726142,0.000007517405,0.0001022886,0.0001660926,0.0000011487912,0.000043195203,0.0006209061,0.004399227],"study_design_scores_gemma":[0.0022143244,0.0005984512,0.860732,0.000008601206,0.13494007,2.2563862e-9,0.0000031487123,0.00007730967,0.00047941649,0.000008385386,0.00082198984,0.0001163017],"about_ca_topic_score_codex":0.0000051042603,"about_ca_topic_score_gemma":0.0000017894477,"teacher_disagreement_score":0.02412581,"about_ca_system_score_codex":0.000030417605,"about_ca_system_score_gemma":0.000012825531,"threshold_uncertainty_score":0.5535908},"labels":[],"label_agreement":null},{"id":"W3005967551","doi":"10.1016/j.cjco.2020.02.002","title":"Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case Report","year":2020,"lang":"en","type":"article","venue":"CJC Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; University of British Columbia","funders":"University of British Columbia","keywords":"Medicine; Sacubitril, Valsartan; Hypoglycemia; Valsartan; Sacubitril; Concomitant; Type 1 diabetes; Diabetes mellitus; Type 2 Diabetes Mellitus; Insulin; Adverse effect; Internal medicine; Endocrinology; Blood pressure","score_opus":0.02583027910980305,"score_gpt":0.2687668326616926,"score_spread":0.24293655355188956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005967551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678583,0.0003380586,0.0000013622663,0.002329328,0.00008729811,0.0019698448,0.000011123573,0.000055913628,0.02734878],"genre_scores_gemma":[0.9943671,0.00004680406,0.00067460607,0.0033327967,0.00004354724,0.00011583449,0.00015840757,0.00003605674,0.0012248334],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986097,0.0000436557,0.00030877852,0.00046740263,0.00024864828,0.00032178493],"domain_scores_gemma":[0.9991139,0.000043966436,0.00011665675,0.0004159132,0.00007736778,0.00023218973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001208739,0.00021204032,0.0006116291,0.000069481386,0.000046478515,0.000069205664,0.00012434057,0.000053065545,0.00031082984],"category_scores_gemma":[0.00009655828,0.0001566711,0.000039331728,0.00046143553,0.000028152941,0.00013348863,0.00016450531,0.0001475024,0.00015543755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009305132,0.002611903,0.07462478,0.000481723,0.0014871577,0.7110744,0.003913915,0.00016546338,0.0006993813,0.00033373683,0.081483886,0.11381853],"study_design_scores_gemma":[0.051161874,0.04558119,0.016139729,0.0030286047,0.0026974438,0.007932474,0.004893721,0.0018771467,0.021971019,0.00034838216,0.8415826,0.0027858214],"about_ca_topic_score_codex":0.00010280542,"about_ca_topic_score_gemma":0.000067283225,"teacher_disagreement_score":0.7600987,"about_ca_system_score_codex":0.00012913118,"about_ca_system_score_gemma":0.00010833022,"threshold_uncertainty_score":0.6388862},"labels":[],"label_agreement":null},{"id":"W3006085306","doi":"10.1111/dom.13997","title":"Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca; American Diabetes Association","keywords":"Saxagliptin; Medicine; Dapagliflozin; Glimepiride; Metformin; Type 2 diabetes; Pharmacology; Fixed-dose combination; Diabetes mellitus; Internal medicine; Urology; Endocrinology; Sitagliptin","score_opus":0.014505288255022824,"score_gpt":0.22342156750597997,"score_spread":0.20891627925095715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006085306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881605,0.0018792247,0.0000010714473,0.000272984,0.00017497872,0.008539888,0.00023198903,0.00003604088,0.0007033216],"genre_scores_gemma":[0.9981101,0.000523764,0.00030820287,0.00035509316,0.00012433728,0.00022759229,0.00024415992,0.000038734215,0.000068013906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970629,0.00038841483,0.00086145964,0.0006220709,0.00059903704,0.00046611877],"domain_scores_gemma":[0.9964416,0.0021286062,0.00062643667,0.00035558201,0.00019589548,0.00025185966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006925852,0.00050929846,0.0036016705,0.0002672414,0.00007223795,0.000033458728,0.00010944153,0.00013282022,0.00003362671],"category_scores_gemma":[0.0009376013,0.0003073527,0.00020574787,0.00037889497,0.0002542348,0.00019181399,0.000062979096,0.00024005068,0.0000026721139],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98255754,0.002801265,0.0022613632,0.000058824455,0.0043187332,0.0000065094796,0.000857519,0.00003920571,0.00033368377,0.00018327059,0.000042082735,0.0065399953],"study_design_scores_gemma":[0.92190814,0.013019183,0.05770471,0.00025445415,0.002422605,1.8505782e-8,0.00008284934,0.00022732963,0.003719399,0.000022683922,0.0003638421,0.0002748138],"about_ca_topic_score_codex":0.00007003136,"about_ca_topic_score_gemma":0.000018160197,"teacher_disagreement_score":0.060649432,"about_ca_system_score_codex":0.000039400235,"about_ca_system_score_gemma":0.00009839386,"threshold_uncertainty_score":0.99993783},"labels":[],"label_agreement":null},{"id":"W3006539699","doi":"10.1186/s40842-019-0088-5","title":"Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data","year":2020,"lang":"en","type":"article","venue":"Clinical Diabetes and Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Lixisenatide; Postprandial; Medicine; Glycemic; Internal medicine; Placebo; Type 2 diabetes; Hypoglycemia; Insulin; Endocrinology; Post-hoc analysis; Diabetes mellitus; Basal (medicine); Insulin glargine; Glucagon-like peptide 1 receptor; Basal insulin; Agonist; Receptor","score_opus":0.019073872888847328,"score_gpt":0.2755363699798128,"score_spread":0.25646249709096547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006539699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514234,0.00076899177,0.000006378915,0.0027262801,0.00008504763,0.0009088904,0.00021629538,0.000046381872,0.00009940412],"genre_scores_gemma":[0.99077475,0.00022629337,0.00017332856,0.008035984,0.00008339093,0.000027917178,0.00064001925,0.000032296506,0.000005991519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744844,0.0001704424,0.00074306,0.0007789821,0.00024329175,0.00061578414],"domain_scores_gemma":[0.9976852,0.0009908376,0.00028979304,0.0005915877,0.00016932773,0.00027324868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017362196,0.00032966607,0.0015636561,0.00029188453,0.00004220957,0.000023120385,0.00025136274,0.00011538368,0.000034064506],"category_scores_gemma":[0.0006017451,0.00022022668,0.0001299933,0.0005474077,0.0003108257,0.00013174229,0.00016994661,0.00033712597,0.000007969823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026910799,0.0010193917,0.9436161,0.000095520736,0.0061951014,0.0000293184,0.000046511337,0.000017975353,0.00026655264,0.00005295282,0.000049221155,0.02170059],"study_design_scores_gemma":[0.039876144,0.04651843,0.9032239,0.00009778018,0.005882107,9.5101406e-8,0.000045057455,0.003868611,0.00004292131,0.00000792875,0.00020464175,0.00023243655],"about_ca_topic_score_codex":0.000013873401,"about_ca_topic_score_gemma":0.000033228767,"teacher_disagreement_score":0.045499038,"about_ca_system_score_codex":0.000022969343,"about_ca_system_score_gemma":0.000062148254,"threshold_uncertainty_score":0.8980583},"labels":[],"label_agreement":null},{"id":"W3006775377","doi":"10.1016/j.diabres.2020.108091","title":"Impact on guidelines: The general practitioner point of view","year":2020,"lang":"en","type":"review","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"NIHR Leicester Biomedical Research Centre; Collaboration for Leadership in Applied Health Research and Care - Greater Manchester; National Institute for Health and Care Research; NIHR Bristol Biomedical Research Centre","keywords":"Medicine; Point (geometry); Diabetes mellitus; Family medicine; Endocrinology; Geometry","score_opus":0.34177217158243295,"score_gpt":0.6029277648212954,"score_spread":0.26115559323886245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006775377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011600785,0.973882,0.000002254663,0.01201008,0.00015086282,0.0023118774,0.000055053948,0.000029078881,0.011442746],"genre_scores_gemma":[0.000046223468,0.9945986,0.0006680818,0.001983281,0.0009357852,0.00019616673,0.00019568641,0.000060725146,0.0013154227],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99409676,0.0018502602,0.0016142508,0.0006921705,0.0011508727,0.000595708],"domain_scores_gemma":[0.98171693,0.015285426,0.00067934475,0.0008740491,0.0009558883,0.00048834],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0067847804,0.0004124751,0.002143472,0.0001922309,0.00014488595,0.00011847725,0.00032209847,0.00028334552,0.00024557885],"category_scores_gemma":[0.026596846,0.00019881364,0.0009009044,0.0006929325,0.00044829637,0.00023088149,0.00038963454,0.0019166319,0.00045076184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001532052,0.0011704455,0.00009773141,0.0038321603,0.002928136,0.000070096896,0.000007939913,9.2827584e-8,1.3937931e-7,0.0006315456,0.074263126,0.9168454],"study_design_scores_gemma":[0.00066481205,0.005403101,0.00020845547,0.005116176,0.0029628105,0.00000791724,0.00004538535,0.00002612772,5.466846e-7,0.00013912492,0.9852637,0.00016181811],"about_ca_topic_score_codex":0.000028464276,"about_ca_topic_score_gemma":8.865498e-7,"teacher_disagreement_score":0.91668355,"about_ca_system_score_codex":0.00012659123,"about_ca_system_score_gemma":0.0006255308,"threshold_uncertainty_score":0.98160255},"labels":[],"label_agreement":null},{"id":"W3006785779","doi":"10.1007/s12020-020-02223-6","title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","year":2020,"lang":"en","type":"review","venue":"Endocrine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Medicine; Pancreatic cancer; Pancreatitis; Odds ratio; Acute pancreatitis; Internal medicine; Placebo; Gastroenterology; Type 2 diabetes; Diabetes mellitus; Meta-analysis; Cancer; Endocrinology; Pathology","score_opus":0.16005052233741446,"score_gpt":0.3853137994025004,"score_spread":0.22526327706508592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006785779","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018860705,0.99343324,0.000004741591,0.00014258939,0.0006648957,0.0031234901,0.0013755991,0.00006890784,0.0009979191],"genre_scores_gemma":[0.00016801147,0.9789431,0.00038307355,0.000110486406,0.0005223672,0.0001334499,0.018805569,0.00007377594,0.0008601404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644023,0.0005010307,0.0013245537,0.0009367417,0.00041087577,0.0003865599],"domain_scores_gemma":[0.99729896,0.00059610157,0.00032469828,0.0015202112,0.000041736097,0.00021826713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051953417,0.00056779425,0.00597304,0.00014878565,0.00003388084,0.000046627076,0.00034655078,0.000100543766,0.00056443096],"category_scores_gemma":[0.0016479979,0.00041293429,0.0005450392,0.00032826254,0.000056099478,0.00009329422,0.0006407656,0.00030643702,0.00038523413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006555867,0.0001663873,0.0050256033,0.0066688843,0.0053341235,0.00020531207,0.000018902123,8.014571e-8,1.0477137e-7,0.000022004782,0.0035987787,0.97889423],"study_design_scores_gemma":[0.0038518691,0.00021170084,0.00075815525,0.0046045003,0.014036706,0.0000015680687,0.000008436854,0.0000029241373,7.236068e-7,0.0000058521014,0.9762036,0.00031395679],"about_ca_topic_score_codex":0.0002131611,"about_ca_topic_score_gemma":0.000013571181,"teacher_disagreement_score":0.9785803,"about_ca_system_score_codex":0.0002617429,"about_ca_system_score_gemma":0.00011427251,"threshold_uncertainty_score":0.9998323},"labels":[],"label_agreement":null},{"id":"W3007720796","doi":"10.1016/j.jacbts.2020.01.011","title":"Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?","year":2020,"lang":"en","type":"letter","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Boehringer Ingelheim; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Sympathetic nervous system; Cardiorenal syndrome; Medicine; Heart failure; Autonomic nervous system; Internal medicine; Cardiology; Pharmacology; Heart rate; Blood pressure","score_opus":0.017246264506385767,"score_gpt":0.2246942681402275,"score_spread":0.20744800363384172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007720796","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19403818,0.00017065424,0.00021742191,0.79930735,0.0007518712,0.002516775,0.00030966641,0.000044573182,0.0026434963],"genre_scores_gemma":[0.91959023,0.0000016619206,0.00023902017,0.079016976,0.00079307513,0.00009502876,0.000033691103,0.000021399956,0.0002088909],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9970587,0.00005790379,0.00043886446,0.00045481854,0.0016928308,0.00029689987],"domain_scores_gemma":[0.998818,0.00009518812,0.0002788971,0.00045666925,0.00024366002,0.00010761637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034034371,0.00023251098,0.00044733586,0.00021940582,0.00017025621,0.000031734187,0.00039921966,0.000098669356,0.000015602345],"category_scores_gemma":[0.000056711226,0.00013252006,0.00027135233,0.0013187485,0.00029960528,0.000082301376,0.000096487376,0.00029819223,0.000025266334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003193799,0.0006053298,0.019772757,0.007209195,0.0011620991,0.0005247445,0.01059092,0.0186615,0.020727135,0.014948434,0.82017803,0.08530046],"study_design_scores_gemma":[0.0037949483,0.001637575,0.6615678,0.016234191,0.0039013184,0.0001362855,0.0012585598,0.0008835376,0.06391419,0.0006745116,0.24438207,0.001614986],"about_ca_topic_score_codex":0.000037102178,"about_ca_topic_score_gemma":0.000012937421,"teacher_disagreement_score":0.7255521,"about_ca_system_score_codex":0.0001267039,"about_ca_system_score_gemma":0.00021311967,"threshold_uncertainty_score":0.5404011},"labels":[],"label_agreement":null},{"id":"W3008335290","doi":"10.1111/dom.14011","title":"Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Diabetes mellitus; Internal medicine; Myocardial infarction; Mace; Type 2 diabetes; Hazard ratio; Stroke (engine); Cardiology; TIMI; Percutaneous coronary intervention; Endocrinology; Confidence interval","score_opus":0.01415808740807647,"score_gpt":0.20265518379180927,"score_spread":0.1884970963837328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008335290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748844,0.02400966,0.000014887209,0.00016350983,0.00005399288,0.00074793777,0.00006474412,0.000018581699,0.00004229096],"genre_scores_gemma":[0.9980064,0.0010390728,0.0002380402,0.0004059664,0.00010038961,0.00001923567,0.00016682365,0.000016534927,0.0000075100033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985598,0.000092793576,0.00026965188,0.000436041,0.00035778462,0.00028393365],"domain_scores_gemma":[0.99927914,0.00011062003,0.00006740962,0.000285462,0.00007622882,0.00018115046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030389146,0.0002343325,0.0009565386,0.00014420223,0.000080537844,0.000048098053,0.00007940903,0.00008107641,0.000018887506],"category_scores_gemma":[0.00008594621,0.00015483802,0.00014591363,0.0006062643,0.00012501839,0.00014063985,0.0001322419,0.00013346366,6.3259847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007809669,0.00015974307,0.98394114,0.00006253304,0.004875265,0.0000024294739,0.00038041075,0.00003975568,0.000027281078,0.000041824318,0.000030946492,0.0096577145],"study_design_scores_gemma":[0.0149690965,0.00037555993,0.97327125,0.00007956741,0.009475249,2.1336781e-8,0.00004906815,0.00019194989,0.00044759092,0.00002126906,0.00095416204,0.00016519167],"about_ca_topic_score_codex":0.000036982805,"about_ca_topic_score_gemma":0.000031819014,"teacher_disagreement_score":0.023122031,"about_ca_system_score_codex":0.000012657208,"about_ca_system_score_gemma":0.00001522798,"threshold_uncertainty_score":0.63141114},"labels":[],"label_agreement":null},{"id":"W3008608911","doi":"10.1016/s0140-6736(19)32541-3","title":"Dulaglutide slows kidney disease in type 2 diabetes − Author's reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"Kowa Company; Boehringer Ingelheim; Novo Nordisk; Abbott Laboratories; Sanofi; Merck; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Renal function; Medicine; Kidney disease; Scopus; Type 2 diabetes; Diabetes mellitus; Internal medicine; Creatinine; Dulaglutide; Urology; Endocrinology; MEDLINE; Chemistry; Exenatide","score_opus":0.029590696561833378,"score_gpt":0.267758336587123,"score_spread":0.23816764002528962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008608911","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041836044,0.0011564305,6.939891e-7,0.98522365,0.0006316186,0.00077889336,0.000098473574,0.00017570567,0.0077509247],"genre_scores_gemma":[0.006519854,0.00023496148,0.00012324324,0.966502,0.007857957,0.00009859944,0.0015739895,0.000067716435,0.017021658],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834,0.0001014683,0.00025077802,0.00042240688,0.00033460459,0.0005507194],"domain_scores_gemma":[0.998534,0.000081946106,0.00010228506,0.0010700166,0.000028189688,0.00018356509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015847138,0.0003071863,0.00079846295,0.00009338144,0.00004368004,0.000048368423,0.00035644285,0.00011157159,0.00028607782],"category_scores_gemma":[0.00033634313,0.00019756323,0.0001404231,0.00026259787,0.000070925315,0.00003784413,0.00016223155,0.00089684816,0.0006131382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001137913,0.000036128047,0.018336955,0.00058896636,0.00024731932,0.0011349799,0.000063639185,0.0000011356492,0.000009235564,0.000046419325,0.9786252,0.0007962725],"study_design_scores_gemma":[0.0012165837,0.00011210662,0.011464778,0.0004635776,0.0005759182,3.569495e-7,0.0000037805962,0.000114254624,0.000014107366,0.00079194456,0.98504096,0.00020160373],"about_ca_topic_score_codex":0.000023649163,"about_ca_topic_score_gemma":0.0000019054781,"teacher_disagreement_score":0.018721636,"about_ca_system_score_codex":0.00009490567,"about_ca_system_score_gemma":0.00011027008,"threshold_uncertainty_score":0.8056395},"labels":[],"label_agreement":null},{"id":"W3009177262","doi":"10.1136/bmjdrc-2019-001025","title":"Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"General Hospital of People’s Liberation Army; National Key Research and Development Program of China; Peking University Third Hospital; Peking University; University of Toronto; National Natural Science Foundation of China; Sun Yat-sen University; Tsinghua University","keywords":"Glucagon receptor; Internal medicine; Endocrinology; Receptor; Glucagon-like peptide 1 receptor; Streptozotocin; Glucagon-like peptide-1; Glucagon; Cell growth; Diabetes mellitus; Receptor antagonist; Antagonist; Type 2 diabetes; Medicine; Biology; Insulin; Agonist; Biochemistry","score_opus":0.10538790915484576,"score_gpt":0.3843523455843713,"score_spread":0.27896443642952556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009177262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820457,0.0021531575,0.0000013066357,0.0063645723,0.00011040706,0.0077008116,0.00003056569,0.000081741426,0.0015117059],"genre_scores_gemma":[0.99551773,0.00007952954,0.0012640619,0.00025099676,0.00031181207,0.00097149913,0.00086237583,0.00007182189,0.0006701914],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99636674,0.00045924055,0.00054777844,0.00096342084,0.0007721986,0.0008906244],"domain_scores_gemma":[0.9982725,0.00017279443,0.000158104,0.00039565007,0.00063909235,0.00036190546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017673796,0.0003213779,0.00054813275,0.00019279422,0.0003969816,0.00071937055,0.00032526936,0.000121126206,0.000091316106],"category_scores_gemma":[0.0022635846,0.00029598028,0.000056029858,0.0010288757,0.00020379845,0.0005988927,0.0007639601,0.0005216868,0.000057249097],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019243098,0.00031744238,0.66673857,0.0028450473,0.00011021302,0.000015698486,0.0039924677,0.000014534032,0.23283465,0.000017483717,0.008503379,0.08441807],"study_design_scores_gemma":[0.005220672,0.005149636,0.0961947,0.003699271,0.00020249934,0.0000029890261,0.0091089625,0.009948282,0.86229163,0.00012985666,0.006996808,0.0010546682],"about_ca_topic_score_codex":0.00007940796,"about_ca_topic_score_gemma":0.000034029257,"teacher_disagreement_score":0.629457,"about_ca_system_score_codex":0.0003202311,"about_ca_system_score_gemma":0.0002733626,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W3009238663","doi":"10.1111/dom.14017","title":"Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute for Health and Care Research","keywords":"Empagliflozin; Medicine; Internal medicine; Cardiology; Myocardial infarction; Risk factor; Heart failure; Type 2 diabetes; Diabetes mellitus; Relative risk; Hazard ratio; Confidence interval; Endocrinology","score_opus":0.05443718887107603,"score_gpt":0.23978317151922038,"score_spread":0.18534598264814434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009238663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738516,0.016525451,0.000019835392,0.006155267,0.00021275206,0.0024414088,0.0006684257,0.0000512008,0.00007405493],"genre_scores_gemma":[0.9962759,0.0015436949,0.00008773918,0.0010569302,0.00034426904,0.00041534583,0.0001427746,0.00003088361,0.00010243201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969286,0.0008526257,0.00040807662,0.00057714945,0.0007187956,0.0005147961],"domain_scores_gemma":[0.99875945,0.00019983487,0.0001479742,0.0006342886,0.00006835795,0.00019007205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001406931,0.00038505418,0.0011772689,0.00011927497,0.00026703867,0.00008392495,0.00025443605,0.000120369965,0.00003657094],"category_scores_gemma":[0.00027473483,0.00022281158,0.00062773895,0.00051795895,0.00020322467,0.00013548222,0.00009989773,0.0005072065,0.000004622949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020154049,0.0012898243,0.9453124,0.00036377888,0.020240067,0.00012481443,0.011358212,0.0003094103,0.0001902778,0.00056493556,0.0016675338,0.016563334],"study_design_scores_gemma":[0.03904348,0.00038955445,0.8881257,0.0000498261,0.005498312,0.0000015802793,0.0022071763,0.000097004515,0.00053704454,0.00008456084,0.0635992,0.00036656737],"about_ca_topic_score_codex":0.0008732135,"about_ca_topic_score_gemma":0.00042212737,"teacher_disagreement_score":0.061931666,"about_ca_system_score_codex":0.000058918045,"about_ca_system_score_gemma":0.000054813274,"threshold_uncertainty_score":0.90859926},"labels":[],"label_agreement":null},{"id":"W3009487420","doi":"10.14740/jocmr4098","title":"Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cardiology; Ejection fraction; Heart failure; Diabetes mellitus; Type 2 Diabetes Mellitus; Renal function; Cardiac function curve; Diastole; Endocrinology; Blood pressure","score_opus":0.07411946207083263,"score_gpt":0.4164913129991116,"score_spread":0.34237185092827893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009487420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876621,0.0013516395,0.000012643512,0.008164068,0.00033210803,0.00069890206,8.7180155e-7,0.000006027042,0.0017716909],"genre_scores_gemma":[0.9977162,0.000631476,0.000104154184,0.0005608444,0.0008697296,0.000009064609,0.000004666756,0.000017701032,0.000086151944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962046,0.0005141609,0.001085163,0.0002083416,0.0016649116,0.0003228297],"domain_scores_gemma":[0.99531996,0.003108586,0.00032712193,0.00017241816,0.00063212926,0.00043977937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029961092,0.00013125637,0.001089,0.00036806366,0.000021474962,0.0000057420184,0.00013178789,0.00009353256,0.000051048944],"category_scores_gemma":[0.0048819045,0.000073330455,0.00017064318,0.00060300226,0.00023413856,0.00007798624,0.000043694752,0.00089671527,0.000015314958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005448728,0.0016451168,0.78105587,0.0007306718,0.0006559704,0.000091900314,0.00014919524,0.0000044276303,0.00025649718,0.00009252141,0.008823086,0.20104599],"study_design_scores_gemma":[0.015404028,0.086885005,0.88524234,0.002117128,0.00040095442,1.246299e-7,0.00011083279,0.000026022679,0.0010140445,0.00012631816,0.008605806,0.00006738351],"about_ca_topic_score_codex":0.000006489849,"about_ca_topic_score_gemma":8.9765376e-7,"teacher_disagreement_score":0.2009786,"about_ca_system_score_codex":0.00005420005,"about_ca_system_score_gemma":0.00012938022,"threshold_uncertainty_score":0.5844448},"labels":[],"label_agreement":null},{"id":"W3009598378","doi":"10.2215/cjn.01260120","title":"Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease","year":2020,"lang":"en","type":"letter","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Liraglutide; Type 2 diabetes; Diabetes mellitus; Disease; Internal medicine; Intensive care medicine; Urology; Endocrinology","score_opus":0.03678359595318251,"score_gpt":0.3288961307687813,"score_spread":0.29211253481559885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009598378","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21550119,0.002637907,0.000013620655,0.78073585,0.00031767788,0.0007209369,0.000056719942,0.000004153275,0.000011948152],"genre_scores_gemma":[0.0339624,0.01953534,0.0010720486,0.9434415,0.001663381,0.000019964398,0.000026914517,0.000039435436,0.00023901642],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784017,0.00026515417,0.0011117494,0.00023808284,0.00024317986,0.0003016785],"domain_scores_gemma":[0.9949446,0.0026468222,0.0016579123,0.00041310352,0.00015917601,0.00017842435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037107538,0.00025081995,0.0016454175,0.00004253373,0.000044318687,0.0000058648247,0.0003237378,0.00014205914,0.00001438103],"category_scores_gemma":[0.00032215827,0.00012838743,0.0014532825,0.00021688032,0.0018980833,0.00002217592,0.00010335348,0.00058793736,8.715575e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011886377,0.00053313986,0.07009924,0.00027844444,0.0034783971,0.000024265635,0.00016651637,0.00000472809,0.00005904917,0.0000038178187,0.9052396,0.018924188],"study_design_scores_gemma":[0.0037145934,0.008057128,0.09208515,0.00019354302,0.003960638,0.000002303753,0.00009017763,0.00022303857,0.000013694671,0.0003145686,0.89124125,0.000103940205],"about_ca_topic_score_codex":0.00000937996,"about_ca_topic_score_gemma":6.7820605e-7,"teacher_disagreement_score":0.18153879,"about_ca_system_score_codex":0.00008352118,"about_ca_system_score_gemma":0.00029422127,"threshold_uncertainty_score":0.6993567},"labels":[],"label_agreement":null},{"id":"W3009687401","doi":"10.1124/jpet.119.263947","title":"Site-Specific and Temporal Effects of Apraglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Receptor Agonist, on Intestinal Growth in Mice","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; National Institutes of Health; University of Toronto; Crohn's and Colitis Foundation of America; Canada Research Chairs; Canadian Association of Gastroenterology; Crohn's and Colitis Foundation; McMaster University","keywords":"Crypt; Agonist; Internal medicine; Glucagon-like peptide-2; Endocrinology; Receptor; Small intestine; Medicine; Biology; Peptide; Biochemistry","score_opus":0.03449864026503059,"score_gpt":0.3143118496580334,"score_spread":0.2798132093930028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009687401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923382,0.005019723,0.000059840295,0.0016838774,0.00036214737,0.00029028632,0.0000021836354,0.000009020042,0.00023473057],"genre_scores_gemma":[0.99405426,0.0007625779,0.0014657029,0.0034512752,0.00018966995,0.0000062932236,0.000004284352,0.000017805669,0.00004814345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906284,0.000058360918,0.00037922664,0.0001665767,0.00014653854,0.0001864405],"domain_scores_gemma":[0.9993438,0.00017709244,0.00027101536,0.00003481538,0.00004782732,0.00012541417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014585245,0.00018033707,0.00039895877,0.00011828726,0.000045196466,0.000013141182,0.00006359405,0.000059672777,0.000040298317],"category_scores_gemma":[0.000009886393,0.00014864895,0.00007119094,0.00011461652,0.00013510368,0.000087556284,0.000056992973,0.00027888027,0.000003256355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032865321,0.0012266471,0.01807596,0.00019742441,0.00038197817,0.00017270558,0.0020811933,0.0000032962466,0.9713639,0.000046798617,0.0010095339,0.002154007],"study_design_scores_gemma":[0.01162324,0.0067863655,0.004093517,0.00022637132,0.00033394506,0.00008474155,0.00087931735,0.00019382621,0.9695154,0.000008553839,0.0060880715,0.00016664308],"about_ca_topic_score_codex":0.000004788706,"about_ca_topic_score_gemma":3.9880211e-7,"teacher_disagreement_score":0.013982442,"about_ca_system_score_codex":0.00007744965,"about_ca_system_score_gemma":0.000033755492,"threshold_uncertainty_score":0.6061728},"labels":[],"label_agreement":null},{"id":"W3009912045","doi":"10.1016/j.jacc.2019.12.063","title":"Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Liraglutide; Hazard ratio; Internal medicine; Heart failure; Myocardial infarction; Placebo; Type 2 diabetes; Diabetes mellitus; Cardiology; Stroke (engine); Adverse effect; Confidence interval; Endocrinology","score_opus":0.005237063704440509,"score_gpt":0.21032030800858392,"score_spread":0.2050832443041434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009912045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968832,0.00011729698,0.000022328953,0.0021574425,0.00005546357,0.00063306274,0.000011087817,0.000004741915,0.00011535503],"genre_scores_gemma":[0.99803525,0.000012686304,0.0011365857,0.0006954752,0.00005618468,0.0000089720925,6.8432814e-7,0.000020125568,0.000034051674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986442,0.00021089087,0.00033723057,0.00014333121,0.000465183,0.00019922084],"domain_scores_gemma":[0.9988304,0.00019050563,0.00045405177,0.0002792199,0.00015579845,0.00009005803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016768317,0.00017477672,0.0019309314,0.00013678402,0.000017089398,0.0000018031499,0.00016041903,0.000027262879,0.0000015986352],"category_scores_gemma":[0.00015234874,0.00007830542,0.00042816548,0.00040886394,0.00027231587,0.00003902642,0.00005218535,0.00017113368,6.5206865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028190317,0.00013714773,0.9901069,0.00013796608,0.004481544,0.00008057517,0.00003276087,0.00070019654,0.00013327798,0.000006999922,0.000999456,0.00036418298],"study_design_scores_gemma":[0.0079258215,0.01652909,0.9687512,0.00029939084,0.0015878327,0.0000097473685,0.00016026727,0.0000074690756,0.0019649845,0.0000035285643,0.0026638142,0.00009684385],"about_ca_topic_score_codex":0.000004551931,"about_ca_topic_score_gemma":0.0000026257328,"teacher_disagreement_score":0.021355651,"about_ca_system_score_codex":0.000055256263,"about_ca_system_score_gemma":0.000097979995,"threshold_uncertainty_score":0.31932023},"labels":[],"label_agreement":null},{"id":"W3010125829","doi":"10.2337/dc19-1745","title":"Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Liraglutide; Medicine; Placebo; Internal medicine; Overweight; Type 2 diabetes; Diabetes mellitus; Insulin; Endocrinology; Population; Weight loss; Tolerability; Weight change; Obesity; Adverse effect","score_opus":0.007631831418664087,"score_gpt":0.21765926380820502,"score_spread":0.21002743238954094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010125829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715943,0.0037879753,9.3872615e-7,0.0010550393,0.000034714918,0.007315248,0.000048872113,0.000053481293,0.00054432784],"genre_scores_gemma":[0.9980362,0.00043211898,0.00027972393,0.00061626843,0.00007944986,0.0003355,0.00012137063,0.000036727695,0.00006264694],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99802876,0.00027571982,0.000542714,0.00042886718,0.0003546653,0.00036927342],"domain_scores_gemma":[0.9982048,0.00094182265,0.00024901523,0.00026561116,0.00015428738,0.00018441181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004004973,0.00036961574,0.0020375804,0.0001611592,0.000086489534,0.000047863537,0.00010806692,0.0001033891,0.000039775106],"category_scores_gemma":[0.00040042205,0.00017308915,0.000103524704,0.00064114603,0.00036258946,0.00010104008,0.0001030295,0.00018692687,0.000004024989],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46257272,0.0002564384,0.53235704,0.00021034495,0.0010790718,0.000008516445,0.0013462137,0.0000059211416,0.000058155638,0.000019002278,0.000047486086,0.0020390747],"study_design_scores_gemma":[0.85236186,0.0039059836,0.13892135,0.00042973622,0.0018924413,1.9801269e-7,0.00059654214,0.00025468995,0.0011637149,0.000011911698,0.00024754778,0.00021401915],"about_ca_topic_score_codex":0.000010172382,"about_ca_topic_score_gemma":0.000022662703,"teacher_disagreement_score":0.39343572,"about_ca_system_score_codex":0.000037349088,"about_ca_system_score_gemma":0.00009831704,"threshold_uncertainty_score":0.7058371},"labels":[],"label_agreement":null},{"id":"W3010194972","doi":"10.1111/dme.14287","title":"Incretin‐based drugs and risk of lung cancer among individuals with type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Canadian HIV Trials Network, Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Dipeptidyl peptidase-4; Incretin; Internal medicine; Type 2 diabetes; Lung cancer; Diabetes mellitus; Oncology; Proportional hazards model; Population; Sitagliptin; Glucagon-like peptide 1 receptor; Cancer; Endocrinology; Pharmacology; Receptor; Confidence interval; Agonist; Environmental health","score_opus":0.009047097360135514,"score_gpt":0.24621615178238482,"score_spread":0.2371690544222493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010194972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98739445,0.0031098884,0.000018594532,0.005637549,0.000066899775,0.00068919285,0.000019189123,0.000061847706,0.0030023728],"genre_scores_gemma":[0.9965013,0.00050011603,0.00044793662,0.001958413,0.00015615045,0.00006144863,0.0000919176,0.000033074703,0.00024962868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984991,0.000059746417,0.00029618447,0.0003195853,0.000529228,0.00029616547],"domain_scores_gemma":[0.99889857,0.00018913153,0.00020210221,0.00023404621,0.00015433213,0.00032182364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032414345,0.00022713699,0.00065167074,0.00012200839,0.000041655272,0.0000074715067,0.00008417948,0.0000585771,0.0005446511],"category_scores_gemma":[0.00030222783,0.00014573697,0.000035458528,0.00042157585,0.00037518702,0.00004743641,0.00005191736,0.00015251631,0.000004342693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006397796,0.000056939192,0.9874904,0.0006490048,0.00074101373,0.0000069150647,0.0012557071,0.000008524666,0.0003726717,0.000028635543,0.0047872663,0.0045389477],"study_design_scores_gemma":[0.008518565,0.0028100577,0.9670551,0.0015634007,0.0050541745,1.6779322e-7,0.00034530138,0.004015365,0.0055315904,0.000021523449,0.0048294156,0.0002553264],"about_ca_topic_score_codex":0.00011332364,"about_ca_topic_score_gemma":0.0000050249323,"teacher_disagreement_score":0.020435285,"about_ca_system_score_codex":0.000025448257,"about_ca_system_score_gemma":0.000055216755,"threshold_uncertainty_score":0.5963548},"labels":[],"label_agreement":null},{"id":"W3010351291","doi":"10.1111/dom.14020","title":"Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Placebo; Medicine; Type 2 diabetes; Adverse effect; Clinical endpoint; Metformin; Internal medicine; Randomized controlled trial; Diabetes mellitus; Randomization; Gastroenterology; Endocrinology; Insulin","score_opus":0.012231868217493709,"score_gpt":0.24304934158717661,"score_spread":0.23081747336968292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010351291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197763,0.0019264322,0.0000019555055,0.00014561703,0.000068945206,0.005039927,0.00006701391,0.000030274125,0.00074219925],"genre_scores_gemma":[0.9991061,0.00019989803,0.00023267545,0.00015091726,0.000034345918,0.00008095699,0.00011325305,0.00002424476,0.000057629008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764776,0.00030092677,0.0008265719,0.00046593056,0.00038962133,0.00036921428],"domain_scores_gemma":[0.9983603,0.00061400456,0.00040254748,0.00025370912,0.00015315162,0.00021629193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008585207,0.00033129152,0.0022882237,0.00025678735,0.00005973558,0.00002114481,0.000099005236,0.0000728871,0.00001292968],"category_scores_gemma":[0.0008057096,0.00023150683,0.00011595169,0.00041979525,0.00020095482,0.00016302375,0.00011689341,0.00016026001,0.000001643829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52720433,0.011112869,0.43528703,0.0006364555,0.003777297,0.000011121444,0.005121208,0.000034332486,0.0004885343,0.00015301436,0.00008391124,0.016089883],"study_design_scores_gemma":[0.6812639,0.0025077579,0.31217372,0.00023048604,0.0020798284,1.5584376e-8,0.00019282791,0.00032361955,0.00081503065,0.000018990177,0.00021517235,0.00017861584],"about_ca_topic_score_codex":0.000033332723,"about_ca_topic_score_gemma":0.000009957026,"teacher_disagreement_score":0.1540596,"about_ca_system_score_codex":0.000023094242,"about_ca_system_score_gemma":0.00003269908,"threshold_uncertainty_score":0.94405746},"labels":[],"label_agreement":null},{"id":"W3010554184","doi":"10.1016/j.amjcard.2020.01.053","title":"Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk","year":2020,"lang":"en","type":"article","venue":"The American Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Janssen Pharmaceuticals; Baxter Healthcare Corporation; Daiichi-Sankyo; Luitpold Pharmaceuticals; Bayer Fund; Roche; Novartis; Vifor Pharma; Pfizer; AstraZeneca; Bristol-Myers Squibb; Cytokinetics; European Commission; Sanofi; Merck; Abbott Laboratories; National Institutes of Health; Medtronic; Singulex; Boehringer Ingelheim","keywords":"Alogliptin; Medicine; Saxagliptin; Sitagliptin; Medical prescription; Linagliptin; Context (archaeology); Vildagliptin; Metformin; Diabetes mellitus; Heart failure; Internal medicine; Dipeptidyl peptidase-4; Pharmacology; Type 2 diabetes; Endocrinology","score_opus":0.014793441611724868,"score_gpt":0.2486671332039748,"score_spread":0.23387369159224994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010554184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929353,0.00056693575,0.000013626213,0.005984802,0.000024550947,0.00015945321,0.000009483041,0.0000018652147,0.00030396727],"genre_scores_gemma":[0.99950755,0.000092836584,0.00007033207,0.0002361324,0.000072391245,0.0000037952784,0.0000050836147,0.000005677621,0.0000062208783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870545,0.00046710199,0.0004986429,0.000082487844,0.0001569198,0.000089377194],"domain_scores_gemma":[0.9988687,0.00015470486,0.0007640972,0.000114535054,0.00006165562,0.00003632262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000626564,0.00008802613,0.0006790977,0.00014956376,0.000010383722,0.0000024581566,0.00008640356,0.000020741747,0.000002251879],"category_scores_gemma":[0.000081070895,0.000050404873,0.00014101001,0.00024485364,0.00035602463,0.00005594438,0.000023429799,0.00018779754,1.4191161e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023204358,0.00011099845,0.9484135,0.00006449869,0.000523553,0.000024655003,0.010473318,0.00007397773,0.008136802,0.00005355455,0.0074569983,0.02234771],"study_design_scores_gemma":[0.0041448097,0.017162126,0.9396325,0.00020462305,0.00041788633,0.00006817796,0.027369484,0.000044060725,0.005586116,0.00005795513,0.0052218046,0.00009046501],"about_ca_topic_score_codex":0.00008452898,"about_ca_topic_score_gemma":0.000017402865,"teacher_disagreement_score":0.022257244,"about_ca_system_score_codex":0.000014227509,"about_ca_system_score_gemma":0.000043613687,"threshold_uncertainty_score":0.20554511},"labels":[],"label_agreement":null},{"id":"W3010648955","doi":"10.1111/dom.14032","title":"Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Dosing; Pharmacokinetics; Placebo; Postprandial; Pharmacodynamics; Type 2 diabetes; Diabetes mellitus; Anesthesia; Urology; Internal medicine; Endocrinology","score_opus":0.019440194938486713,"score_gpt":0.2527941115982972,"score_spread":0.23335391665981048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010648955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303776,0.0051611317,1.7455963e-7,0.00063660933,0.0001281217,0.0005831054,0.0000074209224,0.0000495055,0.00039615878],"genre_scores_gemma":[0.9962846,0.0007009919,0.00018734811,0.0025951015,0.000074896125,0.000026777692,0.000029847391,0.00002143847,0.00007901191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885535,0.00004204329,0.0001890955,0.00036630794,0.00021599038,0.00033120075],"domain_scores_gemma":[0.9994907,0.00007915205,0.00006528502,0.000115698414,0.000064648164,0.00018456625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118577445,0.0002396949,0.0005312822,0.0001481462,0.000071408474,0.000028784487,0.0000497177,0.000041526717,0.000014333967],"category_scores_gemma":[0.0000981497,0.00017439314,0.000030024252,0.0002805897,0.00009445592,0.00012590416,0.00009543968,0.00014053247,0.00001300081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009842387,0.00030694704,0.98354214,0.00031625805,0.00043860122,0.0000065001555,0.0006741095,0.000006143688,0.00034403533,0.00023032018,0.00019088744,0.01384564],"study_design_scores_gemma":[0.0052446607,0.00067271397,0.9869139,0.00017796936,0.0005331272,3.2399882e-8,0.00007782491,0.000104652325,0.0033252756,0.000069102905,0.0026811298,0.00019957918],"about_ca_topic_score_codex":0.0000016776951,"about_ca_topic_score_gemma":0.0000012194215,"teacher_disagreement_score":0.013646061,"about_ca_system_score_codex":0.00001876,"about_ca_system_score_gemma":0.000009915533,"threshold_uncertainty_score":0.7111546},"labels":[],"label_agreement":null},{"id":"W3010732428","doi":"10.1016/j.jval.2019.11.004","title":"Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto","funders":"Arnold Ventures","keywords":"Sitagliptin; Medicine; Dulaglutide; Exenatide; Glipizide; Canagliflozin; Hypoglycemia; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.16055804221929282,"score_gpt":0.4034613075485288,"score_spread":0.242903265329236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010732428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96599936,0.0005697734,0.007859001,0.023063662,0.00007882734,0.0020483509,0.0003439526,0.000019807258,0.00001724159],"genre_scores_gemma":[0.9848108,0.000010949342,0.012936862,0.0016965286,0.000030527277,0.00006158266,0.00044122318,0.000010558585,9.370355e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992067,0.0001079963,0.00021529899,0.00019421201,0.00011652626,0.00015925383],"domain_scores_gemma":[0.99840647,0.0010935109,0.00007690385,0.0002563482,0.00004464136,0.00012213424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037808807,0.00007536696,0.0002550624,0.000045776866,0.00006293065,0.000009040251,0.000091157824,0.000018761213,0.0000017669909],"category_scores_gemma":[0.00074728404,0.00005348455,0.000023989527,0.00012328505,0.000027046937,0.000037180114,0.000052841042,0.000042644744,8.7631815e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047003155,0.00059138157,0.8883508,0.002902212,0.00064252707,0.000006327654,0.003264261,0.063573085,0.001863844,0.0012599443,0.00027982774,0.036795784],"study_design_scores_gemma":[0.0036325066,0.0004859642,0.75026023,0.00041371305,0.00035734754,6.3412536e-8,0.0002664967,0.24343362,0.00035427336,0.00011593162,0.0006085828,0.00007124763],"about_ca_topic_score_codex":0.00051823905,"about_ca_topic_score_gemma":0.000040783427,"teacher_disagreement_score":0.17986053,"about_ca_system_score_codex":0.000056002304,"about_ca_system_score_gemma":0.00015056937,"threshold_uncertainty_score":0.21810366},"labels":[],"label_agreement":null},{"id":"W3010842324","doi":"10.1016/s2213-8587(20)30062-0","title":"Cardiorenal risk reduction guidance in diabetes: can we reach consensus?","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Guideline; Intensive care medicine; Diabetes mellitus; Consensus conference; MEDLINE; Evidence-based medicine; Alternative medicine; Internal medicine","score_opus":0.031881481092899636,"score_gpt":0.26590802918457024,"score_spread":0.23402654809167062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010842324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92026645,0.004318699,0.000002661556,0.06993252,0.00031743853,0.00068298297,0.000044818244,0.00023032686,0.004204094],"genre_scores_gemma":[0.99295413,0.0010826177,0.0004251389,0.0040417924,0.0008991212,0.00020303515,0.000054895663,0.000039596245,0.0002996395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709404,0.00028209045,0.00039476302,0.00052968145,0.00021845535,0.0014809989],"domain_scores_gemma":[0.99882555,0.00016643868,0.00016537277,0.00063999154,0.000053815424,0.00014885025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032723727,0.00030476466,0.00089349644,0.000118758384,0.00009757375,0.000023990695,0.00028571315,0.000079920595,0.000058113117],"category_scores_gemma":[0.00022689452,0.00022282203,0.00015231458,0.0003417963,0.00029738728,0.00003942498,0.00016831515,0.0005027351,0.00012149429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020622779,0.00018301456,0.8882788,0.00025796224,0.0011036058,0.00013648628,0.0012406562,0.00013051229,0.009339856,0.0015530576,0.034173045,0.06339679],"study_design_scores_gemma":[0.016645927,0.0026587131,0.61366296,0.0004677031,0.0023088036,0.000036178837,0.001181768,0.0021955187,0.05262215,0.0062874113,0.30073822,0.0011946377],"about_ca_topic_score_codex":0.00006787117,"about_ca_topic_score_gemma":0.000025821251,"teacher_disagreement_score":0.27461582,"about_ca_system_score_codex":0.000126166,"about_ca_system_score_gemma":0.00004352806,"threshold_uncertainty_score":0.9086419},"labels":[],"label_agreement":null},{"id":"W3010961195","doi":"10.1016/j.echo.2020.02.005","title":"Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial","year":2020,"lang":"en","type":"letter","venue":"Journal of the American Society of Echocardiography","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Trillium Health Centre; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Janssen Biotech; St. Jude Medical; Servier; Biotronik; Novo Nordisk; Medicines Company; Novartis; Bristol-Myers Squibb; Sanofi; Merck; GlaxoSmithKline; Biosensors International Group; Amgen; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Heart failure; Cardiology; Ejection fraction; Dapagliflozin; Placebo; Diabetes mellitus; Type 2 diabetes; Canagliflozin; Coronary artery disease; Myocardial infarction; Endocrinology","score_opus":0.010243983845797446,"score_gpt":0.2453211322036341,"score_spread":0.23507714835783666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010961195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842178,0.002667094,0.000013177634,0.009437007,0.00056795886,0.0030481059,0.0000280126,0.00000966191,0.000011138732],"genre_scores_gemma":[0.97326624,0.0031898073,0.00036411436,0.022497827,0.0005807493,0.00001721061,0.000016831425,0.0000622289,0.0000049792907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943941,0.0017644144,0.0015558465,0.00040228444,0.001531087,0.00035225687],"domain_scores_gemma":[0.9946124,0.001390749,0.002719629,0.00074775866,0.00038188105,0.00014759062],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015876199,0.00048018573,0.004241357,0.00040187806,0.00006349043,0.000013800991,0.00045823574,0.00018424906,9.102993e-7],"category_scores_gemma":[0.000296698,0.00025698406,0.0077046463,0.0014433056,0.0014606596,0.00006332267,0.0001694635,0.0014447185,1.6449897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07934638,0.0005971397,0.8497946,0.00066168734,0.01671526,0.000043601303,0.00011162979,0.00013221127,0.00000996428,1.7643755e-7,0.052102163,0.00048518318],"study_design_scores_gemma":[0.18725103,0.004983729,0.7899334,0.0022690454,0.014077607,0.0000025719057,0.00008192789,0.000052692776,0.000037080714,0.00006156683,0.0009928232,0.00025654037],"about_ca_topic_score_codex":0.0000067233827,"about_ca_topic_score_gemma":9.49638e-8,"teacher_disagreement_score":0.10790465,"about_ca_system_score_codex":0.00005218806,"about_ca_system_score_gemma":0.0001549934,"threshold_uncertainty_score":0.99998826},"labels":[],"label_agreement":null},{"id":"W3010968620","doi":"10.1007/s13300-020-00797-y","title":"Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L","year":2020,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Insulin glargine; Type 2 diabetes; Internal medicine; Glycated hemoglobin; Endocrinology; Diabetes mellitus; Insulin; Quartile; Gastroenterology; Gastric emptying; Exenatide; Insulin degludec; Confidence interval","score_opus":0.01154119011127701,"score_gpt":0.22026403721401855,"score_spread":0.20872284710274153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010968620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99788296,0.0010860263,0.000011044533,0.00028828415,0.000020510219,0.0005230636,0.000009855353,0.0000192147,0.00015901675],"genre_scores_gemma":[0.9990671,0.00021726772,0.00019688105,0.0003100437,0.000011797618,0.000017839386,0.00014269465,0.000019278446,0.000017083368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905646,0.000037406324,0.00028570276,0.00020572454,0.00023697272,0.00017772726],"domain_scores_gemma":[0.99942935,0.00005911523,0.00016392015,0.00015487534,0.0001274232,0.00006533888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011283647,0.00014831858,0.00047160688,0.00017664215,0.000020339534,0.000014539622,0.00005938426,0.00004545191,0.00003702517],"category_scores_gemma":[0.000038205002,0.00011423983,0.000047898415,0.0005637714,0.00007438404,0.00010485272,0.000022778859,0.000059475246,0.0000015704342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027522794,0.0005128957,0.9783879,0.00015312743,0.00043235018,7.4733526e-7,0.00078727974,0.000008168702,0.0020488352,0.00008069118,0.000042477113,0.017270321],"study_design_scores_gemma":[0.008958949,0.003970402,0.96566486,0.00017278524,0.0001891557,6.423949e-9,0.0000907337,0.001007457,0.019591698,0.000052026568,0.00016002462,0.0001419089],"about_ca_topic_score_codex":0.0000068316917,"about_ca_topic_score_gemma":0.0000037142004,"teacher_disagreement_score":0.017542863,"about_ca_system_score_codex":0.000031709293,"about_ca_system_score_gemma":0.000021289885,"threshold_uncertainty_score":0.46585652},"labels":[],"label_agreement":null},{"id":"W3011223442","doi":"10.1093/ndt/gfz294","title":"The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial","year":2020,"lang":"en","type":"letter","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Benzhydryl compounds; Renal function; Internal medicine; Cardiac function curve; Diabetes mellitus; Cardiology; Endocrinology; Heart failure","score_opus":0.00410406241820072,"score_gpt":0.2149903291600831,"score_spread":0.21088626674188238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011223442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946711,0.000084779495,0.000005858207,0.0027473753,0.0002691942,0.0018365232,0.0003212618,0.000013921794,0.000050003844],"genre_scores_gemma":[0.98789954,0.00015668907,0.000016572896,0.009790028,0.0001861922,0.00006377831,0.0018391538,0.000043171553,0.000004864998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723816,0.0007373101,0.0006776862,0.00046387484,0.0005763638,0.0003066085],"domain_scores_gemma":[0.9978757,0.00071517803,0.0006744206,0.000503861,0.00016497081,0.00006587802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020370928,0.0004209863,0.0013230653,0.00049566635,0.00007591798,0.00001312638,0.00014978679,0.00036615544,0.000007075382],"category_scores_gemma":[0.00017385127,0.00023680617,0.0005946493,0.0008749344,0.00023819278,0.000044025306,0.000018710398,0.00046926082,5.7775264e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059552066,0.0003360996,0.88033146,0.0019424133,0.032604028,0.000019823456,0.0006290244,0.00026334482,0.0049877698,0.000006656495,0.01702804,0.0022993053],"study_design_scores_gemma":[0.029076245,0.013719877,0.92509913,0.0006050928,0.027417311,2.3565865e-7,0.000013850524,0.0001466669,0.003344541,0.00008112031,0.00016679264,0.000329115],"about_ca_topic_score_codex":0.00009340035,"about_ca_topic_score_gemma":0.000013122013,"teacher_disagreement_score":0.044767722,"about_ca_system_score_codex":0.00009856598,"about_ca_system_score_gemma":0.00013280797,"threshold_uncertainty_score":0.96566755},"labels":[],"label_agreement":null},{"id":"W3011600512","doi":"10.1016/j.cjca.2020.02.098","title":"The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Liraglutide; Diabetic cardiomyopathy; Agonist; Internal medicine; Endocrinology; Glucagon-like peptide 1 receptor; Diabetes mellitus; Glucagon-like peptide-1; Cardiomyopathy; Cardiology; Receptor; Type 2 diabetes; Heart failure","score_opus":0.01126895309715044,"score_gpt":0.2201785406169657,"score_spread":0.20890958751981525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011600512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982405,0.0111094965,0.0003375041,0.0038005034,0.0006544482,0.0003790598,0.000025306104,0.00001696895,0.0012717138],"genre_scores_gemma":[0.9973062,0.000459014,0.00030311217,0.00084246416,0.00096710416,0.000021047237,0.000038079994,0.000025513988,0.00003743767],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986591,0.00023237409,0.00034711647,0.00020386068,0.00016234862,0.000395215],"domain_scores_gemma":[0.99858063,0.00013442434,0.00016564217,0.0001533916,0.00011976001,0.0008461251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003599308,0.00020666682,0.00062674115,0.00014003139,0.00025776197,0.00008052335,0.00013563568,0.00009183252,0.00001903201],"category_scores_gemma":[0.00024101419,0.00015197786,0.00025028503,0.00013935634,0.0002635665,0.00010128146,0.000034927336,0.0001816884,0.000018039776],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023489879,0.00008504474,0.33856502,0.0002898591,0.016408712,0.003724198,0.004075331,0.0003690141,0.36435765,0.004767411,0.12203265,0.14297614],"study_design_scores_gemma":[0.011205659,0.00966441,0.15852861,0.00028834556,0.003932857,0.0011507095,0.0059330547,0.00015945724,0.34145135,0.0017413078,0.46476066,0.001183595],"about_ca_topic_score_codex":0.0004173441,"about_ca_topic_score_gemma":0.0001215388,"teacher_disagreement_score":0.34272802,"about_ca_system_score_codex":0.00018135931,"about_ca_system_score_gemma":0.00037717272,"threshold_uncertainty_score":0.61974776},"labels":[],"label_agreement":null},{"id":"W3011757834","doi":"10.1139/cjpp-2019-0677","title":"Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease","year":2020,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; Libin Cardiovascular Institute of Alberta","funders":"Canadian Institutes of Health Research; Qatar Foundation","keywords":"Endothelium; Autocrine signalling; Paracrine signalling; Medicine; Endocrinology; Internal medicine; Metformin; Diabetes mellitus; Receptor","score_opus":0.021394653499872043,"score_gpt":0.30006085406593863,"score_spread":0.2786662005660666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011757834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018100442,0.9784756,0.0000012115866,0.016411746,0.00140149,0.0014386679,0.00014894121,0.00001088103,0.0003014234],"genre_scores_gemma":[0.005638628,0.9552245,0.000015959271,0.03693618,0.0013255038,0.00017591118,0.000076639844,0.00006451787,0.0005421651],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974917,0.0008526769,0.0005442389,0.00033121428,0.00013961374,0.00064051215],"domain_scores_gemma":[0.9974156,0.00044782512,0.0004489102,0.00027065608,0.00012508057,0.0012919223],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004482873,0.00043484702,0.0015972134,0.00025855447,0.00029554803,0.00002708001,0.00052759144,0.00017997871,0.0015000893],"category_scores_gemma":[0.00018902215,0.00023061087,0.00067190465,0.0003199775,0.00033560515,0.00004428246,0.00007919817,0.00085241825,0.00008987235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003701391,0.0004118647,0.00021751314,0.008866956,0.02939821,0.003020259,0.001164449,0.000025469857,0.002699506,0.00070766575,0.6630908,0.29002714],"study_design_scores_gemma":[0.0009332945,0.00058527285,0.00013480021,0.00071013556,0.008032694,0.000032973225,0.000023686596,0.00000469592,0.000097039614,0.00031113412,0.98894143,0.00019284687],"about_ca_topic_score_codex":0.00018275861,"about_ca_topic_score_gemma":0.00010884425,"teacher_disagreement_score":0.3258506,"about_ca_system_score_codex":0.00021667643,"about_ca_system_score_gemma":0.0019165062,"threshold_uncertainty_score":0.99941266},"labels":[],"label_agreement":null},{"id":"W3011798818","doi":"10.1016/j.kint.2019.12.021","title":"Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function","year":2020,"lang":"en","type":"editorial","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Toronto General Hospital; University of Toronto","funders":"Boehringer Ingelheim; AstraZeneca","keywords":"Type 2 diabetes; Endocrinology; Cotransporter; Diabetes mellitus; Renal function; Medicine; Internal medicine; Sodium; Hemodynamics; Kidney; Chemistry","score_opus":0.0027456116972190804,"score_gpt":0.19363566141075567,"score_spread":0.1908900497135366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011798818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91625994,0.0004455135,0.000016448632,0.0005765195,0.08101504,0.0007970675,0.00017441128,0.00006802382,0.0006470534],"genre_scores_gemma":[0.94912183,0.00058351085,0.00056915695,0.00055244967,0.041430023,0.00012962938,0.006903822,0.00011842922,0.0005911323],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979761,0.000031074273,0.00036116323,0.0005652095,0.0007324212,0.00033399617],"domain_scores_gemma":[0.9987926,0.00016263852,0.00022008464,0.00019228013,0.0002633889,0.00036901646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000115257106,0.0004370683,0.0006953154,0.00034506875,0.000042741936,0.00006206647,0.0001237831,0.00023982242,0.000075202835],"category_scores_gemma":[0.00026423208,0.00034936008,0.00005749633,0.00029211066,0.00009662258,0.0002338499,0.00010032374,0.0004072393,0.0000071820623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027071352,0.0005896052,0.5521472,0.0044408552,0.0032109825,0.00009243377,0.0010717503,0.000011641763,0.010059843,0.000030783933,0.4226617,0.0029760865],"study_design_scores_gemma":[0.038915657,0.018817881,0.3707939,0.014445692,0.0067722886,0.000012932708,0.00022274352,0.0044787796,0.022955643,0.000080062906,0.52001274,0.0024916683],"about_ca_topic_score_codex":0.00005867965,"about_ca_topic_score_gemma":0.00012524285,"teacher_disagreement_score":0.18135329,"about_ca_system_score_codex":0.00012715945,"about_ca_system_score_gemma":0.00032296433,"threshold_uncertainty_score":0.9998958},"labels":[],"label_agreement":null},{"id":"W3011824422","doi":"10.1016/j.diabres.2020.108107","title":"Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice","year":2020,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research; Kidney Foundation of Canada","keywords":"Canagliflozin; Medicine; Internal medicine; Endocrinology; Insulin; Diabetes mellitus; Albuminuria; Type 2 diabetes; Blood pressure; Glycemic; Renin–angiotensin system; Kidney","score_opus":0.08841084622187859,"score_gpt":0.42051302257636514,"score_spread":0.3321021763544866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011824422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798079,0.0035930264,2.615129e-7,0.014203257,0.000112769434,0.0009496347,0.000003853893,0.000012093496,0.0013171762],"genre_scores_gemma":[0.9983768,0.00042084124,0.00012570895,0.0008514571,0.00011935855,0.000019057225,0.000004299904,0.000014288672,0.00006821385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972021,0.0009970748,0.0005700977,0.00031769945,0.0005854006,0.00032764094],"domain_scores_gemma":[0.9847061,0.014299003,0.00022162539,0.0003158642,0.0002830569,0.0001743568],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0022725444,0.00013219909,0.00053408876,0.00007218667,0.00008006268,0.00003053034,0.00015960702,0.000106415435,0.000005672975],"category_scores_gemma":[0.019738162,0.00007260766,0.000081329636,0.0005642218,0.00047924355,0.00009003871,0.0002920421,0.00071329554,0.000011454001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021815537,0.0022974603,0.9260635,0.0014803468,0.0009294104,0.000023902665,0.0006218389,0.0000017330141,0.011947814,0.002038746,0.016088478,0.036325216],"study_design_scores_gemma":[0.006985167,0.02559196,0.8532724,0.003577821,0.00088993367,7.105118e-7,0.0016330257,0.0037600042,0.07717245,0.00017806626,0.02665682,0.00028168925],"about_ca_topic_score_codex":0.000021480451,"about_ca_topic_score_gemma":0.000004798108,"teacher_disagreement_score":0.072791144,"about_ca_system_score_codex":0.000027151635,"about_ca_system_score_gemma":0.000059543938,"threshold_uncertainty_score":0.988519},"labels":[],"label_agreement":null},{"id":"W3012203700","doi":"10.3389/fendo.2020.00116","title":"Role of the Gut in Diabetic Dyslipidemia","year":2020,"lang":"en","type":"review","venue":"Frontiers in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Diabetes Action Research and Education Foundation","keywords":"Insulin resistance; Chylomicron; Endocrinology; Internal medicine; Dyslipidemia; Type 2 diabetes; Metabolic syndrome; Hypertriglyceridemia; Medicine; Very low-density lipoprotein; Diabetes mellitus; Secretion; Biology; Lipoprotein; Cholesterol; Triglyceride","score_opus":0.016714906773767715,"score_gpt":0.2804987202307369,"score_spread":0.2637838134569692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012203700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000703625,0.98889893,0.000004913085,0.00030651074,0.00093372323,0.001304803,0.000009365578,0.000021017815,0.008450372],"genre_scores_gemma":[0.00028214502,0.997771,0.00065284304,0.00010656059,0.00007938075,0.00024306879,0.00003298178,0.000036193625,0.00079581107],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982131,0.00019149421,0.00062544196,0.0003752792,0.00013047257,0.0004642166],"domain_scores_gemma":[0.99915856,0.000062380415,0.00022411771,0.0004934446,0.000010792016,0.000050674447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006728266,0.00029843103,0.0022314177,0.00040408043,0.000011313771,0.0000029679727,0.00034546122,0.00017818152,0.00003074348],"category_scores_gemma":[0.000114657676,0.00019958506,0.0003540518,0.0005051027,0.0001423661,0.000019957464,0.00026154137,0.00051223545,0.000026176785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008856094,0.00010779803,0.014042079,0.0038345277,0.0003138842,0.00007218191,0.000045849345,5.8675283e-7,5.0671605e-7,0.00053774856,0.0058179074,0.97521806],"study_design_scores_gemma":[0.00074888585,0.0000940655,0.0016524983,0.003076257,0.00084897206,0.0000059381614,0.000082061466,0.0000118558655,0.0000035659966,0.00040720357,0.99294,0.00012866766],"about_ca_topic_score_codex":0.000017399425,"about_ca_topic_score_gemma":0.000014706823,"teacher_disagreement_score":0.9871221,"about_ca_system_score_codex":0.0002979082,"about_ca_system_score_gemma":0.00013979562,"threshold_uncertainty_score":0.81388426},"labels":[],"label_agreement":null},{"id":"W3012220563","doi":"10.1016/j.ekir.2020.02.166","title":"SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS","year":2020,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Albuminuria; Canagliflozin; Medicine; Credence; Internal medicine; Kidney disease; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.01520316141168398,"score_gpt":0.26397422775000334,"score_spread":0.24877106633831936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012220563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8947885,0.0009108834,0.007822019,0.062466376,0.00086898904,0.0013072625,0.00025066244,0.00014605167,0.031439267],"genre_scores_gemma":[0.99078953,0.00006931183,0.002590878,0.0044844584,0.00011557157,0.000026932357,0.0003362201,0.000015154965,0.0015719421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982559,0.000027091377,0.000539087,0.00042821394,0.000595011,0.00015467913],"domain_scores_gemma":[0.9988364,0.000055339846,0.00017459493,0.00033057557,0.00015196145,0.00045115035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041179275,0.000163055,0.0005922481,0.00026713352,0.000032485514,0.000025077201,0.00008538858,0.000039235627,0.00037355852],"category_scores_gemma":[0.0013189279,0.00014071308,0.000411131,0.00038730033,0.000028468763,0.000102232756,0.00015848254,0.00008322806,0.0000071448917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020938949,0.0001463462,0.9243389,0.00012403766,0.030851334,0.0018528873,0.00039735224,0.00040450177,0.00089634757,0.00016548057,0.022060102,0.018553331],"study_design_scores_gemma":[0.0028515065,0.00033678624,0.571468,0.00026190374,0.012071003,0.00010887254,0.00045012488,0.0017400146,0.0039227554,0.000103503844,0.40619943,0.00048614538],"about_ca_topic_score_codex":0.0005472158,"about_ca_topic_score_gemma":0.000049178372,"teacher_disagreement_score":0.3841393,"about_ca_system_score_codex":0.00009721564,"about_ca_system_score_gemma":0.00014059672,"threshold_uncertainty_score":0.5738113},"labels":[],"label_agreement":null},{"id":"W3012269349","doi":"10.1016/j.ijcard.2020.03.025","title":"Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis","year":2020,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Canadian Vascular Network","keywords":"Medicine; Metformin; Sulfonylurea; Type 2 diabetes; Internal medicine; Adverse effect; Population; Diabetes mellitus; Lower risk; Cohort; Insulin; Endocrinology; Confidence interval","score_opus":0.015639166435645478,"score_gpt":0.24954741264594726,"score_spread":0.2339082462103018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012269349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683964,0.0003475283,0.0022778304,0.00019735686,0.00015310367,0.00010650025,0.0000145729255,0.000004534641,0.00005895717],"genre_scores_gemma":[0.9994011,0.00013344189,0.00021227874,0.000121021425,0.00007667691,0.0000020642583,0.000040361323,0.000008009393,0.000005077829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990794,0.00006395629,0.00027756227,0.00012402987,0.00035782883,0.00009723342],"domain_scores_gemma":[0.999156,0.000049026912,0.00034425675,0.00007936853,0.00030653377,0.00006479186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002848438,0.00009301228,0.00057920185,0.00031614193,0.000008134346,0.0000022408922,0.000076740245,0.00004752751,0.000010878842],"category_scores_gemma":[0.00030318077,0.00007333513,0.00033715423,0.00027334807,0.000018267978,0.00006859711,0.000030065947,0.00010278205,5.9234003e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004350848,0.00007123507,0.9107437,0.0000110574465,0.021529477,0.00013372097,0.00003213778,0.066347435,0.0000773199,0.0000012892878,0.00001088616,0.0006066666],"study_design_scores_gemma":[0.004020066,0.00044083947,0.98687273,0.00013421288,0.003996694,0.000003897778,0.000031825566,0.0041726725,0.000059731286,0.000005644857,0.0002029642,0.000058707705],"about_ca_topic_score_codex":0.000019306492,"about_ca_topic_score_gemma":0.000009855176,"teacher_disagreement_score":0.07612905,"about_ca_system_score_codex":0.00011305041,"about_ca_system_score_gemma":0.000026475282,"threshold_uncertainty_score":0.299052},"labels":[],"label_agreement":null},{"id":"W3012329906","doi":"10.1177/1179551420912972","title":"Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism","year":2020,"lang":"en","type":"review","venue":"Clinical Medicine Insights Endocrinology and Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Dipeptidyl peptidase; Inflammation; Incretin; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Endocrinology; Type 2 diabetes; Diabetes mellitus; Internal medicine; Biology; Medicine; Biochemistry","score_opus":0.07743754040244565,"score_gpt":0.3902965182319713,"score_spread":0.31285897782952565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012329906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0151888635,0.97518927,0.0000042354477,0.0044353493,0.00050349394,0.0015228621,0.0000094567085,0.000118430486,0.003028037],"genre_scores_gemma":[0.004727062,0.99022174,0.000042977776,0.0005663326,0.0026881595,0.00018711164,0.00021498791,0.00005528922,0.001296345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962585,0.0006415976,0.0014443648,0.0008910002,0.0002408112,0.0005237155],"domain_scores_gemma":[0.99499685,0.003421761,0.0005327763,0.00057054445,0.000060763785,0.00041729258],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040153047,0.0006765441,0.0037720134,0.0002175329,0.00020639115,0.000022527935,0.00022031448,0.00041229534,0.00008543124],"category_scores_gemma":[0.00092008244,0.0003366657,0.00033788246,0.00023080659,0.0017632743,0.00008446065,0.00070220063,0.0009455828,0.0001303786],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000117002655,0.000029432676,0.0035509476,0.0040610223,0.0017339604,0.000059285892,0.000089540714,1.0585401e-8,0.0000016877817,0.00072984374,0.0015802239,0.9881523],"study_design_scores_gemma":[0.0019278321,0.0008562381,0.0049866233,0.0051225573,0.010703442,0.00001822045,0.000035559253,0.0000034134994,0.000017928578,0.00034816694,0.9756971,0.00028289534],"about_ca_topic_score_codex":0.000005351974,"about_ca_topic_score_gemma":0.000006965521,"teacher_disagreement_score":0.98786944,"about_ca_system_score_codex":0.000041519277,"about_ca_system_score_gemma":0.000059702616,"threshold_uncertainty_score":0.99990857},"labels":[],"label_agreement":null},{"id":"W3012954817","doi":"10.1139/cjas-2019-0124","title":"Molecular cloning, sequence characteristics, and tissue expression analysis of glucagon receptor gene in Bama minipig","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Animal Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Science and Technology Major Project; Agricultural Science and Technology Innovation Program; National Key Laboratory of Animal Nutrition; National Natural Science Foundation of China","keywords":"Glucagon receptor; Biology; Coding region; Gene; Receptor; G protein-coupled receptor; Glucagon; Amino acid; Transmembrane domain; Ligand (biochemistry); Genetics; Biochemistry; Endocrinology; Insulin","score_opus":0.022303703781714222,"score_gpt":0.2687469831731838,"score_spread":0.24644327939146957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012954817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980519,0.00032629544,0.00004371617,0.0012055159,0.000044136825,0.00007600922,0.000011217015,0.0000015849994,0.00023964593],"genre_scores_gemma":[0.9978619,0.00004032692,0.0017309419,0.00031439448,0.000033547767,5.784209e-7,0.0000033468064,0.000003906268,0.000011022953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999141,0.000015924865,0.00025746625,0.00015575207,0.00022167701,0.00020817597],"domain_scores_gemma":[0.9989601,0.000010871613,0.00016490108,0.00008009095,0.00012250476,0.00066156173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002581199,0.00007450616,0.00027861676,0.0004720249,0.00003975029,0.00003089996,0.00014843201,0.000024013863,0.00008972779],"category_scores_gemma":[0.00019732649,0.0000631961,0.000042980304,0.0009674686,0.00021765556,0.00014524776,0.000022008508,0.0000764377,0.000001577497],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004106904,0.000012267233,0.08468101,0.000016085178,0.00004814503,0.00028286484,0.0005760624,0.00000863296,0.9111893,0.0000598377,0.00007979143,0.003004906],"study_design_scores_gemma":[0.00054659846,0.0016773797,0.6427103,0.0001800277,0.00043832016,0.000010092137,0.0002596461,0.0009048003,0.3507467,0.0000054829757,0.0024027792,0.000117814],"about_ca_topic_score_codex":0.0005499734,"about_ca_topic_score_gemma":0.00022968452,"teacher_disagreement_score":0.5604426,"about_ca_system_score_codex":0.00010871554,"about_ca_system_score_gemma":0.00046097575,"threshold_uncertainty_score":0.25770622},"labels":[],"label_agreement":null},{"id":"W3013231790","doi":"10.1016/j.numecd.2020.03.013","title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials","year":2020,"lang":"en","type":"review","venue":"Nutrition Metabolism and Cardiovascular Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Novartis; Merck","keywords":"Medicine; Atrial fibrillation; Heart failure; Internal medicine; Cardiology; Randomized controlled trial; Meta-analysis; Pharmacology","score_opus":0.025011408521433198,"score_gpt":0.27546756289296037,"score_spread":0.2504561543715272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013231790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018997607,0.9812281,0.000044852106,0.000043646694,0.00009217143,0.0149676865,0.0016376524,0.00007483413,0.000011281355],"genre_scores_gemma":[0.0022063463,0.9781856,0.00045447,0.000025682673,0.0004026649,0.0015130573,0.017089196,0.00009186524,0.000031125775],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98763514,0.0066487044,0.0026027265,0.0012837683,0.001454781,0.0003748686],"domain_scores_gemma":[0.99662715,0.0004998067,0.0009615287,0.0010657416,0.00040377272,0.00044197272],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0036304754,0.0010574699,0.047540575,0.0014749166,0.00010277399,0.00012196365,0.000121752055,0.00032181505,0.0001328946],"category_scores_gemma":[0.0005558384,0.0006386508,0.044347856,0.0015366073,0.00017185576,0.00028860138,0.00007301629,0.0001778847,0.0000034714449],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023167906,0.00030021017,0.00029049424,0.0036590856,0.9262367,0.000016954617,0.000014379678,0.00004055798,1.0810181e-7,0.000030396144,0.0001571541,0.046086073],"study_design_scores_gemma":[0.16152145,0.0001175719,0.0002464628,0.00032543336,0.5506562,0.0000016938453,0.000018923214,0.000013002505,6.790677e-7,0.000005477485,0.2867877,0.00030543475],"about_ca_topic_score_codex":0.00013915333,"about_ca_topic_score_gemma":0.000005068062,"teacher_disagreement_score":0.3755805,"about_ca_system_score_codex":0.00006605236,"about_ca_system_score_gemma":0.0001231966,"threshold_uncertainty_score":0.9996065},"labels":[],"label_agreement":null},{"id":"W3013330267","doi":"10.1111/dom.14015","title":"Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: <i>Post hoc</i> analysis of the EMPA‐REG OUTCOME trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; McGill University; University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences","keywords":"Empagliflozin; Medicine; Internal medicine; Myocardial infarction; Post-hoc analysis; Placebo; Diabetes mellitus; Heart failure; Cardiology; Type 2 diabetes; Hazard ratio; Confidence interval; Endocrinology","score_opus":0.017965382220222717,"score_gpt":0.2772640766944761,"score_spread":0.2592986944742534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013330267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99182856,0.0013874287,0.000019564579,0.0027673955,0.00017646574,0.0029044813,0.00089264446,0.000020892148,0.0000025737093],"genre_scores_gemma":[0.99830186,0.00028282302,0.00025718368,0.00045412805,0.00015244019,0.00031259898,0.00021025263,0.000021318683,0.000007410263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978132,0.00026286338,0.0007180852,0.00048057624,0.00031607298,0.00040916726],"domain_scores_gemma":[0.9985491,0.0003657915,0.00042066077,0.00037278768,0.00018554351,0.00010608816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011913248,0.0003005736,0.0014149955,0.00019650478,0.00021147315,0.00006050692,0.00014769248,0.00016428929,0.0000048002835],"category_scores_gemma":[0.0008225667,0.00019409142,0.00058452995,0.0012412242,0.00029468947,0.0002531159,0.00013250677,0.00019239544,2.3603357e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005396788,0.0002486127,0.99182713,0.00025494845,0.0023674956,6.474172e-8,0.0025200492,0.00018954645,0.0012602465,0.00010105661,0.0002103099,0.00048088422],"study_design_scores_gemma":[0.010778936,0.0004598209,0.9696386,0.00004324528,0.008433319,2.318239e-8,0.0013805837,0.00081209047,0.006754344,0.00026835196,0.0012479177,0.0001828117],"about_ca_topic_score_codex":0.000457751,"about_ca_topic_score_gemma":0.0011155829,"teacher_disagreement_score":0.02218855,"about_ca_system_score_codex":0.000027749149,"about_ca_system_score_gemma":0.00004247375,"threshold_uncertainty_score":0.79148185},"labels":[],"label_agreement":null},{"id":"W3013517692","doi":"10.1002/osp4.419","title":"Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program","year":2020,"lang":"en","type":"article","venue":"Obesity Science & Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Persistence (discontinuity); Liraglutide; Medicine; Weight loss; Internal medicine; Weight management; Observational study; Retrospective cohort study; Obesity; Type 2 diabetes; Endocrinology; Diabetes mellitus","score_opus":0.01925399590658443,"score_gpt":0.27622105806351366,"score_spread":0.2569670621569292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013517692","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41374245,0.00042415204,0.0008145352,0.13482739,0.00030737475,0.014107557,0.000012841341,0.00044459116,0.4353191],"genre_scores_gemma":[0.94649816,0.00035119077,0.042113014,0.007195868,0.00006772644,0.0004171163,0.0000127201265,0.000016825259,0.0033273695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980797,0.000042916014,0.00018567791,0.0005695632,0.00069740776,0.00042468862],"domain_scores_gemma":[0.9988438,0.00017765042,0.00016751439,0.00035221022,0.00019443315,0.000264419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007330072,0.00017684764,0.00023206597,0.00008685479,0.00045513856,0.00018838607,0.00023273121,0.000017573766,0.000030138623],"category_scores_gemma":[0.00022220795,0.00010432069,0.000063028696,0.00074461685,0.0007251564,0.00069548964,0.00022587104,0.00011832442,0.000029895395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01366367,0.006015929,0.12250116,0.0018592901,0.00199178,0.0013404404,0.021388067,0.00003714835,0.0003504195,0.16100766,0.033633832,0.6362106],"study_design_scores_gemma":[0.0071286918,0.0051301937,0.042650547,0.00012219367,0.002602605,0.000042205025,0.0077132336,0.0017956854,0.00082933536,0.00012396369,0.93147725,0.0003840916],"about_ca_topic_score_codex":0.00004940795,"about_ca_topic_score_gemma":0.000019775172,"teacher_disagreement_score":0.8978434,"about_ca_system_score_codex":0.00010453478,"about_ca_system_score_gemma":0.00011422866,"threshold_uncertainty_score":0.42540744},"labels":[],"label_agreement":null},{"id":"W3013689722","doi":"10.1093/eurheartj/ehaa183","title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Montreal Heart Institute; St. Michael's Hospital; Université de Montréal; University of Calgary","funders":"Janssen Research and Development; Relypsa; Respicardia; American Regent; Vifor Pharma; University of Glasgow; University of Oxford; GlaxoSmithKline; IFM Therapeutics; Zora Biosciences; Medicines Company; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Sanofi Pasteur; Celladon Corporation; Boston Scientific Corporation; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; British Heart Foundation; Eisai; Cytokinetics; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Heart failure; Internal medicine; Cardiology; Intensive care medicine; Diabetes mellitus; Endocrinology","score_opus":0.04614080568063384,"score_gpt":0.29512790984010806,"score_spread":0.24898710415947423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013689722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98277545,0.00057752617,0.00009856468,0.0129058,0.00016320705,0.00046860488,7.2176823e-7,0.000034521843,0.0029756054],"genre_scores_gemma":[0.98946124,0.000085135434,0.0029389106,0.006734106,0.0005191757,0.0000028490442,0.000002232842,0.00004571779,0.00021065156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871546,0.00021433734,0.00029770395,0.00020699576,0.00026904553,0.00029644527],"domain_scores_gemma":[0.9993391,0.00007148679,0.000063233674,0.00014351556,0.000040127004,0.0003425466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040231258,0.00016298602,0.0003712013,0.00016783267,0.000053555876,0.00005618646,0.000113228874,0.000019960798,0.000103820676],"category_scores_gemma":[0.00007108597,0.00013163337,0.00013950371,0.00031445644,0.000016701477,0.00012713039,0.00008105591,0.00027632332,0.00027990906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001049985,0.0009782339,0.42028412,0.00044727622,0.000555165,0.001733086,0.0028378807,0.00009402854,0.32456958,0.00019114977,0.22068794,0.026571551],"study_design_scores_gemma":[0.0077329357,0.003596434,0.48697552,0.0007654392,0.00009960723,0.00010169212,0.00089124474,0.000045922363,0.021739705,0.000013409043,0.47775504,0.00028306447],"about_ca_topic_score_codex":0.0000027024778,"about_ca_topic_score_gemma":0.000001001416,"teacher_disagreement_score":0.3028299,"about_ca_system_score_codex":0.000047697406,"about_ca_system_score_gemma":0.000029843117,"threshold_uncertainty_score":0.5367853},"labels":[],"label_agreement":null},{"id":"W3013838418","doi":"10.1001/jama.2020.1906","title":"Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes","year":2020,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":536,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Libin Cardiovascular Institute of Alberta; University of Toronto; University of Calgary; St. Michael's Hospital","funders":"Janssen Research and Development; National Heart, Lung, and Blood Institute; Respicardia; National Institutes of Health; Vifor Pharma; Cytokinetics; Eisai; Zora Biosciences; Kidney Research UK; Impulse Dynamics; GlaxoSmithKline; IFM Therapeutics; Daiichi-Sankyo; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; Esperion Therapeutics; Alnylam Pharmaceuticals; MyoKardia; Servier; Gilead Sciences; British Heart Foundation; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; AstraZeneca; Amarin Corporation; Sanofi Pasteur; Celladon Corporation; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Heart failure; Diabetes mellitus; Cardiology; Internal medicine; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.004969097910335985,"score_gpt":0.20145867624169436,"score_spread":0.19648957833135838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013838418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705565,0.00024222638,0.000004396418,0.0015825181,0.000008581892,0.0008997358,0.000004068136,0.00003186843,0.00017094346],"genre_scores_gemma":[0.9980448,0.000004104039,0.0013650031,0.0004425116,0.00003792323,0.000038181563,0.000021522943,0.000027804454,0.000018175826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892396,0.00007721238,0.00012492665,0.0003401824,0.00031095356,0.00022277751],"domain_scores_gemma":[0.99952394,0.00005403436,0.00003414407,0.00021556795,0.000034217195,0.00013809062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017359231,0.00020886683,0.000596806,0.000088933266,0.000029475555,0.000028260663,0.000029924862,0.00005492225,0.000007452837],"category_scores_gemma":[0.00004128767,0.00013074359,0.00005711345,0.00017496772,0.00005392015,0.000101910126,0.000042330852,0.00013907741,0.0000035474566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005925452,0.00006423375,0.9948298,0.000361049,0.00048831094,0.000006391188,0.0001244926,0.000029466488,0.000052946936,0.000008927176,0.0006446559,0.0027971866],"study_design_scores_gemma":[0.01626945,0.0084765935,0.9632313,0.0008159985,0.0007002449,0.0000011645088,0.00006940157,0.00009251862,0.0032133672,0.0000015778281,0.0069428724,0.00018550834],"about_ca_topic_score_codex":0.000016836602,"about_ca_topic_score_gemma":0.000010532438,"teacher_disagreement_score":0.03159849,"about_ca_system_score_codex":0.000017262737,"about_ca_system_score_gemma":0.000010592518,"threshold_uncertainty_score":0.5331569},"labels":[],"label_agreement":null},{"id":"W3014351387","doi":"10.1111/dom.14043","title":"Differential glycaemic control with basal insulin glargine 300 <scp>U/mL</scp> versus degludec 100 <scp>U/mL</scp> according to kidney function in type 2 diabetes: A subanalysis from the <scp>BRIGHT</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Insulin degludec; Medicine; Renal function; Insulin glargine; Internal medicine; Urology; Diabetes mellitus; Type 2 diabetes; Confidence interval; Endocrinology; Kidney disease; Gastroenterology; Randomized controlled trial; Type 1 diabetes","score_opus":0.014324296476900424,"score_gpt":0.22038638604777686,"score_spread":0.20606208957087643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014351387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884522,0.0047371103,0.00032129695,0.0009139665,0.0016425863,0.0027462158,0.00028145782,0.00028350338,0.00062167423],"genre_scores_gemma":[0.9886366,0.00066644856,0.00029751824,0.006262274,0.0021583869,0.00035902055,0.00094485877,0.00013781246,0.0005370719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944259,0.00046322803,0.00095536676,0.0015103414,0.0010567555,0.00158842],"domain_scores_gemma":[0.99488515,0.0022481845,0.0004391704,0.00088880194,0.0002737693,0.0012649363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064016256,0.0010600834,0.0022158863,0.00054262805,0.00041222075,0.00040838777,0.0005847655,0.00040619282,0.00007554275],"category_scores_gemma":[0.0030304787,0.00077461073,0.00050523813,0.0018838929,0.00021493937,0.0005515242,0.00037052511,0.0008088755,0.00018814133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006546162,0.003933531,0.884629,0.0006267429,0.015626002,0.000149539,0.0058929278,0.00023841402,0.023411317,0.00077779975,0.04016674,0.018001815],"study_design_scores_gemma":[0.17713413,0.0040448513,0.6037848,0.00047903394,0.018473966,7.5513793e-7,0.0023486284,0.004307356,0.013798397,0.00035930736,0.1748771,0.00039163674],"about_ca_topic_score_codex":0.0002663262,"about_ca_topic_score_gemma":0.00012038059,"teacher_disagreement_score":0.28084418,"about_ca_system_score_codex":0.00015399608,"about_ca_system_score_gemma":0.00022583296,"threshold_uncertainty_score":0.9994705},"labels":[],"label_agreement":null},{"id":"W3014409190","doi":"10.1111/dom.14041","title":"Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Agence Nationale de la Recherche; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Type 2 diabetes; Adverse effect; Internal medicine; Diabetic ketoacidosis; Diabetes mellitus; Population; Renal function; Urology; Endocrinology; Insulin","score_opus":0.021327916295630935,"score_gpt":0.25585816195749583,"score_spread":0.2345302456618649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014409190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683636,0.0018480083,0.0000037242792,0.00015276988,0.00005057581,0.0009232246,0.000068194124,0.000018118539,0.00009901229],"genre_scores_gemma":[0.9989148,0.000093576586,0.00025040322,0.00039718093,0.00003860958,0.000014500299,0.00026312133,0.000014491767,0.000013337925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998723,0.00011994915,0.0003613762,0.00027775537,0.00031364805,0.0002042961],"domain_scores_gemma":[0.99923784,0.0001153459,0.00017470896,0.00026968637,0.0001108925,0.00009153855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016797059,0.0001851182,0.0006732085,0.00009033153,0.00004370485,0.000012571845,0.00010832169,0.00004877229,0.000044611064],"category_scores_gemma":[0.00012407829,0.00011634393,0.00006604625,0.00049831875,0.00006397384,0.00012346658,0.00009369896,0.00010040299,0.0000022488723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017233679,0.0009746295,0.9925068,0.00007018045,0.00062665174,9.105386e-7,0.0010124993,0.000021917052,0.00028685224,0.000027947295,0.000054169617,0.0042451257],"study_design_scores_gemma":[0.0038409925,0.00048238185,0.99216574,0.000081437756,0.0013609817,3.41183e-9,0.00024526106,0.0001460342,0.0011016787,0.000043205306,0.00042358236,0.000108694956],"about_ca_topic_score_codex":0.00026319755,"about_ca_topic_score_gemma":0.000083179126,"teacher_disagreement_score":0.0041364306,"about_ca_system_score_codex":0.00001311369,"about_ca_system_score_gemma":0.000017030177,"threshold_uncertainty_score":0.4744368},"labels":[],"label_agreement":null},{"id":"W3014553064","doi":"10.1007/s00415-020-09813-4","title":"GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Journal of Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Mace; Internal medicine; Randomized controlled trial; Stroke (engine); Meta-analysis; Myocardial infarction; Placebo; Odds ratio; Adverse effect; Diabetes mellitus; Endocrinology; Pathology","score_opus":0.08980712974745209,"score_gpt":0.3669321051372005,"score_spread":0.2771249753897484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014553064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000053399986,0.99218714,0.000013506227,0.00443324,0.00007573673,0.0032093336,0.000033352277,0.0000060617062,0.000036287867],"genre_scores_gemma":[0.000007049206,0.9962938,0.00030060034,0.0019485083,0.000067593624,0.0004076332,0.000033220513,0.000028165628,0.00091345987],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997118,0.00052714697,0.001662157,0.0002809338,0.00019986124,0.00021188523],"domain_scores_gemma":[0.99731714,0.00040447808,0.0017841677,0.00026257808,0.000098108976,0.00013350698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079068425,0.00033619668,0.011550418,0.0005358141,0.00001781673,0.000020173244,0.00016470341,0.00013716677,0.000118579024],"category_scores_gemma":[0.00035120445,0.00019935236,0.003755066,0.000423963,0.000028629807,0.000051991676,0.00005862865,0.0003273527,0.000008331536],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013312324,0.00011720851,0.000007637361,0.7783552,0.2151334,0.00009407962,0.000005628764,1.1456277e-7,9.879211e-8,0.000018174123,0.001230331,0.005024827],"study_design_scores_gemma":[0.00028649237,0.0011979621,0.000002152214,0.008926468,0.6678313,0.00003928435,7.514669e-7,0.0000014305386,7.0329726e-8,0.000010350937,0.3216317,0.00007204628],"about_ca_topic_score_codex":2.5822973e-7,"about_ca_topic_score_gemma":0.0000021590495,"teacher_disagreement_score":0.76942873,"about_ca_system_score_codex":0.00003825828,"about_ca_system_score_gemma":0.00008573951,"threshold_uncertainty_score":0.8129353},"labels":[],"label_agreement":null},{"id":"W3014639510","doi":"10.1503/cmaj.200426","title":"Should sodium-glucose cotransporter-2 inhibitors be first-line treatment for patients with type 2 diabetes?","year":2020,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Pharmacotherapy; First line; Pharmacology; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.016506037063988656,"score_gpt":0.23073959048699894,"score_spread":0.2142335534230103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014639510","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022393048,0.00026031485,0.000013554431,0.9727284,0.0017670421,0.0015311687,0.0005162289,0.000057958237,0.0007323187],"genre_scores_gemma":[0.012543911,0.00050882844,0.00020282176,0.963418,0.012385207,0.00014523935,0.0067176493,0.00015462414,0.0039236955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585474,0.00006409476,0.0006690018,0.00044426502,0.0019507195,0.0010171647],"domain_scores_gemma":[0.996641,0.00020730245,0.00047623372,0.0002146567,0.0006618268,0.0017989993],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025693004,0.0005150128,0.0008978049,0.0003275708,0.0002954875,0.00011697539,0.00019830192,0.0010398946,0.0015926918],"category_scores_gemma":[0.00036415475,0.00038283766,0.00035708852,0.00027434068,0.000053571064,0.000102480604,0.000011912898,0.0015321963,0.000080353806],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006279178,0.00018133943,0.06874529,0.0001260471,0.0018468904,0.0012347285,0.000096112795,6.6803847e-7,1.8472838e-7,0.0000018881055,0.9144359,0.013268148],"study_design_scores_gemma":[0.007173326,0.0032610314,0.0036951208,0.00035749047,0.0015528797,0.000005666735,0.00001534669,0.000037538644,0.000011991059,0.000020026451,0.98351264,0.00035691893],"about_ca_topic_score_codex":0.00034016705,"about_ca_topic_score_gemma":0.005660594,"teacher_disagreement_score":0.069076754,"about_ca_system_score_codex":0.003477713,"about_ca_system_score_gemma":0.0024364488,"threshold_uncertainty_score":0.9998624},"labels":[],"label_agreement":null},{"id":"W3014701587","doi":"10.1111/dom.13965","title":"What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?","year":2020,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"","keywords":"Medicine; Empagliflozin; Canagliflozin; Clinical trial; Intensive care medicine; Internal medicine; Albuminuria; Clinical endpoint; Type 2 diabetes; Renal function; Diabetes mellitus; Endocrinology","score_opus":0.23986227727852943,"score_gpt":0.36642641467798515,"score_spread":0.1265641373994557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014701587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006412497,0.98869056,0.000035585897,0.0011065311,0.00035978964,0.0031850648,0.00010089028,0.000072646886,0.000036442078],"genre_scores_gemma":[0.00038820325,0.99617666,0.00030858198,0.00037758023,0.0011936802,0.00051124446,0.000602349,0.000055807523,0.00038589526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660087,0.0007656745,0.00084019813,0.000809461,0.00063135615,0.0003524429],"domain_scores_gemma":[0.9981732,0.00045335345,0.0005039357,0.0005455675,0.00010336262,0.00022059203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013205601,0.0006575701,0.004598699,0.00016366046,0.00024796117,0.00041148585,0.00014291397,0.0002748949,0.000032057407],"category_scores_gemma":[0.0003875974,0.00035184473,0.0011569256,0.0003400529,0.00016929959,0.0004007466,0.00017554493,0.00048657655,0.000015154484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003081478,0.00009773382,0.0020557607,0.004049161,0.013046518,0.00001923686,0.00016444731,0.0000014829408,0.0000057907814,0.00008099444,0.00022587585,0.98022217],"study_design_scores_gemma":[0.0016002811,0.00009514063,0.010254538,0.0059570954,0.04034224,0.000002413231,0.00008275676,0.000013815434,0.000035687015,0.00012349528,0.94113827,0.00035426326],"about_ca_topic_score_codex":0.0001033613,"about_ca_topic_score_gemma":0.0000141290975,"teacher_disagreement_score":0.97986794,"about_ca_system_score_codex":0.000048208538,"about_ca_system_score_gemma":0.00010676628,"threshold_uncertainty_score":0.99989337},"labels":[],"label_agreement":null},{"id":"W3014973577","doi":"10.1111/dom.14050","title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Novo Nordisk","keywords":"Liraglutide; Appetite; Medicine; Overweight; Crossover study; Placebo; Type 2 diabetes; Internal medicine; Endocrinology; Insulin; Diabetes mellitus; Obesity","score_opus":0.0086374462452065,"score_gpt":0.22145787819047297,"score_spread":0.21282043194526648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014973577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966103,0.0022035835,0.0000018096548,0.00027661206,0.000044486445,0.0006031284,0.000025453308,0.000051868024,0.0001827515],"genre_scores_gemma":[0.99889845,0.00027336122,0.00028649718,0.00036161827,0.000042158983,0.000028527676,0.000060154864,0.000017485403,0.000031726573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903935,0.000080342375,0.00018029286,0.0002818495,0.00016854242,0.0002496445],"domain_scores_gemma":[0.99941623,0.00017566627,0.00008119009,0.00013843064,0.000039055718,0.00014941512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019229553,0.00019722576,0.00052006164,0.00012870242,0.00006346376,0.00002226243,0.000036415513,0.000056741334,0.000018897545],"category_scores_gemma":[0.00008986719,0.00015021699,0.000041506115,0.00023498254,0.00008267971,0.00009588098,0.00005011313,0.00011954447,0.000005113845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006015069,0.00013856072,0.99385417,0.00048633534,0.00016188879,0.0000024878432,0.00042565737,0.000005927806,0.0011578783,0.00038379923,0.00004164013,0.0032815328],"study_design_scores_gemma":[0.0025084573,0.002006048,0.9775228,0.00033354713,0.00065456063,2.878858e-7,0.000026726693,0.00037723713,0.01609318,0.00002355359,0.00030528352,0.00014831405],"about_ca_topic_score_codex":0.000012182374,"about_ca_topic_score_gemma":0.00002077043,"teacher_disagreement_score":0.016331337,"about_ca_system_score_codex":0.0000109689445,"about_ca_system_score_gemma":0.000012715017,"threshold_uncertainty_score":0.61256707},"labels":[],"label_agreement":null},{"id":"W3015074668","doi":"10.1007/s00125-020-05133-4","title":"Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials","year":2020,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Merck Sharp and Dohme; Diabetes Canada; European Association for the Study of Diabetes; University of Toronto; European Renal Association-European Dialysis and Transplant Association; Pfizer","keywords":"Glimepiride; Medicine; Post-hoc analysis; Placebo; Albuminuria; Creatinine; Internal medicine; Population; Urology; Type 2 diabetes; Renal function; Diabetes mellitus; Endocrinology","score_opus":0.02037022022239715,"score_gpt":0.2835566879555486,"score_spread":0.26318646773315146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015074668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943457,0.0009238457,0.000100510006,0.00027819612,0.000094561656,0.0026774427,0.000050965322,0.000037740414,0.0014909905],"genre_scores_gemma":[0.9987603,0.00011750026,0.00009702579,0.00039174594,0.000048470316,0.00019209067,0.00019222593,0.00001458802,0.0001860682],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978072,0.0004151231,0.0009915192,0.00030164563,0.0002735066,0.000211026],"domain_scores_gemma":[0.9963929,0.0022363316,0.00083641993,0.00027341253,0.0001296986,0.00013122422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005627563,0.00026399633,0.0039323317,0.00045584288,0.000018294486,0.000005448723,0.00007486254,0.00009480182,0.00030676674],"category_scores_gemma":[0.0017852276,0.00016223977,0.0014168209,0.0006537199,0.00007730768,0.000037760172,0.00002407546,0.00005624916,0.000007132272],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35160482,0.005116252,0.04849772,0.001110218,0.15623249,0.0000662696,0.00088345143,0.0006840107,0.39056143,0.0019848149,0.0013154896,0.041943043],"study_design_scores_gemma":[0.5969869,0.03226889,0.07402985,0.00022796028,0.11788413,1.0941457e-7,0.000064856285,0.0030123352,0.17494486,0.0000672615,0.00025808302,0.00025475753],"about_ca_topic_score_codex":0.000044868993,"about_ca_topic_score_gemma":0.0000064232227,"teacher_disagreement_score":0.2453821,"about_ca_system_score_codex":0.00006514618,"about_ca_system_score_gemma":0.000058301626,"threshold_uncertainty_score":0.66159457},"labels":[],"label_agreement":null},{"id":"W3015103140","doi":"10.1503/cmaj.191283","title":"Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study","year":2020,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; Western University","funders":"National Center for Advancing Translational Sciences; Ontario Ministry of Health and Long-Term Care; Academic Medical Organization of Southwestern Ontario","keywords":"Medicine; Interquartile range; Acute kidney injury; Internal medicine; Retrospective cohort study; Population; Poisson regression; Diabetes mellitus; Creatinine; Renal function; Type 2 diabetes; Cohort study; Cohort; Emergency medicine; Endocrinology","score_opus":0.004892999813996349,"score_gpt":0.2103267886175956,"score_spread":0.20543378880359925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015103140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951333,0.000018942159,0.000007755503,0.003886924,0.000068067355,0.00071041443,0.00014083799,0.000007927933,0.000025871519],"genre_scores_gemma":[0.9971136,0.00006296332,0.00010580704,0.0024906273,0.00008897639,0.000015724647,0.00009178582,0.000014395296,0.0000161229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980735,0.0001118517,0.0005229209,0.00016978479,0.00087324576,0.0002486786],"domain_scores_gemma":[0.9980664,0.00006398217,0.00035629456,0.00008425412,0.00018757457,0.0012414685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053238,0.00012828075,0.00042696384,0.00023190885,0.000044174827,0.000018381683,0.000055982244,0.00012066563,0.00021466473],"category_scores_gemma":[0.00045648252,0.00010320856,0.00006155826,0.00031167179,0.00003007904,0.000112674155,0.000006415898,0.00033804838,0.0000013681249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120738805,0.0002407267,0.9919921,0.00005200068,0.00083996705,0.00011902619,0.00067115814,0.0000020490472,0.0000045481293,0.0000014818567,0.0023206305,0.0036355853],"study_design_scores_gemma":[0.0047968756,0.0007742805,0.99190795,0.0003884197,0.0007796546,8.092129e-7,0.00017720906,0.00052567903,0.00006874391,0.0000016051313,0.00049006473,0.00008868274],"about_ca_topic_score_codex":0.004774071,"about_ca_topic_score_gemma":0.0063319528,"teacher_disagreement_score":0.0046761367,"about_ca_system_score_codex":0.00027465343,"about_ca_system_score_gemma":0.0007846854,"threshold_uncertainty_score":0.7216999},"labels":[],"label_agreement":null},{"id":"W3015244826","doi":"10.1097/ede.0000000000001196","title":"Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes","year":2020,"lang":"en","type":"article","venue":"Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Medicine; Weight loss; Breast cancer; Hazard ratio; Internal medicine; Type 2 diabetes; Population; Diabetes mellitus; Obesity; Proportional hazards model; Incidence (geometry); Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Endocrinology; Cancer; Oncology; Liraglutide; Confidence interval; Receptor; Agonist","score_opus":0.01026520311620028,"score_gpt":0.24348750306510972,"score_spread":0.23322229994890945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015244826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684453,0.0010737431,0.00011308601,0.0011731961,0.00015519929,0.00042089954,0.00000724136,0.00003994137,0.00017216224],"genre_scores_gemma":[0.99833816,0.00039343158,0.0003128748,0.0005430856,0.000109788896,0.00014580853,0.000007438978,0.000020411318,0.00012898043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998891,0.0001026559,0.00031346024,0.00029285875,0.000073804185,0.00032623395],"domain_scores_gemma":[0.99896705,0.00042657,0.00022480855,0.00015740488,0.000047159352,0.0001769765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024845498,0.00016697585,0.0007466612,0.00006874466,0.000027597831,0.0000017787545,0.00005163022,0.000079237725,0.000052413146],"category_scores_gemma":[0.00021807097,0.000120663455,0.00004851066,0.00014666517,0.00020065517,0.000061293824,0.00006248529,0.00009899512,0.000003759539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048685083,0.00012500594,0.9042063,0.0016917629,0.0007683947,0.000006613973,0.00072473404,0.00001685689,0.0670761,0.000033366687,0.00038483442,0.024479225],"study_design_scores_gemma":[0.0021958782,0.0025951485,0.9486386,0.00043400313,0.00028569743,0.0000014882243,0.000078265715,0.00026598334,0.043845113,0.000047210182,0.0014628558,0.00014974478],"about_ca_topic_score_codex":0.00009844399,"about_ca_topic_score_gemma":0.000022844757,"teacher_disagreement_score":0.044432357,"about_ca_system_score_codex":0.00006635531,"about_ca_system_score_gemma":0.000019698604,"threshold_uncertainty_score":0.49205127},"labels":[],"label_agreement":null},{"id":"W3015942754","doi":"10.1016/j.molmet.2020.100990","title":"Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion","year":2020,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk; Novo Nordisk Fonden; Club Foundation","keywords":"Secretion; Chemistry; Cell biology; Biology; Endocrinology; Internal medicine; Molecular biology; Medicine","score_opus":0.013059720142769293,"score_gpt":0.25238976753040737,"score_spread":0.23933004738763808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015942754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98834515,0.0013698239,0.0045605255,0.003364351,0.00015211731,0.0012733715,0.000017047787,0.000019789106,0.0008978325],"genre_scores_gemma":[0.99789655,0.000021847589,0.0012970979,0.00037412165,0.000086461274,0.00008867916,0.00002918817,0.000015461519,0.0001905751],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992252,0.00005542794,0.00022877952,0.0001710482,0.00020795084,0.00011158378],"domain_scores_gemma":[0.99935067,0.000020843354,0.00021037782,0.0002564818,0.00012418367,0.000037458245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000134217,0.000101984515,0.00022927474,0.000022808297,0.00003911204,0.000004646135,0.000102215236,0.000027219745,0.000010793328],"category_scores_gemma":[0.00025130325,0.00005618937,0.0001689322,0.00021470229,0.00006681319,0.000036074016,0.000060525163,0.00006810922,7.7681284e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014992709,0.000069884496,0.0013590534,0.00010487862,0.0001129771,0.0000011398039,0.00047982,0.000017129889,0.9912936,0.003373714,0.0016253404,0.00141252],"study_design_scores_gemma":[0.0012265053,0.0001606974,0.027421223,0.000109686094,0.00065323437,0.0000021392964,0.00022572331,0.0002085987,0.9626586,0.0018606401,0.0053958003,0.00007719089],"about_ca_topic_score_codex":0.0000052537457,"about_ca_topic_score_gemma":5.070477e-7,"teacher_disagreement_score":0.028635055,"about_ca_system_score_codex":0.000014327806,"about_ca_system_score_gemma":0.000022684508,"threshold_uncertainty_score":0.22913359},"labels":[],"label_agreement":null},{"id":"W3016855928","doi":"10.1002/osp4.420","title":"Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada","year":2020,"lang":"en","type":"article","venue":"Obesity Science & Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Weight loss; Obesity; Body mass index; Weight change; Internal medicine; Persistence (discontinuity); Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.01501223130347301,"score_gpt":0.25653922829448633,"score_spread":0.24152699699101332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016855928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98290414,0.000095929776,0.000008679998,0.0078038564,0.000039752467,0.0012093759,0.0000022848426,0.0000139406175,0.007922056],"genre_scores_gemma":[0.99761397,0.00006234235,0.00011485231,0.0020588401,0.00001528671,0.00003779506,0.0000020375064,0.0000062867102,0.00008860692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776924,0.00031598864,0.00015967953,0.0005622828,0.0008128042,0.00037999754],"domain_scores_gemma":[0.99875927,0.00057967135,0.00009920769,0.0003094793,0.0000802965,0.00017207413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017338821,0.00016701648,0.00026856354,0.00009152768,0.00020094274,0.00008584751,0.00031861034,0.000015663532,0.000007644787],"category_scores_gemma":[0.0004185682,0.000110423236,0.000015295167,0.0016148975,0.00023378573,0.0007842665,0.00013790069,0.00027598848,0.0000057933057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025253784,0.0008063351,0.99567074,0.000049631446,0.00002363287,0.0006138844,0.0015970916,0.000011058155,0.00012211493,0.00015298375,0.00016439166,0.0005356294],"study_design_scores_gemma":[0.0015744646,0.00063077145,0.9866045,0.000061134175,0.00015370586,0.0000089087225,0.0075984388,0.00026110004,0.00022076356,0.0000060070506,0.0027462535,0.0001339214],"about_ca_topic_score_codex":0.48195192,"about_ca_topic_score_gemma":0.7150718,"teacher_disagreement_score":0.23311986,"about_ca_system_score_codex":0.000675518,"about_ca_system_score_gemma":0.00084706076,"threshold_uncertainty_score":0.5214978},"labels":[],"label_agreement":null},{"id":"W3019508129","doi":"10.1016/s2213-8587(20)30038-3","title":"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials","year":2020,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Western University; St. Michael's Hospital; Canadian VIGOUR Centre; University of Alberta; University Health Network; University of Toronto; Women's College Hospital","funders":"Women's College Research Institute; University of Toronto; Heart and Stroke Foundation of Canada","keywords":"Medicine; Meta-analysis; Mace; Myocardial infarction; Type 2 diabetes; Heart failure; Internal medicine; Diabetes mellitus; Relative risk; Randomized controlled trial; Clinical trial; Stroke (engine); MEDLINE; Intensive care medicine; Confidence interval; Percutaneous coronary intervention; Endocrinology","score_opus":0.08404563886580996,"score_gpt":0.3274024658709334,"score_spread":0.24335682700512345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019508129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01802575,0.971557,0.0000035757462,0.000146679,0.000035611116,0.009950605,0.00021250294,0.00005525198,0.000013002481],"genre_scores_gemma":[0.009636489,0.9879655,0.00018559543,0.00017493602,0.000035117486,0.0015118129,0.0003418713,0.000090821646,0.000057835747],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9914865,0.0038732241,0.002298642,0.0008883541,0.0005429994,0.0009102708],"domain_scores_gemma":[0.99497277,0.0013044062,0.0012894116,0.0021503347,0.00012858158,0.00015451602],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0045557516,0.0008958516,0.037866075,0.00044533573,0.00006543212,0.000030672887,0.00043284037,0.00017827892,0.00015537751],"category_scores_gemma":[0.0006075103,0.0004051947,0.0042185923,0.0015823924,0.00019035269,0.0001067872,0.0002920141,0.00039847032,0.0000048409042],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023144916,0.00008032798,0.0012846845,0.34194624,0.6546321,0.000021181228,0.00009965792,0.00002759689,0.0000017566106,0.000010230232,0.000030387104,0.0016344058],"study_design_scores_gemma":[0.0071805385,0.0005796817,0.00025790918,0.009287932,0.9629593,0.000009665761,0.0001020175,0.000018347335,0.0000104505,0.000003905743,0.01921739,0.00037284428],"about_ca_topic_score_codex":0.00008057783,"about_ca_topic_score_gemma":0.00015449114,"teacher_disagreement_score":0.3326583,"about_ca_system_score_codex":0.00011468358,"about_ca_system_score_gemma":0.00014069886,"threshold_uncertainty_score":0.99984},"labels":[],"label_agreement":null},{"id":"W3019736633","doi":"10.1007/s13300-020-00812-2","title":"Latest Evidence on Sulfonylureas: What’s New?","year":2020,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Servier","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Clinical trial; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.11721029630246166,"score_gpt":0.35704289838259157,"score_spread":0.2398326020801299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019736633","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000626013,0.99306655,8.735568e-7,0.002267982,0.0006903049,0.0024378384,0.000010100462,0.00027775604,0.0011859763],"genre_scores_gemma":[0.000018691328,0.99020296,0.000110475674,0.0031969934,0.0009453527,0.00030597477,0.0002886129,0.00016817646,0.0047627664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744886,0.00011811627,0.0005467724,0.0008294772,0.00046111704,0.00059567037],"domain_scores_gemma":[0.9978832,0.00044408586,0.00028374762,0.00091277313,0.00004634477,0.00042982664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018029733,0.000832376,0.002526263,0.00025386634,0.000060812556,0.0002476013,0.00039233296,0.00028265448,0.00048335711],"category_scores_gemma":[0.000091173395,0.0005781882,0.0009393376,0.00053294987,0.0000555728,0.00030201997,0.000080963284,0.00043424222,0.0022485992],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024634897,0.00020387798,0.00007462954,0.0035273528,0.0014177327,0.00005701405,0.000047998517,6.23175e-8,0.0000017367385,0.00010599466,0.022472883,0.9720661],"study_design_scores_gemma":[0.000828851,0.0014586087,0.00004107516,0.047273178,0.0014003629,0.000001217965,0.000007541276,0.0000015732126,0.00002795198,0.000048806018,0.94846654,0.0004442935],"about_ca_topic_score_codex":0.0000044673393,"about_ca_topic_score_gemma":6.3047366e-7,"teacher_disagreement_score":0.9716218,"about_ca_system_score_codex":0.00021276841,"about_ca_system_score_gemma":0.00030792755,"threshold_uncertainty_score":0.9996669},"labels":[],"label_agreement":null},{"id":"W3021050932","doi":"10.1210/jendso/bvaa046.071","title":"OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind","year":2020,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; McMaster University","funders":"","keywords":"Dulaglutide; Medicine; Hazard ratio; Incidence (geometry); Proportional hazards model; Confidence interval; Hypoglycemia; Population; Adverse effect; Clinical endpoint; Internal medicine; Diabetes mellitus; Randomized controlled trial; Pediatrics; Type 2 diabetes; Exenatide; Insulin; Environmental health; Endocrinology","score_opus":0.029191202016832604,"score_gpt":0.3160561514776508,"score_spread":0.2868649494608182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021050932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772604,0.00019652113,0.00011547248,0.020528425,0.00015715195,0.00037686114,0.0000046487676,0.0000046454848,0.0013558457],"genre_scores_gemma":[0.9941651,0.00011490533,0.0042902688,0.0011575131,0.00007163822,0.0000030293527,0.000004338164,0.000009582294,0.00018357935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876714,0.000053385666,0.00058970565,0.00009012221,0.00033997124,0.00015969691],"domain_scores_gemma":[0.9993808,0.00003404211,0.00031028784,0.00014267316,0.00006422392,0.00006796528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017563112,0.00009648575,0.00032170696,0.000043222266,0.00002473078,0.000005661448,0.00010447871,0.000020052545,0.000060535334],"category_scores_gemma":[0.000060825416,0.00006173744,0.00032848504,0.00031549556,0.000026434605,0.00007782258,0.00010191188,0.00026198718,9.832248e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006775716,0.0009205497,0.970674,0.00014636992,0.0002888808,0.00006385028,0.0022983446,0.0035119602,0.0009933015,0.0005745836,0.017278757,0.003181654],"study_design_scores_gemma":[0.0042760354,0.00031505816,0.9853721,0.00026743818,0.00017012327,0.0000112200005,0.0010997618,0.0010087541,0.0005329779,0.00017613878,0.0067023593,0.00006800782],"about_ca_topic_score_codex":0.000022427403,"about_ca_topic_score_gemma":0.00001268382,"teacher_disagreement_score":0.019370912,"about_ca_system_score_codex":0.00022473093,"about_ca_system_score_gemma":0.00007689299,"threshold_uncertainty_score":0.25175798},"labels":[],"label_agreement":null},{"id":"W3021245828","doi":"10.1146/annurev.nutr.26.061505.111223","title":"Glucagon-Like Peptide-2","year":2006,"lang":"en","type":"review","venue":"Annual Review of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Glucagon-like peptide-2; Gastrointestinal tract; Hormone; Peptide hormone; Peptide; Malabsorption; Glucagon-like peptide-1; Biology; Homeostasis; Glucose homeostasis; Inflammation; Internal medicine; Endocrinology; Medicine; Biochemistry; Insulin; Insulin resistance","score_opus":0.02773689325978667,"score_gpt":0.34455399948240945,"score_spread":0.31681710622262277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021245828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.5199972e-7,0.981726,0.000004314053,0.00016068525,0.0001752813,0.003098212,0.00016943488,0.00004938301,0.014616426],"genre_scores_gemma":[1.9682857e-7,0.98975617,0.00046535512,0.00046461498,0.00028595273,0.0005393817,0.0040951218,0.000046486646,0.004346724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807435,0.00008692024,0.0009150463,0.00033943966,0.00034867547,0.00023556656],"domain_scores_gemma":[0.9986981,0.00006459013,0.00049717486,0.00047503295,0.00018423835,0.00008086465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025104432,0.000380171,0.002616828,0.00020328704,0.00002414854,0.0000073532033,0.00012560646,0.00015297024,0.00012563293],"category_scores_gemma":[0.00004865197,0.00028145764,0.001120839,0.00040163175,0.000044837874,0.00008941793,0.00005667044,0.0001589452,0.00028524396],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000011940737,0.00044481936,2.9098535e-7,0.37828463,0.00012686918,0.000013534343,0.0000010537358,5.31653e-10,1.7076546e-8,0.000082449784,0.15281461,0.46823055],"study_design_scores_gemma":[0.0002688782,0.00020502716,0.0000020035377,0.38802263,0.0046209125,0.0000134889415,0.000003011218,3.1416715e-8,3.3923632e-7,0.00001689303,0.6067247,0.00012210102],"about_ca_topic_score_codex":0.000010808824,"about_ca_topic_score_gemma":7.8557457e-7,"teacher_disagreement_score":0.46810845,"about_ca_system_score_codex":0.00012087265,"about_ca_system_score_gemma":0.000083851206,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W3021279828","doi":"10.1016/b0-12-341103-3/00113-3","title":"Glucagon-like Peptides: GLP-1 and GLP-2","year":2003,"lang":"en","type":"book-chapter","venue":"Encyclopedia of Hormones","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon-like peptide-1; Glucagon-like peptide-2; Glucagon; Glucagon-like peptide 1 receptor; Chemistry; Internal medicine; Endocrinology; Medicine; Peptide; Diabetes mellitus; Biochemistry; Type 2 diabetes; Insulin; Receptor","score_opus":0.01106596976878194,"score_gpt":0.226218447236449,"score_spread":0.21515247746766705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021279828","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068554273,0.018450413,0.0000068054374,0.0003483077,0.0004303488,0.0007943297,0.000030138886,0.00007211226,0.9730121],"genre_scores_gemma":[0.003141029,0.045890693,0.0009942272,0.00038824527,0.00025780345,0.000036795067,0.00015670506,0.00010639355,0.94902813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998444,0.000009863592,0.00045935763,0.00040527398,0.0003805796,0.00030088122],"domain_scores_gemma":[0.9989201,0.000060231123,0.0002462123,0.0005033035,0.000083927065,0.00018623481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000112522015,0.0004916804,0.0008389514,0.00025745353,0.00006150106,0.0000207717,0.00010553973,0.00026518982,0.000333465],"category_scores_gemma":[0.000023488743,0.00041524263,0.00021342534,0.000038229522,0.00022550276,0.00008003258,0.000107579785,0.00020485347,0.0001320666],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047778978,0.0007260965,0.0046032364,0.0026881155,0.004213118,0.0007170585,0.0017093888,9.994314e-7,0.00020271352,0.09331981,0.6094544,0.2818873],"study_design_scores_gemma":[0.0011825265,0.00071834103,0.0013390444,0.00033528244,0.0012382531,0.000014631733,0.00006887388,0.0000011297759,0.000052169624,0.002933751,0.99174476,0.000371247],"about_ca_topic_score_codex":0.00001918607,"about_ca_topic_score_gemma":0.000011588686,"teacher_disagreement_score":0.3822904,"about_ca_system_score_codex":0.00005325026,"about_ca_system_score_gemma":0.000069090594,"threshold_uncertainty_score":0.99982995},"labels":[],"label_agreement":null},{"id":"W3021290569","doi":"10.1111/dom.14079","title":"The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Sun Pharma; Novo Nordisk; Valeant Pharmaceuticals International; American Heart Association; Sanofi; HLS Therapeutics; Amgen; AstraZeneca; Eli Lilly and Company","keywords":"Semaglutide; Liraglutide; Mace; Medicine; Diabetic nephropathy; Internal medicine; Nephropathy; Blood pressure; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Endocrinology; Placebo; Cardiology","score_opus":0.011967852273858442,"score_gpt":0.245136943228653,"score_spread":0.23316909095479457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021290569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92612743,0.07149113,0.000011748355,0.00045184352,0.00013885867,0.0014042843,0.000245127,0.00004141662,0.000088147564],"genre_scores_gemma":[0.9927067,0.0054624653,0.000106360705,0.00044245424,0.00014730041,0.00008336724,0.000061784114,0.00003705192,0.0009524745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996341,0.0009692228,0.00074524997,0.0007020398,0.0006211233,0.0006214017],"domain_scores_gemma":[0.9947472,0.0036076715,0.00045020663,0.00069438294,0.00015942544,0.00034107213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035082945,0.00053535553,0.002684917,0.00015950858,0.00044685614,0.00013050824,0.00020942187,0.0001858863,0.0000029884184],"category_scores_gemma":[0.004618466,0.0002981707,0.0007741868,0.0006853534,0.00065033656,0.00012141476,0.00038087773,0.00029055757,8.541615e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010274411,0.00033997945,0.8965578,0.002761592,0.07189921,0.000015312544,0.0063468223,0.00016025595,0.005221589,0.00040731195,0.0019083924,0.014278994],"study_design_scores_gemma":[0.008237212,0.00079391897,0.746097,0.00017027924,0.08754302,0.0000016018902,0.0019411953,0.0004934661,0.07283845,0.000071609145,0.08166637,0.000145872],"about_ca_topic_score_codex":0.00011124383,"about_ca_topic_score_gemma":0.000027439597,"teacher_disagreement_score":0.15046078,"about_ca_system_score_codex":0.00000957112,"about_ca_system_score_gemma":0.000037954364,"threshold_uncertainty_score":0.9999471},"labels":[],"label_agreement":null},{"id":"W3021320790","doi":"10.1016/j.bbadis.2020.165807","title":"Empagliflozin improves left ventricular diastolic function of db/db mice","year":2020,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Alberta","funders":"Bundesministerium für Bildung und Forschung; Corona-Stiftung; Medizinische Fakultät, RWTH Aachen University; European Regional Development Fund; Deutsche Forschungsgemeinschaft; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Diabetic cardiomyopathy; Endocrinology; Heart failure; Cardiology; Cardiac function curve; Diastole; Diabetes mellitus; Cardiomyopathy; Type 2 diabetes; Blood pressure","score_opus":0.009107570242441188,"score_gpt":0.22961384016079414,"score_spread":0.22050626991835295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021320790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920878,0.00063459296,0.00013992137,0.0056212605,0.00008636778,0.0008668964,0.00012631896,0.00008965437,0.00034718847],"genre_scores_gemma":[0.9969498,0.000109739136,0.0003486267,0.001987946,0.00010074982,0.000038178518,0.00035523824,0.000062574305,0.00004713839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795014,0.000093974675,0.00046931644,0.00057993404,0.0005564657,0.00035016582],"domain_scores_gemma":[0.99836487,0.0000344504,0.0003215598,0.0006055927,0.00013628011,0.00053724105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007349734,0.00037857742,0.00061052665,0.00018105216,0.000041509218,0.000024505634,0.00024221203,0.00007934665,0.000058946123],"category_scores_gemma":[0.0001230924,0.00034482245,0.0006403795,0.00042303864,0.00013810521,0.0001283299,0.00018207423,0.00012327592,0.000034372246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011119255,0.0015421506,0.00015485524,0.0007906161,0.0011833813,0.00007004339,0.00013912946,0.000007445961,0.9916873,0.00026257389,0.0013218359,0.0017287427],"study_design_scores_gemma":[0.002251715,0.001124372,0.042858962,0.00016564866,0.003337543,5.503876e-7,0.00009857637,0.00021240249,0.94907755,0.000088579945,0.00046643417,0.00031765367],"about_ca_topic_score_codex":0.000016051054,"about_ca_topic_score_gemma":3.9866276e-7,"teacher_disagreement_score":0.04270411,"about_ca_system_score_codex":0.00004082504,"about_ca_system_score_gemma":0.00013534684,"threshold_uncertainty_score":0.9999004},"labels":[],"label_agreement":null},{"id":"W3021620728","doi":"10.1016/s1499-2671(11)51001-9","title":"Diabetes in the Elderly","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Diabetes mellitus; Family medicine; Ethnic group; Gerontology; Scopus; Disease; Type 2 diabetes; Clinical Practice; MEDLINE; Internal medicine; Endocrinology","score_opus":0.021228581742529486,"score_gpt":0.21546012885420118,"score_spread":0.1942315471116717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021620728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97631687,0.0014646406,5.2045385e-7,0.0010755253,0.00020886293,0.00016996465,0.0000027289814,0.0000041735952,0.020756727],"genre_scores_gemma":[0.99819016,0.000007846616,0.00021466732,0.0012385927,0.000106717824,0.0000077621235,0.0000028203642,0.000012853714,0.00021855708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902374,0.000046691584,0.0002783912,0.000086139065,0.00014947497,0.00041558823],"domain_scores_gemma":[0.99925196,0.000055334935,0.00010519171,0.00019108891,0.000075082455,0.00032136656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042629256,0.00011790273,0.0002530257,0.00038881385,0.00004791875,0.000030297426,0.00022426902,0.00004451428,0.00025649092],"category_scores_gemma":[0.00008928084,0.000074946955,0.00012287371,0.00023754417,0.00008363971,0.0001305933,0.0000062004187,0.00017669727,0.000025116502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001691546,0.00006422417,0.97562224,0.000026416285,0.00013049463,0.00008405057,0.0008726443,3.688612e-7,0.000050101553,0.0005246787,0.0055177524,0.017105358],"study_design_scores_gemma":[0.0011815185,0.0017001011,0.973691,0.00021651913,0.00026045932,0.0000030108915,0.0006938522,0.000010884904,0.0008774832,0.0013124391,0.01992594,0.00012679298],"about_ca_topic_score_codex":0.00032372275,"about_ca_topic_score_gemma":0.0044166087,"teacher_disagreement_score":0.021873325,"about_ca_system_score_codex":0.00007610597,"about_ca_system_score_gemma":0.00025290286,"threshold_uncertainty_score":0.3056248},"labels":[],"label_agreement":null},{"id":"W3021697953","doi":"10.1136/bmj.m1107","title":"Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Transparency (behavior); Business; Alice (programming language); Internet privacy; Risk analysis (engineering); Medicine; Computer security; Computer science","score_opus":0.0888661690331236,"score_gpt":0.3609147773353201,"score_spread":0.2720486083021965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021697953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577169,0.0024194042,0.00015978838,0.028188389,0.000064434214,0.00058539945,0.0000046004106,0.00004268992,0.010818404],"genre_scores_gemma":[0.9976885,0.0001755822,0.0016562139,0.00023484387,0.000115745635,0.00000941892,0.000018720073,0.0000113948045,0.00008962497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914676,0.000027669954,0.00043689267,0.00011826036,0.00017484152,0.00009558458],"domain_scores_gemma":[0.9994014,0.00004749599,0.0001784075,0.00024336365,0.00005215297,0.00007721789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020821634,0.000091831746,0.00035336238,0.000053710137,0.000021722279,0.0000012862513,0.000069286165,0.000029326931,0.00005775215],"category_scores_gemma":[0.00010213696,0.00007136155,0.000041313608,0.00017379952,0.0001286757,0.00003211822,0.000052078165,0.00005864435,0.0000012046376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005821496,0.000604202,0.4758242,0.0053150537,0.0014188457,0.000040861196,0.019518372,0.00009314912,0.05725067,0.0034730858,0.027713843,0.40816557],"study_design_scores_gemma":[0.050832994,0.009626192,0.5991024,0.013991225,0.008042378,0.000023786008,0.019136982,0.022241756,0.18306717,0.0014352057,0.09098175,0.0015181765],"about_ca_topic_score_codex":0.00008106148,"about_ca_topic_score_gemma":0.0000036002323,"teacher_disagreement_score":0.40664738,"about_ca_system_score_codex":0.0000066130574,"about_ca_system_score_gemma":0.00001205451,"threshold_uncertainty_score":0.29100397},"labels":[],"label_agreement":null},{"id":"W3021808388","doi":"10.1111/dom.14077","title":"<scp>iGlarLixi</scp> effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the <scp>LixiLan‐L</scp> study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Type 2 diabetes; Lixisenatide; Basal insulin; Metformin; Medicine; Insulin glargine; Basal (medicine); Internal medicine; Insulin; Endocrinology; Diabetes mellitus; Gastroenterology","score_opus":0.00812366234545442,"score_gpt":0.20665570532734998,"score_spread":0.19853204298189556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021808388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930127,0.0037824968,6.8392774e-7,0.0003500658,0.00018661207,0.0018768327,0.00017273476,0.00011687307,0.0005009796],"genre_scores_gemma":[0.9955765,0.00019151915,0.00013117131,0.0029332603,0.00031329307,0.000121445395,0.00051856996,0.000057415575,0.00015680071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661183,0.0004229148,0.000439798,0.0009938114,0.0007720395,0.0007595931],"domain_scores_gemma":[0.99743354,0.0011842095,0.00022323294,0.00055303297,0.0002284487,0.00037752415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045966156,0.0006007116,0.0013054713,0.00035961994,0.00024020721,0.00016986646,0.00032856333,0.00016624619,0.000014097113],"category_scores_gemma":[0.0009723058,0.00039412186,0.0001937205,0.0015945606,0.00016434673,0.0002737516,0.00025897074,0.00048181033,0.000056565477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010953825,0.0020861537,0.98543847,0.00004752321,0.0038807455,0.000020495983,0.0038920052,0.000018830724,0.00031073808,0.00002962081,0.0012940862,0.0028718042],"study_design_scores_gemma":[0.0070048887,0.003186478,0.9777996,0.00007918668,0.0051106946,2.6262207e-8,0.0014219702,0.00006574074,0.002338383,0.000041622,0.0028372512,0.00011417479],"about_ca_topic_score_codex":0.00011101521,"about_ca_topic_score_gemma":0.00006922749,"teacher_disagreement_score":0.0076388745,"about_ca_system_score_codex":0.000053058433,"about_ca_system_score_gemma":0.00006138462,"threshold_uncertainty_score":0.99985105},"labels":[],"label_agreement":null},{"id":"W3021856094","doi":"10.2337/dc19-2251","title":"Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; National Institutes of Health; British Heart Foundation","keywords":"Liraglutide; Medicine; Diabetes mellitus; Mediation; Exploratory analysis; Reduction (mathematics); Internal medicine; Cardiology; Type 2 diabetes; Endocrinology","score_opus":0.019461744254906644,"score_gpt":0.22672314404230878,"score_spread":0.20726139978740213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021856094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972836,0.0012059682,0.000022430144,0.00027201927,0.00014521889,0.0007147939,0.000034852088,0.000055115415,0.00026599775],"genre_scores_gemma":[0.99902385,0.00004546371,0.00009368453,0.00019857039,0.00025222448,0.00008382944,0.00027078856,0.00001827272,0.000013331043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884087,0.00012505904,0.00018002928,0.00027204055,0.00042808178,0.00015393339],"domain_scores_gemma":[0.9991552,0.000015589576,0.00011952387,0.00047361295,0.00014168167,0.00009435078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012552502,0.00013127735,0.00043447167,0.00011502133,0.000059171234,0.000013274508,0.000085475716,0.00005049231,0.000018526003],"category_scores_gemma":[0.000051499737,0.00008285426,0.00043942517,0.00089664327,0.000060305174,0.00012492911,0.000031031872,0.00009376871,0.000008905052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019218732,0.00026560796,0.9038705,0.00032090454,0.029286467,0.0000046001373,0.014896742,0.008145528,0.0007924916,0.000035086854,0.0007760371,0.03968416],"study_design_scores_gemma":[0.079571865,0.0075736362,0.6381956,0.00016859331,0.148211,2.0677123e-7,0.059116412,0.0050414307,0.04335195,0.000025357529,0.017825168,0.00091883575],"about_ca_topic_score_codex":0.0000055767878,"about_ca_topic_score_gemma":0.0000078429675,"teacher_disagreement_score":0.26567495,"about_ca_system_score_codex":0.000055584827,"about_ca_system_score_gemma":0.000038274236,"threshold_uncertainty_score":0.33786988},"labels":[],"label_agreement":null},{"id":"W3022490877","doi":"10.1186/s12913-020-05232-3","title":"Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: a linked EMR and administrative data study","year":2020,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada Research Chairs; University of New Brunswick; North York General Hospital; University of Toronto","funders":"Diabetes Canada","keywords":"Medicine; Guideline; Medical prescription; Diabetes mellitus; Health administration; Health informatics; Medical record; Population; Emergency medicine; Family medicine; Polypharmacy; Intensive care medicine; Medical emergency; Internal medicine; Public health; Environmental health; Nursing","score_opus":0.08754575266155817,"score_gpt":0.4319135850219201,"score_spread":0.34436783236036195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022490877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897921,0.00006502089,0.000004651972,0.001757665,0.000020239093,0.0080330605,0.00027185667,0.0000042259344,0.00005116153],"genre_scores_gemma":[0.99826735,0.0000066628527,0.00005736118,0.00032549922,0.000020759056,0.00041790676,0.0008450002,0.000012498888,0.00004693435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765617,0.00026236117,0.00043431894,0.00040041748,0.0008793121,0.0003674518],"domain_scores_gemma":[0.9984062,0.00032461944,0.00014283395,0.00048561607,0.00038074085,0.0002600268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075907435,0.00013216192,0.00030767857,0.000069286274,0.00014966863,0.00001719438,0.00028851308,0.000029558309,0.0000301508],"category_scores_gemma":[0.00012542249,0.00008555239,0.000025057727,0.0003876929,0.000031229047,0.00006831102,0.00017725721,0.00023225049,1.7182737e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018726484,0.0008054018,0.9914548,0.0006996813,0.00026930662,0.0000015302485,0.0030861318,0.000020836993,0.000005427846,0.0000075296825,0.0012636975,0.0021984319],"study_design_scores_gemma":[0.0022341132,0.0023849257,0.9865926,0.00026204952,0.000047143516,2.1595843e-8,0.004456221,0.0037390855,0.0000130788285,0.0000063643524,0.00020592962,0.00005849099],"about_ca_topic_score_codex":0.99603766,"about_ca_topic_score_gemma":0.99988174,"teacher_disagreement_score":0.009043463,"about_ca_system_score_codex":0.0012957208,"about_ca_system_score_gemma":0.010339184,"threshold_uncertainty_score":0.99527127},"labels":[],"label_agreement":null},{"id":"W3022491547","doi":"10.1016/j.biopsych.2020.02.1057","title":"Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study","year":2020,"lang":"en","type":"article","venue":"Biological Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Prediabetes; Metformin; Schizophrenia spectrum; Schizophrenia (object-oriented programming); Type 2 diabetes; Medicine; Comorbidity; Psychiatry; Mental illness; Diabetes mellitus; Psychological intervention; Disease; Double blind; Internal medicine; Psychosis; Mental health; Endocrinology; Placebo; Alternative medicine","score_opus":0.08353953222532454,"score_gpt":0.31652056594509537,"score_spread":0.23298103371977083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022491547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837523,0.0015052472,0.000022627166,0.0055242185,0.0005673151,0.007853623,0.000025804658,0.00018776272,0.00056107953],"genre_scores_gemma":[0.99455994,0.00018094765,0.002545708,0.0010339718,0.0003580213,0.0009706354,0.0001457835,0.000032110962,0.00017288636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978668,0.00014193896,0.0006336639,0.00062384165,0.00018729194,0.0005464735],"domain_scores_gemma":[0.99896216,0.00035297117,0.00015177498,0.00028213084,0.00002532146,0.0002256468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005379884,0.00036871966,0.001150894,0.00014297444,0.00007365325,0.00004870977,0.00022412655,0.000103154416,0.00023762873],"category_scores_gemma":[0.00025541626,0.00021513422,0.00021451239,0.0005009803,0.0001371421,0.00008275254,0.00011648681,0.00021164487,0.00007262784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52369237,0.004321736,0.46771178,0.000111561894,0.0007118744,0.0000058456826,0.00011412364,0.0000013363357,0.000023224646,0.00070998445,0.0014352336,0.0011609149],"study_design_scores_gemma":[0.8249094,0.057677716,0.10816119,0.00010721954,0.00083407806,5.381389e-7,0.00031846322,0.0002128038,0.000072581715,0.0056443578,0.0015366108,0.0005250336],"about_ca_topic_score_codex":0.000022878667,"about_ca_topic_score_gemma":0.0001235009,"teacher_disagreement_score":0.35955057,"about_ca_system_score_codex":0.00003360235,"about_ca_system_score_gemma":0.0000753009,"threshold_uncertainty_score":0.87729186},"labels":[],"label_agreement":null},{"id":"W3022616650","doi":"10.1681/asn.2019111168","title":"Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia; Mount Sinai Hospital","funders":"Janssen Research and Development; Relypsa; Bristol-Myers Squibb; Akebia Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Servier; Eisai; Astellas Pharma; Novo Nordisk; NxStage; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Alnylam Pharmaceuticals; Kidney Foundation of Canada; Kowa Company; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; GlaxoSmithKline; Amgen; Innovent Biologics; Pfizer; Celgene; Eli Lilly and Company; Janssen Pharmaceuticals; University of Washington","keywords":"Canagliflozin; Medicine; Renal function; Randomized controlled trial; Credence; Internal medicine; Urology; Intensive care medicine; Endocrinology; Diabetes mellitus","score_opus":0.011967324804650951,"score_gpt":0.2450311863132118,"score_spread":0.23306386150856084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022616650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94034654,0.002305813,0.0020512145,0.054248124,0.00014376175,0.0006923439,0.00006252455,0.0000050519384,0.0001446126],"genre_scores_gemma":[0.97146946,0.0015950727,0.0010618685,0.025562316,0.000123902,0.0000061006376,0.000005859783,0.000010941565,0.00016446432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980128,0.00050421426,0.00078508235,0.00013442228,0.00043298153,0.00013051827],"domain_scores_gemma":[0.99751896,0.0003966734,0.0014722015,0.0003245406,0.0001749153,0.00011273554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012355947,0.00013539537,0.0021413383,0.000055330525,0.000045642388,0.0000031212653,0.0002144759,0.0000411775,0.00007284219],"category_scores_gemma":[0.00031943366,0.00006933211,0.0030749596,0.0006863801,0.00094416906,0.000037590497,0.00012046855,0.00020352694,1.0333223e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4437017,0.00049360906,0.017148014,0.0002053321,0.20613694,0.0000048065667,0.0015846471,0.0005521064,0.010668447,0.000044661174,0.30920428,0.010255432],"study_design_scores_gemma":[0.7069046,0.003592047,0.08718613,0.00008768605,0.10109466,0.000014490399,0.0018364683,0.0019694723,0.00077641505,0.00009130339,0.09624587,0.00020085346],"about_ca_topic_score_codex":0.00038903908,"about_ca_topic_score_gemma":0.000009182408,"teacher_disagreement_score":0.26320288,"about_ca_system_score_codex":0.000034939414,"about_ca_system_score_gemma":0.00018548178,"threshold_uncertainty_score":0.34788305},"labels":[],"label_agreement":null},{"id":"W3022929430","doi":"10.1093/ajh/hpaa073","title":"Empagliflozin for Patients With Presumed Resistant Hypertension: A <i>Post Hoc</i> Analysis of the EMPA-REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"American Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Relypsa; Idorsia Pharmaceuticals; Fresenius Medical Care North America; Boston Scientific Corporation; Amgen; Boehringer Ingelheim; Sanofi; Servier; Pfizer; Eli Lilly and Company; AstraZeneca; ResMed","keywords":"Empagliflozin; Medicine; Blood pressure; Internal medicine; Post-hoc analysis; Placebo; Cardiology; Diuretic; Heart failure; Nephropathy; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.027792813776370093,"score_gpt":0.24275260539374344,"score_spread":0.21495979161737333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022929430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915348,0.0001285698,0.000046053206,0.0072253593,0.00014354986,0.00084750104,0.000026772634,0.000011119234,0.000036242793],"genre_scores_gemma":[0.99416304,0.00002886855,0.0013596402,0.004218685,0.00010489633,0.000008476431,0.000021657972,0.000026682192,0.000068059315],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99805844,0.00008554211,0.00073081936,0.00022447639,0.0006739767,0.0002267481],"domain_scores_gemma":[0.99751943,0.00017450725,0.0009447699,0.000322661,0.0008226384,0.00021598542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019653032,0.00020707803,0.0012429786,0.00022160402,0.00007469462,0.000013394526,0.00018383656,0.00003106228,0.0000149522775],"category_scores_gemma":[0.0003323702,0.00010222911,0.00064844295,0.0009805354,0.00016510255,0.00010210584,0.00006069873,0.00013480356,0.0000012757006],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6561699,0.0052662212,0.23598216,0.00023306471,0.024948336,0.00033397292,0.0013380576,0.00032957166,0.010095097,0.000044741937,0.0135317305,0.051727157],"study_design_scores_gemma":[0.19412285,0.11279805,0.6063268,0.00055568607,0.06706699,0.00002747371,0.0025889594,0.0011192355,0.0012576284,0.000012908283,0.013490786,0.0006325896],"about_ca_topic_score_codex":0.000026350088,"about_ca_topic_score_gemma":0.0000094940615,"teacher_disagreement_score":0.46204704,"about_ca_system_score_codex":0.000047344696,"about_ca_system_score_gemma":0.00008948223,"threshold_uncertainty_score":0.4168782},"labels":[],"label_agreement":null},{"id":"W3023008009","doi":"10.1016/j.jcjd.2016.11.008","title":"WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Type 2 diabetes; Accidental; Cotransporter; Diabetes mellitus; Endocrinology; Sodium","score_opus":0.008588075431914739,"score_gpt":0.21718095900172643,"score_spread":0.2085928835698117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023008009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98495144,0.0044603096,1.9882559e-7,0.0016255045,0.00027081152,0.000349104,0.0000095854,0.0000020234793,0.008331005],"genre_scores_gemma":[0.99931073,0.00009186441,0.00008919857,0.00024100147,0.00009153111,0.000007762163,0.0000052895743,0.000015823389,0.00014676941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874395,0.00004114788,0.00046520197,0.00010809936,0.00028908812,0.00035248869],"domain_scores_gemma":[0.9986272,0.00005136894,0.00045618348,0.00054308254,0.00014618288,0.00017599168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006062309,0.00015365359,0.0003882829,0.00021968012,0.00012944113,0.000049315066,0.0005527965,0.000048831065,0.000059217862],"category_scores_gemma":[0.00003228109,0.00008714188,0.00016418999,0.00014880793,0.0003188817,0.00014722004,0.000021855358,0.0001698599,0.0000038081798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012245622,0.00010531853,0.9700001,0.00018249029,0.0006785671,0.00004052112,0.00081739004,0.000005769468,0.00050682103,0.0008503829,0.0010215071,0.025778899],"study_design_scores_gemma":[0.001692908,0.00068114634,0.9595777,0.001012129,0.00086518645,0.0000010102983,0.0017024045,0.000028967534,0.013793447,0.0009809567,0.019533455,0.00013069932],"about_ca_topic_score_codex":0.00031769538,"about_ca_topic_score_gemma":0.0016790505,"teacher_disagreement_score":0.0256482,"about_ca_system_score_codex":0.000056479617,"about_ca_system_score_gemma":0.00017188357,"threshold_uncertainty_score":0.35535428},"labels":[],"label_agreement":null},{"id":"W3023253952","doi":"10.1002/ejhf.1845","title":"The Intersecting Role of Glycaemia and Cardiac Function in the Development of Heart Failure Among Patients with Type 2 Diabetes Mellitus After an Acute Coronary Syndrome","year":2020,"lang":"en","type":"letter","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ejection fraction; Acute coronary syndrome; Heart failure; Internal medicine; Cardiology; Diabetes mellitus; Population; Type 2 Diabetes Mellitus; Lixisenatide; Type 2 diabetes; Liraglutide; Myocardial infarction; Endocrinology","score_opus":0.005517785670720785,"score_gpt":0.18993673727151109,"score_spread":0.1844189516007903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023253952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96253675,0.0011429427,0.0000017072535,0.03558063,0.00018599615,0.0004924735,0.00000884314,0.000008229002,0.000042417098],"genre_scores_gemma":[0.99062365,0.000023297143,0.0018376572,0.0071006995,0.0002198628,0.000006580251,0.000076703844,0.000061110506,0.00005045808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977215,0.00050747814,0.0006873646,0.00022779508,0.00057564006,0.00028021558],"domain_scores_gemma":[0.99888235,0.000102131096,0.00045573703,0.00027873926,0.00019869182,0.0000823331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061806967,0.0002923529,0.000638354,0.00016224776,0.000085077314,0.000049151957,0.0001826413,0.00006932993,0.000017611388],"category_scores_gemma":[0.000022516397,0.00015738145,0.00014318952,0.00019537857,0.00012771807,0.00016536936,0.000099587574,0.00094622455,0.000005990414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008520187,0.0001615979,0.7682076,0.00037270185,0.0023352,0.0004958706,0.003203165,0.000002709994,0.00033193844,9.2674003e-7,0.22095585,0.0030803997],"study_design_scores_gemma":[0.0011584745,0.0039206645,0.68628025,0.0010641662,0.0007913535,0.000030010813,0.0012430906,0.0000017669511,0.00007570997,0.0000046647606,0.30526596,0.00016389694],"about_ca_topic_score_codex":0.0000018345747,"about_ca_topic_score_gemma":0.000007658876,"teacher_disagreement_score":0.0843101,"about_ca_system_score_codex":0.000054871853,"about_ca_system_score_gemma":0.00007382412,"threshold_uncertainty_score":0.64178294},"labels":[],"label_agreement":null},{"id":"W3024767421","doi":"10.1002/dmrr.3335","title":"The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The <scp>CANA‐HF</scp> study","year":2020,"lang":"en","type":"article","venue":"Diabetes/Metabolism Research and Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Total (Canada)","funders":"National Center for Advancing Translational Sciences; Janssen Research and Development","keywords":"Cardiorespiratory fitness; Ejection fraction; Canagliflozin; Heart failure; Internal medicine; Sitagliptin; Cardiology; Medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.034726599624026036,"score_gpt":0.31244139067730553,"score_spread":0.2777147910532795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024767421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.925936,0.06716222,4.986734e-7,0.0018286635,0.00012994054,0.0046556024,0.000004479052,0.00001938707,0.00026320794],"genre_scores_gemma":[0.9934816,0.004569599,0.000045224435,0.0008119178,0.00022427436,0.00067270675,0.000010074531,0.000030414429,0.00015422012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682826,0.0009457978,0.00040921685,0.00052336405,0.00066458806,0.0006287832],"domain_scores_gemma":[0.9976893,0.0010833819,0.00010427255,0.00052987505,0.00022449535,0.0003686923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018857082,0.0002825309,0.00094209163,0.00021706228,0.00031188718,0.000107956796,0.0001859201,0.000060777817,0.000006130264],"category_scores_gemma":[0.0012817853,0.00014403841,0.00007606138,0.0013231332,0.00024052417,0.00009240241,0.000151548,0.00048452508,0.000027377799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004691533,0.0016902857,0.7270331,0.0046056737,0.0019709477,0.000059783695,0.004287091,0.000030211853,0.02771898,0.00033904638,0.11493371,0.116862044],"study_design_scores_gemma":[0.0031247786,0.004810772,0.51896846,0.00084402814,0.00045027144,4.116392e-7,0.0026400425,0.000060948005,0.012789129,0.00003013549,0.4561384,0.00014259141],"about_ca_topic_score_codex":0.00010856154,"about_ca_topic_score_gemma":0.00018665656,"teacher_disagreement_score":0.3412047,"about_ca_system_score_codex":0.000057472487,"about_ca_system_score_gemma":0.00007329993,"threshold_uncertainty_score":0.5873715},"labels":[],"label_agreement":null},{"id":"W3025092398","doi":"","title":"Glucagonlike peptide 1 analogs in diabetes care.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Data science; Diabetes mellitus; Medicine; Bioinformatics; Computer science; World Wide Web; Endocrinology; Biology","score_opus":0.02056428358367853,"score_gpt":0.2428194135038702,"score_spread":0.22225512992019167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025092398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87473905,0.00037276722,3.878232e-7,0.001261473,0.00019654424,0.0007485055,0.00000436993,0.000041353906,0.12263556],"genre_scores_gemma":[0.9938408,0.000044907258,0.00008581486,0.0003604765,0.00010243582,0.001109161,0.000028039713,0.000013839475,0.0044145286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913776,0.000009815573,0.00012106959,0.00020059678,0.00013283969,0.00039791444],"domain_scores_gemma":[0.99926597,0.000015048861,0.000059425307,0.00051928475,0.000023355908,0.00011689262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012349557,0.00010712623,0.00020783608,0.00010877007,0.00007853161,0.00006234893,0.00014190459,0.000036889815,0.000023253966],"category_scores_gemma":[0.00010042152,0.00008981193,0.000066324,0.000042731175,0.000054029777,0.000118013486,0.00009286815,0.00006559145,0.00011473153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011331711,0.000082648934,0.76811594,0.000049071812,0.00006111021,0.00003272827,0.00007004348,3.4165774e-7,0.000008131126,0.000086002205,0.0019102531,0.22957239],"study_design_scores_gemma":[0.0014759543,0.00003779172,0.95968634,0.000021522106,0.00009067374,1.9117849e-7,0.00008797307,0.0000069586463,0.00055657467,0.00009542351,0.037856597,0.00008402564],"about_ca_topic_score_codex":0.000041127973,"about_ca_topic_score_gemma":0.0001385022,"teacher_disagreement_score":0.22948836,"about_ca_system_score_codex":0.000097780816,"about_ca_system_score_gemma":0.000010696821,"threshold_uncertainty_score":0.36624244},"labels":[],"label_agreement":null},{"id":"W3026171640","doi":"10.1002/edm2.145","title":"The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews","year":2020,"lang":"en","type":"review","venue":"Endocrinology Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Empagliflozin; Canagliflozin; Dapagliflozin; Cancer; Meta-analysis; Internal medicine; Oncology; Bladder cancer; Placebo; Prostate cancer; Cochrane Library; Systematic review; Diabetes mellitus; MEDLINE; Type 2 diabetes; Endocrinology; Pathology; Alternative medicine","score_opus":0.06932424845159815,"score_gpt":0.3549832022664264,"score_spread":0.2856589538148282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026171640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006224403,0.9924104,0.0000016516155,0.00019359082,0.0005488137,0.005817192,0.00012343346,0.000046709036,0.00023576028],"genre_scores_gemma":[0.00015939667,0.9963837,0.0002646295,0.00012132426,0.0001475263,0.0021101367,0.00020341296,0.00007522719,0.0005346058],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511284,0.0011530789,0.0020230946,0.0005480489,0.00051373575,0.0006492199],"domain_scores_gemma":[0.99482477,0.00083150284,0.0031518803,0.00079108874,0.0002588742,0.00014188264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007194128,0.00069468596,0.007392856,0.00025228952,0.00008117778,0.000019985991,0.00039352948,0.00020207082,0.000042685326],"category_scores_gemma":[0.00032454223,0.0003680086,0.0009435179,0.0006263765,0.00020508368,0.00013237419,0.00007768027,0.0004237674,0.000047037942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003876252,0.00038541,0.0011597766,0.49610445,0.010641461,0.000025920692,0.000388193,2.3814205e-7,0.000015269972,0.008546213,0.00095343974,0.48174086],"study_design_scores_gemma":[0.00097580504,0.00044996978,0.0002568841,0.061250653,0.03169714,0.0000019735462,0.00006358088,0.0000021635842,0.00018128568,0.00003312843,0.9048021,0.0002853386],"about_ca_topic_score_codex":0.000026414316,"about_ca_topic_score_gemma":0.000041065185,"teacher_disagreement_score":0.90384865,"about_ca_system_score_codex":0.00016797024,"about_ca_system_score_gemma":0.0002094546,"threshold_uncertainty_score":0.9998772},"labels":[],"label_agreement":null},{"id":"W3026244952","doi":"10.1210/clinem/dgaa248","title":"Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin","year":2020,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Calgary; Western University; McMaster University; LMC Diabetes & Endocrinology (Canada); Hamilton Health Sciences; Population Health Research Institute","funders":"AstraZeneca","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Insulin glargine; Hazard ratio; Metformin; Confidence interval; Relative risk; Insulin; Randomized controlled trial; Endocrinology","score_opus":0.047678930029664786,"score_gpt":0.35285214320983566,"score_spread":0.3051732131801709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026244952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98334223,0.012065577,0.000093605435,0.0036723933,0.000322746,0.0002139601,9.772004e-7,0.000013654839,0.00027483483],"genre_scores_gemma":[0.9927732,0.004923039,0.0012131112,0.00066968816,0.00032075704,0.0000018041942,0.0000033695458,0.00001602213,0.00007902085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981219,0.000217146,0.0010399618,0.00014089186,0.00025570323,0.00022438826],"domain_scores_gemma":[0.9986993,0.00030739678,0.00047284804,0.00018746634,0.00014850593,0.00018448051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008181316,0.00015348235,0.000961704,0.00009195302,0.00003436812,0.0000073856263,0.00017090754,0.00006600197,0.000035267727],"category_scores_gemma":[0.00063931337,0.00008004427,0.00029504998,0.00017728517,0.00015667576,0.00012757619,0.0001162007,0.0004115619,0.0000026493822],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079943435,0.0014241933,0.375973,0.000354108,0.007535871,0.0004993825,0.00081007776,0.000016385731,0.009335086,0.0010747729,0.0014393867,0.5935434],"study_design_scores_gemma":[0.026432615,0.0130895935,0.83953404,0.0010418413,0.015804075,0.00021271911,0.0007581088,0.00045822532,0.017272385,0.0006384941,0.08438498,0.00037292708],"about_ca_topic_score_codex":0.0000021924727,"about_ca_topic_score_gemma":9.1915445e-7,"teacher_disagreement_score":0.59317046,"about_ca_system_score_codex":0.0000066387283,"about_ca_system_score_gemma":0.0000447707,"threshold_uncertainty_score":0.32641107},"labels":[],"label_agreement":null},{"id":"W3026804276","doi":"10.1053/j.ajkd.2020.03.019","title":"Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study","year":2020,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seven Oaks General Hospital; University of Manitoba","funders":"University of Manitoba","keywords":"Medicine; Retrospective cohort study; Type 2 diabetes; Diabetes mellitus; Cohort; Internal medicine; Acute kidney injury; Cohort study; Kidney disease; Urology; Pharmacology; Endocrinology","score_opus":0.006485378608314902,"score_gpt":0.25060929388403236,"score_spread":0.24412391527571745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026804276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982673,0.00004549421,0.0000037856423,0.00040151516,0.00029170568,0.00075821445,0.000079346006,0.000027852868,0.00012478938],"genre_scores_gemma":[0.9973334,0.000019465013,0.00016810956,0.0022041586,0.00017083378,0.000010839748,0.000027915783,0.00005346465,0.000011785576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981738,0.00007693214,0.00042502748,0.0002972033,0.00069345155,0.00033359727],"domain_scores_gemma":[0.9977771,0.000025204037,0.00047723448,0.00019827264,0.0002176091,0.0013045685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009757605,0.0002735732,0.0007498698,0.0002326316,0.00005028639,0.000022234812,0.0001411148,0.000018951168,0.00006668602],"category_scores_gemma":[0.0005282964,0.00020802465,0.00013534544,0.0007672204,0.000110857196,0.00026093403,0.000080322265,0.00017623894,0.000006791192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048822747,0.0015967629,0.98741865,0.000025486777,0.0025102189,0.00004279126,0.0004866133,0.0000051211964,0.00007720188,5.5820107e-7,0.001304622,0.0016496845],"study_design_scores_gemma":[0.009780693,0.0136138275,0.97204196,0.00037832352,0.0026088955,2.6721216e-7,0.0008000555,0.000026383515,0.0002150908,0.0000035954836,0.00029229038,0.00023861021],"about_ca_topic_score_codex":0.00002979238,"about_ca_topic_score_gemma":3.943499e-7,"teacher_disagreement_score":0.015376697,"about_ca_system_score_codex":0.00036967808,"about_ca_system_score_gemma":0.0003485775,"threshold_uncertainty_score":0.84829986},"labels":[],"label_agreement":null},{"id":"W3026889703","doi":"10.1016/j.jval.2020.04.220","title":"PDB32 COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Semaglutide; Medicine; Type 2 diabetes; Cost effectiveness; Quality-adjusted life year; Metformin; Dapagliflozin; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Endocrinology; Insulin; Liraglutide; Risk analysis (engineering)","score_opus":0.024046204953987165,"score_gpt":0.26741884943052635,"score_spread":0.2433726444765392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026889703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406135,0.00026032355,5.86188e-7,0.0026178092,0.00008384368,0.0024375238,0.000028427961,0.000018904575,0.00049120456],"genre_scores_gemma":[0.9982263,0.000027160777,0.00020092641,0.0012894694,0.000022129827,0.00008678947,0.00009896871,0.000029430545,0.000018827182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796915,0.00029695002,0.0004265967,0.0003451604,0.00024808993,0.00071403955],"domain_scores_gemma":[0.99906427,0.00016771442,0.00011923393,0.00018533254,0.00005661011,0.00040682885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074187457,0.00018652197,0.0005703123,0.0003988341,0.00002789826,0.000008024243,0.00009493352,0.000057982365,0.000016166221],"category_scores_gemma":[0.00020390368,0.00016859337,0.000028080463,0.0009602597,0.000034249744,0.000060447102,0.000034804612,0.00021068001,0.000008519087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028031296,0.00022007772,0.99059635,0.0013383963,0.000039634513,0.000036395722,0.0006704376,0.002310272,0.000009672655,0.000096727774,0.00014420072,0.0042575416],"study_design_scores_gemma":[0.0049568363,0.0016741089,0.9852722,0.0018827828,0.000022665736,9.6877805e-8,0.00012085541,0.004794476,0.00008228675,0.000024782987,0.001027494,0.00014140304],"about_ca_topic_score_codex":0.56984913,"about_ca_topic_score_gemma":0.31337902,"teacher_disagreement_score":0.2564701,"about_ca_system_score_codex":0.0014422144,"about_ca_system_score_gemma":0.0010914518,"threshold_uncertainty_score":0.69915},"labels":[],"label_agreement":null},{"id":"W3028183585","doi":"10.2337/dc20-0279","title":"Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Relypsa; Medical Research Council; Genentech; Gilead Sciences; Servier; Astellas Pharma; Eisai; National Institutes of Health; Bristol-Myers Squibb; CryoLife; Zafgen; Novo Nordisk; Intarcia Therapeutics; Esperion Therapeutics; GlaxoSmithKline; CSL Behring; National Health and Medical Research Council; AstraZeneca; Eli Lilly and Company; Vifor Pharma; Pfizer; Amgen; American Diabetes Association; American Society of Nephrology; AbbVie; Sanofi","keywords":"Linagliptin; Medicine; Albuminuria; Renal function; Kidney disease; Internal medicine; Hazard ratio; Diabetes mellitus; Clinical endpoint; Hypoglycemia; Type 2 diabetes; Randomized controlled trial; Endocrinology","score_opus":0.004392494147614397,"score_gpt":0.19808675425915917,"score_spread":0.19369426011154478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028183585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551684,0.0013729117,0.000002919668,0.0006367045,0.00011006248,0.0018587876,0.00004382177,0.000015938305,0.00044200924],"genre_scores_gemma":[0.99848306,0.000066798624,0.000046135992,0.0010849411,0.00003902818,0.00013955931,0.000089629444,0.000014776748,0.0000360674],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99880433,0.00016991963,0.00028723126,0.00028271755,0.00028951772,0.00016626087],"domain_scores_gemma":[0.99915487,0.0002190279,0.00011610769,0.0002666627,0.00006972215,0.00017361475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019823767,0.00019019542,0.0014919704,0.00018408104,0.00003164688,0.000010435676,0.0000573407,0.00005847798,0.000014627748],"category_scores_gemma":[0.00039377224,0.00011268755,0.00050472555,0.0005513508,0.00010022693,0.000043129472,0.00007169897,0.00011234495,5.4432485e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10162284,0.00019686038,0.8635077,0.002731179,0.022183461,0.00000857368,0.0039938954,0.00008925321,0.00053507613,0.00003383841,0.0002537223,0.0048436085],"study_design_scores_gemma":[0.5991301,0.0015571651,0.36645812,0.00025873195,0.025887942,8.19805e-8,0.00056324794,0.00028137382,0.005253392,0.000003172078,0.00044723682,0.00015943605],"about_ca_topic_score_codex":0.00003612155,"about_ca_topic_score_gemma":0.000008210812,"teacher_disagreement_score":0.49750727,"about_ca_system_score_codex":0.000025072104,"about_ca_system_score_gemma":0.00007646107,"threshold_uncertainty_score":0.45952648},"labels":[],"label_agreement":null},{"id":"W3028216699","doi":"10.1002/oby.22794","title":"Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5","year":2020,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"NIHR Leicester Biomedical Research Centre; Mitsubishi Tanabe Pharma Corporation; Servier; Eisai; Zafgen; Astellas Pharma; Mylan; MannKind Corporation; Bausch Health; University of Pennsylvania; Novo Nordisk; National Institute for Health and Care Research; Intarcia Therapeutics; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Waist; Placebo; Overweight; Obesity; Type 2 diabetes; Tolerability; Weight loss; Population; Circumference; Clinical trial; Physical therapy; Internal medicine; Diabetes mellitus; Adverse effect; Alternative medicine; Endocrinology; Liraglutide; Environmental health","score_opus":0.06482362611717103,"score_gpt":0.3124158583845207,"score_spread":0.24759223226734967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028216699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98683965,0.00037524593,0.0004521823,0.0069284956,0.00016712774,0.0040302263,0.00009120491,0.000021738593,0.0010941018],"genre_scores_gemma":[0.99442315,0.00012201007,0.0015783742,0.0009797552,0.00014040997,0.00015085985,0.000013817502,0.000014285848,0.0025773544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890375,0.00007895604,0.00039789555,0.00018878821,0.0002489762,0.00018163818],"domain_scores_gemma":[0.9989242,0.0003146331,0.00019866385,0.00040210027,0.000069482965,0.000090945585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003840154,0.00014197863,0.00055568427,0.000026109106,0.0000732082,0.0000072532143,0.00015359628,0.000030104187,0.00009701229],"category_scores_gemma":[0.000249237,0.00006874808,0.00034600633,0.0001690277,0.000035946952,0.000016619277,0.00006890726,0.000025185964,0.000016607988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016426732,0.005367277,0.81570315,0.00070143776,0.0042835837,0.000007105579,0.0034894936,0.000043900312,0.010376483,0.0028049261,0.04311175,0.112468235],"study_design_scores_gemma":[0.011838675,0.005991994,0.44586474,0.00015286008,0.004891994,4.4041627e-7,0.000577096,0.00042892408,0.13411027,0.00017448803,0.39576358,0.00020495067],"about_ca_topic_score_codex":0.00007099059,"about_ca_topic_score_gemma":0.000040022,"teacher_disagreement_score":0.36983842,"about_ca_system_score_codex":0.000074022675,"about_ca_system_score_gemma":0.000039001454,"threshold_uncertainty_score":0.28034654},"labels":[],"label_agreement":null},{"id":"W3029761253","doi":"10.1016/j.apsb.2020.05.006","title":"Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment","year":2020,"lang":"en","type":"letter","venue":"Acta Pharmaceutica Sinica B","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Toronto General Hospital","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Pharmacology; 2019-20 coronavirus outbreak; Coronavirus Infections; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Psychology; Virology; Internal medicine","score_opus":0.06922443764198452,"score_gpt":0.3623530509391792,"score_spread":0.29312861329719464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029761253","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058325768,0.0001987047,0.000016829792,0.9884585,0.002291653,0.00315899,0.00021843745,0.00021799329,0.0053805686],"genre_scores_gemma":[0.0056340857,0.00026002436,0.00014888201,0.96107256,0.026207337,0.00063737715,0.0009870982,0.00011795787,0.0049346862],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966156,0.0002567539,0.00046192046,0.000977086,0.0009630557,0.0007255788],"domain_scores_gemma":[0.99683744,0.0011298687,0.00016964285,0.0010442006,0.000054154505,0.000764722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002529172,0.0007576257,0.0008291219,0.0001892475,0.00025429562,0.00014315739,0.00037699562,0.00030825683,0.0005164931],"category_scores_gemma":[0.00014412959,0.00048005272,0.00032025177,0.00021385186,0.00017533485,0.00004067509,0.00021725515,0.0011596602,0.00059594674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045464849,0.00041151614,0.00003476077,0.00026449797,0.0011177225,0.0006091086,0.00030515116,0.000004734835,0.000024924195,0.0000070009028,0.99219096,0.0045749717],"study_design_scores_gemma":[0.0053180223,0.0018289766,0.000012828797,0.00010424653,0.002460549,0.0000030790927,0.00002289424,0.0001265198,0.0003686454,0.000009844779,0.9893184,0.00042602306],"about_ca_topic_score_codex":0.000036101395,"about_ca_topic_score_gemma":0.0000020018965,"teacher_disagreement_score":0.027385946,"about_ca_system_score_codex":0.00088174077,"about_ca_system_score_gemma":0.00026937842,"threshold_uncertainty_score":0.9997651},"labels":[],"label_agreement":null},{"id":"W3029786403","doi":"10.3760/cma.j.issn.1673-4157.2009.06.005","title":"Renin-angiotensin system in diabetes","year":2009,"lang":"en","type":"article","venue":"Intern J Endocrinol Metab","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Medicine; Diabetic nephropathy; Renin–angiotensin system; Nephropathy; Internal medicine; Endocrinology; Blood pressure","score_opus":0.014121550066870433,"score_gpt":0.2571856928883477,"score_spread":0.24306414282147726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029786403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95208067,0.0011998386,0.000031936666,0.0015729913,0.00033052883,0.0005007646,0.000002602527,0.00023749156,0.044043154],"genre_scores_gemma":[0.9937875,0.000021740861,0.0006429516,0.0006365831,0.00011232952,0.000029505105,0.000013531714,0.000017262519,0.004738598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987496,0.000030535484,0.0002856204,0.00029100612,0.00020254898,0.00044070065],"domain_scores_gemma":[0.99943125,0.000025351557,0.00005418489,0.00035947692,0.0000365911,0.000093131624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007120629,0.00019325457,0.00043253522,0.00027544863,0.00001769672,0.000029644802,0.000108891785,0.00003107773,0.00005089587],"category_scores_gemma":[0.000026749629,0.00015567125,0.0001563639,0.00017806453,0.00002116246,0.00008450643,0.00004415956,0.000113951995,0.00029783868],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003206454,0.0014807449,0.37304077,0.00014373411,0.0012434256,0.0031678642,0.000510835,0.000012646558,0.020735703,0.016519958,0.016067125,0.56675655],"study_design_scores_gemma":[0.0072203595,0.0011593844,0.78788334,0.0011143341,0.000874151,0.00005715337,0.00018526393,0.0008066881,0.08991544,0.00026491386,0.1099754,0.00054354785],"about_ca_topic_score_codex":0.00003573363,"about_ca_topic_score_gemma":0.0000118631715,"teacher_disagreement_score":0.566213,"about_ca_system_score_codex":0.00014054171,"about_ca_system_score_gemma":0.000010943093,"threshold_uncertainty_score":0.63480896},"labels":[],"label_agreement":null},{"id":"W3030277028","doi":"10.1016/j.jjcc.2020.04.008","title":"Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry","year":2020,"lang":"en","type":"article","venue":"Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bausch Health (Canada); University of Toronto; LMC Diabetes & Endocrinology (Canada)","funders":"Bausch Health","keywords":"Medicine; Cardiology; Internal medicine; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.024610809404526104,"score_gpt":0.2508587429720107,"score_spread":0.22624793356748463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030277028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793497,0.014451732,0.000003339593,0.005234973,0.00010822352,0.0003423558,0.00006951551,0.0000015113853,0.000438687],"genre_scores_gemma":[0.995254,0.0034905488,0.00007409691,0.0009952334,0.00012955022,0.0000054553184,0.00003847096,0.000010632787,0.0000020350392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804634,0.00063384953,0.00058138865,0.0002196935,0.00028264095,0.00023611619],"domain_scores_gemma":[0.9986209,0.00040233933,0.00024948036,0.00034477081,0.00018457757,0.00019789666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007349747,0.00016221352,0.00096094626,0.00006630069,0.00003334115,0.000005843769,0.00013816127,0.00008455032,0.0000015460616],"category_scores_gemma":[0.0002294157,0.00009222219,0.00012215879,0.00017273054,0.00012658843,0.000035619327,0.00005397277,0.00025882994,6.1439096e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020883736,0.00001517288,0.99246675,0.000046329424,0.0013287243,0.000099372795,0.00084034476,0.00061065523,0.0001989124,0.000078647994,0.00019727726,0.003909004],"study_design_scores_gemma":[0.0034961302,0.00030324847,0.98893505,0.00008860066,0.0010421155,0.000014867428,0.002072873,0.00017943504,0.00002722002,0.000025051671,0.0037503396,0.000065089014],"about_ca_topic_score_codex":0.71664333,"about_ca_topic_score_gemma":0.37508914,"teacher_disagreement_score":0.34155422,"about_ca_system_score_codex":0.00041874306,"about_ca_system_score_gemma":0.001819611,"threshold_uncertainty_score":0.63631386},"labels":[],"label_agreement":null},{"id":"W3031038558","doi":"10.1111/dom.14102","title":"Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel","year":2020,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Merck Sharp and Dohme; TrigoCare International; Hebrew University of Jerusalem; Mylan; KU Leuven; Teva Pharmaceutical Industries; Novo Nordisk; Sanofi; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Type 2 diabetes; Medicine; Metformin; Intensive care medicine; Expert opinion; Diabetes mellitus; Diabetes treatment; Endocrinology","score_opus":0.03341292104257114,"score_gpt":0.27084942317275323,"score_spread":0.23743650213018208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031038558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017124003,0.97796965,0.000029934945,0.000055412263,0.00036904193,0.0034574135,0.0006927135,0.00010841025,0.00019344255],"genre_scores_gemma":[0.00073429657,0.9856082,0.0054981518,0.0002989095,0.00045744004,0.00047493866,0.0066751293,0.00014906781,0.00010382554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742013,0.0002244896,0.0005558098,0.00092672254,0.00026498013,0.0006078937],"domain_scores_gemma":[0.99863666,0.00022828438,0.00028653274,0.00040862392,0.00011513314,0.0003247764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014395642,0.0008028009,0.002584594,0.00026949102,0.00012541018,0.00009583673,0.00013247847,0.00019323934,0.000013418637],"category_scores_gemma":[0.000045120658,0.00058057794,0.000350894,0.00030562902,0.000086422944,0.00008805883,0.00010993461,0.00019920857,0.000023616536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030322273,0.0009234516,0.00227768,0.0012520091,0.0016203993,0.000021091439,0.00030926848,2.1312269e-7,0.0000012665638,0.000013602815,0.00014793052,0.9934028],"study_design_scores_gemma":[0.006966258,0.0009857718,0.010225613,0.007409195,0.004168049,5.9003327e-7,0.000031919768,0.0003560053,0.000009819113,0.00006288151,0.9690506,0.00073333667],"about_ca_topic_score_codex":0.00005405785,"about_ca_topic_score_gemma":0.0000047176545,"teacher_disagreement_score":0.9926694,"about_ca_system_score_codex":0.00017193829,"about_ca_system_score_gemma":0.000118711665,"threshold_uncertainty_score":0.99966455},"labels":[],"label_agreement":null},{"id":"W3031169853","doi":"10.3760/cma.j.issn.1673-4157.2014.06.006","title":"Deciphering metabolic messages from the gut drives therapeutic innovation","year":2014,"lang":"en","type":"article","venue":"Intern J Endocrinol Metab","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incretin; Medal; Diabetes mellitus; Medicine; Management; Library science; Endocrinology; History; Computer science; Art history; Type 2 diabetes; Economics","score_opus":0.024191466818880455,"score_gpt":0.28302423772312835,"score_spread":0.2588327709042479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031169853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649538,0.0038046485,0.005805839,0.00268561,0.0006387821,0.0005264101,0.0000050422304,0.00020162012,0.021378275],"genre_scores_gemma":[0.9931249,0.0002220428,0.0007538893,0.0022144183,0.0003285257,0.00009999351,0.000026528458,0.00003193089,0.0031977436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988173,0.00007694787,0.00028264392,0.00027599596,0.0002561059,0.0002909543],"domain_scores_gemma":[0.9991114,0.00016696024,0.00010097757,0.00051002915,0.00007133285,0.000039262875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012273811,0.00020501016,0.00033151254,0.00010452987,0.00006740263,0.00007384641,0.00018360441,0.00002500795,0.00029879186],"category_scores_gemma":[0.00008183615,0.00012404668,0.00011550312,0.00025172223,0.000058088386,0.0001214935,0.00012188205,0.00013152711,0.00021017964],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098578836,0.00025566743,0.067485705,0.00002357169,0.0028138747,0.000027516744,0.0008155024,0.000007982685,0.025989152,0.053569093,0.0013759376,0.8475374],"study_design_scores_gemma":[0.0023035323,0.00012603856,0.39241612,0.00009624214,0.0012229236,0.0000071235577,0.00031439457,0.0003189989,0.040745124,0.0027516005,0.55947554,0.00022235415],"about_ca_topic_score_codex":0.00012125659,"about_ca_topic_score_gemma":0.000027186936,"teacher_disagreement_score":0.8473151,"about_ca_system_score_codex":0.000024247494,"about_ca_system_score_gemma":0.000010424201,"threshold_uncertainty_score":0.50584763},"labels":[],"label_agreement":null},{"id":"W3032880817","doi":"10.1210/clinem/dgaa321","title":"Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Cardiology; Outcome (game theory); Risk factor; Diabetes mellitus; Type 2 diabetes; Endocrinology; Economics","score_opus":0.07084303969085817,"score_gpt":0.3632531610318854,"score_spread":0.2924101213410272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032880817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95804846,0.02781062,0.000274922,0.011590392,0.0008442025,0.0012295439,0.000045419893,0.000010540576,0.00014589014],"genre_scores_gemma":[0.98798925,0.008491675,0.000059278587,0.0018631315,0.0015255179,0.000013160637,0.0000012401617,0.000024349827,0.000032411037],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933685,0.002160912,0.0026169217,0.0002518406,0.0010632282,0.0005386091],"domain_scores_gemma":[0.9952299,0.0019845758,0.0012726253,0.0011737521,0.0001958719,0.0001432814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059875613,0.0003009016,0.0032237268,0.000088385576,0.00008971747,0.000013228798,0.0010312196,0.0001250631,0.00005243676],"category_scores_gemma":[0.0021055914,0.00012786392,0.0043442314,0.0003388242,0.00061274983,0.00008494665,0.00016823325,0.0013214692,0.000010948474],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1321645,0.0052024983,0.28153914,0.00040737333,0.23074307,0.0014955015,0.015171512,0.013892863,0.00022632747,0.0040535945,0.001904294,0.3131993],"study_design_scores_gemma":[0.15853627,0.0034066394,0.66576964,0.000056483335,0.031263642,0.00010812058,0.0021285848,0.000108710825,0.0006408363,0.00079041184,0.13694768,0.00024295041],"about_ca_topic_score_codex":0.00017443993,"about_ca_topic_score_gemma":0.000016457172,"teacher_disagreement_score":0.3842305,"about_ca_system_score_codex":0.000018383336,"about_ca_system_score_gemma":0.000092597365,"threshold_uncertainty_score":0.57412},"labels":[],"label_agreement":null},{"id":"W3032918433","doi":"10.1093/ndt/gfaa146.lb005","title":"LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; University Health Network","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Renal function; Internal medicine; Diabetic nephropathy; Kidney disease; Type 2 diabetes; Nephropathy; Urology; Diabetes mellitus; Endocrinology; Kidney","score_opus":0.025389172023579917,"score_gpt":0.2888251946873355,"score_spread":0.26343602266375554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032918433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9084595,0.000016602246,0.00090528664,0.08890311,0.00003427756,0.0009907228,0.000055098822,0.000039623967,0.0005957667],"genre_scores_gemma":[0.9833188,0.000028887387,0.00018949655,0.01591718,0.000065708366,0.00022495002,0.0001751212,0.000016969472,0.00006289786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998571,0.00028663757,0.0004129119,0.0002867155,0.00022473368,0.0002180218],"domain_scores_gemma":[0.9991569,0.00022299161,0.00012595262,0.00032608878,0.000068090725,0.00009995943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029959137,0.00016603814,0.00032584489,0.00017102451,0.00009624413,0.00001238924,0.00013170205,0.00008503378,0.000058592184],"category_scores_gemma":[0.000068341775,0.00009765165,0.00012448126,0.0008087473,0.00012452714,0.000092815135,0.00002128371,0.00015449908,0.000029228333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023850145,0.0009041814,0.81088215,0.00033294497,0.0012699093,0.0000967753,0.026252918,0.0025157258,0.12376583,0.0019787694,0.0021972717,0.0059533785],"study_design_scores_gemma":[0.004352463,0.00074578956,0.9824227,0.00005035841,0.0016749353,0.000009586131,0.00027065445,0.0000789261,0.008387291,0.00009720305,0.0017871858,0.00012289615],"about_ca_topic_score_codex":0.0000664082,"about_ca_topic_score_gemma":0.0006182886,"teacher_disagreement_score":0.17154057,"about_ca_system_score_codex":0.000066408065,"about_ca_system_score_gemma":0.00007407361,"threshold_uncertainty_score":0.39821187},"labels":[],"label_agreement":null},{"id":"W3032937380","doi":"10.1093/ndt/gfaa142.p1013","title":"P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Canagliflozin; Medicine; Internal medicine; Placebo; Population; Diabetes mellitus; Kidney disease; Body mass index; Hazard ratio; Renal function; Type 2 diabetes; Endocrinology; Confidence interval; Pathology","score_opus":0.0065351065234023785,"score_gpt":0.220940772280762,"score_spread":0.21440566575735961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032937380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976394,0.00045854037,0.00010141489,0.0009487381,0.000017491895,0.0005933915,0.00018689419,0.000014333744,0.000039778384],"genre_scores_gemma":[0.9967412,0.0026942585,0.000067182285,0.00023222958,0.000017284847,0.000073042895,0.00016209099,0.0000071564746,0.000005590503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990842,0.00015291916,0.00026421226,0.00024719824,0.00012602966,0.00012546888],"domain_scores_gemma":[0.999279,0.0002741379,0.00013996336,0.00012416409,0.000045990746,0.0001367098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011406723,0.00012961467,0.00042863967,0.00034395585,0.00007281992,0.000010116326,0.000031022533,0.000056142624,0.000022634154],"category_scores_gemma":[0.000073949224,0.000093641946,0.00010505422,0.00086521695,0.00017989604,0.000114849296,0.000014300608,0.00009572571,1.8541346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005112496,0.0007141502,0.9878177,0.00015669332,0.002635435,0.0000070972746,0.0018638878,0.0002654105,0.0005348082,0.000037325633,0.0000043401647,0.00085065456],"study_design_scores_gemma":[0.01089611,0.0032097911,0.95670927,0.00002439104,0.02666991,0.0000026196296,0.00008937645,0.002211058,0.00006749037,0.000015668,0.000028242219,0.00007606627],"about_ca_topic_score_codex":0.0004079554,"about_ca_topic_score_gemma":0.0016389375,"teacher_disagreement_score":0.031108424,"about_ca_system_score_codex":0.000012582725,"about_ca_system_score_gemma":0.000050948238,"threshold_uncertainty_score":0.3818608},"labels":[],"label_agreement":null},{"id":"W3033090815","doi":"10.1093/ndt/gfaa142.p1019","title":"P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"National Health and Medical Research Council; Mitsubishi Tanabe Pharma Corporation","keywords":"Medicine; Canagliflozin; Internal medicine; Placebo; Diabetes mellitus; Population; Kidney disease; Adverse effect; Post-hoc analysis; Surgery; Type 2 diabetes; Pathology; Endocrinology","score_opus":0.005322049454673817,"score_gpt":0.22179225970154834,"score_spread":0.21647021024687452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033090815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971483,0.0005198488,0.00022121023,0.001358073,0.000012831949,0.00056408375,0.0001437993,0.000010881011,0.000021014299],"genre_scores_gemma":[0.9969601,0.0022787321,0.0001114088,0.0004115116,0.000014876958,0.000052151656,0.00015767544,0.000006556981,0.0000069737102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991168,0.00013841662,0.0002484486,0.00024599148,0.0001310482,0.000119302655],"domain_scores_gemma":[0.9993273,0.00023342251,0.00013843724,0.0001267641,0.00004120887,0.00013286053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001246082,0.00011942365,0.00045576517,0.00026605077,0.000046937836,0.00000890765,0.00003497232,0.000050193194,0.000020936033],"category_scores_gemma":[0.00007978594,0.00008370433,0.000067657056,0.00075530534,0.00016728892,0.00007695052,0.0000142259705,0.00006946131,1.7377441e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008290724,0.0001887128,0.9803945,0.00025643702,0.0027845069,0.0000045239062,0.0028708088,0.00028400874,0.0012414714,0.000051893436,0.00000888581,0.0036235433],"study_design_scores_gemma":[0.01345134,0.0013756304,0.95256865,0.000032092223,0.029183935,4.4270124e-7,0.00008745148,0.0027584678,0.00037174847,0.000021357597,0.00007181105,0.00007709678],"about_ca_topic_score_codex":0.00057533686,"about_ca_topic_score_gemma":0.0035278285,"teacher_disagreement_score":0.027825858,"about_ca_system_score_codex":0.000009036205,"about_ca_system_score_gemma":0.000041967458,"threshold_uncertainty_score":0.34133637},"labels":[],"label_agreement":null},{"id":"W3033493180","doi":"10.1093/ndt/gfaa141.to001","title":"TO001EFFECTS OF THE BET-INHIBITOR APABETALONE ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ACUTE CORONARY SYNDROME, ACCORDING TO PRESENCE OR ABSENCE OF CHRONIC KIDNEY DISEASE. A BETONMACE TRIAL REPORT","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Resverlogix (Canada)","funders":"","keywords":"Mace; Medicine; Internal medicine; Kidney disease; Acute coronary syndrome; Diabetes mellitus; Type 2 diabetes; Coronary artery disease; Cardiology; Myocardial infarction; Endocrinology; Percutaneous coronary intervention","score_opus":0.008079820061875657,"score_gpt":0.22505686767016692,"score_spread":0.21697704760829126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033493180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713194,0.00020022181,0.00004656564,0.00032022412,0.00012138872,0.0021097665,0.000044584966,0.00001648154,0.0000088429315],"genre_scores_gemma":[0.99896556,0.00018621585,0.00008275251,0.00032768844,0.000030566276,0.00011074105,0.00026730838,0.00001623621,0.00001291603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984838,0.00013572408,0.00035296753,0.00039300753,0.00042204253,0.00021246057],"domain_scores_gemma":[0.9991882,0.0001190556,0.00015567102,0.00031326822,0.000060543287,0.00016329797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016632574,0.00017960164,0.0006057093,0.00012047178,0.000035052766,0.000003220409,0.00009191959,0.00006242823,0.000007651218],"category_scores_gemma":[0.00009037278,0.000118030315,0.00013982068,0.0004928842,0.00007491032,0.000093565395,0.000029017694,0.00008697944,0.0000020377772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04252128,0.00054561615,0.9481179,0.00076972885,0.00286435,0.00022991776,0.00034708224,0.00060563424,0.001676966,0.00000607953,0.000034950222,0.0022804989],"study_design_scores_gemma":[0.024195127,0.005298316,0.963649,0.00039521584,0.004196082,0.0000029529235,0.000009965634,0.00014108694,0.0019344206,0.0000041517346,0.000051091087,0.00012260504],"about_ca_topic_score_codex":0.000016437174,"about_ca_topic_score_gemma":0.000011567955,"teacher_disagreement_score":0.018326152,"about_ca_system_score_codex":0.000048624315,"about_ca_system_score_gemma":0.00010033746,"threshold_uncertainty_score":0.48131365},"labels":[],"label_agreement":null},{"id":"W3033670772","doi":"10.1093/ndt/gfaa140.mo051","title":"MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Semaglutide; Medicine; Hazard ratio; Placebo; Kidney disease; Internal medicine; Post-hoc analysis; Population; Cohort; Urology; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology; Liraglutide; Pathology","score_opus":0.014355712388050204,"score_gpt":0.26683515230035465,"score_spread":0.2524794399123044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033670772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781246,0.0005197041,0.0015480735,0.018172322,0.000035970243,0.00097206124,0.00050578354,0.000055106182,0.00006635016],"genre_scores_gemma":[0.985186,0.00054808357,0.00009674804,0.010695462,0.00008861249,0.00008905065,0.0032403374,0.000013896593,0.000041833482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981515,0.00047550056,0.00048483588,0.00040004874,0.00027179788,0.00021634689],"domain_scores_gemma":[0.99801135,0.001160519,0.00021344794,0.0002939363,0.000062250336,0.000258478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004067101,0.00022615875,0.0010924054,0.00032469482,0.000067386114,0.000018729726,0.00008899617,0.00008700915,0.00019952955],"category_scores_gemma":[0.00030119365,0.00014504923,0.00061197014,0.00089216174,0.000090387206,0.000051100713,0.000013694823,0.00010090034,0.000013997197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02022129,0.000966306,0.7688007,0.00095625955,0.1657317,0.00033355426,0.007656251,0.0054799966,0.016521143,0.0009819986,0.0013679106,0.010982913],"study_design_scores_gemma":[0.0069059385,0.0010084576,0.78686637,0.000027449203,0.20106433,1.7235054e-7,0.000095524425,0.00301648,0.00050466676,0.00005878437,0.00031689106,0.00013495346],"about_ca_topic_score_codex":0.00016642697,"about_ca_topic_score_gemma":0.00021896858,"teacher_disagreement_score":0.035332642,"about_ca_system_score_codex":0.000045091652,"about_ca_system_score_gemma":0.00008007765,"threshold_uncertainty_score":0.5914936},"labels":[],"label_agreement":null},{"id":"W3033877044","doi":"10.1093/ndt/gfaa141.to002","title":"TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Semaglutide; Medicine; Placebo; Renal function; Post-hoc analysis; Internal medicine; Urology; Population; Confidence interval; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.007850138553978515,"score_gpt":0.23422773130554583,"score_spread":0.22637759275156732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033877044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889797,0.00011202119,0.0010989044,0.009191889,0.0000081948965,0.00045436664,0.000028652044,0.000014296599,0.000112006564],"genre_scores_gemma":[0.9964038,0.00033145642,0.00040205594,0.0021803651,0.000019321373,0.00003523238,0.0006021389,0.0000073869996,0.00001820161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990116,0.00017761374,0.00031875164,0.00021254532,0.00014693523,0.00013254985],"domain_scores_gemma":[0.99942243,0.00017712296,0.00014161991,0.0001324903,0.00008693323,0.00003941115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003189414,0.000120428376,0.00047547361,0.00039984353,0.000023587472,0.000005878084,0.000054380667,0.000060548184,0.00003513239],"category_scores_gemma":[0.000021758973,0.000081114806,0.000098021155,0.0010675265,0.0000973027,0.000059221562,0.0000069108064,0.00007155814,9.982034e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08124064,0.0019034449,0.627859,0.0019846593,0.03315824,0.00037279638,0.05562675,0.023358924,0.15642616,0.0027524217,0.00032541307,0.014991558],"study_design_scores_gemma":[0.01002789,0.00263571,0.9235586,0.0000378975,0.051560313,0.00000782528,0.0018281672,0.0066747162,0.0032520418,0.000056831796,0.00021094522,0.0001490448],"about_ca_topic_score_codex":0.00021633711,"about_ca_topic_score_gemma":0.0009983096,"teacher_disagreement_score":0.29569963,"about_ca_system_score_codex":0.000015807185,"about_ca_system_score_gemma":0.000026335465,"threshold_uncertainty_score":0.33077657},"labels":[],"label_agreement":null},{"id":"W3033878193","doi":"10.1093/ndt/gfaa142.p0710","title":"P0710DUAL GPR40/GPR84 FATTY ACID RECEPTOR DELETION IMPROVES ADENINE-INDUCED RENAL INJURY IN MICE","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Liminal BioSciences (Canada); University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Endocrinology; Internal medicine; Creatinine; Free fatty acid receptor 1; Renal function; Hematocrit; Receptor; Agonist","score_opus":0.014039572526225582,"score_gpt":0.2502705363529586,"score_spread":0.236230963826733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033878193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907844,0.000060110597,0.0011210599,0.006580565,0.00011519233,0.00059724133,0.000026666985,0.00013252629,0.0005822568],"genre_scores_gemma":[0.9921733,0.0003488781,0.0015226715,0.0041907476,0.00026484363,0.00012992477,0.0012946939,0.00002549382,0.000049459195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983842,0.00013817598,0.00043673307,0.00047635878,0.00023472279,0.00032984163],"domain_scores_gemma":[0.99949235,0.000050899536,0.000120087425,0.00014404916,0.000052667707,0.00013995134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015889294,0.00023587096,0.0004425237,0.00025228065,0.000054900793,0.000018258015,0.000094089664,0.0002123731,0.00016261076],"category_scores_gemma":[0.000026753582,0.0002240651,0.00014689902,0.00045892448,0.00004705485,0.00019777926,0.000013557157,0.0002242504,0.00016043759],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026416667,0.00021871003,0.009145555,0.0001303232,0.00038769728,0.00006951229,0.0017777472,0.000021343836,0.96048945,0.000102383245,0.00071355636,0.024302075],"study_design_scores_gemma":[0.014299927,0.0038416113,0.29759914,0.0001091403,0.004256794,0.00001759261,0.00021104356,0.0016566819,0.6721187,0.0001225314,0.0051087453,0.0006580844],"about_ca_topic_score_codex":0.00006552011,"about_ca_topic_score_gemma":0.0001492844,"teacher_disagreement_score":0.28845358,"about_ca_system_score_codex":0.00007204978,"about_ca_system_score_gemma":0.000043455628,"threshold_uncertainty_score":0.91371095},"labels":[],"label_agreement":null},{"id":"W3033973587","doi":"10.1093/ndt/gfaa142.p0775","title":"P0775A RETROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS THE PREVALENCE OF CHRONIC KIDNEY DISEASE AMONG TYPE 2 DIABETES MELLITUS PATIENTS IN ONTARIO, CANADA","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Population; Diabetes mellitus; Type 2 diabetes; Internal medicine; Retrospective cohort study; Renal function; Intensive care medicine; Environmental health; Endocrinology","score_opus":0.015979151687159462,"score_gpt":0.23567810632009592,"score_spread":0.21969895463293646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033973587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969095,0.000038440576,0.000018814599,0.000981659,0.00010417583,0.0016951988,0.00006840841,0.0000149209045,0.00016889077],"genre_scores_gemma":[0.9969176,0.00007451375,0.000023192337,0.0020136603,0.0000352538,0.000169562,0.0006585925,0.000010388183,0.00009724841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986038,0.00012279156,0.0003206579,0.0003416679,0.00040833923,0.00020274088],"domain_scores_gemma":[0.9993017,0.00008549272,0.000102885046,0.00018993078,0.00014223781,0.00017776761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015280656,0.0001468174,0.0003238616,0.00007157529,0.00004685591,0.00000800143,0.00011818494,0.000030377825,0.0003148976],"category_scores_gemma":[0.00007740871,0.00011649853,0.000051562456,0.00037805902,0.00004389806,0.00009392022,0.000017028953,0.00012086101,0.0000037846507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004003674,0.00049536844,0.99624497,0.00018841466,0.0004664989,0.000016374135,0.0011874792,0.00042926028,0.00005830904,0.000024031462,0.0003960302,0.00009292071],"study_design_scores_gemma":[0.0016738686,0.0007616114,0.99481833,0.000035699584,0.0020442477,2.7284115e-8,0.000023630075,0.00030808093,0.00008468622,0.000012612753,0.00014677232,0.00009043033],"about_ca_topic_score_codex":0.23728521,"about_ca_topic_score_gemma":0.8140756,"teacher_disagreement_score":0.57679033,"about_ca_system_score_codex":0.00047935467,"about_ca_system_score_gemma":0.00058348005,"threshold_uncertainty_score":0.7677938},"labels":[],"label_agreement":null},{"id":"W3034040592","doi":"10.1042/bcj20200278","title":"The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice","year":2020,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Canagliflozin; AMPK; Endocrinology; Internal medicine; Chemistry; Lipogenesis; AMP-activated protein kinase; Protein kinase A; Acetyl-CoA carboxylase; Type 2 diabetes; Citrate synthase; Diabetes mellitus; Lipid metabolism; Medicine; Biochemistry; Pyruvate carboxylase; Phosphorylation; Enzyme","score_opus":0.01352397678936513,"score_gpt":0.22992683549184245,"score_spread":0.21640285870247733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034040592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97565705,0.0026418543,0.000012490784,0.020387145,0.00014797322,0.00017876357,0.0000052468936,0.00001805573,0.00095140183],"genre_scores_gemma":[0.99761266,0.00062954077,0.00024828428,0.0009614289,0.00042067558,0.000013604698,0.0000033893236,0.000013916552,0.00009651611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900043,0.000035008212,0.0002700518,0.00019072506,0.00022409028,0.00027971316],"domain_scores_gemma":[0.99931705,0.0001959503,0.00006650637,0.000107297405,0.000037380876,0.00027580504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015828211,0.00013813796,0.00021206464,0.000050292438,0.000079740494,0.00009483978,0.00012935989,0.00005162968,0.000033705088],"category_scores_gemma":[0.00031778385,0.000086220054,0.00007580309,0.00012576545,0.00008720541,0.000044227367,0.00012195553,0.00023322855,0.000012649309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017537922,0.0009989829,0.045359854,0.00051432283,0.0009975532,0.0006669713,0.0017319248,0.0000056442905,0.5175655,0.0005468916,0.3202983,0.10956025],"study_design_scores_gemma":[0.0033642447,0.0006094558,0.00822502,0.0007012828,0.00061393285,0.00015802278,0.0015331468,0.0003259265,0.8031128,0.00007112666,0.1808952,0.0003898405],"about_ca_topic_score_codex":0.000017343762,"about_ca_topic_score_gemma":0.000010150458,"teacher_disagreement_score":0.28554732,"about_ca_system_score_codex":0.00008666196,"about_ca_system_score_gemma":0.000043510827,"threshold_uncertainty_score":0.3515952},"labels":[],"label_agreement":null},{"id":"W3034241534","doi":"10.2337/db20-952-p","title":"952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Glimepiride; Linagliptin; Medicine; Hypoglycemia; Type 2 diabetes; Internal medicine; Guideline; Proportional hazards model; Diabetes mellitus; Pediatrics; Endocrinology; Insulin","score_opus":0.01856532411149911,"score_gpt":0.24343281396288138,"score_spread":0.22486748985138227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034241534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904165,0.0016731232,0.0000011925243,0.0057927393,0.00004715274,0.0009535025,0.0000032074627,0.00003069678,0.0010818598],"genre_scores_gemma":[0.9972676,0.00015978512,0.00015728465,0.0020574606,0.00017088388,0.00011050409,0.000018654184,0.000013104706,0.000044701672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991099,0.00004656482,0.0001661431,0.00025791724,0.00019010565,0.00022936368],"domain_scores_gemma":[0.9995658,0.00011233325,0.00005048503,0.0001449496,0.000017664357,0.000108817374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018006627,0.0001525772,0.00027170812,0.000051695733,0.000040191142,0.000038359485,0.00006190894,0.00003564962,0.00000827784],"category_scores_gemma":[0.00007899236,0.00009004144,0.000029307152,0.00015128811,0.00007367729,0.000059553997,0.00006670113,0.00013023018,0.0000061659416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008546524,0.0004655397,0.9118747,0.00042839217,0.00028208317,0.00014164526,0.0045021097,0.000002919031,0.0005460331,0.00045695083,0.002922112,0.06983098],"study_design_scores_gemma":[0.16628137,0.021613417,0.75441986,0.0006249329,0.0017049606,0.000008196004,0.0023590627,0.0014900804,0.0039564623,0.000504042,0.046217732,0.0008198564],"about_ca_topic_score_codex":0.000015951371,"about_ca_topic_score_gemma":0.000014817182,"teacher_disagreement_score":0.15773486,"about_ca_system_score_codex":0.00002093975,"about_ca_system_score_gemma":0.000018625364,"threshold_uncertainty_score":0.36717832},"labels":[],"label_agreement":null},{"id":"W3034246542","doi":"10.2337/db20-132-lb","title":"132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Renal function; Diuretic; Endocrinology; Urology; Type 2 diabetes; Diabetes mellitus; Chemistry","score_opus":0.022780776048890502,"score_gpt":0.3111140167019242,"score_spread":0.2883332406530337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034246542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825396,0.0002201946,0.00003046707,0.012752538,0.00006668847,0.0010537684,0.000036930316,0.00010751019,0.0031923074],"genre_scores_gemma":[0.9950555,0.000011696975,0.00079970877,0.003212835,0.000108331995,0.00030477942,0.00006306623,0.000025352163,0.00041875514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904025,0.00006415638,0.00021171363,0.0002681312,0.00014376413,0.0002719707],"domain_scores_gemma":[0.9990411,0.0002579594,0.000052608906,0.0003099468,0.00005193962,0.00028643958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087991335,0.00017480145,0.00037178939,0.000116438256,0.000039964034,0.000012484312,0.00008460592,0.000042148276,0.00007481346],"category_scores_gemma":[0.00021378332,0.00014251783,0.00013170407,0.0003050595,0.00003518264,0.000044658394,0.000058801255,0.00003870189,0.0001939674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019301929,0.0021841412,0.30477297,0.0006190353,0.0019610424,0.000056833007,0.003652168,0.00002982112,0.48735422,0.0014010996,0.022818778,0.17321971],"study_design_scores_gemma":[0.0047876267,0.009016707,0.3914728,0.00014060848,0.00090907287,3.6618437e-7,0.00011808433,0.00006784535,0.53905815,0.00011710823,0.05404375,0.00026791188],"about_ca_topic_score_codex":0.000008271797,"about_ca_topic_score_gemma":0.0000015292057,"teacher_disagreement_score":0.1729518,"about_ca_system_score_codex":0.00009665128,"about_ca_system_score_gemma":0.000048638227,"threshold_uncertainty_score":0.58117086},"labels":[],"label_agreement":null},{"id":"W3034251945","doi":"10.2337/db20-1038-p","title":"1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Hypoglycemia; Internal medicine; Insulin glargine; Odds ratio; Insulin; Renal function; Endocrinology; Diabetes mellitus; Population; Basal insulin; Clinical endpoint; Gastroenterology; Urology; Clinical trial","score_opus":0.008680612432398828,"score_gpt":0.22713758908476434,"score_spread":0.21845697665236552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034251945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993073,0.0007616877,0.00003072422,0.0020411033,0.00015938863,0.0033447852,0.00030952826,0.000038120328,0.00024168924],"genre_scores_gemma":[0.99810725,0.00015210372,0.00007792264,0.00086014386,0.000080863254,0.00016520327,0.0004905804,0.00005065367,0.000015293772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686295,0.0004972954,0.0010275969,0.0003916647,0.0008143771,0.00040610813],"domain_scores_gemma":[0.9969826,0.0009759239,0.000852853,0.0005420884,0.0005051858,0.00014136567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006941083,0.0004506854,0.0017381379,0.00021598776,0.00009317585,0.000026219906,0.0002374338,0.00013703034,0.00009929697],"category_scores_gemma":[0.001786369,0.00022768973,0.000440006,0.0007686263,0.00025281063,0.00014946485,0.000082684666,0.00026672965,0.0000054181187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039125483,0.0009076914,0.94731057,0.0005124239,0.0036581412,0.0000013066042,0.0016154104,0.0023099522,0.0010508964,0.0003493615,0.00061230216,0.002546482],"study_design_scores_gemma":[0.14380026,0.009640718,0.83013576,0.00059668784,0.0019772337,1.9725901e-8,0.00020554701,0.007260772,0.0058845575,0.00011114667,0.000073308176,0.00031400647],"about_ca_topic_score_codex":0.00007580852,"about_ca_topic_score_gemma":0.00005866938,"teacher_disagreement_score":0.117174804,"about_ca_system_score_codex":0.00017263739,"about_ca_system_score_gemma":0.0002036251,"threshold_uncertainty_score":0.9284918},"labels":[],"label_agreement":null},{"id":"W3034294121","doi":"10.2337/db20-356-or","title":"356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Post-hoc analysis; Medicine; Renal function; Dulaglutide; Type 2 diabetes; Internal medicine; Kidney disease; Placebo; Clinical endpoint; Diabetes mellitus; Randomized controlled trial; Endocrinology; Liraglutide; Pathology","score_opus":0.01233521228149406,"score_gpt":0.2476103579115101,"score_spread":0.23527514563001603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034294121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926878,0.00050712074,5.156734e-7,0.0043156613,0.0003754228,0.001104056,0.000098840166,0.00007549727,0.0008350695],"genre_scores_gemma":[0.99221283,0.000035400284,0.000019305562,0.006347031,0.000114487484,0.00006286245,0.0007858479,0.00002984581,0.00039238398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981709,0.00022158695,0.00047439788,0.00041086695,0.00036395478,0.0003582722],"domain_scores_gemma":[0.9980134,0.0010947847,0.00016685743,0.00047734776,0.000055531582,0.00019210404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033424166,0.00029753134,0.0010038731,0.00022581758,0.000050416365,0.000027432032,0.00017460942,0.00011350849,0.0006934621],"category_scores_gemma":[0.0010671413,0.00016464054,0.00040439918,0.0012909565,0.00007026247,0.00007420612,0.00007759472,0.0001996122,0.00013828854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102502825,0.000328675,0.971072,0.000079410594,0.007046565,0.000009993615,0.00026259827,0.0000405653,0.0011834196,0.00003406888,0.0047289664,0.0049634576],"study_design_scores_gemma":[0.09258312,0.03249292,0.8313348,0.00038942252,0.0191187,2.5801135e-8,0.00020318753,0.0017402641,0.010423411,0.0000791313,0.011056262,0.00057872065],"about_ca_topic_score_codex":0.000050161623,"about_ca_topic_score_gemma":0.000020462076,"teacher_disagreement_score":0.13973716,"about_ca_system_score_codex":0.000057015073,"about_ca_system_score_gemma":0.000044820536,"threshold_uncertainty_score":0.75929236},"labels":[],"label_agreement":null},{"id":"W3034315140","doi":"10.2337/db20-1144-p","title":"1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Cluster (spacecraft); Endocrinology","score_opus":0.02216029644091458,"score_gpt":0.2391320169525555,"score_spread":0.21697172051164093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034315140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98765767,0.006536824,7.906602e-7,0.003734581,0.00027712423,0.0009942617,0.000016440057,0.000082037885,0.00070024515],"genre_scores_gemma":[0.9943032,0.00016955887,0.00010201684,0.0047975536,0.00027799452,0.00007616386,0.00020171935,0.000026519821,0.000045271434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986405,0.00008457066,0.0003618778,0.00036540788,0.00024823294,0.00029944454],"domain_scores_gemma":[0.9992694,0.00021804661,0.00009505763,0.00023666231,0.000041497206,0.00013929135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008155624,0.0002326674,0.0004339019,0.000067018846,0.0000667287,0.000052835097,0.000063391424,0.00007673056,0.000079883335],"category_scores_gemma":[0.00019358206,0.00015085055,0.00008063791,0.0002783653,0.00008071253,0.00013754763,0.00011240202,0.00015333096,0.00008086714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002972142,0.0011471726,0.87561846,0.00029624705,0.00094059773,0.000059109785,0.008105409,0.000018230885,0.008180074,0.0012606174,0.008207588,0.09319436],"study_design_scores_gemma":[0.14375831,0.014085532,0.55562603,0.0013734484,0.0029052533,2.934384e-7,0.0037404378,0.0032811281,0.11771555,0.008156822,0.1471929,0.002164295],"about_ca_topic_score_codex":0.00003581167,"about_ca_topic_score_gemma":0.000018982339,"teacher_disagreement_score":0.31999242,"about_ca_system_score_codex":0.000044449553,"about_ca_system_score_gemma":0.000019011468,"threshold_uncertainty_score":0.61515075},"labels":[],"label_agreement":null},{"id":"W3034329876","doi":"10.2337/db20-1163-p","title":"1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Semaglutide; Medicine; Metformin; Type 2 Diabetes Mellitus; Type 2 diabetes; Dapagliflozin; Glycemic; Internal medicine; Diabetes mellitus; Insulin; Endocrinology; Liraglutide","score_opus":0.015434461894056253,"score_gpt":0.2385889197088481,"score_spread":0.22315445781479185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034329876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957385,0.0003294285,0.0000039283354,0.0008559381,0.00010693022,0.0007542382,0.000027202728,0.00003089836,0.0021529505],"genre_scores_gemma":[0.9984919,0.000011715757,0.00011798969,0.0011152558,0.000026213385,0.000077268654,0.000070721966,0.000021880838,0.000067061155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885714,0.00008124706,0.00023439225,0.00024979483,0.00023332566,0.00034408798],"domain_scores_gemma":[0.99938095,0.00016502297,0.00005947094,0.0001836966,0.000043121705,0.000167737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017234597,0.00017161603,0.00052913436,0.000071057315,0.00001643677,0.0000069223033,0.00009690071,0.000032529242,0.00008098647],"category_scores_gemma":[0.000117001386,0.00015063035,0.000066991175,0.00032066225,0.00003551531,0.00004480409,0.000066818946,0.00009585857,0.000018006753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107744374,0.00011952524,0.9840618,0.0007462061,0.00021333243,0.000051986048,0.000074449374,0.00007723484,0.0052016852,0.00010614926,0.002214023,0.007025901],"study_design_scores_gemma":[0.003449578,0.0004063471,0.8787767,0.00034466994,0.00020449546,1.5190956e-7,0.00012444507,0.0009781156,0.10873593,0.000038152073,0.00674806,0.00019335681],"about_ca_topic_score_codex":0.14475855,"about_ca_topic_score_gemma":0.092683665,"teacher_disagreement_score":0.10528506,"about_ca_system_score_codex":0.00028481142,"about_ca_system_score_gemma":0.00027804184,"threshold_uncertainty_score":0.9238725},"labels":[],"label_agreement":null},{"id":"W3034389451","doi":"10.2337/db20-1224-p","title":"1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs)","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Linagliptin; Medicine; Stage (stratigraphy); Placebo; Type 2 diabetes; Internal medicine; Diabetes mellitus; Kidney disease; Incidence (geometry); Intensive care medicine; Oncology; Pathology; Endocrinology; Alternative medicine","score_opus":0.22784351098048475,"score_gpt":0.34267585784865057,"score_spread":0.11483234686816582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034389451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98702353,0.0073742927,0.0010280916,0.00060371845,0.0005985952,0.002360599,0.0006152714,0.00025588713,0.000140025],"genre_scores_gemma":[0.98858154,0.00004342953,0.0074711125,0.00042282292,0.0007572767,0.00007743743,0.0024766992,0.00011141948,0.000058280482],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965309,0.00018034854,0.0010379511,0.0008963499,0.000677678,0.0006767745],"domain_scores_gemma":[0.99657553,0.000922829,0.00047721056,0.0014995667,0.00020408438,0.000320752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014817016,0.00048567398,0.002462769,0.00019197795,0.00010842444,0.00010903107,0.0005222663,0.0001464609,0.00007157881],"category_scores_gemma":[0.0016960358,0.00040136257,0.0007441543,0.00043125107,0.000063234605,0.00043184753,0.00039073967,0.00012110389,0.00003407566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065341206,0.00014947877,0.9477784,0.0018227632,0.0122723635,0.0000037115678,0.0002122976,0.00030856227,0.019268956,0.00010712869,0.0034413545,0.01456966],"study_design_scores_gemma":[0.031016834,0.0024034968,0.11681453,0.004201238,0.0580454,1.9814368e-7,0.0015048425,0.16658871,0.58626896,0.0010513011,0.0293836,0.0027208726],"about_ca_topic_score_codex":0.000092062546,"about_ca_topic_score_gemma":0.0000029330683,"teacher_disagreement_score":0.83096385,"about_ca_system_score_codex":0.000115080715,"about_ca_system_score_gemma":0.0001366855,"threshold_uncertainty_score":0.99984384},"labels":[],"label_agreement":null},{"id":"W3034390795","doi":"10.2337/db20-141-or","title":"141-OR: Efficacy and Safety of Naltrexone/Bupropion as Add-On to Incretin Agents in Patients with Obesity and T2DM","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incretin; Tolerability; Metformin; Placebo; Internal medicine; Type 2 diabetes; Weight loss; Sitagliptin; Bupropion; Population; Endocrinology; Diabetes mellitus; Pharmacology; Obesity; Adverse effect; Insulin","score_opus":0.012707264750561328,"score_gpt":0.23552664047480384,"score_spread":0.2228193757242425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034390795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975509,0.00006771169,7.642363e-7,0.000582926,0.000016548096,0.0008867162,0.000012995364,0.00002316623,0.00085825735],"genre_scores_gemma":[0.99823457,0.000029991834,0.0002111834,0.0013298922,0.000016052727,0.000015633535,0.000051159765,0.000014369327,0.00009713649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991621,0.000028076678,0.00016672953,0.00026309025,0.00019165468,0.00018837296],"domain_scores_gemma":[0.99956113,0.00006596729,0.00005136694,0.00012459028,0.000029786768,0.00016718615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069017486,0.00014263882,0.0003039764,0.00008402648,0.000025515474,0.000009584891,0.000040430845,0.00003414814,0.000050696766],"category_scores_gemma":[0.0001080019,0.00009843902,0.000016651193,0.00017269983,0.000037625552,0.000045836492,0.00008284258,0.00006195404,0.000016199316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012517812,0.0003756503,0.98174125,0.00018908194,0.00009792079,0.000006074216,0.00039771158,0.0000024208844,0.00016978795,0.000044696444,0.0004545962,0.01526901],"study_design_scores_gemma":[0.006108785,0.0040578167,0.98523855,0.0003389306,0.00009676807,3.7349636e-8,0.000041575666,0.000030585044,0.0026917718,0.000007137379,0.0012809456,0.000107117296],"about_ca_topic_score_codex":0.00001737482,"about_ca_topic_score_gemma":0.000004860431,"teacher_disagreement_score":0.015161893,"about_ca_system_score_codex":0.00002694201,"about_ca_system_score_gemma":0.000011382162,"threshold_uncertainty_score":0.40142268},"labels":[],"label_agreement":null},{"id":"W3034401538","doi":"10.1111/dom.14117","title":"Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian <scp>LMC</scp> diabetes registry ( <scp>SPARE</scp> study)","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Semaglutide; Medicine; Exenatide; Type 2 diabetes; Internal medicine; Liraglutide; Diabetes mellitus; Retrospective cohort study; Glucagon-like peptide 1 receptor; Cohort; Endocrinology; Agonist","score_opus":0.011871058071430296,"score_gpt":0.22199252926547053,"score_spread":0.21012147119404023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034401538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987144,0.002898778,8.1500673e-7,0.00079161645,0.00018396637,0.0014698579,0.0001134619,0.00009201498,0.0045780446],"genre_scores_gemma":[0.9949094,0.00025944517,0.00017015683,0.0019304318,0.00013566564,0.00011706445,0.00013747907,0.00006262627,0.0022777484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621713,0.0002644587,0.000654562,0.0009225644,0.0007325409,0.0012087133],"domain_scores_gemma":[0.9970242,0.00058866036,0.00038581682,0.0009836059,0.00023727244,0.0007804881],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006358048,0.0006015415,0.0018192565,0.0008602716,0.00032205987,0.00013009112,0.0005076384,0.000167013,0.000023992405],"category_scores_gemma":[0.00085994496,0.00044730646,0.00030522502,0.0049738265,0.00027372566,0.00021928057,0.0002766611,0.00048792062,0.000016815404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000045923352,0.0005182697,0.9902513,0.00027430878,0.0031477977,0.000017608183,0.00245319,0.00015015987,0.0004074305,0.00019926995,0.002003023,0.0005730623],"study_design_scores_gemma":[0.001786449,0.00031371496,0.9697601,0.00016285374,0.007548463,1.0109031e-7,0.0013902332,0.00085332786,0.002535051,0.000039245704,0.015473709,0.00013674109],"about_ca_topic_score_codex":0.012551006,"about_ca_topic_score_gemma":0.1925005,"teacher_disagreement_score":0.17994949,"about_ca_system_score_codex":0.0001637998,"about_ca_system_score_gemma":0.00033398275,"threshold_uncertainty_score":0.9997979},"labels":[],"label_agreement":null},{"id":"W3034462014","doi":"10.2337/db20-30-or","title":"30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Insulin; EMPA; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Hypoglycemia","score_opus":0.02020541752418496,"score_gpt":0.22908312840283254,"score_spread":0.2088777108786476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034462014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996023,0.0018861141,0.000012694095,0.00040241968,0.000071581024,0.0013241909,0.00012668001,0.0000842756,0.000069064175],"genre_scores_gemma":[0.99685395,0.000048512215,0.0004272838,0.001375074,0.00008536963,0.00015639725,0.0009710172,0.000048297625,0.00003412599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985517,0.00003403881,0.00028883168,0.0004506357,0.00030256866,0.00037217472],"domain_scores_gemma":[0.9991976,0.0001274473,0.000057823752,0.00027107797,0.0000911482,0.0002549081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011524135,0.00026312444,0.00057479733,0.00012476584,0.000054809367,0.000044368062,0.000081250815,0.00006786625,0.0000674192],"category_scores_gemma":[0.000272103,0.0001970504,0.00012314155,0.000290362,0.00004488097,0.00019009017,0.00006730968,0.00009131356,0.000022896153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030770455,0.00018346778,0.99269426,0.00023205268,0.0010159834,0.0000061315295,0.00029779322,0.000034237903,0.00004005389,0.000013545165,0.00039625127,0.004778535],"study_design_scores_gemma":[0.008039465,0.00099546,0.9856986,0.00015748282,0.0012845757,6.239621e-9,0.00009336582,0.00097130163,0.00051594945,0.000053900876,0.0019184093,0.000271521],"about_ca_topic_score_codex":0.000008467708,"about_ca_topic_score_gemma":0.0000020833772,"teacher_disagreement_score":0.0077317604,"about_ca_system_score_codex":0.000053407635,"about_ca_system_score_gemma":0.000031819094,"threshold_uncertainty_score":0.8035482},"labels":[],"label_agreement":null},{"id":"W3034506926","doi":"10.2337/db20-1188-p","title":"1188-P: Approaches to and Inertia in Cardiovascular and Renal Risk Management of Type 2 Diabetes Patients in Primary Care: Results from a Global Quantitative Survey","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Primary care; Type 2 diabetes; Diabetes mellitus; Type 2 Diabetes Mellitus; Likert scale; Family medicine; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.04133631909498453,"score_gpt":0.2267149521220745,"score_spread":0.18537863302708996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034506926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068433,0.0069150752,0.0000030125436,0.00009954131,0.00003750462,0.00087955623,0.00040730764,0.000018539798,0.0009551245],"genre_scores_gemma":[0.9962135,0.00037621794,0.0023476882,0.00015159715,0.000011760165,0.000041120547,0.0008376339,0.000015027837,0.000005439214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843997,0.00016084712,0.00035127412,0.00051111827,0.00025996604,0.00027684853],"domain_scores_gemma":[0.99938583,0.000118719996,0.00007768889,0.00023335412,0.000048136742,0.00013627128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032059083,0.00020541313,0.00061447604,0.00009725076,0.000018311868,0.00001740562,0.00007560955,0.000053813845,0.0000011931785],"category_scores_gemma":[0.00015169312,0.00018254445,0.000060867023,0.0005202156,0.000060580925,0.00007936667,0.0002226801,0.00007374499,0.000003057043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003491565,0.00016271953,0.9652791,0.00037184492,0.0009027457,0.000008545472,0.001114377,0.00008099166,0.000019478808,0.000035560217,0.000107176966,0.031568293],"study_design_scores_gemma":[0.0049426933,0.0006900633,0.99238527,0.00030743075,0.00034709132,6.1496763e-9,0.00030136024,0.00029772037,0.0003115275,0.000044682925,0.00021008655,0.00016208214],"about_ca_topic_score_codex":0.0006350389,"about_ca_topic_score_gemma":0.00014629922,"teacher_disagreement_score":0.03140621,"about_ca_system_score_codex":0.00009367347,"about_ca_system_score_gemma":0.000014311874,"threshold_uncertainty_score":0.74439466},"labels":[],"label_agreement":null},{"id":"W3034522177","doi":"10.2337/db20-1626-p","title":"1626-P: Differences in Patient-Reported Outcomes (PROs) by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychosocial; Quality of life (healthcare); Observational study; Hypoglycemia; Diabetes mellitus; Demography; Type 1 diabetes; Gerontology; Family medicine; Internal medicine; Psychiatry; Nursing; Endocrinology","score_opus":0.017361015320220802,"score_gpt":0.2294251363886464,"score_spread":0.2120641210684256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034522177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576426,0.0008625426,1.6697692e-7,0.001223328,0.000033139655,0.0017250623,0.0000030738915,0.00003824074,0.00035016407],"genre_scores_gemma":[0.9983436,0.000068322326,0.000018310056,0.0012048986,0.000012041658,0.00022755445,0.000047214646,0.000018849409,0.000059207156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984924,0.00011228168,0.00034388262,0.0004070769,0.0002769741,0.00036738275],"domain_scores_gemma":[0.9994128,0.00015636714,0.0001004688,0.00023742733,0.0000167065,0.00007627063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015527027,0.00024326134,0.00051483786,0.00014241892,0.000028083217,0.00004238958,0.000110837165,0.000048324688,0.000009298073],"category_scores_gemma":[0.00011647355,0.00014202505,0.00002921666,0.000545386,0.00006630009,0.00011204285,0.000066988905,0.00017358684,0.0000029659675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008391529,0.00094578293,0.98245764,0.000105873856,0.0001031253,0.0003368188,0.006771777,4.771643e-7,0.00008901198,0.0000060629527,0.00022992019,0.008869612],"study_design_scores_gemma":[0.0043770485,0.0024280252,0.98758876,0.00029258564,0.000091028116,1.5505933e-7,0.0046399897,0.00009455473,0.00017367683,0.000027619408,0.000117660566,0.00016891447],"about_ca_topic_score_codex":0.000108264394,"about_ca_topic_score_gemma":0.0002618981,"teacher_disagreement_score":0.008700698,"about_ca_system_score_codex":0.00003187048,"about_ca_system_score_gemma":0.0000122798665,"threshold_uncertainty_score":0.57916135},"labels":[],"label_agreement":null},{"id":"W3034648575","doi":"10.2337/db20-131-lb","title":"131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Diabetes mellitus; Placebo; Type 2 diabetes; Endocrinology; Alternative medicine","score_opus":0.03881077172302324,"score_gpt":0.3009238658779918,"score_spread":0.2621130941549686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034648575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924615,0.0007969906,0.0000016362442,0.0047088345,0.000058903777,0.0005271556,0.00002123801,0.00004878208,0.0013749382],"genre_scores_gemma":[0.9988229,0.00006773118,0.000061394254,0.0004804605,0.000077079705,0.00004579103,0.000065147506,0.000018029863,0.00036146355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989884,0.00003945467,0.00031039616,0.00023623889,0.0001953764,0.00023016591],"domain_scores_gemma":[0.99947387,0.000066751905,0.00008491752,0.00023339533,0.000033355893,0.00010772869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013920052,0.0001552569,0.00034164917,0.00006314783,0.00003437043,0.000022994682,0.00009786932,0.00004348155,0.00006201556],"category_scores_gemma":[0.000139669,0.00010700801,0.00007671108,0.00023446172,0.000114925744,0.000102530226,0.00011515854,0.00008252572,0.000010517828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008513662,0.00014047131,0.9916391,0.00013440795,0.0006175639,0.000009104806,0.0021809344,0.000058609516,0.0025387704,0.0005429803,0.00096488296,0.0011646557],"study_design_scores_gemma":[0.0013794067,0.0003770257,0.98364276,0.00008253967,0.000945587,2.81273e-7,0.0015551392,0.0014152619,0.009438262,0.00015060056,0.00082764647,0.00018551324],"about_ca_topic_score_codex":0.000075215365,"about_ca_topic_score_gemma":0.0000061141677,"teacher_disagreement_score":0.007996369,"about_ca_system_score_codex":0.000022726741,"about_ca_system_score_gemma":0.0000152424645,"threshold_uncertainty_score":0.43636602},"labels":[],"label_agreement":null},{"id":"W3034678205","doi":"10.2337/db20-2301-pub","title":"2301-PUB: The Role of Muramyl Dipeptide in Glucagon-Like Peptide-1 Regulation","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Sudbury","funders":"","keywords":"Muramyl dipeptide; Internal medicine; Secretion; Endocrinology; NOD2; Insulin resistance; Glucagon-like peptide-1; Receptor; Glucagon; Insulin; Chemistry; Biology; Medicine; Immune system; Type 2 diabetes; Diabetes mellitus; Immunology","score_opus":0.010481542535970926,"score_gpt":0.21920627845345564,"score_spread":0.20872473591748472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034678205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984798,0.0007781777,0.0000050771764,0.00323313,0.000053523243,0.00047849637,0.0000046174905,0.000051620376,0.010597368],"genre_scores_gemma":[0.99789643,0.000023598379,0.00019184084,0.001189543,0.00007926979,0.000049972372,0.000060500468,0.000018342242,0.0004904822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990855,0.000032457516,0.00024237848,0.00019716505,0.00020481212,0.00023772297],"domain_scores_gemma":[0.99948204,0.00007948037,0.000082396095,0.00024474427,0.00003667065,0.00007469512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012737376,0.00012995882,0.00025782702,0.0000645381,0.00002698207,0.00001394995,0.000106530824,0.000041059473,0.0000957306],"category_scores_gemma":[0.00006984119,0.00008955226,0.00009124856,0.00027285295,0.000059002625,0.000088244815,0.00006740241,0.000082687286,0.000037845035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051482126,0.0002350202,0.91511285,0.00015434138,0.0002105797,0.000004220075,0.0011209989,0.000091811424,0.030776804,0.003450951,0.002978748,0.04581216],"study_design_scores_gemma":[0.0025236001,0.00063911115,0.7878674,0.00021381087,0.00034935883,1.7894467e-7,0.0011878422,0.007761446,0.089567386,0.0020720542,0.10755807,0.00025970166],"about_ca_topic_score_codex":0.000022427312,"about_ca_topic_score_gemma":0.000007629479,"teacher_disagreement_score":0.12724544,"about_ca_system_score_codex":0.000031052856,"about_ca_system_score_gemma":0.00001776149,"threshold_uncertainty_score":0.36518353},"labels":[],"label_agreement":null},{"id":"W3034680684","doi":"10.1016/j.pcd.2020.05.004","title":"A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe","year":2020,"lang":"en","type":"review","venue":"Primary care diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"NIHR Leicester Biomedical Research Centre; Novo Nordisk; National Institute for Health and Care Research","keywords":"Medicine; Primary care; Diabetes mellitus; Disease; Intensive care medicine; Position statement; Disease management; Type 2 diabetes; Health care; Diabetes management; Position paper; MEDLINE; Primary health care; Family medicine; Population; Internal medicine; Environmental health","score_opus":0.018073179043597672,"score_gpt":0.2727382036193489,"score_spread":0.25466502457575124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034680684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014657425,0.9581466,0.0000043745135,0.00026557423,0.00048734146,0.011209867,0.002194181,0.00026000457,0.012774659],"genre_scores_gemma":[0.0034139538,0.9376548,0.0010105935,0.003472363,0.00021520865,0.004249803,0.049244005,0.0003259357,0.0004133636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99252754,0.0007168211,0.0018019292,0.0019413794,0.0014223153,0.0015900066],"domain_scores_gemma":[0.99656236,0.00024678552,0.00071561825,0.0012290443,0.0004699137,0.0007762589],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00042021813,0.0016299249,0.0038077834,0.00056012993,0.00018973452,0.00015916892,0.0011044281,0.00024074042,0.000032034426],"category_scores_gemma":[0.000030566785,0.0011788047,0.0009219869,0.00186596,0.00022685199,0.00025184243,0.0016811476,0.0007887854,0.00010563311],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015398052,0.0010443864,0.0057151117,0.23559313,0.003088113,0.00014232569,0.0008352353,0.000022544911,0.00006229041,0.000016450915,0.008784267,0.7445422],"study_design_scores_gemma":[0.0028545472,0.0015856702,0.0065068025,0.018915623,0.014194058,4.1766677e-7,0.00049754855,0.000018243254,0.000105167375,0.000007396896,0.9538259,0.001488616],"about_ca_topic_score_codex":0.0000071114814,"about_ca_topic_score_gemma":0.0000011516948,"teacher_disagreement_score":0.94504166,"about_ca_system_score_codex":0.0038438484,"about_ca_system_score_gemma":0.00074596517,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W3034748156","doi":"10.2337/db20-977-p","title":"977-P: Alleviating Carbohydrate Counting with a FiASP-and-Pramlintide Artificial Pancreas: A Randomized Pilot Study","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; SMA*; Glycemic; Crossover study; Bolus (digestion); Internal medicine; Insulin; Mathematics; Placebo","score_opus":0.025612654650368598,"score_gpt":0.24269065811155716,"score_spread":0.21707800346118855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034748156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940128,0.0004385419,0.000042308107,0.0016760393,0.000050662777,0.002169025,0.0000037513605,0.0002147664,0.0013921118],"genre_scores_gemma":[0.9969217,0.000017439359,0.00079447235,0.0015343836,0.00022625992,0.0003300148,0.000029757979,0.000044670294,0.00010129907],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982996,0.00013472798,0.00039565013,0.00044267517,0.00032241,0.00040491374],"domain_scores_gemma":[0.9990213,0.00033692573,0.00016457408,0.00020286463,0.00007737529,0.00019697491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005522534,0.00028003208,0.00093533756,0.00007976494,0.000115129966,0.00009454216,0.00007442263,0.000024221374,0.000039464867],"category_scores_gemma":[0.00047342636,0.00019798773,0.000079593665,0.00024096333,0.00009234917,0.00011168634,0.00009516435,0.00014306056,0.000029543995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04113979,0.003475028,0.8915677,0.00090777833,0.008104635,0.00029498435,0.007765017,0.00007844963,0.025642747,0.0013376724,0.00071560114,0.0189706],"study_design_scores_gemma":[0.76685643,0.038759917,0.06595801,0.0017058711,0.019926624,0.0000037233744,0.012160245,0.06944611,0.019783694,0.0008474002,0.0017915394,0.0027604138],"about_ca_topic_score_codex":0.00011821657,"about_ca_topic_score_gemma":0.000020505342,"teacher_disagreement_score":0.8256097,"about_ca_system_score_codex":0.000024401847,"about_ca_system_score_gemma":0.00003146697,"threshold_uncertainty_score":0.8073705},"labels":[],"label_agreement":null},{"id":"W3034761592","doi":"10.2337/db20-490-p","title":"490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal function; Microalbuminuria; Creatinine; Metformin; Cystatin C; Urology; Internal medicine; Population; Kidney disease; Placebo; Endocrinology; Diabetes mellitus; Pathology","score_opus":0.01529842926274158,"score_gpt":0.2453218833266473,"score_spread":0.23002345406390573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034761592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052024,0.0030933989,0.0000013126122,0.0015333855,0.00028692174,0.0011911832,0.0000027820392,0.00005253803,0.0033182409],"genre_scores_gemma":[0.99742216,0.00009161516,0.00031697552,0.0013840771,0.00026187327,0.00008478312,0.00003705351,0.000025739924,0.00037573962],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872494,0.000073768366,0.0003138812,0.00024815492,0.0002752073,0.00036407044],"domain_scores_gemma":[0.99909043,0.0003829133,0.00010138866,0.00027538315,0.000042816897,0.00010706502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025949572,0.00018669317,0.00049219356,0.000092727416,0.000030763622,0.000015610101,0.00015837555,0.00006515515,0.00006114039],"category_scores_gemma":[0.00056155294,0.000119478296,0.00014577698,0.00048149773,0.000084737745,0.00007923676,0.00009533939,0.00014107111,0.000047931582],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012981243,0.0033379365,0.26565927,0.0046212855,0.004100438,0.00041544024,0.0040338133,0.000046831014,0.20092519,0.00549159,0.044642486,0.45374447],"study_design_scores_gemma":[0.10524636,0.012742179,0.03611151,0.0009169067,0.0020044025,7.7455525e-7,0.00024700194,0.0020983603,0.7333236,0.0009773278,0.105621606,0.000709971],"about_ca_topic_score_codex":0.0000065018585,"about_ca_topic_score_gemma":0.0000016808616,"teacher_disagreement_score":0.5323984,"about_ca_system_score_codex":0.00003185098,"about_ca_system_score_gemma":0.00003660903,"threshold_uncertainty_score":0.48721835},"labels":[],"label_agreement":null},{"id":"W3034861499","doi":"10.2337/db20-956-p","title":"956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bolus (digestion); Insulin; Regimen; Internal medicine; Semaglutide; Basal (medicine); Diabetes mellitus; Endocrinology; Placebo; Type 2 diabetes; Insulin aspart; Hypoglycemia","score_opus":0.023918202981516947,"score_gpt":0.25829547790069146,"score_spread":0.2343772749191745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034861499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98660594,0.00064847874,0.000029645105,0.008132938,0.00007974059,0.0011872901,0.000046598492,0.00012671288,0.0031426598],"genre_scores_gemma":[0.9853269,0.00006968553,0.005872068,0.0068003424,0.00011506927,0.000057967558,0.000082752085,0.000048477224,0.0016267775],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99859196,0.00004415438,0.00034646015,0.0003878342,0.00025235434,0.0003772554],"domain_scores_gemma":[0.9990277,0.00016217938,0.00008109455,0.0002901847,0.00006657181,0.0003722147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015482825,0.00023890236,0.00057844305,0.000099768135,0.000043463908,0.000021769836,0.00012147772,0.000065328575,0.00041096902],"category_scores_gemma":[0.00039988832,0.00018245583,0.00007780421,0.00027107605,0.000063781285,0.000070479524,0.0002021778,0.000096687174,0.00008468231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048844856,0.002073964,0.25523838,0.0028196205,0.0030423426,0.00012510702,0.006168649,0.00008538652,0.05255556,0.0005451771,0.33970314,0.33275816],"study_design_scores_gemma":[0.0309326,0.009732524,0.43916705,0.0014556375,0.0024895547,9.461579e-7,0.0006305472,0.0026995821,0.2088554,0.00042767127,0.30228305,0.001325445],"about_ca_topic_score_codex":0.00001877466,"about_ca_topic_score_gemma":0.0000049605787,"teacher_disagreement_score":0.33143273,"about_ca_system_score_codex":0.000035961115,"about_ca_system_score_gemma":0.00004691758,"threshold_uncertainty_score":0.7440333},"labels":[],"label_agreement":null},{"id":"W3034864865","doi":"10.2337/db20-924-p","title":"924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mace; Medicine; Hazard ratio; Myocardial infarction; Blood pressure; Internal medicine; Population; Placebo; Cardiology; Physical therapy; Percutaneous coronary intervention; Confidence interval","score_opus":0.02130842073088888,"score_gpt":0.20168725964137504,"score_spread":0.18037883891048617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034864865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964037,0.001871598,0.0000029166947,0.0005425782,0.00014772719,0.00031808205,0.0000067180754,0.000016941603,0.00068973715],"genre_scores_gemma":[0.99945575,0.000098185796,0.00010530564,0.00017966214,0.000076963064,0.00003043532,0.0000080388945,0.000015349186,0.00003032897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901754,0.000023628218,0.00025579316,0.00017334797,0.00033202604,0.00019767409],"domain_scores_gemma":[0.99949896,0.000026409587,0.00006842951,0.00030517852,0.000035527468,0.00006549067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013471782,0.00010989198,0.00041348903,0.0000689232,0.0000150176775,0.0000032241485,0.00012119198,0.00002884329,0.000026354131],"category_scores_gemma":[0.000085585445,0.000078258,0.000326089,0.00029732255,0.000053982938,0.00006535335,0.000113455186,0.000071452014,0.000004202625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003048187,0.00017481297,0.96075016,0.0006315761,0.0014242,0.000015086448,0.000988383,0.000884328,0.014860801,0.00033142342,0.00019668035,0.019712094],"study_design_scores_gemma":[0.003069559,0.00027684474,0.6016989,0.00034857297,0.0010719573,1.7311157e-7,0.00047382698,0.00043143274,0.38934588,0.00015197055,0.002963528,0.00016735916],"about_ca_topic_score_codex":0.000028133229,"about_ca_topic_score_gemma":0.0000018103341,"teacher_disagreement_score":0.37448508,"about_ca_system_score_codex":0.000022460492,"about_ca_system_score_gemma":0.000016709424,"threshold_uncertainty_score":0.31912687},"labels":[],"label_agreement":null},{"id":"W3034872168","doi":"10.2337/db20-1102-p","title":"1102-P: Impact of Treatment with Sotagliflozin on the Incidence of Severe Hypoglycemia in Patients with T1D","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Glycemic; Incidence (geometry); Population; Placebo; Internal medicine; Relative risk; Pediatrics; Insulin; Confidence interval","score_opus":0.010584289443311926,"score_gpt":0.2241476838980046,"score_spread":0.2135633944546927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034872168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974576,0.000060966446,5.7477536e-7,0.00030894368,0.000007932586,0.0007728074,0.000025607063,0.000015989133,0.0013495601],"genre_scores_gemma":[0.99947613,0.000010060701,0.0001084322,0.00023061407,0.000012900926,0.000046131485,0.000035566216,0.000018183138,0.0000620009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913365,0.000027466047,0.00018467747,0.00019642607,0.00024207644,0.00021569055],"domain_scores_gemma":[0.9993581,0.000113219496,0.00012537435,0.0002613736,0.00006159509,0.000080319616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004508793,0.00018947503,0.00038296392,0.00006583898,0.000016253312,0.000005669622,0.000083591,0.000027842016,0.000063701315],"category_scores_gemma":[0.00002984643,0.00008642278,0.00007776098,0.00027728057,0.00007736621,0.00005631264,0.000026434485,0.000058869417,0.00000848149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070910057,0.00054345635,0.99301124,0.000063400956,0.00048304055,0.0000041229832,0.00046083383,0.000168351,0.00023710058,0.0000496574,0.00017809904,0.004091626],"study_design_scores_gemma":[0.005574084,0.023503019,0.9629045,0.00033154403,0.00025121952,5.962972e-8,0.00010088735,0.00013817303,0.0069896723,0.0000145207805,0.00007450912,0.000117782154],"about_ca_topic_score_codex":0.000080517595,"about_ca_topic_score_gemma":0.000009472765,"teacher_disagreement_score":0.03010668,"about_ca_system_score_codex":0.00014427079,"about_ca_system_score_gemma":0.00007255746,"threshold_uncertainty_score":0.35242185},"labels":[],"label_agreement":null},{"id":"W3034982546","doi":"10.2337/db20-1128-p","title":"1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Type 2 diabetes; Diabetes mellitus; Waist; Obesity; Cardiology; Placebo; Endocrinology","score_opus":0.03013988583119749,"score_gpt":0.2584047645791251,"score_spread":0.2282648787479276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034982546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914867,0.0010628775,0.00003175334,0.0055443686,0.00018905256,0.00074159756,0.000073234885,0.00012208032,0.00074831565],"genre_scores_gemma":[0.9942967,0.00002156837,0.00020808964,0.004491611,0.00046677544,0.00012093486,0.00020568911,0.000027236687,0.00016138144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984818,0.000093945026,0.00033886786,0.00045776716,0.00029867774,0.00032893888],"domain_scores_gemma":[0.9988965,0.00029574934,0.00012072907,0.0004018185,0.00004700157,0.00023821548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015033066,0.00026567464,0.0006641548,0.000099315,0.00010941756,0.00006898021,0.0001573594,0.000072143266,0.00023692286],"category_scores_gemma":[0.00019879526,0.00017440472,0.00028267372,0.00057114806,0.00012440175,0.0001483841,0.00014629182,0.00015618237,0.00007972631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009129983,0.00015712898,0.9716661,0.000035146615,0.0068174563,0.000019513693,0.0026066618,0.000012265127,0.00029096342,0.00014383749,0.0032503842,0.01408754],"study_design_scores_gemma":[0.06714875,0.0020373354,0.84894025,0.0000544115,0.029468128,1.5833335e-7,0.0077891434,0.0058402293,0.007044812,0.0006590383,0.030019822,0.0009978988],"about_ca_topic_score_codex":0.000031833813,"about_ca_topic_score_gemma":0.000012956069,"teacher_disagreement_score":0.12272584,"about_ca_system_score_codex":0.00003875467,"about_ca_system_score_gemma":0.0000145864815,"threshold_uncertainty_score":0.7112018},"labels":[],"label_agreement":null},{"id":"W3034998851","doi":"10.2337/db20-1119-p","title":"1119-P: Alleviating Carbohydrate Counting Burden in Type 1 Diabetes (T1D) with the Artificial Pancreas and Empagliflozin (EMPA)","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Carbohydrate; Internal medicine; Meal; Diabetes mellitus; Type 1 diabetes; Endocrinology; Type 2 diabetes; Chemistry","score_opus":0.01685079476448152,"score_gpt":0.2257354521016592,"score_spread":0.2088846573371777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034998851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881517,0.0016353925,0.0000013319286,0.00811606,0.00005166676,0.0005627194,0.0000064411706,0.000098208955,0.0013764544],"genre_scores_gemma":[0.99710953,0.000045884302,0.00015982073,0.0021235673,0.00031116238,0.000064607615,0.000045296933,0.00004118139,0.00009896056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998556,0.00006119369,0.00024628578,0.00036953273,0.000264182,0.0005027904],"domain_scores_gemma":[0.9993018,0.0001818242,0.00010258949,0.00020797485,0.000063645006,0.00014216221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028292922,0.00024831577,0.00042310913,0.00007749707,0.000110394394,0.000091009264,0.00010684983,0.000054898228,0.000041324052],"category_scores_gemma":[0.00016355928,0.0001623299,0.000046293244,0.00044471913,0.00010412632,0.000121975,0.00010095266,0.00018862447,0.00002535013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094424184,0.00010346588,0.93627536,0.0003354114,0.00057099777,0.00004073901,0.003116128,0.00009935606,0.02822181,0.0002938119,0.0012519773,0.029596513],"study_design_scores_gemma":[0.013715467,0.0077130846,0.70780635,0.0027656977,0.0048712078,0.0000022959796,0.014927919,0.08503136,0.09449741,0.00077794783,0.064546086,0.0033451472],"about_ca_topic_score_codex":0.00004768318,"about_ca_topic_score_gemma":0.000032626576,"teacher_disagreement_score":0.22846898,"about_ca_system_score_codex":0.000034636952,"about_ca_system_score_gemma":0.00003655162,"threshold_uncertainty_score":0.6619621},"labels":[],"label_agreement":null},{"id":"W3035035902","doi":"10.2337/db20-930-p","title":"930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Liraglutide; Subgroup analysis; Placebo; Internal medicine; Glycated hemoglobin; Exploratory analysis; Type 2 diabetes; Family medicine; Diabetes mellitus; Endocrinology; Alternative medicine; Confidence interval","score_opus":0.03608243598961166,"score_gpt":0.30279636932758436,"score_spread":0.2667139333379727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035035902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712557,0.00007814724,0.000012800135,0.000919374,0.00011471135,0.0014657115,0.000012552305,0.00008195479,0.00018916493],"genre_scores_gemma":[0.9983185,0.0000033597837,0.0007896071,0.0005456085,0.000080673955,0.00013111693,0.000055244163,0.000020649786,0.000055271987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998704,0.00007989964,0.00035521618,0.0002711279,0.00033479516,0.000254934],"domain_scores_gemma":[0.9990914,0.00008350406,0.00014544762,0.00041808048,0.00008719393,0.00017437007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024196878,0.00016121402,0.0006476748,0.00019400928,0.000036749683,0.00001657751,0.00018846589,0.000044328328,0.000046670102],"category_scores_gemma":[0.00023331684,0.00010936025,0.00034673986,0.0015055528,0.000059154136,0.00008249271,0.0001332929,0.000074013835,0.000007775454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025382808,0.0029140725,0.8717651,0.00028889673,0.0070933225,0.0000039323295,0.002808535,0.00047604073,0.027530933,0.0002762172,0.0017384792,0.08256624],"study_design_scores_gemma":[0.06914753,0.012855746,0.6822469,0.0003489683,0.031473786,6.4138455e-8,0.0034965288,0.009639392,0.17620726,0.000040674357,0.013713284,0.0008298604],"about_ca_topic_score_codex":0.000013342305,"about_ca_topic_score_gemma":0.00000824591,"teacher_disagreement_score":0.18951814,"about_ca_system_score_codex":0.000027953218,"about_ca_system_score_gemma":0.00003013194,"threshold_uncertainty_score":0.44595817},"labels":[],"label_agreement":null},{"id":"W3035149598","doi":"10.2337/db20-1018-p","title":"1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Systems, Applications & Products in Data Processing (Canada)","funders":"","keywords":"Insulin lispro; Medicine; Postprandial; Crossover study; Internal medicine; Meal; Endocrinology; Insulin; Type 1 diabetes; Diabetes mellitus; Placebo","score_opus":0.005661108598600446,"score_gpt":0.1907475580013082,"score_spread":0.18508644940270774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035149598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996698,0.00064725,2.1342237e-7,0.0007770726,0.0001120688,0.0014142799,0.000024552566,0.000091387024,0.00023516666],"genre_scores_gemma":[0.9978333,0.00014094023,0.00009436286,0.0011579483,0.00014325698,0.00008383241,0.00046576094,0.000054865224,0.000025699008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980569,0.00006426085,0.00035651153,0.000624742,0.00030264372,0.00059497205],"domain_scores_gemma":[0.9992879,0.000017185645,0.000101676196,0.00024979614,0.0001222157,0.00022122213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010167301,0.0003690995,0.00055425917,0.00033135412,0.000054974887,0.00005593968,0.0001051802,0.00012143252,0.000063114436],"category_scores_gemma":[0.00009334695,0.00029637336,0.000057274014,0.0006487411,0.000112164336,0.00026343548,0.000055951292,0.00023379535,0.000031808067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007033439,0.00058816874,0.9852479,0.00020886002,0.00017371115,0.0000063483217,0.0005262982,0.0000027401836,0.0012427722,0.000009399479,0.0002489823,0.011041465],"study_design_scores_gemma":[0.009292987,0.0030081891,0.9770413,0.0005341944,0.00020798284,2.814148e-7,0.000067983536,0.00004466317,0.009355651,0.000015072054,0.00010642209,0.0003252929],"about_ca_topic_score_codex":0.000025073545,"about_ca_topic_score_gemma":0.000010630778,"teacher_disagreement_score":0.010716172,"about_ca_system_score_codex":0.00007878656,"about_ca_system_score_gemma":0.000024719955,"threshold_uncertainty_score":0.99994886},"labels":[],"label_agreement":null},{"id":"W3035255089","doi":"10.1002/ejhf.1867","title":"Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF","year":2020,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"Defense Acquisition Program Administration; British Heart Foundation; AstraZeneca","keywords":"Dapagliflozin; Ejection fraction; Medicine; Hazard ratio; Heart failure; Internal medicine; Placebo; Cardiology; Clinical endpoint; Confidence interval; Randomized controlled trial; Adverse effect; Diabetes mellitus; Endocrinology","score_opus":0.012583925948587083,"score_gpt":0.24159811401001752,"score_spread":0.22901418806143042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035255089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891346,0.00014561984,0.00087322656,0.009130984,0.000060363156,0.0002761339,0.0000017271226,0.000012653887,0.0003646803],"genre_scores_gemma":[0.9974616,0.000053652337,0.0016711366,0.00058022497,0.0001881318,3.4068282e-7,0.00001155593,0.00001761172,0.000015753178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904746,0.00010356248,0.00040328482,0.00012519461,0.00020148253,0.00011899261],"domain_scores_gemma":[0.9995585,0.000019432966,0.00014601726,0.00006933956,0.000060573777,0.00014615597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036933422,0.00010066246,0.00026726007,0.00018838239,0.00003061571,0.000015414491,0.000028066943,0.000018888772,0.000046451198],"category_scores_gemma":[0.000040205996,0.00008579218,0.00007918315,0.00015764563,0.000014584197,0.00017728258,0.000015157102,0.00018785827,0.000023146136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007663725,0.0013924092,0.61439633,0.0007190247,0.000639795,0.004095726,0.00292469,0.00054451666,0.2951031,0.000054456,0.035349138,0.037117064],"study_design_scores_gemma":[0.012904982,0.004237217,0.66755813,0.0013030224,0.00042346958,0.00022024737,0.0016536013,0.000060321836,0.039259247,0.0000061055453,0.27214617,0.00022745409],"about_ca_topic_score_codex":0.0000015646057,"about_ca_topic_score_gemma":9.596556e-7,"teacher_disagreement_score":0.25584388,"about_ca_system_score_codex":0.000045162866,"about_ca_system_score_gemma":0.000013990009,"threshold_uncertainty_score":0.34985033},"labels":[],"label_agreement":null},{"id":"W3035288914","doi":"10.2337/db20-1021-p","title":"1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin degludec; Medicine; Insulin glargine; Hypoglycemia; Clinical endpoint; Internal medicine; Randomized controlled trial; Insulin","score_opus":0.01937909380700911,"score_gpt":0.23708452396034055,"score_spread":0.21770543015333144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035288914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908856,0.0058631776,0.000073067444,0.0018800289,0.00003959962,0.0007831183,0.0002871579,0.00004635438,0.00014185903],"genre_scores_gemma":[0.9973754,0.00018551754,0.00032277813,0.0010341664,0.00015678265,0.00004984263,0.0007831135,0.000023026632,0.00006935775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854326,0.00008569356,0.0003798906,0.00043538585,0.00029744362,0.00025833357],"domain_scores_gemma":[0.9989374,0.00033771287,0.00019284643,0.00025478267,0.00010291718,0.0001743025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017704153,0.00027370726,0.0006565991,0.000090163405,0.000089558875,0.00007454374,0.00009202312,0.00009127969,0.00012195017],"category_scores_gemma":[0.000103689876,0.00017323268,0.00009629469,0.0005220206,0.00018727005,0.00014514076,0.000070442446,0.00014397032,0.000004333529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07065549,0.001082346,0.6503064,0.00032634143,0.021512894,0.000020829511,0.0027548445,0.00004661871,0.17203867,0.0003168368,0.0043695807,0.07656912],"study_design_scores_gemma":[0.11875387,0.014805833,0.7908631,0.00020243938,0.015296495,5.0004746e-7,0.0012159155,0.0023746993,0.05144873,0.00017785795,0.004174336,0.0006862212],"about_ca_topic_score_codex":0.00014098642,"about_ca_topic_score_gemma":0.0000842997,"teacher_disagreement_score":0.14055668,"about_ca_system_score_codex":0.000021388709,"about_ca_system_score_gemma":0.00004413515,"threshold_uncertainty_score":0.7064224},"labels":[],"label_agreement":null},{"id":"W3035314553","doi":"10.2337/db20-303-or","title":"303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Placebo; TIMI; Urology; Renal function; Internal medicine; Population; Diabetes mellitus; Type 2 diabetes; Endocrinology; Myocardial infarction; Pathology","score_opus":0.0501788175058861,"score_gpt":0.3353668672495178,"score_spread":0.2851880497436317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035314553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994295,0.0005906349,0.00004388774,0.0022540956,0.0001510237,0.001924922,0.00017289988,0.00004788488,0.00051964464],"genre_scores_gemma":[0.99649864,0.00008506212,0.00043074158,0.0019437963,0.0003894836,0.0002361694,0.00027895448,0.000029197883,0.000107934895],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859905,0.00015834405,0.00037099858,0.00032844295,0.00025537395,0.0002877773],"domain_scores_gemma":[0.9972015,0.0021808015,0.0001569774,0.00033130564,0.00003054723,0.00009886677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037149212,0.00023006699,0.00068705826,0.00007938135,0.000045932054,0.00002238331,0.00018271369,0.000071359995,0.00010884234],"category_scores_gemma":[0.0011588292,0.00012381475,0.00027160082,0.00028437024,0.000054167944,0.000046346082,0.00008270332,0.00012685583,0.00002455546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06013592,0.0013200499,0.74853605,0.00045741498,0.00351916,0.000022711538,0.000791642,0.00028845583,0.008504506,0.00009779068,0.030368669,0.14595762],"study_design_scores_gemma":[0.3145943,0.04723372,0.11056833,0.00093997904,0.009118156,8.433159e-8,0.00045439295,0.014212991,0.4453821,0.0004877623,0.05619322,0.00081498385],"about_ca_topic_score_codex":0.0001045916,"about_ca_topic_score_gemma":0.00006880368,"teacher_disagreement_score":0.63796777,"about_ca_system_score_codex":0.0000363592,"about_ca_system_score_gemma":0.000023933368,"threshold_uncertainty_score":0.5049019},"labels":[],"label_agreement":null},{"id":"W3035320430","doi":"10.2337/db20-1101-p","title":"1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; TIMI; Internal medicine; Metformin; Myocardial infarction; Heart failure; Saxagliptin; Insulin; Cardiology; Endocrinology; Diabetes mellitus; Type 2 diabetes; Sitagliptin; Percutaneous coronary intervention","score_opus":0.03418427741917321,"score_gpt":0.28354719528464967,"score_spread":0.24936291786547646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035320430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99132156,0.0025718734,0.00058459473,0.0026913397,0.000098629724,0.00044442524,0.00019519338,0.00025450773,0.0018378465],"genre_scores_gemma":[0.9896091,0.00009984043,0.0020230801,0.006190553,0.00019525546,0.00006611811,0.00120677,0.00006282191,0.00054641644],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814916,0.000044184708,0.00031736365,0.0005463511,0.00046175995,0.00048116257],"domain_scores_gemma":[0.99891186,0.00013491731,0.000097773445,0.00040768215,0.00006986294,0.00037788338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010544151,0.00037869398,0.0007712862,0.00009175997,0.00007355949,0.000068056164,0.00016862364,0.00006745604,0.0005100042],"category_scores_gemma":[0.00012168903,0.00026957956,0.00022812063,0.00030962468,0.00006731585,0.00016708502,0.00011396883,0.00014519568,0.0001390513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013596285,0.0004606401,0.88917947,0.00014141732,0.0050320835,0.00017233225,0.0002670094,0.00012981702,0.027302762,0.000008028536,0.060798414,0.016372085],"study_design_scores_gemma":[0.015514158,0.0024301745,0.18072227,0.0006263565,0.009318775,8.829286e-7,0.00083023944,0.007336275,0.62448335,0.00005060448,0.15698805,0.0016988849],"about_ca_topic_score_codex":0.00009040441,"about_ca_topic_score_gemma":0.000008449609,"teacher_disagreement_score":0.7084572,"about_ca_system_score_codex":0.00006424877,"about_ca_system_score_gemma":0.000028936534,"threshold_uncertainty_score":0.9999756},"labels":[],"label_agreement":null},{"id":"W3035352602","doi":"10.2337/db20-37-lb","title":"37-LB: GLP-2 Regulation of Dietary Fat Absorption and Intestinal Lipoprotein Production: The Role of the Enteric Nervous System via nNOS Signaling","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Postprandial; Endocrinology; Internal medicine; Glucagon-like peptide-1; Chylomicron; Lipoprotein; Chemistry; Dyslipidemia; Apolipoprotein B; Cholesterol; Insulin; Biology; Very low-density lipoprotein; Diabetes mellitus; Type 2 diabetes; Medicine","score_opus":0.011661674652436074,"score_gpt":0.1978786780741638,"score_spread":0.1862170034217277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035352602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626845,0.0011542304,0.00002457467,0.0013462445,0.00009479922,0.0007644056,0.0000022534673,0.000039414695,0.00030561173],"genre_scores_gemma":[0.99939775,0.000008049151,0.00019454795,0.000075301024,0.00018886739,0.00004750212,0.000014240348,0.000011337366,0.00006237347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992301,0.000055733377,0.00023429209,0.00017045651,0.00019600049,0.000113419555],"domain_scores_gemma":[0.9994836,0.00003239833,0.00017917421,0.00020121124,0.00006993287,0.000033711207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013006538,0.00010556557,0.00020043679,0.000026389302,0.000056206616,0.000009310386,0.000072577735,0.00002533837,0.000010603274],"category_scores_gemma":[0.00005634819,0.00006106221,0.00006835499,0.00019161985,0.000068973975,0.00006454959,0.000069887225,0.000062397055,0.00000272473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062219784,0.0000902505,0.09691225,0.0009409858,0.00019314887,5.7918083e-7,0.00076164986,0.0001167849,0.8310334,0.00019789104,0.000085652115,0.06960519],"study_design_scores_gemma":[0.00061685796,0.00074891374,0.25856826,0.0009173707,0.00061746605,0.0000024458782,0.0012500299,0.010214978,0.7262788,0.00025567503,0.00040820133,0.00012099758],"about_ca_topic_score_codex":0.000025658797,"about_ca_topic_score_gemma":0.0000011516087,"teacher_disagreement_score":0.16165602,"about_ca_system_score_codex":0.000023923614,"about_ca_system_score_gemma":0.000007327679,"threshold_uncertainty_score":0.24900445},"labels":[],"label_agreement":null},{"id":"W3035357525","doi":"10.2337/db20-28-or","title":"28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Placebo; Internal medicine; Post-hoc analysis; Type 2 diabetes; EMPA; Proportional hazards model; Cumulative incidence; Diabetes mellitus; Endocrinology; Confidence interval; Pathology; Cohort","score_opus":0.03751761026768973,"score_gpt":0.2624780422234293,"score_spread":0.22496043195573956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035357525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933353,0.0011194142,0.0000035878625,0.0043599615,0.00004226066,0.0006107828,0.00027495195,0.000042821735,0.00021089241],"genre_scores_gemma":[0.99809843,0.0000867119,0.00008625086,0.00088082,0.000061507955,0.00014360728,0.00024559713,0.000022735869,0.00037431016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868023,0.000051698356,0.00037045116,0.00028927418,0.000339895,0.00026841986],"domain_scores_gemma":[0.9989051,0.00012610032,0.0002937492,0.00040316835,0.00015042633,0.00012142069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008740755,0.000248554,0.0007894229,0.00026418557,0.000035222838,0.00002696368,0.00011284602,0.000060817492,0.00012747847],"category_scores_gemma":[0.00007965443,0.00014410839,0.00041990803,0.0008289566,0.000066685665,0.00011245389,0.00006191484,0.00005444921,0.000014620079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025686866,0.00039622182,0.98395485,0.00016317399,0.005144408,0.0000071889785,0.0022668538,0.000053958607,0.00046847682,0.000042457348,0.00014917685,0.007096382],"study_design_scores_gemma":[0.0017424885,0.0022693197,0.97872627,0.00008880444,0.0088728145,5.0764108e-8,0.0011014817,0.00037026536,0.006324216,0.0000045290926,0.0003557307,0.00014400971],"about_ca_topic_score_codex":0.000029859866,"about_ca_topic_score_gemma":0.00006311578,"teacher_disagreement_score":0.0069523724,"about_ca_system_score_codex":0.000064699205,"about_ca_system_score_gemma":0.000022820204,"threshold_uncertainty_score":0.587657},"labels":[],"label_agreement":null},{"id":"W3035359689","doi":"10.1111/jdi.13321","title":"Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Heart failure; Metformin; Diabetes mellitus; Confidence interval; Dipeptidyl peptidase-4; Stroke (engine); Relative risk; Type 2 diabetes; Gastroenterology; Endocrinology","score_opus":0.020248832328924278,"score_gpt":0.2437041947851998,"score_spread":0.22345536245627554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035359689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974897,0.00018055153,0.0000053457206,0.0014244119,0.00010285921,0.0005496369,0.0000028947882,0.000013567725,0.00023106846],"genre_scores_gemma":[0.9990145,0.000013067389,0.00024087132,0.0005373705,0.00013263298,0.000009481452,0.0000056732956,0.00002380168,0.000022590591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833715,0.00007326047,0.00068855274,0.00015820614,0.00054899056,0.00019381806],"domain_scores_gemma":[0.9989069,0.000055233446,0.00056584156,0.00017785604,0.00013897097,0.00015520134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030836134,0.00018271018,0.00052486436,0.0001747853,0.000035203244,0.000022994629,0.00015253575,0.00004059687,0.000023928089],"category_scores_gemma":[0.000042724594,0.00011249044,0.00014091346,0.00051138306,0.00013285287,0.0002229334,0.000028495058,0.0002026937,0.0000021353044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011545464,0.00038262445,0.97081625,0.00012015902,0.0004522475,0.000005413199,0.005565095,0.00027280723,0.02147589,0.000010586068,0.00012040587,0.00066304323],"study_design_scores_gemma":[0.004723229,0.0016068993,0.8353051,0.0005274543,0.00080065447,6.3420214e-7,0.0025152215,0.00032852282,0.15392879,0.000051698375,0.00008301074,0.00012880708],"about_ca_topic_score_codex":0.000039335722,"about_ca_topic_score_gemma":0.000053998894,"teacher_disagreement_score":0.13551119,"about_ca_system_score_codex":0.00008144,"about_ca_system_score_gemma":0.00008972832,"threshold_uncertainty_score":0.45872268},"labels":[],"label_agreement":null},{"id":"W3035367987","doi":"10.2337/db20-238-or","title":"238-OR: Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve Patients with T2D Inadequately Controlled on OADS","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin glargine; Insulin; Internal medicine; Diabetes mellitus; Basal (medicine); Endocrinology; Hypoglycemia","score_opus":0.017359368433317358,"score_gpt":0.2344373411083799,"score_spread":0.21707797267506254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035367987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715925,0.0007732495,0.000011663767,0.0045458875,0.00014734367,0.0032445174,0.00008366231,0.00019589743,0.0038385035],"genre_scores_gemma":[0.99219507,0.0004239049,0.00045755066,0.0056105605,0.00014199103,0.00021380339,0.0004903611,0.00009473783,0.0003720109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962586,0.00018629942,0.0009081688,0.0009460755,0.0007602248,0.00094061415],"domain_scores_gemma":[0.99788797,0.00060331577,0.0003087997,0.00048175236,0.00016320271,0.00055494625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033034311,0.00072349154,0.0018264292,0.00034223273,0.00014634505,0.00009877444,0.00027181374,0.00019414347,0.00017510045],"category_scores_gemma":[0.00043086597,0.0005194442,0.00013521759,0.0008164097,0.00022423507,0.00027530422,0.00016910768,0.0005141365,0.00015066966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06742928,0.0073917275,0.82210255,0.00072139036,0.002043627,0.00021263261,0.0023878585,0.0008335323,0.0003156969,0.000410812,0.0039061394,0.09224474],"study_design_scores_gemma":[0.16654386,0.013910807,0.79848903,0.0007741635,0.000666186,3.1621366e-7,0.00023211037,0.0051216786,0.0017364839,0.00003944313,0.011634843,0.00085106987],"about_ca_topic_score_codex":0.000073681425,"about_ca_topic_score_gemma":0.00004134476,"teacher_disagreement_score":0.09911458,"about_ca_system_score_codex":0.00027877316,"about_ca_system_score_gemma":0.00017254463,"threshold_uncertainty_score":0.9997257},"labels":[],"label_agreement":null},{"id":"W3035383367","doi":"10.2337/db20-2216-pub","title":"2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Empagliflozin; Medicine; Sitagliptin; Type 2 diabetes; Liraglutide; Glycemic; Relative risk; Internal medicine; Diabetes mellitus; Confidence interval; Endocrinology; Insulin","score_opus":0.03205976369791114,"score_gpt":0.2552491845630111,"score_spread":0.22318942086509996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035383367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918535,0.002347925,0.000002956178,0.0027204396,0.0002006154,0.0009181284,0.000015494074,0.0001050773,0.0018359045],"genre_scores_gemma":[0.9946849,0.00007714727,0.00096684496,0.0035679557,0.00010247784,0.00022420398,0.00012870792,0.000028663439,0.00021910401],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883443,0.000028586892,0.00023111593,0.00031079896,0.00017159409,0.00042345028],"domain_scores_gemma":[0.99946254,0.000107435306,0.00005990067,0.00016594255,0.0000736613,0.0001304948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008527663,0.00020232308,0.00038503017,0.00008820553,0.000037038575,0.00003839676,0.00009875225,0.0000591626,0.0001634804],"category_scores_gemma":[0.00012517143,0.00015380645,0.00009518936,0.00025260405,0.00004728222,0.00011705015,0.000056710916,0.000076740245,0.000051427633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009516955,0.00037190088,0.8437067,0.00031190892,0.00042818044,0.0000033670235,0.0014552459,0.000010013155,0.0038516414,0.00038937814,0.014478268,0.13489822],"study_design_scores_gemma":[0.01113781,0.014651867,0.41307378,0.0006591238,0.0010064358,1.1401283e-7,0.0022252942,0.004047552,0.12270409,0.004671476,0.4243776,0.0014448661],"about_ca_topic_score_codex":0.0000062029185,"about_ca_topic_score_gemma":0.000004783014,"teacher_disagreement_score":0.43063295,"about_ca_system_score_codex":0.000031772975,"about_ca_system_score_gemma":0.00002807382,"threshold_uncertainty_score":0.6272045},"labels":[],"label_agreement":null},{"id":"W3035418026","doi":"10.2337/db20-964-p","title":"964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Glycemic; Empagliflozin; Liraglutide; Weight loss; Sitagliptin; Placebo; Internal medicine; Type 2 diabetes; Dulaglutide; Gastroenterology; Diabetes mellitus; Insulin; Endocrinology; Obesity","score_opus":0.023977844610320168,"score_gpt":0.28890640260213096,"score_spread":0.2649285579918108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035418026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981137,0.00035600012,0.0000014530629,0.015077261,0.00007958924,0.0020181062,0.0000051976604,0.00009622905,0.0012291791],"genre_scores_gemma":[0.9924381,0.000018837016,0.00074059295,0.0057452554,0.00018033544,0.00042877003,0.00002523427,0.000016571968,0.00040632786],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900764,0.00007352243,0.00017554277,0.0002467626,0.0001994288,0.00029709665],"domain_scores_gemma":[0.999507,0.00013628865,0.000026721133,0.00018142616,0.000018208546,0.00013035143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019976389,0.00014478319,0.00025667038,0.000085581225,0.00003801053,0.00004673427,0.000095005475,0.000038410722,0.000032323715],"category_scores_gemma":[0.00020315449,0.00009179853,0.000054203716,0.0002947529,0.00004127856,0.000044659297,0.000067609304,0.000096644406,0.000056075143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061090857,0.0031470763,0.6322247,0.0005373191,0.0008790079,0.00032479857,0.0066256225,0.0000028184797,0.011869328,0.0019245831,0.08342413,0.19794975],"study_design_scores_gemma":[0.104804866,0.02285177,0.24706386,0.0002770761,0.00096409535,0.0000020842256,0.0008721998,0.0011311276,0.0060732346,0.00037734275,0.61489666,0.00068570033],"about_ca_topic_score_codex":0.0000087656435,"about_ca_topic_score_gemma":0.0000034994537,"teacher_disagreement_score":0.5314725,"about_ca_system_score_codex":0.000021132819,"about_ca_system_score_gemma":0.000019859206,"threshold_uncertainty_score":0.37434354},"labels":[],"label_agreement":null},{"id":"W3035431059","doi":"10.1111/dom.14117/v2/response1","title":"Author response for \"Semaglutide Once Weekly in Persons with Type 2 Diabetes: Real‐world Analysis of the Canadian &lt;scp&gt;LMC&lt;/scp&gt; Diabetes Registry ( &lt;scp&gt;SPARE&lt;/scp&gt; Study)\"","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Spare part; Type 2 diabetes; Spare time; Medicine; Endocrinology; Diabetes mellitus; Art; Liraglutide; Humanities; Engineering; Operations management","score_opus":0.03600100760678399,"score_gpt":0.30280860240431373,"score_spread":0.26680759479752975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035431059","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52530795,0.08457734,0.000049198286,0.17769666,0.005782964,0.046100724,0.011982303,0.0016061114,0.14689675],"genre_scores_gemma":[0.18851252,0.0023659028,0.0016130774,0.00731215,0.00077038154,0.0032729374,0.005061027,0.0006964312,0.79039556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9850113,0.0014983744,0.0030674203,0.0036414876,0.0032349583,0.0035464691],"domain_scores_gemma":[0.9855434,0.0035886401,0.0023065163,0.005065332,0.0014354321,0.0020606935],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0046101026,0.0028164878,0.0069520655,0.003890317,0.00081549276,0.00037569462,0.0026304228,0.0009555591,0.0006355243],"category_scores_gemma":[0.0061050635,0.0021002044,0.0022033239,0.010467959,0.00080684584,0.00032092366,0.0008539207,0.0016970821,0.00014546428],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031306836,0.0013640883,0.050069675,0.0050045727,0.016052905,0.0002989556,0.0015333791,0.0001278115,0.0003221604,0.00028312788,0.9225969,0.0020333694],"study_design_scores_gemma":[0.003987939,0.0030165724,0.06403242,0.007160381,0.0372287,0.0000023928062,0.0012048292,0.001044426,0.00018392113,0.000033601777,0.8811016,0.0010032085],"about_ca_topic_score_codex":0.012795105,"about_ca_topic_score_gemma":0.6039091,"teacher_disagreement_score":0.64349884,"about_ca_system_score_codex":0.0031298415,"about_ca_system_score_gemma":0.0042204116,"threshold_uncertainty_score":0.9984567},"labels":[],"label_agreement":null},{"id":"W3035452648","doi":"10.1016/s2213-8587(20)30187-x","title":"Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials","year":2020,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Boehringer Ingelheim; Novo Nordisk; Abbott Laboratories; Sanofi; Merck; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Canagliflozin; Dapagliflozin; Empagliflozin; Medicine; Type 2 diabetes; Drug class; Diabetes mellitus; Clinical trial; Internal medicine; Glycemic; Pharmacology; Intensive care medicine; Endocrinology; Drug","score_opus":0.23551056235457685,"score_gpt":0.3721536130965929,"score_spread":0.13664305074201605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035452648","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.073322564,0.0067390157,0.000028693492,0.9063955,0.0035779746,0.0030784167,0.005569712,0.0005127559,0.000775401],"genre_scores_gemma":[0.02188027,0.0025370254,0.0015594579,0.91455257,0.023424238,0.00075702835,0.034087982,0.00018692522,0.0010145162],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98986787,0.0019406837,0.0023298175,0.0018425931,0.0015911087,0.0024279295],"domain_scores_gemma":[0.9875922,0.00702223,0.0011431145,0.0038061452,0.00013973382,0.00029658296],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010611803,0.0010094516,0.0048534567,0.00020176059,0.00020319612,0.00013412698,0.002526986,0.00055204704,0.0062359227],"category_scores_gemma":[0.0054591866,0.00066068745,0.00045436076,0.00037573956,0.000394877,0.00013902201,0.0031637521,0.0028104112,0.0010227694],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030652565,0.00015084258,0.03721362,0.00016536628,0.004229768,0.001958004,0.00012571919,2.7384115e-7,0.000099219345,0.000009597534,0.94483835,0.010902742],"study_design_scores_gemma":[0.00539741,0.0009325967,0.009284605,0.0010066647,0.0043198555,0.000005368526,0.000043868462,0.00034516523,0.00041860927,0.0005045291,0.9771157,0.0006256137],"about_ca_topic_score_codex":0.0012494554,"about_ca_topic_score_gemma":0.00026953468,"teacher_disagreement_score":0.05144229,"about_ca_system_score_codex":0.00032595388,"about_ca_system_score_gemma":0.0003154531,"threshold_uncertainty_score":0.999755},"labels":[],"label_agreement":null},{"id":"W3035468154","doi":"10.1016/s2213-8587(20)30162-5","title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University Health Network; University of Toronto","funders":"Novo Nordisk; Diabetes Australia Research Trust; Rijksuniversiteit Groningen; AstraZeneca","keywords":"Medicine; Dapagliflozin; Kidney disease; Renal function; Proteinuria; Albuminuria; Placebo; Diabetes mellitus; Internal medicine; Crossover study; Type 2 diabetes; Urology; Randomized controlled trial; Kidney; Endocrinology; Pathology","score_opus":0.01359334487993476,"score_gpt":0.24622368326784044,"score_spread":0.23263033838790567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035468154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98054403,0.00039231565,0.0000012364097,0.006631297,0.00041954074,0.011288469,0.000029299032,0.00006159774,0.00063219055],"genre_scores_gemma":[0.9928473,0.000032910044,0.000019084175,0.0038312264,0.00069178734,0.0022882055,0.000052010244,0.00004620259,0.00019124875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99725837,0.00022305617,0.00043562904,0.00050488353,0.00041720812,0.001160836],"domain_scores_gemma":[0.99838823,0.00030318394,0.00025131644,0.00073908514,0.00005778917,0.00026038906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016304314,0.0003906721,0.0010039501,0.00010225975,0.00008688343,0.000030168741,0.0004468114,0.00007385008,0.00005532638],"category_scores_gemma":[0.00029494558,0.0002046784,0.00021363057,0.00041051753,0.00033428703,0.000077391196,0.0002315652,0.0004125995,0.000055078057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7553741,0.0024690933,0.22575806,0.0018961327,0.0013606877,0.00008294981,0.00041919673,0.000083978324,0.0020803707,0.00079601776,0.005454302,0.0042251153],"study_design_scores_gemma":[0.8612431,0.003913642,0.10474439,0.0005828804,0.00094130804,1.4744268e-7,0.000006591645,0.00009109341,0.024245067,0.000093275026,0.0038660131,0.00027247652],"about_ca_topic_score_codex":0.000015321548,"about_ca_topic_score_gemma":0.000009396596,"teacher_disagreement_score":0.12101366,"about_ca_system_score_codex":0.00013898457,"about_ca_system_score_gemma":0.0001679681,"threshold_uncertainty_score":0.83465433},"labels":[],"label_agreement":null},{"id":"W3035486061","doi":"10.3389/fcvm.2020.00100","title":"Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor","year":2020,"lang":"en","type":"review","venue":"Frontiers in Cardiovascular Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prediabetes; Atherosclerotic cardiovascular disease; Risk factor; Internal medicine; Type 2 diabetes; Glycemic; Postprandial; Diabetes mellitus; Confounding; Cohort; Disease; Endocrinology; Cardiology","score_opus":0.05494480979677901,"score_gpt":0.2627094268223655,"score_spread":0.20776461702558646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035486061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045372662,0.99230707,0.0015947595,0.00012566724,0.0010816677,0.0039032744,0.000192834,0.000106517015,0.00023451349],"genre_scores_gemma":[0.0006050457,0.9962213,0.0005419814,0.000036766913,0.0014318465,0.0006756781,0.00016603732,0.00018959641,0.00013176876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99458635,0.0010571954,0.00087571517,0.001436644,0.0013609978,0.0006830993],"domain_scores_gemma":[0.99664754,0.00027167896,0.0002725939,0.0020699564,0.000052697917,0.0006855123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018511473,0.0010464871,0.006400293,0.00044410175,0.00021325913,0.000052964417,0.0003242125,0.00025179444,0.000018922978],"category_scores_gemma":[0.00063758803,0.00064070703,0.0028313112,0.0007045209,0.0005275111,0.00013367189,0.0003685734,0.0012016993,0.000012304145],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038237136,0.000017699316,0.025879458,0.007897643,0.051705252,0.0003273765,0.00020997137,0.00000504805,7.315037e-9,0.0000028305558,0.0010825528,0.9128339],"study_design_scores_gemma":[0.0029128862,0.0001525074,0.042443775,0.009147359,0.104675055,0.000015746025,0.00017285459,0.00002926721,7.5262726e-8,0.000038034923,0.8399436,0.00046883503],"about_ca_topic_score_codex":0.00016715938,"about_ca_topic_score_gemma":0.0000012983679,"teacher_disagreement_score":0.9123651,"about_ca_system_score_codex":0.000355628,"about_ca_system_score_gemma":0.00011704778,"threshold_uncertainty_score":0.9996044},"labels":[],"label_agreement":null},{"id":"W3035499288","doi":"10.2337/db20-271-or","title":"271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Placebo; Type 2 diabetes; Diabetes mellitus; Prediabetes; Internal medicine; Heart failure; Ejection fraction; Incidence (geometry); Urology; Endocrinology; Mathematics","score_opus":0.02648997310134764,"score_gpt":0.2537352544147708,"score_spread":0.22724528131342314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035499288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956394,0.0009899826,0.0000048738116,0.0005263742,0.00006637463,0.0010278699,0.00008892033,0.00008229585,0.0015738956],"genre_scores_gemma":[0.9985577,0.00006684527,0.00006730876,0.000714835,0.00011687808,0.00018151801,0.00011626324,0.000038418875,0.00014025581],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99757415,0.0001915424,0.0005928682,0.00052402535,0.0007034877,0.00041393118],"domain_scores_gemma":[0.9966604,0.0019152489,0.0003800894,0.0007507186,0.000104270264,0.0001892828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045232338,0.00036618058,0.0010968797,0.0002272845,0.000055988283,0.000031270694,0.00041000862,0.000097657874,0.00065716973],"category_scores_gemma":[0.00074195914,0.00022252425,0.00041611627,0.0010663022,0.00014558651,0.00016636489,0.00015714455,0.00020742776,0.000056879082],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055435504,0.0004441633,0.91802365,0.00064637477,0.008418641,0.000017058243,0.0012456911,0.00016297118,0.05747637,0.00007629359,0.0079074,0.005027021],"study_design_scores_gemma":[0.0021369325,0.0029487896,0.3499556,0.00045885364,0.0056944247,1.5238438e-8,0.00022928446,0.0012697388,0.6361601,0.000054166663,0.0008125164,0.00027957305],"about_ca_topic_score_codex":0.000049607486,"about_ca_topic_score_gemma":0.000022437203,"teacher_disagreement_score":0.57868373,"about_ca_system_score_codex":0.000051729974,"about_ca_system_score_gemma":0.000054312575,"threshold_uncertainty_score":0.90742755},"labels":[],"label_agreement":null},{"id":"W3035689851","doi":"10.1016/s2213-8587(20)30130-3","title":"Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Vifor Pharma; Amarin Corporation; Novo Nordisk; Steno Diabetes Center Copenhagen; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Cohort study; Cohort; Multinational corporation; Internal medicine; Pharmacology","score_opus":0.02227324117206337,"score_gpt":0.25364194466514184,"score_spread":0.23136870349307848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035689851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766445,0.0003308916,0.000024067751,0.0005304954,0.000025988842,0.001114898,0.0001362375,0.000048730522,0.00012425963],"genre_scores_gemma":[0.9988834,0.000112431706,0.00012638429,0.00014691766,0.00012788238,0.00010348934,0.00047657857,0.000018295177,0.000004621559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800503,0.0004805146,0.00032551656,0.00034637324,0.00046754422,0.0003750196],"domain_scores_gemma":[0.99859846,0.0003664898,0.00033394544,0.00045995982,0.00017638819,0.00006473569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041058444,0.00020668114,0.0010128525,0.00009024337,0.0000887604,0.000010912159,0.00017113776,0.000037307578,0.000013412106],"category_scores_gemma":[0.00011393063,0.00011085503,0.00013578277,0.0004614103,0.00014820443,0.000078530036,0.00009871551,0.00016396574,9.851301e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019176626,0.00045207777,0.9698588,0.000014361765,0.02660374,0.000008440788,0.0010970008,0.0010842673,0.000059701957,0.00004085155,0.000040170875,0.0005488038],"study_design_scores_gemma":[0.0051263645,0.0012866732,0.9762417,0.000032979595,0.014043061,2.6495474e-7,0.00079515536,0.0014473548,0.0008417029,0.000027711334,0.000048731898,0.00010830861],"about_ca_topic_score_codex":0.00081416353,"about_ca_topic_score_gemma":0.00034253908,"teacher_disagreement_score":0.012560679,"about_ca_system_score_codex":0.000044093053,"about_ca_system_score_gemma":0.000027318782,"threshold_uncertainty_score":0.45205367},"labels":[],"label_agreement":null},{"id":"W3035699722","doi":"10.2337/db20-676-p","title":"676-P: Ideal Ketone Test Training among Type 1 Patients in Context of Risk Associated with SGLT2 Inhibitors","year":2020,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Type 2 diabetes; Context (archaeology); Diabetic ketoacidosis; Medicine; Test (biology); Nursing; Family medicine; Psychology; Endocrinology","score_opus":0.01424103327099491,"score_gpt":0.2145743447652311,"score_spread":0.2003333114942362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035699722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978318,0.00010609037,4.4146597e-7,0.00013301398,0.000054290518,0.00041184927,0.000035772984,0.00005705768,0.0013696731],"genre_scores_gemma":[0.99928224,0.000014068199,0.000048044876,0.00032041664,0.00003947122,0.0000182211,0.00020314702,0.00002679877,0.000047617064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989518,0.000035571808,0.0002702308,0.00021906605,0.0002396844,0.00028365295],"domain_scores_gemma":[0.9992512,0.00023881072,0.00017865658,0.00011063598,0.000098483615,0.00012220557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012348894,0.00016030339,0.00041985663,0.00009480331,0.000024790594,0.000009986041,0.00005883912,0.000057913887,0.000027002818],"category_scores_gemma":[0.00085679424,0.0001279232,0.000052334024,0.00042966698,0.00008118434,0.0001040679,0.000036284415,0.00013045117,0.000011784879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004094133,0.00039845848,0.98787385,0.000046764224,0.00020528816,0.0000070061706,0.0020819835,0.0000071196914,0.00019856366,0.000009406516,0.00047151526,0.008659086],"study_design_scores_gemma":[0.0041512647,0.0017010688,0.9876784,0.00037074415,0.0002331594,9.898363e-9,0.0009631967,0.0004097209,0.004209584,0.000013154258,0.0001314755,0.0001382342],"about_ca_topic_score_codex":0.00007409672,"about_ca_topic_score_gemma":0.000084882704,"teacher_disagreement_score":0.008520852,"about_ca_system_score_codex":0.000052874824,"about_ca_system_score_gemma":0.000028137958,"threshold_uncertainty_score":0.5216557},"labels":[],"label_agreement":null},{"id":"W3036438870","doi":"10.1016/s1474-4422(20)30173-3","title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University; Population Health Research Institute; Hamilton Health Sciences","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Type 2 diabetes; Cognitive impairment; Exploratory analysis; Cognition; Psychology; Medicine; Physical therapy; Physical medicine and rehabilitation; Diabetes mellitus; Psychiatry; Computer science; Data science; Endocrinology","score_opus":0.0314851385831056,"score_gpt":0.2928398577921188,"score_spread":0.2613547192090132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036438870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952574,0.00007100798,3.9509447e-7,0.0032979893,0.00012107766,0.0008296261,0.000012848281,0.000012549915,0.00039711414],"genre_scores_gemma":[0.99490327,0.00003219588,0.000001095379,0.004886937,0.000103866805,0.000035956822,0.000019504289,0.000008355412,0.000008801899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987047,0.0006220766,0.00018915844,0.00017494237,0.00013646173,0.0001726709],"domain_scores_gemma":[0.9991376,0.000383527,0.00011560982,0.00030685155,0.000021950047,0.000034491994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041331383,0.00010165346,0.0005962613,0.000086998894,0.000015167092,0.0000020076516,0.00014052074,0.000037709837,0.000038167564],"category_scores_gemma":[0.00017005495,0.000051695075,0.00011755394,0.0005694644,0.00009442705,0.000017898115,0.0000696354,0.00014138455,0.0000061445453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24763423,0.0013883725,0.7265758,0.00035378,0.004962105,0.00006764347,0.0038523944,0.00082744454,0.0040952326,0.00028377466,0.0015350454,0.008424168],"study_design_scores_gemma":[0.096592985,0.10235802,0.76091766,0.000103458275,0.009933574,3.9870594e-7,0.00014719137,0.0034503064,0.025370516,0.00007726895,0.00085579656,0.00019282188],"about_ca_topic_score_codex":0.000006195962,"about_ca_topic_score_gemma":0.000021686712,"teacher_disagreement_score":0.15104124,"about_ca_system_score_codex":0.000008167786,"about_ca_system_score_gemma":0.000015261283,"threshold_uncertainty_score":0.2108064},"labels":[],"label_agreement":null},{"id":"W3036492313","doi":"10.1007/s10787-020-00732-4","title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","year":2020,"lang":"en","type":"article","venue":"Inflammopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Medicine; Sepsis; Septic shock; Acute kidney injury; Inflammation; Pharmacology; Immunology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.01462935371455746,"score_gpt":0.2833256128969439,"score_spread":0.26869625918238643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036492313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865672,0.00016155506,0.000026927613,0.008316386,0.00013209347,0.0012234633,0.000008690833,0.00018709547,0.0033765687],"genre_scores_gemma":[0.99471635,0.00022482239,0.00042228462,0.0034592457,0.00044337485,0.00022282128,0.000052914325,0.000025952198,0.0004322251],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989417,0.000055495424,0.0002604558,0.00030248376,0.00014919318,0.00029062698],"domain_scores_gemma":[0.9994629,0.000037939317,0.000090680165,0.00011592475,0.000056112793,0.00023646817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000078083365,0.00019275321,0.0003033903,0.00010553638,0.00006389996,0.000026240032,0.00007549162,0.000090588124,0.00022304537],"category_scores_gemma":[0.000046020334,0.00017077287,0.000055390447,0.00016407904,0.000088315195,0.00015249672,0.00013386906,0.0001793214,0.00016715543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010949288,0.00008184423,0.0024308716,0.00031283486,0.0011656237,0.0007266867,0.00065019086,0.00003808831,0.9283346,0.00015774743,0.015436469,0.04957009],"study_design_scores_gemma":[0.010661997,0.0024343333,0.008873446,0.000081045015,0.0015220232,0.000022491942,0.00007301544,0.0030408811,0.8064143,0.00014902915,0.16627085,0.000456553],"about_ca_topic_score_codex":0.0000022293743,"about_ca_topic_score_gemma":0.0000014592965,"teacher_disagreement_score":0.15083438,"about_ca_system_score_codex":0.00005435514,"about_ca_system_score_gemma":0.00006507817,"threshold_uncertainty_score":0.6963916},"labels":[],"label_agreement":null},{"id":"W3036816724","doi":"10.1016/j.jacbts.2020.02.004","title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors","year":2020,"lang":"en","type":"review","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":872,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Alberta","funders":"Boehringer Ingelheim; Novo Nordisk; Sanofi; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Servier; Amgen","keywords":"Medicine; Empagliflozin; Heart failure; Natriuresis; Internal medicine; Diabetes mellitus; Endocrinology; Cardiology; Oxidative stress; Pharmacology; Blood pressure; Type 2 diabetes","score_opus":0.032815215528966296,"score_gpt":0.29039763205206337,"score_spread":0.2575824165230971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036816724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022490136,0.9923477,0.0018599218,0.00029487055,0.0002593868,0.0021136669,0.00024741527,0.000038957587,0.0026131356],"genre_scores_gemma":[0.011066915,0.9820077,0.0060409172,0.00013566433,0.00016357696,0.00013922491,0.0002647591,0.000055691446,0.00012554992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99668306,0.00003091676,0.00074879004,0.0006469221,0.0015735398,0.00031675692],"domain_scores_gemma":[0.99885577,0.000058788002,0.00020538081,0.0004513044,0.00016136044,0.00026738693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059430004,0.00034257022,0.0016650915,0.00044586151,0.00006082031,0.000014957333,0.00036501218,0.00011696513,0.00012166149],"category_scores_gemma":[0.000022455963,0.0002687657,0.0010821462,0.0013630061,0.00021224092,0.00014897132,0.00003177857,0.00013939585,0.000044316657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019351904,0.00015266398,0.000019947063,0.0051982263,0.0007275229,0.000011967744,0.00014430896,0.000055020497,0.00007610373,0.004381254,0.00006751045,0.9891461],"study_design_scores_gemma":[0.00079344615,0.00035441914,0.0007928287,0.0054097194,0.0045865937,0.0000060155126,0.00001186035,0.000012754535,0.002120071,0.00018322947,0.9854061,0.00032296675],"about_ca_topic_score_codex":0.000020910205,"about_ca_topic_score_gemma":0.0000027774656,"teacher_disagreement_score":0.9888232,"about_ca_system_score_codex":0.000077135635,"about_ca_system_score_gemma":0.00060232636,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W3037195855","doi":"10.14740/jocmr4224","title":"Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alogliptin; Medicine; Glycemic; Dyslipidemia; Type 2 diabetes; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Dipeptidyl peptidase-4; Internal medicine; Blood pressure; Body mass index; Observational study; Adverse effect; Endocrinology; Pharmacology; Gastroenterology","score_opus":0.5721658572538768,"score_gpt":0.596172727210349,"score_spread":0.024006869956472165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037195855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9306776,0.00014009881,0.000044697517,0.066414006,0.0005392658,0.0018618775,0.0000062982667,0.000008164162,0.00030797586],"genre_scores_gemma":[0.99422264,0.00007428192,0.0016290965,0.0014965661,0.0023019803,0.000021295933,0.000008317495,0.000022743463,0.00022308421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907963,0.0022560717,0.0038050413,0.0004331275,0.002329707,0.00037971087],"domain_scores_gemma":[0.9885568,0.0074667824,0.0010997038,0.00033428674,0.0020252625,0.0005171399],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008512951,0.00020404042,0.0013864173,0.0002422507,0.00006683515,0.000016604577,0.0003660187,0.00014846114,0.00019687891],"category_scores_gemma":[0.03846565,0.00011408308,0.00066108763,0.0007795933,0.0009531677,0.00016074737,0.00046247838,0.0027464095,0.000023290466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005063808,0.023543037,0.94526243,0.0001821902,0.0008055989,0.0003804982,0.00081274664,0.000003193269,0.000085253116,0.000102906306,0.01981547,0.0039428542],"study_design_scores_gemma":[0.04336016,0.017680101,0.9282062,0.0015328323,0.0002416341,0.000021166425,0.0027388053,0.00029222463,0.000033576478,0.00006672723,0.005748218,0.00007836184],"about_ca_topic_score_codex":0.000012987165,"about_ca_topic_score_gemma":0.000012520014,"teacher_disagreement_score":0.06491744,"about_ca_system_score_codex":0.00011469931,"about_ca_system_score_gemma":0.00059506507,"threshold_uncertainty_score":0.9995543},"labels":[],"label_agreement":null},{"id":"W3037211530","doi":"10.1177/2054358120935701","title":"Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review","year":2020,"lang":"en","type":"review","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Canagliflozin; Empagliflozin; Kidney disease; Intensive care medicine; Type 2 diabetes; Internal medicine; Diabetic ketoacidosis; Albuminuria; Diabetes mellitus; Nephrology; Nephropathy; Clinical trial; Adverse effect; Diabetic nephropathy; Kidney; Endocrinology","score_opus":0.025615206352566186,"score_gpt":0.34262764531332673,"score_spread":0.31701243896076053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037211530","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000020890109,0.8292221,0.0000010757565,0.16866809,0.00023135728,0.0014442902,0.00011880363,0.0000044820445,0.00030775287],"genre_scores_gemma":[0.000005787206,0.7831919,0.00006769263,0.21616694,0.00021890108,0.000034170673,0.00022705633,0.000025410041,0.00006209821],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755627,0.0002967338,0.0011705667,0.00028225148,0.00019876561,0.00049539324],"domain_scores_gemma":[0.9562748,0.00007266069,0.00086389587,0.00019129174,0.00011602008,0.04248132],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045040622,0.00035541225,0.0022395095,0.0005125093,0.00008475727,0.000024400455,0.000111928195,0.00010285664,0.000114964256],"category_scores_gemma":[0.008587796,0.00027635528,0.0003723428,0.00038479213,0.000090698835,0.00014903782,0.000010389344,0.00057148153,0.000014271465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007950423,0.00006647542,0.000095483876,0.075801805,0.0002036485,0.0051901964,0.00033064265,9.269218e-9,2.676679e-9,0.000041422474,0.47093624,0.44725457],"study_design_scores_gemma":[0.0010793722,0.0006200738,0.000008579629,0.08813354,0.0023036283,0.00015494533,0.00014695885,3.1246725e-7,4.8507007e-9,0.000020112393,0.9073798,0.00015270156],"about_ca_topic_score_codex":0.0005363656,"about_ca_topic_score_gemma":0.00040114147,"teacher_disagreement_score":0.44710186,"about_ca_system_score_codex":0.0005371034,"about_ca_system_score_gemma":0.11991761,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W3037551703","doi":"10.2337/dc20-0120","title":"Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"University of Glasgow; British Heart Foundation; Novo Nordisk; Janssen Pharmaceuticals; Merck KGaA; Eli Lilly and Company; AstraZeneca; McKnight Foundation; Sanofi; Diabetes UK; University of Dundee; Amgen","keywords":"Medicine; Metformin; Prediabetes; Diabetes mellitus; Internal medicine; Type 2 diabetes; Glycated hemoglobin; Pioglitazone; Guideline; Endocrinology; Pharmacology; Pathology","score_opus":0.05156963613102298,"score_gpt":0.297946433055281,"score_spread":0.24637679692425804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037551703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806622,0.0072788834,0.00004244559,0.00257577,0.00032585955,0.008394098,0.0005528291,0.00012168871,0.00004618101],"genre_scores_gemma":[0.9872358,0.0016504826,0.0014219672,0.005771933,0.0005599006,0.002310796,0.0007792427,0.00020063037,0.000069245805],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956863,0.0002595455,0.0010757063,0.0013707265,0.00057880906,0.001028942],"domain_scores_gemma":[0.997459,0.0005447174,0.00018582254,0.0010720936,0.00017804197,0.00056031335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010934158,0.0007803627,0.0016388196,0.0002517766,0.00015390481,0.00009429484,0.00041975683,0.00017147633,0.000021238679],"category_scores_gemma":[0.00040986744,0.00053377816,0.00066191074,0.000785175,0.00013105362,0.0001805877,0.00014939853,0.00030629174,0.0000267988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046335403,0.0003173782,0.88865954,0.0021022744,0.0027988593,0.000027237602,0.0030108823,0.010375101,0.002685023,0.000012764806,0.011213295,0.074164115],"study_design_scores_gemma":[0.034911588,0.019164836,0.31260446,0.0070045698,0.0032633452,4.0237006e-7,0.0019428906,0.0044439435,0.0841753,0.00015940687,0.5290172,0.003312055],"about_ca_topic_score_codex":0.0000438229,"about_ca_topic_score_gemma":0.000072758994,"teacher_disagreement_score":0.57605505,"about_ca_system_score_codex":0.00021942255,"about_ca_system_score_gemma":0.0001392173,"threshold_uncertainty_score":0.9997114},"labels":[],"label_agreement":null},{"id":"W3038415136","doi":"10.1007/s13300-020-00869-z","title":"Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"Eli Lilly and Company","keywords":"Medicine; Dulaglutide; Post-hoc analysis; Type 2 diabetes; Diabetes mellitus; Adverse effect; Internal medicine; Randomized controlled trial; Pooled analysis; Post hoc; Traditional medicine; Exenatide; Meta-analysis; Endocrinology","score_opus":0.02863615751985996,"score_gpt":0.30221426936298373,"score_spread":0.27357811184312375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038415136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960622,0.00032558004,0.000017439916,0.00011336173,0.000027868835,0.0032418147,0.00013861971,0.000018283605,0.00005482827],"genre_scores_gemma":[0.9977579,0.00009084688,0.00092763297,0.000115679584,0.000023882616,0.00017114221,0.00086912443,0.000031874297,0.00001188418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966291,0.00074805046,0.0010839875,0.00034014106,0.00091170846,0.00028696956],"domain_scores_gemma":[0.9967966,0.00054098514,0.001149969,0.00035249427,0.001040828,0.00011909453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016463343,0.00035916612,0.0029399346,0.0004685349,0.00001684022,0.0000041115068,0.00010845875,0.000035589226,0.00014171343],"category_scores_gemma":[0.00076249894,0.00020807778,0.00043487534,0.0012470798,0.00012340434,0.00009420791,0.000020452699,0.00006069974,0.0000017376973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0480146,0.0022487785,0.9169344,0.0000900242,0.012983229,0.0000020123837,0.0005783347,0.00040094767,0.0031992863,0.0000046521636,0.0000017111541,0.01554205],"study_design_scores_gemma":[0.2292499,0.009710321,0.73590785,0.00036605785,0.017748043,3.5146638e-8,0.000056909263,0.0052409098,0.0015524735,0.0000140028105,0.000002260603,0.00015125028],"about_ca_topic_score_codex":0.00003957009,"about_ca_topic_score_gemma":0.000027406937,"teacher_disagreement_score":0.1812353,"about_ca_system_score_codex":0.000133855,"about_ca_system_score_gemma":0.00018104675,"threshold_uncertainty_score":0.8485165},"labels":[],"label_agreement":null},{"id":"W3038565842","doi":"10.1097/hjh.0000000000002492","title":"Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Heart failure; Mace; Internal medicine; Blood pressure; Cardiology; Placebo; Type 2 diabetes; Diabetes mellitus; Myocardial infarction; Endocrinology","score_opus":0.021488458302471123,"score_gpt":0.229896331515593,"score_spread":0.20840787321312187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038565842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832029,0.0004036804,0.000003262481,0.016041344,0.000053953445,0.00026318416,0.000013191531,0.000010661531,0.000007832988],"genre_scores_gemma":[0.9926805,0.000016939659,0.0034409044,0.0037098012,0.00007575497,8.5715243e-7,0.000021357082,0.000016704476,0.000037167287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989125,0.000040174215,0.00039775769,0.00020485777,0.00028362893,0.00016107861],"domain_scores_gemma":[0.9992444,0.00010546655,0.00014408663,0.00012105957,0.00014860954,0.00023635778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018241981,0.00015686308,0.00056337105,0.00011928079,0.000030853673,0.000025356554,0.000045302797,0.000048020334,0.0000056789067],"category_scores_gemma":[0.0003893043,0.000093808994,0.000041772462,0.00014245603,0.000015413514,0.00014357622,0.00007211239,0.00017234727,0.0000022796885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014377903,0.00022005713,0.99226254,0.000030283116,0.0003698991,0.00008455534,0.00013189657,0.0000244595,0.002402785,3.6816772e-7,0.0020097862,0.0010255907],"study_design_scores_gemma":[0.01356072,0.0028070454,0.9779305,0.00037842768,0.0012521166,0.000003844902,0.00016218357,0.0001606193,0.00040039062,0.000003359722,0.0032201852,0.00012063022],"about_ca_topic_score_codex":0.000012531776,"about_ca_topic_score_gemma":0.0000072378834,"teacher_disagreement_score":0.014332051,"about_ca_system_score_codex":0.00000894768,"about_ca_system_score_gemma":0.000015432795,"threshold_uncertainty_score":0.38254195},"labels":[],"label_agreement":null},{"id":"W3038567980","doi":"10.1016/j.mayocp.2020.04.034","title":"In Reply — Comparison of Outcomes With Metformin and Sulfonylureas in Chronic Kidney Disease","year":2020,"lang":"en","type":"letter","venue":"Mayo Clinic Proceedings","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seven Oaks General Hospital; University of Manitoba","funders":"","keywords":"Medicine; Metformin; Glipizide; Kidney disease; Type 2 diabetes; Renal function; Lactic acidosis; Sulfonylurea; Internal medicine; Diabetes mellitus; Retrospective cohort study; Endocrinology; Insulin","score_opus":0.03230722572250261,"score_gpt":0.3194722662494137,"score_spread":0.2871650405269111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038567980","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11174,0.0011908273,0.0000012041606,0.8795791,0.00014181914,0.0022229622,0.000037764,0.0000827155,0.0050035617],"genre_scores_gemma":[0.18682602,0.00043457592,0.0006475423,0.79605913,0.0007917478,0.00040817566,0.00043451003,0.00014488227,0.014253406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975932,0.000011441134,0.0008403148,0.00068871025,0.00043744367,0.00042888668],"domain_scores_gemma":[0.9989619,0.00010346418,0.0004164557,0.00021893533,0.00006389269,0.00023533817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002308526,0.00042530254,0.0014760646,0.0004249926,0.000018116423,0.00002883648,0.00016964543,0.00020501511,0.00011026448],"category_scores_gemma":[0.00035077834,0.00032013367,0.00013536142,0.00036968366,0.00015008089,0.00015995008,0.0001552873,0.00097056956,0.000024210038],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032887913,0.00016393627,0.41489795,0.0032129297,0.0002072182,0.0004068023,0.00025686607,5.6943524e-8,0.0000048919983,0.00002603947,0.57973117,0.00076328055],"study_design_scores_gemma":[0.007991223,0.0020057755,0.06855685,0.0023378872,0.0012629514,0.0000040164846,0.0001911609,0.0001484847,0.00006615054,0.0003309935,0.9166196,0.0004848788],"about_ca_topic_score_codex":0.00008378812,"about_ca_topic_score_gemma":0.00001139035,"teacher_disagreement_score":0.3463411,"about_ca_system_score_codex":0.00027630918,"about_ca_system_score_gemma":0.00031149763,"threshold_uncertainty_score":0.9999251},"labels":[],"label_agreement":null},{"id":"W3038598579","doi":"10.1002/ejhf.1958","title":"Association Between Glycated Haemoglobin Levels and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the TECOS Randomized Clinical Trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Interquartile range; Heart failure; Myocardial infarction; Unstable angina; Diabetes mellitus; Type 2 diabetes; Cardiology; Stroke (engine); Randomized controlled trial; Glycated hemoglobin; Sitagliptin; Confidence interval; Endocrinology","score_opus":0.0200420869177983,"score_gpt":0.24495044799100377,"score_spread":0.22490836107320547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038598579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500793,0.0017816626,0.000019311552,0.0022743857,0.000060445378,0.00080024084,0.000021594138,0.0000067426968,0.000027703174],"genre_scores_gemma":[0.9992877,0.000051030616,0.00032967483,0.00018077585,0.00009197212,0.0000018337197,0.00001690497,0.000017296281,0.00002280303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968038,0.0015762801,0.00070129335,0.00020085975,0.0005739159,0.00014380341],"domain_scores_gemma":[0.9988683,0.00023488449,0.0002933979,0.0002542028,0.00017581307,0.00017340672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003230042,0.00014933838,0.0017700745,0.00014764711,0.000034401717,0.000026536227,0.00007943547,0.000030944262,0.000018631028],"category_scores_gemma":[0.00096903724,0.000084011444,0.0011199227,0.00042189434,0.00007453872,0.00008742754,0.000073132534,0.00024307557,0.000001224849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01372675,0.00009307539,0.9295489,0.000038365783,0.05259326,0.000018134291,0.000082004044,0.0000670032,0.0000012189255,4.4579397e-7,0.0006595945,0.0031712526],"study_design_scores_gemma":[0.21681388,0.0005323056,0.7535949,0.00005527727,0.02432864,1.423206e-7,0.000021741469,0.000024286666,0.000004621428,0.0000012114773,0.0045574973,0.00006553148],"about_ca_topic_score_codex":0.000002095584,"about_ca_topic_score_gemma":7.5842814e-7,"teacher_disagreement_score":0.20308712,"about_ca_system_score_codex":0.000025151498,"about_ca_system_score_gemma":0.000049179354,"threshold_uncertainty_score":0.34258872},"labels":[],"label_agreement":null},{"id":"W3039701622","doi":"10.1093/eurheartj/ehaa496","title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; British Heart Foundation; AstraZeneca","keywords":"Medicine; Dapagliflozin; Blood pressure; Heart failure; Adverse effect; Internal medicine; Cardiology; Heart rate; Endocrinology; Diabetes mellitus","score_opus":0.026533650380413745,"score_gpt":0.30222771644088775,"score_spread":0.27569406606047403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039701622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930221,0.00041775056,0.00003006084,0.0046901796,0.0001037621,0.0013901343,0.000005388295,0.000013639758,0.00032702356],"genre_scores_gemma":[0.9984461,0.000025841195,0.00063183,0.000518983,0.00023543769,0.0000097794045,0.0000051981688,0.000025419838,0.00010140186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972794,0.0013269817,0.0005846555,0.00022020843,0.0003540937,0.00023463728],"domain_scores_gemma":[0.9992042,0.00025220052,0.00015475995,0.00020326719,0.000034756333,0.00015081561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002718249,0.00018690247,0.0006362605,0.00024757744,0.000039048075,0.000018404748,0.00013404856,0.0000311179,0.000035319466],"category_scores_gemma":[0.00055554224,0.00012199369,0.00017947833,0.00032995784,0.000029675062,0.00012267432,0.000095044874,0.00031066182,0.000011032918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017128443,0.00148902,0.940291,0.0016114449,0.0010997067,0.00052899384,0.0036430424,0.00048826085,0.014976125,0.00005697608,0.009583927,0.009103096],"study_design_scores_gemma":[0.25033957,0.047178008,0.61771834,0.004954389,0.006127046,0.00037470087,0.0039271126,0.0007656197,0.01022082,0.000022351765,0.05756952,0.00080250046],"about_ca_topic_score_codex":0.0000099200315,"about_ca_topic_score_gemma":0.000008780785,"teacher_disagreement_score":0.32257262,"about_ca_system_score_codex":0.000012945666,"about_ca_system_score_gemma":0.000028823923,"threshold_uncertainty_score":0.49747583},"labels":[],"label_agreement":null},{"id":"W3040262783","doi":"10.1210/clinem/dgaa427","title":"The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments","year":2020,"lang":"en","type":"review","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Context (archaeology); Heart failure; Intensive care medicine; Observational study; Internal medicine; Randomized controlled trial; Ejection fraction; Bioinformatics; Cardiology; Endocrinology","score_opus":0.04077584402108094,"score_gpt":0.36975698523555656,"score_spread":0.32898114121447564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040262783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032504577,0.96294636,0.000020674031,0.0021488906,0.0015011311,0.0007877776,0.000014697575,0.000013729978,0.00006219194],"genre_scores_gemma":[0.0023956748,0.9953671,0.00015048722,0.0007718913,0.0011342864,0.000017497016,0.00001664946,0.000038730996,0.00010767167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956553,0.0011302549,0.0021634938,0.00030665647,0.00031219397,0.00043213041],"domain_scores_gemma":[0.99509245,0.0022226032,0.0017765447,0.0005238042,0.0001470414,0.0002375637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007856321,0.00037350558,0.0037629027,0.0001616463,0.000120013305,0.000012804804,0.00041181265,0.00019377154,0.000029835473],"category_scores_gemma":[0.00083270454,0.0001819216,0.0010332132,0.0002020292,0.00027224087,0.000046000507,0.0002746487,0.0007952495,0.000041256633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018244548,0.00022075471,0.00024494072,0.00029349394,0.005509332,0.00016631615,0.00005472318,0.0000011894709,0.0000104918045,0.000054344404,0.00058569625,0.99267626],"study_design_scores_gemma":[0.0022012969,0.0012467355,0.007169817,0.0009490029,0.022786967,0.000057421337,0.00005881024,0.0000035043038,0.000017179296,0.0005985211,0.96477956,0.0001311607],"about_ca_topic_score_codex":0.0000124456055,"about_ca_topic_score_gemma":0.0000019951979,"teacher_disagreement_score":0.9925451,"about_ca_system_score_codex":0.000036392685,"about_ca_system_score_gemma":0.00015528247,"threshold_uncertainty_score":0.7418548},"labels":[],"label_agreement":null},{"id":"W3040668198","doi":"10.1002/ejhf.1954","title":"Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology","year":2020,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Relypsa; Boston Scientific Corporation; Servier; Universität Zürich; AstraZeneca; MyoKardia; Bristol-Myers Squibb","keywords":"Dapagliflozin; Empagliflozin; Medicine; Canagliflozin; Heart failure; Ejection fraction; Internal medicine; Cardiology; Benzhydryl compounds; Diabetes mellitus; Clinical trial; Type 2 diabetes; Endocrinology","score_opus":0.006179615316602618,"score_gpt":0.2049329562339143,"score_spread":0.1987533409173117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040668198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79195887,0.0003724104,0.00005932155,0.20573728,0.00024773498,0.00077623024,0.00005794737,0.000018382343,0.0007718587],"genre_scores_gemma":[0.99402505,0.000029196646,0.001229795,0.0040821177,0.00047999158,0.0000018757961,0.00001483974,0.000052566924,0.000084579],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9960818,0.0015323798,0.0011418283,0.00024180712,0.0006789818,0.00032318337],"domain_scores_gemma":[0.9982691,0.00010376816,0.0008242895,0.0003550939,0.00031224967,0.00013550215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018333662,0.00026574277,0.000891233,0.00008937396,0.0000766037,0.000016655085,0.00026949245,0.00008395778,0.000048300633],"category_scores_gemma":[0.000103508144,0.00016798041,0.0009954046,0.0003775198,0.00017258928,0.00018628454,0.00007839176,0.0006572203,0.000015586482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025306334,0.00017154656,0.29813758,0.00019416193,0.0006229541,0.000023708293,0.0010975202,0.00019205168,0.2465145,0.00002061387,0.45261922,0.00015306713],"study_design_scores_gemma":[0.009688712,0.001471177,0.49715027,0.000785503,0.0008999068,0.00008114023,0.0010605889,0.00001778577,0.02393058,0.000020690417,0.4646697,0.00022393643],"about_ca_topic_score_codex":0.000006895605,"about_ca_topic_score_gemma":0.000013131431,"teacher_disagreement_score":0.22258392,"about_ca_system_score_codex":0.00011490409,"about_ca_system_score_gemma":0.0001073881,"threshold_uncertainty_score":0.68500423},"labels":[],"label_agreement":null},{"id":"W3041938457","doi":"10.1111/dom.14140","title":"Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 clinical trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Semaglutide; Medicine; Liraglutide; Type 2 diabetes; Hazard ratio; Internal medicine; Empagliflozin; Placebo; Disease; Diabetes mellitus; Macrovascular disease; Adverse effect; Clinical trial; Confidence interval; Surgery; Cardiology; Endocrinology; Pathology","score_opus":0.05417518927297947,"score_gpt":0.3188147998343146,"score_spread":0.2646396105613351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041938457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9543929,0.04273443,0.0000038013334,0.000618692,0.0002502635,0.0015045926,0.0002840521,0.000061147315,0.0001501316],"genre_scores_gemma":[0.99096185,0.0061905473,0.0001289911,0.0018165321,0.00039744924,0.000042458814,0.00026020478,0.00004686469,0.00015508021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99567235,0.0011205343,0.0011095153,0.00086161855,0.0005604514,0.00067555526],"domain_scores_gemma":[0.99369913,0.004251861,0.00033258428,0.0009061903,0.00013542951,0.0006747734],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035858501,0.00051095546,0.002656663,0.0001565641,0.000113618626,0.00008873386,0.00024521438,0.00018952816,0.0000062581908],"category_scores_gemma":[0.015941428,0.0003211868,0.0014128109,0.00042602845,0.00028381072,0.00016347239,0.00024225403,0.00041602796,0.00002017492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069623915,0.00078933866,0.9766267,0.0002106088,0.00753605,0.00004330506,0.0010669868,0.00004094943,0.00020399144,0.00007880268,0.0034800225,0.009853644],"study_design_scores_gemma":[0.008976284,0.00040856123,0.96065843,0.000145773,0.0047244495,9.374076e-8,0.00040961907,0.00018397695,0.00066107325,0.00022076236,0.0235295,0.00008147828],"about_ca_topic_score_codex":0.0001273408,"about_ca_topic_score_gemma":0.0000047685858,"teacher_disagreement_score":0.03656898,"about_ca_system_score_codex":0.00003378734,"about_ca_system_score_gemma":0.00011271363,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W3042095004","doi":"10.2337/dc20-0437","title":"Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial","year":2020,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk; Health Services Research and Development","keywords":"Liraglutide; Medicine; Metformin; Type 2 diabetes; Myocardial infarction; Hazard ratio; Internal medicine; Diabetes mellitus; Post-hoc analysis; Placebo; Stroke (engine); Endocrinology","score_opus":0.018612363490897614,"score_gpt":0.24974954409988873,"score_spread":0.2311371806089911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042095004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640835,0.0043522553,2.5288634e-7,0.005671753,0.00029388024,0.0029823303,0.00022068308,0.000028713937,0.00004176577],"genre_scores_gemma":[0.940743,0.00014250942,0.0001975252,0.056480277,0.000324388,0.00018768344,0.0016006663,0.00013989376,0.00018405335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739033,0.0002473977,0.00048845925,0.0005436916,0.0008993191,0.0004308309],"domain_scores_gemma":[0.9980527,0.000500985,0.00030669963,0.0007586106,0.00030910704,0.00007189646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000116617135,0.00055143604,0.0020228778,0.00033582945,0.000035505065,0.000024316274,0.00020089593,0.00025821288,0.0000071748686],"category_scores_gemma":[0.0005487224,0.0003136713,0.0005968589,0.00044166285,0.00017466082,0.00009151268,0.0001443265,0.00047781883,0.000004164803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012469545,0.0002400025,0.97215796,0.0043517137,0.0064890166,0.000026487005,0.0002393958,0.000011769038,0.0000605137,7.3899446e-7,0.010002319,0.0051731085],"study_design_scores_gemma":[0.09841178,0.013823256,0.7811134,0.005380935,0.026317973,1.3552715e-7,0.00023712771,0.000039169314,0.021666225,0.000008180431,0.05181089,0.0011909632],"about_ca_topic_score_codex":0.000029876555,"about_ca_topic_score_gemma":0.000008363309,"teacher_disagreement_score":0.19104461,"about_ca_system_score_codex":0.000089086665,"about_ca_system_score_gemma":0.00006793498,"threshold_uncertainty_score":0.9999315},"labels":[],"label_agreement":null},{"id":"W3042104705","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4713","title":"Obstructive Sleep Apnoe and Cardiovascular, Heart Failure and Mortality Outcomes with Empagliflozin Versus Placebo in the EMPA-REG Outcome <sup>®</sup> Trial","year":2020,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Placebo; Heart failure; Internal medicine; Cardiology; Diabetes mellitus; Type 2 diabetes; Alternative medicine; Endocrinology","score_opus":0.03559317304680985,"score_gpt":0.2767181746832422,"score_spread":0.24112500163643236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042104705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776895,0.00028187383,0.00002902191,0.00723542,0.00006004396,0.0022205042,0.000007650092,0.00006838786,0.0023281616],"genre_scores_gemma":[0.9975883,0.00001430598,0.00064807094,0.0013133789,0.0001060297,0.000119795804,0.000018818399,0.00002081561,0.00017051624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983583,0.00012312943,0.00027407098,0.00047649274,0.00047098848,0.00029703218],"domain_scores_gemma":[0.99917537,0.00017447336,0.0000382012,0.00041502906,0.000028462966,0.00016849197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034434564,0.00029041676,0.00075761386,0.00006891952,0.00007052065,0.0000644037,0.0000897156,0.00007412117,0.000049312926],"category_scores_gemma":[0.00010497843,0.00015948557,0.00019327372,0.00021311031,0.00012711236,0.00014291264,0.000091349866,0.00019640522,0.000010482301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011096174,0.00015772085,0.9787674,0.00011778266,0.003941213,0.00014293731,0.0024048612,0.000115086834,0.0000017684085,0.0004819554,0.0011793693,0.0015937283],"study_design_scores_gemma":[0.22420442,0.0026837143,0.7421109,0.00003228084,0.0036995963,0.000013098202,0.016404077,0.0005676584,0.00004148813,0.000049464878,0.009738053,0.00045526106],"about_ca_topic_score_codex":0.0001906909,"about_ca_topic_score_gemma":0.00015334599,"teacher_disagreement_score":0.23665652,"about_ca_system_score_codex":0.000036763697,"about_ca_system_score_gemma":0.000021095415,"threshold_uncertainty_score":0.65036327},"labels":[],"label_agreement":null},{"id":"W3042176300","doi":"10.1016/j.kint.2020.06.024","title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment","year":2020,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University; Impact","funders":"National Heart, Lung, and Blood Institute; BERLIN-CHEMIE; Eli Lilly Australia; NIHR Leicester Biomedical Research Centre; GlaxoSmithKline; Hong Kong Government; Gilead Sciences; Servier; Fresenius Medical Care North America; Astellas Pharma; National Institutes of Health; Indian Council of Medical Research; Menarini Group; Novo Nordisk; National Institute for Health and Care Research; Alnylam Pharmaceuticals; Akebia Therapeutics; Steno Diabetes Center Copenhagen; Sanofi; Amgen; Pfizer; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Guideline; Medicine; Executive summary; Diabetes mellitus; Intensive care medicine; Kidney disease; MEDLINE; Diabetes management; Evidence-based practice; Internal medicine; Type 2 diabetes; Alternative medicine; Political science; Business; Pathology; Endocrinology","score_opus":0.024437411522938216,"score_gpt":0.295710383380036,"score_spread":0.2712729718570978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042176300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87584496,0.0059133936,0.000044734978,0.09381399,0.00083934976,0.0017560002,0.000058430654,0.00004530176,0.021683816],"genre_scores_gemma":[0.9926893,0.0027047505,0.0018897515,0.0016357863,0.00014293208,0.00012590128,0.000038211092,0.000010727805,0.000762654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905884,0.000026209638,0.00029612597,0.00022491276,0.00026017148,0.00013374045],"domain_scores_gemma":[0.999621,0.00005952263,0.00007952659,0.00011234245,0.000038436054,0.00008920005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087067456,0.00012424416,0.00018311129,0.00009724332,0.000013777804,0.000012401569,0.000120366116,0.000022354501,0.000038932],"category_scores_gemma":[0.00012580324,0.00008749037,0.000059394635,0.00017970802,0.000040379364,0.000164426,0.00009323484,0.000052617885,0.000003025168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015703973,0.00025949354,0.96552235,0.00010440098,0.00022309997,0.0000386131,0.00024559244,0.000180258,0.00059678924,0.00031435557,0.0042851944,0.028072823],"study_design_scores_gemma":[0.013804795,0.0010756538,0.6767528,0.0052820942,0.00045271163,8.498546e-7,0.0010364626,0.009597334,0.035928007,0.00043759917,0.2552287,0.00040300743],"about_ca_topic_score_codex":0.000023332163,"about_ca_topic_score_gemma":0.000006591638,"teacher_disagreement_score":0.28876957,"about_ca_system_score_codex":0.00019204203,"about_ca_system_score_gemma":0.00004304652,"threshold_uncertainty_score":0.35677537},"labels":[],"label_agreement":null},{"id":"W3042528593","doi":"10.1161/circulationaha.120.047077","title":"Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Montreal Heart Institute; Libin Cardiovascular Institute of Alberta","funders":"Janssen Research and Development; American Regent; Institut de Cardiologie de Montréal; Daiichi Sankyo Europe; Servier; Universidad de Córdoba; Vifor Pharma; Universität des Saarlandes; Rigshospitalet; Universitair Medisch Centrum Groningen; Novo Nordisk; Eisai; Gentofte Hospital; University of Oxford; AstraZeneca; Amarin Corporation; Medicines Company; Intarcia Therapeutics; Univerzita Karlova v Praze; Ionis Pharmaceuticals; Deutsche Forschungsgemeinschaft; Zafgen; Universidad Nacional de Córdoba; Defense Acquisition Program Administration; Boston Scientific Corporation; Esperion Therapeutics; Alere; University of Minnesota; Saint Luke's Health System; GlaxoSmithKline; IFM Therapeutics; Cumming School of Medicine, University of Calgary; Univerzita Komenského v Bratislave; University of Toronto; University of Glasgow; Yale University; Pfizer; University of Missouri; Sahlgrenska Akademin; British Heart Foundation; Brigham and Women's Hospital; Sanofi; Rijksuniversiteit Groningen; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Dapagliflozin; Diuretic; Ejection fraction; Heart failure; Cardiology; Internal medicine; Heart failure with preserved ejection fraction; Loop diuretic; Endocrinology; Diabetes mellitus","score_opus":0.014101637257496982,"score_gpt":0.21887543676712082,"score_spread":0.20477379950962382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042528593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984372,0.000021673666,0.00006459745,0.00087022886,0.000018797364,0.00050063385,6.335017e-7,0.000021765023,0.0000644262],"genre_scores_gemma":[0.99947643,0.0000041732314,0.00022492708,0.0001781489,0.00001991666,0.0000106826055,0.0000697559,0.000008675506,0.0000073081146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995222,0.000019771467,0.000100286685,0.00018137172,0.0000976362,0.00007872466],"domain_scores_gemma":[0.9998328,0.000012806242,0.000030311761,0.00005918893,0.0000192891,0.000045601493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000033523076,0.00006980591,0.00011472956,0.00009704244,0.000017990309,0.000022421036,0.0000064258875,0.00003792962,0.0000063578673],"category_scores_gemma":[0.000030356518,0.00006287278,0.0000078386565,0.00017074772,0.000013248898,0.00025583745,0.0000086424325,0.00006156298,0.0000023862067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103971295,0.00007044899,0.99748236,0.000039033475,0.000010717652,0.0000014484964,0.00011940551,0.000051015657,0.0008790889,0.000029801437,0.000054087956,0.0011586421],"study_design_scores_gemma":[0.0025768126,0.00015926817,0.99481225,0.00006905579,0.000043814824,3.4515475e-7,0.000075622396,0.0018421082,0.000081140184,0.000020609958,0.00025946667,0.00005952633],"about_ca_topic_score_codex":0.000033795146,"about_ca_topic_score_gemma":0.00004117674,"teacher_disagreement_score":0.002670109,"about_ca_system_score_codex":0.00005151803,"about_ca_system_score_gemma":0.000006239555,"threshold_uncertainty_score":0.25638777},"labels":[],"label_agreement":null},{"id":"W3042751537","doi":"10.1016/j.ahj.2020.07.008","title":"Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Principia Biopharma; Sanofi Genzyme; Bausch Health; Intercept Pharmaceuticals; AstraZeneca; Amarin Corporation; Novo Nordisk; Asahi Group Holdings; Medicines Company; Intarcia Therapeutics; Regeneron Pharmaceuticals; Mylan; Ionis Pharmaceuticals; Boston Scientific Corporation; Abbott Vascular; Duke Clinical Research Institute; MannKind Corporation; European Commission; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Overweight; Weight loss; Diabetes mellitus; Obesity; Adverse effect; Internal medicine; Population; Disease; Placebo; Type 2 diabetes; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.016369620108538267,"score_gpt":0.24454460499523412,"score_spread":0.22817498488669585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042751537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309665,0.0002844292,0.00070896855,0.0051205195,0.000024610443,0.0005898521,8.259035e-7,0.00002293416,0.00015120977],"genre_scores_gemma":[0.9903025,0.00013538328,0.0047869384,0.004429265,0.00010635099,0.00002411471,0.0000019111192,0.000016958713,0.00019660161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903387,0.00012124004,0.00012957178,0.00018244456,0.0003247902,0.0002081054],"domain_scores_gemma":[0.99936736,0.0002436492,0.000044554814,0.00011110838,0.000028745237,0.0002045766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017713026,0.00013503572,0.0005252597,0.0000810422,0.00007048273,0.000029015293,0.000031509913,0.000013438648,0.000030853887],"category_scores_gemma":[0.000109247405,0.00008329077,0.00010071561,0.0002646659,0.00004236159,0.000055133565,0.00001689517,0.00016183523,0.000016452736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059757597,0.00020291808,0.98574847,0.00005749674,0.0009202267,0.00052026566,0.00041927764,0.00020931032,0.00018297408,0.000016131944,0.0029786418,0.008146736],"study_design_scores_gemma":[0.0027844983,0.004974534,0.98328304,0.00009210072,0.0003411278,0.00014390693,0.00015236835,0.00020590416,0.001104786,0.000009617321,0.006766961,0.0001411277],"about_ca_topic_score_codex":0.000049613944,"about_ca_topic_score_gemma":0.000019953877,"teacher_disagreement_score":0.008005609,"about_ca_system_score_codex":0.000076623684,"about_ca_system_score_gemma":0.000090483816,"threshold_uncertainty_score":0.3396499},"labels":[],"label_agreement":null},{"id":"W3043216414","doi":"10.1002/pds.5071","title":"Reporting and variability of constructing medication treatment episodes in pharmacoepidemiology studies: A methodologic systematic review using the case study of <scp>DPP</scp>‐4 inhibitors and cardiovascular outcomes","year":2020,"lang":"en","type":"review","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Pharmacoepidemiology; Mace; Medical prescription; Adverse effect; MEDLINE; Internal medicine; Pharmacology","score_opus":0.25346991375768,"score_gpt":0.4839531441368515,"score_spread":0.23048323037917146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043216414","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022250514,0.9687056,0.00014945473,0.00031900575,0.00019866574,0.008301272,0.000019562563,0.000030349885,0.000025559499],"genre_scores_gemma":[0.014922374,0.982071,0.00200669,0.00027827465,0.00005759114,0.00061130733,0.000018646191,0.000028554343,0.0000056036934],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97198844,0.020045314,0.0063210865,0.0010552488,0.00018085806,0.00040906278],"domain_scores_gemma":[0.9509117,0.04216326,0.0059585404,0.0006569136,0.00013035523,0.00017923949],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04296888,0.00072599313,0.013728137,0.00022944604,0.00015538192,0.0000037004295,0.00012004379,0.00020327875,0.000002561124],"category_scores_gemma":[0.05201721,0.00039044805,0.000718031,0.0003859223,0.0007506205,0.000070032766,0.00037264632,0.0005060102,2.0554569e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018355679,0.0003285345,0.05683333,0.7425235,0.021261448,0.00090027944,0.002371789,0.000008896663,0.0000014726943,0.00008088055,0.00004194664,0.1756296],"study_design_scores_gemma":[0.012655793,0.001688533,0.0006993944,0.41969988,0.46081442,0.015198018,0.06984602,0.0012604671,0.00001698598,0.0005829974,0.016510097,0.0010274034],"about_ca_topic_score_codex":0.00050205097,"about_ca_topic_score_gemma":0.000017416578,"teacher_disagreement_score":0.43955296,"about_ca_system_score_codex":0.00018536948,"about_ca_system_score_gemma":0.00012585954,"threshold_uncertainty_score":0.99985474},"labels":[],"label_agreement":null},{"id":"W3044494828","doi":"10.1016/j.cjca.2020.07.230","title":"The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients","year":2020,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Dapagliflozin; Empagliflozin; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Endothelial dysfunction; 2019-20 coronavirus outbreak; Cytokine storm; Exacerbation; Inflammation; Coronavirus; Intensive care medicine; Diabetes mellitus; Immunology; Internal medicine; Disease; Type 2 diabetes; Infectious disease (medical specialty); Virology; Endocrinology","score_opus":0.007537621642020768,"score_gpt":0.2113450530193609,"score_spread":0.20380743137734014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044494828","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1413765,0.006463426,0.0000984486,0.8375356,0.009570257,0.0021279012,0.00016678567,0.000015753474,0.0026452865],"genre_scores_gemma":[0.8287197,0.0004145052,0.000029498433,0.1649444,0.005240124,0.000019635014,0.00024142084,0.000051486757,0.00033926553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983063,0.00017596908,0.0005849223,0.00019677827,0.00025615335,0.00047987717],"domain_scores_gemma":[0.99818677,0.000418624,0.00041728144,0.0002425854,0.00016662171,0.0005681275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018086412,0.00024411351,0.0009666468,0.0004815485,0.00007746561,0.000021321399,0.00026379153,0.00035172154,0.000008373604],"category_scores_gemma":[0.00089965144,0.00017488291,0.0004319865,0.00015649201,0.00021761071,0.000039737304,0.00003288179,0.0009421597,0.000007812585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007828663,0.000004835783,0.08055015,0.00034409345,0.0008751669,0.007835806,0.000081994745,0.00017353114,0.0000074917193,0.000006956814,0.9058307,0.004211028],"study_design_scores_gemma":[0.0038411822,0.0009007225,0.022687633,0.00023136189,0.000665227,0.000060219038,0.000026660871,0.0000033828549,0.00002491281,0.00012804654,0.97128826,0.00014238157],"about_ca_topic_score_codex":0.0008643163,"about_ca_topic_score_gemma":0.0011605087,"teacher_disagreement_score":0.6873432,"about_ca_system_score_codex":0.0005743545,"about_ca_system_score_gemma":0.0011948191,"threshold_uncertainty_score":0.7131518},"labels":[],"label_agreement":null},{"id":"W3044947482","doi":"10.1053/j.ajkd.2020.05.014","title":"We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury","year":2020,"lang":"en","type":"letter","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"","keywords":"Medicine; Canagliflozin; Empagliflozin; Albuminuria; Renal function; Diabetic nephropathy; Kidney disease; Acute kidney injury; Diabetes mellitus; Internal medicine; Type 2 diabetes; Nephropathy; Kidney; Type 2 Diabetes Mellitus; Creatinine; Linagliptin; Urology; Endocrinology","score_opus":0.007719730762906128,"score_gpt":0.24745412017103785,"score_spread":0.23973438940813172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044947482","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006199055,0.0013516295,0.000020377574,0.9895994,0.0006904722,0.0004198057,0.0011183518,0.00006576738,0.00053514674],"genre_scores_gemma":[0.015957247,0.0039284374,0.0007372212,0.9715459,0.0048276517,0.000023003582,0.0005937021,0.00013166093,0.0022551985],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972612,0.00012879215,0.00076066534,0.0004547142,0.0008346299,0.0005599696],"domain_scores_gemma":[0.995445,0.000085085834,0.0011696664,0.00035432482,0.00017288818,0.0027730046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000070482616,0.0005967597,0.0014685012,0.00053172256,0.00010959189,0.00012738297,0.000289489,0.000109959714,0.00015559574],"category_scores_gemma":[0.0006635309,0.00047813976,0.00055767864,0.00041915715,0.0004712176,0.00016534183,0.00016572494,0.0011112328,0.0000173143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035595155,0.00012923719,0.0077226236,0.0004316722,0.0025858134,0.0057657436,0.00024822642,1.217729e-7,0.000054395434,0.0000028133886,0.93457335,0.048130035],"study_design_scores_gemma":[0.001585759,0.0027956888,0.0016271711,0.00239743,0.0076567437,0.00010677753,0.00020473912,0.000004378219,0.00004950707,0.00006930081,0.98303854,0.00046398013],"about_ca_topic_score_codex":0.00003417705,"about_ca_topic_score_gemma":1.8213267e-7,"teacher_disagreement_score":0.04846516,"about_ca_system_score_codex":0.00021635598,"about_ca_system_score_gemma":0.0015875226,"threshold_uncertainty_score":0.999767},"labels":[],"label_agreement":null},{"id":"W3045194982","doi":"10.14740/jocmr4278","title":"Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Type 2 Diabetes Mellitus; Ejection fraction; Cardiology; Heart failure; Endocrinology","score_opus":0.17244648307129815,"score_gpt":0.4300464266999058,"score_spread":0.2575999436286076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045194982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306047,0.0011144732,0.000034932924,0.0040167766,0.00024628252,0.0005095049,0.0000010658205,0.0000039572524,0.0010125402],"genre_scores_gemma":[0.9990327,0.00020626934,0.00016032375,0.00013687702,0.0004164333,0.000007760935,0.000008557202,0.000011273855,0.00001982809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962979,0.00038112316,0.0013218377,0.00020641513,0.0014973913,0.00029534692],"domain_scores_gemma":[0.99786115,0.0010522533,0.00031331924,0.00014860745,0.00033953512,0.00028513404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038435778,0.00012109065,0.0010657079,0.00035476137,0.00001967536,0.000008421618,0.00012221023,0.00009202947,0.00004779027],"category_scores_gemma":[0.0022150215,0.00007134824,0.00016501706,0.0006189618,0.00015709888,0.00013718854,0.000042049844,0.00068261835,0.000002745167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029401702,0.00072942296,0.9651962,0.00015451314,0.00033982596,0.000051162664,0.00015707075,0.0000018302287,0.000035392884,0.00003852845,0.00035188848,0.030003991],"study_design_scores_gemma":[0.008349099,0.019190926,0.9704538,0.0007721041,0.00021136236,9.021012e-8,0.00034102067,0.00010438257,0.00006196406,0.00020031672,0.0002599929,0.000054917065],"about_ca_topic_score_codex":0.0000141788,"about_ca_topic_score_gemma":0.000022754164,"teacher_disagreement_score":0.029949075,"about_ca_system_score_codex":0.00005822411,"about_ca_system_score_gemma":0.000232194,"threshold_uncertainty_score":0.2965675},"labels":[],"label_agreement":null},{"id":"W3045322820","doi":"10.1097/hco.0000000000000774","title":"Sodium–glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care","year":2020,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Heart failure; Multidisciplinary team; Multidisciplinary approach; Disease; Dapagliflozin; Primary care; Ejection fraction; Internal medicine; Cardiology; Endocrinology; Nursing; Family medicine","score_opus":0.05519478152276294,"score_gpt":0.3242765413381991,"score_spread":0.26908175981543614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045322820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005033361,0.9890468,0.000112296446,0.000016182958,0.0023980103,0.002998485,0.00021591711,0.000032004995,0.00014691237],"genre_scores_gemma":[0.01352807,0.9811643,0.000096293195,0.000006527575,0.0003558044,0.0005740567,0.0042232987,0.000047809943,0.000003846046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974731,0.00047528563,0.000688465,0.0008410678,0.00022883169,0.00029320543],"domain_scores_gemma":[0.9989657,0.00003844427,0.0001865469,0.00052246806,0.000102893704,0.00018395156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016571223,0.00050304254,0.002453639,0.00028511113,0.00006670806,0.000014509162,0.00012595653,0.00023179977,0.0000022027098],"category_scores_gemma":[0.000018994531,0.00032681765,0.00071115553,0.00033661528,0.00018606169,0.000055090273,0.00031700448,0.00040493032,0.0000029820826],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012130627,0.0000824723,0.0011450632,0.012537166,0.0015462518,0.000007293243,0.0034333547,0.000020309806,9.888969e-7,0.00001835562,0.00027218502,0.98081523],"study_design_scores_gemma":[0.0014666299,0.0006315407,0.00084835617,0.0042909347,0.0029350398,0.000052191986,0.002186337,0.000012527638,0.000007149494,0.0000011838556,0.98729753,0.00027057255],"about_ca_topic_score_codex":0.00003774177,"about_ca_topic_score_gemma":0.0000072658436,"teacher_disagreement_score":0.9870254,"about_ca_system_score_codex":0.0002763175,"about_ca_system_score_gemma":0.00009878993,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W3046040912","doi":"10.1016/j.jdiacomp.2020.107704","title":"Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis","year":2020,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; St. Michael's Hospital; Sinai Health System; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Placebo; Myocardial infarction; Stroke (engine); Dipeptidyl peptidase-4; Alogliptin; Endocrinology","score_opus":0.07210888676540886,"score_gpt":0.3105362338773174,"score_spread":0.23842734711190852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046040912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799571,0.018527808,0.00020771906,0.0010152156,0.000009700946,0.00016394838,0.000027731661,0.000004739983,0.00008601405],"genre_scores_gemma":[0.99416983,0.005086366,0.0006217883,0.00008100785,0.000012727332,0.000004768745,0.00000582495,0.0000063154653,0.000011395403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913627,0.000029619436,0.00039591242,0.00013059941,0.0002154074,0.00009220127],"domain_scores_gemma":[0.9991103,0.000081348866,0.00034041877,0.00017529973,0.00014259016,0.00015003822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022242854,0.000117767966,0.0008819188,0.0001510452,0.000035606532,0.000013731109,0.000053235388,0.000026088848,0.000012180794],"category_scores_gemma":[0.00006584032,0.00007315563,0.00042834465,0.00021869958,0.00004817049,0.00009227585,0.00007926252,0.00006910545,2.0530867e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007992801,0.00016001047,0.8145094,0.00022816223,0.17943422,0.0000022226786,0.00019842517,0.00016448622,0.0021784806,0.00014394862,0.000064582535,0.0029080617],"study_design_scores_gemma":[0.0010158444,0.00028226402,0.85347754,0.00005523043,0.1412667,0.0000011988727,0.00008879746,0.0012025482,0.0020085876,0.000091106485,0.0004382093,0.00007198344],"about_ca_topic_score_codex":0.000007791766,"about_ca_topic_score_gemma":0.0000015858318,"teacher_disagreement_score":0.03896813,"about_ca_system_score_codex":0.0000065780355,"about_ca_system_score_gemma":0.000008849089,"threshold_uncertainty_score":0.29832},"labels":[],"label_agreement":null},{"id":"W3046216547","doi":"10.1186/s12933-020-01106-4","title":"Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"Novo Nordisk","keywords":"Semaglutide; Mace; Medicine; Placebo; Myocardial infarction; Dulaglutide; Hazard ratio; Post-hoc analysis; Internal medicine; Liraglutide; Lower risk; Type 2 diabetes; Diabetes mellitus; Endocrinology; Confidence interval; Percutaneous coronary intervention","score_opus":0.010311494964445188,"score_gpt":0.2389833533647707,"score_spread":0.2286718584003255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046216547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92742497,0.0678253,0.0013574461,0.00007494072,0.00021148712,0.002642656,0.00036317925,0.000030636213,0.00006937128],"genre_scores_gemma":[0.99531466,0.00413826,0.00018242458,0.000047775975,0.000056895016,0.000103880804,0.00008367509,0.000050218965,0.000022205495],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926004,0.0032510173,0.0014202109,0.0008376483,0.001310501,0.0005802648],"domain_scores_gemma":[0.99483806,0.001049259,0.000946066,0.0022933835,0.000656607,0.00021659811],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005185532,0.00051412865,0.008598047,0.0005440233,0.00008567937,0.000007072462,0.0003835119,0.0003145098,0.000010544848],"category_scores_gemma":[0.0032884765,0.00037438382,0.018039983,0.0024151138,0.000549574,0.00004948281,0.00038173408,0.00030779597,0.0000017713679],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092581357,0.00046459696,0.14442524,0.0020592823,0.81141794,0.000056091398,0.0010913799,0.021132864,0.00053271354,0.00007667871,0.000058088048,0.017759312],"study_design_scores_gemma":[0.014357597,0.0014865348,0.47026163,0.00016092956,0.4824566,0.000001786892,0.00037472972,0.00044993692,0.02769745,0.000040854127,0.0024034637,0.00030849176],"about_ca_topic_score_codex":0.0005617518,"about_ca_topic_score_gemma":0.000014286362,"teacher_disagreement_score":0.32896134,"about_ca_system_score_codex":0.0000687957,"about_ca_system_score_gemma":0.00008302881,"threshold_uncertainty_score":0.99987084},"labels":[],"label_agreement":null},{"id":"W3046517060","doi":"10.1111/dom.14158","title":"Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPA‐REG OUTCOME</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Albuminuria; Renal function; Kidney disease; Internal medicine; Creatinine; Urology; Diabetes mellitus; Post-hoc analysis; Population; Type 2 diabetes; Endocrinology","score_opus":0.013615514011522918,"score_gpt":0.22350527547802146,"score_spread":0.20988976146649854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046517060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318535,0.012724149,0.000010052206,0.0010640094,0.00045644204,0.0020429962,0.00020408344,0.00005141454,0.00026148563],"genre_scores_gemma":[0.994409,0.0006582808,0.000081884355,0.0042800144,0.00020930203,0.00011511213,0.000105517,0.000031753734,0.000109095774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977079,0.00029039007,0.0004968794,0.0005687241,0.00058280997,0.00035327085],"domain_scores_gemma":[0.99708045,0.0010673837,0.00021255059,0.00059356145,0.00011300618,0.0009330332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022193453,0.00042427852,0.0016294216,0.00011422808,0.00012336265,0.000038996117,0.00016747108,0.00010473878,0.000009467985],"category_scores_gemma":[0.0034482477,0.00027130236,0.00058898306,0.0002547456,0.00036745484,0.00011539611,0.00020806602,0.00020426138,0.0000074415075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009771335,0.0015334614,0.9703271,0.002104489,0.010493976,0.000060076323,0.005065858,0.00000588396,0.001042632,0.0034237409,0.0027325512,0.0022331355],"study_design_scores_gemma":[0.034082614,0.0007056677,0.9273242,0.00024502174,0.009671242,7.9897376e-8,0.0002976507,0.00005131522,0.010204374,0.0008992689,0.016361635,0.00015697717],"about_ca_topic_score_codex":0.000096026924,"about_ca_topic_score_gemma":0.0000018136304,"teacher_disagreement_score":0.043002907,"about_ca_system_score_codex":0.000023400095,"about_ca_system_score_gemma":0.00009841635,"threshold_uncertainty_score":0.9999739},"labels":[],"label_agreement":null},{"id":"W3046544717","doi":"10.1111/dom.14164","title":"Cardiometabolic risk factor control in black and white people in the United States initiating sodium‐glucose co‐transporter‐2 inhibitors: A real‐world study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; Toronto General Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Type 2 diabetes; Odds ratio; Confidence interval; Diabetes mellitus; Blood pressure; Endocrinology; Triglyceride; Cholesterol","score_opus":0.013923173439054394,"score_gpt":0.24194294683143033,"score_spread":0.22801977339237595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046544717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544555,0.0010964806,0.0000062549657,0.00092155824,0.00005822539,0.0020075764,0.00017569543,0.00006573736,0.00022293178],"genre_scores_gemma":[0.9952739,0.002135173,0.000034944413,0.0020900592,0.00015503025,0.000116860734,0.00014914549,0.00002891061,0.000015998254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977016,0.00042480393,0.00049928034,0.0005007675,0.000349252,0.0005243356],"domain_scores_gemma":[0.9990719,0.00023197994,0.00015271835,0.00026830594,0.000054133885,0.00022093627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071571476,0.00036141602,0.0010155475,0.0005754336,0.00011386594,0.00011232626,0.00012722585,0.00006941396,0.000019904039],"category_scores_gemma":[0.00008935249,0.00026637354,0.00010025925,0.00126424,0.00010698829,0.0002265291,0.000057474626,0.00038752158,0.000006794611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007701185,0.0006769909,0.96869886,0.00015588813,0.00031270666,0.000048127935,0.027511647,0.000026096464,0.000094037016,0.00003153112,0.0000465723,0.0023205334],"study_design_scores_gemma":[0.008333892,0.00025252262,0.9812883,0.00005745849,0.00090693706,2.4659954e-7,0.005615685,0.001181129,0.00015439562,0.000052016716,0.0019094852,0.0002479474],"about_ca_topic_score_codex":0.001474425,"about_ca_topic_score_gemma":0.0012420482,"teacher_disagreement_score":0.021895962,"about_ca_system_score_codex":0.000021783533,"about_ca_system_score_gemma":0.000024509876,"threshold_uncertainty_score":0.99997884},"labels":[],"label_agreement":null},{"id":"W3046814568","doi":"10.1161/circulationaha.119.044775","title":"Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Myocardial infarction; Internal medicine; Hazard ratio; Stroke (engine); Kidney disease; Diabetes mellitus; Cardiology; Mace; Type 2 diabetes; Percutaneous coronary intervention; Endocrinology; Confidence interval","score_opus":0.010148413958035977,"score_gpt":0.22007541838626257,"score_spread":0.2099270044282266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046814568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99795675,0.00019587271,0.000019550856,0.0011303438,0.000020256168,0.0005489782,0.000006349093,0.000016794795,0.00010512688],"genre_scores_gemma":[0.9991766,0.000018490011,0.00010912628,0.0005373534,0.000015035896,0.000020280724,0.000089067245,0.0000106289235,0.000023394163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994613,0.000019888861,0.00010479416,0.0002049458,0.000106158106,0.00010289591],"domain_scores_gemma":[0.99969786,0.000008744732,0.000024756773,0.00007383909,0.000012958387,0.00018180875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003369127,0.000098814286,0.00019883733,0.00006137959,0.000018540968,0.000025065101,0.000010398784,0.000023715731,0.0000054844068],"category_scores_gemma":[0.00003153909,0.000079634236,0.000013378028,0.000069962734,0.000028910492,0.000126944,0.000022084896,0.000041047515,7.551396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017799261,0.00007517675,0.9960747,0.00008908788,0.00004590619,0.000005754102,0.00042408306,0.000015897867,0.00001580651,0.000026226991,0.000022995115,0.0030263918],"study_design_scores_gemma":[0.003779118,0.00012350564,0.99388283,0.000062391024,0.00011182084,7.2255474e-8,0.000040252555,0.0017691732,0.0000015073467,0.00002350078,0.000120987504,0.00008483415],"about_ca_topic_score_codex":0.000012244675,"about_ca_topic_score_gemma":0.000006054764,"teacher_disagreement_score":0.0036011252,"about_ca_system_score_codex":0.000032086275,"about_ca_system_score_gemma":0.000013925569,"threshold_uncertainty_score":0.32473898},"labels":[],"label_agreement":null},{"id":"W3046891294","doi":"10.1111/dom.14160","title":"Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Semaglutide; Liraglutide; Medicine; Type 2 diabetes; Dulaglutide; Body mass index; Internal medicine; Lixisenatide; Placebo; Glucagon-like peptide 1 receptor; Overweight; Diabetes mellitus; Myocardial infarction; Glucagon-like peptide-1; Endocrinology; Receptor; Agonist","score_opus":0.013947813844310757,"score_gpt":0.24224426339219243,"score_spread":0.22829644954788167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046891294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658842,0.03151638,0.0000042172333,0.00034692266,0.0002766135,0.0016655192,0.0001102137,0.000046724857,0.0001492244],"genre_scores_gemma":[0.9942015,0.004243728,0.00017571097,0.0006241037,0.00013316248,0.000065464206,0.000042608368,0.000046039808,0.000467693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652517,0.00055688113,0.00084173644,0.0007677425,0.0005574668,0.00075099943],"domain_scores_gemma":[0.9966143,0.0019485994,0.00042280735,0.00049993687,0.00015937355,0.00035498827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018103225,0.0005531008,0.0023654425,0.0001936087,0.00019321349,0.00009250903,0.00017992886,0.0002541513,0.000001019505],"category_scores_gemma":[0.004985674,0.00039066095,0.00032960047,0.0005142483,0.0005849626,0.00018524477,0.00036437338,0.00035821053,0.0000018300808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001377183,0.0004969835,0.95150787,0.0048871282,0.004490419,0.00003130803,0.0077880733,0.000031824973,0.020593803,0.0004010768,0.0016983775,0.007935399],"study_design_scores_gemma":[0.009338338,0.0004831378,0.8801148,0.00039765637,0.0019521591,6.148992e-7,0.0014734084,0.00008663392,0.08579885,0.0002936402,0.019937087,0.00012368806],"about_ca_topic_score_codex":0.000107812055,"about_ca_topic_score_gemma":0.000017454706,"teacher_disagreement_score":0.0713931,"about_ca_system_score_codex":0.000032424825,"about_ca_system_score_gemma":0.00006855882,"threshold_uncertainty_score":0.9998545},"labels":[],"label_agreement":null},{"id":"W3047040213","doi":"10.2337/dc20-0267","title":"Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Memorial University of Newfoundland; University of British Columbia; University of Manitoba; Institut National d'Excellence en Santé et en Services Sociaux; Health Sciences Centre; McGill University; Institute for Clinical Evaluative Sciences; Saskatchewan Health Quality Council; Sinai Health System; Jewish General Hospital; Sunnybrook Health Science Centre; University of Toronto; Manitoba Health","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Observational study; Amputation; Internal medicine; Diabetes mellitus; Cohort study; Dipeptidyl peptidase-4; Propensity score matching; Proportional hazards model; Type 2 diabetes; Confidence interval; Surgery; Endocrinology","score_opus":0.020600533883989927,"score_gpt":0.24502641037848188,"score_spread":0.22442587649449197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047040213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960606,0.00074640405,0.0000067467163,0.0014349327,0.0000798394,0.0013239852,0.000053705426,0.00003668481,0.00025707253],"genre_scores_gemma":[0.9981028,0.000028023218,0.00019431258,0.0012489324,0.00009938542,0.00010175924,0.00017447617,0.000015662006,0.000034679102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990847,0.000054042368,0.00025170392,0.00021205464,0.0002535209,0.00014398048],"domain_scores_gemma":[0.9994361,0.00010680458,0.00010015046,0.00014856744,0.00012749099,0.000080906284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009702359,0.00013912843,0.00028727352,0.000034784298,0.000061464154,0.000018254417,0.000052725838,0.00002922532,0.000035288012],"category_scores_gemma":[0.00005418458,0.00008945246,0.000104915925,0.00013529029,0.00010058626,0.000072924384,0.000042643733,0.000087287684,0.000016185102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015781418,0.00016499973,0.98201346,0.00017589644,0.0004911745,0.0000042832626,0.011001987,0.000016116108,0.00007379799,0.000042357744,0.0003225429,0.005535563],"study_design_scores_gemma":[0.010674553,0.00059813005,0.97731936,0.00005280652,0.0012261646,3.3964636e-8,0.0068420894,0.000706998,0.001066035,0.000025568643,0.0013904687,0.00009780407],"about_ca_topic_score_codex":0.0000109906305,"about_ca_topic_score_gemma":0.000010155304,"teacher_disagreement_score":0.0105167385,"about_ca_system_score_codex":0.000016814889,"about_ca_system_score_gemma":0.000016649205,"threshold_uncertainty_score":0.36477652},"labels":[],"label_agreement":null},{"id":"W3047329772","doi":"10.1016/j.ahj.2020.07.014","title":"Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute on Aging; Bayer Canada; Johnson and Johnson; Servier; Roche; Agence Nationale de la Recherche; Boston Scientific Corporation; European Society of Cardiology; Alberta Innovates - Health Solutions; National Institutes of Health; Canadian Cardiovascular Society; Boehringer Ingelheim; Novartis; AstraZeneca Canada","keywords":"Randomization; Medicine; Acute coronary syndrome; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Type 2 diabetes; Cardiology; Randomized controlled trial; Myocardial infarction; Endocrinology","score_opus":0.01025975193420081,"score_gpt":0.24273449063894934,"score_spread":0.23247473870474852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047329772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990339,0.00013384511,0.000023637751,0.00047598165,0.000033844888,0.00023346693,0.0000021548262,0.000010490799,0.000052675754],"genre_scores_gemma":[0.9970836,0.000059813818,0.0017433186,0.0010310881,0.000021350419,0.000005585442,0.000022766213,0.000015214887,0.000017232927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992912,0.00004741684,0.00019183061,0.000110061796,0.00019683111,0.00016266777],"domain_scores_gemma":[0.99959475,0.000019199257,0.00009310225,0.00008041985,0.00006561418,0.00014691782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007056173,0.000089712674,0.00034358195,0.00008329369,0.000019277637,0.000010938916,0.000033540502,0.0000118834905,0.00014318075],"category_scores_gemma":[0.000013567341,0.000065063796,0.00003977924,0.0002471134,0.000060447263,0.00013629308,0.000015541988,0.00009196259,0.0000090347285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021581396,0.00021574109,0.9887994,0.00001655451,0.00022434082,0.000073424635,0.00021954847,0.000026502215,0.000066269524,8.0847144e-7,0.0001438163,0.008055483],"study_design_scores_gemma":[0.0053693545,0.0063039674,0.9873426,0.00008544048,0.0002385921,0.000009237824,0.00006917473,0.000215371,0.00007609834,0.0000031887062,0.00021315564,0.0000738428],"about_ca_topic_score_codex":0.000004889005,"about_ca_topic_score_gemma":9.612305e-7,"teacher_disagreement_score":0.00798164,"about_ca_system_score_codex":0.000031617397,"about_ca_system_score_gemma":0.000028895007,"threshold_uncertainty_score":0.26532248},"labels":[],"label_agreement":null},{"id":"W3048431661","doi":"10.3390/ijms21165756","title":"The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Diabetes Canada; Boehringer Ingelheim","keywords":"Linagliptin; Dipeptidyl peptidase-4; Pharmacology; Saxagliptin; Endocrinology; Nitric oxide; Internal medicine; Sitagliptin; Chemistry; Type 2 diabetes; Biology; Diabetes mellitus; Medicine","score_opus":0.02059333973251631,"score_gpt":0.28455742813935003,"score_spread":0.2639640884068337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048431661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98296815,0.00040005328,0.000669015,0.014771796,0.00019475727,0.00028487702,0.0000052341406,0.000004754083,0.00070139044],"genre_scores_gemma":[0.99814916,0.00014222866,0.0006207173,0.0008804691,0.00008415072,0.00000670649,0.0000015054102,0.000005370103,0.00010971703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983419,0.000068801375,0.00030962584,0.00014003183,0.000992591,0.00014704642],"domain_scores_gemma":[0.9991965,0.00014186792,0.00030880832,0.00007442895,0.00020376302,0.0000745952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005573347,0.000092590424,0.00017303173,0.00006264036,0.00009605832,0.000116827076,0.0002723327,0.000015903992,0.000015964848],"category_scores_gemma":[0.00013531376,0.000047253834,0.000084316795,0.00014905323,0.00017494391,0.00019470463,0.000066903085,0.000094440446,0.000002226577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049307803,0.00032660607,0.025498403,0.000030023684,0.0006211519,0.00033064128,0.005464339,0.002868925,0.94120276,0.0008619176,0.0009811997,0.01688326],"study_design_scores_gemma":[0.0026589448,0.0039635585,0.010174145,0.0006678933,0.000110100256,0.000023369032,0.0025712221,0.0002741983,0.9711997,0.000098594,0.008114761,0.00014353782],"about_ca_topic_score_codex":0.000014058925,"about_ca_topic_score_gemma":0.00006553986,"teacher_disagreement_score":0.029996924,"about_ca_system_score_codex":0.00015624375,"about_ca_system_score_gemma":0.00011775698,"threshold_uncertainty_score":0.19269554},"labels":[],"label_agreement":null},{"id":"W3049028410","doi":"10.1002/alz.12161","title":"Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role <i>APOE</i> carrier status","year":2020,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health; Health Sciences Centre; University of Ottawa; Toronto Dementia Research Alliance; University of Toronto; Institute for Clinical Evaluative Sciences; Heart and Stroke Foundation; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre","funders":"National Institute on Aging; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Wechsler Memory Scale; Dementia; Cognitive decline; Type 2 diabetes; Apolipoprotein E; Diabetes mellitus; Disease; Alzheimer's disease; Medicine; Cognition; Episodic memory; Metformin; Wechsler Adult Intelligence Scale; Psychology; Psychiatry; Internal medicine; Endocrinology","score_opus":0.03787480293801679,"score_gpt":0.2411757358441986,"score_spread":0.2033009329061818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049028410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558363,0.03937978,0.00001639377,0.0021991108,0.00003128965,0.002100975,0.00006051275,0.00003520271,0.00034043935],"genre_scores_gemma":[0.99777305,0.00045107157,0.00072814734,0.00062178035,0.000063210806,0.0001376415,0.00017849742,0.000031314466,0.000015297073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985854,0.000167295,0.00033481178,0.00027289733,0.0003536125,0.00028600357],"domain_scores_gemma":[0.9987701,0.00051824347,0.000168459,0.00022194779,0.00011071475,0.00021051036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037115213,0.000225196,0.0004177959,0.00006795991,0.00013813972,0.00005593624,0.00006928237,0.000042744447,0.000055169978],"category_scores_gemma":[0.00012011552,0.000100018995,0.000039430728,0.00041877903,0.00039157944,0.00030887916,0.00013757827,0.00017166491,0.0000027267597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01033266,0.00010359093,0.9514142,0.000035031466,0.016291479,0.000013417849,0.0018861638,0.00002797184,0.0000108294735,0.0001507856,0.000501226,0.019232612],"study_design_scores_gemma":[0.045925114,0.0021659343,0.7128052,0.00028719526,0.21567586,0.000004311512,0.0027288133,0.001676278,0.0041071274,0.00018337747,0.013873221,0.0005675713],"about_ca_topic_score_codex":0.00020816184,"about_ca_topic_score_gemma":0.0008467964,"teacher_disagreement_score":0.23860903,"about_ca_system_score_codex":0.000004700396,"about_ca_system_score_gemma":0.00012081261,"threshold_uncertainty_score":0.4078656},"labels":[],"label_agreement":null},{"id":"W3049266278","doi":"10.1210/clinem/dgaa534","title":"Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis","year":2020,"lang":"en","type":"review","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico","keywords":"Mace; Medicine; Randomized controlled trial; Internal medicine; Clinical endpoint; Type 2 diabetes; Meta-analysis; Type 2 Diabetes Mellitus; Diabetes mellitus; Heart failure; Adverse effect; Kidney disease; Relative risk; Intensive care medicine; Confidence interval; Endocrinology; Percutaneous coronary intervention; Myocardial infarction","score_opus":0.17979363646731752,"score_gpt":0.42649151365221116,"score_spread":0.24669787718489364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049266278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020465563,0.99316907,0.00010408516,0.0010437908,0.0011318029,0.0041269534,0.000047854483,0.000020677564,0.00015110649],"genre_scores_gemma":[0.000790193,0.99607563,0.0008646842,0.0014304153,0.00047580694,0.00008206854,0.00009329776,0.000054511776,0.0001334053],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97948563,0.0074664825,0.010472604,0.00076117984,0.0012388345,0.0005752389],"domain_scores_gemma":[0.9846907,0.0038021489,0.008835686,0.0017702972,0.0004589384,0.00044218078],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.006556821,0.00088236143,0.028918946,0.0011784632,0.000073493386,0.00003458612,0.00084768364,0.00032887864,0.0004148183],"category_scores_gemma":[0.0011459701,0.00043891356,0.018822297,0.002443249,0.0004869236,0.00006847533,0.00033220436,0.0014690749,0.000044856657],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002823414,0.0014739045,0.000028648776,0.10003188,0.80344003,0.00030213915,0.000010494342,0.000011176765,2.6318657e-8,0.000119972814,0.0006290193,0.09112928],"study_design_scores_gemma":[0.007625451,0.0018553166,0.00004975221,0.011898454,0.774412,0.000009368741,0.000013758793,0.000038179493,4.2859827e-7,0.000012186833,0.2038725,0.00021262837],"about_ca_topic_score_codex":0.0000031030079,"about_ca_topic_score_gemma":0.0000012242435,"teacher_disagreement_score":0.20324348,"about_ca_system_score_codex":0.00005059898,"about_ca_system_score_gemma":0.00019141531,"threshold_uncertainty_score":0.9998063},"labels":[],"label_agreement":null},{"id":"W3079504159","doi":"10.1038/s41598-020-70708-5","title":"Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Servier; Deutsche Forschungsgemeinschaft","keywords":"Empagliflozin; Heart failure; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Blood pressure; Ejection fraction; Diabetic cardiomyopathy; Blood sugar; Type 2 diabetes; Type 2 Diabetes Mellitus; Endocrinology; Cardiomyopathy","score_opus":0.012536587252699499,"score_gpt":0.21119444045889668,"score_spread":0.1986578532061972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3079504159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756247,0.00023229732,0.000018462535,0.0012655128,0.00016704656,0.00069464976,0.0000029085777,0.000019391122,0.00003726995],"genre_scores_gemma":[0.99784756,0.000003845158,0.0017497437,0.00015585982,0.0000058567352,0.0000137041425,0.00003862896,0.000012823908,0.00017199777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986871,0.000016862927,0.00035958973,0.00045375602,0.00029903336,0.00018365408],"domain_scores_gemma":[0.99932194,0.00003070449,0.00015039055,0.00025173769,0.00006863625,0.00017660415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003093219,0.00013244495,0.0004291001,0.00013240369,0.000035193563,0.000026745422,0.00003299359,0.000050438906,0.000006348985],"category_scores_gemma":[0.00018362947,0.00010895306,0.000039600167,0.00028465767,0.000121749516,0.00009299363,0.00011479032,0.0000666912,4.5962773e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019634559,0.00033492854,0.07470046,0.0004758604,0.000035202185,0.000027342532,0.00035808035,0.000015022147,0.92007023,0.000010029598,0.0038275118,0.00012571811],"study_design_scores_gemma":[0.0029862248,0.0005842167,0.051883135,0.00035217596,0.000216371,0.00000375581,0.00013099107,0.018146854,0.92472225,0.00033204595,0.0004662757,0.00017570335],"about_ca_topic_score_codex":0.000015960552,"about_ca_topic_score_gemma":0.000004570284,"teacher_disagreement_score":0.022817327,"about_ca_system_score_codex":0.000017059068,"about_ca_system_score_gemma":0.000057858655,"threshold_uncertainty_score":0.4442977},"labels":[],"label_agreement":null},{"id":"W3080635855","doi":"10.1136/bmj.m2812","title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto","funders":"National Institute on Aging","keywords":"Hazard ratio; Medicine; Canagliflozin; Amputation; Confidence interval; Internal medicine; Cohort; Cohort study; Rate ratio; Propensity score matching; Population; Proportional hazards model; Lower risk; Surgery; Physical therapy; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.019964513738874708,"score_gpt":0.28329029014436047,"score_spread":0.26332577640548577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080635855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675745,0.00036272604,0.0006373046,0.00007155229,0.000018867959,0.001700446,0.00006954905,0.000013910572,0.000368198],"genre_scores_gemma":[0.99895984,0.000106523876,0.0007047841,0.000024369307,0.00002514993,0.000075791424,0.00007298843,0.000009983695,0.000020575397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911135,0.00005739893,0.00022699006,0.00020195662,0.0003017257,0.000100564546],"domain_scores_gemma":[0.9994881,0.000041083276,0.00012397538,0.00023928519,0.00006300497,0.00004453556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046825944,0.00009139901,0.00035816937,0.0000468203,0.000024955754,0.0000068300224,0.000034944318,0.000014181477,0.0000037011573],"category_scores_gemma":[0.00015802048,0.00007027431,0.000043608918,0.00021624596,0.000055718527,0.00007145102,0.00004978862,0.000054344913,9.505665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012683122,0.0001477376,0.9918323,0.00011522693,0.0018051685,0.00010217943,0.001722712,0.0010572704,0.0000051169354,0.00002711423,0.00010109207,0.002957211],"study_design_scores_gemma":[0.0028756524,0.0004607205,0.9923197,0.000031359916,0.0012808891,5.323076e-7,0.0021828103,0.0003236801,0.00016437755,0.000019635354,0.00027653642,0.000064105916],"about_ca_topic_score_codex":0.0151320165,"about_ca_topic_score_gemma":0.015255652,"teacher_disagreement_score":0.0028931051,"about_ca_system_score_codex":0.000018520404,"about_ca_system_score_gemma":0.000030341273,"threshold_uncertainty_score":0.9914263},"labels":[],"label_agreement":null},{"id":"W3081300539","doi":"10.1111/dom.14179","title":"Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from <scp>DECLARE‐TIMI</scp> 58","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Dapagliflozin; Medicine; TIMI; Post-hoc analysis; Baseline (sea); Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.02102524981586148,"score_gpt":0.2515692520510866,"score_spread":0.23054400223522512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081300539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803068,0.015950589,0.00029678075,0.0012015639,0.00016965566,0.00055864424,0.00048432837,0.00020996522,0.0008216666],"genre_scores_gemma":[0.9863691,0.0013293915,0.001977412,0.007829788,0.00033997206,0.00005262208,0.0013181291,0.000067474626,0.00071611925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760145,0.00009291782,0.0003811901,0.0007441799,0.0005410142,0.0006392663],"domain_scores_gemma":[0.9984312,0.00022118079,0.00014604484,0.00043626418,0.00013635124,0.00062892656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021435836,0.00052921515,0.0012320604,0.00015040748,0.00017408264,0.00013407253,0.00019523264,0.0001275018,0.00011120624],"category_scores_gemma":[0.00026570554,0.0003934031,0.00027817363,0.00036645288,0.0001253657,0.00031759893,0.00020195896,0.0002494096,0.00006484807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020699106,0.0014064468,0.883466,0.00046360595,0.010452869,0.00025693802,0.0018759442,0.00006265289,0.03982001,0.00011483678,0.03511578,0.026757894],"study_design_scores_gemma":[0.0076301536,0.0005861239,0.7252916,0.00015951891,0.0069991765,0.0000011392663,0.00066048146,0.00061499386,0.070545316,0.00004675054,0.18704718,0.00041757495],"about_ca_topic_score_codex":0.00011644886,"about_ca_topic_score_gemma":0.0000150649785,"teacher_disagreement_score":0.15817444,"about_ca_system_score_codex":0.000033465545,"about_ca_system_score_gemma":0.000042005162,"threshold_uncertainty_score":0.99985176},"labels":[],"label_agreement":null},{"id":"W3081508721","doi":"10.1002/alz.042909","title":"Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Semaglutide; Liraglutide; Medicine; Post-hoc analysis; Dementia; Placebo; Pooled analysis; Internal medicine; Type 2 diabetes; Population; Adverse effect; Diabetes mellitus; Disease; Meta-analysis; Endocrinology; Alternative medicine","score_opus":0.011713113141355041,"score_gpt":0.2377073595861554,"score_spread":0.22599424644480037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081508721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834487,0.014627555,0.000021172149,0.00060868287,0.0000425623,0.00090594223,0.00002964772,0.000036391884,0.00027938627],"genre_scores_gemma":[0.995778,0.00008744886,0.0027133916,0.001151044,0.000019354009,0.000030983156,0.00018327423,0.000030240175,0.0000062467716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982294,0.00008019048,0.00041166204,0.0004710078,0.00042956875,0.00037818708],"domain_scores_gemma":[0.9989871,0.000039697,0.0001803398,0.00032653954,0.00021383057,0.00025252253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002203329,0.0002630683,0.00056719396,0.00033169537,0.00004783496,0.000025424972,0.000113211165,0.000044316304,0.00027568892],"category_scores_gemma":[0.00005644272,0.0002116425,0.00010509653,0.0011633512,0.000049584214,0.00009490795,0.00016902796,0.0000910378,0.0000482075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004696927,0.00028203116,0.8876666,0.000019930558,0.09202397,0.0000047610283,0.00027159817,0.00009790643,0.00017872255,0.000012138385,0.00044059101,0.018532066],"study_design_scores_gemma":[0.003110986,0.002324063,0.81096435,0.00002905314,0.18083812,2.8524958e-8,0.000047787824,0.00039780114,0.0014884542,0.000007763172,0.0006062747,0.00018531767],"about_ca_topic_score_codex":0.000095391326,"about_ca_topic_score_gemma":0.00012479583,"teacher_disagreement_score":0.08881415,"about_ca_system_score_codex":0.000008685262,"about_ca_system_score_gemma":0.000032108983,"threshold_uncertainty_score":0.8630531},"labels":[],"label_agreement":null},{"id":"W3081745704","doi":"10.1093/ndt/gfaa234","title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Janssen Pharmaceuticals; Defense Acquisition Program Administration; Sanofi Genzyme; Merck Sharp and Dohme; Satellite Healthcare; Alexion Pharmaceuticals; University of Glasgow; Steno Diabetes Center Copenhagen; Menarini Group; Novo Nordisk; Omeros Corporation; Astellas Pharma; Cytokinetics; Fresenius Medical Care North America; Daiichi-Sankyo; ReCor Medical; Alnylam Pharmaceuticals; Servier; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; World Health Organization; Ultragenyx Pharmaceutical; GlaxoSmithKline; Amgen; Angion; Pfizer; CSL Behring; AstraZeneca; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Kidney disease; Adverse effect; Internal medicine; Baseline (sea); Intensive care medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.015261348394907536,"score_gpt":0.26614665982613467,"score_spread":0.2508853114312271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081745704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910407,0.00014854634,0.0010433776,0.0065703844,0.00007733527,0.0009523918,0.00005555349,0.000031977954,0.000079700396],"genre_scores_gemma":[0.9955042,0.0020058234,0.0001140594,0.001319134,0.00008745471,0.00009255219,0.0007491732,0.000011174634,0.00011642694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894726,0.00014061139,0.00039738233,0.00021678387,0.00014277545,0.0001552118],"domain_scores_gemma":[0.9993967,0.00015473942,0.00013266518,0.00014066472,0.00003222468,0.00014304541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024018312,0.00012789313,0.0003499865,0.000093151786,0.000044267927,0.0000056609115,0.000052570427,0.000055142053,0.00003962324],"category_scores_gemma":[0.00011364554,0.00009336831,0.0000968784,0.00016068884,0.00007888271,0.000082912324,0.000009896359,0.00007614311,0.0000073354336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18163806,0.0020565386,0.6295064,0.0030321619,0.004261134,0.0003803171,0.004275197,0.00027680077,0.024852216,0.0025206346,0.0011420571,0.14605848],"study_design_scores_gemma":[0.083958514,0.0022828742,0.8939109,0.00011549981,0.006780822,0.0000012402198,0.000077632736,0.005689661,0.0005633531,0.00022164943,0.006174235,0.00022365301],"about_ca_topic_score_codex":0.000013049722,"about_ca_topic_score_gemma":0.000068725756,"teacher_disagreement_score":0.26440448,"about_ca_system_score_codex":0.000037991624,"about_ca_system_score_gemma":0.000091882896,"threshold_uncertainty_score":0.3807449},"labels":[],"label_agreement":null},{"id":"W3081830235","doi":"10.1056/nejmoa2022190","title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5037,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Heart failure; Medicine; Ejection fraction; Cardiology; Diabetes mellitus; Internal medicine; Benzhydryl compounds; Broad spectrum; Heart failure with preserved ejection fraction; Type 2 diabetes; Endocrinology; Chemistry","score_opus":0.014158844999921186,"score_gpt":0.23656121702678204,"score_spread":0.22240237202686086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081830235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8578954,0.0047080615,0.00026684202,0.13618377,0.00007706907,0.00021220805,4.772132e-7,0.000011728098,0.0006444458],"genre_scores_gemma":[0.9937358,0.00021533805,0.0022043986,0.0026060075,0.001059465,0.0000010682727,0.0000025165864,0.000012721308,0.00016271748],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989972,0.000039133956,0.00027871103,0.00011685072,0.00042640112,0.00014171278],"domain_scores_gemma":[0.99938554,0.00005282484,0.000074556956,0.000103944745,0.00005141409,0.0003316967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037303675,0.00012786873,0.0006850854,0.0001325831,0.0000137883235,0.0000064338856,0.00004463607,0.000028573251,0.00006264349],"category_scores_gemma":[0.00011476944,0.00006717023,0.00008088743,0.00015762368,0.000051028725,0.000067943954,0.00001622957,0.00020464255,0.0000021605654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015498847,0.00010958206,0.84949106,0.00017157632,0.002645425,0.0023922387,0.0026037002,0.00012587728,0.00078588084,0.00009619696,0.044263884,0.09576467],"study_design_scores_gemma":[0.1568662,0.0071080225,0.23660657,0.0008757188,0.0019340118,0.00061518804,0.00068089773,0.000037855236,0.0002545254,0.00008782508,0.59477645,0.0001567163],"about_ca_topic_score_codex":0.000038448285,"about_ca_topic_score_gemma":0.000026920607,"teacher_disagreement_score":0.6128845,"about_ca_system_score_codex":0.0000216377,"about_ca_system_score_gemma":0.00005321517,"threshold_uncertainty_score":0.27391225},"labels":[],"label_agreement":null},{"id":"W3083153332","doi":"10.1161/circulationaha.120.047480","title":"Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Montreal Heart Institute; Libin Cardiovascular Institute of Alberta","funders":"American Regent; Cumming School of Medicine, University of Calgary; Institut de Cardiologie de Montréal; Servier; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; Vifor Pharma; Universität des Saarlandes; Universitair Medisch Centrum Groningen; Novo Nordisk; Daiichi-Sankyo; Gentofte Hospital; Semmelweis Egyetem; University of Minnesota; Saint Luke's Health System; Universidade de São Paulo; AstraZeneca; Amarin Corporation; Uniwersytet Łódzki; Intarcia Therapeutics; Regeneron Pharmaceuticals; Deutsche Forschungsgemeinschaft; Zafgen; Universidad Nacional de Córdoba; Boston Scientific Corporation; Alnylam Pharmaceuticals; Alere; University of Toronto; University of New South Wales; University of Glasgow; Yale University; Pfizer; University of Missouri; British Heart Foundation; Eisai; Cytokinetics; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; University of Missouri-Kansas City; GlaxoSmithKline; Amgen; Eli Lilly and Company; Rijksuniversiteit Groningen; Bristol-Myers Squibb","keywords":"Medicine; Ejection fraction; Dapagliflozin; Heart failure; Cardiology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.008704888395432975,"score_gpt":0.22996762098041076,"score_spread":0.22126273258497778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083153332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988148,0.000009408758,0.00017050863,0.00015603397,0.00003404525,0.0005718926,0.0000014273577,0.000019891912,0.00022196748],"genre_scores_gemma":[0.9996818,7.096329e-7,0.00014882258,0.000040571438,0.000023772467,0.000009783021,0.00008303711,0.000008344709,0.0000032007654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994914,0.000033364973,0.0001226727,0.00012770381,0.00016974016,0.000055137243],"domain_scores_gemma":[0.9997099,0.00003000113,0.00010194501,0.00007350536,0.000048398666,0.000036218644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005564805,0.00007103186,0.00016489808,0.00006384068,0.00001889043,0.0000026314647,0.000008118922,0.000031600666,0.00000889933],"category_scores_gemma":[0.00004023916,0.000054788776,0.000026901667,0.00011974336,0.000013586343,0.00006704067,0.000006274175,0.000042248932,0.0000022747872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006483787,0.000098121556,0.98723125,0.00022891889,0.000060525235,2.1827732e-7,0.000110589724,0.0002766278,0.005806373,0.00001985593,0.000056340905,0.005462768],"study_design_scores_gemma":[0.002263692,0.0030832675,0.9745073,0.00014113332,0.00021574998,8.842992e-8,0.000033335396,0.0009778138,0.018573776,0.0000029127723,0.00015337305,0.000047610236],"about_ca_topic_score_codex":0.0000044951876,"about_ca_topic_score_gemma":3.8406085e-7,"teacher_disagreement_score":0.012767402,"about_ca_system_score_codex":0.00003324835,"about_ca_system_score_gemma":0.000004495071,"threshold_uncertainty_score":0.22342214},"labels":[],"label_agreement":null},{"id":"W3083452684","doi":"10.1161/jaha.120.016976","title":"Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Institutes of Health; Astellas Pharma; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Omeros Corporation; Gilead Sciences; Novo Nordisk; Sanofi; Dialysis Clinics; AstraZeneca; Eli Lilly and Company","keywords":"Post-hoc analysis; Albuminuria; Medicine; EMPA; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Type 2 diabetes; Term (time); Post hoc; Diabetic nephropathy; Outcome (game theory); Endocrinology","score_opus":0.016491099555276594,"score_gpt":0.2714831594105788,"score_spread":0.2549920598553022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083452684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948649,0.0011503423,4.0661394e-7,0.003635137,0.00006562032,0.00026469323,0.000010643925,0.0000017257405,0.0000065203685],"genre_scores_gemma":[0.9986575,0.000987867,0.00004981249,0.00022973235,0.000045723657,0.0000023010311,0.00000113749,0.000005684248,0.000020239855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987106,0.00030028215,0.00040407182,0.00008956994,0.0003824904,0.00011301886],"domain_scores_gemma":[0.9990096,0.0002034347,0.0005211288,0.00013515659,0.000088849076,0.00004181504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009003788,0.00008649886,0.0010303535,0.00017606802,0.000018592496,0.000008670655,0.00006888465,0.000027499456,0.0000024961262],"category_scores_gemma":[0.00061376195,0.000048202663,0.00041927447,0.0007030185,0.000051424337,0.000045360648,0.00005343687,0.00013135714,1.0896323e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077114446,0.00008086014,0.9889701,0.000017302498,0.0052080504,0.0000010867061,0.00063844124,0.00007063267,0.0003803646,6.990597e-7,0.000031517953,0.0038298066],"study_design_scores_gemma":[0.0037249245,0.0008844143,0.9892711,0.000040136383,0.0052750623,1.7899559e-7,0.00024636398,0.000093426424,0.00029396583,0.000005175427,0.00012452433,0.000040732884],"about_ca_topic_score_codex":0.00014511975,"about_ca_topic_score_gemma":0.00018369204,"teacher_disagreement_score":0.0037925916,"about_ca_system_score_codex":0.00011779188,"about_ca_system_score_gemma":0.000021590049,"threshold_uncertainty_score":0.19656475},"labels":[],"label_agreement":null},{"id":"W3083625016","doi":"10.1016/j.jcjd.2020.08.108","title":"Association of Glucagon With Obesity, Glycemic Control and Renal Function in Adults With Type 2 Diabetes Mellitus","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Postprandial; Glycemic; Endocrinology; Glucagon; Hyperglucagonemia; Diabetes mellitus; Type 2 Diabetes Mellitus; Renal function; Waist; Abdominal obesity; Obesity; Insulin","score_opus":0.004682126018457825,"score_gpt":0.17557406638583828,"score_spread":0.17089194036738045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083625016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953313,0.0023724686,0.0000056678523,0.0016900442,0.000057568566,0.00023837888,0.00000906824,0.0000052534238,0.0002902849],"genre_scores_gemma":[0.99910426,0.00004371035,0.00010796264,0.0005857891,0.00008722834,0.0000031447241,0.000011627795,0.0000149404605,0.000041335876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999105,0.00003534578,0.00025711316,0.00012312314,0.00020229662,0.00027714184],"domain_scores_gemma":[0.9989557,0.000064308624,0.0002788274,0.00007037708,0.00022937855,0.00040138015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015879782,0.00012815952,0.00039624466,0.00021582659,0.000027626944,0.000020866828,0.000052013187,0.00005755462,0.00002900952],"category_scores_gemma":[0.00009131977,0.00009402432,0.000037598278,0.00027773654,0.00004758722,0.00014383474,0.0000048865104,0.00014891937,0.0000020270293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037546273,0.00003845017,0.99438405,0.0001624568,0.00055666943,0.000017833905,0.00027953868,0.000033075215,0.0005948377,0.000022355885,0.0005346394,0.003000639],"study_design_scores_gemma":[0.013198576,0.011533451,0.9681658,0.0013242915,0.0012306767,0.0000011357229,0.0002726751,0.00031244103,0.0021248334,0.000057168007,0.0015904219,0.00018849825],"about_ca_topic_score_codex":0.00014935635,"about_ca_topic_score_gemma":0.0037534009,"teacher_disagreement_score":0.02621821,"about_ca_system_score_codex":0.00016639083,"about_ca_system_score_gemma":0.0002908797,"threshold_uncertainty_score":0.38342005},"labels":[],"label_agreement":null},{"id":"W3085703194","doi":"10.1016/s2213-8587(20)30230-8","title":"Diabetes in ageing: pathways for developing the evidence base for clinical guidance","year":2020,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Aging; National Institutes of Health; MannKind Corporation; Eisai; Insulet Corporation; Amarin Corporation; Novo Nordisk; Dexcom; Intarcia Therapeutics; Bigfoot Biomedical; Sanofi; Merck; GlaxoSmithKline; Takeda Pharmaceuticals U.S.A.; Pfizer; AstraZeneca; Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim; Leona M. and Harry B. Helmsley Charitable Trust; U.S. Department of Veterans Affairs","keywords":"Medicine; Life expectancy; Multidisciplinary approach; Comorbidity; Gerontology; MEDLINE; Diabetes mellitus; Health care; Multimorbidity; Geriatrics; Diabetes management; Type 2 diabetes; Psychiatry; Population","score_opus":0.3001917020371686,"score_gpt":0.4297795609243814,"score_spread":0.1295878588872128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085703194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010013041,0.978158,0.00007574676,0.012410332,0.000881456,0.00694542,0.00011188916,0.00017252006,0.00024333863],"genre_scores_gemma":[0.00046711214,0.98085487,0.0023946895,0.005978856,0.0019501217,0.007816489,0.00019178254,0.0001228279,0.00022323977],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994588,0.0005662432,0.0013940125,0.0010277472,0.00021851854,0.0022054783],"domain_scores_gemma":[0.9889178,0.008933908,0.000627509,0.0013021905,0.00010896382,0.00010960205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020809886,0.00072481483,0.004099592,0.0001571853,0.00019835973,0.00006933979,0.0012589167,0.0002485118,0.0000121529],"category_scores_gemma":[0.0031961198,0.00039525877,0.001034052,0.00043164918,0.00035150893,0.00008844703,0.00051906175,0.00072140386,0.00005963428],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049380058,0.00008711022,0.0046626967,0.016048048,0.0012092888,0.000045439003,0.00004503211,4.2796887e-7,0.0000029343694,0.0065566846,0.014830764,0.9564622],"study_design_scores_gemma":[0.0017984278,0.0006383673,0.0008475885,0.012173117,0.0028247838,0.000002818881,0.000021080845,0.00012283801,0.000030969164,0.0014472607,0.9796845,0.00040827377],"about_ca_topic_score_codex":0.0000036406557,"about_ca_topic_score_gemma":0.000018450079,"teacher_disagreement_score":0.9648537,"about_ca_system_score_codex":0.00023126214,"about_ca_system_score_gemma":0.0003738701,"threshold_uncertainty_score":0.9998499},"labels":[],"label_agreement":null},{"id":"W3086149925","doi":"10.1590/2175-8239-jbn-2020-0100","title":"Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection","year":2020,"lang":"en","type":"review","venue":"Brazilian Journal of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Diabetes mellitus; Adverse effect; Clinical trial; Kidney disease; Population; Glucagon-like peptide 1 receptor; Disease; Intensive care medicine; Pharmacology; Internal medicine; Endocrinology; Receptor; Agonist","score_opus":0.08896659119987405,"score_gpt":0.3394004102598413,"score_spread":0.25043381905996726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086149925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005851511,0.98921853,0.001396818,0.002245897,0.00074121135,0.005696984,0.000088898705,0.00001375393,0.000012735614],"genre_scores_gemma":[0.0013356053,0.9915244,0.0043962784,0.00051912793,0.0014082388,0.00045116147,0.000041326068,0.00008909179,0.00023480164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846447,0.00012154644,0.000832483,0.00021319096,0.0001375683,0.00023075915],"domain_scores_gemma":[0.9979616,0.00047155775,0.001077296,0.00018225337,0.00020245656,0.0001048363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039102903,0.00028254715,0.0017316573,0.00022226809,0.000102631166,0.00003219082,0.00009787456,0.00019860969,0.000011058565],"category_scores_gemma":[0.00023161982,0.0001721152,0.0008252343,0.000133576,0.00011926462,0.00007819663,0.00005379922,0.00027523746,0.0000013095987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010033994,0.00008379547,0.000011169878,0.008520385,0.0032585175,0.00036240352,0.00008665977,8.5032184e-7,0.000018766263,0.00008362197,0.016877498,0.96969295],"study_design_scores_gemma":[0.0023385747,0.004149973,0.00001463171,0.002481944,0.0072717834,0.003282822,0.000036092002,0.00003538108,0.000008567646,0.000029185248,0.98023695,0.00011407468],"about_ca_topic_score_codex":0.000004119001,"about_ca_topic_score_gemma":0.000007005989,"teacher_disagreement_score":0.96957886,"about_ca_system_score_codex":0.00009236959,"about_ca_system_score_gemma":0.00019359196,"threshold_uncertainty_score":0.7018654},"labels":[],"label_agreement":null},{"id":"W3086267010","doi":"10.1002/ehf2.12891","title":"Early Benefits of Empagliflozin in Patients with or Without Heart Failure: Findings from EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Relypsa; Sanofi Genzyme; National Institutes of Health; Impulse Dynamics; Eli Lilly and Company; Edwards Lifesciences; Novo Nordisk; Sanofi; GlaxoSmithKline; AstraZeneca","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Heart failure; Placebo; Diabetes mellitus; Type 2 diabetes; Cardiology; Blood pressure; Clinical trial; Endocrinology","score_opus":0.017195216816864506,"score_gpt":0.24217016572713884,"score_spread":0.22497494891027434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086267010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813543,0.0000475182,0.0000061522433,0.017139794,0.00005568564,0.001157991,0.00006165654,0.00009757608,0.00007930625],"genre_scores_gemma":[0.98876697,0.0000015626135,0.0082160905,0.0021985376,0.0000926233,0.00004228435,0.00013547459,0.00005897545,0.00048746844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791527,0.000044729095,0.0004849168,0.0005207761,0.0005810526,0.0004532644],"domain_scores_gemma":[0.9990446,0.000054328862,0.00008916362,0.00040264934,0.00009585826,0.00031342878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010032051,0.00034298134,0.00088679726,0.00016506428,0.000047308687,0.000035371326,0.00013496428,0.00013526193,0.0005057585],"category_scores_gemma":[0.00007436521,0.00024355375,0.00012509096,0.0005247441,0.00006398225,0.0002282494,0.000102099686,0.00027452238,0.00023624783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006529213,0.00035139383,0.9808115,0.00009991282,0.00017265679,0.000009396159,0.00090916915,0.000010592548,0.00017082758,0.000023542885,0.01656684,0.00022129349],"study_design_scores_gemma":[0.008002856,0.0020963245,0.95917517,0.0003374579,0.00020779595,5.5641107e-7,0.00023716144,0.000023543635,0.0010377986,0.0000051982884,0.028611353,0.00026480117],"about_ca_topic_score_codex":0.00026879372,"about_ca_topic_score_gemma":0.00035877567,"teacher_disagreement_score":0.0216363,"about_ca_system_score_codex":0.0000723851,"about_ca_system_score_gemma":0.00006240198,"threshold_uncertainty_score":0.9931833},"labels":[],"label_agreement":null},{"id":"W3086384041","doi":"10.1016/j.jcjd.2020.09.005","title":"Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes","year":2020,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Health Sciences Centre; University of Toronto; St Joseph's Health Care; Lawson Health Research Institute; Sunnybrook Health Science Centre; St. Michael's Hospital; Western University; McMaster University; LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Type 2 diabetes; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Glucagon-like peptide 1 receptor; Endocrinology; Glycated hemoglobin; Nonalcoholic fatty liver disease; Pharmacology; Agonist; Receptor; Disease; Fatty liver","score_opus":0.05099412631323141,"score_gpt":0.3034148042978675,"score_spread":0.2524206779846361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086384041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019070594,0.9729669,0.000006979662,0.0036716883,0.0011069095,0.0028217402,0.00021300967,0.000015977224,0.00012618498],"genre_scores_gemma":[0.015805153,0.97894394,0.001732998,0.0011196303,0.0006150281,0.00025937823,0.0010290757,0.000119515455,0.00037526878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771965,0.00013181567,0.0010269396,0.0003542169,0.00028277718,0.00048460157],"domain_scores_gemma":[0.9974869,0.00059053785,0.00059405307,0.00019193105,0.000394863,0.0007416994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000451621,0.00043824792,0.0016663716,0.0006180199,0.00016335309,0.00019474424,0.00009125928,0.00024718198,0.00015173551],"category_scores_gemma":[0.00044528456,0.00037625816,0.0003445714,0.0002690453,0.00015045941,0.00028075394,0.000013438453,0.00044624356,0.000015886835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011410253,0.0010271939,0.009598858,0.017118244,0.005966781,0.0005072365,0.0013727798,0.0000051349252,0.00010992274,0.0045120674,0.09736819,0.8622995],"study_design_scores_gemma":[0.0038321232,0.0018700365,0.00032769924,0.004410617,0.0016121006,0.000012594219,0.000096521,0.000033368793,0.0001004169,0.00030668278,0.9870011,0.00039673093],"about_ca_topic_score_codex":0.000041136132,"about_ca_topic_score_gemma":0.0012734988,"teacher_disagreement_score":0.88963294,"about_ca_system_score_codex":0.0006297582,"about_ca_system_score_gemma":0.0043349485,"threshold_uncertainty_score":0.9998689},"labels":[],"label_agreement":null},{"id":"W3087054733","doi":"10.1007/s12020-020-02489-w","title":"The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"Endocrine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Glycemic; Psychological intervention; Medicine; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Endocrinology; Psychiatry","score_opus":0.1263194591266592,"score_gpt":0.40352869336890745,"score_spread":0.27720923424224825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087054733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755424,0.00030556167,0.000059986654,0.000037917493,0.000042831598,0.0018421386,0.0000780373,0.0000050572335,0.00007420654],"genre_scores_gemma":[0.9997504,0.000025362971,0.000021710472,0.000007283963,0.000004151691,0.000101667414,0.00007333203,0.0000057085645,0.000010433866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987105,0.00042471543,0.0005136756,0.00010585398,0.0001462028,0.00009902073],"domain_scores_gemma":[0.9983677,0.00086942525,0.00035839924,0.00013795454,0.00023413403,0.0000323528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040035383,0.000086177286,0.0006290086,0.00007348511,0.0000117313375,0.0000019617655,0.00008567931,0.00001112947,0.00006319435],"category_scores_gemma":[0.0004357017,0.00005034886,0.000104713356,0.00021263951,0.000085371474,0.000031834807,0.000035446657,0.000040944964,0.0000019278148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001227147,0.0008097202,0.9877658,0.0051684175,0.0016756392,7.1248655e-7,0.000029696324,0.0004953232,0.00256825,0.00005799411,0.000036319427,0.00016500484],"study_design_scores_gemma":[0.007112461,0.0026972578,0.9665907,0.001164663,0.0017935215,4.5105722e-8,0.00001716302,0.0011959748,0.019373283,0.000011838604,0.0000018579794,0.00004124385],"about_ca_topic_score_codex":0.000059671856,"about_ca_topic_score_gemma":0.00004030818,"teacher_disagreement_score":0.021175086,"about_ca_system_score_codex":0.000045294353,"about_ca_system_score_gemma":0.000038323466,"threshold_uncertainty_score":0.2053167},"labels":[],"label_agreement":null},{"id":"W3087205645","doi":"10.1177/1533317520953041","title":"The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease","year":2020,"lang":"en","type":"article","venue":"American Journal of Alzheimer s Disease & Other Dementias®","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; Lundbeckfonden; Alzheimer Society","keywords":"Liraglutide; Agonist; Dual (grammatical number); Endocrinology; Glucagon-like peptide 1 receptor; Internal medicine; Medicine; Receptor; Type 2 diabetes; Diabetes mellitus; Philosophy","score_opus":0.047810052157710385,"score_gpt":0.2685426082662608,"score_spread":0.22073255610855042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087205645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9153688,0.017415307,0.00070314336,0.060470354,0.00018812402,0.005137133,0.00033662713,0.00006349037,0.00031703062],"genre_scores_gemma":[0.9905407,0.00018055073,0.00047942772,0.00799581,0.00025087313,0.00037599224,0.000019352039,0.000084649655,0.00007267946],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963693,0.0005030628,0.0009819008,0.000433854,0.0011152872,0.0005966115],"domain_scores_gemma":[0.99747473,0.00008594462,0.0006740847,0.0007487122,0.0002689872,0.000747525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006896987,0.0004663158,0.0007622545,0.00015079936,0.00030661677,0.00015116054,0.0007473703,0.000027282465,0.00009220306],"category_scores_gemma":[0.00012392426,0.00023413319,0.0004941142,0.0005854075,0.000716255,0.0002529513,0.00021172415,0.0003570843,0.000029639852],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10284535,0.019734833,0.10643651,0.00077342254,0.105597615,0.0011947909,0.11651941,0.06897641,0.029822294,0.0043904763,0.19522636,0.24848253],"study_design_scores_gemma":[0.046450306,0.024833893,0.28629124,0.0038674925,0.14209613,0.000055419383,0.13915543,0.14237197,0.03583113,0.0016131082,0.17041427,0.0070196036],"about_ca_topic_score_codex":0.00026681213,"about_ca_topic_score_gemma":0.00008952179,"teacher_disagreement_score":0.24146293,"about_ca_system_score_codex":0.000067763416,"about_ca_system_score_gemma":0.00046706898,"threshold_uncertainty_score":0.9547674},"labels":[],"label_agreement":null},{"id":"W3087348426","doi":"10.1161/circulationaha.120.045888","title":"Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure","year":2020,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Heart failure; Glucagon-like peptide-1; Receptor; Internal medicine; Agonist; Endocrinology; Glucagon; Cardiology; Pharmacology; Diabetes mellitus; Insulin; Type 2 diabetes","score_opus":0.0324588064992321,"score_gpt":0.29733709766310534,"score_spread":0.26487829116387324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087348426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008659365,0.99655056,0.000028032831,0.00053099653,0.00022136013,0.0013094376,0.000010441985,0.00010474559,0.0011578436],"genre_scores_gemma":[0.00029564384,0.9963177,0.0008231099,0.00020487214,0.00032556412,0.000103677936,0.0012685076,0.00005251544,0.0006084323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989242,0.00004098079,0.00031095723,0.0003840094,0.00017437057,0.00016549305],"domain_scores_gemma":[0.99942213,0.000031630505,0.00013988638,0.00024281947,0.000028008164,0.00013553606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075665324,0.0002682568,0.0009398704,0.00010863427,0.000053838285,0.000047482066,0.00004115112,0.00015827337,0.0001119083],"category_scores_gemma":[0.000029672667,0.00022523705,0.00023518271,0.00018930766,0.000027507363,0.000062657564,0.000046263332,0.00014287989,0.00046311427],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000031067896,0.00004115553,0.00042241538,0.01132483,0.00037722918,0.0000122639,0.000038189377,1.9876106e-7,0.000005508183,0.00017321853,0.019069688,0.9685322],"study_design_scores_gemma":[0.00031395745,0.00004598835,0.000704274,0.0038805087,0.0017555121,0.000014927476,0.000008209296,0.000010722084,6.4941196e-7,0.0000135771925,0.9930768,0.00017488272],"about_ca_topic_score_codex":0.0000034458856,"about_ca_topic_score_gemma":0.000001263196,"teacher_disagreement_score":0.9740071,"about_ca_system_score_codex":0.00015077,"about_ca_system_score_gemma":0.00007865505,"threshold_uncertainty_score":0.91849},"labels":[],"label_agreement":null},{"id":"W3087646696","doi":"10.2147/vhrm.s270751","title":"&lt;p&gt;Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes&lt;/p&gt;","year":2020,"lang":"en","type":"article","venue":"Vascular Health and Risk Management","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Faculty of Medicine Siriraj Hospital, Mahidol University; Mahidol University; Pfizer","keywords":"Medicine; Atorvastatin; Internal medicine; Glycated hemoglobin; Simvastatin; Type 2 diabetes; Glycemic; Endocrinology; Insulin resistance; Statin; Insulin; Glucose homeostasis; Diabetes mellitus","score_opus":0.008321686799131152,"score_gpt":0.24242821768342257,"score_spread":0.23410653088429142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087646696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97343254,0.022429945,0.00039180345,0.00059047755,0.00015645876,0.0027107578,0.000053268464,0.00006385931,0.00017089938],"genre_scores_gemma":[0.9678966,0.027971366,0.0009487126,0.0026522817,0.000073358075,0.00013612332,0.0002468628,0.000046988996,0.000027748027],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997573,0.00029520082,0.0004887721,0.0006936146,0.00045214235,0.00049724395],"domain_scores_gemma":[0.99866354,0.00022460482,0.00020630517,0.00027318476,0.000045160483,0.0005872117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006575834,0.00035525297,0.0007614078,0.00033344873,0.00012161254,0.00003787764,0.000066226276,0.000058929352,0.00003444278],"category_scores_gemma":[0.0001392945,0.00029126325,0.00009784803,0.00054368784,0.000032109598,0.000086996544,0.00017309228,0.00017189712,0.000047722235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023335032,0.00038732428,0.020281661,0.0021030363,0.0014286782,0.000056356737,0.0013253235,0.00008150453,0.000116559684,0.00023636533,0.0009049467,0.9707447],"study_design_scores_gemma":[0.048620928,0.033894744,0.83964676,0.0044411705,0.0054663382,5.384555e-7,0.00178813,0.0043047327,0.0016688934,0.00041616143,0.05852911,0.0012224762],"about_ca_topic_score_codex":0.00021540171,"about_ca_topic_score_gemma":0.00008525227,"teacher_disagreement_score":0.96952224,"about_ca_system_score_codex":0.00008779565,"about_ca_system_score_gemma":0.000034458324,"threshold_uncertainty_score":0.9999539},"labels":[],"label_agreement":null},{"id":"W3087691613","doi":"10.1016/s2213-8587(20)30313-2","title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; Novo Nordisk Fonden; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Post-hoc analysis; Type 2 diabetes; Renal function; Diabetes mellitus; Post hoc; MEDLINE; Randomized controlled trial; Internal medicine; Endocrinology; Liraglutide","score_opus":0.010137212375282744,"score_gpt":0.23273598781001736,"score_spread":0.2225987754347346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087691613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049795,0.00067211385,0.000002095356,0.0048495233,0.000104436775,0.003501331,0.00003646022,0.0000333761,0.00030270824],"genre_scores_gemma":[0.99474174,0.00013712472,0.000022644568,0.0047598733,0.0000543243,0.00012900314,0.00006661271,0.000019833748,0.00006883256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724966,0.0008623751,0.00067170284,0.00031495985,0.00027315313,0.0006281501],"domain_scores_gemma":[0.9962616,0.0025698983,0.00051016954,0.00041126195,0.0001520132,0.000095077536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006590743,0.00026671845,0.0028301533,0.00022809528,0.000048656148,0.0000092514765,0.00018371119,0.000060894727,0.00003553797],"category_scores_gemma":[0.0020575959,0.0001277279,0.00031468482,0.0007574645,0.0002015416,0.000027588207,0.000093588584,0.00018623516,0.0000024860647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18086879,0.0007828625,0.7818214,0.0006801103,0.019146167,0.000018502195,0.00043388986,0.00026650887,0.004763468,0.00069709757,0.0006873704,0.00983382],"study_design_scores_gemma":[0.2612187,0.013728099,0.6976696,0.00027031198,0.021719057,2.0397721e-7,0.00012194713,0.00083534216,0.0033989048,0.000109114895,0.0006960994,0.00023263026],"about_ca_topic_score_codex":0.000012968015,"about_ca_topic_score_gemma":0.000011322158,"teacher_disagreement_score":0.08415181,"about_ca_system_score_codex":0.000056207147,"about_ca_system_score_gemma":0.000057362795,"threshold_uncertainty_score":0.52085924},"labels":[],"label_agreement":null},{"id":"W3087889571","doi":"10.1016/j.molmet.2020.101090","title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","year":2020,"lang":"en","type":"review","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden","keywords":"Amylin; Medicine; Exenatide; Semaglutide; Liraglutide; Agonist; Type 2 diabetes; Glycemic; Glucagon-like peptide 1 receptor; Weight loss; Steatohepatitis; Bioinformatics; Diabetes mellitus; Pharmacology; Disease; Internal medicine; Endocrinology; Receptor; Obesity; Biology; Fatty liver; Islet","score_opus":0.027325895981913543,"score_gpt":0.3265732227397154,"score_spread":0.29924732675780186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087889571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026188543,0.98941344,0.0005903475,0.0003393177,0.0007943217,0.0055596367,0.00048486222,0.000277052,0.0025148396],"genre_scores_gemma":[0.000013505649,0.979032,0.0051927795,0.0010316634,0.00085672707,0.0027667203,0.0044415863,0.00035849083,0.0063065225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613935,0.00022126593,0.00095721096,0.0012434941,0.00061096554,0.00082774047],"domain_scores_gemma":[0.9972989,0.00010419209,0.00050983636,0.0010771798,0.000120409415,0.0008894696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026415565,0.0011549435,0.0042646234,0.0003955945,0.00016243722,0.00014567675,0.00039665052,0.00021728424,0.00017807136],"category_scores_gemma":[0.0002699325,0.0009285127,0.00274764,0.00056148233,0.00008783666,0.00009465887,0.00017646431,0.00035328654,0.00060453475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000684699,0.00029417482,0.0000033348997,0.013905757,0.003917535,0.00028752955,0.000047215195,3.7166794e-7,0.000037992813,0.0038730106,0.008730744,0.96883386],"study_design_scores_gemma":[0.0017757202,0.00008060293,0.000015344798,0.0028250553,0.032076027,0.00000656008,0.0000097873835,0.000010959575,0.00010988434,0.00005787637,0.96232367,0.0007085357],"about_ca_topic_score_codex":0.000010136135,"about_ca_topic_score_gemma":5.1165847e-7,"teacher_disagreement_score":0.96812534,"about_ca_system_score_codex":0.000121082376,"about_ca_system_score_gemma":0.0004956054,"threshold_uncertainty_score":0.9993166},"labels":[],"label_agreement":null},{"id":"W3088399797","doi":"10.1016/j.jcjd.2020.08.002","title":"Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide","year":2020,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Manitoba; LMC Diabetes & Endocrinology (Canada); McMaster University; Queen's University; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Evidence-based medicine; Best practice; Best evidence; Balance (ability); Diabetes management; Alternative medicine; Diabetes mellitus; Evidence-based practice; Quality (philosophy); Clinical Practice; Intensive care medicine; Family medicine; Physical therapy; Pathology; Endocrinology","score_opus":0.0210681104056871,"score_gpt":0.2897417853694287,"score_spread":0.26867367496374156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088399797","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006610103,0.9882476,1.3841617e-7,0.0010406368,0.0007804796,0.0012788695,0.000081964674,0.0000109437815,0.0019493098],"genre_scores_gemma":[0.0025450056,0.99554265,0.00019010385,0.0007866205,0.00028446672,0.000051589253,0.00011431498,0.00007332349,0.0004119068],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707633,0.00015985085,0.0013931635,0.00032646506,0.00033097607,0.00071321306],"domain_scores_gemma":[0.99767554,0.00014219029,0.0009506851,0.00039428656,0.0001789251,0.0006583633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041211737,0.0005189898,0.0022416764,0.00058095803,0.000057644815,0.000041548104,0.00077106204,0.0001732672,0.00039136113],"category_scores_gemma":[0.00009320664,0.0003361917,0.0006508644,0.0010531971,0.00016299439,0.00011429611,0.00009613776,0.0006006087,0.00007950535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024671344,0.00008696395,0.004767007,0.018461587,0.0038724828,0.00063338625,0.000060448085,0.0000037556483,6.8614196e-7,0.00013401361,0.049952,0.922003],"study_design_scores_gemma":[0.0015155805,0.0006739337,0.00041492708,0.024304165,0.005088925,0.0000036377744,0.00009149156,0.000011220945,0.000006799804,0.000032618624,0.9675968,0.00025985952],"about_ca_topic_score_codex":0.0000773921,"about_ca_topic_score_gemma":0.00041872382,"teacher_disagreement_score":0.92174315,"about_ca_system_score_codex":0.0005520791,"about_ca_system_score_gemma":0.0010801194,"threshold_uncertainty_score":0.999909},"labels":[],"label_agreement":null},{"id":"W3088446089","doi":"10.1136/bmj.m3342","title":"Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Quality Council; University of Calgary; Memorial University of Newfoundland; Institut National d'Excellence en Santé et en Services Sociaux; University of British Columbia; Health Sciences Centre; Jewish General Hospital; Sunnybrook Health Science Centre; University of Manitoba; Institute for Clinical Evaluative Sciences; McGill University; University of Toronto; Manitoba Health","funders":"Fonds de Recherche du Québec - Santé; McGill University","keywords":"Retrospective cohort study; Medicine; Adverse effect; Cohort; Cohort study; Cotransporter; Database; Sodium; Internal medicine; Emergency medicine; Computer science; Chemistry","score_opus":0.013152126923681319,"score_gpt":0.25173099409904576,"score_spread":0.23857886717536445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088446089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951439,0.0005712877,0.00018230198,0.00023854738,0.00011559067,0.003210727,0.00008591066,0.000051956173,0.0003997845],"genre_scores_gemma":[0.9983579,0.00026161462,0.00072144245,0.00010883553,0.00013078672,0.000118849806,0.0000720693,0.00002250258,0.00020602203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986831,0.00006304938,0.0002931887,0.00038145095,0.00041242185,0.00016677291],"domain_scores_gemma":[0.9992688,0.000012264688,0.000100247955,0.0003879039,0.00007464431,0.00015614377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038251403,0.00017063027,0.0005264998,0.000056987617,0.000037196653,0.0000035087521,0.00004913045,0.000035864603,0.000054331224],"category_scores_gemma":[0.00007297133,0.00014129146,0.00022751765,0.0001476394,0.00004461556,0.00008479337,0.000061077,0.00010636828,0.000024551513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020134103,0.00072506064,0.99099684,0.00010704945,0.0050817877,0.00019682111,0.00064169895,0.0000044515687,0.0001179921,0.000004481967,0.0012501905,0.0006722912],"study_design_scores_gemma":[0.008076516,0.0006860957,0.982107,0.000054159125,0.0052913064,0.0000012564332,0.0007881606,0.0000734529,0.0012745821,0.000002293268,0.0015126527,0.00013254338],"about_ca_topic_score_codex":0.00029693492,"about_ca_topic_score_gemma":0.00003440024,"teacher_disagreement_score":0.008889852,"about_ca_system_score_codex":0.0000493845,"about_ca_system_score_gemma":0.000019700046,"threshold_uncertainty_score":0.57616985},"labels":[],"label_agreement":null},{"id":"W3088863916","doi":"10.1093/ajh/hpaa100","title":"SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution","year":2020,"lang":"en","type":"article","venue":"American Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of British Columbia","funders":"Department of Medicine, Georgetown University; University of Ottawa","keywords":"Medicine; Blood pressure; Resistant hypertension; Cardiology; Internal medicine; Pharmacology","score_opus":0.029466794839517984,"score_gpt":0.23315566004216934,"score_spread":0.20368886520265136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088863916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715202,0.0007654191,0.00005559305,0.026864508,0.00016899046,0.00017148392,6.349628e-7,0.000022196256,0.00043098108],"genre_scores_gemma":[0.9915157,0.00027550122,0.0019930059,0.005899479,0.0002474523,0.0000017751382,0.000004002577,0.000021617458,0.000041490937],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986089,0.00006363548,0.00050107983,0.00018751115,0.0003988549,0.00024004182],"domain_scores_gemma":[0.9990644,0.000048267906,0.00030767225,0.00013391917,0.00018615881,0.00025957124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020111132,0.00015623336,0.00062185165,0.00021349831,0.000037194597,0.000012722342,0.00007499582,0.000031610267,0.000022497623],"category_scores_gemma":[0.00015791928,0.00011195919,0.00016907408,0.0004889952,0.000100814425,0.00015568547,0.000049285503,0.00021195249,0.000025580144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008921997,0.0020531577,0.033918064,0.0001665525,0.00076851033,0.017043112,0.0015613706,0.00012176809,0.45415244,0.00016079872,0.069280244,0.41185197],"study_design_scores_gemma":[0.052304585,0.09200886,0.54893094,0.0061237155,0.005165585,0.00501851,0.019394081,0.009752016,0.03398881,0.0004702318,0.22443597,0.0024067184],"about_ca_topic_score_codex":0.000053071457,"about_ca_topic_score_gemma":0.0000045229162,"teacher_disagreement_score":0.51501286,"about_ca_system_score_codex":0.000091615286,"about_ca_system_score_gemma":0.000073081115,"threshold_uncertainty_score":0.45655632},"labels":[],"label_agreement":null},{"id":"W3088988988","doi":"10.1111/ijcp.13731","title":"Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance","year":2020,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of British Columbia","funders":"Novo Nordisk; Novo Nordisk Fonden; Steno Diabetes Center Copenhagen","keywords":"Medicine; Semaglutide; Formulary; Adverse effect; Intensive care medicine; Dosing; Type 2 diabetes; Internal medicine; Pharmacology; Diabetes mellitus; Liraglutide","score_opus":0.15261968283837507,"score_gpt":0.5290970665913604,"score_spread":0.3764773837529853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088988988","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3070802,0.0014010544,0.0018948836,0.67132473,0.0028547284,0.00042623826,0.0000074306463,0.000036960708,0.01497377],"genre_scores_gemma":[0.7986644,0.0031688265,0.15129322,0.04128503,0.005423353,0.000004313364,0.000008600095,0.00003271691,0.000119557066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939643,0.0009351539,0.0032445863,0.00040786268,0.0012081566,0.00023993668],"domain_scores_gemma":[0.9775137,0.018049348,0.0024178864,0.00018914347,0.0012414983,0.00058843597],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066175526,0.00020737457,0.0008797233,0.00011296699,0.00003793257,0.00013621581,0.00022290209,0.000212314,0.00008793915],"category_scores_gemma":[0.14274305,0.00017206577,0.00031281883,0.00014266373,0.00015215231,0.000992837,0.00021420208,0.0015974329,0.00009408662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025203658,0.005957919,0.29249713,0.0000701756,0.0066806944,0.018165095,0.0009540002,0.00000867675,0.00021224047,0.0029592316,0.106903315,0.54038787],"study_design_scores_gemma":[0.008344722,0.0023321456,0.07032151,0.00029522582,0.0006686429,0.00077850587,0.0008283521,0.00023567484,0.000043199365,0.00016129803,0.91580236,0.0001883777],"about_ca_topic_score_codex":0.000022354881,"about_ca_topic_score_gemma":0.000001728132,"teacher_disagreement_score":0.80889904,"about_ca_system_score_codex":0.0000968883,"about_ca_system_score_gemma":0.000466231,"threshold_uncertainty_score":0.864478},"labels":[],"label_agreement":null},{"id":"W3089612515","doi":"10.1681/asn.2020050723","title":"Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Canagliflozin; Albuminuria; Post-hoc analysis; Medicine; Credence; Internal medicine; Post hoc; Endocrinology; Kidney disease; Diabetes mellitus; Statistics; Type 2 diabetes; Mathematics","score_opus":0.022319103255677358,"score_gpt":0.25338130003802645,"score_spread":0.2310621967823491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089612515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93992573,0.0008104593,0.000033682853,0.058747515,0.000039149534,0.00040465515,0.000019131166,0.000004430334,0.000015246507],"genre_scores_gemma":[0.9600402,0.00049645145,0.0008302596,0.038330253,0.0002629038,0.000010935478,0.0000028934521,0.000010479625,0.000015604463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987596,0.00017500667,0.00031813228,0.00016354756,0.00039914311,0.00018452828],"domain_scores_gemma":[0.9988289,0.0001480535,0.00048405144,0.00030252198,0.00008585845,0.0001505997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032060544,0.00013904621,0.0009636855,0.00004455021,0.000039682436,0.000011375775,0.00024200721,0.0000367381,0.000015483649],"category_scores_gemma":[0.000073854266,0.00006796066,0.0008052114,0.0006341046,0.00044110173,0.00006467057,0.00009711953,0.00022440833,4.70122e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026068283,0.00035762333,0.8533501,0.000048764152,0.06725256,0.00010736338,0.019438913,0.000111405905,0.00096082385,0.000007868421,0.022776976,0.009519299],"study_design_scores_gemma":[0.01758524,0.0045320257,0.96060807,0.000038605474,0.008300016,0.0000064997275,0.002050362,0.00021999254,0.000012800276,0.0000082482975,0.0065642805,0.00007386433],"about_ca_topic_score_codex":0.0049391715,"about_ca_topic_score_gemma":0.00020853023,"teacher_disagreement_score":0.10725795,"about_ca_system_score_codex":0.000044394215,"about_ca_system_score_gemma":0.00010626479,"threshold_uncertainty_score":0.74665827},"labels":[],"label_agreement":null},{"id":"W3090300628","doi":"10.1016/j.cjca.2020.07.214","title":"METFORMIN CONTINUATION VERSUS INTERRUPTION FOLLOWING CORONARY ANGIOGRAPHY: CONTEMPORARY RISK OF LACTIC ACIDOSIS. A PILOT SINGLE-CENTER RANDOMIZED CONTROL TRIAL","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Saskatoon Medical Imaging","funders":"","keywords":"Medicine; Lactic acidosis; Metformin; Cardiogenic shock; Internal medicine; Randomized controlled trial; Cardiology; Coronary artery disease; Conventional PCI; Kidney disease; Diabetes mellitus; Percutaneous coronary intervention; Myocardial infarction; Renal replacement therapy; Single Center; Acute coronary syndrome; Hyperlactatemia; Endocrinology; Insulin","score_opus":0.06468025993288964,"score_gpt":0.27145191916265016,"score_spread":0.2067716592297605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090300628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768759,0.00542972,0.0053300504,0.0019787943,0.0025438983,0.0018963874,0.000047173457,0.00001537115,0.0058827307],"genre_scores_gemma":[0.9988633,0.000052686537,0.00014429975,0.00033578285,0.00051639334,0.000021436475,0.00003549744,0.000015746842,0.000014856019],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983227,0.00049094314,0.0006758866,0.00013604305,0.0001543783,0.00022002237],"domain_scores_gemma":[0.99837667,0.00037969224,0.0005769965,0.0001116179,0.00015707171,0.00039795347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086789083,0.00015508402,0.001327961,0.0003757807,0.000037882262,0.000013817183,0.00009138798,0.00007656271,0.000019389763],"category_scores_gemma":[0.00085716037,0.00012520923,0.0013096412,0.00014350134,0.0001294365,0.00015006588,0.0000084995245,0.00017277412,0.0000035390276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9252123,0.000049826187,0.04340486,0.00003679327,0.016192053,0.00041338985,0.0003794931,0.000058328624,0.0003268137,0.00007115425,0.0032141283,0.010640862],"study_design_scores_gemma":[0.9694379,0.009719948,0.0026799627,0.00009041929,0.004953482,0.000029159157,0.00025694218,0.000053257874,0.000056228197,0.000044922297,0.012562836,0.00011497155],"about_ca_topic_score_codex":0.0002442982,"about_ca_topic_score_gemma":0.00013470603,"teacher_disagreement_score":0.044225574,"about_ca_system_score_codex":0.00012359236,"about_ca_system_score_gemma":0.00032600085,"threshold_uncertainty_score":0.51058847},"labels":[],"label_agreement":null},{"id":"W3090535413","doi":"10.2215/cjn.14901219","title":"Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories","year":2020,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Medicine; Empagliflozin; Internal medicine; Benzhydryl compounds; Intensive care medicine; MEDLINE; Kidney; Cardiology; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.03628522442843783,"score_gpt":0.33972736927244024,"score_spread":0.3034421448440024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090535413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556178,0.0015049223,0.00016842732,0.04243658,0.00009828197,0.000130347,0.000009622801,0.000007263374,0.000026789132],"genre_scores_gemma":[0.91911614,0.007299919,0.0030543176,0.07023308,0.0002370849,0.0000013328083,7.623171e-7,0.000012697972,0.000044686018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867886,0.00019633729,0.00055563025,0.0001707655,0.0002097364,0.0001886539],"domain_scores_gemma":[0.99843097,0.00032782232,0.0006386186,0.0002238913,0.000093649745,0.0002850279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007297736,0.00012777686,0.0010946655,0.000009858956,0.000070310365,0.000009895955,0.00014706759,0.000058171518,0.000006657707],"category_scores_gemma":[0.0003565662,0.000074601085,0.001052322,0.00012662188,0.0017694526,0.000044516608,0.00023035987,0.00035043192,0.0000010207203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028714427,0.000112115,0.908597,0.000048825448,0.0068694563,0.000012121321,0.0010503579,0.0000049137952,0.00011654441,0.00001238239,0.051479902,0.031409267],"study_design_scores_gemma":[0.0034287265,0.002210417,0.83618885,0.000018301671,0.0021150243,0.00003319308,0.001991321,0.00006990306,0.000033987923,0.00014427006,0.15368588,0.00008013973],"about_ca_topic_score_codex":0.000039167964,"about_ca_topic_score_gemma":9.051933e-7,"teacher_disagreement_score":0.102205984,"about_ca_system_score_codex":0.000010410259,"about_ca_system_score_gemma":0.00006112004,"threshold_uncertainty_score":0.65196216},"labels":[],"label_agreement":null},{"id":"W3091188386","doi":"10.1152/ajpendo.00309.2020","title":"GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia","year":2020,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Liraglutide; Olanzapine; Antipsychotic; Pharmacology; Atypical antipsychotic; Medicine; Receptor; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Diabetes mellitus; Internal medicine; Endocrinology; Type 2 diabetes; Schizophrenia (object-oriented programming); Agonist; Psychiatry","score_opus":0.014475159487274465,"score_gpt":0.25376120164799154,"score_spread":0.23928604216071708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091188386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884165,0.0014771111,0.000025074682,0.008682678,0.00042145155,0.00033085648,0.0000072095736,0.00005290605,0.0005862141],"genre_scores_gemma":[0.9863271,0.0030642773,0.0022921257,0.007423062,0.0007178952,0.000021679221,0.000012276689,0.000028870269,0.000112721566],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836814,0.00016046736,0.00046068738,0.00034114494,0.00016083117,0.0005087383],"domain_scores_gemma":[0.9987124,0.000055959543,0.00051441375,0.00021005215,0.00014474205,0.00036243157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008166329,0.00029386117,0.001145119,0.00017630796,0.000097725155,0.000011151069,0.00018596144,0.00006958219,0.00005657569],"category_scores_gemma":[0.00009117157,0.00021764885,0.00022488926,0.00025973687,0.00040594206,0.00013387774,0.00012294247,0.0005653355,0.00004764278],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014676162,0.00017417512,0.0003313405,0.00003906277,0.0020165036,0.00017426914,0.00046039626,0.000001984918,0.86305577,0.0007696428,0.0022371563,0.1292721],"study_design_scores_gemma":[0.027143573,0.018299371,0.27151307,0.00020090649,0.004469705,0.0010866612,0.0027928532,0.00007140413,0.21583596,0.0007809181,0.45656177,0.0012438018],"about_ca_topic_score_codex":0.000008540003,"about_ca_topic_score_gemma":3.006788e-7,"teacher_disagreement_score":0.6472198,"about_ca_system_score_codex":0.000023722107,"about_ca_system_score_gemma":0.0000997724,"threshold_uncertainty_score":0.88754624},"labels":[],"label_agreement":null},{"id":"W3091775909","doi":"10.1016/j.clinre.2020.08.011","title":"Abnormal post-prandial glucagon-like peptide release in patients with Crohn's disease","year":2020,"lang":"en","type":"article","venue":"Clinics and Research in Hepatology and Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Internal medicine; Endocrinology; Medicine; Basal (medicine); Inflammation; Insulin resistance; Insulin; Glucagon-like peptide-1; Gastric inhibitory polypeptide; Immune system; Secretion; Glucagon; Subclinical infection; Diabetes mellitus; Type 2 diabetes; Immunology","score_opus":0.027936722623941767,"score_gpt":0.31291259108030844,"score_spread":0.2849758684563667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091775909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671204,0.00022354843,0.0000045453403,0.01224869,0.000071831644,0.00062583224,0.00001675409,0.000011432563,0.00008533788],"genre_scores_gemma":[0.9949498,0.0006089022,0.00008359264,0.004114033,0.00004168791,0.000055494987,0.00009022007,0.000013125129,0.000043111206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981837,0.00027791693,0.00030603175,0.0004629933,0.00016544868,0.0006039073],"domain_scores_gemma":[0.9991091,0.00015275354,0.000045096545,0.00015736623,0.00008956235,0.00044614688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038617363,0.00014797538,0.0004041574,0.00025152,0.000067961155,0.000014000386,0.00007590796,0.00010374017,0.000023082514],"category_scores_gemma":[0.00013881693,0.00011229844,0.000034466582,0.00014216285,0.00050661515,0.00006989119,0.00020839355,0.0005059689,0.000007871527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023037769,0.00060199475,0.97078216,0.00013128461,0.000062725296,0.0016873693,0.00015446474,0.0000021956823,6.5573454e-7,0.00009904967,0.00024019866,0.003200128],"study_design_scores_gemma":[0.011754447,0.0065759136,0.97962296,0.00005005228,0.00004345192,0.0000051581264,0.00007545269,0.0004981338,5.447856e-7,0.00010275701,0.0012095007,0.000061638435],"about_ca_topic_score_codex":0.00005184923,"about_ca_topic_score_gemma":0.00021549645,"teacher_disagreement_score":0.011283323,"about_ca_system_score_codex":0.000022745351,"about_ca_system_score_gemma":0.00006555862,"threshold_uncertainty_score":0.45793974},"labels":[],"label_agreement":null},{"id":"W3091830550","doi":"10.1038/s41366-020-00694-1","title":"Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity","year":2020,"lang":"en","type":"article","venue":"International Journal of Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"CHIST-ERA; Institut de Cardiométabolisme et Nutrition; Fondation Nestlé; Assistance publique-Hôpitaux de Paris; European Foundation for the Study of Diabetes; Agence Nationale de la Recherche; Sorbonne Université; Groupe Lipides et Nutrition; Institut National de la Santé et de la Recherche Médicale; École Normale Supérieure","keywords":"Enteroendocrine cell; Type 2 diabetes; Obesity; Internal medicine; Diabetes mellitus; Endocrinology; Medicine; Lineage (genetic); Insulin resistance; Endocrine system; Biology; Gene; Genetics; Hormone","score_opus":0.01591628656581257,"score_gpt":0.2607853469245722,"score_spread":0.24486906035875966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091830550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958849,0.00011304438,0.00003094213,0.002666925,0.00021071131,0.00015109612,0.000013386641,0.000020771287,0.0009082257],"genre_scores_gemma":[0.99717784,0.000036671547,0.00024260317,0.001778026,0.00025174406,0.0000014373587,0.00003944917,0.000014897334,0.00045730744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986137,0.000043101565,0.0003988084,0.00016068811,0.00058308523,0.0002006094],"domain_scores_gemma":[0.9989573,0.000036660545,0.00031995104,0.00008759444,0.00042688014,0.00017162673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001611517,0.00015660947,0.00036665078,0.0001707698,0.000028768092,0.00003965867,0.00024122462,0.000034651435,0.00033519758],"category_scores_gemma":[0.00008810995,0.00012309354,0.00013422202,0.00017222279,0.0000356362,0.00017745081,0.000088724235,0.00024316942,0.00001996172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031841215,0.0013783145,0.9883756,0.000027483427,0.00067993224,0.0011360329,0.00031313772,0.000019999545,0.0030191063,0.000020973046,0.004468875,0.00024212712],"study_design_scores_gemma":[0.0077467896,0.0023820153,0.9564556,0.00033203833,0.00027833358,0.000017034896,0.000077338314,0.00036673888,0.030433718,0.00005029394,0.0016996434,0.00016043994],"about_ca_topic_score_codex":0.000014589093,"about_ca_topic_score_gemma":0.000014825216,"teacher_disagreement_score":0.03191999,"about_ca_system_score_codex":0.0002262473,"about_ca_system_score_gemma":0.00005737299,"threshold_uncertainty_score":0.5019609},"labels":[],"label_agreement":null},{"id":"W3092361090","doi":"10.1111/dom.14223","title":"Design and baseline characteristics of the <scp>AMPLITUDE‐O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Internal medicine; Placebo; Adverse effect; Diabetes mellitus; Renal function; Glucagon-like peptide 1 receptor; Stroke (engine); Myocardial infarction; Type 2 diabetes; Kidney disease; Agonist; Endocrinology; Receptor; Pathology","score_opus":0.017930540110283284,"score_gpt":0.21955812251201745,"score_spread":0.20162758240173417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092361090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919595,0.004722987,0.00041567665,0.0006584945,0.00036757073,0.0015776019,0.000087311455,0.00003975504,0.00017106156],"genre_scores_gemma":[0.99343485,0.0016305652,0.0029455582,0.0009982394,0.00021995518,0.00007071133,0.00005947258,0.0000354039,0.0006052758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797714,0.000253173,0.0005311973,0.00040205292,0.00050502067,0.0003313919],"domain_scores_gemma":[0.9984685,0.00038142048,0.00025769716,0.0005001457,0.00016758584,0.00022465581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008670337,0.00031035035,0.0013642746,0.00008793951,0.00010783487,0.000039341,0.00016995957,0.00011039103,0.000013257405],"category_scores_gemma":[0.00083537225,0.00021380183,0.00043496068,0.00025135462,0.00023592751,0.00010756404,0.00022069667,0.00016536383,0.000005097443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026643435,0.005467412,0.77405834,0.006597257,0.025417,0.000033128013,0.007007328,0.000043797365,0.038345817,0.0033866023,0.012516277,0.12446271],"study_design_scores_gemma":[0.04232004,0.0009014849,0.7810914,0.0002186645,0.00752577,8.8973275e-7,0.00025524123,0.00034796822,0.025677446,0.00015487493,0.14127313,0.00023311374],"about_ca_topic_score_codex":0.000022425558,"about_ca_topic_score_gemma":6.059274e-7,"teacher_disagreement_score":0.12875685,"about_ca_system_score_codex":0.000012908088,"about_ca_system_score_gemma":0.000058541475,"threshold_uncertainty_score":0.8718586},"labels":[],"label_agreement":null},{"id":"W3092379111","doi":"10.1001/jamacardio.2020.4511","title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes","year":2020,"lang":"en","type":"review","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Vetenskapsrådet; Novo Nordisk; Sanofi; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Type 2 diabetes; Hazard ratio; Internal medicine; Kidney disease; Population; Diabetes mellitus; Stroke (engine); Meta-analysis; Randomized controlled trial; Myocardial infarction; Intensive care medicine; Confidence interval; Endocrinology","score_opus":0.00868940045644245,"score_gpt":0.2293920422134082,"score_spread":0.22070264175696575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092379111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011199957,0.9856142,0.0000014550534,0.00015444423,0.00019110164,0.0016648998,0.00005376448,0.00003097504,0.0010892024],"genre_scores_gemma":[0.0028400966,0.9957287,0.00013581257,0.00013781435,0.00014309709,0.00011471699,0.0006268952,0.00005561306,0.00021729335],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985165,0.00019607229,0.00034105673,0.00038205017,0.00030744972,0.0002568481],"domain_scores_gemma":[0.9990998,0.00010887686,0.0002524808,0.00031495737,0.000112329864,0.00011158315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023849221,0.0003206805,0.003434353,0.00019864048,0.000013754774,0.00000956325,0.00006121354,0.00027992245,0.0000044608996],"category_scores_gemma":[0.00023060248,0.00019317675,0.000366454,0.0002954814,0.00005053395,0.00004667971,0.00007458692,0.00022996888,0.000006812056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031882006,0.000042158816,0.7097538,0.004353718,0.013671697,0.000032861473,0.000017332583,0.000001125016,1.9501314e-8,0.000005040324,0.0012035212,0.27088684],"study_design_scores_gemma":[0.0029269755,0.0011099275,0.080562994,0.0025289196,0.010055447,0.0000010916327,0.0000057708917,3.0812026e-7,3.730472e-7,0.000001381428,0.902619,0.00018779241],"about_ca_topic_score_codex":0.000009760762,"about_ca_topic_score_gemma":0.0000016133375,"teacher_disagreement_score":0.9014155,"about_ca_system_score_codex":0.00022076444,"about_ca_system_score_gemma":0.00012554572,"threshold_uncertainty_score":0.7877519},"labels":[],"label_agreement":null},{"id":"W3092434593","doi":"10.1161/circulationaha.120.050255","title":"Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Hazard ratio; Placebo; Internal medicine; Heart failure; Ejection fraction; Diabetes mellitus; Proportional hazards model; Type 2 Diabetes Mellitus; Dapagliflozin; Cardiology; Gastroenterology; Confidence interval; Endocrinology; Pathology","score_opus":0.010057427029290576,"score_gpt":0.19859793201188078,"score_spread":0.1885405049825902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092434593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832416,0.00039585432,0.00000816398,0.0002623019,0.000030395315,0.0009045205,0.0000021427657,0.000028348171,0.00004411401],"genre_scores_gemma":[0.9996178,0.000009291968,0.000057843426,0.00012107078,0.00001261059,0.000011303209,0.00014825672,0.000017974038,0.0000038449148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991609,0.000041717507,0.00016075239,0.00023792265,0.00026961343,0.00012912163],"domain_scores_gemma":[0.99953675,0.000025118949,0.000042344924,0.00020129471,0.000048495993,0.00014596696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068335954,0.0001122374,0.0002575616,0.000075580305,0.000017484053,0.000006030671,0.000025201713,0.00003316841,0.000018978764],"category_scores_gemma":[0.00010348926,0.00009209179,0.000065073735,0.000271833,0.00002169817,0.00008191289,0.000015338941,0.00005234636,0.000011079309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023547605,0.0002919369,0.99403566,0.0001109372,0.00035595457,0.0000012461928,0.00010871298,0.0022032165,0.00007915966,0.000027442427,0.000019900974,0.0025303632],"study_design_scores_gemma":[0.005639698,0.0003009405,0.99205494,0.00017897582,0.00041938614,1.6540335e-8,0.000007009759,0.0010632708,0.000062785555,0.000022738079,0.0001671832,0.000083037114],"about_ca_topic_score_codex":0.0000047460317,"about_ca_topic_score_gemma":3.476345e-7,"teacher_disagreement_score":0.005404222,"about_ca_system_score_codex":0.000040076666,"about_ca_system_score_gemma":0.000017948296,"threshold_uncertainty_score":0.37553942},"labels":[],"label_agreement":null},{"id":"W3092582090","doi":"10.1161/circulationaha.120.050391","title":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Montreal Heart Institute","funders":"Relypsa; American Regent; Japan Heart Foundation; Servier; Intarcia Therapeutics; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; GlaxoSmithKline; Universität des Saarlandes; Institut de Cardiologie de Montréal; Shionogi; Rigshospitalet; Novo Nordisk; Fudan University; Gentofte Hospital; Bristol-Myers Squibb; Semmelweis Egyetem; British Heart Foundation; Zora Biosciences; Saint Luke's Health System; Alnylam Pharmaceuticals; Zafgen; AstraZeneca; Amarin Corporation; Regeneron Pharmaceuticals; Universidad Nacional de Córdoba; Defense Acquisition Program Administration; Boston Scientific Corporation; Alere; University of Minnesota; University of Toronto; University of New South Wales; Toa Eiyo; University of Glasgow; Daiichi Sankyo Europe; Yale University; Pfizer; University of Missouri; Eisai; Cytokinetics; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; National Cerebral and Cardiovascular Center; Universitair Medisch Centrum Groningen; Kowa Company; Amgen; Eli Lilly and Company; Rijksuniversiteit Groningen","keywords":"Medicine; Ejection fraction; Dapagliflozin; Heart failure; Cardiology; Renal function; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.011547376606644597,"score_gpt":0.2256000164590015,"score_spread":0.2140526398523569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092582090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814105,0.0000034019,0.00034823245,0.0006668701,0.000022662749,0.00057233433,7.7720296e-7,0.000029689078,0.00021497981],"genre_scores_gemma":[0.999497,4.766609e-7,0.00019755475,0.0001512456,0.000024599702,0.000011662586,0.00009931117,0.000010017557,0.000008162153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994439,0.00001741238,0.000115477844,0.00017271689,0.00018192377,0.00006855879],"domain_scores_gemma":[0.99975145,0.000017147171,0.00006966303,0.00008286957,0.000040208608,0.00003868717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000033630462,0.000082344246,0.0001550381,0.00009542418,0.000022092623,0.000007628561,0.00000824236,0.000033461816,0.000013297368],"category_scores_gemma":[0.000019554156,0.00005994414,0.000017265178,0.00017111936,0.000013581955,0.00011898442,0.000004197347,0.00005816185,0.0000049883033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013421178,0.00025175893,0.99441564,0.000034106994,0.00006795098,3.2113428e-7,0.000047140293,0.00047354025,0.0013213397,0.000043557266,0.00005434129,0.0019482024],"study_design_scores_gemma":[0.005835989,0.0012265487,0.9917942,0.00007897335,0.00014097929,1.1938025e-7,0.00003771536,0.00029044558,0.00039535132,0.000009619456,0.00013252223,0.00005748996],"about_ca_topic_score_codex":0.000008603852,"about_ca_topic_score_gemma":0.000004548753,"teacher_disagreement_score":0.0044938712,"about_ca_system_score_codex":0.0000550919,"about_ca_system_score_gemma":0.000009204913,"threshold_uncertainty_score":0.24444512},"labels":[],"label_agreement":null},{"id":"W3092786508","doi":"10.1503/cmaj.76686","title":"Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors","year":2020,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Presentation (obstetrics); Medicine; Intensive care medicine; Computer science; Endocrinology; Pharmacology; Surgery","score_opus":0.010210863295968138,"score_gpt":0.2180012521767158,"score_spread":0.20779038888074766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092786508","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006062848,0.0004455683,0.0000090339845,0.9854629,0.0019647693,0.00041459975,0.00016108672,0.00006858205,0.005410596],"genre_scores_gemma":[0.010382376,0.00051582034,0.00004071989,0.96899503,0.014541798,0.000028019691,0.0012721318,0.00009105931,0.0041330187],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480665,0.00014356287,0.0007991796,0.0004113741,0.0028462447,0.000992988],"domain_scores_gemma":[0.9963449,0.00010941788,0.00048092747,0.00019603825,0.00029665648,0.0025720547],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00047384415,0.0004301166,0.0008275283,0.00037401894,0.00025027015,0.00016533719,0.0002933165,0.0018050589,0.005565175],"category_scores_gemma":[0.00043531467,0.0003968847,0.00042274618,0.00032603325,0.000044841818,0.0001224064,0.00002139353,0.005118629,0.00068436185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007755284,0.000038241975,0.002652765,0.00007321511,0.0010220138,0.0071049538,0.00009936045,1.548018e-8,0.000022091343,0.0000022308066,0.9747173,0.014260027],"study_design_scores_gemma":[0.0019760912,0.00025529604,0.0004985983,0.00029523822,0.0006838897,0.00008452889,0.000057726695,0.000007904731,0.00010406098,0.000029819554,0.9956699,0.00033693758],"about_ca_topic_score_codex":0.001525631,"about_ca_topic_score_gemma":0.0023000871,"teacher_disagreement_score":0.020952579,"about_ca_system_score_codex":0.0029850279,"about_ca_system_score_gemma":0.0034873777,"threshold_uncertainty_score":0.9998483},"labels":[],"label_agreement":null},{"id":"W3093015048","doi":"10.1002/ejhf.2026","title":"Heart Failure Association of the European Society of Cardiology Update on Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure","year":2020,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Empagliflozin; Dapagliflozin; Medicine; Canagliflozin; Heart failure; Internal medicine; Benzhydryl compounds; Cardiology; Diabetes mellitus; Ejection fraction; Type 2 diabetes; Type 2 Diabetes Mellitus; Intensive care medicine; Endocrinology","score_opus":0.010712329798872868,"score_gpt":0.22326951459022093,"score_spread":0.21255718479134805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093015048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7578847,0.00026245814,0.000058601567,0.23934163,0.00029712284,0.00063058943,0.000043601718,0.000038669932,0.0014426571],"genre_scores_gemma":[0.99158365,0.00004471485,0.0031818703,0.004141887,0.0007684861,0.0000013722187,0.000027112459,0.00007504285,0.00017588832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620163,0.0012647936,0.0011022086,0.00031289388,0.0007110937,0.000407358],"domain_scores_gemma":[0.9984436,0.000078745754,0.0006414173,0.0003716171,0.00024154999,0.00022304924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019477038,0.0003199234,0.0009519971,0.00014264499,0.000076067656,0.000025299034,0.00026945813,0.00008491435,0.000074315554],"category_scores_gemma":[0.000096986136,0.00022710765,0.00089272554,0.0003978398,0.00014021175,0.00016764892,0.000088010645,0.0008309765,0.0001015272],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015829856,0.00016943194,0.22673008,0.00015655078,0.00044266204,0.00006957644,0.00072541204,0.00022722398,0.023808746,0.000021731763,0.74723625,0.0002540434],"study_design_scores_gemma":[0.0039110132,0.0012474748,0.15863484,0.00048361663,0.0002904452,0.000034642533,0.0006328843,0.000008066414,0.009957309,0.0000062031354,0.8246157,0.0001778034],"about_ca_topic_score_codex":0.0000029903385,"about_ca_topic_score_gemma":0.000007180031,"teacher_disagreement_score":0.23519975,"about_ca_system_score_codex":0.00012245646,"about_ca_system_score_gemma":0.000092113056,"threshold_uncertainty_score":0.92611814},"labels":[],"label_agreement":null},{"id":"W3093341334","doi":"10.1016/s2213-8587(20)30300-4","title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; National Health and Medical Research Council; Medical Research Council; University of New South Wales; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Japan Society for the Promotion of Science; Mitsubishi Tanabe Pharma Corporation; Janssen Scientific Affairs","keywords":"Canagliflozin; Medicine; Post-hoc analysis; Placebo; Internal medicine; Kidney disease; Type 2 diabetes; Diabetes mellitus; Erythropoiesis; Anemia; Endocrinology; Pathology","score_opus":0.009670599550727556,"score_gpt":0.23195711636645489,"score_spread":0.22228651681572734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093341334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877586,0.0022794458,4.6180153e-7,0.008472074,0.00009817192,0.0012036839,0.00008018317,0.000040263254,0.000067132794],"genre_scores_gemma":[0.9929681,0.00019807379,0.00002365003,0.0062282714,0.00021825483,0.00011274349,0.00021087522,0.000018890545,0.000021174259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982922,0.00018355422,0.00022459107,0.00037370092,0.00023338293,0.0006925806],"domain_scores_gemma":[0.9984935,0.00067955843,0.00012572262,0.00047445536,0.000053440584,0.00017331354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008970646,0.00023044737,0.0007514702,0.0000995563,0.000054485834,0.000017959721,0.0002676199,0.000036991547,0.00004859735],"category_scores_gemma":[0.00040268793,0.00012287797,0.000086023116,0.00058084016,0.00021206566,0.000043973505,0.00013921226,0.00018362045,0.0000084656585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008047605,0.00022670333,0.98332167,0.00014845027,0.0020161192,0.000019451643,0.0001919795,0.00002490743,0.00022805911,0.00019362483,0.0014102224,0.0041712327],"study_design_scores_gemma":[0.029956209,0.004782343,0.9591633,0.00012783369,0.0030293083,1.3890405e-8,0.000021700003,0.00021712719,0.00079004845,0.00005196324,0.0017200725,0.00014005699],"about_ca_topic_score_codex":0.00015089069,"about_ca_topic_score_gemma":0.00018808628,"teacher_disagreement_score":0.024158321,"about_ca_system_score_codex":0.00006898266,"about_ca_system_score_gemma":0.00008182521,"threshold_uncertainty_score":0.5010818},"labels":[],"label_agreement":null},{"id":"W3093635194","doi":"10.2337/dbi20-0040","title":"SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation","year":2020,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centers for Disease Control and Prevention; National Institutes of Health; Duke Clinical Research Institute; Eisai; Astellas Pharma; Novo Nordisk; Steno Diabetes Center Copenhagen; Edwards Lifesciences; Providence Health Care; Ironwood Pharmaceuticals, Incorporated; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; Bayer HealthCare; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Amgen; Pfizer; University of Michigan","keywords":"Foundation (evidence); Medicine; Type 2 diabetes; Diabetes mellitus; Disease; Intensive care medicine; Kidney disease; Internal medicine; Endocrinology; Political science; Law","score_opus":0.04082269923470357,"score_gpt":0.3037415153421549,"score_spread":0.2629188161074513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093635194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006672384,0.9891874,0.0000072510356,0.0004261898,0.00029082046,0.003014477,0.00020677068,0.00003441093,0.00016028623],"genre_scores_gemma":[0.00695485,0.9723917,0.00024320348,0.00031407352,0.00028349637,0.0017492225,0.016760485,0.000095979136,0.0012069381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792874,0.00011394693,0.00056376075,0.00059737,0.0005246575,0.00027150096],"domain_scores_gemma":[0.9986974,0.0002828238,0.00025721328,0.0003790997,0.00020365945,0.00017977986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011137926,0.0002967099,0.0011260106,0.0002720093,0.00008906316,0.00008961813,0.00009216428,0.00010399424,0.000019436386],"category_scores_gemma":[0.0017336839,0.00021160551,0.00052651844,0.00068933185,0.00017909137,0.00011298291,0.00008287047,0.00012653116,0.000009229771],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004041727,0.00035634902,0.0021347401,0.03297712,0.00368228,0.000030269932,0.00007638829,0.000003344025,0.000026089892,0.0002230839,0.03238909,0.9280608],"study_design_scores_gemma":[0.00068433094,0.000069712,0.00011976344,0.0064746635,0.0038105627,7.5824664e-7,0.000009377692,0.0001681327,0.00002804209,0.00016246742,0.98828375,0.00018844134],"about_ca_topic_score_codex":0.0000019650313,"about_ca_topic_score_gemma":4.2812056e-7,"teacher_disagreement_score":0.95589465,"about_ca_system_score_codex":0.00013513809,"about_ca_system_score_gemma":0.00037118557,"threshold_uncertainty_score":0.8629022},"labels":[],"label_agreement":null},{"id":"W3093724929","doi":"","title":"Discussion on Key Heart Failure Risk Factors in Patients With Type 2 Diabetes Mellitus","year":2021,"lang":"en","type":"article","venue":"The Medical Roundtable Cardiovascular Edition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Heart failure; Diabetes mellitus; Medicine; Dapagliflozin; Type 2 Diabetes Mellitus; Internal medicine; Type 2 diabetes; Family medicine; Gerontology; Endocrinology","score_opus":0.006888904747527772,"score_gpt":0.21016291582618446,"score_spread":0.2032740110786567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093724929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940565,0.0012858992,0.00038418247,0.0024778328,0.00075017166,0.0005662508,0.000011347435,0.00006352002,0.00040429202],"genre_scores_gemma":[0.9973076,0.00030754964,0.000104251696,0.0004029103,0.00041782783,0.000045846256,0.00079733034,0.000032652184,0.0005840466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971471,0.00027050122,0.00020887458,0.0003771738,0.0016127125,0.00038365737],"domain_scores_gemma":[0.99884355,0.00010678363,0.000055767945,0.00065523,0.00013556071,0.00020308729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064062834,0.00021629105,0.0005079998,0.00008244821,0.00012787567,0.00006817965,0.00009177917,0.00012648647,0.000227188],"category_scores_gemma":[0.00053252326,0.00010037377,0.00030992442,0.00047007995,0.000054365995,0.00023150134,0.00006613553,0.00036702296,0.000053987304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049066386,0.003284701,0.91551566,0.0003576234,0.0073720934,0.00025410167,0.00041579123,0.0009731893,0.00004335009,0.0005866181,0.022895226,0.047810957],"study_design_scores_gemma":[0.007409438,0.0012410497,0.7644452,0.0009296595,0.0019155169,0.000003139004,0.00035528452,0.00010545147,0.0015180988,0.00030269564,0.22142553,0.00034891625],"about_ca_topic_score_codex":0.000057133493,"about_ca_topic_score_gemma":0.000028381237,"teacher_disagreement_score":0.19853032,"about_ca_system_score_codex":0.0002872037,"about_ca_system_score_gemma":0.00009898123,"threshold_uncertainty_score":0.40931234},"labels":[],"label_agreement":null},{"id":"W3095574760","doi":"10.1002/cpdd.884","title":"Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Bioequivalence; Medicine; Crossover study; Pharmacology; Type 2 diabetes; Pharmacokinetics; Confidence interval; Diabetes mellitus; Internal medicine; Endocrinology; Placebo","score_opus":0.05629632715691588,"score_gpt":0.35134043514486146,"score_spread":0.29504410798794556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095574760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98635197,0.00030510983,0.000113665476,0.010000479,0.000280628,0.0023316413,0.000019784638,0.00004497349,0.0005517512],"genre_scores_gemma":[0.98193276,0.0003418579,0.0059777964,0.010405678,0.000039695686,0.00030526647,0.00016074078,0.000041358577,0.0007948623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965392,0.00020216935,0.0014573052,0.0007198181,0.00034873156,0.00073278876],"domain_scores_gemma":[0.9978584,0.00063417404,0.00027001704,0.00020168198,0.00015333993,0.00088237756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012426071,0.00041033755,0.0011191191,0.0006206783,0.00006940143,0.000020309548,0.0002566283,0.00017003591,0.0001907422],"category_scores_gemma":[0.0002616874,0.0003401108,0.00006981022,0.0009015371,0.00022730134,0.00017265725,0.00023334096,0.000387018,0.000043309738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020893674,0.009821299,0.5740121,0.0027765287,0.005140921,0.0048447275,0.03014837,0.0011795247,0.008470632,0.00086676166,0.05046527,0.2913802],"study_design_scores_gemma":[0.10315658,0.011414297,0.6116032,0.0017007686,0.0018865262,0.00006551433,0.009129513,0.010700472,0.08372082,0.000432302,0.1631705,0.0030194805],"about_ca_topic_score_codex":0.001424064,"about_ca_topic_score_gemma":0.01046594,"teacher_disagreement_score":0.28836071,"about_ca_system_score_codex":0.00049355795,"about_ca_system_score_gemma":0.0009178395,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W3096077207","doi":"10.1210/endocr/bqaa201","title":"GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice","year":2020,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Japan Society for the Promotion of Science; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Novo Nordisk; Japan Association for Diabetes Education and Care; Japan Agency for Medical Research and Development; Novo Nordisk Fonden; Japan Foundation for Applied Enzymology","keywords":"Inflammation; Agonist; Immunology; Liraglutide; Receptor; Medicine; Context (archaeology); Influenza A virus; Glucagon-like peptide 1 receptor; Lung; Formyl peptide receptor; Bleomycin; Proinflammatory cytokine; Virus; Internal medicine; Endocrinology; Biology; Type 2 diabetes; Diabetes mellitus; Chemotherapy","score_opus":0.021396996393669775,"score_gpt":0.24876337771155296,"score_spread":0.2273663813178832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096077207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988744,0.00012697047,0.000055199394,0.008184797,0.00013456565,0.00036641906,0.0000037299142,0.00003394852,0.0023503634],"genre_scores_gemma":[0.99810016,0.00005729295,0.0002361422,0.0004219675,0.00008295871,0.000046893994,0.000041592597,0.000009856139,0.0010031309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992428,0.000053426986,0.00024062755,0.00015490197,0.000102310914,0.00020592334],"domain_scores_gemma":[0.999681,0.00006450927,0.0000754689,0.00013118603,0.000017399267,0.00003046202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002982228,0.000107296655,0.00027408893,0.00006515469,0.000022212576,0.000006370528,0.00009819634,0.000030131729,0.0003591475],"category_scores_gemma":[0.000034905337,0.00007350096,0.00006266979,0.00007067343,0.000056845973,0.000053578267,0.00010046928,0.00009163853,0.00006668032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013846974,0.00045428835,0.5850357,0.00041461186,0.0008346386,0.00024653075,0.00246875,0.00013934473,0.33076945,0.008440893,0.0009888271,0.06882226],"study_design_scores_gemma":[0.0057611493,0.001588523,0.73835146,0.00009673789,0.00047730768,0.00001938642,0.0014154454,0.0019039325,0.22548214,0.0004671359,0.024076015,0.0003607742],"about_ca_topic_score_codex":0.00003864132,"about_ca_topic_score_gemma":0.000009993877,"teacher_disagreement_score":0.15331575,"about_ca_system_score_codex":0.000022725477,"about_ca_system_score_gemma":0.00001058783,"threshold_uncertainty_score":0.39324132},"labels":[],"label_agreement":null},{"id":"W3096197614","doi":"10.1016/j.jcjd.2020.08.069","title":"63 - Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Semaglutide; Medicine; Empagliflozin; Sitagliptin; Liraglutide; Glycemic; Placebo; Weight loss; Type 2 diabetes; Internal medicine; Diabetes mellitus; Urology; Endocrinology; Insulin; Obesity","score_opus":0.022751980261764764,"score_gpt":0.2666239491038843,"score_spread":0.24387196884211956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096197614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724729,0.0008784141,9.470979e-7,0.025169544,0.00014524818,0.0007403664,0.0000070540923,0.0000079883375,0.0005775043],"genre_scores_gemma":[0.99379987,0.000008431073,0.000520854,0.0052043637,0.00027734067,0.00002624658,0.0000039879487,0.000013149177,0.00014574216],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990349,0.00007743005,0.0002732903,0.000117728385,0.00017011628,0.00032657935],"domain_scores_gemma":[0.99901044,0.000094066156,0.00006946502,0.0001089038,0.000050929044,0.00066618697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030437813,0.00012090714,0.00028913637,0.0002517698,0.00004935688,0.00006805792,0.00013479602,0.000037998823,0.000049782968],"category_scores_gemma":[0.0003448942,0.000079173355,0.000075056625,0.00029321815,0.000055468037,0.00007146047,0.000012971309,0.00016658887,0.000010742836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074421037,0.00036976955,0.8126316,0.0001779572,0.00073278113,0.0009967162,0.0050191814,0.0000058601613,0.00075853436,0.0005614457,0.094369374,0.076934665],"study_design_scores_gemma":[0.057083648,0.020683043,0.399041,0.000441755,0.0008233269,0.000015516074,0.001082016,0.00016014051,0.00040719315,0.0002722514,0.5196042,0.00038589092],"about_ca_topic_score_codex":0.00012427462,"about_ca_topic_score_gemma":0.00094424415,"teacher_disagreement_score":0.42523485,"about_ca_system_score_codex":0.00006919665,"about_ca_system_score_gemma":0.00032319696,"threshold_uncertainty_score":0.32285956},"labels":[],"label_agreement":null},{"id":"W3096302582","doi":"10.1016/j.jcjd.2020.08.068","title":"62 - Once-Weekly Semaglutide Reduces HbA1c and Body Weight Across Baseline HbA1c Subgroups in the SUSTAIN 1–5 and 7–10 Clinical Trials","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Baseline (sea); Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.062218833267710834,"score_gpt":0.3506325396176199,"score_spread":0.2884137063499091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096302582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95184004,0.0070496695,0.0000032356793,0.04000651,0.00017877403,0.00045749743,0.000042553915,0.0000073487095,0.0004143916],"genre_scores_gemma":[0.99346495,0.0002794236,0.00020853893,0.004761903,0.0008045858,0.000008613822,0.000017184822,0.000022535361,0.0004322967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727684,0.0005604755,0.0010935079,0.00026309676,0.00024324165,0.0005628355],"domain_scores_gemma":[0.9970337,0.0011979272,0.00037940044,0.00017608846,0.00013304649,0.0010798284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060302755,0.00022869375,0.0009525456,0.00017377362,0.00012533397,0.00014756367,0.0002012619,0.00010997358,0.00012084268],"category_scores_gemma":[0.0032557666,0.00014823371,0.00019147596,0.00027784237,0.00028330233,0.000158105,0.00003381241,0.00039272234,0.000005794197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012192099,0.00015482509,0.8824838,0.00020123043,0.00075805606,0.0006388241,0.0024278653,0.0000024279764,0.0003688245,0.00032931523,0.05606485,0.056448072],"study_design_scores_gemma":[0.013293496,0.00464118,0.75962424,0.0007389541,0.0017603658,0.000026505042,0.007774494,0.0007477842,0.00070677826,0.000939696,0.20919017,0.00055635796],"about_ca_topic_score_codex":0.00020224154,"about_ca_topic_score_gemma":0.0017457698,"teacher_disagreement_score":0.15312532,"about_ca_system_score_codex":0.00007622402,"about_ca_system_score_gemma":0.0004046655,"threshold_uncertainty_score":0.60447955},"labels":[],"label_agreement":null},{"id":"W3096365000","doi":"10.14740/jocmr4351","title":"Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Renal function; Kidney disease; Internal medicine; Diabetes mellitus; Urology; Gastroenterology; Logistic regression; Endocrinology","score_opus":0.08443448294136362,"score_gpt":0.4378582455564702,"score_spread":0.35342376261510655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096365000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95568174,0.0004861381,0.000060374212,0.04249755,0.00020731946,0.0009139061,0.000014874436,0.0000114985905,0.00012659596],"genre_scores_gemma":[0.9945021,0.0008042207,0.00024367978,0.0030539145,0.0011682006,0.00002745508,0.00012854172,0.000029770552,0.000042070224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954213,0.00046112135,0.0018176507,0.00033571676,0.0014811719,0.00048303156],"domain_scores_gemma":[0.9970169,0.0004857705,0.00031147935,0.0002322466,0.0005862299,0.0013673815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030938187,0.0002087486,0.0009665007,0.000494667,0.000028217553,0.000020243364,0.0001853576,0.00011310812,0.00038943166],"category_scores_gemma":[0.0028074794,0.00013194085,0.00013501568,0.0008620798,0.0003452802,0.00026071473,0.00006738024,0.0012113656,0.000025135672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03465197,0.0019343664,0.9404153,0.00036757282,0.00028923596,0.004521924,0.00015448465,0.0000150580245,0.000104456725,0.0000074922027,0.0030250275,0.014513092],"study_design_scores_gemma":[0.041127287,0.015330691,0.93600917,0.002770685,0.00037643407,0.0000019378265,0.000027875994,0.00082076347,0.00017665593,0.00006442359,0.0031730551,0.00012101368],"about_ca_topic_score_codex":0.000022811313,"about_ca_topic_score_gemma":0.00003505503,"teacher_disagreement_score":0.039443634,"about_ca_system_score_codex":0.00017692185,"about_ca_system_score_gemma":0.0010346166,"threshold_uncertainty_score":0.53803915},"labels":[],"label_agreement":null},{"id":"W3096422353","doi":"10.1016/j.jcjd.2020.08.063","title":"57 - Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Discontinuation; Adverse effect; Internal medicine; Glycated hemoglobin; Clinical trial; Diabetes mellitus; Type 2 diabetes; Endocrinology; Liraglutide","score_opus":0.044813579689113585,"score_gpt":0.31516492968598303,"score_spread":0.27035134999686944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096422353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871545,0.0012579316,0.000003675476,0.010285234,0.00013567787,0.00073858234,0.000017206869,0.0000051964753,0.00040198996],"genre_scores_gemma":[0.99685013,0.000040754225,0.00055203884,0.0022542754,0.00020704274,0.0000067932983,0.000021900725,0.0000119502965,0.0000550886],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986372,0.0001595787,0.00064634543,0.00011970978,0.00017680919,0.0002603599],"domain_scores_gemma":[0.9988611,0.00025328997,0.0001804315,0.00011832731,0.000058638692,0.00052825076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010802891,0.000116798896,0.00047496182,0.00010634312,0.000030701955,0.000026470852,0.0001343683,0.00005687948,0.000049482693],"category_scores_gemma":[0.00073566585,0.00007583514,0.00012988703,0.00020758649,0.0001455619,0.00004930805,0.000012240268,0.0002410701,0.0000022886006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022345341,0.0010779016,0.5270382,0.00018994597,0.0008658382,0.0003472435,0.0011122252,0.0000115936655,0.00012918095,0.00015679684,0.10480195,0.3620346],"study_design_scores_gemma":[0.1375807,0.017986888,0.36116347,0.00052626,0.0014736911,0.0000043428327,0.0006279683,0.00035736244,0.00018887456,0.0000936544,0.47966683,0.0003299691],"about_ca_topic_score_codex":0.00010509897,"about_ca_topic_score_gemma":0.0008947295,"teacher_disagreement_score":0.37486488,"about_ca_system_score_codex":0.000032126733,"about_ca_system_score_gemma":0.0002356121,"threshold_uncertainty_score":0.30924672},"labels":[],"label_agreement":null},{"id":"W3096866421","doi":"10.1016/j.jcjd.2020.08.066","title":"60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Subgroup analysis; Sitagliptin; Placebo; Liraglutide; Glycated hemoglobin; Internal medicine; Exploratory analysis; Type 2 diabetes; Diabetes mellitus; Endocrinology; Confidence interval","score_opus":0.03384419962993197,"score_gpt":0.2799177338264537,"score_spread":0.24607353419652173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096866421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966662,0.0002562741,0.000007700624,0.002062429,0.00022722504,0.0006530515,0.00001962497,0.0000092244145,0.00009825076],"genre_scores_gemma":[0.99855655,0.0000022187435,0.0005745912,0.0006459231,0.00014580772,0.000012225255,0.0000128784095,0.000019338582,0.000030486744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857557,0.00009354178,0.00055676734,0.00015013936,0.00030685283,0.00031713516],"domain_scores_gemma":[0.9982242,0.00006799038,0.00034423018,0.0002677938,0.00022596207,0.0008698256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038839647,0.00015185721,0.00073448924,0.00054324465,0.00005381124,0.000028843258,0.00027315845,0.000049419505,0.00006735312],"category_scores_gemma":[0.00041424012,0.00010655883,0.00044047087,0.0013820926,0.000084543724,0.00012848216,0.000030349445,0.00014258291,0.0000027316632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008729577,0.0006056628,0.9299415,0.00016627871,0.007902802,0.000044519846,0.0035112028,0.0011562076,0.0036143532,0.00012714748,0.004133766,0.04792363],"study_design_scores_gemma":[0.048597172,0.015003174,0.86451936,0.00070913683,0.02598989,9.058859e-7,0.0053021577,0.0017731051,0.014057683,0.000045438024,0.02337459,0.00062740175],"about_ca_topic_score_codex":0.0001477157,"about_ca_topic_score_gemma":0.0015997146,"teacher_disagreement_score":0.065422125,"about_ca_system_score_codex":0.00009995333,"about_ca_system_score_gemma":0.00044099003,"threshold_uncertainty_score":0.43453428},"labels":[],"label_agreement":null},{"id":"W3096880011","doi":"10.2337/dc20-1073","title":"Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes","year":2020,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dapagliflozin; Medicine; Breast cancer; Internal medicine; Type 2 diabetes; Population; Placebo; Diabetes mellitus; Cancer; Prediabetes; Oncology; Endocrinology; Pathology","score_opus":0.005072789175467773,"score_gpt":0.19841503521894133,"score_spread":0.19334224604347355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096880011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95594084,0.0040181885,1.5260657e-7,0.03659673,0.00030667253,0.0014882734,0.0010094476,0.00010032194,0.0005393548],"genre_scores_gemma":[0.9238008,0.0011112466,0.000020382251,0.07146035,0.0013114356,0.0005819357,0.0012828863,0.00015332142,0.00027761998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974812,0.000101414094,0.0004340763,0.0006630043,0.00057021703,0.0007500494],"domain_scores_gemma":[0.99854565,0.00013569895,0.0002807453,0.0006087938,0.00024656474,0.00018257095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010256041,0.00065066095,0.0012999638,0.0001621387,0.00010658317,0.000065699795,0.00023167604,0.00032121522,0.00016205068],"category_scores_gemma":[0.000011986475,0.0003832305,0.00020739397,0.0003044363,0.0007641683,0.00010906163,0.00010998999,0.0009343113,0.000014895647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020494286,0.000036785004,0.90772307,0.0023171967,0.0028044167,0.00008509348,0.00254928,0.000001154576,0.000062925574,0.0000010472681,0.07660743,0.007606655],"study_design_scores_gemma":[0.0062977117,0.0011504719,0.90182966,0.0021893869,0.00857419,9.973269e-7,0.0010313493,0.000032342934,0.0019177765,0.00002700207,0.07601817,0.0009309407],"about_ca_topic_score_codex":0.000040952888,"about_ca_topic_score_gemma":0.00002695358,"teacher_disagreement_score":0.034863625,"about_ca_system_score_codex":0.00015775696,"about_ca_system_score_gemma":0.00008883264,"threshold_uncertainty_score":0.99986196},"labels":[],"label_agreement":null},{"id":"W3096911464","doi":"10.2174/1381612826666201103122813","title":"Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure","year":2020,"lang":"en","type":"article","venue":"Current Pharmaceutical Design","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Heart failure; Empagliflozin; Diabetes mellitus; Natriuresis; Afterload; Canagliflozin; Preload; Internal medicine; Cardiology; Ejection fraction; Intensive care medicine; Type 2 diabetes; Endocrinology; Hemodynamics; Blood pressure","score_opus":0.05336148290961519,"score_gpt":0.3325920760833871,"score_spread":0.2792305931737719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096911464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67981046,0.029941065,0.15963799,0.0668649,0.0057849986,0.045547094,0.00023068367,0.0024387299,0.009744051],"genre_scores_gemma":[0.997879,0.00011868206,0.00049180584,0.00085654616,0.00038710635,0.00018741419,0.000025123523,0.00003808912,0.00001620463],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818003,0.00016710888,0.00031511442,0.00045634215,0.00048052976,0.00040086015],"domain_scores_gemma":[0.99897856,0.00019395273,0.000062017316,0.0002195077,0.00006555708,0.0004804049],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016687055,0.00030852607,0.0005673881,0.00009444723,0.000045587632,0.000016392774,0.000100372374,0.00008040748,0.00010533203],"category_scores_gemma":[0.000073647054,0.00024947838,0.00029570723,0.00023983541,0.00011597106,0.00008315888,0.000030246805,0.00039159562,0.00026491223],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008367455,0.0073202522,0.01100266,0.009644628,0.0035088195,0.00063374976,0.0019584617,0.00007551141,0.31261417,0.0026066755,0.19207719,0.4501904],"study_design_scores_gemma":[0.006513141,0.0026261476,0.0016534673,0.00047115455,0.0010705244,0.0000019162335,0.00002208651,0.00043120375,0.92808646,0.00018075995,0.058673486,0.00026965156],"about_ca_topic_score_codex":0.0000010806978,"about_ca_topic_score_gemma":5.4021953e-8,"teacher_disagreement_score":0.61547226,"about_ca_system_score_codex":0.00007785665,"about_ca_system_score_gemma":0.000050934406,"threshold_uncertainty_score":0.99999577},"labels":[],"label_agreement":null},{"id":"W3097267969","doi":"10.1016/j.jcjd.2020.08.044","title":"38 - Cost Effectiveness of Oral Semaglutide 14 mg Vs Empagliflozin 25 mg in Canada","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Semaglutide; Medicine; Glycated hemoglobin; Type 2 diabetes; Metformin; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.015216800550152275,"score_gpt":0.22483252097937764,"score_spread":0.20961572042922536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097267969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479455,0.0010609293,0.0000033875535,0.0020138829,0.0002887876,0.0003891083,0.000048084057,0.000004120357,0.001397126],"genre_scores_gemma":[0.99866533,0.000008270234,0.00010881818,0.0010465672,0.00007031514,0.000008044095,0.000014792662,0.000024125498,0.000053754382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985269,0.00011544749,0.0004521433,0.0001566503,0.00026040943,0.0004884946],"domain_scores_gemma":[0.9982771,0.00014562,0.00024571002,0.00014681832,0.00016295149,0.0010217895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035704163,0.00018782537,0.00070051017,0.00027729763,0.00003342778,0.000017321872,0.00018137186,0.000047031594,0.00016251873],"category_scores_gemma":[0.00035231962,0.00016701072,0.00012050136,0.00038692876,0.00006343707,0.00008929804,0.000018297613,0.0002222033,0.000005648882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040852134,0.000033441618,0.9863196,0.00039432824,0.00036549795,0.00039091997,0.00015167588,0.00014768886,0.00063485856,0.0000673792,0.006808987,0.004644784],"study_design_scores_gemma":[0.0043797214,0.0008879868,0.9705089,0.0009329789,0.0003322221,0.0000034805275,0.00031749127,0.00023417744,0.005068686,0.000056522375,0.017062806,0.00021508227],"about_ca_topic_score_codex":0.41314268,"about_ca_topic_score_gemma":0.9068755,"teacher_disagreement_score":0.49373284,"about_ca_system_score_codex":0.00094425085,"about_ca_system_score_gemma":0.0039032202,"threshold_uncertainty_score":0.69241446},"labels":[],"label_agreement":null},{"id":"W3097384753","doi":"10.1053/j.ajkd.2020.08.003","title":"SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation","year":2020,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, University of North Carolina at Chapel Hill; Providence Health Care; Feinberg School of Medicine; University of New South Wales; Anschutz Medical Campus, University of Colorado; Rijksuniversiteit Groningen; Steno Diabetes Center Copenhagen; Joslin Diabetes Center; University of Washington; Universidad de la República Uruguay; Università degli Studi di Padova; Northwestern University","keywords":"Medicine; Canagliflozin; Kidney disease; Albuminuria; Renal function; Diabetes mellitus; Diabetic nephropathy; Intensive care medicine; Internal medicine; Creatinine; Type 2 diabetes; Type 2 Diabetes Mellitus; Endocrinology; Urology","score_opus":0.018620008547638147,"score_gpt":0.2676160775919139,"score_spread":0.24899606904427576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097384753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97947294,0.0015728406,0.00024692455,0.017784966,0.00014282338,0.000557055,0.00014818275,0.000011149932,0.00006311593],"genre_scores_gemma":[0.9962558,0.000103430466,0.00028528637,0.002794282,0.00012416972,0.000023702332,0.0003316293,0.000013399858,0.00006826235],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870837,0.00007111531,0.00037151773,0.00019575737,0.0005131225,0.00014013666],"domain_scores_gemma":[0.9983386,0.000105734,0.00031129218,0.00013521146,0.00033752437,0.00077167357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041201306,0.00010791649,0.00033831358,0.00013819784,0.000059429818,0.00004587558,0.000061678074,0.000011317953,0.000023823623],"category_scores_gemma":[0.0052761016,0.00007750619,0.00023054684,0.00047682077,0.0003103296,0.00016599453,0.00002802909,0.000057030982,0.000001134756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005892737,0.0022047334,0.45288724,0.0013148393,0.005445479,0.00035922485,0.0010260254,0.00038485267,0.0041605476,0.00024337975,0.42556974,0.10051123],"study_design_scores_gemma":[0.026299141,0.0064466367,0.32683942,0.0039755814,0.01747255,0.00008670237,0.0037540284,0.008580869,0.002751849,0.0024589952,0.6000901,0.0012441259],"about_ca_topic_score_codex":0.000003924139,"about_ca_topic_score_gemma":1.2341904e-7,"teacher_disagreement_score":0.17452037,"about_ca_system_score_codex":0.00005465194,"about_ca_system_score_gemma":0.00058463414,"threshold_uncertainty_score":0.63163674},"labels":[],"label_agreement":null},{"id":"W3097633218","doi":"10.1016/j.jcjd.2020.08.013","title":"9 - Regulation of Glucose Metabolism via the Intra-Islet DPP4/Incretin Axis","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Incretin; Medicine; Internal medicine; Glucagon-like peptide-1; Endocrinology; Islet; Hormone; Secretion; Glucagon; Gastric inhibitory polypeptide; Liraglutide; Type 2 diabetes; Insulin; Diabetes mellitus","score_opus":0.010459451342921396,"score_gpt":0.20384717784870424,"score_spread":0.19338772650578284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097633218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780826,0.0037238905,0.00003621789,0.016131122,0.00022070951,0.00022457122,0.00001386806,0.0000066798,0.0015603554],"genre_scores_gemma":[0.99701166,0.0000235573,0.00037203802,0.0020852515,0.0003662893,0.0000029555017,0.000011754397,0.000016860757,0.00010962143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998997,0.000055942404,0.00037832838,0.00009845,0.00020925376,0.00026103324],"domain_scores_gemma":[0.9988293,0.00006447242,0.00025272134,0.00016614253,0.00016956872,0.0005178073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000278409,0.00012446001,0.00036285797,0.00015871887,0.000058301488,0.00002441443,0.00016619533,0.000046046975,0.00037838673],"category_scores_gemma":[0.00021381519,0.00008395249,0.0001646489,0.00025629374,0.00011101322,0.00011021816,0.000013132569,0.00014708747,0.000015309302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001412141,0.000241971,0.41018632,0.0007799715,0.005281396,0.00015298236,0.0079902345,0.000267619,0.13698515,0.007449203,0.1525352,0.27798873],"study_design_scores_gemma":[0.003980454,0.0015286766,0.63873285,0.0003606292,0.0023272515,0.00000685744,0.00059023243,0.00090171985,0.10883583,0.0016307753,0.24076685,0.00033785624],"about_ca_topic_score_codex":0.00020530538,"about_ca_topic_score_gemma":0.00029457748,"teacher_disagreement_score":0.2776509,"about_ca_system_score_codex":0.00005875175,"about_ca_system_score_gemma":0.0002510503,"threshold_uncertainty_score":0.41430694},"labels":[],"label_agreement":null},{"id":"W3097721621","doi":"10.1016/j.jcjd.2020.08.014","title":"10 - Novel Fully Automated Fiasp-Plus-Pramlintide Artificial Pancreas for Type 1 Diabetes: Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Artificial pancreas; Crossover study; Type 1 diabetes; Diabetes mellitus; Dosing; Liter; Internal medicine; Randomized controlled trial; Type 2 diabetes; Gastroenterology; Urology; Endocrinology; Placebo; Pathology","score_opus":0.03250572013318338,"score_gpt":0.26528733278473776,"score_spread":0.2327816126515544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097721621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807307,0.0019995647,0.00007677,0.00781408,0.0014718408,0.005989438,0.00006969694,0.00012034445,0.0017275717],"genre_scores_gemma":[0.9918098,0.000011451738,0.0014090547,0.0030057859,0.0018063653,0.00023741076,0.00010753246,0.0000767192,0.0015358799],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972096,0.00013736714,0.0012888266,0.000278355,0.0003276107,0.0007582281],"domain_scores_gemma":[0.9961839,0.00085935823,0.0006939692,0.0002159939,0.0006574406,0.0013893635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001252985,0.00036285145,0.002717141,0.0003986504,0.00013803467,0.00014108073,0.00024233093,0.00015415241,0.0009962888],"category_scores_gemma":[0.00577735,0.00027238196,0.0010464938,0.0003357439,0.00017074724,0.00017291072,0.000017848837,0.00021859792,0.00008649261],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85569954,0.00042598275,0.001548877,0.00041518194,0.011065209,0.0000647614,0.00051947235,0.00025276246,0.002477913,0.0009495687,0.12193429,0.004646475],"study_design_scores_gemma":[0.9510961,0.0039602704,0.00014912352,0.000223965,0.0039800783,7.57575e-7,0.00008093799,0.01578577,0.00071347744,0.00012843714,0.02358085,0.00030023957],"about_ca_topic_score_codex":0.000050941213,"about_ca_topic_score_gemma":0.00019033873,"teacher_disagreement_score":0.09835344,"about_ca_system_score_codex":0.00020333403,"about_ca_system_score_gemma":0.0017173154,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W3097926417","doi":"10.1136/bmjdrc-2020-001706","title":"Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events","year":2020,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk","keywords":"Semaglutide; Dulaglutide; Medicine; Nausea; Liraglutide; Vomiting; Adverse effect; Exenatide; Internal medicine; Glycated hemoglobin; Weight loss; Gastroenterology; Type 2 diabetes; Diabetes mellitus; Endocrinology; Obesity","score_opus":0.07570763770123608,"score_gpt":0.378554508493092,"score_spread":0.30284687079185596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097926417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815216,0.00033183294,0.0000054212564,0.0043973243,0.00014005389,0.005966433,0.00025185855,0.00006690726,0.010687989],"genre_scores_gemma":[0.98741686,0.00005086599,0.004249665,0.0008334166,0.0002703181,0.00097134826,0.0002660653,0.000134398,0.0058070496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949845,0.00028322075,0.0005531723,0.0009461033,0.0020182193,0.0012147939],"domain_scores_gemma":[0.99699014,0.0002071437,0.00018934236,0.0009178848,0.00093054154,0.0007649329],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066893065,0.00045047488,0.0008551323,0.00020178777,0.000210155,0.00008705523,0.00097643555,0.00009376231,0.0020315028],"category_scores_gemma":[0.00031605692,0.00035792758,0.00022707136,0.000783669,0.00037276556,0.00031447574,0.0012754088,0.000538241,0.0006102418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007253766,0.000765175,0.93724483,0.0018067278,0.0013828811,0.00034056787,0.0029963157,0.000024617297,0.0044193137,0.000079467,0.037044287,0.006642028],"study_design_scores_gemma":[0.0814226,0.054580115,0.3675247,0.013569443,0.0018327658,0.000028061873,0.04149039,0.0006896295,0.11146166,0.000060385235,0.32442775,0.0029124534],"about_ca_topic_score_codex":0.00028973373,"about_ca_topic_score_gemma":0.00011749357,"teacher_disagreement_score":0.56972015,"about_ca_system_score_codex":0.00047900394,"about_ca_system_score_gemma":0.00073363434,"threshold_uncertainty_score":0.9998873},"labels":[],"label_agreement":null},{"id":"W3097946151","doi":"10.1016/j.jcmg.2020.08.020","title":"Softening the Stiff Heart","year":2020,"lang":"en","type":"letter","venue":"JACC. Cardiovascular imaging","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"FURTHERMORE grants in publishing","keywords":"Softening; Materials science; Mechanics; Composite material; Physics","score_opus":0.015131311529714371,"score_gpt":0.22493905767317995,"score_spread":0.2098077461434656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097946151","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000101608275,0.023688657,0.0009728827,0.95903915,0.0009185179,0.0013362754,0.000011497949,0.00040760238,0.013523829],"genre_scores_gemma":[0.0047429535,0.00023949984,0.0013134708,0.9794688,0.0097323395,0.00020910114,0.00049756264,0.0002227673,0.003573492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691606,0.0001600379,0.0003249319,0.0007807274,0.001151985,0.0006662839],"domain_scores_gemma":[0.9981399,0.00009212656,0.00008294331,0.0014841997,0.000095325995,0.0001054824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003763084,0.00051611156,0.001131155,0.00015477031,0.00021108783,0.0002126256,0.00029814706,0.00014661154,0.00009026273],"category_scores_gemma":[0.0000921249,0.00035983333,0.0027355591,0.0002747177,0.000110325636,0.00010867018,0.0002979208,0.0015010117,0.000495892],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000062721138,0.000011294138,0.00072517176,0.0003252017,0.0061945207,0.003638201,0.00006823951,0.000012837587,0.000012146872,0.000003911769,0.95490766,0.034094535],"study_design_scores_gemma":[0.0009783484,0.000024756024,0.0008377488,0.00024323397,0.006621195,0.00015251378,0.000058413218,0.00020115796,0.000055646087,0.00004561564,0.99043214,0.00034925545],"about_ca_topic_score_codex":0.000055538836,"about_ca_topic_score_gemma":2.5132607e-7,"teacher_disagreement_score":0.035524447,"about_ca_system_score_codex":0.00017044626,"about_ca_system_score_gemma":0.000083463616,"threshold_uncertainty_score":0.9998854},"labels":[],"label_agreement":null},{"id":"W3098120343","doi":"10.1161/circ.142.suppl_3.14960","title":"Abstract 14960: Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Myocardial infarction; Placebo; Mace; Cardiology; Unstable angina; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Confidence interval; Endocrinology","score_opus":0.08794141391870566,"score_gpt":0.3224492498242907,"score_spread":0.23450783590558502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098120343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439615,0.0007210836,0.000028301745,0.0023201697,0.00027909564,0.0015929076,0.0000030355125,0.000021499716,0.00063773186],"genre_scores_gemma":[0.9993334,0.000029323372,0.000013791427,0.00007783038,0.00039335675,0.000064045016,0.000056899626,0.000012802135,0.000018554752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984974,0.0001167259,0.00041957592,0.00022405507,0.0005732081,0.00016900201],"domain_scores_gemma":[0.9994051,0.00006551041,0.00014264525,0.00030484993,0.000036490503,0.00004540969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066775444,0.00013788778,0.0003230055,0.000067616325,0.00006500282,0.000009693632,0.00014162276,0.000050592233,0.000028510061],"category_scores_gemma":[0.00016514119,0.0000840099,0.00033145762,0.00027371338,0.000020718782,0.00009874129,0.000053652533,0.00013537121,0.000021655072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012633234,0.002969107,0.5002774,0.0016406096,0.010544684,0.00012843045,0.054783314,0.06941839,0.0072662937,0.0007318338,0.0016901636,0.33791655],"study_design_scores_gemma":[0.017384786,0.00023010757,0.97706294,0.00017183524,0.0009163173,0.0000020408938,0.0012433999,0.001416798,0.00029435137,0.00015441733,0.0009756727,0.00014736068],"about_ca_topic_score_codex":0.00006701576,"about_ca_topic_score_gemma":0.0000012109432,"teacher_disagreement_score":0.47678554,"about_ca_system_score_codex":0.000092540235,"about_ca_system_score_gemma":0.000026401176,"threshold_uncertainty_score":0.34258243},"labels":[],"label_agreement":null},{"id":"W3099621323","doi":"10.1161/circ.142.suppl_3.13814","title":"Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Semaglutide; Mace; Medicine; Placebo; Internal medicine; Myocardial infarction; Type 2 diabetes; Dulaglutide; Post-hoc analysis; Gastroenterology; Diabetes mellitus; Endocrinology; Exenatide; Liraglutide; Percutaneous coronary intervention","score_opus":0.03447193575835076,"score_gpt":0.28532189790672213,"score_spread":0.25084996214837135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099621323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978434,0.0001834312,0.000029138817,0.00090135256,0.000033231143,0.0008491639,0.00008287419,0.000016518843,0.000060911167],"genre_scores_gemma":[0.9992154,0.000005927569,0.000069686976,0.00034902594,0.000018490442,0.000010893339,0.0002896172,0.000010618142,0.000030312414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988315,0.00009425168,0.00042067337,0.00023512566,0.00025278618,0.00016565982],"domain_scores_gemma":[0.99912786,0.00016870126,0.0002599162,0.00018352852,0.00019315528,0.00006683904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052244466,0.00012703371,0.0005639674,0.00016591614,0.000038982176,0.000022692799,0.000044296077,0.000045499364,0.00006066628],"category_scores_gemma":[0.00047636,0.00008253758,0.00013667512,0.0013342906,0.00005434858,0.000071448114,0.000030152603,0.000058770263,0.0000016508643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053476146,0.00015770437,0.9865788,0.00009474446,0.0027190158,0.000002210307,0.00067690626,0.0020850657,0.0012866396,0.000012454501,0.000033780158,0.0058179223],"study_design_scores_gemma":[0.0031028343,0.0001655634,0.98940015,0.000049651328,0.0042379973,2.7186761e-8,0.00028179408,0.0022352382,0.0003736906,0.000004442808,0.000064803906,0.000083817715],"about_ca_topic_score_codex":0.00002487316,"about_ca_topic_score_gemma":0.00003883409,"teacher_disagreement_score":0.0057341047,"about_ca_system_score_codex":0.000062351355,"about_ca_system_score_gemma":0.000040750507,"threshold_uncertainty_score":0.3365785},"labels":[],"label_agreement":null},{"id":"W3100058299","doi":"10.1093/eurheartj/ehaa777","title":"Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Dulaglutide; Metformin; Hazard ratio; Internal medicine; Type 2 diabetes; Myocardial infarction; Diabetes mellitus; Proportional hazards model; Sitagliptin; Stroke (engine); Clinical endpoint; Cardiology; Confidence interval; Randomized controlled trial; Insulin; Endocrinology; Liraglutide","score_opus":0.014694491875824407,"score_gpt":0.22010128508237659,"score_spread":0.20540679320655217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100058299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685377,0.0008378245,0.00030078276,0.0005463392,0.000015700674,0.0013090073,0.000046301422,0.0000493557,0.000040913674],"genre_scores_gemma":[0.99139374,0.0001879016,0.0073212497,0.0007122411,0.00007687239,0.000023846877,0.00008381364,0.00009765518,0.00010270231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981961,0.00024886066,0.00027138248,0.00043009027,0.0004636913,0.00038982835],"domain_scores_gemma":[0.99878794,0.00007580946,0.000112442074,0.00028050123,0.00012587683,0.0006174128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056949176,0.0003485048,0.00075267855,0.0001405183,0.00015697569,0.000099430974,0.0000636921,0.000020201109,0.000018854513],"category_scores_gemma":[0.00013706011,0.00018173049,0.00011544054,0.000199216,0.0000994309,0.00029241032,0.000054615542,0.00021072045,0.0000021678447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036111432,0.00026604344,0.9884635,0.0001360078,0.0023099016,0.00040882445,0.00009929682,0.00021548184,0.0000021909214,0.000001276999,0.0002079813,0.004278339],"study_design_scores_gemma":[0.023862142,0.005010695,0.9630087,0.0002886741,0.0030433852,0.000013101147,0.00007669822,0.00041100287,0.000018995866,0.0000021373428,0.0039961287,0.00026831156],"about_ca_topic_score_codex":0.000009279833,"about_ca_topic_score_gemma":0.000007732665,"teacher_disagreement_score":0.025454786,"about_ca_system_score_codex":0.00003946552,"about_ca_system_score_gemma":0.00005207432,"threshold_uncertainty_score":0.7410754},"labels":[],"label_agreement":null},{"id":"W3100542962","doi":"10.1056/nejmoa2030183","title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1824,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Rijksuniversiteit Groningen; Massachusetts Medical Society; Sanofi","keywords":"Heart failure; Diabetes mellitus; Medicine; Intensive care medicine; Cardiology; Internal medicine; Endocrinology","score_opus":0.009861050130002576,"score_gpt":0.2174310771971121,"score_spread":0.20757002706710953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100542962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93207467,0.0008027833,0.00002336422,0.06656773,0.00008477687,0.00018586786,4.289726e-7,0.000008408785,0.00025197736],"genre_scores_gemma":[0.9943517,0.00011425728,0.0018015675,0.0028248844,0.00083323964,9.212482e-7,0.000007359548,0.000013552678,0.000052544914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990265,0.00003373344,0.00029940464,0.000114510374,0.00035211453,0.00017373117],"domain_scores_gemma":[0.9993124,0.000060969505,0.00012623928,0.00006731121,0.00009198801,0.0003410712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024026533,0.00012581589,0.0004431895,0.00013529876,0.000016904472,0.000007867301,0.000040024657,0.00003061659,0.00010483877],"category_scores_gemma":[0.00017540282,0.00007167574,0.00002190236,0.00020196696,0.000044670367,0.00008296567,0.000019333267,0.00023100403,0.0000019902566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006904336,0.000082706865,0.89173394,0.000052806277,0.00013972532,0.00005660606,0.00076459657,0.000008067889,0.00018616926,0.000013151098,0.014611434,0.09166034],"study_design_scores_gemma":[0.1449145,0.010339103,0.64170766,0.0013068601,0.0005031472,0.000012283947,0.00035755246,0.000041642405,0.00026193963,0.00006601231,0.20034273,0.0001465677],"about_ca_topic_score_codex":0.0000036681097,"about_ca_topic_score_gemma":0.000007702639,"teacher_disagreement_score":0.2500263,"about_ca_system_score_codex":0.000027897104,"about_ca_system_score_gemma":0.000038380214,"threshold_uncertainty_score":0.2922852},"labels":[],"label_agreement":null},{"id":"W3101044784","doi":"10.1056/nejmoa2030186","title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Women's College Hospital; University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Diabetes mellitus; Medicine; Kidney disease; Disease; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.007553549224811723,"score_gpt":0.21492786989877008,"score_spread":0.20737432067395836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101044784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614594,0.0017673352,0.000026851118,0.036097165,0.000096274096,0.00021688825,0.0000019134031,0.000008166619,0.0003259811],"genre_scores_gemma":[0.9949267,0.00014496646,0.00016435016,0.003437237,0.0011922986,0.0000012418334,0.000016321284,0.000012763106,0.00010410466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991087,0.000025762665,0.000258921,0.000111525136,0.00033210457,0.00016302352],"domain_scores_gemma":[0.99881655,0.000040234423,0.00012057404,0.00007691896,0.000060743692,0.0008849845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015057392,0.00012240422,0.0003671508,0.00011697926,0.000013967234,0.000006256401,0.00004821897,0.000019677898,0.00011688996],"category_scores_gemma":[0.00024432427,0.000068464935,0.000024934965,0.0001377917,0.00005821864,0.00008338207,0.000019369298,0.00016360443,0.0000023422033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012218496,0.00012152048,0.911196,0.00016282397,0.00016505967,0.00015955932,0.0003592353,0.000006648607,0.00008271148,0.00003058051,0.010520996,0.075973034],"study_design_scores_gemma":[0.16586405,0.009029322,0.7780489,0.0012947178,0.00073730707,0.0000024296653,0.00004165258,0.00011045968,0.000062197,0.000092942966,0.044605523,0.00011051993],"about_ca_topic_score_codex":0.0000027927617,"about_ca_topic_score_gemma":0.0000022830993,"teacher_disagreement_score":0.16464221,"about_ca_system_score_codex":0.000045893026,"about_ca_system_score_gemma":0.00013020734,"threshold_uncertainty_score":0.2791919},"labels":[],"label_agreement":null},{"id":"W3101372907","doi":"10.1111/dom.14254","title":"Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Boehringer Ingelheim","keywords":"Linagliptin; Glimepiride; Medicine; Hazard ratio; Type 2 diabetes; Mace; Internal medicine; Clinical endpoint; Diabetes mellitus; Randomized controlled trial; Lower risk; Dipeptidyl peptidase-4 inhibitor; Adverse effect; Myocardial infarction; Confidence interval; Endocrinology; Percutaneous coronary intervention","score_opus":0.006807630801666101,"score_gpt":0.19952963826545225,"score_spread":0.19272200746378615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101372907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897677,0.0054197945,0.000037321082,0.00090516114,0.00006445712,0.0035080472,0.00003526847,0.00005282309,0.00020944477],"genre_scores_gemma":[0.99797076,0.0003696364,0.00022891599,0.00085539743,0.0000990664,0.00023811574,0.00007847729,0.000038176007,0.000121428675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970939,0.0004453587,0.0005161949,0.0006458274,0.0007400553,0.00055863097],"domain_scores_gemma":[0.9978163,0.0007225144,0.00030712597,0.00071495457,0.00019727349,0.00024178094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010391878,0.00052954734,0.003097561,0.00025432845,0.00019040056,0.00007713148,0.00021676396,0.000111236826,0.000008729931],"category_scores_gemma":[0.00024053387,0.00024120064,0.0005686876,0.0019171544,0.0005535449,0.00016930125,0.0001847361,0.0003199134,0.0000014336288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019092804,0.0005650906,0.95136905,0.0003480659,0.021952145,0.0000131057295,0.00546282,0.0004113449,0.00008810001,0.00013755025,0.00012045848,0.0004394856],"study_design_scores_gemma":[0.23003839,0.00040768756,0.7406622,0.00014858207,0.025450831,5.184671e-7,0.00069833384,0.0006713306,0.00052841305,0.0000081432045,0.0012268629,0.00015869038],"about_ca_topic_score_codex":0.0001452013,"about_ca_topic_score_gemma":0.00041307523,"teacher_disagreement_score":0.21094558,"about_ca_system_score_codex":0.000025783911,"about_ca_system_score_gemma":0.00008024877,"threshold_uncertainty_score":0.9835877},"labels":[],"label_agreement":null},{"id":"W3101633024","doi":"10.2215/cjn.10140620","title":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","year":2020,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; University of British Columbia","funders":"Janssen Pharmaceuticals; Janssen Research and Development; University of Chicago; Relypsa; Bristol-Myers Squibb; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Novo Nordisk; Eisai; University of Chicago Medicine; Pfizer; Innovent Biologics; AstraZeneca; Amarin Corporation; Regeneron Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Alnylam Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Celgene; Eli Lilly and Company","keywords":"Canagliflozin; Medicine; Renal function; Hazard ratio; Internal medicine; Confidence interval; Population; Empagliflozin; Urology; Diabetes mellitus; Creatinine; Placebo; Albuminuria; Type 2 diabetes; Gastroenterology; Endocrinology","score_opus":0.01464695768332685,"score_gpt":0.2888342332748628,"score_spread":0.27418727559153594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101633024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810991,0.00016847861,0.00013041253,0.018143564,0.00008455883,0.00031747832,0.000003997884,0.0000047789595,0.00004759854],"genre_scores_gemma":[0.95007026,0.00025504953,0.0035658663,0.04587702,0.00017110315,0.0000024205817,0.0000023130438,0.000017515393,0.000038421058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981007,0.00029580438,0.0008679417,0.00017257784,0.00033770353,0.0002253001],"domain_scores_gemma":[0.9975213,0.00069865555,0.0012002573,0.00021138188,0.00019423262,0.00017416435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052326417,0.00014944084,0.0010636175,0.000035124584,0.000018551997,0.0000023085834,0.00026350518,0.00006344324,0.000041214025],"category_scores_gemma":[0.00022912945,0.000088003086,0.0005451873,0.00028361764,0.00085275696,0.000037040823,0.000121729245,0.00038207168,0.0000038215253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030919332,0.0020906345,0.8799501,0.00021691524,0.0019176394,0.00002469941,0.00050913554,0.00004962344,0.0013927327,0.0000140118955,0.0870999,0.023642674],"study_design_scores_gemma":[0.009477574,0.010716367,0.95746833,0.00013321047,0.00089818967,0.0000021521996,0.00022278517,0.00016480428,0.00019574909,0.000022855218,0.020606307,0.00009167188],"about_ca_topic_score_codex":0.000050491184,"about_ca_topic_score_gemma":0.00000713752,"teacher_disagreement_score":0.07751824,"about_ca_system_score_codex":0.000050411443,"about_ca_system_score_gemma":0.00013093527,"threshold_uncertainty_score":0.35886618},"labels":[],"label_agreement":null},{"id":"W3101690455","doi":"10.1016/s2213-8587(20)30344-2","title":"Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"Abbott Vascular; St. Jude Medical; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Myocardial infarction; Placebo; Diabetes mellitus; Type 2 diabetes; Clinical trial; Adverse effect; Hazard ratio; Cardiology; Confidence interval; Endocrinology","score_opus":0.029464730661604415,"score_gpt":0.2747470569956991,"score_spread":0.24528232633409472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101690455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549454,0.0018838034,3.260962e-7,0.00095087016,0.0001460676,0.0014551649,0.000024119237,0.000016942977,0.000028141072],"genre_scores_gemma":[0.9989109,0.00032576936,0.000014309079,0.0005672851,0.00006554748,0.00006742818,0.000023348886,0.000016459704,0.000008927082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818903,0.00033074786,0.00041379812,0.00035476394,0.000260873,0.00045079485],"domain_scores_gemma":[0.99865496,0.00050227914,0.00017441643,0.00052639167,0.000040037306,0.00010188592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002819083,0.00020676947,0.0013007759,0.00010875054,0.000043083503,0.0000045298298,0.00017944133,0.000043756394,0.000009775606],"category_scores_gemma":[0.00033773942,0.00011029803,0.0002740442,0.0004369147,0.00023955257,0.000029968913,0.00019311572,0.00021938584,0.0000016647601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031897305,0.00042559227,0.984089,0.00038392303,0.0058125556,0.0000026197338,0.0001155526,0.000027991884,0.0000055468417,0.00003066565,0.000039179235,0.0058776042],"study_design_scores_gemma":[0.027886,0.0027348353,0.96181834,0.00014154922,0.0067573097,1.943175e-8,0.000010106016,0.00013078406,0.00009339106,0.000022837823,0.0003082065,0.000096610456],"about_ca_topic_score_codex":0.0000053768727,"about_ca_topic_score_gemma":0.000009431918,"teacher_disagreement_score":0.02469627,"about_ca_system_score_codex":0.000022147786,"about_ca_system_score_gemma":0.000018153536,"threshold_uncertainty_score":0.44978234},"labels":[],"label_agreement":null},{"id":"W3101995399","doi":"10.1161/circ.142.suppl_3.14959","title":"Abstract 14959: Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Placebo; Internal medicine; Type 2 diabetes; Myocardial infarction; Cardiology; Diabetes mellitus; Endocrinology; Pathology","score_opus":0.026918994317222198,"score_gpt":0.296740735120399,"score_spread":0.2698217408031768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101995399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965432,0.00002250587,0.000014273099,0.0007177862,0.00014593011,0.0010442616,0.0000095438245,0.000013677173,0.0014887863],"genre_scores_gemma":[0.9995898,0.0000024984463,0.0000044178337,0.00013448302,0.00010027255,0.000030502488,0.00011238994,0.000007982816,0.000017677996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991678,0.000070561684,0.00028277203,0.00012361073,0.000263071,0.00009217367],"domain_scores_gemma":[0.9995608,0.00012459206,0.00011412907,0.0001489602,0.000018684415,0.000032887918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000248725,0.000090801135,0.00025602515,0.00006808687,0.000017369026,0.0000038011615,0.000044027525,0.00004687305,0.000040364503],"category_scores_gemma":[0.00014958742,0.000063443724,0.0001365085,0.00018824288,0.000016916198,0.000049127877,0.000010226462,0.000078520636,0.00002407537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066833925,0.0004914777,0.9792258,0.00020230917,0.00024408143,0.000004552948,0.00069418654,0.00068125245,0.0038798244,0.00009705307,0.00087657676,0.006919478],"study_design_scores_gemma":[0.01642553,0.0011425996,0.98087525,0.0000367468,0.000215761,2.6138554e-7,0.000034896424,0.00019050883,0.00085305533,0.000018178956,0.0001557607,0.000051436502],"about_ca_topic_score_codex":0.00003065364,"about_ca_topic_score_gemma":0.0000014927442,"teacher_disagreement_score":0.009742136,"about_ca_system_score_codex":0.000040331277,"about_ca_system_score_gemma":0.000013311802,"threshold_uncertainty_score":0.258716},"labels":[],"label_agreement":null},{"id":"W3102626203","doi":"10.1016/j.diabres.2020.108535","title":"Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel","year":2020,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Novo Nordisk Pharma; Esperion Therapeutics; Sanofi; Wörwag Pharma; Mylan; Novo Nordisk; Valeant Pharmaceuticals International; Servier; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Reimbursement; Family medicine; MEDLINE; Health care","score_opus":0.30912208424076193,"score_gpt":0.5127033763357394,"score_spread":0.20358129209497744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102626203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9065049,0.0010544604,0.000028580711,0.08621408,0.00018810426,0.0006135673,0.00015657717,0.000023205745,0.0052165166],"genre_scores_gemma":[0.9699531,0.00959233,0.0030356832,0.015714861,0.00082090445,0.000021833897,0.00032296524,0.000038849583,0.0004994527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950476,0.002717834,0.00089831295,0.0005247572,0.00055536826,0.0002560936],"domain_scores_gemma":[0.9879909,0.010195427,0.00031971638,0.00032210493,0.00087325036,0.00029857949],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006894948,0.00014508449,0.00035344902,0.000053760745,0.00010354152,0.00014204664,0.00020298481,0.00008668233,0.000051637966],"category_scores_gemma":[0.033550806,0.000105899955,0.00005635365,0.00019996765,0.000391214,0.0007064401,0.00041573573,0.00056934665,0.00004574627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013080654,0.0014768109,0.7774902,0.00003408717,0.0005394144,0.000015382564,0.00064317515,7.7229197e-7,0.000023022209,0.00009482855,0.0033664436,0.2150078],"study_design_scores_gemma":[0.003835995,0.0021794264,0.648077,0.00020328978,0.00019086497,6.7175097e-7,0.0053292955,0.0042546415,0.000009168101,0.000089247646,0.3356722,0.00015820183],"about_ca_topic_score_codex":0.00042975228,"about_ca_topic_score_gemma":0.00013042032,"teacher_disagreement_score":0.33230576,"about_ca_system_score_codex":0.00001953236,"about_ca_system_score_gemma":0.00007406885,"threshold_uncertainty_score":0.97459},"labels":[],"label_agreement":null},{"id":"W3103002140","doi":"10.1016/j.kint.2020.10.031","title":"Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","year":2020,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University Health Network; University of Toronto","funders":"National Institutes of Health; Akebia Therapeutics; Relypsa; Astellas Pharma; Boston Scientific Corporation; Amgen; Boehringer Ingelheim; Daiichi-Sankyo; Novo Nordisk; Intarcia Therapeutics; Nestlé Health Science; Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Renal function; Internal medicine; Diuretic; Hazard ratio; Placebo; Kidney disease; Odds ratio; Urology; Confidence interval; Type 2 diabetes; Diabetes mellitus; Endocrinology; Pathology","score_opus":0.03952805095619276,"score_gpt":0.2999901772128829,"score_spread":0.26046212625669013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103002140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503647,0.0000063184616,0.0010653555,0.046640202,0.0001237763,0.0010673098,0.00016619936,0.000026229529,0.00053992233],"genre_scores_gemma":[0.9935711,0.000017099153,0.0001265202,0.003916334,0.00013399102,0.000112911315,0.0020525358,0.000010962422,0.000058555055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905044,0.000060670187,0.00034629216,0.0001874363,0.00025352914,0.000101606376],"domain_scores_gemma":[0.99949217,0.000032035266,0.00017220777,0.00014560697,0.00008847705,0.000069493835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001594109,0.000121312034,0.00016069792,0.00007769364,0.000051245912,0.000037292826,0.000101190206,0.000042875767,0.00008569436],"category_scores_gemma":[0.00010883945,0.000073880765,0.000051992305,0.00022685323,0.000055389606,0.00018780732,0.000020369898,0.00010197342,0.00000514068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022538608,0.0026461263,0.5835837,0.0004172608,0.0011757128,0.000066938795,0.008654982,0.00012132745,0.35519066,0.012650402,0.0024677827,0.010486453],"study_design_scores_gemma":[0.031868238,0.0006891881,0.93629086,0.0001941239,0.00040122555,0.000010102312,0.00015846777,0.0021999893,0.024746438,0.00014277193,0.0031376814,0.00016094139],"about_ca_topic_score_codex":0.000018793036,"about_ca_topic_score_gemma":0.00002116175,"teacher_disagreement_score":0.3527071,"about_ca_system_score_codex":0.000041550113,"about_ca_system_score_gemma":0.0000695936,"threshold_uncertainty_score":0.301277},"labels":[],"label_agreement":null},{"id":"W3103126890","doi":"10.1161/circulationaha.120.051824","title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Baseline (sea); Heart failure; Internal medicine; Cardiology; Benzhydryl compounds; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.0046062899895161135,"score_gpt":0.2042207130546001,"score_spread":0.19961442306508398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103126890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987826,0.00012154195,0.000035454912,0.00034268748,0.000011733109,0.00063625706,0.000011696753,0.000018819856,0.000039257844],"genre_scores_gemma":[0.99945366,0.0000025141717,0.00008962898,0.00017573395,0.000011815496,0.000017410755,0.00023404001,0.000011352003,0.000003843687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992759,0.00007041667,0.000121815545,0.0001755033,0.00023307608,0.0001232595],"domain_scores_gemma":[0.99969494,0.00005707302,0.00003153327,0.00012365195,0.000023633025,0.000069177586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013814365,0.00010410861,0.00032540652,0.000056675563,0.000012352657,0.0000060205048,0.000013234259,0.000028458657,0.000008905561],"category_scores_gemma":[0.000064064414,0.00007328437,0.00006257729,0.00011094093,0.000016582948,0.000051629126,0.000010254863,0.00004471059,0.0000033940892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012877466,0.0000820947,0.99423015,0.00014294186,0.00022478285,7.116773e-7,0.000041766598,0.00021337433,0.00026210645,0.0000023417617,0.00026946835,0.0044014724],"study_design_scores_gemma":[0.0053193965,0.0014250083,0.9897405,0.000071044014,0.00030183262,1.5443364e-8,0.0000052606388,0.0005751958,0.0017341921,0.0000013571137,0.0007596645,0.00006653262],"about_ca_topic_score_codex":0.0000074715244,"about_ca_topic_score_gemma":9.969542e-7,"teacher_disagreement_score":0.005190622,"about_ca_system_score_codex":0.000030554642,"about_ca_system_score_gemma":0.000005478494,"threshold_uncertainty_score":0.298845},"labels":[],"label_agreement":null},{"id":"W3103548509","doi":"10.1016/j.jcjd.2020.10.002","title":"Glycated Hemoglobin and Blood Pressure Levels in Adults With Type 2 Diabetes: How Many Patients Are on Target?","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul; Conselho Nacional de Desenvolvimento Científico e Tecnológico","keywords":"Medicine; Glycated hemoglobin; Blood pressure; Diabetes mellitus; Glycemic; Type 2 diabetes; Interquartile range; Internal medicine; Outpatient clinic; Diabetic retinopathy; Endocrinology","score_opus":0.009553204650839538,"score_gpt":0.18474324183904867,"score_spread":0.17519003718820914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103548509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992716,0.0025569743,2.7090726e-7,0.003822027,0.00010310281,0.0003883276,0.000052420106,0.0000105419995,0.00035032595],"genre_scores_gemma":[0.997561,0.0000135128375,0.00017095327,0.0019495368,0.000093462884,0.000005903473,0.000024343071,0.00003163628,0.00014965434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883896,0.00003675378,0.00023233122,0.00022252603,0.00022162551,0.00044781476],"domain_scores_gemma":[0.99855924,0.000035810986,0.0002047921,0.00013530505,0.00020327642,0.000861601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008254871,0.00022217071,0.00046389844,0.00026501753,0.000046728328,0.00005622669,0.00011995005,0.000074093456,0.000062998326],"category_scores_gemma":[0.00017903245,0.0001700546,0.00005263938,0.00032127832,0.000067447276,0.00016077688,0.000014706286,0.00022690035,0.000005841399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004869598,0.00013853025,0.9933971,0.00028924493,0.0005819676,0.00010517276,0.0003883132,0.000016396742,0.000048990692,0.000014358764,0.0032563806,0.0017148108],"study_design_scores_gemma":[0.0091401655,0.0050331443,0.9745901,0.0017065653,0.0007244013,6.8294736e-7,0.00024315153,0.0001368627,0.0016260851,0.000020921485,0.0065293345,0.000248587],"about_ca_topic_score_codex":0.000033399432,"about_ca_topic_score_gemma":0.00041239508,"teacher_disagreement_score":0.01880704,"about_ca_system_score_codex":0.000049237704,"about_ca_system_score_gemma":0.00019410768,"threshold_uncertainty_score":0.69346255},"labels":[],"label_agreement":null},{"id":"W3103705001","doi":"10.1161/circ.142.suppl_3.14962","title":"Abstract 14962: Empagliflozin’s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; COPD; Internal medicine; EMPA; Diabetes mellitus; Type 2 diabetes; Placebo; Mace; Cardiology; Hazard ratio; Heart failure; Population; Coronary artery disease; Myocardial infarction; Endocrinology; Confidence interval; Pathology; Percutaneous coronary intervention","score_opus":0.019828005641708675,"score_gpt":0.2475164934100979,"score_spread":0.22768848776838924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103705001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997743,0.0012654383,0.000013925561,0.000051445717,0.00008909889,0.00067537,0.0000637317,0.000060824073,0.000037150472],"genre_scores_gemma":[0.99843544,0.000024301495,0.00008184186,0.000093032,0.0001387047,0.000028992816,0.0011631668,0.000032568514,0.0000019640877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879605,0.00004730465,0.00021449974,0.0004196475,0.00031347887,0.00020902406],"domain_scores_gemma":[0.9992394,0.00002796711,0.000085858985,0.0003078019,0.000068278285,0.00027072546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006734045,0.0002103294,0.0003714345,0.000093629795,0.00004087312,0.00003092168,0.00004471787,0.0000592061,0.000055452183],"category_scores_gemma":[0.00005569964,0.0001665262,0.00010214827,0.00021221096,0.000047475165,0.00036310867,0.00003130666,0.000113202324,0.000016079715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002969112,0.00016804926,0.9794403,0.00006582439,0.00055908354,0.0000497612,0.0005344397,0.001168974,0.000026923304,0.000002980222,0.0000058739197,0.017680923],"study_design_scores_gemma":[0.0020016364,0.00014373672,0.9957139,0.00005090339,0.00083395146,7.6486344e-8,0.000101091784,0.00080738805,0.000009502093,0.00012734553,0.000028627095,0.00018182791],"about_ca_topic_score_codex":0.00016878509,"about_ca_topic_score_gemma":0.0000071483137,"teacher_disagreement_score":0.017499095,"about_ca_system_score_codex":0.00013576954,"about_ca_system_score_gemma":0.00002645649,"threshold_uncertainty_score":0.6790741},"labels":[],"label_agreement":null},{"id":"W3104353694","doi":"10.1146/annurev-physiol-031620-095920","title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","year":2020,"lang":"en","type":"review","venue":"Annual Review of Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":482,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; National Institute on Aging; Canadian Institutes of Health Research; University of California, San Diego; Sun Pharma; National Heart, Lung, and Blood Institute; Heart and Stroke Foundation of Canada; Novo Nordisk; Sanofi; Fresenius Medical Care North America; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; National Institutes of Health; HLS Therapeutics; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; U.S. Department of Veterans Affairs","keywords":"Renal glucose reabsorption; Renal function; Internal medicine; Endocrinology; Albuminuria; Glomerular hyperfiltration; Medicine; Reabsorption; Kidney; Renal physiology; Diabetes mellitus; Type 2 diabetes; Chemistry","score_opus":0.010235755409913434,"score_gpt":0.27853262841674276,"score_spread":0.2682968730068293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104353694","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009432873,0.99693644,0.0000011773267,0.00006174314,0.00023270638,0.0019657563,0.000030391126,0.000016156957,0.0007461941],"genre_scores_gemma":[0.000024793246,0.99825275,0.000019475132,0.0010104649,0.00019530587,0.00014141854,0.00024296287,0.000029097726,0.00008372956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984952,0.00023047344,0.00052942353,0.00039766848,0.00019322417,0.00015398364],"domain_scores_gemma":[0.9989572,0.00014239705,0.00032157812,0.00037984442,0.000073522046,0.00012541888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016748787,0.0003282177,0.0039450093,0.00010096543,0.000012274286,0.0000010224638,0.00007576632,0.00013373488,0.000027833572],"category_scores_gemma":[0.00027635504,0.00021592705,0.0012604842,0.00022249132,0.00008302632,0.000025948388,0.000101400794,0.00015844005,0.00004430195],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009080641,0.000069698595,2.653147e-7,0.42248476,0.0020391154,0.0000058618443,0.000005796984,8.533972e-9,0.000010246507,0.00010841126,0.009708094,0.5655587],"study_design_scores_gemma":[0.0003199441,0.0013782168,0.00002569099,0.17439476,0.013238465,0.0000019374634,0.0000025098805,4.865579e-8,0.00002369528,0.0000130091175,0.81049985,0.00010189494],"about_ca_topic_score_codex":0.0000049243627,"about_ca_topic_score_gemma":2.6932398e-8,"teacher_disagreement_score":0.80079174,"about_ca_system_score_codex":0.000023946548,"about_ca_system_score_gemma":0.00008905853,"threshold_uncertainty_score":0.880525},"labels":[],"label_agreement":null},{"id":"W3104397728","doi":"10.1161/circulationaha.120.051901","title":"Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function","year":2020,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Renal function; Function (biology); Cardiology; Kidney; Internal medicine","score_opus":0.018328211070364354,"score_gpt":0.20544285654327024,"score_spread":0.18711464547290588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104397728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7794903,0.02127244,0.031115899,0.14793363,0.0012353627,0.009919458,0.0025135465,0.00031932892,0.0062000337],"genre_scores_gemma":[0.98843986,0.0001759685,0.00014234064,0.008013122,0.00021089234,0.00002139912,0.0029253766,0.00003276407,0.0000382659],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99873316,0.00007933071,0.00030551825,0.00022857716,0.0005536449,0.00009977],"domain_scores_gemma":[0.99901056,0.00006843447,0.00040971496,0.00027475983,0.00017827748,0.000058268713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013892927,0.00015028735,0.0005869226,0.0001378624,0.000024927287,0.0000043665664,0.000032140306,0.00014831964,0.000007803791],"category_scores_gemma":[0.0002387196,0.00012793511,0.00023431782,0.00018658054,0.000055178672,0.00003771459,0.000013696622,0.00017333074,0.0000010292621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001863762,0.00038317047,0.33883125,0.0023471178,0.017081881,0.000015706253,0.0007932601,0.0004523599,0.0014963928,0.00007783557,0.61018205,0.02815262],"study_design_scores_gemma":[0.0058328183,0.0005703281,0.7407019,0.0006545974,0.022137236,0.0000014036592,0.000043326378,0.00025547782,0.0010413498,0.0001665115,0.22830504,0.0002899759],"about_ca_topic_score_codex":0.00010737476,"about_ca_topic_score_gemma":0.0000013513085,"teacher_disagreement_score":0.4018707,"about_ca_system_score_codex":0.000068181354,"about_ca_system_score_gemma":0.00005547171,"threshold_uncertainty_score":0.52170426},"labels":[],"label_agreement":null},{"id":"W3105831470","doi":"10.1161/circ.142.suppl_3.14961","title":"Abstract 14961: External Applicability of REDUCE-IT in a Large Diabetes Cardiovascular Outcomes Trial: A Post Hoc Analysis of EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Mace; Empagliflozin; EMPA; Internal medicine; Type 2 diabetes; Diabetes mellitus; Placebo; Cardiology; Endocrinology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.042774726730111824,"score_gpt":0.30971158644311386,"score_spread":0.266936859713002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105831470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735814,0.0003368044,0.00020571689,0.0005024055,0.000037197602,0.0011619562,0.000031736985,0.000028726388,0.00033732314],"genre_scores_gemma":[0.99945307,0.000008887648,0.00012263242,0.00016680441,0.000033822555,0.000059262926,0.00013228547,0.000013501824,0.000009714095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826556,0.00005000528,0.0007094857,0.00032524738,0.00045507454,0.00019461435],"domain_scores_gemma":[0.99902844,0.00007310462,0.00022386559,0.0004898656,0.00009783367,0.00008690539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055252574,0.00015522931,0.0010782205,0.00029873534,0.000015860136,0.000008052376,0.00008516703,0.00007326652,0.000097170494],"category_scores_gemma":[0.00019568331,0.00013491101,0.000938828,0.0007393808,0.00003308555,0.00009036688,0.00003908394,0.00007826377,0.0000065673057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070758513,0.0005181763,0.9850984,0.0002969815,0.0037852565,0.000005961092,0.00033498922,0.00084321393,0.0022284423,0.000052137024,0.0000059758922,0.0061228424],"study_design_scores_gemma":[0.013043498,0.00014686603,0.98038226,0.00003437178,0.004010936,4.7102283e-8,0.00012334393,0.0016136037,0.0004188853,0.000019930081,0.00010862356,0.00009765625],"about_ca_topic_score_codex":0.00007035869,"about_ca_topic_score_gemma":0.0000204701,"teacher_disagreement_score":0.012335912,"about_ca_system_score_codex":0.00007780483,"about_ca_system_score_gemma":0.000025267971,"threshold_uncertainty_score":0.5501511},"labels":[],"label_agreement":null},{"id":"W3106563718","doi":"10.1016/j.jdiacomp.2020.107813","title":"Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management","year":2020,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Heart Research Centre","funders":"AstraZeneca","keywords":"Medicine; Type 2 diabetes; Intensive care medicine; Diabetes mellitus; Primary care; Medical prescription; Diabetes management; Family medicine; Nursing; Endocrinology","score_opus":0.045601738343296824,"score_gpt":0.28527160860174783,"score_spread":0.239669870258451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106563718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993643,0.00429924,0.000008510087,0.00083191606,0.00004736385,0.00030636246,0.000057599736,0.000010201354,0.000795836],"genre_scores_gemma":[0.99730575,0.0011342837,0.0011872518,0.0002602683,0.000046632074,0.000010648888,0.000032305128,0.000009709736,0.00001317797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989275,0.000077102435,0.0004910598,0.00015581389,0.00015891716,0.0001896337],"domain_scores_gemma":[0.99906135,0.0000920151,0.00032974101,0.00013333214,0.00018898859,0.00019455889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018797143,0.00014743295,0.00045319088,0.00010799575,0.00004354395,0.000019590645,0.00008777387,0.0000308246,0.000011312044],"category_scores_gemma":[0.00012657732,0.000112702044,0.0000948801,0.00045572905,0.000046660844,0.00009138788,0.0000584889,0.000068886584,0.0000034068578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013783561,0.00020039841,0.9883391,0.00011415148,0.00069620885,0.0000022114355,0.00012816419,0.00017355855,0.00049767026,0.00039806427,0.00043757935,0.008999055],"study_design_scores_gemma":[0.0014467558,0.0012736262,0.9939168,0.00017213766,0.0005443571,6.406188e-7,0.00008642951,0.0010330976,0.00049295544,0.00020831026,0.0007358636,0.000089024725],"about_ca_topic_score_codex":0.000021451595,"about_ca_topic_score_gemma":0.000023583985,"teacher_disagreement_score":0.008910031,"about_ca_system_score_codex":0.00010040018,"about_ca_system_score_gemma":0.000047064354,"threshold_uncertainty_score":0.4595856},"labels":[],"label_agreement":null},{"id":"W3107120908","doi":"10.1093/ehjci/ehaa946.3353","title":"Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; McMaster University","funders":"","keywords":"Medicine; Dulaglutide; Metformin; Hazard ratio; Type 2 diabetes; Internal medicine; Myocardial infarction; Diabetes mellitus; Sitagliptin; Placebo; Coronary artery disease; Stroke (engine); Clinical endpoint; Saxagliptin; Randomized controlled trial; Liraglutide; Endocrinology; Insulin; Confidence interval","score_opus":0.02490379856362115,"score_gpt":0.2462646052056605,"score_spread":0.22136080664203933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107120908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715936,0.00013337063,0.00013404056,0.00031058083,0.000056486708,0.002078226,0.00006478442,0.000012382471,0.00005077556],"genre_scores_gemma":[0.99792504,0.000033310644,0.00126528,0.00038124033,0.00011830348,0.000029112003,0.00002220633,0.000044611003,0.00018088245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826396,0.00031658448,0.00033768694,0.00032249378,0.00047747744,0.00028179196],"domain_scores_gemma":[0.9989644,0.00009787348,0.00025466387,0.00028338586,0.00013382571,0.00026583343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005664216,0.00022356723,0.0007087787,0.00018686858,0.00014305764,0.000068618676,0.00010721777,0.000020196007,0.00006373586],"category_scores_gemma":[0.00014031514,0.00010337833,0.00022753478,0.0007334124,0.000098870565,0.00020520562,0.00007814015,0.00021689774,0.0000011907061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052051716,0.00026174125,0.9404727,0.00007233779,0.0048089027,0.000049731883,0.0005085828,0.00007377579,0.0000046396085,0.000001897312,0.00028307157,0.0014108638],"study_design_scores_gemma":[0.05042126,0.006090099,0.9334356,0.00017844372,0.008109216,0.0000016501099,0.00023671314,0.00034149355,0.000026982796,0.000004404435,0.0010094623,0.00014466717],"about_ca_topic_score_codex":0.000014882355,"about_ca_topic_score_gemma":0.000027775672,"teacher_disagreement_score":0.0070371316,"about_ca_system_score_codex":0.000067025445,"about_ca_system_score_gemma":0.000090301415,"threshold_uncertainty_score":0.42156458},"labels":[],"label_agreement":null},{"id":"W3107636597","doi":"10.1093/ehjci/ehaa946.3352","title":"Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Internal medicine; Post-hoc analysis; Renal function; Type 2 diabetes; Cardiology; Placebo; Diabetes mellitus; Coronary artery disease; Stroke (engine); Proportional hazards model; Endocrinology; Pathology","score_opus":0.06697306310473594,"score_gpt":0.327283424615357,"score_spread":0.26031036151062104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107636597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952413,0.0026553797,0.000031381267,0.0013879916,0.00007161188,0.00023243696,0.00002735351,0.00002817647,0.0003243685],"genre_scores_gemma":[0.998371,0.0001583649,0.00015507179,0.00091276836,0.0002487033,0.0000016131405,0.00003439538,0.000037968155,0.000080106656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998278,0.00030632643,0.00039898098,0.00028146262,0.00046955963,0.0002656204],"domain_scores_gemma":[0.99896723,0.000052987947,0.00010110636,0.0003155469,0.000054848635,0.00050828874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003820784,0.00023293031,0.00069631764,0.00022888731,0.00005954457,0.000049957263,0.00007654944,0.000021446158,0.00012391384],"category_scores_gemma":[0.00020103263,0.00015931253,0.0009486614,0.00017956666,0.000043009,0.0001355362,0.00006474577,0.00024828766,0.000052335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034719132,0.00021879701,0.98929274,0.000033213,0.003271499,0.00048363648,0.00013111488,0.00046275608,0.0017232547,0.0000013334578,0.00059227523,0.0034421994],"study_design_scores_gemma":[0.0035916371,0.0015351278,0.99200153,0.00014437032,0.0012402058,0.0000038160374,0.00005062125,0.00011133692,0.00010676814,0.0000040213167,0.0010750049,0.00013557314],"about_ca_topic_score_codex":0.000031578824,"about_ca_topic_score_gemma":0.0000012454492,"teacher_disagreement_score":0.0033066263,"about_ca_system_score_codex":0.000084680956,"about_ca_system_score_gemma":0.000037544633,"threshold_uncertainty_score":0.6496576},"labels":[],"label_agreement":null},{"id":"W3107654124","doi":"10.2215/cjn.08310520","title":"Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD","year":2020,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Western University","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"Sitagliptin; Medicine; Heart failure; Hazard ratio; Internal medicine; Confidence interval; Proportional hazards model; Cardiology; Population; Relative risk; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.017549795148158017,"score_gpt":0.29599357115472047,"score_spread":0.27844377600656245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107654124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88605624,0.00030360706,0.000018285506,0.11328183,0.000033239823,0.0002724055,0.0000032841056,0.0000029412206,0.000028129465],"genre_scores_gemma":[0.9632275,0.0007161002,0.0028587433,0.03303703,0.00012562341,0.0000025571796,4.464918e-7,0.000008896279,0.00002311492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856937,0.0003711868,0.00059907156,0.00013837148,0.0001786887,0.00014330451],"domain_scores_gemma":[0.9974531,0.0010217689,0.0011267728,0.00017287262,0.00012808695,0.0000973933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006351712,0.00011078827,0.0008958558,0.000014680171,0.000024546605,0.000002941827,0.00016515727,0.000050373263,0.000017087283],"category_scores_gemma":[0.00013614347,0.00005083532,0.00042425774,0.00021069238,0.0025209514,0.000030060812,0.00010869354,0.00046805464,8.425197e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012271943,0.00064890314,0.9013398,0.00008162288,0.0024896676,0.00001371793,0.0027014378,0.00003818867,0.00023773163,0.00008619819,0.071726434,0.008364333],"study_design_scores_gemma":[0.015879272,0.0048567075,0.96618,0.00013838842,0.0009062745,0.000014435912,0.003090975,0.00017234858,0.00003064519,0.00009504149,0.008579496,0.000056410754],"about_ca_topic_score_codex":0.000045058358,"about_ca_topic_score_gemma":0.000008440299,"teacher_disagreement_score":0.08024481,"about_ca_system_score_codex":0.0000128265,"about_ca_system_score_gemma":0.00006037484,"threshold_uncertainty_score":0.9288551},"labels":[],"label_agreement":null},{"id":"W3107866787","doi":"10.1093/ehjci/ehaa946.3067","title":"Impact of timing of randomization after an acute coronary syndrome and subsequent events in patients with type 2 diabetes mellitus: an analysis of the EXAMINE trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Acute coronary syndrome; Internal medicine; Randomized controlled trial; Myocardial infarction; Hazard ratio; Randomization; Heart failure; Stroke (engine); Type 2 Diabetes Mellitus; Diabetes mellitus; Placebo; Comorbidity; Type 2 diabetes; Post-hoc analysis; Atrial fibrillation; Cardiology; Confidence interval","score_opus":0.024460709905629287,"score_gpt":0.27134834012578635,"score_spread":0.24688763022015706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107866787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99942154,0.00010631855,0.0000058605447,0.000028900515,0.000029799097,0.00037709932,0.000009608781,0.0000029192802,0.000017972683],"genre_scores_gemma":[0.9997355,0.000035161687,0.000112362264,0.00003855564,0.000016456584,0.000001001009,0.00003929609,0.000013730852,0.000007969045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891543,0.00030985384,0.00032488906,0.000109281056,0.00023443492,0.00010610816],"domain_scores_gemma":[0.99945086,0.000021286109,0.00020633294,0.00013740592,0.000081438484,0.00010269891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033051087,0.00009465597,0.00041645483,0.00015652337,0.000017027212,0.0000054871866,0.000056246477,0.000012099464,0.00008138235],"category_scores_gemma":[0.000028576029,0.000053680324,0.000110801186,0.0003491907,0.000034384062,0.00013459845,0.00003276698,0.0000709732,4.0925843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016345916,0.00044404026,0.9802515,0.000020322015,0.0015292787,0.000014199833,0.0003867408,0.00024306918,0.00023976839,2.4057087e-7,0.0000061927626,0.000518758],"study_design_scores_gemma":[0.03202402,0.007265182,0.9581471,0.00009801074,0.0018094035,0.0000018215495,0.000019332489,0.00053403067,0.000053805532,5.7420976e-7,0.0000022405497,0.000044500623],"about_ca_topic_score_codex":0.0000037534767,"about_ca_topic_score_gemma":0.000002115291,"teacher_disagreement_score":0.022104396,"about_ca_system_score_codex":0.000027706717,"about_ca_system_score_gemma":0.000022605429,"threshold_uncertainty_score":0.218902},"labels":[],"label_agreement":null},{"id":"W3108024872","doi":"10.1093/ehjci/ehaa946.3350","title":"Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Eli Lilly and Company","keywords":"Medicine; Albuminuria; Hazard ratio; Mace; Type 2 diabetes; Internal medicine; Post-hoc analysis; Subgroup analysis; Dulaglutide; Renal function; Myocardial infarction; Diabetes mellitus; Placebo; Clinical endpoint; Randomized controlled trial; Confidence interval; Endocrinology; Percutaneous coronary intervention; Exenatide; Pathology","score_opus":0.014641429411843715,"score_gpt":0.2226427919959884,"score_spread":0.2080013625841447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108024872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962049,0.0016171393,0.0000018488746,0.0013044658,0.00004235592,0.00021354952,0.0000026400928,0.00001681168,0.0005962512],"genre_scores_gemma":[0.99827325,0.00012065159,0.00044574248,0.00089535845,0.000079981786,8.85394e-7,0.000017093598,0.000026679221,0.00014035075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989231,0.00015247437,0.00019259675,0.00023860182,0.0002715904,0.0002216279],"domain_scores_gemma":[0.9994342,0.000022190572,0.000051868734,0.00016449805,0.00007027731,0.00025701404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030753083,0.00015435483,0.0005015036,0.0001834851,0.00006411571,0.000075838725,0.000042245505,0.000017641703,0.00003331551],"category_scores_gemma":[0.000062099745,0.000106704065,0.00013534543,0.00034473487,0.000040137293,0.000112264504,0.00006156483,0.00017154876,0.000017429842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001491401,0.00009216057,0.9916243,0.000025247697,0.0031580739,0.00013923337,0.0003837366,0.000007359936,0.000068440546,0.0000013516371,0.00045402764,0.0038969412],"study_design_scores_gemma":[0.0034135522,0.0015271921,0.9886653,0.000047448266,0.0019087427,0.000004337478,0.000073299016,0.000016576952,0.000019028716,8.4908316e-7,0.0042102733,0.00011340882],"about_ca_topic_score_codex":0.0000022794177,"about_ca_topic_score_gemma":0.0000018285275,"teacher_disagreement_score":0.0037835324,"about_ca_system_score_codex":0.000027358465,"about_ca_system_score_gemma":0.000013178514,"threshold_uncertainty_score":0.43512654},"labels":[],"label_agreement":null},{"id":"W3108090279","doi":"10.1111/dom.14283","title":"Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes ( <scp> TRS‐HF <sub>DM</sub> </scp> ) in patients in the <scp>ACCORD</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; St. Michael's Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Myocardial infarction; Cardiology; Diabetes mellitus; Thrombolysis; Framingham Risk Score; Creatinine; Clinical endpoint; Randomized controlled trial; Endocrinology; Disease","score_opus":0.0097584222737263,"score_gpt":0.20343287014692,"score_spread":0.19367444787319368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108090279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942771,0.00039993032,0.0000015447526,0.0003644608,0.0002877532,0.0044449796,0.0001852073,0.000024882094,0.000014119553],"genre_scores_gemma":[0.9985103,0.00013358303,0.00012863179,0.00035298965,0.00008796841,0.00035772467,0.00038643766,0.00003845339,0.00000392963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964996,0.0005848588,0.0009712328,0.0006012918,0.00068625185,0.00065675343],"domain_scores_gemma":[0.9982032,0.0006706627,0.00042395736,0.00041872272,0.0001782836,0.00010517502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010823208,0.00044033356,0.001398536,0.00064666156,0.000078664365,0.000049549635,0.00022436693,0.00026400955,0.0000019423762],"category_scores_gemma":[0.0013825775,0.00030350528,0.00024378396,0.0016673055,0.00015484128,0.0005096067,0.0001264975,0.00046310067,0.0000018596205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017280584,0.0016995927,0.99362403,0.0002639978,0.0002195906,1.8419297e-7,0.0019654161,0.00021104034,0.00066221895,0.00002112095,0.00030058666,0.0008594097],"study_design_scores_gemma":[0.029711904,0.0011138696,0.9561414,0.00027802036,0.0004537811,1.0642745e-8,0.0005273962,0.00017603615,0.010738257,0.00019128993,0.00058440014,0.00008362257],"about_ca_topic_score_codex":0.00012811083,"about_ca_topic_score_gemma":0.00032922454,"teacher_disagreement_score":0.037482623,"about_ca_system_score_codex":0.00009372466,"about_ca_system_score_gemma":0.00007029957,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W3108391623","doi":"10.1714/3472.34545","title":"Grey zones sul diabete mellito in ambito cardiologico. Opinioni degli esperti","year":2020,"lang":"en","type":"article","venue":"Giornale italiano di cardiologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Medicine; Glycated hemoglobin; Expert opinion; Disease; Grey literature; Diabetes mellitus; Clinical Practice; MEDLINE; Family medicine; Intensive care medicine; Pathology; Type 2 diabetes; Endocrinology; Law","score_opus":0.0349047472607102,"score_gpt":0.2523949385724192,"score_spread":0.217490191311709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108391623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96645707,0.0051490404,0.00017521215,0.004151515,0.0007641525,0.0011927513,0.000049234084,0.00034783033,0.021713214],"genre_scores_gemma":[0.9949065,0.00056081335,0.00044832707,0.0018922304,0.0007022603,0.00018578317,0.00019345629,0.00004815852,0.0010625027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725574,0.00019554583,0.0005610149,0.000820304,0.00036236312,0.0008050301],"domain_scores_gemma":[0.9987403,0.0000974745,0.000116132316,0.00057174393,0.000103785715,0.00037055352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033094085,0.00045921863,0.0012331489,0.00015641333,0.00008196618,0.0000613672,0.00028710056,0.00024295467,0.00008164951],"category_scores_gemma":[0.00029211436,0.00036671633,0.00058963377,0.00050204404,0.00017424673,0.00017875046,0.00024043975,0.0002982131,0.0005495536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033078695,0.00016164739,0.96324015,0.00024343493,0.0011620659,0.0012520652,0.0003251967,0.0003831064,0.0026295562,0.0005344582,0.019795582,0.009941928],"study_design_scores_gemma":[0.004741061,0.0019733724,0.90006924,0.00022592743,0.00066773687,0.00004420505,0.00052857376,0.00024994017,0.0033138478,0.00037091775,0.086918265,0.00089692534],"about_ca_topic_score_codex":0.00006014575,"about_ca_topic_score_gemma":0.00000589267,"teacher_disagreement_score":0.06712268,"about_ca_system_score_codex":0.00018119952,"about_ca_system_score_gemma":0.00006054037,"threshold_uncertainty_score":0.99987847},"labels":[],"label_agreement":null},{"id":"W3108521091","doi":"10.1093/ehjci/ehaa946.3356","title":"Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Glimepiride; Linagliptin; Medicine; Type 2 diabetes; Sulfonylurea; Mace; Internal medicine; Diabetes mellitus; Post-hoc analysis; Randomized controlled trial; Insulin; Endocrinology; Myocardial infarction","score_opus":0.06894472863885248,"score_gpt":0.2982087993829037,"score_spread":0.2292640707440512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108521091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994341,0.001827531,0.0000050933927,0.00075574307,0.00045831228,0.0023188246,0.000005689553,0.000025786698,0.0002619785],"genre_scores_gemma":[0.99868053,0.00016605714,0.00022270915,0.00037950347,0.00041936844,0.000016133718,0.000013458923,0.000057601173,0.000044653043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955462,0.0017540039,0.0010740117,0.00038864434,0.00079258333,0.00044453322],"domain_scores_gemma":[0.9982641,0.00061366725,0.0003194277,0.0004846484,0.00011572139,0.00020246324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023473306,0.00032952928,0.0011419586,0.00023847954,0.00006622202,0.0000663599,0.00033283638,0.00006125915,0.000017243703],"category_scores_gemma":[0.0012977567,0.0002417976,0.00042462206,0.0006379377,0.00006889635,0.00017810272,0.00014362138,0.00072434027,0.000026633317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09617626,0.011759487,0.8340022,0.0017250009,0.005510094,0.0048411684,0.013973682,0.001320965,0.011175927,0.000032077925,0.0065222112,0.012960925],"study_design_scores_gemma":[0.22031453,0.033354018,0.7238698,0.00048238478,0.0022836903,0.000012456189,0.0019982022,0.00023744235,0.0045229727,0.0000050139492,0.012421445,0.0004980653],"about_ca_topic_score_codex":0.00004377998,"about_ca_topic_score_gemma":0.00002168118,"teacher_disagreement_score":0.124138266,"about_ca_system_score_codex":0.00006930704,"about_ca_system_score_gemma":0.00007168489,"threshold_uncertainty_score":0.98602206},"labels":[],"label_agreement":null},{"id":"W3108601871","doi":"10.1093/ehjci/ehaa946.3355","title":"Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Glimepiride; Hazard ratio; Type 2 diabetes; Linagliptin; Internal medicine; Proportional hazards model; Diabetes mellitus; Population; Body mass index; Confidence interval; Endocrinology","score_opus":0.05201807535087904,"score_gpt":0.27817322073760326,"score_spread":0.2261551453867242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108601871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994518,0.001189601,0.000047887417,0.0026440993,0.00010737424,0.00034315258,0.0000019136578,0.000006041578,0.0011419685],"genre_scores_gemma":[0.9990142,0.00035132593,0.00005379536,0.00026885243,0.00026983072,0.000002311182,0.000010867382,0.0000083268205,0.000020517444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989389,0.0002802928,0.0002352524,0.00012076929,0.00031646676,0.00010830016],"domain_scores_gemma":[0.99965185,0.000027461769,0.00006811884,0.00014269468,0.000028645485,0.000081213155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008747211,0.0000787162,0.00031348984,0.00013101721,0.000050919414,0.000014485425,0.00006190357,0.0000105398285,0.000022339444],"category_scores_gemma":[0.00007795131,0.0000515556,0.000329664,0.00034105155,0.000017359727,0.00004941962,0.000031933647,0.0001281681,0.0000060479106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004190531,0.000425566,0.95695746,0.00012794703,0.008675755,0.000330126,0.009406315,0.0012153927,0.000017942373,0.000032435484,0.00468956,0.013930941],"study_design_scores_gemma":[0.016544702,0.0011058699,0.9585203,0.00005145782,0.0033495715,0.00001084984,0.00024688232,0.00081633386,0.0000048752563,0.0000034571726,0.019284088,0.00006164357],"about_ca_topic_score_codex":0.000008171184,"about_ca_topic_score_gemma":0.0000039211577,"teacher_disagreement_score":0.014594528,"about_ca_system_score_codex":0.000033402335,"about_ca_system_score_gemma":0.000012394412,"threshold_uncertainty_score":0.21023764},"labels":[],"label_agreement":null},{"id":"W3108719605","doi":"10.1002/ejhf.2073","title":"Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in <scp>DECLARE‐TIMI</scp> 58","year":2020,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Deutsche Forschungsgemeinschaft; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Heart failure; Internal medicine; Cardiology; TIMI; Transporter; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.025278402926551865,"score_gpt":0.24562268572199855,"score_spread":0.22034428279544668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108719605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841658,0.00270839,0.0020420104,0.009797921,0.000054442484,0.0011045103,0.000034593246,0.0000352526,0.00005711405],"genre_scores_gemma":[0.9806265,0.00020460335,0.017894393,0.0005758799,0.00046240404,0.000009090492,0.00009354943,0.00007711748,0.000056420544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823165,0.00032253604,0.00048433882,0.00032780014,0.000366414,0.00026725003],"domain_scores_gemma":[0.9990059,0.00017212486,0.00014205684,0.00020005982,0.00015521255,0.00032462098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011030487,0.00027256933,0.000692983,0.0001945948,0.00009912176,0.00007475524,0.000063353385,0.000057637793,0.000007881497],"category_scores_gemma":[0.00016646023,0.0001890875,0.00023251027,0.00024300425,0.00007147846,0.0002717262,0.000018276789,0.00023851408,0.000004520949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004053576,0.00006260976,0.9661715,0.00015099252,0.00094681216,0.000085139356,0.0007439768,0.000020699523,0.00024981404,0.0000066949356,0.029941315,0.0012150765],"study_design_scores_gemma":[0.008615031,0.0029660526,0.59633756,0.0003106369,0.0008335053,0.00003563018,0.0008589084,0.000030302459,0.0008599916,0.0000051747525,0.3890149,0.00013231023],"about_ca_topic_score_codex":0.0000025802403,"about_ca_topic_score_gemma":0.0000033394927,"teacher_disagreement_score":0.36983395,"about_ca_system_score_codex":0.000030289633,"about_ca_system_score_gemma":0.00007021549,"threshold_uncertainty_score":0.77107644},"labels":[],"label_agreement":null},{"id":"W3108873181","doi":"10.1186/s12933-020-01174-6","title":"Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial","year":2020,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Medicine; Empagliflozin; Internal medicine; Metabolic syndrome; Type 2 diabetes; Hazard ratio; Population; Diabetes mellitus; Post-hoc analysis; Waist; Diabetic nephropathy; Blood pressure; Cardiology; Body mass index; Obesity; Endocrinology; Confidence interval; Kidney","score_opus":0.02747816782053568,"score_gpt":0.24492729968299362,"score_spread":0.21744913186245796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108873181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96131134,0.03617517,0.000007276936,0.00028941862,0.0001736752,0.0019321427,0.000020495609,0.000039571114,0.000050934163],"genre_scores_gemma":[0.99912155,0.00022366355,0.00005730822,0.00032382112,0.000050815157,0.000098811346,0.0000560524,0.000047991045,0.000019983172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975649,0.0003328986,0.0004218615,0.0005969939,0.0006372517,0.0004461053],"domain_scores_gemma":[0.99833286,0.0000644409,0.000102017875,0.0011001931,0.00015456144,0.00024590624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031874448,0.00033858747,0.0019424662,0.00015921997,0.00005356428,0.00001632678,0.00020753291,0.0001023869,0.000018498598],"category_scores_gemma":[0.00032405558,0.00021461087,0.0013272804,0.0007038108,0.0002580161,0.00008968566,0.00019145868,0.00017666433,0.000009969068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019689153,0.00031115153,0.96576667,0.0003424038,0.025420332,0.000064113556,0.000109871915,0.0004958724,0.00004016151,0.000042333064,0.000015370922,0.0054228064],"study_design_scores_gemma":[0.03486938,0.0009918783,0.94927835,0.00007387752,0.012611599,0.00000127949,0.00003025146,0.000033411066,0.00012247353,0.000008981577,0.0017559826,0.00022250578],"about_ca_topic_score_codex":0.000022570002,"about_ca_topic_score_gemma":0.0000017188985,"teacher_disagreement_score":0.037810236,"about_ca_system_score_codex":0.000039274724,"about_ca_system_score_gemma":0.000064775275,"threshold_uncertainty_score":0.8751578},"labels":[],"label_agreement":null},{"id":"W3108967412","doi":"10.1186/s12933-020-01179-1","title":"Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","year":2020,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; University of Toronto; St. Michael's Hospital; Université Laval","funders":"Eli Lilly and Company","keywords":"Medicine; Mace; Dulaglutide; Hazard ratio; Myocardial infarction; Internal medicine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Unstable angina; Stroke (engine); Cardiology; Physical therapy; Exenatide; Confidence interval; Percutaneous coronary intervention; Endocrinology","score_opus":0.01062127665504808,"score_gpt":0.20141676260696809,"score_spread":0.19079548595192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108967412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716633,0.025643557,0.00012727888,0.00017426735,0.000048273694,0.0020179297,0.00004782848,0.0000919834,0.00018559035],"genre_scores_gemma":[0.99757814,0.001225835,0.00019208198,0.00017726507,0.000083377396,0.00023595676,0.00039574166,0.000087498156,0.000024093979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504685,0.0009884048,0.0005120761,0.0013804709,0.0010731431,0.00099908],"domain_scores_gemma":[0.9975724,0.00018975817,0.00010323597,0.0016625295,0.00016031571,0.00031172647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011018349,0.00072447176,0.0033672415,0.0006314402,0.00013274726,0.00004667601,0.00029812843,0.0002576046,0.000033912926],"category_scores_gemma":[0.00019662754,0.00042537675,0.0023485757,0.0035478277,0.00023661363,0.00020922767,0.00013757644,0.0005222503,0.000012713009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006729587,0.00020679312,0.86575973,0.00018504371,0.11416392,0.0010912041,0.0018969065,0.009243054,0.0000115572675,0.0000057834363,0.000016717282,0.0067463326],"study_design_scores_gemma":[0.009612274,0.0022402806,0.9334132,0.00008320415,0.048993234,0.0000640328,0.0023869618,0.0005032846,0.00014315476,0.0000031423733,0.0019411223,0.00061608176],"about_ca_topic_score_codex":0.0009503138,"about_ca_topic_score_gemma":0.0005804555,"teacher_disagreement_score":0.0676535,"about_ca_system_score_codex":0.00014160162,"about_ca_system_score_gemma":0.00012270079,"threshold_uncertainty_score":0.9998198},"labels":[],"label_agreement":null},{"id":"W3109391147","doi":"10.1139/bcb-2020-0491","title":"Knockdown of SGLT1 prevents the apoptosis of cardiomyocytes induced by glucose fluctuation via relieving oxidative stress and mitochondrial dysfunction","year":2020,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gene knockdown; Oxidative stress; Apoptosis; Reactive oxygen species; Intracellular; Mitochondrion; Downregulation and upregulation; Mitochondrial ROS; Inner mitochondrial membrane; Biology; Diabetes mellitus; Oxidative phosphorylation; Cell biology; Internal medicine; Endocrinology; Medicine; Biochemistry","score_opus":0.009250630336584796,"score_gpt":0.22080861271257038,"score_spread":0.21155798237598558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109391147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711555,0.0014650276,0.000108233886,0.00024125072,0.000051359937,0.00023871682,0.000026419895,0.0000082342385,0.0007451872],"genre_scores_gemma":[0.9991447,0.0003419153,0.000091596456,0.000050271665,0.00007379618,0.000015376214,0.00018749456,0.000004402298,0.000090459114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99948525,0.000030618994,0.00015769177,0.00018885316,0.000053421372,0.00008414214],"domain_scores_gemma":[0.9996579,0.000043164706,0.000118685486,0.000101755206,0.000033089822,0.00004537829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040578107,0.00009609129,0.0001978053,0.000012527379,0.00002927533,0.000003374587,0.000037702528,0.0000906942,0.00001568849],"category_scores_gemma":[0.000037946164,0.00006718238,0.00003726036,0.000061524144,0.000083459556,0.00001843837,0.00005629409,0.00005200005,4.7022786e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016813878,0.0000671323,0.0020549176,0.0002688568,0.00014080876,1.2897284e-7,0.00014889709,2.686989e-7,0.9842583,0.0000045328798,0.00022186058,0.012666167],"study_design_scores_gemma":[0.0010497984,0.00046479606,0.00050825306,0.000037072674,0.00022867096,2.2810137e-7,0.00023619647,0.000029860887,0.9967443,0.000015062012,0.0006310737,0.0000547382],"about_ca_topic_score_codex":0.000018641122,"about_ca_topic_score_gemma":1.627222e-7,"teacher_disagreement_score":0.012611429,"about_ca_system_score_codex":0.000009619571,"about_ca_system_score_gemma":0.00001243248,"threshold_uncertainty_score":0.2739618},"labels":[],"label_agreement":null},{"id":"W3109406169","doi":"10.1530/joe-20-0255","title":"Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys","year":2020,"lang":"en","type":"article","venue":"Journal of Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Yunnan Provincial Science and Technology Department","keywords":"Glucose homeostasis; Internal medicine; Endocrinology; Dipeptidyl peptidase-4; Fructosamine; Diabetes mellitus; Medicine; Homeostasis; Glucagon-like peptide-1; Insulin; Glucagon; Type 2 diabetes; Insulin resistance","score_opus":0.02541592689723789,"score_gpt":0.2682533236483448,"score_spread":0.2428373967511069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109406169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805547,0.003381714,0.00017979102,0.013844772,0.00024057137,0.00021510052,0.0000047703975,0.000020492296,0.0015580886],"genre_scores_gemma":[0.99451107,0.0014311282,0.0015825394,0.002120031,0.00021502117,0.0000062545723,0.0000051269067,0.000018331712,0.000110514346],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99864405,0.000032503514,0.00052235846,0.00017792243,0.00019208688,0.00043106408],"domain_scores_gemma":[0.99925035,0.000077316894,0.00022699476,0.00015016107,0.000083965555,0.00021121865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006722349,0.00016494532,0.00058726344,0.00033012315,0.000020059653,0.000012587655,0.00015363572,0.000049971844,0.000099194614],"category_scores_gemma":[0.000201338,0.00013099215,0.00017306981,0.0002729047,0.000068799505,0.00011501111,0.00009083848,0.00029983625,0.00003522471],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022421672,0.0036474494,0.27800056,0.00056581,0.0029904747,0.00980249,0.0012464578,0.00014295714,0.29539296,0.0038618762,0.014163906,0.3879429],"study_design_scores_gemma":[0.033327192,0.012432645,0.7597701,0.00028109763,0.0017806072,0.0008473397,0.0013699341,0.0005578039,0.09538613,0.0008216896,0.092786975,0.0006384841],"about_ca_topic_score_codex":0.000022821328,"about_ca_topic_score_gemma":0.000013654623,"teacher_disagreement_score":0.48176953,"about_ca_system_score_codex":0.00009821592,"about_ca_system_score_gemma":0.00006880175,"threshold_uncertainty_score":0.5341705},"labels":[],"label_agreement":null},{"id":"W3109808840","doi":"10.1093/ehjci/ehaa946.3316","title":"Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"Janssen Scientific Affairs","keywords":"Medicine; Canagliflozin; Renal function; Hazard ratio; Internal medicine; Heart failure; Diabetes mellitus; Proportional hazards model; Placebo; Empagliflozin; Confidence interval; Type 2 diabetes; Cardiology; Urology; Endocrinology; Pathology","score_opus":0.038019695266729846,"score_gpt":0.3006680305944684,"score_spread":0.26264833532773857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109808840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797308,0.0072850785,0.0057860063,0.005563544,0.00006273462,0.0014242585,0.000048484762,0.00005803161,0.000041057407],"genre_scores_gemma":[0.9931277,0.00035087072,0.0050120745,0.0010531688,0.00014973385,0.00001618123,0.00023239513,0.00002890636,0.00002893627],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988926,0.00034249612,0.00020992204,0.00021061927,0.0001971302,0.00014719968],"domain_scores_gemma":[0.9993807,0.00014931693,0.00007451314,0.0001199443,0.00011153489,0.00016395676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043530008,0.0001520539,0.00030253522,0.000039899922,0.00012548873,0.00009247464,0.000045552926,0.000022515023,0.0000096728545],"category_scores_gemma":[0.00039950566,0.000097980395,0.000111574824,0.00016526306,0.00004230706,0.00008360784,0.00002003797,0.00011951244,0.000001916084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015443797,0.0012256168,0.24898791,0.0013484771,0.010036847,0.00044555272,0.002153571,0.002303363,0.1879448,0.00010281859,0.4541405,0.08976614],"study_design_scores_gemma":[0.012166417,0.010104306,0.5563269,0.0020827097,0.007052597,0.000071836555,0.00066188903,0.03447921,0.07468345,0.000031702148,0.3016947,0.000644284],"about_ca_topic_score_codex":0.00014865573,"about_ca_topic_score_gemma":0.000008832814,"teacher_disagreement_score":0.30733898,"about_ca_system_score_codex":0.000024845824,"about_ca_system_score_gemma":0.000032911394,"threshold_uncertainty_score":0.39955243},"labels":[],"label_agreement":null},{"id":"W3109936864","doi":"10.15829/1560-4071-2020-4142","title":"Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases","year":2020,"lang":"en","type":"article","venue":"Russian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dapagliflozin; Heart failure; Ejection fraction; Population; Cause of death; Internal medicine; Canadian Cardiovascular Society; Cardiology; Intensive care medicine; Myocardial infarction; Environmental health; Diabetes mellitus; Disease; Endocrinology","score_opus":0.012819091159329707,"score_gpt":0.25055764327580443,"score_spread":0.2377385521164747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109936864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970488,0.0010339675,0.000044071527,0.00040270173,0.00007466406,0.001013765,0.000005162719,0.000004734063,0.00037212708],"genre_scores_gemma":[0.9996959,0.00004394007,0.000051198724,0.000042000145,0.00011859955,0.0000195053,0.000010140593,0.000015745545,0.000002979025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976049,0.000989402,0.00046691773,0.00021289094,0.00053078996,0.00019512193],"domain_scores_gemma":[0.9992356,0.00009459107,0.00019609569,0.00035494615,0.000049174934,0.00006961482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096628506,0.0001804444,0.0014286522,0.0001981717,0.00001968623,0.0000056721833,0.000101609956,0.000063903746,0.000002851497],"category_scores_gemma":[0.00014893633,0.000100542304,0.0010655972,0.0002631915,0.000074966985,0.000058584,0.000027645889,0.00023999892,7.973623e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027824491,0.00020185886,0.966228,0.0004825648,0.008088449,0.00012659814,0.00013922324,0.017999688,0.000030189305,0.000059125196,0.00026967598,0.003592175],"study_design_scores_gemma":[0.007666026,0.012360024,0.97526574,0.0009337754,0.0019280594,0.0000073171964,0.00006969499,0.000019476127,0.00092498254,0.00001200279,0.000710694,0.000102208774],"about_ca_topic_score_codex":0.000020157655,"about_ca_topic_score_gemma":0.0000010552513,"teacher_disagreement_score":0.01798021,"about_ca_system_score_codex":0.000084842344,"about_ca_system_score_gemma":0.00008030212,"threshold_uncertainty_score":0.4099996},"labels":[],"label_agreement":null},{"id":"W3110162467","doi":"10.1016/j.cjca.2020.11.014","title":"How Diabetes and Heart Failure Modulate Each Other and Condition Management","year":2020,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lawson Health Research Institute; Western University","funders":"Department of Medicine, University of Toronto","keywords":"Medicine; Heart failure; Internal medicine; Ejection fraction; Diabetes mellitus; Cardiology; Insulin resistance; Diabetic cardiomyopathy; Heart failure with preserved ejection fraction; Cardiomyopathy; Intensive care medicine; Endocrinology","score_opus":0.018179712044339737,"score_gpt":0.2515888206957187,"score_spread":0.23340910865137895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110162467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019924669,0.99415535,0.000029067372,0.0031286,0.00022544689,0.00052743516,0.00004105418,0.0000061343976,0.001687643],"genre_scores_gemma":[0.005427777,0.9925013,0.00034684592,0.00041949798,0.0006850672,0.000020582764,0.000051255836,0.00004360451,0.0005040567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900216,0.00011155482,0.00028074317,0.00022063064,0.00008826689,0.0002966664],"domain_scores_gemma":[0.99899125,0.000033355685,0.00019090246,0.00014582908,0.000046026467,0.0005926621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016410234,0.00026359374,0.0017673438,0.00041238221,0.000053343814,0.00006325566,0.00007104132,0.00017275658,0.000010641347],"category_scores_gemma":[0.000021301943,0.00020080795,0.00029096977,0.00009532251,0.00013139068,0.000061759594,0.000025041709,0.00025465555,0.000005856163],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000044175436,0.0000024568794,0.0017912334,0.0072022653,0.005232526,0.00078506966,0.00003159889,0.0000011757697,9.511373e-7,0.0005292916,0.05509322,0.9293258],"study_design_scores_gemma":[0.0005332314,0.00029687906,0.0005868427,0.0021268665,0.0038840577,0.00025288772,0.00003762025,7.8127715e-7,3.2182993e-7,0.00008048328,0.99205756,0.00014245356],"about_ca_topic_score_codex":0.000012734048,"about_ca_topic_score_gemma":0.000037263795,"teacher_disagreement_score":0.93696433,"about_ca_system_score_codex":0.0001258135,"about_ca_system_score_gemma":0.00017213706,"threshold_uncertainty_score":0.818871},"labels":[],"label_agreement":null},{"id":"W3110605433","doi":"10.1093/ehjci/ehaa946.1175","title":"Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Canagliflozin; Internal medicine; Kidney disease; Renal function; Diabetes mellitus; Placebo; Type 2 diabetes; Creatinine; Population; Endocrinology; Pathology","score_opus":0.02037651402002895,"score_gpt":0.23219037069255757,"score_spread":0.2118138566725286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110605433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994669,0.0005769686,0.00001249745,0.0040735863,0.00013323298,0.0004241806,0.000011348093,0.0000139346785,0.000085225125],"genre_scores_gemma":[0.99818945,0.00004382592,0.00017713396,0.0010322477,0.00048635088,0.0000018014591,0.000025113399,0.000022222055,0.000021837503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989198,0.00015202096,0.00022677612,0.00016964668,0.0003492142,0.00018257611],"domain_scores_gemma":[0.99936694,0.000031222087,0.00006693792,0.00013647281,0.00005235005,0.0003461005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020769892,0.000118651165,0.00021100989,0.000038623184,0.00006260552,0.000044860928,0.000081854545,0.000013649022,0.00009761765],"category_scores_gemma":[0.000130305,0.00007111301,0.000046416735,0.000113330716,0.00004020793,0.000105977364,0.00007731877,0.00023918634,0.000011080237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028161947,0.00013563283,0.98680925,0.000027728905,0.00012849642,0.000015178303,0.00024587158,0.00022647034,0.00007595492,0.0000019283646,0.009285628,0.0002316412],"study_design_scores_gemma":[0.030839413,0.0030094774,0.9526202,0.00059354847,0.0002623074,7.0473226e-7,0.000077204815,0.0017837548,0.000030370293,0.0000076455035,0.010656336,0.000119030046],"about_ca_topic_score_codex":0.0000026412656,"about_ca_topic_score_gemma":0.0000016931381,"teacher_disagreement_score":0.034189068,"about_ca_system_score_codex":0.000037897327,"about_ca_system_score_gemma":0.00010388205,"threshold_uncertainty_score":0.28999043},"labels":[],"label_agreement":null},{"id":"W3110662830","doi":"10.1210/endrev/bnaa032","title":"Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation","year":2020,"lang":"en","type":"review","venue":"Endocrine Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; Novo Nordisk Fonden; Diabetes UK; British Heart Foundation; European Research Council; National Institutes of Health; Medical Research Council; American Diabetes Association","keywords":"Enteroendocrine cell; Gastric emptying; Glucagon-like peptide-1; Islet; Hormone; Biology; Receptor; Appetite; Endocrinology; Internal medicine; Endocrine system; Insulin; Diabetes mellitus; Type 2 diabetes; Medicine","score_opus":0.22801375883828054,"score_gpt":0.39442749814333394,"score_spread":0.1664137393050534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110662830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020401247,0.9927799,0.000051991337,0.0014572642,0.00008440363,0.0032989727,0.00008157518,0.000029681514,0.0021957762],"genre_scores_gemma":[0.000033760087,0.99511397,0.003089354,0.00009783889,0.0005899314,0.00040263578,0.0003631234,0.000033515837,0.00027589453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976652,0.00036120802,0.0011501717,0.00035910305,0.0002863852,0.00017790114],"domain_scores_gemma":[0.99757725,0.00052019005,0.0011182491,0.0006246551,0.00007276028,0.00008688237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032956325,0.00036234566,0.003125171,0.000121680285,0.000037389724,0.000011574657,0.00021427254,0.000049205184,0.00066903455],"category_scores_gemma":[0.0015215263,0.00020986148,0.00079672766,0.0005228043,0.000059565216,0.000057120993,0.00015042524,0.00020310584,0.00022791147],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013274713,0.000042574567,0.000010774979,0.031402413,0.0004003464,0.0000011004416,0.000026362399,3.0571073e-8,0.00007382907,0.0001667217,0.0037795228,0.9640831],"study_design_scores_gemma":[0.000089548106,0.00006845713,0.000029958848,0.047403995,0.0032637443,0.0000010442749,0.000020555808,0.0000010177931,0.00061377237,0.000010737054,0.94836766,0.00012954303],"about_ca_topic_score_codex":0.000077375815,"about_ca_topic_score_gemma":0.0000024900028,"teacher_disagreement_score":0.9639535,"about_ca_system_score_codex":0.00013161618,"about_ca_system_score_gemma":0.00004865992,"threshold_uncertainty_score":0.85579026},"labels":[],"label_agreement":null},{"id":"W3110989969","doi":"10.1111/dom.14296","title":"Effects of <b>da</b> pagliflozin on prevention of major clinical events and recovery in patients with <b>re</b> spiratory failure because of COVID‐ <b>19</b> : Design and rationale for the DARE‐19 study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; Kidney disease; Internal medicine; Clinical endpoint; Placebo; Respiratory failure; Population; Clinical trial; Intensive care medicine; Acute kidney injury; Type 2 diabetes; Diabetes mellitus; Pathology; Endocrinology","score_opus":0.029813648003676117,"score_gpt":0.27801396143111434,"score_spread":0.24820031342743823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110989969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936273,0.0015413979,0.00031884396,0.00028574085,0.000044732293,0.004133987,0.000035089826,0.0000089859395,0.00000393014],"genre_scores_gemma":[0.9983911,0.0001691614,0.00083308364,0.00038936557,0.000027496946,0.00012654725,0.000027130614,0.000013623439,0.00002251024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867827,0.00024082584,0.00039795134,0.00029730296,0.00024038962,0.00014525584],"domain_scores_gemma":[0.9985667,0.000794693,0.0002517932,0.00015717642,0.00008067685,0.00014896657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006723365,0.00016659546,0.00060785766,0.000100760975,0.000052589814,0.000008726529,0.00006149907,0.00006534817,0.000004797283],"category_scores_gemma":[0.00047548866,0.00011264005,0.00006743907,0.0001450067,0.00011330374,0.00011256966,0.00006865254,0.00008470905,2.3105119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011776167,0.0027474666,0.9830264,0.0013753123,0.0006297082,0.000001381308,0.000805705,0.000021551385,0.00023524705,0.00014591866,0.00021207113,0.009621658],"study_design_scores_gemma":[0.014441192,0.004438441,0.9768544,0.00014866705,0.0014789149,2.9550737e-8,0.00021126492,0.000064178676,0.001634999,0.00032982777,0.0002963331,0.0001017757],"about_ca_topic_score_codex":0.000009798622,"about_ca_topic_score_gemma":0.000010768922,"teacher_disagreement_score":0.013263576,"about_ca_system_score_codex":0.000010236935,"about_ca_system_score_gemma":0.00005803019,"threshold_uncertainty_score":0.45933282},"labels":[],"label_agreement":null},{"id":"W3111093755","doi":"10.3399/bjgp20x714089","title":"Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care","year":2020,"lang":"en","type":"article","venue":"British Journal of General Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Diabetes Canada; University of Toronto; Toronto General Hospital; North York General Hospital","funders":"Australian Government; Royal College of General Practitioners; Public Health England; Diabetes Action Research and Education Foundation","keywords":"Medicine; Drug class; Medical prescription; Metformin; Primary care; Cross-sectional study; Diabetes mellitus; Type 2 diabetes; Drug; Family medicine; Pediatrics; Pharmacology; Endocrinology","score_opus":0.023268108843216898,"score_gpt":0.288261369042398,"score_spread":0.2649932601991811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111093755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969447,0.0015377322,0.0000028700458,0.0011467881,0.000062249506,0.00009415371,0.000018061348,0.0000047910066,0.00018862629],"genre_scores_gemma":[0.9973451,0.00043790104,0.000639433,0.0009288877,0.00012205015,0.000004809576,0.00018753565,0.000009815934,0.00032449336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856275,0.00014291887,0.0005432863,0.00019401548,0.00037206875,0.00018495561],"domain_scores_gemma":[0.99926895,0.00011680209,0.00026421054,0.000064196865,0.00013286271,0.00015298546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043535815,0.00009537521,0.00034518092,0.00039915834,0.000022055143,0.00009632491,0.000055288685,0.00005811976,0.000039779654],"category_scores_gemma":[0.00043183618,0.00010303077,0.000060447055,0.00075690134,0.000024414914,0.0005387888,0.000026248428,0.00031792032,3.925578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026809316,0.000120195495,0.98223376,0.000046772187,0.00030784297,0.002131254,0.00023483217,0.0005397096,0.00011250722,0.0000010592519,0.00050487596,0.013499113],"study_design_scores_gemma":[0.004258413,0.00017103642,0.9914371,0.000097899894,0.0003620212,0.00011037298,0.000082338265,0.00026994286,0.000039318762,0.0000020378925,0.003083326,0.00008623325],"about_ca_topic_score_codex":0.2225514,"about_ca_topic_score_gemma":0.4756978,"teacher_disagreement_score":0.25314638,"about_ca_system_score_codex":0.0003916949,"about_ca_system_score_gemma":0.00015879155,"threshold_uncertainty_score":0.7826257},"labels":[],"label_agreement":null},{"id":"W3111267765","doi":"10.1016/j.amjmed.2020.10.046","title":"Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study","year":2020,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Empagliflozin; Type 2 diabetes; Internal medicine; Dapagliflozin; Cohort; Hazard ratio; Diabetes mellitus; Incidence (geometry); Population; Rate ratio; Cohort study; Confidence interval; Endocrinology","score_opus":0.005829812173994317,"score_gpt":0.2275400635773863,"score_spread":0.22171025140339198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111267765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449897,0.00052518374,0.0000043623186,0.0038893265,0.000062793966,0.0008515128,0.0000020139923,0.000005371759,0.0001604832],"genre_scores_gemma":[0.99792707,0.00041816686,0.00002701668,0.001441625,0.00015530712,0.0000053489916,0.000003248309,0.00001615114,0.0000060835423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985369,0.00018459934,0.00045938848,0.00011756131,0.00054089556,0.00016068049],"domain_scores_gemma":[0.99874455,0.00015647501,0.00065547717,0.00019653265,0.00013155479,0.000115407434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085877266,0.00014818602,0.0010005177,0.00009049857,0.000035191817,0.0000040490754,0.00013589863,0.000010789622,0.000022882925],"category_scores_gemma":[0.00009989935,0.000057837606,0.000049871098,0.0003784939,0.00093953684,0.00004157008,0.000020619567,0.0002573301,0.0000013033397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030369696,0.0005927089,0.97598547,0.00002295129,0.0012112792,0.000025711799,0.0074054194,0.000006307431,0.00002306528,0.000003896444,0.0003647067,0.0113215055],"study_design_scores_gemma":[0.015492237,0.019502886,0.95857257,0.00018280967,0.0022914626,0.0000017948736,0.0036792392,0.00001203424,0.00003791522,0.00002049218,0.00015142783,0.000055109427],"about_ca_topic_score_codex":0.000084194646,"about_ca_topic_score_gemma":0.0000052601226,"teacher_disagreement_score":0.018910177,"about_ca_system_score_codex":0.000022828879,"about_ca_system_score_gemma":0.000035413843,"threshold_uncertainty_score":0.34617627},"labels":[],"label_agreement":null},{"id":"W3111560048","doi":"10.1177/1479164120975256","title":"Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME <sup>®</sup>","year":2020,"lang":"en","type":"article","venue":"Diabetes and Vascular Disease Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Mace; Cholesterol; Diabetes mellitus; Placebo; Ldl cholesterol; Statin; Endocrinology; Cardiology; Type 2 diabetes; Myocardial infarction; Conventional PCI","score_opus":0.08545386706290661,"score_gpt":0.34089772032119503,"score_spread":0.25544385325828844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111560048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807278,0.0136074005,0.000014911554,0.0039246874,0.000015947531,0.0013227558,0.000032150696,0.000063924184,0.00029042765],"genre_scores_gemma":[0.99738204,0.00092741783,0.0000725781,0.0009944802,0.000078976416,0.00019606734,0.000051283674,0.000051163457,0.00024598956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670625,0.00027523804,0.00034437396,0.0007794414,0.0010611819,0.0008335458],"domain_scores_gemma":[0.99800503,0.00013956115,0.000024745279,0.00064795004,0.000105416606,0.0010772898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011187588,0.0003132293,0.0008375432,0.00032130728,0.00014604584,0.0001455898,0.00015107082,0.000088028115,0.00006220678],"category_scores_gemma":[0.00037385413,0.00024970857,0.00044878587,0.00044672855,0.00020969249,0.00019247257,0.00040398625,0.00035099286,0.00005486697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029607307,0.00021948741,0.9762899,0.000956431,0.001526031,0.0001248992,0.0003928821,0.000075543045,0.000023196495,0.00013675194,0.00018839899,0.020036835],"study_design_scores_gemma":[0.0047750967,0.00022009898,0.9793156,0.00014586875,0.0006194474,3.1101914e-7,0.00037161045,0.0032338868,0.00003747691,0.00013071539,0.010891338,0.00025854245],"about_ca_topic_score_codex":0.000042689186,"about_ca_topic_score_gemma":0.0000024482674,"teacher_disagreement_score":0.019778293,"about_ca_system_score_codex":0.00006652431,"about_ca_system_score_gemma":0.000058867037,"threshold_uncertainty_score":0.9999955},"labels":[],"label_agreement":null},{"id":"W3111728018","doi":"10.23889/ijpds.v5i5.1421","title":"Trends in diabetes medications in Canada, England, Scotland and Australia: a repeated cross-sectional analysis (2012-2017)","year":2020,"lang":"en","type":"article","venue":"International Journal for Population Data Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Metformin; Medicine; Sulfonylurea; Diabetes mellitus; Medical prescription; Type 2 diabetes; Drug class; Internal medicine; Endocrinology; Pharmacology; Drug","score_opus":0.08260748629867751,"score_gpt":0.38886614170050915,"score_spread":0.3062586554018316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111728018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954748,0.00004832844,0.00017620799,0.0035260166,0.00033259156,0.00011588358,0.00024710307,0.000006353823,0.00007267334],"genre_scores_gemma":[0.99699813,0.000021707387,0.00065158954,0.00025494717,0.00013560412,0.000008681958,0.0016902322,0.000003752997,0.00023535082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983734,0.000015689913,0.0004095347,0.0003394325,0.00065306027,0.00020891467],"domain_scores_gemma":[0.99926805,0.0000502018,0.00015470272,0.0001653771,0.00016762712,0.00019406174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006456983,0.00008390279,0.0001623557,0.00079915894,0.00009079087,0.00015555929,0.0003939477,0.0000233671,0.0001470417],"category_scores_gemma":[0.00030506632,0.00007263378,0.00003363972,0.00095580454,0.000064844346,0.0009310377,0.0001211254,0.000114165414,0.0000013663605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004229003,0.000031361746,0.9953421,0.0000038104054,0.00014927701,0.000015874382,0.00003802378,0.0006126126,0.000060010618,0.00011113993,0.00037400404,0.0032195402],"study_design_scores_gemma":[0.0014107132,0.000033619166,0.96032596,0.00001673169,0.00008736073,0.000007500457,0.00001700131,0.0358596,0.000011491869,0.00004816041,0.0021171689,0.00006471377],"about_ca_topic_score_codex":0.06994687,"about_ca_topic_score_gemma":0.4100449,"teacher_disagreement_score":0.34009805,"about_ca_system_score_codex":0.00042292764,"about_ca_system_score_gemma":0.0002514228,"threshold_uncertainty_score":0.93624645},"labels":[],"label_agreement":null},{"id":"W3112169554","doi":"10.1016/j.revmed.2020.11.008","title":"Chez les sujets avec insuffisance rénale chronique modérée et macroalbuminurie, diabétiques ou non, est-ce que la dapagliflozine amène un bénéfice rénal et cardiovasculaire comparativement au placébo ?","year":2020,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine","score_opus":0.017082343284956416,"score_gpt":0.2723848854478378,"score_spread":0.2553025421628814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112169554","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23961133,0.01891441,0.025320692,0.60191566,0.0026985167,0.0064465893,0.0010073561,0.0008568366,0.1032286],"genre_scores_gemma":[0.8583452,0.005850904,0.005033853,0.090030946,0.0070357234,0.0013633677,0.0037835874,0.0005604424,0.027995951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99041307,0.002294801,0.0019262412,0.0022921066,0.0011905053,0.0018832658],"domain_scores_gemma":[0.9946176,0.001435398,0.00093860785,0.0018081398,0.00044381854,0.00075643446],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019856247,0.0022126494,0.0034944357,0.00047655663,0.00020394701,0.0003622713,0.0013144001,0.0011300712,0.0007295302],"category_scores_gemma":[0.0003970335,0.002174108,0.001454888,0.0006335207,0.000810926,0.0004719274,0.0010830131,0.0037310591,0.0004914936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033068678,0.011031722,0.1223158,0.01911871,0.03987801,0.062439032,0.072665654,0.003702543,0.0030557478,0.032019835,0.59066004,0.03980604],"study_design_scores_gemma":[0.011917666,0.0022579806,0.059205357,0.011966321,0.0044813845,0.00075088366,0.0005232806,0.0035256466,0.0064013046,0.00037059118,0.8964957,0.0021038863],"about_ca_topic_score_codex":0.0037622051,"about_ca_topic_score_gemma":0.0023091284,"teacher_disagreement_score":0.6187339,"about_ca_system_score_codex":0.0029603587,"about_ca_system_score_gemma":0.0012065715,"threshold_uncertainty_score":0.99906135},"labels":[],"label_agreement":null},{"id":"W3112463192","doi":"10.1111/nep.13839","title":"Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors","year":2020,"lang":"en","type":"review","venue":"Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Renal function; Effective renal plasma flow; Diabetes mellitus; Type 2 diabetes; Kidney disease; Renal blood flow; Hemodynamics; Tubuloglomerular feedback; Kidney; Internal medicine; Pharmacology; Intensive care medicine; Urology; Cardiology; Endocrinology","score_opus":0.00980959717931278,"score_gpt":0.27173022605842706,"score_spread":0.26192062887911427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112463192","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01667957,0.97825027,0.000008390802,0.00013526772,0.00018183158,0.004050175,0.000004559869,0.00004149536,0.0006484236],"genre_scores_gemma":[0.008555807,0.9902418,0.00015363844,0.0001443612,0.000118423275,0.00054767606,0.000106776926,0.000057481746,0.00007400755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873227,0.00017273892,0.00030972037,0.00043374946,0.00011903464,0.00023246741],"domain_scores_gemma":[0.9991756,0.00022728088,0.00029944355,0.00018432511,0.00004473083,0.00006862866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077952995,0.00032675418,0.0016045301,0.00036369127,0.000016256245,0.000005927918,0.000054951655,0.00022948395,0.000009461114],"category_scores_gemma":[0.000053523854,0.00023148964,0.00010284288,0.00038405193,0.000119761426,0.00006148913,0.00008221869,0.00043139025,0.00001318118],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033723164,0.00017963086,0.00008659457,0.016537072,0.001412639,0.00009888278,0.00040609523,4.219347e-7,0.000031390875,0.000041374944,0.00014102111,0.9807277],"study_design_scores_gemma":[0.004357666,0.013079921,0.00087472674,0.03791775,0.0074608666,0.000036540372,0.00010288137,0.000087106695,0.00016530401,0.00015293341,0.935237,0.00052729325],"about_ca_topic_score_codex":0.000027356413,"about_ca_topic_score_gemma":0.000026854437,"teacher_disagreement_score":0.98020035,"about_ca_system_score_codex":0.00022358027,"about_ca_system_score_gemma":0.00011866245,"threshold_uncertainty_score":0.94398737},"labels":[],"label_agreement":null},{"id":"W3112498330","doi":"10.1016/j.kint.2020.10.042","title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","year":2020,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development; University of California, San Francisco; Astellas Pharma; Eisai; Celgene; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Medical Research Council; Verily Life Sciences; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Pfizer; Innovent Biologics; Janssen Pharmaceuticals; Ablynx; University of Washington; Ironwood Pharmaceuticals, Incorporated; Relypsa; University of Chicago; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; Kidney Foundation of Canada; Kowa Company; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Japan Society for the Promotion of Science; GlaxoSmithKline; Amgen; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Canagliflozin; Medicine; Renal function; Placebo; Kidney disease; Internal medicine; Post-hoc analysis; Confidence interval; Odds ratio; Proportional hazards model; Diabetes mellitus; Type 2 diabetes; Urology; Endocrinology; Pathology","score_opus":0.07070988077867671,"score_gpt":0.38264246931491847,"score_spread":0.31193258853624173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112498330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95883054,0.000034144537,0.0022060699,0.035401866,0.00014984577,0.0019111732,0.0002577058,0.000090087415,0.0011185997],"genre_scores_gemma":[0.9728879,0.0001220552,0.019725224,0.0026018908,0.0003598401,0.00067726173,0.0033725512,0.000028574976,0.000224718],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99872893,0.00005873891,0.00038086908,0.00046036975,0.00021359627,0.00015748576],"domain_scores_gemma":[0.9989491,0.00012894969,0.00021877211,0.0002086701,0.00015660498,0.0003378656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007171414,0.00018280935,0.00026868927,0.000104442224,0.000067162946,0.000070448004,0.0001303069,0.00005775209,0.000046534304],"category_scores_gemma":[0.00026396636,0.00013258522,0.00005327121,0.00018084627,0.000049124217,0.00042469887,0.000022375425,0.00009388606,0.0000149284715],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47126412,0.019893134,0.36985323,0.00016926412,0.031301163,0.0016863233,0.0072235013,0.0007926554,0.04550625,0.015535272,0.010864623,0.025910454],"study_design_scores_gemma":[0.30714563,0.027147513,0.56130135,0.00046289578,0.0051078717,0.000029173028,0.00049161515,0.02052099,0.006375652,0.00048305868,0.07005752,0.0008767335],"about_ca_topic_score_codex":0.00028047638,"about_ca_topic_score_gemma":0.00015461247,"teacher_disagreement_score":0.19144814,"about_ca_system_score_codex":0.00023419861,"about_ca_system_score_gemma":0.00031361333,"threshold_uncertainty_score":0.5406669},"labels":[],"label_agreement":null},{"id":"W3112891931","doi":"10.2174/1574886315999201208212356","title":"Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues","year":2020,"lang":"en","type":"review","venue":"Current Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Semaglutide; Medicine; Lixisenatide; Dulaglutide; Exenatide; Liraglutide; Tolerability; Type 2 diabetes; Incretin; Glucagon-like peptide 1 receptor; Pharmacology; Empagliflozin; Clinical trial; Adverse effect; Diabetes mellitus; Internal medicine; Endocrinology; Receptor; Agonist","score_opus":0.04296746936968761,"score_gpt":0.31658479611249357,"score_spread":0.273617326742806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112891931","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000059012045,0.99402624,0.00004885233,0.00011174322,0.00072980905,0.002373137,0.00026835644,0.00009147291,0.0023444807],"genre_scores_gemma":[0.000019548515,0.99682,0.00018921128,0.000015627642,0.00041215413,0.000068137364,0.002097968,0.00006767142,0.000309722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973482,0.00020597107,0.00090095814,0.0007328334,0.0004745503,0.00033752288],"domain_scores_gemma":[0.9984089,0.00016457938,0.0002945386,0.0007785588,0.00006929982,0.000284127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041080202,0.0006010558,0.0036681741,0.00020140203,0.00006535219,0.00001618485,0.00020121169,0.00013508693,0.0001196239],"category_scores_gemma":[0.00010325646,0.0004500393,0.0015376689,0.0004313225,0.00013127904,0.000053521315,0.00028355478,0.00038160087,0.00015057113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006659385,0.00019936322,0.000025807129,0.030671664,0.0042315796,0.000013781019,0.00008009367,3.6632238e-7,5.5440328e-8,0.00022365627,0.0062046726,0.95828235],"study_design_scores_gemma":[0.0018144827,0.00010122111,0.00008993309,0.017177353,0.012600264,0.0000045210536,0.00001845086,0.0000021866279,9.721853e-7,0.0000044803946,0.9678614,0.00032470233],"about_ca_topic_score_codex":0.000006044694,"about_ca_topic_score_gemma":6.7437225e-7,"teacher_disagreement_score":0.96165675,"about_ca_system_score_codex":0.0001605046,"about_ca_system_score_gemma":0.00017257578,"threshold_uncertainty_score":0.99979514},"labels":[],"label_agreement":null},{"id":"W3112956508","doi":"10.1002/alz.041312","title":"Relationships between oral hypoglycemic drugs and memory decline in people with type 2 diabetes: A stratified longitudinal observational study","year":2020,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Heart and Stroke Foundation; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; University of Ottawa; University of Toronto","funders":"","keywords":"Medicine; Confounding; Type 2 diabetes; Dementia; Diabetes mellitus; Internal medicine; Poisson regression; Metformin; Thiazolidinedione; Cognitive decline; Demography; Disease; Endocrinology; Population","score_opus":0.12363041655377191,"score_gpt":0.3026803825169512,"score_spread":0.17904996596317926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112956508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214804,0.003860021,0.000017388837,0.002168175,0.000037899234,0.001054913,0.0000052495598,0.000058156977,0.0006501633],"genre_scores_gemma":[0.9975644,0.000012839044,0.0016063277,0.00041556987,0.000079686615,0.00007006509,0.0002063429,0.000025279365,0.000019513993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985715,0.000074974654,0.0003292527,0.00038755086,0.0003827069,0.00025401436],"domain_scores_gemma":[0.9993695,0.00009814821,0.000087278284,0.00018852878,0.00009085361,0.00016570637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003101936,0.00020177734,0.00034580877,0.00009091824,0.00008759982,0.00004257852,0.000084315725,0.000047724287,0.00011540554],"category_scores_gemma":[0.000042541044,0.00017142994,0.000030681556,0.0004490923,0.00004177098,0.00019466752,0.0001076377,0.00019041222,0.000036715028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001643864,0.00029852465,0.986757,0.0000136547005,0.0067632273,0.000012181194,0.0010663152,0.000013470996,0.00003971708,0.00004422674,0.0004708885,0.004356432],"study_design_scores_gemma":[0.0037410068,0.0012385458,0.9784352,0.000024431416,0.014839227,3.7201994e-7,0.0008075065,0.00022837294,0.00013504889,0.000046816465,0.0003349867,0.00016845218],"about_ca_topic_score_codex":0.00009178275,"about_ca_topic_score_gemma":0.00047127015,"teacher_disagreement_score":0.008321742,"about_ca_system_score_codex":0.000011371702,"about_ca_system_score_gemma":0.00009010847,"threshold_uncertainty_score":0.699071},"labels":[],"label_agreement":null},{"id":"W3112981338","doi":"10.1111/dom.14300","title":"Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Sinai Health System; University of Toronto","funders":"Institute of Chemical and Engineering Sciences; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Hazard ratio; Diabetic ketoacidosis; Internal medicine; Diabetes mellitus; Confidence interval; Cohort study; Rate ratio; Heart failure; Cohort; Endocrinology","score_opus":0.0051031615147639105,"score_gpt":0.2022933258319656,"score_spread":0.19719016431720168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112981338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99162614,0.0044414974,0.0000036546417,0.0007015864,0.000116562216,0.0028815726,0.00006605431,0.000059967897,0.00010295054],"genre_scores_gemma":[0.99850005,0.0005936069,0.00023287069,0.00024215301,0.00014073499,0.00016471974,0.000070386195,0.000035565092,0.000019898127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763024,0.0002019355,0.00057837315,0.00056501024,0.00062345667,0.00040098303],"domain_scores_gemma":[0.99851143,0.00030232104,0.0003434533,0.0003780295,0.00018732925,0.00027743474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058911,0.00040324565,0.0012007117,0.00016429376,0.00016372999,0.000038859816,0.00012159592,0.00010143291,0.000021854885],"category_scores_gemma":[0.00011731296,0.0002597561,0.00017611857,0.00040947442,0.00051006826,0.00022766765,0.0000862856,0.0002517997,0.0000032209496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086005434,0.0011290477,0.9878976,0.00048630615,0.0017635196,0.000003443993,0.005360141,0.000004634669,0.00040378617,0.000108771805,0.00029808725,0.001684647],"study_design_scores_gemma":[0.026602697,0.0011855407,0.9409497,0.00025239552,0.0041702013,1.773989e-7,0.0024329727,0.00010275268,0.023010643,0.000022713297,0.0010004814,0.00026975077],"about_ca_topic_score_codex":0.00012383464,"about_ca_topic_score_gemma":0.00007038125,"teacher_disagreement_score":0.046947885,"about_ca_system_score_codex":0.00001219254,"about_ca_system_score_gemma":0.00003395838,"threshold_uncertainty_score":0.99998546},"labels":[],"label_agreement":null},{"id":"W3113095196","doi":"10.3389/fphys.2020.603247","title":"The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy","year":2020,"lang":"en","type":"review","venue":"Frontiers in Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Diabetic cardiomyopathy; Heart failure; Ejection fraction; Diastole; Internal medicine; Diabetes mellitus; Cardiology; Cardiomyopathy; Dipeptidyl peptidase-4; Type 2 diabetes; Endocrinology; Blood pressure","score_opus":0.01600022447856078,"score_gpt":0.2828268609204816,"score_spread":0.26682663644192084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113095196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008161116,0.9897807,0.000006564275,0.000049008733,0.00059249887,0.0010354995,0.000016480195,0.000020947944,0.00033717975],"genre_scores_gemma":[0.016168943,0.9832695,0.000048339007,0.000027388001,0.00012841471,0.00016242641,0.00007250709,0.000038733546,0.00008376002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865055,0.00022327836,0.00035355825,0.00036317474,0.00010333599,0.0003060775],"domain_scores_gemma":[0.9991749,0.00014807335,0.00021408213,0.0003766454,0.000018913368,0.00006737399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116199655,0.00035715278,0.0020573938,0.00022515199,0.000045865643,0.000009451041,0.00012102286,0.00015344717,0.0000061656933],"category_scores_gemma":[0.000042678494,0.00019332154,0.00050193624,0.00027722042,0.00022836693,0.000022379441,0.0000717676,0.00024825617,0.000010119321],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007197089,0.00009919693,0.0010479718,0.0025429507,0.0017350029,0.000008882685,0.000077785786,0.0000011977651,0.0000071527293,0.000028247967,0.004324126,0.9900555],"study_design_scores_gemma":[0.0018213975,0.004175879,0.03228098,0.004974318,0.0029663614,0.000005322546,0.00012454075,0.00006882865,0.0000073663655,0.0010199923,0.95212877,0.00042623602],"about_ca_topic_score_codex":0.0000147833425,"about_ca_topic_score_gemma":3.455418e-7,"teacher_disagreement_score":0.98962927,"about_ca_system_score_codex":0.0001590654,"about_ca_system_score_gemma":0.00008322682,"threshold_uncertainty_score":0.78834236},"labels":[],"label_agreement":null},{"id":"W3113100320","doi":"10.1177/1715163520976149","title":"A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease","year":2020,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Regina General Hospital","funders":"","keywords":"Type 2 diabetes; Medicine; Disease; Atherosclerotic cardiovascular disease; Diabetes mellitus; Cardiology; Internal medicine; Reduction (mathematics); Intensive care medicine; Pharmacology; Endocrinology","score_opus":0.032776718199938215,"score_gpt":0.21999282938133058,"score_spread":0.18721611118139236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113100320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281836,0.0036020048,0.00040425875,0.000038838836,0.00030423512,0.002211494,0.0004962326,0.00003154079,0.00009306188],"genre_scores_gemma":[0.9944527,0.0029200616,0.0009223658,0.0008293115,0.00036773333,0.000107541375,0.00023498721,0.0001124069,0.0000528681],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971159,0.00010403984,0.0004073056,0.0007454443,0.00069662445,0.0009306719],"domain_scores_gemma":[0.99647933,0.000022872251,0.00016652393,0.0003548862,0.00044783112,0.0025285834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037042305,0.00050264393,0.0007826064,0.00029572126,0.000389762,0.00012677719,0.00022709966,0.0000466333,0.000029054445],"category_scores_gemma":[0.000069930386,0.0004281953,0.0002941333,0.0007314526,0.00017058499,0.00034161878,0.00003639805,0.00042623933,0.0000012782024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012164529,0.001510188,0.6264282,0.0054848953,0.03974341,0.019688437,0.0026775831,0.09493073,0.0005520855,0.000010905309,0.007350843,0.18945822],"study_design_scores_gemma":[0.40117505,0.009359893,0.056072604,0.0013297924,0.1004697,0.03781537,0.00037233531,0.20429464,0.00252355,0.000034795936,0.17542857,0.011123703],"about_ca_topic_score_codex":0.0011277861,"about_ca_topic_score_gemma":0.00020526555,"teacher_disagreement_score":0.5703556,"about_ca_system_score_codex":0.0012939392,"about_ca_system_score_gemma":0.0011206792,"threshold_uncertainty_score":0.999817},"labels":[],"label_agreement":null},{"id":"W3113238274","doi":"10.1016/s2213-8587(20)30374-0","title":"SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond","year":2020,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Providence Health Care","keywords":"Diabetes mellitus; Medicine; Kidney disease; Type 2 diabetes; Disease; Kidney; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.01780741140234083,"score_gpt":0.253928814049395,"score_spread":0.23612140264705417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113238274","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28878224,0.0051759267,3.9797396e-7,0.7035045,0.0002454098,0.001009782,0.0001656158,0.00014497105,0.0009711399],"genre_scores_gemma":[0.14644921,0.002280972,0.000065894455,0.84604883,0.0022128264,0.00053934206,0.0013088456,0.00009302989,0.0010010357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665636,0.00018902076,0.00040277847,0.00077753654,0.00025286348,0.0017214329],"domain_scores_gemma":[0.99855715,0.00033240108,0.00016484402,0.0006718858,0.000027501008,0.00024619512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013420921,0.00058797677,0.001477542,0.00027038,0.00009736443,0.00006809691,0.00019962717,0.00021008015,0.000091389025],"category_scores_gemma":[0.0001798942,0.00041175197,0.0001322738,0.0001729115,0.00048643968,0.00009943911,0.0004430544,0.0012556995,0.0000652877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000365695,0.00008713646,0.35404557,0.0017859912,0.0008075446,0.0010063607,0.00010555882,3.438386e-7,0.00023515908,0.00036842842,0.6359614,0.0055599483],"study_design_scores_gemma":[0.007899657,0.00091521617,0.10787288,0.0006172492,0.0020288294,0.0000063382995,0.00003191765,0.0001498462,0.0004314535,0.0059672957,0.87332046,0.00075887365],"about_ca_topic_score_codex":0.000007470651,"about_ca_topic_score_gemma":0.0000074940613,"teacher_disagreement_score":0.24617268,"about_ca_system_score_codex":0.00015498993,"about_ca_system_score_gemma":0.00009004982,"threshold_uncertainty_score":0.9998334},"labels":[],"label_agreement":null},{"id":"W3113765054","doi":"10.1002/ejhf.2083","title":"Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <scp>DAPA‐HF</scp>","year":2020,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of British Columbia","funders":"Janssen Research and Development; National Heart, Lung, and Blood Institute; Relypsa; Respicardia; Vifor Pharma; Shionogi; Daiichi-Sankyo; University of Oxford; British Heart Foundation; Kidney Research UK; Zora Biosciences; GlaxoSmithKline; IFM Therapeutics; Mitsubishi Tanabe Pharma Corporation; Toa Eiyo; Medicines Company; Intarcia Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; AstraZeneca; Amarin Corporation; Sanofi Pasteur; Universitair Medisch Centrum Groningen; Kowa Company; Celladon Corporation; Zafgen; Defense Acquisition Program Administration; Boston Scientific Corporation; Esperion Therapeutics; Alere; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Servier; Gilead Sciences; Astellas Pharma; Eisai; Cytokinetics; Brigham and Women's Hospital; Ironwood Pharmaceuticals, Incorporated; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Amgen; Pfizer; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Heart failure; Ejection fraction; Pulmonary disease; Cardiology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.006881245322832636,"score_gpt":0.22220581084947907,"score_spread":0.21532456552664644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113765054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585134,0.000910436,0.00012060026,0.0026077286,0.00004435069,0.00034064276,0.000005853133,0.000015751475,0.00010331495],"genre_scores_gemma":[0.9968637,0.00004942302,0.0026942368,0.00012249868,0.0001745926,0.0000024020228,0.000023870776,0.00003203742,0.000037214577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831355,0.00037835265,0.00046984127,0.0002581495,0.00038639823,0.00019370999],"domain_scores_gemma":[0.99887305,0.000103707425,0.0003726836,0.0001817876,0.00015939397,0.00030935748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031353228,0.00019562876,0.0006589928,0.0004991093,0.00003870843,0.000019558325,0.00007405318,0.00003123098,0.000023120456],"category_scores_gemma":[0.00013010114,0.00015379075,0.00018126552,0.00078807987,0.000087142354,0.00034132824,0.000036639063,0.00028604807,0.000003626067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013735186,0.0013951932,0.6749129,0.0016696631,0.004239076,0.0012779348,0.0014485874,0.002487188,0.298198,0.000041148654,0.007732998,0.0052237557],"study_design_scores_gemma":[0.0022776537,0.0029398226,0.9663725,0.00045979803,0.0033145256,0.00003368332,0.001099509,0.00072112447,0.009898329,0.0000052481037,0.012799308,0.0000785196],"about_ca_topic_score_codex":0.00000705082,"about_ca_topic_score_gemma":0.000011026244,"teacher_disagreement_score":0.29145956,"about_ca_system_score_codex":0.00009180269,"about_ca_system_score_gemma":0.000074074094,"threshold_uncertainty_score":0.62714046},"labels":[],"label_agreement":null},{"id":"W3113772690","doi":"10.1111/obr.13177","title":"GLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"Obesity Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Medical Research Council Canada","keywords":"Medicine; Diabetes mellitus; Obesity; Internal medicine; Hypoglycemia; Type 2 diabetes; Adverse effect; Endocrinology; Randomized controlled trial; Agonist; Type 2 Diabetes Mellitus; Weight loss; Confidence interval; Childhood obesity; Overweight; Receptor","score_opus":0.05381413229609096,"score_gpt":0.32919219859491894,"score_spread":0.275378066298828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113772690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000074443046,0.9791606,0.000003924418,0.00019256149,0.000022380942,0.020387508,0.0000645758,0.000038012302,0.0001229618],"genre_scores_gemma":[0.0000030226697,0.9949101,0.00047642406,0.0009906369,0.000034532462,0.0020559065,0.000562575,0.000046678513,0.00092011027],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9965994,0.0005360465,0.0014404407,0.00086326664,0.00019357202,0.00036730696],"domain_scores_gemma":[0.9979275,0.00017864096,0.00079199235,0.0007996656,0.000057198948,0.00024501118],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0013735931,0.0007876003,0.018072601,0.00026789156,0.00007346314,0.00006703639,0.00020428894,0.00017646965,0.00008127568],"category_scores_gemma":[0.0003818111,0.0004901174,0.002399319,0.0011403913,0.0000544391,0.000078507226,0.00019895972,0.0002344539,0.000091346206],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[7.689957e-7,0.0001217792,0.0006941618,0.9060648,0.076321,0.0000044007597,0.000005703213,2.9001295e-9,6.622889e-9,0.000043772223,0.00068855914,0.016055057],"study_design_scores_gemma":[0.00013240438,0.00008842846,0.000081845756,0.071831696,0.6080538,0.000004332361,4.5495887e-7,0.0000012883735,4.2568672e-8,0.0000066787397,0.31955475,0.00024426004],"about_ca_topic_score_codex":0.000009075012,"about_ca_topic_score_gemma":0.00001901646,"teacher_disagreement_score":0.8342331,"about_ca_system_score_codex":0.00009609676,"about_ca_system_score_gemma":0.0000530509,"threshold_uncertainty_score":0.999755},"labels":[],"label_agreement":null},{"id":"W3114561183","doi":"10.1016/j.ahj.2020.12.008","title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development; Relypsa; NxStage; Janssen Scientific Affairs; Janssen Pharmaceuticals; Gilead Sciences; Novo Nordisk; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Canagliflozin; Medicine; Heart failure; Type 2 diabetes; Kidney disease; Diabetes mellitus; Nephropathy; Internal medicine; Placebo; Clinical trial; Cardiology; Intensive care medicine; Endocrinology; Pathology","score_opus":0.02275117013111997,"score_gpt":0.2595466790822277,"score_spread":0.23679550895110776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114561183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793155,0.0021849445,0.000004330203,0.009165349,0.000086768385,0.00059088366,0.000013586648,0.0000069662588,0.000015644175],"genre_scores_gemma":[0.9971171,0.00022376576,0.00032122515,0.0021732769,0.00011535555,0.000013916256,0.000003614581,0.000012927141,0.00001878868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987791,0.0001635371,0.00028924886,0.0002182461,0.00031339997,0.00023647597],"domain_scores_gemma":[0.9987965,0.0003880899,0.00011082188,0.00019653338,0.00003683927,0.00047121468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002889847,0.00013455423,0.00064510334,0.000064463726,0.000035151574,0.0000110211795,0.000057756788,0.00001351996,0.0000053211083],"category_scores_gemma":[0.0008618366,0.0000832431,0.00009848658,0.00018337964,0.00017224601,0.000052448988,0.000048772017,0.0001462666,0.0000011436294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04107378,0.00034154308,0.9136399,0.0002269752,0.0024605095,0.000121302124,0.0020598401,0.00026626015,0.004625751,0.000007120908,0.02527016,0.00990687],"study_design_scores_gemma":[0.03793822,0.010442509,0.91072905,0.0013659506,0.0016355222,0.0000022261777,0.0005517406,0.00015006059,0.0013166054,0.000005637848,0.035624657,0.00023783032],"about_ca_topic_score_codex":0.0005755373,"about_ca_topic_score_gemma":0.000052035874,"teacher_disagreement_score":0.010354496,"about_ca_system_score_codex":0.00016971784,"about_ca_system_score_gemma":0.00031345472,"threshold_uncertainty_score":0.33945552},"labels":[],"label_agreement":null},{"id":"W3114565741","doi":"10.2337/dc20-1815","title":"HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression","year":2020,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"University of Oxford; Novo Nordisk; Abbott Laboratories; Sanofi; AstraZeneca; Duke Clinical Research Institute; Eli Lilly and Company; Amgen","keywords":"Medicine; Retinopathy; Internal medicine; Diabetic retinopathy; Odds ratio; Glycemic; Diabetes mellitus; Meta-analysis; Blood pressure; Type 2 diabetes; Endocrinology","score_opus":0.2222023027765259,"score_gpt":0.3554718015894979,"score_spread":0.13326949881297204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114565741","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078059465,0.9928014,0.000001468639,0.00029984015,0.00018734405,0.004495089,0.0011288676,0.00017120164,0.00013414596],"genre_scores_gemma":[0.0015666764,0.99081004,0.00036431945,0.00022092237,0.00035139345,0.003946136,0.0020245009,0.00017939399,0.00053664396],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9939701,0.0012043493,0.0015670082,0.0016751213,0.00084734056,0.0007361043],"domain_scores_gemma":[0.99665314,0.0004514645,0.0008154509,0.0013730684,0.00014518139,0.0005617099],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0012706139,0.0015410597,0.023703119,0.0008275192,0.00022146005,0.00022649959,0.0002545912,0.00044842795,0.00038143713],"category_scores_gemma":[0.00046265664,0.0008765068,0.016375158,0.0011078885,0.00014948475,0.00014898981,0.0005392983,0.0004862607,0.00009119689],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008732873,0.00004350132,0.0020431937,0.039426014,0.71327347,0.000087481516,0.0002716402,1.0884538e-7,0.0000010158694,0.0000038271173,0.00008638273,0.24475461],"study_design_scores_gemma":[0.00052301196,0.00011179293,0.00018936029,0.0003472063,0.57198125,0.0000010658068,0.0000708265,0.0000011400842,0.00001602495,0.0000012418465,0.42633432,0.00042276885],"about_ca_topic_score_codex":0.000020170246,"about_ca_topic_score_gemma":0.0000052629957,"teacher_disagreement_score":0.42624795,"about_ca_system_score_codex":0.00021653803,"about_ca_system_score_gemma":0.000049189886,"threshold_uncertainty_score":0.9997338},"labels":[],"label_agreement":null},{"id":"W3114726363","doi":"10.1007/s13300-020-00984-x","title":"Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study","year":2020,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia","funders":"Novo Nordisk Canada; Novo Nordisk","keywords":"Semaglutide; Dulaglutide; Liraglutide; Medicine; Internal medicine; Tolerability; Type 2 diabetes; Interquartile range; Body mass index; Exenatide; Glycated hemoglobin; Gastroenterology; Type 2 Diabetes Mellitus; Endocrinology; Diabetes mellitus; Adverse effect","score_opus":0.01455503054483066,"score_gpt":0.2668258907390139,"score_spread":0.25227086019418327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114726363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542564,0.0003062523,0.000010172045,0.00040041542,0.00008654619,0.0033301725,0.000069789996,0.00010765643,0.00026337593],"genre_scores_gemma":[0.99807775,0.000074392585,0.0001946429,0.0010716032,0.000071497554,0.00022000467,0.00016877073,0.00007634191,0.00004498942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969065,0.0004098385,0.000584651,0.00080929726,0.000694301,0.00059537933],"domain_scores_gemma":[0.9976922,0.00074691256,0.00026247758,0.000822165,0.00024357358,0.000232625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005607403,0.00047695165,0.0014644577,0.0005793874,0.000102665865,0.000053672033,0.00033288696,0.000060277274,0.00010370904],"category_scores_gemma":[0.00019766057,0.00027918592,0.00022031361,0.004530461,0.00006783408,0.00012324927,0.00012895126,0.00024489322,0.0000141255705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002373225,0.0013930704,0.97875994,0.0000492561,0.007636328,0.000011407628,0.0028276858,0.00038524522,0.0009102328,0.000029084626,0.00006686936,0.005557674],"study_design_scores_gemma":[0.0056298333,0.0050572236,0.98217046,0.00020070835,0.002283269,4.3233275e-9,0.00038007504,0.00037696047,0.0033927094,0.000059389597,0.00013750745,0.00031186698],"about_ca_topic_score_codex":0.00093185145,"about_ca_topic_score_gemma":0.001142374,"teacher_disagreement_score":0.005353059,"about_ca_system_score_codex":0.0002784155,"about_ca_system_score_gemma":0.000060602822,"threshold_uncertainty_score":0.999966},"labels":[],"label_agreement":null},{"id":"W3115628228","doi":"10.1093/eurheartj/ehaa943","title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Boehringer Ingelheim","keywords":"Medicine; Empagliflozin; Ejection fraction; Heart failure; Heart failure with preserved ejection fraction; Cardiology; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.01009931732513293,"score_gpt":0.24419322156052553,"score_spread":0.2340939042353926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115628228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984442,0.00014995149,0.0000013066218,0.00068554445,0.00002511779,0.0005315045,0.0000012499429,0.000018025086,0.00014307351],"genre_scores_gemma":[0.99946827,0.000028261718,0.00027640568,0.00012769931,0.000047121976,0.0000032483072,0.0000050048397,0.000023033508,0.00002093389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990628,0.00023573617,0.00015740424,0.00021545024,0.00018512658,0.00014349277],"domain_scores_gemma":[0.99953675,0.000048284135,0.00007310259,0.00010170833,0.000061433064,0.00017872863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034295977,0.0001439633,0.00031388048,0.00008188602,0.000060304345,0.00004054269,0.000020267054,0.000019423578,0.000012318058],"category_scores_gemma":[0.000070012386,0.000090072936,0.00001798337,0.000131217,0.00006403703,0.00014723703,0.000029405654,0.0001971388,0.0000024075725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019197683,0.000104555525,0.9946413,0.00017682345,0.000068560475,0.000004675481,0.00010124892,0.0000047122153,0.00071391,3.4791503e-7,0.00046172188,0.0018023498],"study_design_scores_gemma":[0.0048213704,0.014168163,0.97810405,0.00055369345,0.00017151432,0.0000046667437,0.0000323331,0.000057984395,0.0013475375,0.0000012041752,0.00065308367,0.00008439874],"about_ca_topic_score_codex":0.0000026399948,"about_ca_topic_score_gemma":0.0000016060094,"teacher_disagreement_score":0.016537275,"about_ca_system_score_codex":0.00002050232,"about_ca_system_score_gemma":0.000011057307,"threshold_uncertainty_score":0.36730677},"labels":[],"label_agreement":null},{"id":"W3115855235","doi":"10.2337/dc20-1675","title":"Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF","year":2020,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health; Vifor Pharma; Deutsche Forschungsgemeinschaft; Cytokinetics; Eisai; University of Oxford; Zora Biosciences; Kidney Research UK; HLS Therapeutics; IFM Therapeutics; Medicines Company; American Heart Association; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; British Heart Foundation; Brigham and Women's Hospital; Eli Lilly and Company; AstraZeneca; Sanofi Pasteur; Celladon Corporation; Pfizer; Amgen; Sanofi; Defense Acquisition Program Administration; American Diabetes Association","keywords":"Dapagliflozin; Medicine; Ejection fraction; Heart failure; Diabetes mellitus; Internal medicine; Type 2 diabetes; Incidence (geometry); Cardiology; Benzhydryl compounds; Type 1 diabetes; Endocrinology","score_opus":0.008748223849020815,"score_gpt":0.21704969288431664,"score_spread":0.2083014690352958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115855235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981117,0.0007448854,0.000001290714,0.0005815253,0.00003146781,0.000435568,0.000024397112,0.0000298473,0.000039288316],"genre_scores_gemma":[0.99882776,0.00002436075,0.00024413866,0.0005024981,0.000043235435,0.00003552175,0.00030470366,0.000014917427,0.0000028460822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990482,0.000087299755,0.00017954508,0.00031690238,0.00021186075,0.00015619204],"domain_scores_gemma":[0.9993688,0.00007644555,0.000087145694,0.00023054522,0.00013270728,0.00010435238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007908618,0.00015192622,0.00043747394,0.000128064,0.000049004608,0.000030091554,0.000051909163,0.000052372943,0.000022871394],"category_scores_gemma":[0.00005611904,0.00010295836,0.00004385229,0.0006160216,0.000115028764,0.0002508602,0.000055441662,0.000107470514,0.0000034186048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001584806,0.00005572197,0.9966605,0.0000694046,0.0004154549,5.713549e-7,0.0011814921,0.000016692551,0.00041489475,0.000005874908,0.00011945307,0.00090149423],"study_design_scores_gemma":[0.0029113719,0.0007726965,0.9880097,0.00008115493,0.0012800522,7.484172e-9,0.0041126558,0.0007231562,0.0017001998,0.000016439115,0.0002746386,0.00011793634],"about_ca_topic_score_codex":0.000028293063,"about_ca_topic_score_gemma":0.00008271837,"teacher_disagreement_score":0.008650774,"about_ca_system_score_codex":0.00003390131,"about_ca_system_score_gemma":0.000017259405,"threshold_uncertainty_score":0.41985202},"labels":[],"label_agreement":null},{"id":"W3116501842","doi":"10.1002/ehf2.13148","title":"Early Initiation of SGLT2 Inhibitors is Important, Irrespective of Ejection Fraction: SOLOIST-WHF in Perspective","year":2020,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Heart failure; Empagliflozin; Medicine; Ejection fraction; Dapagliflozin; Internal medicine; Cardiology; Valsartan; Canagliflozin; ACE inhibitor; Diabetes mellitus; Angiotensin-converting enzyme; Type 2 diabetes; Blood pressure; Endocrinology","score_opus":0.014760768533138945,"score_gpt":0.26811258360782825,"score_spread":0.2533518150746893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116501842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98186004,0.00020119897,0.000060380957,0.013164606,0.000104834806,0.0006390255,0.000013320227,0.000045420336,0.003911144],"genre_scores_gemma":[0.99846715,0.00001961215,0.0007976614,0.00041119737,0.00016683569,0.000021385105,0.0000137505995,0.000015105952,0.000087301036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989755,0.000036942576,0.00033677474,0.00025301485,0.00025362533,0.00014410267],"domain_scores_gemma":[0.99942386,0.000033431428,0.00015798472,0.00013652211,0.0001738496,0.000074366035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106324514,0.00012581443,0.00033474946,0.00017638608,0.000025157926,0.000007296003,0.00003085035,0.000086069136,0.00020318067],"category_scores_gemma":[0.00009844251,0.00012113302,0.000113961614,0.00047660922,0.000047383743,0.00018499306,0.000026171718,0.00017106818,0.00002688896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006944686,0.0007788606,0.9346293,0.00026034363,0.0004300063,0.000038591443,0.011811656,0.000009539041,0.025256146,0.0020164652,0.02343842,0.0006361754],"study_design_scores_gemma":[0.0049279714,0.0036324433,0.8250378,0.00036861977,0.0003557618,0.0000052944297,0.018357683,0.00018770077,0.12281081,0.00094945973,0.023059476,0.00030700545],"about_ca_topic_score_codex":0.00034261047,"about_ca_topic_score_gemma":0.000049461,"teacher_disagreement_score":0.10959156,"about_ca_system_score_codex":0.00017924768,"about_ca_system_score_gemma":0.000064409265,"threshold_uncertainty_score":0.4939661},"labels":[],"label_agreement":null},{"id":"W3116633224","doi":"10.1111/dom.14308","title":"The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; TIMI; Myocardial infarction; Placebo; Population; Unstable angina; Quality-adjusted life year; Stroke (engine); Heart failure; Internal medicine; Intensive care medicine; Cost effectiveness; Emergency medicine; Type 2 diabetes; Diabetes mellitus; Environmental health; Thrombolysis; Risk analysis (engineering); Alternative medicine","score_opus":0.045958767042678206,"score_gpt":0.2840855385992422,"score_spread":0.23812677155656398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116633224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99345475,0.003605389,0.000012675841,0.0000817384,0.00023897426,0.0023226133,0.00023110415,0.000020154717,0.000032604596],"genre_scores_gemma":[0.99773043,0.00040606677,0.00036311115,0.00012393006,0.00018805091,0.00005725188,0.0011062833,0.000023202627,0.0000016839257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790114,0.0007295516,0.00031840004,0.00046628006,0.00029307822,0.0002915541],"domain_scores_gemma":[0.99815625,0.000780148,0.00023404538,0.00061828684,0.00010166044,0.000109582084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014730404,0.00022250107,0.0005380167,0.000048144775,0.00019723889,0.00007991879,0.00027334533,0.00006722412,0.0000240437],"category_scores_gemma":[0.00037923746,0.00012907074,0.000044552653,0.00019201069,0.00012197152,0.0003636772,0.00018843696,0.00014792291,0.0000041232474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002299502,0.0003609147,0.94207233,0.00005614128,0.0006222485,4.3826432e-7,0.00032621005,0.0002835733,0.00018078556,0.00008654062,0.000027485747,0.053683836],"study_design_scores_gemma":[0.02823527,0.0004857524,0.9450004,0.0001297125,0.0023723745,1.10583285e-8,0.00012644206,0.021057023,0.00151888,0.00024450955,0.00066449505,0.00016512486],"about_ca_topic_score_codex":0.00042759866,"about_ca_topic_score_gemma":0.00015342126,"teacher_disagreement_score":0.053518713,"about_ca_system_score_codex":0.000058051653,"about_ca_system_score_gemma":0.00008884759,"threshold_uncertainty_score":0.52633524},"labels":[],"label_agreement":null},{"id":"W3117203930","doi":"10.14740/jem.v10i6.708","title":"Combination Therapy of Alpha-Glucosidase Inhibitor, Thiazolidinedione and Sodium Glucose Co-Transporter-2 Inhibitor in Japanese Type 2 Diabetes Patients","year":2020,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Internal medicine; Glycated hemoglobin; Type 2 diabetes; Endocrinology; Pharmacology; Dipeptidyl peptidase-4 inhibitor; Thiazolidinedione; Type 2 Diabetes Mellitus; Diabetes mellitus","score_opus":0.01509987971814005,"score_gpt":0.25176795213170855,"score_spread":0.2366680724135685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117203930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671633,0.010720138,0.0000012322521,0.0017274456,0.00040151246,0.00028545017,0.000005423749,0.00000930078,0.00013317613],"genre_scores_gemma":[0.9899241,0.009029415,0.00010325552,0.00070630957,0.00017378252,0.0000046287732,0.000018681732,0.000012838533,0.000027031652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988835,0.000060903327,0.00049042125,0.00015475432,0.00018803973,0.0002224034],"domain_scores_gemma":[0.9992618,0.00006151233,0.00027086842,0.00008182286,0.00017725947,0.00014674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012481834,0.00016353832,0.00059537473,0.00023082852,0.000027976424,0.000008444031,0.00005564291,0.000070828275,0.00002032061],"category_scores_gemma":[0.000068190486,0.00012366023,0.00007005375,0.00015198861,0.00011192512,0.00018925629,0.000025892887,0.00018429967,0.0000014404953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035556636,0.0034913872,0.8009056,0.00039808694,0.0011075103,0.00027587655,0.004857833,0.0000018776112,0.11108826,0.0013948892,0.0019141674,0.07100886],"study_design_scores_gemma":[0.024158772,0.003232295,0.8011433,0.00012482221,0.00036696796,0.000013902004,0.00027827747,0.000017287499,0.1520134,0.00021581931,0.018256515,0.00017863505],"about_ca_topic_score_codex":0.0000055286364,"about_ca_topic_score_gemma":0.0000013824853,"teacher_disagreement_score":0.070830226,"about_ca_system_score_codex":0.000011599703,"about_ca_system_score_gemma":0.000031876283,"threshold_uncertainty_score":0.50427175},"labels":[],"label_agreement":null},{"id":"W3117696772","doi":"10.1016/s1530-891x(20)39691-9","title":"Abstract #806359: SGLT 2 Inhibitors; Glycemic Control, Weight Loss and Safety Profile in Patients with Type 2 Diabetes, at Medicell Institute: a Private Care Facility","year":2020,"lang":"en","type":"article","venue":"Endocrine Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juvenile Diabetes Research Foundation","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Weight loss; Safety profile; Internal medicine; Adverse effect; Endocrinology; Obesity","score_opus":0.0062450726377890784,"score_gpt":0.2256919841390936,"score_spread":0.21944691150130452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117696772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845082,0.000949948,0.0000059785725,0.0047003236,0.00020498448,0.0017253566,0.00008411578,0.00009975682,0.007721327],"genre_scores_gemma":[0.99686533,0.00020197425,0.00049786747,0.0014660339,0.00010841384,0.000060994294,0.0006218223,0.000024045303,0.00015353021],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814624,0.00005890318,0.00038084222,0.0005279216,0.0004526549,0.0004334544],"domain_scores_gemma":[0.998857,0.00017151023,0.00020628289,0.00030254145,0.00017568794,0.0002869857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109944514,0.00029794997,0.00044693757,0.00007277124,0.000080618265,0.000027553313,0.00009017544,0.000051068164,0.00016539148],"category_scores_gemma":[0.00055809866,0.00023075622,0.000040818213,0.00028520357,0.00011293931,0.0006297919,0.00016427047,0.00033423761,0.00012935582],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015861336,0.00090068113,0.9627851,0.0009849044,0.0005249381,0.0005919796,0.00075744186,0.0000145081485,0.0002396179,0.00009603085,0.0026149296,0.014628526],"study_design_scores_gemma":[0.029510757,0.0021853563,0.35574034,0.00019691266,0.00065795553,0.000005618711,0.00015529653,0.00003677255,0.001041365,0.000004430583,0.61008686,0.00037832712],"about_ca_topic_score_codex":0.00007268014,"about_ca_topic_score_gemma":0.000034587832,"teacher_disagreement_score":0.60747194,"about_ca_system_score_codex":0.00025650425,"about_ca_system_score_gemma":0.000081547056,"threshold_uncertainty_score":0.9409965},"labels":[],"label_agreement":null},{"id":"W3117993076","doi":"10.1016/j.jdiacomp.2020.107841","title":"Sex-related differences in diabetic kidney disease: A review on the mechanisms and potential therapeutic implications","year":2020,"lang":"en","type":"review","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Center for Research Resources; Boettcher Foundation","keywords":"Medicine; Disease; Diabetes mellitus; Sexual dimorphism; Psychological intervention; Bioinformatics; Sex characteristics; Internal medicine; Endocrinology; Psychiatry; Biology","score_opus":0.04482526705635146,"score_gpt":0.30047966025214445,"score_spread":0.255654393195793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117993076","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018273144,0.97049975,0.000014699039,0.027377332,0.00004909843,0.0016116541,0.000066011824,0.00001346876,0.00018524022],"genre_scores_gemma":[0.0077623366,0.98911464,0.00004244541,0.0025911212,0.000040487255,0.00023836289,0.000062094216,0.00002721534,0.00012128381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983899,0.00016680834,0.0007569493,0.00026910604,0.00020853608,0.00020872576],"domain_scores_gemma":[0.9984136,0.0002770809,0.00056553434,0.0003023925,0.00008647595,0.00035486897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023911784,0.00030671933,0.0013132503,0.00019441718,0.00012471326,0.00005872265,0.00021994105,0.00006865411,0.000045797806],"category_scores_gemma":[0.00012694497,0.00017012318,0.00029706198,0.00036306083,0.000061201376,0.00005904895,0.00008190601,0.00036735443,0.000013575985],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004224328,0.00060746924,0.00050041545,0.020543395,0.0017410885,0.000008690563,0.000056811507,1.6184862e-7,0.000015670399,0.032513715,0.0021074149,0.94190097],"study_design_scores_gemma":[0.001372532,0.001063416,0.035471328,0.12579179,0.02021941,0.000036033718,0.000044038472,0.00021555243,0.0000016388209,0.011519621,0.8036273,0.0006373263],"about_ca_topic_score_codex":1.7382148e-7,"about_ca_topic_score_gemma":6.630399e-8,"teacher_disagreement_score":0.9412636,"about_ca_system_score_codex":0.000050742212,"about_ca_system_score_gemma":0.0001530964,"threshold_uncertainty_score":0.6937422},"labels":[],"label_agreement":null},{"id":"W3118238033","doi":"10.7326/acpj202101190-011","title":"Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD","year":2021,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Canagliflozin; Medicine; Amputation; Cohort; Type 2 diabetes; Internal medicine; Cohort study; Endocrinology; Diabetes mellitus; Surgery","score_opus":0.024628659747263682,"score_gpt":0.29634730925450403,"score_spread":0.27171864950724034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118238033","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29746225,0.003023755,0.00006177521,0.6923047,0.0006841149,0.0014899444,0.000021262358,0.00003921475,0.0049130106],"genre_scores_gemma":[0.2445096,0.0008213296,0.0005480681,0.72770166,0.002500449,0.00009476602,0.0010791969,0.00010289669,0.022642067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997738,0.000062470666,0.0005935586,0.00055499,0.0006331816,0.00041776677],"domain_scores_gemma":[0.9985562,0.000112610076,0.00025610995,0.0003776629,0.000500672,0.00019675156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019412194,0.000403204,0.0010275835,0.0005317804,0.000018117235,0.00002097626,0.0001551863,0.00024411536,0.0002999487],"category_scores_gemma":[0.00023312107,0.00028588387,0.000069710826,0.00034363926,0.000121425655,0.000066484485,0.00009877394,0.0006024962,0.000017716558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001631249,0.00014159842,0.004128785,0.0014235489,0.0007403381,0.0030287716,0.0017030803,0.000005348894,0.00007759378,0.000008078353,0.97157836,0.015533256],"study_design_scores_gemma":[0.016053796,0.013281563,0.100618474,0.05693239,0.0012332043,0.00011732419,0.00084183936,0.00018622309,0.0011992243,0.00008501673,0.8086243,0.0008266323],"about_ca_topic_score_codex":0.0047882884,"about_ca_topic_score_gemma":0.00095480896,"teacher_disagreement_score":0.16295403,"about_ca_system_score_codex":0.00006558695,"about_ca_system_score_gemma":0.00010287424,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W3118272438","doi":"10.1038/s41467-020-20301-1","title":"Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"Université de Paris; Société Francophone du Diabète; Société Nationale Française de Gastro-Entérologie; University of Toronto; Institut National de la Santé et de la Recherche Médicale","keywords":"Glucagon-like peptide-1; Ghrelin; Sleeve gastrectomy; Somatostatin; Internal medicine; Enteroendocrine cell; Medicine; Gastric inhibitory polypeptide; Glucagon-like peptide-2; Endocrinology; Stomach; Gastric mucosa; Secretion; Glucagon; Cancer research; Receptor; Biology; Diabetes mellitus; Insulin; Peptide; Gastric bypass; Weight loss; Type 2 diabetes; Obesity; Endocrine system; Hormone","score_opus":0.027823376220748406,"score_gpt":0.258692583448085,"score_spread":0.2308692072273366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118272438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89314526,0.04710736,0.0012138697,0.013340155,0.0010199614,0.0011485955,0.000040033206,0.0005170666,0.04246771],"genre_scores_gemma":[0.97286737,0.0007698761,0.020988202,0.0014323167,0.00018135362,0.000048422084,0.0009504374,0.000031798907,0.0027302373],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9987976,0.00011851163,0.0002369802,0.00028002128,0.0003185966,0.00024830343],"domain_scores_gemma":[0.9974152,0.00052229373,0.00012763034,0.0014948772,0.0002507583,0.00018924291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015838204,0.0001934924,0.00029355971,0.000251649,0.00026676213,0.00007800381,0.00023773688,0.00016741717,0.00021338419],"category_scores_gemma":[0.00012736226,0.00016202895,0.00012420221,0.0010337695,0.000062252424,0.00016000068,0.00024972012,0.0006116841,0.000056684337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006068804,0.0056096064,0.121359,0.0002957027,0.0031160128,0.00021871546,0.00075467373,0.00006997261,0.045325693,0.0072864085,0.73125386,0.08410345],"study_design_scores_gemma":[0.004589384,0.00019963694,0.50076765,0.0005803496,0.002504715,0.00007748788,0.00068407384,0.00021866617,0.008137371,0.000265167,0.4812691,0.00070639554],"about_ca_topic_score_codex":0.00007505012,"about_ca_topic_score_gemma":0.00014011815,"teacher_disagreement_score":0.37940866,"about_ca_system_score_codex":0.00011372248,"about_ca_system_score_gemma":0.0007047347,"threshold_uncertainty_score":0.66073495},"labels":[],"label_agreement":null},{"id":"W3118491390","doi":"10.1093/eurheartj/ehaa1007","title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Royal Victoria Hospital; St. Michael's Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Ejection fraction; Heart failure; Internal medicine; Clinical endpoint; Randomized controlled trial; Cardiology; Confidence interval; Diabetes mellitus; Type 2 diabetes","score_opus":0.061946398596760884,"score_gpt":0.3117903103496614,"score_spread":0.24984391175290055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118491390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96180105,0.000070051356,0.000007807214,0.03682818,0.00012567754,0.0008187507,0.0000022613124,0.000029109453,0.00031708233],"genre_scores_gemma":[0.99722326,0.000009928356,0.00039669118,0.0020700574,0.00016192952,0.0000042290912,0.000010120628,0.000029062467,0.00009471737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980055,0.0005759407,0.0005764963,0.00021510542,0.0004116051,0.00021536076],"domain_scores_gemma":[0.9991124,0.0000518044,0.00030989497,0.00017118722,0.000086388165,0.00026830588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089063856,0.00016768843,0.00052611216,0.00009264533,0.00015093696,0.000047895563,0.00005343436,0.000024911918,0.000070725735],"category_scores_gemma":[0.00011413254,0.0000929175,0.0000764465,0.00025076262,0.000060068207,0.00014978474,0.000030443958,0.00041211693,0.000015619253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010790749,0.00043831594,0.9801449,0.000044025048,0.00028107656,0.0000069504854,0.0005891351,0.000015885431,0.000109821434,0.0000063730677,0.0071536857,0.00041908666],"study_design_scores_gemma":[0.038255233,0.004575999,0.9541087,0.000114069575,0.00006907548,0.0000071777677,0.00050970213,0.000005440797,0.000033990083,0.0000017562846,0.0022261017,0.00009273961],"about_ca_topic_score_codex":0.000031821528,"about_ca_topic_score_gemma":0.000011624556,"teacher_disagreement_score":0.035422184,"about_ca_system_score_codex":0.00006575639,"about_ca_system_score_gemma":0.000107467284,"threshold_uncertainty_score":0.37890655},"labels":[],"label_agreement":null},{"id":"W3119023686","doi":"10.1002/pds.5192","title":"<scp>SGLT</scp>‐2 inhibitors and the risk of hospitalization for <scp>community‐acquired</scp> pneumonia: A population‐based cohort study","year":2021,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Internal medicine; Pneumonia; Community-acquired pneumonia; Pharmacoepidemiology; Type 2 diabetes; Confidence interval; Proportional hazards model; Cohort study; Diabetes mellitus; Population; Cohort; Endocrinology; Pharmacology","score_opus":0.015725220639257718,"score_gpt":0.3014562589684523,"score_spread":0.28573103832919455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119023686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914159,0.0024179965,0.0010793527,0.0012436027,0.00029695634,0.0024268478,0.0000590914,0.000065187305,0.0009950408],"genre_scores_gemma":[0.9952828,0.0013923233,0.000460312,0.0012382085,0.00010927654,0.00029480355,0.0004630362,0.000025970663,0.00073322473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603826,0.0024226569,0.00069262617,0.00036774192,0.00015208966,0.0003266495],"domain_scores_gemma":[0.98960555,0.009318383,0.00040425884,0.00037392692,0.00016756734,0.00013030978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048848754,0.00026863697,0.00086328795,0.00011598917,0.0004924402,0.000013094571,0.0000986858,0.00009859868,0.000007364646],"category_scores_gemma":[0.0045421636,0.00018936019,0.00017217013,0.0002423744,0.00024427235,0.00010692461,0.00015921716,0.00023997862,0.000002026094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009620532,0.0006354918,0.9902613,0.00018599656,0.0010173536,0.00000513604,0.0013100007,0.000185722,0.000056003737,0.0008341785,0.0038121948,0.0016004099],"study_design_scores_gemma":[0.009848864,0.0002662323,0.97345454,0.000055746877,0.002924852,0.000004127062,0.0021695802,0.004663461,0.00051791756,0.0014786756,0.0045673656,0.000048655354],"about_ca_topic_score_codex":0.0004115415,"about_ca_topic_score_gemma":0.00008114365,"teacher_disagreement_score":0.016806785,"about_ca_system_score_codex":0.000046187346,"about_ca_system_score_gemma":0.000042247546,"threshold_uncertainty_score":0.7721884},"labels":[],"label_agreement":null},{"id":"W3119901445","doi":"10.1002/psp4.12577","title":"Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes","year":2021,"lang":"en","type":"article","venue":"CPT Pharmacometrics & Systems Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Physiologically based pharmacokinetic modelling; Dapagliflozin; Pharmacokinetics; Dosing; Pharmacology; Context (archaeology); Medicine; Drug; Internal medicine; Endocrinology; Biology","score_opus":0.056117851728890875,"score_gpt":0.3404270299676117,"score_spread":0.2843091782387208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119901445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594117,0.011157648,0.008935757,0.0015651442,0.006268165,0.0056764334,0.00025599226,0.00061953714,0.006109629],"genre_scores_gemma":[0.9783994,0.0016046244,0.005006447,0.0021719937,0.0011760278,0.0015463473,0.00076065195,0.00009161927,0.009242879],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743056,0.00010052425,0.00066254154,0.00061508734,0.00044856628,0.0007427236],"domain_scores_gemma":[0.998278,0.00036057728,0.00037099654,0.00012705538,0.000492757,0.0003705775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005544448,0.00040402674,0.00068854657,0.0011942617,0.00026195528,0.00008142078,0.00017709895,0.00017076785,0.00015774387],"category_scores_gemma":[0.0001325336,0.0004042279,0.00014910728,0.0028714908,0.000037899204,0.00022533584,0.00015733972,0.000265234,0.000059044654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004865615,0.0018377518,0.035812348,0.0031678604,0.0020093254,0.00010880478,0.00030928425,0.001132043,0.319358,0.00027748916,0.6146953,0.020805204],"study_design_scores_gemma":[0.0410986,0.0014612918,0.00079470896,0.00009944708,0.007004127,0.00028084454,0.0006301939,0.29800633,0.26982787,0.000052341446,0.37901855,0.0017257215],"about_ca_topic_score_codex":0.00001244706,"about_ca_topic_score_gemma":0.0000048732577,"teacher_disagreement_score":0.29687428,"about_ca_system_score_codex":0.0008920716,"about_ca_system_score_gemma":0.00061126036,"threshold_uncertainty_score":0.999841},"labels":[],"label_agreement":null},{"id":"W3120094266","doi":"10.1161/circ.142.suppl_3.14849","title":"Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Medicine; Empagliflozin; Insulin; Diabetes mellitus; Internal medicine; Type 2 diabetes; Glycemic; EMPA; Survival analysis; Hypoglycemia; Endocrinology","score_opus":0.03831896366291487,"score_gpt":0.2731643735641567,"score_spread":0.2348454099012418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120094266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806094,0.0012707695,0.000042383184,0.000094642346,0.000058084854,0.00031819896,0.000052780928,0.000017497256,0.00008468209],"genre_scores_gemma":[0.99884033,0.00007316823,0.000103933,0.000030185733,0.000066876986,0.000007745974,0.00086391217,0.000012940378,9.247409e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987964,0.00004840965,0.0004468049,0.00028144266,0.00030321014,0.000123712],"domain_scores_gemma":[0.99933165,0.00007434043,0.00012922443,0.00031047838,0.00005463857,0.00009964292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002608851,0.0001228106,0.0005699449,0.00038993693,0.000012700599,0.000011246497,0.000061254344,0.0000643941,0.00007815517],"category_scores_gemma":[0.0002419405,0.00012491617,0.00015768768,0.00071513717,0.000022518936,0.00020221638,0.000036961374,0.00006442098,0.0000014077589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012720244,0.00014461849,0.97580653,0.000094654955,0.0013799259,0.000009819463,0.00056860334,0.01304656,0.0016401267,0.00004644563,0.0000012491687,0.0071342406],"study_design_scores_gemma":[0.0019393944,0.00004929741,0.9724776,0.00005848819,0.0023705442,1.1495256e-8,0.00010156531,0.022600103,0.00014737058,0.00015380875,0.000007661056,0.00009416287],"about_ca_topic_score_codex":0.00031420492,"about_ca_topic_score_gemma":0.00010727792,"teacher_disagreement_score":0.009553543,"about_ca_system_score_codex":0.000053811455,"about_ca_system_score_gemma":0.000020676205,"threshold_uncertainty_score":0.50939333},"labels":[],"label_agreement":null},{"id":"W3120289699","doi":"10.2337/dc20-2265","title":"Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes","year":2021,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Lunenfeld-Tanenbaum Research Institute; University Health Network; University of Toronto; Toronto General Hospital; Sinai Health System; Heart and Stroke Foundation; Ted Rogers Centre for Heart Research","funders":"Canadian Institutes of Health Research; Merck Sharp and Dohme; Pfizer","keywords":"Medicine; Dapagliflozin; Internal medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Renal function; Natriuretic peptide; Heart failure; Biomarker; Canagliflozin; Endocrinology","score_opus":0.005200583048983188,"score_gpt":0.17946273506453767,"score_spread":0.17426215201555448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120289699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9399054,0.01836141,8.566727e-8,0.038279127,0.00024513187,0.0024873957,0.0005432364,0.00007501594,0.000103198436],"genre_scores_gemma":[0.8720166,0.00044048176,0.00001639862,0.09858038,0.0006497762,0.000818846,0.026931252,0.00025488585,0.0002913642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663895,0.00021463305,0.0003066329,0.00096900365,0.0008690034,0.0010017972],"domain_scores_gemma":[0.9983441,0.00011259913,0.00015942052,0.00086893875,0.0002603738,0.00025452813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001794071,0.0007565168,0.0012472399,0.00041361546,0.000080142636,0.00009610857,0.00019334118,0.0003940492,0.00005046392],"category_scores_gemma":[0.000073174844,0.00048653508,0.00023247726,0.000760217,0.00024073123,0.00011210621,0.000099459634,0.0007989938,0.000009072838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011145088,0.0001704838,0.9361467,0.0016889501,0.0044675656,0.0004974617,0.0002849439,0.000004273647,0.000008766407,2.5596674e-7,0.053891774,0.0027274273],"study_design_scores_gemma":[0.008541167,0.0010335036,0.87314767,0.0047224765,0.004247878,7.988212e-8,0.0001374989,0.000014429599,0.00021429472,0.0000016286328,0.10720137,0.00073803763],"about_ca_topic_score_codex":0.000025207117,"about_ca_topic_score_gemma":0.00051787274,"teacher_disagreement_score":0.06788879,"about_ca_system_score_codex":0.00064074155,"about_ca_system_score_gemma":0.00031231655,"threshold_uncertainty_score":0.99975866},"labels":[],"label_agreement":null},{"id":"W3120335165","doi":"10.1016/j.cjca.2021.01.005","title":"When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Heart failure; Ejection fraction; Dapagliflozin; Internal medicine; Cardiology; Kidney disease; Preload; Diabetes mellitus; Adverse effect; Type 2 diabetes; Endocrinology; Hemodynamics","score_opus":0.00727884172734301,"score_gpt":0.1993329078490957,"score_spread":0.1920540661217527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120335165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99081695,0.00008645228,0.00013188427,0.00841424,0.0001800784,0.0002880656,0.000017354998,0.000003865234,0.00006109794],"genre_scores_gemma":[0.9984139,0.000015687508,0.0003566353,0.000671245,0.00022711055,0.000008483847,0.000057987243,0.000015430005,0.00023349765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931407,0.000054927037,0.00012865673,0.00016260997,0.00011230867,0.00022740483],"domain_scores_gemma":[0.99871963,0.000014516078,0.00006181582,0.00012678986,0.00018418324,0.0008930866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006840333,0.0001149008,0.000325929,0.00027049013,0.000038312268,0.000033420256,0.00002326272,0.000051195337,0.000026877831],"category_scores_gemma":[0.00006376854,0.00007947578,0.00004625433,0.00013906871,0.00004630808,0.00019476286,0.0000038724447,0.00014266862,0.0000015735205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000765711,0.00001203758,0.97520995,0.000035327168,0.00022655117,0.00058721175,0.00005295508,0.00006658783,0.00011931954,0.0000028875718,0.021944892,0.0009765556],"study_design_scores_gemma":[0.0034319335,0.0013354243,0.8070325,0.0002446677,0.00031061826,0.000042421158,0.000094665964,0.0000013312324,0.00018550172,0.000003671746,0.1872276,0.00008962783],"about_ca_topic_score_codex":0.00018008576,"about_ca_topic_score_gemma":0.006007577,"teacher_disagreement_score":0.16817743,"about_ca_system_score_codex":0.0003799937,"about_ca_system_score_gemma":0.0012728348,"threshold_uncertainty_score":0.33523688},"labels":[],"label_agreement":null},{"id":"W3120821309","doi":"10.1136/bmj.m4573","title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","year":2021,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":672,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; University of Alberta; Hôpital Maisonneuve-Rosemont; Impact; University of Calgary; McMaster University","funders":"National Institute on Aging","keywords":"Medicine; Type 2 diabetes; Internal medicine; Glucagon-like peptide 1 receptor; Diabetes mellitus; Kidney disease; Placebo; Endocrinology; Receptor; Agonist; Pathology","score_opus":0.110454468005884,"score_gpt":0.37211457853147917,"score_spread":0.2616601105255952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120821309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014649593,0.9314919,0.000019285773,0.00034857035,0.00023625544,0.0675433,0.00017230933,0.000039951687,0.00013376329],"genre_scores_gemma":[0.000013790033,0.9688956,0.0009003278,0.00045407913,0.00023071624,0.02246539,0.0017635517,0.00009745181,0.005179056],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99087095,0.0019743412,0.0052437726,0.0008752733,0.0005249054,0.0005107635],"domain_scores_gemma":[0.99125516,0.0029258402,0.004086772,0.001040222,0.00043346893,0.00025854373],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010091947,0.0010070697,0.046612274,0.00041832417,0.000087093475,0.00008679902,0.00016945973,0.00032732778,0.0003308248],"category_scores_gemma":[0.0029002498,0.0005613067,0.009800919,0.000995632,0.00010512287,0.00007045032,0.00007111539,0.0001855027,0.000008336012],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037692903,0.00012250201,0.0000017381567,0.56710047,0.42181623,0.000007704057,0.000016009462,2.680114e-7,0.0000013373102,0.00002823662,0.007108469,0.003420092],"study_design_scores_gemma":[0.015269029,0.00024325364,2.9809678e-7,0.1258607,0.7174872,0.0000012375034,0.000008773832,0.000006364186,0.0000041455146,0.0000037781983,0.14077677,0.00033846416],"about_ca_topic_score_codex":0.000004227504,"about_ca_topic_score_gemma":0.0000064919955,"teacher_disagreement_score":0.44123977,"about_ca_system_score_codex":0.00007585078,"about_ca_system_score_gemma":0.00025207613,"threshold_uncertainty_score":0.99968386},"labels":[],"label_agreement":null},{"id":"W3121555704","doi":"10.1016/j.jcjd.2021.01.009","title":"Quantifying the Risk Continuum for Cardiovascular Death in Adults with Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Boehringer Ingelheim","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Cardiology; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.01825830009671702,"score_gpt":0.22559799383165788,"score_spread":0.20733969373494085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121555704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97278637,0.025409905,0.000011187544,0.00063942885,0.00029583988,0.0003621868,0.00001560424,0.0000054479865,0.000474006],"genre_scores_gemma":[0.9982416,0.00013047473,0.00085371564,0.00035546796,0.00017840134,0.000018767521,0.000018536726,0.000028199598,0.00017481217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988109,0.00007224973,0.0002843948,0.00016771324,0.00018581588,0.00047894535],"domain_scores_gemma":[0.9986965,0.00016593233,0.0001395959,0.00028680929,0.00039794628,0.00031322904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005439536,0.00015754021,0.0004940445,0.00020280907,0.00010675074,0.00005966435,0.0001221008,0.00005127874,0.000031391704],"category_scores_gemma":[0.00038297538,0.0000995071,0.00035673488,0.00030555174,0.00006051303,0.000099231045,0.0000105815125,0.00019049793,0.0000035876367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015089547,0.000032077824,0.9881772,0.00013025184,0.0018836007,0.00009092204,0.00022817079,0.00005343805,0.000031467534,0.00009997338,0.0013693068,0.007888529],"study_design_scores_gemma":[0.0067883683,0.001329194,0.91981894,0.0019285952,0.0029388603,0.0000076075444,0.0009881522,0.00018670595,0.0029813878,0.0002660053,0.062466845,0.00029933776],"about_ca_topic_score_codex":0.0002458591,"about_ca_topic_score_gemma":0.017519964,"teacher_disagreement_score":0.06835823,"about_ca_system_score_codex":0.00012449987,"about_ca_system_score_gemma":0.00061934174,"threshold_uncertainty_score":0.9776551},"labels":[],"label_agreement":null},{"id":"W3122912123","doi":"10.3390/biomedicines9020106","title":"Liraglutide-Induced Hepatotoxicity","year":2021,"lang":"en","type":"article","venue":"Biomedicines","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Liraglutide; Medicine; Pharmacovigilance; Drug; Pharmacology; Incretin; Exenatide; Saxagliptin; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Sitagliptin","score_opus":0.02925193603583427,"score_gpt":0.28688493726494174,"score_spread":0.2576330012291075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122912123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594462,0.0009671308,0.000053067153,0.0065767667,0.00054721086,0.00024105802,0.0000027564947,0.00015474194,0.032011088],"genre_scores_gemma":[0.986519,0.00012028312,0.0006508136,0.0023359428,0.00040383072,0.000022473629,0.000076540186,0.00001610502,0.009855051],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991031,0.000016198146,0.00017128215,0.00024295264,0.00023872576,0.00022772951],"domain_scores_gemma":[0.9993736,0.00002597789,0.000034127544,0.00031665698,0.000097351985,0.00015227257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000832624,0.00012922929,0.00026253227,0.000107579806,0.00004422376,0.000011413517,0.000043385095,0.00005194004,0.00042082256],"category_scores_gemma":[0.00007870225,0.00009667352,0.0000845812,0.0003709867,0.00004330868,0.000040747775,0.000054474614,0.000056164587,0.00018999827],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013117264,0.0019643987,0.20801409,0.00056945084,0.0011880299,0.0035555875,0.00039157068,1.6555042e-7,0.49462706,0.0031670812,0.10072879,0.18566261],"study_design_scores_gemma":[0.006412642,0.0010875757,0.28472543,0.00046026325,0.0008591986,0.00015396027,0.00057247357,0.00012125382,0.26836333,0.0005147282,0.43633,0.0003991634],"about_ca_topic_score_codex":0.00002319824,"about_ca_topic_score_gemma":0.000007694703,"teacher_disagreement_score":0.3356012,"about_ca_system_score_codex":0.000047082514,"about_ca_system_score_gemma":0.00007122817,"threshold_uncertainty_score":0.46077117},"labels":[],"label_agreement":null},{"id":"W3123116101","doi":"10.14740/cr1194","title":"Combination of Linagliptin and Empagliflozin Preserves Cardiac Systolic Function in an Ischemia-Reperfusion Injury Mice With Diabetes Mellitus","year":2021,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Cardiology; Internal medicine; Cardiac function curve; Linagliptin; Diabetes mellitus; Blood pressure; Ventricle; Dipeptidyl peptidase-4; Ischemia; Dipeptidyl peptidase-4 inhibitor; Streptozotocin; Heart failure; Anesthesia; Type 2 Diabetes Mellitus; Type 2 diabetes; Endocrinology","score_opus":0.030410046940256487,"score_gpt":0.3231635396066506,"score_spread":0.2927534926663941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123116101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903016,0.0063841282,0.0000058383257,0.00034110012,0.00008045899,0.00056836236,0.0000087348435,0.000023343071,0.0022864407],"genre_scores_gemma":[0.9981992,0.0007001353,0.000096764044,0.000023825474,0.00008259855,0.00013369753,0.00015940637,0.000017575558,0.000586772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981242,0.00058083405,0.00020885047,0.00040520012,0.00031989996,0.00036106142],"domain_scores_gemma":[0.99881566,0.00018669628,0.000039926188,0.00039308475,0.00045845707,0.00010616077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011403551,0.00012448822,0.00056928105,0.00030716037,0.00006469632,0.000018782333,0.00006852251,0.00014331621,0.000012570338],"category_scores_gemma":[0.00017481604,0.00010174758,0.000058403628,0.00046496984,0.00023158647,0.00013009342,0.00016376813,0.000276632,0.000005406487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045838868,0.0002237615,0.833119,0.0004839059,0.00034947283,0.000060330367,0.00022441895,0.000012193009,0.1536225,0.00041544324,0.0006557011,0.010374942],"study_design_scores_gemma":[0.0037796693,0.0052944585,0.74306643,0.0005080443,0.00045007133,0.000008072932,0.0021193905,0.00033921524,0.24086194,0.000395041,0.0029184131,0.00025925142],"about_ca_topic_score_codex":0.000028809245,"about_ca_topic_score_gemma":0.000015693164,"teacher_disagreement_score":0.090052515,"about_ca_system_score_codex":0.00007879257,"about_ca_system_score_gemma":0.00009979615,"threshold_uncertainty_score":0.41491458},"labels":[],"label_agreement":null},{"id":"W3123510151","doi":"10.1007/s00125-020-05370-7","title":"Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study","year":2021,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; The Scarborough Hospital; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto; Ontario Ministry of Health and Long-Term Care; Diabetes Canada; Heart and Stroke Foundation of Canada","keywords":"Medicine; Diabetes mellitus; Population; Retrospective cohort study; Propensity score matching; Adverse effect; Cohort study; Cohort; Intensive care; Risk assessment; Internal medicine; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.005491634186181,"score_gpt":0.22041596792111007,"score_spread":0.21492433373492906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123510151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984835,0.0001288889,0.0000032477426,0.00002977294,0.00011298736,0.0010546792,0.000012410343,0.000029906783,0.00014462411],"genre_scores_gemma":[0.99888015,0.0000101242495,0.0003299318,0.000047937956,0.000008102842,0.00012465776,0.00025547927,0.0000145997565,0.00032903432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986655,0.0001026572,0.0003295062,0.00039098095,0.0002320245,0.00027931028],"domain_scores_gemma":[0.99934,0.00006533387,0.00013937753,0.0003084311,0.00006107083,0.00008575917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012986913,0.00020190372,0.0004924046,0.00014993918,0.000039072045,0.0000040484183,0.000044212953,0.00007426044,0.00016728311],"category_scores_gemma":[0.00006221075,0.00017017103,0.00010324792,0.00017243426,0.000025835157,0.000072615505,0.00006852725,0.00011765109,0.0000041039657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075311495,0.003172347,0.99405557,0.00007029563,0.0005091406,0.00013016902,0.00029967236,0.00007595496,0.00001652889,0.000005262389,0.00001134603,0.001578381],"study_design_scores_gemma":[0.008107896,0.0005748466,0.9889762,0.00021794035,0.00077512674,1.9140329e-7,0.00039844765,0.000374164,0.0004090509,0.000029985293,0.000004519152,0.00013168063],"about_ca_topic_score_codex":0.012977568,"about_ca_topic_score_gemma":0.04717071,"teacher_disagreement_score":0.034193143,"about_ca_system_score_codex":0.00018886181,"about_ca_system_score_gemma":0.00006584199,"threshold_uncertainty_score":0.9935951},"labels":[],"label_agreement":null},{"id":"W3123953428","doi":"10.1093/ckj/sfaa225","title":"Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial","year":2020,"lang":"en","type":"article","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Janssen Research and Development; Relypsa; Medical Research Council; Genentech; European Renal Association-European Dialysis and Transplant Association; Gilead Sciences; Servier; Astellas Pharma; Eisai; National Institutes of Health; Bristol-Myers Squibb; CryoLife; AstraZeneca; National Health and Medical Research Council; Zafgen; Eli Lilly and Company; CSL Behring; Novo Nordisk; Intarcia Therapeutics; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Linagliptin; Proteinuria; Medicine; Randomized controlled trial; Placebo; Type 2 diabetes; Diabetes mellitus; Internal medicine; Urology; Kidney; Endocrinology; Alternative medicine; Pathology","score_opus":0.026810204191362867,"score_gpt":0.3218022814298558,"score_spread":0.2949920772384929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123953428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752623,0.0018256945,0.000008580526,0.011422735,0.0011760049,0.00962784,0.000004688185,0.000021543314,0.00065062736],"genre_scores_gemma":[0.99269176,0.0016391433,0.00017742215,0.00390826,0.0010124061,0.00034863575,0.000007507492,0.000038162463,0.00017673404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956576,0.002122333,0.0011649355,0.00031440947,0.000448158,0.00029253465],"domain_scores_gemma":[0.99373883,0.0047435053,0.0003501799,0.00028097114,0.00008310081,0.0008034103],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0073448867,0.00028927188,0.003235253,0.00008815595,0.00007390179,0.000052944513,0.00012413475,0.00014871571,0.000053493564],"category_scores_gemma":[0.0361883,0.00014282337,0.0011451939,0.00013828048,0.00029448452,0.000054030792,0.00008396062,0.00062063866,0.00000850357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9720726,0.00025701162,0.013195165,0.0001795382,0.0057636956,0.00006928892,0.0001425816,0.0000038345875,0.0000103240645,0.000023202754,0.0016904358,0.006592312],"study_design_scores_gemma":[0.976987,0.012318025,0.0008837757,0.00029950787,0.0050375583,0.0000019466768,0.000026955982,0.0005652837,0.00003899888,0.000021938904,0.00369357,0.00012545522],"about_ca_topic_score_codex":0.0000041268095,"about_ca_topic_score_gemma":3.349614e-7,"teacher_disagreement_score":0.028843414,"about_ca_system_score_codex":0.000030388403,"about_ca_system_score_gemma":0.0001620418,"threshold_uncertainty_score":0.97193027},"labels":[],"label_agreement":null},{"id":"W3124438206","doi":"10.1007/s00592-020-01661-y","title":"The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)","year":2021,"lang":"en","type":"article","venue":"Acta Diabetologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Humber River Regional Hospital; Queen's University","funders":"AstraZeneca Canada","keywords":"Medicine; Saxagliptin; Ejection fraction; Internal medicine; Cardiology; Heart failure; Cardiac magnetic resonance imaging; Natriuretic peptide; Cardiac function curve; Cohort; Prospective cohort study; Preload; Magnetic resonance imaging; Radiology; Hemodynamics","score_opus":0.008127690486295802,"score_gpt":0.22944930713378436,"score_spread":0.22132161664748856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124438206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125904,0.0049509574,0.0000037594143,0.00045163243,0.0008216467,0.00043310598,0.000011247283,0.000034704808,0.0020339328],"genre_scores_gemma":[0.9981185,0.0008552933,0.00016779176,0.00023736186,0.00010820376,0.000017422606,0.000037750335,0.000013190797,0.0004444597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903065,0.00012030115,0.00014646465,0.0002662239,0.00018848894,0.00024788824],"domain_scores_gemma":[0.9990269,0.00040745997,0.00008096192,0.0003535931,0.0000624016,0.00006869992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010222997,0.00016113983,0.00040949287,0.000038345057,0.00013164179,0.000028074815,0.000047223435,0.000093862545,0.000019462586],"category_scores_gemma":[0.00017884558,0.00009698624,0.00013371797,0.00015153937,0.00008447407,0.00003857366,0.000085034895,0.00011540541,0.0000028630375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003939096,0.0004430092,0.42193395,0.001037335,0.0047583333,0.00011293656,0.0003671747,0.000013007564,0.36384124,0.0067314645,0.015017036,0.18535061],"study_design_scores_gemma":[0.0019114729,0.0018868581,0.69349414,0.0003024019,0.0033876775,0.000003051939,0.00044268777,0.000053943917,0.20793618,0.0012032724,0.08903765,0.00034067995],"about_ca_topic_score_codex":0.0000060409925,"about_ca_topic_score_gemma":0.0000011471344,"teacher_disagreement_score":0.27156016,"about_ca_system_score_codex":0.00003784128,"about_ca_system_score_gemma":0.000029518833,"threshold_uncertainty_score":0.39549842},"labels":[],"label_agreement":null},{"id":"W3124579964","doi":"10.1016/j.kint.2020.10.003","title":"Therapeutic transformation for diabetic kidney disease","year":2021,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Albuminuria; Diabetic nephropathy; Urology; Kidney disease; Internal medicine; Kidney; Post-hoc analysis; Endocrinology; Pharmacology","score_opus":0.02166637520982314,"score_gpt":0.27338050276594456,"score_spread":0.25171412755612144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124579964","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000081799444,0.00018113802,0.0016829885,0.97569543,0.0024238545,0.0011496465,0.0012889616,0.00009555335,0.017400626],"genre_scores_gemma":[0.0023207574,0.000094426694,0.0005495865,0.8898013,0.0033077265,0.00065667543,0.05655999,0.00006439223,0.046645127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843645,0.000024944056,0.00031632802,0.00037048306,0.0005505962,0.00030121888],"domain_scores_gemma":[0.9989888,0.000056840003,0.0001079661,0.00029565635,0.0002090714,0.00034167487],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000778065,0.00029043385,0.00031973238,0.00022993586,0.0000518657,0.000099031255,0.00018759751,0.00020658752,0.0019440046],"category_scores_gemma":[0.00017521136,0.00026121968,0.00040480337,0.00007181871,0.000037355374,0.00012518751,0.000029586576,0.00033080083,0.00011966966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059891245,0.00015030395,0.0003600824,0.0007067627,0.001497303,0.00010169369,0.0000604592,5.882259e-7,0.000038019498,0.00076662516,0.9921907,0.0040675327],"study_design_scores_gemma":[0.002413131,0.000082884246,0.0005264092,0.00050599803,0.0013178735,0.000003403815,0.0000074024497,0.0006214126,0.00015730158,0.0009330044,0.99319875,0.00023245228],"about_ca_topic_score_codex":0.0000030294423,"about_ca_topic_score_gemma":2.2414186e-7,"teacher_disagreement_score":0.085894115,"about_ca_system_score_codex":0.00024214308,"about_ca_system_score_gemma":0.00042881825,"threshold_uncertainty_score":0.999984},"labels":[],"label_agreement":null},{"id":"W3125106283","doi":"10.1177/2042098621989134","title":"Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Adverse effect; Systematic review; Transporter; Pharmacology; MEDLINE; Intensive care medicine; Bioinformatics; Biochemistry","score_opus":0.09842730358675036,"score_gpt":0.40746611403547806,"score_spread":0.3090388104487277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125106283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004751908,0.991724,0.000070673595,0.000015648498,0.00019624946,0.0069852555,0.00007498267,0.00004966529,0.00083596655],"genre_scores_gemma":[0.00021334986,0.9965862,0.0004913286,0.00012101258,0.000036988098,0.00068960816,0.0011487831,0.00009802856,0.00061471865],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947991,0.0013815855,0.0021332293,0.0006587557,0.0005854657,0.0004418974],"domain_scores_gemma":[0.9965753,0.00056410284,0.0017127356,0.0008922829,0.00013243845,0.00012316515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015425906,0.00079104217,0.006223913,0.00027259483,0.00004782952,0.0000057561033,0.00028252506,0.00017350959,0.00010998079],"category_scores_gemma":[0.00008350394,0.000500944,0.00073064736,0.00082306174,0.00012780033,0.00036253413,0.0000385592,0.00036184434,0.000034168537],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015264463,0.0017347512,0.00016716293,0.5739786,0.002748599,0.00012379301,0.0008455578,0.000005139746,4.1764375e-7,0.0012425564,0.000015608075,0.41898516],"study_design_scores_gemma":[0.0016584658,0.00038276517,0.000051242587,0.48850456,0.0075022727,0.0000057305797,0.00034231012,0.000004895103,0.0000034470258,0.000059652124,0.50105095,0.00043375173],"about_ca_topic_score_codex":0.000008228258,"about_ca_topic_score_gemma":0.00011595913,"teacher_disagreement_score":0.50103533,"about_ca_system_score_codex":0.00046825525,"about_ca_system_score_gemma":0.00024866103,"threshold_uncertainty_score":0.99974424},"labels":[],"label_agreement":null},{"id":"W3125150772","doi":"10.1111/dom.14326","title":"Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of <scp>EMPA‐REG OUTCOME</scp>","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Empagliflozin; Medicine; Internal medicine; Mace; Hazard ratio; Cardiology; Type 2 diabetes; Heart failure; Post-hoc analysis; Population; Diabetes mellitus; Proportional hazards model; Placebo; Confidence interval; Myocardial infarction; Endocrinology; Conventional PCI; Pathology","score_opus":0.01055226278675396,"score_gpt":0.249620035423218,"score_spread":0.23906777263646406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125150772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98909247,0.009643082,0.0000089983405,0.000092132956,0.00005669268,0.0006125594,0.0002460224,0.000031349435,0.00021669724],"genre_scores_gemma":[0.9979418,0.0007334645,0.00015672662,0.00037744947,0.000024973757,0.000049674753,0.0003938959,0.000030781623,0.000291224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763876,0.00016902824,0.00048576022,0.0005992327,0.00063335994,0.0004738648],"domain_scores_gemma":[0.9981768,0.00011882234,0.00019139837,0.0007684028,0.00022189588,0.0005226584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045964125,0.00041814402,0.0021597636,0.0007777427,0.000064036336,0.00003642745,0.000081263635,0.00009981987,0.000018690165],"category_scores_gemma":[0.00038481326,0.00029750867,0.0010959444,0.00089722703,0.00018013222,0.00016873066,0.00008942983,0.00015224723,0.0000021454287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007730903,0.0011883306,0.97196704,0.00047789054,0.023097409,0.00002410675,0.00021458027,0.00014140301,0.00051155104,0.000107598455,0.00001893995,0.0021738256],"study_design_scores_gemma":[0.004964014,0.00053952466,0.9693892,0.00018537826,0.022480393,3.4310398e-7,0.0001368665,0.00021417231,0.0013808336,0.000018041575,0.0005438555,0.00014736278],"about_ca_topic_score_codex":0.00012395676,"about_ca_topic_score_gemma":0.000021680444,"teacher_disagreement_score":0.008909617,"about_ca_system_score_codex":0.000061767336,"about_ca_system_score_gemma":0.000106309686,"threshold_uncertainty_score":0.9999477},"labels":[],"label_agreement":null},{"id":"W3126282519","doi":"10.1210/clinem/dgab065","title":"Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial","year":2021,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Hamilton Health Sciences; University of Toronto; McMaster University; Population Health Research Institute","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Internal medicine; Mace; Placebo; Myocardial infarction; Randomized controlled trial; Discontinuation; Subgroup analysis; Post-hoc analysis; Diabetes mellitus; Stroke (engine); Type 2 diabetes; Liraglutide; Endocrinology; Percutaneous coronary intervention; Confidence interval","score_opus":0.027343850959031687,"score_gpt":0.3483941103978601,"score_spread":0.3210502594388284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126282519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991009,0.003089462,0.000006311645,0.0046939612,0.00051444373,0.0003532623,0.000008185688,0.0000022160068,0.00032314178],"genre_scores_gemma":[0.99464345,0.0039063226,0.00015282352,0.00094685314,0.00015013425,0.0000015801133,0.0000046428336,0.000007848024,0.00018632642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671656,0.0008166217,0.0017822149,0.00014027843,0.0003290328,0.00021529323],"domain_scores_gemma":[0.99669266,0.0013189946,0.0010326218,0.0004326507,0.00044897667,0.00007409058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001148982,0.00012713355,0.0014357099,0.00022952187,0.000030409828,0.0000036258507,0.00021219088,0.00007632628,0.000091237736],"category_scores_gemma":[0.00244157,0.00006354753,0.00059152883,0.00058991794,0.0003345888,0.000049701695,0.00018524175,0.00041505176,8.9869457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2189497,0.015250158,0.50490546,0.00012825745,0.038499136,0.00024170318,0.0021542837,0.0002788644,0.000846585,0.0047741528,0.0011288194,0.21284285],"study_design_scores_gemma":[0.07543331,0.0008360707,0.9081601,0.000063942956,0.010839422,0.0000092470345,0.00015425467,0.000008480095,0.00036003548,0.00009537079,0.0039944677,0.00004533229],"about_ca_topic_score_codex":0.000018904306,"about_ca_topic_score_gemma":0.000030136971,"teacher_disagreement_score":0.4032546,"about_ca_system_score_codex":0.000012451821,"about_ca_system_score_gemma":0.00012713372,"threshold_uncertainty_score":0.29229635},"labels":[],"label_agreement":null},{"id":"W3126553617","doi":"10.1161/circulationaha.120.048740","title":"Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Canagliflozin; Medicine; Kidney disease; Blood pressure; Internal medicine; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Empagliflozin; Placebo; Population; Diuretic; Endocrinology; Confidence interval; Pathology","score_opus":0.010225193545903606,"score_gpt":0.2737580328074643,"score_spread":0.2635328392615607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126553617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178785,0.0074056424,0.0000019424558,0.00031434844,0.00009907641,0.00027191892,0.0000025957452,0.000010334865,0.000106273284],"genre_scores_gemma":[0.9992909,0.00029162545,0.000035874855,0.00014655064,0.000029206813,0.000007447571,0.00005286558,0.000006175189,0.00013939357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995226,0.00003425125,0.00013544194,0.00015103999,0.00007301963,0.00008363248],"domain_scores_gemma":[0.99962074,0.00008432396,0.000033831573,0.00012222587,0.000027475435,0.00011139764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006295189,0.00006044593,0.00018913604,0.000040817114,0.000010748093,0.000006784883,0.000010841803,0.000031765678,0.000012616032],"category_scores_gemma":[0.00032213988,0.0000532892,0.000028347356,0.00007573831,0.00002782075,0.00003933159,0.000025927784,0.000035288984,8.8050524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000084429485,0.00018658655,0.9931772,0.00073307764,0.00032533554,0.000023029843,0.000022846947,0.000005033393,0.00044747035,0.00014881144,0.000050541836,0.004871655],"study_design_scores_gemma":[0.0021493032,0.000075379045,0.9946362,0.0001748084,0.0014552707,1.6647515e-7,0.000003452605,0.0007082537,0.00034762334,0.00010876366,0.00029527396,0.000045556764],"about_ca_topic_score_codex":0.000011129004,"about_ca_topic_score_gemma":0.000020381292,"teacher_disagreement_score":0.007502993,"about_ca_system_score_codex":0.000010230658,"about_ca_system_score_gemma":0.00006566698,"threshold_uncertainty_score":0.21730705},"labels":[],"label_agreement":null},{"id":"W3126782463","doi":"10.1155/2021/7320217","title":"Corrigendum to “A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes”","year":2021,"lang":"en","type":"erratum","venue":"Case Reports in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Canagliflozin; Medicine; Type 2 diabetes; Acute kidney injury; Diabetes mellitus; Renal injury; Intensive care medicine; Internal medicine; Kidney; Endocrinology","score_opus":0.010425496158522769,"score_gpt":0.25761606879446797,"score_spread":0.2471905726359452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126782463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95821434,0.0027703212,0.0000016097209,0.00043739792,0.0151587995,0.0023716101,0.00044381674,0.00008428596,0.020517807],"genre_scores_gemma":[0.73002195,0.001721458,0.0007502786,0.0034387866,0.0003282204,0.0010961915,0.009285047,0.00034123645,0.25301686],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962978,0.00012617717,0.001149315,0.0010962873,0.000291965,0.0010384697],"domain_scores_gemma":[0.99750626,0.000026140764,0.000548406,0.001207817,0.0002683792,0.00044297185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000114600865,0.0006125538,0.0015964546,0.000893006,0.000037140846,0.00001490676,0.00007246916,0.0003990655,0.00033715589],"category_scores_gemma":[0.00029094567,0.00054687314,0.000117577074,0.001017574,0.00012271178,0.0000535977,0.0003128554,0.0008474673,0.0000075170037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104924155,0.00035419894,0.004770389,0.00024882107,0.00051502435,0.53848696,0.00016407829,0.0000029698224,0.000046681584,0.0000058853425,0.45144188,0.0038581835],"study_design_scores_gemma":[0.001599851,0.0027917337,0.0002676982,0.0012542949,0.0011760502,0.34340224,0.00049711164,0.000021727106,0.0010681087,0.000010589787,0.6472562,0.0006543995],"about_ca_topic_score_codex":0.0042872895,"about_ca_topic_score_gemma":0.004095877,"teacher_disagreement_score":0.23249905,"about_ca_system_score_codex":0.0007689305,"about_ca_system_score_gemma":0.0010917976,"threshold_uncertainty_score":0.9996983},"labels":[],"label_agreement":null},{"id":"W3127160886","doi":"","title":"Pioglitazone for Type 2 Diabetes Mellitus and Pre-Diabetes: A Review of Safety [Internet]","year":2020,"lang":"en","type":"review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes; Pioglitazone; Insulin resistance; Glycated hemoglobin; Type 2 Diabetes Mellitus; Glycemic; Insulin","score_opus":0.044214818010975085,"score_gpt":0.3361450641731885,"score_spread":0.2919302461622134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127160886","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026747764,0.98736197,0.000019545832,0.00033184304,0.00016772708,0.0056385086,0.00008155923,0.00008339996,0.0063127587],"genre_scores_gemma":[0.0000011106367,0.9887213,0.0025213675,0.0009530441,0.00012716939,0.000454654,0.00079489563,0.0000772279,0.0063492157],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773985,0.00006316833,0.0010001526,0.0005792957,0.00023308396,0.00038445703],"domain_scores_gemma":[0.99848735,0.00027749687,0.00039414165,0.0004909607,0.0001339719,0.00021606873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035996642,0.0005423551,0.0038660422,0.00013554009,0.000019557598,0.000015795253,0.00017077099,0.00016325696,0.00032788026],"category_scores_gemma":[0.00024421187,0.0003618304,0.00072723464,0.00033681127,0.00007245654,0.000050881546,0.00018208193,0.00014660649,0.00005786307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001005479,0.00007431161,0.000008685666,0.39387766,0.0013606636,0.000001857233,0.000009194317,1.3363355e-9,2.1219068e-7,0.00041839576,0.013712057,0.59052694],"study_design_scores_gemma":[0.00049443846,0.00089203403,0.0000035557364,0.19018622,0.010035968,6.812433e-7,0.0000030741696,0.000009475767,0.0000060862253,0.00001819849,0.7981227,0.0002275473],"about_ca_topic_score_codex":0.0000025107556,"about_ca_topic_score_gemma":9.21807e-7,"teacher_disagreement_score":0.78441066,"about_ca_system_score_codex":0.00009708224,"about_ca_system_score_gemma":0.00012585244,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W3127371223","doi":"10.1056/nejmoa2032183","title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4502,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Steno Diabetes Center Aarhus; Novo Nordisk Fonden; Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Obesity; Overweight; Medicine; Weight loss; Intervention (counseling); Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Psychiatry","score_opus":0.012183625469993978,"score_gpt":0.2496546729605695,"score_spread":0.23747104749057552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127371223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96957284,0.0023394783,0.00016745256,0.017601617,0.0003063475,0.00017802176,9.526942e-7,0.000012079237,0.009821188],"genre_scores_gemma":[0.98149186,0.0011014328,0.0026199003,0.0014914623,0.0020012483,0.0000015665364,0.000011578804,0.000017817736,0.011263152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986526,0.000054001368,0.00041370018,0.00014931492,0.0005106749,0.00021973414],"domain_scores_gemma":[0.9990355,0.00012940996,0.00018808129,0.0001802931,0.00017966036,0.00028706336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037761292,0.0001544492,0.000572759,0.00018257531,0.000021639427,0.000006742333,0.000070492235,0.00004097513,0.0007182449],"category_scores_gemma":[0.0002221943,0.000079114645,0.000051550833,0.00032897005,0.000053454252,0.00007440302,0.000023032348,0.00025567538,0.0000066762523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015001705,0.0017741018,0.43569326,0.0006141577,0.0010236165,0.046864066,0.004273663,0.000045004876,0.0008975891,0.0006072829,0.06289327,0.43031228],"study_design_scores_gemma":[0.33075097,0.015159392,0.34709427,0.011955111,0.0013598133,0.00420523,0.0021544476,0.00007546522,0.0021393616,0.0006022327,0.28419235,0.0003113248],"about_ca_topic_score_codex":0.00008132705,"about_ca_topic_score_gemma":0.0005039642,"teacher_disagreement_score":0.43000093,"about_ca_system_score_codex":0.00010017542,"about_ca_system_score_gemma":0.0003180518,"threshold_uncertainty_score":0.7864278},"labels":[],"label_agreement":null},{"id":"W3127398127","doi":"10.1016/j.jacbts.2020.10.005","title":"DAPA-CKD","year":2021,"lang":"en","type":"article","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto General Hospital; University of Toronto","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Janssen Pharmaceuticals; AstraZeneca; Bayer; Diabetes Canada; Boehringer Ingelheim","keywords":"Medicine","score_opus":0.0204931639784963,"score_gpt":0.28761122551821977,"score_spread":0.26711806153972345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127398127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72708446,0.0001960384,0.003461324,0.03841295,0.0003548413,0.00043617788,0.000010746726,0.000091290945,0.22995219],"genre_scores_gemma":[0.98127794,0.0000043133277,0.011276294,0.002208438,0.00007198767,0.000014090953,0.000015544978,0.000004667248,0.0051267445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989404,0.000005687424,0.00009851565,0.00027395374,0.0004829317,0.0001985281],"domain_scores_gemma":[0.9995327,0.000024986892,0.000011344691,0.00016463951,0.00010529492,0.00016103467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016861018,0.00006448529,0.00008804585,0.00009079025,0.00010301335,0.000037542322,0.00008222476,0.000014060835,0.0007267394],"category_scores_gemma":[0.00003465437,0.00005548446,0.000043193733,0.00076991157,0.00007814088,0.00016019121,0.00002181479,0.00003586846,0.00023904981],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011141408,0.0010921232,0.10330394,0.00008632553,0.00012951778,0.00023982087,0.0015310124,0.00047601594,0.16278313,0.18111992,0.008947091,0.54017967],"study_design_scores_gemma":[0.0010240446,0.00011031408,0.8302717,0.000050142826,0.00006940699,0.000012353726,0.000061067985,0.0004329878,0.02086473,0.00169788,0.14525804,0.00014729261],"about_ca_topic_score_codex":0.0000048574825,"about_ca_topic_score_gemma":0.000011293056,"teacher_disagreement_score":0.7269678,"about_ca_system_score_codex":0.000038916252,"about_ca_system_score_gemma":0.00023872536,"threshold_uncertainty_score":0.7957287},"labels":[],"label_agreement":null},{"id":"W3127426737","doi":"10.1007/s00125-021-05393-8","title":"Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study","year":2021,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute on Aging; European Association for the Study of Diabetes; National Institute for Health and Care Research; British Heart Foundation; Boehringer Ingelheim; McGill University; University of Oxford","keywords":"Linagliptin; Medicine; Type 2 diabetes; Internal medicine; Glimepiride; Physical therapy; Diabetes mellitus; Albuminuria; Cognitive decline; Dementia; Blood pressure; Endocrinology","score_opus":0.018277991025904078,"score_gpt":0.27305256563126523,"score_spread":0.2547745746053611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127426737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961055,0.00034571893,4.8127856e-7,0.00012945858,0.0002954692,0.0052112434,0.000012958148,0.000027495087,0.004366612],"genre_scores_gemma":[0.99872035,0.00012200491,0.000018789266,0.00017294075,0.00003833844,0.00050497043,0.00008892882,0.000019967885,0.0003137294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979829,0.00032773096,0.00061382697,0.0003917464,0.000348586,0.0003351973],"domain_scores_gemma":[0.9976771,0.0011769253,0.00037475873,0.00034752252,0.00036909318,0.000054639062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052373926,0.00025705696,0.001125369,0.00020191813,0.00004873765,0.000008549078,0.00012313113,0.00011363874,0.000013945261],"category_scores_gemma":[0.0011850818,0.0001704201,0.00021477432,0.0006613261,0.000109629545,0.00006955028,0.000095260584,0.00023855112,0.000013464185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63291675,0.013022791,0.31978473,0.0019418263,0.0035634753,0.00015580993,0.0021449057,0.000066753884,0.012600311,0.000043057342,0.00010818121,0.013651441],"study_design_scores_gemma":[0.35157353,0.0025812914,0.30787653,0.0008465361,0.0012514367,2.367838e-7,0.00028462624,0.00007401274,0.335375,0.000013782926,0.000010903198,0.00011212187],"about_ca_topic_score_codex":0.000007929953,"about_ca_topic_score_gemma":0.000016995355,"teacher_disagreement_score":0.3227747,"about_ca_system_score_codex":0.00006350343,"about_ca_system_score_gemma":0.0001040471,"threshold_uncertainty_score":0.69495296},"labels":[],"label_agreement":null},{"id":"W3127779833","doi":"10.2217/fca-2021-0004","title":"Cardiovascular Outcome Trials in Type 2 Diabetes: Food for Thought","year":2021,"lang":"en","type":"editorial","venue":"Future Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Heart failure; Internal medicine; Library science; Family medicine; Endocrinology","score_opus":0.03336132517115692,"score_gpt":0.3113234489566965,"score_spread":0.2779621237855396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127779833","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006185405,0.090384096,0.00007969849,0.0004672504,0.9036115,0.0024092004,0.0004116131,0.00008970648,0.0019284374],"genre_scores_gemma":[0.00057859306,0.0048534605,0.0007362332,0.00023868152,0.98211735,0.0008936167,0.007781279,0.00012603813,0.0026747275],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959126,0.0007953474,0.0010610294,0.0009799594,0.0005162931,0.0007347833],"domain_scores_gemma":[0.996276,0.0017278122,0.00025752388,0.0011788646,0.00042686955,0.00013290512],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035040171,0.00059721235,0.006345559,0.0003381742,0.000047090158,0.00003217989,0.00022765124,0.0018809814,0.00003806979],"category_scores_gemma":[0.0052963565,0.00047145743,0.0032677616,0.00032532684,0.000054507076,0.00003724756,0.00014608643,0.00072191074,0.000029041916],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018897669,0.000050145125,0.0014835281,0.0009437186,0.013255322,0.00019455476,0.000022775619,0.000020227306,0.0000059149515,0.00011071288,0.97716445,0.006559653],"study_design_scores_gemma":[0.0053078695,0.0011144417,0.00040849196,0.00018595353,0.0066413083,0.0000019437166,0.00007633382,0.0000012569008,0.000021298161,0.00006021213,0.98580295,0.00037796368],"about_ca_topic_score_codex":0.0000031793313,"about_ca_topic_score_gemma":0.000013282289,"teacher_disagreement_score":0.08553064,"about_ca_system_score_codex":0.0003230343,"about_ca_system_score_gemma":0.00033984898,"threshold_uncertainty_score":0.99977374},"labels":[],"label_agreement":null},{"id":"W3127860572","doi":"10.1016/j.ijcha.2021.100725","title":"Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes","year":2021,"lang":"en","type":"review","venue":"IJC Heart & Vasculature","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary","funders":"Fonds de Recherche du Québec - Santé; Canadian Society of Endocrinology and Metabolism; Hypertension Canada","keywords":"Medicine; Meta-analysis; Blood pressure; Intensive care medicine; Internal medicine","score_opus":0.03779094101248879,"score_gpt":0.31116541973437273,"score_spread":0.2733744787218839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127860572","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.926208e-7,0.9925812,0.0000015958265,0.00044897542,0.00006517986,0.0065935086,0.00007497714,0.00008848305,0.000145508],"genre_scores_gemma":[0.000006782901,0.9923885,0.00031829198,0.0010019706,0.00007829514,0.0011081954,0.0003899331,0.000089455716,0.0046186103],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99548894,0.00078941655,0.0011661004,0.0012220129,0.0008999265,0.00043360225],"domain_scores_gemma":[0.99665684,0.00017252655,0.00028923745,0.0024004453,0.00016163956,0.0003193074],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0012937598,0.0010347377,0.023340266,0.0003444986,0.00010096159,0.00014974372,0.00014082035,0.00051803555,0.00018343104],"category_scores_gemma":[0.00022512588,0.0005936136,0.015066929,0.00092849834,0.00006253247,0.000101719976,0.00026409572,0.0005792774,0.000019485655],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[1.4124834e-7,0.00005586798,0.000006604039,0.4819789,0.51598555,0.00007469251,0.000009031247,2.16354e-7,6.90275e-9,0.000018494566,0.0013509494,0.00051953667],"study_design_scores_gemma":[0.00018663565,0.000021864002,0.000009526852,0.04164557,0.53784084,0.000092524104,0.0000043676805,1.6949178e-7,7.712089e-8,0.0000010926342,0.41994753,0.00024977123],"about_ca_topic_score_codex":0.00001820011,"about_ca_topic_score_gemma":0.000004026663,"teacher_disagreement_score":0.4403333,"about_ca_system_score_codex":0.000017809192,"about_ca_system_score_gemma":0.000084593004,"threshold_uncertainty_score":0.99965155},"labels":[],"label_agreement":null},{"id":"W3127915609","doi":"10.1111/dom.14339","title":"The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: Results from the <scp>ADVANCE</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council","keywords":"Medicine; Diabetes mellitus; Hazard ratio; Internal medicine; Confidence interval; Randomized controlled trial; Proportional hazards model; Relative risk; Clinical trial; Type 2 diabetes; Endocrinology","score_opus":0.012246029300390374,"score_gpt":0.24313643000418003,"score_spread":0.23089040070378966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127915609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865155,0.010667564,0.0000017113125,0.00016842312,0.00089813146,0.0013946304,0.00010183654,0.000027378588,0.00022477226],"genre_scores_gemma":[0.99615383,0.0017390072,0.0001460662,0.00089818804,0.00020530782,0.000108867105,0.00019932337,0.00002004496,0.00052939326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803275,0.00024246374,0.00046711325,0.00043367187,0.00034513662,0.00047887614],"domain_scores_gemma":[0.9954965,0.003359753,0.00023771152,0.0004865449,0.00030482965,0.00011466263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037980673,0.00028029748,0.0008365668,0.00006604554,0.00015204381,0.000072772586,0.00017408379,0.000090655005,0.0000037955206],"category_scores_gemma":[0.0032316,0.0001653173,0.00015271989,0.0003758729,0.00022242281,0.00016730627,0.00024327163,0.00023900879,0.00000765497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009782263,0.009414349,0.71024436,0.0010780493,0.009066386,0.00035505148,0.05287589,0.000046163506,0.026757954,0.0010347969,0.020947544,0.15839723],"study_design_scores_gemma":[0.044571765,0.00039922367,0.85404783,0.00044296865,0.0006934561,6.884724e-8,0.0010908376,0.000039282455,0.08367215,0.0004021221,0.014539872,0.00010041076],"about_ca_topic_score_codex":0.000047137524,"about_ca_topic_score_gemma":0.00016636506,"teacher_disagreement_score":0.15829681,"about_ca_system_score_codex":0.000033491448,"about_ca_system_score_gemma":0.00005238542,"threshold_uncertainty_score":0.6741444},"labels":[],"label_agreement":null},{"id":"W3128006140","doi":"10.1016/j.jchf.2020.11.009","title":"Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists","year":2021,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"Janssen Pharmaceuticals; Servier; Vifor Pharma; Region Hovedstaden; Novo Nordisk; Eisai; British Heart Foundation; Novartis; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Boehringer Ingelheim; Amgen; Sanofi; Deutsche Forschungsgemeinschaft; Merck; Abbott Laboratories; Hjerteforeningen; Medtronic","keywords":"Medicine; Dapagliflozin; Mineralocorticoid receptor; Internal medicine; Mineralocorticoid; Heart failure; Aldosterone; Endocrinology; Pharmacology; Cardiology; Diabetes mellitus","score_opus":0.007203022588247876,"score_gpt":0.22729242866286026,"score_spread":0.2200894060746124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128006140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989819,0.00008719358,0.0000027048313,0.0073770797,0.00006960467,0.00056168385,0.000012399525,0.00007375648,0.0019965814],"genre_scores_gemma":[0.97986525,0.000019815721,0.0052644345,0.0013260213,0.00009208161,0.00009497613,0.0006665613,0.00003917118,0.0126316985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987286,0.00004522794,0.00023740676,0.00036835665,0.0002622194,0.00035820756],"domain_scores_gemma":[0.9993144,0.000021047936,0.0000404315,0.0003518158,0.000118151875,0.00015410884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055493336,0.0001998002,0.00036126008,0.00011543673,0.00004078913,0.000048482998,0.000042209762,0.00007893137,0.00042342197],"category_scores_gemma":[0.000035815123,0.00015187368,0.000068138965,0.00044493287,0.000032433883,0.00014846174,0.000041006242,0.00013096281,0.00017388206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001309352,0.0010178554,0.92123926,0.00007298714,0.00011527853,0.00017877205,0.00007771262,0.0000020390296,0.004556076,0.00005862014,0.0705839,0.0019665894],"study_design_scores_gemma":[0.006760372,0.0007409148,0.5207631,0.00024570202,0.00013868892,0.000009817068,0.00012794876,0.000019161542,0.011572136,0.0000055753458,0.45938173,0.00023489547],"about_ca_topic_score_codex":0.00007806752,"about_ca_topic_score_gemma":0.00031531104,"teacher_disagreement_score":0.40047616,"about_ca_system_score_codex":0.00012507834,"about_ca_system_score_gemma":0.00008053583,"threshold_uncertainty_score":0.6193229},"labels":[],"label_agreement":null},{"id":"W3128163814","doi":"10.2217/cer-2020-0137","title":"Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; End stage renal disease; Renal function; Type 2 diabetes; Clinical endpoint; Internal medicine; Intensive care medicine; Clinical trial; Creatinine; Diabetes mellitus; Urology; Disease; Endocrinology","score_opus":0.20559037985098247,"score_gpt":0.4711150407476389,"score_spread":0.2655246608966564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128163814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898834,0.008480419,0.000049700782,0.00013666952,0.0001422476,0.00062051794,0.0000029996386,0.0000022710235,0.0006817716],"genre_scores_gemma":[0.9992546,0.00037235298,0.0002417077,0.000008711926,0.000049434446,0.00002491596,0.00000495395,0.000009755301,0.000033599055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99127984,0.0063220477,0.0008146401,0.0002055554,0.001055311,0.00032259207],"domain_scores_gemma":[0.9946212,0.003770258,0.00020466991,0.0002759486,0.001026585,0.00010132759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016066622,0.00014694652,0.0023107722,0.0008194181,0.00002586409,0.000022038404,0.00012759457,0.000063040745,0.00005998424],"category_scores_gemma":[0.002133158,0.00010515175,0.0005658225,0.0009963177,0.00012314031,0.00013603696,0.00010565689,0.0004411383,0.0000072160997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001979525,0.0018687523,0.95747703,0.0004999768,0.0052219103,0.0007956814,0.0003948973,0.0013286866,0.02296924,0.0002224983,0.00010007486,0.007141736],"study_design_scores_gemma":[0.0054248455,0.0010389801,0.7642286,0.0007670454,0.00015616356,0.000005163805,0.00015060682,0.000052442778,0.22706933,0.00039537865,0.00064519583,0.00006628127],"about_ca_topic_score_codex":0.000023922461,"about_ca_topic_score_gemma":0.000032459924,"teacher_disagreement_score":0.20410009,"about_ca_system_score_codex":0.0003203854,"about_ca_system_score_gemma":0.00031748708,"threshold_uncertainty_score":0.55684024},"labels":[],"label_agreement":null},{"id":"W3128371024","doi":"10.1681/asn.20203110s1349c","title":"Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Semaglutide; Post-hoc analysis; Post hoc; Pooled analysis; Medicine; Psychology; Internal medicine; Meta-analysis; Endocrinology; Type 2 diabetes; Liraglutide; Diabetes mellitus","score_opus":0.015547255433366344,"score_gpt":0.283302593747254,"score_spread":0.26775533831388765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128371024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91835207,0.0005428548,0.00018456037,0.08055721,0.000030682757,0.00029902067,0.00001437014,0.0000044775966,0.000014759785],"genre_scores_gemma":[0.95469505,0.0003100916,0.0009964468,0.043824352,0.000104213796,0.0000027167648,0.0000028795428,0.000008601145,0.000055678058],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99846154,0.00040827983,0.0005515227,0.00012468733,0.00029780078,0.00015616752],"domain_scores_gemma":[0.9961566,0.0019986453,0.0014190928,0.00021733838,0.00012359096,0.00008475702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006261563,0.00014007928,0.0015595962,0.000070978094,0.000039608432,0.0000063155135,0.0001984172,0.000038165585,0.000022913571],"category_scores_gemma":[0.00041079536,0.0000659239,0.0015378295,0.0007206281,0.00038292876,0.000021247037,0.00009647064,0.00018363002,7.452775e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009630607,0.0015721368,0.33293903,0.00032415148,0.3582764,0.00007149408,0.015104945,0.0008162477,0.1509984,0.0002209615,0.10981886,0.020226773],"study_design_scores_gemma":[0.0036582502,0.003352419,0.94326746,0.000024492048,0.042839885,0.0000016680265,0.00272747,0.00028652285,0.00071166625,0.0000809499,0.0029828183,0.00006640119],"about_ca_topic_score_codex":0.00015775903,"about_ca_topic_score_gemma":0.000006815666,"teacher_disagreement_score":0.61032844,"about_ca_system_score_codex":0.000038035712,"about_ca_system_score_gemma":0.000049817976,"threshold_uncertainty_score":0.26882985},"labels":[],"label_agreement":null},{"id":"W3128709333","doi":"10.1161/circep.120.009115","title":"Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas","year":2021,"lang":"en","type":"article","venue":"Circulation Arrhythmia and Electrophysiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"U.S. National Library of Medicine; National Heart, Lung, and Blood Institute","keywords":"Atrial fibrillation; Metformin; Cardiology; Internal medicine; Medicine; Insulin","score_opus":0.007421982471687144,"score_gpt":0.21529050618492462,"score_spread":0.20786852371323747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128709333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973579,0.0014258216,0.0004278441,0.00023239483,0.000030582123,0.00034073016,0.000007355631,0.000028274615,0.00014906503],"genre_scores_gemma":[0.99868,0.00037315683,0.00036386505,0.000058047117,0.00016147565,0.0000050487624,0.00021101795,0.000016065133,0.00013135085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990578,0.000075772914,0.00018404679,0.00031304685,0.00015349932,0.00021580215],"domain_scores_gemma":[0.9992935,0.00007149562,0.00020405785,0.00017276774,0.00018358971,0.000074601725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006731284,0.0001633185,0.00045190798,0.00009234752,0.00008129212,0.000013156707,0.00001258449,0.00008444581,0.00004403839],"category_scores_gemma":[0.000053652937,0.000120899014,0.0000735273,0.0002947456,0.00008906736,0.00007324112,0.000017198881,0.000084454216,0.0000020962714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016676083,0.00042353294,0.7551926,0.00076167437,0.019237999,0.004485314,0.0017555566,0.014606072,0.07539212,0.006009113,0.0005241947,0.10493575],"study_design_scores_gemma":[0.015638597,0.003769032,0.9465886,0.00026291324,0.0034367898,0.0009254928,0.00010596082,0.018546162,0.005471804,0.0013167938,0.003418369,0.00051952654],"about_ca_topic_score_codex":0.000013426701,"about_ca_topic_score_gemma":0.000009292256,"teacher_disagreement_score":0.19139597,"about_ca_system_score_codex":0.000050566774,"about_ca_system_score_gemma":0.00007596503,"threshold_uncertainty_score":0.49301186},"labels":[],"label_agreement":null},{"id":"W3129003080","doi":"10.1038/s41371-021-00482-y","title":"The “discordant doppelganger dilemma”: SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?","year":2021,"lang":"en","type":"article","venue":"Journal of Human Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"","keywords":"Medicine; Dilemma; Carbohydrate; Internal medicine","score_opus":0.037564993288985556,"score_gpt":0.27668281608972756,"score_spread":0.239117822800742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129003080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910156,0.0035580643,0.000013913464,0.0037411202,0.0008799783,0.00018737988,0.0000017019612,0.000018558834,0.00058367755],"genre_scores_gemma":[0.9949809,0.002311506,0.000060569193,0.0012395133,0.0005422718,0.0000043252826,0.000012091419,0.000029502022,0.0008193535],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986527,0.00006310875,0.00042874325,0.00016243075,0.0004414343,0.00025156964],"domain_scores_gemma":[0.9988485,0.00012729176,0.0002860796,0.00029407235,0.0003259693,0.000118092816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022157513,0.00017080712,0.0003210041,0.0001175781,0.0003562184,0.000089466426,0.00010185484,0.00004182714,0.000067843146],"category_scores_gemma":[0.000060322185,0.000099064615,0.000244882,0.00019872074,0.00004408202,0.00017080033,0.000060888015,0.0002618372,0.000010913661],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008261999,0.003948475,0.044204947,0.00032594352,0.0058815135,0.005513179,0.0005385244,0.00015853584,0.81232315,0.0033768967,0.0994261,0.023476552],"study_design_scores_gemma":[0.015724607,0.0063239615,0.38504893,0.001198046,0.00635376,0.0012837709,0.00076327036,0.00094889157,0.044563856,0.0017006829,0.53539705,0.00069318054],"about_ca_topic_score_codex":0.000014647408,"about_ca_topic_score_gemma":0.00005708411,"teacher_disagreement_score":0.76775926,"about_ca_system_score_codex":0.00012337267,"about_ca_system_score_gemma":0.00005837497,"threshold_uncertainty_score":0.40397376},"labels":[],"label_agreement":null},{"id":"W3129151551","doi":"10.1038/s41598-021-82276-3","title":"Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Center for Translational Molecular Medicine; Diabetes Fonds; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Nierstichting","keywords":"Medicine; Disease; Kidney disease; Comorbidity; Type 2 diabetes; Single-nucleotide polymorphism; Diabetes mellitus; Genome-wide association study; Bioinformatics; Internal medicine; Genotype; Genetics; Biology; Endocrinology; Gene","score_opus":0.00738333394532102,"score_gpt":0.24188053317656458,"score_spread":0.23449719923124357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129151551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965986,0.0005748571,0.0000010231323,0.000024372952,0.0015258526,0.000628243,0.0000030549925,0.0000178271,0.00062614045],"genre_scores_gemma":[0.9979274,0.000010583902,0.00004368631,0.000030508745,0.000017473767,0.000022579381,0.00026507425,0.000013470017,0.0016692005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983764,0.00007595348,0.0002741424,0.00051310647,0.00051562587,0.0002447383],"domain_scores_gemma":[0.9987202,0.00003219772,0.0001373428,0.0007993025,0.00015740498,0.00015350818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037415448,0.00014522948,0.00033582028,0.00016267312,0.0000480699,0.000044343506,0.000045901463,0.000024109631,0.00016881926],"category_scores_gemma":[0.0001653451,0.00010103349,0.00006581033,0.0005408306,0.000100306504,0.00005870391,0.0000578163,0.000054027485,0.000020324582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012340663,0.00078817725,0.98871994,0.00019115947,0.000101032245,0.0011482657,0.000016730884,0.000013483114,0.00025298496,0.000009353509,0.0003452771,0.008290201],"study_design_scores_gemma":[0.0012169352,0.0004908317,0.985214,0.0002238763,0.00035741768,0.0000012041097,8.292155e-7,0.000010975978,0.011921341,0.00003999797,0.0004336313,0.00008896986],"about_ca_topic_score_codex":0.0000029391374,"about_ca_topic_score_gemma":0.0000065446084,"teacher_disagreement_score":0.011668356,"about_ca_system_score_codex":0.00002515695,"about_ca_system_score_gemma":0.000118500524,"threshold_uncertainty_score":0.41200262},"labels":[],"label_agreement":null},{"id":"W3129664562","doi":"10.1016/j.kint.2020.12.006","title":"Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies","year":2021,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Steno Diabetes Center Copenhagen","keywords":"Clinical trial; Medicine; Randomized controlled trial; Nephrology; Intensive care medicine; MEDLINE; Internal medicine; Family medicine; Political science; Law","score_opus":0.11818879024656126,"score_gpt":0.40654198260676966,"score_spread":0.2883531923602084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129664562","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02450984,0.0018498935,0.00010345082,0.9627759,0.0053524324,0.0011496302,0.0016217236,0.000049738122,0.002587419],"genre_scores_gemma":[0.014495948,0.013111715,0.0028603345,0.8961878,0.0088840425,0.00040220493,0.03589959,0.0001491645,0.028009217],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99564177,0.00027284035,0.0022751936,0.0005602752,0.0009834566,0.00026643818],"domain_scores_gemma":[0.9978189,0.0003862592,0.000890313,0.00031715972,0.0004763463,0.000111033936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019746392,0.0003473611,0.0015947322,0.00024603787,0.000022104023,0.000034812347,0.0001673182,0.0003561322,0.00061545736],"category_scores_gemma":[0.0026091407,0.00027970655,0.00053186255,0.00011848671,0.00012241125,0.00012060855,0.000065217,0.000797139,0.000008393773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018975434,0.00039078004,0.050587937,0.00021334566,0.003795525,0.00045273858,0.00011704039,4.9080955e-7,0.0002497195,0.000026169166,0.9401431,0.0038333905],"study_design_scores_gemma":[0.00555409,0.00022338431,0.0030273376,0.0010844979,0.0008116744,0.0000025193917,0.000119288336,0.000011518437,0.0019134841,0.000111820875,0.98689383,0.0002465363],"about_ca_topic_score_codex":0.000009228643,"about_ca_topic_score_gemma":0.00002411433,"teacher_disagreement_score":0.06658809,"about_ca_system_score_codex":0.0004142047,"about_ca_system_score_gemma":0.00038163963,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W3129813952","doi":"10.1007/s00125-021-05399-2","title":"The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus","year":2021,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Esperion Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; Servier; Novo Nordisk; Duke Clinical Research Institute; Eisai; Belvoir Media Group; Medicines Company; Regado Biosciences; AstraZeneca; Amarin Corporation; Daiichi-Sankyo; Zora Biosciences; American Heart Association; Intarcia Therapeutics; MSD K.K.; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Ono Pharmaceutical; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; GlaxoSmithKline; Amgen; Pfizer; Bayer HealthCare; Sanofi","keywords":"Dapagliflozin; Medicine; Internal medicine; Mace; Type 2 diabetes; Myocardial infarction; Diabetes mellitus; Heart failure; Type 2 Diabetes Mellitus; Stroke (engine); Hazard ratio; Cardiology; Endocrinology; Percutaneous coronary intervention","score_opus":0.007995582588430441,"score_gpt":0.22800712435917878,"score_spread":0.22001154177074833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129813952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98585194,0.007983337,7.254682e-7,0.00065197307,0.000028115206,0.00026921384,0.000002162254,0.000016854048,0.005195653],"genre_scores_gemma":[0.9966462,0.002360315,0.00019252104,0.00015606731,0.00001052351,0.00002683717,0.0000121009725,0.000009421769,0.00058601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922514,0.000045511333,0.00016014428,0.00019806552,0.000101369646,0.00026974478],"domain_scores_gemma":[0.99937624,0.00025299395,0.000045119752,0.00021323087,0.000045915105,0.00006651355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000211657,0.000109746274,0.0003048248,0.000042507236,0.000043648484,0.00001744784,0.000041605148,0.000040995157,0.000019898807],"category_scores_gemma":[0.00010340227,0.0000645786,0.0000121877,0.00021203577,0.00016219099,0.00003364149,0.000081359474,0.00007241423,0.0000025452543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005227621,0.00030716305,0.8613722,0.00019474639,0.00057682424,0.000063376,0.00084576476,0.000002969932,0.0015135942,0.002021304,0.0006665827,0.13191275],"study_design_scores_gemma":[0.0038676737,0.00075384666,0.9806059,0.0001244573,0.00011475821,0.0000015649094,0.0006288338,0.00006273713,0.0039557633,0.00038859382,0.009378834,0.00011701753],"about_ca_topic_score_codex":0.000003425721,"about_ca_topic_score_gemma":0.000009181763,"teacher_disagreement_score":0.13179573,"about_ca_system_score_codex":0.000032590593,"about_ca_system_score_gemma":0.000032165583,"threshold_uncertainty_score":0.26334387},"labels":[],"label_agreement":null},{"id":"W3129971886","doi":"10.1002/cpt.2213","title":"Defining Clinically Relevant Target Populations Using Real‐World Data to Guide the Design of Representative Antidiabetic Drug Trials","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Liraglutide; Medicine; Clinical trial; Type 2 diabetes; Population; Representativeness heuristic; Diabetes mellitus; Disease; Internal medicine; Endocrinology; Environmental health; Psychology","score_opus":0.5210139882154484,"score_gpt":0.5680565267547004,"score_spread":0.047042538539252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129971886","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.858203,0.004569797,0.027461907,0.092655234,0.0073761516,0.0068428745,0.00034213482,0.00027099793,0.002277936],"genre_scores_gemma":[0.36362657,0.007520154,0.5039658,0.11696974,0.0014391178,0.00011357024,0.0005288117,0.00015240154,0.0056838198],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99290943,0.003232857,0.002424643,0.00071594975,0.0003075245,0.0004096011],"domain_scores_gemma":[0.98773664,0.009592841,0.0008355418,0.0012741709,0.00035613732,0.00020466106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077504846,0.00023097926,0.0013195123,0.00010090564,0.00016296621,0.00003093975,0.0005061489,0.00009131834,0.0002531514],"category_scores_gemma":[0.0013672126,0.00017245793,0.0003073523,0.00062504405,0.00043190044,0.00008030335,0.0006252681,0.00042942818,0.000040868068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035009596,0.006104519,0.56927264,0.00013610086,0.016800933,0.00042960173,0.0011593057,0.0043442473,0.023007968,0.0005795418,0.33825722,0.036406986],"study_design_scores_gemma":[0.040770836,0.0059731794,0.32449058,0.0011063804,0.09909547,0.000033790355,0.0034038026,0.10403746,0.033450197,0.00882471,0.37670228,0.0021113087],"about_ca_topic_score_codex":0.000069239526,"about_ca_topic_score_gemma":0.000047119553,"teacher_disagreement_score":0.4945764,"about_ca_system_score_codex":0.000067535024,"about_ca_system_score_gemma":0.00046843023,"threshold_uncertainty_score":0.70326304},"labels":[],"label_agreement":null},{"id":"W3129981552","doi":"10.1111/dom.14352","title":"Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINE‐HF</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"Novo Nordisk; Eisai; Sanofi; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Dapagliflozin; Ejection fraction; Placebo; Heart failure; Medicine; Randomized controlled trial; Cardiology; Internal medicine; Urology; Endocrinology; Diabetes mellitus","score_opus":0.005336022667569256,"score_gpt":0.20323578025193384,"score_spread":0.1978997575843646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129981552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512905,0.0018790577,0.0000019263014,0.0009953661,0.0004604381,0.0010686248,0.000046084668,0.00005064802,0.00036881366],"genre_scores_gemma":[0.9972336,0.00016836404,0.00029845795,0.0009742018,0.00041545872,0.00007186913,0.000404855,0.000021649286,0.0004115332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983984,0.00018599605,0.0002427337,0.0005100614,0.00034786292,0.0003149137],"domain_scores_gemma":[0.9988111,0.00053443457,0.00009110114,0.00034985683,0.000089774265,0.00012369054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002788696,0.00025202328,0.0005149735,0.0001011542,0.00017128157,0.00009934498,0.00004793678,0.0001276593,0.000008306311],"category_scores_gemma":[0.00045576197,0.000172702,0.00006924973,0.00028254546,0.000059858972,0.00019292816,0.00006815352,0.00025178085,0.0000091141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001736578,0.0013149043,0.9700186,0.00012660008,0.0005947022,0.0000151384,0.00039193803,0.0000037761727,0.0015190211,0.00014883984,0.015682379,0.008447516],"study_design_scores_gemma":[0.04121406,0.00044521334,0.9217166,0.00020981753,0.0006208478,2.0059426e-7,0.000107331274,0.000043986158,0.0074316813,0.00007397348,0.028054837,0.00008147431],"about_ca_topic_score_codex":0.00007958779,"about_ca_topic_score_gemma":0.000043290827,"teacher_disagreement_score":0.048302032,"about_ca_system_score_codex":0.000037110574,"about_ca_system_score_gemma":0.00003542724,"threshold_uncertainty_score":0.7042583},"labels":[],"label_agreement":null},{"id":"W3129988434","doi":"10.1016/j.jcjd.2021.02.003","title":"Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Trillium Health Centre; Canadian Heart Research Centre; University of Toronto; St. Michael's Hospital; University of British Columbia","funders":"Merck Canada; Department of Medicine, University of Toronto; University of Toronto; Heart and Stroke Foundation of Canada","keywords":"Medicine; Glycemic; Diabetes mellitus; Kidney disease; Type 2 Diabetes Mellitus; Internal medicine; Risk factor; Type 2 diabetes; Disease; Endocrinology; Cotransporter; Sodium","score_opus":0.004002380985410612,"score_gpt":0.16927333619392904,"score_spread":0.16527095520851842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129988434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451195,0.05276144,0.0000010372684,0.00030155663,0.00010944659,0.0011403403,0.00053805904,0.000006214698,0.000022420998],"genre_scores_gemma":[0.99849886,0.0006639967,0.00006946002,0.00037297822,0.00008996561,0.000059301336,0.00017796039,0.0000524651,0.0000149989055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747306,0.00025955,0.00050084654,0.0004671086,0.00047047398,0.0008289499],"domain_scores_gemma":[0.9976174,0.00010787843,0.00021135458,0.00043762158,0.00022467782,0.001401069],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022877406,0.00041545578,0.0008758471,0.0002581744,0.000104362494,0.00009588806,0.00014040514,0.00006444617,0.000030087866],"category_scores_gemma":[0.00009618605,0.00026692162,0.00008924148,0.00044229548,0.00020148809,0.00022807452,0.000023328943,0.0003847224,6.8158556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024343023,0.000049974467,0.98597825,0.0003047967,0.0023744975,0.00042098062,0.00036848054,0.00004861851,0.00002338211,0.0000043261466,0.00007302866,0.010110251],"study_design_scores_gemma":[0.01183786,0.00070962054,0.9812657,0.0027985305,0.001070887,7.2233064e-7,0.00036991105,0.00016445287,0.00034115725,0.000038491435,0.0010903532,0.00031230567],"about_ca_topic_score_codex":0.28108782,"about_ca_topic_score_gemma":0.9686948,"teacher_disagreement_score":0.687607,"about_ca_system_score_codex":0.0007707412,"about_ca_system_score_gemma":0.0040390007,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W3130695847","doi":"10.14740/cr1221","title":"A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure","year":2021,"lang":"en","type":"review","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Diabetes mellitus; Glycemic; Drug class; Internal medicine; Cotransporter; Drug; Intensive care medicine; Cardiology; Pharmacology; Endocrinology; Sodium","score_opus":0.148240596412992,"score_gpt":0.4311847106673874,"score_spread":0.28294411425439536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130695847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021956417,0.9928642,0.0000015922652,0.0008221403,0.00012469044,0.0050884555,0.00007074754,0.0000049469936,0.0008036456],"genre_scores_gemma":[0.0013642606,0.99731183,0.00004192774,0.000033544697,0.00008701359,0.0006490107,0.0002025242,0.000022469045,0.0002874111],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641484,0.0016600032,0.00076659734,0.0003403814,0.00048311558,0.00033503713],"domain_scores_gemma":[0.9977873,0.00051695894,0.0002151108,0.0011133314,0.00031978686,0.000047537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013975046,0.0002514821,0.0031835919,0.0002698557,0.000050027324,0.0000033809306,0.00028841707,0.00021220984,0.000041588035],"category_scores_gemma":[0.00017146033,0.000118124575,0.0012494423,0.0010686566,0.00043109624,0.000013082088,0.00006712573,0.00039040885,0.000005952983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007244903,0.00264212,0.0009836952,0.47845662,0.0063685738,0.00027338546,0.00044600703,5.066712e-7,0.00020160706,0.0017777383,0.027592827,0.48118448],"study_design_scores_gemma":[0.0004954431,0.0010351321,0.000067262066,0.06616686,0.0029427437,0.000039093105,0.00015923103,1.3237296e-7,0.0002042887,0.000018186673,0.92880344,0.0000681662],"about_ca_topic_score_codex":0.000036019428,"about_ca_topic_score_gemma":0.000018349905,"teacher_disagreement_score":0.9012106,"about_ca_system_score_codex":0.00020327154,"about_ca_system_score_gemma":0.00073376956,"threshold_uncertainty_score":0.48169804},"labels":[],"label_agreement":null},{"id":"W3131254615","doi":"10.1111/dom.14360","title":"Applying <scp>REWIND</scp> cardiovascular disease criteria to <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6: An exploratory analysis of cardiovascular outcomes with semaglutide","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto; Toronto General Hospital; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Semaglutide; Mace; Hazard ratio; Medicine; Dulaglutide; Placebo; Internal medicine; Subgroup analysis; Type 2 diabetes; Confidence interval; Pooled analysis; Lower risk; Diabetes mellitus; Endocrinology; Exenatide; Myocardial infarction; Liraglutide","score_opus":0.013043416719402885,"score_gpt":0.23010970592467944,"score_spread":0.21706628920527657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131254615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92791665,0.06879306,0.0006861809,0.000048544636,0.00021104109,0.0015872037,0.00016745001,0.00017417606,0.00041569976],"genre_scores_gemma":[0.99120826,0.002629685,0.0023986176,0.0009115841,0.00023384255,0.0007465473,0.000497697,0.00012471713,0.0012490278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99487525,0.0004706615,0.0006551171,0.001486363,0.0013364663,0.001176129],"domain_scores_gemma":[0.995371,0.0004785667,0.00018911128,0.0020051748,0.00056660164,0.0013895541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013826228,0.0008359609,0.0032122293,0.0010271593,0.0003679791,0.00024311687,0.00026276204,0.00020911766,0.000007882232],"category_scores_gemma":[0.0011327505,0.0007258201,0.0015085785,0.0018995109,0.00024900163,0.00055631367,0.00047544343,0.00028853363,0.0000108272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000121790945,0.0015879824,0.8582968,0.001970603,0.1121637,0.0007846805,0.0049716593,0.0028583126,0.0014016606,0.0006506634,0.0012978683,0.014003892],"study_design_scores_gemma":[0.0031987117,0.0001529265,0.75417596,0.00016526002,0.06985142,0.0000030591339,0.005427996,0.0005382115,0.005003575,0.00011161609,0.16120586,0.00016538096],"about_ca_topic_score_codex":0.000103101054,"about_ca_topic_score_gemma":0.000024476187,"teacher_disagreement_score":0.15990798,"about_ca_system_score_codex":0.00007620922,"about_ca_system_score_gemma":0.00016703957,"threshold_uncertainty_score":0.9995193},"labels":[],"label_agreement":null},{"id":"W3131399962","doi":"10.2215/cjn.15260920","title":"Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria","year":2021,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; University of British Columbia","funders":"Janssen Research and Development; Mitsubishi Tanabe Pharma Corporation; NSW Ministry of Health; Astellas Pharma; Eisai; University of New South Wales; George Institute for Global Health; Kidney Foundation of Canada; NxStage; Medical Research Council; Verily Life Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Mundipharma International; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Relypsa; University of Chicago; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Janssen Pharmaceuticals; University of Washington; Ablynx; Daiichi Sankyo Europe; Servier; Gilead Sciences; Innovent Biologics; Pfizer; Victor Chang Cardiac Research Institute; Japan Society for the Promotion of Science; GlaxoSmithKline; Celgene; CSL Behring; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb; Amgen; Kowa Company; American Heart Association","keywords":"Medicine; Albuminuria; Canagliflozin; Baseline (sea); Acute kidney injury; Internal medicine; Urology; Kidney; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.029976847431530007,"score_gpt":0.33521033431992286,"score_spread":0.30523348688839286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131399962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95917916,0.0007870679,0.0005312175,0.038958974,0.0002599893,0.0001574897,0.000010731312,0.0000042572883,0.00011113607],"genre_scores_gemma":[0.896783,0.0026394501,0.021135552,0.07880455,0.00028375446,0.0000019571023,0.0000033642523,0.000020492713,0.00032789962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981027,0.00030830357,0.0009207472,0.00017828174,0.00029528906,0.00019462906],"domain_scores_gemma":[0.9977433,0.0006087273,0.0006873631,0.00042485454,0.0002895309,0.0002462273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014231637,0.00012835897,0.00143838,0.000034526278,0.000034743807,0.0000037522325,0.00018717362,0.000057193047,0.000018996569],"category_scores_gemma":[0.000560578,0.000082873325,0.0016425357,0.0002821112,0.000585627,0.000029809282,0.0002582155,0.00024328711,0.0000010134321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080848916,0.0006725747,0.7674958,0.00013674855,0.015955064,0.000056930832,0.0002557244,0.00006836099,0.0037365842,0.000047832335,0.099478155,0.11128772],"study_design_scores_gemma":[0.0055202725,0.0019736725,0.73091227,0.00020008683,0.004121681,0.000100903075,0.0022199007,0.00007026578,0.00077666267,0.00010522958,0.25385198,0.00014708423],"about_ca_topic_score_codex":0.000092733535,"about_ca_topic_score_gemma":0.000007525899,"teacher_disagreement_score":0.15437384,"about_ca_system_score_codex":0.00004093564,"about_ca_system_score_gemma":0.00024331898,"threshold_uncertainty_score":0.33794764},"labels":[],"label_agreement":null},{"id":"W3131645431","doi":"10.1161/circulationaha.120.053058","title":"Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?","year":2021,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.031072452263078323,"score_gpt":0.2402918851635232,"score_spread":0.20921943290044487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131645431","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5968428,0.00088354974,0.00017816215,0.3978456,0.00080114265,0.0017159474,0.00009616139,0.00025284593,0.0013837606],"genre_scores_gemma":[0.31490424,0.00009967892,0.00078137923,0.6379051,0.010741178,0.00012658411,0.028158065,0.0002180135,0.0070657628],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984609,0.00006840375,0.0002808239,0.0005314262,0.0003715737,0.00028687064],"domain_scores_gemma":[0.9991233,0.000050583112,0.00013995792,0.00049513084,0.000077070734,0.0001139801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008787207,0.00029764458,0.00044626129,0.00022285829,0.00007206622,0.00016091115,0.000054779808,0.00042910353,0.00012327135],"category_scores_gemma":[0.00003723972,0.00029114512,0.00010822782,0.00011510694,0.00004188288,0.00023439528,0.00005657076,0.00040882375,0.000013671663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004643307,0.000045030658,0.29457664,0.00032586063,0.00043593164,0.00024506135,0.00031430865,0.000002755251,0.00007607571,0.000012387112,0.6872639,0.016697396],"study_design_scores_gemma":[0.00086518173,0.00005437268,0.32406846,0.00026610628,0.0011575528,0.0000042176825,0.00002202079,0.00003519828,0.0000493284,0.00015431241,0.6730605,0.0002627732],"about_ca_topic_score_codex":0.00031875094,"about_ca_topic_score_gemma":0.000025536801,"teacher_disagreement_score":0.28193858,"about_ca_system_score_codex":0.00021069543,"about_ca_system_score_gemma":0.000049237253,"threshold_uncertainty_score":0.99995404},"labels":[],"label_agreement":null},{"id":"W3132186621","doi":"10.1002/ejhf.2124","title":"Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <scp>DAPA‐HF</scp> trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Defense Acquisition Program Administration; British Heart Foundation; AstraZeneca","keywords":"Heart failure; Ejection fraction; Medicine; Dapagliflozin; Internal medicine; Cardiology; Endocrinology","score_opus":0.014853880749564686,"score_gpt":0.24612530911277436,"score_spread":0.23127142836320969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132186621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98185074,0.00045435468,0.00012812286,0.0161661,0.00029959087,0.00047469154,0.0000028029683,0.000014174776,0.00060942105],"genre_scores_gemma":[0.9911409,0.00004843031,0.0071491254,0.000713624,0.0007476912,0.0000028771149,0.000015666725,0.000030296991,0.000151387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980682,0.00063259515,0.00055713754,0.0002518102,0.00028995948,0.00020030419],"domain_scores_gemma":[0.9987798,0.00038910154,0.00023427252,0.00026894742,0.00017992167,0.00014800901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053437805,0.0001810162,0.00053236244,0.00017889682,0.00009668127,0.00004511951,0.00008846534,0.00004536219,0.00004697205],"category_scores_gemma":[0.0003597254,0.000116361545,0.00010857154,0.00037616747,0.00006046622,0.0001628246,0.00007556651,0.0004260469,0.000023876792],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03794508,0.0032006712,0.19838041,0.00020861167,0.0036758173,0.002705421,0.006785327,0.0009555086,0.3134891,0.00043981714,0.41743997,0.014774279],"study_design_scores_gemma":[0.04557082,0.004205113,0.25292367,0.00092816405,0.00042884267,0.00025851055,0.005982672,0.000008473885,0.0057508857,0.000026020964,0.68381923,0.00009762144],"about_ca_topic_score_codex":0.000011426523,"about_ca_topic_score_gemma":0.00004401557,"teacher_disagreement_score":0.3077382,"about_ca_system_score_codex":0.00006336724,"about_ca_system_score_gemma":0.00009711368,"threshold_uncertainty_score":0.4745086},"labels":[],"label_agreement":null},{"id":"W3132426811","doi":"10.1007/s40262-020-00956-1","title":"Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia","funders":"Universitair Medisch Centrum Groningen; Novo Nordisk Fonden; AstraZeneca","keywords":"Dapagliflozin; Renal function; Medicine; Kidney disease; Diabetes mellitus; Urology; Pharmacokinetics; Confidence interval; Internal medicine; Type 2 diabetes; Proteinuria; Creatinine; Volume of distribution; Endocrinology; Kidney","score_opus":0.052089754498444794,"score_gpt":0.36596830066246133,"score_spread":0.31387854616401656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132426811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962605,0.0015940483,0.000004919121,0.0009098,0.000157364,0.0008520737,0.000030718755,0.000008835693,0.0001817426],"genre_scores_gemma":[0.9987671,0.00033258484,0.00020607488,0.00041779768,0.000048499875,0.000029167926,0.00003497086,0.000019219116,0.00014462801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977608,0.0006344425,0.00056928344,0.00027815654,0.0005916672,0.00016566734],"domain_scores_gemma":[0.9983806,0.00045189704,0.00021627496,0.00030199898,0.0004216,0.00022762171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013775019,0.00015014347,0.0003330289,0.000071776594,0.000027837676,0.000008672153,0.00006710868,0.000049387767,0.00005313789],"category_scores_gemma":[0.0017722356,0.000105564475,0.000063266794,0.00026758778,0.0003042215,0.000049947277,0.00012467561,0.00018017569,7.9081696e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084952347,0.0008577999,0.98323476,0.00023526969,0.00019987342,0.0000026852551,0.00005708261,0.0001029288,0.00072633656,0.00001960399,0.00033185573,0.013382258],"study_design_scores_gemma":[0.01672092,0.0005944496,0.97016704,0.00034317834,0.0029900104,2.2828652e-7,0.00001245023,0.0052878847,0.0029713959,0.0001163951,0.00069469464,0.00010134334],"about_ca_topic_score_codex":8.356475e-7,"about_ca_topic_score_gemma":0.0000021442577,"teacher_disagreement_score":0.015871398,"about_ca_system_score_codex":0.00005252295,"about_ca_system_score_gemma":0.000340426,"threshold_uncertainty_score":0.43047944},"labels":[],"label_agreement":null},{"id":"W3132617889","doi":"10.1542/peds.2020-1610","title":"Efficacy and Safety of Metformin for Obesity: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"PEDIATRICS","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metformin; Cochrane Library; Placebo; Adverse effect; Internal medicine; Context (archaeology); Obesity; Population; Insulin resistance; Randomized controlled trial; Meta-analysis; Homeostatic model assessment; Insulin; Environmental health; Alternative medicine","score_opus":0.040555570666835045,"score_gpt":0.3376473028565318,"score_spread":0.29709173218969676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132617889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.732506e-7,0.99036556,0.00006986975,0.000021371086,0.000095828465,0.008935321,0.000054594217,0.000021784854,0.0004350808],"genre_scores_gemma":[1.1172271e-7,0.9960611,0.0010543155,0.00007515074,0.00012737462,0.00056413905,0.00043219252,0.000036777896,0.0016488706],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830455,0.00006926459,0.00092806306,0.00028351427,0.00022834285,0.0001862544],"domain_scores_gemma":[0.99810857,0.0006594778,0.0005666296,0.00045709708,0.000112033136,0.000096207674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061109295,0.00029552987,0.004313183,0.00017299117,0.00002589004,0.000010834462,0.0000909809,0.00011927758,0.000017632807],"category_scores_gemma":[0.00088705606,0.00020000106,0.00059967476,0.0004193975,0.00001544298,0.00002491249,0.00009934322,0.000093429364,0.000010742346],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002176924,0.00011438891,0.0000022460647,0.83076847,0.00044305183,0.0000104910305,0.0000053015697,2.8417941e-9,9.734527e-10,0.00023850938,0.0016277403,0.16678765],"study_design_scores_gemma":[0.00045363675,0.00010208712,4.295603e-7,0.42161164,0.07100952,0.000011937916,0.0000030227998,3.7562867e-7,3.7759598e-8,0.0000033411982,0.50669473,0.00010925801],"about_ca_topic_score_codex":8.366457e-7,"about_ca_topic_score_gemma":2.2281269e-7,"teacher_disagreement_score":0.505067,"about_ca_system_score_codex":0.00007651742,"about_ca_system_score_gemma":0.00016454307,"threshold_uncertainty_score":0.8155806},"labels":[],"label_agreement":null},{"id":"W3133124837","doi":"10.1001/jamacardio.2020.7585","title":"Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction","year":2021,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; British Heart Foundation","keywords":"Medicine; Dapagliflozin; Ejection fraction; Heart failure; Hazard ratio; Internal medicine; Placebo; Cardiology; Randomized controlled trial; Randomization; Clinical trial; Diabetes mellitus; Confidence interval; Type 2 diabetes","score_opus":0.006707475344645062,"score_gpt":0.24448916791206715,"score_spread":0.2377816925674221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133124837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738026,0.0000300922,0.00010735726,0.0015211883,0.00004880439,0.00067318993,0.0000087640765,0.00001454558,0.00021580038],"genre_scores_gemma":[0.99652624,0.0000070843275,0.0029150255,0.00016520143,0.00006497348,0.00003551508,0.00011909239,0.000013847664,0.00015300137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990407,0.00009013792,0.00028055912,0.00030349026,0.00015011536,0.00013500314],"domain_scores_gemma":[0.9993159,0.000057006608,0.000102741426,0.00021819542,0.00024738378,0.000058780133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016579067,0.000108590655,0.0005509395,0.00010439989,0.000016644528,0.000005683195,0.000022074257,0.000119326374,0.000027255313],"category_scores_gemma":[0.0000852891,0.000085844586,0.000049583297,0.00026244594,0.00006864861,0.000086633096,0.000026915011,0.00009538275,0.000007572921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064538635,0.00018893831,0.99294895,0.000065635344,0.00019832673,0.000004139914,0.00003351904,0.0002168925,0.0016350856,0.000018920977,0.002428654,0.001615533],"study_design_scores_gemma":[0.003292225,0.0027262033,0.98424065,0.00014478396,0.00017590406,0.0000036348993,0.00013348003,0.000021270615,0.0019664248,0.00000757649,0.0072031463,0.0000846961],"about_ca_topic_score_codex":0.000016352802,"about_ca_topic_score_gemma":0.000023808321,"teacher_disagreement_score":0.008708314,"about_ca_system_score_codex":0.000049580056,"about_ca_system_score_gemma":0.000048297905,"threshold_uncertainty_score":0.35006407},"labels":[],"label_agreement":null},{"id":"W3133567567","doi":"10.1016/j.molmet.2021.101207","title":"Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist","year":2021,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research; Novo Nordisk Foundation Center for Basic Metabolic Research; Carlsbergfondet; Novo Nordisk Fonden; Københavns Universitet","keywords":"Agonist; Hormone; Pharmacology; Chemistry; Endocrinology; Medicine; Internal medicine; Receptor","score_opus":0.010110498290377166,"score_gpt":0.2513204844033388,"score_spread":0.24120998611296166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133567567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910876,0.0010379634,0.00094080094,0.0004312628,0.000063644664,0.00034589547,0.00002746905,0.000057172278,0.0060081817],"genre_scores_gemma":[0.9929841,0.000029368819,0.0053837444,0.0005182731,0.00004342734,0.000037832928,0.0002557074,0.000037037087,0.00071048306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866617,0.00010713287,0.00022618301,0.0003786999,0.00032435602,0.0002974832],"domain_scores_gemma":[0.99893343,0.000015690013,0.00011370127,0.00038939185,0.00035377304,0.00019400648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008089099,0.0002165189,0.00043814376,0.00009542155,0.0000476676,0.000026490154,0.0000881371,0.00003909582,0.00006448119],"category_scores_gemma":[0.00014133986,0.00020165634,0.00014975673,0.0003407156,0.00005338556,0.000121281875,0.00006993522,0.00015586932,0.00001551278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020471888,0.0008843307,0.00039218253,0.0000372719,0.00035420913,0.0003782211,0.00014493687,0.0000034391362,0.9826098,0.0015227143,0.00055607513,0.012912102],"study_design_scores_gemma":[0.002396427,0.00052451744,0.04044154,0.00006221971,0.00080207526,0.00003773251,0.00024639192,0.00004943278,0.95194155,0.00035643333,0.0029494225,0.00019227374],"about_ca_topic_score_codex":0.000079662525,"about_ca_topic_score_gemma":0.00000741341,"teacher_disagreement_score":0.040049355,"about_ca_system_score_codex":0.000042839398,"about_ca_system_score_gemma":0.00015455636,"threshold_uncertainty_score":0.8223307},"labels":[],"label_agreement":null},{"id":"W3133658442","doi":"10.1038/s41598-021-85467-0","title":"Author Correction: Compatibility of endoclips in the gastrointestinal tract with magnetic resonance imaging","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Magnetic resonance imaging; Nuclear magnetic resonance; Medicine; Physics; Radiology","score_opus":0.01744063906638451,"score_gpt":0.2632692610113033,"score_spread":0.2458286219449188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133658442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987822,0.0007349669,0.00006693491,0.000830068,0.0012163769,0.00039197635,7.862459e-7,0.000022450608,0.008914441],"genre_scores_gemma":[0.98995894,7.575408e-7,0.0014945344,0.000040630115,0.000019399125,0.000018929095,0.000027139855,0.0000051284164,0.0084345685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862415,0.00005643518,0.00031179585,0.00040817933,0.00041566565,0.00018377359],"domain_scores_gemma":[0.9989718,0.0000556874,0.00012605576,0.0006539565,0.00015141771,0.000041044892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009415737,0.00008528372,0.00016968351,0.000071533,0.00007119189,0.00006023531,0.000045784585,0.000006930486,0.00014033589],"category_scores_gemma":[0.00016692374,0.000054237473,0.000050307328,0.0005315133,0.00019580804,0.00006559654,0.00002500114,0.00009080725,0.0000033264546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023804414,0.0005397307,0.97087264,0.000038029648,0.000001948072,0.004176319,0.0002747381,0.000010947307,0.0009872735,0.00002389537,0.0073450194,0.015705649],"study_design_scores_gemma":[0.0004218323,0.00017968839,0.97394425,0.00034470716,0.00006720311,0.0036009836,0.0008021451,0.0004628873,0.0031412898,0.00026059456,0.016711058,0.00006336401],"about_ca_topic_score_codex":0.000026706632,"about_ca_topic_score_gemma":0.00009110144,"teacher_disagreement_score":0.015642283,"about_ca_system_score_codex":0.00004016456,"about_ca_system_score_gemma":0.00013912821,"threshold_uncertainty_score":0.221174},"labels":[],"label_agreement":null},{"id":"W3133746780","doi":"10.1016/s0140-6736(21)00213-0","title":"Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1302,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Placebo; Overweight; Type 2 diabetes; Internal medicine; Body mass index; Diabetes mellitus; Randomized controlled trial; Glycated hemoglobin; Physical therapy; Endocrinology; Liraglutide","score_opus":0.03487184394042082,"score_gpt":0.2963627505833139,"score_spread":0.2614909066428931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133746780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98172086,0.0018840049,0.000008457387,0.0032983301,0.00021120443,0.004823789,0.0000110675,0.00007631468,0.007965976],"genre_scores_gemma":[0.9894935,0.000672371,0.00051953323,0.001012759,0.0008645568,0.0007468836,0.00008217701,0.000040762105,0.006567459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998228,0.00012686939,0.00036448627,0.0004219822,0.00033177817,0.0005268863],"domain_scores_gemma":[0.99862695,0.000430324,0.00014505972,0.00058312446,0.000085830536,0.00012873013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006209242,0.00029719988,0.0012623045,0.00009934528,0.00009370006,0.000098834265,0.00016208274,0.00007468906,0.00020683242],"category_scores_gemma":[0.00009203162,0.00015801775,0.00010025398,0.0004017768,0.000095230986,0.000101427584,0.00012669724,0.00022662594,0.00003348245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98753965,0.0013127107,0.003656688,0.0002466573,0.0007060678,0.00034389846,0.00038264427,0.000008822999,0.00008323399,0.00033509734,0.0033899923,0.0019945244],"study_design_scores_gemma":[0.9877294,0.0021827265,0.00033954755,0.00062632374,0.00079625077,0.000011986658,0.00019727887,0.0006027428,0.0007168607,0.000046178735,0.0065367958,0.00021393331],"about_ca_topic_score_codex":0.00005995534,"about_ca_topic_score_gemma":0.00064788124,"teacher_disagreement_score":0.0077726427,"about_ca_system_score_codex":0.00007071379,"about_ca_system_score_gemma":0.00015335943,"threshold_uncertainty_score":0.64437765},"labels":[],"label_agreement":null},{"id":"W3133996690","doi":"10.1016/j.xkme.2021.02.001","title":"Management of Diabetes 100 Years After the Discovery of Insulin: Nuances for the Kidney","year":2021,"lang":"en","type":"editorial","venue":"Kidney Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Diabetes mellitus; Medicine; Diabetic nephropathy; Kidney disease; Population; Disease; Type 1 diabetes; Type 2 diabetes; Nephropathy; Internal medicine; Epidemiology; Endocrinology; Environmental health","score_opus":0.010516445229701854,"score_gpt":0.27124333837129194,"score_spread":0.2607268931415901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133996690","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024577044,0.03879211,0.0001624106,0.032783624,0.9100206,0.0056816274,0.0016205681,0.000071007344,0.008410331],"genre_scores_gemma":[0.030413484,0.026911901,0.00084799936,0.006232586,0.85958856,0.002907981,0.00619184,0.0002641999,0.06664147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694294,0.00006661762,0.00077093334,0.00049216364,0.0013020139,0.0004253484],"domain_scores_gemma":[0.9967202,0.001105319,0.0004933782,0.0011680453,0.00028660067,0.00022643908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008486041,0.0004299902,0.0011539743,0.00015414202,0.000060213802,0.00002220121,0.00049484445,0.00024450882,0.00024987833],"category_scores_gemma":[0.0014254628,0.00021458452,0.00038258982,0.00038227616,0.0005933929,0.00007963396,0.0002744372,0.00033947467,0.000005972906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033992686,0.00024388559,0.0003806697,0.00451604,0.0036525284,0.000031171803,0.00030669934,6.037093e-7,0.00003844564,0.00021955025,0.9829726,0.0072978367],"study_design_scores_gemma":[0.0045010615,0.00080992904,0.0016152165,0.007051196,0.0062452974,2.2027457e-7,0.0005369602,0.000014944191,0.00023995696,0.00014364475,0.9786588,0.00018275682],"about_ca_topic_score_codex":0.00005198077,"about_ca_topic_score_gemma":0.000004188829,"teacher_disagreement_score":0.05823114,"about_ca_system_score_codex":0.00008354377,"about_ca_system_score_gemma":0.00036954327,"threshold_uncertainty_score":0.8750503},"labels":[],"label_agreement":null},{"id":"W3134228882","doi":"10.1007/s13300-021-01018-w","title":"Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV","year":2021,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Cardiac Care Centre","funders":"Merck Sharp and Dohme; Pfizer","keywords":"Medicine; Internal medicine; Cohort; Sulfonylurea; Placebo; Diabetes mellitus; Adverse effect; Gastroenterology; Insulin; Endocrinology","score_opus":0.006761234587167101,"score_gpt":0.2156693836597361,"score_spread":0.208908149072569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134228882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835022,0.01410344,0.0000038755456,0.00028089355,0.000044578104,0.0017750615,0.000036960737,0.000028253893,0.00022471664],"genre_scores_gemma":[0.9966908,0.0023035936,0.00015565126,0.0003830455,0.000011228761,0.00012055052,0.00017621466,0.00004666773,0.00011222044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980759,0.00013488707,0.0005956469,0.00039373108,0.0003756035,0.0004242124],"domain_scores_gemma":[0.9987517,0.00030819312,0.00022898258,0.00041438438,0.00018525476,0.000111470814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024102491,0.0003234166,0.0012428166,0.00017892041,0.00003267694,0.0000169899,0.00010155536,0.000090597765,0.00009193793],"category_scores_gemma":[0.000049428574,0.00023672631,0.000118342556,0.00042353722,0.00013932538,0.00010117433,0.000033696273,0.00010766004,0.0000018197525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050495225,0.0033652298,0.9026153,0.00010246954,0.001838584,0.0000037146317,0.0004797452,0.000004670005,0.009485343,0.00005333115,0.000108981396,0.07689309],"study_design_scores_gemma":[0.097460516,0.0031081203,0.8527462,0.00028380178,0.00018902257,3.1181454e-8,0.000058809852,0.000059513386,0.044968333,0.00004332518,0.00085167366,0.000230677],"about_ca_topic_score_codex":0.00001530652,"about_ca_topic_score_gemma":0.00000857018,"teacher_disagreement_score":0.092411,"about_ca_system_score_codex":0.000052408323,"about_ca_system_score_gemma":0.000051535433,"threshold_uncertainty_score":0.96534187},"labels":[],"label_agreement":null},{"id":"W3135377013","doi":"10.1152/ajpendo.00646.2020","title":"GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism","year":2021,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Augustinus Fonden; European Research Council; Novo Nordisk Fonden; Department of Health and Aged Care, Australian Government; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Adipose tissue; Endocrinology; Internal medicine; Lipid metabolism; Obesity; Insulin resistance; Energy expenditure; Receptor; Energy metabolism; Metabolism; Biology; Medicine","score_opus":0.007983953558277504,"score_gpt":0.2467735683901429,"score_spread":0.2387896148318654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135377013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98912203,0.0058787903,0.00010515101,0.0040754075,0.00053009664,0.00017101334,0.000008498204,0.000012117893,0.0000968955],"genre_scores_gemma":[0.99083483,0.0037025157,0.002809005,0.0019207441,0.0003527158,0.00003308578,0.000027747634,0.000016311613,0.00030304294],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99821585,0.00037928176,0.0004806335,0.00038579662,0.00011792995,0.00042050544],"domain_scores_gemma":[0.99909306,0.00010843604,0.0002674998,0.0001958252,0.00013965071,0.0001955544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012000781,0.00024013095,0.0009972195,0.0003938238,0.000073749536,0.000014139119,0.00009584704,0.000075189535,0.00007420956],"category_scores_gemma":[0.00008004002,0.00021007542,0.00006897111,0.0003279077,0.00021110415,0.00016601798,0.0000919265,0.00034119177,0.000005116441],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014158664,0.00050979725,0.0012024832,0.000033313445,0.0004330329,0.00020522895,0.0009303306,0.000018648734,0.9371512,0.008468678,0.00083240354,0.048799027],"study_design_scores_gemma":[0.006297083,0.0012250639,0.70663106,0.00015462624,0.0006479691,0.00014003903,0.0012654418,0.000008674457,0.19018725,0.0016368408,0.091391,0.00041497705],"about_ca_topic_score_codex":0.00025219715,"about_ca_topic_score_gemma":0.0003934218,"teacher_disagreement_score":0.7469639,"about_ca_system_score_codex":0.00004513118,"about_ca_system_score_gemma":0.00006719821,"threshold_uncertainty_score":0.8566627},"labels":[],"label_agreement":null},{"id":"W3135386071","doi":"10.1016/j.jclinane.2021.110201","title":"Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Anesthesia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Perioperative; Ketoacidosis; Diabetes mellitus; Anesthesia; Cardiac surgery; Surgery; Endocrinology; Type 1 diabetes","score_opus":0.050956013115362866,"score_gpt":0.3239559812840192,"score_spread":0.27299996816865635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135386071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950986,0.0016557346,0.000007394022,0.002443688,0.0005092797,0.00014275113,0.0000015624968,0.000009661766,0.00013134608],"genre_scores_gemma":[0.99552685,0.00072049577,0.0013849568,0.0008771603,0.0004556821,0.0000073311107,0.000006699714,0.000026276986,0.0009945713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717855,0.00030765732,0.0015734409,0.00020439613,0.0005009331,0.00023503299],"domain_scores_gemma":[0.99747914,0.0011455384,0.00052433426,0.00027053856,0.0003302034,0.0002502723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011065444,0.00018545712,0.0015321836,0.00013853314,0.00002876875,0.00004064525,0.00006313233,0.000129171,0.00010417878],"category_scores_gemma":[0.00096277177,0.00013413354,0.0019054973,0.00024732584,0.00009141753,0.0002542045,0.000035890225,0.00028357052,0.000016492595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005526262,0.00073542964,0.97024494,0.00008480711,0.0012620752,0.004004629,0.00012536993,0.000002463798,0.00039819436,0.000013047336,0.0031264261,0.019450003],"study_design_scores_gemma":[0.0018753776,0.0010347621,0.91328216,0.0012951847,0.002653625,0.00012074426,0.0002319923,0.000014587525,0.0072479513,0.000027664655,0.071978755,0.00023718513],"about_ca_topic_score_codex":0.000003426889,"about_ca_topic_score_gemma":6.706761e-7,"teacher_disagreement_score":0.06885233,"about_ca_system_score_codex":0.000041430605,"about_ca_system_score_gemma":0.0002893732,"threshold_uncertainty_score":0.54698074},"labels":[],"label_agreement":null},{"id":"W3135503392","doi":"10.2215/cjn.20211220","title":"Slowing Progression in CKD","year":2021,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; MEDLINE; Comorbidity; Internal medicine; Endocrinology","score_opus":0.04264825568297314,"score_gpt":0.39603215578209416,"score_spread":0.353383900099121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135503392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704868,0.0004936863,0.000046629717,0.028453268,0.0001837392,0.000080933896,3.7431127e-7,0.0000034400416,0.00025111428],"genre_scores_gemma":[0.9528101,0.0010990544,0.010704617,0.034934763,0.00022665274,0.0000013232305,7.839678e-7,0.0000089307905,0.00021376998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987014,0.00019728254,0.0006440688,0.00010825507,0.00019105902,0.00015794812],"domain_scores_gemma":[0.998645,0.0002979703,0.00065999624,0.00020763214,0.0001203595,0.00006902963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064727594,0.000072655566,0.0006017578,0.000021708742,0.00002080885,0.0000032129349,0.00014108694,0.00004889996,0.000024456202],"category_scores_gemma":[0.00012552665,0.00004400417,0.0007385718,0.0002648632,0.000526388,0.00003094859,0.00013497601,0.00033534932,0.0000020505418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057674677,0.0015990572,0.71130913,0.000050118775,0.0010351123,0.000145073,0.00025781346,0.0000123323325,0.009811876,0.00005357883,0.07883255,0.19631661],"study_design_scores_gemma":[0.0041980976,0.0022725647,0.8876673,0.00025822304,0.00042577868,0.00009364758,0.00096237054,0.00010895668,0.00082016585,0.0004152927,0.10270659,0.00007102712],"about_ca_topic_score_codex":0.0000036025067,"about_ca_topic_score_gemma":0.000001536342,"teacher_disagreement_score":0.19624558,"about_ca_system_score_codex":0.00003579357,"about_ca_system_score_gemma":0.00014002559,"threshold_uncertainty_score":0.19394985},"labels":[],"label_agreement":null},{"id":"W3135510359","doi":"10.1007/s00125-021-05407-5","title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","year":2021,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"European Association for the Study of Diabetes; Pfizer","keywords":"Medicine; Renal function; Creatinine; Dialysis; Albuminuria; Kidney disease; Placebo; Internal medicine; Diabetes mellitus; Urology; Endocrinology; Pathology","score_opus":0.005620229153008505,"score_gpt":0.21498854573157086,"score_spread":0.20936831657856236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135510359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791986,0.00043229098,0.000007746907,0.00026417561,0.00020544165,0.001055539,0.000019997939,0.000025854013,0.000069113834],"genre_scores_gemma":[0.9974778,0.000040412622,0.0001350898,0.0012711579,0.000029056533,0.00006576501,0.00091401464,0.000014124671,0.00005251965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859774,0.0002593066,0.0002921755,0.00035809807,0.00026465763,0.00022799881],"domain_scores_gemma":[0.99877745,0.0005164182,0.00012458283,0.00036202514,0.00008161701,0.00013790253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016677093,0.00020650642,0.0007724664,0.00013562189,0.000041969197,0.000025930016,0.00007221102,0.00008438626,0.000051903487],"category_scores_gemma":[0.000313138,0.00012010774,0.00011711113,0.0004913861,0.000060823477,0.00006923457,0.00003997022,0.00011111586,0.00000486783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030466758,0.0012886352,0.9602423,0.000039575883,0.0033323339,0.000011045784,0.00008427989,0.000010336482,0.000831179,0.000021581758,0.00030106,0.0033709577],"study_design_scores_gemma":[0.14152563,0.001955616,0.8484098,0.00009547825,0.0033840411,9.826459e-9,0.000016040034,0.000091004615,0.004278819,0.000040614625,0.00009368069,0.000109275235],"about_ca_topic_score_codex":0.00005312443,"about_ca_topic_score_gemma":0.0000381543,"teacher_disagreement_score":0.11183246,"about_ca_system_score_codex":0.000046261306,"about_ca_system_score_gemma":0.000038886,"threshold_uncertainty_score":0.48978513},"labels":[],"label_agreement":null},{"id":"W3135537568","doi":"10.1093/jcag/gwab002.031","title":"A32 EMPAGLIFOZIN IMPROVES GASTROINTESTINAL INFLAMMATION IN A MOUSE MODEL OF COLITIS","year":2021,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"EMPA; Inflammation; Empagliflozin; Medicine; Colitis; Type 2 diabetes; Internal medicine; Diabetes mellitus; Lipocalin; Endocrinology; Pharmacology; Chemistry","score_opus":0.009305707925356243,"score_gpt":0.21752899798933245,"score_spread":0.20822329006397622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135537568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99094874,0.0000055976448,0.00006300661,0.00843857,0.000086231455,0.00011884802,0.000026837206,0.0000015213938,0.0003106504],"genre_scores_gemma":[0.9966611,0.000010112569,0.0014632413,0.00040927925,0.00004114419,0.0000022221268,0.0000060961047,0.000006869743,0.0013998833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882936,0.00012755547,0.00052683736,0.00006596037,0.00023015281,0.0002201172],"domain_scores_gemma":[0.998451,0.00003318408,0.0008436885,0.00011488982,0.0004459178,0.000111327514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047921602,0.00007292921,0.00033209214,0.0002480955,0.000020500167,0.0000069939747,0.000091925496,0.000044837605,0.000020306026],"category_scores_gemma":[0.0004434723,0.00006126659,0.00014761873,0.00009782034,0.00002934431,0.00006831971,0.000024325038,0.0001547051,6.8908906e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002314421,0.00009519443,0.98226845,0.000041945405,0.00017376343,0.000019767325,0.00013957085,0.00097151124,0.0146159055,0.0001492982,0.0010866834,0.0002064814],"study_design_scores_gemma":[0.005521555,0.0013227293,0.9815834,0.00027178304,0.00026989196,0.000083295956,0.00018633586,0.0024963904,0.007681467,0.0003597973,0.0001732189,0.000050117003],"about_ca_topic_score_codex":0.0010440846,"about_ca_topic_score_gemma":0.23877876,"teacher_disagreement_score":0.23773468,"about_ca_system_score_codex":0.0009657434,"about_ca_system_score_gemma":0.000529615,"threshold_uncertainty_score":0.77511156},"labels":[],"label_agreement":null},{"id":"W3135562266","doi":"10.2337/dc20-2492","title":"Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58","year":2021,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Research and Development; Daiichi Sankyo Europe; Servier; Eisai; GlaxoSmithKline; IFM Therapeutics; Novo Nordisk; Daiichi-Sankyo; Zora Biosciences; Medicines Company; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; St. Jude Medical; Regeneron Pharmaceuticals; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Allergan; AstraZeneca; CSL Behring; Idorsia Pharmaceuticals; Brigham and Women's Hospital; Sanofi; Esperion Therapeutics; Amgen; Pfizer","keywords":"Dapagliflozin; Medicine; Internal medicine; Hazard ratio; Diabetes mellitus; Placebo; Cohort; Albuminuria; Kidney disease; Blood pressure; Creatinine; TIMI; Type 2 diabetes; Cardiology; Renal function; Endocrinology; Myocardial infarction; Confidence interval; Pathology","score_opus":0.02555874830602093,"score_gpt":0.27540497324855057,"score_spread":0.24984622494252964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135562266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8592479,0.13770096,0.000026333983,0.000041608895,0.00017037458,0.00071325514,0.0000753119,0.00004415185,0.0019800796],"genre_scores_gemma":[0.99345124,0.0026702555,0.0019161624,0.00009644795,0.00006755159,0.00019042945,0.0013850352,0.000043613178,0.00017925614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977457,0.00021929962,0.00041158134,0.0006193063,0.0006485361,0.00035560605],"domain_scores_gemma":[0.99850804,0.00013712341,0.00008629481,0.0009639591,0.00018022255,0.00012434591],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027912357,0.00030860316,0.0016004398,0.00024445658,0.00004301739,0.00003440596,0.000099105,0.00012657474,0.000050677012],"category_scores_gemma":[0.00014429165,0.00027815797,0.0012283142,0.00043707053,0.000069636,0.00013930879,0.00018005332,0.00013494348,0.0000122804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103374914,0.00017575537,0.9315979,0.00035068655,0.029446414,0.00010546251,0.0003132613,0.00029059072,0.0010519841,0.000014209139,0.00014056859,0.036409803],"study_design_scores_gemma":[0.01060954,0.0001390978,0.9434887,0.00025377888,0.015546347,5.256001e-7,0.0008582403,0.000044820983,0.019757707,0.00002956991,0.008991703,0.0002799414],"about_ca_topic_score_codex":0.00013836476,"about_ca_topic_score_gemma":0.00007696503,"teacher_disagreement_score":0.1350307,"about_ca_system_score_codex":0.00012807213,"about_ca_system_score_gemma":0.0001025927,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W3136650528","doi":"10.1136/heartjnl-2020-ics.24","title":"24 SGLT-2I therapy in heart failure : challenges and opportunities","year":2020,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dapagliflozin; Heart failure; Cohort; Internal medicine; Ejection fraction; Audit; Retrospective cohort study; Population; Intensive care medicine; Diabetes mellitus; Emergency medicine; Type 2 diabetes","score_opus":0.11709862690251217,"score_gpt":0.2695333844977445,"score_spread":0.15243475759523234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136650528","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4442429,0.013038795,0.0000035951673,0.4774021,0.00004001964,0.00047283736,9.804143e-7,0.00012455868,0.06467422],"genre_scores_gemma":[0.96802384,0.017067792,0.0005889329,0.0107376985,0.00006178025,0.000025576022,0.000008334673,0.0000114393915,0.0034746015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959993,0.000011041264,0.000073675874,0.00012872007,0.000076994766,0.00010964104],"domain_scores_gemma":[0.9998028,0.000013623335,0.000008783293,0.00007696866,0.000008940165,0.000088830675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041405623,0.000078449964,0.00015340341,0.000040696952,0.000010078106,0.000009022695,0.000020548476,0.000023468352,0.00024178106],"category_scores_gemma":[0.000004038609,0.000056204626,0.000021572434,0.000025289382,0.000020932042,0.000050924922,0.000025075718,0.00004061871,0.000018916806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022341529,0.0005118995,0.020372316,0.00037853917,0.00037630938,0.00020870182,0.0068356604,6.1075053e-7,0.0010838475,0.03859793,0.122952126,0.8084586],"study_design_scores_gemma":[0.0024761078,0.0010918089,0.019428821,0.000042331096,0.000026011976,0.0000018687767,0.0045363177,0.000046980316,0.00074111944,0.00021836926,0.9712825,0.000107807275],"about_ca_topic_score_codex":0.000005643135,"about_ca_topic_score_gemma":0.000022982105,"teacher_disagreement_score":0.8483303,"about_ca_system_score_codex":0.000006841495,"about_ca_system_score_gemma":0.000009675717,"threshold_uncertainty_score":0.2647333},"labels":[],"label_agreement":null},{"id":"W3136693186","doi":"10.1111/dom.14386","title":"The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Medicine; Hazard ratio; Heart failure; Internal medicine; Empagliflozin; Proportional hazards model; Renal function; Type 2 diabetes; Diabetes mellitus; Kidney disease; Cardiology; Confidence interval; Endocrinology","score_opus":0.00925961364996951,"score_gpt":0.2186879114533947,"score_spread":0.20942829780342517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136693186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785761,0.0202205,0.000007479933,0.0002720831,0.00021789449,0.00057642086,0.000068386165,0.000010718099,0.000050421382],"genre_scores_gemma":[0.9972306,0.0018474407,0.00005681916,0.0003175125,0.000081328624,0.000053465734,0.000051498115,0.000010862763,0.00035049245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984199,0.00029266527,0.00031317642,0.00029504162,0.00038039632,0.0002988559],"domain_scores_gemma":[0.99838644,0.0006891102,0.00011993829,0.00056354806,0.000112918715,0.00012804508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007194556,0.00018655082,0.0009935274,0.00008082555,0.00014798842,0.00003447641,0.00008681893,0.00006772612,0.0000048931265],"category_scores_gemma":[0.0010511448,0.0001084749,0.00043977168,0.00042486688,0.00014239547,0.000041163956,0.0001078308,0.00011350173,7.034803e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034194253,0.0023314697,0.8753283,0.0016017075,0.061806794,0.00003687685,0.0011986444,0.000025940946,0.02374889,0.0031755203,0.009101954,0.021301983],"study_design_scores_gemma":[0.008835378,0.00025187657,0.8306175,0.00016522793,0.03514922,4.0437985e-7,0.00019089521,0.00024749467,0.058189664,0.000056889818,0.06621679,0.00007866993],"about_ca_topic_score_codex":0.00010241541,"about_ca_topic_score_gemma":0.000041274303,"teacher_disagreement_score":0.057114832,"about_ca_system_score_codex":0.000009325528,"about_ca_system_score_gemma":0.000045735083,"threshold_uncertainty_score":0.4423478},"labels":[],"label_agreement":null},{"id":"W3137324665","doi":"10.1097/mnh.0000000000000703","title":"Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Empagliflozin; Dapagliflozin; Kidney disease; Diabetes mellitus; Canagliflozin; Internal medicine; Renal function; Heart failure; Hazard ratio; Clinical endpoint; Randomized controlled trial; Glycemic; Type 2 diabetes; Urology; Endocrinology; Confidence interval","score_opus":0.03913448343923256,"score_gpt":0.314318908370095,"score_spread":0.2751844249308625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137324665","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029243017,0.9635736,8.7027536e-7,0.000628897,0.001496195,0.004901815,0.00010824336,0.000043288288,0.0000040900804],"genre_scores_gemma":[0.0015299749,0.98405325,0.000092655486,0.00045919666,0.00039416,0.0011366779,0.0121990675,0.00009955323,0.00003546981],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966992,0.0002356081,0.0010362781,0.0010590543,0.00025523626,0.00071459805],"domain_scores_gemma":[0.9986895,0.0001354677,0.00023679744,0.0005033242,0.00009253093,0.00034239382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030462982,0.00065983733,0.0025303618,0.00079916895,0.000044000342,0.000023005783,0.00011533693,0.00040101,0.0000337567],"category_scores_gemma":[0.00010712084,0.0005506872,0.00030134738,0.00040461533,0.00013573967,0.00013469683,0.00013949025,0.00051959086,0.000033552842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043256365,0.005585151,0.1798685,0.04945606,0.0005073265,0.00004472259,0.000084198415,0.0000018646202,0.000057925175,0.00004602921,0.06347296,0.7004427],"study_design_scores_gemma":[0.0071196915,0.0006388566,0.0174405,0.035586406,0.0008739062,0.0000021747658,0.0000025428483,0.00013528732,0.0000034928576,0.000013843671,0.9377439,0.00043940896],"about_ca_topic_score_codex":0.0000075158473,"about_ca_topic_score_gemma":0.000009671158,"teacher_disagreement_score":0.8742709,"about_ca_system_score_codex":0.00047131375,"about_ca_system_score_gemma":0.0005413034,"threshold_uncertainty_score":0.99969447},"labels":[],"label_agreement":null},{"id":"W3138928489","doi":"10.2139/ssrn.3552809","title":"Empagliflozin Suppresses Inflammation and Protects Against Acute Septic Renal Injury","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Empagliflozin; Inflammation; Medicine; Acute kidney injury; Renal injury; Intensive care medicine; Internal medicine; Diabetes mellitus; Kidney; Type 2 diabetes; Endocrinology","score_opus":0.007259518316795558,"score_gpt":0.2358822936622976,"score_spread":0.22862277534550204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138928489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985976,0.0010436634,0.0005637579,0.006560597,0.000041194267,0.0005019878,0.0000018816581,0.000064614214,0.0013625552],"genre_scores_gemma":[0.99496096,0.0030183839,0.00016132912,0.0004709228,0.0003935256,0.000020677136,0.000018042874,0.000023092023,0.0009330667],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998414,0.000036137393,0.00020911384,0.00017754242,0.00022568242,0.00093751744],"domain_scores_gemma":[0.99957913,0.000011384583,0.00010130007,0.00009457601,0.00004822798,0.00016539826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002661417,0.00015238796,0.00021032218,0.000087992215,0.000101806196,0.000057936304,0.00007101814,0.000048953494,0.000024545265],"category_scores_gemma":[0.00004882747,0.000121319725,0.00006867958,0.00013965012,0.000030108538,0.00019672836,0.000046378955,0.0006878069,0.000036731806],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028292185,0.00039796214,0.007360033,0.00048021667,0.00915916,0.0004295178,0.0024574313,0.000075032614,0.2360716,0.024565576,0.0065539596,0.7096203],"study_design_scores_gemma":[0.080529176,0.066157594,0.023113947,0.0023717026,0.013515899,0.0027387748,0.009647991,0.011981515,0.408771,0.15663825,0.21971829,0.0048158458],"about_ca_topic_score_codex":0.0000023270566,"about_ca_topic_score_gemma":0.000013030056,"teacher_disagreement_score":0.7048044,"about_ca_system_score_codex":0.00031216003,"about_ca_system_score_gemma":0.00053223915,"threshold_uncertainty_score":0.4947275},"labels":[],"label_agreement":null},{"id":"W3139300663","doi":"10.1161/jaha.120.020053","title":"Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; Sinai Health System; St. Michael's Hospital; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Sanofi Genzyme; Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg; LivaNova; Boston Scientific Corporation; Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; Amgen","keywords":"Empagliflozin; Medicine; Post-hoc analysis; Internal medicine; Renal function; Heart failure; Hazard ratio; Kidney disease; Proportional hazards model; Creatinine; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology; Confidence interval","score_opus":0.013018659664322802,"score_gpt":0.2914725871727032,"score_spread":0.2784539275083804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139300663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737495,0.00008416771,0.000006490321,0.025076104,0.00044212744,0.00019086835,0.000026671505,0.0000049607893,0.00041909065],"genre_scores_gemma":[0.99336946,0.00003608335,0.00023600039,0.004524849,0.00019872467,0.000002100817,0.0000075531307,0.000008670175,0.0016165302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811673,0.0003953671,0.0005171139,0.00009144619,0.00072815066,0.00015119364],"domain_scores_gemma":[0.9979662,0.00019357195,0.0010672058,0.00028313152,0.0004074213,0.00008250087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079197384,0.000095316354,0.00086620153,0.00014258167,0.00007369136,0.000024368634,0.00011902316,0.000027072736,0.000040745697],"category_scores_gemma":[0.00089248066,0.00005362058,0.0013437342,0.0011013182,0.000043429565,0.00006521262,0.00007356968,0.00016886671,0.0000036648196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015012831,0.00030150634,0.97795004,0.000010227485,0.008652512,0.000006307763,0.0002445624,0.00005794463,0.0035559603,0.000012597482,0.0067123147,0.0009947686],"study_design_scores_gemma":[0.006838503,0.0005916381,0.9750103,0.000050691644,0.0095601035,0.000005728207,0.00028123506,0.000044622335,0.0011540437,0.000017145025,0.006387553,0.000058488553],"about_ca_topic_score_codex":0.000081452556,"about_ca_topic_score_gemma":0.000021724023,"teacher_disagreement_score":0.020551257,"about_ca_system_score_codex":0.0005209532,"about_ca_system_score_gemma":0.0001529451,"threshold_uncertainty_score":0.21865839},"labels":[],"label_agreement":null},{"id":"W3140752562","doi":"10.1016/j.lfs.2021.119440","title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","year":2021,"lang":"en","type":"article","venue":"Life Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Contractility; Medicine; Cardiology; Internal medicine; Inotrope; Ventricular fibrillation; Ischemia; Heart failure; Perfusion; Asystole; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.009322479110822708,"score_gpt":0.2567251399605157,"score_spread":0.247402660849693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140752562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066424,0.0029301092,0.000018835359,0.0006115419,0.0003554266,0.00014898143,4.6041467e-7,0.000020037953,0.005250391],"genre_scores_gemma":[0.99777144,0.00014402953,0.0011889507,0.00041007664,0.00008826034,0.0000074554614,0.0000020538328,0.0000036413057,0.00038407886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926287,0.00002022605,0.00011008747,0.00020886023,0.00023572106,0.00016226187],"domain_scores_gemma":[0.9996879,0.000068675676,0.00003311752,0.0001123718,0.000017194776,0.00008074392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011119545,0.00007547743,0.0002358269,0.00005809419,0.00006489916,0.000018938526,0.00004199471,0.000024448,0.000012642019],"category_scores_gemma":[0.00016885219,0.000057770096,0.00007479698,0.0002718877,0.00011800138,0.00009147597,0.00006947914,0.00003451538,0.0000067187852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012396681,0.00017779811,0.85627246,0.00057970185,0.00051669445,0.0003887094,0.0006039276,0.000010259428,0.12165645,0.001432515,0.002378235,0.015970858],"study_design_scores_gemma":[0.0041858824,0.00087123126,0.6605668,0.0006561478,0.0009128976,0.000016193599,0.00075492595,0.00033379253,0.32453015,0.0003998098,0.006465724,0.00030646368],"about_ca_topic_score_codex":0.000008633267,"about_ca_topic_score_gemma":0.0000011206647,"teacher_disagreement_score":0.20287369,"about_ca_system_score_codex":0.000008433683,"about_ca_system_score_gemma":0.00008749506,"threshold_uncertainty_score":0.23557961},"labels":[],"label_agreement":null},{"id":"W3141800661","doi":"10.4021/jmc807w","title":"Potential Linagliptin-Induced Renal Impairment","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Linagliptin; Medicine; Sitagliptin; Renal function; Nausea; Creatinine; Urology; Impaired renal function; Drug; Internal medicine; Gastroenterology; Intensive care medicine; Pharmacology; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.025882947791180937,"score_gpt":0.3078572396093436,"score_spread":0.28197429181816264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141800661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914707,0.0015104607,0.00012912597,0.0071480228,0.0010034695,0.00012242763,8.3394195e-7,0.000015392316,0.00092321564],"genre_scores_gemma":[0.9950395,0.0002616733,0.00053412927,0.0010543504,0.0026223937,0.000002731932,0.0000032618045,0.000011899264,0.00047005923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977611,0.000044861896,0.00041982284,0.00007003633,0.0013889198,0.0003152723],"domain_scores_gemma":[0.99876434,0.00007760957,0.00019521404,0.000117442585,0.00008814438,0.00075722375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009211489,0.00011613038,0.0003152501,0.00013519023,0.00003661701,0.000014778525,0.00010652748,0.00009322969,0.0015889389],"category_scores_gemma":[0.00039829902,0.000073774085,0.00022205387,0.00008740702,0.000037819893,0.00013453327,0.00006322673,0.00026349965,0.00005405169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002548322,0.0142391,0.07710397,0.00047846825,0.00313481,0.03766753,0.0009400165,0.0000073265705,0.0064579495,0.0012480116,0.32756862,0.5286059],"study_design_scores_gemma":[0.041804295,0.030757925,0.3023894,0.0033696322,0.0077484148,0.04487152,0.0026369265,0.0004715877,0.025259968,0.00029872457,0.53934246,0.0010491101],"about_ca_topic_score_codex":0.000009788357,"about_ca_topic_score_gemma":9.49304e-7,"teacher_disagreement_score":0.5275568,"about_ca_system_score_codex":0.00008752998,"about_ca_system_score_gemma":0.00012534583,"threshold_uncertainty_score":0.9993237},"labels":[],"label_agreement":null},{"id":"W3142577573","doi":"10.34067/kid.0001172021","title":"eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined","year":2021,"lang":"en","type":"article","venue":"Kidney360","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine","score_opus":0.008749515198004034,"score_gpt":0.23814324374267373,"score_spread":0.2293937285446697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142577573","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3841697,0.009848722,0.00011351941,0.54394245,0.0011263265,0.0016579693,0.00005557168,0.00017625239,0.05890948],"genre_scores_gemma":[0.9497652,0.00034195717,0.00042455358,0.031930372,0.00056823913,0.00018549174,0.000119885975,0.000019042287,0.016645256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992667,0.00005094012,0.00015565859,0.0001806856,0.00019555588,0.00015050296],"domain_scores_gemma":[0.99934137,0.000084409956,0.00003750216,0.00035670778,0.000086938344,0.00009304494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017637412,0.000112309885,0.00016456735,0.000022682618,0.000086791384,0.00007037203,0.000053902975,0.0000294056,0.00064976705],"category_scores_gemma":[0.00020072593,0.00005061902,0.00007145748,0.00013106804,0.00010890877,0.00007529388,0.00014776566,0.0000979015,0.00007151407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021636696,0.00097306754,0.15594432,0.0005593937,0.0017494583,0.0015496971,0.004152178,0.0000020090813,0.0008401359,0.015183995,0.69491863,0.121963434],"study_design_scores_gemma":[0.00981942,0.000109278975,0.118904494,0.00018768304,0.0008436189,0.000032345935,0.00042849203,0.00021969897,0.0018931488,0.0011813417,0.86620766,0.0001728089],"about_ca_topic_score_codex":0.000011185823,"about_ca_topic_score_gemma":0.000024850879,"teacher_disagreement_score":0.5655955,"about_ca_system_score_codex":0.000027655642,"about_ca_system_score_gemma":0.00006379261,"threshold_uncertainty_score":0.7114494},"labels":[],"label_agreement":null},{"id":"W3143631615","doi":"","title":"Évaluation de l’usage des inhibiteurs du SGLT2 au Centre intégré universitaire de santé et de services sociaux de l’Estrie-Centre hospitalier universitaire de Sherbrooke","year":2021,"lang":"fr","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Political science; Gynecology; Medicine","score_opus":0.011815319872285722,"score_gpt":0.24644354997682416,"score_spread":0.23462823010453843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143631615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9173005,0.0032463467,0.0018596072,0.015753789,0.00031062256,0.0006218852,0.00004772459,0.00022542494,0.060634047],"genre_scores_gemma":[0.9178147,0.0047405246,0.009101627,0.0025138229,0.0004423355,0.0000069858315,0.0003600821,0.0000866189,0.064933315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958605,0.0007670189,0.00034991663,0.0006682894,0.00046727204,0.0018869969],"domain_scores_gemma":[0.99801373,0.00028212616,0.00017720555,0.00043403273,0.00029469878,0.0007982305],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010165637,0.0005752992,0.0005240033,0.00020558789,0.0005060729,0.00018133987,0.00032043402,0.00045133795,0.0018506454],"category_scores_gemma":[0.00012962239,0.00065922225,0.0003475905,0.0006755863,0.00026099465,0.00075334305,0.00040210955,0.0003634099,0.00015559993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014317487,0.0014521772,0.83337855,0.0014443195,0.0015772827,0.0035242755,0.03400495,0.00094945397,0.0010134572,0.012288893,0.018114496,0.09210895],"study_design_scores_gemma":[0.0118072145,0.00090364,0.5603971,0.005003552,0.008538231,0.00011143984,0.33093843,0.016093472,0.016106004,0.00570415,0.04287759,0.0015191786],"about_ca_topic_score_codex":0.0026264975,"about_ca_topic_score_gemma":0.008971858,"teacher_disagreement_score":0.2969335,"about_ca_system_score_codex":0.011074577,"about_ca_system_score_gemma":0.003485735,"threshold_uncertainty_score":0.9995859},"labels":[],"label_agreement":null},{"id":"W3144795195","doi":"10.1136/heartjnl-2021-319243","title":"Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses","year":2021,"lang":"en","type":"review","venue":"Heart","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McMaster University; University of Toronto; University Health Network; Toronto General Hospital; Impact; Ted Rogers Centre for Heart Research","funders":"","keywords":"Medicine; Observational study; Kidney disease; Meta-analysis; Type 2 diabetes; Internal medicine; Stroke (engine); Guideline; Intensive care medicine; Risk assessment; Diabetes mellitus; Randomized controlled trial; Myocardial infarction; Endocrinology; Pathology","score_opus":0.1094367980984575,"score_gpt":0.3523260843854083,"score_spread":0.2428892862869508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3144795195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006219038,0.9910312,0.000021209999,0.000059393795,0.000023724364,0.008693936,0.00009056811,0.000016875356,0.000056827626],"genre_scores_gemma":[0.000009383328,0.99574816,0.0005234486,0.0006775673,0.000007473697,0.0019960958,0.00038994395,0.000043662745,0.00060428906],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99833125,0.0001920554,0.000524872,0.00045203097,0.00028606746,0.00021375064],"domain_scores_gemma":[0.99890226,0.00013256771,0.00013865382,0.00054470496,0.00013787956,0.00014395948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039222944,0.00039727756,0.008307524,0.00014065616,0.00002569137,0.000025586021,0.000041628173,0.0000824556,0.000013649041],"category_scores_gemma":[0.00023226101,0.00020548947,0.001136737,0.00021164266,0.000027655684,0.00007468048,0.000058860503,0.00009081914,0.0000024445776],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000020349619,0.00009585495,0.00028152947,0.90918237,0.088817686,0.0000035978167,0.000008464348,7.142577e-7,7.1143696e-10,0.000008664887,0.00072025845,0.00087883516],"study_design_scores_gemma":[0.00073262124,0.00032912867,0.000036033947,0.18070021,0.7365783,0.0000012964856,0.000004466898,0.000009909459,3.401397e-8,0.000005383716,0.08140504,0.00019760751],"about_ca_topic_score_codex":0.0000040650057,"about_ca_topic_score_gemma":6.117055e-7,"teacher_disagreement_score":0.7284821,"about_ca_system_score_codex":0.000060739017,"about_ca_system_score_gemma":0.00008097494,"threshold_uncertainty_score":0.83796173},"labels":[],"label_agreement":null},{"id":"W3147684643","doi":"10.4021/jem171w","title":"Effects of Sitagliptin May Depend on Clinical and Laboratory Data at the Baseline","year":2013,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sitagliptin; Medicine; Baseline (sea); Internal medicine; Insulin","score_opus":0.02832988625619021,"score_gpt":0.3194677746599843,"score_spread":0.2911378884037941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147684643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770583,0.018228777,0.000009678807,0.0036687234,0.00041036523,0.00024174785,0.000007777366,0.0000042767033,0.00037039054],"genre_scores_gemma":[0.9883767,0.00826533,0.0006056659,0.0014895867,0.00032491158,0.0000047304857,0.000005628719,0.000009019023,0.00091842323],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901265,0.00018361275,0.00037581378,0.00014194501,0.00012305393,0.00016294619],"domain_scores_gemma":[0.9987336,0.00056433346,0.00022853544,0.00027474156,0.0000955812,0.00010324504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046110718,0.00010401993,0.00043307364,0.00008548387,0.00004139663,0.0000072270914,0.00011464478,0.000048592316,0.00007578676],"category_scores_gemma":[0.0004108993,0.000055515884,0.00005039225,0.000047512025,0.00018686174,0.0001019575,0.00019505649,0.00021595064,0.000012970465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017174359,0.0024060719,0.2399781,0.00054713123,0.005281884,0.0010926251,0.0002795527,0.0000023910382,0.019546937,0.010018191,0.15735015,0.56177956],"study_design_scores_gemma":[0.0070986953,0.000905468,0.6589511,0.00007550062,0.0018113647,0.00013215473,0.000072699986,0.000018597171,0.0072992346,0.00021262388,0.32333577,0.00008678346],"about_ca_topic_score_codex":0.0000071934237,"about_ca_topic_score_gemma":0.0000041561007,"teacher_disagreement_score":0.5616928,"about_ca_system_score_codex":0.000004394202,"about_ca_system_score_gemma":0.000025414482,"threshold_uncertainty_score":0.2263872},"labels":[],"label_agreement":null},{"id":"W3147955627","doi":"10.1161/circulationaha.121.053350","title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Becton Dickinson (Canada); The King's University; University of Alberta; Juvenile Diabetes Research Foundation","funders":"Vlaamse regering; Fonds Wetenschappelijk Onderzoek; Canadian Institutes of Health Research; Alberta Innovates; European Commission","keywords":"Empagliflozin; Sodium channel; Medicine; Pharmacology; Ranolazine; Mexiletine; Canagliflozin; Heart failure; Internal medicine; Endocrinology; Sodium; Chemistry; Diabetes mellitus; Type 2 diabetes","score_opus":0.018120494809253335,"score_gpt":0.2589870226497534,"score_spread":0.24086652784050003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147955627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636886,0.0117856525,0.013762359,0.005462098,0.0019067852,0.0022905723,0.00008949331,0.00011963207,0.0008948177],"genre_scores_gemma":[0.9971885,0.00018228147,0.0002061823,0.00068960444,0.000352029,0.00025003744,0.00070101133,0.000031895426,0.00039845577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893975,0.000024653486,0.00022071353,0.00030881734,0.00024859043,0.00025750042],"domain_scores_gemma":[0.99931574,0.000031779287,0.00006584654,0.00034656128,0.0001596494,0.000080451355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014252221,0.00016597418,0.00024075799,0.00005654023,0.000101860925,0.000038912847,0.00004785038,0.000059804548,0.000078432706],"category_scores_gemma":[0.000017913562,0.0001304602,0.00028589994,0.00016147565,0.000026609461,0.00007779934,0.000021202351,0.00008140192,0.00004503008],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012163213,0.005184977,0.27705866,0.0050696554,0.011003928,0.00050244026,0.015471946,0.0026567935,0.26281792,0.009511905,0.09515854,0.3143469],"study_design_scores_gemma":[0.00934464,0.00027861132,0.31087923,0.00043693063,0.0047545475,0.000005141026,0.00036215395,0.02380824,0.249879,0.00414162,0.39525414,0.00085573754],"about_ca_topic_score_codex":0.000004696591,"about_ca_topic_score_gemma":0.0000013220287,"teacher_disagreement_score":0.31349117,"about_ca_system_score_codex":0.000074753465,"about_ca_system_score_gemma":0.00006170741,"threshold_uncertainty_score":0.5320013},"labels":[],"label_agreement":null},{"id":"W3148003265","doi":"10.1042/cs20210094","title":"Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice","year":2021,"lang":"en","type":"article","venue":"Clinical Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Endocrinology; Internal medicine; Renin–angiotensin system; Angiotensin II; Glomerulosclerosis; Losartan; Chemistry; Kidney; Albuminuria; Renal function; Renal physiology; Medicine; Blood pressure; Proteinuria","score_opus":0.03498072648980277,"score_gpt":0.33126419184555145,"score_spread":0.2962834653557487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148003265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948311,0.00031291647,0.000001691829,0.003753007,0.00042383446,0.00031273116,0.000005813706,0.000044100267,0.00031480283],"genre_scores_gemma":[0.9959651,0.00014083862,0.00088553375,0.0016727931,0.00017283688,0.000010471705,0.00002595277,0.000012606694,0.0011138584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978117,0.000055218676,0.00052058086,0.0007638272,0.00040162876,0.00044709328],"domain_scores_gemma":[0.99888766,0.00015244621,0.000103848535,0.00033224255,0.00021496387,0.0003088371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007352072,0.0001901289,0.0004842155,0.00013444824,0.00026891107,0.00004505342,0.0001349502,0.00012272551,0.000050879185],"category_scores_gemma":[0.00044991786,0.00014371131,0.00011482733,0.0005275261,0.0005843255,0.00027697152,0.0002696663,0.0002245461,0.0000182586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015927732,0.00053544756,0.028882794,0.000019801655,0.000025562691,0.00016941385,0.000371039,3.9126147e-7,0.9449724,0.000020030246,0.002613394,0.022230467],"study_design_scores_gemma":[0.002586268,0.0009188687,0.24609265,0.00057210756,0.00011650246,0.0000135647515,0.0003034178,0.00023058354,0.7466723,0.00008906994,0.0021683376,0.00023634115],"about_ca_topic_score_codex":0.000021613037,"about_ca_topic_score_gemma":0.000014082,"teacher_disagreement_score":0.21720985,"about_ca_system_score_codex":0.000051188144,"about_ca_system_score_gemma":0.00016573892,"threshold_uncertainty_score":0.5860377},"labels":[],"label_agreement":null},{"id":"W3148497311","doi":"10.1161/circulationaha.121.053659","title":"Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Libin Cardiovascular Institute of Alberta","funders":"Janssen Research and Development; Relypsa; Respicardia; American Regent; National Heart, Lung, and Blood Institute; Japan Heart Foundation; Brigham and Women's Hospital; Vifor Pharma; Shionogi; Daiichi-Sankyo; Toa Eiyo; University of Glasgow; Sanofi Pasteur; University of Oxford; British Heart Foundation; Kidney Research UK; Japan Agency for Medical Research and Development; Zora Biosciences; Ironwood Pharmaceuticals, Incorporated; Medicines Company; Intarcia Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; AstraZeneca; Alnylam Pharmaceuticals; Zafgen; Esperion Therapeutics; Kowa Company; Servier; Celladon Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; GlaxoSmithKline; National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences; IFM Therapeutics; AstraZeneca Canada; Alere; Novo Nordisk; MyoKardia; Eisai; Cytokinetics; Sanofi; Amgen; Moderna; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Heart failure; Ejection fraction; Hazard ratio; Internal medicine; Cardiology; Natriuretic peptide; Placebo; Proportional hazards model; Confidence interval; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.012301896453721485,"score_gpt":0.26379686529760843,"score_spread":0.25149496884388695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148497311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963541,0.00012638976,0.0010818428,0.001845904,0.000048648188,0.00031804625,0.000004488447,0.0000347914,0.00018577176],"genre_scores_gemma":[0.9969511,0.00001251692,0.0020435206,0.000066798944,0.000037959628,0.000027109287,0.0008118106,0.00001145392,0.000037752274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991336,0.00005492379,0.00021054469,0.00029422893,0.0001955259,0.00011120464],"domain_scores_gemma":[0.9994383,0.000017278571,0.00007611811,0.00024981363,0.00015469566,0.000063792235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009714425,0.00010477476,0.00028524996,0.0003774563,0.00005268288,0.000028372599,0.00001587884,0.00006198802,0.00010448924],"category_scores_gemma":[0.00002815719,0.00010033669,0.000060898343,0.0012412975,0.000025294366,0.00026059648,0.000011531273,0.00006658406,0.0000025120823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026379632,0.00034405114,0.9886923,0.00005254466,0.00041434684,0.000003305681,0.00020011087,0.0020610797,0.0066540623,0.0003860209,0.00047427462,0.00069153076],"study_design_scores_gemma":[0.00081409246,0.0001487312,0.98488533,0.00008924743,0.0013247003,0.000004070382,0.00091798726,0.008232806,0.00126551,0.00004192839,0.0021747297,0.00010089121],"about_ca_topic_score_codex":0.00004502301,"about_ca_topic_score_gemma":0.0005012752,"teacher_disagreement_score":0.0061717266,"about_ca_system_score_codex":0.000114515504,"about_ca_system_score_gemma":0.00004189071,"threshold_uncertainty_score":0.40916118},"labels":[],"label_agreement":null},{"id":"W3148783972","doi":"10.31128/ajgp-02-20-5222","title":"Management of patients with type 2 diabetes and cardiovascular disease in primary care","year":2021,"lang":"en","type":"article","venue":"Australian Journal of General Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Disease; Life expectancy; Blood pressure; Metformin; Diabetes management; Intensive care medicine; Internal medicine; Emergency medicine; Population; Environmental health; Endocrinology","score_opus":0.012074945864348857,"score_gpt":0.2457279982048105,"score_spread":0.23365305234046166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148783972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267733,0.0047728927,0.0000032414853,0.0004308299,0.000093782655,0.00018057413,0.0000036829088,0.0000024878796,0.0018351639],"genre_scores_gemma":[0.9912514,0.0009174789,0.00667501,0.00014301411,0.00004237471,0.0000021064777,0.000038874638,0.000012138846,0.0009176145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905,0.000069447975,0.00023854843,0.00013048867,0.00037159148,0.00013990923],"domain_scores_gemma":[0.9991459,0.000020580104,0.00014900207,0.00019793595,0.00035516938,0.00013140611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016052772,0.000100657046,0.00028438948,0.0000771194,0.0000154346,0.000016447093,0.000041714393,0.000020173258,0.000022774633],"category_scores_gemma":[0.000028195147,0.000077076416,0.000089114845,0.00017871431,0.000029042798,0.0002619641,0.00003790622,0.00010084106,0.0000013526541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011644976,0.00093561306,0.93885607,0.0015401461,0.0061145886,0.004018099,0.00023565454,0.00065534445,0.00009157835,0.00008405226,0.00068287837,0.045621496],"study_design_scores_gemma":[0.004158188,0.0006428069,0.97092414,0.0004964234,0.0038166004,0.000007127629,0.00061448466,0.0000017143781,0.00042356184,0.0000105109875,0.0188035,0.00010094161],"about_ca_topic_score_codex":0.0000039948113,"about_ca_topic_score_gemma":4.3512702e-7,"teacher_disagreement_score":0.04552055,"about_ca_system_score_codex":0.000060512586,"about_ca_system_score_gemma":0.00006131759,"threshold_uncertainty_score":0.31430852},"labels":[],"label_agreement":null},{"id":"W3149011094","doi":"10.4103/ijem.ijem_22_18","title":"Commentary on “Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force”","year":2018,"lang":"en","type":"article","venue":"Indian Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sulfonylurea; Hypoglycemia; Randomized controlled trial; Intensive care medicine; Type 2 Diabetes Mellitus; Adverse effect; Diabetes mellitus; Clinical trial; Internal medicine; Endocrinology","score_opus":0.015212868015367306,"score_gpt":0.28069195826288246,"score_spread":0.26547909024751515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149011094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94554305,0.0013275056,0.0000046756854,0.04714705,0.00073102035,0.0002981324,0.000017889563,0.0000054311367,0.004925254],"genre_scores_gemma":[0.9918996,0.0031514626,0.0006220767,0.0039729453,0.00013854883,0.000009792865,0.000028182902,0.000007727692,0.00016962498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990605,0.00009562399,0.0003548846,0.00012752207,0.00015924127,0.00020222124],"domain_scores_gemma":[0.999312,0.0001675148,0.00019744705,0.00015572937,0.00010738507,0.000059947448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027298828,0.00012861766,0.00027749775,0.0004409551,0.00007899134,0.000015010856,0.0001306399,0.000038728256,0.00004444166],"category_scores_gemma":[0.000028217784,0.00008874667,0.00005312524,0.00015053088,0.00022314572,0.000059307557,0.000045900215,0.00020188525,0.0000046050654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017379951,0.0055199163,0.06106641,0.00028143605,0.008095342,0.0013963754,0.00857812,0.000013732528,0.0005682252,0.32108858,0.072141245,0.5195126],"study_design_scores_gemma":[0.019287437,0.0045490414,0.40829256,0.0008482514,0.0016620699,0.00031794413,0.0050444617,0.00003834141,0.0031305128,0.012386833,0.5441089,0.00033361846],"about_ca_topic_score_codex":0.000006559504,"about_ca_topic_score_gemma":0.0000077391605,"teacher_disagreement_score":0.519179,"about_ca_system_score_codex":0.000022897235,"about_ca_system_score_gemma":0.000014185374,"threshold_uncertainty_score":0.36189842},"labels":[],"label_agreement":null},{"id":"W3150559894","doi":"10.1016/j.jcjd.2021.02.001","title":"Equity in Health Services Research—Finding Our Way Back","year":2021,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Equity (law)","score_opus":0.048983336989821616,"score_gpt":0.37325515384594893,"score_spread":0.3242718168561273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150559894","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05101981,0.037376005,6.014053e-7,0.0064980015,0.8927845,0.0009910645,0.0002567451,0.000014878573,0.011058446],"genre_scores_gemma":[0.14095092,0.0012491622,0.0004977716,0.0008074697,0.8454176,0.000022737275,0.00075506413,0.00017284988,0.010126428],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99581933,0.00031129154,0.00090896524,0.0003590038,0.0011606448,0.0014407347],"domain_scores_gemma":[0.9962891,0.00031972953,0.00050924707,0.00039454122,0.00078464695,0.0017027799],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033805275,0.0003274226,0.0012067591,0.0018450829,0.00015562736,0.00023856723,0.00049027975,0.00042681728,0.00021579671],"category_scores_gemma":[0.00047641798,0.00029934585,0.00026353358,0.0006798292,0.00006222422,0.00018936982,0.000118584976,0.0017612486,0.000065835105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005864634,0.00007191611,0.022201886,0.0025922668,0.00039762305,0.0003631807,0.00045647623,0.0000033707838,0.000007345101,0.000024828734,0.96554226,0.008332965],"study_design_scores_gemma":[0.0018014417,0.00086782867,0.004566319,0.012372272,0.0001269512,0.0000010136423,0.0015794955,0.000006484464,0.000047761223,0.00014794827,0.97825336,0.00022914486],"about_ca_topic_score_codex":0.005407326,"about_ca_topic_score_gemma":0.079419255,"teacher_disagreement_score":0.08993111,"about_ca_system_score_codex":0.0027401838,"about_ca_system_score_gemma":0.008922108,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3151303043","doi":"10.1093/cvr/cvab120","title":"Concurrent diabetes and heart failure: interplay and novel therapeutic approaches","year":2021,"lang":"en","type":"review","venue":"Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Innovates; Killam Trusts; University of Alberta","keywords":"Heart failure; Diabetes mellitus; Medicine; Intensive care medicine; Cardiology; Internal medicine; Endocrinology","score_opus":0.22870149846726995,"score_gpt":0.4020246421185828,"score_spread":0.17332314365131285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151303043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008499075,0.99670446,0.00006526878,0.00014561748,0.00010539375,0.002180281,0.0000143939815,0.00003645405,0.0006631433],"genre_scores_gemma":[0.00074803265,0.99738616,0.00015784749,0.000029278848,0.0002161289,0.00064934004,0.00021761109,0.00008408248,0.00051151455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665254,0.0005341574,0.0003246305,0.0009263992,0.0009099636,0.00065228477],"domain_scores_gemma":[0.99830645,0.0002928567,0.000037484297,0.00094409374,0.00013844993,0.0002806488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021765681,0.00043198047,0.002700235,0.0004108174,0.00013327779,0.00021146811,0.00014574651,0.0002441015,0.00002721717],"category_scores_gemma":[0.00012018727,0.00031487946,0.001344247,0.0004734875,0.00038319177,0.000060533217,0.00061892276,0.00076370966,0.000030984273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.7199965e-7,0.00011461739,0.00006649775,0.019158259,0.011333559,0.000034791712,0.000035260073,7.459052e-8,0.0000012029644,0.00054809736,0.0010601726,0.9676466],"study_design_scores_gemma":[0.00079027633,0.00015873276,0.000054398897,0.0086882375,0.0049433205,0.00006301777,0.00011770405,0.000011506572,0.0000066236944,0.000008097686,0.9849067,0.0002514167],"about_ca_topic_score_codex":0.000004823888,"about_ca_topic_score_gemma":8.5040216e-7,"teacher_disagreement_score":0.9838465,"about_ca_system_score_codex":0.00015089866,"about_ca_system_score_gemma":0.00018598912,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W3152222315","doi":"10.1159/000513659","title":"The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease","year":2021,"lang":"en","type":"review","venue":"Glomerular Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Disease; Intensive care medicine; Internal medicine","score_opus":0.07548689593111788,"score_gpt":0.3771470490637957,"score_spread":0.3016601531326778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152222315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012102862,0.9870595,0.000057761015,0.0007928371,0.00033353016,0.010659592,0.0008792679,0.00007205916,0.000024473886],"genre_scores_gemma":[0.000074586475,0.97757846,0.00022776912,0.00017121782,0.0005633898,0.013593999,0.0029329483,0.00010033641,0.004757287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974684,0.00011113745,0.0005824886,0.0008826655,0.00039402492,0.00056127395],"domain_scores_gemma":[0.99670035,0.001427073,0.0002792254,0.0008047753,0.0001695116,0.0006190904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016458417,0.0006748062,0.0015398203,0.00015903095,0.00045533467,0.00022624718,0.00015689341,0.00010979401,0.00003549655],"category_scores_gemma":[0.0009004417,0.0004235728,0.0015043693,0.00026082018,0.00017162379,0.00012602641,0.000105600186,0.00006344234,0.000034374818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019091276,0.0006475148,0.00031450283,0.030523399,0.0027606357,0.00008106676,0.000025948926,8.237014e-7,3.5439555e-7,0.0013110248,0.0038732227,0.9602706],"study_design_scores_gemma":[0.0016843232,0.00061132724,0.00010684057,0.014606507,0.024715438,0.000004690309,0.000054082262,0.000018044344,0.000002456398,0.00027061874,0.9575411,0.00038457595],"about_ca_topic_score_codex":0.000007503686,"about_ca_topic_score_gemma":0.000003943127,"teacher_disagreement_score":0.959886,"about_ca_system_score_codex":0.0003806738,"about_ca_system_score_gemma":0.0009257243,"threshold_uncertainty_score":0.9998216},"labels":[],"label_agreement":null},{"id":"W3152341695","doi":"10.1093/cvr/cvab128","title":"Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial","year":2021,"lang":"en","type":"article","venue":"Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Janssen Research and Development; National Health and Medical Research Council; Medical Research Council; Sanofi Pasteur; Merck Sharp and Dohme; Mitsubishi Tanabe Pharma Corporation; Servier; Relypsa; Astellas Pharma; Gilead Sciences; European Association for the Study of Diabetes; Verily Life Sciences; Novo Nordisk; Sanofi; GlaxoSmithKline; Amgen; Pfizer; European Foundation for the Study of Diabetes; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Canagliflozin; Medicine; Myocardial infarction; Internal medicine; Empagliflozin; Hazard ratio; Type 2 diabetes; Post-hoc analysis; Placebo; Credence; Cardiology; Population; Diabetes mellitus; Confidence interval; Endocrinology; Pathology","score_opus":0.038260424634737354,"score_gpt":0.3120144546755305,"score_spread":0.2737540300407932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152341695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98704237,0.008074676,0.000011811961,0.0005020718,0.00016339509,0.0016515686,0.00000854821,0.000011383565,0.0025341883],"genre_scores_gemma":[0.9982128,0.00078725757,0.00004950276,0.0000632604,0.00012300964,0.0001874932,0.00002213686,0.000013602591,0.0005409395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99709344,0.00057885936,0.0002107856,0.0003480618,0.0014360636,0.0003327773],"domain_scores_gemma":[0.998161,0.00027380194,0.00003914898,0.00087929476,0.0005196414,0.00012710162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014375797,0.0001172623,0.00069382624,0.00033154237,0.00009260056,0.000026898118,0.00012095884,0.000067755034,0.000014190579],"category_scores_gemma":[0.0007520487,0.000081719896,0.0012281727,0.0021003492,0.00025444446,0.000030099178,0.00021448664,0.00020943201,0.0000022110441],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025631944,0.0032474867,0.032239757,0.004357281,0.36005995,0.0013818719,0.002211723,0.00084821193,0.010486274,0.0035785837,0.0036554956,0.5523014],"study_design_scores_gemma":[0.14549154,0.011005852,0.4789994,0.0012529608,0.08598984,0.000035776353,0.0021662912,0.00035168402,0.1174362,0.00013884799,0.15642421,0.0007073834],"about_ca_topic_score_codex":0.0010786584,"about_ca_topic_score_gemma":0.0001627179,"teacher_disagreement_score":0.551594,"about_ca_system_score_codex":0.00011582613,"about_ca_system_score_gemma":0.0002994352,"threshold_uncertainty_score":0.33324406},"labels":[],"label_agreement":null},{"id":"W3153098695","doi":"10.1016/j.jdiacomp.2021.107928","title":"NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia – A brief report from the ORIGIN trial","year":2021,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Prohormone; Internal medicine; Natriuretic peptide; Diabetes mellitus; Multivariate analysis; Cardiology; Endocrinology; Heart failure; Hormone","score_opus":0.05705930098717575,"score_gpt":0.32394777430005056,"score_spread":0.2668884733128748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153098695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661314,0.0015320153,0.000052839063,0.0007323901,0.00021524601,0.00055645773,0.00004292063,0.0000075562516,0.00024742467],"genre_scores_gemma":[0.99813217,0.00075142406,0.0006482239,0.000054812826,0.00018988871,0.000023856066,0.00006646561,0.000013548752,0.000119584656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838316,0.000127519,0.00074179936,0.0002163508,0.0003667917,0.00016435457],"domain_scores_gemma":[0.9980949,0.0005638357,0.000512068,0.0004118068,0.00028165893,0.00013568548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000424597,0.00013653484,0.0006362303,0.000059591723,0.00006397111,0.000019942801,0.00011187309,0.00005562678,0.000040984032],"category_scores_gemma":[0.000710477,0.00007511563,0.00030386797,0.0002581747,0.000034645473,0.00008808363,0.00005977902,0.0002190503,0.0000015015695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024834618,0.0007636204,0.9916427,0.000021260517,0.0034301667,0.000038154016,0.00015356415,0.000039075756,0.0000150017995,0.00010043663,0.0002916247,0.0010209202],"study_design_scores_gemma":[0.0382613,0.0019716069,0.95060664,0.00021889039,0.0026754525,0.000011782174,0.00019596129,0.00013075421,0.00010603169,0.00010107401,0.005638327,0.00008219239],"about_ca_topic_score_codex":0.00008681879,"about_ca_topic_score_gemma":0.000049889477,"teacher_disagreement_score":0.041036088,"about_ca_system_score_codex":0.000051328854,"about_ca_system_score_gemma":0.00027915,"threshold_uncertainty_score":0.30631265},"labels":[],"label_agreement":null},{"id":"W3153821777","doi":"10.1007/s10557-021-07190-2","title":"Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy","year":2021,"lang":"en","type":"article","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; St. Michael's Hospital","funders":"University of Toronto; Diabetes Canada; Heart and Stroke Foundation of Canada","keywords":"Empagliflozin; Medicine; Internal medicine; Muscle hypertrophy; Endocrinology; Downregulation and upregulation; Heart failure; Ventricular remodeling; Cardiology; Diabetes mellitus; Type 2 Diabetes Mellitus; Biology","score_opus":0.012318528423553075,"score_gpt":0.22061887340640396,"score_spread":0.20830034498285088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153821777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8734843,0.12266102,0.00020732221,0.00064326904,0.00022294912,0.0008294387,0.000011085556,0.00012766317,0.0018129476],"genre_scores_gemma":[0.97722167,0.019158866,0.00041691292,0.00082973135,0.0002273399,0.00008117453,0.00027929962,0.000071704315,0.0017132808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981201,0.00011016961,0.00020644486,0.00057128584,0.00055792625,0.00043405342],"domain_scores_gemma":[0.9988138,0.00004055872,0.000047505593,0.00073392194,0.00012700699,0.0002372129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002867136,0.00032746297,0.0007953577,0.00011309142,0.00012928148,0.000095323085,0.00008232526,0.00011231402,0.00011951916],"category_scores_gemma":[0.00003157194,0.00024956508,0.0010202661,0.00025676683,0.00007586563,0.00010780849,0.0000785851,0.00013399374,0.000048112746],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039883945,0.0017269959,0.04823624,0.00056157046,0.044579245,0.0068526096,0.0020260846,0.000029633697,0.0049657137,0.0002927905,0.002335681,0.8879946],"study_design_scores_gemma":[0.02453803,0.0008333712,0.05787199,0.0003592021,0.0041958713,0.00044176224,0.0013369736,0.00041943506,0.040960107,0.00034154803,0.86759156,0.0011101217],"about_ca_topic_score_codex":0.00001766034,"about_ca_topic_score_gemma":8.540955e-7,"teacher_disagreement_score":0.88688445,"about_ca_system_score_codex":0.00004956876,"about_ca_system_score_gemma":0.000061738356,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W3154580191","doi":"10.1161/strokeaha.120.031623","title":"Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease","year":2021,"lang":"en","type":"article","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Medical Research Council; National Institutes of Health; HLS Therapeutics; Bristol-Myers Squibb; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Daiichi Sankyo Europe; Servier; Astellas Pharma; Novo Nordisk; Daiichi-Sankyo; Medical Research Council; Verily Life Sciences; Canadian Institutes of Health Research; Pfizer; Innovent Biologics; Janssen Scientific Affairs; Kidney Foundation of Canada; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Kowa Company; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Ablynx; Alnylam Pharmaceuticals; Amgen; Eli Lilly and Company","keywords":"Medicine; Stroke (engine); Canagliflozin; Internal medicine; Diabetes mellitus; Atrial fibrillation; Hazard ratio; Kidney disease; Renal function; Placebo; Albuminuria; Cardiology; Type 2 diabetes; Endocrinology; Confidence interval; Pathology","score_opus":0.005815299851430893,"score_gpt":0.24819050641982654,"score_spread":0.24237520656839565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154580191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948878,0.00041564106,0.0000011304412,0.00052187056,0.00020196848,0.00037590545,0.000058244892,0.000016701602,0.0035207253],"genre_scores_gemma":[0.99682087,0.000054982014,0.00003250121,0.000053762098,0.00023591911,0.000005816379,0.00010989633,0.000010062536,0.0026761824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928397,0.000063583975,0.00014849076,0.00018468732,0.00017892367,0.00014035535],"domain_scores_gemma":[0.9995232,0.00010432064,0.000039310395,0.0001611734,0.000016983442,0.0001549616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011425064,0.00010444689,0.00023576543,0.00010468401,0.00001503816,0.000009775591,0.000015804524,0.000030989177,0.00005988622],"category_scores_gemma":[0.00023587092,0.000086445834,0.000105184445,0.00008583387,0.000027089847,0.000035135166,0.00003453269,0.000049205606,0.000011613956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076203933,0.000050336268,0.94092596,0.0004178993,0.00014296145,0.00007323769,0.00004238648,0.000038395545,0.0021706412,0.00014205642,0.00076593424,0.054468136],"study_design_scores_gemma":[0.039101087,0.0072496748,0.81242853,0.0016550827,0.001837085,0.0000024222618,0.00008075207,0.0009879333,0.1097256,0.000107098436,0.026361989,0.00046275413],"about_ca_topic_score_codex":0.00000641164,"about_ca_topic_score_gemma":0.0000026458015,"teacher_disagreement_score":0.12849745,"about_ca_system_score_codex":0.00004008853,"about_ca_system_score_gemma":0.000040397346,"threshold_uncertainty_score":0.35251588},"labels":[],"label_agreement":null},{"id":"W3154836626","doi":"10.1111/dom.14401","title":"Prevalence and progression of chronic kidney disease among patients with type <scp>2</scp> diabetes: Insights from the <scp>DISCOVER</scp> study","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Interquartile range; Kidney disease; Renal function; Medicine; Creatinine; Internal medicine; Type 2 diabetes; Diabetes mellitus; Urology; Stage (stratigraphy); Observational study; Gastroenterology; Endocrinology; Biology","score_opus":0.005908242942561242,"score_gpt":0.21395183185815883,"score_spread":0.2080435889155976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154836626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700727,0.027568154,0.0000016490844,0.000037164635,0.00022905874,0.0016233987,0.00012353761,0.00005037291,0.00029398376],"genre_scores_gemma":[0.99706876,0.0011275803,0.000078395926,0.00034920088,0.00014032098,0.0001090694,0.00030280295,0.00003572754,0.00078813394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782133,0.00019756902,0.00030833212,0.0006483678,0.0005646741,0.0004597476],"domain_scores_gemma":[0.9980496,0.0003914529,0.0002143848,0.00062618434,0.00023703098,0.0004813183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016292353,0.00037450626,0.0006338638,0.000087836714,0.0002196781,0.0001061492,0.00016210724,0.00008061335,0.000013641443],"category_scores_gemma":[0.00066574663,0.00023086384,0.00008429999,0.00037063364,0.0002913078,0.00037400963,0.00034162754,0.00019221427,0.000006511122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008240428,0.0023196128,0.99234045,0.0005067881,0.00071797933,0.0000149051875,0.0010959153,0.0000014167766,0.00022715957,0.00008115658,0.00079604547,0.0018903093],"study_design_scores_gemma":[0.00386091,0.00060768565,0.9841221,0.00073546584,0.0026698457,4.4575874e-8,0.00030503795,0.0000779298,0.002437314,0.0001828056,0.0049330657,0.00006776927],"about_ca_topic_score_codex":0.000018712068,"about_ca_topic_score_gemma":0.000013683869,"teacher_disagreement_score":0.026996087,"about_ca_system_score_codex":0.000029557623,"about_ca_system_score_gemma":0.0001585414,"threshold_uncertainty_score":0.9414354},"labels":[],"label_agreement":null},{"id":"W3155093803","doi":"10.1097/mol.0000000000000751","title":"Lipid effects of sodium-glucose cotransporter 2 inhibitors","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Lipidology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"Lipid profile; Lipolysis; Medicine; Internal medicine; Diabetes mellitus; Endocrinology; Lipid metabolism; Type 2 diabetes; Cholesterol; Pharmacology; Adipose tissue","score_opus":0.06495617215069509,"score_gpt":0.37489594109657026,"score_spread":0.30993976894587516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155093803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019695632,0.9088092,0.000015889202,0.00004859974,0.08907628,0.0017113523,0.000016614349,0.000041297055,0.000261075],"genre_scores_gemma":[0.0000073840683,0.9884665,0.00007806281,0.000020171989,0.009086532,0.00041825115,0.0017013905,0.000058511632,0.00016320655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726725,0.00028158614,0.0011057168,0.0006433661,0.00024883018,0.0004532566],"domain_scores_gemma":[0.9984304,0.00035066833,0.0004307064,0.00058556703,0.00006574201,0.00013693707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021632065,0.0005351241,0.003143988,0.000647094,0.000019498062,0.000008423924,0.00017745783,0.0004004369,0.00014376595],"category_scores_gemma":[0.00009835193,0.00043852138,0.0007960604,0.0005104524,0.00013677917,0.000049503735,0.00012918418,0.00052116904,0.00008308764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012344219,0.00093582564,0.00037358157,0.13854568,0.00033072248,0.0000021435333,0.000058729267,7.696508e-8,8.041824e-7,0.00054179295,0.03899513,0.8202032],"study_design_scores_gemma":[0.0015254362,0.00037059994,0.00009608104,0.070896186,0.001146929,0.000010867944,0.000006487759,6.6721225e-7,0.00000873361,0.000011533829,0.9256613,0.0002651352],"about_ca_topic_score_codex":0.0000041834583,"about_ca_topic_score_gemma":0.0000010742262,"teacher_disagreement_score":0.88666624,"about_ca_system_score_codex":0.00015210082,"about_ca_system_score_gemma":0.0002745355,"threshold_uncertainty_score":0.99980664},"labels":[],"label_agreement":null},{"id":"W3155125407","doi":"10.1016/s0140-6736(21)00845-x","title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Novo Nordisk","keywords":"Tolerability; Medicine; Semaglutide; Pharmacokinetics; Pharmacodynamics; Concomitant; Pharmacology; Adverse effect; Internal medicine; Endocrinology","score_opus":0.02132443635642622,"score_gpt":0.3119172657700074,"score_spread":0.29059282941358117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155125407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885007,0.0008003961,0.0011780774,0.0015717295,0.00013989613,0.0050655464,0.00026952146,0.00001723438,0.002456895],"genre_scores_gemma":[0.99549454,0.0009750739,0.002561552,0.000120032346,0.00016053637,0.00017389239,0.000110229674,0.0000141146975,0.00039000617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998728,0.00009379541,0.0005991601,0.00019565375,0.00020824514,0.0001751888],"domain_scores_gemma":[0.9985381,0.00056652137,0.00035058867,0.00031676283,0.00017975617,0.000048314003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055451406,0.00015562997,0.0010876597,0.000046181976,0.00003242315,0.00000806677,0.00009507527,0.00002630377,0.000032912165],"category_scores_gemma":[0.00010320332,0.00009499182,0.00015039688,0.00010515093,0.00016217493,0.000031510313,0.000051961935,0.000056619345,2.1924627e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96378,0.002907869,0.001375435,0.0017888225,0.003016717,0.000032959597,0.00019618092,0.000051430743,0.015533369,0.0016289278,0.0008099786,0.008878325],"study_design_scores_gemma":[0.9261215,0.0017003252,0.00029939332,0.00018558369,0.003243988,0.0000055592122,0.00018444315,0.006352465,0.05900432,0.00017833766,0.002627955,0.00009617579],"about_ca_topic_score_codex":0.000008028721,"about_ca_topic_score_gemma":0.000029175073,"teacher_disagreement_score":0.043470953,"about_ca_system_score_codex":0.000020904225,"about_ca_system_score_gemma":0.00005492534,"threshold_uncertainty_score":0.3873654},"labels":[],"label_agreement":null},{"id":"W3155173546","doi":"10.22374/cjgim.v16i1.432","title":"Important Things Internists Should Know about Sodium-Glucose Co-Transporter 2 Inhibitors","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of General Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Canagliflozin; Diabetes mellitus; Heart failure; Type 2 Diabetes Mellitus; Intensive care medicine; Internal medicine; Pharmacology; Endocrinology","score_opus":0.01875972511932398,"score_gpt":0.2785290626789593,"score_spread":0.2597693375596353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155173546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9229392,0.021686012,0.00034105039,0.024388628,0.0044083013,0.00027376605,0.000022906954,0.000025656895,0.025914468],"genre_scores_gemma":[0.9589212,0.0012153636,0.000626912,0.01142713,0.002779067,0.0000048088646,0.0000806919,0.00005752561,0.02488733],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740475,0.000048068905,0.0011371257,0.00028068258,0.0005818978,0.0005474536],"domain_scores_gemma":[0.99716836,0.000032549608,0.0004183777,0.00029697147,0.0004968694,0.0015868702],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005092932,0.00032472273,0.00076941634,0.0005451235,0.00007749802,0.00005999678,0.0002732131,0.000121731915,0.0026864626],"category_scores_gemma":[0.00015736147,0.00023804585,0.00032280444,0.00020639284,0.00024093445,0.00022581981,0.00002051691,0.0005752128,0.000032702457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053137686,0.00030510133,0.28996876,0.00033888657,0.0028954935,0.07769697,0.0039217817,0.000007782112,0.034882937,0.0012325667,0.5227244,0.06549392],"study_design_scores_gemma":[0.0072725774,0.0026446383,0.038426254,0.0051689115,0.0013552192,0.0038016855,0.00085782097,0.00011177887,0.053881183,0.0003770157,0.88564485,0.00045807115],"about_ca_topic_score_codex":0.004595777,"about_ca_topic_score_gemma":0.0070829527,"teacher_disagreement_score":0.36292043,"about_ca_system_score_codex":0.00042272778,"about_ca_system_score_gemma":0.00091017294,"threshold_uncertainty_score":0.9982252},"labels":[],"label_agreement":null},{"id":"W3155657235","doi":"10.46747/cfp.6704e94","title":"Principales études pertinentes aux soins primaires en 2020","year":2021,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Musée de la Civilisation; McMaster University; Queen's University; University of Alberta; Home and Community Care Support Services; Seven Oaks General Hospital; University of Winnipeg","funders":"","keywords":"Humanities; Medicine; Political science; Gynecology; Art","score_opus":0.022082854067356873,"score_gpt":0.25494796070878806,"score_spread":0.23286510664143117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155657235","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24269646,0.10866442,0.0000118124435,0.03679203,0.003464745,0.0009171092,0.00036306473,0.00013372459,0.6069566],"genre_scores_gemma":[0.73848635,0.0035222685,0.000624221,0.14700134,0.0045675645,0.00012416195,0.0010166619,0.00018444304,0.10447302],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971485,0.00012054049,0.0003670942,0.00067323353,0.0003420703,0.0013485604],"domain_scores_gemma":[0.99782616,0.00009075101,0.00008910942,0.000669707,0.00018518971,0.0011390982],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012761736,0.00047809497,0.0005829096,0.00017477604,0.00024869907,0.000145441,0.00024758815,0.00016741718,0.00011396245],"category_scores_gemma":[0.00006261868,0.00052354933,0.00030249523,0.0005173355,0.00020747211,0.00023153228,0.000118072894,0.00027748852,0.0014978356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029962723,0.0011568427,0.011103181,0.0012335574,0.0027647882,0.005642226,0.0010104905,0.00006455911,0.0071474956,0.1537605,0.28971568,0.5263707],"study_design_scores_gemma":[0.00096561806,0.00020345024,0.098410875,0.0009731231,0.0008600787,0.0000024796668,0.0029786732,0.00025362775,0.0014960004,0.0003587169,0.8930303,0.00046709314],"about_ca_topic_score_codex":0.015226459,"about_ca_topic_score_gemma":0.08967393,"teacher_disagreement_score":0.6033146,"about_ca_system_score_codex":0.0013239103,"about_ca_system_score_gemma":0.004596201,"threshold_uncertainty_score":0.9997216},"labels":[],"label_agreement":null},{"id":"W3155930593","doi":"10.1161/circ.142.suppl_3.15701","title":"Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Mace; Internal medicine; Cardiology; Biomarker; Hazard ratio; Myocardial infarction; TIMI; Troponin; Stroke (engine); Copeptin; Heart failure; Dapagliflozin; Proportional hazards model; Diabetes mellitus; Type 2 diabetes; Endocrinology; Confidence interval; Percutaneous coronary intervention","score_opus":0.038890355688117786,"score_gpt":0.257387556069385,"score_spread":0.21849720038126724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155930593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558645,0.0008404554,0.0001939168,0.00067132176,0.000061010353,0.00070774107,0.0000069603648,0.000055255954,0.0018768675],"genre_scores_gemma":[0.9992632,0.000020310015,0.0002152358,0.0000824084,0.00009846098,0.000025269448,0.00025816046,0.000017678574,0.000019263907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990759,0.000042165724,0.0002128202,0.0002733581,0.00023978543,0.00015599333],"domain_scores_gemma":[0.9995496,0.00006189898,0.000048089678,0.00018945552,0.0000239431,0.00012700295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002244794,0.000120738194,0.00027313756,0.00011701596,0.000045944955,0.0000071760746,0.000030722473,0.00008183472,0.00002127256],"category_scores_gemma":[0.000106810025,0.00012355049,0.00016985509,0.0002482117,0.000018952387,0.0001516106,0.000025073741,0.00008463378,0.000054559892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020907055,0.00002066076,0.992254,0.00011828486,0.0005298036,0.000010953773,0.00016861793,0.00014415238,0.00008967678,0.0000495452,0.000093749964,0.006499607],"study_design_scores_gemma":[0.0015947359,0.000022538667,0.9959607,0.000058952366,0.00062692066,3.3320214e-7,0.00008345965,0.0001576112,0.0000396933,0.00012638702,0.001220518,0.000108162276],"about_ca_topic_score_codex":0.000046446497,"about_ca_topic_score_gemma":0.0000020090863,"teacher_disagreement_score":0.0063914447,"about_ca_system_score_codex":0.000105369705,"about_ca_system_score_gemma":0.000020568195,"threshold_uncertainty_score":0.5038243},"labels":[],"label_agreement":null},{"id":"W3155932096","doi":"10.3803/enm.2021.987","title":"Cardiorenal Protection in Diabetic Kidney Disease","year":2021,"lang":"en","type":"review","venue":"Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto General Hospital; Diabetes Canada; University of Toronto; University Health Network","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Department of Medicine, University of Toronto; University of Toronto; Diabetes Canada","keywords":"Medicine; Kidney disease; Mineralocorticoid receptor; Diabetes mellitus; Type 2 diabetes; Kidney; Disease; Population; Internal medicine; Dulaglutide; Intensive care medicine; Endocrinology; Liraglutide; Aldosterone","score_opus":0.030970323744690817,"score_gpt":0.3000467220051859,"score_spread":0.26907639826049506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155932096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010913174,0.99638164,0.000008488901,0.0002188268,0.00058842485,0.0012939827,0.000024027244,0.000048093872,0.0013273762],"genre_scores_gemma":[0.0001144288,0.99523985,0.00006864049,0.00019035955,0.00026941288,0.00090225996,0.0002909345,0.000031389605,0.0028927089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847615,0.00018626502,0.0003206532,0.0004895009,0.00011183573,0.00041557103],"domain_scores_gemma":[0.9992608,0.000026291062,0.00008634108,0.00033126387,0.000022855878,0.00027247597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007519095,0.0003351584,0.0018063299,0.00037137547,0.00004142104,0.000015610729,0.000057739875,0.00013380534,0.00010360493],"category_scores_gemma":[0.00010916257,0.00025835307,0.00033313976,0.00019432022,0.000083601655,0.00004107075,0.000120142904,0.00037994582,0.000056801957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009107858,0.00012892137,0.000070464645,0.0057500484,0.00060673704,0.00077520165,0.000015831276,4.4440778e-8,2.748337e-7,0.003822739,0.00042513947,0.9883955],"study_design_scores_gemma":[0.0010242525,0.000026189993,0.00093937654,0.0032288493,0.005222002,0.000059292724,0.000007038641,6.7664854e-7,0.0000021301041,0.000102228565,0.9892005,0.00018748849],"about_ca_topic_score_codex":0.000010755459,"about_ca_topic_score_gemma":0.0000012963415,"teacher_disagreement_score":0.9887753,"about_ca_system_score_codex":0.000048114776,"about_ca_system_score_gemma":0.00022885685,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W3156815314","doi":"10.1111/bph.15497","title":"The therapeutic potential of GLP‐1 receptor biased agonism","year":2021,"lang":"en","type":"review","venue":"British Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Imperial Biomedical Research Centre; Biotechnology and Biological Sciences Research Council; Medical Research Council; Medical Research Council Canada; European Foundation for the Study of Diabetes; Academy of Medical Sciences; British Society for Neuroendocrinology; Society for Endocrinology; Engineering and Physical Sciences Research Council; Sunesis; National Institute for Health and Care Research","keywords":"Downregulation and upregulation; Receptor; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Appetite; Pharmacology; Agonist; Intracellular; Functional selectivity; Signal transduction; Signalling; Biology; Bioinformatics; Type 2 diabetes; Endocrinology; Medicine; Internal medicine; Diabetes mellitus; Cell biology; Biochemistry","score_opus":0.03835100197603851,"score_gpt":0.3596929980729513,"score_spread":0.3213419960969128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156815314","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014131491,0.99555725,0.000018246315,0.00039481773,0.0029583483,0.00056533946,0.000024651785,0.000007861407,0.0003321563],"genre_scores_gemma":[0.00020370285,0.996664,0.0001251714,0.00030009326,0.0009848139,0.00002457508,0.00004545963,0.000042156014,0.0016100624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977293,0.00045077153,0.0010258774,0.0001724977,0.0003190792,0.00030249116],"domain_scores_gemma":[0.9981256,0.00025431655,0.0011004425,0.00010664839,0.00029878784,0.00011421328],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000603535,0.0002297275,0.0018021703,0.00014773416,0.000095034,0.000044606677,0.0002943541,0.00016771069,0.0009374342],"category_scores_gemma":[0.000043960914,0.00017076876,0.0011046482,0.00020650757,0.00015550789,0.000045650733,0.00008423146,0.0005706202,0.00001877494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036730882,0.00035646305,6.306789e-7,0.0019909423,0.004480675,0.0018665262,0.000006162162,3.7169772e-7,0.00018943261,0.00002212058,0.058848333,0.9322016],"study_design_scores_gemma":[0.0020199234,0.00045910114,0.0000076244055,0.006293341,0.011907444,0.0028606907,0.000021520775,0.000001124483,0.00013998666,0.000012186242,0.9761613,0.00011573884],"about_ca_topic_score_codex":0.000006005261,"about_ca_topic_score_gemma":0.0000013540662,"teacher_disagreement_score":0.9320859,"about_ca_system_score_codex":0.00012494368,"about_ca_system_score_gemma":0.00054698257,"threshold_uncertainty_score":0.99997586},"labels":[],"label_agreement":null},{"id":"W3157504641","doi":"10.1210/jendso/bvab048.019","title":"Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Semaglutide; Overweight; Medicine; Tolerability; Placebo; Type 2 diabetes; Body mass index; Obesity; Weight loss; Internal medicine; Randomized controlled trial; Confidence interval; Diabetes mellitus; Physical therapy; Adverse effect; Endocrinology; Liraglutide","score_opus":0.007206146587111358,"score_gpt":0.23665077036558432,"score_spread":0.22944462377847297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157504641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449235,0.0020125085,0.0000038052187,0.0027717748,0.00008576702,0.00019756486,0.000003193487,0.000004428104,0.0004286325],"genre_scores_gemma":[0.99259925,0.002409461,0.0028433541,0.0003697222,0.00008217957,0.0000011755853,0.0000019905278,0.000011650555,0.0016812432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999147,0.000043721982,0.00028166527,0.00011862986,0.00023545366,0.00017353438],"domain_scores_gemma":[0.99929607,0.00012890581,0.00020318909,0.00016334813,0.00013319081,0.000075290474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015867072,0.00011866277,0.00037671326,0.000024455912,0.000045413493,0.000010721638,0.000063633284,0.000023054392,0.000035706988],"category_scores_gemma":[0.00009285114,0.000061826955,0.00010967394,0.00022819472,0.00009121125,0.0000660218,0.00012019982,0.00018493555,3.5467323e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022638417,0.0012515519,0.9697881,0.00095864356,0.0014902967,0.00025196373,0.0015079879,0.000023686502,0.0017641399,0.00018270306,0.009651478,0.010865619],"study_design_scores_gemma":[0.014699096,0.0013754121,0.9646576,0.0018288429,0.0006340426,0.0001293916,0.0010989009,0.00015289838,0.0051684855,0.000058933983,0.01007221,0.00012420835],"about_ca_topic_score_codex":0.000009443123,"about_ca_topic_score_gemma":0.000025974306,"teacher_disagreement_score":0.012435254,"about_ca_system_score_codex":0.00006162971,"about_ca_system_score_gemma":0.00009352574,"threshold_uncertainty_score":0.25212303},"labels":[],"label_agreement":null},{"id":"W3157770810","doi":"10.1210/jendso/bvab048.030","title":"Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"","keywords":"Overweight; Semaglutide; Lean body mass; Medicine; Body mass index; Obesity; Placebo; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Body weight; Liraglutide","score_opus":0.011409370615471644,"score_gpt":0.28297403344599303,"score_spread":0.2715646628305214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157770810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887973,0.000108372304,0.000008515142,0.0004727425,0.0000679753,0.00030100535,0.000009339045,0.0000027274398,0.0001495825],"genre_scores_gemma":[0.99927974,0.00007839764,0.00016049849,0.00013079429,0.000037664595,0.0000032187338,0.0000029661485,0.000008575088,0.0002981368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872905,0.00014155652,0.0003833496,0.00010175882,0.00051397603,0.00013033776],"domain_scores_gemma":[0.998844,0.000078507175,0.00047161544,0.00035006047,0.00021365288,0.000042131094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020939458,0.0001202027,0.00050941965,0.00008145872,0.000038586666,0.000006935695,0.00013366362,0.000014882884,0.000056168243],"category_scores_gemma":[0.000027802227,0.000050114377,0.00080305705,0.00094581005,0.000043746826,0.00005918172,0.00008925727,0.00019131291,2.7123113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087131717,0.004815293,0.97681606,0.00008350991,0.010292627,0.00009627359,0.0021181863,0.001201697,0.0012525443,0.000013715652,0.0021808324,0.0002579712],"study_design_scores_gemma":[0.0051501784,0.0021016197,0.9790445,0.0004944431,0.004479202,0.000013387652,0.0040853852,0.00035596485,0.0041692886,0.0000061830046,0.000045915825,0.00005391375],"about_ca_topic_score_codex":0.000036100537,"about_ca_topic_score_gemma":0.00008497388,"teacher_disagreement_score":0.005813425,"about_ca_system_score_codex":0.00022389552,"about_ca_system_score_gemma":0.00013985725,"threshold_uncertainty_score":0.2043605},"labels":[],"label_agreement":null},{"id":"W3157908362","doi":"10.1210/jendso/bvab048.708","title":"Is DPP-4 Use Associated With a Decreased Mortality for COVID-19 Diabetic Patients? A Meta-Analysis","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Medicine; Odds ratio; Confidence interval; Subgroup analysis; Internal medicine; Coronavirus disease 2019 (COVID-19); Publication bias; Diabetes mellitus; Random effects model; MEDLINE; Sample size determination; Disease; Statistics; Endocrinology; Biology; Mathematics","score_opus":0.09832830364426111,"score_gpt":0.3391762866901726,"score_spread":0.24084798304591148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157908362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861104,0.00059590343,0.00079323776,0.011486533,0.00009548047,0.0006391315,0.00015149429,0.00002045663,0.000107392596],"genre_scores_gemma":[0.97877145,0.000057311474,0.0024452165,0.013316987,0.00005257666,0.00003926832,0.00007606659,0.000020307476,0.005220841],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9982943,0.00012665645,0.00045935612,0.0002012186,0.00063959206,0.00027888326],"domain_scores_gemma":[0.99768126,0.00038232934,0.00060189655,0.00042515682,0.00064358057,0.00026578826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040567186,0.0001943794,0.00099764,0.000051115287,0.00013394766,0.00005920206,0.0001406061,0.000033059612,0.00027950827],"category_scores_gemma":[0.0010497016,0.000102313345,0.0042995284,0.00069407147,0.000060742645,0.00012830022,0.000075729804,0.00016207245,7.9900974e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008428795,0.0014336933,0.48198715,0.00008384235,0.47632644,0.000048263966,0.0003250087,0.00014191806,0.000029873478,0.00005647441,0.039419886,0.00006318454],"study_design_scores_gemma":[0.008293633,0.00046435246,0.2460413,0.000020789379,0.7259513,0.000008343909,0.00030330854,0.00031034593,0.0012176832,0.0001959782,0.017014302,0.00017864158],"about_ca_topic_score_codex":0.000034521745,"about_ca_topic_score_gemma":0.000048339843,"teacher_disagreement_score":0.2496249,"about_ca_system_score_codex":0.0003097915,"about_ca_system_score_gemma":0.00029180275,"threshold_uncertainty_score":0.433619},"labels":[],"label_agreement":null},{"id":"W3157923082","doi":"10.1097/mol.0000000000000750","title":"Lipid effects of glucagon-like peptide 1 receptor analogs","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Lipidology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"Chemistry; Glucagon-like peptide-1; Receptor; Peptide; Internal medicine; Endocrinology; Biochemistry; Medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.08168027118250105,"score_gpt":0.3931744243423563,"score_spread":0.31149415315985524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157923082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009218939,0.89232016,0.00002269511,0.000058792335,0.10543097,0.0016411915,0.000020842444,0.000045745637,0.0004504131],"genre_scores_gemma":[0.0000010258088,0.98758894,0.00024658404,0.000029420127,0.0084948875,0.00052167586,0.0023737347,0.00006360237,0.00068010803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968963,0.00047474125,0.0010828382,0.00075869495,0.00026282112,0.0005245546],"domain_scores_gemma":[0.9978719,0.00060608966,0.00053822313,0.0007385615,0.000087301705,0.00015793263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029211023,0.0005799816,0.003455241,0.00075502996,0.000025969162,0.000011427492,0.00025391698,0.0004019677,0.00027265973],"category_scores_gemma":[0.00028575334,0.00048140253,0.0008056374,0.0007168622,0.00014201121,0.00005171321,0.00029635857,0.0005574225,0.00021380416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001083798,0.00074593327,0.00020406154,0.10075048,0.0004347741,7.9023954e-7,0.00004115873,1.737725e-7,6.877818e-7,0.000761279,0.17375937,0.72329044],"study_design_scores_gemma":[0.0012422015,0.0004964552,0.00006439681,0.06631036,0.000975118,0.000010009821,0.000010840676,0.000001173501,0.0000015051937,0.000010750855,0.93058664,0.00029058257],"about_ca_topic_score_codex":0.0000069824987,"about_ca_topic_score_gemma":0.00000125468,"teacher_disagreement_score":0.75682724,"about_ca_system_score_codex":0.00024449182,"about_ca_system_score_gemma":0.0003458349,"threshold_uncertainty_score":0.9997638},"labels":[],"label_agreement":null},{"id":"W3157970388","doi":"10.1111/dom.14415","title":"Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPA‐REG OUTCOME</scp> trial with a focus on Asia","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Body mass index; Internal medicine; Proportional hazards model; Diabetes mellitus; Placebo; Diabetic nephropathy; Type 2 diabetes; Heart failure; Nephropathy; Cardiology; Confidence interval; Endocrinology","score_opus":0.010290191231539795,"score_gpt":0.26770079108212314,"score_spread":0.25741059985058334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157970388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974024,0.0003378486,0.000012594803,0.00012013366,0.00016545554,0.0010714303,0.00006833078,0.000023900724,0.0007978471],"genre_scores_gemma":[0.9992613,0.00003347606,0.00006577978,0.00021413261,0.000058877267,0.00007293109,0.000025300616,0.00001917077,0.00024902067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978467,0.00031174236,0.00041077912,0.00047547885,0.00059457886,0.00036070083],"domain_scores_gemma":[0.9983279,0.0005708539,0.00020781421,0.0006077377,0.00009048929,0.00019522093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008079002,0.0003448653,0.0017752128,0.0003709833,0.000091909955,0.000039734565,0.000119560325,0.00010055634,0.000005440163],"category_scores_gemma":[0.00047079037,0.0001993411,0.00049398915,0.00093963835,0.00010733178,0.00007379734,0.00014239457,0.00017867722,0.000001296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000541519,0.00036281705,0.988307,0.00019719351,0.0062763467,0.00001371066,0.00013122369,0.000027499973,0.00080946885,0.00045470876,0.000018551906,0.0028599505],"study_design_scores_gemma":[0.013294427,0.0011827276,0.9381574,0.00009966612,0.014139715,2.1431971e-7,0.00011671282,0.000054215754,0.032696452,0.000049504106,0.00012538877,0.000083574945],"about_ca_topic_score_codex":0.00007525109,"about_ca_topic_score_gemma":0.000044622764,"teacher_disagreement_score":0.050149605,"about_ca_system_score_codex":0.000029404633,"about_ca_system_score_gemma":0.00003107684,"threshold_uncertainty_score":0.8128894},"labels":[],"label_agreement":null},{"id":"W3157996603","doi":"10.1210/jendso/bvab048.018","title":"Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"","keywords":"Semaglutide; Medicine; Overweight; Tolerability; Body mass index; Placebo; Obesity; Weight management; Randomized controlled trial; Adverse effect; Weight loss; Internal medicine; Confidence interval; Physical therapy; Type 2 diabetes; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.006844144817526228,"score_gpt":0.23593601641366277,"score_spread":0.22909187159613653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157996603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943102,0.0007788722,0.000019670268,0.0035040327,0.000108349115,0.00026624725,0.0000049876685,0.0000065128434,0.0010011503],"genre_scores_gemma":[0.99000514,0.0014726367,0.0039453693,0.00035803867,0.00010650181,0.0000015482848,0.00000233287,0.000014898025,0.0040935487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988522,0.00005309929,0.0003915588,0.00013582577,0.00035789018,0.00020941388],"domain_scores_gemma":[0.99910307,0.00013925332,0.00028892834,0.0002327304,0.00014943937,0.0000865724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015634354,0.00014149354,0.00043943603,0.000027596896,0.000048586768,0.000010328266,0.000102887585,0.00002723125,0.00006730313],"category_scores_gemma":[0.000077986646,0.00007402762,0.00022926593,0.0002556926,0.00008422954,0.00005770271,0.00011931461,0.0002509217,8.175836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035578016,0.011533314,0.7811864,0.0041353283,0.008637647,0.015150938,0.010215522,0.00054018607,0.007449413,0.0012406027,0.057418726,0.0669139],"study_design_scores_gemma":[0.068018064,0.006746191,0.8324343,0.006936551,0.002702683,0.0077263643,0.006131125,0.00069488335,0.017270483,0.00016972744,0.050637346,0.0005323059],"about_ca_topic_score_codex":0.00002219347,"about_ca_topic_score_gemma":0.000059008307,"teacher_disagreement_score":0.066381596,"about_ca_system_score_codex":0.00013356,"about_ca_system_score_gemma":0.00015453629,"threshold_uncertainty_score":0.3018759},"labels":[],"label_agreement":null},{"id":"W3158250219","doi":"10.4239/wjd.v12.i5.541","title":"Recent advances in new-onset diabetes mellitus after kidney transplantation","year":2021,"lang":"en","type":"review","venue":"World Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Kidney transplantation; Transplantation; Internal medicine; Intensive care medicine; Bioinformatics; Endocrinology","score_opus":0.018256388232141107,"score_gpt":0.29977165114244797,"score_spread":0.2815152629103069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158250219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056281075,0.99655396,0.000002471634,0.0005101551,0.00082699413,0.0006191892,0.00004494049,0.000018085646,0.0008614221],"genre_scores_gemma":[0.000098925804,0.9962627,0.0007104206,0.00057975785,0.000426851,0.000056604345,0.000297099,0.000070657865,0.001496941],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996895,0.00022786089,0.0014197683,0.0003588163,0.0005245079,0.00057402963],"domain_scores_gemma":[0.9979563,0.00030361803,0.00079814234,0.00031571064,0.00014344178,0.0004828108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004879375,0.00056086725,0.0028276949,0.0012363944,0.000028462966,0.0000698849,0.000211713,0.00014497498,0.00059522706],"category_scores_gemma":[0.00013937098,0.00041765155,0.00085705135,0.0009993488,0.00005316742,0.00035410665,0.000040001552,0.0005791372,0.000031357915],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020945754,0.0002939325,0.012476456,0.011923585,0.0007943858,0.00018953289,0.000051882875,0.0000010122368,5.0685185e-7,0.000021847234,0.004952545,0.9692734],"study_design_scores_gemma":[0.001345192,0.00025544735,0.00059558376,0.06705996,0.004934611,0.00000869991,0.000012360151,8.4007104e-7,0.000030428046,0.000059690257,0.92538166,0.0003155175],"about_ca_topic_score_codex":6.6067963e-7,"about_ca_topic_score_gemma":0.00003555068,"teacher_disagreement_score":0.96895784,"about_ca_system_score_codex":0.0002962539,"about_ca_system_score_gemma":0.000769164,"threshold_uncertainty_score":0.9998275},"labels":[],"label_agreement":null},{"id":"W3158757081","doi":"10.1097/jac.0000000000000379","title":"Cardiovascular Disease in Patients With Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"Journal of Ambulatory Care Management","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Weyerhauser (Canada)","funders":"","keywords":"Medicine; Guideline; Disease; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; Intensive care medicine; Disease management; MEDLINE; Family medicine; Health care; Internal medicine; Endocrinology; Pathology","score_opus":0.004497034458980197,"score_gpt":0.19608454676281525,"score_spread":0.19158751230383506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158757081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995733,0.005946931,0.0000113371325,0.00012109843,0.00029984256,0.00032812497,0.0000016807772,0.000011543394,0.0033221073],"genre_scores_gemma":[0.9982057,0.00018514159,0.00070988707,0.00029099887,0.00006510952,0.000005530452,0.000028128474,0.00002251967,0.00048697816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986171,0.000038207483,0.00027911022,0.00018516656,0.00066889205,0.0002115217],"domain_scores_gemma":[0.998962,0.0000075407443,0.000098668104,0.00039402515,0.00037059947,0.00016717172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013173759,0.00014794685,0.00037576404,0.00022618107,0.000024777155,0.00002603271,0.000075044816,0.000022411423,0.000057466543],"category_scores_gemma":[0.000013364057,0.00010036894,0.00023486537,0.00029140903,0.000022177057,0.00010902042,0.00008021028,0.000100546575,0.000011654214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027581563,0.00057015783,0.95751923,0.00053918775,0.0035505714,0.0020182643,0.000102636346,0.0013129861,0.0000020966893,0.00008788616,0.001002632,0.033018515],"study_design_scores_gemma":[0.004704728,0.00046903326,0.93994975,0.00038230576,0.0020457741,5.993323e-7,0.0002929967,0.000006614908,0.000055291013,0.000018102153,0.05195138,0.0001234049],"about_ca_topic_score_codex":9.1917053e-7,"about_ca_topic_score_gemma":8.920303e-7,"teacher_disagreement_score":0.050948747,"about_ca_system_score_codex":0.00026034375,"about_ca_system_score_gemma":0.00006554929,"threshold_uncertainty_score":0.40929267},"labels":[],"label_agreement":null},{"id":"W3158972764","doi":"10.1210/jendso/bvab048.838","title":"Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Empagliflozin; Canagliflozin; Renal function; Kidney disease; Internal medicine; Dapagliflozin; Population; Diabetes mellitus; Glycemic; Urology; Type 2 diabetes; Endocrinology","score_opus":0.006046589713263899,"score_gpt":0.24891546562278813,"score_spread":0.24286887590952422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158972764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8794265,0.10311743,0.0000029833484,0.0154581275,0.00087865675,0.00071068155,0.000047831145,0.000003347188,0.000354435],"genre_scores_gemma":[0.87767434,0.12022332,0.00017182587,0.0015701982,0.00011041562,0.0000034900224,0.000014179722,0.000011953862,0.00022030005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988122,0.000095913616,0.00054155133,0.00008480783,0.00033956705,0.00012593919],"domain_scores_gemma":[0.99912417,0.000059137896,0.00035362475,0.00021223405,0.00018469166,0.00006612212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021789513,0.00010926349,0.00039716926,0.000020118254,0.000026270374,0.0000054374827,0.00011397644,0.00001688989,0.000017494796],"category_scores_gemma":[0.00019190385,0.000052823,0.00047360134,0.00032452642,0.000060353323,0.000050413135,0.00008512652,0.0003080395,1.473537e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004154982,0.0057450174,0.6684434,0.049345855,0.0023203064,0.00005676865,0.0061217286,0.000017513239,0.0025082924,0.00033778988,0.13987848,0.12480937],"study_design_scores_gemma":[0.017805845,0.00055069255,0.6246776,0.17417064,0.002763826,0.00005637374,0.0001574129,0.000015320797,0.014571743,0.00016558226,0.16485384,0.00021112009],"about_ca_topic_score_codex":8.232672e-7,"about_ca_topic_score_gemma":4.2577537e-7,"teacher_disagreement_score":0.124824785,"about_ca_system_score_codex":0.00005609911,"about_ca_system_score_gemma":0.000095012685,"threshold_uncertainty_score":0.21540594},"labels":[],"label_agreement":null},{"id":"W3158979900","doi":"10.1161/atvbaha.121.316311","title":"GLP-1 (Glucagon-Like Peptide-1) Is Physiologically Relevant for Chylomicron Secretion Beyond Its Known Pharmacological Role","year":2021,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Saskatchewan; LMC Diabetes & Endocrinology (Canada); Diabetes Canada","funders":"Canadian Institutes of Health Research","keywords":"Lymph; Internal medicine; Endocrinology; Chylomicron; Bolus (digestion); Glucagon-like peptide-1; Secretion; Agonist; Antagonist; Medicine; Triglyceride; Receptor; Chemistry; Type 2 diabetes; Diabetes mellitus; Cholesterol; Lipoprotein; Very low-density lipoprotein","score_opus":0.03363690339051789,"score_gpt":0.2965166200710969,"score_spread":0.262879716680579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158979900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945178,0.00085172453,0.00023618361,0.0024470456,0.00030767804,0.00088699703,0.000056756246,0.000090015485,0.00060578086],"genre_scores_gemma":[0.97797614,0.013547198,0.0017267318,0.0054787523,0.00021685396,0.00031248265,0.0005305404,0.00003181577,0.0001794623],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980813,0.00011757837,0.00036230616,0.00080242817,0.000111926136,0.00052445754],"domain_scores_gemma":[0.99919707,0.00008047886,0.00010958302,0.0003076802,0.00012428129,0.00018091127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022099642,0.00032964707,0.0007101131,0.00006519786,0.0002124904,0.00004920184,0.00010141225,0.00025109723,0.00046692803],"category_scores_gemma":[0.00003415646,0.0002500238,0.00039941832,0.00013736526,0.00014062965,0.00008315939,0.00018971412,0.00012549346,0.0000640702],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027342474,0.00064701535,0.008987123,0.00007839475,0.001118257,4.3613562e-7,0.00016349432,4.609431e-7,0.9813073,0.0006375638,0.0031180934,0.0039144806],"study_design_scores_gemma":[0.005187993,0.002581339,0.8325869,0.00010418068,0.0015034843,0.000001460376,0.00022739939,0.000494546,0.026244095,0.00054531806,0.13006237,0.00046091608],"about_ca_topic_score_codex":0.000007505256,"about_ca_topic_score_gemma":0.0000057564175,"teacher_disagreement_score":0.9550632,"about_ca_system_score_codex":0.000059256232,"about_ca_system_score_gemma":0.000035961064,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W3159023833","doi":"10.1186/s12933-021-01281-y","title":"From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes","year":2021,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Type 2 diabetes; Metformin; Diabetes mellitus; Disease; Intensive care medicine; Population; Internal medicine; Endocrinology","score_opus":0.055921479837071006,"score_gpt":0.31302988211367816,"score_spread":0.25710840227660714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159023833","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006339642,0.98549265,0.00050552835,0.00003717105,0.0007752016,0.0062443954,0.00035806134,0.00009571879,0.00015165225],"genre_scores_gemma":[0.0015315186,0.986376,0.0010017548,0.00011944869,0.0007893885,0.004731836,0.005046616,0.000210719,0.00019272369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99590206,0.00029655983,0.0008778595,0.0013679452,0.0005132493,0.0010422998],"domain_scores_gemma":[0.9958489,0.00067008677,0.0002677819,0.0025617888,0.00022237719,0.00042910047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042534788,0.0009919349,0.006231363,0.00034360262,0.00016136789,0.00006148136,0.0004574535,0.00035348846,0.000063175285],"category_scores_gemma":[0.00019845224,0.00067094533,0.0060316045,0.0006704456,0.00015194378,0.000053662046,0.00024968848,0.00017472253,0.00003939641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020855545,0.0006928988,0.00039110813,0.009944219,0.05388903,0.000034791177,0.00018837664,0.00018834928,0.0000017570906,0.000018988629,0.0010144304,0.9336152],"study_design_scores_gemma":[0.0016488404,0.00041891972,0.00012947599,0.0023139247,0.0604644,7.3659714e-7,0.00010155415,0.00029467023,0.00007241947,0.00001927672,0.9340105,0.00052529],"about_ca_topic_score_codex":0.000022686963,"about_ca_topic_score_gemma":6.42112e-7,"teacher_disagreement_score":0.9330899,"about_ca_system_score_codex":0.00046715108,"about_ca_system_score_gemma":0.00026383574,"threshold_uncertainty_score":0.9995742},"labels":[],"label_agreement":null},{"id":"W3159134974","doi":"10.1210/jendso/bvab048.051","title":"Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"","keywords":"Semaglutide; Tolerability; Medicine; Placebo; Cmax; Adverse effect; Clinical endpoint; Internal medicine; Pharmacodynamics; Randomized controlled trial; Pharmacology; Pharmacokinetics; Endocrinology; Type 2 diabetes; Liraglutide; Diabetes mellitus","score_opus":0.010887400401939008,"score_gpt":0.2618362265112082,"score_spread":0.25094882610926916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159134974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99108917,0.00053238746,0.00094615587,0.005639129,0.00015038927,0.0006578571,0.000024050345,0.0000053794333,0.00095548894],"genre_scores_gemma":[0.98149616,0.00042028032,0.016686844,0.00016723387,0.00005711056,0.0000056171084,0.000005365683,0.000009360474,0.0011520615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897313,0.00003482164,0.00049149094,0.00011006046,0.0002629067,0.00012760353],"domain_scores_gemma":[0.99888426,0.00013281924,0.00043877,0.00022399703,0.00026383417,0.000056327368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027359903,0.00010649113,0.00040179782,0.00001720958,0.00004465218,0.000006461069,0.00007158968,0.000017510447,0.000016206623],"category_scores_gemma":[0.000056637546,0.00006187611,0.0003251994,0.0001060863,0.00009504682,0.000049466154,0.00007049923,0.00008811378,8.413828e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020329416,0.009810422,0.7644244,0.013257736,0.02451161,0.0006071936,0.0042160824,0.0005657282,0.046865445,0.011908316,0.030174274,0.07332941],"study_design_scores_gemma":[0.050005924,0.005023562,0.63709056,0.0018017135,0.006488971,0.0005806633,0.006699591,0.0018198444,0.22012006,0.0011031167,0.068887815,0.00037818175],"about_ca_topic_score_codex":0.0000024880583,"about_ca_topic_score_gemma":0.000008833148,"teacher_disagreement_score":0.17325461,"about_ca_system_score_codex":0.00007320504,"about_ca_system_score_gemma":0.00008256814,"threshold_uncertainty_score":0.25232345},"labels":[],"label_agreement":null},{"id":"W3159474548","doi":"10.1111/dom.14411","title":"Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; Diabetes Canada","keywords":"Dapagliflozin; Tubuloglomerular feedback; Renal function; Urology; Medicine; Internal medicine; Endocrinology; Placebo; Creatinine; Blood pressure; Chemistry; Cardiology; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.01623434562228844,"score_gpt":0.2629193872096659,"score_spread":0.24668504158737747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159474548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932224,0.000848005,0.00041251493,0.0010087984,0.00013399376,0.003994337,0.00020300898,0.000061702995,0.000115218],"genre_scores_gemma":[0.9964521,0.00016464318,0.0009908982,0.0007416233,0.0000836835,0.00055716705,0.00045646925,0.000023572638,0.00052986667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99571455,0.0015742918,0.0012079468,0.00059021194,0.0005394208,0.0003736102],"domain_scores_gemma":[0.9974689,0.0009991223,0.0004425025,0.0005363381,0.00025774052,0.00029540548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064637004,0.000375306,0.005477259,0.0008962566,0.00010302088,0.00007150112,0.00007979736,0.00014659186,0.00018641539],"category_scores_gemma":[0.001879845,0.00023494134,0.0012227256,0.000603295,0.000104419996,0.00016948092,0.000047457143,0.0001481693,0.0000061742526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3627544,0.0026485021,0.004241615,0.00021229225,0.020266123,0.0001260811,0.00075993413,0.000098971985,0.59152466,0.0038996118,0.000012033362,0.013455794],"study_design_scores_gemma":[0.31053662,0.00042931535,0.16731109,0.00029391728,0.042827733,4.6251955e-7,0.000103906736,0.0021770578,0.4747905,0.00094487134,0.0002128858,0.0003716431],"about_ca_topic_score_codex":0.000053143463,"about_ca_topic_score_gemma":0.00043618664,"teacher_disagreement_score":0.16306947,"about_ca_system_score_codex":0.000038973787,"about_ca_system_score_gemma":0.000083942956,"threshold_uncertainty_score":0.958063},"labels":[],"label_agreement":null},{"id":"W3159606901","doi":"10.1210/jendso/bvab048.949","title":"A Point-of-Care Interactive Decision Tool Reveals Variance Between Clinicians and Experts in Selecting Among GLP-1 RAs in T2D","year":2021,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CARE Canada","funders":"","keywords":"Competence (human resources); Medicine; Glycemic; Decision aids; Family medicine; Diabetes mellitus; Alternative medicine; Psychology; Pathology; Social psychology","score_opus":0.012416353950030825,"score_gpt":0.3122473585684871,"score_spread":0.2998310046184563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159606901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967411,0.0009925549,0.00010287197,0.0013964222,0.0001823119,0.0002171463,0.0000019111221,0.0000034640161,0.00036218556],"genre_scores_gemma":[0.99450386,0.00047170595,0.0042524985,0.00031768042,0.00014754108,0.0000037956465,0.0000014902466,0.000011467448,0.0002899539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998785,0.00009509316,0.0005768137,0.00013750796,0.00022655762,0.00017900084],"domain_scores_gemma":[0.9988311,0.0004591574,0.0003568539,0.0001557682,0.00015449169,0.000042648662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038099213,0.000109330016,0.00045397918,0.00005420443,0.000032518656,0.000016876982,0.0000910627,0.00003407342,0.000017007475],"category_scores_gemma":[0.00055282464,0.000074856274,0.00027202407,0.00029400722,0.000033435677,0.00017591612,0.00014660554,0.000311414,3.090094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010528401,0.00016695399,0.9637753,0.000099829165,0.00026703806,0.0001375827,0.0052288813,0.000020740401,0.000846576,0.00001543429,0.0017125405,0.027623843],"study_design_scores_gemma":[0.005452459,0.00036363117,0.967988,0.0029326528,0.00025910107,0.000057041892,0.014809657,0.000077068304,0.0060511595,0.0006047463,0.001290563,0.000113886206],"about_ca_topic_score_codex":0.00002113774,"about_ca_topic_score_gemma":0.000043307085,"teacher_disagreement_score":0.027509958,"about_ca_system_score_codex":0.0002031597,"about_ca_system_score_gemma":0.000068178975,"threshold_uncertainty_score":0.30525503},"labels":[],"label_agreement":null},{"id":"W3159780534","doi":"10.1101/2021.03.17.21253796","title":"SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Calgary; Sinai Health System; University of Toronto","funders":"","keywords":"Diabetic ketoacidosis; Medicine; Randomized controlled trial; Observational study; Relative risk; Meta-analysis; Internal medicine; Diabetes mellitus; Placebo; Hazard ratio; Confidence interval; Insulin; Endocrinology","score_opus":0.02420167206124131,"score_gpt":0.26867807662310406,"score_spread":0.24447640456186276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159780534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001336717,0.99303085,0.0000012653792,0.00010224788,0.000023362662,0.0053096553,0.00003287626,0.000023202108,0.00013980219],"genre_scores_gemma":[0.0018594817,0.9957169,0.00006450856,0.0001406629,0.000015245321,0.0013164672,0.0000879346,0.000050857303,0.0007479118],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99658555,0.0010044329,0.0011052364,0.0005927868,0.00043865052,0.0002733325],"domain_scores_gemma":[0.99668103,0.00073633046,0.0011611353,0.0011007992,0.00017489257,0.00014581945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014838394,0.000604306,0.011981891,0.00029971605,0.00006214221,0.00004322332,0.000157544,0.000115231735,0.00011894399],"category_scores_gemma":[0.000520309,0.00024908473,0.0018979759,0.0015690038,0.0003132666,0.000050135463,0.00015059292,0.00024120302,0.000006836814],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034942414,0.000050530358,0.00199069,0.68051124,0.3159089,0.000009832207,0.000056150137,6.1806496e-8,5.038206e-9,0.000011598868,0.00005465215,0.0014028489],"study_design_scores_gemma":[0.00046814885,0.0001283345,0.00010570317,0.121171914,0.8753971,0.0000019893735,0.000032855212,0.0000053144827,6.576419e-7,0.0000017836738,0.002491632,0.00019459418],"about_ca_topic_score_codex":0.000023470258,"about_ca_topic_score_gemma":0.000023526285,"teacher_disagreement_score":0.5594882,"about_ca_system_score_codex":0.000030187068,"about_ca_system_score_gemma":0.00004472003,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W3160819927","doi":"10.1016/j.jpeds.2021.05.009","title":"Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis","year":2021,"lang":"en","type":"article","venue":"The Journal of Pediatrics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Jewish General Hospital","funders":"Public Health Agency","keywords":"Medicine; Internal medicine; Liraglutide; Body mass index; Glycated hemoglobin; Insulin resistance; Adverse effect; Glucagon-like peptide 1 receptor; Endocrinology; Exenatide; Obesity; Weight loss; Childhood obesity; Weight management; Gastroenterology; Diabetes mellitus; Type 2 diabetes; Overweight; Receptor; Agonist","score_opus":0.013224923559184835,"score_gpt":0.24429966939719705,"score_spread":0.2310747458380122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160819927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98992085,0.0091653485,0.00008391289,0.00055714237,0.000023756214,0.000177909,0.00000782531,0.0000028571044,0.00006038032],"genre_scores_gemma":[0.9919523,0.006886015,0.0006478066,0.00012221235,0.00007143754,5.1350247e-7,0.0000075185917,0.000009317837,0.0003028865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989335,0.000106547595,0.0003818927,0.00011091368,0.00033371555,0.00013346081],"domain_scores_gemma":[0.999155,0.00008412834,0.00033701502,0.00018727634,0.00014040277,0.00009616596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005947669,0.00012510804,0.00072628644,0.00024350203,0.000034632485,0.000015893942,0.00007112701,0.000033478307,0.000025096917],"category_scores_gemma":[0.00005673122,0.00006873903,0.00020282636,0.0006431904,0.000051170395,0.00006181693,0.0000711542,0.0001557239,9.457712e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062620366,0.000669267,0.9831924,0.00014921502,0.013445388,0.000041902098,0.0004427612,0.00008596282,0.000042514148,0.000012859285,0.0002999799,0.0009915913],"study_design_scores_gemma":[0.0029578004,0.00032464773,0.79994476,0.00001977629,0.19634181,0.000039606508,0.000117073454,0.000004320264,0.00009599808,0.000009192868,0.00007663905,0.00006837497],"about_ca_topic_score_codex":0.000022946208,"about_ca_topic_score_gemma":0.000026964219,"teacher_disagreement_score":0.1832476,"about_ca_system_score_codex":0.000031655578,"about_ca_system_score_gemma":0.00006576983,"threshold_uncertainty_score":0.28030962},"labels":[],"label_agreement":null},{"id":"W3161227007","doi":"10.1161/circ.142.suppl_3.15586","title":"Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Dulaglutide; Mace; Hazard ratio; Internal medicine; Myocardial infarction; Type 2 diabetes; Unstable angina; Diabetes mellitus; Placebo; Proportional hazards model; Cardiology; Liraglutide; Confidence interval; Endocrinology; Percutaneous coronary intervention","score_opus":0.016376179329470504,"score_gpt":0.21682674228989543,"score_spread":0.20045056296042493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161227007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970873,0.0015159468,0.000060512124,0.000093179166,0.000018845598,0.001086546,0.000052975647,0.000033073055,0.000051608968],"genre_scores_gemma":[0.99920285,0.000111028654,0.000073408024,0.00002055603,0.00006053987,0.000021574595,0.0004818127,0.000022438597,0.0000058133514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864495,0.00008598248,0.00025657236,0.00037807648,0.00045824703,0.00017618747],"domain_scores_gemma":[0.9991036,0.00013863876,0.00011588652,0.00047004363,0.00008983207,0.00008201555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018702178,0.00021209655,0.00089345087,0.00012863388,0.000052736745,0.00003128856,0.000065199296,0.00006404602,0.00003848266],"category_scores_gemma":[0.00010953384,0.00011167873,0.00040451405,0.00083224464,0.00005075464,0.00011316596,0.000025864289,0.000098604396,0.00000232906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003030021,0.000062258274,0.9468507,0.000036064597,0.030419013,0.000022637267,0.0013905319,0.01574854,0.00005345501,0.000001001804,0.0000033641227,0.0023824174],"study_design_scores_gemma":[0.016301021,0.00060363614,0.96217054,0.00004028413,0.01845821,2.202874e-7,0.00090731913,0.001171219,0.00012227775,0.0000016564203,0.00008440781,0.0001392323],"about_ca_topic_score_codex":0.00377187,"about_ca_topic_score_gemma":0.00028037815,"teacher_disagreement_score":0.015319819,"about_ca_system_score_codex":0.000047437217,"about_ca_system_score_gemma":0.000040582956,"threshold_uncertainty_score":0.5701964},"labels":[],"label_agreement":null},{"id":"W3161790736","doi":"10.1161/circ.142.suppl_3.12923","title":"Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Copeptin; Hazard ratio; Framingham Risk Score; TIMI; Biomarker; Heart failure; Alogliptin; Cardiology; Myocardial infarction; Proportional hazards model; Type 2 diabetes; Dapagliflozin; Natriuretic peptide; Placebo; Diabetes mellitus; Confidence interval; Disease; Endocrinology; Thrombolysis; Pathology","score_opus":0.02679054394714121,"score_gpt":0.2378445993665478,"score_spread":0.2110540554194066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161790736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669164,0.000011645885,0.0017991504,0.00034307555,0.000016023489,0.0010612602,0.000013885587,0.000023040768,0.000040289768],"genre_scores_gemma":[0.98748344,8.462896e-8,0.011917697,0.00013644698,0.000010597616,0.00006283913,0.00037395654,0.000013648775,0.0000012588681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993352,0.0000047890317,0.00020197529,0.00016936037,0.00016224897,0.00012640818],"domain_scores_gemma":[0.999659,0.000028856319,0.00010109151,0.00008990238,0.00006799158,0.000053148677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007481348,0.000094230454,0.00017396845,0.0000839092,0.000025703503,0.0000065010036,0.000024429699,0.000033785698,0.000014077203],"category_scores_gemma":[0.0000391647,0.00007772046,0.000038549253,0.00016012364,0.0000143529005,0.000057238783,0.0000074874315,0.000030653442,0.0000030644437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013573786,0.00041695297,0.99002707,0.00026648722,0.00008130133,1.3424777e-7,0.00011672961,0.00030078512,0.0018497867,0.000007432474,0.00008597083,0.0067116353],"study_design_scores_gemma":[0.0062550968,0.00014098304,0.98829293,0.0001617998,0.000076286866,4.4635837e-9,0.000016483022,0.0030183797,0.0015131269,0.0000041083345,0.0004415173,0.00007929864],"about_ca_topic_score_codex":0.000002654595,"about_ca_topic_score_gemma":0.000008824186,"teacher_disagreement_score":0.010118547,"about_ca_system_score_codex":0.000057599787,"about_ca_system_score_gemma":0.000051066945,"threshold_uncertainty_score":0.31693485},"labels":[],"label_agreement":null},{"id":"W3162129360","doi":"10.1161/circ.142.suppl_3.14799","title":"Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Mace; TIMI; Internal medicine; Myocardial infarction; Cardiology; Framingham Risk Score; Diabetes mellitus; Population; Type 2 diabetes; Disease; Thrombolysis; Conventional PCI; Endocrinology","score_opus":0.020599719632981666,"score_gpt":0.23079991787115833,"score_spread":0.21020019823817668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162129360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966714,0.0009546399,0.00002737328,0.00011189896,0.0000497824,0.0018866173,0.000005004013,0.000016677317,0.000276612],"genre_scores_gemma":[0.9995597,0.00007710636,0.000059300975,0.000061183564,0.0000384448,0.00003743074,0.00015168882,0.000014300428,8.5702067e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863493,0.000121816985,0.00029358143,0.00029450076,0.00051153416,0.00014365054],"domain_scores_gemma":[0.9992904,0.00010244094,0.00009655988,0.00041043144,0.00005604992,0.000044096258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044262203,0.00014717,0.00045609608,0.00010675878,0.00002997317,0.000020841557,0.000061855564,0.00006227122,0.0000064819974],"category_scores_gemma":[0.00017738018,0.000099099925,0.00018308342,0.00030458972,0.000032248303,0.00008985496,0.000010871051,0.00011903394,0.0000052085206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014900183,0.00051994744,0.9480243,0.0000917894,0.0012421801,0.0000041139942,0.0005170918,0.0073027182,0.000017345787,0.00005687669,0.000008944003,0.040724687],"study_design_scores_gemma":[0.025782704,0.00044949804,0.97225475,0.000053938944,0.00073433435,3.1409705e-8,0.000061458166,0.0002987174,0.00006834477,0.00002393612,0.00017882259,0.00009345513],"about_ca_topic_score_codex":0.000043050615,"about_ca_topic_score_gemma":0.000005510694,"teacher_disagreement_score":0.040631235,"about_ca_system_score_codex":0.000052404797,"about_ca_system_score_gemma":0.000020097701,"threshold_uncertainty_score":0.4041178},"labels":[],"label_agreement":null},{"id":"W3162978132","doi":"10.1111/pedi.13234","title":"Use of glucagon‐like peptide‐1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives","year":2021,"lang":"en","type":"article","venue":"Pediatric Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pediatric Endocrine Society","keywords":"Liraglutide; Medicine; Medical prescription; Pediatric endocrinology; Obesity; Diabetes mellitus; Endocrine system; Childhood obesity; Type 2 diabetes; Glucagon-like peptide-1; Intensive care medicine; Internal medicine; Endocrinology; Family medicine; Pharmacology; Hormone","score_opus":0.010566507270751736,"score_gpt":0.2125412900831931,"score_spread":0.20197478281244138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162978132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927619,0.0043205027,0.000010544338,0.00057410443,0.00020548314,0.0017778907,0.00011718959,0.00007658364,0.00015581651],"genre_scores_gemma":[0.99338984,0.00091226195,0.0027932506,0.00031602697,0.00048158073,0.00032029743,0.00022000469,0.000062728126,0.0015040147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979013,0.00007614426,0.00037643852,0.0006166878,0.00044203547,0.0005873485],"domain_scores_gemma":[0.99771416,0.0007241735,0.00026837853,0.0005088943,0.00059484015,0.00018954271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021726533,0.00035620623,0.0005813059,0.00019932323,0.00019546834,0.00011265218,0.00012917569,0.00009314816,0.000045445664],"category_scores_gemma":[0.00048761934,0.0002377335,0.00019169392,0.0006138171,0.00014368001,0.00033943338,0.00015457782,0.00014284122,0.000008636523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060328326,0.0011458815,0.98733103,0.0008677094,0.00036505624,0.0000016521242,0.00051194726,0.0000021415192,0.00003388803,0.00011481668,0.007965177,0.0016003482],"study_design_scores_gemma":[0.0035144133,0.0013934706,0.9844081,0.00004778811,0.0032950386,1.4992827e-7,0.0006512021,0.00005363025,0.0007185292,0.000074716845,0.0054558227,0.00038713135],"about_ca_topic_score_codex":0.000009721546,"about_ca_topic_score_gemma":0.0000075544654,"teacher_disagreement_score":0.003454085,"about_ca_system_score_codex":0.00008053067,"about_ca_system_score_gemma":0.00018434701,"threshold_uncertainty_score":0.9694491},"labels":[],"label_agreement":null},{"id":"W3163025274","doi":"10.2337/dci20-0076","title":"Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes","year":2021,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Glucagon-like peptide-1; Endocrinology; Glucagon-like peptide 1 receptor; Receptor; Agonist; Cardiology; Type 2 diabetes","score_opus":0.015135348075858255,"score_gpt":0.2205781086085961,"score_spread":0.20544276053273786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163025274","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5567636,0.09894015,0.0000073858605,0.30616733,0.008643655,0.0079873055,0.0026104895,0.0014414203,0.017438661],"genre_scores_gemma":[0.029455392,0.007042261,0.0022978385,0.8834656,0.005994577,0.0017928155,0.032115687,0.00087941583,0.036956415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963418,0.00013810306,0.0004364757,0.0012281984,0.00090034644,0.00095506007],"domain_scores_gemma":[0.9976441,0.00010827658,0.00013746478,0.001648366,0.0002545155,0.00020727266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014150867,0.0008870744,0.0020144344,0.000226727,0.00016925087,0.00020517418,0.00023707293,0.00074840325,0.0002486193],"category_scores_gemma":[0.000059544684,0.00077240885,0.0014187428,0.00022010869,0.0001628733,0.000095092495,0.00033472167,0.00095065456,0.00031373496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000013412239,0.00003542852,0.41094834,0.0016654741,0.004921535,0.00004429858,0.00025093442,6.816332e-7,0.000058990663,0.0000022991337,0.5797989,0.0022718376],"study_design_scores_gemma":[0.0015998854,0.00019534251,0.05449028,0.0008458996,0.0040805745,0.0000016069293,0.0005709538,9.660002e-7,0.00076937507,0.000003058359,0.9367442,0.0006978756],"about_ca_topic_score_codex":0.00004076124,"about_ca_topic_score_gemma":0.0000066527914,"teacher_disagreement_score":0.5772982,"about_ca_system_score_codex":0.00028928206,"about_ca_system_score_gemma":0.00011224267,"threshold_uncertainty_score":0.9994727},"labels":[],"label_agreement":null},{"id":"W3163402894","doi":"10.1111/dom.14443","title":"Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; Canadian Institutes of Health Research; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Liraglutide; Semaglutide; Medicine; Mediation; Exploratory analysis; Type 2 diabetes; Endocrinology; Diabetes mellitus","score_opus":0.006874194599851394,"score_gpt":0.20026230806813572,"score_spread":0.19338811346828433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163402894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944964,0.0029076098,0.0005539418,0.0011514529,0.00010961253,0.00038133594,0.000016610651,0.00008032456,0.0003027273],"genre_scores_gemma":[0.99617624,0.0006285839,0.0012208835,0.0008706507,0.00014615383,0.00007871394,0.00017400997,0.00001636441,0.0006883677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882406,0.00007727197,0.00017192082,0.00040103306,0.0002577045,0.00026802835],"domain_scores_gemma":[0.9992435,0.000015482154,0.00007933892,0.00023464592,0.00014085128,0.0002861649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020634386,0.00019324668,0.00046360499,0.00025202343,0.0001489145,0.00006956157,0.000027967228,0.00007791673,0.000055986206],"category_scores_gemma":[0.00007647942,0.00015714008,0.00009121941,0.0005930568,0.00007945401,0.000193739,0.00006850443,0.00011500548,0.0000072584144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014658476,0.001219632,0.90560365,0.0008595593,0.009695893,0.00018978439,0.0010748772,0.00007121302,0.02764767,0.0015823655,0.0008483292,0.051060457],"study_design_scores_gemma":[0.002438986,0.00011813277,0.95954347,0.000051558884,0.00724599,0.00000433672,0.00018358688,0.0011540969,0.017661802,0.00025596775,0.011084911,0.00025717117],"about_ca_topic_score_codex":0.000015304226,"about_ca_topic_score_gemma":0.000021837288,"teacher_disagreement_score":0.053939827,"about_ca_system_score_codex":0.000020549092,"about_ca_system_score_gemma":0.00006133568,"threshold_uncertainty_score":0.6407986},"labels":[],"label_agreement":null},{"id":"W3163431844","doi":"10.1136/bmj.n1091","title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","year":2021,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ted Rogers Centre for Heart Research; Impact","funders":"","keywords":"Medicine; Type 2 diabetes; Glucagon-like peptide 1 receptor; Metformin; Diabetes mellitus; Internal medicine; Guideline; Kidney disease; Pharmacology; Liraglutide; Endocrinology; Type 2 Diabetes Mellitus; Disease; Intensive care medicine; Agonist; Receptor","score_opus":0.0848157208162114,"score_gpt":0.4503752030066565,"score_spread":0.3655594821904451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163431844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008219679,0.98451906,0.000027385695,0.002458529,0.0016957211,0.0069097276,0.0000705094,0.0001257623,0.004185052],"genre_scores_gemma":[3.9614545e-7,0.92005634,0.05342926,0.0019937605,0.0031740826,0.0012419409,0.003487523,0.00015173142,0.016464936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962009,0.0002199746,0.0017472458,0.00086191425,0.00046408334,0.0005058759],"domain_scores_gemma":[0.9959792,0.001118061,0.0009745745,0.00091501296,0.0007299898,0.00028320073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001310519,0.0005945318,0.0027610038,0.00013834532,0.0000684084,0.00006894758,0.000182207,0.00039279088,0.0004021105],"category_scores_gemma":[0.0044572675,0.0003544394,0.0007190638,0.0005244187,0.00007388302,0.00010953322,0.00015106889,0.00035352452,0.00041240393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029075865,0.0004447752,0.000012399167,0.00862402,0.0016744281,0.000103360755,0.000013520326,3.188429e-8,1.9895689e-8,0.000016470609,0.44233856,0.54648167],"study_design_scores_gemma":[0.0025384116,0.0031180244,0.0000012329338,0.03847686,0.009680907,0.00002235906,0.00009868998,0.000004956566,9.91428e-7,8.4983384e-7,0.94564754,0.00040915966],"about_ca_topic_score_codex":0.000006157706,"about_ca_topic_score_gemma":0.0000101995865,"teacher_disagreement_score":0.5460725,"about_ca_system_score_codex":0.00019060227,"about_ca_system_score_gemma":0.0012132893,"threshold_uncertainty_score":0.99989074},"labels":[],"label_agreement":null},{"id":"W3164307722","doi":"10.1053/j.ajkd.2021.05.005","title":"Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial","year":2021,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; National Health and Medical Research Council; Medical Research Council; Novo Nordisk; Daiichi Sankyo Europe; Kidney Foundation of Canada; Gilead Sciences; Servier; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Pfizer; ZOLL Medical Corporation; Eli Lilly and Company; AstraZeneca; University of Washington; GlaxoSmithKline","keywords":"Medicine; Canagliflozin; Credence; Type 2 diabetes; Randomized controlled trial; Kidney disease; Adverse effect; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.006211430291258336,"score_gpt":0.24185154096376696,"score_spread":0.23564011067250862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164307722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886862,0.003090479,0.0000028707616,0.0074253147,0.00026756834,0.00037907498,0.000037505994,0.000008052806,0.00010295013],"genre_scores_gemma":[0.99253607,0.0020871537,0.0002105392,0.0047757807,0.000095188465,0.00001189307,0.000046548234,0.000014275976,0.00022252461],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986785,0.00026049523,0.00042425713,0.0001776271,0.0002600357,0.0001990765],"domain_scores_gemma":[0.998173,0.00053309614,0.0002634382,0.00015109363,0.000090748756,0.00078862405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027713852,0.00015420532,0.0007203901,0.000098509656,0.000050598614,0.00001578431,0.00008062524,0.000021945321,0.0001585805],"category_scores_gemma":[0.0050715962,0.000097908,0.00015074945,0.00030338345,0.00029974026,0.00011763878,0.00006504801,0.00013104638,0.0000023604828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15442584,0.00082863856,0.8054207,0.00007250171,0.003162605,0.0004724284,0.0010207869,0.0000047061953,0.00034191416,0.00007312518,0.018268319,0.015908444],"study_design_scores_gemma":[0.7431526,0.0016825778,0.23940404,0.0016746992,0.0055250386,0.000018139639,0.002314279,0.00020844094,0.0001904438,0.00084297295,0.004652249,0.00033449128],"about_ca_topic_score_codex":0.00018024354,"about_ca_topic_score_gemma":0.0000063871134,"teacher_disagreement_score":0.58872676,"about_ca_system_score_codex":0.00004932993,"about_ca_system_score_gemma":0.00048723322,"threshold_uncertainty_score":0.6071541},"labels":[],"label_agreement":null},{"id":"W3164598916","doi":"10.3390/ijms22115819","title":"A Computational Model of Kidney Function in a Patient with Diabetes","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Tubuloglomerular feedback; Nephron; Renal function; Glomerular hyperfiltration; Diabetes mellitus; Macula densa; Internal medicine; Kidney; Endocrinology; Kidney disease; Renal Hypertrophy; Loop of Henle; Medicine; Chemistry; Urology; Blood pressure; Renin–angiotensin system; Diabetic nephropathy","score_opus":0.026507087734779392,"score_gpt":0.30695548612201456,"score_spread":0.2804483983872352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164598916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006625169,0.9892094,0.0022350554,0.00035956522,0.0002851719,0.00024661573,0.000014561803,0.000003445731,0.0010210305],"genre_scores_gemma":[0.020930503,0.9518069,0.025736896,0.0012078697,0.00007105492,0.000028293407,0.0001080691,0.000028071385,0.00008231918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809563,0.00004827279,0.00055993174,0.00015938099,0.0010293954,0.00010738742],"domain_scores_gemma":[0.9987493,0.000046097117,0.00062468316,0.00006551332,0.00042126336,0.00009311887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025633886,0.00014224587,0.0006508929,0.00063358026,0.0000126432515,0.000036127647,0.00021224236,0.000042855234,0.000021016083],"category_scores_gemma":[0.00008553183,0.00009252299,0.00027020153,0.00030205975,0.00009932039,0.0001083086,0.00005809951,0.00012243152,0.0000011221852],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047527366,0.0008500851,0.00043711026,0.0013614433,0.0022607492,0.00084874936,0.00011651201,0.025709078,0.000023319906,0.0026216086,0.0005003971,0.96522343],"study_design_scores_gemma":[0.009675301,0.012015407,0.00016435079,0.24959633,0.010170303,0.0011859327,0.0005607267,0.048293196,0.00043155678,0.0056488123,0.6607513,0.0015068348],"about_ca_topic_score_codex":0.000001539896,"about_ca_topic_score_gemma":4.8889825e-7,"teacher_disagreement_score":0.96371657,"about_ca_system_score_codex":0.00011286932,"about_ca_system_score_gemma":0.001188693,"threshold_uncertainty_score":0.3772978},"labels":[],"label_agreement":null},{"id":"W3165615499","doi":"10.1097/mnh.0000000000000724","title":"Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Cotransporter; Sodium; Medicine; Endocrinology; Diabetes mellitus; Internal medicine; Chemistry","score_opus":0.05808444666678969,"score_gpt":0.33220905272026274,"score_spread":0.27412460605347305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165615499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002301122,0.9896904,0.0000111175505,0.00076240057,0.0044740187,0.0025649932,0.000059385206,0.0000652333,0.00007132932],"genre_scores_gemma":[0.00066154223,0.98601294,0.00004498664,0.0009786651,0.0005111617,0.0006936092,0.010941088,0.00008700568,0.000068995876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964154,0.00026778813,0.001151776,0.0011132247,0.00034632374,0.0007055323],"domain_scores_gemma":[0.9983162,0.000100073186,0.00027004158,0.00074121065,0.00009739333,0.00047507999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002809386,0.0007336151,0.0026572093,0.0010358499,0.00005270786,0.000024896613,0.00011326716,0.00046978318,0.00020891547],"category_scores_gemma":[0.00007857903,0.00062023994,0.0006272458,0.0007281175,0.00013473594,0.00012417969,0.00015333352,0.000833851,0.00020788386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001668071,0.0036370489,0.0018142421,0.047505014,0.00028971653,0.0012168804,0.00006663753,0.0000022467705,0.00001634499,0.0001400763,0.04688689,0.8982581],"study_design_scores_gemma":[0.0035448533,0.00017812938,0.0024948982,0.062054116,0.0014435162,0.000040768446,0.0000075467715,0.00008574879,0.0000019370543,0.00003801628,0.9296556,0.00045488522],"about_ca_topic_score_codex":0.000008920773,"about_ca_topic_score_gemma":0.0000039771635,"teacher_disagreement_score":0.8978032,"about_ca_system_score_codex":0.00031348376,"about_ca_system_score_gemma":0.0005014791,"threshold_uncertainty_score":0.9996249},"labels":[],"label_agreement":null},{"id":"W3165787706","doi":"10.1002/ejhf.2220","title":"Use of diuretics and outcomes in patients with type 2 diabetes: findings from the <scp>EMPA‐REG OUTCOME</scp> trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Heart Research UK; British Heart Foundation","keywords":"Medicine; Hazard ratio; Internal medicine; Heart failure; EMPA; Diabetes mellitus; Confidence interval; Empagliflozin; Placebo; Type 2 Diabetes Mellitus; Type 2 diabetes; Cardiology; Endocrinology; Pathology","score_opus":0.020590784635069016,"score_gpt":0.23393789824415942,"score_spread":0.2133471136090904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165787706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695563,0.00021026601,0.0000022680376,0.0023415587,0.00016911853,0.00023538746,0.000010402055,0.000005388141,0.000069956615],"genre_scores_gemma":[0.99587935,0.000023766146,0.0027570813,0.00072299666,0.0000752998,5.0431646e-7,0.000016074484,0.000026493348,0.0004984184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869794,0.00020427254,0.00045536403,0.00012828787,0.00033849545,0.00017564531],"domain_scores_gemma":[0.99898857,0.00033473238,0.00018543622,0.00021505072,0.00017972736,0.000096500844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032054624,0.00014439659,0.0004562556,0.00007706685,0.000032367952,0.00004631775,0.00008018235,0.00002188405,0.000025260262],"category_scores_gemma":[0.00057799876,0.00007963821,0.00009775615,0.00016639469,0.00006093576,0.00012528642,0.00007578217,0.00022927702,0.000008985099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033658036,0.00031286653,0.9865497,0.000017967752,0.00028177415,0.00008174911,0.00031715265,0.000003920861,0.00007514765,0.000007851242,0.01162012,0.0003951648],"study_design_scores_gemma":[0.019938074,0.0018015532,0.92189854,0.00022416229,0.0002924779,0.0000015173206,0.00020161149,0.0000016720087,0.00019065387,0.0000054506945,0.055409692,0.000034598943],"about_ca_topic_score_codex":0.0000021152368,"about_ca_topic_score_gemma":0.0000059494546,"teacher_disagreement_score":0.06465117,"about_ca_system_score_codex":0.000021951999,"about_ca_system_score_gemma":0.000033155862,"threshold_uncertainty_score":0.32475516},"labels":[],"label_agreement":null},{"id":"W3166709082","doi":"10.1016/j.ekir.2021.05.022","title":"Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes","year":2021,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Ottawa; Ottawa Hospital; Heart and Stroke Foundation; Sinai Health System; University Health Network; Toronto General Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Department of Medicine, University of Toronto; Merck; Pfizer Canada; University of Toronto; Diabetes Canada","keywords":"Medicine; Renal function; Creatinine; Kidney disease; Internal medicine; Diabetes mellitus; Placebo; Biomarker; Fibrosis; Albuminuria; Gastroenterology; Inflammation; Acute kidney injury; Urology; Endocrinology; Pathology","score_opus":0.003377287914606618,"score_gpt":0.20442770418895279,"score_spread":0.20105041627434617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166709082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408835,0.000028563682,0.000003111053,0.0023422262,0.0000817327,0.00026658727,0.000041618907,0.00001669369,0.003131121],"genre_scores_gemma":[0.99663085,0.000024356901,0.00047229452,0.0005012231,0.00001582544,0.000028051441,0.0008912645,0.000014341923,0.001421775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989425,0.000019573416,0.00029686576,0.00024282398,0.00037270473,0.0001255122],"domain_scores_gemma":[0.99909246,0.000034517918,0.00022190502,0.00013673224,0.00029434153,0.00022004916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013294967,0.00012163428,0.00021784545,0.00014372653,0.000018957604,0.000025928424,0.00002328405,0.000039951297,0.00008875069],"category_scores_gemma":[0.0012699094,0.000094342206,0.000020746,0.00014971603,0.000058624162,0.0001464255,0.00005390557,0.000054042892,4.4582862e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015573062,0.0001949465,0.9916713,0.000059265756,0.00053317624,0.00007721435,0.00005603407,8.366809e-7,0.00028568617,0.0000583493,0.004911146,0.0019962743],"study_design_scores_gemma":[0.0021664617,0.00033789838,0.98592305,0.00079976773,0.00015309072,0.000003670116,0.000020188934,0.00005175361,0.0033902242,0.00009156724,0.0069561373,0.000106217914],"about_ca_topic_score_codex":0.000017126651,"about_ca_topic_score_gemma":0.000012501586,"teacher_disagreement_score":0.0057483176,"about_ca_system_score_codex":0.00007794692,"about_ca_system_score_gemma":0.00016656332,"threshold_uncertainty_score":0.38471636},"labels":[],"label_agreement":null},{"id":"W3167355435","doi":"10.1096/fasebj.24.1_supplement.564.15","title":"Impact of the Mediterranean diet and weight loss on plasma cell adhesion molecule concentrations in men with the metabolic syndrome","year":2010,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Weight loss; Mediterranean diet; Medicine; Internal medicine; Endocrinology; Animal science; Obesity; Biology","score_opus":0.009181560705416862,"score_gpt":0.2378218627881341,"score_spread":0.22864030208271724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167355435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351686,0.00014330234,0.000002755894,0.002973854,0.000078734585,0.00034570973,0.0000062411873,0.0000042274423,0.0029282935],"genre_scores_gemma":[0.99919415,0.00017902574,0.0000194553,0.00011214999,0.00006126554,0.0000072287285,0.0000026703694,0.000009530275,0.00041453773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993063,0.000072863484,0.00013217589,0.00007707924,0.0002466243,0.00016493935],"domain_scores_gemma":[0.9994867,0.000072716975,0.00011316047,0.00023148085,0.000026174275,0.00006976433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002383089,0.00010780975,0.00015973936,0.000044299817,0.00013495192,0.000026250635,0.00014207166,0.000024982608,0.00009285644],"category_scores_gemma":[0.000011313162,0.000035863224,0.00007356861,0.00011844978,0.00014671776,0.000052115487,0.000031328633,0.0003270382,0.0000039548677],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003439705,0.0021027836,0.39923617,0.00006905811,0.002125664,0.0005941682,0.011350766,0.00036687244,0.5601846,0.0017874907,0.012287679,0.0064550387],"study_design_scores_gemma":[0.0075295903,0.003048787,0.825921,0.00019113613,0.00093657547,0.0004832043,0.0006007355,0.0010607274,0.15867506,0.00016800349,0.0012268763,0.00015829841],"about_ca_topic_score_codex":0.00002140245,"about_ca_topic_score_gemma":0.000033498683,"teacher_disagreement_score":0.42668483,"about_ca_system_score_codex":0.000023049164,"about_ca_system_score_gemma":0.00004651495,"threshold_uncertainty_score":0.14624597},"labels":[],"label_agreement":null},{"id":"W3167614637","doi":"10.2215/cjn.18641120","title":"Transforming the Care of Patients with Diabetic Kidney Disease","year":2021,"lang":"en","type":"review","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Diabetic nephropathy; Kidney disease; Irbesartan; Diabetes mellitus; Losartan; Nephrology; Kidney; Renin–angiotensin system; Internal medicine; Valsartan; Disease; Intensive care medicine; Endocrinology; Blood pressure","score_opus":0.0346806606514491,"score_gpt":0.3564671050238471,"score_spread":0.321786444372398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167614637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027385578,0.96806353,0.000025518211,0.0032784347,0.00024167834,0.00088223355,0.00006967586,0.0000042212687,0.000049104343],"genre_scores_gemma":[0.002956259,0.9871337,0.00053306913,0.009034473,0.00020698,0.000010390239,0.000033735185,0.00003393222,0.00005749129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997347,0.00045372633,0.001343046,0.00019505866,0.00042743704,0.00023371908],"domain_scores_gemma":[0.9953278,0.0007273885,0.0027920352,0.00054369186,0.00036570508,0.00024342976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041303504,0.000260683,0.0029368233,0.000034919412,0.000051114224,0.00000503826,0.0004872909,0.00009576807,0.00002493601],"category_scores_gemma":[0.0001391755,0.000111785805,0.0034716125,0.00034572752,0.0017073902,0.000027659957,0.00013225821,0.0006322484,8.853691e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024046838,0.00080020813,0.016241416,0.0048160413,0.006320489,0.000012000058,0.00021263919,0.0000010624626,3.498225e-7,0.000013122718,0.020680163,0.950662],"study_design_scores_gemma":[0.0015818329,0.0019986718,0.009707755,0.005611605,0.01581904,0.000004648791,0.00029860684,7.457923e-7,4.4597584e-7,0.000009137661,0.96486646,0.00010105657],"about_ca_topic_score_codex":0.000003441686,"about_ca_topic_score_gemma":4.1831242e-7,"teacher_disagreement_score":0.950561,"about_ca_system_score_codex":0.000068295245,"about_ca_system_score_gemma":0.0008543621,"threshold_uncertainty_score":0.629095},"labels":[],"label_agreement":null},{"id":"W3168679049","doi":"10.1111/dom.14468","title":"Use of once‐weekly semaglutide in patients with type <scp>2</scp> diabetes in routine clinical practice: Results from the <scp>SURE C</scp> anada multicentre, prospective, observational study","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Boniface Hospital; Nova Scotia Health Authority; Western University; Montreal Clinical Research Institute; Professional Engineers Ontario; McGill University Health Centre","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Observational study; Confidence interval; Prospective cohort study; Waist; Glucagon-like peptide 1 receptor; Diabetes mellitus; Clinical trial; Agonist; Endocrinology; Obesity; Liraglutide","score_opus":0.040906573998949064,"score_gpt":0.2858680078196724,"score_spread":0.24496143382072336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168679049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995513,0.001445469,5.406688e-7,0.00027970521,0.00026499786,0.0019141586,0.0002154454,0.00003330432,0.0003333514],"genre_scores_gemma":[0.9955326,0.00027574514,0.0018367949,0.0009323077,0.00012398715,0.000057085723,0.0005202431,0.00003348821,0.00068777014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964106,0.00060386775,0.00090192124,0.00078800385,0.00073237077,0.00056322094],"domain_scores_gemma":[0.99291,0.0052707456,0.00044107033,0.00061641436,0.00058034505,0.00018141237],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096968975,0.00036842143,0.0009819217,0.00013030942,0.00010333631,0.00008701755,0.00016409736,0.00014480168,0.000005436377],"category_scores_gemma":[0.012644883,0.0002631284,0.000099694,0.0009114305,0.00015210138,0.00047974312,0.00023804288,0.00046527316,0.000006311255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008529972,0.006722507,0.98848736,0.000044922555,0.00071480457,0.000036628237,0.0012534953,0.000034357166,0.000049898,0.000110583394,0.0010589614,0.0014011773],"study_design_scores_gemma":[0.013525079,0.00044219848,0.9726804,0.00020485788,0.00096525304,9.659954e-8,0.0013466261,0.00025993315,0.0006374045,0.000075718446,0.009789557,0.00007289239],"about_ca_topic_score_codex":0.00048730112,"about_ca_topic_score_gemma":0.0010337892,"teacher_disagreement_score":0.015806982,"about_ca_system_score_codex":0.00006524544,"about_ca_system_score_gemma":0.00018552701,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W3169877704","doi":"10.14740/cr1268","title":"Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature","year":2021,"lang":"en","type":"review","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Renal glucose reabsorption; Diabetes mellitus; Heart failure; Clinical trial; Empagliflozin; Intensive care medicine; Mechanism (biology); Glycosuria; Internal medicine; Pharmacology; Type 2 Diabetes Mellitus; Cardiology; Bioinformatics; Endocrinology","score_opus":0.17331447441940034,"score_gpt":0.39691337358520723,"score_spread":0.22359889916580689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169877704","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044411534,0.99464965,0.0000019754032,0.00011264937,0.00015393745,0.0026505096,0.00024373825,0.000009019425,0.0017343838],"genre_scores_gemma":[0.00022665288,0.9978064,0.000024886564,0.00008833837,0.00014849378,0.0002366749,0.0010197156,0.00004135194,0.00040751192],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604166,0.0014041966,0.00078492763,0.000588283,0.0008017485,0.00037918222],"domain_scores_gemma":[0.9967056,0.00041083744,0.00028241094,0.0013419891,0.0011568657,0.00010229375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002078438,0.00036195194,0.0047136797,0.00038558338,0.00006664677,0.000009098368,0.00025272707,0.0003683912,0.0001159368],"category_scores_gemma":[0.00016213414,0.00022497638,0.0015254696,0.0007224122,0.0003747516,0.00003552398,0.00017969523,0.0007185713,0.00002711803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058353773,0.00019813304,0.00006408128,0.5195441,0.021685462,0.0003154192,0.00007806408,9.907352e-7,0.000024837202,0.0022527867,0.05677219,0.39900553],"study_design_scores_gemma":[0.00043683822,0.00036547804,0.000029176595,0.13898757,0.0040536914,0.000049981656,0.000038151724,1.9365717e-7,0.00039140988,0.000019210614,0.85551333,0.000114940885],"about_ca_topic_score_codex":0.0000075192283,"about_ca_topic_score_gemma":2.395206e-7,"teacher_disagreement_score":0.79874116,"about_ca_system_score_codex":0.00007183108,"about_ca_system_score_gemma":0.00023309376,"threshold_uncertainty_score":0.91742706},"labels":[],"label_agreement":null},{"id":"W3170820589","doi":"10.1093/ndt/gfab092.007","title":"MO129COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS","year":2021,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Mace; Hazard ratio; Interquartile range; Internal medicine; Proportional hazards model; Myocardial infarction; Stroke (engine); Propensity score matching; Confidence interval; Percutaneous coronary intervention","score_opus":0.011807420880687288,"score_gpt":0.26304847220400585,"score_spread":0.25124105132331853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170820589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970902,0.0005732573,0.0002443909,0.00014326458,0.000072019044,0.00035811897,0.000016883598,0.000020808415,0.0014810592],"genre_scores_gemma":[0.99872464,0.00030331916,0.00025667925,0.00012544752,0.000018516095,0.00006323044,0.00047904224,0.0000093451645,0.00001977847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886364,0.00028304002,0.00020836882,0.0003079868,0.00018489487,0.00015209736],"domain_scores_gemma":[0.99929875,0.0003596512,0.00004958452,0.00018185702,0.00007435511,0.000035772748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021641285,0.00014560617,0.00061025075,0.00018028512,0.000029196483,0.0000059132476,0.00002887174,0.00008687317,0.000011939163],"category_scores_gemma":[0.000021594999,0.00012839476,0.0002073383,0.00021203712,0.00005452535,0.00005538333,0.000008692845,0.000090183144,0.0000045221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015902884,0.0011430671,0.899582,0.002649753,0.015630936,0.0010031529,0.010876701,0.0066240905,0.02727492,0.0023007551,0.000032170745,0.016979543],"study_design_scores_gemma":[0.016084084,0.0006715628,0.93952173,0.00015831648,0.004051344,0.000004643195,0.00038660612,0.00009023635,0.03868195,0.00005247404,0.00016864616,0.00012840246],"about_ca_topic_score_codex":0.00004017439,"about_ca_topic_score_gemma":0.00008549776,"teacher_disagreement_score":0.039939705,"about_ca_system_score_codex":0.000054501823,"about_ca_system_score_gemma":0.000026975253,"threshold_uncertainty_score":0.52357864},"labels":[],"label_agreement":null},{"id":"W3170972040","doi":"10.3389/fphar.2021.625785","title":"Design and Methodology of a Multicenter Randomized Clinical Trial to Evaluate the Efficacy of Tongmai Jiangtang Capsules in Type 2 Diabetic Coronary Heart Disease Patients","year":2021,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Clinical trial; Diabetes mellitus; Internal medicine; Statistical significance; Type 2 Diabetes Mellitus; Incidence (geometry); Disease; Population; Randomized controlled trial; Clinical research; Coronary heart disease; Physical therapy; Alternative medicine","score_opus":0.08996547117897988,"score_gpt":0.4189177174829723,"score_spread":0.32895224630399245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170972040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001545,0.0018380724,0.0009878329,0.0014296032,0.002219035,0.003472053,0.0000035636567,0.000005774947,0.000028608883],"genre_scores_gemma":[0.9771198,0.0003485242,0.020591388,0.0015417569,0.00005699529,0.00020882464,0.000020749227,0.000013669175,0.000098294644],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99502146,0.0037050743,0.0006450795,0.0002727288,0.00013214872,0.00022351895],"domain_scores_gemma":[0.99733555,0.0022006102,0.00009768841,0.0001615093,0.00009562424,0.00010904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002440049,0.00012522665,0.0009765793,0.00016275523,0.000013698858,0.0000023968423,0.00007956699,0.00006323974,0.00007925135],"category_scores_gemma":[0.0016243871,0.00008895741,0.00011274522,0.00020237593,0.00025773252,0.000024488647,0.000113808695,0.0001285247,0.00000218093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78759456,0.0026369353,0.18823692,0.000100631405,0.0006923591,0.00008933268,0.0004930961,0.0001254626,0.00044896902,0.000015177927,0.007356511,0.012210066],"study_design_scores_gemma":[0.8058089,0.0012005238,0.18663858,0.000075068725,0.0017224826,5.347436e-7,0.000098610355,0.0026017008,0.0011545974,0.00021025447,0.00039001752,0.00009871905],"about_ca_topic_score_codex":0.000007991557,"about_ca_topic_score_gemma":0.0000016358445,"teacher_disagreement_score":0.019603554,"about_ca_system_score_codex":0.00004825987,"about_ca_system_score_gemma":0.00011160509,"threshold_uncertainty_score":0.36275777},"labels":[],"label_agreement":null},{"id":"W3171108650","doi":"10.1002/ehf2.13374","title":"Time to Cardiovascular Benefits of Empagliflozin: A <i>Post Hoc</i> Observation from the EMPA-REG OUTCOME Trial","year":2021,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; McGill University Health Centre; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Hazard ratio; Confidence interval; Placebo; Internal medicine; Statistical significance; Cumulative incidence; Proportional hazards model; Post-hoc analysis; Heart failure; Type 2 diabetes; Cardiology; Diabetes mellitus; Endocrinology; Cohort","score_opus":0.025846588808570492,"score_gpt":0.24574313703026396,"score_spread":0.21989654822169347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171108650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613605,0.0013365329,0.000010126328,0.035458446,0.00020655007,0.0010847652,0.00006948898,0.000057785117,0.0004157793],"genre_scores_gemma":[0.93904877,0.000073963136,0.013946871,0.019516105,0.0025114606,0.0003294263,0.0015660776,0.00013442908,0.022872875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848866,0.00009295354,0.00033377213,0.0003337085,0.00050774805,0.00024317276],"domain_scores_gemma":[0.9987011,0.000105517574,0.000046616195,0.0008258234,0.00019785808,0.00012306205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028659296,0.00018242166,0.00057755626,0.000043570642,0.00006950742,0.00003101433,0.00010406037,0.00008585942,0.0006437058],"category_scores_gemma":[0.00017507747,0.00012964958,0.0004976,0.00034007043,0.000028063017,0.00008330124,0.000110437984,0.000114792965,0.00074716075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011089041,0.002512946,0.09402431,0.0004070023,0.012898424,0.00023007818,0.004184151,0.0012858063,0.016494364,0.00058274704,0.7787853,0.07750584],"study_design_scores_gemma":[0.019050462,0.0006904316,0.064585425,0.00017043769,0.0011382819,0.0000031496952,0.0003040162,0.00002545708,0.0036421262,0.000014408684,0.91018623,0.00018959882],"about_ca_topic_score_codex":0.00011049455,"about_ca_topic_score_gemma":0.00007231613,"teacher_disagreement_score":0.13140091,"about_ca_system_score_codex":0.000052237945,"about_ca_system_score_gemma":0.000078803874,"threshold_uncertainty_score":0.9603489},"labels":[],"label_agreement":null},{"id":"W3172415017","doi":"10.1002/clc.23665","title":"Kidney outcomes using a sustained ≥40% decline in <scp>eGFR</scp>: A meta‐analysis of <scp>SGLT2</scp> inhibitor trials","year":2021,"lang":"en","type":"review","venue":"Clinical Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; Pfizer","keywords":"Medicine; Kidney disease; Internal medicine; Dialysis; Renal function; Type 2 diabetes; Diabetes mellitus; Randomized controlled trial; Kidney transplantation; Clinical trial; Clinical endpoint; Kidney; Meta-analysis; Endocrinology","score_opus":0.30352181464140887,"score_gpt":0.4874931941167706,"score_spread":0.18397137947536174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172415017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015889732,0.9913536,0.00018748008,0.00026028324,0.0012897121,0.0030580843,0.0003804487,0.00008308761,0.0017983528],"genre_scores_gemma":[0.00036969624,0.9893549,0.0014183887,0.0015549463,0.0010452479,0.0004647711,0.0024659885,0.00013395117,0.00319209],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.98348194,0.0063032215,0.006834373,0.0017012565,0.0006019347,0.0010772943],"domain_scores_gemma":[0.9623896,0.032104954,0.0025530483,0.0018123699,0.00044770265,0.00069235277],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.011404467,0.0011775276,0.03964795,0.0019188895,0.000056080913,0.000041782987,0.00052696036,0.0017334898,0.00008371928],"category_scores_gemma":[0.069496766,0.00080371165,0.022840597,0.002712479,0.00041967802,0.00007042916,0.00088001566,0.0011024162,0.00003827938],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029361196,0.0010620634,0.019193688,0.010096265,0.90912473,0.001867966,0.00005522778,0.000053870048,8.7734975e-7,0.00037625706,0.014335319,0.04380439],"study_design_scores_gemma":[0.0021238443,0.00031959955,0.00041376642,0.00069188094,0.47461703,0.0000104578885,0.00012788875,0.000019605854,6.5894676e-7,0.000035833516,0.5215522,0.00008723559],"about_ca_topic_score_codex":0.000055974535,"about_ca_topic_score_gemma":0.000029648869,"teacher_disagreement_score":0.5072169,"about_ca_system_score_codex":0.00031966568,"about_ca_system_score_gemma":0.0014387647,"threshold_uncertainty_score":0.99956244},"labels":[],"label_agreement":null},{"id":"W3172449260","doi":"10.1055/s-0041-1727466","title":"Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME","year":2021,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Renal function; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Urology; Cardiology; Chemistry","score_opus":0.039772670730158846,"score_gpt":0.309240268966238,"score_spread":0.2694675982360792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172449260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863332,0.0008269221,0.00038607983,0.010778885,0.0000715092,0.0012454139,0.00006619438,0.00004361203,0.00024822092],"genre_scores_gemma":[0.9974944,0.00009814802,0.00043773843,0.0014664026,0.000014546833,0.00022818436,0.00015747674,0.000020413047,0.00008266706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824864,0.00034527856,0.00044189932,0.00039567662,0.00024258647,0.00032590952],"domain_scores_gemma":[0.9987658,0.00019259575,0.0000932232,0.00071776623,0.00012215163,0.00010842462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007538173,0.00022088017,0.00051324494,0.00019120102,0.0000904797,0.000029768153,0.00011646033,0.000102927406,0.000013197503],"category_scores_gemma":[0.00042693544,0.00013752394,0.0001367201,0.0009170523,0.00016131176,0.000111415015,0.000071949195,0.00019656224,0.000003916459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015395085,0.0008405207,0.9626582,0.0002632001,0.0008874713,0.00029958613,0.00137449,0.0010251539,0.023807352,0.00073010556,0.0003300722,0.0062443404],"study_design_scores_gemma":[0.0032998559,0.00030481094,0.96066964,0.00025323048,0.00057152164,0.000008222202,0.00030845928,0.00012161187,0.03293357,0.0001934782,0.0011674783,0.00016811682],"about_ca_topic_score_codex":0.00011026093,"about_ca_topic_score_gemma":0.0002555387,"teacher_disagreement_score":0.01116126,"about_ca_system_score_codex":0.00015016271,"about_ca_system_score_gemma":0.00021813829,"threshold_uncertainty_score":0.56080633},"labels":[],"label_agreement":null},{"id":"W3172608072","doi":"10.1016/j.diabres.2021.108920","title":"Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada","year":2021,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Sanofi (Canada); CARE Canada","funders":"Sanofi","keywords":"Medicine; Cohort; Combination therapy; Internal medicine; Type 2 diabetes; Persistence (discontinuity); Basal (medicine); Insulin; Diabetes mellitus; Retrospective cohort study; Glucagon-like peptide 1 receptor; Cohort study; Clinical endpoint; Endocrinology; Agonist; Clinical trial; Receptor","score_opus":0.04636430478376357,"score_gpt":0.3561717611182415,"score_spread":0.3098074563344779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172608072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239725,0.0010390528,3.4401668e-7,0.0022639302,0.000038266156,0.0004997619,0.0000042143006,0.000005946416,0.0037512297],"genre_scores_gemma":[0.99783504,0.00094846735,0.0005229934,0.00035994634,0.000020093146,0.000035708654,0.000051921525,0.000014891335,0.00021092048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975824,0.00041592369,0.00041426267,0.00040571284,0.000712275,0.00046942476],"domain_scores_gemma":[0.9955435,0.0031211334,0.00011734463,0.00027891758,0.0007294772,0.00020962246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001484541,0.00012594524,0.0004111298,0.00014134627,0.000039388666,0.000030641837,0.00009028972,0.00006533624,0.00004432939],"category_scores_gemma":[0.0039891927,0.00009485661,0.00002406275,0.00093132607,0.0002706216,0.00030691334,0.00010219586,0.0005691985,0.0000034436114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010299626,0.0014482124,0.98252153,0.00023821888,0.00018042214,0.00026930842,0.000087933,0.0000032068542,0.00002736792,0.000054588814,0.0002418722,0.013897345],"study_design_scores_gemma":[0.0060180617,0.0041568247,0.9826532,0.0007945025,0.00008471697,5.8553434e-7,0.003617688,0.0010654428,0.0005234601,0.000048784666,0.0009166123,0.00012009919],"about_ca_topic_score_codex":0.05092413,"about_ca_topic_score_gemma":0.38419008,"teacher_disagreement_score":0.33326596,"about_ca_system_score_codex":0.00019709668,"about_ca_system_score_gemma":0.0010989766,"threshold_uncertainty_score":0.9553959},"labels":[],"label_agreement":null},{"id":"W3172917271","doi":"10.7939/r3gt5fx4s","title":"International Comparison of Time to Treatment Intensification and Rates of Complications in Metformin Monotherapy Treated Type 2 Diabetes Patients","year":2018,"lang":"en","type":"article","venue":"University of Alberta Library","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.016645886132802257,"score_gpt":0.2412910731630249,"score_spread":0.22464518703022263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172917271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714244,0.000025218189,0.000004049606,0.00063207245,0.0000113799915,0.00026970526,0.0000071856375,0.0000059432864,0.01190198],"genre_scores_gemma":[0.9955143,0.00005494666,0.0012301654,0.000031115083,0.000003859318,4.6166724e-7,0.00025488017,0.0000047354347,0.0029055483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966925,0.000011348404,0.00011774229,0.00009766318,0.000051740906,0.000052239688],"domain_scores_gemma":[0.99965215,0.00005326451,0.00008431215,0.00010892242,0.00006936688,0.00003199649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000011515953,0.000057807825,0.00018791822,0.00018722929,0.000012470166,0.0000019799695,0.000058299447,0.000021691667,0.00026776368],"category_scores_gemma":[0.00000767856,0.00005425128,0.000024448473,0.00014924236,0.000071229515,0.00012337863,0.000033168613,0.000010018327,0.000014106245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031866392,0.00085859664,0.9774077,0.000014878608,0.00021141596,1.5636489e-7,0.0022075644,0.0000020148636,0.0017669153,0.00016339686,0.00132628,0.01572245],"study_design_scores_gemma":[0.0026441845,0.0022619811,0.92731196,0.00011278907,0.000116574694,5.0866173e-8,0.00042733114,0.0016702989,0.045615397,0.000030422281,0.019734213,0.000074781594],"about_ca_topic_score_codex":0.00024423137,"about_ca_topic_score_gemma":0.000033584976,"teacher_disagreement_score":0.050095692,"about_ca_system_score_codex":0.000021764412,"about_ca_system_score_gemma":0.000011310026,"threshold_uncertainty_score":0.29318246},"labels":[],"label_agreement":null},{"id":"W3173157158","doi":"10.2337/db21-13-lb","title":"13-LB: Measured vs. Estimated GFR in Young Adults with Uncomplicated T1D","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Renal function; Urology; Creatinine; Population; Kidney disease; Internal medicine; Endocrinology","score_opus":0.015383685434383365,"score_gpt":0.23929087592285242,"score_spread":0.22390719048846905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173157158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714405,0.00075700664,0.0000074502186,0.0009840935,0.00008314473,0.0004737615,0.000008973981,0.00019157007,0.010349942],"genre_scores_gemma":[0.9965727,0.00003478035,0.0010548137,0.00042574765,0.000030847412,0.00013274269,0.00042428402,0.000037290396,0.0012868353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986256,0.000037566217,0.00022269046,0.00039869177,0.00027933685,0.00043615774],"domain_scores_gemma":[0.99922305,0.000044415705,0.00005682937,0.0003919172,0.00015596523,0.00012779409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010814849,0.00021901942,0.0004110917,0.00013024866,0.000040967316,0.000035084082,0.00007922253,0.00006217135,0.00013234193],"category_scores_gemma":[0.00007665821,0.0001745468,0.000060787213,0.0005794317,0.000049961134,0.000087170825,0.000054663436,0.00011593442,0.00009413697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014621545,0.00061247667,0.9844814,0.0002072562,0.00033231068,0.00017168363,0.00021889867,0.000030455865,0.0049333884,0.00010707555,0.0014468887,0.007311949],"study_design_scores_gemma":[0.006846384,0.0004789918,0.9405019,0.0010459892,0.0003290084,0.0000042183206,0.00017856406,0.0020281111,0.04690763,0.0000836331,0.0012891077,0.00030644747],"about_ca_topic_score_codex":0.00009116292,"about_ca_topic_score_gemma":0.00031455568,"teacher_disagreement_score":0.043979485,"about_ca_system_score_codex":0.00009805944,"about_ca_system_score_gemma":0.00005841066,"threshold_uncertainty_score":0.7117812},"labels":[],"label_agreement":null},{"id":"W3173189176","doi":"10.2337/db21-1193-p","title":"1193-P: Investigating the Role of Intestinal L-Cell Secretagogin in Circadian GLP-1 Secretion in a Mouse Model of Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Endocrinology; Internal medicine; Biology; Glucagon-like peptide-1; Streptozotocin; Glucagon; Insulin; Secretion; Islet; Circadian rhythm; Gastrointestinal hormone; Type 2 diabetes; Diabetes mellitus; Hormone; Peptide hormone; Medicine","score_opus":0.018487205861488894,"score_gpt":0.23285275519183782,"score_spread":0.21436554933034893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173189176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412996,0.0017206931,0.0000034820466,0.0002459178,0.000031874886,0.00033429157,0.000011671768,0.000022458022,0.0034996835],"genre_scores_gemma":[0.9979408,0.000056250592,0.0012188465,0.00022590037,0.000020628913,0.000046181936,0.00010260852,0.000024335988,0.0003644885],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865097,0.00008544828,0.0004285318,0.00025466763,0.0002319588,0.00034845446],"domain_scores_gemma":[0.9991435,0.00017128045,0.00015299536,0.00032612664,0.00012711092,0.000078983874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034892812,0.00017392915,0.0004230611,0.00021034974,0.000020970638,0.000012447505,0.000121205194,0.00007315439,0.0000323914],"category_scores_gemma":[0.00035792336,0.00014287641,0.00008244834,0.00055446546,0.00012377172,0.00009363884,0.00010142934,0.00018836174,0.000005159823],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000060236857,0.00022206335,0.6106791,0.00024507832,0.000036734327,0.0000020351627,0.00072112394,0.0007073544,0.3841666,0.00046256176,0.000018112933,0.0027332387],"study_design_scores_gemma":[0.0012715653,0.0002427058,0.028982285,0.0005579289,0.000109965746,1.3751158e-7,0.00109454,0.12734298,0.83763325,0.002528845,0.00007229617,0.00016351003],"about_ca_topic_score_codex":0.00006883036,"about_ca_topic_score_gemma":0.00006117625,"teacher_disagreement_score":0.58169675,"about_ca_system_score_codex":0.00006859949,"about_ca_system_score_gemma":0.00013660714,"threshold_uncertainty_score":0.5826331},"labels":[],"label_agreement":null},{"id":"W3173323203","doi":"10.2337/db21-130-lb","title":"130-LB: Dapagliflozin and the Incidence of Type 2 Diabetes in Patients with Chronic Kidney Disease","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Type 2 diabetes; Kidney disease; Hazard ratio; Internal medicine; Albuminuria; Diabetes mellitus; Prediabetes; Placebo; Glycemic; Renal function; Incidence (geometry); Cohort; Endocrinology; Confidence interval","score_opus":0.0048734671657354395,"score_gpt":0.20775306376671096,"score_spread":0.20287959660097551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173323203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497896,0.0031524247,3.459568e-7,0.000784327,0.00007128255,0.00046176423,0.00001444982,0.000018438215,0.00051801204],"genre_scores_gemma":[0.9985013,0.00012669062,0.00007706751,0.00076773035,0.00002951218,0.000050332103,0.00013426486,0.000017022801,0.00029608095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990153,0.000058880247,0.00018380118,0.00023816012,0.00023710479,0.00026676024],"domain_scores_gemma":[0.99920857,0.0001217926,0.0000676945,0.00033661356,0.0001106816,0.00015466103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014240791,0.00014563011,0.00032562783,0.00007053349,0.000033209017,0.000018799468,0.000073219664,0.000026309244,0.00007528756],"category_scores_gemma":[0.0002920591,0.00008868066,0.00004275373,0.0003069802,0.0002028189,0.00009198666,0.00010978007,0.00007692753,0.00000788048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011698239,0.000247172,0.99491227,0.00027756012,0.00016874314,0.000007779811,0.000054465283,0.0000046043924,0.0001398604,0.0004121243,0.00044953986,0.0032089308],"study_design_scores_gemma":[0.006733436,0.00034531683,0.9874173,0.0005222155,0.0003560102,2.4182098e-8,0.000021304208,0.00043276558,0.0027518782,0.00021004975,0.0010900204,0.00011971631],"about_ca_topic_score_codex":0.000009096952,"about_ca_topic_score_gemma":0.000010928298,"teacher_disagreement_score":0.0074949753,"about_ca_system_score_codex":0.000049411326,"about_ca_system_score_gemma":0.00013151353,"threshold_uncertainty_score":0.36162922},"labels":[],"label_agreement":null},{"id":"W3173344671","doi":"10.2337/db21-95-lb","title":"95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Randomized controlled trial; Basal insulin; Titration; Medicine; Clinical endpoint; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Chemistry","score_opus":0.008626961113702028,"score_gpt":0.21814149293114415,"score_spread":0.20951453181744212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173344671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921321,0.0002448383,0.0018051566,0.0023742912,0.0003082426,0.0028091285,0.00003685641,0.000029519113,0.00025983932],"genre_scores_gemma":[0.9908055,0.000019273053,0.005456178,0.0010206188,0.00012390615,0.0010119446,0.0013772451,0.000029867067,0.00015548147],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982949,0.00012937778,0.00049453025,0.00038902898,0.00033160174,0.0003605755],"domain_scores_gemma":[0.9989558,0.000494556,0.000119923396,0.00021116476,0.00010643897,0.000112149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003945409,0.00022140569,0.00090727437,0.00016202709,0.000056986588,0.00007493223,0.0000762605,0.0000539043,0.000025134068],"category_scores_gemma":[0.00022573867,0.00019924318,0.000071060014,0.0003851704,0.000010947364,0.00014335728,0.000043031414,0.00013307371,0.0000023769926],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22852647,0.0035904935,0.6621325,0.0004792121,0.001962787,0.00023768345,0.006775522,0.0016539989,0.007466036,0.0007212625,0.00647482,0.07997922],"study_design_scores_gemma":[0.8122949,0.00060449826,0.06739792,0.00041618547,0.00030970504,2.1461472e-7,0.0007566814,0.10893799,0.008423678,0.00021229836,0.00028647413,0.00035947617],"about_ca_topic_score_codex":0.32611388,"about_ca_topic_score_gemma":0.85028225,"teacher_disagreement_score":0.5947346,"about_ca_system_score_codex":0.00062331156,"about_ca_system_score_gemma":0.0007287643,"threshold_uncertainty_score":0.8124901},"labels":[],"label_agreement":null},{"id":"W3173475545","doi":"10.1093/eurheartj/ehab360","title":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Placebo; Heart failure; Internal medicine; Ejection fraction; Demography; Ethnic group; Cardiology; Endocrinology; Diabetes mellitus","score_opus":0.04391854486262127,"score_gpt":0.3021809448768972,"score_spread":0.2582624000142759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173475545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492534,0.00011449675,0.000001056298,0.049755827,0.00013946946,0.00047860004,8.1402e-7,0.000011976343,0.0002443906],"genre_scores_gemma":[0.99497426,0.000026992866,0.0001700891,0.0040331646,0.00028174958,0.000010577667,0.0000024517258,0.000017255516,0.00048344815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982121,0.0008793494,0.00019446677,0.00020761693,0.0003298019,0.00017667112],"domain_scores_gemma":[0.9993309,0.00021349432,0.00006149552,0.00018641264,0.00008281247,0.00012492109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001056554,0.0001264491,0.0001662097,0.00011175874,0.00025640771,0.00011998209,0.000043438253,0.000021335007,0.000051770465],"category_scores_gemma":[0.0002519338,0.00006554198,0.000043242344,0.0002625153,0.000058094964,0.000103885825,0.00004285147,0.000363932,0.000021127013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2128744,0.0019930636,0.57965714,0.00004635531,0.0007831057,0.00047086392,0.0051693637,0.0000806623,0.019334905,0.000096336815,0.16946362,0.01003016],"study_design_scores_gemma":[0.010892259,0.0024634583,0.947908,0.00021173297,0.000054753433,0.00007718739,0.00080953544,0.0000020926263,0.00018311443,0.000008726375,0.037312508,0.00007665366],"about_ca_topic_score_codex":0.0000028923275,"about_ca_topic_score_gemma":0.000008130908,"teacher_disagreement_score":0.36825082,"about_ca_system_score_codex":0.000056438086,"about_ca_system_score_gemma":0.00006833499,"threshold_uncertainty_score":0.26727244},"labels":[],"label_agreement":null},{"id":"W3173779296","doi":"10.1016/j.jcjd.2021.06.003","title":"Use of Sodium-Glucose Cotransporter-2 Inhibitors in Renal Transplant Patients With Diabetes: A Brief Review of the Current Literature","year":2021,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Renal function; Diabetes mellitus; Glycemic; Internal medicine; Adverse effect; Type 2 diabetes; Population; Nephropathy; Creatinine; Urology; Surgery; Endocrinology","score_opus":0.018930362858012688,"score_gpt":0.2420314902795158,"score_spread":0.2231011274215031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173779296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026827533,0.9705223,2.0479223e-7,0.00010889708,0.0004211782,0.0013590606,0.00071996346,0.0000027764522,0.00003809832],"genre_scores_gemma":[0.0036469067,0.99528855,0.000057410176,0.00022839603,0.00009585696,0.00003235372,0.00055139576,0.000061264596,0.000037891557],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99659246,0.00024613706,0.0017509947,0.00029799924,0.00057226873,0.00054012076],"domain_scores_gemma":[0.9967811,0.00014351876,0.0014507313,0.00053628033,0.0005673595,0.00052098953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038175372,0.0005444645,0.00320695,0.00069887395,0.000036481026,0.00003843814,0.00035039702,0.00016647832,0.000049078764],"category_scores_gemma":[0.00013079081,0.00031460862,0.0011471637,0.0011437918,0.00018645116,0.00019704,0.000017757695,0.0008189832,6.159558e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054801903,0.00037110003,0.15577222,0.16029625,0.0014234962,0.00009641372,0.0001846282,5.508889e-7,7.68742e-7,0.0000151595195,0.002603266,0.6792307],"study_design_scores_gemma":[0.00075497,0.00031385332,0.0065985927,0.5313274,0.0040674005,0.0000015466687,0.0000018771614,2.0245545e-7,0.000024189236,0.0000016695379,0.4567236,0.00018469621],"about_ca_topic_score_codex":0.000041430194,"about_ca_topic_score_gemma":0.0008713013,"teacher_disagreement_score":0.679046,"about_ca_system_score_codex":0.00027027217,"about_ca_system_score_gemma":0.0023965293,"threshold_uncertainty_score":0.9999306},"labels":[],"label_agreement":null},{"id":"W3173855870","doi":"10.1111/dom.14474","title":"Comparative effectiveness and safety of sodium‐glucose cotransporter‐2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sinai Health System; University of Toronto","funders":"National Institute on Aging; Canadian Institutes of Health Research","keywords":"Medicine; Metformin; Internal medicine; Hazard ratio; Diabetic ketoacidosis; Diabetes mellitus; Type 2 diabetes; Dapagliflozin; Propensity score matching; Lactic acidosis; Myocardial infarction; Stroke (engine); Confidence interval; Endocrinology; Insulin","score_opus":0.06893482035059344,"score_gpt":0.3041577007592252,"score_spread":0.23522288040863176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173855870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514407,0.0032897613,0.000003374152,0.0000054596076,0.00018073802,0.0009790867,0.0003531476,0.000016561837,0.000027800705],"genre_scores_gemma":[0.9957376,0.00006286966,0.00079913693,0.000031467745,0.00004139421,0.000013319404,0.0032953701,0.000015765729,0.000003060199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984887,0.00017060363,0.00029385588,0.00051146274,0.00029395326,0.0002414066],"domain_scores_gemma":[0.99892735,0.00015422373,0.00011197088,0.0004320639,0.00025574668,0.00011865602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024686637,0.00024120789,0.0008186387,0.00010506761,0.00007989703,0.000026762733,0.000094509895,0.00006073753,0.000015149544],"category_scores_gemma":[0.000035147794,0.00020082059,0.000028127755,0.00032266433,0.00009370974,0.00046743485,0.00015229,0.00011243394,5.736698e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007591807,0.0016763697,0.9925335,0.00016095457,0.00069348444,0.00000726329,0.0015564974,0.000009224553,0.00055221986,0.000023961116,0.0000016459221,0.002025715],"study_design_scores_gemma":[0.014172555,0.0006174895,0.9745682,0.00020201913,0.0014256282,2.9007312e-8,0.0013667821,0.00020578783,0.007142861,0.000014574159,0.00009236393,0.00019174263],"about_ca_topic_score_codex":0.00012800851,"about_ca_topic_score_gemma":0.000244157,"teacher_disagreement_score":0.017965315,"about_ca_system_score_codex":0.000040893105,"about_ca_system_score_gemma":0.00007726993,"threshold_uncertainty_score":0.81892264},"labels":[],"label_agreement":null},{"id":"W3174204721","doi":"10.2337/db21-131-lb","title":"131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Canagliflozin; Internal medicine; Placebo; Peripheral neuropathy; Adverse effect; Diabetes mellitus; Polyneuropathy; Type 2 diabetes; Anesthesia; Endocrinology; Pathology","score_opus":0.02185372354802957,"score_gpt":0.2676642916691252,"score_spread":0.24581056812109564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174204721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218386,0.0005772595,7.9341766e-7,0.0028114505,0.00022180213,0.0006872168,0.0004699751,0.000014673065,0.0030329607],"genre_scores_gemma":[0.9984982,0.00021452221,0.0000133937065,0.00045796784,0.00018506027,0.00003951658,0.00008531332,0.000015306863,0.00049072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984543,0.0003937455,0.00033824047,0.00022608491,0.00035641203,0.00023126618],"domain_scores_gemma":[0.9964937,0.0021635173,0.0002643081,0.00093101105,0.000101376354,0.000046083518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006219647,0.00016086547,0.00030496108,0.000026460682,0.0000975295,0.000016882761,0.00027541775,0.000033350858,0.00010858776],"category_scores_gemma":[0.0020180887,0.00006288773,0.00031540965,0.00026737762,0.000112090944,0.000033140426,0.000112711445,0.00016809307,0.000014762972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018565787,0.0039182366,0.7637868,0.00008821756,0.00957906,0.00006235279,0.0054937648,0.00066672347,0.013655381,0.0018669373,0.13082571,0.051491026],"study_design_scores_gemma":[0.027982714,0.0028120207,0.9183854,0.00039536034,0.0016903377,2.381152e-7,0.0009839267,0.0006227879,0.042468168,0.0013923888,0.0030802055,0.0001864885],"about_ca_topic_score_codex":0.0017157181,"about_ca_topic_score_gemma":0.00007976498,"teacher_disagreement_score":0.15459856,"about_ca_system_score_codex":0.000038384092,"about_ca_system_score_gemma":0.00009520283,"threshold_uncertainty_score":0.2593664},"labels":[],"label_agreement":null},{"id":"W3174242619","doi":"10.14740/jocmr4510","title":"Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Gulf Medical University","keywords":"Medicine; Metformin; Adipokine; Internal medicine; Endocrinology; Adiponectin; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; Postprandial; Dipeptidyl peptidase-4; Lipid profile; Retinol binding protein 4; Pharmacology; Insulin resistance","score_opus":0.07319209512975035,"score_gpt":0.43929530553641427,"score_spread":0.36610321040666394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174242619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836739,0.010552595,3.4378115e-7,0.0031275908,0.00050243264,0.00048621205,0.0000028830761,0.0000053201456,0.0016487696],"genre_scores_gemma":[0.9802509,0.018281696,0.0000420973,0.00029252123,0.0008913961,0.000006728151,0.00001043814,0.000026200943,0.0001980411],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950417,0.00093150255,0.0018348208,0.00029922478,0.0015062402,0.00038649037],"domain_scores_gemma":[0.9926528,0.005394851,0.0004704158,0.00035207238,0.0007615188,0.00036835312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007892988,0.00022423753,0.0015824066,0.0007178372,0.000028492857,0.000007539708,0.00014107469,0.0001768517,0.00017486063],"category_scores_gemma":[0.0036283096,0.00013022182,0.00028031168,0.0007337443,0.00061678374,0.00007566547,0.00004848081,0.0010087249,0.000005558865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013310565,0.0032694554,0.47200453,0.0011550992,0.00090422726,0.0009139948,0.0003580425,0.000004420293,0.015269062,0.000090107584,0.008689734,0.48403078],"study_design_scores_gemma":[0.041706104,0.14320977,0.2833381,0.014965626,0.000476677,0.000013038829,0.0004157056,0.00004753352,0.4972265,0.00030212887,0.01804665,0.0002521634],"about_ca_topic_score_codex":0.000012755371,"about_ca_topic_score_gemma":0.000006215925,"teacher_disagreement_score":0.4837786,"about_ca_system_score_codex":0.00004789515,"about_ca_system_score_gemma":0.00019713255,"threshold_uncertainty_score":0.53102916},"labels":[],"label_agreement":null},{"id":"W3174356798","doi":"10.1096/fasebj.2019.33.1_supplement.720.2","title":"A human‐origin probiotics cocktail exhibit cardio‐protective effects independent of GLP‐1 receptor signaling","year":2019,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institutes of Health","keywords":"Butyrate; Endocrinology; Internal medicine; Probiotic; Glucagon-like peptide-1; Ejection fraction; Type 2 diabetes; Diet-induced obese; Ventricle; Receptor; Biology; Microbiome; Gut flora; Diabetes mellitus; Medicine; Insulin resistance; Heart failure; Biochemistry; Bioinformatics; Bacteria","score_opus":0.013465228409123089,"score_gpt":0.2489333844730967,"score_spread":0.23546815606397362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174356798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377096,0.00033395836,0.00021215063,0.000203,0.00039781365,0.0013155383,0.0000034416357,0.000026084603,0.0037370499],"genre_scores_gemma":[0.99581325,0.000019173382,0.0003207829,0.00010987574,0.00025635376,0.000015591924,0.000005292846,0.000025021765,0.0034346627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986565,0.00013185557,0.0002914752,0.00016344749,0.00046865584,0.00028806264],"domain_scores_gemma":[0.9991593,0.00006796749,0.0002466342,0.00028735705,0.00012802408,0.00011074189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006770611,0.00017651904,0.00041614563,0.00012346222,0.00012795549,0.000038731003,0.00015532943,0.00006456608,0.00023977413],"category_scores_gemma":[0.00003135519,0.00010856335,0.00022664964,0.0001434946,0.00005419716,0.0000765846,0.000069890164,0.0004007631,0.00014521042],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041101896,0.00047698154,0.02584469,0.0004971171,0.002204949,0.00010175791,0.0013896279,0.0004064837,0.96053916,0.0008982848,0.0015972692,0.005632658],"study_design_scores_gemma":[0.00861584,0.00430472,0.009634749,0.0014555977,0.0013343001,0.000112849775,0.0011282102,0.00008560371,0.970379,0.0008304266,0.0018037568,0.0003149711],"about_ca_topic_score_codex":0.000013709614,"about_ca_topic_score_gemma":0.0000015555613,"teacher_disagreement_score":0.016209941,"about_ca_system_score_codex":0.00020045161,"about_ca_system_score_gemma":0.000073636074,"threshold_uncertainty_score":0.4427085},"labels":[],"label_agreement":null},{"id":"W3174397236","doi":"10.2337/dc21-0300","title":"Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Relypsa; Cytokinetics; Astellas Pharma; Gilead Sciences; Servier; Satellite Healthcare; University of Glasgow; Kidney Research UK; Bristol-Myers Squibb; Akebia Therapeutics; Steno Diabetes Center Copenhagen; Quest Diagnostics; Novo Nordisk; ReCor Medical; Alnylam Pharmaceuticals; Kowa Company; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; GlaxoSmithKline; Defense Acquisition Program Administration; Amgen; Angion; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Dapagliflozin; Kidney disease; Prediabetes; Internal medicine; Renal function; Diabetes mellitus; Hazard ratio; Type 2 diabetes; Glycemic; Adverse effect; Urology; Endocrinology; Confidence interval","score_opus":0.012179359645708614,"score_gpt":0.24980915950314805,"score_spread":0.23762979985743943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174397236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548865,0.010784278,0.000024869696,0.0005293899,0.00011778333,0.0007349864,0.0009707285,0.00004082641,0.001308472],"genre_scores_gemma":[0.9932808,0.00066998176,0.00029394575,0.00045569555,0.00015371556,0.000044421715,0.004709767,0.000022152733,0.00036950532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984756,0.00013011268,0.00036356607,0.0004120539,0.0003068212,0.00031185086],"domain_scores_gemma":[0.9983766,0.0006056296,0.000115167226,0.00062607735,0.00014426587,0.00013223481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001274936,0.00020251042,0.0005997199,0.00008128128,0.000065484026,0.00003722475,0.00010179228,0.00007236732,0.0003880603],"category_scores_gemma":[0.0002364228,0.00014302712,0.00022428147,0.00056092197,0.00008292355,0.000050872994,0.00012772619,0.00011259143,0.000013712863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038713004,0.0015190259,0.75251764,0.00034251084,0.020841792,0.00004729797,0.005403153,0.000067623405,0.012089724,0.0001804843,0.03712137,0.13115636],"study_design_scores_gemma":[0.2795686,0.0027718837,0.3234636,0.0005220016,0.03712982,2.6049756e-7,0.01141432,0.0011355327,0.034097638,0.0000989669,0.3089024,0.00089497265],"about_ca_topic_score_codex":0.000048539212,"about_ca_topic_score_gemma":0.00005071099,"teacher_disagreement_score":0.42905408,"about_ca_system_score_codex":0.00005871007,"about_ca_system_score_gemma":0.00005830129,"threshold_uncertainty_score":0.58324766},"labels":[],"label_agreement":null},{"id":"W3174437546","doi":"10.2337/db21-664-p","title":"664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Discontinuation; Tolerability; Adverse effect; Dosing; Semaglutide; Internal medicine; Intensive care medicine; Endocrinology; Type 2 diabetes","score_opus":0.04656454624171329,"score_gpt":0.30206855428655977,"score_spread":0.25550400804484646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174437546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903255,0.003279251,0.0000058490605,0.0011061457,0.00019822385,0.0005369855,0.0000063588845,0.00007312084,0.004468558],"genre_scores_gemma":[0.99331594,0.00029702653,0.0026336159,0.0013213039,0.00013215415,0.00013072138,0.00017340039,0.000021451273,0.0019743764],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99896085,0.000035305216,0.00018859471,0.00040203813,0.00015855972,0.00025464027],"domain_scores_gemma":[0.999282,0.000052045016,0.000054549542,0.0003277243,0.00010424142,0.00017942932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011706521,0.00018506472,0.00027237475,0.00008679843,0.00010002483,0.00007812663,0.00004151822,0.00003567551,0.00007613618],"category_scores_gemma":[0.000038367056,0.00015255653,0.000072126204,0.00021345339,0.000040619936,0.00011359307,0.000059424703,0.000044085067,0.000029706593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016287979,0.00073822046,0.35910252,0.00008195804,0.00015263696,0.000009013452,0.0005769248,0.0000013000866,0.014215878,0.0002452944,0.0005670559,0.6242929],"study_design_scores_gemma":[0.0060556075,0.0068083564,0.49644008,0.0008921373,0.0010322827,0.000012181741,0.0031224042,0.0001963129,0.36150858,0.0023149743,0.12057373,0.0010433545],"about_ca_topic_score_codex":0.000029648898,"about_ca_topic_score_gemma":0.000017650415,"teacher_disagreement_score":0.62324953,"about_ca_system_score_codex":0.00016914545,"about_ca_system_score_gemma":0.00018570705,"threshold_uncertainty_score":0.6221075},"labels":[],"label_agreement":null},{"id":"W3174528431","doi":"10.2337/db21-317-or","title":"317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Prediabetes; Type 2 diabetes; Kidney disease; Internal medicine; Glycemic; Hazard ratio; Renal function; Diabetes mellitus; Placebo; Creatinine; Endocrinology; Confidence interval","score_opus":0.015938394085550672,"score_gpt":0.2664948316453147,"score_spread":0.250556437559764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174528431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903992,0.0026796632,0.0000014517623,0.00070940075,0.00011007505,0.0006677188,0.00003036646,0.000019741246,0.005382407],"genre_scores_gemma":[0.9974301,0.00062828045,0.00012114223,0.0005642582,0.00006095495,0.000042717773,0.00018056988,0.0000139145595,0.00095809513],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989136,0.00007805768,0.0002668272,0.00022649723,0.00020725488,0.00030778136],"domain_scores_gemma":[0.9991813,0.0003607827,0.000061307124,0.00030243635,0.000028957686,0.00006523155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020553303,0.00013569601,0.00034215438,0.00006142549,0.00003119836,0.000020040487,0.0000725821,0.000049728966,0.00010807715],"category_scores_gemma":[0.00019007789,0.00008551321,0.00005593537,0.00024812864,0.00007411595,0.000053036005,0.000061577506,0.00009615945,0.0000068721943],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07605142,0.010332148,0.38275886,0.0015169855,0.0028052744,0.00033148887,0.0067592617,0.000012857358,0.053753715,0.0044004247,0.08943633,0.37184122],"study_design_scores_gemma":[0.43363285,0.00883487,0.13464254,0.0009054355,0.0019125901,0.0000039580586,0.0034855113,0.00024880038,0.055518072,0.00051110395,0.3595131,0.0007911732],"about_ca_topic_score_codex":0.000019168485,"about_ca_topic_score_gemma":0.000013749114,"teacher_disagreement_score":0.37105006,"about_ca_system_score_codex":0.00003287206,"about_ca_system_score_gemma":0.000053201627,"threshold_uncertainty_score":0.34871274},"labels":[],"label_agreement":null},{"id":"W3174771143","doi":"10.2337/db21-749-p","title":"749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Type 2 diabetes; Weight gain; Insulin; Diabetes mellitus; Weight loss; Type 2 Diabetes Mellitus; Internal medicine; Endocrinology; Obesity; Body weight","score_opus":0.012286850078088602,"score_gpt":0.24370404404243778,"score_spread":0.23141719396434918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174771143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914586,0.0033777012,9.938976e-7,0.0012049176,0.00037529998,0.0009345597,0.000011599552,0.000058145248,0.0025781633],"genre_scores_gemma":[0.99622923,0.00060662784,0.00019110911,0.0011283656,0.00015018864,0.000087605775,0.00010205414,0.000051192106,0.0014536512],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997649,0.00029464363,0.00063063897,0.00044373228,0.00039462314,0.0005873707],"domain_scores_gemma":[0.9982961,0.00036107132,0.00022833339,0.0006994051,0.0003059758,0.00010913996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004571803,0.0003197289,0.0009924063,0.00023554888,0.00006982585,0.000036332265,0.00020331764,0.00009765051,0.00019951025],"category_scores_gemma":[0.00074872025,0.00021430734,0.0003684814,0.001465542,0.000088945504,0.000108417495,0.00013032455,0.00019317078,0.00002728577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028307682,0.0017010315,0.9186867,0.00011248984,0.0021449225,0.000042867166,0.00021617636,0.00015440323,0.04807448,0.0000954295,0.0010645619,0.024876174],"study_design_scores_gemma":[0.17127378,0.0029187077,0.32042804,0.00062502566,0.0023450258,3.1245256e-7,0.00030855837,0.0028423464,0.48932114,0.00045411367,0.0087164,0.0007665451],"about_ca_topic_score_codex":0.000047642763,"about_ca_topic_score_gemma":0.00010017364,"teacher_disagreement_score":0.5982587,"about_ca_system_score_codex":0.000095254174,"about_ca_system_score_gemma":0.00015479537,"threshold_uncertainty_score":0.87391996},"labels":[],"label_agreement":null},{"id":"W3174833183","doi":"10.14814/phy2.14890","title":"Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus","year":2021,"lang":"en","type":"article","venue":"Physiological Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health; National Institute of Biomedical Imaging and Bioengineering; University of Toronto; Canada Research Chairs","keywords":"Medicine; Diabetes mellitus; Gerontology; Library science; Endocrinology","score_opus":0.026670749705807868,"score_gpt":0.26882465582889087,"score_spread":0.242153906123083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174833183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998643,0.000569954,0.000040984236,0.00006911021,0.00003272113,0.00039213942,0.0000068069935,0.000024119137,0.000221189],"genre_scores_gemma":[0.99876404,0.00030786538,0.00037073885,0.00010113748,0.000024329613,0.000027769345,0.00033843986,0.000011745632,0.000053920416],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998394,0.0000441204,0.0006017439,0.0004085464,0.0002961245,0.0002554666],"domain_scores_gemma":[0.99907464,0.00002974383,0.00024043747,0.0004141015,0.00015011054,0.00009097353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018889565,0.00018740527,0.0006512274,0.00009277661,0.000015214601,0.0000039897604,0.000028569624,0.0001052142,0.000053621025],"category_scores_gemma":[0.000087242544,0.00012538281,0.00045203877,0.00018391787,0.00006386323,0.00004234144,0.000045667657,0.000117757736,0.0000022929112],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001584522,0.002217534,0.02049597,0.00012890171,0.00020588345,0.00052592275,0.000050234063,0.0025108906,0.9717234,0.000029179037,0.00008760116,0.0018660678],"study_design_scores_gemma":[0.0012278197,0.0011145873,0.6043732,0.00044678804,0.00020967577,0.000005012959,0.000010565295,0.0031675776,0.38730794,0.0019934273,0.000012900863,0.00013049773],"about_ca_topic_score_codex":0.00003173633,"about_ca_topic_score_gemma":0.0000033249523,"teacher_disagreement_score":0.58441544,"about_ca_system_score_codex":0.00008697108,"about_ca_system_score_gemma":0.00007237165,"threshold_uncertainty_score":0.5112963},"labels":[],"label_agreement":null},{"id":"W3175102295","doi":"10.2337/db21-455-p","title":"455-P: Global Comparisons of Awareness of Chronic Kidney Disease and Renoprotective Therapies among Type 1 Diabetes Patients","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Disease; Type 1 diabetes; Renal replacement therapy; Internal medicine; Pediatrics; Family medicine; Intensive care medicine; Endocrinology","score_opus":0.010560046934102152,"score_gpt":0.2478762412707335,"score_spread":0.23731619433663134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175102295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337065,0.005097381,0.0000039011684,0.00015685213,0.0001432767,0.00043710147,0.00012555326,0.00003201535,0.00063328585],"genre_scores_gemma":[0.99915075,0.00013433526,0.00013625648,0.000102789825,0.00003289885,0.000043459502,0.00027566584,0.000015703827,0.000108118234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894154,0.000053204156,0.00024338868,0.0002715587,0.00022430447,0.0002660044],"domain_scores_gemma":[0.99902695,0.000052623418,0.00013933943,0.00030516327,0.0002717933,0.00020410932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006546046,0.00017984978,0.0004792708,0.000056884823,0.000045641154,0.000012894458,0.0000674368,0.000047214027,0.00006389123],"category_scores_gemma":[0.00017639992,0.00015296569,0.00008950965,0.00029294894,0.00021752635,0.000087406894,0.000115417686,0.000047590776,0.00000237937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003390781,0.000720964,0.9887264,0.00060064485,0.00078109145,0.0000024502879,0.00007965753,0.000003945223,0.0015305062,0.00028547304,0.0007549861,0.0064799935],"study_design_scores_gemma":[0.0017653028,0.0005880148,0.963535,0.0005173299,0.0005865987,1.7700492e-8,0.000074296724,0.00024118321,0.031323604,0.00036243387,0.00086802326,0.00013817434],"about_ca_topic_score_codex":0.000027350401,"about_ca_topic_score_gemma":0.000011752222,"teacher_disagreement_score":0.029793099,"about_ca_system_score_codex":0.000072248105,"about_ca_system_score_gemma":0.0001517644,"threshold_uncertainty_score":0.62377596},"labels":[],"label_agreement":null},{"id":"W3175702793","doi":"10.2337/db21-896-p","title":"896-P: Demographic and Glycemic Parameters across Global Regions in Youth with T2D in Clinical Trials of Sitagliptin","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sitagliptin; Glycemic; Demography; Internal medicine; Type 2 diabetes; Clinical trial; Metformin; Ethnic group; Diabetes mellitus; Endocrinology","score_opus":0.070887622673169,"score_gpt":0.36478149370389296,"score_spread":0.29389387103072395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175702793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997093,0.0015105633,0.000005576759,0.00043488832,0.00006956916,0.00042343812,0.00005902681,0.0000214765,0.00038241036],"genre_scores_gemma":[0.9985982,0.00027382188,0.00065781444,0.00028924597,0.000017557331,0.000027451124,0.00008549017,0.00001114614,0.000039239287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981305,0.00025176632,0.0007583825,0.0003491228,0.00016182588,0.00034837288],"domain_scores_gemma":[0.99890953,0.00045998665,0.00018690877,0.00029059293,0.000044004628,0.00010894864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00128834,0.00015787673,0.00088368804,0.000093272334,0.00001769858,0.000019230438,0.000057970774,0.00009836549,0.000006510158],"category_scores_gemma":[0.0007950351,0.00012153998,0.0001530588,0.0005957177,0.00018727375,0.00006247681,0.00007024082,0.00012767375,0.0000017357924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030594255,0.0004451005,0.98900515,0.00008375263,0.00025320402,0.000055928536,0.00028013234,0.0000064252968,0.00010562342,0.00017328786,0.000050111066,0.009235367],"study_design_scores_gemma":[0.015580125,0.0011407244,0.97630227,0.000946861,0.00057949504,0.0000016894816,0.0027975156,0.00014077961,0.001548719,0.00060814596,0.000121049,0.00023261226],"about_ca_topic_score_codex":0.000057316152,"about_ca_topic_score_gemma":0.00028171515,"teacher_disagreement_score":0.015274183,"about_ca_system_score_codex":0.000034558863,"about_ca_system_score_gemma":0.00005090857,"threshold_uncertainty_score":0.49562564},"labels":[],"label_agreement":null},{"id":"W3175783883","doi":"10.1080/07853890.2021.1925148","title":"Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care","year":2021,"lang":"en","type":"review","venue":"Annals of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Basal insulin; Basal (medicine); Medicine; Regimen; Type 2 diabetes; Insulin; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.18809632695936565,"score_gpt":0.4582673307229053,"score_spread":0.27017100376353964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175783883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011244308,0.96889955,0.000074266856,0.025121018,0.00007971257,0.002363242,0.000021028001,0.0000073980577,0.003422554],"genre_scores_gemma":[0.000055236407,0.98938507,0.0004370154,0.008929549,0.0002211316,0.00027173632,0.00055512995,0.000021582386,0.00012352382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825114,0.00017345173,0.00081325206,0.0002597273,0.0003701358,0.00013231915],"domain_scores_gemma":[0.99723727,0.0009223012,0.000712626,0.00035421894,0.0007124851,0.00006109389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008855557,0.00024431793,0.0018379054,0.00009851417,0.000047582645,0.0000039452675,0.00007418394,0.00008846962,0.000045406992],"category_scores_gemma":[0.00234902,0.00013078895,0.00020977172,0.0002418492,0.000090438225,0.000055051183,0.000038913444,0.00017291821,0.0000012151762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036340436,0.00017682996,0.000008400045,0.22356394,0.0009969731,0.000014156603,0.0009761316,2.7567506e-8,0.0000019019919,0.005774573,0.13223322,0.6362175],"study_design_scores_gemma":[0.0005587185,0.0010254908,0.000036207584,0.26837063,0.0023154537,0.0000049377763,0.00039529026,6.15181e-7,0.000013785128,0.00007208493,0.7271236,0.00008319401],"about_ca_topic_score_codex":0.000003596851,"about_ca_topic_score_gemma":0.0000018620269,"teacher_disagreement_score":0.6361343,"about_ca_system_score_codex":0.000027704478,"about_ca_system_score_gemma":0.0003527169,"threshold_uncertainty_score":0.5333418},"labels":[],"label_agreement":null},{"id":"W3176403805","doi":"10.7326/m21-0651","title":"Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure","year":2021,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Sanofi","keywords":"Medicine; Heart failure; Type 2 diabetes; Diabetes mellitus; Type 1 diabetes; Internal medicine; Intensive care medicine; Cardiology; Endocrinology","score_opus":0.007606110434205619,"score_gpt":0.2720369745081515,"score_spread":0.2644308640739459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176403805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677473,0.00046538617,0.0000028265183,0.0015616972,0.000076431774,0.00020808402,0.000002546627,0.00000708107,0.0009011852],"genre_scores_gemma":[0.99911886,0.00002553311,0.00007926854,0.00046389535,0.000034198296,0.0000053075146,0.000033724133,0.000010525681,0.00022865401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925417,0.000037388076,0.0002120365,0.00014102031,0.00022534201,0.00013002357],"domain_scores_gemma":[0.99944544,0.000115647395,0.000076021286,0.00013093757,0.00017006528,0.000061908184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013747442,0.00011048226,0.00038449577,0.00014474936,0.000009010769,0.0000027260362,0.000026748812,0.000026529513,0.00007935878],"category_scores_gemma":[0.00025735574,0.00007004433,0.000030351035,0.00020721488,0.00007709856,0.000040523,0.000030085484,0.00006699547,0.0000017872454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003940557,0.00023168552,0.9914075,0.00023533808,0.00023575492,0.000014734833,0.00016079191,0.0000072959424,0.0005312388,0.000082067985,0.0025620507,0.004137447],"study_design_scores_gemma":[0.005780637,0.022134015,0.91540426,0.0052486784,0.00020228888,0.0000013884597,0.00010620756,0.000044569144,0.050308798,0.000021779108,0.00064909615,0.00009826995],"about_ca_topic_score_codex":0.000017173039,"about_ca_topic_score_gemma":0.000006022993,"teacher_disagreement_score":0.07600327,"about_ca_system_score_codex":0.000007859513,"about_ca_system_score_gemma":0.0000106506395,"threshold_uncertainty_score":0.2856325},"labels":[],"label_agreement":null},{"id":"W3176418024","doi":"10.2337/db21-731-p","title":"731-P: CGM-Based Measurements for Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Treated Patients with T2D: A Post-hoc Analysis","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Insulin glargine; Insulin; Internal medicine; Endocrinology; Regular insulin; Diabetes mellitus; Hypoglycemia","score_opus":0.015335842374486864,"score_gpt":0.23717105193810203,"score_spread":0.22183520956361516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176418024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993429,0.0017791414,0.00007200665,0.001272097,0.0001301994,0.0020232839,0.00030864045,0.00018653423,0.00079908606],"genre_scores_gemma":[0.9864072,0.00008656518,0.0035516075,0.0023833595,0.000078286284,0.00063655473,0.006071315,0.000107701286,0.0006773754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99586195,0.00015625313,0.0008516301,0.0011105317,0.0009888895,0.0010307565],"domain_scores_gemma":[0.99704874,0.00021725072,0.00033512086,0.0009252201,0.0011167055,0.0003569912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041638076,0.00067703397,0.0014036105,0.00096746034,0.0001395359,0.00011463754,0.00027159677,0.00021379597,0.00022727315],"category_scores_gemma":[0.0003777535,0.00056849053,0.00043839635,0.0027525271,0.00010959097,0.00026204158,0.00011559022,0.00024702467,0.000060780447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020811986,0.004985831,0.95686346,0.00032721186,0.003995565,0.000057549776,0.00019557631,0.0003626352,0.0009821705,0.00002273448,0.0005491346,0.029576922],"study_design_scores_gemma":[0.04439648,0.0049196463,0.91182894,0.0006734766,0.0057679107,1.8867999e-7,0.00015663957,0.0033251112,0.021523848,0.00004786403,0.0064160437,0.000943832],"about_ca_topic_score_codex":0.00015802469,"about_ca_topic_score_gemma":0.00048975763,"teacher_disagreement_score":0.04503451,"about_ca_system_score_codex":0.00049674057,"about_ca_system_score_gemma":0.00031516238,"threshold_uncertainty_score":0.99967664},"labels":[],"label_agreement":null},{"id":"W3176430756","doi":"10.2337/db21-748-p","title":"748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe","year":2021,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Type 2 diabetes; Weight gain; Insulin; Basal insulin; Clinical endpoint; Diabetes mellitus; Internal medicine; Randomized controlled trial; Endocrinology; Body weight","score_opus":0.02102427562539468,"score_gpt":0.2676921464837781,"score_spread":0.2466678708583834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176430756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473566,0.0024794587,1.8750762e-7,0.00072622986,0.00020517725,0.00097118394,0.000006463489,0.000024725283,0.0008509143],"genre_scores_gemma":[0.99816257,0.0005349256,0.00005968738,0.0005760777,0.00005650968,0.00014561688,0.00005395251,0.000035928828,0.00037472515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973859,0.00039378743,0.00075974496,0.0004184951,0.00030952672,0.000732513],"domain_scores_gemma":[0.9986953,0.00036792632,0.00017589764,0.0005118597,0.00016039959,0.000088591376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067254575,0.00027322766,0.001006055,0.0003809054,0.0000290661,0.000023672526,0.00016953466,0.00009378161,0.00013795316],"category_scores_gemma":[0.00085923506,0.00019378116,0.00017312482,0.0025679327,0.00006749218,0.00011188425,0.00010701085,0.00021175975,0.00001283171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019128884,0.0014966882,0.9695593,0.000056065695,0.00036325306,0.000045387053,0.00025519598,0.00027367714,0.015103593,0.000029609244,0.00006539196,0.010838949],"study_design_scores_gemma":[0.10913116,0.0010150645,0.75477797,0.000533053,0.00039098572,5.161582e-8,0.0002234735,0.0040473626,0.12882434,0.00014102433,0.0005905253,0.00032496752],"about_ca_topic_score_codex":0.0001268833,"about_ca_topic_score_gemma":0.0010781612,"teacher_disagreement_score":0.2147813,"about_ca_system_score_codex":0.00013469148,"about_ca_system_score_gemma":0.00016071627,"threshold_uncertainty_score":0.7902167},"labels":[],"label_agreement":null},{"id":"W3176472394","doi":"10.1096/fasebj.27.1_supplement.955.1","title":"<i>COMT</i> rs4680 variant and cardiometabolic side‐effects in children treated with second‐generation antipsychotics","year":2013,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"rs4680; Medicine; Internal medicine; Endocrinology; Catechol-O-methyl transferase; Blood pressure; Waist; Genotype; Body mass index; Chemistry; Biochemistry","score_opus":0.007355003518594145,"score_gpt":0.2083400227874725,"score_spread":0.20098501926887835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176472394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961434,0.0007248922,0.00012507458,0.00045698512,0.000064326465,0.0006897415,0.0000020905989,0.000016943295,0.0017765589],"genre_scores_gemma":[0.99785274,0.00025636773,0.0003782496,0.00050884526,0.00022782577,0.000020168693,0.000016838074,0.000017219721,0.0007217694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922925,0.00008007393,0.00016443121,0.00013063826,0.00017028308,0.00022531171],"domain_scores_gemma":[0.9995658,0.000025176687,0.00007417848,0.00018000203,0.000041863066,0.00011299953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019803683,0.00014375956,0.0002504876,0.00015575191,0.000100129844,0.0001093144,0.00005822328,0.00003274473,0.000061123654],"category_scores_gemma":[0.000008274678,0.000076814234,0.000043743832,0.0001996427,0.00004295694,0.00014365943,0.00001878496,0.00017397593,0.000025206717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021133132,0.0004870197,0.8499549,0.00005008008,0.002044488,0.00027049784,0.00043143707,0.00012567773,0.07235887,0.0005159806,0.0044181067,0.06913158],"study_design_scores_gemma":[0.004677752,0.00047518272,0.9854898,0.000070974325,0.00048332306,0.0007042823,0.0000459937,0.0004573681,0.007183096,0.00010305388,0.00018830603,0.00012088428],"about_ca_topic_score_codex":0.000041045558,"about_ca_topic_score_gemma":0.000016630946,"teacher_disagreement_score":0.13553485,"about_ca_system_score_codex":0.000033909477,"about_ca_system_score_gemma":0.000021697939,"threshold_uncertainty_score":0.31323937},"labels":[],"label_agreement":null},{"id":"W3176497010","doi":"10.1136/bmjdrc-2021-002208","title":"Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study","year":2021,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Liraglutide; Type 2 diabetes; Gastric emptying; Internal medicine; Medicine; Endocrinology; Diabetes mellitus; Randomized controlled trial; Gastroenterology; Stomach","score_opus":0.04963130925560367,"score_gpt":0.3857178612326435,"score_spread":0.33608655197703985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176497010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97917646,0.006902219,0.0000012200167,0.00009411659,0.00018944919,0.012126955,0.000014803072,0.000036541667,0.0014582524],"genre_scores_gemma":[0.99523985,0.0003803727,0.00020939675,0.000091869275,0.00008029954,0.0033761358,0.00025427798,0.00007327347,0.00029452288],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99461895,0.0019446958,0.00053113175,0.00086643756,0.0012144911,0.0008242945],"domain_scores_gemma":[0.9961593,0.0015459157,0.00017188216,0.0008851481,0.0008777943,0.00035996764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002376609,0.00038683577,0.001550825,0.0006258581,0.00016396363,0.0002273736,0.0003344519,0.00009075877,0.00007991383],"category_scores_gemma":[0.0010554052,0.0002961387,0.00011902698,0.0016151514,0.00016699947,0.00046920302,0.0006018175,0.0004298311,0.000023639921],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29902357,0.033908725,0.4902329,0.008254517,0.0076766447,0.0013319305,0.021005247,0.00013525964,0.033179816,0.0002569491,0.00216717,0.10282726],"study_design_scores_gemma":[0.68744355,0.029231507,0.13218442,0.0014376009,0.0027771199,4.8055904e-7,0.02016247,0.00032665973,0.12506548,0.000042150594,0.0006612064,0.0006673589],"about_ca_topic_score_codex":0.000107376734,"about_ca_topic_score_gemma":0.00052547076,"teacher_disagreement_score":0.38842,"about_ca_system_score_codex":0.00019940242,"about_ca_system_score_gemma":0.00042674717,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W3176782477","doi":"10.1096/fasebj.2019.33.1_supplement.531.17","title":"SGLT2 Inhibition Is Predicted to Reduce LV End Diastolic Pressure: A Mathematical Modeling Analysis","year":2019,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Merck; AstraZeneca; Pfizer","keywords":"Medicine; Hemodynamics; Heart failure; Ejection fraction; Internal medicine; Cardiology; Mean arterial pressure; Cardiac output; Blood pressure; Ventricle; Heart rate","score_opus":0.019390322550916782,"score_gpt":0.2654372236558241,"score_spread":0.24604690110490735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176782477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985309,0.00014282527,0.0050682044,0.0029518043,0.00006991108,0.00050773704,0.000015634118,0.00003962307,0.0058952766],"genre_scores_gemma":[0.9901886,0.000028146727,0.0006790841,0.00069700344,0.00018479978,0.000017179702,0.0000183952,0.000016929629,0.008169853],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987461,0.000053841475,0.00029245077,0.00017378479,0.00045811856,0.0002756999],"domain_scores_gemma":[0.9992456,0.000036695117,0.00008714889,0.00034334112,0.000084386375,0.00020284211],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040280007,0.00014170742,0.00031706257,0.00026335102,0.00009885256,0.00007405566,0.000102568956,0.000042962878,0.0032742126],"category_scores_gemma":[0.000036227626,0.00008676366,0.00022464847,0.00044725867,0.000019586165,0.00010296323,0.00006541046,0.00020733933,0.0005023309],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006897873,0.008602597,0.045203157,0.001890704,0.10439114,0.0009561054,0.05324627,0.1862776,0.37215453,0.007988395,0.090666056,0.12172557],"study_design_scores_gemma":[0.009437489,0.002397411,0.009027748,0.0012319131,0.0389783,0.0004011928,0.002038419,0.874099,0.051457703,0.0044838423,0.0056538004,0.00079315127],"about_ca_topic_score_codex":0.000006786162,"about_ca_topic_score_gemma":9.895112e-7,"teacher_disagreement_score":0.68782145,"about_ca_system_score_codex":0.000058940077,"about_ca_system_score_gemma":0.000032417425,"threshold_uncertainty_score":0.9976369},"labels":[],"label_agreement":null},{"id":"W3177134034","doi":"10.1097/hco.0000000000000892","title":"Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Dalhousie University; University of Toronto; York Central Hospital; University of Manitoba; St Joseph's Health Centre; St. Michael's Hospital; Royal Jubilee Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Permission; Diabetes mellitus; Intensive care medicine; Medical emergency; Endocrinology","score_opus":0.13053127548985374,"score_gpt":0.39705528511253807,"score_spread":0.2665240096226843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177134034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018780572,0.9810024,0.00030559264,0.00056773727,0.01042478,0.00575187,0.00022931502,0.00018956112,0.0013409476],"genre_scores_gemma":[0.00038645873,0.987997,0.00035897482,0.00010017566,0.0023065316,0.0038040315,0.004442569,0.00014598678,0.00045828824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99341553,0.0008827181,0.0012753851,0.0021198918,0.00092327956,0.0013831691],"domain_scores_gemma":[0.9956246,0.0003363926,0.00027079822,0.0024750426,0.0002613885,0.0010317555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012562482,0.001178306,0.0062226313,0.0012126811,0.00017671283,0.0000829331,0.000717846,0.0007393993,0.000102535734],"category_scores_gemma":[0.0005998779,0.00093210005,0.0030814835,0.0011658826,0.00013286638,0.00011090257,0.0011994196,0.00087512634,0.00020024541],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020783906,0.00016645728,0.002113656,0.011698447,0.003007999,0.000051586838,0.00012833398,0.00016171808,0.0000013207477,0.00015439781,0.043932937,0.93856233],"study_design_scores_gemma":[0.000932184,0.00039821703,0.0012467382,0.030816678,0.0035824303,0.00006779299,0.000110988076,0.000007602205,0.0000030878239,0.000023838924,0.9620239,0.0007865035],"about_ca_topic_score_codex":0.000015181581,"about_ca_topic_score_gemma":8.384246e-7,"teacher_disagreement_score":0.93777585,"about_ca_system_score_codex":0.0009179415,"about_ca_system_score_gemma":0.000517951,"threshold_uncertainty_score":0.99931294},"labels":[],"label_agreement":null},{"id":"W3177246285","doi":"10.2215/cjn.01130121","title":"Ertugliflozin and Slope of Chronic eGFR","year":2021,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Merck; Pfizer","keywords":"Medicine; Placebo; Confidence interval; Internal medicine; Kidney disease; Renal function; Population; Diabetes mellitus; Urology; Surgery; Endocrinology; Pathology","score_opus":0.03201368279407954,"score_gpt":0.34699807098845303,"score_spread":0.31498438819437347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177246285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97359496,0.0020836666,0.00009162936,0.023698745,0.00015632018,0.00007746827,0.0000015800981,0.000002848726,0.00029276597],"genre_scores_gemma":[0.9643615,0.0067038247,0.0052726706,0.02291467,0.0003109724,8.2701865e-7,8.454978e-7,0.00001092193,0.00042377878],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987116,0.00016169723,0.00068906345,0.0001153559,0.0001756083,0.00014667744],"domain_scores_gemma":[0.9980763,0.00041875802,0.00096609775,0.00025042432,0.00019870665,0.00008970048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004905576,0.000086079,0.0007800975,0.00001803624,0.000022604108,0.0000024944932,0.00014371345,0.000052497388,0.000048113754],"category_scores_gemma":[0.0001104809,0.000054322165,0.0006794974,0.0001820315,0.0012994343,0.000026559484,0.00016814124,0.00025427254,0.0000011114936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00099147,0.0024573782,0.3154985,0.0002851439,0.00690731,0.00007825959,0.0004007604,0.000017795428,0.039740782,0.00035997463,0.26534724,0.3679154],"study_design_scores_gemma":[0.0056255865,0.0071272664,0.75900996,0.00018708577,0.0017017637,0.00017292974,0.0008476713,0.00014305087,0.0020534021,0.0006182715,0.22240661,0.00010640677],"about_ca_topic_score_codex":0.00000676939,"about_ca_topic_score_gemma":0.0000024749882,"teacher_disagreement_score":0.44351146,"about_ca_system_score_codex":0.000035048844,"about_ca_system_score_gemma":0.00022099869,"threshold_uncertainty_score":0.478782},"labels":[],"label_agreement":null},{"id":"W3177365549","doi":"10.1056/nejmoa2108269","title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":777,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Steno Diabetes Center Aarhus; Sanofi","keywords":"Type 2 diabetes; Medicine; Glucagon-like peptide 1 receptor; Diabetes mellitus; Adverse effect; Agonist; Internal medicine; Endocrinology; Receptor; Glucagon-like peptide-1","score_opus":0.011697388121400885,"score_gpt":0.23833279191003628,"score_spread":0.2266354037886354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177365549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96811664,0.020754978,0.000040906318,0.008650652,0.00018949152,0.00009173041,2.6050026e-7,0.0000059737317,0.00214937],"genre_scores_gemma":[0.9942596,0.0020128747,0.0012347202,0.00068349077,0.00062057213,8.7192194e-7,0.000005674662,0.000012714402,0.0011694571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903375,0.000047352958,0.00026215575,0.000110456895,0.000394756,0.0001515388],"domain_scores_gemma":[0.9993594,0.000103828366,0.00007819873,0.00014613535,0.00014160466,0.00017082096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045724522,0.00011398788,0.00060886575,0.00016679567,0.000014214211,0.0000068971085,0.000035596197,0.00002687122,0.00007840669],"category_scores_gemma":[0.00021129489,0.00006178825,0.0000629428,0.00020196765,0.00004891548,0.000059264647,0.000018543238,0.00015823651,0.0000012906289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034111948,0.00012218488,0.69037277,0.000106462256,0.002281227,0.0034304683,0.00048836466,0.000045244837,0.00082320516,0.00012284066,0.0028557584,0.29901034],"study_design_scores_gemma":[0.13653632,0.0043456564,0.6626616,0.0019809476,0.0026795787,0.0006881397,0.00037828914,0.00002979176,0.0017754697,0.0004934112,0.18824317,0.00018762033],"about_ca_topic_score_codex":0.000020415526,"about_ca_topic_score_gemma":0.000033125474,"teacher_disagreement_score":0.29882273,"about_ca_system_score_codex":0.000031907057,"about_ca_system_score_gemma":0.00009662942,"threshold_uncertainty_score":0.25196517},"labels":[],"label_agreement":null},{"id":"W3177697454","doi":"10.1007/s11255-021-02943-2","title":"Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"International Urology and Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hematocrit; Internal medicine; Placebo; Canagliflozin; Type 2 diabetes; Hemoglobin; Meta-analysis; Diabetes mellitus; Dapagliflozin; Randomized controlled trial; Gastroenterology; Kidney disease; Endocrinology; Pathology","score_opus":0.032842032528549565,"score_gpt":0.33184460394258725,"score_spread":0.2990025714140377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177697454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024655014,0.99455047,0.0000013442587,0.000985409,0.00007146401,0.0017418736,0.000051344952,0.0000104665205,0.00012212063],"genre_scores_gemma":[0.008484497,0.9874938,0.000016286895,0.0031279263,0.000018388257,0.00041045394,0.00020902343,0.000019603633,0.00021999626],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99770916,0.0005700735,0.0008424311,0.00052476523,0.00014813368,0.00020545251],"domain_scores_gemma":[0.998429,0.0008087223,0.00035618947,0.0002690719,0.00006600654,0.00007102083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070425175,0.0003997452,0.0064441618,0.00056879857,0.000017770471,0.000009151086,0.00009692816,0.00028623382,0.00022378434],"category_scores_gemma":[0.00013461408,0.00025947037,0.0006161387,0.00028572287,0.00016462522,0.000036380112,0.00008722085,0.00025182165,0.000006745848],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010505866,0.00026777037,0.00047442463,0.68485373,0.3055957,0.00035702132,0.000042711777,3.52678e-7,0.00000186521,0.001160221,0.00032556147,0.0068155807],"study_design_scores_gemma":[0.00094270596,0.001572663,0.00008769712,0.008332243,0.95797217,0.00010112196,0.0000018017672,0.000009940752,0.000009139899,0.000039947983,0.030715516,0.00021504484],"about_ca_topic_score_codex":0.0000051403363,"about_ca_topic_score_gemma":0.000013449807,"teacher_disagreement_score":0.6765215,"about_ca_system_score_codex":0.00002656019,"about_ca_system_score_gemma":0.000029538178,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W3179565049","doi":"10.2147/dddt.s281602","title":"Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date","year":2021,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Type 2 diabetes; Adverse effect; Hypoglycemia; Renal glucose reabsorption; Intensive care medicine; Diabetes mellitus; Diabetes management; Pharmacology; Internal medicine; Endocrinology","score_opus":0.15371710382983725,"score_gpt":0.36263580421117464,"score_spread":0.2089187003813374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179565049","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019012974,0.9908744,0.00014680138,0.00020934615,0.00024140286,0.006560372,0.000013024437,0.00002122692,0.000032117263],"genre_scores_gemma":[0.0001424979,0.98826814,0.0072750044,0.00013876814,0.00010810851,0.0017894395,0.0001734021,0.00005279938,0.0020518382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982007,0.00019062305,0.000609603,0.00041928823,0.00027928545,0.0003005135],"domain_scores_gemma":[0.9981298,0.00073096174,0.00027834406,0.00057704205,0.00018692766,0.00009691941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007139105,0.00043698333,0.0013787998,0.00012623695,0.00012705059,0.00004124164,0.0002363638,0.00008273328,0.000054539167],"category_scores_gemma":[0.00003751958,0.00019882829,0.00022893466,0.000381624,0.000076911805,0.00006604823,0.00004733361,0.000062564664,0.000007884826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121660705,0.00045818218,0.000048713315,0.0014838396,0.0018173532,0.0000028016138,0.001547761,5.718617e-7,0.000014878881,0.000045184403,0.002052552,0.9924065],"study_design_scores_gemma":[0.0008485679,0.0015933792,0.00003370695,0.005050299,0.0011831954,7.6150167e-7,0.00013439721,0.000011862686,0.0030377079,0.000007149108,0.9878869,0.00021207154],"about_ca_topic_score_codex":0.000005229791,"about_ca_topic_score_gemma":0.0000030486779,"teacher_disagreement_score":0.9921944,"about_ca_system_score_codex":0.000073077696,"about_ca_system_score_gemma":0.00049149746,"threshold_uncertainty_score":0.8107982},"labels":[],"label_agreement":null},{"id":"W3179748924","doi":"10.2337/dc21-0076","title":"The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58","year":2021,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"St. Jude Medical; U.S. Food and Drug Administration; Deutsche Forschungsgemeinschaft; Medicines Company; Regado Biosciences; Zora Biosciences; American Heart Association; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; Allergan; AstraZeneca; CSL Behring; Belvoir Media Group; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; Amgen; Pfizer; Bayer HealthCare; Sanofi","keywords":"Albuminuria; Dapagliflozin; Medicine; Renal function; Creatinine; Urology; Internal medicine; Kidney disease; Diabetes mellitus; TIMI; Type 2 diabetes; Placebo; Endocrinology; Myocardial infarction; Pathology; Percutaneous coronary intervention","score_opus":0.005286034132134163,"score_gpt":0.23778142474090613,"score_spread":0.23249539060877197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179748924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846835,0.002699363,1.6063397e-7,0.0005119431,0.00020471546,0.00040947858,0.000011761521,0.000025774705,0.011453304],"genre_scores_gemma":[0.9985487,0.000060448307,0.0000399723,0.0002474263,0.000046420566,0.00008442394,0.00011977569,0.000019683572,0.00083314313],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902946,0.00008995128,0.00017648605,0.00021365088,0.00021321294,0.00027726387],"domain_scores_gemma":[0.99914485,0.00027820253,0.000043408552,0.00042030474,0.000056933724,0.00005627583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013455052,0.000147795,0.00031349956,0.00006455839,0.000041622334,0.000018661232,0.00008551808,0.000054843124,0.00004371772],"category_scores_gemma":[0.00015276491,0.00009387725,0.00013072939,0.00022481265,0.000037098594,0.000026359061,0.000060854283,0.000099493365,0.000084802516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007651959,0.000085634165,0.90689933,0.00036660724,0.00022213673,0.000059658076,0.00027266616,0.0000137180195,0.0021752426,0.00017140713,0.0040199733,0.08563708],"study_design_scores_gemma":[0.005594258,0.002573005,0.36940852,0.000803884,0.0004928521,4.2803117e-7,0.001228341,0.00007111741,0.5751487,0.00006163934,0.04438668,0.00023059704],"about_ca_topic_score_codex":0.0000036193458,"about_ca_topic_score_gemma":0.00003598608,"teacher_disagreement_score":0.57297343,"about_ca_system_score_codex":0.000081797196,"about_ca_system_score_gemma":0.0000258569,"threshold_uncertainty_score":0.3828203},"labels":[],"label_agreement":null},{"id":"W3179935149","doi":"10.1001/jamaophthalmol.2021.2129","title":"Methodological Considerations for the Case-Control Study of Metformin and Age-Related Macular Degeneration","year":2021,"lang":"en","type":"letter","venue":"JAMA Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Macular degeneration; Metformin; Optometry; Degeneration (medical); Control (management); Ophthalmology; Gerontology; Diabetes mellitus; Artificial intelligence; Endocrinology","score_opus":0.16319142698074698,"score_gpt":0.36394604808784203,"score_spread":0.20075462110709505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179935149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6068297,0.0042314823,0.0008097835,0.37692213,0.0008212426,0.008736541,0.00016150498,0.00004966387,0.0014379323],"genre_scores_gemma":[0.8965258,0.00004577417,0.010276336,0.085473575,0.0008352104,0.0016088949,0.00047890126,0.00005943484,0.0046960968],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99790806,0.0007727044,0.00049099734,0.000437244,0.0001369117,0.0002540735],"domain_scores_gemma":[0.99472463,0.0044147186,0.00022351704,0.0004255712,0.00017582384,0.000035757526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000809397,0.0002621198,0.0009177836,0.00013792406,0.00015514041,0.000043146145,0.000059292463,0.00059961167,0.00043819897],"category_scores_gemma":[0.0009478519,0.00016615087,0.00018107981,0.00009585882,0.000138025,0.000037536127,0.00006824293,0.00051473087,0.000001995071],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034177894,0.0014803734,0.0024666814,0.00074237987,0.016103921,0.5418327,0.0012067702,0.00013780633,0.0007855737,0.0022595963,0.41859224,0.014050209],"study_design_scores_gemma":[0.10703629,0.04479307,0.03882775,0.000441875,0.11017989,0.49141383,0.007967552,0.008031888,0.002386783,0.033633552,0.1522786,0.0030088858],"about_ca_topic_score_codex":0.00007085702,"about_ca_topic_score_gemma":0.000012477993,"teacher_disagreement_score":0.29144856,"about_ca_system_score_codex":0.00003758797,"about_ca_system_score_gemma":0.00004853776,"threshold_uncertainty_score":0.6775436},"labels":[],"label_agreement":null},{"id":"W3180020031","doi":"10.1136/bmjopen-2021-049130","title":"Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review","year":2021,"lang":"en","type":"review","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Liraglutide; Glucagon-like peptide 1 receptor; Type 2 diabetes; Glucagon-like peptide-1; MEDLINE; Diabetes mellitus; Exenatide; Meta-analysis; Internal medicine; Pharmacology; Intensive care medicine; Endocrinology; Receptor; Agonist","score_opus":0.07940047159209368,"score_gpt":0.3794363137453456,"score_spread":0.3000358421532519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180020031","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006101325,0.9553082,2.7764446e-7,0.000050911687,0.000049610644,0.043682896,0.000059259124,0.0000036346662,0.00023508139],"genre_scores_gemma":[0.00021388264,0.9912127,0.00022485078,0.000034310735,0.000021784876,0.007414926,0.0005941853,0.000022368355,0.00026099267],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.998485,0.00018920202,0.0007512829,0.00026368516,0.00018806076,0.00012271223],"domain_scores_gemma":[0.998302,0.00031575534,0.0007595609,0.0003745313,0.00020838185,0.000039801096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044143893,0.00025533262,0.0024164922,0.00007673992,0.00002515447,0.000032626467,0.00012600592,0.000065477354,0.000012018269],"category_scores_gemma":[0.00029894544,0.0001222405,0.00009903176,0.00022041576,0.00004442151,0.00006887442,0.00013183022,0.00004072352,0.0000012220232],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028340137,0.00015021117,0.00061094505,0.82920796,0.0010933948,6.703552e-7,0.00018700541,5.7614763e-8,3.6744993e-8,0.000032709442,0.00028159,0.16840708],"study_design_scores_gemma":[0.0017454398,0.0020341966,0.00007948492,0.9674067,0.010066304,5.5976267e-7,0.00012018806,0.000004106622,0.000002270716,0.0000056314598,0.018383637,0.00015147761],"about_ca_topic_score_codex":0.00006968504,"about_ca_topic_score_gemma":0.000024356877,"teacher_disagreement_score":0.16825561,"about_ca_system_score_codex":0.00010175673,"about_ca_system_score_gemma":0.00021406933,"threshold_uncertainty_score":0.4984823},"labels":[],"label_agreement":null},{"id":"W3181897787","doi":"10.1111/dom.14489","title":"Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University Health Network; University of Toronto; Toronto General Hospital; Diabetes Canada","funders":"","keywords":"Empagliflozin; Metabolite; Type 2 diabetes; Urine; Internal medicine; Endocrinology; Diabetes mellitus; Chemistry; Medicine; Pharmacology","score_opus":0.006488083987414294,"score_gpt":0.1940352688528273,"score_spread":0.187547184865413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181897787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939014,0.0048015453,1.3618117e-7,0.00030731192,0.000071271745,0.00049747893,0.000026037358,0.000043095402,0.0003517623],"genre_scores_gemma":[0.9977752,0.000590493,0.0003175918,0.00049828604,0.000033093365,0.000050419472,0.00026253113,0.000030287707,0.00044212065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845,0.00009217126,0.00019940932,0.0004609106,0.00026854532,0.0005289691],"domain_scores_gemma":[0.99928886,0.00010107181,0.00008102615,0.00022138255,0.0001435025,0.00016415834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022782078,0.00029970563,0.0007745275,0.00029288328,0.000055367484,0.0000557905,0.000051428902,0.0000958277,0.000039362843],"category_scores_gemma":[0.00014170533,0.00022154268,0.000027037704,0.0006721438,0.00010671256,0.00018384014,0.00010189775,0.00017471342,0.0000032732166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067601955,0.00094656437,0.99307185,0.00011299283,0.0003934237,0.000026030342,0.00021500143,0.0000015765971,0.00025148096,0.00017451071,0.00002861578,0.004710365],"study_design_scores_gemma":[0.007357585,0.0003344312,0.9836139,0.00030076504,0.0005786686,2.0150331e-7,0.00006467905,0.00004897527,0.005743171,0.000071637485,0.0016252317,0.00026071855],"about_ca_topic_score_codex":0.000015784413,"about_ca_topic_score_gemma":0.0005883523,"teacher_disagreement_score":0.0094579,"about_ca_system_score_codex":0.00003148284,"about_ca_system_score_gemma":0.000039429353,"threshold_uncertainty_score":0.9034248},"labels":[],"label_agreement":null},{"id":"W3183300604","doi":"10.1016/s2213-8587(21)00180-7","title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; Bayer Fund; Novartis; Servier; Amgen; Pfizer; Bristol-Myers Squibb; AstraZeneca; Fundação Lemann; Boehringer Ingelheim","keywords":"Medicine; Dapagliflozin; Discontinuation; Placebo; Internal medicine; Adverse effect; Hazard ratio; Population; Kidney disease; Organ dysfunction; Randomized controlled trial; Clinical trial; Diabetes mellitus; Type 2 diabetes; Confidence interval; Sepsis; Endocrinology; Pathology","score_opus":0.030205094319406333,"score_gpt":0.30034683372907833,"score_spread":0.270141739409672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183300604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865455,0.0011085683,0.000028703478,0.002362067,0.00036982825,0.0076581216,0.00011907444,0.0001914468,0.0016166909],"genre_scores_gemma":[0.9942706,0.00028756,0.00013716407,0.0016426063,0.0003614417,0.002163251,0.00057258096,0.0000698439,0.00049494527],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957499,0.00058344606,0.00060369296,0.00077649707,0.00054131815,0.0017451416],"domain_scores_gemma":[0.9971622,0.00080271857,0.0003754515,0.001146221,0.00014424116,0.00036915982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059596926,0.0005881362,0.0024902835,0.00041054058,0.00019796475,0.00007646558,0.00034843475,0.000113299466,0.00019315085],"category_scores_gemma":[0.00050217554,0.00032880716,0.0003013848,0.00075703114,0.00031352558,0.00013947749,0.00015609404,0.0004896219,0.000028094044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6154218,0.0013704232,0.3766987,0.00006698819,0.0035417671,0.00017687627,0.0003557319,0.00013632404,0.000017359946,0.00022228052,0.000703974,0.0012878142],"study_design_scores_gemma":[0.96348834,0.0032088426,0.020070918,0.000039964114,0.0030480216,0.0000031085262,0.00030253184,0.000027577704,0.00044017847,0.00008389695,0.00889765,0.00038897042],"about_ca_topic_score_codex":0.0001759652,"about_ca_topic_score_gemma":0.00013022701,"teacher_disagreement_score":0.3566278,"about_ca_system_score_codex":0.00024072902,"about_ca_system_score_gemma":0.00035040922,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W3184577461","doi":"10.1016/j.abb.2021.108995","title":"Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy","year":2021,"lang":"en","type":"article","venue":"Archives of Biochemistry and Biophysics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"Indian Council of Medical Research; Department of Biotechnology, Ministry of Science and Technology, India","keywords":"Renal glucose reabsorption; Glucose homeostasis; Canagliflozin; Chemistry; Glucose transporter; In vivo; Endocrinology; Kidney; Carbohydrate metabolism; Reabsorption; Internal medicine; Glucose uptake; Diabetes mellitus; Pharmacology; Insulin; Type 2 diabetes; Biochemistry; Biology; Medicine; Insulin resistance","score_opus":0.00590529903137926,"score_gpt":0.21815430670576413,"score_spread":0.21224900767438487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184577461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571085,0.002704557,0.00026109314,0.00027071274,0.000021968484,0.00046851952,0.00008363871,0.000020935599,0.0004577487],"genre_scores_gemma":[0.9939644,0.0005601895,0.004598779,0.00014202474,0.00009387038,0.00009541884,0.00019485345,0.000016770737,0.00033370647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993295,0.000005993864,0.00011652023,0.0002827904,0.00007828652,0.00018690988],"domain_scores_gemma":[0.99946076,0.0001305532,0.000070079455,0.00020995614,0.00005283303,0.00007579402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023225113,0.00016698879,0.0002732467,0.000022152037,0.000047359452,0.000015818017,0.00003992862,0.00003491041,0.000002008228],"category_scores_gemma":[0.000017300265,0.0001229844,0.00010800343,0.00010170792,0.0001672342,0.00003351366,0.000048206475,0.000051070707,2.3597507e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039769802,0.00063623214,0.0009525301,0.0004490523,0.00048802624,0.0000027594426,0.000093871924,1.3743369e-7,0.80536723,0.000045781395,0.00002371042,0.19154294],"study_design_scores_gemma":[0.00402697,0.0010368067,0.004341656,0.00022203999,0.0001930598,0.0000016001327,0.00011254797,0.00008799987,0.9890901,0.0002726699,0.0004737265,0.00014083256],"about_ca_topic_score_codex":0.0000019011062,"about_ca_topic_score_gemma":3.627735e-7,"teacher_disagreement_score":0.19140211,"about_ca_system_score_codex":0.0000075468283,"about_ca_system_score_gemma":0.000040719202,"threshold_uncertainty_score":0.50151587},"labels":[],"label_agreement":null},{"id":"W3184607597","doi":"10.1111/bph.15638","title":"Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment","year":2021,"lang":"en","type":"review","venue":"British Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Institutes of Health; Medical Research Council Canada; European Foundation for the Study of Diabetes","keywords":"Glucagon-like peptide-1; Receptor; Glucagon-like peptide 1 receptor; Neuroscience; Obesity; Action (physics); Gut–brain axis; Biology; Bioinformatics; Medicine; Endocrinology; Internal medicine; Agonist; Gut flora; Biochemistry; Type 2 diabetes; Diabetes mellitus","score_opus":0.06537051453969978,"score_gpt":0.38771308019052353,"score_spread":0.32234256565082375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184607597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029771838,0.9577011,0.000016550286,0.00923009,0.00024622233,0.0028884527,0.000076880984,0.000004401991,0.00006445814],"genre_scores_gemma":[0.01934364,0.9791523,0.00011352742,0.0004399101,0.0002554088,0.00034420087,0.00012350276,0.0000210543,0.00020645348],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979253,0.0006904947,0.00081702304,0.00023506554,0.00012612437,0.00020603297],"domain_scores_gemma":[0.997899,0.0011171289,0.00070200115,0.000095822536,0.0001293102,0.00005677044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011953175,0.00021237698,0.001268666,0.00022113278,0.00008397007,0.00003994642,0.00012781257,0.00015050295,0.000036553043],"category_scores_gemma":[0.00018810215,0.00014823295,0.00027452258,0.00027986773,0.00011186192,0.0000987781,0.000046342175,0.00027087686,4.9560276e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015973135,0.00065392844,0.000059369344,0.0019875737,0.00082286156,0.000029788087,0.00021534208,0.0000010548941,0.00019872561,0.0006499348,0.009064675,0.986157],"study_design_scores_gemma":[0.018075734,0.0018285352,0.007513119,0.0055066803,0.004593218,0.0020687408,0.00019864438,0.00002128823,0.00017830386,0.00050633686,0.95928633,0.00022308023],"about_ca_topic_score_codex":0.00003104362,"about_ca_topic_score_gemma":0.00024078839,"teacher_disagreement_score":0.98593396,"about_ca_system_score_codex":0.0002972151,"about_ca_system_score_gemma":0.00021595176,"threshold_uncertainty_score":0.60447645},"labels":[],"label_agreement":null},{"id":"W3185437491","doi":"10.1016/s2213-8587(21)00174-1","title":"Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Discontinuation; Type 2 diabetes; Sulfonylurea; Internal medicine; Randomized controlled trial; Diabetes mellitus; Metformin; Physical therapy; Insulin; Endocrinology","score_opus":0.03327913042604658,"score_gpt":0.3050845420511496,"score_spread":0.271805411625103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185437491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175036,0.0013090485,0.0000017631172,0.0015883383,0.00038233775,0.0029116361,0.000024548774,0.00006643141,0.0019655407],"genre_scores_gemma":[0.9980116,0.0003207903,0.00021938115,0.0003626912,0.00022300927,0.0002296625,0.00025147496,0.000040177405,0.00034120004],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972156,0.00020265847,0.000537396,0.0004903161,0.0002874208,0.0012666077],"domain_scores_gemma":[0.99807507,0.000711884,0.00022468736,0.00069907255,0.00017216346,0.00011714856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035827397,0.00034524914,0.0012761789,0.00018244448,0.00008400565,0.000025709614,0.0002099439,0.00008906716,0.00009102848],"category_scores_gemma":[0.00023814419,0.00023312001,0.00010909659,0.00046136492,0.00030279014,0.00007963302,0.00021322437,0.00029466674,0.000011688361],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8345184,0.002506715,0.12359735,0.00024339712,0.0020945568,0.000080006714,0.00024478484,0.000022361437,0.0004580983,0.001159192,0.0007158251,0.034359355],"study_design_scores_gemma":[0.9497751,0.005758414,0.03421823,0.00014913677,0.0010724975,7.8757677e-7,0.00013123275,0.000061684754,0.0030433892,0.000105077626,0.0054316707,0.00025276208],"about_ca_topic_score_codex":0.000015123839,"about_ca_topic_score_gemma":0.000039385395,"teacher_disagreement_score":0.11525677,"about_ca_system_score_codex":0.00009971497,"about_ca_system_score_gemma":0.00011814749,"threshold_uncertainty_score":0.95063585},"labels":[],"label_agreement":null},{"id":"W3185551100","doi":"10.1101/2021.07.17.452799","title":"Sex-Specific Computational Models of Kidney Function in Patients with Diabetes","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Nephron; Renal function; Diabetes mellitus; Kidney; Endocrinology; Internal medicine; Tubuloglomerular feedback; Afferent arterioles; Medicine; Homeostasis; Kidney disease; Blood pressure; Renin–angiotensin system","score_opus":0.011209794054201713,"score_gpt":0.19196761363819445,"score_spread":0.18075781958399273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185551100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966672,0.00040738602,0.0012326789,0.00011440083,0.00034242668,0.0009962197,0.00009473776,0.00010274468,0.000042226104],"genre_scores_gemma":[0.99396545,0.000037923164,0.0053325254,0.0003487998,0.00007174046,0.0001424485,0.000017651433,0.000074559626,0.000008882255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997968,0.000056548208,0.00044181242,0.0006768907,0.0005256311,0.0003311228],"domain_scores_gemma":[0.99830717,0.00002985009,0.00026304723,0.0006426949,0.0005110225,0.00024622268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018842798,0.0003739814,0.00066730625,0.0003584794,0.00003548061,0.00006154706,0.00012423744,0.00020403454,0.000052920608],"category_scores_gemma":[0.000030654115,0.00035429368,0.00010529492,0.00041087455,0.00006926494,0.00015720242,0.00020076404,0.00030045354,0.0000074388367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021283682,0.0021293156,0.9836285,0.0014063248,0.0010612493,0.000027991144,0.000022368193,0.0054117027,0.004480308,0.000752687,0.00084473955,0.00002196206],"study_design_scores_gemma":[0.0041096094,0.00036057996,0.9823644,0.0015451168,0.00036844533,5.007735e-10,0.000004827642,0.0025228017,0.007545623,0.000009235616,0.0007157885,0.0004535311],"about_ca_topic_score_codex":0.0000073252986,"about_ca_topic_score_gemma":4.6728712e-7,"teacher_disagreement_score":0.0040998464,"about_ca_system_score_codex":0.00025450066,"about_ca_system_score_gemma":0.000424783,"threshold_uncertainty_score":0.9998909},"labels":[],"label_agreement":null},{"id":"W3185672928","doi":"10.1016/j.jchf.2021.03.003","title":"Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Alberta Innovates; Boehringer Ingelheim; Novartis","keywords":"Empagliflozin; Medicine; Hazard ratio; Internal medicine; Type 2 diabetes; Diabetes mellitus; Coronary artery disease; Confidence interval; Proportional hazards model; Phenotype; Disease; Endocrinology; Biology; Genetics","score_opus":0.00759867911639544,"score_gpt":0.2256268465341982,"score_spread":0.21802816741780276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185672928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880602,0.001060138,9.151213e-7,0.009081768,0.0000788244,0.00020066381,0.0000018416355,0.00003337928,0.0014823143],"genre_scores_gemma":[0.99564815,0.00005203259,0.002105589,0.0016102729,0.00005112575,0.000018088325,0.00006753066,0.000011163534,0.0004360316],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993983,0.000023921446,0.00011527039,0.00018306554,0.00010829006,0.00017117376],"domain_scores_gemma":[0.99971694,0.000021980484,0.000015610909,0.00013441512,0.00004735641,0.00006370137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049620914,0.00008663551,0.00016945417,0.000063812695,0.000025438869,0.00002140784,0.0000067306296,0.00004666408,0.00019894104],"category_scores_gemma":[0.00003931197,0.00007561313,0.00002747545,0.00018714303,0.000017481667,0.00006733841,0.00004575028,0.000073283045,0.000071417744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008707373,0.0011792372,0.7426834,0.0005503385,0.00022107775,0.00039226335,0.0010912737,0.000011157702,0.039861925,0.0018510865,0.13372391,0.07834726],"study_design_scores_gemma":[0.002527506,0.0007276493,0.26908794,0.000458876,0.00013514212,0.0000118470125,0.00063504267,0.00010699075,0.044136826,0.0006746686,0.68124074,0.00025678796],"about_ca_topic_score_codex":0.000008192209,"about_ca_topic_score_gemma":0.00005642826,"teacher_disagreement_score":0.5475168,"about_ca_system_score_codex":0.000032805918,"about_ca_system_score_gemma":0.000027375405,"threshold_uncertainty_score":0.30834138},"labels":[],"label_agreement":null},{"id":"W3187939351","doi":"10.1371/journal.pone.0255726","title":"GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Clinical trial; Adverse effect; CINAHL; MEDLINE; Disease; Meta-analysis; Exenatide; Parkinson's disease; Animal studies; Randomized controlled trial; Internal medicine; Systematic review; Bioinformatics; Oncology; Diabetes mellitus; Type 2 diabetes; Psychiatry; Psychological intervention; Endocrinology","score_opus":0.3175880123776483,"score_gpt":0.43654271796432065,"score_spread":0.11895470558667237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187939351","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32066104,0.49189577,0.0000040105206,0.019716734,0.000010545957,0.16734457,0.00016423213,0.00001894068,0.00018415171],"genre_scores_gemma":[0.63507533,0.14113703,0.0058622668,0.0012454683,0.00006620176,0.2139913,0.00014704322,0.000031449817,0.0024439008],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9981515,0.00038324558,0.00085244793,0.00025063893,0.0002844657,0.00007770983],"domain_scores_gemma":[0.9987172,0.0006339453,0.00020974656,0.00027474703,0.00009806828,0.00006627665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006902986,0.0001256628,0.0022934566,0.000046356792,0.000018820634,0.0000074714912,0.000029016412,0.000027304266,0.00005672012],"category_scores_gemma":[0.00032140984,0.00006513632,0.0003021162,0.00017662911,0.00013946375,0.000027750633,0.000017789958,0.000037051614,5.486223e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000282743,0.013846663,0.21247856,0.34003946,0.43172362,0.000026708582,0.0008491115,2.4289125e-7,0.000010576354,0.00021596313,0.00007426499,0.00045208225],"study_design_scores_gemma":[0.0023612217,0.00084772403,0.084840536,0.0033257867,0.90800923,4.634099e-7,0.00009440139,0.000033075863,0.000063637584,0.00008632793,0.00025923585,0.00007835247],"about_ca_topic_score_codex":0.0000027809242,"about_ca_topic_score_gemma":0.000024576591,"teacher_disagreement_score":0.47628564,"about_ca_system_score_codex":0.00000791296,"about_ca_system_score_gemma":0.000028887473,"threshold_uncertainty_score":0.2656182},"labels":[],"label_agreement":null},{"id":"W3188095342","doi":"10.1016/j.hlc.2021.06.278","title":"Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial","year":2021,"lang":"en","type":"article","venue":"Heart Lung and Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Internal medicine; Myocardial infarction; Diabetes mellitus; Cardiology; Type 2 diabetes; Endocrinology","score_opus":0.012759277817205525,"score_gpt":0.30446807794458786,"score_spread":0.2917088001273823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188095342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981728,0.00011637952,0.000006137018,0.00042719065,0.00012441087,0.00049924414,0.0000043306727,0.0000061999967,0.0006432684],"genre_scores_gemma":[0.99961257,0.000008385429,0.0000057042253,0.000079058496,0.000044479384,0.00002284896,0.000067303285,0.0000044473745,0.00015523097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934113,0.00013778034,0.0001741447,0.000100683195,0.0001719202,0.00007431188],"domain_scores_gemma":[0.99968266,0.000111345034,0.000038846225,0.00012727838,0.000020228355,0.000019649207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029218188,0.00006187721,0.0002001033,0.00005341028,0.000023828123,0.0000040918776,0.000011855443,0.000035694644,0.000017376415],"category_scores_gemma":[0.00006247104,0.000043791104,0.000078266596,0.00013255242,0.000013327633,0.000029117506,0.00000805685,0.00005034955,0.0000029374796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021102591,0.00036259022,0.9908172,0.00016845844,0.00013051143,0.000003291945,0.00029886042,0.00007219221,0.0022725838,0.00011718598,0.0006459709,0.0030009018],"study_design_scores_gemma":[0.015016434,0.0011936956,0.98149,0.00007092703,0.00028348225,0.0000034380948,0.00005092666,0.0002433555,0.0012276571,0.000024803581,0.00034758323,0.000047675836],"about_ca_topic_score_codex":0.000030497795,"about_ca_topic_score_gemma":0.0000034835473,"teacher_disagreement_score":0.012906174,"about_ca_system_score_codex":0.000023267461,"about_ca_system_score_gemma":0.000013798121,"threshold_uncertainty_score":0.17857493},"labels":[],"label_agreement":null},{"id":"W3188543560","doi":"10.1186/s12933-021-01345-z","title":"Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data","year":2021,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"NIHR Leicester Biomedical Research Centre; Novo Nordisk; Daiichi-Sankyo; Intarcia Therapeutics; National Institute for Health and Care Research; Research Manitoba; Saint Luke's Health System; Mylan; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Angiology; Internal medicine; Cotransporter; Diabetes mellitus; Cardiology; Endocrinology; Pharmacology; Sodium","score_opus":0.015002011755442054,"score_gpt":0.2561136861898236,"score_spread":0.24111167443438156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188543560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97310203,0.023528641,0.0010251409,0.00022482254,0.00033536358,0.00080769556,0.00029578462,0.00010280101,0.0005777363],"genre_scores_gemma":[0.99538064,0.0022397803,0.00034079846,0.00020515884,0.00008987475,0.00011495612,0.0014341513,0.00008995787,0.000104662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956177,0.00019370083,0.0008581759,0.0013105918,0.0010835046,0.000936348],"domain_scores_gemma":[0.9952582,0.0001277074,0.00017761406,0.0039140005,0.00032933353,0.00019313124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011534623,0.0005728213,0.004121723,0.00047854832,0.00008984169,0.000050036782,0.0004690123,0.00026829517,0.00007593078],"category_scores_gemma":[0.0000749437,0.0004835217,0.0024667564,0.0014740565,0.00042731824,0.00027640635,0.0003644754,0.0002636144,0.000017006729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016563371,0.00036124224,0.8475569,0.00034494844,0.14047614,0.0009009189,0.000586045,0.0009489189,0.000107215055,0.000055126187,0.000046077694,0.008450849],"study_design_scores_gemma":[0.01146479,0.00016727185,0.90174496,0.00023051513,0.051199146,0.000019805047,0.00083946186,0.00030295452,0.00815448,0.000013946117,0.025201825,0.00066084607],"about_ca_topic_score_codex":0.0014276445,"about_ca_topic_score_gemma":0.0029859897,"teacher_disagreement_score":0.089276984,"about_ca_system_score_codex":0.00015703138,"about_ca_system_score_gemma":0.0001534018,"threshold_uncertainty_score":0.99976164},"labels":[],"label_agreement":null},{"id":"W3189855140","doi":"10.1111/dom.14513","title":"Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Placebo; Medicine; Renal function; Internal medicine; Clinical endpoint; Gastroenterology; Diabetes mellitus; Blood pressure; Confidence interval; Kidney disease; Type 2 diabetes; Adverse effect; Type 1 diabetes; Randomized controlled trial; Urology; Endocrinology; Pathology","score_opus":0.004508049062991897,"score_gpt":0.1942720261216524,"score_spread":0.1897639770586605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189855140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246705,0.0062825037,8.0085357e-7,0.000073585245,0.0000676811,0.0005547928,0.00002750235,0.000023061062,0.00050303363],"genre_scores_gemma":[0.9976456,0.00088615075,0.00059722306,0.0002614151,0.00003369014,0.000014213338,0.000115403345,0.000019376052,0.00042689423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869734,0.00006491198,0.00025413977,0.00038155686,0.0002307069,0.0003713293],"domain_scores_gemma":[0.9992274,0.00015488127,0.00008871207,0.00022264424,0.00011760548,0.00018877303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019703335,0.00023719294,0.00061475753,0.00013727395,0.00006625824,0.000031713003,0.00004121504,0.0000819331,0.000013697957],"category_scores_gemma":[0.00012421716,0.00018669262,0.00003712205,0.00026524864,0.00013106957,0.00013897086,0.00015562179,0.00012242343,0.0000020516832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060401133,0.000874349,0.9883029,0.00029545178,0.0003795393,0.000007691363,0.00037920926,0.0000020514171,0.0005243775,0.0002346628,0.00017740155,0.008761981],"study_design_scores_gemma":[0.008789589,0.00043941362,0.98134804,0.00024784036,0.000560448,4.2568595e-7,0.000085772335,0.000021586735,0.00371004,0.00010105506,0.004596948,0.000098865414],"about_ca_topic_score_codex":0.000006217503,"about_ca_topic_score_gemma":0.0000073535202,"teacher_disagreement_score":0.008729187,"about_ca_system_score_codex":0.000017683937,"about_ca_system_score_gemma":0.00003736889,"threshold_uncertainty_score":0.7613104},"labels":[],"label_agreement":null},{"id":"W3190919574","doi":"10.1017/s000711452100297x","title":"Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium","year":2021,"lang":"en","type":"article","venue":"British Journal Of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; PepsiCo; Rare Disease Foundation; University of Bath; British Heart Foundation; GlaxoSmithKline","keywords":"Hydrolysate; Calcium; Whey protein; Chemistry; Crossover study; Ingestion; Glucagon; Food science; Endocrinology; Internal medicine; Albumin; Insulin; Glucagon-like peptide-1; Animal science; Placebo; Medicine; Biochemistry; Diabetes mellitus; Biology; Type 2 diabetes","score_opus":0.02012710448510377,"score_gpt":0.26649550889827356,"score_spread":0.2463684044131698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190919574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964451,0.0020570802,0.000061711035,0.00071962137,0.00004902465,0.0004233198,0.000014378428,0.0000059964104,0.00022374059],"genre_scores_gemma":[0.984496,0.00042446624,0.014536826,0.00006156494,0.00007828146,0.000020265568,0.000023472585,0.000013673796,0.00034547775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987037,0.00015500608,0.0005224333,0.00012477185,0.00034788164,0.0001462085],"domain_scores_gemma":[0.9989866,0.000090218295,0.00027935804,0.000088326895,0.00047152044,0.00008395601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004260442,0.0000941533,0.00040430194,0.00033151224,0.000021573751,0.00002281367,0.000047746795,0.000050122828,0.0000178296],"category_scores_gemma":[0.0003895711,0.00009766543,0.00007298108,0.00040939546,0.00003508556,0.00017039588,0.000023836534,0.00011286538,7.3258883e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014467355,0.009401984,0.061252937,0.002999594,0.00051139976,0.0065958435,0.0005098402,0.00007168571,0.83882964,0.00008050315,0.004489405,0.060789812],"study_design_scores_gemma":[0.017451182,0.005273888,0.33649352,0.042585917,0.0005003425,0.0040506897,0.0012576443,0.000032265496,0.58868855,0.00019175363,0.0032127746,0.0002614898],"about_ca_topic_score_codex":0.00020002655,"about_ca_topic_score_gemma":0.00016176872,"teacher_disagreement_score":0.27524057,"about_ca_system_score_codex":0.00010214088,"about_ca_system_score_gemma":0.00010088738,"threshold_uncertainty_score":0.39826807},"labels":[],"label_agreement":null},{"id":"W3192172501","doi":"10.1016/j.cardfail.2021.05.012","title":"Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"National Institute for Health and Care Research","keywords":"Empagliflozin; Medicine; Internal medicine; EMPA; Ejection fraction; Heart failure; Cardiology; Heart failure with preserved ejection fraction; Diabetes mellitus; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.04646457190015184,"score_gpt":0.3090504654428429,"score_spread":0.2625858935426911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192172501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97211605,0.0008862736,0.000020523561,0.023933386,0.0016783909,0.0007079008,0.000085856074,0.000030478112,0.0005411112],"genre_scores_gemma":[0.992721,0.00012949898,0.002715363,0.00026367433,0.0029139584,0.000024814084,0.0005195505,0.000040607178,0.00067149196],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977789,0.00029352878,0.0005951596,0.000312204,0.0007709704,0.0002492495],"domain_scores_gemma":[0.99800104,0.00030965448,0.00032728128,0.0009263772,0.00029273255,0.00014290893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059068965,0.00021684567,0.00073282723,0.000120284676,0.00007743417,0.00010366564,0.00024555903,0.00013424277,0.0002493239],"category_scores_gemma":[0.0004680513,0.00013432374,0.00028212948,0.00046855715,0.000041506628,0.0005565719,0.00013732685,0.0006091765,0.000017562894],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049943708,0.00084436726,0.2772914,0.00006345082,0.0054114205,0.0003878717,0.0002240405,0.000109006236,0.0025470082,0.000012331622,0.6617174,0.001447963],"study_design_scores_gemma":[0.08759091,0.0016399962,0.27988532,0.00046756267,0.0035665296,0.000035171543,0.0041712397,0.00006320798,0.001758854,0.000022019562,0.6205305,0.0002687095],"about_ca_topic_score_codex":0.00006509862,"about_ca_topic_score_gemma":0.00026657447,"teacher_disagreement_score":0.041186973,"about_ca_system_score_codex":0.00019685656,"about_ca_system_score_gemma":0.0003086024,"threshold_uncertainty_score":0.5477563},"labels":[],"label_agreement":null},{"id":"W3192237979","doi":"10.1093/ageing/afab157","title":"Individualisation of glycaemic management in older people with type 2 diabetes: a systematic review of clinical practice guidelines recommendations","year":2021,"lang":"en","type":"review","venue":"Age and Ageing","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Systematic review; Family medicine; Type 2 diabetes; MEDLINE; Alternative medicine; Diabetes management; Clinical Practice; Diabetes mellitus; Gerontology; Pathology","score_opus":0.11144076366603142,"score_gpt":0.44240242896323456,"score_spread":0.33096166529720317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192237979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007954352,0.9954866,0.000017281902,0.00029845952,0.00007770034,0.00269781,0.000005672957,0.000010477215,0.0013264115],"genre_scores_gemma":[0.000028627635,0.9927025,0.0054559326,0.0006471344,0.00003188708,0.00020806653,0.00052707415,0.000023134893,0.00037564753],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971627,0.00031034168,0.0018525063,0.00028545893,0.0002537099,0.00013530412],"domain_scores_gemma":[0.9976929,0.00047642027,0.0011467626,0.00038556196,0.00025496114,0.000043436827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014697249,0.00021908172,0.0027335791,0.00019099131,0.000017694414,0.000014360911,0.00007943267,0.00007966382,0.000032428175],"category_scores_gemma":[0.0012104139,0.00014682079,0.00019713561,0.00059727713,0.000021239524,0.00010005968,0.00010365896,0.00014182787,0.000003064636],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017293219,0.00015613074,0.000023863495,0.7264079,0.0011367404,0.0003489607,0.0000651036,5.034401e-8,1.4931592e-8,0.000063741674,0.0010870248,0.27070877],"study_design_scores_gemma":[0.00043321558,0.00012580791,0.000089604844,0.8097366,0.015908984,0.00000599568,0.00022493325,0.0000023754892,9.0491596e-8,0.0000026538307,0.17336205,0.00010768395],"about_ca_topic_score_codex":0.000012373744,"about_ca_topic_score_gemma":0.000010323005,"teacher_disagreement_score":0.27060106,"about_ca_system_score_codex":0.00003105862,"about_ca_system_score_gemma":0.00007222067,"threshold_uncertainty_score":0.59871787},"labels":[],"label_agreement":null},{"id":"W3192522080","doi":"10.1186/s12913-021-06762-0","title":"Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study","year":2021,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Manitoba Health; University of Calgary; Health Sciences Centre; University of Toronto; Memorial University of Newfoundland; Jewish General Hospital; Sunnybrook Health Science Centre; Saskatchewan Health Quality Council; Institute for Clinical Evaluative Sciences; McGill University; University of British Columbia; Institut National d'Excellence en Santé et en Services Sociaux; University of Manitoba","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Ministry of Health, British Columbia; Ontario Ministry of Health and Long-Term Care; McGill University","keywords":"Medicine; Cohort; Confidence interval; Population; Record linkage; Psychological intervention; Medical prescription; Database; Cause of death; Cohort study; National Death Index; Demography; Algorithm; Internal medicine; Environmental health; Hazard ratio; Disease","score_opus":0.1547995868950372,"score_gpt":0.4885396928762569,"score_spread":0.3337401059812197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192522080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888505,0.0012338883,0.0027214016,0.000384164,0.00016907792,0.005963957,0.00052103953,0.000068330635,0.00005308907],"genre_scores_gemma":[0.9212174,0.00018085066,0.07212958,0.0010113356,0.00018897653,0.000642026,0.0043708095,0.000051476378,0.000207553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992802,0.0026473622,0.0007861307,0.0010028806,0.0019781415,0.0007834495],"domain_scores_gemma":[0.9960813,0.00037475154,0.00016274097,0.0015929382,0.00079582934,0.0009924648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052508437,0.00024227766,0.0010181557,0.0003707398,0.0003327356,0.000075190044,0.0002632619,0.00006726996,0.00014944228],"category_scores_gemma":[0.00009637889,0.00023045891,0.00020722157,0.0010770208,0.000027372202,0.00017349358,0.00022023582,0.00030319334,0.00005100107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016800582,0.004239416,0.96786875,0.002009974,0.0005448446,0.0001292419,0.0017227378,0.000050946466,0.000011518717,0.0000039300658,0.00005789618,0.023192773],"study_design_scores_gemma":[0.0032556518,0.0026401272,0.9792633,0.0005625079,0.00012824986,0.0000010849483,0.008016802,0.004943751,0.00022602017,0.000012569665,0.0008055972,0.00014433677],"about_ca_topic_score_codex":0.07233991,"about_ca_topic_score_gemma":0.028202653,"teacher_disagreement_score":0.06940817,"about_ca_system_score_codex":0.0006764055,"about_ca_system_score_gemma":0.002215735,"threshold_uncertainty_score":0.9895301},"labels":[],"label_agreement":null},{"id":"W3193583674","doi":"10.2139/ssrn.3506105","title":"Gamma-Aminobutyric Acid Requires GLP-1 Receptor to Effectively Exert Its Pancreatic Function During Streptozotocin Challenge","year":2019,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; St. Michael's Hospital; Brock University; Diabetes Canada; University of Toronto","funders":"","keywords":"Streptozotocin; Glucagon-like peptide 1 receptor; Receptor; Chemistry; Function (biology); Glucagon-like peptide-1; Pancreatic function; Pharmacology; Diabetes mellitus; Cell biology; Endocrinology; Internal medicine; Pancreas; Medicine; Biochemistry; Agonist; Biology; Type 2 diabetes","score_opus":0.007734624136762306,"score_gpt":0.23211886980038515,"score_spread":0.22438424566362283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193583674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866063,0.004597923,0.00023181694,0.000973061,0.00042863213,0.0015669365,0.0000024077128,0.000107940454,0.0034306701],"genre_scores_gemma":[0.9756727,0.0030369412,0.000059648308,0.00011113111,0.000462937,0.00011841183,0.000017449309,0.00005983547,0.020460939],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99658287,0.00009536084,0.00034680546,0.000436019,0.00047230916,0.0020666583],"domain_scores_gemma":[0.9991328,0.00004114192,0.00016768479,0.00031112623,0.00011438111,0.00023284052],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007619534,0.00032166843,0.00047748955,0.0003250514,0.00015197427,0.000049630256,0.00015140361,0.00010059228,0.0004164868],"category_scores_gemma":[0.000069341404,0.00026530176,0.00021070753,0.00028586137,0.000014769093,0.00027692085,0.00006984774,0.00084364915,0.001350646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00911757,0.0028162566,0.11298284,0.0014625279,0.010616036,0.00013466927,0.0018984221,0.00010350358,0.4437709,0.03866135,0.0023364616,0.37609947],"study_design_scores_gemma":[0.07376644,0.10685401,0.5326858,0.0056101903,0.009137335,0.0013562638,0.017268902,0.0004555065,0.16473089,0.021092737,0.061845135,0.005196746],"about_ca_topic_score_codex":0.000010794314,"about_ca_topic_score_gemma":0.000041326377,"teacher_disagreement_score":0.419703,"about_ca_system_score_codex":0.0020315927,"about_ca_system_score_gemma":0.00039224734,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W3193981514","doi":"10.1093/eurheartj/ehab563","title":"Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure","year":2021,"lang":"en","type":"letter","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Heart failure; Cardiology; Internal medicine","score_opus":0.017648805363786064,"score_gpt":0.2522604432685067,"score_spread":0.23461163790472064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193981514","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15180333,0.004574849,0.0000033785652,0.82716906,0.0041756355,0.0010920361,0.0000071847585,0.00004701948,0.011127529],"genre_scores_gemma":[0.10820719,0.0012430635,0.0015078573,0.83243215,0.039009906,0.000033596483,0.00017243004,0.00046903623,0.016924772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971903,0.0009468057,0.00046548492,0.00031396735,0.0006182829,0.00046514507],"domain_scores_gemma":[0.9987358,0.00041868168,0.00019441293,0.00047537684,0.00006880786,0.000106924774],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00080905145,0.00033922575,0.0007429229,0.0003390452,0.000110926034,0.00009733818,0.00012747332,0.00012653344,0.000088422836],"category_scores_gemma":[0.00022102316,0.00022488825,0.0005644455,0.00023467868,0.00005975595,0.000056869343,0.00011340834,0.0024171413,0.00015556239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016536453,0.00005415862,0.0069571338,0.0003627394,0.00031232205,0.005716491,0.00015116605,0.000003990619,0.0003649951,0.000003974958,0.98438185,0.0016746471],"study_design_scores_gemma":[0.0009806736,0.00055955595,0.015985036,0.0037145207,0.00028616347,0.00023026147,0.000053721185,0.0000011992882,0.0010829989,0.000005160175,0.976922,0.00017872629],"about_ca_topic_score_codex":0.0000035122855,"about_ca_topic_score_gemma":0.0000011512592,"teacher_disagreement_score":0.043596145,"about_ca_system_score_codex":0.00015581156,"about_ca_system_score_gemma":0.000084090665,"threshold_uncertainty_score":0.9998843},"labels":[],"label_agreement":null},{"id":"W3194143113","doi":"10.1038/s41386-021-01163-7","title":"Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Neuropsychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Diabetes Canada; McMaster University; University of Toronto; Centre for Addiction and Mental Health","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; National Health and Medical Research Council; Department of Psychiatry, University of Toronto; HLS Therapeutics; Mitsubishi Tanabe Pharma Corporation; University of Toronto; Physicians' Services Incorporated Foundation","keywords":"Olanzapine; Quetiapine; Risperidone; Weight gain; Medicine; Meta-analysis; Adverse effect; Internal medicine; Population; Psychiatry; Schizophrenia (object-oriented programming); Body weight","score_opus":0.09085089620600695,"score_gpt":0.38013715552298144,"score_spread":0.2892862593169745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194143113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011679898,0.99247414,0.0000020944385,0.00013775556,0.00020672224,0.0059275837,0.00004265951,0.000009533692,0.0000315304],"genre_scores_gemma":[0.000624468,0.99486434,0.00012782092,0.002932941,0.000030412762,0.000731597,0.00025038762,0.000032797067,0.00040523123],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955668,0.0019649256,0.0014994325,0.00048672804,0.00028887513,0.00019327013],"domain_scores_gemma":[0.9972841,0.0006269476,0.0011300601,0.00071842654,0.00018054736,0.000059902275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042274254,0.00042915714,0.007962151,0.00055172306,0.000022853766,0.00001098965,0.00017010982,0.00013336299,0.00018193755],"category_scores_gemma":[0.00019894716,0.00025289188,0.0014616027,0.0016068873,0.000050702714,0.00007297342,0.00004685395,0.00024957606,0.000004477066],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001112578,0.0006478762,0.000017787688,0.85554767,0.13751276,0.00011208664,0.00004241134,0.0000012276191,0.00001839798,0.00016556057,0.0009837926,0.0049392954],"study_design_scores_gemma":[0.0008973299,0.00015856305,0.00020098832,0.007940256,0.97301215,0.00002346594,0.0000031224884,0.000018752504,0.0000022575407,7.118254e-7,0.017601326,0.00014107321],"about_ca_topic_score_codex":0.0000072513244,"about_ca_topic_score_gemma":0.000023885555,"teacher_disagreement_score":0.84760743,"about_ca_system_score_codex":0.000018067209,"about_ca_system_score_gemma":0.00003614506,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W3194414195","doi":"10.1093/eurheartj/ehab530","title":"Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Medicine; Dapagliflozin; Internal medicine; Overweight; Body mass index; Hazard ratio; Type 2 Diabetes Mellitus; Obesity; Diabetes mellitus; TIMI; Placebo; Endocrinology; Cardiology; Confidence interval; Myocardial infarction","score_opus":0.01374369213229089,"score_gpt":0.2298093427218164,"score_spread":0.2160656505895255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194414195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962864,0.0024046304,0.0000013217099,0.00018918945,0.000102182734,0.00038084565,7.5577907e-7,0.000003902079,0.00063077774],"genre_scores_gemma":[0.99912155,0.00025487534,0.00016538534,0.00033330047,0.00005648564,0.0000018311636,0.0000046439013,0.000012788094,0.000049127524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871755,0.00049712084,0.0001745734,0.00014901655,0.00029842046,0.00016331975],"domain_scores_gemma":[0.9995351,0.00013145788,0.00004190642,0.00018578938,0.00004069155,0.00006507596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006602872,0.00011063412,0.00034809703,0.00009570128,0.00004097423,0.000033106433,0.000039625516,0.000016222044,0.0000066736493],"category_scores_gemma":[0.00012814508,0.000063837164,0.00007434835,0.00013151253,0.000035533703,0.000049404676,0.00004013596,0.00019104274,0.000002856071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010158337,0.000589528,0.99123394,0.00006644023,0.00038534089,0.00038017464,0.00023459607,0.000009591992,0.000024398463,0.00001061101,0.00027452802,0.0057749967],"study_design_scores_gemma":[0.02781681,0.001957927,0.9669328,0.00027819257,0.00021450924,0.000005488171,0.000027994805,0.0000031025627,0.00021629734,0.000008692392,0.002476046,0.000062142135],"about_ca_topic_score_codex":0.0000023666487,"about_ca_topic_score_gemma":0.0000036777758,"teacher_disagreement_score":0.026800975,"about_ca_system_score_codex":0.00002183169,"about_ca_system_score_gemma":0.000019276331,"threshold_uncertainty_score":0.2603204},"labels":[],"label_agreement":null},{"id":"W3195404919","doi":"10.1016/s2213-8587(21)00203-5","title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","year":2021,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1502,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"British Heart Foundation","keywords":"Medicine; Type 2 diabetes; Meta-analysis; Glucagon-like peptide 1 receptor; Diabetes mellitus; MEDLINE; Internal medicine; Intensive care medicine; Bioinformatics; Pharmacology; Receptor; Endocrinology; Agonist","score_opus":0.11400685831002075,"score_gpt":0.35453262479431596,"score_spread":0.24052576648429522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195404919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027507895,0.98754203,5.798544e-7,0.0003191404,0.000053441756,0.009013883,0.00020853512,0.000033249562,0.00007833735],"genre_scores_gemma":[0.00037822677,0.9948336,0.00012871218,0.0011247735,0.000022644212,0.0023895442,0.0008762476,0.000060721864,0.00018555368],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99368566,0.0025404969,0.0016608357,0.0007564456,0.00049327424,0.00086329697],"domain_scores_gemma":[0.9952771,0.0014525902,0.0011668042,0.0017526735,0.00019812831,0.00015272136],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0027030648,0.0007991219,0.03427921,0.00044068,0.000045773948,0.00004184892,0.00029463327,0.00013072594,0.00011467517],"category_scores_gemma":[0.0013247498,0.0003454382,0.0024019901,0.0011010725,0.00025928157,0.0000547156,0.00021982187,0.00029982565,0.0000036885135],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042371754,0.00013199843,0.017306793,0.35277817,0.62790245,0.000012152604,0.00001768603,3.6671625e-7,2.9142909e-8,0.000034388686,0.0001808596,0.0015927415],"study_design_scores_gemma":[0.008046284,0.0003256675,0.001360664,0.024369178,0.94918144,0.0000011160508,0.000006327069,5.974013e-7,8.802857e-7,0.0000026240332,0.016385494,0.00031975054],"about_ca_topic_score_codex":0.000023806399,"about_ca_topic_score_gemma":0.00001753774,"teacher_disagreement_score":0.328409,"about_ca_system_score_codex":0.00007271462,"about_ca_system_score_gemma":0.00012104633,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W3196015703","doi":"10.1016/j.clinthera.2021.07.015","title":"Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bayer (Canada); LMC Diabetes & Endocrinology (Canada)","funders":"Bayer Canada","keywords":"Medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Disease; Internal medicine; Disease registry; Endocrinology","score_opus":0.05534864959786159,"score_gpt":0.35797554397610654,"score_spread":0.30262689437824497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196015703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829152,0.008756425,6.937377e-7,0.006104915,0.00049707736,0.0012974621,0.000145592,0.000021297417,0.00026132978],"genre_scores_gemma":[0.99283135,0.0020768119,0.000024130943,0.0034505357,0.00012324273,0.00007864896,0.00008798977,0.000037814105,0.0012894489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971027,0.00037777037,0.0010251803,0.00051164225,0.00041073727,0.00057201774],"domain_scores_gemma":[0.9968127,0.0005055237,0.0002465048,0.0013743042,0.00015318429,0.00090778194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007864252,0.00028352832,0.0007564335,0.00014353757,0.000052961863,0.00002400094,0.0004047319,0.00011423605,0.00024025228],"category_scores_gemma":[0.0014397115,0.00020654169,0.0002760662,0.0005577677,0.0004004929,0.000068015914,0.00015951488,0.00038327454,0.000013822423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098680466,0.003349014,0.98883426,0.001028599,0.00058284536,0.00008540354,0.00011042144,0.000038900896,0.000025467907,0.00010386187,0.0003673837,0.0053751874],"study_design_scores_gemma":[0.0039343787,0.0009734774,0.9841308,0.0008837475,0.0012565337,3.9926938e-8,0.00006560287,0.0017906979,0.00007360287,0.0002448849,0.0064484547,0.0001977774],"about_ca_topic_score_codex":0.0006458544,"about_ca_topic_score_gemma":0.0057755862,"teacher_disagreement_score":0.009916169,"about_ca_system_score_codex":0.00045305007,"about_ca_system_score_gemma":0.0039416812,"threshold_uncertainty_score":0.84225255},"labels":[],"label_agreement":null},{"id":"W3196348514","doi":"10.1016/j.jcjd.2021.08.012","title":"Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research; China Scholarship Council; Novo Nordisk","keywords":"Liraglutide; Semaglutide; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.010482925363970745,"score_gpt":0.24902262852315832,"score_spread":0.23853970315918757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196348514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969249,0.028969819,0.0000019733864,0.0003289938,0.00015827834,0.0001451,0.000010118627,0.0000018131767,0.0011348728],"genre_scores_gemma":[0.9987815,0.00006821752,0.0007120729,0.00012175412,0.00006700659,0.000002372485,0.000005613535,0.000013786304,0.00022764778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988724,0.000056408386,0.000498418,0.0001152531,0.0001623808,0.0002951334],"domain_scores_gemma":[0.998942,0.00015421314,0.00025995984,0.0001332281,0.00016869137,0.00034187926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018916212,0.00013018458,0.00076461525,0.0004307707,0.000023972047,0.00001144898,0.00007954184,0.000056759345,0.000072731826],"category_scores_gemma":[0.00026395908,0.000120515724,0.00011997688,0.00028518488,0.000086928565,0.000064308944,0.00001936352,0.0001413154,0.0000018724343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007435367,0.00015171664,0.97278,0.00058658497,0.00035381,0.00011057089,0.00045114235,0.000027072207,0.010571616,0.00026647316,0.0006514987,0.014042096],"study_design_scores_gemma":[0.0023313556,0.0005125463,0.8198008,0.0009807898,0.00075751386,0.0000074126024,0.000371839,0.000094763156,0.1705993,0.00013365073,0.00428806,0.00012199297],"about_ca_topic_score_codex":0.00054477016,"about_ca_topic_score_gemma":0.0076007284,"teacher_disagreement_score":0.16002768,"about_ca_system_score_codex":0.000055493805,"about_ca_system_score_gemma":0.00043822257,"threshold_uncertainty_score":0.49144885},"labels":[],"label_agreement":null},{"id":"W3196465494","doi":"10.1007/s00125-021-05542-z","title":"Consensus report: definition and interpretation of remission in type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Astellas Pharma; Vetenskapsrådet; Eli Lilly and Company; AstraZeneca; Science Foundation Ireland; Sanofi; Pacira BioSciences; Kowa Company; Novo Nordisk; GlaxoSmithKline; Irish Research Council; McMaster University; Diabetes UK","keywords":"Terminology; Medicine; Pharmacotherapy; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Psychological intervention; MEDLINE; Family medicine; Psychology; Internal medicine; Psychiatry; Endocrinology; Political science","score_opus":0.021208752833130038,"score_gpt":0.2700885735896935,"score_spread":0.24887982075656348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196465494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897792,0.0013028571,0.000005946911,0.00044357148,0.000106558844,0.00012325271,0.0000015869666,0.000021793941,0.008215244],"genre_scores_gemma":[0.9978474,0.00011697915,0.0015274631,0.00013505157,0.0000074137906,0.000007631015,0.00013115119,0.000005755014,0.00022116142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939424,0.000034124096,0.00021610667,0.000166146,0.00007613011,0.00011326969],"domain_scores_gemma":[0.99957603,0.00008568272,0.00007720672,0.00014325707,0.000083566476,0.000034281293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001274944,0.000069206064,0.0002291924,0.000078310404,0.00001059238,0.000005446193,0.000014173647,0.0000545146,0.000038722817],"category_scores_gemma":[0.0004522559,0.000060074264,0.000025721605,0.00016997964,0.00004464917,0.000022033078,0.000033586177,0.00005141903,0.0000046697696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059938986,0.00020483247,0.9379726,0.0002383574,0.000079857076,0.00046005982,0.00012439945,0.0000022417098,0.018418778,0.00087744795,0.0006268598,0.04093462],"study_design_scores_gemma":[0.0017791969,0.0004445228,0.91389954,0.00062318274,0.00022875197,0.000031809624,0.00026354514,0.0011223749,0.077166855,0.0033565245,0.0009288783,0.00015480988],"about_ca_topic_score_codex":0.0000032113212,"about_ca_topic_score_gemma":0.000004081521,"teacher_disagreement_score":0.058748074,"about_ca_system_score_codex":0.000023519471,"about_ca_system_score_gemma":0.00003104361,"threshold_uncertainty_score":0.24497575},"labels":[],"label_agreement":null},{"id":"W3196592155","doi":"10.7759/cureus.17668","title":"Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dapagliflozin; Empagliflozin; Canagliflozin; Diabetes mellitus; Internal medicine; Renal function; Intensive care medicine; Cochrane Library; Type 2 Diabetes Mellitus; Randomized controlled trial; Kidney disease; Myocardial infarction; Albuminuria; Endocrinology","score_opus":0.016967439208476365,"score_gpt":0.2841104091777009,"score_spread":0.26714296996922454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196592155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012862003,0.9912948,2.6888048e-7,0.00002707579,0.0004925646,0.0072553684,0.000038755657,0.00005500308,0.0007075336],"genre_scores_gemma":[0.000043424756,0.9965214,0.00009539558,0.00018438716,0.000085835956,0.0009871878,0.0007743958,0.000094224015,0.0012137321],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969609,0.00018478424,0.0011101692,0.0006495797,0.0006074408,0.00048716186],"domain_scores_gemma":[0.997872,0.00011142321,0.0005324664,0.0011286587,0.00019009713,0.00016537585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038284948,0.0007329652,0.0062403847,0.00018404474,0.0000492099,0.000045328903,0.00022087345,0.00019661787,0.00009638619],"category_scores_gemma":[0.00028970113,0.00042041187,0.0007495548,0.00059317535,0.000038298305,0.00009331318,0.00023346646,0.0003007768,0.00009735857],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028606278,0.00052387844,0.0014615926,0.9283446,0.0041522807,0.000049414364,0.00003218428,3.4371624e-8,1.9026004e-8,0.000026832518,0.0013849387,0.064021386],"study_design_scores_gemma":[0.0008497514,0.00064201414,0.000049609946,0.7528636,0.02211839,9.0215957e-7,0.000011651901,1.3649247e-7,4.068921e-7,0.0000015028037,0.22306858,0.00039348064],"about_ca_topic_score_codex":0.000006477367,"about_ca_topic_score_gemma":0.000004065525,"teacher_disagreement_score":0.22168365,"about_ca_system_score_codex":0.0004840852,"about_ca_system_score_gemma":0.0002032776,"threshold_uncertainty_score":0.99982476},"labels":[],"label_agreement":null},{"id":"W3196921676","doi":"10.2337/dci21-0034","title":"Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes","year":2021,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Astellas Pharma; Vetenskapsrådet; Novo Nordisk; Eli Lilly and Company; AstraZeneca; Science Foundation Ireland; Pacira BioSciences; Kowa Company; Sanofi; Cystic Fibrosis Trust; GlaxoSmithKline; Irish Research Council; McMaster University; Diabetes UK","keywords":"Medicine; Terminology; Pharmacotherapy; Diabetes mellitus; Psychological intervention; Intensive care medicine; Type 2 diabetes; MEDLINE; Family medicine; Pediatrics; Internal medicine; Psychiatry; Endocrinology","score_opus":0.03309017942270221,"score_gpt":0.31068109526727344,"score_spread":0.27759091584457124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196921676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022540065,0.9738855,1.7507516e-7,0.00002134381,0.00022086344,0.00071473815,0.00003710533,0.000029752395,0.0025504532],"genre_scores_gemma":[0.010325407,0.9851739,0.00036408464,0.000038541682,0.000039101968,0.00007986575,0.0038230815,0.000044011875,0.00011201364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984586,0.000102981074,0.0006272654,0.0004046535,0.00017969596,0.00022677678],"domain_scores_gemma":[0.9988446,0.00019694361,0.0003463721,0.00035733424,0.0001775864,0.00007713629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014578547,0.00029096854,0.0015625092,0.00030537936,0.00001884912,0.000018271377,0.000047007114,0.00021575698,0.00003099353],"category_scores_gemma":[0.0003462087,0.00024282197,0.00022537634,0.00035801198,0.00005628345,0.000029425248,0.00008922625,0.00016935602,0.000013279023],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004161075,0.000059393973,0.017986549,0.03617601,0.0002589062,0.000115087496,0.00014494463,1.691857e-7,0.0000068303084,0.000038953993,0.00038169333,0.9448273],"study_design_scores_gemma":[0.0011442216,0.0006269114,0.0021003734,0.16037694,0.0060080686,0.00001429922,0.000624506,0.00005112043,0.00017563567,0.000099565405,0.82816786,0.0006105041],"about_ca_topic_score_codex":0.000001997875,"about_ca_topic_score_gemma":0.0000026835316,"teacher_disagreement_score":0.9442168,"about_ca_system_score_codex":0.000131125,"about_ca_system_score_gemma":0.0001332294,"threshold_uncertainty_score":0.99019927},"labels":[],"label_agreement":null},{"id":"W3196972091","doi":"10.7326/acpj202109210-106","title":"Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA<sub>1c</sub> in T2DM","year":2021,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Insulin; Basal (medicine); Internal medicine; Basal insulin; Endocrinology; Bolus (digestion); Diabetes mellitus; Type 2 diabetes; Regimen","score_opus":0.06214203046749707,"score_gpt":0.3303907499153438,"score_spread":0.26824871944784673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196972091","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1402686,0.003450545,0.00087244506,0.84635377,0.003112506,0.0039146314,0.00019071746,0.00010924553,0.0017275371],"genre_scores_gemma":[0.086449414,0.0024720528,0.001133549,0.8860405,0.010475631,0.0009880515,0.002409043,0.00029322566,0.009738522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945171,0.00014832213,0.002032412,0.0011681892,0.0011445709,0.0009894385],"domain_scores_gemma":[0.9957291,0.00063613645,0.0007759334,0.0010203123,0.0014483836,0.00039016418],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009127394,0.00091915205,0.0025004814,0.0014864389,0.00005161239,0.000044384407,0.00052938436,0.0007186814,0.00041077982],"category_scores_gemma":[0.0026172851,0.0006982321,0.00046521728,0.00077428645,0.00024148001,0.00016559323,0.00032979067,0.001319666,0.000117992975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003842196,0.00039532484,0.0002571172,0.0018104275,0.0009542882,0.00190983,0.0008181309,0.0000059774666,0.0068761967,0.00002334634,0.9483905,0.03471671],"study_design_scores_gemma":[0.01595527,0.009644279,0.004240122,0.02384883,0.0011221572,0.00006047265,0.0007151375,0.00040916068,0.104561135,0.00021787858,0.8381273,0.0010982607],"about_ca_topic_score_codex":0.00044889265,"about_ca_topic_score_gemma":0.00019211898,"teacher_disagreement_score":0.11026316,"about_ca_system_score_codex":0.0004093555,"about_ca_system_score_gemma":0.0004725564,"threshold_uncertainty_score":0.9995469},"labels":[],"label_agreement":null},{"id":"W3197198596","doi":"10.1161/jaha.121.022222","title":"Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials","year":2021,"lang":"en","type":"review","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Impact; University of Toronto; Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Heart failure; Atrial fibrillation; Meta-analysis; Randomized controlled trial; Placebo; Relative risk; Cardiology; Confidence interval","score_opus":0.039418326425243164,"score_gpt":0.35468853954878626,"score_spread":0.3152702131235431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197198596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011867313,0.9926144,0.0000058736514,0.001422964,0.00010524241,0.0056802263,0.000029586063,0.0000042000656,0.000018844028],"genre_scores_gemma":[0.00020916639,0.99870306,0.00009543629,0.00025706462,0.00024422072,0.000057411526,0.000021604536,0.00001658135,0.00039545263],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98853946,0.0062293643,0.004202989,0.00016164119,0.00073570985,0.00013082173],"domain_scores_gemma":[0.9795302,0.007019265,0.012748633,0.00023581402,0.0003865021,0.00007959527],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.017558193,0.00030851472,0.053555608,0.00044012745,0.0000426992,0.000045663044,0.00006272138,0.00008286459,0.0000401904],"category_scores_gemma":[0.0073305545,0.0001367909,0.019861998,0.00075528416,0.00006777391,0.000065490625,0.000022006781,0.00017247969,6.1930984e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013499862,0.000022245684,0.00013686185,0.12993234,0.86662024,0.000003119723,0.000040365405,0.0000012788339,3.1745353e-7,0.000006210487,0.00044233756,0.0014446882],"study_design_scores_gemma":[0.025344787,0.000095949435,0.000015991827,0.029480968,0.9385338,0.000010782127,0.000015910495,0.000005158582,5.2566236e-7,0.000003317251,0.00640142,0.000091394606],"about_ca_topic_score_codex":0.000011516037,"about_ca_topic_score_gemma":0.0000017459779,"teacher_disagreement_score":0.10045138,"about_ca_system_score_codex":0.00019372899,"about_ca_system_score_gemma":0.00017904518,"threshold_uncertainty_score":0.9899538},"labels":[],"label_agreement":null},{"id":"W3197311219","doi":"10.1111/dme.14669","title":"Consensus report: Definition and interpretation of remission in type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Terminology; Pharmacotherapy; Diabetes mellitus; Intensive care medicine; MEDLINE; Type 2 diabetes; Psychological intervention; Family medicine; Pediatrics; Internal medicine; Psychiatry; Endocrinology","score_opus":0.02219698646231498,"score_gpt":0.27628185420974866,"score_spread":0.25408486774743366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197311219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792469,0.00352511,0.000014783798,0.002978997,0.00019086288,0.00019001246,9.671596e-7,0.000018481735,0.013833899],"genre_scores_gemma":[0.9977146,0.00035329734,0.0007777616,0.000379419,0.00003641555,0.000008876604,0.00017250176,0.0000098310975,0.0005472889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990765,0.000042831372,0.000359026,0.00020389972,0.00017933718,0.0001384481],"domain_scores_gemma":[0.99932563,0.00015325262,0.00010521167,0.00020323799,0.00013322628,0.00007940937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002704481,0.000096951364,0.00035800686,0.00013741627,0.0000122648935,0.0000027959416,0.000017771807,0.00004736932,0.00016232439],"category_scores_gemma":[0.0009797474,0.000076469994,0.000022517013,0.00026379662,0.00010441157,0.00001862986,0.000028651162,0.00006707771,0.0000040739396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024759586,0.0006330166,0.70176435,0.0019453622,0.0003133495,0.0017549952,0.0016351661,0.000005222843,0.10274635,0.0023200081,0.0051207845,0.18151383],"study_design_scores_gemma":[0.014033961,0.003040679,0.8642827,0.010835995,0.0016446026,0.00016611752,0.002037489,0.005297478,0.08115444,0.010524437,0.0065059243,0.00047613378],"about_ca_topic_score_codex":0.000008444582,"about_ca_topic_score_gemma":0.000004036315,"teacher_disagreement_score":0.1810377,"about_ca_system_score_codex":0.000029269895,"about_ca_system_score_gemma":0.000040981417,"threshold_uncertainty_score":0.3118356},"labels":[],"label_agreement":null},{"id":"W3197432116","doi":"10.1007/s10928-021-09779-4","title":"A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmacokinetics and Pharmacodynamics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Convolution (computer science); Acceleration; Series (stratigraphy); Function (biology); Code (set theory); Power series","score_opus":0.04224006955800325,"score_gpt":0.32203993519298957,"score_spread":0.2797998656349863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197432116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9069752,0.017437741,0.061921265,0.0069496394,0.0039596413,0.002120066,0.00036773604,0.00003166464,0.0002370628],"genre_scores_gemma":[0.96509635,0.020921469,0.011320429,0.00040916563,0.00048077345,0.000034883677,0.00013438237,0.00004359938,0.0015589511],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99891156,0.000035262627,0.0005670341,0.00015682963,0.000144184,0.00018511938],"domain_scores_gemma":[0.9982239,0.00022705848,0.00037888752,0.000091814145,0.0009501505,0.00012820539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033434195,0.00017737766,0.0003349133,0.000117665935,0.00012079866,0.000046461537,0.000067948655,0.000055454682,0.000048708756],"category_scores_gemma":[0.000053253254,0.0001340291,0.00014374801,0.00019531809,0.000109058106,0.00014756495,0.000052269963,0.00016290673,2.5597055e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031095948,0.0012925651,0.0012895217,0.0015311452,0.006452536,0.00008312035,0.00075865095,0.0013271049,0.48849005,0.0030334352,0.022857478,0.46977478],"study_design_scores_gemma":[0.020684944,0.002702188,0.0020321398,0.0002436049,0.010979279,0.00058989006,0.0007044726,0.74153155,0.06264547,0.001161915,0.15637237,0.0003521645],"about_ca_topic_score_codex":0.0000010734198,"about_ca_topic_score_gemma":0.0000025105703,"teacher_disagreement_score":0.74020445,"about_ca_system_score_codex":0.000042366773,"about_ca_system_score_gemma":0.00008784343,"threshold_uncertainty_score":0.5465548},"labels":[],"label_agreement":null},{"id":"W3197695207","doi":"10.1210/clinem/dgab585","title":"Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Terminology; Pharmacotherapy; Medicine; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Psychological intervention; Family medicine; Psychology; Internal medicine; Psychiatry; Endocrinology","score_opus":0.054010276718537475,"score_gpt":0.3689348567791057,"score_spread":0.3149245800605682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197695207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843738,0.008942365,0.000015331547,0.0045785466,0.000538144,0.000081216065,5.646813e-7,0.0000043024825,0.0014657222],"genre_scores_gemma":[0.9916968,0.0062203286,0.0012840896,0.00050303806,0.00011950719,7.558023e-7,0.0000042200795,0.000006077739,0.00016523192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982108,0.00035389414,0.0010659115,0.00009490436,0.00014039048,0.00013412985],"domain_scores_gemma":[0.9980832,0.00080966303,0.00060478353,0.00017571235,0.0002671829,0.000059479713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009897569,0.00007605343,0.00060314883,0.000094531766,0.000015382575,0.0000033238773,0.000049873583,0.000057819365,0.00003500963],"category_scores_gemma":[0.00262347,0.000046687324,0.00010991798,0.00012475872,0.00016342674,0.000033313165,0.000053503893,0.00028128433,0.0000022444392],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045429375,0.0019628927,0.39201975,0.0002522555,0.0021160287,0.004140819,0.0007881201,0.000039133593,0.019964969,0.008099053,0.0031176896,0.56295633],"study_design_scores_gemma":[0.006961887,0.00095166574,0.9475677,0.00042940804,0.00210736,0.0013484918,0.00042007654,0.00021736328,0.0127151385,0.010334404,0.016839448,0.00010705223],"about_ca_topic_score_codex":0.0000033006895,"about_ca_topic_score_gemma":0.0000030910808,"teacher_disagreement_score":0.5628493,"about_ca_system_score_codex":0.0000075048306,"about_ca_system_score_gemma":0.00009579672,"threshold_uncertainty_score":0.31407282},"labels":[],"label_agreement":null},{"id":"W3197785709","doi":"10.1111/dom.14535","title":"Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <scp>EMPA‐REG OUTCOME</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Insulin; Placebo; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.011845454628464088,"score_gpt":0.21517571711972322,"score_spread":0.20333026249125913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197785709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219745,0.006306121,0.0000020892537,0.000083985135,0.0002015046,0.0011186305,0.000032510583,0.0000224178,0.00003529869],"genre_scores_gemma":[0.99819624,0.00067506253,0.000096686745,0.0005077754,0.00008028503,0.00006624632,0.00028956245,0.000018762583,0.0000693865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986088,0.00016917783,0.00026340864,0.00037248334,0.00034895926,0.00023716284],"domain_scores_gemma":[0.9987351,0.0005620165,0.00008486188,0.0003403785,0.00015904332,0.000118620235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027845358,0.0002104535,0.0006074045,0.00010843495,0.000069260146,0.000040038212,0.000061614955,0.00007378897,0.0000060382595],"category_scores_gemma":[0.0012604039,0.00013112256,0.000101820246,0.0003325015,0.000081616876,0.00013414201,0.000073374875,0.00013313582,0.000004330923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006195168,0.0007618319,0.9903357,0.00022923296,0.00082145963,0.000008166504,0.00040937762,0.0000034730306,0.00013155858,0.000097714925,0.000091878916,0.0064900885],"study_design_scores_gemma":[0.022031497,0.00037282566,0.97003627,0.0002246812,0.0018865056,2.0538492e-8,0.000076404045,0.00003030498,0.0038695936,0.00009271501,0.0013108071,0.00006835057],"about_ca_topic_score_codex":0.0000143976995,"about_ca_topic_score_gemma":0.00000517888,"teacher_disagreement_score":0.021411981,"about_ca_system_score_codex":0.000020321953,"about_ca_system_score_gemma":0.000036952617,"threshold_uncertainty_score":0.5347023},"labels":[],"label_agreement":null},{"id":"W3198399789","doi":"10.1016/j.xcrm.2021.100387","title":"Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden; Novo Nordisk; Pfizer","keywords":"Semaglutide; Medicine; Type 2 diabetes; Nausea; Adverse effect; Diabetes mellitus; Dulaglutide; Body weight; Internal medicine; Vomiting; Pharmacodynamics; Oral administration; Pharmacology; Liraglutide; Endocrinology; Pharmacokinetics","score_opus":0.014010151235004795,"score_gpt":0.24457456010019898,"score_spread":0.2305644088651942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198399789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98619616,0.0023307945,0.000007869635,0.0007114857,0.00016859693,0.00030700257,6.0789625e-7,0.000017906548,0.010259603],"genre_scores_gemma":[0.99600995,0.00013945781,0.00072578597,0.000095246614,0.000073940704,0.000016991553,0.000036696074,0.000018942827,0.0028829842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987178,0.000025013052,0.0004895708,0.0003184501,0.0002235682,0.0002255995],"domain_scores_gemma":[0.9992417,0.00006698695,0.00017487178,0.00032302886,0.00010124756,0.00009216045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002738136,0.00014308773,0.0005026144,0.00022455302,0.000020638909,0.000003654557,0.00002033014,0.000042795207,0.000184609],"category_scores_gemma":[0.0001968879,0.00010685851,0.000022492466,0.00057971646,0.000089392604,0.00004391249,0.00003957636,0.00010756833,7.4030464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017352546,0.00027482808,0.90825623,0.0004778929,0.00006924704,0.0030804286,0.0006950692,0.000014356315,0.082699895,0.000015994307,0.00021875044,0.0041799294],"study_design_scores_gemma":[0.0025519545,0.0005494496,0.9625076,0.0015496798,0.00039507597,0.000280019,0.0008268225,0.00031653338,0.029398588,0.00014372723,0.0013230034,0.00015751633],"about_ca_topic_score_codex":0.00007623712,"about_ca_topic_score_gemma":0.00015086225,"teacher_disagreement_score":0.054251377,"about_ca_system_score_codex":0.000060488434,"about_ca_system_score_gemma":0.000100253375,"threshold_uncertainty_score":0.43575636},"labels":[],"label_agreement":null},{"id":"W3198792931","doi":"10.1016/j.amsu.2021.102796","title":"Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis","year":2021,"lang":"en","type":"review","venue":"Annals of Medicine and Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Stephen's University","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Meta-analysis; Ejection fraction; Randomized controlled trial; Diabetes mellitus; Angiotensin receptor; Dapagliflozin; MEDLINE; Population; Type 2 diabetes; Endocrinology; Angiotensin II; Blood pressure","score_opus":0.09174846511056114,"score_gpt":0.3283096855970049,"score_spread":0.23656122048644376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198792931","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14841038,0.8481303,6.3554137e-7,0.0020778924,0.00006340358,0.0011400124,0.00011374974,0.0000352055,0.000028439312],"genre_scores_gemma":[0.025074536,0.9582967,0.00021766443,0.0005913336,0.00018611453,0.00006620462,0.01527133,0.000100556324,0.00019555225],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99528086,0.00040074444,0.002093094,0.0008740755,0.00085945864,0.00049177936],"domain_scores_gemma":[0.9969028,0.00041685108,0.000931007,0.0008209597,0.00057154894,0.00035679407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010502188,0.00080955337,0.010417327,0.002172619,0.00003643343,0.000013447079,0.00008818197,0.0003675206,0.0003973728],"category_scores_gemma":[0.000094757066,0.0005007082,0.0023041011,0.0028022907,0.00034326702,0.00013822054,0.00004519581,0.0003116349,0.0000028085733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009859344,0.007440143,0.077533066,0.009876159,0.39434555,0.0007225881,0.0005752949,0.0000024084218,0.000032802294,0.00001569121,0.26470074,0.24376962],"study_design_scores_gemma":[0.002593489,0.0012564973,0.0034525692,0.0064079426,0.34588087,0.000007829336,0.00011882318,0.0000015647792,0.0004391995,9.979375e-7,0.63930243,0.0005377687],"about_ca_topic_score_codex":0.0003379608,"about_ca_topic_score_gemma":0.00012785116,"teacher_disagreement_score":0.3746017,"about_ca_system_score_codex":0.00002746635,"about_ca_system_score_gemma":0.00022017774,"threshold_uncertainty_score":0.9997445},"labels":[],"label_agreement":null},{"id":"W3198951773","doi":"10.2337/dc21-1170","title":"A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Internal medicine; Copeptin; TIMI; Dapagliflozin; Saxagliptin; Myocardial infarction; Hazard ratio; Diabetes mellitus; Alogliptin; Framingham Risk Score; Placebo; Type 2 Diabetes Mellitus; Heart failure; Cardiology; Thrombolysis; Sitagliptin; Endocrinology; Confidence interval","score_opus":0.006605933916149059,"score_gpt":0.21800330221570385,"score_spread":0.2113973682995548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198951773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966547,0.00032662274,0.00009312171,0.00024295117,0.00007209383,0.0020103478,0.0005251697,0.000033738295,0.000041259387],"genre_scores_gemma":[0.9899166,0.0000018376589,0.005245682,0.00021855776,0.00002007248,0.0005670427,0.0039635412,0.000039767798,0.000026898872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989587,0.000024952542,0.00021800531,0.00030438212,0.00018015348,0.00031382818],"domain_scores_gemma":[0.99895036,0.00011994753,0.000107784595,0.00027524008,0.00048333307,0.00006334413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007258008,0.00017570959,0.00038615734,0.00014679428,0.00004195568,0.000017987879,0.000048153284,0.00006878417,0.000013463697],"category_scores_gemma":[0.00014843109,0.00014505518,0.00015197704,0.00029796828,0.000038156293,0.00007222986,0.00002083062,0.00003488137,0.0000018995914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008449524,0.00037121656,0.99249,0.0012895799,0.00022089249,3.267477e-7,0.00009231303,0.000033455446,0.0002125634,0.000027567468,0.0012980041,0.0038796135],"study_design_scores_gemma":[0.009101858,0.0016502291,0.96345276,0.000582659,0.0005464484,3.553239e-9,0.00026823295,0.00051324785,0.020871844,0.000048773076,0.0027882797,0.00017563906],"about_ca_topic_score_codex":0.0000015545161,"about_ca_topic_score_gemma":0.000031290067,"teacher_disagreement_score":0.029037189,"about_ca_system_score_codex":0.00007250171,"about_ca_system_score_gemma":0.00006599589,"threshold_uncertainty_score":0.5915178},"labels":[],"label_agreement":null},{"id":"W3199001556","doi":"10.1111/dom.14551","title":"Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); McMaster University; York University","funders":"","keywords":"Semaglutide; Weight loss; Tolerability; Overweight; Adverse effect; Medicine; Obesity; Weight management; Gastrointestinal system; Anti obesity; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.013496819939861935,"score_gpt":0.23526608980532987,"score_spread":0.22176926986546794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199001556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695593,0.0009914965,0.000052806972,0.0009148807,0.00002961095,0.0007075561,0.000044471682,0.000028446297,0.0002747743],"genre_scores_gemma":[0.9933242,0.00012650306,0.0057761637,0.00012169694,0.00007744359,0.00003378195,0.000056368255,0.000018094184,0.00046572732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980313,0.00023906869,0.00044308492,0.0005222307,0.00033098538,0.00043329128],"domain_scores_gemma":[0.99825275,0.0008293446,0.00018742484,0.00035267373,0.00015047647,0.0002273498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062812486,0.0003146793,0.000827667,0.00012995141,0.00014678262,0.000019289253,0.00008781957,0.000045857854,0.000029984267],"category_scores_gemma":[0.0005633465,0.00020019048,0.00008281971,0.00033831145,0.000534493,0.00019152767,0.00022500432,0.0003001358,0.0000023251207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005746557,0.00044150415,0.9954285,0.0005983328,0.00009100435,0.0000838617,0.0002815233,0.0000018117643,0.000036800684,0.0016263623,0.000018303195,0.0008173553],"study_design_scores_gemma":[0.009971759,0.00031325393,0.98498213,0.0016636853,0.0006684856,0.00009160819,0.00020428636,0.00013351155,0.00026987933,0.0014115935,0.000110079614,0.00017971217],"about_ca_topic_score_codex":0.00009107394,"about_ca_topic_score_gemma":0.00014424641,"teacher_disagreement_score":0.01044634,"about_ca_system_score_codex":0.000034480483,"about_ca_system_score_gemma":0.00009970338,"threshold_uncertainty_score":0.8163531},"labels":[],"label_agreement":null},{"id":"W3199553988","doi":"10.1161/jaha.120.019918","title":"Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression","year":2021,"lang":"en","type":"review","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hamilton Health Sciences; Impact; McMaster University; Queen's University; St. Michael's Hospital","funders":"University of Toronto; Yale University","keywords":"Empagliflozin; Dapagliflozin; Canagliflozin; Medicine; Internal medicine; Relative risk; Placebo; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Myocardial infarction; Randomized controlled trial; Confidence interval; Endocrinology","score_opus":0.04230468860633751,"score_gpt":0.32659254736407667,"score_spread":0.28428785875773915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199553988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044682786,0.95409554,0.000004477852,0.0005312423,0.000070463466,0.0005803629,0.000015914156,0.000007373721,0.00001181578],"genre_scores_gemma":[0.0194955,0.97959673,0.00028201932,0.000307978,0.00006892394,0.000032992368,0.00003048509,0.000034002893,0.00015134398],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99729687,0.0006206828,0.0007169121,0.0002907491,0.00082792126,0.00024687368],"domain_scores_gemma":[0.998012,0.0002331155,0.001077031,0.00037319667,0.00017512454,0.00012953811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011669414,0.0003827852,0.007175329,0.00038629718,0.000044912504,0.000054647102,0.00008514989,0.00009677167,0.000017702943],"category_scores_gemma":[0.00010289466,0.00017827748,0.0036603392,0.0009553226,0.00005713662,0.00012665949,0.000058757472,0.00035194706,5.14723e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015494566,0.00014549609,0.21059413,0.00096974516,0.7792019,0.000053423948,0.00007707155,0.0000032302257,4.4674718e-7,6.7401635e-7,0.0001587626,0.0087796105],"study_design_scores_gemma":[0.0005680559,0.0002702429,0.035020042,0.0008983773,0.9295042,0.000008400042,0.00005612506,0.0000033362942,0.0000052357977,0.000002696391,0.033489615,0.0001736709],"about_ca_topic_score_codex":0.0001603185,"about_ca_topic_score_gemma":0.00018125669,"teacher_disagreement_score":0.1755741,"about_ca_system_score_codex":0.00023535086,"about_ca_system_score_gemma":0.00011061422,"threshold_uncertainty_score":0.72699445},"labels":[],"label_agreement":null},{"id":"W3199764101","doi":"10.1002/ccr3.4811","title":"Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail","year":2021,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kirkland and District Hospital","funders":"","keywords":"Medicine; Dulaglutide; Glycemic; Type 2 diabetes; Glucagon-like peptide 1 receptor; Girl; Agonist; Intensive care medicine; Glucagon-like peptide-1; Pediatrics; Internal medicine; Diabetes mellitus; Endocrinology; Exenatide; Insulin; Receptor","score_opus":0.08173027980468255,"score_gpt":0.3277021246927583,"score_spread":0.24597184488807572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199764101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501526,0.0006326054,0.0000127829335,0.0007749211,0.00039724557,0.0007746328,0.000011425881,0.000061239785,0.0023198712],"genre_scores_gemma":[0.96847516,0.0007708539,0.0075235353,0.00090604427,0.00016233361,0.00010896442,0.000318867,0.00005675186,0.02167748],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973834,0.00015814304,0.0011243008,0.0006575003,0.00031397192,0.0003626862],"domain_scores_gemma":[0.99764687,0.0004241807,0.0004131518,0.0009460401,0.000312555,0.00025721447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006609039,0.00025164173,0.0007941253,0.00009886503,0.000054683584,0.0000569971,0.000041652285,0.00015778944,0.00046052993],"category_scores_gemma":[0.00069509255,0.00019368564,0.0002511912,0.00037085553,0.00021987261,0.00014915437,0.00009169981,0.00029008117,0.000025531577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013016366,0.008078723,0.8006333,0.00038167599,0.0021071683,0.10017229,0.0007439734,0.000027625932,0.0011133226,0.0002930528,0.036132757,0.049014486],"study_design_scores_gemma":[0.015368655,0.009113399,0.10601864,0.0017071202,0.0018081246,0.0031885786,0.0018479489,0.00021767423,0.0048603886,0.0006428255,0.8539702,0.0012564216],"about_ca_topic_score_codex":0.0001690278,"about_ca_topic_score_gemma":0.0003373262,"teacher_disagreement_score":0.8178375,"about_ca_system_score_codex":0.00011811093,"about_ca_system_score_gemma":0.000338592,"threshold_uncertainty_score":0.7898271},"labels":[],"label_agreement":null},{"id":"W3199769651","doi":"10.1161/circulationaha.121.054439","title":"Outcomes of Participants With Diabetes in the ISCHEMIA Trials","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; Spinal Cord Injury BC; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute","keywords":"Medicine; Interquartile range; Diabetes mellitus; Internal medicine; Hazard ratio; Revascularization; Kidney disease; Myocardial infarction; Coronary artery disease; Cardiology; Surgery; Confidence interval; Endocrinology","score_opus":0.0769999284474272,"score_gpt":0.32824431841779056,"score_spread":0.25124438997036336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199769651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964449,0.00012699963,0.000019759513,0.000825443,0.000021805457,0.0002474412,8.422197e-7,0.0000072422645,0.002305596],"genre_scores_gemma":[0.9995224,0.0000032766432,0.00010400202,0.00020936843,0.0000145673,0.00003216094,0.000033472377,0.0000038071757,0.00007694805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994608,0.000060818173,0.00017397659,0.000078379344,0.00013388965,0.00009213686],"domain_scores_gemma":[0.9996098,0.00013060785,0.000061482715,0.0001537714,0.000030125413,0.000014200514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003816418,0.00004648769,0.00022291549,0.000029616776,0.000009923576,0.0000067707897,0.000019406087,0.000017188977,0.00004338115],"category_scores_gemma":[0.00018723377,0.000025356474,0.000042245934,0.00013689253,0.000013437725,0.00003582843,0.0000062453073,0.00002297882,0.000004524768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000086309465,0.00012174908,0.9922971,0.000034072684,0.00011303329,0.0000060221646,0.00019401014,0.000031198,0.0032238874,0.00033528093,0.000055186592,0.0035798333],"study_design_scores_gemma":[0.0010013283,0.000024476823,0.985334,0.00004081651,0.00025101815,1.3643157e-7,0.00016871085,0.00016481415,0.012692882,0.00013981207,0.00015425932,0.000027738977],"about_ca_topic_score_codex":0.0000034781706,"about_ca_topic_score_gemma":0.000010329052,"teacher_disagreement_score":0.009468995,"about_ca_system_score_codex":0.00001463543,"about_ca_system_score_gemma":0.000019219726,"threshold_uncertainty_score":0.1034007},"labels":[],"label_agreement":null},{"id":"W3199804663","doi":"10.2139/ssrn.3517409","title":"Ileo-Colonic Delivery of Conjugated Bile Acids Improves Glucose Homeostasis &lt;i&gt;via&lt;/i&gt; Colonic GLP-1-Producing Enteroendocrine Cells in Human Obesity and Diabetes","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Enteroendocrine cell; Glucose homeostasis; Internal medicine; Endocrinology; Homeostasis; Medicine; Glucagon-like peptide-1; Diabetes mellitus; Endocrine system; Type 2 diabetes; Chemistry; Insulin resistance; Hormone","score_opus":0.006889431027573604,"score_gpt":0.21730416945129916,"score_spread":0.21041473842372554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199804663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727285,0.02485953,0.000021394018,0.0012353373,0.00010888555,0.00087557774,0.000014229536,0.00006658729,0.000089974405],"genre_scores_gemma":[0.98308533,0.015933067,0.00007578876,0.000318703,0.0001624976,0.000032717635,0.00004041187,0.000055137705,0.00029634897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959302,0.00014683876,0.0007317182,0.00058487523,0.00039788947,0.0022084794],"domain_scores_gemma":[0.9988211,0.000079546895,0.00036641565,0.00028911044,0.00015467523,0.00028919175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007756045,0.0004118807,0.00085698464,0.0003489867,0.00018472514,0.00005796136,0.0002602071,0.00009229723,0.00006436599],"category_scores_gemma":[0.00007135475,0.0003736113,0.00022110871,0.00048597483,0.00016516833,0.00029178645,0.00021494408,0.00096413755,0.000015452555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005001535,0.0010288807,0.027187087,0.00035234404,0.0013585258,0.000099422396,0.000529887,0.000017753924,0.94897956,0.000995643,0.0003515817,0.01859918],"study_design_scores_gemma":[0.034507368,0.02706197,0.16180621,0.00088197464,0.0036388186,0.00016575017,0.0011464182,0.0016307005,0.75164115,0.007088658,0.008785327,0.0016456161],"about_ca_topic_score_codex":0.000043313055,"about_ca_topic_score_gemma":0.000540072,"teacher_disagreement_score":0.19733836,"about_ca_system_score_codex":0.0008714355,"about_ca_system_score_gemma":0.00058573054,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W3199848349","doi":"10.46747/cfp.6709e247","title":"Les inhibiteurs du cotransporteur du sodium-glucose de type 2 pour l’insuffisance cardiaque avec fraction d’éjection réduite","year":2021,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Prairie Improvement Network; University of Winnipeg","funders":"","keywords":"Medicine; Gynecology","score_opus":0.014257066896940207,"score_gpt":0.2263202642777696,"score_spread":0.2120631973808294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199848349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7759917,0.027646188,0.00023077877,0.007044862,0.0056351363,0.0006824705,0.0002320341,0.00013688106,0.18239994],"genre_scores_gemma":[0.94110703,0.006264395,0.00017566951,0.03653042,0.003958614,0.00005166142,0.0008137397,0.0001348112,0.010963664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99727714,0.00017328988,0.00037799706,0.00068258506,0.0003088474,0.0011801303],"domain_scores_gemma":[0.9979513,0.00006936293,0.00014808368,0.0005355947,0.0003665042,0.00092915137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020556006,0.0004909063,0.000590421,0.00028682768,0.0003710418,0.00012216355,0.00013958088,0.00029880903,0.00009634563],"category_scores_gemma":[0.000043576394,0.0006118416,0.00030958382,0.0008305879,0.00014679258,0.0003506575,0.000025969859,0.00046573498,0.0008881905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013237819,0.0015330204,0.06406475,0.0010295796,0.0022462164,0.007817219,0.0021926668,0.0009408337,0.021083407,0.010718643,0.18944983,0.69879144],"study_design_scores_gemma":[0.0017362969,0.00023146311,0.17458402,0.0007808577,0.001225965,0.0000110421515,0.0024969433,0.0009146932,0.006403038,0.00027400357,0.81076175,0.00057995046],"about_ca_topic_score_codex":0.046528995,"about_ca_topic_score_gemma":0.04222967,"teacher_disagreement_score":0.6982115,"about_ca_system_score_codex":0.002887659,"about_ca_system_score_gemma":0.0019037249,"threshold_uncertainty_score":0.99988973},"labels":[],"label_agreement":null},{"id":"W3199855777","doi":"10.14740/cr1315","title":"Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors","year":2021,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Heart failure; Cardiology; Internal medicine","score_opus":0.016820010558940824,"score_gpt":0.3220559903411067,"score_spread":0.3052359797821659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199855777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970646,0.0035889074,0.000037736703,0.0022964147,0.00018594075,0.0006379636,0.00001068379,0.000033439523,0.0035024593],"genre_scores_gemma":[0.9933646,0.00027709993,0.0003004623,0.00010635849,0.0001608122,0.000099153396,0.00018222102,0.00002103389,0.005488266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983238,0.0002860195,0.0002047802,0.00034512827,0.0003444877,0.00049577246],"domain_scores_gemma":[0.99898386,0.00021941085,0.000026310958,0.0003921525,0.00025108844,0.00012720478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004431836,0.00011961504,0.0005821966,0.00013202959,0.00007034954,0.000009952631,0.00008035623,0.00013796263,0.00005408275],"category_scores_gemma":[0.00011304321,0.00010250449,0.00021911152,0.00030919423,0.00021170106,0.000044600874,0.00011487447,0.0003159256,0.00005655771],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011667259,0.0002496888,0.17215617,0.00085015054,0.0022784993,0.0017208765,0.00014980264,9.408203e-7,0.56398046,0.00012345813,0.2546921,0.0036811882],"study_design_scores_gemma":[0.003010468,0.0008010299,0.023364915,0.00026060562,0.0005599278,0.000079753285,0.00019121674,0.0000044830385,0.84556025,0.000111419875,0.1259171,0.00013882158],"about_ca_topic_score_codex":0.000005062501,"about_ca_topic_score_gemma":0.0000018869375,"teacher_disagreement_score":0.2815798,"about_ca_system_score_codex":0.000050392297,"about_ca_system_score_gemma":0.0000989414,"threshold_uncertainty_score":0.4180012},"labels":[],"label_agreement":null},{"id":"W3200044811","doi":"10.1016/j.jacc.2021.07.046","title":"Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Internal medicine; Heart failure; Quartile; Ejection fraction; Cardiology; Placebo; Clinical endpoint; Natriuretic peptide; Randomization; Randomized controlled trial; Endocrinology; Type 2 diabetes; Diabetes mellitus; Confidence interval","score_opus":0.01119809056760367,"score_gpt":0.27573364941952994,"score_spread":0.26453555885192626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200044811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959776,0.0008410096,0.0000030865806,0.0016510109,0.0002050132,0.00056206185,0.000011588582,0.0000012414619,0.0007474235],"genre_scores_gemma":[0.99935,0.00017358067,0.00016305501,0.00010543596,0.00012052825,0.000011280146,9.182422e-7,0.000007131127,0.00006806803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984176,0.00056046154,0.00055065006,0.000098119286,0.00023956387,0.00013360703],"domain_scores_gemma":[0.99817485,0.0005829098,0.00080555526,0.00027260944,0.00013182942,0.00003225687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008505726,0.000105750434,0.0011338892,0.00009862121,0.000015261197,0.0000016239749,0.0001608226,0.000028823384,0.0000043668765],"category_scores_gemma":[0.0006732828,0.00005310046,0.0003253925,0.00037952326,0.00035088565,0.000022715592,0.000065541455,0.00013808791,1.383678e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018862646,0.00025640926,0.9531278,0.00026487617,0.0021174627,0.00056650216,0.0002169936,0.00006788465,0.01825733,0.0002455645,0.0035415974,0.0024749506],"study_design_scores_gemma":[0.0475191,0.021992305,0.90547997,0.000475398,0.0033085751,0.00078680576,0.0025991215,0.000021825581,0.016161777,0.00033063054,0.0011780702,0.00014641757],"about_ca_topic_score_codex":0.0000043831237,"about_ca_topic_score_gemma":0.0000043798773,"teacher_disagreement_score":0.047647808,"about_ca_system_score_codex":0.000028292423,"about_ca_system_score_gemma":0.00015047689,"threshold_uncertainty_score":0.21653739},"labels":[],"label_agreement":null},{"id":"W3200915536","doi":"10.1016/j.kint.2021.09.005","title":"A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function","year":2021,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Janssen Pharmaceuticals; Novo Nordisk Fonden; Relypsa; Cytokinetics; Astellas Pharma; Satellite Healthcare; University of Glasgow; Bristol-Myers Squibb; Akebia Therapeutics; Steno Diabetes Center Copenhagen; Novo Nordisk; ReCor Medical; Eli Lilly and Company; AstraZeneca; CSL Behring; Alnylam Pharmaceuticals; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; GlaxoSmithKline; Defense Acquisition Program Administration; Amgen; Angion; Pfizer","keywords":"Kidney disease; Dapagliflozin; Medicine; Renal function; Incidence (geometry); Adverse effect; Randomized controlled trial; Internal medicine; Intensive care medicine; Acute kidney injury; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.015394656365335654,"score_gpt":0.29140131335399555,"score_spread":0.2760066569886599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200915536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830956,0.00010850272,0.00016348845,0.0070374226,0.00050549436,0.0026168039,0.000089418085,0.0000070994265,0.001162188],"genre_scores_gemma":[0.9961723,0.0001468008,0.000053109772,0.00083343463,0.000051758063,0.00031148258,0.00018709338,0.000007474731,0.002236537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788016,0.00033854938,0.0008963564,0.00023797646,0.00053549325,0.000111459165],"domain_scores_gemma":[0.99829835,0.0005610272,0.0005178264,0.0003101391,0.00018419724,0.00012847537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000875433,0.00015144743,0.0010019615,0.00043730738,0.000018420418,0.0000071775225,0.00014407044,0.00004721039,0.0004971621],"category_scores_gemma":[0.0065583014,0.000085651234,0.00061792886,0.0004932454,0.0001285716,0.00008489854,0.00008780624,0.00009720062,9.167751e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83756036,0.0019068161,0.13829646,0.00017925516,0.009613497,0.000012424425,0.00040020107,0.000549985,0.0014361395,0.0084227435,0.001051408,0.00057070213],"study_design_scores_gemma":[0.7213883,0.00019507289,0.26104668,0.0007810092,0.004372647,1.9052727e-7,0.000084570485,0.010152107,0.0006939273,0.00084914913,0.0003520308,0.00008433356],"about_ca_topic_score_codex":0.0000970068,"about_ca_topic_score_gemma":0.0001566659,"teacher_disagreement_score":0.12275023,"about_ca_system_score_codex":0.00014884223,"about_ca_system_score_gemma":0.00056609215,"threshold_uncertainty_score":0.7851373},"labels":[],"label_agreement":null},{"id":"W3200962633","doi":"10.1177/19322968211035411","title":"Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy","year":2021,"lang":"en","type":"review","venue":"Journal of Diabetes Science and Technology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Glycemic; Glycated hemoglobin; Insulin; Diabetic ketoacidosis; Postprandial; Intensive care medicine; Closed loop; Placebo; Diabetes mellitus; Type 2 diabetes; Type 1 diabetes; Ketoacidosis; Internal medicine; Endocrinology","score_opus":0.025943361477540835,"score_gpt":0.30731297651809036,"score_spread":0.2813696150405495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200962633","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1822639,0.81533086,0.0000010655634,0.0010050852,0.0001671997,0.00055609434,0.0000020148238,0.000031140095,0.00064265815],"genre_scores_gemma":[0.009261511,0.9887892,0.0011798366,0.0003575684,0.000121109886,0.000036417405,0.000004181786,0.000030917556,0.00021927417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975284,0.00003153546,0.0006648473,0.00047206983,0.0007365339,0.0005666449],"domain_scores_gemma":[0.9981034,0.00007889999,0.0005523895,0.00037303293,0.0005981792,0.0002941455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075877487,0.0003865339,0.0017561982,0.0013754839,0.00017176682,0.00015553023,0.00046220934,0.00027311317,0.000033670975],"category_scores_gemma":[0.00024863594,0.000223833,0.0001785879,0.0033225913,0.00056635315,0.00024176417,0.00020056398,0.0005835767,0.000016396569],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009254971,0.00022048436,0.0012811818,0.0006213772,0.0003369034,0.00022603596,0.000018804425,2.2049552e-7,0.0001885307,0.00037419525,0.00029104235,0.99643195],"study_design_scores_gemma":[0.0032971005,0.017587485,0.00035850206,0.03599946,0.0022056503,0.00048946805,0.00046200986,0.000010977849,0.0018049541,0.0004669454,0.93647873,0.0008387209],"about_ca_topic_score_codex":0.0000017022642,"about_ca_topic_score_gemma":0.0000010570393,"teacher_disagreement_score":0.99559325,"about_ca_system_score_codex":0.00018325004,"about_ca_system_score_gemma":0.0016625703,"threshold_uncertainty_score":0.9127645},"labels":[],"label_agreement":null},{"id":"W3201928742","doi":"10.1002/cpt.2430","title":"Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Internal medicine; Incretin; Gastroenterology; Type 2 diabetes; Confidence interval; Adverse effect; Diabetes mellitus; Proportional hazards model; Exenatide; Vildagliptin; Glucagon-like peptide-1; Endocrinology","score_opus":0.02719847512076245,"score_gpt":0.3351393835277968,"score_spread":0.30794090840703436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201928742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981135,0.00027115492,0.00001714474,0.00055282604,0.00045073612,0.0002747091,0.0000063429793,0.000032964297,0.00028062932],"genre_scores_gemma":[0.99368244,0.00038799393,0.001672926,0.0038967363,0.00009169105,0.0000098660785,0.00007428457,0.000018167108,0.00016591519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989223,0.00018749683,0.00032003352,0.00024142202,0.00015368544,0.00017509761],"domain_scores_gemma":[0.9987073,0.00047972126,0.00019122897,0.00014558567,0.00037974268,0.00009641786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023833658,0.00012910142,0.00033195718,0.000042890413,0.00004255915,0.0000064211763,0.000046627116,0.00008761956,0.00013077744],"category_scores_gemma":[0.000041086143,0.00009796809,0.00006433922,0.00015716297,0.00041463034,0.0000350388,0.000051776235,0.00024326895,0.0000054854145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004212402,0.00074215,0.97647816,0.00004475856,0.0013161598,0.0000065952736,0.000032853266,0.0000048056127,0.0003192352,0.0000029043879,0.00056406535,0.020067092],"study_design_scores_gemma":[0.006392048,0.0018001517,0.9778698,0.000047357196,0.0047622514,3.8970717e-7,0.000035720626,0.0006930068,0.005140954,0.000040554987,0.0031167197,0.000101039914],"about_ca_topic_score_codex":0.0000022381773,"about_ca_topic_score_gemma":0.0000015044401,"teacher_disagreement_score":0.019966053,"about_ca_system_score_codex":0.000021271375,"about_ca_system_score_gemma":0.000063246545,"threshold_uncertainty_score":0.39950228},"labels":[],"label_agreement":null},{"id":"W3202291872","doi":"10.1136/bmjdrc-2021-002484","title":"Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial","year":2021,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Pfizer","keywords":"Medicine; Kidney disease; Glycemic; Internal medicine; Type 2 diabetes; Renal function; Placebo; Glycated hemoglobin; Diabetes mellitus; Gastroenterology; Urology; Blood pressure; Endocrinology; Pathology","score_opus":0.023099526021228244,"score_gpt":0.3440394884501255,"score_spread":0.3209399624288973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202291872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849746,0.004244512,2.1612088e-7,0.0010059198,0.000082593455,0.009129007,0.00034959902,0.0000110268575,0.0002024998],"genre_scores_gemma":[0.997028,0.00038549962,0.00004391625,0.00023521758,0.0000972612,0.00061230495,0.0012220488,0.000032108343,0.00034367433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604994,0.0013635893,0.00046547444,0.0006176471,0.0009631011,0.0005402238],"domain_scores_gemma":[0.99681014,0.0011319242,0.00013911058,0.0010754885,0.00047694286,0.00036640186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011509857,0.00024880478,0.0010036229,0.00015448936,0.000213098,0.0002346186,0.0004224705,0.00007167026,0.00023241952],"category_scores_gemma":[0.00221414,0.00013349336,0.00014585297,0.0012554125,0.0004920795,0.00022292642,0.0010614805,0.0002970443,0.00000297755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22843432,0.00044558212,0.76085234,0.00021200495,0.00212992,0.0000089895675,0.00059848314,0.00001871877,0.0001176984,0.000027769742,0.00040678543,0.0067474092],"study_design_scores_gemma":[0.41585454,0.0010873569,0.5787865,0.0006589144,0.0013052418,9.281323e-9,0.00045852878,0.00037486097,0.00046977994,0.000021341448,0.0008241777,0.00015874476],"about_ca_topic_score_codex":0.00025652946,"about_ca_topic_score_gemma":0.00043907977,"teacher_disagreement_score":0.1874202,"about_ca_system_score_codex":0.00022433401,"about_ca_system_score_gemma":0.0006802757,"threshold_uncertainty_score":0.5443701},"labels":[],"label_agreement":null},{"id":"W3202292925","doi":"10.1002/ehf2.13645","title":"SGLT2 Inhibitors and Cardiac Remodelling: A Systematic Review and Meta-Analysis of Randomized Cardiac Magnetic Resonance Imaging Trials","year":2021,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Ejection fraction; Internal medicine; Cardiology; Heart failure; Cardiac magnetic resonance imaging; Placebo; Clinical endpoint; Meta-analysis; Body surface area; Randomized controlled trial; Diabetes mellitus; Magnetic resonance imaging; Ventricular remodeling; Endocrinology; Pathology; Radiology","score_opus":0.05668372803940746,"score_gpt":0.33517970352355664,"score_spread":0.27849597548414917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202292925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.174205e-7,0.98660475,0.000008646229,0.0011144729,0.000082856895,0.011896123,0.0001551961,0.00003398615,0.000103079],"genre_scores_gemma":[0.0000057810344,0.9937965,0.0016070768,0.00019435768,0.00006327287,0.0013328182,0.0002698747,0.00006238989,0.0026678904],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9910022,0.0042798244,0.0029675341,0.00083614566,0.00057620445,0.00033809457],"domain_scores_gemma":[0.99541736,0.002047074,0.0010414894,0.0010729075,0.000214483,0.0002066985],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.008651444,0.0007536885,0.04938653,0.00058591826,0.00005885865,0.00008101964,0.000093799805,0.00017767759,0.00013801148],"category_scores_gemma":[0.0016166533,0.00045365497,0.011097942,0.0011197437,0.00013810594,0.000070722264,0.0001424949,0.00026959585,0.000008073827],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004330099,0.00003738663,0.0000042660395,0.766164,0.22214253,0.000016410899,0.00004178211,1.6123896e-7,2.367287e-7,0.00010799924,0.004695839,0.006746073],"study_design_scores_gemma":[0.0024377399,0.000018101295,1.9353078e-7,0.06714015,0.6190763,0.000003193659,0.000017156171,0.000007614114,4.2646823e-7,0.000002741197,0.3111016,0.0001947909],"about_ca_topic_score_codex":0.00003064291,"about_ca_topic_score_gemma":0.0000012503102,"teacher_disagreement_score":0.69902384,"about_ca_system_score_codex":0.00006256345,"about_ca_system_score_gemma":0.00013160889,"threshold_uncertainty_score":0.9997915},"labels":[],"label_agreement":null},{"id":"W3202781181","doi":"10.1016/j.molmet.2021.101351","title":"GLP-1 physiology informs the pharmacotherapy of obesity","year":2021,"lang":"en","type":"review","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":469,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden; Azrieli Foundation; Israel Science Foundation; Institute of Nutrition, Metabolism and Diabetes; International Development Research Centre","keywords":"Anorectic; Liraglutide; Gastric emptying; Endocrinology; Type 2 diabetes; Glucagon-like peptide-1; Internal medicine; Medicine; Obesity; Insulin; Biology; Diabetes mellitus; Food intake","score_opus":0.023939364522419803,"score_gpt":0.3330863591800766,"score_spread":0.3091469946576568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202781181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023671174,0.9953562,0.00004153205,0.00006571946,0.00034982018,0.0011524113,0.00001774192,0.00002861612,0.0027512538],"genre_scores_gemma":[0.00003868096,0.9966776,0.0002142858,0.0008067624,0.0001454094,0.00016374831,0.00031094253,0.000049381848,0.0015932339],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855936,0.00015331259,0.00044742945,0.00029737523,0.00027199078,0.00027051766],"domain_scores_gemma":[0.9987901,0.000039273673,0.0002862114,0.0007347233,0.00007768892,0.00007202116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018010961,0.00037190705,0.0021124682,0.00012928611,0.000035344394,0.000013474314,0.00025063116,0.00012091131,0.00028342727],"category_scores_gemma":[0.000022549628,0.00020023831,0.0010728813,0.00035912907,0.000089745634,0.000027961092,0.00014138718,0.0002463498,0.00005471985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005301286,0.00021727625,0.0000010100246,0.0044563976,0.0028777758,0.000050697905,0.000034522942,3.1397977e-7,0.00029583985,0.0025836376,0.0014357166,0.9880415],"study_design_scores_gemma":[0.00063031755,0.00002790862,0.000045748613,0.0013076075,0.0065474273,0.000008283831,0.0000064654782,8.892137e-7,0.00081201363,0.00005878905,0.99039614,0.00015843345],"about_ca_topic_score_codex":0.000010778348,"about_ca_topic_score_gemma":2.7735118e-7,"teacher_disagreement_score":0.9889604,"about_ca_system_score_codex":0.000027741688,"about_ca_system_score_gemma":0.00015286809,"threshold_uncertainty_score":0.8165481},"labels":[],"label_agreement":null},{"id":"W3202919277","doi":"10.1186/s12933-021-01390-8","title":"Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tobacco Research Unit; Trillium Health Centre; University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Cardiology; Internal medicine; Angiology; Ejection fraction; Placebo; Stroke volume; Diabetes mellitus; Coronary artery disease; Type 2 Diabetes Mellitus; Endocrinology; Heart failure","score_opus":0.00565256334890054,"score_gpt":0.20247042272585544,"score_spread":0.1968178593769549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202919277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960009,0.0027827062,0.000033236483,0.000016575586,0.00018077849,0.00041830406,0.000006965099,0.00003174135,0.0005287782],"genre_scores_gemma":[0.99931854,0.00009042608,0.00016926709,0.00005994933,0.000026027383,0.000028381173,0.00022977708,0.00002530017,0.00005234932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987226,0.00012481668,0.00017534352,0.00038368988,0.0002811615,0.00031239467],"domain_scores_gemma":[0.9990003,0.00005556049,0.00006558039,0.00053705316,0.00021586618,0.00012565104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013130068,0.00020872598,0.0007505158,0.00014826684,0.000038795344,0.000012191043,0.000039849772,0.000102407794,0.00005830695],"category_scores_gemma":[0.00007184537,0.00014727334,0.00049718044,0.00031866026,0.00012843923,0.00006211398,0.000043886117,0.00009994276,0.000012933722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099212986,0.00034158214,0.9786662,0.00008110633,0.01071925,0.00015862951,0.000013456031,0.0001831743,0.000026552458,0.000028824596,0.00023240024,0.009449618],"study_design_scores_gemma":[0.0033057919,0.002055545,0.9885384,0.000079785124,0.0032672007,0.0000024131837,0.000011940423,0.000033962286,0.0015725062,0.000034681103,0.0009496732,0.00014813896],"about_ca_topic_score_codex":0.00000935224,"about_ca_topic_score_gemma":0.0000017496509,"teacher_disagreement_score":0.009872168,"about_ca_system_score_codex":0.00007501606,"about_ca_system_score_gemma":0.000042021384,"threshold_uncertainty_score":0.6005633},"labels":[],"label_agreement":null},{"id":"W3203247882","doi":"10.1093/eurheartj/ehab709","title":"Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights","year":2021,"lang":"en","type":"letter","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Obesity; Internal medicine; Comorbidity; Heart failure; Body mass index; Confounding; Myocardial infarction; Type 2 diabetes; TIMI; Cardiology; Endocrinology; Percutaneous coronary intervention","score_opus":0.03270287104433721,"score_gpt":0.2537597992952448,"score_spread":0.22105692825090756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203247882","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05996206,0.006699008,0.00003491927,0.90782005,0.0009407544,0.00083506,0.0000127224475,0.00016673484,0.023528678],"genre_scores_gemma":[0.016696637,0.0008616837,0.0061967685,0.9270871,0.016335895,0.000013896663,0.000515487,0.00027427202,0.032018226],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722594,0.0005456846,0.00048518853,0.0005356254,0.0006754052,0.0005321434],"domain_scores_gemma":[0.9988164,0.000074345386,0.00017946004,0.00042861584,0.00019037008,0.00031084009],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003979982,0.0004711972,0.0007258769,0.00036237732,0.0003348243,0.0005322415,0.00010162988,0.0001939698,0.0006443044],"category_scores_gemma":[0.0000603344,0.00038225725,0.00032790273,0.00018250296,0.000113127826,0.00024018646,0.00027771085,0.0020998137,0.00042098638],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012356244,0.00012382401,0.004303918,0.0003005319,0.000316629,0.013979115,0.00008459642,4.643801e-7,0.00014336444,0.00001069424,0.9802343,0.00049019826],"study_design_scores_gemma":[0.0014417392,0.0005129688,0.011962152,0.0015239979,0.00047146497,0.0036745714,0.00004333699,0.0000027964043,0.00020351587,0.00007015629,0.97974896,0.0003443604],"about_ca_topic_score_codex":0.0000029953894,"about_ca_topic_score_gemma":0.000003921131,"teacher_disagreement_score":0.04326542,"about_ca_system_score_codex":0.00012781606,"about_ca_system_score_gemma":0.00014063052,"threshold_uncertainty_score":0.9998629},"labels":[],"label_agreement":null},{"id":"W3203938281","doi":"10.1159/000519905","title":"Are Post Hoc Analyses on Subgroups Sufficient to Support New Treatment Algorithms of Heart Failure? The Case of SGLT2 Inhibitors Associated with Sacubitril/Valsartan","year":2021,"lang":"en","type":"letter","venue":"Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"","keywords":"Sacubitril; Valsartan; Sacubitril, Valsartan; Guideline; Medicine; Heart failure; First line treatment; Post-hoc analysis; Internal medicine; Clinical Practice; Clinical trial; Ejection fraction; Intensive care medicine; Family medicine; Chemotherapy; Pathology","score_opus":0.04485363475866544,"score_gpt":0.30478481074569463,"score_spread":0.2599311759870292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203938281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80732274,0.0011631699,0.000028397197,0.18732725,0.0006175095,0.0021761842,0.00066516077,0.00006489975,0.000634683],"genre_scores_gemma":[0.8562733,0.000096164316,0.00037337263,0.12872106,0.0026213427,0.00024879168,0.0049594697,0.00016919682,0.0065373317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736345,0.00034846386,0.0006024702,0.00071560865,0.00038971606,0.000580265],"domain_scores_gemma":[0.99750173,0.00039590508,0.0005469968,0.001004166,0.00038757618,0.0001636221],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023247808,0.00057846133,0.002729863,0.00040964579,0.000070270886,0.000017529472,0.00014647462,0.0004903965,0.0000851945],"category_scores_gemma":[0.00014772141,0.0003396153,0.00075694977,0.0005337206,0.00019475612,0.000021123296,0.000096288386,0.00043116152,0.0000188979],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017501238,0.00032865713,0.010522979,0.00012556753,0.007528236,0.025175542,0.00029201256,0.00018308469,0.00029842588,0.000008965762,0.95430505,0.0010564385],"study_design_scores_gemma":[0.009269738,0.039971918,0.020110711,0.0014853092,0.022033824,0.0023240235,0.0049814363,0.000013327561,0.010632157,0.000010208304,0.88791275,0.0012546161],"about_ca_topic_score_codex":0.00040321524,"about_ca_topic_score_gemma":0.0003032924,"teacher_disagreement_score":0.06639235,"about_ca_system_score_codex":0.0004650717,"about_ca_system_score_gemma":0.0003110004,"threshold_uncertainty_score":0.9999056},"labels":[],"label_agreement":null},{"id":"W3204087467","doi":"10.3389/fcell.2021.703966","title":"Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract","year":2021,"lang":"en","type":"review","venue":"Frontiers in Cell and Developmental Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Diabetes Canada; University of Ottawa Heart Institute Foundation","keywords":"Enteroendocrine cell; Biology; Endocrinology; Internal medicine; Glucagon-like peptide-1; Receptor; G protein-coupled receptor; Paracrine signalling; Gastrointestinal tract; Gastric inhibitory polypeptide; Nutrient sensing; Type 2 diabetes; Cell biology; Signal transduction; Hormone; Endocrine system; Diabetes mellitus; Glucagon; Medicine","score_opus":0.02743471583115587,"score_gpt":0.2734058119809106,"score_spread":0.2459710961497547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204087467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028783688,0.9686998,0.0004464835,0.000012671543,0.0003393394,0.00063985604,0.000030936357,0.000012958679,0.0010342624],"genre_scores_gemma":[0.013347069,0.9674216,0.018241338,0.000052108688,0.000055252858,0.00005331974,0.00026696443,0.00003290784,0.00052945176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836874,0.00014435932,0.0005812311,0.0005077686,0.00011017255,0.00028773624],"domain_scores_gemma":[0.99929875,0.0001521956,0.0002951072,0.00012546947,0.000025280066,0.00010317758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037576407,0.00036565802,0.0013002992,0.00017474408,0.000097766824,0.000044894976,0.00010258315,0.00013732642,0.00001765122],"category_scores_gemma":[0.0000435863,0.00024468874,0.00009588111,0.00016122987,0.00033379975,0.00007457013,0.00024591543,0.00026523194,0.0000013557498],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028685257,0.00029910152,0.07835846,0.0120696165,0.0002815153,0.00023310764,0.00051768776,1.4688176e-7,0.00073592237,0.00006260447,0.00089626736,0.9065169],"study_design_scores_gemma":[0.013938228,0.0028124861,0.02551526,0.11152697,0.0101201,0.0029745847,0.013989818,0.00012191734,0.0052258666,0.0019411815,0.8075459,0.0042876946],"about_ca_topic_score_codex":0.000019231364,"about_ca_topic_score_gemma":0.0000073585625,"teacher_disagreement_score":0.9022292,"about_ca_system_score_codex":0.000097986245,"about_ca_system_score_gemma":0.00015777153,"threshold_uncertainty_score":0.9978117},"labels":[],"label_agreement":null},{"id":"W3204118678","doi":"10.1186/s12933-021-01386-4","title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND","year":2021,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Eli Lilly and Company","keywords":"Medicine; Dulaglutide; Angiology; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Exenatide","score_opus":0.019300161869762838,"score_gpt":0.2038539448527608,"score_spread":0.18455378298299796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204118678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767581,0.021248829,0.000005206841,0.00006641057,0.0009150729,0.00053101475,0.000007824499,0.000013496531,0.00045400695],"genre_scores_gemma":[0.9977365,0.0018582835,0.00011911765,0.00004808588,0.00005548259,0.00007115958,0.000052761876,0.000033135315,0.000025456207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976099,0.00025779926,0.0005739842,0.00046566152,0.0006150999,0.00047752372],"domain_scores_gemma":[0.99828833,0.000057747195,0.00009932371,0.0012306278,0.00024945752,0.000074488045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005747584,0.00023043013,0.0014876456,0.00029747837,0.000024425994,0.0000046313316,0.00019198911,0.00012134593,0.000021247411],"category_scores_gemma":[0.0003235762,0.00019162083,0.0014848467,0.0009884076,0.00014497286,0.00010677747,0.0002716899,0.00017681115,0.000004514617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029584939,0.00039018627,0.95937705,0.00041128186,0.0059604873,0.00012590655,0.0002099158,0.0030933958,0.00040296259,0.00011765486,0.000023377544,0.0298582],"study_design_scores_gemma":[0.0044234213,0.00009840333,0.9625925,0.0002607668,0.0017619828,0.0000026874166,0.0001447513,0.000041322943,0.027871842,0.000108055705,0.0025185945,0.00017567493],"about_ca_topic_score_codex":0.00008180348,"about_ca_topic_score_gemma":0.000041935953,"teacher_disagreement_score":0.029682525,"about_ca_system_score_codex":0.00012614294,"about_ca_system_score_gemma":0.00009253015,"threshold_uncertainty_score":0.78140706},"labels":[],"label_agreement":null},{"id":"W3204118732","doi":"10.1016/j.jcjd.2021.09.006","title":"Foregone Opportunities? Time to Treatment Intensification Among Adults With Type 2 Diabetes and Elevated Glycated Hemoglobin on Metformin Monotherapy, 2009–2018","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta; Alberta Health","keywords":"Medicine; Metformin; Glycated hemoglobin; Type 2 diabetes; Glycated haemoglobin; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.019803929409342315,"score_gpt":0.21444048354407227,"score_spread":0.19463655413472997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204118732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530834,0.0013801792,0.000002279007,0.0018723536,0.0000958919,0.0004351467,0.000032700027,0.000017863911,0.00085523794],"genre_scores_gemma":[0.99353963,0.00011015081,0.00043443873,0.0014056301,0.00008077003,0.000020966385,0.0001547241,0.000043938624,0.0042097378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876183,0.0000403418,0.00033309788,0.00023285463,0.0001804518,0.00045144465],"domain_scores_gemma":[0.99807364,0.000058084344,0.00018301101,0.00026317904,0.000516485,0.0009056307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014327564,0.0002569556,0.00050953677,0.0004485341,0.00008637352,0.00007287748,0.00007809127,0.00007104238,0.00027500596],"category_scores_gemma":[0.00008736853,0.00019033534,0.000076961165,0.0003763965,0.000096986936,0.00015717561,0.000008933673,0.00009361531,0.000036014404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075173273,0.0011058409,0.5611467,0.00030655888,0.007215115,0.0012868074,0.00289653,0.00010020304,0.017061492,0.00021908236,0.040704176,0.3672058],"study_design_scores_gemma":[0.026426319,0.049318433,0.5194098,0.006294736,0.0040066615,0.000067948895,0.0053646863,0.0019602594,0.23523003,0.00023904162,0.14972486,0.001957244],"about_ca_topic_score_codex":0.00014227525,"about_ca_topic_score_gemma":0.00092918705,"teacher_disagreement_score":0.36524853,"about_ca_system_score_codex":0.00036321246,"about_ca_system_score_gemma":0.0005302858,"threshold_uncertainty_score":0.776165},"labels":[],"label_agreement":null},{"id":"W3204397265","doi":"10.2218/gtopdb/f29/2021.3","title":"Glucagon receptor family in GtoPdb v.2021.3","year":2021,"lang":"en","type":"article","venue":"IUPHAR/BPS Guide to Pharmacology CITE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon; Secretin family; Secretin; Receptor; Endocrinology; Internal medicine; Glucagon-like peptide-1; Peptide hormone; Hormone; Peptide; Chemistry; Biology; Secretion; Medicine; Vasoactive intestinal peptide; Biochemistry; Neuropeptide; Diabetes mellitus; Type 2 diabetes","score_opus":0.017358062489890736,"score_gpt":0.34400448335694983,"score_spread":0.3266464208670591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204397265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8994715,0.0028415527,0.00013252022,0.018071748,0.0027601134,0.0013416023,0.000057950947,0.00018053189,0.07514245],"genre_scores_gemma":[0.6562125,0.0030168106,0.009545404,0.122725405,0.002209611,0.0012681492,0.0009263823,0.00018045313,0.20391527],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976525,0.00014334144,0.00054281903,0.0006809225,0.00027471513,0.0007057142],"domain_scores_gemma":[0.9989481,0.000103640836,0.00007773332,0.00035849155,0.00014862638,0.00036341572],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034620502,0.0003132877,0.00056918873,0.0003639028,0.00006291899,0.000031088606,0.00017858943,0.00013798586,0.006695395],"category_scores_gemma":[0.000067888635,0.00031366255,0.00016003178,0.0007245758,0.000058147456,0.00012801793,0.00024036998,0.0002827136,0.0025678186],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026654056,0.00072947686,0.0075117503,0.00007246938,0.00043390124,0.0013388771,0.00022416067,0.000032438486,0.366464,0.00025522147,0.59953296,0.02313821],"study_design_scores_gemma":[0.005764783,0.00027331186,0.010719526,0.00006879972,0.00037061112,0.000012242257,0.00013258337,0.000051049174,0.11212584,0.000033272565,0.8701775,0.0002704814],"about_ca_topic_score_codex":0.000051544666,"about_ca_topic_score_gemma":0.000026475,"teacher_disagreement_score":0.27064455,"about_ca_system_score_codex":0.00034465978,"about_ca_system_score_gemma":0.00020591277,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W3204839494","doi":"10.1002/ehf2.13615","title":"Mediators of the Improvement in Heart Failure Outcomes with Empagliflozin in the EMPA-REG OUTCOME Trial","year":2021,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Internal medicine; Heart failure; Uric acid; Cardiology; Diabetes mellitus; Creatinine; Placebo; Post-hoc analysis; Renal function; Endocrinology; Type 2 diabetes","score_opus":0.012512051552316562,"score_gpt":0.2685577194016096,"score_spread":0.25604566784929306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204839494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88427454,0.00010163348,0.000001479186,0.11336014,0.00022202698,0.0017689728,0.000008858681,0.000024263858,0.0002380767],"genre_scores_gemma":[0.99352705,0.0000043786235,0.0009193696,0.003950963,0.00011271991,0.00020616195,0.00002315173,0.00002824387,0.0012279857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766487,0.0001950644,0.0005826048,0.00037796496,0.0007280507,0.00045146912],"domain_scores_gemma":[0.9987378,0.00016320671,0.00010275054,0.0008439673,0.000063677086,0.000088608635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060786377,0.00028751465,0.00070977444,0.00015219403,0.0000614578,0.00003545541,0.00021140039,0.000113656046,0.00019303501],"category_scores_gemma":[0.0001581334,0.00014263298,0.00025797842,0.00073697383,0.00009425953,0.00009887546,0.00012953299,0.00039549213,0.000028320066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059675466,0.0008949425,0.9738685,0.000117408556,0.00017375634,0.000057757086,0.0010148948,0.000012573012,0.00058355794,0.00028848142,0.022083163,0.00030821137],"study_design_scores_gemma":[0.059995294,0.0014173681,0.7471089,0.00036674837,0.0003695085,0.000013834635,0.0070460653,0.000013119938,0.0052034124,0.00010477801,0.17800345,0.00035756416],"about_ca_topic_score_codex":0.00017745225,"about_ca_topic_score_gemma":0.0038672972,"teacher_disagreement_score":0.22675964,"about_ca_system_score_codex":0.00012022553,"about_ca_system_score_gemma":0.00019903945,"threshold_uncertainty_score":0.5816404},"labels":[],"label_agreement":null},{"id":"W3205081723","doi":"10.1016/j.cjca.2021.07.181","title":"CARDIOVASCULAR RISK AND UPTAKE OF EVIDENCE-BASED THERAPIES IN PATIENTS WITH TYPE 2 DIABETES AFTER AN ACUTE CARDIOVASCULAR EVENT: INSIGHTS FROM THE CANHEART REGISTRY","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Hazard ratio; Myocardial infarction; Stroke (engine); Type 2 diabetes; Population; Internal medicine; Cohort; Heart failure; Proportional hazards model; Emergency medicine; Diabetes mellitus; Adverse effect; Retrospective cohort study; Intensive care medicine; Confidence interval","score_opus":0.016449911865687804,"score_gpt":0.20966476805690962,"score_spread":0.1932148561912218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205081723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92373514,0.075509,0.00005276402,0.00019188189,0.00020411344,0.00020838728,0.00003381121,0.0000023804546,0.000062535146],"genre_scores_gemma":[0.9980851,0.0012522845,0.00019714893,0.0002034404,0.00019351013,0.000008833681,0.000028382663,0.000018206418,0.0000130934395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985533,0.000394511,0.000303036,0.00022099866,0.00027947113,0.0002486903],"domain_scores_gemma":[0.9985317,0.00008770416,0.000115216964,0.00061348494,0.00039185493,0.00026005434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037410835,0.00016374447,0.0008486147,0.00014370441,0.000049742488,0.000020874044,0.000111921596,0.000092807924,0.000011321847],"category_scores_gemma":[0.00012671208,0.00009524995,0.00042231867,0.0002101176,0.00019258307,0.00012079595,0.0000150827545,0.0002109952,8.829749e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018659052,0.000010335675,0.9718545,0.000022449065,0.009953355,0.00054627616,0.00027329542,0.001226506,0.000011542604,0.0000043762734,0.00015317535,0.015757592],"study_design_scores_gemma":[0.0022109528,0.0007294044,0.9492878,0.00032218994,0.0032213042,0.000008767168,0.00016316691,0.000006118283,0.00008263434,0.000047086884,0.043820493,0.00010011086],"about_ca_topic_score_codex":0.0012606982,"about_ca_topic_score_gemma":0.0019706907,"teacher_disagreement_score":0.07434997,"about_ca_system_score_codex":0.000108449225,"about_ca_system_score_gemma":0.00076305,"threshold_uncertainty_score":0.388418},"labels":[],"label_agreement":null},{"id":"W3205235877","doi":"10.1182/blood.2021013996","title":"<i>JAK2</i> wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy","year":2021,"lang":"en","type":"letter","venue":"Blood","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Internal medicine; Medicine; Cotransporter; Sodium; Chemistry; Pharmacology; Endocrinology","score_opus":0.016707203998869272,"score_gpt":0.21686241698928493,"score_spread":0.20015521299041567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205235877","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6221408,0.008404892,0.0000068525073,0.3489126,0.0012893383,0.0031940357,0.00021109014,0.0008452326,0.014995122],"genre_scores_gemma":[0.045322455,0.0035373291,0.00048321718,0.89445305,0.0046055173,0.0002981124,0.014203645,0.0004155886,0.03668109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973361,0.00006661745,0.00038826675,0.00076058455,0.00077188364,0.0006765822],"domain_scores_gemma":[0.9985884,0.00007099148,0.00023204887,0.0007474497,0.00024169065,0.00011946505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010087147,0.000654981,0.0010453482,0.00018201837,0.00008945335,0.00008015058,0.00016623185,0.00071114843,0.0005225079],"category_scores_gemma":[0.000016625778,0.0004933378,0.00031863188,0.00043334303,0.000096712225,0.00008605996,0.00003950232,0.00095403753,0.00008714281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014821439,0.0024610232,0.012408665,0.00025124292,0.007901645,0.0067631616,0.00013277918,1.2530637e-7,0.0008021528,0.000002696387,0.96795094,0.0011773378],"study_design_scores_gemma":[0.015083709,0.0020259393,0.0033310421,0.0012183688,0.0060272533,0.00002903864,0.00002445891,6.700177e-7,0.020913143,0.000010285544,0.95061654,0.0007195408],"about_ca_topic_score_codex":0.00002330784,"about_ca_topic_score_gemma":0.000024279341,"teacher_disagreement_score":0.5768184,"about_ca_system_score_codex":0.00010152068,"about_ca_system_score_gemma":0.00020702745,"threshold_uncertainty_score":0.9997518},"labels":[],"label_agreement":null},{"id":"W3205464671","doi":"10.1093/eurheartj/ehab724.0831","title":"Prevalence of and factors associated with undiagnosed stage 3 chronic kidney disease in patient with a history of heart failure: a report from REVEAL-CKD","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca","keywords":"Medicine; Kidney disease; Heart failure; Internal medicine; Renal function; Comorbidity; Confidence interval; Population; Cohort; Pediatrics; Intensive care medicine","score_opus":0.023035263853058496,"score_gpt":0.2400657774443398,"score_spread":0.2170305135912813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205464671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654347,0.0019768765,0.000004556199,0.000530006,0.000054777072,0.000250354,0.00003873169,0.000012595826,0.0005886118],"genre_scores_gemma":[0.9963586,0.00009081348,0.00033776747,0.00017088547,0.00003159806,0.0000027304754,0.000049709375,0.000025855647,0.002932096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859375,0.0002474465,0.00036163922,0.00023372595,0.00037220068,0.00019121102],"domain_scores_gemma":[0.99893314,0.00006524804,0.00029211905,0.0002591658,0.00011962004,0.00033070118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002553812,0.00014600872,0.00033754847,0.00010144836,0.000024069277,0.000011123938,0.000038087648,0.000015910186,0.00021664417],"category_scores_gemma":[0.00026519672,0.000105232575,0.00006439504,0.000121511344,0.00009098763,0.00009528495,0.00004519669,0.00018403001,0.0000013685918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015050625,0.00048420206,0.98036253,0.00023321889,0.00022086898,0.005146907,0.00040533784,0.00002053639,0.00109004,0.0000019562658,0.011792115,0.00009175948],"study_design_scores_gemma":[0.0027036336,0.0010565199,0.9754229,0.0021676398,0.0002981768,0.000051867126,0.00008948229,0.00001665666,0.00038735935,0.0000018076826,0.01769643,0.000107518405],"about_ca_topic_score_codex":0.000032107157,"about_ca_topic_score_gemma":0.000029967581,"teacher_disagreement_score":0.005904316,"about_ca_system_score_codex":0.00041282506,"about_ca_system_score_gemma":0.0006766069,"threshold_uncertainty_score":0.42912596},"labels":[],"label_agreement":null},{"id":"W3205468492","doi":"10.1172/jci.insight.153732","title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","year":2021,"lang":"en","type":"article","venue":"JCI Insight","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; National Institutes of Health; Novo Nordisk Fonden; Zafgen; Novo Nordisk; Robarts Research Institute; University of Pennsylvania; Aarhus Universitet; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Semaglutide; Endocrinology; Internal medicine; Spleen; Biology; Bone marrow; Type 2 diabetes; Medicine; Liraglutide; Diabetes mellitus","score_opus":0.025003946198218118,"score_gpt":0.2712105109895353,"score_spread":0.2462065647913172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205468492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009323,0.0011419428,0.00016711764,0.00012480395,0.00035668942,0.0003932641,0.000052419407,0.000016635278,0.007653895],"genre_scores_gemma":[0.99684113,0.00026951998,0.00085136056,0.000029927816,0.000079935046,0.00005037489,0.00004417967,0.000015915268,0.0018176276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992579,0.000015582613,0.00024336544,0.00017833174,0.00015671666,0.00014810743],"domain_scores_gemma":[0.9994145,0.00008399471,0.000105683896,0.00025053034,0.000082095,0.00006321125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029894381,0.00011320927,0.00042324726,0.00009428818,0.000029555653,0.00000633419,0.000033503144,0.00003898494,0.000092903545],"category_scores_gemma":[0.00003831895,0.00009641962,0.00015344968,0.00015102682,0.00005282138,0.00003106487,0.000042061332,0.00003921226,0.0000022545712],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027297859,0.006016118,0.17102723,0.010341359,0.006312077,0.00020615406,0.0039396277,0.00002536333,0.74348396,0.025477298,0.005094103,0.02534694],"study_design_scores_gemma":[0.017281136,0.0010918467,0.037309196,0.00018977292,0.0039309408,0.000008982742,0.0006130285,0.00020681249,0.8965974,0.00037483365,0.042101037,0.00029500536],"about_ca_topic_score_codex":0.0000168976,"about_ca_topic_score_gemma":0.000027885151,"teacher_disagreement_score":0.15311347,"about_ca_system_score_codex":0.000023239532,"about_ca_system_score_gemma":0.000052502837,"threshold_uncertainty_score":0.39318782},"labels":[],"label_agreement":null},{"id":"W3206074040","doi":"10.1016/j.numecd.2021.10.003","title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","year":2021,"lang":"en","type":"article","venue":"Nutrition Metabolism and Cardiovascular Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetic ketoacidosis; Adverse Event Reporting System; Medicine; Adverse effect; Quarter (Canadian coin); Glucagon-like peptide 1 receptor; Diabetes mellitus; Insulin; Ketosis; Internal medicine; Agonist; Endocrinology; Receptor","score_opus":0.009685610747845201,"score_gpt":0.22820148142540908,"score_spread":0.21851587067756387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206074040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85125613,0.1459543,0.00003469361,0.0011088001,0.00019994137,0.0008373808,0.000053099368,0.00004716244,0.0005084871],"genre_scores_gemma":[0.987974,0.010823744,0.00005666493,0.000108112516,0.00037932376,0.00032876135,0.00020978037,0.00001269351,0.00010692613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811757,0.0003761115,0.00043777894,0.00030092342,0.0005387222,0.00022890365],"domain_scores_gemma":[0.9990648,0.0001473795,0.000198889,0.00038325522,0.00010625509,0.00009941132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011458622,0.0001436126,0.0004890061,0.000050495077,0.00028018028,0.00011535438,0.000048800786,0.000053664644,0.00000528334],"category_scores_gemma":[0.0003769487,0.00009296041,0.00047503432,0.00023470377,0.000041173782,0.0000913936,0.000047987065,0.00008747627,0.000004939399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079196645,0.0006821556,0.7826032,0.002248467,0.0081349965,0.00029362642,0.00043746605,0.0000082277775,0.00013073938,0.0018211756,0.0025056815,0.20105505],"study_design_scores_gemma":[0.0026189364,0.000024260024,0.868721,0.00025887805,0.0068926215,0.000010222176,0.003628442,0.000012281353,0.0002747833,0.00009022075,0.1173359,0.00013247345],"about_ca_topic_score_codex":0.000024008288,"about_ca_topic_score_gemma":0.0000036683477,"teacher_disagreement_score":0.20092258,"about_ca_system_score_codex":0.00007471419,"about_ca_system_score_gemma":0.000029427512,"threshold_uncertainty_score":0.37908155},"labels":[],"label_agreement":null},{"id":"W3206353721","doi":"10.1101/2021.10.14.21264803","title":"Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Mace; Medicine; Internal medicine; Meta-analysis; Myocardial infarction; Hazard ratio; Semaglutide; Weight loss; Meta-regression; Cardiology; Type 2 diabetes; Diabetes mellitus; Endocrinology; Obesity; Liraglutide; Confidence interval","score_opus":0.03768547855946419,"score_gpt":0.2873124684903545,"score_spread":0.24962698993089033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206353721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421074,0.054442555,0.0009083987,0.000632192,0.00015330981,0.0013310462,0.000059734874,0.000065664004,0.00029972676],"genre_scores_gemma":[0.98830545,0.0028150138,0.0032743746,0.00028913133,0.00003613362,0.00055155257,0.0005198645,0.000054873268,0.0041536144],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9958512,0.0005188164,0.0007304198,0.0014281474,0.0011127804,0.00035863282],"domain_scores_gemma":[0.99688745,0.0003935521,0.0004587765,0.0017794316,0.00019346748,0.00028730143],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0010382495,0.00087119127,0.00835873,0.0013525855,0.00008185865,0.00009937938,0.00018898533,0.00028638708,0.00033696307],"category_scores_gemma":[0.00019806733,0.00048951356,0.012153309,0.0012042267,0.00013426936,0.000057486657,0.0006870268,0.00037975243,0.000005286995],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052728705,0.00036044786,0.031750653,0.0012478795,0.9646451,0.00019665618,0.00021384435,0.00037477203,0.00030853698,0.000010123504,0.000102898106,0.0007363543],"study_design_scores_gemma":[0.0008967631,0.00014871843,0.08863928,0.000040417275,0.90253645,8.2335396e-7,0.000035222016,0.000103822866,0.0061021643,0.0000122045785,0.0011644064,0.000319712],"about_ca_topic_score_codex":0.0003306676,"about_ca_topic_score_gemma":0.00008084718,"teacher_disagreement_score":0.06210864,"about_ca_system_score_codex":0.000070350274,"about_ca_system_score_gemma":0.000046850277,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W3207064480","doi":"10.2337/dc21-1226","title":"Trends and Factors Associated With Very High Glycemia and Noninitiation of Insulin Therapy in U.S. Adults With Type 2 Diabetes, 1999–2018","year":2021,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Insulin; Type 2 diabetes; Endocrinology; Type 1 diabetes","score_opus":0.010780894566232376,"score_gpt":0.20847053146131456,"score_spread":0.19768963689508218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207064480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874816,0.007086322,5.6647558e-8,0.0041285795,0.00011778208,0.00046485005,0.0002691967,0.000049105034,0.0004024887],"genre_scores_gemma":[0.968724,0.0009691901,0.00004649805,0.013981858,0.00015779008,0.0000663674,0.015772143,0.00009236363,0.00018978378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982347,0.00007428507,0.00028790094,0.00055578176,0.0003969392,0.00045040628],"domain_scores_gemma":[0.99895257,0.00016554825,0.00026111645,0.00032780488,0.00021680574,0.00007612963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000054713488,0.00047943433,0.0009313247,0.0004581769,0.000040105046,0.00004457677,0.00007487318,0.00044282616,0.00004690412],"category_scores_gemma":[0.000034409793,0.0003451726,0.00006212028,0.0006064979,0.00014277079,0.00011259242,0.000053682208,0.0004816305,0.0000012880715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014296394,0.00010818019,0.97218764,0.00083260436,0.0010383963,0.00007609839,0.00097381836,0.000001312802,0.000026031608,0.0000014664083,0.011540397,0.013071099],"study_design_scores_gemma":[0.009310172,0.0044489913,0.9649244,0.0041106944,0.0007432329,2.4668296e-7,0.0004280605,0.000018505532,0.0011331764,0.0000057894986,0.014334286,0.0005424483],"about_ca_topic_score_codex":0.000050348666,"about_ca_topic_score_gemma":0.000099232675,"teacher_disagreement_score":0.018757615,"about_ca_system_score_codex":0.00018027538,"about_ca_system_score_gemma":0.00008810477,"threshold_uncertainty_score":0.99990004},"labels":[],"label_agreement":null},{"id":"W3208494877","doi":"10.1093/eurheartj/ehab724.2925","title":"Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Renal function; Confidence interval; Proportional hazards model; Kidney disease; Internal medicine; Covariate; Diabetes mellitus; Post-hoc analysis; Type 2 diabetes; Placebo; Albuminuria; Endocrinology; Pathology; Statistics","score_opus":0.01808286775778349,"score_gpt":0.254819304640216,"score_spread":0.2367364368824325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208494877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975266,0.0018382025,0.0000010875482,0.00014021105,0.0001263242,0.0002023269,0.000012663268,0.0000051243683,0.00014746029],"genre_scores_gemma":[0.99952006,0.0000646885,0.00006650951,0.0002390421,0.000038964765,0.0000010040793,0.000016038615,0.00002092882,0.000032757904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986395,0.0004711528,0.00022180747,0.00014494183,0.0003886098,0.00013394847],"domain_scores_gemma":[0.9992913,0.00008040455,0.00007730074,0.0002945711,0.000053631065,0.0002027927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024642827,0.00012364586,0.00041004032,0.00007242121,0.000035641573,0.00001478603,0.00005868436,0.000011206031,0.00003334987],"category_scores_gemma":[0.00022412214,0.00006803274,0.0001880274,0.00018571185,0.00005183254,0.000036619705,0.00006122923,0.00012615944,0.0000048352545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019389471,0.0001323919,0.996248,0.00006616246,0.0011852245,0.0000390449,0.000051445957,0.00007737001,0.000722472,4.7229156e-7,0.00020627437,0.0010772587],"study_design_scores_gemma":[0.0037281548,0.0007675992,0.9903914,0.00068441115,0.00102918,5.4914574e-7,0.0000052137552,0.00001736269,0.0028207556,0.0000012233291,0.0004945176,0.00005968622],"about_ca_topic_score_codex":0.0000044835074,"about_ca_topic_score_gemma":4.0549568e-7,"teacher_disagreement_score":0.0058566416,"about_ca_system_score_codex":0.000028444214,"about_ca_system_score_gemma":0.000027526154,"threshold_uncertainty_score":0.2774295},"labels":[],"label_agreement":null},{"id":"W3208839379","doi":"10.1210/endocr/bqab220","title":"Open Chromatin State of <i>Dpp4</i> With Glucocorticoid Treatment—Setting up Shop for Metasteroid Diabetes?","year":2021,"lang":"en","type":"letter","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Glucocorticoid; Diabetes mellitus; Endocrinology; Internal medicine; Chromatin; Medicine; Biology; Genetics; DNA","score_opus":0.03240483364346902,"score_gpt":0.28818787809263324,"score_spread":0.2557830444491642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208839379","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4452226,0.0066836555,0.00029023713,0.49972352,0.0026188972,0.021458402,0.0011884645,0.00036709628,0.022447143],"genre_scores_gemma":[0.037543416,0.0012984448,0.023590932,0.5705343,0.0027355195,0.010748281,0.022109075,0.00093181425,0.3305082],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969429,0.00012391209,0.00065655966,0.00091065775,0.00026488962,0.0011010945],"domain_scores_gemma":[0.9978522,0.00035263642,0.0005497933,0.0010110115,0.00015641507,0.000077930636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008113243,0.0006324561,0.0018925938,0.00025965236,0.00006799476,0.00007131725,0.00040465075,0.00017176454,0.00026207493],"category_scores_gemma":[0.000044062926,0.00047315998,0.0003136194,0.00018008963,0.00014681745,0.00011447439,0.00039590322,0.00037598266,0.000051908202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006192446,0.0011127822,0.012627506,0.0048873853,0.020619782,0.0035766612,0.00047113362,0.000014362678,0.0050602253,0.00015778294,0.812709,0.13814414],"study_design_scores_gemma":[0.011700998,0.005762619,0.00051720196,0.0005026583,0.003967787,0.000058779642,0.00008762589,0.000036848534,0.044366345,0.000088876666,0.9324037,0.0005065582],"about_ca_topic_score_codex":0.000044278677,"about_ca_topic_score_gemma":0.000030390403,"teacher_disagreement_score":0.40767917,"about_ca_system_score_codex":0.00021849207,"about_ca_system_score_gemma":0.00024833297,"threshold_uncertainty_score":0.999772},"labels":[],"label_agreement":null},{"id":"W3209095918","doi":"10.1016/j.revmed.2021.10.001","title":"Chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée, est-ce que l’empagliflozine est efficace pour prévenir la mortalité cardiovasculaire et l’hospitalisation pour insuffisance cardiaque tout en étant sécuritaire ?","year":2021,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine; Gynecology","score_opus":0.011551248919777162,"score_gpt":0.257492589214602,"score_spread":0.24594134029482484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209095918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8694272,0.014583531,0.0024228308,0.08068937,0.004224221,0.003415106,0.00038469592,0.00059415837,0.024258913],"genre_scores_gemma":[0.9343944,0.008495023,0.0010172273,0.0070376038,0.011359343,0.0013817603,0.0041492586,0.0006092458,0.031556096],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893485,0.0028637196,0.0020045296,0.0026747615,0.0013740861,0.0017344289],"domain_scores_gemma":[0.9934907,0.0015760252,0.0012519965,0.002436787,0.0006851896,0.0005592802],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.002183083,0.002128447,0.003437487,0.00066665956,0.0003074355,0.00038659447,0.0007783263,0.0023908408,0.00043401332],"category_scores_gemma":[0.0014784249,0.002283504,0.0023180763,0.0009619991,0.00034814817,0.00070767885,0.0007239577,0.0035251556,0.00043488832],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011973352,0.007039925,0.68933743,0.01607199,0.025564542,0.030705782,0.016202757,0.009496286,0.0057591097,0.006859782,0.14088546,0.05087957],"study_design_scores_gemma":[0.008606901,0.0008557815,0.4325631,0.013043026,0.0061780596,0.0023220247,0.0012664738,0.0022317297,0.0038568836,0.00018762544,0.5265851,0.0023033048],"about_ca_topic_score_codex":0.005394212,"about_ca_topic_score_gemma":0.0025477838,"teacher_disagreement_score":0.38569963,"about_ca_system_score_codex":0.0055904347,"about_ca_system_score_gemma":0.0011235963,"threshold_uncertainty_score":0.9991456},"labels":[],"label_agreement":null},{"id":"W3209484335","doi":"10.1016/j.jcjd.2021.10.003","title":"Response: Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sinai Health System","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Meta-analysis; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Ketoacidosis; Cotransporter; Sodium; Type 1 diabetes","score_opus":0.02065527999833291,"score_gpt":0.2511744243861119,"score_spread":0.230519144387779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209484335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03661598,0.96072155,0.0000012180117,0.00010851063,0.00005810644,0.0021855459,0.0002822394,0.000008647396,0.000018183959],"genre_scores_gemma":[0.015650162,0.98337525,0.00015996555,0.0001980586,0.000023059649,0.00014841842,0.00009873158,0.00008954647,0.00025680612],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9953451,0.0009645644,0.0020538312,0.00052623946,0.00048933894,0.00062092516],"domain_scores_gemma":[0.9942229,0.0006953771,0.0024842324,0.0007557989,0.00063499395,0.0012067268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001904712,0.0008161101,0.012667247,0.0016138983,0.000099296594,0.000090720896,0.00025237384,0.00024763512,0.00022703613],"category_scores_gemma":[0.0005720413,0.0005088388,0.0022867674,0.0017299678,0.00035512645,0.00017423047,0.000026007607,0.0004961695,0.0000023985008],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007990973,0.00006452712,0.015000303,0.6177757,0.3623051,0.000117668766,0.00014267069,5.207515e-7,1.8599005e-7,0.0000014048006,0.00018228719,0.004401624],"study_design_scores_gemma":[0.00048613924,0.00079574244,0.0007529326,0.16630422,0.8278211,0.0000061402775,0.000069856615,0.0000023769667,0.000009269605,0.0000012744645,0.0033840877,0.0003669005],"about_ca_topic_score_codex":0.00016814028,"about_ca_topic_score_gemma":0.0014977775,"teacher_disagreement_score":0.46551597,"about_ca_system_score_codex":0.00017946879,"about_ca_system_score_gemma":0.0009971459,"threshold_uncertainty_score":0.9997363},"labels":[],"label_agreement":null},{"id":"W3209688304","doi":"10.15420/ecr.2021.22","title":"Women and Diabetes: Preventing Heart Disease in a New Era of Therapies","year":2021,"lang":"en","type":"review","venue":"European Cardiology Review","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Cleveland Clinic; Idorsia Pharmaceuticals; Amarin Corporation; AstraZeneca; Bristol-Myers Squibb; CSL Behring; Duke Clinical Research Institute; HLS Therapeutics; Amgen; Eisai; American Heart Association","keywords":"Medicine; Type 2 diabetes; Heart failure; Disease; Intensive care medicine; Diabetes mellitus; Incretin; Aliskiren; Internal medicine; Endocrinology; Renin–angiotensin system; Blood pressure","score_opus":0.040374407731517445,"score_gpt":0.30805942109281587,"score_spread":0.2676850133612984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209688304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013721063,0.99564433,7.551154e-7,0.00024979288,0.00008164439,0.001604724,0.000010303408,0.000025806472,0.0022454348],"genre_scores_gemma":[0.000026723099,0.997293,0.000127605,0.0006792205,0.00016827282,0.00010023856,0.00014060609,0.00006416246,0.001400157],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692345,0.001377629,0.0007517915,0.00049089204,0.00010881356,0.0003474281],"domain_scores_gemma":[0.99880946,0.00012078368,0.00025257596,0.00058918033,0.000027790074,0.00020022808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008777292,0.000377655,0.0041979314,0.00009775488,0.000017530365,0.000009926125,0.00011891206,0.00004886031,0.0000723698],"category_scores_gemma":[0.00020148094,0.00027372828,0.00063006155,0.00027468064,0.00007260294,0.00003120348,0.00023901969,0.00029587676,0.00004859611],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016045183,0.00003034437,0.0023867534,0.12311073,0.0007986483,0.00024929966,0.000029578774,2.7745937e-8,8.227964e-8,0.000015817219,0.0033757442,0.8700014],"study_design_scores_gemma":[0.0002618627,0.00008264089,0.0012351546,0.18488415,0.0023579465,0.000013883615,0.0000037111672,5.3118484e-8,9.57745e-9,0.0000059983336,0.8110052,0.00014944821],"about_ca_topic_score_codex":8.703481e-7,"about_ca_topic_score_gemma":1.3167227e-7,"teacher_disagreement_score":0.86985195,"about_ca_system_score_codex":0.00006447349,"about_ca_system_score_gemma":0.00021587717,"threshold_uncertainty_score":0.9999715},"labels":[],"label_agreement":null},{"id":"W3209913616","doi":"10.2337/dc21-0278","title":"Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Montreal Clinical Research Institute; Western University; Hamilton Health Sciences; University of Calgary; Impact; LMC Diabetes & Endocrinology (Canada); McMaster University; Université de Montréal; Population Health Research Institute","funders":"HLS Therapeutics; Servier; Mitacs; Novo Nordisk; Dexcom; Sanofi; Kowa Company; Insulet Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Hamilton Health Sciences; GlaxoSmithKline; McMaster University; Amgen","keywords":"Medicine; Sitagliptin; Insulin glargine; Internal medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Hazard ratio; Insulin; Randomized controlled trial; Gastroenterology; Endocrinology; Confidence interval","score_opus":0.031799900503335705,"score_gpt":0.3016930816277124,"score_spread":0.2698931811243767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209913616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266875,0.003971792,0.00004037499,0.000092700444,0.0002008407,0.0025050922,0.000036283232,0.000036424713,0.00044774517],"genre_scores_gemma":[0.9892748,0.00016741901,0.008996894,0.00008288741,0.000045389254,0.00014420772,0.0010343172,0.000038835205,0.00021527812],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792635,0.00026664376,0.00071827235,0.0004690358,0.00032372834,0.00029595295],"domain_scores_gemma":[0.9979726,0.00030454854,0.00028994837,0.00046200695,0.00082465715,0.00014621872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006902928,0.0002819642,0.0013625914,0.00015822673,0.000050884944,0.0000526136,0.00015710642,0.00011088626,0.00001542409],"category_scores_gemma":[0.0009706532,0.00020458302,0.00016711223,0.00032758134,0.00010220055,0.00030248048,0.00022937712,0.00011596579,0.0000018205737],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7660141,0.0034165327,0.027813252,0.0025022756,0.006513657,0.00023800536,0.0049835416,0.000034072524,0.038326964,0.00014589212,0.00075004273,0.14926165],"study_design_scores_gemma":[0.8979686,0.010016486,0.0018941296,0.003057215,0.0031793984,0.0000011341922,0.003629088,0.0009909788,0.07855541,0.0000950391,0.0002510053,0.00036150217],"about_ca_topic_score_codex":0.000009028794,"about_ca_topic_score_gemma":0.0000074987097,"teacher_disagreement_score":0.14890015,"about_ca_system_score_codex":0.000048987626,"about_ca_system_score_gemma":0.00008005231,"threshold_uncertainty_score":0.83426535},"labels":[],"label_agreement":null},{"id":"W3210097792","doi":"10.1093/eurheartj/ehab724.2647","title":"Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Canagliflozin; Medicine; Internal medicine; Kidney disease; Hyperkalemia; Placebo; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.009338824022294768,"score_gpt":0.22483516649558236,"score_spread":0.21549634247328758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210097792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085265,0.0049830438,0.0000013598757,0.0030530386,0.00015013179,0.00031750594,0.0000067468322,0.000008291909,0.0006272042],"genre_scores_gemma":[0.9977911,0.0003841806,0.000059019123,0.0011065493,0.00033311758,0.000004595227,0.000009153751,0.000019692561,0.00029256893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989694,0.00028837103,0.00015756949,0.00018780156,0.00021576011,0.00018114716],"domain_scores_gemma":[0.9992656,0.00020150708,0.000060609294,0.00016393122,0.000028775647,0.00027956726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014743026,0.00012805214,0.00024329523,0.00005380319,0.0000877349,0.00005899918,0.000048843685,0.000013258103,0.000030342808],"category_scores_gemma":[0.0001478808,0.00007523029,0.000037886162,0.00012209134,0.00005843413,0.0000670138,0.00006506901,0.00020361833,0.0000044528692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004062865,0.0006741587,0.9645199,0.0004162498,0.0005275687,0.0023707396,0.0010548397,0.000016543108,0.007341388,0.00010948507,0.011778358,0.0071278606],"study_design_scores_gemma":[0.01937472,0.0010649851,0.9706197,0.001087906,0.00025994875,0.0000096261265,0.000057649773,0.000045541015,0.0014601332,0.000021352374,0.0059115216,0.0000869592],"about_ca_topic_score_codex":0.000013864236,"about_ca_topic_score_gemma":0.00006677999,"teacher_disagreement_score":0.015311856,"about_ca_system_score_codex":0.00005467868,"about_ca_system_score_gemma":0.00017348926,"threshold_uncertainty_score":0.3067802},"labels":[],"label_agreement":null},{"id":"W3210197639","doi":"10.2337/dc20-2806","title":"Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine","year":2021,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; University Health Network; University of Toronto; University of Alberta; Canadian VIGOUR Centre; McGill University","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Internal medicine; Hazard ratio; Sitagliptin; Myocardial infarction; Diabetes mellitus; Coronary artery disease; Type 2 diabetes; Disease; Atherosclerotic cardiovascular disease; Cluster (spacecraft); Angina; Type 2 Diabetes Mellitus; Proportional hazards model; Cardiology; Endocrinology; Confidence interval","score_opus":0.006617222093292714,"score_gpt":0.19595076513987184,"score_spread":0.18933354304657912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210197639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813522,0.016899386,0.00010619188,0.000048095564,0.00008714182,0.0010221746,0.000043398442,0.000030887273,0.00041049012],"genre_scores_gemma":[0.99754953,0.00012680251,0.00077385735,0.00016653103,0.00004607971,0.00008439145,0.001169771,0.00004118422,0.000041861396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975978,0.00013277566,0.0003179299,0.00069485983,0.00086587615,0.00039076674],"domain_scores_gemma":[0.99817026,0.000046592617,0.000056303656,0.0009843566,0.00048965577,0.0002528352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024145415,0.00029093138,0.0012711979,0.00052164687,0.000043573767,0.000030982148,0.00010501452,0.00007163514,0.000029050881],"category_scores_gemma":[0.0001543865,0.00021699557,0.000462506,0.0017613469,0.00008608615,0.00011284119,0.0001615382,0.00009191031,0.0000042553283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120672725,0.00034570618,0.9462419,0.00059181784,0.019875824,0.00000849575,0.0007073048,0.015045649,0.000035738303,0.0000064718233,0.00008881578,0.016931614],"study_design_scores_gemma":[0.004135682,0.0004288643,0.9650994,0.00035195518,0.02676394,3.4359015e-8,0.00043196665,0.0013398471,0.00012551316,0.000006472212,0.001080086,0.00023624337],"about_ca_topic_score_codex":0.000017929906,"about_ca_topic_score_gemma":0.0000042054367,"teacher_disagreement_score":0.018857507,"about_ca_system_score_codex":0.00009007065,"about_ca_system_score_gemma":0.000040683295,"threshold_uncertainty_score":0.8848823},"labels":[],"label_agreement":null},{"id":"W3210357221","doi":"10.1016/j.metabol.2021.154918","title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","year":2021,"lang":"en","type":"review","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Kidney disease; Diabetes mellitus; Heart failure; Cardiorenal syndrome; Type 2 diabetes; Disease; Internal medicine; Glycemic; Type 2 Diabetes Mellitus; Kidney; Adverse effect; Bioinformatics; Endocrinology; Biology","score_opus":0.016219749928384836,"score_gpt":0.278569400818442,"score_spread":0.2623496508900572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210357221","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16602722,0.82777834,0.0000020049574,0.00061268586,0.00034906057,0.004983663,0.0001846901,0.000044024015,0.000018288969],"genre_scores_gemma":[0.017142855,0.9677198,0.00399251,0.0015236132,0.00071938883,0.0047953087,0.0034023789,0.00037205225,0.0003320823],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686825,0.0003954094,0.000786008,0.0009558217,0.0005108708,0.00048363442],"domain_scores_gemma":[0.9984081,0.000111180736,0.00018630286,0.00056424335,0.00006946594,0.00066071935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034009165,0.00063359825,0.0032635203,0.0005521025,0.000034930225,0.000074293566,0.00009722587,0.00019622088,0.000030876312],"category_scores_gemma":[0.00021062941,0.000392632,0.00035543158,0.00062090874,0.00009912835,0.00010025571,0.00013645072,0.00039499957,0.000019944895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009818305,0.000656306,0.70355976,0.0025148334,0.0016137933,0.000048655133,0.000031398384,4.4074247e-7,6.106265e-8,0.0000033692897,0.00080214354,0.29067105],"study_design_scores_gemma":[0.0034808156,0.00022451596,0.3927183,0.01303261,0.0039166063,1.2397182e-7,0.00001412235,7.361171e-7,8.960225e-7,0.0000043472587,0.58623725,0.00036965567],"about_ca_topic_score_codex":0.0001136055,"about_ca_topic_score_gemma":0.00007232675,"teacher_disagreement_score":0.58543515,"about_ca_system_score_codex":0.00012221084,"about_ca_system_score_gemma":0.00025212267,"threshold_uncertainty_score":0.99985254},"labels":[],"label_agreement":null},{"id":"W3210450725","doi":"10.1016/j.cmet.2021.10.011","title":"EMPEROR-Preserved: A promise fulfilled","year":2021,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Heart failure; Empagliflozin; Medicine; Heart failure with preserved ejection fraction; Ejection fraction; Internal medicine; Cardiology; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.021824633172831523,"score_gpt":0.23690542552206423,"score_spread":0.21508079234923272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210450725","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019847378,0.037298013,0.000013214623,0.7080146,0.0036826795,0.003312143,0.00007808501,0.0004281552,0.22732572],"genre_scores_gemma":[0.00061995036,0.0010835167,0.0014589889,0.5259334,0.00650399,0.00046093165,0.0024071408,0.0001808419,0.46135128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972948,0.00012034861,0.000422043,0.0008154205,0.00065320026,0.0006942302],"domain_scores_gemma":[0.9980813,0.000058708785,0.00018537688,0.0013416839,0.00016288819,0.00017001544],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014746879,0.00058805244,0.001269416,0.00027047488,0.000070884256,0.00010485265,0.00029619236,0.0006648724,0.0031746998],"category_scores_gemma":[0.000056319215,0.0004800418,0.00060494296,0.00026115813,0.00006198026,0.000078283374,0.00029249076,0.0011552866,0.0008094915],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023343122,0.00020011114,0.00007054877,0.0009181689,0.0006647543,0.0026601162,0.000078425765,1.9176926e-7,0.00061722443,0.000021398215,0.9930694,0.001676312],"study_design_scores_gemma":[0.0031522145,0.00006056886,0.0005797251,0.00017172168,0.0028879438,0.0000072072485,0.000029575256,0.00000580667,0.0036931396,0.00008290108,0.98891765,0.00041156096],"about_ca_topic_score_codex":0.000026866473,"about_ca_topic_score_gemma":0.0000017348783,"teacher_disagreement_score":0.23402555,"about_ca_system_score_codex":0.00006858119,"about_ca_system_score_gemma":0.000170328,"threshold_uncertainty_score":0.99996847},"labels":[],"label_agreement":null},{"id":"W3211362776","doi":"10.1161/circ.144.suppl_1.9295","title":"Abstract 9295: Ertugliflozin Has Favorable Effects on Kidney Outcomes in Patients With Baseline Evidence of Heart Failure in VERTIS CV","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Heart failure; Cardiology; Baseline (sea); Internal medicine","score_opus":0.016187011521316786,"score_gpt":0.24997252695414515,"score_spread":0.23378551543282836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211362776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966468,0.00008146208,0.000028665092,0.0024602518,0.00006192887,0.0005714397,0.0000022913816,0.000016401225,0.00013072489],"genre_scores_gemma":[0.9987338,0.0000050382478,0.000346703,0.00068123697,0.000012507054,0.000025575075,0.00013335554,0.000012325221,0.000049468836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907064,0.000044878914,0.00022259259,0.00022339524,0.00027650892,0.00016198153],"domain_scores_gemma":[0.9994278,0.00013766995,0.00005922472,0.0002328259,0.00007296854,0.000069505986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016265752,0.00011420837,0.00027959232,0.00015331515,0.000016850627,0.000013335492,0.00002725445,0.00004716766,0.000056159133],"category_scores_gemma":[0.00037734132,0.00009425699,0.000042136224,0.00027687952,0.000014194883,0.0001552533,0.000013829424,0.000077972894,0.000020983614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013098738,0.0005522588,0.99399567,0.00032299678,0.000041263815,0.000019385461,0.000077424644,0.00037019548,0.0012998264,0.00001994134,0.00047679656,0.0026932738],"study_design_scores_gemma":[0.0037704452,0.00020832218,0.99024624,0.0018774552,0.000044894143,1.3888481e-7,0.000013553486,0.0002451858,0.003202521,0.000022579226,0.00028735286,0.00008130338],"about_ca_topic_score_codex":0.00007106467,"about_ca_topic_score_gemma":0.000118968914,"teacher_disagreement_score":0.0037494008,"about_ca_system_score_codex":0.00012420113,"about_ca_system_score_gemma":0.000083573155,"threshold_uncertainty_score":0.38436887},"labels":[],"label_agreement":null},{"id":"W3211378706","doi":"10.1161/circ.144.suppl_1.9041","title":"Abstract 9041: Provider Evaluation for Selection of Evidence-Based Therapies to Reduce Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus Study - Primary Results of the PREFER-DM Study","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shell (Canada); McMaster University; St. Michael's Hospital; Université de Saint-Boniface; McGill University Health Centre","funders":"","keywords":"Medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Selection (genetic algorithm); Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.09311150001664602,"score_gpt":0.315812666190995,"score_spread":0.22270116617434899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211378706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149525,0.0003695335,0.000067683846,0.00014404456,0.000045318775,0.007795966,0.000006582273,0.000012044639,0.000063548665],"genre_scores_gemma":[0.9991748,0.0000026026341,0.00020414237,0.000025492636,0.00001433423,0.00045551185,0.00010217509,0.000011938627,0.000009022205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859893,0.00015684281,0.0003213999,0.00026896814,0.0005584332,0.00009543142],"domain_scores_gemma":[0.9983584,0.00010437467,0.00015414243,0.00038506222,0.0009778661,0.000020115802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068979507,0.00009496989,0.00023899307,0.000100491736,0.000047162837,0.000011256165,0.0000494317,0.000024559793,0.0000046459913],"category_scores_gemma":[0.00025299576,0.00006316398,0.000072416886,0.0005376796,0.000015127763,0.000114965565,0.000015351157,0.00003747528,6.228117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039829945,0.0027299277,0.9454092,0.00015296074,0.0006255506,7.849828e-8,0.0009581432,0.014038882,0.0019153467,0.0000023063542,0.000013800998,0.033755507],"study_design_scores_gemma":[0.0051615755,0.00086121203,0.98967826,0.00027213438,0.0008911543,1.6588016e-8,0.00030433122,0.0005643805,0.0021618295,0.000018144527,0.000024977478,0.00006197524],"about_ca_topic_score_codex":0.000033621087,"about_ca_topic_score_gemma":0.000041100386,"teacher_disagreement_score":0.044269074,"about_ca_system_score_codex":0.0001941554,"about_ca_system_score_gemma":0.00016211974,"threshold_uncertainty_score":0.2575752},"labels":[],"label_agreement":null},{"id":"W3211468684","doi":"10.1002/ejhf.2381","title":"Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPA‐HF</scp>","year":2021,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Defense Acquisition Program Administration; British Heart Foundation; AstraZeneca","keywords":"Heart failure; Medicine; Ejection fraction; Atrial fibrillation; Cardiology; Dapagliflozin; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.011313521802402518,"score_gpt":0.22782552936004627,"score_spread":0.21651200755764374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211468684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858269,0.0014142834,0.00009024179,0.011239426,0.0002980051,0.000219137,0.0000027685808,0.000028487164,0.00088076416],"genre_scores_gemma":[0.98170596,0.0000935898,0.0153498715,0.00027309402,0.0020030818,5.967433e-7,0.000043324748,0.00004239455,0.0004880862],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828804,0.000384288,0.0004592591,0.00027539622,0.0003932952,0.00019970148],"domain_scores_gemma":[0.9990478,0.00013336889,0.00021785995,0.0002132471,0.00020205446,0.00018564597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029565842,0.00019856103,0.00043807694,0.00024145818,0.000090123795,0.000101920545,0.000042847692,0.00005241341,0.00008210218],"category_scores_gemma":[0.00015561281,0.00015647792,0.00014763935,0.00033312873,0.000041714065,0.00038173803,0.000041622403,0.00036129978,0.000056742534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012559352,0.00040764784,0.44684482,0.00022350729,0.00217864,0.0045241383,0.0024123662,0.0014221447,0.12868057,0.00015732617,0.3982609,0.013632019],"study_design_scores_gemma":[0.00567798,0.0011433866,0.20932248,0.00056370714,0.00033206117,0.00038757882,0.0014579712,0.000056864654,0.0044653798,0.00004447153,0.77645344,0.00009471251],"about_ca_topic_score_codex":0.000009518251,"about_ca_topic_score_gemma":0.000048892234,"teacher_disagreement_score":0.37819254,"about_ca_system_score_codex":0.000090550435,"about_ca_system_score_gemma":0.00010017761,"threshold_uncertainty_score":0.6380985},"labels":[],"label_agreement":null},{"id":"W3211623221","doi":"10.1016/s0140-6736(21)01751-7","title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Novo Nordisk Fonden; Novo Nordisk; National Institute for Health and Care Research","keywords":"Medicine; Overweight; Placebo; Physical therapy; Double blind; Obesity; Weight management; Randomized controlled trial; Weight loss; Internal medicine; Alternative medicine","score_opus":0.027769638283157583,"score_gpt":0.300815709648638,"score_spread":0.2730460713654804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211623221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726177,0.0010918477,0.00014472463,0.0036416368,0.00019897727,0.015110356,0.00001689712,0.000048631744,0.0071292445],"genre_scores_gemma":[0.981116,0.0015904121,0.0019351658,0.00067833136,0.00077109964,0.0038879616,0.000100883386,0.00004547677,0.009874667],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99821126,0.00012767824,0.00040614436,0.00048076743,0.00027025628,0.00050388754],"domain_scores_gemma":[0.9985989,0.00062236516,0.00018953784,0.00041110534,0.00005767757,0.00012043106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071350124,0.00031347474,0.0016309245,0.00014357621,0.00015418536,0.000117044416,0.00010721128,0.000064248066,0.000051727042],"category_scores_gemma":[0.0000676009,0.00018166378,0.00015634221,0.0002056989,0.000059589616,0.0001294133,0.00009792663,0.00015999158,0.0000041517706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98566544,0.0011136732,0.001292441,0.00022352826,0.0024568965,0.00016718058,0.00065690355,0.000007579038,0.000079301666,0.001341681,0.00073618593,0.006259203],"study_design_scores_gemma":[0.98729104,0.0007534751,0.0011088926,0.00018838827,0.0028055487,0.000010001377,0.0006747037,0.0014422478,0.00038692146,0.00012775892,0.0050005196,0.00021049997],"about_ca_topic_score_codex":0.000029128112,"about_ca_topic_score_gemma":0.00039980942,"teacher_disagreement_score":0.011222394,"about_ca_system_score_codex":0.0000995553,"about_ca_system_score_gemma":0.000053773558,"threshold_uncertainty_score":0.74080336},"labels":[],"label_agreement":null},{"id":"W3211731066","doi":"10.1080/13696998.2021.2003804","title":"Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; McMaster University; Ted Rogers Centre for Heart Research; Impact","funders":"","keywords":"Medicine; Insulin glargine; Insulin degludec; Confidence interval; Pediatrics; Adverse effect; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Emergency medicine; Endocrinology","score_opus":0.005918474577636413,"score_gpt":0.21089628994057324,"score_spread":0.20497781536293683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211731066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491245,0.0003656461,0.00029518612,0.0015730289,0.0010337736,0.0015193233,0.000057512574,0.000009151286,0.00023392668],"genre_scores_gemma":[0.9944626,0.00056132284,0.003110363,0.00082992186,0.00039966707,0.0000771331,0.00045577224,0.00004368066,0.000059544476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984031,0.0000615948,0.000519619,0.00023795942,0.00048595585,0.00029181901],"domain_scores_gemma":[0.99797803,0.00046858005,0.00030133256,0.0002596453,0.00028313996,0.000709242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069307693,0.00020549135,0.0013058601,0.00014627699,0.0000700763,0.00004698215,0.0001311585,0.00011901802,0.00015519117],"category_scores_gemma":[0.000903097,0.00013515637,0.00029548426,0.00010667166,0.000057485253,0.00007477942,0.00004156168,0.00012833605,0.000008934422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75724685,0.0009854253,0.14589313,0.00006578036,0.031795934,0.00014260515,0.00020581303,0.0008457186,0.0000012004731,0.00066096894,0.0043177083,0.057838857],"study_design_scores_gemma":[0.9479259,0.0026898216,0.026940104,0.00016822007,0.004610209,0.0000011175908,0.000074088966,0.00020161856,0.00008226909,0.000040077677,0.017028134,0.00023841455],"about_ca_topic_score_codex":0.0015520228,"about_ca_topic_score_gemma":0.011602466,"teacher_disagreement_score":0.19067906,"about_ca_system_score_codex":0.0010199411,"about_ca_system_score_gemma":0.0006136106,"threshold_uncertainty_score":0.64744484},"labels":[],"label_agreement":null},{"id":"W3211833142","doi":"10.1016/j.jcjd.2021.10.001","title":"Sodium-Glucose Cotransporter-2 Inhibitors Increase Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: Should We Be Concerned in People Without Diabetes?","year":2021,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Diabetes mellitus; Type 2 diabetes; Ketoacidosis; Type 1 diabetes; Population; Internal medicine; Endocrinology; Dapagliflozin; Environmental health","score_opus":0.013316346050766823,"score_gpt":0.21659378473841778,"score_spread":0.20327743868765097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211833142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94867134,0.012010905,3.6004855e-7,0.03649168,0.000713056,0.001250924,0.00041858054,0.00002356223,0.00041960814],"genre_scores_gemma":[0.9591177,0.00086204096,0.000215112,0.037398946,0.00087541534,0.00010056266,0.00086675806,0.0002486073,0.00031484975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99363476,0.00046544746,0.0020157886,0.0008680286,0.001058174,0.0019577935],"domain_scores_gemma":[0.99509305,0.0005168734,0.0015737328,0.0009270669,0.00072052074,0.0011687691],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00089047756,0.0011323689,0.0033788804,0.002733858,0.000090031135,0.00011033029,0.0006219988,0.0009710662,0.00046498387],"category_scores_gemma":[0.00045260435,0.0009768542,0.00060762063,0.0017979514,0.00049191294,0.0003798545,0.00005622836,0.0028546331,0.000009492156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076295095,0.00026399095,0.9473424,0.0026140742,0.0016196165,0.0010225531,0.0010983755,0.000028567429,0.00013736,0.0000016160799,0.043844834,0.0019503338],"study_design_scores_gemma":[0.027913636,0.0077594216,0.8065793,0.05211568,0.00944022,0.000009874253,0.0015592892,0.00030718918,0.01203887,0.00012275213,0.07895426,0.0031995412],"about_ca_topic_score_codex":0.0036161623,"about_ca_topic_score_gemma":0.05967963,"teacher_disagreement_score":0.1407631,"about_ca_system_score_codex":0.0010509168,"about_ca_system_score_gemma":0.0030388783,"threshold_uncertainty_score":0.9994458},"labels":[],"label_agreement":null},{"id":"W3211902271","doi":"10.1016/j.jcjd.2021.09.084","title":"Real-World Use of Once-Weekly Semaglutide in Diverse Patient Populations With Type 2 Diabetes: Pooled Analysis of Four SURE Studies","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Discontinuation; Population; Internal medicine; Diabetes mellitus; Endocrinology; Liraglutide; Environmental health","score_opus":0.058332238904741894,"score_gpt":0.2777609664598422,"score_spread":0.21942872755510032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211902271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997425,0.0014462614,6.584249e-7,0.00048426207,0.0001450251,0.00016857969,0.00005013755,0.000003964235,0.0002760794],"genre_scores_gemma":[0.99796516,0.00008081558,0.0011791992,0.00014799974,0.00002468621,0.0000037044751,0.00004815856,0.000016925454,0.0005333291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846494,0.0000911217,0.00064004585,0.00016513842,0.00029346283,0.00034527024],"domain_scores_gemma":[0.99784595,0.00016508313,0.00046142744,0.00028007093,0.00091776164,0.00032971258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018797193,0.00017601665,0.00096340966,0.0015251192,0.00004546543,0.000017793567,0.00008303842,0.000040702223,0.00010422946],"category_scores_gemma":[0.00034829683,0.00014057706,0.0002317686,0.0021722906,0.00011997482,0.000148487,0.000025137733,0.00012804147,0.0000011412319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001311714,0.00012499189,0.985488,0.00010974799,0.0071610287,0.00013185621,0.00058241084,0.0021112922,0.00026154763,0.00010118621,0.0010444599,0.002870385],"study_design_scores_gemma":[0.001052121,0.0007492176,0.98508817,0.00078854855,0.008577069,3.7769792e-7,0.0013366379,0.00026014858,0.0012085504,0.00004441526,0.0007559277,0.00013883533],"about_ca_topic_score_codex":0.0016999841,"about_ca_topic_score_gemma":0.1653484,"teacher_disagreement_score":0.16364841,"about_ca_system_score_codex":0.00028575497,"about_ca_system_score_gemma":0.00060417515,"threshold_uncertainty_score":0.8498818},"labels":[],"label_agreement":null},{"id":"W3212040591","doi":"10.1016/j.jcjd.2021.09.073","title":"Combining Heart Failure and Diabetes Guidelines to Better Improve Chronic Disease Management","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Disease management; Intensive care medicine; Disease; Heart disease; Chronic disease; Diabetes management; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.011922007533320816,"score_gpt":0.2443882994668748,"score_spread":0.23246629193355398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212040591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94938177,0.0065704244,0.0000066250154,0.042780537,0.00041144644,0.00029685622,0.000022879478,0.00001312048,0.0005163254],"genre_scores_gemma":[0.9819527,0.000031326374,0.004582768,0.011781239,0.00041730562,0.000022529453,0.00002556187,0.000038818005,0.001147737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984585,0.000032892414,0.00043101946,0.00025721625,0.00023153516,0.0005888297],"domain_scores_gemma":[0.99763286,0.00004005369,0.00010052773,0.00028532842,0.00031852062,0.0016226845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022970606,0.00022114156,0.0004394972,0.0003733507,0.00011226301,0.00012930854,0.000111832705,0.000044044595,0.00016147042],"category_scores_gemma":[0.0001388957,0.00019603861,0.00015876011,0.00023839652,0.00006326206,0.00015518075,0.000060338945,0.00014190598,0.000022824815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004473441,0.000057998954,0.8647006,0.00044734994,0.0009126082,0.00037708852,0.000064560874,0.000021370528,0.0021600972,0.00033642806,0.09991946,0.030997925],"study_design_scores_gemma":[0.0037003548,0.0010490967,0.5001495,0.0019389245,0.0017140998,0.0000056261288,0.0003536994,0.0001593301,0.005920091,0.00068850047,0.48378372,0.0005370832],"about_ca_topic_score_codex":0.000022328863,"about_ca_topic_score_gemma":0.0006786321,"teacher_disagreement_score":0.38386428,"about_ca_system_score_codex":0.00021997161,"about_ca_system_score_gemma":0.0004664898,"threshold_uncertainty_score":0.79942226},"labels":[],"label_agreement":null},{"id":"W3212157490","doi":"10.1016/j.jcjd.2021.09.048","title":"Body Weight Loss With Oral Semaglutide is Independent of Gastrointestinal Adverse Events","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Semaglutide; Medicine; Placebo; Adverse effect; Weight loss; Appetite; Internal medicine; Vomiting; Nausea; Acarbose; Gastroenterology; Endocrinology; Obesity; Type 2 diabetes; Diabetes mellitus; Liraglutide","score_opus":0.008438854850860074,"score_gpt":0.21703639480827785,"score_spread":0.20859753995741778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212157490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996453,0.0004988289,0.000022950106,0.001240536,0.00013507112,0.00012187609,0.000027485172,0.0000046296473,0.0014956362],"genre_scores_gemma":[0.9947074,0.000007701803,0.0032130564,0.00051881024,0.00008910595,0.0000023868904,0.000014211849,0.00002241969,0.001424925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867797,0.000036423204,0.0003724446,0.00015204542,0.00033554726,0.00042555796],"domain_scores_gemma":[0.9983195,0.000031179985,0.00025608842,0.0002138405,0.0004432308,0.000736175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001722223,0.00017262454,0.0004554325,0.00028309622,0.000046205303,0.0000086790205,0.000120069024,0.000033504686,0.00061920675],"category_scores_gemma":[0.00007471975,0.00013533465,0.00016855581,0.00023447398,0.00009103495,0.00010494469,0.000018902167,0.00018077415,0.000013687184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018730134,0.00012251605,0.9937735,0.00010166211,0.00052788766,0.0011182027,0.00009860906,0.000010114907,0.00062413287,0.00007446128,0.0026010463,0.0009291449],"study_design_scores_gemma":[0.004780404,0.0018307515,0.9713446,0.0018580509,0.0010525831,0.00025422216,0.00034487553,0.000051067913,0.01128312,0.00018114988,0.006807879,0.00021132313],"about_ca_topic_score_codex":0.00018136304,"about_ca_topic_score_gemma":0.0020414283,"teacher_disagreement_score":0.022428919,"about_ca_system_score_codex":0.00018834401,"about_ca_system_score_gemma":0.0013105244,"threshold_uncertainty_score":0.67798793},"labels":[],"label_agreement":null},{"id":"W3212265083","doi":"10.1016/j.jcjd.2021.09.085","title":"Achievement of Near-Normal HbA1c With Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Semaglutide; Placebo; Subgroup analysis; Type 2 diabetes; Internal medicine; Exploratory analysis; Diabetes mellitus; Gastroenterology; Insulin; Endocrinology; Confidence interval","score_opus":0.016416109737928633,"score_gpt":0.2279615960292506,"score_spread":0.21154548629132197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212265083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985875,0.00063922536,0.000034754175,0.00023216875,0.00006786108,0.000110189496,0.000047765658,0.0000028659654,0.00027770153],"genre_scores_gemma":[0.99840915,0.000009439618,0.0012469275,0.0001578618,0.00002462914,0.0000032341763,0.00007004686,0.000015506117,0.00006322709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986333,0.000077730794,0.0005734091,0.000120059,0.0003441015,0.00025134583],"domain_scores_gemma":[0.99797344,0.00003802094,0.00049607886,0.0002480477,0.0008500989,0.00039429462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035568167,0.00013477227,0.0006614787,0.0006732713,0.000035394674,0.000017478978,0.0001001501,0.00004928657,0.00019274706],"category_scores_gemma":[0.00006258415,0.00011287489,0.00020336379,0.00087385543,0.00013149856,0.00024469037,0.000013294966,0.00009918772,7.5233487e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025234824,0.00023542522,0.9883593,0.00013643081,0.004165876,0.000057343696,0.0011518808,0.00039844654,0.0026277127,0.00017051052,0.00016051064,0.002511381],"study_design_scores_gemma":[0.0017194665,0.0021057879,0.96581715,0.00026417515,0.0055541038,0.0000010236887,0.0011382103,0.00020554771,0.022686927,0.000028307453,0.00035674745,0.00012256013],"about_ca_topic_score_codex":0.0004316812,"about_ca_topic_score_gemma":0.008953372,"teacher_disagreement_score":0.022542104,"about_ca_system_score_codex":0.000096344804,"about_ca_system_score_gemma":0.0007875639,"threshold_uncertainty_score":0.4996192},"labels":[],"label_agreement":null},{"id":"W3212849362","doi":"10.1002/ccr3.5057","title":"Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy","year":2021,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Glycosuria; Ketosis; Intensive care medicine; Drug; Pediatrics; Pharmacology; Diabetes mellitus; Endocrinology","score_opus":0.049749390363696556,"score_gpt":0.35657620798261697,"score_spread":0.3068268176189204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212849362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895982,0.001117858,0.0000065188606,0.0025490571,0.0005904057,0.000617611,0.0000036014485,0.000071647824,0.005445101],"genre_scores_gemma":[0.9909927,0.0002881725,0.000957558,0.0034111529,0.00037653666,0.00006758966,0.00003456209,0.000022650616,0.0038490696],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984093,0.00006853197,0.0006301056,0.00051835657,0.00016602025,0.00020774081],"domain_scores_gemma":[0.9987628,0.00014945086,0.00011625433,0.0004999099,0.000109745626,0.00036188157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005979828,0.00014324866,0.00042436618,0.000044606557,0.000056890854,0.000035148314,0.000012433913,0.00010130894,0.00031737782],"category_scores_gemma":[0.0004667835,0.00011370302,0.000156765,0.00013667135,0.000052715925,0.000048373757,0.00009848259,0.00016107573,0.000023777433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026245238,0.0010795858,0.1586003,0.00008829804,0.00048881734,0.5355067,0.00010846358,1.7315125e-7,0.0005330976,0.000022015962,0.018228589,0.28508148],"study_design_scores_gemma":[0.0058558113,0.0032214758,0.22944783,0.00023195651,0.0007061552,0.05037838,0.00020246992,0.000010514153,0.0116708325,0.0004006091,0.6974024,0.00047155426],"about_ca_topic_score_codex":0.000008829224,"about_ca_topic_score_gemma":0.000015391059,"teacher_disagreement_score":0.6791738,"about_ca_system_score_codex":0.0000239559,"about_ca_system_score_gemma":0.00013005029,"threshold_uncertainty_score":0.46366745},"labels":[],"label_agreement":null},{"id":"W3213283278","doi":"10.1080/00325481.2021.2002616","title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","year":2021,"lang":"en","type":"article","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); McMaster University; York University","funders":"","keywords":"Medicine; Adverse effect; Clinical Practice; Type 2 diabetes; Overweight; Glucagon-like peptide-1; Obesity; Management of obesity; Side effect (computer science); Intensive care medicine; Weight loss; Diabetes mellitus; Internal medicine; Family medicine; Endocrinology","score_opus":0.05382149360145335,"score_gpt":0.38267726180819,"score_spread":0.3288557682067367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213283278","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13997488,0.003911823,0.0033385814,0.8282195,0.0016069175,0.0031952092,0.000014086516,0.00010116964,0.019637832],"genre_scores_gemma":[0.85930806,0.008247737,0.0975834,0.021762155,0.0015041586,0.00048447962,0.0011609293,0.00011622108,0.009832862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834794,0.00020220217,0.0005979539,0.00030583818,0.00026216486,0.00028390545],"domain_scores_gemma":[0.996303,0.0026893942,0.00022625447,0.00038022653,0.00029209387,0.00010903699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010932114,0.00016314496,0.00048685074,0.00010722703,0.00006745899,0.000010057368,0.000097338445,0.000028901382,0.000032916556],"category_scores_gemma":[0.0054841195,0.00010906484,0.00011542527,0.00033618882,0.00014634727,0.00007805852,0.0000776888,0.00020918141,0.000016357142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00183548,0.0063234745,0.13073716,0.0034781955,0.0013546379,0.0014979038,0.0022994627,0.0000053661965,0.0064288005,0.011702242,0.18931852,0.64501876],"study_design_scores_gemma":[0.037117146,0.011239283,0.2976446,0.013675642,0.005966951,0.00058445946,0.0057250387,0.0012137227,0.009234506,0.0053675924,0.6115885,0.00064258435],"about_ca_topic_score_codex":0.000074879536,"about_ca_topic_score_gemma":0.000041962856,"teacher_disagreement_score":0.80645734,"about_ca_system_score_codex":0.000072963114,"about_ca_system_score_gemma":0.00008470552,"threshold_uncertainty_score":0.6565399},"labels":[],"label_agreement":null},{"id":"W3213447899","doi":"10.1161/circulationaha.121.057812","title":"Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Heart failure; Heart failure with preserved ejection fraction; Quality of life (healthcare); Ejection fraction; Clinical trial","score_opus":0.037752365239763754,"score_gpt":0.29518134397254897,"score_spread":0.2574289787327852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213447899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967622,0.0003191448,0.000036192727,0.0018055314,0.000053794633,0.00094242016,0.0000041690164,0.000014651905,0.00006185141],"genre_scores_gemma":[0.99939907,0.000029321014,0.00013358425,0.00018226235,0.000039929535,0.000027864737,0.0001543966,0.000007503691,0.00002608453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902,0.00017717024,0.00026746304,0.00018710677,0.00022748225,0.00012078757],"domain_scores_gemma":[0.9994382,0.0000598383,0.00012861374,0.00019764257,0.00010560106,0.00007008363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027917355,0.00007862861,0.0002408857,0.000052119583,0.00006252531,0.00002270079,0.000014142308,0.00003957193,0.000023044708],"category_scores_gemma":[0.00014051334,0.000056602545,0.00002456937,0.00017292754,0.000030270918,0.00016114471,0.000026002037,0.00007255172,5.169416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019608235,0.0002229496,0.99695206,0.00014598628,0.00006140155,1.1777177e-7,0.00009673766,0.000025216314,0.00004649879,0.0000607453,0.00014950417,0.00027796873],"study_design_scores_gemma":[0.023356969,0.00028572557,0.9753022,0.00005860345,0.000038401005,4.9233616e-8,0.00034690456,0.000087586974,0.00003001042,0.00004751169,0.0003978344,0.000048199963],"about_ca_topic_score_codex":0.00038481472,"about_ca_topic_score_gemma":0.00048527902,"teacher_disagreement_score":0.021649847,"about_ca_system_score_codex":0.00006425942,"about_ca_system_score_gemma":0.00007812484,"threshold_uncertainty_score":0.23081848},"labels":[],"label_agreement":null},{"id":"W3213458621","doi":"10.2139/ssrn.3947642","title":"Comparative Effectiveness of SGLT2i Versus GLP1-RA on Cardiovascular Outcomes in Routine Clinical Practice","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Mace; Hazard ratio; Internal medicine; Myocardial infarction; Stroke (engine); Proportional hazards model; Heart failure; Confidence interval; Propensity score matching; Population; Physical therapy; Conventional PCI","score_opus":0.03359927065151736,"score_gpt":0.37089434897371015,"score_spread":0.3372950783221928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213458621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724663,0.00473434,0.00039536445,0.00040531045,0.00041680236,0.00036186955,0.0000013792054,0.000016195092,0.0064221295],"genre_scores_gemma":[0.99692154,0.0022416664,0.00027214785,0.000085069245,0.00011606884,0.000011777861,0.000017818187,0.000016419173,0.0003174778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969724,0.00093390496,0.0004334917,0.00028661982,0.00047997435,0.0008936325],"domain_scores_gemma":[0.9983631,0.00080625917,0.00015383975,0.0003650382,0.00021552523,0.000096276555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004664933,0.00017533953,0.0009222262,0.000113769296,0.000043771823,0.000017081895,0.00009680766,0.00007298169,0.000014333364],"category_scores_gemma":[0.00060814613,0.0001387471,0.00046829123,0.00023104069,0.000045340494,0.00017313138,0.000039774503,0.0011376356,0.000020860127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03789774,0.025223874,0.41785812,0.00036287832,0.08456582,0.0023066718,0.0009601668,0.002316181,0.00057339104,0.2715109,0.00012155128,0.1563027],"study_design_scores_gemma":[0.10822471,0.033508424,0.801528,0.00084637594,0.009397189,0.0005615896,0.013221929,0.00024280333,0.005241087,0.011372172,0.014975553,0.0008802166],"about_ca_topic_score_codex":0.00004169347,"about_ca_topic_score_gemma":0.0001227756,"teacher_disagreement_score":0.38366982,"about_ca_system_score_codex":0.00081115984,"about_ca_system_score_gemma":0.001123503,"threshold_uncertainty_score":0.5657943},"labels":[],"label_agreement":null},{"id":"W3213551190","doi":"10.1016/j.jchf.2021.08.006","title":"Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction","year":2021,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Montreal Heart Institute; St. Michael's Hospital; University of Calgary","funders":"Janssen Research and Development; Sanofi Pasteur; National Institutes of Health; University Hospital Foundation; Vifor Pharma; Eisai; National Heart and Lung Institute; British Heart Foundation; Novo Nordisk; MyoKardia; GlaxoSmithKline; IFM Therapeutics; Daiichi-Sankyo; Zora Biosciences; Medicines Company; Medtronic; Gilead UK and Ireland Corporate Contributions; Roche; Respicardia; Novartis; Sanofi; MedImmune; Merck; Servier; Bayer; Bristol-Myers Squibb; AstraZeneca; Actelion Pharmaceuticals; Pfizer; Boehringer Ingelheim; Amgen; Abbott Laboratories","keywords":"Medicine; Ejection fraction; Heart failure; Dapagliflozin; Cardiology; Internal medicine; Benzhydryl compounds; Endocrinology; Diabetes mellitus","score_opus":0.010076645435182852,"score_gpt":0.24744264376752834,"score_spread":0.23736599833234548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213551190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269265,0.00004298935,0.00000813009,0.0059441966,0.00011846235,0.00057127647,0.0000044237167,0.00003925139,0.00057861087],"genre_scores_gemma":[0.99549174,0.000008981838,0.0037031923,0.00016966026,0.000073504954,0.000020067086,0.00013951749,0.000022757895,0.00037059785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888587,0.000055831093,0.00022281265,0.0003379494,0.0002723739,0.00022516104],"domain_scores_gemma":[0.9993778,0.000055442855,0.00006232465,0.00027624346,0.00012976551,0.000098428485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000900677,0.00016487131,0.0003449204,0.00015515833,0.00003981304,0.000024671337,0.00002371285,0.00010259257,0.00013439509],"category_scores_gemma":[0.00006924359,0.00014143018,0.000058866284,0.00040021018,0.0000459875,0.00017673269,0.000038134174,0.000174225,0.000028477098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012288485,0.000991,0.96778196,0.00017865923,0.00018488079,0.000013041109,0.00019288418,0.00003453976,0.0040955055,0.00003265797,0.024180368,0.001085641],"study_design_scores_gemma":[0.01213226,0.00094563904,0.91698444,0.00026155423,0.00019106636,0.0000023705086,0.0006757631,0.000040641844,0.0039285324,0.0000063119264,0.06468155,0.00014989189],"about_ca_topic_score_codex":0.000034243287,"about_ca_topic_score_gemma":0.00017190684,"teacher_disagreement_score":0.050797556,"about_ca_system_score_codex":0.00009551835,"about_ca_system_score_gemma":0.000056836096,"threshold_uncertainty_score":0.57673556},"labels":[],"label_agreement":null},{"id":"W3213645653","doi":"10.1016/j.medj.2021.10.004","title":"Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","year":2021,"lang":"en","type":"review","venue":"Med","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Women's College Hospital; University of Toronto; University Health Network","funders":"Institute of Nutrition, Metabolism and Diabetes; Janssen Pharmaceuticals; Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Novo Nordisk Fonden; Pfizer; Heart and Stroke Foundation of Canada; Diabetes Canada; Novartis; Bayer; AstraZeneca; Amgen; Novo Nordisk; Women's College Research Institute; Sanofi; Ministry of Colleges and Universities; Merck","keywords":"Medicine; Type 2 diabetes; Myocardial infarction; Heart failure; Diabetes mellitus; Renal function; Internal medicine; Stroke (engine); Endocrinology; Empagliflozin; Cardiology; Pharmacology","score_opus":0.035464070873921796,"score_gpt":0.30209436557245484,"score_spread":0.26663029469853305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213645653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001372131,0.99542755,0.00008048554,0.000037189835,0.00085447513,0.0012183187,0.00006749247,0.000034506542,0.00090782496],"genre_scores_gemma":[0.0010131832,0.99439853,0.0007423043,0.000024373054,0.00013670076,0.00011310953,0.0010569534,0.00005567736,0.0024591847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981956,0.00008310932,0.0006964902,0.0003992962,0.00039323047,0.0002322579],"domain_scores_gemma":[0.99889857,0.000048953472,0.0004164651,0.00040471906,0.00010487768,0.000126405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023445902,0.00037372325,0.00230213,0.00022876849,0.000026536103,0.000010692958,0.00007702317,0.00023782361,0.0001499631],"category_scores_gemma":[0.000019794637,0.00028957365,0.0006226478,0.0002484828,0.00008527895,0.00004973508,0.000051009192,0.00017435101,0.000012078515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036602705,0.00026175118,0.000024575413,0.029557511,0.0022122862,0.000049821094,0.00009717574,6.531173e-8,0.0006386041,0.00018170955,0.0026501257,0.9642898],"study_design_scores_gemma":[0.001124901,0.00033514074,0.000027386928,0.015088925,0.0070956754,0.000011661559,0.00007480104,5.3510456e-7,0.011929656,0.000018359915,0.9640555,0.00023745466],"about_ca_topic_score_codex":0.000028750377,"about_ca_topic_score_gemma":0.000008545088,"teacher_disagreement_score":0.9640523,"about_ca_system_score_codex":0.00010450668,"about_ca_system_score_gemma":0.00016775394,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W3214004110","doi":"10.2139/ssrn.3947641","title":"Comparative Effectiveness of SGLT2i Versus DPP4i on Cardiovascular, Kidney and Hyperkalemia Outcomes in Individuals from Routine Clinical Practice: Observational Cohort Study","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Observational study; Medicine; Hyperkalemia; Cohort; Cohort study; Intensive care medicine; Environmental health; Internal medicine","score_opus":0.05523495320756626,"score_gpt":0.3780601132233976,"score_spread":0.32282516001583134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214004110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485224,0.0024888918,0.000054121123,0.0004805081,0.0002776628,0.0008244234,0.0000128883,0.00001088938,0.0009983919],"genre_scores_gemma":[0.99795747,0.0012165098,0.00026827023,0.00014793868,0.00010265521,0.00003612186,0.00010276655,0.0000152953,0.00015295022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967959,0.0009586274,0.00054912025,0.00037189538,0.00067883777,0.0006456022],"domain_scores_gemma":[0.9976464,0.001517792,0.00020522975,0.00028478267,0.00021809923,0.00012768927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049445694,0.00020224568,0.0010614067,0.00010841036,0.0000624423,0.000027165857,0.00008725388,0.000075713164,0.000019028215],"category_scores_gemma":[0.0012704734,0.00016408662,0.00026073353,0.00021379195,0.00005237255,0.00015778726,0.00007559046,0.0010166147,0.0000066338616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009631993,0.0024246413,0.9764152,0.000015573763,0.015789952,0.00006481558,0.00014342656,0.000032292504,0.00001583184,0.0022833364,0.000034643006,0.0018170926],"study_design_scores_gemma":[0.018968629,0.0024927754,0.971876,0.00011299849,0.0024310416,0.000019340652,0.0022122173,0.000012388038,0.000081972954,0.0011324779,0.0005324315,0.00012768844],"about_ca_topic_score_codex":0.000115936775,"about_ca_topic_score_gemma":0.0000949825,"teacher_disagreement_score":0.018005429,"about_ca_system_score_codex":0.00057978893,"about_ca_system_score_gemma":0.00142035,"threshold_uncertainty_score":0.66912585},"labels":[],"label_agreement":null},{"id":"W3214076022","doi":"10.1503/cmaj.202627-f","title":"Association possible entre l’acidocétose diabétique et l’utilisation d’un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabète de type 2","year":2021,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"","keywords":"Medicine; Humanities; Philosophy","score_opus":0.006083928841268351,"score_gpt":0.2274238366293462,"score_spread":0.22133990778807786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214076022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7810104,0.005125819,0.0004612223,0.2031089,0.0023352779,0.0004121101,0.00020254476,0.000072256546,0.0072714505],"genre_scores_gemma":[0.90249646,0.015358133,0.0006690367,0.041151788,0.00526857,0.000038011403,0.00098899,0.00011326552,0.033915766],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931652,0.0014553355,0.0010169107,0.00046766878,0.0018184071,0.0020764973],"domain_scores_gemma":[0.9938289,0.0005797814,0.0007392784,0.00025676,0.00092861295,0.0036666535],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007039429,0.00045174523,0.0006839743,0.00033904947,0.000508939,0.00034515097,0.00026360556,0.0012376554,0.016179144],"category_scores_gemma":[0.0049130637,0.00051246746,0.0003728766,0.0007469479,0.000071613984,0.00043134144,0.000035659148,0.0019303248,0.00036047184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004117813,0.0006250117,0.7902828,0.00011153337,0.0018557408,0.005638788,0.00560142,0.000069079986,0.0006544679,0.001191403,0.15566278,0.038265843],"study_design_scores_gemma":[0.0073089143,0.00036619193,0.45120525,0.0010585157,0.002207997,0.0006098464,0.002998447,0.002141839,0.009289173,0.001732096,0.52034324,0.0007384647],"about_ca_topic_score_codex":0.0041987468,"about_ca_topic_score_gemma":0.037995875,"teacher_disagreement_score":0.3646805,"about_ca_system_score_codex":0.014994109,"about_ca_system_score_gemma":0.011163801,"threshold_uncertainty_score":0.9997327},"labels":[],"label_agreement":null},{"id":"W3214476949","doi":"10.1007/s10557-021-07291-y","title":"The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus","year":2021,"lang":"en","type":"review","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Stroke (engine); Myocardial infarction; Diabetes mellitus; Type 2 Diabetes Mellitus; Glycemic; Internal medicine; Incidence (geometry); Heart failure; Cardiology; Clinical trial; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.0072821266201930305,"score_gpt":0.22312815584430523,"score_spread":0.2158460292241122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214476949","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23871623,0.76013595,4.0857063e-7,0.0000091949005,0.00005358509,0.00094890036,0.00000459705,0.0000035303694,0.00012760775],"genre_scores_gemma":[0.14324348,0.8565425,0.000010111752,0.000009543782,0.000026947613,0.00007161414,0.00006472191,0.000018323826,0.00001273051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865746,0.00025803037,0.0003456825,0.00025318825,0.0003223025,0.00016330634],"domain_scores_gemma":[0.9991922,0.000111571535,0.00015451593,0.00041103575,0.00010128863,0.000029438928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006955375,0.00020901428,0.0011813304,0.00012261306,0.00004617717,0.000022511218,0.00004661756,0.00008723995,0.0000018662141],"category_scores_gemma":[0.000022269769,0.000109613415,0.00040131056,0.00032450922,0.00012769093,0.00005180445,0.000053424195,0.00016166245,2.4450912e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000519999,0.00007684833,0.005687883,0.0007005622,0.002981989,0.0000019555573,0.00023049691,0.0000064928163,0.0000017935363,0.00005523885,0.000004288436,0.99020046],"study_design_scores_gemma":[0.012697547,0.0019886403,0.0582858,0.025286006,0.006793183,0.0000047020626,0.00094684894,0.00002943146,0.00026129658,0.00017271526,0.8929146,0.00061921723],"about_ca_topic_score_codex":0.00006838757,"about_ca_topic_score_gemma":0.0000035871826,"teacher_disagreement_score":0.9895812,"about_ca_system_score_codex":0.00004582404,"about_ca_system_score_gemma":0.000063696,"threshold_uncertainty_score":0.44699052},"labels":[],"label_agreement":null},{"id":"W3214731876","doi":"10.1161/circulationaha.121.057934","title":"Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Type 2 diabetes; Glucagon-like peptide 1 receptor; Unstable angina; Diabetes mellitus; Placebo; Angina; Endocrinology; Cardiology; Myocardial infarction; Agonist; Confidence interval; Receptor","score_opus":0.046452769403401185,"score_gpt":0.30111618193706186,"score_spread":0.25466341253366065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214731876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990102,0.00017075821,0.00006353959,0.00014608941,0.00006890285,0.0004847629,0.0000054959523,0.000011832993,0.00003843274],"genre_scores_gemma":[0.99945325,0.000088967536,0.00012002148,0.00018586105,0.000013920294,0.000014795173,0.000096867356,0.000008224358,0.00001811176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991003,0.00008632835,0.00033828293,0.00021614398,0.00016623543,0.0000926694],"domain_scores_gemma":[0.9994143,0.00011737901,0.00012073159,0.0002123776,0.000091653965,0.000043534994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022450036,0.000094300725,0.00039851127,0.000119963675,0.00002506911,0.00002097207,0.0000152423945,0.00005214184,0.00000900926],"category_scores_gemma":[0.0000882742,0.000062661886,0.00008074654,0.00040940414,0.00008550392,0.00012918959,0.000017181994,0.00006737216,3.8458876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000631496,0.00021762005,0.9965112,0.000034029043,0.0008982687,0.0000057394363,0.00017994175,0.000022227905,0.0004045447,0.00010753008,0.0000030180606,0.0009843907],"study_design_scores_gemma":[0.015318709,0.00013206173,0.98079985,0.0000899449,0.0025534753,2.6002925e-7,0.00009981324,0.0005985813,0.00027780503,0.00003731663,0.000026458269,0.00006574602],"about_ca_topic_score_codex":0.000016494818,"about_ca_topic_score_gemma":0.0004580393,"teacher_disagreement_score":0.015711365,"about_ca_system_score_codex":0.000033778422,"about_ca_system_score_gemma":0.00004246897,"threshold_uncertainty_score":0.25552776},"labels":[],"label_agreement":null},{"id":"W3215449569","doi":"10.1161/circheartfailure.121.008837","title":"Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial","year":2021,"lang":"en","type":"article","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"Novo Nordisk; British Heart Foundation; AstraZeneca","keywords":"Dapagliflozin; Heart failure; Ejection fraction; Benzhydryl compounds; Natriuretic peptide; Clinical trial","score_opus":0.020040660424834517,"score_gpt":0.2731626258761793,"score_spread":0.2531219654513448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215449569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99118644,0.00014660615,0.00012156197,0.0063783196,0.00018979896,0.001803688,0.0000031488707,0.000042951775,0.00012745752],"genre_scores_gemma":[0.9968918,0.000007476268,0.0022300398,0.00025675536,0.0002914687,0.00004827662,0.0001649485,0.00002356799,0.0000856979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985392,0.00014077398,0.00036329307,0.00042813164,0.00034358236,0.00018500988],"domain_scores_gemma":[0.9990954,0.00018292677,0.00010347597,0.0003438975,0.0001797194,0.00009457031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016158234,0.0001843559,0.00038981056,0.00016331732,0.00012601598,0.00005585848,0.000041947413,0.00011859679,0.000061439445],"category_scores_gemma":[0.00019350903,0.0001406563,0.0000640868,0.00071455527,0.00003987546,0.0002181308,0.000040856023,0.00022034819,0.000017707967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035113864,0.0017272342,0.64372706,0.00041861634,0.0008949878,0.00012307217,0.0033204278,0.0019740206,0.29113543,0.0007456406,0.011884425,0.008935251],"study_design_scores_gemma":[0.04272521,0.0013481645,0.8865379,0.0011672053,0.0006511624,0.00005865753,0.0033350105,0.0006972286,0.0078215,0.0001426064,0.055123538,0.00039181343],"about_ca_topic_score_codex":0.00009258471,"about_ca_topic_score_gemma":0.00019860436,"teacher_disagreement_score":0.28331393,"about_ca_system_score_codex":0.00014360753,"about_ca_system_score_gemma":0.0001276286,"threshold_uncertainty_score":0.5735797},"labels":[],"label_agreement":null},{"id":"W3215673038","doi":"10.1161/circ.144.suppl_1.11033","title":"Abstract 11033: Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled Trials","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Glycemic; Randomized controlled trial; Gerontology; Diabetes mellitus; Surgery","score_opus":0.014463687397026937,"score_gpt":0.29443614720510736,"score_spread":0.27997245980808044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215673038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927682,0.0037576065,0.00042760547,0.00046542808,0.000066437206,0.0021896106,0.00011086832,0.0000148905365,0.00019931265],"genre_scores_gemma":[0.99792165,0.00065629417,0.00006490407,0.00008697536,0.0000314895,0.000032366308,0.0010763624,0.000010763533,0.00011916949],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976181,0.00045397933,0.0012328911,0.0002517361,0.00030449685,0.00013879735],"domain_scores_gemma":[0.9964491,0.0020854827,0.0008042411,0.00029388224,0.00028656094,0.000080701684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002271873,0.00016963898,0.0025473386,0.00022710343,0.00006165003,0.000020822063,0.00003409589,0.00007291436,0.0003712948],"category_scores_gemma":[0.0029075826,0.000103839666,0.0005265692,0.0004945699,0.000092536924,0.00007290603,0.00003435963,0.000053974632,5.828378e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75019306,0.0023674527,0.01346203,0.00037747735,0.03519965,0.00001221029,0.001300195,0.00056421204,0.1319889,0.0005641769,0.0002607057,0.06370996],"study_design_scores_gemma":[0.89791626,0.00015380092,0.05158806,0.00017395552,0.039793365,8.034043e-7,0.00019528664,0.0084335515,0.0012943139,0.000044249577,0.00028226577,0.00012409886],"about_ca_topic_score_codex":0.00009568259,"about_ca_topic_score_gemma":0.00003089011,"teacher_disagreement_score":0.14772321,"about_ca_system_score_codex":0.000046765243,"about_ca_system_score_gemma":0.00008332715,"threshold_uncertainty_score":0.42344588},"labels":[],"label_agreement":null},{"id":"W3215786952","doi":"10.1161/circ.144.suppl_1.10413","title":"Abstract 10413: Clinical Outcomes with Metformin and Sulfonylurea Initiation Among Patients with Heart Failure and Diabetes: From Get with the Guidelines-Heart Failure","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Heart failure; Metformin; Diabetes mellitus; Internal medicine; Gerontology; Endocrinology","score_opus":0.02317045241614255,"score_gpt":0.277676939092653,"score_spread":0.25450648667651043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215786952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940322,0.00011674043,0.00013716519,0.004791255,0.00003187096,0.000733913,0.000016209697,0.00004718225,0.000093476156],"genre_scores_gemma":[0.99344724,0.000008078289,0.0046515837,0.0009940147,0.00007797523,0.000041638716,0.00071671157,0.000028790746,0.000033933396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986566,0.000047563804,0.00033969586,0.00038890328,0.00036675748,0.00020048457],"domain_scores_gemma":[0.99892306,0.00018053829,0.00016354427,0.00031545467,0.00030622454,0.00011115958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023247534,0.00021992094,0.00038156356,0.000059353035,0.00011796683,0.00009764312,0.00003263997,0.00009510085,0.000039478848],"category_scores_gemma":[0.0000857966,0.00011977348,0.000048190588,0.00016485614,0.00011769737,0.00035389405,0.000030149065,0.00014913634,0.000005033172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005147611,0.00011263405,0.9965781,0.000036250778,0.00032059714,0.0000061666005,0.00007265827,0.000035581823,0.000034130906,0.00001899222,0.0012823585,0.0014510853],"study_design_scores_gemma":[0.0037036932,0.00022527466,0.9909413,0.00018576575,0.0005884277,0.0000018418862,0.00025438823,0.00017300727,0.00007135403,0.00003215054,0.0036582588,0.00016452208],"about_ca_topic_score_codex":0.000044956032,"about_ca_topic_score_gemma":0.00041718525,"teacher_disagreement_score":0.005636752,"about_ca_system_score_codex":0.000033200715,"about_ca_system_score_gemma":0.00005551109,"threshold_uncertainty_score":0.4884221},"labels":[],"label_agreement":null},{"id":"W3216369407","doi":"10.1016/j.kint.2021.10.033","title":"GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes","year":2021,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"National Key Research and Development Program of China; Vetenskapsrådet; Hjärt-Lungfonden; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; National Natural Science Foundation of China","keywords":"Medicine; Hazard ratio; Internal medicine; Renal function; Mace; Dipeptidyl peptidase-4; Kidney disease; Type 2 diabetes; Sitagliptin; Myocardial infarction; Lixisenatide; Diabetes mellitus; Endocrinology; Confidence interval; Percutaneous coronary intervention; Liraglutide","score_opus":0.021534280941999603,"score_gpt":0.3214877594713957,"score_spread":0.2999534785293961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216369407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329027,0.002478523,0.000004130394,0.03738142,0.0036712897,0.00037379298,0.000057774883,0.00003689289,0.023093501],"genre_scores_gemma":[0.96252775,0.0058498513,0.01038971,0.012697887,0.0008054693,0.00008834941,0.0007099862,0.000050797848,0.006880177],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873865,0.00008407012,0.00033289334,0.0003531634,0.00031887897,0.00017232442],"domain_scores_gemma":[0.99911076,0.00027063664,0.00005175983,0.00019494814,0.00011784083,0.00025408273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004625269,0.00013210374,0.00034878778,0.00012242158,0.00002085864,0.000057546345,0.000055615794,0.00007912929,0.00018747481],"category_scores_gemma":[0.006227451,0.00012199817,0.00010284868,0.00012730001,0.00006634239,0.00018138203,0.0001420323,0.00017153505,0.000030416995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032542256,0.00069972186,0.92921966,0.00007092721,0.002573323,0.00026221672,0.0001628052,0.0000012823074,0.00014305938,0.000763709,0.03282567,0.03295217],"study_design_scores_gemma":[0.00942343,0.00021515152,0.18375453,0.00018096398,0.0002987381,0.0000050721524,0.00018154221,0.00012100728,0.00030079504,0.000035631794,0.80532795,0.00015517721],"about_ca_topic_score_codex":0.00004826984,"about_ca_topic_score_gemma":0.000015474932,"teacher_disagreement_score":0.7725023,"about_ca_system_score_codex":0.00008604465,"about_ca_system_score_gemma":0.00016416043,"threshold_uncertainty_score":0.745529},"labels":[],"label_agreement":null},{"id":"W3216437086","doi":"10.1161/circ.144.suppl_1.10249","title":"Abstract 10249: Association of Eligibility for a Sodium-Glucose Co-Transporter 2 Inhibitor and Cardiovascular Outcomes in Patients with Atrial Fibrillation","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Atrial fibrillation; Population; Internal medicine; Gerontology; Cardiology","score_opus":0.010183451625983761,"score_gpt":0.2508452741782624,"score_spread":0.24066182255227864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216437086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847615,0.00016222031,0.00014344553,0.00007104934,0.00008070404,0.0009066733,0.000022151466,0.000014023642,0.00012357096],"genre_scores_gemma":[0.9990963,0.000013493165,0.00019729105,0.000012674851,0.0000663968,0.000007383268,0.0005791276,0.000009297794,0.00001806818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916404,0.000018257197,0.00024058332,0.00020118315,0.00027486292,0.000101049714],"domain_scores_gemma":[0.9994953,0.000054438264,0.00010101526,0.00015706962,0.00016466877,0.00002747947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002396372,0.00008370168,0.00029832765,0.00006264114,0.000020630137,0.000010860728,0.000009169573,0.000066096945,0.000009425494],"category_scores_gemma":[0.000078342375,0.00007340732,0.00016854532,0.0000852845,0.000009459429,0.000117062526,0.0000039928555,0.00002828428,9.591134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017067586,0.000073706564,0.99061376,0.00015960092,0.00046481538,0.0000010056137,0.000094548,0.00029125123,0.00014472693,0.000014409443,0.000010660833,0.007960871],"study_design_scores_gemma":[0.006889324,0.00006737972,0.9913143,0.00004688156,0.00043026367,5.8656713e-8,0.000016884163,0.00010899729,0.00071241026,0.00006140709,0.00028415635,0.000067920104],"about_ca_topic_score_codex":0.000014588508,"about_ca_topic_score_gemma":0.000018169398,"teacher_disagreement_score":0.00789295,"about_ca_system_score_codex":0.00013326363,"about_ca_system_score_gemma":0.00003258262,"threshold_uncertainty_score":0.29934636},"labels":[],"label_agreement":null},{"id":"W3216543422","doi":"10.1016/s2213-8587(21)00292-8","title":"Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute for Health and Care Research; Boehringer Ingelheim","keywords":"Empagliflozin; Heart failure; Ejection fraction; Benzhydryl compounds; MEDLINE","score_opus":0.045067551808763276,"score_gpt":0.3194892456944029,"score_spread":0.27442169388563964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216543422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490584,0.0009737677,0.00000399352,0.011877459,0.0000646411,0.0019828794,0.000020738855,0.000017039934,0.00015365191],"genre_scores_gemma":[0.9977275,0.00043120224,0.00015541281,0.00045690744,0.00006574927,0.00091336115,0.00018723654,0.000012295556,0.000050306517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99844563,0.00034928368,0.00035537238,0.00027881024,0.00018122423,0.00038966542],"domain_scores_gemma":[0.99883485,0.0004672045,0.00014068247,0.00042009712,0.000108367036,0.000028779641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027845064,0.00018498264,0.0008529174,0.0004895786,0.00005817742,0.000023841363,0.00008287906,0.000054556072,0.00007423984],"category_scores_gemma":[0.000018122233,0.00010612274,0.00013826988,0.0010907325,0.000113603455,0.00006307842,0.000017944589,0.00011195382,0.000002173681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5960172,0.018378025,0.15461539,0.00029074695,0.028415233,0.00007553648,0.021507954,0.0006571074,0.11887874,0.0067606685,0.0007551291,0.053648278],"study_design_scores_gemma":[0.63646656,0.013883371,0.29930872,0.0001427851,0.0070596053,0.000011031879,0.0116367955,0.00019148945,0.025881063,0.00046390216,0.004653995,0.0003006959],"about_ca_topic_score_codex":0.00013443032,"about_ca_topic_score_gemma":0.0010656279,"teacher_disagreement_score":0.14469334,"about_ca_system_score_codex":0.0001097358,"about_ca_system_score_gemma":0.00005026456,"threshold_uncertainty_score":0.43275595},"labels":[],"label_agreement":null},{"id":"W3216568701","doi":"10.3390/ijms222312677","title":"Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Qingdao University of Science and Technology; Qatar University","keywords":"Cotransporter; Heart failure; Medicine; Glucose homeostasis; Endocrinology; Diabetes mellitus; Internal medicine; Insulin resistance; Endothelial dysfunction; Crosstalk; Natriuresis; Homeostasis; Type 2 Diabetes Mellitus; Type 2 diabetes; Sodium–hydrogen antiporter; Glucagon-like peptide-1; Diabetic cardiomyopathy; Pharmacology; Cardiomyopathy; Sodium; Chemistry; Kidney","score_opus":0.028826997928221496,"score_gpt":0.3306603069489468,"score_spread":0.3018333090207253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216568701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10126849,0.89777553,0.000016483991,0.00023991887,0.00028272404,0.00021745598,0.00003211444,0.000004423384,0.0001628442],"genre_scores_gemma":[0.04108988,0.958187,0.00018976502,0.00011282657,0.00029016891,0.000010453568,0.00003948874,0.00001550833,0.0000649138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980369,0.000076415425,0.00057850115,0.00029395442,0.0008198853,0.00019432977],"domain_scores_gemma":[0.99917436,0.00006299725,0.00034952423,0.00009681663,0.00014670315,0.00016959112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039679298,0.00023848054,0.0010918023,0.00083643734,0.00003716643,0.00016672093,0.00023898989,0.00008019354,0.000019413157],"category_scores_gemma":[0.000043768054,0.00017195354,0.00035762604,0.00031780856,0.00026723125,0.00019165075,0.00012395484,0.00016567727,0.0000015722244],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013126117,0.00012658708,0.010653875,0.0007962297,0.0014346569,0.002478466,0.00010199842,0.0000015090712,0.000026321046,0.00007387932,0.0000561852,0.9842372],"study_design_scores_gemma":[0.0022902712,0.00035622623,0.006483486,0.014390305,0.004859083,0.00058767165,0.00015250134,0.00000463955,0.00038255082,0.00018485195,0.96982324,0.00048519802],"about_ca_topic_score_codex":0.000012954135,"about_ca_topic_score_gemma":0.00000344232,"teacher_disagreement_score":0.98375195,"about_ca_system_score_codex":0.00007303674,"about_ca_system_score_gemma":0.00026710783,"threshold_uncertainty_score":0.7012062},"labels":[],"label_agreement":null},{"id":"W3217055532","doi":"10.1016/j.diabet.2021.101305","title":"Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs","year":2021,"lang":"en","type":"review","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Waterloo; Sunnybrook Health Science Centre; Université Laval; University of Alberta; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Diabetes mellitus; Cotransporter; Canagliflozin; Pharmacology; Internal medicine; Endocrinology; Sodium; Type 2 diabetes; Chemistry","score_opus":0.013121564733855189,"score_gpt":0.26545848914516923,"score_spread":0.25233692441131406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217055532","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2839086,0.7141143,0.000011227351,0.000008365342,0.00008260152,0.0013357798,0.00024421528,0.000038179795,0.00025669407],"genre_scores_gemma":[0.08001474,0.9172974,0.0004769042,0.00003483551,0.00008328277,0.00017773775,0.0013674835,0.00013323958,0.00041436031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707407,0.0002637622,0.0009697017,0.000627815,0.00059718813,0.0004674435],"domain_scores_gemma":[0.9971397,0.0002486172,0.0015437412,0.0005403245,0.0003718415,0.00015577016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033491926,0.00071876013,0.0045082592,0.000383428,0.00005215226,0.000036510457,0.00013566745,0.0002787828,0.00004559277],"category_scores_gemma":[0.00007385808,0.00047734854,0.00039552222,0.0007449147,0.00020948077,0.00013170937,0.0000552642,0.0002732611,0.0000035590583],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000892687,0.0042047226,0.44843104,0.035331175,0.028777322,0.000042154545,0.0020753576,0.0000064207497,0.000030777614,0.00065929163,0.0006604386,0.47969204],"study_design_scores_gemma":[0.013287092,0.0034276382,0.08779859,0.14071359,0.18513793,0.0000025706947,0.00079409586,0.000116722396,0.0054724542,0.00006343416,0.5607821,0.0024037983],"about_ca_topic_score_codex":0.000045466746,"about_ca_topic_score_gemma":0.000013059118,"teacher_disagreement_score":0.56012166,"about_ca_system_score_codex":0.00005577809,"about_ca_system_score_gemma":0.00015865968,"threshold_uncertainty_score":0.99976784},"labels":[],"label_agreement":null},{"id":"W3217154890","doi":"10.1093/eurheartj/ehab724.1004","title":"Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; McGill University Health Centre","funders":"Eli Lilly and Company","keywords":"Empagliflozin; EMPA; Medicine; Blood pressure; Diabetes mellitus; Ambulatory blood pressure; Type 2 diabetes; Internal medicine; Ambulatory; Type 2 Diabetes Mellitus; Cardiology; Endocrinology","score_opus":0.01266924389298836,"score_gpt":0.23480208053695203,"score_spread":0.22213283664396366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217154890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735343,0.0016626536,4.1392987e-8,0.0003366384,0.000025327525,0.00024457692,0.0000014258536,0.0000040669706,0.00037184072],"genre_scores_gemma":[0.99960786,0.000145875,0.00004071236,0.000058709757,0.000035941062,0.000002096648,0.0000029972907,0.00001640868,0.000089386216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999259,0.00018441024,0.00012890875,0.00012977928,0.00014800107,0.0001498952],"domain_scores_gemma":[0.9996955,0.000027117478,0.000059129175,0.0001145126,0.00004814398,0.000055632376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025155072,0.00010037108,0.00020832113,0.00016080948,0.000025084422,0.000022192047,0.000023803626,0.000013361034,0.00002221345],"category_scores_gemma":[0.000024999319,0.000055302007,0.000013996114,0.00020256726,0.000038216054,0.000060530212,0.000023796947,0.0001785842,0.0000012653535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026100155,0.00035927346,0.99751943,0.00007325963,0.00018277345,0.00012160758,0.00037940856,0.000023034721,0.00023658267,0.000007626255,0.00022840395,0.0006075827],"study_design_scores_gemma":[0.0026868104,0.001755026,0.9936969,0.0010252774,0.00014047763,0.000040036655,0.000077082055,0.000011346876,0.00032547596,0.0000017946361,0.00018319173,0.00005657451],"about_ca_topic_score_codex":0.0000072210405,"about_ca_topic_score_gemma":0.000025763105,"teacher_disagreement_score":0.0038225395,"about_ca_system_score_codex":0.000019446199,"about_ca_system_score_gemma":0.000029998015,"threshold_uncertainty_score":0.22551504},"labels":[],"label_agreement":null},{"id":"W3217188991","doi":"10.1161/circ.144.suppl_1.11143","title":"Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Gerontology","score_opus":0.013217947266271015,"score_gpt":0.2898804505532845,"score_spread":0.2766625032870135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217188991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925021,0.0023595141,0.0012124296,0.00078093127,0.00011120755,0.0026700788,0.00008936836,0.000020367039,0.00025399963],"genre_scores_gemma":[0.99816686,0.00039812492,0.00007000265,0.00009391177,0.0000563585,0.00004863174,0.0009430156,0.00001472887,0.00020837593],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970271,0.00059898413,0.0014788207,0.00032264247,0.00041932717,0.00015310454],"domain_scores_gemma":[0.9959515,0.0022062776,0.0009934226,0.00037450652,0.00038047953,0.00009381702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003493201,0.00022218237,0.0029586295,0.0003073408,0.0000890693,0.00003131713,0.000053069056,0.00010991005,0.00042611163],"category_scores_gemma":[0.0029468092,0.00013857876,0.0006448746,0.0006444021,0.0001055449,0.000096967924,0.00004229346,0.0000775988,8.464369e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.542041,0.0041979942,0.06956153,0.0006447936,0.060248703,0.000035806603,0.0010765434,0.0012771332,0.25361425,0.0014995816,0.000494041,0.0653086],"study_design_scores_gemma":[0.8077612,0.00014093421,0.13426085,0.00020909302,0.038498126,0.0000012438078,0.00016188256,0.016472206,0.0018962034,0.00009199308,0.00032775325,0.00017851834],"about_ca_topic_score_codex":0.00008936743,"about_ca_topic_score_gemma":0.000027161803,"teacher_disagreement_score":0.2657202,"about_ca_system_score_codex":0.000055296263,"about_ca_system_score_gemma":0.00009285797,"threshold_uncertainty_score":0.5651078},"labels":[],"label_agreement":null},{"id":"W3217367208","doi":"10.1161/circ.144.suppl_1.12120","title":"Abstract 12120: Cost-Effectiveness of Earlier Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With a History of Heart Failure","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Alberta Health; University of Calgary","funders":"","keywords":"Medicine; Dapagliflozin; Heart failure; Incidence (geometry); Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.01333708017907656,"score_gpt":0.22553136240099797,"score_spread":0.2121942822219214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217367208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998235,0.00011573415,0.000053303997,0.000019154417,0.00006330264,0.00065152365,0.0000064652963,0.0000064901105,0.0008490183],"genre_scores_gemma":[0.99944484,0.0000025628551,0.00011999116,0.00001320363,0.000008293315,0.000021349151,0.00037040337,0.000008717272,0.000010660486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927795,0.00003364948,0.0002723231,0.00012599125,0.000216556,0.00007350549],"domain_scores_gemma":[0.9994381,0.00003347058,0.00015545622,0.00013702174,0.0002129248,0.000023012679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012759762,0.00007434041,0.00024179668,0.00012899066,0.0000045291213,0.0000011191206,0.00001455669,0.00005006861,0.00005940986],"category_scores_gemma":[0.000016582586,0.000069253554,0.00005164967,0.00013540297,0.00003631815,0.00011147766,0.000004930652,0.000042738626,0.000001309281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023957022,0.0006864656,0.9787621,0.00074691087,0.00006943766,0.000002919704,0.00025277399,0.00014950689,0.017595692,0.00005428796,0.000044960612,0.0013953717],"study_design_scores_gemma":[0.003588008,0.0001158906,0.9722352,0.0004569532,0.0001124289,1.4384074e-7,0.00002770446,0.000022543345,0.023146339,0.000016017011,0.00022648614,0.000052310817],"about_ca_topic_score_codex":0.000028338734,"about_ca_topic_score_gemma":0.000018396335,"teacher_disagreement_score":0.006526929,"about_ca_system_score_codex":0.0002129918,"about_ca_system_score_gemma":0.00009405844,"threshold_uncertainty_score":0.28240782},"labels":[],"label_agreement":null},{"id":"W3217462347","doi":"10.1161/circ.144.suppl_1.10401","title":"Abstract 10401: Uptake and Predictors of SGLT2i in Patients with Type 2 Diabetes and Cardiovascular Disease","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Type 2 diabetes; Comorbidity; Diabetes mellitus; Cohort; Population; Kidney disease; Logistic regression; Odds ratio; Disease; Concomitant; Cohort study; Endocrinology; Environmental health","score_opus":0.007880008320989278,"score_gpt":0.193344401027066,"score_spread":0.1854643927060767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217462347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754566,0.001836022,0.0000028722727,0.000017507158,0.000034034372,0.00022583343,0.0000031620184,0.000009000601,0.00032589826],"genre_scores_gemma":[0.99972063,0.000053047566,0.000042304066,0.000015212657,0.000013361046,0.00000517006,0.00013121063,0.000006972067,0.000012095977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954766,0.000008349921,0.00009012042,0.00014053103,0.00014205844,0.00007129443],"domain_scores_gemma":[0.99972045,0.000008912959,0.000022290733,0.00013864321,0.000055753848,0.000053954627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004920239,0.000058168946,0.00013702207,0.000046967256,0.000011428197,0.0000069798352,0.0000076163396,0.000018421153,0.000013024758],"category_scores_gemma":[0.000027175258,0.0000487818,0.000024774456,0.0000962143,0.000021759308,0.00006329062,0.000012064265,0.000021625377,7.095168e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026286996,0.00010074947,0.9883165,0.0001488651,0.0002773498,0.000006413856,0.00004918855,0.00009821121,0.00004952271,0.000019126248,0.000009074802,0.010898745],"study_design_scores_gemma":[0.0015249263,0.000041942934,0.9975596,0.00010024152,0.0003476121,5.758471e-8,0.00001790789,0.000100251586,0.000049245024,0.000027182927,0.00018752563,0.0000435275],"about_ca_topic_score_codex":0.000002996842,"about_ca_topic_score_gemma":0.00000118676,"teacher_disagreement_score":0.010855217,"about_ca_system_score_codex":0.00001474441,"about_ca_system_score_gemma":0.0000165148,"threshold_uncertainty_score":0.1989264},"labels":[],"label_agreement":null},{"id":"W3217716605","doi":"10.1016/s2213-8587(21)00310-7","title":"SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes","year":2021,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Dapagliflozin; Type 2 diabetes; Kidney disease; Diabetes mellitus; Disease; Fluid ounce (US); Population; Incidence (geometry)","score_opus":0.016731972708270423,"score_gpt":0.2671351638708697,"score_spread":0.2504031911625993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217716605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9179845,0.002041819,0.0000011930916,0.057637017,0.0011077356,0.0005262407,0.000017810748,0.00019161806,0.02049209],"genre_scores_gemma":[0.97132546,0.0007074329,0.0003244609,0.016665287,0.0011817088,0.00018823998,0.00013760275,0.000057353765,0.009412427],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970226,0.000196664,0.00036235971,0.00051954563,0.00024994742,0.0016488673],"domain_scores_gemma":[0.9983054,0.00024578779,0.00011764856,0.0010939544,0.00012279209,0.00011444187],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002440417,0.00034557708,0.00079693063,0.00009622036,0.0001292959,0.00006192706,0.00031852224,0.00009001357,0.001893325],"category_scores_gemma":[0.000101721496,0.00020017667,0.00019080123,0.00021626144,0.00017091216,0.00010363125,0.00042259676,0.0003199411,0.0014083363],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007223448,0.00086343614,0.7860023,0.0004312063,0.002353804,0.00021592953,0.0005738216,0.0000163394,0.01626462,0.0028779993,0.16858613,0.021742212],"study_design_scores_gemma":[0.004043378,0.0007723146,0.22297832,0.0004142729,0.0015483374,0.000020061589,0.00052222493,0.00007179811,0.14781798,0.0072052665,0.6139118,0.0006942548],"about_ca_topic_score_codex":0.000011717102,"about_ca_topic_score_gemma":0.00003255285,"teacher_disagreement_score":0.5630239,"about_ca_system_score_codex":0.00008767883,"about_ca_system_score_gemma":0.000058442696,"threshold_uncertainty_score":0.9993692},"labels":[],"label_agreement":null},{"id":"W34139288","doi":"10.1016/j.diabres.2021.108920","title":"Особенности реабилитации больных с переломами челюстей и костей лицевого скелета, их осложнения","year":2013,"lang":"ru","type":"article","venue":"Международный журнал прикладных и фундаментальных исследований","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.011036450240773247,"score_gpt":0.2331635945721681,"score_spread":0.22212714433139485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34139288","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44898382,0.028728615,0.00058849686,0.022752317,0.015272492,0.018702224,0.00095617585,0.0041387375,0.4598771],"genre_scores_gemma":[0.7809041,0.0066204662,0.0029476788,0.008942054,0.0060409964,0.0026326138,0.0019152719,0.0014279982,0.1885688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9741492,0.0011576067,0.005376938,0.006019747,0.0048715426,0.008424968],"domain_scores_gemma":[0.9828642,0.0012911895,0.001732715,0.0076415977,0.0017813618,0.0046889293],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0024297277,0.005536503,0.0059734145,0.0027965342,0.0019064758,0.0021235337,0.0038397007,0.002643789,0.075080685],"category_scores_gemma":[0.0010133237,0.0053257733,0.0032049865,0.004156798,0.0018850266,0.0031627957,0.002871787,0.0036632814,0.100582354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010764626,0.0096731605,0.032422345,0.0032362728,0.009412825,0.0022024643,0.0035711634,0.00016678234,0.009487436,0.0107524935,0.68974614,0.22825247],"study_design_scores_gemma":[0.029692316,0.007185978,0.12826481,0.0051885606,0.011086497,0.00041992567,0.005546963,0.0060176146,0.0112668825,0.0061095036,0.77914244,0.010078501],"about_ca_topic_score_codex":0.0031472603,"about_ca_topic_score_gemma":0.00039105493,"teacher_disagreement_score":0.3319203,"about_ca_system_score_codex":0.0024027808,"about_ca_system_score_gemma":0.0014088158,"threshold_uncertainty_score":0.9993929},"labels":[],"label_agreement":null},{"id":"W4200081815","doi":"10.51731/cjht.2021.226","title":"Liraglutide (Saxenda)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liraglutide; Reimbursement; Medicine; Dyslipidemia; Overweight; Type 2 diabetes; Weight loss; Weight management; Obesity; Diabetes mellitus; Intervention (counseling); Family medicine; Physical therapy; Gerontology; Internal medicine; Health care; Nursing; Endocrinology; Political science","score_opus":0.027145564048585976,"score_gpt":0.27998161503450353,"score_spread":0.25283605098591755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200081815","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30669662,0.29731825,0.00039353038,0.38064995,0.0012374265,0.00042858027,0.000015205247,0.0002632202,0.012997214],"genre_scores_gemma":[0.99418396,0.0009590849,0.0021467109,0.0016796499,0.000012340118,0.0000023537139,0.0000040070922,0.000009924584,0.0010019667],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910337,0.000019413563,0.00031970927,0.00009193748,0.00011758771,0.00034796356],"domain_scores_gemma":[0.99934226,0.00001794638,0.00016022405,0.00021468937,0.00015532784,0.00010953525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000234147,0.00008257817,0.0003071412,0.00037120955,0.00010405242,0.00002088129,0.000101003745,0.000065339475,0.00007426985],"category_scores_gemma":[0.000313169,0.000068203284,0.00008287806,0.00027662618,0.00008372814,0.000056097764,0.000017227416,0.00021384105,0.000016926579],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000058574237,0.00003848722,0.015472945,0.00012856294,0.00015133525,0.0022984704,0.000090734626,0.00000202962,0.00004230794,0.004055177,0.031844214,0.94586986],"study_design_scores_gemma":[0.00075060845,0.00050814694,0.021173216,0.0003318764,0.00005616474,0.00045770564,0.0024645845,0.0000026130294,0.0022818325,0.0026216367,0.96927106,0.0000805371],"about_ca_topic_score_codex":0.0003521079,"about_ca_topic_score_gemma":0.0011720046,"teacher_disagreement_score":0.94578934,"about_ca_system_score_codex":0.00032694964,"about_ca_system_score_gemma":0.0026520547,"threshold_uncertainty_score":0.4704631},"labels":[],"label_agreement":null},{"id":"W4200101053","doi":"10.1161/circulationaha.121.055459","title":"Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Liraglutide; Medicine; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Type 2 diabetes; Internal medicine; Exenatide; Dulaglutide; Diabetes mellitus; Endocrinology; Lixisenatide; Receptor; Agonist","score_opus":0.005272779020068145,"score_gpt":0.22975328733556158,"score_spread":0.22448050831549343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200101053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99895376,0.00011031745,0.0000030829872,0.00024028421,0.000048334157,0.00047203558,0.000008332733,0.000007872284,0.00015597806],"genre_scores_gemma":[0.9994009,0.000007495226,0.00003543165,0.00020239766,0.0000047626477,0.000009220662,0.00014216425,0.000010445778,0.00018718878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916434,0.000102407255,0.00019760536,0.0002005254,0.00020823878,0.00012687499],"domain_scores_gemma":[0.99938196,0.000113211514,0.00011608975,0.00023925935,0.00009809102,0.00005137629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016529598,0.00012048057,0.0004063269,0.00018708035,0.000026325883,0.000008987655,0.000026257303,0.000041211613,0.000016919052],"category_scores_gemma":[0.00020868922,0.00007601113,0.00006630105,0.00060442847,0.000057177713,0.00003927617,0.000032265023,0.00005068308,7.7272165e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011291977,0.00015695805,0.99427915,0.0002483807,0.0012145374,0.0000010099433,0.0001726266,0.00015018217,0.0007155537,0.000031936695,0.000047730537,0.0028690184],"study_design_scores_gemma":[0.0024081077,0.00034903394,0.9912474,0.00017827359,0.0024204967,3.9539955e-8,0.000047165016,0.00044432117,0.0027768142,0.0000073860356,0.000053647756,0.00006729895],"about_ca_topic_score_codex":0.000017127577,"about_ca_topic_score_gemma":0.000016786875,"teacher_disagreement_score":0.0030317307,"about_ca_system_score_codex":0.00006302384,"about_ca_system_score_gemma":0.000031947427,"threshold_uncertainty_score":0.3099644},"labels":[],"label_agreement":null},{"id":"W4200119495","doi":"10.46747/cfp.6712912","title":"Rapid recommendations","year":2021,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"College of Family Physicians of Canada","funders":"","keywords":"Guideline; Computer science; Medicine; Data science; Pathology","score_opus":0.025890382298507007,"score_gpt":0.245146469608298,"score_spread":0.219256087309791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200119495","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018227607,0.0010811794,0.000011387801,0.0114338435,0.00034033862,0.00018783454,0.00003945538,0.000049857852,0.9686285],"genre_scores_gemma":[0.36651117,0.0003598651,0.001777543,0.5979167,0.0005598848,0.00007697993,0.001626415,0.00006138368,0.03111004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993615,0.000014491686,0.00009022064,0.00018146548,0.00007667142,0.00027565632],"domain_scores_gemma":[0.9992927,0.000010619504,0.000017131513,0.00027936097,0.000065296925,0.00033493194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002774261,0.00009254458,0.00014107805,0.00010044297,0.00009102993,0.00002770097,0.000041752348,0.000027792268,0.00007631697],"category_scores_gemma":[0.0000051972966,0.00009767709,0.00007722888,0.0002586822,0.00001972103,0.000058522917,0.0000130906965,0.00006346515,0.00052320067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002444965,0.00009662994,0.000198844,0.000017276496,0.00019285688,0.0001961105,0.000036743928,6.150293e-7,0.001076661,0.005374106,0.44178236,0.5510254],"study_design_scores_gemma":[0.0004588712,0.00004415116,0.010231429,0.000040736948,0.00010594029,4.739836e-7,0.0003968062,0.000018287621,0.000800182,0.00027287193,0.9875328,0.00009746911],"about_ca_topic_score_codex":0.0010136345,"about_ca_topic_score_gemma":0.003650595,"teacher_disagreement_score":0.9375185,"about_ca_system_score_codex":0.00020740091,"about_ca_system_score_gemma":0.00037840023,"threshold_uncertainty_score":0.67248607},"labels":[],"label_agreement":null},{"id":"W4200143795","doi":"10.1016/j.eclinm.2021.101240","title":"Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes","year":2021,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Daiichi-Sankyo; Novo Nordisk; Intarcia Therapeutics; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Renal function; Kidney disease; Internal medicine; Proteinuria; Type 2 diabetes; Placebo; Creatinine; Diabetes mellitus; Kidney; Endocrinology; Pathology","score_opus":0.02353991349163101,"score_gpt":0.36444511736460017,"score_spread":0.3409052038729692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200143795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852369,0.0013763065,0.0000032104988,0.010217225,0.0006638203,0.0016221203,0.000004260925,0.0000514557,0.0008247146],"genre_scores_gemma":[0.9883222,0.0008253979,0.0010152333,0.0081753,0.00028024928,0.000092859285,0.00008243554,0.00003419793,0.0011721441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977101,0.00022140324,0.0008434508,0.0005051388,0.0004076099,0.00031230415],"domain_scores_gemma":[0.99737924,0.0011566599,0.00016909937,0.0005682168,0.0000989484,0.0006278443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006845315,0.00023504303,0.00096555,0.0001250179,0.000024247589,0.000008274515,0.00007767554,0.00012819674,0.00014167206],"category_scores_gemma":[0.0073581543,0.00015882954,0.00017197365,0.0003093498,0.00022452527,0.000045646328,0.00011821842,0.00029877253,0.00003586778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006378354,0.0028116803,0.96000504,0.0009160345,0.0002742539,0.0006963014,0.0000385108,1.383317e-7,0.00006185914,0.00011302586,0.0037669623,0.030678356],"study_design_scores_gemma":[0.011421314,0.0041199015,0.973761,0.0035255363,0.00074479997,5.96454e-7,0.000015867146,0.0000990192,0.00021609062,0.0002199204,0.0057376465,0.00013831137],"about_ca_topic_score_codex":0.0000028526083,"about_ca_topic_score_gemma":0.0000041837766,"teacher_disagreement_score":0.030540045,"about_ca_system_score_codex":0.000033035725,"about_ca_system_score_gemma":0.00017456814,"threshold_uncertainty_score":0.880893},"labels":[],"label_agreement":null},{"id":"W4200183746","doi":"10.1016/j.dsx.2021.102382","title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial","year":2021,"lang":"en","type":"review","venue":"Diabetes & Metabolic Syndrome Clinical Research & Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Merck Sharp and Dohme; Novo Nordisk; University of Glasgow; British Heart Foundation; Sanofi; Kowa Company; Amgen; Boehringer Ingelheim; Novartis; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Abbott Laboratories","keywords":"Glucagon-like peptide 1 receptor; Exenatide; Agonist; Medicine; Mace; Internal medicine; Receptor; Clinical trial; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Pharmacology; Endocrinology; Myocardial infarction","score_opus":0.23854344924251078,"score_gpt":0.44512288676511563,"score_spread":0.20657943752260485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200183746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.092308804,0.8849657,0.0000024517362,0.00011240727,0.0001957552,0.022164777,0.00011675274,0.000057681467,0.00007562931],"genre_scores_gemma":[0.0019517785,0.98611677,0.00048728564,0.00018535652,0.00015284789,0.009244801,0.00090702216,0.00026035623,0.00069380406],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9718414,0.013673608,0.0036556923,0.0033532209,0.005410348,0.0020657498],"domain_scores_gemma":[0.9854853,0.0036149812,0.0010616531,0.0077849547,0.0011068677,0.0009462066],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.030926498,0.0020631156,0.039906934,0.0012884471,0.0003224919,0.0004479304,0.001268806,0.0005612366,0.00031384383],"category_scores_gemma":[0.0039281156,0.00085709715,0.016939728,0.007410071,0.0012548536,0.0002811404,0.0008577256,0.002597143,0.00011668037],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022098939,0.0018656901,0.25634444,0.003499383,0.5710535,0.00013722957,0.000025096733,0.0000031448249,9.942862e-10,0.000007974485,0.00018267207,0.16665986],"study_design_scores_gemma":[0.010441687,0.0021885205,0.08113919,0.0011378877,0.4231559,8.7242165e-7,0.000018883244,6.7839954e-7,1.9012099e-8,0.0000011120529,0.4813796,0.00053563516],"about_ca_topic_score_codex":0.00017777599,"about_ca_topic_score_gemma":0.0001634427,"teacher_disagreement_score":0.48119694,"about_ca_system_score_codex":0.00022395805,"about_ca_system_score_gemma":0.0008013294,"threshold_uncertainty_score":0.9997039},"labels":[],"label_agreement":null},{"id":"W4200256788","doi":"10.1016/j.jcjd.2021.12.005","title":"Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort Study","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Waterloo; Sunnybrook Health Science Centre; University of Alberta; Université Laval; University of Toronto","funders":"Canadian Institutes of Health Research; University of Manitoba","keywords":"Medicine; Propensity score matching; Urinary system; Cohort; Cotransporter; Cohort study; Internal medicine; Population; Sodium; Environmental health","score_opus":0.01762895826957856,"score_gpt":0.23025108208371237,"score_spread":0.2126221238141338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200256788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971981,0.0010544846,0.0000024490041,0.0005786262,0.00027922596,0.0006516271,0.000009798307,0.000014152997,0.00021154851],"genre_scores_gemma":[0.99926275,0.0000098158,0.00008430174,0.00032665924,0.00011182896,0.00001713349,0.00004789111,0.00002142427,0.00011819467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882615,0.00006804735,0.00040746664,0.00019542893,0.00021466959,0.00028822696],"domain_scores_gemma":[0.9987323,0.00005317668,0.00016555475,0.00019381341,0.0002517955,0.0006033402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031348763,0.00017294896,0.00047959623,0.00033856343,0.0001435462,0.000071246104,0.000050860694,0.00005549842,0.00010833199],"category_scores_gemma":[0.00009790172,0.00015169839,0.00012436441,0.00025341017,0.000050719238,0.00018545343,0.0000073269825,0.00018603205,0.0000034897564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006746785,0.0011599588,0.99582446,0.00006858848,0.00037138493,0.00062061835,0.00013793855,0.000011894689,0.00009030343,0.0000060946822,0.0001785394,0.0015234774],"study_design_scores_gemma":[0.0020400372,0.0017159822,0.99375325,0.00024679178,0.0008057602,0.000017097322,0.00015210848,0.000018888393,0.0006924242,0.000028772229,0.00039109835,0.00013775675],"about_ca_topic_score_codex":0.00094837503,"about_ca_topic_score_gemma":0.0067985784,"teacher_disagreement_score":0.0058502033,"about_ca_system_score_codex":0.00019807933,"about_ca_system_score_gemma":0.0007671186,"threshold_uncertainty_score":0.61860806},"labels":[],"label_agreement":null},{"id":"W4200307947","doi":"10.1097/mnh.0000000000000778","title":"Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"","keywords":"Kidney disease; Lead (geology); Heart failure; Cardiorenal syndrome; Kidney; Disease","score_opus":0.010366472755191994,"score_gpt":0.24333380283328074,"score_spread":0.23296733007808873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200307947","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.385779,0.024896637,0.00006879755,0.5587268,0.002470636,0.02467763,0.0012081066,0.0015146605,0.00065774133],"genre_scores_gemma":[0.9527288,0.00011961886,0.00039964347,0.00938975,0.0019751645,0.022206731,0.00090653315,0.00021305261,0.012060697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935339,0.00022247151,0.0006653801,0.0017187307,0.001416616,0.0024428929],"domain_scores_gemma":[0.9925995,0.000066729284,0.00016827343,0.0014078281,0.00009681994,0.005660873],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061134464,0.00086607056,0.00095769315,0.0006631455,0.0008197528,0.0002969796,0.00051994034,0.000102852006,0.0009630525],"category_scores_gemma":[0.00038574392,0.00072155334,0.00037891383,0.0010777852,0.00021415741,0.00032823713,0.001318834,0.00062786497,0.0001788883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010877388,0.0012670975,0.07789857,0.0033365875,0.0009887959,0.0005604681,0.00029784173,0.0005681033,0.0014198413,0.0003956554,0.804176,0.10800331],"study_design_scores_gemma":[0.00567308,0.0011955461,0.089179754,0.0007143087,0.0009147838,0.00001228332,0.000113580994,0.0003773739,0.00064169645,0.00006446776,0.9001966,0.0009164887],"about_ca_topic_score_codex":0.000109475375,"about_ca_topic_score_gemma":0.00061913655,"teacher_disagreement_score":0.56694984,"about_ca_system_score_codex":0.006024443,"about_ca_system_score_gemma":0.0028339622,"threshold_uncertainty_score":0.99995023},"labels":[],"label_agreement":null},{"id":"W4200320890","doi":"10.1111/dom.14622/v1/review2","title":"Review for \"Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis between 2010‐2020\"","year":2021,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kidney disease; Basal (medicine); Medicine; Basal insulin; Gerontology; Population; Disease; Diabetes mellitus; Internal medicine; Endocrinology; Type 2 diabetes; Environmental health","score_opus":0.023171798776688454,"score_gpt":0.2785324229556209,"score_spread":0.25536062417893246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320890","genre_codex":"review","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010882357,0.7629923,0.00010781884,0.20010509,0.0008846416,0.019622898,0.0024734174,0.00011189975,0.002819573],"genre_scores_gemma":[0.04923429,0.0436134,0.0019733263,0.049609352,0.00045107093,0.007189095,0.48847657,0.00026247205,0.35919043],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99630576,0.00012789681,0.0012068215,0.0010576838,0.00066888274,0.0006329271],"domain_scores_gemma":[0.99808395,0.000096402466,0.0003260146,0.00086240045,0.00015983006,0.00047138144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045471752,0.00062621426,0.0025399663,0.0010704343,0.000027643842,0.000024513649,0.00020783032,0.0001402871,0.0046842494],"category_scores_gemma":[0.00021252208,0.00050430617,0.0004163357,0.0026305916,0.000015087735,0.000095570605,0.00009611808,0.000489143,0.000002167439],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008058198,0.0002947772,0.45261928,0.029727466,0.00081868406,0.00019543969,0.000013085121,0.00006507698,8.316779e-9,0.000001518867,0.5052869,0.010897221],"study_design_scores_gemma":[0.0051161,0.000102085745,0.66847533,0.1251855,0.00904166,1.116401e-7,0.0000035297182,0.00034476267,2.2519873e-7,0.0000010731954,0.19130458,0.0004250107],"about_ca_topic_score_codex":0.9725293,"about_ca_topic_score_gemma":0.99937725,"teacher_disagreement_score":0.7193789,"about_ca_system_score_codex":0.0049610427,"about_ca_system_score_gemma":0.0056064427,"threshold_uncertainty_score":0.99974084},"labels":[],"label_agreement":null},{"id":"W4200340627","doi":"10.22541/au.163913208.81687299/v1","title":"The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs -- Therapeutic potential exploration in lung injury","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; China Scholarship Council; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk","keywords":"Medicine; Liraglutide; Therapeutic approach; Type 2 diabetes; Lung; Diabetes mellitus; Internal medicine; Disease; Endocrinology","score_opus":0.009944586641006769,"score_gpt":0.2471684403404368,"score_spread":0.23722385369943003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200340627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854352,0.00849632,0.00008069298,0.0029057048,0.00055635115,0.0014606488,0.000008886443,0.00006266137,0.0009935639],"genre_scores_gemma":[0.99451816,0.0020251654,0.00019633437,0.0004333557,0.00008627354,0.00019667463,0.00026769226,0.00003752766,0.0022388273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983748,0.00012166882,0.00037540167,0.0004540961,0.0003716607,0.0003023333],"domain_scores_gemma":[0.9989963,0.00008464378,0.00020395707,0.0005026069,0.00014005197,0.00007240802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038205963,0.00032973234,0.0005298289,0.00020342537,0.000072290524,0.00010683824,0.00013866025,0.00023394568,0.00004272865],"category_scores_gemma":[0.000022043492,0.0002266777,0.0001712885,0.00014851122,0.00006650631,0.00013904188,0.00032810302,0.0003660962,0.0000028338522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022838837,0.005872547,0.48385793,0.036290515,0.015857587,0.00054384035,0.0114151845,0.0034228957,0.14057152,0.0062464476,0.034062598,0.25957507],"study_design_scores_gemma":[0.017684255,0.0013776309,0.54682577,0.009766637,0.00787247,0.0000027121691,0.010767094,0.15325509,0.23371775,0.0014334568,0.014316263,0.0029808695],"about_ca_topic_score_codex":0.000011233813,"about_ca_topic_score_gemma":0.00002291715,"teacher_disagreement_score":0.25659418,"about_ca_system_score_codex":0.00008933512,"about_ca_system_score_gemma":0.00017048459,"threshold_uncertainty_score":0.92436486},"labels":[],"label_agreement":null},{"id":"W4200351168","doi":"10.1002/ehf2.13760","title":"A Year in Heart Failure: An Update of Recent Findings","year":2021,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Ejection fraction; Cardiology; Hazard ratio; Heart failure with preserved ejection fraction; Spironolactone; Atrial fibrillation; Empagliflozin; Diabetes mellitus; Confidence interval; Endocrinology; Type 2 diabetes","score_opus":0.03463644319745247,"score_gpt":0.32521854546342877,"score_spread":0.2905821022659763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200351168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037594093,0.99035096,0.0000015432724,0.0065816287,0.0002238569,0.0018216223,0.000046180845,0.00007681847,0.0005214182],"genre_scores_gemma":[0.000052908057,0.98783165,0.0088334335,0.0004330646,0.00019539856,0.00016253575,0.001148329,0.00010038029,0.0012422687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974934,0.00019517362,0.0007289334,0.0006572247,0.00042041918,0.00050486665],"domain_scores_gemma":[0.9986595,0.000051971685,0.00012831969,0.0008371817,0.00008951578,0.00023349609],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004142558,0.00048176027,0.0025533426,0.0004351591,0.00003443091,0.000042747375,0.00016038059,0.00036386252,0.0020708032],"category_scores_gemma":[0.00007193716,0.00040248147,0.00052434846,0.00084440515,0.000054781543,0.000116399846,0.00015387742,0.0005163326,0.0004657906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025119734,0.0014628449,0.0018001283,0.023904104,0.0009632106,0.00023279912,0.00017711575,5.812142e-7,0.000018151148,0.0013675464,0.58136284,0.38868558],"study_design_scores_gemma":[0.0007791985,0.00025368866,0.00008087149,0.011462628,0.0008183513,0.000023854835,0.00008610852,6.2527494e-7,0.00002204581,0.000009845426,0.98617285,0.00028995285],"about_ca_topic_score_codex":0.000027427435,"about_ca_topic_score_gemma":0.0000902662,"teacher_disagreement_score":0.40481,"about_ca_system_score_codex":0.00020670143,"about_ca_system_score_gemma":0.00036829992,"threshold_uncertainty_score":0.9998427},"labels":[],"label_agreement":null},{"id":"W4200364763","doi":"10.1136/bmjdrc-2021-002496","title":"Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study","year":2021,"lang":"en","type":"review","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta; Université Laval; University of Waterloo","funders":"Institute of Population and Public Health; Canadian Institutes of Health Research","keywords":"Medicine; Diabetes mellitus; Cohort study; Population; Cohort; Pharmacology; Internal medicine; Urology; Endocrinology; Environmental health","score_opus":0.06847628644468327,"score_gpt":0.43386344214949984,"score_spread":0.36538715570481656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200364763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.074381284,0.87825125,3.3522068e-7,0.00005130377,0.00015210012,0.046062645,0.00022807517,0.000022946973,0.00085002504],"genre_scores_gemma":[0.17716686,0.80098665,0.000080760095,0.000046126916,0.00026428013,0.017040774,0.0035978397,0.0002109253,0.000605757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934034,0.002499477,0.0009033808,0.00095850136,0.0015985729,0.0006366722],"domain_scores_gemma":[0.99612176,0.0010700151,0.00031551218,0.0015395465,0.000730001,0.00022316215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035090349,0.0005120465,0.002911002,0.0003102546,0.00030326605,0.00021276045,0.0007258657,0.00022380221,0.000106834894],"category_scores_gemma":[0.00042689417,0.00032689158,0.0005682,0.0011659452,0.00019691665,0.000120917684,0.0010309963,0.000665154,0.000008598172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007036911,0.0006177458,0.61061674,0.035080027,0.0017869646,0.00006500303,0.000102572616,0.0000016503171,0.000002106798,0.000017794635,0.00024665604,0.3513924],"study_design_scores_gemma":[0.0044095353,0.0014992902,0.7060832,0.10646342,0.005541692,0.0000015619343,0.0006076768,0.0000050347744,0.00015726763,0.000008296489,0.17464012,0.0005829108],"about_ca_topic_score_codex":0.00045292493,"about_ca_topic_score_gemma":0.00020053555,"teacher_disagreement_score":0.35080948,"about_ca_system_score_codex":0.0005975825,"about_ca_system_score_gemma":0.0011505353,"threshold_uncertainty_score":0.99991834},"labels":[],"label_agreement":null},{"id":"W4200381646","doi":"10.1111/dom.14622/v2/review1","title":"Review for \"Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis between 2010‐2020\"","year":2021,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kidney disease; Medicine; Basal (medicine); Gerontology; Basal insulin; Disease; Population; Diabetes mellitus; Demography; Internal medicine; Endocrinology; Type 2 diabetes; Environmental health; Sociology","score_opus":0.023171798776688454,"score_gpt":0.2785324229556209,"score_spread":0.25536062417893246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200381646","genre_codex":"review","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010882357,0.7629923,0.00010781884,0.20010509,0.0008846416,0.019622898,0.0024734174,0.00011189975,0.002819573],"genre_scores_gemma":[0.04923429,0.0436134,0.0019733263,0.049609352,0.00045107093,0.007189095,0.48847657,0.00026247205,0.35919043],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99630576,0.00012789681,0.0012068215,0.0010576838,0.00066888274,0.0006329271],"domain_scores_gemma":[0.99808395,0.000096402466,0.0003260146,0.00086240045,0.00015983006,0.00047138144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045471752,0.00062621426,0.0025399663,0.0010704343,0.000027643842,0.000024513649,0.00020783032,0.0001402871,0.0046842494],"category_scores_gemma":[0.00021252208,0.00050430617,0.0004163357,0.0026305916,0.000015087735,0.000095570605,0.00009611808,0.000489143,0.000002167439],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008058198,0.0002947772,0.45261928,0.029727466,0.00081868406,0.00019543969,0.000013085121,0.00006507698,8.316779e-9,0.000001518867,0.5052869,0.010897221],"study_design_scores_gemma":[0.0051161,0.000102085745,0.66847533,0.1251855,0.00904166,1.116401e-7,0.0000035297182,0.00034476267,2.2519873e-7,0.0000010731954,0.19130458,0.0004250107],"about_ca_topic_score_codex":0.9725293,"about_ca_topic_score_gemma":0.99937725,"teacher_disagreement_score":0.7193789,"about_ca_system_score_codex":0.0049610427,"about_ca_system_score_gemma":0.0056064427,"threshold_uncertainty_score":0.99974084},"labels":[],"label_agreement":null},{"id":"W4200417285","doi":"10.1016/j.jchf.2021.11.001","title":"Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes","year":2021,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Novo Nordisk; Cytokinetics; European Society of Cardiology; Boston Scientific Corporation; Duke University; National Institutes of Health; Medtronic; Novartis; Merck; GlaxoSmithKline; Bayer; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Sanofi; American Heart Association","keywords":"Medicine; Metformin; Sulfonylurea; Internal medicine; Diabetes mellitus; Heart failure; Glycemic; Type 2 diabetes; Ejection fraction; Medical prescription; Insulin; Endocrinology; Pharmacology","score_opus":0.009194427982262134,"score_gpt":0.25236986774669246,"score_spread":0.24317543976443032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200417285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653126,0.00039170854,0.000005527683,0.012062981,0.000047360725,0.00070543744,0.000012431259,0.00008488054,0.00015843293],"genre_scores_gemma":[0.97878224,0.000039763214,0.017830271,0.0018661267,0.000066061315,0.00006771476,0.00009965142,0.00004654596,0.0012016146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983267,0.00007597299,0.000302237,0.00052324426,0.00035476295,0.0004170748],"domain_scores_gemma":[0.99889654,0.00019110901,0.00007257571,0.00040414627,0.00015818383,0.00027743107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021326696,0.00032710825,0.0007535267,0.000092330265,0.00012778172,0.000111010384,0.00004501204,0.00013260149,0.000102718965],"category_scores_gemma":[0.00005659618,0.00019693671,0.00009738417,0.00020274846,0.00024331648,0.0002888556,0.000097714415,0.0002369277,0.000012582555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055248453,0.00031031208,0.9864763,0.000099271565,0.0006061775,0.000020717289,0.000096642616,2.2439718e-7,0.000021241922,0.000060877654,0.01033573,0.0019172488],"study_design_scores_gemma":[0.004306215,0.0009653702,0.86905354,0.00016896114,0.00037505035,0.0000052781925,0.00041973984,0.0000054412576,0.0001627795,0.000026414844,0.12428895,0.00022228074],"about_ca_topic_score_codex":0.000021160435,"about_ca_topic_score_gemma":0.00030863084,"teacher_disagreement_score":0.11742278,"about_ca_system_score_codex":0.000020988115,"about_ca_system_score_gemma":0.00005850389,"threshold_uncertainty_score":0.8030846},"labels":[],"label_agreement":null},{"id":"W4200466927","doi":"10.1177/20543581211065528","title":"SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Nephrectomy; Single Center; Diabetes mellitus; Type 2 Diabetes Mellitus; Center (category theory); Series (stratigraphy); Nephrology; Type 2 diabetes; Internal medicine; Kidney; Endocrinology","score_opus":0.008737547155096467,"score_gpt":0.21740100413762506,"score_spread":0.20866345698252858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200466927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968454,0.0034960334,7.583954e-7,0.027383018,0.00014946942,0.00024572382,0.000110492314,0.0000040251707,0.00015649444],"genre_scores_gemma":[0.95117813,0.00010334302,0.00019068604,0.048087984,0.000056159373,0.000003681941,0.00025367783,0.000014219509,0.00011211736],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915415,0.000047993395,0.00023838595,0.00012295082,0.00011645488,0.00032007185],"domain_scores_gemma":[0.98649555,0.000010899896,0.00009704471,0.0000994411,0.00025565847,0.013041422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007714594,0.00011006767,0.00023167074,0.000230125,0.000078287565,0.000040479445,0.000013928838,0.000022493095,0.00009203099],"category_scores_gemma":[0.0014240778,0.00008871493,0.000036350633,0.00018709824,0.000043421915,0.00017375017,0.000006906548,0.00008940674,0.000002487621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006132028,0.0003853271,0.95089996,0.0004991379,0.00007527616,0.011989714,0.0003197485,6.702399e-7,0.000002762575,0.000037814625,0.02821375,0.00696262],"study_design_scores_gemma":[0.06614464,0.022476805,0.35591725,0.01043151,0.0013002167,0.0029690426,0.0034843425,0.000030639516,0.00014942672,0.00075011404,0.53509533,0.0012506784],"about_ca_topic_score_codex":0.0002649469,"about_ca_topic_score_gemma":0.0024314902,"teacher_disagreement_score":0.59498274,"about_ca_system_score_codex":0.00023675586,"about_ca_system_score_gemma":0.012546959,"threshold_uncertainty_score":0.993051},"labels":[],"label_agreement":null},{"id":"W4200474402","doi":"10.1136/bmjdrc-2021-002352","title":"Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study","year":2021,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute; Seven Oaks General Hospital; Institute for Clinical Evaluative Sciences; University of Manitoba","funders":"Diagnostic Services Manitoba; University of Manitoba; AstraZeneca Canada; AstraZeneca","keywords":"Metformin; Sulfonylurea; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Population; Proportional hazards model; Combination therapy; Retrospective cohort study; Cohort; Cohort study; Endocrinology; Insulin; Pharmacology","score_opus":0.09335445883372799,"score_gpt":0.42785719303460235,"score_spread":0.33450273420087434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200474402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870511,0.00025049667,1.0379937e-7,0.00009851218,0.000058931462,0.008093445,0.000048238704,0.000021102756,0.004378059],"genre_scores_gemma":[0.9973211,0.000025070078,0.0004369562,0.00012937,0.000036998783,0.00045980123,0.0010192045,0.000060053502,0.0005114313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963709,0.00046447845,0.00050451787,0.0005850919,0.0013635227,0.0007114753],"domain_scores_gemma":[0.9970682,0.00036746217,0.00014158346,0.00096188457,0.001290373,0.00017046495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010153358,0.00027546694,0.0007695672,0.00056237605,0.00015212975,0.000121307916,0.00034729237,0.00006402788,0.00032849197],"category_scores_gemma":[0.0002781829,0.00020836208,0.00008551438,0.0020751478,0.00007020577,0.00022898222,0.00032772298,0.00027171982,0.000011695803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011661581,0.0020856848,0.97436047,0.00022675385,0.00043257393,0.00003391218,0.00033976132,0.00019323388,0.00008097228,0.000037422324,0.0001859815,0.02085707],"study_design_scores_gemma":[0.009739265,0.0049818964,0.9790215,0.0009259759,0.000095126816,1.833151e-8,0.0011620431,0.00018886568,0.0032294192,0.000018539884,0.00040965225,0.00022772557],"about_ca_topic_score_codex":0.0007827463,"about_ca_topic_score_gemma":0.0015151276,"teacher_disagreement_score":0.020629343,"about_ca_system_score_codex":0.00053629343,"about_ca_system_score_gemma":0.00051797414,"threshold_uncertainty_score":0.8496759},"labels":[],"label_agreement":null},{"id":"W4200481930","doi":"10.37765/ajmc.2021.88806","title":"ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease","year":2021,"lang":"en","type":"article","venue":"The American Journal of Managed Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; AstraZeneca; Bayer; University of Toronto; Diabetes Canada","keywords":"Medicine; Kidney disease; Internal medicine; Albuminuria; Retrospective cohort study; Cohort; Type 2 diabetes; Diabetes mellitus; Renal function; Intensive care medicine; Endocrinology","score_opus":0.004893490047993276,"score_gpt":0.21626745713280843,"score_spread":0.21137396708481515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200481930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960793,0.001409285,0.000006179297,0.0018164543,0.00007240352,0.00029910286,0.000014270569,0.0000142313,0.0002887363],"genre_scores_gemma":[0.9975143,0.000335036,0.00020363962,0.0007191269,0.00015426699,0.000014986068,0.000030030616,0.000025247515,0.0010033876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902886,0.000091045105,0.00018850464,0.00016359583,0.0002985726,0.00022941294],"domain_scores_gemma":[0.99885386,0.000055956658,0.00027591534,0.00029409278,0.0001674804,0.0003527083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006245221,0.00018253816,0.00039830722,0.000080855425,0.00009312076,0.00004333405,0.00008268347,0.000009590567,0.000042049625],"category_scores_gemma":[0.000047669215,0.00008864869,0.00010606257,0.0002304648,0.00022986071,0.00009333968,0.00006014127,0.000102843514,0.0000029841349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012544955,0.0004496593,0.83543843,0.00020805009,0.0017480314,0.00066598045,0.0010685218,0.000025277684,0.00005006646,0.000014971309,0.0018552447,0.15722129],"study_design_scores_gemma":[0.0069751525,0.007919848,0.96544296,0.00069531635,0.0031248755,0.0000048156157,0.004635192,0.000017411938,0.0005882509,0.000014022495,0.010381608,0.00020053022],"about_ca_topic_score_codex":0.00000488838,"about_ca_topic_score_gemma":0.000013650547,"teacher_disagreement_score":0.15702076,"about_ca_system_score_codex":0.0002573473,"about_ca_system_score_gemma":0.00017784757,"threshold_uncertainty_score":0.36149886},"labels":[],"label_agreement":null},{"id":"W4200498388","doi":"10.1007/s10557-021-07308-6","title":"Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus","year":2021,"lang":"en","type":"erratum","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Myocardial infarction; Stroke (engine); Diabetes mellitus; Incidence (geometry); Type 2 Diabetes Mellitus; Internal medicine; Type 2 diabetes; Ischemic stroke; Cardiology; Intensive care medicine; Endocrinology; Ischemia","score_opus":0.0036856243073711365,"score_gpt":0.19047279683273033,"score_spread":0.1867871725253592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200498388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9338917,0.061710045,0.0000032863443,0.000082120685,0.001917844,0.0011349102,0.000007950458,0.0000073557308,0.0012448017],"genre_scores_gemma":[0.9832629,0.015599318,0.000013246837,0.00007376705,0.0001484231,0.00007108862,0.00019414724,0.000024325924,0.00061279384],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986929,0.00017550564,0.0002582355,0.00029404246,0.00041442714,0.00016487585],"domain_scores_gemma":[0.99922585,0.000053948817,0.00011548772,0.0004029131,0.00016705271,0.000034770892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054586557,0.00019648424,0.00062904705,0.00017541402,0.000045516066,0.00002310075,0.000043536304,0.00010361785,0.0000045069796],"category_scores_gemma":[0.00003749753,0.00011760894,0.00021643235,0.00037729958,0.00008348733,0.000060587277,0.00005448881,0.0002712747,3.608332e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011966948,0.000552196,0.1835506,0.0004004946,0.008656973,0.000009187519,0.0051876083,0.0007425707,0.00029595703,0.00004162192,0.0088670505,0.79049903],"study_design_scores_gemma":[0.008672202,0.0023309821,0.8884065,0.0030530512,0.0014629168,0.000002277942,0.0017928698,0.00031248486,0.0024234948,0.00007157835,0.09109144,0.00038019338],"about_ca_topic_score_codex":0.00038343688,"about_ca_topic_score_gemma":0.000038960035,"teacher_disagreement_score":0.7901189,"about_ca_system_score_codex":0.000061206425,"about_ca_system_score_gemma":0.000064176595,"threshold_uncertainty_score":0.47959533},"labels":[],"label_agreement":null},{"id":"W4200514620","doi":"10.1002/dmrr.3515","title":"Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta‐analysis of randomized controlled trials","year":2021,"lang":"en","type":"review","venue":"Diabetes/Metabolism Research and Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Calgary; Public Health Agency of Canada; University of Ottawa","funders":"","keywords":"Metformin; Medicine; Adverse effect; Type 2 diabetes; Internal medicine; Pharmacology; Randomized controlled trial; Diabetes mellitus; Hypoglycemia; Sitagliptin; Meta-analysis; Insulin; Endocrinology","score_opus":0.09614539618507106,"score_gpt":0.399473025514376,"score_spread":0.30332762932930496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200514620","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014126862,0.94571084,0.0000087011485,0.000044322103,0.00003531912,0.052625604,0.00011695977,0.00001192621,0.000033658693],"genre_scores_gemma":[0.00021640069,0.9890658,0.0015742312,0.00007104189,0.000040207273,0.007962607,0.0006970777,0.00006572503,0.00030687678],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9858679,0.0074697803,0.0042226887,0.0008815541,0.0008323533,0.00072569196],"domain_scores_gemma":[0.97895443,0.015682207,0.003253286,0.0008243589,0.0009930906,0.00029264562],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.021016989,0.001007913,0.08302217,0.0009530883,0.0001620275,0.00010112334,0.00022069759,0.00017763124,0.00004254934],"category_scores_gemma":[0.0037260454,0.0004215469,0.004671133,0.002497057,0.00045865754,0.00014938165,0.00013991827,0.00035727883,0.0000010594546],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037686604,0.00030046504,0.00006144178,0.5156953,0.4743385,0.0000014720252,0.000061966486,3.252024e-7,6.2899585e-7,0.00010406698,0.00026782302,0.0053993626],"study_design_scores_gemma":[0.06433159,0.000535691,0.000005685127,0.18540663,0.72917724,2.6913872e-7,0.00002127172,0.0000111205045,0.0000023747173,0.000008065358,0.020193402,0.0003066589],"about_ca_topic_score_codex":0.000004576476,"about_ca_topic_score_gemma":0.0000065918816,"teacher_disagreement_score":0.33028868,"about_ca_system_score_codex":0.000031109364,"about_ca_system_score_gemma":0.00019378557,"threshold_uncertainty_score":0.99982363},"labels":[],"label_agreement":null},{"id":"W4200569406","doi":"10.1097/mnh.0000000000000778","title":"Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression","year":2021,"lang":"en","type":"article","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"","keywords":"Kidney disease; Heart failure; Lead (geology); Cardiorenal syndrome; Disease; Kidney","score_opus":0.02208544761768798,"score_gpt":0.29981130450755905,"score_spread":0.27772585688987106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200569406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5777535,0.069649726,0.00015413397,0.33893034,0.007034026,0.0057189628,0.00020813277,0.0005249129,0.000026274349],"genre_scores_gemma":[0.9763249,0.0033552581,0.0009367196,0.010894904,0.0038759098,0.0011859592,0.0027463941,0.0001897468,0.00049017905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99446076,0.00032350144,0.0008208949,0.0019559106,0.00079019496,0.0016487216],"domain_scores_gemma":[0.9954654,0.00009756415,0.00016268542,0.0012681924,0.0002532091,0.0027529465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034523924,0.0008778314,0.0011974517,0.0006905377,0.00039553593,0.00013874278,0.0002897739,0.00027226593,0.00035222323],"category_scores_gemma":[0.00039882548,0.00071446423,0.00031989178,0.000931067,0.00028613818,0.00029462154,0.00087595143,0.00074582914,0.00027704562],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015406637,0.002348732,0.10760744,0.006547463,0.0004777237,0.00048640592,0.00026088938,0.00042015748,0.06584311,0.0005537379,0.7564461,0.05746752],"study_design_scores_gemma":[0.007903952,0.0020334523,0.052463755,0.008389606,0.00052271556,0.000056732468,0.00006291805,0.0026581457,0.0013034936,0.00010452614,0.9236224,0.0008782674],"about_ca_topic_score_codex":0.00003608908,"about_ca_topic_score_gemma":0.00033322402,"teacher_disagreement_score":0.39857143,"about_ca_system_score_codex":0.0019362405,"about_ca_system_score_gemma":0.003137532,"threshold_uncertainty_score":0.9995307},"labels":[],"label_agreement":null},{"id":"W4200570113","doi":"10.2174/1573399818666211216144900","title":"Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure inPatients with Type 2 Diabetes?","year":2021,"lang":"en","type":"article","venue":"Current Diabetes Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Type 2 diabetes; Dipeptidyl peptidase-4; Diabetes mellitus; Intensive care medicine; Clinical trial; Heart failure; Linagliptin; Bioinformatics; Pharmacology; Internal medicine; Endocrinology","score_opus":0.01944323695489544,"score_gpt":0.27357652188541176,"score_spread":0.25413328493051635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200570113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9105864,0.08611275,0.0000024114722,0.00042974873,0.00042199163,0.0016230517,0.00004025544,0.000050299015,0.0007330941],"genre_scores_gemma":[0.9835368,0.012906374,0.0011447511,0.00062683935,0.00034002378,0.0003966061,0.000532756,0.000078338286,0.00043754926],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972642,0.00039516605,0.0007156192,0.0005440051,0.000514177,0.0005668008],"domain_scores_gemma":[0.99771696,0.00016460671,0.00045164512,0.0010977165,0.0003124477,0.00025663138],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062128843,0.0004387846,0.0010610811,0.00012479266,0.00013105344,0.000057832756,0.00019859245,0.00006990248,0.0004068033],"category_scores_gemma":[0.00054191233,0.00024636972,0.000395512,0.00093633065,0.00018188848,0.00015792598,0.00021322237,0.00035622556,0.00025987905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019942334,0.0008156742,0.853661,0.0013270013,0.0003820727,0.0000032277871,0.00011139687,0.000002501289,0.00059253664,0.000041142568,0.07652013,0.0665234],"study_design_scores_gemma":[0.0018810825,0.0008149755,0.073068045,0.004211035,0.0020847104,8.6871864e-7,0.00009228002,0.000035189743,0.006377481,0.00006430566,0.9109894,0.0003806297],"about_ca_topic_score_codex":0.000004022777,"about_ca_topic_score_gemma":0.000008434958,"teacher_disagreement_score":0.83446926,"about_ca_system_score_codex":0.000079913414,"about_ca_system_score_gemma":0.000105463565,"threshold_uncertainty_score":0.99999887},"labels":[],"label_agreement":null},{"id":"W4200603578","doi":"10.1111/dom.14622","title":"Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis from 2010 to 2020","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Care; Lawson Health Research Institute; Western University","funders":"Schulich School of Medicine and Dentistry; Western University; Ontario Ministry of Health and Long-Term Care; Academic Medical Organization of Southwestern Ontario; Lawson Health Research Institute","keywords":"Medicine; Insulin glargine; Kidney disease; Insulin degludec; Medical prescription; Diabetes mellitus; Internal medicine; Population; Type 2 diabetes; Intensive care medicine; Endocrinology; Pharmacology; Environmental health","score_opus":0.005974535116680456,"score_gpt":0.19893583274309798,"score_spread":0.19296129762641753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200603578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996069,0.0019197318,0.0000050979074,0.0013469264,0.00009876917,0.00037174587,0.00010214156,0.000013830299,0.00007277179],"genre_scores_gemma":[0.9951072,0.000029686556,0.00040361375,0.0015384445,0.000041883945,0.000094466624,0.0021712822,0.000014951871,0.0005984792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983705,0.00007782277,0.00030668417,0.0005485898,0.00028363866,0.00041274147],"domain_scores_gemma":[0.9991152,0.000038687496,0.00005339412,0.00032110006,0.000038978866,0.00043259875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011592999,0.00023284816,0.0006530028,0.000644582,0.000033115324,0.00003431664,0.00006857226,0.000058278285,0.00051983155],"category_scores_gemma":[0.000061047715,0.00021263614,0.000077450684,0.0015211892,0.000014181053,0.00013082643,0.00006798042,0.00019936662,0.0000015797874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001369022,0.0005204888,0.9940035,0.0000539491,0.00023877138,0.00019514344,0.0003564576,0.0006279952,0.000021699032,0.000010789955,0.00031997316,0.003514357],"study_design_scores_gemma":[0.0059972657,0.00002799988,0.9890877,0.00037175292,0.0009333391,2.5954472e-8,0.00003358229,0.0022494057,0.00015477424,0.000014021245,0.0009097057,0.00022043801],"about_ca_topic_score_codex":0.91314965,"about_ca_topic_score_gemma":0.99620324,"teacher_disagreement_score":0.08305359,"about_ca_system_score_codex":0.0004812565,"about_ca_system_score_gemma":0.00069885503,"threshold_uncertainty_score":0.867105},"labels":[],"label_agreement":null},{"id":"W4205103349","doi":"10.1007/s00592-021-01823-6","title":"Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial","year":2022,"lang":"en","type":"article","venue":"Acta Diabetologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen's University; Sunnybrook Health Science Centre; University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Cardiology; Internal medicine; Coronary artery disease; Diabetes mellitus; Type 2 Diabetes Mellitus; Randomized controlled trial; EMPA; Diastole; Type 2 diabetes; Diabetic cardiomyopathy; Heart failure; Blood pressure; Endocrinology; Cardiomyopathy","score_opus":0.015597325478907811,"score_gpt":0.2485314688016832,"score_spread":0.2329341433227754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205103349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127185,0.0028687282,0.0000016035065,0.0011976218,0.00084540556,0.0035975995,0.00006506124,0.00008004732,0.00007209239],"genre_scores_gemma":[0.99641544,0.00030722033,0.000028800694,0.0018165099,0.00021162917,0.00043435855,0.00068098784,0.000028525923,0.00007655505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963138,0.0015993315,0.00053558085,0.0006162478,0.00050010387,0.00043490453],"domain_scores_gemma":[0.99701715,0.00202054,0.00018755588,0.0005311333,0.000048192873,0.0001954305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011269598,0.00032038285,0.0012285138,0.00011414485,0.00022155876,0.000043497523,0.00015938944,0.00009105771,0.00025064618],"category_scores_gemma":[0.00051762915,0.00016293438,0.00028663027,0.00022878475,0.00023790644,0.000113136055,0.0002587177,0.00038648958,0.0000132268815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18339115,0.0010311861,0.80952984,0.00001625594,0.0010259366,0.00007710433,0.00008797522,0.000007742886,0.0000074309287,0.000012248992,0.001040389,0.0037727612],"study_design_scores_gemma":[0.21934146,0.0020408025,0.77066797,0.000033528275,0.0014353954,4.683617e-7,0.000046249042,0.000054934615,0.000010892212,0.00010555829,0.0060758707,0.00018687245],"about_ca_topic_score_codex":0.00001277893,"about_ca_topic_score_gemma":0.0000062671056,"teacher_disagreement_score":0.03886184,"about_ca_system_score_codex":0.00008751298,"about_ca_system_score_gemma":0.000059642847,"threshold_uncertainty_score":0.66442704},"labels":[],"label_agreement":null},{"id":"W4205144121","doi":"10.1111/dom.14637","title":"<scp>Glucagon‐like peptide</scp> ‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Type 2 diabetes; Type 1 diabetes; Glucagon-like peptide-1; Narrative review; Adjunctive treatment; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.18476293404873256,"score_gpt":0.3183659521337006,"score_spread":0.13360301808496805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205144121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011629241,0.9701374,0.0000039673323,0.00010142816,0.0018942547,0.0066223987,0.0008329053,0.00030635938,0.008472026],"genre_scores_gemma":[0.00007071307,0.9451338,0.0011526446,0.00065176794,0.00075952336,0.005057913,0.012471495,0.00027004135,0.034432087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947583,0.00043154933,0.0010454981,0.0016438054,0.00064819056,0.0014726258],"domain_scores_gemma":[0.99632734,0.00094293384,0.0008093246,0.0011703776,0.00016987903,0.0005801645],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006298644,0.0016654205,0.0050892546,0.0005346887,0.0006542911,0.00021603155,0.00041971428,0.00056520663,0.00032074374],"category_scores_gemma":[0.0003531109,0.0013338763,0.0015379982,0.00062241533,0.00033692986,0.00037634617,0.0004311298,0.00048664634,0.00010093189],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049665443,0.0026100564,0.00023810394,0.018775025,0.0124312695,0.00003645555,0.0014425117,9.957084e-7,0.0000054914726,0.0038477783,0.028750554,0.9318121],"study_design_scores_gemma":[0.0028663583,0.0015510597,0.00010848636,0.0016908512,0.018891033,0.0000030007718,0.00073042116,0.000010150929,0.00008579664,0.00043200186,0.9730594,0.0005714157],"about_ca_topic_score_codex":0.000040079423,"about_ca_topic_score_gemma":0.000006330298,"teacher_disagreement_score":0.9443089,"about_ca_system_score_codex":0.00051751593,"about_ca_system_score_gemma":0.00066120306,"threshold_uncertainty_score":0.9996093},"labels":[],"label_agreement":null},{"id":"W4205183771","doi":"10.2337/dc21-1744","title":"Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"St. Jude Medical; Esperion Therapeutics; Silence Therapeutics; Idorsia Pharmaceuticals; Duke Clinical Research Institute; FibroGen; Eisai; Servier; Pfizer; Moderna; HLS Therapeutics; IFM Therapeutics; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Boston Scientific Corporation; Akebia Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Novo Nordisk; MyoKardia; Sanofi; Amgen; Daiichi-Sankyo; Medicines Company; Intarcia Therapeutics; Teva Pharmaceutical Industries; U.S. Department of Veterans Affairs","keywords":"Medicine; Dapagliflozin; Internal medicine; Myocardial infarction; Mace; Hazard ratio; Population; Diabetes mellitus; Cardiology; Stroke (engine); Type 2 diabetes; TIMI; Placebo; Heart failure; Endocrinology; Percutaneous coronary intervention; Confidence interval","score_opus":0.014861781158885777,"score_gpt":0.24981484117305536,"score_spread":0.23495306001416957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205183771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360234,0.004531617,0.00002966737,0.0003238864,0.000059941514,0.00034021403,0.00031099172,0.000046180925,0.00075519155],"genre_scores_gemma":[0.9968211,0.00004791982,0.0009162235,0.00036921966,0.00003982272,0.00009451783,0.0011924905,0.00002204583,0.00049662637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866045,0.00009633708,0.00018351506,0.00026754604,0.00058786303,0.00020431772],"domain_scores_gemma":[0.999244,0.00011892725,0.00010688948,0.00034440137,0.00011658298,0.000069214424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020977031,0.0001526001,0.00053626084,0.00012217768,0.00008493412,0.00001380496,0.00006246872,0.000033976008,0.00019122577],"category_scores_gemma":[0.000060429975,0.000118562726,0.00022934722,0.00020955595,0.000020867868,0.000051631494,0.000101959966,0.0000971484,0.000004949418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025655261,0.00008503271,0.98462415,0.00008370079,0.0054866225,0.000015049582,0.0003537454,0.00033194586,0.0005024382,0.0000039427778,0.0015898909,0.006897803],"study_design_scores_gemma":[0.0063876887,0.0009973272,0.9176635,0.00011422327,0.011192112,3.283706e-7,0.0041838083,0.00042346687,0.00871866,0.0000356053,0.049942777,0.00034048798],"about_ca_topic_score_codex":0.000083223655,"about_ca_topic_score_gemma":0.000023434304,"teacher_disagreement_score":0.066960655,"about_ca_system_score_codex":0.0001889209,"about_ca_system_score_gemma":0.000028221815,"threshold_uncertainty_score":0.48348475},"labels":[],"label_agreement":null},{"id":"W4205252071","doi":"10.1053/j.ackd.2021.11.002","title":"A New Therapeutic Era in the Management of Diabetic Kidney Disease","year":2021,"lang":"en","type":"editorial","venue":"Advances in Chronic Kidney Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; Department of Medicine, University of Toronto; Diabetes Canada; Joslin Diabetes Center","keywords":"Medicine; Disease; Kidney disease; Intensive care medicine; Clinical trial; Clinical Practice; Internal medicine; Family medicine","score_opus":0.007437004482449932,"score_gpt":0.28962909527338326,"score_spread":0.2821920907909333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205252071","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055870024,0.42941687,0.00022522443,0.010059221,0.5319274,0.008626165,0.0016820172,0.00019207314,0.017312327],"genre_scores_gemma":[0.05194403,0.27659887,0.001768575,0.010376405,0.599086,0.00516506,0.025102116,0.00060526293,0.029353706],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959055,0.00018011325,0.00074965024,0.00097117346,0.001413626,0.00077991385],"domain_scores_gemma":[0.99648327,0.00026727258,0.00027623214,0.0015399336,0.00007630089,0.0013569939],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031618497,0.0006529971,0.00089770416,0.00032331934,0.000051331084,0.000058988127,0.00067334296,0.00017078457,0.0007654023],"category_scores_gemma":[0.0003612355,0.0004984932,0.0004023665,0.0007565426,0.00015041904,0.0002594076,0.00026434826,0.0006446019,0.000040143903],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007776333,0.0014680702,0.0024113688,0.014363242,0.000747094,0.0023210128,0.00013197801,0.00010520876,0.0000023466941,0.0010626789,0.924714,0.05189535],"study_design_scores_gemma":[0.008002829,0.0002163887,0.003110879,0.008673964,0.0027994462,1.7159819e-7,0.000108031905,0.000093829585,0.000005365251,0.002318315,0.97421443,0.0004563426],"about_ca_topic_score_codex":0.00003900254,"about_ca_topic_score_gemma":0.00002641216,"teacher_disagreement_score":0.15281798,"about_ca_system_score_codex":0.0011750397,"about_ca_system_score_gemma":0.005109767,"threshold_uncertainty_score":0.9997467},"labels":[],"label_agreement":null},{"id":"W4205521731","doi":"10.2337/dbi20-0049","title":"Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials","year":2022,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Incretin; Medicine; Diabetes mellitus; Glycemic; Type 2 diabetes; Clinical trial; Glucagon-like peptide-1; Bioinformatics; Hormone; Disease; Type 2 Diabetes Mellitus; Internal medicine; Pharmacology; Endocrinology; Biology","score_opus":0.04606818369049879,"score_gpt":0.2972898569937763,"score_spread":0.2512216733032775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205521731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026605386,0.992259,0.00058217824,0.000009053697,0.000375296,0.0055700643,0.000046222805,0.00016371161,0.0007283644],"genre_scores_gemma":[0.00044039657,0.99147326,0.0034423182,0.000112101836,0.00015666183,0.003284925,0.0006954694,0.00023526417,0.00015963391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942468,0.0016151245,0.0013335401,0.00083681295,0.0013779104,0.0005898258],"domain_scores_gemma":[0.9950026,0.0021925466,0.00071346975,0.0018520545,0.000087775596,0.0001515084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043569254,0.0009456952,0.010690195,0.00058680377,0.00011484082,0.000042214346,0.0003692866,0.00024241548,0.0001767768],"category_scores_gemma":[0.0009967333,0.0005859007,0.008443568,0.00070583256,0.00009462483,0.000051590203,0.00015619733,0.00048085768,0.00001437373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013801525,0.00017787442,0.00015203629,0.07251195,0.061417118,0.00010742437,0.0000482311,0.000010745721,0.000003532197,0.0002285921,0.000047812428,0.86528087],"study_design_scores_gemma":[0.0027395599,0.0011489632,0.000008126119,0.014100902,0.07712942,0.0000018293202,0.00006547799,0.000008829006,0.0002860359,0.000029481587,0.90392905,0.0005523179],"about_ca_topic_score_codex":0.000045715544,"about_ca_topic_score_gemma":5.2745713e-7,"teacher_disagreement_score":0.90388125,"about_ca_system_score_codex":0.00028742655,"about_ca_system_score_gemma":0.00024181658,"threshold_uncertainty_score":0.99965924},"labels":[],"label_agreement":null},{"id":"W4206145164","doi":"10.1111/dom.14634","title":"Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the <scp>REWIND</scp> randomized trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université Laval; Population Health Research Institute; Hamilton Health Sciences; University of Toronto; St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Atrial fibrillation; Post-hoc analysis; Internal medicine; Heart failure; Placebo; Atrial flutter; Cardiology; Stroke (engine); Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Exenatide; Endocrinology","score_opus":0.0062953249637689975,"score_gpt":0.20741575548699737,"score_spread":0.20112043052322837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206145164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927126,0.004074068,0.0000025254237,0.00022972956,0.000328279,0.0024581086,0.000106125495,0.000037376798,0.000051176445],"genre_scores_gemma":[0.997237,0.0002649639,0.00014615779,0.00089146366,0.0003243128,0.00008884626,0.00076046825,0.000023720893,0.00026303323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767,0.0004947896,0.00042324926,0.0004750452,0.00052743824,0.00040946816],"domain_scores_gemma":[0.99821556,0.000990431,0.00022437106,0.00034312383,0.000092370334,0.00013414191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886047,0.00029341047,0.00119772,0.00033511824,0.0002678502,0.000099923294,0.0001096683,0.00006945318,0.000109049004],"category_scores_gemma":[0.00047238657,0.00017528933,0.0002665203,0.000815077,0.00012961235,0.00017904006,0.00025923227,0.0001962786,0.0000045310917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056791823,0.00020565726,0.9343372,0.00002255588,0.003420095,0.0000049653677,0.00096887356,0.000070308786,0.000018141815,0.00004022689,0.00018486819,0.0039353105],"study_design_scores_gemma":[0.32429478,0.00056410895,0.6647271,0.00001777078,0.0061527337,5.101351e-8,0.00011276557,0.0003258349,0.00001840479,0.00007242523,0.0036320721,0.00008198286],"about_ca_topic_score_codex":0.00015646819,"about_ca_topic_score_gemma":0.00008603033,"teacher_disagreement_score":0.26961008,"about_ca_system_score_codex":0.000056590467,"about_ca_system_score_gemma":0.00005301707,"threshold_uncertainty_score":0.7148091},"labels":[],"label_agreement":null},{"id":"W4206193390","doi":"10.1016/j.kint.2019.09.027","title":"The authors reply","year":2019,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine","score_opus":0.014522318577036961,"score_gpt":0.2685287189511979,"score_spread":0.25400640037416095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206193390","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023658084,0.000050627237,0.00000996705,0.77824146,0.004876258,0.00031130202,0.0000528471,0.00005273194,0.21638115],"genre_scores_gemma":[0.00006574512,0.00004721343,0.000111925285,0.56472325,0.0031746454,0.000038354257,0.0015251208,0.000021725817,0.43029204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986845,0.000020108408,0.00020978544,0.00027755267,0.0005835296,0.00022448406],"domain_scores_gemma":[0.9991707,0.00010245347,0.00011941255,0.00044333373,0.00010328776,0.000060771694],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001326534,0.0001787775,0.00017795837,0.00010579203,0.000055687993,0.00009715211,0.00030409478,0.00016719764,0.00097598723],"category_scores_gemma":[0.0002598095,0.00011228297,0.00018871139,0.000043046468,0.000045901175,0.00004079107,0.000105022846,0.00059427315,0.0018642053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014752405,0.000021001932,0.00064613466,0.000034665616,0.0009956753,0.00013529272,0.000013990245,1.10143894e-7,0.0000033566357,0.0005099561,0.9954665,0.0021585897],"study_design_scores_gemma":[0.0005837433,0.000060736205,0.00047155426,0.00012409363,0.0002049005,0.000010062724,0.0000044741337,0.000054765263,0.000019848725,0.00022910861,0.9981309,0.00010580732],"about_ca_topic_score_codex":0.00001348661,"about_ca_topic_score_gemma":3.868193e-7,"teacher_disagreement_score":0.2139109,"about_ca_system_score_codex":0.0001810743,"about_ca_system_score_gemma":0.00013247685,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W4206323065","doi":"10.1136/bmjdrc-2021-002207","title":"Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline","year":2022,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Glycemic; Balance (ability); Baseline (sea); Diabetes mellitus; Randomized controlled trial; Population; Research design; Body weight","score_opus":0.03407773991031357,"score_gpt":0.3562069094858895,"score_spread":0.3221291695755759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206323065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655305,0.01022839,3.9368007e-7,0.0013697903,0.000074449774,0.020636145,0.0008917169,0.000019855743,0.0012487584],"genre_scores_gemma":[0.9902015,0.0010428972,0.00020119008,0.00032363363,0.000042684544,0.005252861,0.0020574294,0.000043083484,0.0008347427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937951,0.0026140516,0.00082622207,0.00070258125,0.001238973,0.00082305545],"domain_scores_gemma":[0.9936552,0.0049227634,0.00022272106,0.0007712384,0.00018569948,0.0002423629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00429737,0.00029398326,0.0012259957,0.00015957924,0.0003893419,0.00017769022,0.0004544296,0.00006490263,0.0004672509],"category_scores_gemma":[0.0017202838,0.00020609985,0.00010981714,0.0004868367,0.00044843476,0.00016253156,0.0022336668,0.00046654916,0.000003237987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60226786,0.001825466,0.27798826,0.00080029265,0.0016065608,0.00007945844,0.010267867,0.00006879716,0.006093086,0.0002190387,0.042806286,0.055977046],"study_design_scores_gemma":[0.89912474,0.0038672097,0.06639709,0.00066193915,0.0003386142,2.3815548e-7,0.005808807,0.0012781845,0.0041461443,0.00023511265,0.017689286,0.00045260089],"about_ca_topic_score_codex":0.0011055231,"about_ca_topic_score_gemma":0.00044827352,"teacher_disagreement_score":0.2968569,"about_ca_system_score_codex":0.0003236388,"about_ca_system_score_gemma":0.00016892799,"threshold_uncertainty_score":0.8404508},"labels":[],"label_agreement":null},{"id":"W4206381116","doi":"10.1007/s10557-021-07309-5","title":"Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”","year":2022,"lang":"en","type":"letter","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Stroke (engine); Incidence (geometry); Myocardial infarction; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Type 2 diabetes; Cardiology; Ischemic stroke; Infarction; Endocrinology; Ischemia","score_opus":0.005263621629368385,"score_gpt":0.18851234008850912,"score_spread":0.18324871845914073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206381116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94747853,0.005853007,6.987611e-7,0.04484892,0.00010659561,0.0015681657,0.000015198602,0.000006003031,0.00012286783],"genre_scores_gemma":[0.9554147,0.0010339331,0.0000073171914,0.04303302,0.00014455388,0.00019856017,0.00006997075,0.000030273459,0.00006765044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805415,0.0006158962,0.0002425037,0.00029502605,0.00059492956,0.00019750129],"domain_scores_gemma":[0.99899143,0.00022774488,0.00010379841,0.00059019943,0.000066631845,0.00002017441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013516343,0.00020835815,0.0005035951,0.00020525286,0.00007492765,0.000021962407,0.00008522919,0.00008927872,0.000015133138],"category_scores_gemma":[0.00003408505,0.00010541786,0.0002226351,0.0003022232,0.00011416035,0.000041438463,0.00007669591,0.00044838703,8.3371725e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036292695,0.0013946617,0.24178593,0.0007869144,0.03336752,0.00016997477,0.029042631,0.003037265,0.0026033258,0.00020526446,0.13743187,0.5138819],"study_design_scores_gemma":[0.0070142676,0.0033518672,0.21337269,0.00062609883,0.00069993635,0.0000012763118,0.00056561024,0.000028938764,0.0016233921,0.00008944233,0.7723242,0.0003022543],"about_ca_topic_score_codex":0.00011545645,"about_ca_topic_score_gemma":0.000002460917,"teacher_disagreement_score":0.63489234,"about_ca_system_score_codex":0.00006893473,"about_ca_system_score_gemma":0.000028403447,"threshold_uncertainty_score":0.42988154},"labels":[],"label_agreement":null},{"id":"W4206445899","doi":"10.1056/nejmoa1901118","title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1932,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Ted Rogers Centre for Heart Research","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology","score_opus":0.006867429810484486,"score_gpt":0.21579295578609767,"score_spread":0.20892552597561317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206445899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553823,0.0019099467,0.0000043224454,0.0010803204,0.0002563001,0.00023549875,3.3715102e-7,0.000005470599,0.00096956134],"genre_scores_gemma":[0.9982768,0.000116488496,0.00034456965,0.00034490347,0.00019796452,5.037783e-7,0.000004746511,0.000011920399,0.0007020452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990438,0.00003171226,0.00023844975,0.00010337639,0.00042499654,0.00015764915],"domain_scores_gemma":[0.9994558,0.00005607707,0.00008546193,0.00015586344,0.00009889534,0.00014790794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041824902,0.00012037105,0.00066196907,0.00019071209,0.000008951669,0.0000048730776,0.000042928423,0.000026143036,0.00009671512],"category_scores_gemma":[0.0000811115,0.000062023224,0.000052040585,0.00012614964,0.00003459597,0.00006027096,0.000016890166,0.00012841691,0.000005392189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031364404,0.00008164809,0.9253252,0.000042467746,0.00077737356,0.00004345698,0.0001271005,0.0000150033175,0.000016621058,0.000011796583,0.00063419435,0.07261149],"study_design_scores_gemma":[0.07911597,0.0041684634,0.8984727,0.0003607375,0.0006106264,0.000007216791,0.000049936792,0.000007847475,0.000019377767,0.000045953828,0.017076341,0.00006482471],"about_ca_topic_score_codex":0.000024761097,"about_ca_topic_score_gemma":0.00000769666,"teacher_disagreement_score":0.07880233,"about_ca_system_score_codex":0.000027815304,"about_ca_system_score_gemma":0.000032714775,"threshold_uncertainty_score":0.25292337},"labels":[],"label_agreement":null},{"id":"W4206482853","doi":"10.1093/eurheartj/ehab876","title":"The year in cardiovascular medicine 2021: diabetes and metabolic disorders","year":2021,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Obesity; Disease; Kidney disease; Type 2 diabetes; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.03687959996257272,"score_gpt":0.30326078727856814,"score_spread":0.2663811873159954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206482853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000494386,0.98619455,0.0000015932874,0.0006805803,0.0004328259,0.00044349363,0.00000158821,0.000011171065,0.012184784],"genre_scores_gemma":[0.000036121208,0.99689066,0.00007446528,0.000111060945,0.0010475657,0.000011736597,0.000021470958,0.00007584497,0.0017310621],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742585,0.000985462,0.00049975706,0.00030205556,0.00039468432,0.00039218375],"domain_scores_gemma":[0.99899673,0.0001736347,0.00012509945,0.00047131447,0.000035120807,0.00019810778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021315785,0.0003232673,0.00180658,0.00022634387,0.00016948716,0.000099478755,0.00013959451,0.000045927696,0.00012664695],"category_scores_gemma":[0.00019956594,0.00017538603,0.0007605355,0.00032488172,0.00012799687,0.000049823168,0.00020832734,0.0006470274,0.00009442021],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000013100116,0.000029627823,0.0007194377,0.0007047332,0.0018403734,0.00020849983,0.00003931745,2.5574624e-7,6.839066e-8,0.00007633608,0.008888186,0.98749185],"study_design_scores_gemma":[0.0007647516,0.00010768395,0.0022827731,0.008419062,0.0033713083,0.00009415356,0.00007467837,5.846596e-7,7.247464e-8,0.000012709234,0.98472697,0.00014525143],"about_ca_topic_score_codex":0.0000024023307,"about_ca_topic_score_gemma":0.0000022609647,"teacher_disagreement_score":0.9873466,"about_ca_system_score_codex":0.000045175464,"about_ca_system_score_gemma":0.00007575208,"threshold_uncertainty_score":0.71520346},"labels":[],"label_agreement":null},{"id":"W4206524","doi":"10.1136/jim-52-06-30","title":"Effects of Type 2 Diabetes on the Regulation of Hepatic Glucose Metabolism","year":2004,"lang":"en","type":"review","venue":"Journal of Investigative Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"","keywords":"Internal medicine; Endocrinology; Insulin; Postprandial; Glucagon; Diabetes mellitus; Carbohydrate metabolism; Stimulation; Basal (medicine); Medicine; Glucose uptake; Type 2 diabetes; Ingestion; Biology","score_opus":0.04382331428193785,"score_gpt":0.30343605028636833,"score_spread":0.25961273600443047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012685781,0.9840944,0.000004234179,0.0010889089,0.00047847393,0.0011555789,0.0000026887885,0.0000059813256,0.0004839888],"genre_scores_gemma":[0.008128647,0.99050295,0.0003563145,0.00023379756,0.00042311093,0.000017540335,0.000022109656,0.0000408185,0.0002746934],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972466,0.00032269626,0.0013036018,0.0001539508,0.0007943506,0.0001787642],"domain_scores_gemma":[0.99522805,0.0011249133,0.0026779198,0.0003083795,0.0004986046,0.00016214594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090527494,0.00037383268,0.0029873734,0.0005390007,0.000027061096,0.00000339303,0.00020978635,0.000119898556,0.00006737384],"category_scores_gemma":[0.0027034197,0.00016764685,0.0004342421,0.00069450116,0.00087772676,0.000057783385,0.000038371873,0.00040850023,0.00000682379],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019147074,0.0014351895,0.00015474022,0.20538728,0.014622865,0.00012184375,0.001988588,0.000014979997,0.0055038966,0.022539306,0.008456793,0.7395831],"study_design_scores_gemma":[0.0060597733,0.011837191,0.00444567,0.55937546,0.04702729,0.000023832712,0.00011871686,0.00001091763,0.035596084,0.011986023,0.323132,0.00038702806],"about_ca_topic_score_codex":0.0000063362145,"about_ca_topic_score_gemma":2.9075437e-7,"teacher_disagreement_score":0.739196,"about_ca_system_score_codex":0.00016035013,"about_ca_system_score_gemma":0.00036535176,"threshold_uncertainty_score":0.68364406},"labels":[],"label_agreement":null},{"id":"W4206528639","doi":"10.1111/dom.14645","title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Prediabetes; Placebo; Medicine; Internal medicine; Diabetes mellitus; Gastroenterology; Impaired fasting glucose; Type 2 diabetes; Post-hoc analysis; Endocrinology; Impaired glucose tolerance","score_opus":0.0415527206936868,"score_gpt":0.32807263884282367,"score_spread":0.28651991814913685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206528639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96664184,0.02897818,0.0000073798215,0.00007837808,0.00016755336,0.0014227679,0.00266371,0.000032889584,0.0000072948405],"genre_scores_gemma":[0.99392927,0.0011337098,0.0007613159,0.00044691455,0.00008157024,0.00003477749,0.0035670002,0.000032411415,0.000013044161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963155,0.0007948563,0.0010290231,0.0008969851,0.00046199778,0.00050168607],"domain_scores_gemma":[0.99722296,0.0010316686,0.000527684,0.00078023167,0.00013813998,0.00029929343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024531165,0.00039035192,0.0025424769,0.0006240999,0.00016271407,0.000059383634,0.00023486953,0.00013386415,0.00009736962],"category_scores_gemma":[0.0006984443,0.00031612662,0.00013979987,0.0008788212,0.00024902125,0.00030156202,0.00055403623,0.0003420397,8.325677e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001839643,0.0025395977,0.95004195,0.00010083206,0.007720016,0.0000065637137,0.00017819593,0.000010721324,0.0016033563,0.00001851422,0.00005388279,0.035886712],"study_design_scores_gemma":[0.037496667,0.0017866316,0.9245165,0.00007976056,0.030217327,9.8857925e-8,0.00006311762,0.003982447,0.00026354904,0.000034549932,0.0012383441,0.00032100733],"about_ca_topic_score_codex":0.000082842234,"about_ca_topic_score_gemma":0.000031449737,"teacher_disagreement_score":0.035657022,"about_ca_system_score_codex":0.000035732006,"about_ca_system_score_gemma":0.000079728095,"threshold_uncertainty_score":0.9999291},"labels":[],"label_agreement":null},{"id":"W4206566081","doi":"10.2337/db19-1228-p","title":"1228-P: Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Genital Mycotic and Urinary Tract Infections: A Population-Based Study of Older Women and Men with Diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Systems, Applications & Products in Data Processing (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Diabetes mellitus; Internal medicine; Genitourinary system; Urinary system; Population; Dapagliflozin; Cohort study; Gynecology; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.004113004948241882,"score_gpt":0.20393775680984902,"score_spread":0.19982475186160714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206566081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976973,0.0007151924,5.0559305e-7,0.000019459769,0.000026363938,0.0013417255,0.00001840957,0.00003040413,0.00015064096],"genre_scores_gemma":[0.99957997,0.000045175366,0.00005995476,0.000024267423,0.000015781654,0.00010243419,0.000039294875,0.000024559338,0.000108561784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894863,0.000045918856,0.0002799885,0.0002898646,0.00019514207,0.00024047175],"domain_scores_gemma":[0.9993141,0.00016105351,0.00016027792,0.0002054762,0.000050867253,0.00010821255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016790346,0.00020774698,0.00048408346,0.00022810377,0.000046351674,0.000016382011,0.000027602566,0.00005053488,0.000038567498],"category_scores_gemma":[0.000014699008,0.00015691342,0.00003419739,0.00014659294,0.00007166302,0.00015405111,0.000025022624,0.00008103575,0.0000011764268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005698922,0.0029169386,0.9919273,0.0005529508,0.0006304144,0.0000033725562,0.0014512832,0.000010250076,0.0007713868,0.0000039225883,0.000006940927,0.0016682149],"study_design_scores_gemma":[0.0057465625,0.007467691,0.98239475,0.00016960209,0.0007549811,2.9605647e-7,0.00091887766,0.00031275596,0.0020391312,0.000029513101,0.0000102131535,0.00015561473],"about_ca_topic_score_codex":0.0000649954,"about_ca_topic_score_gemma":0.0000062528375,"teacher_disagreement_score":0.009532575,"about_ca_system_score_codex":0.00002788363,"about_ca_system_score_gemma":0.0000151878185,"threshold_uncertainty_score":0.63987434},"labels":[],"label_agreement":null},{"id":"W4206605138","doi":"10.2337/dc21-1160","title":"HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Wellcome Trust","keywords":"Dulaglutide; Medicine; Post-hoc analysis; Placebo; Diabetes mellitus; Glycated hemoglobin; Internal medicine; Type 2 diabetes; Surgery; Endocrinology; Exenatide","score_opus":0.005503052521459519,"score_gpt":0.2101760020309916,"score_spread":0.20467294950953208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206605138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950942,0.002542471,3.2300056e-7,0.00015553446,0.00011636893,0.0014338007,0.00059157965,0.000016632564,0.000049080987],"genre_scores_gemma":[0.99574894,0.000037674257,0.000031912186,0.000050941206,0.00004137724,0.00019772725,0.0038500358,0.000016868698,0.000024500776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984584,0.00020330398,0.00040146685,0.00034840155,0.00038607334,0.00020235326],"domain_scores_gemma":[0.99901694,0.000093643815,0.00023654642,0.00039842963,0.0001903978,0.000064057574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015762109,0.00016840348,0.0004840123,0.00032752697,0.00009135573,0.000013842821,0.00009258069,0.000036338173,0.00006446465],"category_scores_gemma":[0.00009928366,0.00013413734,0.0002558484,0.0008986146,0.00007959148,0.000084041036,0.00012788363,0.00010254864,0.0000012699003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002231881,0.00046784565,0.98730206,0.00007256819,0.0022770455,0.0000019156214,0.0013681378,0.00006771127,0.0019684285,0.0000099537465,0.00011841737,0.0041140025],"study_design_scores_gemma":[0.016142258,0.0011888228,0.97172165,0.00006194282,0.004646663,1.0863414e-8,0.0023386045,0.00012827865,0.00345176,0.00004722459,0.00015211133,0.00012068349],"about_ca_topic_score_codex":0.00017085792,"about_ca_topic_score_gemma":0.000055102715,"teacher_disagreement_score":0.015580452,"about_ca_system_score_codex":0.00018987108,"about_ca_system_score_gemma":0.00003845839,"threshold_uncertainty_score":0.54699624},"labels":[],"label_agreement":null},{"id":"W4206994334","doi":"10.2215/cjn.08980621","title":"Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Creatinine; Credence; Internal medicine; Randomized controlled trial; Renal function; Kidney disease; Placebo; Pathology; Statistics; Mathematics","score_opus":0.024229225704604646,"score_gpt":0.34675984101303353,"score_spread":0.32253061530842886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206994334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97824043,0.00009925844,0.00018433144,0.020576583,0.00027928266,0.0005805584,0.0000023303912,0.0000011723489,0.000036036545],"genre_scores_gemma":[0.9943429,0.00014083985,0.00025258076,0.005123334,0.00008180859,0.000008212957,8.679167e-7,0.0000050395633,0.000044372468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743754,0.0010105956,0.00086762256,0.00009963212,0.00045154782,0.00013308805],"domain_scores_gemma":[0.99688834,0.0012537601,0.0014653608,0.00027751658,0.00009095634,0.000024086881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018154734,0.000075716525,0.00052867475,0.000045800043,0.000050924213,0.0000020497587,0.00042939757,0.000035155335,0.000013299718],"category_scores_gemma":[0.00032171333,0.00004011846,0.0006861754,0.000526124,0.0011160421,0.000020944546,0.00020701812,0.00042684368,2.2071893e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087465346,0.04929782,0.3545668,0.0008594357,0.005758967,0.00012531219,0.031376228,0.13780831,0.052509785,0.00299925,0.1790033,0.09822943],"study_design_scores_gemma":[0.024236238,0.0071687014,0.9559936,0.00008417431,0.0007207326,0.000014927368,0.0039127422,0.004130468,0.0002547625,0.00026815338,0.0031553474,0.000060144335],"about_ca_topic_score_codex":0.000047617326,"about_ca_topic_score_gemma":0.000005944122,"teacher_disagreement_score":0.6014268,"about_ca_system_score_codex":0.00007026624,"about_ca_system_score_gemma":0.0001281635,"threshold_uncertainty_score":0.41121036},"labels":[],"label_agreement":null},{"id":"W4210251206","doi":"10.2337/dc21-1953","title":"Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Nonalcoholic fatty liver disease; Hazard ratio; Liraglutide; Type 2 diabetes; Endocrinology; Vildagliptin; Gastroenterology; Dipeptidyl peptidase-4; Diabetes mellitus; Dulaglutide; Glucagon-like peptide-1; Exenatide; Lower risk; Transaminase; Fatty liver; Disease; Confidence interval; Biochemistry; Enzyme; Chemistry","score_opus":0.00462301008921247,"score_gpt":0.1888263286970101,"score_spread":0.18420331860779762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210251206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449587,0.0034619763,2.376559e-7,0.0000340342,0.00019708222,0.0009910184,0.0005956279,0.000057414592,0.00016673566],"genre_scores_gemma":[0.9972763,0.0004016035,0.00013151996,0.00021076178,0.000046359222,0.00016667844,0.0015538093,0.000054727003,0.00015825967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998351,0.00006974905,0.00025908087,0.00047549588,0.00044060417,0.00040411108],"domain_scores_gemma":[0.9989551,0.000060597136,0.00017625085,0.00033540963,0.00015858319,0.00031410283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008996212,0.00030784958,0.00044482082,0.0001627224,0.00020743147,0.000029527278,0.00008774388,0.0000443925,0.00013694476],"category_scores_gemma":[0.000021458089,0.0002548542,0.00009599037,0.00023840014,0.00024742042,0.00014534338,0.00016164404,0.00017889956,0.0000088645065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018658843,0.00032586363,0.98938453,0.0005471926,0.0005303692,0.000009629426,0.0009501214,0.000007128977,0.00013723057,0.000006292163,0.0007839171,0.007131156],"study_design_scores_gemma":[0.0028960533,0.001111631,0.98770905,0.00016837631,0.001341117,4.975301e-8,0.00039209067,0.00004941767,0.0015446666,0.000007873455,0.0044972748,0.00028239645],"about_ca_topic_score_codex":0.000034880213,"about_ca_topic_score_gemma":0.000019753925,"teacher_disagreement_score":0.0068487595,"about_ca_system_score_codex":0.00008531379,"about_ca_system_score_gemma":0.000041863736,"threshold_uncertainty_score":0.99999034},"labels":[],"label_agreement":null},{"id":"W4210312677","doi":"10.1007/s11033-022-07183-w","title":"Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study","year":2022,"lang":"en","type":"review","venue":"Molecular Biology Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Qingdao University of Science and Technology; Qatar University","keywords":"Dapagliflozin; Medicine; Renin–angiotensin system; Diabetes mellitus; Coronavirus disease 2019 (COVID-19); Type 2 Diabetes Mellitus; Pharmacology; Disease; Internal medicine; Endocrinology; Infectious disease (medical specialty); Blood pressure","score_opus":0.02825611378280104,"score_gpt":0.33732036362375745,"score_spread":0.30906424984095643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210312677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8536345,0.13312015,0.000023416915,0.00009872373,0.00022680053,0.012730657,0.00009647277,0.000055764296,0.00001354989],"genre_scores_gemma":[0.9897139,0.0035976747,0.000073074676,0.0011937865,0.000037512964,0.0020789665,0.0031458496,0.0001511056,0.000008142309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99251014,0.0028416088,0.0017457585,0.0015125856,0.00081530784,0.0005746117],"domain_scores_gemma":[0.9955169,0.0012299041,0.001588499,0.0012937093,0.00016051886,0.00021045904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016191045,0.00086041435,0.0026558586,0.00066206756,0.00015429073,0.000030960673,0.00029462232,0.00036556704,0.000023524095],"category_scores_gemma":[0.0017485789,0.00048900495,0.00027638604,0.0010737653,0.00029226334,0.00006385476,0.00024311889,0.0008888215,0.0000014092714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009518097,0.0015770105,0.9790645,0.0015220806,0.0021289943,0.0042871153,0.0057668854,0.000013154785,0.000026700453,0.000007417365,0.0000946263,0.0045596845],"study_design_scores_gemma":[0.07320438,0.036257517,0.77048284,0.034163732,0.018237695,0.00004343828,0.010029774,0.000010137191,0.000110358735,0.000064214335,0.054497916,0.002897986],"about_ca_topic_score_codex":0.005086335,"about_ca_topic_score_gemma":0.0026188313,"teacher_disagreement_score":0.20858167,"about_ca_system_score_codex":0.0023028874,"about_ca_system_score_gemma":0.0010615124,"threshold_uncertainty_score":0.99975616},"labels":[],"label_agreement":null},{"id":"W4210408078","doi":"10.1139/cjpp-2021-0399","title":"Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis","year":2022,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Heart failure; Cardiorenal syndrome; Diabetes mellitus; Adipokine; Renin–angiotensin system; Internal medicine; Kidney; Type 2 diabetes; Endocrinology; Pharmacology; Cardiology; Bioinformatics; Blood pressure; Insulin resistance; Biology","score_opus":0.030993817025765962,"score_gpt":0.29912542895533106,"score_spread":0.2681316119295651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210408078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06581072,0.9312121,0.0000026302132,0.00024209541,0.0017816016,0.0006808548,0.000064720545,0.000002282268,0.00020300015],"genre_scores_gemma":[0.18003197,0.8192536,0.000007099953,0.00027833282,0.00032666608,0.00002586438,0.000022327806,0.000016761247,0.000037340724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989274,0.00033684712,0.0003544573,0.00013656933,0.00006176407,0.00018294946],"domain_scores_gemma":[0.9987371,0.00048389335,0.00048473198,0.000085466476,0.000040357052,0.00016844663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028729555,0.00019996641,0.0012175911,0.00034100428,0.00009077068,0.0000020537707,0.00009673232,0.00013679724,0.00045488254],"category_scores_gemma":[0.000021492053,0.00011688668,0.00027534837,0.00011379749,0.00017013174,0.000019215226,0.000029474777,0.0004107674,5.907809e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019599198,0.00009002655,0.000015194277,0.01185951,0.0047454634,0.00011292086,0.00027279655,0.0000043158966,0.014909448,0.0016190673,0.003830488,0.96234477],"study_design_scores_gemma":[0.001704035,0.0056412793,0.00021760921,0.0018367192,0.00701387,0.0001936984,0.00015872062,0.000003884629,0.02377827,0.0015798615,0.9576527,0.00021934995],"about_ca_topic_score_codex":0.00011224416,"about_ca_topic_score_gemma":0.000063902815,"teacher_disagreement_score":0.9621254,"about_ca_system_score_codex":0.00008018041,"about_ca_system_score_gemma":0.00044135484,"threshold_uncertainty_score":0.4980645},"labels":[],"label_agreement":null},{"id":"W4210584476","doi":"10.1016/j.jcjd.2022.01.009","title":"Benefits and Harms of Deprescribing Antihyperglycemics for Adults With Type 2 Diabetes: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; Ottawa Hospital; Bruyère; University of Ottawa; University of British Columbia; University of Waterloo; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Deprescribing; Type 2 diabetes; Diabetes mellitus; Gerontology; Intensive care medicine; Polypharmacy; Endocrinology","score_opus":0.03789541420328985,"score_gpt":0.25873506283852604,"score_spread":0.2208396486352362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210584476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018442048,0.9945357,4.916684e-7,0.00004584685,0.00021732153,0.0031262792,0.00014074135,0.0000065881914,0.00008281513],"genre_scores_gemma":[0.0003693921,0.998508,0.000285913,0.0002940548,0.00007240907,0.00017282293,0.00013786236,0.00008641632,0.00007316198],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99776757,0.00009102534,0.0011298477,0.00025823648,0.00027668054,0.00047664656],"domain_scores_gemma":[0.9971447,0.00034627787,0.0012754332,0.00037396382,0.00029520647,0.00056439464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005714577,0.00041863765,0.0038214857,0.00059899286,0.00008741396,0.000034322995,0.0002708726,0.00010186311,0.000056930923],"category_scores_gemma":[0.000574382,0.00028148125,0.00048925605,0.0004479618,0.00007604607,0.00010361394,0.000033018907,0.00026932507,0.0000014074584],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004604031,0.000030386342,0.0007770985,0.8701059,0.0024511958,0.000014153884,0.00005583272,6.347992e-7,9.06187e-8,0.000025307692,0.00076365843,0.12577109],"study_design_scores_gemma":[0.00087412,0.0016519522,0.000016316639,0.8212837,0.025757376,0.00001805135,0.00006993314,0.000004687847,0.0000018546194,0.0000033743188,0.15005101,0.00026761397],"about_ca_topic_score_codex":0.000025827061,"about_ca_topic_score_gemma":0.00015358292,"teacher_disagreement_score":0.14928736,"about_ca_system_score_codex":0.00023271254,"about_ca_system_score_gemma":0.0011254752,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W4210702087","doi":"10.1002/ehf2.13805","title":"Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced or Preserved Ejection Fraction: A Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University","funders":"","keywords":"Heart failure; Ejection fraction; Medicine; Hazard ratio; Internal medicine; Randomized controlled trial; Meta-analysis; Placebo; Cardiology; Confidence interval; Pathology","score_opus":0.06968690091974725,"score_gpt":0.3195163975540541,"score_spread":0.24982949663430684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210702087","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003654941,0.98393035,0.000018730645,0.008073312,0.00025933387,0.006350677,0.00011733002,0.00032452546,0.00056024804],"genre_scores_gemma":[0.0016482311,0.94703484,0.00918063,0.0012247125,0.00091987656,0.009023577,0.006481599,0.00047239562,0.02401413],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99530804,0.00053201866,0.0011517637,0.0013094547,0.0010198788,0.00067884906],"domain_scores_gemma":[0.9977548,0.00018601838,0.00039108022,0.0012818389,0.00008846906,0.00029776042],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007084088,0.0009687583,0.005809118,0.0014881884,0.00019595811,0.00011206965,0.00020696824,0.000436303,0.015761439],"category_scores_gemma":[0.0000400756,0.00062195526,0.0034511716,0.0035526135,0.0000680745,0.00032186173,0.00009734625,0.0012355844,0.00019050762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090780633,0.0040258323,0.003876203,0.029753579,0.5523879,0.0013720995,0.00030720534,0.00007890202,0.000023455817,0.000038406608,0.37735242,0.029876195],"study_design_scores_gemma":[0.0008492576,0.00047273142,0.000082935716,0.0005171538,0.2599676,0.000031197927,0.00014234206,0.0000036018187,0.000017073779,0.0000016558616,0.7374883,0.0004261255],"about_ca_topic_score_codex":0.0002684309,"about_ca_topic_score_gemma":0.0017840663,"teacher_disagreement_score":0.3601359,"about_ca_system_score_codex":0.0005477408,"about_ca_system_score_gemma":0.00044405463,"threshold_uncertainty_score":0.9996232},"labels":[],"label_agreement":null},{"id":"W4210774959","doi":"10.1093/aje/kwac021","title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study","year":2022,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute on Aging; Fonds de Recherche du Québec - Santé; National Institutes of Health; Union Chimique Belge; National Heart, Lung, and Blood Institute; Boehringer Ingelheim; Brigham and Women's Hospital; McGill University; Canadian Institutes of Health Research; Harvard Medical School","keywords":"Medicine; Type 2 diabetes; Cohort; Population; Internal medicine; Glucagon; Cohort study; Glucagon-like peptide 1 receptor; Diabetes mellitus; Type 1 diabetes; Endocrinology; Receptor; Immunology; Insulin; Agonist; Environmental health","score_opus":0.00993951626341752,"score_gpt":0.26768067490404834,"score_spread":0.25774115864063085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210774959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99892366,0.00011659729,0.00003479438,0.00009990977,0.00020001688,0.0005739823,0.000010290139,0.000009725259,0.0000310313],"genre_scores_gemma":[0.9976746,0.00007443068,0.0018214871,0.00023506906,0.00003297978,0.00002612482,0.00007895009,0.000019353818,0.00003699416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977557,0.0009277214,0.0006347082,0.00022437904,0.00023119515,0.0002262667],"domain_scores_gemma":[0.99681723,0.0008550842,0.0017851604,0.00022274567,0.0001846311,0.00013514305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014745508,0.00015176114,0.0008828762,0.0002724031,0.00010023016,0.0000028653533,0.00007031647,0.000019231238,0.000051122577],"category_scores_gemma":[0.0007394335,0.00011252819,0.000090001435,0.0003296784,0.00016694608,0.00007551612,0.00003776951,0.00025434408,0.0000010000471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009082703,0.00091026386,0.9871764,0.0000148098225,0.0012188815,0.0000064092937,0.00010209523,0.0003875083,0.00001833632,0.0000019039443,0.00023641721,0.009018691],"study_design_scores_gemma":[0.0022238465,0.016670253,0.9788709,0.000033253993,0.0009446453,0.0000016337992,0.0004652529,0.00019169238,0.000004029967,0.000009711725,0.00049224705,0.0000924926],"about_ca_topic_score_codex":0.0014606112,"about_ca_topic_score_gemma":0.00006913213,"teacher_disagreement_score":0.01575999,"about_ca_system_score_codex":0.00018473896,"about_ca_system_score_gemma":0.000039518403,"threshold_uncertainty_score":0.45887667},"labels":[],"label_agreement":null},{"id":"W4210783935","doi":"10.2196/31629","title":"Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study","year":2022,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Hypoglycemia; Diabetes management; Glycated hemoglobin; Prospective cohort study; Discontinuation; Telemedicine; Diabetes mellitus; Sulfonylurea; Medical prescription; Dosing; Internal medicine; Endocrinology; Health care; Pharmacology","score_opus":0.027047086418549842,"score_gpt":0.37061812014564344,"score_spread":0.3435710337270936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210783935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927179,0.00009545023,0.000013651398,0.000075023505,0.000070319016,0.005931385,0.0000048798256,0.00009615816,0.0009952314],"genre_scores_gemma":[0.97580546,0.00001004571,0.0002782493,0.0000048649035,0.000040689894,0.023595264,0.00011389761,0.000025890397,0.0001256356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753195,0.00032955513,0.00025601822,0.00029499823,0.0010831086,0.00050439703],"domain_scores_gemma":[0.9990283,0.000101812606,0.00009965424,0.00023693938,0.00042492844,0.00010835483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006359651,0.0001436458,0.00027806795,0.0003943476,0.00035089324,0.000060466286,0.00013142561,0.000027987411,0.000099048775],"category_scores_gemma":[0.000079563244,0.000115751805,0.000027783915,0.0013411213,0.00009303431,0.0002851016,0.00027231357,0.00044134932,0.000009529271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002620415,0.0024462964,0.90622073,0.00007956832,0.00015485245,0.000020359694,0.07619094,0.0022960783,0.000015404072,0.000021887916,0.00008160008,0.012210238],"study_design_scores_gemma":[0.0034646313,0.016681891,0.834533,0.00011503766,0.000053555967,4.4984108e-7,0.13353015,0.011049821,0.0003650534,0.0000059617923,0.000076559576,0.00012390286],"about_ca_topic_score_codex":0.00008875799,"about_ca_topic_score_gemma":0.00008254799,"teacher_disagreement_score":0.07168775,"about_ca_system_score_codex":0.0007374742,"about_ca_system_score_gemma":0.000110566565,"threshold_uncertainty_score":0.47202218},"labels":[],"label_agreement":null},{"id":"W4211081656","doi":"10.14740/jocmr2417wc1","title":"Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study","year":2016,"lang":"en","type":"erratum","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Interim; Medicine; Type 2 diabetes; Outcome (game theory); Safety profile; Interim analysis; Diabetes mellitus; Internal medicine; Intensive care medicine; Adverse effect; Clinical trial; Endocrinology; Law","score_opus":0.13504443035172647,"score_gpt":0.48377802337860326,"score_spread":0.3487335930268768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211081656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96553427,0.0014670641,0.0000012621508,0.0032826308,0.016240807,0.0021379795,0.0000064500405,0.0000051036345,0.011324446],"genre_scores_gemma":[0.9625749,0.0016465262,0.000017236316,0.000100920355,0.0016806963,0.000009132878,0.000009722468,0.00004510238,0.033915784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927052,0.0012006505,0.0029702785,0.00031931637,0.0024338851,0.00037061737],"domain_scores_gemma":[0.9914555,0.004109888,0.0016085586,0.00062834733,0.0019160634,0.00028166632],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008649776,0.00026940534,0.002357729,0.0007110598,0.00004179973,0.0000076121114,0.00044601248,0.00028432423,0.00018594447],"category_scores_gemma":[0.014017709,0.00011222848,0.00019433213,0.00077113917,0.0009663669,0.000076050565,0.00031896928,0.0025302905,0.00000346574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040476746,0.003223078,0.79284847,0.00041152333,0.00096498337,0.0000397498,0.00032271555,2.594566e-7,0.0000034424925,0.0000014568134,0.17412776,0.02400888],"study_design_scores_gemma":[0.019204523,0.036589094,0.9053255,0.011448612,0.00069849106,0.000002470035,0.00072630745,0.0000060649104,0.000005087328,0.000011186019,0.025888605,0.00009409132],"about_ca_topic_score_codex":0.000037664366,"about_ca_topic_score_gemma":0.000045506054,"teacher_disagreement_score":0.14823915,"about_ca_system_score_codex":0.00014630094,"about_ca_system_score_gemma":0.00045259853,"threshold_uncertainty_score":0.99977094},"labels":[],"label_agreement":null},{"id":"W4211100132","doi":"10.1111/dom.14666","title":"Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A <scp>meta‐analysis</scp> and <scp>meta‐regression</scp> analysis","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Mace; Medicine; Internal medicine; Meta-analysis; Myocardial infarction; Meta-regression; Hazard ratio; Semaglutide; Weight loss; Endocrinology; Diabetes mellitus; Type 2 diabetes; Obesity; Liraglutide; Confidence interval","score_opus":0.030950195687448515,"score_gpt":0.275676389128329,"score_spread":0.24472619344088048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211100132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056523647,0.93994135,0.000018758581,0.000018973726,0.00026312086,0.0023617372,0.00032160745,0.00010605625,0.00044475406],"genre_scores_gemma":[0.0015776688,0.991012,0.000523495,0.00030861536,0.00013880251,0.0010586986,0.001118885,0.000118079006,0.0041437894],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9931073,0.0012573258,0.0012488632,0.0019473309,0.0014041339,0.0010350394],"domain_scores_gemma":[0.99336493,0.0032314386,0.0009783693,0.0015277658,0.00013719262,0.0007602885],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0018517021,0.0017453778,0.016632667,0.0026900866,0.00045557923,0.00018462882,0.0003969991,0.0005300058,0.00009808997],"category_scores_gemma":[0.00072111667,0.0011378614,0.011428425,0.0030473752,0.00037534747,0.00021113455,0.0007642218,0.00080818334,0.000015735432],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003826195,0.0007555154,0.0027019698,0.016847275,0.9176542,0.00007104457,0.00024394576,0.000010426441,0.000006311666,0.00014262243,0.0006894145,0.060873456],"study_design_scores_gemma":[0.00083740545,0.00013562074,0.0070497897,0.0002740805,0.520652,0.0000012630777,0.000033718417,0.000006995857,0.000056197034,0.00002086329,0.47078,0.00015204649],"about_ca_topic_score_codex":0.000112659705,"about_ca_topic_score_gemma":0.000013422922,"teacher_disagreement_score":0.47009057,"about_ca_system_score_codex":0.000078883684,"about_ca_system_score_gemma":0.00010255046,"threshold_uncertainty_score":0.99952924},"labels":[],"label_agreement":null},{"id":"W4211243347","doi":"10.1016/j.jcjd.2017.11.004","title":"Chronic Kidney Disease in Diabetes","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Renal function; Proteinuria; Dialysis; Internal medicine; Creatinine; Type 2 diabetes; Kidney; Endocrinology; Intensive care medicine; Urology","score_opus":0.0088975385284513,"score_gpt":0.2243996921981018,"score_spread":0.2155021536696505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211243347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882519,0.0031842839,0.0000010924522,0.0041752206,0.00053126185,0.00019860994,0.000017404984,0.000009193785,0.0036310258],"genre_scores_gemma":[0.99633086,0.000012393576,0.00011107722,0.0018504282,0.0009166752,0.000007580855,0.000015127863,0.000024639645,0.00073123816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870855,0.00003097311,0.00033652937,0.00014746866,0.0001708335,0.0006056391],"domain_scores_gemma":[0.9975216,0.000032092365,0.00012026511,0.0002218112,0.00015299559,0.0019512514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023963221,0.00016137447,0.00033911812,0.00064088614,0.0000641183,0.00004360514,0.00015910866,0.00004679111,0.0006501739],"category_scores_gemma":[0.0002887036,0.00013706998,0.00013810473,0.00029771717,0.0001950745,0.0001767839,0.000014396007,0.00014617413,0.00008247674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038318303,0.00003730042,0.9749025,0.000088789486,0.00015004248,0.000069923495,0.00007921325,0.0000025811037,0.0002466536,0.00015910184,0.015461718,0.00879834],"study_design_scores_gemma":[0.002501176,0.0012091496,0.86649877,0.0009869722,0.0003297687,5.280636e-7,0.000028836548,0.00017419083,0.001577735,0.0005545817,0.12593001,0.0002082461],"about_ca_topic_score_codex":0.00013259533,"about_ca_topic_score_gemma":0.0027655298,"teacher_disagreement_score":0.1104683,"about_ca_system_score_codex":0.0004593382,"about_ca_system_score_gemma":0.0017843131,"threshold_uncertainty_score":0.71189487},"labels":[],"label_agreement":null},{"id":"W4212798424","doi":"10.1016/j.jcmgh.2022.02.011","title":"Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells","year":2022,"lang":"en","type":"article","venue":"Cellular and Molecular Gastroenterology and Hepatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Muscular Dystrophy Canada","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Novo Nordisk; Novo Nordisk Fonden; University of Toronto; Lunds Universitet; Canadian Association of Gastroenterology","keywords":"LGR5; Stem cell; Biology; Cell cycle; Glucagon-like peptide-2; Internal medicine; Endocrinology; Intestinal epithelium; Cell biology; Molecular biology; Cell; Cancer stem cell; Epithelium; Biochemistry; Medicine; Peptide","score_opus":0.00898717945186504,"score_gpt":0.2326760549056534,"score_spread":0.22368887545378838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212798424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947791,0.0015727065,0.002226125,0.00061317283,0.00019736854,0.0003531278,0.0000149672405,0.000028481105,0.00021493326],"genre_scores_gemma":[0.996999,0.00014682127,0.00042962848,0.0017576996,0.000012624957,0.000050407445,0.00007521632,0.000019356281,0.00050924876],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867386,0.00015808211,0.000295331,0.00038504344,0.00011562214,0.00037209253],"domain_scores_gemma":[0.99945,0.000032176828,0.00011687347,0.00022466395,0.00003352387,0.00014274297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014922881,0.00020506539,0.00049919105,0.00017453746,0.00011448094,0.000007942706,0.00008203867,0.00006571027,0.00010085541],"category_scores_gemma":[0.0000039492656,0.0002002209,0.00009850671,0.000062485095,0.00026723294,0.000033204902,0.000316721,0.00021197379,0.000002353808],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005261589,0.0029199396,0.6699595,0.00061039836,0.0015752607,0.0045830416,0.0006124285,0.00006231233,0.29965225,0.0031690402,0.002696037,0.008898215],"study_design_scores_gemma":[0.117346056,0.109242134,0.023842223,0.00032624995,0.011122061,0.007532421,0.0043660235,0.018861126,0.56444377,0.0021284304,0.13886122,0.0019282814],"about_ca_topic_score_codex":0.000014999345,"about_ca_topic_score_gemma":0.0000035354037,"teacher_disagreement_score":0.64611727,"about_ca_system_score_codex":0.000022818875,"about_ca_system_score_gemma":0.000023891995,"threshold_uncertainty_score":0.81647706},"labels":[],"label_agreement":null},{"id":"W4212828000","doi":"10.1055/s-0041-1742196","title":"Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Treatment in Type 1 Diabetes in a Tertiary Care Center in Saudi Arabia","year":2022,"lang":"en","type":"article","venue":"Avicenna Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Empagliflozin; Glycemic; Diabetic ketoacidosis; Hypoglycemia; Diabetes mellitus; Body mass index; Adjunctive treatment; Type 2 diabetes; Internal medicine; Type 1 diabetes; Ketoacidosis; Lipid profile; Insulin; Endocrinology","score_opus":0.008231702220691733,"score_gpt":0.25615181129535725,"score_spread":0.24792010907466552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212828000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831738,0.011680676,1.8306632e-7,0.003338106,0.00027974206,0.00060184667,0.000004071019,0.000004113176,0.00091747375],"genre_scores_gemma":[0.99777085,0.0013810009,0.000037914942,0.00054516504,0.00009833123,0.000017679042,0.000025651436,0.000016910433,0.0001064923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982234,0.00013897308,0.0007269168,0.00018883325,0.00046227165,0.00025959636],"domain_scores_gemma":[0.99922645,0.0001438334,0.00026855286,0.0001500589,0.00009603547,0.00011507061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050679623,0.00018980388,0.0006748029,0.00062539324,0.000023241337,0.00000254434,0.00008030513,0.00004003265,0.0001736554],"category_scores_gemma":[0.00011862625,0.00013536679,0.00006152999,0.0004538209,0.000089234454,0.00007909399,0.000076000535,0.0002796064,0.0000012921713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002132271,0.0012850843,0.95043546,0.00014340805,0.0002130042,0.0006798578,0.0081062475,0.000044137192,0.0010386447,0.000016308746,0.0004035686,0.035502005],"study_design_scores_gemma":[0.041244477,0.007486746,0.93742377,0.0017909578,0.0002727971,0.00003299082,0.0055572563,0.000030556454,0.00037848338,0.00005948615,0.0056043523,0.000118126794],"about_ca_topic_score_codex":0.0002915288,"about_ca_topic_score_gemma":0.00027180853,"teacher_disagreement_score":0.039112207,"about_ca_system_score_codex":0.00090538064,"about_ca_system_score_gemma":0.00014440084,"threshold_uncertainty_score":0.5520097},"labels":[],"label_agreement":null},{"id":"W4212848208","doi":"10.1016/j.ekir.2022.01.1060","title":"Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions","year":2022,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Steno Diabetes Center Copenhagen; AstraZeneca","keywords":"Medicine; Dapagliflozin; Endocrinology; Diabetes mellitus","score_opus":0.006348138457247109,"score_gpt":0.24654592138076642,"score_spread":0.24019778292351932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212848208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992193,0.000029890303,0.000009387337,0.0014460249,0.0002205559,0.00047960467,0.000046653895,0.000018132363,0.005556756],"genre_scores_gemma":[0.99720895,0.000012070372,0.00017786639,0.000420305,0.000015782016,0.000060574006,0.0004971879,0.000011156148,0.0015961109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889326,0.000014567306,0.00029201148,0.00022348033,0.00044688268,0.00012981324],"domain_scores_gemma":[0.9994366,0.000021932994,0.00017577852,0.0001931617,0.00007260567,0.00009990084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017106578,0.0000878141,0.000158075,0.00015993198,0.000055047403,0.000008763156,0.00005076177,0.00001558949,0.00018807301],"category_scores_gemma":[0.00011925372,0.00007431542,0.000037749043,0.00015693852,0.000050833052,0.0000578261,0.00014515282,0.00008498083,7.7475465e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000528634,0.00077372254,0.99380785,0.000018086093,0.0002823709,0.00022996076,0.00016935282,0.000016033184,0.000014954097,0.0004667096,0.0021256413,0.0015666689],"study_design_scores_gemma":[0.0042876992,0.0003316103,0.94998544,0.00007535305,0.00006375793,0.000024598874,0.0000612718,0.00001303644,0.000030009916,0.00012555318,0.044932056,0.00006961792],"about_ca_topic_score_codex":0.00007758008,"about_ca_topic_score_gemma":0.000010775936,"teacher_disagreement_score":0.04382243,"about_ca_system_score_codex":0.000082267004,"about_ca_system_score_gemma":0.00004577161,"threshold_uncertainty_score":0.3030495},"labels":[],"label_agreement":null},{"id":"W4212853658","doi":"10.1016/j.pcd.2022.02.002","title":"2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care","year":2022,"lang":"en","type":"review","venue":"Primary care diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Servier; Boehringer Ingelheim; Roche; Novo Nordisk; National Institute for Health and Care Research; Novartis; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Bayer; Pfizer; Sanofi; Abbott Laboratories","keywords":"Medicine; Primary care; Disease; Diabetes mellitus; Intensive care medicine; Position statement; Type 2 diabetes; Disease management; Health care; Position paper; Diabetes management; Family medicine; Internal medicine","score_opus":0.01833706451432611,"score_gpt":0.2760231594997077,"score_spread":0.2576860949853816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212853658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018560829,0.95201886,0.0000029082569,0.0005335779,0.0007857927,0.014181537,0.0039463625,0.00019209603,0.009778039],"genre_scores_gemma":[0.0020322942,0.9130724,0.00048184246,0.007095801,0.00020207849,0.01018051,0.06580851,0.0003169645,0.00080958294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991822,0.0011387788,0.0016588168,0.0018964636,0.0017980796,0.0016858333],"domain_scores_gemma":[0.99630207,0.00031731647,0.0006421754,0.0017608072,0.0003601404,0.00061749533],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008573001,0.0014959062,0.0028863642,0.0006476796,0.00042376094,0.00018001927,0.0016999813,0.00015953302,0.00014765025],"category_scores_gemma":[0.000033544653,0.00097319466,0.0008380751,0.0023448083,0.000176701,0.00021601147,0.003156884,0.00094286015,0.00010654231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016791039,0.0009942473,0.003364204,0.111548625,0.0027068958,0.00008760601,0.0011578024,0.00014163648,0.000024213821,0.000021487831,0.030457957,0.8493274],"study_design_scores_gemma":[0.0014985183,0.0010616895,0.004245467,0.005661502,0.008281415,3.5435966e-7,0.0010218255,0.000009470879,0.000046682857,0.0000050640147,0.97710437,0.0010636162],"about_ca_topic_score_codex":0.000010819283,"about_ca_topic_score_gemma":0.0000036005595,"teacher_disagreement_score":0.94664645,"about_ca_system_score_codex":0.004526515,"about_ca_system_score_gemma":0.00062657415,"threshold_uncertainty_score":0.999779},"labels":[],"label_agreement":null},{"id":"W4212871029","doi":"10.1016/j.diabet.2022.101331","title":"The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial","year":2022,"lang":"en","type":"article","venue":"Diabetes & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; University of British Columbia","funders":"Medical Science and Technology Foundation of Guangdong Province; Sanming Project of Medicine in Shenzhen; National Health and Medical Research Council; Janssen Research and Development; China Scholarship Council; University of New South Wales","keywords":"Medicine; Canagliflozin; Internal medicine; Peripheral neuropathy; Adverse effect; Placebo; Diabetes mellitus; Type 2 diabetes; Polyneuropathy; Randomized controlled trial; Endocrinology; Pathology","score_opus":0.012839158153503373,"score_gpt":0.254405754392585,"score_spread":0.24156659623908164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212871029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945408,0.002727808,7.055729e-7,0.00050269876,0.0004070138,0.0010897387,0.00033377056,0.000011936352,0.0003855257],"genre_scores_gemma":[0.9988153,0.00030290766,0.000006455698,0.0002538793,0.00006177806,0.000226789,0.000022615408,0.000020780388,0.00028948917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716955,0.0009396544,0.0005385777,0.00024184705,0.0007915312,0.0003188438],"domain_scores_gemma":[0.9972008,0.00070166297,0.0006965624,0.0011621763,0.0001744933,0.00006432872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014095565,0.00021657441,0.0007167198,0.00025691884,0.00025540183,0.000010624321,0.00058810634,0.000026320706,0.00023000002],"category_scores_gemma":[0.00061257684,0.00009584307,0.001111278,0.0015840933,0.00017522952,0.00005264093,0.00030671371,0.00024040068,0.0000027212925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04005499,0.010562919,0.6418624,0.00025065243,0.11781823,0.000019499335,0.015240791,0.014040418,0.040990997,0.0152403405,0.018579857,0.08533889],"study_design_scores_gemma":[0.01472382,0.0034113124,0.94310385,0.000051606865,0.022043344,1.2637587e-7,0.0021871934,0.0015172266,0.0068798903,0.0005024473,0.0053458023,0.00023336388],"about_ca_topic_score_codex":0.00040758916,"about_ca_topic_score_gemma":0.000035003035,"teacher_disagreement_score":0.30124146,"about_ca_system_score_codex":0.00006477614,"about_ca_system_score_gemma":0.00012717815,"threshold_uncertainty_score":0.3908367},"labels":[],"label_agreement":null},{"id":"W4213191053","doi":"10.1016/j.jcjd.2022.02.002","title":"Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta; University of Calgary","funders":"Diabetes Action Canada","keywords":"Medicine; Guideline; Cross-sectional study; Primary care; Diabetes mellitus; Type 2 diabetes; Cardiorenal syndrome; Intensive care medicine; Internal medicine; Family medicine; Endocrinology; Heart failure; Pathology","score_opus":0.02144451747565802,"score_gpt":0.253000106553092,"score_spread":0.231555589077434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213191053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978818,0.00055041944,7.5639036e-7,0.00003868528,0.00029400294,0.0010025165,0.00010354743,0.0000053543736,0.00012290984],"genre_scores_gemma":[0.99934614,0.0000043593686,0.00023699822,0.000149869,0.000057735775,0.000050366034,0.00008411006,0.00003148837,0.00003893855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979143,0.00012666789,0.0008314812,0.00022708054,0.00051379023,0.00038667573],"domain_scores_gemma":[0.9982693,0.00006975822,0.00048549788,0.00024014268,0.00065958506,0.00027570841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036562176,0.00020557565,0.0006669919,0.00080640666,0.00009639373,0.000024488529,0.00018968634,0.00004576346,0.000091825255],"category_scores_gemma":[0.000093664385,0.00017555447,0.00014522177,0.0005887048,0.000087525026,0.0001845738,0.000054643486,0.00031536416,6.3957026e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031271242,0.000510628,0.99262434,0.0002301184,0.0009282212,0.000073723204,0.0012185681,0.0015213608,0.00033101861,0.0000015696787,0.00050189183,0.0017458649],"study_design_scores_gemma":[0.0072443364,0.0087173525,0.9804084,0.00030875116,0.00025838352,0.0000038328303,0.001505226,0.00005288427,0.0009637629,0.0000061923906,0.0003724057,0.00015848207],"about_ca_topic_score_codex":0.0012875763,"about_ca_topic_score_gemma":0.0028074244,"teacher_disagreement_score":0.012215933,"about_ca_system_score_codex":0.00077589514,"about_ca_system_score_gemma":0.0010714915,"threshold_uncertainty_score":0.71589035},"labels":[],"label_agreement":null},{"id":"W4213221768","doi":"10.1503/cmaj.210191-f","title":"Hypoglycémie artéfactuelle chez une patiente atteinte d’anémie falciforme","year":2022,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Gynecology","score_opus":0.007010294634444486,"score_gpt":0.2161830690481675,"score_spread":0.209172774413723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213221768","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.124247506,0.02165823,0.00031051788,0.6512292,0.038095396,0.0013605821,0.0006869749,0.000108089385,0.16230349],"genre_scores_gemma":[0.59526604,0.0023226195,0.00020874702,0.08863658,0.008638688,0.00011049102,0.00039432145,0.00013498538,0.30428755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99341196,0.00048392807,0.00086851744,0.00035661706,0.0032074896,0.0016715027],"domain_scores_gemma":[0.994871,0.00024564352,0.00051123236,0.00024692394,0.0003122604,0.0038129217],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028736747,0.0003438928,0.00056501804,0.00047424348,0.0011866128,0.00014778164,0.00040964608,0.00034327214,0.15004133],"category_scores_gemma":[0.0010047142,0.0003633281,0.0003886035,0.0007674631,0.000108584434,0.00023381358,0.00014528004,0.0023287826,0.0026003767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002947401,0.0003331127,0.027078854,0.000040288323,0.00106025,0.0029410813,0.0007622703,0.000038778395,0.0000029501532,0.0018622176,0.696924,0.26892677],"study_design_scores_gemma":[0.0034834603,0.0007470031,0.007492628,0.00019342615,0.00044658998,0.0002880679,0.0027106227,0.0007355433,0.000010524644,0.0004398181,0.98313403,0.000318305],"about_ca_topic_score_codex":0.007827924,"about_ca_topic_score_gemma":0.015547345,"teacher_disagreement_score":0.5625926,"about_ca_system_score_codex":0.011886096,"about_ca_system_score_gemma":0.005478017,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W4213254336","doi":"10.26226/morressier.59d5184bd462b80296ca3307","title":"Antidiabetic medication persistence and implementation in patients with chronic kidney disease","year":2017,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; The Quebec Population Health Research Network","funders":"","keywords":"Persistence (discontinuity); Kidney disease; Medicine; Medication adherence; Disease; Intensive care medicine; Internal medicine","score_opus":0.012433985791652577,"score_gpt":0.2753459556819084,"score_spread":0.26291196989025584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213254336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932197,0.00034583386,0.00003341135,0.002418394,0.00011819084,0.0018873302,0.00003141714,0.00003548075,0.0019102963],"genre_scores_gemma":[0.99658334,0.00028385903,0.0002685296,0.00023794564,0.000037403945,0.00016290111,0.0018370233,0.000015084287,0.00057391275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989774,0.00001571184,0.00016319405,0.00038503628,0.00027563015,0.00018302481],"domain_scores_gemma":[0.99909157,0.0000070080364,0.00014511445,0.00046030912,0.000049646093,0.0002463533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008904204,0.00017538451,0.00023040811,0.00013598299,0.000050202656,0.000046115576,0.000081857026,0.00004840162,0.0002010488],"category_scores_gemma":[0.000024451461,0.00013133172,0.000032915297,0.000026246167,0.00006747461,0.00008448221,0.0001934158,0.00010489487,0.000008916272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066766705,0.00018354919,0.9732371,0.0007381789,0.00012369914,0.000006301971,0.00007494298,0.000001347321,0.0000014885542,0.000049459428,0.000865334,0.024651852],"study_design_scores_gemma":[0.0043070437,0.00026743376,0.9931194,0.00067323056,0.00053109735,4.7036224e-8,0.00003405487,0.00015698439,0.00002239307,0.000094191346,0.0006576658,0.00013646505],"about_ca_topic_score_codex":0.00010297707,"about_ca_topic_score_gemma":0.00006594143,"teacher_disagreement_score":0.024515385,"about_ca_system_score_codex":0.00022866002,"about_ca_system_score_gemma":0.00025977378,"threshold_uncertainty_score":0.5355552},"labels":[],"label_agreement":null},{"id":"W4214607566","doi":"10.3389/fendo.2022.838410","title":"Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes","year":2022,"lang":"en","type":"review","venue":"Frontiers in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Incretin; Medicine; Type 2 diabetes; Diabetes mellitus; Hormone; Glucagon-like peptide-1; Internal medicine; Obesity; Exenatide; Endocrinology; Pharmacology; Receptor; Bioinformatics; Biology","score_opus":0.03325403817097436,"score_gpt":0.32815795631677597,"score_spread":0.29490391814580164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214607566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040855512,0.9953584,0.00002063515,0.00019214091,0.0007171896,0.00304162,0.000049877133,0.000018045974,0.00019351141],"genre_scores_gemma":[0.000027136757,0.99574596,0.00092636555,0.00007802648,0.000042376647,0.002841288,0.00013317594,0.000030280533,0.00017539751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985717,0.00015306857,0.000421656,0.0003559718,0.000097732904,0.00039986195],"domain_scores_gemma":[0.99898946,0.0005051898,0.00019835177,0.00026367928,0.000012075786,0.000031254243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110319466,0.00030825095,0.0015757495,0.00043697658,0.000043745204,0.0000043972705,0.000132585,0.00006305001,0.000084945714],"category_scores_gemma":[0.000027796445,0.0001985882,0.0002107079,0.00022739812,0.00016661786,0.000025577905,0.00003803648,0.00012729652,4.820098e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008427973,0.00057146803,0.01964948,0.00338968,0.0005009645,0.000018504647,0.00005832745,0.000004106986,9.208812e-8,0.00004048084,0.00052254385,0.97516006],"study_design_scores_gemma":[0.0030154723,0.0011831812,0.00021132722,0.0004955438,0.0012333854,0.0000011619179,0.000108078726,0.00005746867,0.000013175185,0.000057123263,0.9934885,0.00013560476],"about_ca_topic_score_codex":0.000008714048,"about_ca_topic_score_gemma":0.000019421654,"teacher_disagreement_score":0.99296594,"about_ca_system_score_codex":0.0003927011,"about_ca_system_score_gemma":0.0000807574,"threshold_uncertainty_score":0.80981916},"labels":[],"label_agreement":null},{"id":"W4214667647","doi":"10.1016/j.jchf.2021.11.006","title":"Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Ejection fraction; Medicine; Dapagliflozin; Heart failure; Internal medicine; Cardiology; Atrial fibrillation; Placebo; Diabetes mellitus; Ambulatory; Randomized controlled trial; Type 2 diabetes; Endocrinology","score_opus":0.007128539568638024,"score_gpt":0.21464951828254653,"score_spread":0.2075209787139085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214667647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973077,0.000017794815,0.000047056845,0.0017358318,0.0000475921,0.00062852807,0.000029604433,0.000034998702,0.00015089815],"genre_scores_gemma":[0.9965369,0.0000038388703,0.002049548,0.00021526104,0.000045687742,0.00007879894,0.00037898403,0.000018064195,0.00067291193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992316,0.0000440523,0.00013795185,0.00018556832,0.00027687248,0.00012395554],"domain_scores_gemma":[0.99955153,0.000022402292,0.00008736181,0.00017873988,0.000100453384,0.00005948445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110500376,0.00010254843,0.00020998695,0.00008757398,0.00009132813,0.000010852847,0.00002283071,0.000023318167,0.00020189905],"category_scores_gemma":[0.000018293256,0.0000758415,0.0000223877,0.00016050115,0.000021616528,0.00009942164,0.000040010633,0.00011472825,0.0000022855697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011030965,0.00062257494,0.9868195,0.00012192823,0.00015251253,0.000005061866,0.000050358492,0.000006254249,0.00082885724,0.00001070292,0.0088263005,0.0014528302],"study_design_scores_gemma":[0.0028638593,0.0023716325,0.8928874,0.000049457387,0.00022629288,0.0000019432525,0.00018980978,0.00011853263,0.00064142625,0.0000030354568,0.100555316,0.000091269794],"about_ca_topic_score_codex":0.000030561478,"about_ca_topic_score_gemma":0.000009730562,"teacher_disagreement_score":0.0939321,"about_ca_system_score_codex":0.000054436645,"about_ca_system_score_gemma":0.000027719057,"threshold_uncertainty_score":0.30927265},"labels":[],"label_agreement":null},{"id":"W4214676574","doi":"10.1002/trc2.12268","title":"Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers","year":2022,"lang":"en","type":"article","venue":"Alzheimer s & Dementia Translational Research & Clinical Interventions","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Dementia; Medical prescription; Medicine; Incidence (geometry); Disease; Internal medicine; Randomized controlled trial; Clinical trial; Oncology; Pharmacology; Endocrinology; Bioinformatics; Biology","score_opus":0.3494612786909006,"score_gpt":0.48594302588448296,"score_spread":0.13648174719358236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214676574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75680315,0.2071324,0.0024803234,0.015439756,0.0003946875,0.015806774,0.001317322,0.000068314504,0.0005572576],"genre_scores_gemma":[0.98625284,0.0050798957,0.0029856118,0.00009164772,0.00008837643,0.0019982355,0.0031032818,0.000028377863,0.0003717278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928186,0.0026535867,0.0021387215,0.0008728815,0.0011958737,0.00032036056],"domain_scores_gemma":[0.9925741,0.0054491414,0.0006319762,0.00060738914,0.00034909858,0.00038832417],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009778953,0.0002839095,0.0018116306,0.00039119567,0.00045392558,0.00015386743,0.00022910624,0.000064114356,0.000932991],"category_scores_gemma":[0.00094712037,0.00020618594,0.0005977485,0.00024134794,0.0008063747,0.00041284834,0.00035895937,0.0003009759,0.000004368877],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71092373,0.005280382,0.052897226,0.00019851554,0.1978759,0.00004518652,0.00043072755,0.00002575365,0.00034276454,0.004668012,0.0021167095,0.025195086],"study_design_scores_gemma":[0.8006683,0.0038133487,0.050902486,0.0005959064,0.12737574,0.0000050901835,0.00039805283,0.0065689413,0.000056817447,0.0028160454,0.0064170538,0.00038222354],"about_ca_topic_score_codex":0.0005035912,"about_ca_topic_score_gemma":0.0004246824,"teacher_disagreement_score":0.22944967,"about_ca_system_score_codex":0.00002670965,"about_ca_system_score_gemma":0.0002552475,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W4214893005","doi":"10.1111/dom.14677","title":"The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Merck KGaA; Pfizer","keywords":"Natriuresis; Renal function; Medicine; Placebo; Internal medicine; Kidney disease; Albuminuria; Endocrinology; Uric acid; Diabetes mellitus; Urology; Confidence interval; Gastroenterology; Cardiology; Pathology","score_opus":0.012070645568670666,"score_gpt":0.23946648804927426,"score_spread":0.2273958424806036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214893005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972391,0.02550985,0.0000068479953,0.00020001463,0.00045684382,0.00067846786,0.00008416404,0.00004673094,0.000626064],"genre_scores_gemma":[0.9958541,0.0026684033,0.000090439215,0.00030155212,0.00013311098,0.00011957548,0.00008674559,0.000022537593,0.0007235635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982593,0.0002481366,0.0002713876,0.00040985196,0.00044804282,0.00036330317],"domain_scores_gemma":[0.99801093,0.0012226291,0.00014697091,0.0003902707,0.000039125105,0.00019008943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020415192,0.0002656636,0.0005966922,0.00018834707,0.000404417,0.000067644585,0.00015722537,0.00006219221,0.00004376537],"category_scores_gemma":[0.000329393,0.00018536879,0.00017635681,0.0002458601,0.00015178476,0.00007331125,0.00031957007,0.00016342552,0.000003369916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010229341,0.005574812,0.31324524,0.0012911059,0.023019683,0.00013839046,0.0025140643,0.000012549972,0.37096924,0.008356632,0.03811059,0.23574476],"study_design_scores_gemma":[0.0035786387,0.00033709226,0.8415831,0.000055661767,0.002015304,3.0512817e-7,0.00014965766,0.000114231596,0.108285524,0.0007256198,0.043055482,0.00009937983],"about_ca_topic_score_codex":0.000098354416,"about_ca_topic_score_gemma":0.00000822777,"teacher_disagreement_score":0.5283379,"about_ca_system_score_codex":0.000024762205,"about_ca_system_score_gemma":0.000021591082,"threshold_uncertainty_score":0.75591195},"labels":[],"label_agreement":null},{"id":"W4214940159","doi":"10.1038/s41591-021-01659-1","title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":895,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Duke Clinical Research Institute; Max Rady College of Medicine, University of Manitoba; Akershus Universitetssykehus; Sahlgrenska Universitetssjukhuset; Capital Medical University; Rijksuniversiteit Groningen; Institut National de la Santé et de la Recherche Médicale; Göteborgs Universitet; Boehringer Ingelheim; National University of Singapore; School of Medicine, University of Missouri; Universität Heidelberg; Masarykova Univerzita; Universidade do Porto; Uniwersytet Łódzki; Vanderbilt University Medical Center; KU Leuven; University of Missouri; University of Missouri-Kansas City; Saint Luke's Health System; Université de Lorraine; Vanderbilt University; Universitair Medisch Centrum Groningen; Eli Lilly and Company; National University Health System; University of New South Wales; U.S. Department of Veterans Affairs","keywords":"Empagliflozin; Medicine; Heart failure; Ejection fraction; Clinical endpoint; Placebo; Internal medicine; Randomized controlled trial; Acute decompensated heart failure; Cardiology; Hazard ratio; Confidence interval; Randomization; Clinical trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.004595019715807455,"score_gpt":0.27943613582091753,"score_spread":0.2748411161051101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214940159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9102087,0.0011069585,0.000026157626,0.07221526,0.003925583,0.01168925,0.000048560476,0.00008122051,0.0006982881],"genre_scores_gemma":[0.98742557,0.000028913906,0.0007894816,0.0033461275,0.0008254374,0.003606426,0.0008845327,0.000035471803,0.0030580647],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99777937,0.00018145298,0.00050878397,0.00031987115,0.00088036945,0.0003301235],"domain_scores_gemma":[0.99851716,0.00081752415,0.00015934388,0.0002617558,0.0001528317,0.00009138069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001486929,0.00021392934,0.00076769036,0.00022621588,0.000259166,0.000013772812,0.00014774513,0.00010349093,0.00017846856],"category_scores_gemma":[0.0015666642,0.0001228122,0.00023021387,0.0003688635,0.00013859077,0.00005014033,0.00010324435,0.0005109491,0.0000038829867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77000934,0.0009563514,0.0029740783,0.00003094432,0.00083595153,0.000011059803,0.0003611087,0.000002393956,0.00005495887,0.0020051629,0.22029974,0.0024589247],"study_design_scores_gemma":[0.81711704,0.002376083,0.003634175,0.00004336602,0.0006163464,9.767192e-7,0.00009524805,0.00015372253,0.000052129206,0.00037075955,0.17543496,0.00010522601],"about_ca_topic_score_codex":0.000010736499,"about_ca_topic_score_gemma":0.000007118441,"teacher_disagreement_score":0.07721683,"about_ca_system_score_codex":0.00022985082,"about_ca_system_score_gemma":0.000064204294,"threshold_uncertainty_score":0.5008136},"labels":[],"label_agreement":null},{"id":"W4214951480","doi":"10.1007/s00125-021-05623-z","title":"Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]","year":2022,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Servier; Pfizer; Vetenskapsrådet; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Novo Nordisk; Eisai; Sanofi; Esperion Therapeutics; Merck; GlaxoSmithKline","keywords":"Confounding; Wasting; Human physiology; Medicine; Internal medicine","score_opus":0.011626656362627549,"score_gpt":0.24761818307606667,"score_spread":0.23599152671343912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214951480","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09207279,0.000410685,0.00029215962,0.9008363,0.0016444696,0.0019439117,0.00021908505,0.0003739892,0.0022066042],"genre_scores_gemma":[0.010167162,0.0000755409,0.0007140009,0.97688943,0.0007470849,0.0004793429,0.0034752013,0.00012679369,0.0073254304],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968521,0.00020051698,0.00047446703,0.0010845702,0.00059662835,0.00079170865],"domain_scores_gemma":[0.99871063,0.00014615421,0.00025701747,0.0006359664,0.000094930234,0.00015527342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004579355,0.00055851345,0.00083027885,0.00040863795,0.00026532492,0.00014602604,0.00021611854,0.0003188442,0.0006669557],"category_scores_gemma":[0.00025336884,0.0005299104,0.00018682022,0.0002675456,0.000096311676,0.000118586446,0.00038953387,0.0014581687,0.00007233403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064054395,0.00009345834,0.00078697375,0.00024040852,0.0003752293,0.00079943595,0.0001050476,0.0000045464167,0.0046741045,0.0000106184625,0.98757076,0.0052753515],"study_design_scores_gemma":[0.0012425467,0.0013541114,0.0018525916,0.00017499461,0.000517406,0.000030373454,0.00007265904,0.000040927698,0.0003161769,0.000021703612,0.99387443,0.0005020524],"about_ca_topic_score_codex":0.00022054267,"about_ca_topic_score_gemma":0.0000062302124,"teacher_disagreement_score":0.081905626,"about_ca_system_score_codex":0.00029425535,"about_ca_system_score_gemma":0.00004701612,"threshold_uncertainty_score":0.99971527},"labels":[],"label_agreement":null},{"id":"W4220671970","doi":"10.1161/strokeaha.121.038151","title":"Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists","year":2022,"lang":"en","type":"article","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Trillium Health Centre; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada)","funders":"University of Toronto","keywords":"Stroke (engine); Type 2 diabetes; Diabetes mellitus; Clinical trial; Receptor; Call to action; Disease; Neuroprotection; Type 2 Diabetes Mellitus","score_opus":0.03233677815345037,"score_gpt":0.288355682631964,"score_spread":0.2560189044785136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220671970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933268,0.0002222459,0.000060092138,0.0018530736,0.0014200809,0.0023482486,0.00035511886,0.000053993055,0.00036038973],"genre_scores_gemma":[0.98163867,0.00004784512,0.0024644458,0.00039283672,0.00020159037,0.0015016998,0.00043526883,0.000040447154,0.013277171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987279,0.000031941545,0.0002887493,0.00036605098,0.00022056451,0.00036475505],"domain_scores_gemma":[0.99936604,0.00006359873,0.00012221659,0.00026067637,0.00009958062,0.00008789802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002491749,0.00016018766,0.00032541613,0.00026300992,0.000093382834,0.000011259635,0.00010186351,0.00004897604,0.00005539485],"category_scores_gemma":[0.000094268675,0.00016366917,0.00013898386,0.00021650296,0.000024387742,0.00006284334,0.00008289611,0.00010636075,0.0000065983527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016039131,0.004354052,0.07836316,0.0020283635,0.0014846073,0.000007755499,0.0020579437,0.010309668,0.32420176,0.0019665393,0.19493869,0.3642483],"study_design_scores_gemma":[0.012418619,0.026550781,0.08656642,0.00014750285,0.0008146015,0.0000043732543,0.0011254821,0.00093981205,0.06598418,0.00013364367,0.8046738,0.0006407889],"about_ca_topic_score_codex":0.000049635953,"about_ca_topic_score_gemma":0.00006145463,"teacher_disagreement_score":0.60973513,"about_ca_system_score_codex":0.00023052664,"about_ca_system_score_gemma":0.000054077995,"threshold_uncertainty_score":0.66742355},"labels":[],"label_agreement":null},{"id":"W4220706492","doi":"10.1111/dom.14698","title":"Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"AstraZeneca Pharma Poland; AstraZeneca","keywords":"Medicine; Observational study; Multinational corporation; Type 2 diabetes; Disease; Diabetes mellitus; Health care; Intensive care medicine; Internal medicine; Endocrinology; Economic growth; Finance","score_opus":0.053073966119162624,"score_gpt":0.29522077216829157,"score_spread":0.24214680604912894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220706492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125856,0.006476744,0.000004625492,0.0002435294,0.00004153492,0.0016558396,0.00028400857,0.000027097632,0.000008039237],"genre_scores_gemma":[0.9981306,0.00019670476,0.00009097471,0.00033144528,0.000019843443,0.0003520835,0.00079365174,0.000018755498,0.00006590631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998105,0.00020748546,0.0002620726,0.00034921727,0.00077872217,0.0002975306],"domain_scores_gemma":[0.9991655,0.000105897554,0.00015523519,0.0002030684,0.00023343474,0.00013690416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085225626,0.00019213425,0.000551478,0.00015796216,0.0002515292,0.000036195102,0.00006594491,0.00003213177,0.000017470045],"category_scores_gemma":[0.00012177296,0.00015812244,0.00004699572,0.00043433657,0.000119757184,0.00018888207,0.00015698042,0.00013179485,3.067693e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008856638,0.0010498221,0.99433315,0.00014511065,0.0010610091,0.000011203352,0.0017393826,0.0003681793,0.000006429435,0.00021086134,0.000019135729,0.0009671355],"study_design_scores_gemma":[0.00505844,0.00048285688,0.98964614,0.00011556029,0.0008524047,1.9962079e-7,0.0007426107,0.0003101181,0.00004805437,0.000048343074,0.0025377066,0.00015758612],"about_ca_topic_score_codex":0.00010782529,"about_ca_topic_score_gemma":0.00016805124,"teacher_disagreement_score":0.0068720537,"about_ca_system_score_codex":0.000084462816,"about_ca_system_score_gemma":0.00012324998,"threshold_uncertainty_score":0.6448046},"labels":[],"label_agreement":null},{"id":"W4220787570","doi":"10.1097/xce.0000000000000260","title":"A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada","year":2022,"lang":"en","type":"article","venue":"Cardiovascular Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CARE Canada","funders":"","keywords":"Semaglutide; Discontinuation; Type 2 diabetes; Minimisation (clinical trials); Glycemic; Patient satisfaction","score_opus":0.01683837524699674,"score_gpt":0.22412523038319043,"score_spread":0.2072868551361937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220787570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932398,0.005123484,0.000012908838,0.000028724833,0.000309123,0.0011179283,0.000080187376,0.000016787844,0.00007103743],"genre_scores_gemma":[0.9986864,0.00020169806,0.00016360548,0.00007123265,0.000022742795,0.00067140686,0.000121523306,0.000020616533,0.000040793144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986813,0.00016221032,0.00020149884,0.00034519914,0.00026420664,0.000345565],"domain_scores_gemma":[0.99935347,0.00006380875,0.00007052624,0.00034473347,0.00011316059,0.000054320702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098401695,0.00017410163,0.00063656777,0.00014486995,0.00011420064,0.0000054608035,0.000054197877,0.000016023727,0.000007650297],"category_scores_gemma":[0.00003955279,0.00015025033,0.00012423698,0.00030224049,0.0000561699,0.000051799274,0.000071677314,0.000078445984,2.3832717e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015312881,0.00016444243,0.92192364,0.000024376079,0.0020434426,0.000011338652,0.00019149137,0.00060635805,0.00006281435,0.00003693861,0.000049375005,0.07473267],"study_design_scores_gemma":[0.003956898,0.00062081846,0.9848605,0.00001113229,0.0008014271,0.0000019833249,0.00035719384,0.00007942356,0.00053315,0.000005442824,0.008651214,0.00012081374],"about_ca_topic_score_codex":0.40278944,"about_ca_topic_score_gemma":0.17217006,"teacher_disagreement_score":0.23061937,"about_ca_system_score_codex":0.00041361243,"about_ca_system_score_gemma":0.0002454939,"threshold_uncertainty_score":0.8429357},"labels":[],"label_agreement":null},{"id":"W4220790895","doi":"10.1111/dom.14691","title":"Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from <scp>VERTIS CV</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck KGaA","keywords":"Medicine; Hazard ratio; Metformin; Mace; Internal medicine; Myocardial infarction; Diabetes mellitus; Type 2 diabetes; Confidence interval; Placebo; Stroke (engine); Insulin; Endocrinology; Percutaneous coronary intervention","score_opus":0.010409421984768243,"score_gpt":0.2339835748773109,"score_spread":0.22357415289254265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220790895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951688,0.0020410728,0.0008582861,0.00024038965,0.00027698424,0.00060837413,0.0002443436,0.00017766144,0.000384077],"genre_scores_gemma":[0.9939418,0.00013434683,0.0021061376,0.001977132,0.00017304615,0.000207847,0.00078286364,0.00004822863,0.0006286321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973762,0.00016791321,0.0003479815,0.0007795291,0.0006817839,0.0006466031],"domain_scores_gemma":[0.99840856,0.00022115083,0.00012278548,0.0006487585,0.000086974636,0.0005117945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059693924,0.00041804343,0.0012285518,0.0006223427,0.0004220233,0.00013918403,0.0002319714,0.000059379683,0.00012153507],"category_scores_gemma":[0.00012452666,0.00034892792,0.00032113676,0.0010842958,0.000044570894,0.0003008861,0.0003917246,0.00023898603,0.000014861028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003213522,0.00066463015,0.9763497,0.0000376766,0.0054136207,0.00008548417,0.00057108083,0.00068950956,0.0035622565,0.00008214831,0.00023081938,0.012280951],"study_design_scores_gemma":[0.0023661724,0.0002475064,0.9567767,0.000024873536,0.008059536,7.461346e-7,0.0011129449,0.0014851264,0.006829246,0.00004063371,0.022837138,0.00021939525],"about_ca_topic_score_codex":0.0004492481,"about_ca_topic_score_gemma":0.00008694027,"teacher_disagreement_score":0.022606319,"about_ca_system_score_codex":0.00009716885,"about_ca_system_score_gemma":0.000042114112,"threshold_uncertainty_score":0.9998963},"labels":[],"label_agreement":null},{"id":"W4220804056","doi":"10.2337/dc21-2434","title":"Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institutes of Health; Diabetes Action Research and Education Foundation; American Heart Association","keywords":"Empagliflozin; Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Ejection fraction; Heart failure with preserved ejection fraction; Cardiology; Insulin; Heart failure; Endocrinology","score_opus":0.004680233650283503,"score_gpt":0.21359021193065425,"score_spread":0.20890997828037075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220804056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962826,0.0010462789,9.551806e-7,0.0003142876,0.00008151518,0.0018142466,0.00004000468,0.00010211542,0.00031804485],"genre_scores_gemma":[0.9976109,0.000015108947,0.00018745757,0.0004821648,0.00005246044,0.0008824651,0.0005880521,0.000047505193,0.00013384878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848187,0.00007743372,0.0001722449,0.000489062,0.00036083322,0.000418531],"domain_scores_gemma":[0.9993696,0.00006741417,0.00008552267,0.00021273115,0.00015079557,0.00011392819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009977494,0.00026323943,0.0003613728,0.00023355111,0.0001614481,0.000045498626,0.000051007468,0.000053725948,0.00016526176],"category_scores_gemma":[0.000018521441,0.00020577182,0.000045979858,0.00043684605,0.000058521255,0.00021346807,0.00010525219,0.00025814903,0.000013526063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045051659,0.00036252855,0.9925869,0.00042644193,0.00028399916,0.000011959479,0.0013048225,0.000014903076,0.0005077429,0.0000019292365,0.0010482542,0.0029999788],"study_design_scores_gemma":[0.0067726336,0.0058907648,0.9554225,0.0005871852,0.0003880419,9.5274265e-7,0.025020964,0.00019287992,0.0035214429,0.00000618974,0.0019065986,0.000289813],"about_ca_topic_score_codex":0.000032889886,"about_ca_topic_score_gemma":0.00011380909,"teacher_disagreement_score":0.03716439,"about_ca_system_score_codex":0.00022327954,"about_ca_system_score_gemma":0.000053551652,"threshold_uncertainty_score":0.8391131},"labels":[],"label_agreement":null},{"id":"W4220809339","doi":"10.1007/s11010-022-04411-6","title":"Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Qatar University","keywords":"Empagliflozin; Muscle hypertrophy; Gene isoform; Renin–angiotensin system; EMPA; Intracellular; Diabetic cardiomyopathy; Polyol pathway; Angiotensin II","score_opus":0.025725500239571694,"score_gpt":0.22422582272719252,"score_spread":0.19850032248762084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220809339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897059,0.0003689875,0.000006876661,0.0013421506,0.00025529705,0.0015498189,0.000015299564,0.00006862667,0.0066870046],"genre_scores_gemma":[0.996088,0.000018982893,0.00027154447,0.00053318316,0.000091116606,0.0019495018,0.00007396413,0.000030399942,0.0009432531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834436,0.000089733185,0.00034410754,0.00033744157,0.00047422491,0.0004101211],"domain_scores_gemma":[0.99938786,0.000028830513,0.00011460613,0.0003318534,0.000047160025,0.000089711735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026730774,0.00017689577,0.0004201366,0.00027430884,0.0001038281,0.000008647916,0.000067126144,0.000051673203,0.00005994566],"category_scores_gemma":[0.000053654276,0.00016262304,0.00015636436,0.0005431397,0.000032880365,0.00014052066,0.0003287948,0.00017492175,0.0000051306747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027164111,0.010239126,0.0862244,0.000718647,0.0016180963,0.001707224,0.008691598,0.0007723715,0.4075361,0.0017326926,0.09968915,0.3783542],"study_design_scores_gemma":[0.011918293,0.0009525699,0.4719883,0.00018103856,0.00043040953,0.000028860186,0.0010302286,0.000051703635,0.47433275,0.00067739707,0.037850052,0.0005583889],"about_ca_topic_score_codex":0.00007662037,"about_ca_topic_score_gemma":0.0000063342145,"teacher_disagreement_score":0.38576388,"about_ca_system_score_codex":0.0002334279,"about_ca_system_score_gemma":0.000029578545,"threshold_uncertainty_score":0.6631575},"labels":[],"label_agreement":null},{"id":"W4220897970","doi":"10.1007/s13300-022-01231-1","title":"Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study","year":2022,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Japan Society for the Promotion of Science","keywords":"Dulaglutide; Glycemic; Medicine; Internal medicine; Postprandial; Diabetes mellitus; Type 2 diabetes; Confounding; Endocrinology; Insulin; Liraglutide","score_opus":0.025611590432546776,"score_gpt":0.24125545096083223,"score_spread":0.21564386052828546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220897970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683356,0.00019541822,2.5572757e-7,0.00010455818,0.00014287303,0.002420356,0.00001824666,0.00005503762,0.00022966461],"genre_scores_gemma":[0.99810255,0.000014343769,0.00009285028,0.0003476602,0.000015391564,0.0010046196,0.00003109447,0.000055645323,0.00033584342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802256,0.00021648311,0.0002917073,0.00041817556,0.00055399607,0.0004970986],"domain_scores_gemma":[0.99908465,0.0000940308,0.000096723394,0.00050751626,0.00011623937,0.00010085688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000623896,0.00023238751,0.0005217834,0.00047313317,0.00008390595,0.0000144662035,0.00015922295,0.000019434825,0.00023359028],"category_scores_gemma":[0.0000708228,0.00019450785,0.000062187006,0.0011678109,0.000028087463,0.00014709293,0.00015049159,0.00017203351,0.000010882171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016998496,0.0030196102,0.9722612,0.00001776425,0.0004906946,0.0000096162585,0.0020759297,0.00004683129,0.0012382938,0.000005554056,0.000091551075,0.0037444711],"study_design_scores_gemma":[0.01090986,0.02680614,0.9592585,0.00006513546,0.00006606262,2.684733e-8,0.0009163893,0.000013208717,0.0007170995,0.000015309079,0.0010400601,0.00019223931],"about_ca_topic_score_codex":0.000019459032,"about_ca_topic_score_gemma":0.000006815131,"teacher_disagreement_score":0.02378653,"about_ca_system_score_codex":0.00040348034,"about_ca_system_score_gemma":0.00004942231,"threshold_uncertainty_score":0.79318},"labels":[],"label_agreement":null},{"id":"W4220916416","doi":"10.1007/s40264-022-01166-3","title":"Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data","year":2022,"lang":"en","type":"letter","venue":"Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Drug; Rhabdomyolysis; Drug-drug interaction; Myopathy; Pharmacology; Drug interaction; Adverse effect; Transporter; Statin; Internal medicine","score_opus":0.027004083362397423,"score_gpt":0.2980044733781853,"score_spread":0.2710003900157879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220916416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9452022,0.00013340612,0.00016789086,0.05018443,0.00048426614,0.0015939735,0.001584109,0.00006140864,0.0005883734],"genre_scores_gemma":[0.9448265,0.00009018226,0.0008042773,0.022024635,0.0005819036,0.00006212337,0.027836397,0.000094270734,0.0036797118],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961436,0.00020923244,0.0014668184,0.00081654574,0.0010462845,0.00031756767],"domain_scores_gemma":[0.995471,0.000097678996,0.002886754,0.0013609551,0.0001141212,0.00006947578],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012000697,0.00038380083,0.0008543006,0.00028654793,0.00023334884,0.000013315652,0.00025576737,0.000075446136,0.00033038214],"category_scores_gemma":[0.00006605157,0.0002614634,0.00031781942,0.000578821,0.00012509475,0.00027270676,0.00031493654,0.00081372086,0.0000013416492],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008850459,0.0006414674,0.8914294,0.0016565874,0.010576408,0.0008699239,0.0028694295,0.0004837792,0.00006410861,0.000007490007,0.08866262,0.0018536922],"study_design_scores_gemma":[0.0046323095,0.00014674762,0.4413457,0.001532281,0.053274497,0.00006218924,0.0051789857,0.0034001824,0.0007468328,0.00005069813,0.4884342,0.0011953868],"about_ca_topic_score_codex":0.001082637,"about_ca_topic_score_gemma":0.00037873007,"teacher_disagreement_score":0.45008376,"about_ca_system_score_codex":0.00029004295,"about_ca_system_score_gemma":0.00019377339,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W4220920855","doi":"10.1016/j.yjmcc.2022.03.005","title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","year":2022,"lang":"en","type":"review","venue":"Journal of Molecular and Cellular Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Deutsche Forschungsgemeinschaft; European Foundation for the Study of Diabetes","keywords":"Heart failure; Medicine; Oxidative stress; Homeostasis; Ejection fraction; Inflammation; Endothelial dysfunction; Bioinformatics; Pharmacology; Internal medicine; Biology","score_opus":0.012240565463447565,"score_gpt":0.2595573017893961,"score_spread":0.24731673632594856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220920855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053365435,0.9895864,0.0015023988,0.000079892896,0.0014270607,0.0020328243,0.000011085186,0.0000030578083,0.000020726224],"genre_scores_gemma":[0.05897814,0.93958414,0.0008505542,0.000054047647,0.0002991029,0.00012483494,0.00002809597,0.00005664803,0.000024469762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974397,0.00077630393,0.0008345199,0.00026321088,0.0004151726,0.00027108533],"domain_scores_gemma":[0.998292,0.00046316846,0.00075595704,0.00032367863,0.000083654006,0.00008149395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009496702,0.000320816,0.0030590112,0.00032284367,0.00003995064,0.0000063579582,0.00019821318,0.00024922553,0.000004307783],"category_scores_gemma":[0.00027080145,0.0002151788,0.002433287,0.0002326405,0.000080471575,0.000032959084,0.00019923745,0.00039311848,2.5700095e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010536971,0.00094717694,0.0009988198,0.23488319,0.024762955,0.004111989,0.00024051717,0.00050338253,0.104807675,0.0025296009,0.0048533804,0.6203076],"study_design_scores_gemma":[0.005652445,0.00889017,0.00017027631,0.027891275,0.03826196,0.00044834698,0.000092720446,0.000011865937,0.066690624,0.0014328752,0.84977746,0.000680008],"about_ca_topic_score_codex":0.000004942853,"about_ca_topic_score_gemma":2.572679e-7,"teacher_disagreement_score":0.84492403,"about_ca_system_score_codex":0.00010444759,"about_ca_system_score_gemma":0.000230803,"threshold_uncertainty_score":0.8774737},"labels":[],"label_agreement":null},{"id":"W4220936928","doi":"10.1007/s40258-022-00726-z","title":"Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting","year":2022,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health","funders":"Novo Nordisk Canada; Novo Nordisk","keywords":"Canagliflozin; Quality of Life Research; Health economics; Medicine; Semaglutide; Health administration; Type 2 Diabetes Mellitus; Health care management; Cost effectiveness; Diabetes mellitus; Public health; Internal medicine; Type 2 diabetes; Endocrinology; Nursing","score_opus":0.03358624011243446,"score_gpt":0.3194926053907286,"score_spread":0.28590636527829416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220936928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856398,0.00056692323,1.9618365e-7,0.008923029,0.00010990672,0.0031001512,0.00011053933,0.000011881608,0.0015375721],"genre_scores_gemma":[0.9934083,0.0007355338,0.00014424021,0.0049817865,0.000041348343,0.00037817447,0.00025967645,0.000033566233,0.000017327222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794453,0.000096612755,0.0005167028,0.00036826453,0.00009187814,0.0009820178],"domain_scores_gemma":[0.9988233,0.00011247041,0.0002498227,0.00021623581,0.000022010487,0.00057617313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011451697,0.00019221875,0.0006702509,0.0006602915,0.00019131573,0.000010009129,0.00008019864,0.000041369014,0.000014559381],"category_scores_gemma":[0.0000115274515,0.00020340124,0.00002265041,0.00040058262,0.000041267725,0.00003155347,0.00007396171,0.00022420299,0.0000026533903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018127763,0.0005949745,0.83964086,0.0026346631,0.00017975098,0.000004573977,0.0022622675,0.0018956838,9.545649e-7,0.039708424,0.0005663071,0.110698745],"study_design_scores_gemma":[0.01318198,0.0024247393,0.9545353,0.00016247208,0.000019401823,2.305149e-7,0.00048655472,0.000549138,0.0000047503568,0.00025823017,0.028163081,0.00021409712],"about_ca_topic_score_codex":0.5999537,"about_ca_topic_score_gemma":0.54179806,"teacher_disagreement_score":0.11489444,"about_ca_system_score_codex":0.0046276413,"about_ca_system_score_gemma":0.0044120764,"threshold_uncertainty_score":0.99919343},"labels":[],"label_agreement":null},{"id":"W4220945193","doi":"10.1016/j.jacasi.2022.02.004","title":"Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF","year":2022,"lang":"en","type":"article","venue":"JACC Asia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"University of Glasgow; Defense Acquisition Program Administration; British Heart Foundation; AstraZeneca","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Medicine; Endocrinology","score_opus":0.003278052973868847,"score_gpt":0.21043745905132,"score_spread":0.20715940607745115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220945193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964894,0.000035560523,0.0000031481961,0.00059369707,0.000064022264,0.00077588455,0.000001476556,0.000019647388,0.0020171453],"genre_scores_gemma":[0.9992599,0.0000035486669,0.0002872017,0.00006660635,0.000014513324,0.00010959972,0.000047115962,0.000012899633,0.00019861694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999367,0.000050173963,0.00012359269,0.00016977316,0.00017129438,0.00011815432],"domain_scores_gemma":[0.9997871,0.000019999083,0.000052601074,0.00009821991,0.0000104422115,0.000031637148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000691476,0.00008231824,0.0001814463,0.00023966674,0.000027795017,0.000006091804,0.000021654785,0.000025348665,0.00004160423],"category_scores_gemma":[0.000014109107,0.00007242374,0.000017854687,0.00029784857,0.000012103764,0.000105578794,0.000037807367,0.0001199881,0.0000019526474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003250654,0.0007757845,0.98955846,0.00013183114,0.000036466434,0.00001421436,0.00018053359,0.000010019592,0.00145256,0.000041389823,0.0012699442,0.0062037073],"study_design_scores_gemma":[0.0040109763,0.0009976925,0.98804176,0.00008261952,0.000056375695,8.7867187e-7,0.00056185044,0.000033841134,0.0019464035,0.000023909146,0.004180365,0.000063338055],"about_ca_topic_score_codex":0.000059054873,"about_ca_topic_score_gemma":0.000048653936,"teacher_disagreement_score":0.0061403695,"about_ca_system_score_codex":0.00011907353,"about_ca_system_score_gemma":0.000015545076,"threshold_uncertainty_score":0.29533544},"labels":[],"label_agreement":null},{"id":"W4220949041","doi":"10.1111/dom.14700","title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Semaglutide; Liraglutide; Mace; Medicine; Hazard ratio; Type 2 diabetes; Internal medicine; Myocardial infarction; Placebo; Empagliflozin; Diabetes mellitus; Confidence interval; Gastroenterology; Surgery; Endocrinology; Percutaneous coronary intervention","score_opus":0.006453551494449718,"score_gpt":0.1985013044114067,"score_spread":0.192047752916957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220949041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634762,0.03530276,0.0000023729233,0.0002287018,0.00005082773,0.0007116611,0.000058033933,0.00003223533,0.00013723079],"genre_scores_gemma":[0.9983088,0.00051123736,0.0004247576,0.00036948494,0.000042319396,0.0001303744,0.00005124771,0.000023891356,0.00013791835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843526,0.0001376342,0.00023470524,0.0004388323,0.00036121646,0.0003923329],"domain_scores_gemma":[0.9992523,0.00008263408,0.000070738366,0.00031655323,0.000026818021,0.00025093206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000485718,0.0002474649,0.0007619434,0.00023645887,0.00014683556,0.000033401342,0.00006672548,0.000033943423,0.00003234555],"category_scores_gemma":[0.00004463467,0.00020906678,0.000114250906,0.00022453876,0.00020574432,0.00011695989,0.0002685501,0.00016662973,4.6059233e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004054647,0.0004364748,0.9828992,0.00031537435,0.00096381904,0.000027801372,0.0005439796,0.000047300473,0.00016564497,0.00026955357,0.00004434548,0.014245945],"study_design_scores_gemma":[0.0047001685,0.0001962232,0.9846961,0.00008785518,0.0015789777,0.0000014828155,0.00017410958,0.00017975943,0.00028288495,0.00020526818,0.0076777916,0.00021940659],"about_ca_topic_score_codex":0.000019444156,"about_ca_topic_score_gemma":0.0000029918467,"teacher_disagreement_score":0.03483259,"about_ca_system_score_codex":0.000022705546,"about_ca_system_score_gemma":0.000034326473,"threshold_uncertainty_score":0.8525496},"labels":[],"label_agreement":null},{"id":"W4220961894","doi":"10.1016/s0735-1097(22)02518-9","title":"ASSOCIATION OF SODIUM/GLUCOSE COTRANSPORTER-2 INHIBITORS WITH OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND ATRIAL FIBRILLATION","year":2022,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Atrial fibrillation; Type 2 diabetes; Internal medicine; Diabetes mellitus; Cotransporter; Cardiology; Endocrinology; Sodium","score_opus":0.00430442274479376,"score_gpt":0.20844989756449808,"score_spread":0.20414547481970433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220961894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874604,0.00008860323,0.0000014477184,0.00066235143,0.00014676327,0.00024608013,0.000028799272,0.0000016724972,0.00007821708],"genre_scores_gemma":[0.99966455,0.00003227194,0.00011858491,0.000037989917,0.0000655387,0.0000011065423,0.000004155667,0.000006971437,0.00006884194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991375,0.0001249128,0.000281296,0.000064491454,0.00029571736,0.00009607163],"domain_scores_gemma":[0.9988346,0.00010110951,0.0008192334,0.0000891865,0.00013296522,0.000022906115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002448957,0.00007113099,0.00060780824,0.00013367618,0.000024394885,0.000001059929,0.00004858897,0.000013852344,0.0000032348862],"category_scores_gemma":[0.000039441293,0.000040966468,0.00011025173,0.00026727022,0.00008466481,0.00003454065,0.000028296956,0.00008521881,4.3930793e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001681984,0.000025093932,0.9954449,0.000013445065,0.00096633803,0.000006651264,0.00003823761,0.0007206752,0.00008342429,0.0000058113224,0.00023295701,0.00078049884],"study_design_scores_gemma":[0.004185634,0.005461706,0.988349,0.000025087014,0.0005750049,0.0000031204768,0.00018153968,0.0000065728686,0.00015391487,0.000013664767,0.0010035341,0.00004122506],"about_ca_topic_score_codex":0.000005303544,"about_ca_topic_score_gemma":0.000004573479,"teacher_disagreement_score":0.007095887,"about_ca_system_score_codex":0.00012057391,"about_ca_system_score_gemma":0.0000649561,"threshold_uncertainty_score":0.16705641},"labels":[],"label_agreement":null},{"id":"W4220977619","doi":"10.1007/s12265-022-10220-5","title":"Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling","year":2022,"lang":"en","type":"review","venue":"Journal of Cardiovascular Translational Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Heart, Lung, and Blood Institute","keywords":"Empagliflozin; Heart failure; Dapagliflozin; Ejection fraction; Medicine; Internal medicine; Ventricular remodeling; Cardiac function curve; Cardiology; Autophagy; Type 2 diabetes; Diabetes mellitus; Endocrinology; Apoptosis; Biology","score_opus":0.1331280920644828,"score_gpt":0.3844339596036406,"score_spread":0.25130586753915773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220977619","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000101439284,0.9961602,0.00016507122,0.00013117853,0.0003316308,0.0010922739,0.000032663556,0.000010678482,0.0019748835],"genre_scores_gemma":[0.00019091621,0.9976778,0.0006471426,0.000008420414,0.0008303747,0.000055493954,0.00016453693,0.000077586505,0.0003476973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99365693,0.00070963526,0.0010166512,0.00037957806,0.0038085594,0.00042862853],"domain_scores_gemma":[0.99818903,0.00044801112,0.00018683971,0.0004349539,0.0004426535,0.00029848202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006403514,0.0003313978,0.0025328633,0.0012093127,0.0002025316,0.000067673405,0.00020708366,0.00019685965,0.00017645714],"category_scores_gemma":[0.00008423858,0.00025715653,0.0045619863,0.00062956876,0.00012921907,0.00017116884,0.000056385426,0.0015333842,0.000010323015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006772317,0.00010187723,0.000024251009,0.0066488907,0.013101024,0.00040337892,0.00008069142,0.00006710135,7.98408e-7,0.000107121814,0.00046041454,0.97893673],"study_design_scores_gemma":[0.0011147677,0.00025667157,0.000041060528,0.0033783198,0.010531747,0.00015665499,0.000042394888,0.000011788184,0.000001980633,0.00010184806,0.9841764,0.00018635263],"about_ca_topic_score_codex":0.000008945781,"about_ca_topic_score_gemma":2.7084153e-7,"teacher_disagreement_score":0.983716,"about_ca_system_score_codex":0.0002636257,"about_ca_system_score_gemma":0.00095118367,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W4221032209","doi":"10.1016/j.diabres.2022.109837","title":"Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease","year":2022,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; COPD; Internal medicine; Diabetes mellitus; Placebo; Type 2 Diabetes Mellitus; Type 2 diabetes; Heart failure; Endocrinology; Pathology","score_opus":0.0378731214306312,"score_gpt":0.3782320886644657,"score_spread":0.3403589672338345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221032209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867949,0.007664457,1.4359739e-7,0.0019116692,0.000100558245,0.0010287736,0.000023868564,0.000025873453,0.0024497763],"genre_scores_gemma":[0.99723566,0.0011120805,0.00016062304,0.0005174432,0.00008957349,0.00016296854,0.00014405322,0.00002908851,0.00054849917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693483,0.000626119,0.00035041105,0.00060365937,0.0008220918,0.00066288095],"domain_scores_gemma":[0.99647355,0.0023156088,0.000093904266,0.000356297,0.00025843907,0.0005022037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016992794,0.00017400179,0.0003610415,0.00021354426,0.0002645844,0.000067573965,0.00011779129,0.0000479075,0.00015583124],"category_scores_gemma":[0.0020034183,0.00013964047,0.000041998268,0.000572886,0.00040988697,0.00036406302,0.00051588303,0.000869157,0.000018941655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016171564,0.0025668605,0.9245045,0.00013025271,0.00028556946,0.00009934705,0.00003343436,0.0000018791958,0.0000051754687,0.00017544003,0.0004464428,0.07013392],"study_design_scores_gemma":[0.0029002253,0.0057944846,0.9562807,0.00005636,0.00022057867,2.9687078e-7,0.00028886314,0.00027876793,0.0000075487796,0.00053832534,0.033476826,0.00015701665],"about_ca_topic_score_codex":0.000013615938,"about_ca_topic_score_gemma":0.0000044627313,"teacher_disagreement_score":0.069976896,"about_ca_system_score_codex":0.00019175402,"about_ca_system_score_gemma":0.00017247569,"threshold_uncertainty_score":0.5694373},"labels":[],"label_agreement":null},{"id":"W4221061708","doi":"10.1016/j.jcjd.2022.02.010","title":"Potential Overtreatment and Overtesting Among Older Adults With Type 2 Diabetes Across Canada: An Observational, Retrospective Cohort Study","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; University of Manitoba","funders":"Canadian Institutes of Health Research; Public Health Agency of Canada; International Business Machines Corporation","keywords":"Medicine; Observational study; Retrospective cohort study; Cohort; Type 2 diabetes; Pediatrics; Cohort study; Diabetes mellitus; Emergency medicine; Internal medicine; Endocrinology","score_opus":0.0118851312819064,"score_gpt":0.22606948943036914,"score_spread":0.21418435814846273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221061708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977549,0.00069202547,3.2829962e-7,0.00022768365,0.0003015715,0.00082331244,0.00007246193,0.000010937072,0.000116818934],"genre_scores_gemma":[0.9990064,0.0000028833367,0.00008301441,0.00043786154,0.00010843424,0.00005213109,0.00007745415,0.000036102992,0.00019571537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817145,0.000073576775,0.00033119452,0.0002996782,0.000586423,0.000537655],"domain_scores_gemma":[0.99844056,0.000046239395,0.00026100347,0.00022122003,0.00035218723,0.000678804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034007008,0.000233721,0.00048721055,0.00011528242,0.00048813966,0.000077670156,0.00012967708,0.000027035652,0.00017747478],"category_scores_gemma":[0.00007861523,0.0001953717,0.000050137598,0.00030671133,0.00008475944,0.00025341014,0.000044361757,0.00023940956,3.5472243e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002043031,0.00024438146,0.99528205,0.00002444394,0.00096082455,0.00025370417,0.0007512435,0.000119897195,0.000010763023,0.000007271848,0.001060666,0.0012643416],"study_design_scores_gemma":[0.0027874545,0.00361446,0.98897624,0.00011416148,0.0005640981,0.000005303468,0.0032329522,0.00028579633,0.000028321556,0.000010181647,0.00018770772,0.0001933151],"about_ca_topic_score_codex":0.12715971,"about_ca_topic_score_gemma":0.65163463,"teacher_disagreement_score":0.5244749,"about_ca_system_score_codex":0.0013412432,"about_ca_system_score_gemma":0.0012415652,"threshold_uncertainty_score":0.8786526},"labels":[],"label_agreement":null},{"id":"W4221072938","doi":"10.1016/j.ijcard.2022.01.042","title":"Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice","year":2022,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Medicine; Mace; Hazard ratio; Internal medicine; Myocardial infarction; Stroke (engine); Proportional hazards model; Heart failure; Propensity score matching; Confidence interval; Population; Percutaneous coronary intervention","score_opus":0.0609612650375356,"score_gpt":0.4193902435184045,"score_spread":0.35842897848086885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221072938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871589,0.0004515399,0.00030614703,0.00055268075,0.0030306492,0.00023021085,0.000011465641,0.0000051815528,0.008253217],"genre_scores_gemma":[0.99905825,0.00007948158,0.00034836875,0.00016253012,0.00028002617,0.000015418549,0.000020387533,0.0000072533176,0.00002830603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973246,0.0012170335,0.0005362784,0.0001488913,0.00066629273,0.000106940446],"domain_scores_gemma":[0.99761474,0.001458629,0.00030636415,0.0001746207,0.00039379793,0.000051852807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028000912,0.00010038772,0.0009622602,0.00026151616,0.000017258579,0.0000050357867,0.00021078772,0.000037194586,0.000022234488],"category_scores_gemma":[0.000576225,0.00008092508,0.00058199075,0.000078996,0.000060274244,0.00010383634,0.00010581724,0.0003220743,0.0000040617797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05994973,0.003075421,0.75679994,0.00004160448,0.06117856,0.0056968103,0.00043742487,0.08387842,0.0002221879,0.008000093,0.00079851784,0.019921303],"study_design_scores_gemma":[0.024496222,0.010022109,0.9074425,0.00006726587,0.0012757652,0.00035324143,0.0008917926,0.00008007779,0.00023382096,0.00019115953,0.054822665,0.00012339372],"about_ca_topic_score_codex":0.00001842648,"about_ca_topic_score_gemma":9.65565e-7,"teacher_disagreement_score":0.15064256,"about_ca_system_score_codex":0.0002802032,"about_ca_system_score_gemma":0.000090081114,"threshold_uncertainty_score":0.33000287},"labels":[],"label_agreement":null},{"id":"W4223506727","doi":"10.1016/j.neubiorev.2022.104654","title":"Glucose-lowering drugs, cognition, and dementia: The clinical evidence","year":2022,"lang":"en","type":"review","venue":"Neuroscience & Biobehavioral Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Toronto Dementia Research Alliance; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; Heart and Stroke Foundation; Institute for Clinical Evaluative Sciences","funders":"Canadian Institutes of Health Research","keywords":"Dementia; Context (archaeology); Neuropsychology; Cognition; Neuroimaging; Neurology; Extant taxon; Neuroscience; Psychology; Medicine; Psychiatry; Internal medicine; Disease; Biology","score_opus":0.3495738675750645,"score_gpt":0.47260144006254434,"score_spread":0.12302757248747986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223506727","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000136796,0.99380636,0.000006904278,0.000029977462,0.0011485751,0.004425724,0.000013879147,0.000068429435,0.00036333522],"genre_scores_gemma":[0.00007705681,0.99667776,0.00009651725,0.0013761936,0.00014016086,0.0011514433,0.00003977478,0.000045335117,0.00039574312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960536,0.0003824966,0.0013416403,0.001069975,0.0006553141,0.0004970122],"domain_scores_gemma":[0.9980419,0.000036574005,0.0006956543,0.00093179825,0.000033564727,0.00026048682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024176054,0.00055438955,0.0019242709,0.00015047973,0.00044809998,0.00018043593,0.00057922845,0.000112991955,0.00038927732],"category_scores_gemma":[0.00052120566,0.00031955942,0.00082922727,0.0007872299,0.00048698785,0.00023705992,0.0007583744,0.0007187743,0.000103416365],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000033244103,0.00018614117,0.00020516156,0.0025179018,0.000001823013,0.000046918456,0.000012005737,3.6302799e-9,0.0000038467115,0.000012747503,0.0022860616,0.99472404],"study_design_scores_gemma":[0.0001883915,0.0005231369,0.00021925995,0.007270732,0.0076449406,0.00005036136,0.000013053088,7.8400194e-7,4.86949e-7,0.0000030179176,0.9838196,0.00026623582],"about_ca_topic_score_codex":0.0000072055705,"about_ca_topic_score_gemma":0.0000017910555,"teacher_disagreement_score":0.99445784,"about_ca_system_score_codex":0.00009196052,"about_ca_system_score_gemma":0.00020316498,"threshold_uncertainty_score":0.9999257},"labels":[],"label_agreement":null},{"id":"W4223542536","doi":"10.1097/ede.0000000000001486","title":"Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Dipeptidyl peptidase-4; Oncology; Proportional hazards model; Type 2 diabetes; Incidence (geometry); Confounding; Cancer; Incretin; Propensity score matching; Cohort study; Confidence interval; Cohort; Endocrinology; Diabetes mellitus","score_opus":0.010230844965140203,"score_gpt":0.2586926382314632,"score_spread":0.248461793266323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223542536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941539,0.00080880494,0.0000018338916,0.0037805487,0.00007801192,0.00060096866,0.000010446511,0.000014833417,0.0005506563],"genre_scores_gemma":[0.9963003,0.00004378463,0.00017103444,0.0026569895,0.000013661799,0.00024861976,0.000057768066,0.000009031446,0.0004988505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990028,0.0003229842,0.00019928026,0.00016756148,0.000117914824,0.00018943533],"domain_scores_gemma":[0.9986844,0.00086049864,0.00017293189,0.00017261687,0.00007101117,0.000038539965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000989004,0.00008590907,0.000361129,0.000045365377,0.000075810276,0.0000012703475,0.000062754574,0.000017346081,0.0001337302],"category_scores_gemma":[0.00045166287,0.00004692659,0.000027942287,0.0001268011,0.00035483507,0.000018705605,0.0001023387,0.00010439456,0.0000012595218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048053835,0.000059146576,0.994587,0.00003891249,0.00011103716,9.252867e-7,0.00024643962,0.00016161363,0.0000037564525,0.00035745953,0.0015771887,0.0023759957],"study_design_scores_gemma":[0.0038223083,0.0009416864,0.9897081,0.000036147045,0.00018447329,7.399064e-8,0.000063890635,0.0009081634,0.000045071072,0.00033292323,0.0038960662,0.00006107259],"about_ca_topic_score_codex":0.00031404008,"about_ca_topic_score_gemma":0.000016504187,"teacher_disagreement_score":0.0048788623,"about_ca_system_score_codex":0.00003898382,"about_ca_system_score_gemma":0.000035859295,"threshold_uncertainty_score":0.19136108},"labels":[],"label_agreement":null},{"id":"W4223917188","doi":"10.1016/j.jcjd.2022.04.004","title":"New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Diabetes Action Canada; University Hospital Foundation; Novo Nordisk","keywords":"Medicine; Diabetes mellitus; Kidney disease; Glycated hemoglobin; Disease; Type 2 diabetes; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.016152411986575254,"score_gpt":0.2643357332616482,"score_spread":0.24818332127507298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223917188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916513,0.0031274573,0.0000016794322,0.0031488761,0.00095349044,0.00069846306,0.00027888545,0.000008263224,0.00013156561],"genre_scores_gemma":[0.99652517,0.000036288457,0.00051214686,0.002150314,0.000256078,0.00004253462,0.000107979264,0.00004531188,0.00032420343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976003,0.000060011153,0.00083549874,0.000323252,0.00038773366,0.0007932104],"domain_scores_gemma":[0.997674,0.00017621035,0.000376518,0.0002792004,0.00019053833,0.0013035382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006179233,0.00033048642,0.0007304428,0.0005111044,0.00018314735,0.00005057259,0.00021078016,0.000050969415,0.00030747527],"category_scores_gemma":[0.00019987983,0.0002842971,0.00024454444,0.00031755574,0.00005403363,0.00013658275,0.000023363435,0.00031246903,0.0000015618218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056409022,0.000062878826,0.8526258,0.000105506806,0.0003329642,0.000053271797,0.00017378152,0.00020062998,0.00037226197,0.000015571492,0.124413855,0.021587076],"study_design_scores_gemma":[0.010737478,0.0059455493,0.7669092,0.0008565561,0.0007521793,0.000008399417,0.0014727468,0.00040611593,0.005892238,0.0004655065,0.2056153,0.0009387634],"about_ca_topic_score_codex":0.40227687,"about_ca_topic_score_gemma":0.8140563,"teacher_disagreement_score":0.4117794,"about_ca_system_score_codex":0.002626336,"about_ca_system_score_gemma":0.007763907,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W4223922377","doi":"10.1016/s2213-8587(22)00043-2","title":"Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; Seventh Framework Programme; Novo Nordisk; Boston Scientific Corporation; AstraZeneca; Biotronik; Bristol-Myers Squibb; Cleveland Clinic; Sanofi; Cardiological Society of India; Novartis; Merck; Mayo Clinic; Bayer; Abbott Laboratories; CSL Behring; Roche; St. Jude Medical; Astellas Pharma US; Philips; Pfizer; Boehringer Ingelheim; Amgen; National Institutes of Health; Regeneron Pharmaceuticals; Hartstichting; American Heart Association","keywords":"Alirocumab; Randomized controlled trial; MEDLINE; Acute coronary syndrome; Diabetes mellitus; Cardiovascular event","score_opus":0.008161324328906525,"score_gpt":0.24630018301507098,"score_spread":0.23813885868616447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223922377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031335,0.0042624655,4.5392397e-7,0.0004268459,0.0003587405,0.004322225,0.00020796541,0.00003377241,0.00007418436],"genre_scores_gemma":[0.99726737,0.0005194067,0.000006359015,0.0003074777,0.000023796554,0.0016298918,0.00005580992,0.000023615888,0.0001662603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651533,0.0015412391,0.00047462652,0.0003427495,0.00049561163,0.0006304238],"domain_scores_gemma":[0.9972425,0.0012866824,0.00034580406,0.0010357106,0.000038750288,0.00005055789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086929527,0.00032742415,0.0034336366,0.0003102693,0.00013647902,0.0000059563868,0.00033265748,0.000041848416,0.0001334587],"category_scores_gemma":[0.00019432888,0.0001527226,0.0018378891,0.00042513438,0.0001697566,0.000030052639,0.00035141173,0.00025896347,0.0000018874545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17155391,0.00025798831,0.7131703,0.000038561466,0.113023505,0.000033815522,0.00016226516,0.00013181167,0.00010163877,0.000054250333,0.000030964376,0.0014409896],"study_design_scores_gemma":[0.34994164,0.003006998,0.5893088,0.000008042613,0.05681279,0.0000029158734,0.00003335708,0.000042559997,0.00047119244,0.000024521512,0.00025115986,0.00009599658],"about_ca_topic_score_codex":0.00007247746,"about_ca_topic_score_gemma":0.0000062092527,"teacher_disagreement_score":0.17838775,"about_ca_system_score_codex":0.00004470139,"about_ca_system_score_gemma":0.000020746967,"threshold_uncertainty_score":0.6227847},"labels":[],"label_agreement":null},{"id":"W4224048273","doi":"10.3233/jad-215195","title":"Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia: Data from the ORIGIN Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Alzheimer s Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Cognition; Medicine; Psychology; Clinical psychology; Internal medicine; Psychiatry","score_opus":0.041464587223143806,"score_gpt":0.2969094664494448,"score_spread":0.255444879226301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224048273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921256,0.005396179,0.000018535424,0.00134062,0.00020439857,0.0007053923,0.00012908044,0.000003331722,0.000076895456],"genre_scores_gemma":[0.99927634,0.00017880063,0.00006131744,0.00020186168,0.00010143838,0.000024604224,0.00012653715,0.000009467952,0.000019609746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998888,0.00010735535,0.00030456504,0.00014655635,0.00045507282,0.00009840563],"domain_scores_gemma":[0.9991465,0.00013106524,0.0003086397,0.00023074537,0.000057652505,0.00012536735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003440685,0.00009344827,0.00023506225,0.000100852936,0.000047897607,0.0000131425695,0.00011937916,0.000011058706,0.00023706396],"category_scores_gemma":[0.000069312315,0.00005637684,0.000052235693,0.00016359953,0.000046335637,0.00014688329,0.00018439832,0.00013459534,0.0000010163221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17271914,0.002040669,0.8010425,0.000038054728,0.0049370453,0.0003703481,0.00054677646,0.000026551686,0.000035332043,0.000013220056,0.007041909,0.011188465],"study_design_scores_gemma":[0.06438898,0.0024637184,0.9185166,0.00018234362,0.0109651005,0.0000100996385,0.0019894037,0.00022563894,0.000050254337,0.000049833136,0.0010688757,0.000089160705],"about_ca_topic_score_codex":0.000105725994,"about_ca_topic_score_gemma":0.0000387788,"teacher_disagreement_score":0.11747409,"about_ca_system_score_codex":0.00005074632,"about_ca_system_score_gemma":0.00020132062,"threshold_uncertainty_score":0.2595684},"labels":[],"label_agreement":null},{"id":"W4224218205","doi":"10.1111/dom.14725","title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; York University","funders":"Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Medicine; Placebo; Weight loss; Body mass index; Randomized controlled trial; Internal medicine; Physical therapy; Diabetes mellitus; Obesity; Type 2 diabetes; Endocrinology","score_opus":0.005126095142822623,"score_gpt":0.20570540382778232,"score_spread":0.2005793086849597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224218205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962288,0.034658436,0.0000073557853,0.00022789245,0.00062238367,0.0014727118,0.000028061726,0.00004789494,0.0006472416],"genre_scores_gemma":[0.9959238,0.00072303077,0.00025114682,0.0008502105,0.00027556007,0.00039983133,0.00002786609,0.000029412136,0.0015191417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980699,0.00030215707,0.0002883507,0.0004299586,0.00048170687,0.0004279576],"domain_scores_gemma":[0.99884504,0.000317493,0.00014063931,0.00047052818,0.000058996582,0.00016727785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079274736,0.00027839685,0.0008365853,0.0002442577,0.00028755047,0.000036684844,0.000114121496,0.00006303848,0.000019917856],"category_scores_gemma":[0.00016160471,0.00019073095,0.00019302731,0.00040246482,0.00020069948,0.000091371454,0.00042417113,0.0002382965,0.000004124277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047471756,0.004453789,0.66686255,0.0033720005,0.008098166,0.00041268347,0.0065089283,0.000020790381,0.02216901,0.0155421095,0.026076036,0.24173675],"study_design_scores_gemma":[0.028561125,0.0006605579,0.76623297,0.00006904605,0.0031479434,0.000007686556,0.00022744898,0.00014193126,0.004798244,0.00051105156,0.19550768,0.00013431927],"about_ca_topic_score_codex":0.000031372765,"about_ca_topic_score_gemma":0.000002708498,"teacher_disagreement_score":0.24160244,"about_ca_system_score_codex":0.00001972313,"about_ca_system_score_gemma":0.000032343505,"threshold_uncertainty_score":0.77777827},"labels":[],"label_agreement":null},{"id":"W4224226215","doi":"10.1161/circulationaha.121.058910","title":"Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; Relypsa; Defense Acquisition Program Administration; Respicardia; American Regent; Vifor Pharma; Daiichi-Sankyo; University of Glasgow; Zora Biosciences; GlaxoSmithKline; IFM Therapeutics; Janssen Research and Development; Sarepta Therapeutics; Medicines Company; Intarcia Therapeutics; Ionis Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; AstraZeneca; Amarin Corporation; Sanofi Pasteur; Celladon Corporation; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Harvard Catalyst; Eisai; Cytokinetics; FibroGen; Daiichi Sankyo Europe; Servier; Bayer; Gilead Sciences; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Amgen; Moderna; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ejection fraction; Dapagliflozin; Heart failure; Renal function; Cardiology; Internal medicine; Filtration fraction; Fraction (chemistry); Urology; Endocrinology; Chromatography; Diabetes mellitus; Renal blood flow","score_opus":0.013160293113738154,"score_gpt":0.246951857979413,"score_spread":0.23379156486567484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224226215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985787,0.00006533881,0.00019720168,0.00019177409,0.000088234934,0.00074895035,0.000012444166,0.000026553802,0.00009076055],"genre_scores_gemma":[0.99736965,0.0000032930493,0.0004016911,0.0001241857,0.00003470157,0.00012345944,0.0019258539,0.0000144042915,0.0000027578571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989892,0.00011417607,0.00030343427,0.00024472765,0.00025075526,0.00009771122],"domain_scores_gemma":[0.9996011,0.000034339795,0.00013220012,0.00013041068,0.00007093509,0.000030973275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108110136,0.000112911475,0.00020363963,0.00034138947,0.00005038809,0.000016029382,0.0000189398,0.000051749135,0.00009466716],"category_scores_gemma":[0.000030888135,0.0001135771,0.000020610385,0.00044244688,0.00001908932,0.0003647301,0.000026234637,0.00011514708,0.0000021194144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008061075,0.00040688642,0.9912664,0.00003366095,0.000034933026,0.0000063436896,0.00023471923,0.0021107977,0.0041383975,0.000025711674,0.000017975413,0.000918051],"study_design_scores_gemma":[0.0045238473,0.00028295172,0.9871035,0.00009206561,0.000087455104,5.050917e-7,0.00013585042,0.006407615,0.0009180665,0.00025343284,0.00009418126,0.00010051733],"about_ca_topic_score_codex":0.00012835255,"about_ca_topic_score_gemma":0.00012543803,"teacher_disagreement_score":0.0042968174,"about_ca_system_score_codex":0.0002196147,"about_ca_system_score_gemma":0.000031140647,"threshold_uncertainty_score":0.463154},"labels":[],"label_agreement":null},{"id":"W4224231338","doi":"10.1007/s40258-022-00734-z","title":"Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting","year":2022,"lang":"en","type":"erratum","venue":"Applied Health Economics and Health Policy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health","funders":"","keywords":"Semaglutide; Quality of Life Research; Health economics; Health administration; Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Health care management; Public health; Type 2 diabetes; Internal medicine; Endocrinology; Nursing","score_opus":0.02269673428453388,"score_gpt":0.3126448371870627,"score_spread":0.2899481029025288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224231338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86840934,0.0046038954,0.0000013166106,0.031383343,0.020476082,0.026818663,0.0013068162,0.00009288769,0.04690768],"genre_scores_gemma":[0.9452041,0.015131366,0.0003997147,0.023177683,0.0010567732,0.0026336682,0.008250477,0.00034163083,0.0038046062],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9968223,0.00012867925,0.0008362373,0.0006849918,0.00014661727,0.001381168],"domain_scores_gemma":[0.99790096,0.00018568317,0.00051833136,0.00037291105,0.000049694823,0.00097244047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012821755,0.00040835835,0.001374291,0.0014964862,0.00020155808,0.000021767575,0.00012337674,0.00016606832,0.000024339162],"category_scores_gemma":[0.000044810626,0.00044216946,0.000044318345,0.000636832,0.00004379319,0.000035222,0.00009698302,0.0006964942,0.0000063293037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004343073,0.0011089058,0.27181023,0.014799162,0.0006809737,0.00001104083,0.0034368008,0.002209019,2.9739445e-7,0.008551767,0.35238263,0.3406661],"study_design_scores_gemma":[0.007365536,0.0032760354,0.5346389,0.0011181873,0.00004521392,2.5195408e-7,0.00024467256,0.00051863835,8.6240726e-7,0.00006033162,0.4523598,0.00037159197],"about_ca_topic_score_codex":0.79688025,"about_ca_topic_score_gemma":0.8670549,"teacher_disagreement_score":0.34029448,"about_ca_system_score_codex":0.010932599,"about_ca_system_score_gemma":0.0118721,"threshold_uncertainty_score":0.999803},"labels":[],"label_agreement":null},{"id":"W4224235109","doi":"10.1007/s00125-022-05694-6","title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","year":2022,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Defense Acquisition Program Administration; Steno Diabetes Center Copenhagen; AstraZeneca","keywords":"Post-hoc analysis; Medicine; Dapagliflozin; Baseline (sea); Internal medicine; Post hoc; Kidney disease; Renal function; Diabetes mellitus; Endocrinology; Type 2 diabetes; Biology","score_opus":0.005373868576763515,"score_gpt":0.23431867540084975,"score_spread":0.22894480682408624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224235109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586535,0.0011596971,0.000010062326,0.0004335563,0.00025901108,0.0011751945,0.000548837,0.00002967506,0.0005186292],"genre_scores_gemma":[0.9984943,0.000100126264,0.000021708454,0.00048102505,0.000016410995,0.0001690449,0.00035951418,0.000016197015,0.0003416602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997833,0.0006727497,0.00036457102,0.0003556029,0.0005383245,0.00023572995],"domain_scores_gemma":[0.99828714,0.0005307747,0.00021620469,0.00082164083,0.000050335802,0.00009391758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015327322,0.00022565424,0.0013012375,0.00027439723,0.00011693694,0.0000083450805,0.00018630346,0.00005573577,0.00014901636],"category_scores_gemma":[0.00080382323,0.00013400817,0.00087004347,0.00081869063,0.00013322131,0.00002721206,0.0002162757,0.00017654234,0.0000018307882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011892107,0.0010998087,0.8936586,0.00027007557,0.04763141,0.00002203368,0.00038739512,0.00040667888,0.00041278783,0.00023132045,0.014897507,0.029090323],"study_design_scores_gemma":[0.2471253,0.062060077,0.32088533,0.00014946946,0.23334652,0.0000032364917,0.0016250884,0.0032841163,0.030749485,0.000106021194,0.09927738,0.0013879739],"about_ca_topic_score_codex":0.00024386735,"about_ca_topic_score_gemma":0.000006759988,"teacher_disagreement_score":0.5727732,"about_ca_system_score_codex":0.000057617857,"about_ca_system_score_gemma":0.000038851802,"threshold_uncertainty_score":0.54646945},"labels":[],"label_agreement":null},{"id":"W4224284592","doi":"10.1007/s42399-022-01182-5","title":"The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review","year":2022,"lang":"en","type":"review","venue":"SN Comprehensive Clinical Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Internal medicine; Disease; MEDLINE; Incidence (geometry); Type 2 diabetes; Endocrinology","score_opus":0.08780975076763388,"score_gpt":0.43302406636088203,"score_spread":0.34521431559324817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224284592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004905141,0.9858282,0.000004770742,0.002765302,0.0006896615,0.0101367505,0.000074227704,0.00005569419,0.00044043895],"genre_scores_gemma":[0.000017689983,0.99567044,0.000019798144,0.0009100522,0.0006237455,0.0010645762,0.00096465717,0.0000471904,0.000681849],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921564,0.0025521403,0.003151531,0.00070042216,0.0010649436,0.00037458024],"domain_scores_gemma":[0.98075193,0.014384914,0.0027386327,0.0012552092,0.0002960492,0.00057323836],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004463106,0.00051742303,0.006605946,0.00010490686,0.00017401742,0.000011063475,0.00033779917,0.0002071726,0.00019939158],"category_scores_gemma":[0.018479481,0.00025981446,0.00081002305,0.000495283,0.00040619785,0.000031707572,0.0004588643,0.00083289953,0.000017709244],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018028004,0.0001383551,0.00063113455,0.7179786,0.002098248,0.00001404971,0.0000045531383,3.442485e-9,1.4153655e-8,0.000070444046,0.008037115,0.27100945],"study_design_scores_gemma":[0.0007438793,0.00083384645,0.00022299192,0.43534943,0.03466291,0.0000022227937,0.000005477091,0.0000026300427,5.9651306e-9,0.000044170163,0.52802473,0.000107672],"about_ca_topic_score_codex":0.000002423232,"about_ca_topic_score_gemma":2.5800725e-7,"teacher_disagreement_score":0.51998764,"about_ca_system_score_codex":0.00068000134,"about_ca_system_score_gemma":0.00061138347,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W4224310469","doi":"10.1080/17512433.2022.2070473","title":"Pharmacological profile of once-weekly injectable semaglutide for chronic weight management","year":2022,"lang":"en","type":"article","venue":"Expert Review of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Medicine; Tolerability; Weight loss; Overweight; Weight management; Obesity; Pharmacology; Type 2 diabetes; Diabetes mellitus; Internal medicine; Liraglutide; Adverse effect; Endocrinology","score_opus":0.06276375467588204,"score_gpt":0.46045669976235126,"score_spread":0.39769294508646924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224310469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.099081405,0.68408334,0.00069131906,0.053526066,0.02102447,0.039811265,0.00032749097,0.0004237209,0.101030916],"genre_scores_gemma":[0.2280006,0.60993004,0.02924512,0.07387186,0.0052599083,0.019535452,0.0006791722,0.00017312032,0.033304747],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656713,0.00042176055,0.0016736572,0.00051326194,0.00039091875,0.0004332561],"domain_scores_gemma":[0.9982242,0.0005288227,0.0006486578,0.00029617097,0.00013150311,0.00017065657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017012601,0.00024026397,0.0015584441,0.00010870277,0.00009003557,0.0000018065798,0.00035385328,0.00006333553,0.01212985],"category_scores_gemma":[0.00009063616,0.00018940866,0.0007127157,0.0003145911,0.00020626295,0.000038794664,0.0004880807,0.0002898302,0.000027420157],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091509667,0.0038689384,0.00040280653,0.009234249,0.00203767,0.00007010943,0.00002317614,0.000009058914,0.0025827514,0.000611245,0.8146304,0.16561453],"study_design_scores_gemma":[0.0085460935,0.004935403,0.0004503585,0.000660902,0.0018976793,0.0000068374807,0.000033197633,0.00043822403,0.005681697,0.000050187264,0.97712636,0.00017303714],"about_ca_topic_score_codex":0.0000042048664,"about_ca_topic_score_gemma":2.3020023e-7,"teacher_disagreement_score":0.1654415,"about_ca_system_score_codex":0.00017589139,"about_ca_system_score_gemma":0.00018438188,"threshold_uncertainty_score":0.9887732},"labels":[],"label_agreement":null},{"id":"W4224321083","doi":"10.51731/cjht.2022.318","title":"Tirzepatide for Type 2 Diabetes Mellitus","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Metformin; Type 2 diabetes; Medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Glycemic; Liraglutide; Insulin; Endocrinology; Internal medicine; Clinical trial; Pharmacology","score_opus":0.039217028697575984,"score_gpt":0.29623674319022597,"score_spread":0.25701971449265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224321083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56476927,0.27452806,0.00011814891,0.15566307,0.0018892352,0.0016033805,0.0000754493,0.00023065269,0.0011227399],"genre_scores_gemma":[0.9963273,0.0003921828,0.0014282063,0.0014058497,0.000010956654,0.000038587412,0.000013696261,0.000014196653,0.00036905555],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908084,0.00002145396,0.0003038584,0.00009005213,0.000121532175,0.00038224607],"domain_scores_gemma":[0.9994176,0.00004214978,0.0002120357,0.00015531093,0.00009665445,0.00007624486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045742615,0.00008237377,0.00029806703,0.0005120869,0.00028220765,0.00001227097,0.00016626448,0.000030588955,0.0000685597],"category_scores_gemma":[0.00020914548,0.000070926806,0.000078373036,0.00026755186,0.000059173097,0.00003884561,0.000025963373,0.0001831075,0.0000030882363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029207513,0.000048752503,0.014369918,0.0001779568,0.00019080986,0.00006603151,0.0001187942,0.000022933546,0.000022994109,0.0023714239,0.07287081,0.90971035],"study_design_scores_gemma":[0.0007101873,0.0027238007,0.002350531,0.000054201115,0.000060988143,0.000017719201,0.0015994941,0.000026825988,0.00032264838,0.003006548,0.9890553,0.000071764596],"about_ca_topic_score_codex":0.00029948843,"about_ca_topic_score_gemma":0.00027585417,"teacher_disagreement_score":0.9161845,"about_ca_system_score_codex":0.0005422778,"about_ca_system_score_gemma":0.0011844134,"threshold_uncertainty_score":0.28923112},"labels":[],"label_agreement":null},{"id":"W4224323287","doi":"10.1136/bmjdrc-2021-002619","title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups","year":2022,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Professional Engineers Ontario; Royal Victoria Hospital; McGill University Health Centre","funders":"Steno Diabetes Center Aarhus; Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Pooled analysis; Internal medicine; Endocrinology","score_opus":0.17279017606381553,"score_gpt":0.4247926598405251,"score_spread":0.2520024837767096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224323287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893345,0.00089489814,3.1322074e-7,0.00031997685,0.000056561315,0.003966867,0.005204926,0.00001935442,0.00020258226],"genre_scores_gemma":[0.9723734,0.00017723399,0.0004488234,0.00011369281,0.000028406106,0.00060175505,0.024679426,0.000055914912,0.0015213081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947263,0.0010003836,0.0008061197,0.0008957931,0.0018208409,0.00075056887],"domain_scores_gemma":[0.9947962,0.0013155986,0.00036711505,0.002088585,0.0012472087,0.00018529408],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021581575,0.00031310716,0.0015949084,0.0010291452,0.00015629845,0.000083953455,0.0011869401,0.000045759072,0.0006442114],"category_scores_gemma":[0.0010550459,0.00025641004,0.00011475667,0.0040866947,0.00021626666,0.0004300832,0.0036116631,0.00039619053,0.000008784049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008533375,0.0010317478,0.9675797,0.0004388208,0.00862706,0.00002731842,0.00044732657,0.00008530868,0.00044789695,0.00000478189,0.014172342,0.006284324],"study_design_scores_gemma":[0.0034658627,0.0020284252,0.9825116,0.0005360798,0.0035671978,1.0234153e-8,0.0020741492,0.0020582536,0.00041172252,0.000007594747,0.0030577164,0.0002813824],"about_ca_topic_score_codex":0.002457413,"about_ca_topic_score_gemma":0.0030889339,"teacher_disagreement_score":0.019474499,"about_ca_system_score_codex":0.0004817997,"about_ca_system_score_gemma":0.00026273268,"threshold_uncertainty_score":0.9999888},"labels":[],"label_agreement":null},{"id":"W4224327037","doi":"10.1111/dme.14858","title":"Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus","year":2022,"lang":"en","type":"review","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; University of Waterloo; Sunnybrook Health Science Centre; Université Laval; University of Alberta; Provincial Laboratory of Public Health","funders":"","keywords":"Medicine; Dapagliflozin; Type 2 Diabetes Mellitus; Diabetes mellitus; Canagliflozin; Internal medicine; Endocrinology","score_opus":0.05354782043790375,"score_gpt":0.3201276623514315,"score_spread":0.26657984191352774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224327037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19515526,0.79598075,0.0000064925557,0.00015668858,0.0006393642,0.005007361,0.00017581944,0.000072373674,0.002805901],"genre_scores_gemma":[0.18380763,0.8116493,0.000019870704,0.00015593517,0.00015438633,0.00091458694,0.0030225248,0.00007010289,0.00020565015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964332,0.00061496254,0.0011230909,0.00053653825,0.0008045555,0.0004876602],"domain_scores_gemma":[0.9964149,0.0018053863,0.0008496931,0.00053605804,0.00018738142,0.00020660143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011110938,0.0006028861,0.0029715616,0.00072057714,0.00013267166,0.000015313513,0.00020360893,0.0001739052,0.00052803603],"category_scores_gemma":[0.00052735966,0.00035471263,0.00026596576,0.0019697978,0.00025316875,0.0000812225,0.000079631354,0.0007593917,0.000018557826],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024003624,0.011101853,0.15754698,0.015008249,0.016530791,0.00046925992,0.012876521,0.00015436372,0.000011897227,0.00029705543,0.007085919,0.77867705],"study_design_scores_gemma":[0.008724305,0.018477282,0.09041172,0.049361724,0.05410421,0.0000129307455,0.0022350852,0.00012111617,0.00010506813,0.000115089104,0.774775,0.0015564198],"about_ca_topic_score_codex":0.00008818275,"about_ca_topic_score_gemma":0.0001265365,"teacher_disagreement_score":0.77712065,"about_ca_system_score_codex":0.00046049646,"about_ca_system_score_gemma":0.0002956305,"threshold_uncertainty_score":0.9998905},"labels":[],"label_agreement":null},{"id":"W4224444601","doi":"10.1093/pch/pxac026","title":"What do I need to know about liraglutide (Saxenda), the glucagon-like peptide 1 receptor agonist for weight management in children with obesity?","year":2022,"lang":"en","type":"article","venue":"Paediatrics & Child Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; University of Toronto","keywords":"Liraglutide; Medicine; Family medicine; Sick child; Library science; Gerontology; Pediatrics; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.006949527689918862,"score_gpt":0.24649788091180144,"score_spread":0.2395483532218826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224444601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.689495,0.06587493,0.0007598843,0.19220082,0.004708297,0.037319817,0.00044124734,0.0006059503,0.008594001],"genre_scores_gemma":[0.76502633,0.09384803,0.017254926,0.08705344,0.003384867,0.009250499,0.0032353334,0.0005096688,0.020436922],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966013,0.00015218095,0.0005966203,0.00079482456,0.00078734657,0.0010677538],"domain_scores_gemma":[0.9983419,0.000103722006,0.0002699054,0.0008140046,0.000061008814,0.0004094475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011694131,0.0004186513,0.000593334,0.00058512914,0.0009679921,0.00015916977,0.00044081575,0.000049602113,0.00012382244],"category_scores_gemma":[0.000020863856,0.00031066616,0.00019277548,0.0013921002,0.000045952278,0.00018144013,0.00045262923,0.00045466068,0.000069178015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001295668,0.0037642992,0.39400917,0.000811369,0.001393878,0.000048778256,0.005126691,0.0006432454,0.0000019269166,0.010634532,0.4036998,0.17857064],"study_design_scores_gemma":[0.0070959493,0.0024068183,0.19230565,0.00025713668,0.0005060596,0.00001910896,0.0034407782,0.00005361381,0.00001140948,0.00014433303,0.79326665,0.0004925095],"about_ca_topic_score_codex":0.00016277962,"about_ca_topic_score_gemma":0.00016419482,"teacher_disagreement_score":0.38956684,"about_ca_system_score_codex":0.0009659357,"about_ca_system_score_gemma":0.0002172094,"threshold_uncertainty_score":0.99993455},"labels":[],"label_agreement":null},{"id":"W4225003979","doi":"10.1111/dom.14729","title":"Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; AstraZeneca; Juvenile Diabetes Research Foundation United States of America; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Boettcher Foundation; American Heart Association","keywords":"Dapagliflozin; Medicine; Kidney disease; Internal medicine; Endocrinology; Renal function; Albuminuria; Urology; Creatinine; Diabetes mellitus; Aldosterone; Excretion; Type 2 diabetes","score_opus":0.0035316257272561143,"score_gpt":0.18532639046903926,"score_spread":0.18179476474178313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225003979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844307,0.011678218,0.0000032299092,0.00004917815,0.0003140595,0.002161858,0.0011160229,0.00008221823,0.0001645154],"genre_scores_gemma":[0.9961446,0.0009265011,0.00011386569,0.00047338175,0.000085476255,0.00026287782,0.0011789766,0.00007174193,0.0007425692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967461,0.0002796577,0.0005202966,0.0009296263,0.00064543565,0.0008788407],"domain_scores_gemma":[0.99759454,0.00061274454,0.00034129687,0.00053801603,0.00008217161,0.0008312473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038317105,0.00054394256,0.0011660568,0.00044810597,0.00020769902,0.00007154157,0.00015252556,0.0001101452,0.0000036186066],"category_scores_gemma":[0.0006146436,0.00047355957,0.0000904587,0.00039325113,0.0002626089,0.00025608044,0.00038478556,0.00037824342,0.000003883474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101841106,0.0011568542,0.9918087,0.0013479558,0.00054620055,0.000020077097,0.0010593752,0.000050859508,0.00036702678,0.00011982716,0.00061871903,0.00280256],"study_design_scores_gemma":[0.01689286,0.0010619164,0.9726652,0.00075482304,0.0015355739,1.5164972e-7,0.00013399794,0.0019831269,0.0004741629,0.00016760906,0.004186755,0.00014384733],"about_ca_topic_score_codex":0.00016984636,"about_ca_topic_score_gemma":0.000021159041,"teacher_disagreement_score":0.019143527,"about_ca_system_score_codex":0.00020867199,"about_ca_system_score_gemma":0.00017919939,"threshold_uncertainty_score":0.9997716},"labels":[],"label_agreement":null},{"id":"W4225114697","doi":"10.1186/s12933-022-01489-6","title":"Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","year":2022,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital; University of Toronto","funders":"Novo Nordisk","keywords":"Metformin; Semaglutide; Medicine; Post-hoc analysis; Hazard ratio; Mace; Internal medicine; Type 2 diabetes; Subgroup analysis; Sitagliptin; Placebo; Lixisenatide; Diabetes mellitus; Confidence interval; Endocrinology; Liraglutide; Insulin; Myocardial infarction","score_opus":0.04116419944125316,"score_gpt":0.2882567812633015,"score_spread":0.24709258182204835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225114697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02594116,0.9708359,0.00005627538,0.000011759296,0.00027457142,0.0023370478,0.00026939102,0.0000509773,0.00022291394],"genre_scores_gemma":[0.0024161155,0.994125,0.00038609063,0.00001865188,0.000064387066,0.00054548716,0.0019008289,0.00012645283,0.00041695422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418175,0.0012063055,0.0014180233,0.001247676,0.0012086252,0.0007376023],"domain_scores_gemma":[0.9956485,0.00056045776,0.0006295945,0.0026167554,0.00030682413,0.0002378638],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0023430774,0.0008519502,0.012568712,0.0025135449,0.00009721404,0.000017276685,0.00040840852,0.00049133576,0.00013133988],"category_scores_gemma":[0.0005033384,0.0007293479,0.014487913,0.0025671902,0.0003270559,0.0001101849,0.0006479078,0.0004438477,0.000004302474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033560507,0.00019703271,0.0005288552,0.014558697,0.33594278,0.00029547018,0.000085353386,0.00006356484,9.4334604e-7,0.00014152373,0.00006823122,0.648084],"study_design_scores_gemma":[0.0011032367,0.00026211466,0.00074464764,0.0009852325,0.30325568,0.00006758253,0.00015795219,0.000007228948,0.000012178796,0.0000070056726,0.69299495,0.0004022273],"about_ca_topic_score_codex":0.00020161198,"about_ca_topic_score_gemma":0.0000086616465,"teacher_disagreement_score":0.6929267,"about_ca_system_score_codex":0.00035871094,"about_ca_system_score_gemma":0.00029876773,"threshold_uncertainty_score":0.9995158},"labels":[],"label_agreement":null},{"id":"W4225128259","doi":"10.2215/cjn.14231021","title":"Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Hazard ratio; Confidence interval; Internal medicine; Placebo; Clinical endpoint; Randomized controlled trial; Population; Kidney disease; Renal function; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.01060013507857715,"score_gpt":0.24356841384073477,"score_spread":0.23296827876215762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225128259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832119,0.000054566033,0.000018023367,0.0021661266,0.00021015563,0.013570214,0.00003111814,0.000033647117,0.0007042988],"genre_scores_gemma":[0.9810689,0.000017750019,0.000018765157,0.002097817,0.000010278374,0.015326714,0.00013157977,0.000011457142,0.0013167543],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980518,0.0005608213,0.0004651862,0.00025956935,0.00045062052,0.00021199066],"domain_scores_gemma":[0.9987479,0.00030452796,0.000300399,0.00035317973,0.000040151903,0.00025383092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013578436,0.00016055671,0.00159778,0.00046998844,0.00010406261,0.000020868374,0.00008490997,0.000025729172,0.00013670206],"category_scores_gemma":[0.0016041002,0.00008602559,0.00034520187,0.00077274645,0.000097140524,0.000070310685,0.00010135839,0.000081982005,1.3034078e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35067585,0.00087183056,0.6430943,0.000019167703,0.0043090438,0.0000023116338,0.00019205152,0.00009105721,9.247159e-8,0.00008936094,0.00014267577,0.00051228114],"study_design_scores_gemma":[0.53665024,0.00015511476,0.4575704,0.000001507351,0.0048820153,5.734877e-8,0.000029900084,0.00011045911,5.25605e-7,0.000021603659,0.00052438915,0.00005379827],"about_ca_topic_score_codex":0.00046768083,"about_ca_topic_score_gemma":0.0000880137,"teacher_disagreement_score":0.18597436,"about_ca_system_score_codex":0.00020872604,"about_ca_system_score_gemma":0.00008024218,"threshold_uncertainty_score":0.35080218},"labels":[],"label_agreement":null},{"id":"W4225275230","doi":"10.1177/08968608221096556","title":"The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients","year":2022,"lang":"en","type":"review","venue":"Peritoneal Dialysis International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Peritoneal dialysis; Medicine; Intensive care medicine; Dialysis; Internal medicine; Urology","score_opus":0.03820474378086038,"score_gpt":0.3384869658807683,"score_spread":0.30028222209990796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225275230","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05206167,0.8897254,0.0001590826,0.004632751,0.008711794,0.036389496,0.0027602185,0.00022568746,0.005333886],"genre_scores_gemma":[0.01974692,0.93642247,0.00021621444,0.0005568706,0.0021452955,0.024559753,0.0099004535,0.00017663446,0.006275368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955163,0.00025510413,0.0013307758,0.00083930575,0.0015635558,0.00049493014],"domain_scores_gemma":[0.9972963,0.0012038453,0.00040970187,0.00071939285,0.00020800238,0.00016277024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011165391,0.000603472,0.0014592547,0.0006198535,0.0006475916,0.00020599064,0.0009370552,0.00012022485,0.0010055441],"category_scores_gemma":[0.00035006445,0.00037859735,0.0013098904,0.0007759182,0.00009827038,0.00013011992,0.00028695166,0.00041983454,0.00007014063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045721067,0.004081648,0.010845344,0.00054094306,0.0072527495,0.000043427128,0.0024633512,0.00003881183,0.0000014127054,0.00015844958,0.0033308344,0.9707858],"study_design_scores_gemma":[0.0022622312,0.00042156057,0.0048418446,0.00020322826,0.0045427843,0.0000014688167,0.00081002444,0.00010644952,0.0000040130035,0.000010208368,0.9864459,0.00035029917],"about_ca_topic_score_codex":0.00017583094,"about_ca_topic_score_gemma":0.0004592417,"teacher_disagreement_score":0.9831151,"about_ca_system_score_codex":0.0009092171,"about_ca_system_score_gemma":0.00024339725,"threshold_uncertainty_score":0.9999077},"labels":[],"label_agreement":null},{"id":"W4225337509","doi":"10.22541/au.164864421.14975800/v1","title":"Association of metformin with the mortality and incidence of cardiovascular events in patients with pre-existing cardiovascular diseases","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Hazard ratio; Internal medicine; Metformin; Incidence (geometry); Myocardial infarction; Heart failure; Unstable angina; Angina; Stroke (engine); Cardiology; Confidence interval; Insulin","score_opus":0.014931347754205909,"score_gpt":0.2503384520101541,"score_spread":0.23540710425594819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225337509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408406,0.0027772964,0.00016807108,0.00002266141,0.00003669264,0.0020236205,0.00004549887,0.000016761067,0.0008253671],"genre_scores_gemma":[0.9988123,0.00020083903,0.00028720766,0.0000123343225,0.000013093933,0.00023163987,0.00017741205,0.000018929444,0.00024621727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997608,0.00016240613,0.00030638688,0.00037449112,0.00137704,0.00017168038],"domain_scores_gemma":[0.99860543,0.0000717302,0.00031805836,0.0007933703,0.00016600665,0.000045395223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088126835,0.0002131137,0.0009208795,0.00010772211,0.000036771133,0.0000061091037,0.00012501447,0.00005617473,0.00002025401],"category_scores_gemma":[0.00009359893,0.00012487089,0.00036013132,0.00019349075,0.00004617736,0.00006380725,0.000466136,0.000183387,1.210716e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012393008,0.00030140136,0.9720572,0.0008511783,0.017872278,0.0000070302362,0.00018880301,0.004864107,1.2452139e-7,0.00001626909,0.000014783772,0.0037029013],"study_design_scores_gemma":[0.00229899,0.00030368933,0.9862534,0.00028123352,0.010129769,1.6332594e-7,0.00015080106,0.000075303215,0.000020698564,0.000032379037,0.00032818958,0.00012542807],"about_ca_topic_score_codex":0.0021112934,"about_ca_topic_score_gemma":0.00010760444,"teacher_disagreement_score":0.014196161,"about_ca_system_score_codex":0.00027604462,"about_ca_system_score_gemma":0.000077509925,"threshold_uncertainty_score":0.5092087},"labels":[],"label_agreement":null},{"id":"W4225399996","doi":"10.1038/s41574-022-00669-4","title":"Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Centre for Global Health Research; Public Health Ontario","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Incretin; Medicine; Type 2 Diabetes Mellitus; Insulin resistance; Diabetes mellitus; Disease; Insulin; Internal medicine; Type 2 diabetes; Phenotype; Pathophysiology; Endocrinology; Pathogenesis; Bioinformatics; Biology; Genetics; Gene","score_opus":0.03563565609691405,"score_gpt":0.3499638775589322,"score_spread":0.31432822146201816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225399996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093604927,0.995178,9.3158974e-8,0.00008769947,0.00031302823,0.002422154,0.000019765323,0.000021502326,0.001021734],"genre_scores_gemma":[0.00016083266,0.9976388,0.0008374764,0.0001734486,0.0000474213,0.00043307926,0.0004755253,0.000034011806,0.00019935479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980814,0.00025941565,0.0006667699,0.0005222685,0.00010711804,0.0003630486],"domain_scores_gemma":[0.9990433,0.00010129568,0.0003291941,0.00044223294,0.000015323896,0.000068675865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016915167,0.00042093315,0.0025957217,0.0004865989,0.000043668788,0.0000059344356,0.00013407193,0.00025458005,0.00010017288],"category_scores_gemma":[0.00006501707,0.00029075684,0.00020761167,0.00057793513,0.000101841775,0.0000334557,0.0003631805,0.0006915525,0.000010325089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000063740144,0.000111469264,0.0009463708,0.040985245,0.00033785074,0.000102359765,0.000022029199,4.3344006e-8,1.856535e-7,0.0027744519,0.00020464078,0.95450896],"study_design_scores_gemma":[0.00044444663,0.00022280369,0.0025748666,0.0043114824,0.0017407193,0.000017552353,0.000009524687,5.4069733e-7,8.109408e-8,0.00052951166,0.9899611,0.00018737245],"about_ca_topic_score_codex":0.000007900397,"about_ca_topic_score_gemma":0.000012082184,"teacher_disagreement_score":0.98975646,"about_ca_system_score_codex":0.00007689869,"about_ca_system_score_gemma":0.000024659153,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W4225423449","doi":"10.1096/fasebj.2022.36.s1.r4017","title":"A predictive model for estimating protection against CKD and CVD with SGLT2 inhibition in patients with diabetes","year":2022,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Medicine; Kidney disease; Renal function; Type 2 diabetes; Diabetes mellitus; Dialysis; Internal medicine; Glycemic; Albuminuria; Endocrinology; Intensive care medicine; Urology","score_opus":0.011026477533969391,"score_gpt":0.20669950979251928,"score_spread":0.19567303225854987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225423449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763365,0.000019575331,0.010607537,0.0003189188,0.000027028713,0.0012474005,0.000013076393,0.00001492805,0.000117881864],"genre_scores_gemma":[0.9959473,0.0000012934776,0.003392365,0.00016539035,0.000035802695,0.00032330098,0.000030243189,0.000014134798,0.000090187496],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993834,0.00003256297,0.00011160092,0.00010195388,0.000215284,0.00015521387],"domain_scores_gemma":[0.99972355,0.000017163338,0.00010692324,0.00006397251,0.000047106943,0.000041298426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023820222,0.00008540582,0.00011265045,0.00009347933,0.00028534277,0.000026664757,0.000020563944,0.00001009408,0.00000397054],"category_scores_gemma":[0.0000127665935,0.00004857418,0.000018890441,0.00009771854,0.000029656238,0.00011419144,0.000030520598,0.00017492568,2.1909688e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009043987,0.0024788294,0.45789927,0.0004336604,0.0012149401,0.000055001576,0.008606352,0.42567974,0.0048143775,0.00012701446,0.0006282711,0.08901855],"study_design_scores_gemma":[0.011511271,0.005603911,0.028914003,0.00036399174,0.0003001265,0.0000089294235,0.0006504352,0.9508109,0.0012177596,0.00048479225,0.000009485744,0.00012436624],"about_ca_topic_score_codex":0.0000015574117,"about_ca_topic_score_gemma":0.0000035254948,"teacher_disagreement_score":0.52513117,"about_ca_system_score_codex":0.00014067173,"about_ca_system_score_gemma":0.000031195417,"threshold_uncertainty_score":0.21946546},"labels":[],"label_agreement":null},{"id":"W4226110186","doi":"10.2337/figshare.16709122.v1","title":"Remission of type 2 diabetes following a short-term intensive intervention with insulin glargine, sitagliptin and metformin: results of an open-label randomized parallel-design trial","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Manitoba; Montreal Clinical Research Institute; Health Sciences Centre; McMaster University; LMC Diabetes & Endocrinology (Canada); London Health Sciences Centre; University of Calgary; Western University","funders":"","keywords":"Medicine; Sitagliptin; Metformin; Internal medicine; Insulin glargine; Type 2 diabetes; Insulin; Endocrinology; Hazard ratio; Diabetes mellitus; Gastroenterology; Confidence interval","score_opus":0.05427143487268528,"score_gpt":0.32847728407386867,"score_spread":0.2742058492011834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226110186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795986,0.001715525,0.001466268,0.00015871471,0.00036032975,0.007085187,0.000013410281,0.000047725083,0.001192949],"genre_scores_gemma":[0.9384492,0.0005817692,0.057700727,0.000056554283,0.00005741819,0.00029299714,0.0013270727,0.000051191037,0.0014830519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694407,0.00039349773,0.0012616126,0.00072304276,0.00041969263,0.00025809882],"domain_scores_gemma":[0.99752176,0.000328442,0.00063327217,0.0006969498,0.00066209305,0.00015749909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020006616,0.00043792286,0.002470075,0.00027149732,0.00003365378,0.000092904884,0.00025478425,0.00024695997,0.00003841571],"category_scores_gemma":[0.0010764834,0.00029073926,0.00026029625,0.00020676562,0.000107074,0.00024607973,0.00093191315,0.0002655459,5.8772366e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9538424,0.002870176,0.00018073904,0.0011795599,0.005621988,0.00012849309,0.0008415511,0.000038406175,0.0028898714,0.00006345954,0.00027506726,0.032068275],"study_design_scores_gemma":[0.96195924,0.009062108,0.000189131,0.00647264,0.005109793,0.0000024040405,0.0010376081,0.003939488,0.011635404,0.00015498769,0.00004771273,0.000389454],"about_ca_topic_score_codex":0.00012986174,"about_ca_topic_score_gemma":0.000022857033,"teacher_disagreement_score":0.056234457,"about_ca_system_score_codex":0.000064164946,"about_ca_system_score_gemma":0.00014733347,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W4226127730","doi":"10.4212/cjhp.v75i2.3066","title":"Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors","year":2022,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Public Health; Sinai Health System; Women's College Hospital; University of Toronto","funders":"","keywords":"Dapagliflozin; Empagliflozin; Canagliflozin; Medicine; Renal function; Diabetes mellitus; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.014769013964084955,"score_gpt":0.26273557814892246,"score_spread":0.2479665641848375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226127730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854797,0.0006110995,0.0000010863345,0.0102006495,0.0006505555,0.00013262051,0.000012962378,0.0000027226515,0.0029085872],"genre_scores_gemma":[0.99894077,0.000016472168,0.000028269356,0.00043875762,0.00010482157,0.000003141345,0.000014156875,0.000012577221,0.00044102682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991075,0.000035101766,0.000330252,0.00006835954,0.00026288815,0.00019591289],"domain_scores_gemma":[0.99945384,0.000017497368,0.00017704864,0.00009535513,0.00006317177,0.00019309326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031401112,0.000085941945,0.00019213773,0.00046955026,0.000107871434,0.000014162566,0.00013000565,0.000008039307,0.00068453624],"category_scores_gemma":[0.000010759642,0.0000647071,0.00012665345,0.00033387105,0.000066691275,0.00011044293,0.000013783423,0.00023030966,0.0000018326402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047581797,0.00086781604,0.8311391,0.000069304246,0.0009254922,0.0036210264,0.010192734,0.0005941949,0.0015369182,0.0009898135,0.042296458,0.10729132],"study_design_scores_gemma":[0.021488735,0.003718181,0.7241478,0.00028505374,0.0015797007,0.00020232987,0.0036444052,0.0004423077,0.019889299,0.001084395,0.2229227,0.0005951192],"about_ca_topic_score_codex":0.0043949303,"about_ca_topic_score_gemma":0.008741308,"teacher_disagreement_score":0.18062624,"about_ca_system_score_codex":0.0002564934,"about_ca_system_score_gemma":0.00029229524,"threshold_uncertainty_score":0.74951917},"labels":[],"label_agreement":null},{"id":"W4226144802","doi":"10.3389/fphys.2022.741121","title":"Sex-Specific Computational Models of Kidney Function in Patients With Diabetes","year":2022,"lang":"en","type":"article","venue":"Frontiers in Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Nephron; Diabetes mellitus; Renal function; Kidney; Tubuloglomerular feedback; Endocrinology; Internal medicine; Medicine; Homeostasis; Kidney disease","score_opus":0.007336269137776684,"score_gpt":0.1918737896590618,"score_spread":0.1845375205212851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226144802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977868,0.000100482444,0.00057217246,0.00010532522,0.0003310636,0.00035764818,0.000018288949,0.000011912231,0.00071631494],"genre_scores_gemma":[0.99671286,0.000004154784,0.0019256879,0.00050502026,0.0000121940175,0.00008549261,0.0005947753,0.00000967457,0.00015014347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993278,0.000049971874,0.00014934823,0.00018354585,0.00013711593,0.00015225528],"domain_scores_gemma":[0.999767,0.000012236323,0.000054455875,0.000109014116,0.000020397145,0.000036913236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005582108,0.00007881034,0.00025233245,0.00021949591,0.000023050181,0.0000012320613,0.00004681396,0.000019827143,0.00006144415],"category_scores_gemma":[0.000003160947,0.000070011345,0.000025909709,0.00019733871,0.000046151054,0.00004938827,0.00005056525,0.000085898544,0.000001029803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076849014,0.0010666822,0.9135523,0.000046808713,0.00014247649,0.0000015420561,0.00018384458,0.04759497,0.00009087072,0.0005830252,0.030449662,0.0055193575],"study_design_scores_gemma":[0.006500289,0.0016365964,0.96017915,0.00002414673,0.000036266018,3.5445314e-8,0.00021003206,0.014438713,0.00002990256,0.013370268,0.0034676434,0.00010697931],"about_ca_topic_score_codex":0.0000035690664,"about_ca_topic_score_gemma":3.0674948e-7,"teacher_disagreement_score":0.04662686,"about_ca_system_score_codex":0.000114561546,"about_ca_system_score_gemma":0.000030429967,"threshold_uncertainty_score":0.28549796},"labels":[],"label_agreement":null},{"id":"W4226156343","doi":"","title":"Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials","year":2022,"lang":"en","type":"review","venue":"UCL Discovery (University College London)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University Health Network","funders":"","keywords":"Medicine; Type 2 diabetes; Hyperkalemia; Randomized controlled trial; Meta-analysis; Diabetes mellitus; Cotransporter; Benzhydryl compounds; Internal medicine; Pharmacology; Sodium; Endocrinology","score_opus":0.1054736338507522,"score_gpt":0.2945311316880456,"score_spread":0.18905749783729342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226156343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10077688,0.86484784,0.000011966373,0.000034303324,0.00008817894,0.006170655,0.027892139,0.00001835677,0.00015970126],"genre_scores_gemma":[0.019729719,0.9695515,0.00017020508,0.000025871752,0.000022443812,0.00009193815,0.008952856,0.000041941454,0.0014134959],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936528,0.0025273173,0.001714926,0.0008944368,0.0008433217,0.00036714895],"domain_scores_gemma":[0.990482,0.0055735465,0.0024774973,0.0012473246,0.00007306712,0.0001466213],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004430683,0.0006502452,0.026713567,0.0017363715,0.000086985594,0.000029306419,0.0005836616,0.00019451948,0.0013573869],"category_scores_gemma":[0.00052660523,0.00041965191,0.004237685,0.0023392353,0.00026832576,0.000445957,0.0005506916,0.00035518804,0.0000025947015],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047055654,0.0009752075,0.0024761138,0.0024220678,0.9425006,0.00019382348,0.00051750214,0.0000242636,5.921872e-7,0.00013054605,0.00044895752,0.0032547042],"study_design_scores_gemma":[0.115844496,0.000275935,0.00033245247,0.0004462467,0.8554252,4.3939127e-7,0.0008149635,0.0001670215,0.000001184923,0.0000056949907,0.02637915,0.00030724634],"about_ca_topic_score_codex":0.0010325036,"about_ca_topic_score_gemma":0.0024568937,"teacher_disagreement_score":0.10470371,"about_ca_system_score_codex":0.000101620826,"about_ca_system_score_gemma":0.00050101156,"threshold_uncertainty_score":0.99982554},"labels":[],"label_agreement":null},{"id":"W4226198019","doi":"10.2215/cjn.14231021","title":"Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection","year":2022,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Castle Biosciences; Moderna; Union Chimique Belge; Novo Nordisk; Dexcom; Cytokinetics; Acceleron; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; Sanofi; Amgen; ViiV Healthcare; GlaxoSmithKline; Pfizer","keywords":"Medicine; Dapagliflozin; Hazard ratio; Confidence interval; Internal medicine; Placebo; Clinical endpoint; Population; Renal function; Kidney disease; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.02345970150911977,"score_gpt":0.34028436473373797,"score_spread":0.3168246632246182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226198019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97209835,0.00003249349,0.000046814508,0.027430821,0.00012604553,0.00023002911,0.0000055302617,0.0000049101786,0.00002501996],"genre_scores_gemma":[0.9036979,0.00022276262,0.0011346452,0.09481681,0.000032126383,0.0000064924634,0.0000031235156,0.0000085553165,0.00007760027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987525,0.00025918803,0.0004986554,0.00011830335,0.00023816935,0.00013323032],"domain_scores_gemma":[0.9984889,0.00028766907,0.0008470902,0.00015757927,0.000055147993,0.00016358813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000603593,0.000088411674,0.00060858426,0.000046862886,0.000062377934,0.000003025852,0.00011003191,0.00002472965,0.00003942343],"category_scores_gemma":[0.00021225357,0.000052492527,0.00031133473,0.00021867675,0.00064100843,0.000034514745,0.00017298556,0.000311284,2.583598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007742403,0.0008769812,0.9625807,0.00001716268,0.0006401129,0.000004805751,0.00017379597,0.000021545191,0.000015957356,0.000010366608,0.03250849,0.002375871],"study_design_scores_gemma":[0.00696697,0.0053195846,0.929197,0.000008894347,0.00028811162,0.000007957965,0.0001688402,0.000022661394,0.0000010265162,0.000102899394,0.05787017,0.000045854962],"about_ca_topic_score_codex":0.00008867314,"about_ca_topic_score_gemma":0.0000035237056,"teacher_disagreement_score":0.06840045,"about_ca_system_score_codex":0.00010547013,"about_ca_system_score_gemma":0.00015827318,"threshold_uncertainty_score":0.23618223},"labels":[],"label_agreement":null},{"id":"W4226239377","doi":"10.1016/j.cardfail.2022.03.128","title":"Identifying Barriers To SGLT2 Inhibitor Use In Eligible Patients With Heart Failure: A Real-world Experience From A Single Centre","year":2022,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Heart failure; Ejection fraction; Observational study; Internal medicine; Concomitant; Adverse effect; Renal function; Pill; Medical record; Intensive care medicine; Emergency medicine; Cardiology; Pharmacology","score_opus":0.011284366783724131,"score_gpt":0.24354194106407384,"score_spread":0.2322575742803497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226239377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961944,0.00011225249,0.000008863937,0.00239481,0.0004780383,0.0005734091,0.000039937626,0.000020854322,0.00017743089],"genre_scores_gemma":[0.9930394,0.0000072355733,0.00544787,0.0006418082,0.00018374254,0.00003636733,0.000032974178,0.00003681507,0.0005737735],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978065,0.00011690185,0.00046489682,0.0002787674,0.0009624821,0.00037045398],"domain_scores_gemma":[0.9987951,0.00006467131,0.00022401493,0.00029027398,0.00016620739,0.00045973726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000204828,0.00021459011,0.00059036346,0.0005171369,0.00012567853,0.000114691175,0.00013319748,0.000032954955,0.00027200303],"category_scores_gemma":[0.00009280022,0.0001769705,0.00023771868,0.0007324398,0.000028208473,0.00046555913,0.00016069686,0.00031920127,0.000009308137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005055365,0.00028742247,0.9280991,0.000019813386,0.0002541975,0.00010068627,0.003001989,0.0001371017,0.0023852328,0.000011411347,0.06480446,0.0003930698],"study_design_scores_gemma":[0.0059800176,0.0015936802,0.3921967,0.0006913854,0.00054101594,0.000005204701,0.014440018,0.0000066330454,0.0044559054,0.00003039243,0.579616,0.00044303507],"about_ca_topic_score_codex":0.00021145462,"about_ca_topic_score_gemma":0.00038381878,"teacher_disagreement_score":0.5359024,"about_ca_system_score_codex":0.0005953128,"about_ca_system_score_gemma":0.00013469219,"threshold_uncertainty_score":0.7216647},"labels":[],"label_agreement":null},{"id":"W4226263934","doi":"10.2337/dc21-2034","title":"Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; Sanofi Genzyme; Centers for Disease Control and Prevention; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; Chugai Pharmaceutical; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Relypsa; Astellas Pharma; Novo Nordisk; Nipro; Kidney Foundation of Canada; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Kowa Company; U.S. Department of Veterans Affairs; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Heart and Stroke Foundation of Canada; Kissei; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Empagliflozin; Medicine; Placebo; Internal medicine; Kidney disease; Discontinuation; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Proportional hazards model; Clinical trial; Adverse effect; Randomized controlled trial; Surgery; Confidence interval; Endocrinology; Pathology","score_opus":0.013955028041133428,"score_gpt":0.29237274350656406,"score_spread":0.27841771546543065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226263934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944487,0.0026008093,4.358153e-7,0.0001171035,0.00012022885,0.0018972137,0.0005840953,0.00002118656,0.0002101782],"genre_scores_gemma":[0.99744636,0.00006757454,0.00004529226,0.00021547289,0.000028499157,0.00019123626,0.0019009224,0.000023863735,0.00008078471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971809,0.00061902177,0.0010473396,0.00038084976,0.00046152453,0.00031041002],"domain_scores_gemma":[0.9980475,0.0006238783,0.00048442316,0.00042891563,0.00017211198,0.00024320465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012457093,0.00022204102,0.002118835,0.0005687152,0.000050085808,0.000008929456,0.00011525218,0.000048577658,0.00039219589],"category_scores_gemma":[0.00091512495,0.00016600589,0.0004113784,0.0009762988,0.00010090646,0.00005307819,0.00015507462,0.00014224026,0.0000019396525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060242955,0.00065301853,0.9763152,0.00032187733,0.009065438,0.000002452757,0.0001757227,0.00023019189,0.00004557366,0.000019437526,0.00027910565,0.0068677],"study_design_scores_gemma":[0.0458512,0.002330366,0.9300528,0.00013899349,0.01956634,2.6494e-9,0.00025011267,0.0010688951,0.00009007532,0.0000069075104,0.00048634227,0.00015793536],"about_ca_topic_score_codex":0.000003535207,"about_ca_topic_score_gemma":0.000009575473,"teacher_disagreement_score":0.046262357,"about_ca_system_score_codex":0.00016072005,"about_ca_system_score_gemma":0.0002110233,"threshold_uncertainty_score":0.67695236},"labels":[],"label_agreement":null},{"id":"W4226298669","doi":"10.2337/figshare.16709122","title":"Remission of type 2 diabetes following a short-term intensive intervention with insulin glargine, sitagliptin and metformin: results of an open-label randomized parallel-design trial","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Manitoba; Montreal Clinical Research Institute; Health Sciences Centre; McMaster University; LMC Diabetes & Endocrinology (Canada); London Health Sciences Centre; University of Calgary; Western University","funders":"","keywords":"Medicine; Sitagliptin; Metformin; Internal medicine; Insulin glargine; Type 2 diabetes; Insulin; Endocrinology; Diabetes mellitus; Hazard ratio; Gastroenterology; Confidence interval","score_opus":0.05427143487268528,"score_gpt":0.32847728407386867,"score_spread":0.2742058492011834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226298669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795986,0.001715525,0.001466268,0.00015871471,0.00036032975,0.007085187,0.000013410281,0.000047725083,0.001192949],"genre_scores_gemma":[0.9384492,0.0005817692,0.057700727,0.000056554283,0.00005741819,0.00029299714,0.0013270727,0.000051191037,0.0014830519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694407,0.00039349773,0.0012616126,0.00072304276,0.00041969263,0.00025809882],"domain_scores_gemma":[0.99752176,0.000328442,0.00063327217,0.0006969498,0.00066209305,0.00015749909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020006616,0.00043792286,0.002470075,0.00027149732,0.00003365378,0.000092904884,0.00025478425,0.00024695997,0.00003841571],"category_scores_gemma":[0.0010764834,0.00029073926,0.00026029625,0.00020676562,0.000107074,0.00024607973,0.00093191315,0.0002655459,5.8772366e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9538424,0.002870176,0.00018073904,0.0011795599,0.005621988,0.00012849309,0.0008415511,0.000038406175,0.0028898714,0.00006345954,0.00027506726,0.032068275],"study_design_scores_gemma":[0.96195924,0.009062108,0.000189131,0.00647264,0.005109793,0.0000024040405,0.0010376081,0.003939488,0.011635404,0.00015498769,0.00004771273,0.000389454],"about_ca_topic_score_codex":0.00012986174,"about_ca_topic_score_gemma":0.000022857033,"teacher_disagreement_score":0.056234457,"about_ca_system_score_codex":0.000064164946,"about_ca_system_score_gemma":0.00014733347,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W4226301126","doi":"10.1177/20543581221081207","title":"A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Toronto General Hospital; Women's College Hospital; Institute for Clinical Evaluative Sciences; Ted Rogers Centre for Heart Research","funders":"","keywords":"Medicine; Intensive care medicine; Nephrology; Internal medicine; Cardiology; Medical physics","score_opus":0.038436419369523064,"score_gpt":0.3594843389097575,"score_spread":0.3210479195402344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226301126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.877575,0.008521127,0.00021790009,0.112001315,0.00031826002,0.00066230947,0.000280002,0.00000857349,0.0004155162],"genre_scores_gemma":[0.9837231,0.00057239353,0.0009510369,0.014326555,0.000033037602,0.000016405555,0.00004397536,0.000008879014,0.00032459892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991337,0.000105996405,0.00033654572,0.000122052006,0.00009743169,0.0002042841],"domain_scores_gemma":[0.9898554,0.0000278148,0.00017874087,0.00009370901,0.000045526616,0.009798778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003077603,0.00009605606,0.00037794205,0.00027864685,0.00017641611,0.000013297064,0.00003507919,0.000012531982,0.000037808048],"category_scores_gemma":[0.0005591162,0.00007843433,0.00006524236,0.00006050289,0.000086510576,0.00007041717,0.00006778299,0.00015813294,1.1978162e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019350945,0.000099687466,0.9310921,0.00042597495,0.00018878252,0.0005326985,0.00033208655,0.000002478747,0.0000056826,0.00017138073,0.060215812,0.006739846],"study_design_scores_gemma":[0.007475954,0.003602586,0.9274468,0.00031899213,0.00049213704,0.0002013442,0.0023898894,0.00039496282,6.5933745e-7,0.00057256344,0.056958605,0.00014549666],"about_ca_topic_score_codex":0.00043580998,"about_ca_topic_score_gemma":0.00019470148,"teacher_disagreement_score":0.10614812,"about_ca_system_score_codex":0.00015797788,"about_ca_system_score_gemma":0.007494774,"threshold_uncertainty_score":0.9981318},"labels":[],"label_agreement":null},{"id":"W4226335524","doi":"10.1111/dom.14703","title":"Healthcare costs and hospitalizations in <scp>US</scp> patients with type 2 diabetes and cardiovascular disease: A retrospective database study ( <scp>OFFSET</scp> )","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; International Business Machines Corporation","keywords":"Medicine; Disease; Type 2 diabetes; Health care; Offset (computer science); Retrospective cohort study; Diabetes mellitus; Medical emergency; Emergency medicine; Internal medicine; Endocrinology","score_opus":0.006169460079034918,"score_gpt":0.21041075406453347,"score_spread":0.20424129398549856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226335524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636274,0.03314107,0.0000016300784,0.00006866668,0.00019106788,0.0023709154,0.00039774895,0.00007385801,0.00012762309],"genre_scores_gemma":[0.9965918,0.001398243,0.000084736304,0.00041541728,0.000060457114,0.00037921485,0.00083808316,0.000046767997,0.00018526202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974344,0.00025564554,0.0002701319,0.00082137005,0.0006446874,0.00057378056],"domain_scores_gemma":[0.9985916,0.00014695407,0.000102939055,0.00056025607,0.0001717686,0.00042646634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047556832,0.00036830985,0.0008034573,0.0003335627,0.00044603177,0.00008820902,0.0001050944,0.000050271545,0.000006564947],"category_scores_gemma":[0.0003308013,0.00032670575,0.000082445324,0.00070263527,0.00013866217,0.00030563126,0.00046065316,0.0002700218,0.0000021362807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009497009,0.001462103,0.99371916,0.00019660362,0.001074529,0.000030355535,0.001104464,0.000007985508,0.000006654432,0.00030951318,0.00038185745,0.0016972661],"study_design_scores_gemma":[0.0048073432,0.00075076113,0.9814397,0.00008085114,0.0017635218,3.1002725e-7,0.0014919363,0.00009195385,0.000025901632,0.000103942555,0.009345208,0.000098567354],"about_ca_topic_score_codex":0.00011236413,"about_ca_topic_score_gemma":0.00004140815,"teacher_disagreement_score":0.0329644,"about_ca_system_score_codex":0.000099349265,"about_ca_system_score_gemma":0.000056312972,"threshold_uncertainty_score":0.9999185},"labels":[],"label_agreement":null},{"id":"W4226524572","doi":"10.1038/s44161-022-00059-z","title":"Publisher Correction: RPM2 deficiency in mice protects against atherosclerosis by inhibiting TRPM2–CD36 inflammatory axis in macrophages","year":2022,"lang":"en","type":"erratum","venue":"Nature Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Heart, Lung, and Blood Institute; American Heart Association; U.S. Department of Health and Human Services","keywords":"TRPM2; CD36; Inflammation; Medicine; Immunology; Cancer research; Chemistry; Internal medicine","score_opus":0.01983163069449319,"score_gpt":0.2875881447332865,"score_spread":0.2677565140387933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226524572","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10110035,0.42417368,0.000010190051,0.0016713762,0.041797895,0.01603658,0.000079196696,0.00050679053,0.41462395],"genre_scores_gemma":[0.37160295,0.01994461,0.00017122379,0.0007763244,0.0029853135,0.008939764,0.0044610407,0.0008147585,0.590304],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899413,0.0014535859,0.0007551412,0.0017761645,0.004444481,0.0016293477],"domain_scores_gemma":[0.997582,0.00019514491,0.00015087165,0.0013161598,0.0004906112,0.00026518008],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0071621146,0.00070074544,0.0015323844,0.0024841598,0.0003632721,0.00033471017,0.00072280725,0.0017359359,0.00020328145],"category_scores_gemma":[0.0015019139,0.000684294,0.0012287825,0.003865568,0.0002299067,0.00034111625,0.0009564081,0.012427759,0.00005093935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010421939,0.00050935696,0.00163302,0.001530783,0.0010445286,0.0011145752,0.00034221867,0.00007665456,0.00032866604,0.00001105775,0.96121573,0.032089207],"study_design_scores_gemma":[0.0038507516,0.00035795342,0.006375216,0.0018520061,0.00021283825,0.000019684232,0.0009768577,0.00007039875,0.0005105043,0.000024911327,0.98506916,0.000679729],"about_ca_topic_score_codex":0.00043207203,"about_ca_topic_score_gemma":0.00023196846,"teacher_disagreement_score":0.40422907,"about_ca_system_score_codex":0.0030958185,"about_ca_system_score_gemma":0.00076053856,"threshold_uncertainty_score":0.99956083},"labels":[],"label_agreement":null},{"id":"W4229002861","doi":"10.1093/ndt/gfac115.003","title":"FC083: Finerenone and Canagliflozin in the Treatment of Chronic Kidney Disease and Type 2 Diabetes: Matching-Adjusted Indirect Treatment Comparison of Fidelio-DKD and Credence","year":2022,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Population; Placebo; Hazard ratio; Odds ratio; Type 2 diabetes; Kidney disease; Renal function; Credence; Diabetes mellitus; Confidence interval; Cardiology; Endocrinology; Statistics; Pathology","score_opus":0.019387350657545235,"score_gpt":0.2691694527585961,"score_spread":0.24978210210105087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229002861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320346,0.0050094593,0.000010515357,0.0008524429,0.00003440313,0.0007054338,0.0001151651,0.000012601158,0.000056518893],"genre_scores_gemma":[0.99198073,0.006800809,0.00006496639,0.00020277392,0.000020065005,0.00019733093,0.00067620806,0.000009653644,0.000047459464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988999,0.00019033268,0.0003102947,0.00026274784,0.0001610975,0.00017564755],"domain_scores_gemma":[0.99941164,0.00018346787,0.00012678292,0.00016961282,0.000019983054,0.00008852239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001229419,0.00017191088,0.0004989216,0.00025222727,0.000089090696,0.000007520682,0.000043551718,0.000037463542,0.000045366352],"category_scores_gemma":[0.0000066772827,0.00012451822,0.000050255047,0.00026703716,0.00011400955,0.00004374565,0.000010884835,0.000051263076,3.418919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023946809,0.0031501271,0.911649,0.0006597384,0.0017816968,0.00009102982,0.021787494,0.00087579555,0.0060198605,0.00016600257,0.00016988533,0.05125471],"study_design_scores_gemma":[0.0109142,0.009876984,0.9627972,0.00007654735,0.0077414904,0.0000069908738,0.00094650185,0.0039724945,0.0016183116,0.0001353661,0.0017233598,0.00019049844],"about_ca_topic_score_codex":0.0008850779,"about_ca_topic_score_gemma":0.0018621427,"teacher_disagreement_score":0.051148273,"about_ca_system_score_codex":0.00011862589,"about_ca_system_score_gemma":0.00007690594,"threshold_uncertainty_score":0.5077706},"labels":[],"label_agreement":null},{"id":"W4229003321","doi":"10.1007/s11010-022-04411-6","title":"Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression","year":2022,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Qatar National Library; Qingdao University of Science and Technology; Qatar University","keywords":"Empagliflozin; EMPA; Chemistry; Internal medicine; Endocrinology; Sodium–hydrogen antiporter; Renin–angiotensin system; Pharmacology; Diabetes mellitus; Medicine; Sodium; Type 2 diabetes","score_opus":0.007289343861091791,"score_gpt":0.2086525609394232,"score_spread":0.2013632170783314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229003321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954682,0.0016771402,0.00009266736,0.00033579883,0.000044870336,0.00028779323,0.000010955376,0.000025964697,0.002056624],"genre_scores_gemma":[0.9988279,0.000008968773,0.0003841141,0.00023874606,0.000028027736,0.00004702692,0.00022409446,0.000024175853,0.00021698028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988088,0.00004512912,0.00023372627,0.00035135687,0.0003170608,0.00024394692],"domain_scores_gemma":[0.9995145,0.0000065945824,0.00007411669,0.00029566957,0.00003237747,0.000076731565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110798435,0.00017809894,0.00029593924,0.00008045608,0.000085675245,0.000007957788,0.00004695917,0.00007759113,0.00003786436],"category_scores_gemma":[0.000014398264,0.00017896725,0.00013262303,0.00023717848,0.00004064205,0.00003125403,0.00028286246,0.00015753589,0.0000010907988],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077502125,0.00033343115,0.0007273765,0.0001267044,0.00006484986,0.00035071082,0.00013808295,0.000012752033,0.99722207,0.00003781297,0.00032239195,0.00058631],"study_design_scores_gemma":[0.0018085585,0.0002829857,0.000107391075,0.0001177674,0.000109909175,0.00001652355,0.0003060204,0.000022448527,0.9964255,0.00009478699,0.0005509516,0.00015715261],"about_ca_topic_score_codex":0.000026796853,"about_ca_topic_score_gemma":2.2784616e-7,"teacher_disagreement_score":0.00335968,"about_ca_system_score_codex":0.00008343963,"about_ca_system_score_gemma":0.000035609377,"threshold_uncertainty_score":0.72980726},"labels":[],"label_agreement":null},{"id":"W4229013083","doi":"10.1093/ndt/gfac126.003","title":"FC 124: Real-World Use of Once-Weekly Semaglutide by Baseline Estimated Glomerular Filtration Rate—A Post-Hoc Analysis of Pooled Data From the Sure Studies (Canada, Denmark/Sweden, Switzerland and UK)","year":2022,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Semaglutide; Interquartile range; Renal function; Kidney disease; Population; Post-hoc analysis; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology; Liraglutide; Environmental health","score_opus":0.03766330427975715,"score_gpt":0.2884670468351103,"score_spread":0.25080374255535315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229013083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904325,0.0013162651,0.00026736376,0.0025186662,0.00006214419,0.00050194096,0.004852127,0.000021163396,0.000027814936],"genre_scores_gemma":[0.9541776,0.003122746,0.0004442626,0.0010613294,0.000024207391,0.000053295724,0.040861186,0.00001537365,0.00023999186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977076,0.00054499554,0.00064703793,0.00047627336,0.00041390755,0.0002101877],"domain_scores_gemma":[0.9974279,0.0013323819,0.00038244782,0.0006119476,0.00018643509,0.000058885642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006727803,0.0002255818,0.000825273,0.00032667696,0.00017806987,0.000015390335,0.00018686973,0.00005099152,0.0003576368],"category_scores_gemma":[0.00008747111,0.00017594265,0.00009812306,0.0010974107,0.00013091121,0.0001313445,0.00006437397,0.00012671325,0.0000010758579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011548394,0.00085221545,0.77121574,0.0003553654,0.067184575,0.00017889976,0.0026660974,0.011820803,0.094087265,0.00009650816,0.03240155,0.007592607],"study_design_scores_gemma":[0.004700862,0.0009988472,0.8558432,0.00005396839,0.09136757,0.000002966677,0.00083810266,0.041846804,0.00206754,0.000027520196,0.0019729375,0.00027967207],"about_ca_topic_score_codex":0.110642835,"about_ca_topic_score_gemma":0.57919425,"teacher_disagreement_score":0.4685514,"about_ca_system_score_codex":0.00008352068,"about_ca_system_score_gemma":0.00013674675,"threshold_uncertainty_score":0.89527947},"labels":[],"label_agreement":null},{"id":"W4229023293","doi":"10.1093/ndt/gfac070.076","title":"MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A <i>Post Hoc</i> Analysis of the Sustain 6 Trial","year":2022,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Semaglutide; Medicine; Kidney disease; Placebo; Post-hoc analysis; Albuminuria; Population; Internal medicine; Odds ratio; Renal function; Type 2 diabetes; Diabetes mellitus; Endocrinology; Liraglutide; Environmental health; Pathology","score_opus":0.011136879719140793,"score_gpt":0.24215652545219932,"score_spread":0.23101964573305853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229023293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581635,0.00013415498,0.000046751506,0.0014745931,0.0000862285,0.0016311414,0.00031789846,0.000035330515,0.0004575522],"genre_scores_gemma":[0.99486357,0.00047277438,0.000065869135,0.0015337757,0.000051370036,0.0010216482,0.0017127877,0.000019159836,0.0002590465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813944,0.00045974166,0.000389388,0.00037452191,0.00033565014,0.00030127657],"domain_scores_gemma":[0.999072,0.00013696305,0.00026548147,0.00039772465,0.000050807623,0.00007703168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032052165,0.00021795736,0.0006589663,0.0008301646,0.00016492802,0.000007969894,0.00012640377,0.000067964575,0.00025633027],"category_scores_gemma":[0.000012202701,0.00014765587,0.00036463892,0.001932594,0.000100225916,0.00006940163,0.000021868325,0.00015070426,0.0000026266302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13119467,0.0037136988,0.8044248,0.00016029125,0.019849503,0.00029936293,0.015848668,0.007906132,0.0015492666,0.0004936915,0.00018557014,0.014374334],"study_design_scores_gemma":[0.13770129,0.010490513,0.7359363,0.00002320924,0.105659254,0.00001156167,0.0013069604,0.0031509143,0.0011188608,0.000073610616,0.004126079,0.00040147337],"about_ca_topic_score_codex":0.0031750787,"about_ca_topic_score_gemma":0.006935095,"teacher_disagreement_score":0.085809745,"about_ca_system_score_codex":0.0002432706,"about_ca_system_score_gemma":0.00013025865,"threshold_uncertainty_score":0.60212314},"labels":[],"label_agreement":null},{"id":"W4229027816","doi":"10.1139/bcb-2021-0365","title":"Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway","year":2021,"lang":"en","type":"review","venue":"Biochemistry and Cell Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of South China; Natural Science Foundation of Hunan Province; National Natural Science Foundation of China","keywords":"MAPK/ERK pathway; Signal transduction; Inflammation; Cell biology; Biology; Protein kinase A; Cell signaling; Kinase; Immunology","score_opus":0.014485851691509913,"score_gpt":0.23889866563269166,"score_spread":0.22441281394118173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229027816","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011225003,0.99369556,0.000008928161,0.000017650389,0.000065125794,0.0011455475,0.000015324615,0.0000137618945,0.0039156163],"genre_scores_gemma":[0.00815438,0.9904018,0.000025953532,0.00002709889,0.00014236332,0.0004076993,0.00014299498,0.000019595242,0.00067808584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989889,0.000117326505,0.00021381432,0.00041303606,0.00008190351,0.00018502015],"domain_scores_gemma":[0.99913025,0.00020210182,0.00013502341,0.0004475688,0.000033072723,0.000051971736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016983613,0.00028918765,0.0012743955,0.000031021827,0.000039360453,0.0000064082483,0.000086080036,0.0003161674,0.000020907597],"category_scores_gemma":[0.000054651773,0.00016245151,0.0006938859,0.00010542757,0.00009761087,0.000003500349,0.00009262034,0.00020560312,0.000005779063],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012607091,0.00017997342,0.0000022206536,0.037884872,0.003052943,0.00009184157,0.00001672263,4.6487386e-8,0.005013023,0.0001686274,0.00007009664,0.953507],"study_design_scores_gemma":[0.0004163678,0.0003505137,3.6280431e-7,0.006823205,0.0028405578,0.000008172063,0.000022184773,1.412518e-7,0.3393178,0.000036716516,0.6500275,0.0001564855],"about_ca_topic_score_codex":0.000005176983,"about_ca_topic_score_gemma":4.1199584e-8,"teacher_disagreement_score":0.95335054,"about_ca_system_score_codex":0.000039831022,"about_ca_system_score_gemma":0.000094757015,"threshold_uncertainty_score":0.66245806},"labels":[],"label_agreement":null},{"id":"W4229036077","doi":"10.1093/ndt/gfac126.001","title":"FC 122: Effects of Canagliflozin on Cardiovascular and Kidney Events in Patients With Chronic Kidney Disease With and Without Peripheral Vascular Disease: Integrated Analysis From the Canvas Program and Credence Trial","year":2022,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of British Columbia","funders":"","keywords":"Canagliflozin; Medicine; Kidney disease; Hazard ratio; Renal function; Internal medicine; Placebo; Empagliflozin; Diabetes mellitus; Type 2 diabetes; Endocrinology; Confidence interval; Pathology","score_opus":0.004026274680170362,"score_gpt":0.20929248842193693,"score_spread":0.20526621374176657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229036077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568415,0.001035308,0.00014439027,0.00028022923,0.000032697117,0.0025430259,0.00024968092,0.000025739855,0.0000047687777],"genre_scores_gemma":[0.9946156,0.0005372266,0.00009501759,0.00045870664,0.000024745763,0.0008907335,0.003348093,0.000018740531,0.000011099235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815595,0.00041407693,0.00022019818,0.00050764147,0.0004790198,0.00022313709],"domain_scores_gemma":[0.99914885,0.00008101523,0.00009695569,0.00032340837,0.00004333676,0.00030644482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001867311,0.00024175615,0.00059657794,0.00023938151,0.0001380614,0.000015603126,0.00006894946,0.000038628124,0.000020354293],"category_scores_gemma":[0.000032324082,0.00015667031,0.00014033931,0.0005702143,0.00016158272,0.00008009139,0.000021630665,0.00014546368,1.3866442e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039800398,0.0007918316,0.943443,0.00023629787,0.010602424,0.00004625053,0.0005307935,0.00087245565,0.00000976564,0.000007378373,0.0000143607695,0.0036450373],"study_design_scores_gemma":[0.064753756,0.002658582,0.8966247,0.00011899059,0.034091204,3.4080014e-7,0.000026882426,0.0012153367,0.0000069698413,0.0000062009613,0.00034982635,0.00014725153],"about_ca_topic_score_codex":0.0025204243,"about_ca_topic_score_gemma":0.0017271317,"teacher_disagreement_score":0.04681835,"about_ca_system_score_codex":0.00011601064,"about_ca_system_score_gemma":0.00019205738,"threshold_uncertainty_score":0.638883},"labels":[],"label_agreement":null},{"id":"W4229050598","doi":"10.1016/j.ekir.2022.04.094","title":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations","year":2022,"lang":"en","type":"review","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; King Abdulaziz University; Department of Medicine, University of Toronto; Diabetes Canada","keywords":"Medicine; Albuminuria; Kidney disease; Renal function; Internal medicine; Diabetes mellitus; Adverse effect; Intensive care medicine; Urology; Endocrinology","score_opus":0.044767252837025935,"score_gpt":0.3435424042892774,"score_spread":0.2987751514522515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229050598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003477307,0.87401766,0.00010499174,0.0067712525,0.0045109284,0.013538161,0.00035961787,0.00036854218,0.09685152],"genre_scores_gemma":[0.009304778,0.9756637,0.0028264984,0.00082508073,0.00024792552,0.0016755656,0.006757792,0.000108365995,0.0025902484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980075,0.000053236337,0.0006869089,0.00047324676,0.0006011506,0.00017795412],"domain_scores_gemma":[0.9987146,0.00019904558,0.00054545386,0.00026778385,0.00006886312,0.00020425566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023473139,0.00024774438,0.00058205414,0.00056934234,0.000103746046,0.000085965155,0.000027503595,0.000081582126,0.00083445484],"category_scores_gemma":[0.0014832944,0.00020005082,0.00010467871,0.00018080811,0.000049207585,0.00020706176,0.00016301409,0.000326003,0.0000061009596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011131272,0.0061488273,0.2912416,0.0081804,0.0074752513,0.01347912,0.000945806,0.0000044441567,6.8626537e-7,0.011434559,0.13524215,0.52573586],"study_design_scores_gemma":[0.00063879095,0.00011590279,0.001820899,0.0034458006,0.00091522274,0.00036293213,0.00002469843,0.0000024382732,5.7968515e-7,0.00013708558,0.99234897,0.00018670398],"about_ca_topic_score_codex":0.000019248642,"about_ca_topic_score_gemma":0.000004479968,"teacher_disagreement_score":0.8571068,"about_ca_system_score_codex":0.00046880412,"about_ca_system_score_gemma":0.0006127578,"threshold_uncertainty_score":0.9136695},"labels":[],"label_agreement":null},{"id":"W4229050670","doi":"10.1093/ndt/gfac070.013","title":"MO399: Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease","year":2022,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Semaglutide; Medicine; Kidney disease; Internal medicine; Clinical trial; Type 2 diabetes; Kidney; Diabetes mellitus; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.010334071418151725,"score_gpt":0.2529341021471317,"score_spread":0.24260003072897995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229050670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567163,0.00022883908,0.00006582607,0.0021267957,0.000103569786,0.0016593391,0.000016481605,0.000019347459,0.00010814863],"genre_scores_gemma":[0.99682146,0.0001777776,0.000043570657,0.0019612822,0.000045248446,0.00066512526,0.00019694088,0.000015288404,0.000073307325],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986278,0.0004330575,0.00019982553,0.00024169697,0.000300747,0.0001968994],"domain_scores_gemma":[0.99883413,0.0007320298,0.000103877064,0.00023406935,0.00002623165,0.000069658294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048984704,0.00013579555,0.00027357246,0.00013489908,0.0001650048,0.000008629484,0.00008071561,0.00002600919,0.00008037586],"category_scores_gemma":[0.00014015568,0.000078633064,0.000058538815,0.00036284173,0.00006554743,0.000026163481,0.000019799727,0.0001452578,0.0000024274946],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4933844,0.0069206194,0.1425984,0.009209411,0.01042388,0.0005382844,0.026026733,0.03132834,0.21129106,0.024039092,0.00313572,0.041104045],"study_design_scores_gemma":[0.2776335,0.08813753,0.31775826,0.0010883216,0.045625616,0.000017899409,0.0007129689,0.25308353,0.0078032403,0.0062344247,0.0008305573,0.0010741918],"about_ca_topic_score_codex":0.00002988965,"about_ca_topic_score_gemma":0.00007383749,"teacher_disagreement_score":0.22175518,"about_ca_system_score_codex":0.00008091285,"about_ca_system_score_gemma":0.0001618013,"threshold_uncertainty_score":0.32065633},"labels":[],"label_agreement":null},{"id":"W4229055197","doi":"10.1161/circulationaha.121.058103","title":"Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Dapagliflozin; TIMI; Internal medicine; Kidney disease; Blood pressure; Hazard ratio; Myocardial infarction; Cardiology; Heart failure; Type 2 diabetes; Diabetes mellitus; Renal function; Placebo; Thrombolysis; Endocrinology; Confidence interval; Pathology","score_opus":0.03702693317826423,"score_gpt":0.2657046649564614,"score_spread":0.22867773177819717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229055197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972947,0.0006494761,0.00008597946,0.0004976885,0.00017783389,0.0010984576,0.000027271451,0.000027339884,0.00014121158],"genre_scores_gemma":[0.99833363,0.00001562485,0.00071537856,0.0001809615,0.000078889345,0.0000696379,0.0005406879,0.000012120806,0.00005305255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991761,0.00006778581,0.00025689902,0.00020191555,0.00018267932,0.00011460733],"domain_scores_gemma":[0.99949825,0.00016069056,0.00007008155,0.0001861502,0.000038480746,0.000046349134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026053988,0.000081140824,0.00020995545,0.00013749371,0.00006298296,0.00000967378,0.000044890465,0.000026370515,0.00013175837],"category_scores_gemma":[0.00022652284,0.00008494037,0.000029590474,0.00037106802,0.000009405793,0.00006890582,0.00007930022,0.00006451066,0.000001985922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004552662,0.00095058384,0.95017105,0.00006466006,0.00051793107,0.0000046492064,0.0004997818,0.010001349,0.016472226,0.00036954982,0.00031477693,0.016080776],"study_design_scores_gemma":[0.029585151,0.00034993913,0.95780116,0.00006464367,0.0009957837,1.3475571e-7,0.0001217441,0.006795261,0.0004861632,0.0001344603,0.0035582238,0.00010730961],"about_ca_topic_score_codex":0.0000480844,"about_ca_topic_score_gemma":0.0000084106205,"teacher_disagreement_score":0.025032489,"about_ca_system_score_codex":0.000032964243,"about_ca_system_score_gemma":0.000026026602,"threshold_uncertainty_score":0.3463768},"labels":[],"label_agreement":null},{"id":"W4229332733","doi":"10.1007/s10198-022-01470-w","title":"Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China","year":2022,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Medicine; Obesity; Type 2 Diabetes Mellitus; Diabetes mellitus; Population; Visual analogue scale; Public health; Insulin; Type 2 diabetes; Hypoglycemia; Internal medicine; Environmental health; Physical therapy; Endocrinology","score_opus":0.01987617201167016,"score_gpt":0.2361367150772313,"score_spread":0.21626054306556114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229332733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924758,0.005167797,3.559635e-7,0.0017998731,0.00007378489,0.00017040763,0.0000047366534,8.3647205e-7,0.0003063775],"genre_scores_gemma":[0.99774945,0.0018032852,0.00004528903,0.00035054274,0.000023891167,9.248149e-7,0.00000462418,0.0000043015493,0.000017715949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998869,0.0005711473,0.00033645704,0.000061193125,0.000057710153,0.00010446267],"domain_scores_gemma":[0.9995868,0.000050216076,0.00024002572,0.00008936931,0.000008386537,0.000025154344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024243572,0.00005461439,0.00019740996,0.000047855006,0.00007508162,0.000009469152,0.0000834473,0.000003410747,0.000010150737],"category_scores_gemma":[0.000012109966,0.00003231649,0.000013125452,0.000053826738,0.00002545031,0.00003847965,0.000049013335,0.0001269077,5.2434554e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058216403,0.00006310227,0.96863514,0.000047832535,0.00003162914,0.0000026127002,0.0019823227,0.00023637181,0.0000015801527,0.00017074797,0.0001212624,0.028649176],"study_design_scores_gemma":[0.00047293646,0.0003882251,0.99713993,0.00001947084,0.00001394997,0.0000032088972,0.0006326968,0.00016111873,0.0000024772858,0.00059302116,0.00054780155,0.000025137952],"about_ca_topic_score_codex":0.026956195,"about_ca_topic_score_gemma":0.046094146,"teacher_disagreement_score":0.028624037,"about_ca_system_score_codex":0.00010049633,"about_ca_system_score_gemma":0.000098375414,"threshold_uncertainty_score":0.97952336},"labels":[],"label_agreement":null},{"id":"W4229334771","doi":"10.1139/cjpp-2022-0082","title":"Lack of renoprotective effects of targeting the endothelin A receptor and (or) sodium glucose transporter 2 in a mouse model of Type 2 diabetic kidney disease","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Internal medicine; Endocrinology; Medicine; Glomerulosclerosis; Dapagliflozin; Endothelin receptor antagonist; Excretion; Type 2 diabetes; Renal function; Endothelin receptor; Albuminuria; Diabetes mellitus; Kidney; Pharmacology; Receptor; Proteinuria","score_opus":0.014861463199215533,"score_gpt":0.2574264593985604,"score_spread":0.24256499619934488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229334771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972379,0.0013878018,0.0000037844566,0.0007647566,0.0001469897,0.00036046037,0.000080432445,0.0000010149475,0.000016831307],"genre_scores_gemma":[0.998769,0.00028005772,0.000056245597,0.0007034316,0.000030088837,0.000020050464,0.0000076201677,0.000007835713,0.00012570329],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99924546,0.00017492555,0.00026947915,0.000096393516,0.000051767987,0.0001619803],"domain_scores_gemma":[0.99933475,0.00011660972,0.00020693237,0.000058041223,0.000060183076,0.00022348973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021537377,0.00008533947,0.0003602995,0.00017287626,0.000043133576,7.0749604e-7,0.00007257744,0.000030503546,0.00030777074],"category_scores_gemma":[0.00005018714,0.00005943646,0.00004921332,0.00009191675,0.00022815983,0.000025125079,0.00001784113,0.00019781734,1.4595447e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002230472,0.00017711165,0.004593124,0.0006836518,0.0003475591,0.00004586887,0.0016675073,0.00039684263,0.9886661,0.00006289726,0.000654778,0.00047406415],"study_design_scores_gemma":[0.012563137,0.0056911474,0.011896206,0.0001681504,0.0014317691,0.000009306999,0.0005155364,0.0029319394,0.9613897,0.0018721424,0.0013335304,0.00019740293],"about_ca_topic_score_codex":0.00019365647,"about_ca_topic_score_gemma":0.00006875036,"teacher_disagreement_score":0.027276393,"about_ca_system_score_codex":0.000036368736,"about_ca_system_score_gemma":0.0004665876,"threshold_uncertainty_score":0.33698738},"labels":[],"label_agreement":null},{"id":"W4229366783","doi":"10.1016/j.amjcard.2022.04.005","title":"Relation of Extracardiac Vascular Disease and Outcomes in Patients With Diabetes (1.1 Million) Hospitalized for Acute Myocardial Infarction","year":2022,"lang":"en","type":"article","venue":"The American Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Ottawa Hospital; Ottawa Public Health; Impact; University of Calgary; University of Ottawa","funders":"","keywords":"Medicine; Odds ratio; Internal medicine; Myocardial infarction; Comorbidity; Stroke (engine); Diabetes mellitus; Confidence interval; Percutaneous coronary intervention; Cardiology; Conventional PCI; Vascular disease; Coronary artery disease","score_opus":0.0042318207430788145,"score_gpt":0.23082900626819608,"score_spread":0.22659718552511726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229366783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99842256,0.00022437816,0.00015519765,0.00052869687,0.00014597691,0.00047412026,0.000016046877,0.0000035438416,0.000029452209],"genre_scores_gemma":[0.9993651,0.00010224619,0.00023273088,0.00015671906,0.000048365626,0.000051178027,0.000021819253,0.000010662685,0.000011185115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991462,0.00018410444,0.00023960098,0.00009063729,0.0002114866,0.00012796547],"domain_scores_gemma":[0.9992881,0.000104613246,0.00033498945,0.00013734965,0.00008306895,0.000051920662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003609253,0.00008753065,0.0006236468,0.00015581101,0.000046145356,0.00000299463,0.000054509746,0.0000089610485,0.0000020240484],"category_scores_gemma":[0.000039686878,0.000053029562,0.00022334712,0.00013823443,0.0001500536,0.000053626758,0.000039315375,0.00009331967,1.17567495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015875672,0.000041987958,0.9867577,0.0000070908823,0.0033239897,0.0000041964017,0.000070082635,0.0009157453,0.000026307489,0.000033434044,0.00007582142,0.007156056],"study_design_scores_gemma":[0.0035183283,0.0037245823,0.98950124,0.000009913687,0.0021477381,0.0000014452723,0.000103592094,0.00001969949,0.0000027639646,0.00014933405,0.0007682424,0.00005310754],"about_ca_topic_score_codex":0.0000024206238,"about_ca_topic_score_gemma":5.2885365e-8,"teacher_disagreement_score":0.007102948,"about_ca_system_score_codex":0.00007274951,"about_ca_system_score_gemma":0.00003389436,"threshold_uncertainty_score":0.21624827},"labels":[],"label_agreement":null},{"id":"W4229453707","doi":"10.1016/j.cjca.2022.05.004","title":"Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Hazard ratio; Atrial fibrillation; Internal medicine; Heart failure; Confidence interval; Proportional hazards model; Randomized controlled trial; Number needed to harm; Cardiology; Relative risk; Number needed to treat","score_opus":0.0069490980227135965,"score_gpt":0.2123281474435848,"score_spread":0.2053790494208712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229453707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825823,0.00056416023,0.00008724751,0.00017755691,0.00026081456,0.00050568784,0.000053014668,0.0000011873747,0.00009207381],"genre_scores_gemma":[0.9995886,0.000019005487,0.000067118424,0.000021792122,0.0002205501,0.000004010528,0.00004684124,0.0000069013818,0.000025155196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923235,0.000088703346,0.0002586042,0.00009832388,0.00017238241,0.00014960782],"domain_scores_gemma":[0.9994615,0.00003818215,0.00015065909,0.00009022389,0.00015153614,0.00010794939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060167385,0.00006424937,0.00043442633,0.00019784976,0.00003681002,0.0000018645345,0.000028666183,0.000039899667,0.000005879864],"category_scores_gemma":[0.00006174968,0.000056236328,0.00024528883,0.00008110625,0.000018849445,0.00004220666,0.0000054931925,0.00007427715,9.819976e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052290584,0.000003343692,0.9922677,0.000027279677,0.0011727428,0.000007529648,0.00008107231,0.0020233847,0.0000036839756,0.0000066488983,0.00040111787,0.0034825415],"study_design_scores_gemma":[0.00801166,0.0012839148,0.95981544,0.000017803468,0.0007461798,0.000004178183,0.00004513425,0.000007687049,0.000016133876,0.00006840955,0.029932389,0.000051049446],"about_ca_topic_score_codex":0.00020030442,"about_ca_topic_score_gemma":0.00036711936,"teacher_disagreement_score":0.03245229,"about_ca_system_score_codex":0.00035863632,"about_ca_system_score_gemma":0.00026115184,"threshold_uncertainty_score":0.22932509},"labels":[],"label_agreement":null},{"id":"W4229728222","doi":"10.2196/34206","title":"Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)","year":2022,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Glycemic; Diabetes mellitus; Glucagon-like peptide 1 receptor; Diabetes management; Internal medicine; Endocrinology; Agonist","score_opus":0.14697251966324465,"score_gpt":0.47221890201071853,"score_spread":0.3252463823474739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229728222","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23948388,0.0000016760216,4.9960136e-7,0.00073183,0.000029288874,0.75884974,0.00003412559,0.000103668004,0.00076527096],"genre_scores_gemma":[0.078304365,0.0000017028894,0.000098557146,0.00022086702,0.000097106655,0.91586095,0.0001618658,0.00010266689,0.00515193],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945473,0.0010045291,0.0007922478,0.0010318067,0.0015972903,0.0010268115],"domain_scores_gemma":[0.9979004,0.00023068444,0.00019928906,0.00083062326,0.00041396142,0.00042499727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037482039,0.00042693908,0.00070877717,0.0010147864,0.00063212303,0.0002266238,0.00040759926,0.00007077364,0.00069586275],"category_scores_gemma":[0.0001082536,0.00037582175,0.000114897615,0.0014933087,0.00017949633,0.00026965883,0.00039306222,0.0007425074,0.000027342712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019513195,0.09111907,0.7886265,0.0021779581,0.0005684969,0.00015754809,0.005773347,0.0000012296862,0.0037035102,0.0002776288,0.060749993,0.027331522],"study_design_scores_gemma":[0.09196619,0.10179687,0.16586256,0.0011493535,0.000034189223,7.970368e-7,0.0031028555,0.000080365055,0.0032015608,0.00036034329,0.63186044,0.00058446877],"about_ca_topic_score_codex":0.00016793623,"about_ca_topic_score_gemma":0.00022928801,"teacher_disagreement_score":0.62276393,"about_ca_system_score_codex":0.0006869109,"about_ca_system_score_gemma":0.00049896387,"threshold_uncertainty_score":0.99986935},"labels":[],"label_agreement":null},{"id":"W4229744709","doi":"10.1016/j.jcjd.2013.11.001","title":"Errata","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.011876359253788105,"score_gpt":0.21088984943543995,"score_spread":0.19901349018165185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229744709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757205,0.0012174003,0.0000022398394,0.0032125213,0.00028710073,0.00014801708,0.0000021747678,0.0000055583205,0.019404452],"genre_scores_gemma":[0.99551755,0.0000048272896,0.00043078928,0.0013046891,0.0001600697,0.0000044780654,0.0000042840297,0.000011534769,0.0025617694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999368,0.000010147443,0.00018585709,0.000060173286,0.000098875185,0.00027691026],"domain_scores_gemma":[0.99893415,0.000018345225,0.00007613761,0.00012773978,0.00014669524,0.0006969096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008655823,0.00008044548,0.00019560939,0.00024635333,0.000038635164,0.00004668174,0.0000897804,0.000031010593,0.0013724525],"category_scores_gemma":[0.000063332016,0.000061430925,0.000091193564,0.00010250075,0.00004583419,0.00016534589,0.000005562506,0.00008778883,0.00019787495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[6.092539e-7,0.000030977764,0.7660249,0.000034543955,0.00030824018,0.000034339122,0.00009589271,0.0000016242259,0.00045894762,0.00034056214,0.19813552,0.034533817],"study_design_scores_gemma":[0.0013840065,0.0007204331,0.85020363,0.0002090844,0.00030900308,0.000006187308,0.00020052546,0.00004274553,0.001270841,0.0009917727,0.14450884,0.00015292631],"about_ca_topic_score_codex":0.0003638234,"about_ca_topic_score_gemma":0.0006557041,"teacher_disagreement_score":0.084178716,"about_ca_system_score_codex":0.000081406084,"about_ca_system_score_gemma":0.0002917909,"threshold_uncertainty_score":0.99954045},"labels":[],"label_agreement":null},{"id":"W4230524024","doi":"10.1007/s40278-018-49835-9","title":"Health Canada: risk of acute pancreatitis with SGLT2 inhibitors","year":2018,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Acute pancreatitis; Medicine; Intensive care medicine; Pancreatitis; Internal medicine","score_opus":0.006869969751831699,"score_gpt":0.23816403292456326,"score_spread":0.23129406317273155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230524024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94924986,0.00012736517,0.00020307895,0.006830761,0.00031833604,0.0005978484,0.00009780066,0.00008312621,0.042491797],"genre_scores_gemma":[0.9886394,0.00027037537,0.001223089,0.00026155877,0.00015436234,0.000020702528,0.000050523304,0.000015557787,0.009364426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992783,0.000019001744,0.0001757067,0.00014700931,0.00019542218,0.00018458227],"domain_scores_gemma":[0.99936956,0.000022558848,0.00014456759,0.0002570805,0.000086890934,0.00011932251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006932985,0.00009585036,0.00023332922,0.000082980296,0.0001027158,0.000005248918,0.000030746563,0.000020963354,0.00007355058],"category_scores_gemma":[0.000010568508,0.000071532995,0.00003704113,0.0002149151,0.00006658366,0.000051599094,0.000013765129,0.00006860669,0.000019802135],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030381928,0.00084997265,0.3859852,0.0002726348,0.0055591944,0.00009849024,0.0003712245,0.0000047020067,0.0007462635,0.0018607645,0.53204864,0.07189906],"study_design_scores_gemma":[0.0022169896,0.0032510809,0.4788969,0.00035570067,0.0015615519,0.00005342543,0.00032821132,0.000040750816,0.004601726,0.000038031318,0.5084704,0.0001852634],"about_ca_topic_score_codex":0.5013851,"about_ca_topic_score_gemma":0.36991844,"teacher_disagreement_score":0.13146669,"about_ca_system_score_codex":0.0002576572,"about_ca_system_score_gemma":0.00047630808,"threshold_uncertainty_score":0.6415789},"labels":[],"label_agreement":null},{"id":"W4230554111","doi":"10.2337/figshare.14597772.v1","title":"The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Albuminuria; Dapagliflozin; Medicine; Renal function; Creatinine; Internal medicine; TIMI; Urology; Placebo; Type 2 diabetes; Kidney disease; Endocrinology; Diabetes mellitus; Myocardial infarction; Percutaneous coronary intervention; Pathology","score_opus":0.010222930701823119,"score_gpt":0.2725719607429898,"score_spread":0.26234903004116666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230554111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90474963,0.0010521921,0.000011985822,0.0015773498,0.0005652289,0.0015420992,0.0000029511737,0.00004387078,0.0904547],"genre_scores_gemma":[0.98403245,0.00034385125,0.00026395233,0.0002176695,0.00007003436,0.0002127523,0.00012950551,0.00002781005,0.014701974],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869615,0.00012300546,0.0003019233,0.000355229,0.0002938559,0.00022985948],"domain_scores_gemma":[0.9987363,0.0002907608,0.00009589986,0.0007891607,0.00003139773,0.00005648486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042544657,0.00025377024,0.0005780422,0.00011635652,0.000022625145,0.000035631583,0.00016264542,0.0001548928,0.0001966068],"category_scores_gemma":[0.00011988656,0.00014027364,0.00022383877,0.00011030617,0.00003730338,0.00001418809,0.0003880526,0.00030705394,0.000033083885],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036869638,0.0028451371,0.22246614,0.007362767,0.008344228,0.0013975932,0.0010669328,0.0009242822,0.002072938,0.0041633015,0.10642299,0.6392467],"study_design_scores_gemma":[0.037038337,0.016592244,0.32404536,0.015772825,0.0073066717,0.000010142045,0.001579429,0.0026313344,0.48585966,0.0011185388,0.10584728,0.0021981974],"about_ca_topic_score_codex":0.00014216822,"about_ca_topic_score_gemma":0.00021376177,"teacher_disagreement_score":0.63704854,"about_ca_system_score_codex":0.00012221528,"about_ca_system_score_gemma":0.000051888135,"threshold_uncertainty_score":0.5720193},"labels":[],"label_agreement":null},{"id":"W4230689817","doi":"10.1111/1753-0407.12451","title":"Diabetes News","year":2016,"lang":"sv","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Liraglutide; Mace; Hazard ratio; Myocardial infarction; Clinical endpoint; Internal medicine; Unstable angina; Diabetes mellitus; Placebo; Cardiology; Randomized controlled trial; Confidence interval; Type 2 diabetes; Percutaneous coronary intervention; Endocrinology","score_opus":0.012111268086890043,"score_gpt":0.24362813160799918,"score_spread":0.23151686352110915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230689817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632366,0.015896684,0.000016387967,0.011981092,0.0026842176,0.00034187405,0.00002230197,0.0000328671,0.00578802],"genre_scores_gemma":[0.98189014,0.0021174075,0.0005265258,0.0014312017,0.002367279,0.000009001052,0.000003240492,0.00007469155,0.0115804905],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965413,0.00014569056,0.0012057363,0.00030759996,0.0007936273,0.0010060034],"domain_scores_gemma":[0.99685365,0.00060927,0.0010802483,0.0004990235,0.0003921856,0.0005656119],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007802083,0.0004744092,0.0011943264,0.00054066064,0.000083674284,0.00008806864,0.00041236638,0.00018343079,0.0012605466],"category_scores_gemma":[0.00054992706,0.00026632386,0.00070374005,0.0003095619,0.00020662196,0.0005980904,0.00014404413,0.00025243778,0.0005918465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037126312,0.0007420824,0.7028545,0.00025810592,0.002610229,0.000056890978,0.00010171926,8.738836e-7,0.031627063,0.0002645452,0.06464171,0.19680513],"study_design_scores_gemma":[0.021049917,0.01204489,0.40778142,0.011725556,0.008598652,0.0000060556963,0.00057792006,0.000041595275,0.102653705,0.0024300928,0.4318232,0.001267008],"about_ca_topic_score_codex":0.0000022322026,"about_ca_topic_score_gemma":0.0000027442534,"teacher_disagreement_score":0.36718148,"about_ca_system_score_codex":0.00028900217,"about_ca_system_score_gemma":0.00017117838,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W4231514753","doi":"10.14740/jem491w","title":"Steroid-Induced Hyperglycemia Successfully Treated With Once-Weekly Dulaglutide in an Old Patient With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dulaglutide; Medicine; Hyperglucagonemia; Internal medicine; Glycemic; Endocrinology; Type 2 diabetes; Postprandial; Prednisolone; Diabetes mellitus; Insulin; Glucagon-like peptide 1 receptor; Glucagon; Exenatide; Receptor; Agonist","score_opus":0.014348569451187662,"score_gpt":0.2524941076810681,"score_spread":0.23814553822988044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231514753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967743,0.0012308067,0.0000027075096,0.00044644973,0.00018588126,0.00023955673,0.0000013885317,0.000018212997,0.0011007035],"genre_scores_gemma":[0.99788034,0.00022621705,0.00078092393,0.0005696745,0.00018856487,0.000008115021,0.000005125858,0.000021155915,0.00031989755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987464,0.00007796958,0.00034864675,0.0002168339,0.00019894789,0.00041121335],"domain_scores_gemma":[0.9990485,0.000034799137,0.00025036692,0.00020580154,0.0002860659,0.00017450454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087484244,0.00021429993,0.0006044653,0.0003451251,0.000056221776,0.000021754227,0.00009006675,0.00006331923,0.000040376166],"category_scores_gemma":[0.000025446965,0.00012715266,0.00003957923,0.00023788301,0.00015910616,0.00026723617,0.000034279394,0.00022909923,0.0000050992376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055703335,0.0011866882,0.9040663,0.000055577926,0.0012279368,0.0017230168,0.00076869206,0.0000065922327,0.02679725,0.00079845847,0.000287305,0.057511844],"study_design_scores_gemma":[0.013765763,0.019062322,0.9151135,0.00023007627,0.0011112373,0.00044520802,0.00048750607,0.00002051373,0.038016956,0.00008060863,0.011388299,0.00027801652],"about_ca_topic_score_codex":0.000034640187,"about_ca_topic_score_gemma":0.00011172662,"teacher_disagreement_score":0.05723383,"about_ca_system_score_codex":0.000034741905,"about_ca_system_score_gemma":0.00006919535,"threshold_uncertainty_score":0.5185135},"labels":[],"label_agreement":null},{"id":"W4231519492","doi":"10.1016/j.jcjd.2017.01.006","title":"Erratum to “Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update”","year":2017,"lang":"en","type":"erratum","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Interim; Type 2 diabetes; Intensive care medicine; Diabetes mellitus; Endocrinology; Law","score_opus":0.022763149326299477,"score_gpt":0.2821901862732799,"score_spread":0.25942703694698044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231519492","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27673507,0.07484275,0.0000071918175,0.011730161,0.15048887,0.0038524375,0.0005906342,0.00008905402,0.48166382],"genre_scores_gemma":[0.3932918,0.0034094227,0.0016986305,0.005654181,0.0040579797,0.00008671193,0.00071418256,0.00034510912,0.590742],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970186,0.00006834891,0.0009588657,0.00041837955,0.0004869382,0.0010489048],"domain_scores_gemma":[0.9957691,0.000032195476,0.0010951564,0.00085907837,0.0006451979,0.0015992799],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005467903,0.00059785764,0.0015767107,0.0013346331,0.00015573035,0.00013608238,0.0010571339,0.000371525,0.0010001517],"category_scores_gemma":[0.00012584544,0.0004970881,0.00049987086,0.00030227995,0.00022267041,0.00019921383,0.00015909292,0.00078350387,0.00024492497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016867252,0.0001110738,0.007933016,0.0012312032,0.0035685136,0.00031804867,0.00006462955,0.000002975531,0.00007263456,0.000051554707,0.971821,0.01480845],"study_design_scores_gemma":[0.0013991091,0.002048432,0.014617951,0.006626959,0.0031252175,0.0000019069853,0.000100933816,0.000010596523,0.00032152692,0.000183336,0.9710953,0.00046868023],"about_ca_topic_score_codex":0.00008622033,"about_ca_topic_score_gemma":0.00040348317,"teacher_disagreement_score":0.14643088,"about_ca_system_score_codex":0.0005697478,"about_ca_system_score_gemma":0.0015987947,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W4231682820","doi":"10.17925/use.2014.10.02.130","title":"The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?","year":2014,"lang":"en","type":"article","venue":"US Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Type 2 diabetes; Insulin; Combination therapy; Diabetes mellitus; Glucagon-like peptide 1 receptor; Internal medicine; Glucagon-like peptide-1; Endocrinology; Pharmacology; Receptor; Agonist","score_opus":0.0074518047766597255,"score_gpt":0.2450223806573442,"score_spread":0.23757057588068448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231682820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901297,0.002312909,0.00000409301,0.0040321914,0.00027730578,0.00036337462,0.0000034600912,0.000019458588,0.002857494],"genre_scores_gemma":[0.99551433,0.0020955782,0.00033223972,0.00048633784,0.00004264338,0.000035458605,0.000027068547,0.000014914559,0.0014514287],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.999126,0.00006558695,0.00023313564,0.00017086099,0.00013435776,0.00027002866],"domain_scores_gemma":[0.9993163,0.00011253352,0.00014520768,0.00029828583,0.000100929996,0.000026763857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089199086,0.00013059005,0.0003194022,0.00012143765,0.000036135647,0.0000053996205,0.00011160546,0.0000452155,0.00007254305],"category_scores_gemma":[0.00002561706,0.00008054038,0.000042713502,0.00017957385,0.0001725577,0.000035966394,0.000046625104,0.00009495572,0.000019521352],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009906829,0.00095858733,0.7324123,0.00034489392,0.0008903853,0.000014453562,0.0024909594,0.0000064489122,0.0039568567,0.018950447,0.0068236063,0.23216042],"study_design_scores_gemma":[0.008283591,0.0059631616,0.27205572,0.00019743234,0.00023097241,0.000006384633,0.0019020902,0.00010960449,0.027644169,0.00085039,0.6825212,0.00023526885],"about_ca_topic_score_codex":0.000027332886,"about_ca_topic_score_gemma":0.00009588145,"teacher_disagreement_score":0.6756976,"about_ca_system_score_codex":0.000029954053,"about_ca_system_score_gemma":0.000025164967,"threshold_uncertainty_score":0.32843417},"labels":[],"label_agreement":null},{"id":"W4232160674","doi":"10.2139/ssrn.3436269","title":"Comparison of New Glucose-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes: A Network Meta-Analysis of Cardiovascular Outcome Trials","year":2019,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Diabetes Canada","funders":"","keywords":"Medicine; Type 2 diabetes; Disease; Diabetes mellitus; Meta-analysis; Internal medicine; Secondary prevention; Clinical trial; Endocrinology","score_opus":0.05226086060829626,"score_gpt":0.3204539053846395,"score_spread":0.26819304477634326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232160674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6969354,0.3000858,0.0018526454,0.000033902303,0.000076409946,0.0009357141,0.0000070149886,0.0000052504142,0.000067857145],"genre_scores_gemma":[0.99333924,0.0057892906,0.0003485928,0.000012623435,0.00006250764,0.000019423256,0.000052272037,0.000022380538,0.0003536604],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971809,0.00021801272,0.00112495,0.00026074043,0.0004931639,0.00072222983],"domain_scores_gemma":[0.9986382,0.00014815491,0.0005257031,0.0004703852,0.00011605792,0.000101500314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061004395,0.00019751186,0.003929136,0.00038774867,0.000021922151,0.00000904703,0.0001108508,0.000059787664,0.0000418719],"category_scores_gemma":[0.00009979596,0.0001539485,0.0048239892,0.00052852154,0.000026888665,0.000106873056,0.000048647576,0.00030087703,5.391497e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006237281,0.0002969733,0.07715975,0.0006728208,0.83619833,0.0000012246292,0.00014770904,0.034000754,0.000096609336,0.0004933926,0.000021248916,0.05028748],"study_design_scores_gemma":[0.00776809,0.0015697345,0.026843227,0.00010702362,0.95561373,8.9812073e-7,0.00034555598,0.0010885043,0.0005456554,0.0032559156,0.0026256794,0.00023598908],"about_ca_topic_score_codex":0.00006028679,"about_ca_topic_score_gemma":0.000020547175,"teacher_disagreement_score":0.29640386,"about_ca_system_score_codex":0.00023684184,"about_ca_system_score_gemma":0.0006357512,"threshold_uncertainty_score":0.6277838},"labels":[],"label_agreement":null},{"id":"W4232551337","doi":"10.1016/j.amjmed.2012.10.016","title":"The Reply","year":2013,"lang":"en","type":"letter","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Rosiglitazone; Pioglitazone; Medicine; Myocardial infarction; Internal medicine; Heart failure; Placebo; Type 2 diabetes; Scopus; Diabetes mellitus; Type 2 Diabetes Mellitus; Clinical trial; Endocrinology; MEDLINE; Alternative medicine; Pathology","score_opus":0.013776056579517628,"score_gpt":0.26533222472667656,"score_spread":0.2515561681471589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232551337","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031287682,0.0033502062,0.000019961619,0.98532355,0.0008148406,0.00034227842,8.0025626e-7,0.000014197526,0.007005374],"genre_scores_gemma":[0.0028127166,0.0033403726,0.0001167036,0.9485597,0.013858134,0.000013079478,0.000010106985,0.000048641505,0.031240514],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997683,0.0001903273,0.0006618329,0.00013862376,0.0009612827,0.00036495292],"domain_scores_gemma":[0.99649775,0.000735859,0.0016246174,0.0007537842,0.0002816003,0.0001063925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010423358,0.00026687194,0.00095518446,0.00015458005,0.00012738165,0.000024576017,0.0005525055,0.00004601138,0.0002071098],"category_scores_gemma":[0.0002758119,0.000091728245,0.00024188378,0.00025594165,0.0015816209,0.00003561106,0.00006255118,0.0015433824,0.00008992582],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009848059,0.0000146810935,0.000062172345,0.000022270671,0.0009203978,0.00049006095,0.00011867588,1.7540047e-7,0.000014239016,0.000018711582,0.8824438,0.115796335],"study_design_scores_gemma":[0.0011644446,0.003969653,0.0010035136,0.00051538827,0.0016797894,0.00049430534,0.0004996386,0.0000033493593,0.00000714959,0.00034728058,0.99023056,0.00008494884],"about_ca_topic_score_codex":0.000087804736,"about_ca_topic_score_gemma":5.7038204e-7,"teacher_disagreement_score":0.11571138,"about_ca_system_score_codex":0.00010309497,"about_ca_system_score_gemma":0.00009534674,"threshold_uncertainty_score":0.67053145},"labels":[],"label_agreement":null},{"id":"W4233190623","doi":"10.1016/j.jcjd.2013.02.029","title":"Chronic Kidney Disease in Diabetes","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.007336918081107649,"score_gpt":0.2069486878711049,"score_spread":0.19961176978999726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233190623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856051,0.0044167717,5.6721996e-7,0.006997322,0.00031431825,0.00034173386,0.00001084456,0.000008811213,0.0023044953],"genre_scores_gemma":[0.9967313,0.000017598048,0.000104187464,0.0018303995,0.00032065302,0.000026799258,0.000018730077,0.000024823541,0.0009255449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869126,0.000030479398,0.000357338,0.00013692744,0.0001677915,0.0006162257],"domain_scores_gemma":[0.99725914,0.00003950235,0.000119238975,0.0002087898,0.0001264259,0.0022468795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016095163,0.0001674739,0.00035684952,0.00061111845,0.00004458658,0.00006733605,0.00015384227,0.000046658373,0.0012623292],"category_scores_gemma":[0.00023792095,0.00013874054,0.00015174843,0.00024438588,0.000089322006,0.00028802984,0.000013231632,0.00017240025,0.00014456674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[9.65795e-7,0.000037790433,0.96553236,0.000114985975,0.00013696219,0.000045574176,0.00004519134,0.0000120766945,0.00027711235,0.000099784775,0.02234842,0.011348786],"study_design_scores_gemma":[0.0018328081,0.00041643283,0.96076113,0.0006786058,0.00020579301,3.3184003e-7,0.000031191885,0.00021531786,0.00044842757,0.0006703591,0.03456787,0.00017172331],"about_ca_topic_score_codex":0.0004319709,"about_ca_topic_score_gemma":0.001146132,"teacher_disagreement_score":0.012219449,"about_ca_system_score_codex":0.00045140227,"about_ca_system_score_gemma":0.0013750686,"threshold_uncertainty_score":0.99965066},"labels":[],"label_agreement":null},{"id":"W4233255620","doi":"10.14740/jem634","title":"Evaluation of Age-Specific Efficacy and Safety of 12 Months of Sitagliptin Therapy Administered by Non-Diabetologists","year":2020,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kidney Foundation, Japan","keywords":"Medicine; Sitagliptin; Context (archaeology); Diabetes mellitus; Observational study; Dialysis; Internal medicine; Diabetic nephropathy; Renal function; Age groups; Retrospective cohort study; Type 2 diabetes; Endocrinology; Demography","score_opus":0.054738561301310475,"score_gpt":0.30841665197396556,"score_spread":0.25367809067265507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233255620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654603,0.03190482,0.000036794387,0.000988461,0.00013519102,0.0003560048,0.000010927605,0.0000033116041,0.0011041716],"genre_scores_gemma":[0.9871994,0.011950669,0.0006053119,0.00011712976,0.00006488555,0.0000034234017,0.000005892804,0.0000076706865,0.00004556948],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986947,0.00013614638,0.0005936801,0.00012881427,0.0002968924,0.00014973547],"domain_scores_gemma":[0.99884725,0.000103510756,0.00057273003,0.000120275996,0.00026249973,0.00009371628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040641497,0.00012494146,0.0007629347,0.0001214829,0.000017943406,0.0000029244898,0.00007238326,0.0000578641,0.00005403976],"category_scores_gemma":[0.00013761477,0.00009114544,0.000096166055,0.00007738423,0.0001984009,0.00006331164,0.000038106584,0.00011998901,3.803488e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006861149,0.0017853784,0.032245565,0.00032484633,0.0042944327,0.00010930166,0.0031147583,0.000023156857,0.28023532,0.0017566873,0.004718587,0.6645308],"study_design_scores_gemma":[0.037595093,0.0038957978,0.7821586,0.00014272558,0.0029211456,0.00004739725,0.0005189367,0.00006561267,0.11800862,0.00032965076,0.05415164,0.00016479146],"about_ca_topic_score_codex":0.0000033877016,"about_ca_topic_score_gemma":8.762005e-7,"teacher_disagreement_score":0.74991304,"about_ca_system_score_codex":0.000008929382,"about_ca_system_score_gemma":0.000047826084,"threshold_uncertainty_score":0.37168032},"labels":[],"label_agreement":null},{"id":"W4233285781","doi":"10.1111/1753-0407.12066","title":"Journal of Diabetes <scp>NEWS</scp>","year":2013,"lang":"fr","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Medicine; Diabetes mellitus; Obesity; Family medicine; Disease; Quarter (Canadian coin); Gerontology; Political science; Internal medicine; Endocrinology; History","score_opus":0.010428931719747857,"score_gpt":0.23292396000838875,"score_spread":0.2224950282886409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233285781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86850476,0.11385368,0.000023767276,0.0045198975,0.0070690913,0.00041330693,0.000011354857,0.000014026185,0.0055901273],"genre_scores_gemma":[0.96300906,0.0047516422,0.0034510905,0.0018203777,0.007122542,0.000013148258,0.000007015815,0.000120845594,0.019704292],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947161,0.0002832304,0.0022039476,0.00023910137,0.00121436,0.0013432362],"domain_scores_gemma":[0.9930264,0.0012613232,0.00278964,0.0004140593,0.0015432572,0.0009653507],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015327174,0.00057328533,0.0017475325,0.00088730955,0.00010530941,0.0002645712,0.00064216944,0.00028930468,0.0010799859],"category_scores_gemma":[0.001646654,0.00043892744,0.0010901622,0.00052373623,0.00032192795,0.0015061179,0.00016089287,0.0008980638,0.0004903238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005598562,0.0016583035,0.55613256,0.00080959324,0.004586276,0.00010111824,0.000574825,0.000053739037,0.008980579,0.0002998687,0.31174317,0.11505436],"study_design_scores_gemma":[0.014305081,0.015867194,0.4073773,0.0109715415,0.011058438,0.000066405046,0.004811601,0.0005424738,0.055147015,0.0065704607,0.4727604,0.0005220826],"about_ca_topic_score_codex":0.000011342191,"about_ca_topic_score_gemma":0.0000024150277,"teacher_disagreement_score":0.16101724,"about_ca_system_score_codex":0.00037066775,"about_ca_system_score_gemma":0.00032190664,"threshold_uncertainty_score":0.99983317},"labels":[],"label_agreement":null},{"id":"W4233546327","doi":"10.2337/figshare.12652454","title":"Sodium Glucose Co-transporter-2 Inhibitors and the Risk of Below-knee Amputation: a Multicenter Observational Study","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hazard ratio; Medicine; Amputation; Internal medicine; Confidence interval; Observational study; Diabetes mellitus; Dipeptidyl peptidase-4; Proportional hazards model; Lower risk; Cohort study; Type 2 diabetes; Pharmacology; Endocrinology; Surgery","score_opus":0.04169467717783543,"score_gpt":0.2939587047032263,"score_spread":0.2522640275253909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233546327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945606,0.00026775573,0.00042807157,0.0035152498,0.00025993888,0.003916213,0.00005535325,0.00007066556,0.0020306755],"genre_scores_gemma":[0.99638444,0.00015169752,0.0012761137,0.0006017088,0.00015785686,0.00024386305,0.00041388263,0.000023082335,0.00074737705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984139,0.00008855492,0.0005175283,0.00040864412,0.00043156065,0.00013981022],"domain_scores_gemma":[0.99904066,0.00014943049,0.00027366195,0.00032920044,0.000121014906,0.00008604118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032571913,0.0002641361,0.0005574437,0.000076625714,0.00005588223,0.00003426445,0.00009426627,0.00008095605,0.000113334536],"category_scores_gemma":[0.000047138237,0.00016056282,0.0001912889,0.00008363534,0.0001368968,0.000045045712,0.00019049156,0.00027527122,0.000012719436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012755792,0.0016454301,0.97942036,0.000612857,0.0037585692,0.000037364356,0.0057001403,0.00007471917,0.000026526954,0.0005264605,0.0018646414,0.005057375],"study_design_scores_gemma":[0.018605012,0.00060213736,0.9695328,0.00017633013,0.004118457,4.0075753e-7,0.0019373903,0.0022725372,0.00036265163,0.0008089111,0.0013697997,0.00021360948],"about_ca_topic_score_codex":0.00025694058,"about_ca_topic_score_gemma":0.00006617811,"teacher_disagreement_score":0.017329434,"about_ca_system_score_codex":0.000035071695,"about_ca_system_score_gemma":0.00006143284,"threshold_uncertainty_score":0.6547562},"labels":[],"label_agreement":null},{"id":"W4233816767","doi":"10.2337/figshare.16451109.v1","title":"A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Copeptin; Natriuretic peptide; Placebo; Heart failure; Hazard ratio; Dapagliflozin; Framingham Risk Score; TIMI; Biomarker; Diabetes mellitus; Type 2 diabetes; Gastroenterology; Endocrinology; Myocardial infarction; Biology","score_opus":0.010516391682966086,"score_gpt":0.23546001476556427,"score_spread":0.2249436230825982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233816767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798394,0.00007712013,0.0055920724,0.00037695497,0.00010161428,0.0055754906,0.00017426643,0.000036162957,0.00008234758],"genre_scores_gemma":[0.95977306,0.000003696894,0.033343624,0.00013511124,0.0000166543,0.0012016984,0.005338553,0.00003945043,0.00014812814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989013,0.00002046227,0.0002848516,0.00039053673,0.00018827502,0.00021458356],"domain_scores_gemma":[0.99901825,0.000081450635,0.00019100316,0.00035202934,0.0003074969,0.000049746923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013490189,0.00022389789,0.00053007697,0.00021392557,0.000019697953,0.000022550383,0.000057391077,0.00013193075,0.000025962127],"category_scores_gemma":[0.000094579125,0.00016680798,0.0001892852,0.00013682627,0.000029508057,0.00003879621,0.000068697576,0.000058812584,2.9907227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024733518,0.000967949,0.99181265,0.002285123,0.0005299055,2.4132837e-7,0.000029002325,0.00013550305,0.000014515353,0.000034109216,0.0020772347,0.0018664314],"study_design_scores_gemma":[0.012012621,0.0020908075,0.97503674,0.001833664,0.0012592011,5.0018847e-9,0.00007107429,0.0038138195,0.002624766,0.00010596528,0.00088870607,0.00026263276],"about_ca_topic_score_codex":0.000034014094,"about_ca_topic_score_gemma":0.00013513988,"teacher_disagreement_score":0.028210886,"about_ca_system_score_codex":0.000078025885,"about_ca_system_score_gemma":0.00010141593,"threshold_uncertainty_score":0.6802232},"labels":[],"label_agreement":null},{"id":"W4234219786","doi":"10.14740/jem486w","title":"Improved Glycemic Control due to Reduction in Glucagon Levels by the Administration of Once-Weekly Dulaglutide in a Non-Obese Patient With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dulaglutide; Medicine; Hyperglucagonemia; Glycemic; Postprandial; Type 2 diabetes; Internal medicine; Glucagon; Endocrinology; Diabetes mellitus; Glucagon-like peptide 1 receptor; Insulin; Liraglutide; Receptor; Agonist","score_opus":0.009233962460068879,"score_gpt":0.2531080958761106,"score_spread":0.24387413341604172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234219786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599326,0.0013132666,0.000036717283,0.001784691,0.00028328723,0.00039433237,0.0000034217562,0.000002818382,0.00018823448],"genre_scores_gemma":[0.99908644,0.00012700206,0.0003105979,0.00024585286,0.000109005785,0.000014476054,0.0000019626634,0.0000069588855,0.00009772235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991347,0.000057849044,0.0003666239,0.000116807154,0.000106507134,0.0002174918],"domain_scores_gemma":[0.9994144,0.00003773196,0.00022811035,0.000113360635,0.00014688178,0.00005953153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014009254,0.000108371925,0.00038679823,0.0002037832,0.000024000252,0.000006392845,0.000055629866,0.000040922292,0.000010902613],"category_scores_gemma":[0.00006849786,0.00006512533,0.00003326581,0.00017967279,0.00010818471,0.00009458309,0.00001791389,0.00015204314,0.0000011775439],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029485399,0.0022207447,0.023079745,0.00014090592,0.001298878,0.00039646958,0.00404135,0.000029813276,0.70347434,0.00074697187,0.00190864,0.23317672],"study_design_scores_gemma":[0.027296325,0.022592492,0.6203732,0.00044588977,0.0010465059,0.00070949574,0.0016925252,0.00021347943,0.31338346,0.00037066467,0.011594097,0.00028188401],"about_ca_topic_score_codex":0.0000332151,"about_ca_topic_score_gemma":0.000052853124,"teacher_disagreement_score":0.59729344,"about_ca_system_score_codex":0.000030050052,"about_ca_system_score_gemma":0.000066352266,"threshold_uncertainty_score":0.26557338},"labels":[],"label_agreement":null},{"id":"W4234324351","doi":"10.14740/jocmr4623","title":"Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Saitama Medical University","keywords":"Lathosterol; Internal medicine; Endocrinology; Medicine; Campesterol; Diabetes mellitus; Type 2 Diabetes Mellitus; Lipoprotein; Familial hypercholesterolemia; Cholesterol; Low-density lipoprotein; Sterol","score_opus":0.10144862865709332,"score_gpt":0.40169215508598843,"score_spread":0.3002435264288951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234324351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948819,0.0010421074,0.000027531365,0.0018512219,0.0002814505,0.0018548422,0.0000057879806,0.000009111009,0.000046011617],"genre_scores_gemma":[0.99765086,0.00033130206,0.0011644715,0.000111686066,0.0005588877,0.00002631505,0.0000111268455,0.000036335943,0.00010901782],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99552745,0.00065491884,0.0018127022,0.00046761628,0.0010746663,0.00046267998],"domain_scores_gemma":[0.99584603,0.0013379608,0.00079839904,0.00030618676,0.0013580472,0.00035338427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057869875,0.00025546824,0.0014424082,0.00043599406,0.00007498112,0.00005268277,0.00014565627,0.00020805697,0.000020146283],"category_scores_gemma":[0.004299189,0.00017703066,0.00016585388,0.00040655344,0.00042506465,0.0002263481,0.0001531384,0.000802738,7.304799e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045559715,0.003985558,0.15255143,0.00084332156,0.0005218701,0.00005977043,0.00040628584,0.000002402297,0.0039186035,0.0000043459813,0.000055914657,0.7920908],"study_design_scores_gemma":[0.15233138,0.053359892,0.7617425,0.008663504,0.0003642514,0.000007035084,0.00048690615,0.00022423321,0.022269612,0.00017290175,0.00018398672,0.0001938146],"about_ca_topic_score_codex":0.000078914854,"about_ca_topic_score_gemma":0.0001595437,"teacher_disagreement_score":0.79189694,"about_ca_system_score_codex":0.000088419096,"about_ca_system_score_gemma":0.00013371503,"threshold_uncertainty_score":0.72191006},"labels":[],"label_agreement":null},{"id":"W4234992737","doi":"10.1007/978-1-4614-1533-6_245","title":"Sodium/Glucose Co-transporters, Structure and Function","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Transporter; Glucose transporter; Sodium; Function (biology); Chemistry; Structure function; Internal medicine; Medicine; Biochemistry; Cell biology; Biology; Physics; Insulin; Organic chemistry","score_opus":0.01011030631466581,"score_gpt":0.20908510941717998,"score_spread":0.19897480310251417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234992737","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039761313,0.001060674,0.00004802457,0.00032301585,0.0002219728,0.00085508416,0.000030301499,0.00012692287,0.9933579],"genre_scores_gemma":[0.027656017,0.0006181181,0.00026624676,0.001039089,0.00019718411,0.0000094294555,0.000907825,0.000050153383,0.9692559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991873,0.0000018473487,0.000166921,0.0003047808,0.00018644333,0.00015272258],"domain_scores_gemma":[0.9995198,0.0000079273805,0.00006392688,0.0002513592,0.00003496366,0.000122020814],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021344591,0.00028826526,0.00034836575,0.00011755436,0.000032140782,0.000025105259,0.00003024567,0.00022217089,0.013740505],"category_scores_gemma":[6.665889e-7,0.00021004124,0.00008754072,0.000007878828,0.00005193143,0.000059917707,0.000014627265,0.00015071905,0.00036624027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003297358,0.00010456011,0.0022918324,0.001137129,0.0036659923,0.00017965285,0.00013479304,2.3097928e-7,0.00066430034,0.26704803,0.27681902,0.4476247],"study_design_scores_gemma":[0.0015572456,0.0004987644,0.004632718,0.00013702601,0.001627987,0.0000061987566,0.000011920866,0.0000049147693,0.00027265944,0.005825329,0.9851613,0.00026395603],"about_ca_topic_score_codex":0.0000137969955,"about_ca_topic_score_gemma":0.000013860666,"teacher_disagreement_score":0.70834225,"about_ca_system_score_codex":0.00003806985,"about_ca_system_score_gemma":0.000016370443,"threshold_uncertainty_score":0.98716104},"labels":[],"label_agreement":null},{"id":"W4236221361","doi":"10.2337/figshare.14597772","title":"The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Albuminuria; Dapagliflozin; Medicine; Renal function; Creatinine; Internal medicine; TIMI; Urology; Placebo; Type 2 diabetes; Kidney disease; Endocrinology; Diabetes mellitus; Myocardial infarction; Percutaneous coronary intervention; Pathology","score_opus":0.010222930701823119,"score_gpt":0.2725719607429898,"score_spread":0.26234903004116666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236221361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90474963,0.0010521921,0.000011985822,0.0015773498,0.0005652289,0.0015420992,0.0000029511737,0.00004387078,0.0904547],"genre_scores_gemma":[0.98403245,0.00034385125,0.00026395233,0.0002176695,0.00007003436,0.0002127523,0.00012950551,0.00002781005,0.014701974],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869615,0.00012300546,0.0003019233,0.000355229,0.0002938559,0.00022985948],"domain_scores_gemma":[0.9987363,0.0002907608,0.00009589986,0.0007891607,0.00003139773,0.00005648486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042544657,0.00025377024,0.0005780422,0.00011635652,0.000022625145,0.000035631583,0.00016264542,0.0001548928,0.0001966068],"category_scores_gemma":[0.00011988656,0.00014027364,0.00022383877,0.00011030617,0.00003730338,0.00001418809,0.0003880526,0.00030705394,0.000033083885],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036869638,0.0028451371,0.22246614,0.007362767,0.008344228,0.0013975932,0.0010669328,0.0009242822,0.002072938,0.0041633015,0.10642299,0.6392467],"study_design_scores_gemma":[0.037038337,0.016592244,0.32404536,0.015772825,0.0073066717,0.000010142045,0.001579429,0.0026313344,0.48585966,0.0011185388,0.10584728,0.0021981974],"about_ca_topic_score_codex":0.00014216822,"about_ca_topic_score_gemma":0.00021376177,"teacher_disagreement_score":0.63704854,"about_ca_system_score_codex":0.00012221528,"about_ca_system_score_gemma":0.000051888135,"threshold_uncertainty_score":0.5720193},"labels":[],"label_agreement":null},{"id":"W4236404548","doi":"10.1007/s00125-005-1964-3","title":"EASD News Section October 2005","year":2005,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Tampereen Yliopisto; University of Toronto; University of Bristol; European Association for the Study of Diabetes; Universiteit Leiden; University of Cambridge; Johns Hopkins University; University of Washington; University of Oxford; Harvard University; University of Miami","keywords":"Section (typography); Human physiology; Medicine; Internal medicine; Business; Advertising","score_opus":0.014557676660673004,"score_gpt":0.25727997282954085,"score_spread":0.24272229616886784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236404548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8707715,0.00058696227,0.00019131275,0.0046923766,0.00046670795,0.00045786804,0.0000027724252,0.00031343338,0.12251703],"genre_scores_gemma":[0.96673447,0.00008495011,0.0018729427,0.002754683,0.00058532803,0.000055096523,0.00006029476,0.00001808558,0.027834127],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913895,0.000017070755,0.00015247092,0.00022336158,0.00013324394,0.0003349012],"domain_scores_gemma":[0.99954563,0.00002665585,0.000042429918,0.00025095986,0.00002662463,0.00010768034],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000082366656,0.0001342133,0.0002203949,0.00009640782,0.000044904966,0.000018128883,0.000053360538,0.000083763705,0.0009805821],"category_scores_gemma":[0.000037164777,0.00010651183,0.00008574443,0.0001117585,0.000033371463,0.00010164198,0.00003540346,0.00009685753,0.0010683427],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007356209,0.0008652491,0.43794614,0.000061182865,0.0004061375,0.00004244472,0.000109462075,0.000077837045,0.0014858884,0.0018199796,0.2724925,0.2846196],"study_design_scores_gemma":[0.001635673,0.00022733505,0.1273962,0.000024879291,0.00022529294,0.0000034773302,0.000048603437,0.00039454974,0.0037770225,0.00008106976,0.8660165,0.00016937847],"about_ca_topic_score_codex":0.000017245437,"about_ca_topic_score_gemma":0.000051696097,"teacher_disagreement_score":0.59352404,"about_ca_system_score_codex":0.00010737704,"about_ca_system_score_gemma":0.000016975591,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W4237666970","doi":"10.1111/1753-0407.12227","title":"Journal of Diabetes NEWS","year":2014,"lang":"fr","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Citation; Diabetes mellitus; Quarter (Canadian coin); Medicine; Library science; Family medicine; Computer science; History","score_opus":0.010585851135490267,"score_gpt":0.24323773026064896,"score_spread":0.2326518791251587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237666970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89876187,0.07702463,0.00011950158,0.00836048,0.009588064,0.00020787933,0.000007466782,0.00001056335,0.005919547],"genre_scores_gemma":[0.9769873,0.002487728,0.0035250166,0.0017512611,0.008838245,0.0000026115597,0.000003929052,0.00007928519,0.0063246395],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956641,0.00034958532,0.0018825013,0.00018560777,0.00097438355,0.00094378955],"domain_scores_gemma":[0.99486405,0.0007432357,0.0024620427,0.00036277063,0.000884845,0.0006830408],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024565875,0.00043539685,0.001582434,0.0006965975,0.000080977086,0.00012674853,0.0005025842,0.0002126295,0.0006551924],"category_scores_gemma":[0.0011887803,0.00033303446,0.0009466019,0.0003789944,0.00024994282,0.0007299469,0.00010838052,0.0006837142,0.00011618339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041396408,0.0014308008,0.5716164,0.0008576098,0.0034704048,0.00006172158,0.00032111522,0.00010154894,0.0048004934,0.001112818,0.096237205,0.31994846],"study_design_scores_gemma":[0.013526232,0.017889984,0.13814563,0.009589866,0.010173352,0.000038357026,0.0008835179,0.00079956884,0.026537037,0.0050306628,0.77663547,0.00075032545],"about_ca_topic_score_codex":0.0000033984093,"about_ca_topic_score_gemma":0.0000031269612,"teacher_disagreement_score":0.6803983,"about_ca_system_score_codex":0.0002739012,"about_ca_system_score_gemma":0.00022540029,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W4237673286","doi":"10.14740/jem289w","title":"Autonomic Diabetic Neuropathy Impairs Glucose and Dipeptidyl Peptidase 4 Inhibitor-Regulated Glucagon Concentration in Type 1 Diabetic Patients","year":2015,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharma; Centre Hospitalier Universitaire de Toulouse; Institut National de la Santé et de la Recherche Médicale","keywords":"Internal medicine; Glucagon; Endocrinology; Medicine; Vildagliptin; Diabetes mellitus; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Secretion","score_opus":0.012952147027423784,"score_gpt":0.24222309451517532,"score_spread":0.22927094748775154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237673286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903962,0.007779566,0.0000023086338,0.00041846812,0.0007732582,0.00028964458,0.0000023174975,0.00001475934,0.00032346128],"genre_scores_gemma":[0.99807066,0.0011207025,0.00015379944,0.00034853956,0.0001415503,0.000004863476,0.0000123499285,0.0000137480465,0.00013379096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987625,0.00011817441,0.00045327417,0.00018525423,0.00014964363,0.00033117476],"domain_scores_gemma":[0.9991742,0.00004586261,0.00023073435,0.00012378067,0.00016887925,0.00025658912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001802621,0.0001828163,0.0005035809,0.00023355987,0.000032720553,0.000022245213,0.000053530417,0.00006829607,0.000009177575],"category_scores_gemma":[0.00013098259,0.00014413278,0.000053303615,0.00013638125,0.00012564084,0.00021483183,0.00006145403,0.00022252384,0.000007050463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018337171,0.0020434633,0.86066955,0.000133978,0.00061241083,0.0006931674,0.0017418459,0.000053139916,0.017460559,0.0018439476,0.0018850728,0.11102917],"study_design_scores_gemma":[0.013956307,0.0015832025,0.966752,0.00009714579,0.000575304,0.000067178284,0.00014994855,0.00013317181,0.0064574527,0.00031689912,0.009743214,0.00016817488],"about_ca_topic_score_codex":0.000007897637,"about_ca_topic_score_gemma":0.0000022850345,"teacher_disagreement_score":0.110860996,"about_ca_system_score_codex":0.000059904414,"about_ca_system_score_gemma":0.00008186612,"threshold_uncertainty_score":0.5877564},"labels":[],"label_agreement":null},{"id":"W4237757320","doi":"10.1111/dom.14117/v1/review2","title":"Review for \"Semaglutide Once Weekly in Persons with Type 2 Diabetes: Real‐world Analysis of the Canadian &lt;scp&gt;LMC&lt;/scp&gt; Diabetes Registry ( &lt;scp&gt;SPARE&lt;/scp&gt; Study)\"","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Type 2 diabetes; Spare part; Spare time; Medicine; Diabetes mellitus; Endocrinology; Business; Liraglutide; Art; Humanities; Marketing","score_opus":0.03180830995914949,"score_gpt":0.291297509698438,"score_spread":0.2594891997392885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237757320","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02334518,0.62981623,0.000020978545,0.081975915,0.0031798943,0.039689355,0.0057835877,0.00087635266,0.21531253],"genre_scores_gemma":[0.039634872,0.16576858,0.0019367646,0.03548101,0.0013864894,0.0066916794,0.013873514,0.0010758681,0.73415124],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857285,0.0009043437,0.0034702613,0.003580759,0.0029645546,0.0033516048],"domain_scores_gemma":[0.9868384,0.0018226837,0.0027096332,0.005229007,0.0015429908,0.001857261],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003201764,0.0029187277,0.008854737,0.002490709,0.0006605658,0.0002821302,0.0027497103,0.00074795814,0.00088300393],"category_scores_gemma":[0.0037328103,0.0021083218,0.0026068569,0.010666198,0.0006767036,0.00032321244,0.00083581026,0.0016224365,0.00017810968],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002891665,0.0010542099,0.0319633,0.027521241,0.01480687,0.00014412795,0.00045867654,0.000041168718,0.000052128467,0.0002554211,0.91932976,0.004344193],"study_design_scores_gemma":[0.002689681,0.0017328056,0.014040756,0.037346914,0.05563232,0.0000022409347,0.00038531705,0.00036790484,0.00005069164,0.000025406356,0.8867862,0.0009397307],"about_ca_topic_score_codex":0.012919188,"about_ca_topic_score_gemma":0.5988121,"teacher_disagreement_score":0.5858929,"about_ca_system_score_codex":0.0025583622,"about_ca_system_score_gemma":0.0030654375,"threshold_uncertainty_score":0.9983544},"labels":[],"label_agreement":null},{"id":"W4237872556","doi":"10.1038/nrd2245","title":"Sitagliptin","year":2007,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Sitagliptin; Dipeptidyl peptidase-4; Sitagliptin Phosphate; Pharmacology; Dipeptidyl peptidase; Medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Chemistry; Type 2 diabetes; Internal medicine; Endocrinology; Biochemistry; Enzyme","score_opus":0.042792264228988505,"score_gpt":0.38042016572998016,"score_spread":0.33762790150099165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237872556","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.455326e-7,0.9515443,0.000011267831,0.00008543027,0.00093090796,0.0043352568,0.00003544959,0.000099870755,0.04295686],"genre_scores_gemma":[5.180682e-7,0.9373447,0.0004780345,0.0009716286,0.0010064148,0.00026838435,0.001074777,0.00011977312,0.058735806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996751,0.00016485236,0.001159979,0.0008267428,0.00050053373,0.0005968615],"domain_scores_gemma":[0.997768,0.00016895418,0.0006106366,0.0011943704,0.00004483892,0.00021322668],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009626777,0.0009333088,0.0047232527,0.000449322,0.00006042852,0.000105796724,0.00033668577,0.0007990708,0.00017150097],"category_scores_gemma":[0.00017427627,0.000566866,0.0025243734,0.00075904996,0.000057075624,0.00023876296,0.00019846852,0.0017063079,0.0017544286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005222286,0.00017959875,0.0000045584075,0.06357274,0.0004492965,0.00012293669,0.0000065662975,5.3476557e-9,2.8282244e-8,0.0007442978,0.09488697,0.84002775],"study_design_scores_gemma":[0.00029364176,0.000043388627,0.0000030392273,0.062111046,0.007523219,0.000029147002,0.0000042340994,7.42961e-8,5.143162e-7,0.000015157576,0.92953444,0.00044207982],"about_ca_topic_score_codex":0.0000023989155,"about_ca_topic_score_gemma":0.0000050498907,"teacher_disagreement_score":0.8395857,"about_ca_system_score_codex":0.00040252105,"about_ca_system_score_gemma":0.00019881046,"threshold_uncertainty_score":0.99967825},"labels":[],"label_agreement":null},{"id":"W4238291200","doi":"10.1111/dom.14468/v1/review2","title":"Review for \"Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicenter, prospective, observational study\"","year":2021,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Observational study; Medicine; Type 2 diabetes; Clinical Practice; Multicenter study; Diabetes mellitus; Internal medicine; Family medicine; Endocrinology; Randomized controlled trial","score_opus":0.11433827173932894,"score_gpt":0.3799380588777268,"score_spread":0.2655997871383979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238291200","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34529677,0.31625032,0.0000034815464,0.24472074,0.0041506384,0.078757614,0.008265593,0.00007973602,0.0024750947],"genre_scores_gemma":[0.060620334,0.27592298,0.03791714,0.20963915,0.0015712738,0.00613673,0.18672915,0.00058140146,0.22088182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578935,0.00042863967,0.0017656614,0.00077048986,0.00090958434,0.00033630134],"domain_scores_gemma":[0.993117,0.0032970253,0.00094410236,0.0008710905,0.0016829879,0.00008784322],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015795672,0.00040866676,0.0017402774,0.000050807408,0.000029978453,0.000020061118,0.00021692694,0.000103241255,0.00008601129],"category_scores_gemma":[0.01117673,0.00024054373,0.00014681343,0.00057437806,0.000044232213,0.000119389646,0.00016187482,0.00046249924,0.000001804969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048422284,0.0023098201,0.5181627,0.0025927601,0.00072240847,0.000012843328,0.000013476335,0.0000013756841,1.404378e-8,0.0000027875158,0.47323942,0.0024581032],"study_design_scores_gemma":[0.00798631,0.00079026574,0.5244555,0.029457271,0.0018462999,3.8130484e-8,0.000044315926,0.000026256652,3.4659053e-7,8.587714e-7,0.43523854,0.00015401847],"about_ca_topic_score_codex":0.1438095,"about_ca_topic_score_gemma":0.59876186,"teacher_disagreement_score":0.45495236,"about_ca_system_score_codex":0.00042657286,"about_ca_system_score_gemma":0.0013755849,"threshold_uncertainty_score":0.99715257},"labels":[],"label_agreement":null},{"id":"W4238911911","doi":"10.1016/s1499-2671(08)24182-1","title":"Cost-Effectiveness of Glargine Compared with Detemir for Type 1 Diabetes mellitus patients in Canada","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin detemir; Medicine; Insulin glargine; Type 2 Diabetes Mellitus; Type 1 diabetes; Diabetes mellitus; Pediatrics; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.026837799823741515,"score_gpt":0.2383606480954922,"score_spread":0.2115228482717507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238911911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971498,0.0014611909,0.0000034675727,0.00006533771,0.0002345915,0.000827532,0.00005480879,0.0000026492132,0.00020058974],"genre_scores_gemma":[0.9994044,0.000021016247,0.00028221367,0.00011840886,0.000031393534,0.000027975228,0.000059608672,0.000024158144,0.00003086572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987617,0.00005111442,0.0003753453,0.0001316903,0.00021804235,0.00046206848],"domain_scores_gemma":[0.99838567,0.00023051408,0.00027403608,0.00015201666,0.00048973924,0.00046803209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020550603,0.00017216551,0.00063353084,0.00031786168,0.00004959148,0.0000067437254,0.00012390029,0.000036376892,0.000031936863],"category_scores_gemma":[0.00014877123,0.0001366524,0.00007266674,0.00030350048,0.00008137668,0.000095647774,0.0000071306163,0.0001024815,7.188762e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006783242,0.0000823373,0.9955684,0.00027427453,0.0003053724,0.00003555417,0.00006353048,0.00014015877,0.000053219523,0.000011825367,0.000835169,0.0025623387],"study_design_scores_gemma":[0.005439938,0.0012953008,0.98560435,0.0007091901,0.00019029196,0.0000012063405,0.00006559707,0.00009775682,0.0034144367,0.000019802128,0.003017225,0.00014491308],"about_ca_topic_score_codex":0.15063514,"about_ca_topic_score_gemma":0.8027455,"teacher_disagreement_score":0.6521104,"about_ca_system_score_codex":0.0008289635,"about_ca_system_score_gemma":0.003014189,"threshold_uncertainty_score":0.8550209},"labels":[],"label_agreement":null},{"id":"W4239195922","doi":"10.14740/jocmr4626","title":"Effect of Treatment With Sodium-Glucose Cotransporter 2 Inhibitor on the Initiation of Continuous Positive Airway Pressure Therapy in Type 2 Diabetic Patients With Obstructive Sleep Apnea Syndrome","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Continuous positive airway pressure; Obstructive sleep apnea; Internal medicine; Type 2 Diabetes Mellitus; Dapagliflozin; Empagliflozin; Diabetes mellitus; Canagliflozin; Gastroenterology; Body mass index; Type 2 diabetes; Endocrinology","score_opus":0.035592324311363,"score_gpt":0.3709213748352483,"score_spread":0.3353290505238853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239195922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528503,0.0007496698,0.0000038166745,0.0016214536,0.0001374667,0.0012018301,0.000008452112,0.0000028076217,0.0009894709],"genre_scores_gemma":[0.998951,0.00060074276,0.00003720311,0.000082506085,0.00013211512,0.000020814497,0.000022402352,0.000018321032,0.00013486636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639577,0.001009125,0.0009453796,0.00021438142,0.0011811034,0.00025425223],"domain_scores_gemma":[0.99381816,0.0037762283,0.0005103099,0.00028372993,0.0014586846,0.00015291267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022301949,0.00018235832,0.0011618097,0.000255253,0.000031418505,0.0000059362037,0.00010967709,0.00009346506,0.000106415326],"category_scores_gemma":[0.00074296416,0.00007597904,0.00013124678,0.0005277105,0.00046238033,0.000072706884,0.000018224244,0.00054177834,0.0000019190172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029672036,0.003753549,0.8683205,0.0002559953,0.0027146256,0.0007360993,0.0008157567,0.000011210214,0.0004161039,0.00006109121,0.00011103944,0.09313196],"study_design_scores_gemma":[0.028152326,0.24037822,0.70661134,0.0024231244,0.0007097749,0.000014755584,0.000292991,0.000016968892,0.021063123,0.000025735044,0.00023741704,0.00007423633],"about_ca_topic_score_codex":0.000023955625,"about_ca_topic_score_gemma":0.000009830177,"teacher_disagreement_score":0.23662466,"about_ca_system_score_codex":0.0000881677,"about_ca_system_score_gemma":0.0002250355,"threshold_uncertainty_score":0.30983356},"labels":[],"label_agreement":null},{"id":"W4240233769","doi":"10.2337/figshare.16451109","title":"A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Copeptin; Natriuretic peptide; Heart failure; Placebo; Hazard ratio; Dapagliflozin; Framingham Risk Score; TIMI; Biomarker; Diabetes mellitus; Type 2 diabetes; Gastroenterology; Cardiology; Endocrinology; Myocardial infarction; Biology; Pathology; Disease; Confidence interval","score_opus":0.010516391682966086,"score_gpt":0.23546001476556427,"score_spread":0.2249436230825982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240233769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798394,0.00007712013,0.0055920724,0.00037695497,0.00010161428,0.0055754906,0.00017426643,0.000036162957,0.00008234758],"genre_scores_gemma":[0.95977306,0.000003696894,0.033343624,0.00013511124,0.0000166543,0.0012016984,0.005338553,0.00003945043,0.00014812814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989013,0.00002046227,0.0002848516,0.00039053673,0.00018827502,0.00021458356],"domain_scores_gemma":[0.99901825,0.000081450635,0.00019100316,0.00035202934,0.0003074969,0.000049746923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013490189,0.00022389789,0.00053007697,0.00021392557,0.000019697953,0.000022550383,0.000057391077,0.00013193075,0.000025962127],"category_scores_gemma":[0.000094579125,0.00016680798,0.0001892852,0.00013682627,0.000029508057,0.00003879621,0.000068697576,0.000058812584,2.9907227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024733518,0.000967949,0.99181265,0.002285123,0.0005299055,2.4132837e-7,0.000029002325,0.00013550305,0.000014515353,0.000034109216,0.0020772347,0.0018664314],"study_design_scores_gemma":[0.012012621,0.0020908075,0.97503674,0.001833664,0.0012592011,5.0018847e-9,0.00007107429,0.0038138195,0.002624766,0.00010596528,0.00088870607,0.00026263276],"about_ca_topic_score_codex":0.000034014094,"about_ca_topic_score_gemma":0.00013513988,"teacher_disagreement_score":0.028210886,"about_ca_system_score_codex":0.000078025885,"about_ca_system_score_gemma":0.00010141593,"threshold_uncertainty_score":0.6802232},"labels":[],"label_agreement":null},{"id":"W4240910181","doi":"10.1016/j.cjca.2016.06.013","title":"Erratum","year":2016,"lang":"en","type":"erratum","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.013769757729131443,"score_gpt":0.2358398254066669,"score_spread":0.22207006767753545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240910181","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008272971,0.010047797,0.00014310125,0.004215952,0.05963022,0.00018487059,0.000048855203,0.0000078871735,0.9256386],"genre_scores_gemma":[0.024405314,0.0023931703,0.000099297176,0.0011920274,0.02591717,0.000007546517,0.00013382305,0.000082107945,0.94576955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870193,0.00006642468,0.0004012965,0.00017086067,0.00016261435,0.0004968698],"domain_scores_gemma":[0.9981663,0.000026844626,0.0002911987,0.00032470917,0.00029498694,0.000895961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002355493,0.00024184478,0.0011159225,0.0007246714,0.000047963702,0.000018265897,0.00021046727,0.00049453776,0.00015795637],"category_scores_gemma":[0.00013813582,0.00016439981,0.0005416051,0.00008373511,0.00016356145,0.00004471058,0.000015370475,0.0006342753,0.00013547952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017995631,0.0000011581715,0.0014727205,0.000051246225,0.0014174535,0.0020922115,0.00001318435,0.0000010727091,0.0000037952323,0.00019213326,0.9833935,0.0113435155],"study_design_scores_gemma":[0.0008494756,0.0005632108,0.003728222,0.00041228993,0.00095955696,0.0005096521,0.000015660105,1.5815363e-7,0.0000021441667,0.00048714905,0.9923308,0.00014171706],"about_ca_topic_score_codex":0.00011518576,"about_ca_topic_score_gemma":0.000551306,"teacher_disagreement_score":0.03371305,"about_ca_system_score_codex":0.0004642147,"about_ca_system_score_gemma":0.003821272,"threshold_uncertainty_score":0.67787725},"labels":[],"label_agreement":null},{"id":"W4242273118","doi":"10.1007/s00125-017-4241-3","title":"Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","year":2017,"lang":"en","type":"erratum","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Mount Sinai Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"Human physiology; Glomerular hyperfiltration; Medicine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology; Urology; Diabetic nephropathy","score_opus":0.011243875389194104,"score_gpt":0.24433039603228676,"score_spread":0.23308652064309265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242273118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410677,0.00016442993,0.000005156853,0.00038693662,0.0016183814,0.0015372866,0.00008760898,0.000040813542,0.0020526068],"genre_scores_gemma":[0.9841287,0.00006796872,0.0003845022,0.00034242458,0.00012954307,0.00013896001,0.0040948126,0.00004996996,0.010663107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828565,0.00007850193,0.00038384675,0.0005269144,0.00036082984,0.0003642522],"domain_scores_gemma":[0.99873704,0.000038428225,0.00031733362,0.0005333977,0.00023775679,0.00013604332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023529492,0.00035246118,0.0007973035,0.00064135774,0.000068626745,0.000055610195,0.00008774854,0.00031344048,0.00001937849],"category_scores_gemma":[0.00030878145,0.0002915169,0.000047917852,0.00026545522,0.00008493401,0.00017701364,0.000099192024,0.0002717697,0.00002380205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014984605,0.0006963926,0.88009435,0.0007926192,0.00037710057,0.000036216636,0.00036654918,0.0000044825756,0.0038213048,0.000034917597,0.09839568,0.013881919],"study_design_scores_gemma":[0.001481065,0.0030915174,0.9875846,0.0014724073,0.00028506134,2.9101153e-7,0.000016246839,0.000031004707,0.0009423808,0.00003787381,0.0047615645,0.00029602536],"about_ca_topic_score_codex":0.000018066588,"about_ca_topic_score_gemma":0.000041567728,"teacher_disagreement_score":0.107490204,"about_ca_system_score_codex":0.00016199106,"about_ca_system_score_gemma":0.0001120559,"threshold_uncertainty_score":0.9999537},"labels":[],"label_agreement":null},{"id":"W4242710605","doi":"10.1007/bf03278876","title":"Pioglitazone economically attractive for type 2 DM in Canada","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pioglitazone; Quality of Life Research; Public health; Type 2 diabetes; Medicine; Endocrinology","score_opus":0.04886457988781469,"score_gpt":0.3300135550347344,"score_spread":0.2811489751469197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242710605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96402323,0.00027965638,0.000012279724,0.016423471,0.0010312567,0.0012217049,0.00004992055,0.000034090503,0.016924378],"genre_scores_gemma":[0.9695685,0.00037296512,0.00088617584,0.021910489,0.00015478086,0.00013903498,0.000054847933,0.000046555815,0.006866686],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877226,0.000012791936,0.00041764206,0.0003388148,0.00005221321,0.0004062651],"domain_scores_gemma":[0.99926895,0.00017694173,0.00011235548,0.00023326864,0.000027455355,0.00018100666],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000082327395,0.00022115611,0.000516953,0.00011264554,0.000039250168,0.000022377877,0.00012259715,0.000034331162,0.0011505653],"category_scores_gemma":[0.000024227602,0.00021337256,0.00012555333,0.00005579778,0.000014302428,0.00014889242,0.000043818953,0.000112049005,0.00021530298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039026176,0.00062456034,0.70431924,0.00012254389,0.001225196,0.00005619938,0.00023346285,0.0004438042,0.00027735493,0.0007843629,0.22553861,0.06598442],"study_design_scores_gemma":[0.015405717,0.0002898481,0.1144395,0.000024736994,0.0004961467,0.00000506306,0.00031305567,0.017709602,0.0012323093,0.00029533045,0.84912443,0.0006642413],"about_ca_topic_score_codex":0.19687267,"about_ca_topic_score_gemma":0.45730737,"teacher_disagreement_score":0.6235858,"about_ca_system_score_codex":0.0015729362,"about_ca_system_score_gemma":0.00019847833,"threshold_uncertainty_score":0.99976254},"labels":[],"label_agreement":null},{"id":"W4242822936","doi":"10.1016/j.jcjd.2013.02.028","title":"Treatment of Diabetes in People with Heart Failure","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Intensive care medicine; Cardiology; Endocrinology","score_opus":0.0065547365030433555,"score_gpt":0.19759007956470895,"score_spread":0.19103534306166559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242822936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374664,0.0011335384,3.8593356e-7,0.0038022446,0.000079211604,0.00042461927,0.000007436481,0.0000052862906,0.0008006271],"genre_scores_gemma":[0.9985009,0.000009339017,0.0007787832,0.00021200655,0.000072753995,0.000031316715,0.000009651758,0.000023022902,0.0003622567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988505,0.000028526962,0.00035707187,0.00012786762,0.00016804131,0.00046799605],"domain_scores_gemma":[0.9988481,0.00006294327,0.00015606018,0.00019996641,0.00017215693,0.0005607637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007749142,0.00018619907,0.000605143,0.00054649665,0.00003166762,0.00003169736,0.00008747293,0.000054761862,0.00035598202],"category_scores_gemma":[0.000029726967,0.00012725776,0.00013322783,0.00029834724,0.00008344663,0.00019098616,0.000005244575,0.00007894233,0.000023248413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023667299,0.00014535412,0.99292105,0.000059320722,0.00024852683,0.000008433335,0.00022030297,0.000013177547,0.0005771593,0.000033150653,0.0030866603,0.0026845015],"study_design_scores_gemma":[0.0028337454,0.0035615717,0.97868556,0.00030694355,0.0002485787,0.0000021160804,0.0003716895,0.000048715003,0.0038860755,0.000077048695,0.00983868,0.00013926091],"about_ca_topic_score_codex":0.0016881044,"about_ca_topic_score_gemma":0.021570388,"teacher_disagreement_score":0.019882284,"about_ca_system_score_codex":0.00027431193,"about_ca_system_score_gemma":0.00045031268,"threshold_uncertainty_score":0.9962834},"labels":[],"label_agreement":null},{"id":"W4242846579","doi":"10.2196/preprints.13605","title":"Pharmacogenetics of Type 2 diabetes mellitus: A Systematic Review Protocol (Preprint)","year":2019,"lang":"en","type":"review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Medicine; Pharmacogenetics; MEDLINE; Protocol (science); Data extraction; Systematic review; Meta-analysis; Scopus; Publication bias; Randomized controlled trial; Family medicine; Alternative medicine; Medical physics; Internal medicine; Pathology","score_opus":0.057385044289622676,"score_gpt":0.3883522521700563,"score_spread":0.33096720788043366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242846579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.7059146e-8,0.64222443,0.0000016081069,0.000008907985,0.00006024795,0.35009095,0.000004105906,0.0000410384,0.007568679],"genre_scores_gemma":[4.5853298e-8,0.7747253,0.00029029456,0.00018948983,0.000026645766,0.21802261,0.00006256463,0.000050815812,0.006632182],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974453,0.00013847442,0.0013582292,0.00040849685,0.00037531028,0.0002741967],"domain_scores_gemma":[0.99773663,0.00013027074,0.0007560694,0.0011093454,0.00016208798,0.000105574894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047758783,0.0004809563,0.005276398,0.00015293267,0.000010803534,0.000012061029,0.00026379572,0.00012232603,0.0010154109],"category_scores_gemma":[0.000117306794,0.00028111663,0.0008253671,0.00038008697,0.00002851072,0.000026193045,0.00017300156,0.00014360095,0.0014488925],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000018413643,0.00018500227,0.0000037397626,0.8412404,0.0018669734,0.0000035244238,0.000002217471,2.7516394e-8,1.530731e-7,0.00005336123,0.0023450796,0.15429765],"study_design_scores_gemma":[0.00022671533,0.00016812512,9.88094e-8,0.48762566,0.019963976,0.0000013668028,8.2160307e-7,0.0000027004878,0.0000049552646,0.0000015398421,0.4918817,0.00012231989],"about_ca_topic_score_codex":7.6251706e-7,"about_ca_topic_score_gemma":7.77861e-8,"teacher_disagreement_score":0.48953664,"about_ca_system_score_codex":0.000096578624,"about_ca_system_score_gemma":0.00018884106,"threshold_uncertainty_score":0.9999641},"labels":[],"label_agreement":null},{"id":"W4243078815","doi":"10.1210/en.141.10.3703","title":"Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice","year":2000,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Internal medicine; Endocrinology; Insulin; Incretin; Glucagon-like peptide-1; Gastric inhibitory polypeptide; Islet; Glucagon; Medicine; Biology; Diabetes mellitus; Type 2 diabetes","score_opus":0.012031824560453033,"score_gpt":0.2418101985818617,"score_spread":0.22977837402140866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243078815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977226,0.0019975104,0.0000069893263,0.0013491417,0.00028310335,0.0006294743,0.000008706802,0.00017728504,0.005775533],"genre_scores_gemma":[0.9817735,0.002197658,0.00088542013,0.0011551839,0.00016878365,0.00008339777,0.00004050525,0.00005020473,0.013645353],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975191,0.00007958598,0.00052072515,0.00071323814,0.00023881202,0.00092853874],"domain_scores_gemma":[0.99919766,0.0000936669,0.0001039276,0.00040114828,0.000040225306,0.0001633407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000076212855,0.00037429627,0.0006006216,0.0002540016,0.000102685866,0.000039490336,0.00017706558,0.00011352317,0.00038037938],"category_scores_gemma":[0.000038665094,0.00035778384,0.00009944421,0.00018942326,0.00017653048,0.00017646719,0.00016692096,0.00036465624,0.0003777736],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009266002,0.0025397888,0.21709912,0.000777079,0.0011716569,0.006370276,0.0022209326,0.0005240804,0.09844833,0.0017278483,0.0022018163,0.6576531],"study_design_scores_gemma":[0.021729069,0.0019130401,0.8624362,0.00047018583,0.00037520492,0.0006292931,0.0004492541,0.0016155978,0.06583482,0.00022732174,0.04347935,0.0008406891],"about_ca_topic_score_codex":0.00051452103,"about_ca_topic_score_gemma":0.00021484747,"teacher_disagreement_score":0.65681237,"about_ca_system_score_codex":0.00016403558,"about_ca_system_score_gemma":0.000035012632,"threshold_uncertainty_score":0.9998874},"labels":[],"label_agreement":null},{"id":"W4243449583","doi":"10.31525/ct1-nct04175665","title":"Real-world Health Outcomes in Canadian Patients Using Semaglutide","year":2019,"lang":"en","type":"article","venue":"Case Medical Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.09477151904223455,"score_gpt":0.45534287001723966,"score_spread":0.36057135097500514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243449583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97086513,0.00006979884,6.160025e-7,0.0070678857,0.00015152188,0.0010481289,0.000007905637,0.000016906522,0.020772133],"genre_scores_gemma":[0.98996156,0.00005559214,0.0001262653,0.0011726248,0.000045113793,0.000024576957,0.00004060292,0.000020565289,0.008553094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968455,0.0001961232,0.0002831837,0.00030055043,0.0012817563,0.0010928841],"domain_scores_gemma":[0.99757326,0.00028018173,0.000024176255,0.00035316823,0.00010746817,0.001661742],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021839822,0.00011007902,0.00035695816,0.00093414815,0.000092573,0.000019054369,0.000106260995,0.00006866049,0.001597754],"category_scores_gemma":[0.0008803392,0.00008521713,0.000050853756,0.0006635876,0.000092167604,0.000036891113,0.00011142447,0.00045992844,0.00037866866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020676918,0.0002545508,0.94175875,0.00014470518,0.000037622547,0.0056861653,0.00011705866,8.028034e-7,0.0000015636537,0.00050582946,0.0036541065,0.04781816],"study_design_scores_gemma":[0.0073699816,0.0010279571,0.8101258,0.0008986362,0.00002613273,0.00006577613,0.0004316126,0.0041894605,0.000024044059,0.00013249712,0.17546892,0.00023913008],"about_ca_topic_score_codex":0.77423185,"about_ca_topic_score_gemma":0.78459,"teacher_disagreement_score":0.17181481,"about_ca_system_score_codex":0.0017863725,"about_ca_system_score_gemma":0.0020112738,"threshold_uncertainty_score":0.9993149},"labels":[],"label_agreement":null},{"id":"W4243808946","doi":"10.1007/978-3-319-67199-4_101838","title":"SLC28 and SLC29","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"History","score_opus":0.02443389534749311,"score_gpt":0.2535689143801437,"score_spread":0.22913501903265057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243808946","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000055237026,0.000818781,0.0000044514413,0.0012931692,0.000075575525,0.00031725256,0.000001936459,0.000056312354,0.9973773],"genre_scores_gemma":[0.0010426835,0.00085822603,0.00029188168,0.0006347102,0.00013578757,0.000005588071,0.000038098093,0.000028355216,0.9969647],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99949795,6.8770214e-7,0.00008478738,0.00020056372,0.00011409522,0.00010188817],"domain_scores_gemma":[0.9994431,0.000007942549,0.00005629208,0.00038843666,0.00002054479,0.00008364802],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000031789743,0.00016769541,0.00027493693,0.00006408551,0.00004308211,0.000029049801,0.000042610165,0.00010397777,0.0018265428],"category_scores_gemma":[0.0000036405756,0.00012213105,0.00006742458,0.0000010169891,0.000056383415,0.000026532694,0.00006523188,0.000074478536,0.00051247346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021911008,0.0000350872,0.0003248124,0.0002362828,0.0009431858,0.00044292922,0.000022447215,5.823669e-9,0.000007072681,0.5976295,0.19299766,0.20733912],"study_design_scores_gemma":[0.0006471831,0.00013382634,0.0005901193,0.0001683544,0.00054062123,0.000008055446,0.0000015397553,0.0000015453784,0.000010235588,0.006126371,0.9916541,0.00011804242],"about_ca_topic_score_codex":0.0000064949236,"about_ca_topic_score_gemma":0.0000060001316,"teacher_disagreement_score":0.79865646,"about_ca_system_score_codex":0.000021022253,"about_ca_system_score_gemma":0.000013550341,"threshold_uncertainty_score":0.9990859},"labels":[],"label_agreement":null},{"id":"W4244009236","doi":"10.1016/s1499-2671(10)43014-2","title":"The authors respond:","year":2010,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine","score_opus":0.008869459926984947,"score_gpt":0.23166571641528566,"score_spread":0.2227962564883007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244009236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836141,0.0006935394,6.7326437e-7,0.007108461,0.0012258556,0.00009869814,0.0000026782816,0.000005349634,0.007250681],"genre_scores_gemma":[0.9943229,0.000006938895,0.00023475617,0.00044540095,0.00028397408,0.000002607304,0.0000016896955,0.000012521732,0.0046892148],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926305,0.000019889223,0.0002019816,0.00006124509,0.0001344406,0.00031940604],"domain_scores_gemma":[0.9987903,0.00009635198,0.00010014987,0.00019215894,0.0001695633,0.00065142504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004894653,0.00008152003,0.00015131594,0.00019001981,0.00016703445,0.00006978505,0.00015508165,0.000046446483,0.00014458019],"category_scores_gemma":[0.0004164444,0.000048945734,0.00009547761,0.00015532452,0.00011903037,0.00007091483,0.0000070080655,0.00027621276,0.00002900879],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010308958,0.00003116448,0.81035626,0.000019309027,0.00043094505,0.00009545449,0.00024139814,0.0000010248702,0.0029118452,0.004945216,0.09398894,0.08696813],"study_design_scores_gemma":[0.0006053083,0.0003087966,0.3350663,0.00004276823,0.00016413534,0.0000053162894,0.00010627946,0.000010297185,0.0013371112,0.00060361094,0.66168016,0.00006992439],"about_ca_topic_score_codex":0.00007921906,"about_ca_topic_score_gemma":0.0067204833,"teacher_disagreement_score":0.5676912,"about_ca_system_score_codex":0.000046055327,"about_ca_system_score_gemma":0.0005770215,"threshold_uncertainty_score":0.37501875},"labels":[],"label_agreement":null},{"id":"W4244885500","doi":"10.2337/dc14-1392","title":"Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076–1082","year":2014,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Glucagon; Internal medicine; Type 2 diabetes; Endocrinology; Type 1 diabetes; Insulin","score_opus":0.029654120845583734,"score_gpt":0.3206584022804947,"score_spread":0.29100428143491097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244885500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73373777,0.0029948393,3.4153254e-7,0.25768,0.00050911034,0.0030438502,0.001366279,0.000117424555,0.00055036845],"genre_scores_gemma":[0.52368665,0.00019760986,0.00028848177,0.4715094,0.00023922398,0.00054217374,0.0028987015,0.00032483257,0.00031293771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99182767,0.0016785826,0.0014260908,0.0016176366,0.0014740106,0.0019759955],"domain_scores_gemma":[0.993199,0.001966282,0.000636193,0.002706295,0.00089708605,0.00059516093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014992221,0.0015646858,0.003184833,0.0019762595,0.000079369354,0.00007851374,0.0008947433,0.00093964237,0.00030370295],"category_scores_gemma":[0.0010664408,0.0013680415,0.000999045,0.0009039331,0.00020199013,0.00014403994,0.0006010327,0.0014758732,0.0011943526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00731909,0.0005685237,0.0834108,0.0020485686,0.0012022811,0.00009910888,0.0046775276,0.00012696076,0.0047157207,0.0000037801194,0.89060247,0.005225164],"study_design_scores_gemma":[0.0057615493,0.02422834,0.034619935,0.005093297,0.0008169948,2.006689e-7,0.0009790452,0.000023212007,0.014288401,0.000018665647,0.91284704,0.0013233153],"about_ca_topic_score_codex":0.00008497196,"about_ca_topic_score_gemma":0.00003533388,"teacher_disagreement_score":0.21382938,"about_ca_system_score_codex":0.001744431,"about_ca_system_score_gemma":0.00043124278,"threshold_uncertainty_score":0.99971014},"labels":[],"label_agreement":null},{"id":"W4245097826","doi":"10.14740/jem531w","title":"Effects of SGLT2 Inhibition on eGFR and Glomerular and Tubular Damage Markers in Japanese Patients With Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Medicine; Type 2 diabetes; Renal function; Internal medicine; Endocrinology; Urinary system; Diabetes mellitus; Urology; Excretion; Gastroenterology","score_opus":0.004103295353995121,"score_gpt":0.21697571349124484,"score_spread":0.21287241813724972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245097826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995448,0.003759076,5.647745e-7,0.00015644445,0.00013233414,0.00020585684,0.0000010229063,0.0000032303608,0.00029346073],"genre_scores_gemma":[0.9984289,0.0010447124,0.00019501962,0.00020536181,0.00005414908,0.0000024463807,0.0000025410513,0.0000075541193,0.000059332047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937826,0.000054611573,0.00018302456,0.00011066536,0.00010631698,0.00016714142],"domain_scores_gemma":[0.99957204,0.000066209235,0.00012960966,0.00006758759,0.00009341633,0.00007116651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009485163,0.00010884757,0.0003583178,0.00025333455,0.000026416077,0.0000055795304,0.00001974804,0.00003923697,0.000007882945],"category_scores_gemma":[0.00006760948,0.00007254716,0.000019958406,0.00008901698,0.00019429483,0.00009702731,0.000030414769,0.00010701549,7.2514496e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002926291,0.0011679331,0.93021756,0.00068878237,0.001195324,0.0003891575,0.0010134138,6.2926193e-7,0.017306596,0.0012404902,0.00039566206,0.043458126],"study_design_scores_gemma":[0.007737322,0.0027172277,0.9763502,0.0002272764,0.00048690743,0.000012739403,0.000064935564,0.0000029644239,0.010427484,0.00013248756,0.0017748132,0.00006567224],"about_ca_topic_score_codex":0.0000050795247,"about_ca_topic_score_gemma":0.0000021111418,"teacher_disagreement_score":0.046132576,"about_ca_system_score_codex":0.000008635844,"about_ca_system_score_gemma":0.000009386702,"threshold_uncertainty_score":0.29583874},"labels":[],"label_agreement":null},{"id":"W4245347340","doi":"10.14740/jem708","title":"Combination Therapy of Alpha-Glucosidase Inhibitor, Thiazolidinedione and Sodium Glucose Co-Transporter-2 Inhibitor in Japanese Type 2 Diabetes Patients","year":2020,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Internal medicine; Glycated hemoglobin; Endocrinology; Type 2 diabetes; Pharmacology; Thiazolidinedione; Diabetes mellitus; Type 2 Diabetes Mellitus; Dipeptidyl peptidase-4 inhibitor","score_opus":0.01509987971814005,"score_gpt":0.25176795213170855,"score_spread":0.2366680724135685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245347340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671633,0.010720138,0.0000012322521,0.0017274456,0.00040151246,0.00028545017,0.000005423749,0.00000930078,0.00013317613],"genre_scores_gemma":[0.9899241,0.009029415,0.00010325552,0.00070630957,0.00017378252,0.0000046287732,0.000018681732,0.000012838533,0.000027031652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988835,0.000060903327,0.00049042125,0.00015475432,0.00018803973,0.0002224034],"domain_scores_gemma":[0.9992618,0.00006151233,0.00027086842,0.00008182286,0.00017725947,0.00014674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012481834,0.00016353832,0.00059537473,0.00023082852,0.000027976424,0.000008444031,0.00005564291,0.000070828275,0.00002032061],"category_scores_gemma":[0.000068190486,0.00012366023,0.00007005375,0.00015198861,0.00011192512,0.00018925629,0.000025892887,0.00018429967,0.0000014404953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035556636,0.0034913872,0.8009056,0.00039808694,0.0011075103,0.00027587655,0.004857833,0.0000018776112,0.11108826,0.0013948892,0.0019141674,0.07100886],"study_design_scores_gemma":[0.024158772,0.003232295,0.8011433,0.00012482221,0.00036696796,0.000013902004,0.00027827747,0.000017287499,0.1520134,0.00021581931,0.018256515,0.00017863505],"about_ca_topic_score_codex":0.0000055286364,"about_ca_topic_score_gemma":0.0000013824853,"teacher_disagreement_score":0.070830226,"about_ca_system_score_codex":0.000011599703,"about_ca_system_score_gemma":0.000031876283,"threshold_uncertainty_score":0.50427175},"labels":[],"label_agreement":null},{"id":"W4245586614","doi":"10.1016/j.jcjd.2016.02.006","title":"Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Interim; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.018143760467450778,"score_gpt":0.2597050012906354,"score_spread":0.24156124082318461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245586614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877792,0.0031991415,0.00000950782,0.0022483976,0.00083651446,0.00024153435,0.000019345918,0.000011563565,0.0056547727],"genre_scores_gemma":[0.9961333,0.00034074858,0.000538474,0.0007544704,0.000119664575,0.0000062936906,0.0000050457124,0.000023783907,0.0020781718],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868727,0.000037022397,0.0004554647,0.00014949995,0.00018353018,0.0004872367],"domain_scores_gemma":[0.99865144,0.00004706204,0.00027454883,0.0002199751,0.00022770291,0.00057927566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030162823,0.00017983302,0.0004397228,0.00041666906,0.000038304912,0.000016761738,0.00023421738,0.00005320473,0.0012556462],"category_scores_gemma":[0.00003639833,0.000110985566,0.0001723841,0.00022042108,0.00014505172,0.00016594504,0.00003369663,0.00008207713,0.00012197015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050474588,0.00030182238,0.5792077,0.0006477655,0.0049004653,0.00028269025,0.000114038805,0.000003910566,0.015010326,0.0013178046,0.12868448,0.2694785],"study_design_scores_gemma":[0.015353772,0.0069425446,0.3174945,0.00832298,0.005004121,0.0000070638453,0.00042143758,0.000037818398,0.07718902,0.0022439351,0.56601,0.0009727756],"about_ca_topic_score_codex":0.00001229329,"about_ca_topic_score_gemma":0.000039330127,"teacher_disagreement_score":0.43732554,"about_ca_system_score_codex":0.00020286572,"about_ca_system_score_gemma":0.00024161454,"threshold_uncertainty_score":0.99965733},"labels":[],"label_agreement":null},{"id":"W4245650535","doi":"10.1038/nrd3148","title":"Liraglutide","year":2010,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Liraglutide; Medicine; Pharmacology; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.02378343885504945,"score_gpt":0.34793214512829074,"score_spread":0.32414870627324127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245650535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010828297,0.9620459,0.0000033558174,0.00015580365,0.0015338422,0.0044372533,0.0000488636,0.00010231069,0.031671565],"genre_scores_gemma":[4.7059697e-7,0.9376865,0.00046403217,0.0008408749,0.0011304523,0.00054142694,0.001049936,0.0001264043,0.058159873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701947,0.00016826254,0.0010192418,0.00084046327,0.00042672554,0.0005258347],"domain_scores_gemma":[0.99748194,0.00013164169,0.00062722224,0.0014977057,0.000042201194,0.0002192786],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060371123,0.00094289664,0.004785024,0.00032825448,0.00006989655,0.00013383426,0.00040450293,0.0010383523,0.00017735187],"category_scores_gemma":[0.00024725148,0.0005583721,0.0025979632,0.0005489784,0.00007191253,0.00026551698,0.0002235688,0.003064929,0.001692187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000029801922,0.00016475134,0.000003896435,0.047511335,0.0003089326,0.000066832516,0.0000051064562,2.6776106e-9,1.1435113e-7,0.0008686217,0.07706569,0.87400174],"study_design_scores_gemma":[0.00026351312,0.00003605053,0.000003040998,0.051028922,0.008186641,0.000038452526,0.0000016672034,9.173932e-8,8.355804e-7,0.00003120826,0.93996257,0.0004470292],"about_ca_topic_score_codex":0.0000028036445,"about_ca_topic_score_gemma":0.000009568907,"teacher_disagreement_score":0.8735547,"about_ca_system_score_codex":0.00021467253,"about_ca_system_score_gemma":0.00028749407,"threshold_uncertainty_score":0.9996868},"labels":[],"label_agreement":null},{"id":"W4246182724","doi":"10.1111/dom.14117/v2/decision1","title":"Decision letter for \"Semaglutide Once Weekly in Persons with Type 2 Diabetes: Real‐world Analysis of the Canadian &lt;scp&gt;LMC&lt;/scp&gt; Diabetes Registry ( &lt;scp&gt;SPARE&lt;/scp&gt; Study)\"","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Spare part; Type 2 diabetes; Spare time; Medicine; Diabetes mellitus; Endocrinology; Engineering; Humanities; Art; Operations management","score_opus":0.026077668666118548,"score_gpt":0.28219225630924416,"score_spread":0.2561145876431256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246182724","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44549894,0.1004395,0.00018886037,0.14163901,0.0094961915,0.04992126,0.008404259,0.001440765,0.24297121],"genre_scores_gemma":[0.22320324,0.007738067,0.004066343,0.031233897,0.0019658895,0.0038829083,0.009823675,0.0010549445,0.71703106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9866511,0.00060792774,0.002870222,0.0034239802,0.0033197317,0.0031270278],"domain_scores_gemma":[0.9881189,0.0025490737,0.0019719752,0.0045715296,0.0012214252,0.001567082],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023450362,0.0025847433,0.006333989,0.0031975992,0.00067870016,0.00037061787,0.0024554485,0.0008328021,0.0006977505],"category_scores_gemma":[0.0026940617,0.0018486861,0.0020855558,0.008223194,0.000608738,0.00033811,0.00086324126,0.0015076195,0.00016759812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000664992,0.0010094065,0.062859595,0.003408845,0.011133631,0.00019717084,0.0006573731,0.00014604915,0.00016921214,0.00014114671,0.9152602,0.0049508796],"study_design_scores_gemma":[0.003915143,0.0018337297,0.040898796,0.008223265,0.030955238,0.0000017805587,0.00043220632,0.0009795069,0.00014773439,0.00004704892,0.91165787,0.0009076617],"about_ca_topic_score_codex":0.011168795,"about_ca_topic_score_gemma":0.654235,"teacher_disagreement_score":0.6430662,"about_ca_system_score_codex":0.0024375464,"about_ca_system_score_gemma":0.001964957,"threshold_uncertainty_score":0.99868876},"labels":[],"label_agreement":null},{"id":"W4247235803","doi":"10.2337/figshare.14597772.v3","title":"The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Albuminuria; Dapagliflozin; Medicine; Renal function; Creatinine; Internal medicine; TIMI; Urology; Placebo; Type 2 diabetes; Kidney disease; Endocrinology; Diabetes mellitus; Myocardial infarction; Percutaneous coronary intervention; Pathology","score_opus":0.010222930701823119,"score_gpt":0.2725719607429898,"score_spread":0.26234903004116666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247235803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90474963,0.0010521921,0.000011985822,0.0015773498,0.0005652289,0.0015420992,0.0000029511737,0.00004387078,0.0904547],"genre_scores_gemma":[0.98403245,0.00034385125,0.00026395233,0.0002176695,0.00007003436,0.0002127523,0.00012950551,0.00002781005,0.014701974],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869615,0.00012300546,0.0003019233,0.000355229,0.0002938559,0.00022985948],"domain_scores_gemma":[0.9987363,0.0002907608,0.00009589986,0.0007891607,0.00003139773,0.00005648486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042544657,0.00025377024,0.0005780422,0.00011635652,0.000022625145,0.000035631583,0.00016264542,0.0001548928,0.0001966068],"category_scores_gemma":[0.00011988656,0.00014027364,0.00022383877,0.00011030617,0.00003730338,0.00001418809,0.0003880526,0.00030705394,0.000033083885],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036869638,0.0028451371,0.22246614,0.007362767,0.008344228,0.0013975932,0.0010669328,0.0009242822,0.002072938,0.0041633015,0.10642299,0.6392467],"study_design_scores_gemma":[0.037038337,0.016592244,0.32404536,0.015772825,0.0073066717,0.000010142045,0.001579429,0.0026313344,0.48585966,0.0011185388,0.10584728,0.0021981974],"about_ca_topic_score_codex":0.00014216822,"about_ca_topic_score_gemma":0.00021376177,"teacher_disagreement_score":0.63704854,"about_ca_system_score_codex":0.00012221528,"about_ca_system_score_gemma":0.000051888135,"threshold_uncertainty_score":0.5720193},"labels":[],"label_agreement":null},{"id":"W4247248979","doi":"10.1002/14651858.cd012990","title":"GLP-1 receptor agonists for Parkinson's disease","year":2018,"lang":"en","type":"article","venue":"Cochrane Database of Systematic Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Parkinson's disease; Neuroscience; Medicine; Receptor; Pharmacology; Disease; Psychology; Internal medicine","score_opus":0.06473197757540569,"score_gpt":0.34643057345071626,"score_spread":0.28169859587531054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247248979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026938485,0.8537793,0.015400471,0.0027366146,0.0038929572,0.08344106,0.002006539,0.0003392562,0.011465321],"genre_scores_gemma":[0.3462079,0.38012674,0.15033239,0.0058236,0.0052600424,0.035260443,0.019076895,0.0005236567,0.05738834],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791026,0.0001446812,0.001028182,0.0003428166,0.00032268406,0.0002513701],"domain_scores_gemma":[0.9974989,0.00018771776,0.00053339946,0.0013161185,0.00021832545,0.00024551185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014260977,0.00024615723,0.0014794087,0.000096996446,0.00006487192,0.00002079508,0.0001883616,0.000029237885,0.00035412674],"category_scores_gemma":[0.0015963194,0.00015939257,0.0003449474,0.00017242898,0.00010298298,0.00011145916,0.000064971275,0.000034942503,0.000716975],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016440428,0.00035568536,0.0003534489,0.87119603,0.00025119877,0.0000094848265,0.0000845985,2.249802e-8,0.0008057486,0.0012751686,0.12404404,0.0014601675],"study_design_scores_gemma":[0.0030456642,0.00074378896,0.0003328388,0.45958462,0.0042200596,0.0000063479793,0.00009078067,0.00020393501,0.0013694379,0.00004803814,0.529998,0.0003564795],"about_ca_topic_score_codex":0.0000044498397,"about_ca_topic_score_gemma":0.0000027780998,"teacher_disagreement_score":0.47365254,"about_ca_system_score_codex":0.00005012581,"about_ca_system_score_gemma":0.000047245037,"threshold_uncertainty_score":0.9215503},"labels":[],"label_agreement":null},{"id":"W4249177352","doi":"10.1093/ehjci/ehaa946.2883","title":"Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Placebo; Mace; Internal medicine; Type 2 diabetes; Diabetes mellitus; Heart failure; Hazard ratio; Cardiology; Myocardial infarction; Endocrinology; Confidence interval; Conventional PCI","score_opus":0.06519948828535468,"score_gpt":0.30116526597121573,"score_spread":0.23596577768586105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249177352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875876,0.00059510494,0.000018499615,0.009028165,0.00018501541,0.00083852094,0.000003671755,0.000030063646,0.0017134137],"genre_scores_gemma":[0.9972678,0.000031654006,0.0006245,0.0015541391,0.00041244284,0.0000077282175,0.0000038858648,0.00003131342,0.00006655922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811673,0.0004998359,0.00030673586,0.0003048462,0.00048255542,0.00028929394],"domain_scores_gemma":[0.99925864,0.00011608245,0.00006578519,0.00027031428,0.00003389971,0.0002552939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009811703,0.00023490348,0.0005676587,0.0000781599,0.00014816724,0.00013621939,0.00009303342,0.00002809795,0.000030882326],"category_scores_gemma":[0.00013791463,0.00013557017,0.00021423511,0.00015452267,0.00010450054,0.00015436251,0.00008106963,0.00045152602,0.000020332876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071426462,0.000099752266,0.9842696,0.000045200475,0.0017145922,0.00086366653,0.0015351435,0.000030932533,0.000010168105,0.000035822413,0.003022239,0.0012302077],"study_design_scores_gemma":[0.06457752,0.001538992,0.90709114,0.00003680301,0.0008216392,0.0001755351,0.00184534,0.000017752105,0.0000084662015,0.0000059935887,0.023717655,0.00016316473],"about_ca_topic_score_codex":0.000011359065,"about_ca_topic_score_gemma":0.000016019078,"teacher_disagreement_score":0.07717849,"about_ca_system_score_codex":0.00003213197,"about_ca_system_score_gemma":0.000022853324,"threshold_uncertainty_score":0.5528391},"labels":[],"label_agreement":null},{"id":"W4249181773","doi":"10.1016/j.jval.2017.08.443","title":"Economic Burden of Cardiovascular Disease In Type 2 Diabetes: A Systematic Review","year":2017,"lang":"en","type":"review","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Indirect costs; Disease burden; Disease; Type 2 diabetes; Population; Burden of disease; MEDLINE; Coronary artery disease; Environmental health; Diabetes mellitus; Demography; Internal medicine; Accounting; Business","score_opus":0.10946144812439924,"score_gpt":0.3608086619003093,"score_spread":0.25134721377591007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249181773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001821815,0.9907073,1.7783076e-7,0.00012494295,0.00024077533,0.008594037,0.000024475292,0.000015707388,0.00027440532],"genre_scores_gemma":[0.000038485316,0.99871737,0.000029345698,0.000067898705,0.00007884135,0.00062143855,0.00012935074,0.00004851757,0.00026873444],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968386,0.00057552115,0.0015431733,0.00042986468,0.00024147404,0.0003713605],"domain_scores_gemma":[0.99710923,0.0001235342,0.00077806594,0.0017635683,0.00002160676,0.00020397018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021857037,0.00034194873,0.006584024,0.00037275002,0.000021273312,0.0000114846125,0.00027434254,0.00008722595,0.000018534609],"category_scores_gemma":[0.00033904734,0.00025835537,0.0009451471,0.0001622779,0.000031363645,0.000042564196,0.000086479355,0.00018722413,0.00014189696],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017915243,0.000055419412,0.00003645417,0.91559565,0.0010413397,0.00003673121,0.000017342989,0.000083756284,1.351374e-10,0.000049545182,0.00013333325,0.08294864],"study_design_scores_gemma":[0.00025164225,0.00007925416,0.0000065203244,0.6644657,0.0050144573,6.303936e-7,0.0000019702288,0.0000828318,2.2745472e-9,0.000009342605,0.32997903,0.00010858131],"about_ca_topic_score_codex":0.0013783643,"about_ca_topic_score_gemma":0.000004998281,"teacher_disagreement_score":0.3298457,"about_ca_system_score_codex":0.00093629345,"about_ca_system_score_gemma":0.0010805434,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4249352426","doi":"10.1017/9781139939508.114","title":"FMC-7","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science; Content (measure theory); Database; World Wide Web; Mathematics","score_opus":0.019869297544743716,"score_gpt":0.19878770675060772,"score_spread":0.178918409205864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249352426","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008145477,0.00012400388,0.00006450336,0.000080854225,0.00019363659,0.0005927691,0.00011046721,0.00018191966,0.9985704],"genre_scores_gemma":[0.0006409352,0.0001796261,0.00006895493,0.00016235368,0.00018167184,8.6554e-7,0.000058094574,0.0000505127,0.998657],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899656,0.000008234009,0.00011758954,0.0003991771,0.0002287546,0.00024970007],"domain_scores_gemma":[0.99903524,0.000026180143,0.000111359375,0.0005453421,0.00008598277,0.00019591783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00003737428,0.0003129436,0.00041382745,0.00018026076,0.000071374656,0.000014089266,0.00016765323,0.0002263993,0.000037119273],"category_scores_gemma":[0.0000030975734,0.00027809964,0.00026286131,0.0000032160044,0.00014339664,0.000041051633,0.00024517457,0.00016795081,0.00018340416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012199701,0.00001715649,0.000010393261,0.00011457663,0.0006281275,0.0008714307,0.0000064819333,1.6464247e-8,0.00003174553,0.8873624,0.0983814,0.012454243],"study_design_scores_gemma":[0.0016582869,0.00014784966,0.000052458978,0.00041866364,0.0011452687,0.0000071784766,0.000004987921,0.0000013571688,0.00022073004,0.0000108649865,0.99605924,0.0002731306],"about_ca_topic_score_codex":0.000008947296,"about_ca_topic_score_gemma":4.098792e-7,"teacher_disagreement_score":0.89767784,"about_ca_system_score_codex":0.00026303084,"about_ca_system_score_gemma":0.000060754548,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W4249926269","doi":"10.21203/rs.3.rs-64853/v2","title":"Metabolic Syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A post hoc analyses of the EMPA-REG OUTCOME trial","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Internal medicine; Metabolic syndrome; Type 2 diabetes; Waist; Hazard ratio; Population; Blood pressure; Diabetic nephropathy; Cardiology; Diabetes mellitus; Post-hoc analysis; Proportional hazards model; Body mass index; Obesity; Endocrinology; Confidence interval; Kidney","score_opus":0.08915646955207664,"score_gpt":0.36541079487114614,"score_spread":0.2762543253190695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249926269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847532,0.009612017,4.90619e-7,0.00049361936,0.00009488519,0.0048462553,0.00010223222,0.000024878529,0.0000724387],"genre_scores_gemma":[0.99885595,0.00036553154,0.000029909988,0.000034188444,0.000049690025,0.00025508917,0.00019582303,0.000048523198,0.00016531082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963968,0.00047379854,0.00036588247,0.0006116572,0.0016901419,0.00046172747],"domain_scores_gemma":[0.99792767,0.00014053138,0.00010156901,0.0011849729,0.00038661287,0.00025865756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000626889,0.00029816333,0.0011170895,0.00038752047,0.00006662467,0.000055523127,0.00029480975,0.00010661761,0.00003577692],"category_scores_gemma":[0.00065716245,0.00017309001,0.00044881238,0.00077063666,0.00021833775,0.000051886967,0.000985812,0.00058487465,0.0000093973595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00574922,0.000835375,0.98287785,0.0028181414,0.0052003805,0.000057767305,0.0001766204,0.0001327103,0.000018155612,0.000036613485,0.000045101784,0.0020520547],"study_design_scores_gemma":[0.017593207,0.0017291819,0.9771428,0.0010968704,0.0018144364,9.226413e-8,0.000065259635,0.000041722185,0.000031066713,0.000058434813,0.00027056353,0.00015636081],"about_ca_topic_score_codex":0.00015407536,"about_ca_topic_score_gemma":0.000010687536,"teacher_disagreement_score":0.01410275,"about_ca_system_score_codex":0.00011259507,"about_ca_system_score_gemma":0.000228859,"threshold_uncertainty_score":0.7058406},"labels":[],"label_agreement":null},{"id":"W4250073682","doi":"10.17925/ee.2011.07.01.24","title":"Pioglitazone in Combination with Insulin – An Overview of Results from PROactive","year":2010,"lang":"en","type":"article","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pioglitazone; Medicine; Insulin; Internal medicine; Heart failure; Population; Adverse effect; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.05407405549379813,"score_gpt":0.3307190044240813,"score_spread":0.2766449489302832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250073682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986856,0.0042622946,0.000005872345,0.00067491026,0.00010885292,0.0012729871,0.00001583788,0.000024770601,0.006778463],"genre_scores_gemma":[0.98951685,0.0061313887,0.0036126047,0.0001807645,0.00003076503,0.00016726088,0.00020109066,0.000014384785,0.00014489642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99870396,0.00010611453,0.0004890107,0.00032816568,0.00012174338,0.00025102685],"domain_scores_gemma":[0.999192,0.00008312289,0.00016379917,0.000464233,0.00005092147,0.00004591467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018224999,0.00015250283,0.0005864859,0.0002351118,0.000009337248,0.0000032824016,0.00010875483,0.000058786696,0.000083960804],"category_scores_gemma":[0.00013042384,0.0001135697,0.00003821893,0.00028369902,0.00009114276,0.00011507213,0.00004906944,0.00025465214,0.000023566703],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015930863,0.0051792483,0.09964293,0.00040221112,0.00021226429,0.00029740643,0.0014191949,0.00000486899,0.0028035275,0.026972944,0.00017753802,0.8612948],"study_design_scores_gemma":[0.020583594,0.0026548181,0.92996985,0.0006512101,0.00022178324,0.000014828605,0.00020596983,0.000106797386,0.006040991,0.0027757783,0.036512703,0.00026168526],"about_ca_topic_score_codex":0.00078055606,"about_ca_topic_score_gemma":0.0023284939,"teacher_disagreement_score":0.8610331,"about_ca_system_score_codex":0.000053232714,"about_ca_system_score_gemma":0.00003781364,"threshold_uncertainty_score":0.4631238},"labels":[],"label_agreement":null},{"id":"W4250185040","doi":"10.1016/j.cjca.2017.12.030","title":"Prediabetes","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prediabetes; Metformin; Incretin; Diabetes mellitus; Internal medicine; Type 2 diabetes; Insulin resistance; Impaired glucose tolerance; Endocrinology; Sitagliptin; Insulin","score_opus":0.040891565621933454,"score_gpt":0.2955153483236855,"score_spread":0.254623782701752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250185040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006904501,0.96092135,0.000019269024,0.0000707043,0.001463395,0.00030009713,0.000025440397,0.0000051124994,0.037187718],"genre_scores_gemma":[0.000067274355,0.99403965,0.00013236768,0.000079614176,0.0040218197,0.000009833843,0.00004425995,0.00003649502,0.0015687088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872345,0.000108002074,0.0005311418,0.00015333535,0.000095203504,0.00038888256],"domain_scores_gemma":[0.9984439,0.000066513756,0.0003430402,0.0002762867,0.00017885651,0.0006913986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030542826,0.00024435177,0.0023650094,0.000682636,0.000038694,0.000017624647,0.00020027038,0.00027784272,0.00007320209],"category_scores_gemma":[0.00013383066,0.00017144633,0.0009972967,0.0001466609,0.00017396962,0.000033335946,0.000015142745,0.00028323746,0.00015843852],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000020468372,0.0000013118056,0.00026760253,0.0024053913,0.0026581658,0.00055029884,0.000008907141,3.54522e-7,1.352593e-8,0.0000779812,0.19760111,0.79642683],"study_design_scores_gemma":[0.0002702533,0.00056512275,0.000059503705,0.004188467,0.0055202,0.00049542787,0.0000048075717,6.1592196e-8,1.3423383e-7,0.000048906386,0.9887431,0.00010398903],"about_ca_topic_score_codex":0.000026450187,"about_ca_topic_score_gemma":0.000065575085,"teacher_disagreement_score":0.7963228,"about_ca_system_score_codex":0.00031691353,"about_ca_system_score_gemma":0.0025239782,"threshold_uncertainty_score":0.69913787},"labels":[],"label_agreement":null},{"id":"W4250410978","doi":"10.1007/978-1-4614-6438-9_101838-1","title":"SLC28 and SLC29","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Computer science","score_opus":0.02443389534749311,"score_gpt":0.2535689143801437,"score_spread":0.22913501903265057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250410978","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000055237026,0.000818781,0.0000044514413,0.0012931692,0.000075575525,0.00031725256,0.000001936459,0.000056312354,0.9973773],"genre_scores_gemma":[0.0010426835,0.00085822603,0.00029188168,0.0006347102,0.00013578757,0.000005588071,0.000038098093,0.000028355216,0.9969647],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99949795,6.8770214e-7,0.00008478738,0.00020056372,0.00011409522,0.00010188817],"domain_scores_gemma":[0.9994431,0.000007942549,0.00005629208,0.00038843666,0.00002054479,0.00008364802],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000031789743,0.00016769541,0.00027493693,0.00006408551,0.00004308211,0.000029049801,0.000042610165,0.00010397777,0.0018265428],"category_scores_gemma":[0.0000036405756,0.00012213105,0.00006742458,0.0000010169891,0.000056383415,0.000026532694,0.00006523188,0.000074478536,0.00051247346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021911008,0.0000350872,0.0003248124,0.0002362828,0.0009431858,0.00044292922,0.000022447215,5.823669e-9,0.000007072681,0.5976295,0.19299766,0.20733912],"study_design_scores_gemma":[0.0006471831,0.00013382634,0.0005901193,0.0001683544,0.00054062123,0.000008055446,0.0000015397553,0.0000015453784,0.000010235588,0.006126371,0.9916541,0.00011804242],"about_ca_topic_score_codex":0.0000064949236,"about_ca_topic_score_gemma":0.0000060001316,"teacher_disagreement_score":0.79865646,"about_ca_system_score_codex":0.000021022253,"about_ca_system_score_gemma":0.000013550341,"threshold_uncertainty_score":0.9990859},"labels":[],"label_agreement":null},{"id":"W4250677920","doi":"10.14740/jem333w","title":"Plasma B-Type Natriuretic Peptide Levels May Increase Because of Fat Mass Loss by Metformin or Sodium-Glucose Transporter 2 Inhibitors Treatment","year":2016,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Glycemic; Diabetes mellitus; Natriuretic peptide; Dapagliflozin; Pharmacology; Heart failure","score_opus":0.020329637866798644,"score_gpt":0.26741453179254765,"score_spread":0.247084893925749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250677920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059725,0.0067397044,0.00006476061,0.0013100313,0.0005335096,0.00032745735,0.00005960147,0.000015948885,0.00035171333],"genre_scores_gemma":[0.9815049,0.009375231,0.0010861811,0.0001539381,0.00024474118,0.000011247013,0.000008426693,0.000025696825,0.0075896294],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982736,0.00008113176,0.00072627695,0.00022692056,0.0002547344,0.00043735452],"domain_scores_gemma":[0.9987403,0.00017267141,0.0004202394,0.00022612643,0.00017055855,0.0002700673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016309023,0.0003048196,0.0009496101,0.0003646698,0.000047776295,0.000008270795,0.000109178174,0.000113331604,0.00031251894],"category_scores_gemma":[0.00008479518,0.00015508571,0.00024202635,0.00013518562,0.00023030757,0.00022799142,0.000026730457,0.00014033073,0.000012164294],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017195433,0.004683275,0.0959085,0.0004708274,0.01232832,0.009879055,0.0015526993,0.0000026688467,0.40242583,0.005401233,0.015757337,0.43439484],"study_design_scores_gemma":[0.031808272,0.004138257,0.027044058,0.00027014827,0.0056440625,0.0011965384,0.00023242447,0.0000018853012,0.5577972,0.0005281139,0.37099093,0.000348104],"about_ca_topic_score_codex":0.000026868884,"about_ca_topic_score_gemma":0.000011791005,"teacher_disagreement_score":0.43404672,"about_ca_system_score_codex":0.000071616465,"about_ca_system_score_gemma":0.000111007386,"threshold_uncertainty_score":0.6324212},"labels":[],"label_agreement":null},{"id":"W4251372763","doi":"10.1111/jdi.12504","title":"Preface","year":2016,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Wife; Attendance; Medicine; Banquet; Library science; Gerontology; Environmental ethics; Art history; History; Political science; Law; Philosophy","score_opus":0.016921679246190455,"score_gpt":0.24216471028588613,"score_spread":0.22524303103969567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251372763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198246,0.00022622744,0.000111382236,0.0057849367,0.00019646656,0.00010535925,7.7307584e-7,0.000015320544,0.0015770452],"genre_scores_gemma":[0.9950615,0.00003516225,0.0025685832,0.00059314416,0.00018850442,0.000002815623,0.0000014001937,0.0000091273905,0.0015397421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993279,0.000021348666,0.00025041253,0.0000631544,0.00021655325,0.00012064026],"domain_scores_gemma":[0.9993662,0.00005464305,0.00021863471,0.000102246646,0.0001305159,0.00012774635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022482578,0.00006980406,0.0001636848,0.00012084953,0.000017619945,0.000010719742,0.000048868198,0.000030265786,0.00007068195],"category_scores_gemma":[0.0001715608,0.000037778173,0.00007865488,0.00008779479,0.000057081368,0.00023810637,0.00001407902,0.000042221833,0.000040532846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001985583,0.00010482146,0.7242987,0.00006909798,0.00031571914,0.0000084581325,0.00010910014,0.0000022417873,0.18012878,0.0010919197,0.014182131,0.07966917],"study_design_scores_gemma":[0.0050151213,0.0020855698,0.55413264,0.0013102718,0.0006661581,0.00000806031,0.000043688884,0.000039355742,0.3941424,0.011622209,0.030756135,0.00017841879],"about_ca_topic_score_codex":1.6236343e-7,"about_ca_topic_score_gemma":1.2839062e-7,"teacher_disagreement_score":0.21401359,"about_ca_system_score_codex":0.000073692216,"about_ca_system_score_gemma":0.000045131917,"threshold_uncertainty_score":0.15405491},"labels":[],"label_agreement":null},{"id":"W4251911811","doi":"10.1111/1753-0407.12109","title":"Journal of Diabetes <scp>NEWS</scp>","year":2013,"lang":"fr","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.010428931719747857,"score_gpt":0.23292396000838875,"score_spread":0.2224950282886409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251911811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86850476,0.11385368,0.000023767276,0.0045198975,0.0070690913,0.00041330693,0.000011354857,0.000014026185,0.0055901273],"genre_scores_gemma":[0.96300906,0.0047516422,0.0034510905,0.0018203777,0.007122542,0.000013148258,0.000007015815,0.000120845594,0.019704292],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947161,0.0002832304,0.0022039476,0.00023910137,0.00121436,0.0013432362],"domain_scores_gemma":[0.9930264,0.0012613232,0.00278964,0.0004140593,0.0015432572,0.0009653507],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015327174,0.00057328533,0.0017475325,0.00088730955,0.00010530941,0.0002645712,0.00064216944,0.00028930468,0.0010799859],"category_scores_gemma":[0.001646654,0.00043892744,0.0010901622,0.00052373623,0.00032192795,0.0015061179,0.00016089287,0.0008980638,0.0004903238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005598562,0.0016583035,0.55613256,0.00080959324,0.004586276,0.00010111824,0.000574825,0.000053739037,0.008980579,0.0002998687,0.31174317,0.11505436],"study_design_scores_gemma":[0.014305081,0.015867194,0.4073773,0.0109715415,0.011058438,0.000066405046,0.004811601,0.0005424738,0.055147015,0.0065704607,0.4727604,0.0005220826],"about_ca_topic_score_codex":0.000011342191,"about_ca_topic_score_gemma":0.0000024150277,"teacher_disagreement_score":0.16101724,"about_ca_system_score_codex":0.00037066775,"about_ca_system_score_gemma":0.00032190664,"threshold_uncertainty_score":0.99983317},"labels":[],"label_agreement":null},{"id":"W4253312709","doi":"10.26226/morressier.59d51840d462b80296ca2dbe","title":"Clinico-economic outcomes of liraglutide in patients with type 2 diabetes at high risk of cardiovascular event in Canada","year":2017,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liraglutide; Type 2 diabetes; Medicine; Event (particle physics); Diabetes mellitus; Internal medicine; Cardiovascular event; Endocrinology; Disease","score_opus":0.00907522216637734,"score_gpt":0.22373667602479533,"score_spread":0.21466145385841798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253312709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963432,0.0006214049,7.3516645e-7,0.00004588923,0.0004528381,0.0011289718,0.00009089754,0.000006810192,0.0013092305],"genre_scores_gemma":[0.99839705,0.0004768752,0.00021016126,0.00002704105,0.000013502111,0.000042646774,0.00020307818,0.00002644252,0.00060320465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982724,0.000059824808,0.00065957475,0.00041082432,0.0003297284,0.00026762608],"domain_scores_gemma":[0.9980295,0.00007398329,0.0005147409,0.0012412714,0.000068634516,0.00007188932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031814995,0.00028097912,0.0015684895,0.00018797175,0.000013787505,0.0000048196307,0.00021462898,0.00010006802,0.000093484996],"category_scores_gemma":[0.00006517373,0.00020473526,0.000259741,0.0000351122,0.00004783699,0.000030069968,0.0004956607,0.00019304882,0.000006713007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107473825,0.00021754202,0.9847683,0.0003192052,0.0042098067,0.000007586714,0.00002048232,0.0042780954,1.0248667e-7,0.000008174622,0.00025032889,0.0058129206],"study_design_scores_gemma":[0.0044392115,0.00023112987,0.9928189,0.00036308554,0.0011972387,1.23459944e-8,0.000015451093,0.0001062823,0.00013798603,0.000042379674,0.00047286454,0.00017545203],"about_ca_topic_score_codex":0.86589783,"about_ca_topic_score_gemma":0.8043609,"teacher_disagreement_score":0.061536927,"about_ca_system_score_codex":0.0013018214,"about_ca_system_score_gemma":0.00069379015,"threshold_uncertainty_score":0.83488613},"labels":[],"label_agreement":null},{"id":"W4253320120","doi":"10.1056/nejmc1917241","title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","year":2020,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cumming School of Medicine, University of Calgary; Taipei Veterans General Hospital; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; Uppsala Universitet; Universidad de Córdoba; National Yang-Ming University; Institut de Cardiologie de Montréal; Universität des Saarlandes; Semmelweis Egyetem; University of Toronto; National Cerebral and Cardiovascular Center; Uniwersytet Łódzki; Universidad Nacional de Córdoba; Univerzita Komenského v Bratislave; Rijksuniversiteit Groningen; Univerzita Karlova v Praze; Fudan University; University of Missouri; University of Minnesota; Sahlgrenska Akademin; AstraZeneca","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Hazard ratio; Medicine; Placebo; Internal medicine; Confidence interval; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.00970690984256987,"score_gpt":0.22908595888501312,"score_spread":0.21937904904244326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253320120","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.152018,0.00034688014,0.000035954443,0.84626794,0.000485835,0.00039942312,0.0000016402879,0.000014041447,0.00043025785],"genre_scores_gemma":[0.39142787,0.00041855453,0.0019818828,0.5682687,0.035413485,0.000008188317,0.00044408778,0.0001192009,0.0019179832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984981,0.00006947162,0.0004325423,0.00019633252,0.0006198696,0.00018369421],"domain_scores_gemma":[0.99915004,0.000077828976,0.00035306095,0.00012457492,0.00012782608,0.00016664968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018329444,0.00023721532,0.0007689506,0.0004234182,0.000023741788,0.000012541675,0.000048541,0.00016169202,0.00009442682],"category_scores_gemma":[0.00010821005,0.00014283099,0.000047677415,0.0001900493,0.00004985625,0.00011419001,0.0000145999875,0.0012417722,0.0000035657088],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009104838,0.00005940463,0.07823362,0.00015698244,0.00024776443,0.0004674817,0.00009524201,9.5338925e-7,0.00005017113,7.7867537e-7,0.90903664,0.01074047],"study_design_scores_gemma":[0.058648117,0.0062898975,0.05911842,0.0015905474,0.0008931701,0.00008216045,0.000054960332,0.0000037746372,0.000019791383,0.00005310193,0.8731229,0.00012316207],"about_ca_topic_score_codex":0.00003895273,"about_ca_topic_score_gemma":0.000009733476,"teacher_disagreement_score":0.27799922,"about_ca_system_score_codex":0.00012545956,"about_ca_system_score_gemma":0.00007988223,"threshold_uncertainty_score":0.5824479},"labels":[],"label_agreement":null},{"id":"W4253704988","doi":"10.1111/1753-0407.12171","title":"Journal of Diabetes NEWS","year":2014,"lang":"fr","type":"article","venue":"Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Las vegas; Citation; Medicine; Diabetes mellitus; Health care; Quarter (Canadian coin); Family medicine; Memphis; Library science; Political science; History; Computer science; Pathology","score_opus":0.010585851135490267,"score_gpt":0.24323773026064896,"score_spread":0.2326518791251587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253704988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89876187,0.07702463,0.00011950158,0.00836048,0.009588064,0.00020787933,0.000007466782,0.00001056335,0.005919547],"genre_scores_gemma":[0.9769873,0.002487728,0.0035250166,0.0017512611,0.008838245,0.0000026115597,0.000003929052,0.00007928519,0.0063246395],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956641,0.00034958532,0.0018825013,0.00018560777,0.00097438355,0.00094378955],"domain_scores_gemma":[0.99486405,0.0007432357,0.0024620427,0.00036277063,0.000884845,0.0006830408],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024565875,0.00043539685,0.001582434,0.0006965975,0.000080977086,0.00012674853,0.0005025842,0.0002126295,0.0006551924],"category_scores_gemma":[0.0011887803,0.00033303446,0.0009466019,0.0003789944,0.00024994282,0.0007299469,0.00010838052,0.0006837142,0.00011618339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041396408,0.0014308008,0.5716164,0.0008576098,0.0034704048,0.00006172158,0.00032111522,0.00010154894,0.0048004934,0.001112818,0.096237205,0.31994846],"study_design_scores_gemma":[0.013526232,0.017889984,0.13814563,0.009589866,0.010173352,0.000038357026,0.0008835179,0.00079956884,0.026537037,0.0050306628,0.77663547,0.00075032545],"about_ca_topic_score_codex":0.0000033984093,"about_ca_topic_score_gemma":0.0000031269612,"teacher_disagreement_score":0.6803983,"about_ca_system_score_codex":0.0002739012,"about_ca_system_score_gemma":0.00022540029,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W4253926197","doi":"10.7326/0003-4819-157-1-201207030-00017","title":"Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus","year":2012,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Guideline; Type 2 diabetes; Internal medicine; Family medicine; Miami; Type 2 Diabetes Mellitus; Endocrinology; Pathology","score_opus":0.08569665577630856,"score_gpt":0.36730275428933595,"score_spread":0.2816060985130274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253926197","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17002301,0.08658406,0.0000065841086,0.7079814,0.0038411838,0.0016383053,0.00007780202,0.00009665154,0.02975099],"genre_scores_gemma":[0.2923066,0.022748161,0.00024238785,0.64418817,0.009194998,0.00009930558,0.0009249377,0.00013394518,0.030161526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769235,0.000078894074,0.00076894416,0.00031966084,0.00057541433,0.0005647233],"domain_scores_gemma":[0.9982359,0.00020431078,0.00057537935,0.00044724147,0.0003787963,0.00015841665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022807744,0.00048029685,0.0016573186,0.00042651728,0.000015465403,0.0000033880212,0.0002126314,0.00030153577,0.002546656],"category_scores_gemma":[0.00007756728,0.00029513575,0.0003430994,0.00019406262,0.00031918366,0.000056379773,0.000059139842,0.00032088635,0.00007987712],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028557354,0.00070653,0.0070614247,0.00087644527,0.00381972,0.0002826256,0.00018168108,2.5245473e-7,0.0009623111,0.00002022877,0.9376203,0.048182953],"study_design_scores_gemma":[0.00260827,0.0124786515,0.0014117395,0.001412444,0.0026149473,0.0000069703565,0.000025233725,0.000009898306,0.022923551,0.00009236733,0.95621884,0.00019707774],"about_ca_topic_score_codex":0.00017983462,"about_ca_topic_score_gemma":0.0000013467526,"teacher_disagreement_score":0.12228358,"about_ca_system_score_codex":0.000069902,"about_ca_system_score_gemma":0.000044125172,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W4254352082","doi":"10.2165/00128413-200816570-00002","title":"The 2008 clinical type 2 diabetes guidelines from the Canadian Diabetes Association (CDA) include the new class of DPP-IV* inhibitors.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Drug class; Diabetes mellitus; Internal medicine; Pharmacology; Endocrinology; Drug","score_opus":0.05587108759421896,"score_gpt":0.3279714595386067,"score_spread":0.27210037194438774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254352082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8655581,0.0052868957,9.429637e-7,0.12340935,0.0017389258,0.0007529889,0.00004147935,0.00005901748,0.0031522808],"genre_scores_gemma":[0.9754122,0.0018653373,0.00013337111,0.011096316,0.0024113704,0.000040453753,0.000103253806,0.000040771563,0.008896937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974491,0.00024923915,0.00079429534,0.00028676505,0.0006481974,0.00057242904],"domain_scores_gemma":[0.99680096,0.0015389569,0.0003745032,0.0006117979,0.00040769752,0.00026609335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012919802,0.00024510908,0.00041424014,0.00006061572,0.00067313237,0.0000675448,0.00045566104,0.00015893644,0.0001312183],"category_scores_gemma":[0.0016039846,0.00012207066,0.00024071748,0.000377514,0.00025831864,0.00010782481,0.00015498292,0.00037862998,0.00018610507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017506129,0.00005221519,0.4152302,0.0000040832247,0.00048218673,0.000004319903,0.0001537321,0.0000040696723,0.00014641983,0.000038057104,0.57424486,0.009622326],"study_design_scores_gemma":[0.0013515179,0.00020843689,0.31744012,0.00006372382,0.0004772244,3.63719e-7,0.00009887531,0.00039447457,0.0016066178,0.00031057437,0.6779058,0.00014225628],"about_ca_topic_score_codex":0.013283481,"about_ca_topic_score_gemma":0.024468856,"teacher_disagreement_score":0.11231304,"about_ca_system_score_codex":0.0002770172,"about_ca_system_score_gemma":0.0006495944,"threshold_uncertainty_score":0.993332},"labels":[],"label_agreement":null},{"id":"W4254901101","doi":"10.3821/1913-701x-142.sp1.s19","title":"Pharmacologic Management of Type 2 Diabetes","year":2009,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Type 2 diabetes; Diabetes mellitus; Medicine; Computer science; Endocrinology","score_opus":0.028922086526539093,"score_gpt":0.28008067075376697,"score_spread":0.25115858422722787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254901101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8292167,0.102032706,0.000026339625,0.002017374,0.0240613,0.0017420846,0.0005567349,0.000065089574,0.04028167],"genre_scores_gemma":[0.88869554,0.08495523,0.0005314305,0.0054286704,0.0018408828,0.000013931078,0.000076452,0.00006960494,0.018388236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947812,0.00023372917,0.0011224756,0.00062312814,0.000765329,0.0024741143],"domain_scores_gemma":[0.9945329,0.0000896616,0.0005009214,0.00043049466,0.00072153704,0.0037245173],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008783033,0.00076759234,0.00096002273,0.0006681066,0.00057829596,0.00015283051,0.0008163878,0.0001358223,0.0055823787],"category_scores_gemma":[0.00005454196,0.0008200993,0.0003577893,0.0014384013,0.00036931006,0.0004581344,0.00007697063,0.0008071363,0.00011052362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019723194,0.00051673065,0.0020642036,0.0017915025,0.003011264,0.15351066,0.00036437542,0.0009646536,0.0019495675,0.0008062049,0.15661448,0.6782091],"study_design_scores_gemma":[0.016004605,0.0019168768,0.0008490226,0.0012946993,0.011583626,0.09962724,0.00009162943,0.0077638505,0.014892379,0.00076941604,0.84279567,0.002410973],"about_ca_topic_score_codex":0.003848251,"about_ca_topic_score_gemma":0.003608851,"teacher_disagreement_score":0.6861812,"about_ca_system_score_codex":0.0053761997,"about_ca_system_score_gemma":0.0028474578,"threshold_uncertainty_score":0.999425},"labels":[],"label_agreement":null},{"id":"W4255338662","doi":"10.14740/jem604","title":"Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice","year":2019,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma","keywords":"Sitagliptin; Medicine; Type 2 diabetes; Glycemic; Internal medicine; Blood pressure; Renal function; Diabetes mellitus; Dipeptidyl peptidase-4; Gastroenterology; Body mass index; Dipeptidyl peptidase-4 inhibitor; Endocrinology; Urology; Pharmacology","score_opus":0.04423308407548011,"score_gpt":0.36871825773709205,"score_spread":0.32448517366161195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255338662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98136604,0.009090826,0.0000055931664,0.0025442,0.002741347,0.0003035456,0.0000011914186,0.000006767284,0.0039405013],"genre_scores_gemma":[0.9868861,0.0032782347,0.0067847483,0.0011980752,0.00054386054,0.0000073087867,0.000004012127,0.000014744733,0.0012829128],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895334,0.00007769021,0.0004715261,0.00013462576,0.000102833976,0.00025997686],"domain_scores_gemma":[0.9986666,0.0006937518,0.00025516117,0.00012254622,0.0001774276,0.00008452834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052372896,0.00010171067,0.0005154859,0.00017868828,0.00001616973,0.000008688258,0.00006110242,0.00007042279,0.000044799504],"category_scores_gemma":[0.0010584325,0.00007615572,0.00011806767,0.00008642888,0.000045992958,0.0001760414,0.00003808901,0.00024232619,0.000022172204],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020384718,0.0032179155,0.53176457,0.00033931015,0.005759953,0.0006776744,0.00039037105,0.000017245684,0.0031718283,0.059301592,0.020450799,0.35452402],"study_design_scores_gemma":[0.017726291,0.0022720655,0.1883494,0.000042043495,0.0011102888,0.000043481075,0.00024243239,0.000025915702,0.00041613966,0.00032018192,0.78935826,0.00009351585],"about_ca_topic_score_codex":0.0000018144483,"about_ca_topic_score_gemma":0.0000018440894,"teacher_disagreement_score":0.7689074,"about_ca_system_score_codex":0.000014963922,"about_ca_system_score_gemma":0.000055483775,"threshold_uncertainty_score":0.310554},"labels":[],"label_agreement":null},{"id":"W4255508422","doi":"10.2337/figshare.12652454.v1","title":"Sodium Glucose Co-transporter-2 Inhibitors and the Risk of Below-knee Amputation: a Multicenter Observational Study","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hazard ratio; Medicine; Internal medicine; Amputation; Dipeptidyl peptidase-4; Observational study; Diabetes mellitus; Confidence interval; Proportional hazards model; Cohort study; Lower risk; Type 2 diabetes; Pharmacology; Endocrinology; Surgery","score_opus":0.04169467717783543,"score_gpt":0.2939587047032263,"score_spread":0.2522640275253909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255508422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945606,0.00026775573,0.00042807157,0.0035152498,0.00025993888,0.003916213,0.00005535325,0.00007066556,0.0020306755],"genre_scores_gemma":[0.99638444,0.00015169752,0.0012761137,0.0006017088,0.00015785686,0.00024386305,0.00041388263,0.000023082335,0.00074737705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984139,0.00008855492,0.0005175283,0.00040864412,0.00043156065,0.00013981022],"domain_scores_gemma":[0.99904066,0.00014943049,0.00027366195,0.00032920044,0.000121014906,0.00008604118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032571913,0.0002641361,0.0005574437,0.000076625714,0.00005588223,0.00003426445,0.00009426627,0.00008095605,0.000113334536],"category_scores_gemma":[0.000047138237,0.00016056282,0.0001912889,0.00008363534,0.0001368968,0.000045045712,0.00019049156,0.00027527122,0.000012719436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012755792,0.0016454301,0.97942036,0.000612857,0.0037585692,0.000037364356,0.0057001403,0.00007471917,0.000026526954,0.0005264605,0.0018646414,0.005057375],"study_design_scores_gemma":[0.018605012,0.00060213736,0.9695328,0.00017633013,0.004118457,4.0075753e-7,0.0019373903,0.0022725372,0.00036265163,0.0008089111,0.0013697997,0.00021360948],"about_ca_topic_score_codex":0.00025694058,"about_ca_topic_score_gemma":0.00006617811,"teacher_disagreement_score":0.017329434,"about_ca_system_score_codex":0.000035071695,"about_ca_system_score_gemma":0.00006143284,"threshold_uncertainty_score":0.6547562},"labels":[],"label_agreement":null},{"id":"W4255512187","doi":"10.14740/jem564","title":"Dapagliflozin Add-On Therapy Improves Body Composition and Metabolic Parameters in Overweight Type 2 Diabetic Patients: A Pilot Study","year":2019,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Overweight; Internal medicine; Body mass index; Endocrinology; Metformin; Diabetes mellitus; Type 2 diabetes; Weight loss; Type 2 Diabetes Mellitus; Body water; Obesity; Body weight","score_opus":0.015119072170726814,"score_gpt":0.2606104893906222,"score_spread":0.2454914172198954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255512187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904125,0.0076448265,6.8996735e-7,0.00022018804,0.0005641135,0.00070762786,0.0000019167592,0.000008444856,0.00043971802],"genre_scores_gemma":[0.9956256,0.0033581743,0.00014758392,0.0006126503,0.00006145234,0.000011271475,0.000004823958,0.000012166826,0.00016623538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889636,0.00012562588,0.00035285787,0.00019539741,0.00017095826,0.00025882263],"domain_scores_gemma":[0.99939317,0.00008582829,0.00019324906,0.00015273727,0.00008368573,0.00009135325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014537439,0.00018076447,0.0006202789,0.00039419855,0.00003041073,0.00001857633,0.000060383827,0.00003134754,0.000025160365],"category_scores_gemma":[0.000027535465,0.0001245491,0.00004735704,0.00012712122,0.000054399836,0.00015131036,0.000039091552,0.00022867156,0.000007937248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006767886,0.013090097,0.86242265,0.00007089874,0.002710489,0.00021737021,0.00091304316,0.000007884557,0.027715102,0.00523275,0.0004689904,0.08038283],"study_design_scores_gemma":[0.015514774,0.011002749,0.9624237,0.00004206178,0.00046232637,0.000019682277,0.00014197092,0.000007145031,0.0026926536,0.00016082337,0.0074157533,0.000116383766],"about_ca_topic_score_codex":0.000015330126,"about_ca_topic_score_gemma":0.0000023685207,"teacher_disagreement_score":0.10000102,"about_ca_system_score_codex":0.00001598098,"about_ca_system_score_gemma":0.00001859689,"threshold_uncertainty_score":0.5078965},"labels":[],"label_agreement":null},{"id":"W4255752214","doi":"10.1016/j.jcjd.2013.12.005","title":"Letter to the Editor","year":2014,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myocardial infarction; Diabetes mellitus; Internal medicine; Type 2 diabetes; Cardiology; Cohort; Disease; Scopus; Coronary heart disease; Risk factor; MEDLINE; Endocrinology","score_opus":0.010344737356757347,"score_gpt":0.20884963183062388,"score_spread":0.19850489447386654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255752214","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023427848,0.00070386037,0.000005792419,0.9842188,0.008706736,0.00034680948,0.000021783539,0.000007562821,0.0036459013],"genre_scores_gemma":[0.0041003698,0.0000025031766,0.00011443705,0.85691005,0.13144769,0.000013896312,0.000041802155,0.00005305188,0.0073162117],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837554,0.00006563669,0.00037063012,0.00017165924,0.0003720043,0.00064450625],"domain_scores_gemma":[0.99842703,0.00012273033,0.00022741985,0.0004298837,0.00021287338,0.00058007665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003341188,0.0002725421,0.0005550785,0.00053511356,0.00009587695,0.000110847854,0.00041076506,0.00028743412,0.0002962611],"category_scores_gemma":[0.00015375363,0.00016732168,0.00031657235,0.00015026086,0.000074886695,0.000053659183,0.000018243696,0.0011254604,0.0003210763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[7.4730764e-7,0.0000047669264,0.003969643,0.0000810677,0.00043081294,0.0001898331,0.00005518381,0.0000017278119,0.0000027817186,0.0000040775467,0.9930884,0.002170952],"study_design_scores_gemma":[0.0003533896,0.00041372897,0.0014549085,0.0003863338,0.00063159096,0.000003975511,0.000005658963,0.0000017652454,0.0000308253,0.000027891332,0.9965251,0.00016480987],"about_ca_topic_score_codex":0.00013934221,"about_ca_topic_score_gemma":0.0007781718,"teacher_disagreement_score":0.12730873,"about_ca_system_score_codex":0.00024742365,"about_ca_system_score_gemma":0.0005044861,"threshold_uncertainty_score":0.682318},"labels":[],"label_agreement":null},{"id":"W4255863743","doi":"10.14740/jem426w","title":"Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure","year":2017,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Sodium; Cotransporter; Internal medicine; Cardiology; Pharmacology; Endocrinology","score_opus":0.016040725887744252,"score_gpt":0.27869793194568426,"score_spread":0.26265720605794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255863743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780673,0.004667823,0.000088782785,0.014862056,0.0010831174,0.00028604324,0.0000056680947,0.000010402049,0.0009288398],"genre_scores_gemma":[0.9928481,0.00074184797,0.0037109454,0.000696054,0.00067930395,0.000010439763,0.0000032524692,0.000011887066,0.0012982003],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926615,0.000012673905,0.00026607755,0.0001120366,0.00009620586,0.00024684437],"domain_scores_gemma":[0.99929726,0.000028272065,0.00024076815,0.00020145926,0.00011289487,0.000119323195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012418986,0.00011704787,0.00044405813,0.0001265619,0.00016212356,0.000028503799,0.00008987045,0.0000568723,0.000033162083],"category_scores_gemma":[0.0000603768,0.00008260055,0.00018239039,0.000014011996,0.00012803318,0.00018338067,0.000027197739,0.00014544402,0.0000041357375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038421783,0.0021772548,0.3471589,0.00069440337,0.0066367034,0.0014908155,0.0010847708,0.0000025498193,0.07847313,0.0547407,0.24729493,0.25640363],"study_design_scores_gemma":[0.0058534043,0.00031744904,0.19164076,0.000040722953,0.00088962005,0.0002214949,0.00005777868,0.0000012673376,0.019651437,0.0008111068,0.7804404,0.00007452947],"about_ca_topic_score_codex":0.0000041935923,"about_ca_topic_score_gemma":0.000005501771,"teacher_disagreement_score":0.5331455,"about_ca_system_score_codex":0.000007748265,"about_ca_system_score_gemma":0.000032177224,"threshold_uncertainty_score":0.33683527},"labels":[],"label_agreement":null},{"id":"W4280488682","doi":"10.1111/dom.14775","title":"Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Semaglutide; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.01808116998617759,"score_gpt":0.24334209779018834,"score_spread":0.22526092780401075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546975,0.0027703538,2.00507e-7,0.00004001822,0.00017369677,0.0010173139,0.000062042796,0.00005473846,0.0004119025],"genre_scores_gemma":[0.9986073,0.00010542565,0.00029618887,0.00008998382,0.00003241515,0.00008844758,0.0004971544,0.000031208132,0.00025190893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826205,0.00016244652,0.00032946756,0.0004536784,0.00035442066,0.00043794222],"domain_scores_gemma":[0.99907166,0.00013448621,0.00016720736,0.00034901928,0.000074097115,0.0002035335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021458465,0.00031338964,0.000893153,0.00032728844,0.00014569928,0.000022883485,0.00009091855,0.000057213132,0.00014807138],"category_scores_gemma":[0.000048043727,0.00025524967,0.000062520776,0.00045287245,0.00010903905,0.00012385407,0.00014406709,0.00014036059,0.0000048640627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010298566,0.00337158,0.9645594,0.00009781976,0.00058649376,0.0000044100034,0.00072308234,0.00003149604,0.0001362741,0.000046976813,0.00010566175,0.029306952],"study_design_scores_gemma":[0.018775871,0.0039229654,0.9680959,0.000051089963,0.0011925105,7.445768e-8,0.00016303356,0.0003009067,0.0012971386,0.000011384785,0.0059469314,0.0002422013],"about_ca_topic_score_codex":0.000080538295,"about_ca_topic_score_gemma":0.000077260025,"teacher_disagreement_score":0.02906475,"about_ca_system_score_codex":0.00009861144,"about_ca_system_score_gemma":0.000044812183,"threshold_uncertainty_score":0.99999},"labels":[],"label_agreement":null},{"id":"W4280518629","doi":"10.2337/figshare.19723642","title":"Vertical Sleeve Gastrectomy Lowers SGLT2/Slc5a2 Expression in the Mouse Kidney","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Cotransporter; Kidney; Endocrinology; Internal medicine; Glucose homeostasis; Type 2 diabetes; Homeostasis; Chemistry; Medicine; Diabetes mellitus; Biology; Sodium; Insulin resistance","score_opus":0.01831931537910099,"score_gpt":0.277155297633357,"score_spread":0.258835982254256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280518629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6972613,0.00024169413,0.00022765611,0.015476828,0.00093862513,0.0035202722,0.00003692335,0.0003082427,0.28198847],"genre_scores_gemma":[0.95413566,0.00024677019,0.002174806,0.010036147,0.00022733776,0.0012588582,0.0012414256,0.00007578294,0.030603206],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807715,0.00012901159,0.00029912114,0.0005392545,0.00057432824,0.0003811204],"domain_scores_gemma":[0.99878025,0.0000757212,0.00003941818,0.00089850684,0.000020871994,0.00018521669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003280089,0.0003039417,0.00039605593,0.00019260294,0.00005809241,0.000050643197,0.0003407461,0.00012377606,0.005975619],"category_scores_gemma":[0.00010458777,0.00018707605,0.00020735647,0.00014154053,0.000047649264,0.000037520025,0.0010103169,0.0007096248,0.00009425757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008421447,0.0046320353,0.084100366,0.00093643775,0.0008044259,0.0011634987,0.00302386,0.00026151628,0.002338212,0.0018311788,0.89144117,0.008625154],"study_design_scores_gemma":[0.021303046,0.0026240505,0.06609752,0.0019535627,0.002958276,0.000026044787,0.013409706,0.0024182,0.024463907,0.0025289382,0.8599638,0.002252979],"about_ca_topic_score_codex":0.000091252856,"about_ca_topic_score_gemma":0.000011127279,"teacher_disagreement_score":0.25687438,"about_ca_system_score_codex":0.00020821123,"about_ca_system_score_gemma":0.000117501375,"threshold_uncertainty_score":0.99493307},"labels":[],"label_agreement":null},{"id":"W4280518784","doi":"10.2174/1573403x18666220511114443","title":"Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomesof Heart and Kidney Disease","year":2022,"lang":"en","type":"review","venue":"Current Cardiology Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Disease; Intensive care medicine; Clinical trial; Canagliflozin; Kidney disease; Internal medicine; Diabetology; Semaglutide; Liraglutide; Endocrinology","score_opus":0.13887835712257068,"score_gpt":0.3760041638747533,"score_spread":0.23712580675218264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280518784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001407559,0.9858167,0.000018868588,0.0004164337,0.0018313809,0.010436452,0.0010093867,0.000070215436,0.00038648164],"genre_scores_gemma":[0.0000011094476,0.98368293,0.00028732477,0.0015277202,0.00053678866,0.0074721957,0.0053683515,0.00010485213,0.00101874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964282,0.00038046483,0.0011713296,0.0010885289,0.00026181358,0.00066969206],"domain_scores_gemma":[0.997133,0.0005486881,0.0005222375,0.0011065655,0.0000394006,0.00065007934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010262548,0.00092898787,0.006559392,0.00032163263,0.00016468536,0.000036729074,0.000253057,0.00015984016,0.00012265901],"category_scores_gemma":[0.00094590057,0.00064375094,0.0025381965,0.00017536024,0.00011980305,0.000048845006,0.0003012863,0.00046834658,0.00014435055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011074414,0.0001598827,0.00089325063,0.07500191,0.00089219003,0.0000026234961,0.000013044153,2.9688618e-7,5.4227947e-8,0.00012425154,0.080106035,0.8427954],"study_design_scores_gemma":[0.0011309463,0.00030708045,0.00020756018,0.021003617,0.014393208,0.0000063543634,0.0000026414873,0.0000062872346,4.5612204e-8,0.000017847897,0.96244526,0.00047917545],"about_ca_topic_score_codex":5.69987e-7,"about_ca_topic_score_gemma":9.853239e-8,"teacher_disagreement_score":0.8823392,"about_ca_system_score_codex":0.000252343,"about_ca_system_score_gemma":0.00016316256,"threshold_uncertainty_score":0.99960136},"labels":[],"label_agreement":null},{"id":"W4280523671","doi":"10.1111/dom.14760","title":"Efficacy and safety outcomes of dulaglutide by baseline <scp>HbA1c</scp> : A post hoc analysis of the <scp>REWIND</scp> trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Post-hoc analysis; Baseline (sea); Subgroup analysis; Body mass index; Internal medicine; Proportional hazards model; Placebo; Diabetes mellitus; Type 2 diabetes; Liraglutide; Confidence interval; Endocrinology","score_opus":0.00729499682094312,"score_gpt":0.2230150266327257,"score_spread":0.2157200298117826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280523671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890148,0.007872544,0.0000099183935,0.0003373085,0.0002898389,0.0012212783,0.00070282735,0.000040072326,0.0005113894],"genre_scores_gemma":[0.995038,0.0006532392,0.00014550464,0.0008642568,0.00006294632,0.000069142174,0.0003576937,0.0000272545,0.0027820098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742943,0.00034089474,0.0006370576,0.00048225533,0.0006362542,0.00047410539],"domain_scores_gemma":[0.9975347,0.0011336786,0.00039905266,0.00061299105,0.000117259886,0.00020234556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001135485,0.0003437235,0.0014746742,0.0004418411,0.00029230842,0.000027193397,0.00024494575,0.00008839355,0.0000490116],"category_scores_gemma":[0.0009215679,0.00024710654,0.00050015684,0.0010916388,0.0002251734,0.00010881761,0.00052135356,0.00024210622,0.0000016400822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074602006,0.0056139096,0.9341063,0.00042135565,0.019807108,0.000010792755,0.0031247775,0.000114770235,0.00846273,0.0020099792,0.0073616677,0.018220603],"study_design_scores_gemma":[0.026816314,0.0005451488,0.8931045,0.000024670542,0.01460393,3.9774628e-7,0.0005261532,0.0002541885,0.0030371784,0.00006601499,0.060958337,0.00006314685],"about_ca_topic_score_codex":0.00009096497,"about_ca_topic_score_gemma":0.000016586511,"teacher_disagreement_score":0.053596668,"about_ca_system_score_codex":0.000033024407,"about_ca_system_score_gemma":0.000056159282,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W4280526617","doi":"10.26685/urncst.335","title":"The Effect of GLP-1 and GIP on the Microvascular Blood Flow after Consuming a Mixed Nutrient Meal: A Research Protocol","year":2022,"lang":"en","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Internal medicine; Endocrinology; Incretin; Insulin; Blood flow; Medicine; Gastric inhibitory polypeptide; Glucagon-like peptide-1; Diabetes mellitus; Glucagon; Type 2 diabetes","score_opus":0.04513495377035022,"score_gpt":0.41514973973565594,"score_spread":0.37001478596530574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280526617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9157945,0.0017908333,5.511668e-7,0.07153371,0.0000738504,0.010637022,0.0000010324138,0.000011668387,0.00015683706],"genre_scores_gemma":[0.99300903,0.0016746329,0.000061188104,0.000074907766,0.000035978464,0.004929026,3.5834458e-7,0.0000072791468,0.00020761733],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9955191,0.0011340322,0.00044814905,0.00045579713,0.0016398818,0.00080301],"domain_scores_gemma":[0.9963232,0.0027016324,0.0000950632,0.00032567442,0.0003569469,0.00019745255],"candidate_categories":["sts","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.025766896,0.00013970927,0.00032594844,0.00075112353,0.0019609127,0.00017074167,0.00045270126,0.00009065104,0.000009953602],"category_scores_gemma":[0.0025097951,0.00006316609,0.00007485621,0.0021740634,0.0056631956,0.00008617905,0.0011516018,0.0030357945,0.0000021804412],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00636251,0.0018510972,0.25857893,0.0003883682,0.00092207687,0.0015556175,0.00021451479,0.0000013482103,0.0056091286,0.025377259,0.0043838187,0.6947553],"study_design_scores_gemma":[0.077833146,0.12524854,0.13696443,0.0039713685,0.00085742574,0.004074187,0.009388094,0.008511933,0.04502561,0.3968248,0.1899346,0.001365895],"about_ca_topic_score_codex":0.000022750815,"about_ca_topic_score_gemma":0.000027855533,"teacher_disagreement_score":0.6933894,"about_ca_system_score_codex":0.0001335083,"about_ca_system_score_gemma":0.00023191908,"threshold_uncertainty_score":0.9993384},"labels":[],"label_agreement":null},{"id":"W4280556789","doi":"10.1161/strokeaha.121.037775","title":"Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6","year":2022,"lang":"en","type":"article","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; St. Michael's Hospital","funders":"","keywords":"Medicine; Semaglutide; Type 2 diabetes; Post-hoc analysis; Stroke (engine); Randomized controlled trial; Diabetes mellitus; Internal medicine; Physical therapy; Endocrinology","score_opus":0.0035568676156478426,"score_gpt":0.21677458095741545,"score_spread":0.21321771334176762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280556789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964379,0.0011455552,0.0000012168538,0.00036987357,0.00008589029,0.0008225359,0.000038178674,0.000009147649,0.0010896695],"genre_scores_gemma":[0.99652106,0.00006499496,0.00003420625,0.00018088582,0.0000078828725,0.000058424175,0.000024901074,0.000009056257,0.0030985961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990013,0.00018630804,0.00022134678,0.00015319699,0.00027641834,0.00016140587],"domain_scores_gemma":[0.9991531,0.00042942003,0.00011557866,0.00022495432,0.000045742076,0.000031227868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039407428,0.000105699735,0.00062884745,0.00039717634,0.0000348746,0.0000038602248,0.00007452361,0.000020933674,0.00007708418],"category_scores_gemma":[0.00018877012,0.00006933924,0.00021118914,0.00053924444,0.00007952777,0.000014435853,0.00011366637,0.00009547284,7.126326e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08670573,0.002895657,0.81749415,0.001699189,0.023133425,0.0000729261,0.0028951007,0.002217104,0.03988144,0.00647489,0.0012279437,0.015302419],"study_design_scores_gemma":[0.21002004,0.0043451525,0.73426074,0.00021015051,0.0192166,3.9699626e-7,0.0020436815,0.002987601,0.02452004,0.00014183023,0.0019176794,0.00033610215],"about_ca_topic_score_codex":0.00005598457,"about_ca_topic_score_gemma":0.000030987543,"teacher_disagreement_score":0.12331431,"about_ca_system_score_codex":0.000059255075,"about_ca_system_score_gemma":0.000028274502,"threshold_uncertainty_score":0.28275725},"labels":[],"label_agreement":null},{"id":"W4280574301","doi":"10.1161/jaha.121.024833","title":"Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2022,"lang":"en","type":"review","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; University of Alberta; McGill University Health Centre","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Heart failure; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Intensive care medicine; MEDLINE; Systematic review; Internal medicine; Cardiology; Endocrinology","score_opus":0.05447732190983982,"score_gpt":0.36455373857665424,"score_spread":0.3100764166668144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280574301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062902116,0.9951091,0.000031139192,0.0016265212,0.00013443874,0.002984036,0.000035288682,0.000009226473,0.0000073491265],"genre_scores_gemma":[0.00011395967,0.99753714,0.0004309313,0.0012216918,0.00007029247,0.00027068047,0.000049988466,0.000026417158,0.0002789135],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964628,0.0011677187,0.0015154765,0.0001954784,0.00048544878,0.00017304513],"domain_scores_gemma":[0.9959891,0.0007995708,0.0026847054,0.00026966375,0.00019198308,0.000064965585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038211166,0.00021315205,0.006919023,0.0003367374,0.000060791666,0.000028992392,0.00011029708,0.00007388326,0.000020234893],"category_scores_gemma":[0.0011333567,0.00012620284,0.003059565,0.001382208,0.000021726366,0.00012551146,0.00005277559,0.00029655028,0.0000011585807],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001963743,0.0005357822,0.014138884,0.5553835,0.40129283,0.0000016039498,0.00006534031,0.00010296663,6.3780625e-8,0.000020442738,0.025261808,0.0031771266],"study_design_scores_gemma":[0.00022015527,0.0005951056,0.00032835972,0.01269345,0.87992764,0.0000032607727,0.000023074012,0.00018679572,1.8898737e-8,0.000027220252,0.105895676,0.00009925763],"about_ca_topic_score_codex":0.0000054445636,"about_ca_topic_score_gemma":0.0000047861245,"teacher_disagreement_score":0.54269004,"about_ca_system_score_codex":0.00068374415,"about_ca_system_score_gemma":0.00013711727,"threshold_uncertainty_score":0.5146402},"labels":[],"label_agreement":null},{"id":"W4280585270","doi":"10.1016/j.jacc.2022.03.353","title":"Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction","year":2022,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Janssen Pharmaceuticals; Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Ministry of Colleges and Universities; Servier; St. Jude Medical; Assistance publique-Hôpitaux de Paris; Agency for Healthcare Research and Quality; Vifor Pharma; MyoKardia; Novo Nordisk; Daiichi-Sankyo; Women's College Hospital; Impulse Dynamics; Boston VA Research Institute; Regado Biosciences; Boston Scientific Corporation; University of Toronto; British Heart Foundation; Bristol-Myers Squibb; Cleveland Clinic; American Heart Association; Sanofi; AstraZeneca; Amgen","keywords":"Medicine; Myocardial infarction; Heart failure; Diabetes mellitus; Internal medicine; Cardiology; Type 2 Diabetes Mellitus; Disease; Canagliflozin; Kidney disease; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.025464474903191765,"score_gpt":0.31112578986805506,"score_spread":0.2856613149648633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280585270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025234413,0.9883797,0.0003105255,0.00092871976,0.00281014,0.0026028352,0.0009650484,0.000016334337,0.001463236],"genre_scores_gemma":[0.0012394158,0.99675936,0.0003164751,0.00021966294,0.0008792623,0.000115036135,0.000081288235,0.000043132466,0.00034637935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980319,0.00029755812,0.00091588317,0.00018441034,0.00033657192,0.00023364666],"domain_scores_gemma":[0.99707085,0.00021871779,0.0021407488,0.00034992042,0.00014362627,0.00007610805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050722866,0.00027380156,0.0034555737,0.00035672114,0.0000778377,0.000003574774,0.00021554851,0.0000860474,0.00001911392],"category_scores_gemma":[0.000054119595,0.00017302722,0.0029175943,0.00042424648,0.00024791958,0.00004383319,0.000084228814,0.00036401825,0.000001325071],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020413299,0.00023569317,0.0003395302,0.0043638814,0.039842814,0.0006815641,0.00002944525,0.000035918176,0.00006237214,0.00031980182,0.062391505,0.8896561],"study_design_scores_gemma":[0.0012942846,0.002694511,0.00019302766,0.0007368472,0.023514954,0.0011726143,0.00005920349,7.4036325e-7,0.000010714232,0.00006343518,0.97013474,0.00012490954],"about_ca_topic_score_codex":0.0000023526075,"about_ca_topic_score_gemma":4.8799063e-7,"teacher_disagreement_score":0.9077433,"about_ca_system_score_codex":0.0003460314,"about_ca_system_score_gemma":0.00045002543,"threshold_uncertainty_score":0.7055845},"labels":[],"label_agreement":null},{"id":"W4280609207","doi":"10.1016/j.ahj.2022.05.010","title":"Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial","year":2022,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"British Heart Foundation","keywords":"Empagliflozin; Medicine; Myocardial infarction; Ejection fraction; Heart failure; Placebo; Internal medicine; Hazard ratio; Population; Cardiology; Clinical endpoint; Randomized controlled trial; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Confidence interval","score_opus":0.018375111954122756,"score_gpt":0.26274651027862905,"score_spread":0.2443713983245063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280609207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996183,0.00003510959,0.000015346453,0.0028234005,0.00026391444,0.000562631,0.000006133982,0.000003660968,0.00010680266],"genre_scores_gemma":[0.9981717,0.000017291428,0.00019524066,0.0013842491,0.000091962866,0.000026357053,0.00000577521,0.0000068463446,0.00010060006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990854,0.00020904443,0.00019193396,0.00007730196,0.00032096345,0.00011535434],"domain_scores_gemma":[0.9996395,0.00005588706,0.00011487315,0.000084165185,0.000053787004,0.00005179878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030340647,0.000059497812,0.00017554607,0.000113845905,0.00011607698,0.0000119961305,0.000037426933,0.0000073485244,0.00011318138],"category_scores_gemma":[0.0000837523,0.00004362076,0.00007073759,0.00019824956,0.000069027905,0.000055684093,0.000051417956,0.00015920581,0.0000014035309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016484804,0.0011247775,0.9465797,0.000008411278,0.00033869344,0.000007109821,0.0016927033,0.00079605164,0.00080438633,0.000024460727,0.015029778,0.01710912],"study_design_scores_gemma":[0.018636823,0.0049750796,0.97078675,0.000012502932,0.00009982717,0.000018499239,0.00096193963,0.00005432692,0.0000699062,0.000040094208,0.0042838375,0.00006038759],"about_ca_topic_score_codex":0.000059699716,"about_ca_topic_score_gemma":0.0000020086256,"teacher_disagreement_score":0.02420707,"about_ca_system_score_codex":0.00009964839,"about_ca_system_score_gemma":0.00009817363,"threshold_uncertainty_score":0.17788029},"labels":[],"label_agreement":null},{"id":"W4280612763","doi":"10.1016/j.ekir.2022.05.007","title":"Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial","year":2022,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; Merck; Pfizer","keywords":"Medicine; Albuminuria; Renal function; Hazard ratio; Placebo; Internal medicine; Creatinine; Kidney disease; Diabetes mellitus; Urology; Post-hoc analysis; Proportional hazards model; Confidence interval; Cardiology; Endocrinology; Pathology","score_opus":0.004860688556775885,"score_gpt":0.23464999265442243,"score_spread":0.22978930409764656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280612763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9422695,0.00016295047,0.00005272059,0.05312037,0.00056245754,0.002251976,0.00028147377,0.000051595736,0.001246939],"genre_scores_gemma":[0.97627974,0.000036079244,0.0003037894,0.014918949,0.00011047226,0.001325869,0.0026347658,0.00003663873,0.004353686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718046,0.00016395177,0.0006076621,0.0006216889,0.0011322185,0.00029401225],"domain_scores_gemma":[0.9978529,0.0004041992,0.00032286523,0.0005591654,0.00012006183,0.0007408003],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006121983,0.0003062047,0.0009214746,0.00040084284,0.00014370357,0.00009853397,0.00015517046,0.00003183946,0.0013712159],"category_scores_gemma":[0.0019351162,0.00018160054,0.00030648016,0.00062660116,0.0001167321,0.00013576371,0.00019238536,0.00020413937,0.000004699034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14453025,0.00078717165,0.8220125,0.000021938005,0.0067100334,0.0009188218,0.00055019563,0.00005641612,0.000035415633,0.000046511337,0.024151897,0.00017887542],"study_design_scores_gemma":[0.34114316,0.0007701078,0.6100913,0.00017963363,0.0060510235,0.000040096027,0.00019464009,0.0017814636,0.00001846551,0.00012224622,0.039243322,0.00036452402],"about_ca_topic_score_codex":0.0016859483,"about_ca_topic_score_gemma":0.00016481584,"teacher_disagreement_score":0.21192116,"about_ca_system_score_codex":0.00026309333,"about_ca_system_score_gemma":0.0006689799,"threshold_uncertainty_score":0.99954164},"labels":[],"label_agreement":null},{"id":"W4280622945","doi":"10.2337/figshare.19723642.v1","title":"Vertical Sleeve Gastrectomy Lowers SGLT2/Slc5a2 Expression in the Mouse Kidney","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Cotransporter; Endocrinology; Internal medicine; Kidney; Glucose homeostasis; Type 2 diabetes; Homeostasis; Medicine; Chemistry; Diabetes mellitus; Biology; Sodium; Insulin resistance","score_opus":0.01831931537910099,"score_gpt":0.277155297633357,"score_spread":0.258835982254256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280622945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6972613,0.00024169413,0.00022765611,0.015476828,0.00093862513,0.0035202722,0.00003692335,0.0003082427,0.28198847],"genre_scores_gemma":[0.95413566,0.00024677019,0.002174806,0.010036147,0.00022733776,0.0012588582,0.0012414256,0.00007578294,0.030603206],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807715,0.00012901159,0.00029912114,0.0005392545,0.00057432824,0.0003811204],"domain_scores_gemma":[0.99878025,0.0000757212,0.00003941818,0.00089850684,0.000020871994,0.00018521669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003280089,0.0003039417,0.00039605593,0.00019260294,0.00005809241,0.000050643197,0.0003407461,0.00012377606,0.005975619],"category_scores_gemma":[0.00010458777,0.00018707605,0.00020735647,0.00014154053,0.000047649264,0.000037520025,0.0010103169,0.0007096248,0.00009425757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008421447,0.0046320353,0.084100366,0.00093643775,0.0008044259,0.0011634987,0.00302386,0.00026151628,0.002338212,0.0018311788,0.89144117,0.008625154],"study_design_scores_gemma":[0.021303046,0.0026240505,0.06609752,0.0019535627,0.002958276,0.000026044787,0.013409706,0.0024182,0.024463907,0.0025289382,0.8599638,0.002252979],"about_ca_topic_score_codex":0.000091252856,"about_ca_topic_score_gemma":0.000011127279,"teacher_disagreement_score":0.25687438,"about_ca_system_score_codex":0.00020821123,"about_ca_system_score_gemma":0.000117501375,"threshold_uncertainty_score":0.99493307},"labels":[],"label_agreement":null},{"id":"W4281295175","doi":"10.1111/dom.14769","title":"Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute; Merck; National Institutes of Health; Pfizer","keywords":"Medicine; Internal medicine; Diabetes mellitus; Microalbuminuria; Glycated hemoglobin; Kidney disease; Type 2 Diabetes Mellitus; Renal function; Type 2 diabetes; Endocrinology","score_opus":0.0029302933040736517,"score_gpt":0.18838291019564649,"score_spread":0.18545261689157283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281295175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961871,0.0020195553,3.077279e-7,0.00043347335,0.00030165882,0.00081878423,0.000055245244,0.000054778404,0.00012910915],"genre_scores_gemma":[0.9972854,0.0001019081,0.00030185876,0.0018064986,0.000042908614,0.00009191811,0.00016296098,0.000031538453,0.000174992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984394,0.00010981366,0.00021242637,0.0003809968,0.0004644707,0.0003928922],"domain_scores_gemma":[0.9990253,0.00017281849,0.00011171423,0.00029434057,0.00006993534,0.00032591692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021360356,0.00029012174,0.00075395853,0.00023674298,0.00017921672,0.000023246004,0.00008204696,0.00005834399,0.000069118156],"category_scores_gemma":[0.0001260639,0.00021395828,0.00008329183,0.0002725208,0.00013395243,0.00012392898,0.0001755775,0.00018797688,0.000003843513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041681295,0.0005411954,0.9935137,0.0003150709,0.00054251176,0.0000027794224,0.00014024386,0.0000013893532,0.00015088514,0.00023543516,0.0018024468,0.0027126344],"study_design_scores_gemma":[0.0036311343,0.00087363477,0.9694606,0.000083086255,0.000837399,6.923587e-8,0.000032642543,0.000013655016,0.004254583,0.00007701768,0.020524256,0.00021192657],"about_ca_topic_score_codex":0.000017844188,"about_ca_topic_score_gemma":0.000003141379,"teacher_disagreement_score":0.02405313,"about_ca_system_score_codex":0.00002440805,"about_ca_system_score_gemma":0.000028844423,"threshold_uncertainty_score":0.8724965},"labels":[],"label_agreement":null},{"id":"W4281392406","doi":"10.1186/s12875-022-01731-w","title":"Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study","year":2022,"lang":"en","type":"article","venue":"BMC Primary Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"University of Alberta; Government of Alberta","keywords":"Medicine; Diabetes mellitus; Heart failure; Internal medicine; Blood pressure; Cardiorenal syndrome; Cross-sectional study; Type 2 diabetes; Kidney disease; Endocrinology; Pathology","score_opus":0.015875879973106154,"score_gpt":0.2536180320238267,"score_spread":0.23774215205072055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281392406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933178,0.00048894604,0.0000036354209,0.0000041321896,0.00028210983,0.0038280655,0.0002972257,0.00004114633,0.0017369575],"genre_scores_gemma":[0.9968228,0.000008814271,0.00017300366,0.00009727819,0.000038845337,0.001347386,0.0014121174,0.00003645307,0.00006330398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751776,0.00027691343,0.0004832752,0.000530952,0.00084107555,0.00034999807],"domain_scores_gemma":[0.999138,0.00007414119,0.00017916494,0.00039132702,0.00014882612,0.00006853139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025585046,0.00024193349,0.0005340155,0.00043058212,0.000118529635,0.000019816904,0.00017185631,0.000055638997,0.000035399968],"category_scores_gemma":[0.000042039275,0.0002375637,0.00016160512,0.0005019264,0.000057012818,0.0001217343,0.0005077696,0.00029055588,0.000003884493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055611425,0.0018224242,0.98984164,0.0007578895,0.00022105192,0.000032369357,0.002371374,0.0007148351,0.000017097485,0.00000480242,0.000038374823,0.0036220276],"study_design_scores_gemma":[0.012116755,0.0020647363,0.9835471,0.000056101624,0.00015203429,2.6035516e-7,0.0016920149,0.000005424313,0.00008262098,0.000030651052,0.00006347027,0.00018883967],"about_ca_topic_score_codex":0.0008609898,"about_ca_topic_score_gemma":0.00044878712,"teacher_disagreement_score":0.011560641,"about_ca_system_score_codex":0.0035796107,"about_ca_system_score_gemma":0.0003139794,"threshold_uncertainty_score":0.9687567},"labels":[],"label_agreement":null},{"id":"W4281609271","doi":"10.2337/dci22-0014","title":"Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association","year":2022,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Abbott Diagnostics; National Institute of Diabetes and Digestive and Kidney Diseases; Dexcom; Cleveland Clinic; Novo Nordisk; American Heart Association; Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Prediabetes; Heart failure; Population; Complication; Intensive care medicine; Type 2 diabetes; Incidence (geometry); Disease; Heart disease; Internal medicine; Cardiology; Environmental health; Endocrinology","score_opus":0.030314019471468938,"score_gpt":0.3023059852314534,"score_spread":0.27199196575998447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281609271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19831823,0.795666,1.5931114e-7,0.00042044843,0.00039057527,0.0035052241,0.00089632376,0.00014690218,0.0006561378],"genre_scores_gemma":[0.17324755,0.78636307,0.0012498684,0.0014342421,0.00044520243,0.0041888575,0.031297244,0.0006929325,0.001081062],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959961,0.0005749659,0.0012536776,0.00069871906,0.0008840889,0.00059244153],"domain_scores_gemma":[0.994395,0.0006555663,0.0029536542,0.0014952298,0.0003611148,0.00013940831],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005560935,0.00056405115,0.0030665144,0.0003388152,0.00014385457,0.000029520974,0.00039338303,0.00019224225,0.000093459785],"category_scores_gemma":[0.00043096437,0.00043205768,0.0011130499,0.0013632379,0.00023010802,0.000054422868,0.0002681625,0.00042480952,0.000015539466],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050811677,0.00061372126,0.6028401,0.020970901,0.0034660583,0.0000036464307,0.00017194965,0.0000057115517,0.00008626565,0.00006237012,0.010045977,0.36172816],"study_design_scores_gemma":[0.0005589215,0.000638773,0.021603797,0.0034537101,0.006056212,8.8779683e-7,0.00028223344,0.000019007413,0.00029887757,0.000025675923,0.9666441,0.00041777824],"about_ca_topic_score_codex":0.00001691317,"about_ca_topic_score_gemma":0.000016127387,"teacher_disagreement_score":0.95659816,"about_ca_system_score_codex":0.0009158765,"about_ca_system_score_gemma":0.0003436352,"threshold_uncertainty_score":0.99981314},"labels":[],"label_agreement":null},{"id":"W4281623679","doi":"10.2215/cjn.02980322","title":"Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease","year":2022,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Providence Health Care","funders":"","keywords":"Medicine; Kidney disease; Intensive care medicine; Reimbursement; Disease; Diabetes mellitus; Health care; Internal medicine; Endocrinology","score_opus":0.055339501540826425,"score_gpt":0.4002121525238839,"score_spread":0.3448726509830575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281623679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93996185,0.00044492458,0.0005915226,0.05835989,0.00019039604,0.00038815156,0.00005604584,0.0000038938574,0.000003313578],"genre_scores_gemma":[0.9300439,0.00036105327,0.007391786,0.06195048,0.00017277511,0.000024422643,0.0000052324485,0.000011505982,0.000038850314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984778,0.00022170659,0.0007230027,0.00013933422,0.0002780011,0.00016013841],"domain_scores_gemma":[0.99732393,0.0009795222,0.0011546377,0.00025293182,0.00013323232,0.00015574203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070848275,0.00008972241,0.00057297316,0.000027980032,0.00007148532,0.0000034361399,0.00028660204,0.000014965372,0.000120517856],"category_scores_gemma":[0.0001722878,0.000062833504,0.0007956328,0.00018086984,0.0003899918,0.000048331854,0.0002223101,0.00015039335,4.832954e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031295281,0.0009842765,0.59511274,0.00010552869,0.0034337423,0.0000045394736,0.0022444415,0.00009609504,0.016536674,0.00007187249,0.25589117,0.1223894],"study_design_scores_gemma":[0.0031556229,0.006815449,0.923676,0.000103454884,0.0016273438,0.0000024345945,0.0053995196,0.00010034683,0.0003771194,0.0013727052,0.05727865,0.000091314214],"about_ca_topic_score_codex":0.0000864821,"about_ca_topic_score_gemma":0.0000017713733,"teacher_disagreement_score":0.3285633,"about_ca_system_score_codex":0.00006425506,"about_ca_system_score_gemma":0.00021204805,"threshold_uncertainty_score":0.25622758},"labels":[],"label_agreement":null},{"id":"W4281638337","doi":"10.2337/db22-1433-p","title":"1433-P: Comparative Weight Loss with GLP-1 Receptor Agonists vs. Bariatric Surgery in Obesity: A Systematic Review and Pair-Wise Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Observational study; Weight loss; Randomized controlled trial; MEDLINE; Meta-analysis; Internal medicine; Body mass index; Publication bias; Obesity; Surgery","score_opus":0.07733537474619667,"score_gpt":0.30605849489026093,"score_spread":0.22872312014406426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281638337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001439031,0.992578,0.0000013265343,0.00024552064,0.00006218429,0.006437308,0.00014442125,0.00007951124,0.00030780226],"genre_scores_gemma":[0.0001256834,0.98929185,0.00011957429,0.00052591384,0.00003449125,0.0059589185,0.0019063214,0.0000744305,0.0019628273],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99476945,0.001329762,0.0016032899,0.0010186827,0.0006683235,0.00061046163],"domain_scores_gemma":[0.99571705,0.0017238904,0.0011475773,0.0010827052,0.00008177693,0.0002470121],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017707739,0.0010192338,0.019405263,0.0013740305,0.00011413837,0.000079102574,0.00025493096,0.00014780796,0.0017245001],"category_scores_gemma":[0.00016583745,0.00061203295,0.003119001,0.0034592394,0.000100798105,0.00012768358,0.00021589607,0.00041462987,0.000084787884],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048766515,0.00038904944,0.0021509677,0.7645013,0.22810155,0.00008152812,0.000047525322,1.4822209e-7,7.773336e-9,0.000029099843,0.0028434198,0.0018505644],"study_design_scores_gemma":[0.00021905279,0.00013064085,0.00003380926,0.044848446,0.71091336,0.0000027063215,0.000013091712,0.000002833157,4.017674e-7,0.000002943604,0.24337016,0.000462575],"about_ca_topic_score_codex":0.00002267084,"about_ca_topic_score_gemma":0.00002113449,"teacher_disagreement_score":0.71965283,"about_ca_system_score_codex":0.0003527016,"about_ca_system_score_gemma":0.00019193573,"threshold_uncertainty_score":0.9996331},"labels":[],"label_agreement":null},{"id":"W4281658340","doi":"10.2337/db22-1102-p","title":"1102-P: Identifying Blood Biomarkers for Type 2 Diabetes Subtyping: A Report from the ORIGIN Trial","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Internal medicine; Subtyping; Logistic regression; Diabetes mellitus; Type 2 diabetes; Population; Biomarker; Oncology; Endocrinology; Biology; Genetics","score_opus":0.053709544207090835,"score_gpt":0.30802645467223466,"score_spread":0.2543169104651438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281658340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990427,0.0025835384,0.0000062926024,0.0016254984,0.0019120165,0.002097751,0.00006894433,0.00016439511,0.0011145343],"genre_scores_gemma":[0.992421,0.000029346333,0.00062372413,0.0011676878,0.0006297257,0.0013444537,0.0012579216,0.00006364092,0.0024625268],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980807,0.00008585391,0.00040332534,0.0004895565,0.00041009163,0.0005305129],"domain_scores_gemma":[0.9984512,0.0005467516,0.00020889471,0.0006194592,0.00007370537,0.00010003484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007525797,0.00023678679,0.00041243868,0.00011500592,0.00041689642,0.00008589668,0.00025047455,0.000045695728,0.0004129898],"category_scores_gemma":[0.00037055917,0.00017820217,0.0002777077,0.0004007741,0.000066527195,0.0000924036,0.00022385045,0.00014285477,0.00002113081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045542656,0.001954292,0.793575,0.00024719126,0.009645106,0.00018549802,0.00063083734,0.000011371328,0.022962507,0.0007459916,0.14538899,0.020098975],"study_design_scores_gemma":[0.10615939,0.004788372,0.04887171,0.00026355355,0.009551615,0.000005134516,0.0015136685,0.0008617763,0.035927158,0.0040848367,0.7867889,0.0011838953],"about_ca_topic_score_codex":0.000049604398,"about_ca_topic_score_gemma":0.0000046443656,"teacher_disagreement_score":0.7447033,"about_ca_system_score_codex":0.000093632625,"about_ca_system_score_gemma":0.00008734546,"threshold_uncertainty_score":0.7266874},"labels":[],"label_agreement":null},{"id":"W4281661632","doi":"10.2337/db22-721-p","title":"721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Insulin; Medicine; Placebo; Hypoglycemia; Randomization; Internal medicine; Post-prandial; Endocrinology; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes","score_opus":0.010063248678010589,"score_gpt":0.24735572374909312,"score_spread":0.23729247507108253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281661632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805117,0.0006575764,0.000012544998,0.00005901751,0.00009533462,0.00028836765,0.000014493018,0.00003949191,0.00078201963],"genre_scores_gemma":[0.998746,0.000012370983,0.00045489636,0.0001564681,0.000012200933,0.00007185096,0.00016292767,0.000015178468,0.00036814832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898756,0.000057450205,0.0002401595,0.00019840481,0.00030772822,0.00020868107],"domain_scores_gemma":[0.9993252,0.000091548594,0.00012140013,0.00034356545,0.000047458092,0.00007078419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020456642,0.00011689381,0.0005359703,0.00048258537,0.00004710569,0.0000045838456,0.00010136934,0.00002157975,0.0001777078],"category_scores_gemma":[0.000044282664,0.00010640641,0.00019432226,0.0008631233,0.000039844395,0.000046607158,0.00014095583,0.00006949515,0.0000024115782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030453162,0.0010946661,0.9526468,0.00037452433,0.004452587,0.000010696948,0.00042937676,0.0012131325,0.021768568,0.0005850653,0.00025931612,0.017134836],"study_design_scores_gemma":[0.002032227,0.0015460039,0.8779787,0.000051610896,0.008959907,1.0033553e-7,0.0002464589,0.009451217,0.09764597,0.0000862157,0.0018232366,0.00017840258],"about_ca_topic_score_codex":0.00006662503,"about_ca_topic_score_gemma":0.0000063834823,"teacher_disagreement_score":0.0758774,"about_ca_system_score_codex":0.0000504604,"about_ca_system_score_gemma":0.000015463405,"threshold_uncertainty_score":0.43391275},"labels":[],"label_agreement":null},{"id":"W4281665492","doi":"10.2337/db22-290-or","title":"290-OR: A Randomized Controlled Trial to Alleviate Carbohydrate Counting in Type 1 Diabetes with Automated Fiasp and Pramlintide Closed-Loop Delivery","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Type 1 diabetes; Crossover study; Randomized controlled trial; Diabetes mellitus; Internal medicine; Anesthesia; Endocrinology; Pathology","score_opus":0.009422986540621028,"score_gpt":0.2402916206819416,"score_spread":0.23086863414132058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281665492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885089,0.0014991686,8.2745703e-7,0.00069985265,0.00033584223,0.0077421675,0.000011857403,0.00035413893,0.0008472428],"genre_scores_gemma":[0.99317086,0.00010080725,0.00036216265,0.0015149888,0.00008306696,0.0032623245,0.0001057252,0.000058673773,0.0013413869],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99724275,0.00040181985,0.0006683995,0.00051103276,0.00046074175,0.00071528443],"domain_scores_gemma":[0.9982134,0.00095645455,0.00024537195,0.00030657553,0.000107998065,0.00017019548],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016799256,0.00037406106,0.0020088956,0.00045929692,0.00017176387,0.00007947758,0.00012940221,0.000057478905,0.0001822246],"category_scores_gemma":[0.0005899795,0.00025334218,0.00017471994,0.0006260519,0.00008890663,0.00011744488,0.00023682293,0.00020985145,0.000015046536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9543129,0.0008998794,0.032393,0.00021060693,0.0030118925,0.00013350829,0.0006006803,0.0004901607,0.003077468,0.00010375677,0.0020063538,0.002759786],"study_design_scores_gemma":[0.9664531,0.0027735666,0.0012845887,0.00020198156,0.0013653125,5.1682656e-7,0.00020374029,0.025638035,0.0006476573,0.000033414733,0.0010268189,0.00037128836],"about_ca_topic_score_codex":0.00008345565,"about_ca_topic_score_gemma":0.000038997074,"teacher_disagreement_score":0.031108411,"about_ca_system_score_codex":0.0001363721,"about_ca_system_score_gemma":0.00012664373,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W4281668764","doi":"10.2337/db22-1136-p","title":"1136-P: A Population-Based Assessment of the Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and Peptidomimetic Dipeptidyl Peptidase-4 Inhibitors","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concomitant; Peptidomimetic; Hypoglycemia; Internal medicine; Alogliptin; Retrospective cohort study; Vildagliptin; Sitagliptin; Population; Pharmacology; Type 2 diabetes; Endocrinology; Diabetes mellitus; Insulin; Chemistry","score_opus":0.009139980605944842,"score_gpt":0.2232320043057986,"score_spread":0.21409202369985375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281668764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982781,0.00013462192,0.0000050710723,0.00012573125,0.00005649358,0.00089774793,0.0001772133,0.000018478291,0.00030658257],"genre_scores_gemma":[0.9979831,0.00000884618,0.0014963134,0.00008573478,0.000013620403,0.00009231869,0.000086951026,0.000026530342,0.00020658814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984468,0.00016220094,0.00041625608,0.00023996716,0.00052502577,0.0002097032],"domain_scores_gemma":[0.99843717,0.00042290654,0.00051594066,0.00045422345,0.00010138533,0.00006837804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026623893,0.00019600926,0.0005360727,0.0001553968,0.00009909836,0.000009017401,0.000102484184,0.000034474513,0.000076504075],"category_scores_gemma":[0.00008964929,0.00012844296,0.00015976984,0.0003431857,0.00016251314,0.000069523005,0.00014040743,0.00015352231,2.143316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001233841,0.0004493808,0.9923206,0.0003010134,0.00047107568,0.0000019041381,0.00010698373,0.0014569067,0.0036681327,0.00022989439,0.00020459844,0.00066610216],"study_design_scores_gemma":[0.003922138,0.0013006373,0.9832367,0.00028589056,0.00113571,6.666244e-7,0.0002434308,0.0018734784,0.007596293,0.000056065222,0.00020760615,0.00014139019],"about_ca_topic_score_codex":0.0003350912,"about_ca_topic_score_gemma":0.000024244398,"teacher_disagreement_score":0.00908393,"about_ca_system_score_codex":0.00009882179,"about_ca_system_score_gemma":0.00010974116,"threshold_uncertainty_score":0.5237752},"labels":[],"label_agreement":null},{"id":"W4281671995","doi":"10.1016/j.bbalip.2022.159194","title":"Glucagon-like peptide-2 mobilization of intestinal lipid does not require canonical enterocyte chylomicron synthetic machinery","year":2022,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Lymph; Chylomicron; Internal medicine; Endocrinology; Chemistry; Medicine; Cholesterol; Lipoprotein; Pathology; Very low-density lipoprotein","score_opus":0.00797941305459901,"score_gpt":0.23735762654891782,"score_spread":0.2293782134943188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281671995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968515,0.00027145856,0.000078726116,0.001040411,0.00029767858,0.00050396286,0.0001038924,0.000042751253,0.0008095957],"genre_scores_gemma":[0.9977284,0.0002605392,0.0004004965,0.0005712415,0.00007040524,0.00006848405,0.00039070137,0.00003652034,0.00047323082],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981873,0.00022022953,0.0005049649,0.0005600052,0.00020376679,0.00032371245],"domain_scores_gemma":[0.99896216,0.000079671336,0.00031812314,0.00046606682,0.000060951414,0.00011304622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021572803,0.00030849714,0.00060920086,0.00019762758,0.00009409676,0.000010833287,0.00022705756,0.00010329327,0.00006561306],"category_scores_gemma":[0.000026055528,0.00024603072,0.00025727105,0.00019184744,0.00040748753,0.000051265935,0.00044418644,0.0002190953,0.0000027560727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059539493,0.0009118282,0.0002804377,0.0002917894,0.0002511276,0.000007688971,0.00017448238,0.0000065068334,0.99572575,0.0003719692,0.0001481539,0.0012348526],"study_design_scores_gemma":[0.001597204,0.002564259,0.0010557976,0.000073976276,0.00046232447,0.000010428122,0.00014758964,0.00016471764,0.9917054,0.000063813,0.0019233181,0.00023112644],"about_ca_topic_score_codex":0.00006932012,"about_ca_topic_score_gemma":0.0000029033072,"teacher_disagreement_score":0.0040203226,"about_ca_system_score_codex":0.000058318135,"about_ca_system_score_gemma":0.00009159003,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W4281694200","doi":"10.1159/000524889","title":"Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial","year":2022,"lang":"en","type":"article","venue":"American Journal of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pfizer; American Society of Nephrology","keywords":"Medicine; Internal medicine; Natriuresis; Renal function; Placebo; Endocrinology; Diabetes mellitus; Gastroenterology; Pathology","score_opus":0.07393361000148514,"score_gpt":0.37162366334852615,"score_spread":0.297690053347041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281694200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97795206,0.00023822328,0.000096243515,0.02122663,0.00011806058,0.00022953108,0.000019008812,0.000008407752,0.00011184296],"genre_scores_gemma":[0.983649,0.00017666763,0.0018330016,0.0138795795,0.00037458254,0.000019134444,0.000019693873,0.000012878996,0.000035425466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987144,0.00042174564,0.00026826788,0.00014391256,0.00027507628,0.00017661354],"domain_scores_gemma":[0.9983299,0.0008240567,0.0005389039,0.0001495793,0.00006348783,0.00009407582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035834571,0.00010966868,0.0005350057,0.00009260098,0.00012287208,0.000017008342,0.00010737013,0.00001912182,0.00008376645],"category_scores_gemma":[0.00007121368,0.000059409285,0.00008306486,0.00022490765,0.00040149686,0.000043191016,0.00006019005,0.00029984946,0.0000012174263],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18053682,0.0025658747,0.3682644,0.0000058333867,0.022941122,0.0016106609,0.003372496,0.00017237237,0.00032399205,0.00014324652,0.034204982,0.38585818],"study_design_scores_gemma":[0.09106346,0.150885,0.6450053,0.00003653866,0.006939384,0.00031047137,0.0075497227,0.000105781706,0.000044381304,0.0001929118,0.097575046,0.00029204693],"about_ca_topic_score_codex":0.00022888674,"about_ca_topic_score_gemma":0.00019247703,"teacher_disagreement_score":0.38556615,"about_ca_system_score_codex":0.000055962533,"about_ca_system_score_gemma":0.000104738916,"threshold_uncertainty_score":0.24226403},"labels":[],"label_agreement":null},{"id":"W4281733354","doi":"10.1007/s11892-022-01471-2","title":"SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis","year":2022,"lang":"en","type":"review","venue":"Current Diabetes Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Diabetic ketoacidosis; Diabetes mellitus; Intensive care medicine; Type 1 diabetes; Kidney disease; Type 2 diabetes; Clinical trial; Type 2 Diabetes Mellitus; Internal medicine; Endocrinology","score_opus":0.021791293205428146,"score_gpt":0.268806374889667,"score_spread":0.24701508168423889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281733354","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1066163,0.88593525,0.0000012084564,0.000037664096,0.0018611341,0.004186269,0.00096092426,0.00014519527,0.0002560779],"genre_scores_gemma":[0.049668558,0.9357716,0.00006213957,0.0000446134,0.0003153574,0.0023576997,0.011227962,0.00027540876,0.0002766572],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99238294,0.0005481427,0.0022261336,0.0017633839,0.0015737788,0.0015055884],"domain_scores_gemma":[0.99470633,0.00020411778,0.002134944,0.0017441894,0.00020348764,0.0010069533],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00092823926,0.0014026734,0.004455199,0.001282586,0.00019872973,0.000093143586,0.00024361751,0.0002610328,0.0007388275],"category_scores_gemma":[0.00046462016,0.0011472389,0.0013364317,0.001817587,0.00025127063,0.00021828762,0.0005271029,0.0010246286,0.000018088525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004254312,0.00210218,0.25371954,0.048799913,0.0031792994,0.0006033163,0.00005658886,0.00011210158,0.0000029080857,0.000012532199,0.0025924733,0.6887766],"study_design_scores_gemma":[0.0029091272,0.0017051746,0.021411074,0.07592627,0.049011953,0.000025576168,0.000028550647,0.00010015942,0.00016458442,0.00022691178,0.84601957,0.002471044],"about_ca_topic_score_codex":0.000029068817,"about_ca_topic_score_gemma":0.0000075131115,"teacher_disagreement_score":0.8434271,"about_ca_system_score_codex":0.00090159185,"about_ca_system_score_gemma":0.0011889543,"threshold_uncertainty_score":0.9998723},"labels":[],"label_agreement":null},{"id":"W4281761574","doi":"10.1016/j.jchf.2022.05.004","title":"Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved","year":2022,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; Servier; Amarin Corporation; Novo Nordisk; Harvard Medical School; Massachusetts General Hospital; Novartis; Bayer; Abbott Diagnostics; Eli Lilly and Company; AstraZeneca; Vifor Pharma; Pfizer; Boehringer Ingelheim; Amgen; AbbVie; Sanofi; Abbott Laboratories","keywords":"Empagliflozin; Medicine; Internal medicine; Natriuretic peptide; Cardiology; Heart failure; Ejection fraction; Quartile; Troponin T; Renal function; Biomarker; Troponin complex; Troponin; Myocardial infarction; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.013972446840794807,"score_gpt":0.2602131073134179,"score_spread":0.2462406604726231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281761574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768234,0.00021801244,0.0000029113883,0.010456069,0.000068203066,0.0012538511,0.000033913693,0.00003907074,0.00024565536],"genre_scores_gemma":[0.99745,0.000010943087,0.0013599858,0.00015359037,0.0000450635,0.00023174293,0.00010499954,0.0000191472,0.00062454207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883413,0.00016397679,0.00022667315,0.00028964176,0.0002333711,0.0002521785],"domain_scores_gemma":[0.9993378,0.00012257493,0.00005589228,0.0003268696,0.00006660545,0.000090254915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032046757,0.00013681393,0.0003753334,0.00017019777,0.00009700635,0.000013392149,0.000050664534,0.00004178716,0.000101371515],"category_scores_gemma":[0.00011095083,0.00012895564,0.00007603193,0.00037178482,0.000060631137,0.00006703302,0.0001872396,0.00020439467,0.000008186918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012569746,0.00044559312,0.9688311,0.00021562543,0.000114923794,0.00007252649,0.00029596646,0.000021471675,0.0130766425,0.00070339337,0.015155899,0.0009411123],"study_design_scores_gemma":[0.001190934,0.0007398032,0.97504354,0.00005232753,0.00020998411,0.00002542622,0.00032303503,0.000096885604,0.00060216227,0.00014566212,0.021446683,0.0001235899],"about_ca_topic_score_codex":0.00018975163,"about_ca_topic_score_gemma":0.00009577002,"teacher_disagreement_score":0.01247448,"about_ca_system_score_codex":0.00009743982,"about_ca_system_score_gemma":0.000090918016,"threshold_uncertainty_score":0.5258658},"labels":[],"label_agreement":null},{"id":"W4281784085","doi":"10.2337/db22-20-or","title":"20-OR: The Renal and Vascular Effects of Combined SGLT2 and Angiotensin Converting Enzyme Inhibition","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ramipril; Empagliflozin; Medicine; Urology; Placebo; Renal function; Blood pressure; Internal medicine; Effective renal plasma flow; Endocrinology; Ambulatory blood pressure; Renal blood flow; Cardiology; Diabetes mellitus; Type 2 diabetes","score_opus":0.006328170487605003,"score_gpt":0.20258925270000258,"score_spread":0.19626108221239758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281784085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963633,0.0018189962,0.0000030593744,0.0011091006,0.000057187244,0.00047022774,0.0000037402122,0.00002684236,0.00014757802],"genre_scores_gemma":[0.9986883,0.00005227698,0.000079758254,0.00070595986,0.000023820527,0.00005670099,0.000037954356,0.000010989445,0.00034428624],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993627,0.0000616182,0.000120779725,0.0001425457,0.00016094094,0.0001513986],"domain_scores_gemma":[0.99957246,0.00017375588,0.000057042664,0.00013584174,0.00002016764,0.000040713818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020175485,0.000091588845,0.00020210238,0.000059625923,0.00011835309,0.000010427723,0.000024008623,0.000017183911,0.000029104105],"category_scores_gemma":[0.000051430583,0.000054198663,0.000045910227,0.000107495165,0.00007625727,0.000036387322,0.0001281161,0.00006817093,9.008558e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036318495,0.0011816707,0.4473894,0.0022546276,0.003038157,0.00014427013,0.0033868034,0.000029525494,0.4422625,0.0025616183,0.024543088,0.07284518],"study_design_scores_gemma":[0.01960886,0.007406274,0.35339788,0.00079384306,0.0031480026,0.00000787659,0.0009618417,0.0051422976,0.5746173,0.0012738905,0.03306513,0.0005768167],"about_ca_topic_score_codex":0.000009029746,"about_ca_topic_score_gemma":0.0000011384742,"teacher_disagreement_score":0.13235481,"about_ca_system_score_codex":0.000017893368,"about_ca_system_score_gemma":0.000008924472,"threshold_uncertainty_score":0.22101572},"labels":[],"label_agreement":null},{"id":"W4281807760","doi":"10.2337/db22-856-p","title":"856-P: Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Manitoba Beekeepers' Association","funders":"","keywords":"Medicine; Canagliflozin; Creatinine; Hazard ratio; Renal function; Type 2 diabetes; Internal medicine; Urology; Kidney disease; Placebo; Proportional hazards model; Cystatin C; Diabetes mellitus; Endocrinology; Confidence interval; Pathology","score_opus":0.030050460016979544,"score_gpt":0.2611717621154277,"score_spread":0.23112130209844817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281807760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98088455,0.010726836,0.0000035843816,0.005017077,0.00020096131,0.0020036092,0.0008419956,0.0001342338,0.00018714515],"genre_scores_gemma":[0.9893153,0.0004328976,0.0019849325,0.0032551321,0.0001438895,0.00088757725,0.0028191789,0.000073154806,0.0010879926],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759144,0.00014600655,0.00023446961,0.0008677819,0.00053197914,0.0006283188],"domain_scores_gemma":[0.99777126,0.00030087758,0.0000749306,0.0013469876,0.000058272322,0.00044768822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047109573,0.00040669236,0.0007257509,0.00010739784,0.0004941235,0.00010212634,0.0003239474,0.000036995814,0.00013321699],"category_scores_gemma":[0.00020768774,0.00025592552,0.00010014652,0.00034676256,0.000109437606,0.00013767439,0.0010591352,0.00012629613,0.000008815455],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062431915,0.00023291583,0.9337636,0.000056301258,0.003966446,0.000046970094,0.00025162403,0.000038024886,0.00033858058,0.000011646967,0.009988599,0.051242817],"study_design_scores_gemma":[0.0056072227,0.0038166987,0.2715891,0.00022163837,0.0064707124,0.000003290768,0.0016400794,0.0037448218,0.0024992079,0.000028783565,0.7034905,0.0008879327],"about_ca_topic_score_codex":0.0039107553,"about_ca_topic_score_gemma":0.0011342491,"teacher_disagreement_score":0.6935019,"about_ca_system_score_codex":0.00030416544,"about_ca_system_score_gemma":0.00012541786,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W4281810395","doi":"10.2337/db22-1324-p","title":"1324-P: Short-Term Effects of Glycemia-Lowering Medications on ß-Cell Function in the GRADE Study","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Insulin glargine; Internal medicine; Glycemic; Type 2 diabetes; Endocrinology; Glimepiride; C-peptide; Insulin; Diabetes mellitus; Basal insulin; Sitagliptin","score_opus":0.011461405834368672,"score_gpt":0.2513131573388754,"score_spread":0.23985175150450672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281810395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501413,0.00029086618,0.0000028619575,0.0002646165,0.00022397071,0.0011888735,0.0000022218137,0.00003239737,0.0029800765],"genre_scores_gemma":[0.9985384,0.000010545233,0.000007003385,0.00032946563,0.00003768106,0.0007650473,0.00004753769,0.000012703405,0.00025164182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999023,0.0000767876,0.00016846662,0.00018118527,0.00037125818,0.00017930877],"domain_scores_gemma":[0.9993701,0.00022143825,0.000044022967,0.00032229125,0.000010518375,0.00003162346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002541399,0.00010483918,0.00018358974,0.00016201191,0.000087669556,0.0000076136685,0.00012455478,0.000015484698,0.000050019866],"category_scores_gemma":[0.000022003644,0.000075933174,0.00005878655,0.00029053088,0.000022975586,0.000030924493,0.00007079036,0.00014292818,0.000006612314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000657385,0.007175113,0.96728015,0.0002732451,0.00030267605,0.000036032114,0.0025914635,0.00004911137,0.009616486,0.00020685278,0.0013151874,0.011087923],"study_design_scores_gemma":[0.0040998706,0.006714644,0.9677146,0.000093300194,0.0008916941,2.7944094e-7,0.0026861955,0.000111497975,0.015432894,0.00010705164,0.0019886317,0.00015933067],"about_ca_topic_score_codex":0.000010028238,"about_ca_topic_score_gemma":0.0000038011801,"teacher_disagreement_score":0.010928593,"about_ca_system_score_codex":0.00006554224,"about_ca_system_score_gemma":0.000012376597,"threshold_uncertainty_score":0.3096465},"labels":[],"label_agreement":null},{"id":"W4281817250","doi":"10.1111/dom.14794","title":"In vivo and in vitro characterization of <scp>GL0034</scp> , a novel long‐acting <scp>glucagon‐like peptide</scp> ‐1 receptor agonist","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Medical Research Council; European Commission; Engineering and Physical Sciences Research Council; European Foundation for the Study of Diabetes; Innovative Medicines Initiative; Imperial College London; Wellcome Trust; Steno Diabetes Center Copenhagen; National Institute for Health and Care Research; Society for Endocrinology; Medical Research Council Canada; Diabetes UK; Juvenile Diabetes Research Foundation International; British Society for Neuroendocrinology; Horizon 2020 Framework Programme; Academy of Medical Sciences","keywords":"Agonist; Medicine; In vitro; In vivo; Receptor; Pharmacology; Internal medicine; Biochemistry; Biology; Biotechnology","score_opus":0.009129238576364142,"score_gpt":0.21480356351233348,"score_spread":0.20567432493596935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281817250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585366,0.0015638524,0.000019295701,0.00015566341,0.00043598306,0.0008548874,0.00016889138,0.000047629583,0.0009001144],"genre_scores_gemma":[0.9937185,0.0006188016,0.0005212324,0.0008293351,0.00012913479,0.00018431271,0.00031675067,0.000044049062,0.0036378691],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997878,0.000121416655,0.0005014601,0.0005441017,0.00036949018,0.0005855248],"domain_scores_gemma":[0.9989842,0.00024466825,0.00027262757,0.00028347567,0.000059598882,0.00015540727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006801207,0.00032675973,0.0008181902,0.00054621673,0.00018087977,0.00005916208,0.00012996916,0.00010116981,0.000042018524],"category_scores_gemma":[0.00024616285,0.00033796404,0.00010310248,0.00061237835,0.00010938331,0.00036961422,0.00032656363,0.0003290563,0.0000052171526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003101812,0.0016047583,0.22503357,0.0005031265,0.0002301929,0.000021890055,0.002904947,0.00000634054,0.7644425,0.00034380477,0.0004931518,0.00438468],"study_design_scores_gemma":[0.0051343995,0.00017797029,0.68212956,0.00012806967,0.00040452837,0.000003268223,0.0011880818,0.00035139074,0.20934086,0.00009188347,0.10092456,0.00012541832],"about_ca_topic_score_codex":0.00008737684,"about_ca_topic_score_gemma":0.000019842833,"teacher_disagreement_score":0.5551017,"about_ca_system_score_codex":0.000082831684,"about_ca_system_score_gemma":0.00005156672,"threshold_uncertainty_score":0.99990726},"labels":[],"label_agreement":null},{"id":"W4281839833","doi":"10.2337/db22-405-p","title":"405-P: Glycemic Control Impacts Renal Function Decline among People with Type 1 Diabetes after the Onset of Diabetic Kidney Disease","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal function; Albuminuria; Type 2 diabetes; Internal medicine; Glycemic; Diabetes mellitus; Kidney disease; Endocrinology; Creatinine; Proteinuria; Urology; Kidney","score_opus":0.004300570826806898,"score_gpt":0.20157809559865866,"score_spread":0.19727752477185176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281839833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949278,0.0016500745,0.0000069039643,0.0015180903,0.00025031547,0.0010899105,0.00020050583,0.000089896035,0.00026645008],"genre_scores_gemma":[0.9943452,0.00002483265,0.000026904669,0.003709967,0.00010006416,0.00075253664,0.000515238,0.00005470004,0.00047057885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980199,0.00013440917,0.00032392694,0.00036617805,0.00057833834,0.0005772985],"domain_scores_gemma":[0.99847424,0.00021659659,0.00019415873,0.00061109615,0.0001160735,0.0003878375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030900058,0.00029890725,0.00048896443,0.00017621297,0.00018661373,0.00003615236,0.00018219561,0.00003623342,0.001084614],"category_scores_gemma":[0.0001750204,0.00019312813,0.00016960435,0.0005392491,0.00017456694,0.00013133328,0.00018413617,0.00021721117,0.000024849714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025939215,0.00048988865,0.98688114,0.00019416574,0.0008316781,0.000015743577,0.000118520264,0.000099862205,0.0011702777,0.000020611189,0.0068341726,0.00075004756],"study_design_scores_gemma":[0.0053854943,0.0033246102,0.9811557,0.00018894582,0.0026751948,5.648469e-7,0.00010036002,0.0012813278,0.0011549742,0.00020531114,0.004244591,0.00028295393],"about_ca_topic_score_codex":0.00002548784,"about_ca_topic_score_gemma":0.00001709413,"teacher_disagreement_score":0.005725439,"about_ca_system_score_codex":0.00010293507,"about_ca_system_score_gemma":0.00014831635,"threshold_uncertainty_score":0.9998285},"labels":[],"label_agreement":null},{"id":"W4281933898","doi":"10.2215/cjn.04900422","title":"Safety of SGLT2 Inhibitors in CKD","year":2022,"lang":"en","type":"letter","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Renal glucose reabsorption; Phlorizin; Cotransporter; Internal medicine; Diabetes mellitus; Endocrinology; Proximal tubule; Kidney; Albuminuria; Canagliflozin; Type 2 diabetes; Glucose transporter; Insulin; Sodium; Chemistry","score_opus":0.03295625312792339,"score_gpt":0.33708697415676175,"score_spread":0.30413072102883837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281933898","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26619375,0.0005455642,0.000009586666,0.73169714,0.00075680576,0.00034499876,0.00001999595,0.0000055358305,0.0004266049],"genre_scores_gemma":[0.020592267,0.0030011632,0.0016066951,0.9718594,0.0020045873,0.000005470377,0.00001714606,0.000041886222,0.00087137864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961869,0.0006134529,0.0020608609,0.0002366534,0.00057993934,0.00032219876],"domain_scores_gemma":[0.9940457,0.0011753632,0.0040415726,0.0005219881,0.0001469719,0.000068422276],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013857579,0.00023479118,0.0021194643,0.00011674729,0.000033706372,0.0000025896454,0.0006042481,0.00028128285,0.00021078094],"category_scores_gemma":[0.00013203308,0.00015689436,0.0024446521,0.0004316221,0.0018675039,0.00002982074,0.00042065472,0.002834249,0.0000020825373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070122763,0.00044244475,0.028399525,0.00011300302,0.0019058557,0.000091750495,0.00012254843,0.000010687982,0.000098594865,0.0000040784066,0.9583023,0.0098079685],"study_design_scores_gemma":[0.0025657064,0.004315448,0.040397402,0.00015512986,0.0010066073,0.000042129705,0.00030471466,0.000008958822,0.000015282607,0.0001532079,0.95093024,0.00010514716],"about_ca_topic_score_codex":0.000050849198,"about_ca_topic_score_gemma":0.0000020748323,"teacher_disagreement_score":0.24560149,"about_ca_system_score_codex":0.00016707498,"about_ca_system_score_gemma":0.00029792622,"threshold_uncertainty_score":0.99946624},"labels":[],"label_agreement":null},{"id":"W4281934192","doi":"10.1056/nejmoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Eli Lilly and Company","keywords":"Obesity; Agonist; Medicine; Glucagon-like peptide-1; Endocrinology; Diabetes mellitus; Receptor; Internal medicine; Disease; Type 2 diabetes","score_opus":0.02657164938863743,"score_gpt":0.28388897251447426,"score_spread":0.2573173231258368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281934192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94055104,0.011234579,0.0014861376,0.04214491,0.0012860299,0.000977693,0.000011270951,0.000012546662,0.00229581],"genre_scores_gemma":[0.98888856,0.0015680349,0.000826593,0.00048667565,0.0017987882,0.000018024495,0.000010591831,0.000012345982,0.0063904137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901104,0.000041049858,0.00035150646,0.000076577766,0.00039041182,0.00012944188],"domain_scores_gemma":[0.99895465,0.00040396664,0.00028365554,0.00016354622,0.00008661733,0.0001075788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005066027,0.000100697485,0.00040486074,0.00010454023,0.000091827504,0.0000023644693,0.00009864768,0.000011688943,0.00032911875],"category_scores_gemma":[0.00007258871,0.000049509013,0.0001333787,0.00011602743,0.00004919769,0.000025879437,0.000016180962,0.000079059544,6.899924e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024998984,0.0012222884,0.02846654,0.00006783432,0.00132984,0.00014134886,0.0030846004,0.00021207819,0.00097529666,0.00066397036,0.047523655,0.91381264],"study_design_scores_gemma":[0.070844166,0.026017368,0.01529595,0.00009668643,0.0019349536,0.00012874867,0.00094382477,0.00017019629,0.0006949934,0.0005350632,0.88327956,0.000058505997],"about_ca_topic_score_codex":0.00009675004,"about_ca_topic_score_gemma":0.00001468802,"teacher_disagreement_score":0.91375417,"about_ca_system_score_codex":0.00013445652,"about_ca_system_score_gemma":0.00009119629,"threshold_uncertainty_score":0.36036193},"labels":[],"label_agreement":null},{"id":"W4281950795","doi":"10.2337/db22-176-or","title":"176-OR: The Effect of Low-Dose Empagliflozin on Glucose Control in Suboptimally Controlled Adults with Type 1 Diabetes on a Closed-Loop Insulin Delivery System","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Glycemic; Placebo; Medicine; Adverse effect; Type 2 diabetes; Insulin; Diabetes mellitus; Randomized controlled trial; Internal medicine; Anesthesia; Endocrinology","score_opus":0.004384168816590873,"score_gpt":0.20402288127574236,"score_spread":0.1996387124591515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281950795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195224,0.0013973005,3.1350243e-7,0.00031305294,0.00024737656,0.004624331,0.00006570879,0.00012357283,0.0012761265],"genre_scores_gemma":[0.9966531,0.00004134017,0.000015935366,0.000986546,0.00007053655,0.0016939325,0.000086423745,0.000066618406,0.00038557392],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969186,0.00062887865,0.0005621668,0.00051858835,0.000720622,0.0006511153],"domain_scores_gemma":[0.9969571,0.0018481859,0.0002983513,0.0006694637,0.00009872061,0.00012815137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010232184,0.00047597525,0.0013572973,0.000384667,0.00015193028,0.000031656677,0.0002953879,0.00007461535,0.00010418493],"category_scores_gemma":[0.00022774132,0.00023822043,0.00023820334,0.00061956886,0.000108547785,0.00006821311,0.000102664635,0.00036732428,0.00005104325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1829195,0.0047832467,0.7389994,0.0038696793,0.005695838,0.0005922275,0.0010413012,0.0048678666,0.008778566,0.00046416302,0.0026480136,0.045340165],"study_design_scores_gemma":[0.41368383,0.22156547,0.22997266,0.008189431,0.005488665,0.000004636567,0.0024147662,0.051024236,0.06389166,0.000016311951,0.0019209209,0.0018274181],"about_ca_topic_score_codex":0.000026362331,"about_ca_topic_score_gemma":0.000017434275,"teacher_disagreement_score":0.50902677,"about_ca_system_score_codex":0.0002882279,"about_ca_system_score_gemma":0.00008656301,"threshold_uncertainty_score":0.9714347},"labels":[],"label_agreement":null},{"id":"W4281969363","doi":"10.2337/db22-1146-p","title":"1146-P: SGLT2 Inhibitors and the Risk of Early Bladder Cancer Events","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bladder cancer; Hazard ratio; Cancer; Cohort; Confidence interval; Internal medicine; Incidence (geometry); Proportional hazards model; Cancer registry; Oncology; Surgery","score_opus":0.0069310122128127,"score_gpt":0.22893550258827258,"score_spread":0.22200449037545988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281969363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99399996,0.0030479645,4.1055137e-7,0.00091798784,0.00018500705,0.0004431882,0.000031908792,0.000021700926,0.0013518801],"genre_scores_gemma":[0.997215,0.00024596995,0.0000257829,0.00035569665,0.000056708417,0.00026506477,0.000012059067,0.000013582737,0.0018101559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992401,0.00007509884,0.00013953184,0.00014277057,0.00023010236,0.00017240137],"domain_scores_gemma":[0.99957013,0.00009279161,0.000093088376,0.0001798471,0.000022141456,0.000041987547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025268833,0.0000943491,0.00021434696,0.000060071092,0.000115967596,0.0000063186426,0.00006424993,0.000014140493,0.0002373039],"category_scores_gemma":[0.000026922788,0.00005957144,0.00008319168,0.00013553779,0.00009130704,0.000034917703,0.00015322056,0.00010094026,0.0000041568564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062657426,0.00012377664,0.97910666,0.000037108086,0.0007561618,0.0000013447279,0.0005719656,0.000013217585,0.00024038334,0.0003338797,0.003386966,0.0153659],"study_design_scores_gemma":[0.0090432465,0.00079938804,0.95233333,0.00007307624,0.0021041117,3.0537296e-7,0.0006119827,0.00031805786,0.007313045,0.0014395498,0.025756292,0.00020763278],"about_ca_topic_score_codex":0.00022135994,"about_ca_topic_score_gemma":0.000005214073,"teacher_disagreement_score":0.026773328,"about_ca_system_score_codex":0.000029122248,"about_ca_system_score_gemma":0.000016184416,"threshold_uncertainty_score":0.25983113},"labels":[],"label_agreement":null},{"id":"W4282043345","doi":"10.2337/db22-718-p","title":"718-P: Patients Achieving an HbA1c &amp;lt;5.7% with =5% Weight Loss and without Hypoglycemia: A Post Hoc Analysis of SURPASS 1 to 5","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglycemia; Semaglutide; Placebo; Weight loss; Type 2 diabetes; Post-hoc analysis; Clinical endpoint; Internal medicine; Insulin degludec; Insulin; Endocrinology; Diabetes mellitus; Gastroenterology; Insulin glargine; Clinical trial; Liraglutide; Obesity","score_opus":0.007282755106463217,"score_gpt":0.2285145377531891,"score_spread":0.22123178264672588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282043345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979382,0.00025278536,0.000009359276,0.00033585707,0.000054937038,0.0005603319,0.00015436178,0.00005740714,0.0006367153],"genre_scores_gemma":[0.99670565,0.0000140702,0.0010644351,0.00067089655,0.000024006136,0.00013565739,0.0007459092,0.000034680714,0.0006046985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983985,0.00007026313,0.0002567456,0.0004290531,0.00047665168,0.00036877842],"domain_scores_gemma":[0.9989987,0.00006117161,0.00013043359,0.00045919968,0.00012966557,0.0002208394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019754164,0.00022762257,0.0006197866,0.00059284666,0.00014057233,0.000025698091,0.00012913335,0.000032636555,0.00016532063],"category_scores_gemma":[0.00003200039,0.0001817109,0.00010626129,0.0010032892,0.0000637594,0.00012694325,0.00021741331,0.0001106542,0.000005245682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003544407,0.0007000753,0.9860968,0.00007544083,0.002835834,0.0000053369617,0.00066391163,0.000063624044,0.0009757942,0.000060389822,0.00025879542,0.007909544],"study_design_scores_gemma":[0.003144933,0.004702787,0.9739042,0.00005915391,0.0062133316,4.2529288e-7,0.00020739796,0.0001977588,0.00056957867,0.000009676504,0.010682091,0.00030866923],"about_ca_topic_score_codex":0.00004143132,"about_ca_topic_score_gemma":0.00011546015,"teacher_disagreement_score":0.012192616,"about_ca_system_score_codex":0.00008937835,"about_ca_system_score_gemma":0.000028042567,"threshold_uncertainty_score":0.7409956},"labels":[],"label_agreement":null},{"id":"W4282573439","doi":"10.1016/j.biopha.2022.113270","title":"Targeting cholesteryl ester accumulation in the heart improves cardiac insulin response","year":2022,"lang":"en","type":"article","venue":"Biomedicine & Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondo para la Investigación Científica y Tecnológica; European Regional Development Fund; Instituto de Salud Carlos III; Center for International Business Education and Research, University of Illinois at Urbana-Champaign; Secretaria de Ciencia y Tecnología - Universidad Nacional de Córdoba; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas; Banco Bilbao Vizcaya Argentaria; Consejo Nacional de Investigaciones Científicas y Técnicas; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares; Generalitat de Catalunya; Fundación BBVA; Fundació la Marató de TV3; Universitat de Barcelona; International Union of Biochemistry and Molecular Biology; Consejo Superior de Investigaciones Científicas; Universidad Nacional de Córdoba; European Foundation for the Study of Diabetes; Ministerio de Ciencia, Innovación y Universidades","keywords":"LRP1; GLUT4; Insulin receptor; Insulin; Internal medicine; Glucose transporter; Endocrinology; Biology; Chemistry; Insulin resistance; Cholesterol; Lipoprotein; LDL receptor; Medicine","score_opus":0.03228562616174602,"score_gpt":0.3495473836895343,"score_spread":0.3172617575277883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282573439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97396475,0.003021859,0.000024286048,0.02070013,0.00056498515,0.0014101409,0.000011700228,0.000074185155,0.0002279356],"genre_scores_gemma":[0.9812629,0.00025239322,0.00012463081,0.01655935,0.00042530338,0.00038458305,0.000124823,0.00003458981,0.0008313957],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981557,0.0004034342,0.0003245035,0.0002926256,0.0005091414,0.00031460778],"domain_scores_gemma":[0.999381,0.00016407428,0.00008374973,0.00027573135,0.000024484163,0.00007095889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016754381,0.00018877679,0.00029325453,0.00033981603,0.0001489237,0.000023869943,0.0001553648,0.000026040809,0.00036029768],"category_scores_gemma":[0.000019146808,0.00012881057,0.000102458216,0.0006095322,0.00005623869,0.000096098636,0.000054688055,0.00022800213,0.000020346271],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043397928,0.00086548337,0.029433781,0.00005424208,0.00023983288,0.00008246046,0.0042141476,0.000044291683,0.8537415,0.000018079358,0.043491192,0.06347517],"study_design_scores_gemma":[0.008928907,0.0013989682,0.17776592,0.000033478802,0.00015174077,0.000008604348,0.001143939,0.0006393703,0.0029480553,0.000021392409,0.8067736,0.00018603937],"about_ca_topic_score_codex":0.000042366904,"about_ca_topic_score_gemma":3.7360837e-7,"teacher_disagreement_score":0.8507935,"about_ca_system_score_codex":0.00016193945,"about_ca_system_score_gemma":0.000050971128,"threshold_uncertainty_score":0.5252743},"labels":[],"label_agreement":null},{"id":"W4282939145","doi":"10.1016/j.cjca.2022.05.026","title":"Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction","year":2022,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Ejection fraction; Heart failure; Internal medicine; Cardiology; Fraction (chemistry); Endocrinology; Diabetes mellitus; Chromatography","score_opus":0.010993041886708294,"score_gpt":0.23660255912154932,"score_spread":0.22560951723484102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282939145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96784276,0.00025752353,0.000022961955,0.028991573,0.000333033,0.00048236534,0.00003723003,0.0000030468634,0.0020295072],"genre_scores_gemma":[0.99553114,0.000009393714,0.00018783065,0.0034406283,0.00042249,0.000008679638,0.00017983386,0.000025419109,0.00019461116],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882793,0.00014517916,0.00040764877,0.00016079955,0.0002292005,0.00022926147],"domain_scores_gemma":[0.99896055,0.000043105596,0.0004840436,0.0001693083,0.00021511265,0.0001278895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015953124,0.00016895976,0.0010766184,0.00080434553,0.00003192861,0.0000058559704,0.00006332164,0.00020555168,0.00008852255],"category_scores_gemma":[0.000027414486,0.00013124025,0.000094201154,0.00017590924,0.000115981224,0.00005789821,0.00000965484,0.00073874125,6.9497156e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030849403,0.000010658675,0.6152535,0.000106656196,0.00058853906,0.00007866738,0.000053836462,0.00012752689,0.000016734837,0.0000012017447,0.38308856,0.00036565046],"study_design_scores_gemma":[0.002783102,0.004825173,0.4052041,0.00023243156,0.000708618,0.000039825027,0.00024469182,0.0000023055698,0.000032829474,0.000004922106,0.58581394,0.00010808325],"about_ca_topic_score_codex":0.0006245718,"about_ca_topic_score_gemma":0.0012407443,"teacher_disagreement_score":0.2100494,"about_ca_system_score_codex":0.00033051975,"about_ca_system_score_gemma":0.0004517458,"threshold_uncertainty_score":0.5351822},"labels":[],"label_agreement":null},{"id":"W4282960868","doi":"10.1161/hypertensionaha.122.19586","title":"SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients","year":2022,"lang":"en","type":"article","venue":"Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Empagliflozin; Medicine; Oxidative stress; Diabetes mellitus; Internal medicine; Endothelial dysfunction; Reactive oxygen species; Endocrinology; Cardiology; Type 2 diabetes; Biology; Biochemistry","score_opus":0.009764256147212628,"score_gpt":0.1939850788124737,"score_spread":0.18422082266526107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282960868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965186,0.0010525594,0.000018228822,0.00034915557,0.0008260415,0.00087100366,0.00007072487,0.00007251683,0.00022112907],"genre_scores_gemma":[0.99701136,0.0001065104,0.0002649456,0.0011785631,0.00025652646,0.00012260131,0.00083769404,0.000028517024,0.00019328324],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985336,0.000098260454,0.0002408775,0.0005351887,0.00037513406,0.00021690865],"domain_scores_gemma":[0.9993341,0.00008705105,0.00011947723,0.0001950999,0.00013123645,0.00013306447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000031859498,0.00024365654,0.00038990407,0.00017564381,0.0003198444,0.000038316975,0.000032288754,0.00006953681,0.000060863837],"category_scores_gemma":[0.000054575117,0.00020001405,0.000057793914,0.00012773913,0.00008693775,0.00020121748,0.00020443958,0.00017163221,0.00001240198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012282748,0.0010866116,0.0063442653,0.000042614698,0.00039086578,0.00006364231,0.0007551819,0.0000026198652,0.94992906,0.00005579728,0.0038113869,0.036289696],"study_design_scores_gemma":[0.048214983,0.015710905,0.64003444,0.00060328655,0.0052633244,0.000040553165,0.0067729703,0.0029173396,0.25667223,0.0049410313,0.017224297,0.0016046425],"about_ca_topic_score_codex":0.00015793023,"about_ca_topic_score_gemma":0.000010155701,"teacher_disagreement_score":0.6932568,"about_ca_system_score_codex":0.00007382727,"about_ca_system_score_gemma":0.000020689025,"threshold_uncertainty_score":0.8156336},"labels":[],"label_agreement":null},{"id":"W4282975086","doi":"10.1053/j.jvca.2022.06.008","title":"Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors After Cardiac Surgery: A Review of Current Literature","year":2022,"lang":"en","type":"review","venue":"Journal of Cardiothoracic and Vascular Anesthesia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Perioperative; Discontinuation; Intensive care medicine; Ketoacidosis; Empagliflozin; Diabetes mellitus; Cardiac surgery; Canagliflozin; Complication; Population; Type 2 diabetes; Surgery; Type 1 diabetes; Endocrinology","score_opus":0.02088193490619482,"score_gpt":0.28281699049954195,"score_spread":0.2619350555933471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282975086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022322282,0.99603385,0.0000068202203,0.000058161717,0.0002197671,0.0013353619,0.00004983521,0.000019991976,0.000043996144],"genre_scores_gemma":[0.000836675,0.9980185,0.000045230583,0.000110006746,0.00025865913,0.00015724714,0.00041256862,0.00011215894,0.0000489233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99557376,0.00081045425,0.0015277026,0.0004227122,0.001261117,0.00040423783],"domain_scores_gemma":[0.99700403,0.0002450098,0.0015718534,0.00056077,0.00031138177,0.0003069251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022548137,0.0007338395,0.0068023885,0.00064145407,0.0000626612,0.00005035301,0.00016739496,0.00023611475,0.000069548994],"category_scores_gemma":[0.00008842593,0.00048011163,0.004861202,0.0009660543,0.000094795105,0.00016385975,0.000037945465,0.00085666386,0.000001830639],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012060486,0.00033612692,0.0025231063,0.19294006,0.009486589,0.0016719874,0.00011050961,9.52927e-8,2.0730015e-7,0.0000025479692,0.001981651,0.7908265],"study_design_scores_gemma":[0.00034290808,0.0003760878,0.0005527676,0.25040573,0.03720548,0.00036685256,0.000010892788,1.3045323e-7,0.0000022767308,0.0000011519087,0.7104175,0.0003182392],"about_ca_topic_score_codex":9.661939e-7,"about_ca_topic_score_gemma":1.1117156e-7,"teacher_disagreement_score":0.7905083,"about_ca_system_score_codex":0.00027151412,"about_ca_system_score_gemma":0.0005256148,"threshold_uncertainty_score":0.99976504},"labels":[],"label_agreement":null},{"id":"W4283011660","doi":"10.1016/j.semnephrol.2022.04.007","title":"Sex and Gender Related Differences in Diabetic Kidney Disease","year":2022,"lang":"en","type":"review","venue":"Seminars in Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Disease; Medicine; Pathogenesis; Kidney disease; Epidemiology; Sex characteristics; Bioinformatics; Pathology; Internal medicine; Biology","score_opus":0.03719216918697536,"score_gpt":0.2989741828120814,"score_spread":0.261782013625106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283011660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052000675,0.990214,1.4067996e-7,0.00023390014,0.00019793746,0.0012544735,0.000022972286,0.000036073365,0.0028404219],"genre_scores_gemma":[0.00071694795,0.99412954,0.000032971067,0.00079716195,0.0000296953,0.00064292323,0.0004837925,0.000042287855,0.0031247016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798363,0.00031562944,0.0005004194,0.0005958699,0.00016174128,0.00044272823],"domain_scores_gemma":[0.9989763,0.00027399033,0.00013451638,0.00037247525,0.0000043158425,0.00023838882],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028325533,0.00037501135,0.0016428008,0.00062129553,0.000033861343,0.0000096712,0.00014563845,0.00022425727,0.00093998865],"category_scores_gemma":[0.00012063789,0.0003091282,0.00014775654,0.00039811045,0.00014415798,0.000029046425,0.00029247065,0.0005168066,0.00002199511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042964595,0.0004680175,0.021354713,0.011767728,0.00043849222,0.0018421018,0.00039280072,1.8436279e-7,1.5266839e-7,0.00037606223,0.0043808664,0.9589359],"study_design_scores_gemma":[0.0010397604,0.00024559777,0.0034317637,0.0025352284,0.0015888961,0.000020319429,0.00003960354,0.000020761427,2.2867518e-8,0.00095982157,0.9898693,0.00024890163],"about_ca_topic_score_codex":0.000008902628,"about_ca_topic_score_gemma":0.0000032215523,"teacher_disagreement_score":0.9854885,"about_ca_system_score_codex":0.00020504999,"about_ca_system_score_gemma":0.00018080941,"threshold_uncertainty_score":0.9999733},"labels":[],"label_agreement":null},{"id":"W4283213321","doi":"10.3389/fneur.2022.823569","title":"The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD","year":2022,"lang":"en","type":"review","venue":"Frontiers in Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Kidney disease; Medicine; Diabetes mellitus; Disease; Type 2 diabetes; Intensive care medicine; Cognitive decline; Renal function; Internal medicine; Dementia; Endocrinology","score_opus":0.018162395626218467,"score_gpt":0.28115006372890894,"score_spread":0.2629876681026905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283213321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005732869,0.993963,0.000014967322,0.00012030775,0.0021508571,0.0013816104,0.000012884823,0.000016965323,0.0017661288],"genre_scores_gemma":[0.00025754495,0.9986051,0.000031663785,0.00015521923,0.0000664243,0.00029207868,0.000083298524,0.000025936404,0.00048276977],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988119,0.00023390204,0.0003504401,0.0002919645,0.00010395363,0.00020782772],"domain_scores_gemma":[0.99938154,0.00018404449,0.0002213112,0.00016656132,0.000010396413,0.000036166537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021233353,0.00019716943,0.0008552581,0.00023337587,0.00005350837,0.0000064366222,0.00007827795,0.00010838262,0.000028262313],"category_scores_gemma":[0.000056326535,0.00013533405,0.00016498654,0.00019955893,0.00016474057,0.000021419972,0.00017751574,0.00037816248,0.0000017198408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015520194,0.00011349052,0.001742132,0.0018309013,0.00039839867,0.00006895542,0.00006442478,4.433203e-8,2.4425988e-8,0.00004569705,0.014509078,0.98107165],"study_design_scores_gemma":[0.0007974211,0.0015811579,0.00025783325,0.0005464422,0.0010882581,0.00002956376,0.00010510355,0.000007357363,3.216839e-7,0.00009077474,0.9954172,0.000078609395],"about_ca_topic_score_codex":0.000010425132,"about_ca_topic_score_gemma":0.000006663864,"teacher_disagreement_score":0.98099303,"about_ca_system_score_codex":0.00007699771,"about_ca_system_score_gemma":0.000052904736,"threshold_uncertainty_score":0.5518762},"labels":[],"label_agreement":null},{"id":"W4283313762","doi":"10.54022/shsv3n2-002","title":"Uso dos inibidores de SGLT2 na insuficiência cardíaca: uma revisão de literatura","year":2022,"lang":"pt","type":"article","venue":"STUDIES IN HEALTH SCIENCES","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine","score_opus":0.08964799316671314,"score_gpt":0.4170940167910214,"score_spread":0.3274460236243083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283313762","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46799096,0.5068094,0.000006476022,0.016445447,0.003124604,0.0017897469,0.00005488757,0.000085412954,0.003693025],"genre_scores_gemma":[0.9481165,0.03305873,0.00055654655,0.012986514,0.00034368612,0.0004529695,0.000012634483,0.000021611417,0.0044508157],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99523395,0.00064330257,0.0008549122,0.00079477445,0.0009462081,0.0015268226],"domain_scores_gemma":[0.99849236,0.00042976323,0.0003580793,0.00037459526,0.00008296148,0.0002622328],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0054946686,0.00035562122,0.0008733999,0.0005494721,0.001846499,0.000104501436,0.000526898,0.000049163646,0.00017566777],"category_scores_gemma":[0.0005345004,0.00029791225,0.00012772364,0.0020995364,0.0008657366,0.00020437625,0.0009375549,0.0005091162,0.000022126758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002072166,0.0011519926,0.6144909,0.005944283,0.0006531793,0.00048229838,0.13981836,0.0009072483,0.000016052354,0.0074646426,0.15181038,0.07705342],"study_design_scores_gemma":[0.005447928,0.0133441975,0.1837502,0.0064641684,0.00042714653,0.00005755356,0.24912797,0.0040293434,0.00005136753,0.0014155342,0.534614,0.0012705815],"about_ca_topic_score_codex":0.00082105474,"about_ca_topic_score_gemma":0.0001555861,"teacher_disagreement_score":0.48012552,"about_ca_system_score_codex":0.0021364584,"about_ca_system_score_gemma":0.0011023277,"threshold_uncertainty_score":0.9999473},"labels":[],"label_agreement":null},{"id":"W4283318677","doi":"10.1016/j.ijcard.2022.06.054","title":"Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+/H+ exchanger-1","year":2022,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Eli Lilly and Company","keywords":"Medicine; Ischemia; Canagliflozin; Cardiology; Internal medicine; Anesthesia; Cardiac function curve; Hemodynamics; Endocrinology; Heart failure; Type 2 diabetes; Diabetes mellitus","score_opus":0.010056964084414298,"score_gpt":0.2687648860016924,"score_spread":0.2587079219172781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283318677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894904,0.0011571784,0.00012670034,0.00068033615,0.0030864135,0.00025592002,0.00006699153,0.000013456786,0.005122641],"genre_scores_gemma":[0.9972836,0.00058164983,0.00015386459,0.0000833148,0.00097395835,0.000042307252,0.000038791542,0.000017896022,0.00082463707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982664,0.00010106055,0.0005019351,0.00018971978,0.00071971945,0.00022118598],"domain_scores_gemma":[0.9989941,0.00005761501,0.0003968602,0.00018406958,0.0002733905,0.00009397793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002996747,0.00017028123,0.0006776926,0.00038591272,0.000057307476,0.000011327181,0.00026857102,0.000052008265,0.00008520099],"category_scores_gemma":[0.000029125253,0.00013919074,0.00070416764,0.00009473593,0.00006443359,0.00007715033,0.00023204893,0.00018896753,0.000005061029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071001844,0.0013079218,0.1505823,0.00008841826,0.061534863,0.0065619345,0.0019562435,0.0035769928,0.6849747,0.0010517491,0.006284352,0.07498035],"study_design_scores_gemma":[0.04707663,0.022366622,0.3083148,0.00022020249,0.011091698,0.007117459,0.0033999616,0.00018868413,0.3305684,0.0005512572,0.26790264,0.0012016294],"about_ca_topic_score_codex":0.000009312449,"about_ca_topic_score_gemma":2.3669453e-7,"teacher_disagreement_score":0.35440627,"about_ca_system_score_codex":0.0006544412,"about_ca_system_score_gemma":0.00014387698,"threshold_uncertainty_score":0.56760335},"labels":[],"label_agreement":null},{"id":"W4283460639","doi":"10.1007/s11886-022-01715-3","title":"Synchronous Health Care Delivery for the Optimization of Cardiovascular and Renal Care in Patients with Type 2 Diabetes","year":2022,"lang":"en","type":"review","venue":"Current Cardiology Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Guideline; Health care; Type 2 diabetes; Specialty; Intensive care medicine; Health care delivery; Diabetes mellitus; Family medicine","score_opus":0.02089670311029459,"score_gpt":0.2823579109967112,"score_spread":0.26146120788641664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283460639","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008815108,0.993951,0.00005447125,0.000003380752,0.00077678106,0.0041929926,0.000058980142,0.000018545412,0.00006233352],"genre_scores_gemma":[0.002159307,0.99212056,0.0001214786,0.000009116012,0.00009650618,0.0007350851,0.0047096354,0.000043142638,0.000005166766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820966,0.00017754918,0.0005674818,0.0005161025,0.00024386037,0.00028536076],"domain_scores_gemma":[0.99857897,0.000108179505,0.00045045838,0.0006316974,0.00017170288,0.000058979625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002981661,0.0003075175,0.002171987,0.00018463601,0.00009223541,0.0000066069647,0.00006699423,0.0000968614,0.000006256699],"category_scores_gemma":[0.00004935888,0.00019234522,0.00054166134,0.00020912832,0.00008564235,0.000025595682,0.00012217608,0.00019976411,1.6967255e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002783712,0.000038383085,0.012398768,0.017416513,0.0031596671,0.00003215366,0.00013992339,0.0024065822,6.6273914e-10,0.0000010228638,0.00024791405,0.96413124],"study_design_scores_gemma":[0.0008500966,0.0012409062,0.0010730345,0.002737418,0.007896976,0.000015297306,0.00010614608,0.000006125468,4.8942344e-8,4.6450484e-7,0.9858945,0.00017897284],"about_ca_topic_score_codex":0.000009693247,"about_ca_topic_score_gemma":0.000001819664,"teacher_disagreement_score":0.9856466,"about_ca_system_score_codex":0.0004095589,"about_ca_system_score_gemma":0.00044347203,"threshold_uncertainty_score":0.78436106},"labels":[],"label_agreement":null},{"id":"W4283515565","doi":"10.1016/j.jval.2022.04.712","title":"EE464 The Cost-Effectiveness of Subcutaneous Semaglutide 2.4MG Injection in the Management of Obesity in Canada Using the Core Obesity Model","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Obesity; Core (optical fiber); Medicine; Management of obesity; Internal medicine; Computer science; Endocrinology; Diabetes mellitus; Weight loss; Type 2 diabetes; Telecommunications","score_opus":0.06628811665079676,"score_gpt":0.30435177880656766,"score_spread":0.2380636621557709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283515565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529994,0.00044203066,0.00007905003,0.00053589017,0.00012473887,0.0031955289,0.000018395787,0.0000051367065,0.00029931316],"genre_scores_gemma":[0.99919015,0.000098279204,0.00009398723,0.0003481387,0.0000068659256,0.00021264901,0.0000105028585,0.000009816585,0.000029612853],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9978895,0.0007664976,0.0003953854,0.00019560906,0.0004686161,0.0002843875],"domain_scores_gemma":[0.9990792,0.00030524604,0.00017610037,0.00039084407,0.00002172813,0.000026861899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00257597,0.00011829024,0.000307036,0.000114535265,0.00013306386,0.0000037161174,0.00021412125,0.000016445421,0.000007298662],"category_scores_gemma":[0.000013100124,0.000071837625,0.000043880274,0.00067538203,0.000040549818,0.0000201481,0.00014729664,0.00026304126,1.486109e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025912502,0.00045063175,0.2026282,0.0010830032,0.00005578126,0.000104047904,0.0014057516,0.78969395,0.000016784605,0.0024706011,0.000056591987,0.0017755209],"study_design_scores_gemma":[0.0020933603,0.00055794517,0.5287701,0.0006585668,0.00011280529,0.000036684978,0.0088896165,0.45683545,0.00007336192,0.0017020494,0.0001479695,0.00012207103],"about_ca_topic_score_codex":0.8560611,"about_ca_topic_score_gemma":0.35245496,"teacher_disagreement_score":0.50360614,"about_ca_system_score_codex":0.0030602997,"about_ca_system_score_gemma":0.00071718014,"threshold_uncertainty_score":0.80025774},"labels":[],"label_agreement":null},{"id":"W4283574351","doi":"10.3389/fphys.2022.904626","title":"New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease","year":2022,"lang":"en","type":"review","venue":"Frontiers in Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Myocardial infarction; Cardioprotection; Type 2 Diabetes Mellitus; Type 2 diabetes; Disease; Diabetes mellitus; Stroke (engine); Cardiology; Internal medicine; Population; Intensive care medicine; Endocrinology","score_opus":0.036924875680641456,"score_gpt":0.3217761631128741,"score_spread":0.28485128743223265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283574351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030180515,0.9967786,0.00004058413,0.000106798456,0.0007685667,0.0017378469,0.000092469294,0.00003842999,0.00013490337],"genre_scores_gemma":[0.00012252752,0.99512935,0.0008924249,0.0003835324,0.00018019778,0.0005087038,0.0019252489,0.000059348262,0.0007986586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872977,0.00009469488,0.00026745631,0.0004487242,0.000058486676,0.00040086333],"domain_scores_gemma":[0.9991899,0.00013048407,0.000105355284,0.0003855542,0.000012263692,0.00017641172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008888602,0.00039136014,0.0015453885,0.00024754816,0.0000607836,0.000011497055,0.0001260865,0.000113407616,0.00009687691],"category_scores_gemma":[0.000027368555,0.00026044092,0.00043345164,0.00022867131,0.00006597658,0.00003805441,0.00009939327,0.000211863,0.000005609988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007437771,0.00012785403,0.00015734448,0.00348783,0.001042937,0.0000018321902,0.00002709752,0.0000027518065,0.000014298342,0.000034865745,0.091085896,0.90394294],"study_design_scores_gemma":[0.0006334082,0.0003689982,0.00029316507,0.000722601,0.0011845514,4.2730932e-7,0.000025575186,0.000057115776,9.459149e-7,0.0010504263,0.99544764,0.00021512802],"about_ca_topic_score_codex":0.0000034630946,"about_ca_topic_score_gemma":2.6426684e-7,"teacher_disagreement_score":0.9043618,"about_ca_system_score_codex":0.00022467368,"about_ca_system_score_gemma":0.00026198247,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W4283782941","doi":"10.1139/cjpp-2022-0065","title":"Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks","year":2022,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Blood pressure; Glycated hemoglobin; Stroke (engine); Intensive care medicine; Heart failure; Disease; Internal medicine; Diabetes management; Type 2 diabetes; Endocrinology","score_opus":0.09998965145274515,"score_gpt":0.36549374138349955,"score_spread":0.2655040899307544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283782941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002370446,0.99224657,0.000011595477,0.00016775442,0.0032647182,0.0014351353,0.00018039272,0.000013352412,0.00031003103],"genre_scores_gemma":[0.004763922,0.9924557,0.00008272698,0.00065140566,0.0012088689,0.00036803551,0.00019747474,0.00005457434,0.00021725618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756086,0.00054370024,0.0006417786,0.0004663061,0.00011261132,0.0006747211],"domain_scores_gemma":[0.9978713,0.00035183228,0.0004560995,0.00024301895,0.000111309506,0.00096644514],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005952561,0.00046324191,0.002846901,0.00065829506,0.00032496706,0.000020329515,0.00027147352,0.00026170883,0.0023067307],"category_scores_gemma":[0.000041683303,0.0003772978,0.0016217537,0.00019267347,0.00035600536,0.000096950534,0.000059320726,0.00078700006,0.000006725105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003824129,0.00020789988,0.000043169952,0.030729454,0.046537843,0.003108431,0.00019281748,0.0005363698,0.0002841882,0.0003832967,0.06424393,0.85335016],"study_design_scores_gemma":[0.0017317281,0.00071002037,0.000037014317,0.00032025733,0.035935823,0.00019203713,0.000052920688,0.000007919033,0.0000140434295,0.00036710745,0.9603576,0.00027350063],"about_ca_topic_score_codex":0.00019707133,"about_ca_topic_score_gemma":0.0000125762235,"teacher_disagreement_score":0.8961137,"about_ca_system_score_codex":0.0003283005,"about_ca_system_score_gemma":0.004158211,"threshold_uncertainty_score":0.9998679},"labels":[],"label_agreement":null},{"id":"W4284975704","doi":"10.1016/j.jdiacomp.2022.108257","title":"Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines","year":2022,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Steno Diabetes Center Copenhagen","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Disease; Intensive care medicine; Cotransporter; Internal medicine; Endocrinology; Sodium","score_opus":0.01739849001848684,"score_gpt":0.24957874358338414,"score_spread":0.2321802535648973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284975704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9269128,0.06881008,0.000009617923,0.003121137,0.00008266555,0.0008908528,0.00011030077,0.000010495404,0.00005204728],"genre_scores_gemma":[0.99347824,0.0052522887,0.000048719434,0.0007238981,0.00008619518,0.00015294751,0.00008265094,0.000020741043,0.00015431283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899596,0.00006848381,0.0002785628,0.00019037172,0.00028576594,0.00018087061],"domain_scores_gemma":[0.9990657,0.00021153808,0.0001740624,0.00019934402,0.00017973973,0.00016962709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049479736,0.00015876183,0.00036477039,0.00010500619,0.00034972612,0.000042988035,0.00007729984,0.000021162281,0.000022463357],"category_scores_gemma":[0.000049588292,0.00009925823,0.00019234284,0.00012763285,0.00007764889,0.00007714963,0.000035180834,0.00014271197,7.695631e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057798983,0.0053545884,0.44712836,0.0009052957,0.03568222,0.000016767164,0.0033141447,0.0029307327,0.023552978,0.009792757,0.0370782,0.42846406],"study_design_scores_gemma":[0.035765313,0.007953772,0.7136443,0.00034296088,0.010561031,0.000007937121,0.00041960727,0.010178976,0.0032000255,0.005617182,0.21166107,0.0006478259],"about_ca_topic_score_codex":0.0000020477921,"about_ca_topic_score_gemma":2.7347755e-7,"teacher_disagreement_score":0.42781624,"about_ca_system_score_codex":0.000023992014,"about_ca_system_score_gemma":0.000028279333,"threshold_uncertainty_score":0.4047633},"labels":[],"label_agreement":null},{"id":"W4285012547","doi":"10.1161/circulationaha.122.060526","title":"Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”","year":2022,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute","funders":"","keywords":"Medicine; Concomitant; Cotransporter; Diabetes mellitus; Exploratory analysis; Type 2 diabetes; Internal medicine; Population; Endocrinology; Sodium","score_opus":0.038350605497576656,"score_gpt":0.28574766559193754,"score_spread":0.24739706009436088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285012547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601937,0.00015666883,0.000030913856,0.03810705,0.00008179012,0.0013623022,0.000039874132,0.000019252479,0.0000084365265],"genre_scores_gemma":[0.9376214,0.000040141615,0.00006680688,0.06176705,0.000043499153,0.00008367521,0.0002664236,0.000029304789,0.000081661194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805707,0.00040626116,0.00056147884,0.00046225518,0.00031888983,0.00019403758],"domain_scores_gemma":[0.9988076,0.0004450857,0.00025704436,0.00036860886,0.00005983432,0.00006183315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008039188,0.00022393063,0.00075930153,0.00040525413,0.0000600642,0.000054957924,0.00003933316,0.00015966843,0.000015506786],"category_scores_gemma":[0.00015235855,0.0001602907,0.000109353394,0.00048288307,0.00012282172,0.00015908803,0.000053113323,0.000344971,3.9137223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044893487,0.00008822294,0.9864272,0.000074768046,0.0013612292,0.000029259112,0.00033407315,0.000015299473,0.00087143166,0.0000033293961,0.0060135126,0.0002923552],"study_design_scores_gemma":[0.014528733,0.00053332193,0.96762145,0.00021682585,0.0042592287,8.0341437e-7,0.00007663985,0.00020485256,0.00010305172,0.000009452032,0.012222328,0.00022330655],"about_ca_topic_score_codex":0.00003390044,"about_ca_topic_score_gemma":0.00009435074,"teacher_disagreement_score":0.023659997,"about_ca_system_score_codex":0.000120605226,"about_ca_system_score_gemma":0.000030990723,"threshold_uncertainty_score":0.6536465},"labels":[],"label_agreement":null},{"id":"W4285094022","doi":"10.1021/acsptsci.2c00122","title":"Diabetes and its Complications","year":2022,"lang":"en","type":"editorial","venue":"ACS Pharmacology & Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Citation; Social media; Icon; Altmetrics; Computer science; Library science; World Wide Web; Information retrieval","score_opus":0.019325825119456626,"score_gpt":0.33448071938535834,"score_spread":0.3151548942659017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285094022","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08074251,0.0057182238,0.000015320806,0.016191352,0.87284917,0.0025566213,0.00069874874,0.00024040967,0.020987652],"genre_scores_gemma":[0.53955275,0.0020089294,0.0010012764,0.004290193,0.44019952,0.0017709414,0.004082849,0.00009420382,0.0069993236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979756,0.000033419823,0.00021022832,0.0005662724,0.0008584443,0.00035603173],"domain_scores_gemma":[0.9989708,0.00044979274,0.00008745604,0.0001305416,0.0001971992,0.0001641764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042849034,0.00018923127,0.00025944266,0.00027429982,0.0005064406,0.000030976124,0.00028890316,0.000106481886,0.00096818997],"category_scores_gemma":[0.000046823003,0.00018153791,0.000053090953,0.00047465772,0.00042709772,0.00018752796,0.00011973105,0.00038689256,0.000037173206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002611797,0.00026050833,0.0008281862,0.00009001829,0.00021896817,0.000008565063,0.00011001885,0.000022233775,0.015944775,0.0011159107,0.9790656,0.0023091156],"study_design_scores_gemma":[0.0012974973,0.00017102869,0.0057452656,0.000015053608,0.0006666352,9.999476e-7,0.0000073062743,0.00036015344,0.00094657246,0.00023589355,0.99038273,0.00017085458],"about_ca_topic_score_codex":0.0000023387965,"about_ca_topic_score_gemma":0.0000011787986,"teacher_disagreement_score":0.45881024,"about_ca_system_score_codex":0.00011574651,"about_ca_system_score_gemma":0.00057641714,"threshold_uncertainty_score":0.99994504},"labels":[],"label_agreement":null},{"id":"W4285267325","doi":"10.2139/ssrn.4109078","title":"Duration of Diabetes, Glycemic Control and Risk of Heart Failure Among Adults with Diabetes: A Cohort Study","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Cargill (Canada)","funders":"","keywords":"Glycemic; Medicine; Diabetes mellitus; Duration (music); Cohort; Internal medicine; Heart failure; Cohort study; Type 2 diabetes; Endocrinology","score_opus":0.002155646273419,"score_gpt":0.19303831972404728,"score_spread":0.1908826734506283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285267325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969024,0.0013964471,0.00003769738,0.00021334845,0.000032323755,0.0013472355,0.000011203172,0.000016306396,0.00004301984],"genre_scores_gemma":[0.9993825,0.00022044533,0.00004439119,0.000031293315,0.000036843532,0.00011359636,0.000015643933,0.000022967371,0.00013230312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979291,0.00015998186,0.0003777176,0.00021368345,0.00047334924,0.0008461791],"domain_scores_gemma":[0.99917793,0.000054787735,0.0003962082,0.0001976324,0.00009821145,0.00007522208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011757575,0.00016314811,0.0004805332,0.00018215989,0.00014990314,0.000011341974,0.000082866936,0.000025446805,0.000030714524],"category_scores_gemma":[0.00003387368,0.00012494672,0.000084450185,0.00021605997,0.00006811586,0.00010887415,0.000042085798,0.0007370318,5.923432e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006963588,0.0006404097,0.9940071,0.00003751431,0.002624968,0.0000021572162,0.00023897308,0.000040695184,0.00029717947,0.000119920514,0.000080382866,0.001214324],"study_design_scores_gemma":[0.01692985,0.021370085,0.9516356,0.00009172095,0.0026091156,0.000011801728,0.0059573366,0.0004459435,0.00016036694,0.0005107814,0.000120537174,0.00015685502],"about_ca_topic_score_codex":0.00007159148,"about_ca_topic_score_gemma":0.00051881606,"teacher_disagreement_score":0.04237151,"about_ca_system_score_codex":0.00034142716,"about_ca_system_score_gemma":0.00033104344,"threshold_uncertainty_score":0.50951797},"labels":[],"label_agreement":null},{"id":"W4286308558","doi":"10.1055/s-0042-1746295","title":"Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial","year":2022,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"","keywords":"Empagliflozin; EMPA; Medicine; Diabetes mellitus; Internal medicine; Type 2 diabetes; Type 2 Diabetes Mellitus; Kidney disease; Cardiology; Endocrinology","score_opus":0.016080965894199394,"score_gpt":0.2427321547403872,"score_spread":0.22665118884618782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286308558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944431,0.0024587521,0.0000018860934,0.00089498196,0.0003806111,0.0013359833,0.00007444715,0.000047169004,0.00036307477],"genre_scores_gemma":[0.9981274,0.00007780694,0.00010728367,0.00087352184,0.00002820961,0.00013636568,0.00029185286,0.000022109187,0.00033542604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980421,0.00024154896,0.00037950234,0.00035532587,0.00067404925,0.00030745578],"domain_scores_gemma":[0.99870366,0.0004088462,0.00019064441,0.00051661755,0.000082071914,0.00009817164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039978776,0.00022056716,0.0008554205,0.00013979849,0.00011705401,0.00001919762,0.00017078288,0.00007781763,0.000047172005],"category_scores_gemma":[0.00067092956,0.00013587456,0.00017564434,0.00034717517,0.00006137146,0.00008498266,0.0001925693,0.0002268576,0.0000045609168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009365769,0.0006302858,0.99118185,0.000024195457,0.0028935662,0.0000048640477,0.00023250778,0.00002365383,0.0000049027503,0.00007306337,0.0011650393,0.0028294818],"study_design_scores_gemma":[0.03571382,0.0014365356,0.94700646,0.0000243684,0.0015377377,1.8602082e-8,0.00021655703,0.000021259462,0.0000766077,0.0002574295,0.013528694,0.00018050527],"about_ca_topic_score_codex":0.000112448724,"about_ca_topic_score_gemma":0.000019473335,"teacher_disagreement_score":0.0441754,"about_ca_system_score_codex":0.00023932492,"about_ca_system_score_gemma":0.00007562343,"threshold_uncertainty_score":0.5540804},"labels":[],"label_agreement":null},{"id":"W4286308701","doi":"10.1055/s-0042-1746271","title":"Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses","year":2022,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Internal medicine; Body weight; Subgroup analysis; Diabetes mellitus; Endocrinology; Meta-analysis","score_opus":0.030266006416621218,"score_gpt":0.3196822911872899,"score_spread":0.2894162847706687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286308701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546726,0.007763442,0.00038002664,0.0028510222,0.00012339478,0.0012112486,0.0002244629,0.00016669801,0.0018124789],"genre_scores_gemma":[0.9928996,0.0009840642,0.0012013916,0.00076267426,0.000038024336,0.000115526615,0.000516423,0.000044146815,0.0034381293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974806,0.00020895315,0.0005760064,0.00065574644,0.00044435402,0.00063437934],"domain_scores_gemma":[0.99835306,0.0005652875,0.00024026324,0.00052870554,0.00008533043,0.00022735684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000774195,0.0003786952,0.00094590784,0.00031449413,0.00028294904,0.000029603387,0.00019194023,0.00009732703,0.00015864766],"category_scores_gemma":[0.00028942103,0.00033075042,0.00013792155,0.0004909789,0.00028594807,0.00009652233,0.00047221428,0.00028399547,0.0000039083357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058966638,0.006023088,0.5141021,0.0018093532,0.00694153,0.00065453374,0.0011055518,0.0003580461,0.024240294,0.0063636024,0.12386797,0.30863723],"study_design_scores_gemma":[0.047178708,0.012291534,0.4485279,0.0003372881,0.009993456,0.00004581662,0.0059595304,0.010595593,0.013085026,0.0019564661,0.4477099,0.0023187895],"about_ca_topic_score_codex":0.00017363476,"about_ca_topic_score_gemma":0.000020983196,"teacher_disagreement_score":0.3238419,"about_ca_system_score_codex":0.00018670897,"about_ca_system_score_gemma":0.00008680038,"threshold_uncertainty_score":0.99991447},"labels":[],"label_agreement":null},{"id":"W4286310808","doi":"10.1055/s-0042-1746288","title":"Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa","year":2022,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine","score_opus":0.026838351273948995,"score_gpt":0.2757442942263151,"score_spread":0.2489059429523661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286310808","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45434597,0.52041507,0.00011329606,0.010883184,0.0051822336,0.004137136,0.00031678446,0.000546672,0.0040596346],"genre_scores_gemma":[0.96670777,0.008939448,0.00037636133,0.015221618,0.00071913685,0.0014128411,0.00073733565,0.0004230618,0.005462432],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889656,0.0016310043,0.0019503108,0.0024566888,0.0015814579,0.0034149527],"domain_scores_gemma":[0.9948802,0.0011061333,0.0008159312,0.002239087,0.0003878558,0.00057077286],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0022580184,0.0018297607,0.0032101027,0.0015814087,0.00088600407,0.0002483184,0.0014868248,0.00044544364,0.0015812506],"category_scores_gemma":[0.00039819823,0.0016387603,0.0011693994,0.0021119362,0.00060282246,0.00039440423,0.0013925182,0.0019341826,0.0011756157],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018293052,0.0083242,0.7277775,0.000720791,0.06422023,0.0031250261,0.0042568315,0.0009722764,0.0013999231,0.00083475205,0.045850575,0.14068861],"study_design_scores_gemma":[0.037736464,0.008415854,0.14519857,0.001017003,0.045076203,0.0000041128087,0.004908257,0.013659241,0.0016191574,0.0018471081,0.7352609,0.0052571055],"about_ca_topic_score_codex":0.00019987869,"about_ca_topic_score_gemma":0.00015459335,"teacher_disagreement_score":0.6894103,"about_ca_system_score_codex":0.001818777,"about_ca_system_score_gemma":0.00038483302,"threshold_uncertainty_score":0.9996021},"labels":[],"label_agreement":null},{"id":"W4286311454","doi":"10.1055/s-0042-1746277","title":"Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie","year":2022,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine","score_opus":0.039469074966253105,"score_gpt":0.2865539012631247,"score_spread":0.2470848262968716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286311454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71025914,0.27431133,0.00011842712,0.003721448,0.0041466546,0.003651624,0.00023490697,0.00037937003,0.00317706],"genre_scores_gemma":[0.9756242,0.00711464,0.00089202006,0.0080602085,0.000476907,0.001763192,0.0008636015,0.00028581097,0.004919405],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99183005,0.0010716347,0.0014433672,0.0018230194,0.0011888538,0.002643084],"domain_scores_gemma":[0.9963679,0.00076229207,0.0006139122,0.0014668345,0.00038344547,0.0004056164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016560924,0.0013177908,0.0020170845,0.0012039051,0.0008880743,0.00017805213,0.00094025425,0.00038505963,0.0015964821],"category_scores_gemma":[0.00035056038,0.0012013565,0.0006922982,0.0014334595,0.000681165,0.00047218526,0.0012362768,0.0012100152,0.0007441975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013494141,0.006026597,0.6603617,0.0006272093,0.020040361,0.00083038525,0.005942991,0.0004328521,0.0011362177,0.00069404684,0.025270792,0.27728745],"study_design_scores_gemma":[0.028910527,0.011889634,0.3970341,0.0014940476,0.01830359,0.0000063363736,0.00759245,0.0042381687,0.0028731662,0.0066405893,0.51654077,0.0044766422],"about_ca_topic_score_codex":0.00026248954,"about_ca_topic_score_gemma":0.00014379396,"teacher_disagreement_score":0.49126995,"about_ca_system_score_codex":0.0017232522,"about_ca_system_score_gemma":0.00022977193,"threshold_uncertainty_score":0.9999573},"labels":[],"label_agreement":null},{"id":"W4286311985","doi":"10.1055/s-0042-1746380","title":"Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial","year":2022,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Gout; Uric acid; Internal medicine; EMPA; Type 2 diabetes; Placebo; Diabetes mellitus; Endocrinology; Chemistry; Alternative medicine","score_opus":0.08393320591649933,"score_gpt":0.31648631741784067,"score_spread":0.23255311150134134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286311985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927646,0.0012005265,0.000036655216,0.002898251,0.0005561685,0.001727414,0.00012760458,0.00010456506,0.0005841951],"genre_scores_gemma":[0.9954589,0.000033140383,0.00033628044,0.0020092968,0.00009173434,0.00042281454,0.00012060144,0.00002531555,0.0015019069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831456,0.00020741968,0.0003750297,0.0003741793,0.00039865923,0.0003301647],"domain_scores_gemma":[0.9979688,0.0012321386,0.00017460852,0.0005070195,0.000034438315,0.00008301628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033280885,0.0002408241,0.0005705324,0.00012365737,0.00026306408,0.00002190693,0.00024968563,0.000068478934,0.000091920105],"category_scores_gemma":[0.000472399,0.00016409662,0.00016459753,0.00032745278,0.000113635324,0.000060935145,0.00027604407,0.00027328407,0.000016194914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008353344,0.0050594164,0.9002764,0.0003759536,0.003512514,0.00021586388,0.0022568097,0.00007185284,0.00809124,0.011761029,0.0211255,0.03890003],"study_design_scores_gemma":[0.037375018,0.0038490254,0.9332206,0.00005410457,0.0017010544,7.236689e-7,0.0004015794,0.00008870967,0.005203016,0.0017853501,0.016025377,0.00029539134],"about_ca_topic_score_codex":0.00006256249,"about_ca_topic_score_gemma":0.000009699337,"teacher_disagreement_score":0.038604636,"about_ca_system_score_codex":0.00013082527,"about_ca_system_score_gemma":0.000056067114,"threshold_uncertainty_score":0.6691666},"labels":[],"label_agreement":null},{"id":"W4286312234","doi":"10.1055/s-0042-1746335","title":"Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies","year":2022,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Semaglutide; Observational study; Medicine; Real world evidence; Type 2 diabetes; Real world data; Pooled analysis; Diabetes mellitus; Meta-analysis; Internal medicine; Demography; Pediatrics; Endocrinology; Data science; Computer science","score_opus":0.11644691352645586,"score_gpt":0.33386604410343934,"score_spread":0.21741913057698348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286312234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975046,0.00061119185,0.000005034765,0.0002946207,0.00014224777,0.0007027809,0.00010325269,0.000060616185,0.0005756522],"genre_scores_gemma":[0.9963874,0.00014776937,0.0017868341,0.00013925078,0.000007066966,0.000112365204,0.00028238405,0.00002190903,0.0011149877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797475,0.00017558511,0.00056843105,0.00039252898,0.0004951672,0.00039353356],"domain_scores_gemma":[0.9984447,0.00031677334,0.00037371402,0.00055469223,0.0002361672,0.000074001866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025403657,0.00024934005,0.001141524,0.0013483164,0.00010312717,0.000008179101,0.00014113306,0.000042061314,0.00010108783],"category_scores_gemma":[0.00019710662,0.00020089524,0.0002073559,0.0032597487,0.00015105632,0.000094592775,0.00027500757,0.00017444493,0.0000023893442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002008215,0.00092181924,0.9709209,0.00010967887,0.007986483,0.00006238427,0.0006332101,0.012066784,0.00021547785,0.00064054277,0.001104054,0.0051378417],"study_design_scores_gemma":[0.0018215749,0.0021606416,0.97540563,0.00011077113,0.012922656,1.9370918e-7,0.0025770583,0.0023310327,0.0004932729,0.00014037798,0.0017601382,0.0002766299],"about_ca_topic_score_codex":0.0005835388,"about_ca_topic_score_gemma":0.001886162,"teacher_disagreement_score":0.009735752,"about_ca_system_score_codex":0.00034907382,"about_ca_system_score_gemma":0.00008558301,"threshold_uncertainty_score":0.81922704},"labels":[],"label_agreement":null},{"id":"W4286592247","doi":"10.1161/circulationaha.122.059150","title":"Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Boehringer Ingelheim (Canada); Toronto General Hospital","funders":"","keywords":"Ramipril; Empagliflozin; Medicine; Renal function; Urology; Effective renal plasma flow; Renal blood flow; Internal medicine; Endocrinology; Aliskiren; Tubuloglomerular feedback; Blood pressure; Renin–angiotensin system; Diabetes mellitus; Type 2 diabetes","score_opus":0.007226421578070862,"score_gpt":0.20524884725718345,"score_spread":0.1980224256791126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286592247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984953,0.0005111052,0.00021276949,0.0001982082,0.00004434283,0.00036851168,6.0807605e-7,0.00002203163,0.00014713634],"genre_scores_gemma":[0.9996235,0.000012054258,0.00011617572,0.00011810913,0.000017395805,0.000016859974,0.00006377054,0.000006739367,0.00002543663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956995,0.000027775184,0.00009748216,0.00011390742,0.00012360117,0.00006728088],"domain_scores_gemma":[0.99980044,0.000026064132,0.000050690534,0.00007535604,0.00001989898,0.00002756266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102267055,0.0000523281,0.000114538096,0.00007603425,0.00006601313,0.000005059228,0.0000065525815,0.000015363212,0.000013542311],"category_scores_gemma":[0.00001963604,0.00005308122,0.000028774934,0.00008094584,0.000018969471,0.000045578734,0.00003685135,0.00003398035,5.9767405e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013791866,0.0003969323,0.5241958,0.0009590152,0.00054718094,0.00005980973,0.0015146249,0.00021523416,0.4256068,0.003835751,0.0004974093,0.042033568],"study_design_scores_gemma":[0.003184946,0.00027373637,0.9791422,0.00007578438,0.00033781957,0.000005491263,0.00004940724,0.004271225,0.0117810955,0.00046852138,0.00033926757,0.00007052669],"about_ca_topic_score_codex":0.00000974313,"about_ca_topic_score_gemma":3.5236715e-7,"teacher_disagreement_score":0.4549464,"about_ca_system_score_codex":0.000032731947,"about_ca_system_score_gemma":0.0000056871195,"threshold_uncertainty_score":0.21645893},"labels":[],"label_agreement":null},{"id":"W4287307425","doi":"10.1111/dom.14823","title":"The <scp>Real‐World</scp> Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes ( <scp>TROPHIES</scp> ): Patient disposition, clinical characteristics and treatment persistence at 12 months","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Liraglutide; Dulaglutide; Observational study; Type 2 diabetes; Persistence (discontinuity); Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.020050611484245643,"score_gpt":0.24656024290133,"score_spread":0.22650963141708436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287307425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950103,0.0018556883,3.4250775e-7,0.00015113178,0.0001262297,0.0026321504,0.00012321894,0.000030145637,0.000070794056],"genre_scores_gemma":[0.9977255,0.00079317606,0.00014139185,0.00029102288,0.000027527092,0.00032260333,0.00020306332,0.000029597479,0.00046614205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974639,0.00031651332,0.00061053206,0.00057311147,0.0005323312,0.00050361094],"domain_scores_gemma":[0.99815327,0.000691332,0.00044946081,0.00033450482,0.00016361888,0.00020778735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047943584,0.00036852297,0.0010031712,0.00017855135,0.00066364114,0.000049355647,0.000089319874,0.000038228784,0.0000022706797],"category_scores_gemma":[0.000148092,0.0002302355,0.00006453519,0.00034700288,0.00028579353,0.00015128904,0.0002658175,0.00018194037,5.7774315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007491634,0.0034118104,0.9885796,0.0000659129,0.0008511639,0.000005370111,0.0026686203,0.00000767836,0.0000047409258,0.00017941157,0.000064546875,0.0040862574],"study_design_scores_gemma":[0.0062388643,0.0063263085,0.9834096,0.000059971266,0.00069842034,2.6593847e-7,0.0017355679,0.00005943753,0.000023458162,0.00003954188,0.0013378512,0.00007071135],"about_ca_topic_score_codex":0.00013149796,"about_ca_topic_score_gemma":0.00038557462,"teacher_disagreement_score":0.0061639477,"about_ca_system_score_codex":0.00019598355,"about_ca_system_score_gemma":0.000078093915,"threshold_uncertainty_score":0.9388731},"labels":[],"label_agreement":null},{"id":"W4288032971","doi":"10.1016/j.jchf.2022.03.006","title":"Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines","year":2022,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Heart, Lung, and Blood Institute; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Canadian Institutes of Health Research; Canada Research Chairs; National Institutes of Health; Amgen; Boehringer Ingelheim; Genentech; Bristol-Myers Squibb; AstraZeneca; AbbVie; Innovációs és Technológiai Minisztérium; Roche","keywords":"Medicine; Heart failure; Internal medicine; Ejection fraction; Cardiotoxicity; Cardiomyopathy; Cancer; Incidence (geometry); Diabetes mellitus; Cardiology; Chemotherapy; Endocrinology","score_opus":0.0063553635463102845,"score_gpt":0.2321019812078786,"score_spread":0.2257466176615683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288032971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959876,0.00011103037,8.583699e-7,0.0021371797,0.00011781713,0.00097625435,0.0000697616,0.00013189789,0.0004676133],"genre_scores_gemma":[0.9967106,0.000018000965,0.00027268264,0.0003977895,0.000058895635,0.0001873974,0.00049204275,0.000039564336,0.0018230543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986543,0.000049468254,0.00023349165,0.00035539013,0.0003968036,0.00031051476],"domain_scores_gemma":[0.99940807,0.000033735534,0.000064993525,0.0002779111,0.00004686099,0.00016845622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010583288,0.00024375596,0.00048094665,0.00014703794,0.00022199756,0.000029791634,0.00004763741,0.00004639814,0.00017487312],"category_scores_gemma":[0.0000071640457,0.00017804728,0.00012058964,0.00019761382,0.00008395611,0.00013921196,0.00004809891,0.00016825322,0.000014462272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010387672,0.00043963426,0.98018116,0.00005024757,0.00027946287,0.000039188566,0.00018636254,0.0000018094398,0.00010352224,0.000010759257,0.017224908,0.0013790624],"study_design_scores_gemma":[0.0031087874,0.0008205933,0.8823942,0.00003171409,0.00033301362,0.0000012687688,0.00035039996,0.00000603603,0.00075024966,0.0000025986267,0.11202212,0.00017902847],"about_ca_topic_score_codex":0.00017724796,"about_ca_topic_score_gemma":0.00003957643,"teacher_disagreement_score":0.09778697,"about_ca_system_score_codex":0.0000642584,"about_ca_system_score_gemma":0.00002447924,"threshold_uncertainty_score":0.72605574},"labels":[],"label_agreement":null},{"id":"W4288045904","doi":"10.1016/j.ijcard.2022.07.017","title":"Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group","year":2022,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Mylan; Kowa Company; Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Servier; Amgen","keywords":"Medicine; Liraglutide; Dulaglutide; Semaglutide; Glucagon-like peptide 1 receptor; Incretin; Glucagon-like peptide-1; Type 2 Diabetes Mellitus; Internal medicine; Clinical trial; Type 2 diabetes; Diabetes mellitus; Exenatide; Endocrinology; Receptor; Agonist","score_opus":0.05594745286082843,"score_gpt":0.3558025854240979,"score_spread":0.29985513256326946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288045904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89488345,0.007471472,0.0028203377,0.08662511,0.0054019564,0.0006729856,0.00055599806,0.000037015678,0.0015316979],"genre_scores_gemma":[0.98195755,0.001259731,0.009908431,0.003490824,0.002499512,0.00005380736,0.00053121196,0.000040498104,0.00025843474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99582154,0.0017994634,0.001174677,0.0003139819,0.00072106504,0.00016929036],"domain_scores_gemma":[0.99508804,0.0033395216,0.0007988184,0.00030559258,0.0003689975,0.0000990538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039407723,0.00019118232,0.001029785,0.000099947494,0.00014436977,0.0000696618,0.0003273545,0.000054412238,0.00008013983],"category_scores_gemma":[0.0019067221,0.00011573814,0.0006336612,0.000080218284,0.00011553197,0.00016406008,0.00017961899,0.0004290796,0.000012439187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009350245,0.00055746373,0.33938357,0.000008762234,0.097355366,0.0008536008,0.009876204,0.0007551777,0.00064983114,0.00011607552,0.023212617,0.5178811],"study_design_scores_gemma":[0.012435128,0.0011536826,0.023016911,0.0001252815,0.0024279861,0.000070088245,0.005215293,0.000088962435,0.000016661277,0.00016073528,0.95510375,0.00018550048],"about_ca_topic_score_codex":0.00022881781,"about_ca_topic_score_gemma":0.000012372531,"teacher_disagreement_score":0.93189114,"about_ca_system_score_codex":0.00009896739,"about_ca_system_score_gemma":0.00008706948,"threshold_uncertainty_score":0.47196645},"labels":[],"label_agreement":null},{"id":"W4289639427","doi":"10.1016/j.ekir.2022.07.167","title":"Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs","year":2022,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Post-hoc analysis; Agonist; Baseline (sea); Internal medicine; Hemoglobin; Reduction (mathematics); Urology; Endocrinology; Receptor; Diabetes mellitus; Type 2 diabetes; Mathematics","score_opus":0.006053277513093916,"score_gpt":0.23155451039196429,"score_spread":0.22550123287887036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289639427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635036,0.0001025014,0.0000434619,0.032818962,0.00033191888,0.0007285379,0.00009912527,0.000018418084,0.0023534729],"genre_scores_gemma":[0.9876138,0.000018381024,0.00023756066,0.0009494108,0.00004295502,0.00009071814,0.0005712983,0.000011497047,0.0104643665],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983799,0.0000542877,0.0003595446,0.00024655,0.0008448451,0.000114908245],"domain_scores_gemma":[0.9987793,0.000021851105,0.00045745567,0.0003508826,0.00031615605,0.00007433419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056301604,0.000113034104,0.0002169501,0.00018358044,0.00010101292,0.000019021527,0.00010472633,0.000020893487,0.0004887339],"category_scores_gemma":[0.00011492322,0.00006508255,0.00015119843,0.00050230086,0.00010849675,0.000041689822,0.00017968546,0.000107426415,4.6902414e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032580963,0.005524155,0.61343235,0.00041333085,0.036186274,0.00053807005,0.0062891804,0.0012730953,0.021853685,0.0036307697,0.23973739,0.0678636],"study_design_scores_gemma":[0.0046065105,0.0028469726,0.16659339,0.00032093673,0.012749529,0.0006685173,0.013058781,0.0029841205,0.020583207,0.00033007876,0.77470034,0.0005576306],"about_ca_topic_score_codex":0.00025168157,"about_ca_topic_score_gemma":0.000021122152,"teacher_disagreement_score":0.53496295,"about_ca_system_score_codex":0.00020785914,"about_ca_system_score_gemma":0.00015982296,"threshold_uncertainty_score":0.5351293},"labels":[],"label_agreement":null},{"id":"W4289868958","doi":"10.1161/jaha.121.025045","title":"Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Relypsa; National Health and Medical Research Council; Medical Research Council; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Servier; Novo Nordisk; Eisai; Innovent Biologics; Amarin Corporation; Regeneron Pharmaceuticals; Heart Research Australia; Alnylam Pharmaceuticals; Daiichi Sankyo Europe; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Canagliflozin; Internal medicine; Post-hoc analysis; Hazard ratio; Empagliflozin; Myocardial infarction; Diabetes mellitus; Type 2 diabetes; Unstable angina; Albuminuria; Renal function; Cardiology; Endocrinology; Confidence interval","score_opus":0.0028488416376645253,"score_gpt":0.21358689342748063,"score_spread":0.2107380517898161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289868958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702483,0.00037958144,4.074952e-7,0.0019413965,0.00009443372,0.0004972614,0.00005201889,0.0000025394345,0.000007544095],"genre_scores_gemma":[0.99949825,0.000014037148,0.000007177306,0.0002794867,0.00011904203,0.00001937866,0.00001662672,0.000007144326,0.00003886104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808306,0.0006481427,0.00021404863,0.000102927705,0.0008213266,0.00013050232],"domain_scores_gemma":[0.9988154,0.00042985534,0.0004126659,0.00020450754,0.000066535235,0.000070994836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008914077,0.00008817103,0.0005740772,0.00011643883,0.00008109492,0.000014770626,0.00008425342,0.000008923621,0.000014412516],"category_scores_gemma":[0.00049314543,0.00004670675,0.00040442072,0.00055049045,0.000035093166,0.000043624703,0.000057168963,0.00015256005,2.7277875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072054025,0.00011715723,0.98290384,0.000008820898,0.004801484,0.000002241497,0.00012819201,0.001584864,0.000028369635,4.0257743e-7,0.0005182061,0.0027010394],"study_design_scores_gemma":[0.01301625,0.0073434934,0.9735096,0.000052624986,0.005374011,7.820217e-8,0.00006267294,0.00016796192,0.000026294536,0.0000017906822,0.00039877853,0.000046440437],"about_ca_topic_score_codex":0.00067427225,"about_ca_topic_score_gemma":0.000027137718,"teacher_disagreement_score":0.009394216,"about_ca_system_score_codex":0.00077602733,"about_ca_system_score_gemma":0.00011406747,"threshold_uncertainty_score":0.20292845},"labels":[],"label_agreement":null},{"id":"W4290047908","doi":"10.18433/jpps32879","title":"Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Propidium iodide; Apoptosis; Cell growth; IC50; Chemistry; Cisplatin; Cell culture; Cancer cell; Annexin; MTT assay; Sulforhodamine B; Dapagliflozin; Pharmacology; Cancer; Cancer research; Molecular biology; Biology; Programmed cell death; Medicine; Biochemistry; Endocrinology; Internal medicine; Cytotoxicity; In vitro; Chemotherapy; Diabetes mellitus; Type 2 Diabetes Mellitus","score_opus":0.17138189033056733,"score_gpt":0.4102798452016666,"score_spread":0.23889795487109927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290047908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96654207,0.015221018,0.000054558426,0.015445653,0.0007807007,0.00062026427,0.00001134262,0.000012330625,0.0013120505],"genre_scores_gemma":[0.99070865,0.0051308274,0.0005724125,0.002760505,0.00040608385,0.0000896843,0.0000012457084,0.000011391001,0.00031917714],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982707,0.0000598716,0.00040928222,0.00015643443,0.0007819071,0.00032184046],"domain_scores_gemma":[0.9991815,0.00013870127,0.00022433892,0.00007818192,0.000089290654,0.00028797274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009588937,0.00013050715,0.00027669934,0.00012913955,0.00026241536,0.000026857493,0.00037680787,0.0000064120636,0.0019469216],"category_scores_gemma":[0.000023122017,0.000075761825,0.00026181404,0.00037815433,0.00017630548,0.00030881667,0.000053525513,0.00023037272,0.000002249893],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026919085,0.0009858479,0.026762405,0.000047700752,0.00065056235,0.000038958024,0.0016639716,0.00042330835,0.11629221,0.0009846528,0.0041008703,0.8453576],"study_design_scores_gemma":[0.0039148326,0.0008251686,0.00047004927,0.000017986451,0.00029401213,0.000018622744,0.0005500484,0.0011196011,0.2450502,0.0005851299,0.74708235,0.00007201846],"about_ca_topic_score_codex":0.00006540533,"about_ca_topic_score_gemma":0.0000010882067,"teacher_disagreement_score":0.8452856,"about_ca_system_score_codex":0.000074310316,"about_ca_system_score_gemma":0.00043579834,"threshold_uncertainty_score":0.99896544},"labels":[],"label_agreement":null},{"id":"W4290775002","doi":"10.1016/j.cjca.2022.05.011","title":"The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Université de Montréal; Montreal Heart Institute; University of Manitoba; University of British Columbia; McMaster University","funders":"Canadian Cardiovascular Society","keywords":"Medicine; Glucagon-like peptide-1; Meta-analysis; Dipeptidyl peptidase-4; Internal medicine; Endocrinology; Pharmacology; Diabetes mellitus; Type 2 diabetes","score_opus":0.038389299044466155,"score_gpt":0.29336468079760303,"score_spread":0.2549753817531369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290775002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046938407,0.99632186,0.000008121345,0.00016225205,0.00035832528,0.0023257392,0.00018134192,0.0000037255134,0.0005916899],"genre_scores_gemma":[0.0015633237,0.99744654,0.000012045004,0.00018531375,0.000072294686,0.00026641862,0.00010058004,0.00004031012,0.00031316717],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99528134,0.002215812,0.0014550438,0.0003454282,0.00033319753,0.00036919882],"domain_scores_gemma":[0.9962041,0.0014298978,0.0011059014,0.0006057029,0.00016169771,0.0004927282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003768646,0.00052315416,0.01265449,0.0007137491,0.00015954183,0.000031262476,0.00025492941,0.0001645629,0.000044425917],"category_scores_gemma":[0.00029565775,0.0002709325,0.00467641,0.0004401004,0.00027728642,0.000039450377,0.000033110504,0.000487045,0.0000030171657],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030537678,0.000007604573,0.0002510538,0.4447888,0.5482557,0.00031887807,0.00002654303,0.0000044927574,8.0806295e-8,0.000087152875,0.0014057582,0.004823419],"study_design_scores_gemma":[0.0002579799,0.0003121469,0.00011299988,0.008837416,0.5938925,0.00014509406,0.000020494917,3.269133e-8,2.943049e-7,0.000004708415,0.3962814,0.00013493966],"about_ca_topic_score_codex":0.0001420016,"about_ca_topic_score_gemma":0.00017304486,"teacher_disagreement_score":0.43595138,"about_ca_system_score_codex":0.00034790605,"about_ca_system_score_gemma":0.00069055386,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W4290776063","doi":"10.1016/j.cjca.2022.04.029","title":"2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults","year":2022,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Population Health Research Institute; McMaster University; Selkirk College; University of Ottawa; McGill University; McGill University Health Centre; Diabetes Canada; Humber River Regional Hospital; LMC Diabetes & Endocrinology (Canada); St. Michael's Hospital; Ottawa Hospital; Libin Cardiovascular Institute of Alberta; University Health Network; University of Toronto; Trillium Health Centre; University of Manitoba; Institut universitaire de cardiologie et de pneumologie de Québec; University of British Columbia; Montreal Heart Institute; University of Alberta; Université Laval; University of Saskatchewan; Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Guideline; Kidney disease; Heart failure; Ejection fraction; Renal function; Diabetes mellitus; Intensive care medicine; Myocardial infarction; Population; Cardiology; Endocrinology; Pathology","score_opus":0.015923970759126105,"score_gpt":0.22488482608630875,"score_spread":0.20896085532718264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290776063","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15341264,0.098350026,0.004186462,0.64428574,0.039213978,0.023172481,0.035222113,0.00006917423,0.002087403],"genre_scores_gemma":[0.30934176,0.046881706,0.08108518,0.29720104,0.19432606,0.004855304,0.053611543,0.0023618885,0.010335524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713784,0.00024991727,0.0010499328,0.00046918239,0.00030567238,0.00078747445],"domain_scores_gemma":[0.99765074,0.00014010535,0.00055539305,0.0004419033,0.00061618834,0.0005956931],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014269366,0.00037907515,0.0018758592,0.0010341236,0.00018393133,0.000027833525,0.00017863131,0.0006272833,0.00003367003],"category_scores_gemma":[0.00033721898,0.00037535632,0.0020489788,0.00023512852,0.00019004759,0.00010023962,0.000026483141,0.0010579703,4.956776e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018847178,0.000002769606,0.0032780562,0.0003442424,0.005577608,0.00026692558,0.00017436678,0.0009393211,0.000006348911,0.000004768345,0.97415656,0.015060546],"study_design_scores_gemma":[0.003303484,0.0010933771,0.00057981466,0.0002103372,0.0027168514,0.00025177246,0.00026255366,0.000036759404,0.000018848947,0.00003995115,0.9912106,0.00027565967],"about_ca_topic_score_codex":0.09577567,"about_ca_topic_score_gemma":0.042502627,"teacher_disagreement_score":0.34708467,"about_ca_system_score_codex":0.0018114512,"about_ca_system_score_gemma":0.0030699319,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W4290791415","doi":"10.1016/j.jcjd.2022.08.002","title":"Patterns and Patients’ Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With Type 2 Diabetes: A Population-based Cohort Study","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"Alberta Health; M.S.I. Foundation","keywords":"Medicine; Diabetes mellitus; Cohort; Odds ratio; Type 2 diabetes; Retrospective cohort study; Internal medicine; Confidence interval; Medical prescription; Cohort study; Logistic regression; Population; Renal function; Endocrinology; Environmental health; Pharmacology","score_opus":0.007189290255387364,"score_gpt":0.1836600541734173,"score_spread":0.17647076391802993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290791415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986225,0.000047281148,5.9652143e-7,0.00003974975,0.00013892906,0.0009258045,0.00020816394,0.000009496239,0.0000075235585],"genre_scores_gemma":[0.99917954,0.0000016688546,0.000030842275,0.00016645223,0.000026208936,0.000030598952,0.0004967466,0.000039320166,0.000028596342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998488,0.0000821067,0.00046205585,0.00019027828,0.0004390687,0.0003384603],"domain_scores_gemma":[0.9983699,0.000090509,0.0005468981,0.00018114291,0.00038068203,0.00043091422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021832273,0.00021030045,0.00055688975,0.00041002283,0.0001347009,0.000039633553,0.0000781507,0.000035034613,0.00006887329],"category_scores_gemma":[0.00008185562,0.00016564858,0.000059297246,0.00030398238,0.00006198016,0.00016530055,0.0000110260735,0.000200426,2.0182854e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006800509,0.0005788435,0.99711406,0.000073750656,0.00085145177,0.00005595422,0.00039675547,0.000029322944,0.0000043736854,5.662902e-7,0.00007493297,0.0007519805],"study_design_scores_gemma":[0.004233129,0.0065368284,0.9869619,0.0005324869,0.0010844036,1.7120603e-7,0.00027935646,0.00009754832,0.000050929837,6.779318e-7,0.000050761944,0.00017180502],"about_ca_topic_score_codex":0.0013473389,"about_ca_topic_score_gemma":0.012538241,"teacher_disagreement_score":0.011190902,"about_ca_system_score_codex":0.0002583483,"about_ca_system_score_gemma":0.00029368667,"threshold_uncertainty_score":0.69966334},"labels":[],"label_agreement":null},{"id":"W4292264737","doi":"10.1016/j.jdiacomp.2022.108285","title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Retinopathy; Diabetic retinopathy; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Meta-analysis; Internal medicine; Receptor; Endocrinology; Agonist","score_opus":0.057036602041967345,"score_gpt":0.30437699293217574,"score_spread":0.2473403908902084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292264737","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009911602,0.99562943,0.0000015430937,0.00022328987,0.000018076655,0.0029879273,0.00005731802,0.000009083224,0.00008219132],"genre_scores_gemma":[0.00075637706,0.99750364,0.0007226335,0.00010734273,0.000012485045,0.00060780975,0.00014282843,0.000042224743,0.00010465193],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972191,0.00030937733,0.0012516424,0.00037494063,0.000597352,0.0002475747],"domain_scores_gemma":[0.9969325,0.00024117081,0.001662079,0.0006381373,0.0003608161,0.00016530676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009876974,0.00042779974,0.007191857,0.00062591943,0.000088543384,0.00003895424,0.00020148365,0.00007065341,0.000062825646],"category_scores_gemma":[0.00009092767,0.00022769147,0.0012832412,0.0014282315,0.00006431891,0.00010928224,0.00010647849,0.00028691802,0.0000015554266],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007834795,0.00043186292,0.0005000221,0.6980454,0.2866914,0.000007400789,0.000055480297,0.000009195422,7.2374706e-7,0.000083459774,0.00011501629,0.014052224],"study_design_scores_gemma":[0.0003932004,0.0012642497,0.00027073867,0.068193056,0.88877463,0.000017207147,0.000026587903,0.0000071920717,0.0000016639696,0.0000026188548,0.040804937,0.0002438964],"about_ca_topic_score_codex":0.0000011026162,"about_ca_topic_score_gemma":0.0000018004131,"teacher_disagreement_score":0.6298523,"about_ca_system_score_codex":0.00007903505,"about_ca_system_score_gemma":0.00011652903,"threshold_uncertainty_score":0.92849886},"labels":[],"label_agreement":null},{"id":"W4292495782","doi":"10.1093/eurheartj/ehab724.2650","title":"Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Metformin; Internal medicine; Propensity score matching; Post-hoc analysis; Type 2 diabetes; Placebo; Clinical trial; Diabetes mellitus; Endocrinology; Insulin","score_opus":0.06261069038348649,"score_gpt":0.32526278224751015,"score_spread":0.26265209186402366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292495782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910776,0.0016573385,0.00013348118,0.003640949,0.00040090308,0.0002974229,0.000031368414,0.000023384644,0.0027375724],"genre_scores_gemma":[0.9763933,0.00040488297,0.003196629,0.0031881048,0.0005507691,0.0000039624756,0.000059599104,0.00007245729,0.016130311],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814576,0.0004726294,0.00039206832,0.0001837979,0.0005529617,0.00025279287],"domain_scores_gemma":[0.99895597,0.00011892284,0.00014767879,0.00037604588,0.00023026076,0.00017115552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006402858,0.0001818312,0.00046518174,0.0000863116,0.00012491625,0.00007645262,0.00011087959,0.000019429026,0.00027451286],"category_scores_gemma":[0.00028944496,0.0000943597,0.00039784674,0.00024884832,0.00006222399,0.00014491845,0.00009201218,0.00024218207,0.000027716826],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02741697,0.0029001068,0.3475267,0.00015320846,0.011884409,0.0047008176,0.00062197266,0.00015322513,0.050540894,0.000085893334,0.49260223,0.061413556],"study_design_scores_gemma":[0.07967566,0.0049941465,0.36503655,0.0005399454,0.00346342,0.0011044028,0.00040812045,0.000056441568,0.030374706,0.000006711221,0.51390964,0.0004302621],"about_ca_topic_score_codex":0.000012396777,"about_ca_topic_score_gemma":0.000006486362,"teacher_disagreement_score":0.060983293,"about_ca_system_score_codex":0.000049993887,"about_ca_system_score_gemma":0.00012643075,"threshold_uncertainty_score":0.38478768},"labels":[],"label_agreement":null},{"id":"W4292656547","doi":"10.1161/circulationaha.121.058294","title":"Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial","year":2022,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Memphis; Library science; Family medicine; Internal medicine","score_opus":0.04087158316520392,"score_gpt":0.28937300201321475,"score_spread":0.24850141884801083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292656547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7266958,0.0022713644,0.0005816079,0.2587672,0.0019671721,0.006814858,0.0010534233,0.00018297185,0.0016656222],"genre_scores_gemma":[0.65723115,0.00016275462,0.000524957,0.29588893,0.0024361848,0.0006504668,0.028602595,0.00025073125,0.014252229],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980697,0.00015240445,0.0003910761,0.00032474007,0.00084889005,0.0002132149],"domain_scores_gemma":[0.9987706,0.00016832037,0.00031007442,0.0006040527,0.00011322447,0.000033746433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002004681,0.0002759264,0.00066025334,0.0001953497,0.00008427667,0.00002848986,0.00012980081,0.00016005307,0.00035253365],"category_scores_gemma":[0.000112406626,0.0001637783,0.00041005175,0.0003029788,0.00005487925,0.0001077651,0.000064994674,0.00036879117,0.000005216445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038530556,0.00023235637,0.04337082,0.00026693192,0.004825346,0.000112161135,0.00008799031,0.00021851322,0.0004983297,0.000012706401,0.9384233,0.00809849],"study_design_scores_gemma":[0.034065206,0.0010907673,0.072270095,0.00018752164,0.008845802,0.000010470176,0.000044386416,0.00029266282,0.00048307353,0.000015100228,0.8822458,0.0004491079],"about_ca_topic_score_codex":0.00021502578,"about_ca_topic_score_gemma":0.000008858113,"teacher_disagreement_score":0.06946466,"about_ca_system_score_codex":0.00022754236,"about_ca_system_score_gemma":0.000093718256,"threshold_uncertainty_score":0.6678685},"labels":[],"label_agreement":null},{"id":"W4292688549","doi":"10.1016/j.cjca.2022.08.223","title":"Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke","year":2022,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Cardiology; Meta-analysis; Stroke (engine); Endocrinology","score_opus":0.018814391946213534,"score_gpt":0.2336191932507107,"score_spread":0.21480480130449717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292688549","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42859367,0.0028360037,0.000012322999,0.5661611,0.0003141505,0.0004846942,0.00033048677,0.0000038007508,0.0012637768],"genre_scores_gemma":[0.9507694,0.00015844006,0.00013558877,0.04702755,0.0013289358,0.000016533264,0.00010693364,0.000021138509,0.00043543446],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998437,0.0003035943,0.00045144706,0.0001899665,0.00024933027,0.0003686992],"domain_scores_gemma":[0.998958,0.0003455856,0.00024296185,0.00021680687,0.000057404584,0.00017924572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004308687,0.0002320588,0.0013274564,0.00066080585,0.00006577251,0.00002671684,0.00020339037,0.0002471536,0.000044331722],"category_scores_gemma":[0.000077135475,0.00014982322,0.00021849219,0.00009821185,0.00028206044,0.000039298644,0.00003662282,0.0010836447,7.5646005e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007795663,0.0000011839076,0.55953884,0.000039149098,0.0008636771,0.00078407204,0.00009290498,0.0000012598576,0.0000018034854,0.000014486753,0.43792713,0.0007277269],"study_design_scores_gemma":[0.0007648858,0.00059082283,0.3734343,0.000034503424,0.00066336105,0.00021964166,0.00020544633,9.19813e-8,0.00000125756,0.00010313039,0.62389964,0.000082915605],"about_ca_topic_score_codex":0.0011394726,"about_ca_topic_score_gemma":0.0022067723,"teacher_disagreement_score":0.5221758,"about_ca_system_score_codex":0.00009917312,"about_ca_system_score_gemma":0.0003471139,"threshold_uncertainty_score":0.6109613},"labels":[],"label_agreement":null},{"id":"W4292702022","doi":"10.1038/s42255-022-00617-6","title":"GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice","year":2022,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Société Francophone du Diabète; Helmholtz Zentrum München; Novo Nordisk; Société Française de Nutrition; Novo Nordisk Fonden; Institut National de la Santé et de la Recherche Médicale; Deutsche Forschungsgemeinschaft; European Genomic Institute for Diabetes; Alexander von Humboldt-Stiftung; Banting and Best Diabetes Centre, University of Toronto; Agence Nationale de la Recherche; Pfizer","keywords":"Metabolism; Carbohydrate metabolism; Endocrinology; Internal medicine; Obesity; Medicine; Biology","score_opus":0.0043251404453863475,"score_gpt":0.21794862799249162,"score_spread":0.21362348754710528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292702022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91642845,0.0797344,0.0000012204298,0.0005328474,0.00050375814,0.00068979384,0.00008985971,0.00004811569,0.001971533],"genre_scores_gemma":[0.9945116,0.0012137617,0.0010101121,0.0012289925,0.00011615098,0.000094422445,0.00012984846,0.000029705108,0.0016653783],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982989,0.00011806251,0.00033977887,0.0004153125,0.00047473464,0.000353235],"domain_scores_gemma":[0.9992136,0.00009650659,0.00013922052,0.0003389786,0.000086142674,0.00012556936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043875424,0.00024824878,0.00066903856,0.00041727524,0.00008380441,0.00001307169,0.0001663916,0.00015746657,0.0002380693],"category_scores_gemma":[0.00011194633,0.00021658039,0.00012996925,0.00060301716,0.000075203316,0.00014166252,0.0003326119,0.000684545,0.000007848862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003293181,0.01006867,0.11120578,0.0016077603,0.0035754084,0.0014178253,0.004823109,0.000032829394,0.6628216,0.031722467,0.020272654,0.14915873],"study_design_scores_gemma":[0.007879678,0.00020777016,0.733853,0.000037041824,0.0011633985,0.000026885564,0.00065172015,0.00017115183,0.019292118,0.0005770334,0.2357733,0.00036692293],"about_ca_topic_score_codex":0.00016217233,"about_ca_topic_score_gemma":0.000025103587,"teacher_disagreement_score":0.6435295,"about_ca_system_score_codex":0.00005896562,"about_ca_system_score_gemma":0.0000658757,"threshold_uncertainty_score":0.88318914},"labels":[],"label_agreement":null},{"id":"W4292731103","doi":"10.2337/dc22-0382","title":"Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; Janssen Research and Development; Merck Sharp and Dohme; St. Jude Medical; Genentech; Idorsia Pharmaceuticals; Duke Clinical Research Institute; Eisai; Hebrew University of Jerusalem; Daiichi-Sankyo; Deutsche Forschungsgemeinschaft; University of Liverpool; Bayer HealthCare; Zora Biosciences; Belvoir Media Group; HLS Therapeutics; GlaxoSmithKline; IFM Therapeutics; Allergan; AstraZeneca; Amarin Corporation; Regado Biosciences; Medicines Company; American Heart Association; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bristol-Myers Squibb; Cleveland Clinic; CSL Behring; Eli Lilly and Company; Moderna; Pfizer; Amgen; Sanofi; Esperion Therapeutics; Alnylam Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Dapagliflozin; TIMI; Type 2 diabetes; Post-hoc analysis; Diabetes mellitus; Post hoc; Kidney disease; Internal medicine; Endocrinology; Myocardial infarction","score_opus":0.013875605330121877,"score_gpt":0.25288391343570266,"score_spread":0.23900830810558077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292731103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953421,0.0017290367,6.904505e-7,0.00024667068,0.00021563635,0.0014315019,0.0007640873,0.00004076309,0.0002295405],"genre_scores_gemma":[0.99298954,0.000023164592,0.000095874944,0.00082945055,0.00007368618,0.00021311315,0.0055747805,0.000032100408,0.0001683194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985595,0.00013258072,0.00023766639,0.00033694404,0.0004690865,0.00026426098],"domain_scores_gemma":[0.99886006,0.000105703606,0.00016514778,0.0004387622,0.00017284609,0.00025749853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000879534,0.00020727917,0.00036089134,0.000097948454,0.00017438245,0.000033859866,0.00014047198,0.00003029763,0.0003162622],"category_scores_gemma":[0.00017726139,0.00013758088,0.00012967316,0.00029960054,0.000103358616,0.000111660906,0.00020121025,0.00011520618,0.000005629238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026281807,0.00035229343,0.98642784,0.00011096404,0.00074688316,0.0000029326486,0.00039913057,0.000016034797,0.000084826235,0.000007111762,0.003796526,0.005427275],"study_design_scores_gemma":[0.024484608,0.004072275,0.9622172,0.00020943815,0.0028362663,7.822398e-9,0.0013010567,0.00007238207,0.0003102791,0.000052783143,0.004231936,0.00021177795],"about_ca_topic_score_codex":0.00001972548,"about_ca_topic_score_gemma":0.000010691037,"teacher_disagreement_score":0.024210652,"about_ca_system_score_codex":0.00007744649,"about_ca_system_score_gemma":0.000107105814,"threshold_uncertainty_score":0.56103855},"labels":[],"label_agreement":null},{"id":"W4292731204","doi":"10.2337/figshare.20365530","title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Kidney disease; Medicine; Renal function; Type 2 diabetes; Hazard ratio; Internal medicine; Diabetes mellitus; Post-hoc analysis; Kidney; Lower risk; Urology; Endocrinology","score_opus":0.025794297123213454,"score_gpt":0.2884126804880696,"score_spread":0.26261838336485616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292731204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356425,0.00063120684,0.000016920898,0.0005289862,0.0003817905,0.0028513963,0.00037676576,0.000049556264,0.0015991254],"genre_scores_gemma":[0.9834099,0.00018242943,0.0006521097,0.00076700834,0.00013327725,0.00026562842,0.011187007,0.000044766417,0.0033579043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982815,0.00013954392,0.00034772564,0.0004970819,0.00053187396,0.00020230553],"domain_scores_gemma":[0.9984379,0.00009869762,0.0002981499,0.00071396993,0.00014645625,0.00030482485],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015042712,0.00029676146,0.0005402721,0.00012003854,0.00007850663,0.000049597114,0.00017530358,0.000075794414,0.0017877513],"category_scores_gemma":[0.0002308248,0.00017326871,0.00018290267,0.00016177371,0.00010127378,0.00006972666,0.000677282,0.00021871288,0.000003676172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020149488,0.0016851033,0.95067936,0.00033474882,0.0043553594,0.0000107690275,0.00014780369,0.000047283098,0.000019514762,0.000041073952,0.016395167,0.006134315],"study_design_scores_gemma":[0.0374455,0.0033354028,0.94457513,0.00058668747,0.009462202,1.3350986e-8,0.00015848443,0.00017867042,0.00007128999,0.0003773187,0.0034756572,0.00033362128],"about_ca_topic_score_codex":0.00021956163,"about_ca_topic_score_gemma":0.000040808765,"teacher_disagreement_score":0.01729601,"about_ca_system_score_codex":0.00007508937,"about_ca_system_score_gemma":0.00023100684,"threshold_uncertainty_score":0.99912477},"labels":[],"label_agreement":null},{"id":"W4292731332","doi":"10.2337/figshare.20365530.v1","title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Kidney disease; Medicine; Renal function; Hazard ratio; Type 2 diabetes; Internal medicine; Post-hoc analysis; Kidney; Diabetes mellitus; Albuminuria; Urology; Endocrinology","score_opus":0.025794297123213454,"score_gpt":0.2884126804880696,"score_spread":0.26261838336485616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292731332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356425,0.00063120684,0.000016920898,0.0005289862,0.0003817905,0.0028513963,0.00037676576,0.000049556264,0.0015991254],"genre_scores_gemma":[0.9834099,0.00018242943,0.0006521097,0.00076700834,0.00013327725,0.00026562842,0.011187007,0.000044766417,0.0033579043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982815,0.00013954392,0.00034772564,0.0004970819,0.00053187396,0.00020230553],"domain_scores_gemma":[0.9984379,0.00009869762,0.0002981499,0.00071396993,0.00014645625,0.00030482485],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015042712,0.00029676146,0.0005402721,0.00012003854,0.00007850663,0.000049597114,0.00017530358,0.000075794414,0.0017877513],"category_scores_gemma":[0.0002308248,0.00017326871,0.00018290267,0.00016177371,0.00010127378,0.00006972666,0.000677282,0.00021871288,0.000003676172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020149488,0.0016851033,0.95067936,0.00033474882,0.0043553594,0.0000107690275,0.00014780369,0.000047283098,0.000019514762,0.000041073952,0.016395167,0.006134315],"study_design_scores_gemma":[0.0374455,0.0033354028,0.94457513,0.00058668747,0.009462202,1.3350986e-8,0.00015848443,0.00017867042,0.00007128999,0.0003773187,0.0034756572,0.00033362128],"about_ca_topic_score_codex":0.00021956163,"about_ca_topic_score_gemma":0.000040808765,"teacher_disagreement_score":0.01729601,"about_ca_system_score_codex":0.00007508937,"about_ca_system_score_gemma":0.00023100684,"threshold_uncertainty_score":0.99912477},"labels":[],"label_agreement":null},{"id":"W4292791027","doi":"10.1002/ejhf.2652","title":"Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","year":2022,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; AstraZeneca; American Regent; Amgen","keywords":"Ejection fraction; Medicine; Internal medicine; Heart failure; Hazard ratio; Cardiology; Dapagliflozin; Clinical endpoint; Confidence interval; Odds ratio; Placebo; Randomized controlled trial; Endocrinology; Diabetes mellitus","score_opus":0.03280294761519501,"score_gpt":0.2400311687853486,"score_spread":0.2072282211701536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292791027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8794937,0.00035045316,0.000048977312,0.11824268,0.0006199391,0.0008226906,0.0000045201487,0.000033519103,0.000383489],"genre_scores_gemma":[0.98381877,0.000016094085,0.004162592,0.0023040157,0.0016463661,0.000018859475,0.000024784147,0.00005347502,0.007955059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739534,0.0008824649,0.00047272016,0.0002346114,0.0007597796,0.0002550967],"domain_scores_gemma":[0.999072,0.0001563374,0.0002871146,0.00020165317,0.00012650774,0.00015637682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016647078,0.00018297137,0.00037409482,0.00021657589,0.0002953222,0.00009094032,0.00008833519,0.000034828994,0.000781945],"category_scores_gemma":[0.00012891808,0.00011794089,0.00014421016,0.00040560376,0.000028333698,0.00025667445,0.00007367144,0.0007208983,0.000029862047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0155339865,0.00030261895,0.03693375,0.000015944752,0.00032182006,0.00007147657,0.00016724042,0.00037675432,0.001252111,0.0000116244255,0.94473034,0.00028233568],"study_design_scores_gemma":[0.026756896,0.003984349,0.10053603,0.000087694316,0.00026064992,0.00022978078,0.0011902222,0.00004101774,0.000096678246,0.000008486679,0.86668617,0.00012203182],"about_ca_topic_score_codex":0.000029407713,"about_ca_topic_score_gemma":0.000071613256,"teacher_disagreement_score":0.11593867,"about_ca_system_score_codex":0.00035381678,"about_ca_system_score_gemma":0.0001913752,"threshold_uncertainty_score":0.85617495},"labels":[],"label_agreement":null},{"id":"W4292849656","doi":"10.1002/ejhf.2660","title":"Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony Outcomes","year":2022,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Post-hoc analysis; Heart failure; Type 2 diabetes; Post hoc; Harmony (color); Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.006089949227595974,"score_gpt":0.20339512858608577,"score_spread":0.1973051793584898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292849656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98407924,0.0005014173,0.000002582383,0.015004529,0.000084552325,0.00021194638,0.000023043318,0.000016117474,0.00007658583],"genre_scores_gemma":[0.9915265,0.000007255712,0.0059778322,0.0021420016,0.000049254468,0.000002342717,0.00007481213,0.00003571051,0.00018429066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826485,0.00031772154,0.00041631542,0.00022987885,0.0004988498,0.00027240178],"domain_scores_gemma":[0.99918693,0.000063886044,0.00018494549,0.00024868906,0.00013448001,0.00018105135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044804363,0.0002006635,0.00060881884,0.0005131119,0.00010100516,0.00004789128,0.000114575465,0.000013640374,0.0004417366],"category_scores_gemma":[0.00004307522,0.000144516,0.00017446511,0.00059404084,0.000041534247,0.00014918816,0.00014350102,0.0003336653,0.000023427165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032176642,0.00033225896,0.9649788,0.000010860588,0.0014110472,0.00011893112,0.00024488263,0.000054393007,0.00018676798,0.0000029911857,0.0317768,0.0005604765],"study_design_scores_gemma":[0.0041707386,0.003054725,0.87009215,0.000044835273,0.001034818,0.0000034525444,0.00032861516,0.00001076684,0.000025563284,0.000004265529,0.12109967,0.00013041485],"about_ca_topic_score_codex":0.000012122579,"about_ca_topic_score_gemma":0.000026400314,"teacher_disagreement_score":0.09488669,"about_ca_system_score_codex":0.00007504853,"about_ca_system_score_gemma":0.000036852834,"threshold_uncertainty_score":0.58931917},"labels":[],"label_agreement":null},{"id":"W4293044628","doi":"10.1016/j.cmet.2022.08.003","title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","year":2022,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Sinai Health System","funders":"Institute of Nutrition, Metabolism and Diabetes; Canadian Institutes of Health Research; Novo Nordisk Fonden; Novo Nordisk","keywords":"Intraepithelial lymphocyte; Gut flora; Inflammation; Biology; Glucose homeostasis; Enteroendocrine cell; Cell biology; Glucagon-like peptide-1; Receptor; Immunology; Type 2 diabetes; Endocrinology; Immune system; Insulin resistance; Endocrine system; Insulin; Diabetes mellitus; Biochemistry; Hormone","score_opus":0.007769838161778892,"score_gpt":0.21106195761932162,"score_spread":0.20329211945754272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293044628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811384,0.014760562,0.00020749228,0.0007072336,0.00065375643,0.001958127,0.00008499131,0.000024808729,0.00046462365],"genre_scores_gemma":[0.9970367,0.0008481209,0.00029327965,0.00030798741,0.00020590468,0.0004353876,0.000045260073,0.000027307013,0.0008000413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987206,0.0001000074,0.0003845546,0.00027120352,0.00023645702,0.00028717332],"domain_scores_gemma":[0.99924994,0.0001243729,0.00019852164,0.00029458464,0.000064747204,0.00006785064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047240648,0.00020192619,0.00048375057,0.00018950133,0.0001464069,0.000019512272,0.00015564122,0.00004623466,0.00010630597],"category_scores_gemma":[0.000025796848,0.00014864885,0.0001494698,0.00018338185,0.000047023444,0.000070303475,0.00014902715,0.00010934745,0.000005472114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078629307,0.00040883262,0.0007185683,0.00019495594,0.0003168513,0.0000074840436,0.0016451427,0.00029081904,0.9450758,0.0018203224,0.0004835061,0.048251424],"study_design_scores_gemma":[0.029415736,0.00027429964,0.052486356,0.00002409498,0.0028520573,0.0000032037394,0.0012412972,0.0023868876,0.6318049,0.00031368955,0.27885425,0.0003432604],"about_ca_topic_score_codex":0.00009601808,"about_ca_topic_score_gemma":0.000013251732,"teacher_disagreement_score":0.31327093,"about_ca_system_score_codex":0.000072319795,"about_ca_system_score_gemma":0.00007359327,"threshold_uncertainty_score":0.6061724},"labels":[],"label_agreement":null},{"id":"W4293072321","doi":"10.1016/j.apsb.2022.06.003","title":"The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury","year":2022,"lang":"en","type":"review","venue":"Acta Pharmaceutica Sinica B","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Therapeutic approach; Immune system; Incretin; Bioinformatics; Type 2 diabetes; Diabetes mellitus; Immunology; Internal medicine; Biology; Endocrinology; Disease","score_opus":0.046915130155956074,"score_gpt":0.35545652694381963,"score_spread":0.3085413967878636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293072321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002273848,0.9921708,6.8251586e-7,0.0014250211,0.0006074369,0.0028454447,0.00005251091,0.000068517715,0.00055574096],"genre_scores_gemma":[0.026566569,0.97112817,0.000025900319,0.0004713102,0.00012352696,0.0005596825,0.00033272954,0.00009772297,0.00069441803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970426,0.00048361538,0.00081379747,0.000583744,0.00053809385,0.00053815835],"domain_scores_gemma":[0.9979772,0.00067644054,0.00053265155,0.00059481134,0.00005450107,0.00016439133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008858593,0.0005536078,0.0014517098,0.00036049803,0.00019967173,0.000066243825,0.000349711,0.00021656799,0.0001745712],"category_scores_gemma":[0.0000688989,0.0003977249,0.00043298342,0.0005321304,0.00013542674,0.00020680936,0.00028636123,0.00077540806,0.000010691112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001711084,0.0005731839,0.00020792722,0.019475518,0.0019387908,0.00004795692,0.00012827675,0.0000021853373,0.00016592139,0.00009300288,0.007024906,0.9701712],"study_design_scores_gemma":[0.0014969655,0.00018516277,0.00008231722,0.0023660671,0.0049676667,0.0000019435677,0.00006361815,0.0007675335,0.00012522515,0.000007326756,0.98960745,0.00032870637],"about_ca_topic_score_codex":0.0000010092903,"about_ca_topic_score_gemma":8.392014e-7,"teacher_disagreement_score":0.98258257,"about_ca_system_score_codex":0.00020966813,"about_ca_system_score_gemma":0.00033934833,"threshold_uncertainty_score":0.9998475},"labels":[],"label_agreement":null},{"id":"W4293102417","doi":"10.18553/jmcp.2022.28.9.958","title":"Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist","year":2022,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Basal insulin; Persistence (discontinuity); Agonist; Type 2 diabetes; Basal (medicine); Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Medicine; Insulin; Endocrinology; Internal medicine; Receptor; Diabetes mellitus","score_opus":0.01925624183233251,"score_gpt":0.2697511568846674,"score_spread":0.2504949150523349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293102417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389416,0.0020835986,0.0000056827967,0.0018322087,0.00030081897,0.000642889,0.000024162855,0.000009502713,0.0012069861],"genre_scores_gemma":[0.9969043,0.0011389364,0.0010266993,0.00034270156,0.00010627197,0.00003542897,0.000017810584,0.000022984705,0.00040484563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985755,0.00011002463,0.0003992828,0.0002367144,0.0004371348,0.00024131642],"domain_scores_gemma":[0.99906296,0.00009438018,0.00028095616,0.00019900814,0.00016752705,0.00019515079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002547133,0.00020290198,0.0004975266,0.0003725489,0.00018407012,0.00004783954,0.00016985576,0.000013799328,0.00013483428],"category_scores_gemma":[0.000053517975,0.00016858456,0.000081439124,0.000459001,0.000045077453,0.00015901025,0.0001973315,0.00024264654,0.0000019307122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005741909,0.003933045,0.8037912,0.0007752898,0.0015343437,0.000606212,0.029831259,0.00038549263,0.005911031,0.00030011943,0.006504295,0.14068577],"study_design_scores_gemma":[0.07104764,0.026847836,0.69797397,0.0009805823,0.0031087578,0.00009249738,0.049837112,0.00057091034,0.0050800233,0.00017134096,0.14330085,0.0009884776],"about_ca_topic_score_codex":0.00018747558,"about_ca_topic_score_gemma":0.0004954643,"teacher_disagreement_score":0.13969728,"about_ca_system_score_codex":0.00046275428,"about_ca_system_score_gemma":0.00014875898,"threshold_uncertainty_score":0.68746793},"labels":[],"label_agreement":null},{"id":"W4293280727","doi":"10.1093/ckj/sfac189","title":"SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence","year":2022,"lang":"en","type":"review","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Vifor Pharma; GlaxoSmithKline Australia; Kyowa Kirin Pharmaceutical Development; Idorsia Pharmaceuticals; Amicus Therapeutics; Novo Nordisk; AstraZeneca; Chiesi Farmaceutici; Menarini Group; Astellas Pharma US; Alexion Pharmaceuticals; Fresenius Medical Care North America; Bayer; Amgen","keywords":"Proteinuria; Albuminuria; Medicine; Nephrotic syndrome; Kidney disease; Randomized controlled trial; Internal medicine; Glycemic; Diabetes mellitus; Urology; Intensive care medicine; Kidney; Endocrinology","score_opus":0.26348113733427014,"score_gpt":0.489166837747945,"score_spread":0.22568570041367486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293280727","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009103126,0.98680365,0.00001376253,0.002360524,0.0053342837,0.0033506348,0.000012337537,0.00008054384,0.001953226],"genre_scores_gemma":[0.000011258759,0.9884982,0.0009916507,0.0022660196,0.0051276665,0.00032756192,0.00006029989,0.00014060877,0.0025767002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888786,0.0023387785,0.005775254,0.0010500699,0.001067646,0.00088961393],"domain_scores_gemma":[0.9925896,0.0025601168,0.001954093,0.0009643343,0.00010114154,0.0018307467],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010589425,0.00075906614,0.004737273,0.00060868706,0.00022323382,0.00014659361,0.0007463912,0.00068488595,0.0033676366],"category_scores_gemma":[0.015119635,0.00056422845,0.003485205,0.000859462,0.0002707502,0.00028007492,0.00066875917,0.0058553466,0.00043921484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010458839,0.0013246806,0.008709141,0.0049290494,0.0009577949,0.002452124,0.000022878261,1.3807906e-7,1.4080272e-8,0.000020709156,0.0646528,0.91682607],"study_design_scores_gemma":[0.0027155934,0.0016779932,0.000548915,0.052408423,0.004281229,0.0002528332,0.000032693053,0.000006331409,3.0223738e-8,0.0000775177,0.9375459,0.0004525441],"about_ca_topic_score_codex":0.000007018546,"about_ca_topic_score_gemma":0.0000030143876,"teacher_disagreement_score":0.91637355,"about_ca_system_score_codex":0.0006330395,"about_ca_system_score_gemma":0.0025393716,"threshold_uncertainty_score":0.99968094},"labels":[],"label_agreement":null},{"id":"W4293332312","doi":"10.1161/circulationaha.122.061754","title":"Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Relypsa; National Medical Research Council; Respicardia; American Regent; National Heart, Lung, and Blood Institute; Japan Heart Foundation; Vifor Pharma; Daiichi-Sankyo; University of Glasgow; Pfizer; Moderna; Medical Research Council; Verily Life Sciences; British Heart Foundation; Cytokinetics; Ionis Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Sarepta Therapeutics; Japan Agency for Medical Research and Development; Sanofi Pasteur; Universitair Medisch Centrum Groningen; Kowa Company; Celladon Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Bayer; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Lundbeckfonden; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Heart failure; Ejection fraction; Hazard ratio; Clinical endpoint; Internal medicine; Tolerability; Randomized controlled trial; Canadian Cardiovascular Society; Cardiology; Confidence interval; Adverse effect; Myocardial infarction; Diabetes mellitus; Angina; Type 2 diabetes","score_opus":0.018946354777056303,"score_gpt":0.24875048315974851,"score_spread":0.2298041283826922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293332312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855375,0.00000938353,0.000066952096,0.00014669223,0.000026851534,0.0010807742,0.00000716381,0.00000438284,0.00010403996],"genre_scores_gemma":[0.99975526,3.1466456e-7,0.00010984378,0.00004286128,0.0000069218004,0.000024878966,0.000044784752,0.000004279186,0.000010840536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993732,0.000045991244,0.00017000039,0.000118884,0.00023004171,0.000061885614],"domain_scores_gemma":[0.99967283,0.000036103807,0.00007325108,0.00016778437,0.00003065306,0.000019404508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012000273,0.00004876281,0.0001925431,0.00019521706,0.000034206707,0.0000031672732,0.000032419644,0.0000116703795,0.00004288884],"category_scores_gemma":[0.00002858621,0.000035147157,0.000045701392,0.0007212655,0.000012191836,0.00003052638,0.000057756784,0.00003541657,2.1791115e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068431236,0.00025604785,0.9838997,0.0000098907885,0.00032552864,1.13029e-7,0.0002826138,0.0056693214,0.00021538448,0.00006184913,0.0000356108,0.0024008034],"study_design_scores_gemma":[0.01988222,0.00022859828,0.978272,0.000016600961,0.00068231724,1.7610741e-8,0.00009495352,0.00047575095,0.000044780834,0.0000051306015,0.00026538337,0.000032219268],"about_ca_topic_score_codex":0.000028927881,"about_ca_topic_score_gemma":0.000017695282,"teacher_disagreement_score":0.013039097,"about_ca_system_score_codex":0.000064741565,"about_ca_system_score_gemma":0.000010555406,"threshold_uncertainty_score":0.14332594},"labels":[],"label_agreement":null},{"id":"W4293354571","doi":"10.1016/j.jacc.2022.07.021","title":"Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Dapagliflozin; Medicine; Ejection fraction; Heart failure; Internal medicine; Placebo; Cardiology; Adverse effect; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.008411457646182301,"score_gpt":0.2394371500511069,"score_spread":0.2310256924049246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293354571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578017,0.000049326914,0.0000075333564,0.0033271809,0.00019571604,0.000417434,0.000013594131,0.000003922679,0.00020514555],"genre_scores_gemma":[0.9987701,0.00004876952,0.00063351926,0.00020786242,0.0000556615,0.000016993195,0.0000028335928,0.000010619517,0.00025364736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989168,0.00030847508,0.00028085217,0.00010957704,0.00025844487,0.00012585148],"domain_scores_gemma":[0.99916726,0.000047798912,0.0004760963,0.0001609674,0.0001056776,0.00004222524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002736843,0.00008903555,0.00057357,0.00017414478,0.000057250963,0.0000025732627,0.00008401248,0.000016784514,0.000015675841],"category_scores_gemma":[0.000074415,0.000052518186,0.00010614702,0.00039852614,0.000107008695,0.00006134974,0.00008104412,0.00018420898,1.857147e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006363425,0.00016030647,0.9714781,0.00001692754,0.0004588046,0.000036362722,0.000015283136,0.00026277264,0.0006500501,0.0000055918285,0.02032086,0.00023151378],"study_design_scores_gemma":[0.0051208637,0.00867143,0.9567115,0.00004308984,0.00030368174,0.00008878362,0.00083887525,0.0000136153385,0.00022831066,0.00002447207,0.027891133,0.00006428224],"about_ca_topic_score_codex":0.00001874388,"about_ca_topic_score_gemma":0.00000527885,"teacher_disagreement_score":0.014766639,"about_ca_system_score_codex":0.00017688115,"about_ca_system_score_gemma":0.000081141254,"threshold_uncertainty_score":0.21416295},"labels":[],"label_agreement":null},{"id":"W4293354639","doi":"10.1056/nejmoa2206286","title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2658,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Université de Montréal; Montreal Heart Institute","funders":"AstraZeneca","keywords":"Ejection fraction; Dapagliflozin; Heart failure; Cardiology; Internal medicine; Medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.020180251956848045,"score_gpt":0.27029304298268486,"score_spread":0.25011279102583683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293354639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96005845,0.00045416527,0.00011018819,0.03733315,0.00044096762,0.00035215882,8.086213e-7,0.000017610051,0.0012324911],"genre_scores_gemma":[0.99305695,0.000074323005,0.0012427729,0.00077450695,0.0014491028,0.00001118064,0.000016181484,0.000017869044,0.0033571075],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986357,0.000120112105,0.0003626183,0.00012997954,0.00058357243,0.00016797864],"domain_scores_gemma":[0.9993248,0.000088404464,0.00020964527,0.00014315364,0.00007435394,0.00015963826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007592986,0.000121522186,0.00040639055,0.00038600914,0.00006110953,0.000006776328,0.00006964275,0.000026092332,0.0012054575],"category_scores_gemma":[0.000124226,0.000070336406,0.000043008284,0.0003879072,0.000026631114,0.00012755723,0.000024937044,0.000406565,0.0000025453264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030778911,0.0014926184,0.30965114,0.00021614738,0.0010671807,0.00233462,0.0017981926,0.0012317168,0.024078121,0.000088623776,0.55616146,0.07110127],"study_design_scores_gemma":[0.11779085,0.017120106,0.069766164,0.00058392633,0.0006397887,0.0011017598,0.0025849198,0.00012871624,0.0008744301,0.00014549354,0.789118,0.00014582858],"about_ca_topic_score_codex":0.00015329977,"about_ca_topic_score_gemma":0.00014499425,"teacher_disagreement_score":0.23988497,"about_ca_system_score_codex":0.0002021508,"about_ca_system_score_gemma":0.0001453719,"threshold_uncertainty_score":0.9997076},"labels":[],"label_agreement":null},{"id":"W4293569876","doi":"10.1016/j.ekir.2022.08.016","title":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations","year":2022,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dapagliflozin; Medicine; Diuretic; Heart failure; Placebo; Concomitant; Internal medicine; Ejection fraction; Kidney disease; Renal function; Intensive care medicine; Endocrinology; Diabetes mellitus; Alternative medicine; Type 2 diabetes; Pathology","score_opus":0.014989321382075867,"score_gpt":0.2792084448926254,"score_spread":0.26421912351054955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293569876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744399,0.000014801773,0.00006117211,0.010036739,0.00038532622,0.0006599952,0.000017934644,0.00004046562,0.014343675],"genre_scores_gemma":[0.99599797,0.0000028366705,0.0015239244,0.0010861459,0.00003592218,0.00019680145,0.00035728214,0.000011210501,0.0007879134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989223,0.000022057722,0.00026234324,0.00023340671,0.00044555817,0.00011437075],"domain_scores_gemma":[0.9994789,0.000053625266,0.0001480575,0.0001301667,0.00006662012,0.00012267545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016173626,0.00008175764,0.000106115076,0.0002417166,0.00012849018,0.00004076722,0.0000130867875,0.000016026583,0.0004914491],"category_scores_gemma":[0.00056678156,0.00007417402,0.000021390639,0.00010129401,0.000031382006,0.0001810111,0.00010948403,0.0001297023,0.0000020074633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043248034,0.0006049064,0.9789167,0.000007998853,0.00015048696,0.0006151949,0.0002977119,0.000018134342,0.000046665846,0.0028736861,0.016134515,0.00029074153],"study_design_scores_gemma":[0.0038134216,0.0004967748,0.94168156,0.00014564063,0.00021031324,0.0005054195,0.00046200474,0.00018266508,0.00034287843,0.0020160337,0.04990012,0.00024313827],"about_ca_topic_score_codex":0.000027675564,"about_ca_topic_score_gemma":0.0000053213516,"teacher_disagreement_score":0.03723512,"about_ca_system_score_codex":0.00020641989,"about_ca_system_score_gemma":0.00015625595,"threshold_uncertainty_score":0.53810227},"labels":[],"label_agreement":null},{"id":"W4293767313","doi":"10.1016/j.molmet.2022.101586","title":"Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis","year":2022,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Inflammation; Endocrinology; Internal medicine; Apolipoprotein E; Adipose tissue; Bone marrow; Biology; Lipid metabolism; Medicine","score_opus":0.00906108914812894,"score_gpt":0.22280194299816222,"score_spread":0.21374085385003327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293767313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958431,0.0017287817,0.0000720414,0.0006695428,0.00015954598,0.00062243897,0.000006579945,0.000015676416,0.0008822795],"genre_scores_gemma":[0.9981403,0.000034083656,0.00060542696,0.00046082443,0.000016164353,0.00016502451,0.000007910724,0.0000187424,0.0005515721],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991006,0.00010317897,0.000171368,0.00017224548,0.00029567294,0.00015692883],"domain_scores_gemma":[0.99956983,0.0000073181786,0.000067766574,0.00030995283,0.000016936885,0.000028216678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012934452,0.000097097465,0.0001928905,0.00008375045,0.00004767358,0.0000061771657,0.00012536655,0.000015176982,0.00010489243],"category_scores_gemma":[0.000018445124,0.000072007,0.00012291041,0.00033040595,0.00003155542,0.000018693781,0.00017658813,0.00009324605,0.0000050442886],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006308328,0.0013247237,0.053137794,0.00012332395,0.00030162145,0.000025767447,0.0012516532,0.0004059054,0.9143851,0.0038804342,0.0002612187,0.024839403],"study_design_scores_gemma":[0.0022037458,0.00010414807,0.8849989,0.00003445312,0.00048811117,0.000003661041,0.00014497318,0.00023900093,0.09233932,0.00054517935,0.018767804,0.00013067758],"about_ca_topic_score_codex":0.00007139617,"about_ca_topic_score_gemma":0.000004860789,"teacher_disagreement_score":0.83186114,"about_ca_system_score_codex":0.000038632632,"about_ca_system_score_gemma":0.000019337402,"threshold_uncertainty_score":0.29363602},"labels":[],"label_agreement":null},{"id":"W4294193007","doi":"10.51731/cjht.2022.434","title":"Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Formulary; Reimbursement; Business; Drug; Pharmacology; Medicine; Health care; Economic growth; Economics","score_opus":0.048603727892597356,"score_gpt":0.3054348629377528,"score_spread":0.2568311350451554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294193007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85116154,0.115877315,0.00044929626,0.02880166,0.0022948352,0.00086027215,0.00012505059,0.00012673668,0.000303304],"genre_scores_gemma":[0.99714595,0.0021176194,0.00023080649,0.0002538611,0.000010133048,0.000017714872,0.000034931356,0.000013284526,0.00017568254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987924,0.000046719768,0.0005006112,0.000113245005,0.00023067079,0.00031636987],"domain_scores_gemma":[0.9990908,0.000017607808,0.00047674577,0.00021806918,0.00010906748,0.0000877155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039969757,0.000104309605,0.00034555132,0.0006901594,0.00019515038,0.000010186869,0.0002067841,0.00003462714,0.0001649288],"category_scores_gemma":[0.00009186562,0.00009316217,0.000088872606,0.0002931011,0.00006533972,0.000055353943,0.00004879322,0.00028095054,0.000003235178],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023357417,0.000112903566,0.0524303,0.00033423415,0.00009955073,0.00004493486,0.00032186293,0.000020840633,0.000020902942,0.00095895,0.020652993,0.92497915],"study_design_scores_gemma":[0.0008933177,0.0015446763,0.019892028,0.00031247656,0.000058446018,0.000038862683,0.0045048497,0.000009545824,0.00046564473,0.00042550656,0.97175896,0.000095683856],"about_ca_topic_score_codex":0.0009738294,"about_ca_topic_score_gemma":0.0005760878,"teacher_disagreement_score":0.95110595,"about_ca_system_score_codex":0.0006955924,"about_ca_system_score_gemma":0.0012905679,"threshold_uncertainty_score":0.3799043},"labels":[],"label_agreement":null},{"id":"W4294992557","doi":"10.1002/ejhf.2670","title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial","year":2022,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université Laval; Population Health Research Institute; Hamilton Health Sciences; University of Toronto; St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Eli Lilly and Company","keywords":"Medicine; Post-hoc analysis; Heart failure; Randomized controlled trial; Internal medicine; Cardiology; Post hoc","score_opus":0.006023277513529365,"score_gpt":0.205660668129868,"score_spread":0.19963739061633862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294992557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693585,0.00234605,0.00001921564,0.026731009,0.00008557449,0.0013832861,0.00003799948,0.000016675034,0.000021688704],"genre_scores_gemma":[0.9928393,0.000039338553,0.005552763,0.0012456364,0.00013231036,0.00001662714,0.000039266986,0.000049037404,0.00008572341],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99590224,0.0017841752,0.0007080716,0.00042179454,0.00085317873,0.0003305643],"domain_scores_gemma":[0.99865925,0.0002605962,0.00024223053,0.00046177604,0.00013592222,0.00024022462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002619726,0.00034532128,0.0018194789,0.00039429442,0.0002653992,0.00014030184,0.00012586522,0.000033034506,0.000092645925],"category_scores_gemma":[0.0001750916,0.00020288736,0.000587427,0.00042913517,0.00019358192,0.00020454398,0.00022900874,0.0005503571,0.000002831139],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.122622065,0.00032819906,0.85320944,0.000025109437,0.009832083,0.00011323794,0.0009420907,0.000085106505,0.000037093272,0.000008816278,0.0123370895,0.00045964893],"study_design_scores_gemma":[0.4715169,0.0025864088,0.4172217,0.000093423114,0.005658072,0.000057230423,0.0010825861,0.000017833792,0.000005238434,0.000009774174,0.10152514,0.00022570191],"about_ca_topic_score_codex":0.000071268616,"about_ca_topic_score_gemma":0.00007441876,"teacher_disagreement_score":0.43598777,"about_ca_system_score_codex":0.000048695816,"about_ca_system_score_gemma":0.000053072825,"threshold_uncertainty_score":0.8273506},"labels":[],"label_agreement":null},{"id":"W4295084553","doi":"10.1111/dom.14862","title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the <scp>FIGHT</scp> trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Heart, Lung, and Blood Institute; Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Ejection fraction; Liraglutide; Heart failure; Lightheadedness; Internal medicine; Placebo; Post-hoc analysis; Cardiology; Rate ratio; Hazard ratio; Myocardial infarction; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.005161291033091831,"score_gpt":0.20780536470486644,"score_spread":0.20264407367177462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295084553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981809,0.0003780381,0.000004255938,0.00016408843,0.000113330934,0.0008911584,0.000072434224,0.000017428449,0.00017833977],"genre_scores_gemma":[0.9989285,0.000060790706,0.0003217377,0.00013831133,0.00003975587,0.00010320143,0.00006755216,0.000012673652,0.00032747482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985749,0.00022234813,0.00026406907,0.00028224904,0.00043458442,0.0002218218],"domain_scores_gemma":[0.99909747,0.00010311787,0.00029854785,0.00034270526,0.00009116354,0.00006702815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040009833,0.00017005535,0.0006665436,0.00045281617,0.0001524236,0.000004064067,0.00008444806,0.000044804256,0.00004359061],"category_scores_gemma":[0.00006854946,0.00010890004,0.0002015302,0.0014603416,0.000071757204,0.00012578524,0.000089607696,0.00021946104,8.523546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013129187,0.0011521504,0.99142605,0.00006387492,0.00329773,0.0000024411538,0.00043702236,0.00042788172,0.0013011724,0.0000782786,0.00017875177,0.00032170827],"study_design_scores_gemma":[0.015870813,0.0009653759,0.96438,0.000043071523,0.008208713,5.8611795e-7,0.0009786589,0.000117251286,0.003074186,0.000027351463,0.0062795333,0.00005442479],"about_ca_topic_score_codex":0.00020119429,"about_ca_topic_score_gemma":0.00016606135,"teacher_disagreement_score":0.027046034,"about_ca_system_score_codex":0.0000475599,"about_ca_system_score_gemma":0.000058937054,"threshold_uncertainty_score":0.4440815},"labels":[],"label_agreement":null},{"id":"W4295277450","doi":"10.1016/j.ijcard.2022.09.009","title":"Patient preferences for newer oral therapies in type 2 diabetes","year":2022,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Medicine; Semaglutide; Empagliflozin; Sitagliptin; Type 2 diabetes; Dulaglutide; Internal medicine; Liraglutide; Type 2 Diabetes Mellitus; Diabetes mellitus; Endocrinology","score_opus":0.02468053951443426,"score_gpt":0.2936505194972363,"score_spread":0.26896997998280203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295277450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353254,0.0010191085,0.00005371889,0.0017081463,0.001856473,0.0001370348,0.000008074985,0.0000038334733,0.001681054],"genre_scores_gemma":[0.99859,0.000099251396,0.00040228936,0.0005139901,0.00020649537,0.000024720806,0.000018221337,0.000004920365,0.0001401445],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940145,0.000050177936,0.00020081336,0.00006239325,0.00019422814,0.00009092399],"domain_scores_gemma":[0.99957603,0.000068258014,0.00010753373,0.000042228377,0.00018490913,0.000021043159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018877555,0.000051143026,0.0002048406,0.00017647848,0.000015188538,0.000006640934,0.00009987216,0.000014815727,0.00009669813],"category_scores_gemma":[0.000047905985,0.000038686943,0.00010330646,0.000043046886,0.000019319248,0.000040249193,0.000052887186,0.00007981656,0.0000013887482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017865909,0.0002609929,0.7610248,0.000014145356,0.003570134,0.00021141535,0.0006895743,0.0025628125,0.0011124042,0.001644174,0.024682276,0.20244072],"study_design_scores_gemma":[0.0046957247,0.006011476,0.22788003,0.000039150356,0.00018867427,0.00008664322,0.0009749256,0.00010750151,0.00041922918,0.006718038,0.7527546,0.00012398385],"about_ca_topic_score_codex":0.0000019049287,"about_ca_topic_score_gemma":0.0000011088584,"teacher_disagreement_score":0.72807235,"about_ca_system_score_codex":0.00009683236,"about_ca_system_score_gemma":0.000043180757,"threshold_uncertainty_score":0.15776077},"labels":[],"label_agreement":null},{"id":"W4295419496","doi":"10.1111/dom.14872","title":"Ethnicity and risks of severe <scp>COVID</scp> ‐19 outcomes associated with glucose‐lowering medications: A cohort study","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"NIHR Leicester Biomedical Research Centre; Medical Research Council; University of Oxford; National Institute for Health and Care Research; UK Research and Innovation; Public Health England; Department of Health and Social Care; Cancer Research UK; Wellcome Trust","keywords":"Medicine; Metformin; Pandemic; Diabetes mellitus; Ethnic group; Cohort; Cohort study; Type 2 diabetes; Population; Internal medicine; Observational study; Insulin; Coronavirus disease 2019 (COVID-19); Disease; Endocrinology; Environmental health; Infectious disease (medical specialty)","score_opus":0.023701621004731468,"score_gpt":0.2798515955079793,"score_spread":0.25614997450324783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295419496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940718,0.00342489,0.000008502984,0.000113241884,0.00009856338,0.0014703474,0.00006956403,0.00009274059,0.000650357],"genre_scores_gemma":[0.9977506,0.00033353362,0.000107019965,0.0005476397,0.00001960884,0.00029911206,0.00009336089,0.000021806274,0.00082732615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825275,0.00016284357,0.00029042014,0.00041003758,0.0005526975,0.0003312519],"domain_scores_gemma":[0.9987898,0.00035973563,0.00020923009,0.0003281909,0.00007569941,0.00023734619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010030033,0.00023674675,0.00076916144,0.00019670225,0.0003247984,0.000023979748,0.00011456982,0.000053071064,0.000044469216],"category_scores_gemma":[0.00043676211,0.00018977204,0.00007376139,0.00035235102,0.00013305525,0.00011389967,0.00030643828,0.00023539575,0.0000013453192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008148112,0.0014732684,0.99336797,0.00007656632,0.0019522491,0.000012347177,0.0014144116,0.00001107461,0.00007814928,0.00011592222,0.00017083167,0.0013190414],"study_design_scores_gemma":[0.0035446237,0.00036144714,0.9893635,0.000026204305,0.002654749,0.0000011650993,0.00123524,0.00004302334,0.0001258027,0.00014470352,0.0024079627,0.00009160062],"about_ca_topic_score_codex":0.00021031454,"about_ca_topic_score_gemma":0.00005039039,"teacher_disagreement_score":0.0040045124,"about_ca_system_score_codex":0.00006224544,"about_ca_system_score_gemma":0.00006253166,"threshold_uncertainty_score":0.7738679},"labels":[],"label_agreement":null},{"id":"W4295487285","doi":"10.1161/circulationaha.122.059755","title":"Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"","keywords":"Empagliflozin; Medicine; Ejection fraction; Hazard ratio; Internal medicine; Heart failure; Cardiology; Placebo; Heart failure with preserved ejection fraction; Diabetes mellitus; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.006063424415387385,"score_gpt":0.21729898620714233,"score_spread":0.21123556179175496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295487285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99879414,0.00010913403,0.000045369146,0.00022496739,0.000012419797,0.0005205914,4.0531214e-7,0.000014798715,0.00027816466],"genre_scores_gemma":[0.9996444,0.0000065377667,0.00009510507,0.000036123147,0.000010175038,0.00013146577,0.000013624599,0.0000057587476,0.000056819143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996182,0.000033321612,0.000068331145,0.000107341395,0.00010596372,0.00006688516],"domain_scores_gemma":[0.99985397,0.000023005898,0.000034697325,0.00005453315,0.000010804014,0.00002300979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009467394,0.000045284454,0.000102334,0.000104285224,0.000035380566,0.000005600736,0.0000070529563,0.000014465741,0.000016353804],"category_scores_gemma":[0.000008696516,0.00004147362,0.00000706769,0.00011872386,0.0000103142875,0.000087967754,0.000018375968,0.00004338802,2.8582778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015958167,0.000110662826,0.98642325,0.0002057026,0.000042799205,0.0000024846318,0.00028485217,0.00016285817,0.011340585,0.000034850378,0.00013614917,0.0010962271],"study_design_scores_gemma":[0.0019530939,0.0002948683,0.99409294,0.000026993957,0.000044217984,0.0000016416882,0.00042314746,0.0016594441,0.0007123684,0.000146283,0.00060744304,0.00003754195],"about_ca_topic_score_codex":0.00003555277,"about_ca_topic_score_gemma":0.0000052096398,"teacher_disagreement_score":0.010628216,"about_ca_system_score_codex":0.000104195235,"about_ca_system_score_gemma":0.000006896112,"threshold_uncertainty_score":0.16912451},"labels":[],"label_agreement":null},{"id":"W4296751031","doi":"","title":"Role of GPR88 in ethanol drinking: A new pharmacological target","year":2022,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Douglas Mental Health University Institute; McGill University Health Centre","funders":"","keywords":"Ethanol; Pharmacology; Chemistry; Psychology; Medicine; Biochemistry","score_opus":0.018921293878398037,"score_gpt":0.2654536753672777,"score_spread":0.24653238148887968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296751031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65107495,0.0048619146,0.0030761657,0.017142402,0.0003361072,0.0023252491,0.0000433724,0.00031815667,0.3208217],"genre_scores_gemma":[0.94516134,0.00078410323,0.028802896,0.00021161036,0.000026797266,0.00020907819,0.0007433817,0.000043156313,0.02401761],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99630684,0.0017568874,0.0005189515,0.00061390334,0.00047369718,0.00032973147],"domain_scores_gemma":[0.99753284,0.00045219116,0.00036757332,0.0010981116,0.00036842967,0.00018083838],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023262857,0.00027923062,0.00055009616,0.00032282382,0.00008151249,0.00005510152,0.0006583598,0.0001784653,0.0021541193],"category_scores_gemma":[0.00038693307,0.00028169493,0.00024294721,0.00039240014,0.00010420023,0.000051293213,0.0019332049,0.0006935193,0.00001984451],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000597382,0.020700837,0.2968863,0.0017266005,0.003001528,0.00024854433,0.0494396,0.0011684188,0.089853615,0.14900726,0.020697813,0.3666721],"study_design_scores_gemma":[0.012654691,0.000017072416,0.112127446,0.00568282,0.0014722273,0.000015533193,0.0012632658,0.019922426,0.42971486,0.041491,0.3738684,0.0017702607],"about_ca_topic_score_codex":0.00079686247,"about_ca_topic_score_gemma":0.00022240466,"teacher_disagreement_score":0.36490184,"about_ca_system_score_codex":0.00022956276,"about_ca_system_score_gemma":0.00034097207,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W4297235947","doi":"10.3390/ijms231911203","title":"Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System","year":2022,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Reabsorption; Cell biology; Chemistry; Transforming growth factor; Endocrinology; Internal medicine; Kidney; Biology; Medicine","score_opus":0.031530617290842854,"score_gpt":0.3061561208087825,"score_spread":0.2746255035179397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297235947","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029528125,0.99330574,0.00039407384,0.00075635716,0.001239228,0.0007746617,0.0000034596212,0.000013637986,0.0005600393],"genre_scores_gemma":[0.0073616505,0.99130416,0.0006622737,0.00011714882,0.000261407,0.00006394102,0.000041638355,0.000023639217,0.00016414688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722475,0.00024084115,0.00063042605,0.00026285197,0.0014556934,0.0001854124],"domain_scores_gemma":[0.9987736,0.00005058142,0.00078107964,0.00019796276,0.0001471623,0.00004961628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014451727,0.00021907192,0.00065372145,0.0008131017,0.0000777467,0.00010438647,0.000705562,0.000070312126,0.00007370686],"category_scores_gemma":[0.000037370395,0.00013358155,0.00047658943,0.00046326546,0.00010736465,0.00013164626,0.00015942367,0.00027182532,0.000007889385],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028055396,0.00016063696,0.000039267252,0.0012896045,0.001087608,0.0009445512,0.00008423536,0.00020940162,0.0002671333,0.0010452649,0.00007916451,0.9947651],"study_design_scores_gemma":[0.000758925,0.0004707713,0.00013944447,0.006731467,0.0011835231,0.0012755652,0.00014454933,0.0005378846,0.00019186368,0.00016056026,0.9882072,0.00019823061],"about_ca_topic_score_codex":0.000018612156,"about_ca_topic_score_gemma":0.000004741178,"teacher_disagreement_score":0.99456686,"about_ca_system_score_codex":0.00057753787,"about_ca_system_score_gemma":0.0002005376,"threshold_uncertainty_score":0.54472977},"labels":[],"label_agreement":null},{"id":"W4297266462","doi":"10.1210/endocr/bqac159","title":"The Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell","year":2022,"lang":"en","type":"review","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Temerty Faculty of Medicine, University of Toronto; Canadian Institutes of Health Research; University of Toronto","keywords":"Secretion; Paracrine signalling; Glucagon-like peptide-1; Glucagon-like peptide-2; Endocrinology; Biology; Internal medicine; Intestinal epithelium; Hormone; Gastrointestinal hormone; Cell; Peptide hormone; Stimulation; Endogeny; Glucagon; Epithelium; Peptide; Receptor; Medicine; Biochemistry; Type 2 diabetes; Diabetes mellitus","score_opus":0.03010775907578622,"score_gpt":0.31134263482192837,"score_spread":0.28123487574614214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297266462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004954455,0.98910546,0.000010476921,0.000115818206,0.00045663991,0.0011080786,0.0000148731015,0.000033225802,0.008659997],"genre_scores_gemma":[0.00021942996,0.98920417,0.000043687407,0.0001203949,0.000043140626,0.0005100703,0.00017702807,0.000041309886,0.009640764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983146,0.00025306205,0.00046279797,0.00031431357,0.00021978065,0.00043544805],"domain_scores_gemma":[0.99849147,0.00040705476,0.00037350768,0.0006600127,0.00002377657,0.000044208875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014526646,0.00029918255,0.00087242445,0.00008863342,0.00014708108,0.000011974415,0.00040635146,0.000061061066,0.00021259942],"category_scores_gemma":[0.00006889868,0.0001571832,0.00037789307,0.00017026375,0.00019742348,0.00001428385,0.0003743027,0.00039177833,0.00006039668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000134566035,0.000113663446,0.00004598565,0.0022057504,0.00025781203,0.00021129665,0.000021597956,1.4526762e-7,0.000005758344,0.00042110585,0.0070133517,0.98969007],"study_design_scores_gemma":[0.00035196854,0.00047915598,0.000009817631,0.0004884655,0.0018457705,0.00018688639,0.000065994616,0.0000046097903,0.000072317634,0.00003206251,0.9963461,0.00011682184],"about_ca_topic_score_codex":0.00003523002,"about_ca_topic_score_gemma":0.0000060538355,"teacher_disagreement_score":0.98957324,"about_ca_system_score_codex":0.00011350542,"about_ca_system_score_gemma":0.000104948085,"threshold_uncertainty_score":0.64097446},"labels":[],"label_agreement":null},{"id":"W4297399206","doi":"10.1016/j.ijcard.2022.09.053","title":"How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases","year":2022,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Renal function; Ejection fraction; Population; Database; Internal medicine; Emergency medicine; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.022081751055595924,"score_gpt":0.29277716255628633,"score_spread":0.27069541150069043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297399206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748023,0.0012129865,0.000045504254,0.02305998,0.00018971234,0.00024880905,0.00037992792,0.0000030752915,0.00005767787],"genre_scores_gemma":[0.99828804,0.00007980595,0.0003962061,0.00085428037,0.00013294148,0.0000132356845,0.00017921525,0.000006414592,0.00004987391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912655,0.000141547,0.0001715211,0.00011525926,0.00037233788,0.000072768984],"domain_scores_gemma":[0.9990429,0.00016460428,0.00020541948,0.00008622059,0.00044731895,0.00005348864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012216995,0.00007960943,0.0002815252,0.00011962646,0.000054846878,0.00001833556,0.0000803449,0.0000156759,0.0000037756724],"category_scores_gemma":[0.000061716986,0.000052387775,0.000043741806,0.00004972561,0.0000607419,0.00009366273,0.00013274884,0.000117563926,1.2464756e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018131164,0.000051991643,0.9882185,0.000027677439,0.0005208884,0.00005009957,0.0004854274,0.00001016411,0.0001475278,0.0002876597,0.00634207,0.0020449008],"study_design_scores_gemma":[0.002423188,0.0022562577,0.9458081,0.00019050593,0.00012454887,0.00005022103,0.0038855998,7.675614e-7,0.00032789705,0.000059453898,0.044819918,0.000053520376],"about_ca_topic_score_codex":0.00002313156,"about_ca_topic_score_gemma":0.00001835154,"teacher_disagreement_score":0.042410355,"about_ca_system_score_codex":0.00010722285,"about_ca_system_score_gemma":0.0000756075,"threshold_uncertainty_score":0.21363115},"labels":[],"label_agreement":null},{"id":"W4297457272","doi":"10.1016/j.diabres.2022.110094","title":"Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes","year":2022,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; McGill University","keywords":"Medicine; Hazard ratio; Mace; Internal medicine; Body mass index; Type 2 diabetes; Proportional hazards model; Diabetes mellitus; Overweight; Obesity; Cohort; Cohort study; Confidence interval; Endocrinology; Myocardial infarction","score_opus":0.048983846060823476,"score_gpt":0.38344409484689834,"score_spread":0.3344602487860749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297457272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98918027,0.0060326257,5.0764766e-7,0.00045456272,0.00020271708,0.0012004199,0.000012968247,0.000010284045,0.0029056745],"genre_scores_gemma":[0.99858034,0.00093825,0.00004620159,0.0001278942,0.00003954516,0.00010464583,0.000019200068,0.000017897744,0.00012602731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952004,0.0022852367,0.0005363708,0.0003969778,0.0011528622,0.00042817535],"domain_scores_gemma":[0.99402326,0.004725592,0.0001373067,0.0006147723,0.00035746288,0.00014160028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01030726,0.00013466454,0.000649966,0.00016430883,0.0001356274,0.000013912253,0.00022274216,0.0000803467,0.000056071436],"category_scores_gemma":[0.0037887048,0.00009937582,0.00031978852,0.0008667145,0.00047275698,0.00015526172,0.00042397343,0.0008178156,0.0000063618572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012339387,0.0045645535,0.9697519,0.00089181005,0.0018563021,0.000042431,0.000114719085,0.000022673448,0.001615615,0.0005254353,0.00020873432,0.019171912],"study_design_scores_gemma":[0.005148263,0.005934924,0.94522184,0.00033707893,0.0008480255,0.0000012131105,0.0007559365,0.00016705491,0.019401958,0.0013319028,0.02067477,0.00017704058],"about_ca_topic_score_codex":0.0001743943,"about_ca_topic_score_gemma":0.000005512746,"teacher_disagreement_score":0.024530046,"about_ca_system_score_codex":0.00008168108,"about_ca_system_score_gemma":0.00017781134,"threshold_uncertainty_score":0.4535707},"labels":[],"label_agreement":null},{"id":"W4297492332","doi":"10.1186/s12933-022-01614-5","title":"Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling","year":2022,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Natural Science Foundation of China","keywords":"Medicine; Internal medicine; Cardiology; Ventricle; Heart failure; Pulmonary hypertension; Dapagliflozin; Connexin; Sudden cardiac death; Gap junction; Endocrinology; Diabetes mellitus; Chemistry","score_opus":0.016069117016032804,"score_gpt":0.22856712212705801,"score_spread":0.2124980051110252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297492332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990908,0.0039265193,0.00011964826,0.0026115065,0.00073812035,0.001321347,0.000018126833,0.000064379856,0.00029235234],"genre_scores_gemma":[0.99830765,0.000009978561,0.00029824537,0.00028978268,0.00036544522,0.0005049771,0.00009129932,0.00004030186,0.00009232087],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99727845,0.00051347987,0.00035461335,0.0006594316,0.0006796948,0.00051432755],"domain_scores_gemma":[0.9983632,0.0001078646,0.000086521235,0.0011447988,0.00012869062,0.00016890939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092428655,0.0002822272,0.0010710144,0.00015408525,0.0003603622,0.000017964312,0.00020183568,0.000085867374,0.00007040682],"category_scores_gemma":[0.00008736532,0.00019352778,0.0005696768,0.00049360166,0.000111661044,0.00006067929,0.0002569374,0.00031763816,0.000009817333],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002189507,0.001849627,0.027055975,0.0005526608,0.022948299,0.0061859093,0.00088917,0.0047178874,0.8694378,0.0003032402,0.024888111,0.038981795],"study_design_scores_gemma":[0.0050613983,0.00170356,0.015882324,0.000149502,0.004725975,0.0010534535,0.00093813974,0.00015700865,0.4411369,0.00006600221,0.5283743,0.0007514055],"about_ca_topic_score_codex":0.000051594823,"about_ca_topic_score_gemma":0.0000015194659,"teacher_disagreement_score":0.5034862,"about_ca_system_score_codex":0.00018711352,"about_ca_system_score_gemma":0.00008507566,"threshold_uncertainty_score":0.78918344},"labels":[],"label_agreement":null},{"id":"W4297518766","doi":"10.2337/dc22-1174","title":"Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Cancer Research UK; McGill University; Canadian Institutes of Health Research; National Institute on Aging; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Hazard ratio; Internal medicine; Bladder cancer; Propensity score matching; Proportional hazards model; Population; Type 2 diabetes; Cohort study; Cancer registry; Oncology; Cohort; Dipeptidyl peptidase-4; Cancer; Diabetes mellitus; Endocrinology; Confidence interval; Environmental health","score_opus":0.007182695729157482,"score_gpt":0.25164124009434263,"score_spread":0.24445854436518516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297518766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593353,0.0009728653,5.3076315e-7,0.0001108822,0.00038324433,0.0015997748,0.00030715915,0.000038130063,0.0006538745],"genre_scores_gemma":[0.99821997,0.00022732078,0.000020092984,0.00018203884,0.00009773811,0.0006737116,0.0004093648,0.000023278435,0.00014650692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987527,0.000093715935,0.00024201452,0.00030159118,0.00042577717,0.00018417876],"domain_scores_gemma":[0.99938846,0.000042795695,0.00008667564,0.0003240334,0.000088133515,0.00006992294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022921394,0.00015752764,0.0003168362,0.00009788929,0.00014186864,0.000022084658,0.00014602534,0.000021733531,0.00031659575],"category_scores_gemma":[0.000007774682,0.00011172392,0.00010105947,0.00010202894,0.000110717956,0.00009456451,0.00013195901,0.00014994433,0.0000027989367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012262451,0.00039519707,0.9774029,0.00003404004,0.0013103475,0.000012059867,0.004186595,0.000026937056,0.000125729,0.000013804325,0.00017401045,0.016195731],"study_design_scores_gemma":[0.0040963963,0.0004806779,0.98590946,0.000018803734,0.0014384107,2.4640008e-7,0.0052822228,0.00020722774,0.0008880551,0.0000064312258,0.001558567,0.00011349305],"about_ca_topic_score_codex":0.00016098426,"about_ca_topic_score_gemma":0.00014794587,"teacher_disagreement_score":0.016082238,"about_ca_system_score_codex":0.00008168778,"about_ca_system_score_gemma":0.000016623058,"threshold_uncertainty_score":0.45559692},"labels":[],"label_agreement":null},{"id":"W4298001471","doi":"10.1186/s12902-022-01140-1","title":"Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom","year":2022,"lang":"en","type":"article","venue":"BMC Endocrine Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Université de Montréal; University of Calgary; Health Sciences Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Saskatchewan Health Quality Council; Institut National d'Excellence en Santé et en Services Sociaux; University of Manitoba; Memorial University of Newfoundland; University of British Columbia; McGill University Health Centre; Institute for Clinical Evaluative Sciences; McGill University; Centre Hospitalier de l’Université de Montréal; Manitoba Health","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Cohort; Diabetes mellitus; Glucagon-like peptide-1; Coronary artery disease; Type 2 diabetes; Internal medicine; First line; Cohort study; Pharmacology; Endocrinology","score_opus":0.017349906455472526,"score_gpt":0.24485729126733452,"score_spread":0.227507384811862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298001471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722654,0.00016014041,0.000003929647,0.0015703288,0.000097745506,0.00046260716,0.000013342181,0.000006008885,0.000459386],"genre_scores_gemma":[0.9987598,0.0005767781,0.00006861162,0.00021107716,0.0000059662734,0.00002851671,0.000079232756,0.000011369822,0.0002586369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991783,0.00005633015,0.00025474472,0.00011802816,0.00022156099,0.00017106063],"domain_scores_gemma":[0.999527,0.000107817716,0.00011411376,0.0001886684,0.00001935014,0.00004307426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009217617,0.00009433109,0.00028058176,0.00012928866,0.000027669206,0.0000024283108,0.00007853586,0.0000045614183,0.00017016457],"category_scores_gemma":[0.00006300923,0.000072429204,0.000035438847,0.00036592348,0.000058637936,0.000014465052,0.00010931735,0.00007737826,1.9945007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038179927,0.00015368995,0.98641384,0.0001805755,0.00010113024,0.000005338392,0.00041332588,0.000099702134,0.000020766089,0.0011517949,0.0008353479,0.010242686],"study_design_scores_gemma":[0.013407356,0.00021570585,0.9367108,0.000049202445,0.00028165238,0.0000016565024,0.0030385018,0.0007003318,0.00023791552,0.00019417598,0.04502607,0.00013664275],"about_ca_topic_score_codex":0.7145381,"about_ca_topic_score_gemma":0.32640812,"teacher_disagreement_score":0.38813,"about_ca_system_score_codex":0.00010646985,"about_ca_system_score_gemma":0.0003473203,"threshold_uncertainty_score":0.68588316},"labels":[],"label_agreement":null},{"id":"W4298327040","doi":"10.1210/clinem/dgac558","title":"Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock","year":2022,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Septic shock; Relative risk; Internal medicine; Pneumonia; Placebo; Randomized controlled trial; Subgroup analysis; Context (archaeology); Glycemic; Intensive care medicine; Meta-analysis; Insulin; Sepsis; Confidence interval; Pathology","score_opus":0.01886908617206605,"score_gpt":0.30298670069985084,"score_spread":0.2841176145277848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298327040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97572464,0.0135519495,0.000011105557,0.009401233,0.00059479126,0.0003087166,0.000006479988,0.000007496014,0.00039357043],"genre_scores_gemma":[0.97954476,0.01830727,0.000117560616,0.0013425401,0.00029208354,0.000007913288,0.0000011466932,0.000013031238,0.00037366612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737734,0.00085758197,0.0010872841,0.00013071517,0.00031176215,0.00023530454],"domain_scores_gemma":[0.9975821,0.001174646,0.0007870021,0.00027450905,0.000076826946,0.00010493031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023139159,0.00014436379,0.00093643094,0.00009849124,0.00015154236,0.000006441631,0.00019706205,0.000038808317,0.000092742586],"category_scores_gemma":[0.0002453561,0.00006843666,0.00030235652,0.000101425845,0.0008655457,0.000051479245,0.00018193724,0.0008308689,0.0000020653486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026414007,0.0034196968,0.58752716,0.00021153683,0.016429083,0.00082033075,0.006178862,0.00017004112,0.0026737456,0.02241183,0.007561601,0.3261821],"study_design_scores_gemma":[0.026241146,0.001690652,0.848116,0.000032789456,0.011294119,0.00066564657,0.0011099527,0.000099369834,0.0006545241,0.004592268,0.10536721,0.00013631071],"about_ca_topic_score_codex":0.000029924193,"about_ca_topic_score_gemma":0.0000048857046,"teacher_disagreement_score":0.32604578,"about_ca_system_score_codex":0.0000076794795,"about_ca_system_score_gemma":0.00005163039,"threshold_uncertainty_score":0.3609758},"labels":[],"label_agreement":null},{"id":"W4299340080","doi":"10.17615/ct1e-g414","title":"Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharma; National Institutes of Health; Servier; Belvoir Media Group; Duke Clinical Research Institute; Novo Nordisk; Dexcom; Intarcia Therapeutics; Medicines Company; St. Jude Medical; MannKind Corporation; Regeneron Pharmaceuticals; Cleveland Clinic; Valeant Pharmaceuticals International; Kowa Company; Sanofi; AstraZeneca; Eli Lilly and Company; Esperion Therapeutics; GlaxoSmithKline; Amgen","keywords":"Liraglutide; Medicine; Internal medicine; Statin; Baseline (sea); Type 2 Diabetes Mellitus; Diabetes mellitus; Type 2 diabetes; Cholesterol; Cardiology; Endocrinology; Biology","score_opus":0.0592623738909814,"score_gpt":0.2493397760040744,"score_spread":0.19007740211309299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299340080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337816,0.0035153667,0.000017612718,0.0017140196,0.0000975769,0.0010446701,0.00016878791,0.00003384971,0.000029964458],"genre_scores_gemma":[0.9978958,0.00011137514,0.0009964557,0.00056763546,0.00016172238,0.000017556586,0.00015547944,0.000017849146,0.00007616719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839187,0.00022395198,0.00041549327,0.00040014082,0.00036408237,0.00020445674],"domain_scores_gemma":[0.9990708,0.00030722475,0.00011582581,0.00035272905,0.000041805917,0.000111565256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044442923,0.00019514051,0.00053859147,0.000044689434,0.00005512481,0.000099819095,0.00009110515,0.00007798137,0.000013226993],"category_scores_gemma":[0.0006105569,0.0001356444,0.00008741872,0.00017718658,0.00019121125,0.00041608317,0.00017863083,0.00015555968,0.00000255477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042627882,0.0014457944,0.7860337,0.0010386744,0.010154828,0.00020634543,0.02275734,0.00010853024,0.0029349683,0.0015807392,0.0024364311,0.12867479],"study_design_scores_gemma":[0.036401674,0.00068234734,0.9200508,0.0003115368,0.00083833263,2.8781824e-7,0.0007573326,0.00020257004,0.037573464,0.001766466,0.0011817658,0.00023342347],"about_ca_topic_score_codex":0.001096453,"about_ca_topic_score_gemma":0.000105900755,"teacher_disagreement_score":0.13401712,"about_ca_system_score_codex":0.000012194907,"about_ca_system_score_gemma":0.000066085246,"threshold_uncertainty_score":0.55314183},"labels":[],"label_agreement":null},{"id":"W4301387559","doi":"","title":"[Comments on current guidelines of type 2 diabetes mellitus treatment].","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetology; Medicine; Glycemic; Compliance (psychology); Diabetes mellitus; Intensive care medicine; Alternative medicine; Family medicine; Psychology; Endocrinology; Pathology","score_opus":0.10665939375761549,"score_gpt":0.3365159353149602,"score_spread":0.22985654155734472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301387559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95557857,0.004002428,0.000001727599,0.0043204334,0.0013121449,0.0016696813,0.000016350725,0.000064768516,0.033033874],"genre_scores_gemma":[0.99291444,0.0016216874,0.00010397922,0.00023079413,0.00019133056,0.0005763659,0.00004460213,0.000017989885,0.004298812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990552,0.000012416441,0.00022644261,0.00020571698,0.00019287369,0.00030737242],"domain_scores_gemma":[0.99891686,0.000024503179,0.00016004965,0.0006783358,0.000095412826,0.00012482297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001215297,0.00015859508,0.00030689902,0.000083262676,0.00008519165,0.000031409596,0.00013474446,0.000029818706,0.00003235217],"category_scores_gemma":[0.00016105342,0.00011033011,0.00010669731,0.000039054983,0.00005343343,0.00006712145,0.00006021813,0.00003393709,0.000050913233],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063468884,0.0006607016,0.09950097,0.000049362472,0.0002658225,0.0000039939937,0.000014679932,8.079504e-7,0.000012066642,0.00025875733,0.008774649,0.89039475],"study_design_scores_gemma":[0.0031386258,0.00052305235,0.6426497,0.000088111396,0.00048386556,1.5220579e-7,0.000007612486,0.000034283898,0.007016081,0.00020589183,0.34572378,0.00012881767],"about_ca_topic_score_codex":0.000017570643,"about_ca_topic_score_gemma":0.0000028804006,"teacher_disagreement_score":0.8902659,"about_ca_system_score_codex":0.00008970423,"about_ca_system_score_gemma":0.0000125880715,"threshold_uncertainty_score":0.44991314},"labels":[],"label_agreement":null},{"id":"W4302292984","doi":"10.1111/dom.14890","title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: <scp>STEP</scp> 1 and 4 exploratory analyses","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Medicine; Overweight; Semaglutide; Obesity; Internal medicine; Gerontology; Type 2 diabetes; Endocrinology; Diabetes mellitus; Liraglutide","score_opus":0.014075579139428468,"score_gpt":0.23548500658293253,"score_spread":0.22140942744350406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302292984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837478,0.014440296,0.0000066989533,0.000041597727,0.00019974489,0.00096015213,0.00012692441,0.00011555224,0.00036124137],"genre_scores_gemma":[0.99485266,0.0030094527,0.00042197763,0.0003267087,0.00013121517,0.00024340663,0.000108716944,0.000050836665,0.00085500476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737906,0.00026572714,0.00036085086,0.00075228536,0.0005376716,0.00070440857],"domain_scores_gemma":[0.99862236,0.00029429235,0.00020906156,0.00046339474,0.0000639161,0.00034696946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004687308,0.0004895877,0.0011980821,0.0007404014,0.00041953745,0.00007886272,0.00014552534,0.000085374704,0.000030432511],"category_scores_gemma":[0.00017468921,0.00035086466,0.00015040788,0.0009442136,0.00018429704,0.00030874938,0.0003949241,0.00039417922,0.0000042874426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008531907,0.0007597912,0.9867438,0.00031775047,0.0011018893,0.0000785446,0.00213735,0.000014330423,0.00078164117,0.0001437141,0.00047151188,0.0073643723],"study_design_scores_gemma":[0.0043914164,0.00044708353,0.95575154,0.00008200607,0.0020194203,0.0000034665154,0.0039020292,0.00016744561,0.0036715704,0.00007888303,0.029256385,0.00022874345],"about_ca_topic_score_codex":0.00041029224,"about_ca_topic_score_gemma":0.00013496309,"teacher_disagreement_score":0.030992236,"about_ca_system_score_codex":0.000064187996,"about_ca_system_score_gemma":0.00007900414,"threshold_uncertainty_score":0.9998943},"labels":[],"label_agreement":null},{"id":"W4303859053","doi":"10.14740/jem834","title":"The Difference in Glucagon Response to Breakfast Between Non-Obese Patients With Long-Duration Type 1 and Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Postprandial; Internal medicine; Endocrinology; Glucagon; Type 1 diabetes; Meal; Type 2 diabetes; Insulin; Diabetes mellitus; Body mass index; Hemoglobin","score_opus":0.00945876683130445,"score_gpt":0.2469521125195562,"score_spread":0.23749334568825176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303859053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961593,0.0018856631,0.0000048749025,0.0014383704,0.00023384496,0.00022376968,0.0000026210594,0.0000035196367,0.00004803125],"genre_scores_gemma":[0.99881405,0.00036621594,0.000102783524,0.00023207921,0.000054082415,0.000009319407,0.0000051107854,0.000007151702,0.00040921976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992136,0.00011981877,0.00021072457,0.00010486575,0.0001506337,0.00020037543],"domain_scores_gemma":[0.9994426,0.00014690285,0.00011793292,0.00009890594,0.00011502111,0.0000786777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023378916,0.00009216733,0.00025505983,0.00019044169,0.000120180564,0.000015117071,0.000064340995,0.000017575663,0.000011242682],"category_scores_gemma":[0.00012673545,0.00005468399,0.000016450742,0.0002175809,0.000051942166,0.000056600613,0.00009671762,0.0001906898,0.0000012996405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024065678,0.00012618676,0.9442685,0.000009939222,0.00017210777,0.000037517897,0.00024024716,0.000001823073,0.0006913716,0.000067607005,0.00013840478,0.05183969],"study_design_scores_gemma":[0.0025373823,0.0017432257,0.9792429,0.000022812412,0.00020942837,0.000011082606,0.000083156025,0.0000020271523,0.000380565,0.000070648166,0.015643127,0.00005365043],"about_ca_topic_score_codex":0.0000049883693,"about_ca_topic_score_gemma":0.000010241066,"teacher_disagreement_score":0.051786043,"about_ca_system_score_codex":0.000025672927,"about_ca_system_score_gemma":0.000041750543,"threshold_uncertainty_score":0.22299483},"labels":[],"label_agreement":null},{"id":"W4303946044","doi":"10.3390/jcm11195956","title":"Association between SGLT2 Inhibitors and Cardiac Rehabilitation Outcomes in Patients with Cardiovascular Disease and Type 2 Diabetes Mellitus","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Kaken Pharmaceutical","keywords":"Medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Internal medicine; Dapagliflozin; Outpatient clinic; Type 2 diabetes; Rehabilitation; Disease; Grip strength; Physical therapy; Isometric exercise; Cardiology; Endocrinology","score_opus":0.01515746514495953,"score_gpt":0.30011846277148035,"score_spread":0.28496099762652083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303946044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894692,0.003948428,0.0000011599019,0.005684539,0.00044645963,0.000383243,0.0000053093518,0.0000055920164,0.000056086876],"genre_scores_gemma":[0.9987582,0.00048319699,0.00014427138,0.00018152197,0.00029491947,0.0000075937187,0.000020650119,0.000011178772,0.00009849478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978335,0.00027861286,0.00075099245,0.00016002588,0.000839615,0.00013725052],"domain_scores_gemma":[0.99797434,0.001117901,0.00036707072,0.00014553688,0.00017003792,0.0002251299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027952322,0.00010660094,0.0009339845,0.00016832165,0.000040612522,0.0000058243772,0.000035246725,0.000035998128,0.000016203749],"category_scores_gemma":[0.0025045143,0.000067733265,0.00014946877,0.00017505969,0.00007337453,0.000088569876,0.0000495481,0.00027769912,4.2683914e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030850444,0.0002321964,0.96269286,0.00006198774,0.0021967161,0.000009770723,0.000100377314,0.000007925336,3.369962e-7,0.0000068693093,0.0007265552,0.033655897],"study_design_scores_gemma":[0.0071700923,0.0059261736,0.97539973,0.00015307276,0.0031288965,7.1177865e-8,0.000123283,0.000004964605,4.7940085e-7,0.00012207164,0.007909802,0.00006136649],"about_ca_topic_score_codex":0.000007753879,"about_ca_topic_score_gemma":4.2095013e-7,"teacher_disagreement_score":0.03359453,"about_ca_system_score_codex":0.000120847435,"about_ca_system_score_gemma":0.000041826017,"threshold_uncertainty_score":0.29983184},"labels":[],"label_agreement":null},{"id":"W4304080455","doi":"10.1038/s41591-022-02026-4","title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":787,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Medicine; Placebo; Overweight; Discontinuation; Weight loss; Internal medicine; Body mass index; Obesity; Randomized controlled trial; Adverse effect; Confidence interval; Weight change; Physical therapy; Diabetes mellitus; Type 2 diabetes; Liraglutide; Endocrinology","score_opus":0.003848795909790984,"score_gpt":0.24354432689274125,"score_spread":0.23969553098295027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304080455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793101,0.002285587,0.0000043850478,0.00424388,0.00065848447,0.0026024205,0.0000041216276,0.000037492922,0.010853513],"genre_scores_gemma":[0.99400634,0.000062609724,0.0001895276,0.0018706106,0.00038565087,0.00018561105,0.000042751544,0.000021715416,0.0032351639],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99839807,0.0001109069,0.00023765542,0.0002521824,0.0007657,0.00023550363],"domain_scores_gemma":[0.99904835,0.0003321279,0.000119307115,0.00038850395,0.000043658896,0.00006802639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041579513,0.00017376443,0.0004790545,0.00019435828,0.00006487921,0.0000024624858,0.00015201428,0.000059666905,0.00039779558],"category_scores_gemma":[0.00019869824,0.00007933693,0.000052251264,0.0006376039,0.00010227385,0.000022753457,0.00010310575,0.00064071256,0.0000031909203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6058892,0.009651248,0.12844725,0.005846168,0.0031857227,0.0073895575,0.010126526,0.000045512716,0.0012756779,0.028410481,0.15823147,0.041501172],"study_design_scores_gemma":[0.7486761,0.047506377,0.079884596,0.0037791033,0.0024452768,0.00006826451,0.0060319733,0.0002214531,0.0028211724,0.00023674767,0.1078598,0.00046909897],"about_ca_topic_score_codex":0.00011081946,"about_ca_topic_score_gemma":0.00014740009,"teacher_disagreement_score":0.14278692,"about_ca_system_score_codex":0.00011974816,"about_ca_system_score_gemma":0.000072580726,"threshold_uncertainty_score":0.43555826},"labels":[],"label_agreement":null},{"id":"W4304206680","doi":"10.21203/rs.3.rs-2135939/v1","title":"The Cost-effectiveness of Subcutaneous Semaglutide 2.4 mg Injection for Chronic Weight Management in Canada: A Societal Perspective","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Semaglutide; Medicine; Liraglutide; Overweight; Quality-adjusted life year; Body mass index; Weight loss; Weight management; Obesity; Internal medicine; Cost effectiveness; Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.04112214824703318,"score_gpt":0.3808431305934685,"score_spread":0.33972098234643533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304206680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8713804,0.021293713,0.00034661204,0.0039053364,0.001848456,0.06497786,0.00073633733,0.00012595445,0.035385348],"genre_scores_gemma":[0.98579395,0.0012912478,0.00006935115,0.000012940751,0.00011426633,0.009511514,0.00026804412,0.000055281096,0.002883401],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99625957,0.0006184292,0.0003376079,0.0006771646,0.001310617,0.0007966094],"domain_scores_gemma":[0.9975734,0.0010447308,0.00012244617,0.0006898623,0.000462403,0.000107154636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022455924,0.00027085314,0.0005226365,0.0003650711,0.0003320295,0.000038556034,0.00034712665,0.000092041446,0.00009488042],"category_scores_gemma":[0.00012680715,0.00021379738,0.00026673148,0.0005271633,0.0001427402,0.000023221575,0.0011640296,0.0009399762,0.0000028851966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033297475,0.007767505,0.06556414,0.13003369,0.031736165,0.010417153,0.0067885392,0.04120077,0.00082449196,0.19702572,0.03963776,0.4357066],"study_design_scores_gemma":[0.041875616,0.03128479,0.45057568,0.015126372,0.0037144274,0.00015807872,0.16513267,0.031713992,0.003640404,0.059678435,0.19388258,0.003216931],"about_ca_topic_score_codex":0.37681413,"about_ca_topic_score_gemma":0.48768982,"teacher_disagreement_score":0.43248966,"about_ca_system_score_codex":0.02615411,"about_ca_system_score_gemma":0.0033794877,"threshold_uncertainty_score":0.9775843},"labels":[],"label_agreement":null},{"id":"W4306166068","doi":"10.1111/dom.14893","title":"Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Oxford; National Institute for Health and Care Research","keywords":"Observational study; Meta-analysis; Medicine; Type 2 diabetes; Clinical trial; Systematic review; Randomized controlled trial; Internal medicine; Diabetes mellitus; Heart failure; Clinical Practice; MEDLINE; Intensive care medicine; Physical therapy; Endocrinology","score_opus":0.26656893213608385,"score_gpt":0.4697742417022192,"score_spread":0.20320530956613536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306166068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015122656,0.973232,1.3346217e-7,0.00057211076,0.00031267258,0.010296242,0.0004065805,0.000037003636,0.00002060395],"genre_scores_gemma":[0.00024343368,0.99305636,0.00072553963,0.0014108709,0.00014186639,0.0027866706,0.0014513744,0.000057291945,0.0001265798],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.991334,0.0019765415,0.0044552553,0.00110542,0.0005884049,0.000540342],"domain_scores_gemma":[0.99040806,0.006142005,0.0021688803,0.00071562757,0.0003396293,0.00022581799],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008124824,0.0007589816,0.018386882,0.0012301034,0.00009628175,0.000037758855,0.00021960969,0.0003533099,0.000049535356],"category_scores_gemma":[0.004263914,0.0005614546,0.0026171587,0.0025950437,0.00019833988,0.0002515202,0.00016695782,0.00073232857,0.00000203845],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042455937,0.0027276734,0.013215341,0.7434776,0.23276152,0.000014611108,0.00010207782,6.7360986e-7,6.546017e-8,0.00033594106,0.00096019247,0.005979769],"study_design_scores_gemma":[0.0065524178,0.0004553028,0.007262256,0.026792074,0.74726516,3.122189e-7,0.00006587905,0.000004962073,4.329864e-7,0.000024909517,0.21117103,0.0004052607],"about_ca_topic_score_codex":0.000015982107,"about_ca_topic_score_gemma":0.00028682305,"teacher_disagreement_score":0.7166855,"about_ca_system_score_codex":0.00009008491,"about_ca_system_score_gemma":0.00023092183,"threshold_uncertainty_score":0.9996837},"labels":[],"label_agreement":null},{"id":"W4306254909","doi":"10.1093/eurheartj/ehac544.3004","title":"GLP-2 as an indicator and modulator of acute inflammation improves cardiac function and survival in sepsis","year":2022,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University Health Network; Mount Sinai Hospital","funders":"European Research Area Network on Cardiovascular Diseases; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; European Foundation for the Study of Diabetes","keywords":"Medicine; Sepsis; Inflammation; Proinflammatory cytokine; Internal medicine; Immune system; Systemic inflammation; Glucagon-like peptide-2; Endocrinology; Calprotectin; Immunology; Inflammatory bowel disease; Biology; Peptide","score_opus":0.014386573614022319,"score_gpt":0.25876862528356565,"score_spread":0.24438205166954333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306254909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977132,0.00023345987,0.000005432126,0.00045501872,0.00019614908,0.00017030379,0.0000046752243,0.000012238271,0.001209537],"genre_scores_gemma":[0.9992108,0.000118065116,0.00015240462,0.00010085762,0.00013949285,0.0000033800504,0.000014666733,0.000015779882,0.0002445767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916005,0.00022602927,0.00017796463,0.00012353691,0.00020124952,0.000111140806],"domain_scores_gemma":[0.99968815,0.000012597916,0.000082873696,0.000092066955,0.000016110565,0.00010820625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066822907,0.000074595,0.00016895377,0.00018038665,0.00010045592,0.000027129263,0.000026097885,0.00000967249,0.00005895044],"category_scores_gemma":[0.000010102163,0.00006684386,0.000037240843,0.000083806925,0.00002373226,0.00014649557,0.00008018778,0.00015285546,0.0000044045914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047797183,0.00020647208,0.8836274,0.00006185184,0.00057295425,0.00009802378,0.0011505616,0.000014103004,0.059057694,0.00033040653,0.0010048595,0.05339769],"study_design_scores_gemma":[0.0013152136,0.0012468189,0.98760897,0.000016024249,0.00019060023,0.00003366747,0.0003622379,0.000083523955,0.00029544704,0.00007507908,0.008711586,0.00006084511],"about_ca_topic_score_codex":0.000006830372,"about_ca_topic_score_gemma":6.682646e-7,"teacher_disagreement_score":0.10398155,"about_ca_system_score_codex":0.000037818343,"about_ca_system_score_gemma":0.000020744275,"threshold_uncertainty_score":0.27258134},"labels":[],"label_agreement":null},{"id":"W4306290848","doi":"10.1093/eurheartj/ehac544.962","title":"Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Heart failure; Ejection fraction; Post-hoc analysis; Population; Placebo; Internal medicine; Clinical trial; Post hoc; Diabetes mellitus; Randomized controlled trial; Cardiology; Endocrinology","score_opus":0.04126096342597871,"score_gpt":0.34397939297123603,"score_spread":0.3027184295452573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306290848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937924,0.00009161231,0.00011606967,0.0034558186,0.0009801264,0.0013781034,0.00008033246,0.000010682859,0.000094829076],"genre_scores_gemma":[0.998857,0.000013869266,0.000053887976,0.00014593065,0.0006457157,0.000018694163,0.00007899843,0.00001615483,0.00016974531],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982752,0.00047688987,0.00046237084,0.0001318787,0.0005037963,0.00014983838],"domain_scores_gemma":[0.9989317,0.00018312642,0.00041909333,0.00026194294,0.00015687782,0.0000472356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010476183,0.00010659131,0.0002605789,0.000055026554,0.0003796702,0.000023845934,0.000112842274,0.000019434652,0.000080375525],"category_scores_gemma":[0.00040876676,0.0000641311,0.00041879574,0.00024366766,0.00006696792,0.000083086765,0.00007003095,0.00022117786,0.0000019547006],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7827634,0.006259696,0.016857548,0.00018338616,0.0021644991,0.000008662918,0.0019332943,0.003853764,0.036576748,0.0003035694,0.13619636,0.01289904],"study_design_scores_gemma":[0.22778237,0.03323845,0.5791429,0.00023019842,0.0010401539,0.00003768502,0.0015848572,0.00019710526,0.021929696,0.000037151625,0.13459149,0.00018791009],"about_ca_topic_score_codex":0.000014861524,"about_ca_topic_score_gemma":0.0000017113764,"teacher_disagreement_score":0.56228536,"about_ca_system_score_codex":0.00012260448,"about_ca_system_score_gemma":0.00006073984,"threshold_uncertainty_score":0.29201546},"labels":[],"label_agreement":null},{"id":"W4306316594","doi":"10.46747/cfp.6810e283","title":"Inhibiteurs du cotransporteur sodium-glucose de type 2","year":2022,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Prairie Improvement Network; Francophone University Association; University of Alberta; University of Winnipeg","funders":"","keywords":"Medicine; Gynecology","score_opus":0.013186670091319734,"score_gpt":0.2126678358901029,"score_spread":0.19948116579878317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306316594","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46049038,0.048482344,0.00001112446,0.010561725,0.008063448,0.001243191,0.00076700194,0.00013249808,0.47024828],"genre_scores_gemma":[0.7560009,0.00091118965,0.000072288196,0.20341578,0.0016546764,0.00011939235,0.00084559916,0.00013569926,0.03684448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972818,0.00012505818,0.00028895572,0.00049323944,0.0003622909,0.0014486508],"domain_scores_gemma":[0.9981014,0.0000346329,0.00008772033,0.0005129315,0.00007529397,0.001187986],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025872487,0.00037516063,0.00042888784,0.00035116912,0.0005169308,0.000054734097,0.00029669175,0.00008652201,0.00031666135],"category_scores_gemma":[0.000008212976,0.00047782637,0.0002088878,0.00085131894,0.00015848532,0.00013974536,0.0000680468,0.00044709755,0.0010287983],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011272053,0.0008971278,0.006607535,0.00028297052,0.0009467106,0.004924992,0.0011240229,0.00047420268,0.0025632782,0.023724893,0.6721745,0.28616706],"study_design_scores_gemma":[0.0015147423,0.000690428,0.016774628,0.0001227611,0.0007655664,0.0000035802987,0.0025752936,0.00035797388,0.00031915578,0.00046314384,0.97598016,0.00043256226],"about_ca_topic_score_codex":0.037150823,"about_ca_topic_score_gemma":0.010898324,"teacher_disagreement_score":0.43340382,"about_ca_system_score_codex":0.0026453875,"about_ca_system_score_gemma":0.0017504315,"threshold_uncertainty_score":0.99976736},"labels":[],"label_agreement":null},{"id":"W4306318992","doi":"10.1093/eurheartj/ehac544.1939","title":"Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis","year":2022,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"","keywords":"Medicine; Semaglutide; Type 2 diabetes; Internal medicine; Stroke (engine); Diabetes mellitus; Dipeptidyl peptidase-4; Gestational diabetes; Pediatrics; Pregnancy; Endocrinology; Gestation; Liraglutide","score_opus":0.017496127007683573,"score_gpt":0.25883735858486423,"score_spread":0.24134123157718065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306318992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957388,0.00008755238,0.000005951264,0.000092104754,0.00012582874,0.00034171998,0.00010102614,0.000031999745,0.0034750004],"genre_scores_gemma":[0.9942171,0.00007508185,0.0015652012,0.00019466544,0.00012108247,0.0000069321204,0.00013462007,0.000053216903,0.0036321296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974432,0.0006582172,0.0005046636,0.00030705731,0.00067400426,0.00041288362],"domain_scores_gemma":[0.9987993,0.000105426334,0.00034230057,0.0004296503,0.00010847935,0.00021484491],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011952595,0.00021571497,0.0005331978,0.0009987091,0.00021903733,0.000042018128,0.00014339996,0.000011011131,0.0009271577],"category_scores_gemma":[0.00008662068,0.00015628211,0.00018250823,0.0014852962,0.0000490495,0.00013183757,0.00024827043,0.0005487435,0.00002599744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070306764,0.00076729065,0.9889754,0.00003573791,0.0012689667,0.00023509527,0.00018991962,0.00052441517,0.00017276286,0.0000020475543,0.005679961,0.0014453433],"study_design_scores_gemma":[0.0034779818,0.002106413,0.9841467,0.00018462249,0.0015808099,0.000004465443,0.00013241799,0.00018131554,0.00008197628,0.0000014516511,0.00793665,0.00016518094],"about_ca_topic_score_codex":0.000046566583,"about_ca_topic_score_gemma":0.00021571112,"teacher_disagreement_score":0.004828677,"about_ca_system_score_codex":0.0002212251,"about_ca_system_score_gemma":0.000076352575,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W4306319388","doi":"10.1093/eurheartj/ehac544.2400","title":"Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute","funders":"","keywords":"Medicine; Dulaglutide; Post-hoc analysis; Internal medicine; Hazard ratio; Myocardial infarction; Clinical endpoint; Placebo; Type 2 diabetes; Stroke (engine); Cardiology; Diabetes mellitus; Randomized controlled trial; Liraglutide; Confidence interval; Endocrinology","score_opus":0.07176318798663013,"score_gpt":0.360744396456621,"score_spread":0.28898120846999087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306319388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484116,0.00009243435,0.000006526967,0.0018561613,0.00054184947,0.00037201043,0.00002193114,0.000025810745,0.0022421305],"genre_scores_gemma":[0.99648213,0.000011396247,0.00025425293,0.0009650367,0.00024148577,0.000003763044,0.0000104234805,0.00003303384,0.0019985032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771607,0.00074222,0.00051687885,0.00018835599,0.0005462246,0.00029024694],"domain_scores_gemma":[0.998996,0.000077654724,0.0003384391,0.00038445488,0.000069217625,0.00013419297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014830254,0.00015856874,0.0004710511,0.0003412392,0.00052887265,0.00006746177,0.0002027287,0.000011498622,0.000673648],"category_scores_gemma":[0.0000776714,0.000077255485,0.00097446766,0.0008013208,0.000039123166,0.00006678035,0.00027569663,0.00042993997,0.000011595894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010588997,0.0009038227,0.94993,0.000021986263,0.0066331965,0.00011141139,0.0017885505,0.001067827,0.023945708,0.00001639531,0.0024836538,0.002508426],"study_design_scores_gemma":[0.015790308,0.0029577184,0.9680009,0.000047654325,0.0034410062,0.000052459593,0.00038214415,0.00012680968,0.00016932873,0.0000058128853,0.008898912,0.00012695412],"about_ca_topic_score_codex":0.000018958164,"about_ca_topic_score_gemma":0.000005361068,"teacher_disagreement_score":0.023776378,"about_ca_system_score_codex":0.00021755077,"about_ca_system_score_gemma":0.000045665707,"threshold_uncertainty_score":0.73759735},"labels":[],"label_agreement":null},{"id":"W4306319520","doi":"10.1093/eurheartj/ehac544.2324","title":"Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University Health Centre; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of British Columbia","funders":"","keywords":"Canagliflozin; Medicine; Placebo; Internal medicine; Kidney disease; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Type 2 Diabetes Mellitus; Empagliflozin; Myocardial infarction; Endocrinology; Confidence interval; Pathology","score_opus":0.019720705355503805,"score_gpt":0.26765978874838964,"score_spread":0.24793908339288584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306319520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97782105,0.020207485,0.000010956147,0.00035684975,0.00010481543,0.0010530882,0.000017224256,0.000012305934,0.0004161971],"genre_scores_gemma":[0.99791086,0.0011396229,0.0002254961,0.00043189005,0.00010659104,0.00003519041,0.000024458657,0.000017473369,0.00010840419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771804,0.0010459457,0.00028081957,0.00030448346,0.00047580723,0.00017488368],"domain_scores_gemma":[0.9992844,0.00012390435,0.00007964466,0.00029640459,0.000021319205,0.00019433479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018211548,0.00016058945,0.0007003412,0.0001554951,0.00019726087,0.00006627024,0.00005994195,0.000016921025,0.000021893742],"category_scores_gemma":[0.00009198459,0.000114070164,0.00038446888,0.00021638893,0.00009372951,0.0000689998,0.00019869732,0.00030372656,2.1266702e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011313397,0.00040008008,0.87855136,0.00024291482,0.034185946,0.0009973465,0.0006197867,0.00006694614,0.000050274277,0.000010809579,0.0006886564,0.083054565],"study_design_scores_gemma":[0.017283298,0.0008699327,0.9606584,0.000076389064,0.009408049,0.00004345613,0.00010418218,0.000032742955,0.000013630342,0.000012967455,0.011397457,0.000099548226],"about_ca_topic_score_codex":0.0005097242,"about_ca_topic_score_gemma":0.000037208483,"teacher_disagreement_score":0.08295501,"about_ca_system_score_codex":0.000056260007,"about_ca_system_score_gemma":0.000072108385,"threshold_uncertainty_score":0.46516463},"labels":[],"label_agreement":null},{"id":"W4306353000","doi":"10.1038/s41467-022-33867-9","title":"The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; University of Toronto; Government of Canada","keywords":"Exenatide; Medicine; Insulin glargine; Insulin lispro; Internal medicine; Type 2 diabetes; Glycemic; Lixisenatide; Endocrinology; Randomized controlled trial; Insulin; Population; Liraglutide; Glucagon-like peptide 1 receptor; Diabetes mellitus; Agonist; Receptor","score_opus":0.026026153476310744,"score_gpt":0.3479655666161127,"score_spread":0.32193941313980196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306353000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94378287,0.0459336,0.000001710036,0.0058944514,0.00038132715,0.0030969651,0.0000025396337,0.00002572957,0.0008808079],"genre_scores_gemma":[0.98988336,0.0056037107,0.0027381796,0.00068024854,0.000046521727,0.00081847544,0.00005761032,0.000016885188,0.00015501742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694914,0.0018189381,0.00062445836,0.00016800323,0.0002504914,0.00018897197],"domain_scores_gemma":[0.99301946,0.0057956288,0.00018477633,0.0008765732,0.00006864104,0.000054899545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004089897,0.0001122368,0.00059505954,0.00022472863,0.00017241783,0.000016065826,0.0005530851,0.00008683288,0.000014000882],"category_scores_gemma":[0.005028287,0.00007585202,0.00016168602,0.0006224836,0.00007180042,0.00004257605,0.0004827466,0.00090291223,0.0000022406427],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46500263,0.007910542,0.15245979,0.00010053192,0.0017955342,0.000016451058,0.008603835,0.00007553588,0.004395147,0.018152747,0.01907936,0.3224079],"study_design_scores_gemma":[0.7097531,0.0013356346,0.051053226,0.0002925668,0.00027945216,1.4578319e-7,0.0003329862,0.0015888655,0.0010649102,0.0014364031,0.23261309,0.00024963025],"about_ca_topic_score_codex":0.00004681937,"about_ca_topic_score_gemma":0.00006041068,"teacher_disagreement_score":0.32215828,"about_ca_system_score_codex":0.0000632216,"about_ca_system_score_gemma":0.00007247779,"threshold_uncertainty_score":0.60196924},"labels":[],"label_agreement":null},{"id":"W4306783500","doi":"10.1016/j.kint.2022.06.013","title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","year":2022,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"International Society of Nephrology","keywords":"Medicine; Guideline; Kidney disease; Intensive care medicine; Diabetes mellitus; Executive summary; Disease; Clinical Practice; Internal medicine; Physical therapy; Pathology; Endocrinology","score_opus":0.029580812149936846,"score_gpt":0.3635569716271384,"score_spread":0.33397615947720155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306783500","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023996424,0.0021080226,0.0036201752,0.9161293,0.008607252,0.008964623,0.0015342643,0.00020167575,0.034838263],"genre_scores_gemma":[0.48152107,0.0015734257,0.04426799,0.41131204,0.0026299336,0.0027368714,0.009373001,0.00021436866,0.046371292],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758035,0.00019154053,0.0006819448,0.00045170213,0.000837277,0.00025716185],"domain_scores_gemma":[0.9984223,0.00029004342,0.0003229659,0.0004885352,0.00013257601,0.00034354976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012236551,0.00017692936,0.00023885288,0.00023329168,0.00009563773,0.000023405308,0.00047678882,0.00002443101,0.00093666516],"category_scores_gemma":[0.001857095,0.00014653518,0.00020917878,0.0002569385,0.000050869126,0.00025173894,0.00035271895,0.0002048703,0.0000064565147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014739237,0.0013880992,0.028592795,0.0001250348,0.0007347716,0.000037929618,0.000051902276,0.0017443424,0.00008854569,0.0041719563,0.94501615,0.01657457],"study_design_scores_gemma":[0.0047874004,0.000645458,0.009986798,0.00048018538,0.00050252944,3.5279234e-7,0.00010085096,0.048997782,0.00011327956,0.0003448258,0.9338924,0.00014807914],"about_ca_topic_score_codex":0.000027442982,"about_ca_topic_score_gemma":0.000004881415,"teacher_disagreement_score":0.50481725,"about_ca_system_score_codex":0.0006239746,"about_ca_system_score_gemma":0.000909568,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W4306848286","doi":"10.3390/microorganisms10102061","title":"GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk","year":2022,"lang":"en","type":"review","venue":"Microorganisms","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Crosstalk; Immune system; Gut flora; Biology; Endocrine system; Enteroendocrine cell; Homeostasis; Hormone; Small intestine; Cell biology; Gut–brain axis; Glucagon-like peptide-2; Immunology; Endocrinology; Biochemistry; Peptide","score_opus":0.04432581816741878,"score_gpt":0.2981601740085296,"score_spread":0.25383435584111086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306848286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001261895,0.99379987,0.000013789451,0.000114402734,0.00034714243,0.0019699286,0.0001617039,0.00023376795,0.0020975065],"genre_scores_gemma":[0.0005827708,0.98894113,0.0013267057,0.00008750445,0.00013579846,0.00015287721,0.0009571764,0.00018218702,0.0076338756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997437,0.00013591204,0.0008105877,0.0008792151,0.00020298832,0.0005343175],"domain_scores_gemma":[0.99857086,0.00013549066,0.00036986615,0.00064914883,0.000049300954,0.0002253319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042628302,0.00082039647,0.0023349803,0.00030798727,0.00029302624,0.00029881438,0.00025521524,0.00029120734,0.00037737683],"category_scores_gemma":[0.000046384022,0.00065658754,0.00029602143,0.0003811764,0.00029028062,0.00007479507,0.00093908503,0.0008349067,0.00012337402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003639405,0.00037387744,0.00006755142,0.07604273,0.0017197683,0.00090401404,0.00025388246,1.7507732e-8,0.005582894,0.0009687127,0.0018454638,0.9122047],"study_design_scores_gemma":[0.001216363,0.00048109717,0.00009554366,0.009622112,0.003862781,0.0014506165,0.00025994127,0.0000010538989,0.00034268177,0.000016833137,0.9820952,0.0005557971],"about_ca_topic_score_codex":0.00012997775,"about_ca_topic_score_gemma":0.000009304004,"teacher_disagreement_score":0.9802497,"about_ca_system_score_codex":0.00051351567,"about_ca_system_score_gemma":0.00027522244,"threshold_uncertainty_score":0.99958855},"labels":[],"label_agreement":null},{"id":"W4307024783","doi":"10.1016/j.cjca.2022.08.044","title":"INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 AS A MARKER OF CARDIAC REVERSE REMODELING WITH EMPAGLIFLOZIN: A SECONDARY ANALYSIS OF THE EMPA-HEART CARDIOLINK-6 RANDOMIZED CONTROLLED TRIAL","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Internal medicine; Cardiology; Placebo; Diabetes mellitus; EMPA; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.009892441322550266,"score_gpt":0.2226472935789946,"score_spread":0.21275485225644433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307024783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892056,0.0013472028,0.000047783058,0.0006985802,0.00083222776,0.0035039573,0.00013099502,0.0000053826634,0.004228294],"genre_scores_gemma":[0.99844366,0.000064276544,0.00016110914,0.00018482727,0.0002525724,0.00015304273,0.0000208475,0.00002679116,0.0006928506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99605215,0.001669055,0.0011450656,0.00023756656,0.00050886057,0.00038732527],"domain_scores_gemma":[0.9974443,0.0003581559,0.00095157704,0.00042584288,0.00047298786,0.00034718824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026562363,0.00025186373,0.004555329,0.001287528,0.00016404058,0.000011730763,0.00025022318,0.00010044593,0.0001378986],"category_scores_gemma":[0.0006390276,0.0001565512,0.0030088606,0.00085813116,0.00027016317,0.00006435739,0.00005583173,0.00050286786,8.335646e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8776223,0.00003792803,0.019083265,0.00010406436,0.09110639,0.00020556456,0.0010015791,0.005974867,0.0012280906,0.00016448302,0.0027182682,0.0007531935],"study_design_scores_gemma":[0.9391347,0.0020605058,0.0041470747,0.00014889044,0.036000248,0.00010335531,0.0012873467,0.00017684352,0.00020641365,0.00007842368,0.01637708,0.00027909444],"about_ca_topic_score_codex":0.00095137453,"about_ca_topic_score_gemma":0.00015527481,"teacher_disagreement_score":0.061512418,"about_ca_system_score_codex":0.0003694686,"about_ca_system_score_gemma":0.002522387,"threshold_uncertainty_score":0.63839734},"labels":[],"label_agreement":null},{"id":"W4307379091","doi":"10.14740/cr1441","title":"A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Mace; Internal medicine; Type 2 diabetes; Diabetes mellitus; Urology; Kidney disease; Endocrinology; Cardiology; Cholesterol; Liraglutide; Gastroenterology; Myocardial infarction","score_opus":0.02474636891721717,"score_gpt":0.29432929374162303,"score_spread":0.2695829248244059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307379091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963172,0.00035670947,6.0636324e-7,0.000019483936,0.00009158307,0.0012615205,0.000024888996,0.000018304048,0.0019096867],"genre_scores_gemma":[0.9994699,0.0000247601,0.00001083462,0.000009574539,0.000017562934,0.00019261066,0.000108671484,0.000021791759,0.00014429685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968281,0.0014868479,0.00014715274,0.00034937973,0.0007139843,0.0004745629],"domain_scores_gemma":[0.99887013,0.00038642803,0.000032063952,0.0005206077,0.00011267655,0.00007810073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020524021,0.0001398497,0.000808878,0.00042628273,0.000102886355,0.000003991231,0.00012981215,0.000046130117,0.000039183607],"category_scores_gemma":[0.00026104267,0.000092511604,0.00019831114,0.0005991657,0.00017863051,0.000014360659,0.00018963263,0.00048254346,0.000013896606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091733434,0.00013252953,0.9915628,0.00006111782,0.0018732409,0.00006341942,0.000052314812,0.0014218567,0.000048908445,0.000011802286,0.0006555143,0.0031991485],"study_design_scores_gemma":[0.003890649,0.015088294,0.97564447,0.00002299345,0.00032802235,2.4503822e-7,0.000085485735,0.00001829657,0.0010107176,0.000010099282,0.0038113974,0.00008933246],"about_ca_topic_score_codex":0.00008593056,"about_ca_topic_score_gemma":0.0000011552213,"teacher_disagreement_score":0.015918346,"about_ca_system_score_codex":0.000220043,"about_ca_system_score_gemma":0.00004999256,"threshold_uncertainty_score":0.37725136},"labels":[],"label_agreement":null},{"id":"W4307379141","doi":"10.14740/cr1424","title":"Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence","year":2022,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Stage (stratigraphy); Kidney disease; Disease; Cardiology; Intensive care medicine; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.08083094076121128,"score_gpt":0.39148686402912514,"score_spread":0.31065592326791386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307379141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93784535,0.045835298,0.00022863105,0.0063632876,0.0002684694,0.008478396,0.0006979878,0.000080869046,0.00020171136],"genre_scores_gemma":[0.9861846,0.00030014117,0.00010177585,0.00036528712,0.00009114003,0.0073807877,0.0011834564,0.000051759165,0.0043410645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616325,0.0010958909,0.00028073174,0.00081446994,0.0005659816,0.0010796485],"domain_scores_gemma":[0.9980505,0.0005269706,0.000040421004,0.0007435431,0.0001753632,0.0004631743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013237128,0.000257096,0.00056234666,0.00051769085,0.00038408127,0.000042278465,0.00027897963,0.000092570925,0.000110433764],"category_scores_gemma":[0.00016233891,0.00021361753,0.00024635688,0.00069353986,0.00018649212,0.00009257951,0.00046012353,0.0006364718,0.000015717857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015279111,0.0058782566,0.7423857,0.0058257505,0.0034067763,0.0039458754,0.0032090025,0.002550806,0.07762369,0.00020411548,0.022423344,0.11726761],"study_design_scores_gemma":[0.08615961,0.07556102,0.5075031,0.0037093933,0.002208558,0.000031239782,0.00333788,0.17043242,0.010211568,0.00044144003,0.13799827,0.002405537],"about_ca_topic_score_codex":0.000018050016,"about_ca_topic_score_gemma":0.0000027543651,"teacher_disagreement_score":0.2348826,"about_ca_system_score_codex":0.0013497116,"about_ca_system_score_gemma":0.000776022,"threshold_uncertainty_score":0.87110704},"labels":[],"label_agreement":null},{"id":"W4307396495","doi":"10.1016/j.jacc.2022.08.772","title":"Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria","year":2022,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"","keywords":"Canagliflozin; Medicine; Renal function; Albuminuria; Internal medicine; Empagliflozin; Diabetes mellitus; Diabetic nephropathy; Urology; Proportional hazards model; Creatinine; Type 2 diabetes; Endocrinology","score_opus":0.0051995397349747325,"score_gpt":0.21310055541876352,"score_spread":0.2079010156837888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307396495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970437,0.0009967291,0.00014252242,0.0007485073,0.0003064972,0.0003193491,0.00000613253,0.0000016226851,0.0004349129],"genre_scores_gemma":[0.9993738,0.000059863836,0.00020768898,0.00013476406,0.00007231444,0.000011307773,6.538117e-7,0.0000067866017,0.00013281939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899024,0.00029772054,0.00027945935,0.00008343474,0.00025192753,0.00009722532],"domain_scores_gemma":[0.9993262,0.00009615125,0.0002962573,0.00018227224,0.000058280435,0.000040807783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005047692,0.00006646561,0.0006546774,0.00023525575,0.000026883808,6.8566044e-7,0.0000749963,0.000013576699,0.0000027254378],"category_scores_gemma":[0.00009870528,0.00004784526,0.00027280475,0.00039384773,0.00007952318,0.000021040434,0.000091939226,0.00011933156,1.4798371e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00885149,0.00037497425,0.7847936,0.00044265226,0.016730329,0.0012135707,0.00048689236,0.06658398,0.04701389,0.0014574899,0.030395504,0.041655593],"study_design_scores_gemma":[0.0029085125,0.004622024,0.96764255,0.000075212156,0.0015483809,0.00021509186,0.00046407897,0.000027621549,0.00082529,0.00021855402,0.021386685,0.000066011526],"about_ca_topic_score_codex":0.000060517585,"about_ca_topic_score_gemma":0.0000066398657,"teacher_disagreement_score":0.1828489,"about_ca_system_score_codex":0.00013505138,"about_ca_system_score_gemma":0.000067761655,"threshold_uncertainty_score":0.19510731},"labels":[],"label_agreement":null},{"id":"W4307636191","doi":"10.2147/ott.s370244","title":"Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge","year":2022,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital; Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Ketoacidosis; Type 2 diabetes; Type 1 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.03314721665539851,"score_gpt":0.24566408464348818,"score_spread":0.21251686798808966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307636191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868082,0.009838304,0.0000029857663,0.0015131638,0.000046672285,0.0003878639,0.000002732888,0.000032759173,0.0013673452],"genre_scores_gemma":[0.9907711,0.007593297,0.0006221587,0.0006882419,0.000022327384,0.00008839754,0.000037297457,0.000020527601,0.00015665573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992451,0.00004701138,0.00013977432,0.00024663855,0.00014725862,0.000174185],"domain_scores_gemma":[0.99969023,0.000051042054,0.000067336485,0.00010078285,0.000032534655,0.000058065787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019390183,0.00012318227,0.00020362576,0.00012509215,0.00017991744,0.000033718086,0.000021802567,0.0000251258,0.00003444715],"category_scores_gemma":[0.000015432814,0.000098524484,0.000015139621,0.00016265808,0.00003148546,0.00014863507,0.000063510415,0.00012168099,3.8363342e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044372925,0.00030959418,0.7842428,0.000084109335,0.00026766342,0.000058037735,0.0063922554,0.00003219466,0.002398964,0.0008266884,0.00034671865,0.20459726],"study_design_scores_gemma":[0.012345624,0.0103474045,0.7709318,0.00041228684,0.00020927262,0.000025050644,0.0054101176,0.0017526044,0.0009903264,0.0013729375,0.19554971,0.00065287226],"about_ca_topic_score_codex":0.00002876837,"about_ca_topic_score_gemma":0.000015839605,"teacher_disagreement_score":0.20394439,"about_ca_system_score_codex":0.000048845137,"about_ca_system_score_gemma":0.000015080314,"threshold_uncertainty_score":0.4017712},"labels":[],"label_agreement":null},{"id":"W4307659022","doi":"10.1016/j.medj.2022.10.001","title":"One size fits all: The story of SGLT2 inhibitors in heart failure","year":2022,"lang":"no","type":"article","venue":"Med","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Vetenskapsrådet; Deutsche Forschungsgemeinschaft; Novo Nordisk; Merck; AstraZeneca; Bayer; Pfizer; Hjärt-Lungfonden; Boehringer Ingelheim","keywords":"Heart failure; Emperor; Heart failure with preserved ejection fraction; Ejection fraction; Medicine; Cardiology; Internal medicine; Management of heart failure; History; Ancient history","score_opus":0.014715882063480377,"score_gpt":0.23511531623009846,"score_spread":0.22039943416661809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307659022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92750144,0.004310349,4.6492684e-7,0.062705226,0.00088262424,0.0013746353,0.000024939845,0.000035237223,0.003165075],"genre_scores_gemma":[0.98217887,0.000060143928,0.000092108196,0.0017654899,0.00015600966,0.00019189755,0.000032667278,0.00002843549,0.015494365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807906,0.0003867948,0.00031180648,0.00026429252,0.0005928467,0.0003651915],"domain_scores_gemma":[0.9989223,0.000407672,0.00011772744,0.00044772332,0.000026114654,0.000078480014],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009597124,0.00017219406,0.00040483513,0.00012318481,0.0001244569,0.000009418188,0.0001874709,0.000044906545,0.0020264979],"category_scores_gemma":[0.0001875157,0.00014169031,0.00012636249,0.00036377038,0.00009068386,0.000043389995,0.0002994023,0.00045804217,0.00007628947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000559349,0.004853213,0.07405991,0.00075798656,0.0018494154,0.00014118396,0.016266959,0.00020084257,0.0119570205,0.0010059373,0.85740733,0.030940834],"study_design_scores_gemma":[0.0043317685,0.0010369075,0.09025597,0.00019980449,0.0005320771,0.0000010320247,0.005816824,0.00004085664,0.002528922,0.00007575846,0.89498997,0.00019011172],"about_ca_topic_score_codex":0.00014436297,"about_ca_topic_score_gemma":0.00014831299,"teacher_disagreement_score":0.060939737,"about_ca_system_score_codex":0.00025566632,"about_ca_system_score_gemma":0.00008319535,"threshold_uncertainty_score":0.9988858},"labels":[],"label_agreement":null},{"id":"W4307804882","doi":"10.1210/jendso/bvac150.572","title":"LBODP062 SGLT2 Inhibition Ameliorates Cognitive And Physical Impairment In Patients With HFpEF And Diabetes","year":2022,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Metformin; Internal medicine; Diabetes mellitus; Heart failure with preserved ejection fraction; Montreal Cognitive Assessment; Cardiology; Insulin; Type 2 diabetes; Ejection fraction; Cognitive impairment; Heart failure; Endocrinology; Disease","score_opus":0.003985147391811402,"score_gpt":0.2171895137354003,"score_spread":0.21320436634358889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307804882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99796903,0.00016453346,0.0000010412273,0.0014275239,0.0000464856,0.00031787026,0.000008547248,0.000004417703,0.000060543836],"genre_scores_gemma":[0.9991324,0.00003997288,0.00011844759,0.0005232476,0.000051098177,0.000015232568,0.0000061248948,0.0000090208305,0.00010444792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929047,0.000046762652,0.00014106648,0.00009152556,0.00028745335,0.0001427446],"domain_scores_gemma":[0.9996378,0.000049067214,0.0001488254,0.000054789085,0.000059367794,0.000050161092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001242784,0.00009481347,0.00020724634,0.000037269667,0.000093259536,0.000015013681,0.00002889964,0.000006259765,0.000013191332],"category_scores_gemma":[0.000013754694,0.000054524175,0.000091891816,0.00014874391,0.00006666058,0.00009035257,0.00014565015,0.00020055837,2.2964107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001832281,0.0010369491,0.9926139,0.00005008241,0.00034088033,0.000012124357,0.0010704324,0.000011891566,0.00015170082,0.000017775148,0.0016897839,0.002821224],"study_design_scores_gemma":[0.009298826,0.0029577874,0.98331887,0.00015077223,0.00041302963,0.000009036118,0.0021480748,0.000099647936,0.00092881697,0.00022445983,0.0003692322,0.00008146859],"about_ca_topic_score_codex":0.0000027799983,"about_ca_topic_score_gemma":5.870751e-7,"teacher_disagreement_score":0.009295079,"about_ca_system_score_codex":0.00009450083,"about_ca_system_score_gemma":0.000019669846,"threshold_uncertainty_score":0.22234313},"labels":[],"label_agreement":null},{"id":"W4308058331","doi":"10.1002/oby.23563","title":"Weight loss between glucagon‐like peptide‐1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta‐analysis","year":2022,"lang":"en","type":"review","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Sinai Health System","funders":"","keywords":"Weight loss; Medicine; Glucagon-like peptide-1; Obesity; Meta-analysis; Glucagon-like peptide 1 receptor; MEDLINE; Obesity Surgery; Internal medicine; Endocrinology; Surgery; Receptor; Diabetes mellitus; Gastric bypass; Agonist; Type 2 diabetes; Chemistry; Biochemistry","score_opus":0.03226169337099124,"score_gpt":0.27441084519403824,"score_spread":0.242149151823047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308058331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043767903,0.9933005,0.0000038633843,0.00014234429,0.000041026495,0.0056441566,0.0001269265,0.000064585816,0.00023893612],"genre_scores_gemma":[0.00016512882,0.9949548,0.00015014225,0.00018553293,0.000045762896,0.0013298595,0.0010784164,0.00006511925,0.0020252261],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9958524,0.00082803256,0.0012173075,0.0010462761,0.00057866867,0.00047729403],"domain_scores_gemma":[0.9970356,0.0008237215,0.0008316231,0.00095507246,0.000056410194,0.00029754516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016506923,0.00083820324,0.0125916535,0.0009858935,0.00014845528,0.00006318257,0.0001970311,0.00018582812,0.0006052587],"category_scores_gemma":[0.0001071704,0.0005440306,0.0014748067,0.0022713058,0.000078079844,0.00012233321,0.00032288194,0.0004334218,0.000038201015],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008911579,0.00022844983,0.009675035,0.8741173,0.112108506,0.00016871725,0.000034184384,1.6833617e-8,6.168645e-10,0.000013921333,0.000508599,0.0031363182],"study_design_scores_gemma":[0.0003456666,0.00010597837,0.00087705196,0.06228773,0.8258891,0.000020764712,0.000011038128,4.041554e-7,3.6497923e-8,0.0000031776576,0.10999712,0.00046194124],"about_ca_topic_score_codex":0.0001623284,"about_ca_topic_score_gemma":0.00010682468,"teacher_disagreement_score":0.8118296,"about_ca_system_score_codex":0.00030884397,"about_ca_system_score_gemma":0.00017818449,"threshold_uncertainty_score":0.99970114},"labels":[],"label_agreement":null},{"id":"W4308062270","doi":"10.1001/jamacardio.2022.4210","title":"Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ejection fraction; Heart failure; Dapagliflozin; Renal function; Kidney disease; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Placebo; Kidney; Urology; Endocrinology; Diabetes mellitus; Pathology; Type 2 diabetes","score_opus":0.009261931084520135,"score_gpt":0.23141299321614414,"score_spread":0.222151062131624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308062270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948718,0.000018994346,0.000017330942,0.0033190763,0.000114646085,0.0008038161,0.000014773785,0.000043849293,0.000795694],"genre_scores_gemma":[0.9969185,0.0000049999403,0.0005812981,0.00096142443,0.00004804263,0.00026229356,0.00020307058,0.000018055409,0.0010022906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990713,0.00014009203,0.00012690373,0.00028522586,0.00017962097,0.00019686001],"domain_scores_gemma":[0.9995807,0.00003958771,0.000052173833,0.00021031627,0.000039126593,0.00007812679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013764597,0.00012851004,0.00039277706,0.0001556339,0.00007792322,0.000011907285,0.000035137968,0.000051481467,0.000080617756],"category_scores_gemma":[0.00005406409,0.00008260795,0.00003464028,0.00017192522,0.000035685094,0.00010611405,0.00006798135,0.00018368197,0.0000032884589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002021824,0.00014500473,0.9836599,0.000028287055,0.0003443619,0.000027156857,0.000033977765,0.00006698139,0.00006931947,0.000009276805,0.013196216,0.000397683],"study_design_scores_gemma":[0.0076278853,0.0028694784,0.9247436,0.000018205654,0.00017954425,0.000009771315,0.00024951634,0.000017732153,0.000033874123,0.0000059813697,0.064147726,0.00009670065],"about_ca_topic_score_codex":0.00008342177,"about_ca_topic_score_gemma":0.000030865507,"teacher_disagreement_score":0.058916327,"about_ca_system_score_codex":0.00014289276,"about_ca_system_score_gemma":0.000046427947,"threshold_uncertainty_score":0.33686543},"labels":[],"label_agreement":null},{"id":"W4308192739","doi":"10.2337/figshare.21313074","title":"Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in sub-optimally controlled adults with type 1 diabetes: a randomized crossover controlled trial","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Placebo; Crossover study; Randomized controlled trial; Randomization; Type 2 diabetes; Internal medicine; Insulin; Endocrinology; Diabetes mellitus","score_opus":0.010303845863138787,"score_gpt":0.26284726832335165,"score_spread":0.2525434224602129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308192739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90457284,0.0027686453,0.000028256763,0.0011454008,0.0016307825,0.07254437,0.000054756998,0.00030490538,0.016950013],"genre_scores_gemma":[0.94226086,0.002418904,0.00061687024,0.0054871575,0.000472705,0.02984377,0.0010634315,0.0002391798,0.017597117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922939,0.0010208368,0.0022017104,0.001790283,0.0014866624,0.0012066353],"domain_scores_gemma":[0.9951429,0.0014236552,0.0008830647,0.0015382776,0.00048573368,0.000526408],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00268709,0.0014750857,0.008290994,0.0010950302,0.00013308148,0.0002705,0.000600995,0.00032427904,0.005209386],"category_scores_gemma":[0.0014162231,0.00094748137,0.0016399692,0.0006171041,0.00018816655,0.00012387976,0.0007260852,0.0011402692,0.00032250152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9758414,0.005078182,0.00021794929,0.00021122035,0.008764054,0.00048576397,0.00047243733,0.00086086843,0.0001311109,0.00007867858,0.0032474087,0.004610936],"study_design_scores_gemma":[0.97986716,0.011598477,0.00019327243,0.0007405984,0.00218341,0.0000016990198,0.00013853173,0.0022582123,0.00048857933,0.00013483173,0.0014239494,0.00097127486],"about_ca_topic_score_codex":0.00029255217,"about_ca_topic_score_gemma":0.00013322955,"teacher_disagreement_score":0.042700607,"about_ca_system_score_codex":0.0005950661,"about_ca_system_score_gemma":0.0011871371,"threshold_uncertainty_score":0.99979985},"labels":[],"label_agreement":null},{"id":"W4308192881","doi":"10.2337/figshare.21313074.v1","title":"Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in sub-optimally controlled adults with type 1 diabetes: a randomized crossover controlled trial","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Crossover study; Placebo; Randomized controlled trial; Randomization; Type 2 diabetes; Internal medicine; Insulin; Endocrinology; Diabetes mellitus","score_opus":0.010303845863138787,"score_gpt":0.26284726832335165,"score_spread":0.2525434224602129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308192881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90457284,0.0027686453,0.000028256763,0.0011454008,0.0016307825,0.07254437,0.000054756998,0.00030490538,0.016950013],"genre_scores_gemma":[0.94226086,0.002418904,0.00061687024,0.0054871575,0.000472705,0.02984377,0.0010634315,0.0002391798,0.017597117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922939,0.0010208368,0.0022017104,0.001790283,0.0014866624,0.0012066353],"domain_scores_gemma":[0.9951429,0.0014236552,0.0008830647,0.0015382776,0.00048573368,0.000526408],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00268709,0.0014750857,0.008290994,0.0010950302,0.00013308148,0.0002705,0.000600995,0.00032427904,0.005209386],"category_scores_gemma":[0.0014162231,0.00094748137,0.0016399692,0.0006171041,0.00018816655,0.00012387976,0.0007260852,0.0011402692,0.00032250152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9758414,0.005078182,0.00021794929,0.00021122035,0.008764054,0.00048576397,0.00047243733,0.00086086843,0.0001311109,0.00007867858,0.0032474087,0.004610936],"study_design_scores_gemma":[0.97986716,0.011598477,0.00019327243,0.0007405984,0.00218341,0.0000016990198,0.00013853173,0.0022582123,0.00048857933,0.00013483173,0.0014239494,0.00097127486],"about_ca_topic_score_codex":0.00029255217,"about_ca_topic_score_gemma":0.00013322955,"teacher_disagreement_score":0.042700607,"about_ca_system_score_codex":0.0005950661,"about_ca_system_score_gemma":0.0011871371,"threshold_uncertainty_score":0.99979985},"labels":[],"label_agreement":null},{"id":"W4308294046","doi":"10.1161/circulationaha.122.062769","title":"Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Western University; Public Health Ontario; University of British Columbia; Robarts Clinical Trials; Ontario Council of University Libraries; University of Toronto","funders":"Daiichi Sankyo Europe; National Institutes of Health; St. Jude Medical; Assistance publique-Hôpitaux de Paris; Cleveland Clinic; University of Toronto; Boston VA Research Institute; Regado Biosciences; Boston Scientific Corporation; AstraZeneca; Bristol-Myers Squibb; Amgen; MyoKardia; Duke Clinical Research Institute; Novo Nordisk; American Heart Association","keywords":"Empagliflozin; Medicine; Heart failure; Internal medicine; Cardiology; Ejection fraction; Diabetes mellitus; Placebo; Interquartile range; Type 2 diabetes; Endocrinology","score_opus":0.025468119524546293,"score_gpt":0.29130076261058413,"score_spread":0.2658326430860378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308294046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957066,0.0004912612,0.000046399386,0.0005179363,0.00031261938,0.002256933,0.000005848408,0.00002120826,0.0006411895],"genre_scores_gemma":[0.9993015,0.000028412895,0.00011376296,0.0002022923,0.00011132592,0.00005539763,0.00009496916,0.000012670355,0.00007969259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979298,0.0006355652,0.0006772996,0.00025827123,0.00034830847,0.00015075819],"domain_scores_gemma":[0.99912286,0.00028958925,0.00019841288,0.00030960984,0.00003769512,0.0000418393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029431218,0.000101489524,0.0006778731,0.000111285815,0.000080278594,0.0000087955705,0.000057962116,0.000048506332,0.000009367926],"category_scores_gemma":[0.0005084696,0.00007562684,0.00026219277,0.00020253293,0.00005113503,0.000048707865,0.00010779066,0.00016684797,0.0000010106877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075059466,0.00034335305,0.9149647,0.00008422212,0.00025114726,0.000004225708,0.0005777944,0.005462634,0.00017873176,0.00003575929,0.00019446356,0.0028435125],"study_design_scores_gemma":[0.4630914,0.00012447436,0.5136159,0.000070047514,0.00053401367,0.0000025036043,0.000083739666,0.021552632,0.000027940067,0.00017008682,0.0006398183,0.00008742214],"about_ca_topic_score_codex":0.00002534272,"about_ca_topic_score_gemma":0.000005255877,"teacher_disagreement_score":0.40134877,"about_ca_system_score_codex":0.00012012983,"about_ca_system_score_gemma":0.00007210069,"threshold_uncertainty_score":0.3083973},"labels":[],"label_agreement":null},{"id":"W4308315831","doi":"10.1007/s40501-022-00281-3","title":"Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders","year":2022,"lang":"en","type":"article","venue":"Current Treatment Options in Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Mood disorders; Mood; Cognition; Medicine; Neuroprotection; Neurology; Comorbidity; Major depressive disorder; Cognitive decline; Psychology; Disease; Clinical psychology; Psychiatry; Dementia; Internal medicine","score_opus":0.09155150134304245,"score_gpt":0.3685113170498969,"score_spread":0.27695981570685446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308315831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714596,0.0044279303,0.00022406125,0.0011835726,0.0010103662,0.0056224163,0.00024769615,0.000020852896,0.000117143325],"genre_scores_gemma":[0.98619205,0.0027002261,0.0019924112,0.00003128403,0.000054230757,0.008034976,0.0005287826,0.00003134249,0.00043467604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984759,0.0001395711,0.0004450126,0.00033873384,0.00033757437,0.0002631838],"domain_scores_gemma":[0.99869823,0.000565221,0.00025289014,0.0003992208,0.000050936993,0.000033491837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021621578,0.00025625215,0.000352051,0.00029446,0.00022829138,0.000014988153,0.0000891429,0.000025695093,0.000056122],"category_scores_gemma":[0.000021628899,0.00013965977,0.00020965477,0.00059082825,0.000115789386,0.00008350266,0.000034485274,0.00008870231,0.0000014202454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010644501,0.01979982,0.77864206,0.000085126056,0.0014635889,4.0553863e-7,0.0031328362,0.012766924,0.0000058086857,0.0011942334,0.00026008868,0.18158464],"study_design_scores_gemma":[0.054750584,0.05068787,0.837693,0.0008561418,0.0073467833,0.000006373807,0.016956432,0.009640545,0.000049277187,0.0008298901,0.020728987,0.00045411702],"about_ca_topic_score_codex":0.00013870942,"about_ca_topic_score_gemma":0.0007830164,"teacher_disagreement_score":0.18113051,"about_ca_system_score_codex":0.00043698578,"about_ca_system_score_gemma":0.00017416936,"threshold_uncertainty_score":0.569516},"labels":[],"label_agreement":null},{"id":"W4308372801","doi":"10.1161/circulationaha.122.062832","title":"Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; Defense Acquisition Program Administration; National Medical Research Council; National Institutes of Health; British Heart Foundation; AstraZeneca; Medical Research Council; Foundation for the National Institutes of Health","keywords":"Medicine; Ejection fraction; Dapagliflozin; Heart failure; Internal medicine; Cardiology; Fraction (chemistry); Endocrinology; Diabetes mellitus","score_opus":0.012355928895326083,"score_gpt":0.2250087883727271,"score_spread":0.212652859477401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308372801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896115,0.00004910396,0.000017764436,0.00021663556,0.000026349095,0.00069433794,0.000018266606,0.000009544295,0.0000068641634],"genre_scores_gemma":[0.99966496,0.000008642217,0.000042138287,0.000046683665,0.000008067503,0.00007721586,0.00012350988,0.000008075936,0.000020711332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992938,0.00011195801,0.00014542171,0.00018534833,0.00017793749,0.00008550295],"domain_scores_gemma":[0.9996635,0.000084906154,0.00008609569,0.00012065935,0.000022482474,0.000022356853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087907596,0.00010148979,0.0002166556,0.00009352174,0.000080760066,0.000015423437,0.00001605264,0.000023001954,0.000009504291],"category_scores_gemma":[0.000010311001,0.00006155895,0.000012247554,0.00012941615,0.000038077884,0.00010478926,0.000020275746,0.000059755,3.5146078e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001980628,0.0003071962,0.99345,0.0000081031485,0.000062840045,0.0000026467958,0.0014246193,0.00001386837,0.00011474247,0.0000057576062,0.00000270927,0.0026268866],"study_design_scores_gemma":[0.004857931,0.00064583594,0.9929191,0.000033033964,0.00007815127,3.9643632e-7,0.00085665396,0.00039541264,0.000024953773,0.000014233075,0.00010987112,0.00006444735],"about_ca_topic_score_codex":0.00044971096,"about_ca_topic_score_gemma":0.0003829934,"teacher_disagreement_score":0.0028773027,"about_ca_system_score_codex":0.00018977966,"about_ca_system_score_gemma":0.000011851148,"threshold_uncertainty_score":0.25103015},"labels":[],"label_agreement":null},{"id":"W4308373036","doi":"10.1161/circulationaha.122.062644","title":"Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled","year":2022,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Medicine; Empagliflozin; Emperor; White (mutation); Heart failure; Cardiology; Internal medicine; Endocrinology; Ancient history; Diabetes mellitus","score_opus":0.012865831581358575,"score_gpt":0.23386882589909613,"score_spread":0.22100299431773757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308373036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580929,0.000027940538,0.000013868671,0.039770443,0.00014541844,0.0009428622,0.00004467111,0.000035182416,0.0009266559],"genre_scores_gemma":[0.9676342,0.0000023630084,0.00012555947,0.02000154,0.00012444978,0.000071894974,0.011690414,0.00004006226,0.00030950733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983827,0.00007042847,0.0003354024,0.00037806883,0.00061236654,0.00022102975],"domain_scores_gemma":[0.99918,0.000044945176,0.0002060766,0.00044773018,0.000089006215,0.00003222466],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009318782,0.00022097636,0.0006459509,0.0010587951,0.000027176884,0.000014700756,0.000069343405,0.0001697713,0.00097506854],"category_scores_gemma":[0.000018359991,0.00020030922,0.00020933323,0.0012796689,0.00003789157,0.00007210443,0.000039455408,0.00033737568,0.000016226133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019689715,0.00015627332,0.90492547,0.0001338591,0.0029051467,0.000016646773,0.00017901989,0.001792168,0.0000043365376,0.000003257085,0.08953975,0.00014719709],"study_design_scores_gemma":[0.0039689546,0.00027180402,0.9370005,0.000060038616,0.008192042,5.0863783e-8,0.000048909675,0.0004404847,0.0000028754048,0.0000034780705,0.049833525,0.0001773346],"about_ca_topic_score_codex":0.00004354771,"about_ca_topic_score_gemma":0.000062945386,"teacher_disagreement_score":0.039706223,"about_ca_system_score_codex":0.00034559143,"about_ca_system_score_gemma":0.000039622755,"threshold_uncertainty_score":0.9999382},"labels":[],"label_agreement":null},{"id":"W4308387643","doi":"10.1016/j.molmet.2022.101633","title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy","year":2022,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Novo Nordisk Fonden","keywords":"Glucagon receptor; Agonist; Pharmacology; Gastric emptying; Glucagon-like peptide 1 receptor; Receptor; Glucagon-like peptide-1; Glucose homeostasis; Semaglutide; Anorectic; Endocrinology; Internal medicine; Glucagon; Medicine; Type 2 diabetes; Insulin; Insulin resistance; Diabetes mellitus; Liraglutide; Food intake","score_opus":0.020762949033599105,"score_gpt":0.2829915569895362,"score_spread":0.2622286079559371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308387643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278563,0.002692664,0.0010456532,0.00076968374,0.0002788537,0.0009215611,0.00005348191,0.000045608092,0.0014068726],"genre_scores_gemma":[0.9949916,0.00010921419,0.0022906763,0.000875215,0.00009889306,0.000105884814,0.00009738875,0.000038278835,0.0013928667],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984084,0.00011240145,0.00031440973,0.0004483252,0.00040208257,0.00031442114],"domain_scores_gemma":[0.9992819,0.00006364333,0.00015014279,0.00032042144,0.000050796833,0.0001331187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028113349,0.00022710826,0.00061594514,0.00014581007,0.00012262494,0.00002571361,0.00011376357,0.000039514016,0.0001979387],"category_scores_gemma":[0.000033261418,0.00018611652,0.00014889287,0.000270184,0.0001935711,0.00008263584,0.00035443102,0.00024237433,0.0000044336152],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075304136,0.040088832,0.030961186,0.0010391603,0.013385283,0.0041170674,0.0013794625,0.006904189,0.8345945,0.028999144,0.009750526,0.02125025],"study_design_scores_gemma":[0.09992436,0.003691402,0.47535214,0.00012581142,0.015332741,0.00026877582,0.00046762443,0.0017390844,0.14448203,0.00009036252,0.2571909,0.001334763],"about_ca_topic_score_codex":0.000044621713,"about_ca_topic_score_gemma":0.0000019736513,"teacher_disagreement_score":0.6901125,"about_ca_system_score_codex":0.00003152783,"about_ca_system_score_gemma":0.00009337667,"threshold_uncertainty_score":0.75896114},"labels":[],"label_agreement":null},{"id":"W4308559734","doi":"10.1016/j.jcjd.2022.11.002","title":"Prescribing Trends of the Sodium–Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015–2021)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Medical prescription; Guideline; Confidence interval; Internal medicine; Diabetes mellitus; Defined daily dose; Clinical trial; Type 2 diabetes; Emergency medicine; Pharmacology; Endocrinology","score_opus":0.008296747767984359,"score_gpt":0.18707638947065194,"score_spread":0.17877964170266758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308559734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524474,0.0011193268,1.3916838e-7,0.0011838555,0.0009865316,0.00017388248,0.00006481048,0.0000019248314,0.0012247851],"genre_scores_gemma":[0.998971,0.00000778245,0.0000069091698,0.00034445734,0.00018360474,0.000011836743,0.000014689841,0.000020535996,0.00043918777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843574,0.00007480537,0.000502545,0.0001308892,0.0004249047,0.0004311041],"domain_scores_gemma":[0.99903226,0.000038918297,0.00031447975,0.00022410642,0.000059146623,0.00033109103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016168857,0.00017328151,0.00046030682,0.00043167104,0.00012693802,0.000016050288,0.00025325458,0.000021528343,0.0002834661],"category_scores_gemma":[0.000018124025,0.00013019798,0.00019214505,0.0004002444,0.00009298241,0.000090565234,0.000033800563,0.0003054611,2.4484126e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007021662,0.000074276686,0.97733104,0.00004292162,0.00018946585,0.00005896423,0.0005060313,0.00014500141,0.00031781447,0.00003661676,0.0067064175,0.014584452],"study_design_scores_gemma":[0.001326447,0.0002457388,0.98374045,0.00025039993,0.00022931631,7.55655e-7,0.0016373029,0.00004314502,0.0056369686,0.000041585023,0.006715231,0.00013263329],"about_ca_topic_score_codex":0.44242534,"about_ca_topic_score_gemma":0.9733618,"teacher_disagreement_score":0.5309364,"about_ca_system_score_codex":0.001446508,"about_ca_system_score_gemma":0.001785498,"threshold_uncertainty_score":0.5612876},"labels":[],"label_agreement":null},{"id":"W4308649007","doi":"10.1136/heartjnl-2022-321545","title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","year":2022,"lang":"en","type":"article","venue":"Heart","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital; University of Toronto","funders":"National Heart, Lung, and Blood Institute; Chung Shan Medical University Hospital; National Institutes of Health; Chung Shan Medical University","keywords":"Medicine; Internal medicine; Proportional hazards model; Diabetes mellitus; Retrospective cohort study; Adverse effect; Propensity score matching; Cancer; Cohort study; Heart failure; Surgery; Endocrinology","score_opus":0.009694425866875763,"score_gpt":0.2666460106092748,"score_spread":0.25695158474239904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308649007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99878085,0.000062820116,1.2256498e-7,0.0003645333,0.00004293094,0.0005252417,0.000050954943,0.000014099701,0.00015846385],"genre_scores_gemma":[0.99947375,0.0000052317387,0.00003669314,0.0002417254,0.000013973769,0.000064600434,0.00006337995,0.000011739335,0.000088889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927115,0.000021334848,0.00013235246,0.00016715784,0.0002513407,0.00015668594],"domain_scores_gemma":[0.99972117,0.000008547384,0.00003097991,0.0001534104,0.000019245726,0.000066624845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070248876,0.00010006362,0.00023207637,0.00009015194,0.000032055075,0.0000037978637,0.00001796159,0.000016449347,0.00028406913],"category_scores_gemma":[0.000001700421,0.00007400451,0.00005119223,0.00013875413,0.000030704934,0.00003912212,0.000018801902,0.00009344753,0.0000018101294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002886831,0.00072617043,0.9951748,0.000041549098,0.00009327335,0.000006925569,0.00011307478,0.000027413125,0.00014484393,0.0000065915565,0.0030777303,0.00029894343],"study_design_scores_gemma":[0.0030396592,0.0022095991,0.9914318,0.000057116198,0.000069217225,3.887321e-7,0.00003521473,0.0000056418344,0.00046149534,0.0000045338097,0.0026179478,0.00006742831],"about_ca_topic_score_codex":0.00076246983,"about_ca_topic_score_gemma":0.00017079267,"teacher_disagreement_score":0.0037430436,"about_ca_system_score_codex":0.00011145409,"about_ca_system_score_gemma":0.000043841996,"threshold_uncertainty_score":0.31103578},"labels":[],"label_agreement":null},{"id":"W4308697810","doi":"10.1016/s2213-8587(22)00313-8","title":"Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status","year":2022,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Type 2 diabetes; Glycated hemoglobin; Diabetes mellitus; Coronary artery disease; Impaired glucose tolerance; Cardiology; Endocrinology","score_opus":0.01663995489241324,"score_gpt":0.2617943424152707,"score_spread":0.24515438752285748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308697810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5016666,0.0009395626,2.5791414e-7,0.49416664,0.00052115915,0.0011429234,0.00006299739,0.00011132319,0.0013885244],"genre_scores_gemma":[0.6838777,0.000655076,0.00095399783,0.30061674,0.003957928,0.0019980418,0.00169359,0.00027910358,0.0059678066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996594,0.0002675064,0.00043437237,0.00058092584,0.00043053337,0.0016926798],"domain_scores_gemma":[0.9984355,0.00026263014,0.00029533225,0.0009167783,0.000045686855,0.000044100972],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018572505,0.00045850308,0.0015566798,0.0005056302,0.00007377232,0.000015211787,0.0002934654,0.00019073988,0.0002976634],"category_scores_gemma":[0.00004820657,0.00029752406,0.00019019414,0.00040946738,0.00035281305,0.000066348584,0.0002444357,0.0018265712,0.000027254566],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022468474,0.00015035375,0.2710716,0.00027236636,0.0012019614,0.00021758239,0.00027836658,0.000012918535,0.00028716182,0.00013376452,0.7251129,0.0010363373],"study_design_scores_gemma":[0.0042122095,0.0016537937,0.05026929,0.00019059387,0.00076155196,0.000033308475,0.00045348532,0.0000026105647,0.001692435,0.0005194787,0.9398657,0.00034553322],"about_ca_topic_score_codex":0.00020624441,"about_ca_topic_score_gemma":0.000061971885,"teacher_disagreement_score":0.22080232,"about_ca_system_score_codex":0.00041099865,"about_ca_system_score_gemma":0.00010344246,"threshold_uncertainty_score":0.99994767},"labels":[],"label_agreement":null},{"id":"W4308702501","doi":"10.1016/s2213-8587(22)00308-4","title":"Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Heart, Lung, and Blood Institute; Respicardia; Sanofi Pasteur; National Institutes of Health; Daiichi-Sankyo; Moderna; Sarepta Therapeutics; Alnylam Pharmaceuticals; MyoKardia; Gilead Sciences; Cytokinetics; American Regent; Sanofi; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Korea; GlaxoSmithKline; Celladon Corporation; Amgen","keywords":"Medicine; Heart failure; Ejection fraction; Dapagliflozin; Internal medicine; Atrial fibrillation; Placebo; Cardiology; Prediabetes; Type 2 diabetes; Adverse effect; Diabetes mellitus; Endocrinology","score_opus":0.01639903670994819,"score_gpt":0.2730839111137107,"score_spread":0.25668487440376253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308702501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927663,0.00016363422,0.000023264965,0.0009909892,0.00013544453,0.0056781843,0.00013075216,0.00005496895,0.000056449182],"genre_scores_gemma":[0.99582195,0.00013047701,0.0003817209,0.00024748212,0.00010904657,0.0011007892,0.0020897964,0.000026152115,0.00009260916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739254,0.00058987865,0.00050158345,0.0004984334,0.00040190291,0.000615693],"domain_scores_gemma":[0.99835336,0.0006293476,0.0003490334,0.00049396895,0.00008561998,0.0000886717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004564107,0.0002634469,0.0011720797,0.00036015632,0.000116772,0.000025931393,0.0001925909,0.000047911784,0.00030366698],"category_scores_gemma":[0.00009732905,0.00016164883,0.00009565369,0.00048407144,0.00009148698,0.00018614283,0.00010897601,0.0003084377,0.0000016404925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68382096,0.0012707926,0.30981195,0.000011185464,0.003331149,0.0000039667243,0.0000957383,0.0005361711,0.0003906261,0.0000036684191,0.00026117475,0.00046260032],"study_design_scores_gemma":[0.89498746,0.0031485413,0.093752205,0.000026909409,0.0032915073,3.6114e-7,0.0002861086,0.0022099668,0.00044927892,0.0000036718507,0.001679587,0.00016440627],"about_ca_topic_score_codex":0.00057936047,"about_ca_topic_score_gemma":0.0005179506,"teacher_disagreement_score":0.21605974,"about_ca_system_score_codex":0.00018503658,"about_ca_system_score_gemma":0.000042024447,"threshold_uncertainty_score":0.6591848},"labels":[],"label_agreement":null},{"id":"W4308711092","doi":"10.1136/bmjdrc-2022-002995","title":"Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada","year":2022,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Carbon Engineering (Canada); University of British Columbia","funders":"University of British Columbia; Ministry of Health, British Columbia","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Family medicine; Endocrinology","score_opus":0.07328592286994774,"score_gpt":0.40378544776971215,"score_spread":0.3304995248997644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308711092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577404,0.001627735,1.2137691e-7,0.0018395307,0.00016327243,0.004899963,0.0009114246,0.000015479673,0.004768413],"genre_scores_gemma":[0.974233,0.00007122865,0.00008542073,0.00021279781,0.000056958095,0.010434027,0.002094659,0.000040959003,0.0127709815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972311,0.00022614504,0.00039881372,0.00046042431,0.0009314713,0.00075201667],"domain_scores_gemma":[0.9984033,0.0003218765,0.00009377754,0.00059033727,0.00038277608,0.00020790288],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064448634,0.00012794563,0.000543708,0.00020007878,0.00032243805,0.00015695576,0.00052585127,0.00003886587,0.001648234],"category_scores_gemma":[0.00013112549,0.00017168034,0.00009611162,0.0009901893,0.000093253126,0.00008711544,0.00067158754,0.00017441883,0.0000030923668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018263127,0.00041605879,0.73699766,0.00023646542,0.00037506202,0.000039714003,0.00020246714,0.000009603755,0.000057500016,0.0000057923794,0.04169161,0.2199498],"study_design_scores_gemma":[0.006661682,0.005356724,0.79864776,0.00032330226,0.00030010476,0.0000012521136,0.007599658,0.0005266811,0.00054236955,0.00006932076,0.17962433,0.00034678448],"about_ca_topic_score_codex":0.69232273,"about_ca_topic_score_gemma":0.95590365,"teacher_disagreement_score":0.2635809,"about_ca_system_score_codex":0.0015712332,"about_ca_system_score_gemma":0.0015068826,"threshold_uncertainty_score":0.9992644},"labels":[],"label_agreement":null},{"id":"W4308784348","doi":"10.1016/j.jcjd.2022.09.079","title":"Treatment With Once-weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity and Type 2 Diabetes: STEP 2 Post Hoc Analysis","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health; Calgary Laboratory Services","funders":"","keywords":"Medicine; Semaglutide; Overweight; Type 2 diabetes; Obesity; Post-hoc analysis; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.0058477197400291095,"score_gpt":0.19722326900156506,"score_spread":0.19137554926153594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308784348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945671,0.004075083,0.0000012011369,0.00027855684,0.000108928354,0.0005345461,0.00021969737,0.000013108327,0.00020179713],"genre_scores_gemma":[0.9986317,0.0001999624,0.00031064826,0.00015673792,0.00006146319,0.000032070962,0.00008015095,0.000040700263,0.00048654442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980113,0.00014151308,0.00040155876,0.00035914895,0.00039737154,0.00068909675],"domain_scores_gemma":[0.9981464,0.00012449712,0.00036700288,0.0003361269,0.00019311765,0.0008328355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023129117,0.0003797741,0.001097348,0.0015953662,0.0002477324,0.00006914438,0.00015750693,0.000050745995,0.00016541731],"category_scores_gemma":[0.000045376088,0.00023322714,0.00020319723,0.0017057701,0.00013776947,0.00017326849,0.000033443448,0.00027204936,0.000001435612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026191835,0.00021020042,0.98038375,0.000061282015,0.0054735397,0.00023676823,0.0009870951,0.0001409606,0.000036346843,0.000006938257,0.00009749213,0.012103707],"study_design_scores_gemma":[0.0054913233,0.018082416,0.96077186,0.000141503,0.0064134668,0.0000058406704,0.0028895694,0.000278176,0.00015338208,0.0000052222745,0.005433342,0.0003339287],"about_ca_topic_score_codex":0.0056733554,"about_ca_topic_score_gemma":0.047017295,"teacher_disagreement_score":0.04134394,"about_ca_system_score_codex":0.0008014516,"about_ca_system_score_gemma":0.00095723255,"threshold_uncertainty_score":0.97037214},"labels":[],"label_agreement":null},{"id":"W4308784619","doi":"10.1016/j.jcjd.2022.09.038","title":"Two-year Effect of Semaglutide 2.4 mg Versus Placebo in Adults With Overweight or Obesity: STEP 5","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health; Calgary Laboratory Services","funders":"","keywords":"Semaglutide; Medicine; Overweight; Placebo; Obesity; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Alternative medicine","score_opus":0.006118509424386324,"score_gpt":0.21437992426294902,"score_spread":0.2082614148385627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308784619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398607,0.00064862147,3.5523115e-7,0.00025984578,0.00028660047,0.00045955935,0.000026517499,0.0000055809523,0.0043268786],"genre_scores_gemma":[0.9990824,0.0000061578316,0.00023309706,0.00011734649,0.00007191785,0.000021822236,0.000011922322,0.00002482405,0.0004305416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987038,0.00011815012,0.00030753895,0.00014320479,0.00032293578,0.00040441085],"domain_scores_gemma":[0.9988927,0.00022407783,0.00020979176,0.00018874447,0.00006527752,0.00041935575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043929848,0.00016893125,0.00051352126,0.00056984223,0.00007165351,0.000013728238,0.0001569564,0.000026587839,0.0005371339],"category_scores_gemma":[0.00010375872,0.00012020382,0.000107421016,0.00038684925,0.00006676949,0.00007683936,0.000029026745,0.00024690284,0.000004556838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022821883,0.00011238382,0.98843616,0.00029036036,0.0005985416,0.00059580687,0.0003318993,0.00012794034,0.00004913342,0.00015702496,0.0030878608,0.003930685],"study_design_scores_gemma":[0.21699853,0.08753933,0.6369508,0.005006008,0.0037528907,0.0000562681,0.0067754886,0.00064245024,0.0071241492,0.00007157587,0.03385896,0.0012235824],"about_ca_topic_score_codex":0.0008499787,"about_ca_topic_score_gemma":0.013936774,"teacher_disagreement_score":0.3514854,"about_ca_system_score_codex":0.00045370788,"about_ca_system_score_gemma":0.00062086823,"threshold_uncertainty_score":0.7777047},"labels":[],"label_agreement":null},{"id":"W4308922652","doi":"10.1016/j.jcjd.2022.09.055","title":"New Diabetes Guidelines: Impact on Eligibility for SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Glucagon-like peptide 1 receptor; Diabetes mellitus; Pharmacology; Internal medicine; Receptor; Agonist; Endocrinology","score_opus":0.017304973061220846,"score_gpt":0.2761830632504586,"score_spread":0.25887809018923774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308922652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910403,0.002672377,7.587605e-7,0.0047751204,0.0006661377,0.00050713524,0.00015944205,0.0000051728543,0.00017358725],"genre_scores_gemma":[0.99695307,0.000013118513,0.0005200053,0.0018883118,0.00026202423,0.0000296038,0.000044492368,0.000030737283,0.00025861574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982073,0.00005346314,0.00059607654,0.0002312605,0.00030110558,0.0006108265],"domain_scores_gemma":[0.9981254,0.00017755428,0.0002861995,0.00021149487,0.0001494504,0.0010499287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054439675,0.00023254231,0.000551808,0.00043299206,0.00017150021,0.00005280633,0.00015979653,0.00003500122,0.00028894053],"category_scores_gemma":[0.00043092013,0.0001944322,0.0001646426,0.0002730557,0.00004166569,0.000094378476,0.000028499895,0.00023473617,0.0000011977766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023727142,0.000029564952,0.80180967,0.000055192835,0.00020017193,0.000022117816,0.00009169641,0.00016370362,0.0001260928,0.000023859415,0.16891651,0.028537685],"study_design_scores_gemma":[0.007922913,0.005454377,0.73410594,0.00065337936,0.0004517645,0.0000057188768,0.0011521189,0.0004427274,0.0025265107,0.0008161578,0.24577416,0.00069424044],"about_ca_topic_score_codex":0.4586041,"about_ca_topic_score_gemma":0.8111339,"teacher_disagreement_score":0.35252982,"about_ca_system_score_codex":0.00276708,"about_ca_system_score_gemma":0.008269117,"threshold_uncertainty_score":0.9973531},"labels":[],"label_agreement":null},{"id":"W4308922991","doi":"10.1016/j.jcjd.2022.10.004","title":"Remission of Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Alberta Canola Producers Commission; Alberta Innovates; Novo Nordisk; Australian Spinal Research Foundation; Winnipeg Foundation; Canadian Cancer Society; Public Health Agency of Canada; McMaster University; Gilead Sciences; Roche; Kidney Foundation of Canada; Sanofi; Natural Sciences and Engineering Research Council of Canada; Abbott Laboratories; Merck; Bayer; Pfizer; PepsiCo; Eli Lilly and Company","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.012318769598429717,"score_gpt":0.22288648802945038,"score_spread":0.21056771843102065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308922991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901556,0.0037962056,3.3389097e-7,0.0010052987,0.00052238395,0.000118841665,0.000012905281,0.000005276097,0.0043832054],"genre_scores_gemma":[0.9980154,0.000011180701,0.00020775455,0.00048261936,0.00008721684,0.0000034443062,0.000014860831,0.00001752779,0.0011599669],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990174,0.000042695214,0.00031224248,0.00008895161,0.00024178221,0.00029693352],"domain_scores_gemma":[0.9989628,0.000045214467,0.00021243014,0.00016690032,0.00015836125,0.00045425593],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031852408,0.000100061814,0.00032702557,0.00042125792,0.00010269616,0.000010446747,0.0001501003,0.00002544694,0.001159862],"category_scores_gemma":[0.0001269314,0.000086875894,0.00013335569,0.00031639487,0.000054997865,0.000066792345,0.00002862446,0.00016752831,0.0000049704686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009841245,0.0000950329,0.9371494,0.00010674563,0.00039749575,0.000040799307,0.00020659872,0.000058994447,0.0043859086,0.00022841884,0.040249486,0.017071255],"study_design_scores_gemma":[0.0041324273,0.0074268784,0.37726173,0.000596474,0.0012962888,0.000009361672,0.001018763,0.00025595605,0.020930538,0.0011885412,0.5854436,0.00043944715],"about_ca_topic_score_codex":0.000058815236,"about_ca_topic_score_gemma":0.000065439155,"teacher_disagreement_score":0.5598877,"about_ca_system_score_codex":0.00018497925,"about_ca_system_score_gemma":0.0005809365,"threshold_uncertainty_score":0.99975324},"labels":[],"label_agreement":null},{"id":"W4308923410","doi":"10.1016/j.jcjd.2022.09.015","title":"Patterns of Metformin Use and A1C Trends Among Patients With Incident Type 2 Diabetes","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton; Calgary Laboratory Services","funders":"","keywords":"Metformin; Medicine; Discontinuation; Type 2 diabetes; Context (archaeology); Medical prescription; Diabetes mellitus; Internal medicine; Endocrinology; Pharmacology","score_opus":0.009915214004155397,"score_gpt":0.19862394945670048,"score_spread":0.18870873545254507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308923410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987034,0.0006304044,4.208623e-7,0.00011780751,0.00018032875,0.00014237127,0.00006963353,0.000004399762,0.00015122344],"genre_scores_gemma":[0.9991185,0.000008891633,0.00010294251,0.00021347757,0.000031221134,0.000008200394,0.000055057208,0.000023721283,0.00043799408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988861,0.00004187062,0.00031314846,0.00012394522,0.0003027956,0.00033215727],"domain_scores_gemma":[0.99881893,0.00005775932,0.00028868185,0.00016249408,0.0001947322,0.0004774279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019343919,0.00014910546,0.00038740234,0.00065536157,0.00009746327,0.000034939614,0.00011010443,0.00002554507,0.000341262],"category_scores_gemma":[0.00006306527,0.00011647447,0.00007678214,0.00027554334,0.00006374204,0.00025628685,0.000039730607,0.00015488594,5.759378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010806366,0.000082071456,0.9861256,0.000045800945,0.00043274264,0.000023290077,0.00020573096,0.000013539542,0.000018936167,0.000023449651,0.0009700823,0.012047968],"study_design_scores_gemma":[0.001708558,0.0023181392,0.99072814,0.00011903989,0.0004654862,7.5307537e-7,0.00016329523,0.000015590083,0.00030080698,0.000013905254,0.0040512877,0.00011501853],"about_ca_topic_score_codex":0.0004791837,"about_ca_topic_score_gemma":0.0020477122,"teacher_disagreement_score":0.01193295,"about_ca_system_score_codex":0.00017012034,"about_ca_system_score_gemma":0.00017299292,"threshold_uncertainty_score":0.4749691},"labels":[],"label_agreement":null},{"id":"W4308924537","doi":"10.1016/j.jcjd.2022.09.014","title":"Insulin-sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Semaglutide; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.010325934186573859,"score_gpt":0.22891132029792988,"score_spread":0.21858538611135603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308924537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738467,0.0016824855,0.000008110725,0.0001793381,0.00021128186,0.00014324367,0.000021276433,0.000003955724,0.00036562173],"genre_scores_gemma":[0.9992117,0.00000701861,0.00036191702,0.00019862175,0.000028203209,0.0000058897544,0.00002355199,0.000014505955,0.0001485729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988585,0.00007172076,0.00041292468,0.00010718001,0.00028284942,0.00026682005],"domain_scores_gemma":[0.99880266,0.00007541081,0.00032301262,0.0002170067,0.00015143327,0.00043046608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003596461,0.00011268088,0.0006316586,0.0013615293,0.00006770135,0.00000931783,0.00016271649,0.00002613609,0.00024966834],"category_scores_gemma":[0.00010138521,0.00010302205,0.00027248755,0.00084513484,0.00006137858,0.00007885166,0.000028023893,0.00014079013,6.9601407e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001052654,0.00018944484,0.9790524,0.00017062113,0.0043977136,0.00008395244,0.0005458086,0.0020074507,0.0018367387,0.00023421862,0.0006381768,0.010832929],"study_design_scores_gemma":[0.0019877243,0.0022423067,0.97545767,0.0001274678,0.008124958,0.0000018608969,0.00046398182,0.0012855758,0.0067755426,0.00009130836,0.003292575,0.00014900482],"about_ca_topic_score_codex":0.00089476694,"about_ca_topic_score_gemma":0.0022235303,"teacher_disagreement_score":0.010683924,"about_ca_system_score_codex":0.00018538588,"about_ca_system_score_gemma":0.0003103331,"threshold_uncertainty_score":0.42011175},"labels":[],"label_agreement":null},{"id":"W4308925513","doi":"10.1016/j.jcjd.2022.09.010","title":"Improving Equality in Outcomes for Indigenous Peoples With Type 2 Diabetes: Use of Special Authority Criteria","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Indigenous; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.03137355699869786,"score_gpt":0.2702288673568063,"score_spread":0.23885531035810842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308925513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800813,0.0003650165,0.000005830163,0.00030309666,0.0005581474,0.00051648164,0.00013590242,0.0000055142777,0.00010188831],"genre_scores_gemma":[0.9980496,0.0000032056869,0.0011246213,0.0003123491,0.00020221803,0.000025319596,0.000035507328,0.00002606724,0.0002210728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853235,0.000081781545,0.0004861261,0.00015715667,0.00024422357,0.0004983818],"domain_scores_gemma":[0.99869955,0.00023225111,0.0003332634,0.00019384445,0.0001989444,0.00034212333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005934776,0.00016702102,0.0006118015,0.00054734654,0.00013664318,0.00004429744,0.00015953585,0.000040262854,0.00021253011],"category_scores_gemma":[0.00037931028,0.00013967091,0.00014216328,0.00030961388,0.00007161461,0.0001932666,0.00003197689,0.00018961327,6.3134127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003859589,0.00013788883,0.9915029,0.00023491537,0.00029093577,0.000022357992,0.0016355222,0.000029448101,0.00032046324,0.00009537938,0.0008237428,0.0048678666],"study_design_scores_gemma":[0.0029052547,0.003589062,0.98275334,0.00016546958,0.00047747826,0.0000015233608,0.0015203377,0.00007703393,0.0007751819,0.00015491236,0.007339497,0.00024089587],"about_ca_topic_score_codex":0.0011647352,"about_ca_topic_score_gemma":0.016830774,"teacher_disagreement_score":0.015666038,"about_ca_system_score_codex":0.0004111577,"about_ca_system_score_gemma":0.001238485,"threshold_uncertainty_score":0.93919665},"labels":[],"label_agreement":null},{"id":"W4308925926","doi":"10.1016/j.jcjd.2022.09.069","title":"SGLT-2 Inhibitor Associated Acidosis in the Inpatient Setting: A Retrospective Analysis","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Acidosis; Intensive care medicine; Diabetes mellitus; Emergency medicine; Anesthesia; Endocrinology","score_opus":0.007836137994383945,"score_gpt":0.21402116205014363,"score_spread":0.20618502405575967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308925926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939165,0.00053937326,9.092368e-7,0.0035790647,0.00018721873,0.00023557837,0.000043064392,0.0000051091038,0.0014931613],"genre_scores_gemma":[0.9980635,0.0000032559126,0.00003781553,0.0015894577,0.000058855218,0.00003002615,0.000039381637,0.000011873413,0.00016585474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985427,0.00017967084,0.00035705278,0.0001318646,0.00041549743,0.0003731812],"domain_scores_gemma":[0.999114,0.00008114031,0.00026802774,0.00017828967,0.00011709448,0.00024146422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090959,0.000122053694,0.00038687288,0.0010442232,0.00019375731,0.000045196088,0.00020173471,0.000029435661,0.0002977387],"category_scores_gemma":[0.00025749273,0.00009178329,0.0002771917,0.0016374333,0.000043010674,0.00007646337,0.000026627713,0.0003450767,0.0000023796515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032802939,0.0001314737,0.9900873,0.0000059097993,0.0013538459,0.00007988199,0.0016045347,0.000098492455,0.000027941593,0.00006452402,0.0049231197,0.0016197073],"study_design_scores_gemma":[0.0011581263,0.0009621067,0.9889333,0.000037458314,0.0016841292,0.0000011688707,0.0018385884,0.00015458015,0.000076797485,0.00014607527,0.0049046306,0.00010302103],"about_ca_topic_score_codex":0.0004576895,"about_ca_topic_score_gemma":0.005968632,"teacher_disagreement_score":0.005510943,"about_ca_system_score_codex":0.0011084654,"about_ca_system_score_gemma":0.00035805465,"threshold_uncertainty_score":0.37428138},"labels":[],"label_agreement":null},{"id":"W4308979115","doi":"10.1016/j.molmet.2022.101641","title":"Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","year":2022,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Liraglutide; Myocardial infarction; Internal medicine; Endocrinology; Medicine; Glucagon-like peptide-1; Receptor; Biology; Cardiology; Type 2 diabetes; Diabetes mellitus","score_opus":0.009199309763359309,"score_gpt":0.2395745435384851,"score_spread":0.23037523377512578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308979115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894322,0.0026093184,0.002067655,0.00072462735,0.0010505284,0.0029973297,0.00007549676,0.000041718606,0.0010011251],"genre_scores_gemma":[0.9956945,0.000035967845,0.0012594477,0.0003036267,0.0001255481,0.0019251553,0.000051673105,0.00003941659,0.0005646369],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875546,0.000104695035,0.00020809984,0.00030082968,0.00038500119,0.00024592524],"domain_scores_gemma":[0.9993392,0.000033089003,0.00013749023,0.00037313192,0.00006695739,0.00005013665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019987859,0.0001790579,0.0003588092,0.00017157725,0.00017251504,0.00001508648,0.00013856185,0.000029822522,0.000068525864],"category_scores_gemma":[0.000017001545,0.00013914096,0.00024042773,0.00032973668,0.00006804956,0.00006259432,0.00015345574,0.00017631301,0.000004081145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018553371,0.0009756101,0.00037586121,0.00006788533,0.002564226,0.000035969373,0.002150542,0.003885876,0.98121774,0.00074483216,0.0027271071,0.0033990082],"study_design_scores_gemma":[0.0059344787,0.0005404179,0.0064574974,0.000031640477,0.0013519163,0.000009714165,0.0050760363,0.00022901574,0.8006138,0.000037488,0.1794649,0.00025309317],"about_ca_topic_score_codex":0.00031759305,"about_ca_topic_score_gemma":0.000011629507,"teacher_disagreement_score":0.18060395,"about_ca_system_score_codex":0.0001580892,"about_ca_system_score_gemma":0.00006539296,"threshold_uncertainty_score":0.56740034},"labels":[],"label_agreement":null},{"id":"W4309165571","doi":"10.1210/clinem/dgac642","title":"Duration of Diabetes, Glycemic Control, and Risk of Heart Failure Among Adults With Diabetes: A Cohort Study","year":2022,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Medical Research Council","keywords":"Glycemic; Medicine; Diabetes mellitus; Duration (music); Cohort; Internal medicine; Heart failure; Cohort study; Proportional hazards model; Cardiology; Endocrinology","score_opus":0.010353217989493388,"score_gpt":0.2813567601923002,"score_spread":0.2710035422028068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309165571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949125,0.002386878,0.000010309067,0.001296114,0.0002324925,0.0010928657,0.000015835389,0.000010665234,0.000042319843],"genre_scores_gemma":[0.99861693,0.00061571354,0.00023935633,0.00027107488,0.00015124369,0.000039415303,0.000003804288,0.000018334305,0.000044151286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963252,0.0011344719,0.0015195283,0.00019379,0.0005250408,0.0003019929],"domain_scores_gemma":[0.9965433,0.0010094531,0.001690753,0.00038485887,0.00025469897,0.00011695644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183397,0.0001865356,0.0015444624,0.00018262933,0.000099451354,0.000005041719,0.00021241563,0.00004600338,0.000058946986],"category_scores_gemma":[0.0004827055,0.00010735915,0.00023510799,0.0001962385,0.00045003742,0.00010331087,0.00013406803,0.00071601063,8.9323356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030959412,0.0012297796,0.9887596,0.0000309741,0.0037929507,0.00001339684,0.00025225757,0.00005368614,0.0001728021,0.000043832868,0.00046674692,0.0020880704],"study_design_scores_gemma":[0.01973739,0.008321643,0.9612772,0.000051435298,0.0073779062,0.00001342401,0.0010090732,0.00009671219,0.00018887594,0.000074855336,0.0017706403,0.00008086563],"about_ca_topic_score_codex":0.000043012325,"about_ca_topic_score_gemma":0.000029091721,"teacher_disagreement_score":0.027482385,"about_ca_system_score_codex":0.000015645708,"about_ca_system_score_gemma":0.000078078505,"threshold_uncertainty_score":0.4377979},"labels":[],"label_agreement":null},{"id":"W4309277383","doi":"10.3389/fphar.2022.977582","title":"Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database","year":2022,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adverse Event Reporting System; Food and drug administration; Medicine; Acute pancreatitis; Pancreatitis; Drug; Adverse effect; Pharmacology; Adverse drug reaction; Database; Intensive care medicine; Internal medicine; Computer science","score_opus":0.00693646368040624,"score_gpt":0.24865917072583624,"score_spread":0.24172270704543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309277383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741787,0.00007376767,0.00022104253,0.0000784091,0.0003158855,0.00079498324,0.0008983344,0.000013300917,0.0001863879],"genre_scores_gemma":[0.99902385,0.000031001997,0.00013673128,0.000040042305,0.0000076134893,0.00011207506,0.00054912904,0.000008924226,0.0000905985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882156,0.00025456608,0.00029652254,0.00024892736,0.00025174237,0.00012670008],"domain_scores_gemma":[0.99923253,0.00007709866,0.0004365259,0.00016460274,0.000037627895,0.00005160746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003429737,0.000121583296,0.00042603066,0.00033429172,0.00007429365,0.0000018293533,0.00005125531,0.000026661697,0.000017092281],"category_scores_gemma":[0.000026028874,0.00008740546,0.00007326074,0.00045070893,0.000085242544,0.000039669492,0.00006652729,0.00012943886,1.4457025e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072249735,0.00040408343,0.9894153,0.000048682297,0.0065208348,0.00012947843,0.00031653035,0.0009913128,0.00007967877,0.000009155273,0.0012708909,0.000091572474],"study_design_scores_gemma":[0.0051546656,0.0026817778,0.931348,0.000086686116,0.02681464,0.0000055027035,0.0021795249,0.025887227,0.005595405,0.000003539419,0.0001273661,0.000115649425],"about_ca_topic_score_codex":0.00006180419,"about_ca_topic_score_gemma":0.000027442553,"teacher_disagreement_score":0.058067266,"about_ca_system_score_codex":0.0002559121,"about_ca_system_score_gemma":0.00008222111,"threshold_uncertainty_score":0.35642913},"labels":[],"label_agreement":null},{"id":"W4309413429","doi":"10.2337/dc22-1318","title":"Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Dapagliflozin; Medicine; Insulin; Internal medicine; Hazard ratio; Regimen; Diabetes mellitus; Type 2 diabetes; Placebo; Endocrinology; Adverse effect; Confidence interval","score_opus":0.013467394364401794,"score_gpt":0.2644101944108675,"score_spread":0.2509428000464657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309413429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96882814,0.027795305,0.0000033361086,0.00074827624,0.00006210948,0.0005467027,0.0013109307,0.00005269192,0.0006525271],"genre_scores_gemma":[0.99354565,0.00062961417,0.00060648646,0.0008454936,0.000045961297,0.000057228615,0.003933569,0.000031736414,0.00030424423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864495,0.000100787096,0.00028911865,0.00040674792,0.00029781894,0.00026060877],"domain_scores_gemma":[0.99907637,0.00021599625,0.00011299673,0.00036118258,0.000083759674,0.00014967802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014300115,0.0002186952,0.00049299217,0.00014297903,0.00013345126,0.0000217193,0.00009856236,0.00004866552,0.00033115924],"category_scores_gemma":[0.000075296404,0.00019553909,0.000074920215,0.00023368321,0.00008580351,0.00006691504,0.00029545577,0.00013254341,0.0000064195833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019610394,0.0011520516,0.6091556,0.0007058131,0.0030241413,0.000065237255,0.004203897,0.00007134852,0.055546876,0.00007498029,0.03593676,0.28810227],"study_design_scores_gemma":[0.036672316,0.006648216,0.6199909,0.0005093109,0.0055397153,0.0000020615566,0.014880541,0.0011248231,0.036156986,0.000099220706,0.27720076,0.0011751525],"about_ca_topic_score_codex":0.000072461786,"about_ca_topic_score_gemma":0.000009858557,"teacher_disagreement_score":0.28692713,"about_ca_system_score_codex":0.00007552552,"about_ca_system_score_gemma":0.000030313784,"threshold_uncertainty_score":0.7973853},"labels":[],"label_agreement":null},{"id":"W4309648547","doi":"10.1016/s2589-7500(22)00197-2","title":"Treating type 2 diabetes: moving towards precision medicine","year":2022,"lang":"en","type":"letter","venue":"The Lancet Digital Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Type 2 diabetes; Precision medicine; Medicine; Diabetes mellitus; Computer science; Endocrinology; Pathology","score_opus":0.050564331004269436,"score_gpt":0.3240693205195262,"score_spread":0.27350498951525676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309648547","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034007165,0.0038356285,0.0000052933715,0.8917218,0.0008708975,0.0012237598,0.00011185723,0.0002670838,0.09856299],"genre_scores_gemma":[0.012138702,0.0010494188,0.000109283035,0.93648034,0.009505298,0.00013105864,0.004122868,0.0001316128,0.03633143],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714625,0.00010942155,0.000500169,0.0004920111,0.00085485313,0.00089727435],"domain_scores_gemma":[0.9981816,0.00036063147,0.0003334634,0.0009489788,0.00005549923,0.00011984958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000599577,0.00040367537,0.0012391687,0.00017085971,0.00025640242,0.00008788947,0.00038565748,0.00013822298,0.00068091345],"category_scores_gemma":[0.00022142965,0.00023803438,0.00014293927,0.00038570777,0.00010247989,0.00012412625,0.00030880657,0.0012221938,0.000099843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005585284,0.000041364212,0.0007872934,0.00071029895,0.0001855154,0.0000742368,0.00026100583,0.0000013504769,3.6160185e-7,0.000024112207,0.83258075,0.16527788],"study_design_scores_gemma":[0.0011857924,0.0021679346,0.0011533219,0.0009060229,0.00016091306,0.000007816711,0.000107869826,0.00005695636,0.0000017334515,0.0005332455,0.9935251,0.0001933032],"about_ca_topic_score_codex":0.00008830682,"about_ca_topic_score_gemma":0.0000029660266,"teacher_disagreement_score":0.16508459,"about_ca_system_score_codex":0.00045979393,"about_ca_system_score_gemma":0.00023002266,"threshold_uncertainty_score":0.970676},"labels":[],"label_agreement":null},{"id":"W4309715592","doi":"10.1007/s41030-022-00203-x","title":"Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence","year":2022,"lang":"en","type":"review","venue":"Pulmonary Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; College of Family Physicians of Canada; Diabetes Canada; University of Toronto","funders":"","keywords":"Asthma; Receptor; Medicine; Internal medicine","score_opus":0.08417312563525742,"score_gpt":0.35277352268566253,"score_spread":0.2686003970504051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309715592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000072880903,0.99251974,0.0000013491909,0.00083214877,0.0006602582,0.003813083,0.00005239374,0.000040448176,0.0020732768],"genre_scores_gemma":[0.0000017694018,0.99315244,0.00007008249,0.00054396334,0.00014788234,0.0013750575,0.00024629637,0.000059528764,0.0044029844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977124,0.00034804456,0.0006803644,0.00049502315,0.0005105784,0.00025359113],"domain_scores_gemma":[0.9981242,0.00027774228,0.0005163743,0.00093237584,0.000054005355,0.000095324984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052451773,0.0004365833,0.0014828625,0.00012079938,0.00015924702,0.000018676537,0.0003622298,0.00005788985,0.0014645337],"category_scores_gemma":[0.00007684516,0.0002608533,0.0007108695,0.0005992478,0.00011917452,0.000088459965,0.0002616657,0.00040538874,0.00003177898],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013769683,0.00030759844,0.00002485127,0.07692078,0.00031627374,0.0000054809434,0.000025197194,1.6259278e-8,4.575211e-7,0.00007236038,0.011338822,0.9109744],"study_design_scores_gemma":[0.0001525872,0.00020861732,0.000054507844,0.14473684,0.00087260216,0.0000199216,0.0000070777637,8.142502e-7,3.8557056e-7,0.00001978471,0.853745,0.00018189209],"about_ca_topic_score_codex":0.000008298258,"about_ca_topic_score_gemma":5.672147e-7,"teacher_disagreement_score":0.9107925,"about_ca_system_score_codex":0.00021846127,"about_ca_system_score_gemma":0.00029411257,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W4309829245","doi":"10.3390/biom12121736","title":"Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice","year":2022,"lang":"en","type":"article","venue":"Biomolecules","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Université de Lausanne; University of Toronto; Diabetes UK; Wellcome Trust; Medical Research Council; Wellcome","keywords":"Biology; Endocrinology; Internal medicine; Receptor; Function (biology); Medicine; Cell biology","score_opus":0.043431450078022855,"score_gpt":0.281290581614541,"score_spread":0.23785913153651816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309829245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204105,0.0043850685,0.000047411097,0.0023501555,0.000082581166,0.0009836762,0.0000035682742,0.000006936533,0.00009953372],"genre_scores_gemma":[0.9984894,0.00011581817,0.0006571954,0.00014482177,0.000022268707,0.00024918502,0.000014560887,0.000006677272,0.00030011102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992954,0.00006623505,0.00017134678,0.00024129456,0.00012350336,0.000102200494],"domain_scores_gemma":[0.9996496,0.00011365078,0.00007241661,0.00012670817,0.000021365657,0.00001626498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060417264,0.0000695041,0.00014740742,0.00010000064,0.000059437305,0.000008382801,0.000032041207,0.0000128473985,0.000010839849],"category_scores_gemma":[0.00014257302,0.0000524188,0.000023592947,0.00017680909,0.00012765024,0.00004429369,0.000107119406,0.000038005513,1.2787673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015372186,0.0013374415,0.43782696,0.0019025921,0.0006635859,0.000028657616,0.026072519,0.00012426417,0.19267146,0.020880729,0.0031327868,0.29998684],"study_design_scores_gemma":[0.032849234,0.0061909645,0.8362072,0.0015645103,0.0008174662,0.000012455051,0.038237937,0.00256455,0.05425989,0.006384129,0.020265482,0.00064619014],"about_ca_topic_score_codex":0.0006050817,"about_ca_topic_score_gemma":0.0001874964,"teacher_disagreement_score":0.39838025,"about_ca_system_score_codex":0.00007153433,"about_ca_system_score_gemma":0.00001905878,"threshold_uncertainty_score":0.21375766},"labels":[],"label_agreement":null},{"id":"W4310356568","doi":"10.3389/fneur.2022.1018027","title":"Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis","year":2022,"lang":"en","type":"review","venue":"Frontiers in Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Cochrane Library; Placebo; Randomized controlled trial; Montreal Cognitive Assessment; Strictly standardized mean difference; Mini–Mental State Examination; Disease; Dementia; Pathology; Alternative medicine","score_opus":0.02354620256567543,"score_gpt":0.26240411965668686,"score_spread":0.23885791709101142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310356568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022792509,0.98770154,0.000013339474,0.000035878915,0.000060831477,0.009794917,0.00008382636,0.000009126026,0.000021286276],"genre_scores_gemma":[0.009520988,0.9878228,0.00003739895,0.0005051275,0.0000074205914,0.0015216519,0.00053257676,0.00003762725,0.000014439677],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968107,0.00097028835,0.0009558134,0.0007328278,0.00020728292,0.0003231245],"domain_scores_gemma":[0.9984486,0.0005172264,0.00065914897,0.00022671148,0.000032572305,0.00011575361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055672927,0.0004532512,0.0056732004,0.00083007757,0.000036021782,0.000008899675,0.00006216781,0.00010172237,0.000021988224],"category_scores_gemma":[0.00011990197,0.00032818952,0.0002970574,0.0009787915,0.00014059538,0.00006650055,0.0001755067,0.00037780686,2.8373546e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072708675,0.0011077067,0.08487118,0.6321452,0.20575713,0.0001685012,0.00024945254,0.000007170283,8.0274437e-10,0.0000073570714,0.000098044904,0.0683174],"study_design_scores_gemma":[0.0062111705,0.001667425,0.026743548,0.023328751,0.9413393,0.0000022704926,0.000045035093,0.000040885454,2.3275697e-9,0.000010005142,0.00035240353,0.00025916114],"about_ca_topic_score_codex":0.000024595049,"about_ca_topic_score_gemma":0.00001558012,"teacher_disagreement_score":0.73558223,"about_ca_system_score_codex":0.000047598784,"about_ca_system_score_gemma":0.00005288661,"threshold_uncertainty_score":0.99991703},"labels":[],"label_agreement":null},{"id":"W4310388086","doi":"10.21109/kesmas.v17i4.6303","title":"Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea","year":2022,"lang":"en","type":"article","venue":"Kesmas National Public Health Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Sulfonylurea; Medicine; Diabetes mellitus; Cognition; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; Cognitive decline; Endocrinology; Psychiatry; Disease","score_opus":0.05154473159804134,"score_gpt":0.3113905814523122,"score_spread":0.25984584985427084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310388086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974004,0.005982525,0.00011771468,0.009127029,0.0008932338,0.0009077115,0.000035555262,0.00004218805,0.0088900775],"genre_scores_gemma":[0.9945088,0.00045070445,0.00032053445,0.0036740082,0.0001513813,0.00007056454,0.0003657183,0.000018462972,0.00043983286],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977769,0.00015400798,0.00047375518,0.00020989215,0.0009257555,0.00045965513],"domain_scores_gemma":[0.99869895,0.00015135063,0.0003704426,0.000055507415,0.00042536375,0.00029838894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021326498,0.00014376086,0.00027499103,0.00078100193,0.0004627779,0.000069894966,0.000063545085,0.000035686233,0.0007628656],"category_scores_gemma":[0.0004937306,0.00012986851,0.000055203778,0.0006276882,0.000033074833,0.00042627644,0.000089812456,0.00042579573,0.000010716087],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023378199,0.0013545161,0.23330234,0.000115102324,0.00049967447,0.000026546595,0.00070071226,0.00001866398,0.0000034684617,0.008963989,0.00491211,0.7498691],"study_design_scores_gemma":[0.009697885,0.0033227094,0.65206486,0.00011772486,0.00013408609,0.000079295816,0.001304357,0.00084796915,0.000007785073,0.003208579,0.32893932,0.00027539433],"about_ca_topic_score_codex":0.000013183312,"about_ca_topic_score_gemma":0.000008734601,"teacher_disagreement_score":0.7495937,"about_ca_system_score_codex":0.00083202735,"about_ca_system_score_gemma":0.0007541148,"threshold_uncertainty_score":0.8352843},"labels":[],"label_agreement":null},{"id":"W4310776373","doi":"10.1172/jci.insight.154314","title":"Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression","year":2022,"lang":"en","type":"article","venue":"JCI Insight","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; Institute of Infection and Immunity; Carleton University; Ottawa Hospital; University of Alberta; Diabetes Québec; University of Ottawa","funders":"Canadian Institutes of Health Research; Diabetes Canada; Medicure; Novo Nordisk; Meso Scale Diagnostics; University of Ottawa; University of Alberta","keywords":"Internal medicine; Endocrinology; Insulin resistance; Dipeptidyl peptidase-4; Nonalcoholic fatty liver disease; Metabolic syndrome; Steatosis; Fatty liver; Biology; Type 2 diabetes; Medicine; Diabetes mellitus; Disease","score_opus":0.01680819699244619,"score_gpt":0.25674648525956995,"score_spread":0.23993828826712377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310776373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910159,0.0027717252,0.0000015688296,0.0028890974,0.00039114233,0.0011337923,0.000006480433,0.00018561202,0.0016046625],"genre_scores_gemma":[0.996089,0.00022790427,0.0005033627,0.0002308984,0.00014707075,0.00030457307,0.000089428984,0.000029938428,0.002377866],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984233,0.00005979109,0.00025818235,0.00050989207,0.00046498704,0.0002838393],"domain_scores_gemma":[0.9992859,0.000021246344,0.00014739414,0.00035103667,0.00006503911,0.00012940874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015128974,0.00023128431,0.00030979482,0.00019343186,0.00033396418,0.00005341746,0.00008628111,0.00004693269,0.00029020337],"category_scores_gemma":[0.00004174879,0.0001809365,0.00007284918,0.00022186186,0.00012528771,0.0002592689,0.00031128447,0.0001539803,0.000013011875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001268989,0.005620247,0.6245363,0.00072544074,0.0018131718,0.0008568906,0.007795519,0.00015519101,0.19659586,0.0013972927,0.026617264,0.13261783],"study_design_scores_gemma":[0.0041029584,0.0036243491,0.38366157,0.00043212855,0.00087476114,0.00017611434,0.0014671967,0.0012223632,0.4308673,0.0024118535,0.1701804,0.0009790058],"about_ca_topic_score_codex":0.000068818255,"about_ca_topic_score_gemma":0.000023146304,"teacher_disagreement_score":0.24087472,"about_ca_system_score_codex":0.00010098065,"about_ca_system_score_gemma":0.00004729412,"threshold_uncertainty_score":0.7378376},"labels":[],"label_agreement":null},{"id":"W4310779922","doi":"10.1038/s41591-022-02041-5","title":"Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"Roche Diagnostics; Amgen Canada; Pfizer Japan; Novartis Pharma; Esperion Therapeutics; HLS Therapeutics; Daiichi Sankyo Europe; Servier; Teijin Pharma; Otsuka Pharmaceutical; Cytokinetics; Astellas Pharma; Deutsche Forschungsgemeinschaft; Astellas Foundation for Research on Metabolic Disorders; Boehringer Ingelheim Japan; ReCor Medical; Mitsubishi Tanabe Pharma Corporation; Medicines Company; MSD K.K.; AstraZeneca Canada; Siemens Medical Solutions USA; AstraZeneca; Amarin Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Regeneron Pharmaceuticals; Intercept Pharmaceuticals; Bayer HealthCare; Omron Healthcare; Kowa Company; Sanofi; Amgen; Anthera; Vifor Pharma; Actelion Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Ejection fraction; Hazard ratio; Medicine; Heart failure; Internal medicine; Cardiology; Placebo; Clinical endpoint; Confidence interval; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.019712547377804476,"score_gpt":0.2940950505511354,"score_spread":0.2743825031733309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310779922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091566,0.0015388918,0.00001704321,0.0044874353,0.00028592325,0.0010315063,0.000018447776,0.000049207407,0.0016558716],"genre_scores_gemma":[0.99800014,0.000043457178,0.00041677573,0.00016756625,0.00013989155,0.0001233793,0.00038284328,0.000024419982,0.0007015258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976663,0.00015182143,0.000490872,0.00041399218,0.0010243736,0.0002526211],"domain_scores_gemma":[0.99852854,0.00029308698,0.00025694704,0.00065329636,0.00016692247,0.000101201564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049648935,0.00022702798,0.0009778553,0.0011538006,0.00006226741,0.00000403891,0.00017752024,0.00014812544,0.0017568659],"category_scores_gemma":[0.00024779452,0.00016825009,0.00019136546,0.0031210429,0.00010734081,0.00009446123,0.00010494052,0.00069722417,0.0000013195314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06076367,0.00400855,0.85934323,0.0007808637,0.013692943,0.00015344626,0.002140142,0.002499683,0.014433445,0.00022735538,0.04021041,0.0017462887],"study_design_scores_gemma":[0.02418851,0.003691205,0.9312982,0.00021410106,0.0054798345,0.0000018970021,0.001879836,0.00047381097,0.0029377085,0.000008547271,0.029660754,0.00016558213],"about_ca_topic_score_codex":0.00042891732,"about_ca_topic_score_gemma":0.00075583835,"teacher_disagreement_score":0.07195501,"about_ca_system_score_codex":0.0002227503,"about_ca_system_score_gemma":0.000054128694,"threshold_uncertainty_score":0.99915564},"labels":[],"label_agreement":null},{"id":"W4311182072","doi":"10.1038/s41574-022-00783-3","title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Incretin; Medicine; Glucose homeostasis; Gastric inhibitory polypeptide; Agonist; Glucagon-like peptide-1; Type 2 diabetes; Receptor; Adipose tissue; Insulin; Diabetes mellitus; Insulin resistance; Glucagon","score_opus":0.06677817964917755,"score_gpt":0.3705905864240467,"score_spread":0.30381240677486915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311182072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000073582755,0.97898287,0.0000019717356,0.00023517832,0.00062676833,0.0029511384,0.000048188613,0.000040878458,0.017105674],"genre_scores_gemma":[0.000025057554,0.9966706,0.00016250774,0.0004347348,0.0002970134,0.0009893555,0.00020079677,0.00004498695,0.0011749464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755794,0.0005226495,0.0007778189,0.00047782392,0.00021736872,0.0004464082],"domain_scores_gemma":[0.997983,0.0005328539,0.0006164635,0.00074830966,0.000037648766,0.000081749],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003860548,0.00046152342,0.003899315,0.00035292027,0.00013834021,0.000012029709,0.00025101542,0.0002564251,0.00022096906],"category_scores_gemma":[0.0004354057,0.00025880613,0.00087543216,0.0006202919,0.00015577488,0.000033168766,0.00029552926,0.0014697891,0.000021430773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041434523,0.000052959283,0.000027559025,0.012033701,0.0013088061,0.000037148686,0.000014451973,1.0674165e-8,3.7937713e-7,0.005746268,0.002962293,0.9778123],"study_design_scores_gemma":[0.00039467268,0.00011350268,0.00006734117,0.0018749476,0.012034632,0.00043697565,0.00001789773,1.6315079e-7,5.7605837e-7,0.000039494545,0.98485667,0.00016316102],"about_ca_topic_score_codex":0.00001538783,"about_ca_topic_score_gemma":0.0000038258927,"teacher_disagreement_score":0.9818943,"about_ca_system_score_codex":0.00009879726,"about_ca_system_score_gemma":0.00010653975,"threshold_uncertainty_score":0.9999864},"labels":[],"label_agreement":null},{"id":"W4311187271","doi":"10.2337/figshare.21445284.v1","title":"Association of sodium-glucose cotransporter-2 inhibitors with time to dementia: a population-based cohort study","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Medicine; Hazard ratio; Cohort; Internal medicine; Population; Type 2 diabetes; Cohort study; Lower risk; Proportional hazards model; Confidence interval; Diabetes mellitus; Endocrinology; Disease; Environmental health","score_opus":0.006886652546839565,"score_gpt":0.2359571027205278,"score_spread":0.22907045017368824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311187271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503435,0.000028186305,0.00010999932,0.00081828766,0.00016250563,0.006344581,0.00005052088,0.00014418465,0.007307399],"genre_scores_gemma":[0.9798764,0.000002939328,0.0009986076,0.00029437526,0.000050552128,0.00090828835,0.0022599194,0.000044149663,0.01556479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762416,0.00006869353,0.00051569234,0.00052791316,0.0010288071,0.00023473828],"domain_scores_gemma":[0.9988077,0.000044009153,0.00036749116,0.0005252174,0.00014475724,0.00011079735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005082087,0.00029391816,0.00069350755,0.00032695252,0.0000572175,0.000023924069,0.000114931914,0.00009354898,0.004779769],"category_scores_gemma":[0.00001700344,0.0002469294,0.00015260218,0.00024067755,0.000007003411,0.000032263597,0.00014518887,0.00020957083,0.000053548607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020156857,0.0022950293,0.98807955,0.00017106258,0.0040253806,0.000023119113,0.00012460894,0.0007770794,0.000028035254,0.0000049700534,0.0037918098,0.00047779098],"study_design_scores_gemma":[0.0029151528,0.0015618494,0.98694897,0.00011407912,0.005982098,7.783301e-8,0.00010851549,0.00018450618,0.00033706063,0.000008314073,0.0015931646,0.0002462356],"about_ca_topic_score_codex":0.0009608952,"about_ca_topic_score_gemma":0.00031918308,"teacher_disagreement_score":0.008257391,"about_ca_system_score_codex":0.0006383452,"about_ca_system_score_gemma":0.00012658816,"threshold_uncertainty_score":0.9999983},"labels":[],"label_agreement":null},{"id":"W4311187287","doi":"10.2337/figshare.21445284","title":"Association of sodium-glucose cotransporter-2 inhibitors with time to dementia: a population-based cohort study","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Medicine; Hazard ratio; Cohort; Internal medicine; Population; Proportional hazards model; Cohort study; Lower risk; Confidence interval; Disease; Environmental health","score_opus":0.006886652546839565,"score_gpt":0.2359571027205278,"score_spread":0.22907045017368824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311187287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503435,0.000028186305,0.00010999932,0.00081828766,0.00016250563,0.006344581,0.00005052088,0.00014418465,0.007307399],"genre_scores_gemma":[0.9798764,0.000002939328,0.0009986076,0.00029437526,0.000050552128,0.00090828835,0.0022599194,0.000044149663,0.01556479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762416,0.00006869353,0.00051569234,0.00052791316,0.0010288071,0.00023473828],"domain_scores_gemma":[0.9988077,0.000044009153,0.00036749116,0.0005252174,0.00014475724,0.00011079735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005082087,0.00029391816,0.00069350755,0.00032695252,0.0000572175,0.000023924069,0.000114931914,0.00009354898,0.004779769],"category_scores_gemma":[0.00001700344,0.0002469294,0.00015260218,0.00024067755,0.000007003411,0.000032263597,0.00014518887,0.00020957083,0.000053548607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020156857,0.0022950293,0.98807955,0.00017106258,0.0040253806,0.000023119113,0.00012460894,0.0007770794,0.000028035254,0.0000049700534,0.0037918098,0.00047779098],"study_design_scores_gemma":[0.0029151528,0.0015618494,0.98694897,0.00011407912,0.005982098,7.783301e-8,0.00010851549,0.00018450618,0.00033706063,0.000008314073,0.0015931646,0.0002462356],"about_ca_topic_score_codex":0.0009608952,"about_ca_topic_score_gemma":0.00031918308,"teacher_disagreement_score":0.008257391,"about_ca_system_score_codex":0.0006383452,"about_ca_system_score_gemma":0.00012658816,"threshold_uncertainty_score":0.9999983},"labels":[],"label_agreement":null},{"id":"W4311187428","doi":"10.2337/dc22-1705","title":"Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Ottawa; Toronto Dementia Research Alliance; University of Toronto; University Health Network; Health Sciences Centre; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre","funders":"Banting and Best Diabetes Centre, University of Toronto; University of Toronto; Canada Research Chairs; Government of Ontario; Michael J. Fox Foundation for Parkinson's Research; Alzheimer's Research Trust; Weston Brain Institute; Canadian Institutes of Health Research; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Sunnybrook Research Institute; Natural Sciences and Engineering Research Council of Canada; Fondation Brain Canada; Alzheimer's Association","keywords":"Medicine; Dementia; Dapagliflozin; Empagliflozin; Hazard ratio; Internal medicine; Cohort; Type 2 diabetes; Population; Cohort study; Proportional hazards model; Diabetes mellitus; Lower risk; Endocrinology; Disease; Confidence interval; Environmental health","score_opus":0.0035887747422072283,"score_gpt":0.203365788053382,"score_spread":0.19977701331117478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311187428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965197,0.000072749855,0.000001721629,0.00029337325,0.00007218937,0.0021217687,0.000089434456,0.000066803324,0.0007622779],"genre_scores_gemma":[0.9967733,3.264177e-7,0.0001131089,0.00042790975,0.000029654217,0.00058510056,0.0012805903,0.000027866849,0.00076213566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856013,0.000053756627,0.00023888906,0.00026270523,0.0006518375,0.0002326999],"domain_scores_gemma":[0.99938434,0.00003411051,0.00013185649,0.00024620484,0.0001254913,0.00007800306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018733533,0.00014644573,0.00032765887,0.00017747874,0.00009948425,0.000012042986,0.00006694324,0.000024279252,0.000736316],"category_scores_gemma":[0.000011641063,0.00013159966,0.00008211149,0.0003230153,0.000006273184,0.00004277894,0.000036701633,0.00007643075,0.000056780304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005998608,0.000611709,0.99433595,0.00007127483,0.00096093526,0.000007027557,0.000479545,0.0002423293,0.00021065901,0.0000012143107,0.0020539046,0.00096547615],"study_design_scores_gemma":[0.00242782,0.0018730623,0.9889532,0.00003287858,0.0017674085,2.5912087e-8,0.0007224583,0.00006335806,0.0015373767,0.0000013447051,0.0024845349,0.00013656296],"about_ca_topic_score_codex":0.000041245425,"about_ca_topic_score_gemma":0.000038059483,"teacher_disagreement_score":0.0053827697,"about_ca_system_score_codex":0.0003731013,"about_ca_system_score_gemma":0.000038133134,"threshold_uncertainty_score":0.80621445},"labels":[],"label_agreement":null},{"id":"W4311480480","doi":"10.1111/dom.14943","title":"Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A <i>post hoc</i> analysis of the <scp>SURPASS</scp> ‐1 to ‐5 studies","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Semaglutide; Type 2 diabetes; Medicine; Weight loss; Internal medicine; Glucagon-like peptide 1 receptor; Placebo; Basal insulin; Basal (medicine); Hypoglycemia; Exenatide; Clinical endpoint; Endocrinology; Post-hoc analysis; Randomized controlled trial; Diabetes mellitus; Insulin; Agonist; Obesity; Liraglutide; Receptor","score_opus":0.00725095975743336,"score_gpt":0.21771508767922182,"score_spread":0.21046412792178845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311480480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97309166,0.023888636,0.0000029408493,0.0013191766,0.0001370868,0.0013052827,0.00015807798,0.000025595791,0.00007154793],"genre_scores_gemma":[0.99438727,0.0028597987,0.0006207715,0.001075938,0.00003999055,0.00023229879,0.00006843162,0.000037444017,0.0006780512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735785,0.00025829606,0.00048423177,0.00063251547,0.0007072007,0.0005599264],"domain_scores_gemma":[0.9983307,0.00028819445,0.00038448203,0.0005912871,0.00022097229,0.00018437738],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006018782,0.0004559624,0.001325124,0.0004097011,0.00035708208,0.000043192187,0.0002674038,0.00006158329,0.000011006872],"category_scores_gemma":[0.00009229715,0.0002611046,0.00012467889,0.001431939,0.00053123274,0.00013898649,0.0006539812,0.00031577965,0.0000010583801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025264628,0.0005915022,0.9800617,0.00030557878,0.005084711,0.0000066873927,0.003494504,0.0000977229,0.0067699,0.00022544133,0.00038711648,0.0027224955],"study_design_scores_gemma":[0.0036471558,0.0017308507,0.9614456,0.00017815942,0.006421248,0.0000014697549,0.0026889916,0.00008188939,0.012547168,0.000037760885,0.011019852,0.0001998439],"about_ca_topic_score_codex":0.00018239478,"about_ca_topic_score_gemma":0.0005393966,"teacher_disagreement_score":0.021295622,"about_ca_system_score_codex":0.00009378026,"about_ca_system_score_gemma":0.000093736,"threshold_uncertainty_score":0.99998415},"labels":[],"label_agreement":null},{"id":"W4311500730","doi":"10.1016/j.pharmthera.2022.108330","title":"Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease","year":2022,"lang":"en","type":"review","venue":"Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Empagliflozin; Canagliflozin; Medicine; Dapagliflozin; Kidney disease; Diabetes mellitus; Population; Heart failure; Disease; Internal medicine; Pharmacology; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.03482235961102632,"score_gpt":0.33522370355686626,"score_spread":0.30040134394583995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311500730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011559945,0.99281704,0.0000012799536,0.0003085585,0.0008506061,0.004006147,0.00019666711,0.00010019697,0.00056351733],"genre_scores_gemma":[0.00059744436,0.98825604,0.000014416011,0.0055955118,0.00025202913,0.0010653409,0.0034004627,0.00014004181,0.00067868887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768734,0.00019129354,0.00054687966,0.0005895262,0.00038519088,0.0005997915],"domain_scores_gemma":[0.99890196,0.0000715451,0.00025866658,0.00037067814,0.000029177483,0.0003679887],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014201536,0.0006142071,0.0013713167,0.0004052322,0.00008576133,0.000013996899,0.00024039928,0.00014277747,0.0029116438],"category_scores_gemma":[0.000001144851,0.00045994626,0.0003478714,0.0003742566,0.00013930303,0.00006783942,0.00007115884,0.00066987774,0.0000989708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069857365,0.0035788086,0.015512588,0.011521506,0.00559349,0.00045548574,0.00009315308,0.0000015887238,0.000001244044,0.000008300882,0.005276261,0.957259],"study_design_scores_gemma":[0.0067514116,0.00079486653,0.0010520183,0.0011764602,0.02211717,0.0000010420761,0.0000029914847,0.0000038194926,0.000006011227,0.0000032268163,0.9677,0.00039095854],"about_ca_topic_score_codex":0.0000033912359,"about_ca_topic_score_gemma":0.0000022508284,"teacher_disagreement_score":0.96242374,"about_ca_system_score_codex":0.00094013085,"about_ca_system_score_gemma":0.0008545779,"threshold_uncertainty_score":0.99978524},"labels":[],"label_agreement":null},{"id":"W4311668626","doi":"10.1038/s41591-022-02102-9","title":"Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Université de Montréal; St. Boniface Hospital; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; Relypsa; National Medical Research Council; Respicardia; American Regent; Vifor Pharma; Daiichi-Sankyo; University of Glasgow; Bayer HealthCare; Pfizer; Moderna; Impulse Dynamics; Sarepta Therapeutics; Ionis Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Sanofi Pasteur; Kowa Company; Celladon Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Medical Research Council; Verily Life Sciences; Brigham and Women's Hospital; Heart Failure Society of America; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Servier; Bayer; Gilead Sciences; Cytokinetics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Amgen; Sanofi; American Heart Association","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Medicine; Internal medicine; Cardiology; Fraction (chemistry); Chemistry; Diabetes mellitus; Endocrinology","score_opus":0.008697059207868693,"score_gpt":0.2606465506638542,"score_spread":0.25194949145598555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311668626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824933,0.0006030582,0.00003173091,0.012277785,0.00049404806,0.0014545112,0.000007189843,0.00003199887,0.0026063763],"genre_scores_gemma":[0.9965768,0.000009831071,0.00015759958,0.0011731798,0.00022022698,0.00009390189,0.00006859276,0.000011385667,0.0016884727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867904,0.000096262636,0.00024924663,0.00025161268,0.00057536,0.0001485043],"domain_scores_gemma":[0.9992885,0.00007582529,0.00013490448,0.00038745394,0.00007017863,0.000043138316],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003563936,0.00012701773,0.00046469693,0.00049241184,0.000077177305,0.0000033547528,0.000096356336,0.00008196031,0.0010057653],"category_scores_gemma":[0.000078874764,0.00007019889,0.00012283621,0.0021814064,0.00006165931,0.000040979285,0.00006151468,0.00062531215,8.958475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20017368,0.006286841,0.45290688,0.00039800254,0.022440786,0.00017731026,0.0031938087,0.0019051334,0.04458398,0.0019841222,0.25030947,0.015639974],"study_design_scores_gemma":[0.14942536,0.0081054615,0.41297165,0.00019268015,0.014594134,0.000013334522,0.0038262662,0.0027812927,0.003067006,0.00006175728,0.40465575,0.00030529045],"about_ca_topic_score_codex":0.00013806146,"about_ca_topic_score_gemma":0.00032828638,"teacher_disagreement_score":0.15434629,"about_ca_system_score_codex":0.00019491406,"about_ca_system_score_gemma":0.000042889613,"threshold_uncertainty_score":0.99990743},"labels":[],"label_agreement":null},{"id":"W4311781891","doi":"10.1016/s2213-8587(22)00357-6","title":"Predicting the response to GLP-1 receptor agonists: an unexpected role for β-arrestin-1","year":2022,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill Genome Centre","funders":"","keywords":"Exenatide; Heterotrimeric G protein; G protein-coupled receptor; Gs alpha subunit; Receptor; Medicine; Signal transduction; Intracellular; Adenylyl cyclase; Allosteric regulation; Pharmacology; Cell biology; G protein; Type 2 diabetes; Internal medicine; Endocrinology; Biology; Diabetes mellitus","score_opus":0.029142787363878285,"score_gpt":0.28663356711345067,"score_spread":0.2574907797495724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311781891","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27244064,0.0011890779,0.0000042847028,0.718889,0.0014122534,0.0033299457,0.00046286438,0.0005032412,0.001768704],"genre_scores_gemma":[0.02261273,0.000158717,0.0009533607,0.9334706,0.013413785,0.009185427,0.0033541003,0.00030358668,0.016547715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99465597,0.00092226797,0.00050850527,0.0008990039,0.000469902,0.002544355],"domain_scores_gemma":[0.9953086,0.0021127674,0.00029408128,0.002047978,0.00011594159,0.00012064668],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097505626,0.000607154,0.0012064092,0.000260302,0.0006400876,0.0001039321,0.0012893977,0.00023915032,0.0006291493],"category_scores_gemma":[0.00074160355,0.0003771954,0.00029279586,0.0003739189,0.00025153515,0.00006235032,0.00063135393,0.0016755533,0.00013298568],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017230059,0.0001239394,0.0053272415,0.00015919596,0.0012233474,0.00011159904,0.000700197,0.000011597604,0.0025176085,0.00022142818,0.98084867,0.0070321816],"study_design_scores_gemma":[0.0021398133,0.00269552,0.0027510652,0.00007798939,0.0009395529,0.000012912878,0.00041809733,0.000074078176,0.0007076837,0.00038809655,0.9894275,0.00036766613],"about_ca_topic_score_codex":0.000061461215,"about_ca_topic_score_gemma":0.000019999197,"teacher_disagreement_score":0.24982792,"about_ca_system_score_codex":0.00035121347,"about_ca_system_score_gemma":0.00013276502,"threshold_uncertainty_score":0.999868},"labels":[],"label_agreement":null},{"id":"W4311927977","doi":"10.1161/circulationaha.122.059595","title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes","year":2022,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":449,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Institutes of Health Research; St. Michael's Hospital; Ted Rogers Centre for Heart Research; University Health Network","funders":"British Heart Foundation","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Heart failure; Myocardial infarction; Internal medicine; Postprandial; Stroke (engine); Disease; Cardiology; Weight loss; Endocrinology; Obesity","score_opus":0.03240278091542229,"score_gpt":0.2577570198148468,"score_spread":0.2253542388994245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311927977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017095404,0.9776494,0.00002945459,0.000005479978,0.00040890998,0.004692722,0.000027606582,0.000020962694,0.00007009379],"genre_scores_gemma":[0.02215288,0.9753608,0.00010298391,0.0000038146839,0.0000939742,0.0006744175,0.0015086404,0.000053989086,0.00004848964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989367,0.00009894868,0.00028746985,0.00025442799,0.00028217584,0.000140286],"domain_scores_gemma":[0.99912524,0.000082604776,0.00027354006,0.00043347094,0.00006346551,0.000021661366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032092776,0.00017694279,0.0007509389,0.00012986342,0.00006935496,0.000009254004,0.00006722904,0.00006969087,0.00005644084],"category_scores_gemma":[0.000064684355,0.000113105336,0.00038876687,0.0003616391,0.000029667208,0.000040600837,0.00002315547,0.00011284522,0.000005614813],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023088696,0.00014822891,0.017810674,0.0042111548,0.0018524012,1.0226542e-7,0.00004403765,0.0001596974,1.9650096e-7,0.000014303659,0.00006936679,0.97566676],"study_design_scores_gemma":[0.0015495473,0.00034548913,0.07876617,0.0022771156,0.00926294,1.5069274e-7,0.000018098459,0.000039779658,0.0000010463971,0.000013937627,0.90755594,0.00016981096],"about_ca_topic_score_codex":0.000013073458,"about_ca_topic_score_gemma":6.2501573e-7,"teacher_disagreement_score":0.97549695,"about_ca_system_score_codex":0.00028416695,"about_ca_system_score_gemma":0.000055602697,"threshold_uncertainty_score":0.4612302},"labels":[],"label_agreement":null},{"id":"W4312018283","doi":"10.1503/cmaj.221674","title":"Correction to “Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update”","year":2022,"lang":"en","type":"erratum","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guideline; Primary care; Medicine; Disease management; Disease; Computer science; Family medicine; Pathology","score_opus":0.014850645078757576,"score_gpt":0.2512050234932376,"score_spread":0.23635437841448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312018283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006647312,0.4859978,0.00632008,0.27803355,0.15257335,0.027091233,0.004515133,0.00014483584,0.044659298],"genre_scores_gemma":[0.018557535,0.36178812,0.010639064,0.17092738,0.05491604,0.013840894,0.0863827,0.001160238,0.28178802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99385214,0.00027740045,0.0011342604,0.00051042903,0.0035640434,0.00066174683],"domain_scores_gemma":[0.99629855,0.000082006314,0.0003389612,0.00040358407,0.0011571973,0.0017197088],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0055338573,0.00034051365,0.0008495491,0.0010278377,0.0004058138,0.00007692143,0.00031670718,0.0003201483,0.0010579701],"category_scores_gemma":[0.00076827937,0.0003089248,0.0010182819,0.00057198893,0.000031196894,0.00010915043,0.00010179615,0.0010511598,0.000009416741],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000049226666,0.00004157095,0.00039160915,0.00024936075,0.0068265083,0.00034738213,0.000085962754,0.0004273257,5.1625257e-8,0.000041133462,0.8278048,0.16373508],"study_design_scores_gemma":[0.0028565517,0.00012128325,0.005003973,0.00053886604,0.0036453565,0.000024025747,0.0003669318,0.0012859262,2.5668174e-7,0.000054775013,0.9858518,0.0002502121],"about_ca_topic_score_codex":0.05868838,"about_ca_topic_score_gemma":0.11016887,"teacher_disagreement_score":0.23712872,"about_ca_system_score_codex":0.010414337,"about_ca_system_score_gemma":0.0070646564,"threshold_uncertainty_score":0.9999363},"labels":[],"label_agreement":null},{"id":"W4312018802","doi":"10.1503/cmaj.220934","title":"Drug eruption associated with empagliflozin","year":2022,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Empagliflozin; Medicine; Rash; Atrial fibrillation; Heart failure; Drug; Internal medicine; Kidney disease; Cardiology; Intensive care medicine; Surgery; Pharmacology; Endocrinology; Diabetes mellitus","score_opus":0.006022426463346897,"score_gpt":0.21437057983601393,"score_spread":0.20834815337266704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312018802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8974229,0.00017368834,0.000020081581,0.07318812,0.00079127506,0.00032895125,0.000036102403,0.000064659755,0.027974194],"genre_scores_gemma":[0.9700568,0.000024603183,0.000047613055,0.015037161,0.00043217905,0.00003560236,0.00010973361,0.000021759666,0.014234563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971293,0.00017468908,0.00025087586,0.00013891744,0.0018619137,0.000444294],"domain_scores_gemma":[0.9983378,0.00007421931,0.00018485055,0.00008718329,0.00018543968,0.0011305135],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015292211,0.000107713786,0.00021014406,0.000249386,0.0005113809,0.000052640546,0.00011297208,0.000077754026,0.013126784],"category_scores_gemma":[0.00047875594,0.00009231024,0.00008596834,0.00036314692,0.000018673403,0.00008109374,0.000023924344,0.00077999994,0.000079534424],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004136187,0.00026466325,0.32019547,0.000006576604,0.0010894602,0.002091669,0.00048770502,0.000033994987,0.0000048391157,0.00036474914,0.6490116,0.026407883],"study_design_scores_gemma":[0.004384345,0.0004501564,0.1709634,0.000072658695,0.00031851078,0.00023199942,0.0011919827,0.00034244888,0.0000064926603,0.0001209179,0.82172227,0.000194794],"about_ca_topic_score_codex":0.0006252514,"about_ca_topic_score_gemma":0.012370849,"teacher_disagreement_score":0.17271067,"about_ca_system_score_codex":0.003560249,"about_ca_system_score_gemma":0.0017959364,"threshold_uncertainty_score":0.9877753},"labels":[],"label_agreement":null},{"id":"W4312052526","doi":"10.1093/eurheartjsupp/suac114","title":"Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe","year":2022,"lang":"en","type":"article","venue":"European Heart Journal Supplements","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"Deutsche Forschungsgemeinschaft; Novartis Pharma; Corona-Stiftung","keywords":"Medicine; Heart failure; Ejection fraction; Kidney disease; Diabetes mellitus; Internal medicine; Mineralocorticoid receptor; Guideline; Intensive care medicine; Cardiology; Clinical trial; Aldosterone; Endocrinology; Pathology","score_opus":0.018432546785619886,"score_gpt":0.2704604007150507,"score_spread":0.2520278539294308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312052526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841459,0.00061215553,0.00024888112,0.009513031,0.0005257279,0.000783365,0.0000103033635,0.000034097367,0.0041265334],"genre_scores_gemma":[0.9978145,0.000072796975,0.0004218164,0.0006005061,0.0004119549,0.00001982486,0.000046624227,0.00002954798,0.00058243214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981015,0.0005918587,0.00035722283,0.00018746332,0.0005628765,0.00019908258],"domain_scores_gemma":[0.9993828,0.000036336263,0.00019016385,0.00019629285,0.00009341046,0.000101010635],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013643657,0.00014659498,0.00034626666,0.00018238391,0.00041528288,0.000026915988,0.000064188745,0.000009806231,0.00096585974],"category_scores_gemma":[0.000030954554,0.00008851779,0.00010489477,0.0002510661,0.000098395954,0.00012640914,0.00009939995,0.00035069848,0.000010063195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006766543,0.0008487903,0.40335846,0.0001682832,0.0047483477,0.00021211572,0.004190371,0.00037659385,0.04807819,0.00067154324,0.5119235,0.018657234],"study_design_scores_gemma":[0.012785326,0.0027137122,0.16528498,0.00014475078,0.00094789953,0.0009293626,0.004435046,0.0000576408,0.0012242467,0.000051306048,0.8112898,0.00013594676],"about_ca_topic_score_codex":0.00008038926,"about_ca_topic_score_gemma":0.000007803124,"teacher_disagreement_score":0.29936627,"about_ca_system_score_codex":0.0001232712,"about_ca_system_score_gemma":0.000024971769,"threshold_uncertainty_score":0.99994737},"labels":[],"label_agreement":null},{"id":"W4312063023","doi":"10.51731/cjht.2022.524","title":"Semaglutide (Wegovy)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reimbursement; Overweight; Semaglutide; Dyslipidemia; Obesity; Type 2 diabetes; Weight loss; Body mass index; Comorbidity; Obstructive sleep apnea; Diabetes mellitus; Physical therapy; Internal medicine; Health care; Endocrinology","score_opus":0.02399447771287723,"score_gpt":0.2672215931424719,"score_spread":0.2432271154295947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312063023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5807449,0.12862779,0.00008980386,0.28260225,0.0012502183,0.00081303064,0.0000326821,0.00029302266,0.005546273],"genre_scores_gemma":[0.9968409,0.00012705888,0.0006244717,0.0015989712,0.0000070421747,0.000012619512,0.0000032203127,0.000010296469,0.0007754132],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906313,0.00002943272,0.00031041368,0.00008255264,0.00016695386,0.00034749735],"domain_scores_gemma":[0.9994453,0.000020445987,0.00021398428,0.00018654756,0.000047712572,0.00008601079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043917238,0.0000774834,0.00026904233,0.00066293345,0.00029583782,0.000010796398,0.00018238368,0.000026302687,0.00016858385],"category_scores_gemma":[0.0001404239,0.00006673869,0.000073677154,0.00030363156,0.000072424424,0.0000297501,0.000039389837,0.00031281993,0.000007398943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018048704,0.000056738416,0.02636235,0.00009006017,0.00014513699,0.0009466245,0.0002040897,0.00003136832,0.000015903472,0.0034095794,0.07848604,0.89023405],"study_design_scores_gemma":[0.00063655816,0.0012329434,0.011317352,0.000049822927,0.00003612005,0.00026746874,0.0041734194,0.000005207124,0.000095656156,0.0015876308,0.98053265,0.00006520056],"about_ca_topic_score_codex":0.0011102732,"about_ca_topic_score_gemma":0.0005089653,"teacher_disagreement_score":0.90204656,"about_ca_system_score_codex":0.0007525973,"about_ca_system_score_gemma":0.0015499633,"threshold_uncertainty_score":0.27495682},"labels":[],"label_agreement":null},{"id":"W4312086992","doi":"10.1002/alz.069035","title":"Association of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors with time to dementia: a population‐based cohort study","year":2022,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Health Sciences Centre; Sunnybrook Hospital; Toronto Dementia Research Alliance; University of Toronto; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dementia; Hazard ratio; Internal medicine; Population; Dipeptidyl peptidase-4; Diabetes mellitus; Cohort; Cohort study; Stroke (engine); Confidence interval; Type 2 diabetes; Disease; Endocrinology; Environmental health","score_opus":0.010877141757206346,"score_gpt":0.2371346631203627,"score_spread":0.22625752136315636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312086992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99162483,0.0014388041,0.000021473577,0.0006408878,0.00040916938,0.0040128995,0.000054481858,0.00015195465,0.0016454979],"genre_scores_gemma":[0.9968494,0.0000028983122,0.0006941344,0.00028705221,0.00009400872,0.00077245006,0.00094128243,0.00006773568,0.00029102733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966681,0.00014232723,0.0006760446,0.0005984084,0.0014276293,0.00048751163],"domain_scores_gemma":[0.99863917,0.0000657765,0.00041938672,0.000522957,0.0001524803,0.00020021923],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000644119,0.00035930285,0.00056351663,0.00039743548,0.00027632213,0.00003602828,0.00017701116,0.000055313805,0.0023900357],"category_scores_gemma":[0.000015376487,0.00034676117,0.00018664515,0.0007014332,0.000023253977,0.00016627382,0.00014401998,0.00017988846,0.00013261542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009922696,0.0026762814,0.9362344,0.000014993501,0.045288637,0.00003934904,0.0002956687,0.00024040542,0.0005359102,0.000009133117,0.010909355,0.002763609],"study_design_scores_gemma":[0.013529763,0.0062717176,0.84162533,0.000053356456,0.11956812,8.240715e-7,0.0004982784,0.00013581081,0.0068470375,0.000004553228,0.010919105,0.00054612075],"about_ca_topic_score_codex":0.0003788461,"about_ca_topic_score_gemma":0.00017940575,"teacher_disagreement_score":0.094609074,"about_ca_system_score_codex":0.00014161119,"about_ca_system_score_gemma":0.000089405345,"threshold_uncertainty_score":0.99989843},"labels":[],"label_agreement":null},{"id":"W4312095491","doi":"10.1080/14779072.2023.2159810","title":"The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors","year":2022,"lang":"en","type":"review","venue":"Expert Review of Cardiovascular Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sunnybrook Health Science Centre; Women's College Hospital; University Health Network; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Natriuresis; Diabetes mellitus; Blood pressure; Diuretic; Kidney disease; Empagliflozin; Internal medicine; Canagliflozin; Heart failure; Clinical trial; Type 2 diabetes; Loop diuretic; Cardiology; Endocrinology; Hemodynamics; Disease; Pharmacology","score_opus":0.022543079590935895,"score_gpt":0.2977998100996166,"score_spread":0.2752567305086807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312095491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009140653,0.9916176,0.000012211694,0.00007883586,0.000987795,0.006575197,0.000011439546,0.000043383578,0.000664367],"genre_scores_gemma":[0.0000050298945,0.997212,0.00007731892,0.0004983076,0.00029590214,0.001398798,0.00024732132,0.0001283851,0.00013697054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957448,0.00069677446,0.0013006326,0.0005800978,0.0012845532,0.00039312034],"domain_scores_gemma":[0.9964202,0.0003941386,0.00064492255,0.0022502574,0.00017556135,0.000114906536],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0011518501,0.0007231733,0.0075018117,0.00016747102,0.0001233854,0.0000118354565,0.0004829839,0.0001509128,0.00010829124],"category_scores_gemma":[0.00009665084,0.00040060445,0.010336901,0.0005909661,0.00019292271,0.00004898964,0.00009718117,0.0003239462,0.000012509833],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011125842,0.000196348,7.397269e-7,0.13141379,0.022222852,0.00013257653,0.000046158464,6.882447e-8,0.00000341354,0.000020545618,0.003545974,0.8424064],"study_design_scores_gemma":[0.0011259154,0.00039253448,0.000003308672,0.09590537,0.010468617,0.000036811256,0.000015547826,9.626094e-8,0.00025240312,0.0000019873607,0.8915077,0.00028970977],"about_ca_topic_score_codex":0.000028172028,"about_ca_topic_score_gemma":1.717093e-7,"teacher_disagreement_score":0.88796175,"about_ca_system_score_codex":0.00012453177,"about_ca_system_score_gemma":0.00022718904,"threshold_uncertainty_score":0.9998446},"labels":[],"label_agreement":null},{"id":"W4312203905","doi":"10.1016/j.jcjd.2022.12.003","title":"Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence","year":2022,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Hospital Research Foundation","keywords":"Medicine; Colonoscopy; Diabetic ketoacidosis; Complication; Cotransporter; Ketoacidosis; Diabetes mellitus; Type 2 diabetes; Incidence (geometry); Intensive care medicine; Internal medicine; Surgery; Gastroenterology; Endocrinology; Colorectal cancer; Sodium; Type 1 diabetes; Cancer","score_opus":0.08816771921127446,"score_gpt":0.3162277360777935,"score_spread":0.228060016866519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312203905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016550744,0.99493766,4.0175667e-7,0.0004762577,0.00033346575,0.0014506694,0.00025369908,0.0000061740393,0.00088662753],"genre_scores_gemma":[0.00043385327,0.99789286,0.00020598306,0.0004836637,0.00012553585,0.00015596866,0.00012752465,0.000060708586,0.0005138886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971311,0.0001522535,0.001635093,0.00027379146,0.0003578733,0.00044988925],"domain_scores_gemma":[0.9963942,0.00032317624,0.0017160974,0.0006252983,0.00032816746,0.0006130385],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075113226,0.000404647,0.0028703078,0.0007349341,0.000080859565,0.000017494778,0.0005253683,0.00012315724,0.0041807503],"category_scores_gemma":[0.00022092291,0.0003219089,0.0011263057,0.0006879092,0.00018538331,0.00015333176,0.000025076475,0.00037410573,0.000017947646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010460338,0.00029591276,0.0062905923,0.15595414,0.0025500907,0.00004108809,0.00013384815,9.916881e-8,0.000027777445,0.000052231466,0.043355733,0.791288],"study_design_scores_gemma":[0.00041303932,0.0013445116,0.00028699366,0.1278659,0.003999543,0.0000069980433,0.000016603968,1.1884765e-7,0.000090177695,0.000008143937,0.86577994,0.00018802163],"about_ca_topic_score_codex":0.00019079803,"about_ca_topic_score_gemma":0.0002502685,"teacher_disagreement_score":0.82242423,"about_ca_system_score_codex":0.000416265,"about_ca_system_score_gemma":0.0049838913,"threshold_uncertainty_score":0.9999233},"labels":[],"label_agreement":null},{"id":"W4312956944","doi":"10.1177/20543581221145068","title":"Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Kidney disease; Renal function; Internal medicine; Dialysis; Population; Creatinine; Cohort; Nephrology; Diabetic nephropathy; Diabetes mellitus; Kidney; Endocrinology","score_opus":0.02173734371083872,"score_gpt":0.29243861490349404,"score_spread":0.2707012711926553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312956944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.837749,0.0015894817,0.000012335893,0.1459239,0.001306057,0.006850155,0.006083157,0.000024227056,0.00046166466],"genre_scores_gemma":[0.91612875,0.000035435176,0.000045131826,0.08227263,0.00030303904,0.00014885518,0.0006953037,0.000040741234,0.00033012294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651456,0.00020742985,0.0013768103,0.00043328162,0.00067612034,0.0007917806],"domain_scores_gemma":[0.90187824,0.000031595846,0.00048218167,0.00037876537,0.00017638497,0.09705282],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001632272,0.00032406926,0.0012805135,0.0012528644,0.0005302913,0.000055073862,0.00019553011,0.00003859522,0.0010330823],"category_scores_gemma":[0.008354636,0.00030674154,0.00027821262,0.0005475396,0.000064193206,0.000117599615,0.00002972379,0.00031200098,0.0000060454663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009944042,0.00026038135,0.7808012,0.00040981258,0.0002837972,0.0006297905,0.00052816264,0.000006657361,0.0000030481522,0.00022645999,0.21541287,0.00044347087],"study_design_scores_gemma":[0.009237343,0.002344955,0.8874777,0.0003237327,0.0014089526,0.000009022785,0.0005578618,0.000015633676,0.000002949827,0.00020074134,0.09809465,0.00032644608],"about_ca_topic_score_codex":0.09783586,"about_ca_topic_score_gemma":0.034286473,"teacher_disagreement_score":0.11731821,"about_ca_system_score_codex":0.0038462037,"about_ca_system_score_gemma":0.091610305,"threshold_uncertainty_score":0.9999984},"labels":[],"label_agreement":null},{"id":"W4313205069","doi":"10.1016/j.jcjd.2022.10.009","title":"Remission of Type 2 Diabetes: A Brand New Diabetes Canada Clinical Practice Guidelines Chapter and Accompanying User’s Guide","year":2022,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Clinical Practice; Type 1 diabetes; Family medicine; Endocrinology","score_opus":0.03593804345717454,"score_gpt":0.3343334340436145,"score_spread":0.29839539058643993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313205069","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35602528,0.05530724,7.344512e-7,0.0097854845,0.5744326,0.0010286709,0.00043900002,0.00003102267,0.0029499496],"genre_scores_gemma":[0.039883822,0.007042702,0.011690139,0.013048041,0.9026813,0.000045320212,0.0015662876,0.0007975708,0.023244826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471456,0.00018099103,0.0023845322,0.00053764315,0.0012880906,0.00089418836],"domain_scores_gemma":[0.99114823,0.001943309,0.0019030569,0.0006031736,0.0023762747,0.0020259356],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001857545,0.0006043669,0.001964274,0.00065315823,0.0002016045,0.0001064362,0.0005389062,0.0004454959,0.0006608537],"category_scores_gemma":[0.017515263,0.0005299996,0.00036801086,0.00034125644,0.00016780754,0.00034649918,0.00015668925,0.0012497575,0.0000029178477],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032863045,0.00005562864,0.040592343,0.00035581406,0.001647173,0.00009190307,0.00005541063,0.0000073573847,0.000028387274,0.000007842009,0.9130709,0.04405436],"study_design_scores_gemma":[0.0027891917,0.0009154845,0.0044695046,0.0018074277,0.002567429,0.0000017813237,0.00020408904,0.00002593698,0.00008745881,0.00003403373,0.9866691,0.00042856822],"about_ca_topic_score_codex":0.077698804,"about_ca_topic_score_gemma":0.15719905,"teacher_disagreement_score":0.32824865,"about_ca_system_score_codex":0.00065158965,"about_ca_system_score_gemma":0.013656932,"threshold_uncertainty_score":0.99971515},"labels":[],"label_agreement":null},{"id":"W4313367794","doi":"10.1016/j.jad.2022.12.089","title":"Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test","year":2022,"lang":"en","type":"article","venue":"Journal of Affective Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Toronto Western Hospital; University of Toronto; Brain and Cognition Discovery Foundation; Western University","funders":"Inje University","keywords":"Morris water navigation task; Liraglutide; Depression (economics); Cognition; Psychology; Test (biology); Behavioural despair test; Clinical psychology; Neuroscience; Medicine; Endocrinology; Hippocampus; Antidepressant; Biology","score_opus":0.00756276360523321,"score_gpt":0.2522370974264429,"score_spread":0.2446743338212097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313367794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976144,0.00016648669,0.000040330964,0.00011945402,0.00004052008,0.0018313227,0.00000602088,0.0000022557633,0.00017924623],"genre_scores_gemma":[0.9995152,0.00008358408,0.00004688709,0.000059309426,0.0000106518255,0.00024295737,0.000005542198,0.00001077942,0.000025108602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990216,0.00016860459,0.00026325884,0.000108779095,0.0003141654,0.00012362648],"domain_scores_gemma":[0.9993326,0.00030817243,0.0002123495,0.00008169543,0.000039689105,0.000025505436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033443116,0.00010467006,0.00029416513,0.0003087266,0.00002598324,0.00000460088,0.00006594357,0.000028104227,0.0000050573926],"category_scores_gemma":[0.00014544837,0.00006127981,0.000091537964,0.00011149922,0.00004058578,0.000077224686,0.00005141959,0.0002196837,1.3927544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09114368,0.044701457,0.43887687,0.0011464681,0.0006908441,0.00047505146,0.018828837,0.009322572,0.31188768,0.000064852764,0.00037506555,0.08248663],"study_design_scores_gemma":[0.2455504,0.03233183,0.51756823,0.0007994125,0.001963681,0.000024042469,0.0038410497,0.0026094671,0.19336295,0.0016223479,0.000025905334,0.00030068564],"about_ca_topic_score_codex":0.000049509614,"about_ca_topic_score_gemma":0.000044900702,"teacher_disagreement_score":0.15440673,"about_ca_system_score_codex":0.00006232436,"about_ca_system_score_gemma":0.000022317667,"threshold_uncertainty_score":0.2498918},"labels":[],"label_agreement":null},{"id":"W4313397315","doi":"10.1016/j.yjmcc.2022.08.152","title":"Insulin-like growth factor binding protein 7 as a predictor marker of cardiac remodelling and SGLT2-inhibitor meditated cardiac reverse remodelling in patients with type 2 diabetes and coronary artery disease","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular and Cellular Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Coronary artery disease; Internal medicine; Medicine; Cardiology; Type 2 diabetes; Diabetes mellitus; Diabetic cardiomyopathy; Endocrinology; Heart failure; Cardiomyopathy","score_opus":0.0058283969865186615,"score_gpt":0.18358349491215134,"score_spread":0.17775509792563268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313397315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99026424,0.008555721,0.00006626862,0.00006315387,0.0002725537,0.0006852741,0.00004199929,0.000007731889,0.000043052663],"genre_scores_gemma":[0.99870723,0.0006384965,0.00037735727,0.00004920524,0.00006078856,0.000015565414,0.000075039105,0.00003182739,0.00004450988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998332,0.00032871327,0.00041067856,0.0002846941,0.00038478064,0.0002590936],"domain_scores_gemma":[0.9991725,0.000051435905,0.0002364193,0.00015980561,0.00015426317,0.00022554303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044769183,0.0002141744,0.00076928193,0.000287978,0.00006804715,0.0000118871485,0.000055504377,0.000067561516,0.0000056777744],"category_scores_gemma":[0.000050260496,0.00017674276,0.0001424477,0.00016269907,0.00010488415,0.00009471053,0.00012153524,0.0002812778,2.5206043e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003704337,0.00022708066,0.9317121,0.0004670759,0.002555589,0.0012941705,0.00047847725,0.00033752294,0.057233907,0.000030467767,0.00011650686,0.0018427881],"study_design_scores_gemma":[0.047252912,0.03270124,0.85584915,0.0036243643,0.014310918,0.00020737642,0.00352621,0.004245747,0.028454466,0.0015459425,0.0054219584,0.0028597014],"about_ca_topic_score_codex":0.000003549026,"about_ca_topic_score_gemma":7.70038e-8,"teacher_disagreement_score":0.07586291,"about_ca_system_score_codex":0.00007586897,"about_ca_system_score_gemma":0.00008624675,"threshold_uncertainty_score":0.7207361},"labels":[],"label_agreement":null},{"id":"W4313422733","doi":"10.5853/jos.2022.02306","title":"Diabetes and Stroke: What Are the Connections?","year":2023,"lang":"en","type":"review","venue":"Journal of Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Diabetes mellitus; Stroke (engine); Internal medicine; Glycemic; Atrial fibrillation; Intensive care medicine; Physical therapy; Endocrinology","score_opus":0.05644788280584732,"score_gpt":0.32498008754953356,"score_spread":0.2685322047436862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313422733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006490495,0.99670154,0.0000014908967,0.0009434211,0.0008370915,0.00046328106,0.000024043937,0.000018533332,0.00036156978],"genre_scores_gemma":[0.00005410949,0.9904702,0.000044904467,0.00012633829,0.0006127847,0.000022386801,0.000008666266,0.00003755503,0.00862309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872273,0.000065016124,0.0005477348,0.0001354063,0.00031534143,0.00021377733],"domain_scores_gemma":[0.99846417,0.00033031267,0.0007717675,0.00021665532,0.00009759863,0.00011949818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040762805,0.00024264482,0.0013370742,0.00030437674,0.00008117865,0.00017218378,0.00013013795,0.00010421696,0.000034420842],"category_scores_gemma":[0.00009814337,0.00012391602,0.0005613751,0.00015592788,0.00006306723,0.00018716285,0.000078008794,0.00042712886,0.000042649117],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005745254,0.000068139685,0.0003780213,0.005895539,0.0030869204,0.000097328964,0.000025606509,2.1169122e-7,5.3255985e-7,0.000058090198,0.00813177,0.9822521],"study_design_scores_gemma":[0.00050967204,0.0003521185,0.00020047663,0.020585494,0.0064264005,0.000052360145,0.00070811727,0.0000011932851,0.0000016584521,0.000020834872,0.97104585,0.00009584752],"about_ca_topic_score_codex":7.097733e-7,"about_ca_topic_score_gemma":0.0000017978699,"teacher_disagreement_score":0.9821562,"about_ca_system_score_codex":0.000092194445,"about_ca_system_score_gemma":0.00007867931,"threshold_uncertainty_score":0.5053149},"labels":[],"label_agreement":null},{"id":"W4313429958","doi":"10.1101/2022.12.27.22283968","title":"Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"Metformin; Medicine; Observational study; Type 2 Diabetes Mellitus; Type 2 diabetes; Drug class; Diabetes mellitus; Internal medicine; Pharmacology; Drug; Endocrinology","score_opus":0.05638760004203079,"score_gpt":0.34754044793651867,"score_spread":0.29115284789448787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313429958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185926,0.0032558262,0.00037031254,0.00020613815,0.0008433861,0.0024332367,0.00040982012,0.00008675835,0.0005352539],"genre_scores_gemma":[0.9910183,0.0014317308,0.00018229682,0.0002039519,0.00019908615,0.0010071644,0.0057019186,0.0000475401,0.00020803654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955468,0.0012054687,0.000996696,0.00084396166,0.0010081077,0.00039894972],"domain_scores_gemma":[0.9981336,0.00023894924,0.00065091555,0.0005630487,0.0003288112,0.000084693354],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005285353,0.00041154242,0.0011535013,0.0003689608,0.0001239347,0.000027138123,0.00021515078,0.00018088464,0.001591726],"category_scores_gemma":[0.00038883323,0.00038966737,0.0005882279,0.00030119906,0.000043961292,0.000110282395,0.0005711367,0.00079381,0.000015292362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015781971,0.0007045155,0.9407623,0.0007909452,0.0021625648,0.00007140565,0.0008418396,0.043556318,0.0005383261,0.000020183366,0.00015346118,0.010240319],"study_design_scores_gemma":[0.008048982,0.00015757242,0.9456324,0.00028514254,0.0019456965,0.000004320792,0.0006275669,0.038814798,0.0026618077,0.00015465096,0.0012678378,0.00039922277],"about_ca_topic_score_codex":0.0004977445,"about_ca_topic_score_gemma":0.00017997275,"teacher_disagreement_score":0.009841097,"about_ca_system_score_codex":0.00057966553,"about_ca_system_score_gemma":0.0001647842,"threshold_uncertainty_score":0.9998555},"labels":[],"label_agreement":null},{"id":"W4313522178","doi":"10.1161/jaha.122.027652","title":"Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause","year":2022,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Relypsa; Institut National de la Santé et de la Recherche Médicale; Universität des Saarlandes; Servier; Universität Heidelberg; Deutsche Forschungsgemeinschaft; LivaNova; Imperial College London; Pfizer; Moderna; University of Toronto; Cytokinetics; AstraZeneca; Amarin Corporation; Baylor University; Vifor Pharma; Massachusetts General Hospital; Université de Lorraine; Baylor University Medical Center; Boston Scientific Corporation; Eli Lilly and Company; CSL Behring; Novo Nordisk; Amgen; Sanofi","keywords":"Medicine; Ejection fraction; Empagliflozin; Cardiology; Heart failure; Internal medicine; Stroke volume; Heart failure with preserved ejection fraction; Diabetes mellitus; Type 2 diabetes","score_opus":0.007391182000384138,"score_gpt":0.2656724656123379,"score_spread":0.2582812836119538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313522178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986489,0.0000083853765,0.0000012347267,0.0009043872,0.000084713334,0.0002820463,0.0000037192108,0.0000046509795,0.00006195605],"genre_scores_gemma":[0.9995194,0.0000037386885,0.00028642447,0.00007052272,0.000035691963,0.000010529419,0.0000069657594,0.000012968435,0.000053777116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879974,0.00013409664,0.00027613592,0.00009402917,0.0005403587,0.00015563304],"domain_scores_gemma":[0.9989506,0.00007357121,0.0006941294,0.00012342016,0.00012263714,0.000035633253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003500763,0.000094439165,0.00039223523,0.0002306669,0.00004303709,0.000008129778,0.000049770893,0.000018938574,0.000021942265],"category_scores_gemma":[0.00008634227,0.00006160381,0.000122982,0.0007184228,0.000019763127,0.00015224371,0.000024492172,0.00031924224,9.656261e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028354086,0.00051839376,0.9851878,0.0000055032738,0.00033998294,0.0000015455639,0.00012128377,0.00070820935,0.0057607424,1.7182401e-7,0.0043936106,0.00012730766],"study_design_scores_gemma":[0.0052542863,0.0038848051,0.9886992,0.000060196584,0.00019588917,0.0000035079465,0.00042711684,0.00003329424,0.0009964278,0.0000010253849,0.00038426858,0.00005998743],"about_ca_topic_score_codex":0.00029760812,"about_ca_topic_score_gemma":0.000053089407,"teacher_disagreement_score":0.0047643143,"about_ca_system_score_codex":0.0025358794,"about_ca_system_score_gemma":0.00015352134,"threshold_uncertainty_score":0.6631236},"labels":[],"label_agreement":null},{"id":"W4313523124","doi":"10.14740/jem843","title":"Combination of a Glucagon-Like Peptide 1 Analog and a Sodium-Glucose Cotransporter 2 Inhibitor Improves Lipid Metabolism Compared to the Monotherapies in Experimental Metabolic Syndrome","year":2022,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro","keywords":"Liraglutide; Canagliflozin; Medicine; Dyslipidemia; Endocrinology; Internal medicine; Metabolic syndrome; Type 2 diabetes; Lipid profile; Fatty liver; Insulin resistance; Diabetes mellitus; Pharmacology; Disease","score_opus":0.012313153500204305,"score_gpt":0.2516291761740277,"score_spread":0.23931602267382338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313523124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488956,0.04786623,0.000013412528,0.0018751358,0.00067857216,0.0005469724,0.000012817169,0.000009417646,0.00010188497],"genre_scores_gemma":[0.9964369,0.00180938,0.00043096277,0.0008745232,0.00009544889,0.00008737713,0.00000788318,0.000018099228,0.00023943817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984133,0.00016294586,0.0006145695,0.00021339179,0.00028422178,0.00031154597],"domain_scores_gemma":[0.999242,0.000060553622,0.00032000744,0.00018471459,0.00007575924,0.000116970295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003353761,0.00021413511,0.0008875598,0.0005976812,0.00011900712,0.000016758153,0.00014742745,0.00003582192,0.000053931093],"category_scores_gemma":[0.000017509305,0.00015097082,0.00014408612,0.0002612828,0.00014916813,0.00016516763,0.00012796443,0.0002991211,9.2652755e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012258359,0.012767588,0.06986807,0.00042720904,0.011363356,0.0022271404,0.05338705,0.00021588359,0.6907586,0.047762137,0.0052831853,0.09368143],"study_design_scores_gemma":[0.0150280995,0.0012447437,0.7629393,0.000045870376,0.0013315683,0.00094616925,0.0045229574,0.00004594439,0.03777381,0.00035582867,0.1755124,0.0002533453],"about_ca_topic_score_codex":0.00006795348,"about_ca_topic_score_gemma":0.000018269684,"teacher_disagreement_score":0.6930712,"about_ca_system_score_codex":0.000025696969,"about_ca_system_score_gemma":0.000048600257,"threshold_uncertainty_score":0.6156412},"labels":[],"label_agreement":null},{"id":"W4313855017","doi":"10.7326/m22-2904","title":"Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update","year":2023,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Monash University; Chinese University of Hong Kong; Rijksuniversiteit Groningen; University of Leicester; Steno Diabetes Center Copenhagen; Universitair Medisch Centrum Groningen; Northwest Kidney Centers; University of Sydney; Johns Hopkins University; University of Washington; Flinders University; Cleveland Clinic Foundation; Cleveland Clinic; University of Minnesota; U.S. Department of Veterans Affairs","keywords":"Medicine; Guideline; Kidney disease; Clinical Practice; Intensive care medicine; Diabetes mellitus; Disease management; Disease; Internal medicine; Pathology; Physical therapy; Endocrinology","score_opus":0.04645045197266437,"score_gpt":0.40360960516629857,"score_spread":0.3571591531936342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313855017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61250234,0.00793368,0.000058073434,0.3342255,0.002049863,0.0019695053,0.00006993699,0.000110842804,0.041080214],"genre_scores_gemma":[0.93603516,0.012593585,0.00039419174,0.038761392,0.0006449313,0.00009229124,0.00015634333,0.000048324513,0.011273794],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718297,0.00013164013,0.0012742453,0.00031905892,0.0007327705,0.000359308],"domain_scores_gemma":[0.9981077,0.0002735235,0.0004595685,0.0006520022,0.00024887105,0.00025833608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018766103,0.00019856547,0.0006002906,0.00033195954,0.000022359329,0.000004427001,0.0003553267,0.000045739307,0.00044088496],"category_scores_gemma":[0.0020500731,0.00012172147,0.00023019749,0.0007306242,0.0002578108,0.000101588106,0.00036759282,0.0002012827,0.000055259967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058717624,0.00061285193,0.08614298,0.00076637353,0.0017763495,0.00027681355,0.00008095507,0.000028080656,0.00031717418,0.0016536056,0.8455242,0.06223345],"study_design_scores_gemma":[0.004928591,0.0014641506,0.20382823,0.00480809,0.0011993976,0.0000018844923,0.0003194418,0.0014583463,0.001438789,0.00080448744,0.7795818,0.00016680209],"about_ca_topic_score_codex":0.00007405308,"about_ca_topic_score_gemma":0.0000074106856,"teacher_disagreement_score":0.3235328,"about_ca_system_score_codex":0.00005456539,"about_ca_system_score_gemma":0.000086892374,"threshold_uncertainty_score":0.49636573},"labels":[],"label_agreement":null},{"id":"W4313857531","doi":"10.1139/cjpp-2022-0045","title":"The effect of dapagliflozin on myocardial ischemia–reperfusion injury in diabetic rats","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Internal medicine; Medicine; Endocrinology; Diabetes mellitus; Nitric oxide synthase; Reperfusion injury; Ischemia; Diabetic cardiomyopathy; Enos; Nitric oxide; Type 2 diabetes; Cardiomyopathy","score_opus":0.007481173913471742,"score_gpt":0.27390592123194535,"score_spread":0.2664247473184736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313857531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966601,0.00042187664,7.082489e-8,0.0013806403,0.00085810764,0.00020639514,0.0000047025424,0.0000034974428,0.00046458404],"genre_scores_gemma":[0.9987994,0.00038596836,0.0000020955038,0.00045202562,0.00019035133,0.000010889217,0.0000058923956,0.0000075210173,0.00014589513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915963,0.00019179928,0.00022077632,0.00010188691,0.000055293836,0.00027058387],"domain_scores_gemma":[0.9992647,0.00033750114,0.000100647085,0.000077402095,0.000028962819,0.0001907409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045207868,0.00010105361,0.0003393448,0.00027153647,0.00007622526,0.0000029885266,0.00008181959,0.00007639863,0.000119197095],"category_scores_gemma":[0.00004757081,0.00006352475,0.000078814235,0.00018497539,0.0001992206,0.000024510216,0.000018855017,0.00023215405,0.0000136980925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009269966,0.00002275925,0.023263806,0.00009694316,0.0003287938,0.00018633806,0.00015513322,0.00004617677,0.9393612,0.000074660675,0.023871114,0.011666041],"study_design_scores_gemma":[0.0036989553,0.005229116,0.043681387,0.00007841622,0.00035936155,0.000011332571,0.000038595557,0.00008275164,0.9339382,0.0002879727,0.012499482,0.00009439816],"about_ca_topic_score_codex":0.00007072237,"about_ca_topic_score_gemma":0.00008267017,"teacher_disagreement_score":0.020417579,"about_ca_system_score_codex":0.0000475157,"about_ca_system_score_gemma":0.00014912576,"threshold_uncertainty_score":0.2590464},"labels":[],"label_agreement":null},{"id":"W4315752826","doi":"10.1111/dom.14973","title":"Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross‐sectional survey","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Sanofi","keywords":"Medicine; Cross-sectional study; Type 2 diabetes; Basal insulin; Basal (medicine); Diabetes mellitus; Family medicine; Endocrinology; Pathology","score_opus":0.019274948283101334,"score_gpt":0.252886190038437,"score_spread":0.23361124175533565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315752826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988113,0.0033795668,3.7202875e-7,0.007315181,0.00020946993,0.00080436526,0.000067146386,0.000041447085,0.0000694763],"genre_scores_gemma":[0.95205045,0.001356254,0.000039838313,0.043210343,0.0003082658,0.00033831142,0.0024293452,0.00004100204,0.00022618368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979342,0.0003386412,0.00030477086,0.0005498585,0.0004210414,0.00045144025],"domain_scores_gemma":[0.999079,0.0003825041,0.000117974996,0.00022737219,0.00013770726,0.00005545153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061974366,0.0003433953,0.00052254763,0.00058964634,0.00011383654,0.00018768564,0.00010138091,0.0002464732,0.00002451612],"category_scores_gemma":[0.00014128257,0.0002256521,0.000044603046,0.0008413762,0.00028639304,0.00017156405,0.00007036634,0.0006210363,0.0000071388636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006077958,0.00026287846,0.9747559,0.00020035397,0.00019785854,0.000057032823,0.015478745,0.000009321655,0.000003378778,0.000027945067,0.008583176,0.00036264557],"study_design_scores_gemma":[0.001169823,0.00034100199,0.9800784,0.00012497384,0.000096001924,4.747488e-7,0.00439991,0.00022628382,0.000028703276,0.000090802976,0.013187315,0.00025629022],"about_ca_topic_score_codex":0.0005188494,"about_ca_topic_score_gemma":0.0003337756,"teacher_disagreement_score":0.03606252,"about_ca_system_score_codex":0.00004897752,"about_ca_system_score_gemma":0.00005354734,"threshold_uncertainty_score":0.9201825},"labels":[],"label_agreement":null},{"id":"W4315754527","doi":"10.1093/aje/kwad011","title":"Emulating a Target Trial Using Primary-Care Electronic Health Records: Sodium-Glucose Cotransporter 2 Inhibitor Medications and Hemoglobin A1c","year":2023,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Glycemic; Randomized controlled trial; Observational study; Diabetes mellitus; Clinical trial; Intensive care medicine; Internal medicine; Emergency medicine; Endocrinology","score_opus":0.03268185196738731,"score_gpt":0.3416124992935737,"score_spread":0.30893064732618636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315754527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98502725,0.0030930939,0.0020994607,0.008738298,0.00034458635,0.0004981478,0.000008170179,0.00004053652,0.00015048285],"genre_scores_gemma":[0.9714092,0.0026953008,0.020417934,0.0045043374,0.00071184005,0.000016324553,0.00013444475,0.00003250848,0.000078110184],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974892,0.0004464766,0.0010543772,0.00024459383,0.00015761703,0.00060772855],"domain_scores_gemma":[0.997674,0.00067664625,0.0010728749,0.00018495535,0.00010025908,0.0002912723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002054891,0.00017188735,0.0011473555,0.0003171705,0.00010364152,0.000004727563,0.00008590518,0.000049806742,0.000033096763],"category_scores_gemma":[0.00041283746,0.00013524292,0.00018113287,0.000398744,0.00025546298,0.00007915037,0.00003280567,0.00031644234,0.000005817375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015358483,0.00076991064,0.3108111,0.00060561433,0.0028396482,0.00022421828,0.0036855144,0.00044141882,0.0010727281,0.0011680911,0.010957101,0.6520662],"study_design_scores_gemma":[0.22433174,0.123384446,0.38294467,0.00400875,0.0055036964,0.0013595333,0.019000074,0.009801322,0.0004391325,0.0104889935,0.21658492,0.0021527319],"about_ca_topic_score_codex":0.000117190655,"about_ca_topic_score_gemma":0.0000151849445,"teacher_disagreement_score":0.64991343,"about_ca_system_score_codex":0.00039519212,"about_ca_system_score_gemma":0.0005325062,"threshold_uncertainty_score":0.5515046},"labels":[],"label_agreement":null},{"id":"W4315866014","doi":"10.1186/s13223-023-00761-y","title":"The first successful desensitization protocol in exenatide allergy: a case report","year":2023,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Desensitization (medicine); Exenatide; Allergy; Protocol (science); Medicine; Immunology; Internal medicine; Endocrinology; Receptor; Pathology; Alternative medicine","score_opus":0.0232110252358868,"score_gpt":0.34162868787188183,"score_spread":0.318417662635995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315866014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95814323,0.00016056113,0.000042997475,0.015017668,0.00042880749,0.018918851,0.0000013143375,0.00021864186,0.007067919],"genre_scores_gemma":[0.9467698,0.0017293564,0.00020529084,0.0012708813,0.00024159593,0.033029888,0.0001259172,0.00006238265,0.016564926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841976,0.00012956867,0.00065081863,0.0003531583,0.000110632966,0.00033607509],"domain_scores_gemma":[0.9988094,0.00053874747,0.00014475848,0.00037618694,0.000067387475,0.00006352875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008012146,0.00014574273,0.00030353895,0.00010184494,0.00018356371,0.000029607589,0.00007472149,0.000157356,0.000044865577],"category_scores_gemma":[0.00042452337,0.000099085075,0.00009056058,0.00027895137,0.00024078965,0.00006195945,0.00018579558,0.00020728867,0.000078677906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003082699,0.002218202,0.121558934,0.00012721102,0.005646941,0.3429345,0.00054579973,0.000050124956,0.00007226962,0.0137879085,0.019339738,0.49063566],"study_design_scores_gemma":[0.0050652963,0.0010059146,0.28549406,0.00007484211,0.000027117678,0.003523746,0.00049591373,0.0011933789,0.000034329983,0.0006428509,0.7022713,0.00017125852],"about_ca_topic_score_codex":0.00019722842,"about_ca_topic_score_gemma":0.0035736735,"teacher_disagreement_score":0.68293154,"about_ca_system_score_codex":0.000030053536,"about_ca_system_score_gemma":0.000045134486,"threshold_uncertainty_score":0.4040572},"labels":[],"label_agreement":null},{"id":"W4315880810","doi":"10.2337/figshare.21755030","title":"Rural Residence is Associated with a Delayed Trend Away From Sulfonylurea Use for Treatment Intensification of Type 2 Diabetes","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sulfonylurea; Residence; Medicine; Demography; Metformin; Metropolitan area; Type 2 diabetes; Logistic regression; Diabetes mellitus; Rural area; Environmental health; Internal medicine; Endocrinology; Sociology","score_opus":0.06768833793110218,"score_gpt":0.2939029027828841,"score_spread":0.22621456485178193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315880810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945923,0.00027183763,0.000112723385,0.0012751394,0.0002591934,0.0021913708,0.0007215592,0.0002518397,0.00032405564],"genre_scores_gemma":[0.96216446,0.0005027878,0.0022377071,0.00021373454,0.00006760717,0.0005136864,0.010842219,0.00007943143,0.023378372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836296,0.000035409965,0.00044350905,0.00053630176,0.00029496223,0.00032683002],"domain_scores_gemma":[0.9979677,0.00044898246,0.00036292445,0.000731506,0.00038461963,0.000104221566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012049206,0.00039938962,0.0008758214,0.0002292105,0.00003934114,0.000049442115,0.00011972434,0.00022883211,0.00007242369],"category_scores_gemma":[0.00020463331,0.00027363794,0.00022719656,0.00022767035,0.00006901995,0.00007631717,0.0001265167,0.000087286666,0.00001786792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005996044,0.005622604,0.7636797,0.0009231254,0.0516454,0.00011443841,0.0053767567,0.0002960744,0.006479248,0.0011956694,0.122495905,0.03617508],"study_design_scores_gemma":[0.018563963,0.013928178,0.8745294,0.0064549935,0.023245996,7.7345135e-7,0.0018836771,0.0138350725,0.038331967,0.0033581124,0.0041809306,0.0016869174],"about_ca_topic_score_codex":0.002012729,"about_ca_topic_score_gemma":0.0012723354,"teacher_disagreement_score":0.118314974,"about_ca_system_score_codex":0.00036548078,"about_ca_system_score_gemma":0.00012620653,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W4315880859","doi":"10.2337/figshare.21755030.v1","title":"Rural Residence is Associated with a Delayed Trend Away From Sulfonylurea Use for Treatment Intensification of Type 2 Diabetes","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sulfonylurea; Residence; Medicine; Demography; Metropolitan area; Metformin; Type 2 diabetes; Logistic regression; Diabetes mellitus; Rural area; Environmental health; Internal medicine; Endocrinology; Sociology","score_opus":0.06768833793110218,"score_gpt":0.2939029027828841,"score_spread":0.22621456485178193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315880859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945923,0.00027183763,0.000112723385,0.0012751394,0.0002591934,0.0021913708,0.0007215592,0.0002518397,0.00032405564],"genre_scores_gemma":[0.96216446,0.0005027878,0.0022377071,0.00021373454,0.00006760717,0.0005136864,0.010842219,0.00007943143,0.023378372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836296,0.000035409965,0.00044350905,0.00053630176,0.00029496223,0.00032683002],"domain_scores_gemma":[0.9979677,0.00044898246,0.00036292445,0.000731506,0.00038461963,0.000104221566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012049206,0.00039938962,0.0008758214,0.0002292105,0.00003934114,0.000049442115,0.00011972434,0.00022883211,0.00007242369],"category_scores_gemma":[0.00020463331,0.00027363794,0.00022719656,0.00022767035,0.00006901995,0.00007631717,0.0001265167,0.000087286666,0.00001786792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005996044,0.005622604,0.7636797,0.0009231254,0.0516454,0.00011443841,0.0053767567,0.0002960744,0.006479248,0.0011956694,0.122495905,0.03617508],"study_design_scores_gemma":[0.018563963,0.013928178,0.8745294,0.0064549935,0.023245996,7.7345135e-7,0.0018836771,0.0138350725,0.038331967,0.0033581124,0.0041809306,0.0016869174],"about_ca_topic_score_codex":0.002012729,"about_ca_topic_score_gemma":0.0012723354,"teacher_disagreement_score":0.118314974,"about_ca_system_score_codex":0.00036548078,"about_ca_system_score_gemma":0.00012620653,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W4315928173","doi":"10.2337/dc22-1223","title":"Rural Residence Is Associated With a Delayed Trend Away From Sulfonylurea Use for Treatment Intensification of Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Sulfonylurea; Residence; Diabetes mellitus; Type 2 diabetes; Internal medicine; Gerontology; Demography; Endocrinology","score_opus":0.028776161684272637,"score_gpt":0.2631159359164842,"score_spread":0.23433977423221156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315928173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669844,0.00056497887,0.0000017507388,0.00039565153,0.000121905934,0.0009875449,0.00090907986,0.00019305531,0.0001275867],"genre_scores_gemma":[0.98942924,0.00012849623,0.0002414577,0.00022563247,0.000047825717,0.00027359047,0.008577993,0.000049648268,0.0010261385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986837,0.00003136527,0.0002744269,0.00034050536,0.00024767747,0.00042230557],"domain_scores_gemma":[0.9985309,0.00038642494,0.00016391567,0.0004413048,0.00037246066,0.00010498418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006802875,0.00026347153,0.0005361009,0.00020371862,0.00006823883,0.000037437145,0.00008789591,0.00009889037,0.000033152694],"category_scores_gemma":[0.00017760368,0.00019601178,0.0001557281,0.00055827235,0.000071350274,0.00014047607,0.00003406894,0.000039684848,0.000045775396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021099666,0.00022241811,0.96870863,0.00009750256,0.0017906778,0.0000077044615,0.0024140608,0.000014574853,0.0061229295,0.000043912325,0.0070953774,0.013271239],"study_design_scores_gemma":[0.0057116183,0.004842994,0.9236414,0.0008613569,0.0026714527,7.522198e-8,0.003698605,0.0016945329,0.05280942,0.0001505223,0.0035182687,0.000399783],"about_ca_topic_score_codex":0.00006490643,"about_ca_topic_score_gemma":0.00012151014,"teacher_disagreement_score":0.046686493,"about_ca_system_score_codex":0.00021414118,"about_ca_system_score_gemma":0.00005122602,"threshold_uncertainty_score":0.79931283},"labels":[],"label_agreement":null},{"id":"W4316466443","doi":"10.1002/ejhf.2777","title":"Cost-Effectiveness of Immediate Initiation of Dapagliflozin in Patients with a History of Heart Failure","year":2023,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Libin Cardiovascular Institute of Alberta","funders":"AstraZeneca","keywords":"Medicine; Heart failure; Dapagliflozin; Cardiology; Internal medicine; Intensive care medicine; Endocrinology; Diabetes mellitus","score_opus":0.021397369517176905,"score_gpt":0.24334492983541933,"score_spread":0.22194756031824242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316466443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978642,0.00018182283,0.000025157937,0.0008034197,0.00015124584,0.00054174976,0.000010760869,0.000010940001,0.0004107345],"genre_scores_gemma":[0.99835086,0.000014258352,0.0013602017,0.00005102761,0.000042645337,0.0000032820042,0.000034746114,0.000028793836,0.00011421329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821866,0.0004404142,0.00059139275,0.00012704746,0.000446801,0.000175691],"domain_scores_gemma":[0.99883074,0.00010848554,0.00043941586,0.00019341367,0.00034065056,0.00008732193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011186578,0.00014078467,0.0005628522,0.00052279385,0.000010272236,0.0000029865355,0.00008716315,0.000026482452,0.000042686934],"category_scores_gemma":[0.00009843762,0.00010813495,0.00012997993,0.00035186956,0.00010043953,0.00015470252,0.000043346463,0.00017814587,0.000015406278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020105408,0.0010620054,0.91912425,0.0011988615,0.0004120601,0.00011760862,0.0010134653,0.00024086997,0.009620915,0.00006007438,0.063927196,0.0012121247],"study_design_scores_gemma":[0.0085785715,0.0032338037,0.9362574,0.0015186005,0.00018739162,0.000005221437,0.00020286265,0.000008732137,0.0022875722,0.0000066527864,0.047618363,0.00009478064],"about_ca_topic_score_codex":0.0000052438754,"about_ca_topic_score_gemma":0.000004546484,"teacher_disagreement_score":0.017133173,"about_ca_system_score_codex":0.00015018541,"about_ca_system_score_gemma":0.000121589444,"threshold_uncertainty_score":0.44096154},"labels":[],"label_agreement":null},{"id":"W4316469640","doi":"10.3390/medicina59010182","title":"Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Medicina","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Clinical trial; Type 2 Diabetes Mellitus; MEDLINE; Diabetes mellitus; Intensive care medicine; Internal medicine; Insulin; Endocrinology","score_opus":0.10076704849913322,"score_gpt":0.40966238411008904,"score_spread":0.30889533561095583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316469640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000555896,0.98776954,7.8459664e-7,0.00031739,0.0003851258,0.007982478,0.0000037775508,0.00004961017,0.003485731],"genre_scores_gemma":[0.0000056243302,0.9964767,0.000075761185,0.0008059937,0.00010087792,0.00064537086,0.00017674419,0.00005291045,0.0016600074],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960253,0.00044241204,0.002125812,0.00039871974,0.00066623336,0.00034150347],"domain_scores_gemma":[0.9974835,0.0005890704,0.00061514194,0.0011789219,0.000051545452,0.000081857055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003835538,0.0004002887,0.0048951884,0.00024978325,0.000017753437,0.000007836336,0.00047176494,0.00014168341,0.000052844454],"category_scores_gemma":[0.00028077615,0.0001919177,0.0006444753,0.0012842384,0.000095263815,0.000021041946,0.00014652078,0.00034123805,0.0004642797],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016096853,0.00017159517,0.000014409132,0.80479544,0.0018284611,0.00017862182,0.000028694676,6.72623e-9,9.115339e-10,0.00017716657,0.0055785584,0.18722543],"study_design_scores_gemma":[0.0003012523,0.00023996066,0.000022352358,0.68100107,0.028766206,0.0000025692523,0.000070877264,0.0000019091992,7.756096e-9,0.000014552167,0.2894791,0.000100136705],"about_ca_topic_score_codex":0.0000042198076,"about_ca_topic_score_gemma":0.0000016457665,"teacher_disagreement_score":0.28390056,"about_ca_system_score_codex":0.00008318655,"about_ca_system_score_gemma":0.0000666578,"threshold_uncertainty_score":0.7826177},"labels":[],"label_agreement":null},{"id":"W4317213523","doi":"10.1093/ndt/gfad009","title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Centers for Disease Control and Prevention; National Institutes of Health; National Heart, Lung, and Blood Institute; Vifor Pharma; Astellas Pharma; Novo Nordisk; Eli Lilly and Company; AstraZeneca; CSL Behring; MyoKardia; McMaster University; Gilead Sciences; FibroGen; Alnylam Pharmaceuticals; European Commission; Sanofi; American Society of Nephrology; GlaxoSmithKline; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen","keywords":"Semaglutide; Medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Urology; Internal medicine; Endocrinology; Liraglutide","score_opus":0.01992195976321406,"score_gpt":0.25954917319596843,"score_spread":0.23962721343275437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317213523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903545,0.00025233062,0.001193176,0.00651724,0.000045605328,0.0014428359,0.00012808514,0.000044141725,0.000022078873],"genre_scores_gemma":[0.9885827,0.0028465001,0.0016842469,0.0012104255,0.00007104268,0.0002590501,0.0050719697,0.000024058525,0.00025005228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885225,0.0001646575,0.00024271422,0.00032317304,0.0002067224,0.00021045661],"domain_scores_gemma":[0.998821,0.00058324035,0.00008354149,0.00031417934,0.00004746168,0.00015054586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005240916,0.00015266566,0.00033825258,0.00018080903,0.00008280306,0.000018412173,0.00008133047,0.000042325846,0.00001576856],"category_scores_gemma":[0.00012932856,0.000091236885,0.00002266753,0.0004371645,0.00014168957,0.00011676379,0.000020514017,0.000066205685,0.0000032337698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08400442,0.0006852962,0.8850851,0.0011097242,0.0031928916,0.00014569653,0.0018117676,0.003451972,0.0016546428,0.00023984442,0.0056892033,0.01292942],"study_design_scores_gemma":[0.0902218,0.003424495,0.8010402,0.0002616971,0.007386888,0.000003806444,0.00012535353,0.094683535,0.00029872148,0.00015061385,0.0020934176,0.00030949173],"about_ca_topic_score_codex":0.00002535768,"about_ca_topic_score_gemma":0.0005942685,"teacher_disagreement_score":0.09123156,"about_ca_system_score_codex":0.000022736744,"about_ca_system_score_gemma":0.00027126895,"threshold_uncertainty_score":0.37205324},"labels":[],"label_agreement":null},{"id":"W4317401655","doi":"10.1002/oby.23673","title":"Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: <scp>STEP</scp> 5","year":2023,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"National Institute for Health and Care Research","keywords":"Semaglutide; Placebo; Medicine; Overweight; Obesity; Craving; Emotional eating; Physical therapy; Internal medicine; Type 2 diabetes; Eating behavior; Endocrinology; Psychiatry; Diabetes mellitus; Addiction","score_opus":0.004609965984111035,"score_gpt":0.22405936718670386,"score_spread":0.21944940120259282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317401655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644036,0.00005543899,0.00001674862,0.000036173107,0.000053550848,0.0009580077,0.000015046747,0.00007445753,0.01235024],"genre_scores_gemma":[0.9986322,0.000019732113,0.00018747454,0.00005633326,0.000047524703,0.000034329496,0.00002980568,0.000021233118,0.0009713465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998727,0.00009379919,0.00024596576,0.00026976812,0.00035983045,0.00030360674],"domain_scores_gemma":[0.9989438,0.0004627079,0.00014620394,0.00032484464,0.000044886136,0.0000775416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042283122,0.0001888725,0.00059531315,0.0002242236,0.000030547177,0.000005418367,0.00008138957,0.000052563733,0.00001275621],"category_scores_gemma":[0.00015926713,0.00013759919,0.00009960707,0.00042319734,0.000051154573,0.000042087762,0.000052353724,0.000114561364,0.000067519926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032959113,0.00040914558,0.99466586,0.0009221393,0.00019888373,0.00009681376,0.00021099775,0.000052884443,0.0007225082,0.0004907205,0.0005671701,0.0013332786],"study_design_scores_gemma":[0.014447366,0.003395579,0.96283495,0.0021338686,0.0002995023,0.0000010970441,0.0002004261,0.0011174215,0.015305316,0.000034676632,0.00016134446,0.00006841914],"about_ca_topic_score_codex":0.00019245845,"about_ca_topic_score_gemma":0.00010913997,"teacher_disagreement_score":0.031830885,"about_ca_system_score_codex":0.000066719665,"about_ca_system_score_gemma":0.000022994227,"threshold_uncertainty_score":0.56111324},"labels":[],"label_agreement":null},{"id":"W4317568827","doi":"10.1016/j.jcjd.2023.01.006","title":"Use of Classes of Antihyperglycemic Agents in People With Type 2 Diabetes Based on Level of Estimated Glomerular Filtration Rate","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Glycemic; Kidney disease; Renal function; Disease; Kidney; Diabetes management; Gerontology; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.08556521302164181,"score_gpt":0.2778557559491304,"score_spread":0.1922905429274886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317568827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991215,0.00015864371,0.0000033345611,0.00020827126,0.0001083385,0.00022113127,0.00007454031,0.000005940441,0.000098319615],"genre_scores_gemma":[0.9992416,0.000028827271,0.00039819974,0.0001122942,0.000014014242,0.0000032851626,0.000079147314,0.000022341763,0.00010027889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988398,0.000055061653,0.00046987782,0.00011522093,0.00022697299,0.00029304976],"domain_scores_gemma":[0.9987462,0.00019059106,0.00036648204,0.00019086119,0.00030440977,0.0002014366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025964912,0.0001456123,0.00054097845,0.0009832733,0.000019955527,0.000011553794,0.00009726922,0.00005617661,0.000060203416],"category_scores_gemma":[0.00030239424,0.000116715695,0.00008258244,0.0009687682,0.00008909057,0.00014686094,0.0000068380205,0.00009282006,0.0000030714898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059856866,0.00011006891,0.98259676,0.00033789204,0.0002506487,0.000022326834,0.0001019721,0.0035697152,0.010710116,0.000025707675,0.0012684782,0.00094644784],"study_design_scores_gemma":[0.0017573449,0.0021217423,0.9509208,0.001500195,0.00026318996,2.1715658e-7,0.000072847964,0.00513511,0.03797076,0.000022169674,0.00013498357,0.00010060239],"about_ca_topic_score_codex":0.00049211725,"about_ca_topic_score_gemma":0.0026261222,"teacher_disagreement_score":0.031675935,"about_ca_system_score_codex":0.000088804445,"about_ca_system_score_gemma":0.0005804031,"threshold_uncertainty_score":0.4759528},"labels":[],"label_agreement":null},{"id":"W4317623094","doi":"10.1016/j.ekir.2023.01.011","title":"Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial","year":2023,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute; Merck Sharp and Dohme; National Institutes of Health; Pfizer; American Heart Association","keywords":"Medicine; Hazard ratio; Heart failure; Placebo; Ejection fraction; Internal medicine; Renal function; Kidney disease; Confidence interval; Randomized controlled trial; Cardiology; Pathology","score_opus":0.01291011998325041,"score_gpt":0.27712976477470175,"score_spread":0.2642196447914513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317623094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909895,0.000037970447,0.0000044501603,0.00511945,0.0004528757,0.0028283186,0.000032318905,0.000022813823,0.00051228167],"genre_scores_gemma":[0.99767596,0.000022933946,0.000087258384,0.0010758762,0.00003588153,0.00019110694,0.00057840155,0.000020381412,0.00031223247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965337,0.00023584966,0.00070617354,0.0003747354,0.0019572182,0.00019235977],"domain_scores_gemma":[0.99850583,0.00043722958,0.0002449343,0.00044071354,0.00022602222,0.00014528733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020629242,0.00021509767,0.0006373683,0.00044112332,0.000026861633,0.000011271282,0.00009160909,0.00006818183,0.000056674824],"category_scores_gemma":[0.0064114914,0.00013440476,0.00021119461,0.00031262482,0.000050147235,0.000087098066,0.00008110654,0.000107865,0.0000057306315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004002744,0.0013025011,0.98144007,0.00012326828,0.0012944252,0.00009461172,0.00022493224,0.00022874695,0.00005416064,0.00003888448,0.008366332,0.0028293163],"study_design_scores_gemma":[0.05281208,0.00060304475,0.9378538,0.0004254544,0.0005152377,0.0000026735677,0.000022142338,0.00022295288,0.00045537393,0.00004052243,0.006933915,0.00011276373],"about_ca_topic_score_codex":0.00012511812,"about_ca_topic_score_gemma":0.000031149073,"teacher_disagreement_score":0.048809335,"about_ca_system_score_codex":0.00023459244,"about_ca_system_score_gemma":0.00016058459,"threshold_uncertainty_score":0.76756173},"labels":[],"label_agreement":null},{"id":"W4317830857","doi":"10.51731/cjht.2023.547","title":"Empagliflozin (Jardiance)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Empagliflozin; Medicine; Drug class; Family medicine; Drug; Intensive care medicine; Health care; Pharmacology; Political science","score_opus":0.03664097978150487,"score_gpt":0.30055596266128615,"score_spread":0.26391498287978127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317830857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64934164,0.059367165,0.00008816269,0.28205872,0.0014168873,0.0007405296,0.000019106883,0.00081808714,0.006149729],"genre_scores_gemma":[0.9967658,0.0010492607,0.00039274155,0.0007741576,0.000015329128,0.0000059763456,0.0000051165503,0.000012605726,0.000979016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900734,0.000014933506,0.00031971253,0.00008829489,0.0001264671,0.00044323632],"domain_scores_gemma":[0.99943656,0.000021203452,0.00015751465,0.00019851416,0.00007441953,0.00011178125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042843446,0.00008813601,0.00031617287,0.0009608354,0.000115042094,0.000018136756,0.0001425547,0.000067310495,0.00003095066],"category_scores_gemma":[0.00021880028,0.00007005796,0.00008446205,0.0006033234,0.0000943665,0.00006195423,0.0000159015,0.000186257,0.00012383526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067402066,0.000012818834,0.022245374,0.00011692481,0.0001231034,0.0006861434,0.00015019967,0.000006808428,0.000009553381,0.001178165,0.1358991,0.83956504],"study_design_scores_gemma":[0.0007643344,0.00068108947,0.08191112,0.00031415,0.000044053828,0.000071489936,0.0028168573,0.000010778414,0.00022779376,0.0025579962,0.9105084,0.000091941445],"about_ca_topic_score_codex":0.00055952324,"about_ca_topic_score_gemma":0.0007790368,"teacher_disagreement_score":0.8394731,"about_ca_system_score_codex":0.00028743292,"about_ca_system_score_gemma":0.0011362392,"threshold_uncertainty_score":0.28568807},"labels":[],"label_agreement":null},{"id":"W4317867152","doi":"10.1080/00325481.2022.2147326","title":"Efficacy and safety of semaglutide for weight management: evidence from the STEP program","year":2022,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Novo Nordisk","keywords":"Semaglutide; Liraglutide; Medicine; Dulaglutide; Exenatide; Weight loss; Lixisenatide; Type 2 diabetes; Weight management; Tolerability; Overweight; Diabetes mellitus; Internal medicine; Placebo; Obesity; Endocrinology; Adverse effect; Alternative medicine","score_opus":0.08466178539150584,"score_gpt":0.3625780760882124,"score_spread":0.27791629069670654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317867152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037281847,0.98165244,0.000049774117,0.003410632,0.00038887333,0.012401146,0.000105779196,0.000104682455,0.0018494218],"genre_scores_gemma":[0.00002065807,0.99128,0.0020570655,0.000272115,0.0003758558,0.001816153,0.001328922,0.00008680759,0.002762413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709064,0.00017593276,0.00097034033,0.0006949573,0.0006436322,0.00042451388],"domain_scores_gemma":[0.9962038,0.0020835842,0.00055040466,0.0009434674,0.00006013666,0.0001586556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082600414,0.0005786219,0.0022815785,0.00021639215,0.0001643303,0.000014899742,0.00039896517,0.000087501394,0.00027379955],"category_scores_gemma":[0.00029568342,0.00030891917,0.00036698405,0.0005115488,0.0003116279,0.000039227478,0.0003811712,0.000298987,0.000011439998],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024654338,0.00024232741,0.000039161016,0.018872583,0.0025471419,0.00005915542,0.00013690325,5.5041905e-8,1.8782481e-7,0.00038676208,0.011412928,0.9660562],"study_design_scores_gemma":[0.003701192,0.0016374838,0.0003398369,0.038767178,0.02119915,0.000013944696,0.00008513144,0.000018337103,5.0475495e-7,0.00006401424,0.93394834,0.00022490924],"about_ca_topic_score_codex":0.00011869439,"about_ca_topic_score_gemma":0.000008580036,"teacher_disagreement_score":0.96583134,"about_ca_system_score_codex":0.00014296162,"about_ca_system_score_gemma":0.00006418437,"threshold_uncertainty_score":0.9999363},"labels":[],"label_agreement":null},{"id":"W4317871157","doi":"10.1080/00325481.2022.2149005","title":"Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg","year":2022,"lang":"en","type":"editorial","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"","keywords":"Semaglutide; Medicine; Primary care; Obesity; Physical therapy; Subcutaneous fat; Internal medicine; Family medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes; Liraglutide","score_opus":0.013985592926006447,"score_gpt":0.28100956799597965,"score_spread":0.2670239750699732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317871157","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049165115,0.0145974355,0.00011037089,0.01780108,0.90088886,0.011782728,0.0011571205,0.00078889367,0.003708379],"genre_scores_gemma":[0.00415155,0.0050886995,0.0029071772,0.0045045107,0.92272824,0.0016000052,0.04214105,0.00051818485,0.016360562],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936206,0.00014452351,0.0011842931,0.001770774,0.0021480878,0.0011317722],"domain_scores_gemma":[0.9957395,0.00061602436,0.00052358664,0.0017013352,0.0006925052,0.0007270043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011624782,0.0010430093,0.0022050422,0.00066138455,0.0003765442,0.000049959926,0.00060441485,0.00036895444,0.00037622568],"category_scores_gemma":[0.00074354204,0.00082605507,0.0003658593,0.000536696,0.00015469248,0.00008312429,0.00029090274,0.0009524134,0.000028545901],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032198692,0.0006905964,0.0005239634,0.0013188064,0.00087998627,0.00089684693,0.0020908026,0.000008011626,0.0008896851,0.000031268617,0.9475016,0.04194856],"study_design_scores_gemma":[0.0076718107,0.022471623,0.0005307686,0.00063944707,0.0018529255,0.00003163835,0.0006444598,0.000021851107,0.00015904066,0.00011368901,0.96512574,0.0007369776],"about_ca_topic_score_codex":0.0011263032,"about_ca_topic_score_gemma":0.0001550618,"teacher_disagreement_score":0.045013566,"about_ca_system_score_codex":0.0019505393,"about_ca_system_score_gemma":0.0007899269,"threshold_uncertainty_score":0.99941903},"labels":[],"label_agreement":null},{"id":"W4317930838","doi":"10.1002/oby.23633","title":"<scp>Glucagon‐like peptide</scp>‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial","year":2023,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; National Institute of General Medical Sciences; Sanofi; Novo Nordisk; Florida State University; York University; Eli Lilly and Company","keywords":"Internal medicine; Endocrinology; Medicine; Placebo; Metabolic adaptation; Calorie; Weight loss; Glucagon; Overweight; Ketogenesis; Lean body mass; Obesity; Glucagon-like peptide-1; Insulin; Metabolism; Diabetes mellitus; Type 2 diabetes; Body weight; Ketone bodies","score_opus":0.021386302374451112,"score_gpt":0.24812058215145666,"score_spread":0.22673427977700555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317930838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897844,0.0005202578,0.00005429324,0.0009085577,0.0006779672,0.0023685445,0.000010127731,0.00035735435,0.0053184656],"genre_scores_gemma":[0.91496813,0.0010830156,0.0016258815,0.0003310065,0.0006081022,0.00051743636,0.000666973,0.000056017532,0.08014341],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99812347,0.00024106096,0.0003410987,0.00045496825,0.0004534018,0.0003859979],"domain_scores_gemma":[0.99873674,0.00044245878,0.00023946841,0.0002878284,0.00012497982,0.00016853967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007794682,0.00028893718,0.00085287826,0.00019961585,0.00018621505,0.00009459622,0.0000792385,0.0001231524,0.00009338666],"category_scores_gemma":[0.00030074685,0.00021725522,0.00017324477,0.00046520907,0.000099368845,0.00022246096,0.00006918509,0.00013955208,0.0002480525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5025451,0.0056110555,0.021604227,0.0011398891,0.01708175,0.00025254325,0.0155900875,0.000074270814,0.056619275,0.016427469,0.30651867,0.056535613],"study_design_scores_gemma":[0.87120324,0.00082465203,0.04611671,0.00014450171,0.0029321304,0.0000018481571,0.00089760317,0.00024651195,0.013646162,0.0006046442,0.06313699,0.0002449848],"about_ca_topic_score_codex":0.00010447057,"about_ca_topic_score_gemma":0.000029350951,"teacher_disagreement_score":0.36865813,"about_ca_system_score_codex":0.00008616946,"about_ca_system_score_gemma":0.000057610905,"threshold_uncertainty_score":0.8859411},"labels":[],"label_agreement":null},{"id":"W4317932188","doi":"10.1177/20543581221150556","title":"Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care","year":2023,"lang":"en","type":"review","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Fraser Health; University of British Columbia; Lakeridge Health; Nova Scotia Health Authority; Health Sciences Centre; University of Toronto; Western University; McGill University; University of Calgary; Toronto General Hospital; St. Michael's Hospital; Jewish General Hospital","funders":"Janssen Pharmaceuticals; Bayer HealthCare; AstraZeneca Canada","keywords":"Medicine; Primary care; Intensive care medicine; Kidney disease; Diabetic nephropathy; Disease; Type 2 diabetes; Kidney; Internal medicine; Diabetes mellitus; Family medicine; Endocrinology","score_opus":0.03625679485549682,"score_gpt":0.3442955656528997,"score_spread":0.3080387707974029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317932188","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020748963,0.985542,6.6492504e-7,0.0094177555,0.00033279706,0.0032910625,0.0011600632,0.0000048769475,0.00023000731],"genre_scores_gemma":[0.000008133362,0.9814366,0.00008536506,0.016118601,0.00014433362,0.00011577346,0.0014481576,0.000044412613,0.00059862173],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797535,0.00011666408,0.0009320904,0.0003033926,0.0002238286,0.0004486564],"domain_scores_gemma":[0.9701822,0.000048801667,0.00055087917,0.000254993,0.00015587446,0.028807286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035040014,0.000326589,0.0017857385,0.00059555273,0.00008693142,0.000022504319,0.00011521209,0.00005445934,0.00003980572],"category_scores_gemma":[0.0025470702,0.00026503246,0.00029630863,0.0004212403,0.00009026242,0.000063021005,0.000034287008,0.00017074433,0.0000026749424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009502543,0.000042757896,0.0005716766,0.5395995,0.00028529952,0.0007849263,0.00017948933,3.172818e-8,1.2255745e-9,0.00013354633,0.21362333,0.24468447],"study_design_scores_gemma":[0.0011303052,0.00027005406,0.0003135239,0.2378928,0.0026369407,0.000002919662,0.00013309722,5.3155054e-7,2.2552098e-9,0.00008672163,0.75738716,0.00014593457],"about_ca_topic_score_codex":0.00015170072,"about_ca_topic_score_gemma":0.00009144271,"teacher_disagreement_score":0.5437638,"about_ca_system_score_codex":0.0006159575,"about_ca_system_score_gemma":0.044572864,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W4318016588","doi":"10.1016/j.cjca.2023.01.019","title":"Randomized, Double-Blind, Pilot Study Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction","year":2023,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Ejection fraction; Medicine; Heart failure; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Randomized controlled trial; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.03763604173971753,"score_gpt":0.27483359888336334,"score_spread":0.23719755714364582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318016588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98374665,0.00016429882,0.00003578118,0.012684405,0.0003137511,0.0023360401,0.000019884437,0.000006127336,0.0006930683],"genre_scores_gemma":[0.997878,0.000011426643,0.00007298992,0.00097138784,0.000523308,0.000048550868,0.00013502431,0.000040962943,0.0003183561],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980156,0.0003821762,0.0007302519,0.00023212172,0.00033676898,0.00030307606],"domain_scores_gemma":[0.9982593,0.00017211659,0.00070792413,0.00025078128,0.00044195866,0.00016793415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059087924,0.00025764044,0.002277178,0.0011752014,0.000034184726,0.000014763622,0.00009976546,0.00020472833,0.000020318406],"category_scores_gemma":[0.00006392298,0.00017927955,0.00013463007,0.00026824238,0.00019006219,0.00009247539,0.000016202644,0.0007606901,0.0000022581396],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09611796,0.000067715926,0.73226047,0.00018308575,0.0026807466,0.00011254679,0.00008509643,0.00025734276,0.0000020351763,0.000001032463,0.16816752,0.00006443456],"study_design_scores_gemma":[0.56274754,0.020972874,0.3521113,0.0006919526,0.003839031,0.000018503119,0.0006420566,0.000009525105,0.0000130567105,0.000011247357,0.05869187,0.00025101088],"about_ca_topic_score_codex":0.003109087,"about_ca_topic_score_gemma":0.013108427,"teacher_disagreement_score":0.4666296,"about_ca_system_score_codex":0.00019971086,"about_ca_system_score_gemma":0.00038852298,"threshold_uncertainty_score":0.73148096},"labels":[],"label_agreement":null},{"id":"W4318168210","doi":"10.1111/dom.14990","title":"Safety and tolerability of semaglutide across the <scp>SUSTAIN</scp> and <scp>PIONEER</scp> phase <scp>IIIa</scp> clinical trial programmes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Tolerability; Placebo; Adverse effect; Dulaglutide; Internal medicine; Clinical trial; Diabetes mellitus; Type 2 diabetes; Pharmacology; Exenatide; Endocrinology; Liraglutide","score_opus":0.02576372130846005,"score_gpt":0.327358820115485,"score_spread":0.30159509880702495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318168210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532116,0.009191479,0.000021524518,0.00039002384,0.0006702547,0.0031954779,0.00019705211,0.00027354874,0.00073949003],"genre_scores_gemma":[0.9875181,0.0060938816,0.00037709685,0.00063728506,0.00065207883,0.00024301968,0.00022926554,0.00006887158,0.004180427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99525285,0.00047214903,0.001238811,0.0010534124,0.000631961,0.0013508315],"domain_scores_gemma":[0.994031,0.003758249,0.00046139353,0.00084491813,0.0002586564,0.0006458003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004211858,0.0006296865,0.001845003,0.00020853916,0.0005889589,0.00021853727,0.00027567745,0.00037527306,0.000004200611],"category_scores_gemma":[0.0048884964,0.00045435474,0.00040552433,0.00076961843,0.0012006921,0.000288977,0.0006854952,0.00055201654,0.000018133791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004870557,0.0067948014,0.7284037,0.0023403962,0.0034846321,0.00009248519,0.009957737,0.000009928801,0.00080665515,0.003876057,0.015018377,0.22872819],"study_design_scores_gemma":[0.047329452,0.0012489869,0.6561965,0.00012636128,0.0019444716,0.0000036199142,0.004198906,0.00047553072,0.0019072556,0.0015967399,0.28488418,0.00008801138],"about_ca_topic_score_codex":0.00006528309,"about_ca_topic_score_gemma":0.000026876587,"teacher_disagreement_score":0.2698658,"about_ca_system_score_codex":0.00003416459,"about_ca_system_score_gemma":0.00010702406,"threshold_uncertainty_score":0.99979085},"labels":[],"label_agreement":null},{"id":"W4318187648","doi":"10.1210/clinem/dgac764","title":"Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV","year":2023,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Alnylam Pharmaceuticals; Amryt Pharma; Amarin Corporation; Dexcom; Novo Nordisk; Daiichi Sankyo Europe; Sanofi; Amgen; Vetenskapsrådet; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Insulin; Hypoglycemia; Internal medicine; Placebo; Context (archaeology); Diabetes mellitus; Type 2 diabetes; Hazard ratio; Incidence (geometry); Glycated hemoglobin; Endocrinology; Confidence interval; Biology; Mathematics","score_opus":0.09064762867114946,"score_gpt":0.3887378995742824,"score_spread":0.29809027090313295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318187648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339664,0.003699809,0.000003995231,0.0017996207,0.00057888735,0.00030565294,0.0000081262615,0.000026322181,0.00018094179],"genre_scores_gemma":[0.9875032,0.010514159,0.000368209,0.0011729948,0.00030376422,0.000006347407,0.000046574867,0.000021457596,0.00006332282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732524,0.00046571094,0.001215564,0.00022100036,0.00039989236,0.00037256614],"domain_scores_gemma":[0.998007,0.00071671535,0.00061380275,0.0002748013,0.00024201258,0.0001456441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008369753,0.00020243184,0.0009079194,0.00036400615,0.00005837759,0.000017152848,0.00020244224,0.0000969485,0.000052870742],"category_scores_gemma":[0.00096800853,0.000116646115,0.000113601585,0.00054468075,0.00020853271,0.00022473915,0.00013177036,0.00045939835,0.000043046115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053725396,0.0014420018,0.82641053,0.00002451466,0.0029158087,0.00014921003,0.00055817823,0.00007569188,0.00086487265,0.00008556428,0.0018116084,0.16028947],"study_design_scores_gemma":[0.011765003,0.0012939518,0.9810164,0.000117857126,0.0012088665,0.0000016367795,0.000118311,0.000071475915,0.00063220324,0.00052700704,0.0031410996,0.0001061748],"about_ca_topic_score_codex":0.00003436684,"about_ca_topic_score_gemma":0.000012306919,"teacher_disagreement_score":0.1601833,"about_ca_system_score_codex":0.000026624031,"about_ca_system_score_gemma":0.00008781371,"threshold_uncertainty_score":0.47566906},"labels":[],"label_agreement":null},{"id":"W4318262703","doi":"10.1146/annurev-med-042921-102135","title":"SGLT2 Inhibitors: The Sweet Success for Kidneys","year":2023,"lang":"en","type":"review","venue":"Annual Review of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Banting and Best Diabetes Centre, University of Toronto; Kidney Foundation of Canada; University of Toronto; Diabetes Canada","keywords":"Albuminuria; Medicine; Renal function; Kidney; Diabetes mellitus; Clinical trial; Empagliflozin; Kidney disease; Intensive care medicine; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.059724583607411265,"score_gpt":0.40489505418727906,"score_spread":0.34517047057986777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318262703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.2981849e-7,0.9772887,0.000008577049,0.010379912,0.00079144014,0.007262355,0.00018695439,0.000082944505,0.0039989394],"genre_scores_gemma":[3.5622213e-7,0.9823961,0.000050732237,0.003784281,0.001743505,0.0013510577,0.0015640467,0.00010805566,0.009001849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660873,0.00015611722,0.0016087929,0.00048633048,0.00071676733,0.00042324088],"domain_scores_gemma":[0.99670786,0.00088747544,0.0008841933,0.00097335863,0.00033110523,0.00021600645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021728806,0.00058444904,0.004495273,0.00024435794,0.00006544233,0.000005916488,0.00046335932,0.00016684487,0.00021632103],"category_scores_gemma":[0.0021548897,0.00026674167,0.0010232929,0.0008893796,0.00030136516,0.00005926227,0.00017231258,0.00028464606,0.00017857496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000029588941,0.00003393038,8.6313486e-7,0.28417584,0.0004893234,0.000009391996,0.000019025618,1.6329389e-9,1.477359e-8,0.00027012886,0.3082994,0.40669915],"study_design_scores_gemma":[0.0005593321,0.0005211367,0.000002096619,0.4005342,0.0104549825,0.000007945672,0.00003278007,1.7331963e-7,2.4841987e-7,0.000027189782,0.58774066,0.00011926375],"about_ca_topic_score_codex":0.000028578204,"about_ca_topic_score_gemma":0.0000023900257,"teacher_disagreement_score":0.40657988,"about_ca_system_score_codex":0.000088318564,"about_ca_system_score_gemma":0.0002669387,"threshold_uncertainty_score":0.9999785},"labels":[],"label_agreement":null},{"id":"W4318559824","doi":"10.1101/2023.01.28.526057","title":"Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Stanford Bio-X; Novo Nordisk; National Institute of Diabetes and Digestive and Kidney Diseases; Stanford Diabetes Research Center; National Institutes of Health; National Science Foundation","keywords":"Self-healing hydrogels; Diabetes treatment; Pharmacology; Medicine; Diabetes mellitus; Glucagon-like peptide 1 receptor; Receptor; Agonist; Type 2 diabetes; Chemistry; Internal medicine; Endocrinology","score_opus":0.01476186783159089,"score_gpt":0.22416083934965725,"score_spread":0.20939897151806636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318559824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138284,0.0041083046,0.000023298151,0.00021508786,0.0008917298,0.0020656562,0.0009059148,0.00038579697,0.000021382777],"genre_scores_gemma":[0.9935535,0.001161308,0.004143362,0.000044213073,0.00027195027,0.00047104125,0.000018148417,0.00020175941,0.0001346734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99663836,0.00010245849,0.0009608315,0.0010766276,0.0005068239,0.00071488426],"domain_scores_gemma":[0.9965168,0.00019326502,0.0007880212,0.0016808631,0.00052285084,0.00029819348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027690997,0.00077627273,0.0017173126,0.0006538332,0.0000704861,0.00006252159,0.00034266495,0.0004594228,0.000088575376],"category_scores_gemma":[0.00013065779,0.0007174587,0.0004908101,0.0006628598,0.00022246432,0.00010439127,0.00056385744,0.0001986347,0.00007901036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001558154,0.0015262155,0.045822166,0.0016573009,0.0039088274,0.000042885185,0.00003697084,0.000010228165,0.94608915,0.00009012914,0.0005715175,0.00008877052],"study_design_scores_gemma":[0.0030574338,0.0012605138,0.05615108,0.0010605206,0.002216974,1.2195887e-9,0.000022771195,0.00021934792,0.9333734,0.00001066564,0.0020434367,0.0005838543],"about_ca_topic_score_codex":0.00056840124,"about_ca_topic_score_gemma":0.0000049406567,"teacher_disagreement_score":0.012715774,"about_ca_system_score_codex":0.0006683672,"about_ca_system_score_gemma":0.00063566276,"threshold_uncertainty_score":0.99952763},"labels":[],"label_agreement":null},{"id":"W4318592691","doi":"10.3389/fendo.2023.1147752","title":"Editorial: Endocrine-related cardiovascular diseases: Recent advances in diagnosis and treatment","year":2023,"lang":"en","type":"editorial","venue":"Frontiers in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Science and Engineering Research Board; Indian Council of Medical Research; Department of Science and Technology, Ministry of Science and Technology, India","keywords":"Endocrine system; Medicine; Intensive care medicine; Bioinformatics; Physiology; Internal medicine; Biology; Hormone","score_opus":0.007695094315316425,"score_gpt":0.25874812631304345,"score_spread":0.251053031997727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318592691","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031299586,0.15031233,0.00000486885,0.00029774787,0.84656197,0.0015097938,0.00016156309,0.0001982911,0.00064043025],"genre_scores_gemma":[0.0000557592,0.51112115,0.00015048626,0.00001074841,0.4845857,0.0019298955,0.0010653444,0.0000927284,0.0009881946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959944,0.00021278339,0.0007218666,0.0012315944,0.0006872606,0.001152093],"domain_scores_gemma":[0.9982731,0.00048513463,0.00015934918,0.0007729115,0.00009693494,0.00021256779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013964342,0.0007053489,0.002206476,0.0012009508,0.00005126569,0.000029848428,0.00021041435,0.0005442394,0.00002792623],"category_scores_gemma":[0.00082507654,0.00063709373,0.00040502782,0.00058300135,0.0002159481,0.00015054471,0.00021616132,0.00065503153,0.000037899044],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022651555,0.00048573918,0.031708647,0.00021683707,0.0018195495,0.0014856311,0.00007934614,0.00004486722,9.466608e-8,0.000015962463,0.78225666,0.18166016],"study_design_scores_gemma":[0.009620515,0.0009533766,0.0012274234,0.000313201,0.0017313423,0.0000024909396,0.000201211,0.000013226707,0.0000061478313,0.00039022678,0.98510814,0.00043271983],"about_ca_topic_score_codex":0.00030869775,"about_ca_topic_score_gemma":0.00023421815,"teacher_disagreement_score":0.3619763,"about_ca_system_score_codex":0.0016263048,"about_ca_system_score_gemma":0.00023404436,"threshold_uncertainty_score":0.99960804},"labels":[],"label_agreement":null},{"id":"W4318619200","doi":"10.9778/cmajo.20210281","title":"Use of sodium–glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation","year":2023,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"Novo Nordisk; Otsuka Pharmaceutical; Alexion Pharmaceuticals; Janssen Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Alberta Health Services; Amgen","keywords":"Medicine; Kidney disease; Diabetes mellitus; Renal function; Internal medicine; Odds ratio; Cross-sectional study; Canagliflozin; Guideline; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.05303451414863605,"score_gpt":0.33733475775748006,"score_spread":0.284300243608844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318619200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943658,0.00011920588,0.0000050886874,0.00016615012,0.00015898194,0.004185268,0.00004752417,0.000050497365,0.0009014592],"genre_scores_gemma":[0.99588,0.000017082879,0.00005222707,0.0000633902,0.000051574694,0.0004973484,0.0008074436,0.000034961344,0.0025959758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987371,0.00001883513,0.0003729877,0.00033397067,0.00028655978,0.00025052327],"domain_scores_gemma":[0.99925375,0.000043688422,0.000063490625,0.00029487052,0.00010932172,0.0002348709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013343027,0.00017217497,0.0002701567,0.00030034364,0.00007385153,0.000115439485,0.00014637962,0.00003928235,0.000084050414],"category_scores_gemma":[0.000029359255,0.00014302226,0.00006461038,0.0007252202,0.000032601045,0.000532042,0.000090659,0.00007824266,0.00011230797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013546379,0.00046213865,0.97920245,0.0006460384,0.00015491903,0.00004366694,0.011627528,0.0000883111,0.000054716842,0.000018312434,0.00047184058,0.00587547],"study_design_scores_gemma":[0.0072842175,0.0007039872,0.981247,0.00077801617,0.00015599733,3.4748606e-7,0.0007087972,0.00010429391,0.00043488498,0.0000035049668,0.008421941,0.00015702141],"about_ca_topic_score_codex":0.003065479,"about_ca_topic_score_gemma":0.025991663,"teacher_disagreement_score":0.022926183,"about_ca_system_score_codex":0.00020428421,"about_ca_system_score_gemma":0.00023096225,"threshold_uncertainty_score":0.9917815},"labels":[],"label_agreement":null},{"id":"W4318619576","doi":"10.9778/cmajo.20210207","title":"Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study","year":2023,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Sanofi; Clinical Science Research and Development; Agency for Healthcare Research and Quality; National Institutes of Health; Pfizer; Centers for Disease Control and Prevention; U.S. Department of Veterans Affairs","keywords":"Medicine; Hazard ratio; Renal function; Retrospective cohort study; Metformin; Kidney disease; Internal medicine; Cohort; Proportional hazards model; Type 2 diabetes; Cohort study; Veterans Affairs; Diabetes mellitus; Confidence interval; Endocrinology; Insulin","score_opus":0.03918766792025844,"score_gpt":0.32047633304464945,"score_spread":0.281288665124391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318619576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716935,0.000004339144,0.000037404654,0.000054149095,0.00063465553,0.008925747,0.000048762002,0.00011408366,0.018487353],"genre_scores_gemma":[0.9945011,0.0000040168275,0.000059047226,0.00018371748,0.0000570873,0.0011574522,0.0010929904,0.00003926183,0.0029052885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792606,0.00019685942,0.00031323347,0.0006294642,0.00063233305,0.0003020426],"domain_scores_gemma":[0.99838334,0.00018864042,0.00021505707,0.0005429987,0.0003646144,0.0003053413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075089576,0.00032389272,0.00091159355,0.00025156286,0.00014973733,0.00005799863,0.0001900698,0.00006694059,0.0002435151],"category_scores_gemma":[0.00022999893,0.00021516072,0.00008284811,0.00095413934,0.00007176538,0.00031813802,0.0002724275,0.00015080554,0.00010876083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04615981,0.0023586135,0.9402313,0.00009625743,0.0033401113,0.000029477756,0.0002806198,0.000016718683,0.000038986567,0.0002206777,0.006664945,0.0005624598],"study_design_scores_gemma":[0.0253662,0.022468558,0.94693536,0.00042528697,0.0019795962,2.708328e-7,0.0004763787,0.000034228473,0.0007694194,0.000051717387,0.0012756009,0.00021741184],"about_ca_topic_score_codex":0.0006150838,"about_ca_topic_score_gemma":0.00014301324,"teacher_disagreement_score":0.022807632,"about_ca_system_score_codex":0.0003927137,"about_ca_system_score_gemma":0.00019699191,"threshold_uncertainty_score":0.8774},"labels":[],"label_agreement":null},{"id":"W4318754175","doi":"10.1111/dom.14997","title":"Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Internal medicine; Hazard ratio; Heart failure; Placebo; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Confidence interval; Meta-analysis; Endocrinology; Pathology","score_opus":0.03912709330418561,"score_gpt":0.3085626076375541,"score_spread":0.2694355143333685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15562585,0.83471096,0.0000014940082,0.000068721725,0.00013793426,0.009156255,0.00018078019,0.000083877305,0.000034128996],"genre_scores_gemma":[0.007471492,0.9853548,0.0011205615,0.0001633846,0.00011946962,0.0026930526,0.0014442377,0.00017835038,0.0014546898],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935504,0.0016759423,0.002180338,0.0010594147,0.0007252513,0.0008086094],"domain_scores_gemma":[0.995227,0.0019223292,0.0015304289,0.00074066786,0.00025217934,0.00032740057],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004543639,0.0011869238,0.029426621,0.0018309148,0.00010713455,0.00011736714,0.0001929315,0.00035007324,0.00011453861],"category_scores_gemma":[0.0007540062,0.00064292795,0.0026414243,0.0018681136,0.00038923434,0.00019059727,0.00017410328,0.00042143808,0.000016794227],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016003715,0.0010423884,0.07152537,0.02214981,0.8763078,0.0000041803005,0.0001589513,0.0000072711427,0.0000023306511,0.00013079247,0.00022308055,0.012444303],"study_design_scores_gemma":[0.18218733,0.0004228067,0.006771306,0.0021108733,0.7508198,1.3115601e-7,0.000012715542,0.00002262235,0.0000060306315,0.000010429557,0.057002854,0.00063306757],"about_ca_topic_score_codex":0.00004255573,"about_ca_topic_score_gemma":0.00013787307,"teacher_disagreement_score":0.16618362,"about_ca_system_score_codex":0.000091362475,"about_ca_system_score_gemma":0.00021699611,"threshold_uncertainty_score":0.9996022},"labels":[],"label_agreement":null},{"id":"W4318755799","doi":"10.1111/dom.15000","title":"Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Faculty of Medicine and Health, University of Sydney; McGill University","keywords":"Metformin; Medicine; Hazard ratio; Type 2 diabetes; Internal medicine; Confidence interval; Cohort; Proportional hazards model; Cohort study; Propensity score matching; Population; Diabetes mellitus; Combination therapy; Relative risk; Lower risk; Endocrinology; Insulin","score_opus":0.007082311232602926,"score_gpt":0.21893171097360017,"score_spread":0.21184939974099726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318755799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556816,0.0019906668,0.0000027533,0.00008855345,0.0001789601,0.0019405452,0.00001819044,0.000085464555,0.00012668139],"genre_scores_gemma":[0.9989496,0.00032629856,0.00011412919,0.00004956473,0.00006512819,0.00016960209,0.00013321584,0.000023698514,0.00016877253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985087,0.00015869946,0.00025280484,0.000341444,0.00039427594,0.0003440625],"domain_scores_gemma":[0.9988619,0.0003276502,0.00017538361,0.00039756572,0.00010584701,0.00013162142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009326629,0.00024141681,0.0007485996,0.00023260029,0.00018456856,0.000040556402,0.000076091346,0.000060446426,0.000020339081],"category_scores_gemma":[0.00022035686,0.00014415881,0.000099052006,0.0008383615,0.0001491457,0.00012490754,0.00009304119,0.00012997487,0.00000777522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022599277,0.00024312975,0.99595076,0.00009521165,0.0014010594,0.000013564433,0.00031300817,0.000038052924,0.0000044465623,0.00016182443,0.00006288632,0.0014900493],"study_design_scores_gemma":[0.009910437,0.00033803895,0.98267794,0.000047679998,0.0047671027,2.5524525e-7,0.000263747,0.0011340713,0.00022740864,0.00009789459,0.000380374,0.00015502886],"about_ca_topic_score_codex":0.00039825487,"about_ca_topic_score_gemma":0.00013842617,"teacher_disagreement_score":0.013272813,"about_ca_system_score_codex":0.000018037248,"about_ca_system_score_gemma":0.00002402981,"threshold_uncertainty_score":0.58786255},"labels":[],"label_agreement":null},{"id":"W4318764485","doi":"10.1016/j.jchf.2022.11.014","title":"Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum","year":2023,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"British Heart Foundation","keywords":"Medicine; Ejection fraction; Heart failure; Dapagliflozin; Cardiology; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.007594884030211336,"score_gpt":0.24676945330388514,"score_spread":0.2391745692736738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318764485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538903,0.000011650754,0.000008581472,0.044669047,0.00009919369,0.00093265984,0.000008702502,0.0001404109,0.00023942694],"genre_scores_gemma":[0.99724746,0.000011717088,0.00036439855,0.00080289494,0.00014328123,0.00006635336,0.00010570421,0.000031253352,0.0012269497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869686,0.00005078272,0.00018255119,0.0003433479,0.00030973068,0.0004167008],"domain_scores_gemma":[0.9994692,0.00004440036,0.000045939716,0.0003083443,0.00004094955,0.00009112189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023927147,0.00019036191,0.00026117818,0.00013909409,0.00015089114,0.00008187835,0.000043987155,0.00009500307,0.00007914876],"category_scores_gemma":[0.000024766625,0.00012338998,0.000052800733,0.00066119846,0.00007356947,0.00022567208,0.000066782595,0.00025480142,0.00029136555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009080734,0.00012396956,0.92686623,0.00005123602,0.000050318253,0.0000052937876,0.0003257049,0.000028098875,0.00009359212,0.000014384309,0.0720193,0.00033103212],"study_design_scores_gemma":[0.001945394,0.00037787657,0.8250254,0.0000895139,0.00004840198,0.0000022388622,0.0013889387,0.0001431522,0.00014306033,0.00004085249,0.17068164,0.00011357533],"about_ca_topic_score_codex":0.00010660615,"about_ca_topic_score_gemma":0.0009599032,"teacher_disagreement_score":0.1018409,"about_ca_system_score_codex":0.000094911455,"about_ca_system_score_gemma":0.000020419779,"threshold_uncertainty_score":0.5031697},"labels":[],"label_agreement":null},{"id":"W4318980736","doi":"10.1016/j.kint.2022.12.028","title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","year":2023,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Novo Nordisk","keywords":"Semaglutide; Post-hoc analysis; Type 2 diabetes; Placebo; Medicine; Diabetes mellitus; Renal function; Internal medicine; Post hoc; Cardiology; Endocrinology; Alternative medicine; Liraglutide; Pathology","score_opus":0.013782836977215046,"score_gpt":0.2479104250524754,"score_spread":0.23412758807526035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318980736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971964,0.0001178386,0.00017471633,0.0007047764,0.000084155996,0.00073543744,0.0005202159,0.00011266856,0.00035382644],"genre_scores_gemma":[0.99051625,0.00010335432,0.00036452495,0.00023000578,0.000035666508,0.00014902609,0.0051687527,0.00002877782,0.0034036164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980668,0.00010260214,0.00028011014,0.00045426094,0.00080906576,0.00028715434],"domain_scores_gemma":[0.99850684,0.00015966798,0.00023765564,0.00037660752,0.00042053236,0.00029867663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044372882,0.00026114867,0.0009342108,0.00080599845,0.00009288123,0.00004968476,0.00009760176,0.00005158416,0.00038436716],"category_scores_gemma":[0.00021735586,0.00016724909,0.00019412706,0.0016503037,0.00011329071,0.0001472103,0.00007204892,0.00007382994,0.000008202009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004637398,0.00014859212,0.9294734,0.00006774059,0.056657203,0.000038596652,0.0009292469,0.00407653,0.00025003531,0.00004386985,0.0035082283,0.00016918119],"study_design_scores_gemma":[0.009704236,0.0013284009,0.9408046,0.00015354798,0.032455184,0.0000029234614,0.0017298905,0.006988711,0.0019117615,0.0000041685503,0.0046296185,0.00028697788],"about_ca_topic_score_codex":0.0008121994,"about_ca_topic_score_gemma":0.00030463585,"teacher_disagreement_score":0.024202017,"about_ca_system_score_codex":0.0001829708,"about_ca_system_score_gemma":0.00011501258,"threshold_uncertainty_score":0.68202204},"labels":[],"label_agreement":null},{"id":"W4319031169","doi":"10.1016/j.ijcard.2023.01.080","title":"Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction","year":2023,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Memorial University of Newfoundland","funders":"","keywords":"Empagliflozin; Dapagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus","score_opus":0.036661414817984336,"score_gpt":0.3444589822618868,"score_spread":0.30779756744390246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319031169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957343,0.00010817021,0.0023108674,0.00069061667,0.00042022284,0.0004804745,0.00001686723,0.000008715414,0.00022978369],"genre_scores_gemma":[0.99858767,0.00018187487,0.0008300064,0.000012593802,0.00024146783,0.000040297466,0.000039079117,0.0000090723615,0.000057917085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993327,0.000068108,0.00024415422,0.00009652358,0.00017531475,0.00008318892],"domain_scores_gemma":[0.99899846,0.00023763055,0.00021125734,0.000067119334,0.0004491504,0.000036382713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002753718,0.000082346,0.00044173043,0.00031198005,0.000012485269,0.000004315377,0.00003766339,0.00004752807,0.0000044083795],"category_scores_gemma":[0.000054618795,0.00005797766,0.00014452264,0.00008531897,0.00005147282,0.00007005064,0.000010731738,0.000029610115,0.0000011224066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0200987,0.0006770036,0.6558727,0.00041017923,0.017571013,0.00019354615,0.00032369266,0.00426967,0.24391283,0.0011219628,0.005618809,0.049929895],"study_design_scores_gemma":[0.019656071,0.014870485,0.7636956,0.00055698096,0.0016212714,0.0005959918,0.00085568667,0.00024952763,0.13688098,0.0007081838,0.06014569,0.00016355552],"about_ca_topic_score_codex":0.0000072184926,"about_ca_topic_score_gemma":0.0000017300292,"teacher_disagreement_score":0.10782288,"about_ca_system_score_codex":0.00013102635,"about_ca_system_score_gemma":0.00004940088,"threshold_uncertainty_score":0.23642604},"labels":[],"label_agreement":null},{"id":"W4319460681","doi":"10.1111/dom.15009","title":"Comparative efficacy of <scp>sodium‐glucose</scp> co‐transporter‐2 inhibitors, <scp>glucagon‐like</scp> peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network <scp>meta‐analysis</scp>","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Mace; Internal medicine; Type 2 diabetes; Kidney disease; Mineralocorticoid receptor; Glucagon-like peptide 1 receptor; Myocardial infarction; Endocrinology; Gastroenterology; Diabetes mellitus; Percutaneous coronary intervention; Receptor","score_opus":0.026744199475365646,"score_gpt":0.28922584845590626,"score_spread":0.2624816489805406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2039371,0.7866764,0.0000022468348,0.000043569995,0.0003680087,0.0078878,0.00087765383,0.00013668906,0.00007050431],"genre_scores_gemma":[0.005005419,0.985443,0.00023497942,0.00059573544,0.00045670252,0.0014572446,0.0045747366,0.00020827597,0.002023918],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99089146,0.0011513577,0.0030428036,0.00220263,0.00089760195,0.0018141476],"domain_scores_gemma":[0.9919747,0.0025056875,0.0020293484,0.0013387491,0.00030504016,0.0018464718],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0020585377,0.0021725437,0.015941761,0.001206752,0.00033987555,0.00032426443,0.00046767632,0.0006296232,0.000017589178],"category_scores_gemma":[0.0010992083,0.0017290729,0.0016832774,0.002635575,0.0008033293,0.0004433304,0.00044618413,0.0009285501,0.00006002992],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010233589,0.0010498605,0.0111769475,0.88092214,0.090001464,0.0000697944,0.0010296279,0.0000041597514,0.00010414675,0.00005773718,0.014061606,0.001512289],"study_design_scores_gemma":[0.0039555402,0.00063002226,0.017845202,0.12475388,0.61734414,0.0000052966157,0.00016296969,0.000089926034,0.0001458903,0.00003536798,0.23447672,0.0005550734],"about_ca_topic_score_codex":0.000045525547,"about_ca_topic_score_gemma":0.000052292766,"teacher_disagreement_score":0.75616825,"about_ca_system_score_codex":0.00020071577,"about_ca_system_score_gemma":0.0005326693,"threshold_uncertainty_score":0.9991015},"labels":[],"label_agreement":null},{"id":"W4319950074","doi":"10.1186/s12916-023-02765-2","title":"Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study","year":2023,"lang":"en","type":"article","venue":"BMC Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; National Research Foundation of Korea; Ministry of Food and Drug Safety; National Research Foundation; McGill University","keywords":"Medicine; Internal medicine; Hazard ratio; Dipeptidyl peptidase-4; Propensity score matching; Type 2 diabetes; Cohort; Population; Cohort study; Adverse effect; Proportional hazards model; Diabetes mellitus; Confidence interval; Endocrinology","score_opus":0.012971287089721527,"score_gpt":0.23995602422587883,"score_spread":0.2269847371361573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319950074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959324,0.000028383132,0.0000012552357,0.00005865886,0.00038556723,0.002864034,0.000014176834,0.00012109748,0.0005944001],"genre_scores_gemma":[0.99818236,0.000007745078,0.000041211548,0.00007182294,0.0001526516,0.00020727751,0.00046955756,0.00005496953,0.0008124228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691725,0.000113626156,0.00065708306,0.000506675,0.0013634558,0.00044193675],"domain_scores_gemma":[0.99840033,0.00019606415,0.00045082078,0.0004096297,0.00036141108,0.00018172935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087924046,0.00033864542,0.00069486885,0.00069082924,0.000059660935,0.0000040245636,0.00009881406,0.0001020754,0.00005966653],"category_scores_gemma":[0.00031713702,0.00023075691,0.00006337131,0.0013725652,0.00011822059,0.00019130464,0.000041720865,0.00019150757,0.000030695875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001400442,0.0010355501,0.9937718,0.00017199523,0.00066862867,0.000036471738,0.0018200208,0.000033096298,0.00004916242,0.0000018382223,0.00086152676,0.0001494847],"study_design_scores_gemma":[0.029158656,0.0052199108,0.96098655,0.00084260013,0.0011827286,3.0430424e-8,0.0019887907,0.000032662952,0.00025888768,0.0000021430826,0.00011633258,0.00021068116],"about_ca_topic_score_codex":0.000101206126,"about_ca_topic_score_gemma":0.0013713375,"teacher_disagreement_score":0.032785207,"about_ca_system_score_codex":0.0003146227,"about_ca_system_score_gemma":0.000113930815,"threshold_uncertainty_score":0.9409993},"labels":[],"label_agreement":null},{"id":"W4319996127","doi":"10.5837/bjc.2023.002","title":"Evaluating initiation and real-world tolerability of dapagliflozin for the management of HFrEF","year":2023,"lang":"en","type":"article","venue":"British Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Dapagliflozin; Tolerability; Medicine; Discontinuation; Heart failure; Ejection fraction; Observational study; Internal medicine; Emergency medicine; Intensive care medicine; Adverse effect","score_opus":0.07378935006361992,"score_gpt":0.3680081705581415,"score_spread":0.2942188204945216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319996127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283165,0.0012285307,0.00047616826,0.00044950904,0.00022250946,0.0005172628,0.000013584736,0.000007602322,0.004253158],"genre_scores_gemma":[0.9951069,0.0030650299,0.0014082529,0.00003395442,0.00012604681,0.000019677722,0.00001078157,0.000006951729,0.00022244979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99913085,0.000077606215,0.00042487393,0.00008546977,0.00016759604,0.00011360234],"domain_scores_gemma":[0.9991592,0.0002481289,0.00025625897,0.0001060316,0.00020228757,0.000028080423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001547449,0.000053545402,0.00039061293,0.000093882525,0.00003414545,0.000005656205,0.00005811915,0.00002514188,0.0000068606782],"category_scores_gemma":[0.00008802673,0.0000438551,0.00014074158,0.000142262,0.00007507353,0.000038696253,0.000047152997,0.000055538454,3.9932124e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051408034,0.00008951636,0.08564228,0.00131448,0.004012861,0.00022108898,0.0001653534,0.0010866201,0.0009576667,0.0019481272,0.0065276665,0.89752024],"study_design_scores_gemma":[0.003054241,0.0008638539,0.9891439,0.0004274434,0.0013913256,0.00010699562,0.00038489842,0.000315038,0.00028407332,0.0015067233,0.002472684,0.000048823316],"about_ca_topic_score_codex":0.000019392257,"about_ca_topic_score_gemma":0.000009460611,"teacher_disagreement_score":0.90350163,"about_ca_system_score_codex":0.000027254313,"about_ca_system_score_gemma":0.000020545322,"threshold_uncertainty_score":0.1788359},"labels":[],"label_agreement":null},{"id":"W4320709102","doi":"10.1111/dom.15019","title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; University of Toronto; Diabetes Canada; Heart and Stroke Foundation of Canada; Department of Medicine, University of Toronto; Sanofi","keywords":"Albuminuria; Medicine; Placebo; Renal function; Internal medicine; Kidney disease; Creatinine; Diabetes mellitus; Type 2 diabetes; Urology; Gastroenterology; Clinical trial; Endocrinology; Pathology","score_opus":0.005905114787099368,"score_gpt":0.21212779298316764,"score_spread":0.20622267819606827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320709102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949997,0.0037587895,3.4828898e-7,0.00017588855,0.00007580632,0.0007367907,0.00008200706,0.000051343406,0.00011930523],"genre_scores_gemma":[0.9974924,0.0014678629,0.00006345489,0.00021917131,0.000035588426,0.000021210546,0.00023671189,0.000021644306,0.00044198762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886024,0.00004199087,0.00020162195,0.0003321845,0.00019741643,0.0003665397],"domain_scores_gemma":[0.99924517,0.00007014192,0.00006954844,0.00021754157,0.00005101609,0.0003466065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019216428,0.00020749141,0.00048349163,0.0002342206,0.000064170956,0.000023173705,0.00004545617,0.00005045158,0.000024262466],"category_scores_gemma":[0.00011237083,0.00016067331,0.000028219467,0.00035915707,0.00016458199,0.00014019296,0.00013496872,0.0000904267,0.000005838306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001842091,0.00032263604,0.9873956,0.00064424606,0.00020380953,0.000004494064,0.00013165819,0.0000027692158,0.00017629692,0.00034999495,0.0001625276,0.0104217455],"study_design_scores_gemma":[0.007822927,0.00029415896,0.983989,0.00025128148,0.000441439,1.3724508e-8,0.000016291298,0.00012261275,0.00036219426,0.00006582868,0.006471812,0.00016244239],"about_ca_topic_score_codex":0.0000076128545,"about_ca_topic_score_gemma":0.0000039164324,"teacher_disagreement_score":0.010259303,"about_ca_system_score_codex":0.000018953087,"about_ca_system_score_gemma":0.00004982738,"threshold_uncertainty_score":0.65520674},"labels":[],"label_agreement":null},{"id":"W4321182840","doi":"10.2337/dc22-1889","title":"Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"NIHR Leicester Biomedical Research Centre; Takeda Pharmaceuticals International; Intarcia Therapeutics; Novo Nordisk; National Institute for Health and Care Research; Gilead Sciences; Maze Therapeutics; Sanofi; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Placebo; Renal function; Albuminuria; Type 2 diabetes; Urology; Internal medicine; Overweight; Creatinine; Diabetes mellitus; Endocrinology; Obesity; Liraglutide","score_opus":0.013539401673993513,"score_gpt":0.24174652378251862,"score_spread":0.22820712210852512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321182840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974195,0.0008594375,0.0000031296868,0.00016353036,0.000076678945,0.001267594,0.00008081217,0.00006863161,0.00006072958],"genre_scores_gemma":[0.99822384,0.00017357571,0.00011620183,0.00058571255,0.000060116137,0.0001906348,0.0003411075,0.00003394442,0.0002748652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851507,0.00021251092,0.00025812542,0.0004152581,0.00030600224,0.00029300633],"domain_scores_gemma":[0.99824,0.0010138608,0.0001588658,0.0003534688,0.000088930814,0.00014489991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032800643,0.0002700947,0.0009867526,0.00027427246,0.0000678665,0.000036173005,0.00006444074,0.000072537296,0.000042329597],"category_scores_gemma":[0.00027066874,0.00012769623,0.0000675438,0.0013505685,0.000085361586,0.000088205816,0.00006047259,0.000102431826,0.000009640867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013709206,0.00012219885,0.9890052,0.0006080763,0.0023978902,0.000016206872,0.0016114966,0.000009113594,0.00038442336,0.000005413515,0.0012446188,0.003224412],"study_design_scores_gemma":[0.005701588,0.0030704257,0.9757585,0.0008492735,0.0066773794,5.731889e-8,0.0024246,0.0003289984,0.0039440943,0.0000075775833,0.001036099,0.00020143516],"about_ca_topic_score_codex":0.00006982083,"about_ca_topic_score_gemma":0.0012466015,"teacher_disagreement_score":0.013246757,"about_ca_system_score_codex":0.000060861912,"about_ca_system_score_gemma":0.00009411237,"threshold_uncertainty_score":0.52073014},"labels":[],"label_agreement":null},{"id":"W4321201232","doi":"10.1016/j.obmed.2023.100483","title":"Tirzepatide, a new class of incretin-based drug for diabetes","year":2023,"lang":"en","type":"article","venue":"Obesity Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; Juvenile Diabetes Research Foundation Canada; Eli Lilly and Company","keywords":"Medicine; Dyslipidemia; Diabetes mellitus; Obesity; Weight loss; Internal medicine; Type 2 diabetes; Pediatrics; Endocrinology","score_opus":0.019972062192976977,"score_gpt":0.27467838282373835,"score_spread":0.2547063206307614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321201232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738989,0.00024261736,0.00016484922,0.018118372,0.0002549273,0.0010783749,0.000013000826,0.00022151346,0.006007459],"genre_scores_gemma":[0.97553813,0.000048112342,0.0011312139,0.0018096986,0.00036285957,0.00007278224,0.0004080509,0.00003272827,0.020596415],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99878436,0.000022796123,0.00029603648,0.0002413605,0.0003343904,0.00032102678],"domain_scores_gemma":[0.9989136,0.0003498916,0.00010941777,0.00033727707,0.00009543339,0.00019437968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004611744,0.00016664254,0.0005291453,0.0002801083,0.00004434102,0.0000033938409,0.00010080942,0.000039306666,0.00024373941],"category_scores_gemma":[0.0003604435,0.00012505997,0.000115715055,0.00047925345,0.00010491752,0.000030351823,0.000040943876,0.0000636862,0.000072683775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001807745,0.00029912425,0.38815752,0.0013238031,0.00034831464,0.00001979372,0.00036415618,0.000013786263,0.0050706146,0.0009719157,0.58878964,0.014460574],"study_design_scores_gemma":[0.03218878,0.0044732727,0.5394224,0.0030466982,0.0033272847,8.426045e-7,0.0005334619,0.012275979,0.057266936,0.002611946,0.34424362,0.0006088001],"about_ca_topic_score_codex":0.000125077,"about_ca_topic_score_gemma":0.00003116568,"teacher_disagreement_score":0.24454603,"about_ca_system_score_codex":0.00004754643,"about_ca_system_score_gemma":0.00008222829,"threshold_uncertainty_score":0.5099798},"labels":[],"label_agreement":null},{"id":"W4321230315","doi":"10.3390/medicina59020388","title":"SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?","year":2023,"lang":"en","type":"review","venue":"Medicina","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Diabetes mellitus; Clinical trial; Stroke (engine); Intensive care medicine; Disease; Adverse effect; Heart failure; Dialysis; Drug class; Drug; Internal medicine; Pharmacology; Endocrinology","score_opus":0.0989961047689478,"score_gpt":0.35007996043591216,"score_spread":0.25108385566696434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321230315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003290755,0.9863489,0.0000019781057,0.0017559895,0.0014119805,0.0031482843,0.000009311176,0.0003302621,0.006960351],"genre_scores_gemma":[0.000014866681,0.9212044,0.000035334837,0.0005859065,0.0014175897,0.00033612136,0.0003174836,0.00013464138,0.07595368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974489,0.00013340138,0.00069719396,0.0005413423,0.00063695596,0.0005421957],"domain_scores_gemma":[0.99813,0.00036946865,0.0002694424,0.0009743873,0.00005554584,0.0002011552],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055822014,0.0005868764,0.0018932056,0.00032520745,0.00011390768,0.0000488185,0.00031022725,0.00021491181,0.00032861304],"category_scores_gemma":[0.00017242882,0.0002920392,0.00061672664,0.00070744654,0.00016309282,0.000049200687,0.00023945807,0.00056219916,0.0036103358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041613134,0.000079592195,0.000006307223,0.012397115,0.0008680078,0.00019083299,0.00026728283,6.622435e-8,1.0626916e-7,0.000012049413,0.19854544,0.787629],"study_design_scores_gemma":[0.0008515842,0.00012668825,0.000011028357,0.029612385,0.007018361,0.0000184374,0.00031070603,0.000012980524,0.0000010499188,0.000009939729,0.9617887,0.00023811794],"about_ca_topic_score_codex":0.000049235725,"about_ca_topic_score_gemma":0.000019397927,"teacher_disagreement_score":0.7873909,"about_ca_system_score_codex":0.00020469133,"about_ca_system_score_gemma":0.00015366412,"threshold_uncertainty_score":0.99995315},"labels":[],"label_agreement":null},{"id":"W4321374183","doi":"10.1161/circulationaha.122.063716","title":"Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Medical Research Council; National Institutes of Health; Impulse Dynamics; National Medical Research Council; Cytokinetics; Amarin Corporation; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; McMaster University; Amgen; Pfizer; Novo Nordisk; ReCor Medical; Intarcia Therapeutics; Daiichi Sankyo Europe; Kowa Company; Sanofi; Abbott Laboratories","keywords":"Medicine; Mace; Hazard ratio; Internal medicine; Placebo; Myocardial infarction; Renal function; Diabetes mellitus; Cardiology; Type 2 diabetes; Stroke (engine); Angina; Percutaneous coronary intervention; Endocrinology; Confidence interval","score_opus":0.16998934597801585,"score_gpt":0.29662474448661796,"score_spread":0.12663539850860211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321374183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702054,0.00062548026,0.000014748464,0.00086523575,0.00026266926,0.00093330414,0.0000020793295,0.00007034676,0.00020559506],"genre_scores_gemma":[0.99931395,0.00005755394,0.0000149214175,0.00007225371,0.00020413827,0.00014535362,0.0001438687,0.0000137568095,0.00003418577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911046,0.00010450197,0.00019377729,0.00019521799,0.00026144367,0.0001345794],"domain_scores_gemma":[0.9984709,0.0010654418,0.000034840083,0.00037637958,0.000022160708,0.000030277966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033325993,0.00009850722,0.00022456159,0.00010016468,0.00012253228,0.00004136987,0.000058644786,0.0000331296,0.0000033795905],"category_scores_gemma":[0.00041823508,0.00005665676,0.00009866678,0.00043501228,0.00003062644,0.00015179225,0.000045672336,0.000102946906,0.0000481407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005417302,0.000015579797,0.98965997,0.0000106414645,0.00031759712,0.0000025545612,0.00079843804,0.00012771152,0.000009274353,0.00052644,0.0000333332,0.008444291],"study_design_scores_gemma":[0.005893936,0.000028554383,0.99018985,0.00004785032,0.00032707897,3.4264957e-8,0.00019098465,0.00014170478,0.000005801801,0.0023571213,0.00075541675,0.000061662504],"about_ca_topic_score_codex":0.00007063084,"about_ca_topic_score_gemma":0.000017195247,"teacher_disagreement_score":0.008382628,"about_ca_system_score_codex":0.000049387854,"about_ca_system_score_gemma":0.000013260193,"threshold_uncertainty_score":0.23103957},"labels":[],"label_agreement":null},{"id":"W4321444920","doi":"10.1172/jci.insight.164296","title":"Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition","year":2023,"lang":"en","type":"article","venue":"JCI Insight","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Novo Nordisk; European Foundation for the Study of Diabetes; Foundation for the National Institutes of Health; Hebrew University of Jerusalem; U.S. Department of Veterans Affairs; Israel Science Foundation","keywords":"Renal glucose reabsorption; Internal medicine; Endocrinology; Dapagliflozin; Diabetes mellitus; AMPK; Medicine; mTORC1; Kidney; Chemistry; Type 2 diabetes; PI3K/AKT/mTOR pathway; Biochemistry; Signal transduction; Protein kinase A","score_opus":0.03850091187473373,"score_gpt":0.257476227262374,"score_spread":0.21897531538764028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321444920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981163,0.00094695133,0.000048780912,0.0037765123,0.00024057596,0.00072835834,0.0000040382406,0.0003606941,0.01273106],"genre_scores_gemma":[0.9937521,0.00035194188,0.000083669314,0.0013453731,0.00016151842,0.00017248318,0.000317339,0.000027964183,0.0037875879],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989235,0.0000260829,0.00022233087,0.00027084028,0.00025606013,0.0003012167],"domain_scores_gemma":[0.99944717,0.000027977674,0.0000610815,0.00035371014,0.000035254558,0.000074794916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020449131,0.00014941412,0.00021539522,0.00015737202,0.00012599598,0.000043723634,0.000058195554,0.0000620879,0.0000831235],"category_scores_gemma":[0.000016141577,0.00009689499,0.0001101444,0.0006449551,0.000034505556,0.000109185785,0.000038531238,0.00013161045,0.0003726055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001340972,0.0010775351,0.013203006,0.0002854763,0.0014595054,0.00049900054,0.0108014215,0.0000028516813,0.3047206,0.0043398645,0.09096782,0.5725088],"study_design_scores_gemma":[0.0016144417,0.0001306838,0.03295037,0.000088892564,0.00023919698,0.0000026005862,0.00053725764,0.000069766385,0.059594143,0.00016907671,0.9044392,0.00016436006],"about_ca_topic_score_codex":0.000035630896,"about_ca_topic_score_gemma":0.0000088053075,"teacher_disagreement_score":0.8134714,"about_ca_system_score_codex":0.000029232564,"about_ca_system_score_gemma":0.000016571976,"threshold_uncertainty_score":0.4789214},"labels":[],"label_agreement":null},{"id":"W4321769000","doi":"10.1016/j.ejphar.2023.175626","title":"Analysis of the cardiac effects of sodium-glucose co-transporter 2 inhibitors in animals without diabetes and a clinical perspective","year":2023,"lang":"en","type":"review","venue":"European Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Pharmacology; Sodium-calcium exchanger; Calcium; Calcium in biology; Glucose transporter; Population; Medicine; Internal medicine; Endocrinology; Chemistry; Insulin","score_opus":0.03476260018374964,"score_gpt":0.38777877528187277,"score_spread":0.3530161750981231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321769000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19671878,0.8011077,7.523454e-7,0.00007512281,0.00072537793,0.0008906242,0.000025696734,0.000007182007,0.00044878936],"genre_scores_gemma":[0.09551656,0.90394545,0.00002412678,0.0000663225,0.00029627144,0.0000065608488,0.0000070003266,0.00005117703,0.0000865432],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99561507,0.0020645957,0.0015703359,0.00026069622,0.00025650888,0.00023280326],"domain_scores_gemma":[0.99727416,0.0007037726,0.0015759651,0.00017493541,0.00015736073,0.000113782386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021478182,0.00029085408,0.0034500696,0.0009331291,0.00001861839,0.0000057292937,0.00022652121,0.00007413663,0.000025510504],"category_scores_gemma":[0.0001320842,0.00017462284,0.0016955246,0.0008397552,0.0002871834,0.000034325472,0.000096475116,0.00055447774,0.0000053546473],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054419093,0.0023551402,0.30253318,0.032761693,0.16999729,0.0024568865,0.0018465514,0.000005424264,0.00097495783,0.000044314867,0.0052423812,0.48123798],"study_design_scores_gemma":[0.010869076,0.005720375,0.28950003,0.02187855,0.42939973,0.000014052412,0.00029248255,0.000017299522,0.0011536565,0.000009003218,0.24057122,0.0005745361],"about_ca_topic_score_codex":0.0000025107183,"about_ca_topic_score_gemma":0.0000016419792,"teacher_disagreement_score":0.48066345,"about_ca_system_score_codex":0.000096465235,"about_ca_system_score_gemma":0.0001320299,"threshold_uncertainty_score":0.71209127},"labels":[],"label_agreement":null},{"id":"W4322012331","doi":"10.14740/cr1459","title":"Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes","year":2023,"lang":"en","type":"review","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Internal medicine; Type 2 diabetes; Glucagon-like peptide-1; Endocrinology; Atherosclerotic cardiovascular disease; Diabetes mellitus; Glucagon-like peptide 1 receptor; Cardiology; Disease; Receptor; Agonist","score_opus":0.10788993664725911,"score_gpt":0.3552464441656118,"score_spread":0.2473565075183527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322012331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035057094,0.9533412,0.000002204595,0.00003586565,0.0015110536,0.009398222,0.0002439751,0.00013296277,0.00027744946],"genre_scores_gemma":[0.0024451192,0.98548746,0.000058736314,0.000017862281,0.000638689,0.0037133882,0.0056195157,0.00028663222,0.0017325844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99512434,0.000616325,0.0006319168,0.0012690846,0.00092689664,0.0014314239],"domain_scores_gemma":[0.9969052,0.0006441459,0.00010907959,0.0014064704,0.00048325653,0.00045184686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015967874,0.0006508951,0.0035776717,0.00084540376,0.00016141126,0.000045876313,0.00037377918,0.00044367986,0.000023263705],"category_scores_gemma":[0.00033837158,0.0004786855,0.0014248308,0.0011267948,0.0004615437,0.000073728064,0.00019983086,0.0007770328,0.00046134656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055481,0.0011225601,0.098916344,0.08395935,0.05769936,0.00075328967,0.00015818352,0.00007347245,0.0000017178355,0.00006000525,0.031040223,0.7206674],"study_design_scores_gemma":[0.0062397793,0.0019910985,0.007154172,0.0072958604,0.0060420185,2.9714877e-7,0.000021360003,0.0000027847318,0.000001473694,0.0000083082805,0.97075444,0.0004884074],"about_ca_topic_score_codex":0.000015022294,"about_ca_topic_score_gemma":0.0000053352687,"teacher_disagreement_score":0.9397142,"about_ca_system_score_codex":0.00069430796,"about_ca_system_score_gemma":0.00061990856,"threshold_uncertainty_score":0.99976647},"labels":[],"label_agreement":null},{"id":"W4322720273","doi":"10.1001/jamacardio.2023.0019","title":"Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes","year":2023,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Mace; Dapagliflozin; Internal medicine; Hazard ratio; Myocardial infarction; Cardiology; Type 2 diabetes; Copeptin; TIMI; Natriuretic peptide; Diabetes mellitus; Stroke (engine); Heart failure; Kidney disease; Confidence interval; Percutaneous coronary intervention; Endocrinology","score_opus":0.0038732936639413137,"score_gpt":0.1907802720890141,"score_spread":0.18690697842507278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322720273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724656,0.00017059967,0.0000055847277,0.0001881181,0.00021854129,0.0009072557,0.00007735348,0.00007046484,0.0011155347],"genre_scores_gemma":[0.99858624,0.00013625318,0.00014523826,0.00003553215,0.000084761814,0.00016115444,0.00047686402,0.00003082414,0.00034313602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983115,0.0002510192,0.00023330252,0.000345201,0.00043958216,0.00041936326],"domain_scores_gemma":[0.99909604,0.00012563448,0.00015865464,0.00040794708,0.0001425377,0.000069197085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065079756,0.00019043902,0.0008829399,0.00032169741,0.00003119392,0.0000028052723,0.00006959776,0.00014627253,0.0000067938154],"category_scores_gemma":[0.00011277296,0.0001379739,0.00029068222,0.00060910836,0.00004721243,0.00008679552,0.00006042225,0.00012088604,0.000040417763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023823284,0.000060270675,0.9787046,0.00007885842,0.012120694,0.00002190737,0.000042360047,0.0003567484,0.000013396087,0.000010076379,0.0013881358,0.006964767],"study_design_scores_gemma":[0.0070256684,0.0007107408,0.98532796,0.00007882153,0.002354362,1.5888185e-7,0.000086885455,0.00001204717,0.000100420366,0.000020596439,0.004142803,0.00013952522],"about_ca_topic_score_codex":0.00016492482,"about_ca_topic_score_gemma":0.000021227768,"teacher_disagreement_score":0.009766332,"about_ca_system_score_codex":0.00024896843,"about_ca_system_score_gemma":0.00003509508,"threshold_uncertainty_score":0.56264126},"labels":[],"label_agreement":null},{"id":"W4323033037","doi":"10.1016/s0735-1097(23)02484-1","title":"EMPAGLIFLOZIN REDUCED CIRCULATING PRO-INFLAMMATORY PRECURSOR CELL CONTENT IN PEOPLE WITHOUT DIABETES: A SUBSTUDY OF THE EMPA-HEART 2 CARDIOLINK 6 TRIAL","year":2023,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; EMPA; Diabetes mellitus; Benzhydryl compounds; Internal medicine; Type 2 diabetes; Cardiology; Endocrinology","score_opus":0.02745678516738801,"score_gpt":0.27278680022795854,"score_spread":0.24533001506057053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323033037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952188,0.00019930331,0.0000015361436,0.001355898,0.00074013043,0.0016586498,0.000020951615,0.000012382476,0.0007923288],"genre_scores_gemma":[0.9988941,0.000048753154,0.000067822235,0.000113857066,0.00030093166,0.00005006091,0.0000011739809,0.00002692202,0.0004963907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973177,0.0006912296,0.0009532228,0.0001912909,0.00048996985,0.0003566371],"domain_scores_gemma":[0.9976169,0.00028367355,0.0012500412,0.0005305776,0.00023870965,0.00008009879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013297888,0.00019862998,0.0017041878,0.00027014315,0.000056117042,0.0000038478115,0.0003544341,0.000057926492,0.0000028915083],"category_scores_gemma":[0.0004121048,0.00011413624,0.0008892423,0.0008755175,0.00032040858,0.000039617833,0.00018504134,0.00029912803,0.0000022403945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004247823,0.00015390574,0.967465,0.00013583884,0.0013764094,0.000053584972,0.000491038,0.0012058356,0.02096727,0.000013397075,0.0036629185,0.00022698173],"study_design_scores_gemma":[0.020338131,0.002329847,0.9652755,0.00031370835,0.0010643273,0.00005006987,0.0031297402,0.00011487339,0.00625562,0.000038233982,0.0009528937,0.0001370572],"about_ca_topic_score_codex":0.000019012909,"about_ca_topic_score_gemma":0.000014234634,"teacher_disagreement_score":0.01609031,"about_ca_system_score_codex":0.0001695845,"about_ca_system_score_gemma":0.00035003526,"threshold_uncertainty_score":0.46543407},"labels":[],"label_agreement":null},{"id":"W4323036455","doi":"10.1016/s2213-8587(23)00009-8","title":"Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Eisai; Janssen Pharmaceuticals; Hebrew University of Jerusalem; University of Liverpool; IFM Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Alnylam Pharmaceuticals; Brigham and Women's Hospital; Novo Nordisk; Daiichi-Sankyo; Zora Biosciences; Intarcia Therapeutics; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Dapagliflozin; Type 2 diabetes; Diabetes mellitus; Post-hoc analysis; Internal medicine; TIMI; Placebo; Population; Hazard ratio; Disease; Endocrinology; Myocardial infarction; Confidence interval; Pathology; Environmental health","score_opus":0.030754293599564886,"score_gpt":0.3036016177759771,"score_spread":0.2728473241764122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323036455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353594,0.00056779524,3.830419e-7,0.0030499655,0.0003241873,0.0013610335,0.000018091856,0.000077262746,0.0010653717],"genre_scores_gemma":[0.99819374,0.00024172463,0.00004763348,0.0007819901,0.000120877936,0.00022072825,0.000056694033,0.00002653466,0.00031010516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820143,0.00020090424,0.00031356115,0.0002581773,0.0002603235,0.00076562725],"domain_scores_gemma":[0.99814606,0.0008419753,0.00018456233,0.0007000981,0.000088457906,0.000038852446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022160042,0.00020949933,0.0007880982,0.00025659087,0.000056895766,0.000008473714,0.00033791002,0.000055141947,0.000032836786],"category_scores_gemma":[0.000313863,0.000110131725,0.00013499623,0.0010658458,0.00022302166,0.00004281118,0.0001532854,0.00018530936,0.00003140951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007214636,0.0015931528,0.9344181,0.0009954514,0.0032486208,0.00004061987,0.0012178727,0.00059937313,0.030745704,0.0043419106,0.006940599,0.008644003],"study_design_scores_gemma":[0.03094509,0.0072179204,0.8812958,0.0003727921,0.0012442988,5.177224e-7,0.00022263952,0.0001775918,0.07644244,0.0004159682,0.00145748,0.0002074303],"about_ca_topic_score_codex":0.000045785426,"about_ca_topic_score_gemma":0.00010793675,"teacher_disagreement_score":0.05312223,"about_ca_system_score_codex":0.00004513197,"about_ca_system_score_gemma":0.00005783113,"threshold_uncertainty_score":0.44910416},"labels":[],"label_agreement":null},{"id":"W4323309098","doi":"10.1053/j.ajkd.2022.12.015","title":"Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial","year":2023,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; University of British Columbia","funders":"Sydney Medical School; Medical Research Council; School of Medicine, Indiana University; School of Medicine, Stanford University; George Institute for Global Health; National Health and Medical Research Council; Peking University; York University; Universitair Medisch Centrum Groningen; Brigham and Women's Hospital; University College London; University of Toronto; Janssen Research and Development; Rijksuniversiteit Groningen; University of New South Wales; Peking University First Hospital; NYU Langone Medical Center; University of Chicago Medicine; Imperial College London","keywords":"Medicine; Canagliflozin; Kidney disease; Internal medicine; Creatinine; Placebo; Renal function; Population; Randomized controlled trial; Diabetes mellitus; Endocrinology; Type 2 diabetes; Pathology","score_opus":0.012288246833782093,"score_gpt":0.3022892696714148,"score_spread":0.2900010228376327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323309098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964834,0.0010112469,0.000079961996,0.0013499968,0.0001972012,0.0007642452,0.000049581373,0.0000097458,0.00005460955],"genre_scores_gemma":[0.99696624,0.0011868388,0.00019429713,0.0014427513,0.00010375604,0.000017696213,0.000010033309,0.000012780619,0.000065592685],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99790657,0.00055199454,0.0006797998,0.00019690827,0.00048443748,0.00018029261],"domain_scores_gemma":[0.99691373,0.0011034182,0.0004888338,0.00032625307,0.000119538534,0.0010482004],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011181891,0.00015094585,0.0019738546,0.0004758571,0.00004183693,0.000019525312,0.0001383124,0.00002078637,0.0000065156646],"category_scores_gemma":[0.010835312,0.000091492104,0.0013258499,0.0011670516,0.00046583352,0.000056747806,0.0001302203,0.000084271545,3.817066e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33181185,0.0010626387,0.33215678,0.00086550077,0.108110264,0.00091452495,0.0012665187,0.00011703157,0.00049446453,0.0000712661,0.0103534395,0.2127757],"study_design_scores_gemma":[0.58004045,0.008574444,0.2478268,0.0016058652,0.1552139,0.000012782069,0.0035886208,0.00037907623,0.00028965113,0.00007899968,0.002013467,0.00037592318],"about_ca_topic_score_codex":0.00025837342,"about_ca_topic_score_gemma":0.0000031117863,"teacher_disagreement_score":0.24822861,"about_ca_system_score_codex":0.000022002545,"about_ca_system_score_gemma":0.00030908096,"threshold_uncertainty_score":0.99749684},"labels":[],"label_agreement":null},{"id":"W4323363011","doi":"10.1016/j.cjca.2023.03.001","title":"Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?","year":2023,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Boehringer Ingelheim","keywords":"Medicine; Ejection fraction; Heart failure; Medical therapy; Cardiology; Heart failure with preserved ejection fraction; Internal medicine; Benzhydryl compounds","score_opus":0.02140189878953966,"score_gpt":0.2549290315748952,"score_spread":0.23352713278535556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323363011","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070233695,0.0002393045,0.00003967858,0.9915135,0.0016571919,0.00079318945,0.0002940802,0.000015807993,0.0047449158],"genre_scores_gemma":[0.0012220653,0.000024431174,0.00083600596,0.88335544,0.025321845,0.000073818264,0.00033953364,0.00013855057,0.08868831],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981297,0.00007422201,0.0005196314,0.00030112354,0.00020442544,0.00077088666],"domain_scores_gemma":[0.99821204,0.00014729988,0.00017602423,0.00036260337,0.00033296784,0.00076907245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038002752,0.00030298028,0.0012479235,0.00094137405,0.00007256119,0.000039344803,0.00020640172,0.0005538091,0.00027312216],"category_scores_gemma":[0.00020672617,0.00026593445,0.00073932996,0.00017666403,0.000086230146,0.000043006723,0.000024784333,0.00072083046,0.001595099],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030752308,9.332312e-7,0.00022465627,0.0001134946,0.0011568343,0.0016383891,0.00005839465,0.000015396032,0.000032679436,0.0000040262366,0.9961038,0.0006206173],"study_design_scores_gemma":[0.0011054882,0.0010711214,0.00038979526,0.00033362393,0.00084919576,0.00021784334,0.000025141597,0.0000012282565,0.00003537061,0.00011492411,0.99564505,0.00021125113],"about_ca_topic_score_codex":0.00017757464,"about_ca_topic_score_gemma":0.00021385668,"teacher_disagreement_score":0.10815805,"about_ca_system_score_codex":0.000445665,"about_ca_system_score_gemma":0.0011930133,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W4323363471","doi":"10.47391/jpma.7558","title":"Semaglutide: new dawn for diabetics","year":2023,"lang":"en","type":"letter","venue":"Journal of the Pakistan Medical Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Dulaglutide; Sitagliptin; Type 2 diabetes; Weight loss; Diabetes mellitus; Metformin; Internal medicine; Blood pressure; Insulin; Pharmacology; Liraglutide; Endocrinology; Obesity","score_opus":0.018215346567285677,"score_gpt":0.3046712336726688,"score_spread":0.2864558871053831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323363471","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095413264,0.0002273349,0.0002518405,0.9935189,0.0037189592,0.0005328658,0.000025478936,0.00004612764,0.0007243651],"genre_scores_gemma":[0.0007067945,0.00031964807,0.00083128153,0.7038729,0.028128738,0.000019821824,0.000086720414,0.0001600141,0.2658741],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959299,0.00010554355,0.00090922584,0.00014538241,0.0025314132,0.00037855803],"domain_scores_gemma":[0.99652594,0.0013206885,0.0013943288,0.00023571061,0.00034482178,0.00017851709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001870233,0.00020438831,0.0006519521,0.000104797036,0.0000770644,0.000059396705,0.00033611525,0.00076878374,0.00015905662],"category_scores_gemma":[0.004502415,0.00012395896,0.00069248356,0.00021858279,0.000027851427,0.000032868214,0.00007903192,0.001518053,0.000068531815],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020746245,0.00005389752,0.0026833876,0.00020152715,0.0011478936,0.00011506321,0.000059608905,7.2165983e-7,0.0000041511184,0.000029772158,0.9900706,0.0056126234],"study_design_scores_gemma":[0.0020420747,0.00027303086,0.0031630937,0.0007638889,0.0019664716,0.000008661579,0.000023190136,0.00003888459,0.000023452254,0.0017208135,0.98986554,0.00011092035],"about_ca_topic_score_codex":0.000007644646,"about_ca_topic_score_gemma":0.000008974179,"teacher_disagreement_score":0.289646,"about_ca_system_score_codex":0.0012363559,"about_ca_system_score_gemma":0.0006771903,"threshold_uncertainty_score":0.65952694},"labels":[],"label_agreement":null},{"id":"W4323656511","doi":"10.1186/s12933-023-01781-z","title":"The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Temerty Faculty of Medicine, University of Toronto; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; University of Toronto","keywords":"Exenatide; Medicine; Insulin glargine; Internal medicine; Insulin lispro; Type 2 diabetes; Endocrinology; Lixisenatide; Insulin; Diabetes mellitus; Context (archaeology)","score_opus":0.013420238613929351,"score_gpt":0.23732239073634445,"score_spread":0.2239021521224151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323656511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818025,0.014921242,0.00005409537,0.0002749173,0.00094931974,0.0015355689,0.0000025245026,0.0001344433,0.0003253935],"genre_scores_gemma":[0.9941808,0.0045212135,0.00013454867,0.00031305483,0.00015373545,0.00037599917,0.000049132745,0.00005781436,0.00021373096],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99767035,0.00033388575,0.0003930124,0.00047300078,0.000471161,0.00065855985],"domain_scores_gemma":[0.9982981,0.0005226117,0.00006792337,0.0008288745,0.00014722368,0.00013525797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011119293,0.00027300356,0.00095820863,0.00046165887,0.00009746762,0.00002330701,0.00020321112,0.00016300051,0.000014811123],"category_scores_gemma":[0.0006165154,0.00018300756,0.0005816513,0.0015537159,0.00010249404,0.00007567693,0.00014461853,0.00019292097,0.00017901145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00104165,0.00042028926,0.14991178,0.00065416755,0.017579608,0.00035718564,0.0010666723,0.00089545205,0.004121093,0.0006008952,0.0029423651,0.8204088],"study_design_scores_gemma":[0.007999434,0.0027791148,0.8990924,0.00026297267,0.0011343047,0.0000013252223,0.00015246657,0.00022870897,0.010797141,0.00031502658,0.07687895,0.00035815645],"about_ca_topic_score_codex":0.00004428688,"about_ca_topic_score_gemma":0.000020450885,"teacher_disagreement_score":0.82005066,"about_ca_system_score_codex":0.00009863358,"about_ca_system_score_gemma":0.00007118989,"threshold_uncertainty_score":0.7462832},"labels":[],"label_agreement":null},{"id":"W4324020330","doi":"10.1111/bcp.15711","title":"Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis","year":2023,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; University of Ottawa","funders":"","keywords":"Rhabdomyolysis; Adverse Event Reporting System; Medicine; Statin; Concomitant; Rosuvastatin; Odds ratio; Canagliflozin; Pharmacology; Pharmacovigilance; Internal medicine; Empagliflozin; Dapagliflozin; Adverse effect; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.07101601216909692,"score_gpt":0.41080463234705816,"score_spread":0.33978862017796124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324020330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976813,0.0005461084,0.00006977463,0.0009956931,0.00022831596,0.00034424558,0.00007318635,0.000008535403,0.00005284571],"genre_scores_gemma":[0.9908129,0.008270043,0.00027318735,0.0003822019,0.00013864621,0.0000053810963,0.000018452169,0.000007932144,0.00009127953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957105,0.00044920755,0.0031866464,0.0001815927,0.00031228518,0.00015977492],"domain_scores_gemma":[0.9937941,0.0015948022,0.0040410478,0.000098031385,0.0002990402,0.0001730133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005353187,0.000100886726,0.0012533086,0.00013921157,0.000051209463,0.00001348116,0.0000600895,0.00007694684,0.000093408315],"category_scores_gemma":[0.0018946336,0.00007266779,0.00052197435,0.00029940635,0.000887272,0.000099152465,0.000046502828,0.00035171118,4.5794383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018200146,0.0006428714,0.96829593,0.00010475911,0.006859383,0.00086755544,0.00009584707,0.000030403837,0.0004059798,0.000026848358,0.004709733,0.016140679],"study_design_scores_gemma":[0.009081943,0.0005217288,0.9772656,0.00007093122,0.009983133,0.00006871716,0.00008076096,0.00047458606,0.0010438538,0.0002651357,0.0010832482,0.00006038787],"about_ca_topic_score_codex":0.00015008207,"about_ca_topic_score_gemma":0.000045223194,"teacher_disagreement_score":0.016080292,"about_ca_system_score_codex":0.000010649942,"about_ca_system_score_gemma":0.000086897555,"threshold_uncertainty_score":0.32691908},"labels":[],"label_agreement":null},{"id":"W4327585971","doi":"10.1186/s12933-023-01788-6","title":"CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes","year":2023,"lang":"en","type":"letter","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital","funders":"","keywords":"Medicine; Angiology; Summit; Glycemic; Diabetes mellitus; Internal medicine; Cardiology; Intensive care medicine; Endocrinology","score_opus":0.019525568531533477,"score_gpt":0.24211078229654015,"score_spread":0.22258521376500667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327585971","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009982833,0.21455596,0.0009143802,0.73467785,0.014081634,0.007405,0.0002841231,0.0025174601,0.0155807715],"genre_scores_gemma":[0.0026661567,0.022868589,0.0014118786,0.71766454,0.019616518,0.0020447893,0.019558264,0.0018348306,0.21233441],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932286,0.00036679747,0.0009451904,0.0022933136,0.001588308,0.0015777923],"domain_scores_gemma":[0.99426043,0.0002207472,0.00025174304,0.004434585,0.00018875407,0.0006437208],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00097173563,0.0012294813,0.005404326,0.0008718401,0.00016309982,0.0000966295,0.00043553454,0.0018128472,0.00016819836],"category_scores_gemma":[0.00074039557,0.0011016446,0.006966501,0.0005958028,0.00034429494,0.000113672344,0.00066325755,0.0019181274,0.0007601113],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027966147,0.00003354411,0.008789579,0.0009183311,0.08410009,0.040818036,0.000028089,0.00001148369,0.000002126875,0.000018555653,0.8384173,0.02683488],"study_design_scores_gemma":[0.0050781933,0.00020247893,0.0036217296,0.0002122962,0.02789426,0.00074733683,0.00002166972,0.000007658562,0.000025288036,0.00024179801,0.9610502,0.0008970558],"about_ca_topic_score_codex":0.0003730298,"about_ca_topic_score_gemma":0.000009894304,"teacher_disagreement_score":0.19675364,"about_ca_system_score_codex":0.00033357326,"about_ca_system_score_gemma":0.00047725797,"threshold_uncertainty_score":0.999483},"labels":[],"label_agreement":null},{"id":"W4327742216","doi":"10.1038/s41591-023-02302-x","title":"Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","year":2023,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Université de Montréal; St. Boniface Hospital; Montreal Heart Institute","funders":"","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Medicine; Cardiology; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.014282662668998601,"score_gpt":0.28944506738647674,"score_spread":0.27516240471747816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327742216","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.097940914,0.016985228,0.00046953766,0.1728302,0.5355194,0.033759378,0.0002679297,0.0017679917,0.14045939],"genre_scores_gemma":[0.08868363,0.00031659333,0.0002025099,0.0014460494,0.009427647,0.00035126257,0.002256742,0.00015423533,0.8971613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970647,0.00014813535,0.00065326877,0.0006875044,0.0011109017,0.0003355035],"domain_scores_gemma":[0.9979437,0.00020255217,0.0005025049,0.0009146784,0.00032498362,0.00011156931],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005773248,0.00045624797,0.0015828033,0.001599141,0.00008730111,0.000015447498,0.0001977154,0.0011603398,0.00054891483],"category_scores_gemma":[0.0005080799,0.00025350516,0.0003992223,0.004864939,0.00016517167,0.00007143362,0.000076479635,0.0027696094,0.00001157184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008597837,0.00025561682,0.0018067943,0.00017662595,0.0042228987,0.000026635691,0.00013037988,0.000018699775,0.0000906899,0.0000150201095,0.9835358,0.0011229817],"study_design_scores_gemma":[0.029451162,0.002427686,0.05034061,0.0016731569,0.01842242,0.0000062760187,0.0006570887,0.0014407883,0.00013035107,0.000011249949,0.89516526,0.00027392321],"about_ca_topic_score_codex":0.0003943954,"about_ca_topic_score_gemma":0.0035620797,"teacher_disagreement_score":0.75670195,"about_ca_system_score_codex":0.00043479854,"about_ca_system_score_gemma":0.0002205229,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W4327861557","doi":"10.1186/s12933-023-01773-z","title":"Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials","year":2023,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Meta-analysis; Angiology; Meta-regression; Heart failure; Randomized controlled trial; Internal medicine; Outcome (game theory); Physical therapy; Intensive care medicine","score_opus":0.16484879037177336,"score_gpt":0.3841381822756808,"score_spread":0.21928939190390745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327861557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006018356,0.9860015,0.00045368285,0.000078614896,0.00016647656,0.006581446,0.00049791957,0.00017137585,0.000030648323],"genre_scores_gemma":[0.009841177,0.9842541,0.0010017303,0.0000719036,0.000070281116,0.0014679922,0.0029087553,0.00024182226,0.00014220832],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9787664,0.011317823,0.004381013,0.002560482,0.0020886988,0.0008855942],"domain_scores_gemma":[0.98857594,0.003109546,0.0015278154,0.0059466823,0.00041192968,0.0004281092],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.017449027,0.002176979,0.11813004,0.005973126,0.00014579252,0.00006893732,0.0005367045,0.001163857,0.00019198682],"category_scores_gemma":[0.0012584814,0.0011804929,0.18778796,0.0050096735,0.0008816879,0.00015232024,0.0004017013,0.0006239588,0.000012028671],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008261931,0.00025904216,0.0004174305,0.004905458,0.9601676,0.00010202266,0.00007708034,0.0007399416,8.996518e-7,0.000064391694,0.000035564848,0.032404386],"study_design_scores_gemma":[0.029708123,0.00019056922,0.0005166965,0.00014111078,0.86909723,0.000013272871,0.00004804565,0.000034078945,0.000011185458,0.000011907852,0.09950099,0.00072677585],"about_ca_topic_score_codex":0.00034199387,"about_ca_topic_score_gemma":0.000018820063,"teacher_disagreement_score":0.09946543,"about_ca_system_score_codex":0.00010276083,"about_ca_system_score_gemma":0.000120305485,"threshold_uncertainty_score":0.99909705},"labels":[],"label_agreement":null},{"id":"W4328048371","doi":"10.1111/dom.15057","title":"Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the <scp>CANVAS</scp> programme and <scp>CREDENCE</scp>","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; University of Manitoba; NOSM University; McGill University Health Centre","funders":"Janssen Canada; Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Medicine; Empagliflozin; Internal medicine; Type 2 diabetes; Nephropathy; Type 2 Diabetes Mellitus; Diabetes mellitus; Diabetic nephropathy; Creatinine; Post-hoc analysis; Kidney disease; Endocrinology","score_opus":0.031398394816738076,"score_gpt":0.2413543484380646,"score_spread":0.20995595362132652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328048371","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9039095,0.058147036,0.00000821559,0.03091393,0.0008578248,0.0033798069,0.002292193,0.0003065059,0.0001849771],"genre_scores_gemma":[0.097453706,0.073150806,0.008816058,0.6832999,0.015503477,0.0038424607,0.069209315,0.0017238109,0.04700046],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450684,0.00033089277,0.00053781446,0.0020018215,0.00096634985,0.0016562879],"domain_scores_gemma":[0.99465597,0.0018111342,0.00024442354,0.002241946,0.00017557919,0.0008709777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010018789,0.0012688374,0.0025098117,0.00033787097,0.0005557697,0.00045035413,0.0005897686,0.00052465644,0.0000125855595],"category_scores_gemma":[0.0014202435,0.00080134446,0.00031635366,0.000526677,0.0003073415,0.000316404,0.0014282966,0.0006806331,0.00006560411],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000044413746,0.00013660153,0.5608813,0.0004611766,0.010804211,0.00021790556,0.00045746335,0.0000022203715,0.000048024343,0.000008320548,0.41645235,0.010525968],"study_design_scores_gemma":[0.0022627984,0.0002946233,0.1952863,0.0003618917,0.01085804,0.0000024649296,0.0003000315,0.00009512547,0.0002862994,0.000040416006,0.7900139,0.00019813099],"about_ca_topic_score_codex":0.0020781583,"about_ca_topic_score_gemma":0.000432112,"teacher_disagreement_score":0.8064558,"about_ca_system_score_codex":0.00015692909,"about_ca_system_score_gemma":0.00019560261,"threshold_uncertainty_score":0.99944377},"labels":[],"label_agreement":null},{"id":"W4328053483","doi":"10.1016/j.jcjd.2023.03.001","title":"Impact of the COVID-19 Pandemic on Antihyperglycemic Prescriptions for Adults With Type 2 Diabetes in Canada: A Cross-sectional Study","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Western University; LMC Diabetes & Endocrinology (Canada); Trillium Health Centre","funders":"Novo Nordisk Canada; Novo Nordisk","keywords":"Medicine; Medical prescription; Pandemic; Type 2 diabetes; Context (archaeology); Diabetes mellitus; Diabetes management; Coronavirus disease 2019 (COVID-19); Family medicine; Demography; Internal medicine; Disease; Pharmacology; Infectious disease (medical specialty)","score_opus":0.036725695759405264,"score_gpt":0.29698474586823714,"score_spread":0.2602590501088319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328053483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832296,0.00015371079,1.6542276e-7,0.00021819294,0.00032026216,0.00079121627,0.0001295934,0.0000072034577,0.0000566807],"genre_scores_gemma":[0.999391,0.000004981104,0.000007686413,0.00027445788,0.000066298126,0.000031380278,0.000021882017,0.000020712267,0.00018155952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874717,0.000043766944,0.00036902784,0.00015349552,0.00026390053,0.00042264542],"domain_scores_gemma":[0.9987251,0.00019889527,0.00019660962,0.00020297297,0.00021314652,0.0004632684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003049747,0.0001511232,0.00033440237,0.00043012595,0.000107612585,0.000023993336,0.0001791096,0.000038530256,0.000045179815],"category_scores_gemma":[0.0004060901,0.00009268187,0.0001352733,0.00060823554,0.00007646766,0.000073499934,0.000012689295,0.00016349122,0.0000016029986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010814448,0.00008397181,0.9938428,0.000068936024,0.00047083056,0.000014403808,0.00020352445,0.0015079328,0.00007171318,0.000006185652,0.0034325833,0.00018897378],"study_design_scores_gemma":[0.0036618353,0.00280415,0.9923426,0.00014522193,0.0001265084,0.0000016077267,0.00028734762,0.0001460347,0.000018456974,0.000027694061,0.00034967536,0.00008888462],"about_ca_topic_score_codex":0.2802816,"about_ca_topic_score_gemma":0.94026107,"teacher_disagreement_score":0.65997946,"about_ca_system_score_codex":0.0016511858,"about_ca_system_score_gemma":0.007195032,"threshold_uncertainty_score":0.99843323},"labels":[],"label_agreement":null},{"id":"W4328053915","doi":"10.46747/cfp.6903186","title":"Aide à la décision d’utiliser ou non les gliflozines pour l’insuffisance cardiaque avec fraction d’éjection supérieure à 40 %, à l’intention des patients","year":2023,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02381310223630991,"score_gpt":0.2500623404432696,"score_spread":0.22624923820695966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328053915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85658944,0.0023500691,0.00020617076,0.0012308494,0.0048758932,0.0012132196,0.00030119237,0.00023161735,0.13300157],"genre_scores_gemma":[0.9665357,0.0018711373,0.00013127261,0.004934629,0.001588987,0.00014781645,0.0016078979,0.00015824258,0.023024336],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99686205,0.00019203009,0.0004601281,0.000758305,0.0004837874,0.0012436804],"domain_scores_gemma":[0.9980669,0.00011917211,0.00017443896,0.00053322926,0.00039229228,0.00071394356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029260607,0.0005708915,0.0005708875,0.00075648754,0.0005778721,0.0001620252,0.00019092967,0.00037141758,0.00003354846],"category_scores_gemma":[0.00007726927,0.0006251063,0.00036694392,0.0012549652,0.00023392256,0.00069540937,0.00006519024,0.00041791186,0.0021006276],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013288968,0.0005768405,0.03024462,0.00055979495,0.000629058,0.00025722155,0.00077473785,0.0007426657,0.0012676312,0.00042176488,0.21057695,0.7538158],"study_design_scores_gemma":[0.0019267657,0.00040112252,0.59044164,0.001429569,0.00064280094,6.5261935e-7,0.0028435872,0.0047206418,0.00044172365,0.0005836246,0.39607206,0.00049578457],"about_ca_topic_score_codex":0.06710906,"about_ca_topic_score_gemma":0.035290193,"teacher_disagreement_score":0.75332004,"about_ca_system_score_codex":0.0018422143,"about_ca_system_score_gemma":0.00037914686,"threshold_uncertainty_score":0.99962},"labels":[],"label_agreement":null},{"id":"W4328117350","doi":"10.3390/pharmaceutics15031002","title":"Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences","year":2023,"lang":"en","type":"review","venue":"Pharmaceutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Fonds de recherche du Québec – Nature et technologies; Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada","keywords":"Heart failure; Medicine; Disease; Intensive care medicine; Drug; Pharmacology; Bioinformatics; Internal medicine; Biology","score_opus":0.3654215399922088,"score_gpt":0.4016513460179812,"score_spread":0.036229806025772415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328117350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027174785,0.9940909,0.0007497918,0.0004584246,0.0003348149,0.0037303725,0.00007632552,0.00007388911,0.00021370928],"genre_scores_gemma":[0.012894641,0.9859219,0.00026605427,0.000030997162,0.0000865683,0.0003823295,0.000027736043,0.00006663684,0.00032314355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835867,0.00019071235,0.00039976797,0.00043988283,0.0002966825,0.0003142712],"domain_scores_gemma":[0.99878925,0.0006050592,0.0002545223,0.00018890543,0.000027752503,0.0001344914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019296138,0.00048706197,0.0014941138,0.00026041162,0.00012653011,0.000051240146,0.00007054974,0.000107322325,0.0000062362938],"category_scores_gemma":[0.0000021007827,0.00025271974,0.00013169588,0.00027414624,0.0002004707,0.00004741043,0.000059386533,0.00017524438,0.000005562494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010614605,0.0032289668,0.00026434843,0.07111461,0.039948843,0.0006009656,0.008596188,0.00025644232,0.00012785627,0.30913424,0.0073896395,0.5582764],"study_design_scores_gemma":[0.008922213,0.009795576,0.000004249343,0.018658485,0.02823792,0.00010922513,0.0073125097,0.0059524644,0.00032605618,0.0034207685,0.9161762,0.0010843506],"about_ca_topic_score_codex":0.000013204423,"about_ca_topic_score_gemma":0.00000615477,"teacher_disagreement_score":0.90878654,"about_ca_system_score_codex":0.00030603586,"about_ca_system_score_gemma":0.00006448879,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W4353021269","doi":"10.1111/dom.15058","title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp> , a randomized trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Randomized controlled trial; Kidney disease; Disease; Diabetes mellitus; Internal medicine; Physical therapy; Endocrinology","score_opus":0.011004047311891228,"score_gpt":0.22011931855942451,"score_spread":0.2091152712475333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353021269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96825814,0.027129311,0.00004464584,0.000062123065,0.00013125878,0.0042128093,0.00009916138,0.000058113426,0.0000044346343],"genre_scores_gemma":[0.9895139,0.009160538,0.00043151123,0.00013705489,0.000070991395,0.00038135765,0.00013509158,0.00005084964,0.00011873042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997158,0.00070860755,0.00047741496,0.0005921176,0.00056640856,0.0004974379],"domain_scores_gemma":[0.99725467,0.0014330272,0.00016625552,0.00049542834,0.00009556523,0.0005550469],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023087026,0.00044252162,0.00276498,0.0004338856,0.000076017954,0.000057858964,0.00008401824,0.00009689508,0.0000030800052],"category_scores_gemma":[0.003230186,0.0002999853,0.00035736457,0.00046272486,0.00038321177,0.0001464336,0.00015266264,0.00014292689,0.0000011936548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038132984,0.0021777907,0.8819379,0.013301203,0.033471774,0.00019406233,0.0009589414,0.00021047301,0.0007176339,0.00026697974,0.00021041665,0.028419843],"study_design_scores_gemma":[0.28406268,0.000536019,0.6965424,0.0007801822,0.015108157,2.1457402e-7,0.00001965513,0.001093345,0.00081191974,0.00011298682,0.00075133436,0.00018113074],"about_ca_topic_score_codex":0.00002277306,"about_ca_topic_score_gemma":7.583735e-7,"teacher_disagreement_score":0.2459297,"about_ca_system_score_codex":0.000021426433,"about_ca_system_score_gemma":0.00012595445,"threshold_uncertainty_score":0.9999452},"labels":[],"label_agreement":null},{"id":"W4353046709","doi":"10.1016/j.jcjd.2023.03.002","title":"Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis","year":2023,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Agios Pharmaceuticals","keywords":"Lixisenatide; Medicine; Liraglutide; Insulin glargine; Insulin degludec; Type 2 diabetes; Glycated hemoglobin; Internal medicine; Randomized controlled trial; Odds ratio; Diabetes mellitus; Endocrinology","score_opus":0.1222648773573692,"score_gpt":0.3463703615829895,"score_spread":0.22410548422562032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353046709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033923204,0.9945754,0.000022768816,0.00020329705,0.00010129155,0.0009084654,0.0003604072,0.000007129189,0.0004289095],"genre_scores_gemma":[0.05362257,0.94370615,0.0014975559,0.00007574191,0.00008261515,0.000031924243,0.00037758896,0.00008093192,0.0005249437],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99616605,0.0002958806,0.0024344653,0.0002782663,0.000404208,0.000421119],"domain_scores_gemma":[0.9948922,0.001110336,0.0024400302,0.0004285951,0.00056055555,0.00056828966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011751287,0.00044528733,0.006830165,0.00166607,0.00010245267,0.00003391932,0.00027838742,0.00021266531,0.0001491359],"category_scores_gemma":[0.00052039366,0.000353037,0.001317687,0.0017617225,0.0003065622,0.000107414235,0.00007286271,0.00036829768,0.000003419316],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050001145,0.0013583947,0.059523758,0.029302638,0.58515793,0.000052004598,0.0008139318,0.0005885492,0.000004265433,0.0028718899,0.01790981,0.30236682],"study_design_scores_gemma":[0.0047245836,0.001466196,0.012544166,0.006784767,0.7077185,0.0000032495204,0.000114842034,0.000306527,0.000028080625,0.00014302554,0.26561645,0.00054963754],"about_ca_topic_score_codex":0.00057980244,"about_ca_topic_score_gemma":0.0046515316,"teacher_disagreement_score":0.3018172,"about_ca_system_score_codex":0.00012924935,"about_ca_system_score_gemma":0.0011283066,"threshold_uncertainty_score":0.9998922},"labels":[],"label_agreement":null},{"id":"W4360604402","doi":"10.1016/j.heliyon.2023.e14796","title":"The development of an in-situ biopolymer-based floating gel for the oral delivery of metformin hydrochloride","year":2023,"lang":"en","type":"article","venue":"Heliyon","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta; Prince of Songkla University; Burapha University","keywords":"Metformin; Bioavailability; Biopolymer; Pectin; Diabetes mellitus; Pharmacology; Drug delivery; Medicine; Hydrochloride; Metformin Hydrochloride; Sodium; Chemistry; Polymer; Food science; Endocrinology; Biochemistry; Organic chemistry","score_opus":0.034408933226369356,"score_gpt":0.2888674723783821,"score_spread":0.2544585391520128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360604402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739003,0.0008541398,0.00016906869,0.00026534466,0.00010515746,0.0006010894,0.0000028753918,0.00002737674,0.0005848912],"genre_scores_gemma":[0.99574375,0.00014521457,0.0033987586,0.00007997093,0.00002771095,0.00009982735,0.000039357295,0.000014081875,0.00045133216],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992057,0.000013603327,0.00028660073,0.00011151615,0.0001822965,0.00020025324],"domain_scores_gemma":[0.9993822,0.00025231525,0.00008821341,0.00020747421,0.00004104377,0.000028783146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051809585,0.000086793356,0.00016592005,0.00010613914,0.00008897349,0.0000066460307,0.000101795194,0.0000253121,0.000004793652],"category_scores_gemma":[0.000043387485,0.000048006263,0.00006097306,0.00025671747,0.00004070323,0.00003801514,0.00004149758,0.00003541918,0.000007184191],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086031645,0.0004969823,0.007625803,0.0015024517,0.00050541095,0.00001239561,0.0024194622,0.0001972715,0.16902693,0.0007956503,0.00023896598,0.8163184],"study_design_scores_gemma":[0.0022816435,0.00035073425,0.016240718,0.00035525387,0.00015794438,2.5868036e-7,0.0019035849,0.0026113265,0.9672312,0.000044556567,0.008731934,0.000090815105],"about_ca_topic_score_codex":0.00001920415,"about_ca_topic_score_gemma":0.00035357862,"teacher_disagreement_score":0.81622756,"about_ca_system_score_codex":0.000039823113,"about_ca_system_score_gemma":0.0000799823,"threshold_uncertainty_score":0.19576387},"labels":[],"label_agreement":null},{"id":"W4360942056","doi":"10.1210/endocr/bqad055","title":"Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice","year":2023,"lang":"en","type":"article","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Fonds Léon Fredericq; Diabetes Research Center, University of Washington; University of Washington; University of Toronto; National Institute of Diabetes and Digestive and Kidney Diseases; Fonds De La Recherche Scientifique - FNRS; Belgian American Educational Foundation; U.S. Department of Veterans Affairs","keywords":"Thiorphan; Neprilysin; Internal medicine; Endocrinology; Glucagon-like peptide-1; Chemistry; Biology; Medicine; Type 2 diabetes; Diabetes mellitus; Biochemistry","score_opus":0.016284523885806867,"score_gpt":0.2706252210643854,"score_spread":0.25434069717857855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360942056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961616,0.00014179046,0.0002816385,0.0009860655,0.0001881901,0.0002930144,0.000004360088,0.00009540129,0.0018479677],"genre_scores_gemma":[0.9965492,0.00028265853,0.0014547368,0.000115144656,0.000075328724,0.00006373148,0.00023507889,0.000012044938,0.0012120899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990486,0.000050979692,0.0002698034,0.00022822549,0.00011007231,0.00029232548],"domain_scores_gemma":[0.9996372,0.0000686899,0.00009058623,0.00012487575,0.000041873987,0.000036761892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090652946,0.00011120701,0.00025640786,0.0003558151,0.00002139747,0.000004131556,0.000046732228,0.000046164478,0.00032172754],"category_scores_gemma":[0.00004780361,0.000106662876,0.000052296324,0.00042707165,0.00006543951,0.00006705535,0.00007090558,0.00011738077,0.00031814296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002555645,0.00019478526,0.014382903,0.00010434745,0.00013227097,0.00026309522,0.0003100728,0.000024827295,0.9571606,0.0006507574,0.00083283405,0.025687972],"study_design_scores_gemma":[0.0034833485,0.00113668,0.026747039,0.0003013878,0.00020387364,0.000058198577,0.00042895947,0.00055375753,0.9623405,0.0008297346,0.003730756,0.00018577884],"about_ca_topic_score_codex":0.000058189482,"about_ca_topic_score_gemma":0.000022809594,"teacher_disagreement_score":0.025502194,"about_ca_system_score_codex":0.00006309813,"about_ca_system_score_gemma":0.000019682639,"threshold_uncertainty_score":0.43495858},"labels":[],"label_agreement":null},{"id":"W4361190342","doi":"10.1111/dom.15065","title":"Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of British Columbia","funders":"","keywords":"Medicine; Kidney disease; Diabetology; Library science; George (robot); Family medicine; Internal medicine; Diabetes mellitus; History; Art history; Endocrinology","score_opus":0.005120574803165702,"score_gpt":0.20186903255608327,"score_spread":0.19674845775291758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361190342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839161,0.0077635576,0.000004078552,0.0014596569,0.0003095758,0.00531358,0.0011349476,0.000086953325,0.000011540992],"genre_scores_gemma":[0.9609013,0.0032640495,0.00018788183,0.019394381,0.0018629342,0.002091368,0.011200788,0.00023964273,0.00085763936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961023,0.00047239437,0.0004396416,0.0012157374,0.0009785112,0.00079143164],"domain_scores_gemma":[0.9975423,0.0003776009,0.0002896999,0.0007206428,0.00012877988,0.0009409706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033015077,0.00088051695,0.0020873095,0.00046032577,0.0001829519,0.00016005414,0.00019117848,0.00029557216,0.0000043115147],"category_scores_gemma":[0.0005633181,0.00054822606,0.0003161227,0.0007056299,0.00048212954,0.00019004525,0.00018596346,0.00066050846,0.0000011471293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092861394,0.0007140824,0.9655694,0.0017626185,0.016562667,0.00011033913,0.0003364308,0.0000071663144,0.000006181472,0.0000053080407,0.011080444,0.0029167654],"study_design_scores_gemma":[0.04088303,0.0009786304,0.8751115,0.0013614475,0.031561114,1.3938586e-7,0.000027954642,0.00012924,0.000020039988,0.000027808755,0.049734432,0.00016463282],"about_ca_topic_score_codex":0.001048034,"about_ca_topic_score_gemma":0.00015639086,"teacher_disagreement_score":0.09045786,"about_ca_system_score_codex":0.00009886133,"about_ca_system_score_gemma":0.00035498402,"threshold_uncertainty_score":0.9996969},"labels":[],"label_agreement":null},{"id":"W4361190528","doi":"10.2217/fca-2022-0093","title":"Effect of Glucagon-Like Peptide-1 Receptor Agonists Administration During Coronary Artery Bypass Grafting: A Systematic Review and Meta-Analysis of Randomized Control Trials","year":2023,"lang":"en","type":"review","venue":"Future Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bypass grafting; Glucagon-like peptide-1; Randomized controlled trial; Internal medicine; Artery; Cardiology; Meta-analysis; Pharmacology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.04923367906511985,"score_gpt":0.35392485551631564,"score_spread":0.3046911764511958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361190528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060547543,0.9811534,0.000016475777,0.00013699074,0.0003752719,0.017746173,0.00036166754,0.000053734184,0.00009572314],"genre_scores_gemma":[0.0006426972,0.9910929,0.000025606487,0.000068904825,0.00025993283,0.005521807,0.0014583514,0.000056028264,0.0008737316],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9853207,0.009772108,0.0036441872,0.0006359608,0.00033218187,0.00029486668],"domain_scores_gemma":[0.98969436,0.0057831993,0.003375277,0.0008734496,0.00016118748,0.00011252201],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.010576469,0.0007447159,0.06015136,0.0006549227,0.000041029623,0.000013005056,0.00016601823,0.00041394186,0.00006781908],"category_scores_gemma":[0.0023836482,0.000397713,0.013164156,0.0006256492,0.00014942858,0.000033046843,0.00006766068,0.00022595473,0.000014496387],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015792745,0.000015095597,0.0000019366005,0.51065105,0.48702806,0.00004312191,0.000007887042,3.826535e-7,9.00153e-7,0.000018151688,0.00024836182,0.00040579223],"study_design_scores_gemma":[0.023621166,0.00056948833,0.0000038305616,0.024099616,0.9458716,0.000057167363,0.0000089115365,0.000001095763,0.0000022694612,0.0000011059404,0.0055541033,0.0002096571],"about_ca_topic_score_codex":0.000002028849,"about_ca_topic_score_gemma":0.0000015167063,"teacher_disagreement_score":0.48655143,"about_ca_system_score_codex":0.00007815252,"about_ca_system_score_gemma":0.00009571852,"threshold_uncertainty_score":0.9998475},"labels":[],"label_agreement":null},{"id":"W4361190766","doi":"10.1007/s00125-023-05906-7","title":"The expanding incretin universe: from basic biology to clinical translation","year":2023,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk","keywords":"Incretin; Human physiology; Translation (biology); Universe; Biology; Medicine; Computational biology; Diabetes mellitus; Internal medicine; Genetics; Endocrinology; Type 2 diabetes; Physics; Astronomy; Gene","score_opus":0.19085641060318217,"score_gpt":0.4436457614919297,"score_spread":0.25278935088874754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361190766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007659385,0.99287456,0.000043287666,0.00043079132,0.0012354625,0.001755116,0.000084774736,0.0002387476,0.002571316],"genre_scores_gemma":[0.00009951948,0.9964652,0.0003003628,0.0001510359,0.00035650708,0.00018440382,0.0011648431,0.000049646336,0.0012285028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794114,0.00034542682,0.00066521723,0.0005245093,0.00012079819,0.000402907],"domain_scores_gemma":[0.99703985,0.0020714786,0.00020785687,0.0005158102,0.000027327713,0.00013764542],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068243133,0.00032089264,0.0015700787,0.00018283365,0.00011708035,0.000031734482,0.00026398923,0.00038835377,0.00007370241],"category_scores_gemma":[0.0002885155,0.00018953597,0.0005076313,0.00043017985,0.00010932598,0.000023372355,0.00018446891,0.00033680088,0.0014742191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013578483,0.00003267755,0.0010831346,0.00058128877,0.0008091373,0.000026918686,0.000019109148,2.9314423e-8,2.2002169e-7,0.00049673807,0.0037602887,0.9931769],"study_design_scores_gemma":[0.00045562832,0.00023516543,0.00051109784,0.0024681254,0.0021400643,3.5233776e-7,0.00003934315,0.0000032135674,5.888751e-7,0.00021457406,0.99375296,0.00017887828],"about_ca_topic_score_codex":0.00002075095,"about_ca_topic_score_gemma":0.000013498059,"teacher_disagreement_score":0.992998,"about_ca_system_score_codex":0.00011192514,"about_ca_system_score_gemma":0.00009437547,"threshold_uncertainty_score":0.9993032},"labels":[],"label_agreement":null},{"id":"W4361195578","doi":"10.1016/s2666-7568(23)00032-6","title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Healthy Longevity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; Pfizer","keywords":"Medicine; Type 2 diabetes; Heart failure; Diabetes mellitus; Stroke (engine); Kidney disease; Renal function; Internal medicine; Myocardial infarction; Placebo; Adverse effect; Cardiology; Endocrinology; Pathology","score_opus":0.051160986011572936,"score_gpt":0.3270218507543562,"score_spread":0.27586086474278326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361195578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98469114,0.00083771104,0.000015752421,0.009446633,0.0002852977,0.003361829,0.00010585129,0.0001616674,0.0010940951],"genre_scores_gemma":[0.9877591,0.00041317273,0.00013607326,0.009894436,0.00036881433,0.0003602844,0.00032759533,0.000054161374,0.0006863392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785197,0.00020998013,0.00042854823,0.00050557696,0.0004196863,0.0005842611],"domain_scores_gemma":[0.99849,0.00037544244,0.0001645294,0.00064774754,0.000063444604,0.00025885866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007926396,0.00035086798,0.0013522955,0.00018477213,0.00014822096,0.00004814463,0.00013231763,0.000093062205,0.00016053038],"category_scores_gemma":[0.000069713504,0.00017714704,0.00011426038,0.000600884,0.00012782683,0.0001227157,0.00007333048,0.00032430014,0.000040021172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40800604,0.00020032226,0.5819491,0.00017176563,0.0013266354,0.000021807187,0.00038035598,0.000010195186,0.000003855692,0.000018004765,0.0040159174,0.0038959829],"study_design_scores_gemma":[0.40166742,0.0008357918,0.59332293,0.00019850912,0.00054391,6.4678966e-7,0.00011558138,0.000042573414,0.000014317223,0.00003371271,0.003065079,0.00015955449],"about_ca_topic_score_codex":0.0012330936,"about_ca_topic_score_gemma":0.0016396655,"teacher_disagreement_score":0.011373784,"about_ca_system_score_codex":0.000101739235,"about_ca_system_score_gemma":0.00019807031,"threshold_uncertainty_score":0.72238463},"labels":[],"label_agreement":null},{"id":"W4361219083","doi":"10.1038/s41569-023-00849-3","title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","year":2023,"lang":"en","type":"review","venue":"Nature Reviews Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":504,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University of Alberta","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Postprandial; Blood pressure; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Receptor; Pharmacology; Agonist","score_opus":0.07305258595395173,"score_gpt":0.3432898077657878,"score_spread":0.27023722181183607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361219083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025349223,0.99276084,0.00008616339,0.00004198232,0.0017529732,0.003875482,0.000085080545,0.000110579655,0.0012843604],"genre_scores_gemma":[0.0000026739963,0.995149,0.0009016818,0.000108545326,0.0006142962,0.0007115552,0.0010916662,0.00011902486,0.0013015255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667436,0.00057851366,0.0010235527,0.0009251204,0.00034901287,0.0004494678],"domain_scores_gemma":[0.99782544,0.00016114657,0.0005550449,0.0011838457,0.00011399185,0.000160544],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013627106,0.0007273478,0.008134306,0.00041678906,0.00006282818,0.000013950212,0.00021069885,0.0014526318,0.000021926786],"category_scores_gemma":[0.0002573894,0.0005061092,0.0035096759,0.0005893225,0.000093131326,0.00004913714,0.00022754987,0.0009902276,0.00025623728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008087101,0.000018893217,0.0000027743117,0.051647846,0.0070648296,0.000040563158,0.000004391452,5.1622214e-7,0.0000016971268,0.0019874107,0.009278615,0.9299444],"study_design_scores_gemma":[0.00041117668,0.00022492217,0.000010078875,0.01979132,0.01964165,0.000140445,0.000008904279,2.0475085e-7,0.0000036887823,0.00008496573,0.95935947,0.00032320415],"about_ca_topic_score_codex":0.0000066570137,"about_ca_topic_score_gemma":0.0000028990128,"teacher_disagreement_score":0.9500808,"about_ca_system_score_codex":0.00022655443,"about_ca_system_score_gemma":0.00013852846,"threshold_uncertainty_score":0.9998437},"labels":[],"label_agreement":null},{"id":"W4361221666","doi":"10.1111/jdi.14001","title":"Stimulatory effect of imeglimin on incretin secretion","year":2023,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Ono Pharmaceutical; University of Toronto","keywords":"Medicine; Incretin; Secretion; Diabetes mellitus; Internal medicine; Glucagon-like peptide-1; Endocrinology; Type 2 diabetes; Pharmacology","score_opus":0.013636814236317548,"score_gpt":0.2627806202050395,"score_spread":0.24914380596872196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361221666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818,0.00010177728,0.0000049474766,0.0005371198,0.0002469542,0.00025935046,0.0000020548166,0.000033926095,0.00063391734],"genre_scores_gemma":[0.9991805,0.000021618986,0.00021257703,0.00019961146,0.00015484309,0.0000067660385,0.000039060214,0.000016587293,0.0001684453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998823,0.00011020503,0.00040457168,0.000095877134,0.00041173262,0.00015464658],"domain_scores_gemma":[0.9989262,0.00028825877,0.00041208352,0.00013957333,0.00011562989,0.00011825449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095667737,0.00012063879,0.00034813545,0.00045422086,0.000026801054,0.000009807688,0.00006151657,0.000062684,0.000028992803],"category_scores_gemma":[0.00046343455,0.00008956894,0.0001428994,0.00035886865,0.000072350005,0.00011968666,0.000022044816,0.00012862185,0.000045186975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020476089,0.0000948807,0.83865666,0.00067222747,0.00047722599,0.00001560979,0.00027751212,0.0006833175,0.13271552,0.00037432078,0.0081127295,0.017715253],"study_design_scores_gemma":[0.0040213647,0.008100642,0.56066597,0.001323704,0.00077356945,0.0000014650881,0.000043631757,0.003104153,0.4201111,0.0010046444,0.0007142077,0.0001355424],"about_ca_topic_score_codex":8.044545e-7,"about_ca_topic_score_gemma":1.06577055e-7,"teacher_disagreement_score":0.28739557,"about_ca_system_score_codex":0.00007875071,"about_ca_system_score_gemma":0.00003883952,"threshold_uncertainty_score":0.36525154},"labels":[],"label_agreement":null},{"id":"W4362455913","doi":"10.1111/eci.13997","title":"Meta‐analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus","year":2023,"lang":"en","type":"review","venue":"European Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Jordan University of Science and Technology","keywords":"Medicine; Metformin; Type 2 Diabetes Mellitus; Internal medicine; Odds ratio; Thiazolidinedione; Confidence interval; Type 2 diabetes; Sulfonylurea; Diabetes mellitus; Body mass index; Insulin; Endocrinology","score_opus":0.4822714473138278,"score_gpt":0.42957941692046747,"score_spread":0.052692030393360345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362455913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021909297,0.9763525,0.000031791235,0.00010224337,0.00038580815,0.00095355936,0.00005981569,0.00004267371,0.0001622718],"genre_scores_gemma":[0.0039934446,0.99314296,0.00073645817,0.000089476125,0.00022286066,0.000008398229,0.0007860864,0.00013342562,0.0008868747],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945589,0.0014592301,0.0029431302,0.0003031517,0.0004901141,0.0002455256],"domain_scores_gemma":[0.9915366,0.0029822139,0.0043390277,0.0003177194,0.0005484966,0.0002758967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005548977,0.000361994,0.005396877,0.0007169316,0.000041027793,0.000036281563,0.0002350273,0.00008902767,0.000025872565],"category_scores_gemma":[0.0026816842,0.0002126954,0.0033799405,0.0012520386,0.00017832982,0.00011094817,0.000052898824,0.00039815297,0.000009040584],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004051923,0.0003637779,0.003960988,0.0075344252,0.91491914,0.000042337942,0.0001314207,0.000061936764,0.0000011448375,0.0000446156,0.0016919535,0.07120772],"study_design_scores_gemma":[0.0009153263,0.0013867556,0.0038581684,0.0071312706,0.92899954,2.0919364e-7,0.000018718818,0.00006644836,0.000015108931,0.000034997604,0.05736144,0.00021201672],"about_ca_topic_score_codex":9.609425e-7,"about_ca_topic_score_gemma":0.0000019847764,"teacher_disagreement_score":0.0709957,"about_ca_system_score_codex":0.000043842854,"about_ca_system_score_gemma":0.00022214695,"threshold_uncertainty_score":0.8673467},"labels":[],"label_agreement":null},{"id":"W4362457940","doi":"10.2215/cjn.0000000000000161","title":"Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR","year":2023,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Canagliflozin; Medicine; Glycemic; Type 2 diabetes; Albuminuria; Renal function; Glycated hemoglobin; Internal medicine; Placebo; Diabetes mellitus; Randomized controlled trial; Urology; Post-hoc analysis; Endocrinology","score_opus":0.01678652540834203,"score_gpt":0.326281220733221,"score_spread":0.309494695324879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362457940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792857,0.000574369,0.000009267074,0.011157814,0.00011631754,0.00018617512,0.0000010047573,0.00000397886,0.000022479562],"genre_scores_gemma":[0.9892623,0.0021411965,0.0005494843,0.007893079,0.00008806112,0.0000018720792,2.9097666e-7,0.000008147091,0.00005558291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886703,0.00016158567,0.0005701436,0.000114217335,0.00012345031,0.00016358405],"domain_scores_gemma":[0.9978922,0.0011514081,0.0006809818,0.00014420343,0.00005058155,0.000080644924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064007763,0.00008446322,0.0007634358,0.000053287597,0.000017142223,0.0000021020096,0.00009860673,0.000051176354,0.0000016965209],"category_scores_gemma":[0.00017199287,0.000055419263,0.0002545343,0.00023661643,0.0009748423,0.000023925775,0.00008372073,0.00022433975,3.8773177e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041342517,0.0006103064,0.7496117,0.00051787816,0.0032023247,0.0000931601,0.0013722325,0.000034327957,0.047263704,0.000069399626,0.08555874,0.10753198],"study_design_scores_gemma":[0.009419632,0.0042377287,0.98046696,0.00023975644,0.00068491587,0.000031587962,0.0006033172,0.00035068797,0.00022919793,0.0002992701,0.0033752266,0.00006172159],"about_ca_topic_score_codex":0.00013755677,"about_ca_topic_score_gemma":0.000008579488,"teacher_disagreement_score":0.23085527,"about_ca_system_score_codex":0.000024258306,"about_ca_system_score_gemma":0.000060703078,"threshold_uncertainty_score":0.3591847},"labels":[],"label_agreement":null},{"id":"W4362465321","doi":"10.1097/md.0000000000033366","title":"Management of diabetic kidney disease: where do we stand?: A narrative review","year":2023,"lang":"en","type":"review","venue":"Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rogue Research (Canada)","funders":"","keywords":"Medicine; Kidney disease; Narrative review; MEDLINE; Disease management; Disease; Intensive care medicine; Internal medicine","score_opus":0.04674425817462664,"score_gpt":0.3635987022351573,"score_spread":0.31685444406053065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362465321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.904969e-7,0.9770574,0.000006519009,0.008662275,0.00046685679,0.0053819004,0.00009216143,0.00015003547,0.008182576],"genre_scores_gemma":[5.605582e-7,0.95398456,0.00007583204,0.00025760318,0.000258238,0.001019931,0.00048711424,0.00011875178,0.043797415],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964854,0.00015032741,0.0012390028,0.00070491724,0.00094920176,0.00047116683],"domain_scores_gemma":[0.99735194,0.00012056921,0.0005937143,0.0011557306,0.00011257609,0.0006654669],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059946044,0.0007232205,0.0041904133,0.00041309546,0.000051423347,0.000007675128,0.00030681753,0.00011231579,0.0019904668],"category_scores_gemma":[0.00014011738,0.00044523823,0.00061268685,0.0012334697,0.00021365793,0.000040108924,0.00023089319,0.0002743414,0.00037513237],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008407863,0.000092219016,0.0000032672197,0.39889097,0.0017495821,0.00041991664,0.000060120477,1.0552762e-8,9.051979e-9,0.00026684048,0.20086552,0.39764312],"study_design_scores_gemma":[0.00074874674,0.00022776482,0.000006275156,0.45897236,0.017380822,0.0000017092837,0.000096262775,3.6897092e-7,2.5260773e-8,0.000054043492,0.5223519,0.00015968904],"about_ca_topic_score_codex":0.00000383417,"about_ca_topic_score_gemma":5.095926e-7,"teacher_disagreement_score":0.39748344,"about_ca_system_score_codex":0.0002440929,"about_ca_system_score_gemma":0.00023722116,"threshold_uncertainty_score":0.99979997},"labels":[],"label_agreement":null},{"id":"W4362522313","doi":"10.1161/circulationaha.122.062440","title":"Letter by Wong and Demers Regarding Article, “Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial”","year":2023,"lang":"en","type":"letter","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; University of Ottawa","funders":"","keywords":"Medicine; Heart failure; Dapagliflozin; Ejection fraction; Internal medicine; Emergency medicine; Gerontology; Diabetes mellitus","score_opus":0.02056292523390971,"score_gpt":0.24361365099557655,"score_spread":0.22305072576166685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362522313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97085816,0.000029706966,0.000089672765,0.027423909,0.00004788713,0.0014790708,0.000017056907,0.000012337326,0.00004222547],"genre_scores_gemma":[0.98706037,0.0000044495714,0.00011556405,0.012441065,0.00007678155,0.000028342949,0.00019632152,0.00002326427,0.000053857828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879146,0.0000729864,0.0003455736,0.000298919,0.00033144202,0.00015962629],"domain_scores_gemma":[0.99932796,0.00012595321,0.00017583475,0.00028095164,0.000058488302,0.00003083189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017382117,0.0001494141,0.0004887257,0.000388725,0.000032911787,0.000017156834,0.00004690173,0.000121538724,0.000008500843],"category_scores_gemma":[0.00006814181,0.00010689101,0.00008131025,0.0007836701,0.00004005128,0.00007260537,0.00006141667,0.00016594863,7.833761e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017185584,0.00006577943,0.9280519,0.00011492253,0.0014469264,0.000001655552,0.00021342903,0.0003009027,0.00025948448,0.000002949531,0.06551938,0.0023041498],"study_design_scores_gemma":[0.012722831,0.00010132936,0.9751273,0.00029365488,0.002399988,4.286855e-8,0.0000301634,0.00022014519,0.00005642533,0.000003632547,0.008934567,0.00010992526],"about_ca_topic_score_codex":0.000046651807,"about_ca_topic_score_gemma":0.000020565261,"teacher_disagreement_score":0.056584813,"about_ca_system_score_codex":0.00007326897,"about_ca_system_score_gemma":0.000009048135,"threshold_uncertainty_score":0.4358889},"labels":[],"label_agreement":null},{"id":"W4362601025","doi":"10.1111/dom.15081","title":"Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6 trials","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Post-hoc analysis; Type 2 diabetes; Medicine; Triglyceride; Diabetes mellitus; Adverse effect; Internal medicine; Baseline (sea); Post hoc; Endocrinology; Cholesterol; Liraglutide; Biology","score_opus":0.024800301952432297,"score_gpt":0.2642104988669024,"score_spread":0.2394101969144701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362601025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739447,0.019072847,0.0000014091562,0.0014981343,0.00057295803,0.0029955767,0.0018231203,0.000050233026,0.00004101885],"genre_scores_gemma":[0.9787587,0.0043757115,0.00020349008,0.011654954,0.00071023963,0.0002449711,0.0011371821,0.00019363323,0.002721108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99389815,0.0016121189,0.0013133025,0.0008957846,0.001252627,0.0010279856],"domain_scores_gemma":[0.9932774,0.0032938884,0.0013092101,0.0012457672,0.0007014959,0.0001722865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038076304,0.0008440306,0.0034672972,0.0004756377,0.00028550596,0.00005613032,0.00043895986,0.00050925877,0.0000066316256],"category_scores_gemma":[0.0060519073,0.0004727539,0.0010843279,0.0011555346,0.00062600814,0.00017229091,0.00047856604,0.0009009514,0.0000058169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008444538,0.00085814233,0.9221317,0.0031370593,0.029554222,0.000051093484,0.0016662349,0.00011876385,0.0004978854,0.000008887167,0.036524218,0.0053673047],"study_design_scores_gemma":[0.00821256,0.00037450815,0.9191238,0.0009231804,0.018642088,5.152147e-7,0.00094518013,0.000021607786,0.0048800507,0.00007016673,0.04664753,0.00015876703],"about_ca_topic_score_codex":0.00022679858,"about_ca_topic_score_gemma":0.000031460364,"teacher_disagreement_score":0.014697136,"about_ca_system_score_codex":0.00006626187,"about_ca_system_score_gemma":0.00017436121,"threshold_uncertainty_score":0.9997724},"labels":[],"label_agreement":null},{"id":"W4362603676","doi":"10.1016/j.numecd.2023.03.023","title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review","year":2023,"lang":"en","type":"review","venue":"Nutrition Metabolism and Cardiovascular Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Liraglutide; Transplantation; Internal medicine; Kidney transplantation; Glycemic; Weight loss; Type 2 diabetes; Kidney disease; Hemodialysis; Dialysis; Endocrinology; Diabetes mellitus; Insulin; Obesity","score_opus":0.02282223103365606,"score_gpt":0.29038384695346464,"score_spread":0.2675616159198086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362603676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035825648,0.99063355,0.000010485834,0.00037509925,0.0003284451,0.004959762,0.0033706017,0.00015580631,0.00013040614],"genre_scores_gemma":[0.000010089744,0.97944295,0.0001292704,0.0010112816,0.00041488843,0.0035985191,0.014775297,0.00009849454,0.0005191873],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964558,0.0006170495,0.00074081164,0.0010461118,0.0007058624,0.00043437228],"domain_scores_gemma":[0.9975818,0.0000842104,0.00016575745,0.0007001155,0.000097059885,0.0013710755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004474195,0.00073542993,0.0035358344,0.0004669323,0.00016411104,0.000099308796,0.00012365455,0.00015764481,0.00019244378],"category_scores_gemma":[0.00024836423,0.0006149784,0.002030928,0.0007087146,0.00016244591,0.00022726304,0.000072728224,0.00025495858,0.00004250415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013852293,0.0006456884,0.00005175838,0.5189412,0.008424292,0.00082874624,0.00014577432,1.3921209e-7,3.25631e-7,0.00017648841,0.039911225,0.4307358],"study_design_scores_gemma":[0.003317521,0.00003681195,0.00047138496,0.097559646,0.05110114,0.000023216202,0.000071588045,6.473438e-7,4.389331e-7,0.000035651,0.8469049,0.000477102],"about_ca_topic_score_codex":0.0000264617,"about_ca_topic_score_gemma":0.0000018934309,"teacher_disagreement_score":0.8069936,"about_ca_system_score_codex":0.00006929632,"about_ca_system_score_gemma":0.00038629066,"threshold_uncertainty_score":0.99963015},"labels":[],"label_agreement":null},{"id":"W4362693001","doi":"10.1136/bmj-2022-074068","title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","year":2023,"lang":"en","type":"review","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"West China Hospital, Sichuan University; Sichuan University; University of Otago","keywords":"Medicine; Type 2 diabetes; Internal medicine; Randomized controlled trial; Meta-analysis; Odds ratio; Diabetes mellitus; Endocrinology","score_opus":0.27593104973532695,"score_gpt":0.4256376924669705,"score_spread":0.14970664273164352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362693001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004013861,0.9530432,0.000002165817,0.00016682154,0.00006582862,0.046403673,0.00021596588,0.000020812313,0.00007750518],"genre_scores_gemma":[0.0000040341292,0.98284096,0.00018675713,0.00008526024,0.000058602458,0.012672277,0.00047301923,0.000045178123,0.0036339369],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947423,0.00092255935,0.0034665584,0.00038898934,0.00024515815,0.00023445106],"domain_scores_gemma":[0.9891494,0.0067795124,0.0031991582,0.0006019482,0.00016883331,0.00010114055],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.006941218,0.00052800914,0.044935055,0.0003828557,0.000027264508,0.000016548021,0.00008347896,0.00010230121,0.00006305305],"category_scores_gemma":[0.0023998357,0.000246291,0.0070368247,0.0007112523,0.00003583154,0.000020929867,0.000043710083,0.000037965136,0.000003632149],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017127117,0.00005912247,0.0000010001112,0.5019278,0.48926744,7.9871796e-7,0.000009789028,0.0000023411685,1.227425e-8,0.000041153187,0.0013315425,0.0071877236],"study_design_scores_gemma":[0.019111922,0.00028458476,6.188067e-7,0.108477786,0.8634773,2.8247936e-7,0.0000053919916,0.000024677736,2.957099e-7,0.000007527316,0.008471196,0.00013843077],"about_ca_topic_score_codex":0.000005390326,"about_ca_topic_score_gemma":0.0000052913965,"teacher_disagreement_score":0.39345002,"about_ca_system_score_codex":0.000042767762,"about_ca_system_score_gemma":0.000071593095,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W4363651493","doi":"10.1002/ehf2.14357","title":"Impact of Diabetes Duration on Left Ventricular Mass Regression with Empagliflozin","year":2023,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital","funders":"University of Toronto; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Cardiology; Ejection fraction; Type 2 Diabetes Mellitus; Diabetes mellitus; Heart failure; Coronary artery disease; Population; Body surface area; Body mass index; Endocrinology","score_opus":0.009669168456760262,"score_gpt":0.2675634718326111,"score_spread":0.25789430337585084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4363651493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457693,0.000043978765,0.000009082322,0.0044234185,0.00005172523,0.00045667033,0.0000075802227,0.00012169541,0.00030890395],"genre_scores_gemma":[0.99739337,0.0000055264736,0.00054784736,0.00009267163,0.000071471855,0.000019177058,0.0001784848,0.00002157487,0.0016698997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990439,0.00003183555,0.00015777262,0.00020079166,0.0003101027,0.00025561388],"domain_scores_gemma":[0.99947906,0.000035403278,0.000059267968,0.00028018246,0.000049043465,0.00009707372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012771631,0.00015098468,0.00026540502,0.00020381989,0.00004729739,0.000014656252,0.000037736525,0.000058073656,0.00019826867],"category_scores_gemma":[0.000032483946,0.00008972054,0.00012765185,0.00033932852,0.000025270523,0.00007162868,0.000018871935,0.0000856948,0.00015993918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113581664,0.00025864647,0.83685154,0.00014735619,0.00041920785,0.00008756647,0.000112109155,0.0002090753,0.01680226,0.0000584459,0.14380519,0.0011350284],"study_design_scores_gemma":[0.0028106393,0.0039033373,0.9402238,0.0009016297,0.00028933943,0.0000036066313,0.00012169411,0.0010170795,0.030408567,0.000064955435,0.020038815,0.0002165477],"about_ca_topic_score_codex":0.000007670299,"about_ca_topic_score_gemma":0.0000038515177,"teacher_disagreement_score":0.12376638,"about_ca_system_score_codex":0.00006993936,"about_ca_system_score_gemma":0.000037256526,"threshold_uncertainty_score":0.36586976},"labels":[],"label_agreement":null},{"id":"W4363674983","doi":"10.1016/j.revmed.2023.03.002","title":"Chez les sujets avec insuffisance rénale chronique modérée, diabétiques ou non, est-ce que l’empagliflozine entraîne un bénéfice rénal et cardiovasculaire comparativement au placebo, tout en étant sécuritaire ?","year":2023,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine; Gynecology","score_opus":0.015417597179509173,"score_gpt":0.2722194997078633,"score_spread":0.2568019025283541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4363674983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.625398,0.01837158,0.006182655,0.29801035,0.0043043,0.007700822,0.0009884388,0.0010995537,0.03794432],"genre_scores_gemma":[0.87464213,0.010020788,0.0016535765,0.022874178,0.0098797735,0.0023051214,0.0039660144,0.0006838458,0.07397458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.989756,0.0017662876,0.002160871,0.0023944457,0.0013828741,0.0025395257],"domain_scores_gemma":[0.99383795,0.0019317403,0.00091404555,0.0021005708,0.00047518595,0.00074050226],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0026343926,0.0022873643,0.0035657252,0.00069067505,0.00031126526,0.00024924765,0.0013358447,0.0013693913,0.0010392849],"category_scores_gemma":[0.0005121289,0.0022258803,0.001601554,0.0007188287,0.0006343533,0.0003993459,0.0014174712,0.0028931596,0.0011703613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036738482,0.0086239,0.19554654,0.018204007,0.03986831,0.050776727,0.053368922,0.004817073,0.0027122272,0.013204857,0.5755848,0.03361879],"study_design_scores_gemma":[0.017975302,0.002890962,0.13019273,0.021163188,0.006251614,0.00091770047,0.00095334736,0.005414334,0.008613995,0.0003526064,0.80235344,0.002920753],"about_ca_topic_score_codex":0.0041823997,"about_ca_topic_score_gemma":0.0048948526,"teacher_disagreement_score":0.27513617,"about_ca_system_score_codex":0.0065144226,"about_ca_system_score_gemma":0.00082213565,"threshold_uncertainty_score":0.99992704},"labels":[],"label_agreement":null},{"id":"W4363677724","doi":"10.1016/j.ejim.2023.04.005","title":"Tirzepatide decreases systolic and diastolic blood pressure","year":2023,"lang":"en","type":"letter","venue":"European Journal of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Glycated hemoglobin; Endocrinology; Glycemic; Insulin glargine; Glucagon-like peptide 1 receptor; Blood pressure; Type 2 diabetes; Insulin; Creatinine; Renal function; Diabetes mellitus; Agonist; Receptor","score_opus":0.01890915046227384,"score_gpt":0.25115837832855187,"score_spread":0.23224922786627802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4363677724","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058292486,0.044969987,0.00016031342,0.84002435,0.004874458,0.001023466,0.000042999138,0.0002321817,0.050379734],"genre_scores_gemma":[0.11124968,0.0075916504,0.0006596542,0.7260347,0.04858639,0.000012136672,0.00014964472,0.00061947334,0.10509666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707454,0.00034180505,0.0010489831,0.0003133189,0.0008364405,0.00038492854],"domain_scores_gemma":[0.99778026,0.00030047802,0.0009622787,0.00036740885,0.00026164312,0.00032791137],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008002377,0.00046124563,0.0011813723,0.0007922049,0.000042612184,0.00003670107,0.00035227052,0.00009627287,0.00026274208],"category_scores_gemma":[0.0006996409,0.0002973625,0.00025383057,0.00016787663,0.00021564408,0.00008137747,0.0001683524,0.0014386202,0.000117634845],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001341732,0.00007527948,0.001619466,0.0009027059,0.0044250507,0.055113435,0.0002533336,5.6207074e-7,0.00009171811,0.0000062976856,0.92808867,0.009289319],"study_design_scores_gemma":[0.0046455786,0.004640486,0.007702621,0.012806963,0.012517753,0.0042150854,0.00007636423,0.000008863307,0.00006332353,0.000020861049,0.95306915,0.00023293693],"about_ca_topic_score_codex":0.000050253664,"about_ca_topic_score_gemma":0.0000015935693,"teacher_disagreement_score":0.113989666,"about_ca_system_score_codex":0.0000323992,"about_ca_system_score_gemma":0.000050166156,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W4364352053","doi":"10.1111/dom.15083","title":"Control of human pancreatic beta cell kinome by glucagon‐like peptide‐1 receptor biased agonism","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; Diabetes UK; UK Research and Innovation; European Foundation for the Study of Diabetes; Eli Lilly and Company","keywords":"Kinome; Agonist; Medicine; Glucagon-like peptide 1 receptor; Receptor; Glucagon-like peptide-1; Internal medicine; Beta cell; Endocrinology; BETA (programming language); Beta adrenergic receptor kinase; Pharmacology; Cell biology; Kinase; G protein-coupled receptor; Biology; Diabetes mellitus; Type 2 diabetes","score_opus":0.010038426379119572,"score_gpt":0.22407242030774752,"score_spread":0.21403399392862793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364352053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204457,0.0043181055,0.000010498426,0.0004672684,0.00026830053,0.0008170751,0.00018094297,0.00019392685,0.001699299],"genre_scores_gemma":[0.98989415,0.0006334437,0.00012845374,0.0006876699,0.00012955401,0.00009721243,0.0006024905,0.00004308659,0.007783937],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981232,0.00009216631,0.00040965906,0.00044407047,0.00033949572,0.0005913994],"domain_scores_gemma":[0.9988801,0.00012925905,0.00017758396,0.00045187783,0.00008402191,0.0002771971],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041545118,0.00032842794,0.0009581334,0.00029185548,0.0001615483,0.000040812552,0.0001449801,0.00012875278,0.0001799781],"category_scores_gemma":[0.00003293863,0.00028714864,0.00021951419,0.00039748085,0.00022167647,0.0001402886,0.00009578076,0.00014641033,0.0001591594],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008766804,0.0020556701,0.33021206,0.0016838573,0.0019231354,0.000023568604,0.0007759301,0.000003567384,0.6100326,0.003756109,0.04234766,0.0070981695],"study_design_scores_gemma":[0.013746827,0.0007084703,0.6199957,0.00024267675,0.004132939,4.3048945e-7,0.00030068852,0.00017091044,0.22117619,0.00048168268,0.13833186,0.0007116295],"about_ca_topic_score_codex":0.000101765785,"about_ca_topic_score_gemma":0.000003331651,"teacher_disagreement_score":0.38885644,"about_ca_system_score_codex":0.000023665843,"about_ca_system_score_gemma":0.000028290622,"threshold_uncertainty_score":0.99995804},"labels":[],"label_agreement":null},{"id":"W4365133573","doi":"10.1101/2023.04.07.23288197","title":"Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"H. Lundbeck A/S; Novo Nordisk Fonden; Canadian Institutes of Health Research; Danmarks Frie Forskningsfond; Lundbeckfonden; University of Oxford; Duke Clinical Research Institute; Novo Nordisk; National Institute for Health and Care Research; Wellcome Trust; Department of Health and Social Care; European Commission; Strategiske Forskningsråd; European Foundation for the Study of Diabetes; Eli Lilly and Company; AstraZeneca; Amylin Pharmaceuticals; Pfizer; Diabetes UK","keywords":"Type 2 diabetes; Agonist; Glycated hemoglobin; Glycemic; Incretin; Pharmacology; Medicine; Endocrinology; Internal medicine; Glucagon-like peptide 1 receptor; Insulin resistance; Diabetes mellitus; Receptor","score_opus":0.03337730364273106,"score_gpt":0.29794261046427334,"score_spread":0.2645653068215423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365133573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336743,0.0010935289,0.0000118790995,0.002591315,0.00050929585,0.0018427946,0.0001539484,0.0003045355,0.00012529836],"genre_scores_gemma":[0.9912388,0.0008986629,0.0025810476,0.00049399433,0.00018625225,0.0004077402,0.00021018003,0.00013471257,0.0038486486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965555,0.00027197698,0.0007365296,0.0011911404,0.00049277453,0.0007520718],"domain_scores_gemma":[0.99757016,0.0005079429,0.00030316293,0.0010336525,0.00017658033,0.00040848184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017803368,0.0006293123,0.0010077712,0.0007207405,0.000114167524,0.00012200452,0.00033500124,0.00028182456,0.000101639365],"category_scores_gemma":[0.0024958323,0.0005746678,0.00013341683,0.0005899624,0.0001067553,0.0001058516,0.0012612687,0.00065216445,0.00045506368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015004314,0.0003139928,0.94293755,0.00093925814,0.0007029325,0.00029014965,0.0020728305,0.0006891008,0.034337614,0.000018725315,0.0034482798,0.0127491625],"study_design_scores_gemma":[0.001959207,0.00073214696,0.9805974,0.0016127386,0.00031669866,0.0000010259005,0.00021135937,0.00039766528,0.005477681,0.00019944116,0.007901993,0.0005926733],"about_ca_topic_score_codex":0.00027998438,"about_ca_topic_score_gemma":0.00021129836,"teacher_disagreement_score":0.037659846,"about_ca_system_score_codex":0.0002956931,"about_ca_system_score_gemma":0.0001664706,"threshold_uncertainty_score":0.9996705},"labels":[],"label_agreement":null},{"id":"W4365483438","doi":"10.1111/dom.15092","title":"Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the <scp>CVD‐REAL</scp> 2 study","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"Taipei Veterans General Hospital; Syddansk Universitet; Saint Luke's Health System; Novo Nordisk Fonden; AstraZeneca","keywords":"Medicine; Family medicine; Advisory committee; Management","score_opus":0.01354308518714901,"score_gpt":0.21625870016536491,"score_spread":0.2027156149782159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365483438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040145,0.005998476,0.0000056831245,0.00055016775,0.00036882775,0.0014192061,0.0011034233,0.000065455046,0.00008732621],"genre_scores_gemma":[0.9895767,0.004944485,0.000032045442,0.0014430436,0.00042780963,0.00010125881,0.0032309094,0.000069843765,0.00017387736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686253,0.00043473605,0.0005378865,0.00069049955,0.001020526,0.00045380305],"domain_scores_gemma":[0.9972949,0.0009309242,0.00062048977,0.00077799585,0.00026308824,0.00011261159],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008546203,0.0005432643,0.0021021727,0.0004519505,0.0001348431,0.00003527804,0.00018078047,0.00040626954,0.00000814413],"category_scores_gemma":[0.0002305882,0.00037301626,0.00072682404,0.00090032077,0.00014036952,0.00013055139,0.00010645491,0.00058213447,0.000002656151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042677526,0.00068742974,0.90260667,0.00015873858,0.0910865,0.000076877586,0.001135378,0.000016592558,0.000012062858,0.000002858652,0.0034086236,0.00076561986],"study_design_scores_gemma":[0.0056265257,0.0003993043,0.8643763,0.00019712679,0.12344358,5.886876e-8,0.00030532986,0.000023408633,0.00034668137,0.000038614664,0.0051077353,0.00013534862],"about_ca_topic_score_codex":0.0021157223,"about_ca_topic_score_gemma":0.0002987429,"teacher_disagreement_score":0.038230356,"about_ca_system_score_codex":0.000043681997,"about_ca_system_score_gemma":0.000054507917,"threshold_uncertainty_score":0.99987215},"labels":[],"label_agreement":null},{"id":"W4366083577","doi":"10.1002/ejhf.2857","title":"Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Renal function; Hazard ratio; Kidney disease; Heart failure; Internal medicine; Ejection fraction; Dialysis; Confidence interval; Cardiology; Creatinine; Urology; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.018506397207437398,"score_gpt":0.24613449219936187,"score_spread":0.22762809499192446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366083577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9003678,0.00094192737,0.0000023824991,0.09732695,0.0005789431,0.0005363231,0.000063446736,0.000018193523,0.00016406627],"genre_scores_gemma":[0.99646986,0.0001598889,0.00037955673,0.0016083556,0.0009526407,0.0000045991465,0.000038197883,0.000042498967,0.00034440818],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975856,0.0006247392,0.0007428292,0.00021652758,0.00053825823,0.00029205746],"domain_scores_gemma":[0.99857044,0.00022156561,0.00029736606,0.0004827576,0.00012449421,0.00030337193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012706004,0.00021738741,0.0006473523,0.00014031363,0.00012395672,0.000053533196,0.00024135956,0.000047239675,0.00009133275],"category_scores_gemma":[0.000452212,0.000119337405,0.00031723635,0.00051645975,0.00015612706,0.00016734927,0.00021364247,0.00041553573,0.000031982057],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047991453,0.00021867981,0.078857504,0.000092031434,0.00094657944,0.000068719906,0.0028294604,0.0000615582,0.0054414123,0.000116753195,0.90613663,0.0004315289],"study_design_scores_gemma":[0.021913702,0.0020827865,0.34403834,0.0007599448,0.00040428212,0.000011192169,0.0024977594,0.00001419109,0.001756782,0.00008018287,0.62629825,0.0001425861],"about_ca_topic_score_codex":0.0000480125,"about_ca_topic_score_gemma":0.000047150515,"teacher_disagreement_score":0.27983835,"about_ca_system_score_codex":0.000025823543,"about_ca_system_score_gemma":0.00013092914,"threshold_uncertainty_score":0.48664382},"labels":[],"label_agreement":null},{"id":"W4366331096","doi":"10.1503/cmaj.220934-f","title":"Éruption cutanée d’origine médicamenteuse associée à l’empagliflozine","year":2023,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.012346194899122904,"score_gpt":0.2682723244629239,"score_spread":0.25592612956380095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366331096","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16054697,0.012985121,0.00012368025,0.70845205,0.037861202,0.0010279291,0.0003523298,0.0003607437,0.07828996],"genre_scores_gemma":[0.23782422,0.037157997,0.00021795247,0.04079201,0.03727353,0.00008451327,0.00080264156,0.00022246403,0.6456247],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993,0.00036559443,0.0009544884,0.0003926278,0.0032081816,0.0020791143],"domain_scores_gemma":[0.9933766,0.00035629334,0.00045198982,0.000268854,0.0005235997,0.005022672],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004357942,0.00038948,0.00064228405,0.000868695,0.00050356274,0.00027846682,0.00034787963,0.00092964055,0.028431581],"category_scores_gemma":[0.0029623278,0.00039185915,0.00037682755,0.0014233211,0.00010649419,0.0003697548,0.00006600935,0.0016709355,0.017894557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012812749,0.00016487173,0.0599647,0.00006682426,0.0013778465,0.0043794257,0.00024148186,0.000015737027,0.000010114661,0.0020313694,0.79064167,0.14109313],"study_design_scores_gemma":[0.0027993768,0.00030340353,0.031623453,0.00075140875,0.0006654431,0.00020691834,0.00068787386,0.0018717846,0.000012602151,0.0005301094,0.9602257,0.00032190277],"about_ca_topic_score_codex":0.0027639265,"about_ca_topic_score_gemma":0.009495466,"teacher_disagreement_score":0.66766006,"about_ca_system_score_codex":0.008182738,"about_ca_system_score_gemma":0.003941698,"threshold_uncertainty_score":0.9998533},"labels":[],"label_agreement":null},{"id":"W4366333524","doi":"10.1503/cmaj.220673-f","title":"Atteinte des cibles thérapeutiques pour le diabète de type 2 en 2015 et 2020 en médecine de soins primaires au Canada","year":2023,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.010509449987006933,"score_gpt":0.27544236681174017,"score_spread":0.26493291682473324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366333524","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4216249,0.0052637337,0.00016569514,0.56010467,0.0029479538,0.00026615956,0.00011446024,0.00006373714,0.009448698],"genre_scores_gemma":[0.8667442,0.012505021,0.0007907284,0.031115681,0.010480096,0.00002519628,0.00020100204,0.00010505656,0.07803298],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957849,0.0007564054,0.0005031796,0.00024368503,0.0011514352,0.0015604313],"domain_scores_gemma":[0.9955695,0.0008124834,0.00021341591,0.00015334124,0.00030998598,0.0029412713],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004003811,0.00026914055,0.00043495122,0.00026564914,0.00034452745,0.0001203096,0.00030227797,0.00041006668,0.0018557075],"category_scores_gemma":[0.004127025,0.00026648695,0.00013703665,0.00055669184,0.00008268182,0.00018746677,0.000062105915,0.0009638471,0.0002859917],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011007173,0.00006765104,0.27549067,0.00007441078,0.00082610047,0.0022345914,0.0008238495,0.000058742935,0.00003527728,0.0015197631,0.67368937,0.04516859],"study_design_scores_gemma":[0.0014214555,0.00013292233,0.40527225,0.00060762226,0.0002845499,0.000108239255,0.0013287535,0.0009394367,0.00006260146,0.0011817436,0.58846545,0.00019499],"about_ca_topic_score_codex":0.8387272,"about_ca_topic_score_gemma":0.9864705,"teacher_disagreement_score":0.52898896,"about_ca_system_score_codex":0.0148159005,"about_ca_system_score_gemma":0.08456811,"threshold_uncertainty_score":0.9999787},"labels":[],"label_agreement":null},{"id":"W4366352141","doi":"10.1002/ajh.26933","title":"Sodium‐glucose co‐transporter‐2 inhibitor use and <i>JAK2</i> unmutated erythrocytosis in 100 consecutive cases","year":2023,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Erythropoietin; Canagliflozin; Internal medicine; Hematocrit; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.024676470683525832,"score_gpt":0.28041496752649064,"score_spread":0.2557384968429648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366352141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8340897,0.0008128322,0.000013395703,0.1639318,0.00042833295,0.00047901008,0.00007710663,0.00005231431,0.000115504896],"genre_scores_gemma":[0.7017079,0.0033085083,0.00088333833,0.29193255,0.0007607864,0.000050505303,0.00037583627,0.00018932216,0.00079126353],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975052,0.000191786,0.0009839067,0.0003882461,0.00035380793,0.00057706336],"domain_scores_gemma":[0.99744177,0.0009734553,0.00097418245,0.00026575776,0.000179237,0.00016562632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019720643,0.00045088376,0.0021515402,0.000993138,0.000041576528,0.00003501884,0.00013343806,0.00026793077,0.000044199965],"category_scores_gemma":[0.0001313269,0.00037187114,0.0002610781,0.00045015308,0.0008630638,0.00014397601,0.000044602064,0.0011634206,0.00003162753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008884034,0.00032166063,0.073772766,0.0004824269,0.002153525,0.16071714,0.0006719383,8.0762624e-7,0.00011587347,0.000030266816,0.7579608,0.0028844075],"study_design_scores_gemma":[0.018014044,0.019128678,0.021080276,0.005552056,0.0070274286,0.038875055,0.00475126,0.000014494066,0.0076488433,0.0002337359,0.8757848,0.0018893406],"about_ca_topic_score_codex":0.00027553705,"about_ca_topic_score_gemma":0.00006390737,"teacher_disagreement_score":0.13238181,"about_ca_system_score_codex":0.00014718554,"about_ca_system_score_gemma":0.00022056204,"threshold_uncertainty_score":0.99987334},"labels":[],"label_agreement":null},{"id":"W4366433723","doi":"10.1177/20451253231165169","title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Psychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; National Health and Medical Research Council; Department of Psychiatry, University of Toronto; HLS Therapeutics; Physicians' Services Incorporated Foundation; University of Toronto; Steno Diabetes Center Copenhagen","keywords":"Metformin; Semaglutide; Antipsychotic; Weight gain; Medicine; Risperidone; Series (stratigraphy); Internal medicine; Psychiatry; Psychology; Body weight; Psychotherapist; Schizophrenia (object-oriented programming); Endocrinology; Type 2 diabetes; Diabetes mellitus; Biology; Insulin","score_opus":0.027828118838062427,"score_gpt":0.37738513456743106,"score_spread":0.34955701572936865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366433723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919287,0.0018829559,0.00007014451,0.0016924737,0.0009977012,0.0030359493,0.00003624888,0.00005598773,0.00029983983],"genre_scores_gemma":[0.991069,0.004320215,0.00040063,0.00090558786,0.00005031818,0.0010320214,0.000026771804,0.000034511588,0.0021609075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984995,0.00010146305,0.00044101436,0.0003275532,0.00014652144,0.00048394658],"domain_scores_gemma":[0.9987858,0.000737103,0.00012476373,0.00023715668,0.00005157931,0.000063626445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037742846,0.00022112107,0.00047629137,0.0008218606,0.00006554171,0.0000053659833,0.00011418286,0.00006270297,0.000051736723],"category_scores_gemma":[0.000033573055,0.00015307605,0.00010383708,0.0014851367,0.00007843666,0.00009032055,0.00001959702,0.000067770045,0.000016087793],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034442347,0.0055820965,0.115596294,0.0001930422,0.0014087205,0.0009097828,0.0059657916,0.0009433677,0.0034885209,0.0013502279,0.000838373,0.82928145],"study_design_scores_gemma":[0.14163727,0.030130498,0.1597374,0.00047660526,0.0023305146,0.00008685521,0.0036447495,0.0038112272,0.01607934,0.005147443,0.63574773,0.0011703487],"about_ca_topic_score_codex":0.000007752601,"about_ca_topic_score_gemma":0.00011189512,"teacher_disagreement_score":0.8281111,"about_ca_system_score_codex":0.00025010496,"about_ca_system_score_gemma":0.000022590033,"threshold_uncertainty_score":0.62422603},"labels":[],"label_agreement":null},{"id":"W4366463088","doi":"10.1111/jgs.18360","title":"Adoption of sodium‐glucose cotransporter‐2 inhibitors among prescribers caring for nursing home residents","year":2023,"lang":"en","type":"article","venue":"Journal of the American Geriatrics Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute on Aging; U.S. Department of Veterans Affairs","keywords":"Medicine; Nursing homes; Nursing; Cotransporter; Sodium; Family medicine; Gerontology","score_opus":0.014214338997458404,"score_gpt":0.26719666290396105,"score_spread":0.25298232390650266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366463088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976039,0.00018937887,0.00029905394,0.0007650022,0.0006543118,0.00038742123,0.000008915909,0.000024594214,0.00006741582],"genre_scores_gemma":[0.9954213,0.0008575047,0.0029536702,0.00010406454,0.00031195878,0.000006654621,0.000008481879,0.000027767977,0.0003086154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986485,0.000029571785,0.0004882401,0.00012312918,0.00045797537,0.00025255323],"domain_scores_gemma":[0.99844974,0.00007497842,0.000999647,0.00020278862,0.00018029065,0.00009257938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047525225,0.000128813,0.000422068,0.00012534944,0.00009293891,0.000019820453,0.00016682004,0.000038403334,0.0000017078213],"category_scores_gemma":[0.000039308004,0.00009273245,0.0007760949,0.0007788808,0.0001934434,0.00013031831,0.000036075384,0.00015217098,9.65405e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090639194,0.0007823011,0.84323853,0.00071817817,0.0022494802,0.000026295475,0.008786035,0.0009339394,0.024039133,0.00006115727,0.08031941,0.037939128],"study_design_scores_gemma":[0.0027270222,0.00075004686,0.9846251,0.00045551124,0.001678292,0.0000062060863,0.003838791,0.00045757496,0.0045420714,0.000263149,0.0005098579,0.00014635493],"about_ca_topic_score_codex":0.00005938479,"about_ca_topic_score_gemma":0.000002131434,"teacher_disagreement_score":0.14138657,"about_ca_system_score_codex":0.0002516482,"about_ca_system_score_gemma":0.00008727799,"threshold_uncertainty_score":0.37815195},"labels":[],"label_agreement":null},{"id":"W4366974690","doi":"10.1186/s12933-023-01825-4","title":"Correction: Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials","year":2023,"lang":"en","type":"erratum","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Meta-regression; Meta-analysis; Angiology; Heart failure; Randomized controlled trial; MEDLINE; Internal medicine; Outcome (game theory); Intensive care medicine","score_opus":0.07018820773443565,"score_gpt":0.3262447057996008,"score_spread":0.2560564980651652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366974690","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10150687,0.87218267,0.002448347,0.0009245226,0.009114362,0.011240482,0.0011842527,0.00064015936,0.0007583248],"genre_scores_gemma":[0.877693,0.059258576,0.0032099218,0.0008727977,0.0011866223,0.0043540765,0.026458729,0.0011729508,0.025793307],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98272,0.0078158425,0.0033638806,0.002638225,0.0025624067,0.00089961925],"domain_scores_gemma":[0.9898076,0.002133872,0.0013067788,0.0056342487,0.00069505186,0.00042244996],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.014085949,0.0019645428,0.06809859,0.005659439,0.00019826744,0.00008153848,0.0004677985,0.0015245483,0.00033098456],"category_scores_gemma":[0.0016673369,0.0011830062,0.11856799,0.0043561235,0.0009902007,0.00017396863,0.0003560485,0.0009952824,0.000009623298],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00236454,0.0003223948,0.0031371834,0.0005096223,0.9795154,0.00011816791,0.0001706459,0.0040229093,0.000009525723,0.000024928144,0.008226951,0.0015777607],"study_design_scores_gemma":[0.038910717,0.00032771655,0.010512073,0.00003125017,0.9098805,0.0000133268395,0.0001514709,0.00040638843,0.00010685172,0.000014808487,0.038868017,0.0007768385],"about_ca_topic_score_codex":0.00086147303,"about_ca_topic_score_gemma":0.0000784404,"teacher_disagreement_score":0.8129241,"about_ca_system_score_codex":0.000119164164,"about_ca_system_score_gemma":0.00013340096,"threshold_uncertainty_score":0.99977165},"labels":[],"label_agreement":null},{"id":"W4366992499","doi":"10.1097/01.hjh.0000935612.24932.1d","title":"58. Blood Pressure Reduction Effect of Dapagliflozin in Patients with Type 2 Diabetes Mellitus: a Systematic Review","year":2023,"lang":"en","type":"review","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Blood pressure; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.023993022354148203,"score_gpt":0.2690935117406415,"score_spread":0.2451004893864933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366992499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029477358,0.9932368,8.6858876e-8,0.00002308756,0.00031025225,0.0034443792,0.0000037316422,0.000013854647,0.000020113783],"genre_scores_gemma":[0.00028367864,0.99921757,0.000061364226,0.000025324636,0.00007133781,0.0000383055,0.000059335598,0.00006050606,0.00018258674],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971937,0.00033339337,0.0014130822,0.00021215495,0.0006423138,0.00020538963],"domain_scores_gemma":[0.99726516,0.00020118259,0.0016739944,0.000401585,0.0003688218,0.00008927434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010134461,0.00036694718,0.005042682,0.000513222,0.000017139813,0.000010099709,0.00013503604,0.00013951724,0.000011480238],"category_scores_gemma":[0.00047736434,0.00018051686,0.00048504406,0.00065411296,0.00002513428,0.00009381323,0.0000458373,0.00031067105,0.00001843444],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006300682,0.00039272156,0.00014269188,0.9721293,0.004289686,0.00009435102,0.0000068487725,6.0552156e-7,0.000001977089,7.336615e-7,0.0011518042,0.021726295],"study_design_scores_gemma":[0.0018485799,0.0037137726,0.00006424232,0.87019634,0.11386981,0.000048469297,0.0000031289328,0.0000017720172,0.000008389304,8.796392e-7,0.010110869,0.00013377206],"about_ca_topic_score_codex":0.0000016523031,"about_ca_topic_score_gemma":2.1848702e-7,"teacher_disagreement_score":0.10958012,"about_ca_system_score_codex":0.000051673604,"about_ca_system_score_gemma":0.00008456009,"threshold_uncertainty_score":0.73612636},"labels":[],"label_agreement":null},{"id":"W4366992528","doi":"10.1097/01.hjh.0000935608.32755.d1","title":"57. Effect of Sodium-Glucose Cotransporter-2 Inhibitor on Blood Pressure in Patient with Type 2 Diabetes Mellitus with Renal Impairment: a Systematic Review","year":2023,"lang":"en","type":"review","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blood pressure; Diabetes mellitus; Internal medicine; Type 2 Diabetes Mellitus; Comorbidity; Cohort; Population; Cohort study; Endocrinology","score_opus":0.01772425732067012,"score_gpt":0.2508037036163056,"score_spread":0.23307944629563548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366992528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016089242,0.9790263,2.0507464e-7,0.00004544012,0.00014607814,0.004631301,0.000010862928,0.000020232996,0.000030320043],"genre_scores_gemma":[0.0031284508,0.99628747,0.000060254588,0.00010767228,0.0000715604,0.00010507759,0.00006074337,0.000091903785,0.00008686759],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963526,0.00035734053,0.0016689685,0.00032001338,0.0009702434,0.00033083296],"domain_scores_gemma":[0.9968428,0.0003206316,0.0018689589,0.0005036942,0.00029307485,0.00017084193],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084955065,0.0005957441,0.0057974122,0.0005589493,0.00002601345,0.000015012891,0.00015174825,0.00015175952,0.000012175843],"category_scores_gemma":[0.00010874265,0.00026627813,0.00057603535,0.0006385515,0.00004329618,0.00007839858,0.000031222793,0.0004623137,0.000015143914],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054059806,0.0009841253,0.000050350558,0.9707659,0.0059461147,0.0043001478,0.000030388024,0.0000026845319,0.000015845186,0.0000011457481,0.00051840674,0.01684428],"study_design_scores_gemma":[0.003070918,0.029386856,0.0000145548975,0.8669497,0.09138593,0.0004719071,0.0000072499456,0.0000033391077,0.00017930493,5.67715e-7,0.008307077,0.0002226366],"about_ca_topic_score_codex":0.0000034678133,"about_ca_topic_score_gemma":0.0000025537927,"teacher_disagreement_score":0.103816256,"about_ca_system_score_codex":0.000074114105,"about_ca_system_score_gemma":0.00017230932,"threshold_uncertainty_score":0.99997896},"labels":[],"label_agreement":null},{"id":"W4366992677","doi":"10.1097/01.hjh.0000935492.05025.c6","title":"28. Effect of Ertugliflozin on Blood Pressure in Patient with Type 2 Diabetes Mellitus: a Systematic Review","year":2023,"lang":"en","type":"review","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blood pressure; Type 2 Diabetes Mellitus; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.029221413446748955,"score_gpt":0.27725830746588975,"score_spread":0.2480368940191408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366992677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001131475,0.99513775,6.760911e-8,0.000057515612,0.00020542761,0.0033771787,0.0000041172234,0.000014146579,0.00007232429],"genre_scores_gemma":[0.00021156087,0.9992274,0.000047365957,0.00017128137,0.00005087575,0.00006275058,0.00002309704,0.00006669263,0.00013899987],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969579,0.00038021468,0.0014897665,0.00022862943,0.0007083495,0.00023513733],"domain_scores_gemma":[0.9969832,0.0006027792,0.0015802195,0.0004664077,0.00023425586,0.00013319524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009342334,0.0004309111,0.0058891163,0.00053093216,0.000015693242,0.000010021582,0.00014780255,0.0001365119,0.000014406557],"category_scores_gemma":[0.00081001426,0.00019744756,0.00061249395,0.0005815004,0.000022397267,0.000048381473,0.000050285584,0.00037066356,0.000032254145],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007687655,0.00039033024,0.000009922898,0.95290965,0.004443544,0.00148345,0.000010079442,0.0000014301943,0.000003116691,0.0000021436294,0.0014402835,0.03922919],"study_design_scores_gemma":[0.0011178271,0.010213246,0.0000028361503,0.8722001,0.08821906,0.00020823025,0.0000044657595,0.0000046795594,0.000021073549,9.70658e-7,0.027864834,0.0001427296],"about_ca_topic_score_codex":0.000001941413,"about_ca_topic_score_gemma":6.4772786e-7,"teacher_disagreement_score":0.08377552,"about_ca_system_score_codex":0.000051384042,"about_ca_system_score_gemma":0.000118522745,"threshold_uncertainty_score":0.8051678},"labels":[],"label_agreement":null},{"id":"W4367055583","doi":"10.1097/hep.0000000000000424","title":"Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?","year":2023,"lang":"en","type":"letter","venue":"Hepatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Sweet spot; Medicine; Chronic hepatitis; Diabetes mellitus; Internal medicine; Endocrinology; Virology; Biology","score_opus":0.011133974521115362,"score_gpt":0.222352207670559,"score_spread":0.21121823314944363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367055583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8919387,0.0016215084,4.6838224e-7,0.103567995,0.00061317894,0.0017510394,0.00007529504,0.000097802695,0.00033403147],"genre_scores_gemma":[0.96105105,0.001222511,0.000061317194,0.03127702,0.0011679472,0.0007810129,0.002156559,0.00018846884,0.0020941421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975889,0.00014607707,0.00056214095,0.000573453,0.00038549368,0.0007439405],"domain_scores_gemma":[0.9984351,0.00029510033,0.00044955793,0.00068167003,0.00008589487,0.000052668707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007840713,0.0005021126,0.0012409935,0.00040219797,0.000058399306,0.000013849318,0.00015596925,0.00043739274,0.000060330116],"category_scores_gemma":[0.00003081922,0.00030411486,0.00020499392,0.0003719666,0.00021284213,0.000040082436,0.000084287625,0.00039933276,0.00009099476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034205477,0.00028806826,0.8976438,0.00047607263,0.0007379211,0.000510475,0.00011320317,0.0000017035875,7.7215935e-7,0.000008965464,0.09211245,0.008072363],"study_design_scores_gemma":[0.0061443727,0.0047395043,0.58210903,0.0009236127,0.0012961981,0.0000025178524,0.000024757699,0.00011610635,0.00023444956,0.000051085764,0.40393016,0.00042819986],"about_ca_topic_score_codex":0.0007303401,"about_ca_topic_score_gemma":0.0013413707,"teacher_disagreement_score":0.31553477,"about_ca_system_score_codex":0.0007234743,"about_ca_system_score_gemma":0.00012550765,"threshold_uncertainty_score":0.9999411},"labels":[],"label_agreement":null},{"id":"W4367555137","doi":"10.1503/cmaj.221691","title":"Sodium–glucose cotransporter-2 inhibitors in patients without diabetes","year":2023,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Renal function; Creatinine; Urology; Kidney disease; Medicine; Cotransporter; Diabetes mellitus; Sodium; Albuminuria; Urinary system; Internal medicine; Endocrinology; Chemistry","score_opus":0.00568547825264714,"score_gpt":0.2160537796881719,"score_spread":0.21036830143552476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367555137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982668,0.00005078775,7.7996987e-7,0.012835685,0.0007568511,0.00023300196,0.000011629143,0.000043745637,0.0033995463],"genre_scores_gemma":[0.99271995,0.00009441688,0.000019753757,0.005121368,0.00048758456,0.000014791553,0.000110502355,0.000020412428,0.0014112428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976178,0.00005731489,0.00039841663,0.00015340927,0.0011463326,0.0006267476],"domain_scores_gemma":[0.99838257,0.00004904098,0.000113756054,0.000087886714,0.00014833595,0.0012184277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009263818,0.00012616617,0.0002686414,0.0005124834,0.00009927384,0.000044649096,0.0000960769,0.00021003166,0.0008779208],"category_scores_gemma":[0.00041778033,0.00011221511,0.00009762158,0.00050289556,0.000023183256,0.00011190727,0.00001112336,0.00046270297,0.00045064068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000063282628,0.00007094069,0.9064453,0.000012152594,0.00010055767,0.00020114421,0.00012158593,8.4472435e-7,0.0000031856368,0.000015929576,0.0591672,0.0338548],"study_design_scores_gemma":[0.0033144073,0.00011804375,0.87280524,0.00015105227,0.00005375964,0.0000014271313,0.000091980895,0.00010942386,0.00003605842,0.000055886157,0.12315728,0.0001054409],"about_ca_topic_score_codex":0.0003966643,"about_ca_topic_score_gemma":0.0074643167,"teacher_disagreement_score":0.06399008,"about_ca_system_score_codex":0.0010249044,"about_ca_system_score_gemma":0.0006965877,"threshold_uncertainty_score":0.9612617},"labels":[],"label_agreement":null},{"id":"W4367666908","doi":"10.12775/jehs.2023.25.01.003","title":"use of SGLT2 inhibitors in the treatment of cognitive disorders","year":2023,"lang":"en","type":"article","venue":"Journal of Education Health and Sport","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Medicine; Cognition; Cognitive decline; Verbal fluency test; Disease; Alzheimer's disease; Population; Type 2 diabetes; Diabetes mellitus; Psychiatry; Neuropsychology; Gerontology; Internal medicine; Endocrinology","score_opus":0.04216168106044976,"score_gpt":0.35955098386626166,"score_spread":0.3173893028058119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367666908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939531,0.0010575489,7.779443e-7,0.004291398,0.00017148265,0.0003161552,0.0000016731061,0.0000014434681,0.00020640698],"genre_scores_gemma":[0.9904664,0.0087065315,0.000048353464,0.0003330947,0.000056560068,0.000008197703,0.000022019833,0.0000030199164,0.00035581394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994189,0.000013858121,0.00032566552,0.00004173684,0.00012401813,0.000075830736],"domain_scores_gemma":[0.9994856,0.000069096466,0.0002653261,0.000048609516,0.000060953556,0.000070398026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001925406,0.000044842276,0.00018917653,0.00021524796,0.000015092758,0.000002812656,0.000014284353,0.000012773121,0.0000064803453],"category_scores_gemma":[0.000030774085,0.00002647833,0.000046067635,0.00020292104,0.000023106018,0.00004935587,0.0000019884076,0.000028620627,6.0732225e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013584767,0.0017034339,0.7908643,0.00010936165,0.00004869652,0.0000028169125,0.006558068,0.0000014746753,0.0000024301087,0.00010602218,0.0028655124,0.19760203],"study_design_scores_gemma":[0.0010772294,0.0031004741,0.95327324,0.00034006962,0.000079323196,0.0000043799323,0.013832318,0.0000043413993,0.000035963778,0.00008631613,0.028142266,0.000024072557],"about_ca_topic_score_codex":0.00014975313,"about_ca_topic_score_gemma":0.000029439127,"teacher_disagreement_score":0.19757795,"about_ca_system_score_codex":0.000041346524,"about_ca_system_score_gemma":0.00037728218,"threshold_uncertainty_score":0.1079755},"labels":[],"label_agreement":null},{"id":"W4367668169","doi":"10.1080/15563650.2023.2196372","title":"Expanding the evidence for managing metformin poisoning to support decision-making","year":2023,"lang":"en","type":"review","venue":"Clinical Toxicology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Medicine; Metformin; Lactic acidosis; Extracorporeal; Workgroup; Intensive care medicine; Renal replacement therapy; Retrospective cohort study; Intensive care unit; Hemofiltration; Hemoperfusion; Hemodialysis; Internal medicine; Surgery; Insulin","score_opus":0.43576533186950783,"score_gpt":0.5817812728849375,"score_spread":0.1460159410154297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367668169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008311322,0.98417306,0.0031264778,0.0010457706,0.0031610422,0.0063421377,0.000012384197,0.00021584523,0.0018401401],"genre_scores_gemma":[0.00004650179,0.9836918,0.0063869413,0.0020311323,0.00096805405,0.0015851262,0.000034210792,0.0001082454,0.0051479787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963397,0.00019552805,0.0016471292,0.0008659428,0.00025256904,0.000699128],"domain_scores_gemma":[0.97338414,0.025088742,0.00046245646,0.00078863814,0.00006265328,0.00021338208],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003915907,0.00041462967,0.0025869433,0.00035117968,0.0001971307,0.000063841486,0.0005552876,0.0004018566,0.00019588044],"category_scores_gemma":[0.010384877,0.00024974626,0.001299859,0.00055321224,0.00010347944,0.0000713172,0.0007022337,0.00048091073,0.0010404582],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006910886,0.00007417053,0.00004747345,0.0035947228,0.0007038285,0.00013971995,0.000023726096,6.971423e-7,5.122839e-8,0.00038926612,0.018126683,0.97683054],"study_design_scores_gemma":[0.00046373118,0.0017614245,0.00004295941,0.033240426,0.0043381033,0.000024161467,0.000055569635,0.000015465957,2.0806348e-7,0.0010571026,0.9587591,0.00024171444],"about_ca_topic_score_codex":8.611544e-7,"about_ca_topic_score_gemma":0.000010328661,"teacher_disagreement_score":0.97658885,"about_ca_system_score_codex":0.0002495491,"about_ca_system_score_gemma":0.00025168562,"threshold_uncertainty_score":0.99999547},"labels":[],"label_agreement":null},{"id":"W4367674424","doi":"10.1055/s-0043-1767871","title":"The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide &amp; Liraglutide in Type 2 Diabetes Patients (TROPHIES): final 24-month primary endpoint analysis","year":2023,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Liraglutide; Dulaglutide; Medicine; Type 2 diabetes; Clinical endpoint; Observational study; Internal medicine; Glucagon-like peptide 1 receptor; Diabetes mellitus; Endocrinology; Receptor; Clinical trial; Agonist","score_opus":0.07179920862189368,"score_gpt":0.3300207498317619,"score_spread":0.2582215412098682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367674424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474794,0.00034774817,0.000007342424,0.0013272181,0.0001891671,0.0022933187,0.000039433708,0.00017705176,0.00087075547],"genre_scores_gemma":[0.9951293,0.00025016844,0.00050664187,0.0002994978,0.000018687879,0.0003374049,0.00073992455,0.000036029942,0.0026823608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675614,0.00024503347,0.0008440633,0.0006055474,0.00076929963,0.00077992305],"domain_scores_gemma":[0.9977654,0.00065656746,0.0004465047,0.0007584176,0.00026326292,0.000109810404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008571689,0.00037520603,0.0012474314,0.0009234226,0.00024764854,0.00003686469,0.00027362737,0.00006158514,0.000014100792],"category_scores_gemma":[0.00028489862,0.00023486342,0.00018202233,0.0038978641,0.00017439901,0.00012810243,0.00021710638,0.00022878182,0.00001926821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024706568,0.002065803,0.98778427,0.00008400765,0.0031446514,0.000013577828,0.00045294853,0.00039111104,0.000004981422,0.0004416348,0.0011165468,0.0042534284],"study_design_scores_gemma":[0.0035261656,0.0018375437,0.99159694,0.00005202296,0.0009882825,2.541322e-8,0.00044279924,0.00011614413,0.000017842522,0.00034495216,0.0008643732,0.00021290575],"about_ca_topic_score_codex":0.0005373472,"about_ca_topic_score_gemma":0.0063024596,"teacher_disagreement_score":0.0057651126,"about_ca_system_score_codex":0.0005683453,"about_ca_system_score_gemma":0.0002208174,"threshold_uncertainty_score":0.95774525},"labels":[],"label_agreement":null},{"id":"W4367674465","doi":"10.1055/s-0043-1767999","title":"Patients achieving a HbA1c less than 5.7% with greater than or equal to 5% weight loss and without hypoglycaemia: A post hoc analysis of SURPASS 1 to 5","year":2023,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"","keywords":"Post-hoc analysis; Hypoglycemia; Placebo; Medicine; Post hoc; Weight loss; Comparator; Internal medicine; Diabetes mellitus; Endocrinology; Obesity","score_opus":0.03258893351236473,"score_gpt":0.2914224509018662,"score_spread":0.25883351738950144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367674465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960019,0.00006858436,0.00023031808,0.001387899,0.000110235895,0.0011930679,0.0001927187,0.00021795722,0.0005973019],"genre_scores_gemma":[0.9955398,0.000040075483,0.0012140372,0.0005251064,0.00003239182,0.00018133156,0.00030904007,0.00005323811,0.0021050237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974752,0.00007990801,0.00041440688,0.00074522564,0.0005223983,0.0007628299],"domain_scores_gemma":[0.9984332,0.00018448944,0.0001462812,0.00063993677,0.00022272591,0.00037337042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002950215,0.00042484122,0.001172241,0.0013129928,0.000111582376,0.00005167921,0.00023750811,0.00014078266,0.000028321843],"category_scores_gemma":[0.00015467063,0.0002748163,0.00017089756,0.0025070577,0.00011605162,0.00012649427,0.0003534447,0.00014362276,0.0000502555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017416851,0.00033645684,0.97727907,0.00015294329,0.004167989,0.00012064355,0.0010653695,0.000049311348,0.00018662013,0.00013928661,0.00063112675,0.014129481],"study_design_scores_gemma":[0.0032143483,0.004453336,0.9835332,0.00021748367,0.0049428237,0.0000013245082,0.0005548478,0.00013173542,0.0008738685,0.000013761923,0.0016450763,0.00041821794],"about_ca_topic_score_codex":0.00012506048,"about_ca_topic_score_gemma":0.00066244183,"teacher_disagreement_score":0.013711263,"about_ca_system_score_codex":0.00010253054,"about_ca_system_score_gemma":0.00006546763,"threshold_uncertainty_score":0.9999704},"labels":[],"label_agreement":null},{"id":"W4367839763","doi":"10.1126/sciadv.adf7737","title":"Divergent acute versus prolonged pharmacological GLP-1R responses in adult β cell–specific β-arrestin 2 knockout mice","year":2023,"lang":"en","type":"article","venue":"Science Advances","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; National Heart and Lung Institute; Imperial College London; Society for Endocrinology; UK Research and Innovation","keywords":"Agonist; Arrestin; Internal medicine; Endocrinology; Knockout mouse; Receptor; Signal transduction; G protein-coupled receptor; Biology; Chemistry; Pharmacology; Cell biology; Medicine","score_opus":0.03678138040161391,"score_gpt":0.3461380204642374,"score_spread":0.30935664006262353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367839763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148726,0.0008496146,0.000003862879,0.0014711835,0.0012053523,0.0006212525,0.000009526154,0.00018270624,0.0041692383],"genre_scores_gemma":[0.99314713,0.0014721216,0.000885302,0.00021850396,0.000078400924,0.00014805609,0.000013359934,0.000009026294,0.0040281108],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806607,0.000040691688,0.00020265422,0.0005481704,0.0005561476,0.000586239],"domain_scores_gemma":[0.99933034,0.00015478252,0.000065102,0.00019483826,0.00009151345,0.00016341943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004323201,0.00016148742,0.00020766424,0.00035165012,0.00019058684,0.00003706549,0.00030572579,0.000030025227,0.00010337696],"category_scores_gemma":[0.00017538705,0.00012122294,0.000052296662,0.0017162457,0.0005333767,0.0003826583,0.00019777453,0.00011822514,0.00047106142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011880853,0.0018542784,0.06356928,0.00017974291,0.0001801083,0.0028411315,0.0024548727,0.00057047285,0.69901484,0.0008152146,0.016714618,0.19992456],"study_design_scores_gemma":[0.02154229,0.004845265,0.27956632,0.00029146107,0.0005091684,0.000008557018,0.004404095,0.0009987672,0.5272704,0.00049967057,0.15905374,0.0010102928],"about_ca_topic_score_codex":0.000005652479,"about_ca_topic_score_gemma":0.000010877363,"teacher_disagreement_score":0.21599704,"about_ca_system_score_codex":0.00016864523,"about_ca_system_score_gemma":0.000106092724,"threshold_uncertainty_score":0.6054699},"labels":[],"label_agreement":null},{"id":"W4372335432","doi":"10.1111/jdi.14015","title":"Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies","year":2023,"lang":"en","type":"review","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Peking University; National Natural Science Foundation of China","keywords":"Medicine; Incretin; Cochrane Library; Meta-analysis; Internal medicine; Randomized controlled trial; Type 2 Diabetes Mellitus; Exenatide; Diabetes mellitus; Type 2 diabetes; Publication bias; Dementia; Endocrinology; Disease","score_opus":0.14312240703007503,"score_gpt":0.381840375204701,"score_spread":0.23871796817462596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4372335432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007812959,0.987457,0.000003951472,0.00015255672,0.000050529998,0.004477882,0.00002316213,0.000016719567,0.0000052747355],"genre_scores_gemma":[0.004891545,0.9934193,0.00042453367,0.00056368014,0.000028690774,0.00044783484,0.0001539729,0.000052623076,0.00001780651],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99567705,0.0010639529,0.0021274937,0.00030225015,0.00062852923,0.00020072391],"domain_scores_gemma":[0.9939196,0.0015627053,0.0032809386,0.00026773394,0.00085558824,0.0001134266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027562042,0.0004364412,0.0072748614,0.0012196257,0.000033073855,0.0000224544,0.000100128644,0.00014743124,0.000009976946],"category_scores_gemma":[0.0021300789,0.0002403887,0.0009940348,0.0017394526,0.00021834517,0.00011602655,0.000027590546,0.00035693686,0.0000037619654],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029722196,0.00030227992,0.009586749,0.79440767,0.19209614,0.0000025195764,0.00004226963,0.0000068291865,7.312951e-8,0.0000030367169,0.000021189991,0.0035015044],"study_design_scores_gemma":[0.0010620096,0.0033511505,0.0013937367,0.3042547,0.6895862,5.2521898e-8,0.000027911468,0.000056670786,0.000004459492,0.000023835726,0.000065918524,0.00017328629],"about_ca_topic_score_codex":0.0000010316685,"about_ca_topic_score_gemma":0.00000222454,"teacher_disagreement_score":0.4974901,"about_ca_system_score_codex":0.00011534605,"about_ca_system_score_gemma":0.00017952498,"threshold_uncertainty_score":0.9802767},"labels":[],"label_agreement":null},{"id":"W4375859757","doi":"10.1016/j.nupar.2023.03.012","title":"Le maintien de sémaglutide (2,4 mg/semaine) a permis une amélioration de la qualité de vie liée à la santé","year":2023,"lang":"fr","type":"article","venue":"Nutrition Clinique et Métabolisme","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Alberta","funders":"","keywords":"Gynecology; Medicine","score_opus":0.018705090454263364,"score_gpt":0.3805874149225233,"score_spread":0.3618823244682599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375859757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77326876,0.012665093,0.014095638,0.11329054,0.0019205284,0.0032776238,0.00050505536,0.0015320824,0.079444684],"genre_scores_gemma":[0.917856,0.044278666,0.011691351,0.0059216185,0.0030895995,0.000938995,0.0009682025,0.00017371938,0.015081875],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941779,0.0028202813,0.0007958372,0.0006023828,0.0004217243,0.0011818884],"domain_scores_gemma":[0.996749,0.0018731209,0.0002652981,0.00048080116,0.00015433953,0.000477477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0057849097,0.00044500807,0.00068071013,0.00048498274,0.00024911645,0.00021524324,0.00022778673,0.00064801815,0.00021755286],"category_scores_gemma":[0.0011273003,0.00052268105,0.00036543133,0.0008935923,0.0003432228,0.00037013993,0.00012988139,0.0007422614,0.0004493993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048540454,0.0056722,0.01114417,0.0030746795,0.00053752586,0.0013267255,0.009345539,0.00012811666,0.006995426,0.5751463,0.30454233,0.081601605],"study_design_scores_gemma":[0.008464467,0.00047555048,0.08689594,0.0027353456,0.0007579933,0.00007854766,0.0035727723,0.002124056,0.00222377,0.067778565,0.82429475,0.0005982695],"about_ca_topic_score_codex":0.0007593755,"about_ca_topic_score_gemma":0.00020266442,"teacher_disagreement_score":0.5197524,"about_ca_system_score_codex":0.0004608914,"about_ca_system_score_gemma":0.0010815216,"threshold_uncertainty_score":0.9997225},"labels":[],"label_agreement":null},{"id":"W4375946687","doi":"10.1016/j.metabol.2023.155470","title":"Dapagliflozin Initiation and eGFR Trajectories Across uACR Subgroups in Clinical Practice","year":2023,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dapagliflozin; Renal function; Urology; Creatinine; Medicine; Urine; Clinical Practice; Internal medicine; Endocrinology; Diabetes mellitus; Physical therapy","score_opus":0.043402027908180714,"score_gpt":0.38096232815374004,"score_spread":0.33756030024555933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375946687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049467,0.0012714055,0.000016412247,0.002570369,0.0006382211,0.00036789596,0.000008259667,0.00013002066,0.004502758],"genre_scores_gemma":[0.9940722,0.0016678303,0.0009446523,0.0011070857,0.00038171592,0.000059910704,0.00008070168,0.000021130056,0.0016648021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881077,0.00009916612,0.00034056703,0.0002590079,0.00021223904,0.00027827968],"domain_scores_gemma":[0.99931514,0.0002781417,0.00007517595,0.00019565699,0.000050410585,0.00008546191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001082,0.00011917564,0.00032023873,0.00010810514,0.000049755763,0.00004246772,0.00004428483,0.00007713944,0.000022245727],"category_scores_gemma":[0.0007595854,0.000101609396,0.000056837234,0.00043770493,0.00006034848,0.00027410197,0.00007328861,0.00014707191,0.00013054821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096685736,0.0017082277,0.49783188,0.00033927456,0.000881265,0.0010129148,0.012162569,0.000010569598,0.00062928314,0.027415695,0.017916195,0.43912527],"study_design_scores_gemma":[0.0024776729,0.00007901782,0.7833607,0.000021850736,0.00019850602,0.0000035674893,0.0010640525,0.00007573338,0.00011204278,0.00029880728,0.21222007,0.00008793898],"about_ca_topic_score_codex":0.00005947531,"about_ca_topic_score_gemma":0.000054268832,"teacher_disagreement_score":0.43903732,"about_ca_system_score_codex":0.000020198726,"about_ca_system_score_gemma":0.00002212177,"threshold_uncertainty_score":0.41435108},"labels":[],"label_agreement":null},{"id":"W4375946705","doi":"10.1016/j.metabol.2023.155429","title":"Advancing Type 2 Diabetes Therapy with iGlarLixi in Older People: Pooled Analysis of Four Randomized Controlled Trials","year":2023,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Type 2 diabetes; Randomized controlled trial; Medicine; Gerontology; Population; Diabetes mellitus; Physical therapy; Internal medicine; Endocrinology; Environmental health","score_opus":0.015454775484420147,"score_gpt":0.2845980668638719,"score_spread":0.26914329137945175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375946705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98863816,0.006246896,0.000053998872,0.0008975384,0.00020628494,0.003074569,0.000005739954,0.00008728026,0.0007895538],"genre_scores_gemma":[0.9940371,0.0027262005,0.00035823474,0.00028465583,0.000075111624,0.0005195282,0.00009698343,0.000028703073,0.0018735197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973622,0.00067450147,0.0009308664,0.0002745461,0.00039987874,0.0003579959],"domain_scores_gemma":[0.99737346,0.001651168,0.00041688344,0.0003364979,0.00014537101,0.0000765924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005014385,0.0002444138,0.0065153316,0.0013987832,0.000025974472,0.00002210226,0.00008274178,0.000058450536,0.0003891108],"category_scores_gemma":[0.0014358234,0.00013168778,0.0009048389,0.0028177504,0.000039643764,0.00007747798,0.000027270715,0.00007843634,0.000015645483],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4422921,0.0022859604,0.19335456,0.00032067325,0.2686499,0.00013472892,0.0057028783,0.0025980943,0.016244732,0.0024431047,0.0023390048,0.063634254],"study_design_scores_gemma":[0.6956013,0.0001376219,0.25612828,0.00008648079,0.041614607,1.1361745e-7,0.00022183494,0.0038420416,0.0013064576,0.0001606802,0.0007111596,0.0001894464],"about_ca_topic_score_codex":0.00005070825,"about_ca_topic_score_gemma":0.00007972857,"teacher_disagreement_score":0.2533092,"about_ca_system_score_codex":0.00001978783,"about_ca_system_score_gemma":0.000049729566,"threshold_uncertainty_score":0.53700715},"labels":[],"label_agreement":null},{"id":"W4376107294","doi":"10.1016/j.jchf.2023.03.022","title":"Time Is of the Essence","year":2023,"lang":"en","type":"letter","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Ejection fraction; Kidney disease; Cause of death; Placebo; Cardiology; Type 2 Diabetes Mellitus; Diabetes mellitus; Disease; Endocrinology; Pathology","score_opus":0.012406777818758038,"score_gpt":0.24335892009964283,"score_spread":0.2309521422808848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376107294","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013982574,0.00004763264,9.847868e-7,0.9945358,0.0003040977,0.0006289046,0.00004117348,0.00008787461,0.0029552733],"genre_scores_gemma":[0.00081957557,0.000009581409,0.0002593296,0.7116234,0.0014655129,0.000052121122,0.00014806088,0.00006612863,0.28555632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878067,0.000033034565,0.00019841777,0.00027275074,0.00043837068,0.00027676407],"domain_scores_gemma":[0.99902725,0.00007060512,0.00008363557,0.00073008577,0.000055056236,0.00003333597],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008547012,0.00020203268,0.00042261614,0.000090908514,0.00004712778,0.000013755487,0.00016909192,0.00031814136,0.0009727799],"category_scores_gemma":[0.000030439589,0.0001248611,0.00027968272,0.00026455452,0.00008272954,0.000027182878,0.0001453178,0.0005552943,0.0025265068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024367323,0.00002107229,0.0007104437,0.0003322785,0.00018135246,0.000046512316,0.00004553542,1.7633185e-7,0.00017456117,0.000011000443,0.9983289,0.00014572701],"study_design_scores_gemma":[0.00028486073,0.00007093843,0.0017152696,0.0004268417,0.00030205777,0.0000039015895,0.00001383984,0.0000097861775,0.00046446986,0.00008869571,0.99651515,0.00010420894],"about_ca_topic_score_codex":0.000024507417,"about_ca_topic_score_gemma":0.0000026400674,"teacher_disagreement_score":0.28291243,"about_ca_system_score_codex":0.00004104546,"about_ca_system_score_gemma":0.00006690332,"threshold_uncertainty_score":0.99994045},"labels":[],"label_agreement":null},{"id":"W4376121968","doi":"10.1111/dom.15091","title":"<scp>The sodium‐glucose cotransporter‐2</scp> inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> randomized double‐blind trials","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Hazard ratio; Placebo; Internal medicine; Proportional hazards model; Post-hoc analysis; Diabetes mellitus; Confidence interval; Type 2 diabetes; Urology; Surgery; Endocrinology; Pathology","score_opus":0.009550942729889354,"score_gpt":0.24690151203213107,"score_spread":0.23735056930224172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376121968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97590584,0.017320089,0.000014378427,0.00021569434,0.0002567276,0.005270411,0.0007725979,0.00016526054,0.00007903301],"genre_scores_gemma":[0.98412806,0.012513469,0.0002853905,0.0002672784,0.00030772528,0.0009853407,0.0010000735,0.000067381305,0.00044528831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952169,0.00097344257,0.0011619941,0.0009542887,0.0007043308,0.0009890113],"domain_scores_gemma":[0.99000186,0.007712255,0.0007208773,0.00073298905,0.00034258762,0.0004894281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039126715,0.00076812896,0.0031115087,0.0008537426,0.0005050628,0.0003502316,0.0002874422,0.0002982349,0.00001270119],"category_scores_gemma":[0.0025299815,0.00043125174,0.00047137242,0.0024153641,0.00080393575,0.00040196456,0.00023168387,0.0005092308,0.000011238715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020196263,0.0019477176,0.9396886,0.0005441219,0.019184433,0.000044262175,0.013009661,0.00006254696,0.0053248904,0.0001330101,0.00071311806,0.017327974],"study_design_scores_gemma":[0.12718202,0.00089869683,0.7891243,0.00027918242,0.045078438,0.0000017254234,0.00411312,0.0011369841,0.02602023,0.00043719163,0.0055462066,0.00018190515],"about_ca_topic_score_codex":0.007244038,"about_ca_topic_score_gemma":0.012384278,"teacher_disagreement_score":0.15056434,"about_ca_system_score_codex":0.00004018958,"about_ca_system_score_gemma":0.00018623732,"threshold_uncertainty_score":0.9998139},"labels":[],"label_agreement":null},{"id":"W4376128787","doi":"10.2337/ds22-0085","title":"Trends in Time in Range–Related Publications and Clinical Trials: A Bibliometric Review","year":2023,"lang":"en","type":"review","venue":"Diabetes Spectrum","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"Abbott Diabetes Care; Abbott Laboratories","keywords":"Medicine; Clinical trial; Observational study; MEDLINE; Trial registration; Family medicine; Internal medicine","score_opus":0.20441163780054222,"score_gpt":0.4697637114838882,"score_spread":0.26535207368334596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376128787","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013944345,0.9895162,7.972993e-8,0.0022277362,0.00018906867,0.0029382,0.000056612895,0.00020535378,0.004727314],"genre_scores_gemma":[0.0000061303713,0.9843892,0.000027421987,0.00021329835,0.000121650504,0.0007958396,0.0014107015,0.000101268,0.012934511],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99390006,0.0011112358,0.0030238305,0.00087188586,0.00040786812,0.0006851345],"domain_scores_gemma":[0.9959575,0.0022488222,0.00075257476,0.0007567082,0.000027468452,0.00025696162],"candidate_categories":["metaepi_narrow","bibliometrics","insufficient_payload"],"consensus_categories":["bibliometrics","insufficient_payload"],"category_scores_codex":[0.009228255,0.00054906966,0.006161773,0.06175073,0.00002686509,0.00009220825,0.00030364544,0.00043005683,0.0009950969],"category_scores_gemma":[0.003170419,0.00041339797,0.0011191136,0.10038867,0.00008354299,0.00012020432,0.00023115311,0.00071141165,0.001092177],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028348568,0.00045682144,0.009641639,0.018677723,0.0008496551,0.000030903007,0.0000030619565,8.021528e-9,9.779146e-9,0.00009996069,0.01659996,0.9536374],"study_design_scores_gemma":[0.0021304903,0.00027115154,0.018440701,0.06492896,0.005563202,0.0000022223603,0.0000011461083,0.00002372864,3.6690178e-8,0.00013024056,0.90814054,0.00036759448],"about_ca_topic_score_codex":0.000014480322,"about_ca_topic_score_gemma":0.000026848546,"teacher_disagreement_score":0.95326984,"about_ca_system_score_codex":0.0002551376,"about_ca_system_score_gemma":0.0001418314,"threshold_uncertainty_score":0.9999181},"labels":[{"model":"gemma","categories":["bibliometrics"],"domain":null,"study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["bibliometrics"],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4376132656","doi":"10.1016/j.jacc.2023.03.390","title":"Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories","year":2023,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Heart failure; Internal medicine; Renal function; Ejection fraction; Kidney disease; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.006284045763379681,"score_gpt":0.25261479653647245,"score_spread":0.24633075077309277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376132656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747074,0.00002870761,0.000006870201,0.0017755929,0.00016098708,0.00028333467,0.00009345813,0.0000060253965,0.0001742732],"genre_scores_gemma":[0.999247,0.00004729896,0.0003340326,0.00013599436,0.000071635004,0.0000036780282,0.0000044655367,0.000013187249,0.00014266395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988185,0.00016800995,0.0004074602,0.000100718644,0.00028206405,0.0002232346],"domain_scores_gemma":[0.99865884,0.0001407457,0.000661769,0.0002670024,0.00019049083,0.00008116273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003657152,0.00011464669,0.0009263136,0.00017776027,0.000031527255,0.0000020201828,0.00016099401,0.000028891853,0.0000033370306],"category_scores_gemma":[0.0002850162,0.00006461248,0.00024548132,0.000780424,0.00040039426,0.00003897297,0.000091330425,0.00016405436,0.000002354521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014991701,0.000098599885,0.97525394,0.000028480576,0.0007276406,0.000030310466,0.0001013347,0.0004910221,0.00010192864,0.000017696548,0.021170802,0.00047909076],"study_design_scores_gemma":[0.0045382883,0.0024050595,0.980634,0.00009256174,0.0003103492,0.000013517819,0.0008256521,0.00000414629,0.00031780804,0.000037495145,0.010764617,0.00005654459],"about_ca_topic_score_codex":0.000024946887,"about_ca_topic_score_gemma":0.0000091865895,"teacher_disagreement_score":0.010406186,"about_ca_system_score_codex":0.000058468675,"about_ca_system_score_gemma":0.00013219786,"threshold_uncertainty_score":0.26348206},"labels":[],"label_agreement":null},{"id":"W4376270189","doi":"10.2337/dc23-0129","title":"The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Astellas Pharma; Merck Canada; University of Toronto; Sanofi; Kidney Foundation of Canada; Diabetes Canada; Novo Nordisk; Dexcom; Gilead Sciences; Heart and Stroke Foundation of Canada; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Diabetes mellitus; Type 1 diabetes; Cardiorenal syndrome; Type 2 diabetes; Intensive care medicine; Internal medicine; Endocrinology; Heart failure","score_opus":0.020347221168426726,"score_gpt":0.27996519207721354,"score_spread":0.2596179709087868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376270189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822885,0.00042117035,3.2110793e-7,0.000051940642,0.0002018515,0.00075631106,0.000020049307,0.00006906662,0.00025043578],"genre_scores_gemma":[0.9993011,0.00009906124,0.000008640988,0.00006175661,0.000033324974,0.00017379012,0.00024569436,0.000023947436,0.000052734697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983736,0.00028390973,0.0003769152,0.00028416858,0.00037034944,0.0003110399],"domain_scores_gemma":[0.99848765,0.00062418415,0.00017916273,0.00041920075,0.00020563604,0.000084184976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063505274,0.00017271549,0.0006872874,0.00042426406,0.000052628853,0.0000127114035,0.000110313325,0.00009765337,0.0000063029984],"category_scores_gemma":[0.0004862159,0.00011160082,0.00022867018,0.0019609083,0.0001492646,0.000058497008,0.000048290258,0.00016235282,0.000010271341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014918688,0.0001779734,0.97460806,0.00020266262,0.0047790576,0.000010270797,0.0004099576,0.000104424216,0.00030007274,0.000013165865,0.00025371037,0.018991446],"study_design_scores_gemma":[0.0017070783,0.0044851326,0.98454213,0.0004224304,0.0027220058,7.3807516e-9,0.0014413573,0.00064995786,0.0037176097,0.00001192463,0.00017752539,0.00012284177],"about_ca_topic_score_codex":0.000004292078,"about_ca_topic_score_gemma":0.00011186439,"teacher_disagreement_score":0.018868605,"about_ca_system_score_codex":0.00009841294,"about_ca_system_score_gemma":0.00005506012,"threshold_uncertainty_score":0.45509493},"labels":[],"label_agreement":null},{"id":"W4376270679","doi":"10.2218/gtopdb/f29/2023.1","title":"Glucagon receptor family in GtoPdb v.2023.1","year":2023,"lang":"en","type":"article","venue":"IUPHAR/BPS Guide to Pharmacology CITE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon; Secretin family; Secretin; Endocrinology; Receptor; Internal medicine; Glucagon-like peptide-1; Peptide hormone; Hormone; Peptide; Chemistry; Biology; Secretion; Biochemistry; Vasoactive intestinal peptide; Medicine; Neuropeptide; Diabetes mellitus; Type 2 diabetes","score_opus":0.02509053307915479,"score_gpt":0.3625235709769066,"score_spread":0.3374330378977518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376270679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93505836,0.00056016,0.00003417101,0.013879058,0.0025894747,0.0018423602,0.000069191155,0.0005942493,0.045373004],"genre_scores_gemma":[0.6444028,0.0021610297,0.0021761882,0.07196463,0.0018322213,0.0022239785,0.0010759986,0.00020098701,0.2739622],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759394,0.00010052209,0.00053332845,0.0006193989,0.0002960082,0.00085680705],"domain_scores_gemma":[0.999054,0.00012800607,0.00007748372,0.0003119138,0.00007332868,0.00035526446],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005625268,0.0003177876,0.00052673364,0.0008704517,0.00007196946,0.000024489782,0.00024289447,0.00013693499,0.0022735016],"category_scores_gemma":[0.000054872067,0.00030617276,0.00014314026,0.0013341623,0.00006505089,0.00012695752,0.00025050866,0.00026007878,0.010833889],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027580772,0.00026290258,0.006139639,0.00006857239,0.0002872266,0.0004748224,0.00020877508,0.00006775567,0.1622593,0.00013951371,0.81681955,0.012996149],"study_design_scores_gemma":[0.0056115924,0.00043051215,0.030268528,0.00006257654,0.00028447338,0.0000036754673,0.0001314009,0.00020351644,0.019763444,0.000046373654,0.94290066,0.00029323343],"about_ca_topic_score_codex":0.0000956491,"about_ca_topic_score_gemma":0.000019294139,"teacher_disagreement_score":0.29065555,"about_ca_system_score_codex":0.00029780943,"about_ca_system_score_gemma":0.000094731055,"threshold_uncertainty_score":0.999939},"labels":[],"label_agreement":null},{"id":"W4376613148","doi":"10.1111/dom.15112","title":"Kidney protection with canagliflozin: A combined analysis of the randomized <scp>CANVAS</scp> program and <scp>CREDENCE</scp> trials","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"Janssen Research and Development; Mitsubishi Tanabe Pharma Corporation; American Society of Nephrology","keywords":"Canagliflozin; Medicine; Albuminuria; Renal function; Kidney disease; Empagliflozin; Internal medicine; Population; Urology; Creatinine; Kidney; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.019082076094144345,"score_gpt":0.25315936492035485,"score_spread":0.2340772888262105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916136,0.0015165005,0.000020400184,0.00046429876,0.000201366,0.0051047388,0.000077192475,0.00020296419,0.0007989141],"genre_scores_gemma":[0.99263436,0.0011267186,0.00038304942,0.00045298666,0.00010314898,0.0013021973,0.00019896342,0.000034757595,0.0037638252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972516,0.0005821638,0.00060215266,0.00050045655,0.00052861846,0.0005350425],"domain_scores_gemma":[0.99766034,0.00089419103,0.00045707688,0.000471574,0.00017706455,0.00033973804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002621721,0.00036524987,0.00232784,0.00063519797,0.0002354487,0.00010514521,0.00014429283,0.00013898294,0.000009089492],"category_scores_gemma":[0.0030808025,0.00021323978,0.00048981415,0.002134498,0.00039527979,0.00015280464,0.00015394657,0.00018950703,0.0000049704217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029568244,0.004450837,0.7672881,0.003764335,0.10217845,0.000056109675,0.009466478,0.00018383916,0.011706514,0.0074549643,0.017600605,0.072892964],"study_design_scores_gemma":[0.11640453,0.00063162716,0.7704717,0.00038045496,0.05812088,0.0000013934708,0.0009251216,0.0047463933,0.012664708,0.000848504,0.034658954,0.00014573109],"about_ca_topic_score_codex":0.0003585095,"about_ca_topic_score_gemma":0.00010646956,"teacher_disagreement_score":0.1134477,"about_ca_system_score_codex":0.000024843212,"about_ca_system_score_gemma":0.00010328521,"threshold_uncertainty_score":0.86956656},"labels":[],"label_agreement":null},{"id":"W4376616668","doi":"10.1111/bcp.15787","title":"Sodium‐glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population‐based cohort study","year":2023,"lang":"en","type":"review","venue":"British Journal of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Hazard ratio; Confidence interval; Cohort study; Proportional hazards model; Internal medicine; Retrospective cohort study; Dipeptidyl peptidase-4; Cohort; Diabetes mellitus; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.06412030601415204,"score_gpt":0.4251570621696322,"score_spread":0.3610367561554802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376616668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12342291,0.870115,0.0000038938992,0.00015023349,0.0026120662,0.0035143578,0.00006092087,0.000023056215,0.00009754489],"genre_scores_gemma":[0.020878883,0.97716963,0.00005178723,0.0003044309,0.0012945674,0.00007482245,0.00005163344,0.000058290978,0.00011595718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99401146,0.0015128311,0.0034006191,0.000327002,0.00048377446,0.0002643247],"domain_scores_gemma":[0.99443877,0.00211759,0.0028084042,0.00019401507,0.00022221338,0.00021901469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048693186,0.0002965437,0.0054565114,0.00022411144,0.00008668647,0.000025986801,0.00024753026,0.00026126168,0.00013853979],"category_scores_gemma":[0.00045231776,0.00020471358,0.0014028783,0.000273713,0.00035774882,0.00005859161,0.000076725504,0.001214335,0.000011205684],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060930324,0.004679072,0.063094966,0.0043109558,0.015226916,0.0023819986,0.000038270016,0.000004666351,6.536465e-8,0.0000045818188,0.009931159,0.89971805],"study_design_scores_gemma":[0.038281947,0.004359875,0.50029,0.011180403,0.14853138,0.00051786675,0.00005715681,0.000024991195,7.7787337e-7,0.00014731636,0.2962087,0.00039960127],"about_ca_topic_score_codex":0.00017279605,"about_ca_topic_score_gemma":0.000038487007,"teacher_disagreement_score":0.89931846,"about_ca_system_score_codex":0.000050126484,"about_ca_system_score_gemma":0.00031023228,"threshold_uncertainty_score":0.83479774},"labels":[],"label_agreement":null},{"id":"W4376642154","doi":"10.1161/circulationaha.122.063263","title":"Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium–Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials","year":2023,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"National Institute on Minority Health and Health Disparities; National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Medicine; Heart failure; Placebo; Ejection fraction; Quality of life (healthcare); Internal medicine; Clinical endpoint; Canagliflozin; Clinical trial; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.19589290670007736,"score_gpt":0.33605246377618,"score_spread":0.14015955707610261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376642154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8895646,0.10595627,0.000005631372,0.00005618839,0.000023877788,0.0040033464,0.00035868894,0.000017771586,0.000013632601],"genre_scores_gemma":[0.97768646,0.02021671,0.000051754723,0.000018018776,0.000017782428,0.00035185658,0.0016016656,0.00003608629,0.000019674611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959729,0.00079441565,0.0018436669,0.00048541767,0.00069582596,0.0002077943],"domain_scores_gemma":[0.99752367,0.00033139015,0.001423949,0.0004931632,0.00015789644,0.0000699448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008234511,0.0004185804,0.005313494,0.0007616931,0.000029529267,0.000020625685,0.000098395154,0.00019544092,0.000036868045],"category_scores_gemma":[0.00022055622,0.00020984917,0.00096673786,0.001815109,0.000095007,0.000117146716,0.00003784565,0.00016157505,8.5573566e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026288684,0.00061171915,0.9537532,0.004700822,0.035196837,0.0000010343042,0.00025653047,0.000021991431,9.773913e-7,0.000013949512,0.000012028337,0.0051680724],"study_design_scores_gemma":[0.0027291407,0.00023109945,0.8578966,0.0015358912,0.13707404,4.2479353e-8,0.000035839446,0.000012516162,0.0000041882317,0.0000074295112,0.00028957322,0.00018361003],"about_ca_topic_score_codex":0.0007753951,"about_ca_topic_score_gemma":0.003293178,"teacher_disagreement_score":0.101877205,"about_ca_system_score_codex":0.00007761354,"about_ca_system_score_gemma":0.00012439843,"threshold_uncertainty_score":0.8557401},"labels":[],"label_agreement":null},{"id":"W4377093422","doi":"10.1161/circheartfailure.122.009837","title":"Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials","year":2023,"lang":"en","type":"article","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"National Heart, Lung, and Blood Institute; Relypsa; Vifor Pharma; Impulse Dynamics; Intercept Pharmaceuticals; Prothena; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Dexcom; Regeneron Pharmaceuticals; Emory University; Boston Scientific Corporation; University of Pittsburgh; United Therapeutics Corporation; Eli Lilly and Company; U.S. Department of Defense; Sanofi; National Institute on Aging; CSL Behring; Bristol-Myers Squibb; Allergan; AstraZeneca; Edwards Lifesciences; Amgen; Pfizer; Tenax Therapeutics; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Gilead Sciences; Eisai; Cytokinetics; Brigham and Women's Hospital","keywords":"Dapagliflozin; Ejection fraction; Medicine; Placebo; Heart failure; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Randomized controlled trial; Atrial fibrillation; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.051632211784369796,"score_gpt":0.30408598795462427,"score_spread":0.2524537761702545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377093422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878709,0.0002822652,0.00030892814,0.010038152,0.00009801491,0.001113571,0.00014529345,0.00011596168,0.000026919859],"genre_scores_gemma":[0.99809283,0.000025191981,0.0006463415,0.0001628569,0.00020665539,0.00015641024,0.00058428204,0.000022940867,0.000102466896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982492,0.0002234067,0.00047884724,0.00042099884,0.00038078823,0.00024681116],"domain_scores_gemma":[0.99831635,0.0007707774,0.00021568048,0.00039460463,0.00019226328,0.000110337554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044009497,0.00021445035,0.00068583805,0.00024147877,0.00026245124,0.000099673925,0.00004663669,0.00012157285,0.00003743632],"category_scores_gemma":[0.00040101,0.00016061227,0.00029440748,0.0010472162,0.00009951168,0.00029713617,0.0000715655,0.00014622076,0.000024148236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035490168,0.0005074461,0.8948648,0.00021934394,0.005912646,0.0000037727361,0.0031428752,0.0010737261,0.06731999,0.00032607594,0.012897343,0.013377062],"study_design_scores_gemma":[0.0022342226,0.00027776088,0.9720384,0.000057949375,0.0032027208,0.0000016802961,0.0023273304,0.009777231,0.0007752544,0.0003852691,0.008748719,0.0001734734],"about_ca_topic_score_codex":0.00020921265,"about_ca_topic_score_gemma":0.0003485536,"teacher_disagreement_score":0.077173576,"about_ca_system_score_codex":0.00004398818,"about_ca_system_score_gemma":0.000025794378,"threshold_uncertainty_score":0.65495783},"labels":[],"label_agreement":null},{"id":"W4377139872","doi":"10.1002/pds.5641","title":"A methodology to assess the population size and estimate the needed resources for new licensed medications by combining clinical and administrative databases: The example of glycated haemoglobin in type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"AstraZeneca Pharma Poland","keywords":"Medicine; Database; Pharmacoepidemiology; Logistic regression; Missing data; Population; Covariate; Type 2 diabetes; Medical prescription; Glycated haemoglobin; Imputation (statistics); Health care; Type 2 Diabetes Mellitus; Statistics; Diabetes mellitus; Data mining; Internal medicine; Mathematics; Computer science; Environmental health; Endocrinology; Pharmacology","score_opus":0.2650371947792778,"score_gpt":0.49573204218726086,"score_spread":0.23069484740798307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377139872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.922863,0.0011274224,0.00038320065,0.074257664,0.00011752281,0.0011317014,0.00004690667,0.000029752215,0.000042835065],"genre_scores_gemma":[0.98943263,0.001316356,0.0031743327,0.005439888,0.00006511386,0.00012948136,0.00021423856,0.000011147652,0.00021681986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973611,0.0015816782,0.00049201533,0.0002793219,0.000059855716,0.00022600945],"domain_scores_gemma":[0.96750975,0.03199002,0.00017445661,0.00019435029,0.000034007317,0.00009740728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069183167,0.00012674944,0.00044816535,0.000044961755,0.0001983621,0.000006799271,0.000097381664,0.000048963626,0.000011713097],"category_scores_gemma":[0.005009924,0.000064220694,0.00003329368,0.0002638775,0.00035686148,0.000042017982,0.00013467357,0.00016701066,0.0000010845272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025605056,0.000182137,0.8387416,0.00018024762,0.0010784843,0.000003233312,0.0056853523,0.0001242858,0.0011877187,0.0075883353,0.092713825,0.04995428],"study_design_scores_gemma":[0.004032152,0.00036371525,0.9439463,0.00008662778,0.0008677328,0.0000034171974,0.002151241,0.009852999,0.0002187538,0.001939689,0.036404714,0.0001326831],"about_ca_topic_score_codex":0.0008498032,"about_ca_topic_score_gemma":0.0001583553,"teacher_disagreement_score":0.10520469,"about_ca_system_score_codex":0.000007969979,"about_ca_system_score_gemma":0.00003215154,"threshold_uncertainty_score":0.5997709},"labels":[],"label_agreement":null},{"id":"W4377193379","doi":"10.1016/j.jchf.2023.05.010","title":"Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype","year":2023,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Heart failure with preserved ejection fraction; Internal medicine; Heart failure; Cardiology; Semaglutide; Ejection fraction; Body mass index; Placebo; Type 2 diabetes; Diabetes mellitus; Endocrinology; Liraglutide; Pathology","score_opus":0.019465160798852417,"score_gpt":0.2801980734755654,"score_spread":0.260732912676713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377193379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968806,0.000022974064,0.00017856143,0.0007941746,0.000036843092,0.0019155346,0.000008546788,0.00011212737,0.00005065082],"genre_scores_gemma":[0.94639486,0.0000061198825,0.052825093,0.00014068316,0.000039790826,0.00009602015,0.00017946422,0.000027292766,0.0002906464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987444,0.00009947733,0.00027039493,0.00025969738,0.00033593483,0.00029004712],"domain_scores_gemma":[0.99933356,0.000108501314,0.00008339719,0.00023187247,0.00014810605,0.0000945454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006168408,0.0001616715,0.00037304783,0.0001555455,0.000042223648,0.000018740937,0.00004064374,0.000057928177,0.00004114017],"category_scores_gemma":[0.00013480711,0.00012493534,0.000030137182,0.00041428738,0.000039967614,0.000063773594,0.00006364985,0.00011127395,0.00003126444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030660353,0.0007982754,0.9334283,0.00033539467,0.00009340456,0.000016946096,0.00016647454,0.000019642435,0.00017448628,0.000014061811,0.0033164953,0.06132994],"study_design_scores_gemma":[0.003394726,0.0019520683,0.9854294,0.00031245424,0.00017038036,5.34516e-7,0.00006174406,0.0048165913,0.000114709626,0.000012895266,0.0036050433,0.00012945516],"about_ca_topic_score_codex":0.000025103973,"about_ca_topic_score_gemma":0.000016142034,"teacher_disagreement_score":0.061200485,"about_ca_system_score_codex":0.0000424937,"about_ca_system_score_gemma":0.000053530028,"threshold_uncertainty_score":0.50947154},"labels":[],"label_agreement":null},{"id":"W4377223615","doi":"10.1111/dom.15122","title":"Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Renal function; Hazard ratio; Internal medicine; Meta-analysis; Meta-regression; Confidence interval; Heart failure; Diabetes mellitus; Type 2 diabetes; Placebo; Kidney disease; Blood pressure; Cardiology; Randomized controlled trial; Proportional hazards model; Endocrinology; Pathology","score_opus":0.029766468517735373,"score_gpt":0.28738270151207396,"score_spread":0.25761623299433856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377223615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048741408,0.94909596,0.000053238004,0.00019296262,0.000069802554,0.0015840132,0.00019537387,0.000058109803,0.000009136554],"genre_scores_gemma":[0.019659795,0.97687465,0.00045728465,0.00008677898,0.00008638814,0.0003619505,0.0021543812,0.00005292043,0.00026587164],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974246,0.00028414963,0.0007247566,0.00081517966,0.00042461255,0.00032672257],"domain_scores_gemma":[0.99866796,0.000076465556,0.00044340693,0.00038756212,0.00010648534,0.00031810266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006874691,0.0006189827,0.005569126,0.0021865522,0.000089766036,0.000044019005,0.000054609292,0.00028737387,0.00006795933],"category_scores_gemma":[0.00003391197,0.00038026556,0.0012588426,0.0028741702,0.00012591221,0.00029782107,0.00005732684,0.0002302602,0.0000019615813],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079274374,0.00079182134,0.044998176,0.025570186,0.9110447,0.0000057412394,0.00025277768,0.000008383073,0.000038899812,0.00008731703,0.00025759346,0.016865091],"study_design_scores_gemma":[0.00081405276,0.00011774808,0.019126015,0.0005402766,0.9258539,7.0099213e-7,0.000046248308,0.000018536473,0.00009674838,0.00006192731,0.053015146,0.00030870776],"about_ca_topic_score_codex":0.00011226896,"about_ca_topic_score_gemma":0.000119754026,"teacher_disagreement_score":0.052757554,"about_ca_system_score_codex":0.000028740687,"about_ca_system_score_gemma":0.000067284556,"threshold_uncertainty_score":0.99986494},"labels":[],"label_agreement":null},{"id":"W4377564423","doi":"10.1111/jgs.18397","title":"Association of sulfonylureas with the risk of dementia: A population‐based cohort study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Geriatrics Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Work & Health; Health Sciences Centre; Toronto Dementia Research Alliance; University Health Network; Toronto General Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; University of Ottawa; Ontario Brain Institute; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre","funders":"Banting and Best Diabetes Centre, University of Toronto; Weston Brain Institute; Canadian Institutes of Health Research; University of Toronto; Canada Research Chairs; Government of Ontario; Ministry of Colleges and Universities; Michael J. Fox Foundation for Parkinson's Research; Alzheimer's Research Trust; Natural Sciences and Engineering Research Council of Canada; Fondation Brain Canada; Alzheimer's Association","keywords":"Medicine; Dementia; Sulfonylurea; Hazard ratio; Cohort; Cohort study; Population; Internal medicine; Propensity score matching; Proportional hazards model; Type 2 diabetes; Retrospective cohort study; Lower risk; Diabetes mellitus; Confidence interval; Disease; Endocrinology; Insulin; Environmental health","score_opus":0.006515227675235883,"score_gpt":0.24577861704046156,"score_spread":0.23926338936522568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377564423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969895,0.000056027136,0.00011430192,0.0021364903,0.00009524452,0.0005167738,0.000008300151,0.000009779004,0.00007356681],"genre_scores_gemma":[0.9985114,0.00018357273,0.00073672604,0.0001421588,0.00007818491,0.000007552981,0.0000037119607,0.000012656245,0.00032405698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984237,0.00015941435,0.00037696975,0.000082766055,0.00081919803,0.00013795542],"domain_scores_gemma":[0.9966488,0.00025108655,0.0025067122,0.0002551518,0.000303539,0.000034748868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015448029,0.00009585712,0.00041029294,0.000068274545,0.000087374596,0.00001052473,0.00016627907,0.000019883279,0.000008429668],"category_scores_gemma":[0.00015123894,0.000046501762,0.00041129484,0.0013139494,0.000054004176,0.000040862637,0.000053112388,0.00015326265,8.864284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079023004,0.00033303341,0.9822569,0.000019974106,0.003751051,0.0000012039237,0.00043320167,0.000803017,0.000068437905,0.000003815766,0.011785538,0.00046482513],"study_design_scores_gemma":[0.0014791433,0.0007968164,0.9897101,0.000015813148,0.005348517,6.497699e-7,0.0019768856,0.00023926882,0.000058741243,0.000019850511,0.00031121494,0.000043015665],"about_ca_topic_score_codex":0.00026230558,"about_ca_topic_score_gemma":0.000020785192,"teacher_disagreement_score":0.0114743225,"about_ca_system_score_codex":0.00018316275,"about_ca_system_score_gemma":0.00009424136,"threshold_uncertainty_score":0.18962868},"labels":[],"label_agreement":null},{"id":"W4377939048","doi":"10.1001/jamacardio.2023.1090","title":"Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction","year":2023,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; Respicardia; HLS Therapeutics; Servier; Pfizer; Vifor Pharma; Sanofi; Bayer HealthCare; Amarin Corporation; Novo Nordisk; Cytokinetics; Amgen; Abbott Diagnostics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Diuretic; Medicine; Heart failure; Ejection fraction; Furosemide; Internal medicine; Loop diuretic; Placebo; Cardiology; Heart failure with preserved ejection fraction; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.010014638768881935,"score_gpt":0.2312000383380245,"score_spread":0.22118539956914257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377939048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887,0.0000568504,0.000011937207,0.00045654175,0.000033251046,0.00042628148,0.0000053572203,0.000023757908,0.00011601522],"genre_scores_gemma":[0.9995421,0.0001027772,0.00011441239,0.00004346766,0.000024585468,0.0000104032515,0.0000616229,0.000007642023,0.00009294633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994763,0.00006128908,0.000108567634,0.00017477712,0.000066574066,0.00011250785],"domain_scores_gemma":[0.9996905,0.00010795518,0.000031310894,0.0001037737,0.000028647184,0.000037836617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010252757,0.00007482944,0.00027597806,0.0001274291,0.000020699592,0.000008762646,0.0000094839825,0.00007006653,0.0000023175417],"category_scores_gemma":[0.00007867983,0.000056901084,0.000016475436,0.00012116039,0.000061199695,0.00009513716,0.000041154624,0.00006883673,0.0000012271861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064145203,0.000030487909,0.99721956,0.000055386878,0.00011356578,0.0000054437824,0.000029167564,0.00001882014,0.000079617785,0.000023268694,0.00052353804,0.0012597066],"study_design_scores_gemma":[0.005556367,0.00069859956,0.9898973,0.00004603777,0.00012229336,0.0000018870853,0.000072494,0.00006540153,0.000028600747,0.000013444697,0.003450506,0.00004707144],"about_ca_topic_score_codex":0.000048349273,"about_ca_topic_score_gemma":0.00003063496,"teacher_disagreement_score":0.0073222476,"about_ca_system_score_codex":0.000015806098,"about_ca_system_score_gemma":0.000005290866,"threshold_uncertainty_score":0.23203589},"labels":[],"label_agreement":null},{"id":"W4377968542","doi":"10.1016/j.jchf.2023.03.025","title":"Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk","year":2023,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University; Population Health Research Institute","funders":"National Center for Advancing Translational Sciences","keywords":"Canagliflozin; Medicine; Internal medicine; Diabetes mellitus; Heart failure; Placebo; Body mass index; Framingham Risk Score; Relative risk; Cumulative incidence; Incidence (geometry); Absolute risk reduction; Cardiology; Type 2 diabetes; Confidence interval; Endocrinology; Disease; Cohort","score_opus":0.00578626864078755,"score_gpt":0.2588535843401489,"score_spread":0.2530673156993613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377968542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95482415,0.00008097719,0.000022561577,0.04185645,0.00027264433,0.0024192843,0.00007125711,0.00033786957,0.000114784496],"genre_scores_gemma":[0.99416715,0.000013763559,0.002521295,0.0016418516,0.000309237,0.00035288773,0.00038038343,0.00010763691,0.0005057712],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965033,0.00041332058,0.0006402372,0.0008012017,0.0007076259,0.00093434553],"domain_scores_gemma":[0.99801224,0.0005620966,0.00012517147,0.00079516164,0.00012723608,0.00037808612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016175447,0.00053207454,0.0011308679,0.0010705766,0.00014108588,0.00006910787,0.00017269603,0.00025395604,0.00017649872],"category_scores_gemma":[0.0008560923,0.00045487488,0.0003207485,0.002188239,0.000051046984,0.0002316132,0.0001737663,0.00040489453,0.00071646564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011699749,0.00017314362,0.64804363,0.00043871874,0.00013945879,0.000015576887,0.00013772026,0.00068544946,0.005644215,0.000048461807,0.34297407,0.0015825842],"study_design_scores_gemma":[0.008136306,0.008232384,0.2592674,0.002632343,0.00071533554,0.0000049505406,0.0012943856,0.0027026199,0.07307579,0.000071878945,0.6427567,0.0011099279],"about_ca_topic_score_codex":0.00050651183,"about_ca_topic_score_gemma":0.0010356482,"teacher_disagreement_score":0.3887762,"about_ca_system_score_codex":0.0002367669,"about_ca_system_score_gemma":0.000082337974,"threshold_uncertainty_score":0.9997903},"labels":[],"label_agreement":null},{"id":"W4378234851","doi":"10.1016/j.cmet.2023.05.001","title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","year":2023,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Medical Research Council; Versus Arthritis; University of Dundee; Diabetes UK; Cancer Research UK; Swansea University; Wellcome Trust; Francis Crick Institute","keywords":"Canagliflozin; Autoimmunity; T cell; Effector; Biology; mTORC1; Cell biology; Immunology; Cancer research; Immune system; Signal transduction; PI3K/AKT/mTOR pathway; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.009362512334906566,"score_gpt":0.2320566233945393,"score_spread":0.22269411105963274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378234851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795788,0.004522632,0.000053633627,0.00020821042,0.0015760568,0.0010416777,0.000012054298,0.0003820436,0.0126249185],"genre_scores_gemma":[0.9857887,0.0006082141,0.00015002799,0.00026703262,0.0001935659,0.0001877501,0.00029159125,0.000056966866,0.012456137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981791,0.00017144525,0.00033143815,0.0003912785,0.00034276687,0.00058396935],"domain_scores_gemma":[0.9990064,0.000078608304,0.00009478198,0.00058179145,0.00004438266,0.00019406021],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004987141,0.00030065177,0.0005897464,0.00061613036,0.00009763471,0.000030104338,0.00014467201,0.00012550394,0.00036307253],"category_scores_gemma":[0.0000309564,0.00024775686,0.00018965175,0.0010204923,0.000040785773,0.00015465154,0.00015334824,0.00027056842,0.001343773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010506946,0.0037008803,0.07497174,0.0020522939,0.00073674094,0.00054169534,0.0024783625,0.0005038965,0.67346936,0.00079160795,0.088660136,0.15104257],"study_design_scores_gemma":[0.0053252173,0.00015965331,0.68016946,0.0000603604,0.00091336755,0.0000011167673,0.00017144892,0.001161296,0.07739269,0.00019800178,0.23413748,0.00030989147],"about_ca_topic_score_codex":0.0008312713,"about_ca_topic_score_gemma":0.000058095924,"teacher_disagreement_score":0.6051977,"about_ca_system_score_codex":0.00006332468,"about_ca_system_score_gemma":0.000054104745,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W4378364283","doi":"10.1016/j.mad.2023.111825","title":"RETRACTED: A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk – Study rationale and design","year":2023,"lang":"en","type":"article","venue":"Mechanisms of Ageing and Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"National Institutes of Health; Alzheimer's Association","keywords":"Dementia; Metabolic syndrome; Cognition; Medicine; Insulin; Diabetes mellitus; Dulaglutide; Cognitive decline; Gerontology; Internal medicine; Psychiatry; Endocrinology; Type 2 diabetes; Exenatide; Disease","score_opus":0.017486159511635728,"score_gpt":0.22860151228049727,"score_spread":0.21111535276886154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378364283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259365,0.00004057086,0.0025088007,0.000029823363,0.000020311334,0.004781931,0.0000073132173,0.000013977075,0.0000036432866],"genre_scores_gemma":[0.9945375,0.00001947419,0.0051000477,0.000006522748,0.0000012903502,0.00026463807,0.00003785095,0.000010066757,0.000022616285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897176,0.00006491832,0.00031308274,0.00022290343,0.00031867254,0.00010865518],"domain_scores_gemma":[0.9994633,0.00006599234,0.00020592067,0.000118006166,0.00011975931,0.000027009319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065777736,0.00011594045,0.00030530946,0.00015831788,0.000078797944,0.0000056906492,0.00003527959,0.000027554725,0.000004038041],"category_scores_gemma":[0.000023093857,0.00007442778,0.000012340344,0.00024627362,0.000026402275,0.00005080507,0.00005190264,0.000046712248,1.4898531e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007435473,0.016803926,0.9197582,0.0014520702,0.003898306,0.000090027206,0.03482393,0.00039130065,0.0019204346,0.0005184308,0.000023021908,0.012884867],"study_design_scores_gemma":[0.014625505,0.0031820522,0.9662258,0.00027845503,0.0005283373,0.0000016635964,0.005423805,0.00014709194,0.009233404,0.00027707635,8.759237e-7,0.00007594104],"about_ca_topic_score_codex":0.00010487102,"about_ca_topic_score_gemma":0.00051460945,"teacher_disagreement_score":0.046467584,"about_ca_system_score_codex":0.000027187418,"about_ca_system_score_gemma":0.000043171818,"threshold_uncertainty_score":0.30350766},"labels":[],"label_agreement":null},{"id":"W4378640039","doi":"10.1111/dom.15119","title":"The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University; University of British Columbia; St. Michael's Hospital","funders":"University of Toronto; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Cardiology; Type 2 diabetes; Waist; Body mass index; Coronary artery disease; Diabetes mellitus; Placebo; Anthropometry; Obesity; Endocrinology","score_opus":0.006149460745457394,"score_gpt":0.20428899293108377,"score_spread":0.19813953218562638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378640039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953547,0.0036500134,9.053583e-7,0.00011496507,0.000077153054,0.00066930364,0.000056246598,0.000038621834,0.00003805781],"genre_scores_gemma":[0.9969089,0.0026166004,0.00007636791,0.00004367066,0.00003784984,0.000018489472,0.00013772414,0.000019656352,0.0001407091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986376,0.00009662437,0.00021457831,0.00031744328,0.00036098118,0.00037275118],"domain_scores_gemma":[0.999091,0.00026239807,0.00015758241,0.00020959262,0.00008397802,0.00019539603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051570125,0.00020270613,0.0005301562,0.00043192654,0.00017682159,0.000039227427,0.000053924006,0.00007134461,0.0000019746797],"category_scores_gemma":[0.000101923935,0.00013346669,0.000036195826,0.0010304332,0.00017523208,0.00018741196,0.000096583644,0.00013404529,0.0000022267043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065924294,0.00016869591,0.99139774,0.00016143767,0.0005359444,0.0000030418682,0.00016953207,0.0000022864592,0.0000074068817,0.00005079531,0.00007707141,0.0073601333],"study_design_scores_gemma":[0.0018764018,0.00027002074,0.995475,0.0001307069,0.0011793505,1.4691988e-8,0.00008404745,0.000047074653,0.00009201361,0.000096129006,0.0005947632,0.00015446961],"about_ca_topic_score_codex":0.000011940066,"about_ca_topic_score_gemma":0.0000037669452,"teacher_disagreement_score":0.0072056637,"about_ca_system_score_codex":0.000039629795,"about_ca_system_score_gemma":0.00003140212,"threshold_uncertainty_score":0.54426134},"labels":[],"label_agreement":null},{"id":"W4378648413","doi":"10.1152/physiol.2023.38.s1.5730313","title":"Amylin receptor agonism protects against metabolic side effects of acute olanzapine","year":2023,"lang":"en","type":"article","venue":"Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph","funders":"","keywords":"Liraglutide; Olanzapine; Amylin; Medicine; Endocrinology; Internal medicine; Dyslipidemia; Glucose homeostasis; Insulin resistance; Pharmacology; Insulin; Diabetes mellitus; Type 2 diabetes; Schizophrenia (object-oriented programming)","score_opus":0.01034448587972774,"score_gpt":0.26096661202826904,"score_spread":0.2506221261485413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378648413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550784,0.00023046457,0.000007889371,0.0007182486,0.00035382435,0.0010022798,0.00000891702,0.00019263147,0.001977927],"genre_scores_gemma":[0.99445117,0.0009503878,0.00036752067,0.00065947755,0.00019393458,0.00030998208,0.00029837654,0.00002893805,0.0027402274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990956,0.0000545673,0.00017589885,0.00025222788,0.00010883384,0.0003128726],"domain_scores_gemma":[0.9994286,0.00007676537,0.00008337708,0.00030263964,0.00003718256,0.00007145056],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000070973314,0.00015455086,0.00048465162,0.00016113903,0.00003086113,0.0000028841316,0.00008325134,0.00006513718,0.000019467547],"category_scores_gemma":[0.000051780622,0.00011876576,0.00012447986,0.0003139705,0.000065709115,0.000032970896,0.0001007775,0.00008737278,0.0008282805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012487113,0.00018646421,0.00009009505,0.00034955054,0.0010287119,0.000032212927,0.00011752447,0.000006746481,0.9728261,0.0006694042,0.0035044912,0.021063782],"study_design_scores_gemma":[0.004949184,0.0013220485,0.16779004,0.00016870521,0.000669851,0.0000012358196,0.000025935798,0.00018615606,0.7744871,0.0014096163,0.048754256,0.00023585692],"about_ca_topic_score_codex":0.0000132611685,"about_ca_topic_score_gemma":8.603454e-7,"teacher_disagreement_score":0.19833905,"about_ca_system_score_codex":0.000016525184,"about_ca_system_score_gemma":0.000023545801,"threshold_uncertainty_score":0.9999497},"labels":[],"label_agreement":null},{"id":"W4378745174","doi":"10.20945/2359-3997000000652","title":"Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study","year":2023,"lang":"en","type":"article","venue":"Archives of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Odds ratio; Internal medicine; Glycated hemoglobin; Sitagliptin; Gastroenterology; Confidence interval; Diabetes mellitus; Retrospective cohort study; Type 1 diabetes; Type 2 diabetes; Surgery; Endocrinology","score_opus":0.019066154376280984,"score_gpt":0.28351025712338634,"score_spread":0.26444410274710534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378745174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983457,0.00018347958,0.0000037457276,0.00024526686,0.0000973623,0.00092565746,0.00004556081,0.00003555655,0.0001176755],"genre_scores_gemma":[0.9983661,0.00029202754,0.00024245704,0.000063018735,0.000057465633,0.000017045257,0.000038331014,0.000015195945,0.00090834196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986067,0.000208908,0.00033592735,0.00035767644,0.00014360322,0.0003472011],"domain_scores_gemma":[0.9986277,0.0008493839,0.00016172894,0.00019526447,0.000042861815,0.00012305225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020722646,0.00016575876,0.0006463293,0.0002939128,0.000054963755,0.000011476082,0.00004457837,0.000060783375,0.0000069546422],"category_scores_gemma":[0.00058210426,0.00012690821,0.00004638556,0.00019960135,0.000096579955,0.000087662884,0.000104882674,0.00020765947,0.000002849038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004991611,0.00029330052,0.9834687,0.00001676625,0.0011162071,0.00007814892,0.00062544656,9.162469e-7,0.000020586107,0.000064896834,0.0001373447,0.013678514],"study_design_scores_gemma":[0.014682538,0.0015399351,0.98155063,0.00004429219,0.0012879446,0.0000018648581,0.0001849698,0.000032069664,0.000022692253,0.00025781212,0.0002901049,0.0001051352],"about_ca_topic_score_codex":0.000060256585,"about_ca_topic_score_gemma":0.00007235826,"teacher_disagreement_score":0.014183377,"about_ca_system_score_codex":0.000023091294,"about_ca_system_score_gemma":0.00003265496,"threshold_uncertainty_score":0.5175167},"labels":[],"label_agreement":null},{"id":"W4378783299","doi":"10.1007/s13300-023-01413-5","title":"Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators","year":2023,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Liraglutide; Medicine; Empagliflozin; Sitagliptin; Weight loss; Placebo; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Obesity","score_opus":0.03918269970728713,"score_gpt":0.28839835964490207,"score_spread":0.24921565993761494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378783299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565965,0.00017568926,0.0000014939553,0.0014495051,0.00020536671,0.0006899966,0.000025007419,0.00020352857,0.0015897837],"genre_scores_gemma":[0.98888993,0.000239024,0.00033064507,0.00016480312,0.00006524525,0.0001269629,0.00016024275,0.000049275062,0.009973844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987123,0.00004242891,0.00026606605,0.0003358976,0.00024855867,0.00039474893],"domain_scores_gemma":[0.9991319,0.000096482545,0.00010696649,0.0004121803,0.000094650066,0.00015780622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118458935,0.0002653718,0.0005145235,0.00023836843,0.000093770905,0.000028530487,0.00009657995,0.000059287355,0.0005538246],"category_scores_gemma":[0.000012266771,0.00017127629,0.00007919719,0.00057570357,0.00022215047,0.00008006077,0.000044660468,0.00007322615,0.00009581841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02166258,0.0021866534,0.8716161,0.0006680378,0.009775419,0.00027116254,0.0016254869,0.000012335319,0.01395088,0.0014809774,0.05745846,0.019291863],"study_design_scores_gemma":[0.066683345,0.02950344,0.7046645,0.0005741174,0.0015502981,0.0000070487795,0.00072642486,0.0006216846,0.062620975,0.0002534342,0.13169141,0.00110329],"about_ca_topic_score_codex":0.000004161016,"about_ca_topic_score_gemma":0.0000047889507,"teacher_disagreement_score":0.16695163,"about_ca_system_score_codex":0.000034317716,"about_ca_system_score_gemma":0.00005403663,"threshold_uncertainty_score":0.6984445},"labels":[],"label_agreement":null},{"id":"W4378799384","doi":"10.1136/ard-2023-223845","title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Osteoarthritis; Weight loss; Cohort; Internal medicine; Glucagon-like peptide 1 receptor; Agonist; Exenatide; Receptor; Glucagon-like peptide-1; Endocrinology; Diabetes mellitus; Obesity; Pathology; Type 2 diabetes; Alternative medicine","score_opus":0.023535050042451797,"score_gpt":0.28100615259784706,"score_spread":0.25747110255539524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378799384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96323866,0.015710318,0.0000061252194,0.013569262,0.00060087064,0.0035016562,0.0028756547,0.00023224246,0.00026523875],"genre_scores_gemma":[0.979506,0.008425453,0.000037311216,0.0034452025,0.00012389554,0.0016671141,0.0030685267,0.0000996503,0.0036268213],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99734074,0.00013626665,0.0005973487,0.00051050575,0.0007831319,0.00063200004],"domain_scores_gemma":[0.9971613,0.0010984737,0.000277529,0.0009343746,0.00016932395,0.0003589948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032501115,0.00041060074,0.0006636905,0.00010590697,0.00038044582,0.00011679447,0.00048930733,0.00007630856,0.00048668057],"category_scores_gemma":[0.00075203803,0.00025521172,0.00064967235,0.0004998638,0.00030849985,0.00019884914,0.00020850854,0.00010320282,0.00027797298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001882614,0.0011018595,0.13871706,0.00057592354,0.0029210236,0.000035351204,0.0011052289,0.0000074291056,0.00029993936,0.00032953336,0.56162196,0.2914021],"study_design_scores_gemma":[0.027168509,0.0049660807,0.6734849,0.010734283,0.0034111713,0.000005560125,0.0018158195,0.00060363417,0.0042589703,0.011845126,0.26003274,0.0016731868],"about_ca_topic_score_codex":0.00014889549,"about_ca_topic_score_gemma":0.000015016598,"teacher_disagreement_score":0.53476787,"about_ca_system_score_codex":0.000038598784,"about_ca_system_score_gemma":0.00013469213,"threshold_uncertainty_score":0.99999},"labels":[],"label_agreement":null},{"id":"W4378979210","doi":"10.1016/j.cjca.2023.05.018","title":"A Dose Comparison Study of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction","year":2023,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Empagliflozin; Medicine; Ejection fraction; Heart failure; Heart failure with preserved ejection fraction; Cardiology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.01858967469551994,"score_gpt":0.24550114393812605,"score_spread":0.2269114692426061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378979210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709729,0.000044471497,0.000019668798,0.027008468,0.00040758055,0.0010971784,0.000016868602,0.000008543882,0.0004243394],"genre_scores_gemma":[0.99468625,0.0000026203704,0.00007261701,0.003881076,0.00092542224,0.000025326399,0.00013976339,0.00004666955,0.00022024596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846363,0.00021834718,0.00046648015,0.00020879196,0.00031328824,0.000329456],"domain_scores_gemma":[0.99878633,0.000057988174,0.00040872392,0.0002663348,0.00031479402,0.00016581811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020717418,0.00021909941,0.0011793927,0.0010817903,0.00003364583,0.000014628643,0.00010373552,0.00026817762,0.000014220979],"category_scores_gemma":[0.000037674356,0.00015706367,0.00010918474,0.00031327872,0.00006171952,0.0000808993,0.000010563606,0.000969129,0.0000061736646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002489741,0.00002832102,0.62698585,0.000057239915,0.0009174249,0.0003300044,0.00006281077,0.00049711927,4.141297e-7,1.3067208e-7,0.37079206,0.000079662066],"study_design_scores_gemma":[0.0053400956,0.0077115605,0.73384,0.0002643488,0.00083964434,0.000010951609,0.00053281925,0.0000028216493,0.0000014478951,0.000002655325,0.2513414,0.00011228918],"about_ca_topic_score_codex":0.0033860793,"about_ca_topic_score_gemma":0.023290927,"teacher_disagreement_score":0.11945068,"about_ca_system_score_codex":0.00040286125,"about_ca_system_score_gemma":0.0004596738,"threshold_uncertainty_score":0.99453145},"labels":[],"label_agreement":null},{"id":"W4379032199","doi":"10.1007/978-3-031-13177-6_33","title":"SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease","year":2023,"lang":"en","type":"book-chapter","venue":"Contemporary cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Dapagliflozin; Canagliflozin; Heart failure; Mace; Ejection fraction; Internal medicine; Type 2 diabetes; Diabetes mellitus; Cardiology; Endocrinology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.02985853484703164,"score_gpt":0.22858064618833634,"score_spread":0.1987221113413047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379032199","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029568247,0.08667601,0.0000045351753,0.0014968081,0.0016750561,0.0026546225,0.00037466208,0.0004987345,0.87705135],"genre_scores_gemma":[0.664859,0.005907642,0.000016363469,0.00076817814,0.0012053078,0.00014980155,0.0011519118,0.00021289903,0.3257289],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981074,0.000056373472,0.00032636258,0.000909076,0.00027398628,0.00032684382],"domain_scores_gemma":[0.9985947,0.00012442475,0.00009162363,0.00077537744,0.00004418322,0.0003696682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026954556,0.0005359661,0.001508244,0.0003014737,0.0000863036,0.000028850094,0.00007171411,0.00031902152,0.00001254446],"category_scores_gemma":[0.000043050182,0.00046242075,0.0005856969,0.00003109947,0.00037458574,0.000052980246,0.00023944133,0.00027553894,0.00010424056],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014748645,0.00011299207,0.28925997,0.004433074,0.07947558,0.027795628,0.00020083727,0.000029964896,0.00008151409,0.061379623,0.39302093,0.142735],"study_design_scores_gemma":[0.0028260578,0.0011486277,0.014182355,0.00069600757,0.0031353917,0.000020526382,0.000024321214,0.000009531372,0.000018249815,0.0026953856,0.97460294,0.0006405827],"about_ca_topic_score_codex":0.0000054712173,"about_ca_topic_score_gemma":3.8035998e-7,"teacher_disagreement_score":0.63529074,"about_ca_system_score_codex":0.00005054263,"about_ca_system_score_gemma":0.00008273413,"threshold_uncertainty_score":0.99978274},"labels":[],"label_agreement":null},{"id":"W4379208377","doi":"10.1016/j.dsx.2023.102804","title":"Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus","year":2023,"lang":"en","type":"article","venue":"Diabetes & Metabolic Syndrome Clinical Research & Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; Internal medicine; Endocrinology; Type 2 Diabetes Mellitus; Diabetes mellitus; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Type 2 diabetes; Glucagon; Receptor; Insulin; Agonist","score_opus":0.04332912982466097,"score_gpt":0.348287279341532,"score_spread":0.304958149516871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379208377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402001,0.05461749,2.4885233e-7,0.00033865962,0.0006076319,0.003960245,0.000031421703,0.0000649523,0.00017926842],"genre_scores_gemma":[0.8647494,0.13300848,0.0003082236,0.0003098254,0.00009062241,0.0006351617,0.00032992603,0.00010869794,0.00045970923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99373436,0.0012428282,0.0013528257,0.001117578,0.0013397266,0.0012126891],"domain_scores_gemma":[0.99593574,0.0016188944,0.00023829268,0.0010259242,0.00026546666,0.00091570965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005431277,0.00055155193,0.0031895947,0.0007769565,0.00011476784,0.00006473707,0.00027171613,0.00022965233,0.000038707018],"category_scores_gemma":[0.0039191227,0.00038003342,0.0005739282,0.0017448966,0.00064439315,0.00018939399,0.0002452966,0.00069342076,0.00015557923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003304613,0.0010244146,0.81725365,0.0023746267,0.0020429739,0.00005607037,0.000121794415,3.928962e-7,0.000051882344,0.000024904786,0.0012680296,0.17545082],"study_design_scores_gemma":[0.008695818,0.0038072893,0.8368569,0.0021143039,0.0010220286,1.9691376e-7,0.000024126153,0.000007939269,0.00034668474,0.000019566069,0.14679444,0.00031073036],"about_ca_topic_score_codex":0.000020481022,"about_ca_topic_score_gemma":0.000008049044,"teacher_disagreement_score":0.17514008,"about_ca_system_score_codex":0.00006687691,"about_ca_system_score_gemma":0.000128893,"threshold_uncertainty_score":0.9998652},"labels":[],"label_agreement":null},{"id":"W4379379336","doi":"10.1016/j.jpsychires.2023.05.041","title":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review","year":2023,"lang":"en","type":"review","venue":"Journal of Psychiatric Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"National Institute of Mental Health; National Institute on Aging","keywords":"Dulaglutide; Glucagon-like peptide 1 receptor; Medicine; Exenatide; Neuroprotection; PsycINFO; Diabetes mellitus; Depression (economics); Internal medicine; Antidepressant; Agonist; Pharmacology; Bioinformatics; Endocrinology; Type 2 diabetes; Receptor; MEDLINE; Biology","score_opus":0.06363075089020193,"score_gpt":0.40461718148610315,"score_spread":0.3409864305959012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379379336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074388424,0.97361755,0.000009961626,0.00017526142,0.00042696533,0.024845004,0.000058373942,0.000023709274,0.00009929587],"genre_scores_gemma":[0.00004729563,0.9944025,0.0008412314,0.000052575157,0.00028185837,0.0031795518,0.000094097086,0.00015460172,0.0009462873],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99259,0.00092808146,0.0024322672,0.0006014976,0.0025737958,0.0008743711],"domain_scores_gemma":[0.9944252,0.0010295695,0.0021186925,0.0007381355,0.0012961122,0.0003922843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004119387,0.0006024286,0.00457658,0.0023819886,0.00014407767,0.00011420953,0.0006328838,0.00026296993,0.0000463303],"category_scores_gemma":[0.0018415169,0.00033525933,0.001046986,0.0024490694,0.00006727272,0.00016513442,0.00019229477,0.0012907865,0.00014865122],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025847997,0.00082860555,0.0011027141,0.9241224,0.0019725224,0.000034068296,0.00006919038,1.3152045e-7,9.002585e-8,0.0000065751956,0.0068466826,0.06475858],"study_design_scores_gemma":[0.003222483,0.005081441,0.0007541114,0.894483,0.0056478074,0.000006993252,0.00006139093,0.0000013304158,6.8112524e-7,0.000059923583,0.090330325,0.00035053564],"about_ca_topic_score_codex":0.000013447501,"about_ca_topic_score_gemma":0.000008529681,"teacher_disagreement_score":0.083483644,"about_ca_system_score_codex":0.001304766,"about_ca_system_score_gemma":0.0011873975,"threshold_uncertainty_score":0.99990994},"labels":[],"label_agreement":null},{"id":"W4379387532","doi":"10.1016/j.cardfail.2023.05.017","title":"A Patient-Level Pooled Analysis of 2 Empagliflozin Trials of Left Ventricular Remodeling","year":2023,"lang":"en","type":"letter","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Heart failure; Internal medicine; Diabetes mellitus; Cardiology; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.03386344265671,"score_gpt":0.2855142172112363,"score_spread":0.25165077455452634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379387532","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.459579,0.024684861,0.0009756593,0.4982271,0.0068438356,0.0046353294,0.003227054,0.00012311651,0.0017040371],"genre_scores_gemma":[0.65365785,0.014823069,0.047276482,0.20601426,0.03993421,0.00014772727,0.013188246,0.0016477787,0.023310384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946805,0.0004545114,0.002648494,0.0002673584,0.0016049483,0.0003441565],"domain_scores_gemma":[0.99430484,0.0004978939,0.0036007462,0.00055353076,0.00092844176,0.00011457731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020694202,0.0003861625,0.0049726437,0.0026234454,0.000025378127,0.000024401115,0.00019802724,0.0005058387,0.0001258776],"category_scores_gemma":[0.000810063,0.00028053942,0.0056726313,0.0010911013,0.00004421092,0.00009204355,0.00008623686,0.00083513604,0.000007646882],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016251659,0.00012613874,0.0022413982,0.000691394,0.09216659,0.0008911305,0.00025673574,0.0008947972,0.00057921215,0.0000031548966,0.8959781,0.0060088257],"study_design_scores_gemma":[0.0027432065,0.0010911935,0.0032301175,0.0021958959,0.2521964,0.000021846174,0.00043968967,0.0002517319,0.0015743853,0.000067793975,0.7357844,0.00040334926],"about_ca_topic_score_codex":0.000021868229,"about_ca_topic_score_gemma":0.000002265982,"teacher_disagreement_score":0.29221284,"about_ca_system_score_codex":0.00016791967,"about_ca_system_score_gemma":0.00021781247,"threshold_uncertainty_score":0.99996465},"labels":[],"label_agreement":null},{"id":"W4379467794","doi":"10.32388/t6y97s","title":"Examining Off-Label Prescribing of Ozempic for Weight-Loss","year":2023,"lang":"en","type":"preprint","venue":"Qeios","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Metropolitan University","funders":"","keywords":"Weight loss; Medicine; Type 2 diabetes; Medical prescription; Semaglutide; Weight management; Economic shortage; Psychological intervention; Intensive care medicine; Diabetes mellitus; Obesity; Liraglutide; Pharmacology; Nursing; Internal medicine; Endocrinology","score_opus":0.12110556874020867,"score_gpt":0.3188238373586375,"score_spread":0.19771826861842884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379467794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97358847,0.001805782,0.0015386082,0.0014276651,0.0024376458,0.004957438,0.00015691035,0.00052587286,0.013561609],"genre_scores_gemma":[0.94658935,0.00044939347,0.008284123,0.00019774912,0.00058578094,0.00096593867,0.00072237436,0.00014039726,0.04206491],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985259,0.000018609298,0.00039026243,0.00047525106,0.00026611748,0.00032382394],"domain_scores_gemma":[0.9988546,0.00013559623,0.00021277269,0.00061467104,0.000098825294,0.00008353173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002491598,0.00026292665,0.0006064966,0.00022183705,0.000036800957,0.000019026975,0.00017380933,0.00017979767,0.000046502566],"category_scores_gemma":[0.00011114407,0.00023441638,0.00016181185,0.00009528392,0.000040457293,0.000033039494,0.0004965046,0.00018572804,0.00005190388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010880876,0.0038576818,0.21730885,0.035192437,0.0134155145,0.0005003177,0.0047331485,0.00028216245,0.00890637,0.008779945,0.20116168,0.5047738],"study_design_scores_gemma":[0.066622,0.010981667,0.27575797,0.038118646,0.026992947,0.000019670795,0.002424901,0.028092558,0.09213338,0.02827668,0.42523488,0.0053446987],"about_ca_topic_score_codex":0.000025566516,"about_ca_topic_score_gemma":0.0000049565883,"teacher_disagreement_score":0.4994291,"about_ca_system_score_codex":0.00008734591,"about_ca_system_score_gemma":0.00007796741,"threshold_uncertainty_score":0.95592225},"labels":[],"label_agreement":null},{"id":"W4379508906","doi":"10.1002/ejhf.2922","title":"Liver Tests, Cardiovascular Outcomes and Effects of Empagliflozin in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim España","keywords":"Empagliflozin; Medicine; Ejection fraction; Heart failure; Internal medicine; Placebo; Cardiology; Heart failure with preserved ejection fraction; Gastroenterology; Endocrinology; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.010965859758215665,"score_gpt":0.22200402598814864,"score_spread":0.211038166229933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379508906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445933,0.0006005019,0.000005833779,0.0038475783,0.00013681198,0.0008914694,0.0000016860798,0.000020911793,0.00003590014],"genre_scores_gemma":[0.9987363,0.00006728438,0.0007605115,0.00011329893,0.00013770188,0.000006713111,0.000006295583,0.00003087932,0.00014097814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824345,0.0005174023,0.00036163826,0.00018427706,0.0004991014,0.00019411328],"domain_scores_gemma":[0.9991349,0.00017957742,0.00014622955,0.00029719828,0.0001360083,0.00010610431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009380682,0.00017543107,0.00054822536,0.00022620705,0.00007784065,0.00004430889,0.00007836244,0.00003285342,0.0000125691495],"category_scores_gemma":[0.00020434715,0.000101654165,0.00019184574,0.00028246813,0.00006900975,0.00023921009,0.00009370034,0.0002733247,0.000008498679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023404725,0.00021485722,0.9737298,0.00021682327,0.0008840345,0.00012183223,0.00012746741,0.000032268035,0.00011622409,0.0000019518177,0.021806836,0.0004074265],"study_design_scores_gemma":[0.03303095,0.002808732,0.928902,0.00032798477,0.0004581137,0.000008857172,0.00020548873,0.000011490619,0.00012560409,0.000003259411,0.03402891,0.000088651315],"about_ca_topic_score_codex":0.000016892376,"about_ca_topic_score_gemma":0.00001556225,"teacher_disagreement_score":0.044827852,"about_ca_system_score_codex":0.000026872138,"about_ca_system_score_gemma":0.000022522454,"threshold_uncertainty_score":0.41453364},"labels":[],"label_agreement":null},{"id":"W4379517728","doi":"10.21203/rs.3.rs-2915427/v1","title":"Impact of SGLT-2 inhibitors on cardiovascular and renal outcomes according to baseline renal function A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Research Square","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"European Society of Cardiology; Alberta Innovates - Health Solutions","keywords":"Medicine; Renal function; Internal medicine; Meta-analysis; Placebo; Discontinuation; Heart failure; Randomized controlled trial; Hazard ratio; Relative risk; Diabetes mellitus; Adverse effect; Acute kidney injury; Kidney disease; Confidence interval; Endocrinology","score_opus":0.21789407675111422,"score_gpt":0.47065250095724354,"score_spread":0.2527584242061293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379517728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003836351,0.99151856,0.000028170238,0.00017374523,0.000014832646,0.007963843,0.00013427966,0.000043814172,0.000084409585],"genre_scores_gemma":[0.0002402126,0.9960832,0.00003958004,0.000037499954,0.000048887923,0.0015772255,0.000284453,0.00006674793,0.0016221962],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947514,0.0013209406,0.0010780203,0.0007560011,0.0016147312,0.00047893892],"domain_scores_gemma":[0.99681634,0.0009925851,0.00026086005,0.0012177146,0.00036210634,0.0003504002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0067822104,0.0005213327,0.010167056,0.002311658,0.00009742737,0.00006835343,0.00014155482,0.00013980287,0.000080641315],"category_scores_gemma":[0.0016181386,0.00027677618,0.006394064,0.0030393726,0.00005234147,0.00006465178,0.00029578764,0.0003956785,0.000065105836],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011009886,0.00005872214,0.00004778884,0.60798585,0.38205194,0.00004126827,0.00001078676,0.000004020719,7.980079e-8,0.000009056271,0.00054212305,0.009237305],"study_design_scores_gemma":[0.00025173512,0.00092270796,0.00009479205,0.1213991,0.8658039,0.000004065209,0.000035397385,0.0000051611764,2.293776e-7,0.0000028611,0.011289024,0.00019100761],"about_ca_topic_score_codex":0.0001524419,"about_ca_topic_score_gemma":0.000009480275,"teacher_disagreement_score":0.48658678,"about_ca_system_score_codex":0.0003098111,"about_ca_system_score_gemma":0.00012865111,"threshold_uncertainty_score":0.99996847},"labels":[],"label_agreement":null},{"id":"W4379520771","doi":"10.1136/annrheumdis-2023-eular.2163","title":"OP0025 MORTALITY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST INITIATION IN PATIENTS WITH AUTOIMMUNE DISEASES AND TYPE 2 DIABETES: A POPULATION-BASED STUDY","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Population; Mace; Psoriatic arthritis; Hazard ratio; Type 1 diabetes; Diabetes mellitus; Immunology; Rheumatoid arthritis; Myocardial infarction; Percutaneous coronary intervention; Endocrinology","score_opus":0.021803871294045665,"score_gpt":0.2701286533260557,"score_spread":0.24832478203201003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379520771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706334,0.0009214061,6.481238e-7,0.00013892776,0.000097969954,0.0016013535,0.000120905774,0.00004538922,0.000010061157],"genre_scores_gemma":[0.99915206,0.000076460325,0.0000147885185,0.00012677808,0.000007370658,0.00019885747,0.00033597308,0.000021800992,0.00006587919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985959,0.00013373193,0.00031964862,0.00026435862,0.00047314586,0.00021323276],"domain_scores_gemma":[0.99909735,0.000083839455,0.00013425478,0.0004827353,0.0000966456,0.00010517593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017065692,0.00019272315,0.0004453275,0.00015080956,0.00007571889,0.000019649635,0.00007518324,0.000024340141,0.000029020894],"category_scores_gemma":[0.0001845077,0.00012937745,0.00013754063,0.00038205454,0.000053108095,0.00015113028,0.000098097895,0.0000377777,0.0000065277777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027425686,0.0012038108,0.99351066,0.00059119886,0.0011984934,0.0000030908036,0.00013588664,0.00010381681,1.9945652e-7,0.000003035908,0.000112131485,0.0028634137],"study_design_scores_gemma":[0.0031987145,0.00038209363,0.9936393,0.0008007746,0.0013720609,1.657164e-8,0.00017268134,0.00020015037,0.0000025416882,0.00007877213,0.000021391115,0.0001314832],"about_ca_topic_score_codex":0.00016670636,"about_ca_topic_score_gemma":0.000021775666,"teacher_disagreement_score":0.0029244577,"about_ca_system_score_codex":0.000029441186,"about_ca_system_score_gemma":0.000042366475,"threshold_uncertainty_score":0.5275859},"labels":[],"label_agreement":null},{"id":"W4379768142","doi":"10.1111/apha.14011","title":"Did you know how SGLT2 inhibitors protect the kidney?","year":2023,"lang":"en","type":"editorial","venue":"Acta Physiologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Tubuloglomerular feedback; Nephron; Renal glucose reabsorption; Reabsorption; Internal medicine; Endocrinology; Dapagliflozin; Renal function; Diabetes mellitus; Glomerular hyperfiltration; Kidney; Kidney disease; Chemistry; Tubular fluid; Medicine; Glycosuria; Type 2 diabetes; Diabetic nephropathy","score_opus":0.01383176866058951,"score_gpt":0.25449079116492956,"score_spread":0.24065902250434004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379768142","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038516165,0.00028574147,5.606692e-7,0.012613051,0.97493213,0.0030122192,0.00016052391,0.0007884301,0.004355706],"genre_scores_gemma":[0.019493202,0.0017988042,0.000041137733,0.00055130414,0.9265028,0.0014430314,0.0032587464,0.00013903418,0.046771895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748254,0.0001152276,0.0002584506,0.000784289,0.00073072565,0.00062877213],"domain_scores_gemma":[0.99778473,0.00059298467,0.00028096436,0.0010120173,0.00012910274,0.00020020973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022859225,0.00056937704,0.0007952463,0.00011894951,0.00023556335,0.000101415644,0.00048824455,0.00065539917,0.00010220258],"category_scores_gemma":[0.0020582385,0.00029533092,0.00035914592,0.00036544117,0.00014782786,0.00007443012,0.0004905565,0.0009326996,0.00043443937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109558576,0.00024137666,0.000003783068,0.00025066445,0.00058703835,0.000047052803,0.00006360537,5.372976e-7,0.0021006654,0.0000085179345,0.99256796,0.0040192306],"study_design_scores_gemma":[0.0010699354,0.0015004472,0.00020272951,0.00039406872,0.00054034416,2.6705706e-7,0.00008747341,0.00000770035,0.00018290318,0.00017932852,0.99551845,0.0003163311],"about_ca_topic_score_codex":0.00004259565,"about_ca_topic_score_gemma":0.000004123832,"teacher_disagreement_score":0.04842931,"about_ca_system_score_codex":0.00014803841,"about_ca_system_score_gemma":0.000157592,"threshold_uncertainty_score":0.9999499},"labels":[],"label_agreement":null},{"id":"W4379791218","doi":"10.1097/01.hjh.0000938980.77721.18","title":"THE EFFECT OF SEMAGLUTIDE ON BLOOD PRESSURE IN PATIENTS WITHOUT DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Semaglutide; Cochrane Library; Meta-analysis; Placebo; Internal medicine; Blood pressure; Diabetes mellitus; MEDLINE; Type 2 diabetes; Randomized controlled trial; CINAHL; Weight loss; Liraglutide; Obesity; Endocrinology; Psychological intervention; Alternative medicine; Psychiatry","score_opus":0.05367453093261881,"score_gpt":0.30813721841571107,"score_spread":0.25446268748309225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379791218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005763839,0.9960918,6.65625e-8,0.00011657095,0.000045103126,0.003137498,0.000009208804,0.0000061192786,0.000017284587],"genre_scores_gemma":[0.0005470448,0.99859613,0.000012779887,0.00012715603,0.000014120549,0.00009320081,0.0000123084,0.000035073033,0.0005621923],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966457,0.00074385677,0.0015862655,0.00020831657,0.0006258565,0.00019004087],"domain_scores_gemma":[0.99637,0.0009857476,0.0018722154,0.0005081524,0.00017897577,0.000084915046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021084754,0.00037649163,0.0105745625,0.00053426984,0.000035333494,0.000018151915,0.00015750591,0.000096160715,0.000006296245],"category_scores_gemma":[0.00088357716,0.00014045581,0.0025166105,0.0006538415,0.000029470411,0.000031771033,0.00007011537,0.00028608527,0.000006414067],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000144751,0.0001187861,0.00021302915,0.6824216,0.31504864,0.00004163292,0.0000033068732,8.5158626e-7,6.8787e-8,7.0567586e-7,0.00030433817,0.0018325371],"study_design_scores_gemma":[0.00070504897,0.0015783047,0.000058090434,0.16509457,0.8291902,0.000007941588,0.0000014960023,0.0000046694204,8.313212e-7,8.900712e-7,0.0032759272,0.00008202068],"about_ca_topic_score_codex":0.0000020566886,"about_ca_topic_score_gemma":0.0000015205972,"teacher_disagreement_score":0.5173271,"about_ca_system_score_codex":0.00002409868,"about_ca_system_score_gemma":0.00002628606,"threshold_uncertainty_score":0.722856},"labels":[],"label_agreement":null},{"id":"W4380154583","doi":"10.1016/j.jval.2023.03.1183","title":"HPR36 Utilization of Glucagon-like Peptide-1 Receptor Agonists in Canada","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Reimbursement; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Medicine; Diabetes mellitus; Receptor; Business; Internal medicine; Type 2 diabetes; Endocrinology; Economics; Agonist; Health care; Economic growth","score_opus":0.058496546352470515,"score_gpt":0.30340409613507235,"score_spread":0.24490754978260185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380154583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941878,0.00039505627,0.0000042515535,0.0029594167,0.00041502842,0.0006202806,0.000010877569,0.000031103125,0.0013762283],"genre_scores_gemma":[0.99662346,0.000998597,0.00020779102,0.0005514512,0.000025643925,0.00003194935,0.0001400688,0.0000149197485,0.0014061376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988907,0.00006363408,0.00036316746,0.0001690716,0.00022375178,0.00028968597],"domain_scores_gemma":[0.99957234,0.000059110374,0.0000851308,0.00017704585,0.000020336089,0.00008601577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035037848,0.00008301419,0.00025592258,0.00022263911,0.000017932165,0.000002825405,0.0000482578,0.000024111741,0.00004802413],"category_scores_gemma":[0.000049051494,0.000079457954,0.000021707774,0.0006913608,0.000012019194,0.000029183388,0.000027321817,0.00006545185,0.000025000212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013708227,0.000419478,0.8488346,0.0027545781,0.000069488706,0.00009372275,0.001623473,0.005422547,0.00014786604,0.0022042915,0.066239186,0.072053745],"study_design_scores_gemma":[0.004001826,0.0006163618,0.869047,0.0015854507,0.000024497549,0.0000012534648,0.0015565126,0.016878858,0.00072795915,0.00027427092,0.105065644,0.00022035328],"about_ca_topic_score_codex":0.8669577,"about_ca_topic_score_gemma":0.57557315,"teacher_disagreement_score":0.29138455,"about_ca_system_score_codex":0.00096051255,"about_ca_system_score_gemma":0.0012204068,"threshold_uncertainty_score":0.43217152},"labels":[],"label_agreement":null},{"id":"W4380202220","doi":"10.1016/j.ajpc.2023.100510","title":"Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome","year":2023,"lang":"en","type":"article","venue":"American Journal of Preventive Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Post-hoc analysis; Type 2 diabetes; Internal medicine; Population; Placebo; EMPA; Diabetes mellitus; Generalizability theory; Endocrinology; Psychology; Alternative medicine","score_opus":0.029932307673360973,"score_gpt":0.37592102882750644,"score_spread":0.3459887211541455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380202220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973953,0.00075606926,0.00014735518,0.00048659428,0.0002774494,0.0006784855,0.000117308344,0.000015785407,0.0001256621],"genre_scores_gemma":[0.99892575,0.00029251399,0.00034528167,0.00014629916,0.00006895247,0.000035595716,0.00006903847,0.000020579226,0.00009596746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956128,0.0013866518,0.0016401716,0.000402864,0.00048856647,0.000468927],"domain_scores_gemma":[0.9971252,0.00041254333,0.00096809963,0.0008063612,0.0005490951,0.00013870763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004579713,0.00027419208,0.004439618,0.0013178843,0.000023577024,0.000005819581,0.00024942224,0.000079205856,0.0000529367],"category_scores_gemma":[0.0010019346,0.00021152527,0.003537075,0.0020701408,0.00043692364,0.000097848824,0.00016162879,0.00019173142,0.0000027469948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027658793,0.0004611041,0.9567409,0.00011987073,0.033294804,0.00011475165,0.00044434407,0.00024724918,0.00094582886,0.000022206152,0.00020070083,0.0046423585],"study_design_scores_gemma":[0.013268773,0.0033295774,0.969843,0.000056669774,0.011202282,0.000003901752,0.0012743644,0.000050689836,0.00032063999,0.000078969286,0.00041637043,0.0001547934],"about_ca_topic_score_codex":0.00013312479,"about_ca_topic_score_gemma":0.000027968355,"teacher_disagreement_score":0.022092521,"about_ca_system_score_codex":0.00016750282,"about_ca_system_score_gemma":0.00010509616,"threshold_uncertainty_score":0.86257505},"labels":[],"label_agreement":null},{"id":"W4380447835","doi":"10.1093/ndt/gfad063c_2999","title":"#2999 APABETALONE REDUCES CARDIAC EVENTS IN CKD PATIENTS BY DOWNREGULATING FIBROTIC AND INFLAMMATORY PROCESSES","year":2023,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Resverlogix (Canada)","funders":"","keywords":"Medicine; Mace; Fibrosis; Kidney disease; Inflammation; Internal medicine; Gene expression; Extracellular matrix; Endocrinology; Kidney; Diabetes mellitus; Nephrology; Myocardial infarction; Gene; Cell biology; Biochemistry; Biology","score_opus":0.0065355146421667825,"score_gpt":0.22687021301543175,"score_spread":0.22033469837326497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380447835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99848455,0.00021291501,0.000010448428,0.00024594457,0.000069009584,0.0006092012,0.000026183663,0.000109219625,0.00023252674],"genre_scores_gemma":[0.9960999,0.001137142,0.0000762093,0.00013558287,0.00003733227,0.00016354596,0.0021568579,0.000017710157,0.0001757123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988594,0.00007520857,0.00029609486,0.00030899918,0.00019496708,0.00026534233],"domain_scores_gemma":[0.9995849,0.00011700914,0.000082826846,0.00010602401,0.00004744445,0.00006179852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017383126,0.00015924628,0.0003332586,0.00031976655,0.00006264172,0.000008889286,0.000041244944,0.00010206608,0.000012241892],"category_scores_gemma":[0.000028632632,0.0001483184,0.000053053293,0.0004977195,0.00005028533,0.00016765336,0.000012396055,0.00007272857,0.000032488406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026861607,0.00018205262,0.9781161,0.000783534,0.00040655944,0.000016010501,0.0015129938,0.000106176936,0.009465633,0.00001558585,0.00033355213,0.008793212],"study_design_scores_gemma":[0.0028769807,0.0001972388,0.9921689,0.0001147829,0.00080346054,6.57767e-7,0.00007390965,0.00014204753,0.0031816775,0.00008770524,0.0002166453,0.00013600537],"about_ca_topic_score_codex":0.00002556262,"about_ca_topic_score_gemma":0.000048397997,"teacher_disagreement_score":0.014052815,"about_ca_system_score_codex":0.00003319876,"about_ca_system_score_gemma":0.000024773606,"threshold_uncertainty_score":0.6048249},"labels":[],"label_agreement":null},{"id":"W4380482107","doi":"10.9778/cmajo.20220039","title":"Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease","year":2023,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Toronto Public Health; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"Novavax; Janssen Pharmaceuticals; Sanofi; GlaxoSmithKline","keywords":"Diabetes mellitus; Medicine; Atherosclerotic cardiovascular disease; Disease; Type 2 Diabetes Mellitus; Internal medicine; Cotransporter; Endocrinology; Sodium; Chemistry","score_opus":0.026119357430414023,"score_gpt":0.22139074374161258,"score_spread":0.19527138631119856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380482107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678713,0.00033247937,0.0000055222645,0.000059526927,0.000039566374,0.0025646524,0.0000637838,0.00008318809,0.00006413837],"genre_scores_gemma":[0.9990215,0.00007267044,0.000018551427,0.000055413853,0.000014302168,0.00015578422,0.00046704058,0.00005302469,0.00014175441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984667,0.000056635596,0.00019781796,0.00049988314,0.00036024937,0.0004187344],"domain_scores_gemma":[0.9992571,0.000048081958,0.00006156956,0.0003472647,0.000044603967,0.00024141005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021180783,0.00026475772,0.00049548515,0.00013080597,0.00009128093,0.00014616686,0.00010534526,0.000045977664,0.000010915466],"category_scores_gemma":[0.000030168261,0.00018613959,0.000056006662,0.0002377385,0.00006681483,0.0003377876,0.0001592705,0.00010125947,0.0000024297026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001340402,0.00025176618,0.9942685,0.00017349092,0.0009802962,0.000040751605,0.00062421843,0.000029133493,0.000020847703,0.0000043841624,0.000022625833,0.0034499732],"study_design_scores_gemma":[0.0072305556,0.00045184724,0.989089,0.0012864158,0.000922321,3.240715e-8,0.00020083666,0.0001480236,0.00032148324,0.000007724062,0.000103139435,0.00023862137],"about_ca_topic_score_codex":0.00022850794,"about_ca_topic_score_gemma":0.00014644513,"teacher_disagreement_score":0.0070965155,"about_ca_system_score_codex":0.0000704706,"about_ca_system_score_gemma":0.000027518867,"threshold_uncertainty_score":0.75905526},"labels":[],"label_agreement":null},{"id":"W4380536921","doi":"10.1136/bmjdrc-2022-003270","title":"Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering","year":2023,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Janssen Biotech; Janssen Research and Development","keywords":"Canagliflozin; Medicine; Renal function; Glycemic; Internal medicine; Empagliflozin; Creatinine; Placebo; Urology; Type 2 diabetes; Diabetes mellitus; Diabetic nephropathy; Kidney disease; Hypoglycemia; Gastroenterology; Endocrinology; Kidney","score_opus":0.07299496357041176,"score_gpt":0.44201230051436596,"score_spread":0.3690173369439542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380536921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801126,0.00048206493,0.0000032712635,0.00043262783,0.000116082185,0.012410089,0.000015356345,0.00005426943,0.006373648],"genre_scores_gemma":[0.99318546,0.000040867308,0.00018289502,0.000060056027,0.00007822965,0.005746328,0.000038054768,0.000042355103,0.0006257286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699676,0.00021751758,0.00029883537,0.0005382434,0.00097539,0.0009732351],"domain_scores_gemma":[0.9982177,0.0004256833,0.000048080543,0.00062863005,0.0003962753,0.0002836417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015544897,0.00019465681,0.0006012271,0.00079247437,0.00011517861,0.0001247793,0.0005710774,0.00006891476,0.000018923849],"category_scores_gemma":[0.0017180803,0.00017530353,0.00010452755,0.0024117,0.000079862206,0.00021316629,0.0017842308,0.00031177112,0.00013687585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057526445,0.00028049052,0.66456044,0.0068368902,0.0007748782,0.0013306859,0.0052681467,0.0004165719,0.06436146,0.00013314994,0.005494119,0.2499679],"study_design_scores_gemma":[0.003588377,0.0025975073,0.5636406,0.0068795425,0.000099630015,6.889041e-7,0.011901199,0.0002582689,0.40889192,0.00017471102,0.0015471992,0.0004203534],"about_ca_topic_score_codex":0.0016839282,"about_ca_topic_score_gemma":0.0005587863,"teacher_disagreement_score":0.34453046,"about_ca_system_score_codex":0.0005820529,"about_ca_system_score_gemma":0.00029557824,"threshold_uncertainty_score":0.71486706},"labels":[],"label_agreement":null},{"id":"W4380590474","doi":"10.2337/dc23-0222","title":"Insulin Use in Type 2 Diabetes and the Risk of Dementia: A Comparative Population-Based Cohort Study","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Women's College Hospital; University of Toronto; University of Waterloo","funders":"","keywords":"Medicine; Confounding; Dementia; Hazard ratio; Type 2 diabetes; Cohort; Diabetes mellitus; Propensity score matching; Insulin; Internal medicine; Interquartile range; Cohort study; Population; Proportional hazards model; Gerontology; Disease; Endocrinology; Confidence interval; Environmental health","score_opus":0.019401051939782213,"score_gpt":0.2706495095510645,"score_spread":0.2512484576112823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380590474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968157,0.0008406129,1.969575e-7,0.00006505729,0.00008034134,0.0019350284,0.000037388127,0.00005467239,0.00017104998],"genre_scores_gemma":[0.9991431,0.000060644532,0.000046466746,0.000095748874,0.000015277788,0.0002137837,0.00037254437,0.000014602415,0.000037787384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988858,0.00016421825,0.00025972867,0.00023630068,0.00023100099,0.0002229336],"domain_scores_gemma":[0.99898016,0.0004805215,0.00010635863,0.00028357893,0.000105549196,0.00004384475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031718897,0.00015128117,0.00046917106,0.00020345623,0.00006106573,0.00002615617,0.00006431529,0.000034814777,0.0000169223],"category_scores_gemma":[0.00016579758,0.00010083072,0.000063820684,0.00058541994,0.00007506077,0.00006574168,0.00006789087,0.00009201583,0.00002608134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059408285,0.00016704117,0.99601793,0.000086393025,0.0006965323,0.000002334643,0.0016329592,0.00019519508,0.00000931993,0.000030994514,0.00024784432,0.0008540408],"study_design_scores_gemma":[0.0047046416,0.00035522506,0.9884851,0.00007451208,0.0009410001,5.05846e-9,0.0026927947,0.0023954909,0.00013463547,0.00004052472,0.000086003936,0.000090068446],"about_ca_topic_score_codex":0.00015397355,"about_ca_topic_score_gemma":0.00025932235,"teacher_disagreement_score":0.0075328387,"about_ca_system_score_codex":0.000039056977,"about_ca_system_score_gemma":0.000017480954,"threshold_uncertainty_score":0.41117576},"labels":[],"label_agreement":null},{"id":"W4380625725","doi":"10.1093/ndt/gfad063b_4441","title":"#4441 KIDNEY DISEASE OUTCOMES WITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6","year":2023,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Karolinska Institutet; Universiteit Leiden; Leids Universitair Medisch Centrum; McMaster University; Brigham and Women's Hospital","keywords":"Medicine; Semaglutide; Kidney disease; Post-hoc analysis; Renal function; Albuminuria; Type 2 diabetes; Placebo; Internal medicine; Urology; Creatinine; Diabetes mellitus; Endocrinology; Liraglutide; Pathology","score_opus":0.009890579674154668,"score_gpt":0.2758131340475431,"score_spread":0.2659225543733884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380625725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402446,0.00005555437,0.001434647,0.0021196199,0.00009142794,0.0006602037,0.0012477812,0.00021506187,0.00015121902],"genre_scores_gemma":[0.98541915,0.0007171544,0.00025873422,0.00081279775,0.00004119732,0.00017029456,0.01191156,0.00003209266,0.0006370238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979152,0.00020242603,0.00046956795,0.00050064054,0.00041293676,0.0004992487],"domain_scores_gemma":[0.99815845,0.0006050006,0.0002420223,0.00046912904,0.00022242991,0.0003029517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005308132,0.00030484903,0.000843321,0.00088642194,0.00014885039,0.0000214429,0.00011466519,0.000108543005,0.00014583474],"category_scores_gemma":[0.00017405953,0.00023679996,0.00037433684,0.002558535,0.00018544347,0.00011550992,0.000020119507,0.00012420287,0.000046043588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049564846,0.000620495,0.89362884,0.00051797606,0.032351177,0.0006556363,0.005015849,0.010654335,0.0004982136,0.0002801996,0.0008104745,0.0054019485],"study_design_scores_gemma":[0.019562462,0.0011999201,0.8840598,0.00003015773,0.08473906,0.0000011327805,0.0013669174,0.0071629663,0.00030785232,0.0000330731,0.00122067,0.00031597368],"about_ca_topic_score_codex":0.00047687386,"about_ca_topic_score_gemma":0.0023662557,"teacher_disagreement_score":0.052387882,"about_ca_system_score_codex":0.00007833489,"about_ca_system_score_gemma":0.00015222898,"threshold_uncertainty_score":0.96564215},"labels":[],"label_agreement":null},{"id":"W4380625917","doi":"10.1093/ndt/gfad063c_4494","title":"#4494 DRUG UTILIZATION FOLLOWING INCIDENT CHRONIC KIDNEY DISEASE: AN OBSERVATIONAL STUDY IN THE UNITED STATES AND JAPAN","year":2023,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Kidney disease; Dialysis; Discontinuation; Renal function; Internal medicine; Diabetes mellitus; Heart failure; Hemodialysis; Creatinine; Endocrinology","score_opus":0.052698531458276646,"score_gpt":0.31844565298359706,"score_spread":0.26574712152532043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380625917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961215,0.000066581975,0.000092467446,0.0025882272,0.000060587903,0.0009298928,0.000020015848,0.00009621927,0.00002445614],"genre_scores_gemma":[0.98311275,0.0007845822,0.000019576652,0.0020790633,0.00005290411,0.00025103948,0.013615502,0.000013192597,0.00007136444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987517,0.00022640951,0.00025265652,0.00028104178,0.000285345,0.00020284484],"domain_scores_gemma":[0.9994922,0.0001470056,0.00005397042,0.00018363196,0.000030748255,0.00009242128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048989715,0.00013620412,0.00019336857,0.00045314425,0.00012359124,0.000034856617,0.00007551807,0.000036677484,0.000023859133],"category_scores_gemma":[0.000024768273,0.00010554463,0.000054396372,0.00090303196,0.000035864003,0.00019874008,0.00001018562,0.00007646442,0.000011829271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025037164,0.00043570445,0.98569083,0.00008356229,0.0002908297,0.00011365279,0.009247373,0.0015683302,0.00025431789,0.00019307366,0.00031043007,0.001561529],"study_design_scores_gemma":[0.0031029466,0.00027195245,0.9812873,0.000025825888,0.0015506939,9.336148e-7,0.0011489103,0.011609691,0.000017862314,0.00021737086,0.00067917875,0.00008736061],"about_ca_topic_score_codex":0.00036839882,"about_ca_topic_score_gemma":0.0017975495,"teacher_disagreement_score":0.013595486,"about_ca_system_score_codex":0.000059931575,"about_ca_system_score_gemma":0.00005609026,"threshold_uncertainty_score":0.4303985},"labels":[],"label_agreement":null},{"id":"W4380762751","doi":"10.1161/circ.146.suppl_1.9920","title":"Abstract 9920: Utilizing Synchronous Healthcare Delivery to Optimize the Use of Guideline Directed Medical Therapies in Patients With Type 2 Diabetes: Results From the DECIDE-CV Clinic","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Guideline; Type 2 diabetes; Internal medicine; Diabetes mellitus; Health care; Healthcare delivery; Endocrinology; Pathology","score_opus":0.0482007309709521,"score_gpt":0.28579449230698234,"score_spread":0.23759376133603025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380762751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949296,0.0004524369,0.000021047535,0.0033067553,0.00015774189,0.000977647,0.00005363419,0.00004194698,0.00005917162],"genre_scores_gemma":[0.99625194,0.00004485867,0.0006105137,0.002035308,0.00004598687,0.000048503363,0.0009294382,0.00001910415,0.000014342279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828357,0.00014462342,0.00054957357,0.0002489698,0.00058880827,0.00018448677],"domain_scores_gemma":[0.99852717,0.00064204173,0.00018837696,0.00041413557,0.00016429862,0.000063961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005276668,0.00012083126,0.00023060219,0.00007324276,0.0001223073,0.000016562482,0.00012824922,0.000041328127,0.00026156768],"category_scores_gemma":[0.00039299534,0.000070793,0.000048570477,0.00036325952,0.00003940835,0.000071641014,0.00008651252,0.00016837756,0.00000756723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012051793,0.000406257,0.9279077,0.000018582068,0.000285228,0.000006994455,0.0014819121,0.0050756675,0.00003052439,0.000007837133,0.003269907,0.060304195],"study_design_scores_gemma":[0.0026412455,0.00026417105,0.99099946,0.00014987671,0.00008951862,9.295585e-8,0.00038939278,0.0031680707,0.000006922343,0.000014390661,0.0022024235,0.00007444045],"about_ca_topic_score_codex":0.00069027086,"about_ca_topic_score_gemma":0.0001817453,"teacher_disagreement_score":0.06309174,"about_ca_system_score_codex":0.00016411614,"about_ca_system_score_gemma":0.00010713331,"threshold_uncertainty_score":0.2886855},"labels":[],"label_agreement":null},{"id":"W4380785499","doi":"10.1161/circ.146.suppl_1.14915","title":"Abstract 14915: Efficacy of Canagliflozin on Heart Failure Hospitalization Across Diabetes-Specific Risk Scores","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Canagliflozin; Internal medicine; Diabetes mellitus; Heart failure; Confidence interval; Cohort; Placebo; Number needed to treat; Proportional hazards model; Framingham Risk Score; Absolute risk reduction; Hazard ratio; Relative risk; Type 2 diabetes; Endocrinology; Disease; Pathology","score_opus":0.013078038467566097,"score_gpt":0.2536115864898261,"score_spread":0.24053354802226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380785499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978159,0.00020536406,0.000039592527,0.00034745183,0.0002170246,0.0006866508,0.000046296715,0.000068992,0.0005727237],"genre_scores_gemma":[0.9990543,0.000012046674,0.00007475186,0.00010825239,0.00008104357,0.000059525133,0.0005323095,0.000024758376,0.000053024196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988375,0.000040537045,0.00024856807,0.00026228777,0.0003960141,0.00021513087],"domain_scores_gemma":[0.99935365,0.000056306922,0.00016479452,0.0003145024,0.00005247463,0.000058258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002243796,0.0001272597,0.00021091879,0.00012196603,0.00019228057,0.000020475565,0.000059597813,0.000035293175,0.00029057564],"category_scores_gemma":[0.00004169741,0.00012756209,0.00011211126,0.00030239465,0.000031707717,0.00007946547,0.00004041976,0.00011268593,0.000029380179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063935506,0.00050706975,0.9663838,0.00007044164,0.0001362521,0.0000040174145,0.00039656943,0.012265775,0.003489866,0.00050600455,0.0052659423,0.010910321],"study_design_scores_gemma":[0.0015550547,0.00021230706,0.9871127,0.000044363638,0.00008016874,3.2186668e-7,0.00014046312,0.00061445415,0.0011964836,0.00008642298,0.008848584,0.000108656146],"about_ca_topic_score_codex":0.00006638189,"about_ca_topic_score_gemma":0.000014054592,"teacher_disagreement_score":0.020728916,"about_ca_system_score_codex":0.0002166252,"about_ca_system_score_gemma":0.00002214781,"threshold_uncertainty_score":0.5201831},"labels":[],"label_agreement":null},{"id":"W4380794938","doi":"10.1161/circ.146.suppl_1.12880","title":"Abstract 12880: Left Ventricular Mass Predicts Cardiac Reverse Remodeling in Patients With Type 2 Diabetes and Coronary Artery Disease Who Are Treated With Empagliflozin","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Cardiology; Internal medicine; Type 2 diabetes; Placebo; Coronary artery disease; Diabetes mellitus; Cohort; Endocrinology","score_opus":0.007726469869569019,"score_gpt":0.19073818718119415,"score_spread":0.18301171731162513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380794938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837583,0.00041359116,0.0000061730057,0.00007167324,0.000051618637,0.0009105735,0.000029733175,0.000045700795,0.00009511051],"genre_scores_gemma":[0.99863166,0.00001188404,0.000042900876,0.00009139639,0.000022458511,0.00004088191,0.0010696033,0.000024740015,0.00006449355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990031,0.000039400144,0.00014941403,0.00028715012,0.0003300833,0.00019085286],"domain_scores_gemma":[0.99951285,0.00001587469,0.00008913863,0.00020636646,0.00006668662,0.00010907159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009110495,0.00014485231,0.0002315745,0.00014590457,0.000090923146,0.000017180371,0.000028242537,0.000024122253,0.00004629869],"category_scores_gemma":[0.00001247799,0.00012079356,0.000030162597,0.00019279997,0.000021445605,0.00014034082,0.000025489322,0.00009168908,0.0000028352995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041706106,0.00021087527,0.991444,0.00010971928,0.00017223645,0.00012776787,0.000077446435,0.0061303736,0.000027924865,0.000002361073,0.00011162674,0.00116864],"study_design_scores_gemma":[0.0027520403,0.00023878443,0.9926602,0.00025939613,0.000431715,5.3529135e-7,0.000096483374,0.0032677848,0.0000065120744,0.000016371469,0.00013506033,0.000135117],"about_ca_topic_score_codex":0.000007843545,"about_ca_topic_score_gemma":0.0000016896244,"teacher_disagreement_score":0.002862589,"about_ca_system_score_codex":0.0002155041,"about_ca_system_score_gemma":0.000030057801,"threshold_uncertainty_score":0.4925818},"labels":[],"label_agreement":null},{"id":"W4380795398","doi":"10.1161/circ.146.suppl_1.12767","title":"Abstract 12767: Sodium-Glucose Cotransporter-2 Inhibitors Are Associated With Lower Risks of Hospitalization for Heart Failure and All-Cause Mortality in Patients With Diabetes Mellitus and Cancer","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Internal medicine; Myocardial infarction; Diabetes mellitus; Proportional hazards model; Heart failure; Stroke (engine); Retrospective cohort study; Cohort; Lower risk; Cancer; Adverse effect; Cohort study; Cardiology; Confidence interval; Endocrinology","score_opus":0.02128417401739377,"score_gpt":0.2611786472247352,"score_spread":0.23989447320734145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380795398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829024,0.00023441782,0.000012991986,0.00011415925,0.000038411417,0.0012020873,0.000077788245,0.000019528761,0.000010362456],"genre_scores_gemma":[0.9989598,0.000015442272,0.000025450812,0.000043073407,0.000009473479,0.00016161893,0.0007637237,0.00001786097,0.0000035483506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992234,0.000016514889,0.00018275317,0.0002113793,0.00022900871,0.00013695928],"domain_scores_gemma":[0.99958587,0.000019229601,0.00017137008,0.000098333025,0.00008240138,0.000042770203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010989683,0.00011420136,0.00021565882,0.0000840531,0.000052075804,0.000011213241,0.000015514877,0.000036368874,0.000017668413],"category_scores_gemma":[0.000009469447,0.00009683707,0.000021814021,0.00013588612,0.00003705818,0.00013134438,0.000009545302,0.000052075793,6.0991326e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010857334,0.00042335535,0.9975431,0.00013303926,0.00047169818,0.0000016439126,0.0001906572,0.00052350527,0.00010971983,0.000011955757,0.00003101862,0.00045176462],"study_design_scores_gemma":[0.0039532795,0.0003589741,0.993981,0.0001520069,0.0006582961,3.5912194e-8,0.00011279886,0.0003603038,0.0002282061,0.00002476916,0.00006194379,0.00010836305],"about_ca_topic_score_codex":0.00006733246,"about_ca_topic_score_gemma":0.00021344845,"teacher_disagreement_score":0.003844706,"about_ca_system_score_codex":0.00010599501,"about_ca_system_score_gemma":0.000018235956,"threshold_uncertainty_score":0.39489013},"labels":[],"label_agreement":null},{"id":"W4380795717","doi":"10.1161/circ.146.suppl_1.14726","title":"Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Heart failure; Hazard ratio; Cardiology; Biomarker; Natriuretic peptide; Dyslipidemia; Cohort; Type 2 diabetes; Randomized controlled trial; Surrogate endpoint; TIMI; Dapagliflozin; Diabetes mellitus; Myocardial infarction; Endocrinology; Disease; Conventional PCI","score_opus":0.014078410280937256,"score_gpt":0.2639967105789067,"score_spread":0.24991830029796946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380795717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99697196,0.00044044515,0.0009237416,0.000060196155,0.00012607349,0.0012758462,0.000054414515,0.000012737241,0.00013457822],"genre_scores_gemma":[0.9973067,0.00010149771,0.002053052,0.0000069089583,0.000027342468,0.00014052188,0.00034280017,0.000013324488,0.000007859816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991828,0.000053522774,0.00023135294,0.00017939796,0.00025246746,0.000100421916],"domain_scores_gemma":[0.99958414,0.00003870203,0.00011189722,0.00018123744,0.00005592923,0.00002811891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044258492,0.00008382898,0.00030784414,0.00014239403,0.000047349215,0.000006478921,0.000024194092,0.000035831574,0.00003052513],"category_scores_gemma":[0.00003339528,0.00007856449,0.00016915212,0.00016995725,0.00001549754,0.00007195748,0.0000270036,0.000036840334,1.2289193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001262831,0.00016366005,0.97805303,0.00026265785,0.0014631624,0.0000013049357,0.000120265795,0.010631544,0.001602776,0.00015456862,0.00019483315,0.0072259284],"study_design_scores_gemma":[0.0019487679,0.00021274442,0.9893573,0.000034351182,0.00089571404,5.0971596e-7,0.00023009806,0.0031436055,0.00047153348,0.00006736119,0.0035640744,0.0000739333],"about_ca_topic_score_codex":0.00015652688,"about_ca_topic_score_gemma":0.000009836288,"teacher_disagreement_score":0.011304291,"about_ca_system_score_codex":0.00013397375,"about_ca_system_score_gemma":0.000053210708,"threshold_uncertainty_score":0.3203767},"labels":[],"label_agreement":null},{"id":"W4380871434","doi":"10.1002/cpt.2975","title":"Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and <scp>DPP</scp>‐4 Inhibitors: Population‐Based Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University; American Diabetes Association","keywords":"Medicine; Concomitant; Hypoglycemia; Internal medicine; Gliclazide; Sitagliptin; Pharmacology; Population; Saxagliptin; Sulfonylurea; Alogliptin; Hazard ratio; Endocrinology; Insulin; Metformin; Confidence interval","score_opus":0.07703914487866334,"score_gpt":0.379905066417467,"score_spread":0.30286592153880365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380871434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968921,0.0002824351,0.000007829442,0.00027365712,0.0002686314,0.002093482,0.000053165742,0.00009399617,0.000034684068],"genre_scores_gemma":[0.9952131,0.0017399115,0.00033272174,0.0023457007,0.00009566085,0.00007339249,0.000054310716,0.00003203997,0.0001131649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977643,0.00048409076,0.0007417319,0.00046154225,0.00025109228,0.0002972525],"domain_scores_gemma":[0.99675536,0.0022032051,0.00045773102,0.00024627082,0.00015545398,0.0001819538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080393674,0.00026477728,0.0008489681,0.00015499024,0.00007857625,0.000011599054,0.000089210196,0.00016361866,0.00001641632],"category_scores_gemma":[0.00006608932,0.00019569018,0.00010501008,0.0003235669,0.00043306279,0.00007704546,0.00013036795,0.0003115056,0.000004236271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007627459,0.0017758666,0.9877516,0.000086106775,0.0048475917,0.000054768767,0.00007800851,0.00013962037,0.0015936806,0.0000018976868,0.001449486,0.0014585967],"study_design_scores_gemma":[0.012176647,0.004434286,0.9685524,0.000029997027,0.00996486,0.0000038684484,0.000113302995,0.0014104893,0.0017431269,0.000019050905,0.0014605992,0.000091334994],"about_ca_topic_score_codex":0.000042645905,"about_ca_topic_score_gemma":0.000024048073,"teacher_disagreement_score":0.019199194,"about_ca_system_score_codex":0.000038210303,"about_ca_system_score_gemma":0.00006539811,"threshold_uncertainty_score":0.7980014},"labels":[],"label_agreement":null},{"id":"W4381194418","doi":"10.1016/j.jacc.2023.04.034","title":"Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations","year":2023,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Ejection fraction; Kidney disease; Dapagliflozin; Placebo; Cause of death; Cardiology; Diabetes mellitus; Type 2 Diabetes Mellitus; Endocrinology; Disease","score_opus":0.030555327472571312,"score_gpt":0.3457751061898783,"score_spread":0.31521977871730694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381194418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04821897,0.94559604,0.000017081536,0.00019258074,0.0026374182,0.0022901557,0.00038758156,0.000020902178,0.00063929637],"genre_scores_gemma":[0.040830273,0.9580778,0.00011935606,0.00005613722,0.00040789726,0.000059502872,0.000016221995,0.000090057714,0.00034274164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965515,0.0010079953,0.0012598219,0.0002134829,0.00067745027,0.00028971248],"domain_scores_gemma":[0.99594045,0.00069920375,0.0022827392,0.0008198653,0.00016762796,0.00009014232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011164983,0.00038031698,0.0068714507,0.0003661613,0.000057295736,0.000003396292,0.00032060614,0.00011735906,0.0000016930558],"category_scores_gemma":[0.00049607793,0.0001951763,0.006157954,0.00073379494,0.00032378806,0.000021463622,0.00021358549,0.0003738371,0.0000065603067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034459564,0.0001434476,0.0073622577,0.008230103,0.047370594,0.0008403036,0.00004802269,0.0010256782,0.0000014582856,0.00009150545,0.008504584,0.92603743],"study_design_scores_gemma":[0.0019837234,0.011293697,0.0041024936,0.008404906,0.031864703,0.00051335414,0.000115972136,0.0000014088743,0.000024441166,0.000030417084,0.94138026,0.00028464373],"about_ca_topic_score_codex":0.000020312682,"about_ca_topic_score_gemma":0.0000015233151,"teacher_disagreement_score":0.93287563,"about_ca_system_score_codex":0.0002583365,"about_ca_system_score_gemma":0.00017365199,"threshold_uncertainty_score":0.7959059},"labels":[],"label_agreement":null},{"id":"W4381233952","doi":"10.2337/db23-800-p","title":"800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Type 2 diabetes; Basal insulin; Medicine; Logistic regression; Internal medicine; Diabetes mellitus; Basal (medicine); Insulin; Endocrinology","score_opus":0.06186928358178144,"score_gpt":0.2939043970536072,"score_spread":0.23203511347182576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381233952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974619,0.00095322274,1.6838752e-7,0.00016651514,0.00023127289,0.0007772711,0.000043337845,0.00004963722,0.0003166774],"genre_scores_gemma":[0.9991633,0.000114711285,0.00005838994,0.000093252645,0.00004456386,0.00008912277,0.000042123967,0.00002624868,0.00036827978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985886,0.00012578114,0.0003657716,0.00025152325,0.00036021255,0.00030810767],"domain_scores_gemma":[0.9989567,0.00030301465,0.00018012736,0.00039418048,0.000094187904,0.00007178011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028322215,0.00018849211,0.00049962004,0.0003733224,0.0000355063,0.00001032011,0.00011494759,0.000065487824,0.000017200631],"category_scores_gemma":[0.00031282537,0.00011571001,0.00008588239,0.0009999797,0.00020697714,0.00010009427,0.00012932067,0.00009298642,0.000004576073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022546065,0.00033503634,0.979382,0.00024384628,0.00059935334,0.000006485049,0.0008005966,0.000015498528,0.011728199,0.000029335813,0.0014233354,0.0031817392],"study_design_scores_gemma":[0.019906873,0.004361885,0.78571033,0.0007298368,0.00078481156,1.1744584e-7,0.0011294696,0.00014714485,0.18565321,0.00008297306,0.0012563025,0.00023705968],"about_ca_topic_score_codex":0.00001645116,"about_ca_topic_score_gemma":0.000014606163,"teacher_disagreement_score":0.19367166,"about_ca_system_score_codex":0.000028839198,"about_ca_system_score_gemma":0.00007711123,"threshold_uncertainty_score":0.47185174},"labels":[],"label_agreement":null},{"id":"W4381233953","doi":"10.2337/db23-54-or","title":"54-OR: Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Glycemic; Medicine; Post-hoc analysis; Internal medicine; Metformin; Randomized controlled trial; Type 2 diabetes; Urology; Diabetes mellitus; Endocrinology; Insulin","score_opus":0.024913527161945087,"score_gpt":0.2814759295987474,"score_spread":0.2565624024368023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381233953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957812,0.00044295038,7.9579564e-7,0.00052241836,0.00014696913,0.0006875284,0.00008371093,0.00018424883,0.0021502115],"genre_scores_gemma":[0.9942036,0.00006134015,0.000043952474,0.00027461722,0.000042622498,0.00008274236,0.00013520636,0.000036195263,0.005119703],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859625,0.00007100757,0.00027272274,0.00034441435,0.00031537944,0.00040023486],"domain_scores_gemma":[0.9989176,0.00045980565,0.00009318231,0.00034634882,0.000036640737,0.00014645628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003523246,0.0002523614,0.0005824651,0.00018412457,0.000049531776,0.000017748574,0.00008308944,0.00007856601,0.000050172668],"category_scores_gemma":[0.00024811307,0.00017509138,0.00010729247,0.0003017108,0.00009826778,0.00003748391,0.00007360559,0.000088382745,0.0000991418],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034127824,0.00061291637,0.47900134,0.0034572883,0.0025554558,0.00013902278,0.00055127084,0.000009295465,0.2406216,0.00026248026,0.12607661,0.14329992],"study_design_scores_gemma":[0.012412815,0.012005798,0.1070328,0.0010536826,0.0012309215,0.0000020957598,0.00008962382,0.00050502975,0.84511,0.0001502202,0.019888755,0.00051827886],"about_ca_topic_score_codex":0.000016045706,"about_ca_topic_score_gemma":0.0000050728772,"teacher_disagreement_score":0.6044884,"about_ca_system_score_codex":0.00004196088,"about_ca_system_score_gemma":0.00002288839,"threshold_uncertainty_score":0.71400195},"labels":[],"label_agreement":null},{"id":"W4381337312","doi":"10.2337/db23-268-or","title":"268-OR: The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mace; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Proportional hazards model; Type 2 diabetes; Empagliflozin; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Diabetes mellitus; Canagliflozin; Dulaglutide; Stroke (engine); Confidence interval; Cardiology; Endocrinology; Exenatide; Receptor; Conventional PCI","score_opus":0.012060182992319333,"score_gpt":0.20066635746722186,"score_spread":0.18860617447490252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381337312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812627,0.00025492752,1.5003894e-7,0.00017331912,0.00018038446,0.0010618919,0.000052998752,0.00004888807,0.000101189864],"genre_scores_gemma":[0.99888146,0.0002927307,0.000028866318,0.000084296094,0.000031785006,0.00007631688,0.000117928095,0.00003450995,0.0004521201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855834,0.00014601831,0.00025076568,0.00024729455,0.00049594307,0.0003016234],"domain_scores_gemma":[0.99850434,0.0005118943,0.00017764755,0.0005989182,0.00013932116,0.00006789271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003896077,0.00021307383,0.00046254817,0.000112444985,0.00012512572,0.000024364248,0.000118939985,0.000053599313,0.000025341118],"category_scores_gemma":[0.0003151015,0.00008932857,0.00017280536,0.0005113419,0.00027951473,0.000086359876,0.00011260249,0.00011265161,0.000016326525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009928223,0.00022917005,0.9868738,0.00012604827,0.0030985859,8.4986584e-7,0.00020651106,0.00004065889,0.0000996181,0.00003077822,0.0032719856,0.0059227],"study_design_scores_gemma":[0.001938159,0.0017247639,0.9767189,0.00040425296,0.0013290163,9.917856e-9,0.00010399303,0.000119316,0.012046707,0.00004100321,0.0054359515,0.00013789638],"about_ca_topic_score_codex":0.00005270393,"about_ca_topic_score_gemma":0.0000046665737,"teacher_disagreement_score":0.011947089,"about_ca_system_score_codex":0.000024626745,"about_ca_system_score_gemma":0.000020553674,"threshold_uncertainty_score":0.3642713},"labels":[],"label_agreement":null},{"id":"W4381337438","doi":"10.2337/db23-180-or","title":"180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Insulin glargine; Type 2 diabetes; Diabetes mellitus; Insulin; Insulin resistance; Endocrinology; Logistic regression","score_opus":0.015351670330581262,"score_gpt":0.24938018855701938,"score_spread":0.2340285182264381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381337438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975554,0.00085658726,0.0000015343139,0.00031005108,0.00016029066,0.00076522643,0.00004166383,0.00005816038,0.00025111623],"genre_scores_gemma":[0.9989674,0.000093592986,0.00007021664,0.00012633674,0.000047653128,0.000061946834,0.00015376875,0.000032364187,0.0004467351],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983664,0.00017156792,0.00052351336,0.0002561606,0.0003778964,0.00030442717],"domain_scores_gemma":[0.9985579,0.00060570147,0.00014099636,0.00045547672,0.00014586211,0.00009403578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010315271,0.00019590558,0.0004933502,0.0004741167,0.000026591211,0.000005270211,0.00014245571,0.00008493276,0.00009468562],"category_scores_gemma":[0.000276739,0.00012724863,0.00012945292,0.0010520312,0.000081662896,0.000047251626,0.00006608761,0.00009214945,0.000011116383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018501173,0.0005293317,0.5708052,0.00019081356,0.00012754825,0.0000017603319,0.00019455001,0.00014490695,0.41143858,0.000003927411,0.000716792,0.0139965],"study_design_scores_gemma":[0.0018729958,0.0033871452,0.4696431,0.00035753704,0.0001855481,1.7424616e-8,0.00017745359,0.0020891353,0.51966465,0.000018832083,0.0024882478,0.00011538529],"about_ca_topic_score_codex":0.000012031857,"about_ca_topic_score_gemma":0.0000050845692,"teacher_disagreement_score":0.10822604,"about_ca_system_score_codex":0.000038480423,"about_ca_system_score_gemma":0.00008753582,"threshold_uncertainty_score":0.5189048},"labels":[],"label_agreement":null},{"id":"W4381376853","doi":"10.2337/db23-134-lb","title":"134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Metformin; Diabetes mellitus; Basal (medicine); Insulin; Medical record; Prospective cohort study; Regimen; Internal medicine; Endocrinology; Pediatrics","score_opus":0.0169722325123647,"score_gpt":0.265272298544523,"score_spread":0.2483000660321583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381376853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952397,0.0017462583,2.044843e-8,0.00027780698,0.0002164449,0.0016933781,0.00004064671,0.00007348488,0.000712281],"genre_scores_gemma":[0.9960438,0.0026786064,0.00002418691,0.00024400972,0.000048708138,0.0002514605,0.0001394172,0.000058517504,0.00051131856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978434,0.00007889676,0.00044349162,0.00046850543,0.00043034222,0.0007353848],"domain_scores_gemma":[0.9988212,0.00025186458,0.0001968605,0.0004518916,0.00011719723,0.00016098421],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002882465,0.0003760107,0.0010557186,0.000482827,0.00002999029,0.000026570264,0.00015837868,0.00004390313,0.000038641545],"category_scores_gemma":[0.00016710028,0.00028617607,0.00011763914,0.0017003485,0.000043362295,0.00020198684,0.00010207486,0.00022079966,0.00001936569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013639031,0.0002499717,0.9918753,0.0007406835,0.00030596534,0.00007631995,0.00013548434,0.000029170867,0.00062584714,0.000008804137,0.0015257691,0.004290327],"study_design_scores_gemma":[0.0021863966,0.0009979472,0.9742805,0.007093877,0.00014548202,1.3721316e-7,0.00015698838,0.00017462425,0.014603245,0.000012453406,0.000091474794,0.0002569042],"about_ca_topic_score_codex":0.18114318,"about_ca_topic_score_gemma":0.2655161,"teacher_disagreement_score":0.084372915,"about_ca_system_score_codex":0.0013763204,"about_ca_system_score_gemma":0.00041860697,"threshold_uncertainty_score":0.99995905},"labels":[],"label_agreement":null},{"id":"W4381377332","doi":"10.2337/db23-787-p","title":"787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Internal medicine; Body mass index; Weight loss; Diabetes mellitus; Body weight; Type 2 diabetes; Endocrinology; Gastroenterology; Obesity; Liraglutide","score_opus":0.030913449883613945,"score_gpt":0.30905413401070037,"score_spread":0.2781406841270864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900298,0.00013507092,2.3778196e-7,0.0058717118,0.00019290406,0.00062081165,0.00041722512,0.00010952769,0.0026226745],"genre_scores_gemma":[0.9955451,0.00031255145,0.000052378942,0.0010527534,0.00011600954,0.00007482376,0.00084671297,0.000022656968,0.001977014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976098,0.0004562046,0.0006196663,0.0003663015,0.0004955179,0.00045252233],"domain_scores_gemma":[0.99418,0.00493229,0.00037556808,0.0003613614,0.00008890694,0.000061850405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022731693,0.00018756046,0.0006581238,0.00009495291,0.000081163744,0.000055007997,0.00019048221,0.000121149365,0.0000134070115],"category_scores_gemma":[0.001997903,0.00011515663,0.00013200333,0.0006451202,0.00018792329,0.000075900105,0.00010554253,0.0002591178,0.000018180206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000571039,0.0002882535,0.96925914,0.000011795305,0.00067749503,0.00004856765,0.00022888031,0.0000020642344,0.000012821467,0.000055860055,0.020362077,0.008995957],"study_design_scores_gemma":[0.005160401,0.00028907924,0.9906888,0.00022148743,0.0005111681,7.8484845e-8,0.00018654982,0.00015991525,0.000111037516,0.0003897848,0.0021517053,0.0001299649],"about_ca_topic_score_codex":0.0013407865,"about_ca_topic_score_gemma":0.0078180265,"teacher_disagreement_score":0.021429703,"about_ca_system_score_codex":0.00009887237,"about_ca_system_score_gemma":0.00004527887,"threshold_uncertainty_score":0.4695951},"labels":[],"label_agreement":null},{"id":"W4381377391","doi":"10.2337/db23-788-p","title":"788-P: Predictors of Achieving Target HbA1c &amp;lt;7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Glycemic; Post-hoc analysis; Internal medicine; Insulin; Logistic regression; Endocrinology; Diabetes mellitus; Post hoc","score_opus":0.008139535473311758,"score_gpt":0.22671784084784832,"score_spread":0.21857830537453657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958461,0.0009410877,0.000005394868,0.00027000226,0.00013116025,0.0008885295,0.000020122838,0.00024578552,0.0016518512],"genre_scores_gemma":[0.99586433,0.00019743525,0.0015222282,0.00010004594,0.000082471204,0.00021838657,0.00042878327,0.00007734509,0.0015089833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980101,0.00004696032,0.00032939474,0.00045107323,0.00038621377,0.0007762839],"domain_scores_gemma":[0.99893194,0.00019424969,0.00014135416,0.00047235913,0.000090765316,0.00016933655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022600136,0.00036642485,0.00074385555,0.0004718125,0.00006437318,0.000024082652,0.0001113101,0.00007192536,0.00007789018],"category_scores_gemma":[0.000060453716,0.0002461471,0.00008748778,0.0012562831,0.000087311186,0.00019049035,0.000068476504,0.0001048292,0.000054140404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090631795,0.0004198336,0.98764455,0.0003069924,0.00078872294,0.000019266905,0.00089466275,0.00037379717,0.0061047245,0.000025699257,0.00040388567,0.0029272116],"study_design_scores_gemma":[0.005833936,0.0068796794,0.94388103,0.0012424553,0.0010162145,5.9912037e-7,0.0005492706,0.00084201957,0.021203743,0.000042107502,0.017966777,0.00054218475],"about_ca_topic_score_codex":0.000044445853,"about_ca_topic_score_gemma":0.00025897546,"teacher_disagreement_score":0.04376356,"about_ca_system_score_codex":0.00019867424,"about_ca_system_score_gemma":0.00009546882,"threshold_uncertainty_score":0.9999991},"labels":[],"label_agreement":null},{"id":"W4381377561","doi":"10.2337/db23-413-p","title":"413-P: Intensive Insulin Therapy Delays the “Breakpoint” to Progressive Kidney Function Decline—New Findings and Implications of eGFR Trajectory Analysis in DCCT/EDIC Data","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breakpoint; Medicine; Internal medicine; Renal function; Cohort; Kidney disease; Albuminuria; Endocrinology; Biology; Genetics; Chromosomal translocation; Gene","score_opus":0.03653778995333633,"score_gpt":0.30374327381169813,"score_spread":0.2672054838583618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851146,0.001475643,0.000052195257,0.011997854,0.00006904378,0.00091410003,0.00010115488,0.000072114824,0.00020333],"genre_scores_gemma":[0.993131,0.00046323182,0.00022126114,0.0044599827,0.00006852555,0.00016185048,0.0012200761,0.000020533007,0.00025353138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987885,0.000040245202,0.00030526723,0.00039978948,0.00018752298,0.00027870238],"domain_scores_gemma":[0.9987301,0.0002067876,0.0000936591,0.0006555795,0.00014154248,0.00017228308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003587299,0.00016469402,0.00037333512,0.0005962962,0.000059798273,0.000027060216,0.00022589217,0.000054740893,0.000058720343],"category_scores_gemma":[0.0003852733,0.00011223023,0.000083920946,0.0019368918,0.00007882613,0.00011394073,0.00024993252,0.000099766556,0.000025443273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011541153,0.00020787491,0.837363,0.00006978157,0.0023721885,0.0000049958003,0.0012717154,0.000029421171,0.004728026,0.00021322769,0.046061117,0.107563265],"study_design_scores_gemma":[0.0016322162,0.0004561147,0.9848199,0.00012154732,0.0012608193,2.9610536e-7,0.00067222543,0.0010290508,0.002147899,0.00045458128,0.007267449,0.0001379259],"about_ca_topic_score_codex":0.00010963451,"about_ca_topic_score_gemma":0.00007246672,"teacher_disagreement_score":0.1474569,"about_ca_system_score_codex":0.000040121962,"about_ca_system_score_gemma":0.0000721314,"threshold_uncertainty_score":0.4576616},"labels":[],"label_agreement":null},{"id":"W4381377638","doi":"10.2337/db23-799-p","title":"799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Glycemic; Type 2 diabetes; Medicine; Hypoglycemia; Post-hoc analysis; Logistic regression; Internal medicine; Meal; Diabetes mellitus; Insulin; Endocrinology","score_opus":0.0032668025227064455,"score_gpt":0.20422421554282624,"score_spread":0.2009574130201198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972439,0.00071815384,0.000046523735,0.0002409763,0.000039462477,0.0012933064,0.000097442455,0.0001523001,0.00016794313],"genre_scores_gemma":[0.99757653,0.000035027915,0.0003143738,0.00017425187,0.000031971078,0.00037819234,0.00082866626,0.000052302654,0.00060867175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983948,0.000035759313,0.00030050354,0.00037685534,0.00028316016,0.0006089277],"domain_scores_gemma":[0.99894184,0.00032920024,0.00015205932,0.00031470493,0.00013821188,0.00012399416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022305583,0.00026472317,0.0009413378,0.00052290084,0.000042785963,0.000017537039,0.00010681697,0.0000683008,0.00005542393],"category_scores_gemma":[0.000087830216,0.0001918962,0.00013760461,0.0017560328,0.000065453685,0.00012570262,0.000027893202,0.00007463608,0.000017587181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006213762,0.0001999838,0.9631924,0.0002578563,0.0046655866,0.000004367549,0.00021897459,0.00031114236,0.028570239,0.0000036263239,0.0012358167,0.00071865733],"study_design_scores_gemma":[0.032994594,0.008171173,0.8554523,0.00071951625,0.021514531,1.9270335e-7,0.0005677998,0.027375331,0.051332247,0.000043615913,0.001023253,0.0008054723],"about_ca_topic_score_codex":0.00002573431,"about_ca_topic_score_gemma":0.000088138404,"teacher_disagreement_score":0.1077401,"about_ca_system_score_codex":0.0000694299,"about_ca_system_score_gemma":0.00004450812,"threshold_uncertainty_score":0.78252995},"labels":[],"label_agreement":null},{"id":"W4381377701","doi":"10.2337/db23-775-p","title":"775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Glycemic; Medicine; Type 2 diabetes; Post-hoc analysis; Internal medicine; Logistic regression; Population; Endocrinology; Diabetes mellitus; Basal insulin; Insulin","score_opus":0.004255156684363225,"score_gpt":0.20647543549551262,"score_spread":0.2022202788111494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975355,0.0004135599,0.0000046193654,0.00022949999,0.00003733469,0.00082399545,0.000030647065,0.00020804169,0.0007167971],"genre_scores_gemma":[0.9981901,0.000033908527,0.000060481878,0.00014056051,0.000031162454,0.00017791982,0.00047778277,0.000047138514,0.0008409652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982742,0.000043397096,0.0003191026,0.00040784877,0.00038206452,0.0005734012],"domain_scores_gemma":[0.99899095,0.00014006035,0.00013990598,0.00043116548,0.00016219681,0.00013573942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015074537,0.00029636105,0.00091751834,0.0012198273,0.000036467525,0.000021792743,0.0001136928,0.000082788654,0.00010900343],"category_scores_gemma":[0.000037076275,0.00019979972,0.00012461064,0.0051615066,0.00009095091,0.000113260896,0.00003299964,0.00010493361,0.000033435634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031311304,0.00033036942,0.98904866,0.00015162645,0.006340636,0.000022460732,0.00023314355,0.0003208852,0.0023625067,0.000013229514,0.0003225113,0.0005408795],"study_design_scores_gemma":[0.008055885,0.0019833534,0.97189397,0.0002673994,0.008037425,1.1007924e-7,0.00023879793,0.0030356369,0.0061425795,0.000009727673,0.000099856756,0.0002352417],"about_ca_topic_score_codex":0.000058133974,"about_ca_topic_score_gemma":0.000116616124,"teacher_disagreement_score":0.017154653,"about_ca_system_score_codex":0.00006348132,"about_ca_system_score_gemma":0.00004966894,"threshold_uncertainty_score":0.8147596},"labels":[],"label_agreement":null},{"id":"W4381377712","doi":"10.2337/db23-797-p","title":"797-P: Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Semaglutide; Population; Family medicine; Drug Company; Type 2 diabetes; Management; Diabetes mellitus; Environmental health; Endocrinology; Liraglutide","score_opus":0.011311521686635968,"score_gpt":0.25249113286279096,"score_spread":0.241179611176155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829137,0.000036354348,7.934681e-7,0.00058692554,0.000058603087,0.00076829194,0.000024658766,0.00017798807,0.01543274],"genre_scores_gemma":[0.9900202,0.000051425643,0.00054985995,0.00010528629,0.00004151944,0.00009731413,0.0005138907,0.000031864314,0.0085886335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874663,0.00003082643,0.00031068912,0.00026661824,0.0002758552,0.00036937234],"domain_scores_gemma":[0.99937165,0.0000943559,0.000107903456,0.00028335303,0.000070959504,0.00007179393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014323251,0.00016793422,0.00039313346,0.000373262,0.000031604905,0.000009087333,0.00006590213,0.00004221742,0.00006733076],"category_scores_gemma":[0.000044799683,0.0001319271,0.000061582854,0.00090591674,0.000042192583,0.000060828697,0.00004218608,0.00007995505,0.000068898255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020376862,0.00021978108,0.9763864,0.00034936488,0.00014901363,0.0000940689,0.00019403646,0.0000928031,0.0011745933,0.001050874,0.0013066608,0.018778628],"study_design_scores_gemma":[0.0021910905,0.0009314838,0.98667294,0.00064507115,0.00019581741,8.206652e-7,0.00017596497,0.002399615,0.0055352114,0.00019841097,0.00085619785,0.0001973748],"about_ca_topic_score_codex":0.0006023699,"about_ca_topic_score_gemma":0.00079922576,"teacher_disagreement_score":0.018581253,"about_ca_system_score_codex":0.00011525282,"about_ca_system_score_gemma":0.000027755563,"threshold_uncertainty_score":0.53798306},"labels":[],"label_agreement":null},{"id":"W4381377770","doi":"10.2337/db23-271-or","title":"271-OR: Capillary Blood Ketone Level and Future Ketoacidosis Risk in Type 1 Diabetes Using Sodium–Glucose Linked Transporter Inhibitors","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ketosis; Ketone bodies; Diabetic ketoacidosis; Medicine; Empagliflozin; Internal medicine; Ketoacidosis; Diabetes mellitus; Ketone; Type 1 diabetes; Endocrinology; Type 2 diabetes; Chemistry; Metabolism","score_opus":0.0257123024809426,"score_gpt":0.24984890294716552,"score_spread":0.2241366004662229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192405,0.0056769275,4.855698e-7,0.00064609415,0.0005141537,0.00069395767,0.000061002447,0.00024974323,0.00023359181],"genre_scores_gemma":[0.99218583,0.0053461455,0.0005019948,0.0004237689,0.0005584606,0.000064461776,0.00028645797,0.00008275106,0.00055012526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784076,0.000069856804,0.00043856777,0.0005558057,0.00032014094,0.0007748607],"domain_scores_gemma":[0.9990907,0.00012774032,0.00011858685,0.00038284523,0.00006354809,0.00021658164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037226963,0.00040121182,0.00066451746,0.00053662714,0.00012295977,0.000049790127,0.00010478521,0.00021672071,0.00009867225],"category_scores_gemma":[0.000051592204,0.0003209026,0.0001375684,0.001014413,0.000111279856,0.0001987556,0.000081533544,0.00026911532,0.000047168425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066798384,0.00035266497,0.94610226,0.00040355045,0.00064240076,0.00010149221,0.000711612,0.0000070275855,0.019273644,0.000016858588,0.0009863701,0.031335335],"study_design_scores_gemma":[0.006448289,0.0009238773,0.9020459,0.0005749805,0.00213606,0.0000014040739,0.00077786215,0.0014591669,0.0755108,0.00016976339,0.0092076035,0.0007442711],"about_ca_topic_score_codex":0.000047175832,"about_ca_topic_score_gemma":0.000043147727,"teacher_disagreement_score":0.056237154,"about_ca_system_score_codex":0.000060076385,"about_ca_system_score_gemma":0.000054646112,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W4381377783","doi":"10.2337/db23-1161-p","title":"1161-P: Patterns of Diabetes Distress (DD) and Glycemic Outcomes in Teens with Type 1 Diabetes (T1D)","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Distress; Type 1 diabetes; Internal medicine; Type 2 diabetes; Pediatrics; Endocrinology","score_opus":0.011137068611620836,"score_gpt":0.2420465564859497,"score_spread":0.23090948787432886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972602,0.0005531941,4.836482e-7,0.0005752434,0.00013181067,0.0005891395,0.00008853243,0.00017695727,0.00062443287],"genre_scores_gemma":[0.99797446,0.00014508351,0.00007243794,0.0002475295,0.000037995014,0.00011754554,0.00034015815,0.000058305137,0.0010064779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980879,0.00003825846,0.00036763947,0.0004505478,0.00032819493,0.00072747265],"domain_scores_gemma":[0.99890655,0.00029968118,0.00012518294,0.00044181006,0.00007222407,0.00015456123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016636016,0.00034875047,0.00080083776,0.00041844847,0.00004670234,0.00003286356,0.00014066376,0.00009215735,0.000058408277],"category_scores_gemma":[0.00009749797,0.0002568073,0.00009107203,0.0005970276,0.00013987305,0.00014256193,0.00015758682,0.00014075979,0.000041665568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003109483,0.00025264453,0.9888708,0.0006048515,0.00043352545,0.000014548095,0.00016867611,0.000008374,0.0033345772,0.00009351937,0.000306006,0.0058813957],"study_design_scores_gemma":[0.002951023,0.0011423735,0.98117286,0.00058668014,0.0003149562,9.220854e-8,0.00024003646,0.00036760487,0.012297271,0.00013946448,0.00048329966,0.00030434004],"about_ca_topic_score_codex":0.00002602381,"about_ca_topic_score_gemma":0.00003821308,"teacher_disagreement_score":0.008962694,"about_ca_system_score_codex":0.000044705135,"about_ca_system_score_gemma":0.0000217585,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W4381377969","doi":"10.2337/db23-52-or","title":"52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Weight loss; Tolerability; Overweight; Waist; Obesity; Internal medicine; Weight change; Clinical endpoint; Body mass index; Adverse effect; Gastroenterology; Clinical trial","score_opus":0.027934662307719918,"score_gpt":0.3226337539480178,"score_spread":0.2946990916402979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381377969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965316,0.000049352355,5.719361e-7,0.00012982092,0.00012824853,0.0023025104,0.000030489755,0.00017576566,0.0006516243],"genre_scores_gemma":[0.99576783,0.000025846392,0.000104619765,0.000088232715,0.00004620284,0.00044340448,0.00014596392,0.000047430844,0.0033304933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978598,0.00014287423,0.00039480618,0.00044813182,0.00042431094,0.00073011604],"domain_scores_gemma":[0.99890745,0.00026473266,0.00012912808,0.0004697024,0.000047575275,0.00018143974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067648175,0.00033353365,0.000856412,0.00027289605,0.00006896822,0.000027533968,0.0001397875,0.000064124586,0.00036920136],"category_scores_gemma":[0.00017613104,0.00019159305,0.000089691726,0.0009053898,0.00009463676,0.00017527425,0.00011664391,0.00012900538,0.00018643058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024157034,0.0037297497,0.97441024,0.0005246479,0.000662487,0.0002192717,0.00063767086,0.000006603211,0.0024486708,0.000013513873,0.0020195232,0.0129119465],"study_design_scores_gemma":[0.05547073,0.07446934,0.6294838,0.0012489172,0.0025821768,8.97118e-7,0.0015883563,0.0009219929,0.22657715,0.000020328505,0.006792547,0.0008437462],"about_ca_topic_score_codex":0.00009441425,"about_ca_topic_score_gemma":0.00038627535,"teacher_disagreement_score":0.3449264,"about_ca_system_score_codex":0.000112549526,"about_ca_system_score_gemma":0.00006658498,"threshold_uncertainty_score":0.78129375},"labels":[],"label_agreement":null},{"id":"W4381378176","doi":"10.2337/db23-123-or","title":"123-OR: SGLT2 Inhibitors Are Associated with Kidney Benefits at All Degrees of Proteinuria—A Cohort Study","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Albuminuria; Proteinuria; Internal medicine; Renal function; Creatinine; Diabetes mellitus; Retrospective cohort study; Cohort; Kidney disease; Propensity score matching; Hazard ratio; Urology; Kidney; Endocrinology; Confidence interval","score_opus":0.023226408317584487,"score_gpt":0.24778346061274115,"score_spread":0.22455705229515666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381378176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948983,0.00013169367,6.257789e-8,0.0003799234,0.00011533275,0.0028079576,0.000057975176,0.00030725956,0.0013014537],"genre_scores_gemma":[0.98976403,0.000020255033,0.000040455536,0.00022030134,0.000057195513,0.0005665859,0.000380116,0.000056345016,0.008894727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981733,0.000057966445,0.0003148217,0.00039362762,0.0005700499,0.0004902454],"domain_scores_gemma":[0.9989336,0.0001080341,0.00022459145,0.0003921964,0.00012638353,0.00021515573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036769776,0.00027114394,0.00060788536,0.00021859394,0.00007203955,0.000019058336,0.000112769776,0.000077265926,0.00010249861],"category_scores_gemma":[0.000289154,0.00018211275,0.0000935889,0.0005952103,0.000065529435,0.00008191974,0.00015022363,0.000085991924,0.00010667289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007220881,0.0009994273,0.9782624,0.000117450196,0.0021578392,0.00005248419,0.00036666758,0.000026920588,0.000430349,0.000008625564,0.016387943,0.0011176792],"study_design_scores_gemma":[0.0033131524,0.0020407643,0.98341984,0.000588904,0.0010146768,1.5744908e-7,0.00037483903,0.00008438523,0.007439683,0.0000050752437,0.0015041203,0.00021440785],"about_ca_topic_score_codex":0.00003182588,"about_ca_topic_score_gemma":0.00019386731,"teacher_disagreement_score":0.014883823,"about_ca_system_score_codex":0.00014593985,"about_ca_system_score_gemma":0.000047099576,"threshold_uncertainty_score":0.74263424},"labels":[],"label_agreement":null},{"id":"W4381378253","doi":"10.2337/db23-1230-p","title":"1230-P: Low Real-World Use of SGLT2 Inhibitors in People with Diabetes and Heart Failure—A Population Cohort Study","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Comorbidity; Internal medicine; Population; Cohort; Kidney disease; Heart failure; Cohort study; Endocrinology; Environmental health","score_opus":0.0109059604911554,"score_gpt":0.2440652410848397,"score_spread":0.2331592805936843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381378253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976518,0.000039997914,1.123534e-7,0.00029659318,0.000066510845,0.0016475933,0.000008567481,0.00013468259,0.00015414362],"genre_scores_gemma":[0.99865276,0.000017009323,0.00017169531,0.00008175076,0.000040295465,0.00022317063,0.0002100377,0.000037625177,0.0005656517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852306,0.000058738788,0.00032654393,0.00037049752,0.00033631077,0.00038485692],"domain_scores_gemma":[0.99926347,0.0001770081,0.00009188008,0.0003173211,0.00005184787,0.000098465774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030669273,0.00021474664,0.0005704861,0.0005859843,0.000044653967,0.000038348295,0.00004437154,0.000042717194,0.000018110326],"category_scores_gemma":[0.000057677527,0.00017171107,0.000049858027,0.001035896,0.000048768434,0.00023306538,0.000080185964,0.00008873934,0.000013419267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001612411,0.00042604154,0.9957983,0.00018522094,0.00022183215,0.0000052563246,0.00025671237,0.000038468817,0.0007576808,0.000029918676,0.0014910739,0.00077339675],"study_design_scores_gemma":[0.0014683242,0.0006377566,0.9942305,0.00027299635,0.00024199592,4.138146e-8,0.0002495059,0.0003544685,0.0021162587,0.000023879798,0.00024173871,0.00016254678],"about_ca_topic_score_codex":0.0006152588,"about_ca_topic_score_gemma":0.0021992377,"teacher_disagreement_score":0.0015839789,"about_ca_system_score_codex":0.000063623374,"about_ca_system_score_gemma":0.000015512866,"threshold_uncertainty_score":0.7002175},"labels":[],"label_agreement":null},{"id":"W4381378358","doi":"10.2337/db23-318-or","title":"318-OR: Tirzepatide Reduces Albuminuria in Patients with T2D—Post Hoc Pooled Analysis of SURPASS 1–5","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Post-hoc analysis; Renal function; Albuminuria; Urology; Creatinine; Population; Placebo; Internal medicine; Pooled analysis; Type 2 diabetes; Endocrinology; Diabetes mellitus; Confidence interval; Pathology","score_opus":0.008324926192824897,"score_gpt":0.23577692665475364,"score_spread":0.22745200046192873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381378358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982075,0.00009046327,2.124946e-7,0.00024784234,0.00006232982,0.00046362553,0.000051959545,0.00008264163,0.0007934246],"genre_scores_gemma":[0.996968,0.000029751545,0.00012754714,0.00012843646,0.000016982693,0.000068118505,0.00093748,0.000025161777,0.0016985651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863195,0.00003897169,0.00031031494,0.00029823417,0.00035344285,0.0003670554],"domain_scores_gemma":[0.9991999,0.00013873042,0.00012468883,0.00033352198,0.000117425145,0.00008572032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018060215,0.00018107759,0.00061734935,0.00094052736,0.000025712334,0.000015281279,0.00010154903,0.000050432387,0.00011398637],"category_scores_gemma":[0.000095869655,0.00012843407,0.00013145212,0.002347979,0.000050996838,0.000098286175,0.000058662234,0.000057979047,0.00004307129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002238368,0.00047309094,0.97528815,0.00008744895,0.003782658,0.0000125033175,0.0002544897,0.00004073656,0.00051490986,0.000016157315,0.0010452725,0.018260771],"study_design_scores_gemma":[0.00251052,0.0010485359,0.9861626,0.00013753826,0.0035318714,8.274157e-9,0.00018769778,0.00028312718,0.0056653516,0.000008190905,0.00031378947,0.00015075716],"about_ca_topic_score_codex":0.000063881875,"about_ca_topic_score_gemma":0.00014700381,"teacher_disagreement_score":0.018110014,"about_ca_system_score_codex":0.000058430232,"about_ca_system_score_gemma":0.00003263557,"threshold_uncertainty_score":0.5237389},"labels":[],"label_agreement":null},{"id":"W4381486577","doi":"10.2337/dc23-0231","title":"Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Eli Lilly and Company","keywords":"Medicine; Renal function; Post-hoc analysis; Hazard ratio; Kidney disease; Internal medicine; Type 2 diabetes; Placebo; Albuminuria; Diabetes mellitus; Creatinine; Dulaglutide; Urology; Endocrinology; Confidence interval; Exenatide; Pathology","score_opus":0.007856856192912584,"score_gpt":0.2365761880970454,"score_spread":0.2287193319041328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381486577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944712,0.0015424732,2.3543664e-7,0.0013032889,0.0002698869,0.0004691523,0.00008099174,0.00025887147,0.0016039208],"genre_scores_gemma":[0.99366146,0.00015729113,0.000052756466,0.0018945982,0.00002775228,0.00006537882,0.0020152815,0.000037861115,0.0020876233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983927,0.00004658801,0.0003090153,0.00045521223,0.0002577873,0.0005386975],"domain_scores_gemma":[0.99904794,0.000099020566,0.000067207955,0.00040915754,0.00013126357,0.00024540114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015693592,0.00026227804,0.0006355163,0.0010212108,0.000075018834,0.000047342957,0.0000793954,0.00012142087,0.00020687187],"category_scores_gemma":[0.00018287239,0.00022213873,0.00020455803,0.0024168442,0.000058683625,0.00011783518,0.0001197475,0.00013955533,0.0004163161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026828395,0.00006805239,0.9869487,0.00018500618,0.0023591935,0.000024617526,0.00060587993,0.000023204984,0.0002740974,0.000042747983,0.0021255573,0.007316093],"study_design_scores_gemma":[0.0018797162,0.00062300835,0.9846058,0.000105564155,0.0027156207,6.164708e-8,0.001106198,0.00054612284,0.00012546049,0.000058768437,0.008000968,0.00023275132],"about_ca_topic_score_codex":0.000014108548,"about_ca_topic_score_gemma":0.00003756502,"teacher_disagreement_score":0.007083342,"about_ca_system_score_codex":0.00010411834,"about_ca_system_score_gemma":0.00004244207,"threshold_uncertainty_score":0.9058555},"labels":[],"label_agreement":null},{"id":"W4381546514","doi":"10.12688/f1000research.130973.1","title":"Is metformin the only culprit for cognitive impairment in diabetes?","year":2023,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Diabetes mellitus; Type 2 diabetes; Culprit; Internal medicine; Montreal Cognitive Assessment; Cognition; Cognitive impairment; Endocrinology; Psychiatry; Disease","score_opus":0.11096767573143279,"score_gpt":0.4086582359036271,"score_spread":0.2976905601721943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381546514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93505925,0.0019872955,0.00012469846,0.030693013,0.00069477095,0.020752873,0.00078084227,0.00030051806,0.009606739],"genre_scores_gemma":[0.8089854,0.0022697113,0.0010674148,0.0027302206,0.00085778156,0.017179094,0.0027260366,0.00034770707,0.16383663],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99678695,0.000114618764,0.00042722566,0.00074153184,0.00093244226,0.0009972558],"domain_scores_gemma":[0.9978559,0.00086106587,0.00009342746,0.0007348066,0.00027072345,0.00018409998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001949554,0.00035109124,0.00060028053,0.0006033623,0.000115365445,0.00012366437,0.00045536947,0.00022413707,0.000333111],"category_scores_gemma":[0.00036376782,0.00023896048,0.00037676017,0.00044037815,0.00016399441,0.00005104914,0.0016212043,0.00080173986,0.00058249943],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015505838,0.0035795318,0.32279223,0.008182007,0.006161123,0.00049045734,0.004650637,0.000032599277,0.0001138024,0.002190637,0.44487056,0.20538583],"study_design_scores_gemma":[0.021679189,0.005529114,0.7321463,0.008132267,0.002704699,0.000005433659,0.0053111226,0.012123183,0.008369425,0.033761553,0.16856705,0.0016706565],"about_ca_topic_score_codex":0.0002235385,"about_ca_topic_score_gemma":0.00012903362,"teacher_disagreement_score":0.40935406,"about_ca_system_score_codex":0.000438725,"about_ca_system_score_gemma":0.00046460665,"threshold_uncertainty_score":0.97445256},"labels":[],"label_agreement":null},{"id":"W4381598155","doi":"10.1111/dom.15148","title":"Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Eli Lilly and Company","keywords":"Semaglutide; Medicine; Regimen; Body weight; Weight loss; Weight change; Internal medicine; Propensity score matching; Mean difference; Obesity; Animal science; Confidence interval; Endocrinology; Diabetes mellitus; Type 2 diabetes; Liraglutide; Biology","score_opus":0.03178952701191406,"score_gpt":0.2765193998934975,"score_spread":0.24472987288158343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381598155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055994,0.006363478,0.000016638178,0.00035653258,0.00010308898,0.0020605987,0.00012622164,0.00014405487,0.00026945028],"genre_scores_gemma":[0.99321014,0.0025489747,0.0008759204,0.00010240106,0.00012307154,0.00043767347,0.00034708908,0.000038191243,0.0023165552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841666,0.00007370126,0.00031281196,0.00046463785,0.00024060093,0.00049155677],"domain_scores_gemma":[0.9987431,0.0003251706,0.00015465902,0.00045845518,0.00008919999,0.00022940828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022261545,0.00039050583,0.0010755843,0.00021499474,0.00028250727,0.00005658685,0.000085083,0.00007555603,0.000030140935],"category_scores_gemma":[0.000017908253,0.00022727378,0.0001456197,0.0003121292,0.00020330123,0.00010164646,0.000041078645,0.000046126348,0.000012518458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047369231,0.0041979863,0.8640124,0.00031718786,0.003268273,0.000014707069,0.0036394817,0.000047459598,0.0010325628,0.0005027901,0.0008744906,0.12161892],"study_design_scores_gemma":[0.008031061,0.003454494,0.89273006,0.000075590026,0.004232175,0.0000011797356,0.00056148507,0.004113061,0.012738231,0.00014040555,0.0736476,0.00027463541],"about_ca_topic_score_codex":0.00017744652,"about_ca_topic_score_gemma":0.00029004968,"teacher_disagreement_score":0.12134428,"about_ca_system_score_codex":0.0000620014,"about_ca_system_score_gemma":0.000041070198,"threshold_uncertainty_score":0.9267956},"labels":[],"label_agreement":null},{"id":"W4381716537","doi":"10.1056/nejmoa2302392","title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Eli Lilly and Company","keywords":"Medicine; Placebo; Weight loss; Overweight; Body mass index; Weight change; Obesity; Randomization; Clinical endpoint; Internal medicine; Randomized controlled trial","score_opus":0.017889680604319374,"score_gpt":0.2679620818097543,"score_spread":0.2500724012054349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381716537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737418,0.000536234,0.00058168924,0.021188388,0.0008782219,0.0006710391,0.000006563444,0.000064730026,0.0023312871],"genre_scores_gemma":[0.9737833,0.0006783108,0.0042766524,0.0009052241,0.0053040558,0.000013598402,0.00014703487,0.00004593985,0.014845881],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987308,0.000025244652,0.00036034262,0.00015028453,0.00045598578,0.0002773445],"domain_scores_gemma":[0.9989668,0.0000992463,0.00022872248,0.0001639118,0.00021678268,0.00032451545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069376203,0.00016951778,0.00052109075,0.0002262399,0.00006604116,0.000010942695,0.00009965636,0.0000457088,0.00018721158],"category_scores_gemma":[0.000190263,0.00009338897,0.000080265665,0.00027817048,0.00007232851,0.00009088027,0.00001973706,0.00015783969,0.000026306372],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011090637,0.00031828292,0.036158666,0.00045638718,0.0006811244,0.00046143858,0.0022030417,0.000015923057,0.0009854449,0.0003742575,0.43420824,0.51304656],"study_design_scores_gemma":[0.19031778,0.021110198,0.027509307,0.0020030912,0.0013639092,0.0001790706,0.0013250434,0.00012636477,0.0007628042,0.00040119214,0.75469613,0.00020507876],"about_ca_topic_score_codex":0.000046443023,"about_ca_topic_score_gemma":0.000049827573,"teacher_disagreement_score":0.51284146,"about_ca_system_score_codex":0.000068492525,"about_ca_system_score_gemma":0.00011875672,"threshold_uncertainty_score":0.38082916},"labels":[],"label_agreement":null},{"id":"W4381885413","doi":"10.1016/s0140-6736(23)01163-7","title":"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical endpoint; Internal medicine; Randomized controlled trial; Adverse effect; Intention-to-treat analysis; Exenatide; Diabetes mellitus; Dulaglutide; Physical therapy; Liraglutide; Endocrinology","score_opus":0.055635612838149315,"score_gpt":0.33893580047556005,"score_spread":0.2833001876374107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381885413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842341,0.00041157176,0.00000537102,0.0032899855,0.00022517554,0.0073541314,0.00006023623,0.00012708962,0.0042923302],"genre_scores_gemma":[0.99443674,0.000608164,0.00019121429,0.00036611417,0.000533263,0.00039476418,0.00020747248,0.000048826238,0.0032134333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755955,0.00021079252,0.00067086355,0.00046185954,0.0004226336,0.00067428796],"domain_scores_gemma":[0.9977571,0.00094437867,0.00033419108,0.0007110697,0.00009081223,0.00016249772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009937581,0.0003672389,0.0017679485,0.00022559268,0.000098130804,0.0000449104,0.00025172462,0.00009552115,0.000081160215],"category_scores_gemma":[0.00025298208,0.00021940943,0.00015544798,0.0006113921,0.00022167513,0.00009518943,0.000095008094,0.00027313386,0.00006200995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98090285,0.0012355458,0.0020642176,0.00019654041,0.0012016833,0.000078967874,0.00093685684,0.000044720724,0.00094448635,0.000080925696,0.002754233,0.009559001],"study_design_scores_gemma":[0.97958016,0.003262362,0.005449585,0.0004365923,0.0010698152,0.0000019818965,0.00049095077,0.0008075427,0.0014394852,0.000024442379,0.007195456,0.00024163368],"about_ca_topic_score_codex":0.000055947046,"about_ca_topic_score_gemma":0.000117944335,"teacher_disagreement_score":0.01020264,"about_ca_system_score_codex":0.00009674313,"about_ca_system_score_gemma":0.00013205383,"threshold_uncertainty_score":0.8947257},"labels":[],"label_agreement":null},{"id":"W4381953497","doi":"10.1016/s0140-6736(23)01127-3","title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Physical therapy; Endocrinology","score_opus":0.023093975627776788,"score_gpt":0.2799489399427412,"score_spread":0.25685496431496446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381953497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504083,0.00043206866,0.0000045997863,0.0010985116,0.00006169919,0.0023834351,0.000022971462,0.00007113412,0.00088475895],"genre_scores_gemma":[0.9982222,0.00038713322,0.00038560125,0.00016832167,0.00013071876,0.00007063794,0.00009843453,0.000021980446,0.0005149745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988659,0.000084757994,0.00024253217,0.00024236075,0.0002204567,0.00034401403],"domain_scores_gemma":[0.99920017,0.00025325408,0.000106402804,0.0003120247,0.000044085766,0.00008409394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035831492,0.00019074816,0.00078077335,0.00008969857,0.00004906754,0.000020068923,0.00008691587,0.000034818586,0.000021822741],"category_scores_gemma":[0.00007667667,0.00010387033,0.000027781607,0.00030822543,0.00014963235,0.0000499271,0.000059872236,0.000113312904,0.000009294515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95443314,0.000736568,0.024434099,0.00050127995,0.000712697,0.000060369268,0.003040114,0.00013947957,0.0004659243,0.00008451864,0.0046271957,0.010764592],"study_design_scores_gemma":[0.9284661,0.0021653913,0.058472473,0.00086653413,0.00057005667,0.0000014591134,0.00042221212,0.005473352,0.00015540865,0.000014915612,0.0032204066,0.00017173427],"about_ca_topic_score_codex":0.000054887,"about_ca_topic_score_gemma":0.00017946,"teacher_disagreement_score":0.034038376,"about_ca_system_score_codex":0.000032203883,"about_ca_system_score_gemma":0.00003523752,"threshold_uncertainty_score":0.4235709},"labels":[],"label_agreement":null},{"id":"W4382051235","doi":"10.1016/j.amjmed.2023.06.013","title":"Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease","year":2023,"lang":"en","type":"review","venue":"The American Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Kidney disease; Coronary artery disease; Population; Internal medicine; Disease; Aspirin; Intensive care medicine","score_opus":0.01790810866245235,"score_gpt":0.3024876346896499,"score_spread":0.28457952602719755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382051235","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048090294,0.988458,0.000015961783,0.0044606505,0.0003336841,0.0016887614,0.000032684457,0.000021743857,0.00017949789],"genre_scores_gemma":[0.004617532,0.993603,0.00003317188,0.00062085356,0.00038697151,0.00004811369,0.00015459019,0.00007432799,0.00046144263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99617577,0.00022394238,0.0012176007,0.00025557703,0.0017720619,0.00035506612],"domain_scores_gemma":[0.99648684,0.0001941126,0.0015096568,0.00061809836,0.000104945415,0.0010863404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008139281,0.00041470045,0.00255515,0.000549142,0.00002715211,0.0000042953698,0.0004971702,0.000031061827,0.0002092948],"category_scores_gemma":[0.00013770367,0.0001897351,0.00033715522,0.0008763858,0.0009409285,0.000047219324,0.00015266557,0.0004574079,0.000021841277],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00157282,0.0006805287,0.0078433845,0.016901096,0.0034542298,0.004659138,0.00003759008,0.0000021663216,5.367813e-9,0.000054652417,0.0049619046,0.9598325],"study_design_scores_gemma":[0.014774864,0.00929677,0.18862309,0.34212345,0.030595548,0.00004712189,0.00014790644,0.000013793334,1.518611e-8,0.00008130811,0.4138974,0.00039873875],"about_ca_topic_score_codex":0.000009474631,"about_ca_topic_score_gemma":0.0000011617486,"teacher_disagreement_score":0.95943373,"about_ca_system_score_codex":0.00033129434,"about_ca_system_score_gemma":0.0008363663,"threshold_uncertainty_score":0.77371734},"labels":[],"label_agreement":null},{"id":"W4382051681","doi":"10.1016/s2213-8587(23)00128-6","title":"Predicting and preventing heart failure in type 2 diabetes","year":2023,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Houston Methodist Research Institute","keywords":"Medicine; Heart failure; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Psychological intervention; Incidence (geometry); Internal medicine; Psychiatry; Endocrinology","score_opus":0.056194141244418946,"score_gpt":0.33099809991354023,"score_spread":0.2748039586691213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382051681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03663413,0.9587322,5.4981985e-8,0.0016655389,0.00040149398,0.0016463132,0.000020405607,0.00032137334,0.00057848153],"genre_scores_gemma":[0.0012684606,0.9957493,0.00016244972,0.00038148608,0.0007084429,0.0005091813,0.00018077964,0.00011594897,0.00092396134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643,0.0002827418,0.0006175155,0.00062207115,0.00018422153,0.0018634707],"domain_scores_gemma":[0.99816537,0.0007580834,0.000241732,0.0007130414,0.000032371452,0.00008940863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052394567,0.000520289,0.0028103718,0.00037219774,0.000101442376,0.00005217321,0.00031750416,0.00020156408,0.0000390365],"category_scores_gemma":[0.00028342928,0.00034375113,0.00024418902,0.00062409986,0.00017086299,0.00006431738,0.00055789354,0.00074714585,0.00021644258],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009512152,0.00012411462,0.1835895,0.029744817,0.0021631601,0.00009370223,0.00008225153,8.658695e-7,0.000007657964,0.00057266187,0.008649506,0.77496225],"study_design_scores_gemma":[0.00085013226,0.00025867386,0.0037092583,0.010714592,0.0021176068,0.00001356751,0.000034712913,0.000028825423,0.000008709167,0.00027330822,0.9816807,0.00030992684],"about_ca_topic_score_codex":0.000013582901,"about_ca_topic_score_gemma":0.000049804312,"teacher_disagreement_score":0.97303116,"about_ca_system_score_codex":0.0000960757,"about_ca_system_score_gemma":0.00006901498,"threshold_uncertainty_score":0.9999015},"labels":[],"label_agreement":null},{"id":"W4382139368","doi":"10.22374/cjgim.v17isp2.684","title":"SGLT2 Inhibitors in the Prevention and Treatment of Cardiovascular Disease","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of General Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Heart failure; Ejection fraction; Type 2 diabetes; Population; Clinical trial; Diabetes mellitus; Clinical Practice; Internal medicine; Endocrinology; Physical therapy","score_opus":0.025468376010701534,"score_gpt":0.26675496650612135,"score_spread":0.2412865904954198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382139368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830932,0.010468172,0.000015173812,0.0047416287,0.00037269888,0.00024266694,0.0000031467464,0.000002755775,0.0010605569],"genre_scores_gemma":[0.9958175,0.0014673382,0.000033598895,0.00014946933,0.0005412798,0.0000071923023,0.000010142991,0.000008482308,0.001965007],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99911964,0.000056172787,0.00032248558,0.00008961737,0.00024673686,0.00016534112],"domain_scores_gemma":[0.99932396,0.000026404963,0.00009169145,0.00015109622,0.000060669627,0.0003461868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036874015,0.00010002791,0.00032333532,0.00047572653,0.000022827437,0.0000073994156,0.00007165586,0.000020862766,0.000039650495],"category_scores_gemma":[0.000062130806,0.00005556965,0.00016941002,0.0002252067,0.00010047238,0.000044878503,0.0000056626845,0.00006097692,0.0000024444535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005768335,0.00036749928,0.35813665,0.00029010745,0.0060426746,0.015260037,0.00761841,0.0008388291,0.0008607589,0.0010413752,0.04918322,0.5597836],"study_design_scores_gemma":[0.013738885,0.010765608,0.62035453,0.0029657704,0.0044406913,0.00035156737,0.0025519284,0.00066932436,0.0007372906,0.0012833575,0.34190342,0.00023762221],"about_ca_topic_score_codex":0.0063215285,"about_ca_topic_score_gemma":0.0019343501,"teacher_disagreement_score":0.559546,"about_ca_system_score_codex":0.00013511934,"about_ca_system_score_gemma":0.0001650127,"threshold_uncertainty_score":0.95563024},"labels":[],"label_agreement":null},{"id":"W4382363273","doi":"10.1111/dom.15073","title":"Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Internal medicine; Type 2 diabetes; Insulin glargine; Insulin resistance; Insulin; Diabetes mellitus; Endocrinology; Body mass index; Exenatide","score_opus":0.0135811436169266,"score_gpt":0.24927126617245227,"score_spread":0.23569012255552566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382363273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954191,0.0035413092,0.000001462842,0.00014060186,0.00012513444,0.00062154606,0.000032260003,0.000027322394,0.00009126429],"genre_scores_gemma":[0.99896175,0.00050512375,0.000102797516,0.00014674001,0.000034320805,0.000028775456,0.00004479095,0.00001928126,0.00015643756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985844,0.00018945233,0.00042262356,0.0002459603,0.000276368,0.00028121468],"domain_scores_gemma":[0.9990045,0.00027795593,0.00012898487,0.00036352672,0.0001252557,0.0000998098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011829634,0.00018359764,0.0005965623,0.0003881968,0.00004061467,0.0000067497986,0.000112261405,0.00008629957,0.000026650907],"category_scores_gemma":[0.00015207005,0.0001268528,0.0001110433,0.00072738127,0.0000882539,0.00006991615,0.00009061423,0.00008985483,0.0000048648335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077720056,0.00052198704,0.6404324,0.0002030815,0.00006828816,0.0000016062057,0.00026792058,0.000019227413,0.30912423,0.000010680377,0.00006979089,0.048503563],"study_design_scores_gemma":[0.0012319767,0.0004998247,0.6970791,0.00015263497,0.00018552555,2.7516023e-8,0.0000751344,0.000931315,0.2982432,0.000044610402,0.0014760663,0.000080564256],"about_ca_topic_score_codex":0.000019767516,"about_ca_topic_score_gemma":0.000007643258,"teacher_disagreement_score":0.056646697,"about_ca_system_score_codex":0.000011310875,"about_ca_system_score_gemma":0.00004873928,"threshold_uncertainty_score":0.5172907},"labels":[],"label_agreement":null},{"id":"W4382394533","doi":"10.1101/2023.06.26.23291881","title":"Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Australian Commission on Safety and Quality in Health Care","keywords":"Medicine; Kidney disease; Population; Internal medicine; Intensive care medicine; Diabetes mellitus; Endocrinology; Environmental health","score_opus":0.02236808704173624,"score_gpt":0.2532780559759659,"score_spread":0.2309099689342297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382394533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962435,0.00011262663,0.0000038628896,0.0005619675,0.0004095113,0.0021539289,0.0004081748,0.00003908467,0.000067371475],"genre_scores_gemma":[0.994367,0.000011480888,0.00084293704,0.00007562066,0.000075306976,0.00017335692,0.004126608,0.000059877322,0.000267798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799234,0.000044492488,0.00072660047,0.00046424454,0.00046154312,0.0003108088],"domain_scores_gemma":[0.9984897,0.000030826614,0.0004274596,0.00067360216,0.0001414464,0.0002369734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021151366,0.00032011542,0.00059911545,0.00034687712,0.000027946911,0.000013750484,0.00021979406,0.00011791235,0.000015357416],"category_scores_gemma":[0.00028276534,0.00022620294,0.00011149866,0.00040118193,0.00006393599,0.000058921523,0.00035169613,0.00030706773,0.0000027725764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001197754,0.00028471634,0.98446745,0.004609358,0.00014288207,0.0000074296904,0.00040786274,0.0047463095,0.000012865775,0.000013517272,0.00009617743,0.005091684],"study_design_scores_gemma":[0.003104421,0.00018379168,0.9890421,0.006446487,0.00032271232,3.0781276e-8,0.00003019567,0.0005705534,0.00006338142,0.000030779913,0.00003176953,0.00017379016],"about_ca_topic_score_codex":0.0010783167,"about_ca_topic_score_gemma":0.00024812444,"teacher_disagreement_score":0.0049178936,"about_ca_system_score_codex":0.00046232043,"about_ca_system_score_gemma":0.00046906478,"threshold_uncertainty_score":0.92242885},"labels":[],"label_agreement":null},{"id":"W4382399784","doi":"10.1186/s12933-023-01849-w","title":"Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin","year":2023,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Western University; McMaster University; University of Toronto; Public Health Ontario; University of British Columbia","funders":"University of Toronto","keywords":"Empagliflozin; Angiology; Medicine; Cardiology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.009643433346066219,"score_gpt":0.2023560938428178,"score_spread":0.1927126604967516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382399784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945922,0.0018435143,0.00011793806,0.00013447017,0.00028948017,0.001354514,0.000016878492,0.0002758686,0.0013751453],"genre_scores_gemma":[0.99731046,0.0003725495,0.00029810093,0.00010705632,0.00009318232,0.00012258904,0.0008109585,0.00006954381,0.00081556884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754673,0.00020046633,0.0003181838,0.0006608269,0.0005293943,0.0007444129],"domain_scores_gemma":[0.99869996,0.000043667274,0.000058550264,0.00087583467,0.00013801774,0.00018394247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049994804,0.00031972432,0.0011581648,0.00053431874,0.00006117333,0.000016527283,0.00012066807,0.00018955015,0.000025329047],"category_scores_gemma":[0.00006241757,0.00026756173,0.00064186595,0.000839459,0.00008508426,0.00009518146,0.00007230701,0.00019659498,0.00022946397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010892625,0.00015559173,0.9831428,0.00016482692,0.0053284364,0.0013776276,0.00009527664,0.0029016263,0.000020587384,0.000030835556,0.0015634971,0.0051099965],"study_design_scores_gemma":[0.012092652,0.0007211353,0.92834806,0.00036002128,0.005007042,0.000010021259,0.00011413562,0.0010810647,0.0010135693,0.00006718449,0.05060923,0.00057586253],"about_ca_topic_score_codex":0.000042000953,"about_ca_topic_score_gemma":0.0000031052539,"teacher_disagreement_score":0.05479469,"about_ca_system_score_codex":0.0002435268,"about_ca_system_score_gemma":0.000044700842,"threshold_uncertainty_score":0.99997765},"labels":[],"label_agreement":null},{"id":"W4382775808","doi":"10.1093/ehjqcco/qcad038","title":"Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus: Reply","year":2023,"lang":"en","type":"letter","venue":"European Heart Journal - Quality of Care and Clinical Outcomes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Impact; McMaster University; Population Health Research Institute","funders":"","keywords":"Library science; Medicine; University hospital; Sociology; Family medicine","score_opus":0.16414155310063774,"score_gpt":0.4129388067836798,"score_spread":0.24879725368304204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382775808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87557024,0.0008478217,0.0000013668268,0.12291484,0.00010215743,0.0003656367,0.000057575828,0.000023965733,0.00011640758],"genre_scores_gemma":[0.9539552,0.0009027156,0.00090552267,0.042762663,0.0007126724,0.000004081369,0.000094188035,0.000083558785,0.00057942956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448603,0.0020609808,0.0020326143,0.00042952053,0.0005835397,0.00040732877],"domain_scores_gemma":[0.9933711,0.0049146097,0.0008554567,0.00047288486,0.00015793281,0.00022801531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004131075,0.0003149156,0.0018542949,0.00022973338,0.00008111459,0.000049211372,0.00011099417,0.00019595325,0.000007790892],"category_scores_gemma":[0.0020796806,0.00021069673,0.0005021309,0.00015345727,0.0003135291,0.000102217884,0.00011896486,0.0017349229,0.00001343724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006791628,0.000060515933,0.9626726,0.0008770274,0.00072947494,0.00006176862,0.00029035058,3.6043377e-7,4.262781e-7,0.0000028953334,0.033788,0.0014486599],"study_design_scores_gemma":[0.002438269,0.0017235553,0.93405205,0.0013838203,0.0013857767,0.000002785941,0.00033987217,3.106994e-7,0.0000040199247,0.0000659139,0.05841649,0.00018711704],"about_ca_topic_score_codex":0.000054874592,"about_ca_topic_score_gemma":0.00008120407,"teacher_disagreement_score":0.080152184,"about_ca_system_score_codex":0.000029614024,"about_ca_system_score_gemma":0.000060666054,"threshold_uncertainty_score":0.85919636},"labels":[],"label_agreement":null},{"id":"W4382918428","doi":"10.1111/dom.15196","title":"Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Food and Drug Administration; Novo Nordisk; McGill University; Brigham and Women's Hospital; Pfizer; National Institute on Aging; U.S. Food and Drug Administration; Patient-Centered Outcomes Research Institute; Bristol-Myers Squibb","keywords":"Metformin; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; First line; Pharmacology; Endocrinology","score_opus":0.09025694862777887,"score_gpt":0.3301188495014631,"score_spread":0.2398619008736842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382918428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990809,0.0039695334,0.0000016711912,0.004001939,0.00008418212,0.0009003144,0.0000395398,0.00003190196,0.00016188396],"genre_scores_gemma":[0.99387604,0.0016519539,0.000017126853,0.003201082,0.000049827857,0.00015806289,0.000896628,0.000010759187,0.00013851745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875206,0.00037229713,0.00026375143,0.00018726052,0.00016364623,0.00026100542],"domain_scores_gemma":[0.99865425,0.0009910605,0.00009291701,0.00016706214,0.00006437761,0.000030320145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015328366,0.00016917243,0.00039633084,0.00046691336,0.00010630907,0.00004323297,0.00014798486,0.00006172749,0.000024069544],"category_scores_gemma":[0.000098809185,0.00007715309,0.00006388911,0.0015057495,0.00028297876,0.00008029762,0.000056045265,0.000137288,8.786939e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001200366,0.0020355107,0.888654,0.0007872901,0.0017944217,0.000020555108,0.023868222,0.0001227547,0.002675745,0.033735793,0.016970018,0.0281353],"study_design_scores_gemma":[0.0088181,0.00028630657,0.90509,0.000057564077,0.00051465037,2.1755885e-7,0.0021830052,0.008529871,0.0010723987,0.0025991502,0.07070778,0.00014095756],"about_ca_topic_score_codex":0.00008610023,"about_ca_topic_score_gemma":0.00003036409,"teacher_disagreement_score":0.053737767,"about_ca_system_score_codex":0.0000057962775,"about_ca_system_score_gemma":0.000010621927,"threshold_uncertainty_score":0.31462115},"labels":[],"label_agreement":null},{"id":"W4382931920","doi":"10.1016/j.jacc.2023.05.011","title":"Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure","year":2023,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"AstraZeneca","keywords":"Medicine; Dapagliflozin; Heart failure; Internal medicine; Association (psychology); Antigen; Cardiology; Immunology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.006646742773356782,"score_gpt":0.23327979891189637,"score_spread":0.2266330561385396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382931920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751872,0.000005504749,0.0000018581213,0.02407919,0.000107862725,0.00033837114,0.00002695447,0.0000031898123,0.000249894],"genre_scores_gemma":[0.998842,0.000011251471,0.000090238245,0.0004916673,0.000042474767,0.000005257616,0.0000010056013,0.000008785561,0.00050729397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987047,0.00045599043,0.00028166786,0.00007795482,0.00032887713,0.000150836],"domain_scores_gemma":[0.998699,0.00039293745,0.00046866387,0.00023037802,0.0001729343,0.000036047677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001005068,0.000078798694,0.000551637,0.00025280294,0.000022936807,0.000001727636,0.00013625142,0.000023031818,0.0000035963315],"category_scores_gemma":[0.00042955062,0.00003939829,0.00014589637,0.00080626935,0.00007537589,0.000018805269,0.00005121445,0.000112644426,0.000005026357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003957109,0.000055990076,0.9372706,0.0000064353158,0.0006275657,0.000018217952,0.00006312586,0.0010709609,0.0023757603,0.000022631913,0.054439243,0.00009238725],"study_design_scores_gemma":[0.0013160362,0.0024902627,0.9832096,0.00008103435,0.00014307692,0.000001811337,0.0003481607,0.000005905797,0.00063624274,0.000020015514,0.011711143,0.000036713776],"about_ca_topic_score_codex":0.000007825066,"about_ca_topic_score_gemma":0.000008743905,"teacher_disagreement_score":0.045939025,"about_ca_system_score_codex":0.00014388638,"about_ca_system_score_gemma":0.000084904605,"threshold_uncertainty_score":0.16066156},"labels":[],"label_agreement":null},{"id":"W4383301637","doi":"10.1111/dom.15201","title":"Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Memorial University of Newfoundland","funders":"","keywords":"Canagliflozin; Dapagliflozin; Medicine; Kidney disease; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Disease; Internal medicine; Endocrinology","score_opus":0.013360940474585125,"score_gpt":0.24448621324006434,"score_spread":0.2311252727654792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383301637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918924,0.005519757,0.000003486656,0.00007796267,0.000100593636,0.001968975,0.00037041065,0.000035813555,0.000030587624],"genre_scores_gemma":[0.997318,0.0015729262,0.00012310542,0.00004980361,0.00003976862,0.00021095987,0.00053210376,0.000025541867,0.00012774671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989475,0.000055984983,0.00018194281,0.0003307079,0.00015643233,0.00032745567],"domain_scores_gemma":[0.9990537,0.00018557713,0.00009182649,0.00021349435,0.00012605733,0.00032931595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017945959,0.0002336836,0.0006814541,0.00019289271,0.00007082312,0.000014560834,0.00003697895,0.00004969197,0.000006314837],"category_scores_gemma":[0.00008090086,0.00017035118,0.00005896294,0.00024493548,0.00018328699,0.00009888515,0.000054490545,0.000023956589,9.420967e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033475118,0.00053611957,0.97870046,0.002243628,0.00087179895,0.0000016767948,0.00011331831,0.0000032967623,0.0007653124,0.00047135237,0.00010562177,0.015852652],"study_design_scores_gemma":[0.0074963593,0.0012432146,0.9768563,0.0002760089,0.0019961689,2.6755277e-8,0.000014587265,0.00020222695,0.0063337404,0.00021692249,0.005204913,0.0001595626],"about_ca_topic_score_codex":0.00003664026,"about_ca_topic_score_gemma":0.000011929003,"teacher_disagreement_score":0.015693089,"about_ca_system_score_codex":0.000037085523,"about_ca_system_score_gemma":0.000078045916,"threshold_uncertainty_score":0.6946719},"labels":[],"label_agreement":null},{"id":"W4383302677","doi":"10.1210/clinem/dgad398","title":"Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure","year":2023,"lang":"en","type":"review","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Heart failure; Ejection fraction; Overweight; Internal medicine; Glycemic; Cardiology; Glucagon-like peptide-1; Myocardial infarction; Diabetes mellitus; Natriuretic peptide; Glucagon-like peptide 1 receptor; Type 2 diabetes; Stroke (engine); Weight loss; Obesity; Endocrinology; Receptor; Agonist","score_opus":0.10329162142194022,"score_gpt":0.44181239552686635,"score_spread":0.33852077410492615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026623907,0.97732335,0.000006556827,0.014070976,0.004421082,0.0011609072,0.000040789902,0.00004585227,0.00026809482],"genre_scores_gemma":[0.00018169801,0.9897512,0.000339415,0.0009237691,0.0031630618,0.000029105277,0.000021795393,0.00010091652,0.005489008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99241036,0.0016064628,0.003999416,0.0003683583,0.0007165265,0.00089888583],"domain_scores_gemma":[0.99157536,0.0033772755,0.0032911422,0.0012626528,0.0002443981,0.00024918548],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00410393,0.0006114722,0.0061499784,0.00022301321,0.00017716407,0.000031855834,0.0012632286,0.00039145487,0.00019799473],"category_scores_gemma":[0.001185636,0.00027049336,0.0032294025,0.00056484964,0.0010589939,0.0000836128,0.0005615823,0.0025424277,0.0005218],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005474903,0.0009956905,0.00020164852,0.004334159,0.016034812,0.0002407953,0.0002758455,0.0000027242286,0.0000044045114,0.0021401795,0.18509983,0.79012245],"study_design_scores_gemma":[0.001957997,0.0006171237,0.00090556184,0.002760669,0.011950435,0.00046035013,0.00017254068,4.0546513e-7,0.0000130785165,0.00028530412,0.9806889,0.000187618],"about_ca_topic_score_codex":0.000026290598,"about_ca_topic_score_gemma":0.000021963802,"teacher_disagreement_score":0.7955891,"about_ca_system_score_codex":0.000050163126,"about_ca_system_score_gemma":0.0005327042,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W4383645757","doi":"10.1016/j.cjca.2023.07.007","title":"Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection","year":2023,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Incretin; Type 2 Diabetes Mellitus; Adverse effect; Diabetes mellitus; Type 2 diabetes; Glucagon-like peptide-1; Receptor; Disease; Internal medicine; Bioinformatics; Pharmacology; Endocrinology; Intensive care medicine; Biology","score_opus":0.12051063320908495,"score_gpt":0.36234645815752714,"score_spread":0.2418358249484422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383645757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018601883,0.9947245,0.000068565954,0.00012844647,0.0018077403,0.0010934734,0.000043433523,0.0000072489975,0.00026640596],"genre_scores_gemma":[0.0004429925,0.99828875,0.00016528647,0.000036209763,0.00064835703,0.000026186352,0.000062097104,0.00003803849,0.00029211058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762344,0.00054556306,0.001165366,0.00025531882,0.00007676723,0.00033351823],"domain_scores_gemma":[0.9984212,0.00020772169,0.0005721217,0.00026005082,0.00013451422,0.0004043849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010337849,0.00023986396,0.0029289662,0.0009991976,0.000025733581,0.000011827554,0.000115442825,0.00050718535,0.000010277218],"category_scores_gemma":[0.0005492411,0.0001846114,0.0008305164,0.00028002306,0.000259181,0.000044949556,0.000030549476,0.00054361,0.000018500008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025841742,0.00000938936,0.006517939,0.0033221212,0.003957366,0.00034256701,0.000017524027,0.0000047186227,6.1346907e-7,0.000099325414,0.005659258,0.98004335],"study_design_scores_gemma":[0.000715268,0.00086571765,0.0028381986,0.0038756207,0.002099317,0.00010959901,0.000011433744,8.152257e-7,1.11579574e-7,0.000034797635,0.98932916,0.00011995737],"about_ca_topic_score_codex":0.0009936361,"about_ca_topic_score_gemma":0.0014826109,"teacher_disagreement_score":0.9836699,"about_ca_system_score_codex":0.0002730873,"about_ca_system_score_gemma":0.001390184,"threshold_uncertainty_score":0.7528234},"labels":[],"label_agreement":null},{"id":"W4383683903","doi":"10.58931/cpct.2023.119","title":"Modern Management of Chronic Kidney Disease in T2MD: A Practical Overview for Primary Care Providers","year":2023,"lang":"en","type":"article","venue":"Canadian Primary Care Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Kidney disease; Intensive care medicine; Mineralocorticoid receptor; Blood pressure; Heart failure; Comorbidity; Internal medicine; Aldosterone","score_opus":0.0185810473242333,"score_gpt":0.2731335065179758,"score_spread":0.2545524591937425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383683903","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2514451,0.13444217,0.00060115097,0.07604183,0.003931049,0.057951435,0.0075541064,0.001542164,0.46649098],"genre_scores_gemma":[0.9578167,0.00255431,0.0019321915,0.010229888,0.00023171345,0.0023257786,0.015411598,0.00019634928,0.009301431],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981063,0.000041504303,0.00032782435,0.0005024546,0.00032619268,0.0006957159],"domain_scores_gemma":[0.9982195,0.0000497752,0.000073268246,0.0005741843,0.000109780594,0.0009735239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014833159,0.00026278922,0.00044281135,0.0004742403,0.000066939094,0.000026452975,0.00014771438,0.000081543985,0.000064064094],"category_scores_gemma":[0.000036272148,0.0002621167,0.00019903471,0.0004455159,0.0000611781,0.00016570068,0.00010405737,0.00011748912,0.00004179369],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007917412,0.0004301708,0.029973866,0.113125585,0.0014382309,0.005280086,0.003397483,0.00025109423,0.00009236885,0.0065531004,0.13413584,0.7045304],"study_design_scores_gemma":[0.0112599535,0.0009288307,0.23478235,0.00529,0.0023946317,0.000004013789,0.002397719,0.00084591354,0.00008694513,0.0005297393,0.7405528,0.00092711527],"about_ca_topic_score_codex":0.0024989457,"about_ca_topic_score_gemma":0.008659668,"teacher_disagreement_score":0.7063716,"about_ca_system_score_codex":0.0045206686,"about_ca_system_score_gemma":0.0034781194,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W4383710102","doi":"10.1111/dom.15211","title":"A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Novo Nordisk","keywords":"Semaglutide; Overweight; Weight loss; Medicine; Obesity; Demographics; Population; Dosing; Internal medicine; Diabetes mellitus; Type 2 diabetes; Demography; Endocrinology; Environmental health; Liraglutide","score_opus":0.014379455177132398,"score_gpt":0.22045006541803472,"score_spread":0.2060706102409023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383710102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949746,0.00027250178,0.00049369375,0.00047321978,0.00005055168,0.0015026401,0.00009796184,0.00025213553,0.0018826548],"genre_scores_gemma":[0.9893547,0.00009355942,0.006741535,0.0011251456,0.0000875415,0.00037497302,0.0002876988,0.00005320507,0.0018816298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997552,0.000065126755,0.00026088246,0.0007018274,0.0006199058,0.0008002769],"domain_scores_gemma":[0.9989082,0.00007568012,0.000076117285,0.00046425767,0.000072664036,0.00040305714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043410412,0.0004188486,0.0008304912,0.0005691395,0.00014170606,0.00006893395,0.00017644504,0.00011651652,0.000023019025],"category_scores_gemma":[0.000031870582,0.0002673262,0.00007328249,0.0014155017,0.00010875993,0.00019094256,0.00016814322,0.00022064496,0.000029488163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044935208,0.0016637747,0.990009,0.0005156346,0.00047110725,0.00008268105,0.0011175903,0.0014765633,0.000060604256,0.0009817625,0.0013982577,0.0017736759],"study_design_scores_gemma":[0.006192062,0.00044944588,0.96840143,0.00023157778,0.0009778547,0.0000029672242,0.00010853313,0.018296253,0.0009895413,0.00012066856,0.0038037328,0.00042591905],"about_ca_topic_score_codex":0.000057941525,"about_ca_topic_score_gemma":0.00019294325,"teacher_disagreement_score":0.021607552,"about_ca_system_score_codex":0.000052376097,"about_ca_system_score_gemma":0.00015857989,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W4383711165","doi":"10.1111/dom.15203","title":"Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Boston VA Research Institute; University of Toronto; Kidney Foundation of Canada; Heart and Stroke Foundation of Canada; Bristol-Myers Squibb","keywords":"Medicine; Albuminuria; Hazard ratio; Renal function; Kidney disease; Internal medicine; Type 2 diabetes; Clinical endpoint; Diabetes mellitus; Microalbuminuria; Dapagliflozin; Creatinine; Randomized controlled trial; Confidence interval; Urology; Endocrinology","score_opus":0.0035999479209241183,"score_gpt":0.20997615246005044,"score_spread":0.20637620453912633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383711165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972441,0.0014602118,5.4132304e-8,0.00013864112,0.00013839302,0.000780247,0.000033881694,0.000055801487,0.00014865352],"genre_scores_gemma":[0.9988829,0.00026994778,0.000014430111,0.00022667511,0.000051195155,0.000048094065,0.00020326774,0.00002380871,0.0002796619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884146,0.00007951413,0.0001628144,0.00031950916,0.00022791851,0.0003687767],"domain_scores_gemma":[0.99927086,0.00010006313,0.000059192855,0.00023999954,0.000037425638,0.00029245688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026303044,0.0002287274,0.00052264356,0.0002682313,0.000045683013,0.000017971699,0.000051722047,0.00005298066,0.00001930921],"category_scores_gemma":[0.00013755113,0.00016094181,0.000046973197,0.00037907477,0.0000920409,0.00009691366,0.00007616956,0.0000933694,0.00002219092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022575892,0.00029078493,0.9815113,0.00081487,0.00019758467,0.000005597182,0.0000551747,0.0000025380532,0.00024860236,0.00012262276,0.0005447786,0.015980368],"study_design_scores_gemma":[0.0059841983,0.0014790607,0.9844608,0.00036072562,0.0005992515,1.017966e-8,0.0000038125024,0.000091704365,0.004980636,0.00005342151,0.0018330769,0.00015334297],"about_ca_topic_score_codex":0.0000040129503,"about_ca_topic_score_gemma":0.0000016774902,"teacher_disagreement_score":0.015827024,"about_ca_system_score_codex":0.000023872697,"about_ca_system_score_gemma":0.000032820008,"threshold_uncertainty_score":0.6563017},"labels":[],"label_agreement":null},{"id":"W4384028530","doi":"10.58931/cpct.2023.1s0717","title":"The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists","year":2023,"lang":"en","type":"article","venue":"Canadian Primary Care Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Type 2 diabetes; Medicine; Blindness; Diabetes mellitus; Intensive care medicine; Endocrinology; Optometry","score_opus":0.01150929183735773,"score_gpt":0.23772370522105532,"score_spread":0.22621441338369758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384028530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466984,0.0010912851,0.000005123595,0.018686675,0.0001341825,0.0015243611,0.00007072596,0.000078220226,0.031710997],"genre_scores_gemma":[0.99161863,0.00013053221,0.00039074014,0.0028726256,0.000056314264,0.0003110338,0.0004032324,0.000042875112,0.0041739894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890137,0.000029977211,0.00013451137,0.00032144578,0.0001357202,0.00047695494],"domain_scores_gemma":[0.9988954,0.00008635634,0.000021059577,0.00035483157,0.000070638634,0.00057170313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010578237,0.00017000965,0.00020222133,0.00033206103,0.00024121693,0.000060580773,0.00011847639,0.000038792754,0.000042983094],"category_scores_gemma":[0.00004236873,0.00012508646,0.000028631797,0.0006168422,0.000032770513,0.00004077122,0.000044976667,0.00009559835,0.00024242834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032992297,0.00012056711,0.49000597,0.0004796394,0.00032547518,0.0005869972,0.0048949295,0.00019237398,0.0020537148,0.002371524,0.084483385,0.41415548],"study_design_scores_gemma":[0.0008891871,0.0011736064,0.9294564,0.000386463,0.00008979352,0.0000023741975,0.00032925102,0.000008457659,0.0006814248,0.00003781499,0.06663153,0.00031370248],"about_ca_topic_score_codex":0.0014033895,"about_ca_topic_score_gemma":0.037313983,"teacher_disagreement_score":0.4394504,"about_ca_system_score_codex":0.000861047,"about_ca_system_score_gemma":0.00030638685,"threshold_uncertainty_score":0.9802525},"labels":[],"label_agreement":null},{"id":"W4384264234","doi":"10.1093/eurheartj/ehad445","title":"Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; St. Michael's Hospital","funders":"European Society of Cardiology","keywords":"Medicine; Diabetes mellitus; Insulin resistance; Kidney disease; Internal medicine; Type 2 diabetes; Obesity; Overweight; Disease; Liraglutide; Type 2 Diabetes Mellitus; Intensive care medicine; Endocrinology","score_opus":0.032545491185742036,"score_gpt":0.2533016751405672,"score_spread":0.22075618395482513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384264234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7139075,0.010364024,0.0013861492,0.00022109137,0.0010040328,0.00057261175,0.000042982745,0.00028420842,0.2722174],"genre_scores_gemma":[0.9774543,0.013096675,0.0026562477,0.0002887773,0.002015176,0.0000055234063,0.00009654247,0.00013168242,0.0042550424],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971502,0.00097573374,0.000442828,0.00039957598,0.00056467135,0.00046700457],"domain_scores_gemma":[0.9987395,0.000046801186,0.0001530647,0.00071705814,0.00009879897,0.00024481482],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014923763,0.00026252348,0.0008155731,0.00031074637,0.000254619,0.00007274291,0.00021695351,0.000032691874,0.000041330106],"category_scores_gemma":[0.000027043321,0.00021639846,0.0012624777,0.0007463164,0.00009364115,0.0001372932,0.00031868607,0.0003665938,0.0009885188],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002003953,0.00029906057,0.20915437,0.00041052155,0.06260812,0.008539772,0.0020848606,0.006846552,0.0018084437,0.00034797413,0.548241,0.15945889],"study_design_scores_gemma":[0.0020422142,0.00011837074,0.36093768,0.000083852836,0.0016682136,0.00006161804,0.000337683,0.000056985573,0.000052281226,0.00006434176,0.6344343,0.00014248212],"about_ca_topic_score_codex":0.000023368815,"about_ca_topic_score_gemma":3.5949313e-7,"teacher_disagreement_score":0.26796234,"about_ca_system_score_codex":0.00006522726,"about_ca_system_score_gemma":0.000022717346,"threshold_uncertainty_score":0.9997893},"labels":[],"label_agreement":null},{"id":"W4384297186","doi":"10.46747/cfp.6907452","title":"Family medicine drives improvement in diabetes care","year":2023,"lang":"en","type":"letter","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guideline; Diabetes mellitus; Value (mathematics); Alternative medicine; Family medicine; Medicine; Computer science; Medical education; Endocrinology; Pathology","score_opus":0.017885387874239524,"score_gpt":0.23458302389435204,"score_spread":0.21669763602011252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384297186","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040316638,0.0062558497,6.223617e-7,0.5342421,0.003397712,0.0040856856,0.00084867777,0.00044244985,0.41041026],"genre_scores_gemma":[0.0074333274,0.00021967875,0.000024810019,0.9749322,0.0046327114,0.00045271835,0.005722277,0.00025772076,0.0063245515],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961298,0.000051387815,0.0005584417,0.0009882227,0.0006410718,0.0016310794],"domain_scores_gemma":[0.99812204,0.00008219974,0.00016524548,0.0009991769,0.00013908092,0.0004922538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010965096,0.00080087886,0.0012659344,0.0016071666,0.00011887408,0.000052868094,0.0004033212,0.00055340404,0.00001210563],"category_scores_gemma":[0.000015802081,0.0007412696,0.0002769347,0.000841458,0.00021660754,0.00009583839,0.00008742332,0.001189007,0.0015516558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000037759241,0.000024055198,0.00085681974,0.00070249004,0.00039547132,0.0015498005,0.0001883986,0.0000017615824,0.0005273809,0.00002381438,0.94761455,0.048111685],"study_design_scores_gemma":[0.0016319555,0.00067916774,0.022933267,0.0015941841,0.000574237,7.1727726e-8,0.0019742313,0.000015605752,0.00004954999,0.00018807166,0.9697254,0.00063431665],"about_ca_topic_score_codex":0.020502362,"about_ca_topic_score_gemma":0.013692756,"teacher_disagreement_score":0.4406901,"about_ca_system_score_codex":0.0019451529,"about_ca_system_score_gemma":0.0006701942,"threshold_uncertainty_score":0.99950385},"labels":[],"label_agreement":null},{"id":"W4384340137","doi":"10.1161/strokeaha.122.042053","title":"Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials","year":2023,"lang":"en","type":"article","venue":"Stroke","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"National Center for Advancing Translational Sciences; Lilly Deutschland; Amicus Therapeutics; Biogen; Yale University; Novo Nordisk; Intarcia Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Chiesi Farmaceutici; Sanofi; Amgen; Pfizer; ZOLL Medical Corporation","keywords":"Medicine; Stroke (engine); Internal medicine; Risk factor; Diabetes mellitus; Disease; Type 2 diabetes; Cardiology; Secondary prevention; Coronary heart disease; Clinical trial; Endocrinology","score_opus":0.020893644028872754,"score_gpt":0.2558380100810967,"score_spread":0.23494436605222394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384340137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909443,0.0050255987,0.000042610092,0.000026309304,0.00019115987,0.0010866554,0.0025042132,0.00005890483,0.00012023897],"genre_scores_gemma":[0.99839973,0.00045838652,0.000062324696,0.000031252443,0.000041960076,0.00005294181,0.00071119296,0.000028223369,0.00021399921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773026,0.00032972323,0.0005050807,0.00043014452,0.00066398125,0.00034081173],"domain_scores_gemma":[0.99848574,0.00035202102,0.00014134994,0.0006924343,0.00012329353,0.00020518363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011312532,0.00025561565,0.0018452706,0.0006592958,0.000040027695,0.00001531212,0.0000762864,0.00005880148,0.00012126129],"category_scores_gemma":[0.00046046535,0.00018919665,0.0011136273,0.0007074094,0.00007043792,0.000088168126,0.000060207727,0.00013144777,0.00001004903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017510585,0.00014903882,0.8921673,0.00010873599,0.07295278,0.00003684338,0.000029647284,0.0019965088,0.000005084781,0.0000022205452,0.000053555978,0.030747201],"study_design_scores_gemma":[0.02143187,0.0006383341,0.9289525,0.000025169504,0.046446584,1.4166683e-8,0.000057371515,0.0007305906,0.000017137552,0.0000013234616,0.0015413383,0.00015772153],"about_ca_topic_score_codex":0.00005578898,"about_ca_topic_score_gemma":0.000014149404,"teacher_disagreement_score":0.03678522,"about_ca_system_score_codex":0.000070504204,"about_ca_system_score_gemma":0.000051034087,"threshold_uncertainty_score":0.77152157},"labels":[],"label_agreement":null},{"id":"W4385246430","doi":"10.1021/acs.jmedchem.3c00464","title":"Computational Design of Potent and Selective <scp>d</scp>-Peptide Agonists of the Glucagon-like Peptide-2 Receptor","year":2023,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Chemistry; Glucagon-like peptide 1 receptor; Receptor; Peptide; Phosphorylation; Glucagon-like peptide-1; Protein kinase B; Agonist; Protein kinase A; Pharmacology; Biochemistry; Endocrinology; Biology; Diabetes mellitus; Type 2 diabetes","score_opus":0.015410651520279437,"score_gpt":0.25125510723669714,"score_spread":0.2358444557164177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385246430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492264,0.00073212566,0.00043155387,0.0010150683,0.00020667615,0.00023435515,0.0000066897,0.00001773981,0.002433178],"genre_scores_gemma":[0.9945597,0.0002705933,0.0016997792,0.00014014172,0.00021792596,0.000004387712,0.000008817792,0.000020525737,0.00307811],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983949,0.00003960608,0.00052013836,0.0001301664,0.0007267607,0.0001884053],"domain_scores_gemma":[0.9983894,0.0003958584,0.0005875374,0.00013300421,0.00035004033,0.00014410738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058334746,0.00014765408,0.0004343628,0.00008185828,0.000047140897,0.0000063664834,0.00013923085,0.0000683204,0.000019759585],"category_scores_gemma":[0.0004449925,0.00009572173,0.00014769554,0.00030929534,0.00019949846,0.00004706289,0.00006475391,0.0002410056,0.0000034784202],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010745173,0.0016962234,0.06164549,0.004009618,0.005341978,0.00042192117,0.005295692,0.0065857577,0.44663042,0.00010133527,0.44915688,0.018040169],"study_design_scores_gemma":[0.017069051,0.0041313902,0.23109663,0.0058655133,0.0036751132,0.0010094289,0.010480519,0.0033841229,0.70291007,0.0022287648,0.017856367,0.00029303055],"about_ca_topic_score_codex":0.0000045741285,"about_ca_topic_score_gemma":1.682543e-7,"teacher_disagreement_score":0.43130052,"about_ca_system_score_codex":0.000100153506,"about_ca_system_score_gemma":0.0002469209,"threshold_uncertainty_score":0.39034188},"labels":[],"label_agreement":null},{"id":"W4385331114","doi":"10.1111/dom.15221","title":"Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Research Foundation of Korea; Ministry of Food and Drug Safety","keywords":"Medicine; Hazard ratio; Amputation; Cohort; Type 2 diabetes; Internal medicine; Retrospective cohort study; Propensity score matching; Cohort study; Diabetes mellitus; Proportional hazards model; Confidence interval; Surgery; Endocrinology","score_opus":0.008389640401609506,"score_gpt":0.21497732013791918,"score_spread":0.20658767973630968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385331114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720854,0.0017531617,0.000005584372,0.000035643512,0.00009845114,0.0006406245,0.00021027535,0.00003612598,0.000011595731],"genre_scores_gemma":[0.9978822,0.0010765989,0.000083614716,0.00006377567,0.00002993467,0.000017599672,0.0007887518,0.000023025177,0.000034515575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862057,0.000068249035,0.0003163937,0.00031040062,0.0003760865,0.00030830107],"domain_scores_gemma":[0.99920887,0.00010362275,0.00009891047,0.00028526137,0.0001509916,0.00015233901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041643516,0.0002168522,0.0006422358,0.0001968343,0.000056053075,0.000018515126,0.000042703163,0.00006396699,0.0000033907731],"category_scores_gemma":[0.00009907602,0.00017097077,0.00010041086,0.00042051577,0.00020275648,0.00018116225,0.000040320603,0.00008595278,0.0000017503635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030811253,0.000473658,0.9892365,0.0005471858,0.0006757505,0.0000059886966,0.0004872421,0.000111378,0.000113913375,0.000116283554,0.000023829383,0.007900187],"study_design_scores_gemma":[0.0039957743,0.00027500515,0.9874751,0.0002038384,0.0010467584,1.3855804e-8,0.000066984605,0.00015602694,0.005832954,0.00007810222,0.00071288587,0.00015657127],"about_ca_topic_score_codex":0.000031650638,"about_ca_topic_score_gemma":0.000008907284,"teacher_disagreement_score":0.007743615,"about_ca_system_score_codex":0.0000140167185,"about_ca_system_score_gemma":0.00002327857,"threshold_uncertainty_score":0.69719857},"labels":[],"label_agreement":null},{"id":"W4385409351","doi":"10.1016/j.jacc.2023.05.048","title":"GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes","year":2023,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Fundação para a Ciência e a Tecnologia; Duke Clinical Research Institute; Daiichi-Sankyo; Novo Nordisk; Sanofi; GlaxoSmithKline; U.S. Food and Drug Administration; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Type 2 diabetes; Agonist; Pharmacology; Glucagon-like peptide 1 receptor; Diabetes mellitus; Receptor; Internal medicine; Endocrinology","score_opus":0.017680942435238624,"score_gpt":0.2788603693305108,"score_spread":0.2611794268952722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385409351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33561853,0.66177505,6.289742e-7,0.0002313053,0.00042509218,0.001494339,0.00006921191,0.0000115735575,0.00037430576],"genre_scores_gemma":[0.015083289,0.9839178,0.00023142384,0.00008027097,0.00022445132,0.000023299386,0.000013615506,0.00006930824,0.0003565698],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998396,0.0002739953,0.0005703226,0.00019801281,0.00031506506,0.0002466257],"domain_scores_gemma":[0.997901,0.0001351368,0.0013783854,0.00030841824,0.00019476465,0.00008229786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002998059,0.00030885445,0.0030774176,0.0003396703,0.00003258366,0.0000063040047,0.00019456788,0.00007040035,0.000002821025],"category_scores_gemma":[0.000053289765,0.00014053423,0.00029639393,0.0008015706,0.0005024517,0.000036344754,0.00007950281,0.0003098781,0.0000021580477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018170163,0.00020981487,0.6695921,0.0024143422,0.009251601,0.00008204981,0.000031544987,0.000008514219,0.0000021141107,0.00001524851,0.0077346493,0.308841],"study_design_scores_gemma":[0.0042017084,0.012650563,0.050446063,0.010612845,0.003135758,0.000048421185,0.00011213632,3.2518682e-7,0.0000044751246,0.000009087298,0.9184948,0.00028380228],"about_ca_topic_score_codex":0.0000041225844,"about_ca_topic_score_gemma":0.0000033348108,"teacher_disagreement_score":0.91076016,"about_ca_system_score_codex":0.00013526724,"about_ca_system_score_gemma":0.00030206388,"threshold_uncertainty_score":0.573082},"labels":[],"label_agreement":null},{"id":"W4385472415","doi":"10.14740/jocmr4987","title":"Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Semaglutide; Internal medicine; Type 2 diabetes; Endocrinology; Weight loss; Bioelectrical impedance analysis; Glycemic; Diabetes mellitus; Liraglutide; Lean body mass; Skeletal muscle; Body weight; Obesity; Body mass index","score_opus":0.13443655252986406,"score_gpt":0.4739512162359017,"score_spread":0.33951466370603767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385472415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457526,0.00017959966,0.000005562324,0.0029827205,0.00039044998,0.00052745955,0.0000013005964,0.000016701131,0.0013209583],"genre_scores_gemma":[0.9981245,0.00024042833,0.00048766713,0.00009094656,0.00054330844,0.0000052528367,0.0000100155685,0.00003151228,0.0004664069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953557,0.0005404853,0.0013477624,0.00025224226,0.0019188817,0.0005849135],"domain_scores_gemma":[0.9958616,0.0019601462,0.00049076584,0.00029815148,0.001035977,0.0003533777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008665681,0.00016825844,0.0011816855,0.0009234061,0.000046930414,0.000012103374,0.00024074895,0.00012397223,0.0000973604],"category_scores_gemma":[0.0059839278,0.00009765378,0.00012480354,0.0015673422,0.00043939205,0.00011792928,0.00010039595,0.0010747594,0.000025903266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010232225,0.00053870585,0.9734622,0.00027108064,0.00035391722,0.000187979,0.00012380061,0.00001068481,0.0008358774,0.000013059498,0.0024498163,0.020729642],"study_design_scores_gemma":[0.011243444,0.01350987,0.9700536,0.0023786945,0.00018988666,7.8611396e-7,0.0006118822,0.00013967439,0.0005452407,0.00030851748,0.0009282263,0.00009019152],"about_ca_topic_score_codex":0.000020210453,"about_ca_topic_score_gemma":0.0000073779715,"teacher_disagreement_score":0.02063945,"about_ca_system_score_codex":0.00008846361,"about_ca_system_score_gemma":0.00017711254,"threshold_uncertainty_score":0.71637523},"labels":[],"label_agreement":null},{"id":"W4385521434","doi":"10.2196/48586","title":"The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis","year":2023,"lang":"en","type":"article","venue":"JMIR Medical Education","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Continuing medical education; Intervention (counseling); Glycemic; Odds ratio; Type 2 diabetes; Internal medicine; Diabetes mellitus; Family medicine; Continuing education; Medical education; Nursing; Insulin; Endocrinology","score_opus":0.012103942012228074,"score_gpt":0.3630980020171875,"score_spread":0.3509940600049594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385521434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967481,0.00007922122,0.000021511441,0.0009729231,0.0003306795,0.0012508958,0.000004355855,0.00007468854,0.0005176234],"genre_scores_gemma":[0.99876153,0.00006867946,0.000034452216,0.0001900045,0.00019696148,0.0003207592,0.00018174491,0.000021797236,0.00022405075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782133,0.00020996403,0.000525554,0.0003334811,0.0007953961,0.00031427311],"domain_scores_gemma":[0.99853504,0.0004173875,0.00026256996,0.00024630412,0.0002694664,0.00026926066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005919766,0.00020646722,0.00042611442,0.0009782957,0.00010365138,0.000026391603,0.00006447616,0.00013862652,0.00034712086],"category_scores_gemma":[0.0010478693,0.00013711,0.00023336196,0.0029612705,0.00006892439,0.000074402866,0.000012584465,0.00016987888,0.0000135345745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003965627,0.0035045738,0.7024935,0.000045144727,0.0010331318,0.000021765438,0.0009252727,0.0099416105,0.000075623044,0.00012443062,0.0010912156,0.28034717],"study_design_scores_gemma":[0.0016666054,0.0010622767,0.52113473,0.0002861751,0.00061907596,0.0000015339499,0.00029788841,0.47455254,0.000051111463,0.000044942662,0.00018567545,0.000097457945],"about_ca_topic_score_codex":0.0013537827,"about_ca_topic_score_gemma":0.0012653606,"teacher_disagreement_score":0.46461093,"about_ca_system_score_codex":0.002048454,"about_ca_system_score_gemma":0.0022529317,"threshold_uncertainty_score":0.55911833},"labels":[],"label_agreement":null},{"id":"W4385583930","doi":"10.14740/cr1523","title":"The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review","year":2023,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Mace; Internal medicine; Hazard ratio; Exenatide; Meta-analysis; Liraglutide; Dulaglutide; Myocardial infarction; Type 2 diabetes; Confidence interval; Type 2 Diabetes Mellitus; Heart failure; Diabetes mellitus; Cardiology; Adverse effect; Glucagon-like peptide 1 receptor; Endocrinology; Agonist; Percutaneous coronary intervention; Receptor","score_opus":0.07564375780323644,"score_gpt":0.3564210144494387,"score_spread":0.28077725664620223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385583930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8912036,0.10239708,8.006519e-7,0.0012132094,0.00004120166,0.004335619,0.000026661499,0.00002550664,0.00075636705],"genre_scores_gemma":[0.9844842,0.01338855,0.0000059138115,0.00007980237,0.000011843519,0.0007784517,0.000077950164,0.000020248437,0.0011530449],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99658835,0.0015676119,0.00035941543,0.00032553892,0.0006966172,0.000462443],"domain_scores_gemma":[0.9966311,0.0016365773,0.00007890575,0.0012346869,0.0003459017,0.00007286548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057371077,0.00018881354,0.0026584228,0.00033915296,0.00014668064,0.000025784242,0.0002207539,0.000053848587,0.000022126454],"category_scores_gemma":[0.0010325881,0.0000679507,0.0014282084,0.001816973,0.00033183422,0.00002548539,0.00014310054,0.0002287535,0.00006618228],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000895135,0.00007830261,0.40413895,0.0109471865,0.5798562,0.000017000755,0.00008180157,0.00007246603,0.0000031023953,0.00007278981,0.0044711567,0.00017152762],"study_design_scores_gemma":[0.0014585161,0.002726072,0.7191991,0.0024273414,0.27263653,7.3939106e-7,0.0003743539,0.000044302134,0.00002506905,0.00006340381,0.00080666493,0.00023789147],"about_ca_topic_score_codex":0.000050533912,"about_ca_topic_score_gemma":0.0000061500114,"teacher_disagreement_score":0.31506017,"about_ca_system_score_codex":0.00009589162,"about_ca_system_score_gemma":0.000051182804,"threshold_uncertainty_score":0.27709493},"labels":[],"label_agreement":null},{"id":"W4385621416","doi":"10.1016/j.cardfail.2023.06.024","title":"Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Empagliflozin; Heart failure; Hazard ratio; Ejection fraction; Internal medicine; Coronary artery disease; Cardiology; Disease; Diabetes mellitus; Proportional hazards model; Vascular disease; Placebo; Type 2 diabetes; Confidence interval; Pathology","score_opus":0.012382415346899298,"score_gpt":0.24240316788280053,"score_spread":0.23002075253590124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385621416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96627134,0.0029693793,9.442006e-7,0.029622741,0.00034937207,0.00070653687,0.000015206403,0.000026550948,0.000037915397],"genre_scores_gemma":[0.9980131,0.00033415924,0.000309517,0.00036744063,0.0007208042,0.000032044856,0.000030101157,0.000030375559,0.00016246455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998369,0.00012350621,0.00038727702,0.00021201491,0.00066333794,0.00024489991],"domain_scores_gemma":[0.9989565,0.00019885751,0.00014592665,0.0003322827,0.00010640386,0.00026002864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030173644,0.0002269864,0.0007197349,0.00021956646,0.000072243674,0.00008206643,0.00011069153,0.00006678996,0.000017712593],"category_scores_gemma":[0.00012340872,0.00011952982,0.00038400243,0.00038502846,0.000056479737,0.00019177966,0.00006550367,0.00026290413,0.000018743853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015338889,0.00056853984,0.7975384,0.00015187409,0.008876424,0.0008178057,0.0038627472,0.0007655457,0.0012504583,0.0004133404,0.16176736,0.008648622],"study_design_scores_gemma":[0.030244002,0.0006520521,0.8587196,0.0003881173,0.001714233,0.000003200444,0.0015072876,0.000013017279,0.000119840646,0.00015048607,0.10629612,0.00019207597],"about_ca_topic_score_codex":0.000038758953,"about_ca_topic_score_gemma":0.00005170684,"teacher_disagreement_score":0.061181176,"about_ca_system_score_codex":0.000058759473,"about_ca_system_score_gemma":0.000121523866,"threshold_uncertainty_score":0.48742846},"labels":[],"label_agreement":null},{"id":"W4385622725","doi":"10.1016/j.jchf.2023.05.026","title":"Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events","year":2023,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; St. Michael's Hospital","funders":"National Institutes of Health; St. Jude Medical; Assistance publique-Hôpitaux de Paris; Boston VA Research Institute; Regado Biosciences; Boston Scientific Corporation; University of Pittsburgh; Cleveland Clinic; Duke Clinical Research Institute; Novo Nordisk; American Heart Association; Daiichi Sankyo Europe; Sanofi; AstraZeneca; Bristol-Myers Squibb; MyoKardia","keywords":"Medicine; Placebo; Internal medicine; Heart failure; Clinical endpoint; Ejection fraction; Cardiology; Diabetes mellitus; Renal function; Natriuretic peptide; Clinical trial; Endocrinology; Pathology","score_opus":0.012847665165815774,"score_gpt":0.28875189777690524,"score_spread":0.2759042326110895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385622725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913953,0.000056624027,7.451664e-7,0.0065877405,0.00015206642,0.0010392655,0.0000142066965,0.00021036426,0.0005436875],"genre_scores_gemma":[0.9975341,0.000009662166,0.00018056793,0.00025518914,0.000066237524,0.00006813502,0.00007076691,0.00003448877,0.0017808705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984056,0.00013733674,0.00029867492,0.0003750033,0.0004057033,0.00037768963],"domain_scores_gemma":[0.99911374,0.00017285184,0.000058968388,0.00043153233,0.000037932015,0.00018497293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057118817,0.00024407702,0.0005591142,0.00021648176,0.00006936833,0.000017486198,0.000059088692,0.0001442488,0.0001372919],"category_scores_gemma":[0.00009782283,0.00018900633,0.00017794424,0.0004493517,0.000057205998,0.00009140851,0.000082548926,0.00019504446,0.00059136975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016956,0.00023427428,0.8679859,0.0005564506,0.000640137,0.000041322528,0.00017232976,0.000009591237,0.006656935,0.00026643474,0.12128118,0.001985856],"study_design_scores_gemma":[0.0040908335,0.0032727045,0.91723776,0.00035865032,0.00042586477,0.0000053545855,0.000045771973,0.000084151805,0.010976286,0.000112418966,0.063186325,0.00020389583],"about_ca_topic_score_codex":0.00010575051,"about_ca_topic_score_gemma":0.000024123168,"teacher_disagreement_score":0.05809485,"about_ca_system_score_codex":0.00004119865,"about_ca_system_score_gemma":0.0000236435,"threshold_uncertainty_score":0.77074546},"labels":[],"label_agreement":null},{"id":"W4385661341","doi":"10.2215/cjn.0000000000000251","title":"Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD","year":2023,"lang":"en","type":"review","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Intensive care medicine; Internal medicine; Cardiology","score_opus":0.1158366673488509,"score_gpt":0.43327531881542947,"score_spread":0.31743865146657857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385661341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068394314,0.9890778,0.00015028632,0.0019414563,0.00032779467,0.0016333134,0.000017134887,0.000006091416,0.0000067132964],"genre_scores_gemma":[0.0006856962,0.99735725,0.0002923216,0.0011730884,0.00024936008,0.000051749532,0.000012527703,0.00002802706,0.00014995724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973702,0.00057821575,0.0014030131,0.00016851223,0.00031058682,0.00016947862],"domain_scores_gemma":[0.99452835,0.00220565,0.0025754718,0.00047043516,0.00017118409,0.00004889229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017925183,0.00018189845,0.0027766959,0.00006670203,0.000034210607,0.0000039956467,0.00041372137,0.00011633953,0.0000048480033],"category_scores_gemma":[0.00020316608,0.000090223046,0.0071202074,0.00041021255,0.00079466135,0.00002683072,0.00010721704,0.00034917542,0.0000011049048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021234388,0.0008315279,0.00048204605,0.0017106199,0.012582872,0.000002197414,0.000033313467,0.0000128394,7.4858855e-7,0.000028832756,0.015579613,0.968523],"study_design_scores_gemma":[0.0031319056,0.0032956672,0.010817243,0.0022769242,0.010664833,0.0000072081575,0.00012710001,0.000033603814,5.2700193e-7,0.00046089964,0.9691059,0.00007817643],"about_ca_topic_score_codex":0.000013789566,"about_ca_topic_score_gemma":9.943756e-7,"teacher_disagreement_score":0.9684449,"about_ca_system_score_codex":0.0000642544,"about_ca_system_score_gemma":0.00026476552,"threshold_uncertainty_score":0.718092},"labels":[],"label_agreement":null},{"id":"W4385693606","doi":"10.2337/dc23-0492","title":"Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Heart, Lung, and Blood Institute; Genentech; Esperion Therapeutics; Silence Therapeutics; HLS Therapeutics; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Pfizer; Moderna; Regado Biosciences; Hebrew University of Jerusalem; Belvoir Media Group; Novo Nordisk; MyoKardia; Allergan; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Amgen; St. Jude Medical; Kowa Company; Sanofi; American Heart Association; U.S. Department of Veterans Affairs","keywords":"Medicine; Dapagliflozin; Kidney disease; Internal medicine; Type 2 diabetes; Renal function; Glycated hemoglobin; TIMI; Myocardial infarction; Framingham Risk Score; Diabetes mellitus; Hazard ratio; Creatinine; Endocrinology; Disease; Percutaneous coronary intervention; Confidence interval","score_opus":0.005707628824073473,"score_gpt":0.2592585962387875,"score_spread":0.253550967414714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385693606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983797,0.00019303577,2.0941752e-7,0.000077537254,0.00005162495,0.00084567466,0.000121023986,0.000044541488,0.00028664758],"genre_scores_gemma":[0.9981512,0.00004956266,0.00017810758,0.000057706784,0.000012439891,0.000053946016,0.0014588255,0.000020536747,0.00001769759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902177,0.000040070394,0.00020502017,0.00022167897,0.00029201753,0.00021946512],"domain_scores_gemma":[0.99926317,0.000052412906,0.00013139228,0.0002134975,0.00015310865,0.00018642315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008878771,0.00013804661,0.00029297548,0.00023123994,0.000025142212,0.000008201815,0.00002755422,0.000035690853,0.000014181199],"category_scores_gemma":[0.00014516374,0.0001017297,0.00004200767,0.00043237535,0.00006906197,0.00007842902,0.00007273814,0.000064904605,0.000005051435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007853782,0.0004001192,0.98376316,0.0008827659,0.00010089391,0.000003151848,0.00016911332,0.000013243798,0.00017429823,0.00001755018,0.00034664822,0.014050524],"study_design_scores_gemma":[0.0045202677,0.001191015,0.9905194,0.0011957714,0.00030745374,2.5997318e-9,0.00009644996,0.00017629018,0.0017354406,0.000022793596,0.00013810208,0.00009699856],"about_ca_topic_score_codex":0.0000016031462,"about_ca_topic_score_gemma":8.4126924e-7,"teacher_disagreement_score":0.013953526,"about_ca_system_score_codex":0.000044021766,"about_ca_system_score_gemma":0.000058926802,"threshold_uncertainty_score":0.41484168},"labels":[],"label_agreement":null},{"id":"W4385738101","doi":"10.26442/20751753.2023.4.202277","title":"Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation","year":2023,"lang":"en","type":"article","venue":"Consilium Medicum","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Glycated hemoglobin; Type 2 diabetes; Metformin; Internal medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Pharmacology; Endocrinology; Gastroenterology","score_opus":0.012277239836288187,"score_gpt":0.2550011761178074,"score_spread":0.24272393628151923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385738101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893575,0.00032297435,0.000086962034,0.005381244,0.0012870169,0.0015155311,0.000008927024,0.00034979824,0.0016900561],"genre_scores_gemma":[0.99635196,0.0000624176,0.00003079224,0.000725006,0.0004960429,0.00012214198,0.00022610539,0.000044440258,0.0019411026],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980856,0.000089095105,0.00035304454,0.0005146827,0.00043644683,0.0005210987],"domain_scores_gemma":[0.9992219,0.000079179736,0.00008351823,0.0003025973,0.00013919985,0.0001735582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031270378,0.0002531354,0.00038864292,0.00046790965,0.000073793,0.000021235575,0.0000842036,0.00014183331,0.00014623739],"category_scores_gemma":[0.00015062961,0.0002304867,0.00010121482,0.0010850276,0.00013911452,0.0001339779,0.000050411916,0.00030206752,0.00046998853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029827976,0.0016871644,0.10204742,0.0014424436,0.0020296401,0.0089378515,0.0061051287,0.000821729,0.64831376,0.0011742641,0.1625546,0.061903186],"study_design_scores_gemma":[0.015736202,0.002878276,0.89879394,0.0005499256,0.0007381719,0.000037003898,0.00061453786,0.009308147,0.051213313,0.000966056,0.018404407,0.00076004874],"about_ca_topic_score_codex":0.00011014318,"about_ca_topic_score_gemma":0.00016146069,"teacher_disagreement_score":0.7967465,"about_ca_system_score_codex":0.00046625745,"about_ca_system_score_gemma":0.0003827991,"threshold_uncertainty_score":0.9398974},"labels":[],"label_agreement":null},{"id":"W4385752248","doi":"10.1111/dom.15241","title":"Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval; Health Sciences Centre; University of Waterloo; Sunnybrook Health Science Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Discontinuation; Cohort; Medicine; Cotransporter; Cohort study; Internal medicine; Sodium; Chemistry","score_opus":0.022532548089796562,"score_gpt":0.25419073524909547,"score_spread":0.2316581871592989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385752248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970502,0.0002537218,0.0000033849176,0.00030917564,0.000308151,0.0017712031,0.0001608828,0.000046033034,0.000097248914],"genre_scores_gemma":[0.99903023,0.00006450535,0.000012790256,0.00013363517,0.00010362262,0.00006906511,0.00050820335,0.000010397983,0.00006755518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870515,0.00017131481,0.00035573286,0.00021467976,0.00037846685,0.00017464388],"domain_scores_gemma":[0.9990292,0.00019851055,0.00023744804,0.0003213419,0.0001651712,0.000048328664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000439321,0.00016191622,0.0004660249,0.0001334518,0.000112556365,0.00001829095,0.000116860676,0.00004842249,0.000013884286],"category_scores_gemma":[0.000065502165,0.000092263515,0.000115304036,0.00057540037,0.00016173469,0.00012211785,0.0000752734,0.000102664824,0.0000035419248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035760528,0.00065557944,0.9897756,0.00002956798,0.00073242583,8.010863e-7,0.004943866,0.0000070045835,0.0031225216,0.00025658828,0.00017272028,0.0002675639],"study_design_scores_gemma":[0.0017973364,0.00015424608,0.9739925,0.00010625569,0.0018265733,3.1252657e-8,0.0012321103,0.0001499237,0.019963613,0.00008983169,0.000608904,0.00007861936],"about_ca_topic_score_codex":0.0005831982,"about_ca_topic_score_gemma":0.00010565803,"teacher_disagreement_score":0.016841091,"about_ca_system_score_codex":0.000011975339,"about_ca_system_score_gemma":0.000024997422,"threshold_uncertainty_score":0.37623972},"labels":[],"label_agreement":null},{"id":"W4385827492","doi":"10.1111/dom.15234","title":"Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Professional Engineers Ontario; Western University; Ottawa Hospital; University of Ottawa; Hamilton Health Sciences; McGill University; University of Calgary; Impact; LMC Diabetes & Endocrinology (Canada); McMaster University; Population Health Research Institute","funders":"Obesity Canada; Canadian Institutes of Health Research; Bayer Canada; National Institutes of Health; HLS Therapeutics; Bausch Health; Mitacs; Novo Nordisk; Dexcom; Insulet Corporation; Diabetes Canada; University of Calgary; Kowa Company; Sanofi; Hamilton Health Sciences; GlaxoSmithKline; McMaster University; Lawson Foundation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Alberta Health Services; Pfizer","keywords":"Medicine; Metformin; Diabetes mellitus; Type 2 diabetes; Insulin glargine; Internal medicine; Hazard ratio; Lixisenatide; Confidence interval; Insulin; Endocrinology; Liraglutide","score_opus":0.022017787339578987,"score_gpt":0.2561282778115219,"score_spread":0.23411049047194293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385827492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98362935,0.011876458,0.000007721283,0.00022260043,0.0004287558,0.0033343278,0.000024828032,0.00014072318,0.00033524606],"genre_scores_gemma":[0.9961032,0.0017273454,0.0006425638,0.00015218345,0.00014836545,0.00034359738,0.000290156,0.0000398233,0.00055272813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973158,0.00035386084,0.0008756177,0.00061612646,0.00035218656,0.00048635903],"domain_scores_gemma":[0.9981301,0.00058499316,0.00039874783,0.00034712872,0.00020065035,0.0003383762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025603906,0.0003970667,0.0018357824,0.00057153404,0.00018016541,0.00008110812,0.00009379334,0.0001794635,0.0000045636966],"category_scores_gemma":[0.0031325638,0.00030831067,0.00034693588,0.00045142075,0.00015545638,0.00046709998,0.00022201835,0.00021705855,0.0000024652147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44164765,0.007907164,0.1114151,0.004133882,0.020629536,0.00016927303,0.023888351,0.000023501345,0.03257744,0.0071711377,0.002015633,0.34842134],"study_design_scores_gemma":[0.9281725,0.0010316487,0.04638503,0.00057075446,0.0047268188,9.793632e-7,0.0015704256,0.0053530885,0.0087467935,0.0008333661,0.002174558,0.000434005],"about_ca_topic_score_codex":0.000028188791,"about_ca_topic_score_gemma":0.0000043588284,"teacher_disagreement_score":0.48652488,"about_ca_system_score_codex":0.000013136712,"about_ca_system_score_gemma":0.000027707018,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W4385933624","doi":"10.1016/j.jdiacomp.2023.108588","title":"Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Cardiology; Blood pressure; Hemodynamics; Type 2 diabetes; Internal medicine; Diabetes mellitus; Heart failure; Renal function; Kidney disease; Endocrinology","score_opus":0.009223526334988187,"score_gpt":0.24023929403353797,"score_spread":0.23101576769854978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385933624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288505,0.005299106,0.0000015758162,0.0012560845,0.00006329845,0.0004286062,0.00001480783,0.0000069139587,0.00004457438],"genre_scores_gemma":[0.99558765,0.0040216325,0.00015341914,0.00013181598,0.000019559053,0.000027173173,0.000024570536,0.000015189545,0.000019007335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989955,0.000045465753,0.00032150786,0.00017584662,0.00023703351,0.00022464088],"domain_scores_gemma":[0.9994287,0.00006005859,0.0001233423,0.00015730452,0.00009257848,0.0001380459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041391156,0.00014086242,0.0006349119,0.0005969885,0.000025820891,0.000017728205,0.000058581856,0.00004971672,0.0000024394324],"category_scores_gemma":[0.00008354473,0.0001083065,0.00007759259,0.000457704,0.00005324938,0.00011095521,0.000073070216,0.00011546651,6.699399e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009440806,0.00013226927,0.9907044,0.00022353539,0.0007975402,0.000006198395,0.00024506132,0.00005592636,0.001465005,0.000095618445,0.000030890667,0.0062340866],"study_design_scores_gemma":[0.0024007764,0.00042949832,0.9941335,0.00029390038,0.00038541292,5.37508e-7,0.00028383353,0.0013123145,0.00024390942,0.00014632534,0.00026887775,0.00010112634],"about_ca_topic_score_codex":0.000020409723,"about_ca_topic_score_gemma":0.000031626743,"teacher_disagreement_score":0.0061329603,"about_ca_system_score_codex":0.000036796915,"about_ca_system_score_gemma":0.00004122717,"threshold_uncertainty_score":0.4416611},"labels":[],"label_agreement":null},{"id":"W4385993416","doi":"10.1016/j.kint.2023.06.008","title":"The authors reply","year":2023,"lang":"en","type":"letter","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Novo Nordisk","keywords":"Semaglutide; Renal function; Medicine; Type 2 diabetes; Agonist; Kidney disease; Internal medicine; Glucagon-like peptide 1 receptor; Kidney; Diabetes mellitus; Endocrinology; Exenatide; Clinical trial; Urology; Receptor; Liraglutide","score_opus":0.022362442253654392,"score_gpt":0.2870950990605518,"score_spread":0.2647326568068974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385993416","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017657087,0.000029307483,0.000007731064,0.88433206,0.005907395,0.00025933576,0.000078812416,0.00017001954,0.10919767],"genre_scores_gemma":[0.000024425513,0.00007616489,0.00008093744,0.5398086,0.0042438167,0.00007726274,0.0020061352,0.000032376025,0.45365033],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986348,0.000019456362,0.0002184004,0.00027332138,0.00061307894,0.00024093963],"domain_scores_gemma":[0.999233,0.00011552879,0.00010091719,0.00036759797,0.000095147356,0.00008782887],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016418891,0.00017054199,0.00015985977,0.00014092446,0.00008284376,0.00010083632,0.0002910193,0.00015440736,0.00051389774],"category_scores_gemma":[0.0004174812,0.000109798355,0.00018423758,0.000082071856,0.000054859007,0.000031950065,0.00012382798,0.0005717047,0.0022150904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010076311,0.000015305499,0.0002875956,0.000027824877,0.0010630442,0.0004175688,0.000017185916,1.0154641e-7,0.000001989928,0.00049863284,0.99483806,0.0028226299],"study_design_scores_gemma":[0.00041105563,0.0000451416,0.00065893226,0.0001288111,0.00019672776,0.0000073506103,0.000007337139,0.000055357956,0.0000135916935,0.00063230295,0.99774593,0.00009748338],"about_ca_topic_score_codex":0.00002195919,"about_ca_topic_score_gemma":0.0000012802486,"teacher_disagreement_score":0.34452352,"about_ca_system_score_codex":0.00016760951,"about_ca_system_score_gemma":0.00010667405,"threshold_uncertainty_score":0.9985618},"labels":[],"label_agreement":null},{"id":"W4386084628","doi":"10.18553/jmcp.2023.29.9.1045","title":"Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Empagliflozin; Dapagliflozin; Medicine; Ejection fraction; Heart failure with preserved ejection fraction; Cost effectiveness; Hazard ratio; Heart failure; Intensive care medicine; Internal medicine; Emergency medicine; Diabetes mellitus; Type 2 diabetes; Risk analysis (engineering); Confidence interval","score_opus":0.026722205193785323,"score_gpt":0.3308528337624001,"score_spread":0.3041306285686148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386084628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740416,0.000160074,0.00007842924,0.0003423296,0.00016537719,0.0011839069,0.00001516381,0.00002065648,0.00062991184],"genre_scores_gemma":[0.99921143,0.00008467052,0.00029790582,0.000064646585,0.00017210579,0.000029022933,0.000059616876,0.000017918625,0.00006265553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981053,0.00030816928,0.0004926991,0.00024083172,0.0006155995,0.00023740312],"domain_scores_gemma":[0.99868375,0.00015344721,0.00040561458,0.00018500318,0.0004291033,0.00014308695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005295064,0.00021298659,0.0009284921,0.001169914,0.00007066517,0.000036689853,0.000093939016,0.00003888026,0.000073223506],"category_scores_gemma":[0.000039446353,0.00016876105,0.00021740352,0.0017881874,0.000057993573,0.00032109633,0.00006283946,0.0003035755,0.0000057984566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035754072,0.00045989384,0.9876306,0.0003009456,0.0025382875,0.000059801143,0.00041101407,0.0021094242,0.000123816,0.000018889526,0.0017306703,0.001041258],"study_design_scores_gemma":[0.011267586,0.00094761857,0.9728688,0.00023907878,0.0030037968,0.0000013885149,0.0014836265,0.00032425908,0.0014279714,0.000018606788,0.008278954,0.0001383078],"about_ca_topic_score_codex":0.000086325366,"about_ca_topic_score_gemma":0.00020083638,"teacher_disagreement_score":0.014761786,"about_ca_system_score_codex":0.0003184417,"about_ca_system_score_gemma":0.000060423976,"threshold_uncertainty_score":0.6881876},"labels":[],"label_agreement":null},{"id":"W4386151402","doi":"10.1002/ejhf.2990","title":"Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Janssen Pharmaceuticals; St. Jude Medical; HLS Therapeutics; Daiichi Sankyo Europe; Servier; Assistance publique-Hôpitaux de Paris; Agency for Healthcare Research and Quality; Vifor Pharma; Pfizer; Moderna; Idorsia Pharmaceuticals; Impulse Dynamics; Medicines Company; Regado Biosciences; Belvoir Media Group; Novo Nordisk; MyoKardia; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; British Heart Foundation; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Empagliflozin; Myocardial infarction; Internal medicine; Heart failure; Cardiology; Ejection fraction; Population; Interquartile range; Diabetes mellitus; Type 2 diabetes; Placebo","score_opus":0.017112991885173567,"score_gpt":0.2542449277176738,"score_spread":0.23713193583250025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386151402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989653,0.000026122403,0.000007818011,0.009098682,0.0002475668,0.00030068096,0.000007727394,0.000008715529,0.0006496749],"genre_scores_gemma":[0.99848783,0.000027579494,0.00031273038,0.00043229744,0.00032659425,0.000001089827,0.000027022748,0.000016621354,0.0003682414],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99854165,0.00037761332,0.0005189276,0.00006977775,0.000344171,0.00014784942],"domain_scores_gemma":[0.9993345,0.00010368264,0.00022507866,0.00016251896,0.00011314223,0.00006105469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017190877,0.00009090907,0.0002994037,0.00020807493,0.000021746806,0.000016522286,0.00011236007,0.000012876993,0.00009665486],"category_scores_gemma":[0.00030817502,0.000053951637,0.0001477022,0.00025287096,0.000023250554,0.000058150137,0.00003142564,0.00017146234,0.00008732568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027261522,0.0031732959,0.17121391,0.00022832585,0.00058799516,0.0018988559,0.0045948313,0.000014798168,0.0010526042,0.000054631044,0.7619182,0.028001059],"study_design_scores_gemma":[0.06400509,0.0044803326,0.6391383,0.0002465194,0.00022024866,0.000011060966,0.0005462496,0.000019330102,0.00011809153,0.000008742877,0.2911135,0.00009256824],"about_ca_topic_score_codex":5.604794e-7,"about_ca_topic_score_gemma":5.859113e-7,"teacher_disagreement_score":0.47080466,"about_ca_system_score_codex":0.000014822568,"about_ca_system_score_gemma":0.000027996599,"threshold_uncertainty_score":0.22000839},"labels":[],"label_agreement":null},{"id":"W4386304505","doi":"10.1016/j.cjca.2023.08.023","title":"Sodium-Glucose Cotransporter 2 Inhibitor Among Patients With Cancer Therapy–Induced Left Ventricular Dysfunction","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University; Bayer","keywords":"Medicine; Internal medicine; Cancer therapy; Cardiology; Cancer; Endocrinology","score_opus":0.011265389244938152,"score_gpt":0.21209225048599653,"score_spread":0.2008268612410584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386304505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966742,0.00034192114,0.000034664125,0.00051669957,0.0010851539,0.0002982256,0.000011991266,0.000014086712,0.0010231019],"genre_scores_gemma":[0.9985745,0.00014047601,0.000008581088,0.00022887916,0.0005910059,0.000010037892,0.000064248125,0.00002174148,0.00036055496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991074,0.000039796836,0.00022157877,0.00013156854,0.00016554701,0.0003340689],"domain_scores_gemma":[0.999131,0.000013892295,0.00011825606,0.00013260325,0.0002144149,0.00038983076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013661882,0.00013202534,0.00037554596,0.00038942017,0.0000638324,0.000013000512,0.00006356062,0.00008501029,0.00008115586],"category_scores_gemma":[0.000011660974,0.000092970266,0.00014815025,0.00019331269,0.0000628291,0.00008877542,0.0000036245506,0.00015045352,0.000017922996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014572998,0.000007749892,0.97346354,0.000013392986,0.00087704806,0.0008488047,0.000094128925,0.00020829294,0.00010216234,0.000005815709,0.01356461,0.01066871],"study_design_scores_gemma":[0.0036791617,0.0008742636,0.9088018,0.000067563284,0.00030310816,0.00001691259,0.000049394715,0.0000035288158,0.00047564646,0.00001114857,0.08562323,0.000094230054],"about_ca_topic_score_codex":0.0005306733,"about_ca_topic_score_gemma":0.0012499761,"teacher_disagreement_score":0.07205862,"about_ca_system_score_codex":0.00020219943,"about_ca_system_score_gemma":0.00037713195,"threshold_uncertainty_score":0.37912175},"labels":[],"label_agreement":null},{"id":"W4386424201","doi":"10.7326/j23-0071","title":"SGLT2 inhibitors improved health status in Black and White patients with HF regardless of race","year":2023,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Race (biology); Heart failure; Internal medicine; White (mutation); Racial differences; Cardiology; Ethnic group; Biochemistry","score_opus":0.024877126276948075,"score_gpt":0.30423711717983554,"score_spread":0.27935999090288743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386424201","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.550238,0.00086915446,0.0000072280586,0.44548208,0.0004278496,0.0013202649,0.00008168598,0.000033207398,0.0015405309],"genre_scores_gemma":[0.46095952,0.0050407443,0.00022854727,0.513058,0.001936478,0.00007780788,0.0013637422,0.0002462903,0.017088871],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99738115,0.00006945967,0.0009156108,0.00042650016,0.00067921024,0.00052805303],"domain_scores_gemma":[0.9981731,0.00013136135,0.0008127353,0.00038859333,0.00032432482,0.0001698572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037526168,0.00037439662,0.0014072879,0.0007180111,0.000012195851,0.000005598174,0.00013142875,0.00018212432,0.00004745355],"category_scores_gemma":[0.00015378556,0.00024712924,0.00008754664,0.0002967969,0.00034465833,0.00006216048,0.00011385923,0.0006159753,0.0000047288504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065346825,0.00018965003,0.26260355,0.0028392232,0.00064219686,0.00012934352,0.0009844154,6.9164514e-7,0.000011285417,0.000003286285,0.7249598,0.006983097],"study_design_scores_gemma":[0.021876143,0.027176643,0.64737374,0.048607312,0.0006723992,0.000004541856,0.0009781923,0.000061655126,0.00060217537,0.0001094164,0.2518942,0.000643573],"about_ca_topic_score_codex":0.0018145338,"about_ca_topic_score_gemma":0.00015571952,"teacher_disagreement_score":0.47306558,"about_ca_system_score_codex":0.00006534532,"about_ca_system_score_gemma":0.00008786872,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W4386461022","doi":"10.1503/cmaj.221691-f","title":"Les inhibiteurs du cotransporteur sodium–glucose de type 2 pour les personnes non diabétiques","year":2023,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; British Columbia Institute of Technology","funders":"","keywords":"Medicine; Gynecology","score_opus":0.013202138020606066,"score_gpt":0.24966099035911454,"score_spread":0.23645885233850847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386461022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8185653,0.0068688113,0.00005475662,0.1609813,0.003849225,0.00027236872,0.00006519114,0.00009309948,0.009249914],"genre_scores_gemma":[0.8924001,0.028491449,0.00018084423,0.008724963,0.015327271,0.000021119735,0.0002134685,0.00009926815,0.054541532],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963175,0.00027198473,0.00054697756,0.00027182445,0.0012511811,0.001340517],"domain_scores_gemma":[0.9963547,0.00028811427,0.00024946668,0.00013144345,0.0004434825,0.0025328186],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0025049178,0.00029711187,0.00045318375,0.00049159396,0.0004978705,0.00015259765,0.00023168248,0.0006975904,0.00839405],"category_scores_gemma":[0.0015971484,0.00029241882,0.00024141627,0.00062861695,0.00010276178,0.00018540824,0.000023443894,0.0010819265,0.0016611814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013530886,0.00010642258,0.43355146,0.00011606064,0.00055085454,0.003086742,0.0019147746,0.000010366622,0.00004557561,0.000501957,0.40378797,0.15631428],"study_design_scores_gemma":[0.002247229,0.0002562226,0.28847116,0.0010775506,0.00059278234,0.00012154909,0.0046672625,0.001144746,0.0001729914,0.00018431981,0.7007554,0.00030875986],"about_ca_topic_score_codex":0.013160185,"about_ca_topic_score_gemma":0.046043675,"teacher_disagreement_score":0.29696745,"about_ca_system_score_codex":0.0028247337,"about_ca_system_score_gemma":0.0029373325,"threshold_uncertainty_score":0.9999528},"labels":[],"label_agreement":null},{"id":"W4386498169","doi":"10.1093/eurheartj/ehad389","title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Heart failure; Heart failure with preserved ejection fraction; Ejection fraction; Internal medicine; Cardiology; Endocrinology; Pharmacology; Bioinformatics","score_opus":0.024202268040883757,"score_gpt":0.2502979869362903,"score_spread":0.22609571889540653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386498169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702126,0.00006732259,0.000114454706,0.0010891708,0.00014897736,0.000277392,0.0000032920263,0.00003966203,0.0012384667],"genre_scores_gemma":[0.99810266,0.000060488663,0.001211149,0.0000821677,0.000103573846,0.0000028917743,0.000019177294,0.000031478445,0.00038643472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988992,0.0001031958,0.0003308227,0.00014141474,0.00033092886,0.0001944122],"domain_scores_gemma":[0.9995207,0.000021534235,0.00013326203,0.00015016574,0.00008522296,0.00008909979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056528277,0.0001140095,0.00026476494,0.00035903353,0.000041738407,0.000013424836,0.000043766846,0.000027605845,0.00010606915],"category_scores_gemma":[0.000014953724,0.00008851513,0.00009621436,0.00037558394,0.000024309898,0.00016748805,0.00001966921,0.0002038581,0.000048974704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009474146,0.0009187079,0.8319581,0.000367035,0.0003723644,0.0002513099,0.00045316518,0.000866335,0.13339601,0.00018960064,0.027220968,0.003059001],"study_design_scores_gemma":[0.002790929,0.0014104797,0.9228406,0.00068927306,0.00011990338,0.0000453765,0.0003622949,0.00006099339,0.06240788,0.000053467575,0.00911976,0.000099036995],"about_ca_topic_score_codex":0.000013047116,"about_ca_topic_score_gemma":0.000021701651,"teacher_disagreement_score":0.09088252,"about_ca_system_score_codex":0.00003725827,"about_ca_system_score_gemma":0.00002502696,"threshold_uncertainty_score":0.36095423},"labels":[],"label_agreement":null},{"id":"W4386545412","doi":"10.1038/s42003-023-05289-w","title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy","year":2023,"lang":"en","type":"article","venue":"Communications Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; McMaster University; Health Sciences Centre; Discovery Centre","funders":"Government of Canada; Canadian Association of Radiation Oncology; Canadian Institutes of Health Research; Hamilton Health Sciences","keywords":"Canagliflozin; Prostate cancer; Cancer research; Medicine; Radiation therapy; Oncology; Internal medicine; Cancer; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.024101601274713176,"score_gpt":0.3414823232464657,"score_spread":0.31738072197175254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386545412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8528646,0.01071326,0.000008198914,0.13439563,0.00014404785,0.0007542249,0.0000329424,0.0001172221,0.0009698506],"genre_scores_gemma":[0.9548065,0.039414898,0.0006440565,0.0009080179,0.00003817854,0.0007412389,0.00005974988,0.000012197767,0.0033751721],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932975,0.00017523974,0.00012726683,0.0001375775,0.000039122016,0.00019107781],"domain_scores_gemma":[0.9984696,0.00066828774,0.000033452183,0.00072069507,0.000045806377,0.00006219669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025576339,0.00008158815,0.00012756368,0.00010189911,0.00027722563,0.000023356444,0.0002545647,0.00003137723,0.000010615173],"category_scores_gemma":[0.00017339781,0.000052424897,0.000021839629,0.0003022355,0.0002315569,0.00002527863,0.00023580015,0.00006355085,0.000021279136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030008596,0.00038119504,0.16651334,0.0001252598,0.0014794891,0.000011288626,0.0071322476,0.000006436883,0.36265376,0.02228913,0.11450639,0.3219006],"study_design_scores_gemma":[0.0008399637,0.00044122786,0.053022403,0.000048350947,0.00006317994,0.0000012958909,0.00044733507,0.00008953109,0.0072952514,0.0005034249,0.937138,0.00011002082],"about_ca_topic_score_codex":0.00025518765,"about_ca_topic_score_gemma":0.0006508782,"teacher_disagreement_score":0.8226316,"about_ca_system_score_codex":0.000037667112,"about_ca_system_score_gemma":0.000051897467,"threshold_uncertainty_score":0.21378252},"labels":[],"label_agreement":null},{"id":"W4386569541","doi":"10.51731/cjht.2023.732","title":"Dapagliflozin","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Reimbursement; Medicine; Kidney disease; Intensive care medicine; Renal function; Drug; Disease; Internal medicine; Pharmacology; Endocrinology; Diabetes mellitus; Economic growth; Health care; Economics","score_opus":0.03969015294780756,"score_gpt":0.2983118014589129,"score_spread":0.25862164851110536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386569541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59633154,0.05004282,0.00008275824,0.34463307,0.001194776,0.00066740083,0.000013771724,0.00082494196,0.006208923],"genre_scores_gemma":[0.9973054,0.0006577388,0.0003573272,0.0006444601,0.000010103032,0.000004167471,0.0000045358315,0.000010041308,0.0010062131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999173,0.000011701377,0.00027506155,0.000070695845,0.000105844294,0.0003636855],"domain_scores_gemma":[0.99953365,0.000018489967,0.0001325108,0.00016638672,0.000060541814,0.000088390596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037746064,0.00007082136,0.00024799028,0.00092668826,0.000096475764,0.000014195103,0.00012548271,0.000055146404,0.000026048489],"category_scores_gemma":[0.0002024998,0.000055052344,0.000059915295,0.00051107846,0.00007885407,0.000048789912,0.00001432893,0.00015558406,0.00008857321],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000052349465,0.000012027635,0.014864832,0.00009590085,0.00009013339,0.0005946861,0.00011076833,0.000004172277,0.000014054185,0.0019570591,0.12118013,0.861071],"study_design_scores_gemma":[0.00070521317,0.00073808496,0.045939732,0.0002512278,0.00003665325,0.00007509688,0.0027006336,0.000013076368,0.00025501987,0.0031049112,0.94610506,0.000075276],"about_ca_topic_score_codex":0.00051747554,"about_ca_topic_score_gemma":0.00055827195,"teacher_disagreement_score":0.8609957,"about_ca_system_score_codex":0.00022683424,"about_ca_system_score_gemma":0.00094293326,"threshold_uncertainty_score":0.22449695},"labels":[],"label_agreement":null},{"id":"W4386584390","doi":"10.1097/01.eem.0000795832.50340.e7","title":"Toxicology Rounds","year":2021,"lang":"en","type":"article","venue":"Emergency Medicine News","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Canagliflozin; Dapagliflozin; Glycosuria; Diabetic ketoacidosis; Diabetes mellitus; Sitagliptin; Type 2 Diabetes Mellitus; Insulin; Pharmacology; Endocrinology; Internal medicine","score_opus":0.041926489825740244,"score_gpt":0.33305963684788586,"score_spread":0.2911331470221456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386584390","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22313704,0.0053883106,0.00028302305,0.036998518,0.0045716395,0.00036164836,0.0000014502743,0.00015655547,0.72910184],"genre_scores_gemma":[0.45614058,0.00499762,0.0008860125,0.0048220702,0.002567539,0.00009679819,0.00026619365,0.000053891512,0.5301693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987309,0.000036169007,0.00036333827,0.00031184056,0.00025689395,0.00030087936],"domain_scores_gemma":[0.99920815,0.00002081842,0.000058997095,0.00041356287,0.000113239694,0.00018520869],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011053557,0.00016028673,0.00036604333,0.000095583564,0.000050779,0.0000017825906,0.000064677406,0.00006273466,0.034191154],"category_scores_gemma":[0.00018802738,0.00012171729,0.00010114231,0.00038098983,0.000046880647,0.00004817337,0.000057195717,0.000105931256,0.0003379889],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041486288,0.0004841972,0.062186383,0.000118955075,0.00037115224,0.00031642962,0.00039544146,0.0000010924717,0.010101171,0.004944614,0.89498997,0.026049085],"study_design_scores_gemma":[0.0022471433,0.0007807152,0.036089897,0.00006308314,0.00045899244,0.00002420696,0.00065541686,0.000024114537,0.0013060035,0.00077025435,0.9574457,0.00013449557],"about_ca_topic_score_codex":0.00005676608,"about_ca_topic_score_gemma":0.00011962492,"teacher_disagreement_score":0.23300354,"about_ca_system_score_codex":0.000055534092,"about_ca_system_score_gemma":0.000059457307,"threshold_uncertainty_score":0.96669173},"labels":[],"label_agreement":null},{"id":"W4386593110","doi":"10.1007/s00592-023-02177-x","title":"Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI","year":2023,"lang":"en","type":"article","venue":"Acta Diabetologica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca Canada","keywords":"Saxagliptin; Medicine; Cardiology; Internal medicine; Ejection fraction; Diastole; Preload; Subclinical infection; Heart failure; Cardiac function curve; Cardiac magnetic resonance imaging; Magnetic resonance imaging; Hemodynamics; Blood pressure; Radiology; Sitagliptin; Insulin","score_opus":0.04236795969518519,"score_gpt":0.26708388810636524,"score_spread":0.22471592841118004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386593110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581325,0.00039124928,0.000035880676,0.0018303299,0.00016954966,0.0005776909,0.000038618742,0.00036688705,0.0007765544],"genre_scores_gemma":[0.9961754,0.00014067804,0.00011461807,0.00023625989,0.00009544051,0.00005260239,0.0010013286,0.000023592815,0.0021600446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998685,0.000100756595,0.00021605182,0.0003750144,0.00022833198,0.00039486727],"domain_scores_gemma":[0.9987549,0.0006464381,0.00008575726,0.00030964086,0.000040131818,0.00016309602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025750545,0.00019898602,0.00040862558,0.00018311135,0.00015028747,0.00007335735,0.0000640112,0.00014779427,0.000055051678],"category_scores_gemma":[0.00036253317,0.00016085275,0.00010762514,0.00039987496,0.000056105273,0.00022108546,0.00009524151,0.0001534313,0.00020007593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012705466,0.00006752019,0.94316834,0.0000397163,0.00019166351,0.000023852412,0.000038037095,8.6283893e-7,0.00031853,0.00016898675,0.054550517,0.0014192892],"study_design_scores_gemma":[0.0006364109,0.00024526133,0.9223313,0.000021371123,0.0006128143,7.6042784e-7,0.00006863129,0.000016678277,0.00026068176,0.0002368802,0.07542088,0.00014834211],"about_ca_topic_score_codex":0.000012087714,"about_ca_topic_score_gemma":0.0000010585384,"teacher_disagreement_score":0.02087036,"about_ca_system_score_codex":0.00005735296,"about_ca_system_score_gemma":0.000015230032,"threshold_uncertainty_score":0.6559385},"labels":[],"label_agreement":null},{"id":"W4386660152","doi":"10.1093/eurheartj/ehab724.2961","title":"Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca","keywords":"Dapagliflozin; Medicine; Internal medicine; Diabetes mellitus; Hazard ratio; Heart failure; Type 2 Diabetes Mellitus; Type 2 diabetes; Cardiology; Endocrinology; Confidence interval","score_opus":0.015873529788144485,"score_gpt":0.23396227950785983,"score_spread":0.21808874971971534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386660152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623936,0.0013994739,5.7484937e-7,0.0003947684,0.000044400753,0.0004239515,0.0000014655978,0.0000026008056,0.0014934008],"genre_scores_gemma":[0.99919224,0.0003551576,0.00006441027,0.0002994243,0.000048560254,0.0000015346006,0.000003935146,0.0000121041985,0.00002261287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984348,0.00061517,0.0002775255,0.00012405142,0.00039412448,0.00015437423],"domain_scores_gemma":[0.9992939,0.00020621257,0.00007664899,0.00029285334,0.00008906988,0.000041273524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012534872,0.000097997654,0.00029035247,0.00007629285,0.000041138755,0.000018394567,0.000088688954,0.000013619386,0.00001638103],"category_scores_gemma":[0.00020258302,0.000049382757,0.000082430866,0.00026462346,0.00006421283,0.00004509792,0.00004439445,0.00021570773,0.000004243732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01879436,0.0032396747,0.92790335,0.00018386218,0.0023602562,0.0003592116,0.004921528,0.0066549345,0.00020159727,0.00024160114,0.0014750711,0.033664536],"study_design_scores_gemma":[0.024383519,0.0014512134,0.9643224,0.00044514562,0.00019441698,0.0000025846623,0.0001457927,0.0000058864493,0.00025911815,0.0000070195724,0.0087259775,0.00005692383],"about_ca_topic_score_codex":0.0000032311236,"about_ca_topic_score_gemma":0.0000011429817,"teacher_disagreement_score":0.036419034,"about_ca_system_score_codex":0.000022657207,"about_ca_system_score_gemma":0.00003767397,"threshold_uncertainty_score":0.20137705},"labels":[],"label_agreement":null},{"id":"W4386660617","doi":"10.1093/eurheartj/ehab724.2649","title":"Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Placebo; Diabetes mellitus; Covariate; Type 2 diabetes; Mediation; Disease; Clinical trial; Confidence interval; Heart failure; Cardiology; Endocrinology; Pathology; Statistics","score_opus":0.018768991625896292,"score_gpt":0.2492968578643199,"score_spread":0.2305278662384236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386660617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978936,0.00064096117,0.0000048379507,0.0006023262,0.00015066894,0.00067720335,0.000010448358,0.0000032608154,0.000016717888],"genre_scores_gemma":[0.9995952,0.000022118911,0.000074825584,0.0001190426,0.00012734045,0.000005719826,0.00003093501,0.00001456589,0.0000102245285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988601,0.00045568997,0.00017243513,0.000115115814,0.00030341055,0.00009322819],"domain_scores_gemma":[0.9993797,0.00018703926,0.000077769924,0.00022258582,0.000074681266,0.00005821926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040211165,0.00008688679,0.00024346753,0.00003380174,0.00005121609,0.000019276815,0.000040661213,0.000011400449,0.000011532194],"category_scores_gemma":[0.00041905412,0.00004234734,0.00017085152,0.00012529673,0.000034399065,0.000048138907,0.000019250772,0.000075309246,0.000001120987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002454552,0.00012584617,0.9938117,0.0000348932,0.0006679925,0.0000018889516,0.00011237339,0.00019619077,0.00037879826,0.0000015673826,0.000811702,0.0014024932],"study_design_scores_gemma":[0.018560002,0.0019962438,0.97575736,0.00027014108,0.00068399985,1.30674e-7,0.000020678,0.0000410081,0.002029349,0.000004895677,0.00059519993,0.000040986462],"about_ca_topic_score_codex":0.0000036376648,"about_ca_topic_score_gemma":0.0000017425499,"teacher_disagreement_score":0.018054336,"about_ca_system_score_codex":0.000023852755,"about_ca_system_score_gemma":0.000026909696,"threshold_uncertainty_score":0.17268744},"labels":[],"label_agreement":null},{"id":"W4386700150","doi":"10.1016/j.jchf.2023.06.036","title":"Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF","year":2023,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Diuretic; Heart failure; Ejection fraction; Internal medicine; Furosemide; Placebo; Population; Cardiology; Randomized controlled trial; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.03279375946446031,"score_gpt":0.2967692754357149,"score_spread":0.26397551597125457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386700150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918723,0.000038123093,0.0000091553575,0.006877486,0.00006877593,0.0007188906,0.0000056720546,0.000072707575,0.00033690166],"genre_scores_gemma":[0.9957863,0.000026417403,0.0021020286,0.00046738112,0.00005231142,0.000024642786,0.000029339528,0.000021786365,0.0014898089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902135,0.000030331084,0.00023502948,0.00025089167,0.0001776777,0.0002847288],"domain_scores_gemma":[0.9993953,0.00015403917,0.000025487649,0.00026321402,0.000026320178,0.00013565035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001964717,0.00013144572,0.00033471218,0.00029506208,0.000032152908,0.000028984437,0.000045696965,0.000059562324,0.000055436773],"category_scores_gemma":[0.00010057357,0.00011293174,0.000048763628,0.00061323005,0.000026625305,0.000113347385,0.00012026979,0.00009488956,0.0001516009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047932952,0.00032625676,0.9260224,0.00035382152,0.00018444883,0.00009786452,0.00077718106,0.00006143539,0.009389731,0.0010014263,0.052421,0.008885073],"study_design_scores_gemma":[0.003296545,0.00031750512,0.89273447,0.00036456154,0.00008514778,0.0000030189017,0.0008638257,0.0000864282,0.0006175877,0.000028673185,0.101470515,0.00013169587],"about_ca_topic_score_codex":0.00007648064,"about_ca_topic_score_gemma":0.00013230914,"teacher_disagreement_score":0.04904952,"about_ca_system_score_codex":0.000040477626,"about_ca_system_score_gemma":0.000021851878,"threshold_uncertainty_score":0.46052226},"labels":[],"label_agreement":null},{"id":"W4386740781","doi":"10.1038/s42255-023-00889-6","title":"Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity","year":2023,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Institutes of Health; Conseil Régional Hauts-de-France; National Natural Science Foundation of China; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; National Institute of General Medical Sciences; Centre National de la Recherche Scientifique; CHIST-ERA; European Commission","keywords":"Endocrinology; Internal medicine; Biology; Type 2 diabetes; Glucose homeostasis; Receptor; Glucagon-like peptide 1 receptor; Insulin; Insulin resistance; Diabetes mellitus; Medicine; Agonist","score_opus":0.006227454656451524,"score_gpt":0.23453807313569275,"score_spread":0.22831061847924122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386740781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928661,0.004006141,0.000010303769,0.00027403358,0.00021933742,0.0010824383,0.000053586424,0.00045097075,0.0010370918],"genre_scores_gemma":[0.9973254,0.000049742255,0.0002718704,0.0004768983,0.00013720056,0.000026654712,0.00019081516,0.000053625827,0.0014677532],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981475,0.00020236391,0.00021207544,0.0004878512,0.0004634139,0.00048682472],"domain_scores_gemma":[0.99889046,0.00016693138,0.00023038968,0.00034819578,0.00012686965,0.00023713347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005949451,0.00033358118,0.00069117185,0.00016506627,0.00027401926,0.00006517338,0.00010493477,0.00033839574,0.000027399758],"category_scores_gemma":[0.00020725657,0.00024003175,0.00010333088,0.00052882894,0.000046461202,0.00014761231,0.0000920879,0.00052646647,0.000017953691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011925754,0.0016552819,0.21656068,0.00042461941,0.0022469766,0.00095600524,0.00089250546,0.000036519912,0.7586275,0.00022596038,0.015253983,0.0019274082],"study_design_scores_gemma":[0.016005272,0.00020672519,0.9460859,0.0003415345,0.0016759296,0.00000310872,0.00012630306,0.00023923605,0.034038167,0.000056370915,0.0009389377,0.00028256097],"about_ca_topic_score_codex":0.00007112713,"about_ca_topic_score_gemma":0.000041390573,"teacher_disagreement_score":0.72952515,"about_ca_system_score_codex":0.00006411153,"about_ca_system_score_gemma":0.000030972038,"threshold_uncertainty_score":0.97882104},"labels":[],"label_agreement":null},{"id":"W4386752574","doi":"10.1002/hsr2.1549","title":"The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis","year":2023,"lang":"en","type":"review","venue":"Health Science Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Systematic review; Repurposing; Glucagon-like peptide 1 receptor; Population; Coronavirus disease 2019 (COVID-19); MEDLINE; Liraglutide; Diabetes mellitus; Disease; Intensive care medicine; Internal medicine; Bioinformatics; Type 2 diabetes; Receptor; Agonist; Endocrinology; Environmental health","score_opus":0.1573230169784394,"score_gpt":0.4450649162182528,"score_spread":0.2877418992398134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386752574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030316005,0.98612213,4.8814553e-7,0.00013290411,0.00003895674,0.010550119,0.0000814578,0.000026784724,0.0000155361],"genre_scores_gemma":[0.0015934356,0.9968163,0.00005134601,0.00015089281,0.000003527714,0.0011089374,0.00012089842,0.000024372419,0.00013030258],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99478775,0.00031734118,0.0023562016,0.00076448574,0.0012511857,0.00052306283],"domain_scores_gemma":[0.99316704,0.00069787883,0.0037180884,0.0015326535,0.00023397311,0.00065037125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005580386,0.00042279475,0.0067762886,0.00069823465,0.00015629147,0.000045980956,0.00018819245,0.00006989939,0.000021506676],"category_scores_gemma":[0.0023353607,0.0001822492,0.0009584213,0.0038699836,0.0003472516,0.00013366168,0.00012486654,0.00015204553,0.0000015337886],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000493553,0.00038006628,0.06962799,0.90003616,0.02829626,0.000016208822,0.000036087225,0.000004820954,4.333636e-9,0.0000046557475,0.00030283988,0.001289966],"study_design_scores_gemma":[0.00030904546,0.0019827962,0.046241146,0.30976292,0.63877374,0.0000045596507,0.000014623134,0.00000952508,3.3691043e-7,0.0000092438895,0.0025291068,0.00036293536],"about_ca_topic_score_codex":0.0005250756,"about_ca_topic_score_gemma":0.000050843806,"teacher_disagreement_score":0.6104775,"about_ca_system_score_codex":0.00067023095,"about_ca_system_score_gemma":0.0024531009,"threshold_uncertainty_score":0.7431907},"labels":[],"label_agreement":null},{"id":"W4386760097","doi":"10.1097/md.0000000000034906","title":"Heart failure and diabetes: Understanding the bidirectional relationship","year":2023,"lang":"en","type":"review","venue":"Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Diabetes mellitus; Heart failure; Insulin resistance; Glycemic; Dyslipidemia; Intensive care medicine; Risk factor; Internal medicine; Diabetic cardiomyopathy; Bioinformatics; Cardiology; Endocrinology; Cardiomyopathy","score_opus":0.19099574629526253,"score_gpt":0.36369068708874636,"score_spread":0.17269494079348383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386760097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011796745,0.9849062,0.000023725894,0.011035758,0.000381356,0.0010719161,0.0000062496915,0.00015716608,0.002405824],"genre_scores_gemma":[0.00015124257,0.98949486,0.00005073324,0.00036905403,0.0007189705,0.00017981831,0.00025170826,0.000059694878,0.008723902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869806,0.000082030165,0.00034804313,0.00030309317,0.00032483166,0.00024396922],"domain_scores_gemma":[0.99854463,0.0009102175,0.00011389876,0.000302529,0.000019962627,0.00010877353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054499746,0.00027512512,0.0010244973,0.0003322043,0.0001815132,0.000017853177,0.00006785845,0.00013018961,0.00013004],"category_scores_gemma":[0.00027547602,0.00013961742,0.00015193126,0.00061722234,0.00020223958,0.000031181175,0.00006357968,0.0003260288,0.00015226091],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008787819,0.00010266674,0.008702593,0.04873034,0.0031691655,0.00006815303,0.00028766316,4.3979202e-7,3.67811e-7,0.017130915,0.6746471,0.24715184],"study_design_scores_gemma":[0.0004212323,0.00015183273,0.0004659428,0.018530583,0.0034063368,0.0000134085085,0.00020229339,0.000005772121,2.6979325e-8,0.000772185,0.97591925,0.0001111465],"about_ca_topic_score_codex":0.0000056538643,"about_ca_topic_score_gemma":0.000008984742,"teacher_disagreement_score":0.30127218,"about_ca_system_score_codex":0.00022491121,"about_ca_system_score_gemma":0.00006234329,"threshold_uncertainty_score":0.5693433},"labels":[],"label_agreement":null},{"id":"W4386883451","doi":"10.1111/joim.13722","title":"Sodium‐glucose cotransporter‐2 inhibitor‐associated erythrocytosis: A retrospective cohort study","year":2023,"lang":"en","type":"letter","venue":"Journal of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Cotransporter; Retrospective cohort study; Sodium; Cohort study; Cohort; Internal medicine; Endocrinology; Intensive care medicine","score_opus":0.016555399574583556,"score_gpt":0.2763507803234276,"score_spread":0.259795380748844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386883451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5284381,0.0015847897,0.000056130782,0.44909972,0.01091949,0.0031389957,0.000056320037,0.00023759781,0.006468858],"genre_scores_gemma":[0.6045145,0.0013786204,0.000061297134,0.32752812,0.030134134,0.00011288454,0.00029812776,0.00038080418,0.035591498],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9936492,0.00017447888,0.0021054684,0.0005651734,0.0028480324,0.0006576449],"domain_scores_gemma":[0.9956873,0.00022820418,0.0021256933,0.00053296564,0.0011337432,0.00029209763],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015389464,0.00075154705,0.0030181631,0.0013267635,0.000073649055,0.000043903954,0.00048175658,0.00052322546,0.00053827744],"category_scores_gemma":[0.0006338295,0.00050897617,0.0006652579,0.0005650887,0.00021943172,0.00016561792,0.00009901159,0.0035232985,0.00010516626],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004266093,0.00071882334,0.2694731,0.00016890114,0.008642256,0.025448484,0.0006301967,2.5168774e-7,0.000082245155,0.0000012626167,0.69403535,0.00037252676],"study_design_scores_gemma":[0.024041194,0.034242198,0.677948,0.016487986,0.020429006,0.0006787146,0.001453669,0.0000135945575,0.00029384106,0.0002016945,0.22343907,0.0007710306],"about_ca_topic_score_codex":0.0002578748,"about_ca_topic_score_gemma":0.000057567882,"teacher_disagreement_score":0.47059628,"about_ca_system_score_codex":0.00156035,"about_ca_system_score_gemma":0.00017600573,"threshold_uncertainty_score":0.9997362},"labels":[],"label_agreement":null},{"id":"W4386884028","doi":"10.1155/2023/9946924","title":"Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management","year":2023,"lang":"en","type":"review","venue":"Advances in Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University; University of Toronto","funders":"","keywords":"Popularity; Medicine; Glucagon-like peptide 1 receptor; Weight management; Medical prescription; Weight loss; Clinical trial; Obesity; Type 2 diabetes; Glucagon-like peptide-1; Intensive care medicine; Diabetes mellitus; Pharmacology; Agonist; Endocrinology; Receptor; Internal medicine; Psychology","score_opus":0.04056175803984855,"score_gpt":0.3845440747368657,"score_spread":0.3439823166970171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386884028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.366139e-7,0.9734665,0.00016893513,0.0005059008,0.003101298,0.006032367,0.00003025883,0.0002353294,0.016458547],"genre_scores_gemma":[6.9993285e-7,0.9372485,0.001864534,0.00026278722,0.0016046896,0.0035426803,0.0018610262,0.00018357695,0.053431503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963418,0.000061699364,0.0011869853,0.0010101318,0.0005649448,0.00083441776],"domain_scores_gemma":[0.9980581,0.00035812735,0.00043522668,0.00088360667,0.00005808478,0.00020689056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061187573,0.00079114997,0.003148201,0.0008577071,0.00008345116,0.000013823236,0.00040191828,0.00022006485,0.00028622436],"category_scores_gemma":[0.00008779095,0.00054952985,0.0004755593,0.0009993787,0.0002152404,0.00014985916,0.00019120616,0.0003446215,0.0005682872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031409803,0.0001247021,0.000007379768,0.090943776,0.0008231219,0.00018942212,0.000031554646,0.000001121171,1.3347056e-7,0.001732452,0.03673147,0.86938345],"study_design_scores_gemma":[0.0032297864,0.0009437114,0.000005398382,0.07725333,0.0038681724,0.000008164063,0.00006342067,0.000007730348,6.696306e-7,0.00033563498,0.9138847,0.00039927152],"about_ca_topic_score_codex":0.0000073063998,"about_ca_topic_score_gemma":0.00004494015,"teacher_disagreement_score":0.8771532,"about_ca_system_score_codex":0.0010441211,"about_ca_system_score_gemma":0.00012386768,"threshold_uncertainty_score":0.9996956},"labels":[],"label_agreement":null},{"id":"W4386987092","doi":"10.1038/s41598-023-42989-z","title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Alberta Innovates; European Society of Cardiology","keywords":"Medicine; Renal function; Internal medicine; Placebo; Meta-analysis; Discontinuation; Heart failure; Randomized controlled trial; Hazard ratio; Relative risk; Diabetes mellitus; Adverse effect; Kidney disease; Acute kidney injury; Confidence interval; Endocrinology","score_opus":0.03834882501351367,"score_gpt":0.2911956641627597,"score_spread":0.25284683914924605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386987092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009261854,0.9909206,0.0000015436085,0.000028496692,0.00029359636,0.00851417,0.000018800118,0.000050666025,0.00007952645],"genre_scores_gemma":[0.000060445887,0.9861901,0.0000928135,0.000040796716,0.0000102759395,0.0015796308,0.00052092446,0.00006383174,0.011441208],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9952345,0.00020061707,0.0016590328,0.0014420055,0.0011134339,0.00035040572],"domain_scores_gemma":[0.9966762,0.000069216265,0.00096852647,0.0019534929,0.00014806581,0.00018449964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032245005,0.0005719334,0.010709271,0.0010643726,0.000088842666,0.0001939844,0.00008654503,0.000108622015,0.000021379601],"category_scores_gemma":[0.00023664592,0.00029354106,0.0027206384,0.0019741948,0.00013785477,0.00010813083,0.00019490704,0.00016235952,0.00001313966],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[7.6079573e-7,0.00008850352,0.00063750683,0.6853338,0.31091952,0.00048005153,0.000017212416,2.5902617e-7,5.160165e-9,0.0000016958759,0.00030915972,0.0022115626],"study_design_scores_gemma":[0.00020364558,0.000058622747,0.00008832754,0.035269693,0.93260854,0.000014848878,0.0000056453287,3.4557056e-7,1.1968488e-7,0.00001107286,0.031475015,0.00026411033],"about_ca_topic_score_codex":0.000030275287,"about_ca_topic_score_gemma":0.000023304889,"teacher_disagreement_score":0.65006405,"about_ca_system_score_codex":0.000110985595,"about_ca_system_score_gemma":0.00009676896,"threshold_uncertainty_score":0.99995166},"labels":[],"label_agreement":null},{"id":"W4387002690","doi":"10.1111/joim.13723","title":"No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes","year":2023,"lang":"en","type":"article","venue":"Journal of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Work & Health; Health Sciences Centre; University Health Network; Toronto General Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; University of Ottawa; Ontario Brain Institute; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Medicine; Metformin; Hazard ratio; Dementia; Diabetes mellitus; Internal medicine; Proportional hazards model; Confounding; Type 2 diabetes; Cohort study; Cohort; Population; Retrospective cohort study; Confidence interval; Disease; Endocrinology; Environmental health","score_opus":0.009615762586892741,"score_gpt":0.2613753125022202,"score_spread":0.25175954991532745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387002690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962111,0.00050741865,0.00005837741,0.0016804253,0.0002584571,0.00027480134,0.000001616249,0.000016471082,0.0009912952],"genre_scores_gemma":[0.99775594,0.00041744226,0.00022233994,0.00048790628,0.00054924656,0.000010962568,0.000019207073,0.000015375981,0.00052158703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845195,0.000041841766,0.0005796117,0.00012012798,0.00058404094,0.000222415],"domain_scores_gemma":[0.9986808,0.000301118,0.0005545196,0.00007653811,0.00025214223,0.00013489574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008950181,0.00013803228,0.00045798332,0.000571628,0.00002026262,0.000015442138,0.0000698055,0.000052486914,0.0000838674],"category_scores_gemma":[0.000556562,0.0000876297,0.00004735673,0.00029062678,0.000027496393,0.00022811386,0.00003748271,0.00020425137,0.000017308499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020329516,0.00008524134,0.9800029,0.000113701084,0.00062876684,0.000296425,0.00073879224,0.0000024270378,0.00014758215,0.000006678705,0.0040050927,0.013769118],"study_design_scores_gemma":[0.01095028,0.0024683096,0.9803719,0.0031962795,0.0007580865,0.0000078935,0.0004688593,0.00012926248,0.0003447794,0.00004494192,0.0011829957,0.00007641032],"about_ca_topic_score_codex":0.00006688638,"about_ca_topic_score_gemma":0.00004699863,"teacher_disagreement_score":0.013692708,"about_ca_system_score_codex":0.00022868213,"about_ca_system_score_gemma":0.000028770773,"threshold_uncertainty_score":0.35734352},"labels":[],"label_agreement":null},{"id":"W4387008365","doi":"10.1016/j.ahj.2023.09.007","title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics","year":2023,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Type 2 diabetes; Disease; Adverse effect; Internal medicine; Diabetes mellitus; Dulaglutide; Cardiology; Baseline (sea); Atherosclerotic cardiovascular disease; Exenatide; Endocrinology","score_opus":0.04428377292565371,"score_gpt":0.2943771667910323,"score_spread":0.2500933938653786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387008365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974076,0.0017870441,0.000102945494,0.00015485543,0.000045012723,0.00047033807,0.0000075778494,0.000020099213,0.0000045362344],"genre_scores_gemma":[0.99755687,0.0015777799,0.0006393203,0.00008618061,0.00004404876,0.000021179301,0.000014069824,0.000029590807,0.000030979085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983798,0.00026588843,0.00030445948,0.00026488947,0.0004168049,0.00036814227],"domain_scores_gemma":[0.9990847,0.0001591096,0.00009803513,0.0002661253,0.00006800261,0.0003240183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009191615,0.0001896313,0.0008716705,0.00020206285,0.00007323663,0.000013612642,0.00003487576,0.000021294916,0.0000064307396],"category_scores_gemma":[0.000150426,0.0001471296,0.00012286304,0.00032843495,0.00017922322,0.000067929555,0.000044827517,0.00014202997,0.0000048582197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026472917,0.00013077038,0.98610014,0.00010742373,0.0017497686,0.000092216804,0.00019139469,0.000641534,0.00019062414,0.0000018327687,0.00008130699,0.010448238],"study_design_scores_gemma":[0.001734849,0.0011746136,0.99001825,0.00042494168,0.0015606682,0.000008748656,0.00026811266,0.0040394627,0.00013996176,0.000007794247,0.00047861418,0.00014400134],"about_ca_topic_score_codex":0.00006400867,"about_ca_topic_score_gemma":0.0000043651153,"teacher_disagreement_score":0.010304237,"about_ca_system_score_codex":0.000040591214,"about_ca_system_score_gemma":0.00004737769,"threshold_uncertainty_score":0.5999771},"labels":[],"label_agreement":null},{"id":"W4387173793","doi":"10.1097/xce.0000000000000293","title":"Success story of GLP-1 agonist (Liraglutide) treatment in someone with type 1 diabetes: a life transformed","year":2023,"lang":"en","type":"article","venue":"Cardiovascular Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Liraglutide; Gastric emptying; Endocrinology; Internal medicine; Agonist; Glucagon-like peptide-1; Incretin; Medicine; Insulin; Type 2 diabetes; Glucagon-like peptide 1 receptor; Glucagon; Diabetes mellitus; Receptor; Stomach","score_opus":0.018198621826070457,"score_gpt":0.24771820859941876,"score_spread":0.2295195867733483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387173793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95635337,0.039076623,0.00002326035,0.0005414733,0.0004445906,0.0012963818,0.000018612427,0.00021631015,0.002029371],"genre_scores_gemma":[0.9891757,0.008472549,0.00018151978,0.00015891662,0.00015328612,0.000446514,0.00016282908,0.000067589805,0.0011811323],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974028,0.0002549719,0.0003939717,0.0005976227,0.0004491866,0.00090144965],"domain_scores_gemma":[0.9985728,0.0000887795,0.000078993224,0.0009371404,0.000119378856,0.00020287519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036274065,0.00040590923,0.0016902541,0.0007263663,0.00008681472,0.000011999019,0.00017284582,0.0001129482,0.000055594708],"category_scores_gemma":[0.00007428019,0.00030900995,0.0007682272,0.0010570474,0.000291696,0.00011271966,0.000058901627,0.0002616104,0.00011013952],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020369394,0.0033206928,0.22690053,0.002034884,0.092914864,0.0063107125,0.0037360587,0.0025449712,0.0071527218,0.0048700217,0.0016867643,0.6464908],"study_design_scores_gemma":[0.024764901,0.0014336492,0.6115298,0.00018213278,0.009608264,0.000041489056,0.0007701235,0.000075191725,0.01738377,0.00008851935,0.33347484,0.00064728153],"about_ca_topic_score_codex":0.00014758245,"about_ca_topic_score_gemma":0.000057007157,"teacher_disagreement_score":0.64584357,"about_ca_system_score_codex":0.00014297738,"about_ca_system_score_gemma":0.00025772688,"threshold_uncertainty_score":0.9999362},"labels":[],"label_agreement":null},{"id":"W4387188597","doi":"10.1152/ajpheart.00141.2023","title":"Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling","year":2023,"lang":"en","type":"article","venue":"American Journal of Physiology-Heart and Circulatory Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of British Columbia; University of Toronto; Robarts Clinical Trials; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Proinflammatory cytokine; Aldehyde dehydrogenase; Diabetes mellitus; Progenitor cell; CD14; Medicine; CD34; Flow cytometry; Cancer research; Immunology; Chemistry; Stem cell; Inflammation; Endocrinology; Cell biology; Type 2 diabetes; Biology; Biochemistry; Enzyme","score_opus":0.016329497724366714,"score_gpt":0.24118904041071695,"score_spread":0.22485954268635025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387188597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987282,0.00036360355,0.000006441233,0.00007702437,0.00018776809,0.00057084975,0.000013041461,0.000035863595,0.000017221828],"genre_scores_gemma":[0.9986462,0.00018691734,0.00057017297,0.000231517,0.00019536857,0.00004774772,0.00004882911,0.000044516815,0.000028759248],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981006,0.00022413945,0.00049095595,0.0004761476,0.00017050601,0.00053764327],"domain_scores_gemma":[0.99855804,0.00026340305,0.0005245411,0.00028719354,0.00019233093,0.00017448577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039811298,0.00031829605,0.0013269617,0.00030200958,0.00013886932,0.000008189352,0.00009060568,0.00007825141,0.0000054933266],"category_scores_gemma":[0.0000640994,0.00023015609,0.00035987655,0.00034258582,0.0003270046,0.00011637685,0.000053375188,0.00028634752,0.0000034516797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016391178,0.00010564209,0.19152403,0.00008705912,0.0006090987,5.2241404e-7,0.00077429565,0.0015377747,0.8047969,0.00001156594,0.000056847864,0.00033239022],"study_design_scores_gemma":[0.0023043128,0.0023775685,0.98272866,0.000098748846,0.0005581573,0.000002070608,0.004909052,0.0023690173,0.004092842,0.00015551726,0.00015635754,0.00024770404],"about_ca_topic_score_codex":0.00010088877,"about_ca_topic_score_gemma":0.000008233225,"teacher_disagreement_score":0.800704,"about_ca_system_score_codex":0.000086136475,"about_ca_system_score_gemma":0.00010383588,"threshold_uncertainty_score":0.9385493},"labels":[],"label_agreement":null},{"id":"W4387210122","doi":"10.1111/hdi.13113","title":"Metformin‐associated lactic acidosis (<scp>MALA</scp>): Is it an underestimated entity? A retrospective, single‐center case series","year":2023,"lang":"en","type":"review","venue":"Hemodialysis International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Single Center; Metformin; Lactic acidosis; Hemodialysis; Series (stratigraphy); Retrospective cohort study; Diabetes mellitus; Acidosis; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.08954737690254437,"score_gpt":0.35812408647601607,"score_spread":0.2685767095734717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387210122","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011352916,0.9040434,0.00020819265,0.0014662711,0.0054244045,0.006027428,0.004378308,0.0021741844,0.0649249],"genre_scores_gemma":[0.0025835217,0.93273085,0.0005843973,0.0004064511,0.0004930867,0.0004986978,0.009116158,0.00023442062,0.053352404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996221,0.00015149351,0.001027838,0.000999651,0.0010132829,0.0005867243],"domain_scores_gemma":[0.9975452,0.00026076497,0.000781756,0.0006933836,0.0004466223,0.0002722699],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041739354,0.0007727083,0.0021480164,0.001198283,0.00018195414,0.00036222814,0.0003978135,0.00041702305,0.0008933394],"category_scores_gemma":[0.0008344857,0.000682958,0.0012349209,0.0010540566,0.00011017863,0.00062435697,0.00033601114,0.0004186797,0.0009811196],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001377257,0.012628405,0.012833524,0.016989231,0.12562782,0.02596633,0.0024176103,0.0000068284135,0.000015140508,0.0021608865,0.14338376,0.65783274],"study_design_scores_gemma":[0.0021375243,0.00043659675,0.00010084009,0.005414291,0.018111655,0.0017115605,0.00030531193,0.00035417316,0.000029502797,0.00026926902,0.97068626,0.0004430106],"about_ca_topic_score_codex":0.00008834023,"about_ca_topic_score_gemma":0.00035570175,"teacher_disagreement_score":0.8273025,"about_ca_system_score_codex":0.0020078,"about_ca_system_score_gemma":0.0001672476,"threshold_uncertainty_score":0.99979675},"labels":[],"label_agreement":null},{"id":"W4387337682","doi":"10.1016/j.cjca.2023.06.344","title":"REAL-WORLD USE OF GUIDELINE-DIRECTED CARDIOPROTECTIVE THERAPY IN TYPE 2 DIABETES MELLITUS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A RETROSPECTIVE COHORT ANALYSIS USING ADMINISTRATIVE HEALTH DATA","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Stroke (engine); Diabetes mellitus; Type 2 Diabetes Mellitus; Atherosclerotic cardiovascular disease; Internal medicine; Guideline; Type 2 diabetes; Disease; Cohort; Intensive care medicine; Macrovascular disease; Endocrinology; Pathology","score_opus":0.0902160636538988,"score_gpt":0.32363223749247527,"score_spread":0.2334161738385765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305344,0.004237526,0.00042125216,0.00032166127,0.0002296952,0.0011690604,0.00029953642,0.000028091099,0.00023972841],"genre_scores_gemma":[0.9963479,0.0021647308,0.0008736006,0.00006282158,0.000185104,0.00001406226,0.00026062437,0.0000350895,0.00005608862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750334,0.0004719789,0.00069447624,0.00043013308,0.0003794396,0.0005206448],"domain_scores_gemma":[0.9973569,0.00009417549,0.00036191058,0.0009439275,0.0006746025,0.00056850165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014494148,0.00024315275,0.00192457,0.001510799,0.00007203507,0.000022530903,0.00021654429,0.00006775659,0.000010686728],"category_scores_gemma":[0.00027183912,0.00019260959,0.0004657058,0.0028897836,0.0002141425,0.00015347522,0.000034243367,0.00023855861,0.0000013521774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026770993,0.000011473872,0.93462515,0.000030143796,0.031465016,0.000499031,0.00016824547,0.02921394,0.000023537274,0.00002310166,0.0010786145,0.0025940198],"study_design_scores_gemma":[0.0013042215,0.0009385429,0.9859193,0.00015770223,0.00420181,0.000007300272,0.00015363499,0.0016216135,0.000025243276,0.00003388691,0.0054749306,0.00016180775],"about_ca_topic_score_codex":0.011705486,"about_ca_topic_score_gemma":0.008863595,"teacher_disagreement_score":0.05129414,"about_ca_system_score_codex":0.0008558235,"about_ca_system_score_gemma":0.0024579677,"threshold_uncertainty_score":0.99487567},"labels":[],"label_agreement":null},{"id":"W4387337777","doi":"10.1016/j.cjca.2023.06.243","title":"LOW-DOSE EMPAGLIFLOZIN AS ADJUNCT TO HYBRID CLOSED-LOOP INSULIN THERAPY IN SUB-OPTIMALLY CONTROLLED ADULTS WITH TYPE 1 DIABETES: A RANDOMIZED CROSSOVER CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Adjunct; Type 2 diabetes; Diabetes mellitus; Crossover study; Closed loop; Randomized controlled trial; Insulin; Placebo; Internal medicine; Endocrinology","score_opus":0.009511147499518754,"score_gpt":0.24161120832579458,"score_spread":0.23210006082627582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98521477,0.0016256431,0.000019183166,0.0015798056,0.001236183,0.0068116193,0.000016173219,0.000023568577,0.0034730337],"genre_scores_gemma":[0.9954825,0.00070951704,0.000045505272,0.0016333872,0.00080420537,0.0004111423,0.00004267648,0.00005232106,0.00081872335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968901,0.00057907787,0.0010473785,0.00032795998,0.0003225878,0.0008328585],"domain_scores_gemma":[0.9972299,0.00070613984,0.00037728078,0.0003214775,0.00049394736,0.00087126944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019550866,0.00037407567,0.0037635847,0.0012353318,0.00007060432,0.000056642984,0.00022257025,0.00014048997,0.000097123986],"category_scores_gemma":[0.0017191614,0.00024343471,0.00075477996,0.0005865204,0.00019878402,0.000093606504,0.000018709612,0.0003362312,0.00015572447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97665906,0.000045265955,0.0014912498,0.000018479437,0.0038421554,0.0022723086,0.00023552032,0.001387573,0.0001718807,0.000028545579,0.009193517,0.0046544196],"study_design_scores_gemma":[0.98158634,0.008244338,0.0024698116,0.00023553148,0.0006905864,0.00003476666,0.000099922676,0.00015873731,0.00012517364,0.00006834256,0.006052006,0.00023442358],"about_ca_topic_score_codex":0.00026188442,"about_ca_topic_score_gemma":0.000955551,"teacher_disagreement_score":0.010267732,"about_ca_system_score_codex":0.0002750558,"about_ca_system_score_gemma":0.0019687868,"threshold_uncertainty_score":0.99269795},"labels":[],"label_agreement":null},{"id":"W4387337818","doi":"10.1016/j.cjca.2023.06.316","title":"IMPACT OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ON QUALITY OF LIFE IN HEART FAILURE ACROSS THE EJECTION FRACTION SPECTRUM: SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Medicine; Ejection fraction; Heart failure; Fraction (chemistry); Internal medicine; Cardiology; Broad spectrum; Quality of life (healthcare); Cotransporter; Sodium; Chromatography","score_opus":0.0422549483948191,"score_gpt":0.3284586281701882,"score_spread":0.28620367977536915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98529416,0.009757524,0.0000325551,0.0040909937,0.000065586035,0.0006140581,0.000050682673,0.000003564876,0.000090860194],"genre_scores_gemma":[0.99909943,0.00060934934,0.000006483152,0.00018233448,0.000044386303,0.000010884641,0.000012189733,0.000006391787,0.000028551342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984079,0.00035810596,0.000792094,0.000105149666,0.0001501272,0.00018659548],"domain_scores_gemma":[0.998869,0.00013573284,0.0004813826,0.00022915138,0.000106406646,0.00017833592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017338891,0.0001150764,0.0023030222,0.00042550484,0.00003079619,0.000006241693,0.00005805798,0.000061955725,0.000024741887],"category_scores_gemma":[0.00020301789,0.00006520422,0.001151728,0.00062857085,0.000078651276,0.00005073783,0.000004445984,0.00015429464,0.0000022551035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013248366,0.000026964553,0.78138995,0.022949327,0.18735947,0.00007098829,0.00037673058,0.0015968707,0.00017042355,0.00006180383,0.005830997,0.000033975208],"study_design_scores_gemma":[0.000844868,0.0008470338,0.8043622,0.00074446155,0.19213232,0.000025157256,0.0005814587,0.0000071416616,0.000077839395,0.00005374714,0.00022579436,0.00009797851],"about_ca_topic_score_codex":0.0031293267,"about_ca_topic_score_gemma":0.007348847,"teacher_disagreement_score":0.022972219,"about_ca_system_score_codex":0.00014265414,"about_ca_system_score_gemma":0.00017897662,"threshold_uncertainty_score":0.4730627},"labels":[],"label_agreement":null},{"id":"W4387337822","doi":"10.1016/j.cjca.2023.06.226","title":"SAFETY AND EFFICACY OF TIRZEPATIDE FOR SURPASS-2 THROUGH -5 PARTICIPANTS OVER 65 YEARS OLD WITH BMI BELOW 30 KG/M2: A POST HOC ANALYSIS","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Post-hoc analysis; Type 2 diabetes; Post hoc; Weight loss; Obesity; Agonist; Internal medicine; Diabetes mellitus; Weight management; Body weight; Glucagon-like peptide-1; Endocrinology; Hypoglycemia; Receptor","score_opus":0.022279151095415464,"score_gpt":0.2747368635259882,"score_spread":0.25245771243057274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723446,0.00034840274,0.00027149383,0.0009616934,0.00011922239,0.0002719853,0.00009741236,0.000006816637,0.0006885362],"genre_scores_gemma":[0.9986741,0.00019607674,0.00026468636,0.00024783457,0.0001489031,0.000006828097,0.00004982601,0.00001701919,0.00039475417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989419,0.000052874886,0.0003319409,0.00015090434,0.00012454376,0.00039783985],"domain_scores_gemma":[0.9989663,0.00017258052,0.00017250165,0.00018098447,0.00016321748,0.00034441042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003523941,0.00011985156,0.0007762023,0.00042680756,0.000045489593,0.000010055969,0.00007434359,0.000066953304,0.000034977253],"category_scores_gemma":[0.00013236841,0.00009348489,0.00024787616,0.00042116464,0.00013513857,0.00005704163,0.000013216147,0.00008315941,0.0000046198043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014696656,0.000021523274,0.941932,0.00011343509,0.020009886,0.0010730076,0.00126233,0.0032731274,0.00012422615,0.0007051734,0.0132590225,0.016756557],"study_design_scores_gemma":[0.0041574393,0.0017443654,0.9292636,0.000062560764,0.0048073316,0.000020754005,0.00020794454,0.00006177022,0.00002700864,0.000047109967,0.05949521,0.00010491052],"about_ca_topic_score_codex":0.0008334183,"about_ca_topic_score_gemma":0.0039425734,"teacher_disagreement_score":0.046236187,"about_ca_system_score_codex":0.00009564496,"about_ca_system_score_gemma":0.0003221898,"threshold_uncertainty_score":0.3812203},"labels":[],"label_agreement":null},{"id":"W4387337840","doi":"10.1016/j.cjca.2023.06.219","title":"IMPROVED GLYCEMIC MANAGEMENT WITH ONCE-WEEKLY INSULIN ICODEC WITH A DOSING GUIDE APP VS ONCE-DAILY BASAL INSULIN ANALOGS IN INSULIN-NAÏVE TYPE 2 DIABETES: ONWARDS 5","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Insulin glargine; Glycemic; Dosing; Insulin; Basal insulin; Insulin degludec; Type 2 diabetes; Basal (medicine); Diabetes mellitus; Diabetes management; Internal medicine; Endocrinology","score_opus":0.01178211822671012,"score_gpt":0.23562010139803818,"score_spread":0.22383798317132805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774668,0.0016776896,0.00041095386,0.003923348,0.0006714368,0.0010075129,0.000038576363,0.000071258684,0.01473241],"genre_scores_gemma":[0.9940778,0.0008071048,0.0016089513,0.0017528137,0.00051214563,0.00004533748,0.00009718558,0.000085256914,0.0010133979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969916,0.0001610391,0.00082262483,0.0005058736,0.00038284867,0.0011360444],"domain_scores_gemma":[0.99782044,0.00010079331,0.00035978822,0.00051892264,0.00036367346,0.0008363561],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007245006,0.00045224506,0.0012800569,0.0016280578,0.00011888854,0.00006343182,0.00037437267,0.00021099696,0.00003165024],"category_scores_gemma":[0.00011518796,0.00034916605,0.00019948988,0.0015666707,0.0002992106,0.00019170216,0.00006808162,0.00058670086,0.000053371597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015193931,0.00024070789,0.5766025,0.00109755,0.014666502,0.03308169,0.0028328837,0.022453625,0.00091530697,0.0007730222,0.115946494,0.21619578],"study_design_scores_gemma":[0.041545536,0.02237052,0.5520628,0.0025680314,0.0029527314,0.0003951289,0.0033790017,0.0015788584,0.00029629187,0.0004271869,0.37091333,0.0015105703],"about_ca_topic_score_codex":0.001266279,"about_ca_topic_score_gemma":0.0051737614,"teacher_disagreement_score":0.25496686,"about_ca_system_score_codex":0.0008766487,"about_ca_system_score_gemma":0.001653415,"threshold_uncertainty_score":0.99989605},"labels":[],"label_agreement":null},{"id":"W4387337843","doi":"10.1016/j.cjca.2023.06.225","title":"PREVALANCE OF STATIN USE IN YOUNG ADULTS WITH TYPE 1 DIABETES IN A SINGLE TERTIARY DIABETES CENTRE IN LONDON, ONTARIO","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Statin; Diabetes mellitus; Type 2 diabetes; Guideline; Disease; Internal medicine; Physical therapy; Endocrinology","score_opus":0.010512919083325915,"score_gpt":0.2002804141988176,"score_spread":0.18976749511549168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825555,0.00042894934,7.2505446e-7,0.00029237676,0.00016586593,0.00026686947,0.000009441588,0.000003928181,0.0005763036],"genre_scores_gemma":[0.9994188,0.000046779256,0.00009046144,0.00007714954,0.000043671516,0.000005913121,0.000027990485,0.000014968936,0.00027429577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987936,0.000098473254,0.0003948503,0.00014679524,0.00010397508,0.00046231796],"domain_scores_gemma":[0.9993499,0.00009893977,0.00012835547,0.00014306245,0.000095495365,0.00018427873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028395778,0.0001260738,0.00057902077,0.00080826075,0.000009114262,0.000009002774,0.00008797456,0.00006788827,0.00001679096],"category_scores_gemma":[0.00014049187,0.00010477848,0.00005787486,0.0004515947,0.00007221137,0.0001134516,0.00001331142,0.0002048291,0.0000039608735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010911496,0.000016779182,0.9944052,0.000078575926,0.00012995348,0.00067889487,0.000948594,0.00096838106,0.00021496996,0.000005429465,0.001105801,0.0013382792],"study_design_scores_gemma":[0.0027231802,0.0006266618,0.9936081,0.00081160903,0.000059143378,0.000005744583,0.0002474345,0.00004259555,0.0002058877,0.00003289991,0.0015484929,0.00008825497],"about_ca_topic_score_codex":0.017759731,"about_ca_topic_score_gemma":0.7853754,"teacher_disagreement_score":0.76761574,"about_ca_system_score_codex":0.00047815198,"about_ca_system_score_gemma":0.00053582137,"threshold_uncertainty_score":0.9887811},"labels":[],"label_agreement":null},{"id":"W4387337850","doi":"10.1016/j.cjca.2023.06.335","title":"ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG IN ADOLESCENTS WITH OVERWEIGHT OR OBESITY","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Semaglutide; Overweight; Percentile; Body mass index; Obesity; Comorbidity; Physical therapy; Pediatrics; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.014266878433607268,"score_gpt":0.2301047949056542,"score_spread":0.21583791647204692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916721,0.00027302824,0.000039882212,0.0013316524,0.0003732202,0.00022214752,0.000007630656,0.000013851875,0.0060664876],"genre_scores_gemma":[0.9974486,0.00007946222,0.00005910876,0.00035348296,0.00032741344,0.000003357097,0.000006127423,0.00001770748,0.0017046924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989309,0.00006553689,0.0002561751,0.0001423141,0.00014128661,0.0004638375],"domain_scores_gemma":[0.99913865,0.000023420858,0.00009339864,0.00017195848,0.00008949929,0.0004830414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022340246,0.00013381727,0.0005242665,0.00053816376,0.000042285737,0.000011508692,0.000114197566,0.00007990659,0.000024825194],"category_scores_gemma":[0.00006046237,0.00009245939,0.00010806842,0.0003680637,0.00009112715,0.00003972719,0.000013140491,0.00020916773,0.000056956153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005046916,0.000012772701,0.9325222,0.00008104771,0.000336488,0.04248895,0.00013296005,0.0005669205,0.000044467743,0.000070662136,0.018351236,0.0048876284],"study_design_scores_gemma":[0.0032907694,0.0022631937,0.896679,0.00067269854,0.0003063949,0.0022642673,0.00029829924,0.000025743768,0.000038507584,0.00011587683,0.09387452,0.00017074117],"about_ca_topic_score_codex":0.00066229847,"about_ca_topic_score_gemma":0.011298745,"teacher_disagreement_score":0.07552328,"about_ca_system_score_codex":0.00035061073,"about_ca_system_score_gemma":0.000854317,"threshold_uncertainty_score":0.6304965},"labels":[],"label_agreement":null},{"id":"W4387337855","doi":"10.1016/j.cjca.2023.06.218","title":"IMPROVED A1C AND TIME IN RANGE WITH ONCE-WEEKLY INSULIN ICODEC VERSUS INSULIN GLARGINE U100 IN INSULIN-NAÏVE TYPE 2 DIABETES: ONWARDS 1","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin glargine; Insulin; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Hypoglycemia","score_opus":0.014891996372859562,"score_gpt":0.23334290572496805,"score_spread":0.21845090935210848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989947,0.003160206,0.000006639621,0.0029055832,0.0004670328,0.00041497964,0.000027462365,0.000018181794,0.0030528733],"genre_scores_gemma":[0.9977145,0.00085555244,0.00015757425,0.00040066885,0.0003554347,0.000016738322,0.000053098378,0.00003736592,0.00040904636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834317,0.0001251193,0.0004660636,0.00026561084,0.00015715417,0.00064288435],"domain_scores_gemma":[0.99879384,0.0001403096,0.00014233506,0.00023481977,0.00016103286,0.0005276509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062146364,0.00024032852,0.00090817956,0.0011389949,0.000039359827,0.000023132825,0.00015215008,0.0001802361,0.000034015124],"category_scores_gemma":[0.0002501092,0.0001994812,0.00009429244,0.0008608343,0.0001680669,0.000117421034,0.000034136425,0.00040967303,0.000048167218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007523045,0.00011781418,0.7952679,0.00034472535,0.0034157892,0.011518973,0.002297998,0.0026524393,0.0011873977,0.00024709737,0.026560873,0.148866],"study_design_scores_gemma":[0.03425093,0.0075779725,0.83964205,0.00047236992,0.0005134223,0.000083365776,0.00049721374,0.0010249557,0.00009370106,0.00016649957,0.11518599,0.00049150654],"about_ca_topic_score_codex":0.00078405195,"about_ca_topic_score_gemma":0.0052931127,"teacher_disagreement_score":0.14837448,"about_ca_system_score_codex":0.00043260693,"about_ca_system_score_gemma":0.0009551129,"threshold_uncertainty_score":0.81346077},"labels":[],"label_agreement":null},{"id":"W4387337873","doi":"10.1016/j.cjca.2023.06.347","title":"RENAL TUBULE-SPECIFIC ANGIOTENSINOGEN KNOCKOUT AMELIORATES DIABETIC KIDNEY DISEASE IN TYPE 1 DIABETIC AKITA MICE","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Renin–angiotensin system; Internal medicine; Endocrinology; Kidney; Diabetes mellitus; Disease; Proximal tubule; Kidney disease; Knockout mouse; Type 2 diabetes; Receptor; Blood pressure","score_opus":0.019948640252757475,"score_gpt":0.2366999434858278,"score_spread":0.21675130323307032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846525,0.004851363,0.000014613636,0.0059808204,0.001296699,0.00031552822,0.00004345717,0.00002483166,0.0028201481],"genre_scores_gemma":[0.9972221,0.000429293,0.000069968155,0.0007011691,0.00075870345,0.0000071395325,0.000084644584,0.00003467733,0.0006922902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840546,0.00012797903,0.00041346098,0.00023204199,0.00016288963,0.00065819675],"domain_scores_gemma":[0.9978019,0.00007915918,0.00011270235,0.00028738272,0.00021664285,0.0015022288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035376058,0.00019986344,0.00065174524,0.0010483296,0.00005989196,0.000030004696,0.00017397336,0.00010273006,0.000072565716],"category_scores_gemma":[0.00032856636,0.0001761389,0.00023132168,0.00075353717,0.00015997908,0.00007316104,0.000027329585,0.00023846686,0.0002654554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024485556,0.000020497986,0.5589829,0.000095827665,0.0009429651,0.010743156,0.00027483888,0.0018080906,0.0020519143,0.0003489067,0.41252494,0.011961075],"study_design_scores_gemma":[0.0019655628,0.0005240051,0.6069473,0.00027432377,0.0004680218,0.000053324587,0.00009515943,0.0000629461,0.00016945846,0.0006253672,0.38858196,0.00023258523],"about_ca_topic_score_codex":0.00016002438,"about_ca_topic_score_gemma":0.00017719899,"teacher_disagreement_score":0.047964353,"about_ca_system_score_codex":0.00028012448,"about_ca_system_score_gemma":0.0010442487,"threshold_uncertainty_score":0.7182736},"labels":[],"label_agreement":null},{"id":"W4387337918","doi":"10.1016/j.cjca.2023.06.194","title":"ANTIHYPERGLYCEMIC MEDICATION INITIATION AFTER CARDIOVASCULAR HOSPITALIZATION IN OLDER ADULTS WITH DIABETES INCREASES HYPOGLYCEMIA WITHOUT IMPROVING SURVIVAL","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Hypoglycemia; Diabetes mellitus; Disease; Intensive care medicine; Type 2 diabetes; Population; Emergency medicine; Pediatrics; Internal medicine; Endocrinology; Environmental health","score_opus":0.0061230042023349245,"score_gpt":0.20278252002816458,"score_spread":0.19665951582582966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969936,0.0011234838,0.00041783627,0.0002037493,0.00030916723,0.00034203916,0.000008258383,0.000019095422,0.0005827687],"genre_scores_gemma":[0.9990925,0.00013318346,0.00006953229,0.000092366216,0.00039629388,0.000039120983,0.000120466924,0.000026650945,0.000029862618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987906,0.00011267781,0.00031908756,0.0001894188,0.00023956095,0.00034861703],"domain_scores_gemma":[0.9991177,0.000053312524,0.00013404846,0.00020849935,0.00020591496,0.000280544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047127766,0.00014679949,0.0005514282,0.00073463895,0.000045504577,0.000013622183,0.000077626166,0.00010864369,0.000011289493],"category_scores_gemma":[0.00020400512,0.00012001181,0.00016297531,0.00039754112,0.000100823134,0.00016835728,0.000012041399,0.00013939063,0.00000986625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002012877,0.0000053375275,0.9935415,0.00008643318,0.00050752284,0.00052159815,0.00019597482,0.00050144567,0.000024144403,0.000009149382,0.00026201434,0.0041436395],"study_design_scores_gemma":[0.0039850804,0.00047191637,0.99277675,0.00032879203,0.0005339318,0.000049629038,0.00029498443,0.00015668976,0.000049997016,0.000017628028,0.0012047135,0.00012988836],"about_ca_topic_score_codex":0.00070363336,"about_ca_topic_score_gemma":0.0012311141,"teacher_disagreement_score":0.004013751,"about_ca_system_score_codex":0.00022860011,"about_ca_system_score_gemma":0.00053734216,"threshold_uncertainty_score":0.48939398},"labels":[],"label_agreement":null},{"id":"W4387338007","doi":"10.1016/j.cjca.2023.06.215","title":"IMPACT OF GLP-1 RECEPTOR AGONISTS COMPARED TO BASAL INSULIN START ON METABOLIC TARGETS IN PEOPLE LIVING WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (IMPACT GLP-1 CKD)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Type 2 diabetes; Kidney disease; Glucagon-like peptide 1 receptor; Internal medicine; Basal (medicine); Basal insulin; Diabetes mellitus; Glycemic; Endocrinology; Agonist; Insulin; Receptor","score_opus":0.012046893480577862,"score_gpt":0.258867247020885,"score_spread":0.24682035354030712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625784,0.0019589479,0.0000052518135,0.0007376528,0.0002474969,0.00032350715,0.00013140988,0.000008817247,0.00032906022],"genre_scores_gemma":[0.9989728,0.00030284002,0.000043381304,0.00020792506,0.00029648197,0.000008980644,0.00006624172,0.000027863338,0.00007348353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986737,0.00012825923,0.00030730368,0.00018926781,0.00015388621,0.00054759654],"domain_scores_gemma":[0.9977637,0.00010434105,0.00012977791,0.00021359064,0.0001435463,0.0016450342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033778627,0.0002082327,0.000871363,0.00083257724,0.00004326696,0.000019363488,0.00010885887,0.000055464414,0.00010205942],"category_scores_gemma":[0.00041635853,0.00015045376,0.00018295847,0.00054831244,0.00008265728,0.00007419963,0.000024079427,0.00016906003,0.000021435628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036619665,0.00001854604,0.9655372,0.00006403001,0.0010978852,0.00015944667,0.00036279298,0.0035661878,0.00045712877,0.000011905867,0.026360858,0.0019978036],"study_design_scores_gemma":[0.0017426494,0.0028746377,0.9875902,0.000338314,0.00024509925,0.0000054806774,0.00006495742,0.000073608826,0.000046730143,0.000015099821,0.0068693496,0.00013384993],"about_ca_topic_score_codex":0.0008795501,"about_ca_topic_score_gemma":0.0019717468,"teacher_disagreement_score":0.022053005,"about_ca_system_score_codex":0.0005268648,"about_ca_system_score_gemma":0.0023317575,"threshold_uncertainty_score":0.61353266},"labels":[],"label_agreement":null},{"id":"W4387338057","doi":"10.1016/j.cjca.2023.06.309","title":"GLP-1RA THERAPY IS ASSOCIATED WITH HIGHER VASCULAR REGENERATIVE CELL CONTENT AND LOWER INFLAMMATORY BURDEN IN PEOPLE LIVING WITH TYPE 2 DIABETES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Empagliflozin; Type 2 diabetes; Diabetes mellitus; Coronary artery disease; Disease; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.014798437961083297,"score_gpt":0.20046470298793012,"score_spread":0.18566626502684683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951638,0.0019777638,0.000003194309,0.00073565077,0.0001771948,0.0001987259,0.0000035171804,0.0000085336105,0.0017316042],"genre_scores_gemma":[0.9977189,0.0003998311,0.000019916195,0.00033807856,0.00018378948,0.000008414019,0.000008296665,0.000021905113,0.0013009252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991534,0.00009729629,0.0001735608,0.00013628132,0.00011878913,0.0003206684],"domain_scores_gemma":[0.99925125,0.00008031148,0.00010382745,0.00012108991,0.00019058149,0.00025291703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029723076,0.00013577985,0.00048320633,0.00029819788,0.00004292138,0.000018387038,0.000056762026,0.00007560183,0.000036796115],"category_scores_gemma":[0.000035836714,0.00009129599,0.0000641609,0.00025362198,0.00008336406,0.000060741077,0.000009560886,0.00014707836,0.0000054036873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005845206,0.000006188263,0.98958,0.00001803076,0.001524835,0.00066145847,0.0009966708,0.00037233753,0.0004019063,0.000023179577,0.0055211154,0.0008358715],"study_design_scores_gemma":[0.0027779813,0.0017173424,0.97415215,0.0002500807,0.0002158633,0.000009397912,0.0004767525,0.000017610688,0.00014118341,0.000011634444,0.020094901,0.00013510615],"about_ca_topic_score_codex":0.00022598004,"about_ca_topic_score_gemma":0.001731707,"teacher_disagreement_score":0.015427808,"about_ca_system_score_codex":0.0001652738,"about_ca_system_score_gemma":0.00035917532,"threshold_uncertainty_score":0.37229425},"labels":[],"label_agreement":null},{"id":"W4387338058","doi":"10.1016/j.cjca.2023.06.162","title":"INTEGRATING ARTIFICIAL INTELLIGENCE FOR QUALITY IMPROVEMENT: SGLT2-INHIBITOR INITIATION FOR PATIENTS MEETING CLINICAL PRACTICE GUILDELINE CRITERIA. A NURSE PRACTITIONER PATIENT OPTIMIZATION INITIATIVE","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Medicine; Guideline; Coronary artery disease; Clinical Practice; Intensive care medicine; Ejection fraction; Diabetes mellitus; Heart failure; Type 2 diabetes; Nursing; Internal medicine; Pathology; Endocrinology","score_opus":0.08054182740256316,"score_gpt":0.3956789276709912,"score_spread":0.31513710026842806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338058","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17626886,0.00012948661,0.7964937,0.0118110785,0.0068728905,0.0043141698,0.0005167573,0.000058664922,0.0035344078],"genre_scores_gemma":[0.9478009,0.0000492551,0.047532868,0.0014608644,0.0021271796,0.00016608505,0.000812076,0.000033142962,0.000017645447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976066,0.00027042846,0.0013548065,0.00023929664,0.00018125105,0.0003476701],"domain_scores_gemma":[0.9951159,0.0012052972,0.00097420515,0.0001453768,0.0022697577,0.00028950264],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019909865,0.0001578605,0.0005045007,0.00035389425,0.00017521519,0.000050526218,0.00007741348,0.00013491529,0.000013446458],"category_scores_gemma":[0.016167836,0.00014144703,0.00027797132,0.00021792007,0.00006408566,0.00034648445,0.000014231842,0.00017624763,0.0000046243263],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042294203,0.00047574035,0.025121523,0.0004947561,0.0034880284,0.00014270788,0.004433012,0.042448755,0.00037874933,0.007505848,0.073621824,0.83765966],"study_design_scores_gemma":[0.025651313,0.08744582,0.02708043,0.0031184242,0.011499998,0.00014965174,0.08518354,0.10749547,0.0054986277,0.018797506,0.6250252,0.0030540018],"about_ca_topic_score_codex":0.00011106962,"about_ca_topic_score_gemma":0.00016546276,"teacher_disagreement_score":0.83460563,"about_ca_system_score_codex":0.0003057485,"about_ca_system_score_gemma":0.00061119546,"threshold_uncertainty_score":0.9921194},"labels":[],"label_agreement":null},{"id":"W4387338070","doi":"10.1016/j.cjca.2023.06.198","title":"CLINICAL OUTCOMES ASSOCIATED WITH THE USE OF ORAL SEMAGLUTIDE IN AN ADULT POPULATION WITH TYPE 2 DIABETES IN CANADA: A PROSPECTIVE REAL-WORLD STUDY (PIONEER REAL CANADA)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Population; Clinical trial; Gerontology; Internal medicine; Endocrinology; Environmental health","score_opus":0.04113082382713044,"score_gpt":0.2897971052239228,"score_spread":0.2486662813967924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811065,0.000008360844,2.9175064e-7,0.00095902185,0.00016939713,0.00052122166,0.00001837369,0.0000039247902,0.00020877823],"genre_scores_gemma":[0.9995055,0.000008672942,0.000019451483,0.00020004777,0.0000432936,0.000011575509,0.00003228241,0.00001676084,0.00016242084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984531,0.0003106853,0.0004590198,0.00015531863,0.00026715596,0.00035471524],"domain_scores_gemma":[0.9987583,0.00024134443,0.00023745158,0.00018609574,0.00033223032,0.00024453472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005090498,0.00013513278,0.00077501463,0.00033137883,0.000035995923,0.000008389205,0.00009449759,0.00004065402,0.0000028413397],"category_scores_gemma":[0.00027010718,0.00008098336,0.000043280816,0.00067853986,0.000063648906,0.0000646874,0.000010152293,0.00025391203,1.5791115e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013896372,0.000016284355,0.99158615,0.000004672145,0.0007189233,0.0008599213,0.00012463589,0.0034535264,4.2437657e-7,0.000025592832,0.0026336482,0.00043728392],"study_design_scores_gemma":[0.0021488233,0.0011857814,0.99502873,0.000066754845,0.0002681767,0.0000025292957,0.00086506136,0.000098476354,5.877342e-7,0.000007411291,0.00024490114,0.00008278777],"about_ca_topic_score_codex":0.99657136,"about_ca_topic_score_gemma":0.9999945,"teacher_disagreement_score":0.003832243,"about_ca_system_score_codex":0.0017358732,"about_ca_system_score_gemma":0.005568116,"threshold_uncertainty_score":0.9877599},"labels":[],"label_agreement":null},{"id":"W4387338115","doi":"10.1016/j.cjca.2023.06.232","title":"TRENDS IN A1C LEVELS IN INDIVIDUALS TESTED AT COMMUNITY PHARMACIES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine; Environmental health; Gerontology","score_opus":0.08846893769883143,"score_gpt":0.32373534519599184,"score_spread":0.2352664074971604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98024803,0.0002802947,0.0000015333085,0.0019012503,0.00025756605,0.00008085539,0.000027028624,0.0000075618873,0.017195886],"genre_scores_gemma":[0.99793935,0.000047701764,0.000019164798,0.0003110712,0.000112736554,0.0000053272324,0.000039570077,0.000010031179,0.0015150614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894375,0.0002493382,0.00029916156,0.00006773622,0.00008619976,0.00035384626],"domain_scores_gemma":[0.9993506,0.00011786042,0.00007560277,0.00014359281,0.000041836614,0.00027051423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008084306,0.000096906675,0.00046386773,0.0017508727,0.000051644045,0.000007928238,0.00012892907,0.00006983518,0.00008216324],"category_scores_gemma":[0.00011018378,0.00008581646,0.000107178676,0.0006543218,0.00008720181,0.0000537135,0.000031046395,0.00032671998,0.000028248147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012302065,0.0000057366497,0.9487039,0.000013295718,0.00020620112,0.0009890299,0.0006991246,0.0003713606,0.00013468659,0.000036414975,0.02946316,0.019364806],"study_design_scores_gemma":[0.0021367462,0.00020089059,0.90609175,0.000048020625,0.00007189794,0.00008962246,0.00032963886,0.0000061045657,0.00006573569,0.00010798083,0.090790205,0.00006142771],"about_ca_topic_score_codex":0.0009921421,"about_ca_topic_score_gemma":0.011808492,"teacher_disagreement_score":0.06132704,"about_ca_system_score_codex":0.00039535502,"about_ca_system_score_gemma":0.00020616395,"threshold_uncertainty_score":0.65894157},"labels":[],"label_agreement":null},{"id":"W4387338189","doi":"10.1016/j.cjca.2023.06.235","title":"A COMPARATIVE STUDY ON THE USE OF GLUCOSE-LOWERING AGENTS AS ADJUVANT THERAPY IN INDIVIDUALS WITH TYPE 1 DIABETES MELLITUS","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Adjuvant; Diabetes mellitus; Type 2 diabetes; Type 2 Diabetes Mellitus; Internal medicine; Adjuvant therapy; Pharmacology; Disease; Endocrinology; Cancer","score_opus":0.09190993508327006,"score_gpt":0.30372857936633596,"score_spread":0.2118186442830659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974682,0.00048614063,0.0000013501865,0.00046598059,0.00017230737,0.00049256004,0.000006613616,0.000004033865,0.00090282713],"genre_scores_gemma":[0.9993821,0.00018796162,0.000011817943,0.00024840905,0.00006369672,0.0000115081475,0.0000055613627,0.000010681207,0.00007826589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909365,0.00015046731,0.00024099938,0.000102593745,0.00015321352,0.00025904467],"domain_scores_gemma":[0.99924386,0.00019218375,0.00012508419,0.0001766125,0.000104900166,0.00015735257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003684926,0.000113787195,0.0005588134,0.00041515427,0.000034538403,0.000013523092,0.00010873058,0.000033505432,0.000020927351],"category_scores_gemma":[0.00006759859,0.00006498484,0.00007113604,0.0003669859,0.000086875225,0.000044409186,0.000011166993,0.00014954292,0.000016011194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013665776,0.00003545378,0.9816965,0.0000069223333,0.002235381,0.0004911408,0.0029548402,0.0021525268,0.00011919662,0.00006176332,0.0058511775,0.004258446],"study_design_scores_gemma":[0.0021317415,0.0057430402,0.9569708,0.0001209109,0.00015750411,0.000007916419,0.0020240212,0.000009973438,0.0005736372,0.000048231068,0.032138396,0.00007383349],"about_ca_topic_score_codex":0.00023556717,"about_ca_topic_score_gemma":0.0006045461,"teacher_disagreement_score":0.026287217,"about_ca_system_score_codex":0.00008258321,"about_ca_system_score_gemma":0.00025677867,"threshold_uncertainty_score":0.2650005},"labels":[],"label_agreement":null},{"id":"W4387345288","doi":"10.1038/s43856-023-00359-w","title":"Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review","year":2023,"lang":"en","type":"review","venue":"Communications Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Population Health Research Institute; University of Manitoba; Université de Sherbrooke; McMaster University; Centre Hospitalier Universitaire Sainte-Justine; Impact; University of Calgary","funders":"National Heart, Lung, and Blood Institute; Research England; Medical Research Council; National Institutes of Health; Novo Nordisk; National Institute for Health and Care Research; European Association for the Study of Diabetes; National Institute of Diabetes and Digestive and Kidney Diseases; Lunds Universitet; European Foundation for the Study of Diabetes; Department of Health and Social Care; U.S. Department of Veterans Affairs; British Heart Foundation; National Center for Advancing Translational Sciences; Wellcome Trust; Novo Nordisk Fonden; Boettcher Foundation; American Diabetes Association","keywords":"Type 2 diabetes; Medicine; Computational biology; Pharmacology; Diabetes mellitus; Bioinformatics; Internal medicine; Biology; Endocrinology","score_opus":0.07529574964778132,"score_gpt":0.38171573001459763,"score_spread":0.3064199803668163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387345288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000099963865,0.98483396,9.061215e-7,0.0011647252,0.00023495931,0.01265867,0.000029974408,0.0003197478,0.0006571128],"genre_scores_gemma":[0.00009609435,0.9870143,0.00022351075,0.0001394861,0.00014598714,0.006755426,0.0028825474,0.00016829289,0.0025743318],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99635416,0.0007871277,0.0012468033,0.00068553566,0.00043097034,0.00049542094],"domain_scores_gemma":[0.99346024,0.0014186262,0.00066221115,0.004009219,0.00009928488,0.00035044065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000617778,0.0011100826,0.0066591,0.00040291785,0.0002995941,0.000043654054,0.00048420153,0.00018658335,0.000022661845],"category_scores_gemma":[0.000298913,0.00055380596,0.0007193059,0.000983377,0.00028267654,0.000068993606,0.00027402164,0.0002157459,0.00031085705],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011562552,0.00047041566,0.00013874797,0.77654356,0.01099541,0.000051281666,0.0001071145,1.2743823e-8,0.0000013472616,0.000029539828,0.0013499623,0.21030103],"study_design_scores_gemma":[0.0015338203,0.005451664,0.0000031117781,0.5474017,0.05854284,0.000022236947,0.000020701957,0.0000050918766,0.000002516619,0.0000010633601,0.3867257,0.0002895592],"about_ca_topic_score_codex":0.000054659147,"about_ca_topic_score_gemma":0.000045623627,"teacher_disagreement_score":0.3853757,"about_ca_system_score_codex":0.001119635,"about_ca_system_score_gemma":0.00020873897,"threshold_uncertainty_score":0.99969137},"labels":[],"label_agreement":null},{"id":"W4387347395","doi":"10.1097/hco.0000000000001084","title":"Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data","year":2023,"lang":"en","type":"review","venue":"Current Opinion in Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Type 2 diabetes; Semaglutide; Internal medicine; Glucagon-like peptide 1 receptor; Endocrinology; Exenatide; Agonist; Diabetes mellitus; Glucagon-like peptide-1; Dulaglutide; Receptor; Pharmacology; Liraglutide","score_opus":0.18744366487739664,"score_gpt":0.44583718075402445,"score_spread":0.25839351587662784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387347395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007191998,0.98630816,0.00016495601,0.00007986087,0.007340948,0.005296025,0.0006160988,0.00007954246,0.00004246495],"genre_scores_gemma":[0.000010264033,0.9921701,0.00054428604,0.000044446588,0.00089739356,0.0006631981,0.005485014,0.000087365195,0.00009791482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958815,0.0005568385,0.0015728141,0.0012353619,0.00027369166,0.00047978107],"domain_scores_gemma":[0.9972902,0.0005481312,0.00062332384,0.0011877944,0.00016230259,0.00018822784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019060622,0.0005596241,0.0045076557,0.00035927206,0.00006706605,0.000020155614,0.00033679666,0.00042147242,0.000009647971],"category_scores_gemma":[0.00072220777,0.00046049702,0.0005241432,0.00036515656,0.00020850523,0.000073907446,0.00068706716,0.00051709916,0.000040181763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032366028,0.00012085062,0.0021036605,0.26098916,0.0018479212,0.00000326162,0.000007246782,1.0529789e-7,5.734134e-7,0.00019932295,0.014280114,0.7204154],"study_design_scores_gemma":[0.0012447803,0.0008231946,0.00050181866,0.086532496,0.0027953342,0.000020912492,0.000011512536,0.000009822731,6.5035783e-7,0.000094824296,0.9076352,0.00032946432],"about_ca_topic_score_codex":0.000009518071,"about_ca_topic_score_gemma":0.0000021981111,"teacher_disagreement_score":0.8933551,"about_ca_system_score_codex":0.0001473259,"about_ca_system_score_gemma":0.00029877786,"threshold_uncertainty_score":0.99978465},"labels":[],"label_agreement":null},{"id":"W4387357834","doi":"10.1001/jama.2023.19574","title":"Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss","year":2023,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":424,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Semaglutide; Liraglutide; Adverse effect; Weight loss; Glucagon; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Internal medicine; Endocrinology; Exenatide; Agonist; Receptor; Diabetes mellitus; Type 2 diabetes; Obesity; Insulin","score_opus":0.011585090516040206,"score_gpt":0.24704987447347423,"score_spread":0.23546478395743403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387357834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615085,0.00001420075,0.00015815925,0.00072344026,0.00015894497,0.0008032289,0.0001316901,0.00015267388,0.0017068315],"genre_scores_gemma":[0.9651019,0.0000537913,0.004116986,0.00014305739,0.00014726224,0.00015657967,0.0008220601,0.000049335038,0.029409014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988958,0.000031116855,0.0002168946,0.00024022358,0.00027476042,0.0003411567],"domain_scores_gemma":[0.9991471,0.00014457578,0.00020301914,0.00022940002,0.00016920971,0.000106649786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002696844,0.00016234354,0.00029646073,0.00011953113,0.00006136215,0.000005175685,0.000081314414,0.00004163156,0.00009090095],"category_scores_gemma":[0.00029274952,0.00012268352,0.0001399505,0.00030896766,0.00005018185,0.00007489571,0.00004663902,0.00008718609,0.00013968194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012903936,0.00075712526,0.9105325,0.00022206652,0.0011740174,0.00008873232,0.0001980442,0.000031341693,0.0005607969,0.00015152401,0.07660998,0.00838353],"study_design_scores_gemma":[0.016558262,0.0030044413,0.94761705,0.0012071619,0.0011227207,0.000007741894,0.00022981412,0.0006798579,0.001764935,0.00017609804,0.027392581,0.00023931559],"about_ca_topic_score_codex":0.000024791767,"about_ca_topic_score_gemma":0.000022032296,"teacher_disagreement_score":0.04921739,"about_ca_system_score_codex":0.000107326996,"about_ca_system_score_gemma":0.000051498337,"threshold_uncertainty_score":0.50028884},"labels":[],"label_agreement":null},{"id":"W4387382384","doi":"10.14740/jocmr4995","title":"Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Liraglutide; Type 2 diabetes; Glycemic; Glycated hemoglobin; Type 2 Diabetes Mellitus; Body mass index; Diabetes mellitus; Clinical endpoint; Internal medicine; Glucagon-like peptide 1 receptor; Urology; Insulin; Agonist; Endocrinology; Receptor; Clinical trial","score_opus":0.09869213890342232,"score_gpt":0.451708753867343,"score_spread":0.35301661496392067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387382384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980297,0.0002978023,0.000003168638,0.000100328245,0.00013505999,0.0012756094,0.000004238223,0.0000056849703,0.00014838354],"genre_scores_gemma":[0.99951065,0.00023009708,0.00002576759,0.000004590173,0.00007487019,0.0000137021325,0.000021763519,0.00001873058,0.000099859615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517256,0.0009967327,0.0016750013,0.00027950367,0.0015740847,0.0003021408],"domain_scores_gemma":[0.99287176,0.0038274142,0.0008564545,0.00035461428,0.001874361,0.00021540253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005121425,0.00019262296,0.0021219784,0.0019902163,0.000028087872,0.0000066162033,0.00015123542,0.00009099815,0.00007482211],"category_scores_gemma":[0.0031456933,0.00011026297,0.00023865978,0.0041620787,0.00025141975,0.00012908288,0.00007049081,0.00035887357,0.000001190802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028999313,0.005276269,0.9784669,0.00022390112,0.0060763066,0.00003399866,0.0041447342,0.000100492856,0.00008249247,0.00000767805,0.000054306667,0.002632936],"study_design_scores_gemma":[0.013935843,0.058433402,0.9172423,0.0009396428,0.0024639096,9.097092e-8,0.0064755296,0.000117254116,0.00027464418,0.00004863362,0.0000048804927,0.00006391122],"about_ca_topic_score_codex":0.0006381824,"about_ca_topic_score_gemma":0.00028755786,"teacher_disagreement_score":0.061224695,"about_ca_system_score_codex":0.00031282793,"about_ca_system_score_gemma":0.00022278434,"threshold_uncertainty_score":0.44963932},"labels":[],"label_agreement":null},{"id":"W4387391918","doi":"10.1007/s00125-023-06015-1","title":"Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes","year":2023,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Novo Nordisk Fonden; Steno Diabetes Center Copenhagen","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Human physiology; Kidney disease; Disease; Translation (biology); Type 1 diabetes; Internal medicine; Endocrinology; Biology; Genetics; Messenger RNA","score_opus":0.07947311887942868,"score_gpt":0.3366386174175607,"score_spread":0.257165498538132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387391918","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045601595,0.94804376,0.000002668643,0.00033022297,0.00080463913,0.004228064,0.00037241008,0.00029363664,0.0003230219],"genre_scores_gemma":[0.008389863,0.98300683,0.00086182286,0.00081623415,0.00032391143,0.00069474074,0.004838876,0.0003734847,0.00069426047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99564993,0.0001883945,0.0011680544,0.0010558815,0.0006649419,0.0012727856],"domain_scores_gemma":[0.99699426,0.00054092286,0.00052769925,0.0011147541,0.00026577775,0.0005565629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005903813,0.001042239,0.0033739551,0.0011678514,0.000068776964,0.00006514335,0.00050518266,0.00050525845,0.00014061718],"category_scores_gemma":[0.000351146,0.00077620434,0.00038670676,0.0035195611,0.00020312774,0.00014935696,0.00019382406,0.00053308543,0.00034299085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009730487,0.0015320897,0.19271463,0.05655298,0.0069730957,0.000036952737,0.00024006431,0.00006269366,0.000115266506,0.00017210335,0.0023712954,0.7391315],"study_design_scores_gemma":[0.0031612087,0.0042057913,0.016393304,0.041733477,0.0123737585,2.4924702e-7,0.000023467026,0.00020327733,0.00012728508,0.000072572555,0.92014104,0.0015645793],"about_ca_topic_score_codex":0.0000057267575,"about_ca_topic_score_gemma":0.000012410804,"teacher_disagreement_score":0.91776973,"about_ca_system_score_codex":0.0003950594,"about_ca_system_score_gemma":0.0010542742,"threshold_uncertainty_score":0.99946886},"labels":[],"label_agreement":null},{"id":"W4387432435","doi":"10.1016/j.diabres.2023.110946","title":"Preconception SGLT2 or DPP4 inhibitor use and adverse pregnancy outcomes","year":2023,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Pregnancy; Obstetrics; Miscarriage; Diabetes mellitus; Population; Cohort study; Cohort; Sulfonylurea; Internal medicine; Endocrinology; Environmental health","score_opus":0.24484990114582583,"score_gpt":0.503161853708032,"score_spread":0.2583119525622062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387432435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898037,0.00048722522,0.0000014383698,0.0056627267,0.00018317124,0.0010243633,0.000012399107,0.00013003836,0.0026949954],"genre_scores_gemma":[0.9569989,0.008745057,0.0011049549,0.0010042463,0.00020286643,0.00012938208,0.00008223015,0.000039408416,0.031693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975546,0.00037232647,0.00043044236,0.0005097076,0.00054739445,0.0005855093],"domain_scores_gemma":[0.99056476,0.0082907425,0.000091442256,0.00034770745,0.00028801966,0.00041730382],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002062812,0.0001565398,0.00037057677,0.0001950951,0.00017923243,0.00013785393,0.00007352852,0.00013235182,0.00012148209],"category_scores_gemma":[0.016448233,0.00010730726,0.000081229344,0.00044250293,0.00036102193,0.0009567855,0.00030799583,0.00048642218,0.000361454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041499714,0.0009414216,0.83995116,0.00022192218,0.00055239536,0.0001599208,0.00012344035,1.3282848e-7,0.000053829594,0.00028148302,0.011042891,0.14625639],"study_design_scores_gemma":[0.004079589,0.0039829914,0.9057388,0.00042899334,0.00030599677,0.0000015589089,0.0010369624,0.00024899773,0.0000783524,0.00032385052,0.08360019,0.00017374184],"about_ca_topic_score_codex":0.000021714073,"about_ca_topic_score_gemma":0.000015389134,"teacher_disagreement_score":0.14608265,"about_ca_system_score_codex":0.000035152232,"about_ca_system_score_gemma":0.00006756797,"threshold_uncertainty_score":0.99183667},"labels":[],"label_agreement":null},{"id":"W4387459404","doi":"10.2217/vjbm-2023-0008","title":"Safety evaluation of empagliflozin for patients with type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Video Journal of Biomedicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care","funders":"","keywords":"Empagliflozin; Type 2 diabetes; Medicine; Kidney disease; Diabetes mellitus; Intensive care medicine; Disease; Internal medicine; Endocrinology","score_opus":0.015706956849606834,"score_gpt":0.28423237653799477,"score_spread":0.26852541968838795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387459404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950226,0.0014333169,0.000031658346,0.0024364947,0.00026719683,0.000695022,0.00002680852,0.000011501011,0.00007542646],"genre_scores_gemma":[0.9986198,0.00036182516,0.0002391909,0.00019425183,0.00021381874,0.000010136681,0.0001978954,0.000015663525,0.00014744558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987681,0.00002713859,0.00034095603,0.00010507744,0.0005981057,0.00016062961],"domain_scores_gemma":[0.998636,0.0000764297,0.00025402004,0.00012451675,0.0006406713,0.00026834395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078312325,0.00010326952,0.00031750498,0.00038184505,0.000028969716,0.0000047705385,0.000044221473,0.000022770328,0.00006333118],"category_scores_gemma":[0.00043219255,0.00006273837,0.000050310307,0.00040986037,0.00008313414,0.000080912076,0.000020364196,0.000042516473,0.000002773121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042669857,0.0010623994,0.6687149,0.0020433925,0.0026646878,0.00002502982,0.00037272973,0.000042594835,0.0050291237,0.000058135087,0.06303985,0.25268015],"study_design_scores_gemma":[0.03086058,0.012020581,0.9287875,0.002132103,0.005379378,0.0000011585166,0.00009319827,0.0022227862,0.0007247277,0.00029145353,0.017356684,0.00012980358],"about_ca_topic_score_codex":7.41362e-7,"about_ca_topic_score_gemma":4.794692e-7,"teacher_disagreement_score":0.26007265,"about_ca_system_score_codex":0.0001028345,"about_ca_system_score_gemma":0.00023867738,"threshold_uncertainty_score":0.25583965},"labels":[],"label_agreement":null},{"id":"W4387502279","doi":"10.1016/j.jdiacomp.2023.108628","title":"Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk","year":2023,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Risk factor; Diabetes mellitus; Kidney disease; Internal medicine; Placebo; Categorization; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.016243190204554305,"score_gpt":0.25194021347265894,"score_spread":0.23569702326810463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387502279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942886,0.0003985194,0.00013518246,0.004404856,0.00006357219,0.0003905149,0.0001253402,0.00001976718,0.00017359994],"genre_scores_gemma":[0.99887246,0.00062245945,0.00015441356,0.000130526,0.000106945474,0.000029639006,0.000041917338,0.0000133479925,0.00002829142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902004,0.00006339791,0.00037144823,0.00014015603,0.00021059335,0.00019436813],"domain_scores_gemma":[0.9989941,0.00013952887,0.00046261636,0.00019790548,0.00010169493,0.00010412178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035494822,0.00011510362,0.0002627883,0.00016996636,0.00015310216,0.000034709956,0.00007410477,0.000039424805,0.000016503382],"category_scores_gemma":[0.00012018381,0.00007153536,0.000079984384,0.0005075418,0.00006166299,0.00015671115,0.00004741168,0.0002298567,0.000012853057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016577914,0.00086508703,0.9609966,0.00013892056,0.0009921629,0.000009311655,0.0037521382,0.00031571023,0.0071376604,0.001355009,0.0022187014,0.022052875],"study_design_scores_gemma":[0.0018075409,0.00049495156,0.98906803,0.00030767857,0.00030137534,0.0000012595393,0.000650834,0.0011847502,0.0015659402,0.003889497,0.0006535456,0.000074578464],"about_ca_topic_score_codex":0.000048240505,"about_ca_topic_score_gemma":0.00006463399,"teacher_disagreement_score":0.028071404,"about_ca_system_score_codex":0.000041285683,"about_ca_system_score_gemma":0.000026653093,"threshold_uncertainty_score":0.29171273},"labels":[],"label_agreement":null},{"id":"W4387563425","doi":"10.1210/endocr/bqad153","title":"Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases","year":2023,"lang":"en","type":"review","venue":"Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk","keywords":"Weight loss; Medicine; Internal medicine; Endocrinology; Agonist; Hormone; Type 2 Diabetes Mellitus; Glucagon-like peptide-1; Diabetes mellitus; Glucagon-like peptide 1 receptor; Exenatide; Type 2 diabetes; Obesity; Glucagon; Pancreas; Insulin; Insulin resistance; Receptor","score_opus":0.06624649780036372,"score_gpt":0.37718587356410826,"score_spread":0.31093937576374453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387563425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058048853,0.9957928,0.000040373285,0.0000693161,0.00014275065,0.0028063976,0.0003103061,0.00006610631,0.00019145387],"genre_scores_gemma":[0.0011990006,0.9925618,0.00026028167,0.000035893092,0.00002936946,0.003135242,0.0012024128,0.000059472273,0.001516495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849826,0.00008555011,0.0005078291,0.00039316667,0.00011965041,0.00039552618],"domain_scores_gemma":[0.99883455,0.00047395873,0.00023497609,0.0003415176,0.000039794428,0.00007517813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000431227,0.00034663465,0.0018319148,0.00060802477,0.000037426616,0.000006918399,0.000101050704,0.00007678941,0.000016338507],"category_scores_gemma":[0.00010996379,0.00026856942,0.0002656837,0.00028803034,0.00010728104,0.000032320455,0.000060258208,0.00007548481,0.00001695826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072657655,0.0018474947,0.0007008273,0.008364503,0.0039758235,0.000088217486,0.00002553335,7.909848e-7,0.0000021182282,0.0109229265,0.00032291556,0.9736762],"study_design_scores_gemma":[0.00961803,0.00091805845,0.003546584,0.0029023585,0.012434246,0.0000025770105,0.000035156885,0.000014638183,0.0000035883204,0.0007964723,0.9694748,0.00025351447],"about_ca_topic_score_codex":0.00003160232,"about_ca_topic_score_gemma":0.000010132541,"teacher_disagreement_score":0.9734227,"about_ca_system_score_codex":0.00009094717,"about_ca_system_score_gemma":0.00010242062,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W4387563674","doi":"10.1111/dom.15309","title":"Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from <scp>SUSTAIN</scp> 1‐5, 7‐10 and <scp>SUSTAIN</scp> China","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FSD Pharma (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Post-hoc analysis; Type 2 diabetes; Internal medicine; Clinical endpoint; Placebo; Logistic regression; Covariate; Randomized controlled trial; Diabetes mellitus; Endocrinology; Mathematics; Statistics","score_opus":0.014177814722031596,"score_gpt":0.24719868808648404,"score_spread":0.23302087336445246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387563674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590094,0.011495263,0.000015566637,0.00016800941,0.00012294504,0.0015340362,0.00022760591,0.0002699775,0.000265678],"genre_scores_gemma":[0.9950668,0.0013478973,0.0008635404,0.00011870662,0.00013339776,0.00017946362,0.0011866373,0.00007732997,0.0010262189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600106,0.00025244508,0.00068385125,0.0010152967,0.0007336826,0.0013136864],"domain_scores_gemma":[0.9971841,0.0005271546,0.0005416274,0.0007265772,0.0003914309,0.0006291251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049931067,0.00081530574,0.0022321595,0.00090138917,0.0003445218,0.00017207555,0.00018090068,0.00017323966,0.000020417197],"category_scores_gemma":[0.00023372483,0.0005816881,0.00028006904,0.002105068,0.00039626757,0.00035711974,0.00017952741,0.00023203134,0.000023724875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040443512,0.001583898,0.9570363,0.00047210683,0.022708116,0.000107806096,0.003816706,0.00027939075,0.007978672,0.00042260092,0.00022182647,0.0049681305],"study_design_scores_gemma":[0.0075627565,0.0021257354,0.9308031,0.00017522262,0.030107662,5.888165e-7,0.002239219,0.001301238,0.020392524,0.00006556292,0.005017476,0.00020887199],"about_ca_topic_score_codex":0.00027727694,"about_ca_topic_score_gemma":0.00015907036,"teacher_disagreement_score":0.026233168,"about_ca_system_score_codex":0.000100584344,"about_ca_system_score_gemma":0.00015342883,"threshold_uncertainty_score":0.9996635},"labels":[],"label_agreement":null},{"id":"W4387582042","doi":"10.58931/cdet.2023.1318","title":"Glucagon-like Peptide-1 Receptor Agonist Treatment in Type 1 Diabetes","year":2023,"lang":"en","type":"article","venue":"Canadian Diabetes & Endocrinology Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Glycemic; Incretin; Type 1 diabetes; Insulin; Type 2 diabetes; Glucagon-like peptide 1 receptor; Population; Diabetes mellitus; Insulin resistance; Endocrinology; Internal medicine; Agonist; Receptor","score_opus":0.018822481644195487,"score_gpt":0.25337586870285184,"score_spread":0.23455338705865636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387582042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714393,0.0016371423,1.0671905e-7,0.0068572336,0.0014780125,0.0010565876,0.00007865182,0.00036104035,0.017091932],"genre_scores_gemma":[0.9641558,0.0009892227,0.00013712441,0.0027696067,0.00022882849,0.0005539164,0.0011696871,0.000102577025,0.029893268],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960727,0.00009418513,0.00043565477,0.0007639356,0.00019204733,0.0024414447],"domain_scores_gemma":[0.9981698,0.00015917877,0.00007830418,0.0007438598,0.000080607955,0.0007682855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015121858,0.0004974486,0.00077614957,0.0013441206,0.00017990955,0.000053280346,0.0002500774,0.00018771988,0.0009951307],"category_scores_gemma":[0.00010922451,0.0004635345,0.0001948654,0.0012025678,0.00021815523,0.00012086329,0.00008859347,0.00023252638,0.0043212734],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003189669,0.00027059202,0.8300881,0.00010548099,0.0008220548,0.0007174379,0.00031683463,0.000021013266,0.0019265418,0.0012876624,0.09999381,0.064418584],"study_design_scores_gemma":[0.0026837103,0.0012743525,0.21959549,0.000114173796,0.0002783062,0.0000027557871,0.0002328054,0.0001515265,0.0048429673,0.00018286485,0.7701367,0.00050435495],"about_ca_topic_score_codex":0.007594834,"about_ca_topic_score_gemma":0.04063167,"teacher_disagreement_score":0.6701429,"about_ca_system_score_codex":0.0013225252,"about_ca_system_score_gemma":0.00057685014,"threshold_uncertainty_score":0.9999181},"labels":[],"label_agreement":null},{"id":"W4387599318","doi":"10.1136/bmjmed-2023-000651","title":"Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM","year":2023,"lang":"en","type":"article","venue":"BMJ Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"U.S. National Library of Medicine; National Institute of General Medical Sciences; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Wellcome Trust; U.S. Department of Veterans Affairs","keywords":"Metformin; Medicine; Type 2 Diabetes Mellitus; Pharmacoepidemiology; Type 2 diabetes; Diabetes mellitus; Pharmacology; Sitagliptin; Vildagliptin; Internal medicine; Dipeptidyl peptidase-4; Drug; Endocrinology; Medical prescription","score_opus":0.08371541989353905,"score_gpt":0.40101931936246893,"score_spread":0.3173038994689299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387599318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372786,0.0010566183,0.0003144535,0.0018287023,0.00037048443,0.0016694037,0.000048861042,0.00009978742,0.00088382576],"genre_scores_gemma":[0.995559,0.0007756711,0.00006771726,0.00040723247,0.0004521821,0.00024825108,0.0020470177,0.000020998506,0.00042195365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972611,0.00042599745,0.0007587694,0.0003951661,0.00082379184,0.00033516754],"domain_scores_gemma":[0.99876213,0.0003601512,0.00024577937,0.00025217867,0.00028403578,0.00009572853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005425554,0.00020793553,0.0007181682,0.00029726682,0.00007120749,0.00000582067,0.00007784459,0.000090568756,0.00065068743],"category_scores_gemma":[0.00095121225,0.00015596532,0.00017185892,0.00059345394,0.00007271998,0.00011107821,0.00007022701,0.00020856151,0.000047845177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047728483,0.00060214486,0.89196867,0.0006824951,0.0017881904,0.00027063082,0.0023487736,0.0044375984,0.004627418,0.00013475666,0.009269958,0.08339208],"study_design_scores_gemma":[0.014055904,0.0003448005,0.93795294,0.00042475256,0.00077977544,0.000009200296,0.0011896776,0.041292835,0.0021270586,0.00010347728,0.0015517478,0.00016783508],"about_ca_topic_score_codex":0.00024180577,"about_ca_topic_score_gemma":0.00012904515,"teacher_disagreement_score":0.08322425,"about_ca_system_score_codex":0.00015427811,"about_ca_system_score_gemma":0.000051028845,"threshold_uncertainty_score":0.7124571},"labels":[],"label_agreement":null},{"id":"W4387605261","doi":"10.3389/fphar.2023.1275060","title":"Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies","year":2023,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Dapagliflozin; Hypoglycemia; Type 2 diabetes; Diabetic ketoacidosis; Cohort study; Diabetes mellitus; Cohort; Gastroenterology; Insulin; Endocrinology; Confidence interval","score_opus":0.0574437973488994,"score_gpt":0.3501851902616527,"score_spread":0.29274139291275325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387605261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007879991,0.98756003,0.0000030514018,0.000028779144,0.00093263993,0.0032642842,0.00017000934,0.000025436031,0.00013576624],"genre_scores_gemma":[0.0011951507,0.9964269,0.0003546732,0.00007349568,0.000027624355,0.0005442204,0.00087120384,0.000064059685,0.00044266848],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968778,0.00025947977,0.0014941804,0.00057167176,0.0003690676,0.00042783847],"domain_scores_gemma":[0.9985484,0.00015493746,0.00071221724,0.00034489267,0.00016354216,0.00007604178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005791203,0.0005116019,0.0084079625,0.0025075139,0.000014655256,0.0000021411768,0.00020198053,0.00021520085,0.0001492673],"category_scores_gemma":[0.00002383338,0.0003424043,0.0012698136,0.0029879743,0.00023734488,0.00005500068,0.00007524969,0.0002929777,0.000004654002],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034221582,0.0010650945,0.13719453,0.012263695,0.7940615,0.000054857515,0.00023467858,0.000026536076,2.684613e-7,0.0000022775266,0.0077117374,0.047042597],"study_design_scores_gemma":[0.0029229482,0.0006025183,0.0060049244,0.0008254762,0.87569463,4.360252e-8,0.00006841831,0.000012045696,0.0000136029375,0.000005583689,0.113578856,0.00027093408],"about_ca_topic_score_codex":0.000012704727,"about_ca_topic_score_gemma":0.000027978498,"teacher_disagreement_score":0.1311896,"about_ca_system_score_codex":0.00031220118,"about_ca_system_score_gemma":0.00012785483,"threshold_uncertainty_score":0.9999028},"labels":[],"label_agreement":null},{"id":"W4387618192","doi":"10.3390/diabetology4040038","title":"A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes","year":2023,"lang":"en","type":"review","venue":"Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Type 2 diabetes; Checklist; Systematic review; MEDLINE; Disease management; Cost effectiveness; Insulin; Intensive care medicine; Insulin degludec; Diabetes mellitus; Diabetes management; Meta-analysis; Alternative medicine; Health management system; Internal medicine; Basal insulin; Risk analysis (engineering); Endocrinology; Pathology; Political science; Psychology","score_opus":0.07235393018914756,"score_gpt":0.38995349298578974,"score_spread":0.3175995627966422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387618192","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020016925,0.98979014,0.0000066973653,0.00009343392,0.00030445706,0.009151401,0.000106515174,0.000017850198,0.0005094638],"genre_scores_gemma":[0.000020867812,0.9960582,0.00020186076,0.00005177243,0.00002173079,0.0024593163,0.0003553036,0.00004307194,0.0007878406],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977013,0.00014973493,0.0015333104,0.0002422,0.00015448374,0.0002189785],"domain_scores_gemma":[0.9967239,0.0010387098,0.0012645003,0.0008006625,0.00014081258,0.000031410258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010361841,0.00025511775,0.0041379,0.0002319019,0.000018631807,0.000002101024,0.00029257682,0.00011030914,0.000065985005],"category_scores_gemma":[0.00018730915,0.00015429982,0.00071888074,0.00032569235,0.00010677329,0.000014922646,0.0001259171,0.000066927474,0.00007000678],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000025615448,0.00008373336,0.0000062540103,0.91815436,0.00903026,7.065613e-7,0.000009426596,6.193797e-7,6.6582416e-8,0.003627081,0.00087073597,0.06821421],"study_design_scores_gemma":[0.0004662994,0.0003671854,0.00001495359,0.8674194,0.070027195,5.2831217e-7,0.000023414845,0.000043709842,0.000003990127,0.00017868062,0.061336115,0.00011847685],"about_ca_topic_score_codex":0.0000024274327,"about_ca_topic_score_gemma":0.0000011648067,"teacher_disagreement_score":0.06809573,"about_ca_system_score_codex":0.00007908161,"about_ca_system_score_gemma":0.00012838804,"threshold_uncertainty_score":0.62921643},"labels":[],"label_agreement":null},{"id":"W4387749619","doi":"10.14309/01.ajg.0000955036.53703.f0","title":"S1349 Glucagon-Like Peptide-1 Receptor Agonist and Pioglitazone Therapy Have Superior Mortality and Liver Outcomes for Patients With Type 2 Diabetes and a Diagnosis or at Risk for Undiagnosed Non-alcoholic Fatty Liver Disease","year":2023,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Pioglitazone; Internal medicine; Hazard ratio; Type 2 diabetes; Proportional hazards model; Nonalcoholic fatty liver disease; Adverse effect; Diabetes mellitus; Fatty liver; Gastroenterology; Disease; Confidence interval; Endocrinology","score_opus":0.02124647502310324,"score_gpt":0.2758207880232398,"score_spread":0.25457431300013655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387749619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969775,0.00031301836,0.000033306093,0.001163163,0.00011309313,0.001216557,0.0001675457,0.000014970211,8.3617397e-7],"genre_scores_gemma":[0.990471,0.0068588904,0.0010051522,0.0012083987,0.00007185811,0.00020948857,0.000045601253,0.000036715617,0.00009288125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998759,0.00011491821,0.00029459942,0.0002626088,0.00016047436,0.00040841723],"domain_scores_gemma":[0.9984712,0.0005166601,0.0004019245,0.00020460688,0.00014590197,0.0002597219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029221343,0.0002463897,0.00073528365,0.00014217633,0.00018118328,0.00003365286,0.00009679625,0.00002198597,0.000013059212],"category_scores_gemma":[0.000118137265,0.00013264168,0.000115858194,0.00009881772,0.0006280814,0.0000901528,0.00009637488,0.00009297856,0.0000013688602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017235909,0.00033176373,0.972505,0.00006694296,0.0014385392,0.000018687784,0.00040569302,0.0000014165506,0.000018556873,8.38779e-7,0.0014562523,0.006520424],"study_design_scores_gemma":[0.007696238,0.0278504,0.9620646,0.000057661466,0.0010889221,0.0000041835683,0.00026444436,0.000094296156,0.000023091552,0.0000148614645,0.000748867,0.000092395065],"about_ca_topic_score_codex":0.000043866603,"about_ca_topic_score_gemma":0.00008131667,"teacher_disagreement_score":0.027518636,"about_ca_system_score_codex":0.000052425465,"about_ca_system_score_gemma":0.000024004301,"threshold_uncertainty_score":0.5408971},"labels":[],"label_agreement":null},{"id":"W4387775935","doi":"10.51731/cjht.2023.752","title":"Semaglutide for Type 2 Diabetes (2 mg)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Discontinuation; Medicine; Placebo; Adverse effect; Diabetes mellitus; Type 2 diabetes; Glycemic; Internal medicine; Randomized controlled trial; Dulaglutide; Endocrinology; Exenatide; Alternative medicine; Liraglutide","score_opus":0.05726240410101599,"score_gpt":0.3232356622110811,"score_spread":0.2659732581100651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387775935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8035866,0.041733276,0.00003971764,0.15174527,0.0010681348,0.00087707327,0.000024569268,0.0004435708,0.0004817636],"genre_scores_gemma":[0.9965174,0.0005622598,0.0010642819,0.0008139654,0.000022112912,0.000015369536,0.000013103059,0.00001794094,0.0009735683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901694,0.000010491132,0.00029795791,0.00009194249,0.00008974682,0.00049294165],"domain_scores_gemma":[0.99936736,0.00007395948,0.00015889488,0.00016917856,0.00013644905,0.000094191484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004613665,0.00009061225,0.00031352649,0.0007654874,0.00012818289,0.000016433441,0.00013413467,0.00006771893,0.000013641202],"category_scores_gemma":[0.0006141838,0.00007171415,0.00007784876,0.00049065374,0.00007885141,0.000037594928,0.000014295031,0.000121800185,0.000031208754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012733264,0.000018994226,0.034792624,0.00041354174,0.00020839534,0.00010214268,0.000100123645,0.000007596346,0.00007697233,0.0017871181,0.17192619,0.79055357],"study_design_scores_gemma":[0.00097572466,0.0017296864,0.032178797,0.00035669765,0.00007732735,0.000012847239,0.001412528,0.000042712323,0.0008190997,0.004826777,0.9574601,0.0001077231],"about_ca_topic_score_codex":0.00016481114,"about_ca_topic_score_gemma":0.000438952,"teacher_disagreement_score":0.79044586,"about_ca_system_score_codex":0.00022611854,"about_ca_system_score_gemma":0.0009359679,"threshold_uncertainty_score":0.29244182},"labels":[],"label_agreement":null},{"id":"W4387844472","doi":"10.1093/eurheartj/ehad639","title":"Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Akebia Therapeutics; Novo Nordisk; Cytokinetics; Amarin Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Amryt Pharma; Alnylam Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Esperion Therapeutics; Merck; Amgen; Vetenskapsrådet; Pfizer","keywords":"Medicine; Post-hoc analysis; Ejection fraction; Post hoc; Heart failure; Fraction (chemistry); Cardiology; Internal medicine; Clinical trial","score_opus":0.03887443828179558,"score_gpt":0.34620773616791467,"score_spread":0.3073332978861191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387844472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899676,0.00017142328,0.00012131968,0.0075224936,0.00092397135,0.0010846703,0.000011502843,0.000025811274,0.00017120223],"genre_scores_gemma":[0.9976017,0.00012024513,0.000125545,0.0002075116,0.0011112354,0.000009307595,0.000013611021,0.000023732759,0.0007871474],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998855,0.0002112485,0.0003366323,0.00013077274,0.0002883311,0.00017801659],"domain_scores_gemma":[0.99934334,0.000101717786,0.00020154114,0.00019878917,0.00010221788,0.00005237018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008008979,0.000103753926,0.00022912878,0.00008076458,0.0002608123,0.000056135897,0.000072259165,0.000026120484,0.000033508077],"category_scores_gemma":[0.00020696958,0.000058124286,0.00023195104,0.00030086824,0.00006807335,0.00011788423,0.000060597387,0.00012901862,0.0000072438215],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38744774,0.002118075,0.12415451,0.0005585663,0.004023768,0.000041841988,0.004470512,0.0007181767,0.053608973,0.00038527825,0.4054799,0.016992649],"study_design_scores_gemma":[0.14957498,0.0139796,0.68618834,0.00032678005,0.00085928885,0.00006513692,0.0014915655,0.00043953155,0.010808465,0.00015633398,0.13590837,0.00020159918],"about_ca_topic_score_codex":0.000010400602,"about_ca_topic_score_gemma":0.0000083231525,"teacher_disagreement_score":0.56203383,"about_ca_system_score_codex":0.000032676122,"about_ca_system_score_gemma":0.00003346131,"threshold_uncertainty_score":0.23702396},"labels":[],"label_agreement":null},{"id":"W4387865855","doi":"10.1111/dom.15331","title":"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Université de Sherbrooke; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Medicine; Metformin; Pioglitazone; Dementia; Cochrane Library; Meta-analysis; Internal medicine; Type 2 diabetes; Diabetes mellitus; CINAHL; Cohort study; Relative risk; Pharmacology; Endocrinology; Insulin; Confidence interval; Psychiatry; Disease; Psychological intervention","score_opus":0.04235189374697281,"score_gpt":0.3084662030670428,"score_spread":0.26611430932007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387865855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014767131,0.9936942,0.000004691517,0.00012750365,0.00006553973,0.0040337583,0.00041338304,0.00009370488,0.00009054193],"genre_scores_gemma":[0.00025671854,0.9971474,0.00029257097,0.0002235336,0.000037383885,0.00097326894,0.0003708501,0.00007333837,0.00062496756],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959882,0.0006724288,0.0014052894,0.0008898931,0.00047576491,0.00056841125],"domain_scores_gemma":[0.9965413,0.00083937886,0.0011550962,0.0009181423,0.00014005475,0.00040600466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001972136,0.0008107423,0.01156267,0.0009593554,0.0001792015,0.00006270635,0.00020528652,0.0002840438,0.000068484274],"category_scores_gemma":[0.0003574407,0.00055632804,0.0015686341,0.0015857236,0.00030803008,0.000116538155,0.00037848495,0.00033715306,0.000024437299],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[2.826576e-7,0.00012897675,0.0013965149,0.59868354,0.39269146,0.0000027743868,0.00002600025,3.6201566e-8,1.6644651e-7,0.00017175825,0.00014605903,0.006752439],"study_design_scores_gemma":[0.00034491403,0.00004800916,0.0023730164,0.024435632,0.93194807,0.0000011087081,0.000009950492,0.000013201296,0.0000023748644,0.00008183543,0.040356036,0.00038588382],"about_ca_topic_score_codex":0.000034349698,"about_ca_topic_score_gemma":0.0000117106465,"teacher_disagreement_score":0.5742479,"about_ca_system_score_codex":0.00001832094,"about_ca_system_score_gemma":0.00006899911,"threshold_uncertainty_score":0.9996888},"labels":[],"label_agreement":null},{"id":"W4387931360","doi":"10.1111/dme.15248","title":"Glucagon like peptide‐1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population‐based cohort study","year":2023,"lang":"en","type":"article","venue":"Diabetic Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Skin cancer; Hazard ratio; Internal medicine; Cohort; Melanoma; Population; Cohort study; Type 2 diabetes; Oncology; Proportional hazards model; Propensity score matching; Diabetes mellitus; Cancer; Confidence interval; Endocrinology; Cancer research; Environmental health","score_opus":0.008144184670383973,"score_gpt":0.24664021175828071,"score_spread":0.23849602708789674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387931360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526983,0.00030981313,0.000002064753,0.00058290944,0.00035459662,0.0028724088,0.00001620565,0.000080775535,0.00051136996],"genre_scores_gemma":[0.9973789,0.00019587646,0.00003981451,0.00031200776,0.00010354811,0.00034612653,0.00043177663,0.000039496204,0.001152441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980821,0.00015415184,0.0003978581,0.00036367908,0.0006792716,0.00032290988],"domain_scores_gemma":[0.99858797,0.000311798,0.00026266018,0.00049201516,0.00020014014,0.00014541956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075715047,0.00024976293,0.000716073,0.00022218116,0.000111539084,0.000011209344,0.0001034246,0.000048141443,0.00027260275],"category_scores_gemma":[0.00025893093,0.00013056892,0.00005082841,0.000759638,0.00034259883,0.00004820315,0.000057411136,0.00013517309,0.000018240715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022878847,0.00031290008,0.9913904,0.00014493399,0.0008758873,0.000002203051,0.00071126217,0.00002813399,0.0000068154545,0.000009216366,0.0026836528,0.0036057767],"study_design_scores_gemma":[0.012661164,0.0015766667,0.9815646,0.00042618258,0.0022409526,1.953351e-8,0.00028240134,0.00054833916,0.00004596552,0.000017654174,0.0005077268,0.00012836095],"about_ca_topic_score_codex":0.0009585304,"about_ca_topic_score_gemma":0.00013141498,"teacher_disagreement_score":0.012432375,"about_ca_system_score_codex":0.00006714476,"about_ca_system_score_gemma":0.000033223565,"threshold_uncertainty_score":0.5324446},"labels":[],"label_agreement":null},{"id":"W4387933749","doi":"10.1016/j.jcjd.2023.10.303","title":"EMPAGLIFLOZIN IMPROVES VASCULAR REGENERATIVE CELL CONTENT IN PEOPLE WITHOUT DIABETES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Empagliflozin; Medicine; Diabetes mellitus; Type 2 diabetes; Kidney disease; Progenitor cell; Disease; Heart failure; Vascular disease; Internal medicine; Cardiology; Endocrinology; Stem cell","score_opus":0.018006325214764474,"score_gpt":0.22177681665490903,"score_spread":0.20377049144014456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387933749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339825,0.0026701624,0.0000010436555,0.0014310406,0.0004218911,0.00039606716,0.000014508588,0.000023364832,0.0016436686],"genre_scores_gemma":[0.99630386,0.000056993154,0.00018648787,0.0007152629,0.00018124378,0.000029190545,0.000032510787,0.000040493105,0.0024539675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982315,0.00006946082,0.00048147063,0.00021660126,0.00026204655,0.0007389647],"domain_scores_gemma":[0.99855304,0.000078073565,0.00018879691,0.00024724944,0.0001959073,0.0007369146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005168287,0.000236178,0.00063862116,0.0009436206,0.00008037834,0.00006687148,0.00017580173,0.0000834267,0.00008853129],"category_scores_gemma":[0.00016798223,0.00019531786,0.00024463524,0.0005971174,0.000081141734,0.0001586465,0.000024622303,0.00022732411,0.00006731835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035238527,0.000064487795,0.9808662,0.00011918613,0.0003544467,0.0000623927,0.0006790106,0.00003781046,0.006241151,0.000055596203,0.00870938,0.0028067953],"study_design_scores_gemma":[0.0035317836,0.0009302876,0.9654789,0.00041955247,0.00041645177,6.6667985e-7,0.0012133387,0.00040628662,0.017897004,0.00014162507,0.009271858,0.00029227656],"about_ca_topic_score_codex":0.0006044463,"about_ca_topic_score_gemma":0.010600917,"teacher_disagreement_score":0.015387351,"about_ca_system_score_codex":0.0002912667,"about_ca_system_score_gemma":0.0005612564,"threshold_uncertainty_score":0.7964831},"labels":[],"label_agreement":null},{"id":"W4387934162","doi":"10.1016/j.jcjd.2023.10.338","title":"ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG IN ADOLESCENTS WITH OVERWEIGHT OR OBESITY","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Overweight; Semaglutide; Percentile; Body mass index; Obesity; Comorbidity; Pediatrics; Internal medicine; Physical therapy; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.012045379659443666,"score_gpt":0.2199324090773391,"score_spread":0.20788702941789544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387934162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996817,0.00045551156,9.357126e-7,0.0011308442,0.00021144359,0.00025588876,0.000010341779,0.00002098502,0.0010970362],"genre_scores_gemma":[0.9969688,0.000022245658,0.00009907223,0.00057997816,0.00012388274,0.000004841026,0.0000075506136,0.00002943432,0.0021642097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859613,0.000034201104,0.00031874597,0.00016384124,0.0002631919,0.00062387367],"domain_scores_gemma":[0.998815,0.00003236705,0.00013713792,0.00019166822,0.000104821986,0.0007190278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021972762,0.00018325464,0.00042504555,0.00071024516,0.000064921165,0.000039514165,0.00015221923,0.000060970877,0.00009939046],"category_scores_gemma":[0.00008223295,0.00012813057,0.00009217188,0.00065948884,0.000078076046,0.000101524594,0.000015206743,0.00021203278,0.00006815053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004838102,0.000091620575,0.98646325,0.00016213892,0.0001509756,0.0038577013,0.00017698736,0.000031261006,0.00007899769,0.000026599893,0.0050056814,0.0039064186],"study_design_scores_gemma":[0.0028186871,0.0018950044,0.98430324,0.0024718544,0.00025071294,0.000041642314,0.00030409318,0.00009618801,0.0003573443,0.00009995416,0.0071453825,0.00021592123],"about_ca_topic_score_codex":0.0005460412,"about_ca_topic_score_gemma":0.027809782,"teacher_disagreement_score":0.02726374,"about_ca_system_score_codex":0.000364535,"about_ca_system_score_gemma":0.0007992757,"threshold_uncertainty_score":0.98993015},"labels":[],"label_agreement":null},{"id":"W4387934345","doi":"10.1016/j.jcjd.2023.10.233","title":"LOW-DOSE EMPAGLIFLOZIN AS ADJUNCT TO HYBRID CLOSED-LOOP INSULIN THERAPY IN SUB-OPTIMALLY CONTROLLED ADULTS WITH TYPE 1 DIABETES: A RANDOMIZED CROSSOVER CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Adjunct; Crossover study; Closed loop; Randomized controlled trial; Type 2 diabetes; Crossover; Diabetes mellitus; Insulin; Loop (graph theory); Internal medicine; Endocrinology; Artificial intelligence; Alternative medicine","score_opus":0.008816025266629323,"score_gpt":0.23579583323185455,"score_spread":0.2269798079652252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387934345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98469204,0.0028501116,0.0000011911693,0.0016307649,0.00093416206,0.00875644,0.000027260092,0.000043779328,0.0010642606],"genre_scores_gemma":[0.9947463,0.000290456,0.00008294076,0.002579137,0.0004077122,0.00059774914,0.00006008929,0.00009406183,0.0011415479],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99597645,0.00036917848,0.0013975332,0.00042609137,0.00062209996,0.0012086371],"domain_scores_gemma":[0.996029,0.0009800366,0.0005848084,0.00040774187,0.00062635384,0.0013720557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020563796,0.0005574373,0.0033965802,0.0017395975,0.00011878104,0.00018262868,0.00033116664,0.00013103617,0.00033997628],"category_scores_gemma":[0.0023098167,0.00037203825,0.00072812935,0.0010940592,0.0002025311,0.00023868518,0.000026279135,0.0003942393,0.00021788967],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96768737,0.0004975598,0.010620895,0.00007633597,0.0038993498,0.0006881226,0.0006252826,0.00027162186,0.0005907232,0.000029601078,0.006983441,0.008029722],"study_design_scores_gemma":[0.9815686,0.008653766,0.0047761234,0.00095649925,0.00075409515,0.0000020154976,0.00014013704,0.00058581604,0.00109055,0.00008379409,0.0009960193,0.00039260936],"about_ca_topic_score_codex":0.00025778622,"about_ca_topic_score_gemma":0.0021907848,"teacher_disagreement_score":0.01388123,"about_ca_system_score_codex":0.00033231406,"about_ca_system_score_gemma":0.0020383885,"threshold_uncertainty_score":0.99987316},"labels":[],"label_agreement":null},{"id":"W4387934390","doi":"10.1016/j.jcjd.2023.10.206","title":"IMPACT OF GLP-1 RECEPTOR AGONISTS COMPARED TO BASAL INSULIN START ON METABOLIC TARGETS IN PEOPLE LIVING WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (IMPACT GLP-1 CKD)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Glucagon-like peptide 1 receptor; Kidney disease; Glycemic; Type 2 diabetes; Basal (medicine); Basal insulin; Diabetes mellitus; Internal medicine; Agonist; Endocrinology; Insulin; Disease; Receptor","score_opus":0.011327845435443736,"score_gpt":0.2528811910281848,"score_spread":0.24155334559274105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387934390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486065,0.003331419,3.97037e-7,0.0007895719,0.00019985411,0.00047387317,0.00021250731,0.000017528218,0.00011420298],"genre_scores_gemma":[0.9989957,0.000133264,0.00008347942,0.00034890353,0.00016299135,0.000015408543,0.00009198263,0.000053001062,0.00011527697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980747,0.00008869922,0.00044286522,0.00025864752,0.00031390684,0.000821173],"domain_scores_gemma":[0.99658436,0.00016345568,0.00021568876,0.00028266283,0.00019831324,0.002555499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003894469,0.0003268116,0.0008510771,0.0012267468,0.000075731485,0.00006688105,0.00017153905,0.000055487206,0.0003519136],"category_scores_gemma":[0.0006061938,0.00024123165,0.00019259269,0.0010615933,0.00008949637,0.00019442326,0.000034433004,0.00020919977,0.000032850952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083361374,0.00013372017,0.9816762,0.00016420739,0.0007745889,0.000035265148,0.00060670596,0.00049541413,0.0010190357,0.000008802777,0.01262214,0.0023805497],"study_design_scores_gemma":[0.0020286913,0.0031579877,0.990962,0.0013724599,0.00027906903,3.5274445e-7,0.00009082668,0.000286046,0.0004160041,0.00002034495,0.001153761,0.00023244605],"about_ca_topic_score_codex":0.00082245696,"about_ca_topic_score_gemma":0.0041213646,"teacher_disagreement_score":0.01146838,"about_ca_system_score_codex":0.00063092523,"about_ca_system_score_gemma":0.002428712,"threshold_uncertainty_score":0.98371416},"labels":[],"label_agreement":null},{"id":"W4387949792","doi":"10.1136/dtb.2023.000007","title":"Semaglutide: a new drug for the treatment of obesity","year":2023,"lang":"en","type":"review","venue":"Drug and Therapeutics Bulletin","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; York University; University of Toronto","funders":"","keywords":"Semaglutide; Medicine; Drug; Obesity; Intensive care medicine; Pharmacology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Liraglutide","score_opus":0.07444368465809824,"score_gpt":0.34033123435977497,"score_spread":0.2658875497016767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387949792","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044732813,0.9940364,0.00001678246,0.002184842,0.00019836193,0.0030589164,0.00005737922,0.00006598158,0.00033665053],"genre_scores_gemma":[0.00001066388,0.92078847,0.00020669823,0.0001702927,0.00022980539,0.00028064425,0.000102917766,0.00006804149,0.07814244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988077,0.000048946367,0.00039091078,0.00032101307,0.00016206935,0.00026930918],"domain_scores_gemma":[0.99837375,0.0008435206,0.00020835939,0.0004491888,0.000035867262,0.00008928936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020148279,0.00038750508,0.0013026852,0.0001004832,0.00009747439,0.000026426254,0.0001160298,0.000088592635,0.00005638272],"category_scores_gemma":[0.0000067434876,0.00020620863,0.0005941036,0.00014045568,0.000071558905,0.000004127535,0.000038358357,0.00008027273,0.00008962838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024447885,0.00034875757,0.000014255603,0.005567196,0.0029144408,0.0000054992743,0.00037054313,1.3380152e-7,5.180442e-8,0.00045644082,0.011262149,0.9790361],"study_design_scores_gemma":[0.0012378818,0.00029152475,0.00001626653,0.0022368117,0.01106291,0.0000027459291,0.000084720254,0.0000070034207,0.0000047299377,0.00013455965,0.9847588,0.00016204406],"about_ca_topic_score_codex":0.00010088379,"about_ca_topic_score_gemma":0.00001709598,"teacher_disagreement_score":0.978874,"about_ca_system_score_codex":0.000077901095,"about_ca_system_score_gemma":0.000106092484,"threshold_uncertainty_score":0.8408944},"labels":[],"label_agreement":null},{"id":"W4387950612","doi":"10.1111/dom.15340","title":"Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Paul's Hospital; University of British Columbia; St. Michael's Hospital; McGill University Health Centre","funders":"Janssen Canada; Janssen Research and Development; McGill University Health Centre; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Canagliflozin; Credence; Type 2 diabetes; Empagliflozin; Heart failure; Medicine; Diabetes mellitus; Clinical trial; Pharmacology; Internal medicine; Endocrinology; Computer science","score_opus":0.013380282846031787,"score_gpt":0.22747753760283193,"score_spread":0.21409725475680014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387950612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852944,0.008203705,0.0000037890054,0.0012513828,0.00030239634,0.0040274835,0.00084631646,0.000047639234,0.000022871065],"genre_scores_gemma":[0.9420645,0.0022983823,0.011841918,0.027042313,0.0023107622,0.0022651358,0.010722011,0.00048491213,0.0009700452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972386,0.00014526017,0.00056518405,0.0007221467,0.00068529404,0.00064354634],"domain_scores_gemma":[0.9968424,0.0019711978,0.00025914473,0.0005417789,0.000224679,0.00016083791],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036646012,0.00055847305,0.0021364475,0.0002814044,0.00011410698,0.00007937041,0.00016814537,0.0004213198,0.0000024717724],"category_scores_gemma":[0.00063587166,0.0003680466,0.00027202538,0.00030784286,0.00036589566,0.00013235095,0.00019178585,0.00049448,0.0000013940333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008876526,0.00063871505,0.9120467,0.002266676,0.008751211,0.00001788889,0.00090643513,0.0000047901303,0.00002334014,0.00017371005,0.06835878,0.006723048],"study_design_scores_gemma":[0.018693466,0.0010893501,0.8025984,0.00053438474,0.0059091058,9.773133e-8,0.00016617813,0.00004321218,0.000129753,0.0005731214,0.17014726,0.00011563463],"about_ca_topic_score_codex":0.0004845145,"about_ca_topic_score_gemma":0.00017836438,"teacher_disagreement_score":0.10944821,"about_ca_system_score_codex":0.0000292724,"about_ca_system_score_gemma":0.00007713487,"threshold_uncertainty_score":0.99987715},"labels":[],"label_agreement":null},{"id":"W4388205111","doi":"10.58931/cpct.2023.1322","title":"Redefining Diabetes Strategies in Primary Care: Four New Pillars of Management","year":2023,"lang":"en","type":"article","venue":"Canadian Primary Care Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk; Amgen","keywords":"Hypoglycemia; Type 2 Diabetes Mellitus; Medicine; Primary care; Intensive care medicine; Disease; Disease management; Order (exchange); Diabetes mellitus; Nursing; Family medicine; Business; Pathology","score_opus":0.013188434252945871,"score_gpt":0.2178362010826352,"score_spread":0.20464776682968933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388205111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49742612,0.0038573965,0.000002728088,0.0010991711,0.00038321313,0.0010124838,0.000062747975,0.00016079152,0.49599534],"genre_scores_gemma":[0.9885211,0.000503565,0.000994484,0.0017991725,0.000091677175,0.00008543307,0.0017830931,0.00006834134,0.006153129],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981242,0.000032129934,0.00035655874,0.00041893314,0.0003343198,0.00073384907],"domain_scores_gemma":[0.9988718,0.000039184117,0.000074666765,0.00051151525,0.00007077533,0.00043205204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013121363,0.00027067165,0.0004957413,0.00093282777,0.00006534285,0.000045920704,0.00019992537,0.000103088605,0.000073311014],"category_scores_gemma":[0.00001031204,0.00027811635,0.00013300033,0.00081465003,0.00005782041,0.00015032204,0.00011401123,0.00013875822,0.00008461087],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100564896,0.00007437417,0.2552152,0.010364503,0.001023112,0.0031390893,0.0067100716,0.00040134919,0.0005699895,0.006812077,0.10004127,0.61554843],"study_design_scores_gemma":[0.0036967837,0.0004477137,0.84688455,0.0012807085,0.00044774974,0.0000023503796,0.009651357,0.00001209823,0.00036353528,0.00036495435,0.13630916,0.0005390255],"about_ca_topic_score_codex":0.0065563577,"about_ca_topic_score_gemma":0.01818604,"teacher_disagreement_score":0.61500937,"about_ca_system_score_codex":0.0019102923,"about_ca_system_score_gemma":0.0012902312,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W4388265322","doi":"10.1016/j.jcjd.2023.10.126","title":"DOES TEXTING IMPROVE GLYCEMIC CONTROL IN DIABETES? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","year":2023,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Glycemic; Meta-analysis; Randomized controlled trial; Diabetes mellitus; Systematic review; MEDLINE; Internal medicine; Endocrinology","score_opus":0.05499978679569613,"score_gpt":0.32826632520700616,"score_spread":0.27326653841131004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388265322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087814406,0.9834539,0.0000015329931,0.0004304472,0.00019630305,0.015412213,0.00033555512,0.000010425431,0.00007178897],"genre_scores_gemma":[0.0014150048,0.99496245,0.000033921904,0.0006229971,0.00007067811,0.0020025156,0.000057432404,0.00008148248,0.0007535151],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98543197,0.0038766463,0.009091316,0.0004077018,0.0004974259,0.0006949691],"domain_scores_gemma":[0.97518414,0.01325329,0.009833832,0.00057853776,0.0004527504,0.00069745077],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.023651985,0.0008456738,0.10027609,0.0044504795,0.00004734373,0.00009985992,0.00035151458,0.00026295715,0.00022616508],"category_scores_gemma":[0.025189225,0.00035181013,0.01896587,0.0014964443,0.00018504729,0.00011676618,0.000028075223,0.0004497976,0.000005988285],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013870996,0.000022311973,0.00003679687,0.44804996,0.55074805,0.000023349348,0.000020685806,6.8616487e-7,2.8435548e-7,0.00002088651,0.00005856561,0.00087972847],"study_design_scores_gemma":[0.06109004,0.00014454559,0.0000015663828,0.12179854,0.81595683,5.6531695e-7,0.000020260277,0.0000380255,2.756645e-7,0.000032001517,0.0006796314,0.00023770053],"about_ca_topic_score_codex":0.00015524104,"about_ca_topic_score_gemma":0.00096915866,"teacher_disagreement_score":0.32625142,"about_ca_system_score_codex":0.00028928337,"about_ca_system_score_gemma":0.0010512149,"threshold_uncertainty_score":0.99989337},"labels":[],"label_agreement":null},{"id":"W4388290823","doi":"10.1101/2023.11.01.23297949","title":"Cost-utility analysis of low-dose pioglitazone in a population with prediabetes and a history of stroke and TIA","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Pioglitazone; Medicine; Stroke (engine); Prediabetes; Population; Insulin resistance; Diabetes mellitus; Internal medicine; Type 2 diabetes; Emergency medicine; Environmental health; Endocrinology","score_opus":0.034845406379198605,"score_gpt":0.2679267891368218,"score_spread":0.23308138275762316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388290823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997012,0.0015777844,0.000023216659,0.00006328376,0.00006946008,0.00081555254,0.000079954065,0.000028643422,0.0003301079],"genre_scores_gemma":[0.99729,0.00016560819,0.0004454859,0.000010641708,0.000009945969,0.00008314086,0.0002887167,0.000016576627,0.0016898548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988137,0.000052346066,0.00037050256,0.00038264095,0.0002371231,0.0001436773],"domain_scores_gemma":[0.99916035,0.00007798137,0.0002363356,0.00039454218,0.00006341441,0.000067406676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037149977,0.00017865804,0.00081978604,0.000745817,0.0000062614263,0.0000041394533,0.000050256098,0.000098769306,0.000028433158],"category_scores_gemma":[0.00006593052,0.00014704443,0.00008721438,0.0002593126,0.00012041937,0.000033598953,0.00017925448,0.00013161152,4.918238e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001551333,0.00021312469,0.99173486,0.0014302331,0.0018011744,0.000010548051,0.0005158769,0.000052841388,0.00014632195,0.000013884753,0.00006684567,0.00385917],"study_design_scores_gemma":[0.0010948909,0.00017888432,0.9905381,0.00038365368,0.003564778,8.81827e-8,0.000053243766,0.0038785255,0.00006624359,0.00004619621,0.00010278776,0.00009260447],"about_ca_topic_score_codex":0.0008124113,"about_ca_topic_score_gemma":0.00084431656,"teacher_disagreement_score":0.003825684,"about_ca_system_score_codex":0.00015304846,"about_ca_system_score_gemma":0.000049553186,"threshold_uncertainty_score":0.59962976},"labels":[],"label_agreement":null},{"id":"W4388406321","doi":"10.7326/l23-0410","title":"Correction: Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes","year":2023,"lang":"en","type":"erratum","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Basal insulin; Insulin; Dosing; Diabetes mellitus; Basal (medicine); Type 2 diabetes; Internal medicine; Endocrinology; Type 1 diabetes","score_opus":0.04887248155840731,"score_gpt":0.3297608706133196,"score_spread":0.2808883890549123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388406321","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24769947,0.076452665,0.00012209453,0.03471498,0.18048388,0.0047172015,0.00029299152,0.0011840644,0.45433265],"genre_scores_gemma":[0.30964407,0.060431786,0.0008134766,0.012524152,0.017454753,0.0003527143,0.0060125757,0.000786849,0.5919796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468803,0.00015914901,0.0016792929,0.0010572678,0.0014502499,0.0009660353],"domain_scores_gemma":[0.99600863,0.0006609875,0.0010338114,0.00085256353,0.0010318384,0.000412158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008812594,0.00097862,0.0023724034,0.0016242663,0.00008039587,0.000042550077,0.000596719,0.0005554941,0.00035324873],"category_scores_gemma":[0.0018800928,0.00073354586,0.0002873814,0.0016612005,0.0005977037,0.00022269643,0.00029648803,0.001617823,0.00020209185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047418834,0.0005899575,0.007701862,0.00073914236,0.002422883,0.0008102298,0.0010400318,0.00003212406,0.00006291258,0.000029657791,0.9401025,0.04172678],"study_design_scores_gemma":[0.025492217,0.03976383,0.07519811,0.06181658,0.002582837,0.000023939914,0.0037736862,0.0016722905,0.002063062,0.0002740853,0.78565365,0.0016857139],"about_ca_topic_score_codex":0.0031209406,"about_ca_topic_score_gemma":0.0012266784,"teacher_disagreement_score":0.16302913,"about_ca_system_score_codex":0.0003557817,"about_ca_system_score_gemma":0.0006859938,"threshold_uncertainty_score":0.99951154},"labels":[],"label_agreement":null},{"id":"W4388519616","doi":"10.21203/rs.3.rs-3508820/v1","title":"Canagliflozin produces a vasorelaxation effect on isolated rat thoracic aorta via NO/cGMP pathways","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"King Saud University","keywords":"Glibenclamide; Canagliflozin; Chemistry; Phenylephrine; Endocrinology; Pharmacology; Internal medicine; Methylene blue; Medicine; Anesthesia; Diabetes mellitus; Blood pressure; Type 2 diabetes; Biochemistry","score_opus":0.07306121642755271,"score_gpt":0.39980240136075545,"score_spread":0.32674118493320276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388519616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675961,0.00096170773,0.00009325545,0.0030033435,0.00167793,0.013089911,0.00011686231,0.0010263892,0.012434461],"genre_scores_gemma":[0.97604716,0.00053153036,0.00009761253,0.00006327458,0.000646723,0.0023441406,0.0026886938,0.00017181983,0.017409071],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943782,0.0007870232,0.00044271105,0.0013377139,0.001985868,0.0010685017],"domain_scores_gemma":[0.9966634,0.000552836,0.00016931105,0.001552932,0.000700189,0.0003613617],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002766743,0.00053347,0.0007778577,0.0011854395,0.00026347593,0.00019979046,0.00038031104,0.00042645342,0.00023908883],"category_scores_gemma":[0.0011972338,0.0004145286,0.00031187362,0.00091969734,0.0000953365,0.00007898218,0.0009005293,0.0017184855,0.0052325074],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009308787,0.0048071845,0.07356445,0.06563496,0.007754616,0.0055248034,0.0029337944,0.0011715435,0.01357358,0.0009729319,0.2429907,0.5717626],"study_design_scores_gemma":[0.029184887,0.111553974,0.28059563,0.11718733,0.008175618,0.000040833183,0.0018518838,0.12838177,0.13131863,0.015263462,0.16679177,0.009654228],"about_ca_topic_score_codex":0.0011001882,"about_ca_topic_score_gemma":0.00029866127,"teacher_disagreement_score":0.5621084,"about_ca_system_score_codex":0.00088325655,"about_ca_system_score_gemma":0.00040180897,"threshold_uncertainty_score":0.99983066},"labels":[],"label_agreement":null},{"id":"W4388538929","doi":"10.1007/s12325-023-02652-5","title":"Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cardiorenal syndrome; Heart failure; Diabetes mellitus; Kidney disease; Intensive care medicine; Internal medicine; Renal function; Type 2 diabetes; Disease; Cardiology; Endocrinology","score_opus":0.060654851084780644,"score_gpt":0.3441065490192637,"score_spread":0.28345169793448305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388538929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028925412,0.9964199,0.00018236497,0.000034301902,0.000808427,0.0014930271,0.000024903526,0.00007205374,0.0006757581],"genre_scores_gemma":[0.001264879,0.99733335,0.00029864992,0.00006697393,0.00017384999,0.00032563752,0.00017672447,0.000090575806,0.00026937958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980428,0.00008090702,0.00068430335,0.00040184267,0.00042232109,0.0003678178],"domain_scores_gemma":[0.99901205,0.00013533466,0.00033146393,0.00043373523,0.00003432296,0.00005310757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036440173,0.00041544903,0.0014846927,0.00028700742,0.000065983375,0.000017432983,0.00023829324,0.00014984063,0.000028338036],"category_scores_gemma":[0.0000073622837,0.00025118428,0.0005872085,0.00047235144,0.000082448205,0.0001396537,0.000042597283,0.0002793075,0.000018305207],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003973839,0.000074495925,0.0000139541535,0.0027469238,0.0005929813,0.00005136882,0.00016794575,0.000043818294,0.00000373453,0.0019030033,0.00001973845,0.99434227],"study_design_scores_gemma":[0.0028009657,0.0006744411,0.00006970051,0.025286905,0.001799779,0.000017021439,0.00049948227,0.0000119041,0.00020893758,0.0015005227,0.9665982,0.0005321463],"about_ca_topic_score_codex":0.000011357817,"about_ca_topic_score_gemma":0.000017727778,"teacher_disagreement_score":0.9938102,"about_ca_system_score_codex":0.00008713964,"about_ca_system_score_gemma":0.00007220782,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W4388586266","doi":"10.1161/circulationaha.123.067530","title":"Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute on Minority Health and Health Disparities; National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Medicine; Internal medicine; Cardiology; Diabetes mellitus; Heart failure; Cohort; Framingham Risk Score; Natriuretic peptide; Type 2 diabetes; Disease; Endocrinology","score_opus":0.009442785117831011,"score_gpt":0.22014528417723633,"score_spread":0.21070249905940533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388586266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149615,0.0003108345,0.0062401067,0.00008034339,0.0000116318215,0.0017563008,0.000012831438,0.00008385409,0.00000792277],"genre_scores_gemma":[0.9977121,0.000010109899,0.0017367543,0.000007122772,0.000046266952,0.00025035013,0.00019170737,0.000021923746,0.000023703016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989999,0.000057696943,0.00018309255,0.00027562678,0.00029081464,0.00019285611],"domain_scores_gemma":[0.99934465,0.00008852376,0.00012440191,0.00029678148,0.00008054237,0.00006508095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005957559,0.0001186607,0.00032879104,0.00014514022,0.00015315687,0.000028571214,0.00003415097,0.000028957138,0.0000027613921],"category_scores_gemma":[0.0001047315,0.00008123813,0.0002833111,0.00052862347,0.000054194887,0.00010014976,0.00002959369,0.00005071694,4.912457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003437664,0.000018872433,0.91342044,0.00017678815,0.008551809,5.0907397e-7,0.00017283097,0.07601492,0.000044888842,0.0000029001176,0.000007898023,0.0015537417],"study_design_scores_gemma":[0.0009252059,0.000039989834,0.70510966,0.00022180194,0.015960744,7.4044465e-8,0.0001794002,0.27745363,0.000036104564,0.0000044764924,0.000012471933,0.00005643797],"about_ca_topic_score_codex":0.00003732878,"about_ca_topic_score_gemma":0.000009943118,"teacher_disagreement_score":0.2083108,"about_ca_system_score_codex":0.000018079489,"about_ca_system_score_gemma":0.000010191223,"threshold_uncertainty_score":0.3312795},"labels":[],"label_agreement":null},{"id":"W4388595659","doi":"10.1093/eurheartj/ehad655.1429","title":"GLP-2 predicts cardiovascular outcomes in patients with myocardial infarction and increases atherosclerosis in mice","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"European Research Area Network on Cardiovascular Diseases; European Foundation for the Study of Diabetes","keywords":"Medicine; Mace; Myocardial infarction; Internal medicine; Diabetes mellitus; Glucagon-like peptide-1; Incretin; Cardiology; Postprandial; Proportional hazards model; Type 2 diabetes; Gastroenterology; Endocrinology; Insulin; Percutaneous coronary intervention","score_opus":0.018584459443584344,"score_gpt":0.2287845551578027,"score_spread":0.21020009571421835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388595659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982134,0.00012183706,0.00000222263,0.0002604092,0.00009942162,0.0002964036,0.0000032757437,0.000040767918,0.000962277],"genre_scores_gemma":[0.99912566,0.00024181721,0.00010260022,0.0002301271,0.00009129326,0.0000049634573,0.000014739668,0.0000288257,0.00015996626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988781,0.0001968559,0.0001883996,0.00016901013,0.0003335164,0.00023407019],"domain_scores_gemma":[0.9996539,0.000029352688,0.000035629622,0.00013325221,0.000030104697,0.000117788404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006088482,0.00012321041,0.00029697447,0.00030288563,0.00005411304,0.000042995624,0.00003611324,0.00001771181,0.0000099659965],"category_scores_gemma":[0.000058007256,0.000090853384,0.00009886393,0.00025741453,0.000028273374,0.0001357615,0.000057740166,0.00016385973,0.000046401943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083576255,0.00015932707,0.99382514,0.000014647266,0.0003074386,0.00007080885,0.00013847266,0.00005305725,0.000014617281,0.0000013883184,0.0007479948,0.004583506],"study_design_scores_gemma":[0.0055283247,0.00046054774,0.9883261,0.00017864662,0.00012729628,0.000009264015,0.000056798643,0.000011859205,0.0000050215467,0.0000024614003,0.0052111032,0.00008263006],"about_ca_topic_score_codex":0.0000394746,"about_ca_topic_score_gemma":0.0000076238935,"teacher_disagreement_score":0.0054991194,"about_ca_system_score_codex":0.000066668435,"about_ca_system_score_gemma":0.000015432073,"threshold_uncertainty_score":0.37048936},"labels":[],"label_agreement":null},{"id":"W4388598156","doi":"10.1093/eurheartj/ehad655.2570","title":"Cardioprotective pharmacotherapy in patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Medicine; Type 2 diabetes; Metformin; Pharmacotherapy; Internal medicine; Diabetes mellitus; Renal function; Albuminuria; Body mass index; Observational study; Creatinine; Population; Insulin; Endocrinology; Environmental health","score_opus":0.06354456113237592,"score_gpt":0.28584754727119976,"score_spread":0.22230298613882385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642324,0.00030979878,5.2593737e-7,0.0008061332,0.00013370834,0.0008309586,0.0000026045827,0.000029257202,0.0014637912],"genre_scores_gemma":[0.99868405,0.000046179724,0.000008906018,0.00026690116,0.00015827361,0.000011318395,0.0000016860955,0.000030483787,0.0007921773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888414,0.0002683998,0.00012780122,0.00014295334,0.00027871245,0.00029797855],"domain_scores_gemma":[0.9996035,0.000040173272,0.000049663508,0.00017186177,0.000061281564,0.00007350207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091385137,0.0001227191,0.00016458136,0.00005541952,0.00027479947,0.00009775635,0.000085746484,0.000007658264,0.000020782278],"category_scores_gemma":[0.000019884883,0.000054844502,0.000040057523,0.0003516556,0.00006404512,0.00006916581,0.00006988072,0.00026918328,0.00007485806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019372112,0.0002730045,0.9762342,0.000007035338,0.00040073745,0.0000726539,0.012497996,0.000016747987,0.000057232828,9.2452e-7,0.0029722415,0.0072735315],"study_design_scores_gemma":[0.0033787333,0.0014146891,0.97725034,0.000053049578,0.000074681775,0.0000036523759,0.004060287,0.000013872366,0.000017074768,0.0000041943117,0.013663414,0.000066025794],"about_ca_topic_score_codex":0.0000022654026,"about_ca_topic_score_gemma":0.0000026940425,"teacher_disagreement_score":0.0106911715,"about_ca_system_score_codex":0.00003272969,"about_ca_system_score_gemma":0.00001168857,"threshold_uncertainty_score":0.2236494},"labels":[],"label_agreement":null},{"id":"W4388599898","doi":"10.1093/eurheartj/ehad655.1085","title":"Short term effect of sodium glucose cotransporter 2 inhibitors and sacubitril/valsartan on comprehensive geriatric assessment and oxidative stress in elderly with chronic heart failure (from MAGIC-HF)","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Montreal Cognitive Assessment; Ejection fraction; Geriatric Depression Scale; Cardiology; Tolerability; Population; Valsartan; Diabetes mellitus; Cognitive decline; Endocrinology; Dementia; Blood pressure; Disease; Adverse effect","score_opus":0.014377861090862,"score_gpt":0.2797240746194387,"score_spread":0.26534621352857674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388599898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733007,0.000653123,0.0000062698095,0.00072258955,0.00011592798,0.00070031715,0.000026739426,0.000037150985,0.0004078407],"genre_scores_gemma":[0.99881774,0.00034465615,0.00025929755,0.000093495124,0.00024211437,0.000006535792,0.00006784031,0.000047562087,0.00012078228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982748,0.00032038355,0.00035109307,0.0003414865,0.00037238284,0.00033986126],"domain_scores_gemma":[0.9992803,0.00016153892,0.0000981901,0.00019689821,0.000051497962,0.00021160238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003628445,0.00028516818,0.0006625307,0.00035160102,0.00008433112,0.000070269954,0.000056897024,0.00003698913,0.00004036762],"category_scores_gemma":[0.000005467708,0.00019997955,0.00008188751,0.00026832713,0.00010348093,0.00013638419,0.0000508055,0.00039458077,0.000016839334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004867154,0.00020340813,0.9590912,0.00023109146,0.00031942996,0.0010648649,0.00031171663,0.00002302613,0.028665526,0.0000045888055,0.003062603,0.0065358286],"study_design_scores_gemma":[0.004687653,0.0066212295,0.9727663,0.00093248015,0.0002949443,0.000061869636,0.00016224224,0.00003278621,0.011527323,0.0000036869924,0.0027275155,0.00018201188],"about_ca_topic_score_codex":0.000013605797,"about_ca_topic_score_gemma":0.000023063378,"teacher_disagreement_score":0.017138202,"about_ca_system_score_codex":0.000102190235,"about_ca_system_score_gemma":0.000049116312,"threshold_uncertainty_score":0.8154929},"labels":[],"label_agreement":null},{"id":"W4388601005","doi":"10.1093/eurheartj/ehad655.2568","title":"Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Medicine; Mace; Semaglutide; Internal medicine; Type 2 diabetes; Population; Cardiology; Myocardial infarction; Post-hoc analysis; Vascular disease; Diabetes mellitus; Endocrinology; Liraglutide; Percutaneous coronary intervention","score_opus":0.00685189600965008,"score_gpt":0.2203711664141536,"score_spread":0.21351927040450353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388601005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983125,0.0005750766,5.700037e-7,0.00014087628,0.000108843684,0.0007661273,0.0000068144036,0.000011319215,0.000077905774],"genre_scores_gemma":[0.9995033,0.000060693244,0.000019744175,0.000081982085,0.00004919096,0.000003673454,0.00001793364,0.000024513494,0.00023894766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982831,0.00046650125,0.0002511966,0.00018065619,0.0005829479,0.00023563334],"domain_scores_gemma":[0.99923444,0.0000923957,0.000113712966,0.0003186376,0.000101310645,0.00013950579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006522661,0.00014144812,0.0004766671,0.0004549329,0.000057295198,0.000006719411,0.000084852436,0.000014882817,0.000010044168],"category_scores_gemma":[0.0002256706,0.000085674736,0.0004493863,0.0009896052,0.00005060967,0.000042825715,0.000081454236,0.0001292889,0.0000065622344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006743552,0.00056606,0.9821154,0.00020073698,0.007172774,0.00013056197,0.00016121585,0.0005058801,0.000061024883,0.0000047740286,0.0002516617,0.0020863742],"study_design_scores_gemma":[0.02513901,0.0020146647,0.966932,0.00035633528,0.004845147,3.0071567e-7,0.0000481578,0.00004376035,0.000057742604,0.0000020990467,0.00048479735,0.00007596348],"about_ca_topic_score_codex":0.000006589041,"about_ca_topic_score_gemma":0.0000017274928,"teacher_disagreement_score":0.01839546,"about_ca_system_score_codex":0.000052114676,"about_ca_system_score_gemma":0.000044625333,"threshold_uncertainty_score":0.34937143},"labels":[],"label_agreement":null},{"id":"W4388601262","doi":"10.1093/eurheartj/ehad655.810","title":"Effect of vericiguat on cardiovascular outcomes in patients with heart failure with and without diabetes: Insights from the VICTORIA trial","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Bayer","keywords":"Medicine; Hazard ratio; Ejection fraction; Heart failure; Internal medicine; Diabetes mellitus; Type 2 diabetes; Placebo; Cardiology; Proportional hazards model; Post-hoc analysis; Confidence interval; Cause of death; Disease; Endocrinology; Pathology","score_opus":0.01066854564611852,"score_gpt":0.23597643002400437,"score_spread":0.22530788437788585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388601262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981433,0.00011707398,0.000001187843,0.00035331515,0.00020200577,0.00084258715,0.0000035923956,0.000029213286,0.00030768936],"genre_scores_gemma":[0.9993852,0.000012582689,0.00007692525,0.0001931703,0.00020347525,0.000008558556,0.000015771722,0.000040222927,0.00006412284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982412,0.00055729493,0.00020387316,0.00020941408,0.0005661293,0.00022212346],"domain_scores_gemma":[0.9992625,0.00019582688,0.00006972264,0.00032820372,0.000039048875,0.00010470049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006123832,0.00019839637,0.0005740392,0.0001300303,0.000088423854,0.000047198413,0.00007140732,0.00002041292,0.000010561537],"category_scores_gemma":[0.00006709461,0.00008948758,0.00014026984,0.00023347592,0.00005800132,0.000080692815,0.000045971447,0.00023921454,0.000041503798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004656996,0.00011906238,0.991919,0.00002110925,0.00086780166,0.000028292246,0.00020194471,0.000035001154,0.000016900376,0.0000015845799,0.0014251121,0.0007072049],"study_design_scores_gemma":[0.051373128,0.00799286,0.9273971,0.0003604679,0.00043031634,0.0000011953615,0.00003178995,0.000005991586,0.000117728305,0.0000018391482,0.012190873,0.00009676346],"about_ca_topic_score_codex":0.000006661372,"about_ca_topic_score_gemma":0.0000041088174,"teacher_disagreement_score":0.064521946,"about_ca_system_score_codex":0.00003421801,"about_ca_system_score_gemma":0.000017540498,"threshold_uncertainty_score":0.36491975},"labels":[],"label_agreement":null},{"id":"W4388607953","doi":"10.1001/jamacardio.2023.4664","title":"Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction","year":2023,"lang":"en","type":"article","venue":"JAMA Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Novo Nordisk; American Heart Association","keywords":"Medicine; Dapagliflozin; Ejection fraction; Heart failure; Renal function; Heart failure with preserved ejection fraction; Placebo; Internal medicine; Cardiology; Dialysis; Kidney disease; Diabetes mellitus; Hazard ratio; Type 2 diabetes; Endocrinology; Confidence interval","score_opus":0.022872737537913294,"score_gpt":0.2869178087086902,"score_spread":0.2640450711707769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388607953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252963,0.00006779143,0.00009560108,0.0058142054,0.00014907098,0.0008103542,0.0000056146764,0.00013889841,0.00038883422],"genre_scores_gemma":[0.9969458,0.00007780359,0.00086889014,0.00046180713,0.00014834617,0.0004376591,0.000440153,0.000023141562,0.000596395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987439,0.00021900826,0.00026114084,0.00035062374,0.00012527868,0.00030003107],"domain_scores_gemma":[0.99949825,0.00008994133,0.000052010313,0.0002531727,0.00005525308,0.00005136962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047603447,0.00015596468,0.0004285951,0.00040508012,0.000023941157,0.000020814026,0.000039957722,0.0001722352,0.0000647616],"category_scores_gemma":[0.00016842067,0.000117785006,0.000056860907,0.0007858268,0.000033370594,0.00019188192,0.000039128798,0.00018533734,0.0001053301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005399517,0.00015521911,0.95048106,0.00015956718,0.00031987086,0.0010146276,0.000092731476,0.0045788107,0.017340941,0.000015382398,0.017542139,0.0029001092],"study_design_scores_gemma":[0.0045307702,0.0006761552,0.97351754,0.00015073433,0.0001130627,0.00001915549,0.00016654679,0.0029302654,0.0015459647,0.000057342695,0.016161857,0.00013058064],"about_ca_topic_score_codex":0.00018021933,"about_ca_topic_score_gemma":0.0007427578,"teacher_disagreement_score":0.02303648,"about_ca_system_score_codex":0.00015390747,"about_ca_system_score_gemma":0.000048446684,"threshold_uncertainty_score":0.4803133},"labels":[],"label_agreement":null},{"id":"W4388682487","doi":"10.1186/s12872-023-03549-5","title":"Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial","year":2023,"lang":"en","type":"article","venue":"BMC Cardiovascular Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; St. Michael's Hospital; Western University","funders":"University of Toronto","keywords":"Empagliflozin; Medicine; Internal medicine; Placebo; Cardiology; Ejection fraction; Type 2 Diabetes Mellitus; Angiology; Coronary artery disease; Diabetes mellitus; Heart failure; Endocrinology; Pathology","score_opus":0.023455176370298023,"score_gpt":0.28360193277688367,"score_spread":0.26014675640658563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388682487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824906,0.0029947108,0.00017771074,0.00012952162,0.0006633895,0.005344049,0.000041271625,0.000107498985,0.0022927572],"genre_scores_gemma":[0.9980604,0.0006455697,0.00012269996,0.000058634443,0.0004842275,0.0003169927,0.0001869151,0.00007428896,0.000050284678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951428,0.0018270587,0.00080120884,0.00083755655,0.0009136828,0.00047764677],"domain_scores_gemma":[0.9973427,0.0010201238,0.00014531401,0.0012705991,0.000033448763,0.00018783752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040554553,0.00045007656,0.002202476,0.00033084393,0.00011794691,0.00004767801,0.00020280016,0.00026567138,0.000004410673],"category_scores_gemma":[0.0005932213,0.00030610277,0.003051012,0.0006413341,0.00018543484,0.00006865645,0.00014648201,0.0004056266,0.000053109936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074489094,0.00047136535,0.7640008,0.0006060567,0.026765162,0.00007652524,0.019051261,0.006003763,0.000014849736,0.000031837608,0.0011973642,0.10729195],"study_design_scores_gemma":[0.47173434,0.0030862337,0.4995383,0.0006586633,0.0105217835,7.741135e-7,0.0048176614,0.0012320278,0.00012569054,0.00016172619,0.0074055335,0.00071726943],"about_ca_topic_score_codex":0.00011940544,"about_ca_topic_score_gemma":0.0000356182,"teacher_disagreement_score":0.39724526,"about_ca_system_score_codex":0.000051631847,"about_ca_system_score_gemma":0.00009416637,"threshold_uncertainty_score":0.9999391},"labels":[],"label_agreement":null},{"id":"W4388693803","doi":"10.1093/eurheartj/ehad664","title":"The cardiovascular effects of novel weight loss therapies","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Weight loss; Overweight; Obesity; Type 2 diabetes; Pharmacotherapy; Diabetes mellitus; Psychological intervention; Weight management; Population; Internal medicine; Disease; Intensive care medicine; Endocrinology; Environmental health; Psychiatry","score_opus":0.02397203348032112,"score_gpt":0.2588156546384401,"score_spread":0.23484362115811896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388693803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96749794,0.010943284,0.00023197265,0.004719771,0.0011088208,0.00039571858,0.000001149899,0.00010323789,0.014998121],"genre_scores_gemma":[0.9904063,0.0033850046,0.00029257758,0.00023721866,0.0006058411,0.0000031853233,0.0000023324412,0.00003812764,0.0050294516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910265,0.0001308474,0.00014938938,0.000090529196,0.00031397145,0.00021260767],"domain_scores_gemma":[0.99946785,0.00011003091,0.000042934902,0.0002622327,0.00003703776,0.00007991463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008793324,0.00008910223,0.00019084114,0.000075884185,0.00017039593,0.000033525073,0.00008876116,0.000009676833,0.000012984342],"category_scores_gemma":[0.000049566825,0.000049376056,0.0003343052,0.00017110733,0.000059173355,0.000039101284,0.000055880933,0.00012891495,0.00018483358],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039408746,0.0013230405,0.18585517,0.0010724013,0.024691528,0.0067989556,0.003936258,0.00025620288,0.019117285,0.0042342665,0.39410877,0.35821205],"study_design_scores_gemma":[0.0019383254,0.0002529316,0.32975176,0.0001459202,0.00024996317,0.000108412685,0.000045946636,0.000022504537,0.0011001345,0.000028382734,0.66629905,0.00005666737],"about_ca_topic_score_codex":8.260993e-7,"about_ca_topic_score_gemma":1.2054541e-7,"teacher_disagreement_score":0.35815537,"about_ca_system_score_codex":0.000016780485,"about_ca_system_score_gemma":0.000014492862,"threshold_uncertainty_score":0.23757233},"labels":[],"label_agreement":null},{"id":"W4388724274","doi":"10.1161/atvbaha.123.320032","title":"Release of Lipids Stored in the Intestine by Glucagon-Like Peptide-2 Involves a Gut-Brain Neural Pathway","year":2023,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Internal medicine; Small intestine; Endocrinology; Hypothalamus; Lipid metabolism; Chylomicron; Chemistry; Biology; Lipoprotein; Medicine; Cholesterol; Very low-density lipoprotein","score_opus":0.03643262128889811,"score_gpt":0.27843625125278515,"score_spread":0.24200362996388702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388724274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941667,0.00022476462,0.000013243768,0.004734445,0.00012478288,0.00048934075,0.000024000617,0.00006236346,0.00016036267],"genre_scores_gemma":[0.99582046,0.0015563956,0.000079846766,0.0020553363,0.000043004504,0.0001294486,0.00024463344,0.000020996176,0.000049888306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861157,0.00019513596,0.00034095446,0.00036757134,0.00013281981,0.00035194543],"domain_scores_gemma":[0.99921304,0.0001698752,0.0000912054,0.00041503122,0.0000341088,0.00007671396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048589305,0.00021764624,0.0004846846,0.00016774015,0.00007034889,0.000021163987,0.00014896461,0.000094926945,0.00002553387],"category_scores_gemma":[0.00008689366,0.00014326599,0.0001672535,0.00043609043,0.00022314578,0.000069873626,0.00012901214,0.00011279955,0.000017502947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020175132,0.0008205978,0.4852779,0.00016453976,0.00059953425,0.000001166049,0.0022407845,0.0000027486205,0.47623134,0.0008754282,0.029662259,0.0041035675],"study_design_scores_gemma":[0.0019826053,0.0011649107,0.9787133,0.000097949975,0.0001306564,3.1994125e-7,0.00081233773,0.000410576,0.000308969,0.000074560434,0.01615217,0.00015169391],"about_ca_topic_score_codex":0.00014036996,"about_ca_topic_score_gemma":0.000060035243,"teacher_disagreement_score":0.49343538,"about_ca_system_score_codex":0.000020991742,"about_ca_system_score_gemma":0.000015982521,"threshold_uncertainty_score":0.5842218},"labels":[],"label_agreement":null},{"id":"W4388737168","doi":"10.1111/obr.13663","title":"Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists","year":2023,"lang":"en","type":"review","venue":"Obesity Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health; Cardiome (Canada); University of British Columbia; Island Health; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada)","funders":"Eli Lilly Canada; Novo Nordisk; Novo Nordisk Canada; AstraZeneca; Eli Lilly and Company","keywords":"Type 2 diabetes; Medicine; Liraglutide; Nonalcoholic fatty liver disease; Steatohepatitis; Glucagon-like peptide 1 receptor; Fatty liver; Obesity; Diabetes mellitus; Internal medicine; Bioinformatics; Pharmacology; Endocrinology; Disease; Receptor; Agonist; Biology","score_opus":0.06433320283290306,"score_gpt":0.3341029985553939,"score_spread":0.2697697957224908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388737168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024535265,0.98470706,0.0000057679895,0.0001207106,0.0004975401,0.009453204,0.00028775053,0.00023806255,0.0022363656],"genre_scores_gemma":[0.00004275155,0.9713547,0.0041939686,0.0002013599,0.0002001355,0.000995962,0.0033754131,0.00023947725,0.019396212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945473,0.00053034746,0.0017168777,0.0014121904,0.0008815616,0.00091172074],"domain_scores_gemma":[0.99611855,0.00020495403,0.0012861177,0.001711717,0.00018825321,0.0004904156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0011778233,0.0013755969,0.006236315,0.00047285436,0.00024966546,0.00015899075,0.0005547644,0.0004082833,0.0009927156],"category_scores_gemma":[0.00007998194,0.00092466566,0.00075403065,0.0016029445,0.0003405018,0.00014219525,0.00043725947,0.000482433,0.0023120116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010227145,0.0011589759,0.0030782924,0.22434619,0.00285736,0.00021624513,0.000027232729,1.540331e-7,0.0000012706217,0.00026577213,0.028555531,0.73939073],"study_design_scores_gemma":[0.0017357618,0.0012121013,0.001008303,0.08623238,0.008350508,0.000006512187,0.000005919594,0.0000021862709,0.000012852127,0.000008293653,0.90063393,0.0007912654],"about_ca_topic_score_codex":0.00008536117,"about_ca_topic_score_gemma":0.00006849449,"teacher_disagreement_score":0.87207836,"about_ca_system_score_codex":0.00052483124,"about_ca_system_score_gemma":0.0003821584,"threshold_uncertainty_score":0.9999205},"labels":[],"label_agreement":null},{"id":"W4388764309","doi":"10.22541/au.170022092.29999283/v1","title":"A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Metabolomics Innovation Centre; University of Alberta","funders":"","keywords":"Internal medicine; Medicine; Endocrinology; Glycemic; Diabetes mellitus; Metabolic syndrome; Creatinine; Insulin","score_opus":0.06021849384243057,"score_gpt":0.32045477237083264,"score_spread":0.2602362785284021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388764309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771918,0.0018221784,0.008680923,0.0004132326,0.00055860175,0.010260142,0.00087789714,0.00009896693,0.00009622475],"genre_scores_gemma":[0.99465245,0.0010195151,0.0013369672,0.0002777351,0.00005132951,0.0013266044,0.0004321417,0.00006346761,0.00083979976],"study_design_codex":"meta_analysis","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997534,0.0000710546,0.00083518884,0.0005937214,0.00057422544,0.0003918369],"domain_scores_gemma":[0.9968972,0.0013124152,0.000482652,0.001021753,0.00018900023,0.00009693577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007837784,0.0004186365,0.0016945673,0.00023203656,0.000050500603,0.00001957306,0.0004129402,0.00025252142,0.000011604367],"category_scores_gemma":[0.00019999532,0.00025765604,0.00075874355,0.00013263748,0.00011843309,0.000030466152,0.00043235818,0.00033841806,0.0000064523183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028689073,0.13847066,0.2228619,0.09660282,0.23377894,0.00027220623,0.0070722294,0.0539733,0.119656585,0.028698051,0.021073973,0.04885026],"study_design_scores_gemma":[0.24118851,0.02631039,0.276745,0.007307522,0.05146986,0.00001886951,0.0005778296,0.32809126,0.045891326,0.018970827,0.0006496751,0.0027789231],"about_ca_topic_score_codex":0.000055929217,"about_ca_topic_score_gemma":0.0000074603886,"teacher_disagreement_score":0.27411798,"about_ca_system_score_codex":0.00004113109,"about_ca_system_score_gemma":0.00015369568,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W4388766983","doi":"10.1007/s40256-023-00618-0","title":"The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review","year":2023,"lang":"en","type":"review","venue":"American Journal of Cardiovascular Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Coronary artery disease; Internal medicine; Percutaneous coronary intervention; Revascularization; Cardiology; Diabetes mellitus; Heart failure; Intensive care medicine; Myocardial infarction; Endocrinology","score_opus":0.0360141364876529,"score_gpt":0.28026528714409443,"score_spread":0.24425115065644154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388766983","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016793872,0.9952841,0.00006960979,0.0004417367,0.00029537283,0.0038179995,0.000017674705,0.000024725912,0.000032029817],"genre_scores_gemma":[0.000024047353,0.99887776,0.000157123,0.00008681576,0.00015415157,0.00020071052,0.00004091985,0.00012783958,0.00033065103],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934233,0.0012084825,0.0029483696,0.0003729868,0.0016517158,0.0003951511],"domain_scores_gemma":[0.9942903,0.00047005896,0.0031428693,0.0014618086,0.00043685507,0.00019808898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002750494,0.0006040166,0.009001831,0.000493285,0.0000623744,0.000047547204,0.00045572082,0.00011445137,0.000006265366],"category_scores_gemma":[0.00017192373,0.0003575645,0.007484179,0.0017063901,0.00027788276,0.00016707681,0.000086087464,0.00056585006,0.00002664555],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017468501,0.00009353129,0.000029663237,0.63040406,0.024461186,0.0008207316,0.00007276176,0.000016995229,1.8010095e-8,0.0000049826554,0.0017273618,0.34235126],"study_design_scores_gemma":[0.00046091215,0.00016589533,0.000010803808,0.47618604,0.043185364,0.00019095285,0.0001653302,0.0000013369234,2.2352737e-7,0.0000013954544,0.47946745,0.00016428108],"about_ca_topic_score_codex":0.000026544974,"about_ca_topic_score_gemma":0.000009713172,"teacher_disagreement_score":0.4777401,"about_ca_system_score_codex":0.0003344657,"about_ca_system_score_gemma":0.0004037777,"threshold_uncertainty_score":0.99988765},"labels":[],"label_agreement":null},{"id":"W4388831620","doi":"10.1503/cmaj.230820","title":"Novel obesity treatments","year":2023,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sinai Health System; Toronto East General Hospital; Toronto Rehabilitation Institute; University of Toronto","funders":"Novo Nordisk; University of Toronto; American Diabetes Association","keywords":"Obesity; Body mass index; Medicine; Dyslipidemia; Obstructive sleep apnea; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.012840028749127107,"score_gpt":0.24863414891468827,"score_spread":0.23579412016556117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388831620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8811114,0.00009609427,0.0000556797,0.07116887,0.0014007541,0.00031719002,0.000029932362,0.00013926985,0.04568084],"genre_scores_gemma":[0.90227574,0.00051617436,0.0003966176,0.022538433,0.0024183097,0.000029648803,0.00016969617,0.000043484237,0.07161191],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99824667,0.00002527511,0.00020337048,0.00011366106,0.00096512894,0.00044588427],"domain_scores_gemma":[0.99820226,0.0000509966,0.00007443635,0.00008295376,0.0001267384,0.0014626046],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006548822,0.00009129003,0.00017600425,0.00025506702,0.00017889096,0.000044769393,0.00007749255,0.00016227081,0.002527711],"category_scores_gemma":[0.0004575139,0.00007625585,0.000104353894,0.00035286267,0.000013350805,0.00006639419,0.000013523028,0.0002709165,0.0018220255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006758723,0.00016772475,0.40973926,0.000010601305,0.0008070383,0.0014770837,0.00013680906,0.0000016335025,0.000034258082,0.00036929408,0.5124422,0.07480739],"study_design_scores_gemma":[0.0023552116,0.000100069825,0.54014075,0.00005167185,0.00014751621,0.00009549922,0.00013017983,0.0001823129,0.000016227694,0.00009309495,0.45660442,0.0000830324],"about_ca_topic_score_codex":0.0009001862,"about_ca_topic_score_gemma":0.003728029,"teacher_disagreement_score":0.13040152,"about_ca_system_score_codex":0.0012421837,"about_ca_system_score_gemma":0.00096346653,"threshold_uncertainty_score":0.9989552},"labels":[],"label_agreement":null},{"id":"W4388835417","doi":"10.1136/bmjopen-2023-073081","title":"Impact of deintensifying hypoglycaemic drugs in older adults with type 2 diabetes: protocol for an emulation of a target trial","year":2023,"lang":"en","type":"article","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fondation de France; Fonds De La Recherche Scientifique - FNRS","keywords":"Medicine; Protocol (science); Diabetes mellitus; Type 2 diabetes; Clinical trial; Emulation; Epidemiology; Gerontology; Alternative medicine; Pharmacology; Internal medicine; Endocrinology","score_opus":0.08922320148422654,"score_gpt":0.44021636804374653,"score_spread":0.35099316655952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388835417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6775599,6.2287296e-7,0.000004168392,0.000028373675,0.000016651566,0.3219262,0.0000050251906,0.00001390054,0.00044513997],"genre_scores_gemma":[0.74989825,1.5550685e-7,0.0010045255,0.000019605535,0.000033951805,0.2486152,0.000122036115,0.00001972403,0.00028655116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991846,0.000028785456,0.00028532094,0.00017159594,0.00015273664,0.00017698003],"domain_scores_gemma":[0.9993605,0.000048689388,0.00016756436,0.00024495012,0.00013469018,0.00004360303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004024759,0.00010094878,0.00036114317,0.00015661932,0.000012827594,0.000011846177,0.00009819954,0.000035103665,0.00004257014],"category_scores_gemma":[0.00009520767,0.00006839344,0.00005986491,0.00033018453,0.000016928667,0.00015037144,0.00006657008,0.000030076364,0.0000044721646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37717277,0.0027368045,0.5751549,0.003251831,0.00084040704,0.000011891449,0.005877032,0.0005576112,0.0019680562,0.000060622668,0.008132669,0.02423537],"study_design_scores_gemma":[0.34243947,0.02772927,0.605201,0.004431561,0.0002048008,4.9881004e-7,0.0010538733,0.014920503,0.0032287294,0.00021414222,0.0002718611,0.0003042777],"about_ca_topic_score_codex":0.00013183747,"about_ca_topic_score_gemma":0.000026684538,"teacher_disagreement_score":0.073311016,"about_ca_system_score_codex":0.000049079445,"about_ca_system_score_gemma":0.00012409437,"threshold_uncertainty_score":0.27890036},"labels":[],"label_agreement":null},{"id":"W4388871128","doi":"10.1016/j.xcrm.2023.101292","title":"Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management","year":2023,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Natural Sciences and Engineering Research Council of Canada; Stanford Bio-X; Novo Nordisk; National Institute of Diabetes and Digestive and Kidney Diseases; Stanford Diabetes Research Center; National Institutes of Health; National Science Foundation","keywords":"Medicine; Incretin; Type 2 diabetes; Glucagon-like peptide-1; Pharmacology; Insulin; Drug delivery; Exenatide; Glucagon-like peptide 1 receptor; Diabetes mellitus; Receptor; Internal medicine; Endocrinology; Agonist; Chemistry","score_opus":0.01937045084234176,"score_gpt":0.2564997799042893,"score_spread":0.23712932906194753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388871128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342793,0.0014591578,0.000028175675,0.0013454541,0.00032011964,0.00180433,0.000009839725,0.00011721249,0.0014878006],"genre_scores_gemma":[0.9886137,0.00065839797,0.0020709506,0.000031231855,0.0000720349,0.00016140995,0.0002360107,0.00004200046,0.008114227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976653,0.000015848307,0.0010808416,0.00041674075,0.00042711885,0.00039416563],"domain_scores_gemma":[0.997901,0.00017474583,0.0008033365,0.0006905755,0.000322797,0.000107520355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050077453,0.00024044776,0.0009388748,0.0011144556,0.000032769934,0.0000028721126,0.00011793304,0.00011681882,0.00006574189],"category_scores_gemma":[0.00029618698,0.00018798411,0.0001642947,0.0010525469,0.00043018497,0.000051393334,0.00014765067,0.000061467996,0.0000031473287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033098928,0.00091997633,0.023540951,0.0092522055,0.0022649465,0.0006237715,0.00069765357,0.000051177507,0.87839985,0.0005454697,0.030415801,0.052957185],"study_design_scores_gemma":[0.0037637576,0.0029830618,0.0019336053,0.0018241212,0.0026602237,0.000008039299,0.003193109,0.0003688043,0.961012,0.00091105927,0.021095859,0.00024638008],"about_ca_topic_score_codex":0.000048965372,"about_ca_topic_score_gemma":0.0000010715239,"teacher_disagreement_score":0.082612105,"about_ca_system_score_codex":0.00006192432,"about_ca_system_score_gemma":0.000059978433,"threshold_uncertainty_score":0.766577},"labels":[],"label_agreement":null},{"id":"W4388979842","doi":"10.14740/jem892","title":"The Safety of Sodium Glucose Cotransporter 2 Inhibitors for the Elderly Diabetic Patients","year":2023,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Global Health and Medicine","keywords":"Medicine; Diabetes mellitus; Cotransporter; Internal medicine; Sodium; Endocrinology; Metallurgy","score_opus":0.011688395267943718,"score_gpt":0.25057623895876957,"score_spread":0.23888784369082586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388979842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603535,0.007244008,0.00003303307,0.00464954,0.0012822881,0.00042827192,0.000009746322,0.00000937052,0.00030838425],"genre_scores_gemma":[0.99089915,0.0076140347,0.00007113173,0.00018109949,0.00020128726,0.000017959292,0.000005976875,0.000008600987,0.0010007758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991077,0.00003142573,0.0003856341,0.00007733086,0.00014542001,0.0002524644],"domain_scores_gemma":[0.99910295,0.00033961312,0.00022108461,0.00013366346,0.00014998487,0.00005272754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024910626,0.000096213415,0.00030223816,0.00009876389,0.00013297508,0.000007638862,0.000095587464,0.00003372273,0.000007994976],"category_scores_gemma":[0.0000672573,0.000045114975,0.00016289469,0.00010273614,0.00015657546,0.00005020982,0.000026513435,0.00012548911,0.0000025465645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002359116,0.0006046499,0.094147734,0.00019822408,0.0038235537,0.00007035111,0.00089673774,0.000009038414,0.0019297099,0.019542856,0.023233129,0.8531849],"study_design_scores_gemma":[0.0058134343,0.00076809915,0.48550236,0.00003565578,0.0013431559,0.000010294759,0.00023437594,0.000008776471,0.0048404536,0.00078551826,0.50060105,0.000056813813],"about_ca_topic_score_codex":0.0000024889882,"about_ca_topic_score_gemma":0.0000026799503,"teacher_disagreement_score":0.8531281,"about_ca_system_score_codex":0.000007159609,"about_ca_system_score_gemma":0.000026162683,"threshold_uncertainty_score":0.18397354},"labels":[],"label_agreement":null},{"id":"W4389009172","doi":"10.1016/j.psychres.2023.115636","title":"Central insulin dysregulation in antipsychotic-naïve first-episode psychosis: In silico exploration of gene expression signatures","year":2023,"lang":"en","type":"article","venue":"Psychiatry Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research; Department of Psychiatry, University of Toronto; University of Toronto; National Institute of Mental Health; Novo Nordisk; Physicians' Services Incorporated Foundation; Pittsburgh Foundation; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Banting and Best Diabetes Centre, University of Toronto; U.S. Department of Defense","keywords":"Psychosis; Insulin resistance; Transcriptome; Antipsychotic; Psychology; Medicine; Neuroscience; Internal medicine; Insulin; Schizophrenia (object-oriented programming); Bioinformatics; Endocrinology; Psychiatry; Biology; Gene expression; Gene; Genetics","score_opus":0.06666729244140472,"score_gpt":0.37026936753502393,"score_spread":0.3036020750936192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389009172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989707,0.0011310293,0.00006989657,0.0059958384,0.00048672655,0.0013558224,0.000007300779,0.00006880494,0.0011775796],"genre_scores_gemma":[0.9967833,0.0008111345,0.0013262238,0.00004965888,0.00016757679,0.00024558412,0.00017336632,0.00003126386,0.00041186088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746716,0.00018623775,0.00048060174,0.00045681198,0.000780275,0.0006289327],"domain_scores_gemma":[0.99915576,0.00010550084,0.00007449689,0.0004483785,0.00009937143,0.00011647459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091730047,0.00016315057,0.00029730308,0.0013805645,0.00006988246,0.000025955918,0.00016557645,0.00015450166,0.0000739841],"category_scores_gemma":[0.000094787734,0.00014720226,0.00007812863,0.0022137593,0.000068046254,0.00029042893,0.000058625526,0.00035423556,0.0000628672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009846198,0.0013848419,0.9725094,0.0003893771,0.000043515556,0.000015303667,0.0009877878,0.0014691438,0.0050062793,0.00040709192,0.011792139,0.005010495],"study_design_scores_gemma":[0.003821515,0.00044795166,0.98322433,0.0007855721,0.000017174056,3.6613412e-7,0.0008198695,0.0032455972,0.0036240197,0.0031447238,0.0007346596,0.00013422866],"about_ca_topic_score_codex":0.00015374774,"about_ca_topic_score_gemma":0.00129566,"teacher_disagreement_score":0.011057479,"about_ca_system_score_codex":0.00011876763,"about_ca_system_score_gemma":0.00004249597,"threshold_uncertainty_score":0.6002734},"labels":[],"label_agreement":null},{"id":"W4389099108","doi":"10.1056/evide2300260","title":"Incremental Progress in Pharmacotherapy for Pediatric Type 2 Diabetes","year":2023,"lang":"en","type":"editorial","venue":"NEJM Evidence","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"","keywords":"Socioeconomic status; Type 2 diabetes; Incidence (geometry); Pharmacotherapy; Demography; Medicine; Type 1 diabetes; Diabetes mellitus; Disease; Pediatrics; Gerontology; Environmental health; Internal medicine; Endocrinology; Sociology; Population","score_opus":0.03660221438744786,"score_gpt":0.3698837364323121,"score_spread":0.3332815220448642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389099108","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032897867,0.032648977,0.0000014325836,0.0005564673,0.9306018,0.0028697706,0.00006309866,0.00026484556,0.00009574988],"genre_scores_gemma":[0.006471948,0.0306997,0.0005223346,0.00020568287,0.9551373,0.0018225169,0.00067362585,0.00019936322,0.004267509],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977377,0.000040553285,0.0003760947,0.0005782868,0.0007085034,0.0005588337],"domain_scores_gemma":[0.997972,0.0012378539,0.00017085225,0.00032091446,0.00018487252,0.00011348667],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005338893,0.00034735026,0.00057627796,0.00037536974,0.000044840122,0.000059274087,0.00025649538,0.00029351102,0.000076674056],"category_scores_gemma":[0.00062028307,0.00030912014,0.00015164963,0.00057395815,0.00004528668,0.00016670098,0.000102806545,0.0003260524,0.00019621899],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002537715,0.00017339227,0.033597663,0.0015584786,0.000163515,0.000032203698,0.000046853776,4.078643e-7,0.000050793784,0.0000032467547,0.9478408,0.016278854],"study_design_scores_gemma":[0.0035975887,0.0016244319,0.002941985,0.0016477291,0.0010274088,7.500652e-8,0.0000183815,0.00007955039,0.00041844754,0.000039036335,0.98818475,0.00042061324],"about_ca_topic_score_codex":0.000013939907,"about_ca_topic_score_gemma":0.0000123425925,"teacher_disagreement_score":0.040343933,"about_ca_system_score_codex":0.00029580726,"about_ca_system_score_gemma":0.0002694237,"threshold_uncertainty_score":0.9999361},"labels":[],"label_agreement":null},{"id":"W4389109661","doi":"10.1111/dom.15381","title":"A comment on tirzepatide versus glucagon‐like peptide‐1 receptor agonists and heart rate with regard to ‘Impact of a dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis’","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Diabetes mellitus; Type 2 diabetes; Receptor; Agonist; Medicine; Internal medicine; Chemistry; Endocrinology","score_opus":0.029839198786723593,"score_gpt":0.28017882106944203,"score_spread":0.25033962228271844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389109661","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38002175,0.60996336,0.0000011859045,0.00028767047,0.00025204284,0.008783976,0.0005197801,0.00013474702,0.00003549438],"genre_scores_gemma":[0.010088377,0.9804367,0.0008183727,0.00303702,0.00017648077,0.0022858914,0.0019066302,0.0003288673,0.00092164846],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9916519,0.0018255654,0.0019486328,0.0020658858,0.0010668132,0.0014412298],"domain_scores_gemma":[0.9937607,0.001436423,0.0014692345,0.0016059441,0.00049193954,0.0012357458],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022232456,0.0021259133,0.012201963,0.0009834042,0.00046848104,0.00034686213,0.00029401138,0.0003862475,0.000067653986],"category_scores_gemma":[0.00042870612,0.0013789453,0.0012711002,0.0020056306,0.00045112814,0.00030698846,0.0004826257,0.0007750842,0.00007426668],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016668375,0.0028109364,0.042582523,0.589534,0.34461433,0.0000606781,0.00067797105,0.00006160207,0.000010447386,0.00011381539,0.014008795,0.0038580806],"study_design_scores_gemma":[0.008227383,0.011326687,0.07854255,0.14552492,0.67203146,0.0000033131141,0.00008908453,0.000039516806,0.000031374144,0.00001401759,0.08140097,0.0027687128],"about_ca_topic_score_codex":0.00020912867,"about_ca_topic_score_gemma":0.00017462045,"teacher_disagreement_score":0.44400907,"about_ca_system_score_codex":0.0003015614,"about_ca_system_score_gemma":0.0002440239,"threshold_uncertainty_score":0.9991482},"labels":[],"label_agreement":null},{"id":"W4389180501","doi":"10.1111/dom.15367","title":"Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"McGill University","keywords":"Medicine; Incretin; Meta-analysis; Type 2 diabetes; Observational study; Internal medicine; Confidence interval; Diabetic retinopathy; Cochrane Library; Diabetes mellitus; Retinopathy; Relative risk; Endocrinology","score_opus":0.06251447739997212,"score_gpt":0.31274015845991415,"score_spread":0.25022568105994203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389180501","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04842354,0.9463409,4.3745308e-7,0.0001314236,0.000032693955,0.004599906,0.00040811845,0.00003690114,0.000026071735],"genre_scores_gemma":[0.0023489883,0.9953566,0.0002047423,0.0003291966,0.000017567385,0.0010677127,0.00035500535,0.00005190583,0.00026824287],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957285,0.0012317278,0.0013593759,0.00060426455,0.000705023,0.00037110236],"domain_scores_gemma":[0.99371123,0.0031080393,0.0018368057,0.00072525087,0.00047413856,0.00014452336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043419697,0.00069775747,0.0131941,0.00065259496,0.0001370993,0.00004232053,0.00020545423,0.00016696392,0.000017465527],"category_scores_gemma":[0.0015072104,0.00034653093,0.0010421651,0.0019052423,0.0009542285,0.00010300158,0.00028392745,0.0002815662,0.0000020076316],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048333827,0.00008057359,0.013694252,0.6664013,0.318812,0.0000010985984,0.00022928874,5.00497e-7,5.8449135e-8,0.00026018402,0.000040855964,0.00047498697],"study_design_scores_gemma":[0.00088130054,0.00010160287,0.012593255,0.055910453,0.92878467,1.5826463e-7,0.00007171341,0.000027216862,0.0000031031882,0.00008679709,0.0012514992,0.00028824405],"about_ca_topic_score_codex":0.000019200515,"about_ca_topic_score_gemma":0.0000075123125,"teacher_disagreement_score":0.6104909,"about_ca_system_score_codex":0.00001824827,"about_ca_system_score_gemma":0.0000768179,"threshold_uncertainty_score":0.9998987},"labels":[],"label_agreement":null},{"id":"W4389304454","doi":"10.1016/j.isci.2023.108628","title":"Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine","year":2023,"lang":"en","type":"article","venue":"iScience","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Guelph","funders":"Canadian Institutes of Health Research","keywords":"Liraglutide; Olanzapine; Amylin; Dyslipidemia; Endocrinology; Medicine; Glucagon; Internal medicine; Insulin resistance; Glucose homeostasis; Pharmacology; Insulin; Diabetes mellitus; Type 2 diabetes; Schizophrenia (object-oriented programming)","score_opus":0.009057891915520139,"score_gpt":0.2631314054741117,"score_spread":0.25407351355859153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389304454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428934,0.0014897134,0.000035546822,0.001229124,0.00034773117,0.0015828592,0.0000011946347,0.000043182576,0.0009812871],"genre_scores_gemma":[0.9976992,0.0007296238,0.00020444006,0.00024332023,0.000045969417,0.00022855683,0.0000023119321,0.00000911707,0.00083747954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878645,0.000116104275,0.00022728818,0.0002231846,0.0003507313,0.00029623578],"domain_scores_gemma":[0.9986932,0.00074758875,0.00014887011,0.00034088743,0.00003346072,0.000035947258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079146854,0.00012372981,0.00028155794,0.00013741708,0.00010559958,0.000014785574,0.00028566233,0.000026703347,0.0000022711943],"category_scores_gemma":[0.0008146257,0.0000615658,0.00007889446,0.0011616714,0.0002381176,0.000083754516,0.00014843211,0.00013512663,0.000026148478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026774962,0.000105897285,0.0011049411,0.0004816363,0.000112323825,0.000025951274,0.0023574915,0.00002640663,0.888978,0.00027593636,0.00017912601,0.10632549],"study_design_scores_gemma":[0.00092037296,0.00034084605,0.06269663,0.00058834587,0.00013181909,6.6619344e-7,0.00022992847,0.00038167994,0.9332076,0.0001432286,0.0012852049,0.000073709365],"about_ca_topic_score_codex":0.00007472176,"about_ca_topic_score_gemma":0.000024389072,"teacher_disagreement_score":0.10625178,"about_ca_system_score_codex":0.000020270661,"about_ca_system_score_gemma":0.000043810553,"threshold_uncertainty_score":0.25105804},"labels":[],"label_agreement":null},{"id":"W4389372311","doi":"10.1371/journal.pone.0295284","title":"Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Kidney Foundation of Canada","keywords":"Canagliflozin; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Creatinine; Renal function; Type 2 diabetes; Kidney","score_opus":0.023001718275912682,"score_gpt":0.20397727051926584,"score_spread":0.18097555224335315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389372311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612427,0.00003486386,5.3722204e-7,0.0013002228,0.000058789497,0.0015683438,0.0000029109974,0.00011767009,0.0007923694],"genre_scores_gemma":[0.995222,0.000044116045,0.000102080005,0.0005336465,0.000026675474,0.00017747389,0.000048535836,0.0000260149,0.0038194836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990282,0.000034610515,0.00014078387,0.00021534118,0.00035359146,0.00022743839],"domain_scores_gemma":[0.9995108,0.00007006543,0.000050803283,0.00020784931,0.000060414717,0.00010005369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010729686,0.00012884881,0.0003490107,0.00026183805,0.000023410332,0.000005941407,0.0000442085,0.000044153956,0.000013454538],"category_scores_gemma":[0.00015918311,0.00009855439,0.000023635952,0.00043436157,0.000021653763,0.000034654393,0.000031642274,0.00009746744,0.000084669395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013238562,0.011590237,0.13580105,0.00547031,0.0026716408,0.0004178122,0.0003624873,0.000035821155,0.8348109,0.00011373341,0.0026142818,0.0047878944],"study_design_scores_gemma":[0.0070830532,0.0067272647,0.067097776,0.0031957582,0.0008123681,3.8297824e-7,0.000059856524,0.0015067732,0.91318,0.000066980065,0.000077829194,0.00019198081],"about_ca_topic_score_codex":0.00016811104,"about_ca_topic_score_gemma":0.000051136696,"teacher_disagreement_score":0.078369096,"about_ca_system_score_codex":0.000079670426,"about_ca_system_score_gemma":0.000038087306,"threshold_uncertainty_score":0.40189314},"labels":[],"label_agreement":null},{"id":"W4389442129","doi":"10.1161/circulationaha.123.065061","title":"Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Ejection fraction; Placebo; Dapagliflozin; Heart failure; Internal medicine; Cardiology; Randomized controlled trial; Diabetes mellitus; Endocrinology","score_opus":0.029291364384935764,"score_gpt":0.333477941314425,"score_spread":0.30418657692948925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389442129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966657,0.000028332865,0.000038432077,0.00032877826,0.00016027532,0.0026214127,0.0000030116432,0.000027534172,0.00012649673],"genre_scores_gemma":[0.9996381,0.000008828368,0.000019305453,0.00003253039,0.000039874354,0.0001201036,0.000093531824,0.00001056242,0.00003719292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826705,0.00080347096,0.00041913954,0.00018076522,0.00021598989,0.0001135803],"domain_scores_gemma":[0.9956095,0.003983629,0.00015373796,0.0001940094,0.000023233484,0.000035851805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039041492,0.00010718738,0.000660685,0.000088747,0.000024739571,0.000010596266,0.000027919135,0.00004409977,0.0000064887895],"category_scores_gemma":[0.0013932153,0.00005660118,0.00010215269,0.00018931291,0.0000782511,0.000042343072,0.000015378015,0.00006225308,0.000009401904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1822596,0.000121601886,0.78345513,0.000102339916,0.00028001962,0.00000243252,0.00006983028,0.00009250027,0.000017079965,0.0001067261,0.0002813572,0.033211388],"study_design_scores_gemma":[0.34369773,0.0010689095,0.6517569,0.00016787628,0.00050628046,7.0339695e-8,0.0000067917695,0.0024517006,0.00009373953,0.000017398579,0.00017355071,0.000059107017],"about_ca_topic_score_codex":0.000004363848,"about_ca_topic_score_gemma":0.000008034053,"teacher_disagreement_score":0.16143812,"about_ca_system_score_codex":0.000033116503,"about_ca_system_score_gemma":0.000009063118,"threshold_uncertainty_score":0.2308129},"labels":[],"label_agreement":null},{"id":"W4389469329","doi":"10.1016/j.ahj.2023.08.044","title":"Patients achieving a HbA1c &lt;5.7% with ≥5% weight loss and without hypoglycemia: A post hoc analysis of SURPASS 1 to 5","year":2023,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Hypoglycemia; Placebo; Type 2 diabetes; Semaglutide; Weight loss; Post-hoc analysis; Clinical endpoint; Internal medicine; Diabetes mellitus; Insulin; Endocrinology; Clinical trial; Obesity; Liraglutide","score_opus":0.00857121346233103,"score_gpt":0.26532360288692114,"score_spread":0.2567523894245901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389469329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694824,0.000053813787,0.00004264849,0.0023098267,0.000042511965,0.00023598311,0.000016976779,0.000034403984,0.0003155856],"genre_scores_gemma":[0.9966263,0.00015503196,0.0018605116,0.00085760513,0.000054038184,0.000011372915,0.000025829493,0.000023665165,0.00038563245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986816,0.00005002962,0.00027332918,0.00022332458,0.00042964544,0.00034208855],"domain_scores_gemma":[0.99905634,0.00006715243,0.00015925335,0.00020798646,0.00018338763,0.00032585446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020622271,0.00016250554,0.0006607179,0.0008194281,0.00009546583,0.000033032982,0.000062771964,0.000019647607,0.00004343974],"category_scores_gemma":[0.000046491277,0.00011404322,0.00013973514,0.0019444005,0.00013304116,0.000087114,0.00006989518,0.00013779289,0.000021048936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006495106,0.00015602227,0.9764326,0.000019796405,0.0023233208,0.000055220065,0.00041823415,0.000027432718,0.00033234316,0.000007115691,0.0015077017,0.018070681],"study_design_scores_gemma":[0.0014605178,0.0040905303,0.98476624,0.00010864383,0.0023552598,0.000025694266,0.00035263112,0.000103425635,0.000056579433,0.0000021577853,0.006547348,0.00013094915],"about_ca_topic_score_codex":0.0000704869,"about_ca_topic_score_gemma":0.00006605328,"teacher_disagreement_score":0.017939731,"about_ca_system_score_codex":0.00006540501,"about_ca_system_score_gemma":0.000052668507,"threshold_uncertainty_score":0.46505475},"labels":[],"label_agreement":null},{"id":"W4389473678","doi":"10.1186/s12933-023-02071-4","title":"Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study","year":2023,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Abbott Vascular; Novo Nordisk; AstraZeneca Mölndal; Karolinska Institutet; Canada Excellence Research Chairs, Government of Canada; AstraZeneca","keywords":"Exenatide; Medicine; Restenosis; Stent; Type 2 diabetes; Internal medicine; Randomized controlled trial; Clinical endpoint; Coronary artery disease; Cardiology; Diabetes mellitus; Urology; Surgery; Endocrinology","score_opus":0.009023221132378485,"score_gpt":0.23313461757093473,"score_spread":0.22411139643855624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389473678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748167,0.0033855618,0.000018200188,0.00014538615,0.0005669885,0.020080706,0.0000011611414,0.00010273002,0.0008825721],"genre_scores_gemma":[0.99476546,0.0005399406,0.000014481565,0.00015894527,0.00006841236,0.003923524,0.000037866874,0.000044272507,0.00044708885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964097,0.0016663953,0.0005379876,0.00042671067,0.0005497445,0.00040944264],"domain_scores_gemma":[0.9970243,0.0018940715,0.00017516006,0.00072309515,0.00012343486,0.000059966904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025145083,0.0002873882,0.0031004257,0.00044955523,0.000050990275,0.00001221903,0.00014675214,0.000092944734,0.000009994208],"category_scores_gemma":[0.0011076608,0.00015716406,0.000857348,0.0007935981,0.00017229281,0.000040140603,0.00006388746,0.0001457682,0.00003034632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9221878,0.0022521724,0.028177034,0.00046891975,0.03735925,0.000710608,0.0009032942,0.0012214112,0.00023216692,0.00051947334,0.00030943882,0.0056584207],"study_design_scores_gemma":[0.97323453,0.0030876722,0.01516786,0.0001775404,0.006573026,0.0000018513524,0.00020237926,0.00024720255,0.000823424,0.000072994175,0.00026051348,0.0001510113],"about_ca_topic_score_codex":0.000019899477,"about_ca_topic_score_gemma":0.000009957147,"teacher_disagreement_score":0.051046714,"about_ca_system_score_codex":0.0000718213,"about_ca_system_score_gemma":0.00006976108,"threshold_uncertainty_score":0.64089644},"labels":[],"label_agreement":null},{"id":"W4389514004","doi":"10.1016/j.cjco.2023.12.002","title":"Impact of SGLT2 Inhibitors on Quality of Life in Heart Failure Across the Ejection Fraction Spectrum: Systematic Review and Meta-analysis","year":2023,"lang":"en","type":"article","venue":"CJC Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ejection fraction; Heart failure; Meta-analysis; Fraction (chemistry); Internal medicine; Medicine; Cardiology; Chemistry; Chromatography","score_opus":0.07987907343208377,"score_gpt":0.41137670908094787,"score_spread":0.3314976356488641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389514004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869355,0.0033990846,0.0000042336046,0.005446841,0.000020211657,0.0036840076,0.00002469056,0.000018027304,0.0004673782],"genre_scores_gemma":[0.99875677,0.00026462026,0.000014921462,0.0002247723,0.0000072908288,0.00013494548,0.000025586027,0.0000063912053,0.00056467764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998825,0.00021964387,0.00049152167,0.00015941296,0.00019629914,0.000108112734],"domain_scores_gemma":[0.9991324,0.00012909225,0.000278424,0.00038862467,0.000034175988,0.000037291775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016757537,0.00010106548,0.0017270461,0.000115386705,0.000029771807,0.000024374467,0.00007959807,0.000027653783,0.00011311275],"category_scores_gemma":[0.00021787928,0.000051817984,0.00044338015,0.0009379866,0.00002358085,0.00009936158,0.00008203493,0.000062158295,0.000019384039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033084533,0.0011742717,0.4550799,0.18713632,0.33239996,0.000007464831,0.0011217943,0.0002808618,0.0004310374,0.00040860617,0.021558318,0.00007061867],"study_design_scores_gemma":[0.0015699218,0.0008410033,0.64818805,0.0027778032,0.34428948,9.058437e-7,0.0014367377,0.00008187168,0.00040132328,0.00013481895,0.0000904579,0.00018760664],"about_ca_topic_score_codex":0.0014493775,"about_ca_topic_score_gemma":0.00038604075,"teacher_disagreement_score":0.19310814,"about_ca_system_score_codex":0.00006046131,"about_ca_system_score_gemma":0.000017199663,"threshold_uncertainty_score":0.21910349},"labels":[],"label_agreement":null},{"id":"W4389609315","doi":"10.1111/dom.15396","title":"Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Internal medicine; Post-hoc analysis; Population; Placebo; Myocardial infarction; Physical therapy; Stroke (engine); Cardiology; Diabetes mellitus; Endocrinology; Liraglutide; Pathology","score_opus":0.0060700517841647175,"score_gpt":0.20066669162208325,"score_spread":0.19459663983791853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389609315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9018945,0.0818917,0.0000011550687,0.014643036,0.00016068584,0.0010802872,0.00023181678,0.00006137923,0.000035461086],"genre_scores_gemma":[0.94645697,0.027565535,0.00018266222,0.020544589,0.0009002064,0.00032841408,0.0018604334,0.0001714474,0.0019897404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673665,0.0004098739,0.00043356387,0.0008540324,0.0008467217,0.0007191784],"domain_scores_gemma":[0.9980002,0.00031740137,0.00027034982,0.0010349447,0.00018150898,0.00019557055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008376263,0.0005986898,0.0021150808,0.0008020683,0.0001603547,0.000048715006,0.0002422192,0.000278629,0.000018297711],"category_scores_gemma":[0.00020397763,0.00038605827,0.00082003203,0.0016300341,0.00025725266,0.00011174831,0.00024786292,0.00068558636,0.000009010583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008657451,0.0002703377,0.93099254,0.0014499617,0.054135203,0.00010220656,0.00050372595,0.000114468006,0.000036839163,0.000012694581,0.0073539168,0.0049415156],"study_design_scores_gemma":[0.0014196642,0.0001864552,0.88910043,0.00034440818,0.06007778,3.4507866e-7,0.000088012406,0.00011975375,0.00011851038,0.00008362559,0.04806669,0.00039433967],"about_ca_topic_score_codex":0.00054742914,"about_ca_topic_score_gemma":0.00009509778,"teacher_disagreement_score":0.05432616,"about_ca_system_score_codex":0.00004104546,"about_ca_system_score_gemma":0.00009611457,"threshold_uncertainty_score":0.99985915},"labels":[],"label_agreement":null},{"id":"W4389616884","doi":"10.5530/ptb.2023.9.3","title":"Drug Review: Tirzepatide","year":2023,"lang":"en","type":"article","venue":"Pharmacology Toxicology and Biomedical Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Christian ministry; Drug; Medicine; Postprandial; Type 2 Diabetes Mellitus; Glucagon-like peptide-1; Internal medicine; Endocrinology; Diabetes mellitus; Pharmacology; Type 2 diabetes; Political science","score_opus":0.01857589238476463,"score_gpt":0.34303104402674567,"score_spread":0.324455151641981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389616884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88525456,0.008913291,0.000013334388,0.09141603,0.0022514507,0.0012387582,0.0000050282283,0.00050231855,0.010405256],"genre_scores_gemma":[0.8936157,0.038483236,0.00026099646,0.04464219,0.000441708,0.00039137786,0.0002856001,0.000027588285,0.021851577],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857557,0.00006951304,0.00038258737,0.00038487194,0.00019038904,0.00039707153],"domain_scores_gemma":[0.999233,0.00014495179,0.00011021324,0.00015051545,0.00004127775,0.00032002243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000692547,0.00014895247,0.00041820874,0.00019417945,0.00008738158,0.0000035598891,0.000043098167,0.00011366141,0.0018226816],"category_scores_gemma":[0.00016769637,0.000112051006,0.000078205405,0.0003790815,0.00036354558,0.000036532874,0.00014556354,0.000178491,0.00023941346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045928657,0.00039093517,0.015106688,0.0005547965,0.00039727314,0.011130794,0.000030467942,5.8398967e-8,0.008924792,0.00007562359,0.9269027,0.03643992],"study_design_scores_gemma":[0.0013199172,0.0004946064,0.045123566,0.00018588378,0.0011347927,0.0007270224,0.000017743358,0.00005927866,0.002534823,0.00065906235,0.94757676,0.00016655959],"about_ca_topic_score_codex":0.0000049320233,"about_ca_topic_score_gemma":0.0000014733864,"teacher_disagreement_score":0.046773836,"about_ca_system_score_codex":0.00003390372,"about_ca_system_score_gemma":0.00009076599,"threshold_uncertainty_score":0.9990898},"labels":[],"label_agreement":null},{"id":"W4389660755","doi":"10.1056/nejmc2311840","title":"GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","year":2023,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Agonist; Obesity; Receptor; Internal medicine; Endocrinology","score_opus":0.017699248890230484,"score_gpt":0.254476336837708,"score_spread":0.2367770879474775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389660755","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011682377,0.0012427575,0.00037371865,0.98019975,0.002850661,0.0014147564,0.000032894597,0.0000744845,0.0021285892],"genre_scores_gemma":[0.006417206,0.0037778604,0.00820294,0.5581499,0.23272048,0.000091036345,0.0029974042,0.00049722823,0.18714598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976228,0.000048261387,0.00066745485,0.0002977893,0.0009157011,0.00044799558],"domain_scores_gemma":[0.9979432,0.0003350146,0.00070589106,0.00032716632,0.000399532,0.0002891445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000649275,0.0004169737,0.001265256,0.00042171788,0.0000713123,0.000019707133,0.00020875495,0.00029364845,0.00027425122],"category_scores_gemma":[0.00025980707,0.00023138864,0.00020670904,0.00021439239,0.00011847039,0.0000721215,0.000030054367,0.0010777287,0.00003586856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002355243,0.000073086216,0.00066604593,0.001008959,0.0010171424,0.0014351784,0.0003873253,9.643948e-7,0.000019681138,0.000011970559,0.92625093,0.06677346],"study_design_scores_gemma":[0.07171818,0.011367492,0.0003675483,0.0048208735,0.0023891793,0.0002175452,0.00012772356,0.0000057846382,0.00005523553,0.00013054351,0.90860105,0.00019886819],"about_ca_topic_score_codex":0.00007628587,"about_ca_topic_score_gemma":0.000036969133,"teacher_disagreement_score":0.4220499,"about_ca_system_score_codex":0.00018061005,"about_ca_system_score_gemma":0.00027999879,"threshold_uncertainty_score":0.9435755},"labels":[],"label_agreement":null},{"id":"W4389681767","doi":"10.1080/14740338.2023.2295397","title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University Health Network; Brain and Cognition Discovery Foundation; University of Toronto","funders":"","keywords":"Medicine; Adverse Event Reporting System; Suicidal ideation; Liraglutide; Adverse effect; Odds ratio; Internal medicine; Poison control; Pharmacology; Psychiatry; Suicide prevention; Emergency medicine; Endocrinology; Diabetes mellitus","score_opus":0.02239137260098223,"score_gpt":0.3025923590626875,"score_spread":0.28020098646170527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389681767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90192395,0.0012175408,0.00006249426,0.08519384,0.003723155,0.0037001956,0.000043908036,0.00054018555,0.0035946982],"genre_scores_gemma":[0.9913294,0.001067655,0.000077854405,0.00052304997,0.0006394724,0.0002495214,0.00036471654,0.00003609238,0.0057122596],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969943,0.00021618223,0.0011346266,0.0005641606,0.0006869462,0.00040379434],"domain_scores_gemma":[0.9975878,0.00046850753,0.0010460798,0.0005853133,0.000107784814,0.00020453603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036703576,0.00026091587,0.00039332767,0.000091744485,0.0007147008,0.000104729086,0.0000858812,0.00008036574,0.0000061804744],"category_scores_gemma":[0.0007200663,0.00016796461,0.0001282274,0.00030781835,0.000038918133,0.00011298317,0.00015403582,0.00016269073,0.00003963595],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012105536,0.00043521044,0.29772297,0.00066005724,0.0029727626,0.00018763836,0.021576526,0.000085351865,0.0004114086,0.0045874007,0.5012256,0.1689245],"study_design_scores_gemma":[0.0011644257,0.00043018343,0.1619805,0.0005558938,0.00009050243,0.000016086358,0.009544909,0.000109438486,0.0012235999,0.000029157181,0.8245617,0.00029356798],"about_ca_topic_score_codex":0.00008480977,"about_ca_topic_score_gemma":0.0000857908,"teacher_disagreement_score":0.32333612,"about_ca_system_score_codex":0.0005236121,"about_ca_system_score_gemma":0.000088909335,"threshold_uncertainty_score":0.6849398},"labels":[],"label_agreement":null},{"id":"W4389737787","doi":"10.1002/ehf2.14560","title":"Obesity, Heart Failure with Preserved Ejection Fraction, and the Role of Glucagon-Like Peptide-1 Receptor Agonists","year":2023,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Heart failure; Heart failure with preserved ejection fraction; Internal medicine; Ejection fraction; Overweight; Endocrinology; Diabetes mellitus; Obesity; Glucagon-like peptide-1; Cardiology; Type 2 diabetes","score_opus":0.017982909682166894,"score_gpt":0.2767835834274033,"score_spread":0.2588006737452364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389737787","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009997182,0.98637563,0.0000091083,0.005159037,0.00034668017,0.0057168044,0.0000553172,0.0003251206,0.0010126105],"genre_scores_gemma":[0.00051227416,0.98094225,0.0025263848,0.00021104794,0.0006504567,0.00089412933,0.0006693467,0.00020656397,0.01338753],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975156,0.00028868194,0.00058993045,0.00063552975,0.00054892583,0.00042130577],"domain_scores_gemma":[0.9982723,0.00026178078,0.0003162339,0.00080990436,0.0001625427,0.00017723447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000568406,0.0005508933,0.0020601319,0.00026227755,0.00021647998,0.000099166886,0.0001605064,0.0003413401,0.00021821054],"category_scores_gemma":[0.00008235571,0.0003253872,0.00048274908,0.0006531458,0.00022606018,0.00016531194,0.0001986924,0.000579652,0.0004204068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004933543,0.00109492,0.013245741,0.05521632,0.0075219357,0.000028285078,0.00030257663,0.000003389588,0.000046830606,0.0011294115,0.8385678,0.08234944],"study_design_scores_gemma":[0.0015087222,0.00035271878,0.00032004336,0.008524329,0.0024505565,0.000027023312,0.00029914224,0.0000055252967,0.000028366781,0.00005645695,0.986153,0.00027409094],"about_ca_topic_score_codex":0.0002499862,"about_ca_topic_score_gemma":0.00024898807,"teacher_disagreement_score":0.14758523,"about_ca_system_score_codex":0.00013842301,"about_ca_system_score_gemma":0.00021638458,"threshold_uncertainty_score":0.99991983},"labels":[],"label_agreement":null},{"id":"W4389899331","doi":"10.1016/j.lanwpc.2023.100988","title":"Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data","year":2023,"lang":"en","type":"article","venue":"The Lancet Regional Health - Western Pacific","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"University of New South Wales; Australian Commission on Safety and Quality in Health Care; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Kidney disease; Medicine; Population; Observational study; Internal medicine; Intensive care medicine; Environmental health","score_opus":0.20113470466087127,"score_gpt":0.3865813933527346,"score_spread":0.18544668869186334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389899331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526924,0.00010077875,0.000009078267,0.0014899683,0.00015002648,0.002195341,0.00073334534,0.000039364,0.000012860687],"genre_scores_gemma":[0.99266833,0.0000062427835,0.00035978795,0.00017814797,0.00022295504,0.000054536187,0.0063288473,0.000023293867,0.0001578442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777275,0.000110456946,0.0006838436,0.00034853167,0.00069798337,0.00038645367],"domain_scores_gemma":[0.9983491,0.00009985286,0.00051864615,0.00069894595,0.00019082357,0.00014264586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005822803,0.00019425232,0.00044584766,0.0001422463,0.00021308596,0.000030639043,0.0002732308,0.000035728077,0.000004907366],"category_scores_gemma":[0.00006526842,0.00011791455,0.000047785168,0.00076001044,0.00013037767,0.00017606956,0.00012352804,0.000165189,0.0000014106287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008113774,0.00032117043,0.9953132,0.0008945502,0.00013609412,0.000002324993,0.00070528366,0.0009494716,0.000006905065,0.0000129173995,0.00044021438,0.00040646366],"study_design_scores_gemma":[0.0048727915,0.000494599,0.9906372,0.000669334,0.00007046227,8.87561e-7,0.00024058273,0.002827565,6.156419e-7,0.000016735245,0.00007549607,0.0000937324],"about_ca_topic_score_codex":0.00094411115,"about_ca_topic_score_gemma":0.00044834908,"teacher_disagreement_score":0.005595502,"about_ca_system_score_codex":0.00052980985,"about_ca_system_score_gemma":0.001045105,"threshold_uncertainty_score":0.48084158},"labels":[],"label_agreement":null},{"id":"W4389900307","doi":"10.1210/clinem/dgad746","title":"Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; McMaster University; University of Toronto; Mount Sinai Hospital","funders":"McMaster University; Sanofi","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.10289323697260255,"score_gpt":0.4189349304194874,"score_spread":0.3160416934468848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389900307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97701913,0.008145762,0.000004368774,0.008489165,0.0017400371,0.00023175393,0.0000017707339,0.000041733223,0.0043263],"genre_scores_gemma":[0.9820332,0.014215559,0.00033257436,0.0009452818,0.0013635636,0.0000016997872,0.000004579784,0.000022601862,0.0010809583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962483,0.00088870263,0.0019470353,0.00020200916,0.0003762106,0.00033774597],"domain_scores_gemma":[0.99515,0.0028256003,0.0011016311,0.00037453944,0.00036947176,0.00017871581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004134083,0.00017416563,0.0013143559,0.00021534052,0.00006136089,0.000005454806,0.0002973049,0.00012649113,0.00009027765],"category_scores_gemma":[0.0050775893,0.00009451566,0.00057886157,0.00032176607,0.0004554578,0.00007437574,0.00014236577,0.00082954555,0.00008388909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010521216,0.004947757,0.43176085,0.000174031,0.008122228,0.0006795697,0.0016189028,0.000066793116,0.00391914,0.0072699874,0.3639384,0.16698115],"study_design_scores_gemma":[0.010996874,0.0060886615,0.69743747,0.0003424147,0.0020230918,0.00002333127,0.0033265764,0.0001381271,0.0025635324,0.0016163074,0.27522925,0.00021434798],"about_ca_topic_score_codex":0.000002913189,"about_ca_topic_score_gemma":9.8050286e-8,"teacher_disagreement_score":0.26567665,"about_ca_system_score_codex":0.00001147474,"about_ca_system_score_gemma":0.00016200126,"threshold_uncertainty_score":0.60787153},"labels":[],"label_agreement":null},{"id":"W4389940516","doi":"10.1161/circ.148.suppl_1.13678","title":"Abstract 13678: Initial Decline in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Insights From DELIVER","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Ejection fraction; Dapagliflozin; Heart failure; Placebo; Renal function; Heart failure with preserved ejection fraction; Cardiology; Internal medicine; Dialysis; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.02425300205720489,"score_gpt":0.2669502282164694,"score_spread":0.24269722615926453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389940516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983403,0.000016904427,0.00015117213,0.00017330798,0.00006451566,0.0010787062,0.000013486702,0.000073181625,0.00008843837],"genre_scores_gemma":[0.9961494,0.0000058149612,0.00057620776,0.00008086829,0.000050145984,0.0001247788,0.002980469,0.000024788918,0.00000752293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987538,0.0000720291,0.00038954045,0.00030357737,0.00032682798,0.00015426031],"domain_scores_gemma":[0.9993339,0.000066796485,0.00017231524,0.00020033393,0.00018176879,0.000044882636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011952303,0.00016425546,0.00026158872,0.00044716592,0.000032733125,0.000025675983,0.000030669908,0.00010983733,0.00011897648],"category_scores_gemma":[0.000060142134,0.00012953761,0.0000289587,0.00086633075,0.000024949684,0.0006357714,0.0000150342075,0.000111885456,0.00002600366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031548468,0.00042245342,0.986245,0.00009161403,0.00007899406,0.000022639962,0.00018432434,0.0054339953,0.0037682257,0.000004166698,0.00006106459,0.0005326834],"study_design_scores_gemma":[0.006353059,0.00030616426,0.9839934,0.00048533743,0.00011229319,2.2428918e-7,0.00008573528,0.0060762498,0.0023365864,0.00007061941,0.000043626875,0.00013669177],"about_ca_topic_score_codex":0.0003060235,"about_ca_topic_score_gemma":0.0010346033,"teacher_disagreement_score":0.0031982118,"about_ca_system_score_codex":0.00017110429,"about_ca_system_score_gemma":0.000054656597,"threshold_uncertainty_score":0.528239},"labels":[],"label_agreement":null},{"id":"W4389944828","doi":"10.1161/circ.148.suppl_1.18221","title":"Abstract 18221: Interleukin-6 in Patients With HFrEF and the Effect of Dapagliflozin: Insights From DAPA-HF","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Medicine; Interquartile range; Ejection fraction; Heart failure; Quartile; Internal medicine; Dapagliflozin; Inflammation; Pathophysiology; Proinflammatory cytokine; Gastroenterology; Cardiology; Endocrinology; Confidence interval","score_opus":0.006149447900382548,"score_gpt":0.21146574472450733,"score_spread":0.20531629682412478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389944828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976918,0.00006576249,0.000005680599,0.0000806864,0.00005678913,0.0006443102,0.000002259399,0.000027321708,0.0014254064],"genre_scores_gemma":[0.99966985,0.000005838333,0.000008566067,0.00002796568,0.000017737719,0.000023749659,0.00021636247,0.00000918367,0.00002076704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994757,0.000028752265,0.0001335319,0.00013203819,0.00015336885,0.00007658672],"domain_scores_gemma":[0.9996231,0.00012113379,0.000061086874,0.0001538959,0.00001873463,0.000022014585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085081556,0.000080534075,0.00018166682,0.00010700323,0.00001933568,0.000009729007,0.00002852749,0.000028092732,0.000012624581],"category_scores_gemma":[0.0000265896,0.000044676857,0.000025294183,0.00017925818,0.00004733799,0.00007214207,0.000020964337,0.00004518382,0.00001652292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045568313,0.000041248793,0.98144096,0.000055386226,0.000107564905,0.0000041774747,0.00046451102,0.00006015931,0.00015416168,0.00012699116,0.00005808687,0.01703106],"study_design_scores_gemma":[0.008524067,0.0001634503,0.9897756,0.00014293898,0.00011051129,4.292734e-8,0.00002956421,0.0006835003,0.00027111243,0.00016766397,0.00008850463,0.000043065626],"about_ca_topic_score_codex":0.00007611382,"about_ca_topic_score_gemma":0.000022950859,"teacher_disagreement_score":0.016987994,"about_ca_system_score_codex":0.00003240384,"about_ca_system_score_gemma":0.0000047484473,"threshold_uncertainty_score":0.18218695},"labels":[],"label_agreement":null},{"id":"W4389956676","doi":"10.1161/circ.148.suppl_1.15741","title":"Abstract 15741: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Individuals With Obesity or Overweight but Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2023,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Semaglutide; Medicine; Overweight; Weight loss; Randomized controlled trial; Placebo; Internal medicine; Meta-analysis; Type 2 diabetes; Relative risk; Diabetes mellitus; Adverse effect; Obesity; Confidence interval; Body mass index; Liraglutide; Endocrinology","score_opus":0.0902491528993612,"score_gpt":0.3629101776418813,"score_spread":0.27266102474252013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389956676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004223482,0.94767404,0.00010267807,0.000053849122,0.000019999388,0.047593992,0.00027571307,0.000027307833,0.000028947008],"genre_scores_gemma":[0.016146718,0.9775796,0.00016022717,0.00003403058,0.000020746822,0.0048627513,0.00084974366,0.00005772364,0.00028844934],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99203527,0.0015589684,0.0049795927,0.0005954237,0.00056449574,0.00026622816],"domain_scores_gemma":[0.9838407,0.009580551,0.005648447,0.0006024631,0.00022400232,0.000103859544],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011682668,0.0006612845,0.04854687,0.0010627904,0.00003946232,0.00003195107,0.00011602463,0.0002156564,0.00007054575],"category_scores_gemma":[0.0040566837,0.00031512644,0.00402872,0.0009497185,0.00013444443,0.000089152716,0.00004577501,0.00012313348,0.0000015963095],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023427687,0.0002087241,0.001715212,0.617691,0.37701187,0.0000050086296,0.00003933303,0.0000041601375,2.0933493e-7,0.000044287925,0.000003447938,0.00093400537],"study_design_scores_gemma":[0.089105435,0.000077605524,0.004526921,0.11303999,0.7929342,0.0000013471533,0.000003667994,0.00004948673,5.7565387e-7,0.000010086815,0.00003360016,0.00021709158],"about_ca_topic_score_codex":0.000011671645,"about_ca_topic_score_gemma":0.000021115204,"teacher_disagreement_score":0.504651,"about_ca_system_score_codex":0.000113016176,"about_ca_system_score_gemma":0.00014954034,"threshold_uncertainty_score":0.9999301},"labels":[],"label_agreement":null},{"id":"W4389956801","doi":"10.1161/circ.148.suppl_1.13531","title":"Abstract 13531: Uptake of SGLT2i and Outcomes in Patients With Diabetes and Chronic Heart Failure: A Community-Based Cohort and a Specialized Clinic Cohort","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cohort; Hazard ratio; Proportional hazards model; Diabetes mellitus; Heart failure; Internal medicine; Cohort study; Endocrinology; Confidence interval","score_opus":0.017558378204392107,"score_gpt":0.26629255606196844,"score_spread":0.24873417785757634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389956801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99842036,0.00006487757,0.0000019053065,0.00022107601,0.000024855957,0.0010894368,0.000008423269,0.00003667628,0.000132418],"genre_scores_gemma":[0.99938816,0.000015831845,0.000101654594,0.00008826859,0.000011148816,0.00004351996,0.00031677049,0.000014518719,0.000020101637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921805,0.000042004256,0.00024797348,0.00016292761,0.00017976262,0.000149271],"domain_scores_gemma":[0.99950963,0.00012321983,0.00008455189,0.00018672206,0.000040613828,0.000055288754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036423933,0.00011996483,0.0003589398,0.00018054276,0.000056196142,0.000018248595,0.000020944373,0.0000502591,0.000020502803],"category_scores_gemma":[0.000040715157,0.00009932367,0.000025627474,0.00017812754,0.00008823818,0.00008182666,0.000026842876,0.00009446748,0.0000039559013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004094295,0.0001577154,0.9973508,0.00025021628,0.00014163398,9.592271e-7,0.000078646066,0.000008900779,0.00011946443,0.00001088927,0.00006726501,0.001772547],"study_design_scores_gemma":[0.0053142975,0.00024268121,0.99347955,0.00015848345,0.0001896499,6.478055e-8,0.000036691046,0.00021057542,0.00003540321,0.000049401795,0.00019787655,0.00008530286],"about_ca_topic_score_codex":0.000029105347,"about_ca_topic_score_gemma":0.00007014344,"teacher_disagreement_score":0.0052733542,"about_ca_system_score_codex":0.00005304644,"about_ca_system_score_gemma":0.000025640944,"threshold_uncertainty_score":0.40503016},"labels":[],"label_agreement":null},{"id":"W4389956937","doi":"10.1161/circ.148.suppl_1.14120","title":"Abstract 14120: Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in People With HF and a History of CABG Surgery: A Pooled Analysis From DAPA-HF and DELIVER","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Ejection fraction; Hazard ratio; Mace; Dapagliflozin; Internal medicine; Heart failure; Cardiology; Diabetes mellitus; Myocardial infarction; Confidence interval; Percutaneous coronary intervention; Type 2 diabetes; Endocrinology","score_opus":0.0199453341382059,"score_gpt":0.2490501563141452,"score_spread":0.2291048221759393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389956937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990427,0.00025862004,0.00004460441,0.00016528035,0.000027415601,0.00039772427,0.000027229118,0.000019393141,0.000017026749],"genre_scores_gemma":[0.9994765,0.00017640721,0.000024288487,0.000017060931,0.000010318671,0.000033628523,0.00016050073,0.00001054173,0.00009073805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992914,0.000054740038,0.00020635595,0.00020191149,0.0001441248,0.00010146719],"domain_scores_gemma":[0.9992729,0.00029310025,0.0001901569,0.00015930788,0.00005088457,0.000033654745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027654192,0.000116258554,0.00039500225,0.00026256012,0.000033435972,0.0000107881815,0.000011815077,0.000041407264,0.000011226547],"category_scores_gemma":[0.000037861817,0.00007490131,0.00004034199,0.00029686905,0.000066276625,0.0001075112,0.000010651253,0.0000358479,6.0857565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018555537,0.000105489766,0.98585063,0.000045676876,0.00095264317,0.000010342379,0.0024299773,0.00003771903,0.0010916748,0.0000020524367,0.000012826619,0.0076054027],"study_design_scores_gemma":[0.0019003158,0.000130286,0.99355435,0.000064258675,0.0016371489,9.2098384e-7,0.0007419446,0.001791332,0.00004592419,0.0000037122006,0.00006121348,0.000068566085],"about_ca_topic_score_codex":0.002141895,"about_ca_topic_score_gemma":0.0017999536,"teacher_disagreement_score":0.007703736,"about_ca_system_score_codex":0.00023883044,"about_ca_system_score_gemma":0.000033116106,"threshold_uncertainty_score":0.3237919},"labels":[],"label_agreement":null},{"id":"W4389957626","doi":"10.1161/circ.148.suppl_1.13640","title":"Abstract 13640: Baseline Kidney Function and the Effects of Dapagliflozin on Health Status in Heart Failure: A Pooled Patient-Level Analysis From DFEINE-HF and PRESERVED-HF","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Dapagliflozin; Placebo; Renal function; Confidence interval; Internal medicine; Clinical endpoint; Heart failure; Clinical trial; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.01507276707219807,"score_gpt":0.2503213841321797,"score_spread":0.23524861705998162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389957626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444115,0.00041047554,0.00016073664,0.0038228107,0.000075450174,0.0009725438,0.000034790588,0.000039501414,0.000042549815],"genre_scores_gemma":[0.9980712,0.00010887762,0.00009204628,0.0006874094,0.00003077952,0.000051581334,0.00092521316,0.00001159969,0.000021310405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989232,0.0001198256,0.00028606434,0.00025533602,0.0002349911,0.00018057297],"domain_scores_gemma":[0.99916947,0.0003268659,0.0001251638,0.00022850206,0.000034956207,0.00011505377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035149496,0.00012003395,0.0003411249,0.00033883855,0.000048012793,0.000018891986,0.000019901257,0.000045090455,0.000021517435],"category_scores_gemma":[0.00028252302,0.000087901484,0.00006862599,0.0006182803,0.00003405156,0.00008179658,0.00002720361,0.000072908515,0.0000061073256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052072457,0.00023356847,0.9728165,0.00042980685,0.0009899989,0.0000035375178,0.00052381016,0.0007015891,0.0021337583,0.0001720895,0.002371437,0.019103164],"study_design_scores_gemma":[0.0051614298,0.00018775465,0.982785,0.00017485436,0.00071139104,5.814035e-8,0.000097518314,0.009947766,0.00012304314,0.00033762126,0.00040956645,0.00006402797],"about_ca_topic_score_codex":0.0014868916,"about_ca_topic_score_gemma":0.00041544242,"teacher_disagreement_score":0.019039135,"about_ca_system_score_codex":0.000060304268,"about_ca_system_score_gemma":0.000032567023,"threshold_uncertainty_score":0.35845184},"labels":[],"label_agreement":null},{"id":"W4389957742","doi":"10.1161/circ.148.suppl_1.15244","title":"Abstract 15244: Synchronous Care in Cardiovascular Disease: The DECIDE-CV Clinic Program","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; McNemar's test; Internal medicine; Diabetes mellitus; Type 2 diabetes; Kidney disease; Nephrology; Glycemic; Cardiology; Albuminuria; Guideline; Insulin; Endocrinology; Pathology","score_opus":0.02333193877878051,"score_gpt":0.29393752845945814,"score_spread":0.2706055896806776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389957742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895756,0.0043544,0.000018066292,0.00030559953,0.00017594059,0.0015390237,0.0000027424508,0.0002399428,0.0037886864],"genre_scores_gemma":[0.99887335,0.00013750103,0.000030486859,0.000051352443,0.00011487273,0.0002835107,0.0003653969,0.000018530332,0.00012500091],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99908715,0.000025959214,0.00017724125,0.00022993972,0.0002790075,0.0002006785],"domain_scores_gemma":[0.99937487,0.00004004359,0.000032667325,0.00044956186,0.00003782214,0.00006502048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023436226,0.000098480064,0.00017106265,0.00010396223,0.000057817717,0.000027052109,0.00005472398,0.000039117254,0.00005627426],"category_scores_gemma":[0.000041513562,0.00007314755,0.00022295908,0.0003493914,0.000026695043,0.000061092614,0.00002607845,0.00007160029,0.00044838208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030423951,0.00012783652,0.39678085,0.0002185241,0.00040958665,0.00013133131,0.0002998624,0.0027538387,0.000014510875,0.000054232765,0.00043036498,0.5987486],"study_design_scores_gemma":[0.0008551651,0.000033109198,0.98431516,0.000083508276,0.0003687824,4.8132847e-7,0.0002759226,0.00094035454,0.0000052239475,0.00010335804,0.0129455095,0.00007341847],"about_ca_topic_score_codex":0.000035854362,"about_ca_topic_score_gemma":0.000013792312,"teacher_disagreement_score":0.5986752,"about_ca_system_score_codex":0.0001430079,"about_ca_system_score_gemma":0.00004643166,"threshold_uncertainty_score":0.5763194},"labels":[],"label_agreement":null},{"id":"W4389957888","doi":"10.1161/circ.148.suppl_1.16789","title":"Abstract 16789: Modeling the Optimal Strategy of Natriuretic Peptide Testing for Heart Failure Prevention in Diabetes: A Pooled Cohort Analysis","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Atherosclerosis Risk in Communities; Natriuretic peptide; Heart failure; Internal medicine; Diabetes mellitus; Cumulative incidence; Cohort; Incidence (geometry); Type 2 diabetes; Framingham Risk Score; Hazard ratio; Cardiology; Disease; Confidence interval; Endocrinology","score_opus":0.03563482830526982,"score_gpt":0.2951094983178147,"score_spread":0.2594746700125449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389957888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681705,0.000054886288,0.0015773665,0.00025928585,0.00001987581,0.0010521385,0.0000038599833,0.000054544307,0.00016101137],"genre_scores_gemma":[0.9985472,0.0000018509459,0.00089886924,0.00001554523,0.00003576736,0.00014031315,0.00030240495,0.000013021755,0.000045037166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999088,0.000021872778,0.00031537947,0.00019705699,0.00019022216,0.00018748887],"domain_scores_gemma":[0.9994764,0.00012309063,0.00009747435,0.0001758403,0.00009970217,0.000027508197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005351092,0.00009468136,0.00024653453,0.00032682702,0.000048927854,0.000020253794,0.000040664207,0.000049633905,0.000013625922],"category_scores_gemma":[0.00013244514,0.00007687273,0.00016377035,0.001036732,0.000014165809,0.000092852446,0.000013659078,0.00005910912,0.000005310261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010578887,0.000052858835,0.5250672,0.00011166442,0.00043755205,6.7152905e-7,0.000056902874,0.46876773,0.0037001611,0.000043936107,0.000034502584,0.0017161897],"study_design_scores_gemma":[0.00041733746,0.000036331938,0.52780545,0.00006267568,0.0009066151,7.5099464e-8,0.00012633229,0.47030047,0.000080585334,0.00022101458,0.000004010386,0.000039084076],"about_ca_topic_score_codex":0.000029428762,"about_ca_topic_score_gemma":0.000026533267,"teacher_disagreement_score":0.0036195759,"about_ca_system_score_codex":0.000066913,"about_ca_system_score_gemma":0.00003393911,"threshold_uncertainty_score":0.3134779},"labels":[],"label_agreement":null},{"id":"W4389958017","doi":"10.1161/circ.148.suppl_1.15007","title":"Abstract 15007: Time to SGLT2i Initiation in Patients With Heart Failure","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Medical prescription; Diabetes mellitus; Internal medicine; Heart failure; Cohort; Cohort study; Emergency medicine; Endocrinology","score_opus":0.010569086326312625,"score_gpt":0.23064799511736664,"score_spread":0.22007890879105402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389958017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583316,0.0000018443421,0.000014304511,0.0010267014,0.000025906369,0.0006078454,0.0000021126698,0.000087522974,0.0024006336],"genre_scores_gemma":[0.99880135,1.9796202e-7,0.00014316273,0.00023936137,0.00002978118,0.00002940994,0.0005500077,0.00001171724,0.00019502567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994512,0.000006777823,0.00011453071,0.00013282565,0.00017463516,0.00012004014],"domain_scores_gemma":[0.99976814,0.000012793037,0.000026675378,0.00011073543,0.000038436257,0.000043220967],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007892875,0.00006357969,0.00009491347,0.00020534964,0.00002000179,0.000012952931,0.000015476622,0.00002842264,0.00018976995],"category_scores_gemma":[0.0000204969,0.000055667395,0.000018094684,0.00036628102,0.000004369541,0.000104519175,0.0000094420675,0.00003107554,0.0021156762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039645078,0.00009450078,0.9922958,0.000024288174,0.000016777045,0.0000025208456,0.000079007,0.00062065636,0.00028684994,0.000021284051,0.0039279126,0.0025907638],"study_design_scores_gemma":[0.0013338743,0.00007848831,0.99538726,0.00006633595,0.000022477361,6.701093e-8,0.000011128101,0.00023680174,0.00004245968,0.000029158959,0.0027336595,0.000058268564],"about_ca_topic_score_codex":0.0000051472916,"about_ca_topic_score_gemma":0.000004997497,"teacher_disagreement_score":0.0030914864,"about_ca_system_score_codex":0.000082234874,"about_ca_system_score_gemma":0.000011083977,"threshold_uncertainty_score":0.9986613},"labels":[],"label_agreement":null},{"id":"W4389958644","doi":"10.1161/circ.148.suppl_1.15684","title":"Abstract 15684: Adherence and Persistence to SGLT2 Inhibitors in Patients With Heart Failure","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Empagliflozin; Persistence (discontinuity); Dapagliflozin; Medical prescription; Diabetes mellitus; Cumulative incidence; Internal medicine; Cohort; Canagliflozin; Heart failure; Population; Retrospective cohort study; Incidence (geometry); Medication adherence; Cohort study; Intensive care medicine; Emergency medicine; Type 2 diabetes; Pharmacology; Endocrinology; Environmental health","score_opus":0.016822270103285932,"score_gpt":0.23185009030714185,"score_spread":0.2150278202038559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389958644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984389,0.000009594629,0.0000042773167,0.0005873089,0.00003402056,0.00045694268,0.0000011266656,0.00004204616,0.00042579594],"genre_scores_gemma":[0.9995706,9.18104e-7,0.00016617679,0.0001010992,0.000015783367,0.000021359494,0.00005340297,0.0000068528147,0.00006378014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950385,0.000004369771,0.00008661989,0.00015373845,0.00014043285,0.000111012916],"domain_scores_gemma":[0.9997984,0.000010127417,0.00001977995,0.00009046393,0.000027571465,0.000053632175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054034892,0.00006096412,0.00008416187,0.000121294586,0.000023058285,0.000013845322,0.000014299863,0.000022344044,0.000017865568],"category_scores_gemma":[0.000016433816,0.000051157476,0.00001318603,0.00026312255,0.000011249179,0.00008360978,0.000014236829,0.000031389038,0.00008010303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020208738,0.00004201659,0.99464333,0.000035596848,0.000009274016,0.0000022682493,0.00018308536,0.000094580326,0.00021326906,0.0000117964355,0.00062625273,0.0041183257],"study_design_scores_gemma":[0.0008365442,0.00012010348,0.9979323,0.00013090287,0.000018262064,1.3050527e-7,0.000121268095,0.00007161596,0.00005182583,0.0000142534545,0.00064702344,0.000055736662],"about_ca_topic_score_codex":0.000015128889,"about_ca_topic_score_gemma":0.000022367618,"teacher_disagreement_score":0.004062589,"about_ca_system_score_codex":0.000044757224,"about_ca_system_score_gemma":0.0000084908925,"threshold_uncertainty_score":0.20861413},"labels":[],"label_agreement":null},{"id":"W4390191629","doi":"10.1002/alz.082663","title":"Early metformin initiation was not associated with incident dementia: a population‐based cohort study","year":2023,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Dementia; Cohort; Diabetes mellitus; Hazard ratio; Internal medicine; Population; Cohort study; Confounding; Retrospective cohort study; Disease; Endocrinology; Environmental health; Confidence interval","score_opus":0.0319778729953591,"score_gpt":0.28156683063722404,"score_spread":0.24958895764186495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390191629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409777,0.0009928345,0.00006712154,0.00028096113,0.00019263825,0.0027800372,0.000011256268,0.000410131,0.0011672679],"genre_scores_gemma":[0.99689794,0.000011655341,0.00037527044,0.0004343787,0.000051351144,0.00060890015,0.0014585726,0.000058111116,0.000103843915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975952,0.0000966034,0.0004675844,0.00047194076,0.0009017162,0.00046694645],"domain_scores_gemma":[0.99895793,0.000071383496,0.00024840372,0.0004337864,0.00015189807,0.00013661609],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006587839,0.00029377505,0.0004108713,0.00040285027,0.00020099399,0.00008372799,0.00012490261,0.00007001944,0.00029610484],"category_scores_gemma":[0.000048133577,0.00024899282,0.00010840377,0.00082678394,0.00002463226,0.0002811135,0.00010130348,0.0001134015,0.00028990707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009028343,0.0008247051,0.9504487,0.000005647291,0.0433845,0.00010629237,0.0001827778,0.000042117925,0.0000395831,0.00006397415,0.0012190604,0.0035923496],"study_design_scores_gemma":[0.0037612864,0.0009538758,0.9212714,0.000039696275,0.072084315,5.814842e-7,0.000117729935,0.00040860215,0.00075334957,0.000026235697,0.0003472613,0.00023567298],"about_ca_topic_score_codex":0.00047497518,"about_ca_topic_score_gemma":0.00036112027,"teacher_disagreement_score":0.029177314,"about_ca_system_score_codex":0.000044509772,"about_ca_system_score_gemma":0.00005554236,"threshold_uncertainty_score":0.99999624},"labels":[],"label_agreement":null},{"id":"W4390192909","doi":"10.1002/alz.076540","title":"Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes","year":2023,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Toronto Public Health","funders":"","keywords":"Semaglutide; Overweight; Medicine; Placebo; Obesity; Body mass index; Clinical trial; Weight loss; Internal medicine; Type 2 diabetes; Gerontology; Physical therapy; Diabetes mellitus; Endocrinology; Liraglutide; Alternative medicine","score_opus":0.04423079381061202,"score_gpt":0.34587211825194086,"score_spread":0.30164132444132885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390192909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97690076,0.02042439,0.00001393802,0.00093178113,0.00009720711,0.0012855009,0.00015405589,0.000055357796,0.00013703946],"genre_scores_gemma":[0.99637705,0.00086730014,0.0010888776,0.00021331248,0.000052501127,0.000045525194,0.0012664056,0.000020130372,0.000068871355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986587,0.000105242405,0.00040421652,0.00036950962,0.00020385176,0.0002584645],"domain_scores_gemma":[0.99899274,0.00024879695,0.00010081701,0.0005584742,0.00001811802,0.00008107393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007760876,0.0001349137,0.00032318296,0.00006955708,0.000045138622,0.000028061499,0.00015432353,0.000050507435,0.0001229334],"category_scores_gemma":[0.00007091885,0.00010071661,0.000041471103,0.0002637365,0.00010541228,0.00009060475,0.0004896194,0.00011044177,0.000018901423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037652848,0.0007645447,0.59417915,0.000029696334,0.010860934,0.000067619185,0.0005453008,3.7445326e-7,0.00010526576,0.00014603036,0.04055906,0.3523655],"study_design_scores_gemma":[0.008308784,0.00028067912,0.9553138,0.00005905576,0.012328622,6.18253e-7,0.00088161294,0.0015255188,0.00009572568,0.00008531872,0.02099387,0.00012640478],"about_ca_topic_score_codex":0.00064408703,"about_ca_topic_score_gemma":0.0007875098,"teacher_disagreement_score":0.36113465,"about_ca_system_score_codex":0.0000040441955,"about_ca_system_score_gemma":0.000041308627,"threshold_uncertainty_score":0.4107104},"labels":[],"label_agreement":null},{"id":"W4390262441","doi":"10.1016/j.jns.2023.121052","title":"Independent associations of plasma GFAP with amyloid-Β and tau in Alzheimer's disease","year":2023,"lang":"en","type":"article","venue":"Journal of the Neurological Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Amyloid (mycology); Alzheimer's disease; Disease; Neuroscience; Medicine; Pathology; Psychology","score_opus":0.04444352391846475,"score_gpt":0.29073486422572886,"score_spread":0.24629134030726413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390262441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896324,0.00008785058,4.0240226e-7,0.009670709,0.00007310066,0.000102818994,0.0000014201521,0.000004498535,0.0004267707],"genre_scores_gemma":[0.99949384,0.00005294968,0.000046241672,0.00034174777,0.00001837483,0.0000015385939,1.6759172e-7,0.0000012959589,0.00004382449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992403,0.000049172228,0.00015080429,0.00007707484,0.00037159087,0.00011109862],"domain_scores_gemma":[0.9995834,0.00012004096,0.00015676381,0.000048052665,0.000023230155,0.00006850575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041703528,0.00004488702,0.00013080498,0.00008689274,0.00005341362,0.000014180165,0.00012332844,0.000015410453,0.000009954346],"category_scores_gemma":[0.0001443426,0.0000188429,0.000042558127,0.00038988233,0.00016706894,0.000061830746,0.00006906577,0.00008995964,0.0000012247332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075161406,0.00011865985,0.9970761,0.000002516474,0.000032898584,0.00006680139,0.000036727866,0.00045469598,0.000073385425,0.00022590958,0.00023059467,0.001606532],"study_design_scores_gemma":[0.00052161707,0.0010207242,0.99694353,0.000017952445,0.00011863006,0.000005708217,0.000036074365,0.00041099283,0.00006294493,0.0006709173,0.00017061895,0.000020308311],"about_ca_topic_score_codex":0.0000038981516,"about_ca_topic_score_gemma":0.000010264601,"teacher_disagreement_score":0.009861431,"about_ca_system_score_codex":0.0000069970215,"about_ca_system_score_gemma":0.00003541985,"threshold_uncertainty_score":0.07683912},"labels":[],"label_agreement":null},{"id":"W4390311701","doi":"10.1111/dom.15431","title":"Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( <scp> ENDO <sup>2</sup> S‐RWD </scp> )","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Tolerability; Clinical trial; Internal medicine; Dulaglutide; Retrospective cohort study; Medical prescription; Cohort; Diabetes mellitus; Adverse effect; Pharmacology; Liraglutide; Endocrinology","score_opus":0.01697452754513942,"score_gpt":0.2486603731151771,"score_spread":0.23168584557003769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390311701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289364,0.0010395953,0.0000020164732,0.0019479537,0.00021080834,0.003176792,0.00015438232,0.00013690886,0.00043789626],"genre_scores_gemma":[0.98750687,0.0008936248,0.00047802436,0.0066662915,0.00049814995,0.0004134712,0.00071216095,0.00015792412,0.0026735137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962154,0.00052099733,0.00061971537,0.0010220022,0.00080115814,0.0008207483],"domain_scores_gemma":[0.9963415,0.0022305932,0.00036490036,0.00049372134,0.00041180642,0.00015748068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011415298,0.0007041392,0.0019488673,0.0008932936,0.00017512852,0.00008312531,0.00018151541,0.0003146617,0.000019069148],"category_scores_gemma":[0.000889958,0.00060458324,0.00014837405,0.0013691555,0.00017665749,0.00026085819,0.00031034782,0.00088685326,0.000010811696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003491312,0.000728218,0.98936963,0.0014808129,0.0017398923,0.000058523518,0.0019792449,0.00005731231,0.000052018095,0.000075372154,0.003803469,0.0006206125],"study_design_scores_gemma":[0.0044651646,0.00042079372,0.9831801,0.0013826962,0.0021662167,5.058221e-7,0.00052827934,0.0004959743,0.00014298107,0.00012128184,0.0068266406,0.00026933246],"about_ca_topic_score_codex":0.00048531184,"about_ca_topic_score_gemma":0.0007168916,"teacher_disagreement_score":0.006189478,"about_ca_system_score_codex":0.00019788377,"about_ca_system_score_gemma":0.00013982948,"threshold_uncertainty_score":0.9996405},"labels":[],"label_agreement":null},{"id":"W4390346535","doi":"10.1001/jamanetworkopen.2023.49856","title":"Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Daiichi Sankyo Europe; Korea Health Industry Development Institute; Novo Nordisk; National Institute for Health and Care Research; Novo Nordisk Canada; National Research Foundation; Celltrion; National Research Foundation of Korea; McGill University; GlaxoSmithKline; Ministry of Food and Drug Safety; Pfizer","keywords":"Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.016153432868465833,"score_gpt":0.2572877577432961,"score_spread":0.24113432487483027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390346535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946703,0.0005787675,6.572176e-7,0.0002634843,0.00008693718,0.00098924,0.000005223547,0.000040235635,0.0033651607],"genre_scores_gemma":[0.9969964,0.000788261,0.00040177887,0.0003784895,0.00004219218,0.000040897892,0.00011063434,0.000026427844,0.0012148981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912375,0.000030620107,0.00015354052,0.00021492896,0.00016292173,0.00031423182],"domain_scores_gemma":[0.999447,0.00011036555,0.00008676608,0.00020261887,0.000051919676,0.000101329315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019249841,0.00014188133,0.00034935336,0.000057192025,0.00007970127,0.00010341747,0.00008304528,0.000040746716,0.000042501717],"category_scores_gemma":[0.000019430858,0.00009340425,0.000019829142,0.00028538366,0.000075687625,0.00019493188,0.00023367871,0.000062244755,0.000006510856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019504073,0.00007605145,0.9506322,0.00003811056,0.00048580635,0.000005012005,0.00021727377,0.000018672336,0.000004454533,0.00005180369,0.0032474042,0.045028128],"study_design_scores_gemma":[0.00449973,0.000717603,0.9899869,0.00018115655,0.00010675462,4.202808e-8,0.000049268332,0.0001732737,0.000028566921,0.00010587968,0.0040460215,0.0001048273],"about_ca_topic_score_codex":0.000053478114,"about_ca_topic_score_gemma":0.000012807562,"teacher_disagreement_score":0.0449233,"about_ca_system_score_codex":0.000014028996,"about_ca_system_score_gemma":0.000016156047,"threshold_uncertainty_score":0.38089147},"labels":[],"label_agreement":null},{"id":"W4390367090","doi":"10.1016/j.mad.2023.111898","title":"A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design","year":2023,"lang":"en","type":"article","venue":"Mechanisms of Ageing and Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Semaglutide; Medicine; Placebo; Dementia; Randomized controlled trial; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology; Disease; Liraglutide; Pathology","score_opus":0.020851977070059487,"score_gpt":0.2368320512607606,"score_spread":0.21598007419070112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390367090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125344,0.000037650007,0.0039098165,0.000030496716,0.000016892503,0.004729087,0.000006906809,0.000013017623,0.000002682366],"genre_scores_gemma":[0.9923691,0.000011057484,0.0072488054,0.0000071514683,9.595877e-7,0.00030034242,0.000028515773,0.000009359852,0.000024718945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990333,0.00008293884,0.00028686962,0.00020967594,0.0002798762,0.000107366934],"domain_scores_gemma":[0.99952054,0.00006423529,0.00018052109,0.00010529494,0.00010349683,0.000025887512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006199785,0.0001125489,0.00030484772,0.00014297778,0.00007521393,0.0000053210824,0.000033600103,0.000019245153,0.0000038480944],"category_scores_gemma":[0.00002008211,0.00007120807,0.000011749422,0.00021991985,0.00002692329,0.00003832189,0.000056799643,0.000033205175,1.5635409e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007612421,0.016851543,0.91192627,0.0015687274,0.003982034,0.000080436475,0.037154976,0.00062907056,0.0013449435,0.0005714253,0.000025761266,0.018252412],"study_design_scores_gemma":[0.017237699,0.0030798018,0.96530974,0.00024074609,0.0005332151,0.0000014866913,0.005645389,0.00020401743,0.0073553175,0.00031647083,8.9593215e-7,0.000075251206],"about_ca_topic_score_codex":0.00011283548,"about_ca_topic_score_gemma":0.000686799,"teacher_disagreement_score":0.053383462,"about_ca_system_score_codex":0.000025430329,"about_ca_system_score_gemma":0.000043635762,"threshold_uncertainty_score":0.2903781},"labels":[],"label_agreement":null},{"id":"W4390419459","doi":"10.53555/sfs.v10i1.1862","title":"Doe Approach: A Validated Rp -Hplc Method For The Determination Of Dapagliflozin","year":2023,"lang":"en","type":"article","venue":"Journal of Survey in Fisheries Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Chromatography; Chemistry; Reproducibility; Dosage form; Detection limit; Medicine","score_opus":0.29650778297287256,"score_gpt":0.36269820951142717,"score_spread":0.06619042653855461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390419459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97186637,0.00023131144,0.019372456,0.0035817272,0.00073679327,0.00082630356,0.000022444738,0.000022211101,0.003340393],"genre_scores_gemma":[0.9275498,0.00025047944,0.070063785,0.00016619009,0.00009682905,0.000034455777,0.000018732322,0.00001227424,0.0018074553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885017,0.00015857848,0.00036868398,0.0001023013,0.00036188788,0.0001583577],"domain_scores_gemma":[0.99849033,0.00094315276,0.0002773462,0.00009497342,0.0001626355,0.0000315645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006631494,0.00007242189,0.0002522888,0.0002568732,0.00007006038,0.0000428343,0.00020855104,0.00002759488,0.000015780337],"category_scores_gemma":[0.0007310214,0.00003957628,0.00008126718,0.0009792646,0.0001849014,0.00021826438,0.000037441652,0.0000596925,7.658072e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042346693,0.00036355617,0.86552227,0.00020656295,0.00018670078,0.000017168393,0.0020270736,0.00032635813,0.0017256208,0.0002859149,0.010944692,0.11797064],"study_design_scores_gemma":[0.001659368,0.0013773177,0.9755853,0.00010400016,0.0001551466,0.000012272959,0.002131711,0.009907254,0.0030760278,0.00080261956,0.0050890287,0.000099975354],"about_ca_topic_score_codex":0.000106090934,"about_ca_topic_score_gemma":0.00007924778,"teacher_disagreement_score":0.117870666,"about_ca_system_score_codex":0.000027557599,"about_ca_system_score_gemma":0.000077381235,"threshold_uncertainty_score":0.22983567},"labels":[],"label_agreement":null},{"id":"W4390449154","doi":"10.1177/20543581231217857","title":"Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Implementation research; Thematic analysis; Qualitative research; Family medicine; MEDLINE; Health care; Nursing; Psychological intervention","score_opus":0.04886430976686516,"score_gpt":0.36180755319724534,"score_spread":0.31294324343038016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390449154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884124,0.0018038554,0.000049033657,0.0068124784,0.00017760899,0.0011515493,0.0011589226,0.0000029105754,0.0000024090352],"genre_scores_gemma":[0.99562234,0.00021103394,0.0004652404,0.0034506554,0.0000549033,0.000028805487,0.00013083583,0.000014707447,0.000021470636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859285,0.00008288573,0.0004892743,0.00014345867,0.00020912086,0.00048239838],"domain_scores_gemma":[0.99124885,0.00016593713,0.00015557051,0.00008411008,0.00019856727,0.008146979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011905486,0.00007169684,0.0002547655,0.00025236027,0.00039649886,0.0000998011,0.0000518953,0.00003219276,0.00002047116],"category_scores_gemma":[0.004012571,0.00008455536,0.00005015164,0.00030910847,0.00012142576,0.0000932165,0.0000075836865,0.00012245799,3.6463117e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027386713,0.000011856435,0.9022215,0.0016685181,0.00011358622,0.00017502168,0.0016884021,0.0000018231495,0.000024680248,0.00007536117,0.07770949,0.016035903],"study_design_scores_gemma":[0.015019068,0.0013440676,0.7881794,0.0065408135,0.00065840024,0.000049892715,0.11492133,0.0006328394,0.00007154784,0.006598854,0.065545276,0.00043853148],"about_ca_topic_score_codex":0.8345073,"about_ca_topic_score_gemma":0.92442805,"teacher_disagreement_score":0.11404211,"about_ca_system_score_codex":0.0004350847,"about_ca_system_score_gemma":0.0392344,"threshold_uncertainty_score":0.9662123},"labels":[],"label_agreement":null},{"id":"W4390449655","doi":"10.1002/jcsm.13393","title":"Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved","year":2023,"lang":"en","type":"article","venue":"Journal of Cachexia Sarcopenia and Muscle","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Heart failure with preserved ejection fraction; Heart failure; Internal medicine; Ejection fraction; Clinical trial; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.03004170026350691,"score_gpt":0.3013672119398484,"score_spread":0.2713255116763415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390449655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719906,0.00012307486,0.000020370087,0.0017230774,0.00007304057,0.0005282532,0.0000021405958,0.000015987242,0.00031496902],"genre_scores_gemma":[0.998273,0.00008521061,0.0012345613,0.00008901526,0.00005935114,0.000015265538,0.00000844862,0.000020087537,0.0002150706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869645,0.000074207506,0.0004451862,0.00017522502,0.00032618223,0.0002827791],"domain_scores_gemma":[0.9992982,0.000105660074,0.00017005876,0.00016425867,0.00009908232,0.00016272068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005055683,0.00013601381,0.0004660939,0.00065141136,0.00003068098,0.000031210504,0.00007191527,0.00006413861,0.00004275215],"category_scores_gemma":[0.00016209854,0.00010516534,0.00007327179,0.0007607399,0.000021452859,0.00035087677,0.00006928174,0.00022572398,0.00000802904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001955917,0.00043879115,0.9367328,0.00015743468,0.00014933351,0.0000885505,0.0006085856,0.00056302745,0.049037576,0.0000074537124,0.0028459781,0.0074145044],"study_design_scores_gemma":[0.0067999195,0.0010172433,0.97666734,0.000553346,0.00009965985,0.000004835173,0.002232509,0.00014053084,0.003606389,0.000024713187,0.008754345,0.00009914603],"about_ca_topic_score_codex":0.00030503524,"about_ca_topic_score_gemma":0.0005415581,"teacher_disagreement_score":0.04543119,"about_ca_system_score_codex":0.00012990554,"about_ca_system_score_gemma":0.0000827694,"threshold_uncertainty_score":0.42885178},"labels":[],"label_agreement":null},{"id":"W4390502136","doi":"10.1111/dom.15419","title":"Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Metformin; Discontinuation; Medicine; Type 2 diabetes; Retrospective cohort study; Internal medicine; Cohort; Diabetes mellitus; Logistic regression; Cohort study; Pediatrics; Endocrinology","score_opus":0.0063257904242730615,"score_gpt":0.19644827907518556,"score_spread":0.1901224886509125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390502136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708796,0.0019345289,5.3206264e-7,0.00016458637,0.00018771172,0.00039303224,0.00010036484,0.000029687671,0.00010157807],"genre_scores_gemma":[0.9980439,0.0003088298,0.00008926552,0.00021787008,0.000025264013,0.000034590434,0.00032306844,0.000028894434,0.0009283296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986553,0.000041690295,0.00026748396,0.0003760476,0.00025363555,0.00040580335],"domain_scores_gemma":[0.99926585,0.00019034094,0.00006455102,0.00021816255,0.000073214695,0.00018786968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010940838,0.0002761359,0.00059764134,0.00031443025,0.000039654893,0.000067104214,0.00006254931,0.00007566965,0.000036512312],"category_scores_gemma":[0.00006423728,0.0002060801,0.00004508068,0.00045136764,0.00006875486,0.00030351125,0.000075886426,0.00012799587,9.395803e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023291272,0.00022447706,0.97620887,0.00030541417,0.0003787998,0.000027516953,0.00019096087,0.0000022252357,0.000037270576,0.00017999744,0.00028501012,0.022136165],"study_design_scores_gemma":[0.0024866997,0.00017246227,0.9891492,0.00035452348,0.0006815404,1.4646089e-7,0.00002868499,0.00021499509,0.0015429717,0.000023777511,0.005131025,0.00021394288],"about_ca_topic_score_codex":0.14443895,"about_ca_topic_score_gemma":0.2611765,"teacher_disagreement_score":0.11673756,"about_ca_system_score_codex":0.000047232308,"about_ca_system_score_gemma":0.00007321257,"threshold_uncertainty_score":0.8612583},"labels":[],"label_agreement":null},{"id":"W4390651062","doi":"10.2196/50737","title":"Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study","year":2024,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Australian Government","keywords":"Medicine; Workflow; Disease management; Clinical decision support system; Type 2 diabetes; Disease; Diabetes mellitus; Kidney disease; Intensive care medicine; Thematic analysis; Type 2 Diabetes Mellitus; Decision support system; Qualitative research; Computer science; Internal medicine; Database; Data mining","score_opus":0.04403657878656165,"score_gpt":0.43271029730400457,"score_spread":0.3886737185174429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390651062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867122,0.0009482216,0.00059477583,0.0043661017,0.00015246437,0.0052797077,0.000111860194,0.0002835467,0.001551117],"genre_scores_gemma":[0.9946015,0.00006452083,0.0007511282,0.00021022676,0.00027672813,0.0014941632,0.00025237098,0.000054724445,0.0022946429],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9960522,0.00043724364,0.00047965843,0.0004924242,0.0013817415,0.0011567252],"domain_scores_gemma":[0.99879545,0.00020945945,0.0000699741,0.00037862032,0.0003148545,0.00023164168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028773707,0.00028299808,0.00046165558,0.00056481647,0.0004261348,0.00019979224,0.0001413195,0.00005837831,0.00028526178],"category_scores_gemma":[0.00001751532,0.00018689336,0.000117063,0.0009968772,0.00012390215,0.0005854259,0.00016750368,0.0007058137,0.00021044402],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010155545,0.003664323,0.0048998673,0.00360959,0.002067696,0.00051189924,0.7885879,9.889104e-7,0.00008047435,0.0029289892,0.057890348,0.13474235],"study_design_scores_gemma":[0.011200578,0.02705897,0.033207454,0.0024028209,0.00022782109,0.00002110458,0.76850945,0.0003933265,0.0012662306,0.00080658577,0.15417297,0.00073268934],"about_ca_topic_score_codex":0.00008939936,"about_ca_topic_score_gemma":0.00016009001,"teacher_disagreement_score":0.13400966,"about_ca_system_score_codex":0.00049201463,"about_ca_system_score_gemma":0.00036504632,"threshold_uncertainty_score":0.762129},"labels":[],"label_agreement":null},{"id":"W4390669516","doi":"10.1007/s00125-023-06069-1","title":"Remission of type 2 diabetes: always more questions, but enough answers for action","year":2024,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; European Association for the Study of Diabetes","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Weight loss; Internal medicine; Disease; Endocrinology; Obesity","score_opus":0.0820378001961904,"score_gpt":0.38967326913640954,"score_spread":0.30763546894021915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390669516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005160106,0.99427366,0.000014001876,0.00018222879,0.0012221448,0.0022822034,0.00013006406,0.00022941125,0.0011503011],"genre_scores_gemma":[0.0001561603,0.99070793,0.000992142,0.00007805523,0.0002135243,0.00047947138,0.0018978093,0.000091925394,0.005382956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811226,0.000057792,0.00062213634,0.0005624599,0.00022530118,0.00042004327],"domain_scores_gemma":[0.99870795,0.00017907504,0.00030447805,0.0005483828,0.00013599964,0.00012413246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026200645,0.0004904379,0.0019787245,0.00038937255,0.000054118085,0.000024784546,0.00016744525,0.0004686197,0.000058069232],"category_scores_gemma":[0.00025542534,0.00033891597,0.0006625266,0.00047700305,0.00009287843,0.00006497188,0.00009101267,0.0002841945,0.000118992146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015656922,0.00019820643,0.00009479,0.06327434,0.0013053113,0.000012626903,0.000025053327,3.1987602e-7,0.000016368649,0.00042774228,0.03539505,0.89923453],"study_design_scores_gemma":[0.00031598337,0.00059357326,0.000025716774,0.018220974,0.010426876,0.0000018518806,0.00003852182,0.000029468005,0.000082349434,0.00010367624,0.96989113,0.00026984946],"about_ca_topic_score_codex":0.0000053579033,"about_ca_topic_score_gemma":5.810747e-7,"teacher_disagreement_score":0.9344961,"about_ca_system_score_codex":0.00024975257,"about_ca_system_score_gemma":0.00021947487,"threshold_uncertainty_score":0.9999063},"labels":[],"label_agreement":null},{"id":"W4390744429","doi":"10.1016/j.cmet.2023.12.018","title":"Prevention of cardiorenal complications in people with type 2 diabetes and obesity","year":2024,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Breakthrough T1D Canada; Canadian Institutes of Health Research; Novo Nordisk Fonden","keywords":"Cardiorenal syndrome; Type 2 diabetes; Obesity; Medicine; Diabetes mellitus; Intensive care medicine; Heart failure; Internal medicine; Endocrinology","score_opus":0.008889226982106705,"score_gpt":0.23657657918747013,"score_spread":0.22768735220536343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390744429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98232365,0.008478526,0.00005241811,0.00008742929,0.00006676192,0.00026795798,0.0000026825146,0.0000238417,0.008696758],"genre_scores_gemma":[0.99712735,0.00028189766,0.000801213,0.000020090918,0.000023785033,0.00002278148,0.000029626795,0.0000075625244,0.0016856899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996233,0.00001304503,0.000083979554,0.00012220975,0.00007433885,0.0000831082],"domain_scores_gemma":[0.9998,0.00001608349,0.00001617446,0.00011284658,0.00002423012,0.00003061197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006787644,0.000059538423,0.00017329004,0.00009319754,0.000011173189,0.000009627247,0.00002009175,0.000017449294,0.000022757054],"category_scores_gemma":[0.0000032667724,0.000043866417,0.000027032267,0.0002120129,0.000023775841,0.000042866097,0.000019316809,0.000039495346,0.000013141541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075658165,0.0013287958,0.8866624,0.00287325,0.0008818086,0.000023010278,0.0019131888,0.00004281052,0.027401095,0.012505335,0.0032645178,0.06302808],"study_design_scores_gemma":[0.0006291988,0.00010938758,0.9799129,0.00014134885,0.0005126305,6.701447e-7,0.00005397398,0.00024226207,0.006464536,0.00035415782,0.011519383,0.000059567454],"about_ca_topic_score_codex":0.000012682068,"about_ca_topic_score_gemma":0.000014077644,"teacher_disagreement_score":0.09325043,"about_ca_system_score_codex":0.000009925025,"about_ca_system_score_gemma":0.000021658992,"threshold_uncertainty_score":0.17888206},"labels":[],"label_agreement":null},{"id":"W4390747745","doi":"10.1016/j.metabol.2024.155785","title":"Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes","year":2024,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"Merck Canada; University of Toronto; National Heart, Lung, and Blood Institute; Gilead Sciences; Sanofi; Horizon Pharma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cardiorenal syndrome; Diabetes mellitus; Disease; Type 2 diabetes; Kidney disease; Internal medicine; Intensive care medicine; Bioinformatics; Endocrinology; Biology","score_opus":0.01832127634573974,"score_gpt":0.25557465687981223,"score_spread":0.2372533805340725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390747745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95209837,0.04524799,0.00025334756,0.00049365713,0.00038149962,0.001138859,0.000005222471,0.000062490486,0.00031854614],"genre_scores_gemma":[0.99675083,0.0020164403,0.0006314053,0.00005992468,0.00011914705,0.00014313764,0.000016825477,0.000022657787,0.00023963585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993473,0.000024792775,0.00015144671,0.00021498043,0.00008167046,0.00017977966],"domain_scores_gemma":[0.9998163,0.00003211725,0.000022193119,0.000068491165,0.000013647652,0.000047235448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037555696,0.00011625804,0.00025034626,0.00018034018,0.000039994557,0.000049126706,0.000016416025,0.000040748422,0.0000067487676],"category_scores_gemma":[0.00004344444,0.00009466944,0.00004294292,0.0001304013,0.000028524846,0.000101573205,0.000029476878,0.00007136495,0.0000025588345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006298033,0.00013226943,0.043497387,0.013496331,0.0020036618,0.000068499045,0.0015282447,0.000009622085,0.038702376,0.019542705,0.0071355794,0.8732535],"study_design_scores_gemma":[0.007991792,0.001209968,0.17330639,0.0047738394,0.004521318,0.000014302604,0.001891471,0.049392406,0.0056080846,0.015148935,0.73472655,0.0014149448],"about_ca_topic_score_codex":0.000004696868,"about_ca_topic_score_gemma":0.000002854332,"teacher_disagreement_score":0.87183857,"about_ca_system_score_codex":0.00006959989,"about_ca_system_score_gemma":0.000017820097,"threshold_uncertainty_score":0.3860508},"labels":[],"label_agreement":null},{"id":"W4390758410","doi":"10.4081/globcardio.2023.2","title":"SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials","year":2023,"lang":"en","type":"article","venue":"Global Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Dapagliflozin; Medicine; Hazard ratio; Internal medicine; Placebo; Randomized controlled trial; Meta-analysis; Confidence interval; Diabetes mellitus; Relative risk; Type 2 diabetes; Endocrinology","score_opus":0.044553951690806344,"score_gpt":0.33098623453234705,"score_spread":0.2864322828415407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390758410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929552,0.0013430063,0.00016830984,0.00011822888,0.00031723987,0.004087051,0.00057544577,0.000036000754,0.00039951337],"genre_scores_gemma":[0.9969938,0.0011139037,0.00012628335,0.00001964777,0.00007091973,0.0011316945,0.00044645314,0.0000053089802,0.00009201863],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99626,0.0019002933,0.0011446173,0.00031629903,0.0001736146,0.00020520765],"domain_scores_gemma":[0.99780643,0.0010858853,0.00068703806,0.0002324792,0.00013703393,0.000051121286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007681816,0.00017047471,0.009377347,0.00034478703,0.000027971675,0.000006413356,0.000034017125,0.00010548018,0.000015899765],"category_scores_gemma":[0.0044742473,0.00010140492,0.0037624654,0.0006267592,0.000108484724,0.000030100693,0.000037509886,0.000047229903,0.000002226753],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047659673,0.00007860951,0.30459464,0.000026377278,0.6438029,0.0000040186987,0.000030367293,0.00086392765,0.000004369653,0.0005277037,0.0011897868,0.0012176664],"study_design_scores_gemma":[0.23222043,0.00020622759,0.14378583,0.0000018240554,0.621872,1.7940418e-7,0.00004510143,0.00022935179,0.0000088758,0.0015075254,0.00006355271,0.000059111728],"about_ca_topic_score_codex":0.0007888463,"about_ca_topic_score_gemma":0.000059078415,"teacher_disagreement_score":0.18456075,"about_ca_system_score_codex":0.000058010275,"about_ca_system_score_gemma":0.00001676991,"threshold_uncertainty_score":0.6410167},"labels":[],"label_agreement":null},{"id":"W4390776745","doi":"10.4081/globalcard.2023.2","title":"SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials","year":2023,"lang":"en","type":"article","venue":"Global Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Dapagliflozin; Medicine; Hazard ratio; Internal medicine; Placebo; Randomized controlled trial; Meta-analysis; Relative risk; Diabetes mellitus; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.044553951690806344,"score_gpt":0.33098623453234705,"score_spread":0.2864322828415407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390776745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929552,0.0013430063,0.00016830984,0.00011822888,0.00031723987,0.004087051,0.00057544577,0.000036000754,0.00039951337],"genre_scores_gemma":[0.9969938,0.0011139037,0.00012628335,0.00001964777,0.00007091973,0.0011316945,0.00044645314,0.0000053089802,0.00009201863],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99626,0.0019002933,0.0011446173,0.00031629903,0.0001736146,0.00020520765],"domain_scores_gemma":[0.99780643,0.0010858853,0.00068703806,0.0002324792,0.00013703393,0.000051121286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007681816,0.00017047471,0.009377347,0.00034478703,0.000027971675,0.000006413356,0.000034017125,0.00010548018,0.000015899765],"category_scores_gemma":[0.0044742473,0.00010140492,0.0037624654,0.0006267592,0.000108484724,0.000030100693,0.000037509886,0.000047229903,0.000002226753],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047659673,0.00007860951,0.30459464,0.000026377278,0.6438029,0.0000040186987,0.000030367293,0.00086392765,0.000004369653,0.0005277037,0.0011897868,0.0012176664],"study_design_scores_gemma":[0.23222043,0.00020622759,0.14378583,0.0000018240554,0.621872,1.7940418e-7,0.00004510143,0.00022935179,0.0000088758,0.0015075254,0.00006355271,0.000059111728],"about_ca_topic_score_codex":0.0007888463,"about_ca_topic_score_gemma":0.000059078415,"teacher_disagreement_score":0.18456075,"about_ca_system_score_codex":0.000058010275,"about_ca_system_score_gemma":0.00001676991,"threshold_uncertainty_score":0.6410167},"labels":[],"label_agreement":null},{"id":"W4390816339","doi":"10.4081/cardio.2023.2","title":"SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials","year":2023,"lang":"en","type":"article","venue":"Global Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Dapagliflozin; Medicine; Hazard ratio; Internal medicine; Placebo; Randomized controlled trial; Relative risk; Meta-analysis; Diabetes mellitus; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.044553951690806344,"score_gpt":0.33098623453234705,"score_spread":0.2864322828415407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390816339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929552,0.0013430063,0.00016830984,0.00011822888,0.00031723987,0.004087051,0.00057544577,0.000036000754,0.00039951337],"genre_scores_gemma":[0.9969938,0.0011139037,0.00012628335,0.00001964777,0.00007091973,0.0011316945,0.00044645314,0.0000053089802,0.00009201863],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99626,0.0019002933,0.0011446173,0.00031629903,0.0001736146,0.00020520765],"domain_scores_gemma":[0.99780643,0.0010858853,0.00068703806,0.0002324792,0.00013703393,0.000051121286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007681816,0.00017047471,0.009377347,0.00034478703,0.000027971675,0.000006413356,0.000034017125,0.00010548018,0.000015899765],"category_scores_gemma":[0.0044742473,0.00010140492,0.0037624654,0.0006267592,0.000108484724,0.000030100693,0.000037509886,0.000047229903,0.000002226753],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047659673,0.00007860951,0.30459464,0.000026377278,0.6438029,0.0000040186987,0.000030367293,0.00086392765,0.000004369653,0.0005277037,0.0011897868,0.0012176664],"study_design_scores_gemma":[0.23222043,0.00020622759,0.14378583,0.0000018240554,0.621872,1.7940418e-7,0.00004510143,0.00022935179,0.0000088758,0.0015075254,0.00006355271,0.000059111728],"about_ca_topic_score_codex":0.0007888463,"about_ca_topic_score_gemma":0.000059078415,"teacher_disagreement_score":0.18456075,"about_ca_system_score_codex":0.000058010275,"about_ca_system_score_gemma":0.00001676991,"threshold_uncertainty_score":0.6410167},"labels":[],"label_agreement":null},{"id":"W4390919585","doi":"10.1016/j.revmed.2024.01.006","title":"Chez les adultes avec maladie cardiovasculaire et IMC ≥ 27 kg/m2, mais sans diabète, est-ce que le sémaglutide diminue le risque de mortalité cardiovasculaire, d’infarctus du myocarde ou d’AVC comparativement au placebo tout en étant sécuritaire ?","year":2024,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine; Gynecology","score_opus":0.009196212884973793,"score_gpt":0.24076319713411035,"score_spread":0.23156698424913655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390919585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55653167,0.061183915,0.0041574007,0.2521768,0.005774909,0.0076945103,0.0017568942,0.0010577816,0.10966616],"genre_scores_gemma":[0.9143043,0.007018115,0.0011114122,0.011767314,0.008084668,0.002264831,0.002896868,0.0007607092,0.05179176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98779386,0.0026124364,0.002215005,0.0028864976,0.0014712424,0.0030209827],"domain_scores_gemma":[0.9936625,0.0014540426,0.0006386085,0.0029410012,0.00034763737,0.0009562501],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0034324804,0.0027188445,0.004589109,0.0008280754,0.0005058467,0.0004304298,0.001417178,0.0014725594,0.0004434005],"category_scores_gemma":[0.000571136,0.002653869,0.004505241,0.00063739636,0.0008623566,0.00042986133,0.0017080712,0.0033685574,0.00076994393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010796475,0.0029151193,0.36455715,0.016015062,0.08003715,0.050854232,0.023666147,0.008402037,0.0004308331,0.0219315,0.41019264,0.019918492],"study_design_scores_gemma":[0.01333328,0.00090082356,0.1287332,0.016299296,0.015366635,0.0021522576,0.0024465225,0.0037551909,0.002256651,0.0005123779,0.8113942,0.0028495637],"about_ca_topic_score_codex":0.02983123,"about_ca_topic_score_gemma":0.016729632,"teacher_disagreement_score":0.40120158,"about_ca_system_score_codex":0.0065629766,"about_ca_system_score_gemma":0.001676748,"threshold_uncertainty_score":0.99982375},"labels":[],"label_agreement":null},{"id":"W4390942364","doi":"10.1016/j.cmet.2023.12.024","title":"Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease","year":2024,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Institute on Aging; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; National Institutes of Health; American Heart Association; Novo Nordisk; Breakthrough T1D Canada; University of Texas Southwestern Medical Center; Max and Minnie Tomerlin Voelcker Fund; Novo Nordisk Fonden","keywords":"Kidney; Kidney disease; Internal medicine; Endocrinology; Glucagon receptor; Renal function; Homeostasis; Biology; Medicine; Glucagon; Hormone","score_opus":0.005964920685477413,"score_gpt":0.22702986418755383,"score_spread":0.22106494350207642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390942364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87484884,0.09171292,0.009592957,0.0108224135,0.0056642476,0.0058866055,0.0006146009,0.00020726451,0.0006501649],"genre_scores_gemma":[0.9949071,0.00043784038,0.000112688336,0.0004471006,0.00047592865,0.00020253345,0.00030373537,0.000024257553,0.00308882],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991004,0.00003548261,0.00022319674,0.00027041725,0.00018236093,0.0001881609],"domain_scores_gemma":[0.9993296,0.00003525066,0.000058393176,0.00024800992,0.0000730157,0.00025569595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018435168,0.00014438157,0.00025338805,0.00013350202,0.000066499844,0.00005199311,0.00006097789,0.00004680003,0.000054837023],"category_scores_gemma":[0.000096501,0.000096425196,0.00013677526,0.00023123987,0.000040703904,0.000078381454,0.000057896727,0.000050323928,0.00001687652],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010727267,0.00031689272,0.00096065854,0.0060615996,0.0010058363,0.0000025237525,0.00021285708,0.000044248092,0.7607304,0.02419911,0.16555023,0.039842926],"study_design_scores_gemma":[0.004832699,0.0002474633,0.027929097,0.0015946743,0.0053658686,9.547388e-7,0.000048749072,0.0009410538,0.117437705,0.0010715813,0.84031826,0.00021188761],"about_ca_topic_score_codex":0.000007667161,"about_ca_topic_score_gemma":8.210662e-7,"teacher_disagreement_score":0.67476803,"about_ca_system_score_codex":0.00008134263,"about_ca_system_score_gemma":0.0001938389,"threshold_uncertainty_score":0.39321056},"labels":[],"label_agreement":null},{"id":"W4390952355","doi":"10.1111/dom.15459","title":"Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Regional Municipality of Waterloo; University of Waterloo; University of Alberta","funders":"","keywords":"Exenatide; Semaglutide; Liraglutide; Dulaglutide; Lixisenatide; Weight loss; Medicine; Glucagon-like peptide 1 receptor; Adverse effect; Diabetes mellitus; Medical prescription; Obesity; Internal medicine; Type 2 diabetes; Endocrinology; Agonist; Pharmacology; Receptor","score_opus":0.013519707573142727,"score_gpt":0.2560227436641229,"score_spread":0.2425030360909802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390952355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887063,0.008011487,0.000028410062,0.00029589073,0.00052843423,0.00047022532,0.00004676118,0.00020826866,0.0017042159],"genre_scores_gemma":[0.99564254,0.00065919163,0.00081697403,0.00032015884,0.000225774,0.00004112658,0.00016722904,0.00003904888,0.0020879277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826854,0.00008646546,0.0003576688,0.00050761754,0.00032396245,0.00045571965],"domain_scores_gemma":[0.9991024,0.00006938714,0.00008067256,0.0003759014,0.00008439444,0.0002872579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054147444,0.00029154308,0.0006328329,0.00025798735,0.00011451405,0.00009935985,0.00011896848,0.000111362395,0.00029030073],"category_scores_gemma":[0.00003085201,0.0002475462,0.00020287736,0.00034738655,0.00021609654,0.0004568507,0.00010383523,0.00018680272,0.00003270256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009080481,0.0016057604,0.8268236,0.0031952611,0.0029109465,0.00005754335,0.0032139274,0.000012517129,0.04062846,0.012343989,0.005801869,0.10331532],"study_design_scores_gemma":[0.0015673634,0.00032241343,0.8042863,0.00050676387,0.0022852684,9.3459164e-7,0.00058119715,0.0008670761,0.04886363,0.00088104565,0.13931693,0.0005210534],"about_ca_topic_score_codex":0.00016016459,"about_ca_topic_score_gemma":0.000024091833,"teacher_disagreement_score":0.13351506,"about_ca_system_score_codex":0.00003733848,"about_ca_system_score_gemma":0.000045481866,"threshold_uncertainty_score":0.9999977},"labels":[],"label_agreement":null},{"id":"W4390985431","doi":"10.1002/ejhf.3129","title":"The Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Left Cardiac Remodelling in Heart Failure with Reduced Ejection Fraction: Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Surgical Specialties (Canada)","funders":"","keywords":"Ejection fraction; Medicine; Cardiology; Internal medicine; Heart failure; Cardiac function curve; Confidence interval; End-diastolic volume; Stroke volume","score_opus":0.012219073280015903,"score_gpt":0.2477180501234903,"score_spread":0.2354989768434744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390985431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59129286,0.30849764,0.0004496046,0.09227819,0.0005235026,0.0059988545,0.000018240982,0.00011628727,0.0008248356],"genre_scores_gemma":[0.99749523,0.0010764704,0.0007004353,0.0002188583,0.00009011506,0.000008833828,0.0000063356015,0.000037345126,0.00036637584],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99756956,0.00087176054,0.00075343624,0.00021298413,0.0004303495,0.00016193592],"domain_scores_gemma":[0.9990621,0.00021081975,0.00024150538,0.0002976687,0.00009525688,0.00009264586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027388001,0.0002250554,0.0016584632,0.00032500172,0.0000677406,0.00006543213,0.000059999948,0.000025197452,0.000034740064],"category_scores_gemma":[0.000038893137,0.00010754555,0.00086144503,0.0004487483,0.000042122883,0.00015408342,0.000010993706,0.00037195062,0.000016246988],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016412539,0.00051081466,0.018378912,0.32766265,0.50196964,0.0018367862,0.0014926359,0.0017707982,0.0070253415,0.00009253311,0.13711904,0.00049959874],"study_design_scores_gemma":[0.0015709555,0.005018136,0.0018178979,0.028036274,0.9104586,0.0002664536,0.00036596216,0.000119267126,0.0062477677,0.000004661408,0.04575546,0.0003385526],"about_ca_topic_score_codex":0.0000032025814,"about_ca_topic_score_gemma":0.0000066108987,"teacher_disagreement_score":0.40848896,"about_ca_system_score_codex":0.00005409173,"about_ca_system_score_gemma":0.000022220434,"threshold_uncertainty_score":0.438558},"labels":[],"label_agreement":null},{"id":"W4391028843","doi":"10.1161/jaha.123.031586","title":"Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital; BC Innovation Council; University of British Columbia; University of Calgary; McGill University Health Centre","funders":"National Health and Medical Research Council; Medical Research Council; National Institutes of Health; Idorsia Pharmaceuticals; Ingham Institute for Applied Medical Research; Astellas Pharma; Sanofi; Kidney Foundation of Canada; Kowa Company; Gilead Sciences; Pfizer; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Eli Lilly and Company; AstraZeneca; Novo Nordisk; Verily Life Sciences; Canadian Institutes of Health Research; University of Washington; American Heart Association","keywords":"Canagliflozin; Medicine; Kidney disease; Internal medicine; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Proportional hazards model; Empagliflozin; Placebo; Clinical trial; Endocrinology; Confidence interval; Pathology","score_opus":0.00860876618061515,"score_gpt":0.24634341911988247,"score_spread":0.23773465293926732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391028843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98702186,0.00617639,0.000013478024,0.0058547477,0.00017751679,0.00057396066,0.0000053092845,0.0000126949,0.00016402853],"genre_scores_gemma":[0.99630105,0.0011343835,0.0006634701,0.0010417707,0.00039957982,0.000018797895,0.0000055652104,0.000011819725,0.00042352887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99914247,0.00015464098,0.00015966198,0.0001097429,0.00034324737,0.0000902465],"domain_scores_gemma":[0.99947584,0.00013746732,0.00015081487,0.00010449245,0.00005395702,0.00007741003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039527335,0.0000805551,0.000318441,0.000039511364,0.000085402506,0.000097600445,0.00003285169,0.000020290776,0.0000023813516],"category_scores_gemma":[0.00009648215,0.00004004735,0.00011700671,0.00014484965,0.000070315786,0.00013222251,0.000034662204,0.00016285584,2.7962867e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043791384,0.00037194835,0.4431075,0.00026981576,0.016138993,0.00009317826,0.0028017093,0.0000086382015,0.0008560554,0.0000866456,0.04726269,0.4846237],"study_design_scores_gemma":[0.008231981,0.0024826576,0.83878773,0.0005158297,0.0034047696,0.000049829356,0.00035448794,0.000113576134,0.00006235921,0.00019919021,0.14569421,0.000103360566],"about_ca_topic_score_codex":0.00056852616,"about_ca_topic_score_gemma":0.000086431464,"teacher_disagreement_score":0.48452035,"about_ca_system_score_codex":0.00019263875,"about_ca_system_score_gemma":0.00019857628,"threshold_uncertainty_score":0.16330837},"labels":[],"label_agreement":null},{"id":"W4391032221","doi":"10.1007/s12325-023-02773-x","title":"Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; AstraZeneca","keywords":"Dapagliflozin; Medicine; Albuminuria; Kidney disease; Renal function; Internal medicine; Diabetes mellitus; Urology; Comorbidity; Population; Creatinine; Type 2 diabetes; Endocrinology","score_opus":0.01636351137419319,"score_gpt":0.30417992847754594,"score_spread":0.28781641710335276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391032221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020934,0.008333285,0.0000052980704,0.00006514432,0.000063044936,0.0009878746,0.000008704137,0.000007972504,0.0003193208],"genre_scores_gemma":[0.99496514,0.0047194245,0.00000965266,0.000068332934,0.000013611567,0.000106857035,0.000020266767,0.000011815646,0.000084908424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934036,0.000074450785,0.00012933354,0.00020596148,0.0001257664,0.00012414821],"domain_scores_gemma":[0.9997222,0.00008327348,0.000028935821,0.00011166862,0.000013600466,0.00004035579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016978403,0.00011043446,0.00016619143,0.00016762762,0.000011486876,0.0000119502465,0.000040372055,0.000016703842,0.0000140636375],"category_scores_gemma":[0.000013454299,0.00006714178,0.000012689503,0.00035522602,0.000056547186,0.00026494375,0.000013207578,0.00005870105,4.443315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000465023,0.00021359726,0.9519348,0.00035177168,0.00003456825,0.000016949223,0.00043697082,0.00004801219,0.00006262168,0.0005938256,0.0000046968516,0.04583715],"study_design_scores_gemma":[0.0033123444,0.0004539672,0.99321926,0.001128813,0.000027500733,7.078063e-8,0.000026569653,0.00042169983,0.00027024338,0.0003052544,0.0007626805,0.00007161773],"about_ca_topic_score_codex":0.00006312789,"about_ca_topic_score_gemma":0.0013997414,"teacher_disagreement_score":0.045765534,"about_ca_system_score_codex":0.0000847665,"about_ca_system_score_gemma":0.0000361002,"threshold_uncertainty_score":0.27379623},"labels":[],"label_agreement":null},{"id":"W4391092121","doi":"10.2337/dc23-1450","title":"Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials","year":2024,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital; NOSM University; University of British Columbia; CARE Canada; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; National Institutes of Health; Idorsia Pharmaceuticals; Janssen Canada; Ingham Institute for Applied Medical Research; Mitsubishi Tanabe Pharma Corporation; FibroGen; Astellas Pharma; MyoKardia; Novo Nordisk; Verily Life Sciences; Daiichi Sankyo Europe; Gilead Sciences; Servier; Victor Chang Cardiac Research Institute; Pfizer; Moderna; Sunnybrook Research Institute; CSL Behring; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Amgen; American Heart Association; University of Washington; Kidney Foundation of Canada; Kowa Company; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi","keywords":"Canagliflozin; Medicine; Albuminuria; Empagliflozin; Diabetes mellitus; Type 2 diabetes; Internal medicine; Hazard ratio; Kidney disease; Proportional hazards model; Post-hoc analysis; Creatinine; Endocrinology; Confidence interval","score_opus":0.016179993889994585,"score_gpt":0.3008753542724022,"score_spread":0.2846953603824076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391092121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980079,0.017663462,3.8313792e-7,0.00041761086,0.000116818876,0.00095186714,0.0004360126,0.000042613996,0.00029222207],"genre_scores_gemma":[0.99909043,0.00022616527,0.000037275946,0.00014537673,0.000020929141,0.00008459811,0.00025378124,0.000017661838,0.00012378521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986329,0.00012563099,0.0003661755,0.0003072279,0.0003456349,0.0002224237],"domain_scores_gemma":[0.99898654,0.00020767403,0.000096139265,0.00044775795,0.0001270382,0.00013482898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037381708,0.00020994239,0.0010776694,0.00025256505,0.000042012667,0.000052126168,0.000077531855,0.00006434299,0.000037818525],"category_scores_gemma":[0.0004464207,0.000118956865,0.00074900355,0.00083768414,0.00010547696,0.000058779042,0.000059842954,0.00007310084,0.0000013573678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000143224315,0.000069208385,0.9296357,0.00047111599,0.030978082,0.0000022132315,0.00037302182,0.000025175443,0.00095917593,0.00003139143,0.0030129054,0.0344277],"study_design_scores_gemma":[0.0011771091,0.0012048727,0.9480524,0.00049366226,0.038138684,1.0950024e-7,0.00034232181,0.00084729,0.0051784264,0.000016709811,0.0043487162,0.00019968573],"about_ca_topic_score_codex":0.00022113897,"about_ca_topic_score_gemma":0.000039074166,"teacher_disagreement_score":0.034228012,"about_ca_system_score_codex":0.00007300598,"about_ca_system_score_gemma":0.00011338531,"threshold_uncertainty_score":0.485092},"labels":[],"label_agreement":null},{"id":"W4391116156","doi":"10.1111/dom.15450","title":"Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute on Minority Health and Health Disparities; National Center for Chronic Disease Prevention and Health Promotion; National Institute of Diabetes and Digestive and Kidney Diseases; Centers for Disease Control and Prevention; American Diabetes Association; American Heart Association; Centers for Disease Control and Prevention Foundation; Amgen","keywords":"Biostatistics; Family medicine; Medicine; Diabetes mellitus; Public health; Epidemiology; Gerontology; Library science; Nursing; Internal medicine","score_opus":0.018043709059800447,"score_gpt":0.26786741231575556,"score_spread":0.2498237032559551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391116156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9360291,0.018409323,0.0000018006111,0.040469646,0.0010804046,0.0017997228,0.001628804,0.00025305036,0.00032818477],"genre_scores_gemma":[0.73359126,0.0026813112,0.0023696532,0.19911148,0.0033100243,0.0031057063,0.054093104,0.0006778143,0.0010596229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99142784,0.00044351327,0.0015010628,0.0023654397,0.0016460092,0.0026161307],"domain_scores_gemma":[0.9960789,0.0007579827,0.00048041026,0.0017789614,0.00016839408,0.00073535205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015380633,0.0012730185,0.0025583685,0.0035232161,0.00021808918,0.00031458048,0.0008465466,0.0010641745,0.0003069736],"category_scores_gemma":[0.00090316427,0.0011801503,0.0002797031,0.0020453418,0.00034295252,0.0009171609,0.0014656128,0.0019631346,0.00011209389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000063908983,0.00054654374,0.87338674,0.0012321313,0.0009925631,0.000029370733,0.000642743,0.0000045100974,0.000068387184,0.00002897503,0.100935854,0.022125797],"study_design_scores_gemma":[0.0030206155,0.00015617142,0.7816738,0.0045194766,0.0043791397,1.739036e-7,0.000039692182,0.003945334,0.00022449157,0.00023684018,0.20060426,0.0011999918],"about_ca_topic_score_codex":0.00024897963,"about_ca_topic_score_gemma":0.00014766511,"teacher_disagreement_score":0.20243779,"about_ca_system_score_codex":0.00050497334,"about_ca_system_score_gemma":0.00022252128,"threshold_uncertainty_score":0.99906486},"labels":[],"label_agreement":null},{"id":"W4391127165","doi":"10.46747/cfp.700130","title":"Management of type 2 diabetes in patients with frailty","year":2024,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Type 2 diabetes; Medicine; Dipeptidyl peptidase-4; Diabetes mellitus; Bioinformatics; Diabetes management; Dipeptidyl peptidase; Intensive care medicine; Endocrinology; Biology; Biochemistry","score_opus":0.010486211073448538,"score_gpt":0.2137480641951704,"score_spread":0.20326185312172185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391127165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8354448,0.00058003643,6.051103e-7,0.00012211631,0.00013968073,0.00040848076,0.000019106174,0.000026581078,0.16325855],"genre_scores_gemma":[0.9952892,0.000016406497,0.00011563125,0.0034873602,0.000025798141,0.000019434094,0.00012332815,0.000025193904,0.00089763774],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992403,0.000006668522,0.00011368746,0.00020064956,0.00015022884,0.00028847167],"domain_scores_gemma":[0.9995891,0.00000674327,0.000015567479,0.00021072917,0.00003362759,0.000144249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000032256725,0.000122059915,0.00018493591,0.0002572708,0.000016073462,0.000016285092,0.00006108742,0.000025813251,0.0000069727907],"category_scores_gemma":[5.436553e-7,0.0001004852,0.00003677118,0.00050006,0.00003418115,0.00006851382,0.0000146123775,0.00006167954,0.00008246211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009965278,0.00064787513,0.28400847,0.0017859868,0.0021130661,0.00048509307,0.00016253667,0.000036025947,0.00010232762,0.013312608,0.028171495,0.66907483],"study_design_scores_gemma":[0.0010746451,0.0004632226,0.91870815,0.00096834364,0.00023706656,7.858381e-9,0.00012870628,0.00011293306,0.00008336853,0.00017259728,0.07789297,0.00015799311],"about_ca_topic_score_codex":0.0007251752,"about_ca_topic_score_gemma":0.0007475593,"teacher_disagreement_score":0.6689169,"about_ca_system_score_codex":0.0002076561,"about_ca_system_score_gemma":0.000083729574,"threshold_uncertainty_score":0.40976676},"labels":[],"label_agreement":null},{"id":"W4391127221","doi":"10.46747/cfp.7001e10","title":"Prise en charge du diabète de type 2 chez les patients fragiles","year":2024,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital; NOSM University","funders":"","keywords":"Medicine; Physics","score_opus":0.010004645346504854,"score_gpt":0.2142902296292517,"score_spread":0.20428558428274685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391127221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63557833,0.05965225,0.00001088784,0.00521736,0.007519176,0.0010639032,0.0005103414,0.00018276184,0.290265],"genre_scores_gemma":[0.9023574,0.0021094808,0.000078097546,0.037734665,0.003944866,0.00007822254,0.00071356003,0.00017059865,0.052813087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978079,0.0000884265,0.00024110955,0.00048048128,0.00023115837,0.0011508968],"domain_scores_gemma":[0.99852747,0.00007536529,0.00004089091,0.00036429148,0.000087160544,0.0009048281],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017200345,0.0003856328,0.00036927868,0.0003171491,0.00016024959,0.00017453943,0.00020789438,0.00018714085,0.0001548657],"category_scores_gemma":[0.000028519495,0.00040316363,0.00017873211,0.0004989278,0.00014003721,0.0002035505,0.000050185405,0.0002951011,0.004220083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001261604,0.0002925738,0.013611727,0.00067086786,0.000864066,0.0005565313,0.0012021795,0.000006701789,0.00027024373,0.014002099,0.39655635,0.571954],"study_design_scores_gemma":[0.00058105093,0.00030060456,0.047026377,0.0011178396,0.0006925961,2.2771782e-7,0.00036237162,0.0007435634,0.00016514573,0.00030049458,0.94834673,0.00036300873],"about_ca_topic_score_codex":0.020955306,"about_ca_topic_score_gemma":0.003045159,"teacher_disagreement_score":0.571591,"about_ca_system_score_codex":0.0017624662,"about_ca_system_score_gemma":0.0008597741,"threshold_uncertainty_score":0.99984205},"labels":[],"label_agreement":null},{"id":"W4391139593","doi":"10.1161/jaha.123.030683","title":"Association Between Age at Diagnosis of Type 2 Diabetes and Hospitalization for Heart Failure: A Population‐Based Study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Sunnybrook Hospital; University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Population; Heart failure; Internal medicine; Relative risk; Cohort; Cohort study; Demography; Pediatrics; Confidence interval; Endocrinology","score_opus":0.011745432153353726,"score_gpt":0.2843496401222811,"score_spread":0.27260420796892737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391139593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161994,0.0001676489,0.0000134663105,0.0073109823,0.00023944076,0.00061024557,0.000014490837,0.000016445001,0.000007341393],"genre_scores_gemma":[0.9985339,0.00001807187,0.0005339543,0.0002508026,0.00019681799,0.000021526592,0.000020280007,0.000016942615,0.00040769635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987952,0.00014007401,0.00036647977,0.00010510823,0.0004530662,0.00014006958],"domain_scores_gemma":[0.998489,0.0006330549,0.0005102334,0.00009494253,0.0002291565,0.000043610667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087728765,0.00009234216,0.0004691431,0.00015172354,0.000072150986,0.000043247303,0.00004129083,0.00003671079,0.000008118241],"category_scores_gemma":[0.00075735495,0.00006723676,0.00019872843,0.0004276835,0.000010257124,0.00011853698,0.00002561683,0.00007631513,0.0000018104565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002098539,0.00013676687,0.9798326,0.00005345658,0.00080361025,3.4490213e-7,0.0001505681,0.000022252261,0.00022770962,0.0000040417776,0.018156469,0.0005912102],"study_design_scores_gemma":[0.0006718729,0.0013625916,0.9909124,0.00012284465,0.0015278921,1.5069016e-7,0.00008303365,0.00016359011,0.0005201079,0.00007628365,0.0045004934,0.00005876629],"about_ca_topic_score_codex":0.000030232924,"about_ca_topic_score_gemma":0.000021703021,"teacher_disagreement_score":0.013655976,"about_ca_system_score_codex":0.0009917462,"about_ca_system_score_gemma":0.00003798404,"threshold_uncertainty_score":0.27418354},"labels":[],"label_agreement":null},{"id":"W4391211868","doi":"10.1093/ehjcvp/pvae006","title":"Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Max Kade Foundation","keywords":"Medicine; Myocardial infarction; Ischaemic heart disease; Internal medicine; Disease; Type 2 diabetes; Cardiology; Diabetes mellitus; Endocrinology","score_opus":0.013863793144129877,"score_gpt":0.2630256025279066,"score_spread":0.2491618093837767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391211868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574726,0.039203037,0.000007557103,0.0008151104,0.0005335421,0.0018713489,0.000007791598,0.00003363092,0.00005535077],"genre_scores_gemma":[0.9946138,0.003370234,0.000034144483,0.0015472713,0.00027268144,0.00004337108,0.000010525521,0.00007412888,0.000033832974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680287,0.0011068487,0.00037634635,0.00043643164,0.0009277724,0.00034973214],"domain_scores_gemma":[0.9990027,0.00019780976,0.000041662293,0.0004318732,0.00004960516,0.00027632972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016072204,0.00034515423,0.0008587788,0.00040049452,0.00008430465,0.000116084666,0.00009543927,0.000025645808,0.000008043938],"category_scores_gemma":[0.00007661811,0.00020807852,0.00094451406,0.00030430433,0.00009632813,0.00021005966,0.000040826842,0.00039149428,0.00000904711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075903954,0.00071258156,0.9575814,0.0003658928,0.012482962,0.0007568646,0.0004438202,0.00055576785,0.000113601505,0.000008738329,0.00077667844,0.018611284],"study_design_scores_gemma":[0.040298767,0.0008866608,0.9370043,0.00038779617,0.0026395777,0.0000053146455,0.000016973925,0.00004711684,0.00005009931,0.0000134794955,0.018435275,0.00021462729],"about_ca_topic_score_codex":0.000012573662,"about_ca_topic_score_gemma":1.9933867e-7,"teacher_disagreement_score":0.037141178,"about_ca_system_score_codex":0.00006356399,"about_ca_system_score_gemma":0.000051280513,"threshold_uncertainty_score":0.84851956},"labels":[],"label_agreement":null},{"id":"W4391252430","doi":"10.2215/cjn.0000000000000414","title":"Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD","year":2024,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Albuminuria; Renal function; Hazard ratio; Internal medicine; Dialysis; Placebo; Randomized controlled trial; Kidney disease; Kidney; Confidence interval; Clinical endpoint; Intensive care medicine; Pathology","score_opus":0.022404542951970433,"score_gpt":0.3265382218818902,"score_spread":0.30413367892991977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391252430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401772,0.0025777647,0.000011004119,0.05673368,0.00033514813,0.00011734186,0.0000032881846,0.0000074176014,0.000037176364],"genre_scores_gemma":[0.90171015,0.0056797247,0.0017063301,0.09037267,0.00019569552,0.0000019331187,0.0000018901164,0.000016451777,0.00031518232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989156,0.00011934898,0.00051026285,0.00016855594,0.00012020236,0.00016600582],"domain_scores_gemma":[0.9989049,0.000410133,0.0002643162,0.00013554428,0.000056834924,0.00022830961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006878586,0.00011732059,0.00063426263,0.00004960815,0.000026909707,0.0000141165065,0.00007252733,0.000072662144,0.000015894844],"category_scores_gemma":[0.0002375594,0.00007089473,0.00020641675,0.00018769607,0.0009044411,0.00005580524,0.00012377687,0.00033931277,0.000001130428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018628807,0.0001467665,0.748707,0.0001123481,0.0012029223,0.0000076184897,0.00014652597,2.1871692e-7,0.0011155453,0.00007260091,0.22260317,0.025699027],"study_design_scores_gemma":[0.0020762058,0.0024096323,0.84736824,0.00016835135,0.0008148103,0.0000202162,0.00026562746,0.00016440953,0.000017028568,0.0010660683,0.14555296,0.000076475946],"about_ca_topic_score_codex":0.000010951612,"about_ca_topic_score_gemma":0.0000013040278,"teacher_disagreement_score":0.098661244,"about_ca_system_score_codex":0.00001932093,"about_ca_system_score_gemma":0.00010955135,"threshold_uncertainty_score":0.3332451},"labels":[],"label_agreement":null},{"id":"W4391257169","doi":"10.1016/j.molmet.2024.101887","title":"Renal tubule-specific Atgl deletion links kidney lipid metabolism to glucagon-like peptide 1 and insulin secretion independent of renal inflammation or lipotoxicity","year":2024,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Université Laval; University of Manitoba; University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada; Pfizer Canada; Canadian Institutes of Health Research; University of Waterloo; Ontario Ministry of Research, Innovation and Science; Canadian Diabetes Association; Canada Research Chairs; Government of Ontario; Canada Foundation for Innovation; Diabetes Canada","keywords":"Lipotoxicity; Renal tubule; Inflammation; Internal medicine; Endocrinology; Lipid metabolism; Secretion; Kidney; Insulin; Proximal tubule; Glucagon-like peptide-1; Chemistry; Medicine; Diabetes mellitus; Insulin resistance; Type 2 diabetes","score_opus":0.011777638333836658,"score_gpt":0.24339738814429215,"score_spread":0.2316197498104555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391257169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654284,0.008398033,0.019808546,0.0022594584,0.0009370922,0.0016639428,0.000049348975,0.00021027795,0.0012449005],"genre_scores_gemma":[0.9854765,0.002446009,0.0069426657,0.0012808967,0.00095657574,0.00026763597,0.00049215363,0.000101889906,0.002035673],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731815,0.00014869054,0.00066967367,0.0006794188,0.0007761579,0.000407906],"domain_scores_gemma":[0.9987053,0.000036218193,0.00014223288,0.00049050193,0.00019229931,0.00043341357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006055198,0.00039364243,0.0006460025,0.0006759351,0.00007775927,0.00012819801,0.00013941275,0.0002473905,0.00020408224],"category_scores_gemma":[0.00014444221,0.00032151648,0.00022540145,0.00068714964,0.0000711326,0.00024309118,0.00018596677,0.00041075735,0.00009241739],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009690024,0.00026797026,0.00006288681,0.00053625955,0.0010108019,0.00029241393,0.0012070237,0.00018495334,0.85846764,0.010067094,0.0048480746,0.12208591],"study_design_scores_gemma":[0.0028800028,0.0002971462,0.011150434,0.0005927756,0.0013414589,0.00003365485,0.0000589171,0.0013113121,0.31082913,0.0004560019,0.67063206,0.0004170893],"about_ca_topic_score_codex":0.00005107998,"about_ca_topic_score_gemma":0.000012266708,"teacher_disagreement_score":0.665784,"about_ca_system_score_codex":0.00009355449,"about_ca_system_score_gemma":0.0001429664,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W4391357639","doi":"10.1017/s0007114524000321","title":"Effects of physical form of <i>β</i>-lactoglobulin and calcium ingestion on GLP-1 secretion, gastric emptying and energy intake in humans: a randomised crossover trial","year":2024,"lang":"en","type":"article","venue":"British Journal Of Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; European Society for Clinical Nutrition and Metabolism; International Olympic Committee; University of Bath; PepsiCo; Rare Disease Foundation; GlaxoSmithKline; Kellogg's; British Heart Foundation","keywords":"Gastric emptying; Crossover study; Postprandial; Ingestion; Internal medicine; Meal; Gastrointestinal hormone; Endocrinology; Glucagon-like peptide-1; Digestion (alchemy); Chemistry; Calcium; Medicine; Hormone; Stomach; Peptide hormone; Placebo; Insulin; Chromatography; Diabetes mellitus","score_opus":0.00953264459752959,"score_gpt":0.25558640502275454,"score_spread":0.24605376042522495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391357639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937085,0.0053418884,0.00023545594,0.00009378405,0.0001252787,0.00038873215,0.0000061886826,0.0000073448614,0.00009281307],"genre_scores_gemma":[0.9968735,0.002629674,0.00012798542,0.000031940865,0.00025748898,0.000024109691,0.00001677306,0.000010589872,0.000027951111],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99910015,0.00005583639,0.00039316752,0.00011910548,0.00022642584,0.000105321276],"domain_scores_gemma":[0.9994485,0.00021239101,0.00016589755,0.000037324382,0.000078710735,0.00005718006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023727638,0.000091834154,0.00039825548,0.00026820015,0.000021287315,0.00004098873,0.000023502804,0.00005454835,0.000004656305],"category_scores_gemma":[0.00011655003,0.00009048711,0.000109683686,0.00016292943,0.000053062784,0.0001744926,0.000013832914,0.00012430665,1.3393127e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3042201,0.013753371,0.0013661493,0.013435726,0.0011171317,0.002563006,0.0017758904,0.000025910209,0.06118074,0.0019698313,0.003279809,0.5953123],"study_design_scores_gemma":[0.84645253,0.018596696,0.04345313,0.043355357,0.0018143088,0.000671459,0.00021883815,0.0009967821,0.035624865,0.006683819,0.001774508,0.00035773046],"about_ca_topic_score_codex":0.00003942346,"about_ca_topic_score_gemma":0.0000093146555,"teacher_disagreement_score":0.5949546,"about_ca_system_score_codex":0.00006441701,"about_ca_system_score_gemma":0.000022510081,"threshold_uncertainty_score":0.36899573},"labels":[],"label_agreement":null},{"id":"W4391396627","doi":"10.1038/s41366-024-01467-w","title":"Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective","year":2024,"lang":"en","type":"article","venue":"International Journal of Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Novo Nordisk","keywords":"Medicine; Liraglutide; Semaglutide; Orlistat; Cost effectiveness; Weight loss; Quality-adjusted life year; Overweight; Body mass index; Weight management; Internal medicine; Physical therapy; Type 2 diabetes; Obesity; Diabetes mellitus; Endocrinology","score_opus":0.02087816530106476,"score_gpt":0.33021109330501164,"score_spread":0.30933292800394685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391396627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927563,0.00271559,0.00050477684,0.0012048356,0.0011684895,0.00031115537,0.0000127338,0.00000689573,0.004799895],"genre_scores_gemma":[0.9988323,0.000501502,0.00028180785,0.00009124204,0.0000983203,0.0000066454454,0.0000028380953,0.0000069288953,0.00017843953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991032,0.00003769115,0.00022853827,0.00009224203,0.00045042846,0.000087937144],"domain_scores_gemma":[0.9995208,0.000079022946,0.00008130523,0.000043810094,0.00023485474,0.000040205232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029036743,0.00007914304,0.00019465596,0.00020516172,0.00000764397,0.000013692738,0.000118337695,0.000013093571,0.00011039557],"category_scores_gemma":[0.000009778632,0.000062429666,0.00011971051,0.00010232573,0.000022747967,0.00011568648,0.000036587313,0.0001085377,0.0000027723133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043854057,0.005114729,0.68479955,0.0020415708,0.037280798,0.022811474,0.0046751853,0.00091417064,0.010334478,0.074282795,0.021445813,0.13191403],"study_design_scores_gemma":[0.008811631,0.00044973788,0.93095607,0.002983394,0.0007891934,0.00017496475,0.0032836501,0.00088635914,0.02576736,0.0035259968,0.022133239,0.00023840077],"about_ca_topic_score_codex":0.02726602,"about_ca_topic_score_gemma":0.010176777,"teacher_disagreement_score":0.24615651,"about_ca_system_score_codex":0.0019174917,"about_ca_system_score_gemma":0.00035494467,"threshold_uncertainty_score":0.9792115},"labels":[],"label_agreement":null},{"id":"W4391399489","doi":"10.22541/au.170667104.47477358/v1","title":"Crosstalk Between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger- 1 and 3 in Cardiometabolic Diseases","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cotransporter; Heart failure; Medicine; Natriuresis; Diabetes mellitus; Glucose homeostasis; Endocrinology; Endothelial dysfunction; Internal medicine; Insulin resistance; Crosstalk; Type 2 diabetes; Type 2 Diabetes Mellitus; Glucagon-like peptide-1; Diabetic cardiomyopathy; Homeostasis; Sodium; Pharmacology; Cardiomyopathy; Chemistry; Kidney","score_opus":0.016258832256079988,"score_gpt":0.2644411308135009,"score_spread":0.2481822985574209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391399489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594332,0.032857213,0.0000060455827,0.0010597438,0.00032524855,0.0015970628,0.0003221488,0.00021175896,0.0041875714],"genre_scores_gemma":[0.9915697,0.0031056511,0.000105833205,0.00022477415,0.0005578624,0.0002717647,0.00068432145,0.0000799361,0.003400155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771434,0.000034681878,0.00046741558,0.0009513428,0.0003562235,0.00047598712],"domain_scores_gemma":[0.99899644,0.000043370183,0.000074558244,0.00048175562,0.000035502548,0.00036839233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018073778,0.00055656617,0.0011449303,0.0007237855,0.00004573243,0.00016900332,0.00009160931,0.0002728635,0.00008504552],"category_scores_gemma":[0.000010240576,0.00045257143,0.00023745446,0.00023924487,0.00019452898,0.000071558105,0.000844264,0.00041076308,0.000033927052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018217422,0.0003894133,0.88755226,0.0065758866,0.0030265586,0.0009775225,0.0011898504,0.00000395999,0.00030594904,0.00018284602,0.002316576,0.09729703],"study_design_scores_gemma":[0.006644683,0.00034385288,0.92048943,0.0018442718,0.010958594,0.0000125406605,0.00041173326,0.00012570321,0.0062823817,0.0053073126,0.046071485,0.0015080234],"about_ca_topic_score_codex":0.00036658364,"about_ca_topic_score_gemma":0.00010811731,"teacher_disagreement_score":0.095789,"about_ca_system_score_codex":0.0000944546,"about_ca_system_score_gemma":0.000078183126,"threshold_uncertainty_score":0.9997926},"labels":[],"label_agreement":null},{"id":"W4391443824","doi":"10.34067/kid.0000000000000374","title":"Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD)","year":2024,"lang":"en","type":"article","venue":"Kidney360","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca; American Society of Nephrology","keywords":"Medicine; Kidney disease; Hazard ratio; Internal medicine; Discontinuation; Diabetes mellitus; Heart failure; Dapagliflozin; Type 2 diabetes; Cohort study; Observational study; Intensive care medicine; Endocrinology; Confidence interval","score_opus":0.10637746988042987,"score_gpt":0.3859960959308091,"score_spread":0.27961862605037924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391443824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979821,0.0067270934,0.000019759214,0.008037851,0.00020803645,0.0017825968,0.00011823665,0.0001170161,0.003168399],"genre_scores_gemma":[0.9934948,0.00032868914,0.0012187457,0.00031230703,0.00018833143,0.0001627192,0.00043787615,0.000020693715,0.0038358436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989324,0.000027274129,0.0002602839,0.00029391696,0.000323634,0.0001624839],"domain_scores_gemma":[0.9994618,0.000049080118,0.000048108737,0.00020089629,0.00008044903,0.00015963672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009487509,0.00015492222,0.00028918762,0.00012904184,0.000054769018,0.000029061815,0.00003528422,0.000027571115,0.000120346616],"category_scores_gemma":[0.000021871843,0.000120838195,0.00007645603,0.0001551334,0.00003586035,0.00006923845,0.000034816472,0.000034859982,0.000016204258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016165702,0.00459557,0.622917,0.0022177259,0.005006722,0.00029417497,0.034386687,0.00008304836,0.00023380519,0.008028244,0.028341647,0.29373372],"study_design_scores_gemma":[0.0075551234,0.006391797,0.74181724,0.00037565778,0.001225586,0.000006565576,0.0059271934,0.0018678103,0.00017863845,0.00017609943,0.23419559,0.00028270538],"about_ca_topic_score_codex":0.00034559387,"about_ca_topic_score_gemma":0.00004960297,"teacher_disagreement_score":0.293451,"about_ca_system_score_codex":0.000231136,"about_ca_system_score_gemma":0.00022693319,"threshold_uncertainty_score":0.49276385},"labels":[],"label_agreement":null},{"id":"W4391461297","doi":"","title":"SGLT2 inhibitors and the changing landscape for treatment of diabetes","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Geography; Diabetes treatment; Medicine; Type 2 diabetes; Endocrinology","score_opus":0.10963758151222172,"score_gpt":0.47319229589418016,"score_spread":0.3635547143819584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391461297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97051954,0.022313427,0.000012411088,0.0005135891,0.0003290965,0.002056584,0.000019888335,0.000016900887,0.004218559],"genre_scores_gemma":[0.9915731,0.005716346,0.00011862842,0.00018767244,0.00014880982,0.00016676179,0.000022313587,0.00003380319,0.0020325594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985913,0.00006256666,0.00045864016,0.00026233573,0.0003023069,0.0003228214],"domain_scores_gemma":[0.9985815,0.0004088579,0.00043018025,0.00034480335,0.000119217664,0.000115423834],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006424291,0.00023433634,0.000895347,0.00052526686,0.0001002681,0.00021107499,0.00036907376,0.00005025105,0.0011591453],"category_scores_gemma":[0.000059198617,0.00013844491,0.00023891983,0.00036965206,0.000101790254,0.0004427875,0.00026041426,0.000050003582,0.0000058083365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051954156,0.0004723182,0.93889016,0.00033872694,0.0012374887,0.0000035777332,0.00058414007,0.000013737283,0.008755709,0.00031814026,0.005818057,0.043048434],"study_design_scores_gemma":[0.028090676,0.00061829423,0.79655343,0.0018118955,0.0027763557,0.0000041428875,0.0011312494,0.00093074,0.11632885,0.0037402248,0.047375914,0.00063822675],"about_ca_topic_score_codex":0.00005326424,"about_ca_topic_score_gemma":0.0000051046727,"teacher_disagreement_score":0.1423367,"about_ca_system_score_codex":0.000051599156,"about_ca_system_score_gemma":0.00003491453,"threshold_uncertainty_score":0.99975395},"labels":[],"label_agreement":null},{"id":"W4391494390","doi":"10.1016/j.cardfail.2023.10.284","title":"Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction","year":2024,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Ejection fraction; Heart failure; Internal medicine; Renal function; Cardiology; Creatinine; Placebo; Diabetes mellitus; Microalbuminuria; Type 2 diabetes; Endocrinology","score_opus":0.007743989052782825,"score_gpt":0.22026388480828799,"score_spread":0.21251989575550517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391494390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966399,0.0006783696,0.000016048052,0.0016213799,0.00021384045,0.00053481455,0.00006404653,0.000025977854,0.00020564011],"genre_scores_gemma":[0.9986112,0.000051664658,0.00089599314,0.00006664498,0.00014781996,0.000012228433,0.000051348325,0.00004193808,0.00012117566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984293,0.00008666317,0.00034189012,0.00023638953,0.0006799585,0.00022581237],"domain_scores_gemma":[0.9988697,0.000060513546,0.00031064134,0.0001668915,0.0004090591,0.00018315778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031934248,0.00023782701,0.00078193017,0.00040119138,0.00004016501,0.000059224403,0.00003878729,0.00011657253,0.000012975279],"category_scores_gemma":[0.00006365334,0.00014968602,0.00014361876,0.0005365704,0.000049987626,0.0004371277,0.000017426033,0.00036121556,0.0000015815584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064155593,0.00024034125,0.98142314,0.00023881563,0.0024582648,0.000019481156,0.0001742514,0.00012550101,0.00056703965,0.000016850023,0.012661339,0.0014334159],"study_design_scores_gemma":[0.0031816585,0.0024889258,0.9738474,0.0040689646,0.0016772067,0.000005992637,0.0006101608,0.000009946788,0.0014886427,0.00000534565,0.012429923,0.00018583846],"about_ca_topic_score_codex":0.000015592197,"about_ca_topic_score_gemma":0.000025958476,"teacher_disagreement_score":0.0075757504,"about_ca_system_score_codex":0.0002569231,"about_ca_system_score_gemma":0.0001610136,"threshold_uncertainty_score":0.61040187},"labels":[],"label_agreement":null},{"id":"W4391544195","doi":"10.1016/s2213-8587(23)00356-x","title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Placebo; Agonist; Glucagon-like peptide 1 receptor; Liraglutide; Glucagon-like peptide-1; Double blind; Internal medicine; Diabetes mellitus; Pharmacology; Endocrinology; Type 2 diabetes; Receptor; Alternative medicine","score_opus":0.05994524410212917,"score_gpt":0.343542484035551,"score_spread":0.28359723993342184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391544195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706236,0.006258501,0.000042053733,0.008982417,0.0020306732,0.008533866,0.00007852584,0.0003816987,0.0030686676],"genre_scores_gemma":[0.9848518,0.0009769081,0.00034266265,0.0009913733,0.002987877,0.0044619935,0.0003229242,0.00008168218,0.0049828114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968111,0.00019020164,0.0005489176,0.00065825443,0.00022731614,0.0015641991],"domain_scores_gemma":[0.9975756,0.0015373862,0.00013935096,0.00053482567,0.00005621371,0.00015665314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012193007,0.00043396596,0.0015473579,0.00026248125,0.00032414336,0.00027303366,0.00021024067,0.0001205838,0.0001622063],"category_scores_gemma":[0.00019806837,0.0002845785,0.0003714342,0.00021580383,0.00031365984,0.00012720076,0.0001600922,0.00033926632,0.000100457364],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9271325,0.0006501554,0.00077758956,0.00050668867,0.0040597883,0.000102080405,0.00034061135,0.0000024572628,0.004311496,0.010285851,0.014920634,0.03691016],"study_design_scores_gemma":[0.850269,0.0021114226,0.000058185724,0.00012188636,0.002197295,0.0000137169245,0.00008618503,0.0003865813,0.005036033,0.00064243545,0.13880207,0.000275187],"about_ca_topic_score_codex":0.00002316203,"about_ca_topic_score_gemma":0.000023006545,"teacher_disagreement_score":0.12388143,"about_ca_system_score_codex":0.00011602892,"about_ca_system_score_gemma":0.000109028115,"threshold_uncertainty_score":0.99996066},"labels":[],"label_agreement":null},{"id":"W4391607301","doi":"10.1111/dom.15479","title":"Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; Post-hoc analysis; Randomized controlled trial; Post hoc; Physical therapy; Internal medicine","score_opus":0.003015881425071274,"score_gpt":0.22961493926352047,"score_spread":0.2265990578384492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391607301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595425,0.034653693,0.0000055942455,0.00009088877,0.0002777619,0.0049685338,0.00003288389,0.000035022833,0.0003931239],"genre_scores_gemma":[0.9979064,0.0010821506,0.000034012563,0.00008221094,0.000044074284,0.00054627255,0.000058778005,0.000015584696,0.00023053066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99768496,0.00057631184,0.0006800433,0.00036069145,0.00044037378,0.00025759637],"domain_scores_gemma":[0.9978716,0.0014765311,0.0001252724,0.00037365334,0.000069690934,0.00008330025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028084756,0.00028282948,0.005996471,0.0011805322,0.00001968609,0.000021155329,0.00006832126,0.000094806084,0.000037558348],"category_scores_gemma":[0.00065810396,0.00016799908,0.0030936776,0.0006655557,0.00011113468,0.00007006261,0.00004360352,0.00011200674,0.000003282398],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83302486,0.0013677271,0.019731984,0.0015670205,0.115346454,0.000034980756,0.000751303,0.000040574527,0.00011951914,0.0011432577,0.000021491682,0.026850859],"study_design_scores_gemma":[0.8752748,0.00079349725,0.0480611,0.0003966779,0.07292588,6.7517774e-8,0.000023427932,0.0009856179,0.0012418341,0.000018867466,0.00014622058,0.00013200342],"about_ca_topic_score_codex":0.0001056123,"about_ca_topic_score_gemma":0.000009257438,"teacher_disagreement_score":0.04242057,"about_ca_system_score_codex":0.00001909635,"about_ca_system_score_gemma":0.000023208318,"threshold_uncertainty_score":0.6850804},"labels":[],"label_agreement":null},{"id":"W4391630578","doi":"10.1093/ndt/gfae032","title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","year":2024,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; EMPA; Type 2 diabetes; Diabetes mellitus; Kidney disease; Internal medicine; Benzhydryl compounds; Metformin; Endocrinology; Intensive care medicine","score_opus":0.013692976792549329,"score_gpt":0.2652159238348986,"score_spread":0.2515229470423493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391630578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770618,0.0002522234,0.0009732404,0.018985026,0.0005165251,0.0017470681,0.00005793043,0.000091379494,0.00031479428],"genre_scores_gemma":[0.9973825,0.00018267325,0.00004854466,0.00085815135,0.00024798515,0.00032120052,0.000401959,0.00001563426,0.0005413445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841857,0.00022943685,0.0004122185,0.0003177487,0.00042072753,0.00020130406],"domain_scores_gemma":[0.9991285,0.00022670542,0.00015404481,0.0003747435,0.0000572636,0.00005872142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049497193,0.00018346145,0.00046687416,0.000542402,0.00010099833,0.0000628997,0.00013785866,0.00013709458,0.000072707095],"category_scores_gemma":[0.000080828424,0.00009623961,0.0006656348,0.0017522197,0.00012784897,0.00013246253,0.000014182042,0.00017299158,0.000009249886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04813308,0.0027671885,0.52908605,0.0037544607,0.14794676,0.00027485745,0.039731808,0.0032208264,0.07049695,0.011981974,0.011674162,0.13093187],"study_design_scores_gemma":[0.0689207,0.0025988983,0.55391157,0.00029334245,0.29955208,0.000017142098,0.0008641116,0.013017521,0.020581704,0.0011552863,0.038224835,0.0008628447],"about_ca_topic_score_codex":0.000043431544,"about_ca_topic_score_gemma":0.00017625462,"teacher_disagreement_score":0.15160532,"about_ca_system_score_codex":0.00006363247,"about_ca_system_score_gemma":0.00007071651,"threshold_uncertainty_score":0.39245373},"labels":[],"label_agreement":null},{"id":"W4391640453","doi":"10.1101/2024.02.05.24302354","title":"Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"Mace; Medicine; Hazard ratio; Internal medicine; Myocardial infarction; Type 2 diabetes; Population; Clinical endpoint; Clinical trial; Diabetes mellitus; Confidence interval; Percutaneous coronary intervention; Endocrinology","score_opus":0.04438089895017687,"score_gpt":0.34047654415881334,"score_spread":0.29609564520863646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391640453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909047,0.0014357088,0.0005438616,0.00004631108,0.0005434581,0.005358682,0.00068435445,0.000044532022,0.00043839889],"genre_scores_gemma":[0.9973541,0.000021491174,0.00014791096,0.000027893819,0.000029478246,0.00072408235,0.00061918463,0.000037906975,0.0010379849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727327,0.0003961344,0.0006736286,0.0007079865,0.00070113526,0.0002478211],"domain_scores_gemma":[0.99786353,0.00032483513,0.00031096916,0.00093745074,0.000503206,0.000060014754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013752624,0.00041415423,0.0025224937,0.00058013084,0.000074905714,0.000024912615,0.00026873677,0.00013520561,0.00006484818],"category_scores_gemma":[0.00006159986,0.0002656385,0.0026600268,0.0009197363,0.00007246427,0.00002387539,0.0006838611,0.00027750694,0.0000050758426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048989354,0.0035851973,0.7620974,0.0038470142,0.21866441,0.000021768998,0.0017283245,0.008589208,0.00060328003,0.000104620514,0.00011195891,0.00015689842],"study_design_scores_gemma":[0.005090427,0.0004458989,0.9162988,0.0005762185,0.0623787,3.9386433e-7,0.0008195423,0.009255584,0.0044572023,0.000057397818,0.00037252816,0.00024730124],"about_ca_topic_score_codex":0.00006597982,"about_ca_topic_score_gemma":0.00020262769,"teacher_disagreement_score":0.1562857,"about_ca_system_score_codex":0.00014247,"about_ca_system_score_gemma":0.00011638806,"threshold_uncertainty_score":0.99997956},"labels":[],"label_agreement":null},{"id":"W4391652120","doi":"10.1111/dom.15485","title":"Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Intensive care medicine; Specialty; Disease; Health care; Internal medicine; Pathology","score_opus":0.04700399873108236,"score_gpt":0.30869696256568124,"score_spread":0.2616929638345989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391652120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7223309,0.2737667,0.0015334358,0.0007916951,0.000086080676,0.0011323326,0.00011869212,0.00009929817,0.0001408094],"genre_scores_gemma":[0.9830061,0.014152237,0.001947404,0.00006864407,0.00009366051,0.00033639147,0.00019397681,0.000026976917,0.00017458765],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987165,0.00007810666,0.00023312395,0.00057720754,0.00011585043,0.00027926677],"domain_scores_gemma":[0.9991347,0.00024534712,0.00003468716,0.0002761963,0.000065256296,0.00024380656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032692045,0.0002577379,0.0005375274,0.00029362697,0.00033963154,0.0002235454,0.000060887996,0.000077302655,0.0000025798702],"category_scores_gemma":[0.00004942951,0.00021164177,0.00014980228,0.0002208718,0.00016755899,0.00035803608,0.0003715114,0.00015561808,0.0000015792749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023037694,0.00007039175,0.39907077,0.0032928067,0.0037325423,0.000007652589,0.0019204717,0.0000013167333,0.00009474326,0.016000409,0.00028421942,0.5755016],"study_design_scores_gemma":[0.00090217614,0.000096911856,0.9617244,0.0010315037,0.008925975,0.0000028118807,0.0009786686,0.00018418029,0.00006210935,0.0040937853,0.021770462,0.00022704204],"about_ca_topic_score_codex":0.000008099477,"about_ca_topic_score_gemma":0.0000062286026,"teacher_disagreement_score":0.5752746,"about_ca_system_score_codex":0.000027233034,"about_ca_system_score_gemma":0.00001760547,"threshold_uncertainty_score":0.86305016},"labels":[],"label_agreement":null},{"id":"W4391693325","doi":"10.1016/j.cjco.2024.01.013","title":"Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial","year":2024,"lang":"en","type":"article","venue":"CJC Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Women's College Hospital; University of Toronto; University Health Network","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Hazard ratio; Internal medicine; Myocardial infarction; Cardiology; Stroke (engine); Coronary artery disease; Diabetes mellitus; Type 2 Diabetes Mellitus; Placebo; Type 2 diabetes; Confidence interval; Endocrinology; Pathology","score_opus":0.03894981521118861,"score_gpt":0.3187363251043077,"score_spread":0.2797865098931191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391693325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98423654,0.009272399,0.000012764003,0.00013241539,0.00015080959,0.0055689774,0.000035283218,0.000021666074,0.00056917197],"genre_scores_gemma":[0.998061,0.0007404761,0.000029552122,0.000038046106,0.00007350338,0.0008990957,0.000016674532,0.000027910202,0.000113729395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998077,0.00039938645,0.00036781013,0.00040935678,0.00054131617,0.00020513657],"domain_scores_gemma":[0.99842566,0.00045771335,0.00005987023,0.0009468575,0.000021785007,0.00008813242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031959065,0.00021840635,0.0010805703,0.00013745071,0.00004562934,0.00006792714,0.0002609642,0.000051448136,0.00001744222],"category_scores_gemma":[0.00028513995,0.0001294872,0.0008573427,0.0002851302,0.00006747518,0.00012598655,0.00019335999,0.0001467731,0.00000953095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013270995,0.001387478,0.59168714,0.006048132,0.021839958,0.0004631778,0.0024785888,0.0014634856,0.000019087736,0.0010746222,0.00029343183,0.35997394],"study_design_scores_gemma":[0.16150264,0.011930193,0.7449212,0.0056804037,0.053250965,0.000005073623,0.0006852714,0.0009586001,0.003100855,0.00090200343,0.016103694,0.00095909997],"about_ca_topic_score_codex":0.0006204493,"about_ca_topic_score_gemma":0.000009683972,"teacher_disagreement_score":0.35901484,"about_ca_system_score_codex":0.00006174126,"about_ca_system_score_gemma":0.000023489378,"threshold_uncertainty_score":0.5280335},"labels":[],"label_agreement":null},{"id":"W4391721467","doi":"10.1007/s12325-023-02750-4","title":"Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"","keywords":"Medicine; Semaglutide; Type 2 diabetes; Dipeptidyl peptidase-4 inhibitor; Dipeptidyl peptidase-4; Stroke (engine); Internal medicine; Alogliptin; Type 2 Diabetes Mellitus; Sitagliptin; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.01236021062021096,"score_gpt":0.2968267479358921,"score_spread":0.2844665373156811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391721467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98088765,0.013559294,0.0000054282004,0.00012643146,0.00018685005,0.0006882905,0.000025215604,0.00008411201,0.004436726],"genre_scores_gemma":[0.9714712,0.022524724,0.002478258,0.00012354275,0.00009329669,0.00010842031,0.00002320189,0.000042420714,0.0031349747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986233,0.00007196903,0.0003450106,0.00035130617,0.00026685483,0.0003415709],"domain_scores_gemma":[0.99922186,0.00030009967,0.00010197349,0.0002831444,0.000033414948,0.000059527247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034458397,0.00022328077,0.0004382776,0.0005045495,0.000022370632,0.000025231479,0.00009767038,0.000042189913,0.0001328369],"category_scores_gemma":[0.00004619652,0.0001431656,0.00005774871,0.0009538323,0.00008908844,0.0002627346,0.000034344575,0.00019949574,0.000012580158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004113518,0.00028607805,0.86330837,0.0002182298,0.0002457777,0.000096269156,0.0005673186,0.00013528105,0.00081769057,0.000114483606,0.00014616299,0.13365297],"study_design_scores_gemma":[0.009915228,0.0056510023,0.823994,0.006676967,0.00032586156,0.000003394028,0.0006705006,0.0005314984,0.026510846,0.0012555114,0.12376324,0.0007019854],"about_ca_topic_score_codex":0.00009799279,"about_ca_topic_score_gemma":0.0016571984,"teacher_disagreement_score":0.13295099,"about_ca_system_score_codex":0.000117107404,"about_ca_system_score_gemma":0.00006572997,"threshold_uncertainty_score":0.5838124},"labels":[],"label_agreement":null},{"id":"W4391790679","doi":"10.2139/ssrn.4722046","title":"Single Cell Transcriptomic Analysis of SGLT2 Expression Supports an Indirect Role for the Cardioprotective Benefits of Empagliflozin in Heart Failure","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Empagliflozin; Transcriptome; Heart failure; Chemistry; Cell biology; Pharmacology; Gene expression; Internal medicine; Medicine; Biochemistry; Biology; Endocrinology; Diabetes mellitus; Gene; Type 2 diabetes","score_opus":0.009845373015219844,"score_gpt":0.2450834594070299,"score_spread":0.23523808639181007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391790679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977238,0.019689811,0.00047143231,0.0005453588,0.00018343942,0.0015660692,0.0000897722,0.000023900788,0.00019219547],"genre_scores_gemma":[0.9977785,0.0010570987,0.0003047333,0.000019639343,0.0001356462,0.00014615734,0.00010886615,0.000052665993,0.00039668978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997246,0.00011856612,0.0006456051,0.00045238127,0.0004325172,0.0011049322],"domain_scores_gemma":[0.9988693,0.00006861688,0.00035852913,0.00047852873,0.00014246,0.000082585175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015980096,0.00033455493,0.001138386,0.0010374263,0.000059121274,0.000035256562,0.00025235876,0.00022886775,0.000026720158],"category_scores_gemma":[0.000020495178,0.00023229366,0.0010036496,0.0005441833,0.000047267742,0.000060774404,0.00012458919,0.0017906955,9.724945e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073130066,0.010611304,0.0827272,0.0060802735,0.14037456,0.0000661179,0.030406091,0.09708984,0.4016568,0.004083123,0.00202838,0.2175633],"study_design_scores_gemma":[0.013711283,0.014911944,0.04680921,0.0052179783,0.12379961,0.00010792048,0.034706056,0.0093343,0.63562644,0.109900646,0.003817693,0.0020569395],"about_ca_topic_score_codex":0.00026173817,"about_ca_topic_score_gemma":0.0031651754,"teacher_disagreement_score":0.23396961,"about_ca_system_score_codex":0.00091988523,"about_ca_system_score_gemma":0.0010897773,"threshold_uncertainty_score":0.9472661},"labels":[],"label_agreement":null},{"id":"W4391820208","doi":"10.3389/fphys.2024.1358625","title":"GLP-2 regulation of intestinal lipid handling","year":2024,"lang":"en","type":"article","venue":"Frontiers in Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Saskatchewan Health Research Foundation; Heart and Stroke Foundation of Canada","keywords":"Dyslipidemia; Small intestine; Lipid metabolism; Biology; Internal medicine; Chemistry; Endocrinology; Medicine; Diabetes mellitus","score_opus":0.01067985161030242,"score_gpt":0.24928273535214707,"score_spread":0.23860288374184466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391820208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982468,0.0021881515,0.0044785086,0.00049704075,0.0021684216,0.00030702163,0.0000019676077,0.000083404,0.0078075035],"genre_scores_gemma":[0.9904114,0.00006075129,0.007994533,0.000054230295,0.0001337223,0.000013798099,0.000040808995,0.000008259613,0.0012824871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995434,0.00001578831,0.00013226498,0.00014652216,0.00004923624,0.00011277953],"domain_scores_gemma":[0.9998201,0.000020352894,0.000021415766,0.00010469363,0.000014604175,0.000018823463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060686434,0.00006290332,0.00018939094,0.00016603738,0.000007817239,0.0000030754243,0.000031550964,0.00003525745,0.0000424652],"category_scores_gemma":[0.000020919422,0.00005214683,0.00004495397,0.00014565162,0.000051919982,0.000037149777,0.000023223254,0.000059687703,0.000010518122],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000872421,0.0006433946,0.09428012,0.0020976427,0.00088993093,0.000066954904,0.0011168828,0.0004661608,0.2741528,0.011047767,0.17255576,0.4418102],"study_design_scores_gemma":[0.003676536,0.0020110316,0.77494025,0.0020681857,0.0005765556,0.0000115638495,0.0005320862,0.06660326,0.032098133,0.03854687,0.07854941,0.00038613382],"about_ca_topic_score_codex":0.0000074477675,"about_ca_topic_score_gemma":9.229428e-7,"teacher_disagreement_score":0.6806601,"about_ca_system_score_codex":0.00004676163,"about_ca_system_score_gemma":0.000019559686,"threshold_uncertainty_score":0.21264859},"labels":[],"label_agreement":null},{"id":"W4391839719","doi":"10.1186/s12933-024-02154-w","title":"The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Montreal Heart Institute; Université de Montréal; St. Michael's Hospital; University of British Columbia; McMaster University","funders":"","keywords":"Medicine; Mace; Meta-analysis; Randomized controlled trial; Clinical trial; Internal medicine; Heart failure; Intensive care medicine; Angiology; Adverse effect; MEDLINE; Placebo; Percutaneous coronary intervention; Alternative medicine; Pathology","score_opus":0.03646143516486171,"score_gpt":0.32565402456918713,"score_spread":0.2891925894043254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391839719","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004304269,0.99152255,0.000018296163,0.000035250767,0.00018365408,0.0076278616,0.00017163409,0.000079657846,0.00031805094],"genre_scores_gemma":[0.00067660405,0.9947941,0.000011257542,0.00010434893,0.00003131031,0.0025716103,0.001503611,0.000103453436,0.0002037353],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99259603,0.0037062967,0.0014563662,0.0010634579,0.0006899348,0.0004879397],"domain_scores_gemma":[0.9959558,0.0006038772,0.00038960157,0.002692693,0.00015768474,0.00020030497],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0051394207,0.0009945175,0.02504512,0.0006141122,0.000087918335,0.00004631412,0.0003324593,0.00037222405,0.000025747722],"category_scores_gemma":[0.000101564634,0.0004656538,0.021492818,0.0009767724,0.0002755408,0.000053468088,0.00008580368,0.0004431526,0.00006746293],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050388685,0.00004956518,0.000011121486,0.4546869,0.54265743,0.00011579673,0.000004962496,6.3899154e-7,2.9376194e-8,0.00009299185,0.00007292245,0.002302591],"study_design_scores_gemma":[0.00034821365,0.00015585938,0.000034025616,0.020420313,0.9044451,0.00002902842,0.000006638283,5.63003e-7,0.000005671565,0.000011565548,0.074220955,0.00032205976],"about_ca_topic_score_codex":0.0000113585875,"about_ca_topic_score_gemma":0.0000030577132,"teacher_disagreement_score":0.4342666,"about_ca_system_score_codex":0.0001413982,"about_ca_system_score_gemma":0.0000987228,"threshold_uncertainty_score":0.9997795},"labels":[],"label_agreement":null},{"id":"W4391873245","doi":"10.1093/jcag/gwad061.254","title":"A254 CANAGLIFLOZIN EXACERBATES CHEMICALLY INDUCED COLITIS WHEN COMBINED WITH A HIGH SUGAR DIET","year":2024,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Canagliflozin; Sugar; Colitis; Chemistry; Internal medicine; Endocrinology; Medicine; Food science; Diabetes mellitus; Type 2 diabetes","score_opus":0.0064752922931849265,"score_gpt":0.20414591055251194,"score_spread":0.19767061825932702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391873245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540342,0.000024267772,0.00000431161,0.04464209,0.00044759846,0.00021080888,0.00002848283,0.000008172678,0.00060008286],"genre_scores_gemma":[0.9959348,0.000012732261,0.00017970482,0.0017352782,0.0001119871,0.0000056345475,0.00001123937,0.000016338772,0.001992311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885374,0.00009315588,0.00034168694,0.000101005724,0.00029806932,0.0003123569],"domain_scores_gemma":[0.99898124,0.000055845907,0.00036283114,0.00013044038,0.0002462236,0.00022343014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038433465,0.000113535985,0.0003722193,0.00023110483,0.000043888293,0.000030238165,0.00014875659,0.00008236037,0.00010510983],"category_scores_gemma":[0.000109429326,0.00007556424,0.00013300762,0.00011570195,0.00003636538,0.00006465778,0.000023291257,0.00023470772,0.0000041207636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019341225,0.00011852079,0.9063275,0.0000999152,0.0030766975,0.00018237981,0.0003584814,0.000013856047,0.000632628,0.00083252013,0.08616565,0.00025774434],"study_design_scores_gemma":[0.0070772064,0.011620647,0.9600753,0.00051564665,0.0016865311,0.000087817796,0.00012859466,0.000061385814,0.00085474184,0.00076516945,0.017006975,0.000119981676],"about_ca_topic_score_codex":0.009852009,"about_ca_topic_score_gemma":0.3683652,"teacher_disagreement_score":0.3585132,"about_ca_system_score_codex":0.0016637056,"about_ca_system_score_gemma":0.00046341534,"threshold_uncertainty_score":0.9967415},"labels":[],"label_agreement":null},{"id":"W4391886509","doi":"10.1093/jcag/gwad061.192","title":"A192 'GLYCOCAGED' DRUGS: PHARMACOKINETICS AND TRANSLATIONAL POTENTIAL FOR PEOPLE WITH IBD","year":2024,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacokinetics; Pharmacology; Medicine; Translational research; Translational medicine; Pathology","score_opus":0.004788426133030966,"score_gpt":0.22410441302542422,"score_spread":0.21931598689239326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391886509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93656534,0.00012702846,0.0007487052,0.061320547,0.00060628296,0.0003142639,0.00006212913,0.000004825862,0.00025088975],"genre_scores_gemma":[0.9976384,0.000031024876,0.0005950882,0.00075824076,0.00015315867,0.0000037703664,0.000008177596,0.000009331824,0.0008027972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933535,0.000040653107,0.00021005886,0.00006425703,0.00018640363,0.0001633083],"domain_scores_gemma":[0.9994831,0.00004390531,0.00018574385,0.000044211585,0.00013627713,0.00010674817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031549542,0.00006591658,0.00019700971,0.00016690373,0.000046292287,0.000019509593,0.000053425385,0.000037855312,0.000029445044],"category_scores_gemma":[0.000023229806,0.000044307213,0.00010710224,0.00006280044,0.000024602052,0.00005169292,0.0000057585025,0.00010794317,5.13348e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001092142,0.0001039806,0.95554596,0.00019908622,0.002804103,0.000029741517,0.0008810199,0.00037104657,0.000339735,0.0005129143,0.0349772,0.0031430419],"study_design_scores_gemma":[0.01199698,0.0039611435,0.9377677,0.00030398788,0.0036958402,0.00020913612,0.00020996807,0.003106499,0.00027512704,0.00057318754,0.03779208,0.0001083931],"about_ca_topic_score_codex":0.00019670073,"about_ca_topic_score_gemma":0.024664288,"teacher_disagreement_score":0.061073083,"about_ca_system_score_codex":0.0001935598,"about_ca_system_score_gemma":0.00016820933,"threshold_uncertainty_score":0.99313307},"labels":[],"label_agreement":null},{"id":"W4391894241","doi":"10.1093/cvr/cvae016","title":"Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity","year":2023,"lang":"en","type":"article","venue":"Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; LMC Diabetes & Endocrinology (Canada); Canada Research Chairs; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Progenitor cell; Diabetes mellitus; Type 2 diabetes; Empagliflozin; Impaired glucose tolerance; Oxidative stress; Internal medicine; Endocrinology; Bioinformatics; Pharmacology; Stem cell; Biology","score_opus":0.0561817471879226,"score_gpt":0.3269446243214355,"score_spread":0.2707628771335129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391894241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913693,0.006388943,0.000034159915,0.00072578184,0.000018475728,0.001327253,0.0000032622963,0.000009155799,0.00012363378],"genre_scores_gemma":[0.9964801,0.0030413484,0.00009852677,0.000014605663,0.000031073454,0.00018528274,0.00008028022,0.000008146253,0.000060617833],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99888426,0.00023166425,0.00013350048,0.00015998786,0.00044900257,0.00014156903],"domain_scores_gemma":[0.99931365,0.00016460317,0.00002374081,0.00027581345,0.00020024153,0.00002191913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031970488,0.000057174333,0.00021422468,0.00018468073,0.00007748342,0.000023973987,0.000048479134,0.000041165895,9.0303314e-7],"category_scores_gemma":[0.00015815588,0.00004133655,0.00009181177,0.00042120207,0.000111438814,0.000068360416,0.000032200343,0.000084006875,5.2078366e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048471914,0.0019756996,0.39886498,0.0037381104,0.006009255,0.00003660636,0.008037297,0.00017189962,0.10566489,0.015009706,0.0048956946,0.45511115],"study_design_scores_gemma":[0.008704352,0.0018086829,0.88368285,0.00021675497,0.00043451507,0.0000013961244,0.0008138577,0.0024731155,0.0952473,0.0026129298,0.003892574,0.00011169594],"about_ca_topic_score_codex":0.00002708973,"about_ca_topic_score_gemma":0.0000045418656,"teacher_disagreement_score":0.48481786,"about_ca_system_score_codex":0.00001433658,"about_ca_system_score_gemma":0.000028570987,"threshold_uncertainty_score":0.16856556},"labels":[],"label_agreement":null},{"id":"W4391934417","doi":"10.1016/j.cegh.2024.101555","title":"The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients","year":2024,"lang":"en","type":"article","venue":"Clinical Epidemiology and Global Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Type 2 Diabetes Mellitus; Depression (economics); Cognitive impairment; Medicine; Internal medicine; Diabetes mellitus; Type 2 diabetes; Sodium; Endocrinology; Chemistry; Economics; Disease","score_opus":0.02881223030856501,"score_gpt":0.41933425866371427,"score_spread":0.39052202835514926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391934417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96849686,0.027871063,0.0000021774936,0.0018122493,0.0006157317,0.00081039034,0.00002581297,0.000022200627,0.0003435314],"genre_scores_gemma":[0.98207784,0.015946204,0.000015998861,0.0017636882,0.0000691634,0.00002264171,0.00007781064,0.0000055202886,0.000021136282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976516,0.0008149032,0.00076200935,0.00035297155,0.00007851054,0.00034003018],"domain_scores_gemma":[0.99389166,0.0056454088,0.00012201632,0.000111932524,0.000022942277,0.0002060287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038263358,0.00014623538,0.0007259175,0.000032160504,0.00006635549,0.000002609412,0.000031273925,0.00014151937,0.000004340498],"category_scores_gemma":[0.0012637984,0.00007850172,0.00008814142,0.00010214751,0.00031883956,0.00002219672,0.000032342363,0.00022017857,0.0000089846435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009785182,0.00016012246,0.7477337,0.00033776803,0.000084754545,0.000005344988,0.00001498342,2.4613374e-7,5.099621e-8,0.00021222049,0.0011761661,0.24929611],"study_design_scores_gemma":[0.0024275566,0.010506821,0.9830857,0.0009934636,0.000103925806,3.9497172e-7,0.000015189162,0.00009416759,0.000017070432,0.00069532346,0.0020056195,0.000054798238],"about_ca_topic_score_codex":0.000046077283,"about_ca_topic_score_gemma":0.00002267189,"teacher_disagreement_score":0.24924132,"about_ca_system_score_codex":0.000060636416,"about_ca_system_score_gemma":0.000054056778,"threshold_uncertainty_score":0.3201207},"labels":[],"label_agreement":null},{"id":"W4392137095","doi":"10.1177/23969873241234238","title":"Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Stroke Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Mace; Internal medicine; Stroke (engine); Type 2 diabetes; Placebo; Glucagon-like peptide 1 receptor; Liraglutide; Adverse effect; Type 2 Diabetes Mellitus; Gastroenterology; Odds ratio; Diabetes mellitus; Meta-analysis; Dulaglutide; Endocrinology; Myocardial infarction; Agonist; Receptor; Pathology","score_opus":0.06002260691947495,"score_gpt":0.3015468690246069,"score_spread":0.24152426210513198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392137095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018366775,0.9924832,0.000025192034,0.00009963729,0.00006187992,0.005570616,0.0013332547,0.000031268115,0.00021127512],"genre_scores_gemma":[0.0001422004,0.97943866,0.00046424178,0.00006868851,0.00008803729,0.00034200173,0.00024244716,0.000148689,0.019065013],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99532765,0.0016570776,0.0012724808,0.0005895363,0.0007313176,0.00042191558],"domain_scores_gemma":[0.99670565,0.00036332963,0.0016066487,0.00078148395,0.00028144466,0.00026144224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002540079,0.00086831825,0.008047393,0.0003728716,0.00021506037,0.000110413086,0.00019195948,0.00007193624,0.00007954423],"category_scores_gemma":[0.00024597373,0.00030224238,0.0036625492,0.0006309738,0.0001105621,0.000081588616,0.00010075494,0.00038820214,0.00001728528],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006234817,0.00015669616,0.000077484314,0.18331592,0.80881053,0.00017321459,0.000065780085,0.000001421764,6.719479e-8,0.000001496975,0.00077641953,0.00655864],"study_design_scores_gemma":[0.0013538876,0.0026358936,0.00002649057,0.037481934,0.8485559,0.00007063474,0.00006194351,0.000003933765,3.471275e-7,3.085691e-7,0.109542765,0.00026591847],"about_ca_topic_score_codex":0.000008914908,"about_ca_topic_score_gemma":0.000026848591,"teacher_disagreement_score":0.14583398,"about_ca_system_score_codex":0.0002778745,"about_ca_system_score_gemma":0.00018624392,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W4392242464","doi":"10.1093/eurheartj/ehae028","title":"Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk; Hjärt-Lungfonden; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Baseline (sea); Diabetes mellitus; Internal medicine; Empagliflozin; Type 2 diabetes; Endocrinology; Liraglutide","score_opus":0.03606044930705955,"score_gpt":0.30007068056988806,"score_spread":0.2640102312628285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392242464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91444033,0.06498725,0.00020791432,0.017473076,0.00030112645,0.000589514,0.000011938362,0.000058526224,0.0019303057],"genre_scores_gemma":[0.9928404,0.0013553773,0.0002210136,0.001652245,0.00025089693,0.000005664598,0.000008836263,0.00003521505,0.0036303466],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815583,0.0007990561,0.000340126,0.0002028059,0.00025071105,0.0002514522],"domain_scores_gemma":[0.9991501,0.0004668559,0.000029184948,0.0001938473,0.000022563232,0.00013744335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073546707,0.00014797709,0.00053167914,0.0002136589,0.000084572355,0.00019102266,0.000043896758,0.00001763264,0.00006892584],"category_scores_gemma":[0.00043774766,0.00008106914,0.00029085518,0.00021295811,0.00005116977,0.0000708498,0.00006626742,0.00025501568,0.00002160378],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056185974,0.00016598467,0.6670115,0.00025388147,0.010281117,0.0016289738,0.00093038415,0.000057095564,0.00040724938,0.00017840588,0.22823074,0.09079847],"study_design_scores_gemma":[0.001995161,0.00018821111,0.3239826,0.00019463072,0.0023364436,0.000068145964,0.00031409584,0.00043172788,0.00004908932,0.000044406497,0.67025936,0.00013614177],"about_ca_topic_score_codex":0.0000051574984,"about_ca_topic_score_gemma":0.0000014310702,"teacher_disagreement_score":0.4420286,"about_ca_system_score_codex":0.000031033516,"about_ca_system_score_gemma":0.000019531017,"threshold_uncertainty_score":0.33059037},"labels":[],"label_agreement":null},{"id":"W4392244836","doi":"10.14740/cr1600","title":"Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health","year":2024,"lang":"en","type":"review","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Semaglutide; Obesity; Diabetes mellitus; Type 2 diabetes; Glucagon-like peptide-1; Glucagon receptor; Exenatide; Cardiovascular health; Glucagon-like peptide 1 receptor; Type 2 Diabetes Mellitus; Intensive care medicine; Internal medicine; Insulin; Liraglutide; Endocrinology; Receptor; Disease; Glucagon; Agonist","score_opus":0.11511632523184145,"score_gpt":0.4495313398004089,"score_spread":0.3344150145685674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392244836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000036381962,0.9842259,0.000001400688,0.00019331461,0.0002996989,0.013191983,0.0000693398,0.00003339984,0.0019812826],"genre_scores_gemma":[0.000025541382,0.9935621,0.000099639794,0.000037428563,0.00013687304,0.0039501726,0.0004702988,0.00008946527,0.0016284653],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99150515,0.0036230434,0.002040577,0.00085253146,0.0011357346,0.00084294245],"domain_scores_gemma":[0.99660283,0.0003549565,0.0003951611,0.0019868186,0.00045371565,0.00020653481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011251066,0.00049240264,0.014128125,0.0012542235,0.000037147554,0.000012813493,0.0004915575,0.00036118508,0.0000284536],"category_scores_gemma":[0.00077403756,0.00032407194,0.003038963,0.0018058093,0.00053149706,0.000030745337,0.0004712484,0.0009900129,0.0002665776],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000088760125,0.00008307984,0.00002085073,0.87143016,0.0094354,0.0002447973,0.00003563657,6.189856e-8,5.575198e-8,0.00009331258,0.012824662,0.10582312],"study_design_scores_gemma":[0.00022068276,0.0004220937,0.000003124843,0.59657365,0.006507023,0.0000618346,0.000033981923,3.2760732e-7,2.3009416e-7,0.000005833966,0.3960616,0.00010962469],"about_ca_topic_score_codex":0.000042301202,"about_ca_topic_score_gemma":0.0000018347296,"teacher_disagreement_score":0.3832369,"about_ca_system_score_codex":0.0007448468,"about_ca_system_score_gemma":0.0014906375,"threshold_uncertainty_score":0.99992114},"labels":[],"label_agreement":null},{"id":"W4392343662","doi":"10.1016/j.rcsop.2024.100429","title":"Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification","year":2024,"lang":"en","type":"article","venue":"Exploratory Research in Clinical and Social Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"University of Alberta","keywords":"Rurality; Medicine; Residence; Metropolitan area; Metformin; Logistic regression; Confounding; Dipeptidyl peptidase-4 inhibitor; Demography; Retrospective cohort study; Environmental health; Type 2 diabetes; Rural area; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.391123538730319,"score_gpt":0.5072154846503614,"score_spread":0.11609194592004235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392343662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237007,0.0003103584,0.000009837755,0.0055898484,0.0001694618,0.0012655017,0.000085846055,0.000052118783,0.00014694809],"genre_scores_gemma":[0.9973818,0.0006693908,0.000052943513,0.0002782681,0.00033505267,0.00032324364,0.00010544761,0.000026520232,0.0008273511],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804103,0.00028551216,0.00050761946,0.0004120834,0.00038819987,0.00036555238],"domain_scores_gemma":[0.99831605,0.0009392853,0.00005862682,0.00014760769,0.00036932676,0.00016908196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018014059,0.00015372886,0.0004435417,0.0001734643,0.000106384185,0.0000717821,0.00005652576,0.00008140845,0.000039449144],"category_scores_gemma":[0.00024851123,0.000108421285,0.00017108447,0.00036526026,0.00042231602,0.00027067756,0.000058780097,0.00024543583,0.0000160858],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013131196,0.018020283,0.49669498,0.0019916168,0.00461409,0.00070132216,0.015351398,5.635744e-7,0.0038783639,0.0034207487,0.0848082,0.35738724],"study_design_scores_gemma":[0.09993037,0.03151912,0.26101235,0.0059955623,0.0029584928,0.00000430133,0.014058093,0.0063393083,0.01615974,0.013216108,0.54682815,0.0019784067],"about_ca_topic_score_codex":0.00004558622,"about_ca_topic_score_gemma":0.000034717166,"teacher_disagreement_score":0.46201995,"about_ca_system_score_codex":0.00017377589,"about_ca_system_score_gemma":0.00023858596,"threshold_uncertainty_score":0.44212916},"labels":[],"label_agreement":null},{"id":"W4392359058","doi":"10.1152/ajpheart.00574.2023","title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","year":2024,"lang":"en","type":"review","venue":"American Journal of Physiology-Heart and Circulatory Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; Robarts Clinical Trials; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Western University; Canada Research Chairs; Government of Canada; Heart and Stroke Foundation of Canada","keywords":"Medicine; Clinical trial; Endothelium; Bioinformatics; Internal medicine; Biology","score_opus":0.028707532775248134,"score_gpt":0.2804735625696902,"score_spread":0.25176602979444207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392359058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061956998,0.93593234,8.48452e-7,0.0003039489,0.0007173733,0.0009506272,0.000040659143,0.000037619728,0.000059580583],"genre_scores_gemma":[0.023639113,0.9743391,0.00007647348,0.0005493827,0.000901266,0.00011058653,0.000032975517,0.0000835021,0.00026755407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769324,0.00043679064,0.0006686235,0.0005919271,0.00019479288,0.00041463488],"domain_scores_gemma":[0.99847525,0.00010101286,0.0006632544,0.00048346026,0.00009063662,0.00018640148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031730923,0.000551687,0.0024915037,0.00021997296,0.00015764165,0.00003642807,0.00017944849,0.0001749096,0.000088846704],"category_scores_gemma":[0.000020318086,0.0003068636,0.000856853,0.000255403,0.0011133042,0.00007594239,0.00011551716,0.0007576141,0.00005672711],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025762583,0.00095972634,0.00016208808,0.02257533,0.016845351,0.0000070649016,0.00083214114,0.0000027127287,0.47008586,0.00046467516,0.0060600825,0.48174736],"study_design_scores_gemma":[0.0006139926,0.0016282124,0.009837937,0.0025881354,0.003169989,0.0001291238,0.00021677518,0.000003435428,0.0000147028795,0.00007224154,0.98143667,0.0002887876],"about_ca_topic_score_codex":0.000014662651,"about_ca_topic_score_gemma":6.951015e-7,"teacher_disagreement_score":0.9753766,"about_ca_system_score_codex":0.00009445476,"about_ca_system_score_gemma":0.00014816647,"threshold_uncertainty_score":0.99993837},"labels":[],"label_agreement":null},{"id":"W4392451912","doi":"10.2337/ds23-0038","title":"A Qualitative Study of Barriers to Medication-Taking Among People With Type 2 Diabetes Using the Theoretical Domains Framework","year":2024,"lang":"en","type":"article","venue":"Diabetes Spectrum","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto; Canadian Pharmacists Association; Dalhousie University","funders":"Novo Nordisk Canada; Novo Nordisk","keywords":"Medicine; Type 2 diabetes; Medication adherence; Diabetes mellitus; Qualitative research; Internal medicine; Endocrinology","score_opus":0.012385717208187052,"score_gpt":0.3182798616180029,"score_spread":0.3058941444098159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392451912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433285,0.00040885824,0.00029234547,0.0020490414,0.00026345855,0.001342828,0.0000073036986,0.00011770213,0.0011855884],"genre_scores_gemma":[0.9984307,0.0000072810394,0.0008013061,0.00037563438,0.00013342348,0.00012404114,0.00001373119,0.000052197087,0.00006168392],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9981087,0.00016373643,0.00029953942,0.00041170296,0.0005374057,0.00047890632],"domain_scores_gemma":[0.99840033,0.00067884795,0.000101531135,0.0005029286,0.00006035806,0.00025598175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006033806,0.00024558266,0.00044047603,0.00022442307,0.00014860777,0.00007892957,0.00018563222,0.000062609615,0.0005623244],"category_scores_gemma":[0.00042428443,0.00014544424,0.00008253781,0.0010771806,0.00030286916,0.00009169086,0.000103746905,0.00023959223,0.0000211622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011471135,0.0006850039,0.67694134,0.00040772304,0.0037071477,0.000033021395,0.18999302,0.00011611229,0.000620355,0.12579685,0.0005104479,0.001074266],"study_design_scores_gemma":[0.0049695247,0.02061131,0.3506167,0.006670939,0.010134783,0.0000029624962,0.5067597,0.020231342,0.015263791,0.061639104,0.0012132181,0.0018866133],"about_ca_topic_score_codex":0.000034854795,"about_ca_topic_score_gemma":0.00005975035,"teacher_disagreement_score":0.32632464,"about_ca_system_score_codex":0.00011796164,"about_ca_system_score_gemma":0.000113334856,"threshold_uncertainty_score":0.6157058},"labels":[],"label_agreement":null},{"id":"W4392460464","doi":"10.12688/wellcomeopenres.19148.2","title":"Case Report: Diabetic ketoacidosis after co-administration of empagliflozin and probenecid","year":2024,"lang":"en","type":"preprint","venue":"Wellcome Open Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Service Executive; Wellcome Trust; Canadian Institute for Theoretical Astrophysics","keywords":"Empagliflozin; Probenecid; Diabetic ketoacidosis; Medicine; Ketoacidosis; Administration (probate law); Diabetes mellitus; Intensive care medicine; Pharmacology; Type 2 diabetes; Endocrinology; Type 1 diabetes; Political science","score_opus":0.12308007225127802,"score_gpt":0.42305208361613783,"score_spread":0.2999720113648598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392460464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9233232,0.0016032121,0.0000024640356,0.002433077,0.00018324218,0.0049309176,0.00009590231,0.000036994406,0.06739095],"genre_scores_gemma":[0.96617305,0.0002848328,0.0008425021,0.00003895942,0.000117886106,0.0016241283,0.0003000141,0.00006189927,0.03055675],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968446,0.00021599985,0.00064605067,0.00097635435,0.0008416582,0.0004753534],"domain_scores_gemma":[0.99801517,0.00014075864,0.00013479433,0.0011790582,0.00026653765,0.0002636686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025753977,0.00029963316,0.0007127798,0.0005878083,0.00008408796,0.00049672864,0.00032244882,0.00024466548,0.0006545776],"category_scores_gemma":[0.00013528398,0.00024890766,0.00012212891,0.00032349932,0.00026520528,0.000071662274,0.0036443593,0.0009130161,0.0001597358],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028783958,0.003435854,0.0469329,0.03125281,0.0044177533,0.7970047,0.0023529963,0.00000731971,0.0013195899,0.00239514,0.048376415,0.05962614],"study_design_scores_gemma":[0.033067428,0.032898653,0.18850121,0.060796514,0.019231392,0.0775543,0.009081224,0.006023686,0.24156809,0.11231774,0.20984942,0.00911034],"about_ca_topic_score_codex":0.00042855376,"about_ca_topic_score_gemma":0.000107124295,"teacher_disagreement_score":0.7194504,"about_ca_system_score_codex":0.00017601914,"about_ca_system_score_gemma":0.00046172095,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4392470158","doi":"10.54254/2753-8818/32/20240813","title":"Glucagon-like peptide-1 analogs for Alzheimer’s disease -- A systematic meta-analysis","year":2024,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pierre Elliott Trudeau Foundation","funders":"","keywords":"Alzheimer's disease; Medicine; Internal medicine; Meta-analysis; Randomized controlled trial; Dementia; Placebo; Disease; Pathology","score_opus":0.029074830681181302,"score_gpt":0.3159515157028707,"score_spread":0.2868766850216894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392470158","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43837312,0.4713201,0.006915414,0.050438635,0.0019111948,0.012427626,0.00022642144,0.0011302278,0.017257258],"genre_scores_gemma":[0.9974631,0.00005208172,0.0005333631,0.00058021734,0.000026215093,0.00011741302,0.000014876238,0.0000059557815,0.0012067512],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9987006,0.000026104275,0.00018556885,0.00041722643,0.00037420864,0.00029624917],"domain_scores_gemma":[0.9991502,0.00023969574,0.00002224661,0.00023106318,0.000061842286,0.0002949606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007146543,0.00014484757,0.00054422696,0.000235429,0.00012055388,0.00014772263,0.00012864695,0.000019145624,0.0001652809],"category_scores_gemma":[0.000119014796,0.00007194471,0.0005272351,0.00096555037,0.0009009668,0.0001302629,0.00008043378,0.000064656015,0.000023079921],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005918871,0.000057277113,0.000051966177,0.0018982625,0.02600721,0.000035228015,0.000069195456,0.0000015049054,0.00011194069,0.9709497,0.00019408646,0.00056442444],"study_design_scores_gemma":[0.00039265145,0.0003050036,0.0018300415,0.00029049482,0.8882245,0.0000069329226,0.00007503068,0.05968943,0.00035070104,0.04795482,0.0005885961,0.000291809],"about_ca_topic_score_codex":0.0000031442924,"about_ca_topic_score_gemma":0.0000010946773,"teacher_disagreement_score":0.9229949,"about_ca_system_score_codex":0.000024087289,"about_ca_system_score_gemma":0.00004982772,"threshold_uncertainty_score":0.33196497},"labels":[],"label_agreement":null},{"id":"W4392702077","doi":"10.1001/jama.2024.0049","title":"GLP-1 Receptor Agonists and Gastrointestinal Adverse Events—Reply","year":2024,"lang":"en","type":"letter","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; Editor in chief; Neurology; Psychiatry; Management","score_opus":0.012280252370718314,"score_gpt":0.24530116918360367,"score_spread":0.23302091681288536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392702077","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004069053,0.00088747544,0.000011731386,0.9698574,0.00079200167,0.00074573694,0.000077456236,0.00023182548,0.023327312],"genre_scores_gemma":[0.00040675,0.00024202178,0.003161297,0.7471658,0.0056458055,0.000107460255,0.0013518891,0.00010686632,0.24181214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985374,0.000025939442,0.00022619028,0.0005075736,0.0003274242,0.0003754612],"domain_scores_gemma":[0.99935657,0.000048216993,0.00008023956,0.0003617877,0.00005124861,0.000101909674],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000098398916,0.0003309367,0.0003941974,0.00018041069,0.000036638394,0.00003763881,0.00008661879,0.00016167517,0.00053928746],"category_scores_gemma":[0.000055888777,0.0002687615,0.00016504849,0.000098687226,0.000056518584,0.0000633298,0.00014279346,0.0008315021,0.0015190205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043947617,0.000044944274,0.0014834002,0.0010767196,0.00027733634,0.0029611862,0.000028909093,4.2007287e-8,0.000023813593,0.000023877987,0.9832635,0.010772348],"study_design_scores_gemma":[0.0013049159,0.00046336968,0.0019886866,0.0021935601,0.0007218593,0.0001876587,0.000017702443,0.000011155875,0.000020630947,0.00008763753,0.9928043,0.00019850451],"about_ca_topic_score_codex":0.000021008862,"about_ca_topic_score_gemma":0.0000015701057,"teacher_disagreement_score":0.22269164,"about_ca_system_score_codex":0.00014814988,"about_ca_system_score_gemma":0.000053740972,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W4392712963","doi":"10.1111/dom.15493","title":"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( <scp>PIONEER REAL</scp> Canada)","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Calgary; Western University; LMC Diabetes & Endocrinology (Canada); Diabetes Canada; University of British Columbia","funders":"Novo Nordisk Pharma; Novo Nordisk","keywords":"Semaglutide; Medicine; Clinical endpoint; Confidence interval; Type 2 diabetes; Prospective cohort study; Internal medicine; Diabetes mellitus; Clinical trial; Endocrinology","score_opus":0.01958254838142105,"score_gpt":0.29132823680404685,"score_spread":0.2717456884226258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392712963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956829,0.0012889729,9.7113386e-8,0.00020462665,0.00041947357,0.0019404758,0.00006099901,0.00004853357,0.00035392196],"genre_scores_gemma":[0.9970379,0.0012799809,0.00030478637,0.0003746948,0.000055793258,0.00006568386,0.000057316345,0.00004089194,0.0007829616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631226,0.0005329607,0.0010719224,0.0007761572,0.0006396252,0.00066706096],"domain_scores_gemma":[0.9959219,0.0028501484,0.00030908338,0.00034340087,0.0002739299,0.00030154403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015271646,0.000404105,0.0015622476,0.00025867746,0.00005997937,0.00006500795,0.00010308673,0.00012143591,0.0000048197244],"category_scores_gemma":[0.0033175123,0.00030921336,0.00008237714,0.0008451376,0.00016800956,0.00035786643,0.00016337878,0.00059657806,8.7707093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001065758,0.0017578229,0.99177754,0.00014509702,0.0013112702,0.0002674562,0.00069693115,0.00000800976,0.0000019305987,0.00007548564,0.0007127582,0.0031391163],"study_design_scores_gemma":[0.006140752,0.00043486108,0.9870683,0.00048503946,0.001679779,2.2088005e-7,0.0014267215,0.0013261855,0.00002253846,0.000012397141,0.0012309904,0.00017218989],"about_ca_topic_score_codex":0.94043946,"about_ca_topic_score_gemma":0.9967488,"teacher_disagreement_score":0.056309365,"about_ca_system_score_codex":0.00037566668,"about_ca_system_score_gemma":0.0011970601,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W4392738595","doi":"10.1111/dom.15493/v2/review1","title":"Review for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Diabetes mellitus; Gerontology; Physical therapy; Endocrinology","score_opus":0.04216130622802859,"score_gpt":0.36386886419158365,"score_spread":0.32170755796355505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392738595","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7321326,0.15187338,0.000001087458,0.032478515,0.0048382645,0.064995766,0.001902599,0.00029978345,0.011477959],"genre_scores_gemma":[0.15951656,0.46634108,0.0039344477,0.025865838,0.0005344148,0.0041289283,0.0061591296,0.0006783958,0.33284122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99061656,0.000998725,0.003992028,0.00176321,0.0015370715,0.0010924331],"domain_scores_gemma":[0.9883814,0.006689077,0.0018412597,0.0010616685,0.0015468311,0.00047974975],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045436663,0.0010925491,0.005619516,0.00033706272,0.000056240515,0.00004973141,0.00031950473,0.0002986715,0.000052032145],"category_scores_gemma":[0.01833089,0.00076607236,0.0003584553,0.0014971769,0.00016192292,0.00021305158,0.0003607186,0.001281034,0.0000042586476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022215553,0.0015981962,0.5448127,0.0071717333,0.0024505837,0.00031526838,0.000056450044,0.0000011388437,1.8129134e-8,0.000014764364,0.43973556,0.0036214592],"study_design_scores_gemma":[0.009111464,0.0018555423,0.6836524,0.045279205,0.010818388,0.0000010153512,0.00030436422,0.00035307184,2.5663658e-7,0.0000028767533,0.24817842,0.00044299458],"about_ca_topic_score_codex":0.9688848,"about_ca_topic_score_gemma":0.99980843,"teacher_disagreement_score":0.5726161,"about_ca_system_score_codex":0.0028156983,"about_ca_system_score_gemma":0.006631542,"threshold_uncertainty_score":0.999479},"labels":[],"label_agreement":null},{"id":"W4392738806","doi":"10.1111/dom.15493/v1/review2","title":"Review for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Prospective cohort study; Diabetes mellitus; Gerontology; Physical therapy; Internal medicine; Endocrinology","score_opus":0.05141635073132465,"score_gpt":0.3682286588191387,"score_spread":0.316812308087814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392738806","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84273565,0.056329336,0.0000010618977,0.023486877,0.0039237514,0.06452077,0.0016898382,0.00034258812,0.006970124],"genre_scores_gemma":[0.110150404,0.55287087,0.0035024914,0.021857759,0.00048421978,0.004626285,0.0074828235,0.0007518764,0.29827327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99030524,0.0011443854,0.004076416,0.0016809525,0.0016147023,0.0011782913],"domain_scores_gemma":[0.9852465,0.009046914,0.002344488,0.0011137424,0.0017539586,0.00049441203],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005074717,0.001060078,0.005821536,0.00034316082,0.000068956266,0.00003764973,0.0003441577,0.0003004281,0.000039400253],"category_scores_gemma":[0.027971212,0.0007672736,0.0003368933,0.0017155781,0.00016206785,0.00021755566,0.00035923548,0.0011162257,0.000004411323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023290003,0.0015759622,0.5867298,0.0047577526,0.0021030493,0.000259836,0.00005021503,0.0000017554988,1.663248e-8,0.000008568073,0.40097597,0.0033041197],"study_design_scores_gemma":[0.011580723,0.0018042023,0.8124356,0.03351483,0.007462461,6.2333476e-7,0.0003593362,0.00031109562,2.1946215e-7,0.0000019183742,0.13209212,0.00043682806],"about_ca_topic_score_codex":0.97608244,"about_ca_topic_score_gemma":0.99985874,"teacher_disagreement_score":0.73258525,"about_ca_system_score_codex":0.002587216,"about_ca_system_score_gemma":0.0061169122,"threshold_uncertainty_score":0.9995175},"labels":[],"label_agreement":null},{"id":"W4392738811","doi":"10.1111/dom.15493/v2/decision1","title":"Decision letter for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Prospective cohort study; Clinical trial; Diabetes mellitus; Family medicine; Internal medicine; Endocrinology","score_opus":0.03492911217713083,"score_gpt":0.3532967004922339,"score_spread":0.31836758831510303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392738811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682556,0.0028503642,0.0000018815639,0.009310524,0.002704254,0.0141415335,0.00048380933,0.000086941865,0.0021650821],"genre_scores_gemma":[0.70475835,0.014249443,0.006936682,0.01637812,0.0006128444,0.0018230651,0.003279328,0.00052104436,0.25144112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915559,0.00066457747,0.0033112897,0.0016973248,0.0017450195,0.0010258746],"domain_scores_gemma":[0.9866109,0.009536516,0.0013232736,0.0009195264,0.0012073942,0.00040240123],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033134983,0.00097217975,0.0039988714,0.00044228576,0.000058628106,0.00006786053,0.00028594237,0.00033939935,0.00004067468],"category_scores_gemma":[0.013221941,0.00067522435,0.00028695093,0.0011486624,0.00014707826,0.00022580141,0.00037597172,0.0011978291,0.000004047172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005329305,0.0015107135,0.56973815,0.00075256545,0.0017907359,0.0004336997,0.00008252431,0.000004343652,5.8642705e-8,0.000008340567,0.42091456,0.0042313905],"study_design_scores_gemma":[0.012561846,0.0018286279,0.8204117,0.008193883,0.0052514067,7.3683157e-7,0.00031908994,0.0009233171,7.1207745e-7,0.0000052626515,0.15010658,0.00039686012],"about_ca_topic_score_codex":0.96423876,"about_ca_topic_score_gemma":0.9998565,"teacher_disagreement_score":0.27080798,"about_ca_system_score_codex":0.002711467,"about_ca_system_score_gemma":0.0042284676,"threshold_uncertainty_score":0.9995699},"labels":[],"label_agreement":null},{"id":"W4392740900","doi":"10.1111/bcp.16039","title":"Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Hazard ratio; Dipeptidyl peptidase-4; Type 2 diabetes; Internal medicine; Proportional hazards model; Lung cancer; Propensity score matching; Diabetes mellitus; Confidence interval; Cohort study; Pharmacology; Endocrinology","score_opus":0.011021328151746789,"score_gpt":0.3288115901049984,"score_spread":0.3177902619532516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392740900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805408,0.016288834,0.0000043184614,0.00056298135,0.0019848973,0.0003776708,0.000018834064,0.000010579185,0.00021107431],"genre_scores_gemma":[0.9816041,0.017088877,0.000051693398,0.0005409449,0.00055037055,0.000008632333,0.0000053818276,0.000016455697,0.00013355412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985149,0.00018147941,0.0007750153,0.0001437763,0.00021625246,0.00016860853],"domain_scores_gemma":[0.998682,0.00054503273,0.00036194088,0.00005385816,0.00021873639,0.00013839659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008823406,0.000101184625,0.0005874064,0.00006296843,0.000036926725,0.00002230557,0.00007759997,0.00006687635,0.00021002513],"category_scores_gemma":[0.0000914174,0.000063278356,0.00018618545,0.00012685868,0.0005121203,0.00011276318,0.00002736232,0.00045706003,0.000001085403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011667827,0.00040286375,0.90222645,0.00018036267,0.002816901,0.00024376236,0.00006048147,0.00000868517,0.000017989447,0.000005964067,0.017736636,0.075133115],"study_design_scores_gemma":[0.014976153,0.0011800436,0.97033,0.0008008577,0.0057259966,0.000010660982,0.000011269526,0.00034691786,0.0002801567,0.000045016506,0.006212581,0.00008033368],"about_ca_topic_score_codex":0.000042369524,"about_ca_topic_score_gemma":0.000022654718,"teacher_disagreement_score":0.07505278,"about_ca_system_score_codex":0.000018609398,"about_ca_system_score_gemma":0.00009285885,"threshold_uncertainty_score":0.25804165},"labels":[],"label_agreement":null},{"id":"W4392743537","doi":"10.1111/dom.15493/v1/review3","title":"Review for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Prospective cohort study; Diabetes mellitus; Physical therapy; Internal medicine; Endocrinology","score_opus":0.05141635073132465,"score_gpt":0.3682286588191387,"score_spread":0.316812308087814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392743537","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84273565,0.056329336,0.0000010618977,0.023486877,0.0039237514,0.06452077,0.0016898382,0.00034258812,0.006970124],"genre_scores_gemma":[0.110150404,0.55287087,0.0035024914,0.021857759,0.00048421978,0.004626285,0.0074828235,0.0007518764,0.29827327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99030524,0.0011443854,0.004076416,0.0016809525,0.0016147023,0.0011782913],"domain_scores_gemma":[0.9852465,0.009046914,0.002344488,0.0011137424,0.0017539586,0.00049441203],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005074717,0.001060078,0.005821536,0.00034316082,0.000068956266,0.00003764973,0.0003441577,0.0003004281,0.000039400253],"category_scores_gemma":[0.027971212,0.0007672736,0.0003368933,0.0017155781,0.00016206785,0.00021755566,0.00035923548,0.0011162257,0.000004411323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023290003,0.0015759622,0.5867298,0.0047577526,0.0021030493,0.000259836,0.00005021503,0.0000017554988,1.663248e-8,0.000008568073,0.40097597,0.0033041197],"study_design_scores_gemma":[0.011580723,0.0018042023,0.8124356,0.03351483,0.007462461,6.2333476e-7,0.0003593362,0.00031109562,2.1946215e-7,0.0000019183742,0.13209212,0.00043682806],"about_ca_topic_score_codex":0.97608244,"about_ca_topic_score_gemma":0.99985874,"teacher_disagreement_score":0.73258525,"about_ca_system_score_codex":0.002587216,"about_ca_system_score_gemma":0.0061169122,"threshold_uncertainty_score":0.9995175},"labels":[],"label_agreement":null},{"id":"W4392743541","doi":"10.1111/dom.15493/v1/review1","title":"Review for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Diabetes mellitus; Clinical trial; Internal medicine; Family medicine; Endocrinology","score_opus":0.05141635073132465,"score_gpt":0.3682286588191387,"score_spread":0.316812308087814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392743541","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84273565,0.056329336,0.0000010618977,0.023486877,0.0039237514,0.06452077,0.0016898382,0.00034258812,0.006970124],"genre_scores_gemma":[0.110150404,0.55287087,0.0035024914,0.021857759,0.00048421978,0.004626285,0.0074828235,0.0007518764,0.29827327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99030524,0.0011443854,0.004076416,0.0016809525,0.0016147023,0.0011782913],"domain_scores_gemma":[0.9852465,0.009046914,0.002344488,0.0011137424,0.0017539586,0.00049441203],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005074717,0.001060078,0.005821536,0.00034316082,0.000068956266,0.00003764973,0.0003441577,0.0003004281,0.000039400253],"category_scores_gemma":[0.027971212,0.0007672736,0.0003368933,0.0017155781,0.00016206785,0.00021755566,0.00035923548,0.0011162257,0.000004411323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023290003,0.0015759622,0.5867298,0.0047577526,0.0021030493,0.000259836,0.00005021503,0.0000017554988,1.663248e-8,0.000008568073,0.40097597,0.0033041197],"study_design_scores_gemma":[0.011580723,0.0018042023,0.8124356,0.03351483,0.007462461,6.2333476e-7,0.0003593362,0.00031109562,2.1946215e-7,0.0000019183742,0.13209212,0.00043682806],"about_ca_topic_score_codex":0.97608244,"about_ca_topic_score_gemma":0.99985874,"teacher_disagreement_score":0.73258525,"about_ca_system_score_codex":0.002587216,"about_ca_system_score_gemma":0.0061169122,"threshold_uncertainty_score":0.9995175},"labels":[],"label_agreement":null},{"id":"W4392743582","doi":"10.1111/dom.15493/v2/response1","title":"Author response for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Clinical Practice; Type 2 diabetes; Diabetes mellitus; Physical therapy; Endocrinology","score_opus":0.04715222961177945,"score_gpt":0.3743911364847125,"score_spread":0.32723890687293306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392743582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96352357,0.0027305712,5.3154605e-7,0.0147215985,0.0017963276,0.014919548,0.0007934948,0.000111095454,0.001403262],"genre_scores_gemma":[0.5685266,0.0038299873,0.0025148117,0.0035354544,0.00022227323,0.0014850582,0.0015872134,0.0003299447,0.41796863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99011123,0.0017142927,0.0035223116,0.001797748,0.0016932137,0.0011611807],"domain_scores_gemma":[0.9819135,0.013547389,0.0015560555,0.00102414,0.0014256381,0.0005332411],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006728126,0.0010554427,0.0043766396,0.0005388169,0.000070350434,0.000068459485,0.0003053139,0.00038796573,0.000036723643],"category_scores_gemma":[0.030314295,0.00076468004,0.00030203958,0.0014661106,0.00019483583,0.00021247946,0.00036922685,0.0013400908,0.0000034854309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027190098,0.0020751946,0.6171078,0.0011225668,0.0026526079,0.0006710581,0.00020371626,0.000003818694,1.2252812e-7,0.000016547656,0.37175876,0.0016687652],"study_design_scores_gemma":[0.012601307,0.0030661891,0.8403723,0.006987038,0.006326762,9.881447e-7,0.0009420733,0.0009705699,9.126558e-7,0.0000035686232,0.1282925,0.00043578225],"about_ca_topic_score_codex":0.96813995,"about_ca_topic_score_gemma":0.9998096,"teacher_disagreement_score":0.4165654,"about_ca_system_score_codex":0.0035039221,"about_ca_system_score_gemma":0.009203237,"threshold_uncertainty_score":0.9994804},"labels":[],"label_agreement":null},{"id":"W4392743659","doi":"10.1111/dom.15493/v1/decision1","title":"Decision letter for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Diabetes mellitus; Clinical trial; Gerontology; Demography; Internal medicine; Family medicine; Endocrinology","score_opus":0.04259712724156095,"score_gpt":0.35756605241561407,"score_spread":0.3149689251740531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392743659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743353,0.0010246455,0.0000018247883,0.006683984,0.0021781875,0.013945792,0.00042676143,0.00009868219,0.0013047869],"genre_scores_gemma":[0.6561565,0.021988345,0.007876779,0.017647812,0.0007082366,0.0026056792,0.0050829807,0.0007365985,0.2871971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99129975,0.0007615397,0.003381154,0.0016180037,0.0018330481,0.0011064785],"domain_scores_gemma":[0.98271877,0.012857328,0.0016815519,0.000962482,0.0013661198,0.0004137719],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037015213,0.0009432691,0.004142942,0.00045027933,0.00007189026,0.000051368817,0.00030801684,0.0003413965,0.00003079827],"category_scores_gemma":[0.02023396,0.00067628355,0.00026968322,0.0013163501,0.00014721038,0.00023057741,0.0003744227,0.001043644,0.0000041922367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056866044,0.0015162106,0.60180306,0.0005063024,0.0015638242,0.00036379747,0.00007471329,0.000006815892,5.4760825e-8,0.0000049250234,0.38966182,0.00392983],"study_design_scores_gemma":[0.016331939,0.0018205089,0.89374405,0.006143294,0.0037014973,4.630556e-7,0.00038575323,0.0008329762,6.234686e-7,0.0000035927583,0.07663461,0.00040069246],"about_ca_topic_score_codex":0.9724869,"about_ca_topic_score_gemma":0.9998942,"teacher_disagreement_score":0.31817886,"about_ca_system_score_codex":0.0024913312,"about_ca_system_score_gemma":0.0038994183,"threshold_uncertainty_score":0.9995688},"labels":[],"label_agreement":null},{"id":"W4392743897","doi":"10.1111/dom.15493/v2/review2","title":"Review for \"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (&lt;scp&gt;PIONEER REAL&lt;/scp&gt; Canada)\"","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical Practice; Diabetes mellitus; Physical therapy; Endocrinology","score_opus":0.04216130622802859,"score_gpt":0.36386886419158365,"score_spread":0.32170755796355505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392743897","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7321326,0.15187338,0.000001087458,0.032478515,0.0048382645,0.064995766,0.001902599,0.00029978345,0.011477959],"genre_scores_gemma":[0.15951656,0.46634108,0.0039344477,0.025865838,0.0005344148,0.0041289283,0.0061591296,0.0006783958,0.33284122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99061656,0.000998725,0.003992028,0.00176321,0.0015370715,0.0010924331],"domain_scores_gemma":[0.9883814,0.006689077,0.0018412597,0.0010616685,0.0015468311,0.00047974975],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045436663,0.0010925491,0.005619516,0.00033706272,0.000056240515,0.00004973141,0.00031950473,0.0002986715,0.000052032145],"category_scores_gemma":[0.01833089,0.00076607236,0.0003584553,0.0014971769,0.00016192292,0.00021305158,0.0003607186,0.001281034,0.0000042586476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022215553,0.0015981962,0.5448127,0.0071717333,0.0024505837,0.00031526838,0.000056450044,0.0000011388437,1.8129134e-8,0.000014764364,0.43973556,0.0036214592],"study_design_scores_gemma":[0.009111464,0.0018555423,0.6836524,0.045279205,0.010818388,0.0000010153512,0.00030436422,0.00035307184,2.5663658e-7,0.0000028767533,0.24817842,0.00044299458],"about_ca_topic_score_codex":0.9688848,"about_ca_topic_score_gemma":0.99980843,"teacher_disagreement_score":0.5726161,"about_ca_system_score_codex":0.0028156983,"about_ca_system_score_gemma":0.006631542,"threshold_uncertainty_score":0.999479},"labels":[],"label_agreement":null},{"id":"W4392786625","doi":"10.1093/europace/euae054","title":"Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation","year":2024,"lang":"en","type":"article","venue":"EP Europace","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Atrial fibrillation; Internal medicine; Hazard ratio; Clinical endpoint; Diabetes mellitus; Stroke (engine); Proportional hazards model; Cardiology; Heart failure; Confidence interval; Endocrinology; Randomized controlled trial","score_opus":0.008183467400965302,"score_gpt":0.23458179194811907,"score_spread":0.22639832454715375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392786625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997814,0.00054166524,0.000009693904,0.0005772199,0.00012745337,0.0005663554,0.000014286442,0.00007956873,0.00026978343],"genre_scores_gemma":[0.9983402,0.000040908977,0.00012502164,0.00002410807,0.00021768392,0.0000035675605,0.000090927024,0.000023350734,0.0011342579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915904,0.000033261167,0.00018147947,0.00023973217,0.00020490657,0.00018160895],"domain_scores_gemma":[0.999638,0.00014121721,0.00006334122,0.000076507145,0.000024242412,0.00005664517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016347118,0.00013532428,0.00023387212,0.00012320412,0.00003468661,0.000058910384,0.000013000372,0.00004098599,0.0000045892057],"category_scores_gemma":[0.000057559104,0.00010545226,0.00003479439,0.0001339863,0.000018689634,0.00014612089,0.000019606352,0.000082456085,0.000005549954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003935439,0.000011132163,0.9822312,0.00016238501,0.00021437292,0.000008770638,0.0003068992,0.0000046588584,0.000022108808,0.000009149079,0.000056869398,0.0169331],"study_design_scores_gemma":[0.0020896913,0.00039347674,0.9945929,0.00023513606,0.00039436063,1.02017346e-7,0.000012588595,0.00014392394,0.000115534946,0.000019913197,0.0018967652,0.000105631545],"about_ca_topic_score_codex":0.0000124740345,"about_ca_topic_score_gemma":0.000010715549,"teacher_disagreement_score":0.01682747,"about_ca_system_score_codex":0.00008600842,"about_ca_system_score_gemma":0.000011215691,"threshold_uncertainty_score":0.43002182},"labels":[],"label_agreement":null},{"id":"W4392813038","doi":"10.1016/j.molmet.2024.101915","title":"Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice","year":2024,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Helmholtz Zentrum München; Novo Nordisk Fonden; Breakthrough T1D Canada; European Commission; H2020 European Research Council; AstraZeneca; Deutsche Forschungsgemeinschaft; Eli Lilly and Company; Novo Nordisk; Sanofi; Fetzer Institute","keywords":"Internal medicine; Endocrinology; Leptin receptor; Leptin; Biology; Receptor; Insulin resistance; Gastric inhibitory polypeptide; Obesity; Insulin; Medicine; Glucagon","score_opus":0.0038640726402858648,"score_gpt":0.22955123426183963,"score_spread":0.22568716162155375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392813038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529295,0.04431361,0.00035935105,0.00044963523,0.00017809517,0.0009854952,0.00003438378,0.00004678007,0.0007031785],"genre_scores_gemma":[0.99825305,0.00065427413,0.0003986923,0.00031948934,0.00004131106,0.000062733394,0.000029175651,0.000048351954,0.00019291238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984392,0.000120775185,0.00035772758,0.0004693776,0.00023966884,0.00037323392],"domain_scores_gemma":[0.9994829,0.00006798298,0.00007068203,0.00022267658,0.000024316487,0.00013141223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000436881,0.0002849183,0.00066321157,0.00034870562,0.000024411867,0.000052279516,0.00007312777,0.000093651295,0.000015475756],"category_scores_gemma":[0.000033306387,0.0002483758,0.00008901786,0.0002704078,0.00010198392,0.00011003814,0.0000656137,0.0002264775,0.000006342729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020350268,0.0005885369,0.026128199,0.0010374675,0.0010114431,0.00069563603,0.0024033405,0.0000062319086,0.9476711,0.0021839775,0.00052213995,0.017548403],"study_design_scores_gemma":[0.027732272,0.00113617,0.11252557,0.0011534146,0.0025836409,0.000052211588,0.0005783666,0.0029860626,0.8129513,0.0011454773,0.03621386,0.00094164093],"about_ca_topic_score_codex":0.00018677939,"about_ca_topic_score_gemma":0.00004264102,"teacher_disagreement_score":0.1347198,"about_ca_system_score_codex":0.000043136322,"about_ca_system_score_gemma":0.00003412685,"threshold_uncertainty_score":0.99999684},"labels":[],"label_agreement":null},{"id":"W4392925853","doi":"10.1111/acem.14895","title":"<scp>SGLT</scp>‐2 inhibitors and <scp>GLP</scp>‐1 receptor agonists for Type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"Academic Emergency Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Receptor; Pharmacology; Agonist; Diabetes mellitus; Endocrinology; Internal medicine","score_opus":0.035431362292592285,"score_gpt":0.3285796683194881,"score_spread":0.2931483060268958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392925853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85923743,0.11241092,0.00005000052,0.003955486,0.0075693657,0.001684635,0.00003069423,0.000499825,0.014561672],"genre_scores_gemma":[0.74547786,0.08421004,0.00068093603,0.0020096595,0.008588504,0.0006567523,0.00097542093,0.00031884847,0.15708198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665314,0.00005012267,0.0009752691,0.0008538028,0.00057079573,0.0008968995],"domain_scores_gemma":[0.9980546,0.00070410036,0.00018266063,0.0003990898,0.0001666123,0.0004929346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008538094,0.00052986154,0.00076107105,0.00042921546,0.00015197683,0.000006645925,0.00022432912,0.00038958984,0.00026470126],"category_scores_gemma":[0.002212566,0.00040431466,0.00017490548,0.0008466669,0.0002289457,0.00023228607,0.00014345889,0.0006484175,0.00025447906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000839307,0.000075199845,0.057624042,0.0014862632,0.000717973,0.00001289111,0.0015377041,6.8212245e-7,0.017097978,0.001834767,0.91201127,0.0075928117],"study_design_scores_gemma":[0.0015695932,0.0015072944,0.006214425,0.0013405054,0.001423385,0.0000050706753,0.0009340556,0.0003479886,0.0058949264,0.0016681857,0.978986,0.00010852801],"about_ca_topic_score_codex":0.000019548645,"about_ca_topic_score_gemma":0.000003199824,"teacher_disagreement_score":0.14252031,"about_ca_system_score_codex":0.00011876045,"about_ca_system_score_gemma":0.000083244704,"threshold_uncertainty_score":0.99984086},"labels":[],"label_agreement":null},{"id":"W4392967297","doi":"10.2196/55976","title":"Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis","year":2024,"lang":"en","type":"article","venue":"JMIRx Med","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Adverse effect; Adverse Event Reporting System; Medicine; Internal medicine; Preprint; Oncology; Endocrinology","score_opus":0.009644240860508033,"score_gpt":0.2581385626380914,"score_spread":0.24849432177758335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392967297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513304,0.00023073283,0.000015465737,0.0012708743,0.00014828166,0.0011905887,0.000019655976,0.000114097165,0.0018772836],"genre_scores_gemma":[0.99481535,0.000044052416,0.0001182395,0.00007117576,0.00004535477,0.00021345483,0.00021003751,0.00002382003,0.0044585117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980282,0.00012270658,0.0005954816,0.0005102821,0.00046692588,0.00027637774],"domain_scores_gemma":[0.99903005,0.00011461148,0.0004009506,0.00027661116,0.00007185763,0.00010590862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010069109,0.0002403353,0.000478926,0.00026477603,0.00011117399,0.000040224284,0.00005737042,0.00007276849,0.000011102133],"category_scores_gemma":[0.00020948524,0.00015768583,0.00012665291,0.00082143175,0.000050389986,0.00015982919,0.00003951205,0.00018985046,0.0000074939358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038230946,0.00059529423,0.97899634,0.00060935866,0.006546741,0.00095022126,0.0068765767,0.000027103582,0.00035350374,0.0006111537,0.002782958,0.0012684342],"study_design_scores_gemma":[0.0031643563,0.0014862802,0.9743049,0.0012279571,0.00550884,0.0000774754,0.010008293,0.0017982958,0.00029377552,0.00003459724,0.0017549017,0.00034029357],"about_ca_topic_score_codex":0.00004438029,"about_ca_topic_score_gemma":0.0010968884,"teacher_disagreement_score":0.004691411,"about_ca_system_score_codex":0.0003884173,"about_ca_system_score_gemma":0.00009319847,"threshold_uncertainty_score":0.64302415},"labels":[],"label_agreement":null},{"id":"W4392987083","doi":"10.51793/os.2024.27.3.006","title":"Dynamics of chronic heart failure with a low ejection fraction when dapagliflozin is included in standard therapy","year":2024,"lang":"ru","type":"article","venue":"Лечащий врач","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Medicine; Diabetes mellitus; Endocrinology","score_opus":0.006829107804875607,"score_gpt":0.2542040534169471,"score_spread":0.24737494561207146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392987083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957853,0.013170422,0.0019061788,0.017278528,0.0012004311,0.0027861614,0.00017556515,0.00026333,0.0053663487],"genre_scores_gemma":[0.9926562,0.00175927,0.00043359454,0.00031994897,0.00035982465,0.00009083591,0.00020074628,0.00008375221,0.0040958435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978266,0.00008511,0.00046967767,0.00057234603,0.00058941846,0.00045689754],"domain_scores_gemma":[0.9991206,0.00007911072,0.00012471066,0.00047274827,0.00009956121,0.00010330472],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003790306,0.0003770872,0.0006373958,0.0005239349,0.0000670932,0.0000997996,0.00010699231,0.00020835151,0.0014162668],"category_scores_gemma":[0.000013314285,0.00030572506,0.00015626359,0.0006593746,0.0001058639,0.00034598392,0.000061800485,0.000407125,0.00017723138],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007836574,0.0062697055,0.22781035,0.012134564,0.010171609,0.00073032844,0.012401355,0.0007162468,0.015422564,0.007819925,0.18381676,0.51487],"study_design_scores_gemma":[0.03436708,0.028645134,0.036234293,0.0229719,0.0031086938,0.000041444582,0.006612126,0.109351836,0.05022154,0.0048425286,0.70132744,0.0022759915],"about_ca_topic_score_codex":0.0004277103,"about_ca_topic_score_gemma":0.0019475545,"teacher_disagreement_score":0.51751065,"about_ca_system_score_codex":0.0020574399,"about_ca_system_score_gemma":0.00037842087,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W4393004755","doi":"10.51731/cjht.2024.861","title":"Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Glucagon-like peptide-1; Pharmacology; Chemistry; Glucagon-like peptide 1 receptor; Receptor; Endocrinology; Internal medicine; Medicine; Diabetes mellitus; Type 2 diabetes; Agonist","score_opus":0.014926110689431131,"score_gpt":0.25872166032681004,"score_spread":0.2437955496373789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393004755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76337606,0.20769452,0.00014777954,0.025474347,0.0011323706,0.00082308694,0.00003637493,0.00019403541,0.0011214508],"genre_scores_gemma":[0.98826003,0.008947921,0.002016509,0.00022383039,0.000015192487,0.00001132352,0.000014318891,0.00002326862,0.00048762799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985553,0.000015206362,0.0006289991,0.00018561429,0.00019487563,0.0004199905],"domain_scores_gemma":[0.999339,0.000020576328,0.00019642491,0.00022555239,0.00006859312,0.00014985944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041820674,0.00017578561,0.00045425294,0.00080506026,0.00009792649,0.00003733091,0.00014644678,0.000103437575,0.000024989067],"category_scores_gemma":[0.000013652306,0.00014117538,0.0001180083,0.00032961692,0.00021003786,0.00014239026,0.00002675715,0.0002545684,0.0000071070576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039926388,0.00006124875,0.0046126544,0.0034781266,0.0006902716,0.0011919539,0.00041338126,0.0000010422779,0.0001344811,0.0035808184,0.017506573,0.9682895],"study_design_scores_gemma":[0.0018812686,0.0023544475,0.013892457,0.006446943,0.00048573056,0.00019960616,0.006365735,0.000022678836,0.006171325,0.0022100403,0.9596704,0.0002993197],"about_ca_topic_score_codex":0.0005459151,"about_ca_topic_score_gemma":0.0003898837,"teacher_disagreement_score":0.9679902,"about_ca_system_score_codex":0.00032813166,"about_ca_system_score_gemma":0.00058327604,"threshold_uncertainty_score":0.57569647},"labels":[],"label_agreement":null},{"id":"W4393114465","doi":"10.1080/14740338.2024.2335215","title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brain and Cognition Discovery Foundation; University of Toronto","funders":"","keywords":"Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Medicine; Receptor; Glucagon; Peptide; Agonist; Endocrinology; Pharmacology; Internal medicine; Biochemistry; Insulin; Chemistry; Diabetes mellitus; Type 2 diabetes","score_opus":0.008898181884863885,"score_gpt":0.2885847164336534,"score_spread":0.2796865345487895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393114465","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006342575,0.31949055,0.0000028004497,0.024894144,0.65190625,0.0011394317,0.00022347638,0.00025589662,0.0020240357],"genre_scores_gemma":[0.000032128846,0.57471734,0.00016808849,0.0005288665,0.40560102,0.00014011863,0.002450025,0.00013487002,0.016227549],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99583584,0.00016358292,0.0006795038,0.0015241613,0.0011551835,0.00064172305],"domain_scores_gemma":[0.9977825,0.00047027948,0.00022765866,0.00089489215,0.00015636075,0.0004682936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005399607,0.0009896485,0.0012313102,0.0003423069,0.00025361014,0.00064623944,0.00022103889,0.0008138267,0.00036727928],"category_scores_gemma":[0.00008283876,0.00079592265,0.00029020023,0.00024900504,0.00019825659,0.0003466951,0.0004031877,0.00096923433,0.0002816779],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005945816,0.00020820847,0.000008301099,0.000722454,0.00055571384,0.00003423336,0.0014169223,1.02993546e-7,0.000011457963,0.00049713167,0.74016374,0.25578716],"study_design_scores_gemma":[0.0029555832,0.0005449617,0.00003371158,0.0053992616,0.0001457338,0.0000038487274,0.0021678617,0.000008541936,0.000057643338,0.00007753925,0.9878928,0.0007124917],"about_ca_topic_score_codex":0.0000622224,"about_ca_topic_score_gemma":0.000016110678,"teacher_disagreement_score":0.25522676,"about_ca_system_score_codex":0.00048026728,"about_ca_system_score_gemma":0.0002373635,"threshold_uncertainty_score":0.9994492},"labels":[],"label_agreement":null},{"id":"W4393205026","doi":"10.1016/j.molmet.2024.101924","title":"GLP-1R signaling modulates colonic energy metabolism, goblet cell number and survival in the absence of gut microbiota","year":2024,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden; Vetenskapsrådet; Novo Nordisk; Knut och Alice Wallenbergs Stiftelse; National Research Foundation of Korea; Breakthrough T1D Canada; Fondation Leducq; European Foundation for the Study of Diabetes","keywords":"Gut flora; Energy metabolism; Goblet cell; Metabolism; Cell biology; Biology; Signal transduction; Immunology; Endocrinology; Genetics; Epithelium","score_opus":0.00646083267392354,"score_gpt":0.23071996744509277,"score_spread":0.22425913477116924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393205026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955983,0.038959626,0.0003675229,0.00059984217,0.0003145564,0.0003217201,0.000015160853,0.000041156763,0.0033974207],"genre_scores_gemma":[0.9968848,0.00088167854,0.0007242782,0.0005545395,0.00006751576,0.000039472532,0.00003457091,0.00003626608,0.0007768456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858236,0.0001364913,0.00030393488,0.00037181613,0.00028662325,0.0003187908],"domain_scores_gemma":[0.9994013,0.00007666783,0.000056000947,0.00035554092,0.000047174035,0.00006331548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038793476,0.00023632309,0.00046138142,0.00015116934,0.00003216572,0.00006742659,0.00016117464,0.00006706519,0.00007344456],"category_scores_gemma":[0.000017702443,0.00016666649,0.0001534143,0.0004403739,0.00008852989,0.00007332209,0.0001007278,0.0001411104,0.000019002655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033058102,0.0002822948,0.00062485784,0.00031445237,0.0004357198,0.00035367385,0.0008070798,0.000110857254,0.95655036,0.036265716,0.00051624485,0.0037056594],"study_design_scores_gemma":[0.0051879506,0.00014574445,0.05920342,0.00051201304,0.0030029803,0.000055754015,0.0006054821,0.0020592697,0.61804265,0.0055090287,0.30480644,0.000869302],"about_ca_topic_score_codex":0.00030270853,"about_ca_topic_score_gemma":0.000013611829,"teacher_disagreement_score":0.33850774,"about_ca_system_score_codex":0.00001885569,"about_ca_system_score_gemma":0.000047297723,"threshold_uncertainty_score":0.6796462},"labels":[],"label_agreement":null},{"id":"W4393229638","doi":"10.1016/j.jcjd.2024.03.004","title":"Real-world Use and Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Diabetes and Heart Failure: A Population-level Cohort Study in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Libin Cardiovascular Institute of Alberta; Canadian VIGOUR Centre; University of Alberta; Alberta Health; University of Calgary","funders":"Diabetes Canada; American Diabetes Association","keywords":"Medicine; Heart failure; Diabetes mellitus; Type 2 diabetes; Cohort; Cohort study; Population; Internal medicine; Intensive care medicine; Emergency medicine; Endocrinology; Environmental health","score_opus":0.008684257741114657,"score_gpt":0.21681254863073515,"score_spread":0.20812829088962048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393229638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732107,0.00057411764,4.800119e-8,0.0011960018,0.00012236103,0.0007043223,0.00003684674,0.000004041237,0.00004118906],"genre_scores_gemma":[0.9995004,0.000014953451,0.00011745811,0.00014189718,0.0000258937,0.000019335568,0.000023643524,0.000027220127,0.00012922873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985323,0.000043348173,0.0005639506,0.000232728,0.00025286913,0.00037482058],"domain_scores_gemma":[0.9989868,0.00022191,0.00013236719,0.00014438822,0.000075490054,0.00043903434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002612996,0.0002209744,0.0006855662,0.00087415363,0.00003164798,0.00005960183,0.000057382258,0.000041304036,0.000014650304],"category_scores_gemma":[0.00007105891,0.00017124358,0.00004551862,0.00042003294,0.00007242848,0.00029216474,0.000009219882,0.00018919178,2.0713361e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010981353,0.000074798445,0.9974335,0.00022539693,0.0003631456,0.00015149776,0.00056543155,0.000006253305,0.000011778872,0.000029173581,0.0004425595,0.00068549777],"study_design_scores_gemma":[0.0020023887,0.0004685197,0.9949159,0.0013760506,0.00028626723,0.0000011888906,0.0003921268,0.000047768895,0.0000910474,0.000016739385,0.00024579707,0.00015618216],"about_ca_topic_score_codex":0.80092424,"about_ca_topic_score_gemma":0.998309,"teacher_disagreement_score":0.19738476,"about_ca_system_score_codex":0.0002961448,"about_ca_system_score_gemma":0.0007207155,"threshold_uncertainty_score":0.6983111},"labels":[],"label_agreement":null},{"id":"W4393238646","doi":"10.1016/s2213-8587(24)00059-7","title":"How clinically relevant is statin-induced diabetes?","year":2024,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Disease; Blindness; Heart failure; Kidney disease; Statin; Type 2 diabetes; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.04807103858403257,"score_gpt":0.3062347696397802,"score_spread":0.25816373105574764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393238646","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07613976,0.003840027,0.0000024812366,0.90766805,0.0022824404,0.0015851266,0.00023850075,0.0007325397,0.007511036],"genre_scores_gemma":[0.018084146,0.0017169788,0.0005495775,0.9210825,0.01164298,0.000812881,0.0010324708,0.00031580712,0.044762652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926228,0.00034210065,0.0008738207,0.0014494642,0.0007185628,0.0039932807],"domain_scores_gemma":[0.9955794,0.001102734,0.00045738704,0.002543053,0.000155995,0.00016140426],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057723775,0.001063745,0.0025838916,0.00039225392,0.00015459208,0.00031437044,0.0010563256,0.0007876251,0.00040858204],"category_scores_gemma":[0.0002717381,0.00068689766,0.00074783055,0.00033650483,0.00042728367,0.00010507974,0.000753977,0.00414327,0.0023862913],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033014927,0.00009366602,0.0067068753,0.0011819694,0.0036822327,0.00089180766,0.00010369376,1.4268589e-7,0.00033561082,0.00033009297,0.9661982,0.020442665],"study_design_scores_gemma":[0.0019794987,0.0014062445,0.0011288275,0.00041759165,0.0032945813,0.000011643918,0.000031327574,0.00006441225,0.001269424,0.00420403,0.98553306,0.00065933564],"about_ca_topic_score_codex":0.000009566315,"about_ca_topic_score_gemma":0.0000025049958,"teacher_disagreement_score":0.05805562,"about_ca_system_score_codex":0.00021744914,"about_ca_system_score_gemma":0.00015080866,"threshold_uncertainty_score":0.9995582},"labels":[],"label_agreement":null},{"id":"W4393282613","doi":"10.1016/j.peptides.2024.171200","title":"Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut","year":2024,"lang":"en","type":"article","venue":"Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Ottawa","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Incretin; Biology; Enteroendocrine cell; Inflammation; Glucose homeostasis; Glucagon-like peptide-1; Gastric inhibitory polypeptide; Glucagon-like peptide-2; Internal medicine; Gut flora; Endocrinology; Hormone; Receptor; Type 2 diabetes; Endocrine system; Immunology; Diabetes mellitus; Insulin resistance; Medicine; Glucagon; Peptide","score_opus":0.007876188453088222,"score_gpt":0.23049406432311004,"score_spread":0.22261787587002183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140316,0.0041362797,0.00003312164,0.00044565785,0.00005715158,0.00017908594,0.0000010928995,0.000028800427,0.0037156376],"genre_scores_gemma":[0.9980801,0.00009192324,0.00069263356,0.000020054928,0.00006279199,0.00001001281,0.000006568925,0.0000063568277,0.0010295695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996747,0.000010015117,0.000103382496,0.00008599426,0.0000742997,0.000051655057],"domain_scores_gemma":[0.9998113,0.00003891865,0.000028410563,0.000089254754,0.000015795169,0.000016301954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010267317,0.00005446877,0.00007744241,0.00003791268,0.000035941142,0.000051004958,0.000016230882,0.000015255019,0.00001254526],"category_scores_gemma":[0.000008757921,0.000034116987,0.000016069627,0.00004445118,0.000039462888,0.00010312904,0.00002959755,0.000029998619,0.000004864824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045426867,0.00003308115,0.0076777623,0.0005817403,0.0002606782,0.000008278131,0.006520284,0.00006909352,0.7536571,0.007965736,0.00046286563,0.22271793],"study_design_scores_gemma":[0.0022202118,0.0006415881,0.22334202,0.0025995213,0.0012034348,0.00001616695,0.0055584083,0.041652523,0.66210026,0.016968597,0.04331632,0.0003809851],"about_ca_topic_score_codex":0.000018408555,"about_ca_topic_score_gemma":0.000003360298,"teacher_disagreement_score":0.22233695,"about_ca_system_score_codex":0.000010178186,"about_ca_system_score_gemma":0.000008449624,"threshold_uncertainty_score":0.13912503},"labels":[],"label_agreement":null},{"id":"W4393317209","doi":"10.1007/s11886-023-02016-z","title":"Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions","year":2024,"lang":"en","type":"article","venue":"Current Cardiology Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; St. Michael's Hospital; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Obesity; Intensive care medicine; Cardiology; Internal medicine","score_opus":0.02164449055669202,"score_gpt":0.3042007932557674,"score_spread":0.28255630269907533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393317209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849965,0.008713042,0.0015440484,0.0004767016,0.0016966984,0.001897673,0.00019536674,0.00014190676,0.00033807027],"genre_scores_gemma":[0.99660707,0.00077151426,0.00012374701,0.00010327132,0.00061266613,0.0003917948,0.00094409013,0.000027385779,0.0004184938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883455,0.000039649294,0.00018689515,0.00056340115,0.00006800811,0.00030750807],"domain_scores_gemma":[0.9994407,0.000053711534,0.00006994119,0.00020715501,0.00004201652,0.00018645066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020705219,0.00024101076,0.0004769357,0.000117546304,0.0001732602,0.00003714699,0.00002992714,0.00006275657,0.0000140165885],"category_scores_gemma":[0.000008610295,0.00015448178,0.00019047441,0.00006442757,0.000092328315,0.00009236633,0.00004175044,0.00010882726,0.0000010994523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011455661,0.00085492566,0.32401687,0.0016239,0.014920391,0.0014853979,0.0028691506,0.00022718821,0.003684906,0.0026300752,0.16345805,0.48308358],"study_design_scores_gemma":[0.00489876,0.003651407,0.115727484,0.00051748054,0.0078239385,0.00077156106,0.0012919337,0.0030150805,0.0016803229,0.0060520484,0.8536554,0.00091460656],"about_ca_topic_score_codex":0.000002909974,"about_ca_topic_score_gemma":0.0000013694473,"teacher_disagreement_score":0.69019735,"about_ca_system_score_codex":0.00003948061,"about_ca_system_score_gemma":0.00006515048,"threshold_uncertainty_score":0.62995845},"labels":[],"label_agreement":null},{"id":"W4393375870","doi":"10.3949/ccjm.91c.04001","title":"When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?","year":2024,"lang":"en","type":"letter","venue":"Cleveland Clinic Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Acute decompensated heart failure; Empagliflozin; Heart failure; Intensive care medicine; Narrative review; Dapagliflozin; Cardiology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.03634324587217065,"score_gpt":0.3123611375315169,"score_spread":0.27601789165934626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393375870","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.055695906,0.0023419925,0.000009894731,0.93791395,0.0021068582,0.0008470997,0.000020933792,0.000035772588,0.0010275703],"genre_scores_gemma":[0.055859216,0.0013387786,0.002162605,0.90799105,0.010951264,0.00003134871,0.00073786365,0.00032448597,0.020603398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99583834,0.00013468698,0.001726388,0.0004536773,0.0013009966,0.0005459149],"domain_scores_gemma":[0.997789,0.00041555823,0.00074396137,0.0004239273,0.0003752708,0.00025225963],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008643566,0.00058085157,0.0020112356,0.00094076915,0.00003386228,0.000032268166,0.00021590837,0.0006047895,0.0013591967],"category_scores_gemma":[0.00015761479,0.00032368253,0.00028977613,0.0003176989,0.00029810957,0.000116652904,0.00008247753,0.003144357,0.00016010339],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005758507,0.00021411016,0.050032996,0.00036484175,0.0025222818,0.0049522156,0.000237592,2.1353998e-7,0.0000020137413,0.0000023879943,0.9390655,0.002029984],"study_design_scores_gemma":[0.022296298,0.005740833,0.019171959,0.011056222,0.005088837,0.00023747062,0.00014424788,0.0000018290391,0.000009367979,0.0006240829,0.9352976,0.0003312546],"about_ca_topic_score_codex":0.000013600819,"about_ca_topic_score_gemma":0.000022612394,"teacher_disagreement_score":0.030861039,"about_ca_system_score_codex":0.0002352256,"about_ca_system_score_gemma":0.00034746205,"threshold_uncertainty_score":0.9999215},"labels":[],"label_agreement":null},{"id":"W4393379002","doi":"10.1002/ejhf.3221","title":"Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial","year":2024,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"Relypsa; Abbott Vascular; Cytokinetics; British Heart Foundation; Impulse Dynamics; Amarin Corporation; Servier; University of Glasgow; Moderna; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Amgen; Pfizer","keywords":"Empagliflozin; Medicine; Placebo; Heart failure; Body mass index; Internal medicine; Clinical endpoint; Meta-analysis; Ejection fraction; Cardiology; Clinical trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.07333315065106685,"score_gpt":0.32855112109828344,"score_spread":0.2552179704472166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393379002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010001464,0.97687227,0.0000072299085,0.010294286,0.00011256678,0.0024396833,0.000021186612,0.000012449663,0.00023884237],"genre_scores_gemma":[0.044853885,0.9464138,0.0010240331,0.00090104964,0.0010644813,0.00013168452,0.000047989557,0.00021650955,0.0053465646],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627477,0.0015354259,0.0008884426,0.000327363,0.000713777,0.00026023906],"domain_scores_gemma":[0.99868405,0.0002933389,0.00037556008,0.000452676,0.00007183474,0.00012252273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035287235,0.00047098257,0.0035109716,0.0005325104,0.0000870921,0.00028234,0.00030944005,0.00006190722,0.00005644839],"category_scores_gemma":[0.00007385576,0.00016246761,0.0021542115,0.00052613806,0.00011327748,0.00010050348,0.00015288452,0.0009175121,0.0000116732535],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02427883,0.0004633993,0.0014691022,0.004722534,0.88650846,0.0063283485,0.0012699689,0.0000116937645,5.205493e-7,0.00007547927,0.063369215,0.011502438],"study_design_scores_gemma":[0.020735499,0.0010612938,0.0003942384,0.00021112534,0.3967622,0.00007370225,0.00012868585,0.0000011338068,3.8322803e-8,0.0000015100148,0.58051926,0.00011131804],"about_ca_topic_score_codex":0.0000060670973,"about_ca_topic_score_gemma":0.000017664936,"teacher_disagreement_score":0.51715004,"about_ca_system_score_codex":0.000040451294,"about_ca_system_score_gemma":0.0000820591,"threshold_uncertainty_score":0.6625237},"labels":[],"label_agreement":null},{"id":"W4393410319","doi":"10.1111/ctr.15257","title":"Sociodemographic disparities in sodium‐glucose cotransporter‐2 inhibitor use among US kidney transplant recipients: An observational study of real‐world pharmacy records","year":2024,"lang":"en","type":"article","venue":"Clinical Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Hennepin Healthcare Research Institute; Health Resources and Services Administration; American Society of Nephrology; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Odds ratio; Diabetes mellitus; Kidney disease; Pharmacy; Medical prescription; Family medicine; Endocrinology; Pharmacology","score_opus":0.16662290803139226,"score_gpt":0.404024877586913,"score_spread":0.23740196955552076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393410319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634045,0.00007868525,0.00010370589,0.00035228237,0.0009876199,0.0014080212,0.00031064198,0.00015991127,0.00025870462],"genre_scores_gemma":[0.99156857,0.0043777595,0.0003303588,0.00032971677,0.00019294988,0.00015776083,0.0026167228,0.000042331085,0.00038384888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969988,0.00024119632,0.0013789412,0.0006039723,0.00047230357,0.00030482822],"domain_scores_gemma":[0.9988092,0.0004504032,0.00012492038,0.00026097154,0.00008216264,0.00027232766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007733911,0.0002767933,0.0005896465,0.00046440362,0.00006097265,0.000059861704,0.00011753389,0.000106113424,0.000083576866],"category_scores_gemma":[0.000023171118,0.00024802674,0.00025344468,0.00060804636,0.00017631955,0.0008209819,0.0000059029,0.00038096673,0.0000067360197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016315462,0.0039672647,0.986952,0.00070025225,0.00044458036,0.00037425754,0.0015314233,0.000018755716,0.0001836878,0.0002780104,0.00018052715,0.0037377146],"study_design_scores_gemma":[0.0073688184,0.0012002881,0.9863212,0.0013135449,0.0015470653,0.0000020224224,0.00010047825,0.0011313676,0.0003146912,0.00013013142,0.0003435654,0.00022682775],"about_ca_topic_score_codex":0.0018160762,"about_ca_topic_score_gemma":0.0051039015,"teacher_disagreement_score":0.005737272,"about_ca_system_score_codex":0.00005929236,"about_ca_system_score_gemma":0.00011519649,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W4393441758","doi":"10.1002/jcsm.13445","title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal of Cachexia Sarcopenia and Muscle","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Overweight; Medicine; Obesity; Thigh; Randomized controlled trial; Internal medicine; Physical therapy; Endocrinology; Anatomy; Diabetes mellitus; Type 2 diabetes","score_opus":0.015632021445549944,"score_gpt":0.30599285065979603,"score_spread":0.2903608292142461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393441758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948254,0.0015424725,0.000026085474,0.00079817156,0.0003590044,0.0014684345,0.00002526782,0.000019282095,0.0009358503],"genre_scores_gemma":[0.9973402,0.0013508776,0.0005396863,0.00015581565,0.00035970044,0.000019287047,0.000028382221,0.000024994584,0.00018106325],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974226,0.0005763406,0.001038685,0.00033647905,0.00041710772,0.00020882512],"domain_scores_gemma":[0.996637,0.0025397618,0.00036237965,0.00020215589,0.00006833985,0.00019038333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023652245,0.00024571505,0.0013551022,0.00026593867,0.000041347615,0.00006616977,0.00008010265,0.00012309312,0.000037216865],"category_scores_gemma":[0.0003387224,0.00013510422,0.0002523824,0.0001922597,0.00015385958,0.00021855824,0.00005741145,0.0003588177,0.0000042224065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86692035,0.0008085319,0.0006138923,0.00035408576,0.00062025385,0.0007513355,0.00082062976,0.0000041272115,0.00073427806,0.00006399091,0.00077793904,0.12753059],"study_design_scores_gemma":[0.92210156,0.019643584,0.043674104,0.006138695,0.0021768594,0.000023576977,0.00013062706,0.0008684518,0.0017161375,0.000119370976,0.0031813558,0.0002256774],"about_ca_topic_score_codex":0.00012340769,"about_ca_topic_score_gemma":0.000050763818,"teacher_disagreement_score":0.12730491,"about_ca_system_score_codex":0.00006156907,"about_ca_system_score_gemma":0.000078724835,"threshold_uncertainty_score":0.550939},"labels":[],"label_agreement":null},{"id":"W4393717858","doi":"10.1161/jaha.123.032296","title":"Time to SGLT2 Inhibitors Initiation in Patients With Heart Failure","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; St. Michael's Hospital; Health Sciences Centre; North York General Hospital; Sunnybrook Health Science Centre; University of Toronto; Toronto General Hospital; Women's College Hospital","funders":"Department of Medicine, University of Toronto; University of Toronto; Department of Family and Community Medicine, University of Toronto; Women's College Hospital; Ontario Ministry of Health and Long-Term Care; Canadian Institutes of Health Research; Sunnybrook Research Institute; Heart and Stroke Foundation of Canada","keywords":"Library science; Medicine; Gerontology; History","score_opus":0.004096796767777265,"score_gpt":0.23107186274651823,"score_spread":0.22697506597874095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393717858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791194,0.000017550832,0.0000032461967,0.020281585,0.00013787155,0.00025617532,0.0000022927081,0.000012938189,0.00016891661],"genre_scores_gemma":[0.9968995,0.0000016791926,0.0004835178,0.0016026106,0.00016075229,0.0000040246864,0.0000031649151,0.000012614136,0.0008321476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904025,0.00007499587,0.00022523601,0.000077777535,0.00044968154,0.0001320898],"domain_scores_gemma":[0.9995175,0.000074364245,0.00015514203,0.00007915055,0.000119878154,0.000053956097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003620757,0.000073239,0.00026652144,0.00019856871,0.00002536194,0.000035257337,0.00003694266,0.00001873958,0.000030573992],"category_scores_gemma":[0.00012972989,0.000044932847,0.000104501145,0.00055695657,0.000013094215,0.00014994259,0.000018965593,0.00013819349,0.000106221145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077972414,0.000121391844,0.91300327,0.0000095717605,0.000114169314,0.0000015770229,0.00015028844,0.00005027717,0.00025522124,0.000002013908,0.08515938,0.0010548916],"study_design_scores_gemma":[0.0006158878,0.0009718509,0.96370363,0.00025757618,0.00013234766,0.0000012744655,0.000052580996,0.000034177887,0.00019739308,0.0000118619955,0.033969622,0.000051793333],"about_ca_topic_score_codex":0.000010890283,"about_ca_topic_score_gemma":0.000006587188,"teacher_disagreement_score":0.051189765,"about_ca_system_score_codex":0.0007290074,"about_ca_system_score_gemma":0.000063046966,"threshold_uncertainty_score":0.1906329},"labels":[],"label_agreement":null},{"id":"W4393871692","doi":"10.1038/s41581-024-00827-z","title":"Combination therapy for kidney disease in people with diabetes mellitus","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Institute on Minority Health and Health Disparities; National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention; National Institute on Aging; National Institutes of Health","keywords":"Medicine; Diabetes mellitus; Kidney disease; Kidney; Mineralocorticoid receptor; Disease; Type 2 Diabetes Mellitus; Internal medicine; Type 2 diabetes; Intensive care medicine; Endocrinology; Bioinformatics; Pharmacology; Aldosterone","score_opus":0.019925787802651036,"score_gpt":0.32915707080435,"score_spread":0.309231283001699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393871692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016914666,0.9866207,0.0000048744237,0.0017262071,0.0004170174,0.010750277,0.00006458242,0.000076185635,0.00032323983],"genre_scores_gemma":[0.000010473263,0.98487645,0.0002679273,0.004634997,0.00026186617,0.005708547,0.0027462656,0.00010478166,0.001388661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976868,0.00021547283,0.00067058334,0.000755018,0.00018398042,0.0004881403],"domain_scores_gemma":[0.9986406,0.00016497966,0.00028537292,0.0005982651,0.000059406208,0.0002513926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047746304,0.0006624387,0.003285123,0.0005046125,0.000033737677,0.00003190984,0.00019428397,0.0006166266,0.00006794295],"category_scores_gemma":[0.00013380374,0.0003685818,0.0007645333,0.0007051509,0.000053524036,0.000057124216,0.000054231146,0.0008256799,0.00013927011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006976359,0.00035900617,0.00015993776,0.07232675,0.00067917444,0.00003135031,0.000015434825,2.8025635e-8,1.00359e-7,0.0022120979,0.035775106,0.8883712],"study_design_scores_gemma":[0.0014493709,0.0006838253,0.00010128452,0.02015883,0.0069679017,0.0000024250885,5.2868177e-7,0.000008896546,1.3103626e-7,0.00027576464,0.97005785,0.00029321783],"about_ca_topic_score_codex":0.0000015407285,"about_ca_topic_score_gemma":0.000012478081,"teacher_disagreement_score":0.9342827,"about_ca_system_score_codex":0.00021854004,"about_ca_system_score_gemma":0.0003398457,"threshold_uncertainty_score":0.9998766},"labels":[],"label_agreement":null},{"id":"W4393929733","doi":"10.1093/ckj/sfae100","title":"Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD)","year":2024,"lang":"en","type":"article","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca","keywords":"Dapagliflozin; Albuminuria; Medicine; Kidney disease; Diabetes mellitus; Creatinine; Internal medicine; Urology; Type 2 diabetes; Renal function; Urine; Kidney; Endocrinology","score_opus":0.03822317530964899,"score_gpt":0.34728320325350176,"score_spread":0.3090600279438528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393929733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110067,0.0017114735,0.000102811624,0.0036026612,0.0015432648,0.0010408243,0.00046644858,0.00011030181,0.00032155964],"genre_scores_gemma":[0.99166405,0.0006755125,0.00048034923,0.0010675202,0.0010870307,0.000067767985,0.0003000798,0.00009497197,0.0045627328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996662,0.00014934446,0.0011425052,0.0006115071,0.0006726982,0.00076193386],"domain_scores_gemma":[0.99571544,0.00022449136,0.0002972986,0.00058399653,0.00018320372,0.0029955748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036088403,0.00051470095,0.0010603537,0.00014276958,0.00015170498,0.00017227122,0.00020217184,0.00013450891,0.0008176357],"category_scores_gemma":[0.00039983678,0.0002987117,0.0006950499,0.0002068475,0.0003427292,0.00021872934,0.000092701855,0.0003688431,0.000095155076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008639797,0.0047171386,0.9237634,0.0004916437,0.0032034097,0.00020512905,0.00017601403,0.000005800445,0.000053872016,0.000044375654,0.019313736,0.047161527],"study_design_scores_gemma":[0.02246431,0.011191484,0.8550718,0.0031327622,0.0041836165,0.000005386034,0.000032127933,0.00076297345,0.000590041,0.0002056327,0.10183423,0.00052566035],"about_ca_topic_score_codex":0.0000023010514,"about_ca_topic_score_gemma":0.0000022257227,"teacher_disagreement_score":0.08252049,"about_ca_system_score_codex":0.0004952018,"about_ca_system_score_gemma":0.0008703477,"threshold_uncertainty_score":0.9999465},"labels":[],"label_agreement":null},{"id":"W4393986738","doi":"10.1111/dom.15588","title":"A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Meta-analysis; Medicine; Randomized controlled trial; Thyroid cancer; Oncology; Internal medicine; Cancer","score_opus":0.03499213468690576,"score_gpt":0.32371052415221996,"score_spread":0.2887183894653142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393986738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041336942,0.9805862,0.0000017937582,0.00042094907,0.00016284548,0.01726514,0.0010264624,0.000034946603,0.00008834923],"genre_scores_gemma":[0.00009107131,0.9927114,0.00012009616,0.00076293334,0.000041923962,0.0051578125,0.00023538733,0.00004943882,0.0008299256],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99082553,0.004071338,0.0034927567,0.00073188625,0.000525583,0.0003528844],"domain_scores_gemma":[0.99130964,0.0042303847,0.0033470788,0.0006844795,0.00018250292,0.00024588298],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011239682,0.0009864012,0.06786361,0.001075113,0.00007967821,0.00007083436,0.00015060019,0.00023450027,0.00009775719],"category_scores_gemma":[0.0019214075,0.0004902661,0.008157224,0.00073459453,0.0002615341,0.00005953028,0.00018177897,0.00032840925,0.0000046914947],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000450796,0.00018808652,0.0000050802196,0.49710518,0.49945903,0.0000013232255,0.00006718072,6.264077e-8,2.6710558e-7,0.0004268557,0.00048370444,0.0018124335],"study_design_scores_gemma":[0.032481134,0.00010217663,0.0000048324696,0.074992105,0.8586437,3.941661e-7,0.0000140562925,0.000015356665,0.0000035841747,0.000038228893,0.03341452,0.00028989074],"about_ca_topic_score_codex":0.0000993943,"about_ca_topic_score_gemma":0.000011719968,"teacher_disagreement_score":0.42211306,"about_ca_system_score_codex":0.000040927654,"about_ca_system_score_gemma":0.000086704924,"threshold_uncertainty_score":0.9997549},"labels":[],"label_agreement":null},{"id":"W4394004557","doi":"10.1016/j.npep.2024.102427","title":"Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis","year":2024,"lang":"en","type":"article","venue":"Neuropeptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"Canadian Institutes of Health Research","keywords":"Appetite; Weight loss; Addiction; Medicine; Peptide YY; Weight management; Obesity; Mood; Psychology; Pharmacology; Receptor; Endocrinology; Internal medicine; Psychiatry; Neuropeptide; Neuropeptide Y receptor","score_opus":0.044795001614241575,"score_gpt":0.28693633473667884,"score_spread":0.24214133312243727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394004557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891037,0.0024722551,0.000012027453,0.0010430039,0.00014140185,0.00050821534,0.000009731327,0.000040576913,0.00666911],"genre_scores_gemma":[0.9970701,0.0013078063,0.000052517324,0.00043485768,0.000034698256,0.000033003023,0.0000064034734,0.000030954325,0.0010296791],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988358,0.00013198746,0.00028330073,0.00029743067,0.0002498991,0.00020160682],"domain_scores_gemma":[0.99908364,0.00042567152,0.00007588064,0.00033880057,0.000029914663,0.00004607992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002671432,0.00017487387,0.00024198838,0.0001732918,0.00010010836,0.00005962487,0.00013021594,0.00003087484,0.000014122326],"category_scores_gemma":[0.000056739886,0.00009964658,0.00008492281,0.00032813905,0.00018268664,0.00012976903,0.00012070007,0.00017017171,0.0000031070774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047094582,0.001344759,0.18889678,0.0053537847,0.0013072804,0.0004519143,0.020833677,0.00016637602,0.560355,0.0121289445,0.03724258,0.17144793],"study_design_scores_gemma":[0.0019053138,0.0013076321,0.8981311,0.0016972477,0.0013343623,0.00013069401,0.0067193685,0.0010312017,0.013683833,0.00096192793,0.07274785,0.00034951346],"about_ca_topic_score_codex":0.000084254265,"about_ca_topic_score_gemma":0.00006821055,"teacher_disagreement_score":0.7092343,"about_ca_system_score_codex":0.000014088984,"about_ca_system_score_gemma":0.000027606085,"threshold_uncertainty_score":0.40634695},"labels":[],"label_agreement":null},{"id":"W4394014497","doi":"10.1161/circulationaha.124.069217","title":"Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial","year":2024,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto; Toronto General Hospital; University Health Network; Canadian VIGOUR Centre; University of Alberta; Women's College Hospital","funders":"HLS Therapeutics; Idorsia Pharmaceuticals; Novo Nordisk; Eisai; Moderna; MyoKardia; Amarin Corporation; Regeneron Pharmaceuticals; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Alnylam Pharmaceuticals; Sanofi; Amgen; Pfizer; Ironwood Pharmaceuticals, Incorporated","keywords":"Medicine; Empagliflozin; Myocardial infarction; Cardiology; Heart failure; Internal medicine; Clinical trial; Diabetes mellitus; Type 2 diabetes","score_opus":0.009270853414509537,"score_gpt":0.27262365770444297,"score_spread":0.2633528042899334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394014497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407166,0.00020218654,0.000035127312,0.003098728,0.0009995868,0.00095216447,0.000011980655,0.0000747581,0.0005537883],"genre_scores_gemma":[0.9987096,0.000005218839,0.00001759574,0.0003884042,0.00053196395,0.00010510031,0.00012782935,0.0000160397,0.00009825568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916494,0.00010058523,0.00017226515,0.00019034899,0.00027435023,0.00009749409],"domain_scores_gemma":[0.99937797,0.00027582643,0.00003087847,0.000257905,0.000019192856,0.000038242364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012259076,0.00013160915,0.0002463488,0.000087100525,0.000033565848,0.000043293105,0.000032539858,0.000068718204,0.00011399673],"category_scores_gemma":[0.000036569327,0.00007551592,0.00023454336,0.00014260811,0.000026259007,0.000102763515,0.000017121405,0.00009471335,0.00013904626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028703125,0.00043429006,0.88836205,0.00030876292,0.008979056,0.00009357493,0.004118604,0.00017694866,0.005049332,0.0011756587,0.026323242,0.03627538],"study_design_scores_gemma":[0.0143095255,0.0011947933,0.9678155,0.00019398052,0.0020512908,0.0000010884147,0.000028732999,0.0002812038,0.0014659744,0.00025651196,0.0122842565,0.00011711263],"about_ca_topic_score_codex":0.000019842519,"about_ca_topic_score_gemma":0.0000053334625,"teacher_disagreement_score":0.079453506,"about_ca_system_score_codex":0.000067035435,"about_ca_system_score_gemma":0.000020546167,"threshold_uncertainty_score":0.30794498},"labels":[],"label_agreement":null},{"id":"W4394014919","doi":"10.1016/j.jacc.2024.03.405","title":"Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction","year":2024,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Canadian VIGOUR Centre; University of Alberta; University of Toronto; Toronto General Hospital; University Health Network; St. Michael's Hospital; Women's College Hospital","funders":"Novo Nordisk; Sanofi; Novavax; Boehringer Ingelheim; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Empagliflozin; Medicine; Ejection fraction; Myocardial infarction; Hazard ratio; Internal medicine; Cardiology; Heart failure; Placebo; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.0029423095898512366,"score_gpt":0.22357439365939774,"score_spread":0.2206320840695465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394014919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954682,0.0010396697,0.0000720085,0.0022885667,0.000680477,0.00026349,0.000032996697,0.000007331778,0.00014725307],"genre_scores_gemma":[0.9991113,0.00021793495,0.000080815305,0.0001395603,0.0003449767,0.0000057927946,0.0000013141934,0.000010757929,0.00008753322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989025,0.00036077682,0.00029604955,0.00011147135,0.00021814126,0.00011107278],"domain_scores_gemma":[0.999164,0.00024160113,0.00026001027,0.00016644692,0.000115257295,0.00005267423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052110903,0.000115401235,0.0006940126,0.00021826045,0.000026897496,0.0000043536616,0.00004858324,0.00003954352,0.000009580054],"category_scores_gemma":[0.00014350508,0.000066115535,0.0003963606,0.0002262705,0.0002302915,0.000040657495,0.000034642337,0.00018424045,0.0000025065615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033851657,0.000037778034,0.9407547,0.00014939412,0.0040119253,0.00017732105,0.000024501705,0.00046612756,0.0010627263,0.00008418662,0.047334637,0.0025115153],"study_design_scores_gemma":[0.0015227223,0.010413282,0.8958945,0.0002396174,0.003493065,0.00059889635,0.00008976531,0.000027851684,0.0008425199,0.000117823314,0.086685106,0.00007481732],"about_ca_topic_score_codex":0.0000049397427,"about_ca_topic_score_gemma":9.577651e-7,"teacher_disagreement_score":0.044860184,"about_ca_system_score_codex":0.00005939455,"about_ca_system_score_gemma":0.000050199753,"threshold_uncertainty_score":0.26961133},"labels":[],"label_agreement":null},{"id":"W4394061375","doi":"10.1016/s0140-6736(24)00469-0","title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"American Regent; Gedeon Richter; HLS Therapeutics; Gilead Sciences; Servier; Deutsche Forschungsgemeinschaft; Novo Nordisk; Daiichi-Sankyo; National Institutes of Health; Regeneron Pharmaceuticals; Dexcom; British Heart Foundation; Cytokinetics; AstraZeneca; Amarin Corporation; National Heart, Lung, and Blood Institute; Sun Pharma; Boston Scientific Corporation; Bristol-Myers Squibb; U.S. Department of Defense; Eli Lilly and Company; National Institute on Aging; CSL Behring; Sanofi; Amgen; Pfizer; Alnylam Pharmaceuticals","keywords":"Heart failure with preserved ejection fraction; Medicine; Cardiology; Internal medicine; Semaglutide; Placebo; Heart failure; Ejection fraction; Type 2 diabetes; Diabetes mellitus; Endocrinology; Alternative medicine","score_opus":0.02032182835105762,"score_gpt":0.27326548560855085,"score_spread":0.25294365725749324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394061375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891487,0.0006508889,0.00012158684,0.0061227977,0.0001153353,0.0021158615,0.00001581223,0.00008179356,0.0016272721],"genre_scores_gemma":[0.9976662,0.000066396686,0.00026008327,0.00010190396,0.00009907253,0.00015002556,0.00003288614,0.00001875094,0.0016046747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984491,0.00041479093,0.00032784863,0.00027243767,0.00031633978,0.00021952363],"domain_scores_gemma":[0.9983608,0.00089118525,0.00014566614,0.0005117307,0.000046672416,0.0000439091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013066705,0.00018186914,0.0010721195,0.00020492848,0.00007737848,0.00006231569,0.00010451569,0.00006194393,0.00012858484],"category_scores_gemma":[0.00016408376,0.0000830661,0.0001613486,0.0013279286,0.00007008815,0.00008927631,0.000047819904,0.00022075133,0.0000061695523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15107286,0.0007260146,0.76165366,0.0009773939,0.048639946,0.00005523471,0.001947503,0.003281972,0.0015412997,0.0005926769,0.027936894,0.0015745191],"study_design_scores_gemma":[0.20715944,0.0015015859,0.70718926,0.0012510516,0.044871505,0.000009692206,0.0024838746,0.020643499,0.0012619399,0.000059319034,0.013186489,0.00038231825],"about_ca_topic_score_codex":0.00040127066,"about_ca_topic_score_gemma":0.004023693,"teacher_disagreement_score":0.05608658,"about_ca_system_score_codex":0.00008747605,"about_ca_system_score_gemma":0.000058796035,"threshold_uncertainty_score":0.33873373},"labels":[],"label_agreement":null},{"id":"W4394061861","doi":"10.1161/circulationaha.124.069568","title":"Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"Baylor University Medical Center; Universitair Medisch Centrum Groningen; University of Glasgow; Institut National de la Santé et de la Recherche Médicale; National Institutes of Health; Rijksuniversiteit Groningen; British Heart Foundation; Auris Health; University College London; Imperial College London; National Heart, Lung, and Blood Institute; Université de Lorraine; National Institute of Diabetes and Digestive and Kidney Diseases; Baylor University; AstraZeneca United States","keywords":"Medicine; Meta-analysis; Adverse effect; Transporter; Pharmacology; Internal medicine; Intensive care medicine; Biochemistry","score_opus":0.0577880962015906,"score_gpt":0.3140759364985228,"score_spread":0.2562878402969322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394061861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018845635,0.9957319,0.00012402775,0.00006868128,0.00020253376,0.002666951,0.00014976668,0.00011911358,0.000748594],"genre_scores_gemma":[0.0054397522,0.9903808,0.00016240097,0.00005896351,0.000086034386,0.0006372037,0.0022078552,0.000078117824,0.0009488663],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975115,0.00014158145,0.0007381236,0.00080360554,0.00055541744,0.00024974972],"domain_scores_gemma":[0.9986839,0.000055612025,0.00023233684,0.0007540305,0.00012040145,0.0001536763],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041908908,0.0006219195,0.0051082396,0.0008875208,0.00006786752,0.000061534345,0.00006719584,0.00025531737,0.0001303401],"category_scores_gemma":[0.00002007025,0.00041551286,0.006885031,0.0016313707,0.00005872824,0.00012005139,0.00004138577,0.00019967358,0.00014486388],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000044619337,0.00009287301,0.00084207975,0.012014445,0.88575506,0.0001987037,0.00016575499,0.0000137072675,1.4933269e-7,0.000117692485,0.0002004033,0.100594684],"study_design_scores_gemma":[0.00030420633,0.000018634722,0.00065123645,0.0002741704,0.6018582,0.0000026494995,0.000027254238,0.000013001215,3.7309553e-7,0.000013060898,0.39663178,0.00020543773],"about_ca_topic_score_codex":0.00003841423,"about_ca_topic_score_gemma":0.000027869006,"teacher_disagreement_score":0.39643136,"about_ca_system_score_codex":0.00022171656,"about_ca_system_score_gemma":0.00012926232,"threshold_uncertainty_score":0.99982965},"labels":[],"label_agreement":null},{"id":"W4394366993","doi":"10.6084/m9.figshare.4724671","title":"CIFAR10-DVS","year":2017,"lang":"en","type":"dataset","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.05765290908471378,"score_gpt":0.3268070152898326,"score_spread":0.2691541062051188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394366993","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.8133954e-7,0.00051098084,2.5250566e-9,0.00012759195,0.00014331307,0.0004922928,0.9868552,0.000052203806,0.011818153],"genre_scores_gemma":[0.0000020823875,0.00003656603,0.00000887864,0.0005320525,0.00047066607,0.00032206683,0.9825798,0.000020895899,0.016026972],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991122,0.0000069067764,0.00011957821,0.00028938567,0.00023285067,0.00023908837],"domain_scores_gemma":[0.9985113,0.000021996395,0.00015010446,0.0011471679,0.000050316816,0.000119108314],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000016864295,0.00023756865,0.00036592345,0.00009617811,0.00008044115,0.000081122984,0.00028649566,0.00019713584,0.48843458],"category_scores_gemma":[0.00038732315,0.000195959,0.00015133272,0.000027965318,0.000005179819,0.00004869542,0.00025124918,0.00019258357,0.07492777],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000070360834,0.00008296891,0.0000019966312,0.0010352433,0.00019570456,0.00035411987,0.0000011672287,2.0916179e-8,8.763629e-8,2.0718305e-7,0.9956367,0.0026847445],"study_design_scores_gemma":[0.0005331351,0.000120111334,0.00038908355,0.0041286126,0.0003050991,0.0000040172345,0.0000011112203,5.8950457e-7,0.000006060221,0.0000031193722,0.994336,0.00017305913],"about_ca_topic_score_codex":0.000011290836,"about_ca_topic_score_gemma":0.000015501633,"teacher_disagreement_score":0.4135068,"about_ca_system_score_codex":0.000056327168,"about_ca_system_score_gemma":0.00007140618,"threshold_uncertainty_score":0.9257925},"labels":[],"label_agreement":null},{"id":"W4394570526","doi":"10.1139/cjpp-2023-0464","title":"Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Weight loss; Medicine; Discontinuation; Exenatide; Internal medicine; Liraglutide; Pediatrics; Diabetes mellitus; Obesity; Endocrinology; Type 2 diabetes","score_opus":0.008484187340042365,"score_gpt":0.2715048878710269,"score_spread":0.26302070053098453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394570526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98040813,0.013733942,0.00007705344,0.004059108,0.00093559304,0.0003438498,0.00001849989,0.000008770082,0.00041505037],"genre_scores_gemma":[0.9949791,0.0004494632,0.00019823431,0.0009963331,0.0007359785,0.000021892558,0.0000064066317,0.000016309681,0.0025963222],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914646,0.00005437416,0.00020757757,0.00019335277,0.00003260417,0.0003656227],"domain_scores_gemma":[0.99919987,0.00016604576,0.000059518297,0.000053122545,0.00003897463,0.00048245935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016560285,0.0001568222,0.00037217693,0.00021387498,0.000060021648,0.000021988715,0.000052073134,0.000080140766,0.00041498768],"category_scores_gemma":[0.000012105062,0.00011051027,0.00009530882,0.000072337105,0.00017148294,0.00009300549,0.000013365379,0.00019543541,0.000005232461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045359666,0.00013331855,0.040335435,0.004457025,0.0067393268,0.010121712,0.0018648293,0.00004965681,0.50248134,0.0056891846,0.24901238,0.17457981],"study_design_scores_gemma":[0.022195831,0.0123242345,0.13728747,0.0017860008,0.0074742134,0.0022550141,0.00011793138,0.0013765062,0.104476206,0.031020591,0.6787319,0.00095409167],"about_ca_topic_score_codex":0.00013516925,"about_ca_topic_score_gemma":0.0004631752,"teacher_disagreement_score":0.42971954,"about_ca_system_score_codex":0.000057524543,"about_ca_system_score_gemma":0.000364833,"threshold_uncertainty_score":0.4543824},"labels":[],"label_agreement":null},{"id":"W4394598377","doi":"10.1007/s11606-024-08640-x","title":"Association Between SGLT2 Inhibitor Use and Change in Hemoglobin Among Adults with Diabetes: A Nationwide Cohort Study","year":2024,"lang":"en","type":"letter","venue":"Journal of General Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto; St. Michael's Hospital","funders":"Danish Cardiovascular Academy; Cilag; Sanofi Pasteur; Boston Scientific Corporation; Novo Nordisk; Gentofte Hospital; Sanofi; Hjerteforeningen; Seqirus; AstraZeneca; Amgen","keywords":"Medicine; Diabetes mellitus; Cohort study; Cohort; Hemoglobin; Type 2 diabetes; MEDLINE; Hemoglobin A; Gerontology; Internal medicine; Endocrinology","score_opus":0.019899908448599117,"score_gpt":0.2719562691190392,"score_spread":0.25205636067044007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394598377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83593684,0.00085667847,0.000003121152,0.16075265,0.00089948176,0.0013130722,0.000014598704,0.000018688148,0.00020484166],"genre_scores_gemma":[0.8554716,0.00044451968,0.00016779569,0.0996456,0.024198702,0.00013874393,0.00018362867,0.00011962498,0.01962978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663186,0.00014362726,0.0010588873,0.0003856243,0.0013914002,0.00038857924],"domain_scores_gemma":[0.9980166,0.00024188247,0.00095850555,0.0001969861,0.0004164214,0.0001695866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093898183,0.00043805546,0.0013580208,0.0011343167,0.000024790956,0.000088669716,0.00014840973,0.00030016567,0.00005518259],"category_scores_gemma":[0.0002591328,0.00027432395,0.00012634427,0.00031123625,0.00007339601,0.0003689234,0.00008920317,0.001709893,0.0000060321204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109322944,0.00010802951,0.6919342,0.00025431963,0.002589431,0.0023138567,0.00076864904,2.5476422e-7,0.000009624579,2.530772e-7,0.30089286,0.0010191695],"study_design_scores_gemma":[0.0062079467,0.0061325864,0.9382472,0.010395325,0.0045324424,0.00002654578,0.0001210663,0.00006469235,0.000034321,0.000012636438,0.033995815,0.00022943382],"about_ca_topic_score_codex":0.0009852388,"about_ca_topic_score_gemma":0.000370132,"teacher_disagreement_score":0.26689705,"about_ca_system_score_codex":0.00079982926,"about_ca_system_score_gemma":0.000048938247,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W4394739609","doi":"10.1136/gutjnl-2024-331976","title":"Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?","year":2024,"lang":"en","type":"letter","venue":"Gut","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Receptor; Medicine; Glucagon-like peptide-1; Ambiguity; Internal medicine; Endocrinology; Computer science; Diabetes mellitus","score_opus":0.047384587519916976,"score_gpt":0.31530435599396384,"score_spread":0.26791976847404686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394739609","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027722614,0.015941652,0.000015090941,0.94172746,0.004251413,0.0046489956,0.0003414242,0.0010193788,0.029282311],"genre_scores_gemma":[0.00086659676,0.0049465657,0.00026641294,0.25928468,0.0070296647,0.0006969706,0.001199933,0.00018795305,0.7255212],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616355,0.00008318323,0.0005155218,0.0013585319,0.000896037,0.0009832067],"domain_scores_gemma":[0.99757665,0.00019088849,0.00013540692,0.0015084273,0.000104296436,0.00048433492],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001737504,0.0008140612,0.0009338568,0.0005982129,0.000114335686,0.00023545077,0.000436941,0.00030897371,0.003800398],"category_scores_gemma":[0.00009651562,0.0006054296,0.00047879084,0.0006465777,0.000111391295,0.00016991599,0.00043849487,0.00088082836,0.016587688],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002688531,0.00010829639,0.00028283458,0.0048746523,0.0005343662,0.0066263517,0.00009341787,0.0000012518414,0.000055678618,0.000036475398,0.96970046,0.017417384],"study_design_scores_gemma":[0.00063395733,0.00076237734,0.0024392854,0.006698832,0.0030590105,0.0000056283297,0.000005267106,0.000015728952,0.00006447801,0.000027024871,0.9856728,0.0006156122],"about_ca_topic_score_codex":0.00077807816,"about_ca_topic_score_gemma":0.00068466435,"teacher_disagreement_score":0.69623893,"about_ca_system_score_codex":0.0021090747,"about_ca_system_score_gemma":0.00064460025,"threshold_uncertainty_score":0.9996397},"labels":[],"label_agreement":null},{"id":"W4394783940","doi":"10.31083/j.fbl2904145","title":"Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors","year":2024,"lang":"en","type":"article","venue":"Frontiers in Bioscience-Landmark","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Progenitor cell; Medicine; Diabetes mellitus; Stem cell; Vascular remodelling in the embryo; Internal medicine; Endocrinology; Cancer research; Bioinformatics; Cell biology; Biology","score_opus":0.009422401437946563,"score_gpt":0.2060370093117566,"score_spread":0.19661460787381005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394783940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96372294,0.02133738,0.005882622,0.00027624422,0.0037036089,0.00080922846,0.0000062433046,0.00013840369,0.004123308],"genre_scores_gemma":[0.9950309,0.00067017693,0.0026891534,0.000088146815,0.00017004716,0.00004262599,0.000021968528,0.000019608178,0.0012673769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985844,0.00003039612,0.00018951517,0.0005243429,0.00035099508,0.0003203342],"domain_scores_gemma":[0.99960333,0.000011460127,0.000021147222,0.0002223862,0.000018745968,0.00012293996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041801468,0.00017024955,0.00026628308,0.0003134473,0.000076728546,0.000099698496,0.00007065388,0.000091103866,0.000006218237],"category_scores_gemma":[0.000013232064,0.00013566454,0.00011999783,0.0005657502,0.000080687794,0.00019576031,0.000047153877,0.00014022007,0.000011711718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032989972,0.00067209447,0.3463763,0.0013200458,0.0011450574,0.00021568805,0.0012258322,0.00006885135,0.04200829,0.00012384684,0.20629527,0.4002188],"study_design_scores_gemma":[0.011378437,0.0034191418,0.034162816,0.0020386672,0.003581793,0.00003271981,0.004137868,0.07412039,0.054429866,0.002763363,0.8077175,0.002217461],"about_ca_topic_score_codex":0.000034242454,"about_ca_topic_score_gemma":0.0000010807935,"teacher_disagreement_score":0.6014222,"about_ca_system_score_codex":0.00011662654,"about_ca_system_score_gemma":0.00004836676,"threshold_uncertainty_score":0.55322397},"labels":[],"label_agreement":null},{"id":"W4394812762","doi":"10.1007/s11897-024-00655-z","title":"Putting More Weight on Obesity Trials in Heart Failure","year":2024,"lang":"en","type":"article","venue":"Current Heart Failure Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Weight loss; Medicine; Heart failure; Ejection fraction; Semaglutide; Obesity; Cardiac surgery; Clinical trial; Heart failure with preserved ejection fraction; Vascular surgery; Severe obesity; Body weight; Cardiology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.033463058618681006,"score_gpt":0.33591713294578335,"score_spread":0.30245407432710236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394812762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8976175,0.010212556,0.00008043518,0.080704905,0.005156853,0.0038264836,0.000016368045,0.00088053837,0.0015043167],"genre_scores_gemma":[0.99403435,0.0000814212,0.0029758113,0.00036904454,0.0010379285,0.00017713134,0.0001971768,0.00006406106,0.0010630515],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667096,0.00017143338,0.0011080873,0.0008495278,0.0006356864,0.0005642895],"domain_scores_gemma":[0.99863917,0.00025012015,0.00015483992,0.00064278126,0.00006185266,0.000251224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00217256,0.0003840463,0.0011059565,0.0004934692,0.000083907515,0.00013547747,0.00005558477,0.00014071245,0.00039051828],"category_scores_gemma":[0.00046183803,0.00029495585,0.0005124405,0.00053869735,0.00004904276,0.00019115387,0.000088850036,0.00049824594,0.00023498974],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036695696,0.00095513504,0.22113878,0.0011653398,0.00024948834,0.002023178,0.00023314114,0.000013197886,0.00079719455,0.00058702094,0.74234647,0.030454375],"study_design_scores_gemma":[0.00066862715,0.00018510128,0.02153095,0.0025241529,0.00028803336,0.00018854898,0.000052523785,0.000085654574,0.0018392878,0.0004543102,0.97194123,0.000241582],"about_ca_topic_score_codex":0.000019422703,"about_ca_topic_score_gemma":0.000021846794,"teacher_disagreement_score":0.22959478,"about_ca_system_score_codex":0.00025179525,"about_ca_system_score_gemma":0.00017019142,"threshold_uncertainty_score":0.99995023},"labels":[],"label_agreement":null},{"id":"W4394848199","doi":"10.1136/bmjopen-2023-077084","title":"Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study","year":2024,"lang":"en","type":"article","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Metformin; Internal medicine; Myocardial infarction; Type 2 diabetes; Sulfonylurea; Type 2 Diabetes Mellitus; Diabetes mellitus; Retrospective cohort study; Propensity score matching; Endocrinology; Insulin","score_opus":0.023070893783086053,"score_gpt":0.3081933258955875,"score_spread":0.28512243211250143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394848199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982512,0.0004948846,0.0000018653333,0.00006296688,0.000078510915,0.01298419,0.0000051040242,0.000015222955,0.0038452335],"genre_scores_gemma":[0.9982505,0.000045489935,0.00012620146,0.000050600232,0.000017842125,0.00054766313,0.0000484377,0.000015358208,0.0008979028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913675,0.000054175904,0.00018071679,0.00021839007,0.0003028615,0.00010711204],"domain_scores_gemma":[0.9995911,0.00002486497,0.000026160033,0.00026633486,0.000060123777,0.000031422896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006752008,0.00009302539,0.00034226663,0.00009794364,0.000016839334,0.000037539332,0.00005790993,0.000018930054,0.000044463886],"category_scores_gemma":[0.000026991798,0.00006244473,0.00003760566,0.00025984997,0.000017735636,0.00010680028,0.00009299497,0.000040752766,0.00000718051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047152027,0.0004864217,0.97682315,0.00006373316,0.0019249032,0.000018190442,0.00034942766,0.000008109047,0.0000023076655,0.000023426996,0.0002987653,0.019530049],"study_design_scores_gemma":[0.0065931766,0.0018787606,0.98667765,0.00019132993,0.00027801414,1.389747e-7,0.00013412618,0.000051854317,0.000024692385,0.000009211053,0.004084862,0.00007617249],"about_ca_topic_score_codex":0.0000863177,"about_ca_topic_score_gemma":0.000032402037,"teacher_disagreement_score":0.019453876,"about_ca_system_score_codex":0.00003695498,"about_ca_system_score_gemma":0.000051275423,"threshold_uncertainty_score":0.25464222},"labels":[],"label_agreement":null},{"id":"W4394869591","doi":"10.1016/j.jcjd.2024.04.009","title":"Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Type 2 Diabetes Mellitus; Pneumonia; Diabetes mellitus; Adverse effect; Internal medicine; Coronavirus disease 2019 (COVID-19); Type 2 diabetes; Respiratory system; Gastroenterology; Pharmacology; Endocrinology; Disease; Infectious disease (medical specialty)","score_opus":0.023093901325508176,"score_gpt":0.26478174846517044,"score_spread":0.24168784713966227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394869591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034187697,0.96254337,2.1212931e-7,0.00016596024,0.000063327476,0.0027286606,0.00027998327,0.000010386856,0.000020387179],"genre_scores_gemma":[0.05187014,0.94385755,0.00011344617,0.0026315937,0.000089476685,0.0003739541,0.00026606797,0.0002692265,0.00052857003],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99614483,0.0003764786,0.0018104452,0.00047637164,0.0006587874,0.00053310307],"domain_scores_gemma":[0.99593264,0.00024008943,0.0020931764,0.0004143383,0.00033790624,0.0009818239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014402212,0.000712562,0.006877793,0.0019371969,0.0000629779,0.000037948914,0.00017761988,0.00023229742,0.00006579083],"category_scores_gemma":[0.0002716697,0.00042415474,0.0009825922,0.0014959273,0.00013113904,0.00020215772,0.000023222305,0.0004395503,0.000004844083],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009050525,0.00012834405,0.27365533,0.5759358,0.14910598,0.000042144948,0.00018225552,0.0000012925698,1.586788e-7,0.000003863757,0.0003859876,0.00054983504],"study_design_scores_gemma":[0.0011752517,0.0012586772,0.002352008,0.102694824,0.87327856,9.219252e-7,0.00004503488,7.0850894e-7,0.0000018973242,0.0000049431874,0.01874445,0.000442729],"about_ca_topic_score_codex":0.00016006357,"about_ca_topic_score_gemma":0.003561612,"teacher_disagreement_score":0.7241726,"about_ca_system_score_codex":0.000834894,"about_ca_system_score_gemma":0.0011639864,"threshold_uncertainty_score":0.999821},"labels":[],"label_agreement":null},{"id":"W4394873253","doi":"10.1002/ejhf.3240","title":"Time to Clinical Benefit with Sotagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Insights from the SCORED Randomized Trial","year":2024,"lang":"en","type":"letter","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Anschutz Medical Campus, University of Colorado; University of Toronto; National Institutes of Health; Boston Scientific Corporation; Cleveland Clinic; St. Jude Medical; Pfizer; Daiichi Sankyo Europe; Duke Clinical Research Institute; School of Medicine, Duke University; Bristol-Myers Squibb","keywords":"Medicine; Randomized controlled trial; Kidney disease; Diabetes mellitus; Clinical trial; Type 2 diabetes; Disease; Heart failure; Intensive care medicine; Internal medicine; MEDLINE; Endocrinology","score_opus":0.008256180713946843,"score_gpt":0.2252649292296819,"score_spread":0.21700874851573504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394873253","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53612185,0.0025859426,0.0000012146224,0.45812273,0.0005727475,0.002389272,0.00004679323,0.000025337264,0.00013409332],"genre_scores_gemma":[0.13685784,0.0003380644,0.0037206272,0.8142998,0.030246608,0.00007540692,0.0020745806,0.0007735499,0.011613511],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970549,0.0007689935,0.0008392534,0.00039850216,0.0006340617,0.00030433407],"domain_scores_gemma":[0.99834716,0.00039630296,0.00032258258,0.00039964294,0.00017221636,0.00036210156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006859687,0.00039904926,0.0013479892,0.0002263043,0.000047967034,0.00013653476,0.00020067122,0.000082320716,0.00019591281],"category_scores_gemma":[0.0002499859,0.00018442757,0.00025819577,0.00021932156,0.00019521704,0.00009226659,0.00011618655,0.0012868387,0.00030146638],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16713925,0.00014361153,0.0031280345,0.00007996276,0.0014412204,0.0008824975,0.000072168375,0.0000033808553,9.640585e-7,7.6851165e-7,0.82659644,0.0005117345],"study_design_scores_gemma":[0.34551495,0.00418,0.006850186,0.0030867283,0.0019945875,0.0000013876925,0.0000041070844,0.0000073702818,7.5405984e-7,0.000010153824,0.6381729,0.00017683326],"about_ca_topic_score_codex":0.0000015588204,"about_ca_topic_score_gemma":0.0000028752136,"teacher_disagreement_score":0.39926404,"about_ca_system_score_codex":0.00008287385,"about_ca_system_score_gemma":0.0002641421,"threshold_uncertainty_score":0.7520738},"labels":[],"label_agreement":null},{"id":"W4394936471","doi":"10.1055/s-0044-1785400","title":"Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study","year":2024,"lang":"en","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"","keywords":"Overweight; Agonist; Obesity; Medicine; Endocrinology; Glucagon-like peptide 1 receptor; Internal medicine; Phase (matter); Receptor; Chemistry","score_opus":0.02966507264120679,"score_gpt":0.35705144420912993,"score_spread":0.32738637156792316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394936471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366695,0.000532309,0.000043462005,0.00018405502,0.0003116934,0.0031205807,0.000038407983,0.00023342593,0.0018690942],"genre_scores_gemma":[0.99665225,0.00005732328,0.0004143957,0.00006812733,0.0000461741,0.00047064445,0.00009364299,0.000056686626,0.0021407614],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99731475,0.00019824252,0.0005191154,0.00071731565,0.0004456254,0.0008049475],"domain_scores_gemma":[0.9986893,0.000355997,0.00011058045,0.00059012417,0.00005463131,0.0001993969],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000916227,0.00046896737,0.001133082,0.00037270578,0.00007226035,0.0000619736,0.00020536702,0.00013008303,0.0001965681],"category_scores_gemma":[0.00017511855,0.00028055406,0.00014588087,0.0008315534,0.00016220307,0.00020140244,0.00013503691,0.00030077636,0.00011922529],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008572186,0.014668996,0.82746893,0.00289922,0.003559165,0.0031216322,0.002218437,0.000023403387,0.0022067686,0.00026988215,0.0052868295,0.12970455],"study_design_scores_gemma":[0.11985368,0.31316358,0.29085502,0.0063291574,0.018481469,0.000026428374,0.0042293747,0.007209022,0.18454199,0.00026225447,0.051583007,0.0034650143],"about_ca_topic_score_codex":0.00018055078,"about_ca_topic_score_gemma":0.00026887,"teacher_disagreement_score":0.5366139,"about_ca_system_score_codex":0.00029540356,"about_ca_system_score_gemma":0.0001861116,"threshold_uncertainty_score":0.99996465},"labels":[],"label_agreement":null},{"id":"W4394953460","doi":"10.4103/arwy.arwy_5_24","title":"Glucagon-like Peptide-1 Receptor Agonists and Anaesthesia Considerations","year":2024,"lang":"en","type":"article","venue":"Airway","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Glucagon-like peptide-1; Glucagon; Receptor; Glucagon-like peptide 1 receptor; Peptide; Chemistry; Pharmacology; Medicine; Agonist; Internal medicine; Endocrinology; Diabetes mellitus; Insulin; Biochemistry; Type 2 diabetes","score_opus":0.01460738131183764,"score_gpt":0.2583349761140967,"score_spread":0.24372759480225908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394953460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86980397,0.007907342,0.000107184904,0.027398678,0.0008703928,0.00089359004,0.000014018526,0.00056871877,0.09243612],"genre_scores_gemma":[0.96385986,0.0004718589,0.0016029286,0.0012346667,0.000109323424,0.000045570836,0.000042833868,0.000021200112,0.03261173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994099,0.000012287247,0.00011087975,0.0002153088,0.0001004726,0.00015113674],"domain_scores_gemma":[0.9996769,0.000039225833,0.00001176288,0.0001611084,0.00002022464,0.000090765454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072423354,0.00010531263,0.00013623943,0.00008274676,0.00006927936,0.00008802837,0.000017615477,0.00003498274,0.00054276275],"category_scores_gemma":[0.000016688324,0.00008424988,0.000047908947,0.00008986159,0.000053547312,0.00008501722,0.000024759298,0.00006150387,0.00052593264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002804407,0.00024266088,0.006168155,0.00035868376,0.0006656961,0.00041087935,0.0010607551,0.000001966861,0.002399271,0.06169054,0.77568287,0.15129046],"study_design_scores_gemma":[0.00063762045,0.00047372546,0.005743761,0.00019546314,0.00031791092,0.000023075865,0.00011490721,0.00020910331,0.0016735134,0.0009382752,0.98951256,0.00016007584],"about_ca_topic_score_codex":0.000016626198,"about_ca_topic_score_gemma":0.000014116449,"teacher_disagreement_score":0.21382968,"about_ca_system_score_codex":0.000037241356,"about_ca_system_score_gemma":0.000043761982,"threshold_uncertainty_score":0.67599756},"labels":[],"label_agreement":null},{"id":"W4394996872","doi":"10.1101/2024.04.18.590099","title":"Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; NIHR Leicester Biomedical Research Centre; Medical Research Council; National Institutes of Health; Biotechnology and Biological Sciences Research Council; Rosetrees Trust; Canadian Institutes of Health Research; National Institute for Health and Care Research; UK Research and Innovation; British Heart Foundation; Wellcome Trust","keywords":"Dapagliflozin; Endocrinology; Internal medicine; Glucose homeostasis; Immune system; Cytokine; Downregulation and upregulation; Biology; Glucose transporter; Corticosterone; Knockout mouse; Type 2 diabetes; Insulin; Insulin resistance; Diabetes mellitus; Medicine; Receptor; Immunology; Hormone; Biochemistry","score_opus":0.02368510603787371,"score_gpt":0.23048865588409287,"score_spread":0.20680354984621915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394996872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548805,0.00034737453,0.00039931532,0.00020836251,0.0006853685,0.002506941,0.00005604056,0.00028743237,0.000021146925],"genre_scores_gemma":[0.9969868,0.00010976758,0.0013714435,0.000103458224,0.0002728962,0.0009849373,0.000004932511,0.00013809688,0.000027675507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99754804,0.000073726565,0.0005924469,0.0008521286,0.0005215983,0.00041208274],"domain_scores_gemma":[0.9985587,0.00010878402,0.00036106305,0.000614872,0.00020388208,0.00015269541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026493147,0.0005439302,0.00079899264,0.0007736254,0.000040885665,0.00008186044,0.00009842279,0.00027606272,0.00003140373],"category_scores_gemma":[0.000112456524,0.00045342368,0.00009540473,0.00069717935,0.000061016763,0.00015472814,0.0002384268,0.00055097044,0.000052558255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016934172,0.0009766737,0.0049303346,0.009191884,0.0007660435,0.0009355716,0.00007207172,0.00020956395,0.9800874,0.0010094321,0.00008096166,0.00004664434],"study_design_scores_gemma":[0.004092612,0.0015268945,0.2993305,0.0117243305,0.0010744804,3.0638187e-8,0.0000071915288,0.0004096351,0.68126094,0.000012594557,0.0000941351,0.00046666083],"about_ca_topic_score_codex":0.00006507962,"about_ca_topic_score_gemma":0.00001025937,"teacher_disagreement_score":0.29882646,"about_ca_system_score_codex":0.0006885268,"about_ca_system_score_gemma":0.00020279441,"threshold_uncertainty_score":0.99979174},"labels":[],"label_agreement":null},{"id":"W4395009555","doi":"10.14740/jmc4189","title":"Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetic nephropathy; Renal function; Internal medicine; Diabetes mellitus; Endocrinology; Nephrosclerosis; Kidney; Type 2 diabetes; Urology; Albuminuria; Cardiology","score_opus":0.010842630479548997,"score_gpt":0.24592374651370505,"score_spread":0.23508111603415605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395009555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214417,0.0025707663,0.00006122002,0.0036861007,0.0006155907,0.0002534873,0.0000024263031,0.000025572845,0.000640652],"genre_scores_gemma":[0.99716055,0.00032446513,0.00040619072,0.00097307155,0.00035727656,0.000017540247,0.000018977415,0.000024168543,0.000717747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979989,0.000028862127,0.00038862234,0.00017127961,0.0011676719,0.00024465594],"domain_scores_gemma":[0.9992585,0.000110018766,0.00012180727,0.000116272844,0.00011636123,0.00027704798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037362362,0.00016004307,0.0003197059,0.00022935234,0.000029623452,0.00005412487,0.00006670542,0.00006363313,0.00063413393],"category_scores_gemma":[0.00008864037,0.00008515474,0.00007354402,0.0003144872,0.00007864565,0.00012812125,0.000032570562,0.00031954373,0.000021269427],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071269125,0.0030509513,0.021514324,0.0013554362,0.0032912644,0.03816302,0.0007723871,0.00004225227,0.0024908516,0.00031617418,0.17164691,0.75022954],"study_design_scores_gemma":[0.012400377,0.12153595,0.009808397,0.014877283,0.0029380922,0.0019820004,0.002294164,0.0006445508,0.0060997913,0.000091150214,0.8267103,0.0006179892],"about_ca_topic_score_codex":0.00002022365,"about_ca_topic_score_gemma":0.00006499186,"teacher_disagreement_score":0.7496115,"about_ca_system_score_codex":0.00018855058,"about_ca_system_score_gemma":0.00035061978,"threshold_uncertainty_score":0.6943322},"labels":[],"label_agreement":null},{"id":"W4395010706","doi":"10.1101/2024.04.15.589662","title":"The Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin Inhibits Long QT 3 Late Sodium Currents in a Mutation Specific Manner","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Sodium channel; Long QT syndrome; Internal medicine; Endocrinology; Chemistry; Biophysics; Sodium; Pharmacology; Biology; Medicine; Diabetes mellitus; QT interval; Type 2 diabetes","score_opus":0.013118255517157078,"score_gpt":0.2308031895877809,"score_spread":0.2176849340706238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395010706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822846,0.009158142,0.000046823672,0.0012822114,0.0039315084,0.0026081854,0.00012959082,0.00047242813,0.000086525426],"genre_scores_gemma":[0.99590844,0.0014965798,0.00031972845,0.00022636718,0.0009047921,0.000682289,0.000009313498,0.00022770009,0.00022476955],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995741,0.00011810343,0.0010265685,0.0013868848,0.00077417097,0.0009532906],"domain_scores_gemma":[0.9976512,0.00006643382,0.00033493718,0.0013126283,0.00030178865,0.0003330185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007828867,0.0008803536,0.0008262066,0.0006548414,0.00017329404,0.00047076127,0.00038596522,0.00049266015,0.000061062026],"category_scores_gemma":[0.000045559816,0.00071684987,0.00034258154,0.0007928192,0.00017869532,0.00016456812,0.0005218374,0.0013485386,0.0006696715],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005155557,0.01433153,0.3653008,0.035225067,0.01394153,0.045689948,0.0019324536,0.00071343436,0.4404129,0.0099940235,0.06450958,0.0027931668],"study_design_scores_gemma":[0.009392101,0.00050452363,0.48212284,0.010735874,0.002591675,2.612284e-7,0.000042644162,0.0014533644,0.41804293,0.00008864218,0.072058216,0.0029669225],"about_ca_topic_score_codex":0.000033352124,"about_ca_topic_score_gemma":0.000028999153,"teacher_disagreement_score":0.11682202,"about_ca_system_score_codex":0.00068332464,"about_ca_system_score_gemma":0.00037668578,"threshold_uncertainty_score":0.9995283},"labels":[],"label_agreement":null},{"id":"W4395034924","doi":"10.1161/circ.144.suppl_1.9392","title":"Abstract 9392: Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A <i>Post Hoc</i> Analysis of SUSTAIN 6 and PIONEER 6","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"","keywords":"Medicine; Semaglutide; Post-hoc analysis; Post hoc; Gerontology; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Liraglutide","score_opus":0.007162486232941259,"score_gpt":0.22299672116063515,"score_spread":0.21583423492769388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395034924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901526,0.007913801,0.00052863854,0.00030306564,0.000013576657,0.00025642532,0.00001903241,0.000020452953,0.0007924191],"genre_scores_gemma":[0.9985559,0.00035608019,0.00032170452,0.00013056313,0.000008581804,0.000009698592,0.00039161646,0.000010938334,0.00021492789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992147,0.000025208486,0.00017619334,0.00023012233,0.0002339152,0.000119833545],"domain_scores_gemma":[0.999479,0.00003755418,0.00005846822,0.0002551703,0.00010571069,0.000064115295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015990323,0.000114198985,0.0004959103,0.00014949376,0.00003910583,0.000021060265,0.000015195183,0.00003751931,0.000024721356],"category_scores_gemma":[0.000028053737,0.000090094625,0.00016299298,0.00041041936,0.00004142173,0.00006879117,0.000022070599,0.00003950533,7.0029995e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008592841,0.00016443289,0.93741786,0.00022381179,0.02217672,0.00009517437,0.00037245644,0.0008209061,0.0024690547,0.00057951553,0.00007120415,0.035522923],"study_design_scores_gemma":[0.0016379502,0.00002601836,0.9829509,0.000020482008,0.011664741,0.0000028349427,0.00022850287,0.00022193952,0.00027833646,0.000016991906,0.0028619512,0.00008934623],"about_ca_topic_score_codex":0.00008280474,"about_ca_topic_score_gemma":0.000044141532,"teacher_disagreement_score":0.045533035,"about_ca_system_score_codex":0.000026430112,"about_ca_system_score_gemma":0.000022769917,"threshold_uncertainty_score":0.36739522},"labels":[],"label_agreement":null},{"id":"W4395446333","doi":"10.1136/bmj-2023-078242","title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","year":2024,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Type 2 diabetes; Adverse effect; Diabetes mellitus; Glucagon-like peptide-1; Internal medicine; Drug class; Endocrinology; Population; Glucagon-like peptide 1 receptor; Incidence (geometry); Cohort; Heart failure; Pharmacology; Drug; Receptor; Agonist","score_opus":0.0060778627814515405,"score_gpt":0.25575039053756154,"score_spread":0.24967252775611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395446333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952219,0.0008252242,0.00002766644,0.00008940193,0.00011562641,0.0035765215,0.00001052347,0.000040582254,0.00009256515],"genre_scores_gemma":[0.99917614,0.00013117408,0.00008546899,0.000010092437,0.000028862129,0.00023932947,0.00016740858,0.00002090141,0.00014059278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987457,0.000112360714,0.00028199004,0.00032385415,0.00042025518,0.00011586304],"domain_scores_gemma":[0.9994768,0.000072281466,0.000085251704,0.00026051074,0.000043864944,0.00006128026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005138034,0.00019606987,0.0004905783,0.0001581554,0.000034586003,0.000013012206,0.000023878394,0.0000415613,0.0000062535605],"category_scores_gemma":[0.000011047985,0.000134473,0.00010516039,0.00015175896,0.00003713078,0.00007924102,0.000011306992,0.000043936325,0.0000016246537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010856099,0.0008400597,0.9470254,0.0008277813,0.0024946386,0.00008922506,0.00030067813,0.00006717701,0.00056454,0.000012709272,0.00006967822,0.046622496],"study_design_scores_gemma":[0.008183373,0.025241615,0.9431297,0.0012709262,0.0040679253,0.000006271935,0.0000592113,0.00043986345,0.016887436,0.000005240704,0.0005383271,0.00017009646],"about_ca_topic_score_codex":0.00049571024,"about_ca_topic_score_gemma":0.000046861373,"teacher_disagreement_score":0.0464524,"about_ca_system_score_codex":0.00013834698,"about_ca_system_score_gemma":0.00003259152,"threshold_uncertainty_score":0.548365},"labels":[],"label_agreement":null},{"id":"W4395450286","doi":"10.54097/sdhqyz53","title":"The Role of Semaglutide in Weight Management: An Analysis of Clinical Studies for Overweight and Obese Adults","year":2024,"lang":"en","type":"article","venue":"Journal of Education Humanities and Social Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Overweight; Weight management; Medicine; Body weight; Obesity; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Liraglutide","score_opus":0.06664134688054688,"score_gpt":0.419649146969118,"score_spread":0.35300780008857113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395450286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823425,0.014577844,0.000001430787,0.00068499823,0.00023449949,0.00011850022,0.0000021784317,0.0000013882651,0.0020366863],"genre_scores_gemma":[0.9940614,0.005042213,0.00018424293,0.00005886669,0.00014991104,0.0000056026447,0.0000010657575,0.0000016593705,0.00049502536],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.999297,0.000031570922,0.000369817,0.00007559508,0.00015780391,0.00006818016],"domain_scores_gemma":[0.99945986,0.00020255742,0.00018014922,0.000029732098,0.00011327487,0.000014436293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078944524,0.000043578322,0.00024223694,0.00023443747,0.00013922802,0.000040608145,0.000051985295,0.000014162414,0.000006574971],"category_scores_gemma":[0.000030600764,0.000024976462,0.00008831572,0.0001848676,0.00034925397,0.00012244468,0.000018456674,0.000031555715,3.6710937e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019874475,0.0006838038,0.1605669,0.00071580557,0.003476297,0.00000275156,0.04102584,0.0000037949312,0.000010039279,0.40911627,0.0014505301,0.38274923],"study_design_scores_gemma":[0.0008834574,0.001611321,0.5154976,0.0005558423,0.0037493184,0.0000013972381,0.39593393,0.0010231287,0.00003447466,0.024426423,0.056184478,0.000098589684],"about_ca_topic_score_codex":0.000024522056,"about_ca_topic_score_gemma":0.00018222391,"teacher_disagreement_score":0.38468984,"about_ca_system_score_codex":0.000018265966,"about_ca_system_score_gemma":0.00006581381,"threshold_uncertainty_score":0.12868409},"labels":[],"label_agreement":null},{"id":"W4395464280","doi":"10.1111/acem.14922","title":"Metformin for Type 2 diabetes mellitus","year":2024,"lang":"en","type":"review","venue":"Academic Emergency Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metformin; Type 2 Diabetes Mellitus; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.14530295657496833,"score_gpt":0.440479078524952,"score_spread":0.29517612194998366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395464280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010602098,0.9821092,0.000010784892,0.00046603827,0.0059831156,0.0035063908,0.000039598846,0.00026355262,0.007610748],"genre_scores_gemma":[0.0000021539133,0.94377536,0.00013069615,0.00014969936,0.0033514984,0.0009387126,0.0014626588,0.00019653497,0.049992677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960104,0.000046275032,0.001837797,0.0008446137,0.0004916609,0.0007692051],"domain_scores_gemma":[0.99830794,0.00017191524,0.0004269619,0.00063200475,0.00013215993,0.00032902622],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008479255,0.0008555555,0.0031063366,0.00066416233,0.00006372298,0.0000012169236,0.00036815193,0.00069327356,0.0015931488],"category_scores_gemma":[0.0004892251,0.0005145529,0.00080731884,0.0010856725,0.00010721282,0.00007525915,0.00014605724,0.00095093175,0.0008857599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007541254,0.000031783096,0.000017609578,0.057473354,0.0018796095,0.000009897866,0.000053397835,1.5284126e-8,0.0000012097461,0.0011997046,0.34141874,0.5979071],"study_design_scores_gemma":[0.00045223435,0.0008028424,0.0000011312371,0.029697176,0.03771136,0.000006487777,0.000025124482,0.000012640735,0.0000022470576,0.0009350476,0.92996764,0.00038609144],"about_ca_topic_score_codex":0.0000056727076,"about_ca_topic_score_gemma":8.024504e-7,"teacher_disagreement_score":0.59752107,"about_ca_system_score_codex":0.00021600028,"about_ca_system_score_gemma":0.00018216371,"threshold_uncertainty_score":0.9998922},"labels":[],"label_agreement":null},{"id":"W4395482332","doi":"10.1016/j.ahj.2024.04.007","title":"Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort","year":2024,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; Canadian Patient Safety Institute; Alberta Health Services; Alberta Health; University of Alberta","funders":"","keywords":"Medicine; Cohort; Diabetes mellitus; Heart failure; Population; Cohort study; Internal medicine; Randomized controlled trial; Endocrinology; Environmental health","score_opus":0.008463948395159626,"score_gpt":0.27396551374238426,"score_spread":0.26550156534722463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395482332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757504,0.00034433385,0.000003189337,0.0014303869,0.000054687087,0.0005155844,0.0000071978266,0.000017587015,0.00005201438],"genre_scores_gemma":[0.9968823,0.000055395118,0.0024048106,0.0005026294,0.000036179845,0.0000149660555,0.000014911029,0.000019049348,0.000069729846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989316,0.000047248865,0.0003407538,0.00021797288,0.00025829204,0.00020415409],"domain_scores_gemma":[0.99948424,0.00013769865,0.000079749116,0.00010512136,0.000040279003,0.00015292906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028727562,0.00014840331,0.0006015881,0.00023920329,0.00004534422,0.00005841119,0.00001913961,0.00002305417,0.000056336874],"category_scores_gemma":[0.000046479414,0.00010372318,0.000052360978,0.00020327311,0.0001613997,0.00009504971,0.000020295147,0.00014173765,0.0000019207175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077901655,0.0001239888,0.9943074,0.00005518212,0.00027977893,0.0000074846375,0.00004400155,6.026043e-7,0.000013431219,0.000007391296,0.0005191244,0.004563741],"study_design_scores_gemma":[0.0019683759,0.001204802,0.9941768,0.00023464666,0.0002984664,0.0000041205376,0.00005986967,0.00007451394,0.000008192179,0.000024284798,0.0018485034,0.00009740571],"about_ca_topic_score_codex":0.00008333186,"about_ca_topic_score_gemma":0.000032467746,"teacher_disagreement_score":0.0044663353,"about_ca_system_score_codex":0.000041801493,"about_ca_system_score_gemma":0.000047869675,"threshold_uncertainty_score":0.42297083},"labels":[],"label_agreement":null},{"id":"W4395664929","doi":"10.1016/j.amjcard.2024.04.041","title":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"The American Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; McGill University","keywords":"Semaglutide; Meta-analysis; Medicine; Randomized controlled trial; Type 2 diabetes; Diabetes mellitus; Weight loss; Term (time); Internal medicine; Liraglutide; Endocrinology; Obesity","score_opus":0.045439424887022725,"score_gpt":0.3596702672122795,"score_spread":0.3142308423252568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395664929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017861833,0.98498094,0.0000702007,0.00024905108,0.000058983023,0.012733747,0.00008826955,0.000003440259,0.000029212191],"genre_scores_gemma":[0.0100467615,0.98889065,0.0000863624,0.000111511756,0.00004701899,0.00066301046,0.000028118568,0.000030365884,0.000096223994],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98671776,0.00690236,0.0055545783,0.00026514367,0.00032731064,0.00023287501],"domain_scores_gemma":[0.9803185,0.009683747,0.0091339415,0.0004617841,0.00031151777,0.00009054441],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.016366657,0.00049967755,0.08923081,0.00088268047,0.000016975311,0.000009739347,0.00021677802,0.00007064199,0.0000074224426],"category_scores_gemma":[0.003967352,0.00018774628,0.011634226,0.0006035082,0.00059982965,0.000022754986,0.000077130426,0.0002210218,4.4801598e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011760291,0.000053870597,0.00021923614,0.2624958,0.7185009,0.000009494927,0.000031703436,0.0000022247211,6.111954e-8,0.000016740054,0.00003371257,0.0068759946],"study_design_scores_gemma":[0.063907616,0.00091791956,0.00009685034,0.04321294,0.891407,0.000013871738,0.000007808625,0.0000035174255,7.941462e-8,0.000010340648,0.00030825238,0.000113776645],"about_ca_topic_score_codex":0.0000018250392,"about_ca_topic_score_gemma":4.4473924e-7,"teacher_disagreement_score":0.21928284,"about_ca_system_score_codex":0.0000670626,"about_ca_system_score_gemma":0.00011095466,"threshold_uncertainty_score":0.998264},"labels":[],"label_agreement":null},{"id":"W4396224566","doi":"10.1002/ejhf.3262","title":"Association of Sodium–Glucose Cotransporter 2 Inhibitors with Changes in Comprehensive Geriatric Assessment in Elderly Diabetic Patients with Heart Failure: Data from MAGIC-HF","year":2024,"lang":"en","type":"letter","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.01173644313318142,"score_gpt":0.22884546109070278,"score_spread":0.21710901795752136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396224566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56051147,0.0006609746,0.000008013692,0.43690163,0.0004052223,0.0010555194,0.0002990614,0.000024023784,0.00013410849],"genre_scores_gemma":[0.84806913,0.00037164736,0.027357671,0.10580174,0.0054205754,0.000032600434,0.009841416,0.0006506733,0.0024545712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604136,0.00055345806,0.0010162339,0.00058566075,0.0012914664,0.00051179685],"domain_scores_gemma":[0.99786794,0.00015664256,0.00085120124,0.0006552234,0.0003432763,0.00012569096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060386525,0.00053856015,0.0013257123,0.00091838336,0.000027388078,0.00009619587,0.00033423063,0.00018041465,0.00014484304],"category_scores_gemma":[0.000018044102,0.0003810166,0.00014693636,0.0005329275,0.000063220745,0.00028176652,0.00012657043,0.0021298768,0.000047053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016322502,0.00034059788,0.29274264,0.00043986255,0.0006956705,0.0014016206,0.0001442587,0.000005772292,0.00009211397,2.4724773e-7,0.7037371,0.00023691039],"study_design_scores_gemma":[0.0063792462,0.0028204508,0.2963155,0.0033164485,0.0013110079,0.0000100833095,0.00013215038,0.0000056809076,0.00006924991,0.0000037176394,0.68931985,0.0003166304],"about_ca_topic_score_codex":0.00004300094,"about_ca_topic_score_gemma":0.0003483218,"teacher_disagreement_score":0.3310999,"about_ca_system_score_codex":0.00036735507,"about_ca_system_score_gemma":0.00019885307,"threshold_uncertainty_score":0.99986416},"labels":[],"label_agreement":null},{"id":"W4396227861","doi":"10.1503/cmaj.231411","title":"Deprescribing diabetes medications for older adults living with frailty","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Trillium Health Centre; Thompson Rivers University; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC; Diabetes Canada","keywords":"Glycemic; Medicine; Life expectancy; Diabetes mellitus; Deprescribing; Intensive care medicine; Polypharmacy; Adverse effect; Gerontology; Internal medicine; Endocrinology; Environmental health; Population","score_opus":0.007865512474686854,"score_gpt":0.23680108238058165,"score_spread":0.22893556990589478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396227861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7825529,0.0057507926,0.00381253,0.18370351,0.0027237318,0.0016913641,0.00008436512,0.00030756902,0.019373232],"genre_scores_gemma":[0.9880362,0.000093675066,0.00083399663,0.0065160096,0.0015850896,0.00010535067,0.00004668262,0.000035992827,0.0027470132],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998132,0.00003467725,0.00026299155,0.00019496116,0.0008383617,0.00053699827],"domain_scores_gemma":[0.99790484,0.00038801276,0.000068605426,0.0000969869,0.00023015293,0.0013114177],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00094959117,0.000120937904,0.00019446985,0.00025490898,0.00021712214,0.00014804746,0.00009850747,0.00016878262,0.0018587512],"category_scores_gemma":[0.00070371333,0.000091045185,0.000105598774,0.00023384555,0.000026306736,0.00014856341,0.000010933111,0.00040118428,0.000073202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009659093,0.00012579313,0.25017622,0.00028149222,0.002578716,0.00030100535,0.0013624147,0.0000026034468,0.000007676988,0.0011804726,0.22771989,0.51625407],"study_design_scores_gemma":[0.0030510651,0.0003967548,0.27611038,0.0066620647,0.0013700475,0.00010820941,0.0013478631,0.006925582,0.000040809235,0.0001804779,0.70343715,0.00036960523],"about_ca_topic_score_codex":0.00022255555,"about_ca_topic_score_gemma":0.0049378,"teacher_disagreement_score":0.51588446,"about_ca_system_score_codex":0.0008580579,"about_ca_system_score_gemma":0.0019340918,"threshold_uncertainty_score":0.99905366},"labels":[],"label_agreement":null},{"id":"W4396229502","doi":"10.2196/56067","title":"Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Medicine; Kidney disease; Type 2 diabetes; Randomized controlled trial; Disease; Diabetes mellitus; Crossover study; Clinical trial; Protocol (science); Internal medicine; Alternative medicine; Endocrinology; Pathology; Placebo","score_opus":0.061935422734971705,"score_gpt":0.47344381796174284,"score_spread":0.41150839522677113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396229502","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009616728,0.0006159424,0.0000108164095,0.001054362,0.000015410113,0.98834574,0.000066803244,0.000105484185,0.00016868583],"genre_scores_gemma":[0.012983561,0.000024209781,0.00014965527,0.00008584478,0.0002582815,0.9835937,0.000064478176,0.00010036802,0.0027399187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945516,0.0015394042,0.0010502574,0.0008883382,0.00095690903,0.0010134702],"domain_scores_gemma":[0.99512655,0.002664155,0.00024714676,0.0006210948,0.0003115361,0.0010294928],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0058238492,0.0005131391,0.0030360352,0.0008574806,0.00012830386,0.00037597594,0.00021439706,0.0001180214,0.00009944492],"category_scores_gemma":[0.008801718,0.00029252813,0.0003685254,0.00070675625,0.0007760294,0.00027673223,0.00025292343,0.00037337205,0.000008250154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78948057,0.0024094104,0.013650457,0.15811157,0.0031579146,0.00014846156,0.00027518955,0.000002589293,0.0038805003,0.0010700922,0.022341883,0.0054713427],"study_design_scores_gemma":[0.86147285,0.008211673,0.0026844947,0.054977156,0.0009658547,6.449201e-7,0.0000098268965,0.0051420447,0.002890459,0.0010640491,0.062139854,0.00044112178],"about_ca_topic_score_codex":0.000009411772,"about_ca_topic_score_gemma":0.0000049282908,"teacher_disagreement_score":0.103134416,"about_ca_system_score_codex":0.0003887007,"about_ca_system_score_gemma":0.0038871625,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W4396241885","doi":"10.1016/j.jcjd.2024.04.011","title":"Basal Insulin Initiation in Adults With Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using Administrative Health Data in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Novo Nordisk Canada; Novo Nordisk; Alberta Precision Laboratories; Government of Alberta","keywords":"Medicine; Retrospective cohort study; Basal (medicine); Cohort; Basal insulin; Diabetes mellitus; Type 2 Diabetes Mellitus; Gerontology; Demography; Type 2 diabetes; Internal medicine; Endocrinology","score_opus":0.026394081995066397,"score_gpt":0.28497445206391914,"score_spread":0.25858037006885276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396241885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933157,0.0038432584,6.5301407e-7,0.0011593514,0.00032466487,0.0008986424,0.000079476136,0.00000488711,0.00037334612],"genre_scores_gemma":[0.99910897,0.000042713276,0.0001327371,0.00041505566,0.00010079265,0.000011059705,0.0001225366,0.0000299176,0.00003624091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812716,0.00011854614,0.0005551009,0.0003417628,0.0003472215,0.0005101802],"domain_scores_gemma":[0.9987075,0.00013706702,0.0002240519,0.00030197034,0.00015760193,0.0004718138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065684214,0.00021429175,0.0006010421,0.0006237129,0.00005180022,0.000071524395,0.00018827822,0.000044048036,0.000051445022],"category_scores_gemma":[0.0002759657,0.00017761985,0.000028177448,0.0008410396,0.000051740157,0.0003615244,0.000023679087,0.00033881515,0.0000017573566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023877825,0.0001232909,0.9953891,0.00014802467,0.00039633553,0.00039340372,0.0013922267,0.00002148959,0.0000014494451,0.000029884639,0.0007674036,0.0013135049],"study_design_scores_gemma":[0.0016198612,0.002090309,0.9904305,0.0021854595,0.00017608957,0.0000020129057,0.0016853993,0.0012010675,0.000021452603,0.000041552423,0.0003795021,0.0001668063],"about_ca_topic_score_codex":0.6199573,"about_ca_topic_score_gemma":0.9943581,"teacher_disagreement_score":0.37440076,"about_ca_system_score_codex":0.0022479848,"about_ca_system_score_gemma":0.009446714,"threshold_uncertainty_score":0.9961688},"labels":[],"label_agreement":null},{"id":"W4396580817","doi":"10.1016/j.euo.2024.04.006","title":"Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers","year":2024,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"American Urological Association; UroGen Pharma; Bladder Cancer Advocacy Network","keywords":"Medicine; Internal medicine; Prostate; Oncology; Urology; Endocrinology; Cancer","score_opus":0.012779636498212742,"score_gpt":0.2633122084156718,"score_spread":0.2505325719174591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396580817","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010473938,0.0018615553,0.0000026813896,0.86186117,0.0010465479,0.0008008478,0.00010531801,0.00018637405,0.12366156],"genre_scores_gemma":[0.008035988,0.0012474247,0.00015347695,0.87071204,0.004245444,0.000059550588,0.0014811741,0.00015687563,0.113908015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771523,0.00047254915,0.0003495537,0.0007304688,0.00017198132,0.0005602253],"domain_scores_gemma":[0.999052,0.00024478862,0.00023222982,0.00024644367,0.000053997046,0.00017055597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048176514,0.00036907307,0.0007521047,0.00026102707,0.00007839816,0.000046769535,0.00009275668,0.00060081005,0.000116727526],"category_scores_gemma":[0.00012542724,0.00032495908,0.00007835778,0.00009805884,0.00023726192,0.00003848671,0.00027676308,0.00136124,0.00040430148],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039289058,0.000022397984,0.016620958,0.0002471311,0.0024786603,0.003579268,0.00024420393,1.0717233e-7,0.000008630558,0.000015156083,0.9649486,0.011795587],"study_design_scores_gemma":[0.0018503538,0.0019712185,0.020319274,0.00003786798,0.003986035,0.00005889794,0.000009350635,0.000004096416,0.0000026971743,0.000114651884,0.97142106,0.00022448604],"about_ca_topic_score_codex":0.000029257406,"about_ca_topic_score_gemma":0.00001229559,"teacher_disagreement_score":0.011571101,"about_ca_system_score_codex":0.00055044965,"about_ca_system_score_gemma":0.00022218429,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W4396618179","doi":"10.1016/j.mad.2024.111937","title":"Retraction notice to “A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design” [Mech. Ageing Dev. 213 (2023) 111825]","year":2024,"lang":"en","type":"article","venue":"Mechanisms of Ageing and Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"National Institutes of Health","keywords":"Dementia; Notice; Ageing; Medicine; Metabolic syndrome; Cognition; Insulin; Cognitive decline; Insulin resistance; Gerontology; Pediatrics; Diabetes mellitus; Internal medicine; Psychiatry; Endocrinology; Disease","score_opus":0.015194651397583601,"score_gpt":0.23535540946936997,"score_spread":0.22016075807178637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396618179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96858484,0.00013884333,0.025840566,0.000057634214,0.00007535267,0.0052694897,0.0000077014165,0.000018280292,0.000007284075],"genre_scores_gemma":[0.9857353,0.000017159993,0.013861481,0.000014736636,0.0000037745815,0.00028996737,0.0000250344,0.000015723786,0.000036835536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863535,0.000100621444,0.0004008336,0.00033556888,0.0003920477,0.00013554856],"domain_scores_gemma":[0.9993794,0.000118145814,0.00017304934,0.00013473691,0.00015137652,0.000043268756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008336403,0.0001592474,0.00033698548,0.00022386781,0.00010389954,0.000018254092,0.000043088996,0.000040033032,0.000007089992],"category_scores_gemma":[0.00004449471,0.00010839188,0.000017613396,0.00029920216,0.000021194825,0.000106905594,0.00006109318,0.00008277638,3.3877268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032917336,0.05903345,0.513424,0.014875929,0.020719621,0.0010688753,0.1664132,0.005190172,0.022412492,0.0045793788,0.00015246238,0.15921311],"study_design_scores_gemma":[0.008378157,0.003816407,0.9612846,0.0009177745,0.0010601117,0.000005453172,0.0056465664,0.00041380778,0.018074434,0.00026194,0.000005857955,0.00013488662],"about_ca_topic_score_codex":0.00025119042,"about_ca_topic_score_gemma":0.001217444,"teacher_disagreement_score":0.44786063,"about_ca_system_score_codex":0.00007491864,"about_ca_system_score_gemma":0.00006555535,"threshold_uncertainty_score":0.44200927},"labels":[],"label_agreement":null},{"id":"W4396619388","doi":"10.1111/dom.15620","title":"Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the <scp>STEP</scp> 1–4 trials","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University; University of Alberta","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Overweight; Obesity; Quality of life (healthcare); Gerontology; Physical therapy; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Nursing","score_opus":0.023055780584326592,"score_gpt":0.28391158455474164,"score_spread":0.260855803970415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396619388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841272,0.013803207,0.000003648743,0.00033792297,0.00018692629,0.0012997126,0.000067052446,0.000050833554,0.00012347972],"genre_scores_gemma":[0.9987037,0.0006432464,0.000077065444,0.0002747208,0.000060354276,0.000051524174,0.00006283419,0.000020846239,0.000105674524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745786,0.00064765784,0.0007774409,0.00045717208,0.0003668663,0.00029299292],"domain_scores_gemma":[0.9957258,0.003389067,0.00038995082,0.00028127333,0.000045009267,0.00016889525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017813767,0.00031079102,0.0018132647,0.00016523905,0.00008681273,0.00003760132,0.000048132733,0.00009009499,0.000009308386],"category_scores_gemma":[0.00088225625,0.000157708,0.00013953555,0.0003164817,0.00015745948,0.00011664043,0.00008254578,0.00021166155,0.0000013504167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036742204,0.00054819393,0.9628479,0.0014842376,0.0017026553,0.000014294808,0.0024037363,0.0000019033037,0.00018537982,0.0006469827,0.00022412947,0.029573191],"study_design_scores_gemma":[0.0064925924,0.0012744027,0.986585,0.001181245,0.0012083284,6.286793e-7,0.00024998054,0.00030986214,0.0019822428,0.00019236463,0.00044273093,0.00008058521],"about_ca_topic_score_codex":0.0007044758,"about_ca_topic_score_gemma":0.00008440913,"teacher_disagreement_score":0.029492607,"about_ca_system_score_codex":0.000021846088,"about_ca_system_score_gemma":0.00005809515,"threshold_uncertainty_score":0.6431145},"labels":[],"label_agreement":null},{"id":"W4396626883","doi":"10.1097/js9.0000000000001514","title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","year":2024,"lang":"en","type":"review","venue":"International Journal of Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Mendelian randomization; Medicine; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Oncology; Cochrane Library; Single-nucleotide polymorphism; Meta-analysis; Endocrinology; Diabetes mellitus; Genotype; Genetics; Receptor; Genetic variants; Agonist; Gene; Biology","score_opus":0.10593902461952479,"score_gpt":0.4139387721868205,"score_spread":0.30799974756729576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396626883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058934414,0.98865896,0.0001861048,0.0005570738,0.0037090224,0.0005721939,0.00035082025,0.000009365024,0.00006302352],"genre_scores_gemma":[0.0015996839,0.9952355,0.0010224523,0.00003038465,0.00091464346,0.000015756252,0.00019663147,0.00003203098,0.00095289724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946588,0.00092328695,0.0030375433,0.00024169183,0.0010143694,0.00012428503],"domain_scores_gemma":[0.98524594,0.006875812,0.006770514,0.00013891431,0.0008597929,0.00010900014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008406396,0.00026355288,0.0033716953,0.0006109957,0.000015187434,0.000050181912,0.00015789039,0.00015822293,0.00014090995],"category_scores_gemma":[0.004477439,0.00016352022,0.0013231244,0.00019856483,0.00005947528,0.00020654175,0.00005728871,0.00035779065,0.0000065534477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038434784,0.00041237674,0.041557234,0.004545235,0.055676322,0.00013447517,0.00021610959,0.00001457854,0.0000061650035,0.000011821597,0.08634834,0.80723387],"study_design_scores_gemma":[0.006993732,0.00036127836,0.0011529407,0.13599227,0.044258773,0.000026540652,0.0000898249,0.00006593981,0.00006225026,0.00013024823,0.8105234,0.00034280875],"about_ca_topic_score_codex":0.0001798861,"about_ca_topic_score_gemma":0.000024001687,"teacher_disagreement_score":0.8068911,"about_ca_system_score_codex":0.000584519,"about_ca_system_score_gemma":0.0009869857,"threshold_uncertainty_score":0.66681606},"labels":[],"label_agreement":null},{"id":"W4396717974","doi":"10.1007/s40264-024-01434-4","title":"Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study","year":2024,"lang":"en","type":"article","venue":"Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gallbladder disease; Internal medicine; Type 2 diabetes; Population; Diabetes mellitus; Dipeptidyl peptidase-4; Cohort study; Bile duct; Gallbladder; Cohort; Gastroenterology; Endocrinology; Environmental health","score_opus":0.002864337265937815,"score_gpt":0.2028419557039618,"score_spread":0.19997761843802397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396717974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967067,0.00049965625,0.000002544123,0.00016760245,0.00008799918,0.0021367562,0.000038787995,0.00005241408,0.00030752865],"genre_scores_gemma":[0.9991825,0.000041257554,0.000029191557,0.000055098277,0.000036195324,0.00008477274,0.00017441266,0.000024392135,0.0003721614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989717,0.00009157534,0.00021024392,0.00028960846,0.0002894562,0.00014741403],"domain_scores_gemma":[0.9993076,0.00018860074,0.00006963174,0.00026372203,0.000058985894,0.00011149182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030551304,0.0001643717,0.00026829986,0.00009215357,0.000086617605,0.00003322871,0.00003471476,0.000017720264,0.00004217377],"category_scores_gemma":[0.00006176772,0.00008806128,0.00005031583,0.00021217576,0.0001422039,0.00008161705,0.000045392404,0.00008425367,0.0000032754633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039455286,0.00037263747,0.99620724,0.00015698836,0.0005720034,0.0000074225295,0.00049518497,0.000033869954,4.8528995e-7,0.000035343557,0.00033696226,0.0013873393],"study_design_scores_gemma":[0.0037116501,0.000251264,0.9924258,0.00022948282,0.0016559976,2.7528094e-8,0.0002134644,0.0011820954,0.0000049911473,0.00003292195,0.00019179595,0.000100496356],"about_ca_topic_score_codex":0.00022415986,"about_ca_topic_score_gemma":0.000054472723,"teacher_disagreement_score":0.0037813971,"about_ca_system_score_codex":0.000034676872,"about_ca_system_score_gemma":0.000028166283,"threshold_uncertainty_score":0.35910347},"labels":[],"label_agreement":null},{"id":"W4396767723","doi":"10.1038/s41366-024-01526-2","title":"RETRACTED ARTICLE: Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"International Journal of Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Bupropion; Medicine; Naltrexone; Weight loss; Retrospective cohort study; Internal medicine; Cohort; Endocrinology; Obesity; Pharmacology; Antagonist","score_opus":0.0050448245507304194,"score_gpt":0.2700413208389495,"score_spread":0.2649964962882191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396767723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691635,0.00020642317,0.000038007416,0.00077237707,0.0006377598,0.00041923774,0.00001123748,0.000019052122,0.000979564],"genre_scores_gemma":[0.9992503,0.000116422634,0.000059890477,0.00004843192,0.00021788767,0.000005085457,0.000010077921,0.000010095944,0.000281839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856913,0.00007336753,0.000352115,0.00016207155,0.0007458509,0.00009744867],"domain_scores_gemma":[0.99916464,0.00014153548,0.00016674635,0.00010734053,0.00033648434,0.00008326377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062762795,0.00012464677,0.0003777036,0.00029441464,0.000021102174,0.00003744192,0.000100738755,0.000044398043,0.00010425334],"category_scores_gemma":[0.00015871512,0.00008452865,0.000117900134,0.00015567252,0.00005080856,0.00013444177,0.000044725544,0.0002662681,0.000011622521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011458456,0.0013567596,0.98847145,0.000047099984,0.0027244405,0.0012644741,0.00013178581,0.0000016589327,0.00087128236,0.00049737794,0.0009386972,0.0025491135],"study_design_scores_gemma":[0.0032517815,0.005782901,0.98499185,0.00038529953,0.00064786454,0.00006518667,0.000021308319,0.00016241547,0.0042140945,0.00024870722,0.00016829485,0.00006030689],"about_ca_topic_score_codex":0.000024698855,"about_ca_topic_score_gemma":0.0000058979845,"teacher_disagreement_score":0.0044261413,"about_ca_system_score_codex":0.00024002403,"about_ca_system_score_gemma":0.000032558386,"threshold_uncertainty_score":0.34469783},"labels":[],"label_agreement":null},{"id":"W4396866172","doi":"10.1177/10600280241245995","title":"Real-Time Use of SGLT2i Verified in Pre-dialysis: The RSVP Cross-sectional Study","year":2024,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier Universitaire de Sherbrooke; Institut universitaire de cardiologie et de pneumologie de Québec; Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal; Cégep de Rimouski; Royal Victoria Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal; Université Laval","funders":"Amgen Canada; Otsuka Canada Pharmaceutical; AstraZeneca Canada; AstraZeneca; Amgen","keywords":"Medicine; Dialysis; Internal medicine; Kidney disease; Nephrology; Diabetes mellitus; Cross-sectional study; Odds ratio; Logistic regression; Type 2 diabetes; Proteinuria; Intensive care medicine; Endocrinology; Kidney; Pathology","score_opus":0.09038482200048285,"score_gpt":0.4213031705934606,"score_spread":0.33091834859297775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396866172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967903,0.0007811046,0.000003156718,0.0005485914,0.00015496851,0.0008367294,0.000019756999,0.000048251793,0.0008171768],"genre_scores_gemma":[0.9925078,0.001796396,0.000049769384,0.00037169945,0.00010630436,0.000078317156,0.000015082528,0.00002379463,0.0050507938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998814,0.000082403865,0.00038952607,0.00022189232,0.00031792876,0.00017425882],"domain_scores_gemma":[0.99941343,0.00014612089,0.000075866985,0.00023733632,0.00008504553,0.000042170075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005070073,0.00013280954,0.00027696203,0.00020788604,0.000023965602,0.00004117841,0.00010485669,0.000031356576,0.0007062571],"category_scores_gemma":[0.000011552163,0.0000886997,0.00017514946,0.00036665276,0.0000687765,0.00015568285,0.0000228987,0.0000874751,0.00002530876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021274718,0.003644607,0.49326754,0.00022939788,0.004542513,0.00007040109,0.0034042965,0.00035659297,0.46222076,0.00026155176,0.01542064,0.014454216],"study_design_scores_gemma":[0.0036651718,0.0012680166,0.802758,0.000114410126,0.000293331,0.0000012424553,0.0000663884,0.0016318022,0.17103459,0.00013475775,0.018879233,0.00015307665],"about_ca_topic_score_codex":0.0004728496,"about_ca_topic_score_gemma":0.000011819049,"teacher_disagreement_score":0.30949044,"about_ca_system_score_codex":0.000016976177,"about_ca_system_score_gemma":0.000041969157,"threshold_uncertainty_score":0.773302},"labels":[],"label_agreement":null},{"id":"W4396873474","doi":"10.1016/j.jacc.2024.04.022","title":"Semaglutide and NT-proBNP in Obesity-Related HFpEF","year":2024,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Internal medicine; Cardiology; Placebo; Heart failure with preserved ejection fraction; Heart failure; Obesity; Weight loss; Ejection fraction; Endocrinology; Type 2 diabetes; Diabetes mellitus; Liraglutide","score_opus":0.0076200450631770215,"score_gpt":0.24881059169262687,"score_spread":0.24119054662944986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396873474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880429,0.0026352091,0.000014168499,0.004686059,0.00034070105,0.00017410137,0.000007665029,0.0000070778715,0.0040921103],"genre_scores_gemma":[0.99781644,0.00046462778,0.00029339516,0.00017528652,0.0000887807,0.0000020600266,3.520994e-7,0.0000095654905,0.0011494872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918413,0.00011858413,0.00032995114,0.00009594361,0.00013312172,0.0001382959],"domain_scores_gemma":[0.9994305,0.00014616075,0.00018293179,0.00014295492,0.00004849476,0.00004899177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003556763,0.00008835636,0.0006292143,0.00022041214,0.00001587927,0.0000033257174,0.00009228357,0.000027913084,0.0000068023123],"category_scores_gemma":[0.00008198527,0.000052502026,0.00020974073,0.00038648068,0.00025501984,0.000027928296,0.00007179467,0.00018642824,0.000002540994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010140795,0.00023762602,0.88222605,0.00046806218,0.0063403524,0.0063497955,0.0003466217,0.0007603792,0.007821438,0.008417126,0.057022613,0.028995855],"study_design_scores_gemma":[0.00347514,0.0034780109,0.9088291,0.00091169344,0.0018949038,0.0032582302,0.0011832017,0.00037541732,0.00093534973,0.0042484156,0.0712039,0.0002066585],"about_ca_topic_score_codex":0.000008087776,"about_ca_topic_score_gemma":0.0000033469948,"teacher_disagreement_score":0.028789196,"about_ca_system_score_codex":0.00007531074,"about_ca_system_score_gemma":0.000087942084,"threshold_uncertainty_score":0.21409704},"labels":[],"label_agreement":null},{"id":"W4396906791","doi":"10.46747/cfp.7005310","title":"Shared decision-making approach to type 2 diabetes management","year":2024,"lang":"en","type":"review","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Context (archaeology); Randomized controlled trial; Medicine; MEDLINE; Intensive care medicine; Surgery","score_opus":0.03859100110778447,"score_gpt":0.29976054061602414,"score_spread":0.2611695395082397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396906791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000037200946,0.6396323,0.000007793144,0.000028776685,0.00065859256,0.001981269,0.0001570528,0.00010194809,0.35742855],"genre_scores_gemma":[0.00005270544,0.963982,0.0024956372,0.02517769,0.0006523314,0.0007135155,0.0011803937,0.0002987277,0.005447021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713844,0.00003242636,0.00048396637,0.0010253207,0.0003890382,0.00093079946],"domain_scores_gemma":[0.9979892,0.000045053897,0.000090750655,0.0010077468,0.00006358776,0.00080365705],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013051291,0.000760808,0.0017440368,0.001431864,0.000114744806,0.00023276587,0.00045256782,0.00020100227,0.000010405842],"category_scores_gemma":[0.000010166373,0.0006253428,0.0006226284,0.0017169648,0.000033647444,0.00007407283,0.00020593607,0.00032718224,0.0037707458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002110755,0.000058803573,4.690175e-7,0.010421932,0.0013291168,0.00015001195,0.00001366512,0.0000010047169,4.996956e-8,0.0012661092,0.20150498,0.78525174],"study_design_scores_gemma":[0.00013276134,0.00010131138,0.000026426465,0.03342786,0.006586811,4.583588e-7,0.00006458317,0.000018552662,4.0433648e-8,0.00023741063,0.9588747,0.00052905746],"about_ca_topic_score_codex":0.00012414846,"about_ca_topic_score_gemma":0.00015878843,"teacher_disagreement_score":0.7847227,"about_ca_system_score_codex":0.0014127988,"about_ca_system_score_gemma":0.00047110397,"threshold_uncertainty_score":0.9996198},"labels":[],"label_agreement":null},{"id":"W4396937622","doi":"10.1111/dom.15654","title":"Determinants of serious health <scp>outcome‐free</scp> status in <scp>middle‐aged</scp> and older people with dysglycaemia: Exploratory analysis of the <scp>ORIGIN</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"McMaster University; Hamilton Health Sciences; Sanofi","keywords":"Medicine; Internal medicine; Body mass index; Diabetes mellitus; Kidney disease; Type 2 diabetes; Endocrinology","score_opus":0.015330514339238082,"score_gpt":0.258766844180464,"score_spread":0.2434363298412259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396937622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97590953,0.020994049,0.000015498896,0.00006731115,0.000534806,0.001794041,0.00021414309,0.0000916621,0.0003789463],"genre_scores_gemma":[0.9945798,0.002994215,0.000263498,0.00040289588,0.00013297048,0.00017145197,0.00007919084,0.00006552638,0.0013104877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960964,0.00030426978,0.0009812806,0.0008240046,0.0007403898,0.0010536786],"domain_scores_gemma":[0.9970347,0.0010440439,0.0004680155,0.0009030671,0.00012687822,0.00042325616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011370407,0.00058052765,0.0021992275,0.0010189982,0.00018483112,0.000108381275,0.0003024886,0.00022896875,0.0000059369804],"category_scores_gemma":[0.00063074485,0.0004059031,0.00038121757,0.0022622894,0.00033311793,0.0003825846,0.0003495908,0.00045106385,0.0000036998663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032315358,0.00073610176,0.98096687,0.0017104624,0.0019204124,0.000031430645,0.0073565478,0.00001595924,0.00023491016,0.00034705867,0.0009061291,0.005741781],"study_design_scores_gemma":[0.014172929,0.00052380137,0.96540374,0.0004468167,0.0054124114,0.000001744768,0.0027125455,0.0003307743,0.0022773328,0.00015018178,0.008499771,0.000067972804],"about_ca_topic_score_codex":0.00038409416,"about_ca_topic_score_gemma":0.0015005866,"teacher_disagreement_score":0.018670222,"about_ca_system_score_codex":0.00009581429,"about_ca_system_score_gemma":0.00025629575,"threshold_uncertainty_score":0.9998393},"labels":[],"label_agreement":null},{"id":"W4396989849","doi":"10.1681/asn.20223311s1676c","title":"Consistent Kidney Benefits With Semaglutide vs. Placebo Regardless of Baseline Urine Albumin Creatinine Ratio in Subjects With Type 2 Diabetes at High Cardiovascular Risk: A Post Hoc Analysis of SUSTAIN 6","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Semaglutide; Creatinine; Post-hoc analysis; Medicine; Placebo; Type 2 diabetes; Diabetes mellitus; Urine; Internal medicine; Urology; Endocrinology; Alternative medicine; Pathology","score_opus":0.0063406199031656564,"score_gpt":0.2115913736281441,"score_spread":0.20525075372497845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396989849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943235,0.0013356252,0.000022673757,0.0037847115,0.000023830307,0.0003910744,0.00008209007,0.0000048798483,0.00003162361],"genre_scores_gemma":[0.9949583,0.0006553343,0.0022688203,0.0018414103,0.000031817217,0.0000141993205,0.000043211432,0.000023360983,0.00016355673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768573,0.00047187612,0.0006679684,0.0002171487,0.00067442976,0.00028282756],"domain_scores_gemma":[0.99665856,0.0003234065,0.0018644056,0.00051294,0.0005289859,0.0001116827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011746903,0.00021042925,0.0017666621,0.00029177373,0.000073303476,0.0000030010644,0.0002257218,0.00003174143,0.00007997762],"category_scores_gemma":[0.000118516815,0.00013274596,0.0008426576,0.0016349795,0.0006237691,0.000032604697,0.00021292995,0.000259942,1.3629693e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023289403,0.0017012178,0.77732366,0.00036947947,0.081739806,0.00008735206,0.0020974106,0.09199605,0.00938332,0.000045337034,0.00891653,0.0030504514],"study_design_scores_gemma":[0.016867956,0.026447937,0.8990345,0.00022918229,0.035925794,0.000071674556,0.006355393,0.002810159,0.0049572783,0.000009314283,0.006986072,0.0003047298],"about_ca_topic_score_codex":0.00079043425,"about_ca_topic_score_gemma":0.0001947225,"teacher_disagreement_score":0.12171087,"about_ca_system_score_codex":0.0002455246,"about_ca_system_score_gemma":0.00030885707,"threshold_uncertainty_score":0.5413223},"labels":[],"label_agreement":null},{"id":"W4396989942","doi":"10.1681/asn.20223311s1675a","title":"Effect of Sotagliflozin (SOTA) on Albuminuria in Patients With Type 2 Diabetes (T2D) and CKD","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Albuminuria; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Kidney disease","score_opus":0.004161973360459663,"score_gpt":0.22856201699453393,"score_spread":0.22440004363407426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396989942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979996,0.00013235597,3.7097612e-7,0.0015322133,0.000059455797,0.00021507144,0.0000033115446,0.0000020799455,0.000055526813],"genre_scores_gemma":[0.9974046,0.000043192744,0.0002259996,0.0022261539,0.00002566158,0.0000038878184,0.0000017329478,0.000010257378,0.00005855699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910986,0.00017333146,0.00022705423,0.00008492073,0.00026246492,0.0001423497],"domain_scores_gemma":[0.99902326,0.00015669473,0.00058893074,0.0001458442,0.00005082149,0.000034456938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003387482,0.000095566815,0.0005089969,0.000057991598,0.000032186563,0.0000015961283,0.00011206493,0.00001569578,0.000020838896],"category_scores_gemma":[0.00002013699,0.00005550381,0.00014673099,0.00025144746,0.00026065914,0.000021980373,0.00009598721,0.00018806804,2.8853768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031219872,0.0006268345,0.955804,0.00008382512,0.0010250241,0.0000036559707,0.00040456804,0.00008759599,0.005023977,0.00000784387,0.017844101,0.01596659],"study_design_scores_gemma":[0.00495507,0.036722593,0.9524708,0.00004700747,0.00040449708,0.0000026284338,0.00025108783,0.00003500756,0.0011378718,0.000021225542,0.0038956364,0.000056577726],"about_ca_topic_score_codex":0.000014710518,"about_ca_topic_score_gemma":0.0000010038145,"teacher_disagreement_score":0.036095757,"about_ca_system_score_codex":0.00006619235,"about_ca_system_score_gemma":0.000029909832,"threshold_uncertainty_score":0.22633797},"labels":[],"label_agreement":null},{"id":"W4396989951","doi":"10.1681/asn.20223311s1674a","title":"Effects of Canagliflozin (CANA) on Cardiovascular (CV), Kidney, and Albuminuria Outcomes by Diabetes Duration: Pooled Analysis From the CANVAS Program and CREDENCE","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McGill University Health Centre; University of British Columbia; CARE Canada; Sunnybrook Hospital","funders":"","keywords":"Canagliflozin; Albuminuria; Medicine; Credence; Diabetes mellitus; Internal medicine; Urology; Endocrinology; Type 2 diabetes; Mathematics; Statistics","score_opus":0.005813889850042698,"score_gpt":0.23403201355187592,"score_spread":0.22821812370183323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396989951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97433805,0.0028499963,0.000010979396,0.022316366,0.00005528075,0.00038004472,0.000031077863,0.000005045406,0.000013135424],"genre_scores_gemma":[0.9888369,0.0005094702,0.0005689892,0.009918076,0.00004484882,0.000028817098,0.000007992994,0.0000099630315,0.00007494357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863654,0.00028793397,0.00031823243,0.00015381536,0.00043160236,0.0001718507],"domain_scores_gemma":[0.9984812,0.0003971578,0.00067411794,0.0002887345,0.000065555534,0.000093191185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039516075,0.00013684158,0.00085262064,0.00005063053,0.00012751043,0.000009595052,0.00019717836,0.000023658702,0.000013042594],"category_scores_gemma":[0.000072509414,0.00007862324,0.0007342682,0.0004339489,0.0005323532,0.000031112366,0.00014813505,0.00019375743,7.104083e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044737212,0.00077683496,0.66915274,0.00013436838,0.10380323,0.000019655557,0.0018424601,0.00023852172,0.027671397,0.000025622285,0.16084285,0.03504492],"study_design_scores_gemma":[0.0022404832,0.0025103372,0.9406283,0.000029721972,0.018452551,0.000005772793,0.0013023446,0.00031152976,0.0013689697,0.00005426295,0.032993853,0.00010189919],"about_ca_topic_score_codex":0.0021221698,"about_ca_topic_score_gemma":0.000058653648,"teacher_disagreement_score":0.27147552,"about_ca_system_score_codex":0.000076863296,"about_ca_system_score_gemma":0.00007696436,"threshold_uncertainty_score":0.32081002},"labels":[],"label_agreement":null},{"id":"W4396989952","doi":"10.1681/asn.20223311s1675b","title":"Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Semaglutide; Post-hoc analysis; Type 2 diabetes; Placebo; Medicine; Blood pressure; Internal medicine; Baseline (sea); Diabetes mellitus; Endocrinology; Alternative medicine; Political science; Pathology","score_opus":0.004198451427717767,"score_gpt":0.2206141157934651,"score_spread":0.21641566436574733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396989952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930422,0.0016071302,0.000007102003,0.005063981,0.000014707765,0.00022417659,0.00002120813,0.000002475735,0.000017065757],"genre_scores_gemma":[0.9958399,0.0005563674,0.0016359431,0.0017345011,0.000018001072,0.0000053431686,0.0000054029906,0.000011524921,0.00019300256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884534,0.00017782013,0.00039823362,0.00013518328,0.00026771196,0.00017568626],"domain_scores_gemma":[0.998314,0.00026211806,0.0009535105,0.00020992718,0.00020779918,0.000052626914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000617602,0.00012014416,0.0009406029,0.0001863446,0.00003836019,0.0000030922113,0.0001310758,0.000025840514,0.00002821271],"category_scores_gemma":[0.0000525288,0.00007885355,0.00021090331,0.00087817584,0.0004202624,0.000034752313,0.00018698412,0.00016451078,1.8835536e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008952658,0.0017300468,0.803011,0.00072988024,0.034918465,0.00002231477,0.006809997,0.0020697785,0.12862648,0.00004007612,0.00702013,0.006069164],"study_design_scores_gemma":[0.0062972163,0.0132541815,0.9408423,0.00007182207,0.019600322,0.00002885824,0.012235241,0.0033270824,0.0006457218,0.000018604473,0.0035414265,0.00013724639],"about_ca_topic_score_codex":0.00017235515,"about_ca_topic_score_gemma":0.00007830057,"teacher_disagreement_score":0.13783127,"about_ca_system_score_codex":0.000028604314,"about_ca_system_score_gemma":0.0001088156,"threshold_uncertainty_score":0.32155544},"labels":[],"label_agreement":null},{"id":"W4396990340","doi":"10.1681/asn.20223311s1667d","title":"Deletion of iPLA2γ Protects Mice From Diabetic Nephropathy","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Diabetic nephropathy; Medicine; Nephropathy; Diabetes mellitus; Internal medicine; Endocrinology; Urology","score_opus":0.010677035970426978,"score_gpt":0.23999840006673748,"score_spread":0.2293213640963105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396990340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069244,0.00040919133,0.000114855335,0.008278195,0.000110377245,0.00026325035,0.000011407536,0.0000055387304,0.000114754745],"genre_scores_gemma":[0.9889937,0.00013970573,0.0037670692,0.0068404875,0.00012403184,0.000011796892,0.000003268071,0.000013173448,0.00010678822],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987874,0.00017566915,0.0003966737,0.00010215243,0.00037155487,0.00016655981],"domain_scores_gemma":[0.99820393,0.0001060214,0.0013142938,0.00022374387,0.0001046394,0.000047362202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030896187,0.00010077083,0.0005369034,0.000051156763,0.00007134368,0.0000022526372,0.00024014652,0.000022571026,0.00012379489],"category_scores_gemma":[0.000022059647,0.000071336144,0.00050141633,0.0002947367,0.0003819159,0.0000340344,0.00018733463,0.00026781665,0.0000011309554],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014716015,0.0013945387,0.019141788,0.000111615154,0.0030566538,0.000021072956,0.0025247338,0.00042128793,0.84727764,0.00006412631,0.09341908,0.031095874],"study_design_scores_gemma":[0.009316154,0.018528897,0.7376553,0.00015233328,0.0032548402,0.0001710192,0.009286758,0.0011002135,0.030100426,0.002316916,0.18777895,0.00033820124],"about_ca_topic_score_codex":0.00012449987,"about_ca_topic_score_gemma":0.0000013810294,"teacher_disagreement_score":0.8171772,"about_ca_system_score_codex":0.000110058405,"about_ca_system_score_gemma":0.00008882033,"threshold_uncertainty_score":0.29090035},"labels":[],"label_agreement":null},{"id":"W4396990859","doi":"10.1016/s2213-8587(24)00102-5","title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Meta-analysis; Heart failure; Medicine; Disease; Internal medicine; Intensive care medicine; Cardiology","score_opus":0.040512222091693965,"score_gpt":0.34716185231502206,"score_spread":0.3066496302233281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396990859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009548871,0.9886646,3.072182e-7,0.0034204666,0.00009412839,0.0064750435,0.00025042475,0.000083336614,0.00005680235],"genre_scores_gemma":[0.0052039186,0.9904044,0.0000075113817,0.00087677175,0.00012388686,0.0028956716,0.000074011834,0.0000699033,0.00034390463],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99499416,0.0018295065,0.0008698688,0.0007970423,0.00046963428,0.0010397675],"domain_scores_gemma":[0.9959366,0.001145597,0.00031662523,0.0024216075,0.000032787313,0.00014681534],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002231746,0.0009129196,0.019023988,0.00033306913,0.00011839061,0.000075267526,0.00038811867,0.00010102204,0.000018880071],"category_scores_gemma":[0.00028105846,0.00033968635,0.0069070766,0.0008808775,0.00029187405,0.000034988214,0.00047081284,0.00050694647,0.00004470868],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004279705,0.000020257105,0.0005958169,0.5258798,0.46993053,0.000036176243,0.00001582494,6.558457e-7,2.1287528e-8,0.00023773499,0.0005372108,0.0027417194],"study_design_scores_gemma":[0.0003396391,0.00020391983,0.00014958245,0.010792321,0.8744983,0.000016317987,0.000006951072,8.715335e-7,0.0000022441072,0.000026014724,0.11374154,0.00022230881],"about_ca_topic_score_codex":0.00002204927,"about_ca_topic_score_gemma":0.000005376452,"teacher_disagreement_score":0.5150874,"about_ca_system_score_codex":0.000049369784,"about_ca_system_score_gemma":0.0000310045,"threshold_uncertainty_score":0.9999055},"labels":[],"label_agreement":null},{"id":"W4396991335","doi":"10.1681/asn.20223311s1527a","title":"Impact of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes According to Baseline Renal Function: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Renal function; Meta-analysis; Medicine; Urology; Baseline (sea); Internal medicine; Nephrology; Intensive care medicine; Biology","score_opus":0.06110536923731794,"score_gpt":0.34590132197610046,"score_spread":0.2847959527387825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396991335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006633524,0.9965846,0.00006600517,0.0013948702,0.000028635148,0.0012157466,0.000031159623,0.0000040586365,0.000011566347],"genre_scores_gemma":[0.00036210203,0.9952142,0.0005028994,0.003648224,0.000061892264,0.0000586664,0.000007342384,0.000025354513,0.00011929505],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966467,0.0008472588,0.001436591,0.0002615759,0.00061279413,0.00019510456],"domain_scores_gemma":[0.99531215,0.0005451181,0.0032325438,0.0006514117,0.00013083142,0.00012792296],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0022839534,0.000383607,0.012230263,0.00029787837,0.00006167135,0.00000830889,0.0002242933,0.00005709981,0.00008508017],"category_scores_gemma":[0.00016726692,0.00018141286,0.016180607,0.0011203442,0.00020226251,0.00003674827,0.00022912669,0.00037341058,4.9896e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048469636,0.00012067433,0.00008849229,0.10915573,0.87345827,0.000009278986,0.00005860993,0.00004315452,0.0000029497232,0.0000016658718,0.0052750357,0.011737701],"study_design_scores_gemma":[0.0002985058,0.0019049209,0.0002587472,0.0046209805,0.9060278,0.00009694468,0.00010187322,0.0000025304257,1.6022503e-7,0.000001900395,0.08657355,0.00011211226],"about_ca_topic_score_codex":0.000049531434,"about_ca_topic_score_gemma":6.9627237e-7,"teacher_disagreement_score":0.10453475,"about_ca_system_score_codex":0.00018124131,"about_ca_system_score_gemma":0.00012176549,"threshold_uncertainty_score":0.9936721},"labels":[],"label_agreement":null},{"id":"W4396991818","doi":"10.1681/asn.20213210s1391d","title":"Modeling Gene-Targeted Strategies for Therapeutic Correction of PKD1 Loss-of-Function Mice","year":2021,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Function (biology); Loss function; PKD1; Medicine; Computational biology; Gene; Cancer research; Biology; Internal medicine; Intensive care medicine; Genetics; Phenotype; Kidney","score_opus":0.025289700579787064,"score_gpt":0.2855034118176336,"score_spread":0.26021371123784653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396991818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744672,0.0008333807,0.022387592,0.0018305496,0.00028539493,0.00013282197,0.0000027589297,0.0000040017103,0.00005630107],"genre_scores_gemma":[0.99256754,0.000575391,0.0049263295,0.0017086769,0.00011102528,0.000002664219,0.000003179071,0.000009868872,0.0000953475],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99921644,0.00005554904,0.00037525533,0.0000793027,0.00015718071,0.00011625248],"domain_scores_gemma":[0.99860156,0.000084947496,0.00075044145,0.00013676847,0.00040250464,0.000023770062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019090346,0.000081439255,0.00044490007,0.000035673544,0.000030924788,0.0000030340896,0.000079956015,0.00003788507,0.000011530788],"category_scores_gemma":[0.000013249255,0.000056796674,0.0005068843,0.00019511607,0.00020550635,0.000057337504,0.000026020685,0.00010116837,1.5050347e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012760656,0.00043532596,0.0026272675,0.0001547266,0.0032695704,0.0000015338958,0.0008876249,0.016814562,0.95541185,0.00011484292,0.0046179956,0.014388613],"study_design_scores_gemma":[0.019846257,0.029548297,0.14394085,0.0006743066,0.017210938,0.0004014235,0.07743981,0.3569006,0.3171342,0.013451851,0.02276361,0.00068786007],"about_ca_topic_score_codex":0.00003774988,"about_ca_topic_score_gemma":0.0000039259276,"teacher_disagreement_score":0.63827765,"about_ca_system_score_codex":0.000041742464,"about_ca_system_score_gemma":0.00016762898,"threshold_uncertainty_score":0.23161012},"labels":[],"label_agreement":null},{"id":"W4396992811","doi":"10.1681/asn.20213210s1264a","title":"Phase Ib Study of the Soluble Guanylate Cyclase Activator BI 685509 in Patients with Diabetic Kidney Disease","year":2021,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Guanylate cyclase; Activator (genetics); Medicine; Internal medicine; Kidney disease; Diabetes mellitus; Disease; Kidney; Endocrinology; Guanylate cyclase 2C; Gastroenterology; Receptor","score_opus":0.009689184369093867,"score_gpt":0.26161041283173386,"score_spread":0.25192122846264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396992811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931324,0.00005843088,0.000004858063,0.0062645264,0.00010184073,0.0004005348,0.000008696066,0.0000031299285,0.000025576155],"genre_scores_gemma":[0.9940223,0.000038740724,0.00022607035,0.005475512,0.000042218962,0.0000060590332,0.0000022925806,0.000015144063,0.00017165253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865484,0.00018534265,0.00040106795,0.00013838563,0.00040351486,0.00021682812],"domain_scores_gemma":[0.9982454,0.00006955794,0.00093025295,0.000425112,0.0001836787,0.00014595415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016192888,0.00013774016,0.000575563,0.000043196207,0.00005004836,0.0000051126117,0.00022448257,0.000022111526,0.000031652922],"category_scores_gemma":[0.000067746165,0.000071994284,0.00032717313,0.0004737523,0.00038193996,0.000064019536,0.00016820092,0.0002198304,5.269311e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023913838,0.016537966,0.94838697,0.00008209771,0.0021882209,0.000029369368,0.0015828005,0.000074992735,0.007378824,0.000004722927,0.018132864,0.0032097655],"study_design_scores_gemma":[0.017101172,0.005045004,0.9714573,0.000114346956,0.0010917725,0.0000025191462,0.001542619,0.000050952727,0.00068532204,0.000037781403,0.0027952953,0.00007594128],"about_ca_topic_score_codex":0.000035628254,"about_ca_topic_score_gemma":0.00000574549,"teacher_disagreement_score":0.02307028,"about_ca_system_score_codex":0.000087854205,"about_ca_system_score_gemma":0.00026040638,"threshold_uncertainty_score":0.29358417},"labels":[],"label_agreement":null},{"id":"W4396992955","doi":"10.1681/asn.20213210s1263b","title":"Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE","year":2021,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Canagliflozin; Credence; Medicine; Kidney; Urology; Internal medicine; Endocrinology; Computer science; Diabetes mellitus","score_opus":0.021335365924400284,"score_gpt":0.32087311234983906,"score_spread":0.2995377464254388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396992955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96009994,0.00076604483,0.000020284044,0.03869228,0.00008155617,0.00023442533,0.000010078439,0.000005045904,0.000090367575],"genre_scores_gemma":[0.9587475,0.0007775267,0.0030364848,0.037114363,0.00009633289,0.0000069814337,0.0000030360616,0.000011264304,0.00020649284],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9989093,0.00017368981,0.00031347407,0.00012393302,0.00030439429,0.00017519809],"domain_scores_gemma":[0.99815696,0.0005607064,0.0007468183,0.00028003383,0.0001466582,0.000108845685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001680337,0.00013000665,0.0006861721,0.00002712035,0.00005157971,0.000007778311,0.00019601172,0.000033004442,0.000013870141],"category_scores_gemma":[0.00019793832,0.00006592973,0.00046848267,0.00028508357,0.0005734036,0.000026522757,0.00010120029,0.00019126394,3.9811073e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009682818,0.002090927,0.30614,0.0003366566,0.02420522,0.00015747278,0.0023317507,0.00006596036,0.2511172,0.0001170891,0.35182366,0.06064578],"study_design_scores_gemma":[0.0023087761,0.0022354955,0.95374095,0.00020005147,0.0034770365,0.000020916501,0.0016550538,0.00007796758,0.011457098,0.00014086108,0.024603028,0.00008278178],"about_ca_topic_score_codex":0.0019996047,"about_ca_topic_score_gemma":0.00017074986,"teacher_disagreement_score":0.64760095,"about_ca_system_score_codex":0.00006080138,"about_ca_system_score_gemma":0.00023582016,"threshold_uncertainty_score":0.30228177},"labels":[],"label_agreement":null},{"id":"W4396993065","doi":"10.1681/asn.20213210s1262c","title":"Effects of Ertugliflozin on Kidney End Points in Patients with Non-Albuminuric Diabetic Kidney Disease in VERTIS CV","year":2021,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Kidney disease; Urology; Kidney; Albuminuria; Diabetic nephropathy; Internal medicine","score_opus":0.003503254315972399,"score_gpt":0.21595548128170505,"score_spread":0.21245222696573265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396993065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910561,0.00010777505,0.0000067340625,0.008388599,0.00008410267,0.00028921815,0.0000072065627,0.0000023203704,0.000057933634],"genre_scores_gemma":[0.97591305,0.00016420096,0.0006434614,0.02312907,0.00003639395,0.000006829851,0.000005872643,0.00001700581,0.000084135325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986618,0.00015496397,0.0004085588,0.00015626354,0.0003658976,0.00025250754],"domain_scores_gemma":[0.9985921,0.0001660162,0.00059606263,0.00025661706,0.00011329081,0.00027595344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015269147,0.0001548541,0.0006969481,0.000106196676,0.000016310483,0.0000030926135,0.00015660225,0.000035805107,0.000028393728],"category_scores_gemma":[0.00022781458,0.00010095187,0.00029530047,0.00050839584,0.00033395173,0.00004883149,0.0000813258,0.00022716302,0.0000016079254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021233207,0.0033397889,0.9525161,0.00038498626,0.0008644993,0.00009776184,0.00068915455,0.000038129132,0.008118254,0.000006877852,0.02684935,0.0049717776],"study_design_scores_gemma":[0.008084014,0.0025223175,0.98462516,0.0006173395,0.00036356697,0.000001594328,0.000080470636,0.000055346318,0.0020927223,0.000052651285,0.0014270265,0.0000778197],"about_ca_topic_score_codex":0.000040808958,"about_ca_topic_score_gemma":0.0000030278009,"teacher_disagreement_score":0.03210903,"about_ca_system_score_codex":0.000151181,"about_ca_system_score_gemma":0.00032753582,"threshold_uncertainty_score":0.41166976},"labels":[],"label_agreement":null},{"id":"W4396996449","doi":"10.1681/asn.20203110s1b6a","title":"Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Canagliflozin; Albuminuria; Credence; Renal function; Medicine; Urology; Internal medicine; Computer science; Endocrinology; Diabetes mellitus; Type 2 diabetes; Machine learning","score_opus":0.02946095582078751,"score_gpt":0.2792709573739818,"score_spread":0.24981000155319427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89828545,0.0005743645,0.00014053794,0.10072972,0.000063122214,0.000118164346,0.00006105328,0.0000031989273,0.000024367859],"genre_scores_gemma":[0.96969056,0.00082725275,0.0007796965,0.02846179,0.00016665384,7.861358e-7,0.000009008037,0.000007840529,0.00005643541],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99923694,0.00007384642,0.00026521404,0.00012929586,0.00016272414,0.00013197004],"domain_scores_gemma":[0.99882567,0.000113941285,0.0006109898,0.00026948928,0.00005538215,0.00012454441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022113157,0.000093971095,0.00040569797,0.000010025348,0.000051824052,0.000008058565,0.00025588795,0.000028489929,0.000021494168],"category_scores_gemma":[0.00010239433,0.000049951577,0.00009882087,0.00018157625,0.00081582234,0.00006320548,0.00026019986,0.00019668479,3.6550813e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019200197,0.00020557655,0.11265284,0.00011060805,0.0050725252,0.000013545634,0.005114894,0.000012489924,0.10947386,0.000047188405,0.7502311,0.015145381],"study_design_scores_gemma":[0.004170842,0.0041371533,0.80205494,0.00014833688,0.0026505606,0.00006066236,0.016044868,0.0019796467,0.0020803944,0.0004902432,0.1660332,0.00014913933],"about_ca_topic_score_codex":0.002342151,"about_ca_topic_score_gemma":0.00016013437,"teacher_disagreement_score":0.6894021,"about_ca_system_score_codex":0.00002544353,"about_ca_system_score_gemma":0.00012982868,"threshold_uncertainty_score":0.35406473},"labels":[],"label_agreement":null},{"id":"W4396996840","doi":"10.1681/asn.20203110s1345a","title":"Kidney Effects of Empagliflozin in People with Type 1 Diabetes","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Mount Sinai Hospital; University of Toronto; University Health Network","funders":"","keywords":"Empagliflozin; Type 2 diabetes; Medicine; Diabetes mellitus; Kidney; Internal medicine; Urology; Benzhydryl compounds; Endocrinology; Chemistry","score_opus":0.007493449698572214,"score_gpt":0.2352276810011766,"score_spread":0.2277342313026044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806888,0.00021669948,0.000016696104,0.01879064,0.000042256506,0.00015816804,9.3373586e-7,0.0000035968196,0.00008216951],"genre_scores_gemma":[0.9759962,0.00022005846,0.0026389952,0.021020794,0.00007588876,0.0000016591196,7.191302e-7,0.000010389177,0.000035310288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992697,0.00006255959,0.00025621423,0.000076633245,0.00018425474,0.00015059533],"domain_scores_gemma":[0.9989843,0.00011556648,0.0005897295,0.00012734684,0.000087839326,0.0000952232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011070842,0.00009009485,0.0006015774,0.000032596185,0.000011573924,0.0000017002387,0.00014365595,0.000024127865,0.00001386256],"category_scores_gemma":[0.000074602045,0.000052346746,0.00021878557,0.00046019309,0.00027675877,0.000031761403,0.00005885397,0.00015253015,0.0000011156025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009277376,0.0005061336,0.6893781,0.0005679167,0.002124313,0.00001432517,0.0030479073,0.000075549964,0.19069183,0.000016208813,0.10908518,0.0035647966],"study_design_scores_gemma":[0.0037900193,0.010273155,0.96195805,0.00020832343,0.00082574296,0.00000829901,0.0007989544,0.00025651953,0.0106532555,0.00003665132,0.011104971,0.000086062944],"about_ca_topic_score_codex":0.000021633388,"about_ca_topic_score_gemma":0.0000027597534,"teacher_disagreement_score":0.27257994,"about_ca_system_score_codex":0.000031599186,"about_ca_system_score_gemma":0.00010743956,"threshold_uncertainty_score":0.21346384},"labels":[],"label_agreement":null},{"id":"W4396996845","doi":"10.1681/asn.20203110s1344b","title":"Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Albuminuria; Canagliflozin; Medicine; Internal medicine; Kidney disease; Endocrinology; Urology; Diabetes mellitus; Type 2 diabetes","score_opus":0.019543179013225158,"score_gpt":0.24273138080619647,"score_spread":0.2231882017929713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466816,0.00059215573,0.000017145963,0.05232885,0.00003569428,0.0002591556,0.000004546228,0.0000054889833,0.00007532814],"genre_scores_gemma":[0.96187866,0.00045739452,0.0013625349,0.03608524,0.00014880933,0.0000062735276,7.193231e-7,0.000014452969,0.00004592339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990734,0.00007191078,0.0002402162,0.0001285834,0.00028949353,0.00019638546],"domain_scores_gemma":[0.9991949,0.000035526267,0.00033449754,0.0001860893,0.00006044145,0.00018852386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018731404,0.00012584604,0.0007462186,0.000039122282,0.00002287885,0.0000050200792,0.00013834945,0.00003220841,0.000008365548],"category_scores_gemma":[0.000028691975,0.00007385188,0.00038415816,0.00026157976,0.00036711042,0.0000627977,0.0000758146,0.0001875032,5.251888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006414617,0.00013662643,0.9450792,0.00011921206,0.006567403,0.00008151969,0.0042277104,0.000025076617,0.0011139765,0.000015889686,0.033003252,0.008988651],"study_design_scores_gemma":[0.0030956664,0.002091943,0.96870935,0.00005781865,0.0009700205,0.000029996696,0.0007132338,0.00010450305,0.000071203314,0.000010108246,0.024077553,0.00006859162],"about_ca_topic_score_codex":0.0013031183,"about_ca_topic_score_gemma":0.00004698793,"teacher_disagreement_score":0.02363014,"about_ca_system_score_codex":0.00004650692,"about_ca_system_score_gemma":0.00008883983,"threshold_uncertainty_score":0.30115923},"labels":[],"label_agreement":null},{"id":"W4396996885","doi":"10.1681/asn.20203110s1342a","title":"Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"","keywords":"Canagliflozin; Diuretic; Credence; Medicine; Loop diuretic; Internal medicine; Intensive care medicine; Pharmacology; Endocrinology; Computer science","score_opus":0.030933506580097882,"score_gpt":0.27425366986760236,"score_spread":0.24332016328750447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94423896,0.002423906,0.00046062,0.052227363,0.0000971659,0.00046192834,0.00007488581,0.0000048795023,0.00001028404],"genre_scores_gemma":[0.9507805,0.0040524104,0.0017052679,0.042985875,0.00033874356,0.000003380028,0.000020761088,0.000021476731,0.000091582806],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99847734,0.00033542415,0.00042079252,0.00018460152,0.00042791953,0.0001539107],"domain_scores_gemma":[0.99727273,0.0013226051,0.00067902554,0.00056630094,0.00006816472,0.00009119294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049572636,0.00014378363,0.00090270484,0.000013489992,0.000049695183,0.000007993101,0.00045622917,0.00003729365,0.000011297875],"category_scores_gemma":[0.00045610277,0.00007335446,0.0005458801,0.00017557266,0.0005815932,0.000059704802,0.00026666844,0.00024461056,6.370838e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019044619,0.0005630381,0.019243555,0.00013002614,0.018419133,0.00003035898,0.0007657847,0.000115081086,0.02133483,0.00001530309,0.90317357,0.017164718],"study_design_scores_gemma":[0.08450887,0.011975746,0.45857373,0.00037796798,0.016544014,0.000023829556,0.0012738784,0.0018569935,0.0031662039,0.00007091882,0.42127848,0.00034936986],"about_ca_topic_score_codex":0.00068036315,"about_ca_topic_score_gemma":0.000012021611,"teacher_disagreement_score":0.4818951,"about_ca_system_score_codex":0.000027477628,"about_ca_system_score_gemma":0.000074560216,"threshold_uncertainty_score":0.2991308},"labels":[],"label_agreement":null},{"id":"W4396996913","doi":"10.1681/asn.20203110s1345b","title":"Empagliflozin Is Associated with Increased Plasma Lipid Metabolites in Type 1 Diabetes","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; University Health Network","funders":"","keywords":"Empagliflozin; Type 2 diabetes; Diabetes mellitus; Medicine; Benzhydryl compounds; Internal medicine; Endocrinology; Pharmacology; Chemistry","score_opus":0.014873099204146683,"score_gpt":0.2439016319666885,"score_spread":0.22902853276254181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759675,0.00031093706,0.0000029878083,0.02341926,0.000035891208,0.0001394768,0.000005042426,0.000008651124,0.000110252506],"genre_scores_gemma":[0.9624412,0.00026379694,0.0013496355,0.03575134,0.00012677662,0.0000019729837,0.0000024948588,0.000015395695,0.00004738829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989385,0.00011571843,0.00034303512,0.000114184884,0.00025969953,0.00022885346],"domain_scores_gemma":[0.9986625,0.00017130228,0.00077386404,0.00014024563,0.00014915183,0.000102957616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023151419,0.00013299614,0.0007548603,0.00004570314,0.000025143136,0.000005689162,0.00018585705,0.00004047195,0.00004906361],"category_scores_gemma":[0.00012023577,0.00007893997,0.0002969409,0.0006486649,0.000354589,0.000054344277,0.00006716329,0.0002385026,0.0000028395468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014729258,0.0007873724,0.73915106,0.000075479904,0.006382639,0.000025181263,0.0029315392,0.00005649678,0.090662844,0.000020721413,0.15324742,0.005186307],"study_design_scores_gemma":[0.0052517513,0.005515684,0.9448048,0.000117908385,0.0015009224,0.000009596702,0.0012256985,0.00094656815,0.0067355144,0.00004810551,0.033694208,0.00014924371],"about_ca_topic_score_codex":0.000027492093,"about_ca_topic_score_gemma":0.00000450736,"teacher_disagreement_score":0.20565371,"about_ca_system_score_codex":0.000058027512,"about_ca_system_score_gemma":0.00010811949,"threshold_uncertainty_score":0.32190785},"labels":[],"label_agreement":null},{"id":"W4396996958","doi":"10.1681/asn.20203110s1349b","title":"Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Semaglutide; Post-hoc analysis; Agonist; Medicine; Internal medicine; Baseline (sea); Glucagon-like peptide 1 receptor; Urology; Hemoglobin; Endocrinology; Receptor; Diabetes mellitus; Type 2 diabetes; Liraglutide; Political science","score_opus":0.010191561429064928,"score_gpt":0.24371532126672685,"score_spread":0.2335237598376619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9090006,0.00034140892,0.00019856503,0.09014115,0.000019519446,0.0002579431,0.000013295086,0.000004349643,0.000023185368],"genre_scores_gemma":[0.9880705,0.00045533932,0.0037799466,0.007444894,0.00009176894,0.0000031670293,0.000008830484,0.000011871166,0.00013371056],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99874675,0.00013283851,0.00044199024,0.00013770213,0.0003779555,0.00016278774],"domain_scores_gemma":[0.9978817,0.00006538669,0.0013743273,0.00022035697,0.0003764941,0.00008170364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045309155,0.00013158748,0.00073771697,0.00006759145,0.00004758184,0.000005994712,0.00016941865,0.000038089984,0.000030707986],"category_scores_gemma":[0.000022445985,0.00006906765,0.00049674127,0.00086356053,0.0009002082,0.000037839684,0.00009011476,0.00019043208,2.7030634e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01485784,0.0028915568,0.080771245,0.0007993777,0.066747405,0.00002330164,0.023828562,0.0009977993,0.44730958,0.00012647014,0.22615309,0.13549377],"study_design_scores_gemma":[0.018300071,0.06696374,0.47411022,0.00041101014,0.06412144,0.00025416372,0.17649306,0.00639492,0.027764069,0.000106838146,0.1642975,0.00078297354],"about_ca_topic_score_codex":0.00012291822,"about_ca_topic_score_gemma":0.000008319706,"teacher_disagreement_score":0.4195455,"about_ca_system_score_codex":0.000065576256,"about_ca_system_score_gemma":0.000096057425,"threshold_uncertainty_score":0.33168545},"labels":[],"label_agreement":null},{"id":"W4396997385","doi":"10.1681/asn.20203110s1348a","title":"Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Post-hoc analysis; Dulaglutide; Type 2 diabetes; Medicine; Renal function; Internal medicine; Diabetes mellitus; Endocrinology; Exenatide","score_opus":0.014166444241655635,"score_gpt":0.25492403195410607,"score_spread":0.24075758771245043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89804566,0.0004903042,0.000008755315,0.101132214,0.000108222404,0.0001745618,0.000008210858,0.000004664752,0.000027407164],"genre_scores_gemma":[0.92888224,0.0004138572,0.00042500824,0.07006183,0.00013563807,0.0000015136908,0.0000070605315,0.000008643946,0.000064220854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895847,0.00014549239,0.00041885412,0.00012170987,0.00020153442,0.00015395992],"domain_scores_gemma":[0.99868083,0.00028510691,0.00066153426,0.00018629372,0.000085552114,0.00010068516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025018785,0.000112716196,0.00071865774,0.000045536664,0.00004331182,0.0000082227525,0.00016122962,0.00004380557,0.00007276908],"category_scores_gemma":[0.00015675186,0.000058463476,0.00054966327,0.0007216074,0.0003481951,0.000043247303,0.00008852023,0.00024501496,0.0000019056521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01463926,0.00036339,0.8585977,0.000017972437,0.024782065,0.000008370633,0.002432291,0.000090575864,0.009142365,0.000017009404,0.08388285,0.0060261483],"study_design_scores_gemma":[0.014856819,0.0043936833,0.9543542,0.000017276545,0.005473006,0.0000011130523,0.0012913137,0.00038654977,0.000020703059,0.00008039606,0.0190564,0.000068532645],"about_ca_topic_score_codex":0.00009933023,"about_ca_topic_score_gemma":0.0000102990425,"teacher_disagreement_score":0.09575651,"about_ca_system_score_codex":0.000036689504,"about_ca_system_score_gemma":0.000074512245,"threshold_uncertainty_score":0.23840715},"labels":[],"label_agreement":null},{"id":"W4396997477","doi":"10.1681/asn.20203110s1328a","title":"Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Canagliflozin; Albuminuria; Medicine; Internal medicine; Baseline (sea); Renal function; Endocrinology; Diabetes mellitus","score_opus":0.016395467209699817,"score_gpt":0.2607083793822578,"score_spread":0.24431291217255802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537328,0.0010091309,0.0017146897,0.04320992,0.000036161884,0.00020134059,0.000017686387,0.000005593652,0.00007270694],"genre_scores_gemma":[0.97316986,0.00070960604,0.008250749,0.017671049,0.00011420575,0.0000023287935,0.0000020836876,0.00001286844,0.00006727447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985567,0.00014564602,0.0005458934,0.00017944463,0.00037204524,0.00020032263],"domain_scores_gemma":[0.9984762,0.0001650432,0.000710641,0.00031418802,0.00014667299,0.00018726134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005965356,0.00015170127,0.0014375784,0.00010217612,0.000047135945,0.000005274893,0.00023300452,0.000036115267,0.000031471493],"category_scores_gemma":[0.000109450535,0.00010104443,0.0014648759,0.00087449723,0.00032240732,0.00005368759,0.0001796502,0.00020040802,4.8545337e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033865361,0.00047121104,0.55029064,0.00044302954,0.17929022,0.00010899751,0.0049826833,0.0058414633,0.05598617,0.000054535158,0.10734722,0.09179727],"study_design_scores_gemma":[0.0036126776,0.0026873,0.90170574,0.000076808516,0.022712067,0.00003887267,0.0057507306,0.001070883,0.0015533479,0.000029447046,0.060541965,0.00022017436],"about_ca_topic_score_codex":0.00067033735,"about_ca_topic_score_gemma":0.000047275666,"teacher_disagreement_score":0.35141507,"about_ca_system_score_codex":0.000069154725,"about_ca_system_score_gemma":0.0001242423,"threshold_uncertainty_score":0.41204724},"labels":[],"label_agreement":null},{"id":"W4396997482","doi":"10.1681/asn.20203110s1344a","title":"Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of British Columbia","funders":"National Health and Medical Research Council; Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Credence; Diabetes mellitus; Medicine; Kidney disease; Intensive care medicine; Disease; Kidney; Internal medicine; Type 2 Diabetes Mellitus; Endocrinology; Computer science","score_opus":0.008135673883654333,"score_gpt":0.2455997423939866,"score_spread":0.23746406851033228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792663,0.00087239745,0.000025028081,0.01952093,0.000013439789,0.00028213407,0.0000076071938,0.0000015044121,0.000010668186],"genre_scores_gemma":[0.9932051,0.0025478776,0.0004004702,0.0037760625,0.000052681826,0.0000061089067,5.9825607e-7,0.0000048686347,0.0000062450854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993013,0.0001427697,0.00022211189,0.00009016614,0.00012881818,0.000114834205],"domain_scores_gemma":[0.99916893,0.00022495982,0.00037880102,0.000092032,0.000029460714,0.00010584377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025902595,0.0000801815,0.0003837307,0.000035238845,0.000031353444,0.000005955935,0.0000710866,0.000017782248,0.0000038465823],"category_scores_gemma":[0.000116318326,0.000043575845,0.000062901796,0.00025376142,0.0005078587,0.000043484262,0.00005303188,0.00016216155,4.0879108e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025197652,0.00023975088,0.9827941,0.00010210396,0.0004296931,0.0000055423234,0.004030469,0.00004357469,0.00075008615,0.000013811623,0.0034647277,0.005606345],"study_design_scores_gemma":[0.010130918,0.0036833265,0.97955334,0.000059114605,0.00068792223,0.0000062051317,0.0016047468,0.00042397284,0.00004486966,0.0000942119,0.0036606025,0.000050744085],"about_ca_topic_score_codex":0.000821238,"about_ca_topic_score_gemma":0.00024502468,"teacher_disagreement_score":0.015744867,"about_ca_system_score_codex":0.000016633183,"about_ca_system_score_gemma":0.00008132981,"threshold_uncertainty_score":0.18712264},"labels":[],"label_agreement":null},{"id":"W4396997511","doi":"10.1681/asn.20203110s1343c","title":"Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of British Columbia","funders":"","keywords":"Canagliflozin; Urinary system; Medicine; Diabetes mellitus; Credence; Kidney disease; Disease; Internal medicine; Intensive care medicine; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.009779359410250293,"score_gpt":0.24499230141238107,"score_spread":0.23521294200213078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718166,0.000682669,0.000012737123,0.01178011,0.00001698116,0.00029430466,0.000011170247,0.0000019880097,0.000018370056],"genre_scores_gemma":[0.9951943,0.0026672466,0.0002017901,0.0018641419,0.00005358284,0.00000869155,7.6952495e-7,0.0000049134883,0.0000045573115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993002,0.00015155681,0.00022747394,0.00008997295,0.00011677855,0.00011400919],"domain_scores_gemma":[0.9991708,0.000246575,0.00035237483,0.00008839729,0.00003119532,0.000110656285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022142238,0.00008425873,0.0003454677,0.00004893291,0.00004741944,0.0000065202344,0.000057423,0.000019214493,0.0000040186424],"category_scores_gemma":[0.00010729903,0.000047576144,0.00009507647,0.00029780986,0.000502326,0.00006647402,0.000047858004,0.00020734686,4.1021487e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014820779,0.000766428,0.99291015,0.00005346311,0.00035368156,0.0000073810684,0.0021385176,0.00003991781,0.00027584998,0.000007811674,0.0009528941,0.00101185],"study_design_scores_gemma":[0.0075306976,0.00697391,0.982141,0.000035902707,0.0006887068,0.000025003883,0.0012231534,0.0003328528,0.000007592817,0.000054466254,0.0009433775,0.000043295622],"about_ca_topic_score_codex":0.0005939548,"about_ca_topic_score_gemma":0.0001214725,"teacher_disagreement_score":0.010769087,"about_ca_system_score_codex":0.000021265443,"about_ca_system_score_gemma":0.000096678756,"threshold_uncertainty_score":0.19400989},"labels":[],"label_agreement":null},{"id":"W4396997578","doi":"10.1681/asn.20203110s1229a","title":"Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with CKD (DIAMOND): A Randomized Double-Blind Cross-Over Trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dapagliflozin; Proteinuria; Medicine; Urology; Diabetes mellitus; Randomized controlled trial; Internal medicine; Double blind; Endocrinology; Type 2 diabetes; Kidney; Placebo; Pathology; Alternative medicine","score_opus":0.01008939048610664,"score_gpt":0.2632445087463427,"score_spread":0.25315511826023607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134016,0.00006137101,0.000012665228,0.004890144,0.00016973229,0.0034451191,0.0000025618226,0.0000039020974,0.000074343356],"genre_scores_gemma":[0.9934543,0.000027186365,0.00040110532,0.0057245158,0.00024800687,0.000058207243,9.779408e-7,0.000019258316,0.00006648158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981205,0.00028811174,0.00066210533,0.00016759372,0.0005235631,0.00023813001],"domain_scores_gemma":[0.99749964,0.0003797191,0.0016470583,0.00024868673,0.00013753874,0.00008736537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044391956,0.00019951686,0.0012866291,0.000052356412,0.00003957687,0.000009660087,0.0002939142,0.000066045686,0.000014225479],"category_scores_gemma":[0.00012561993,0.00009473363,0.0007827433,0.00045577943,0.00094993523,0.000059735077,0.000115989045,0.00037032473,0.0000012927252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9650026,0.0013379441,0.016933521,0.00019123386,0.0017741907,0.0000052230444,0.00115379,0.00008220594,0.007203061,0.000013301905,0.005300654,0.001002298],"study_design_scores_gemma":[0.8691217,0.007609861,0.11610904,0.00022658115,0.000929972,9.932476e-7,0.000073434356,0.00007960755,0.005092351,0.00003255307,0.000632211,0.00009173983],"about_ca_topic_score_codex":0.00003858123,"about_ca_topic_score_gemma":0.0000023217003,"teacher_disagreement_score":0.09917552,"about_ca_system_score_codex":0.00008020847,"about_ca_system_score_gemma":0.00011591639,"threshold_uncertainty_score":0.3863125},"labels":[],"label_agreement":null},{"id":"W4396997867","doi":"10.1681/asn.20203110s1342b","title":"Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"","keywords":"Canagliflozin; Credence; Clinical Practice; Medicine; Intensive care medicine; Internal medicine; Endocrinology; Physical therapy; Diabetes mellitus; Computer science","score_opus":0.051613862055259384,"score_gpt":0.3685603044387304,"score_spread":0.316946442383471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396997867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8893404,0.00093794445,0.000086324915,0.109260485,0.00002206242,0.00031441567,0.000012405803,0.000004075364,0.000021887838],"genre_scores_gemma":[0.96730244,0.0054196403,0.014105647,0.012893218,0.00021352354,0.000016640493,0.000002658741,0.000011623914,0.00003460059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991576,0.000062095205,0.00039291626,0.00015107344,0.0001037381,0.00013254322],"domain_scores_gemma":[0.99850315,0.0003536092,0.00075601717,0.00013435294,0.00013850424,0.00011435566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007994884,0.00010681775,0.0005203969,0.000024393346,0.000048582675,0.0000057762654,0.00011424274,0.00003283438,0.0000021135245],"category_scores_gemma":[0.00006852461,0.000062237545,0.00020184125,0.00018143766,0.00021204093,0.00008181489,0.000047615627,0.00011858196,2.780963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026178699,0.004157222,0.6479324,0.00022565432,0.0321154,0.0002526005,0.011074634,0.00021702811,0.16570237,0.0007132266,0.046905227,0.064525545],"study_design_scores_gemma":[0.0064368276,0.0070402757,0.92511576,0.000050345185,0.002323874,0.00005523828,0.001460183,0.00031636324,0.00063814124,0.00011247121,0.05635476,0.000095729054],"about_ca_topic_score_codex":0.00018015127,"about_ca_topic_score_gemma":0.00012109991,"teacher_disagreement_score":0.2771834,"about_ca_system_score_codex":0.000087003784,"about_ca_system_score_gemma":0.00013775303,"threshold_uncertainty_score":0.25379735},"labels":[],"label_agreement":null},{"id":"W4396998206","doi":"10.1681/asn.20203110s1657c","title":"The Intrarenal RAS Upregulates SGLT2 Expression and SGLT2 Inhibitors Attenuate Angiotensin-II Induced Hypertensive Kidney Injury in Mice","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Renal injury; Kidney; Renin–angiotensin system; Angiotensin II; Endocrinology; Internal medicine; Pharmacology; Receptor; Blood pressure","score_opus":0.012736155283861293,"score_gpt":0.24464310206656537,"score_spread":0.23190694678270407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396998206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8732226,0.0002848381,0.0000042248776,0.12616755,0.000096124306,0.00019503853,0.0000030037381,0.000006666917,0.000019966283],"genre_scores_gemma":[0.9603673,0.00059679494,0.0010485726,0.03764188,0.00028748167,0.0000023786129,0.000001425589,0.00001599496,0.000038143116],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987487,0.00013622837,0.00045084654,0.00016093759,0.0002481445,0.00025513404],"domain_scores_gemma":[0.9986056,0.0001311248,0.00076217164,0.00016601199,0.00016402265,0.00017106427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024359181,0.00016571624,0.0005913224,0.000041139305,0.0001296333,0.000011477208,0.0001946255,0.000063109874,0.0000049375544],"category_scores_gemma":[0.00013418231,0.000089252324,0.0003095351,0.00030687623,0.00061856996,0.00007766694,0.00026438682,0.0003559662,9.364846e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085433165,0.00010546475,0.009064057,0.000021817796,0.0005562891,0.000015206718,0.002157866,0.00000587363,0.7854504,0.000005931518,0.1936035,0.008159251],"study_design_scores_gemma":[0.010509603,0.012182156,0.690024,0.0008106169,0.0017906418,0.0003165496,0.010092421,0.0012179506,0.16131167,0.0005841527,0.11061506,0.0005451814],"about_ca_topic_score_codex":0.000039737268,"about_ca_topic_score_gemma":0.0000015145442,"teacher_disagreement_score":0.68095994,"about_ca_system_score_codex":0.000049836402,"about_ca_system_score_gemma":0.00009861162,"threshold_uncertainty_score":0.36396042},"labels":[],"label_agreement":null},{"id":"W4397025075","doi":"10.1681/asn.20203110s1476b","title":"SGLT2-Mediated Changes in Urinary Handling of Ketones in Type 1 Diabetes","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Urinary system; Type 2 diabetes; Medicine; Diabetes mellitus; Urology; Chemistry; Internal medicine; Endocrinology","score_opus":0.022416079959388657,"score_gpt":0.26639137928942674,"score_spread":0.2439752993300381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397025075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704702,0.001024424,0.0000025772886,0.028287679,0.00004764028,0.0001132829,0.0000015260568,0.0000033557574,0.00004933598],"genre_scores_gemma":[0.9895942,0.0012924741,0.0007403222,0.008253384,0.000088450804,0.0000015658336,0.0000012748475,0.000008721611,0.000019566174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920595,0.00007021806,0.00032528193,0.00008025961,0.00015271608,0.00016554822],"domain_scores_gemma":[0.99907315,0.0001324763,0.00057978206,0.00009939484,0.00006801876,0.000047201764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020988435,0.00008626228,0.00058674614,0.00006852711,0.000009820191,0.0000014416029,0.00014387905,0.000033574095,0.00001981287],"category_scores_gemma":[0.000066867775,0.000058372916,0.00017272844,0.00050021627,0.00028373874,0.000030397336,0.000083913634,0.0001762812,9.809894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087365415,0.00065471197,0.765391,0.0002408325,0.00080022437,0.000028886014,0.0032159241,0.00013258304,0.21177875,0.000008920871,0.010407662,0.0064668613],"study_design_scores_gemma":[0.0025585324,0.0054678423,0.9767708,0.00017184316,0.00022048569,0.000007631543,0.002043574,0.0008012345,0.0042819516,0.0000586052,0.007537355,0.00008014718],"about_ca_topic_score_codex":0.00003126672,"about_ca_topic_score_gemma":0.000009866061,"teacher_disagreement_score":0.21137981,"about_ca_system_score_codex":0.000036926634,"about_ca_system_score_gemma":0.000051165956,"threshold_uncertainty_score":0.23803785},"labels":[],"label_agreement":null},{"id":"W4397040162","doi":"10.1681/asn.20233411s11179d","title":"Transcriptomic Assessment of GRP78 as a Mediator of CKD","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Population Health Research Institute","funders":"","keywords":"Mediator; Transcriptome; Medicine; Intensive care medicine; Computational biology; Biology; Internal medicine; Genetics; Gene expression; Gene","score_opus":0.01648635525586511,"score_gpt":0.3127404510928289,"score_spread":0.29625409583696377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397040162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792994,0.00016640457,0.0000544827,0.011169932,0.000134269,0.00016318225,0.0000069825496,0.000007305964,0.0003674926],"genre_scores_gemma":[0.99314624,0.00116908,0.002693537,0.0026034573,0.000093081224,0.0000031105337,0.0000018364832,0.000013273249,0.00027639975],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987206,0.0000813146,0.0005427442,0.00008615872,0.0003867494,0.0001824199],"domain_scores_gemma":[0.9982318,0.00013652007,0.0011939671,0.00022901177,0.00014512321,0.000063555926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044371054,0.000104438375,0.0007592112,0.00009093022,0.000020217669,0.0000014273331,0.00023017195,0.000038596827,0.000055725566],"category_scores_gemma":[0.000022733415,0.00006720857,0.0007507639,0.00043825575,0.00059384416,0.00003547631,0.00006149626,0.00016268846,0.0000020553364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058106316,0.00097241165,0.06662312,0.00040758774,0.005789957,0.000018781948,0.002342055,0.00010106024,0.7186383,0.00037060355,0.19333977,0.01081532],"study_design_scores_gemma":[0.0047885156,0.0066181323,0.9330865,0.0001610422,0.0019539532,0.000045563454,0.004401446,0.00048561455,0.0131122125,0.0007531456,0.034475,0.000118883065],"about_ca_topic_score_codex":0.000050096274,"about_ca_topic_score_gemma":0.0000022499148,"teacher_disagreement_score":0.86646336,"about_ca_system_score_codex":0.00005860483,"about_ca_system_score_gemma":0.00018729035,"threshold_uncertainty_score":0.2740686},"labels":[],"label_agreement":null},{"id":"W4397040265","doi":"10.1097/md.0000000000038018","title":"Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis","year":2024,"lang":"en","type":"review","venue":"Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sitagliptin; Incretin; Internal medicine; Cochrane Library; Meta-analysis; Saxagliptin; Relative risk; Incidence (geometry); Prostate cancer; Type 2 diabetes; Subgroup analysis; Exenatide; Confidence interval; Randomized controlled trial; Dipeptidyl peptidase-4; Oncology; Linagliptin; Cancer; Diabetes mellitus; Endocrinology","score_opus":0.02327295623647238,"score_gpt":0.3496772940676455,"score_spread":0.3264043378311732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397040265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009967113,0.9939667,0.0000026734292,0.0022314463,0.00038909755,0.0016012761,0.000042197185,0.00004177571,0.000728097],"genre_scores_gemma":[0.0060534636,0.98819834,0.00003043953,0.00047534928,0.00020981001,0.0003623072,0.00043095148,0.00005501632,0.0041842954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741524,0.0001499017,0.00089103624,0.00048612998,0.00071200833,0.00034566247],"domain_scores_gemma":[0.9981934,0.00035226493,0.00035538865,0.0007191218,0.00019510447,0.00018472916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011260038,0.00044958753,0.0025397483,0.0011295174,0.000026258047,0.0000120685045,0.00026278428,0.00012970676,0.0005646988],"category_scores_gemma":[0.0006213486,0.00022172066,0.00041118398,0.0035477995,0.0002579694,0.000019515332,0.00010656322,0.00041347486,0.000045847828],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009495239,0.00014646721,0.0027638318,0.040524695,0.00542711,0.0002250488,0.00096219184,0.000015937287,8.8810685e-7,0.00007539377,0.0076235333,0.9421399],"study_design_scores_gemma":[0.0011353503,0.00038645611,0.00028999915,0.055978354,0.0893195,0.0000013799602,0.00013121667,0.0004994618,0.0000037373138,0.000035846355,0.8519829,0.00023582521],"about_ca_topic_score_codex":0.0011776095,"about_ca_topic_score_gemma":0.00021593564,"teacher_disagreement_score":0.9419041,"about_ca_system_score_codex":0.00027988298,"about_ca_system_score_gemma":0.0006561229,"threshold_uncertainty_score":0.9041506},"labels":[],"label_agreement":null},{"id":"W4397040534","doi":"10.1681/asn.20233411s11138a","title":"Dapagliflozin in Patients with Low and High uACR","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dapagliflozin; Urology; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.0063881669002388885,"score_gpt":0.231525896283435,"score_spread":0.22513772938319612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397040534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992473,0.000029539753,0.0000060992497,0.007296805,0.00003440574,0.00011487141,0.0000015465378,0.000004770109,0.00003894652],"genre_scores_gemma":[0.99519897,0.00013025236,0.0009110641,0.003562188,0.000040223767,0.000001411979,0.0000014534959,0.000007937927,0.00014651744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940604,0.000032953205,0.00018324712,0.000067250956,0.00017104813,0.0001394334],"domain_scores_gemma":[0.99940103,0.000051243886,0.00033993533,0.00011427564,0.000055469412,0.000038061706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014065191,0.00006796158,0.00032624026,0.000053724918,0.00001869173,0.000002504286,0.000078039135,0.000018470211,0.00000695326],"category_scores_gemma":[0.000009513401,0.000038095728,0.00009888742,0.00032149002,0.00030648572,0.00003250257,0.000060899285,0.00011056386,0.0000015335189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006600994,0.0003286682,0.93993706,0.000053894557,0.0007330715,0.000011408885,0.00055370736,0.00004875128,0.0010763456,0.00002644525,0.042946514,0.013624045],"study_design_scores_gemma":[0.0026402415,0.0017246496,0.99199057,0.00004813991,0.00012882637,0.000003588432,0.00030672454,0.000040432784,0.000046828092,0.00007647623,0.00296054,0.000033011882],"about_ca_topic_score_codex":0.000031188334,"about_ca_topic_score_gemma":0.000004226394,"teacher_disagreement_score":0.052053493,"about_ca_system_score_codex":0.0000325067,"about_ca_system_score_gemma":0.000026294803,"threshold_uncertainty_score":0.15534987},"labels":[],"label_agreement":null},{"id":"W4397041132","doi":"10.1681/asn.20233411s128c","title":"Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pharmacokinetics; Canagliflozin; Hemodialysis; Medicine; Intensive care medicine; Pharmacology; Urology; Internal medicine; Endocrinology","score_opus":0.013468320312816525,"score_gpt":0.2699309347900261,"score_spread":0.2564626144772096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397041132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922558,0.000022379403,0.000006567804,0.007244419,0.00011085867,0.00017016362,0.000008874825,0.0000070601063,0.00017384902],"genre_scores_gemma":[0.98691505,0.0005676546,0.00029205275,0.0108397715,0.00005691687,0.0000031283353,0.0000036750475,0.000014036138,0.0013077104],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988951,0.00007877354,0.0003556917,0.000105341576,0.00030686936,0.0002582043],"domain_scores_gemma":[0.9989201,0.000088666166,0.0006408493,0.00018686568,0.00010050936,0.00006302886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025943643,0.00010765217,0.000468498,0.000101194964,0.000028590935,0.0000025318257,0.00016799217,0.000019949497,0.000017576289],"category_scores_gemma":[0.000023615754,0.00006948151,0.00033373162,0.0005611829,0.0002462891,0.000023411632,0.0001133928,0.00016473129,0.000010434499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016672595,0.000725317,0.41512161,0.000065210734,0.0017717432,0.00003743463,0.0014635468,0.0018522913,0.008097191,0.000009307481,0.53974587,0.029443242],"study_design_scores_gemma":[0.004108145,0.0017064798,0.96077746,0.00004910601,0.00030186106,0.0000027832943,0.00030060788,0.00045214742,0.0005469369,0.000094851646,0.031587813,0.00007178949],"about_ca_topic_score_codex":0.00012562204,"about_ca_topic_score_gemma":0.00002799828,"teacher_disagreement_score":0.54565585,"about_ca_system_score_codex":0.00024932506,"about_ca_system_score_gemma":0.000039373303,"threshold_uncertainty_score":0.28333738},"labels":[],"label_agreement":null},{"id":"W4397041152","doi":"10.1681/asn.20233411s140d","title":"Sotagliflozin and Kidney and Cardiorenal Outcomes in SCORED","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cardiorenal syndrome; Kidney; Medicine; Intensive care medicine; Internal medicine","score_opus":0.014359947248338634,"score_gpt":0.2754075116195315,"score_spread":0.26104756437119286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397041152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97362137,0.00016349943,0.0000075667585,0.025996437,0.000048637754,0.00009148082,0.0000025466834,0.000005191993,0.0000632913],"genre_scores_gemma":[0.987281,0.0012498529,0.0016181649,0.009500222,0.000061866194,0.0000020365503,8.165872e-7,0.00000838923,0.0002776035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993822,0.00004476764,0.00021626799,0.00007407379,0.00014038544,0.00014230183],"domain_scores_gemma":[0.9994452,0.00008056519,0.00026480982,0.00010183933,0.000033007203,0.00007456415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026832637,0.000074590374,0.0004751959,0.00006732038,0.000022715549,0.0000039135566,0.00006519333,0.000025206904,0.0000036675406],"category_scores_gemma":[0.000042599346,0.000044750803,0.00018905156,0.00022278648,0.00043451344,0.000030202415,0.00009669582,0.00013110225,6.259481e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016168044,0.00008322372,0.8938335,0.00005341999,0.001145874,0.000024230716,0.0007789393,0.000008186575,0.014602253,0.000028401406,0.07755294,0.011727351],"study_design_scores_gemma":[0.0017050119,0.0005648688,0.9864177,0.000032703847,0.00021952578,0.000035941473,0.0007212931,0.000106226566,0.0001010511,0.00014926364,0.00990914,0.00003725963],"about_ca_topic_score_codex":0.000044453085,"about_ca_topic_score_gemma":0.0000027172348,"teacher_disagreement_score":0.092584215,"about_ca_system_score_codex":0.000024464358,"about_ca_system_score_gemma":0.00004274722,"threshold_uncertainty_score":0.18248847},"labels":[],"label_agreement":null},{"id":"W4397044190","doi":"10.1681/asn.20233411s1862b","title":"Empagliflozin in Patients with Acute Heart Failure and Diuretic Resistance: Preliminary Data from the DRIP-AHF-1 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Empagliflozin; Diuretic; Medicine; Heart failure; Cardiology; Internal medicine; Intensive care medicine; Endocrinology; Diabetes mellitus","score_opus":0.01573812460269754,"score_gpt":0.2701119835634588,"score_spread":0.25437385896076126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397044190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545939,0.0001517776,0.000005300032,0.044761103,0.00007914072,0.00035760173,0.00003300346,0.0000062532563,0.000011914464],"genre_scores_gemma":[0.99172693,0.0002361337,0.0021758205,0.0054406878,0.00018657999,0.000005013518,0.000032127733,0.000015752064,0.00018093153],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99894285,0.00012461608,0.00029345625,0.00015299371,0.0003022341,0.00018383384],"domain_scores_gemma":[0.99865294,0.00029840178,0.00046218955,0.00048635495,0.000055026765,0.00004509934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029444668,0.000110050096,0.00045670982,0.000033175744,0.000054380544,0.000009012448,0.0003345026,0.000034317796,0.000010276168],"category_scores_gemma":[0.00003979086,0.000054311146,0.00012647039,0.00035113672,0.0005258032,0.000075034106,0.00027085043,0.0002338791,0.0000017086421],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023322204,0.00030330385,0.2316135,0.000017366765,0.0016526954,0.000014651948,0.0006763291,0.000005820019,0.0003918231,0.000004466278,0.74128777,0.00071006006],"study_design_scores_gemma":[0.018545045,0.0028553733,0.94476867,0.00007679979,0.0007879043,0.0000036147624,0.0008736781,0.000042707776,0.000011102991,0.000086268476,0.031894542,0.00005431366],"about_ca_topic_score_codex":0.000042153013,"about_ca_topic_score_gemma":0.00004616715,"teacher_disagreement_score":0.71315515,"about_ca_system_score_codex":0.000028497827,"about_ca_system_score_gemma":0.00006661858,"threshold_uncertainty_score":0.22147442},"labels":[],"label_agreement":null},{"id":"W4397044465","doi":"10.1681/asn.20233411s1854c","title":"Effects of Ertugliflozin by Uric Acid Quintile: Observations from VERTIS CV","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Uric acid; Medicine; Internal medicine; Gout","score_opus":0.013273933150045467,"score_gpt":0.2553555073429219,"score_spread":0.24208157419287643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397044465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857593,0.00064618484,0.00010583163,0.013117834,0.00014195296,0.0001656562,0.000012683059,0.000013521101,0.000037008023],"genre_scores_gemma":[0.98639977,0.0016830304,0.0022186912,0.008883241,0.00014224464,0.000007027302,0.0000103498505,0.00001831339,0.0006373074],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990017,0.00007948373,0.0003696201,0.000097227516,0.00026790082,0.00018409714],"domain_scores_gemma":[0.99854785,0.0002999872,0.0007706818,0.00021401119,0.00010635199,0.000061088824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015434386,0.0001070838,0.00055667054,0.000051814444,0.00003727775,0.0000030307408,0.00022012659,0.000041343406,0.000022542019],"category_scores_gemma":[0.00006657978,0.000071970935,0.0004916569,0.0005521957,0.0003656793,0.000050418665,0.00010316939,0.00015211228,0.0000070386873],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010713071,0.00020884958,0.014489468,0.00004629532,0.0013346493,0.0000048671554,0.00040798855,0.000009009249,0.50741935,0.000009641508,0.47145355,0.004509218],"study_design_scores_gemma":[0.00218958,0.0016266824,0.9109857,0.00009177189,0.0009560627,0.0000054035263,0.000482585,0.0001776776,0.027126867,0.00030840677,0.055973165,0.0000760945],"about_ca_topic_score_codex":0.00010797774,"about_ca_topic_score_gemma":0.000002195655,"teacher_disagreement_score":0.89649624,"about_ca_system_score_codex":0.000053312564,"about_ca_system_score_gemma":0.00005622059,"threshold_uncertainty_score":0.29348895},"labels":[],"label_agreement":null},{"id":"W4397048266","doi":"10.1681/asn.20233411s1210d","title":"Computable Phenotype to Identify ADPKD Patients, A Validation Study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Phenotype; Medicine; Internal medicine; Urology; Computational biology; Biology; Genetics; Gene","score_opus":0.023056615440432606,"score_gpt":0.32071671934722457,"score_spread":0.297660103906792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397048266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940597,0.000017058917,0.000088041605,0.005230145,0.00015895089,0.00035487948,0.0000018548617,0.00001362198,0.00007576485],"genre_scores_gemma":[0.99371636,0.00003649845,0.0011014907,0.004695282,0.00011062587,0.00000405541,0.0000029605858,0.000011090242,0.00032165676],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990399,0.000080110156,0.00030792432,0.000093650866,0.00031153753,0.00016687028],"domain_scores_gemma":[0.99898994,0.00006495544,0.0005064688,0.00018963101,0.00018789338,0.00006109706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033254953,0.000082315506,0.00038287276,0.00007462246,0.000049163362,0.0000074088794,0.00016903506,0.000016738995,0.000019072193],"category_scores_gemma":[0.000029538935,0.00005429228,0.00025450584,0.0006240639,0.000095284086,0.000045719942,0.00014784545,0.000102028964,0.000024856048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048260545,0.0018469446,0.42507407,0.00004458214,0.0022607802,0.000008276787,0.003784264,0.0007667052,0.01126548,0.000014052052,0.5321815,0.022270728],"study_design_scores_gemma":[0.0015634798,0.003411562,0.9765507,0.000018172575,0.00040005025,0.0000020221153,0.0019103654,0.00009333348,0.000153946,0.00007485217,0.01577625,0.000045271812],"about_ca_topic_score_codex":0.00003994806,"about_ca_topic_score_gemma":0.0000013846949,"teacher_disagreement_score":0.5514766,"about_ca_system_score_codex":0.00006401043,"about_ca_system_score_gemma":0.000035254376,"threshold_uncertainty_score":0.22139749},"labels":[],"label_agreement":null},{"id":"W4398135650","doi":"10.1016/j.kint.2024.03.019","title":"Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Kidney Foundation of Canada; Department of Medicine, University of Toronto; Sanofi; University of Toronto; GlaxoSmithKline; Nierstichting; Canadian Society of Nephrology; Diabetes Canada; AstraZeneca; Eli Lilly and Company","keywords":"Kidney; Hemodynamics; Medicine; Pharmacology; Internal medicine","score_opus":0.01751939866468828,"score_gpt":0.31417237376718554,"score_spread":0.2966529751024973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398135650","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19592316,0.0018399715,0.53838575,0.1519991,0.022653395,0.025579384,0.001909613,0.0017758134,0.059933823],"genre_scores_gemma":[0.98781127,0.000013034216,0.00512934,0.000901606,0.0003136055,0.0007719018,0.00022241319,0.00002853156,0.0048082955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904907,0.000017863871,0.00019936323,0.00027429868,0.00031638355,0.00014304084],"domain_scores_gemma":[0.99939483,0.00015038173,0.000049989652,0.00013436015,0.00010967415,0.00016074613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025327696,0.00013583584,0.0001859522,0.00021337494,0.000021084157,0.000035245415,0.00010640511,0.00004881171,0.00021080462],"category_scores_gemma":[0.00094704377,0.00010734188,0.00018849925,0.000115646886,0.000030806168,0.00016048008,0.000057378835,0.00007651927,0.00005503189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025969173,0.0011589838,0.0033250027,0.008539188,0.009183928,0.00017965844,0.0010654937,0.000023576873,0.37867865,0.17907293,0.33600023,0.08017544],"study_design_scores_gemma":[0.010691179,0.008026868,0.0025651632,0.023324603,0.0025923196,0.000058164213,0.000106576044,0.078857705,0.67091113,0.056240786,0.14584392,0.00078157225],"about_ca_topic_score_codex":0.000019654744,"about_ca_topic_score_gemma":8.8833406e-7,"teacher_disagreement_score":0.7918881,"about_ca_system_score_codex":0.00021701526,"about_ca_system_score_gemma":0.0001737013,"threshold_uncertainty_score":0.43772748},"labels":[],"label_agreement":null},{"id":"W4398177417","doi":"10.1016/j.diabres.2024.111715","title":"Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Abbott Vascular; Respicardia; Impulse Dynamics; Novo Nordisk; Sanofi; Servier; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Empagliflozin; EMPA; Medicine; Diabetes mellitus; Outcome (game theory); Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.2303885741920907,"score_gpt":0.5665603329744388,"score_spread":0.33617175878234806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398177417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865519,0.00043026768,0.0000017507788,0.009818495,0.0001496825,0.001807104,0.000006985758,0.000016646907,0.0012171599],"genre_scores_gemma":[0.9985568,0.00047628122,0.000090518755,0.00021245852,0.00017897351,0.00012193958,0.000012609176,0.00001370169,0.0003367356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977399,0.00045735363,0.00049343484,0.00036412568,0.000566564,0.00037858315],"domain_scores_gemma":[0.9914226,0.008003135,0.00006266964,0.00024248476,0.000094999996,0.00017414417],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0060882713,0.00012693138,0.0003280987,0.00027584165,0.00008990066,0.00010752713,0.000100668076,0.00006981184,0.000030077117],"category_scores_gemma":[0.012347683,0.000068680034,0.00010134476,0.00050742517,0.00009167273,0.00026027768,0.000104563325,0.00053070317,0.000034371733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026927948,0.0043617166,0.8182527,0.00058646,0.0007874251,0.00012987728,0.0014818498,0.0000032644052,0.000012235002,0.0004519486,0.0047589513,0.14224565],"study_design_scores_gemma":[0.01968379,0.07457605,0.8843365,0.001450308,0.0004007018,0.0000025818233,0.0012158164,0.0010398144,0.000025274647,0.00044952278,0.016586637,0.00023302186],"about_ca_topic_score_codex":0.000031869047,"about_ca_topic_score_gemma":0.000025543233,"teacher_disagreement_score":0.14201263,"about_ca_system_score_codex":0.00009940442,"about_ca_system_score_gemma":0.000062491614,"threshold_uncertainty_score":0.99597174},"labels":[],"label_agreement":null},{"id":"W4398194417","doi":"10.1016/j.ekir.2024.04.028","title":"Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial","year":2024,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Kidney disease; Intensive care medicine; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Liraglutide","score_opus":0.006760990998999629,"score_gpt":0.2787462297808689,"score_spread":0.27198523878186925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398194417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91492367,0.00044423947,0.000059385206,0.044040978,0.0038123513,0.0027280378,0.00014559487,0.00012513265,0.033720605],"genre_scores_gemma":[0.9759955,0.000067666646,0.000028670076,0.0041037374,0.00016357806,0.0002297626,0.00039779884,0.000021923248,0.018991403],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816364,0.00007738333,0.00046846946,0.00034832727,0.0007430903,0.0001991023],"domain_scores_gemma":[0.99884564,0.0003364547,0.0001692274,0.00031394922,0.000056369023,0.00027835203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050572684,0.00018653412,0.00025738814,0.00023725539,0.000027934993,0.000052709715,0.00012625844,0.000042776042,0.00012087611],"category_scores_gemma":[0.0030667367,0.00011813732,0.0002202106,0.00015347234,0.000049633094,0.00007655847,0.000050655028,0.00017538546,0.000025816298],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030504973,0.002064335,0.09264038,0.0004937901,0.001132086,0.008726012,0.00042692941,0.00001171019,0.00017856865,0.0051994696,0.8800516,0.006024616],"study_design_scores_gemma":[0.022750044,0.0010457166,0.09487564,0.0011756695,0.0012573596,0.000028314842,0.00016321443,0.0005681317,0.0019945449,0.0065601026,0.8692324,0.0003488587],"about_ca_topic_score_codex":0.00021319902,"about_ca_topic_score_gemma":0.0000031016912,"teacher_disagreement_score":0.061071783,"about_ca_system_score_codex":0.00021680107,"about_ca_system_score_gemma":0.00034599012,"threshold_uncertainty_score":0.48175004},"labels":[],"label_agreement":null},{"id":"W4398209975","doi":"10.1097/01.hjh.0001021168.22478.d6","title":"A GENETIC RISK SCORE OF EARLY-ONSET TYPE 2 DIABETES PREDICTS EARLY DEATH AND BENEFITS OF INTENSIVE GLYCEMIC CONTROL IN ADVANCE TRIAL","year":2024,"lang":"en","type":"article","venue":"Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.021697082185094314,"score_gpt":0.24040613074070474,"score_spread":0.21870904855561044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398209975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787929,0.020107463,0.000009919867,0.0002064477,0.00042790073,0.0004168268,0.0000132244,0.000007183323,0.000018118742],"genre_scores_gemma":[0.99672645,0.002603742,0.00034619425,0.00016546162,0.00011239919,0.0000028319832,0.000001930431,0.000016714113,0.000024301778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988706,0.00004331111,0.0005208757,0.00013868354,0.000269322,0.00015721361],"domain_scores_gemma":[0.9987992,0.0001740362,0.00026924867,0.00012835936,0.00054549926,0.00008367574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019817372,0.00012819504,0.0005903908,0.0003134363,0.000012728471,0.000010469692,0.00005227594,0.000062235114,0.0000065749277],"category_scores_gemma":[0.00038037173,0.00008792765,0.00010813251,0.00017948862,0.000050856186,0.00010730519,0.000030692696,0.00018095029,0.000001578655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048011933,0.00045655904,0.9100459,0.00042789165,0.0010258008,0.0005457133,0.0005054187,0.00013548032,0.010279802,0.00001877221,0.0011651531,0.027381547],"study_design_scores_gemma":[0.04740912,0.017436063,0.92620003,0.003564047,0.001757677,0.00008308192,0.000089662906,0.0013679167,0.0016075715,0.00023125512,0.00014053004,0.00011303935],"about_ca_topic_score_codex":0.000022991679,"about_ca_topic_score_gemma":0.0000032410394,"teacher_disagreement_score":0.027268507,"about_ca_system_score_codex":0.000031564523,"about_ca_system_score_gemma":0.00006136954,"threshold_uncertainty_score":0.35855854},"labels":[],"label_agreement":null},{"id":"W4398242914","doi":"10.1111/cob.12676","title":"Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association","year":2024,"lang":"en","type":"article","venue":"Clinical Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; University of Toronto; Centre for Addiction and Mental Health; University Health Network","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Odds ratio; Confounding; Internal medicine; Confidence interval; Cohort; Population; Demography; Environmental health","score_opus":0.06029342697780082,"score_gpt":0.3783346624679802,"score_spread":0.3180412354901794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398242914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924817,0.00012713022,0.0003871313,0.0029241443,0.0013995507,0.0018556989,0.000016420641,0.00022110323,0.0005870857],"genre_scores_gemma":[0.9900229,0.00008193945,0.000492978,0.0007740829,0.0004959671,0.00007136903,0.0001463446,0.000025882398,0.007888516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779963,0.00030980335,0.00060952705,0.00056833046,0.00042619742,0.00028648463],"domain_scores_gemma":[0.99877167,0.00048068672,0.000103775,0.00025683633,0.00010415998,0.00028288446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002210621,0.00019886924,0.00054459326,0.00012831997,0.00010022555,0.00014060037,0.00006821377,0.00012927577,0.00015557946],"category_scores_gemma":[0.0005721819,0.0001663798,0.00018018023,0.00023637556,0.000027190583,0.00013826272,0.00012549416,0.00026096066,0.0003802149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013552946,0.004550427,0.9130903,0.00016639101,0.0022057341,0.00018467779,0.0007045721,0.0000041568132,0.0011374723,0.0001337627,0.049036887,0.02743036],"study_design_scores_gemma":[0.012637933,0.0027630324,0.9624359,0.00022038998,0.0021148084,0.0000019367974,0.00042547475,0.00064859446,0.0002715534,0.00012922876,0.018061513,0.00028961358],"about_ca_topic_score_codex":0.00010883928,"about_ca_topic_score_gemma":0.00010133915,"teacher_disagreement_score":0.049345657,"about_ca_system_score_codex":0.0002959066,"about_ca_system_score_gemma":0.00007640623,"threshold_uncertainty_score":0.67847717},"labels":[],"label_agreement":null},{"id":"W4398252779","doi":"10.1111/dom.15682","title":"Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute on Aging","keywords":"Medicine; Hazard ratio; Adverse effect; Internal medicine; Diabetic ketoacidosis; Diabetes mellitus; Heart failure; Type 2 diabetes; Population; Intensive care medicine; Confidence interval; Endocrinology","score_opus":0.007096238374035541,"score_gpt":0.2402489686211598,"score_spread":0.23315273024712427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398252779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88356537,0.11471349,0.000024219853,0.000057824698,0.0003130885,0.0007324331,0.000037823098,0.000048400816,0.00050733675],"genre_scores_gemma":[0.9927069,0.006759451,0.00022459636,0.000030414942,0.000067638495,0.0000328995,0.00008136882,0.000020550715,0.00007618375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852127,0.00016768872,0.00028776817,0.00049080304,0.00022182438,0.0003106558],"domain_scores_gemma":[0.99939334,0.0001649015,0.00003974475,0.00020112608,0.000045954468,0.00015492634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069265463,0.0002813026,0.0011082494,0.0002728696,0.0000777068,0.000054982833,0.00004115492,0.00010172516,0.000008153468],"category_scores_gemma":[0.000013118221,0.00024079716,0.00016743052,0.00026722217,0.00032604652,0.00022323272,0.000043105614,0.0001645472,0.000002622866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010789431,0.0019201963,0.65040284,0.0141428355,0.008410462,0.00014577416,0.013677172,0.000023568275,0.04486483,0.0088955965,0.00030245256,0.25613534],"study_design_scores_gemma":[0.0030948152,0.0001709692,0.9340457,0.0024512461,0.001754314,0.0000028194536,0.00034823772,0.00012366081,0.048269574,0.0003904906,0.009066134,0.00028204525],"about_ca_topic_score_codex":0.00004977702,"about_ca_topic_score_gemma":0.000007308321,"teacher_disagreement_score":0.28364286,"about_ca_system_score_codex":0.00003803312,"about_ca_system_score_gemma":0.00003115251,"threshold_uncertainty_score":0.9819423},"labels":[],"label_agreement":null},{"id":"W4398759815","doi":"10.1016/j.joca.2024.03.003","title":"Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial","year":2024,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"","keywords":"Semaglutide; Osteoarthritis; Medicine; Obesity; Physical therapy; Internal medicine; Alternative medicine; Endocrinology; Diabetes mellitus; Pathology; Type 2 diabetes","score_opus":0.01210937060350785,"score_gpt":0.2570969779581373,"score_spread":0.24498760735462943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398759815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729796,0.020065045,0.0000046860546,0.0015069349,0.0002530736,0.0025576334,0.00015979186,0.00007869429,0.0023945244],"genre_scores_gemma":[0.9954279,0.0026813634,0.00014478424,0.00034891066,0.00030454993,0.00012669277,0.00011388017,0.00003060677,0.0008213082],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979316,0.00020916533,0.0006174185,0.0006639541,0.0002479776,0.00032990094],"domain_scores_gemma":[0.9981496,0.0012066381,0.0000696375,0.0003442857,0.000027742666,0.0002021379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008916865,0.0002676525,0.00065582414,0.00006431413,0.00014210878,0.00021472115,0.000052518528,0.00011807348,0.000033380988],"category_scores_gemma":[0.00021059782,0.00017659005,0.00009041613,0.00017927331,0.0002574455,0.00012215307,0.000121721794,0.00027438236,0.000010362136],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20714633,0.0004466123,0.033036288,0.00016510727,0.00015408374,0.0012368056,0.0024645068,0.000001056796,0.00039591247,0.0003769935,0.0017932326,0.75278306],"study_design_scores_gemma":[0.82731843,0.010333765,0.109868854,0.0022759454,0.0009051939,0.00006885016,0.0012423021,0.00006589715,0.00014993918,0.00009642962,0.04722056,0.00045380867],"about_ca_topic_score_codex":0.00010193428,"about_ca_topic_score_gemma":0.0027804088,"teacher_disagreement_score":0.7523293,"about_ca_system_score_codex":0.000024306091,"about_ca_system_score_gemma":0.000056284185,"threshold_uncertainty_score":0.72011334},"labels":[],"label_agreement":null},{"id":"W4398794802","doi":"10.1016/j.kint.2024.05.006","title":"Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; Japan Society for the Promotion of Science; Canadian Institutes of Health Research; University of Toronto; Heart and Stroke Foundation of Canada; Kawasaki Medical School; Kidney Foundation of Canada","keywords":"Endocrinology; Internal medicine; Tubuloglomerular feedback; Afferent arterioles; Medicine; Angiotensin II; Glomerular hyperfiltration; Renal circulation; Renal function; Kidney; Renal blood flow; Diabetic nephropathy; Blood pressure","score_opus":0.018193765424106407,"score_gpt":0.29719449187652514,"score_spread":0.27900072645241875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398794802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925553,0.00089577766,0.0001270684,0.0027901041,0.0005879041,0.00036986213,0.000050032402,0.000025688638,0.0025982342],"genre_scores_gemma":[0.9986808,0.00008319372,0.0001754036,0.0003115659,0.00006161922,0.0000301737,0.00043902025,0.000015861475,0.0002023788],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988838,0.000033219916,0.00021430585,0.00020523938,0.00052977697,0.00013366665],"domain_scores_gemma":[0.999697,0.000013392392,0.000038780912,0.00008269247,0.000121057594,0.000047073565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000467397,0.000101958234,0.0001374534,0.00043763052,0.000007911724,0.000020867916,0.000034919878,0.00003234631,0.00053413655],"category_scores_gemma":[0.000046581823,0.00010025806,0.00003743327,0.0002337119,0.000025006508,0.00014824347,0.000016719421,0.000071685776,0.000011236917],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012840502,0.00090865087,0.079083584,0.00056312047,0.00056062645,0.00019865957,0.0012126868,0.0003995588,0.8535596,0.00071393856,0.006245668,0.056425516],"study_design_scores_gemma":[0.005115947,0.00013570138,0.024256065,0.0032058712,0.00083996763,0.000011671037,0.00018364191,0.7535287,0.20351446,0.0018122661,0.0070748986,0.00032082218],"about_ca_topic_score_codex":0.00008881514,"about_ca_topic_score_gemma":0.000051381357,"teacher_disagreement_score":0.7531291,"about_ca_system_score_codex":0.00046988283,"about_ca_system_score_gemma":0.00011318547,"threshold_uncertainty_score":0.584842},"labels":[],"label_agreement":null},{"id":"W4398882178","doi":"10.7910/dvn/x27dse/5smdhr","title":"Scopus_title_abstract_keywords.tab","year":2019,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Scopus; Information retrieval; Library science; Computer science; World Wide Web; Political science; MEDLINE; Law","score_opus":0.02047737156704415,"score_gpt":0.2672098960313179,"score_spread":0.24673252446427374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398882178","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000055673296,0.0000056395324,0.0000019077181,0.000016530337,0.0011579718,0.0008694792,0.9916031,0.0000608385,0.006228891],"genre_scores_gemma":[0.00001861979,0.00069999706,0.00018199811,0.001058087,0.00050052843,0.000037203048,0.9815474,0.000035658577,0.01592048],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832404,0.000020074178,0.00029010215,0.0005218857,0.00044592342,0.00039796726],"domain_scores_gemma":[0.9976339,0.000038620772,0.0001599542,0.0019378054,0.000049654172,0.00018009316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001328371,0.00037797308,0.0005864451,0.0002489857,0.00004339293,0.00006814403,0.00030796646,0.00024712892,0.056841247],"category_scores_gemma":[0.000059959508,0.00032953726,0.00019450256,0.0001248606,0.00005281408,0.00015537793,0.00033582657,0.0003360474,0.62517345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007451066,0.00032742808,0.00003645286,0.00060910225,0.00050499884,0.00036963678,0.000003162717,9.818114e-7,0.000007432933,0.000009611219,0.99717647,0.00088020397],"study_design_scores_gemma":[0.0014619507,0.00021183111,0.00022079542,0.00036807967,0.0014077765,0.000011249072,0.000016587634,0.0000034721834,0.000027807411,0.000004016526,0.995979,0.0002874246],"about_ca_topic_score_codex":0.0001436003,"about_ca_topic_score_gemma":0.000027295167,"teacher_disagreement_score":0.5683322,"about_ca_system_score_codex":0.0001430302,"about_ca_system_score_gemma":0.00014733039,"threshold_uncertainty_score":0.99991566},"labels":[],"label_agreement":null},{"id":"W4399011335","doi":"10.1681/asn.0000000000000418","title":"Effect of Avenciguat on Albuminuria in Patients with CKD","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Albuminuria; Medicine; Urology; Internal medicine; Kidney disease","score_opus":0.004727328556673477,"score_gpt":0.2513789879765259,"score_spread":0.24665165941985243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399011335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969978,0.00012404623,0.000005912096,0.0024516413,0.00007826981,0.000185733,0.0000014054337,0.000003371612,0.00015182595],"genre_scores_gemma":[0.99808216,0.000052676518,0.0003129898,0.0013895385,0.00004852128,0.0000018727372,6.735455e-7,0.0000100953675,0.0001014976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923664,0.00008845523,0.00023807902,0.000077313154,0.00023838501,0.00012111868],"domain_scores_gemma":[0.99929756,0.00015317107,0.00033120034,0.00014271449,0.000045515328,0.000029860532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028066587,0.00009125738,0.00045385293,0.00006260449,0.000009469472,0.000002325724,0.00010244407,0.00002366931,0.00001222015],"category_scores_gemma":[0.0000141375185,0.000045385255,0.00028405932,0.0002499913,0.00019542244,0.000029086628,0.000030911608,0.00016484811,0.0000018108615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010236628,0.0018718555,0.67137486,0.0009367475,0.005891694,0.000058596008,0.0023416907,0.00018991751,0.020395406,0.000100172016,0.1128529,0.1737495],"study_design_scores_gemma":[0.004383548,0.032013886,0.9518507,0.00047897748,0.0007872104,0.000008839695,0.00017049297,0.00007751048,0.0037525627,0.000045425633,0.006361443,0.00006937686],"about_ca_topic_score_codex":0.000017270915,"about_ca_topic_score_gemma":0.0000012087465,"teacher_disagreement_score":0.28047585,"about_ca_system_score_codex":0.000074302014,"about_ca_system_score_gemma":0.000039633476,"threshold_uncertainty_score":0.1850757},"labels":[],"label_agreement":null},{"id":"W4399012115","doi":"10.1038/s41591-024-03015-5","title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Medical Research Council; Eli Lilly Japan; Mitsubishi Tanabe Pharma Corporation; Relypsa; Teijin Pharma; Shionogi; Novo Nordisk; Bayer HealthCare; Intercept Pharmaceuticals; National Institutes of Health; Mylan; Astellas Pharma; FibroGen; MannKind Corporation; CSL Behring; National Institute for Health and Care Research; ReCor Medical; Intarcia Therapeutics; Boehringer Ingelheim Japan; Public Health England; McMaster University; Esperion Therapeutics; Alnylam Pharmaceuticals; British Heart Foundation; Brigham and Women's Hospital; Novartis Pharma; European Commission; Kowa Company; Sanofi; GlaxoSmithKline; Novo Nordisk Pharma; Amgen; Pfizer; Bayer Yakuhin; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Disease; Obesity; Term (time); Internal medicine; Kidney disease; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Liraglutide","score_opus":0.009524700846208177,"score_gpt":0.2818829617407348,"score_spread":0.27235826089452664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399012115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94996405,0.039517127,0.0000061382007,0.007969242,0.00038180704,0.0011544939,0.000005136106,0.000027764054,0.0009742279],"genre_scores_gemma":[0.99748164,0.000572599,0.000017226583,0.0011884719,0.00023283136,0.000041516872,0.00004723796,0.000011618009,0.00040684728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987481,0.00008336072,0.00023357425,0.00026872286,0.00048533652,0.00018090649],"domain_scores_gemma":[0.99935013,0.00014569816,0.000020297488,0.00034724319,0.000021045902,0.00011556551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083969854,0.00015436602,0.0005186764,0.00026817105,0.000013869825,0.0000075273383,0.00008402402,0.00009196452,0.00003584336],"category_scores_gemma":[0.0004534189,0.00007949073,0.00013718456,0.0004413774,0.00008627639,0.00003331983,0.000032961758,0.00040212114,0.0000022194452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017916255,0.00039817873,0.97548306,0.0011854161,0.0011050885,0.0017702527,0.0007415381,0.000002664112,0.00003845473,0.00065694016,0.004123999,0.012702758],"study_design_scores_gemma":[0.024537386,0.0003903744,0.9675826,0.0009715216,0.0014863384,0.0000047415,0.000050511277,0.00006966558,0.000036478126,0.00016612477,0.004622543,0.00008171049],"about_ca_topic_score_codex":0.00008270458,"about_ca_topic_score_gemma":0.000037259288,"teacher_disagreement_score":0.047517586,"about_ca_system_score_codex":0.000046571666,"about_ca_system_score_gemma":0.00006458229,"threshold_uncertainty_score":0.3241538},"labels":[],"label_agreement":null},{"id":"W4399035972","doi":"10.1016/j.fertnstert.2024.05.154","title":"Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists","year":2024,"lang":"en","type":"review","venue":"Fertility and Sterility","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Obesity; Body mass index; Fertility; Infertility; Psychological intervention; Glucagon-like peptide-1; Endocrine system; Pregnancy; Hormone; Gynecology; Endocrinology; Diabetes mellitus; Internal medicine; Intensive care medicine; Type 2 diabetes; Psychiatry; Population; Environmental health; Biology","score_opus":0.043338949872428506,"score_gpt":0.32079555573788476,"score_spread":0.2774566058654563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399035972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26874787,0.7282392,0.0000017104196,0.00011134402,0.00013700199,0.0015811776,0.00012601461,0.000037826456,0.0010178931],"genre_scores_gemma":[0.11919454,0.87949866,0.00012020267,0.0000859914,0.000036883765,0.00018856023,0.0002466648,0.00002675053,0.00060177385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971732,0.00046459038,0.000902492,0.0008201052,0.0002920975,0.00034755317],"domain_scores_gemma":[0.99856794,0.000246796,0.00018072026,0.00083788915,0.000044278186,0.00012237747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013979544,0.0005118475,0.001969709,0.00009078121,0.00009915548,0.000080757694,0.00016786356,0.0002497068,0.000052720432],"category_scores_gemma":[0.0001262705,0.00030420776,0.00037392555,0.000309891,0.00031406785,0.00009482014,0.00028339738,0.0005980646,0.000013518415],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001121158,0.00067769893,0.005490151,0.07145467,0.00035754975,0.000022173523,0.0008820192,8.305523e-9,0.0000010954839,0.000010322534,0.00016260357,0.91982055],"study_design_scores_gemma":[0.0006254543,0.00037093365,0.6651237,0.010955652,0.0031285277,0.000006685254,0.00021039504,0.00002061022,0.000003639031,0.00021494416,0.3190299,0.00030957483],"about_ca_topic_score_codex":0.0003537601,"about_ca_topic_score_gemma":0.00027138097,"teacher_disagreement_score":0.91951096,"about_ca_system_score_codex":0.00015211785,"about_ca_system_score_gemma":0.000120982746,"threshold_uncertainty_score":0.999941},"labels":[],"label_agreement":null},{"id":"W4399300362","doi":"10.1515/mr-2024-0018","title":"Hepatic function of glucagon-like peptide-1 and its based diabetes drugs","year":2024,"lang":"en","type":"review","venue":"Medical Review","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Servier","keywords":"Incretin; Type 2 diabetes; Glucagon-like peptide-1; Glucose homeostasis; Internal medicine; Insulin resistance; Medicine; Hormone; FGF21; Liraglutide; Exenatide; Insulin; Endocrinology; Diabetes mellitus; Receptor; Fibroblast growth factor","score_opus":0.02968044073132548,"score_gpt":0.3308260045596001,"score_spread":0.3011455638282746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399300362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008928314,0.9942749,0.0000049967302,0.0006812869,0.00047087608,0.0023235017,0.000014475458,0.000076567,0.0021444238],"genre_scores_gemma":[0.00000919625,0.9934179,0.000035433986,0.002235566,0.00014948573,0.00050875836,0.00036447047,0.000064959786,0.0032141986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970651,0.00017076709,0.0010244458,0.0005132126,0.0009043315,0.00032214422],"domain_scores_gemma":[0.9985598,0.0002854309,0.0002786046,0.00042823434,0.00006081856,0.0003871101],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010721684,0.0004945095,0.003328398,0.00020261496,0.000023386843,0.000013788074,0.00015285892,0.00023140163,0.0012171594],"category_scores_gemma":[0.00062574685,0.0002927133,0.0007543451,0.0005170551,0.000082260034,0.000036224686,0.00014618324,0.00039509483,0.00054872106],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[9.20146e-7,0.00006867524,0.0000028121535,0.41673923,0.00040586357,0.00001850053,0.0000017488532,5.79415e-10,2.128775e-8,0.000067110996,0.015040819,0.5676543],"study_design_scores_gemma":[0.00019100618,0.00019254077,0.0000017432745,0.3687513,0.019871177,0.00000186549,6.802208e-7,0.000023182309,2.1677032e-7,0.000009695937,0.61083066,0.00012592586],"about_ca_topic_score_codex":0.00000184008,"about_ca_topic_score_gemma":6.828592e-7,"teacher_disagreement_score":0.59578985,"about_ca_system_score_codex":0.00008764213,"about_ca_system_score_gemma":0.00038599866,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W4399305396","doi":"10.1200/jco.2024.42.16_suppl.12041","title":"The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; Body mass index; Internal medicine; Population; Oncology; Immune system; Immunology; Environmental health","score_opus":0.048425392446149594,"score_gpt":0.4182693096533779,"score_spread":0.3698439172072283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399305396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938321,0.00011001211,0.000016656953,0.00087313505,0.002410412,0.00063331815,0.000002451574,0.000015557292,0.0021063574],"genre_scores_gemma":[0.9989315,0.00006026618,0.000052245843,0.00006948894,0.0005234652,0.000010674935,0.000008820933,0.000024867299,0.00031863598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956813,0.0005058095,0.0027397391,0.00020057306,0.0006179144,0.00025470587],"domain_scores_gemma":[0.9949001,0.00294259,0.0014390368,0.0002583016,0.00026515155,0.00019483041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004240904,0.00019028502,0.0011453055,0.00021570119,0.00005743557,0.000033982524,0.00016381913,0.00018911419,0.000073924275],"category_scores_gemma":[0.002095078,0.00010142917,0.0010794264,0.00019042482,0.00007899211,0.00011428829,0.00005434783,0.0007439218,0.000008466715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025705013,0.0036988212,0.9411964,0.000028359289,0.0015741828,0.00013030095,0.000033500317,0.00036087382,0.000015328449,0.000026977004,0.000836291,0.04952848],"study_design_scores_gemma":[0.0072874334,0.023594094,0.96641225,0.00027405008,0.00048799245,7.4464367e-7,0.00006974226,0.0009452261,0.000016231446,0.00019341629,0.00063759554,0.00008122422],"about_ca_topic_score_codex":0.00021623512,"about_ca_topic_score_gemma":0.00005885756,"teacher_disagreement_score":0.049447257,"about_ca_system_score_codex":0.00048804472,"about_ca_system_score_gemma":0.00043493067,"threshold_uncertainty_score":0.41361615},"labels":[],"label_agreement":null},{"id":"W4399327175","doi":"10.1111/dom.15691","title":"Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the <scp>DECIDE</scp> ‐ <scp>CV</scp> clinical programme","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Janssen Research and Development; Novo Nordisk Foundation Center for Basic Metabolic Research; Boehringer Ingelheim","keywords":"Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Kidney disease; Mineralocorticoid receptor; Urology; Creatinine; Endocrinology; Aldosterone; Renal function; Outpatient clinic; Type 2 Diabetes Mellitus","score_opus":0.014026643978323644,"score_gpt":0.24731626414161395,"score_spread":0.2332896201632903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399327175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91538715,0.08043655,0.000027401164,0.0001032201,0.00061862747,0.0026522567,0.0003334095,0.00013479961,0.00030657978],"genre_scores_gemma":[0.99625945,0.0006553631,0.0010780017,0.00054417405,0.0004656614,0.0001401666,0.00057442987,0.000070144524,0.00021260149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632037,0.00026081302,0.00074312993,0.0010890597,0.00064551376,0.0009411236],"domain_scores_gemma":[0.99712336,0.0009782722,0.00021003342,0.00082167785,0.00028432117,0.0005823331],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010477384,0.00049474306,0.0013196623,0.00015757892,0.00023555376,0.00019873297,0.00021469111,0.00018974039,0.0000019549946],"category_scores_gemma":[0.0008498329,0.00032241354,0.00034346088,0.00051363924,0.00037602923,0.00024894424,0.00030624197,0.00042661218,0.0000072012485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021049225,0.0005070821,0.5707463,0.0007116247,0.00420876,0.000017574326,0.005446745,0.0000148578865,0.000022603874,0.00009679729,0.0022749999,0.41593158],"study_design_scores_gemma":[0.0041869553,0.0018055994,0.89956653,0.0010153712,0.002713731,2.0051974e-7,0.0014946446,0.0001271321,0.0015452188,0.00006868445,0.087360874,0.00011504147],"about_ca_topic_score_codex":0.0002224478,"about_ca_topic_score_gemma":0.000047785474,"teacher_disagreement_score":0.41581655,"about_ca_system_score_codex":0.00006740504,"about_ca_system_score_gemma":0.00017744601,"threshold_uncertainty_score":0.9999228},"labels":[],"label_agreement":null},{"id":"W4399395008","doi":"10.2337/dci24-0003","title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","year":2024,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Exenatide; Disease; Glucagon-like peptide-1; Obesity; Bioinformatics; Incretin; Glucagon receptor; Pharmacology; Internal medicine; Insulin; Endocrinology; Glucagon; Biology","score_opus":0.029276794947429324,"score_gpt":0.3232395925593571,"score_spread":0.2939627976119278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008490497,0.98735684,2.151389e-7,0.00006889845,0.00048546892,0.002643183,0.0002955425,0.0000779752,0.00058137893],"genre_scores_gemma":[0.0009546224,0.99646294,0.0001490466,0.00009104592,0.00030395953,0.0001863557,0.0013441062,0.00008453865,0.00042340576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984051,0.00003576865,0.00047243244,0.00053488434,0.00018786707,0.00036395396],"domain_scores_gemma":[0.9988304,0.00035041143,0.0001605386,0.00036130927,0.00013475199,0.00016258571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015811538,0.0004925502,0.0021753858,0.00026205112,0.00005352864,0.000029163502,0.000097273725,0.0002281807,0.000015024204],"category_scores_gemma":[0.00014078485,0.0003330921,0.00028442254,0.00026551506,0.00015696672,0.00004044123,0.00018407722,0.00016292663,0.000022348493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013834481,0.000056890687,0.006347231,0.18191154,0.0014557301,0.000003848906,0.00017917318,1.5579804e-8,0.0000018909028,0.00010306889,0.004535398,0.8053914],"study_design_scores_gemma":[0.0011868841,0.00084882294,0.0011261993,0.032065023,0.017695738,5.328703e-7,0.00010299261,0.0000037978918,0.000014671681,0.000043661337,0.9466248,0.00028684278],"about_ca_topic_score_codex":8.707211e-7,"about_ca_topic_score_gemma":0.0000014476079,"teacher_disagreement_score":0.94208944,"about_ca_system_score_codex":0.00006794397,"about_ca_system_score_gemma":0.00007887175,"threshold_uncertainty_score":0.9999121},"labels":[],"label_agreement":null},{"id":"W4399418656","doi":"10.1016/j.metabol.2024.155931","title":"DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","year":2024,"lang":"en","type":"article","venue":"Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Diabetes mellitus; Medicine; Cardiorenal syndrome; Intensive care medicine; Internal medicine; Heart failure; Endocrinology","score_opus":0.02111665158015343,"score_gpt":0.3091155394949836,"score_spread":0.2879988879148302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399418656","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04785965,0.84334356,0.0054454627,0.06825837,0.0055931583,0.008747122,0.0009639331,0.00050183514,0.019286912],"genre_scores_gemma":[0.85377645,0.07527638,0.04853669,0.0028414764,0.0019861576,0.0029733132,0.00050629687,0.00015481868,0.013948389],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905396,0.00003687846,0.0002305467,0.0002611056,0.00020187629,0.00021561529],"domain_scores_gemma":[0.9991572,0.00031920537,0.00005692649,0.00031340178,0.00007330942,0.000079950965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029831144,0.00015317358,0.00033017463,0.0001126326,0.00010141775,0.00006721365,0.000078640194,0.000025622872,0.000066179746],"category_scores_gemma":[0.000047802554,0.00009681931,0.00017473112,0.00024236809,0.00008650151,0.00017407372,0.000088848115,0.000064644046,0.000011909443],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047914058,0.00027565003,0.000405935,0.0007610457,0.006690365,0.000014989485,0.0002742254,0.0000043808545,0.000049832397,0.12315744,0.03387139,0.83444685],"study_design_scores_gemma":[0.0010124318,0.000037718517,0.030892722,0.00011859303,0.011214569,0.0000013076062,0.00030878728,0.00031650788,0.00025005182,0.00043019655,0.9553242,0.00009292482],"about_ca_topic_score_codex":0.00001239614,"about_ca_topic_score_gemma":0.0000015661741,"teacher_disagreement_score":0.9214528,"about_ca_system_score_codex":0.000015286421,"about_ca_system_score_gemma":0.000018974579,"threshold_uncertainty_score":0.3948177},"labels":[],"label_agreement":null},{"id":"W4399482438","doi":"10.1136/annrheumdis-2024-eular.3243","title":"OP0177 COMPARATIVE EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VS SULFONYLUREAS FOR PRIMARY AND SECONDARY GOUT PREVENTION AMONG PATIENTS WITH TYPE 2 DIABETES RECEIVING METFORMIN MONOTHERAPY: TARGET TRIAL EMULATION STUDIES","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Research Canada","funders":"","keywords":"Metformin; Medicine; Type 2 diabetes; Gout; Internal medicine; Glipizide; Diabetes mellitus; Pharmacology; Cotransporter; Endocrinology; Sodium; Chemistry","score_opus":0.03131485296954073,"score_gpt":0.3135715604556724,"score_spread":0.2822567074861317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399482438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795915,0.008549085,0.000047614183,0.0000542059,0.00021108941,0.0030224759,0.000081696555,0.000028565211,0.00004614075],"genre_scores_gemma":[0.99892604,0.00034975787,0.00016997635,0.000019471725,0.000018629054,0.00019981075,0.00022814171,0.000019839168,0.000068307476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989491,0.00011826203,0.00035778966,0.00019985822,0.0002302836,0.00014471183],"domain_scores_gemma":[0.9988546,0.0005095124,0.00022133611,0.00017153441,0.00019401665,0.00004903076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003233183,0.00018179922,0.0006214338,0.00010733194,0.00005872029,0.000020133215,0.000057423855,0.000029997425,0.000008745454],"category_scores_gemma":[0.00007429597,0.00010951413,0.0001688263,0.00016082071,0.00015089076,0.00027091263,0.000028383403,0.000040401643,3.6411427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062951215,0.004628255,0.7067893,0.042138446,0.018542767,0.0000025387353,0.0047997623,0.00019294038,0.00032788864,0.00045194192,0.001567657,0.15760726],"study_design_scores_gemma":[0.015948469,0.0035372502,0.95741445,0.008226582,0.0017174793,7.1482624e-8,0.00021752183,0.00043307664,0.009885207,0.002375266,0.00006837543,0.00017625807],"about_ca_topic_score_codex":0.000006879858,"about_ca_topic_score_gemma":0.000003145271,"teacher_disagreement_score":0.2506251,"about_ca_system_score_codex":0.000027814467,"about_ca_system_score_gemma":0.00006752712,"threshold_uncertainty_score":0.44658566},"labels":[],"label_agreement":null},{"id":"W4399527310","doi":"10.3389/jpps.2024.13065","title":"Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Diabetes Canada","keywords":"Amylin; Weight loss; Medicine; Type 2 Diabetes Mellitus; Glycemic; Type 2 diabetes; Glucose homeostasis; Obesity; Diabetes mellitus; Weight management; Population; Bioinformatics; Endocrinology; Insulin resistance; Biology; Environmental health","score_opus":0.22175488187480277,"score_gpt":0.43053591592908963,"score_spread":0.20878103405428686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399527310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7988868,0.18910503,0.00032129328,0.009349717,0.0007671771,0.00097063306,0.0000023152625,0.000022540018,0.0005745091],"genre_scores_gemma":[0.9673656,0.031077357,0.00080657395,0.00028390298,0.00019531604,0.000022226885,3.2897327e-7,0.000008408935,0.00024027558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987468,0.000044393793,0.00033316447,0.0001995316,0.00040653662,0.00026953605],"domain_scores_gemma":[0.99905336,0.0005732728,0.00009388653,0.000086104905,0.00006241349,0.00013094784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092120626,0.00014892228,0.0002629623,0.00015088501,0.00013670161,0.0000793153,0.00017171427,0.000013620527,0.00007859768],"category_scores_gemma":[0.000018091072,0.000074642725,0.00017820975,0.00039906125,0.0003224946,0.00019101065,0.000036565656,0.00007860858,0.0000029725377],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024786478,0.0007569746,0.022401052,0.00072993024,0.0014634035,0.00003149101,0.0005727586,0.00008140542,0.0023923344,0.0023049577,0.00037881196,0.968639],"study_design_scores_gemma":[0.004304014,0.004850111,0.0085287355,0.0009803554,0.009314348,0.000038851267,0.0010233227,0.15905735,0.037192855,0.0010216438,0.7734074,0.0002810322],"about_ca_topic_score_codex":0.0000021319386,"about_ca_topic_score_gemma":2.9546868e-7,"teacher_disagreement_score":0.968358,"about_ca_system_score_codex":0.00007662597,"about_ca_system_score_gemma":0.000059592083,"threshold_uncertainty_score":0.3043842},"labels":[],"label_agreement":null},{"id":"W4399545973","doi":"10.1111/dom.15711","title":"No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Semaglutide; Medicine; Pneumonia; Diabetes mellitus; Surgery; General surgery; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.0069880721845607605,"score_gpt":0.20729353006341633,"score_spread":0.20030545787885556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399545973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91573906,0.0062340484,9.3488933e-7,0.07554126,0.0002912246,0.00094334886,0.0001131504,0.00011593858,0.0010210306],"genre_scores_gemma":[0.7289318,0.003481804,0.00045634343,0.23523688,0.0037601602,0.0005905907,0.0025819845,0.00033890118,0.024621528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971465,0.00021070306,0.00041123395,0.00085767155,0.00048560393,0.0008883168],"domain_scores_gemma":[0.9980009,0.0012076031,0.00022341184,0.00026163648,0.00016564497,0.00014076848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005756608,0.0006288738,0.0016890572,0.000669656,0.00013768075,0.0002188208,0.00007639413,0.0005637995,0.000019034314],"category_scores_gemma":[0.00023027719,0.000510736,0.00016199845,0.00048765968,0.00008473592,0.00022894306,0.00014900003,0.0012035705,0.000051529118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009761194,0.00007601361,0.9314925,0.0013148618,0.0020756323,0.00007613401,0.00032645682,3.5322074e-7,0.00009543148,0.000028684566,0.06322305,0.0012810858],"study_design_scores_gemma":[0.0009517689,0.00017583501,0.85665447,0.0011875742,0.003240962,7.731253e-7,0.000030886105,0.000030149495,0.00043719934,0.00028989554,0.13643335,0.00056716875],"about_ca_topic_score_codex":0.00008690348,"about_ca_topic_score_gemma":0.00016478525,"teacher_disagreement_score":0.18680726,"about_ca_system_score_codex":0.00030254887,"about_ca_system_score_gemma":0.00017336267,"threshold_uncertainty_score":0.9997344},"labels":[],"label_agreement":null},{"id":"W4399670772","doi":"10.1093/asj/sjae132","title":"Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging","year":2024,"lang":"en","type":"review","venue":"Aesthetic Surgery Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Adipose tissue; Skin Aging; Stromal vascular fraction; Stem cell; Bioinformatics; Internal medicine; Endocrinology; Cell biology; Dermatology; Biology","score_opus":0.08433096166101105,"score_gpt":0.35079874931230925,"score_spread":0.2664677876512982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399670772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033501184,0.99202836,0.0000056129134,0.0018362285,0.00091526745,0.00060000404,0.00001639418,0.00003752094,0.0012104849],"genre_scores_gemma":[0.0012341418,0.99688625,0.0000570709,0.0001345565,0.00015908499,0.00006635999,0.000069524016,0.000065604705,0.0013274298],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981329,0.00015013396,0.0008013516,0.00030118434,0.0002795567,0.00033486832],"domain_scores_gemma":[0.9986305,0.0003120707,0.00047302735,0.00034623593,0.000080636135,0.0001575312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007970558,0.00037647717,0.0012451923,0.000457717,0.00022222254,0.00017913143,0.00015093002,0.00011895072,0.00009600166],"category_scores_gemma":[0.000023258532,0.00021328851,0.000704202,0.00041405435,0.00010259628,0.000054093776,0.0000782752,0.00053251255,0.00009817695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000068471686,0.00007943194,0.00005107799,0.0010706761,0.00042330273,0.0000399664,0.000069008216,1.7710647e-7,3.2404623e-7,0.00011163725,0.036417887,0.96172965],"study_design_scores_gemma":[0.0001651681,0.000068701986,0.0000351197,0.014203374,0.002457781,0.0027760537,0.000040423478,0.000002270011,0.0000039508154,0.00006671836,0.9799984,0.00018200552],"about_ca_topic_score_codex":0.000004499195,"about_ca_topic_score_gemma":0.0000014473136,"teacher_disagreement_score":0.9615477,"about_ca_system_score_codex":0.00016184636,"about_ca_system_score_gemma":0.0003275537,"threshold_uncertainty_score":0.8697653},"labels":[],"label_agreement":null},{"id":"W4399682276","doi":"10.1001/jama.2024.10510","title":"Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Dapagliflozin; Critically ill; Intensive care medicine; Organ dysfunction; Diabetes mellitus; Heart failure; Kidney disease; Type 2 diabetes; Acute kidney injury; Critical illness; Internal medicine; Endocrinology; Sepsis","score_opus":0.00710971516266763,"score_gpt":0.23965655311377732,"score_spread":0.2325468379511097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399682276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93678564,0.00016643302,0.0069519407,0.024643686,0.0010053616,0.001988127,0.00007443029,0.0004761899,0.02790819],"genre_scores_gemma":[0.96745604,0.000014549522,0.0044809333,0.0068368143,0.00034692415,0.00016618874,0.00046495645,0.000049694398,0.020183917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99943477,0.000004255953,0.00008322811,0.00017977034,0.0001401084,0.00015786213],"domain_scores_gemma":[0.9994719,0.000028821887,0.000008401976,0.00012601289,0.00030085718,0.0000640062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041988213,0.00008792122,0.00010817986,0.0000635217,0.000029127537,0.000057240257,0.00002553134,0.000034738707,0.00012268525],"category_scores_gemma":[0.00006839157,0.00005819034,0.000041939817,0.00010105326,0.00001775461,0.00011183015,0.000015641355,0.000046360263,0.00012352376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012993348,0.0010099147,0.02363744,0.00087758526,0.0026300172,0.00020295338,0.00030158658,0.0000011903109,0.0005422778,0.014518163,0.37164727,0.58333224],"study_design_scores_gemma":[0.01255404,0.005146386,0.1296766,0.00051614805,0.0033446504,0.000005043264,0.00011095532,0.0008699986,0.0019765315,0.000903489,0.8445831,0.00031308067],"about_ca_topic_score_codex":0.0000023951063,"about_ca_topic_score_gemma":0.0000017552283,"teacher_disagreement_score":0.5830192,"about_ca_system_score_codex":0.00005614956,"about_ca_system_score_gemma":0.000021835584,"threshold_uncertainty_score":0.23729332},"labels":[],"label_agreement":null},{"id":"W4399684070","doi":"10.2337/db24-914-p","title":"914-P: Association of Sodium–Glucose Cotransporter 2 Inhibitors with Risk of Diabetic Ketoacidosis among Hospitalized Patients—A Multicentre Cohort Study","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetic ketoacidosis; Medicine; Diabetes mellitus; Internal medicine; Population; Cohort; Ketoacidosis; Retrospective cohort study; Dapagliflozin; Type 2 diabetes; Type 1 diabetes; Endocrinology","score_opus":0.0025649520750894435,"score_gpt":0.19485835059256226,"score_spread":0.19229339851747282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399684070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624383,0.00033759535,0.000003778767,0.00004225106,0.00024408601,0.002354224,0.000078910474,0.00011010201,0.0005852434],"genre_scores_gemma":[0.99889535,0.00008562102,0.000114610586,0.000020650488,0.000039052626,0.00012369643,0.00020201909,0.00004773343,0.00047129052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980019,0.000083965846,0.00051365205,0.00038437152,0.00066610303,0.0003500495],"domain_scores_gemma":[0.99888813,0.00016485501,0.0003033303,0.0003197154,0.00022016489,0.00010380931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036080688,0.00026589574,0.0006678379,0.00023151244,0.00003617188,0.000025821819,0.000080287384,0.000085594664,0.000086413005],"category_scores_gemma":[0.00008217533,0.00019747384,0.00019738646,0.00039410827,0.00007460713,0.00016660306,0.000031267322,0.00013120995,0.000013050847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054288143,0.0018890382,0.98869014,0.000478227,0.003653823,0.000006542682,0.0010698204,0.0000042336037,0.00022522283,0.000003784488,0.0004476853,0.003477179],"study_design_scores_gemma":[0.003972988,0.001501646,0.9662415,0.0004714057,0.005283098,8.82488e-9,0.0002509222,0.0003342124,0.021649523,0.000010627527,0.00010070196,0.00018336636],"about_ca_topic_score_codex":0.00015330428,"about_ca_topic_score_gemma":0.000036439927,"teacher_disagreement_score":0.022448655,"about_ca_system_score_codex":0.00015597568,"about_ca_system_score_gemma":0.000027686658,"threshold_uncertainty_score":0.80527496},"labels":[],"label_agreement":null},{"id":"W4399684251","doi":"10.2337/db24-919-p","title":"919-P: Identifying Clinical Phenotypes in Patients with Type 2 Diabetes Using Unsupervised Cluster Analysis—Insights from the CANVAS Program and CREDENCE Trial","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Canagliflozin; Medicine; Phenotype; Internal medicine; Type 2 diabetes; Disease; Diabetes mellitus; Endocrinology; Genetics; Biology","score_opus":0.038684913586074406,"score_gpt":0.31957867309029725,"score_spread":0.28089375950422285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399684251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453163,0.0032441814,0.000005200601,0.00016816406,0.00040108693,0.0014126058,0.000011885912,0.00010066932,0.00012459856],"genre_scores_gemma":[0.99825615,0.000046516492,0.0006926421,0.00037234678,0.00022146922,0.00007169007,0.00023424381,0.00003022068,0.00007471907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998291,0.00013763331,0.0003980986,0.00050532253,0.000327513,0.00034039086],"domain_scores_gemma":[0.9989397,0.00047991416,0.0000658973,0.00033640862,0.0000731681,0.00010491505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002634847,0.00023221692,0.0005233426,0.00020753324,0.000083150386,0.00023518685,0.00011661771,0.00008545156,0.000041496878],"category_scores_gemma":[0.00009651904,0.00013406912,0.0001358526,0.0008793082,0.00014072614,0.00020593025,0.00010379148,0.00019175794,0.000012639275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064302055,0.00041777082,0.97608006,0.00007216475,0.0023652264,0.000006840406,0.000288203,0.000013683295,0.00003839363,0.000026463475,0.00014671689,0.01990144],"study_design_scores_gemma":[0.01581269,0.0013979457,0.96216303,0.0005664511,0.00549037,1.770551e-8,0.000103304585,0.012606245,0.00013243574,0.00016284238,0.0012940039,0.00027066522],"about_ca_topic_score_codex":0.00011113491,"about_ca_topic_score_gemma":0.00014108974,"teacher_disagreement_score":0.019630775,"about_ca_system_score_codex":0.000056006662,"about_ca_system_score_gemma":0.00005456826,"threshold_uncertainty_score":0.546718},"labels":[],"label_agreement":null},{"id":"W4399684427","doi":"10.2337/db24-911-p","title":"911-P: Effect of Dapagliflozin on Blood and Breath Ketones during Supervised Insulin Withdrawal in Adults with Type 1 Diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Type 2 diabetes; Internal medicine; Insulin; Endocrinology; Diabetes mellitus; Hypoglycemia; Crossover study; Placebo","score_opus":0.003562818521506282,"score_gpt":0.20644700466703805,"score_spread":0.20288418614553178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399684427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925611,0.0051214825,6.413654e-8,0.00012394335,0.00009702097,0.00072763534,0.000013459783,0.0001247234,0.00123055],"genre_scores_gemma":[0.9991247,0.00023361148,0.00007186646,0.000055109736,0.000066753455,0.00009215328,0.00006343208,0.000050075898,0.0002423127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864227,0.00005356388,0.00023584143,0.00043524185,0.00024329785,0.00038977092],"domain_scores_gemma":[0.9993231,0.00023257713,0.000037193033,0.0002673953,0.00003415478,0.00010552929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018209647,0.0003008877,0.00054665876,0.00036346546,0.00003199761,0.000036935755,0.0000700463,0.00007390611,0.000033716817],"category_scores_gemma":[0.00005144567,0.00020243709,0.00006212835,0.00045689353,0.000095028176,0.000121032965,0.000056520144,0.00014843486,0.000017488761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052373856,0.0003490406,0.96247613,0.003967941,0.00072031206,0.00011284116,0.00047857457,0.0000076907,0.020084474,0.00008651059,0.000052595664,0.0111401705],"study_design_scores_gemma":[0.01065997,0.011350286,0.5186046,0.008285995,0.0011272603,0.00000233948,0.00008911535,0.000730099,0.44857946,0.000030247475,0.0001263388,0.00041429416],"about_ca_topic_score_codex":0.000021423937,"about_ca_topic_score_gemma":0.000010079877,"teacher_disagreement_score":0.44387153,"about_ca_system_score_codex":0.000033242,"about_ca_system_score_gemma":0.000024406372,"threshold_uncertainty_score":0.8255145},"labels":[],"label_agreement":null},{"id":"W4399685632","doi":"10.2337/db24-406-p","title":"406-P: Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal function; Diabetic ketoacidosis; Internal medicine; Diabetes mellitus; Hazard ratio; Endocrinology; Relative risk; Proportional hazards model; Kidney disease; Type 1 diabetes; Confidence interval","score_opus":0.007938009751688953,"score_gpt":0.23258106322791042,"score_spread":0.22464305347622146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399685632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980309,0.016791027,7.925751e-7,0.0006482965,0.00026157848,0.00042588174,0.00007036397,0.000108755026,0.001384314],"genre_scores_gemma":[0.9968406,0.0018017504,0.00015512235,0.00028637523,0.000067975445,0.00007531503,0.00010354749,0.00003781638,0.0006315193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987192,0.000052202162,0.0002667004,0.0003692116,0.00020182105,0.00039087527],"domain_scores_gemma":[0.99910736,0.00018965754,0.000045320423,0.00029675543,0.000038247093,0.00032266063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023769705,0.00021667306,0.00040671483,0.0003452548,0.000027908342,0.000041451287,0.000070935544,0.000055814005,0.00015905824],"category_scores_gemma":[0.00030590483,0.00017652562,0.00010606537,0.0004801649,0.00012019699,0.0001260489,0.00008616502,0.00013011685,0.00005331374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020121752,0.00019772157,0.96832204,0.0012809635,0.0005718646,0.000017965793,0.0001186207,0.0000021856924,0.0024187122,0.00033706747,0.0032196818,0.023493072],"study_design_scores_gemma":[0.001612501,0.00064055907,0.95234287,0.0021220404,0.0026843245,1.09350445e-7,0.000059341317,0.00466443,0.021425152,0.0020754782,0.011977362,0.00039582996],"about_ca_topic_score_codex":0.000015986305,"about_ca_topic_score_gemma":0.0000018830456,"teacher_disagreement_score":0.023097241,"about_ca_system_score_codex":0.000045102624,"about_ca_system_score_gemma":0.0000610873,"threshold_uncertainty_score":0.7198506},"labels":[],"label_agreement":null},{"id":"W4399686518","doi":"10.2337/db24-1896-lb","title":"1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Dapagliflozin; Internal medicine; Placebo; TIMI; Type 2 diabetes; Diabetes mellitus; Endocrinology; Gastroenterology; Type 1 diabetes; Insulin; Myocardial infarction","score_opus":0.014935081411401912,"score_gpt":0.24960160459132216,"score_spread":0.23466652317992026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399686518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942191,0.0019983328,8.029757e-7,0.00039798647,0.00031794023,0.0011347199,0.000103097154,0.0002588365,0.0015691791],"genre_scores_gemma":[0.9964268,0.00006567967,0.00029194492,0.0012686771,0.000117505544,0.00012398488,0.00073700113,0.000113457674,0.0008549035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970239,0.0001963389,0.00048874016,0.0009549925,0.0006079545,0.0007280828],"domain_scores_gemma":[0.99778813,0.0011712895,0.00012665268,0.000488015,0.00012271952,0.00030316375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027993688,0.0005640181,0.0009757667,0.00037628715,0.000096757736,0.00018404452,0.00015940348,0.00024193805,0.00009298998],"category_scores_gemma":[0.00031185514,0.00037641078,0.000114397684,0.0006431156,0.00022627783,0.0002432157,0.00010408137,0.00049194734,0.00006708635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000409023,0.0009407625,0.98330104,0.00012680778,0.0018840535,0.00004953585,0.00021206892,0.000011467876,0.00008739188,0.00007548849,0.004597881,0.008304496],"study_design_scores_gemma":[0.00649654,0.003993945,0.981421,0.0024548275,0.0010740736,6.4444286e-8,0.00004237646,0.00031825242,0.0019365223,0.00015310232,0.0016080514,0.00050127733],"about_ca_topic_score_codex":0.00002220097,"about_ca_topic_score_gemma":0.00009089986,"teacher_disagreement_score":0.0078032194,"about_ca_system_score_codex":0.00018516074,"about_ca_system_score_gemma":0.00008270258,"threshold_uncertainty_score":0.9998688},"labels":[],"label_agreement":null},{"id":"W4399687142","doi":"10.2337/db24-749-p","title":"749-P: Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin—Pooled Subgroup Analysis of SURPASS-5 and -6","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Glycemic; Metformin; Post-hoc analysis; Type 2 diabetes; Hypoglycemia; Diabetes mellitus; Internal medicine; Basal insulin; Post hoc; Basal (medicine); Insulin; Insulin glargine; Subgroup analysis; Endocrinology","score_opus":0.02532341608843974,"score_gpt":0.2989148163364842,"score_spread":0.27359140024804446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399687142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775416,0.0006994243,0.00022513553,0.00025756736,0.000059972434,0.0007005431,0.00009448805,0.00007293823,0.00013576513],"genre_scores_gemma":[0.99853724,0.000027313577,0.00052354456,0.0004303801,0.000049194976,0.0001166908,0.0001781092,0.000036539328,0.00010099499],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986838,0.000041069186,0.00027558516,0.00037654713,0.0002191567,0.00040384076],"domain_scores_gemma":[0.9991473,0.00028914883,0.000080681435,0.00026124582,0.000072624534,0.00014902458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024435724,0.00021387002,0.0006254753,0.0004451169,0.000046926787,0.00005084179,0.0000559484,0.000057230187,0.00003839445],"category_scores_gemma":[0.00006515667,0.00015663709,0.00013199334,0.0005203146,0.00008041421,0.00014326048,0.00001953193,0.00006578711,0.0000048551665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004911044,0.0012163843,0.8528754,0.0018059686,0.03931877,0.00010977504,0.0012286826,0.001231691,0.025915027,0.005368458,0.00030187308,0.065716885],"study_design_scores_gemma":[0.018463356,0.014066367,0.1928877,0.0013153427,0.06985802,7.712844e-7,0.00043140905,0.65108037,0.048727483,0.001367826,0.0009138874,0.0008874657],"about_ca_topic_score_codex":0.00008929598,"about_ca_topic_score_gemma":0.000055529723,"teacher_disagreement_score":0.65998775,"about_ca_system_score_codex":0.000065986475,"about_ca_system_score_gemma":0.000052812684,"threshold_uncertainty_score":0.6387475},"labels":[],"label_agreement":null},{"id":"W4399687336","doi":"10.2337/db24-930-p","title":"930-P: Dapagliflozin Improves Glucose Metrics and Decreases Insulin Requirements in Adults with Type 1 Diabetes but Adds Ketosis Risk","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dapagliflozin; Ketosis; Glycemic; Type 1 diabetes; Insulin; Diabetes mellitus; Adverse effect; Basal insulin; Type 2 diabetes; Internal medicine; Crossover study; Diabetic ketoacidosis; Endocrinology; Placebo","score_opus":0.010783935483221633,"score_gpt":0.2384233436393054,"score_spread":0.22763940815608377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399687336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96574587,0.031609118,0.0000022497534,0.00015790576,0.00022268419,0.0008231792,0.00004691355,0.00022568634,0.0011663998],"genre_scores_gemma":[0.9933302,0.0044259825,0.00094394054,0.00031072216,0.000112741596,0.00017652314,0.00020455795,0.000071019196,0.00042432145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978835,0.00006627533,0.00036737593,0.00066236977,0.00038669878,0.00063377566],"domain_scores_gemma":[0.9988441,0.0003377716,0.00008818372,0.0003847921,0.000093156596,0.00025199793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033531844,0.00038984572,0.00053388486,0.0007146808,0.00007209205,0.00013847224,0.00012133071,0.000110634894,0.000063247455],"category_scores_gemma":[0.00039707878,0.00029061217,0.00008217581,0.0012452462,0.00012516399,0.00032583604,0.00013866364,0.00021488634,0.00005549657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015142026,0.00048508457,0.81887287,0.0010016343,0.00085744576,0.000057727237,0.00023336457,0.0000016098447,0.0040411646,0.00009333302,0.0009977506,0.17320658],"study_design_scores_gemma":[0.009610755,0.006692548,0.80684763,0.0059375414,0.0032482846,0.000001625122,0.000664191,0.008115969,0.14538954,0.0006896778,0.011502728,0.0012995171],"about_ca_topic_score_codex":0.00015112698,"about_ca_topic_score_gemma":0.000055655113,"teacher_disagreement_score":0.17190707,"about_ca_system_score_codex":0.00012643369,"about_ca_system_score_gemma":0.00006944975,"threshold_uncertainty_score":0.9999546},"labels":[],"label_agreement":null},{"id":"W4399688429","doi":"10.2337/db24-1086-p","title":"1086-P: Rural Residence Is Associated with a Lower Likelihood of Dipeptidyl Peptidase 4 Inhibitor Use for Treatment Intensification","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Residence; Medicine; Metropolitan area; Confounding; Metformin; Logistic regression; Demography; Cohort; Retrospective cohort study; Odds ratio; Environmental health; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.01979914233750992,"score_gpt":0.2574695701120748,"score_spread":0.23767042777456485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399688429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656427,0.0006634838,0.00003342153,0.0009235357,0.00015546166,0.001140758,0.000102513724,0.00015753736,0.00025901062],"genre_scores_gemma":[0.99384916,0.00006663238,0.00037165274,0.0002362827,0.000085467356,0.00034121072,0.00032398617,0.00004383395,0.0046817823],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988423,0.00001968542,0.00025971208,0.00031366947,0.00022197679,0.00034265986],"domain_scores_gemma":[0.9990446,0.00024204953,0.00008477236,0.00030719955,0.000218476,0.00010292246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011765703,0.00023228557,0.0003862474,0.00017075804,0.000043671345,0.00006796731,0.00005264231,0.00006922238,0.000049401096],"category_scores_gemma":[0.00013863316,0.0001582886,0.0001779918,0.00026285325,0.00007644413,0.00022132407,0.000023296732,0.000043365948,0.000026744545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014093267,0.007144301,0.6194495,0.00209556,0.0101834,0.00019381222,0.006251629,0.000010114367,0.13090864,0.0023679174,0.08140766,0.13857812],"study_design_scores_gemma":[0.019561274,0.034908447,0.274837,0.018888364,0.011427684,0.0000048698,0.0022256754,0.013242705,0.59025925,0.0015740917,0.03120154,0.0018690655],"about_ca_topic_score_codex":0.000030311945,"about_ca_topic_score_gemma":0.000015861726,"teacher_disagreement_score":0.45935065,"about_ca_system_score_codex":0.00020839089,"about_ca_system_score_gemma":0.000065658125,"threshold_uncertainty_score":0.6454822},"labels":[],"label_agreement":null},{"id":"W4399689569","doi":"10.2337/db24-826-p","title":"826-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function—ONWARDS 1–5","year":2024,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin; Internal medicine; Basal (medicine); Renal function; Subgroup analysis; Hypoglycemia; Basal insulin; Diabetes mellitus; Kidney; Endocrinology; Type 2 diabetes; Confidence interval","score_opus":0.008341590277433485,"score_gpt":0.23324896594564204,"score_spread":0.22490737566820856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399689569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837931,0.009654995,0.000007926865,0.0018902817,0.00032980597,0.0009267517,0.00019356374,0.00019138608,0.0030121994],"genre_scores_gemma":[0.99463046,0.00092894357,0.0005260157,0.0015550728,0.00012633312,0.000101493824,0.0006185318,0.000080288715,0.0014328696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975641,0.00008955473,0.00056362856,0.0006610262,0.0005043157,0.0006173967],"domain_scores_gemma":[0.99872535,0.00033293746,0.00011828544,0.0004043339,0.00010433416,0.00031475557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048158923,0.00042987047,0.00079321896,0.00043730202,0.00006607661,0.00009059389,0.00015499844,0.00017234572,0.00019169823],"category_scores_gemma":[0.00021613519,0.00033550384,0.000090549474,0.00097509957,0.00024210119,0.0002813193,0.00013841488,0.00031387014,0.00006905655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048066454,0.0012985467,0.8343673,0.001392727,0.001911596,0.000023471426,0.0008015115,0.000023720264,0.0045882594,0.0005789525,0.05107749,0.10345577],"study_design_scores_gemma":[0.016416704,0.008250538,0.62599516,0.0042579463,0.001907382,9.4273827e-7,0.0002905901,0.0015534805,0.022622248,0.00047905452,0.31717044,0.0010555055],"about_ca_topic_score_codex":0.00003405822,"about_ca_topic_score_gemma":0.000006919931,"teacher_disagreement_score":0.26609296,"about_ca_system_score_codex":0.0001241199,"about_ca_system_score_gemma":0.00021384298,"threshold_uncertainty_score":0.9999097},"labels":[],"label_agreement":null},{"id":"W4399753996","doi":"10.1007/s00213-024-06637-2","title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","year":2024,"lang":"en","type":"article","venue":"Psychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"Copenhagen Graduate School for Nanoscience and Nanotechnology; Københavns Universitet","keywords":"Semaglutide; Agonist; Alcohol; Endocrinology; Alcohol consumption; Glucagon-like peptide-1; Internal medicine; Receptor; Psychology; Pharmacology; Medicine; Biology; Diabetes mellitus; Biochemistry; Type 2 diabetes","score_opus":0.025994507510394355,"score_gpt":0.3494861348855281,"score_spread":0.32349162737513376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399753996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980417,0.0010337341,0.0000037408736,0.0014164323,0.0036533873,0.0015081238,0.000021378008,0.00010208512,0.01184408],"genre_scores_gemma":[0.9920739,0.00043395374,0.000061786865,0.00091416365,0.00017687482,0.00022863474,0.000037045822,0.000037037942,0.0060365982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982339,0.00025937858,0.0003778481,0.00048226208,0.00024466784,0.00040194613],"domain_scores_gemma":[0.99912286,0.0003121305,0.00008654049,0.00035981866,0.00002088685,0.00009774527],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042139145,0.00027963062,0.00042535298,0.0002727438,0.00005911483,0.000021415384,0.00018883485,0.0001180985,0.0015075214],"category_scores_gemma":[0.000028489516,0.00019635611,0.00022684789,0.00032689163,0.00013310395,0.000056474426,0.00007753403,0.00034838635,0.0007000543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007331985,0.0015094191,0.46478996,0.0046402426,0.0026230612,0.00047798135,0.0006469982,0.0005323534,0.21103458,0.0005126634,0.16211334,0.14378743],"study_design_scores_gemma":[0.047304716,0.007971499,0.4020658,0.0034052336,0.0042101704,0.00009590169,0.0000915139,0.005278027,0.27095273,0.00018697325,0.2573012,0.0011362117],"about_ca_topic_score_codex":0.000054901866,"about_ca_topic_score_gemma":0.000024774994,"teacher_disagreement_score":0.14265122,"about_ca_system_score_codex":0.00018868568,"about_ca_system_score_gemma":0.00003169707,"threshold_uncertainty_score":0.99940526},"labels":[],"label_agreement":null},{"id":"W4399782338","doi":"10.1152/physiol.00008.2024","title":"Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies","year":2024,"lang":"en","type":"review","venue":"Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Pharmacology; Cardiomyopathy; Chemistry; Medicine; Internal medicine; Heart failure","score_opus":0.05646146275070022,"score_gpt":0.3346306700683214,"score_spread":0.2781692073176212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399782338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003291836,0.9939533,7.191636e-8,0.000029310318,0.00024600263,0.00096988253,0.000050752402,0.000012044817,0.0014468239],"genre_scores_gemma":[0.004123637,0.9948343,0.00001683918,0.000010657452,0.00021983497,0.00030348852,0.00020874938,0.000022080681,0.00026039637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887496,0.0001038859,0.0004593958,0.0002615509,0.00012162922,0.00017855522],"domain_scores_gemma":[0.9993047,0.00011568871,0.00016018566,0.00037800963,0.000020324975,0.000021054722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008584086,0.00028301793,0.0018504282,0.00027001364,0.000008835453,0.000002775838,0.00010686918,0.00011755884,0.000016126827],"category_scores_gemma":[0.000006938592,0.00013643286,0.00066904083,0.00029097305,0.000095914394,0.000012077074,0.00003595577,0.00008951314,0.000026971815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001545873,0.0006073306,0.000016756128,0.017027086,0.0011086713,0.000022404418,0.0003834981,0.0000015215096,0.0000095814385,0.0009682875,0.0006426919,0.9791967],"study_design_scores_gemma":[0.00043474135,0.0017666848,0.0003632802,0.007734719,0.00625217,0.0000075478542,0.000065170316,7.0767686e-7,0.00003248261,0.00015143545,0.9830773,0.00011380213],"about_ca_topic_score_codex":0.000039792885,"about_ca_topic_score_gemma":0.0000069561784,"teacher_disagreement_score":0.9824346,"about_ca_system_score_codex":0.0000734407,"about_ca_system_score_gemma":0.00006641351,"threshold_uncertainty_score":0.5563571},"labels":[],"label_agreement":null},{"id":"W4399811711","doi":"10.1111/dom.15685","title":"Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the <scp>CREDENCE</scp> randomized trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Kidney disease; Proportional hazards model; Renal function; Stroke (engine); Heart failure; Confidence interval; Demography; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.00452194391986236,"score_gpt":0.20694754608862617,"score_spread":0.20242560216876382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399811711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794456,0.017547755,0.00003116112,0.00022454419,0.00021241223,0.0017227221,0.00008405825,0.00003342175,0.0006983266],"genre_scores_gemma":[0.99737155,0.0018270753,0.00013508066,0.00026903357,0.00005342625,0.0001127725,0.00004319318,0.000013564431,0.00017431495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979459,0.00048214445,0.00040604788,0.000503434,0.000355781,0.00030669378],"domain_scores_gemma":[0.99852735,0.0007420289,0.000078220415,0.00040916938,0.000051388837,0.00019185974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002787282,0.00027371396,0.0018991862,0.00047826918,0.00010357291,0.00007267521,0.000081471175,0.00010687038,0.00001258187],"category_scores_gemma":[0.0005495491,0.00015818697,0.0005997746,0.00096822676,0.0005026686,0.00015381814,0.0001417441,0.00021786807,2.6022198e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065343697,0.0003365579,0.9375233,0.0011138974,0.034779098,0.000020666928,0.001602898,0.000013116847,0.00003086231,0.0031450219,0.000041510346,0.014858716],"study_design_scores_gemma":[0.18692043,0.00005867189,0.77802783,0.00015029592,0.028565885,6.3055904e-7,0.00007608605,0.00057983986,0.00006828544,0.0005642238,0.004906499,0.00008129417],"about_ca_topic_score_codex":0.0005907403,"about_ca_topic_score_gemma":0.00018662398,"teacher_disagreement_score":0.18038607,"about_ca_system_score_codex":0.000019199382,"about_ca_system_score_gemma":0.00010708959,"threshold_uncertainty_score":0.64506775},"labels":[],"label_agreement":null},{"id":"W4399917167","doi":"10.2337/dc24-0491","title":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Center for Advancing Translational Sciences; Novo Nordisk; Bayer; Janssen Biotech; Philips; Pfizer; Eli Lilly and Company","keywords":"Semaglutide; Medicine; Overweight; Diabetes mellitus; Obesity; Internal medicine; Endocrinology; Type 2 diabetes; Liraglutide","score_opus":0.005736181937835766,"score_gpt":0.2722080342651685,"score_spread":0.2664718523273327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399917167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528617,0.0018464642,1.3034298e-7,0.000099622164,0.00007945842,0.0020904678,0.000018411009,0.00003488401,0.0005444101],"genre_scores_gemma":[0.9994201,0.000049124254,0.00005214166,0.00003890557,0.000045999062,0.00023525809,0.00006188972,0.000024654337,0.000071909766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853253,0.00020120741,0.00026216928,0.00032925938,0.000381292,0.00029352587],"domain_scores_gemma":[0.9990053,0.000545006,0.000086245986,0.00028174685,0.000035084893,0.00004657346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003901277,0.0002432599,0.0006102313,0.00025466376,0.000027787632,0.000022486332,0.00009192674,0.0000869016,0.000011421135],"category_scores_gemma":[0.000097740194,0.000109711036,0.00007569169,0.00053788326,0.00007609783,0.00006441325,0.000053269876,0.00018841699,0.0000028014538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008855197,0.00024491546,0.9615386,0.0034779662,0.00009703759,0.000030073707,0.0012337259,0.0000029214755,0.0011560865,0.000025745532,0.0001360078,0.02320171],"study_design_scores_gemma":[0.06765124,0.051407468,0.61608803,0.02264129,0.0011984784,0.0000016216101,0.0011851921,0.0014343689,0.23732528,0.00003799213,0.0005662696,0.0004627436],"about_ca_topic_score_codex":0.000018446339,"about_ca_topic_score_gemma":0.00009733654,"teacher_disagreement_score":0.34545058,"about_ca_system_score_codex":0.00008289657,"about_ca_system_score_gemma":0.000057348694,"threshold_uncertainty_score":0.44738862},"labels":[],"label_agreement":null},{"id":"W4400032054","doi":"10.1016/j.jchf.2024.05.007","title":"Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status","year":2024,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"Merck; Bayer","keywords":"Medicine; Heart failure; Internal medicine; Ejection fraction; Type 2 Diabetes Mellitus; Proportional hazards model; Diabetes mellitus; Cardiology; Clinical endpoint; Randomized controlled trial; Endocrinology","score_opus":0.006895647745036309,"score_gpt":0.23881978518964195,"score_spread":0.23192413744460563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400032054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324863,0.019930044,0.00003246856,0.045541458,0.00027126778,0.0010527774,0.00007168058,0.00030597512,0.00030800476],"genre_scores_gemma":[0.991028,0.0002248176,0.0041876645,0.0019934296,0.00015162045,0.00014606414,0.00019278366,0.00006927062,0.0020063648],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979778,0.000088299705,0.00029373262,0.0005811668,0.00042491677,0.0006340768],"domain_scores_gemma":[0.9990766,0.00013789748,0.000014415956,0.0004878958,0.00003454917,0.00024866144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046644497,0.00031769637,0.0007745442,0.00025175646,0.00005513179,0.000119662254,0.00005325479,0.00013213663,0.00023512609],"category_scores_gemma":[0.00008106965,0.00025048575,0.0003172986,0.0003879299,0.000059657712,0.00021485797,0.000092489674,0.00027446833,0.00017854507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011756915,0.0001769353,0.5109854,0.0004442266,0.00094337657,0.0000685689,0.00013376978,0.000009580879,0.0017365767,0.00006516571,0.47888398,0.006540689],"study_design_scores_gemma":[0.0014113156,0.000218848,0.044272877,0.0002371528,0.00038810648,0.0000050610597,0.00024091854,0.0003019948,0.0010050271,0.000035146368,0.95163953,0.00024400711],"about_ca_topic_score_codex":0.00013209412,"about_ca_topic_score_gemma":0.00006517864,"teacher_disagreement_score":0.47275555,"about_ca_system_score_codex":0.00009718319,"about_ca_system_score_gemma":0.000057283876,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4400040967","doi":"10.58931/cwht.2024.1210","title":"Consideration of Use of Semaglutide and Tirzepatide Prior to Pregnancy","year":2024,"lang":"en","type":"article","venue":"Canadian Women s Health Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Pregnancy; Obstetrics; Medicine; Biology; Endocrinology; Diabetes mellitus","score_opus":0.027723611996314075,"score_gpt":0.28605795128092654,"score_spread":0.25833433928461247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400040967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805237,0.0021124443,0.000024243825,0.0075237593,0.00013327405,0.0010973291,0.00007957779,0.000024245086,0.0009527321],"genre_scores_gemma":[0.9927842,0.0001392522,0.0010394765,0.0021492264,0.000017133485,0.000056836598,0.00001886226,0.000014722216,0.003780317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991705,0.00002469473,0.00025257855,0.00016691028,0.00009771198,0.0002876183],"domain_scores_gemma":[0.99909973,0.00006050904,0.000038636805,0.00016409767,0.000048254224,0.0005887826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014358616,0.000083664694,0.00024967617,0.0003159376,0.000035350047,0.000016163493,0.000019549985,0.000029892666,0.00011456784],"category_scores_gemma":[0.00007040318,0.00007627007,0.00002106114,0.00018462808,0.00002777845,0.000053379554,0.000011561379,0.00004546143,0.000011307874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119951306,0.00019722372,0.098901026,0.015793504,0.00079457817,0.00032657874,0.030044824,0.00003321329,0.00058714295,0.026421798,0.06594099,0.76083916],"study_design_scores_gemma":[0.0029454299,0.0052454304,0.3326869,0.013874459,0.00028641554,0.000026532121,0.0017424386,0.0010023343,0.0018559659,0.0010460238,0.6387076,0.0005805203],"about_ca_topic_score_codex":0.021603448,"about_ca_topic_score_gemma":0.03619137,"teacher_disagreement_score":0.7602587,"about_ca_system_score_codex":0.00047454628,"about_ca_system_score_gemma":0.0008694744,"threshold_uncertainty_score":0.9849118},"labels":[],"label_agreement":null},{"id":"W4400082753","doi":"10.54434/candj.172","title":"Non-Pharmacological Approach to Uncontrolled Type 2 Diabetes: A Case Report","year":2024,"lang":"en","type":"article","venue":"CAND Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Guelph; Canadian College of Naturopathic Medicine","funders":"","keywords":"Type 2 diabetes; Medicine; Type (biology); Diabetes mellitus; Intensive care medicine; Endocrinology; Biology","score_opus":0.024027613751771062,"score_gpt":0.3060956263218326,"score_spread":0.2820680125700616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400082753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9449896,0.001997764,0.00040706908,0.0021865228,0.0014098061,0.00056548166,0.0000021490407,0.00007267279,0.048368905],"genre_scores_gemma":[0.984691,0.00004529947,0.00082069746,0.0010538867,0.00081091933,0.000033975655,0.000009385533,0.00001669998,0.012518128],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910885,0.000016617812,0.00023268457,0.00019501414,0.00017392832,0.0002728745],"domain_scores_gemma":[0.99940324,0.000024999496,0.000032572207,0.000106225954,0.00007121228,0.0003617442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003605753,0.00012384032,0.00026224367,0.00014605602,0.00008138702,0.00011331421,0.000043004722,0.000042721844,0.0002748297],"category_scores_gemma":[0.000042912627,0.00007773531,0.00012207951,0.00023034084,0.000024558547,0.00005576843,0.000031609827,0.00022070948,0.00008697892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032919162,0.00056174374,0.0042452184,0.00018439324,0.0024054481,0.5566481,0.00040158874,0.000074497926,0.0016840802,0.00018730649,0.3970688,0.03620964],"study_design_scores_gemma":[0.01548072,0.0049577854,0.0030267073,0.00066610635,0.006955471,0.22873887,0.0012236697,0.012944239,0.0016593167,0.00039925007,0.72312814,0.00081971043],"about_ca_topic_score_codex":0.0000034021457,"about_ca_topic_score_gemma":9.501108e-7,"teacher_disagreement_score":0.32790923,"about_ca_system_score_codex":0.00013465702,"about_ca_system_score_gemma":0.000120485936,"threshold_uncertainty_score":0.3169954},"labels":[],"label_agreement":null},{"id":"W4400113119","doi":"10.1016/j.physbeh.2024.114622","title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review","year":2024,"lang":"en","type":"review","venue":"Physiology & Behavior","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Glucagon-like peptide-1; Agonist; Extant taxon; Reward system; Repurposing; Neuroscience; Glucagon-like peptide 1 receptor; Glucagon; Receptor; Biology; Medicine; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Insulin; Ecology","score_opus":0.029446049824018584,"score_gpt":0.3442676180926191,"score_spread":0.31482156826860047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400113119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004476714,0.98744047,8.996518e-8,0.00008005021,0.00074699445,0.010716655,0.00004942077,0.00021704883,0.00030157506],"genre_scores_gemma":[0.000056184275,0.98036075,0.000038965565,0.00097521045,0.0001772735,0.009716124,0.00082750944,0.00015280065,0.0076951985],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969267,0.0003056872,0.0009178801,0.001041935,0.00028264424,0.00052512134],"domain_scores_gemma":[0.9979942,0.00019573627,0.00039262776,0.0011451426,0.000045106688,0.0002272005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026714327,0.00096138316,0.005565292,0.0002848715,0.000089335816,0.000044149852,0.000232914,0.00032525597,0.000043619373],"category_scores_gemma":[0.000055409328,0.0006054623,0.0011073935,0.00028341505,0.00012171544,0.000039346607,0.0002499951,0.0005938997,0.0014866599],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005888577,0.0003579284,0.000006926889,0.9219677,0.00086591975,0.00048891787,0.000012713225,1.0976603e-9,0.00000638981,0.00005424571,0.009065112,0.067168295],"study_design_scores_gemma":[0.00028727305,0.00076686614,0.00009579619,0.67985046,0.14620359,0.0000841073,0.000003782045,7.873427e-8,0.000002213386,0.0000048539155,0.17231947,0.0003815202],"about_ca_topic_score_codex":0.00000944286,"about_ca_topic_score_gemma":0.0000015456992,"teacher_disagreement_score":0.24211723,"about_ca_system_score_codex":0.00025003197,"about_ca_system_score_gemma":0.00010750509,"threshold_uncertainty_score":0.9996397},"labels":[],"label_agreement":null},{"id":"W4400149484","doi":"10.14740/jem942","title":"Pharmacological Treatment of Diabetes Mellitus: An Overview of New Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetes Mellitus","year":2024,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Renal glucose reabsorption; Type 2 Diabetes Mellitus; Internal medicine; Blood pressure; Endocrinology; Type 2 diabetes; Insulin; Overweight; Obesity","score_opus":0.050120366969117876,"score_gpt":0.3296565074948773,"score_spread":0.2795361405257594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400149484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61521155,0.38277766,0.000014280785,0.00077661674,0.00059845846,0.00053407234,0.00003714956,0.000009947791,0.000040271745],"genre_scores_gemma":[0.7883747,0.21008578,0.00061858265,0.00008567371,0.00044187735,0.00004733037,0.000016524407,0.000019934176,0.00030959974],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819356,0.00008231779,0.00088037766,0.00023825557,0.00021159228,0.0003938786],"domain_scores_gemma":[0.9986768,0.00040402805,0.000380875,0.00021903765,0.00013941775,0.00017984357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016687234,0.0003087151,0.0012919313,0.00027161618,0.00004388838,0.0000110753535,0.00011443022,0.00009328664,0.0001123459],"category_scores_gemma":[0.000014732049,0.00016107422,0.0006196778,0.00015490274,0.00026721496,0.00013940419,0.000014992736,0.00008661264,0.0000010817158],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008045475,0.0063693034,0.01688287,0.0009019374,0.014178807,0.0000968339,0.0027107277,0.000020464375,0.044960283,0.0061849053,0.00093165465,0.90595764],"study_design_scores_gemma":[0.011880245,0.013819315,0.0399022,0.00027850183,0.018340873,0.00001638499,0.00030153219,0.00009147055,0.5203644,0.0014109976,0.39339626,0.0001978298],"about_ca_topic_score_codex":0.000019900195,"about_ca_topic_score_gemma":0.0000057085626,"teacher_disagreement_score":0.9057598,"about_ca_system_score_codex":0.00005012389,"about_ca_system_score_gemma":0.0001140305,"threshold_uncertainty_score":0.65684164},"labels":[],"label_agreement":null},{"id":"W4400149505","doi":"10.14740/jem946","title":"Dapagliflozin-Saxagliptin Combination - The Quest for Optimal Glycemic Control With Cardio-Renal Protection in Type 2 Diabetes Mellitus: An Expert Consensus in Indian Settings","year":2024,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca","keywords":"Dapagliflozin; Saxagliptin; Medicine; Glycemic; Diabetes mellitus; Type 2 Diabetes Mellitus; Type 2 diabetes; Intensive care medicine; Internal medicine; Endocrinology; Sitagliptin","score_opus":0.012109454695476148,"score_gpt":0.26257052001405345,"score_spread":0.2504610653185773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400149505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735826,0.020386793,0.00006989633,0.0046626613,0.00044632633,0.0007555717,0.000004253387,0.000016150498,0.00007573898],"genre_scores_gemma":[0.99804014,0.0007724721,0.0004806849,0.0003181495,0.00022672808,0.00007702643,0.000007123822,0.000015021922,0.000062626605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989939,0.000119038545,0.00031827114,0.0001701844,0.00011864072,0.00028000507],"domain_scores_gemma":[0.999503,0.00012356305,0.00011655226,0.000095288,0.000101897735,0.000059690643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039525086,0.00013982247,0.00040291963,0.00037376516,0.000046029043,0.000034294968,0.000057696707,0.00005496111,0.0000051492825],"category_scores_gemma":[0.00007705006,0.00008500585,0.000059212536,0.00017269634,0.00010777539,0.0001328662,0.000012673705,0.00030053582,0.0000010229558],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029013006,0.0031232375,0.04577498,0.0013625642,0.0076859663,0.0042566354,0.019757466,0.0011323176,0.049513567,0.03129059,0.0040509677,0.8030387],"study_design_scores_gemma":[0.11184553,0.021133633,0.28230637,0.0031542145,0.0050767465,0.00335485,0.00886449,0.00748397,0.03603173,0.0043071383,0.51509535,0.001345995],"about_ca_topic_score_codex":0.000036840953,"about_ca_topic_score_gemma":0.00004104059,"teacher_disagreement_score":0.8016927,"about_ca_system_score_codex":0.000050118113,"about_ca_system_score_gemma":0.00008499712,"threshold_uncertainty_score":0.34664378},"labels":[],"label_agreement":null},{"id":"W4400193509","doi":"10.2215/cjn.0000000000000498","title":"Frailty, Multimorbidity, and Polypharmacy","year":2024,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council; British Heart Foundation; Kidney Research UK; International Society of Nephrology; University of Oxford; Eli Lilly and Company","keywords":"Medicine; Polypharmacy; Multimorbidity; Comorbidity; MEDLINE; Intensive care medicine; Gerontology; Internal medicine","score_opus":0.07865413586486517,"score_gpt":0.4198363138522999,"score_spread":0.3411821779874348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400193509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96073484,0.0016674993,0.00012607896,0.036765553,0.00039055283,0.00010545003,0.0000025286417,0.0000114501645,0.00019602462],"genre_scores_gemma":[0.9582974,0.004039925,0.0038648546,0.032886278,0.00048380817,9.4618116e-7,5.431025e-7,0.0000122091415,0.00041406119],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99896705,0.00010123005,0.00050160533,0.00012027949,0.0001670447,0.00014280532],"domain_scores_gemma":[0.9988543,0.00046301,0.00035387854,0.00015800756,0.00006375807,0.00010707621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053451845,0.00009067358,0.00050914875,0.000029663333,0.000027364345,0.000009121399,0.0001500882,0.00003989715,0.000046601126],"category_scores_gemma":[0.000043995584,0.00005242121,0.0006852104,0.00016052311,0.0011435557,0.000043840097,0.00016266906,0.00036080668,0.000005469096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042926354,0.0005939185,0.10360511,0.00014463958,0.0037475992,0.00006619594,0.00027617769,0.0000023001114,0.010075592,0.00020035563,0.584434,0.29642487],"study_design_scores_gemma":[0.002458787,0.0028397534,0.37935457,0.0001457647,0.001523608,0.00020051684,0.000256879,0.0006905641,0.00036734648,0.00074783555,0.6113198,0.00009461699],"about_ca_topic_score_codex":0.000017567341,"about_ca_topic_score_gemma":5.549854e-7,"teacher_disagreement_score":0.29633024,"about_ca_system_score_codex":0.000020803665,"about_ca_system_score_gemma":0.00008120453,"threshold_uncertainty_score":0.4213479},"labels":[],"label_agreement":null},{"id":"W4400253430","doi":"10.1016/j.diabres.2024.111764","title":"Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network; Canada Research Chairs","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Cardiorenal syndrome; Diabetes mellitus; Type 2 diabetes; Inflammation; Internal medicine; Endocrinology; Heart failure","score_opus":0.01951353334113367,"score_gpt":0.39248677470615273,"score_spread":0.3729732413650191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400253430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961865,0.0011183495,1.2069293e-7,0.0003186735,0.00004930803,0.0006262327,0.0000083388095,0.000010579638,0.0016818943],"genre_scores_gemma":[0.9988598,0.0008516287,0.000093354094,0.000034501198,0.000038617025,0.000019900634,0.000025369302,0.000014000705,0.00006279263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823296,0.00045840567,0.00032753067,0.00029125667,0.00044388935,0.00024593572],"domain_scores_gemma":[0.9937604,0.005698577,0.000063716114,0.00016551702,0.00017727117,0.00013449497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002925666,0.000117771124,0.00039196303,0.00024380223,0.000027140495,0.00003652865,0.000037078957,0.0000832153,0.000008600948],"category_scores_gemma":[0.0033920428,0.00007805535,0.00003195516,0.00033048147,0.00032806437,0.00022401594,0.0000909262,0.0003573266,0.00000382594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004579621,0.00020959135,0.79741514,0.0009044894,0.00042129194,0.0000070338406,0.000027963673,2.0579098e-7,0.000113567774,0.0000592301,0.00026145348,0.19600044],"study_design_scores_gemma":[0.003537567,0.050177075,0.94032395,0.0010295986,0.00041684374,1.4697802e-7,0.00005652819,0.0002683966,0.001940011,0.00006754645,0.002079052,0.00010331406],"about_ca_topic_score_codex":0.000009182264,"about_ca_topic_score_gemma":0.0000016850179,"teacher_disagreement_score":0.19589713,"about_ca_system_score_codex":0.000024601793,"about_ca_system_score_gemma":0.000039927512,"threshold_uncertainty_score":0.4060837},"labels":[],"label_agreement":null},{"id":"W4400259970","doi":"10.1111/bph.16478","title":"Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge","year":2024,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kirsten og Freddy Johansens Fond; Vetenskapsrådet; Svenska Sällskapet för Medicinsk Forskning; Université de Montréal; Deutsche Forschungsgemeinschaft; Novo Nordisk; European Federation of Pharmaceutical Industries and Associations; Novo Nordisk Fonden; Robert Bosch Stiftung; McGill University","keywords":"Internalization; Arrestin; Receptor; Biology; Endocrinology; Internal medicine; Desensitization (medicine); G protein-coupled receptor; Agonist; Cell biology; Biochemistry; Medicine","score_opus":0.0175439384626931,"score_gpt":0.3069304405211329,"score_spread":0.2893865020584398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400259970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934394,0.007032639,0.0007036765,0.00035961936,0.0021834408,0.0002504051,0.000018739383,0.000021771984,0.000085784304],"genre_scores_gemma":[0.9878592,0.011041907,0.00012209603,0.000112227324,0.0005424113,0.0000054079055,0.000068587055,0.000025875408,0.00022232172],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986768,0.00010835725,0.0005950423,0.00019589087,0.00024820847,0.00017573794],"domain_scores_gemma":[0.999398,0.000035941637,0.00027313785,0.00005754274,0.00012274287,0.00011265695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025275175,0.00012914863,0.00033076908,0.00021085718,0.000041115258,0.000074136726,0.00007955841,0.00004754709,0.00020825471],"category_scores_gemma":[0.000014522132,0.00013212903,0.000091482805,0.00007240409,0.000044027915,0.00040289582,0.00005961857,0.00018367899,0.0000015652588],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003775796,0.005194751,0.07352847,0.002800195,0.007932478,0.015585009,0.0047003487,0.00017433809,0.36297593,0.0024084041,0.010003262,0.510921],"study_design_scores_gemma":[0.08022563,0.0254725,0.34625497,0.009955033,0.014676881,0.0068414123,0.0032897922,0.006489426,0.4872909,0.0017116064,0.015919529,0.0018723197],"about_ca_topic_score_codex":0.00021900468,"about_ca_topic_score_gemma":0.00023222885,"teacher_disagreement_score":0.5090487,"about_ca_system_score_codex":0.00014114715,"about_ca_system_score_gemma":0.00005069405,"threshold_uncertainty_score":0.53880656},"labels":[],"label_agreement":null},{"id":"W4400266239","doi":"10.1093/ndt/gfae150","title":"Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6","year":2024,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institutes of Health; European Commission; McMaster University; Gilead Sciences; Novo Nordisk; Sanofi; Centers for Disease Control and Prevention; American Society of Nephrology; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Albuminuria; Renal function; Semaglutide; Blood pressure; Urology; Body weight; Internal medicine; Bioelectrical impedance analysis; Baseline (sea); Diabetes mellitus; Endocrinology; Body mass index; Type 2 diabetes","score_opus":0.005266156124811175,"score_gpt":0.2516833400352597,"score_spread":0.24641718391044853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400266239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972502,0.0011284598,0.00031642205,0.0004141081,0.000092233706,0.0005571816,0.0001353135,0.000031494525,0.000074578595],"genre_scores_gemma":[0.99846005,0.00065445557,0.000036793645,0.00020371219,0.000043667278,0.000056850804,0.0003165577,0.000015071925,0.00021284321],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99884945,0.00020018712,0.00031427012,0.00030168556,0.00015532733,0.00017905342],"domain_scores_gemma":[0.99936056,0.000356911,0.00006050084,0.00012763578,0.000027591554,0.00006680313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004527584,0.00017841186,0.00045502256,0.00027666765,0.000023079645,0.00000914844,0.000025367677,0.00011805979,0.000037905585],"category_scores_gemma":[0.000026265207,0.0001329385,0.000073331736,0.00017910186,0.00007390846,0.000060889215,0.000009368657,0.000098344404,0.0000013368422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016707312,0.0020154375,0.30814934,0.022105817,0.012377767,0.00037907736,0.0059996424,0.00020157594,0.5444831,0.0019138776,0.00086007715,0.08480694],"study_design_scores_gemma":[0.01775941,0.00751877,0.7637618,0.0009168815,0.033274367,0.000020252557,0.00007223219,0.0058746776,0.16895172,0.00023932473,0.0013108836,0.00029968715],"about_ca_topic_score_codex":0.00004644637,"about_ca_topic_score_gemma":0.000057970126,"teacher_disagreement_score":0.45561245,"about_ca_system_score_codex":0.000010887066,"about_ca_system_score_gemma":0.000014223552,"threshold_uncertainty_score":0.54210746},"labels":[],"label_agreement":null},{"id":"W4400319636","doi":"10.1080/13696998.2024.2367919","title":"The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Insulet Corporation; Gilead Sciences; Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Roche Diabetes Care; Amgen","keywords":"Medicine; Observational study; Liraglutide; Type 2 diabetes; Dulaglutide; Exenatide; Health care; Diabetes mellitus; Glucagon-like peptide 1 receptor; Real world evidence; Intensive care medicine; Internal medicine; Family medicine; Agonist; Endocrinology","score_opus":0.03135285047652705,"score_gpt":0.3399828926197037,"score_spread":0.3086300421431767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400319636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938399,0.0016506392,3.049101e-7,0.0037880922,0.000073152616,0.0005838022,0.000003377182,0.0000019490121,0.000058778056],"genre_scores_gemma":[0.99192595,0.007559306,0.0001875637,0.00023887256,0.000023914401,0.000008517366,0.000002407046,0.000009557333,0.00004392923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833065,0.00014741199,0.001016539,0.00016001544,0.00020756802,0.00013780563],"domain_scores_gemma":[0.9975986,0.0017497705,0.0003887884,0.00009611801,0.000059856844,0.00010688989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016346098,0.00010973311,0.0005970894,0.00021898995,0.000018724071,0.000023839071,0.00004950341,0.000042012154,0.0000014263348],"category_scores_gemma":[0.00056600367,0.0000647902,0.0000279046,0.00015886573,0.00014109944,0.0001962626,0.000053086576,0.00020251403,8.978106e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000345298,0.0011686796,0.9725254,0.00004697853,0.00035834056,0.000037588696,0.00073147495,0.000017686012,1.3126899e-7,0.0003795304,0.00003975349,0.02434913],"study_design_scores_gemma":[0.0062932414,0.0044928333,0.98615766,0.00048916956,0.00010415764,0.000002508034,0.00073109486,0.0005035484,7.4169986e-7,0.00006898025,0.0011098933,0.000046176883],"about_ca_topic_score_codex":0.00035836085,"about_ca_topic_score_gemma":0.0022640422,"teacher_disagreement_score":0.024302954,"about_ca_system_score_codex":0.00025036975,"about_ca_system_score_gemma":0.00023727736,"threshold_uncertainty_score":0.26420677},"labels":[],"label_agreement":null},{"id":"W4400337564","doi":"10.1016/j.jcjd.2024.06.003","title":"Prescription Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes and Heart Failure With Reduced Ejection Fracture Admitted to a Tertiary Care Centre in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Heart failure; Type 2 diabetes; Diabetes mellitus; Medical prescription; Cotransporter; Internal medicine; Sodium; Cardiology; Endocrinology; Intensive care medicine; Emergency medicine; Pharmacology","score_opus":0.003033605051231973,"score_gpt":0.17408126280054292,"score_spread":0.17104765774931094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400337564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638134,0.0015927682,4.1508522e-7,0.0012843475,0.00018534015,0.0004960561,0.00002722678,0.0000065294284,0.0000259691],"genre_scores_gemma":[0.9992965,0.0000058310993,0.000096200434,0.00039437052,0.000048567967,0.000009135921,0.00007199644,0.000026360438,0.000051042618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886477,0.000028617596,0.0003197723,0.00021588392,0.00021101991,0.00035994672],"domain_scores_gemma":[0.99917734,0.00002304838,0.00009271978,0.000119955606,0.00014517023,0.00044177764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007232186,0.00019957933,0.00036432722,0.0005755955,0.000024728335,0.00003499938,0.000055073044,0.00007085165,0.000069104964],"category_scores_gemma":[0.000014771714,0.00015023681,0.000036840116,0.00030139383,0.000026761618,0.00018004917,0.000005128881,0.00029749348,4.0594773e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004372576,0.000030308604,0.9922988,0.0005013341,0.0001551682,0.00020300166,0.0034635598,0.000052297404,0.0006661772,8.6116006e-7,0.0014386163,0.0011461492],"study_design_scores_gemma":[0.0014575571,0.0007856386,0.97964853,0.0065780147,0.00018456843,0.0000036820227,0.0021977946,0.000015164661,0.0055872975,0.0000020217653,0.0033835736,0.00015615643],"about_ca_topic_score_codex":0.6787766,"about_ca_topic_score_gemma":0.99852824,"teacher_disagreement_score":0.31975162,"about_ca_system_score_codex":0.00078264525,"about_ca_system_score_gemma":0.0019988636,"threshold_uncertainty_score":0.61264795},"labels":[],"label_agreement":null},{"id":"W4400405364","doi":"10.1016/s2213-8587(24)00155-4","title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","year":2024,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; Toronto General Hospital; University of Toronto","funders":"Sanofi; Medical Research Council; Ramaciotti Foundations; AstraZeneca; Defense Acquisition Program Administration; National Health and Medical Research Council; Pfizer","keywords":"Medicine; Meta-analysis; MEDLINE; Library science; Internal medicine; Pharmacology; Biochemistry","score_opus":0.07908310206695787,"score_gpt":0.3579486775459569,"score_spread":0.27886557547899904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400405364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050284397,0.9843319,0.0000025401105,0.00075902505,0.00016114154,0.008250226,0.0005037516,0.000064468484,0.00089851755],"genre_scores_gemma":[0.002774131,0.9928476,0.0003653683,0.0001597023,0.00014993054,0.0019906198,0.0003736004,0.000072652976,0.001266367],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9940017,0.001926579,0.0021437085,0.0007602771,0.0003540337,0.00081372855],"domain_scores_gemma":[0.9923018,0.004548753,0.0019290039,0.00088549475,0.0002115977,0.00012330426],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0027452921,0.00087204226,0.026403781,0.0008011284,0.00007569945,0.00004828885,0.0002498749,0.00018387269,0.00012994684],"category_scores_gemma":[0.0008276517,0.00038039716,0.0023792516,0.0011946944,0.0007871512,0.00004735988,0.00022239993,0.00038892814,0.0000073724714],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009371342,0.00022945939,0.00030225478,0.007837633,0.9314799,0.000014275844,0.0002815613,0.000001964855,0.00002472503,0.00078166,0.0016969056,0.04797837],"study_design_scores_gemma":[0.045214973,0.00073489995,0.000032056316,0.0010972823,0.70561516,0.0000029693856,0.00007066708,0.0000065365725,0.000051594056,0.000021229549,0.24691014,0.00024250912],"about_ca_topic_score_codex":0.000021619277,"about_ca_topic_score_gemma":0.00003152239,"teacher_disagreement_score":0.24521324,"about_ca_system_score_codex":0.00006800222,"about_ca_system_score_gemma":0.00020446126,"threshold_uncertainty_score":0.9998648},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4400536929","doi":"10.1186/s12933-024-02328-6","title":"Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial","year":2024,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Eli Lilly and Company; American Heart Association","keywords":"Empagliflozin; Medicine; Internal medicine; Myocardial infarction; Type 2 diabetes; Cardiology; Conventional PCI; Hazard ratio; Percutaneous coronary intervention; Post-hoc analysis; Placebo; Randomized controlled trial; Confidence interval; Diabetes mellitus; Endocrinology","score_opus":0.008745993034455498,"score_gpt":0.25800549413405605,"score_spread":0.24925950109960054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400536929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865663,0.007900175,0.000025656866,0.00043007036,0.0020268175,0.002258121,0.00026650366,0.000081225546,0.00044513436],"genre_scores_gemma":[0.996465,0.0002529084,0.000019475825,0.0002572746,0.00034527804,0.0004158283,0.0018677209,0.00003429822,0.00034217825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743307,0.0009901988,0.00042001033,0.00045149284,0.0004713429,0.00023387955],"domain_scores_gemma":[0.9968836,0.0024228552,0.00006547018,0.00048243374,0.00005537538,0.00009027845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000740049,0.00030577384,0.0017452085,0.00013060296,0.00006664309,0.00001840573,0.0000852545,0.00017735927,0.00024760337],"category_scores_gemma":[0.0006006816,0.00016088723,0.0013280136,0.00019218975,0.00021425652,0.00007256549,0.00008142457,0.00022224442,0.00008628561],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48172414,0.000904788,0.06977692,0.00069382164,0.18138142,0.0004544434,0.0006869218,0.00009265385,0.00026834916,0.0009261034,0.07196148,0.19112895],"study_design_scores_gemma":[0.80726814,0.0052495003,0.09989345,0.0003312306,0.023341903,0.000034627104,0.00004857882,0.00023920501,0.0005239066,0.0005557771,0.061983872,0.00052979914],"about_ca_topic_score_codex":0.000035039244,"about_ca_topic_score_gemma":0.0000010866706,"teacher_disagreement_score":0.325544,"about_ca_system_score_codex":0.0000829322,"about_ca_system_score_gemma":0.000044514825,"threshold_uncertainty_score":0.6560791},"labels":[],"label_agreement":null},{"id":"W4400558398","doi":"10.2196/62667","title":"Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Aging","keywords":"Overweight; Semaglutide; Medicine; Randomized controlled trial; Insulin resistance; Preprint; Gerontology; Physical therapy; Diabetes mellitus; Obesity; Type 2 diabetes; Internal medicine; Endocrinology; Computer science; World Wide Web","score_opus":0.033725395934377816,"score_gpt":0.45878662488189736,"score_spread":0.4250612289475195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400558398","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14112085,0.000009696729,0.0000120097675,0.0001474115,0.0000030599924,0.85800034,0.0000061711185,0.000024232428,0.0006762327],"genre_scores_gemma":[0.12679063,5.7685355e-7,0.00011255957,0.000009513961,0.000052195643,0.8726954,0.00001649822,0.000026714808,0.0002959081],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970689,0.0011110211,0.00050039013,0.00046720973,0.000555512,0.00029698102],"domain_scores_gemma":[0.99744517,0.0018189519,0.00013346558,0.00026546526,0.00022434746,0.00011258368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038791134,0.00021169221,0.0012950874,0.00041780944,0.000071950075,0.00010926686,0.00010323187,0.00005992692,0.0000134222155],"category_scores_gemma":[0.00018167778,0.0001211493,0.00008771117,0.00039230016,0.00028636234,0.0001670619,0.00008496912,0.00018478323,6.559637e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.978456,0.0030614268,0.000119296936,0.010015867,0.00052629545,0.000013597799,0.00026755413,4.049976e-7,0.0020646423,0.0009527816,0.0010046705,0.0035174205],"study_design_scores_gemma":[0.93804497,0.034692362,0.00026442052,0.017036993,0.000092028546,5.12126e-7,0.00003126796,0.0010457018,0.0073426696,0.00020971075,0.0011341918,0.00010518559],"about_ca_topic_score_codex":0.0000145723325,"about_ca_topic_score_gemma":0.000009539988,"teacher_disagreement_score":0.040411085,"about_ca_system_score_codex":0.000065635424,"about_ca_system_score_gemma":0.00012336411,"threshold_uncertainty_score":0.4940325},"labels":[],"label_agreement":null},{"id":"W4400569777","doi":"10.1007/s11912-024-01577-8","title":"Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials","year":2024,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto; University Health Network","funders":"","keywords":"Cardiotoxicity; Medicine; Cancer; Diabetes mellitus; Pharmacology; Heart failure; Clinical trial; Intensive care medicine; Randomized controlled trial; Internal medicine; Chemotherapy; Oncology; Bioinformatics; Endocrinology","score_opus":0.4185682932926339,"score_gpt":0.5452794707253814,"score_spread":0.1267111774327475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400569777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011005729,0.9727743,6.0046295e-7,0.00017859098,0.0114006065,0.0038129846,0.000048938717,0.00020134311,0.000576861],"genre_scores_gemma":[0.00028356438,0.9943262,0.0000377842,0.000060113776,0.0027794177,0.0011300727,0.00044900674,0.00012619443,0.00080769666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935074,0.00053764554,0.0036885159,0.0013462299,0.0003602571,0.000559965],"domain_scores_gemma":[0.9966474,0.00041749407,0.0018075239,0.00065127935,0.000084952844,0.00039133691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003696745,0.0008148411,0.0057895994,0.00042482992,0.0001029654,0.0000636451,0.00009584272,0.00071756216,0.0001694728],"category_scores_gemma":[0.00023004493,0.0005330361,0.0016542698,0.0002723143,0.00018806476,0.00007831866,0.00015998364,0.0011451828,0.000045569068],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041043608,0.00068240816,0.005220993,0.016618742,0.0028494473,0.0023411978,0.00005859762,7.1943184e-8,3.6331863e-7,0.000016181342,0.006848259,0.9653227],"study_design_scores_gemma":[0.0014241304,0.00038655402,0.0011824138,0.025421362,0.01986642,0.000298956,0.000008718066,5.378402e-7,0.0000041210565,0.000028828043,0.9510188,0.00035913943],"about_ca_topic_score_codex":0.000019225465,"about_ca_topic_score_gemma":0.000024307055,"teacher_disagreement_score":0.96496356,"about_ca_system_score_codex":0.00045117832,"about_ca_system_score_gemma":0.0009962948,"threshold_uncertainty_score":0.9997121},"labels":[],"label_agreement":null},{"id":"W4400583524","doi":"10.1152/ajpheart.00446.2024","title":"Vascular regeneration: a new mechanism of glucagon-like peptide-1 receptor agonist-mediated cardioprotection?","year":2024,"lang":"en","type":"letter","venue":"American Journal of Physiology-Heart and Circulatory Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Diabetes Canada","keywords":"Cardioprotection; Agonist; Mechanism (biology); Regeneration (biology); Receptor; Cell biology; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Chemistry; Pharmacology; Internal medicine; Endocrinology; Medicine; Biology; Diabetes mellitus; Ischemia; Type 2 diabetes; Philosophy","score_opus":0.010864002769642065,"score_gpt":0.23022335060184385,"score_spread":0.2193593478322018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400583524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8786014,0.008577102,0.000040493516,0.10572392,0.0050970647,0.0014634168,0.000077584125,0.00014478217,0.0002742576],"genre_scores_gemma":[0.7472594,0.0031069834,0.0018052267,0.22525488,0.017899785,0.00011527098,0.0009639105,0.00033529062,0.0032592744],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971319,0.00032046394,0.00090257445,0.00072526006,0.00040938507,0.00051042024],"domain_scores_gemma":[0.99781597,0.000109785215,0.0009096419,0.0006391604,0.00030471588,0.00022071322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002753783,0.00056682987,0.0022554146,0.0004977845,0.00009691576,0.000018757368,0.00020129739,0.00047908773,0.000192192],"category_scores_gemma":[0.000034119756,0.00045953348,0.0009554553,0.0003829408,0.00066480646,0.00009788251,0.00011109488,0.0014281694,0.00008127269],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010417214,0.0000715495,0.000016025891,0.00035163015,0.0029311064,0.000009465755,0.000106673004,0.0000127090325,0.68490034,0.00006472594,0.31100136,0.00043020345],"study_design_scores_gemma":[0.0023561327,0.0065178913,0.014930511,0.0006611612,0.0037256067,0.00031838717,0.00026316138,0.000058782043,0.0038193583,0.0031018157,0.96350443,0.0007427324],"about_ca_topic_score_codex":0.00008751834,"about_ca_topic_score_gemma":0.0000012251544,"teacher_disagreement_score":0.681081,"about_ca_system_score_codex":0.00014906951,"about_ca_system_score_gemma":0.00048812316,"threshold_uncertainty_score":0.99978566},"labels":[],"label_agreement":null},{"id":"W4400650260","doi":"10.1001/jamainternmed.2024.2559","title":"Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany","year":2024,"lang":"en","type":"article","venue":"JAMA Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Weight loss; Glucagon-like peptide-1; Exenatide; Glucagon-like peptide 1 receptor; Internal medicine; Obesity; Endocrinology; Diabetes mellitus; Receptor; Agonist; Type 2 diabetes","score_opus":0.009186637104439958,"score_gpt":0.2770989490329122,"score_spread":0.26791231192847226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400650260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8111263,0.002143596,0.000031078558,0.15996698,0.0007790746,0.00045141947,0.0000061900073,0.00002729282,0.025468094],"genre_scores_gemma":[0.97152126,0.0003045677,0.000017010014,0.020922635,0.0008055622,0.00005563803,0.000014656068,0.000016145339,0.006342501],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987303,0.0000346499,0.00024938452,0.0002603188,0.00047551733,0.000249841],"domain_scores_gemma":[0.9993588,0.00021331146,0.000026230799,0.0002145319,0.00003163224,0.00015552879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038595602,0.00016389035,0.00026047885,0.00019223547,0.00002857545,0.000074029536,0.00022402212,0.00003895823,0.00028891786],"category_scores_gemma":[0.00009224568,0.000085740925,0.00002857448,0.00025361768,0.0000536488,0.00011478198,0.000109138586,0.00029569384,0.000027197135],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035733345,0.00011596559,0.21588618,0.00069205265,0.00043452933,0.005161995,0.0060020443,0.0000016287102,0.00016640025,0.0019750642,0.6646431,0.10456371],"study_design_scores_gemma":[0.0017187358,0.00037267845,0.35411188,0.0019104345,0.00017657732,0.000085235115,0.00029697534,0.00014670132,0.0001397808,0.00012146084,0.6408155,0.00010406389],"about_ca_topic_score_codex":0.18526454,"about_ca_topic_score_gemma":0.11680017,"teacher_disagreement_score":0.16039501,"about_ca_system_score_codex":0.00016512751,"about_ca_system_score_gemma":0.00009611343,"threshold_uncertainty_score":0.89931595},"labels":[],"label_agreement":null},{"id":"W4400760615","doi":"10.1530/joe-24-0011","title":"Incretin-mediated control of cardiac energy metabolism","year":2024,"lang":"en","type":"review","venue":"Journal of Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Incretin; Internal medicine; Endocrinology; Medicine; Glucagon-like peptide-1; Exenatide; Type 2 diabetes; Diabetes mellitus; Gastric inhibitory polypeptide; Insulin; Glucagon","score_opus":0.021683873185657756,"score_gpt":0.3090530070702104,"score_spread":0.28736913388455265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400760615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019987187,0.99349415,0.000012182516,0.00020808398,0.0019213452,0.0002826037,0.000054404318,0.000019522013,0.003987711],"genre_scores_gemma":[0.00033358956,0.99658287,0.0000933763,0.000112932714,0.00079876557,0.000026692838,0.00004788309,0.000054161745,0.0019497259],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976289,0.00021740238,0.0012741175,0.00020369345,0.00029861165,0.00037725412],"domain_scores_gemma":[0.99805534,0.00028504425,0.0010220843,0.00029347572,0.00020075963,0.00014328248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019902176,0.00037634824,0.0043267305,0.0009414751,0.000012593999,0.0000099164245,0.00021132968,0.00019221671,0.00010661967],"category_scores_gemma":[0.00014920063,0.00023266085,0.0016441911,0.00027033093,0.00009929343,0.000038860017,0.000074566306,0.0004950109,0.00006193983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064284526,0.00015916658,0.000016628273,0.0075841676,0.014415072,0.0010669295,0.000013780269,1.1895259e-7,0.000014697885,0.0042549404,0.012933056,0.9594772],"study_design_scores_gemma":[0.0009861116,0.00049140153,0.000014025849,0.0038263823,0.033610612,0.0003523588,0.000009986001,5.9521744e-7,0.000017168137,0.00007453134,0.96049094,0.00012589249],"about_ca_topic_score_codex":0.000011428127,"about_ca_topic_score_gemma":6.3973437e-7,"teacher_disagreement_score":0.95935124,"about_ca_system_score_codex":0.00010509686,"about_ca_system_score_gemma":0.0003297266,"threshold_uncertainty_score":0.94876343},"labels":[],"label_agreement":null},{"id":"W4400770067","doi":"10.1126/science.adn4128","title":"The benefits of GLP-1 drugs beyond obesity","year":2024,"lang":"en","type":"article","venue":"Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Glucagon-like peptide-1; Weight loss; Obesity; Anti obesity; Glucagon; Pharmacology; Exenatide; Medicine; Chemistry; Endocrinology; Diabetes mellitus; Type 2 diabetes; Insulin","score_opus":0.009595413287777086,"score_gpt":0.25990581905192706,"score_spread":0.25031040576415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400770067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341482,0.003164752,0.000006403143,0.001966429,0.00038028634,0.00014526816,0.0000016749094,0.000034981087,0.060152035],"genre_scores_gemma":[0.9928282,0.0001271837,0.00012537044,0.00009906724,0.000027285323,0.0000043554533,5.9152126e-7,0.0000021815665,0.006785778],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993999,0.0000027202564,0.00005927723,0.00012771277,0.00027564782,0.00013476209],"domain_scores_gemma":[0.9997107,0.000033590837,0.000010367852,0.00017229684,0.000032311716,0.0000407588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035310216,0.000036548812,0.000051034454,0.00004844255,0.00009686975,0.000039971183,0.00011917759,0.0000067327837,0.00001892314],"category_scores_gemma":[0.00002462008,0.00001980349,0.000025780582,0.00040550626,0.0002776532,0.00008088933,0.00006870623,0.000026806205,0.00006418514],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014462336,0.00015968739,0.012297965,0.00016044363,0.00006518679,0.000012412588,0.0014525362,0.000009248518,0.0057476833,0.23561554,0.0064238016,0.73804104],"study_design_scores_gemma":[0.000863983,0.0007930753,0.5237657,0.00055629504,0.00034428947,0.0000062531853,0.001006428,0.0021769716,0.11022408,0.012219623,0.3477911,0.00025222285],"about_ca_topic_score_codex":0.0000057193884,"about_ca_topic_score_gemma":0.000003043399,"teacher_disagreement_score":0.7377888,"about_ca_system_score_codex":0.000029178342,"about_ca_system_score_gemma":0.00006323995,"threshold_uncertainty_score":0.10230247},"labels":[],"label_agreement":null},{"id":"W4400863682","doi":"10.1093/cvr/cvae150","title":"New insights into the effects of glucagon-like peptide-1 on heart rate and sinoatrial node function","year":2024,"lang":"en","type":"letter","venue":"Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Sinoatrial node; Internal medicine; Cardiology; Endocrinology; Heart rate; Medicine; Chemistry; Blood pressure","score_opus":0.028820688549631556,"score_gpt":0.2946964192087164,"score_spread":0.2658757306590849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400863682","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11138952,0.36356187,0.00033432333,0.47917426,0.010693126,0.014928969,0.000008903378,0.00035408098,0.01955496],"genre_scores_gemma":[0.15311831,0.041017357,0.0006655424,0.4029238,0.0804389,0.0025849752,0.0020233502,0.0014243647,0.31580344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99577963,0.00084939273,0.00026788274,0.0007691815,0.0018176915,0.0005162462],"domain_scores_gemma":[0.99751204,0.00069602905,0.00003475527,0.0014233957,0.00020039684,0.00013336257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016184723,0.00034951762,0.0009084817,0.00063115725,0.00015575768,0.00013220192,0.00019305618,0.00041541367,0.00002284681],"category_scores_gemma":[0.00026487716,0.00021555669,0.0011760787,0.000561998,0.00021209902,0.000053585314,0.0003246768,0.0018608803,0.0003403849],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021253398,0.0000308698,0.000021033517,0.0033334722,0.008561011,0.00089822966,0.00028003452,0.000005052665,0.00030829417,0.000059525257,0.9602962,0.02599373],"study_design_scores_gemma":[0.0022086822,0.001194504,0.000680259,0.0010821671,0.0030436027,0.0000070238575,0.000029747398,0.00001079559,0.0011918269,0.00042833958,0.9899523,0.0001707431],"about_ca_topic_score_codex":0.00037664367,"about_ca_topic_score_gemma":0.0000050727303,"teacher_disagreement_score":0.32254452,"about_ca_system_score_codex":0.00020993808,"about_ca_system_score_gemma":0.00022799497,"threshold_uncertainty_score":0.8790147},"labels":[],"label_agreement":null},{"id":"W4400974639","doi":"10.3390/jmahp12030014","title":"Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison","year":2024,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Steno Diabetes Center Copenhagen; Bayer","keywords":"Canagliflozin; Medicine; Internal medicine; Type 2 diabetes; Confounding; Hazard ratio; Randomized controlled trial; Kidney disease; Diabetes mellitus; Confidence interval; Endocrinology","score_opus":0.03849699808939505,"score_gpt":0.3778843863415415,"score_spread":0.3393873882521464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400974639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887472,0.0045028804,0.0000032789621,0.005071009,0.00026447844,0.00067876425,0.000033810906,0.000016358264,0.00068221736],"genre_scores_gemma":[0.99853337,0.00048551828,0.00008798445,0.0004944869,0.00019984948,0.0000075045227,0.000043282664,0.000022086491,0.00012594779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828494,0.00015372732,0.00064148626,0.00018206863,0.00037809537,0.0003597123],"domain_scores_gemma":[0.9984957,0.0002426976,0.00041802254,0.00015873791,0.00012639194,0.00055842416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037621587,0.00020147527,0.0008425454,0.00078679976,0.00003874381,0.000051478033,0.00013528722,0.00003579737,0.000071429364],"category_scores_gemma":[0.00014148488,0.00014346131,0.00006141816,0.0007533923,0.00006425234,0.00023880089,0.00007661082,0.00027062904,0.0000017876216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015571277,0.0020814838,0.86455154,0.005910473,0.002175681,0.00007612511,0.001800664,0.00015644413,0.000004643145,0.00013669596,0.062096976,0.04543802],"study_design_scores_gemma":[0.011424132,0.003132956,0.9757545,0.0029327294,0.0003944352,5.6276457e-7,0.00004065207,0.0004875784,0.000011034431,0.00002390584,0.0056794933,0.00011799414],"about_ca_topic_score_codex":0.00079125445,"about_ca_topic_score_gemma":0.0004717631,"teacher_disagreement_score":0.11120301,"about_ca_system_score_codex":0.0007331494,"about_ca_system_score_gemma":0.0018438839,"threshold_uncertainty_score":0.5850182},"labels":[],"label_agreement":null},{"id":"W4401033823","doi":"10.1111/dom.15798","title":"Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Esperion Therapeutics; Kowa Company; National Institutes of Health; Amarin Corporation; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute; Pfizer; Amgen; AstraZeneca; Eli Lilly and Company; Eisai; American Heart Association","keywords":"Medicine; Pharmacotherapy; Weight loss; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Internal medicine; Obesity; Endocrinology","score_opus":0.012279429574224746,"score_gpt":0.2620909850618799,"score_spread":0.24981155548765516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401033823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404876,0.05808879,0.0000048368006,0.00030936374,0.00024268268,0.00045333986,0.00005951242,0.000067339104,0.00028651705],"genre_scores_gemma":[0.97831506,0.020370169,0.00041295667,0.00020709466,0.00014419448,0.000016254342,0.000030087771,0.000018054778,0.00048615783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988099,0.00007434755,0.0002797942,0.00033299092,0.000199803,0.0003031725],"domain_scores_gemma":[0.9992393,0.0002588545,0.00008484622,0.00017844338,0.000042992608,0.00019551766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031376738,0.00022788918,0.00064057886,0.0001838169,0.000049676324,0.000025841513,0.00007624223,0.00009538592,0.0001329317],"category_scores_gemma":[0.00005356125,0.00015906825,0.00015525575,0.00023113983,0.00024031318,0.00011644887,0.000089808,0.00015168378,0.000006980883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008708499,0.0008026784,0.83801645,0.0003670934,0.0027418234,0.000010274252,0.00055091537,9.20902e-7,0.013131876,0.0013862685,0.0023823678,0.14052226],"study_design_scores_gemma":[0.0033219566,0.0002903399,0.8828224,0.0001241926,0.0022688513,5.535724e-7,0.000015869518,0.00013639306,0.0855447,0.0011174845,0.024199814,0.00015747389],"about_ca_topic_score_codex":0.00001544927,"about_ca_topic_score_gemma":5.893324e-7,"teacher_disagreement_score":0.14036478,"about_ca_system_score_codex":0.0000076020683,"about_ca_system_score_gemma":0.000032531207,"threshold_uncertainty_score":0.6486615},"labels":[],"label_agreement":null},{"id":"W4401067215","doi":"10.1016/s2213-8587(24)00182-7","title":"Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; LMC Diabetes & Endocrinology (Canada)","funders":"Steno Diabetes Center Aarhus; Novo Nordisk","keywords":"Medicine; Semaglutide; Prediabetes; Placebo; Double blind; Physical therapy; Internal medicine; Diabetes mellitus; Type 2 diabetes; Alternative medicine; Endocrinology","score_opus":0.02610063540675881,"score_gpt":0.2991046831145682,"score_spread":0.2730040477078094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401067215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98109096,0.005409844,0.0000056728263,0.0024114975,0.00033541894,0.00794452,0.000034240762,0.0001544219,0.0026134162],"genre_scores_gemma":[0.99637836,0.00094478135,0.00026033277,0.00010987201,0.00033589694,0.000941839,0.000061034032,0.000043327313,0.0009245374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970788,0.0002616204,0.0005860357,0.00061427103,0.00026519608,0.0011941018],"domain_scores_gemma":[0.99635255,0.0027635193,0.00016907317,0.00051122793,0.00005373321,0.00014987646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006992774,0.00043469158,0.0017411968,0.00026484102,0.00009754107,0.0000617004,0.00019752697,0.00010764753,0.00009113256],"category_scores_gemma":[0.00021544422,0.00027154587,0.00013490333,0.00031162708,0.0003723849,0.000110141074,0.00019406286,0.00036604406,0.000018749235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9707719,0.00083640666,0.009095177,0.00049192796,0.002315425,0.00008097535,0.00059076474,0.000029095114,0.0003065887,0.00070951786,0.00057353184,0.014198656],"study_design_scores_gemma":[0.98390406,0.0036905666,0.0024883498,0.00034466165,0.0023688104,0.0000061798373,0.0002419271,0.0026717791,0.0008444218,0.00004313871,0.0031356246,0.00026048147],"about_ca_topic_score_codex":0.000055010383,"about_ca_topic_score_gemma":0.00024226193,"teacher_disagreement_score":0.015287411,"about_ca_system_score_codex":0.00009578718,"about_ca_system_score_gemma":0.00009255655,"threshold_uncertainty_score":0.99997365},"labels":[],"label_agreement":null},{"id":"W4401074676","doi":"10.1681/asn.0000000000000466","title":"Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients with CKD","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Hypoglycemia; Medical prescription; Type 2 Diabetes Mellitus; Renal function; Internal medicine; Kidney disease; Type 2 diabetes; Intensive care medicine; Endocrinology; Pharmacology","score_opus":0.005886983062725041,"score_gpt":0.23394013177686782,"score_spread":0.22805314871414278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401074676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197626,0.00036102315,0.000035137364,0.007163231,0.0001242952,0.00018712338,0.0000025587779,0.000007269183,0.00014309709],"genre_scores_gemma":[0.99346954,0.00018407163,0.00090322056,0.0051431707,0.00010623339,0.0000026716207,0.0000021533936,0.000014761602,0.0001741896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991446,0.00003183127,0.00030609797,0.00010040838,0.00024595959,0.00017107688],"domain_scores_gemma":[0.9994278,0.000043854943,0.00027283095,0.000136041,0.00007122293,0.00004824765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014119112,0.00010573152,0.0003823393,0.00006987046,0.00001652595,0.00000586413,0.00010402765,0.000030236733,0.0000310973],"category_scores_gemma":[0.0000030677113,0.00005721786,0.0003068318,0.00030977605,0.0003460422,0.000066571425,0.000026470378,0.0002186724,0.0000023589773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009816211,0.0013999591,0.8133286,0.00024133845,0.002370393,0.00008210031,0.0030921104,0.000036116115,0.0065672463,0.0000420574,0.13125543,0.040603023],"study_design_scores_gemma":[0.0023906275,0.0016782662,0.95621246,0.00020820236,0.0004337822,0.000013573425,0.00039045417,0.000039069808,0.00045691305,0.000048112935,0.038062733,0.0000658048],"about_ca_topic_score_codex":0.000026846936,"about_ca_topic_score_gemma":0.0000061537685,"teacher_disagreement_score":0.14288385,"about_ca_system_score_codex":0.00007602027,"about_ca_system_score_gemma":0.000069527196,"threshold_uncertainty_score":0.23332766},"labels":[],"label_agreement":null},{"id":"W4401163838","doi":"10.1007/s13300-024-01628-0","title":"Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies","year":2024,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"AstraZeneca; Amgen","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.04936297382883068,"score_gpt":0.383220159848608,"score_spread":0.3338571860197773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401163838","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005047028,0.99449295,9.558339e-7,0.0005767013,0.0003405176,0.0029632712,0.000049602837,0.00009639493,0.00097488257],"genre_scores_gemma":[0.00008653982,0.9972889,0.00030550014,0.0004153713,0.00017608759,0.0008311831,0.0006380226,0.00009077693,0.00016763376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725777,0.00016421787,0.0008541244,0.00078976864,0.00048683627,0.0004472902],"domain_scores_gemma":[0.99842614,0.00022274665,0.00037360578,0.00065801735,0.00009809715,0.00022139489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000535353,0.0007438691,0.0024288546,0.00039811438,0.000048323567,0.00015607235,0.00012993191,0.00023180731,0.000056205023],"category_scores_gemma":[0.000042693304,0.00047646643,0.00041482123,0.0005607143,0.00015188426,0.00019047593,0.00016869158,0.0005091112,0.000026448262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000042480983,0.00016452257,0.000021340447,0.31562892,0.0019301979,0.000017553368,0.000051812312,8.67088e-10,0.0000017752635,0.0019477471,0.002630408,0.67760146],"study_design_scores_gemma":[0.00047549614,0.00032113996,0.000028841687,0.27211574,0.006277476,0.0000038590742,0.000017483473,0.0000022364716,0.0000064123956,0.00042840999,0.7200363,0.00028660335],"about_ca_topic_score_codex":3.7879116e-7,"about_ca_topic_score_gemma":1.4730307e-7,"teacher_disagreement_score":0.7174059,"about_ca_system_score_codex":0.00007085916,"about_ca_system_score_gemma":0.00015576684,"threshold_uncertainty_score":0.9997687},"labels":[],"label_agreement":null},{"id":"W4401246842","doi":"10.1101/2024.08.01.24311352","title":"Glucagon-Like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Obesity; Internal medicine; Odds ratio; Type 2 Diabetes Mellitus; Diabetes mellitus; Observational study; Logistic regression; Type 2 diabetes; Hypoglycemia; Endocrinology; Insulin","score_opus":0.06496898771734538,"score_gpt":0.3090440175968423,"score_spread":0.24407502987949692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401246842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886912,0.00061290554,0.0000027978967,0.002924926,0.0026699072,0.003665003,0.000056508783,0.00024441676,0.001132351],"genre_scores_gemma":[0.96658665,0.00012710055,0.001431695,0.00034734988,0.00030633298,0.00081918214,0.0007253569,0.00010143813,0.029554876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739283,0.00008144272,0.00057247194,0.0009549636,0.00057620916,0.00042210644],"domain_scores_gemma":[0.9986497,0.00010886417,0.00014289809,0.00082279585,0.0001118315,0.00016392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032822153,0.0004775204,0.0006491339,0.0003289161,0.000043129523,0.00019227978,0.00023844953,0.00017527408,0.00024857995],"category_scores_gemma":[0.00018288958,0.00041418913,0.00024096169,0.00029563459,0.00005171631,0.000081408034,0.0010483451,0.0006961102,0.00065668335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010041267,0.0044755423,0.9663873,0.0006979256,0.0010194551,0.0006324408,0.0019773114,0.000046818473,0.000058052505,0.00015224429,0.02308811,0.0013644235],"study_design_scores_gemma":[0.0029267229,0.00060393545,0.9278431,0.001218691,0.0010736539,7.289031e-7,0.000980601,0.0006127602,0.00006478588,0.00022978656,0.06394387,0.00050135097],"about_ca_topic_score_codex":0.00041596038,"about_ca_topic_score_gemma":0.00047732145,"teacher_disagreement_score":0.040855765,"about_ca_system_score_codex":0.00040742572,"about_ca_system_score_gemma":0.00018157632,"threshold_uncertainty_score":0.999831},"labels":[],"label_agreement":null},{"id":"W4401307334","doi":"10.1093/ehjqcco/qcae063","title":"The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Quality of Care and Clinical Outcomes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Heart Institute Foundation","funders":"Novo Nordisk; National Heart Foundation of Australia; Novartis; Boehringer Ingelheim; AstraZeneca; Eli Lilly and Company; National Health and Medical Research Council; Amgen","keywords":"Semaglutide; Medicine; Overweight; Obesity; Cost effectiveness; Population; Diabetes mellitus; Physical therapy; Environmental health; Internal medicine; Type 2 diabetes; Endocrinology; Risk analysis (engineering); Liraglutide","score_opus":0.055080034754642904,"score_gpt":0.36048648352879537,"score_spread":0.30540644877415246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401307334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519407,0.04686721,0.000043389347,0.00008622073,0.00010898999,0.000546393,0.000013384111,0.000017970087,0.00037572818],"genre_scores_gemma":[0.99444467,0.005167601,0.00019928731,0.00002512326,0.000080980375,0.0000052426676,0.0000037013579,0.00002490582,0.000048466445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961883,0.0020720733,0.0006929623,0.00035552544,0.0004635001,0.00022764907],"domain_scores_gemma":[0.9967557,0.002380549,0.00014191882,0.00036836372,0.00011943494,0.0002340212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007527135,0.00019575116,0.0011202565,0.00007468145,0.00016712304,0.00008568234,0.00006168301,0.000033967426,0.0000011871371],"category_scores_gemma":[0.000997526,0.0001146421,0.000780604,0.00011838461,0.00033866512,0.00010442224,0.00012494513,0.00036915884,5.138479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016822103,0.000058683505,0.9667071,0.0013529051,0.0038863295,0.00006626938,0.00031740867,0.000037817303,0.0000034239697,0.000040203875,0.000007592277,0.027354058],"study_design_scores_gemma":[0.001763393,0.00042726364,0.99158216,0.0016589097,0.0024129825,0.000007354483,0.0006793273,0.000052611813,0.000019481211,0.00004850739,0.0012168156,0.00013121769],"about_ca_topic_score_codex":0.00023975444,"about_ca_topic_score_gemma":0.000040910192,"teacher_disagreement_score":0.04250398,"about_ca_system_score_codex":0.000032845757,"about_ca_system_score_gemma":0.00004787674,"threshold_uncertainty_score":0.4674969},"labels":[],"label_agreement":null},{"id":"W4401418059","doi":"10.1371/journal.pone.0308533","title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Research Canada; University of British Columbia","funders":"Canadian Institutes of Health Research; Arthritis Society","keywords":"Medicine; Hazard ratio; Mace; Internal medicine; Population; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Myocardial infarction; Endocrinology; Confidence interval; Exenatide; Percutaneous coronary intervention","score_opus":0.013550830491514494,"score_gpt":0.21736834962704193,"score_spread":0.20381751913552745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401418059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963922,0.0015343687,5.4478863e-7,0.00002948794,0.00006583147,0.0018265365,0.00005080104,0.00008286584,0.000017353408],"genre_scores_gemma":[0.99860585,0.000036039248,0.00006090145,0.000059901184,0.00003231232,0.0003099292,0.00080811395,0.000032060747,0.00005489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986927,0.00007293045,0.00024561942,0.00034382113,0.0004587511,0.0001861986],"domain_scores_gemma":[0.9994617,0.00004439115,0.00004342539,0.00027353363,0.00007348465,0.000103438804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013804327,0.00018790214,0.00037065925,0.00018235554,0.000040992196,0.000030426587,0.000028618984,0.000041215957,0.000038338476],"category_scores_gemma":[0.000056115885,0.00015492062,0.000053845586,0.00022551954,0.000026082202,0.00018852821,0.00004098672,0.00008072829,0.00001732136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027472895,0.0029077064,0.992984,0.0007532223,0.0025912095,0.000027723385,0.00016800649,0.000004115082,0.000015403752,9.00041e-7,0.000006422331,0.00026655482],"study_design_scores_gemma":[0.0039509432,0.00073337805,0.99135184,0.00077306735,0.0027517907,1.5361666e-8,0.000063628904,0.000159618,0.000021264614,0.0000046640907,0.000030323888,0.00015943887],"about_ca_topic_score_codex":0.000067737376,"about_ca_topic_score_gemma":0.00004428957,"teacher_disagreement_score":0.0036762143,"about_ca_system_score_codex":0.00012803769,"about_ca_system_score_gemma":0.000042280946,"threshold_uncertainty_score":0.63174796},"labels":[],"label_agreement":null},{"id":"W4401434535","doi":"10.1111/dom.15834","title":"Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk Canada; Novo Nordisk","keywords":"Medicine; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Endocrinology; Cohort; Basal (medicine); Albuminuria; Diabetes mellitus; Insulin; Kidney disease; Liraglutide; Renal function; Population; Agonist; Receptor","score_opus":0.0077060772296730215,"score_gpt":0.24782676468415807,"score_spread":0.24012068745448506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401434535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98576975,0.010701003,8.970199e-7,0.000086314576,0.000092243725,0.002561785,0.00039840248,0.0001591781,0.00023043081],"genre_scores_gemma":[0.99713254,0.0014736502,0.00008287277,0.00010749852,0.00018440228,0.00024311729,0.00051183463,0.00011063197,0.00015346023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685633,0.00023997914,0.00051840104,0.0009284234,0.000556938,0.0008999538],"domain_scores_gemma":[0.99804616,0.00025677372,0.0002140996,0.0006094449,0.0001484569,0.0007250531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051630207,0.00083888654,0.001449693,0.0006603513,0.00021808506,0.00020748138,0.00017585876,0.00008144667,0.00008396152],"category_scores_gemma":[0.000044655415,0.000444884,0.0001875292,0.0012173563,0.0003701302,0.00042754092,0.000072725205,0.00042881168,0.0000079331685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002375933,0.002767113,0.9831411,0.0006822037,0.0036507132,0.00009703129,0.002754234,0.00004996762,0.0012897088,0.000041834646,0.0004126665,0.002737499],"study_design_scores_gemma":[0.0073993336,0.004530464,0.97689056,0.0034715116,0.0028922865,8.954605e-7,0.00039504326,0.0009243129,0.0024566804,0.000007293402,0.00048247052,0.0005491697],"about_ca_topic_score_codex":0.0010431408,"about_ca_topic_score_gemma":0.00067937473,"teacher_disagreement_score":0.011362786,"about_ca_system_score_codex":0.00019188934,"about_ca_system_score_gemma":0.0004710961,"threshold_uncertainty_score":0.99980026},"labels":[],"label_agreement":null},{"id":"W4401437713","doi":"10.1016/j.ekir.2024.07.038","title":"Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis","year":2024,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Kidney Foundation of Canada; AstraZeneca; American Society of Nephrology","keywords":"Canagliflozin; Medicine; Kidney disease; Hemodialysis; Renal function; Pharmacokinetics; Urology; Diabetes mellitus; Internal medicine; Intensive care medicine; Type 2 diabetes; Pharmacology; Endocrinology","score_opus":0.009052594190455536,"score_gpt":0.26792675571850993,"score_spread":0.2588741615280544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401437713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9046908,0.000054999804,0.000029425131,0.0038425375,0.0025497307,0.0004816142,0.00006845705,0.00009251957,0.088189915],"genre_scores_gemma":[0.9422944,0.00006549947,0.00009111857,0.0021640118,0.000092602015,0.000050159702,0.0005353865,0.000023245057,0.05468356],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851745,0.000012465492,0.00036007696,0.00036237907,0.00053947093,0.00020814876],"domain_scores_gemma":[0.9994267,0.000026220718,0.00007866515,0.00019840863,0.00008908381,0.0001808879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015057423,0.00014625728,0.00017066169,0.00030594523,0.000016830343,0.000039147566,0.00005812777,0.000026376132,0.00055765326],"category_scores_gemma":[0.00018264483,0.0001224141,0.00009204985,0.00016259863,0.000020305222,0.0000736043,0.00007324928,0.00009782666,0.00014136803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000289682,0.00087522133,0.5100071,0.0001488018,0.0011510415,0.007382739,0.00033339259,0.00020794128,0.0002707925,0.00052674947,0.444257,0.03454954],"study_design_scores_gemma":[0.0023586105,0.0002656957,0.16165002,0.00073788787,0.00024723652,0.000027535301,0.000012027305,0.0022809685,0.0024513796,0.00079796696,0.8289107,0.00025996353],"about_ca_topic_score_codex":0.00016901623,"about_ca_topic_score_gemma":0.000044816737,"teacher_disagreement_score":0.38465372,"about_ca_system_score_codex":0.00081670925,"about_ca_system_score_gemma":0.00008062999,"threshold_uncertainty_score":0.61059123},"labels":[],"label_agreement":null},{"id":"W4401447115","doi":"10.1111/dom.15794","title":"Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Real world data; Pooled analysis; Diabetes mellitus; Internal medicine; Meta-analysis; Endocrinology; Data science; Liraglutide","score_opus":0.029476314409815265,"score_gpt":0.28172118628095005,"score_spread":0.2522448718711348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401447115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98117244,0.014255185,0.000008409623,0.001016086,0.00016815893,0.001362376,0.0005306419,0.00011113228,0.0013755644],"genre_scores_gemma":[0.99090445,0.0034289723,0.0018005881,0.00018972595,0.00012370628,0.00008333068,0.0012057405,0.000046041103,0.0022174278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673945,0.00025284887,0.00078297494,0.0009049539,0.0006380889,0.0006816941],"domain_scores_gemma":[0.9967206,0.0010579901,0.00027964503,0.0015524098,0.00019284105,0.00019648156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014892264,0.00042747307,0.0015980953,0.0007792986,0.000091340655,0.000081108985,0.00052843103,0.00008876662,0.00018185056],"category_scores_gemma":[0.00024312398,0.00027860567,0.00021222435,0.00472272,0.0002840761,0.00031769695,0.00044650928,0.00031268984,0.000013278304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015932845,0.00052827195,0.9729276,0.0007462402,0.0060662567,0.00001446363,0.00071674905,0.000030438667,0.0014704408,0.00093949115,0.0011091791,0.015291594],"study_design_scores_gemma":[0.0009743939,0.00017403637,0.96393,0.0015107698,0.016229209,9.2947985e-8,0.00017741251,0.0073769013,0.002232553,0.00014446139,0.006966699,0.000283488],"about_ca_topic_score_codex":0.0055944906,"about_ca_topic_score_gemma":0.02048928,"teacher_disagreement_score":0.015008106,"about_ca_system_score_codex":0.00008348808,"about_ca_system_score_gemma":0.00023586991,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W4401478650","doi":"10.1016/j.revmed.2024.07.011","title":"Chez les sujets avec diabète de type 2 et insuffisance rénale chronique, est-ce que le sémaglutide prévient l’insuffisance rénale terminale, la perte significative de fonction rénale ou le décès de causes rénales ou cardiovasculaires comparativement au placebo, tout en étant sécuritaire ?","year":2024,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine","score_opus":0.01884371438073642,"score_gpt":0.2824222281580641,"score_spread":0.2635785137773277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401478650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76392555,0.06011142,0.0076220296,0.12960957,0.001676389,0.00489232,0.0005537883,0.00063562224,0.030973317],"genre_scores_gemma":[0.8833608,0.013672466,0.0028442515,0.0094909035,0.0035627042,0.0021618872,0.00096141925,0.0004606824,0.083484896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99051815,0.0025306654,0.0016261917,0.0021228075,0.00093644037,0.002265769],"domain_scores_gemma":[0.9945346,0.0020134356,0.0008429058,0.001527235,0.0004310871,0.00065069814],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0027313714,0.0018223425,0.0024488685,0.0006235386,0.00041103226,0.00035104057,0.0010644525,0.00097639475,0.0002474294],"category_scores_gemma":[0.00069898734,0.0018147809,0.0012028009,0.0006290255,0.0009822057,0.000449164,0.0008273068,0.0023955621,0.0003482131],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045037097,0.012048216,0.2230527,0.024669373,0.025442109,0.031311087,0.10864415,0.007758247,0.018981159,0.024784949,0.49575084,0.02305346],"study_design_scores_gemma":[0.007055767,0.0019130914,0.0749073,0.016094394,0.0045095813,0.0018474873,0.0021140683,0.004353462,0.019991018,0.00059024093,0.86467034,0.001953253],"about_ca_topic_score_codex":0.007022978,"about_ca_topic_score_gemma":0.006940335,"teacher_disagreement_score":0.3689195,"about_ca_system_score_codex":0.007939242,"about_ca_system_score_gemma":0.0031651855,"threshold_uncertainty_score":0.99990594},"labels":[],"label_agreement":null},{"id":"W4401486008","doi":"10.1016/j.tem.2024.07.012","title":"Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies","year":2024,"lang":"en","type":"review","venue":"Trends in Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Heart And Stroke Foundation Of Quebec; Diabetes Canada; Heart and Stroke Foundation of Canada","keywords":"Mace; Medicine; Type 2 Diabetes Mellitus; Weight loss; Glucagon-like peptide 1 receptor; Type 2 diabetes; Adverse effect; Obesity; Agonist; Adipose tissue; Diabetes mellitus; Glucagon-like peptide-1; Metabolic syndrome; Internal medicine; Bioinformatics; Intensive care medicine; Endocrinology; Receptor; Biology; Percutaneous coronary intervention","score_opus":0.05173201675650822,"score_gpt":0.32391433564341887,"score_spread":0.27218231888691063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401486008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019308833,0.99498785,8.9815893e-7,0.00018877447,0.0006286678,0.0005542462,0.00013089669,0.00006361667,0.0015141973],"genre_scores_gemma":[0.0013909942,0.99545705,0.00023577984,0.00005181025,0.00018340175,0.0004788352,0.00018270864,0.000058117334,0.0019612717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979075,0.0001743763,0.0006200184,0.00065599004,0.00015983405,0.00048229017],"domain_scores_gemma":[0.9990848,0.00017660788,0.00021319604,0.00039154664,0.000036751073,0.00009709969],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022453551,0.00058162154,0.0037497107,0.0017842483,0.000051297822,0.0000237276,0.000087799075,0.00026684764,0.00007996041],"category_scores_gemma":[0.000033471646,0.0004080613,0.0005549545,0.00061614055,0.00037932943,0.000052702817,0.00012974865,0.00044740364,0.000015122993],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034145585,0.00010399573,0.00014672375,0.004756357,0.0021850683,0.00005149494,0.00012813893,1.2098334e-7,7.82444e-7,0.00837742,0.0003287605,0.983887],"study_design_scores_gemma":[0.0008075911,0.000059630598,0.003931164,0.0025374794,0.009551057,0.00004458469,0.000029114412,6.4205835e-7,0.000033171138,0.00010001956,0.9826252,0.00028036677],"about_ca_topic_score_codex":0.0000704579,"about_ca_topic_score_gemma":0.000017713612,"teacher_disagreement_score":0.98360664,"about_ca_system_score_codex":0.000022163003,"about_ca_system_score_gemma":0.00010716132,"threshold_uncertainty_score":0.9998371},"labels":[],"label_agreement":null},{"id":"W4401598356","doi":"10.1016/j.eclinm.2024.102789","title":"GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review","year":2024,"lang":"en","type":"review","venue":"EClinicalMedicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Liraglutide; Overweight; Weight loss; Semaglutide; Obesity; Blood pressure; Internal medicine; Glucagon-like peptide 1 receptor; Population; Agonist; Type 2 diabetes; Endocrinology; Diabetes mellitus; Receptor; Environmental health","score_opus":0.12303755255895502,"score_gpt":0.4024399890991138,"score_spread":0.27940243654015884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401598356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002497117,0.9850109,0.00001223204,0.0054454827,0.0002346238,0.008931235,0.00009204978,0.00005183484,0.00019666621],"genre_scores_gemma":[0.000017647913,0.99154526,0.00077028584,0.0016648405,0.00031578352,0.0018391229,0.00041027856,0.00009349752,0.0033432592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996779,0.00014383491,0.0015383092,0.0006575351,0.00052299234,0.00035830558],"domain_scores_gemma":[0.9953435,0.0028832846,0.00052054983,0.0010345419,0.00009454165,0.00012359828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009998659,0.0006498015,0.0045500943,0.00029358015,0.00004494851,0.0000124927365,0.00020764493,0.00020456815,0.00017068782],"category_scores_gemma":[0.00027345636,0.00022304073,0.0008478073,0.0007340654,0.0002259899,0.000022016258,0.000037453996,0.00023383288,0.00002722249],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037702455,0.0022244453,0.00013932145,0.113363974,0.0037126108,0.0002876189,0.000050805316,7.3679075e-8,8.4249926e-8,0.0000898726,0.016324164,0.86343],"study_design_scores_gemma":[0.0035754738,0.008714913,0.00010289775,0.21092866,0.033259224,0.000010112919,0.000018988647,0.000007304455,4.2501603e-7,0.000020187243,0.7431955,0.00016631768],"about_ca_topic_score_codex":0.000023336122,"about_ca_topic_score_gemma":0.000044708693,"teacher_disagreement_score":0.86326367,"about_ca_system_score_codex":0.00021641947,"about_ca_system_score_gemma":0.0005846658,"threshold_uncertainty_score":0.9095337},"labels":[],"label_agreement":null},{"id":"W4401609425","doi":"10.1371/journal.pone.0307451","title":"Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Diabetes mellitus; Medicine; Pharmacology; Pandemic; Transporter; Sulfonylurea; Dipeptidyl peptidase-4; Medical prescription; Drug; Drug class; Glucagon receptor; Glucagon; Type 2 diabetes; Internal medicine; Coronavirus disease 2019 (COVID-19); Endocrinology; Chemistry; Insulin; Biochemistry","score_opus":0.057637648854166744,"score_gpt":0.2885231922728533,"score_spread":0.23088554341868653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401609425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944602,0.00067052856,0.000042434203,0.0015498943,0.00007885662,0.00017092371,0.00003469355,0.00011075138,0.002881673],"genre_scores_gemma":[0.99043715,0.000036535122,0.001112979,0.00018997582,0.0002683939,0.00013588209,0.0005979718,0.000017139897,0.007203946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889433,0.00001605916,0.00020508989,0.00033033494,0.00036968148,0.00018447646],"domain_scores_gemma":[0.9995819,0.00006021804,0.000020083597,0.00021452969,0.000025822228,0.000097469965],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014528958,0.00009735702,0.00023716204,0.0008166727,0.000024392735,0.00007373022,0.000055620978,0.00004635972,0.0017224555],"category_scores_gemma":[0.00004237308,0.00008675759,0.00009822077,0.00109203,0.000018860175,0.00009892872,0.00004453624,0.00007942648,0.0002932849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021330137,0.0008295377,0.9773071,0.00004380078,0.0046667326,0.000013133672,0.00017930251,0.000017974302,0.004706024,0.000051483254,0.0014996855,0.010663935],"study_design_scores_gemma":[0.0003998355,0.00011327009,0.9864781,0.00020125907,0.0021460513,2.1130745e-8,0.000010512134,0.006383451,0.0031824952,0.00008047629,0.00091789156,0.00008664817],"about_ca_topic_score_codex":0.00013633729,"about_ca_topic_score_gemma":0.00013144688,"teacher_disagreement_score":0.010577287,"about_ca_system_score_codex":0.0001502699,"about_ca_system_score_gemma":0.000014477943,"threshold_uncertainty_score":0.9991901},"labels":[],"label_agreement":null},{"id":"W4401614784","doi":"10.1530/joe-24-0046","title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","year":2024,"lang":"en","type":"review","venue":"Journal of Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Agonist; Medicine; Postprandial; Glucagon-like peptide 1 receptor; Internal medicine; Weight loss; Diabetes mellitus; Myocardial infarction; Endocrinology; Receptor; Glucagon-like peptide-1; Blood sugar; Blood pressure; Type 2 diabetes; Pharmacology; Obesity","score_opus":0.03315959391580226,"score_gpt":0.3193480125333912,"score_spread":0.2861884186175889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401614784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000054239113,0.99755114,0.00009039051,0.0003940131,0.0006295427,0.00073966075,0.000029393039,0.000016147887,0.00054426806],"genre_scores_gemma":[0.0000066155185,0.9964141,0.0027866054,0.00016547354,0.00018254724,0.000039552873,0.00002201647,0.00004715544,0.0003358815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786425,0.0002809123,0.0010047232,0.00025021852,0.0003335672,0.00026633267],"domain_scores_gemma":[0.9983779,0.00011794621,0.00081980025,0.00042316553,0.00016197356,0.00009921674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005266409,0.00036407384,0.00380266,0.0004542521,0.000024127085,0.000011943502,0.00016312732,0.00012136892,0.0001663201],"category_scores_gemma":[0.00013826652,0.00021714046,0.0021869408,0.00020508235,0.00009662611,0.000030735457,0.00008051774,0.0005077356,0.000031165986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015379826,0.000086699525,0.000003200125,0.15613145,0.011780758,0.00042068964,0.000009202372,6.866136e-8,8.935483e-7,0.00059060066,0.0060591176,0.82490194],"study_design_scores_gemma":[0.00064293505,0.00090490247,0.000001997305,0.10525697,0.038755786,0.0004083393,0.000012563659,2.1791553e-7,0.000008562849,0.00011599275,0.8537732,0.00011858854],"about_ca_topic_score_codex":0.0000059936397,"about_ca_topic_score_gemma":4.4358939e-7,"teacher_disagreement_score":0.847714,"about_ca_system_score_codex":0.00008702279,"about_ca_system_score_gemma":0.00026044683,"threshold_uncertainty_score":0.88547313},"labels":[],"label_agreement":null},{"id":"W4401636491","doi":"10.1097/mco.0000000000001064","title":"Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists","year":2024,"lang":"en","type":"review","venue":"Current Opinion in Clinical Nutrition & Metabolic Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Energy balance; Energy expenditure; Obesity; Balance (ability); Glucagon-like peptide-1; Energy (signal processing); Weight management; Receptor; Glucagon-like peptide 1 receptor; Medicine; Weight loss; Endocrinology; Agonist; Biology; Internal medicine; Type 2 diabetes; Diabetes mellitus; Physics; Physical therapy; Ecology","score_opus":0.0724204451862434,"score_gpt":0.4214604196620168,"score_spread":0.3490399744757734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401636491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013092175,0.9909376,0.0000047674107,0.00022380438,0.0069717085,0.001307812,0.00020209515,0.000058276866,0.00016302492],"genre_scores_gemma":[0.00018343769,0.99517685,0.0000864978,0.000042053754,0.001962937,0.0006061692,0.0017468308,0.000055236673,0.00014000709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658245,0.00033938605,0.001613758,0.00074192474,0.0004043558,0.0003181101],"domain_scores_gemma":[0.9983496,0.0003163595,0.00045457782,0.00057266856,0.00014187982,0.00016490357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048128463,0.0004767859,0.0023222123,0.00034303087,0.000059076105,0.000054025826,0.00022040594,0.00028781383,0.00004335106],"category_scores_gemma":[0.000103666214,0.0003205273,0.0010197229,0.000617266,0.00017703442,0.000065553904,0.00027068102,0.0006761949,0.00003941335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022212256,0.00061446714,0.0003363958,0.044200063,0.00031061703,0.000001043928,0.00009715959,3.4563868e-8,2.1076643e-7,0.0018365552,0.012064316,0.94051695],"study_design_scores_gemma":[0.0011460962,0.0001325951,0.00016624958,0.050457,0.0020967224,0.0000032410767,0.00024424464,0.000010081377,0.0000011145802,0.00019634329,0.94530725,0.00023902836],"about_ca_topic_score_codex":0.00001779041,"about_ca_topic_score_gemma":0.000004507246,"teacher_disagreement_score":0.9402779,"about_ca_system_score_codex":0.0000858566,"about_ca_system_score_gemma":0.00015004246,"threshold_uncertainty_score":0.99992466},"labels":[],"label_agreement":null},{"id":"W4401684784","doi":"10.1111/dom.15829","title":"Opportunities to optimize lifestyle interventions in combination with <scp>glucagon‐like peptide</scp> ‐1‐based therapy","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Weight loss; Medicine; Type 2 diabetes; Discontinuation; Psychological intervention; Obesity; Disease; Diabetes mellitus; Intensive care medicine; Gerontology; Internal medicine; Endocrinology; Psychiatry","score_opus":0.06778202109263012,"score_gpt":0.310770133213144,"score_spread":0.24298811212051388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401684784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013265832,0.98129714,0.000023243356,0.00022513485,0.00041034407,0.0026375502,0.000095564654,0.00016432849,0.0018808831],"genre_scores_gemma":[0.0003620634,0.9830175,0.0010047238,0.0007855169,0.00012245684,0.000985056,0.00086306717,0.0001026129,0.012756998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976818,0.00018321363,0.00061358436,0.0006506465,0.0003394876,0.00053126935],"domain_scores_gemma":[0.9987181,0.00020008892,0.00020031972,0.000464056,0.00009850603,0.00031892373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053961296,0.00066675956,0.0021196494,0.001171994,0.00009226145,0.00018780399,0.00018352136,0.00022398218,0.000034554436],"category_scores_gemma":[0.00006195625,0.00047577743,0.00059795246,0.0005195364,0.000105413936,0.00017157158,0.00014059697,0.00039840766,0.00008238036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013718242,0.0026665349,0.0010874893,0.040673442,0.0027565463,0.00016262595,0.0005072554,0.0000049108025,0.0000015944265,0.0026958308,0.009528268,0.93990177],"study_design_scores_gemma":[0.0017829284,0.00041214988,0.001767406,0.019626612,0.0055888337,0.0000020983157,0.0001050262,0.000021958831,0.000010419214,0.00006395119,0.97039497,0.00022366847],"about_ca_topic_score_codex":0.000025536001,"about_ca_topic_score_gemma":0.000021715861,"teacher_disagreement_score":0.9608667,"about_ca_system_score_codex":0.00009738086,"about_ca_system_score_gemma":0.00020179004,"threshold_uncertainty_score":0.9997694},"labels":[],"label_agreement":null},{"id":"W4401722305","doi":"10.1001/jamapsychiatry.2024.2412","title":"Semaglutide in Psychiatry—Opportunities and Challenges","year":2024,"lang":"en","type":"article","venue":"JAMA Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Semaglutide; Medicine; Psychiatry; Psychology; Psychotherapist; Liraglutide; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.0417691279351668,"score_gpt":0.273377902882065,"score_spread":0.2316087749468982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401722305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40382877,0.21250032,0.000004737161,0.2824119,0.0033260845,0.00042668066,0.000008574483,0.00029062922,0.09720231],"genre_scores_gemma":[0.91312915,0.05973823,0.006659809,0.0061108326,0.0016202148,0.00014426521,0.00004829089,0.0000995015,0.012449694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990439,0.000021242493,0.00020770793,0.0003193259,0.00015605045,0.00025177133],"domain_scores_gemma":[0.99959284,0.000031723135,0.000022156059,0.00023099464,0.0000121774865,0.00011012579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017753332,0.00017329093,0.00022279382,0.0003077098,0.000029139681,0.0000646778,0.00005038918,0.000086131,0.00010058872],"category_scores_gemma":[0.000008473129,0.00014401815,0.00007198515,0.00013594955,0.00004657722,0.00011291386,0.00004179274,0.0001590192,0.000065358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118351876,0.0005690313,0.07741812,0.003993983,0.00043692824,0.00018313904,0.0007234473,7.0001926e-7,0.000009836569,0.38616088,0.09158332,0.43880224],"study_design_scores_gemma":[0.0032433686,0.0006136366,0.2833846,0.0021781833,0.0003744832,0.00006652508,0.0043922197,0.00028980718,0.0000075984344,0.016541881,0.6885541,0.00035355994],"about_ca_topic_score_codex":0.000016710253,"about_ca_topic_score_gemma":0.0001643272,"teacher_disagreement_score":0.5969708,"about_ca_system_score_codex":0.000032039323,"about_ca_system_score_gemma":0.00011112679,"threshold_uncertainty_score":0.587289},"labels":[],"label_agreement":null},{"id":"W4401815221","doi":"10.1016/s0140-6736(24)01498-3","title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Medical Research Council; Daiichi Sankyo Europe; Servier; Shionogi; Novo Nordisk; European Commission; Ipsen; Diabetes UK; Pfizer; Moderna; Allergan; AstraZeneca; Amarin Corporation; Insmed; ReCor Medical; Intarcia Therapeutics; Novavax; Regeneron Pharmaceuticals; Mylan; H. Lundbeck A/S; TG Therapeutics; FibroGen; MannKind Corporation; Akebia Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; BeiGene; Esperion Therapeutics; Alnylam Pharmaceuticals; Brigham and Women's Hospital; Sanofi; GlaxoSmithKline; Amgen","keywords":"Semaglutide; Heart failure; Medicine; Obesity; Internal medicine; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.014087384201099028,"score_gpt":0.24017693276202967,"score_spread":0.22608954856093064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401815221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620557,0.0012106551,0.00000332086,0.0014952866,0.000030998293,0.0008752995,0.000011651041,0.000015448777,0.00015175036],"genre_scores_gemma":[0.99950504,0.00004883809,0.00007001761,0.00008589109,0.000037038157,0.000025662397,0.0000044700964,0.0000053671283,0.00021764888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934465,0.00007344723,0.000101417325,0.00015009317,0.0002188574,0.00011151089],"domain_scores_gemma":[0.99951243,0.00006817858,0.000017531122,0.00036959455,0.0000136362905,0.000018637314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002975047,0.000079370184,0.0004989671,0.00006753503,0.000022179736,0.0000200295,0.00005123703,0.000016254322,0.000008330486],"category_scores_gemma":[0.000024949504,0.000033781613,0.000121213314,0.00032141677,0.000044787514,0.000020289746,0.00005446043,0.00006354859,5.860101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011788795,0.00009398569,0.9910269,0.00010362978,0.005414079,0.0000014018798,0.00021376241,0.000019007695,0.0000031096527,0.00007367368,0.0009812488,0.00089031487],"study_design_scores_gemma":[0.011410384,0.0001936013,0.98038787,0.00006239208,0.0043110093,1.6156297e-7,0.00001724823,0.0000870698,0.000033430977,0.000026553678,0.0034315381,0.00003875274],"about_ca_topic_score_codex":0.000040844472,"about_ca_topic_score_gemma":0.0000783577,"teacher_disagreement_score":0.010639049,"about_ca_system_score_codex":0.00001772803,"about_ca_system_score_gemma":0.000010193023,"threshold_uncertainty_score":0.13775742},"labels":[],"label_agreement":null},{"id":"W4401947582","doi":"10.1186/s12933-024-02344-6","title":"Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Tobacco Research Unit; St. Michael's Hospital","funders":"","keywords":"Empagliflozin; Medicine; Angiology; Cardiology; Internal medicine; Coronary artery disease; Diabetes mellitus; Randomized controlled trial; EMPA; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetic cardiomyopathy; Heart failure; Cardiomyopathy; Endocrinology","score_opus":0.013194835776261921,"score_gpt":0.2450310253374745,"score_spread":0.23183618956121257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401947582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86608934,0.12917742,0.000031509968,0.00035024248,0.0017680874,0.0024134568,0.000020261512,0.00007304679,0.00007666003],"genre_scores_gemma":[0.99522585,0.0030585902,0.000048183603,0.00030723284,0.0008452375,0.00006331195,0.00036758353,0.00004154356,0.000042455296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685884,0.0011903959,0.00051503716,0.0007199979,0.00035092587,0.00036480578],"domain_scores_gemma":[0.99793273,0.001159245,0.000048469043,0.0005896421,0.000068680056,0.00020125766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015759701,0.0003061202,0.0017368082,0.00013502462,0.000072956085,0.000066250024,0.00007002994,0.0001854574,0.000029011157],"category_scores_gemma":[0.000336226,0.00018506042,0.0008721266,0.00017149493,0.00045859482,0.00012393972,0.00010910833,0.00030830072,0.000021843654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15564366,0.00015643412,0.770166,0.00009753222,0.019536348,0.00013901653,0.00014577163,0.00001882429,0.0000010461508,0.00006562632,0.0006930374,0.05333675],"study_design_scores_gemma":[0.30966857,0.0007511318,0.650417,0.00013442797,0.010210841,0.0000020987918,0.000018830719,0.00016553259,0.0000017298485,0.00022173664,0.028207878,0.00020026982],"about_ca_topic_score_codex":0.00001339619,"about_ca_topic_score_gemma":0.0000069642156,"teacher_disagreement_score":0.15402493,"about_ca_system_score_codex":0.000047595462,"about_ca_system_score_gemma":0.0000982337,"threshold_uncertainty_score":0.75465447},"labels":[],"label_agreement":null},{"id":"W4401990854","doi":"10.1371/journal.pone.0307581","title":"Demographics, medication use, and admission characteristics of patients hospitalized with diabetes in Ontario, Canada: A retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; University of Toronto; St. Michael's Hospital","funders":"Temerty Faculty of Medicine, University of Toronto","keywords":"Demographics; Retrospective cohort study; Medicine; Diabetes mellitus; Cohort; Emergency medicine; MEDLINE; Cohort study; Pediatrics; Internal medicine; Demography; Biology","score_opus":0.012032344718646514,"score_gpt":0.19774536677986923,"score_spread":0.18571302206122273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401990854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983287,0.000041251653,4.971479e-7,0.0001087491,0.00003008658,0.0013604651,0.000015184914,0.000020695765,0.000094379655],"genre_scores_gemma":[0.9993068,0.00003623457,0.00010709173,0.00003516202,0.000008035879,0.00009341836,0.00015423472,0.0000132355735,0.00024577606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902195,0.000016674132,0.00018415198,0.00021443033,0.0004437898,0.00011899056],"domain_scores_gemma":[0.9996018,0.00002505239,0.000055580498,0.00013873888,0.00010252523,0.000076302604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095567724,0.000102409926,0.0003366948,0.00012091962,0.00001633233,0.000015190739,0.000025457352,0.000025569932,0.000031379474],"category_scores_gemma":[0.00007113062,0.00007659262,0.000012017426,0.00016013996,0.00002920443,0.00007636668,0.000025834544,0.00009783679,2.8671283e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058746846,0.0030365498,0.9952606,0.00015622994,0.0009793157,0.00001618202,0.0002124059,9.46777e-9,0.00003583096,0.000016603091,0.000073741765,0.00015378327],"study_design_scores_gemma":[0.0012104128,0.0013894704,0.995408,0.0006914177,0.0009927604,2.1103652e-8,0.000024277972,0.000052337313,0.00012370922,0.00000832615,0.000026638736,0.00007263299],"about_ca_topic_score_codex":0.23372994,"about_ca_topic_score_gemma":0.5507847,"teacher_disagreement_score":0.31705475,"about_ca_system_score_codex":0.00031282162,"about_ca_system_score_gemma":0.00017188996,"threshold_uncertainty_score":0.77137274},"labels":[],"label_agreement":null},{"id":"W4402039126","doi":"10.1016/j.molmet.2024.102019","title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice","year":2024,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Steno Diabetes Center Aarhus; Canadian Institutes of Health Research; Novo Nordisk Fonden; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk","keywords":"Semaglutide; Disease; Cognition; Medicine; Neuroscience; Diabetes mellitus; Pathology; Internal medicine; Psychology; Endocrinology; Type 2 diabetes; Liraglutide","score_opus":0.0071276322419077005,"score_gpt":0.25269529777356303,"score_spread":0.24556766553165532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402039126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94200426,0.0520404,0.00014642376,0.0040277117,0.00039036025,0.0008212705,0.000022254784,0.00008552762,0.00046180657],"genre_scores_gemma":[0.99476844,0.0017297217,0.000085997555,0.0015513194,0.00006529538,0.00016009616,0.00006389991,0.000035496338,0.0015397586],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987425,0.00010899662,0.0002500965,0.00041419314,0.00021482434,0.0002693674],"domain_scores_gemma":[0.99946946,0.00012118999,0.000040971558,0.00017536955,0.000046110155,0.00014687922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031278285,0.0002196922,0.00029337118,0.00017977592,0.00007748329,0.00006664665,0.000043125518,0.000058482783,0.000031205942],"category_scores_gemma":[0.00012502319,0.00013164413,0.000064317326,0.00024117145,0.00017675923,0.000065009765,0.00008808112,0.00017640801,0.00001836301],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004745375,0.0010211351,0.065156564,0.0013652253,0.0044925143,0.024647277,0.0046322034,0.000009426964,0.059123524,0.02233069,0.005541433,0.80693465],"study_design_scores_gemma":[0.007841734,0.00045706506,0.9444157,0.0010652953,0.011436745,0.00012830921,0.0009651474,0.0011002998,0.00441886,0.0027401512,0.024888638,0.0005420627],"about_ca_topic_score_codex":0.000044115706,"about_ca_topic_score_gemma":0.00004015115,"teacher_disagreement_score":0.8792591,"about_ca_system_score_codex":0.000017210761,"about_ca_system_score_gemma":0.000034718058,"threshold_uncertainty_score":0.53682923},"labels":[],"label_agreement":null},{"id":"W4402050123","doi":"10.1093/eurheartj/ehae613","title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Astellas Pharma; European Commission; Sanofi; Bayer HealthCare; McMaster University; Gilead Sciences; Novo Nordisk; Steno Diabetes Center Copenhagen; Intas Pharmaceuticals; Eli Lilly and Company; AstraZeneca; Bayer; Pfizer","keywords":"Semaglutide; Medicine; Type 2 diabetes; Kidney disease; Diabetes mellitus; Internal medicine; Disease; Cardiology; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.017146067316193676,"score_gpt":0.2567611198266074,"score_spread":0.2396150525104137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402050123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96928376,0.021103151,0.0000455625,0.0050282697,0.00091860944,0.00076543377,0.000020990872,0.000058608788,0.0027755848],"genre_scores_gemma":[0.99662524,0.0003922296,0.00014072217,0.0006239208,0.00048577663,0.000005818667,0.000017827912,0.000044105862,0.0016643704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986898,0.00026546634,0.00023050682,0.00017438635,0.00038928742,0.00025061192],"domain_scores_gemma":[0.9993279,0.000045562712,0.00003225297,0.00032190647,0.000033736986,0.0002386519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092488324,0.00014508906,0.00033405694,0.0000924173,0.000056737812,0.00006298298,0.00009367976,0.0000121048415,0.00015143123],"category_scores_gemma":[0.0000953852,0.00007772423,0.00029760774,0.00021776438,0.000061019582,0.00006970835,0.00004808031,0.0002696337,0.00007326339],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065162117,0.0013876754,0.4102205,0.0011975048,0.009253269,0.0036756452,0.00068479456,0.0010332548,0.00023091023,0.000048697133,0.4982163,0.06753524],"study_design_scores_gemma":[0.022996064,0.0018232145,0.17724255,0.0011841074,0.0016181607,0.000027828297,0.00004006128,0.0015156283,0.000082708786,0.000020298048,0.79322666,0.0002226895],"about_ca_topic_score_codex":0.000004291534,"about_ca_topic_score_gemma":0.0000011631267,"teacher_disagreement_score":0.2950104,"about_ca_system_score_codex":0.00009165377,"about_ca_system_score_gemma":0.00019497781,"threshold_uncertainty_score":0.3169502},"labels":[],"label_agreement":null},{"id":"W4402066126","doi":"10.1016/j.jacc.2024.08.022","title":"Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT)","year":2024,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Overweight; Obesity; Internal medicine; Gerontology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.00560303773437344,"score_gpt":0.23604974665831796,"score_spread":0.23044670892394453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402066126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950252,0.0010475831,0.0000720401,0.0017103038,0.00034372532,0.00040294218,0.000009089068,0.000011173108,0.0013779216],"genre_scores_gemma":[0.9980736,0.00021665191,0.00028839379,0.0002915266,0.0001691815,0.000010126255,4.449074e-7,0.000018675126,0.0009313951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987192,0.00024024752,0.0002895038,0.00015543049,0.00038086073,0.00021475181],"domain_scores_gemma":[0.99885523,0.000490672,0.00017370514,0.0003480997,0.00007073026,0.00006154477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004224141,0.00016157751,0.0014320542,0.0002641692,0.000024456951,0.000004635577,0.00015151106,0.000030165344,0.0000045175752],"category_scores_gemma":[0.00014570964,0.00007460608,0.0006979403,0.0006318798,0.00012644917,0.000031711737,0.00005252881,0.0002254318,0.0000034451023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022036906,0.00020025251,0.95717096,0.00040899,0.014541491,0.00662601,0.00008861956,0.0013449487,0.00034960508,0.0004046009,0.009736927,0.006923916],"study_design_scores_gemma":[0.0025187128,0.0060270606,0.9623394,0.0005283048,0.0023778717,0.00094427716,0.00016277678,0.00003408127,0.0015856184,0.00007851722,0.023270624,0.00013274644],"about_ca_topic_score_codex":0.000022378692,"about_ca_topic_score_gemma":0.000025789373,"teacher_disagreement_score":0.013533697,"about_ca_system_score_codex":0.00021057256,"about_ca_system_score_gemma":0.00020808111,"threshold_uncertainty_score":0.30423477},"labels":[],"label_agreement":null},{"id":"W4402066452","doi":"10.1161/circulationaha.124.071689","title":"Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Meta-analysis; Type 2 diabetes; Diabetes mellitus; Glucagon-like peptide 1 receptor; Pharmacology; Intensive care medicine; Internal medicine; Endocrinology; Receptor; Agonist","score_opus":0.032436556552091,"score_gpt":0.2866001870614542,"score_spread":0.2541636305093632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402066452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037806653,0.9939541,0.000009547207,0.00026313172,0.000024126066,0.005265678,0.000016280035,0.000028738963,0.000060311344],"genre_scores_gemma":[0.007870945,0.9904195,0.000097151045,0.00012467014,0.0000074135655,0.00062897376,0.0006681328,0.00004415287,0.00013904506],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9979205,0.00026235334,0.00071482814,0.0005808419,0.0003426712,0.00017877457],"domain_scores_gemma":[0.9990651,0.00008110288,0.00026082472,0.0004172928,0.00006719747,0.00010846245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008404617,0.00044067646,0.0057772687,0.000682661,0.000030462235,0.00006864562,0.000037594775,0.00012329083,0.000010804285],"category_scores_gemma":[0.00009418657,0.00024997233,0.00048584252,0.0013479865,0.000051790626,0.00012066153,0.000043865595,0.00016301013,0.0000054788115],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006312954,0.000066915054,0.0052526197,0.84573275,0.14295262,0.000021257605,0.00006502575,0.0000028774934,3.1415034e-8,0.000033707733,0.000028168015,0.005837694],"study_design_scores_gemma":[0.0008000588,0.000083542676,0.0025007923,0.08175117,0.909187,0.0000072525254,0.0000128246975,0.00003297342,5.8834583e-8,0.00000797984,0.0053365077,0.0002798093],"about_ca_topic_score_codex":0.000027611057,"about_ca_topic_score_gemma":0.000044356053,"teacher_disagreement_score":0.7662344,"about_ca_system_score_codex":0.0002088196,"about_ca_system_score_gemma":0.00006284357,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W4402066678","doi":"10.1016/s0140-6736(24)01643-x","title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":264,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute on Aging; National Heart, Lung, and Blood Institute; Novo Nordisk","keywords":"Semaglutide; Heart failure with preserved ejection fraction; Medicine; Heart failure; Cardiology; Internal medicine; Ejection fraction; Placebo; Overweight; Type 2 diabetes; Diabetes mellitus; Obesity; Endocrinology; Liraglutide","score_opus":0.026129206033269944,"score_gpt":0.284585919978344,"score_spread":0.258456713945074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402066678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993806,0.00042358256,0.000033588392,0.003118016,0.00013866877,0.0020946215,0.000030341453,0.000046222096,0.00030894595],"genre_scores_gemma":[0.9982494,0.000060477032,0.00045866115,0.00013353967,0.00013301031,0.00012543927,0.00004170425,0.000016699116,0.00078103703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856097,0.00037678366,0.00032032104,0.00026601407,0.00027252533,0.00020336962],"domain_scores_gemma":[0.9986706,0.0007422962,0.00011716291,0.00037303436,0.000051881907,0.00004505394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095546525,0.00016865616,0.0009003487,0.00017881913,0.00006806003,0.00005931651,0.0000770674,0.000053055854,0.00006218289],"category_scores_gemma":[0.00031855586,0.00007758415,0.000114979375,0.00082011893,0.000056919016,0.00008193858,0.000049942446,0.00015372103,0.0000017049996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36930475,0.00077251636,0.51963955,0.0010625926,0.030710826,0.000019147259,0.0011009279,0.00061523804,0.0018525674,0.00006014076,0.06769434,0.007167365],"study_design_scores_gemma":[0.21842618,0.0017573914,0.72718954,0.00073599746,0.023418996,0.0000016459658,0.0005655114,0.014032823,0.0012668645,0.000024675246,0.012282907,0.00029743437],"about_ca_topic_score_codex":0.00011681542,"about_ca_topic_score_gemma":0.0006746579,"teacher_disagreement_score":0.20754999,"about_ca_system_score_codex":0.00006770331,"about_ca_system_score_gemma":0.00004467046,"threshold_uncertainty_score":0.31637898},"labels":[],"label_agreement":null},{"id":"W4402097645","doi":"10.1016/j.kint.2024.08.023","title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); McMaster University; Université Laval; Bioinformatics Solutions (Canada); Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Centre hospitalier de l'Université Laval","funders":"CSL Behring; Alexion Pharmaceuticals; Novo Nordisk; Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Vifor Pharma; Hispanic Scholarship Consortium","keywords":"Medicine; Agonist; Internal medicine; Glucagon-like peptide 1 receptor; Renal function; Endocrinology; Kidney disease; Glucagon; Kidney; Diabetes mellitus; Glucagon-like peptide-1; Urology; Type 2 diabetes; Receptor; Insulin","score_opus":0.006374980941605441,"score_gpt":0.2530584322524269,"score_spread":0.24668345131082148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402097645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97179115,0.00008222206,0.000016206386,0.018412251,0.003432296,0.004268398,0.00033384815,0.000056944835,0.0016066935],"genre_scores_gemma":[0.9835671,0.0000490077,0.00006031304,0.0067084883,0.00016906134,0.00064231217,0.00070614374,0.000040835002,0.008056743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99791646,0.00021020944,0.00046296784,0.0004114689,0.0007398123,0.00025910212],"domain_scores_gemma":[0.99817413,0.00070901646,0.00015794853,0.00039023373,0.00008513786,0.00048351806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036782667,0.0003153765,0.0005627932,0.00021819405,0.00007377259,0.00010616575,0.00024597644,0.000050122304,0.0001687371],"category_scores_gemma":[0.003465599,0.0001546136,0.00025648056,0.00020782756,0.00027965865,0.00011685083,0.00012301738,0.00019835663,0.000020848394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67613405,0.008275325,0.123896144,0.0014725085,0.0063689644,0.00007808608,0.0012289768,0.0000036426834,0.0003901493,0.00502087,0.17246218,0.004669099],"study_design_scores_gemma":[0.9174055,0.0015175405,0.03382395,0.0027365286,0.0016091536,5.0871205e-7,0.000024216028,0.0007234336,0.0009273368,0.00021787445,0.040736742,0.0002772332],"about_ca_topic_score_codex":0.000040874,"about_ca_topic_score_gemma":0.0000025241684,"teacher_disagreement_score":0.24127144,"about_ca_system_score_codex":0.00017394562,"about_ca_system_score_gemma":0.000331336,"threshold_uncertainty_score":0.63049597},"labels":[],"label_agreement":null},{"id":"W4402102075","doi":"10.1093/eurheartj/ehae564","title":"Semaglutide and blood pressure: an individual patient data meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Semaglutide; Placebo; Blood pressure; Confidence interval; Internal medicine; Randomized controlled trial; Cardiology; Urology; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.3293539047610954,"score_gpt":0.40410624001639484,"score_spread":0.07475233525529945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402102075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012704839,0.9963308,0.0000028812374,0.00019730344,0.00017726123,0.0005638541,0.0004261891,0.00006121281,0.0022277967],"genre_scores_gemma":[0.000046916583,0.9916254,0.0013625419,0.00030281863,0.0005282766,0.000008953143,0.00095653156,0.000116305295,0.005052226],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965663,0.000926371,0.0007756441,0.00075026305,0.0006246855,0.00035673755],"domain_scores_gemma":[0.9977922,0.00007690712,0.00031087524,0.0013093017,0.000045618828,0.00046510785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016600799,0.00052768376,0.0029141377,0.00068471185,0.00012984847,0.0004967643,0.00042551025,0.00006234987,0.00062781194],"category_scores_gemma":[0.00006216521,0.0003090057,0.0016058539,0.0004962739,0.0000498565,0.00016219064,0.0009238474,0.0007799956,0.00028804826],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000027856388,0.000255336,0.000025500174,0.002937662,0.6730144,0.0015508594,0.00007808339,6.6588785e-7,4.34608e-8,0.000011700464,0.04667109,0.27545187],"study_design_scores_gemma":[0.00010358508,0.00021852466,0.00003842111,0.0003320177,0.49423367,0.00044356694,0.0000057756342,0.0000033852461,4.4977114e-8,0.000001501781,0.5044918,0.00012770668],"about_ca_topic_score_codex":0.000002333468,"about_ca_topic_score_gemma":0.0000023331256,"teacher_disagreement_score":0.4578207,"about_ca_system_score_codex":0.0000113263395,"about_ca_system_score_gemma":0.00009260536,"threshold_uncertainty_score":0.9999362},"labels":[],"label_agreement":null},{"id":"W4402121437","doi":"10.7326/annals-24-01579-jc","title":"In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y","year":2024,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; University of Alberta","funders":"","keywords":"Semaglutide; Medicine; Kidney disease; Internal medicine; Clinical trial; Intensive care medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.028118208152825227,"score_gpt":0.31857844709953376,"score_spread":0.2904602389467085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402121437","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03544245,0.003474865,0.0000037723134,0.946505,0.0010932154,0.00090482505,0.00010460452,0.000049378676,0.0124218585],"genre_scores_gemma":[0.020456342,0.00043665423,0.000052243005,0.77766263,0.0030691936,0.00011237488,0.00055409607,0.00011382812,0.19754262],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969606,0.00005880696,0.0007492351,0.0006565858,0.0010029309,0.0005718623],"domain_scores_gemma":[0.99834013,0.000091025955,0.0002962585,0.0006490423,0.00017200847,0.00045155556],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026407294,0.0005579564,0.0011388187,0.00081047945,0.000018773122,0.000008038289,0.00028517438,0.00020611924,0.0018818459],"category_scores_gemma":[0.00024079804,0.00035232838,0.00024356451,0.00029691178,0.00020253615,0.000063334126,0.00020224662,0.0008922591,0.00035549345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012592692,0.00016638321,0.0040369793,0.0029447454,0.0015135724,0.013634983,0.00014056281,3.416702e-7,0.00014338728,0.000021222215,0.97547954,0.0006590167],"study_design_scores_gemma":[0.0034726395,0.0018752981,0.0027258643,0.027939707,0.0015971799,0.00005740526,0.000023738101,0.000015492904,0.0011997676,0.00051185937,0.96026605,0.0003149841],"about_ca_topic_score_codex":0.0003624162,"about_ca_topic_score_gemma":0.000019358784,"teacher_disagreement_score":0.18512076,"about_ca_system_score_codex":0.00016305706,"about_ca_system_score_gemma":0.00014407124,"threshold_uncertainty_score":0.9998929},"labels":[],"label_agreement":null},{"id":"W4402211609","doi":"10.1681/asn.0000000000000491","title":"Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"National Center for Advancing Translational Sciences; Medical Research Council","keywords":"Medicine; Kidney disease; Internal medicine; Diabetes mellitus; Renal function; Hazard ratio; Heart failure; Type 2 Diabetes Mellitus; Type 2 diabetes; Albuminuria; Creatinine; Empagliflozin; Clinical endpoint; Placebo; Endocrinology; Cardiology; Confidence interval; Randomized controlled trial; Pathology","score_opus":0.008090845520210378,"score_gpt":0.2730924642149239,"score_spread":0.2650016186947135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402211609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818047,0.0023416108,0.00021327139,0.0145658,0.00054341083,0.00035877744,0.00008227188,0.000022257913,0.000067867164],"genre_scores_gemma":[0.97602046,0.0018771223,0.0007160357,0.020750526,0.00031207464,0.000010706371,0.0000138489695,0.000029711658,0.00026953727],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833065,0.00014521368,0.0005781169,0.00018020945,0.0004792371,0.00028658184],"domain_scores_gemma":[0.9985168,0.0002816876,0.0004903704,0.00035813905,0.00014028864,0.00021270524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055942143,0.00021055165,0.001170117,0.00009178526,0.000061268955,0.00000920951,0.0002053533,0.00006446614,0.00002501356],"category_scores_gemma":[0.000094886906,0.000129998,0.0025475167,0.00041799698,0.00076222647,0.000070758346,0.000056180066,0.00032004275,0.0000054915727],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008366516,0.0027348618,0.04021742,0.0024135658,0.0522296,0.0002833593,0.0039165644,0.00016992808,0.23621494,0.0003981311,0.61830103,0.04228397],"study_design_scores_gemma":[0.0068003694,0.0031244121,0.37894523,0.00086943473,0.009365708,0.00010822946,0.0008566221,0.00015929746,0.059161626,0.00019634084,0.54014313,0.00026957627],"about_ca_topic_score_codex":0.00005840066,"about_ca_topic_score_gemma":0.000001076945,"teacher_disagreement_score":0.3387278,"about_ca_system_score_codex":0.00006067226,"about_ca_system_score_gemma":0.00019496151,"threshold_uncertainty_score":0.53011644},"labels":[],"label_agreement":null},{"id":"W4402289378","doi":"10.1016/s2213-8587(24)00219-5","title":"Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials","year":2024,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital","funders":"Public Health Scotland; National Heart, Lung, and Blood Institute; NIHR Nottingham Biomedical Research Centre; Medical Research Council; Swansea University; National Institutes of Health; Public Health England; National Institute for Health and Care Research; AstraZeneca; UK Research and Innovation; National Heart and Lung Institute; NIHR Oxford Biomedical Research Centre; Wellcome Trust; World Health Organization; Bill and Melinda Gates Foundation","keywords":"Medicine; Placebo; Coronavirus disease 2019 (COVID-19); Meta-analysis; Randomized controlled trial; MEDLINE; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Internal medicine; Intensive care medicine; Pharmacology; Alternative medicine; Virology; Disease","score_opus":0.12741284742750297,"score_gpt":0.3928776897507555,"score_spread":0.2654648423232525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402289378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014464544,0.9736287,0.000023799039,0.00073561835,0.00027081152,0.020426493,0.0028031808,0.0001736103,0.00049131375],"genre_scores_gemma":[0.005034438,0.96279,0.00025986822,0.0010632202,0.00040685845,0.022940798,0.0067339134,0.00018892455,0.00058198255],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9943916,0.0008295494,0.0018320194,0.0010396098,0.0005766823,0.0013304963],"domain_scores_gemma":[0.9943745,0.002399832,0.0014285542,0.0013244001,0.00024870937,0.0002240003],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0023976632,0.0010005386,0.016943641,0.0010101866,0.0000987729,0.00004908409,0.00050483714,0.00022475977,0.0003359714],"category_scores_gemma":[0.00064754294,0.00046375752,0.006846394,0.0011127988,0.00039783458,0.000060593367,0.00008877742,0.00038988597,0.000021656495],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017816118,0.00070470397,0.0020979117,0.017530497,0.91908956,0.000031654916,0.0002234139,0.000003822139,7.26994e-7,0.00072032824,0.0058521503,0.05196362],"study_design_scores_gemma":[0.018879877,0.0007113825,0.00010452134,0.00028168107,0.6582426,4.952282e-7,0.000016943717,0.0000037587904,0.00003211263,0.000176726,0.321252,0.00029794572],"about_ca_topic_score_codex":0.000019792415,"about_ca_topic_score_gemma":0.000022344502,"teacher_disagreement_score":0.31539983,"about_ca_system_score_codex":0.00031268655,"about_ca_system_score_gemma":0.00039486037,"threshold_uncertainty_score":0.9997814},"labels":[],"label_agreement":null},{"id":"W4402316814","doi":"10.1089/chi.2024.0317","title":"The Unintended Psychosocial Consequences of GLP-1 Receptor Agonists for Children and Adolescents: A Call for More Research","year":2024,"lang":"en","type":"editorial","venue":"Childhood Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University; Université Laval","funders":"Canadian Institutes of Health Research; Concordia University","keywords":"Psychosocial; Psychology; Developmental psychology; Medicine; Clinical psychology; Psychiatry","score_opus":0.015777960067688737,"score_gpt":0.33298323055132456,"score_spread":0.31720527048363584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402316814","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061025705,0.017072199,0.000044527915,0.017809609,0.86884344,0.024917912,0.009075838,0.0003196983,0.00089108583],"genre_scores_gemma":[0.09086282,0.007665213,0.0010449487,0.00023286937,0.8727986,0.0020400134,0.0074064117,0.00029736952,0.017651746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975084,0.00008348601,0.00040202035,0.0006809088,0.0007591736,0.0005660088],"domain_scores_gemma":[0.9979339,0.0006217897,0.00017104408,0.0004483954,0.00066632853,0.00015849505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010708863,0.00034636742,0.00067828246,0.00015986674,0.000422106,0.00012069166,0.00034480292,0.00048350496,0.000005102109],"category_scores_gemma":[0.0012569488,0.00023546332,0.00033277404,0.0001884396,0.0011007154,0.000040828356,0.00018739112,0.00065170607,0.0000097165275],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046346398,0.0004817353,0.00055070984,0.0010856906,0.0010710398,0.0000018980602,0.00041357515,2.3939831e-8,0.000023768918,0.0007525259,0.99199295,0.0031626022],"study_design_scores_gemma":[0.0069497325,0.0022943355,0.019875739,0.0036701832,0.0017399803,0.0000018030668,0.00029350538,0.000003654826,0.00059757184,0.004295081,0.9598429,0.0004354897],"about_ca_topic_score_codex":0.000112752554,"about_ca_topic_score_gemma":0.00006657646,"teacher_disagreement_score":0.03215004,"about_ca_system_score_codex":0.00019192307,"about_ca_system_score_gemma":0.000560453,"threshold_uncertainty_score":0.96019155},"labels":[],"label_agreement":null},{"id":"W4402318599","doi":"10.1111/dom.15926","title":"Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; University of Calgary; Ottawa Hospital; University of Ottawa; Western University; Capital District Health Authority; McMaster University; University of Alberta; Population Health Research Institute","funders":"Novo Nordisk Foundation Center for Basic Metabolic Research","keywords":"Medicine; Liraglutide; Hazard ratio; Type 2 diabetes; Internal medicine; Diabetes mellitus; Randomized controlled trial; Regimen; Confidence interval; Body mass index; Metformin; Insulin; Endocrinology","score_opus":0.04193998720789953,"score_gpt":0.3412835895633655,"score_spread":0.299343602355466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402318599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9008751,0.09470651,0.00010800805,0.00011368215,0.0007310392,0.0031704055,0.0000065725003,0.00009127627,0.00019743216],"genre_scores_gemma":[0.99399227,0.0022003923,0.0028132712,0.000096825504,0.0002808735,0.0001891886,0.000042566753,0.00003376946,0.00035084743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973819,0.00051351596,0.0008846417,0.00046345644,0.00039220828,0.0003642366],"domain_scores_gemma":[0.99850273,0.0006578997,0.00028063444,0.0002232191,0.00017168745,0.00016383622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033806034,0.00033651385,0.0022461177,0.00046660437,0.0001528755,0.00013492684,0.000069607864,0.00013977899,0.000049846236],"category_scores_gemma":[0.0016161263,0.00024207738,0.00045959646,0.0004057423,0.00016384892,0.00031156474,0.00018904885,0.00019299056,0.0000029929504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4709691,0.0026241303,0.016484717,0.005923391,0.015459925,0.00002884838,0.003418603,0.000062067695,0.21459338,0.016822957,0.00017123339,0.25344163],"study_design_scores_gemma":[0.8850923,0.00046173309,0.004768178,0.0016915245,0.011343194,0.0000013120645,0.00007177161,0.07842595,0.015266866,0.0017054534,0.0008285198,0.00034315433],"about_ca_topic_score_codex":0.000028323637,"about_ca_topic_score_gemma":0.0000017680611,"teacher_disagreement_score":0.41412324,"about_ca_system_score_codex":0.000028945553,"about_ca_system_score_gemma":0.000075292235,"threshold_uncertainty_score":0.98716295},"labels":[],"label_agreement":null},{"id":"W4402362722","doi":"10.1016/j.jacc.2024.06.036","title":"Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure","year":2024,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Heart failure; Cardiology; Internal medicine","score_opus":0.004008278776727222,"score_gpt":0.24034657863792444,"score_spread":0.23633829986119723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402362722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528664,0.0004867607,0.000024392699,0.0033841403,0.00022633813,0.00036548526,0.000013135245,0.0000043136233,0.00020877043],"genre_scores_gemma":[0.9987261,0.000066626366,0.00073410245,0.0003212363,0.000066373585,0.0000033119,9.572846e-7,0.000012741846,0.00006851555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989334,0.00018473601,0.0003301071,0.00009595312,0.00025495252,0.0002008902],"domain_scores_gemma":[0.99917114,0.00021551926,0.00032986182,0.00014582455,0.00007134484,0.000066323555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022379514,0.00010130856,0.0008314743,0.00026254504,0.000014447622,0.000001969574,0.00007312017,0.000017975684,0.0000016697646],"category_scores_gemma":[0.000060929084,0.00005542646,0.00018809213,0.0004130719,0.00014777518,0.00002814444,0.000032876305,0.00017479666,8.165233e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026581238,0.0003020703,0.9463004,0.00060476485,0.0020303172,0.00020981804,0.00015090781,0.0009694857,0.00038872098,0.00032826656,0.037052814,0.00900431],"study_design_scores_gemma":[0.0037702618,0.012748299,0.9582869,0.001419656,0.00033465997,0.000025403646,0.00028837746,0.000012860854,0.00061339024,0.00005122523,0.022373265,0.00007569493],"about_ca_topic_score_codex":0.000014168102,"about_ca_topic_score_gemma":0.000005384029,"teacher_disagreement_score":0.014679547,"about_ca_system_score_codex":0.00014379043,"about_ca_system_score_gemma":0.00019069224,"threshold_uncertainty_score":0.22602254},"labels":[],"label_agreement":null},{"id":"W4402381722","doi":"10.1111/dom.15811","title":"Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to <scp>iGlarLixi</scp> : A participant‐level pooled analysis of three phase 3 <scp>LixiLan</scp> randomized controlled trials","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Exenatide","score_opus":0.021043760299329518,"score_gpt":0.2644955457325564,"score_spread":0.24345178543322687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402381722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9427228,0.05170474,0.00008543187,0.000118682416,0.00022852088,0.004524745,0.00024324626,0.00017693621,0.00019487471],"genre_scores_gemma":[0.99502164,0.0013513614,0.0013835775,0.00032422852,0.00014480733,0.000984503,0.00035050555,0.00006918426,0.00037018838],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945579,0.0010353144,0.0016879194,0.0009423794,0.00069542194,0.0010810242],"domain_scores_gemma":[0.99141127,0.0068437834,0.00045609425,0.0005829058,0.0002417356,0.0004642259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054719136,0.00071329495,0.008626542,0.0017646302,0.000082862905,0.00015190405,0.00021523147,0.00022270015,0.00007582118],"category_scores_gemma":[0.006258044,0.00049732934,0.0009997673,0.002507533,0.00012266482,0.0003120365,0.00013146574,0.00029214978,0.000026932834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013944309,0.012291534,0.5309321,0.0015552118,0.19181564,0.00035110555,0.025226338,0.0005998585,0.21064551,0.00035938027,0.0004649207,0.011814053],"study_design_scores_gemma":[0.4278273,0.00066307106,0.33690596,0.0010205563,0.17687513,4.2202507e-7,0.00073333,0.022929532,0.031559195,0.0003684364,0.0008083183,0.0003087533],"about_ca_topic_score_codex":0.00020626064,"about_ca_topic_score_gemma":0.0010290652,"teacher_disagreement_score":0.413883,"about_ca_system_score_codex":0.000060168117,"about_ca_system_score_gemma":0.00016600182,"threshold_uncertainty_score":0.9997478},"labels":[],"label_agreement":null},{"id":"W4402407189","doi":"10.1111/jdi.14306","title":"Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Beijing Medical Award Foundation","keywords":"Medicine; Interquartile range; Internal medicine; Odds ratio; Montreal Cognitive Assessment; Confidence interval; Diabetes mellitus; Type 2 diabetes; Confounding; Gastroenterology; Logistic regression; Type 2 Diabetes Mellitus; Endocrinology; Cognitive impairment; Disease","score_opus":0.010174637561491343,"score_gpt":0.2321844438931792,"score_spread":0.22200980633168785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402407189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652874,0.0014245244,0.000015864705,0.00077831734,0.00034970915,0.0006388889,0.00001278939,0.000045039724,0.00020612286],"genre_scores_gemma":[0.9977997,0.00008288358,0.00077268743,0.00082009006,0.00015506682,0.000022081262,0.0002561846,0.000037422997,0.000053872234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983456,0.000060451235,0.0005669105,0.00022615958,0.0004894001,0.0003114825],"domain_scores_gemma":[0.99906766,0.00008998234,0.0002336102,0.000107780616,0.00036365545,0.00013731157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003027581,0.00023843926,0.00040337266,0.00040025607,0.000037788708,0.00008445136,0.00004847027,0.00008274263,0.000057581055],"category_scores_gemma":[0.000049949125,0.00016847158,0.00010193105,0.0006437496,0.00013662306,0.00080731034,0.000017078462,0.0002561034,0.00003036281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016473168,0.0005351412,0.99056035,0.00047432625,0.0005466307,0.000041713283,0.0009370713,0.000024236248,0.00182595,0.00008694632,0.0011386346,0.0036642791],"study_design_scores_gemma":[0.0060599986,0.0057749245,0.9246871,0.0060399016,0.0011145063,9.686596e-7,0.00022003053,0.00024875836,0.052770767,0.0023443212,0.00044827533,0.00029045495],"about_ca_topic_score_codex":0.0000023685157,"about_ca_topic_score_gemma":0.0000032457554,"teacher_disagreement_score":0.06587325,"about_ca_system_score_codex":0.00020522774,"about_ca_system_score_gemma":0.00012985278,"threshold_uncertainty_score":0.6870071},"labels":[],"label_agreement":null},{"id":"W4402455942","doi":"10.1080/14740338.2024.2401024","title":"Comparative risk of infection of medications used for type 2 diabetes","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Type 2 diabetes; Food and drug administration; Diabetes mellitus; Drug; Urinary system; Canagliflozin; Randomized controlled trial; Intensive care medicine; Pharmacology; Internal medicine; Endocrinology","score_opus":0.08427157789930105,"score_gpt":0.4222656409577348,"score_spread":0.3379940630584337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402455942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025001267,0.99425954,0.000047369176,0.00017724968,0.0014368928,0.002164712,0.00016718886,0.000058062607,0.0016639826],"genre_scores_gemma":[0.00025787743,0.99639183,0.00030393782,0.000024420307,0.00025402257,0.00039272703,0.001627148,0.00003764579,0.00071039266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852395,0.00010850881,0.00066028093,0.00031143782,0.000242009,0.0001538325],"domain_scores_gemma":[0.99852264,0.0004298591,0.00046364206,0.00039708972,0.00011886488,0.0000678883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028370644,0.0002916366,0.0016072869,0.00031835845,0.000042492236,0.0000054101442,0.00007973869,0.00012568825,0.00007161819],"category_scores_gemma":[0.00007178897,0.00019842919,0.0005595663,0.0003773396,0.00007694083,0.000033102842,0.00004725084,0.00015656697,0.00005792113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087354936,0.0011506295,0.00015655183,0.024331039,0.0072393822,4.467884e-7,0.0014574358,0.000004601509,0.0000027654098,0.0042998814,0.11923815,0.8420318],"study_design_scores_gemma":[0.00054462405,0.00046576708,0.00006933674,0.014660695,0.0012367003,1.805293e-7,0.000029480198,0.0000478278,0.000055408844,0.000041012245,0.98271203,0.00013692954],"about_ca_topic_score_codex":0.000024282408,"about_ca_topic_score_gemma":0.0000042726633,"teacher_disagreement_score":0.8634739,"about_ca_system_score_codex":0.00013558757,"about_ca_system_score_gemma":0.00015608736,"threshold_uncertainty_score":0.8091708},"labels":[],"label_agreement":null},{"id":"W4402516471","doi":"10.1111/dom.15938","title":"The association of glycaemic risk factors and diabetes duration with risk of heart failure in people with type 2 diabetes: A systematic review and meta‐analysis","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Health and Medical Research Council; La Trobe University","keywords":"Medicine; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Hazard ratio; Internal medicine; Publication bias; Odds ratio; Confidence interval; Endocrinology","score_opus":0.00996980483077645,"score_gpt":0.24551313731623933,"score_spread":0.2355433324854629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402516471","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16302505,0.8338888,5.0773104e-7,0.000085533306,0.000024879948,0.002754988,0.00018920406,0.000022341734,0.0000086744685],"genre_scores_gemma":[0.026076421,0.97303104,0.00011587907,0.00003786712,0.000014047166,0.000356707,0.00016646922,0.000041480635,0.00016006596],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970134,0.00068205275,0.0009534815,0.00053398474,0.00043357763,0.00038350534],"domain_scores_gemma":[0.9969079,0.0009155278,0.0013724843,0.0004950554,0.0001882373,0.00012082334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016636238,0.0006167723,0.0071534254,0.0004853083,0.00011306142,0.000083331266,0.000108768225,0.0002026391,0.0000069163575],"category_scores_gemma":[0.00038301843,0.00028649648,0.00058807834,0.0015497092,0.0001245629,0.00015680541,0.00009859058,0.0003737526,0.0000017846803],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004397327,0.0001103424,0.26036873,0.573685,0.16503814,5.554721e-7,0.00016023478,5.4640316e-7,7.7058843e-7,0.00005046484,0.00007096503,0.00050988526],"study_design_scores_gemma":[0.0003752642,0.0002110672,0.025608484,0.026796054,0.94157237,2.7988767e-7,0.00006000045,0.000019173924,0.000011175479,0.000024845658,0.005034004,0.00028728743],"about_ca_topic_score_codex":0.00007398736,"about_ca_topic_score_gemma":0.0004467279,"teacher_disagreement_score":0.77653426,"about_ca_system_score_codex":0.000055962675,"about_ca_system_score_gemma":0.000069854694,"threshold_uncertainty_score":0.9999587},"labels":[],"label_agreement":null},{"id":"W4402527334","doi":"10.1002/ejhf.3464","title":"Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study","year":2024,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; McGill University Health Centre; Health Sciences Centre; University Health Network; Ottawa Public Health; University of Toronto; University of Ottawa; Ontario Brain Institute","funders":"Temerty Faculty of Medicine, University of Toronto; Canadian Institutes of Health Research; Health Canada; Servier; University of Toronto; Novo Nordisk; European Society of Cardiology; Ministry of Colleges and Universities; Government of Canada; Alberta Innovates; Heart and Stroke Foundation of Canada; Canadian Cardiovascular Society; Fondation Brain Canada; Canadian Bee Research Fund; Canada First Research Excellence Fund; Canada Research Chairs; AstraZeneca","keywords":"Medicine; Heart failure; Diabetes mellitus; Internal medicine; Cohort; Cardiology; Cohort study; Population; Endocrinology","score_opus":0.009210489063859259,"score_gpt":0.24412213962424578,"score_spread":0.23491165056038651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402527334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990605,0.00019560603,0.000025798321,0.008258111,0.000112628106,0.00071465806,0.000016214963,0.000029356412,0.00004262571],"genre_scores_gemma":[0.9961694,0.0000038934,0.0031974176,0.0003748922,0.00008432744,0.000006589174,0.000051234772,0.000047445195,0.00006478373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836004,0.0001747954,0.0006107697,0.00022441172,0.00041783534,0.00021214242],"domain_scores_gemma":[0.99933374,0.00008224306,0.0001497155,0.00017361986,0.00013602708,0.00012463455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007013893,0.00021503276,0.0005621926,0.0004614599,0.00004227963,0.00006127434,0.000057014237,0.000026662728,0.000078876845],"category_scores_gemma":[0.000027779022,0.00014801846,0.00012626125,0.00023045455,0.000032657223,0.00030300306,0.000018923822,0.00026646734,0.000013018804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012657155,0.00043614878,0.9934232,0.00018007228,0.0005413102,0.00032242556,0.0004989403,0.000013675596,0.0023242452,0.0000047250624,0.0019377645,0.00019088476],"study_design_scores_gemma":[0.0033460988,0.0023707363,0.988525,0.0009521027,0.00080644485,0.000019007373,0.00034432783,0.00008826113,0.00063971116,0.0000018995484,0.0027663663,0.00014009379],"about_ca_topic_score_codex":0.000010266688,"about_ca_topic_score_gemma":0.000045239696,"teacher_disagreement_score":0.007883219,"about_ca_system_score_codex":0.000051857827,"about_ca_system_score_gemma":0.000063129315,"threshold_uncertainty_score":0.60360175},"labels":[],"label_agreement":null},{"id":"W4402548639","doi":"10.2196/58137","title":"Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims","year":2024,"lang":"en","type":"article","venue":"JMIR Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Medicine; Internal medicine; Type 2 Diabetes Mellitus; Diabetes mellitus; Endocrinology; World Wide Web; Computer science","score_opus":0.016724424908295954,"score_gpt":0.26548157027479835,"score_spread":0.2487571453665024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402548639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016315,0.0023747298,0.0000021451754,0.00020386248,0.000788248,0.0058535817,0.00013388466,0.0004060828,0.000074330695],"genre_scores_gemma":[0.99601,0.00060090923,0.0011759943,0.0002702474,0.000489814,0.00057003635,0.00044461628,0.0001998988,0.00023849761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99557364,0.00016923025,0.0009228708,0.0013874852,0.00089997007,0.0010467921],"domain_scores_gemma":[0.9977176,0.00048157864,0.00031572714,0.0007458953,0.00031501433,0.00042418807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060184434,0.00088044157,0.0011812572,0.00063974806,0.00040141062,0.00038787088,0.00022159758,0.00017304282,0.000025494694],"category_scores_gemma":[0.00007029848,0.00070452905,0.00025680472,0.0009643222,0.00025842126,0.00073569623,0.00015688912,0.00056057575,0.0000599745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000524306,0.0017985444,0.9834003,0.0012500645,0.00085994136,0.000011846575,0.0011368924,0.000047914666,0.0017293534,0.000017275186,0.005287369,0.0039362237],"study_design_scores_gemma":[0.0063325106,0.006287137,0.9526341,0.009167423,0.0010940373,2.1327882e-7,0.00075573206,0.00069508574,0.007650573,0.00003021156,0.01419189,0.0011610785],"about_ca_topic_score_codex":0.000097071126,"about_ca_topic_score_gemma":0.00027653988,"teacher_disagreement_score":0.030766161,"about_ca_system_score_codex":0.0004992992,"about_ca_system_score_gemma":0.00013492606,"threshold_uncertainty_score":0.99954057},"labels":[],"label_agreement":null},{"id":"W4402557297","doi":"10.1111/dom.15957","title":"Do nonglycaemic effects such as weight loss account for <scp>HbA1c</scp> lowering with efpeglenatide?: Insights from the <scp>AMPLITUDE‐</scp> O trial","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Sanofi","keywords":"Medicine; Weight loss; Food science; Internal medicine; Obesity","score_opus":0.008594574529834389,"score_gpt":0.22687970568778146,"score_spread":0.21828513115794707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402557297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262111,0.048057962,0.00005900657,0.011992911,0.0040180087,0.0067066727,0.00035542142,0.00035040572,0.002248516],"genre_scores_gemma":[0.45435318,0.011232351,0.0014731887,0.4286576,0.05008551,0.008323881,0.009278746,0.0013578734,0.035237677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99448746,0.00019531803,0.0007599203,0.0018130755,0.0012239164,0.0015203272],"domain_scores_gemma":[0.99306285,0.0045371065,0.00043410395,0.001365688,0.00026241408,0.00033781806],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00051032123,0.0014736591,0.0023822105,0.0005031027,0.00044831017,0.00077843294,0.00070054666,0.0011020113,0.000018431852],"category_scores_gemma":[0.0005909222,0.00091974507,0.00073524157,0.0005240857,0.0003666459,0.00038183326,0.00047117344,0.0019034863,0.00022610658],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003345726,0.0009124607,0.0066693267,0.004999386,0.011484423,0.0011499166,0.002503989,0.0000024298397,0.00045601116,0.0014458034,0.9644101,0.005631557],"study_design_scores_gemma":[0.025359737,0.0007538219,0.009409968,0.0016793067,0.010270634,0.0000057125962,0.000077514815,0.000019337967,0.0043615215,0.004239717,0.94354904,0.0002736638],"about_ca_topic_score_codex":0.00012373763,"about_ca_topic_score_gemma":0.000023702858,"teacher_disagreement_score":0.4718579,"about_ca_system_score_codex":0.00015987642,"about_ca_system_score_gemma":0.00022019722,"threshold_uncertainty_score":0.9998013},"labels":[],"label_agreement":null},{"id":"W4402575583","doi":"10.14341/probl13336","title":"Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation","year":2024,"lang":"en","type":"article","venue":"Problems of Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Transporter; Chemistry; Pharmacology; Type 2 diabetes; Medicine; Endocrinology; Diabetes mellitus; Biochemistry; Gene","score_opus":0.01683454321869467,"score_gpt":0.28457506373986097,"score_spread":0.2677405205211663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402575583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905933,0.0013945381,0.00023315889,0.0026089654,0.00021026297,0.0016953647,0.000032609605,0.000073810814,0.0031579845],"genre_scores_gemma":[0.9989382,0.000107395805,0.00008635915,0.000045681947,0.00004877737,0.00015893225,0.00015920732,0.000021813861,0.00043360365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873763,0.00006281691,0.00049405155,0.00027837054,0.00016342674,0.0002637011],"domain_scores_gemma":[0.9994343,0.00008612435,0.00013636207,0.00017814185,0.00012935912,0.000035720033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013441092,0.00014782595,0.00039429468,0.0005704068,0.000017930437,0.000003914283,0.00005812062,0.00008567803,0.00013193321],"category_scores_gemma":[0.00005807741,0.00013811348,0.0000946582,0.00047189227,0.00015205503,0.000113220674,0.000018443316,0.00016347472,0.00002193309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000351116,0.001418484,0.015951065,0.004038285,0.0011554526,0.0000788473,0.0019344444,0.00057790044,0.9372023,0.020916894,0.0018483031,0.014526917],"study_design_scores_gemma":[0.006266098,0.007682105,0.073277056,0.0016374838,0.0005853718,0.00005078293,0.00020278073,0.0015495601,0.888344,0.008936894,0.011152371,0.0003154913],"about_ca_topic_score_codex":0.0003172771,"about_ca_topic_score_gemma":0.00034292508,"teacher_disagreement_score":0.057325993,"about_ca_system_score_codex":0.00016768927,"about_ca_system_score_gemma":0.00017211815,"threshold_uncertainty_score":0.5632104},"labels":[],"label_agreement":null},{"id":"W4402621680","doi":"10.1056/nejmcibr2409089","title":"Discovery of GLP-1–Based Drugs for the Treatment of Obesity","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Obesity; Medicine; Internal medicine; Pharmacology","score_opus":0.01851403969455445,"score_gpt":0.28647845942964906,"score_spread":0.2679644197350946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402621680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92648935,0.029153692,0.00728172,0.032703847,0.001582042,0.0008599089,0.000020619798,0.000015820373,0.0018930216],"genre_scores_gemma":[0.9920706,0.0016552482,0.00052232493,0.00014253115,0.0016354158,0.000004557824,0.000011486944,0.000012250021,0.003945593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989621,0.000021993908,0.0004207543,0.00008376925,0.0003958254,0.00011553719],"domain_scores_gemma":[0.9988013,0.00064784224,0.00017946707,0.00016263493,0.00013063304,0.00007815497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049857306,0.00011864123,0.00048243656,0.00015622379,0.000019071815,0.000006569161,0.00007225901,0.000026383823,0.000051095827],"category_scores_gemma":[0.00008225402,0.000051206167,0.00021042641,0.00012983452,0.000088891764,0.00005966449,0.000005811344,0.000058471735,7.141457e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003121893,0.0013325443,0.007821275,0.000932921,0.0029983558,0.0001576185,0.0037179794,0.00007441472,0.0048115174,0.002281911,0.03318753,0.939562],"study_design_scores_gemma":[0.14112803,0.03849054,0.016442169,0.0038073878,0.010592786,0.00007180336,0.0011898975,0.0014787564,0.02882531,0.00202091,0.75578094,0.00017146685],"about_ca_topic_score_codex":0.00006415929,"about_ca_topic_score_gemma":0.000008750295,"teacher_disagreement_score":0.9393906,"about_ca_system_score_codex":0.00006766294,"about_ca_system_score_gemma":0.00015013384,"threshold_uncertainty_score":0.20881268},"labels":[],"label_agreement":null},{"id":"W4402640848","doi":"10.1007/s12325-024-02961-3","title":"Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Albuminuria; Dapagliflozin; Kidney disease; Internal medicine; Intensive care medicine; Disease; Urology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.04193459373356344,"score_gpt":0.35978972029929357,"score_spread":0.3178551265657301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402640848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678035,0.011520209,0.0000018789808,0.000061391824,0.00004222295,0.0011194529,0.000013434533,0.0000050861845,0.00045600548],"genre_scores_gemma":[0.99127865,0.008444158,0.0000089970845,0.000024171784,0.000011620678,0.00009827588,0.000021460848,0.000011419529,0.00010125927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990821,0.00017841657,0.00015854159,0.00020700831,0.00022459868,0.00014932331],"domain_scores_gemma":[0.99953973,0.00021257134,0.00003150071,0.00013922204,0.000034074226,0.000042882708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049129035,0.00009477405,0.0001853912,0.0003142129,0.000013028186,0.000008546992,0.00005591236,0.000018984216,0.000011064937],"category_scores_gemma":[0.00003381188,0.00005858937,0.000013391003,0.00060488755,0.0001338089,0.00025251697,0.000023715838,0.00009043247,2.3530315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008969128,0.00030729835,0.9653691,0.0007885422,0.000039561648,0.000018003282,0.0005673526,0.000032908218,0.00015437548,0.00075465016,0.0000109734665,0.031060291],"study_design_scores_gemma":[0.002954552,0.0007067767,0.9919013,0.002299602,0.000017786371,4.7759414e-8,0.00005721258,0.00026630732,0.00068860856,0.0005149175,0.0005366613,0.000056238907],"about_ca_topic_score_codex":0.00012814983,"about_ca_topic_score_gemma":0.0016573574,"teacher_disagreement_score":0.031004053,"about_ca_system_score_codex":0.00009056887,"about_ca_system_score_gemma":0.0000615359,"threshold_uncertainty_score":0.23892051},"labels":[],"label_agreement":null},{"id":"W4402645654","doi":"10.7759/cureus.69711","title":"The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Empagliflozin; Medicine; Dapagliflozin; Meta-analysis; Type 2 diabetes; Diabetes mellitus; Benzhydryl compounds; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.06432516826210248,"score_gpt":0.34440755225797254,"score_spread":0.28008238399587004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402645654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02027411,0.9766503,0.0000030413728,0.000009078375,0.00009174525,0.0028181917,0.000017319462,0.0000039539036,0.00013228202],"genre_scores_gemma":[0.33759886,0.66167724,0.00003381812,0.000006719128,0.000017631237,0.00043704826,0.000101598576,0.00003703309,0.00009007663],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99699694,0.0013251033,0.00070025295,0.00027498812,0.0005179771,0.00018473473],"domain_scores_gemma":[0.9978754,0.0006783712,0.00039168313,0.0009567805,0.00007933675,0.000018414376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183534,0.00029671297,0.004003059,0.0001498273,0.000025897194,0.000013272212,0.00027939762,0.000094293675,0.000004214637],"category_scores_gemma":[0.00009589691,0.0001039248,0.0020324283,0.0015137189,0.000117955,0.000027573979,0.00013411694,0.00020389962,6.5842903e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008212966,0.0009769137,0.251577,0.02097303,0.67550904,0.0000020194843,0.0002657867,0.00042217685,4.650763e-8,0.00024434333,0.0001010575,0.0498465],"study_design_scores_gemma":[0.00081854564,0.00055762887,0.08458565,0.0036321657,0.88371295,7.4837544e-8,0.00006611789,0.000020270156,0.0000022131344,0.000088076486,0.026377246,0.00013904671],"about_ca_topic_score_codex":0.00005380287,"about_ca_topic_score_gemma":0.0001511113,"teacher_disagreement_score":0.31732476,"about_ca_system_score_codex":0.000060751885,"about_ca_system_score_gemma":0.000053596923,"threshold_uncertainty_score":0.42379302},"labels":[],"label_agreement":null},{"id":"W4402654046","doi":"10.1016/j.jcjd.2024.09.003","title":"Use of Sodium-Glucose Cotransporter-2 Inhibitors in Adults Aged ≥65 Years With Type 2 Diabetes and Cardiovascular Disease: A Cross-sectional Study of Different Drug Funding Policies","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; North York General Hospital; University of Alberta","funders":"Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta; Diabetes Action Canada","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Disease; Cross-sectional study; Gerontology; Internal medicine; Endocrinology; Pathology","score_opus":0.016851978472949627,"score_gpt":0.2308834223885646,"score_spread":0.21403144391561496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402654046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900872,0.009132226,2.3895132e-7,0.000034884815,0.00026217208,0.00041334503,0.000045269455,0.000008249178,0.000016401847],"genre_scores_gemma":[0.9996778,0.00008497078,0.000019226762,0.00002041534,0.00008488143,0.000009393802,0.000016735336,0.000028827042,0.000057767993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855304,0.000053715994,0.0004839581,0.00020514612,0.00037418515,0.00032992978],"domain_scores_gemma":[0.9990177,0.000092364666,0.00011300913,0.00019642652,0.00012766881,0.0004528059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002656388,0.0001879494,0.00055144023,0.00079729856,0.000038041362,0.00007679358,0.000080386606,0.000039036404,0.000020896876],"category_scores_gemma":[0.000048063022,0.00014590217,0.00018656896,0.0003533539,0.00016316984,0.00022079513,0.0000142768995,0.0001741094,4.560173e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005332224,0.00018903815,0.9936029,0.00054389564,0.0019352571,0.00015737068,0.0016535196,0.000102421065,0.00016987548,0.000014263737,0.00008813579,0.001490019],"study_design_scores_gemma":[0.0018708154,0.000908699,0.99357635,0.0015134714,0.0007568581,9.5271145e-7,0.0004770395,0.0000464633,0.0005341751,0.000017176622,0.00017256483,0.00012543258],"about_ca_topic_score_codex":0.0012160132,"about_ca_topic_score_gemma":0.0050502825,"teacher_disagreement_score":0.009590569,"about_ca_system_score_codex":0.00012095678,"about_ca_system_score_gemma":0.00025405127,"threshold_uncertainty_score":0.59497184},"labels":[],"label_agreement":null},{"id":"W4402659510","doi":"10.1111/dom.15768","title":"Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; McGill University Health Centre; Sunnybrook Health Science Centre; Ontario Brain Institute; University of Ottawa; Wilfrid Laurier University; McGill University","funders":"Ministry of Colleges and Universities; Canada Research Chairs; Mach-Gaensslen Foundation of Canada","keywords":"Canagliflozin; Medicine; Phenotype; Type 2 diabetes; Hazard ratio; Internal medicine; Clinical endpoint; Proportional hazards model; Latent class model; Empagliflozin; Diabetes mellitus; Clinical trial; Endocrinology; Confidence interval; Biology; Genetics","score_opus":0.012888779664216043,"score_gpt":0.23788790500090937,"score_spread":0.22499912533669333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402659510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9181421,0.07863233,0.0000021451042,0.00008479974,0.0006104192,0.0014897296,0.00003767155,0.00010744883,0.0008933498],"genre_scores_gemma":[0.994303,0.0038684446,0.00017624581,0.00018238087,0.00019928614,0.00017288241,0.000084281615,0.000033973065,0.0009795385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758977,0.00018724382,0.00044220826,0.00063022855,0.00054439984,0.0006061521],"domain_scores_gemma":[0.9986482,0.00036300547,0.00009975813,0.00058933574,0.000104397135,0.0001952612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088547973,0.00036281886,0.0012864149,0.00055599987,0.00010418391,0.0001447498,0.00018355169,0.00018284423,0.000009569747],"category_scores_gemma":[0.00035916918,0.00025063922,0.00066226046,0.0017747367,0.0002561347,0.00018909184,0.00023091976,0.0002788614,0.0000093870585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054333657,0.0018198916,0.8365893,0.0017091398,0.036399122,0.00004030371,0.0026156327,0.00019108724,0.0012915938,0.003065133,0.0019298426,0.11429463],"study_design_scores_gemma":[0.0073382077,0.00038736244,0.81912225,0.00027240484,0.02448853,3.8449394e-7,0.00023249547,0.0026448772,0.0022948077,0.0004195103,0.14271104,0.000088155604],"about_ca_topic_score_codex":0.00007086844,"about_ca_topic_score_gemma":0.000036397792,"teacher_disagreement_score":0.1407812,"about_ca_system_score_codex":0.000041993822,"about_ca_system_score_gemma":0.000072819494,"threshold_uncertainty_score":0.9999946},"labels":[],"label_agreement":null},{"id":"W4402660544","doi":"10.14740/jocmr5230","title":"Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes in Heart Failure Patients With Type 2 Diabetes: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Heart failure; Diabetes mellitus; Cotransporter; Internal medicine; Cardiology; Endocrinology; Sodium; Pharmacology","score_opus":0.09333661375203715,"score_gpt":0.48329967790061984,"score_spread":0.38996306414858267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402660544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013336807,0.9829886,1.11945766e-7,0.0013619218,0.0002742786,0.0019025162,0.00002031389,0.000006340901,0.00010912705],"genre_scores_gemma":[0.0011694824,0.99763364,0.00007587162,0.00014127576,0.0006531086,0.00002391755,0.00008449571,0.000064481836,0.00015372116],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928623,0.0009143679,0.0028664966,0.00047904777,0.0023920622,0.00048575495],"domain_scores_gemma":[0.9958562,0.001316334,0.0006053508,0.00063573127,0.0010621721,0.00052421243],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0075810947,0.00050409226,0.0073218117,0.0013377627,0.000023020692,0.000022671647,0.0002297275,0.00037006362,0.00005881406],"category_scores_gemma":[0.0021153477,0.00021361676,0.0021365008,0.0015363211,0.00037808967,0.000097246186,0.00008077702,0.0032370328,0.000012727087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005672923,0.0016378695,0.10865947,0.14470507,0.014214343,0.0011592505,0.00006417985,1.9710129e-7,2.0685978e-7,0.0000048746306,0.06178318,0.6672041],"study_design_scores_gemma":[0.0033575865,0.014496321,0.012590633,0.47205755,0.00704165,0.000016283242,0.000005158538,2.480488e-7,2.4941173e-7,0.000008734343,0.49029562,0.0001299462],"about_ca_topic_score_codex":0.000006379262,"about_ca_topic_score_gemma":0.000002438755,"teacher_disagreement_score":0.66707414,"about_ca_system_score_codex":0.00018466554,"about_ca_system_score_gemma":0.0006974625,"threshold_uncertainty_score":0.99906254},"labels":[],"label_agreement":null},{"id":"W4402763215","doi":"10.1097/ms9.0000000000002592","title":"Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023","year":2024,"lang":"en","type":"review","venue":"Annals of Medicine and Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glucagon-like peptide-1; Glucagon; Intensive care medicine; Internal medicine; Diabetes mellitus; Endocrinology; Insulin; Type 2 diabetes","score_opus":0.11264312481870956,"score_gpt":0.379397564532647,"score_spread":0.2667544397139374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402763215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023531879,0.9950715,0.0000145495615,0.0008601755,0.00034850766,0.00078526547,0.000114953866,0.000037660942,0.00041424428],"genre_scores_gemma":[0.0010829098,0.9946959,0.000017031605,0.0007405389,0.0004202333,0.00017658072,0.0017993189,0.000045513956,0.0010219581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675274,0.00014562828,0.0011165601,0.00076102634,0.00082907814,0.00039498563],"domain_scores_gemma":[0.9979493,0.00057833764,0.00021646655,0.00074145256,0.00012746078,0.00038699617],"candidate_categories":["metaepi_narrow","bibliometrics"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.0012511866,0.0004999723,0.005705127,0.091722816,0.000025123234,0.00002964918,0.000115422255,0.00019248869,0.00018741106],"category_scores_gemma":[0.00036626696,0.0003368618,0.0022570174,0.0922206,0.00010774771,0.00007654051,0.00013862163,0.00020967089,0.00009020363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022883349,0.00013975777,0.0032838245,0.011957477,0.016998366,0.0004429046,0.000059272883,0.0000011209797,7.7733354e-8,0.0000047271737,0.12259781,0.8444918],"study_design_scores_gemma":[0.00027413707,0.00014804782,0.0111559555,0.022366937,0.050863016,0.000002349101,0.000062745785,0.0000052924315,2.0036808e-7,0.00003670447,0.9148336,0.00025099382],"about_ca_topic_score_codex":0.0011581293,"about_ca_topic_score_gemma":0.00004339561,"teacher_disagreement_score":0.8442408,"about_ca_system_score_codex":0.00005234763,"about_ca_system_score_gemma":0.0001558606,"threshold_uncertainty_score":0.9999083},"labels":[],"label_agreement":null},{"id":"W4402765298","doi":"10.1056/evide2400277","title":"Can SGLT2 Inhibitors ERASe Arrhythmias?","year":2024,"lang":"en","type":"letter","venue":"NEJM Evidence","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chemistry; Computer science","score_opus":0.031912572286523784,"score_gpt":0.2836626159127333,"score_spread":0.2517500436262095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402765298","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002296278,0.013069787,0.0000033879867,0.97311485,0.0022990976,0.0009559937,0.000025071067,0.0003353048,0.007900235],"genre_scores_gemma":[0.0075541385,0.0014664023,0.00023597335,0.8196316,0.012398611,0.00024939745,0.00026892519,0.00013366749,0.15806128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756056,0.00004391611,0.00036203506,0.000768196,0.0007156173,0.00054965564],"domain_scores_gemma":[0.99869484,0.00018187163,0.00010871709,0.0008054653,0.0000742875,0.00013484096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016149336,0.00047119928,0.0005705884,0.000319807,0.0000523571,0.0001345028,0.00017930442,0.00043090913,0.00045890384],"category_scores_gemma":[0.00013982748,0.0003783039,0.00030651502,0.00030728403,0.00008911151,0.000126216,0.00017373746,0.0013226002,0.0024086998],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013359567,0.00001830836,0.00023766964,0.0015615186,0.00029103085,0.01053924,0.00009914305,4.2375873e-7,0.000033689543,0.000026861037,0.9747746,0.01240415],"study_design_scores_gemma":[0.00027017863,0.00027184,0.00013958623,0.006393245,0.0012882769,0.000049169586,0.000013744102,0.000011337547,0.00029811283,0.00024236228,0.99069464,0.00032753366],"about_ca_topic_score_codex":0.00009053418,"about_ca_topic_score_gemma":0.000021105852,"teacher_disagreement_score":0.15348324,"about_ca_system_score_codex":0.0003730491,"about_ca_system_score_gemma":0.00020007287,"threshold_uncertainty_score":0.9998669},"labels":[],"label_agreement":null},{"id":"W4402890485","doi":"10.1177/17562864241281903","title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Liraglutide; Semaglutide; Internal medicine; Mace; Overweight; Odds ratio; Diabetes mellitus; Type 2 diabetes; Placebo; Dulaglutide; Myocardial infarction; Population; Glucagon-like peptide 1 receptor; Endocrinology; Adverse effect; Obesity; Agonist; Receptor; Percutaneous coronary intervention","score_opus":0.06532569228572091,"score_gpt":0.3519981919897024,"score_spread":0.28667249970398145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402890485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027852592,0.9872574,0.00001538993,0.0002756531,0.000036422032,0.009388379,0.00016550692,0.00004407711,0.00003191655],"genre_scores_gemma":[0.004721816,0.990497,0.00008047996,0.0005613744,0.000009893245,0.00366509,0.00010009611,0.00006751413,0.00029672173],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994672,0.0016898835,0.0013412673,0.0011868681,0.0005966389,0.0005133412],"domain_scores_gemma":[0.9972081,0.00080159964,0.0006573873,0.0011590355,0.00003659855,0.00013727449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008478959,0.0010426599,0.008182822,0.000290637,0.00006262141,0.000024731187,0.00023786265,0.00018707603,0.00012269965],"category_scores_gemma":[0.000107594125,0.00036152528,0.0018145065,0.0011444499,0.0003776384,0.00013368779,0.00015233544,0.0004130514,0.0000072188777],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004839648,0.0010341572,0.0036303534,0.35610968,0.61079574,0.00014248127,0.00015045493,0.000038353697,1.2806148e-8,0.000039667877,0.0000041108087,0.027570993],"study_design_scores_gemma":[0.0017863885,0.0022220411,0.00045315086,0.011460689,0.9659539,0.000008585625,0.00008439146,0.0000529376,5.9750185e-8,0.00012955062,0.017427027,0.00042130682],"about_ca_topic_score_codex":0.00008166599,"about_ca_topic_score_gemma":0.0012470324,"teacher_disagreement_score":0.35515812,"about_ca_system_score_codex":0.00010109142,"about_ca_system_score_gemma":0.000074836295,"threshold_uncertainty_score":0.99988365},"labels":[],"label_agreement":null},{"id":"W4402896157","doi":"10.1111/jgh.16752","title":"Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis","year":2024,"lang":"en","type":"review","venue":"Journal of Gastroenterology and Hepatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Publication bias; Meta-analysis; Cirrhosis; Hepatocellular carcinoma; Gastroenterology; Hepatic encephalopathy; Funnel plot; Type 2 diabetes; Diabetes mellitus; Chronic liver disease; Liver disease; Cochrane Library; Endocrinology","score_opus":0.02780056795706364,"score_gpt":0.31987251562303526,"score_spread":0.2920719476659716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402896157","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054439735,0.9439084,9.560193e-7,0.00045950967,0.00009667978,0.0010657007,0.000015142317,0.000005809453,0.000008052058],"genre_scores_gemma":[0.010202961,0.98827296,0.000076691926,0.0011743816,0.000014074746,0.00009090829,0.000023443628,0.000024786617,0.00011977937],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99663824,0.000691532,0.001810121,0.00033988486,0.00018909025,0.00033113966],"domain_scores_gemma":[0.99779576,0.00021248263,0.0014034382,0.0003162418,0.00013021319,0.00014186297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008963135,0.0004503259,0.010017592,0.0011630983,0.000019993564,0.0000061138803,0.0001679955,0.00021754918,0.00003566741],"category_scores_gemma":[0.00014290151,0.00027210408,0.0010929749,0.00044046433,0.00013767005,0.000056932156,0.00010968727,0.0005191135,0.000013685345],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012220898,0.000257688,0.010957521,0.7968523,0.19112003,0.000157781,0.00003671735,0.0000011634384,1.8296925e-7,0.00002329963,0.00024624157,0.00022490263],"study_design_scores_gemma":[0.0005089461,0.0037365553,0.0003328087,0.0790536,0.91293246,0.000254297,0.000006494349,0.000004347303,1.5484491e-7,0.000025809119,0.0030356662,0.00010884242],"about_ca_topic_score_codex":0.0000048837906,"about_ca_topic_score_gemma":0.00003676342,"teacher_disagreement_score":0.7218124,"about_ca_system_score_codex":0.000083871055,"about_ca_system_score_gemma":0.00008217077,"threshold_uncertainty_score":0.9999731},"labels":[],"label_agreement":null},{"id":"W4402905907","doi":"10.1016/j.diabres.2024.111871","title":"A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy","year":2024,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"Sanofi","keywords":"Medicine; Insulin glargine; Type 2 diabetes; Insulin; Diabetes mellitus; Post-hoc analysis; Internal medicine; Glucagon; Endocrinology; Post hoc","score_opus":0.05506594643586577,"score_gpt":0.4092017632911602,"score_spread":0.35413581685529444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402905907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98659503,0.0069190455,0.00000775624,0.0040064356,0.000065998276,0.0020261435,0.000058970614,0.00004368052,0.00027695848],"genre_scores_gemma":[0.9838721,0.010291103,0.0042254245,0.00061819947,0.00006989027,0.00010245871,0.00015061823,0.00005948169,0.0006106942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955867,0.0007822843,0.0009677878,0.00088386313,0.0010721649,0.0007072165],"domain_scores_gemma":[0.98989654,0.007481356,0.00022454486,0.0006456138,0.0012671195,0.00048485518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043251575,0.00033638932,0.0012249992,0.0008142189,0.00010458582,0.00018690214,0.00017974745,0.00015898679,0.00010710628],"category_scores_gemma":[0.005003106,0.00022360838,0.00013590688,0.0030902596,0.00048601552,0.00050542655,0.00024371289,0.0007228098,0.000026676942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04025217,0.0057788845,0.7067778,0.0008714044,0.01726811,0.00007177551,0.0014452967,0.000040586896,0.0027580813,0.00014225217,0.00055828324,0.22403532],"study_design_scores_gemma":[0.015692946,0.04503155,0.886729,0.0013109684,0.005140173,0.0000016853722,0.00093323423,0.0026702452,0.0013736332,0.00003849838,0.040552326,0.00052571564],"about_ca_topic_score_codex":0.00021667298,"about_ca_topic_score_gemma":0.00027690834,"teacher_disagreement_score":0.22350961,"about_ca_system_score_codex":0.000081886246,"about_ca_system_score_gemma":0.00038149089,"threshold_uncertainty_score":0.9118485},"labels":[],"label_agreement":null},{"id":"W4402930241","doi":"10.1016/j.orcp.2024.09.085","title":"Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the STEP-HFpEF DM trial","year":2024,"lang":"en","type":"article","venue":"Obesity Research & Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Semaglutide; Medicine; Heart failure with preserved ejection fraction; Type 2 diabetes; Cardiology; Internal medicine; Ejection fraction; Heart failure; Obesity; Diabetes mellitus; Endocrinology","score_opus":0.06623334692358289,"score_gpt":0.39376535129724055,"score_spread":0.32753200437365765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402930241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97321,0.00026695163,0.000025293379,0.02003462,0.00021511002,0.0030055675,0.000044953038,0.00009468622,0.0031028164],"genre_scores_gemma":[0.99353284,0.00023433859,0.0023165676,0.0005805988,0.00058322796,0.00008719489,0.00020176855,0.000044560635,0.0024188943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99427354,0.0020919305,0.00064923224,0.00094959984,0.0014380942,0.00059761107],"domain_scores_gemma":[0.98613364,0.0120212445,0.00015354522,0.00081660127,0.00058673444,0.00028825717],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0076762326,0.0002497494,0.00051639794,0.00015220814,0.00030490189,0.0003541764,0.00019823565,0.00021010975,0.00008144264],"category_scores_gemma":[0.0117749125,0.00014965737,0.00008344828,0.0009824294,0.0003577039,0.0008000259,0.00025589505,0.0018981971,0.00018519755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06692963,0.0038067386,0.83710366,0.00009120872,0.0005951931,0.00007664081,0.00008004173,0.0000038287913,0.000005625294,0.000037973943,0.08914873,0.0021206897],"study_design_scores_gemma":[0.030797426,0.007874456,0.7905607,0.0005430934,0.0004305719,8.343686e-7,0.0006431161,0.00044323815,0.000013608918,0.00012346849,0.16839455,0.00017491904],"about_ca_topic_score_codex":0.0015401827,"about_ca_topic_score_gemma":0.0012366882,"teacher_disagreement_score":0.07924581,"about_ca_system_score_codex":0.00027289553,"about_ca_system_score_gemma":0.000378545,"threshold_uncertainty_score":0.9965493},"labels":[],"label_agreement":null},{"id":"W4402930263","doi":"10.1016/j.orcp.2024.09.084","title":"Once-weekly semaglutide in heart failure with preserved ejection fraction and obesity: main results from the STEP-HFpEF trial","year":2024,"lang":"en","type":"article","venue":"Obesity Research & Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Heart failure with preserved ejection fraction; Semaglutide; Medicine; Ejection fraction; Cardiology; Heart failure; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.115102427821037,"score_gpt":0.44151622668151835,"score_spread":0.3264137988604814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402930263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8809715,0.0006649128,0.00011958191,0.10253621,0.0002950981,0.0032177814,0.00003730852,0.00013465589,0.012022959],"genre_scores_gemma":[0.9821506,0.0010992741,0.0050554904,0.00091977936,0.0015288749,0.0001626952,0.00013280685,0.00004962458,0.00890087],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937297,0.0027565572,0.00071570947,0.00094288593,0.0013076689,0.0005474884],"domain_scores_gemma":[0.9793558,0.019225772,0.00012673398,0.0007672504,0.0002575151,0.00026689633],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013398271,0.00021683173,0.00048283432,0.0001795466,0.00028449696,0.000425543,0.00018713358,0.000243386,0.000091803486],"category_scores_gemma":[0.01583203,0.0001406346,0.00012712658,0.00081002276,0.00030779402,0.00079154305,0.0002929279,0.0022932033,0.00028517484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1725828,0.007969917,0.24414824,0.00029425995,0.0015697167,0.0014315298,0.0003674546,0.0000090143,0.00018616722,0.00072236033,0.5495664,0.021152139],"study_design_scores_gemma":[0.03512364,0.0051618908,0.27371943,0.0007498768,0.00058851193,0.000015446944,0.0026767475,0.00209347,0.000055640656,0.00066800363,0.6789273,0.00022007682],"about_ca_topic_score_codex":0.004493716,"about_ca_topic_score_gemma":0.002527461,"teacher_disagreement_score":0.13745916,"about_ca_system_score_codex":0.0002931018,"about_ca_system_score_gemma":0.0003640159,"threshold_uncertainty_score":0.99629545},"labels":[],"label_agreement":null},{"id":"W4403001849","doi":"10.1016/j.ando.2024.08.405","title":"CGM chez des patients DT2 insulinotraités switchés pour l’insuline icodec hebdomadaire vs comparateurs journaliers : post-hoc des études ONWARDS 2 et 4","year":2024,"lang":"fr","type":"article","venue":"Annales d Endocrinologie","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.06591817186083727,"score_gpt":0.3317712538675572,"score_spread":0.2658530820067199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403001849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79154897,0.17831302,0.000108081265,0.014319985,0.0031158729,0.00081029284,0.0002672534,0.00061493454,0.01090159],"genre_scores_gemma":[0.8999834,0.07188324,0.0020955321,0.002034534,0.00063833786,0.00009764852,0.0004764335,0.00015416434,0.022636723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944444,0.0003461606,0.0010920385,0.0010847059,0.0007780903,0.0022546567],"domain_scores_gemma":[0.9974554,0.00043160067,0.0002231705,0.00065982953,0.00057927304,0.00065073546],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00043353013,0.001063305,0.0011429557,0.00059455953,0.00044298082,0.00045260208,0.000631986,0.00027177806,0.0012215343],"category_scores_gemma":[0.00037500152,0.0009151515,0.00064872,0.0007058514,0.0012536155,0.0008868446,0.0004910377,0.0009888025,0.0027921393],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012115948,0.00418836,0.111687705,0.003005912,0.004778026,0.004376075,0.0034355547,0.0003781162,0.00036314322,0.021524524,0.044722322,0.8003287],"study_design_scores_gemma":[0.010405672,0.008257656,0.47321454,0.0059700906,0.0031319603,0.00024428117,0.005452602,0.0008924482,0.0028240334,0.0072002998,0.48068628,0.00172013],"about_ca_topic_score_codex":0.00026532257,"about_ca_topic_score_gemma":0.00036654572,"teacher_disagreement_score":0.79860854,"about_ca_system_score_codex":0.0010189485,"about_ca_system_score_gemma":0.0006827277,"threshold_uncertainty_score":0.9996915},"labels":[],"label_agreement":null},{"id":"W4403007949","doi":"10.1136/bmjmed-2024-001009","title":"Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"BMJ Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"National Natural Science Foundation of China","keywords":"Medicine; Kidney disease; Hazard ratio; Meta-analysis; Internal medicine; Diabetes mellitus; Type 2 diabetes; Renal function; Relative risk; Placebo; Randomized controlled trial; Confidence interval; Intensive care medicine; Endocrinology; Pathology","score_opus":0.021867983704913083,"score_gpt":0.29943016646340365,"score_spread":0.27756218275849054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403007949","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30388495,0.62897927,0.00012862246,0.02868558,0.00029339432,0.035547327,0.0001937667,0.0005977688,0.0016893435],"genre_scores_gemma":[0.9886308,0.0019349108,0.00008289642,0.004080143,0.00007586144,0.00091246614,0.0007038075,0.00006379993,0.0035153194],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976992,0.00008516517,0.00065831793,0.00053828483,0.0006789655,0.00034005006],"domain_scores_gemma":[0.99857306,0.00007210993,0.00015133202,0.0006058569,0.000105509745,0.0004921466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005161112,0.00040583804,0.0026541946,0.00045843652,0.0000322557,0.00002329436,0.00008466914,0.000039373957,0.0007311269],"category_scores_gemma":[0.00010565017,0.00017617457,0.0001804159,0.0013144657,0.00015365865,0.00013317748,0.000018624822,0.00014061156,0.000027583546],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006590894,0.0005191083,0.26325962,0.57414174,0.1540721,0.0006293493,0.00032387648,0.0000028421268,0.0000032284233,0.000033128203,0.006206724,0.00014917215],"study_design_scores_gemma":[0.003970411,0.002741068,0.018549832,0.044143748,0.9291972,0.0000018962712,0.000040175168,0.00014061891,0.0000092748805,0.0000035506882,0.0008999263,0.0003023187],"about_ca_topic_score_codex":0.000024045827,"about_ca_topic_score_gemma":0.00007979899,"teacher_disagreement_score":0.7751251,"about_ca_system_score_codex":0.00013315641,"about_ca_system_score_gemma":0.00020158492,"threshold_uncertainty_score":0.8005327},"labels":[],"label_agreement":null},{"id":"W4403021235","doi":"10.1136/bmj-2024-080257","title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline","year":2024,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ted Rogers Centre for Heart Research; Impact","funders":"West China Hospital, Sichuan University; Sichuan University","keywords":"Medicine; Kidney disease; Guideline; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Internal medicine; Disease; Endocrinology; Pathology","score_opus":0.0195236102199244,"score_gpt":0.35508129716076664,"score_spread":0.33555768694084226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403021235","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16629457,0.03964519,0.020988436,0.6829129,0.009903448,0.032757346,0.0010336713,0.0032384936,0.04322593],"genre_scores_gemma":[0.89139116,0.0016209772,0.045059677,0.023793193,0.00977248,0.0021738173,0.0037712918,0.0002584423,0.022158965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981631,0.000029516572,0.00064234214,0.00049268646,0.0003426901,0.00032965065],"domain_scores_gemma":[0.998662,0.00017633443,0.000103120015,0.00041863718,0.0001565624,0.0004833406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005880934,0.00021844106,0.00031512557,0.000087866094,0.000046116565,0.000050105704,0.00007587991,0.00006726994,0.00014059174],"category_scores_gemma":[0.00038504618,0.00015186687,0.00022398836,0.0001727957,0.00006968301,0.0001983403,0.000026530544,0.000139502,0.00014049977],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038007789,0.00088772026,0.0026733172,0.0015316262,0.0010443617,0.0011302189,0.000121738325,0.0000044812305,0.000025526588,0.0007954873,0.8960877,0.09189703],"study_design_scores_gemma":[0.005844774,0.0018609114,0.0015874208,0.0015328395,0.0022898728,0.000011659767,0.00007732888,0.0018761485,0.000118976706,0.000041410956,0.9845581,0.00020054664],"about_ca_topic_score_codex":0.00001943133,"about_ca_topic_score_gemma":0.000020755026,"teacher_disagreement_score":0.7250966,"about_ca_system_score_codex":0.000116059964,"about_ca_system_score_gemma":0.0006254779,"threshold_uncertainty_score":0.6192951},"labels":[],"label_agreement":null},{"id":"W4403041106","doi":"10.1161/circresaha.124.324938","title":"Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity","year":2024,"lang":"en","type":"letter","venue":"Circulation Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Deutsche Stiftung für Herzforschung; Bundesministerium für Bildung und Forschung","keywords":"Thrombogenicity; Pneumonia; Medicine; Endothelium; Intensive care medicine; Cardiology; Internal medicine; Thrombosis","score_opus":0.10188095720195119,"score_gpt":0.37873269152534733,"score_spread":0.27685173432339616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403041106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7214477,0.000465739,0.0000013642358,0.2712026,0.00015998802,0.0017975086,0.000023145072,0.000072452975,0.004829482],"genre_scores_gemma":[0.9682935,0.00014276021,0.00004189127,0.023067536,0.0014315207,0.00029374124,0.0005120638,0.000101133155,0.0061158678],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9973968,0.00024006587,0.00029285968,0.00064531784,0.0008861774,0.0005387421],"domain_scores_gemma":[0.9991152,0.00018002147,0.000044021577,0.00044619222,0.0001304769,0.000084065745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008282252,0.00023694207,0.0003995495,0.0009904521,0.000080068385,0.00017258807,0.00011894387,0.00046573856,0.00015090629],"category_scores_gemma":[0.00013602104,0.00020945758,0.00008788564,0.0005411506,0.00011872529,0.00009901841,0.00019474933,0.0019003986,0.00027365366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016039547,0.0008035813,0.08583181,0.009249408,0.0014915831,0.0082413545,0.0024330637,0.000009980296,0.066106305,0.0006160597,0.7878228,0.03723365],"study_design_scores_gemma":[0.004391545,0.00091474614,0.5344013,0.0022783722,0.00061138545,0.00003153388,0.0001508809,0.004443955,0.002684702,0.006024448,0.4432191,0.0008480563],"about_ca_topic_score_codex":0.00029638145,"about_ca_topic_score_gemma":0.00004808804,"teacher_disagreement_score":0.44856945,"about_ca_system_score_codex":0.00033459897,"about_ca_system_score_gemma":0.00015987945,"threshold_uncertainty_score":0.8541432},"labels":[],"label_agreement":null},{"id":"W4403099004","doi":"10.3390/ph17101322","title":"Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review","year":2024,"lang":"en","type":"review","venue":"Pharmaceuticals","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Incretin; Diabetes mellitus; Intensive care medicine; Bioinformatics; Internal medicine; Endocrinology; Biology","score_opus":0.2782565207119888,"score_gpt":0.5291605532975568,"score_spread":0.25090403258556804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403099004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015201163,0.9898417,5.6916036e-7,0.000090495756,0.0001461887,0.008004528,0.000032503864,0.000053394524,0.00031051898],"genre_scores_gemma":[0.00080947566,0.99748564,0.00004667457,0.00028572904,0.00005862413,0.00091977406,0.000055225628,0.00008881798,0.00025003974],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963402,0.0008700024,0.001172096,0.00046334494,0.0007525411,0.0004018081],"domain_scores_gemma":[0.99767,0.00068835716,0.00028186917,0.0011429221,0.00009166586,0.00012517047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038741976,0.0005959587,0.0052789785,0.0002611859,0.000028413126,0.00004595952,0.00033263883,0.00011216,0.000088074696],"category_scores_gemma":[0.00067785534,0.00025993056,0.0022600244,0.00066824374,0.00006819745,0.000053982105,0.00011709169,0.00047703178,0.0001749401],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008313607,0.00035920562,0.00006908423,0.8762967,0.015536551,0.000013489361,0.00007702724,0.000002378953,0.0000018188388,0.000056367702,0.000075127224,0.107503906],"study_design_scores_gemma":[0.00080929033,0.0011647406,0.000062748375,0.8937047,0.09093989,0.0000037333086,0.000013869453,0.00024366885,0.0000018637697,0.000012542463,0.01270129,0.00034164015],"about_ca_topic_score_codex":0.000018644498,"about_ca_topic_score_gemma":2.3765678e-7,"teacher_disagreement_score":0.10716227,"about_ca_system_score_codex":0.00026530295,"about_ca_system_score_gemma":0.00015119665,"threshold_uncertainty_score":0.9999853},"labels":[],"label_agreement":null},{"id":"W4403107085","doi":"10.4140/tcp.n.2024.350","title":"Geriatric Pharmacotherapy Case Series: Medications for Diabetes—A Focus on Secondary Stroke Prevention","year":2024,"lang":"en","type":"review","venue":"The Senior Care Pharmacist","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Diabetes mellitus; Stroke (engine); Glycemic; Intensive care medicine; Pharmacotherapy; Type 2 diabetes; Disease; Regimen; Diabetes management; Clinical trial; Surgery; Internal medicine","score_opus":0.045564158398580426,"score_gpt":0.3898742060686203,"score_spread":0.34431004767003986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403107085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007927627,0.98358804,0.000018970024,0.00076743535,0.001782231,0.0071692513,0.002046466,0.00028935634,0.004258979],"genre_scores_gemma":[0.00043418084,0.9718392,0.00013616565,0.00036630078,0.0015494486,0.0039244248,0.0016717974,0.00020974838,0.019868763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976154,0.00016925139,0.0006684081,0.0006719199,0.00036687191,0.0005081439],"domain_scores_gemma":[0.9984721,0.00021258989,0.00030396425,0.0006869067,0.00011284404,0.0002115837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003348067,0.0007097437,0.0013142335,0.0004048436,0.0002746535,0.0001080748,0.00028228795,0.00015650677,0.00044661335],"category_scores_gemma":[0.000011783008,0.00043391474,0.0014327287,0.000463719,0.000093250725,0.00009775836,0.00009050205,0.000569011,0.0003765457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059813603,0.00017608119,5.10113e-7,0.026560824,0.004519633,0.0004380435,0.00029023047,1.7861052e-7,0.000008397239,0.00008545231,0.025657235,0.9422036],"study_design_scores_gemma":[0.0019900256,0.00048901676,7.647087e-8,0.0027928706,0.040831923,0.0004299044,0.00014372251,0.000015818996,0.0001276405,0.000058730166,0.9527585,0.00036180337],"about_ca_topic_score_codex":0.0000036931888,"about_ca_topic_score_gemma":0.0000050297645,"teacher_disagreement_score":0.9418418,"about_ca_system_score_codex":0.0004567663,"about_ca_system_score_gemma":0.00038889036,"threshold_uncertainty_score":0.9998113},"labels":[],"label_agreement":null},{"id":"W4403148879","doi":"10.1210/jendso/bvae163.953","title":"8149 The Effect of SGLT2 Inhibitors On NAFLD In Patients With Type 2 Diabetes: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Meta-analysis; Randomized controlled trial; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.029808803840824745,"score_gpt":0.3393760632692384,"score_spread":0.3095672594284137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403148879","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004682085,0.9856039,2.6870612e-7,0.00038396302,0.00014140131,0.013326821,0.000022885753,0.0000035085984,0.000049029433],"genre_scores_gemma":[0.0012836133,0.9974183,0.000018547957,0.00018901113,0.00003682623,0.00041919854,0.00001050809,0.000030882093,0.0005931328],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99042386,0.004339245,0.0040164776,0.0001839874,0.0008594855,0.00017696647],"domain_scores_gemma":[0.98635834,0.0066065267,0.006229936,0.0005228323,0.00023064835,0.000051684085],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.013257847,0.0005049488,0.04178232,0.00029123668,0.000024308532,0.000022140935,0.0002529927,0.000059725815,0.000038356065],"category_scores_gemma":[0.0045079836,0.00012902936,0.022377275,0.0011383628,0.00011337258,0.000033619173,0.00009313834,0.00043729745,0.0000010841788],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017730865,0.00009920276,0.000023036382,0.40494993,0.59165245,0.0000021359913,0.00003378694,0.0000020502227,3.3949362e-8,0.000006168159,0.0011948448,0.00026325163],"study_design_scores_gemma":[0.05194293,0.00074097904,0.0000022903366,0.107744694,0.83861005,0.0000012802948,0.000008938568,0.000004128862,0.0000017699646,0.0000029605003,0.0008641577,0.00007584071],"about_ca_topic_score_codex":0.0000023679652,"about_ca_topic_score_gemma":5.7456424e-7,"teacher_disagreement_score":0.29720524,"about_ca_system_score_codex":0.000110160734,"about_ca_system_score_gemma":0.00007801902,"threshold_uncertainty_score":0.98741335},"labels":[],"label_agreement":null},{"id":"W4403173108","doi":"10.1038/s41397-024-00352-z","title":"Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration","year":2024,"lang":"en","type":"article","venue":"The Pharmacogenomics Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Pharmacodynamics; Metformin; Pharmacokinetics; Single-nucleotide polymorphism; Pharmacology; Medicine; Rotterdam Study; Internal medicine; Genetics; Biology; Genotype; Confidence interval; Gene","score_opus":0.024680254394303075,"score_gpt":0.3387059396730713,"score_spread":0.3140256852787682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403173108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822538,0.010881289,0.000050435716,0.0044698664,0.0010448103,0.0011959702,0.000010024736,0.000025215544,0.00006860491],"genre_scores_gemma":[0.99522674,0.002757729,0.000051429713,0.0010307065,0.0006221474,0.000024934778,0.000008948581,0.00003247594,0.00024489703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998112,0.00071846,0.00050800113,0.00024114347,0.0002478257,0.00017256485],"domain_scores_gemma":[0.99786747,0.0015872243,0.00019816388,0.00018219552,0.00004394138,0.00012103343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013940479,0.0002100287,0.00026261073,0.000099705234,0.00032872148,0.00015598293,0.00016100964,0.00003054167,0.000076439355],"category_scores_gemma":[0.00004078666,0.00010006237,0.00012833804,0.00014259259,0.0001923325,0.00019236945,0.00022729466,0.00045471083,0.000025593043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056208596,0.0005721937,0.0027537842,0.00004363456,0.001989238,0.00021221432,0.006582633,0.000027438782,0.8533529,0.00000954439,0.0017708173,0.12706473],"study_design_scores_gemma":[0.05052093,0.009292587,0.31783387,0.0011263686,0.041832235,0.0018823316,0.0061149094,0.085315265,0.35608265,0.002288584,0.1263463,0.0013639855],"about_ca_topic_score_codex":0.00004982294,"about_ca_topic_score_gemma":0.000026653715,"teacher_disagreement_score":0.49727026,"about_ca_system_score_codex":0.00017148153,"about_ca_system_score_gemma":0.00004132502,"threshold_uncertainty_score":0.4080425},"labels":[],"label_agreement":null},{"id":"W4403226353","doi":"10.1016/j.cjca.2024.08.164","title":"TARGETING CARDIAC FIBROSIS WITH METFORMIN IN PAI-1 DEFICIENCY: ADVANCING PERSONALIZED THERAPEUTICS","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Fibrosis; Internal medicine; Intensive care medicine; Diabetes mellitus; Bioinformatics; Endocrinology","score_opus":0.012237203289164854,"score_gpt":0.24267639277619166,"score_spread":0.2304391894870268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403226353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8577025,0.103160836,0.0049793813,0.003750248,0.0018570586,0.0006556853,0.000031247495,0.000039311177,0.027823722],"genre_scores_gemma":[0.99710816,0.000529033,0.0014688509,0.00021404368,0.00032770477,0.0000065781396,0.000008688991,0.000021971025,0.00031496063],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902403,0.00006869484,0.0002510792,0.0001354798,0.00012238135,0.00039833857],"domain_scores_gemma":[0.99944353,0.000082252176,0.00005232938,0.00009499687,0.000078219986,0.00024864948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054360466,0.00012718084,0.00048296858,0.0004561561,0.000041258594,0.00002810876,0.000069681795,0.00006202785,0.00002177512],"category_scores_gemma":[0.000036907008,0.000089896435,0.00017789817,0.00026554786,0.00009154239,0.00009693604,0.0000064820897,0.00021111,0.0000065204763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005444025,0.000023538301,0.68472284,0.00083805795,0.005798627,0.012268769,0.005968428,0.007818004,0.0056018247,0.006502344,0.03275408,0.23715906],"study_design_scores_gemma":[0.0015025372,0.0012865589,0.01398298,0.0005502868,0.001218993,0.00032766772,0.0021794753,0.00023679795,0.00022258202,0.00024502052,0.97800577,0.00024131719],"about_ca_topic_score_codex":0.00021355307,"about_ca_topic_score_gemma":0.00025178213,"teacher_disagreement_score":0.9452517,"about_ca_system_score_codex":0.00036547123,"about_ca_system_score_gemma":0.0009029084,"threshold_uncertainty_score":0.36658704},"labels":[],"label_agreement":null},{"id":"W4403324763","doi":"10.20944/preprints202410.0929.v1","title":"SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Reducing Heart Failure Hospitalizations in Type-2 Diabetes. A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Preprints.org","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Type 2 diabetes; Meta-analysis; Medicine; Heart failure; Diabetes mellitus; Internal medicine; Glucagon-like peptide 1 receptor; Pharmacology; Receptor; Endocrinology; Agonist","score_opus":0.09972953152592753,"score_gpt":0.37115238492344654,"score_spread":0.27142285339751904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403324763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003607364,0.9917554,3.2053373e-7,0.0012934228,0.00010592232,0.006047151,0.000024687928,0.00008468424,0.00032763786],"genre_scores_gemma":[0.0014244127,0.99162513,0.000102251586,0.00026976064,0.000030157778,0.0024519202,0.00035590475,0.00007858811,0.0036619003],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962225,0.00039983183,0.0015684535,0.0010715004,0.00034818292,0.00038951804],"domain_scores_gemma":[0.9980649,0.00010200161,0.00039101217,0.001210845,0.000078358986,0.00015289157],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013591042,0.0006265602,0.007529133,0.0010857763,0.000035534897,0.000045411423,0.00020029646,0.0002176051,0.00071582623],"category_scores_gemma":[0.0005109756,0.00043953516,0.0015595339,0.00290902,0.000050891347,0.000104478524,0.00037786027,0.00043633438,0.0010230351],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000010098488,0.00017312953,0.0032314085,0.92303723,0.07165074,0.000020865866,0.00011695434,0.0000012778686,5.181196e-7,0.00004734483,0.0014787869,0.00024073191],"study_design_scores_gemma":[0.000121465884,0.000033599543,0.00014084554,0.13201079,0.7493894,0.0000023872499,0.000017277667,0.0000034186157,0.0000035907512,0.000008580755,0.11792481,0.00034381927],"about_ca_topic_score_codex":0.00005444728,"about_ca_topic_score_gemma":0.000048784786,"teacher_disagreement_score":0.7910264,"about_ca_system_score_codex":0.00039908633,"about_ca_system_score_gemma":0.00012378293,"threshold_uncertainty_score":0.9998056},"labels":[],"label_agreement":null},{"id":"W4403432984","doi":"10.1007/s10741-024-10446-2","title":"In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure","year":2024,"lang":"en","type":"review","venue":"Heart Failure Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.015290209512612625,"score_gpt":0.29804715014003835,"score_spread":0.28275694062742573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403432984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009630373,0.98931605,0.0000017361813,0.0011162766,0.00033512057,0.007958351,0.00009282812,0.000051212315,0.00016539445],"genre_scores_gemma":[0.00040738014,0.9948656,0.0015177025,0.00017831674,0.00016672391,0.00085910695,0.0016959661,0.00012757277,0.00018166426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961007,0.00020610921,0.0018420725,0.0007962261,0.00053180597,0.0005230481],"domain_scores_gemma":[0.99855065,0.000051940453,0.00044843642,0.00070339005,0.000076061064,0.00016952404],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048394653,0.0008399597,0.0043253014,0.0008472751,0.000025055178,0.000037683076,0.00014568413,0.00036297942,0.00014393072],"category_scores_gemma":[0.000028647466,0.00055205537,0.0008659871,0.0011709114,0.00007531839,0.00028855613,0.00005592035,0.0006903959,0.00060056214],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009874202,0.004026488,0.027085662,0.23068383,0.0016509875,0.0003758197,0.00047965473,1.7628167e-7,0.000002215543,0.00012832324,0.39121348,0.34425464],"study_design_scores_gemma":[0.0013855157,0.0009266403,0.000623468,0.07315743,0.0033117938,0.000006963419,0.00001035395,1.8850939e-7,0.000005307304,0.0000048553384,0.92015254,0.0004149463],"about_ca_topic_score_codex":0.000019751187,"about_ca_topic_score_gemma":0.00011124272,"teacher_disagreement_score":0.52893907,"about_ca_system_score_codex":0.00031081817,"about_ca_system_score_gemma":0.00024327612,"threshold_uncertainty_score":0.9996931},"labels":[],"label_agreement":null},{"id":"W4403467618","doi":"10.1016/j.jacbts.2024.07.006","title":"Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice","year":2024,"lang":"en","type":"article","venue":"JACC Basic to Translational Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Semaglutide; Internal medicine; Cardiology; Medicine; Heart failure; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.010607089925349549,"score_gpt":0.26765680058326,"score_spread":0.2570497106579105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403467618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835543,0.002773433,0.000056634217,0.0066988007,0.00016736805,0.00038602142,0.000012392334,0.00004024849,0.006310772],"genre_scores_gemma":[0.9951596,0.00008517858,0.0032979099,0.00017055143,0.00006856136,0.000024613997,0.0000028924596,0.0000068020418,0.001183884],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989336,0.000010612982,0.0001215679,0.00038208184,0.00033838503,0.00021376777],"domain_scores_gemma":[0.99958897,0.00014957001,0.000008295034,0.00008644597,0.000024541025,0.00014220258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004555097,0.00009852973,0.000153313,0.0001888125,0.0000660502,0.00008257397,0.000055812412,0.000020954692,0.000021067917],"category_scores_gemma":[0.000042935928,0.000081719314,0.00003429793,0.0006168744,0.00016494199,0.00019629911,0.000022824575,0.00006228623,0.000013880185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018618858,0.0001374047,0.17895606,0.00055519544,0.00024159452,0.0002044805,0.0056415335,0.0002646504,0.32094952,0.025241626,0.0012251685,0.46639654],"study_design_scores_gemma":[0.00062693586,0.00011999917,0.97237045,0.00027515358,0.00012412023,0.000005988258,0.00017532932,0.0009257547,0.0045596836,0.0013972766,0.01923122,0.00018809107],"about_ca_topic_score_codex":0.00004918861,"about_ca_topic_score_gemma":0.0000148842855,"teacher_disagreement_score":0.79341435,"about_ca_system_score_codex":0.00005026644,"about_ca_system_score_gemma":0.000106716856,"threshold_uncertainty_score":0.33324167},"labels":[],"label_agreement":null},{"id":"W4403475255","doi":"10.1002/ehf2.15123","title":"Reframing the Role of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Medicine","year":2024,"lang":"en","type":"editorial","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Cognitive reframing; Medicine; Glucagon-like peptide-1; Heart failure; Internal medicine; Receptor; Endocrinology; Diabetes mellitus; Type 2 diabetes; Psychotherapist; Psychology","score_opus":0.005536746683688958,"score_gpt":0.24381606006334663,"score_spread":0.2382793133796577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403475255","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023970888,0.09724944,0.0000050759063,0.012896964,0.87312984,0.002842182,0.00012845462,0.0002555812,0.011095399],"genre_scores_gemma":[0.011115818,0.0018324626,0.0013277325,0.00029378006,0.95374554,0.0004356782,0.0020357606,0.00029168595,0.028921535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966128,0.00013971022,0.0006173415,0.00068984344,0.0014407622,0.00049955375],"domain_scores_gemma":[0.9980818,0.00032227585,0.00011304768,0.0011802275,0.00016711031,0.0001355497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011335649,0.00048438561,0.0014584094,0.00033929734,0.0000660478,0.000036242232,0.00026492204,0.00059642596,0.00024342429],"category_scores_gemma":[0.00040393256,0.00031005905,0.00062657293,0.0005130328,0.00019597953,0.00005936912,0.00020737527,0.001179532,0.00030425334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047298745,0.00008095807,0.00016842362,0.0008294211,0.0016261014,0.00005847548,0.00055815664,0.000004190499,0.0002852843,0.00006159042,0.9916283,0.004651821],"study_design_scores_gemma":[0.0012755083,0.00037923447,0.000085229214,0.0028416235,0.001556614,0.0000029191533,0.0007674795,0.0000116299725,0.00025795604,0.00009637288,0.9924919,0.0002335446],"about_ca_topic_score_codex":0.00079766836,"about_ca_topic_score_gemma":0.00016004663,"teacher_disagreement_score":0.09541698,"about_ca_system_score_codex":0.00029927434,"about_ca_system_score_gemma":0.00028748458,"threshold_uncertainty_score":0.99993515},"labels":[],"label_agreement":null},{"id":"W4403476213","doi":"10.7759/cureus.71569","title":"Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glucagon-like peptide-1; Population; Endocrinology; Diabetes mellitus; Environmental health; Type 2 diabetes","score_opus":0.05860782859164021,"score_gpt":0.3492840838930007,"score_spread":0.2906762553013605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965821,0.00063057663,0.0012356611,0.00011708657,0.00029833472,0.0006667897,0.00019623264,0.000048092184,0.00022513595],"genre_scores_gemma":[0.99292433,0.00009855675,0.00522257,0.00007009508,0.00008966438,0.0001108504,0.0006529626,0.00002497634,0.0008059916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862206,0.0000628702,0.0004421774,0.00046928413,0.00010725931,0.0002963326],"domain_scores_gemma":[0.99940515,0.00010009924,0.00008838434,0.00027013646,0.000048810198,0.000087413144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030629267,0.00021449322,0.00059192925,0.0005594556,0.00004084849,0.000052251093,0.00007527891,0.000084500454,0.000043807377],"category_scores_gemma":[0.00009553945,0.00018864438,0.000062856554,0.0006364414,0.000047537033,0.00018855829,0.00006448993,0.00013753171,0.0000029769851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016302672,0.0004958575,0.98875844,0.00008054195,0.0008241883,0.00006589862,0.0016963643,0.00009579264,0.000019928915,0.0018743342,0.0005341792,0.0053914646],"study_design_scores_gemma":[0.0020522166,0.0011738595,0.97198343,0.000101958394,0.0007230784,0.0000018966688,0.00046981443,0.021469459,0.0000034451402,0.00062234065,0.0012083477,0.0001901348],"about_ca_topic_score_codex":0.0008647711,"about_ca_topic_score_gemma":0.027312182,"teacher_disagreement_score":0.026447412,"about_ca_system_score_codex":0.0005265992,"about_ca_system_score_gemma":0.00003645478,"threshold_uncertainty_score":0.99043685},"labels":[],"label_agreement":null},{"id":"W4403520235","doi":"10.2215/cjn.0000000000000567","title":"Albuminuria and Rapid Kidney Function Decline as Selection Criteria for Kidney Clinical Trials in Type 1 Diabetes Mellitus","year":2024,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Juvenile Diabetes Research Foundation United States of America; Center for Big Data Analytics, University of Texas at Austin; National Institute on Aging; National Institutes of Health; University of Toronto","keywords":"Medicine; Albuminuria; Renal function; Type 2 Diabetes Mellitus; Diabetes mellitus; Clinical trial; Internal medicine; Kidney; Selection (genetic algorithm); Kidney disease; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.08797562385464312,"score_gpt":0.4382398273105072,"score_spread":0.35026420345586406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403520235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9366446,0.0025786778,0.00030888797,0.057701737,0.0021459912,0.00054792204,0.000010327246,0.000018889661,0.000042966814],"genre_scores_gemma":[0.8159885,0.016932894,0.008746216,0.15505598,0.002823534,0.000018952347,0.000019238814,0.000047094432,0.00036760053],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597085,0.0011863924,0.0021233791,0.0002764975,0.00018897616,0.0002539309],"domain_scores_gemma":[0.99395597,0.004135469,0.0011882164,0.00019405578,0.00021935067,0.00030694398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010348517,0.0001667524,0.0015963677,0.0000841329,0.000040261977,0.000023607294,0.00014691337,0.00017047163,0.00008638728],"category_scores_gemma":[0.0045617116,0.000105199935,0.0013112719,0.00036707133,0.00076829776,0.00008196761,0.0000963766,0.00047715098,0.000004675209],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044118194,0.000701442,0.05139948,0.00022113156,0.0031300837,0.0000045338666,0.000090494425,0.000001318272,0.0053271223,0.00009964372,0.7061683,0.22844465],"study_design_scores_gemma":[0.007001276,0.019161765,0.10108941,0.0004262997,0.0034735475,0.000027536396,0.00018974386,0.0018407549,0.00029760474,0.003896052,0.8624384,0.00015762409],"about_ca_topic_score_codex":0.0000104936935,"about_ca_topic_score_gemma":0.000001630436,"teacher_disagreement_score":0.22828703,"about_ca_system_score_codex":0.000048689362,"about_ca_system_score_gemma":0.00039209888,"threshold_uncertainty_score":0.5461124},"labels":[],"label_agreement":null},{"id":"W4403560559","doi":"10.1080/14017431.2024.2418086","title":"Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials","year":2024,"lang":"en","type":"review","venue":"Scandinavian Cardiovascular Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"NIHR Leicester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Medicine; Blood pressure; Meta-analysis; Type 2 diabetes; Cardiology; Internal medicine; Diabetes mellitus; Baseline (sea); Empagliflozin; Endocrinology","score_opus":0.11477258985884074,"score_gpt":0.3428247729694779,"score_spread":0.22805218311063713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403560559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064288103,0.99299073,0.00016107,0.00003542668,0.00047097908,0.0051179663,0.00048126097,0.00003967169,0.000060017188],"genre_scores_gemma":[0.0066039003,0.99149793,0.00064071466,0.00003418429,0.00030774728,0.0004098115,0.00014924085,0.00019531875,0.00016112295],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9871773,0.0035466931,0.00442171,0.0014695133,0.0025409034,0.00084383786],"domain_scores_gemma":[0.9942143,0.0005402502,0.0010850796,0.0027163296,0.000535926,0.0009080939],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.025005199,0.0014235335,0.03838355,0.004510998,0.00013442287,0.00027651797,0.00049174356,0.0005509406,0.000049057224],"category_scores_gemma":[0.0026521941,0.0009406607,0.048248693,0.003996156,0.00014872565,0.0001926174,0.00048708514,0.00089840346,0.0000069095913],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019192445,0.000099970304,0.00040710485,0.19470032,0.75748235,0.00032521292,0.00010788966,0.000949381,3.3821158e-7,0.000012194798,0.000068538335,0.04582754],"study_design_scores_gemma":[0.0017699262,0.00027543056,0.00006024966,0.035956785,0.8617191,0.00026747375,0.00010745623,0.000036861773,0.00000532686,0.000005338812,0.09918599,0.0006101199],"about_ca_topic_score_codex":0.00014879993,"about_ca_topic_score_gemma":0.0000046155687,"teacher_disagreement_score":0.15874353,"about_ca_system_score_codex":0.00017532942,"about_ca_system_score_gemma":0.0003103709,"threshold_uncertainty_score":0.99985147},"labels":[],"label_agreement":null},{"id":"W4403639466","doi":"10.1136/bmj.q1986","title":"Glucagon-like peptide-1 receptor agonists and aspiration risk","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Glucagon-like peptide-1; Glucagon; Receptor; Agonist; Medicine; Endocrinology; Computer science; Internal medicine; Diabetes mellitus; Insulin; Type 2 diabetes","score_opus":0.010976708817283016,"score_gpt":0.29004823851100453,"score_spread":0.2790715296937215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403639466","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015369705,0.0027452423,0.000010036326,0.0010700987,0.9683999,0.001313556,0.00016904024,0.00021260526,0.024542596],"genre_scores_gemma":[0.00024229952,0.001467636,0.00066562335,0.00011560775,0.8413161,0.00023453655,0.0022637644,0.00008143073,0.153613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984044,0.000036933005,0.0003066688,0.00049121596,0.0005268732,0.00023390079],"domain_scores_gemma":[0.9991407,0.00012840664,0.00015631551,0.00036821212,0.00008949999,0.00011686529],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003422174,0.0002967518,0.00042119803,0.00015062978,0.00006436738,0.00012788505,0.00006548551,0.00040117398,0.00014770728],"category_scores_gemma":[0.00029481237,0.00024306712,0.00012800835,0.000105007326,0.000045743924,0.00005979852,0.00011255697,0.0004145696,0.0010654296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006420065,0.00006610811,0.00009301911,0.00055016595,0.0005468555,0.000048014394,0.0000795954,2.0856992e-7,0.000011795926,0.000037781552,0.9641925,0.03430974],"study_design_scores_gemma":[0.00096525287,0.0006383815,0.00016472791,0.0005107501,0.0014507299,8.2941057e-7,0.00002449944,0.00001958375,0.00002687333,0.000100660414,0.99587655,0.0002211635],"about_ca_topic_score_codex":0.000101851954,"about_ca_topic_score_gemma":0.00004242936,"teacher_disagreement_score":0.1290704,"about_ca_system_score_codex":0.00015688933,"about_ca_system_score_gemma":0.00015830969,"threshold_uncertainty_score":0.99971235},"labels":[],"label_agreement":null},{"id":"W4403731772","doi":"10.1021/acs.jmedchem.4c02081","title":"Structurally Minimalized and Druglike TGase2 Inhibitors Based on 7-Aminoquinoline-5,8-dione Scaffolds for the Treatment of Diabetic Retinopathy","year":2024,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Korea Drug Development Fund; Ministry of Health and Welfare; Ministry of Trade, Industry and Energy","keywords":"Chemistry; Diabetic retinopathy; Pharmacology; Diabetes mellitus; Combinatorial chemistry; Endocrinology; Medicine","score_opus":0.010553717551193558,"score_gpt":0.26599748722416766,"score_spread":0.2554437696729741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403731772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98424095,0.010063561,0.000038155802,0.0043111793,0.0004225724,0.0003899167,0.000016073813,0.000016400532,0.0005011935],"genre_scores_gemma":[0.996683,0.0008202312,0.00051971537,0.00016412002,0.0008604069,0.000021348016,0.000016448137,0.000023554196,0.0008911625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859,0.000017935152,0.0005228454,0.00018149964,0.0004836088,0.00020412449],"domain_scores_gemma":[0.99882394,0.00044748254,0.00022876752,0.00020093874,0.00013300944,0.00016584268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032791615,0.00021956746,0.0005024589,0.00010157643,0.000044939163,0.000021763617,0.00008633997,0.000077537894,0.00008502326],"category_scores_gemma":[0.00007154613,0.00011663869,0.00026918962,0.00012503758,0.00014890482,0.00003652904,0.000011208635,0.0000917549,7.296696e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01231056,0.003644879,0.011924092,0.012046751,0.005710354,0.0022402673,0.003280913,0.00012561714,0.4689742,0.00014009073,0.02786441,0.45173785],"study_design_scores_gemma":[0.029600862,0.021868717,0.010706756,0.007397493,0.010271574,0.00044708516,0.002068922,0.0082023,0.8514135,0.0002776068,0.057248708,0.0004964919],"about_ca_topic_score_codex":0.0000030118879,"about_ca_topic_score_gemma":3.0438383e-7,"teacher_disagreement_score":0.45124137,"about_ca_system_score_codex":0.00015205581,"about_ca_system_score_gemma":0.00013759657,"threshold_uncertainty_score":0.47563878},"labels":[],"label_agreement":null},{"id":"W4403750647","doi":"10.1038/s41591-024-03327-6","title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Women and Children’s Health Research Institute; University of Alberta","funders":"","keywords":"Semaglutide; Medicine; Overweight; Diabetes mellitus; Kidney disease; Obesity; Randomized controlled trial; Placebo; Type 2 diabetes; Disease; Clinical trial; Internal medicine; Physical therapy; Alternative medicine; Endocrinology; Liraglutide; Pathology","score_opus":0.014795129128964107,"score_gpt":0.3201104647047129,"score_spread":0.30531533557574875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403750647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719894,0.007981636,0.000013582185,0.0054927752,0.0012920729,0.011887534,0.000013827059,0.00015029497,0.0011788586],"genre_scores_gemma":[0.9907111,0.0003449146,0.00010876782,0.0020859186,0.0013701414,0.0007050817,0.0002877421,0.000054433487,0.0043319087],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968315,0.0002618738,0.0008850527,0.0007585163,0.0007816721,0.00048139054],"domain_scores_gemma":[0.9974288,0.0011486321,0.0001657147,0.0004363034,0.00009911687,0.0007214568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019334778,0.00046021436,0.0022606754,0.00043312326,0.000055890538,0.000042670483,0.00011114663,0.00029472125,0.00034252703],"category_scores_gemma":[0.001733232,0.00021874369,0.00023252456,0.00046054827,0.0004019176,0.00011693589,0.00007318967,0.0009381672,0.000014926096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92434216,0.0009859465,0.065776266,0.0006136643,0.0015799144,0.00019528497,0.0000865857,4.6722238e-7,0.0000018577665,0.00025417938,0.004392839,0.0017708163],"study_design_scores_gemma":[0.9695044,0.004091132,0.010534307,0.0029765228,0.0049782502,6.7380506e-7,0.000010499282,0.0008625861,0.00000772012,0.00007536161,0.006720523,0.00023801583],"about_ca_topic_score_codex":0.000010579991,"about_ca_topic_score_gemma":0.000034382134,"teacher_disagreement_score":0.055241957,"about_ca_system_score_codex":0.00021881796,"about_ca_system_score_gemma":0.00049522717,"threshold_uncertainty_score":0.89201087},"labels":[],"label_agreement":null},{"id":"W4403768997","doi":"10.1161/jaha.123.034531","title":"Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute; Impact; McMaster University; Population Health Research Institute","funders":"","keywords":"Pioglitazone; Medicine; Interquartile range; Prediabetes; Stroke (engine); Placebo; Internal medicine; Population; Myocardial infarction; Diabetes mellitus; Rosiglitazone; Cardiology; Type 2 diabetes; Endocrinology; Insulin; Environmental health","score_opus":0.018600076133969867,"score_gpt":0.28136854966357494,"score_spread":0.2627684735296051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403768997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839354,0.0006271705,0.000020902204,0.00057257444,0.00006514022,0.00021190815,0.000013649394,0.0000045470842,0.000090553774],"genre_scores_gemma":[0.9988511,0.000079576996,0.0003867431,0.000062095416,0.000020384045,0.000003910354,0.0000044638114,0.0000060187954,0.0005856687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900544,0.00008768699,0.000374367,0.00008574034,0.00034973552,0.000097048745],"domain_scores_gemma":[0.99918896,0.00015956386,0.00041479888,0.00009956331,0.00010221276,0.00003492906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055371725,0.00007085698,0.00055909646,0.00031706455,0.0000075806674,0.0000048664906,0.00003315427,0.000021045313,0.000013244113],"category_scores_gemma":[0.00010888524,0.000042268097,0.00018589714,0.00058778876,0.000047681104,0.0000928163,0.000010398618,0.00009914115,1.5110052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038231586,0.00022002136,0.98640996,0.00012349234,0.0019198878,0.0000022718027,0.00081723253,0.00012922376,0.0029414312,0.0000010369814,0.0024150384,0.004638064],"study_design_scores_gemma":[0.00067067606,0.0005771241,0.9909703,0.0002307249,0.002646705,9.945537e-7,0.00017084854,0.0027785527,0.0002713075,0.0000015163802,0.0016447906,0.00003644745],"about_ca_topic_score_codex":0.00015432031,"about_ca_topic_score_gemma":0.000113595255,"teacher_disagreement_score":0.004601617,"about_ca_system_score_codex":0.00086812157,"about_ca_system_score_gemma":0.00009966573,"threshold_uncertainty_score":0.22701077},"labels":[],"label_agreement":null},{"id":"W4403792839","doi":"10.1002/phar.4620","title":"<scp>ECLIPSES</scp>: Early initiation of sodium glucose <scp>cotransporter</scp>‐2 inhibitors for <scp>cardiovascular</scp> protection in patients with type 2 diabetes following acute coronary syndrome and <scp>subsequent</scp> coronary artery bypass graft surgery","year":2024,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Type 2 diabetes; Cotransporter; Acute coronary syndrome; Medicine; Diabetes mellitus; Sodium; Internal medicine; Pharmacology; Endocrinology; Chemistry; Myocardial infarction","score_opus":0.015723081479143548,"score_gpt":0.25914313768464636,"score_spread":0.2434200562055028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403792839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592388,0.035585444,0.0000659848,0.00012916133,0.0017261809,0.0030507988,0.000053337004,0.00010105872,0.00004919543],"genre_scores_gemma":[0.9833539,0.014411102,0.00006335622,0.0009412354,0.00037332842,0.00024198987,0.00009428133,0.00015972828,0.00036104597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959341,0.0006649699,0.0011938154,0.0005924244,0.0007473491,0.00086732086],"domain_scores_gemma":[0.9964874,0.0019241485,0.0007116486,0.00027860553,0.0002978505,0.0003003964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022461812,0.00072654244,0.0013944544,0.00095712836,0.00036315992,0.0001040973,0.00028119638,0.00022266111,0.000015708976],"category_scores_gemma":[0.000040553652,0.0005328082,0.000681377,0.0006075525,0.00031859634,0.0010006691,0.000047219062,0.0008038363,0.0000038455996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012068215,0.0038378213,0.65806276,0.0013227122,0.046705987,0.0015607423,0.012684016,0.00017861648,0.23869213,0.00002327179,0.017705007,0.018020103],"study_design_scores_gemma":[0.054584984,0.012454116,0.68801415,0.0015605038,0.013373813,0.00049300294,0.0015176518,0.0005202933,0.1992172,0.0011066135,0.02686067,0.0002970156],"about_ca_topic_score_codex":0.000012346699,"about_ca_topic_score_gemma":0.000003432029,"teacher_disagreement_score":0.05337816,"about_ca_system_score_codex":0.00016549992,"about_ca_system_score_gemma":0.00017646517,"threshold_uncertainty_score":0.99971235},"labels":[],"label_agreement":null},{"id":"W4403812054","doi":"10.1681/asn.2024k6fn2ax5","title":"Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"","keywords":"Credence; Medicine; Intensive care medicine; Computer science","score_opus":0.015712945519797145,"score_gpt":0.31502680476433376,"score_spread":0.29931385924453663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403812054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874278,0.0011909782,0.000054805027,0.010666781,0.00016118046,0.0004612247,0.000011621299,0.000008192536,0.000017418608],"genre_scores_gemma":[0.99497646,0.0004913979,0.0022916857,0.0018526288,0.0003494118,0.000010974074,0.0000033367792,0.00000823952,0.000015881551],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906045,0.00013013458,0.0003660875,0.000094713905,0.0002423739,0.00010624606],"domain_scores_gemma":[0.99871856,0.0003058332,0.0007105559,0.00015097238,0.00007687582,0.00003722418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023745539,0.000089622015,0.00033355525,0.00003068679,0.000046972375,0.00001253833,0.00011869514,0.000026378953,0.000017310302],"category_scores_gemma":[0.000021358608,0.000044708162,0.0003293702,0.0002169682,0.0005270798,0.00004787391,0.000050058585,0.00017206861,3.7992646e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01122881,0.0013395789,0.07237601,0.0002582778,0.0096216705,0.000026518306,0.0111201145,0.000055154167,0.074858606,0.00019369497,0.2527406,0.56618094],"study_design_scores_gemma":[0.045513276,0.02707717,0.69031984,0.00053702947,0.007180629,0.00002805638,0.017419247,0.001365508,0.012121963,0.0020052018,0.19616872,0.0002633769],"about_ca_topic_score_codex":0.0009163416,"about_ca_topic_score_gemma":0.000060589122,"teacher_disagreement_score":0.6179438,"about_ca_system_score_codex":0.00004749658,"about_ca_system_score_gemma":0.0001560103,"threshold_uncertainty_score":0.19420475},"labels":[],"label_agreement":null},{"id":"W4403832328","doi":"10.1681/asn.2024856chkmq","title":"Patterns of Care among Patients with Documented CKD in the United States","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.006204696372937141,"score_gpt":0.25071984821012244,"score_spread":0.2445151518371853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403832328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995299,0.0001793186,0.000029894858,0.004198557,0.000040694536,0.00019894763,0.000009578956,0.000003831783,0.000040184255],"genre_scores_gemma":[0.9960518,0.00027510984,0.00020691272,0.00336738,0.000029310615,0.0000029916384,0.00001429844,0.000009256582,0.000042943113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916995,0.00009006175,0.00027055628,0.00007073482,0.0002660929,0.00013263122],"domain_scores_gemma":[0.9991881,0.00010999418,0.00038815755,0.00016044162,0.00012897619,0.000024286259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014625496,0.000089008536,0.00032043,0.00008092533,0.000018200011,0.000006390292,0.00017086172,0.00001905237,0.000014041389],"category_scores_gemma":[0.0000057343796,0.000040419887,0.00021590247,0.00040661189,0.0002660468,0.00004516077,0.000044143733,0.00017931672,3.3676608e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033409434,0.000299712,0.9719732,0.00020294284,0.0013675722,0.00001481918,0.009200223,0.00015117554,0.00023047574,0.000021905284,0.012712373,0.0034915153],"study_design_scores_gemma":[0.0013515359,0.002674715,0.972589,0.00022601735,0.0004639161,0.000004432808,0.011659605,0.000101014695,0.00008315709,0.000028796709,0.010777623,0.00004016674],"about_ca_topic_score_codex":0.00034348204,"about_ca_topic_score_gemma":0.000026883801,"teacher_disagreement_score":0.0034513485,"about_ca_system_score_codex":0.00005915078,"about_ca_system_score_gemma":0.000033456236,"threshold_uncertainty_score":0.16482753},"labels":[],"label_agreement":null},{"id":"W4403832776","doi":"10.1681/asn.2024f7q40fk1","title":"Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Type 2 Diabetes Mellitus; Medicine; Glucagon-like peptide-1; Internal medicine; Glucagon-like peptide 1 receptor; Endocrinology; Primary care; Diabetes mellitus; Type 2 diabetes; Receptor; Agonist; Family medicine","score_opus":0.010959984274904525,"score_gpt":0.2394874245983868,"score_spread":0.22852744032348227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403832776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648607,0.0017782715,0.0000015411,0.0012106472,0.00016120126,0.0002752402,0.000039650728,0.000007673156,0.000039681316],"genre_scores_gemma":[0.99460244,0.0015506163,0.002154243,0.0012846831,0.00005539931,0.0000034572495,0.000041344498,0.000023583683,0.00028421506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872637,0.00008095623,0.00044112446,0.00016945762,0.00029855754,0.00028355714],"domain_scores_gemma":[0.99891806,0.00011898166,0.0005084752,0.00018398909,0.00016751187,0.00010301442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011719669,0.00017300625,0.00059539365,0.0000780701,0.000028194581,0.00001837383,0.00010058492,0.00005625076,0.000013300893],"category_scores_gemma":[0.000012716523,0.0001092788,0.00018996083,0.00035689396,0.00061450666,0.00013098108,0.000064998465,0.00025059746,7.357753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001452757,0.00095974014,0.6438357,0.0012570933,0.0035238452,0.000014551615,0.0052343183,0.00004993211,0.075128436,0.00001373025,0.21477816,0.053751744],"study_design_scores_gemma":[0.0025648256,0.006940018,0.8386318,0.0006230989,0.00083507027,0.0000031808318,0.0022766055,0.000019474917,0.003108111,0.000019886182,0.14477597,0.00020194476],"about_ca_topic_score_codex":0.0001164395,"about_ca_topic_score_gemma":0.000012829225,"teacher_disagreement_score":0.19479612,"about_ca_system_score_codex":0.00017753484,"about_ca_system_score_gemma":0.0001521074,"threshold_uncertainty_score":0.44562602},"labels":[],"label_agreement":null},{"id":"W4403833629","doi":"10.1681/asn.2024wcjmwep0","title":"Trial Design and Baseline Characteristics from REMODEL: A Mechanistic Study of Semaglutide vs. Placebo in People with Type 2 Diabetes and CKD","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Semaglutide; Placebo; Type 2 diabetes; Medicine; Baseline (sea); Diabetes mellitus; Internal medicine; Endocrinology; Biology; Alternative medicine; Pathology","score_opus":0.015242134710491038,"score_gpt":0.2593671360212724,"score_spread":0.24412500131078138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403833629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970378,0.00036009302,0.0006313256,0.001412919,0.00006600805,0.00047792305,0.0000048778115,0.000005070343,0.0000039324404],"genre_scores_gemma":[0.9927667,0.0003726778,0.005986199,0.000735148,0.000086405234,0.0000046482724,0.0000014118326,0.000013526425,0.00003331203],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990736,0.00016484667,0.0003429087,0.00012354602,0.00017031415,0.000124747],"domain_scores_gemma":[0.99890816,0.0004652431,0.0003780242,0.00012899606,0.00007454771,0.00004504694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051540736,0.00010983601,0.00065208424,0.000060534243,0.000019238716,0.000008381082,0.00007172813,0.000026557149,0.0000073111814],"category_scores_gemma":[0.00005244917,0.00006579046,0.00007273798,0.00022374706,0.00018321503,0.000029584422,0.00006191437,0.00015629736,1.7268412e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33255458,0.009931954,0.28876263,0.0016470596,0.024190797,0.00034223023,0.039379004,0.0008350641,0.18390766,0.00014112864,0.036120202,0.08218768],"study_design_scores_gemma":[0.10954246,0.11825488,0.6421436,0.0011833975,0.010758178,0.00009524019,0.012262371,0.10042825,0.0008677029,0.0012685803,0.0026869348,0.0005084108],"about_ca_topic_score_codex":0.00008019946,"about_ca_topic_score_gemma":0.000016435779,"teacher_disagreement_score":0.35338095,"about_ca_system_score_codex":0.00003418193,"about_ca_system_score_gemma":0.00007878012,"threshold_uncertainty_score":0.26828572},"labels":[],"label_agreement":null},{"id":"W4403833769","doi":"10.1681/asn.2024bjyvcgfe","title":"Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Semaglutide; Medicine; Internal medicine; Kidney disease; Urology; Intensive care medicine; Cardiology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.03627022427261408,"score_gpt":0.34421228972089735,"score_spread":0.3079420654482833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403833769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682837,0.00028646443,0.000030182364,0.03041609,0.0002561073,0.0003892226,0.000015716449,0.0000049843793,0.00031754872],"genre_scores_gemma":[0.99289507,0.00020060423,0.0022090622,0.00434995,0.000164893,0.000005884333,0.0000010793581,0.000011121539,0.00016235004],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99848735,0.00024753937,0.00060480804,0.00011684628,0.00036474896,0.00017871402],"domain_scores_gemma":[0.9982978,0.00047273334,0.00079309253,0.00028184336,0.000104720166,0.000049777398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008640656,0.00013008836,0.0008259802,0.00008767035,0.00002388516,0.0000047316958,0.00029532227,0.000047030077,0.000027573771],"category_scores_gemma":[0.00018930138,0.00006708434,0.000887799,0.00043889787,0.0006520446,0.00004055903,0.0000873389,0.00032908953,9.4395233e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04176039,0.005062442,0.07940029,0.0010324427,0.021963231,0.00013204725,0.028663231,0.00020173976,0.13144752,0.0006407572,0.62858856,0.061107375],"study_design_scores_gemma":[0.031251065,0.0077539464,0.91749126,0.0003817926,0.0033089365,0.00008997212,0.008447939,0.0006993445,0.0045768735,0.00251474,0.023295894,0.00018826636],"about_ca_topic_score_codex":0.00022914982,"about_ca_topic_score_gemma":0.000009610904,"teacher_disagreement_score":0.83809096,"about_ca_system_score_codex":0.0000940068,"about_ca_system_score_gemma":0.00021629839,"threshold_uncertainty_score":0.27356198},"labels":[],"label_agreement":null},{"id":"W4403834417","doi":"10.1681/asn.2024s5r4rxwp","title":"Modeling Cardiorenal Protection with SGLT2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and -2","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; University of British Columbia; Sinai Health System; University of Waterloo; University of Calgary; University of Toronto; Toronto General Hospital","funders":"","keywords":"Cardiorenal syndrome; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology; Kidney","score_opus":0.015470415736704091,"score_gpt":0.2612781816980581,"score_spread":0.245807765961354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403834417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972218,0.0004308773,0.0010019784,0.0011904581,0.000021377258,0.000113002665,0.000001479674,0.0000043867967,0.000014589607],"genre_scores_gemma":[0.99788976,0.00026428225,0.0013566704,0.00042653462,0.00004349791,0.0000024478875,0.0000018057806,0.0000065495833,0.00000843045],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993788,0.00005759701,0.00023291587,0.00008637928,0.00015020459,0.00009409509],"domain_scores_gemma":[0.9995673,0.000021212258,0.00019481937,0.00009783878,0.000089623776,0.000029239662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026448793,0.000066948545,0.0004256713,0.00016917413,0.00001493756,0.000004907033,0.000030711817,0.000025099309,0.0000036283504],"category_scores_gemma":[0.0000056680037,0.000040032643,0.00020635876,0.000656732,0.00018009996,0.000071181916,0.00002152719,0.00013022602,9.709945e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030196798,0.0012057034,0.2283151,0.001091485,0.043999325,0.000071654016,0.009559677,0.17067699,0.43222833,0.00013524007,0.0014016281,0.10829522],"study_design_scores_gemma":[0.001903757,0.008539249,0.3732355,0.00044515284,0.011456471,0.000052856914,0.0033217466,0.5977281,0.0024149956,0.00022643195,0.0005226398,0.00015314798],"about_ca_topic_score_codex":0.00009715543,"about_ca_topic_score_gemma":0.000026995498,"teacher_disagreement_score":0.42981333,"about_ca_system_score_codex":0.00005457838,"about_ca_system_score_gemma":0.000042890035,"threshold_uncertainty_score":0.16324838},"labels":[],"label_agreement":null},{"id":"W4403834524","doi":"10.1681/asn.2024w22c75k8","title":"Modeling Cardiorenal Protection with SGLT2 Inhibition in Type 1 Diabetes: An Analysis of EASE-2 and -3","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; University of British Columbia; University of Waterloo; Lunenfeld-Tanenbaum Research Institute; University of Calgary; Toronto General Hospital","funders":"","keywords":"Cardiorenal syndrome; Medicine; Type 2 diabetes; Type 1 diabetes; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology; Kidney","score_opus":0.016147375627963378,"score_gpt":0.26126375446869754,"score_spread":0.24511637884073417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403834524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755436,0.00042511677,0.00061572884,0.0012501776,0.000020895932,0.00011395254,0.0000018506953,0.000004364297,0.0000135564105],"genre_scores_gemma":[0.99815154,0.00022399776,0.00111509,0.00044451203,0.000044753313,0.0000024036037,0.000002044828,0.0000065707413,0.000009110469],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99938023,0.000057735833,0.0002283827,0.00008695512,0.00015396054,0.00009274564],"domain_scores_gemma":[0.9995597,0.000020659152,0.0001966712,0.00009860469,0.00009315202,0.000031242045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026751639,0.00006714819,0.00042188485,0.0001689564,0.000014910376,0.0000049781866,0.000030041683,0.000023990071,0.00000431681],"category_scores_gemma":[0.0000060182397,0.000040139832,0.0002109049,0.00066231465,0.00018910036,0.00007177262,0.00002077448,0.00012747406,1.045787e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035223267,0.0014047534,0.1800526,0.001219723,0.04598601,0.00008669693,0.009495956,0.17294519,0.49404556,0.00013891433,0.0017457535,0.089356534],"study_design_scores_gemma":[0.0021260935,0.009538527,0.32136437,0.00053219654,0.013037179,0.000058125097,0.004006048,0.64582604,0.0025457195,0.00025830773,0.0005385903,0.00016882805],"about_ca_topic_score_codex":0.000105730614,"about_ca_topic_score_gemma":0.000020834686,"teacher_disagreement_score":0.49149984,"about_ca_system_score_codex":0.000054563854,"about_ca_system_score_gemma":0.000045666216,"threshold_uncertainty_score":0.16368549},"labels":[],"label_agreement":null},{"id":"W4403835125","doi":"10.1681/asn.20249nk1bvrb","title":"Exploring Patient and Physician Perspectives on the Use of SGLT2 Inhibitors for Adjunct-to-Insulin Treatment in Patients Living with Type 1 Diabetes","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of British Columbia; University of Waterloo; Sinai Health System; Université de Montréal; University of Alberta; University of Calgary; University of Toronto; University Health Network","funders":"","keywords":"Adjunct; Medicine; Type 2 diabetes; Insulin; Diabetes mellitus; Intensive care medicine; Diabetes treatment; Internal medicine; Endocrinology","score_opus":0.03964427730303999,"score_gpt":0.2502027678174979,"score_spread":0.2105584905144579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403835125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605626,0.0002250475,0.000006721715,0.0031975303,0.00006883791,0.00042886104,0.000004103082,0.000003480908,0.000009173266],"genre_scores_gemma":[0.997068,0.00036484376,0.0010332128,0.0014156688,0.00006581519,0.00002184941,4.688985e-7,0.000014122701,0.000016056427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931586,0.00005149078,0.00021742423,0.000114821545,0.00015640321,0.0001439962],"domain_scores_gemma":[0.9990825,0.00039548278,0.00025676456,0.00012810573,0.000102577935,0.000034586483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009774622,0.00011316153,0.00035504604,0.00006972676,0.000030531704,0.000008215181,0.000054764412,0.000012860389,0.0000013064432],"category_scores_gemma":[0.000038009806,0.00005361258,0.00018363303,0.00026641288,0.00020047688,0.00007362353,0.00004073309,0.000082887054,2.8109127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035054227,0.0058598826,0.4166592,0.00043800994,0.010162667,0.000007921472,0.116580464,0.001332735,0.026478013,0.00040715229,0.02103992,0.39752862],"study_design_scores_gemma":[0.0020147476,0.04669992,0.90942186,0.0013006113,0.0009123573,0.0000013798158,0.021995777,0.0005612603,0.0038774891,0.00004360304,0.013008108,0.0001629115],"about_ca_topic_score_codex":0.000028407338,"about_ca_topic_score_gemma":0.000003611,"teacher_disagreement_score":0.49276263,"about_ca_system_score_codex":0.00012989613,"about_ca_system_score_gemma":0.000036734356,"threshold_uncertainty_score":0.21862577},"labels":[],"label_agreement":null},{"id":"W4403841888","doi":"10.1681/asn.20242wv2xw41","title":"Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKD","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"","keywords":"Semaglutide; Medicine; Obesity; Internal medicine; Kidney disease; Urology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.0040399298695959745,"score_gpt":0.22025331079616056,"score_spread":0.21621338092656459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403841888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969686,0.00017359834,0.000011248502,0.0025316414,0.000054185966,0.00022169198,0.000001997985,0.0000034804063,0.00003353093],"genre_scores_gemma":[0.9931204,0.00012115559,0.0015727717,0.00512021,0.000017520391,0.000001912344,5.803802e-7,0.000008980765,0.00003648064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930733,0.000062742954,0.00021097207,0.000091437745,0.00019349,0.00013400338],"domain_scores_gemma":[0.9993051,0.00019064583,0.0002879138,0.000111353685,0.000040731775,0.00006420469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014197027,0.0000935029,0.00043533105,0.000071240465,0.0000127864205,0.0000032710693,0.000075284275,0.000023670877,0.0000022062263],"category_scores_gemma":[0.0000264048,0.00005249686,0.00017107154,0.00022386976,0.0003975413,0.000025800184,0.000040314884,0.00015934034,5.6450017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012631967,0.0016961507,0.93258715,0.0013014177,0.003162527,0.000031235824,0.0015761389,0.000081449056,0.008143608,0.000056520952,0.033847734,0.016252872],"study_design_scores_gemma":[0.002114116,0.0051478096,0.9890459,0.00042863237,0.00052852236,0.000002857923,0.000088461566,0.000071698174,0.0010673349,0.00008126645,0.0013771855,0.00004619162],"about_ca_topic_score_codex":0.000025291887,"about_ca_topic_score_gemma":8.648411e-7,"teacher_disagreement_score":0.056458775,"about_ca_system_score_codex":0.00005657199,"about_ca_system_score_gemma":0.00005018394,"threshold_uncertainty_score":0.21407598},"labels":[],"label_agreement":null},{"id":"W4403873272","doi":"10.1007/s10557-024-07630-9","title":"International Accolades for GLP-1 Research: Recognizing Pioneers in Diabetes and Obesity Treatment Across Five Prestigious Awards","year":2024,"lang":"en","type":"editorial","venue":"Cardiovascular Drugs and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"","keywords":"Medicine; Obesity; Diabetes mellitus; Gerontology; Family medicine; Internal medicine; Endocrinology","score_opus":0.03723913398797392,"score_gpt":0.3421870963989569,"score_spread":0.304947962410983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403873272","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51934946,0.23920761,0.000010105886,0.0005675886,0.23375838,0.0049710656,0.000662912,0.00014722913,0.0013256819],"genre_scores_gemma":[0.07410773,0.48105952,0.00063253875,0.00010304648,0.4262517,0.004200309,0.0027137727,0.00033037888,0.010601014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974521,0.00011294996,0.00026880845,0.00084977254,0.0007804592,0.00053595455],"domain_scores_gemma":[0.9986331,0.0005060266,0.000046752946,0.00041686546,0.00025132802,0.00014591427],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014370162,0.00040087375,0.0009291507,0.00029832934,0.00016378077,0.00028244022,0.00012874142,0.00038579552,0.0000048748175],"category_scores_gemma":[0.00016428839,0.00031296862,0.0006458796,0.00017010179,0.00016489105,0.00009933675,0.00014648939,0.00036930444,0.0000050132467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003809894,0.00035822237,0.0016667121,0.00091845135,0.020804062,0.00013436914,0.0057832003,0.000009368003,0.000023017892,0.000025862668,0.2643655,0.7055302],"study_design_scores_gemma":[0.0063578654,0.0007016722,0.0005361433,0.00063989597,0.00065354374,0.0000012137835,0.00072784146,0.00008355519,0.00014098593,0.00038869292,0.9894921,0.00027647836],"about_ca_topic_score_codex":0.00023160527,"about_ca_topic_score_gemma":0.000017080332,"teacher_disagreement_score":0.7251266,"about_ca_system_score_codex":0.0003893864,"about_ca_system_score_gemma":0.00012881469,"threshold_uncertainty_score":0.9999322},"labels":[],"label_agreement":null},{"id":"W4403902437","doi":"10.14740/jocmr6033","title":"Comprehensive Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ejection fraction; Heart failure; Sodium; Cotransporter; Cardiology; Internal medicine; Pharmacology; Materials science; Metallurgy","score_opus":0.1702040889571921,"score_gpt":0.5050794700831632,"score_spread":0.33487538112597115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403902437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046728476,0.9860924,0.0000010542878,0.009993917,0.00073575607,0.0021064056,0.000009633404,0.000012463354,0.0005810889],"genre_scores_gemma":[0.00015697395,0.9956915,0.0002950474,0.0003083074,0.0028368284,0.000054133725,0.00008473125,0.00006758386,0.0005049251],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991801,0.0009842454,0.004062213,0.0005199684,0.0021916311,0.00044092193],"domain_scores_gemma":[0.9943058,0.0016194195,0.001205105,0.00053952396,0.0018793758,0.00045078984],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0058840504,0.00046802382,0.006013549,0.0017180034,0.00003626939,0.000024349309,0.00025178946,0.000524703,0.000158743],"category_scores_gemma":[0.0010680523,0.00023923603,0.0010929182,0.0026906119,0.00039849078,0.00016038872,0.00007047875,0.005091894,0.000037655565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005176247,0.00078753405,0.0004101756,0.22268692,0.0016806468,0.0013040509,0.00005344438,1.8651077e-7,0.0000028465424,0.000025748808,0.14823414,0.62429667],"study_design_scores_gemma":[0.0014641511,0.0037600703,0.00019218196,0.43327743,0.003178513,0.00029389135,0.000053653777,4.0655019e-7,0.0000033924764,0.000012899169,0.55767184,0.000091542526],"about_ca_topic_score_codex":0.000009059884,"about_ca_topic_score_gemma":0.0000073775136,"teacher_disagreement_score":0.6242051,"about_ca_system_score_codex":0.00023279464,"about_ca_system_score_gemma":0.0009119215,"threshold_uncertainty_score":0.9972034},"labels":[],"label_agreement":null},{"id":"W4403912607","doi":"10.1056/nejmoa2403664","title":"Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":326,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Semaglutide; Osteoarthritis; Obesity; Medicine; Physical therapy; Internal medicine; Alternative medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.010181547881965961,"score_gpt":0.24220688141968566,"score_spread":0.2320253335377197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403912607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570765,0.016398929,0.00009724414,0.019811222,0.00028448005,0.00019687512,0.0000013286185,0.000019871988,0.006113574],"genre_scores_gemma":[0.9930913,0.00054046453,0.0006332557,0.00038212715,0.0012352162,0.000001692478,0.0000031839934,0.000014287048,0.0040984997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99911475,0.000028913848,0.00025261633,0.00012669551,0.00030798817,0.00016905139],"domain_scores_gemma":[0.99947685,0.000108972024,0.00005828613,0.00008739863,0.000039042883,0.0002294626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040866644,0.0001274987,0.00038429938,0.00028975675,0.000020443991,0.000015570326,0.000035701927,0.00003161206,0.00012260446],"category_scores_gemma":[0.00005549112,0.00007293045,0.000034987705,0.00019689115,0.00008475625,0.000081648104,0.000014655204,0.00025043785,0.000004030455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007383923,0.00012418092,0.111007996,0.000259768,0.00032483827,0.00695659,0.0032087222,0.000006153651,0.0004689438,0.00046787786,0.012326028,0.8641105],"study_design_scores_gemma":[0.17413163,0.03639924,0.27506477,0.01515569,0.0023007435,0.0069339946,0.0027782298,0.00020770685,0.0002503975,0.0011670786,0.485248,0.0003625434],"about_ca_topic_score_codex":0.000080510814,"about_ca_topic_score_gemma":0.00014029803,"teacher_disagreement_score":0.86374795,"about_ca_system_score_codex":0.0000570144,"about_ca_system_score_gemma":0.00010321911,"threshold_uncertainty_score":0.29740176},"labels":[],"label_agreement":null},{"id":"W4403926128","doi":"10.1016/j.jcjd.2024.10.011","title":"Glucagon-like Peptide-1 Receptor Agonist Use in Hospital: A Multicentre Observational Study","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital; Sinai Health System","funders":"Physicians' Services Incorporated Foundation; Ministry of Colleges and Universities; Ministry of Training, Colleges and Universities","keywords":"Medicine; Observational study; Agonist; Glucagon-like peptide-1; Receptor; Pharmacology; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.03670404051928615,"score_gpt":0.26485197981872666,"score_spread":0.2281479392994405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403926128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932191,0.0021002127,0.0000010246792,0.0025315296,0.0012626502,0.00053819886,0.000025635232,0.000017895401,0.00030377455],"genre_scores_gemma":[0.9961907,0.000012111287,0.000434456,0.00041783598,0.00021677456,0.000017591567,0.00003530868,0.00003327948,0.00264194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986608,0.0000422386,0.0004363036,0.00019815634,0.0002479049,0.00041461675],"domain_scores_gemma":[0.9989249,0.00012978277,0.00008773325,0.00016888304,0.00015127075,0.0005374277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002748292,0.00018001247,0.00033443203,0.0005756771,0.000056783243,0.00021684483,0.00012757625,0.000050504965,0.0002406029],"category_scores_gemma":[0.00020119974,0.0001525202,0.00014702692,0.0003875637,0.000053786487,0.0004132214,0.000014591626,0.00023050426,0.00005938043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005512624,0.00034149064,0.9557853,0.00007964152,0.0004874546,0.00037122695,0.0011565242,0.000014822452,0.000055473753,0.00011821616,0.037776906,0.0038074492],"study_design_scores_gemma":[0.001905587,0.0013110709,0.87756777,0.0007678107,0.00037822474,0.0000012363838,0.0014053152,0.00020533672,0.00005995524,0.00004494184,0.116157435,0.0001953057],"about_ca_topic_score_codex":0.0008244527,"about_ca_topic_score_gemma":0.013509812,"teacher_disagreement_score":0.07838053,"about_ca_system_score_codex":0.0004612778,"about_ca_system_score_gemma":0.00079825695,"threshold_uncertainty_score":0.7538792},"labels":[],"label_agreement":null},{"id":"W4403940559","doi":"10.7759/cureus.72771","title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Body Weight, BMI, and Body Composition in Adults With Type 2 Diabetes Mellitus: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Cochrane Library; Observational study; Body mass index; Systematic review; Type 2 Diabetes Mellitus; Type 2 diabetes; MEDLINE; Placebo; Dapagliflozin; Weight loss; Randomized controlled trial; Weight management; Internal medicine; Intensive care medicine; Obesity; Endocrinology; Alternative medicine; Pathology","score_opus":0.007927491419413481,"score_gpt":0.2597491698242845,"score_spread":0.251821678404871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403940559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008466064,0.99048644,4.875798e-7,0.000030894942,0.00024020484,0.007961109,0.000016509915,0.00005684835,0.00036087315],"genre_scores_gemma":[0.0012047009,0.9970935,0.000037740996,0.000116941,0.00007506481,0.0007699763,0.0005001327,0.00007471952,0.00012720672],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99792445,0.00012474364,0.0008391013,0.0004961087,0.000337914,0.00027769868],"domain_scores_gemma":[0.9988805,0.00016285238,0.0003403353,0.00044376202,0.00005810076,0.00011447169],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002289998,0.00056841434,0.0032984929,0.00025443247,0.000018120096,0.000019458232,0.00010332792,0.000166445,0.000012996557],"category_scores_gemma":[0.000024745343,0.00032888763,0.00027635423,0.00041109655,0.000058139303,0.00006131003,0.000034314868,0.00025724902,0.0000663513],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032113225,0.00047425568,0.000018048868,0.9904077,0.0013349125,0.00020850229,0.000051389135,5.521839e-9,0.0000037100333,0.0001109702,0.0007056217,0.0066527943],"study_design_scores_gemma":[0.00094816135,0.001475252,0.000017035696,0.94446445,0.031586744,0.0000065911395,0.0000045587353,0.000004395641,0.00006225557,0.0000071162503,0.021148013,0.0002754181],"about_ca_topic_score_codex":0.0000058873597,"about_ca_topic_score_gemma":0.0000042756647,"teacher_disagreement_score":0.045943215,"about_ca_system_score_codex":0.00016229595,"about_ca_system_score_gemma":0.00006187447,"threshold_uncertainty_score":0.9999163},"labels":[],"label_agreement":null},{"id":"W4403968408","doi":"10.1681/asn.0000000540","title":"Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Kidney Foundation of Canada; Diabetes Canada; Canadian Society of Nephrology; University of Toronto; American Society of Nephrology","keywords":"Medicine; Intensive care medicine; Type 2 diabetes; Internal medicine; Type 1 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.0062857556510445625,"score_gpt":0.23705902293999154,"score_spread":0.23077326728894698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403968408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965783,0.000982069,0.0000036453841,0.0022202914,0.000035655874,0.0001296091,0.0000018722383,0.0000026159134,0.000045962697],"genre_scores_gemma":[0.99732506,0.00055041554,0.0010024769,0.001045918,0.00002695902,5.3125723e-7,7.6272835e-7,0.000007480002,0.000040380768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945337,0.00003328964,0.0002128433,0.00007299176,0.00012348063,0.00010402617],"domain_scores_gemma":[0.99948937,0.00011103837,0.00022354876,0.00008601386,0.000056599318,0.000033448578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014600101,0.00007113661,0.00035851318,0.000046134523,0.000012522587,0.0000033165034,0.000050823153,0.000020083296,0.0000057241023],"category_scores_gemma":[0.000013638668,0.000039461447,0.00007261715,0.00020453322,0.00043264218,0.000035428046,0.00005230241,0.00011292219,2.0224876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015592241,0.00042964861,0.929006,0.00024950565,0.001959186,0.000004477403,0.0012129362,0.00001555452,0.006016593,0.000056387835,0.009441262,0.05004924],"study_design_scores_gemma":[0.0022448339,0.0029984515,0.98897594,0.00015614093,0.00032230647,0.0000025934025,0.0001784604,0.00005782528,0.000117580465,0.000045396355,0.0048654107,0.000035082325],"about_ca_topic_score_codex":0.000007150423,"about_ca_topic_score_gemma":0.0000010700169,"teacher_disagreement_score":0.059969936,"about_ca_system_score_codex":0.000023314378,"about_ca_system_score_gemma":0.00003280655,"threshold_uncertainty_score":0.16091911},"labels":[],"label_agreement":null},{"id":"W4403971650","doi":"10.1016/j.rcsop.2024.100537","title":"Deprescribing oral antidiabetics in elderly patients: Do electronic leaflets across the world address it?","year":2024,"lang":"en","type":"article","venue":"Exploratory Research in Clinical and Social Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fundação de Amparo à Pesquisa do Estado de Minas Gerais; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Universidade Federal de São João del-Rei; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Deprescribing; Medicine; Gerontology; Intensive care medicine; Polypharmacy","score_opus":0.27912792046059853,"score_gpt":0.5263908809496549,"score_spread":0.24726296048905638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403971650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836304,0.0023801515,0.0000010113864,0.011053874,0.00034754587,0.00088315224,0.00001200625,0.00004905555,0.0016427635],"genre_scores_gemma":[0.9953132,0.0023087573,0.00000628538,0.00094320363,0.0004608633,0.0001790633,0.000024020657,0.000031815056,0.00073277205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656224,0.0007708939,0.0005864412,0.00049832626,0.00061468635,0.0009674169],"domain_scores_gemma":[0.99856377,0.00096016674,0.000032749755,0.00018468252,0.00011122212,0.0001474367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046719625,0.00017176302,0.00037212248,0.00022457005,0.00024354391,0.00023281337,0.00020805286,0.00007303367,0.00007015429],"category_scores_gemma":[0.00018276056,0.00012343648,0.00012494964,0.0009252418,0.0005578415,0.00029442823,0.0003193217,0.0016663548,0.00007972842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000587019,0.0016782134,0.58388543,0.00042630435,0.0002806908,0.0002960543,0.004624502,0.0000013770601,0.00004859145,0.0027608175,0.033231717,0.3721793],"study_design_scores_gemma":[0.01680935,0.0013750759,0.119361624,0.0011614267,0.0001388898,6.1184414e-7,0.00588515,0.0007625789,0.00033461733,0.0066365497,0.84697825,0.00055585697],"about_ca_topic_score_codex":0.000041058844,"about_ca_topic_score_gemma":0.0004895056,"teacher_disagreement_score":0.8137466,"about_ca_system_score_codex":0.00015157569,"about_ca_system_score_gemma":0.00022047482,"threshold_uncertainty_score":0.72395754},"labels":[],"label_agreement":null},{"id":"W4404025318","doi":"10.1002/oby.24184","title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (<scp>SYNCHRONIZE™</scp>‐1 and ‐2)","year":2024,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); University of Calgary; McMaster University; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim Stiftung","keywords":"Medicine; Tolerability; Type 2 diabetes; Placebo; Obesity; Internal medicine; Clinical trial; Clinical endpoint; Randomization; Diabetes mellitus; Randomized controlled trial; Weight loss; Physical therapy; Adverse effect; Endocrinology","score_opus":0.12283148267614852,"score_gpt":0.4166436150841353,"score_spread":0.29381213240798676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404025318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96238816,0.008745908,0.023397533,0.00019242182,0.00018803967,0.0046714344,0.00007909633,0.000040494782,0.00029690968],"genre_scores_gemma":[0.9807735,0.004894396,0.01019223,0.000050333107,0.00019305629,0.00026638253,0.00012318885,0.000022366603,0.00348451],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981018,0.0005298875,0.00075115357,0.0003084887,0.0001553085,0.0001534014],"domain_scores_gemma":[0.9918724,0.0075652706,0.00019001489,0.00018285621,0.00007906028,0.00011041476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040186695,0.00017269189,0.0015380515,0.00010362932,0.000043825235,0.000023358498,0.000030892556,0.000065349144,0.000019514397],"category_scores_gemma":[0.0013756155,0.00011979245,0.00031087798,0.00008513726,0.000198418,0.00006844174,0.00002607008,0.00002971744,0.0000028093104],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11066557,0.037061222,0.191011,0.0089678,0.031787425,0.0002979787,0.004072086,0.00007420362,0.01690077,0.053127825,0.028510489,0.51752365],"study_design_scores_gemma":[0.8989836,0.0075606722,0.0073714694,0.0005463396,0.014220962,0.000011712176,0.00014889323,0.0207911,0.029315451,0.007910521,0.01294054,0.00019875832],"about_ca_topic_score_codex":0.0000405774,"about_ca_topic_score_gemma":0.000008033139,"teacher_disagreement_score":0.78831804,"about_ca_system_score_codex":0.00004408032,"about_ca_system_score_gemma":0.00010909375,"threshold_uncertainty_score":0.48849943},"labels":[],"label_agreement":null},{"id":"W4404052195","doi":"10.1111/pan.15038","title":"Interruption of oral hypoglycemic agents before pediatric surgery","year":2024,"lang":"en","type":"letter","venue":"Pediatric Anesthesia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Diabetic ketoacidosis; Diabetes mellitus; Perioperative; Ketogenesis; Metformin; Ketoacidosis; Internal medicine; Type 2 diabetes; Ketosis; Endocrinology; Type 1 diabetes; Intensive care medicine; Anesthesia; Ketone bodies","score_opus":0.03472130086095558,"score_gpt":0.27327093611751974,"score_spread":0.23854963525656414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404052195","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66289026,0.00855041,0.000019775378,0.32192984,0.0018045468,0.0020685971,0.000041471427,0.0006535067,0.002041559],"genre_scores_gemma":[0.29020166,0.014373174,0.0010528094,0.5126253,0.0643394,0.00070875976,0.009237387,0.0011288425,0.10633269],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697036,0.00007116695,0.0008323558,0.0006992449,0.00080110336,0.00062579877],"domain_scores_gemma":[0.9985695,0.00013858118,0.00043698712,0.0006227117,0.00011111459,0.0001210887],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029117623,0.00060565054,0.0011703512,0.0015139468,0.000037097434,0.000044632518,0.00022714565,0.00072559185,0.00034406118],"category_scores_gemma":[0.00004379548,0.0005074619,0.0007748963,0.0008761309,0.0000519214,0.000102950486,0.00009126578,0.00089089316,0.0010441144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003950748,0.00013012116,0.12843403,0.0038474032,0.00021898838,0.0038832906,0.00007362174,3.907783e-7,2.1059036e-7,0.0000071060704,0.8604026,0.0029627758],"study_design_scores_gemma":[0.00084025075,0.0006305249,0.03626164,0.00019652855,0.013175708,0.00024397954,0.000018799468,0.000040235198,0.000005110656,0.00024203319,0.94768345,0.000661749],"about_ca_topic_score_codex":0.000041188014,"about_ca_topic_score_gemma":0.0000012011766,"teacher_disagreement_score":0.37268862,"about_ca_system_score_codex":0.00020541625,"about_ca_system_score_gemma":0.00023499412,"threshold_uncertainty_score":0.9997377},"labels":[],"label_agreement":null},{"id":"W4404098512","doi":"10.1183/13993003.congress-2024.pa3920","title":"Late Breaking Abstract - Do asthma patients prescribed a GLP1 have improved asthma and weight loss outcomes?","year":2024,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Markham Stouffville Hospital","funders":"","keywords":"Asthma; Weight loss; Computer science; Medicine; Internal medicine; Obesity","score_opus":0.008430344764406796,"score_gpt":0.2509201155141678,"score_spread":0.24248977074976102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404098512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95292497,0.00045465457,0.000046911766,0.001193966,0.00040798716,0.0008479314,0.000018339726,0.00027904537,0.043826167],"genre_scores_gemma":[0.97146094,0.000061054154,0.00056611834,0.00045625324,0.00007870755,0.000046248715,0.000073395386,0.000042130934,0.027215172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986311,0.000011037592,0.00028292727,0.00044924626,0.00025600614,0.00036964336],"domain_scores_gemma":[0.99940526,0.000054449323,0.00004765663,0.00027840585,0.00004739217,0.00016680353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012021605,0.0002671266,0.0003250916,0.00015892161,0.0000535085,0.00017138588,0.000065346736,0.00007826519,0.0005691736],"category_scores_gemma":[0.000020047539,0.00018125061,0.00012730533,0.00009648847,0.00004242347,0.0002352241,0.0001249769,0.00013614014,0.0001426278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025378607,0.0011730978,0.54339755,0.0010717589,0.0022503273,0.00059898384,0.0009029805,0.0000018829106,0.00074345595,0.0022245976,0.011000432,0.43638116],"study_design_scores_gemma":[0.004286804,0.00059303537,0.88293564,0.00034988,0.0002851086,0.000005836221,0.000055129352,0.0016600052,0.0006147194,0.0002855354,0.108594246,0.00033403962],"about_ca_topic_score_codex":0.00010601087,"about_ca_topic_score_gemma":0.000030596693,"teacher_disagreement_score":0.4360471,"about_ca_system_score_codex":0.00007890711,"about_ca_system_score_gemma":0.000020833158,"threshold_uncertainty_score":0.7391185},"labels":[],"label_agreement":null},{"id":"W4404118009","doi":"10.1016/j.kint.2024.10.015","title":"Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Health Services Authority; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Michael Smith Health Research BC; Kidney Foundation of Canada","keywords":"Immunosuppression; Medicine; Intensive care medicine; Internal medicine","score_opus":0.02386294879966719,"score_gpt":0.31938623586837556,"score_spread":0.29552328706870834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404118009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198836,0.0032746217,0.0007038611,0.0009244539,0.000653215,0.0010844879,0.00067210937,0.000064974825,0.0006339379],"genre_scores_gemma":[0.9944444,0.00021190238,0.00019898827,0.000059971524,0.00009588365,0.00029338253,0.0011582754,0.000020974192,0.003516263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988888,0.000052543135,0.00016741482,0.000202216,0.00056502817,0.00012399687],"domain_scores_gemma":[0.9994218,0.00013140893,0.00006833711,0.00020824277,0.000101471676,0.00006877165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001568221,0.0001298616,0.00020294072,0.00007291669,0.000059596325,0.000023822342,0.00009864567,0.000025120846,0.00010234409],"category_scores_gemma":[0.00030200699,0.0000661232,0.00035577806,0.00006988434,0.000026986232,0.000060548748,0.000043648157,0.0000500525,0.00000489465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017265339,0.004136129,0.5131218,0.0005928006,0.28147885,0.00006819072,0.0009420111,0.00135874,0.002226485,0.0013386697,0.021604596,0.1714052],"study_design_scores_gemma":[0.017437447,0.0035053252,0.816986,0.0046468396,0.04914146,0.000006531955,0.00016304222,0.064275,0.005280385,0.0019744586,0.036174875,0.00040860564],"about_ca_topic_score_codex":0.000019462277,"about_ca_topic_score_gemma":4.6753746e-7,"teacher_disagreement_score":0.30386424,"about_ca_system_score_codex":0.00016413553,"about_ca_system_score_gemma":0.00005506111,"threshold_uncertainty_score":0.2696426},"labels":[],"label_agreement":null},{"id":"W4404144841","doi":"10.1080/03007995.2024.2418993","title":"Dapagliflozin or saxagliptin in pediatric type 2 diabetes: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group","funders":"","keywords":"Medicine; Dapagliflozin; Saxagliptin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Pediatrics; Endocrinology; Sitagliptin","score_opus":0.07953331488767264,"score_gpt":0.43195344674160274,"score_spread":0.3524201318539301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404144841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80390275,0.18172123,0.000015518171,0.005679936,0.0021620907,0.0011032344,0.000014648365,0.00016360833,0.0052369814],"genre_scores_gemma":[0.8726191,0.119936384,0.000081890306,0.00019067094,0.0025375104,0.00019031111,0.00041823433,0.000049775754,0.003976125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734086,0.00013005584,0.00023733874,0.00039254772,0.001313068,0.0005861053],"domain_scores_gemma":[0.9986317,0.00059875334,0.000012060818,0.00018432278,0.00006810215,0.0005050554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002052571,0.0001359073,0.00023444825,0.00060098927,0.00004884089,0.000067844776,0.00011849068,0.00010133867,0.00062098156],"category_scores_gemma":[0.0018385617,0.000089358466,0.000039306353,0.0009804902,0.00012139148,0.0000872688,0.00020636927,0.00066485425,0.00019895047],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028162744,0.0007142373,0.035317134,0.0034892228,0.00005637144,0.00046371584,0.0005423533,7.4021195e-8,0.000025312986,0.0009871268,0.19821143,0.7599114],"study_design_scores_gemma":[0.0037355898,0.0030212426,0.031127222,0.0056353696,0.000065239095,0.000007733889,0.00049816445,0.004081391,0.00008675575,0.00052630773,0.9508985,0.00031646073],"about_ca_topic_score_codex":0.000017507791,"about_ca_topic_score_gemma":0.000036136586,"teacher_disagreement_score":0.7595949,"about_ca_system_score_codex":0.00013689014,"about_ca_system_score_gemma":0.00047003198,"threshold_uncertainty_score":0.6799312},"labels":[],"label_agreement":null},{"id":"W4404147090","doi":"10.3390/cells13221842","title":"Does Incretin Agonism Have Sustainable Efficacy?","year":2024,"lang":"en","type":"review","venue":"Cells","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; McGill University; University of Toronto","funders":"","keywords":"Agonism; Incretin; Exenatide; Pharmacology; Medicine; Diabetes mellitus; Type 2 diabetes; Political science; Endocrinology","score_opus":0.020128898281232384,"score_gpt":0.3129390724723298,"score_spread":0.29281017419109745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404147090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000041079966,0.9262826,0.000001324688,0.000110399844,0.0006489654,0.0019165642,0.000013230729,0.00015602342,0.07086682],"genre_scores_gemma":[0.0000038916637,0.6254523,0.000060625534,0.000061015693,0.00027628965,0.0001134087,0.00019463604,0.00006417354,0.3737737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840915,0.00004485784,0.00036074017,0.00049565546,0.00020820617,0.0004813683],"domain_scores_gemma":[0.9990831,0.00008103256,0.00010210649,0.00055097474,0.00003666467,0.00014613394],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019761149,0.00044642168,0.001408571,0.00026580837,0.000045183802,0.00010007912,0.00015394401,0.00021615809,0.0004331962],"category_scores_gemma":[0.000021224687,0.00021475693,0.00062092993,0.00019092749,0.000050195624,0.000028930412,0.00025799058,0.00030764737,0.0036077725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000046889736,0.00017299934,8.488637e-7,0.11154621,0.0011175293,0.0015484054,0.00006885706,3.6787785e-8,6.489066e-7,0.001364874,0.11188844,0.7722865],"study_design_scores_gemma":[0.00030057522,0.0001070709,4.394454e-7,0.010618263,0.009857849,0.0000030287429,0.00009389241,7.2159673e-7,0.000025505135,0.0000794643,0.97867364,0.00023957764],"about_ca_topic_score_codex":0.000017636392,"about_ca_topic_score_gemma":6.2226303e-7,"teacher_disagreement_score":0.86678517,"about_ca_system_score_codex":0.00027133172,"about_ca_system_score_gemma":0.00016681904,"threshold_uncertainty_score":0.997168},"labels":[],"label_agreement":null},{"id":"W4404202498","doi":"10.1007/s13300-024-01659-7","title":"Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6","year":2024,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"Novo Nordisk","keywords":"Semaglutide; Post-hoc analysis; Medicine; Baseline (sea); Diabetes mellitus; Post hoc; Internal medicine; Type 2 diabetes; Endocrinology; Liraglutide","score_opus":0.005565111311902527,"score_gpt":0.23040575488444723,"score_spread":0.2248406435725447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404202498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87818915,0.119771324,0.00011351993,0.0010737262,0.00003045102,0.00044810784,0.000095342584,0.000072075,0.00020630483],"genre_scores_gemma":[0.9861527,0.010594753,0.00053759007,0.00074962666,0.000025934261,0.00004644834,0.00033731762,0.000039883205,0.0015157345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987932,0.000065764405,0.00022725819,0.00036089332,0.0002881978,0.0002646948],"domain_scores_gemma":[0.99927014,0.00014756504,0.000035042434,0.00035891164,0.00007730857,0.00011103007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004641511,0.00024028745,0.0008989897,0.00038638467,0.00004080207,0.000049100265,0.000047087018,0.000048155405,0.0000624647],"category_scores_gemma":[0.000017122195,0.00015201214,0.0003056274,0.00063662126,0.000112316135,0.00007534215,0.00003338865,0.000075022486,0.0000016657497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034936896,0.00036087053,0.38353762,0.00042415436,0.13363431,0.00009447752,0.0008100037,0.00005679197,0.0026888957,0.0009254469,0.0011863938,0.47593167],"study_design_scores_gemma":[0.0077755502,0.0015997638,0.677185,0.00017489192,0.035737913,0.0000017156646,0.00051124516,0.0021900772,0.0043525947,0.00008416783,0.2697599,0.00062716077],"about_ca_topic_score_codex":0.000053680084,"about_ca_topic_score_gemma":0.000013722834,"teacher_disagreement_score":0.4753045,"about_ca_system_score_codex":0.000020599244,"about_ca_system_score_gemma":0.000019663557,"threshold_uncertainty_score":0.61988753},"labels":[],"label_agreement":null},{"id":"W4404292283","doi":"10.1101/2024.11.11.24317112","title":"Potential Lives Saved Through Widespread Global Availability of GLP-1 Receptor Agonists: A Modeling Study","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk; Eli Lilly and Company","keywords":"Glucagon-like peptide 1 receptor; Receptor; Business; Agonist; Medicine; Internal medicine","score_opus":0.03168731993103867,"score_gpt":0.3066135868912102,"score_spread":0.27492626696017153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404292283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831018,0.0026697812,0.0004495897,0.0006061253,0.002111363,0.0027265274,0.00013472364,0.0002872601,0.007912863],"genre_scores_gemma":[0.9948399,0.00026939978,0.0026478556,0.00007465973,0.00030568967,0.0002398092,0.00015524657,0.000054857996,0.001412568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967967,0.00014699873,0.00083723216,0.0011138438,0.00069679273,0.0004084091],"domain_scores_gemma":[0.9981502,0.00003921687,0.00021375866,0.0012594634,0.00020069204,0.00013662569],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005525155,0.00053527375,0.0010867387,0.000096269985,0.00005602619,0.00007967557,0.00034083924,0.00020114018,0.00033937488],"category_scores_gemma":[0.00016183926,0.00044401502,0.0004919337,0.000238172,0.00012950403,0.000056033557,0.0017085717,0.0004961852,0.00023135483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043108324,0.03238185,0.81997657,0.02583814,0.031648267,0.0019342075,0.019593993,0.00647574,0.0063335323,0.0024765006,0.011622651,0.037407707],"study_design_scores_gemma":[0.05464451,0.027768109,0.2407583,0.037275273,0.10521437,0.00009540188,0.044409968,0.21596575,0.017314294,0.22372492,0.020401226,0.012427892],"about_ca_topic_score_codex":0.00058582344,"about_ca_topic_score_gemma":0.00006201497,"teacher_disagreement_score":0.57921827,"about_ca_system_score_codex":0.00039317986,"about_ca_system_score_gemma":0.00022358703,"threshold_uncertainty_score":0.99980116},"labels":[],"label_agreement":null},{"id":"W4404338793","doi":"10.1007/s13300-024-01668-6","title":"Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies","year":2024,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Pooled analysis; Prospective cohort study; Meta-analysis; Pediatrics; Internal medicine; Endocrinology","score_opus":0.061546688346997835,"score_gpt":0.3677193614407986,"score_spread":0.30617267309380075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404338793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264014,0.0053188032,5.4199455e-7,0.00035905308,0.00033108643,0.00086598325,0.000054291548,0.00013736733,0.00029271882],"genre_scores_gemma":[0.9945446,0.0035991366,0.00040898548,0.0004362012,0.00004109463,0.000108803346,0.00015758118,0.000042521177,0.00066104415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755585,0.00015469131,0.0009569924,0.0006286269,0.00033153628,0.00037232475],"domain_scores_gemma":[0.99819183,0.00086011854,0.0001959926,0.0004617585,0.00017364064,0.000116681025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044269965,0.00032454845,0.0016034266,0.0007648641,0.000032280765,0.000050301787,0.00007258848,0.00009281889,0.000073479045],"category_scores_gemma":[0.00021269229,0.00023024173,0.00035250478,0.0015645949,0.00018750664,0.00016018939,0.000084437735,0.00018200674,0.000006589209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017189462,0.0004991817,0.92608356,0.000050097344,0.034445494,0.000045787736,0.0012266247,0.000009873729,0.00033100296,0.00008894696,0.0004494737,0.036598045],"study_design_scores_gemma":[0.0023446023,0.00070120057,0.98861665,0.00022680867,0.004933406,2.6371856e-8,0.00024542565,0.00091349066,0.0007373542,0.00043131725,0.00063516764,0.00021458189],"about_ca_topic_score_codex":0.00049952645,"about_ca_topic_score_gemma":0.00083898625,"teacher_disagreement_score":0.06253304,"about_ca_system_score_codex":0.00009203711,"about_ca_system_score_gemma":0.000053504802,"threshold_uncertainty_score":0.9388985},"labels":[],"label_agreement":null},{"id":"W4404346455","doi":"10.1001/jamanetworkopen.2024.46641","title":"Rhabdomyolysis and Sodium-Glucose–Linked Transport Inhibitors in Patients Taking Statins","year":2024,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; St Joseph's Health Care; St. Michael's Hospital; Western University; London Health Sciences Centre; Lawson Health Research Institute","funders":"","keywords":"Rhabdomyolysis; Cotransporter; Sodium; Medicine; Glucose transporter; Pharmacology; Internal medicine; Endocrinology; Chemistry; Insulin","score_opus":0.0142396465660398,"score_gpt":0.26491146004122545,"score_spread":0.25067181347518563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404346455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97616374,0.0010770188,0.000025572786,0.0012430919,0.0003100161,0.0013090214,0.00000733241,0.00006722976,0.019796954],"genre_scores_gemma":[0.99570286,0.00024118464,0.0010349756,0.0005597211,0.00023645065,0.00010249196,0.00019559506,0.000033588516,0.0018931403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987513,0.000037504476,0.00031283035,0.00036356944,0.00020369695,0.00033111894],"domain_scores_gemma":[0.99955904,0.000061522995,0.000060110022,0.00019039436,0.000024259029,0.00010467834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039816697,0.00017217436,0.00033160808,0.00011992491,0.00005529872,0.00017686021,0.000117243086,0.00007186328,0.00014927085],"category_scores_gemma":[0.000015368569,0.00014314488,0.00006129625,0.00043017516,0.000030129477,0.0003138047,0.00013221936,0.00016397686,0.000032949596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021900678,0.000197149,0.72905046,0.00014048594,0.00027146743,0.00013492996,0.00068476173,0.000050607556,0.0000071891186,0.000460863,0.006471968,0.2623111],"study_design_scores_gemma":[0.0038253088,0.0003308949,0.94323754,0.0011353433,0.00031125662,6.140968e-7,0.00010618947,0.000995151,0.000038764618,0.00025801614,0.04957102,0.00018992479],"about_ca_topic_score_codex":0.00016346335,"about_ca_topic_score_gemma":0.0001371909,"teacher_disagreement_score":0.26212117,"about_ca_system_score_codex":0.00008935124,"about_ca_system_score_gemma":0.000037441343,"threshold_uncertainty_score":0.5837279},"labels":[],"label_agreement":null},{"id":"W4404363691","doi":"10.1161/circ.150.suppl_1.4140060","title":"Abstract 4140060: Impact of SGLT2 Inhibitors on Mortality Risk in Type 2 Diabetes Mellitus and Coronary Artery Disease: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Coronary artery disease; Type 2 Diabetes Mellitus; Internal medicine; Cardiology; Diabetes mellitus; Disease; Type 2 diabetes; Endocrinology","score_opus":0.06904751443853402,"score_gpt":0.3568687248895678,"score_spread":0.28782121045103376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404363691","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007847267,0.9886195,4.336169e-7,0.000015060888,0.000029224935,0.003269136,0.00014803743,0.00002243414,0.000048880796],"genre_scores_gemma":[0.17445365,0.82466954,0.000003055953,0.00001801796,0.000012788926,0.0001935486,0.00060001406,0.000023811914,0.00002559122],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9979852,0.00019655783,0.00094422325,0.00044610657,0.00027193138,0.00015601194],"domain_scores_gemma":[0.99860746,0.00015140804,0.0005548545,0.0005186473,0.00004417158,0.00012345868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006213797,0.00039695378,0.0045396923,0.0004940058,0.000018381184,0.000029723313,0.000043123433,0.00009718145,0.00007259744],"category_scores_gemma":[0.00011297003,0.00023649988,0.0015368961,0.00069490523,0.000037139245,0.00007284495,0.00003284939,0.00015633745,0.000017276518],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000026898606,0.000105060826,0.00642336,0.82917047,0.15871726,0.000028346538,0.0000123484915,0.0000071929157,5.7214013e-8,0.000012023718,0.000045169792,0.0054760487],"study_design_scores_gemma":[0.00008854028,0.00004838297,0.09051937,0.056163307,0.85281914,9.199361e-7,0.0000016315049,0.000044387973,2.561227e-8,0.000040236246,0.00012202131,0.0001520591],"about_ca_topic_score_codex":0.000020403526,"about_ca_topic_score_gemma":0.0000050442072,"teacher_disagreement_score":0.77300715,"about_ca_system_score_codex":0.00016604323,"about_ca_system_score_gemma":0.000059999507,"threshold_uncertainty_score":0.96441853},"labels":[],"label_agreement":null},{"id":"W4404367789","doi":"10.1016/j.jcjd.2024.08.003","title":"The User’s Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; LMC Diabetes & Endocrinology (Canada); University of Saskatchewan; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Intensive care medicine; Diabetes mellitus; Diabetes management; Endocrinology","score_opus":0.009781428055507612,"score_gpt":0.2641083192854296,"score_spread":0.25432689122992197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404367789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95882905,0.020925626,0.0000014042294,0.01287638,0.001890012,0.00058567873,0.000016038723,0.000012189683,0.0048636105],"genre_scores_gemma":[0.9939566,0.0007293364,0.00022022481,0.0014029604,0.0001605913,0.000029432013,0.0000064125356,0.000027266495,0.0034671673],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984628,0.000053462707,0.0005213145,0.00017354343,0.00024805797,0.0005408407],"domain_scores_gemma":[0.9990048,0.0001394789,0.0001034472,0.0002671829,0.0001325751,0.00035251366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000661687,0.00018152979,0.00030464138,0.00039464977,0.00008978064,0.000092475835,0.000405183,0.000042158637,0.00017878537],"category_scores_gemma":[0.000060255326,0.000100153055,0.00015103816,0.0007306748,0.00010009646,0.00010111833,0.000052760694,0.0002342758,0.0000848832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013325486,0.00011725844,0.20094779,0.0011503769,0.0035038525,0.0005682957,0.000635142,0.00037394368,0.0003428356,0.004075342,0.6331155,0.1550364],"study_design_scores_gemma":[0.0014713854,0.0010557128,0.03683157,0.0023523353,0.00081033324,0.000002112788,0.0007006364,0.00057751394,0.0007954897,0.00034921977,0.9548638,0.00018991175],"about_ca_topic_score_codex":0.00012456073,"about_ca_topic_score_gemma":0.002239188,"teacher_disagreement_score":0.3217483,"about_ca_system_score_codex":0.00028091547,"about_ca_system_score_gemma":0.00030401745,"threshold_uncertainty_score":0.40841228},"labels":[],"label_agreement":null},{"id":"W4404367805","doi":"10.1016/j.jcjd.2024.08.002","title":"Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Diabetes management; Diabetes mellitus; Intensive care medicine; Endocrinology","score_opus":0.010339606271805907,"score_gpt":0.24936533504286565,"score_spread":0.23902572877105974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404367805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97053504,0.020535301,6.8411526e-7,0.0010771661,0.0013819843,0.00029864028,0.000016179047,0.00001510725,0.0061399057],"genre_scores_gemma":[0.99766237,0.0005056997,0.0003686577,0.00038547307,0.00010234565,0.000010242139,0.000016033386,0.000028157863,0.0009210491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985825,0.000030076219,0.0005026341,0.0001897789,0.00020410611,0.00049089704],"domain_scores_gemma":[0.9991717,0.000048668047,0.00011015878,0.00016129784,0.00010870537,0.00039951634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029635147,0.00019047926,0.00043450555,0.0008854808,0.000025065845,0.00003946086,0.00018658944,0.00006385799,0.00065866526],"category_scores_gemma":[0.000021835376,0.00015569372,0.00016455831,0.0006826849,0.00009033671,0.00016146104,0.000026138705,0.0002288858,0.000062802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013764965,0.000308035,0.7962391,0.0058738883,0.004316575,0.0021701748,0.00049323187,0.00014656482,0.0011195533,0.0027031656,0.060999185,0.1254929],"study_design_scores_gemma":[0.02242419,0.01159126,0.4470719,0.04045993,0.008597666,0.00002450609,0.0023453413,0.00798599,0.014159853,0.006011964,0.4373251,0.0020022995],"about_ca_topic_score_codex":0.00006491224,"about_ca_topic_score_gemma":0.00032174814,"teacher_disagreement_score":0.3763259,"about_ca_system_score_codex":0.00027293983,"about_ca_system_score_gemma":0.00031005216,"threshold_uncertainty_score":0.7211923},"labels":[],"label_agreement":null},{"id":"W4404472753","doi":"10.1016/j.jacc.2024.11.008","title":"Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity","year":2024,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Cardiology; Internal medicine; Obesity; Artery; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.005475545515518712,"score_gpt":0.2015581314824367,"score_spread":0.196082585966918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404472753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946942,0.0038561013,0.000016880462,0.00031202225,0.00032067744,0.00025712332,0.000018027771,0.0000042630827,0.0005207484],"genre_scores_gemma":[0.99900836,0.0001474494,0.0002314144,0.000083192455,0.00003880646,0.0000032363882,8.0402606e-7,0.000010184254,0.00047652787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902946,0.00012761651,0.00032851278,0.000117093456,0.00026772416,0.00012959215],"domain_scores_gemma":[0.99925894,0.00011130103,0.00024036286,0.00024831924,0.00009586856,0.00004521581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028375987,0.000116750554,0.0010865214,0.00019561329,0.000009128502,0.0000012282234,0.000095716256,0.000024258617,0.0000015128771],"category_scores_gemma":[0.000040450985,0.00006533257,0.0004038101,0.00014069058,0.00039282744,0.00004245567,0.00006637844,0.00013013938,2.519646e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004305306,0.00008967956,0.98792475,0.00011917329,0.0053050146,0.0003043569,0.000043174005,0.000048260703,0.00013489809,0.000035360925,0.0025010551,0.0030637528],"study_design_scores_gemma":[0.001704998,0.00173983,0.988339,0.00010676918,0.0013772183,0.000104810155,0.00011265947,0.00000902544,0.000028013372,0.000032948952,0.0063857636,0.00005893015],"about_ca_topic_score_codex":0.000015222648,"about_ca_topic_score_gemma":0.000003115965,"teacher_disagreement_score":0.004314229,"about_ca_system_score_codex":0.00022845606,"about_ca_system_score_gemma":0.00015243488,"threshold_uncertainty_score":0.2664185},"labels":[],"label_agreement":null},{"id":"W4404538309","doi":"10.1016/j.jcjd.2024.09.141","title":"Use of SGLT-2 Inhibitors in Adults (Age ≥ 65) With Type 2 Diabetes and Cardiovascular Disease Is Lower in Alberta and Manitoba Than Ontario: Cross-Sectional Study of Drug-funding Policies","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Type 2 diabetes; Cross-sectional study; Disease; Diabetes mellitus; Environmental health; Drug; Gerontology; Family medicine; Internal medicine; Pharmacology; Endocrinology; Pathology","score_opus":0.01551109419918711,"score_gpt":0.22335679758236873,"score_spread":0.20784570338318162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949593,0.004285076,4.2210406e-8,0.00008451001,0.00021079103,0.00037120635,0.000016674874,0.000002934101,0.00006946114],"genre_scores_gemma":[0.99963284,0.000037440343,0.000021656126,0.00004393882,0.000053527838,0.0000074036316,0.000006465415,0.000023023516,0.00017373366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987314,0.000040757597,0.00042157777,0.00022057639,0.00027016702,0.00031555115],"domain_scores_gemma":[0.9991281,0.00011878437,0.0000876178,0.00017954006,0.00010122857,0.00038475465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027228374,0.0001819545,0.00048779152,0.0008349167,0.00003520993,0.000094318275,0.00006643355,0.000041587136,0.000018745792],"category_scores_gemma":[0.000075176475,0.00014562,0.00010832777,0.00033956053,0.00015236063,0.00029801836,0.000028261133,0.00017562661,4.4486404e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045507644,0.00013384492,0.99407434,0.00034140225,0.0010695991,0.00018328462,0.0033331942,0.0000713422,0.00001824851,0.000016567239,0.000110462715,0.0006021959],"study_design_scores_gemma":[0.0016201481,0.00083111186,0.9939285,0.0015850666,0.00041196958,0.0000013898634,0.00085167045,0.000036405905,0.00009845655,0.00003132286,0.0004779795,0.0001260042],"about_ca_topic_score_codex":0.17009857,"about_ca_topic_score_gemma":0.7072163,"teacher_disagreement_score":0.5371177,"about_ca_system_score_codex":0.00022112839,"about_ca_system_score_gemma":0.00035466775,"threshold_uncertainty_score":0.8354278},"labels":[],"label_agreement":null},{"id":"W4404538582","doi":"10.1016/j.jcjd.2024.09.100","title":"Patient and Physician Perspectives on the Use of SGLT Inhibitors in Patients Living With Type 1 Diabetes","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton; Toronto Public Health; Calgary Laboratory Services","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Family medicine; Endocrinology","score_opus":0.010371468598808742,"score_gpt":0.1941644139910736,"score_spread":0.18379294539226484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965614,0.0021964416,9.499874e-8,0.00049327343,0.00015086892,0.00020979576,0.0000074837276,0.0000043243103,0.0003763296],"genre_scores_gemma":[0.99952716,0.000021074527,0.000047614456,0.00028891696,0.000051724757,0.0000035639139,0.0000019553559,0.000018762375,0.00003925681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999231,0.0000384828,0.00020444507,0.000120188844,0.00016906101,0.00023683553],"domain_scores_gemma":[0.99927133,0.00021717709,0.000088217916,0.000111805486,0.00013296219,0.00017848596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010762727,0.00012623901,0.0002333067,0.00038258114,0.00003734643,0.00006288309,0.00004587742,0.00002680265,0.000018886303],"category_scores_gemma":[0.00014803612,0.000074378564,0.000054119875,0.00028732256,0.00011198972,0.00016643204,0.000011203432,0.00014926853,0.0000020333634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054717702,0.0001040084,0.97463137,0.00008118897,0.00031268934,0.000010179122,0.0026107638,0.000019885065,0.00005599446,0.00028262744,0.0019936068,0.01989222],"study_design_scores_gemma":[0.0005136004,0.004051997,0.9836239,0.0044063446,0.00024491985,1.9235908e-7,0.0022143736,0.00011171691,0.00075964513,0.000047267884,0.0038785865,0.00014742347],"about_ca_topic_score_codex":0.00008134092,"about_ca_topic_score_gemma":0.000383992,"teacher_disagreement_score":0.019744795,"about_ca_system_score_codex":0.00013600325,"about_ca_system_score_gemma":0.00016373328,"threshold_uncertainty_score":0.30330697},"labels":[],"label_agreement":null},{"id":"W4404538731","doi":"10.1016/j.jcjd.2024.09.022","title":"Subcutaneous Weekly Semaglutide as Adjunct to Automated Insulin Delivery: A Double-blinded, Randomized, Crossover Trial","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"MPB Technologies & Communications (Canada); AS Composite (Canada)","funders":"","keywords":"Medicine; Double blinded; Crossover study; Semaglutide; Adjunct; Randomized controlled trial; Blinded study; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes; Placebo; Alternative medicine","score_opus":0.0169052335152223,"score_gpt":0.2703839746561614,"score_spread":0.25347874114093905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980459,0.0066868025,0.000006807807,0.004212341,0.0020697853,0.0016747264,0.000032434364,0.00012435738,0.004733748],"genre_scores_gemma":[0.9933212,0.00003752363,0.0003163126,0.0016363586,0.0006523302,0.00004850494,0.000019863304,0.000063703024,0.0039042386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976719,0.0000857049,0.0007847635,0.00029790084,0.00042735165,0.0007323767],"domain_scores_gemma":[0.9975243,0.00028566635,0.00016236398,0.00026948197,0.00028691476,0.0014712779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000743079,0.0003326002,0.0010598573,0.0011359634,0.0001124927,0.0003437267,0.00022591959,0.00013697652,0.00060295116],"category_scores_gemma":[0.0003430157,0.00025538213,0.0005809919,0.00061082916,0.00014087,0.00017726255,0.000028644887,0.00031609202,0.00046310737],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61238354,0.00056931435,0.0035369124,0.00086085725,0.012995241,0.014913418,0.002741313,0.0005582467,0.0010458915,0.003731275,0.28761733,0.059046675],"study_design_scores_gemma":[0.88278127,0.004192802,0.000401813,0.0014426826,0.0028676542,0.00012804334,0.00016717699,0.001506028,0.001080657,0.0005428645,0.1043689,0.0005200883],"about_ca_topic_score_codex":0.0013872191,"about_ca_topic_score_gemma":0.002344513,"teacher_disagreement_score":0.27039775,"about_ca_system_score_codex":0.00050824275,"about_ca_system_score_gemma":0.0020070893,"threshold_uncertainty_score":0.99998987},"labels":[],"label_agreement":null},{"id":"W4404538829","doi":"10.1016/j.jcjd.2024.09.071","title":"Glucagon-like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Observational study; Agonist; Pharmacology; Receptor; Internal medicine","score_opus":0.03699018487905247,"score_gpt":0.26496008371095486,"score_spread":0.22796989883190238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933946,0.0020216221,9.816022e-7,0.00251855,0.0011971932,0.0005212146,0.000025579853,0.000017388285,0.0003028496],"genre_scores_gemma":[0.9961163,0.000011683538,0.00046745472,0.00042550667,0.0002140184,0.000017449156,0.000035266145,0.00003254834,0.0026797778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986946,0.00004120211,0.00042280354,0.00019270714,0.00024072564,0.00040793556],"domain_scores_gemma":[0.99894875,0.00012905193,0.000085236126,0.00016476255,0.0001432116,0.0005289918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026507018,0.0001753397,0.00032527454,0.000559599,0.000055170443,0.0002076317,0.00012459401,0.000047826783,0.00023157724],"category_scores_gemma":[0.00020223223,0.00014863141,0.00014277098,0.00037306652,0.00005202493,0.00039829587,0.00001411232,0.00022530065,0.000056938814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005486607,0.0003278641,0.9560674,0.00007641331,0.00047975598,0.00037607923,0.001121187,0.00001578129,0.000059772763,0.00010935213,0.037833836,0.0035270697],"study_design_scores_gemma":[0.0018304464,0.0012206063,0.87527037,0.00075425307,0.00036762533,0.0000011869912,0.0013787153,0.0002034214,0.000063105384,0.00004161878,0.11868169,0.00018695717],"about_ca_topic_score_codex":0.0008562307,"about_ca_topic_score_gemma":0.014641982,"teacher_disagreement_score":0.08084785,"about_ca_system_score_codex":0.00046053872,"about_ca_system_score_gemma":0.0007841425,"threshold_uncertainty_score":0.81705695},"labels":[],"label_agreement":null},{"id":"W4404538837","doi":"10.1016/j.jcjd.2024.09.026","title":"Effect of Semaglutide on Kidney Outcomes in People With Overweight or Obesity and Established Cardiovascular Disease in the SELECT Trial","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Semaglutide; Medicine; Overweight; Obesity; Disease; Internal medicine; Gerontology; Physical therapy; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.005552854712490521,"score_gpt":0.21822681912876588,"score_spread":0.21267396441627534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542785,0.0025682491,4.6942606e-7,0.0009212274,0.0001473733,0.00068414083,0.000018153667,0.000003986493,0.00022856124],"genre_scores_gemma":[0.99948674,0.000024767289,0.000013725524,0.0002640011,0.0000656446,0.00002028271,0.000005954602,0.0000142300205,0.00010465886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988822,0.00018697283,0.0002396549,0.00014526657,0.00027575786,0.00027018055],"domain_scores_gemma":[0.9989229,0.000386639,0.000048147867,0.00019849738,0.000028966058,0.00041484908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000977553,0.00015486118,0.00057735207,0.00050063827,0.000026583195,0.00005689731,0.00009488366,0.0000313677,0.000023826686],"category_scores_gemma":[0.00044182714,0.00007574114,0.00018572106,0.00041660824,0.00004992663,0.00009570988,0.000007001337,0.00018195799,0.0000010130636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089195586,0.000082883256,0.992272,0.0004850829,0.00090365915,0.00060483377,0.00033503177,0.00004420021,0.0000033102422,0.000040409923,0.0010361271,0.0033004996],"study_design_scores_gemma":[0.027778981,0.006848135,0.95573556,0.0018822413,0.0022399742,0.0000043836294,0.0000794486,0.00018089461,0.00022806223,0.000047795023,0.004801603,0.0001728937],"about_ca_topic_score_codex":0.0010759438,"about_ca_topic_score_gemma":0.005987882,"teacher_disagreement_score":0.036536418,"about_ca_system_score_codex":0.00015248818,"about_ca_system_score_gemma":0.0007198403,"threshold_uncertainty_score":0.33413786},"labels":[],"label_agreement":null},{"id":"W4404538977","doi":"10.1016/j.jcjd.2024.09.039","title":"Association Between Glucagon-Like Peptide 1 Receptor Agonists and Dementia: A Population-based Cohort Study of Adults Aged 40 Years and Older in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Cohort; Dementia; Association (psychology); Gerontology; Glucagon-like peptide 1 receptor; Cohort study; Internal medicine; Oncology; Receptor; Agonist; Disease","score_opus":0.0061928367669284055,"score_gpt":0.20574119739735808,"score_spread":0.19954836063042966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981212,0.00083300564,2.783984e-7,0.00027918172,0.000240852,0.00044271688,0.00002097517,0.0000036367576,0.000058146514],"genre_scores_gemma":[0.99944454,0.0000053107706,0.00006549698,0.00009356641,0.000041153246,0.00000925012,0.0000522561,0.0000142303015,0.00027419845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895686,0.000045283174,0.00036443854,0.00014858553,0.00025094787,0.00023388983],"domain_scores_gemma":[0.99926776,0.00010823285,0.0001851307,0.000081401435,0.000067300265,0.00029020582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000337279,0.00011517286,0.00035204642,0.00033108165,0.000038413695,0.000046512607,0.000044999084,0.00004737909,0.00008139575],"category_scores_gemma":[0.00006993577,0.000110603796,0.00003590753,0.00014957164,0.000014367374,0.00008806916,0.0000079726715,0.00016769292,3.8478464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000049910973,0.00003566939,0.99361295,0.00008297764,0.0009922656,0.000045161556,0.00059438235,0.0000067232554,0.000007481529,0.0000012055318,0.0027871658,0.0018290164],"study_design_scores_gemma":[0.001625548,0.00033653402,0.9953739,0.00050542376,0.0007916676,2.4101365e-7,0.00027233307,0.000021611628,0.000018288607,0.0000062087774,0.0009611331,0.000087101966],"about_ca_topic_score_codex":0.91433126,"about_ca_topic_score_gemma":0.9976415,"teacher_disagreement_score":0.08331024,"about_ca_system_score_codex":0.0011291349,"about_ca_system_score_gemma":0.001172588,"threshold_uncertainty_score":0.45102918},"labels":[],"label_agreement":null},{"id":"W4404539015","doi":"10.1016/j.jcjd.2024.09.063","title":"Effectiveness and Safety of a Single-Pill Combination of Empagliflozin/Linagliptin in Individuals With Uncontrolled Type 2 Diabetes With CKD: A Single-Centre Outpatient Clinic Real-World Experience","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Empagliflozin; Linagliptin; Pill; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Nursing; Endocrinology","score_opus":0.01304124326376563,"score_gpt":0.24219615529545407,"score_spread":0.22915491203168845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404539015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960114,0.0020470386,0.000002575849,0.00026061814,0.0001775493,0.00079169514,0.000024216843,0.000009668855,0.0006752313],"genre_scores_gemma":[0.99947685,0.000023952747,0.00024996567,0.00004383646,0.000026263891,0.000015887943,0.000015243103,0.00003131188,0.00011669214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827075,0.00015112483,0.00065160077,0.00023500774,0.00031116777,0.00038034937],"domain_scores_gemma":[0.99829686,0.00049136276,0.0003756529,0.00017503716,0.00033442923,0.0003266361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060320983,0.00023396376,0.0008483971,0.0009535721,0.000037029175,0.0000436135,0.00010590443,0.00006662754,0.000046081794],"category_scores_gemma":[0.00017687088,0.00016669482,0.00008529307,0.0007969832,0.00023756297,0.00021327675,0.000017932633,0.00017453857,0.0000011447482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018899346,0.00037205248,0.98852307,0.0007688309,0.0007157869,0.000040446408,0.0022524889,0.00003289095,0.0011006205,0.00012321025,0.00006191337,0.0058196858],"study_design_scores_gemma":[0.012028053,0.013498459,0.94890845,0.011879262,0.0011368523,0.0000019642725,0.0015828459,0.00016274395,0.009588557,0.00015282519,0.0007253867,0.00033458343],"about_ca_topic_score_codex":0.00019699673,"about_ca_topic_score_gemma":0.00622407,"teacher_disagreement_score":0.039614614,"about_ca_system_score_codex":0.0003288116,"about_ca_system_score_gemma":0.00048555052,"threshold_uncertainty_score":0.67976177},"labels":[],"label_agreement":null},{"id":"W4404547136","doi":"10.1111/dom.16079","title":"Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Merck Canada; University of Toronto; Diabetes Canada; Banting and Best Diabetes Centre, University of Toronto; Heart and Stroke Foundation of Canada; Gilead Sciences; Department of Medicine, University of Toronto; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Kidney disease; Internal medicine; Renal function; Placebo; Diabetes mellitus; Erythropoietin; Type 2 diabetes; Anemia; Adverse effect; Clinical trial; Endocrinology; Pathology","score_opus":0.0033236803224837904,"score_gpt":0.19446411755313533,"score_spread":0.19114043723065155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404547136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96227926,0.025800237,8.487809e-8,0.010120225,0.00028463063,0.0012510702,0.00015089472,0.000046245546,0.00006733311],"genre_scores_gemma":[0.89818615,0.004161426,0.00008701761,0.093440875,0.0007782642,0.00016242266,0.001315634,0.00014910112,0.0017190907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810493,0.00008136269,0.0002582477,0.000673415,0.00036174824,0.00052031426],"domain_scores_gemma":[0.9990573,0.00015563985,0.00011478611,0.00031286277,0.00006090531,0.00029853886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012117854,0.0005176145,0.0010188137,0.00046752085,0.000049173483,0.000065233224,0.000076073935,0.000262861,0.0000142395265],"category_scores_gemma":[0.00009579141,0.0003813684,0.00007056755,0.00023407488,0.0002268704,0.00011440549,0.00015716467,0.0005161993,0.000005895969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007378133,0.00041273492,0.9067973,0.015277101,0.0008804379,0.00011892964,0.00009911002,2.984013e-7,0.000055976605,0.000106004816,0.07006961,0.0061087036],"study_design_scores_gemma":[0.0037582584,0.000684988,0.86116743,0.0024821372,0.0028669182,4.493601e-8,0.0000023845512,0.0000149836105,0.00064504123,0.0001447957,0.12786126,0.00037174186],"about_ca_topic_score_codex":0.00001078826,"about_ca_topic_score_gemma":0.0000034101436,"teacher_disagreement_score":0.08332065,"about_ca_system_score_codex":0.00005443834,"about_ca_system_score_gemma":0.000088548535,"threshold_uncertainty_score":0.9998638},"labels":[],"label_agreement":null},{"id":"W4404588359","doi":"10.1038/s41574-024-01066-9","title":"Expanding applications of therapies based on GLP1","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Intensive care medicine; Weight loss; Internal medicine; Obesity","score_opus":0.04573945168726931,"score_gpt":0.39909794415417826,"score_spread":0.353358492466909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404588359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.1687806e-7,0.9797835,0.00004462369,0.00026296472,0.00032707877,0.0039760903,0.000029153578,0.000094885785,0.015481623],"genre_scores_gemma":[0.000009676677,0.9928759,0.0008268818,0.00046038095,0.0002532205,0.0024412924,0.0003355285,0.00006329022,0.0027338844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980789,0.00014319574,0.0007222597,0.00053842244,0.00018039117,0.00033685646],"domain_scores_gemma":[0.9985295,0.00016380705,0.00034974437,0.0008560602,0.00003766374,0.00006320358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015224349,0.00050008885,0.0029455048,0.0006543978,0.000030705378,0.000011122577,0.00023111567,0.00041273987,0.00012775236],"category_scores_gemma":[0.00005372132,0.0002927658,0.0010885777,0.00056994165,0.000073123076,0.000015776519,0.00007541579,0.0010012285,0.0005472883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003840856,0.00013111644,0.0000024594185,0.058807608,0.0004959362,0.000029302762,0.0000055273426,2.060686e-8,2.574816e-7,0.0059087365,0.008089938,0.92652524],"study_design_scores_gemma":[0.0002347448,0.00020283958,8.7104553e-7,0.023694279,0.0067583034,0.000021197611,0.0000029965872,8.7468777e-7,0.000002968092,0.00007404869,0.9688371,0.00016982276],"about_ca_topic_score_codex":0.0000011496996,"about_ca_topic_score_gemma":7.388214e-7,"teacher_disagreement_score":0.9607471,"about_ca_system_score_codex":0.00014160457,"about_ca_system_score_gemma":0.00009941728,"threshold_uncertainty_score":0.99995244},"labels":[],"label_agreement":null},{"id":"W4404665637","doi":"10.1186/s13098-024-01525-3","title":"Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetology & Metabolic Syndrome","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Foundation for Innovation; Kidney Foundation of Canada; St. Michael's Hospital Foundation; St. Michael’s Hospital Foundation; Banting and Best Diabetes Centre, University of Toronto; Heart and Stroke Foundation of Canada","keywords":"Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Downregulation and upregulation; Glucagon receptor; Glucagon-like peptide 1 receptor; Kidney; Receptor; Type 2 diabetes; Glucagon; Mineralocorticoid receptor; Insulin; Biology","score_opus":0.006639344812884509,"score_gpt":0.22003436903015502,"score_spread":0.21339502421727052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404665637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97257084,0.020531982,0.0000018862804,0.004793716,0.0006356542,0.0009882036,0.00013516052,0.00008470169,0.00025788514],"genre_scores_gemma":[0.99531287,0.0016033294,0.0007932918,0.00030325502,0.00008899229,0.00020738106,0.0002547608,0.00005627397,0.0013798247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797404,0.0002147996,0.00045031874,0.00060544617,0.00026097026,0.00049441215],"domain_scores_gemma":[0.99897504,0.00022352589,0.00013491862,0.00040171144,0.000067390036,0.00019739615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044625535,0.00037054394,0.001206831,0.0003513729,0.00007216172,0.000041488096,0.00013368143,0.00018396937,0.00018660707],"category_scores_gemma":[0.00012534684,0.0002449936,0.00012085322,0.00068694266,0.00044586285,0.00017911004,0.00014761572,0.0002450063,0.000044823857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014378683,0.0003804805,0.7552615,0.0011939668,0.0026056678,0.000019840205,0.0013006388,0.0000032410228,0.19296852,0.0030558922,0.007313037,0.03575345],"study_design_scores_gemma":[0.0026080664,0.0006649219,0.8856351,0.0011398159,0.0015342579,0.0000184076,0.00018320998,0.00011017545,0.0394869,0.00016433063,0.06801443,0.00044041043],"about_ca_topic_score_codex":0.00009731223,"about_ca_topic_score_gemma":0.000012165611,"teacher_disagreement_score":0.15348162,"about_ca_system_score_codex":0.000050902527,"about_ca_system_score_gemma":0.00008672897,"threshold_uncertainty_score":0.99905485},"labels":[],"label_agreement":null},{"id":"W4404666716","doi":"10.1017/s1092852924000531","title":"A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain","year":2024,"lang":"en","type":"review","venue":"CNS Spectrums","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University Health Network; Queen's University; Brain and Cognition Discovery Foundation; University of Toronto","funders":"","keywords":"Psychotropic drug; Medicine; Pharmacology; Drug; Weight gain; Oncology; Internal medicine; Body weight","score_opus":0.02087433190477686,"score_gpt":0.31178476661722865,"score_spread":0.2909104347124518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404666716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004407551,0.97812575,3.4251988e-7,0.0016996778,0.0004956912,0.008369271,0.000015982077,0.00008995436,0.01115925],"genre_scores_gemma":[0.000059145033,0.99058133,0.00003865677,0.0003123412,0.00011890284,0.00087194087,0.0001745622,0.00010068574,0.007742456],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965739,0.00039478028,0.0016251667,0.00057790114,0.00043078233,0.00039744365],"domain_scores_gemma":[0.9976456,0.00046680996,0.0006595706,0.0011096471,0.00002451844,0.00009384771],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072626787,0.0006131681,0.003696741,0.00034202533,0.00004171979,0.000034090266,0.00035183755,0.00014724661,0.0004542006],"category_scores_gemma":[0.0003133636,0.00031402402,0.0010301939,0.0011140726,0.000079493286,0.00002878438,0.00007934462,0.000626147,0.0014411906],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038049625,0.00023937988,0.0000014025914,0.9562125,0.0015618092,0.00006344254,0.00008213944,4.0182655e-8,3.9569136e-7,0.0065340665,0.011485648,0.02381534],"study_design_scores_gemma":[0.00040086597,0.00013598538,0.000001888767,0.8322374,0.010564508,0.000010064562,0.000016218788,0.000003615289,0.0000029505477,0.000095009185,0.15631893,0.00021251965],"about_ca_topic_score_codex":0.000008596471,"about_ca_topic_score_gemma":0.0000048109955,"teacher_disagreement_score":0.14483328,"about_ca_system_score_codex":0.0004329386,"about_ca_system_score_gemma":0.000118834294,"threshold_uncertainty_score":0.99993116},"labels":[],"label_agreement":null},{"id":"W4404666942","doi":"10.1503/cmaj.240469","title":"Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Semaglutide; Albuminuria; Medicine; Type 2 diabetes; Renal function; Kidney disease; Internal medicine; Diabetes mellitus; Endocrinology; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Urology; Receptor; Agonist; Liraglutide","score_opus":0.004372911013529544,"score_gpt":0.22134094832158774,"score_spread":0.2169680373080582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404666942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749655,0.001027074,0.000014636462,0.020220345,0.0016358813,0.0007111767,0.00009772054,0.000050476116,0.0012771628],"genre_scores_gemma":[0.9864957,0.00013450734,0.00024455876,0.005757727,0.0014807407,0.000069397414,0.00060500426,0.000053967728,0.005158394],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982337,0.000042523352,0.0002843311,0.00020478138,0.0006980077,0.0005366544],"domain_scores_gemma":[0.99764353,0.000101335296,0.00007784048,0.00008850773,0.00019777706,0.0018910218],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004860408,0.00014635459,0.00022901213,0.00026288952,0.00012215947,0.00012639175,0.00008006996,0.0001180287,0.0012688342],"category_scores_gemma":[0.0008373817,0.00011306031,0.00009020037,0.00030206115,0.000023184512,0.0001349478,0.000009765111,0.00032125847,0.000098167286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052062645,0.00009721333,0.76346236,0.00015692804,0.0004206925,0.00010402001,0.000102188904,0.0000035826029,0.0000027608473,0.00007901083,0.18700841,0.048510797],"study_design_scores_gemma":[0.004299061,0.0007329872,0.2659492,0.0014567684,0.00029883784,0.0000010559995,0.000036661357,0.0011446595,0.000008021171,0.00005398118,0.72581524,0.00020356421],"about_ca_topic_score_codex":0.00017570514,"about_ca_topic_score_gemma":0.002044723,"teacher_disagreement_score":0.5388068,"about_ca_system_score_codex":0.0029425856,"about_ca_system_score_gemma":0.0037855515,"threshold_uncertainty_score":0.99964416},"labels":[],"label_agreement":null},{"id":"W4404685978","doi":"10.1016/s2213-8587(24)00271-7","title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","year":2024,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Meta-analysis; Glucagon-like peptide 1 receptor; Randomized controlled trial; MEDLINE; Semaglutide; Internal medicine; Type 2 diabetes; Disease; Diabetes mellitus; Intensive care medicine; Liraglutide; Agonist; Endocrinology; Receptor","score_opus":0.10556002575108235,"score_gpt":0.36492264539185565,"score_spread":0.2593626196407733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404685978","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004925988,0.98907965,0.0000021599665,0.00085557206,0.00034736216,0.008255055,0.00050533895,0.000073382085,0.00038885084],"genre_scores_gemma":[0.0009893967,0.99240845,0.000045251105,0.0006554989,0.0001670276,0.004368864,0.00037484168,0.00006899449,0.0009216548],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993292,0.0027625675,0.0018148734,0.0007600868,0.00051375414,0.00085673144],"domain_scores_gemma":[0.9893219,0.0077230586,0.00097068003,0.0016666421,0.000081795646,0.00023593828],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0031075054,0.0008855163,0.03953955,0.0009210369,0.00004172102,0.000028584593,0.000377069,0.00015657936,0.00015563822],"category_scores_gemma":[0.0041626645,0.00037125053,0.021511866,0.00063792104,0.00028287104,0.000022825545,0.00020882713,0.00033807848,0.000034478107],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011306122,0.00023331297,0.00005293256,0.027686529,0.9059091,0.000060959355,0.000023391718,0.0000023952152,0.0000035016278,0.00068937923,0.0025786955,0.06162919],"study_design_scores_gemma":[0.023992516,0.00019774392,0.000027024318,0.0008659539,0.6852927,3.6727624e-7,0.0000024685917,0.0000056760923,0.000022781982,0.0000542821,0.28936478,0.00017368313],"about_ca_topic_score_codex":0.000014235085,"about_ca_topic_score_gemma":6.5456265e-7,"teacher_disagreement_score":0.28678608,"about_ca_system_score_codex":0.000056030807,"about_ca_system_score_gemma":0.0001367748,"threshold_uncertainty_score":0.99987394},"labels":[],"label_agreement":null},{"id":"W4404704669","doi":"10.1016/j.molmet.2024.102073","title":"Characterization of LY3324954 a long-acting glucagon-receptor agonist","year":2024,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk; Eli Lilly and Company","keywords":"Agonist; Receptor; Chemistry; Endocrinology; Medicine; Internal medicine","score_opus":0.009176930907005637,"score_gpt":0.2504752803257951,"score_spread":0.24129834941878944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404704669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984061,0.0029263797,0.005222393,0.0006950147,0.0007415358,0.00043046425,0.00001721567,0.00014614413,0.005759824],"genre_scores_gemma":[0.9948704,0.0001524034,0.0008443517,0.00030303583,0.00015360721,0.00004379379,0.0003046155,0.00004307671,0.0032846737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906766,0.000027369033,0.00022318539,0.00024735415,0.00023684998,0.00019755692],"domain_scores_gemma":[0.99956286,0.0000100110055,0.00005448405,0.00024126659,0.000056463377,0.00007489803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011658012,0.00015171847,0.00028413313,0.00016895174,0.00002854481,0.000057038418,0.000060563023,0.000041383457,0.00022453844],"category_scores_gemma":[0.000026982723,0.00013021728,0.00016652193,0.00029586232,0.000032910484,0.00010823817,0.00004698669,0.000078218014,0.0001344938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022275657,0.00011392716,0.00019309505,0.00028126873,0.00040138332,0.00009532246,0.00019417953,8.206639e-7,0.923336,0.0047987998,0.000086015556,0.070476905],"study_design_scores_gemma":[0.000642509,0.0000614082,0.011242303,0.00022123026,0.00079201953,0.000004489041,0.000025934338,0.00018318485,0.76906425,0.000053949334,0.21755685,0.00015190686],"about_ca_topic_score_codex":0.000013920806,"about_ca_topic_score_gemma":5.786876e-7,"teacher_disagreement_score":0.21747082,"about_ca_system_score_codex":0.000027323958,"about_ca_system_score_gemma":0.000042641226,"threshold_uncertainty_score":0.5310106},"labels":[],"label_agreement":null},{"id":"W4404760916","doi":"10.1016/j.revmed.2024.10.441","title":"Essai de phase III randomisé COMMODORE 2 : résultats d’une étude multicentrique évaluant crovalimab vs éculizumab chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) naïfs de traitement par un inhibiteur du complément","year":2024,"lang":"fr","type":"article","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Gynecology","score_opus":0.011886891339982148,"score_gpt":0.27434550939012037,"score_spread":0.2624586180501382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404760916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568914,0.013109583,0.011386668,0.01012306,0.001799286,0.004377003,0.00032150964,0.00039744642,0.0015940029],"genre_scores_gemma":[0.9816617,0.003420455,0.0034039733,0.0015887732,0.001324702,0.0011019504,0.0009156372,0.00028221015,0.006300599],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99220806,0.0012683558,0.002058038,0.001444984,0.00077374454,0.0022467948],"domain_scores_gemma":[0.9960714,0.0009794141,0.000493666,0.00095950207,0.00036780784,0.0011282263],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026992948,0.0013897764,0.0019903071,0.0004398638,0.00026459288,0.0004708411,0.00071157067,0.00051180937,0.001369919],"category_scores_gemma":[0.0005020084,0.0012994126,0.000855005,0.0007684312,0.0005812244,0.00041589024,0.0005626666,0.0010680807,0.00030906784],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030339107,0.058405336,0.2853538,0.01570689,0.015444394,0.025243854,0.047201723,0.002592653,0.009641253,0.012139634,0.02677548,0.47115585],"study_design_scores_gemma":[0.4102065,0.007905449,0.20238118,0.03922867,0.012235432,0.0011119324,0.00171053,0.11486075,0.047207788,0.00297822,0.1570919,0.0030816435],"about_ca_topic_score_codex":0.0016217172,"about_ca_topic_score_gemma":0.00062039396,"teacher_disagreement_score":0.46807423,"about_ca_system_score_codex":0.0041960664,"about_ca_system_score_gemma":0.00033556524,"threshold_uncertainty_score":0.99988526},"labels":[],"label_agreement":null},{"id":"W4404773610","doi":"10.1093/ckj/sfae370","title":"Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications","year":2024,"lang":"en","type":"review","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; University of Toronto","keywords":"Renal function; Glomerular hyperfiltration; Medicine; Internal medicine; Tubuloglomerular feedback; Diabetes mellitus; Endocrinology; Kidney disease; Vasoconstriction; Kidney; Effective renal plasma flow; Renal blood flow; Diabetic nephropathy","score_opus":0.03697801133625948,"score_gpt":0.3929251613412785,"score_spread":0.355947150005019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404773610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005920541,0.98675406,0.000011380462,0.0017386714,0.0031463443,0.0019364777,0.000104331644,0.00005653583,0.00033164799],"genre_scores_gemma":[0.0013465822,0.9944595,0.00032652216,0.001774003,0.0011929218,0.000095870746,0.00035378628,0.00010078703,0.0003500298],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99393594,0.00057285634,0.003803333,0.0008460714,0.00025804705,0.00058374176],"domain_scores_gemma":[0.9953032,0.0013301761,0.00096488546,0.0006401962,0.0001018151,0.0016597274],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016637866,0.0006301037,0.0043197293,0.0005274157,0.000056941244,0.000044203058,0.00030714963,0.0008655935,0.00005455829],"category_scores_gemma":[0.0019116567,0.0004295791,0.002166246,0.00044626475,0.00055493024,0.00009077611,0.00019307618,0.0023955791,0.00010443783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005025105,0.0022364769,0.015460994,0.045862094,0.003458751,0.00024428347,0.000020021405,2.3058243e-8,0.000009410479,0.0001101457,0.034265924,0.89828163],"study_design_scores_gemma":[0.0044011,0.001769258,0.010060813,0.05938229,0.018458283,0.00006807557,0.0000042045426,0.000024352536,0.0000036112056,0.0009073811,0.9044493,0.00047133927],"about_ca_topic_score_codex":0.0000016848904,"about_ca_topic_score_gemma":0.0000012269226,"teacher_disagreement_score":0.8978103,"about_ca_system_score_codex":0.0001431399,"about_ca_system_score_gemma":0.0012348443,"threshold_uncertainty_score":0.99990594},"labels":[],"label_agreement":null},{"id":"W4404789272","doi":"10.1093/eurjpc/zwae379","title":"Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Preventive Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline foundation; Max Kade Foundation","keywords":"Medicine; Atrial fibrillation; Disease; Type 2 diabetes; Internal medicine; Diabetes mellitus; Cardiology; Intensive care medicine; Endocrinology","score_opus":0.010801471108966867,"score_gpt":0.2197693191177639,"score_spread":0.20896784800879703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404789272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967043,0.031359207,0.000043773372,0.00022904223,0.00059671496,0.0004627968,0.000008411207,0.000008734475,0.0002483649],"genre_scores_gemma":[0.99830145,0.00074186525,0.00007550671,0.00004106871,0.00072919915,9.364655e-7,0.000030667226,0.000018526873,0.000060768605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853224,0.0007003946,0.00026404465,0.00019363606,0.00019166636,0.0001180067],"domain_scores_gemma":[0.99938476,0.0002149812,0.00008135846,0.00015871186,0.000081006525,0.00007917111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004979596,0.00012995431,0.00045812398,0.0001032369,0.000031350675,0.000045936256,0.00005067381,0.000016924485,0.0000050405283],"category_scores_gemma":[0.00020174489,0.000069470516,0.00024140894,0.00010268232,0.00008170925,0.00013250909,0.00006783773,0.00012662874,0.0000030526655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006702526,0.00001808619,0.93016446,0.000036406887,0.008410083,0.00048688403,0.00028812338,0.00018157988,0.000009080838,0.000037232683,0.0007138202,0.0529517],"study_design_scores_gemma":[0.019311909,0.0010079232,0.96225196,0.00018186356,0.0021453726,0.000001595677,0.000028884562,0.000018117722,0.0000018926451,0.00009829521,0.014878466,0.00007373892],"about_ca_topic_score_codex":0.0000021183487,"about_ca_topic_score_gemma":5.0618615e-7,"teacher_disagreement_score":0.052877963,"about_ca_system_score_codex":0.000028685437,"about_ca_system_score_gemma":0.000031056894,"threshold_uncertainty_score":0.28329253},"labels":[],"label_agreement":null},{"id":"W4404839124","doi":"10.1101/2024.11.28.24317254","title":"Emulating randomized controlled trials of long-acting insulins and cardiovascular events using real-world data for patients with type 2 diabetes","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Type 2 diabetes; Randomized controlled trial; Real world data; Diabetes mellitus; Medicine; Diabetes treatment; Continuous glucose monitoring; Internal medicine; Type 1 diabetes; Computer science; Data science; Endocrinology","score_opus":0.07565297282209027,"score_gpt":0.34046529020232996,"score_spread":0.2648123173802397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404839124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838946,0.0047803884,0.00018564866,0.00004277216,0.0007061329,0.009817411,0.00016632144,0.000064673266,0.00034207097],"genre_scores_gemma":[0.992848,0.00048342798,0.004756868,0.000017610819,0.00024400135,0.00029117486,0.0010869381,0.00008806808,0.00018392314],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963426,0.000548979,0.0014843763,0.00077704556,0.0005343987,0.00031258402],"domain_scores_gemma":[0.9953947,0.0019719943,0.0010711518,0.0011755849,0.0002884587,0.00009812137],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007657629,0.00044400163,0.0069395336,0.00040318264,0.000058445567,0.00005649731,0.00019227048,0.0001006169,0.000011031436],"category_scores_gemma":[0.0047207535,0.00027192882,0.0009996636,0.00021247455,0.00008800563,0.00005936748,0.00094907096,0.00023170028,9.764959e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082837984,0.00053711963,0.788124,0.007834173,0.09385456,0.000023095023,0.00023556838,0.0006840041,0.00006242521,0.000049643826,0.00005101502,0.025706388],"study_design_scores_gemma":[0.7835087,0.00060707756,0.050625995,0.010520911,0.112556964,3.6723787e-7,0.000068770045,0.040175773,0.00023390535,0.0006441731,0.00027042013,0.00078692904],"about_ca_topic_score_codex":0.00010458245,"about_ca_topic_score_gemma":0.00003069578,"teacher_disagreement_score":0.73749804,"about_ca_system_score_codex":0.000063797685,"about_ca_system_score_gemma":0.000118562355,"threshold_uncertainty_score":0.9999733},"labels":[],"label_agreement":null},{"id":"W4404872333","doi":"10.1016/j.molmet.2024.102074","title":"Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss","year":2024,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; AstraZeneca","keywords":"Agonist; GABAergic; Weight loss; Endocrinology; Chemistry; Neuroscience; Internal medicine; Biology; Cell biology; Receptor; Medicine; Obesity","score_opus":0.01121588496803603,"score_gpt":0.25370276965228444,"score_spread":0.24248688468424842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404872333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726713,0.01813423,0.0004085164,0.0008966861,0.000762446,0.0007159617,0.000010423235,0.00010700697,0.006293448],"genre_scores_gemma":[0.9969308,0.0007744664,0.0006533661,0.00022577499,0.00019564218,0.00009211558,0.000047958485,0.000060790513,0.0010191175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980529,0.00008585984,0.00044392236,0.00052967825,0.00044667424,0.0004409733],"domain_scores_gemma":[0.9992478,0.00004242323,0.00007236617,0.00045409886,0.000055324428,0.0001279731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022723974,0.00030067432,0.000572839,0.00040538504,0.000034646866,0.000059434256,0.00017233138,0.00007375554,0.00022418678],"category_scores_gemma":[0.000022458682,0.0002589645,0.00027084933,0.0006258539,0.00008163959,0.00011282559,0.00009454968,0.00022687178,0.00012219131],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006142267,0.0003730898,0.000294435,0.00028651147,0.00037713928,0.0032805477,0.0002640332,0.000015922607,0.970124,0.01706009,0.00027750045,0.0075852894],"study_design_scores_gemma":[0.0016856138,0.00014701356,0.00474821,0.00039032206,0.000576965,0.000015466316,0.00004314267,0.00019444239,0.89441925,0.0010917892,0.0963901,0.0002976851],"about_ca_topic_score_codex":0.0000328107,"about_ca_topic_score_gemma":0.0000028907475,"teacher_disagreement_score":0.096112594,"about_ca_system_score_codex":0.00005241158,"about_ca_system_score_gemma":0.00007377241,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4404885406","doi":"10.1016/j.ophtha.2024.10.028","title":"Reply","year":2024,"lang":"en","type":"letter","venue":"Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prism Eye Institute","funders":"","keywords":"Medicine","score_opus":0.029365981689705733,"score_gpt":0.2985563835044386,"score_spread":0.26919040181473286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404885406","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012088226,0.00095081405,4.0027106e-7,0.67911893,0.0012675583,0.00029398146,0.000009781536,0.000101961086,0.31704774],"genre_scores_gemma":[0.0007919668,0.00001605123,0.00016214981,0.5917261,0.002388502,0.000074290576,0.00058010675,0.000056806017,0.40420398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987769,0.000027403146,0.00018736834,0.0004868588,0.00016486368,0.00035659684],"domain_scores_gemma":[0.9992965,0.00004450034,0.000046636946,0.0005458685,0.000025779924,0.000040743595],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006160451,0.00025042315,0.00046147103,0.0002203527,0.00001838688,0.000019108202,0.00009888352,0.00046264837,0.0026358073],"category_scores_gemma":[0.000016532764,0.0001990437,0.0002050396,0.00010301021,0.00006343421,0.000014739323,0.0001089295,0.0008511654,0.0057061953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008906741,0.00003011736,0.00030913003,0.00047278573,0.0005292305,0.08726094,0.0000096257045,2.3055861e-8,0.0000035538017,0.0000730025,0.9106321,0.00067060895],"study_design_scores_gemma":[0.000255776,0.00048355034,0.00030283988,0.00012471962,0.00079536013,0.0037139466,0.000002258549,0.000001936287,0.000017149643,0.0010021788,0.99315006,0.00015021538],"about_ca_topic_score_codex":0.000025040144,"about_ca_topic_score_gemma":3.975235e-8,"teacher_disagreement_score":0.08739279,"about_ca_system_score_codex":0.00008747403,"about_ca_system_score_gemma":0.00004921842,"threshold_uncertainty_score":0.99827594},"labels":[],"label_agreement":null},{"id":"W4404975646","doi":"10.1016/j.jcjd.2024.11.007","title":"Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update: An Opportunity Lost to Move Beyond First-line Metformin","year":2024,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Queensway-Carleton Hospital","funders":"","keywords":"Medicine; Metformin; Glycemic; Type 2 diabetes; First line; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.020467873081160787,"score_gpt":0.2642504927738916,"score_spread":0.24378261969273082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404975646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8315937,0.009807386,6.923143e-7,0.14623222,0.0033043788,0.0016012423,0.00048421393,0.000027048667,0.006949133],"genre_scores_gemma":[0.4914687,0.002092788,0.0019558254,0.4818179,0.0033975018,0.00015068281,0.0019412877,0.00043879644,0.016736507],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639046,0.00008514194,0.0012424899,0.00054652995,0.0005770385,0.0011583396],"domain_scores_gemma":[0.9971702,0.0001002213,0.0004892283,0.00056158955,0.00036153905,0.0013172211],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059325644,0.0006663834,0.0014311513,0.0023882666,0.000057644225,0.00008846217,0.0006540439,0.00044430225,0.0017441125],"category_scores_gemma":[0.000081737315,0.0005709115,0.00036844696,0.0010425984,0.00014668862,0.00026193832,0.00011894879,0.0014462419,0.00017070584],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008940839,0.00019386176,0.016760567,0.004760289,0.0027990208,0.005127266,0.00019217953,0.00006146221,0.000019804136,0.000049997478,0.94628614,0.02366002],"study_design_scores_gemma":[0.0036707642,0.004569872,0.004088694,0.0072734347,0.0044033723,0.000009339909,0.0002663652,0.00025796526,0.00052397896,0.0011091186,0.97294176,0.0008853125],"about_ca_topic_score_codex":0.00028806328,"about_ca_topic_score_gemma":0.0018680402,"teacher_disagreement_score":0.34012496,"about_ca_system_score_codex":0.0008980415,"about_ca_system_score_gemma":0.0008672496,"threshold_uncertainty_score":0.99967426},"labels":[],"label_agreement":null},{"id":"W4405073794","doi":"10.46747/cfp.701112684","title":"Correction","year":2024,"lang":"en","type":"erratum","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Information retrieval; World Wide Web; Data science","score_opus":0.012623779683219363,"score_gpt":0.22909578170260322,"score_spread":0.21647200201938385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405073794","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030800806,0.0059839385,0.000001184031,0.0008650006,0.09530058,0.00046913335,0.000093299794,0.0001567368,0.8970993],"genre_scores_gemma":[0.00043937613,0.00028315993,0.000011827655,0.075187795,0.0048981323,0.000070051494,0.0029421344,0.00012623514,0.9160413],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985527,0.0000117321815,0.00017325881,0.00048262632,0.00023945158,0.00054023205],"domain_scores_gemma":[0.99888986,0.000008592908,0.0000478875,0.00046760423,0.00006111353,0.0005249518],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000040814233,0.00036200334,0.00045918216,0.0005879115,0.000081777114,0.00009482742,0.00011290552,0.00030032947,0.000019665993],"category_scores_gemma":[0.000005098823,0.00035181153,0.00026077408,0.00037709982,0.00004590724,0.00005062113,0.000027174507,0.000722999,0.0042953724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002902642,0.000026000778,0.0000026915952,0.0001978081,0.00040753922,0.00031217054,0.000016738479,3.1823353e-7,0.000008330829,0.00022749479,0.9162501,0.08254791],"study_design_scores_gemma":[0.00017579182,0.0001476711,0.0007490102,0.0010180441,0.0009744343,6.767663e-7,0.00010815159,0.00016152568,0.000007373167,0.00018747187,0.9961812,0.0002886493],"about_ca_topic_score_codex":0.011358254,"about_ca_topic_score_gemma":0.017277598,"teacher_disagreement_score":0.09040245,"about_ca_system_score_codex":0.0012447683,"about_ca_system_score_gemma":0.0014249315,"threshold_uncertainty_score":0.99989337},"labels":[],"label_agreement":null},{"id":"W4405168290","doi":"10.1136/thorax-2024-222540","title":"Beyond glycaemic control: reduced pneumonia and sepsis risk with GLP-1 RAs and SGLT2 inhibitors in patients with type 2 diabetes","year":2024,"lang":"en","type":"editorial","venue":"Thorax","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Pneumonia; Sepsis; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Type 1 diabetes; Internal medicine; Endocrinology","score_opus":0.0025528481108972336,"score_gpt":0.2141279947193368,"score_spread":0.21157514660843957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405168290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9132996,0.002752219,2.644915e-7,0.0001421219,0.081195936,0.0013355576,0.00017465085,0.000097097174,0.0010025057],"genre_scores_gemma":[0.89404994,0.0012253121,0.00024659684,0.000108775996,0.09930116,0.00018764439,0.0013776263,0.0002530232,0.0032499142],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997917,0.0000668539,0.00029302828,0.0007058337,0.00058750354,0.0004297583],"domain_scores_gemma":[0.9989357,0.00021366877,0.00017792333,0.00034363795,0.00014551029,0.00018357318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022409069,0.00051682343,0.00086609717,0.0003338417,0.0000568901,0.00010162684,0.00007630588,0.0003371194,0.000013719038],"category_scores_gemma":[0.00010618018,0.00034454942,0.00004289602,0.0003267481,0.00015533676,0.00010289356,0.00009806769,0.0006122417,0.000020391371],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025329182,0.00034382488,0.3599324,0.001117589,0.0019158927,0.00010680294,0.0003312139,0.0000018247808,0.00007882345,0.000010567573,0.6215806,0.012047555],"study_design_scores_gemma":[0.04953329,0.022315476,0.27121714,0.009209493,0.018244896,0.0000018517054,0.0002489271,0.00009090295,0.00034252004,0.00057431683,0.62566394,0.0025572362],"about_ca_topic_score_codex":0.00007323379,"about_ca_topic_score_gemma":0.00007405266,"teacher_disagreement_score":0.08871525,"about_ca_system_score_codex":0.00014878788,"about_ca_system_score_gemma":0.0001251569,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W4405250135","doi":"10.17615/eqw9-qw52","title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease results of the LEADER trial","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Relypsa; Novartis Pharma; Julius Clinical; Novo Nordisk; Astellas Pharma; Eisai; University of Toronto; Swansea University; Diabetes UK; British Heart Foundation; National Institute for Health and Care Research; Quest Diagnostics; AstraZeneca; Amarin Corporation; Medicines Company; School of Medicine, University of North Carolina at Chapel Hill; Intarcia Therapeutics; Valeant Pharmaceuticals International; Amgen; International Society of Hypertension; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Celgene; Osiris Therapeutics; AstraZeneca HealthCare Foundation; Servier; Gilead Sciences; Imperial College London; GlaxoSmithKline; Halozyme; Sanofi; Pfizer; Orexigen Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Liraglutide; Medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Internal medicine; Disease; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.008493302425303143,"score_gpt":0.1907686334204115,"score_spread":0.18227533099510837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405250135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575937,0.0023161734,7.2469925e-7,0.0003981043,0.00007187229,0.0012164037,0.000014418961,0.000014287946,0.00020866861],"genre_scores_gemma":[0.99963325,0.000014181994,0.000051077055,0.00013895279,0.000035351623,0.000015814747,0.000040468236,0.000014397653,0.000056499473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989878,0.00013098665,0.0001882998,0.00019941168,0.00035755453,0.00013593775],"domain_scores_gemma":[0.9993923,0.00010036826,0.00008173661,0.00032164418,0.000020824327,0.00008315036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001261439,0.00013507248,0.00040549057,0.000048115882,0.000022997412,0.000007918187,0.00007192311,0.000029008965,0.0000042843353],"category_scores_gemma":[0.00031248602,0.0000723596,0.00014888139,0.00021920058,0.000119417346,0.00009281069,0.000071135444,0.000060666705,0.0000016257835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08837743,0.00048828006,0.8976782,0.00090155937,0.002037726,0.000006863422,0.0005572741,0.00008340328,0.000010758572,0.000644482,0.00032199163,0.008892056],"study_design_scores_gemma":[0.13102429,0.011034616,0.83969957,0.00064430136,0.0020326574,1.9539309e-8,0.00003178818,0.000044914075,0.013064155,0.00022495115,0.0020213064,0.00017745077],"about_ca_topic_score_codex":0.000009367706,"about_ca_topic_score_gemma":3.9833492e-7,"teacher_disagreement_score":0.057978626,"about_ca_system_score_codex":0.000009578484,"about_ca_system_score_gemma":0.0000392719,"threshold_uncertainty_score":0.2950739},"labels":[],"label_agreement":null},{"id":"W4405332140","doi":"10.1161/atvbaha.124.321850","title":"Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease","year":2024,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; Rhode Island Foundation; National Institutes of Health; Brown University","keywords":"Medicine; Coronary artery disease; Cardiology; Semaglutide; Internal medicine; Ejection fraction; Angina; Perfusion; Myocardial infarction; Canadian Cardiovascular Society; Diabetes mellitus; Artery; Heart failure; Type 2 diabetes; Endocrinology; Liraglutide","score_opus":0.021108884808724616,"score_gpt":0.256192119204276,"score_spread":0.23508323439555137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405332140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981489,0.00086165266,0.000044124125,0.00038123873,0.000068427194,0.00034750355,0.000030332845,0.000035453344,0.00008234116],"genre_scores_gemma":[0.99179316,0.007641409,0.00019987077,0.0002126643,0.00003247615,0.000050165778,0.000043182208,0.00001718984,0.000009865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904716,0.000034972498,0.0002185177,0.0003667745,0.00007762052,0.00025495247],"domain_scores_gemma":[0.9996443,0.000025874393,0.000026100475,0.00018260557,0.00001595885,0.00010519047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018006821,0.00017081363,0.00037343916,0.00013700216,0.000048686554,0.000019598943,0.000036042296,0.00007049424,0.000014808094],"category_scores_gemma":[0.0000075094667,0.00013373353,0.00011247803,0.00008808482,0.00011965356,0.00008773114,0.00012626768,0.00007569558,0.0000036980014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042069332,0.00026539454,0.8215209,0.00040605236,0.00031040554,8.361944e-7,0.00038049748,0.00000243496,0.1706513,0.0006968934,0.00003883282,0.0056843283],"study_design_scores_gemma":[0.0011455562,0.0007984874,0.9651829,0.00026232025,0.00032279786,4.190632e-7,0.000056512472,0.031737354,0.00008929577,0.000042171945,0.00023714238,0.00012503761],"about_ca_topic_score_codex":0.000007701314,"about_ca_topic_score_gemma":0.0000070736023,"teacher_disagreement_score":0.17056201,"about_ca_system_score_codex":0.000021844508,"about_ca_system_score_gemma":0.000027362648,"threshold_uncertainty_score":0.5453495},"labels":[],"label_agreement":null},{"id":"W4405393219","doi":"10.1093/eurheartj/ehae744","title":"Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Semaglutide; Medicine; Ejection fraction; Mace; Heart failure; Glucagon-like peptide 1 receptor; Diabetes mellitus; Type 2 diabetes; Glucagon-like peptide-1; Cardiology; Internal medicine; Agonist; Endocrinology; Receptor; Liraglutide; Percutaneous coronary intervention; Myocardial infarction","score_opus":0.02540282870594842,"score_gpt":0.27264620744890106,"score_spread":0.24724337874295263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405393219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9286176,0.015242472,0.00012764215,0.024417799,0.00081852154,0.0005217534,0.000007800769,0.00009269389,0.030153709],"genre_scores_gemma":[0.98392725,0.0008946968,0.0006070052,0.0008744071,0.0006413504,0.0000032915082,0.000004646499,0.000042498206,0.013004875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902433,0.000114853174,0.00023471542,0.00015445663,0.00026152196,0.00021012874],"domain_scores_gemma":[0.9995485,0.00004601198,0.00004552275,0.00018960792,0.000038294573,0.00013204479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006138833,0.00012640632,0.00017888166,0.0000996428,0.00009992282,0.00009886686,0.000079403355,0.000012428389,0.00016338582],"category_scores_gemma":[0.00002415195,0.000069723064,0.000114006136,0.0001090394,0.000089358655,0.00006531873,0.000088045905,0.0002462106,0.000077932746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030599145,0.0008131897,0.063306965,0.0013735233,0.0025649867,0.0065928358,0.004587729,0.000029544874,0.01024173,0.0028177546,0.70917034,0.19819541],"study_design_scores_gemma":[0.00097628124,0.0004823748,0.15744583,0.0007120502,0.00040636968,0.0010623184,0.00013714992,0.0003190562,0.0013841314,0.00010285587,0.83685434,0.00011725111],"about_ca_topic_score_codex":0.0000029022317,"about_ca_topic_score_gemma":6.4969703e-7,"teacher_disagreement_score":0.19807816,"about_ca_system_score_codex":0.0000282402,"about_ca_system_score_gemma":0.000032840384,"threshold_uncertainty_score":0.2843224},"labels":[],"label_agreement":null},{"id":"W4405409933","doi":"10.1002/ejhf.3558","title":"Tailoring Medical Therapy for Heart Failure with Preserved Ejection Fraction","year":2024,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Heart failure; Ejection fraction; Cardiology; Internal medicine; Medical therapy; Intensive care medicine","score_opus":0.018827876067340373,"score_gpt":0.26891727307697083,"score_spread":0.25008939700963045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405409933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79795843,0.003555136,0.009463874,0.1835875,0.001373975,0.001441401,0.000005782102,0.0002866931,0.0023271744],"genre_scores_gemma":[0.97666126,0.00011269418,0.019109828,0.00081223465,0.0018522008,0.000011306173,0.0000146718985,0.00008410335,0.0013417073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985807,0.00013535364,0.0003366232,0.0001954642,0.000526149,0.00022570314],"domain_scores_gemma":[0.9993103,0.0000802097,0.00008468582,0.00016406261,0.00015309532,0.00020761508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009750434,0.00016465082,0.00029306512,0.00021330135,0.00008545797,0.000108059634,0.00008297916,0.000038232203,0.00036815964],"category_scores_gemma":[0.00006444197,0.00010617459,0.00021219355,0.00018567665,0.00003392621,0.0003260459,0.000021544896,0.00037397168,0.0000828442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012036441,0.0004080883,0.020566598,0.00036841305,0.0012380121,0.00067948835,0.00016605273,0.000039460203,0.0070569273,0.0001489398,0.9528294,0.015294974],"study_design_scores_gemma":[0.002673382,0.0031229402,0.0075386814,0.00088236114,0.00017010653,0.000289597,0.00023123906,0.00013262412,0.0016526887,0.000018818966,0.9831812,0.00010636478],"about_ca_topic_score_codex":0.000001934556,"about_ca_topic_score_gemma":0.0000043534696,"teacher_disagreement_score":0.18277527,"about_ca_system_score_codex":0.00006732912,"about_ca_system_score_gemma":0.00009818813,"threshold_uncertainty_score":0.43296742},"labels":[],"label_agreement":null},{"id":"W4405415894","doi":"10.1503/cmaj.240768","title":"Glucagon-like peptide-1 receptor agonists during pregnancy and lactation","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Dulaglutide; Liraglutide; Semaglutide; Lixisenatide; Medicine; Type 2 diabetes; Exenatide; Lactation; Pregnancy; Glucagon-like peptide 1 receptor; Endocrinology; Glucagon-like peptide-1; Internal medicine; Pharmacology; Agonist; Receptor; Diabetes mellitus; Biology","score_opus":0.006200884508440921,"score_gpt":0.23164269955117908,"score_spread":0.22544181504273816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405415894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89613664,0.007033489,0.000042521035,0.07574554,0.002855996,0.00040727464,0.000021566213,0.00012426954,0.0176327],"genre_scores_gemma":[0.96888965,0.0024835058,0.00025390816,0.0025508266,0.001384831,0.00002133097,0.00005010669,0.000033104614,0.024332752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998544,0.000042264423,0.00023766566,0.00015865428,0.0006844855,0.00033292998],"domain_scores_gemma":[0.9987025,0.000057260393,0.000058065747,0.00005861833,0.000099442565,0.0010240768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003258677,0.00010475367,0.00015694574,0.00021578086,0.00016905181,0.0001804878,0.000047829304,0.00015682637,0.0017481712],"category_scores_gemma":[0.00028291132,0.00009019468,0.00006862546,0.00016712256,0.000020626541,0.0001638207,0.000011762169,0.0003878372,0.00023497164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028678185,0.000108659566,0.107125714,0.00056748575,0.0016090153,0.0046420014,0.0018900997,0.000001145044,0.0003025481,0.0016822984,0.33463353,0.5474088],"study_design_scores_gemma":[0.001935499,0.00017019307,0.09424589,0.002422612,0.00027102258,0.00040305548,0.00039476273,0.00033782667,0.00009972998,0.00018988508,0.89930785,0.0002216933],"about_ca_topic_score_codex":0.00026914943,"about_ca_topic_score_gemma":0.0019753885,"teacher_disagreement_score":0.5646743,"about_ca_system_score_codex":0.0010071449,"about_ca_system_score_gemma":0.0007833547,"threshold_uncertainty_score":0.99916434},"labels":[],"label_agreement":null},{"id":"W4405445936","doi":"10.3390/diagnostics14242829","title":"Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database","year":2024,"lang":"en","type":"article","venue":"Diagnostics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University","funders":"","keywords":"Adverse Event Reporting System; Medicine; Exenatide; Adverse effect; Dulaglutide; Odds ratio; Semaglutide; Internal medicine; Nausea; Liraglutide; Pharmacovigilance; Vomiting; Database; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.017318625564899146,"score_gpt":0.3153186009359868,"score_spread":0.29799997537108763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405445936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98111635,0.0005793344,0.0015040828,0.005615704,0.00038673487,0.0014260504,0.001383384,0.00008013763,0.007908221],"genre_scores_gemma":[0.989977,0.0015322926,0.00483467,0.00060291204,0.00012882357,0.00008439233,0.002423395,0.000019288476,0.00039719982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985479,0.00012768261,0.00035917477,0.00028627177,0.00044055696,0.00023841667],"domain_scores_gemma":[0.9974473,0.0017716617,0.00008435867,0.0005883595,0.000044342254,0.000063973246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004882561,0.00017585192,0.00030877482,0.00018632505,0.000050063776,0.000020264273,0.00021769917,0.000016721371,0.00034401467],"category_scores_gemma":[0.00029773708,0.000100778474,0.00019564951,0.0010498458,0.000071097784,0.00006316631,0.00010570019,0.00020173842,0.00004049869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005013601,0.0005185061,0.9798034,0.00007221911,0.0010435027,0.00028495138,0.0003072077,0.0002246349,0.00003623946,0.0014305132,0.014589191,0.0016395146],"study_design_scores_gemma":[0.00077601493,0.00017700256,0.97637415,0.0007659094,0.0036737297,0.0000014476957,0.0005816995,0.0033110676,0.000029996892,0.000059313137,0.014148245,0.00010139952],"about_ca_topic_score_codex":0.0015097398,"about_ca_topic_score_gemma":0.0020125038,"teacher_disagreement_score":0.008860676,"about_ca_system_score_codex":0.00016964877,"about_ca_system_score_gemma":0.00009371159,"threshold_uncertainty_score":0.4109627},"labels":[],"label_agreement":null},{"id":"W4405462623","doi":"10.2196/68792","title":"Quality Assessment of Medical Institutions’ Websites Regarding Prescription Drug Misuse of Glucagon-Like Peptide-1 Receptor Agonists by Off-Label Use for Weight Loss: Website Evaluation Study","year":2024,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science","keywords":"Preprint; Medical prescription; Quality (philosophy); Business; Advertising; Internet privacy; Medicine; World Wide Web; Computer science; Pharmacology","score_opus":0.16913992949672207,"score_gpt":0.5078717243569811,"score_spread":0.33873179486025906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405462623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883263,0.00093878224,0.00077688077,0.0013782602,0.00043148722,0.0056321626,0.00020260713,0.00007186517,0.0022416632],"genre_scores_gemma":[0.99285084,0.00069968624,0.000693539,0.000025173527,0.00007204567,0.0016624295,0.00075554935,0.000026946243,0.003213797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99374634,0.0008253377,0.0008876882,0.00043752225,0.0036517791,0.00045130917],"domain_scores_gemma":[0.9970892,0.0007931404,0.00019088342,0.0004781785,0.0012498384,0.00019876871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008730887,0.00022459443,0.00053216604,0.00061893003,0.00021228548,0.00013194463,0.00025222794,0.00011944278,0.00033229217],"category_scores_gemma":[0.0005799062,0.00017438074,0.00017358104,0.00076168065,0.0003281534,0.0010122509,0.000256954,0.0004092885,0.000045090153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002075885,0.022460682,0.09999715,0.012232127,0.005757765,0.00003075153,0.022621717,0.00002165159,0.017873293,0.02216481,0.691286,0.103478156],"study_design_scores_gemma":[0.04455576,0.012958773,0.23785853,0.009607327,0.0018766683,0.0000094478,0.020327779,0.10752622,0.020149117,0.0011991265,0.54271567,0.0012155907],"about_ca_topic_score_codex":0.00015588406,"about_ca_topic_score_gemma":0.00006469995,"teacher_disagreement_score":0.14857036,"about_ca_system_score_codex":0.00082233705,"about_ca_system_score_gemma":0.000802151,"threshold_uncertainty_score":0.711104},"labels":[],"label_agreement":null},{"id":"W4405466175","doi":"10.1007/s13300-024-01671-x","title":"Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study","year":2024,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Kidney disease; Cohort; Disease; Internal medicine; Cohort study; Intensive care medicine; Endocrinology","score_opus":0.02515344726231022,"score_gpt":0.3114057257762158,"score_spread":0.28625227851390556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405466175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912429,0.0047083343,3.370094e-7,0.000060774557,0.00018063332,0.0035574306,0.00004425826,0.00012836314,0.00007695452],"genre_scores_gemma":[0.9969918,0.0012751184,0.00011043345,0.0003028017,0.000117577896,0.00060326286,0.0002693148,0.00006027425,0.00026937423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810994,0.00013595494,0.00034384284,0.00074489275,0.0002381927,0.00042719193],"domain_scores_gemma":[0.9989645,0.00007843029,0.000055276185,0.00038559965,0.00005711176,0.00045907265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025218842,0.0003604808,0.00056141015,0.00017886491,0.00005874715,0.000118631964,0.000065206754,0.000063260275,0.00006719825],"category_scores_gemma":[0.00002577172,0.00023886639,0.000054925516,0.00025134694,0.00013703568,0.00026762066,0.0000511364,0.00013403788,0.000016743104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024830937,0.0036696063,0.88754445,0.00010426587,0.0007306087,0.000027235707,0.00038392292,3.1875055e-7,0.000025277028,0.0000068178556,0.000084941785,0.107174255],"study_design_scores_gemma":[0.011162863,0.018259544,0.967832,0.0004525859,0.00035411306,3.6375038e-8,0.00005248513,0.000703008,0.00010271123,0.000018445066,0.0007992153,0.00026293815],"about_ca_topic_score_codex":0.0000144077885,"about_ca_topic_score_gemma":0.000029073357,"teacher_disagreement_score":0.10691132,"about_ca_system_score_codex":0.00013483278,"about_ca_system_score_gemma":0.00014437243,"threshold_uncertainty_score":0.9740689},"labels":[],"label_agreement":null},{"id":"W4405484896","doi":"10.1111/anae.16524","title":"Considerations on peri‐operative management of <scp>GLP</scp> ‐1 receptor agonists","year":2024,"lang":"en","type":"letter","venue":"Anaesthesia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Semaglutide; Medicine; Gastric emptying; Type 2 diabetes; Residual; Glucagon-like peptide 1 receptor; Internal medicine; Diabetes mellitus; Gastroenterology; Receptor; Endocrinology; Agonist; Liraglutide; Computer science; Stomach","score_opus":0.021143051372387346,"score_gpt":0.2730020482761872,"score_spread":0.2518589969037998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405484896","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016497817,0.002427973,0.00001278632,0.73145217,0.0008480556,0.003007461,0.000107920096,0.00034259085,0.24530324],"genre_scores_gemma":[0.023520479,0.0021692202,0.003604921,0.68437785,0.001547248,0.00069829845,0.0020047207,0.0002668763,0.28181037],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787724,0.00007298825,0.00043630667,0.0006483366,0.0005453107,0.00041980043],"domain_scores_gemma":[0.99887145,0.00009709523,0.00014641178,0.0007006824,0.00010038401,0.00008397349],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012571395,0.00049644074,0.000717237,0.0003519037,0.00009600302,0.00009938835,0.00012774023,0.0003333695,0.0003411374],"category_scores_gemma":[0.00002241942,0.00040536388,0.00032053207,0.00021638373,0.00013569233,0.000057022677,0.00007552782,0.00064036716,0.0017648874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054790817,0.00018332462,0.000072169816,0.0008718634,0.0018065542,0.0028790778,0.0003221354,0.0000022329523,0.000013530198,0.009057209,0.98090285,0.0038835665],"study_design_scores_gemma":[0.0006210189,0.001032058,0.00038050776,0.0012517975,0.0015631436,0.000008705538,0.0002128716,0.000010188024,0.0005850756,0.000562159,0.9936335,0.00013899268],"about_ca_topic_score_codex":0.000017795355,"about_ca_topic_score_gemma":0.000003141737,"teacher_disagreement_score":0.047074273,"about_ca_system_score_codex":0.00020204241,"about_ca_system_score_gemma":0.00008422809,"threshold_uncertainty_score":0.99983984},"labels":[],"label_agreement":null},{"id":"W4405585122","doi":"10.4102/phcfm.v16i1.4857","title":"Minimising harms of tight glycaemic control in older patients with type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"African Journal of Primary Health Care & Family Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Gerontology; Pediatrics; Internal medicine; Endocrinology","score_opus":0.010713181801183427,"score_gpt":0.2663892630721524,"score_spread":0.25567608127096897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405585122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.912147,0.07833785,0.00007983233,0.0058388375,0.0008040465,0.00069269555,0.0000106045745,0.000022823862,0.0020663012],"genre_scores_gemma":[0.99292904,0.0009643754,0.0005370544,0.005183058,0.00024119459,0.0000052200526,0.000040527586,0.000035854646,0.00006367216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977644,0.000088761495,0.000867272,0.0002100559,0.0006901158,0.0003793621],"domain_scores_gemma":[0.99856174,0.0001728596,0.00037832538,0.0001990304,0.00039900315,0.00028905296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005208038,0.00021824305,0.0010091222,0.00061344117,0.000028065402,0.0000075623666,0.0001184408,0.000046891586,0.00003784941],"category_scores_gemma":[0.000062712,0.00013348155,0.00008435165,0.0006151042,0.00013934927,0.00012835291,0.000021124015,0.00030327577,0.0000030547099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029794252,0.0010751885,0.54761344,0.008384369,0.0015922338,0.00071870844,0.016402053,0.000019679623,0.0017996319,0.000050910232,0.058425654,0.36093873],"study_design_scores_gemma":[0.02142298,0.01998762,0.88743544,0.013958956,0.0011144045,0.000013366155,0.0032854432,0.000041068517,0.000059809452,0.000025552205,0.05240258,0.00025277567],"about_ca_topic_score_codex":0.000034599147,"about_ca_topic_score_gemma":0.0000041605945,"teacher_disagreement_score":0.36068594,"about_ca_system_score_codex":0.00059032853,"about_ca_system_score_gemma":0.0006636563,"threshold_uncertainty_score":0.54432195},"labels":[],"label_agreement":null},{"id":"W4405600257","doi":"10.1111/dom.16050","title":"Long‐term weight loss and cardiorenal outcomes by baseline <scp>BMI</scp> in the <scp>VERTIS CV</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Pfizer","keywords":"Medicine; Weight loss; Cardiorenal syndrome; Body mass index; Baseline (sea); Term (time); Internal medicine; Cardiology; Heart failure; Obesity","score_opus":0.008480813377605586,"score_gpt":0.2372306698724115,"score_spread":0.22874985649480592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405600257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94866836,0.046588253,0.00003278805,0.0008431848,0.0008270049,0.0011375635,0.00013355445,0.000120498946,0.0016487697],"genre_scores_gemma":[0.98335314,0.0068160873,0.000103238,0.002007911,0.00061643554,0.00018776121,0.00030086483,0.000049547,0.006564998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974635,0.00021912494,0.00043696526,0.000650791,0.00051475887,0.000714837],"domain_scores_gemma":[0.99825835,0.00092882087,0.00007299581,0.00043550393,0.00004671666,0.00025761157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001082179,0.00046624214,0.0009433337,0.0002840217,0.00015205026,0.00025825485,0.00019594967,0.00017993024,0.000016869602],"category_scores_gemma":[0.00034588674,0.00030166263,0.00027226377,0.00039332602,0.00020717729,0.00030077467,0.00016964071,0.0003650149,0.00004173858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000695068,0.0011934416,0.875221,0.0007472484,0.0019350067,0.000374997,0.002142377,8.968979e-7,0.0006435992,0.0019332115,0.06000734,0.055731364],"study_design_scores_gemma":[0.015927676,0.00020845672,0.69428694,0.00016316655,0.0016031055,0.0000061796873,0.00013211196,0.00009748597,0.0016275258,0.0003826369,0.28547323,0.00009151842],"about_ca_topic_score_codex":0.00004911828,"about_ca_topic_score_gemma":0.000019971128,"teacher_disagreement_score":0.22546588,"about_ca_system_score_codex":0.000034242363,"about_ca_system_score_gemma":0.000042777134,"threshold_uncertainty_score":0.99994355},"labels":[],"label_agreement":null},{"id":"W4405623585","doi":"10.1016/j.jdiacomp.2024.108945","title":"Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes","year":2024,"lang":"en","type":"article","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Sinai Health System","funders":"","keywords":"Medicine; Diabetes mellitus; Agonist; Glucagon-like peptide-1; Internal medicine; Endocrinology; Sodium; Glucagon; Glucagon-like peptide 1 receptor; Type 2 diabetes; Receptor; Insulin","score_opus":0.010516339662789295,"score_gpt":0.22721977258813175,"score_spread":0.21670343292534244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405623585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943476,0.004080458,0.000011502623,0.0007243269,0.00020366318,0.00047931608,0.00004627501,0.00002293766,0.00008395101],"genre_scores_gemma":[0.9983741,0.00062336493,0.00059308717,0.000055952925,0.00009538768,0.000031440464,0.000046469162,0.000026178248,0.0001540265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877113,0.000020328434,0.0005175328,0.00022877245,0.00022867719,0.00023358411],"domain_scores_gemma":[0.9991795,0.00011748511,0.00021090424,0.00014880867,0.000169134,0.00017416175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014554047,0.00018338111,0.00038783668,0.00032690226,0.000060763337,0.00011354855,0.000073561074,0.000052880907,0.000013722702],"category_scores_gemma":[0.000024486928,0.00013553516,0.00009245949,0.00025421908,0.00013586244,0.0005639789,0.000035386493,0.00018225964,0.0000021171597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035305635,0.0005120399,0.98705435,0.0007925246,0.00055093743,0.000010229543,0.0011017052,0.000002557998,0.0065887887,0.00018515783,0.0011848912,0.0019814917],"study_design_scores_gemma":[0.0017022385,0.0013057549,0.9855682,0.0034540098,0.0005507946,0.0000018233496,0.00039147734,0.00041974394,0.0047245687,0.000041925454,0.0016767901,0.00016263974],"about_ca_topic_score_codex":0.000005659137,"about_ca_topic_score_gemma":0.000017789374,"teacher_disagreement_score":0.004026524,"about_ca_system_score_codex":0.000042036612,"about_ca_system_score_gemma":0.000041549065,"threshold_uncertainty_score":0.55269635},"labels":[],"label_agreement":null},{"id":"W4405657525","doi":"10.1007/s13300-024-01674-8","title":"A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants","year":2024,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"Novo Nordisk","keywords":"Bioequivalence; Semaglutide; Medicine; Cmax; Pharmacokinetics; Crossover study; Confidence interval; Dosing; Pharmacology; Oral administration; Internal medicine; Type 2 diabetes; Diabetes mellitus; Endocrinology; Placebo; Alternative medicine","score_opus":0.07649554360568715,"score_gpt":0.3842856745036573,"score_spread":0.30779013089797014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405657525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626625,0.0020676379,0.00000882587,0.0002579088,0.000091465874,0.0009346229,0.000007521515,0.000043978278,0.00032177722],"genre_scores_gemma":[0.9992122,0.00014482584,0.00029745887,0.000119845725,0.000014549879,0.00010164712,0.000008657091,0.000016178137,0.000084614534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989576,0.000042279924,0.00034645986,0.00018749939,0.00018825568,0.00027791742],"domain_scores_gemma":[0.99953496,0.00008124232,0.000052524672,0.00024141587,0.000034344066,0.000055529326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026523013,0.000112155336,0.00033626315,0.00025169554,0.000014831899,0.0000078627745,0.00006390412,0.000020772131,0.000062113155],"category_scores_gemma":[0.000012613774,0.000086339605,0.00006588342,0.00045947367,0.000038886756,0.0000644445,0.000023962371,0.00005670564,0.000007869462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014133351,0.0027120435,0.9304507,0.0002533035,0.00045589134,0.000010246867,0.0023182663,0.000032593798,0.0045402143,0.0015459547,0.000076509925,0.057462953],"study_design_scores_gemma":[0.012679758,0.012322709,0.9484655,0.00065929734,0.000370659,2.2400913e-7,0.0006131459,0.0046040732,0.01607028,0.0027962057,0.0011714668,0.00024667577],"about_ca_topic_score_codex":0.00012641557,"about_ca_topic_score_gemma":0.00009742866,"teacher_disagreement_score":0.05721628,"about_ca_system_score_codex":0.000037351736,"about_ca_system_score_gemma":0.00003900987,"threshold_uncertainty_score":0.3520827},"labels":[],"label_agreement":null},{"id":"W4405659923","doi":"10.1016/j.biopha.2024.117771","title":"Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight","year":2024,"lang":"en","type":"article","venue":"Biomedicine & Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"CH Foundation; Welch Foundation","keywords":"Metformin; Type 2 diabetes; Medicine; Diabetes mellitus; Cognitive impairment; Pharmacology; Internal medicine; Endocrinology; Disease","score_opus":0.02287155672492868,"score_gpt":0.3391391405893274,"score_spread":0.31626758386439874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405659923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894869,0.005702167,0.000005436569,0.00038429748,0.00081778195,0.0025631315,0.00013911135,0.00010390596,0.0007972967],"genre_scores_gemma":[0.992898,0.003797454,0.000041569165,0.0018850735,0.00025817612,0.00016300577,0.00030980376,0.000086676955,0.00056024874],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977699,0.00010812219,0.0005314339,0.0005322522,0.0005631191,0.00049517077],"domain_scores_gemma":[0.9990088,0.00031461954,0.00013568024,0.00020859235,0.00012618958,0.00020614541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030422214,0.0005033406,0.00079323776,0.0012291921,0.000040365183,0.00002168913,0.00010977972,0.00009177253,0.000850386],"category_scores_gemma":[0.000025287873,0.00029170603,0.00026368507,0.0011953702,0.00011744198,0.00011019902,0.0000256967,0.0002022601,0.000067187975],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046452735,0.017162925,0.030509952,0.0007500521,0.0135965785,0.0006344395,0.0063204523,0.000010136853,0.21059513,0.00030320813,0.025752649,0.6479117],"study_design_scores_gemma":[0.064127624,0.11351942,0.14812365,0.007251097,0.0019720804,0.0000052035653,0.00030754422,0.0011807756,0.648542,0.000207059,0.013637158,0.0011263771],"about_ca_topic_score_codex":0.000068755115,"about_ca_topic_score_gemma":0.000003474117,"teacher_disagreement_score":0.6467854,"about_ca_system_score_codex":0.00044153468,"about_ca_system_score_gemma":0.00016612528,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W4405729115","doi":"10.1016/j.ophtha.2024.11.019","title":"Reply","year":2024,"lang":"en","type":"letter","venue":"Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prism Eye Institute","funders":"","keywords":"Medicine","score_opus":0.029365981689705733,"score_gpt":0.2985563835044386,"score_spread":0.26919040181473286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405729115","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012088226,0.00095081405,4.0027106e-7,0.67911893,0.0012675583,0.00029398146,0.000009781536,0.000101961086,0.31704774],"genre_scores_gemma":[0.0007919668,0.00001605123,0.00016214981,0.5917261,0.002388502,0.000074290576,0.00058010675,0.000056806017,0.40420398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987769,0.000027403146,0.00018736834,0.0004868588,0.00016486368,0.00035659684],"domain_scores_gemma":[0.9992965,0.00004450034,0.000046636946,0.0005458685,0.000025779924,0.000040743595],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006160451,0.00025042315,0.00046147103,0.0002203527,0.00001838688,0.000019108202,0.00009888352,0.00046264837,0.0026358073],"category_scores_gemma":[0.000016532764,0.0001990437,0.0002050396,0.00010301021,0.00006343421,0.000014739323,0.0001089295,0.0008511654,0.0057061953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008906741,0.00003011736,0.00030913003,0.00047278573,0.0005292305,0.08726094,0.0000096257045,2.3055861e-8,0.0000035538017,0.0000730025,0.9106321,0.00067060895],"study_design_scores_gemma":[0.000255776,0.00048355034,0.00030283988,0.00012471962,0.00079536013,0.0037139466,0.000002258549,0.000001936287,0.000017149643,0.0010021788,0.99315006,0.00015021538],"about_ca_topic_score_codex":0.000025040144,"about_ca_topic_score_gemma":3.975235e-8,"teacher_disagreement_score":0.08739279,"about_ca_system_score_codex":0.00008747403,"about_ca_system_score_gemma":0.00004921842,"threshold_uncertainty_score":0.99827594},"labels":[],"label_agreement":null},{"id":"W4405730135","doi":"10.1002/ehf2.15184","title":"Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF","year":2024,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Saint Luke's Health System; AstraZeneca","keywords":"Medicine; Dapagliflozin; Heart failure; Renal function; Placebo; Internal medicine; Ejection fraction; Confidence interval; Kidney disease; Randomized controlled trial; Cardiology; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.007021955884338477,"score_gpt":0.24661227916750203,"score_spread":0.23959032328316354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405730135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7965751,0.0080902465,0.000026085892,0.19214289,0.00029397933,0.002537868,0.000023773207,0.000093862116,0.00021615085],"genre_scores_gemma":[0.99354786,0.0004075634,0.0008806271,0.004349517,0.00009437278,0.00012014029,0.000074936645,0.000030822877,0.00049415126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843556,0.00024648945,0.0003176072,0.00037980953,0.0002459515,0.0003745661],"domain_scores_gemma":[0.99903727,0.00041306228,0.000034272234,0.00028181256,0.000021089425,0.0002124702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007775931,0.00020783558,0.00048409632,0.00028800487,0.000042799973,0.000042104417,0.00003476538,0.000083540894,0.00004063827],"category_scores_gemma":[0.0002703139,0.00013872457,0.00006306619,0.00038686415,0.00008829627,0.00011196881,0.00006743654,0.00029932178,0.00001782627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012493099,0.0007276459,0.331163,0.007856312,0.00028838913,0.000054259614,0.0010944777,0.00002458864,0.0017952139,0.0066218157,0.6393032,0.009821814],"study_design_scores_gemma":[0.013874428,0.0026146057,0.21852177,0.0041176323,0.00018709924,0.00000744456,0.00038169778,0.0014839038,0.0005199141,0.0007676245,0.75728226,0.00024162709],"about_ca_topic_score_codex":0.00082704535,"about_ca_topic_score_gemma":0.0018688081,"teacher_disagreement_score":0.19697273,"about_ca_system_score_codex":0.00007992231,"about_ca_system_score_gemma":0.00012485558,"threshold_uncertainty_score":0.5657024},"labels":[],"label_agreement":null},{"id":"W4405748759","doi":"10.1016/j.jval.2024.10.134","title":"CO57 Clinical and Patient-Reported Outcomes Associated With Oral Semaglutide Use in Adults With Type 2 Diabetes: A Pooled Analysis of Six Pioneer Real Prospective Real-World Studies","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Pooled analysis; Meta-analysis; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.05708299758418476,"score_gpt":0.3627923401509598,"score_spread":0.305709342566775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969436,0.0007873713,7.024172e-7,0.0006121862,0.00008498489,0.0013356215,0.000020467305,0.00007742119,0.00013766014],"genre_scores_gemma":[0.9980548,0.00084717735,0.00036104035,0.00021117259,0.000008510522,0.0000704105,0.00007463116,0.00002679131,0.00034546078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976711,0.00023569405,0.0008917069,0.00049050216,0.00035426658,0.00035669908],"domain_scores_gemma":[0.9984738,0.00068091706,0.0002783597,0.00025892415,0.00018440097,0.00012359823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077481224,0.00022213759,0.0012582887,0.00081593054,0.000028816794,0.000017608072,0.000033650933,0.000054261433,0.000004822958],"category_scores_gemma":[0.0004140072,0.00014184648,0.0000812224,0.0024837372,0.00014302378,0.00009012109,0.000045231813,0.00020433097,9.164269e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005930696,0.0006853587,0.9856451,0.00038213358,0.0085746115,0.00016877803,0.002056112,0.000369255,8.1455767e-7,0.00017392701,0.00014248308,0.0012083504],"study_design_scores_gemma":[0.003456369,0.0028604756,0.9836425,0.0024906446,0.0024103392,2.8562332e-7,0.0006236759,0.004318865,0.000004973718,0.000038966922,0.000022429695,0.00013045322],"about_ca_topic_score_codex":0.008668601,"about_ca_topic_score_gemma":0.028324798,"teacher_disagreement_score":0.019656198,"about_ca_system_score_codex":0.00039748763,"about_ca_system_score_gemma":0.00022757247,"threshold_uncertainty_score":0.99793273},"labels":[],"label_agreement":null},{"id":"W4405748795","doi":"10.1016/j.jval.2024.10.136","title":"CO59 Do Asthma Patients Prescribed a GLP1 Have Improved Asthma and Weight Loss Outcomes?","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Markham Stouffville Hospital","funders":"","keywords":"Asthma; Medicine; Weight loss; Physical therapy; Internal medicine; Obesity","score_opus":0.01689629746621388,"score_gpt":0.28326133280996835,"score_spread":0.26636503534375444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842038,0.003912153,0.000038453552,0.0063740523,0.0007387847,0.0018767638,0.000037657348,0.00014977252,0.002668532],"genre_scores_gemma":[0.99354166,0.0005581623,0.0008379767,0.0012003704,0.00008896926,0.000095770796,0.00007193637,0.00004178087,0.0035633459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983381,0.00008112163,0.0004139312,0.00044069134,0.0002641108,0.00046203154],"domain_scores_gemma":[0.99928886,0.000093143724,0.000065339875,0.00028487964,0.00003203453,0.00023576243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036143087,0.00021435678,0.0004117299,0.00024029396,0.000049402617,0.00005883221,0.00006290086,0.00006772515,0.00005692278],"category_scores_gemma":[0.000049793445,0.00016449078,0.00007451945,0.00018146515,0.000042095344,0.00010952463,0.00008791968,0.00018208273,0.00004847145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022780758,0.0012188177,0.82234716,0.0035219234,0.00036756112,0.00021084434,0.002380636,0.000020109748,0.00001967914,0.005141352,0.008278375,0.15626575],"study_design_scores_gemma":[0.009071252,0.003071514,0.72122866,0.0018408009,0.000089364126,0.00000878886,0.0001607801,0.016633425,0.000069610694,0.0011434535,0.24628165,0.00040072136],"about_ca_topic_score_codex":0.0009771414,"about_ca_topic_score_gemma":0.000040670133,"teacher_disagreement_score":0.23800328,"about_ca_system_score_codex":0.00029029587,"about_ca_system_score_gemma":0.00011655919,"threshold_uncertainty_score":0.6707739},"labels":[],"label_agreement":null},{"id":"W4405802866","doi":"10.1172/jci.insight.174825","title":"Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice","year":2024,"lang":"en","type":"article","venue":"JCI Insight","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research; Novo Nordisk; AstraZeneca; Amgen; Pfizer; Banting and Best Diabetes Centre, University of Toronto; International Development Research Centre","keywords":"Inflammation; Internal medicine; Incretin; Endocrinology; Glucagon-like peptide-1; Proinflammatory cytokine; Context (archaeology); Gastric inhibitory polypeptide; Receptor; Glucagon-like peptide-2; Stromal cell; Biology; Diabetes mellitus; Type 2 diabetes; Medicine; Hormone; Glucagon; Peptide","score_opus":0.013711104290368703,"score_gpt":0.24800142292423807,"score_spread":0.23429031863386937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405802866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759256,0.0051568733,0.000079483776,0.0020627235,0.00052016246,0.00057993614,0.0000033078977,0.0002537469,0.015418162],"genre_scores_gemma":[0.9922815,0.0005887401,0.0010517205,0.0002698293,0.00038845284,0.000074606825,0.000100432946,0.00003587495,0.0052088737],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988014,0.000034792152,0.0003355478,0.00031143066,0.00026178246,0.00025505974],"domain_scores_gemma":[0.999598,0.00006651319,0.000042968077,0.00017858119,0.000034270743,0.00007963573],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012718672,0.00018097438,0.00023819026,0.00031481104,0.000033616612,0.000080615464,0.0000740109,0.0000822698,0.00037296326],"category_scores_gemma":[0.000033848537,0.00014838293,0.00008303663,0.0002916517,0.000019800562,0.00021767474,0.00005638244,0.00016663957,0.0010146381],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024060157,0.0006352677,0.013659047,0.0012892431,0.0008131635,0.00076984207,0.0044697113,0.0001522413,0.78007466,0.008858603,0.006199402,0.18283825],"study_design_scores_gemma":[0.0037774236,0.00075576035,0.01702282,0.0018813072,0.0004340806,0.00000888035,0.00041520566,0.002302602,0.39969122,0.0006912958,0.57244873,0.0005706931],"about_ca_topic_score_codex":0.0000686473,"about_ca_topic_score_gemma":0.00005474069,"teacher_disagreement_score":0.5662493,"about_ca_system_score_codex":0.0002446548,"about_ca_system_score_gemma":0.000054292203,"threshold_uncertainty_score":0.9997632},"labels":[],"label_agreement":null},{"id":"W4405809532","doi":"10.1002/ejhf.3548","title":"Empagliflozin in Acute Myocardial Infarction in Patients with and Without Type 2 Diabetes: A Pre-Specified Analysis of the EMPACT-MI Trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Boehringer Ingelheim España; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Myocardial infarction; Heart failure; Type 2 diabetes; Internal medicine; Cardiology; Type 2 Diabetes Mellitus; Clinical trial; Diabetes mellitus; Endocrinology","score_opus":0.008454565064452215,"score_gpt":0.23896585637549836,"score_spread":0.23051129131104614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405809532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731606,0.0002500773,0.0000040047,0.0016881309,0.00020564604,0.00034115964,0.0000043310592,0.000006540303,0.00018404561],"genre_scores_gemma":[0.9994193,0.00002846966,0.0002316683,0.00010302253,0.00008879833,0.0000012908117,0.000006592101,0.000017860953,0.00010304605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988189,0.00022769922,0.0003820336,0.00012961864,0.00030043273,0.00014131701],"domain_scores_gemma":[0.9995643,0.000027826729,0.000118030555,0.00015584812,0.00007173064,0.00006225751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052017387,0.00011512929,0.00039957828,0.00054189377,0.000016036349,0.000036484344,0.00006204998,0.000020277503,0.000028676179],"category_scores_gemma":[0.000036941467,0.00006614265,0.00016568773,0.00086954347,0.00004355361,0.00012853231,0.000037633163,0.00023160846,0.000002890457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010042496,0.00025592223,0.9792334,0.00004048293,0.0040740087,0.000032553995,0.0013162534,0.000112299575,0.00012282512,0.000006949971,0.0029730832,0.0017897113],"study_design_scores_gemma":[0.01499169,0.0022062731,0.972521,0.00037105608,0.0023800111,0.0000016032551,0.00008187961,0.00005666471,0.00003785791,0.0000026583207,0.0072849826,0.00006432351],"about_ca_topic_score_codex":0.0000029641792,"about_ca_topic_score_gemma":0.00001905668,"teacher_disagreement_score":0.006712414,"about_ca_system_score_codex":0.00005050229,"about_ca_system_score_gemma":0.000045161545,"threshold_uncertainty_score":0.2697219},"labels":[],"label_agreement":null},{"id":"W4405836136","doi":"10.1016/j.cjco.2024.12.008","title":"Sodium Glucose Cotransporter Inhibition in Acute Heart Failure: An In-Depth Review","year":2024,"lang":"en","type":"review","venue":"CJC Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital; University of Manitoba","funders":"","keywords":"Transporter; Heart failure; Glucose transporter; Sodium; Internal medicine; Cardiology; Medicine; Chemistry; Biochemistry; Insulin","score_opus":0.045954836112372145,"score_gpt":0.36696201674858714,"score_spread":0.321007180636215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405836136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030192432,0.986531,6.275471e-7,0.0015253922,0.0002177652,0.006305182,0.00003598757,0.000048177662,0.005305675],"genre_scores_gemma":[0.000020879586,0.9914211,0.00026211215,0.0015100503,0.00009071548,0.0012013735,0.002674128,0.00008171932,0.0027379056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792016,0.000107558444,0.0007579853,0.00065736874,0.00021501452,0.0003419162],"domain_scores_gemma":[0.99908936,0.000019346367,0.00011158712,0.00062165747,0.000022179229,0.00013587832],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051777397,0.0004507068,0.0027040504,0.0003239533,0.000016690512,0.00010455993,0.00021626492,0.00018106004,0.000346039],"category_scores_gemma":[0.000009359759,0.00032460463,0.00032348387,0.00064313627,0.000028539844,0.0002780349,0.00019354121,0.000421365,0.0011548129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002079723,0.00053622655,0.00005394794,0.13843769,0.0005319486,0.0021623778,0.00005280524,1.8081604e-8,0.0000012933756,0.00025109702,0.09597636,0.76197547],"study_design_scores_gemma":[0.0007318172,0.00016715922,0.000036001784,0.18352492,0.0045010885,0.00003057477,0.0000052940627,3.877069e-7,0.0000024608037,0.000036195284,0.8107259,0.00023818134],"about_ca_topic_score_codex":0.000062851956,"about_ca_topic_score_gemma":0.0004111672,"teacher_disagreement_score":0.7617373,"about_ca_system_score_codex":0.00026731016,"about_ca_system_score_gemma":0.00020935774,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W4405861734","doi":"10.7759/cureus.76519","title":"A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure","year":2024,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Liraglutide; Semaglutide; Blood pressure; Exenatide; Internal medicine; Glucagon-like peptide 1 receptor; Mace; Glucagon-like peptide-1; Endocrinology; Diabetes mellitus; Type 2 diabetes; Myocardial infarction; Agonist; Receptor","score_opus":0.01392051608966947,"score_gpt":0.28131850510918094,"score_spread":0.26739798901951145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405861734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042495253,0.98852295,3.857968e-8,0.000051326442,0.00013135104,0.00470656,0.000058883827,0.000020171019,0.0022592265],"genre_scores_gemma":[0.0014944698,0.9973831,0.000030602598,0.00016459047,0.00002745136,0.00042409156,0.000048661677,0.000051914307,0.00037510137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805874,0.00026724368,0.0005988546,0.0005486126,0.0002739853,0.00025258883],"domain_scores_gemma":[0.9985981,0.00015533315,0.00033324238,0.00079609896,0.00003447981,0.00008277255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023965743,0.00057893846,0.002555211,0.00018107663,0.000023898598,0.000022486114,0.0002323567,0.00013704241,0.000011338948],"category_scores_gemma":[0.00002558989,0.0002972941,0.00044237523,0.00035725228,0.00012833059,0.000035032117,0.00036486756,0.00028259825,0.000006342699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016498489,0.0003728957,0.00011728487,0.349557,0.009018607,0.00004041431,0.0000615085,5.3608165e-8,0.00000423281,0.0005801278,0.00015755385,0.6400738],"study_design_scores_gemma":[0.001157587,0.0006805708,0.0002503652,0.16731615,0.05624884,0.00003054275,0.000012440031,6.4469157e-7,0.00039655046,0.00008653188,0.7736407,0.00017907377],"about_ca_topic_score_codex":0.0000282218,"about_ca_topic_score_gemma":0.00000388879,"teacher_disagreement_score":0.77348316,"about_ca_system_score_codex":0.0000149553225,"about_ca_system_score_gemma":0.000030093586,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W4406047185","doi":"10.2337/db24-0553","title":"Renal Tubule–Specific Angiotensinogen Deletion Attenuates SGLT2 Expression and Ameliorates Diabetic Kidney Disease in Murine Models of Type 1 Diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Nutrition, Metabolism and Diabetes; Canadian Institutes of Health Research; Kidney Foundation of Canada","keywords":"Endocrinology; Internal medicine; Afferent arterioles; Kidney; Angiotensin II; Losartan; Glomerular hyperfiltration; Diabetes mellitus; Streptozotocin; Diabetic nephropathy; Medicine; Renin–angiotensin system; Nephrin; Macula densa; Podocyte; Chemistry; Proteinuria; Receptor; Blood pressure","score_opus":0.01232111068865306,"score_gpt":0.2333498727655421,"score_spread":0.22102876207688904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406047185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98800933,0.009395856,0.000012907774,0.0011163298,0.00014576425,0.0006649413,0.000032169653,0.00007669112,0.0005459819],"genre_scores_gemma":[0.99717706,0.0007341044,0.0006490613,0.000531889,0.00005106406,0.0000791205,0.0003189831,0.000031473508,0.00042723588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983036,0.00006912773,0.00042494386,0.00048474703,0.00024242037,0.0004751665],"domain_scores_gemma":[0.9989233,0.00012677322,0.00010713045,0.00042472332,0.00016032747,0.00025774701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002015395,0.00030321584,0.0005802115,0.00052944775,0.00005971016,0.000036122,0.00010822752,0.00009260069,0.000045924993],"category_scores_gemma":[0.00013846424,0.000257856,0.000104664956,0.0006001364,0.00016181858,0.00019979327,0.00016205691,0.000119144366,0.000010325234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014195195,0.00054380856,0.76415294,0.00068502175,0.00021249567,0.000015079795,0.00009941857,0.00018367791,0.22104046,0.0004628541,0.0058715907,0.0065906947],"study_design_scores_gemma":[0.00593739,0.00071579515,0.47921312,0.0054237596,0.0009251526,1.642396e-7,0.00010048223,0.02003212,0.47437027,0.008729345,0.003845786,0.0007066109],"about_ca_topic_score_codex":0.000011085124,"about_ca_topic_score_gemma":8.757486e-7,"teacher_disagreement_score":0.28493986,"about_ca_system_score_codex":0.00006289717,"about_ca_system_score_gemma":0.000060332382,"threshold_uncertainty_score":0.99998736},"labels":[],"label_agreement":null},{"id":"W4406091261","doi":"10.58931/cdet.2024.2333","title":"Glucagon-like Peptide Receptor Agonists (GLP-1 receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients with Type 2 Diabetes Mellitus","year":2024,"lang":"en","type":"article","venue":"Canadian Diabetes & Endocrinology Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Medicine; Type 2 Diabetes Mellitus; Receptor; Diabetes mellitus; Agonist; Endocrinology; Internal medicine; Type 2 diabetes; Peptide receptor; Pharmacology","score_opus":0.006602325829071511,"score_gpt":0.22619473380327706,"score_spread":0.21959240797420557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98001254,0.0046361987,0.0000014683768,0.004980904,0.0023953044,0.0019714911,0.0007820684,0.00023696787,0.0049830647],"genre_scores_gemma":[0.97480416,0.00043730834,0.0007650276,0.0081863385,0.00035393427,0.00053816615,0.010768506,0.00015578687,0.0039907605],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962975,0.000114587354,0.00045922142,0.0010087866,0.00039342162,0.0017265129],"domain_scores_gemma":[0.99773926,0.00012546747,0.000079160454,0.0006100202,0.00031706414,0.0011290081],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001177673,0.0005789473,0.00065549894,0.0011082187,0.00018199021,0.00017207152,0.00028501553,0.00019179653,0.0033049542],"category_scores_gemma":[0.00012415255,0.0005184555,0.00014566604,0.0009182974,0.00020623599,0.00026863941,0.00007010111,0.0003835383,0.0018638114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005720571,0.00054114015,0.47731945,0.00048116746,0.001952881,0.00017562,0.0016728833,0.000018933708,0.0007001303,0.0016126927,0.31992072,0.19503231],"study_design_scores_gemma":[0.0027393708,0.0024517113,0.09851414,0.00053985254,0.00015357383,8.288064e-7,0.00014542308,0.000015979522,0.0015486247,0.000045445486,0.8932841,0.00056095526],"about_ca_topic_score_codex":0.0013859782,"about_ca_topic_score_gemma":0.006884779,"teacher_disagreement_score":0.57336336,"about_ca_system_score_codex":0.001749781,"about_ca_system_score_gemma":0.0012230686,"threshold_uncertainty_score":0.9997267},"labels":[],"label_agreement":null},{"id":"W4406104964","doi":"10.1016/j.cjca.2024.09.025","title":"Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Pfizer","keywords":"Semaglutide; Medicine; Cost effectiveness; Quality-adjusted life year; Overweight; Myocardial infarction; Cost-effectiveness analysis; Cohort; Population; Diabetes mellitus; Physical therapy; Emergency medicine; Intensive care medicine; Internal medicine; Obesity; Type 2 diabetes; Environmental health; Liraglutide; Endocrinology","score_opus":0.009469830639762677,"score_gpt":0.2214912971721249,"score_spread":0.21202146653236223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406104964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952816,0.0019583483,0.000326586,0.000066413006,0.000111127345,0.00041129455,0.000009004361,0.000001226497,0.0018344275],"genre_scores_gemma":[0.99982846,0.000030316027,0.000040592582,0.000036922804,0.00002237108,0.0000060225716,0.0000054276793,0.0000043012888,0.000025575295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941134,0.00012847502,0.00014110543,0.00009403697,0.00007701371,0.0001480539],"domain_scores_gemma":[0.9993952,0.00004437346,0.00003790772,0.00014978617,0.00013625005,0.00023648958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033768397,0.00007355317,0.0004953241,0.00031146646,0.000017337758,0.000003294284,0.00004135167,0.000031613672,0.000001725455],"category_scores_gemma":[0.000073612726,0.000056309935,0.00012165858,0.00012385742,0.000098121214,0.000025878797,0.000009327517,0.00007530534,2.7907143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027593662,0.0000092021455,0.9904158,0.00013584108,0.0014033946,0.00018311905,0.000012401709,0.0010938586,0.0000012166308,0.00014981629,0.0001499992,0.0061693876],"study_design_scores_gemma":[0.003518834,0.00024600982,0.9878256,0.00027574884,0.0007890504,0.0000032943244,0.00002115355,0.0000026622863,0.000014868553,0.000105708605,0.0071564373,0.00004067422],"about_ca_topic_score_codex":0.000355332,"about_ca_topic_score_gemma":0.00019560367,"teacher_disagreement_score":0.007006438,"about_ca_system_score_codex":0.00012613769,"about_ca_system_score_gemma":0.00043020034,"threshold_uncertainty_score":0.22962525},"labels":[],"label_agreement":null},{"id":"W4406109867","doi":"10.7326/annals-24-01590","title":"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes","year":2025,"lang":"en","type":"review","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Glucagon-like peptide-1; Weight loss; Glucagon-like peptide 1 receptor; Exenatide; Internal medicine; Endocrinology; Glucagon; Agonist; Receptor; Type 2 diabetes; Insulin; Obesity","score_opus":0.030053555722338626,"score_gpt":0.3473649390862578,"score_spread":0.3173113833639192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406109867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004594859,0.9874186,0.00003677448,0.00077489775,0.0007960463,0.0031643522,0.00014576969,0.00003708372,0.003031624],"genre_scores_gemma":[0.0016916645,0.98848987,0.00026626975,0.00040961726,0.00045602027,0.00021313722,0.00044493782,0.000061736486,0.007966745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691457,0.00008040807,0.0015369555,0.0005871263,0.00043382696,0.00044714563],"domain_scores_gemma":[0.9968546,0.000850271,0.0010583373,0.00056227215,0.00042545368,0.0002490809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005761757,0.0006328241,0.0038686127,0.0005620547,0.000038915598,0.0000078664,0.00032189436,0.00023851071,0.00012341078],"category_scores_gemma":[0.00069163577,0.0004111573,0.0005993549,0.00028066692,0.0005362755,0.000070767856,0.0001889209,0.00025732548,0.000005813586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001054853,0.00037309196,0.0032123849,0.09933618,0.004090062,0.000013220284,0.00014910087,4.6784724e-8,0.0000041902326,0.00017767349,0.031036796,0.86055243],"study_design_scores_gemma":[0.0043695127,0.0024982912,0.0007778739,0.2622582,0.0035990817,0.0000027717886,0.000025998444,0.0000043785235,0.00015868698,0.000025026058,0.72605276,0.00022738296],"about_ca_topic_score_codex":0.00007279204,"about_ca_topic_score_gemma":0.000008701482,"teacher_disagreement_score":0.86032504,"about_ca_system_score_codex":0.000044658747,"about_ca_system_score_gemma":0.0001184387,"threshold_uncertainty_score":0.999834},"labels":[],"label_agreement":null},{"id":"W4406159117","doi":"10.1007/s00424-024-03062-4","title":"Lessons from a model: early glucagon dysfunction in type 2 diabetes","year":2025,"lang":"en","type":"letter","venue":"Pflügers Archiv - European Journal of Physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Glucagon; Type 2 diabetes; Diabetes mellitus; Medicine; Type 1 diabetes; Internal medicine; Endocrinology; Insulin","score_opus":0.021218975594243166,"score_gpt":0.25078150406876903,"score_spread":0.22956252847452588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406159117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6476698,0.0015528786,0.0002487414,0.3322232,0.0024341822,0.000581252,0.00012712966,0.000067786896,0.015095046],"genre_scores_gemma":[0.49147677,0.0028665022,0.0037943015,0.4792633,0.008660523,0.000013878332,0.0017185537,0.00031238224,0.011893763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975965,0.0005798353,0.0006881516,0.00040400107,0.00025385065,0.00047768158],"domain_scores_gemma":[0.9986838,0.00019822094,0.0005072356,0.0004132642,0.0001061453,0.00009129461],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028878057,0.00037634955,0.0009647287,0.00069137017,0.000040511495,0.000020823602,0.00033110342,0.00012400465,0.00007622449],"category_scores_gemma":[0.000073603915,0.00030487686,0.0003441528,0.00020315417,0.000113096736,0.000088608256,0.00016124069,0.0016889703,0.00008624505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058902975,0.00027914593,0.00042853193,0.0003013939,0.0015951998,0.0014572142,0.00037242472,0.00042631698,0.020737428,0.000027182487,0.95033747,0.02344869],"study_design_scores_gemma":[0.009665655,0.005723066,0.08907365,0.0038288778,0.0034928904,0.000013474593,0.00008430567,0.0022673793,0.0011087401,0.006702655,0.87702024,0.001019045],"about_ca_topic_score_codex":0.000015569378,"about_ca_topic_score_gemma":0.0000018368158,"teacher_disagreement_score":0.15619299,"about_ca_system_score_codex":0.00011693805,"about_ca_system_score_gemma":0.00013998846,"threshold_uncertainty_score":0.99994034},"labels":[],"label_agreement":null},{"id":"W4406165103","doi":"10.2337/dc24-1903","title":"Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cirrhosis; Internal medicine; Gastroenterology; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Hepatocellular carcinoma; Cohort; Endocrinology; Confidence interval","score_opus":0.003550209465731236,"score_gpt":0.20125665105740206,"score_spread":0.19770644159167083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406165103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487954,0.002535003,0.0000010049416,0.0001675933,0.00021291507,0.0011279574,0.00002898268,0.000039327795,0.0010076897],"genre_scores_gemma":[0.99827325,0.00021877476,0.00012549016,0.00024506875,0.00002456592,0.00010342597,0.00038734474,0.000022228634,0.00059984863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893063,0.000046126985,0.00025467257,0.0003030138,0.00020419946,0.00026135746],"domain_scores_gemma":[0.99927014,0.00007526566,0.00011985103,0.00027092925,0.00018907584,0.00007471094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010623932,0.00021951934,0.00041709666,0.00012640281,0.0000948917,0.00003629759,0.000065928434,0.00007271175,0.000021372489],"category_scores_gemma":[0.000024054645,0.00014016061,0.000081712154,0.00024423737,0.0003466702,0.0001164236,0.000062495565,0.000092235576,0.000003972056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014927542,0.00013027045,0.9801085,0.0006795307,0.00051624246,4.3364255e-7,0.0006558985,4.9480633e-7,0.00024840306,0.000056352477,0.00089092576,0.016563658],"study_design_scores_gemma":[0.006238741,0.0006526009,0.9752665,0.0009262154,0.0012108495,1.514855e-8,0.0005958712,0.000018036291,0.011692834,0.000058373218,0.003174928,0.00016502867],"about_ca_topic_score_codex":0.000012503844,"about_ca_topic_score_gemma":0.00002387946,"teacher_disagreement_score":0.01639863,"about_ca_system_score_codex":0.000039990755,"about_ca_system_score_gemma":0.000028388316,"threshold_uncertainty_score":0.57155836},"labels":[],"label_agreement":null},{"id":"W4406183633","doi":"10.1089/thy.2024.0387","title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study","year":2025,"lang":"en","type":"review","venue":"Thyroid","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"National Health Research Institutes; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Thyroid cancer; Thyroid; Internal medicine; Oncology; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Cohort; Endocrinology; Receptor; Agonist; Diabetes mellitus; Type 2 diabetes","score_opus":0.01924194907735571,"score_gpt":0.33744456998477274,"score_spread":0.318202620907417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406183633","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018085727,0.97179604,0.000004125773,0.000023386905,0.0008222339,0.003994334,0.00041576283,0.00008753455,0.004770886],"genre_scores_gemma":[0.00035131103,0.98194826,0.00039147236,0.000038392707,0.00023616168,0.0006352134,0.00089950796,0.00005257322,0.015447125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977202,0.00017677767,0.00066782755,0.00071221497,0.00044421022,0.00027875992],"domain_scores_gemma":[0.9983634,0.00012798201,0.0004980257,0.0007293421,0.000126331,0.00015493372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000417717,0.00050083897,0.0018947447,0.00036929868,0.00007604861,0.000045176814,0.00031169085,0.00014632988,0.000164551],"category_scores_gemma":[0.0000675278,0.0003908999,0.00030132974,0.0002515792,0.00008242254,0.00011786712,0.000283251,0.00028879507,0.00004021099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076579265,0.0012228932,0.09223083,0.005533871,0.0067399945,0.00002907136,0.0001990702,5.905524e-7,0.0000041198946,0.00003128983,0.005243612,0.8886881],"study_design_scores_gemma":[0.0022725773,0.0010782272,0.01788989,0.0064104674,0.013074342,0.0000035074238,0.00010613155,0.000009512906,0.0000066555085,0.0000054164775,0.9587676,0.00037569404],"about_ca_topic_score_codex":0.00081237336,"about_ca_topic_score_gemma":0.00023902753,"teacher_disagreement_score":0.953524,"about_ca_system_score_codex":0.00026085062,"about_ca_system_score_gemma":0.00016769269,"threshold_uncertainty_score":0.99985427},"labels":[],"label_agreement":null},{"id":"W4406186001","doi":"10.1016/j.ajpc.2024.100922","title":"Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease","year":2025,"lang":"en","type":"article","venue":"American Journal of Preventive Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"National Center for Advancing Translational Sciences; Novo Nordisk","keywords":"Medicine; Type 2 diabetes; Internal medicine; Glucagon-like peptide-1; Endocrinology; Diabetes mellitus; Atherosclerotic cardiovascular disease; Disease; Receptor; Cardiology","score_opus":0.0032104703402801352,"score_gpt":0.21661200962455576,"score_spread":0.21340153928427563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406186001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996124,0.0024288334,0.00020346,0.000021514421,0.00029476758,0.000695625,0.000010966582,0.000013739727,0.00020708106],"genre_scores_gemma":[0.99817723,0.001398684,0.00015229108,0.00003236838,0.00006168678,0.00002200119,0.000019794968,0.00002530805,0.000110626024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978423,0.00088615576,0.00035315857,0.00032963048,0.00029854674,0.00029018815],"domain_scores_gemma":[0.9983081,0.00038379835,0.00042894782,0.00042232114,0.00025400604,0.00020277996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007483351,0.0002867049,0.0014904707,0.0002787598,0.000056127115,0.00001340447,0.00012305808,0.000045696797,0.000009450848],"category_scores_gemma":[0.00036613524,0.00018468096,0.00071388937,0.00036444707,0.000591347,0.00008658745,0.00006334649,0.00022837905,0.0000018351708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017174729,0.000114042996,0.94521254,0.0002449724,0.018264508,0.000049503444,0.00017518073,0.00046601647,0.000118147356,0.0000075519047,0.00024304626,0.03338699],"study_design_scores_gemma":[0.0045232433,0.014571749,0.96692276,0.0012033349,0.009689229,0.000002341464,0.0004456628,0.000017549957,0.0012349572,0.0000126089535,0.0011908275,0.00018574022],"about_ca_topic_score_codex":0.000046029996,"about_ca_topic_score_gemma":8.994105e-7,"teacher_disagreement_score":0.03320125,"about_ca_system_score_codex":0.000096540214,"about_ca_system_score_gemma":0.000076359305,"threshold_uncertainty_score":0.7531071},"labels":[],"label_agreement":null},{"id":"W4406225861","doi":"10.1111/dom.16190","title":"Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Tolerability; Internal medicine; Adverse effect; Renal function; Kidney disease; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.005007696488987766,"score_gpt":0.21690827824916928,"score_spread":0.2119005817601815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406225861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764062,0.018784944,0.000021324351,0.0005645751,0.00017997682,0.0030262133,0.00012519205,0.00009634474,0.0007952412],"genre_scores_gemma":[0.9925176,0.0028910476,0.0006325903,0.0017374248,0.00009618787,0.0005144827,0.0003438106,0.000027354175,0.0012394851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751157,0.00022731954,0.0004299423,0.00077777397,0.00044087993,0.000612505],"domain_scores_gemma":[0.99810433,0.0006741936,0.000120309036,0.00065208034,0.00009784351,0.00035124665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006918083,0.0004632804,0.0015761134,0.0003869903,0.00023907947,0.00019201012,0.00016945672,0.00016532054,0.0000061002825],"category_scores_gemma":[0.0005570864,0.00029799558,0.0003354274,0.0010214933,0.00029207452,0.00018801219,0.00022353772,0.00027485602,0.0000018295876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016329298,0.0006923103,0.9631082,0.00018282526,0.012200148,0.000021188185,0.0011567243,0.000004561051,0.0000061772535,0.00039172213,0.0010131128,0.02105977],"study_design_scores_gemma":[0.042498406,0.00020533905,0.90758723,0.00024092162,0.013666195,2.873127e-7,0.0009602386,0.00022127997,0.000092631984,0.00014592937,0.034309153,0.000072389535],"about_ca_topic_score_codex":0.002558047,"about_ca_topic_score_gemma":0.0011360558,"teacher_disagreement_score":0.055520937,"about_ca_system_score_codex":0.000041889118,"about_ca_system_score_gemma":0.000108960994,"threshold_uncertainty_score":0.9999472},"labels":[],"label_agreement":null},{"id":"W4406231961","doi":"10.1038/s41591-024-03463-z","title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Semaglutide; Medicine; Crossover study; Placebo; Glycemic; Type 2 diabetes; Insulin; Hypoglycemia; Randomized controlled trial; Diabetic ketoacidosis; Internal medicine; Diabetes mellitus; Clinical endpoint; Type 1 diabetes; Endocrinology","score_opus":0.01040249594234493,"score_gpt":0.2929020427763538,"score_spread":0.28249954683400885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406231961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550028,0.011659613,0.000009425384,0.007580658,0.001274602,0.004653966,0.0000036627962,0.0004632505,0.019352067],"genre_scores_gemma":[0.98463285,0.00040954322,0.00029273357,0.0043045734,0.00033990646,0.00023197736,0.0001959998,0.000039402148,0.009553013],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976083,0.00010128305,0.00063349144,0.00053785567,0.0005884942,0.00053057197],"domain_scores_gemma":[0.9984819,0.0004510659,0.00016161079,0.00050020585,0.00025625055,0.00014896173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007006876,0.00041188655,0.0014787043,0.00074388384,0.00006549197,0.00002678576,0.00017458422,0.0004191437,0.00021240352],"category_scores_gemma":[0.0004252462,0.00025104033,0.00013099196,0.0014985297,0.00032233266,0.000068134694,0.000072854724,0.00080559007,0.000040145824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9769087,0.0005356858,0.0008777268,0.00024639568,0.0009969504,0.0006584041,0.00017431896,0.00002192022,0.00016912355,0.00070541847,0.0158736,0.0028317862],"study_design_scores_gemma":[0.978443,0.0022880088,0.00046462513,0.0014298167,0.0015219619,0.000011451681,0.00009116273,0.001160627,0.00039919204,0.0001346784,0.013828525,0.00022694179],"about_ca_topic_score_codex":0.0001193632,"about_ca_topic_score_gemma":0.000130844,"teacher_disagreement_score":0.029630095,"about_ca_system_score_codex":0.00024552556,"about_ca_system_score_gemma":0.00023640649,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W4406236060","doi":"10.1002/ejhf.3511","title":"Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute on Minority Health and Health Disparities; National Heart, Lung, and Blood Institute; National Institute on Aging; Pfizer","keywords":"Medicine; Hazard ratio; Heart failure; Internal medicine; MedDRA; Placebo; Adverse effect; Confidence interval; Cardiology; Proportional hazards model; Diabetes mellitus; Type 2 diabetes; Pharmacovigilance; Pathology; Endocrinology","score_opus":0.030356730654667326,"score_gpt":0.25815648150026005,"score_spread":0.22779975084559273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406236060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693624,0.002959385,0.000032036354,0.026822204,0.00018604564,0.0005946701,0.000007428954,0.000015651318,0.000020195414],"genre_scores_gemma":[0.99712956,0.000039548322,0.0012900257,0.0011170421,0.00010952845,0.0000091506845,0.000018751707,0.000026029424,0.00026035294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796784,0.00035363983,0.0008030002,0.00022339138,0.0003712541,0.0002808884],"domain_scores_gemma":[0.99890125,0.00011487826,0.0003146706,0.00039493412,0.00010612092,0.00016813447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011140305,0.00018789386,0.0005590723,0.00007475958,0.00010174262,0.00004608182,0.00009620947,0.000022737704,0.000023128321],"category_scores_gemma":[0.0006181918,0.00011128899,0.0002669408,0.00023923059,0.000062427156,0.0001315141,0.000061091945,0.0002489736,0.0000067285473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009373948,0.00022068927,0.938277,0.000036434794,0.0017617361,0.00015886818,0.00026083624,0.0003507616,0.00067848037,0.0000071308937,0.057009164,0.000301496],"study_design_scores_gemma":[0.014006913,0.00039263366,0.83057994,0.00066253496,0.0010978687,0.000002649059,0.00039253727,0.000036196718,0.000069632755,0.000011014595,0.1526426,0.00010549385],"about_ca_topic_score_codex":0.000020293406,"about_ca_topic_score_gemma":0.000022911583,"teacher_disagreement_score":0.10769707,"about_ca_system_score_codex":0.000053835043,"about_ca_system_score_gemma":0.00009748547,"threshold_uncertainty_score":0.45382333},"labels":[],"label_agreement":null},{"id":"W4406279195","doi":"10.1159/000543533","title":"The Impact of SGLT2 Inhibitors on Dementia Onset in Patients with Type 2 Diabetes: A Meta-Analysis of Cohort Studies","year":2025,"lang":"en","type":"review","venue":"Neuroendocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Medicine; Internal medicine; Cochrane Library; Type 2 diabetes; Meta-analysis; Cohort study; Cohort; Relative risk; Subgroup analysis; Diabetes mellitus; Confidence interval; Endocrinology; Disease","score_opus":0.06077006199168678,"score_gpt":0.36758803872554685,"score_spread":0.3068179767338601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406279195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026648305,0.9708682,3.162193e-8,0.000046882837,0.00012839462,0.0018811402,0.0000844763,0.000014725879,0.0003278768],"genre_scores_gemma":[0.012112076,0.9869701,0.000007604601,0.000046290155,0.0000063174953,0.0002621844,0.00021671658,0.000024031297,0.0003546788],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977077,0.00031525298,0.0008412991,0.00044990837,0.00028110069,0.00040471752],"domain_scores_gemma":[0.9976497,0.0007410359,0.00059704395,0.00077983324,0.00019343947,0.000038934533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046635054,0.0004502646,0.0049030907,0.0011853885,0.000033423305,0.000005601922,0.00020503029,0.000049780956,0.000039190996],"category_scores_gemma":[0.00019189925,0.00021073286,0.001710882,0.0015405081,0.00018842684,0.000019483447,0.00017524652,0.00022971781,0.0000047893773],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103600796,0.00064370246,0.16682139,0.002870631,0.7781316,0.000030000881,0.000010148845,0.00001720706,2.5187322e-8,0.000035044577,0.0016551593,0.04968146],"study_design_scores_gemma":[0.0008172978,0.0034708946,0.060383935,0.0007387184,0.8991458,3.5569158e-7,0.000007864218,0.0000010429527,0.0000028880868,0.0000051337647,0.035283886,0.00014222886],"about_ca_topic_score_codex":0.000027332175,"about_ca_topic_score_gemma":0.00003401979,"teacher_disagreement_score":0.121014126,"about_ca_system_score_codex":0.00010985447,"about_ca_system_score_gemma":0.0001299825,"threshold_uncertainty_score":0.8593437},"labels":[],"label_agreement":null},{"id":"W4406386984","doi":"10.1016/j.yend.2013.03.046","title":"10.1016/j.yend.2013.03.046","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Type 2 diabetes; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.006642370170176014,"score_gpt":0.18868804924248325,"score_spread":0.18204567907230723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406386984","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002416621,0.00011261509,1.735898e-7,0.0013087954,0.0000018902807,0.00038682416,0.00000459211,0.0001594969,0.995609],"genre_scores_gemma":[0.00033461675,0.0000013934091,0.00019933334,0.00019823552,0.00010112287,0.000039253402,0.000049174923,0.000023951077,0.99905294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992323,0.000011441326,0.00012397808,0.00020088456,0.00017134748,0.00026004788],"domain_scores_gemma":[0.99947435,0.000015365651,0.00001515531,0.00030321552,0.000022916247,0.00016902525],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000065428416,0.00013167056,0.0001907477,0.000078370016,0.000036938633,0.000019802234,0.00007841179,0.000035861634,0.9976496],"category_scores_gemma":[0.000008242271,0.00011091999,0.000068139925,0.00013707833,0.000018678413,0.000052641288,0.000030382122,0.000050837327,0.9977704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062535095,0.00011888643,0.0000010293592,0.000009065284,0.00006424869,0.00001650731,0.000008007126,0.0000035100863,0.000013626516,0.0000019011381,0.46872294,0.5309777],"study_design_scores_gemma":[0.00084767985,0.0004664145,0.00021367181,0.000032868615,0.00013913808,0.0000028124778,0.0000011150511,0.000049109713,0.00011102268,0.0000070191722,0.99801487,0.00011425378],"about_ca_topic_score_codex":0.00001543559,"about_ca_topic_score_gemma":1.4905504e-7,"teacher_disagreement_score":0.53086346,"about_ca_system_score_codex":0.000043863856,"about_ca_system_score_gemma":0.000012547373,"threshold_uncertainty_score":0.45231858},"labels":[],"label_agreement":null},{"id":"W4406426506","doi":"10.1136/bmjopen-2024-089477","title":"Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis","year":2025,"lang":"en","type":"article","venue":"BMJ Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Weight loss; Obesity; Retrospective cohort study; Cohort; Cohort study; Weight management; Epidemiology; Internal medicine","score_opus":0.05195590939017551,"score_gpt":0.370310322091411,"score_spread":0.3183544127012355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406426506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97574884,0.000016526114,0.000328765,0.0016898179,0.000049770824,0.01341751,0.00018831786,0.00006483836,0.008495593],"genre_scores_gemma":[0.9487876,0.0000045799748,0.00028151757,0.00036368443,0.000017084076,0.0025196373,0.00068208535,0.000016053327,0.047327712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867237,0.00010377784,0.00022414251,0.0004773968,0.00022777716,0.0002945158],"domain_scores_gemma":[0.9988611,0.00020178429,0.000107064625,0.00052744005,0.00017431687,0.00012833756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059364113,0.00023874872,0.000848235,0.00040884432,0.00014220826,0.00009060194,0.00018541778,0.00006331656,0.000093774834],"category_scores_gemma":[0.00028592697,0.00015487107,0.00021621148,0.0013466385,0.000034317614,0.00010170509,0.00013903747,0.0000373483,0.0000105296895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003852552,0.00070973136,0.97467536,0.000014120469,0.016198302,0.000030402543,0.00026896037,0.000007552362,0.000020770662,0.00029702744,0.003625413,0.0002998062],"study_design_scores_gemma":[0.004061447,0.0018628788,0.9805686,0.000136567,0.008232012,8.8534016e-8,0.00012560697,0.000058821086,0.0007666792,0.000100013036,0.0039195325,0.00016776186],"about_ca_topic_score_codex":0.00033702538,"about_ca_topic_score_gemma":0.0016507449,"teacher_disagreement_score":0.038832117,"about_ca_system_score_codex":0.0010598329,"about_ca_system_score_gemma":0.00015863293,"threshold_uncertainty_score":0.6315459},"labels":[],"label_agreement":null},{"id":"W4406427641","doi":"10.1016/s1544-8800(13)70019-8","title":"10.1016/s1544-8800(13)70019-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.00574688336225124,"score_gpt":0.1835297954550232,"score_spread":0.17778291209277197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406427641","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029968272,0.00009423471,3.4071377e-7,0.000932355,0.000001802235,0.00041745667,0.0000059945914,0.00016076154,0.99539024],"genre_scores_gemma":[0.00042358876,6.943209e-7,0.00016146818,0.00019200955,0.00013360714,0.000041481417,0.00006479628,0.000025989031,0.9989564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99918115,0.00001223752,0.00013451841,0.00021505449,0.00018157053,0.00027544616],"domain_scores_gemma":[0.99944544,0.000017397859,0.00001662857,0.00031846671,0.000024138188,0.00017795226],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000068890055,0.00014108625,0.00020661464,0.000082591534,0.00003914421,0.000021673239,0.00008307071,0.000038992555,0.9979946],"category_scores_gemma":[0.000010994043,0.000120162986,0.000074960364,0.00015600807,0.000019859739,0.000053568136,0.000033166405,0.000055884993,0.9970769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008092693,0.00013784588,0.000001926765,0.00001083695,0.00007436067,0.000020966661,0.000008722135,0.0000049768914,0.000011867516,0.0000012722242,0.44071457,0.5589317],"study_design_scores_gemma":[0.0009591102,0.0005036349,0.0004996111,0.000037552167,0.00016690182,0.0000031085838,0.0000011737031,0.000055600132,0.00009318415,0.0000056766726,0.9975509,0.00012355146],"about_ca_topic_score_codex":0.00002459182,"about_ca_topic_score_gemma":2.5411026e-7,"teacher_disagreement_score":0.55880815,"about_ca_system_score_codex":0.00005153409,"about_ca_system_score_gemma":0.00001527661,"threshold_uncertainty_score":0.49001044},"labels":[],"label_agreement":null},{"id":"W4406455354","doi":"10.1016/j.yend.2014.04.027","title":"10.1016/j.yend.2014.04.027","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Saxagliptin; Type 2 Diabetes Mellitus; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology; Sitagliptin","score_opus":0.005874481017283675,"score_gpt":0.18761610485235278,"score_spread":0.1817416238350691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406455354","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014250969,0.000112931164,3.268254e-7,0.00092075294,0.0000018903337,0.00037794796,0.000004761857,0.00018078511,0.9969755],"genre_scores_gemma":[0.00033837673,0.0000011403977,0.0001955113,0.00020852347,0.00013344784,0.000036032547,0.000049878967,0.0000250987,0.999012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992262,0.000011946118,0.00012461777,0.00020570995,0.00017192756,0.000259575],"domain_scores_gemma":[0.9994633,0.00001662692,0.000015910186,0.0003129514,0.000021713466,0.00016946782],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007096593,0.00013170703,0.00019313263,0.00008024273,0.000035676345,0.000020052346,0.000079993464,0.00003590434,0.9978858],"category_scores_gemma":[0.000009426607,0.00011118035,0.00007038987,0.00011624432,0.000018697763,0.000050196886,0.00003051617,0.00005097517,0.99752307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000649317,0.00010981309,0.0000010276308,0.000008851925,0.00006250479,0.000016329885,0.0000067778337,0.000002859686,0.000014332768,0.0000013547834,0.49077234,0.5089389],"study_design_scores_gemma":[0.00090407184,0.0004672671,0.0002329371,0.000030850795,0.00015378777,0.0000028631916,9.830883e-7,0.00004234494,0.00013077974,0.0000058110086,0.9979142,0.00011413585],"about_ca_topic_score_codex":0.00001117671,"about_ca_topic_score_gemma":9.9913805e-8,"teacher_disagreement_score":0.50882477,"about_ca_system_score_codex":0.000046016765,"about_ca_system_score_gemma":0.000013658038,"threshold_uncertainty_score":0.45338032},"labels":[],"label_agreement":null},{"id":"W4406473283","doi":"10.1016/s1558-0164(07)70196-7","title":"10.1016/s1558-0164(07)70196-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Disease; Comorbidity; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.005960428579966905,"score_gpt":0.18521635879403847,"score_spread":0.17925593021407157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406473283","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017829101,0.000096245065,3.4441533e-7,0.00091931294,0.000001771413,0.0004178578,0.0000050625304,0.00017167468,0.9966048],"genre_scores_gemma":[0.00038297338,8.142898e-7,0.00020305785,0.00021910085,0.00013358884,0.000041513915,0.000050395643,0.000026332227,0.9989422],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917483,0.000012399023,0.0001357787,0.00021778315,0.00018393892,0.00027525533],"domain_scores_gemma":[0.9994415,0.00001749397,0.000017124583,0.00032144124,0.000024149278,0.00017830794],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000072378745,0.00014208662,0.00020806951,0.00007994784,0.00003956794,0.000021550304,0.00008389692,0.000038687172,0.9986254],"category_scores_gemma":[0.000011697431,0.00012053665,0.0000765684,0.00013991035,0.000019910107,0.000051523843,0.00003314196,0.00005609944,0.9994036],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009797284,0.0001633948,2.6315143e-7,0.000013282701,0.00008969531,0.000027242655,0.0000107721535,0.000004405011,0.00002020023,0.0000018994242,0.6519948,0.34757602],"study_design_scores_gemma":[0.0009189757,0.00051072246,0.000247571,0.00003826281,0.00016258324,0.0000032923094,0.0000011840499,0.000044191256,0.00012754739,0.0000055587843,0.99781513,0.00012495217],"about_ca_topic_score_codex":0.000009802156,"about_ca_topic_score_gemma":7.093457e-8,"teacher_disagreement_score":0.3474511,"about_ca_system_score_codex":0.000054302625,"about_ca_system_score_gemma":0.000015892536,"threshold_uncertainty_score":0.49153417},"labels":[],"label_agreement":null},{"id":"W4406495237","doi":"10.1101/2025.01.13.632834","title":"Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretion <i>in vitro</i> and <i>in vivo</i> of a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Biotechnology and Biological Sciences Research Council; Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Eli Lilly and Company; Society for Endocrinology; Diabetes UK; Wellcome Trust","keywords":"Internalization; In vivo; Agonist; In vitro; Kinetics; Chemistry; Receptor; Endocrinology; Internal medicine; Secretion; Insulin; Dual (grammatical number); Cell biology; Biology; Biochemistry; Medicine; Physics; Philosophy; Genetics","score_opus":0.014138188080954737,"score_gpt":0.22859686466713341,"score_spread":0.21445867658617868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406495237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524254,0.0012999795,0.00041735105,0.0003023236,0.0006929081,0.0016383366,0.00023552391,0.00009633013,0.000074724754],"genre_scores_gemma":[0.9943123,0.0017068741,0.0031171595,0.00040465954,0.00015152873,0.00018289579,0.0000070377514,0.00006276441,0.0000547872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99767643,0.00010866315,0.000633987,0.0008485953,0.00032227943,0.0004100373],"domain_scores_gemma":[0.9986482,0.00013761244,0.00038247116,0.0005088399,0.0001562956,0.00016656726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052220497,0.0004973418,0.00082413276,0.0008716239,0.00003561522,0.000082123945,0.00012324516,0.00036847906,0.000010764684],"category_scores_gemma":[0.00028724538,0.00052216765,0.000082788145,0.00054028,0.00009108102,0.00009107981,0.00034778306,0.00041257212,0.0000028561203],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005730131,0.00085279194,0.019902557,0.003076393,0.0002185793,0.000052447398,0.000029250103,0.000024220259,0.97460175,0.00026823475,0.00031689493,0.00008386276],"study_design_scores_gemma":[0.00645365,0.00044837984,0.034284104,0.0072857575,0.00040525515,3.145573e-8,0.000005700246,0.001593609,0.94482356,0.0000017828525,0.0041482695,0.0005499207],"about_ca_topic_score_codex":0.000114306444,"about_ca_topic_score_gemma":0.000012384527,"teacher_disagreement_score":0.029778214,"about_ca_system_score_codex":0.0004965211,"about_ca_system_score_gemma":0.00016923776,"threshold_uncertainty_score":0.999723},"labels":[],"label_agreement":null},{"id":"W4406503203","doi":"10.1093/ndt/gfaf013","title":"DEFENDER trial: dapagliflozin for critically ill patients with acute organ dysfunction—implications for clinicians","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Critically ill; Intensive care medicine; Organ dysfunction; Internal medicine; Sepsis; Diabetes mellitus","score_opus":0.015654495687648196,"score_gpt":0.29344196025785485,"score_spread":0.27778746457020664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406503203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54267865,0.000027435346,0.42832184,0.019710954,0.00040285368,0.00650335,0.00044176306,0.00019839239,0.0017147899],"genre_scores_gemma":[0.93927866,0.00016843554,0.015444518,0.029920142,0.00017956046,0.004469647,0.009058118,0.00005093834,0.0014299598],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987861,0.00003877694,0.00039059998,0.0004045462,0.000096107535,0.0002838544],"domain_scores_gemma":[0.998292,0.0004035797,0.00008394107,0.00026505353,0.00089121034,0.00006416906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014412464,0.00018054259,0.0003910703,0.00026439698,0.00018326982,0.000021366684,0.00007371981,0.00014463565,0.000023058377],"category_scores_gemma":[0.00010475123,0.0001496484,0.00019149769,0.000282581,0.00007436646,0.00009883199,0.0000050578005,0.00006246317,0.000007321103],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3931591,0.0111463,0.3048048,0.0017877077,0.031428073,0.000014666444,0.0013322836,0.00022710903,0.0034555246,0.08012,0.04776299,0.12476145],"study_design_scores_gemma":[0.29829246,0.007733618,0.5814266,0.00009173969,0.056906067,0.000002566111,0.000103475635,0.00031630305,0.00080886856,0.0064901602,0.04732585,0.0005022576],"about_ca_topic_score_codex":0.000005587999,"about_ca_topic_score_gemma":0.000098437675,"teacher_disagreement_score":0.41287732,"about_ca_system_score_codex":0.00005849572,"about_ca_system_score_gemma":0.00008882348,"threshold_uncertainty_score":0.61024845},"labels":[],"label_agreement":null},{"id":"W4406517057","doi":"10.1016/j.yend.2013.03.048","title":"10.1016/j.yend.2013.03.048","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glimepiride; Medicine; Placebo; Double blind; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Endocrinology; Alternative medicine","score_opus":0.006642370170176014,"score_gpt":0.18868804924248325,"score_spread":0.18204567907230723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406517057","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016120089,0.00011254474,2.167483e-7,0.0013706927,0.0000018725635,0.0003866883,0.0000045032484,0.00015944753,0.996352],"genre_scores_gemma":[0.00033707783,0.0000013787304,0.00020216969,0.0002021532,0.00013036992,0.00003883845,0.000049314942,0.000023956261,0.99901474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923146,0.0000114809145,0.00012443555,0.00020138401,0.00017070242,0.00026056555],"domain_scores_gemma":[0.9994711,0.0000152976,0.000015582817,0.0003040003,0.000022801476,0.00017119152],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006593174,0.00013178022,0.00019170248,0.000079284335,0.000037024976,0.000019835583,0.00007853485,0.000035946116,0.9976219],"category_scores_gemma":[0.0000088304705,0.00011099968,0.000068415415,0.00013897935,0.000018692563,0.000052838845,0.000030425856,0.000051046634,0.99772394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006231599,0.0001194285,8.77099e-7,0.00000918098,0.000066044784,0.000016564265,0.000007695107,0.0000027353024,0.000014069171,0.0000019854922,0.48062727,0.5190718],"study_design_scores_gemma":[0.0008521172,0.0004688068,0.00020718871,0.000034223813,0.00015042587,0.0000028299617,0.0000010438863,0.0000483699,0.00009889925,0.0000054741236,0.99801636,0.000114263225],"about_ca_topic_score_codex":0.00001756504,"about_ca_topic_score_gemma":1.7098505e-7,"teacher_disagreement_score":0.51895756,"about_ca_system_score_codex":0.00004515148,"about_ca_system_score_gemma":0.000012863686,"threshold_uncertainty_score":0.45264357},"labels":[],"label_agreement":null},{"id":"W4406518737","doi":"10.1016/j.yend.2013.03.033","title":"10.1016/j.yend.2013.03.033","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Restructuring; Pathophysiology; Diabetes mellitus; Internal medicine; Endocrinology; Finance","score_opus":0.0066579535885929525,"score_gpt":0.18885164460342546,"score_spread":0.18219369101483252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406518737","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019303807,0.00011932004,2.1578863e-7,0.001350246,0.0000019624542,0.00039620156,0.000004662677,0.00016359531,0.99603343],"genre_scores_gemma":[0.00033106073,0.0000014446822,0.00019056896,0.00020059808,0.00013609664,0.000040362127,0.00005102378,0.000024667204,0.99902415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921423,0.000011610654,0.00012792194,0.0002055522,0.00017425424,0.00026644807],"domain_scores_gemma":[0.9994606,0.000015844516,0.000016076663,0.00030879455,0.000023387422,0.00017533822],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006787033,0.00013475736,0.00019608108,0.00008108567,0.00003788054,0.000020475158,0.00007989781,0.000037020684,0.9974441],"category_scores_gemma":[0.000009014615,0.00011382192,0.00006952645,0.0001420819,0.000019242998,0.000054046457,0.000030698044,0.000052594398,0.9976352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006319776,0.00012109841,8.607981e-7,0.000009194218,0.00006719691,0.000016895594,0.000007835489,0.000003659037,0.00001574608,0.0000015471755,0.48148817,0.51820457],"study_design_scores_gemma":[0.00086342625,0.0004741668,0.0002097129,0.00003445353,0.0001489729,0.0000029409566,0.0000010653707,0.000053928154,0.0001152825,0.0000055141427,0.9979733,0.00011724056],"about_ca_topic_score_codex":0.000018946856,"about_ca_topic_score_gemma":1.8458849e-7,"teacher_disagreement_score":0.5180873,"about_ca_system_score_codex":0.00004610121,"about_ca_system_score_gemma":0.000013151527,"threshold_uncertainty_score":0.46415234},"labels":[],"label_agreement":null},{"id":"W4406537061","doi":"10.1016/s1166-4568(17)79116-4","title":"10.1016/s1166-4568(17)79116-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Philosophy","score_opus":0.005966005345301848,"score_gpt":0.18513282486267907,"score_spread":0.17916681951737723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406537061","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012208248,0.00012529879,3.2948455e-7,0.0010365848,0.0000015876532,0.00042168348,0.000005116686,0.0001788666,0.9970097],"genre_scores_gemma":[0.00020205957,7.983424e-7,0.00020869095,0.00028196984,0.00013761096,0.00004434958,0.000055436776,0.000025675003,0.9990434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991624,0.0000116096835,0.00013903771,0.00022023564,0.00018590405,0.00028085327],"domain_scores_gemma":[0.99943095,0.00001768808,0.000017211956,0.00032632906,0.00002415328,0.00018366752],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000072625415,0.00014471647,0.00021026448,0.00008437122,0.000041118583,0.000021525912,0.00008519379,0.000039722658,0.9979221],"category_scores_gemma":[0.000010255244,0.000123364,0.000077383906,0.00015704875,0.000020740805,0.00005104688,0.000033831195,0.00005726655,0.995661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007310954,0.0001241745,9.171394e-7,0.000008694204,0.00008008083,0.000019973779,0.000007929515,0.000005062132,0.000013540395,0.0000011366149,0.49924842,0.50041693],"study_design_scores_gemma":[0.00091873686,0.0005176607,0.00025047365,0.000039598868,0.00020500713,0.000003262737,9.468689e-7,0.000055326644,0.0001012661,0.000005370348,0.99777555,0.0001267978],"about_ca_topic_score_codex":0.000009503784,"about_ca_topic_score_gemma":1.1052046e-7,"teacher_disagreement_score":0.50029016,"about_ca_system_score_codex":0.000053460375,"about_ca_system_score_gemma":0.00001512605,"threshold_uncertainty_score":0.5030638},"labels":[],"label_agreement":null},{"id":"W4406545032","doi":"10.1016/s1544-8800(11)70353-0","title":"10.1016/s1544-8800(11)70353-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacology; Cardiology; Internal medicine","score_opus":0.005912705795372496,"score_gpt":0.18463655052857245,"score_spread":0.17872384473319994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406545032","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033862297,0.00008250904,3.553885e-7,0.0010661524,0.0000018630681,0.0004161681,0.000004619636,0.00017239313,0.9948697],"genre_scores_gemma":[0.00038577034,7.0341014e-7,0.00022401186,0.00019303977,0.00013716053,0.00004313895,0.000048021113,0.000026022879,0.99894214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991774,0.000012612243,0.00013485373,0.00021584691,0.00018518852,0.00027410802],"domain_scores_gemma":[0.9994381,0.000018997513,0.000016630616,0.00032415782,0.000023750164,0.00017836443],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000072225004,0.00014092152,0.00020530101,0.000081410544,0.000040341096,0.000021640391,0.00008507919,0.000039404644,0.99748814],"category_scores_gemma":[0.000011727705,0.00012017175,0.00007500033,0.00015345095,0.000020785961,0.00005208675,0.000033875007,0.000048337504,0.99623543],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006263446,0.00013834272,0.0000020527148,0.000011630124,0.000060366114,0.000021481064,0.000009304697,0.0000044500075,0.000014728553,0.0000020370694,0.46523464,0.5344383],"study_design_scores_gemma":[0.0009039194,0.00041582045,0.0004290792,0.00003824202,0.000165223,0.000003017164,0.0000011430302,0.000050334227,0.0001321044,0.0000054919446,0.99773234,0.00012326651],"about_ca_topic_score_codex":0.000019653722,"about_ca_topic_score_gemma":2.622543e-7,"teacher_disagreement_score":0.53431505,"about_ca_system_score_codex":0.000052552718,"about_ca_system_score_gemma":0.0000149542,"threshold_uncertainty_score":0.49004617},"labels":[],"label_agreement":null},{"id":"W4406545777","doi":"10.1016/s1544-8800(07)70039-8","title":"10.1016/s1544-8800(07)70039-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Internal medicine; Cardiology; Pharmacology","score_opus":0.006121439834434919,"score_gpt":0.18603627781422188,"score_spread":0.17991483797978697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406545777","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020276243,0.00009303522,4.1931617e-7,0.0009287471,0.000001556243,0.00042090038,0.000004716493,0.00017083476,0.9963522],"genre_scores_gemma":[0.00032136744,8.137788e-7,0.00022693283,0.00019643824,0.00013209268,0.00004226003,0.00004786398,0.000026019838,0.9990062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991783,0.000013384592,0.00013460898,0.00021563319,0.0001830073,0.00027508577],"domain_scores_gemma":[0.99944115,0.000017949056,0.000016622025,0.0003198636,0.0000249959,0.00017939284],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007534636,0.00014144804,0.00020688232,0.00007803431,0.000040651295,0.000021715607,0.00008255073,0.000039807794,0.9981954],"category_scores_gemma":[0.000012476318,0.000120557044,0.00007426732,0.00014509159,0.000020319934,0.000053539545,0.00003260551,0.000056628243,0.99823165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008052243,0.00013742551,8.9040026e-7,0.000011040935,0.00007345679,0.000022121154,0.000008602296,0.000004979734,0.0000139765425,0.0000018573007,0.42523435,0.5744108],"study_design_scores_gemma":[0.00091780326,0.00050997315,0.00032897305,0.00003755147,0.00016703343,0.000003214305,0.0000010568019,0.000053282638,0.00011014374,0.0000063712637,0.99774086,0.0001237158],"about_ca_topic_score_codex":0.000013024966,"about_ca_topic_score_gemma":1.13600315e-7,"teacher_disagreement_score":0.57428706,"about_ca_system_score_codex":0.00005278184,"about_ca_system_score_gemma":0.000016161173,"threshold_uncertainty_score":0.49161735},"labels":[],"label_agreement":null},{"id":"W4406551149","doi":"10.1016/s1544-8800(05)70373-0","title":"10.1016/s1544-8800(05)70373-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Pharmacology; Internal medicine","score_opus":0.006144987505917026,"score_gpt":0.1862020321886038,"score_spread":0.18005704468268677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406551149","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018889656,0.00008380012,3.703424e-7,0.000967551,0.0000020683242,0.00041593696,0.000004844382,0.00017323055,0.99646324],"genre_scores_gemma":[0.00026729523,7.7779595e-7,0.00023765797,0.00023172628,0.00013568968,0.000042509684,0.000049717153,0.000026034375,0.9990086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991789,0.000012348131,0.00013443132,0.0002148721,0.00018236975,0.0002770915],"domain_scores_gemma":[0.9994424,0.000017234981,0.000016642018,0.00031931343,0.000023846016,0.0001805403],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006881441,0.0001416007,0.00020669046,0.00008375385,0.000040142484,0.000021779164,0.00008383087,0.000039053797,0.99733096],"category_scores_gemma":[0.000011086603,0.000120486206,0.00007575151,0.00015651566,0.000020149042,0.000054403183,0.000033703756,0.00005560685,0.9967291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079283156,0.00013610903,5.373213e-7,0.000010725231,0.000071003116,0.000025953597,0.000007943036,0.0000037716795,0.000024943325,0.0000019558554,0.43340752,0.5662303],"study_design_scores_gemma":[0.0009379092,0.0005644084,0.00027896208,0.00003810534,0.00016679971,0.0000039224933,0.0000010675367,0.00005019882,0.00020246916,0.0000056067665,0.99762726,0.00012332012],"about_ca_topic_score_codex":0.000014988421,"about_ca_topic_score_gemma":1.4964662e-7,"teacher_disagreement_score":0.566107,"about_ca_system_score_codex":0.000041443738,"about_ca_system_score_gemma":0.000015482512,"threshold_uncertainty_score":0.4913285},"labels":[],"label_agreement":null},{"id":"W4406552752","doi":"10.1016/s1558-0164(07)70192-x","title":"10.1016/s1558-0164(07)70192-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prediabetes; Metformin; Medicine; Intensive care medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.005983508000237763,"score_gpt":0.18540112666057465,"score_spread":0.1794176186603369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552752","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019092647,0.00009766248,3.6426238e-7,0.0009285153,0.000001796836,0.00041772128,0.000005013727,0.00017390502,0.99646574],"genre_scores_gemma":[0.00033701817,8.5797785e-7,0.0001990595,0.00022215565,0.00013525695,0.000041481995,0.00005081366,0.000026355934,0.998987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991744,0.000012353098,0.00013569831,0.0002178448,0.00018416697,0.00027551636],"domain_scores_gemma":[0.9994408,0.00001757881,0.0000171108,0.00032174552,0.000024348268,0.00017842048],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007282079,0.00014219752,0.00020827424,0.000080296144,0.00003962752,0.000021749367,0.00008403411,0.00003871553,0.9983285],"category_scores_gemma":[0.000011873758,0.00012062538,0.00007778877,0.00014049532,0.000019959947,0.000053604912,0.000033367716,0.000055979654,0.9994195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101423284,0.00016868868,3.0299495e-7,0.000013725746,0.000093843075,0.000028188566,0.000011038179,0.0000044847675,0.00002056041,0.0000021991166,0.68257535,0.31698018],"study_design_scores_gemma":[0.00092107325,0.0005114621,0.00023524172,0.000038291175,0.00016632509,0.0000032927517,0.0000011978655,0.000044291897,0.00012659059,0.000006645382,0.99782056,0.00012505373],"about_ca_topic_score_codex":0.0000107510905,"about_ca_topic_score_gemma":8.872516e-8,"teacher_disagreement_score":0.31685513,"about_ca_system_score_codex":0.00005407681,"about_ca_system_score_gemma":0.000015616843,"threshold_uncertainty_score":0.49189603},"labels":[],"label_agreement":null},{"id":"W4406552789","doi":"10.1016/s1558-0164(07)70040-8","title":"10.1016/s1558-0164(07)70040-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Waist; Medicine; Type 2 diabetes; Circumference; Diabetes mellitus; Disease; Internal medicine; Endocrinology; Obesity; Mathematics","score_opus":0.005956512240909652,"score_gpt":0.18512848086129582,"score_spread":0.17917196862038617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552789","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018742875,0.0000985789,3.6975464e-7,0.00093897077,0.0000017663566,0.00041543608,0.0000048610736,0.00017903476,0.9964867],"genre_scores_gemma":[0.00035353814,8.2945826e-7,0.00020364847,0.00021774168,0.00013477981,0.000042624815,0.000049532682,0.000026344582,0.998971],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991739,0.0000123109385,0.00013585275,0.00021769118,0.0001841858,0.00027610618],"domain_scores_gemma":[0.9994403,0.000017205244,0.000017031225,0.00032065075,0.00002423644,0.00018057994],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007231925,0.00014243381,0.0002077498,0.00008022789,0.00004026318,0.000021767199,0.00008411196,0.000038778864,0.9983719],"category_scores_gemma":[0.000011875784,0.000120819604,0.00007769451,0.00014031112,0.000020345906,0.000053639676,0.000033188422,0.000056083758,0.99939275],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010023023,0.00017009406,3.0867372e-7,0.000013778962,0.00009354209,0.000029217526,0.000010877886,0.0000046190958,0.000020181365,0.0000021902824,0.65849423,0.3410607],"study_design_scores_gemma":[0.00093243225,0.00051347027,0.00023081637,0.00003927467,0.00016650833,0.000003339081,0.0000011406829,0.000043519,0.00013122747,0.0000070258207,0.99780613,0.00012511638],"about_ca_topic_score_codex":0.000010511195,"about_ca_topic_score_gemma":8.929993e-8,"teacher_disagreement_score":0.3409356,"about_ca_system_score_codex":0.00005560894,"about_ca_system_score_gemma":0.000015996395,"threshold_uncertainty_score":0.49268806},"labels":[],"label_agreement":null},{"id":"W4406553154","doi":"10.1016/s1558-0164(10)70272-8","title":"10.1016/s1558-0164(10)70272-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metformin; Intensive care medicine; Internal medicine; Insulin","score_opus":0.006211884612121586,"score_gpt":0.18546237351953196,"score_spread":0.17925048890741038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406553154","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014850663,0.00009800758,3.00497e-7,0.0008668554,0.0000017132634,0.0004134809,0.0000055153755,0.00017795061,0.9969511],"genre_scores_gemma":[0.0002381863,7.764437e-7,0.00018298619,0.00017908867,0.00013849809,0.000044334356,0.00006381786,0.000027868698,0.99912447],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991328,0.000013492928,0.0001436098,0.00022880755,0.00019343029,0.00028786476],"domain_scores_gemma":[0.9994098,0.000019230065,0.00001889266,0.0003382178,0.000028379374,0.00018549978],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000076889344,0.0001512971,0.00021851901,0.000088268935,0.000042115076,0.000023357634,0.00009014685,0.00004157657,0.9989856],"category_scores_gemma":[0.000014242647,0.00012847052,0.00008067638,0.00016050001,0.000021717471,0.00005634009,0.000036217556,0.000053758387,0.9994716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012587848,0.00017810264,1.4425484e-7,0.000014230535,0.000097299904,0.000027073587,0.000010200566,0.0000042962706,0.000020833002,0.0000018500918,0.7757881,0.22373198],"study_design_scores_gemma":[0.0009885218,0.000580492,0.00018726017,0.000039828497,0.00017681341,0.000002739005,0.0000011706309,0.000051343068,0.00014169603,0.0000057734646,0.997692,0.0001323774],"about_ca_topic_score_codex":0.000009466553,"about_ca_topic_score_gemma":1.05338096e-7,"teacher_disagreement_score":0.22359961,"about_ca_system_score_codex":0.000057530033,"about_ca_system_score_gemma":0.000017081034,"threshold_uncertainty_score":0.5238876},"labels":[],"label_agreement":null},{"id":"W4406553623","doi":"10.1016/s1558-0164(09)70226-3","title":"10.1016/s1558-0164(09)70226-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Saxagliptin; Medicine; Type 2 diabetes; Pharmacology; Diabetes mellitus; Endocrinology; Sitagliptin","score_opus":0.006013520290147516,"score_gpt":0.18523289228701356,"score_spread":0.17921937199686605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406553623","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019083294,0.00009892519,4.0378663e-7,0.00091043167,0.0000018094398,0.0004201397,0.0000051428374,0.00017447137,0.99648035],"genre_scores_gemma":[0.00023255046,8.471465e-7,0.00021100797,0.00017115782,0.00013267125,0.000044490098,0.00005229404,0.00002637451,0.9991286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917096,0.000012682002,0.00013593721,0.00021773705,0.00018676747,0.00027593464],"domain_scores_gemma":[0.9994404,0.000017427517,0.00001724721,0.00032171217,0.000023928389,0.00017931976],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007364365,0.00014195671,0.0002072854,0.00008514697,0.00004113553,0.000021324477,0.000084917265,0.00003803845,0.9978497],"category_scores_gemma":[0.000011767431,0.0001207039,0.00007649406,0.00015797642,0.00002021431,0.00005323489,0.000033474127,0.000056787834,0.99902195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095261574,0.00015981884,2.8292618e-7,0.000012582588,0.00008652802,0.000025701416,0.000010398726,0.000004469241,0.000024771784,0.0000021770722,0.59543145,0.40414658],"study_design_scores_gemma":[0.0009246467,0.00051560515,0.00022401371,0.000036645277,0.00016348617,0.0000026713035,0.0000012524146,0.000050577888,0.00015064923,0.000005716472,0.99779975,0.00012498595],"about_ca_topic_score_codex":0.000013521444,"about_ca_topic_score_gemma":1.3267439e-7,"teacher_disagreement_score":0.4040216,"about_ca_system_score_codex":0.000056031255,"about_ca_system_score_gemma":0.000015659325,"threshold_uncertainty_score":0.49221623},"labels":[],"label_agreement":null},{"id":"W4406554208","doi":"10.1016/s1558-0164(11)70482-5","title":"10.1016/s1558-0164(11)70482-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.005832023896507182,"score_gpt":0.1841854070940708,"score_spread":0.1783533831975636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406554208","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002498024,0.000077947065,3.7381972e-7,0.0010031295,0.0000018944248,0.00041163558,0.000004420495,0.00025994002,0.9957426],"genre_scores_gemma":[0.00036640602,7.016547e-7,0.00021105885,0.00020861562,0.00013470397,0.000043125925,0.000034416742,0.00003460588,0.99896634],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917716,0.000012485743,0.00013531202,0.00021611506,0.00018392541,0.00027500125],"domain_scores_gemma":[0.9994391,0.000018649185,0.000016989747,0.00032424505,0.000024076655,0.00017694329],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000074670315,0.00014115105,0.00020618565,0.00008156266,0.000040558065,0.000021633114,0.000085215346,0.000039124123,0.99743235],"category_scores_gemma":[0.00001212259,0.00011990481,0.00007558139,0.00014830574,0.000020738325,0.000051018407,0.000034121305,0.000048282254,0.99897766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075041746,0.00017703538,6.536094e-7,0.000014556611,0.000078165904,0.000027879325,0.000010643029,0.0000051134007,0.000018696926,0.0000028998284,0.7365252,0.26306412],"study_design_scores_gemma":[0.0008898824,0.00041401052,0.00030429717,0.000038091464,0.00016252902,0.000003048218,0.0000011693007,0.00004625339,0.00013162829,0.0000057903694,0.99787945,0.0001238718],"about_ca_topic_score_codex":0.000013621509,"about_ca_topic_score_gemma":2.2931997e-7,"teacher_disagreement_score":0.26294026,"about_ca_system_score_codex":0.000053006188,"about_ca_system_score_gemma":0.000014896699,"threshold_uncertainty_score":0.48895764},"labels":[],"label_agreement":null},{"id":"W4406574443","doi":"10.1016/s1558-0164(11)70344-3","title":"10.1016/s1558-0164(11)70344-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Liraglutide; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.005852700834704206,"score_gpt":0.18436233857295395,"score_spread":0.17850963773824974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406574443","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027547665,0.00008026606,3.770077e-7,0.0009876044,0.0000018712952,0.0004133152,0.00000480818,0.00017559524,0.9955814],"genre_scores_gemma":[0.00034525333,7.395522e-7,0.00022830094,0.0002065493,0.00013657837,0.000043253625,0.00005089291,0.000026338812,0.9989621],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917656,0.000012631633,0.0001353255,0.00021719349,0.00018438713,0.00027392656],"domain_scores_gemma":[0.999439,0.000019066349,0.000017049035,0.00032414103,0.000023961447,0.0001767686],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007411359,0.00014156417,0.00020628779,0.000083337785,0.000040435338,0.000021708976,0.000085636064,0.000039135743,0.99770737],"category_scores_gemma":[0.0000123516775,0.000120181816,0.000075548225,0.00015231888,0.000020488806,0.000052071187,0.000034101,0.000048385195,0.998737],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090215995,0.00018025264,5.645376e-7,0.000015033075,0.00007907658,0.000028446628,0.0000112004045,0.0000051649286,0.000017334914,0.0000030135318,0.7397901,0.2597796],"study_design_scores_gemma":[0.0008775272,0.0004133041,0.00035332565,0.000039565897,0.00016355596,0.000003050562,0.0000011838247,0.000048200098,0.0001313924,0.0000058209084,0.9978388,0.00012428527],"about_ca_topic_score_codex":0.000014290832,"about_ca_topic_score_gemma":1.8663013e-7,"teacher_disagreement_score":0.2596553,"about_ca_system_score_codex":0.00005309974,"about_ca_system_score_gemma":0.000015036891,"threshold_uncertainty_score":0.4900872},"labels":[],"label_agreement":null},{"id":"W4406577083","doi":"10.1016/s1544-8800(11)70287-1","title":"10.1016/s1544-8800(11)70287-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Diabetes mellitus; Medicine; Internal medicine; Cardiology; Endocrinology","score_opus":0.0061597135228546925,"score_gpt":0.18563464352074288,"score_spread":0.1794749299978882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577083","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035110756,0.00008036026,3.613039e-7,0.0010855122,0.0000018928679,0.0004153127,0.0000047567382,0.00017226207,0.99472845],"genre_scores_gemma":[0.000388817,6.894922e-7,0.00022440802,0.00018860823,0.0001352533,0.000043192056,0.000048565544,0.000025994543,0.99894446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991796,0.000012595214,0.00013486108,0.00021600838,0.00018315969,0.00027379455],"domain_scores_gemma":[0.9994399,0.000018953368,0.000016638465,0.00032408134,0.000024038258,0.0001763684],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007148854,0.00014082278,0.00020515328,0.0000815783,0.00004028692,0.000021700218,0.000085098785,0.000039236762,0.9976387],"category_scores_gemma":[0.00001162976,0.00012010357,0.00007492315,0.00015404237,0.000020758845,0.000052038926,0.000033829718,0.00004814576,0.9963275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006288408,0.0001385619,0.0000021916926,0.000011646055,0.00006046127,0.000021588643,0.00000926158,0.0000043043383,0.000015171746,0.0000020338641,0.47448683,0.52518505],"study_design_scores_gemma":[0.00090253976,0.00040969413,0.00045049167,0.000037980164,0.0001652423,0.0000029788775,0.0000011431397,0.000048718495,0.0001313319,0.0000053778704,0.9977213,0.00012320017],"about_ca_topic_score_codex":0.000018838147,"about_ca_topic_score_gemma":2.6950647e-7,"teacher_disagreement_score":0.52506185,"about_ca_system_score_codex":0.000052504154,"about_ca_system_score_gemma":0.000014916409,"threshold_uncertainty_score":0.48976815},"labels":[],"label_agreement":null},{"id":"W4406577813","doi":"10.1016/s1544-8800(08)70430-5","title":"10.1016/s1544-8800(08)70430-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Cardiology; Internal medicine; Heart failure","score_opus":0.0060228503149491255,"score_gpt":0.18533714245723282,"score_spread":0.1793142921422837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577813","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021037576,0.00009598158,3.5382078e-7,0.00096196803,0.0000017934047,0.00041988917,0.000004915718,0.00017329646,0.99623805],"genre_scores_gemma":[0.00039984906,8.8152865e-7,0.0002000952,0.00019785228,0.00013501271,0.00004268046,0.000049326438,0.000026078626,0.9989482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991708,0.000012534577,0.00014068405,0.00021629294,0.00018354393,0.00027618866],"domain_scores_gemma":[0.9994386,0.00001735058,0.000017464183,0.00032210237,0.000024171666,0.00018032434],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007232474,0.00014191493,0.00020718577,0.000083233965,0.000040363288,0.00002176067,0.00008370428,0.00003933684,0.9977648],"category_scores_gemma":[0.000011409313,0.00012089303,0.00007870356,0.0001551948,0.00002031545,0.00005382287,0.00003334535,0.00005626961,0.99760354],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000770569,0.00013369769,9.413417e-7,0.000011032313,0.0000721244,0.000020728863,0.000008720921,0.0000039054485,0.000017678834,0.0000017040325,0.4372568,0.5623956],"study_design_scores_gemma":[0.00094815996,0.00050525164,0.00035840445,0.000038229366,0.00016728605,0.0000030203053,0.0000011439218,0.00004940421,0.0001404971,0.000005862012,0.99765867,0.00012406788],"about_ca_topic_score_codex":0.000013605109,"about_ca_topic_score_gemma":1.2628729e-7,"teacher_disagreement_score":0.56227154,"about_ca_system_score_codex":0.000054265485,"about_ca_system_score_gemma":0.000015658881,"threshold_uncertainty_score":0.49298745},"labels":[],"label_agreement":null},{"id":"W4406606896","doi":"10.1016/s2213-8587(24)00304-8","title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"American Regent; Vifor Pharma; Horizon Therapeutics; Impulse Dynamics; National Institutes of Health; Regeneron Pharmaceuticals; Dexcom; ReCor Medical; Astellas Pharma; Cytokinetics; Prothena; AstraZeneca; Amarin Corporation; Boston Scientific Corporation; Eli Lilly and Company; U.S. Department of Defense; Sanofi; HLS Therapeutics; LivaNova; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; Edwards Lifesciences; Amgen; Moderna; Pfizer; Tenax Therapeutics; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Gilead Sciences","keywords":"Medicine; Heart failure; Heart failure with preserved ejection fraction; Ejection fraction; Internal medicine; Cardiology; Semaglutide; Obesity; Type 2 diabetes; Baseline (sea); Diabetes mellitus; Endocrinology","score_opus":0.017476821309334672,"score_gpt":0.2834660659037371,"score_spread":0.26598924459440243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406606896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857589,0.002963955,0.000021794925,0.0070811887,0.00015760734,0.0037451172,0.000059291164,0.00010270776,0.00010941587],"genre_scores_gemma":[0.997145,0.00017666431,0.0007701199,0.00062537176,0.000088588975,0.00061187934,0.0001118429,0.00002470255,0.00044582295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968207,0.00073739234,0.0007061423,0.0006025312,0.00023862248,0.0008946139],"domain_scores_gemma":[0.99656737,0.0023063445,0.00027113812,0.00064990536,0.00012380393,0.000081412225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009818844,0.00039867702,0.0028697185,0.0005382145,0.00013196332,0.00005815475,0.0001553117,0.0001635774,0.00011283827],"category_scores_gemma":[0.00062898925,0.0002563577,0.000249801,0.0009901739,0.00023587885,0.000136268,0.00016579677,0.00038746675,0.0000044039207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07927671,0.00038261779,0.9025173,0.00008809163,0.012302628,0.000005629561,0.00011801318,0.00011780198,0.0033417798,0.00012176935,0.0010690722,0.0006585371],"study_design_scores_gemma":[0.4022037,0.0004933306,0.5796964,0.00011010095,0.0075096064,5.5583496e-7,0.000261297,0.0022464236,0.0031757716,0.00018076034,0.0039109006,0.00021112352],"about_ca_topic_score_codex":0.00024912768,"about_ca_topic_score_gemma":0.0011420952,"teacher_disagreement_score":0.322927,"about_ca_system_score_codex":0.00005300082,"about_ca_system_score_gemma":0.0000478046,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W4406628966","doi":"10.1096/fba.2024-00151","title":"The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders","year":2025,"lang":"en","type":"review","venue":"FASEB BioAdvances","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Amylin; Neurodegeneration; Neuroprotection; Ghrelin; Neuroscience; Medicine; Glucose homeostasis; Diabetes mellitus; Disease; Endocrinology; Internal medicine; Hormone; Biology; Insulin resistance; Islet","score_opus":0.010611757234022589,"score_gpt":0.29031133670706555,"score_spread":0.27969957947304297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406628966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036219746,0.99466354,0.0000015674873,0.00042677406,0.00007096664,0.001127857,0.00003341776,0.00002452099,0.00328915],"genre_scores_gemma":[0.00038002786,0.99806976,0.00009013342,0.0001095392,0.00002888381,0.00025396905,0.000057972793,0.000012574626,0.0009971401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987326,0.000113271664,0.00040507913,0.00034629912,0.00014910268,0.00025360647],"domain_scores_gemma":[0.99891615,0.0005503711,0.0001672301,0.00030227037,0.000014080045,0.00004987461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018596048,0.0002845956,0.0011782054,0.00019570385,0.00004817848,0.000016927841,0.00016022727,0.000105857165,0.0000075568832],"category_scores_gemma":[0.00013932661,0.00015151949,0.00022390542,0.00041149766,0.0001997152,0.000040797386,0.00013868643,0.00015100875,0.000003892717],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024750425,0.00008008323,0.0006620968,0.0017655006,0.00016078654,0.0000059875447,0.000010852335,1.1038921e-7,0.0000012631998,0.0011326801,0.00021092371,0.995945],"study_design_scores_gemma":[0.0004146718,0.00028409547,0.0010420338,0.0011524096,0.0006026587,8.505095e-7,0.00004158,0.0000054974917,0.0000016854052,0.0007355566,0.9956055,0.000113428076],"about_ca_topic_score_codex":0.000017613422,"about_ca_topic_score_gemma":0.00007445545,"teacher_disagreement_score":0.99583155,"about_ca_system_score_codex":0.000010676197,"about_ca_system_score_gemma":0.000053359745,"threshold_uncertainty_score":0.61787856},"labels":[],"label_agreement":null},{"id":"W4406648761","doi":"10.1016/b978-2-294-76306-9.50791-2","title":"10.1016/b978-2-294-76306-9.50791-2","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry","score_opus":0.009479479107814092,"score_gpt":0.185887052178629,"score_spread":0.1764075730708149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406648761","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013894764,0.000502747,2.3080324e-7,0.00052033796,0.0000064262754,0.0010665469,0.000054339183,0.00026885926,0.9975791],"genre_scores_gemma":[0.0000011978577,0.000004555366,0.00011613813,0.00023764969,0.0005180331,0.00005307773,0.0005588522,0.00015155804,0.99835896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982931,0.000008182233,0.00033413712,0.0005360828,0.00042195243,0.00040656477],"domain_scores_gemma":[0.99876463,0.000033735054,0.000093470866,0.00073153496,0.000060096572,0.000316531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000087494125,0.00051892234,0.0007144624,0.00033346302,0.000054541444,0.000038979226,0.00018680895,0.0002601505,0.9978286],"category_scores_gemma":[0.000009534416,0.00047203308,0.00028782754,0.000047142792,0.00005465154,0.0000487821,0.00012008105,0.00024168304,0.99767774],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113823764,0.00006373477,2.7022027e-8,0.00004591681,0.0004089861,0.0001120435,0.0000047995245,0.0000010042515,0.0000015912308,0.00010367346,0.44031242,0.558832],"study_design_scores_gemma":[0.00094186445,0.0007678951,0.0000037838686,0.00038378115,0.0010321214,0.000008153608,2.6962795e-7,0.000005522878,0.00001183812,0.00017854609,0.99624455,0.00042167548],"about_ca_topic_score_codex":0.000007725796,"about_ca_topic_score_gemma":2.2698157e-7,"teacher_disagreement_score":0.55841035,"about_ca_system_score_codex":0.00016715124,"about_ca_system_score_gemma":0.000055274937,"threshold_uncertainty_score":0.99977314},"labels":[],"label_agreement":null},{"id":"W4406677295","doi":"10.1016/b978-0-323-44355-5.00014-9","title":"10.1016/b978-0-323-44355-5.00014-9","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.009167471310464782,"score_gpt":0.18536969716567236,"score_spread":0.1762022258552076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406677295","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011174886,0.0005548165,2.3198405e-7,0.00050908024,0.00000615866,0.001065551,0.000057349385,0.0002648885,0.99754083],"genre_scores_gemma":[0.0000013282985,0.0000044199924,0.0001004568,0.00025534615,0.00041121015,0.000052704178,0.0005396253,0.00014857153,0.99848634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834126,0.000008181593,0.00032309434,0.00051750196,0.00041246507,0.00039746688],"domain_scores_gemma":[0.9987997,0.00003738174,0.000091236216,0.0006934511,0.00006078448,0.00031744965],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008256547,0.000506028,0.0007123821,0.00029922725,0.000054033713,0.000038167273,0.00018000498,0.00025507723,0.9982399],"category_scores_gemma":[0.000009522482,0.00045908283,0.00026943526,0.000043937533,0.000054964083,0.00004472919,0.00010778179,0.00023174174,0.9976456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012583584,0.000064704334,2.4683457e-8,0.000043697422,0.00038340376,0.00010080393,0.0000046925943,8.0731934e-7,0.0000013352384,0.00009476663,0.4438733,0.5553066],"study_design_scores_gemma":[0.000962583,0.0007736339,0.00000344576,0.00039806406,0.0010041505,0.0000081588705,2.7647792e-7,0.0000075727535,0.000011757527,0.00014368095,0.9962736,0.00041310402],"about_ca_topic_score_codex":0.000008323537,"about_ca_topic_score_gemma":2.3167111e-7,"teacher_disagreement_score":0.55489355,"about_ca_system_score_codex":0.0001691867,"about_ca_system_score_gemma":0.000054139495,"threshold_uncertainty_score":0.9997861},"labels":[],"label_agreement":null},{"id":"W4406688582","doi":"10.1016/b978-2-294-73068-9.00518-1","title":"10.1016/b978-2-294-73068-9.00518-1","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Sodium cromoglycate; Chemistry; Medicine; Internal medicine; Asthma","score_opus":0.009248160841551374,"score_gpt":0.18538812513450087,"score_spread":0.1761399642929495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406688582","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000016397969,0.0005117927,2.3633628e-7,0.00050776877,0.000005904918,0.0010523149,0.00005286453,0.00026780434,0.99759966],"genre_scores_gemma":[0.0000012382744,0.000004394678,0.000119787954,0.0002326733,0.00051385263,0.000048288402,0.00050651544,0.00014949773,0.99842376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831903,0.000007931419,0.00032662132,0.0005303586,0.00040963286,0.00040643406],"domain_scores_gemma":[0.9987868,0.00003298763,0.00009280658,0.00071433757,0.000058359827,0.00031472705],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008425457,0.0005087308,0.0007062899,0.00033203154,0.00005390561,0.000037008682,0.00018534123,0.00025925244,0.99799156],"category_scores_gemma":[0.000008927999,0.00046545122,0.0002824911,0.00004523479,0.000052877436,0.000049292103,0.000121460114,0.00024074687,0.99759674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011390374,0.00006483099,2.5360116e-8,0.00004472154,0.0004181566,0.0001061191,0.0000047305366,0.0000010063251,0.0000020227783,0.00010643703,0.43012044,0.5690176],"study_design_scores_gemma":[0.0009251001,0.00076068816,0.00000361934,0.000379351,0.0010483142,0.000007779231,2.729288e-7,0.00000517156,0.000013999941,0.00017081357,0.9962696,0.00041529106],"about_ca_topic_score_codex":0.0000064235674,"about_ca_topic_score_gemma":2.3191137e-7,"teacher_disagreement_score":0.5686023,"about_ca_system_score_codex":0.00017669688,"about_ca_system_score_gemma":0.00005996923,"threshold_uncertainty_score":0.9997797},"labels":[],"label_agreement":null},{"id":"W4406726190","doi":"10.1136/bmjdrc-2024-004541","title":"Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study","year":2025,"lang":"en","type":"article","venue":"BMJ Open Diabetes Research & Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Institute of Population and Public Health; McGill University","keywords":"Medicine; Dementia; Hazard ratio; Propensity score matching; Internal medicine; Cohort study; Proportional hazards model; Cohort; Confounding; Population; Diabetes mellitus; Type 2 diabetes; Lower risk; Retrospective cohort study; Confidence interval; Disease; Endocrinology","score_opus":0.042917220467280255,"score_gpt":0.3933187039216485,"score_spread":0.3504014834543683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406726190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98519707,0.00043020272,0.0000031074915,0.0004400824,0.000044117576,0.013131548,0.00015855474,0.000014242882,0.00058107777],"genre_scores_gemma":[0.99750704,0.000076692944,0.00011329966,0.000054259195,0.000036601923,0.0012850425,0.00044436695,0.000017165012,0.0004655174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662334,0.00083530886,0.00062411843,0.0003527254,0.0012039323,0.00036055152],"domain_scores_gemma":[0.9966133,0.0016066278,0.00032134575,0.00060153304,0.00077115756,0.00008604104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040118797,0.00016445652,0.0007087482,0.00028602494,0.00020060419,0.00013913214,0.0002835101,0.00008103661,0.00004111638],"category_scores_gemma":[0.0011786893,0.00011615226,0.00012709877,0.000526444,0.00012835911,0.00018797716,0.00030512834,0.00024014413,0.0000030356478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002772628,0.00038627037,0.9903083,0.00042226454,0.0034574247,0.0000028840047,0.00044673725,0.000008564114,0.000050861046,0.00003981703,0.0011963675,0.0034032557],"study_design_scores_gemma":[0.0065956526,0.000547321,0.98501056,0.00034010434,0.00241387,6.1078724e-9,0.0011303038,0.00007791032,0.0033793284,0.00006293859,0.00035226575,0.000089737354],"about_ca_topic_score_codex":0.0031995883,"about_ca_topic_score_gemma":0.00069589895,"teacher_disagreement_score":0.012309988,"about_ca_system_score_codex":0.0002940745,"about_ca_system_score_gemma":0.00019602946,"threshold_uncertainty_score":0.48368415},"labels":[],"label_agreement":null},{"id":"W4406853291","doi":"10.1055/a-2481-2004","title":"Kurzfassung der KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (Leitlinie für die klinische Praxis zur Diabetesbehandlung bei chronischer Nierenkrankheit): eine Aktualisierung auf Grundlage neuer Erkenntnisse","year":2025,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Guideline; Gynecology; Pathology","score_opus":0.026394781070753832,"score_gpt":0.38973854008924674,"score_spread":0.3633437590184929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406853291","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06485295,0.79277897,0.0057827192,0.06526506,0.021523327,0.026379645,0.002454512,0.0015763625,0.019386437],"genre_scores_gemma":[0.4258639,0.19224706,0.08258242,0.14566031,0.017528519,0.026148079,0.03567655,0.0027234906,0.071569666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98136085,0.0017372242,0.0059461826,0.0043935357,0.0016760743,0.004886111],"domain_scores_gemma":[0.98589295,0.0053325337,0.0018315348,0.0038585232,0.0009816218,0.0021028204],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.007891655,0.0027141317,0.0042397715,0.0018257602,0.00089211034,0.00066721125,0.0020287482,0.001496191,0.0005202706],"category_scores_gemma":[0.010353133,0.0025883426,0.0018445805,0.0022206274,0.0011010004,0.0013026609,0.0022167198,0.0023064958,0.00056996127],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036907382,0.015254388,0.22631894,0.009852034,0.060652293,0.002236531,0.00040884444,0.000563716,0.00028045478,0.0070434115,0.4686757,0.20502295],"study_design_scores_gemma":[0.024089014,0.0023088395,0.02518673,0.002774182,0.050928053,2.9183215e-7,0.00032103638,0.015021306,0.0005037174,0.0009664311,0.8756535,0.002246881],"about_ca_topic_score_codex":0.000094782095,"about_ca_topic_score_gemma":0.00012449645,"teacher_disagreement_score":0.60053194,"about_ca_system_score_codex":0.0026477862,"about_ca_system_score_gemma":0.0027881325,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W4406917166","doi":"10.1111/dom.16206","title":"Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Type 2 diabetes; Insulin resistance; Narrative review; Intensive care medicine; Weight loss; Obesity; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.01211267877879356,"score_gpt":0.29370002212965113,"score_spread":0.28158734335085756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406917166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007333796,0.9807795,0.0000036270505,0.00008933664,0.00037787197,0.010243349,0.000061149774,0.000062122905,0.001049227],"genre_scores_gemma":[0.00014786309,0.9940958,0.0004442558,0.0005517055,0.00011456716,0.0025218145,0.00028763394,0.000048826638,0.0017875176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973674,0.00022906139,0.00062769314,0.00090203504,0.0002167826,0.0006570569],"domain_scores_gemma":[0.9985228,0.00048793404,0.0002664062,0.00044285844,0.00009494596,0.00018506608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006696343,0.0007386656,0.0035738465,0.0006217756,0.00013081296,0.000063564905,0.00016513412,0.0002557534,0.000015436555],"category_scores_gemma":[0.00018038168,0.0005831163,0.00040210166,0.00075796695,0.00010228161,0.00015735073,0.00030534086,0.00033662736,0.0000093023955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009463247,0.00018431166,0.00080063596,0.19070017,0.0017506947,0.000011300934,0.000114910035,1.4860168e-8,2.4813315e-7,0.00053903426,0.0010907537,0.8047985],"study_design_scores_gemma":[0.0017798616,0.00020688615,0.005305539,0.1302126,0.01477802,5.783196e-7,0.000022996837,0.000004163471,0.000004565195,0.00028657666,0.8469053,0.0004929024],"about_ca_topic_score_codex":0.000004998096,"about_ca_topic_score_gemma":0.0000036464496,"teacher_disagreement_score":0.8458145,"about_ca_system_score_codex":0.00011116352,"about_ca_system_score_gemma":0.00007140934,"threshold_uncertainty_score":0.99966204},"labels":[],"label_agreement":null},{"id":"W4406919465","doi":"10.1080/03007995.2025.2458538","title":"Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms","year":2025,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bruyère; Queensway-Carleton Hospital; St. Joseph’s Healthcare Hamilton; St. Michael's Hospital; Western University; LMC Diabetes & Endocrinology (Canada); Queen's University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Novo Nordisk Canada; Eli Lilly Canada","keywords":"Medicine; Narrative review; Perioperative; Glucagon-like peptide 1 receptor; Intensive care medicine; Receptor; Agonist; Internal medicine; Anesthesia","score_opus":0.09666611352847027,"score_gpt":0.4688349465877436,"score_spread":0.37216883305927334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406919465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016250557,0.99066156,0.000013225246,0.00403478,0.00023334821,0.0043821028,0.000043252763,0.00001564639,0.00045359257],"genre_scores_gemma":[0.00009025436,0.9977578,0.00011904566,0.00012583348,0.00015460032,0.0007160876,0.00029825544,0.000020008463,0.0007181245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965284,0.0006153452,0.00061829714,0.0007711454,0.0010168408,0.00044997712],"domain_scores_gemma":[0.9981189,0.00069060386,0.00015890329,0.00028499938,0.00020963118,0.00053696154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022415528,0.00045283374,0.0017666597,0.00025565445,0.0003273471,0.00010602764,0.00014289566,0.00018120962,0.00006683416],"category_scores_gemma":[0.0006421602,0.00025446797,0.000110103436,0.0003941989,0.002017159,0.00008754739,0.0006455443,0.00079131545,0.0000017392679],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008339663,0.0001355375,0.000022247223,0.15905079,0.00031922726,0.000008676926,0.00048306008,1.4133467e-9,6.2871294e-8,0.0012845612,0.0041456404,0.8344668],"study_design_scores_gemma":[0.0037664785,0.00083225063,0.00006683209,0.17303975,0.0008037212,0.000012024243,0.0008854342,0.000035329835,9.93584e-7,0.000051023402,0.8202867,0.0002194808],"about_ca_topic_score_codex":0.000017260012,"about_ca_topic_score_gemma":0.00000269346,"teacher_disagreement_score":0.8342473,"about_ca_system_score_codex":0.0000880186,"about_ca_system_score_gemma":0.00038604884,"threshold_uncertainty_score":0.99999076},"labels":[],"label_agreement":null},{"id":"W4407121640","doi":"10.1016/s0140-6736(25)00161-8","title":"First phase 3 trial of GLP-1 receptor agonist for neurodegeneration","year":2025,"lang":"en","type":"letter","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Agonist; Neurodegeneration; Medicine; Neuroscience; Pharmacology; Receptor; Internal medicine; Biology; Disease","score_opus":0.04692468544127923,"score_gpt":0.3130679863088689,"score_spread":0.26614330086758964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407121640","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016189051,0.0001472942,0.00015679622,0.9864991,0.0016143833,0.0026774637,0.00040223708,0.000049285554,0.006834552],"genre_scores_gemma":[0.0011588003,0.000545397,0.0013137355,0.83726096,0.03988631,0.0011072209,0.007163226,0.000056365836,0.11150799],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920243,0.00003313153,0.00021655987,0.00019196248,0.00016215834,0.0001937799],"domain_scores_gemma":[0.9991036,0.00013141343,0.00013775958,0.00056683825,0.00004713589,0.000013249544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015518186,0.00015461027,0.0005708721,0.000055283213,0.00006338185,0.000024264209,0.00016631233,0.00013004875,0.0000784908],"category_scores_gemma":[0.00007132917,0.0000980962,0.00016296495,0.00006916729,0.00003782893,0.000016556509,0.000033451866,0.00021116006,0.000014515346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007593147,0.00013868217,0.000003532415,0.0006870079,0.00024897937,0.000004584199,0.000022130374,0.0000012413421,0.000048590355,0.0001763671,0.9878585,0.003217255],"study_design_scores_gemma":[0.06086273,0.0010139982,0.000003918363,0.00013035958,0.0006922397,1.6967356e-7,0.000001813677,0.000054684522,0.00061700586,0.00008674873,0.93646604,0.000070314156],"about_ca_topic_score_codex":0.0000096603935,"about_ca_topic_score_gemma":0.0000048249362,"teacher_disagreement_score":0.14923812,"about_ca_system_score_codex":0.000037558704,"about_ca_system_score_gemma":0.000044792934,"threshold_uncertainty_score":0.4000247},"labels":[],"label_agreement":null},{"id":"W4407132939","doi":"10.1159/000543162","title":"Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial","year":2025,"lang":"en","type":"article","venue":"Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"European Association for the Study of Diabetes; European Foundation for the Study of Diabetes; Pfizer; American Diabetes Association","keywords":"Mineralocorticoid receptor; Renin–angiotensin system; Aldosterone; Medicine; Internal medicine; Endocrinology; Mineralocorticoid; Pharmacology; Urology; Blood pressure","score_opus":0.03124490371837703,"score_gpt":0.28129306568618817,"score_spread":0.25004816196781116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407132939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804712,0.00766198,0.00041407903,0.0073596914,0.00046077208,0.0019403073,0.0014776821,0.00014278847,0.00007150535],"genre_scores_gemma":[0.9940343,0.00038152057,0.0011837054,0.0012338709,0.00021867958,0.000083865416,0.0010359195,0.00003941132,0.0017887135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981045,0.00016265879,0.0005252594,0.00045918595,0.00048446265,0.00026391319],"domain_scores_gemma":[0.99831736,0.00040023564,0.00016008863,0.00067832076,0.00012798983,0.0003160188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014502453,0.00033076017,0.0009285211,0.0001299189,0.00014142662,0.00008203443,0.00010342812,0.000066712775,0.00003833244],"category_scores_gemma":[0.0007866359,0.00017832631,0.00035623534,0.00028515735,0.00020551101,0.00012164492,0.00014763192,0.00008080166,0.0000032480716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04010489,0.0012116581,0.43610123,0.0005007488,0.024013754,0.0002308615,0.0001877403,0.00003581898,0.01220937,0.000082422,0.47580418,0.00951733],"study_design_scores_gemma":[0.23842618,0.005008941,0.21632421,0.0105431955,0.09467858,0.000011924077,0.0013181744,0.0017208719,0.06501,0.000026182057,0.36492184,0.0020099035],"about_ca_topic_score_codex":0.0010651377,"about_ca_topic_score_gemma":0.000028195815,"teacher_disagreement_score":0.21977703,"about_ca_system_score_codex":0.00009591078,"about_ca_system_score_gemma":0.00013734096,"threshold_uncertainty_score":0.7271936},"labels":[],"label_agreement":null},{"id":"W4407162002","doi":"10.7759/cureus.78570","title":"Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Heart failure; Ejection fraction; Glucagon-like peptide-1; Internal medicine; Endocrinology; Glucagon; Receptor; Pharmacology; Cardiology; Diabetes mellitus; Type 2 diabetes; Insulin","score_opus":0.02939309663071245,"score_gpt":0.3018385928634038,"score_spread":0.2724454962326914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407162002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054667693,0.98452705,0.00003409985,0.00039335183,0.0005567023,0.01279297,0.000015643975,0.00017484691,0.0014506633],"genre_scores_gemma":[0.000090040165,0.99019456,0.0006710044,0.0004235659,0.00017044217,0.0036565044,0.0007407715,0.00008130621,0.0039717816],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965838,0.0002480583,0.00134922,0.0008245052,0.0005117319,0.00048266468],"domain_scores_gemma":[0.99795,0.00012797106,0.00047312124,0.0010739445,0.00013449398,0.00024043502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000508894,0.00075697806,0.0046806675,0.00041005638,0.00008943662,0.00008144755,0.000256728,0.0002550064,0.00012282096],"category_scores_gemma":[0.000107624146,0.000551119,0.0005784327,0.0011219592,0.00003188185,0.0001913464,0.00009404046,0.0004936922,0.00029525417],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028549388,0.0003740752,0.00046766092,0.9609513,0.00094026286,0.00004333322,0.000026515863,7.901395e-7,8.4949176e-7,0.000012425222,0.034317523,0.0028366633],"study_design_scores_gemma":[0.00042114474,0.00019506025,0.000019288644,0.506067,0.0053544864,0.000008946286,0.000033932654,0.0000010111053,0.0000035393891,6.3432987e-7,0.48763734,0.0002576373],"about_ca_topic_score_codex":0.00011439135,"about_ca_topic_score_gemma":0.0004873183,"teacher_disagreement_score":0.45488438,"about_ca_system_score_codex":0.00097511505,"about_ca_system_score_gemma":0.0003025736,"threshold_uncertainty_score":0.99969405},"labels":[],"label_agreement":null},{"id":"W4407192481","doi":"10.1111/dom.16230","title":"Effectiveness of gemigliptin on risk of major adverse kidney events in people with type 2 diabetes: A Korean cohort study","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LG Chem","keywords":"Medicine; Type 2 diabetes; Cohort; Adverse effect; Internal medicine; Cohort study; Diabetes mellitus; Endocrinology","score_opus":0.004209678543887113,"score_gpt":0.2166906158163506,"score_spread":0.21248093727246348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407192481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992802,0.00066170556,9.531683e-7,0.0009609008,0.00034720806,0.0041919965,0.00021941992,0.00003948271,0.00077633635],"genre_scores_gemma":[0.9864965,0.0004447348,0.00009571126,0.010309219,0.00017589772,0.00039821322,0.00085706566,0.00006837004,0.0011542889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687225,0.000630377,0.000537359,0.00078185584,0.0006234187,0.0005547611],"domain_scores_gemma":[0.9980029,0.00046919947,0.00042820233,0.0007875069,0.00017321337,0.00013898696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011117905,0.00060202007,0.0022812067,0.0008007249,0.000055343902,0.000007905202,0.0002181588,0.000362519,0.00003452434],"category_scores_gemma":[0.00027169767,0.00046648143,0.00021653787,0.0007272975,0.00011472009,0.0000879468,0.00017847515,0.00078374456,0.000006174078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025958676,0.0020747844,0.9816964,0.005134079,0.0037168097,0.000028592149,0.00017927233,0.000004380588,0.000071425406,0.000016697273,0.0064193914,0.00039852678],"study_design_scores_gemma":[0.0064358227,0.0012279295,0.97492266,0.0030104124,0.0071964427,1.1529592e-7,0.00004745334,0.000009621666,0.001743764,0.000059017217,0.0049982397,0.00034851444],"about_ca_topic_score_codex":0.0002907199,"about_ca_topic_score_gemma":0.000044022807,"teacher_disagreement_score":0.009348319,"about_ca_system_score_codex":0.00008245727,"about_ca_system_score_gemma":0.00015407773,"threshold_uncertainty_score":0.9997787},"labels":[],"label_agreement":null},{"id":"W4407251962","doi":"10.2215/cjn.0000000641","title":"Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2","year":2025,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; Public Health Ontario; Montreal Clinical Research Institute; University of British Columbia; Sinai Health System; University of Waterloo; Lunenfeld-Tanenbaum Research Institute; University of Calgary; University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Dapagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Kidney disease; Internal medicine; Relative risk; Placebo; Type 1 diabetes; Endocrinology; Confidence interval; Pathology","score_opus":0.026684062059705513,"score_gpt":0.31608566928002224,"score_spread":0.2894016072203167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407251962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537915,0.00020177837,0.0020253737,0.002131189,0.000041162595,0.00019756441,0.0000021755952,0.000004080746,0.000017506503],"genre_scores_gemma":[0.994153,0.00063230144,0.0018235912,0.0033307108,0.000037982194,0.0000034005882,0.0000038624175,0.0000061207925,0.000009032179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986901,0.00017267393,0.0006900088,0.0001477141,0.00016116022,0.00013829801],"domain_scores_gemma":[0.9989548,0.000101852056,0.0005026548,0.0001911664,0.00019428291,0.000055274202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065248675,0.000099560755,0.0008841371,0.00015193422,0.000025070054,0.0000035121254,0.000068832676,0.000071710965,0.000003825733],"category_scores_gemma":[0.000024112875,0.00006306283,0.00044020487,0.0006504307,0.00053547247,0.000060183098,0.000031241,0.00027816367,9.120592e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028533572,0.0010309365,0.93299043,0.00012881002,0.010041513,0.000011585477,0.0005065004,0.0076769716,0.009516801,0.000021575563,0.00028734293,0.034934156],"study_design_scores_gemma":[0.0033705668,0.004592708,0.93128425,0.00020081959,0.007582638,0.0000055339433,0.00079218915,0.050932296,0.00075155176,0.00014460417,0.0002552539,0.000087616754],"about_ca_topic_score_codex":0.000070662405,"about_ca_topic_score_gemma":0.00006256076,"teacher_disagreement_score":0.043255325,"about_ca_system_score_codex":0.00003992892,"about_ca_system_score_gemma":0.00008292048,"threshold_uncertainty_score":0.25716275},"labels":[],"label_agreement":null},{"id":"W4407284953","doi":"10.1093/jcag/gwae059.085","title":"A85 PATTERN OF SEMAGLUTIDE PRESCRIPTION IN A REAL-WORLD PATIENT COHORT","year":2025,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Medical prescription; Cohort; Medicine; Internal medicine; Pharmacology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.006328053305296447,"score_gpt":0.23004344445837802,"score_spread":0.22371539115308156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407284953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873461,0.000013009957,0.000013777488,0.009699735,0.0004089539,0.0002666461,0.000011812788,0.0000015820293,0.002238346],"genre_scores_gemma":[0.99705786,0.000022789753,0.00006390062,0.0012496095,0.000021351792,0.000004160873,0.0000035996475,0.0000043919154,0.0015723649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988443,0.00014861635,0.0005416552,0.00006596929,0.00020825336,0.00019117953],"domain_scores_gemma":[0.99879116,0.000031050404,0.0007744072,0.00012502389,0.00020890222,0.00006948701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048569523,0.00006894792,0.00034472134,0.0005518843,0.00001987201,0.000004305051,0.000099122684,0.000047821748,0.00002606196],"category_scores_gemma":[0.00010999855,0.000053649994,0.00013788245,0.000166918,0.000025148189,0.00003162342,0.000024300312,0.00013819992,6.3813667e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012854462,0.00010191968,0.98706895,0.00003173169,0.00039369566,0.000006436237,0.00009587132,0.000067304136,0.0001125,0.000049389244,0.011034875,0.0009087808],"study_design_scores_gemma":[0.0016423159,0.00049531093,0.995323,0.00019258993,0.00025120785,0.000002301729,0.00004257626,0.000050231698,0.00015105293,0.00007886374,0.0017533101,0.000017245977],"about_ca_topic_score_codex":0.017383326,"about_ca_topic_score_gemma":0.6219274,"teacher_disagreement_score":0.60454404,"about_ca_system_score_codex":0.0015322714,"about_ca_system_score_gemma":0.00020172127,"threshold_uncertainty_score":0.98916},"labels":[],"label_agreement":null},{"id":"W4407284961","doi":"10.1093/jcag/gwae059.081","title":"A81 GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OVERWEIGHT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2025,"lang":"en","type":"review","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto","funders":"","keywords":"Glucagon-like peptide-1; Meta-analysis; Adverse effect; Overweight; Medicine; Internal medicine; Glucagon; Gastroenterology; Endocrinology; Type 2 diabetes; Obesity; Diabetes mellitus; Insulin","score_opus":0.01559027566261878,"score_gpt":0.25984167483104864,"score_spread":0.24425139916842986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407284961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00079776556,0.9899804,0.000010071221,0.0031183,0.00022125333,0.00509456,0.00051753403,0.000008998337,0.00025113407],"genre_scores_gemma":[0.0038206254,0.982166,0.00033527424,0.0042219185,0.000030468094,0.00020041036,0.00030812077,0.000061034934,0.0088561615],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956251,0.0012204736,0.001843889,0.00025500925,0.0005971372,0.0004584299],"domain_scores_gemma":[0.9929272,0.00028345743,0.0055449125,0.00036428304,0.00063074904,0.000249421],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001649881,0.0004220865,0.007010705,0.0011771218,0.00006311437,0.000012438127,0.00032748314,0.00014912934,0.000053550004],"category_scores_gemma":[0.0013314431,0.00024558234,0.002199506,0.00081352994,0.000045477027,0.00008390026,0.000069501424,0.0004896344,0.0000018027832],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085634754,0.000655536,0.24677989,0.30557027,0.44210264,0.000114288,0.00004190237,0.000010837197,1.2054281e-8,0.000015007755,0.004515262,0.00010871172],"study_design_scores_gemma":[0.001511837,0.0009372527,0.013301379,0.080558926,0.900971,0.000040436753,0.000008574478,0.0000015628258,1.1466244e-8,0.0000045114843,0.0025559415,0.0001085537],"about_ca_topic_score_codex":0.00059809076,"about_ca_topic_score_gemma":0.1061849,"teacher_disagreement_score":0.45886838,"about_ca_system_score_codex":0.0033106292,"about_ca_system_score_gemma":0.0007733488,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W4407301560","doi":"10.1001/jamainternmed.2024.7812","title":"Pleotropic Effects of Glucose-Lowering Medications—Need for Cautious Interpretation of Target Trial Emulation Studies","year":2025,"lang":"en","type":"article","venue":"JAMA Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto","funders":"","keywords":"Medicine; Emulation; Interpretation (philosophy); Intensive care medicine; Clinical trial; Medical physics; Continuous glucose monitoring; Pharmacology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.012386008570092474,"score_gpt":0.32743998426873544,"score_spread":0.31505397569864296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407301560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92556983,0.004951212,0.056621842,0.005468675,0.0024578113,0.0025436282,0.000004584519,0.000049978822,0.0023324527],"genre_scores_gemma":[0.99674404,0.00023492234,0.0010064219,0.00032803422,0.00024585542,0.00020101007,0.000047626334,0.000010001459,0.0011820658],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988146,0.000029546445,0.0005972293,0.00017422358,0.00025707594,0.00012732227],"domain_scores_gemma":[0.9984809,0.0006916995,0.00029138642,0.00019457578,0.00029903324,0.000042379343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002608181,0.00013368577,0.00058142137,0.00036371042,0.000024260185,0.000003294899,0.000089239555,0.000055353834,0.000020647323],"category_scores_gemma":[0.0020657363,0.00009786826,0.00010563049,0.00019511399,0.00012899995,0.00006913307,0.000044014083,0.000075805925,0.0000011077557],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15056597,0.003684448,0.035003934,0.035247505,0.02661206,0.00007225299,0.018295802,0.0003486342,0.117988266,0.027027965,0.044191457,0.5409617],"study_design_scores_gemma":[0.4134607,0.027303232,0.073389396,0.035396032,0.009782647,0.000006408099,0.0035713245,0.024649255,0.39016768,0.0126885995,0.009107026,0.0004777034],"about_ca_topic_score_codex":0.000052366067,"about_ca_topic_score_gemma":0.000007061249,"teacher_disagreement_score":0.540484,"about_ca_system_score_codex":0.000119499215,"about_ca_system_score_gemma":0.00003963906,"threshold_uncertainty_score":0.39909518},"labels":[],"label_agreement":null},{"id":"W4407315970","doi":"10.1371/journal.pone.0305511","title":"PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Diabète Québec","keywords":"Metformin; Pharmacogenetics; Type 2 diabetes; Medicine; Odds ratio; Genotyping; Linkage disequilibrium; Candidate gene; Internal medicine; Confidence interval; Allele; Diabetes mellitus; Genotype; Bioinformatics; Genetics; Gene; Biology; Haplotype; Endocrinology; Insulin","score_opus":0.02759821926742782,"score_gpt":0.24323497911564282,"score_spread":0.215636759848215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407315970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948609,0.00050147675,0.0000018480616,0.0015619445,0.00001923946,0.00092139037,0.000007965188,0.0000500796,0.002075158],"genre_scores_gemma":[0.980378,0.00013104452,0.001630148,0.0005283718,0.000011118895,0.00015294825,0.00003859342,0.000015330499,0.017114446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917805,0.000049848608,0.00013775118,0.00023299082,0.00015265803,0.0002486774],"domain_scores_gemma":[0.9994924,0.0001334454,0.000028043936,0.00021023859,0.000049235347,0.00008662855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019910495,0.00014251466,0.00035625984,0.00025602168,0.000031056825,0.000017627615,0.000035715908,0.000043584114,0.000032963257],"category_scores_gemma":[0.00020457774,0.00010484779,0.000017746781,0.00044919792,0.000018698911,0.000043218388,0.0000401976,0.000039987353,0.000023084847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068739313,0.017915709,0.82620806,0.00022752388,0.00927961,0.00038324864,0.0012514197,0.0000056953177,0.10912193,0.0002908201,0.00077328697,0.027668793],"study_design_scores_gemma":[0.008640547,0.0059102178,0.8858092,0.0012513626,0.002121623,3.0166524e-7,0.00007235047,0.00020690968,0.0946262,0.00015324868,0.0009758646,0.00023217975],"about_ca_topic_score_codex":0.000024302031,"about_ca_topic_score_gemma":0.000074025156,"teacher_disagreement_score":0.059601165,"about_ca_system_score_codex":0.00026195776,"about_ca_system_score_gemma":0.00006364304,"threshold_uncertainty_score":0.4275569},"labels":[],"label_agreement":null},{"id":"W4407348727","doi":"10.1002/art.43130","title":"Target Trial Emulations of Sodium‐Glucose Cotransporter 2 Inhibitors in Systemic Lupus Erythematosus","year":2025,"lang":"en","type":"editorial","venue":"Arthritis & Rheumatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; Research Canada; Western University","funders":"","keywords":"Medicine; Pharmacology","score_opus":0.005883712590269578,"score_gpt":0.24352836089545232,"score_spread":0.23764464830518275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407348727","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19266836,0.014107457,0.0000366232,0.0002293245,0.7868902,0.0030038701,0.00026885147,0.00014262235,0.002652648],"genre_scores_gemma":[0.8952723,0.01978224,0.0006660622,0.00006351808,0.07046989,0.0013834024,0.00686075,0.00017430261,0.0053275167],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654233,0.00013908163,0.0016003418,0.0006496123,0.0005194312,0.0005491929],"domain_scores_gemma":[0.9979414,0.0006287324,0.00048185815,0.00062814244,0.00020721802,0.000112650756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031819244,0.0004769814,0.0022386347,0.00082594884,0.00005547384,0.000018737772,0.00019738477,0.0009831822,0.00015874147],"category_scores_gemma":[0.00032502663,0.000479076,0.0003762558,0.00035592497,0.00018306832,0.00008880551,0.00008411143,0.0005392608,0.000051854615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005549378,0.0010140755,0.018062243,0.0023405903,0.0007182753,0.00042169614,0.00044486986,0.0000059197546,0.000017983537,0.001313253,0.96677333,0.003338395],"study_design_scores_gemma":[0.22259662,0.001988734,0.00014377566,0.017403983,0.0008660283,0.00023336163,0.0003191569,0.000044576936,0.0003265246,0.0011073537,0.7541212,0.00084869406],"about_ca_topic_score_codex":0.00030188836,"about_ca_topic_score_gemma":0.0005173789,"teacher_disagreement_score":0.71642035,"about_ca_system_score_codex":0.00016735883,"about_ca_system_score_gemma":0.0005798927,"threshold_uncertainty_score":0.9997661},"labels":[],"label_agreement":null},{"id":"W4407406233","doi":"10.1186/s12911-025-02881-4","title":"Analytical validation of Exandra: a clinical decision support system for promoting guideline-directed therapy of type-2 diabetes in primary care – a collaborative study with experts from Diabetes Canada","year":2025,"lang":"en","type":"article","venue":"BMC Medical Informatics and Decision Making","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Diabetes Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"Diabetes Canada","keywords":"Guideline; Medicine; Health informatics; Clinical decision support system; Test (biology); Type 2 diabetes; Clinical Practice; Family medicine; Decision support system; Diabetes mellitus; Nursing; Computer science; Data mining; Public health; Pathology","score_opus":0.025148498990136065,"score_gpt":0.3485059841574496,"score_spread":0.32335748516731355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199635,0.00046415805,0.005403765,0.000012400187,0.00015901594,0.0015773403,0.00002165198,0.000021379654,0.00034395268],"genre_scores_gemma":[0.9402521,0.000050883456,0.059315957,0.00017352274,0.000023294591,0.000059561604,0.00011044123,0.0000100721,0.0000041390344],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969666,0.000070051916,0.0017367422,0.00020046115,0.00082224986,0.00020391616],"domain_scores_gemma":[0.99572974,0.0028922916,0.0003913384,0.00026128374,0.00061149854,0.00011383699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011470503,0.00017814482,0.0008610022,0.00022936473,0.000046258625,0.000026872262,0.00011743025,0.00010972562,0.000014032254],"category_scores_gemma":[0.0009731865,0.000115262046,0.000057907215,0.0005239937,0.00006039104,0.000091888,0.00011432387,0.00008607933,1.493312e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011644991,0.00035549878,0.6986085,0.0007169794,0.0002732157,0.0000071675504,0.00088613137,0.000049403512,0.000004081744,0.000022032542,0.00089985336,0.2970126],"study_design_scores_gemma":[0.039185572,0.0073839114,0.14366135,0.021675263,0.0008701331,0.0000011752068,0.04539457,0.7386794,0.0011459249,0.00019105438,0.001266069,0.0005456004],"about_ca_topic_score_codex":0.00034094215,"about_ca_topic_score_gemma":0.004092319,"teacher_disagreement_score":0.73863,"about_ca_system_score_codex":0.00013964804,"about_ca_system_score_gemma":0.0013028553,"threshold_uncertainty_score":0.47002497},"labels":[],"label_agreement":null},{"id":"W4407498665","doi":"10.1002/oby.24222","title":"Safety profile of semaglutide versus placebo in the <scp>SELECT</scp> study: a randomized controlled trial","year":2025,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Discontinuation; Adverse effect; Placebo; Internal medicine; Overweight; Obesity; Type 2 diabetes; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.010359851363606114,"score_gpt":0.2730059534200311,"score_spread":0.26264610205642497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407498665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8911454,0.00020114052,0.000026214968,0.00026219187,0.00031009954,0.01764273,0.0000024011667,0.000032491786,0.0903773],"genre_scores_gemma":[0.9887886,0.000026804428,0.00008622387,0.000115109484,0.000048474205,0.0012614988,0.000012943061,0.000006480545,0.009653843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981414,0.00064862147,0.0004823037,0.00021208095,0.00029396208,0.00022160096],"domain_scores_gemma":[0.9968292,0.002609817,0.00014256034,0.00033208868,0.00005626323,0.00003004473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002504874,0.00015980822,0.0013500844,0.00015212831,0.000060502553,0.000014723891,0.00013589056,0.000049716175,0.00003696524],"category_scores_gemma":[0.0017611242,0.00009161676,0.0002936729,0.00033891443,0.0000619733,0.000025392394,0.000058363206,0.00013210367,0.000015945652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9810137,0.0032387513,0.0083484575,0.00006076826,0.001492119,0.000022115408,0.0007251102,0.0000035980163,0.000021239484,0.0012643691,0.003237032,0.00057274854],"study_design_scores_gemma":[0.9867388,0.00080696243,0.008405812,0.00005002471,0.001800925,1.2580627e-7,0.000810165,0.00017702238,0.00013307999,0.00009898169,0.0009535116,0.00002457128],"about_ca_topic_score_codex":0.00009417778,"about_ca_topic_score_gemma":0.00012848339,"teacher_disagreement_score":0.0976432,"about_ca_system_score_codex":0.00008117266,"about_ca_system_score_gemma":0.00011120483,"threshold_uncertainty_score":0.37360233},"labels":[],"label_agreement":null},{"id":"W4407539510","doi":"10.1002/dmrr.70037","title":"Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis","year":2025,"lang":"en","type":"review","venue":"Diabetes/Metabolism Research and Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Qatar National Library","keywords":"Meta-analysis; Suicidal ideation; Observational study; Pharmacovigilance; Systematic review; Medicine; Psychiatry; Internal medicine; MEDLINE; Clinical psychology; Adverse effect; Poison control; Injury prevention; Environmental health; Biology","score_opus":0.05507244476108575,"score_gpt":0.3801042847267796,"score_spread":0.32503183996569385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407539510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013767931,0.9894441,0.0000035997064,0.0001439389,0.000019054669,0.009771617,0.0002966585,0.0000122191805,0.00017112566],"genre_scores_gemma":[0.00003286164,0.9923456,0.00038384457,0.000048675614,0.00002138597,0.001970783,0.00038381046,0.000029160883,0.0047838986],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941884,0.0021421977,0.0017193427,0.00066459825,0.0008059657,0.00047947408],"domain_scores_gemma":[0.99564546,0.0009996298,0.001787472,0.000751932,0.00057948346,0.00023602882],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0067831823,0.00055394915,0.012865389,0.0011010048,0.00011392235,0.000062638755,0.00016807822,0.00023416146,0.00007101836],"category_scores_gemma":[0.0014234212,0.00030390263,0.0011373576,0.002167192,0.00019826982,0.00011140349,0.00020040631,0.00046290114,0.0000067691853],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048006505,0.00014380206,0.001076191,0.8818251,0.094139434,0.0000011260008,0.00002075033,8.4341725e-9,6.167813e-7,0.00008104796,0.00057491765,0.022132227],"study_design_scores_gemma":[0.0003768263,0.00024382983,0.00022694502,0.11077468,0.8547826,6.632551e-7,0.000007866743,9.654955e-7,0.000007053914,0.000017916349,0.03335148,0.00020918432],"about_ca_topic_score_codex":0.000058322687,"about_ca_topic_score_gemma":0.000025700772,"teacher_disagreement_score":0.7710504,"about_ca_system_score_codex":0.00007839633,"about_ca_system_score_gemma":0.00012591004,"threshold_uncertainty_score":0.9999413},"labels":[],"label_agreement":null},{"id":"W4407549600","doi":"10.1038/s44220-025-00390-x","title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","year":2025,"lang":"en","type":"article","venue":"Nature Mental Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Medical Research Council; National Institute for Health and Care Research; UK Research and Innovation; Wellcome Trust","keywords":"Mental health; Receptor; Cognition; Psychology; Medicine; Psychiatry; Internal medicine","score_opus":0.004721124218612232,"score_gpt":0.3117930623470826,"score_spread":0.3070719381284704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407549600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516034,0.007848473,0.000004854736,0.033968266,0.00022755426,0.002061125,0.0001831364,0.000031404496,0.004071786],"genre_scores_gemma":[0.98807764,0.0019390368,0.00012669717,0.008376238,0.000016175405,0.00004185346,0.0008096701,0.000011061054,0.00060161407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859786,0.00014473383,0.00030385354,0.0003567421,0.0002752731,0.0003215236],"domain_scores_gemma":[0.99942183,0.00006326261,0.00013820009,0.00021644197,0.000020148012,0.00014009568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041490258,0.0001821957,0.00045565312,0.00036334843,0.00017990211,0.0000146327475,0.00007999161,0.00008329019,0.000052362764],"category_scores_gemma":[0.000011584433,0.00012830258,0.00009418828,0.0006908425,0.00008705365,0.00005309311,0.00004810368,0.00031873153,0.0000030249798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002036504,0.0051904726,0.57991445,0.0006085502,0.0024408484,0.0000022651902,0.008584484,0.00000405614,0.00022689324,0.00919609,0.016915428,0.37487996],"study_design_scores_gemma":[0.013069946,0.009130306,0.83219457,0.0022650491,0.00067206746,0.0000015992773,0.048873488,0.0014710595,0.0022988177,0.00087886245,0.088617444,0.00052681734],"about_ca_topic_score_codex":0.000786002,"about_ca_topic_score_gemma":0.0027358779,"teacher_disagreement_score":0.37435314,"about_ca_system_score_codex":0.00043675836,"about_ca_system_score_gemma":0.00014376298,"threshold_uncertainty_score":0.5232027},"labels":[],"label_agreement":null},{"id":"W4407556772","doi":"10.1002/ejhf.3604","title":"Empagliflozin's Anti-Inflammatory Spectrum in Type 2 Diabetes Mellitus: Piecing Together the Puzzle","year":2025,"lang":"en","type":"editorial","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Empagliflozin; Medicine; Broad spectrum; Diabetes mellitus; Heart failure; Type 2 diabetes; Type 2 Diabetes Mellitus; Spectrum (functional analysis); Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.006175581370787732,"score_gpt":0.2324845918920742,"score_spread":0.2263090105212865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407556772","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06753307,0.024484925,0.000011513604,0.032804932,0.8615803,0.0012533666,0.000028782728,0.00010358621,0.012199489],"genre_scores_gemma":[0.0547089,0.0033324682,0.0017139433,0.0010707953,0.92397964,0.000007288829,0.000116177085,0.0003048501,0.01476595],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99696684,0.0005668664,0.00086465885,0.00030627826,0.00080569345,0.0004896494],"domain_scores_gemma":[0.9982464,0.00037099948,0.000442523,0.0005508535,0.0002440369,0.00014520211],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020691792,0.00041048366,0.0009090287,0.00047726277,0.0001074874,0.0001225666,0.00042641524,0.00015009857,0.00019028447],"category_scores_gemma":[0.0004885458,0.00026532487,0.0003721998,0.00035612064,0.000086732936,0.00013070853,0.00017750263,0.0015558879,0.00017773951],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000853183,0.00012305306,0.003421428,0.000251828,0.00054785,0.0006344712,0.00022912212,0.00001656756,0.00008049796,0.000013023552,0.9936345,0.000962319],"study_design_scores_gemma":[0.0017874256,0.00055182655,0.0024315105,0.0022028338,0.00053400936,0.000006271692,0.00020310863,0.0000034322125,0.00017205179,0.000021084572,0.9918788,0.00020765861],"about_ca_topic_score_codex":0.0000034011944,"about_ca_topic_score_gemma":0.000018254934,"teacher_disagreement_score":0.06239929,"about_ca_system_score_codex":0.00018024867,"about_ca_system_score_gemma":0.00032218284,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W4407568618","doi":"10.1016/s2213-8587(24)00362-0","title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Women's College Hospital; University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Adverse effect; Randomized controlled trial; Internal medicine; MEDLINE; Intensive care medicine","score_opus":0.012227653886428429,"score_gpt":0.2715166031842844,"score_spread":0.25928894929785595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407568618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857062,0.001845154,0.000006647372,0.00084202096,0.00050238456,0.0028330428,0.0000360669,0.000042585318,0.008185868],"genre_scores_gemma":[0.99779904,0.00015038006,0.00001904848,0.00047608375,0.00011737367,0.00040998627,0.000034732577,0.0000139788735,0.0009793648],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974745,0.00081854657,0.00046945963,0.00032513862,0.0002978027,0.0006145711],"domain_scores_gemma":[0.99722254,0.0010217781,0.00020755435,0.0014606641,0.000054293894,0.000033156186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095656316,0.0002435378,0.0018843486,0.00035126056,0.000066220666,0.000004246411,0.00043013654,0.000067028035,0.00011522491],"category_scores_gemma":[0.00035085174,0.00012657316,0.0014925633,0.0007916039,0.00022077232,0.000025370586,0.00019855422,0.00022257879,0.000007763354],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34668878,0.0016300754,0.19590105,0.0019181618,0.2966677,0.0000488176,0.0003989484,0.0013335295,0.0067665474,0.006198565,0.008892341,0.13355547],"study_design_scores_gemma":[0.6072986,0.0033229832,0.18154801,0.0003415337,0.074877515,6.3973044e-7,0.00006033846,0.00024619992,0.11658803,0.00040312408,0.015056848,0.00025616365],"about_ca_topic_score_codex":0.000027516593,"about_ca_topic_score_gemma":0.000009044484,"teacher_disagreement_score":0.26060984,"about_ca_system_score_codex":0.000059394482,"about_ca_system_score_gemma":0.000051209576,"threshold_uncertainty_score":0.51615036},"labels":[],"label_agreement":null},{"id":"W4407582745","doi":"10.1017/neu.2025.4","title":"Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review","year":2025,"lang":"en","type":"review","venue":"Acta Neuropsychiatrica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Neurogenesis; Association (psychology); Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Receptor; Endocrinology; Internal medicine; Medicine; Chemistry; Neuroscience; Biology; Psychology; Diabetes mellitus; Agonist; Psychotherapist; Type 2 diabetes","score_opus":0.012440304855585357,"score_gpt":0.28378831568267876,"score_spread":0.2713480108270934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407582745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009086322,0.9892143,0.0000010584773,0.000946224,0.0008925042,0.0063938084,0.00005893547,0.00010365644,0.0023804444],"genre_scores_gemma":[0.0000066847556,0.9820426,0.00014856995,0.0012286194,0.0001126159,0.0005903562,0.00019577076,0.00008420306,0.015590566],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99614483,0.0005935358,0.0015646857,0.0007345338,0.00056739914,0.00039503124],"domain_scores_gemma":[0.9962934,0.00060350954,0.0017669521,0.0010161881,0.00015196338,0.0001679338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048597014,0.00066415925,0.0045535946,0.00047233372,0.00007634549,0.000044132343,0.00031078828,0.00022392024,0.00004198174],"category_scores_gemma":[0.00082275993,0.00050041825,0.00094380364,0.0011957292,0.000026180958,0.00006856173,0.00019912528,0.0003048767,0.00008059072],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000070481738,0.00023635922,0.00004078956,0.893213,0.0014139753,0.000011565282,0.000006261932,4.0703383e-9,5.9816193e-7,0.00002331583,0.07272633,0.032320768],"study_design_scores_gemma":[0.00036687552,0.00021349019,0.00001782937,0.34348384,0.03818337,0.00001143116,0.0000023231055,3.9949953e-7,2.2993879e-7,0.0000016961716,0.617506,0.00021253216],"about_ca_topic_score_codex":0.0000045217616,"about_ca_topic_score_gemma":0.0000010660302,"teacher_disagreement_score":0.54972917,"about_ca_system_score_codex":0.00017710017,"about_ca_system_score_gemma":0.00029899584,"threshold_uncertainty_score":0.9997448},"labels":[],"label_agreement":null},{"id":"W4407677557","doi":"10.1017/s1092852925000124","title":"The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro-GDP): potential mechanistically informed therapeutics in the treatment and prevention of mental disorders","year":2025,"lang":"en","type":"review","venue":"CNS Spectrums","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brain and Cognition Discovery Foundation; University of Toronto","funders":"","keywords":"Neurogenesis; Glucagon-like peptide-1; Receptor; Neuroplasticity; Medicine; Endocrinology; Neuroscience; Diabetes mellitus; Biology; Internal medicine; Type 2 diabetes","score_opus":0.010457432381089093,"score_gpt":0.278839902536869,"score_spread":0.26838247015577993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407677557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3174801,0.6747452,0.00009415918,0.00035046288,0.0003926003,0.006550051,0.00013880982,0.000028074362,0.00022054257],"genre_scores_gemma":[0.08509683,0.9141939,0.00003658242,0.000040843544,0.00003268262,0.00020449384,0.00015283091,0.000025175916,0.00021663714],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811846,0.0003030344,0.00060486863,0.0003941714,0.00030542735,0.00027404385],"domain_scores_gemma":[0.99838626,0.0008807411,0.00033959738,0.00031008787,0.000018314911,0.00006496991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016582942,0.00046596126,0.0010144535,0.00019455781,0.00014658253,0.00007472158,0.00014417373,0.00013150313,0.0000054597504],"category_scores_gemma":[0.00007662986,0.00024582614,0.00021714791,0.00018407102,0.00017312886,0.000053735068,0.00010476252,0.00017508671,0.0000011534383],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006063317,0.00061697053,0.0013409948,0.0063923076,0.0011964758,0.000006683596,0.00016031814,6.6717547e-7,0.00007975054,0.0013934787,0.000030507093,0.9881755],"study_design_scores_gemma":[0.06256396,0.12274336,0.15817487,0.044208862,0.07919785,0.00016206376,0.00091371284,0.00071078126,0.009875115,0.0025514525,0.5155897,0.0033082683],"about_ca_topic_score_codex":0.000033892993,"about_ca_topic_score_gemma":0.0002023476,"teacher_disagreement_score":0.9848673,"about_ca_system_score_codex":0.0001383455,"about_ca_system_score_gemma":0.00009763199,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W4407694744","doi":"10.1016/j.cjco.2025.02.008","title":"Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART","year":2025,"lang":"en","type":"article","venue":"CJC Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Heart and Stroke Foundation; Canadian VIGOUR Centre; University of Alberta; Sunnybrook Health Science Centre; St. Michael's Hospital; University Health Network; Health Sciences Centre; Institute for Clinical Evaluative Sciences; University of Toronto; Women's College Hospital; NOSM University; University of British Columbia","funders":"Canadian Institutes of Health Research; Ministry of Long-Term Care; CorHealth Ontario; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; Ministry of Health, Ontario","keywords":"Type 2 diabetes; Cardiovascular event; Medicine; Event (particle physics); Diabetes mellitus; Internal medicine; Intensive care medicine; Cardiology; Disease; Endocrinology; Physics","score_opus":0.01864629622149685,"score_gpt":0.2499085549632428,"score_spread":0.23126225874174594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407694744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918353,0.0056263534,0.00002035532,0.0001700586,0.000087780645,0.0012230688,0.000008629865,0.000010289937,0.0010181726],"genre_scores_gemma":[0.99815863,0.000035984267,0.0006517011,0.0005212174,0.000011020498,0.00014509434,0.000049542377,0.000011721311,0.00041505788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992066,0.000027426193,0.00017872237,0.00023484384,0.00021403548,0.00013838576],"domain_scores_gemma":[0.9993454,0.000050496586,0.00003596652,0.0004392998,0.00009319222,0.000035641457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000907608,0.00012502354,0.00045160533,0.000119162934,0.000017060393,0.000027416352,0.00014287513,0.000035938006,0.00006190337],"category_scores_gemma":[0.000034588684,0.000085962885,0.00008023387,0.00028997738,0.00003644828,0.00015016581,0.000100196354,0.000048800448,0.0000080952705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082484295,0.0007201373,0.9839462,0.00009962474,0.0016941748,0.000007893151,0.00020760474,0.000048508256,0.000082028484,0.00003990939,0.0002506778,0.012078403],"study_design_scores_gemma":[0.006390275,0.0003970925,0.97889423,0.0018127619,0.0004389573,6.090195e-9,0.00003320788,0.000060808867,0.0007640834,0.000034572513,0.011085918,0.00008809765],"about_ca_topic_score_codex":0.00043988568,"about_ca_topic_score_gemma":0.00014807128,"teacher_disagreement_score":0.011990305,"about_ca_system_score_codex":0.00006433153,"about_ca_system_score_gemma":0.00010570686,"threshold_uncertainty_score":0.35054648},"labels":[],"label_agreement":null},{"id":"W4407700738","doi":"10.1080/14740338.2025.2465870","title":"Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Ileus; Systematic review; Bowel obstruction; Internal medicine; Tegaserod; Intensive care medicine; Gastroenterology; MEDLINE; Irritable bowel syndrome; Surgery","score_opus":0.07329668357785438,"score_gpt":0.3981136809968496,"score_spread":0.32481699741899517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003741733,0.9911605,0.0000032720754,0.0004892046,0.00030689436,0.0074550705,0.0000809293,0.00004025415,0.00046012882],"genre_scores_gemma":[0.000009279615,0.99325,0.00023546703,0.0008235167,0.000037039234,0.0018638114,0.0013274533,0.00003713674,0.0024162885],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9958751,0.0008781476,0.0014602813,0.00088133354,0.00063038437,0.00027473085],"domain_scores_gemma":[0.9978783,0.00039695788,0.0007338502,0.0007762425,0.000086367894,0.00012827785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087653514,0.00067155156,0.006235987,0.00065736327,0.00010730478,0.000025469542,0.0001343884,0.00015577821,0.00014828898],"category_scores_gemma":[0.00045744135,0.0004388027,0.0011724834,0.0007425119,0.00002730438,0.00007490348,0.00012956632,0.00025009812,0.0000325729],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005443681,0.00048280015,0.000024414441,0.80403185,0.06145709,0.0000016208711,0.00014302939,0.0000013611594,7.448913e-9,0.00011227722,0.0013782785,0.13231286],"study_design_scores_gemma":[0.0019400902,0.000541471,0.000130095,0.35882595,0.43994513,0.0000013744378,0.000057591824,0.000014091418,2.3472256e-7,0.000011446536,0.19788983,0.0006426901],"about_ca_topic_score_codex":0.00002444912,"about_ca_topic_score_gemma":0.0000030625638,"teacher_disagreement_score":0.44520587,"about_ca_system_score_codex":0.0005376675,"about_ca_system_score_gemma":0.00006583237,"threshold_uncertainty_score":0.9998064},"labels":[],"label_agreement":null},{"id":"W4407714592","doi":"10.1503/cmaj.240469-f","title":"Les agonistes du récepteur du peptide-1 de type glucagon pour traiter la néphropathie chronique associée à un diabète de type 2","year":2025,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine","score_opus":0.005998755874475238,"score_gpt":0.24403584498068098,"score_spread":0.23803708910620575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407714592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5655938,0.016084999,0.0007453475,0.32399553,0.008073865,0.0005552182,0.000083247614,0.00009947407,0.084768556],"genre_scores_gemma":[0.8424546,0.010305469,0.0007951469,0.0332649,0.008250068,0.000025558933,0.00010235966,0.00009005176,0.10471183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579287,0.0009393277,0.00065998774,0.00031503898,0.00090804667,0.0013847612],"domain_scores_gemma":[0.9960899,0.0007188758,0.00032927495,0.00016474462,0.00060662685,0.0020906003],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004076788,0.00035649212,0.0005449908,0.00035056492,0.0005257167,0.00029610304,0.0003192241,0.0009769995,0.011330527],"category_scores_gemma":[0.0049807173,0.00035702772,0.0002699963,0.00054493017,0.00014252175,0.00016390218,0.000053886346,0.0015344853,0.0004887033],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000030593885,0.00028562755,0.3051795,0.00012270799,0.0015180709,0.0025424324,0.00089005916,0.000012398653,0.00006820875,0.0046096407,0.45242164,0.23231912],"study_design_scores_gemma":[0.0024358206,0.00025434452,0.17062779,0.0009458709,0.0008417931,0.00018616192,0.0005795775,0.0009717152,0.00011957086,0.0007812672,0.821989,0.00026707555],"about_ca_topic_score_codex":0.008116519,"about_ca_topic_score_gemma":0.013659947,"teacher_disagreement_score":0.36956736,"about_ca_system_score_codex":0.009900995,"about_ca_system_score_gemma":0.010497983,"threshold_uncertainty_score":0.9998882},"labels":[],"label_agreement":null},{"id":"W4407719917","doi":"10.46747/cfp.710285","title":"Weight normativity in action","year":2025,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Institutes of Health Research","funders":"","keywords":"Action (physics); Computer science; Data science; Physics","score_opus":0.0151647969565321,"score_gpt":0.24693428147287746,"score_spread":0.23176948451634535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407719917","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32524344,0.0001423425,0.000015712989,0.0015344833,0.00022550185,0.00027195565,0.000005852023,0.000026163381,0.6725345],"genre_scores_gemma":[0.93813634,0.000021376245,0.000044212782,0.056336135,0.000055613276,0.00003279667,0.000044129054,0.0000073999413,0.00532201],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945265,0.000013446851,0.00009076271,0.00013564549,0.00006277561,0.0002447005],"domain_scores_gemma":[0.99965495,0.000009649864,0.000015832273,0.00018029177,0.000018027218,0.000121257486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041826635,0.000089534726,0.00014879991,0.00034119553,0.0000429817,0.000014039598,0.000045206692,0.000034843193,0.000003595552],"category_scores_gemma":[0.0000029056603,0.00008909144,0.000043273758,0.0003816043,0.000020320243,0.00009138828,0.000009881352,0.000080677775,0.000121600744],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033704444,0.00027462412,0.02027148,0.0001744122,0.00022503715,0.00011661969,0.00009863421,0.000010333515,0.002102179,0.017856466,0.14244677,0.81638974],"study_design_scores_gemma":[0.0009802114,0.000043737724,0.44599396,0.00014040896,0.00007181989,4.7447415e-8,0.00020602671,0.00017461693,0.0007897768,0.00078968744,0.55070376,0.00010595376],"about_ca_topic_score_codex":0.009059391,"about_ca_topic_score_gemma":0.03430024,"teacher_disagreement_score":0.81628376,"about_ca_system_score_codex":0.0005200077,"about_ca_system_score_gemma":0.00021029814,"threshold_uncertainty_score":0.99753934},"labels":[],"label_agreement":null},{"id":"W4407722337","doi":"10.1093/ehjopen/oeaf013","title":"15-Year trends, predictors, and outcomes of heart failure hospitalization complicating first acute myocardial infarction in the modern percutaneous coronary intervention era","year":2025,"lang":"en","type":"article","venue":"European Heart Journal Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Niilo Helanderin Säätiö; Department of Health and Social Care; National Institute for Health and Care Research","keywords":"Conventional PCI; Myocardial infarction; Medicine; Internal medicine; Cardiology; Heart failure; Emergency medicine; Intensive care medicine","score_opus":0.015533880972799737,"score_gpt":0.29348705248785917,"score_spread":0.27795317151505944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407722337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739264,0.00025333764,0.00011713403,0.019026604,0.00016534817,0.0006573486,0.000008974953,0.00001995393,0.0058249],"genre_scores_gemma":[0.9972275,0.00010084871,0.0008988429,0.000856858,0.000044018467,0.000006678135,0.000046444773,0.000015567974,0.00080325385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891835,0.00023469553,0.00036551713,0.0001623691,0.00018254292,0.0001365004],"domain_scores_gemma":[0.9995585,0.000046528778,0.00010646265,0.00019023064,0.000051009134,0.00004725882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057740865,0.00011959021,0.00027192265,0.0001766566,0.0001369788,0.00014304559,0.00015622593,0.00002247428,0.000043394917],"category_scores_gemma":[0.000028185359,0.00008401805,0.00013151232,0.00017740806,0.000037060297,0.00021523556,0.00014838018,0.00019125635,0.0000069408748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015584315,0.0002894213,0.96239585,0.000043479136,0.0005730241,0.00006191024,0.0011513538,0.00005896046,0.00022667082,0.00012367268,0.027606359,0.007313449],"study_design_scores_gemma":[0.0016629916,0.0005301902,0.9751698,0.00031811604,0.0002651258,0.00024450294,0.00029971448,0.00020504995,0.0000073970036,0.000080682454,0.02114999,0.00006644571],"about_ca_topic_score_codex":0.000030044843,"about_ca_topic_score_gemma":0.000022962025,"teacher_disagreement_score":0.02330109,"about_ca_system_score_codex":0.000055345427,"about_ca_system_score_gemma":0.0000138937885,"threshold_uncertainty_score":0.34261566},"labels":[],"label_agreement":null},{"id":"W4407726381","doi":"10.1017/neu.2025.6","title":"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder","year":2025,"lang":"en","type":"review","venue":"Acta Neuropsychiatrica","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"Health Resources and Services Administration; Substance Abuse and Mental Health Services Administration; Bausch Health; National Natural Science Foundation of China; Patient-Centered Outcomes Research Institute; H. Lundbeck A/S; University of Cambridge; Canadian Institutes of Health Research; Sunovion; Eisai; Purdue University; Biogen; Novo Nordisk; Sanofi; National Institute of Mental Health; Pfizer","keywords":"Alcohol use disorder; Exenatide; Liraglutide; Medicine; PsycINFO; Glucagon-like peptide 1 receptor; Alcohol; Pharmacology; Psychology; MEDLINE; Type 2 diabetes; Receptor; Internal medicine; Agonist; Diabetes mellitus; Endocrinology; Biology","score_opus":0.030193115183768132,"score_gpt":0.3171285740812623,"score_spread":0.28693545889749417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407726381","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006883501,0.97776926,0.0000024167446,0.00071341236,0.00085329544,0.018895559,0.00019165987,0.00011607675,0.0013894859],"genre_scores_gemma":[0.0008359761,0.98727643,0.00003935967,0.0012852526,0.00008888276,0.0028112186,0.00059338147,0.00017148483,0.006898008],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953223,0.0006752398,0.0018245997,0.0009480608,0.00065446086,0.0005753362],"domain_scores_gemma":[0.9953395,0.0010409976,0.0014134592,0.0019088748,0.0001548627,0.00014231859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042801775,0.001009714,0.003625885,0.00046863477,0.00018227499,0.000100974285,0.0006865755,0.0002917908,0.00011497604],"category_scores_gemma":[0.00026898575,0.0005772992,0.0020714202,0.0010639436,0.00007544721,0.00007871171,0.00011585215,0.0005863504,0.0001284409],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012815886,0.0024181136,0.000009428449,0.7996277,0.0040438273,0.000017123135,0.00002123012,0.0000012355628,0.000005592584,0.0013112176,0.0145995,0.17781682],"study_design_scores_gemma":[0.0012668832,0.0020590054,0.000022497054,0.3717852,0.05151463,0.000012605074,0.000023851053,0.000009379818,0.0000014144425,0.00004180664,0.5727404,0.0005223766],"about_ca_topic_score_codex":0.00001526631,"about_ca_topic_score_gemma":0.0000012930569,"teacher_disagreement_score":0.5581409,"about_ca_system_score_codex":0.000120705554,"about_ca_system_score_gemma":0.00030098073,"threshold_uncertainty_score":0.9996678},"labels":[],"label_agreement":null},{"id":"W4407787676","doi":"10.2337/dc24-1533","title":"Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity","year":2025,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Esperion Therapeutics; Novo Nordisk; University of Glasgow; British Heart Foundation; Sanofi; Kowa Company; Alnylam Pharmaceuticals; Glenmark Pharmaceuticals; Eli Lilly and Company; AstraZeneca; CSL Behring; McMaster University; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Pfizer; Abbott Laboratories","keywords":"Medicine; Meta-analysis; Type 2 diabetes; Internal medicine; Randomized controlled trial; Diabetes mellitus; Glucagon-like peptide-1; Endocrinology; Pharmacology","score_opus":0.1623947790216077,"score_gpt":0.40440065389593427,"score_spread":0.24200587487432657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407787676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011553112,0.9757625,0.000010391822,0.000033030654,0.00011625359,0.0214374,0.0014186335,0.000021556287,0.0000449134],"genre_scores_gemma":[0.0045476076,0.98045087,0.0047428855,0.000045683766,0.000018684004,0.0048423456,0.0042043575,0.000064969,0.0010826178],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935359,0.0017915025,0.0032381248,0.00062645524,0.00050670566,0.00030136504],"domain_scores_gemma":[0.9914605,0.0043621557,0.0024597428,0.0010175304,0.0005953787,0.0001046606],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002328796,0.00074878667,0.040742513,0.0010418324,0.00006079263,0.000026840611,0.00018533021,0.00018800318,0.00007305195],"category_scores_gemma":[0.0042996723,0.0003576573,0.0062462385,0.0017476263,0.0001734979,0.00009494458,0.00009613203,0.00012208473,8.7003576e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018685745,0.00019576977,0.0036093064,0.5935757,0.3995455,8.4802326e-7,0.0002903374,0.0000075562875,4.588048e-8,0.000044492666,0.000059782375,0.00080207357],"study_design_scores_gemma":[0.022923328,0.00051289244,0.00031973355,0.0698788,0.90481174,1.10862516e-7,0.0002817553,0.000013687211,0.0000025999136,0.000003048319,0.0009461449,0.00030614404],"about_ca_topic_score_codex":0.000021936223,"about_ca_topic_score_gemma":0.00021327246,"teacher_disagreement_score":0.5236969,"about_ca_system_score_codex":0.00012494651,"about_ca_system_score_gemma":0.00025245533,"threshold_uncertainty_score":0.9998875},"labels":[],"label_agreement":null},{"id":"W4407867088","doi":"10.1681/asn.20233411b13c","title":"Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Type 2 diabetes; Type 1 diabetes; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.008081631606361866,"score_gpt":0.23991341737866217,"score_spread":0.23183178577230032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407867088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975482,0.00014443233,0.0000011271688,0.0021077956,0.000023201432,0.00013877278,0.0000017680818,0.0000030401627,0.000031625776],"genre_scores_gemma":[0.9976896,0.0004910361,0.000634825,0.0011115809,0.00001986604,6.426054e-7,0.0000013296357,0.0000070596516,0.000044050175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941856,0.00003790662,0.0002172345,0.00006688068,0.00013548727,0.00012392117],"domain_scores_gemma":[0.9993004,0.00011323437,0.00038106917,0.00009840523,0.00007100627,0.000035856814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017351267,0.00006855318,0.0003879263,0.00005346063,0.00001710191,0.0000016868207,0.00005854199,0.000020034928,0.0000038407898],"category_scores_gemma":[0.000022925933,0.000039760205,0.00006479347,0.00031052262,0.00043279649,0.000027701602,0.000070204645,0.00009123563,3.357193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009854073,0.00021437302,0.97418964,0.000059178597,0.00068352657,0.0000014806194,0.00055730634,0.00001788138,0.0031630865,0.000010238637,0.00629372,0.013824148],"study_design_scores_gemma":[0.0035172084,0.0026100352,0.9912761,0.000060972947,0.00018591186,0.0000010390786,0.00027084735,0.00003601948,0.00009950843,0.000032793545,0.0018777212,0.000031871856],"about_ca_topic_score_codex":0.000007661397,"about_ca_topic_score_gemma":0.0000012853694,"teacher_disagreement_score":0.017086418,"about_ca_system_score_codex":0.000017631271,"about_ca_system_score_gemma":0.000023898452,"threshold_uncertainty_score":0.16213742},"labels":[],"label_agreement":null},{"id":"W4407896522","doi":"10.1503/cmaj.240922","title":"Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease","year":2025,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Disease; Type 2 Diabetes Mellitus; Endocrinology; Type 2 diabetes; Internal medicine; Kidney; Bioinformatics; Biology","score_opus":0.001900695176846403,"score_gpt":0.1894279060658063,"score_spread":0.1875272108889599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407896522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691845,0.0049615228,0.000004035159,0.0071400525,0.00021001472,0.000420625,0.0001874569,0.000009059938,0.00014881296],"genre_scores_gemma":[0.9923119,0.005351322,0.000015413274,0.0015189073,0.00013662076,0.000012286889,0.00018337957,0.000016003207,0.00045418742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983658,0.000081573075,0.00035481722,0.00023529699,0.0005411778,0.00042128848],"domain_scores_gemma":[0.99686074,0.000059217597,0.00017077412,0.000106831765,0.00010552001,0.0026968964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003673911,0.00018287853,0.0003350751,0.00030509118,0.00011363583,0.000043480195,0.000049634462,0.00010753343,0.00023746095],"category_scores_gemma":[0.0005770059,0.00014727541,0.000044574634,0.00023021121,0.00013697616,0.00013637103,0.000020826279,0.00034048574,0.0000014218682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011710364,0.00014663888,0.96702904,0.00025719375,0.00035372592,0.00003945693,0.000074583615,0.0000018560416,0.000002107176,0.00004293098,0.005745074,0.026190288],"study_design_scores_gemma":[0.0075944266,0.00034467588,0.94835997,0.0006841704,0.0005380957,2.1846567e-7,0.000033910088,0.00036290253,0.000004026913,0.000075680204,0.041864764,0.00013716525],"about_ca_topic_score_codex":0.00067924976,"about_ca_topic_score_gemma":0.010017021,"teacher_disagreement_score":0.036119692,"about_ca_system_score_codex":0.00072024955,"about_ca_system_score_gemma":0.0025174788,"threshold_uncertainty_score":0.6005717},"labels":[],"label_agreement":null},{"id":"W4407947558","doi":"10.1136/bmj-2024-080679","title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Cohort; Type 2 diabetes; Internal medicine; Glucagon-like peptide 1 receptor; Cohort study; Dipeptidyl peptidase-4; Proportional hazards model; Suicidal ideation; Diabetes mellitus; Confidence interval; Endocrinology; Poison control; Emergency medicine; Agonist; Receptor; Injury prevention","score_opus":0.010093136856377215,"score_gpt":0.2736623536871781,"score_spread":0.2635692168308009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407947558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346346,0.00007732615,0.0000055190767,0.000069195994,0.00020302286,0.0028142664,0.000016597927,0.000038272647,0.0033123423],"genre_scores_gemma":[0.99381316,0.000027214215,0.00026810254,0.00009712957,0.000029771429,0.00006899181,0.00007869579,0.000014656458,0.005602284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988763,0.00007609429,0.00026295029,0.00031324345,0.00026786127,0.0002035958],"domain_scores_gemma":[0.9991068,0.000064828346,0.00017339409,0.0003858687,0.00015875552,0.000110347486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019692112,0.00018441258,0.00046624814,0.00009112421,0.0000580405,0.000019766989,0.000067333036,0.00004307377,0.000062475185],"category_scores_gemma":[0.000059186183,0.00013590224,0.000041206094,0.00026210299,0.00008747706,0.000088907706,0.000088181725,0.00009298434,0.000014647114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037881872,0.0010571389,0.96518904,0.00005739955,0.002133052,0.0000017820399,0.00028967677,0.000001749458,0.00000981558,0.000016448308,0.02821362,0.0026514344],"study_design_scores_gemma":[0.00415699,0.0011490536,0.9886986,0.0001287774,0.0013232947,2.0441036e-8,0.0002952416,0.000007768766,0.0004376973,0.000011382839,0.0036712426,0.000119938806],"about_ca_topic_score_codex":0.0004925555,"about_ca_topic_score_gemma":0.00022180147,"teacher_disagreement_score":0.024542376,"about_ca_system_score_codex":0.00007505089,"about_ca_system_score_gemma":0.000083379426,"threshold_uncertainty_score":0.55419326},"labels":[],"label_agreement":null},{"id":"W4408041525","doi":"10.1177/13872877251319054","title":"Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Alzheimer s Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Medicine; Internal medicine; Randomized controlled trial; Placebo; Relative risk; Cognitive decline; Meta-analysis; Type 2 diabetes; Diabetes mellitus; Endocrinology; Confidence interval; Disease","score_opus":0.0550279087445124,"score_gpt":0.3780660092859737,"score_spread":0.3230381005414613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408041525","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011272989,0.99276847,0.000032820142,0.0004143937,0.00003105633,0.0061129117,0.00046412324,0.000005773046,0.000057723057],"genre_scores_gemma":[0.0030530158,0.9952622,0.00006488164,0.00062812574,0.000019498315,0.0007649336,0.000113698,0.000023974411,0.00006969204],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949776,0.0017113046,0.0021070011,0.0002790192,0.00070270477,0.000222354],"domain_scores_gemma":[0.9888682,0.005738296,0.0041679693,0.00038905788,0.0005732101,0.00026331507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029305108,0.00051635574,0.007995378,0.000735747,0.00007431473,0.000019803034,0.00023126983,0.00007171987,0.00024160759],"category_scores_gemma":[0.0028203803,0.00021737511,0.0040879985,0.0011042854,0.00014191728,0.000065396656,0.00014221515,0.00026270133,0.0000048645447],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050522394,0.0002225712,0.00022231633,0.4172899,0.5783644,0.000012664879,0.000013890639,6.588158e-8,2.7534028e-9,0.000009394152,0.00011933228,0.0036949697],"study_design_scores_gemma":[0.0006418863,0.0006210601,0.00026432588,0.22334883,0.7748279,0.0000011224104,0.000025078702,0.0000015962919,0.0000052764613,0.000007200321,0.00013541106,0.00012031699],"about_ca_topic_score_codex":0.0000022789295,"about_ca_topic_score_gemma":0.0000014505476,"teacher_disagreement_score":0.19646356,"about_ca_system_score_codex":0.000038386017,"about_ca_system_score_gemma":0.00056638155,"threshold_uncertainty_score":0.88642997},"labels":[],"label_agreement":null},{"id":"W4408051488","doi":"10.1016/j.molmet.2025.102118","title":"Glucose-dependent insulinotropic polypeptide (GIP)","year":2025,"lang":"en","type":"review","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; European Research Council; Canadian Institutes of Health Research; National Health and Medical Research Council; Novo Nordisk Fonden; Novo Nordisk; Eli Lilly and Company; European Foundation for the Study of Diabetes; Pfizer; European Commission; Deutsche Forschungsgemeinschaft; Diabetes UK; Invest Northern Ireland","keywords":"Endocrinology; Internal medicine; Gastric inhibitory polypeptide; Medicine; Chemistry; Insulin; Glucagon","score_opus":0.01591336142280742,"score_gpt":0.30236166128869685,"score_spread":0.28644829986588943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408051488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027029115,0.97488993,0.00030376916,0.000096650336,0.0008536448,0.0021323084,0.0000370738,0.00020335388,0.021456234],"genre_scores_gemma":[0.000026751337,0.97756636,0.0014417937,0.00080869626,0.0002378929,0.000443361,0.00043226924,0.000111649126,0.018931197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972436,0.00016886582,0.000698455,0.00077531586,0.0005496652,0.0005641438],"domain_scores_gemma":[0.99820644,0.000047986327,0.00024192069,0.0012060986,0.0000730279,0.0002245351],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015232505,0.0007592543,0.00288043,0.0006286452,0.00006113436,0.000066796354,0.00035224657,0.00027202806,0.00017182651],"category_scores_gemma":[0.000084801715,0.0005941364,0.0012716334,0.00057452486,0.000047410882,0.000045915272,0.00033840892,0.00044118732,0.0006741529],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006492641,0.00022914904,0.0000018052767,0.013735227,0.0019113339,0.00060324697,0.000010126224,1.7771531e-7,0.000011806565,0.0042855367,0.000933389,0.9782717],"study_design_scores_gemma":[0.0010319111,0.00004293617,0.000031981468,0.006928424,0.015940515,0.000015214488,0.0000027673254,6.408446e-7,0.00014504757,0.000082811326,0.9753845,0.00039326382],"about_ca_topic_score_codex":0.000032969852,"about_ca_topic_score_gemma":0.0000020953325,"teacher_disagreement_score":0.97787845,"about_ca_system_score_codex":0.00015500677,"about_ca_system_score_gemma":0.00038446768,"threshold_uncertainty_score":0.999651},"labels":[],"label_agreement":null},{"id":"W4408104741","doi":"10.1016/j.japh.2025.102385","title":"Implementation and evaluation of a pharmacist-led glucagon-like peptide-1 receptor agonist titration service in two primary care clinics","year":2025,"lang":"en","type":"article","venue":"Journal of the American Pharmacists Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kimberly-Clark (Canada)","funders":"","keywords":"Medicine; Pharmacist; Primary care; Agonist; Titration; Pharmacology; Family medicine; Pharmacy; Nursing; Internal medicine; Receptor","score_opus":0.02267192107329109,"score_gpt":0.40289909896186593,"score_spread":0.38022717788857485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408104741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601537,0.00029658113,0.00002135753,0.0014218069,0.000532189,0.00066729006,0.000014602434,0.0000069286175,0.001023892],"genre_scores_gemma":[0.99717236,0.00050741073,0.00041561507,0.0015265318,0.00008611573,0.00002029403,0.000061370716,0.000009454918,0.00020084083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980828,0.00031837978,0.00065536966,0.00012557402,0.00068094034,0.0001369074],"domain_scores_gemma":[0.99715304,0.000107894746,0.0017048761,0.000112916256,0.0008815844,0.00003967006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015787195,0.000117056516,0.00035672745,0.00020896262,0.000059221853,0.000027800035,0.00009465196,0.000017348038,0.000018350334],"category_scores_gemma":[0.000080007914,0.00009357095,0.00011793561,0.000591837,0.000028065204,0.00019124289,0.000043785345,0.00015860541,0.00000193837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077031803,0.0003562416,0.68577504,0.0002955697,0.00081497617,0.0000021306948,0.0016493994,0.00019219237,0.024429632,0.000018981871,0.0042077582,0.28148776],"study_design_scores_gemma":[0.027411787,0.0004448057,0.9350163,0.0003733989,0.0049270466,0.000007836008,0.0027397468,0.0031278748,0.019770892,0.00019413684,0.0057682907,0.00021792704],"about_ca_topic_score_codex":0.00004990023,"about_ca_topic_score_gemma":0.00005704497,"teacher_disagreement_score":0.28126985,"about_ca_system_score_codex":0.0017274802,"about_ca_system_score_gemma":0.00035551772,"threshold_uncertainty_score":0.45173004},"labels":[],"label_agreement":null},{"id":"W4408128600","doi":"10.1093/ndt/gfaf044","title":"Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"Janssen Research and Development","keywords":"Medicine; Credence; Type 2 diabetes; Diabetes mellitus; Insulin; Internal medicine; Type 1 diabetes; Endocrinology; Intensive care medicine; Pharmacology","score_opus":0.009821971522031023,"score_gpt":0.23882880057822903,"score_spread":0.229006829056198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408128600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783826,0.0004424795,0.00007380577,0.00047410003,0.00014100256,0.00082022714,0.0000062993927,0.000020319547,0.00018353386],"genre_scores_gemma":[0.9965301,0.0012291047,0.000071115675,0.0017598778,0.000040290364,0.000081214996,0.0002473339,0.000005431052,0.000035543566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915785,0.00016885696,0.00023729728,0.00021710152,0.000109883054,0.000108997476],"domain_scores_gemma":[0.9987548,0.0009908866,0.000065063934,0.00013718689,0.000030939053,0.000021151454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008739696,0.000112299866,0.00028063724,0.00021367839,0.000036730784,0.000012218713,0.00003518988,0.00010397373,0.000007529538],"category_scores_gemma":[0.00007204941,0.00007984489,0.000049362254,0.0003375222,0.00007665825,0.00009175717,0.0000078548555,0.000095811694,0.000004917291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1809535,0.0056188116,0.41563356,0.0018654497,0.0048255706,0.00031430036,0.011981621,0.0004310674,0.29739293,0.010943742,0.0015455997,0.068493836],"study_design_scores_gemma":[0.046813313,0.0012790175,0.91445965,0.0003728801,0.0022744145,1.5759628e-7,0.000031848096,0.00023828262,0.03298505,0.0011368059,0.00031533116,0.0000932416],"about_ca_topic_score_codex":0.00014308984,"about_ca_topic_score_gemma":0.00037578368,"teacher_disagreement_score":0.4988261,"about_ca_system_score_codex":0.000025534533,"about_ca_system_score_gemma":0.000022491233,"threshold_uncertainty_score":0.325598},"labels":[],"label_agreement":null},{"id":"W4408166111","doi":"10.1016/j.jchf.2024.11.023","title":"Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum","year":2025,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Defense Acquisition Program Administration; Novo Nordisk; AstraZeneca","keywords":"Medicine; Ejection fraction; Heart failure; Dapagliflozin; Cardiology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.007849047629921512,"score_gpt":0.2599106331672991,"score_spread":0.2520615855373776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408166111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8492028,0.00034800236,0.0001235538,0.14625405,0.00018673111,0.0015622156,0.000012229463,0.00019738513,0.0021130072],"genre_scores_gemma":[0.9857259,0.000057601897,0.0017692713,0.0019810116,0.00022673147,0.00017917663,0.000048436184,0.00002614715,0.009985764],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987683,0.00005245606,0.00017683624,0.00040686622,0.00021371624,0.0003817803],"domain_scores_gemma":[0.9993121,0.00006688228,0.000044847824,0.00043503387,0.000043570562,0.00009757426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014077488,0.00026516485,0.000347905,0.00009260037,0.00035614092,0.00012135933,0.000045047775,0.00011327466,0.000104324885],"category_scores_gemma":[0.00001104514,0.00015485204,0.000098605015,0.00034850257,0.00007967189,0.00017645725,0.000049352588,0.00019038383,0.00007443331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062821846,0.0008179597,0.6987121,0.00019216577,0.0013638249,0.00004074644,0.00053084263,0.000028547982,0.0019810789,0.00081299,0.2810552,0.013836291],"study_design_scores_gemma":[0.0028070176,0.0011361535,0.10561687,0.00014427735,0.00035515946,0.000051808987,0.001879834,0.00007402457,0.00219872,0.00009985662,0.8854744,0.00016190259],"about_ca_topic_score_codex":0.00026996544,"about_ca_topic_score_gemma":0.0013509911,"teacher_disagreement_score":0.6044192,"about_ca_system_score_codex":0.00025436684,"about_ca_system_score_gemma":0.0000678301,"threshold_uncertainty_score":0.6314683},"labels":[],"label_agreement":null},{"id":"W4408197853","doi":"10.1097/mnh.0000000000001066","title":"Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond","year":2025,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Glucagon-like peptide-1; Receptor; Internal medicine; Endocrinology; Medicine; Chemistry; Diabetes mellitus; Type 2 diabetes","score_opus":0.08593195074826286,"score_gpt":0.36656262079794577,"score_spread":0.2806306700496829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408197853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022782912,0.97961754,0.000042338088,0.0009437424,0.014878197,0.0030435594,0.0010103206,0.00009647501,0.0001399939],"genre_scores_gemma":[0.0000071653403,0.97774965,0.0013425406,0.0011336051,0.0007610752,0.0003793992,0.018150602,0.00006676194,0.00040920574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959317,0.00023982071,0.0010086396,0.0018209402,0.0003606121,0.00063828944],"domain_scores_gemma":[0.99691,0.0004427842,0.00025677506,0.0019845914,0.00010005425,0.00030579857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035712394,0.00086400524,0.0034944376,0.00071680377,0.000105176114,0.00005363131,0.0005347779,0.0005282409,0.00007067035],"category_scores_gemma":[0.0002090425,0.0006510188,0.00037670587,0.0004403384,0.00012641527,0.00013610773,0.0017097144,0.0006844524,0.00026646088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071603514,0.0003265377,0.00027602445,0.007263245,0.00075417425,0.000019987156,0.000028207205,3.384266e-7,0.000004972428,0.000016403923,0.1826044,0.8086341],"study_design_scores_gemma":[0.002060037,0.00030132267,0.0005573454,0.014081902,0.002544009,0.000012835249,0.000017244553,0.000095216674,4.2716113e-7,0.000022441656,0.97984815,0.00045904334],"about_ca_topic_score_codex":0.00004675103,"about_ca_topic_score_gemma":0.000013602898,"teacher_disagreement_score":0.8081751,"about_ca_system_score_codex":0.00021524008,"about_ca_system_score_gemma":0.0003450148,"threshold_uncertainty_score":0.9995941},"labels":[],"label_agreement":null},{"id":"W4408223616","doi":"10.1093/ndt/gfaf046","title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Medical Research Council; Changi General Hospital; Nierstichting; AstraZeneca","keywords":"Medicine; Kidney disease; Dialysis; Clinical endpoint; Renal function; Internal medicine; Dapagliflozin; Population; Placebo; Randomized controlled trial; Kidney transplantation; Clinical trial; Diabetes mellitus; Kidney; Intensive care medicine; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.00984928830048692,"score_gpt":0.27051441654037706,"score_spread":0.26066512823989013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408223616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995356,0.00013742717,0.00088561623,0.0017905276,0.0001018546,0.0014663807,0.000021578111,0.000008549523,0.00023201753],"genre_scores_gemma":[0.9990505,0.00011432633,0.000044884775,0.00042667694,0.000034080345,0.00014811965,0.00008476042,0.0000047638205,0.00009186449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988674,0.0004456092,0.00025429574,0.00015833552,0.00017003699,0.00010432769],"domain_scores_gemma":[0.9990011,0.00067717565,0.00009281594,0.00017978757,0.000018693527,0.000030467092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003301594,0.00010878714,0.0003350429,0.00014230631,0.000056597702,0.000008383057,0.00006369026,0.000051343595,0.00000999734],"category_scores_gemma":[0.00008734959,0.000058989895,0.00013176003,0.00020794752,0.00010816867,0.000052816304,0.000009700352,0.00008126657,5.834203e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054369643,0.0005879435,0.8871656,0.0011323626,0.00343375,0.000027341921,0.0007134256,0.020430185,0.015248172,0.0009543696,0.0007895623,0.0151476525],"study_design_scores_gemma":[0.053444948,0.0010141729,0.93054104,0.00025954915,0.005368797,9.207155e-7,0.0000127919075,0.0020449022,0.006934349,0.00017339451,0.00012749614,0.000077639816],"about_ca_topic_score_codex":0.000019694851,"about_ca_topic_score_gemma":0.00002285954,"teacher_disagreement_score":0.043375447,"about_ca_system_score_codex":0.00004341346,"about_ca_system_score_gemma":0.00012571338,"threshold_uncertainty_score":0.24055381},"labels":[],"label_agreement":null},{"id":"W4408226040","doi":"10.1097/ms9.0000000000003089","title":"Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis","year":2025,"lang":"en","type":"review","venue":"Annals of Medicine and Surgery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bibliometrics; Intensive care medicine; Library science","score_opus":0.3008204073311083,"score_gpt":0.47466993647867667,"score_spread":0.17384952914756835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408226040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012918633,0.99082017,0.00000174061,0.0016479545,0.00016873748,0.00048723747,0.000043578075,0.000026607177,0.0055121267],"genre_scores_gemma":[0.0010188194,0.9964076,0.000007837533,0.00068456354,0.0001599604,0.00006605365,0.0003081867,0.000018660065,0.0013283042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626833,0.00036977546,0.0009458781,0.00071586325,0.0012028106,0.00049734995],"domain_scores_gemma":[0.99544406,0.002765581,0.00021770963,0.0008164777,0.0004449404,0.0003112399],"candidate_categories":["metaepi_narrow","bibliometrics"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.0024716675,0.0004968954,0.0065090405,0.1297539,0.000081712904,0.000023203635,0.000104555154,0.00025599517,0.00005472803],"category_scores_gemma":[0.0007906264,0.00031020035,0.002049924,0.13859461,0.00039965048,0.000047667017,0.00016863631,0.00027089758,0.0000036605745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022651826,0.0001321405,0.011220184,0.014315899,0.022847362,0.00016499672,0.000014306537,2.3352206e-7,4.7125046e-9,0.00006280822,0.105425775,0.84579366],"study_design_scores_gemma":[0.0005778537,0.00040611313,0.025601031,0.016617622,0.021392396,0.0000059849885,0.0000914645,9.3438456e-7,1.9075908e-7,0.000033911227,0.93507314,0.00019933666],"about_ca_topic_score_codex":0.00029511953,"about_ca_topic_score_gemma":0.000007869899,"teacher_disagreement_score":0.8455943,"about_ca_system_score_codex":0.000036155598,"about_ca_system_score_gemma":0.00015325377,"threshold_uncertainty_score":0.99993503},"labels":[{"model":"gemma","categories":["bibliometrics"],"domain":null,"study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["bibliometrics"],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4408243508","doi":"10.1093/eurheartj/ehae938","title":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Empagliflozin; Ejection fraction; Cardiology; Heart failure; Internal medicine; Heart failure with preserved ejection fraction; Resistant hypertension; Blood pressure; Diabetes mellitus; Endocrinology","score_opus":0.03588761116296696,"score_gpt":0.2763711452351873,"score_spread":0.24048353407222034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408243508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97337514,0.000488595,0.000023028968,0.01932569,0.0002632501,0.000686778,7.050554e-7,0.000038752056,0.0057980623],"genre_scores_gemma":[0.9946621,0.00009182423,0.0006075617,0.0012253732,0.0003818001,0.000011203274,0.000004783408,0.000024071904,0.0029912845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984827,0.0004827258,0.0002875437,0.00023051834,0.00027798128,0.00023851937],"domain_scores_gemma":[0.99935365,0.00009703457,0.00006923691,0.00029476263,0.000082881015,0.00010244633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009813614,0.00015398253,0.00027323328,0.00019745773,0.0002849855,0.00015446891,0.000077206256,0.000032951066,0.000085276035],"category_scores_gemma":[0.0001273119,0.00008939746,0.00008157857,0.0002802702,0.00005537384,0.00018665059,0.000083184634,0.00044758676,0.00002409746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05278662,0.0011457292,0.5128917,0.00017402814,0.00079378305,0.0009260738,0.00022291744,0.00006723999,0.013128584,0.00012903486,0.4157326,0.0020016616],"study_design_scores_gemma":[0.027686121,0.0013675981,0.73841345,0.00046563285,0.00018577534,0.00008686344,0.0005387737,0.00007948302,0.00024977827,0.00003542595,0.23078938,0.00010174821],"about_ca_topic_score_codex":0.00002531636,"about_ca_topic_score_gemma":0.00006939422,"teacher_disagreement_score":0.2255217,"about_ca_system_score_codex":0.00007714221,"about_ca_system_score_gemma":0.000058780388,"threshold_uncertainty_score":0.36455223},"labels":[],"label_agreement":null},{"id":"W4408280407","doi":"10.1503/cmaj.240768-f","title":"Agonistes du récepteur du peptide-1 de type glucagon durant la grossesse et l’allaitement","year":2025,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gynecology; Breast feeding; Pediatrics","score_opus":0.0053550564473571665,"score_gpt":0.24968236034895108,"score_spread":0.2443273039015939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408280407","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2295296,0.011897822,0.0003300803,0.59658825,0.011754105,0.0005567706,0.000058754304,0.0000608035,0.14922379],"genre_scores_gemma":[0.820403,0.018420862,0.0003624464,0.06688726,0.0058734817,0.000033356384,0.000110557135,0.000060156777,0.08784892],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604213,0.0006374254,0.00070943125,0.0002833481,0.0011933738,0.001134266],"domain_scores_gemma":[0.9963646,0.0005645572,0.00028959152,0.00018319474,0.0005314521,0.0020666113],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043785204,0.00030127825,0.00047183275,0.00037573642,0.0004263105,0.00039578235,0.00028979455,0.000555406,0.007990121],"category_scores_gemma":[0.0035442386,0.00029246102,0.00022949182,0.0005067589,0.00011233748,0.00019948873,0.00006336913,0.0010849626,0.0006145816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000033953118,0.00037969952,0.22146362,0.00017144576,0.0015553411,0.005446073,0.0007662828,0.000019516698,0.00001923877,0.025250286,0.6784914,0.066403136],"study_design_scores_gemma":[0.002857195,0.00020314712,0.097607546,0.0011152312,0.0006270232,0.00028498113,0.0010265384,0.0005246329,0.000024417837,0.0005323327,0.89498967,0.00020729781],"about_ca_topic_score_codex":0.00668323,"about_ca_topic_score_gemma":0.024212781,"teacher_disagreement_score":0.59087336,"about_ca_system_score_codex":0.005473344,"about_ca_system_score_gemma":0.007814805,"threshold_uncertainty_score":0.99995273},"labels":[],"label_agreement":null},{"id":"W4408283738","doi":"10.1038/s41598-025-93144-9","title":"Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Transcriptome; Heart failure; Computational biology; Bioinformatics; Medicine; Gene expression; Diabetes mellitus; Biology; Internal medicine; Type 2 diabetes; Biochemistry; Endocrinology; Gene","score_opus":0.012817735106341542,"score_gpt":0.25267677871039795,"score_spread":0.2398590436040564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408283738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550354,0.000908159,0.000170865,0.00018362248,0.0007003423,0.0018267152,0.000029346877,0.0000256058,0.00065182685],"genre_scores_gemma":[0.9950261,0.0000049342216,0.001470395,0.000023564573,0.000013784038,0.00017397033,0.00016063788,0.000012513183,0.0031140898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802256,0.00005481387,0.000638437,0.0006072772,0.0004026071,0.00027431015],"domain_scores_gemma":[0.99850297,0.000071135364,0.00028341,0.00088649825,0.0001908186,0.00006518466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012869525,0.00016528938,0.00066825235,0.0009039831,0.00010764187,0.000040111918,0.00010516842,0.00007634496,0.00008370977],"category_scores_gemma":[0.00007910623,0.00010653113,0.00035871015,0.0017269519,0.00012421318,0.00012642921,0.000043136664,0.00007222751,3.699255e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000807709,0.002952177,0.26462978,0.0006911954,0.0028975813,0.0000852214,0.005471674,0.0058576413,0.6848768,0.000025260057,0.015451633,0.016253341],"study_design_scores_gemma":[0.0009020257,0.0003603017,0.050642766,0.00024123026,0.0027646613,0.0000029884964,0.0016056662,0.0008652192,0.9256875,0.00033641746,0.016457058,0.00013414706],"about_ca_topic_score_codex":0.00008912251,"about_ca_topic_score_gemma":0.00050738134,"teacher_disagreement_score":0.24081072,"about_ca_system_score_codex":0.00007932718,"about_ca_system_score_gemma":0.00015959772,"threshold_uncertainty_score":0.43442136},"labels":[],"label_agreement":null},{"id":"W4408405798","doi":"10.1371/journal.pone.0319173","title":"Pooled prevalence and associated factors of ECG abnormality among type 2 diabetic patients in the last ten years: Systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Diabetes mellitus; Population; Abnormality; Type 2 diabetes; Body mass index; Internal medicine; Type 2 Diabetes Mellitus; Pediatrics; Endocrinology; Environmental health; Psychiatry","score_opus":0.07671938988540564,"score_gpt":0.29061917808938575,"score_spread":0.21389978820398012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408405798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010167132,0.9846737,5.9504117e-8,0.000015673315,0.000004635752,0.0048818015,0.000097864075,0.000011465161,0.00014766572],"genre_scores_gemma":[0.005651366,0.9926576,0.000012927535,0.00007307388,0.0000017962866,0.00033343091,0.00025896027,0.0000105844265,0.0010002641],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99777514,0.0005879944,0.0007765821,0.00028681915,0.0004129432,0.00016051291],"domain_scores_gemma":[0.99834615,0.0004326781,0.0005828377,0.00048970873,0.00010308341,0.00004556365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007364399,0.00027994046,0.005613908,0.00025213714,0.000017259346,0.000020343448,0.00015050104,0.00009307551,0.000045593562],"category_scores_gemma":[0.00075261144,0.00014867909,0.0005087584,0.0009415672,0.000046282134,0.000046551166,0.00009876445,0.0001439659,0.0000030764145],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[4.9479047e-7,0.0007216198,0.03133431,0.8116212,0.15611492,0.0000022285371,0.00003693897,7.050863e-9,3.5939958e-9,0.0000020259747,0.000013093862,0.00015318279],"study_design_scores_gemma":[0.00013098933,0.00008477385,0.037354574,0.118609324,0.84369874,3.083212e-8,0.000005614947,9.872451e-7,1.1459571e-7,0.0000013567485,0.000021557149,0.00009194461],"about_ca_topic_score_codex":0.000028095154,"about_ca_topic_score_gemma":0.00002953456,"teacher_disagreement_score":0.6930119,"about_ca_system_score_codex":0.00005817766,"about_ca_system_score_gemma":0.000026646161,"threshold_uncertainty_score":0.6062957},"labels":[],"label_agreement":null},{"id":"W4408507321","doi":"10.1177/20543581251324588","title":"The Real-World Use of Semaglutide to Promote Weight Loss in Obese Adults With Hemodialysis: A Multicenter Cross-Sectional Descriptive Study","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dr. Georges-L.-Dumont University Hospital Centre; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier Universitaire de Sherbrooke; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Université Laval; Université de Montréal; Centre Integre de Sante et de Services Sociaux de Laval; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Medicine; Body mass index; Hemodialysis; Semaglutide; Dialysis; Obesity; Adverse effect; Clinical endpoint; Cross-sectional study; Weight change; Internal medicine; Weight loss; Clinical trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.016206583106239153,"score_gpt":0.2920098236326192,"score_spread":0.27580324052638006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408507321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801441,0.00053630007,0.000007919498,0.01783984,0.00014105337,0.0011225482,0.00007995961,0.000003040923,0.00012526833],"genre_scores_gemma":[0.9892266,0.00010210719,0.0001982255,0.00953808,0.00004299817,0.00003064042,0.000010607698,0.000008781276,0.0008419817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987625,0.00007916169,0.00045984858,0.00017049795,0.00019392672,0.00033409012],"domain_scores_gemma":[0.9901526,0.00004652237,0.00016096234,0.00018047844,0.00024195522,0.009217507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031381627,0.00012621908,0.00028643216,0.00051441445,0.00015845697,0.000058137386,0.000075416916,0.00001530094,0.000013974916],"category_scores_gemma":[0.002019294,0.00008014528,0.0000622268,0.00036966914,0.00008695795,0.00010120701,0.000015675409,0.00012133632,0.0000019192116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035753732,0.00033303353,0.9798144,0.00023506365,0.00020344787,0.00034582842,0.0012541114,0.000013817098,4.160384e-7,0.000058889844,0.012459263,0.0017063656],"study_design_scores_gemma":[0.00592475,0.0008172576,0.97354484,0.0010459326,0.00016080012,0.0000018416077,0.00066637417,0.00007864961,0.0000027824312,0.000041999374,0.017648552,0.000066240165],"about_ca_topic_score_codex":0.01067283,"about_ca_topic_score_gemma":0.058873814,"teacher_disagreement_score":0.048200984,"about_ca_system_score_codex":0.00044236684,"about_ca_system_score_gemma":0.013723347,"threshold_uncertainty_score":0.9959152},"labels":[],"label_agreement":null},{"id":"W4408563529","doi":"10.2337/dc24-2840","title":"Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy?","year":2025,"lang":"en","type":"letter","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal; Public Health Ontario; Montreal Clinical Research Institute; University of British Columbia; Sinai Health System; University of Waterloo; Lunenfeld-Tanenbaum Research Institute; University of Calgary; University of Toronto; University Health Network; Toronto General Hospital","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.01712107209552296,"score_gpt":0.21890427592244052,"score_spread":0.20178320382691756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408563529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8378729,0.024111032,0.0065276115,0.073387206,0.0013086946,0.030913444,0.00052125775,0.0014826217,0.023875207],"genre_scores_gemma":[0.5790948,0.0004545248,0.006825505,0.3843605,0.0025134494,0.010575241,0.014205571,0.00051063136,0.0014597505],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967683,0.00019811612,0.00043533085,0.0010731062,0.00074613234,0.00077899225],"domain_scores_gemma":[0.9982742,0.000034948138,0.00010826907,0.0010788112,0.0004072991,0.000096469106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029470221,0.00066711806,0.0011273462,0.0009640814,0.00010266193,0.00008927416,0.00013436603,0.0005781051,0.0000120868835],"category_scores_gemma":[0.00006912401,0.000546763,0.00048332656,0.0010059,0.00003679205,0.00009197812,0.000070813374,0.0010774711,0.000047848218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053962495,0.0011170332,0.08922505,0.018198105,0.012316419,0.00039742512,0.002075241,0.29074118,0.00021143907,0.0000074071145,0.43297002,0.15220106],"study_design_scores_gemma":[0.011629443,0.003349307,0.00149169,0.008478642,0.00511602,8.593035e-7,0.0008527177,0.058142673,0.003545431,0.000043594435,0.90510845,0.0022411933],"about_ca_topic_score_codex":0.00014504,"about_ca_topic_score_gemma":0.000013609958,"teacher_disagreement_score":0.4721384,"about_ca_system_score_codex":0.0006289524,"about_ca_system_score_gemma":0.0002258046,"threshold_uncertainty_score":0.9996984},"labels":[],"label_agreement":null},{"id":"W4408585020","doi":"10.1111/dom.16328","title":"Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of <scp>ONWARDS</scp> 1–5","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Medicine; Internal medicine; Basal (medicine); Type 2 diabetes; Insulin; Hypoglycemia; Diabetes mellitus; Endocrinology; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Post-hoc analysis; Agonist; Receptor","score_opus":0.011744945684002967,"score_gpt":0.25189143007267056,"score_spread":0.2401464843886676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408585020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892358,0.007997711,0.000016925034,0.0005784538,0.00040225653,0.0012122211,0.00031836084,0.000086415545,0.00015183374],"genre_scores_gemma":[0.9924507,0.0025384186,0.002230877,0.0013732348,0.0000878796,0.00008086268,0.0005828274,0.000048881626,0.00060630566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677575,0.00016537635,0.000792559,0.0009995294,0.00047225237,0.0007945511],"domain_scores_gemma":[0.99739313,0.001049598,0.00025180043,0.00056433206,0.000289212,0.0004519074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007313178,0.0006706932,0.002009954,0.001389961,0.00019423482,0.00018525876,0.00019440228,0.00023971323,0.000016843129],"category_scores_gemma":[0.0006284586,0.0005642797,0.00019845409,0.0019953263,0.00032675394,0.0004432537,0.00020869139,0.0003528008,0.0000075279518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013872901,0.0012278715,0.9566886,0.00048338174,0.004284022,0.000022800248,0.0013075691,0.000029716337,0.007545749,0.00015642881,0.00038058893,0.026486002],"study_design_scores_gemma":[0.013707795,0.0011458349,0.9545956,0.00043229896,0.006465314,1.5629577e-7,0.00075387186,0.00028075496,0.009790359,0.00001547996,0.0124825835,0.00032989832],"about_ca_topic_score_codex":0.00022188059,"about_ca_topic_score_gemma":0.00032682047,"teacher_disagreement_score":0.026156105,"about_ca_system_score_codex":0.00010460568,"about_ca_system_score_gemma":0.00019605857,"threshold_uncertainty_score":0.9996809},"labels":[],"label_agreement":null},{"id":"W4408621302","doi":"10.1007/s13300-025-01717-8","title":"Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study","year":2025,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Agonist; Kidney disease; Disease; Cohort; Internal medicine; Receptor; Endocrinology","score_opus":0.017642522699609454,"score_gpt":0.31012728479725227,"score_spread":0.2924847620976428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408621302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299246,0.0021296872,0.0000010594607,0.0007045031,0.00010487175,0.0036002228,0.00011350108,0.00006285322,0.00029081796],"genre_scores_gemma":[0.9936619,0.0022932296,0.0001351353,0.0011936745,0.00008164274,0.0012061356,0.00048612914,0.000032328302,0.0009098615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982337,0.00016390908,0.0003778692,0.00060097955,0.0002339228,0.0003896261],"domain_scores_gemma":[0.9990518,0.00018781306,0.000099278404,0.00031781857,0.0000714396,0.0002718229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037032668,0.0003244479,0.00062082126,0.00023997865,0.0000886815,0.00007981605,0.00007470284,0.00006593107,0.00013865373],"category_scores_gemma":[0.00006073876,0.00023055669,0.00005944353,0.00026889634,0.00013478208,0.00011427217,0.000070015696,0.00011759252,0.000008230818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015779931,0.0024390935,0.93045634,0.00009567473,0.0014650202,0.000010238734,0.0002497213,4.239622e-7,0.000032584332,0.00003701486,0.0003542262,0.06470184],"study_design_scores_gemma":[0.012904864,0.004252058,0.9766741,0.00041049905,0.00037220272,5.54058e-8,0.00007369383,0.00017799388,0.00021077477,0.000049551512,0.0046630176,0.00021120635],"about_ca_topic_score_codex":0.000018424207,"about_ca_topic_score_gemma":0.00002962283,"teacher_disagreement_score":0.06449063,"about_ca_system_score_codex":0.00016353404,"about_ca_system_score_gemma":0.00021852994,"threshold_uncertainty_score":0.9401829},"labels":[],"label_agreement":null},{"id":"W4408622288","doi":"10.1007/s40256-025-00727-y","title":"Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"review","venue":"American Journal of Cardiovascular Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"","keywords":"Medicine; Semaglutide; Meta-analysis; Pharmacotherapy; Renal function; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.011901759979135762,"score_gpt":0.26119906985954283,"score_spread":0.24929730988040708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408622288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.181432e-7,0.9933238,0.0030719726,0.00022543504,0.00003745952,0.0027384518,0.00016372617,0.000013134387,0.00042508825],"genre_scores_gemma":[0.000024287916,0.9968519,0.0011425704,0.00036368603,0.000036626647,0.00020988124,0.00008962018,0.00003895693,0.0012424673],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9952466,0.0012456048,0.0017496704,0.0005276783,0.0009805583,0.0002498939],"domain_scores_gemma":[0.9963905,0.00030481032,0.0014286205,0.001153148,0.00036780082,0.00035509263],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0035328155,0.00059900054,0.02103661,0.00071530027,0.00008589046,0.000043591153,0.00015176498,0.000095824624,0.000034993434],"category_scores_gemma":[0.00029899448,0.00039074456,0.012830608,0.0015500793,0.00023280631,0.000096977245,0.00014134776,0.00030447458,0.0000011666995],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000043347573,0.000031029682,0.000001849968,0.33500925,0.5982953,0.00001917629,0.000036777772,0.0000030452093,9.8984465e-9,0.000010094703,0.00052171975,0.066067465],"study_design_scores_gemma":[0.000370823,0.00013966221,0.0000021538358,0.018106472,0.6353395,0.00012808849,0.000050472154,0.00000217245,1.2838167e-7,0.0000014551993,0.34570003,0.00015907416],"about_ca_topic_score_codex":0.000037948816,"about_ca_topic_score_gemma":1.5930226e-7,"teacher_disagreement_score":0.34517828,"about_ca_system_score_codex":0.00009742051,"about_ca_system_score_gemma":0.00028665256,"threshold_uncertainty_score":0.99985445},"labels":[],"label_agreement":null},{"id":"W4408673340","doi":"10.1016/j.cardfail.2025.02.019","title":"Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study","year":2025,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"Novartis Pharma; Novartis Farmacéutica; Heart Care Foundation of India; Boehringer Ingelheim","keywords":"Medicine; Heart failure; Ambulatory; Intensive care medicine; Cardiology; Internal medicine","score_opus":0.010056488924979871,"score_gpt":0.2584994206424991,"score_spread":0.24844293171751922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408673340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97060156,0.00090834347,0.00000919052,0.02628106,0.00060795306,0.0013314899,0.00006746338,0.000026021014,0.0001669183],"genre_scores_gemma":[0.99730927,0.000033018707,0.0007334434,0.0010681512,0.00028556024,0.000020946565,0.00014912765,0.00003548805,0.00036502365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674326,0.00021906792,0.0006943978,0.0004487366,0.0014923158,0.00040223316],"domain_scores_gemma":[0.9978512,0.0002716812,0.00023122417,0.001180592,0.00020815321,0.0002571569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007404586,0.00036125767,0.001033587,0.00024504264,0.00012713399,0.00009848864,0.00054253335,0.00014940246,0.0001587696],"category_scores_gemma":[0.00019464665,0.00021059178,0.00026438117,0.00048198647,0.00009858971,0.00037813745,0.0003597911,0.0006114113,0.000038452774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030950204,0.0010526687,0.7291027,0.000022316284,0.0022269888,0.000045157667,0.00018194091,0.000006182872,0.000004470985,0.000006323653,0.26629856,0.0007432095],"study_design_scores_gemma":[0.008012171,0.0008412981,0.7258141,0.000557628,0.0013856805,0.0000033269562,0.00093235174,0.0000068917484,0.000015640513,0.000010951639,0.2622905,0.0001294616],"about_ca_topic_score_codex":0.00016986881,"about_ca_topic_score_gemma":0.0008792957,"teacher_disagreement_score":0.02670768,"about_ca_system_score_codex":0.00025795307,"about_ca_system_score_gemma":0.00033651618,"threshold_uncertainty_score":0.8587684},"labels":[],"label_agreement":null},{"id":"W4408692528","doi":"10.2337/dci24-0104","title":"The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes","year":2025,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Insulin; Type 2 diabetes; Population; Insulin resistance; Type 2 Diabetes Mellitus; Metformin; Basal (medicine); Intensive care medicine; Endocrinology; Internal medicine","score_opus":0.008107305330838576,"score_gpt":0.262869505949313,"score_spread":0.25476220061847443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408692528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036664747,0.9591904,1.2105987e-7,0.000029490095,0.00011154278,0.0018765226,0.000034777255,0.000030010166,0.002062332],"genre_scores_gemma":[0.011378302,0.9871866,0.0000726281,0.0000882758,0.00004144199,0.0005344507,0.0003912235,0.00006204332,0.0002450256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808866,0.00011943059,0.000535864,0.0004232872,0.00026649845,0.00056624087],"domain_scores_gemma":[0.9985731,0.00044479605,0.0002054639,0.00060038024,0.00011451812,0.00006174482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020353048,0.0004468244,0.0017611581,0.00041928355,0.000040699862,0.000026739417,0.0002650492,0.00017191075,0.0000121535],"category_scores_gemma":[0.00008420803,0.00026634845,0.00023078026,0.0010282375,0.000054546534,0.000062195904,0.000117115094,0.00031717643,0.000012907638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018969175,0.00010771164,0.13260666,0.010619606,0.00027375246,0.000003482755,0.0003771659,0.000008787527,0.0000020188606,0.000018013317,0.00006439787,0.85589945],"study_design_scores_gemma":[0.0044343513,0.0019436665,0.01881532,0.08816627,0.0017457756,1.7453735e-7,0.0015545777,0.00022397014,0.00018238238,0.00039368906,0.88158363,0.000956223],"about_ca_topic_score_codex":0.000018433382,"about_ca_topic_score_gemma":0.00034898947,"teacher_disagreement_score":0.8815192,"about_ca_system_score_codex":0.0002606516,"about_ca_system_score_gemma":0.00036226286,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W4408827735","doi":"10.3390/jcm14072239","title":"The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Semaglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.03421268278369183,"score_gpt":0.3847724348525277,"score_spread":0.3505597520688359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408827735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015118131,0.9928313,0.0000011362182,0.00008535764,0.00080459885,0.0044378727,0.0000048746583,0.000006201721,0.0003168705],"genre_scores_gemma":[0.00036265224,0.99910635,0.00001510035,0.00012171986,0.00013751323,0.00003919779,0.00002129705,0.00003124815,0.00016489618],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9917344,0.0023041181,0.004162029,0.00026233928,0.0012671228,0.0002700223],"domain_scores_gemma":[0.98675036,0.008436663,0.0034058772,0.00088775635,0.0003262127,0.00019315092],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009543018,0.0004904747,0.012793735,0.00032902468,0.000031741663,0.0000058848473,0.00034979146,0.00018636373,0.000013366965],"category_scores_gemma":[0.021472005,0.0001658503,0.0021549074,0.00071865966,0.00017539553,0.000025992938,0.000056186076,0.0010391881,0.0000062699523],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001791133,0.00019090908,0.02020823,0.7334085,0.010956562,0.000034683166,0.0000042457004,7.011036e-7,3.7571418e-10,0.0000015758262,0.0012232189,0.23379223],"study_design_scores_gemma":[0.0041571367,0.015620285,0.0023227993,0.8080245,0.088437535,0.0000010859902,0.000003859257,4.3634665e-7,8.1746236e-8,0.000001971894,0.08132977,0.00010052687],"about_ca_topic_score_codex":0.000005338024,"about_ca_topic_score_gemma":0.0000012831474,"teacher_disagreement_score":0.2336917,"about_ca_system_score_codex":0.00012991948,"about_ca_system_score_gemma":0.00021406257,"threshold_uncertainty_score":0.9867706},"labels":[],"label_agreement":null},{"id":"W4408831450","doi":"10.2147/dmso.s479889","title":"Metformin for the Treatment of Type 2 Diabetes in Asian Adults: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Diabetes Metabolic Syndrome and Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Metformin; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.01832872519463748,"score_gpt":0.29098149404150236,"score_spread":0.2726527688468649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408831450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018815943,0.9833793,6.1767594e-7,0.00005203192,0.00022339943,0.01416337,0.00011349958,0.00003494938,0.00015122464],"genre_scores_gemma":[0.00010025138,0.99380666,0.00010294091,0.00014012987,0.00003386545,0.004254611,0.00029039895,0.00004330852,0.001227859],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972685,0.00017606809,0.001221791,0.0005494974,0.00025053258,0.00053364073],"domain_scores_gemma":[0.99749213,0.0008282041,0.0005182914,0.0009403754,0.00010364015,0.00011734494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006708191,0.000695301,0.0073531116,0.00044199772,0.00007532029,0.000025863956,0.00026084555,0.00019759203,0.000024906614],"category_scores_gemma":[0.00029718413,0.0003718144,0.0010339863,0.00093045004,0.0000850523,0.00006953643,0.000077150165,0.0001153351,0.000015457777],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003373585,0.0004940943,0.00074773957,0.7241343,0.0025149768,0.0000064973788,0.000033093744,1.159438e-8,2.0905915e-8,0.000109275905,0.00007427888,0.27188233],"study_design_scores_gemma":[0.0010566971,0.0008415205,0.00046867612,0.6429347,0.054534316,0.0000045061797,0.000027486512,0.000012231321,0.0000042000106,0.00003176384,0.2997785,0.00030545867],"about_ca_topic_score_codex":0.000016040509,"about_ca_topic_score_gemma":0.000010707876,"teacher_disagreement_score":0.2997042,"about_ca_system_score_codex":0.00011123135,"about_ca_system_score_gemma":0.00015289708,"threshold_uncertainty_score":0.9998734},"labels":[],"label_agreement":null},{"id":"W4408857150","doi":"10.2215/cjn.0000000693","title":"Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD","year":2025,"lang":"en","type":"review","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Kidney Foundation of Canada","keywords":"Medicine; Renal function; Kidney disease; Randomized controlled trial; Hazard ratio; Internal medicine; Meta-analysis; Relative risk; Confidence interval; Placebo; Heart failure; Incidence (geometry); Clinical endpoint; Pathology","score_opus":0.02053353541626669,"score_gpt":0.34480333375453565,"score_spread":0.32426979833826897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408857150","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5324143,0.46576178,0.000011425413,0.0006266299,0.00011468284,0.0010105548,0.000015173289,0.000004062111,0.00004136795],"genre_scores_gemma":[0.014206438,0.98228896,0.0017111839,0.0016618575,0.00005507273,0.0000044196995,0.000008356165,0.00001936886,0.00004433449],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975188,0.00024643546,0.0015682903,0.00024067267,0.00023048918,0.00019531364],"domain_scores_gemma":[0.9962275,0.00067012757,0.0025760557,0.00028789576,0.00013176522,0.000106668915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005218481,0.00026548782,0.003326078,0.00008839613,0.000024079387,0.0000028433915,0.0001935534,0.00014320883,0.0000035180083],"category_scores_gemma":[0.0000644615,0.00014683836,0.0007202715,0.000310834,0.001642942,0.000035789984,0.00012130128,0.0005694011,1.4317258e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019468549,0.0008020219,0.12460989,0.003030248,0.0017022598,0.0000029079554,0.000076901924,5.197058e-7,0.0000012296709,0.0000033953395,0.00071536686,0.8671084],"study_design_scores_gemma":[0.018402744,0.009048207,0.5075644,0.01795663,0.008101432,0.000013260494,0.00013227056,0.0000015956829,0.0000017712426,0.000020104751,0.4385328,0.00022478309],"about_ca_topic_score_codex":0.000006871365,"about_ca_topic_score_gemma":0.0000023992425,"teacher_disagreement_score":0.86688364,"about_ca_system_score_codex":0.000043794334,"about_ca_system_score_gemma":0.00023599484,"threshold_uncertainty_score":0.60534877},"labels":[],"label_agreement":null},{"id":"W4408880150","doi":"10.1016/j.jcjd.2024.12.006","title":"Metformin as First-line Therapy: Response to Drs Trinacty and Goldenberg","year":2025,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University; University of Saskatchewan; University of Alberta; LMC Diabetes & Endocrinology (Canada); University of Toronto","funders":"University of Toronto; Merck","keywords":"Medicine; Metformin; Internal medicine","score_opus":0.014958087479587098,"score_gpt":0.24634644132163136,"score_spread":0.23138835384204426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408880150","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39782947,0.0068570026,0.0000013061274,0.59137654,0.0006563926,0.00064287306,0.00006889915,0.000013059192,0.0025544357],"genre_scores_gemma":[0.05738313,0.0005683377,0.00046865488,0.866959,0.0022326873,0.000054331445,0.000097388904,0.000105891406,0.072130576],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809414,0.000101104226,0.0005265119,0.00028597124,0.0003151335,0.00067713077],"domain_scores_gemma":[0.9978751,0.0004087298,0.0002524971,0.00037254547,0.00023423579,0.000856923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059775705,0.00040232774,0.0009283852,0.0016116753,0.000114727656,0.000113734655,0.00026686158,0.00034974562,0.0002927123],"category_scores_gemma":[0.00041339814,0.000324723,0.00028054026,0.00034509198,0.00008604952,0.000109866174,0.000032894215,0.0007982501,0.000031274853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010762406,0.000025465535,0.013726017,0.00016742473,0.0011556826,0.0013505997,0.00016919312,0.0000011677374,0.000018990317,0.000012893964,0.9525463,0.030718623],"study_design_scores_gemma":[0.002056422,0.0021134054,0.010654656,0.0010107425,0.0006460798,0.000014655076,0.00003085837,0.0000018784064,0.00028029075,0.00016140768,0.9827676,0.00026201952],"about_ca_topic_score_codex":0.0005651845,"about_ca_topic_score_gemma":0.001305989,"teacher_disagreement_score":0.34044632,"about_ca_system_score_codex":0.00049724797,"about_ca_system_score_gemma":0.0015253782,"threshold_uncertainty_score":0.9999205},"labels":[],"label_agreement":null},{"id":"W4408893261","doi":"10.2196/63079","title":"Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study","year":2025,"lang":"en","type":"article","venue":"Interactive Journal of Medical Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Dyslipidemia; Medicine; Waist; Metabolic syndrome; Internal medicine; Obesity; Insulin resistance; Digital health; Endocrinology; Blood pressure; Type 2 diabetes; Diabetes mellitus; Health care; Liraglutide","score_opus":0.04834577618793815,"score_gpt":0.4055301496600818,"score_spread":0.3571843734721436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408893261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98238903,0.002585367,0.00012983636,0.011434134,0.00013959425,0.002961853,0.000029995343,0.0000052580954,0.00032493006],"genre_scores_gemma":[0.99714524,0.00086003914,0.00021004565,0.00013447975,0.00006115887,0.00020673787,0.000031412532,0.000016449789,0.0013344529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962375,0.0002354108,0.0005549691,0.00026812812,0.002336466,0.000367496],"domain_scores_gemma":[0.9961013,0.0016316936,0.00028290215,0.00022198969,0.001537002,0.00022508542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012041795,0.00019222437,0.0008706932,0.0004958635,0.00013054059,0.000056697758,0.0002682337,0.00005322763,0.00010081721],"category_scores_gemma":[0.00067968026,0.000095654475,0.00015929538,0.00068499194,0.0003038545,0.0001915291,0.00005812018,0.00048086687,0.0000022176068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08713922,0.025952222,0.7572891,0.0006729567,0.011359081,0.00090160937,0.039890535,0.00000775697,0.000010120874,0.0017276673,0.003175181,0.07187453],"study_design_scores_gemma":[0.039969083,0.07553167,0.79615086,0.0040924144,0.00035239072,0.000045479737,0.06780797,0.000094742376,0.00012516916,0.00007941285,0.015629508,0.000121286],"about_ca_topic_score_codex":0.00027794906,"about_ca_topic_score_gemma":0.0005213833,"teacher_disagreement_score":0.07175324,"about_ca_system_score_codex":0.0010097687,"about_ca_system_score_gemma":0.0016435378,"threshold_uncertainty_score":0.39006764},"labels":[],"label_agreement":null},{"id":"W4408960834","doi":"10.1161/circulationaha.125.074545","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; LMC Diabetes & Endocrinology (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Medicine; Semaglutide; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Physical therapy; Endocrinology","score_opus":0.03739283839786836,"score_gpt":0.3045655191750762,"score_spread":0.2671726807772078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408960834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640334,0.0004139331,0.00033275396,0.00019133477,0.00012304047,0.0020647799,9.140189e-7,0.000016356358,0.00045356157],"genre_scores_gemma":[0.9993577,0.000013050258,0.00021785266,0.000085659536,0.000015284142,0.00007097945,0.000009267545,0.0000072192247,0.00022301164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991883,0.00011362496,0.00022022221,0.00017388475,0.00019181521,0.000112133945],"domain_scores_gemma":[0.99940103,0.00017000262,0.000051994226,0.0002969496,0.00005595531,0.000024092675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003732531,0.0000978597,0.0006414929,0.00017612103,0.000030132269,0.000023531893,0.00003939935,0.000031511267,0.0000052903342],"category_scores_gemma":[0.0003462524,0.00005793879,0.00016483782,0.00047736967,0.000028662987,0.000058110218,0.00004292483,0.000040889678,7.6356366e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028557617,0.00006804671,0.9640418,0.000060547296,0.0015760057,9.3714453e-7,0.00010502145,0.0020441879,0.0003999784,0.00015804707,0.000033846158,0.0029539575],"study_design_scores_gemma":[0.2370835,0.000040603267,0.75990546,0.00010831865,0.0014510332,8.961921e-8,0.00006658455,0.0006918059,0.00041150273,0.00006472764,0.000120802724,0.00005559062],"about_ca_topic_score_codex":0.00019395014,"about_ca_topic_score_gemma":0.00007062698,"teacher_disagreement_score":0.20852587,"about_ca_system_score_codex":0.000046456727,"about_ca_system_score_gemma":0.000032257187,"threshold_uncertainty_score":0.23626752},"labels":[],"label_agreement":null},{"id":"W4408960945","doi":"10.1056/nejmoa2501006","title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology","score_opus":0.00926076328069375,"score_gpt":0.25102814240569676,"score_spread":0.241767379125003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408960945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767984,0.014197194,0.000061142615,0.0067912866,0.0006150692,0.0001636148,6.396156e-7,0.0000100529705,0.0013625595],"genre_scores_gemma":[0.99423605,0.0022493775,0.0006983701,0.00065780134,0.0004170645,0.0000011720555,0.0000030305123,0.000008841444,0.0017282668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896085,0.00007380835,0.00036570043,0.00012078608,0.00029977184,0.00017905117],"domain_scores_gemma":[0.99934196,0.00015492016,0.00009800086,0.00018152923,0.000083873936,0.00013972553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009601199,0.00013647068,0.0008207903,0.00037876825,0.0000225206,0.000007143355,0.00006132451,0.000041625754,0.000050598104],"category_scores_gemma":[0.0004770416,0.00008087208,0.000094617775,0.00024603857,0.000060659426,0.000044768058,0.00003108342,0.00021160522,0.0000020880987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013924541,0.000059125472,0.7048366,0.000055027445,0.0013955453,0.00015235663,0.00011649879,0.00002514806,0.000055404198,0.00015281292,0.004633447,0.2883788],"study_design_scores_gemma":[0.07648379,0.0017252829,0.82987356,0.00076844567,0.0027631912,0.000022393087,0.00014909205,0.00004244512,0.00015823921,0.0019417845,0.08597549,0.00009627463],"about_ca_topic_score_codex":0.0002190017,"about_ca_topic_score_gemma":0.00004891667,"teacher_disagreement_score":0.28828254,"about_ca_system_score_codex":0.000041172752,"about_ca_system_score_gemma":0.00006379925,"threshold_uncertainty_score":0.32978675},"labels":[],"label_agreement":null},{"id":"W4408960968","doi":"10.2337/dc25-0241","title":"Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials","year":2025,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Type 2 diabetes; Internal medicine; Diabetes mellitus; Glucagon-like peptide-1; Systematic review; MEDLINE; Glucagon-like peptide 1 receptor; Endocrinology; Receptor; Agonist","score_opus":0.05742783141103074,"score_gpt":0.33870079415005144,"score_spread":0.2812729627390207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408960968","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006190274,0.98151875,0.0000016954531,0.00003930028,0.000031834716,0.011677826,0.00042839829,0.000032711283,0.00007921981],"genre_scores_gemma":[0.0012551195,0.9941363,0.00049455423,0.00031808688,0.0000081700955,0.0024641594,0.0010441303,0.0000594332,0.00022007537],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99380434,0.0022466427,0.0019631842,0.00096992357,0.0005623357,0.0004535495],"domain_scores_gemma":[0.99499947,0.0022681016,0.0013105695,0.0009129956,0.00025018596,0.000258663],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005449842,0.00095657853,0.035773575,0.0008525773,0.000074219286,0.00013837514,0.00012837116,0.0002101055,0.000028032835],"category_scores_gemma":[0.0028091292,0.0005048232,0.002180363,0.0013466746,0.00025407766,0.00014741624,0.00021025917,0.00023990654,7.1639204e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043470227,0.00003062895,0.03869584,0.55344856,0.4053054,0.000004859489,0.0001301399,3.567803e-7,3.0512073e-8,0.000002999238,0.000024528323,0.0023132074],"study_design_scores_gemma":[0.01185086,0.0001743965,0.0004308826,0.098713964,0.8865689,7.8362353e-7,0.00015077807,0.0000021719989,0.0000014288715,0.0000015383691,0.0016874772,0.0004168097],"about_ca_topic_score_codex":0.000061350955,"about_ca_topic_score_gemma":0.0000430992,"teacher_disagreement_score":0.48126355,"about_ca_system_score_codex":0.000082815284,"about_ca_system_score_gemma":0.00022030306,"threshold_uncertainty_score":0.99974036},"labels":[],"label_agreement":null},{"id":"W4409054418","doi":"10.1016/j.xjon.2025.03.018","title":"Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled","year":2025,"lang":"en","type":"article","venue":"JTCVS Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Emperor; valvular heart disease; Heart failure; Medicine; Internal medicine; Disease; Cardiology; History; Ancient history; Endocrinology","score_opus":0.006409218769405323,"score_gpt":0.23037264734409452,"score_spread":0.2239634285746892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409054418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948014,0.00087503024,0.0000033991557,0.00076903007,0.000054601558,0.0015728992,0.00002604401,0.000012092979,0.0018855237],"genre_scores_gemma":[0.99598354,0.000011722226,0.0006080579,0.00041896527,0.000008084515,0.000039460967,0.00013486073,0.000011866392,0.0027834363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905217,0.00005414449,0.00029049555,0.00027733773,0.0001969696,0.00012887015],"domain_scores_gemma":[0.9993369,0.000057909743,0.00007908307,0.00037134666,0.00005772929,0.000097028096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006870203,0.00014280903,0.00051031954,0.00015735661,0.000017623202,0.000008352844,0.000115226656,0.000042849955,0.000067099565],"category_scores_gemma":[0.000039077295,0.00010892727,0.000048147514,0.0001657012,0.00009806612,0.00014625637,0.00019779318,0.000072119205,0.000003097938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015987693,0.0010175393,0.9770583,0.00017325259,0.00032168312,0.000008168422,0.00039255456,0.000008028818,0.00019442526,0.00013953453,0.018531956,0.00055578473],"study_design_scores_gemma":[0.009277119,0.00026058615,0.9592619,0.00076286885,0.00039309447,1.7503096e-8,0.000055641303,0.000025770456,0.000102846316,0.000058365506,0.02971113,0.00009069358],"about_ca_topic_score_codex":0.000859765,"about_ca_topic_score_gemma":0.00026646903,"teacher_disagreement_score":0.017796436,"about_ca_system_score_codex":0.00016681929,"about_ca_system_score_gemma":0.00013492508,"threshold_uncertainty_score":0.44419253},"labels":[],"label_agreement":null},{"id":"W4409067233","doi":"10.1016/j.ahj.2025.03.015","title":"Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney disease","year":2025,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute","funders":"Danish Cardiovascular Academy; Respicardia; American Regent; Sanofi Pasteur; National Institutes of Health; Seqirus; Region Hovedstaden; Novo Nordisk; GlaxoSmithKline; Gedeon Richter; Servier; Pfizer; Moderna; Sarepta Therapeutics; Dansk Nefrologisk Selskab; Cytokinetics; Novo Nordisk Fonden; Boston Scientific Corporation; National Heart, Lung, and Blood Institute; Acceleron; Alnylam Pharmaceuticals; Hjerteforeningen; Alexion Pharmaceuticals; Sanofi; Amgen; Vifor Pharma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nudge theory; Kidney disease; Guideline; Randomized controlled trial; Clinical trial; Physical therapy; Intensive care medicine; Family medicine; Internal medicine; Pathology","score_opus":0.018018664202248978,"score_gpt":0.329276373518729,"score_spread":0.31125770931648006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409067233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9485247,0.0029019378,0.025923816,0.016242526,0.0005184936,0.0057168514,0.000017786271,0.00004013661,0.00011371839],"genre_scores_gemma":[0.9901157,0.002433774,0.0050378847,0.0016189907,0.00042085504,0.00020460323,0.00004504415,0.00001624532,0.00010690959],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99813396,0.0004282467,0.0007059281,0.00014597268,0.00036841174,0.00021746772],"domain_scores_gemma":[0.9980204,0.0012462322,0.00025371852,0.000098283366,0.00020015711,0.00018117005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001936715,0.00012334011,0.0007545006,0.00030469164,0.000048602888,0.000014115373,0.000058717687,0.000032990763,0.000074631156],"category_scores_gemma":[0.0036983301,0.00009318944,0.00017772887,0.00026392515,0.00020340877,0.000062980216,0.00001577509,0.00012814914,2.146421e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94453007,0.0008873437,0.005181063,0.0000926479,0.0012917564,0.0000071362233,0.00016346399,0.00008428579,0.0038831925,0.0009348669,0.014994289,0.027949912],"study_design_scores_gemma":[0.9627966,0.0031873586,0.002770289,0.00031480202,0.0005269797,0.000008386194,0.000064928994,0.013801394,0.0012112441,0.0022753237,0.012889756,0.00015288497],"about_ca_topic_score_codex":0.00011721697,"about_ca_topic_score_gemma":0.00000795146,"teacher_disagreement_score":0.04159096,"about_ca_system_score_codex":0.00017813525,"about_ca_system_score_gemma":0.002594572,"threshold_uncertainty_score":0.46026593},"labels":[],"label_agreement":null},{"id":"W4409119298","doi":"10.1007/s40120-025-00724-y","title":"Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Liraglutide; Exenatide; Medicine; Semaglutide; Neuroprotection; Glucagon-like peptide 1 receptor; Pharmacology; Internal medicine; Endocrinology; Diabetes mellitus; Receptor; Type 2 diabetes; Agonist","score_opus":0.02608192491742797,"score_gpt":0.30595950502951197,"score_spread":0.279877580112084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409119298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022215248,0.98995686,0.0000017084888,0.0011906319,0.0012466038,0.0036296058,0.000047335412,0.00015860026,0.0035465069],"genre_scores_gemma":[0.000058458187,0.9883707,0.000015517964,0.00539311,0.00023549303,0.0005825146,0.00029173915,0.00005839534,0.0049940557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720883,0.0005178819,0.0006427785,0.00085618306,0.0001972489,0.0005770658],"domain_scores_gemma":[0.9984049,0.00018875756,0.0005493468,0.00060075114,0.00006524118,0.00019097871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021014993,0.00072170683,0.0030259478,0.00020065812,0.00018555929,0.000029978259,0.00022158407,0.0004286148,0.00018872056],"category_scores_gemma":[0.00002952095,0.0005073357,0.00059999677,0.00031690125,0.00013783781,0.000046750305,0.000075945136,0.0005782234,0.000068348236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001703601,0.00019517778,0.000091507565,0.09399542,0.0013429322,0.00027085486,0.00008948665,4.5229758e-8,2.404077e-7,0.0002262603,0.025130674,0.87848705],"study_design_scores_gemma":[0.0011425589,0.0009924866,0.00023187458,0.04270662,0.0019776085,0.00008051835,0.000018875036,6.9128606e-7,4.973025e-7,0.0000057843586,0.95255613,0.00028632258],"about_ca_topic_score_codex":0.00001025132,"about_ca_topic_score_gemma":0.000008776497,"teacher_disagreement_score":0.9274255,"about_ca_system_score_codex":0.00005933426,"about_ca_system_score_gemma":0.0001743726,"threshold_uncertainty_score":0.9997378},"labels":[],"label_agreement":null},{"id":"W4409142118","doi":"10.1002/j.2040-4603.2018.tb00039.x","title":"Glucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function","year":2018,"lang":"en","type":"article","venue":"Comprehensive physiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glucagon-like peptide-2; Glucagon-like peptide-1; Function (biology); Peptide; Glucagon; Chemistry; Internal medicine; Endocrinology; Cell biology; Biology; Biochemistry; Medicine; Insulin; Diabetes mellitus; Type 2 diabetes","score_opus":0.017865394411767106,"score_gpt":0.247173977398076,"score_spread":0.2293085829863089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409142118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691796,0.00035037438,0.00012272457,0.00050784706,0.00015151592,0.00025504,5.2946615e-7,0.0000169044,0.0016770851],"genre_scores_gemma":[0.99859476,0.00006601884,0.00023872616,0.00072011387,0.00012791326,0.000011237624,0.000015297057,0.0000052525147,0.00022065878],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99957496,0.000044327186,0.000102565806,0.00014522861,0.00004607047,0.00008686104],"domain_scores_gemma":[0.99950945,0.00013431946,0.00006334951,0.00012276306,0.0001449494,0.000025152114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030091713,0.000076949895,0.00019474445,0.000040329138,0.000051171548,0.0000034168836,0.00002211103,0.00002421519,0.00002420893],"category_scores_gemma":[0.000029243407,0.000047820886,0.000025311318,0.00005575804,0.0006367281,0.000029955707,0.000072920055,0.000038465416,0.0000071652275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00545761,0.00020407185,0.014174056,0.00044130138,0.00073478726,0.0000017480977,0.0012340695,0.000002434274,0.8982,0.05016952,0.00851128,0.020869164],"study_design_scores_gemma":[0.0030359617,0.0012002176,0.97957116,0.000044744473,0.00024127624,0.000007856485,0.00018254714,0.00052338315,0.0036044596,0.008890805,0.002644259,0.000053340053],"about_ca_topic_score_codex":0.000022837634,"about_ca_topic_score_gemma":0.0000018617168,"teacher_disagreement_score":0.9653971,"about_ca_system_score_codex":0.000005259149,"about_ca_system_score_gemma":0.0000062511936,"threshold_uncertainty_score":0.2346051},"labels":[],"label_agreement":null},{"id":"W4409246821","doi":"10.1016/j.arr.2025.102751","title":"Reducing Alzheimer’s disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection","year":2025,"lang":"en","type":"review","venue":"Ageing Research Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health and Social Services Centre University Institute of Geriatrics of Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Université Sultan Moulay Slimane; Centre National pour la Recherche Scientifique et Technique; Alzheimer Society; Université de Sherbrooke","keywords":"Neuroprotection; Glycemic; Medicine; Alzheimer's disease; Disease; Neuroscience; Diabetes mellitus; Pharmacology; Internal medicine; Endocrinology; Psychology","score_opus":0.10662203457169009,"score_gpt":0.40985423867696397,"score_spread":0.30323220410527385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409246821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051466122,0.9806266,0.00010461417,0.0003093157,0.0002071152,0.017017392,0.000074157666,0.00012679,0.001482555],"genre_scores_gemma":[0.000072029325,0.98996097,0.0005363932,0.00017287234,0.0007771206,0.0051138173,0.00028784157,0.000109495544,0.0029694426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938328,0.0019052934,0.0010229475,0.0013664865,0.0010073684,0.00086508744],"domain_scores_gemma":[0.99615353,0.00078924495,0.00040196397,0.0017324344,0.00021999479,0.0007028299],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023672525,0.0006877486,0.0030292817,0.0009866272,0.00032826266,0.0001915759,0.0004021898,0.00015937688,0.00013394702],"category_scores_gemma":[0.002599041,0.00044196026,0.0007192797,0.0017882772,0.00009511276,0.0001229204,0.00031408714,0.0014616777,0.0013111699],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003315997,0.0001778625,0.000032995787,0.023783257,0.000954902,0.00052686105,0.000023376086,0.0000011150637,0.0000011774222,0.000005925103,0.01080649,0.9633544],"study_design_scores_gemma":[0.0008331648,0.0007531318,0.000039904455,0.17306939,0.009090497,0.0000016778245,0.0000047709923,0.0000072512826,0.000001265463,0.000014269307,0.8159074,0.0002772827],"about_ca_topic_score_codex":0.0007499537,"about_ca_topic_score_gemma":0.000026427984,"teacher_disagreement_score":0.9630771,"about_ca_system_score_codex":0.00043508402,"about_ca_system_score_gemma":0.0005901541,"threshold_uncertainty_score":0.99980325},"labels":[],"label_agreement":null},{"id":"W4409257977","doi":"10.1016/j.yjmcc.2025.04.003","title":"GLP1R upregulation in mitral regurgitation observed at a single nucleus level","year":2025,"lang":"en","type":"letter","venue":"Journal of Molecular and Cellular Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; National Heart, Lung, and Blood Institute; Deutsche Herzstiftung; Deutsche Stiftung für Herzforschung; Deutsche Forschungsgemeinschaft","keywords":"Downregulation and upregulation; Mitral regurgitation; Internal medicine; Cardiology; Medicine; Chemistry; Gene; Biochemistry","score_opus":0.034173447973448665,"score_gpt":0.23013297678042938,"score_spread":0.1959595288069807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409257977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83061004,0.010403761,0.0026279988,0.14887682,0.0009915103,0.00070453866,0.000020450021,0.000019060475,0.0057458207],"genre_scores_gemma":[0.886934,0.00034353067,0.002031996,0.09846521,0.0014303691,0.000019269115,0.0008241277,0.000067964975,0.009883558],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851197,0.00021043562,0.0005166043,0.00024149306,0.00025953315,0.00025994403],"domain_scores_gemma":[0.99922794,0.00005600874,0.00031072812,0.00021853298,0.00013282202,0.000053941443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002586251,0.0002335544,0.00086119963,0.00039290843,0.00002737306,0.0000194429,0.00008314267,0.0004931187,0.000012251187],"category_scores_gemma":[0.000045273155,0.0002051126,0.00053954194,0.00011897323,0.000059377908,0.000048232923,0.00006660634,0.0005199842,0.0000028277495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011047625,0.0002450816,0.011393982,0.0015407464,0.006600779,0.049756613,0.00024479936,0.00040821152,0.13244517,0.00018513249,0.7818114,0.014263278],"study_design_scores_gemma":[0.012289944,0.0024583412,0.022264853,0.0012996058,0.0059152697,0.0010233824,0.0001216403,0.0000994004,0.018550068,0.0012668497,0.93404984,0.00066082855],"about_ca_topic_score_codex":0.0000063495418,"about_ca_topic_score_gemma":0.0000025059474,"teacher_disagreement_score":0.15223837,"about_ca_system_score_codex":0.0002716071,"about_ca_system_score_gemma":0.000069009904,"threshold_uncertainty_score":0.83642495},"labels":[],"label_agreement":null},{"id":"W4409270377","doi":"10.1093/ajhp/zxaf044","title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know","year":2025,"lang":"en","type":"review","venue":"American Journal of Health-System Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Kidney disease; Guideline; Intensive care medicine; Dosing; Renal function; Disease management; Diabetes mellitus; Proteinuria; Disease; Internal medicine; Kidney; Pathology; Endocrinology","score_opus":0.07867796237443565,"score_gpt":0.510744565764108,"score_spread":0.43206660338967234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409270377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020624937,0.9650596,0.00011300141,0.02498393,0.0024994519,0.0057463474,0.000048698326,0.00002604716,0.0015023429],"genre_scores_gemma":[0.00023911074,0.98917186,0.0014695184,0.00718873,0.0007175859,0.00023784778,0.00010373361,0.00006781707,0.00080378575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914512,0.0019574997,0.003940873,0.0006348622,0.0015273438,0.00048823093],"domain_scores_gemma":[0.9922439,0.00069080194,0.004532029,0.0006100311,0.0006830356,0.0012402021],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006163141,0.0006136919,0.0035519463,0.0009307473,0.00008800355,0.00006951424,0.0003100039,0.00004401679,0.00009511932],"category_scores_gemma":[0.00037842046,0.0004555901,0.00072947104,0.0008952289,0.000093202456,0.00026044127,0.00014816779,0.00057637464,0.000058119746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010334194,0.000983144,0.000012552189,0.0512548,0.0031156172,0.00021675856,0.000026485657,0.000009295568,1.0588138e-7,0.00006139255,0.11129963,0.8319868],"study_design_scores_gemma":[0.004563602,0.003185569,0.000009822931,0.13728285,0.01397177,0.000068097,0.0001933599,0.000099723235,8.42813e-7,8.933397e-7,0.8404048,0.00021864097],"about_ca_topic_score_codex":0.000016588201,"about_ca_topic_score_gemma":1.74422e-7,"teacher_disagreement_score":0.83176816,"about_ca_system_score_codex":0.0018562949,"about_ca_system_score_gemma":0.0033040512,"threshold_uncertainty_score":0.9997896},"labels":[],"label_agreement":null},{"id":"W4409332233","doi":"10.14814/phy2.70275","title":"Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure","year":2025,"lang":"en","type":"article","venue":"Physiological Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; Ottawa Hospital; University Health Network","funders":"Merck Canada","keywords":"Medicine; Internal medicine; Endocrinology; Heart failure; Placebo; Supine position; Excretion; Extracellular fluid; Blood pressure; Chemistry; Extracellular","score_opus":0.016130941523986787,"score_gpt":0.27254998910340666,"score_spread":0.25641904757941986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409332233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984518,0.00010910272,0.0000021580893,0.00008776916,0.000038700102,0.00051038736,4.2674742e-7,0.000012859061,0.000786767],"genre_scores_gemma":[0.99947655,0.0000033295594,0.0002590771,0.00012987875,0.000005098432,0.00003173147,0.000043110704,0.0000028270708,0.00004837757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993367,0.000030827294,0.00015853015,0.00018258684,0.00019091922,0.000100426994],"domain_scores_gemma":[0.99962795,0.000026180545,0.000055766566,0.0001370185,0.00012737104,0.000025736923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018610392,0.00007255216,0.00021686254,0.000055066503,0.000012206495,0.000003391809,0.00001213586,0.0000319815,0.000041248095],"category_scores_gemma":[0.00022419608,0.000044195855,0.00001787993,0.00015084838,0.000030385108,0.000022955131,0.000031672433,0.00003771578,9.726789e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008991158,0.0006387083,0.986216,0.00010541822,0.000110352266,0.0000068494974,0.000011763625,0.000024805948,0.005875879,0.00033791378,0.000874567,0.0057078367],"study_design_scores_gemma":[0.0007912611,0.0006510087,0.9929342,0.0001180836,0.00018286867,1.11355064e-7,0.000008665216,0.00013432676,0.00089934195,0.004101408,0.00013688364,0.000041825377],"about_ca_topic_score_codex":0.000003395252,"about_ca_topic_score_gemma":0.0000020625469,"teacher_disagreement_score":0.0067182216,"about_ca_system_score_codex":0.000030317076,"about_ca_system_score_gemma":0.000026723523,"threshold_uncertainty_score":0.18022548},"labels":[],"label_agreement":null},{"id":"W4409410720","doi":"10.1038/s41574-025-01118-8","title":"Older people with type 1 diabetes mellitus: a call for a new management approach","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juvenile Diabetes Research Foundation","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; MEDLINE; Type 2 diabetes; Disease management; Gerontology; Intensive care medicine; Family medicine; Alternative medicine; Endocrinology; Pathology; Health management system","score_opus":0.02533988787448966,"score_gpt":0.32940076487535835,"score_spread":0.3040608770008687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409410720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.1896055e-7,0.96321714,0.00028498456,0.00026435856,0.00052622944,0.0143643,0.00002117168,0.00014194586,0.021179644],"genre_scores_gemma":[4.957117e-7,0.93333095,0.017414572,0.00097395584,0.0003126064,0.003950225,0.0014463251,0.00009402761,0.042476818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965261,0.00016224741,0.0008585825,0.0011949011,0.00024488973,0.0010132344],"domain_scores_gemma":[0.99783397,0.00020830914,0.00043252562,0.0012199406,0.000103046594,0.00020220822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019597172,0.000991389,0.0050756475,0.00062008627,0.000073542375,0.000035444504,0.00045528985,0.00061911903,0.00006388035],"category_scores_gemma":[0.000092833325,0.00060396595,0.0010147344,0.0010217748,0.000057172845,0.000046294055,0.00024980446,0.0009165304,0.000120945464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020007767,0.00022124252,0.000009154595,0.15439042,0.0021707898,0.000026370826,0.000013627931,4.4370637e-8,9.331325e-9,0.0034729475,0.10025027,0.7394251],"study_design_scores_gemma":[0.0015170907,0.00043762173,0.000009168239,0.028526576,0.018920768,0.000030952226,0.0000065780773,0.0000011146021,4.3505804e-7,0.00003426919,0.95006686,0.0004485498],"about_ca_topic_score_codex":0.0000041021813,"about_ca_topic_score_gemma":0.000008904781,"teacher_disagreement_score":0.8498166,"about_ca_system_score_codex":0.00024766717,"about_ca_system_score_gemma":0.0002775322,"threshold_uncertainty_score":0.9996412},"labels":[],"label_agreement":null},{"id":"W4409506664","doi":"10.1002/elps.8139","title":"Characterization of Taurocholic Acid Binding With Insulin for Potential Oral Formulation Using Different Methods","year":2025,"lang":"en","type":"article","venue":"Electrophoresis","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Priority Academic Program Development of Jiangsu Higher Education Institutions; Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Chemistry; Electrospray ionization; Bioavailability; Circular dichroism; Chromatography; Mass spectrometry; Stereochemistry; Pharmacology","score_opus":0.015738778500126668,"score_gpt":0.31154813951706056,"score_spread":0.2958093610169339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409506664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80331767,0.0000856357,0.1957227,0.000104787585,0.000056818215,0.000603996,0.0000044290364,0.00002281891,0.000081127415],"genre_scores_gemma":[0.97616583,0.000073280506,0.022876374,0.000060534298,0.00003204782,0.000052817693,0.00020263605,0.000016123695,0.0005203681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993252,0.000030698513,0.00018264673,0.00016625861,0.000105112435,0.00019006335],"domain_scores_gemma":[0.99964464,0.00001654765,0.000099005636,0.00012890295,0.000082636856,0.000028247165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008848063,0.000118504715,0.00025595172,0.00026823414,0.00006321624,0.00001697098,0.000036616115,0.0000433007,0.000014163622],"category_scores_gemma":[0.00001738755,0.00008892843,0.000072010764,0.00029112247,0.000012453763,0.000067139445,0.000018944624,0.000039385508,3.8633917e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000619473,0.00013719712,0.0018746482,0.00012456477,0.0002905879,9.3924524e-7,0.000031857446,0.000005621246,0.96664387,0.00042861814,0.000017310012,0.029825293],"study_design_scores_gemma":[0.002108616,0.0006097512,0.047111824,0.00010096243,0.0008520065,8.564554e-7,0.000010437282,0.0043972926,0.9441208,0.00011013525,0.000491518,0.00008578221],"about_ca_topic_score_codex":0.000006465255,"about_ca_topic_score_gemma":0.0000018990921,"teacher_disagreement_score":0.17284814,"about_ca_system_score_codex":0.000114126844,"about_ca_system_score_gemma":0.000035224613,"threshold_uncertainty_score":0.3626396},"labels":[],"label_agreement":null},{"id":"W4409534285","doi":"10.1016/j.neubiorev.2025.106159","title":"Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders","year":2025,"lang":"en","type":"review","venue":"Neuroscience & Biobehavioral Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation","funders":"Canadian Institutes of Health Research; AbbVie Canada; National Natural Science Foundation of China; Milken Institute; Global Alliance for Chronic Diseases","keywords":"Neuroscience; Amyloid (mycology); Psychology; Neurodegeneration; Medicine; Internal medicine; Endocrinology; Disease; Pathology","score_opus":0.08961163014664614,"score_gpt":0.3571828336948813,"score_spread":0.26757120354823516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409534285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001346586,0.98990715,0.000026786016,0.000040785228,0.00023160985,0.008230892,0.000032247262,0.000012781514,0.000171138],"genre_scores_gemma":[0.00025502226,0.9950214,0.0010822319,0.00042295788,0.000019224217,0.0022890824,0.00005724786,0.000022311897,0.0008305278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977413,0.00015024556,0.00079285627,0.0007201096,0.00029213558,0.00030336878],"domain_scores_gemma":[0.9991141,0.000041377483,0.00034497541,0.00037725756,0.00003464782,0.00008763701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007586202,0.0004420743,0.001251117,0.0002607621,0.00019281512,0.000056670302,0.00022572563,0.00007329828,0.0000120132745],"category_scores_gemma":[0.00018249181,0.00026494957,0.00021664168,0.00043807153,0.00019662046,0.000085805135,0.00022398424,0.00021667441,0.000003146187],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000941454,0.00026353294,0.00021524324,0.0034527876,0.0000015396962,0.0000011788431,0.000120752,7.989134e-7,0.000051336083,0.00018804045,0.00058581977,0.99510956],"study_design_scores_gemma":[0.00037850565,0.0004186784,0.0009499904,0.003726263,0.00058125984,9.353574e-7,0.000046613106,0.000018024573,0.000014890145,0.000014490154,0.99366134,0.0001890274],"about_ca_topic_score_codex":0.000007355619,"about_ca_topic_score_gemma":0.00003606991,"teacher_disagreement_score":0.99492055,"about_ca_system_score_codex":0.0000799925,"about_ca_system_score_gemma":0.00021697767,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W4409565473","doi":"10.1038/s41591-025-03645-3","title":"Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"David Geffen School of Medicine, University of California, Los Angeles; National Institute of Diabetes and Digestive and Kidney Diseases; Perelman School of Medicine, University of Pennsylvania; National Institutes of Health; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Agencja Badań Medycznych; Tartu Ülikool; National Institute of Mental Health; Université de Lausanne; Eesti Teadusagentuur; Broad Institute; McGill University; American Diabetes Association; Helsingin ja Uudenmaan Sairaanhoitopiiri; UCLA Health System; Clinical and Translational Science Institute, University of California, Los Angeles; Helsingin Yliopisto; University of Pennsylvania; Massachusetts General Hospital","keywords":"Weight loss; Body mass index; Obesity; Medicine; Weight change; Type 2 diabetes; Biobank; Demography; Internal medicine; Gerontology; Diabetes mellitus; Endocrinology; Bioinformatics; Biology","score_opus":0.00643273545341992,"score_gpt":0.24274799935434327,"score_spread":0.23631526390092336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409565473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980949,0.01050989,0.000039681745,0.006284318,0.00045806085,0.000303054,0.000016628752,0.00006435975,0.0013750241],"genre_scores_gemma":[0.9943508,0.0009880826,0.00027292263,0.0010117601,0.00061852555,0.000008421279,0.00030768485,0.000013999609,0.0024278013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884593,0.000043572192,0.00024048606,0.0003302174,0.00031934291,0.00022041934],"domain_scores_gemma":[0.9988939,0.00062688155,0.00009629751,0.0001721087,0.0000626686,0.00014810114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002424467,0.00019589135,0.0005291836,0.00031864765,0.00006868481,0.000016326892,0.000045270393,0.0003105826,0.00013654178],"category_scores_gemma":[0.00028526012,0.00013251502,0.000037257156,0.00033252916,0.000045471123,0.00007246357,0.000047625283,0.00031326877,0.000002985875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026968497,0.000040828163,0.9745264,0.000079340556,0.00055191433,0.000016230455,0.0001030453,6.933214e-8,0.00012039096,0.000092374634,0.014761466,0.009680968],"study_design_scores_gemma":[0.0017948153,0.00013456019,0.9688468,0.00018562264,0.0018839026,4.9583093e-7,0.000049008886,0.000017981969,0.00049523416,0.00059050566,0.025903288,0.00009779754],"about_ca_topic_score_codex":0.00022365632,"about_ca_topic_score_gemma":0.000046374633,"teacher_disagreement_score":0.013401818,"about_ca_system_score_codex":0.0001230655,"about_ca_system_score_gemma":0.000041101328,"threshold_uncertainty_score":0.54038054},"labels":[],"label_agreement":null},{"id":"W4409653991","doi":"10.1097/paf.0000000000001044","title":"Semaglutide and GLP-1 Agonists","year":2025,"lang":"en","type":"article","venue":"American Journal of Forensic Medicine & Pathology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Semaglutide; Context (archaeology); Exenatide; Medicine; Hypoglycemia; Pharmacology; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Biology; Liraglutide","score_opus":0.007517259194087769,"score_gpt":0.2811803041224577,"score_spread":0.27366304492836996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409653991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650961,0.002283234,0.0006055684,0.022677854,0.00043874467,0.00015646397,0.0000011385526,0.000016848962,0.008724041],"genre_scores_gemma":[0.98678327,0.00048329929,0.0043981355,0.006838768,0.00022108684,0.000003539511,0.0000054019333,0.000011101461,0.0012553971],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988992,0.00006642617,0.00045103632,0.00016194285,0.00018527756,0.0002360956],"domain_scores_gemma":[0.9989798,0.00016829862,0.00032800983,0.0002053419,0.0001602305,0.00015829618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039405999,0.00015369013,0.0007949731,0.0003858105,0.000049709182,0.0000056112253,0.00007549567,0.0000310999,0.000041208434],"category_scores_gemma":[0.00029829473,0.00010154236,0.00008017056,0.00029386123,0.0013767838,0.000026939068,0.000045211622,0.00018611862,0.0000033757071],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003857809,0.00012574931,0.06677142,0.000075699405,0.00050645386,0.0021726254,0.00063664175,8.611673e-7,0.002308018,0.0033935627,0.033051502,0.8905717],"study_design_scores_gemma":[0.017123092,0.029862307,0.70739716,0.0022148674,0.004986791,0.0071812826,0.0064170933,0.000054049342,0.002166185,0.006740172,0.21543771,0.00041927275],"about_ca_topic_score_codex":0.00003488717,"about_ca_topic_score_gemma":0.000009746276,"teacher_disagreement_score":0.8901524,"about_ca_system_score_codex":0.000050685183,"about_ca_system_score_gemma":0.0001008511,"threshold_uncertainty_score":0.5072817},"labels":[],"label_agreement":null},{"id":"W4409691646","doi":"10.1111/dom.16371","title":"The interplay between heart failure and chronic kidney disease","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Bayer","keywords":"Medicine; Kidney disease; Heart failure; Mineralocorticoid receptor; Intensive care medicine; Disease; Diabetes mellitus; Blood pressure; Internal medicine; Hyperkalemia; Endocrinology; Cardiology; Aldosterone","score_opus":0.010128089709059636,"score_gpt":0.28731579467443796,"score_spread":0.2771877049653783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409691646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094229385,0.9953453,0.0000020682633,0.001216547,0.00030539383,0.0015712415,0.000212199,0.00007372259,0.000331267],"genre_scores_gemma":[0.00024416044,0.9935038,0.00006996789,0.00050521444,0.0004954723,0.00024364107,0.00049303414,0.00003453864,0.0044101365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981467,0.00015447795,0.00039543072,0.00056394725,0.00021322396,0.0005262043],"domain_scores_gemma":[0.9983014,0.00035008116,0.00013224182,0.0005671391,0.000040563133,0.0006086152],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003348496,0.0005365584,0.0019067532,0.00021006144,0.00032034173,0.00017347217,0.00017884259,0.0001900116,0.000023906396],"category_scores_gemma":[0.00019973259,0.0003250469,0.0004206651,0.0002448531,0.00021681776,0.00009650707,0.0004006843,0.00036448962,0.00003070248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000037491438,0.00008273892,0.0053982777,0.032110177,0.0014902845,0.0000068864015,0.000014387015,6.134912e-9,2.6263828e-7,0.0012083242,0.018871248,0.94081366],"study_design_scores_gemma":[0.00057995936,0.000042370164,0.006506802,0.010957832,0.011919375,5.156966e-7,0.000004054922,0.0000012047321,0.000002770921,0.00017145023,0.96954894,0.00026475344],"about_ca_topic_score_codex":0.0000043481214,"about_ca_topic_score_gemma":0.0000034076857,"teacher_disagreement_score":0.9506777,"about_ca_system_score_codex":0.00006042488,"about_ca_system_score_gemma":0.00033940692,"threshold_uncertainty_score":0.9999201},"labels":[],"label_agreement":null},{"id":"W4409702321","doi":"10.3390/nu17091416","title":"Glucagon-like Peptide-2 Acts Partially Through Central GLP-2R and MC4R in Mobilizing Stored Lipids from the Intestine","year":2025,"lang":"en","type":"article","venue":"Nutrients","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research; University of Saskatchewan; Saskatchewan Health Research Foundation; Heart and Stroke Foundation of Canada","keywords":"Internal medicine; Endocrinology; Glucagon-like peptide-2; Peptide YY; Glucagon-like peptide-1; Small intestine; Lipid metabolism; Receptor antagonist; Biology; Antagonist; Receptor; Medicine; Neuropeptide; Neuropeptide Y receptor; Peptide; Biochemistry; Diabetes mellitus","score_opus":0.017121956632891355,"score_gpt":0.269766436966791,"score_spread":0.25264448033389963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409702321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898078,0.0012368604,0.00009806022,0.0021094896,0.0006352933,0.00082742015,0.0000101026135,0.000066021465,0.0052089696],"genre_scores_gemma":[0.9954042,0.00028442437,0.0006096269,0.0017244577,0.00012650761,0.00006963171,0.000080401056,0.000015245081,0.0016854953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987621,0.000045421464,0.00025892927,0.0003434681,0.00020249138,0.00038761765],"domain_scores_gemma":[0.99934167,0.00014769137,0.00005692037,0.0003380399,0.00003640083,0.00007928935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011971823,0.00018659465,0.00027791737,0.000059645114,0.00007646773,0.000035056877,0.00012703626,0.0000612772,0.000034259236],"category_scores_gemma":[0.00013800863,0.00013155017,0.00005677876,0.000291902,0.00008004981,0.0001244073,0.0001712505,0.00015044291,0.000017584458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034901328,0.0007809882,0.9743082,0.00007314321,0.00023733074,0.000037621845,0.0016596791,0.000007823647,0.00039874835,0.0013877449,0.010422666,0.01033707],"study_design_scores_gemma":[0.008450505,0.0003000191,0.8504112,0.00097493967,0.00036727503,8.5626084e-7,0.000915534,0.0003754677,0.0018955456,0.0016979267,0.13442038,0.0001903626],"about_ca_topic_score_codex":0.00032639087,"about_ca_topic_score_gemma":0.00018359585,"teacher_disagreement_score":0.12399772,"about_ca_system_score_codex":0.0001375409,"about_ca_system_score_gemma":0.000053543426,"threshold_uncertainty_score":0.53644603},"labels":[],"label_agreement":null},{"id":"W4409710300","doi":"10.2147/dmso.s500336","title":"Reduced Weight Gain with Pioglitazone vs Vildagliptin in CREBRF rs373863828 A-allele Carriers: Insights from the WORTH Trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Metabolic Syndrome and Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Maurice Wilkins Centre for Molecular Biodiscovery","keywords":"Vildagliptin; Pioglitazone; Weight gain; Allele; Internal medicine; Medicine; Oncology; Endocrinology; Biology; Genetics; Diabetes mellitus; Body weight; Gene; Type 2 diabetes","score_opus":0.007116610971952699,"score_gpt":0.2199573850061845,"score_spread":0.2128407740342318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409710300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829062,0.011204909,0.000010457624,0.0010733117,0.0003099693,0.0017071614,0.000021158376,0.00009078869,0.0026760413],"genre_scores_gemma":[0.9955223,0.00053851417,0.0003072952,0.0012243803,0.00015145824,0.00023483271,0.00014290535,0.000028778599,0.0018495002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781376,0.00017772759,0.00044294583,0.0006585572,0.0003599026,0.0005471352],"domain_scores_gemma":[0.99872196,0.00020880661,0.000115833565,0.00070829835,0.00006108712,0.00018404666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033682692,0.0004061616,0.0010678179,0.00028588055,0.00019502625,0.00008662028,0.0002282939,0.00014022735,0.000098714496],"category_scores_gemma":[0.000086637876,0.000251294,0.0001513385,0.00078854116,0.00019103053,0.00018273268,0.00016676623,0.00028918646,0.000025990477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039047976,0.0015429828,0.9746003,0.00015035142,0.002687034,0.00019095413,0.0013739205,0.000006285031,0.00042074494,0.0041524796,0.0023706732,0.008599466],"study_design_scores_gemma":[0.03695235,0.0007136736,0.93101877,0.0003648508,0.0014922308,0.0000019788786,0.00038275516,0.000095646894,0.0021808424,0.0014155556,0.025012437,0.0003688946],"about_ca_topic_score_codex":0.00039954975,"about_ca_topic_score_gemma":0.00022343545,"teacher_disagreement_score":0.043581527,"about_ca_system_score_codex":0.000065590604,"about_ca_system_score_gemma":0.00011849701,"threshold_uncertainty_score":0.9999939},"labels":[],"label_agreement":null},{"id":"W4409726138","doi":"10.1016/j.jdiacomp.2025.109046","title":"Response to letter to the editor by Lai-Ming Kathleen Pak et al on: Identifying predictors of SGLT2 inhibitor and GLP1R agonist use in hospital among adults with diabetes","year":2025,"lang":"en","type":"letter","venue":"Journal of Diabetes and its Complications","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; St. Michael's Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Agonist; Gerontology; Internal medicine; Endocrinology; Receptor","score_opus":0.00905605269105403,"score_gpt":0.2412297062796083,"score_spread":0.23217365358855427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409726138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58972496,0.00027313485,0.0000062076065,0.40861502,0.00044161544,0.0007687623,0.00013889685,0.000008688844,0.000022718876],"genre_scores_gemma":[0.6425832,0.00006414618,0.00042282033,0.35322714,0.0023335419,0.00021342022,0.0001511625,0.00006075791,0.0009438383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998005,0.00014467846,0.00062655227,0.00037162675,0.00048983516,0.00036233914],"domain_scores_gemma":[0.99797696,0.0008157787,0.00042242903,0.0003589872,0.00025757746,0.00016829581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044752122,0.00032936933,0.0006230471,0.0005413474,0.00012276776,0.00018332344,0.00022250095,0.00014087139,0.0000038258772],"category_scores_gemma":[0.00029874497,0.00021939122,0.000114102586,0.00032989492,0.00008960667,0.0002454751,0.00016131863,0.0007202918,0.0000022975848],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116016614,0.00019086691,0.113002025,0.00017999084,0.00034147967,0.00001007796,0.00053045194,0.0000049381983,0.0004644341,0.000005796714,0.8849028,0.00025113503],"study_design_scores_gemma":[0.0016220809,0.002318565,0.3728907,0.004721781,0.00041931076,6.7081595e-7,0.000111589456,0.000025128194,0.0003876085,0.000005501728,0.6172504,0.00024668744],"about_ca_topic_score_codex":0.000008248756,"about_ca_topic_score_gemma":0.000015116488,"teacher_disagreement_score":0.26765242,"about_ca_system_score_codex":0.00009101263,"about_ca_system_score_gemma":0.000060229686,"threshold_uncertainty_score":0.8946515},"labels":[],"label_agreement":null},{"id":"W4409737712","doi":"10.1186/s12933-025-02737-1","title":"Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Type 2 diabetes; Mace; Internal medicine; Cohort; Semaglutide; Type 2 Diabetes Mellitus; Myocardial infarction; Diabetes mellitus; Endocrinology; Percutaneous coronary intervention","score_opus":0.013250159550996399,"score_gpt":0.2690949397757306,"score_spread":0.2558447802247342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409737712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816756,0.003926938,0.00025338988,0.00013710032,0.0007700991,0.0010331041,0.0000030159958,0.000050383464,0.01215033],"genre_scores_gemma":[0.9981052,0.00021773818,0.00064622215,0.00017214035,0.00008369793,0.00019328535,0.000099592944,0.000021820646,0.00046028505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998425,0.00030291313,0.00029099672,0.00043003235,0.00018318176,0.0003678485],"domain_scores_gemma":[0.9989794,0.00014855643,0.000036998976,0.00061909424,0.0001406218,0.000075348486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082854275,0.00019310096,0.0010084615,0.0006847283,0.00003137583,0.000010153341,0.000101550926,0.00010466695,0.00002491879],"category_scores_gemma":[0.000176091,0.00018345697,0.0003776791,0.0010295606,0.00005344916,0.000054363027,0.00010951396,0.00010196755,0.000028806298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002398981,0.0004626315,0.81460625,0.0016016653,0.009896386,0.00009946725,0.00013799497,0.002899841,0.03595349,0.010685654,0.002384631,0.12103209],"study_design_scores_gemma":[0.0045376727,0.00039270314,0.87227535,0.00075825304,0.0022861697,8.9863335e-7,0.000038411494,0.00044387634,0.08155076,0.00028352835,0.037099916,0.00033243652],"about_ca_topic_score_codex":0.00009708388,"about_ca_topic_score_gemma":0.000055550023,"teacher_disagreement_score":0.12069965,"about_ca_system_score_codex":0.00021279247,"about_ca_system_score_gemma":0.00007188293,"threshold_uncertainty_score":0.74811584},"labels":[],"label_agreement":null},{"id":"W4409781701","doi":"10.1093/asjof/ojaf030","title":"A Single-Center, Blinded, Placebo-Controlled Study Evaluating Cosmetic Efficacy and Safety of a Novel Topical GLPSGLT in Glucagon-Like Peptide-1 Analog-Treated Patients","year":2025,"lang":"en","type":"article","venue":"Aesthetic Surgery Journal Open Forum","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"College & Association of Registered Nurses of Alberta","funders":"","keywords":"Single Center; Medicine; Placebo; Safety profile; Blinded study; Double blinded; Pharmacology; Surgery; Adverse effect; Alternative medicine; Pathology","score_opus":0.05111225889207887,"score_gpt":0.3320993509811084,"score_spread":0.2809870920890295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409781701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148613,0.00017034807,0.000042306245,0.0029863252,0.00031217618,0.0040197237,0.0000044939407,0.000013906362,0.000964574],"genre_scores_gemma":[0.9978672,0.000055395696,0.00032886735,0.00076930557,0.00000505846,0.00009378936,0.000022324479,0.000023202718,0.000834829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712354,0.00031319394,0.0012251791,0.00037363046,0.00047034814,0.0004941058],"domain_scores_gemma":[0.99818844,0.00065024884,0.00042441385,0.0003281121,0.00023714158,0.0001716708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015942145,0.00029449444,0.0012429248,0.0006181155,0.0001472641,0.00018499773,0.00020250969,0.00007560107,0.000035710116],"category_scores_gemma":[0.00039721257,0.00022419747,0.00021512045,0.0005178774,0.0000618037,0.00024016976,0.0003053755,0.00024921042,0.0000036525703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018784825,0.01215004,0.82203853,0.000017274391,0.0005652805,0.00009884156,0.0001699744,0.000030228155,0.00002159083,0.00003272116,0.002027825,0.14406286],"study_design_scores_gemma":[0.47271886,0.0092736315,0.4964175,0.0040019834,0.0018468247,0.00031366094,0.0017566053,0.0022886181,0.000061874365,0.00008774904,0.010591793,0.000640886],"about_ca_topic_score_codex":0.00010460639,"about_ca_topic_score_gemma":0.000112099064,"teacher_disagreement_score":0.45393404,"about_ca_system_score_codex":0.0002154245,"about_ca_system_score_gemma":0.00016532843,"threshold_uncertainty_score":0.9142508},"labels":[],"label_agreement":null},{"id":"W4409787462","doi":"10.1038/s41573-025-01183-8","title":"GLP-1-based therapies for diabetes, obesity and beyond","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Diabetes mellitus; Obesity; Intensive care medicine; Pharmacology; Internal medicine; Endocrinology","score_opus":0.015817803051984304,"score_gpt":0.3209634593432635,"score_spread":0.30514565629127915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409787462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008058629,0.9877365,0.000028868044,0.0005070121,0.0005632885,0.008402908,0.00027173012,0.00006869197,0.0024129087],"genre_scores_gemma":[0.000004098804,0.97825366,0.0009575713,0.0027538438,0.0002841541,0.0017520525,0.0017324368,0.00006771614,0.01419447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975008,0.00019186376,0.0007540596,0.0008310627,0.00025742,0.00046481448],"domain_scores_gemma":[0.9980165,0.0005233591,0.00043760161,0.00083788077,0.000059449547,0.00012521388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067164085,0.00084415864,0.0041798246,0.0003324997,0.00011419749,0.00014097895,0.00024727714,0.00055547175,0.000022530174],"category_scores_gemma":[0.00024387751,0.0005260311,0.0015805765,0.00042437506,0.00008373434,0.00018242846,0.00013237011,0.0006900942,0.000019273179],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007979812,0.00020167438,0.00007496265,0.18685462,0.0006279166,0.0000043496807,0.0000069470543,1.3249723e-8,7.243733e-8,0.0006033711,0.0488132,0.7628049],"study_design_scores_gemma":[0.00070275227,0.000085555155,0.000023568125,0.058479887,0.0092815645,6.8550725e-7,0.0000028041768,0.0000013137311,0.0000018097363,0.00012536763,0.93090254,0.00039216963],"about_ca_topic_score_codex":0.0000010868714,"about_ca_topic_score_gemma":0.0000050202957,"teacher_disagreement_score":0.8820893,"about_ca_system_score_codex":0.00019055378,"about_ca_system_score_gemma":0.00033422775,"threshold_uncertainty_score":0.99971914},"labels":[],"label_agreement":null},{"id":"W4409886687","doi":"10.1016/j.eprac.2025.04.017","title":"Glucagon-like Peptide-1 Receptor Agonists Are Associated With Improved Survival and Reduced Liver-Related Events in Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease: A Large Real-World Retrospective Study","year":2025,"lang":"en","type":"article","venue":"Endocrine Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Disease; Type 2 diabetes; Glucagon; Receptor; Internal medicine; Diabetes mellitus; Liver disease; Endocrinology; Agonist; Insulin","score_opus":0.006640392242101564,"score_gpt":0.25036653989331265,"score_spread":0.2437261476512111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409886687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943232,0.0007388362,8.5858477e-7,0.00048126292,0.00028752958,0.0026308177,0.00004765176,0.00014532555,0.001344499],"genre_scores_gemma":[0.98911625,0.00046370455,0.000066537454,0.00016224499,0.000020687714,0.00017655338,0.00033906347,0.000053432577,0.009601527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738324,0.0004455064,0.00037825157,0.000750167,0.00048096053,0.0005618541],"domain_scores_gemma":[0.9980308,0.00035722472,0.00046995978,0.00036144067,0.00057595473,0.00020460905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000478117,0.0004183052,0.0007345041,0.00036084087,0.00020485818,0.000061783016,0.00008115954,0.0000528055,0.00005195346],"category_scores_gemma":[0.001685408,0.0003324523,0.000044214004,0.0013390181,0.00006372993,0.00053822785,0.00017826787,0.00039407288,0.0000082181205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028725818,0.0062988964,0.9854836,0.000059720922,0.0039349664,0.00010493865,0.0003322015,0.0000010105427,0.000027665714,0.00010428422,0.00033647747,0.00044366956],"study_design_scores_gemma":[0.019430695,0.0018467547,0.9728347,0.0003920276,0.0033514702,3.4838257e-7,0.0006538883,0.000118151554,0.000022381166,0.000011464924,0.0010311163,0.00030696602],"about_ca_topic_score_codex":0.00054283417,"about_ca_topic_score_gemma":0.0021088265,"teacher_disagreement_score":0.016558113,"about_ca_system_score_codex":0.00043787993,"about_ca_system_score_gemma":0.00012329473,"threshold_uncertainty_score":0.99991274},"labels":[],"label_agreement":null},{"id":"W4409951953","doi":"10.1038/s42255-025-01295-w","title":"GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice","year":2025,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"CIHR Skin Research Training Centre; Canadian Institutes of Health Research; Banting and Best Diabetes Centre, University of Toronto; Novo Nordisk; Government of Canada; Amgen","keywords":"Internal medicine; Endocrinology; Conjugate; Peptide; Glucagon-like peptide-1; Obesity; Weight loss; Body weight; Medicine; Chemistry; Diabetes mellitus; Biochemistry; Mathematics; Type 2 diabetes","score_opus":0.0049783460493694875,"score_gpt":0.2958500834012905,"score_spread":0.290871737351921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409951953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8679485,0.0649217,0.0002423084,0.033159826,0.002391125,0.0043210415,0.0005071229,0.000237297,0.026271138],"genre_scores_gemma":[0.94187486,0.0026992485,0.0029981423,0.013604258,0.00071924063,0.0003827756,0.0008273621,0.000068327616,0.036825754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806446,0.000086574095,0.00038274328,0.00063934736,0.000283101,0.00054375164],"domain_scores_gemma":[0.9987892,0.00038203693,0.00011626968,0.00038044772,0.00018989932,0.00014217381],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044004596,0.00038051195,0.000767195,0.00047633034,0.00011719795,0.00006984186,0.00017144912,0.000376666,0.00008494435],"category_scores_gemma":[0.0005264056,0.000307063,0.00017532312,0.0004873966,0.00017823449,0.00022808378,0.00014798,0.00052291836,0.000021224305],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028995024,0.0017342208,0.01359595,0.0018869805,0.0032104445,0.0005960409,0.0016323889,0.0000027186748,0.027840637,0.38620126,0.4528011,0.10759875],"study_design_scores_gemma":[0.008588767,0.00012943178,0.07938253,0.00044060615,0.00077628635,0.000004476544,0.00010075764,0.00008089632,0.0097323395,0.0036616088,0.89681333,0.00028897732],"about_ca_topic_score_codex":0.00007860451,"about_ca_topic_score_gemma":0.00011256089,"teacher_disagreement_score":0.44401222,"about_ca_system_score_codex":0.000079359794,"about_ca_system_score_gemma":0.00011701939,"threshold_uncertainty_score":0.99993813},"labels":[],"label_agreement":null},{"id":"W4409954291","doi":"10.1016/j.cjca.2025.03.037","title":"Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease","year":2025,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Disease; Obesity; Atherosclerotic cardiovascular disease; Receptor; Internal medicine; Endocrinology","score_opus":0.01686772498551572,"score_gpt":0.24939629587245515,"score_spread":0.23252857088693943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409954291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019752262,0.9954054,0.000008737419,0.00004622383,0.000145031,0.00063851767,0.00002802657,0.0000020723971,0.0017507893],"genre_scores_gemma":[0.010756935,0.98874915,0.00007095344,0.000017986213,0.0001620279,0.000019478195,0.000023752016,0.000016585867,0.00018314712],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989213,0.00014876669,0.0003671077,0.00021011704,0.000112023336,0.00024073415],"domain_scores_gemma":[0.9989603,0.000053589854,0.00016534528,0.00026554373,0.0001035551,0.00045163318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040479287,0.00022085085,0.0022954037,0.00055829535,0.000034898887,0.0000158857,0.000090372625,0.00012735615,0.000008901277],"category_scores_gemma":[0.000043828284,0.00015568585,0.0004472457,0.00018156708,0.00013297873,0.00004470824,0.000018012652,0.00021286494,4.4929615e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015710465,0.0000106064845,0.03134954,0.005323976,0.006654088,0.00053701375,0.00005300317,0.000013609053,2.5826986e-7,0.000089077985,0.0011939598,0.95461774],"study_design_scores_gemma":[0.00237,0.0002980241,0.005023874,0.005776629,0.0032816047,0.00007611545,0.000035582518,4.7001615e-7,6.0406904e-7,0.000023596745,0.982991,0.00012251758],"about_ca_topic_score_codex":0.0007177989,"about_ca_topic_score_gemma":0.00037116208,"teacher_disagreement_score":0.98179704,"about_ca_system_score_codex":0.00016244466,"about_ca_system_score_gemma":0.0017705263,"threshold_uncertainty_score":0.63486844},"labels":[],"label_agreement":null},{"id":"W4410004411","doi":"10.1172/jci192414","title":"GLP-1 receptor agonists for the treatment of alcohol use disorder","year":2025,"lang":"en","type":"letter","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"Canadian Institutes of Health Research; University of Calgary","keywords":"Alcohol use disorder; Alcohol; Receptor; Pharmacology; Agonist; Medicine; Chemistry; Internal medicine; Biochemistry","score_opus":0.14370850584484934,"score_gpt":0.4054309508184011,"score_spread":0.26172244497355174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410004411","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034098372,0.0013244245,0.00037619224,0.95885926,0.0030515855,0.0019357634,0.000069453665,0.000015253886,0.00026967347],"genre_scores_gemma":[0.0054911715,0.020320658,0.021738729,0.8363647,0.02191443,0.00030296785,0.0015123541,0.00013684726,0.09221817],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973048,0.00014817319,0.0017451568,0.00020247973,0.00041781605,0.00018155342],"domain_scores_gemma":[0.99429446,0.003043692,0.0017242709,0.00037009906,0.00047123112,0.00009627132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064281304,0.0002404922,0.0010533058,0.0001575275,0.000054104537,0.00004257043,0.00015155568,0.00043659293,0.000045522567],"category_scores_gemma":[0.0012011615,0.00013155297,0.001042298,0.00013112563,0.0002309306,0.00010921097,0.000017899345,0.000482458,0.000005945874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002890073,0.00045494703,0.01717566,0.0002524819,0.0023715924,0.000019189967,0.00005840691,0.000007297904,0.000012264689,0.00006550774,0.9361453,0.043148316],"study_design_scores_gemma":[0.0044161435,0.0036472355,0.010369637,0.0005728472,0.003915267,0.0000021289834,0.000013761168,0.00008299439,0.00019886032,0.000627202,0.9760583,0.00009560891],"about_ca_topic_score_codex":0.000021776441,"about_ca_topic_score_gemma":0.000005003849,"teacher_disagreement_score":0.12249461,"about_ca_system_score_codex":0.00011815195,"about_ca_system_score_gemma":0.00035161382,"threshold_uncertainty_score":0.5364574},"labels":[],"label_agreement":null},{"id":"W4410064334","doi":"10.7759/cureus.83449","title":"Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; Alberta Health Services","funders":"","keywords":"Empagliflozin; Medicine; Dapagliflozin; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Benzhydryl compounds; Internal medicine; Endocrinology","score_opus":0.11499010359918257,"score_gpt":0.3571953793170559,"score_spread":0.24220527571787334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410064334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046742495,0.9932616,0.0000041180538,0.000007873189,0.0001871139,0.002418109,0.00012528729,0.00003280143,0.0034956976],"genre_scores_gemma":[0.0016912216,0.9942565,0.00040453664,0.00003657783,0.000021153057,0.00047890533,0.0015559733,0.00004661352,0.0015085448],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99726874,0.0002396501,0.0007938937,0.00065686886,0.000670949,0.00036987563],"domain_scores_gemma":[0.99759984,0.00030762528,0.00035225681,0.0014134183,0.00022467833,0.000102176724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002921877,0.00067916,0.011324748,0.0008299258,0.000025222434,0.000018199378,0.00027458637,0.00019136861,0.00021608525],"category_scores_gemma":[0.00008452093,0.00040632577,0.004876265,0.0022474802,0.000075127246,0.00007083008,0.00014607905,0.0002247386,0.000031221552],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006727632,0.0007393761,0.0072058397,0.0058763307,0.96391726,0.000011939369,0.00006515734,0.0000269894,1.7663291e-9,0.00003243041,0.00041492988,0.021642499],"study_design_scores_gemma":[0.001979965,0.0004930764,0.002489428,0.00062288425,0.75820637,1.7551786e-8,0.000020409745,0.0000017543529,3.751795e-7,0.0000015516275,0.23592171,0.00026247272],"about_ca_topic_score_codex":0.000047784586,"about_ca_topic_score_gemma":0.00009294967,"teacher_disagreement_score":0.23550679,"about_ca_system_score_codex":0.00026011455,"about_ca_system_score_gemma":0.00019772131,"threshold_uncertainty_score":0.9998389},"labels":[],"label_agreement":null},{"id":"W4410076281","doi":"10.1503/cmaj.241400","title":"Diabetic ketoacidosis induced by a sodium–glucose cotransporter-2 inhibitor in a 28-year-old man without known diabetes","year":2025,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University Health Network","funders":"","keywords":"Diabetic ketoacidosis; Diabetes mellitus; Ketoacidosis; Medicine; Sodium; Endocrinology; Cotransporter; Internal medicine; Chemistry; Type 1 diabetes","score_opus":0.005319668659537256,"score_gpt":0.22303694323450896,"score_spread":0.2177172745749717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410076281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550207,0.0004180852,0.000006835388,0.036250394,0.0006714172,0.0004206352,0.00002619198,0.00003693115,0.007148763],"genre_scores_gemma":[0.9803088,0.0001732383,0.00007746474,0.014650116,0.00037673596,0.000057897745,0.00006523259,0.00002576019,0.004264798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970634,0.00013238314,0.0006768035,0.00029176782,0.0009935737,0.00084206177],"domain_scores_gemma":[0.99803126,0.00010470852,0.00018186077,0.00017651824,0.00017263278,0.001333015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011376801,0.00024004636,0.00052834733,0.0006246811,0.00016212063,0.00010754988,0.00018825027,0.00041543233,0.0011554606],"category_scores_gemma":[0.00055470184,0.00022200537,0.00015997092,0.0006009823,0.00004588558,0.00013839392,0.000021023548,0.00089159224,0.000093402145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001879952,0.00021947394,0.8875462,0.000057879886,0.00038994692,0.00013596573,0.00013994482,1.5159729e-7,0.00041681013,0.000106108426,0.083088435,0.027880311],"study_design_scores_gemma":[0.014398258,0.00053075794,0.6827578,0.0016987514,0.000747812,0.000008488209,0.000539397,0.00036584242,0.0020432181,0.0003983831,0.29591882,0.0005924545],"about_ca_topic_score_codex":0.0010604264,"about_ca_topic_score_gemma":0.012503136,"teacher_disagreement_score":0.2128304,"about_ca_system_score_codex":0.001923429,"about_ca_system_score_gemma":0.0015521003,"threshold_uncertainty_score":0.99975765},"labels":[],"label_agreement":null},{"id":"W4410080278","doi":"10.1016/j.jchf.2025.02.014","title":"The Role of GLP-1 Receptor Agonists in Heart Failure","year":2025,"lang":"en","type":"editorial","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Glucagon-like peptide 1 receptor; Cardiology; Receptor; Agonist","score_opus":0.0038665979258427343,"score_gpt":0.24828000020701552,"score_spread":0.24441340228117278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410080278","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037167906,0.010017791,0.0000029321354,0.106005535,0.861332,0.0058017713,0.0005586003,0.00036270596,0.012201869],"genre_scores_gemma":[0.007456062,0.0012680001,0.009130783,0.0010246703,0.87737095,0.00122009,0.0038848987,0.00029313145,0.09835143],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970185,0.00014103118,0.0006565453,0.0006130337,0.00093236944,0.000638508],"domain_scores_gemma":[0.997725,0.0006965046,0.00017384069,0.0009915103,0.0002595317,0.00015362911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055932696,0.00048787182,0.0011050056,0.00029637731,0.00014137945,0.00009072977,0.00031351598,0.00088291266,0.00022476488],"category_scores_gemma":[0.0005839084,0.00035211665,0.00039349502,0.0004926177,0.00012453248,0.00008390524,0.00023692544,0.0010437905,0.00021024156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013473262,0.00022092248,0.0022502334,0.00038839618,0.00028210797,0.000006047479,0.00007294639,7.4341295e-7,0.00035827217,0.00018570662,0.9938276,0.0022722904],"study_design_scores_gemma":[0.0016428627,0.00033106835,0.000326963,0.0010155267,0.00024287848,6.3618677e-7,0.0003127948,0.0000044891103,0.0008701399,0.00014154805,0.99486357,0.0002475295],"about_ca_topic_score_codex":0.00028498055,"about_ca_topic_score_gemma":0.00087924424,"teacher_disagreement_score":0.10498086,"about_ca_system_score_codex":0.00028970465,"about_ca_system_score_gemma":0.0006895754,"threshold_uncertainty_score":0.99989307},"labels":[],"label_agreement":null},{"id":"W4410080315","doi":"10.1016/j.jchf.2025.03.014","title":"Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial","year":2025,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Dapagliflozin; Heart failure; TIMI; Cardiology; Internal medicine; Intensive care medicine; Myocardial infarction; Diabetes mellitus; Type 2 diabetes","score_opus":0.011738508558322706,"score_gpt":0.2550688704241228,"score_spread":0.2433303618658001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410080315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677539,0.0006612754,0.00021540835,0.023038939,0.00051416963,0.0073615303,0.000014081653,0.000056285706,0.00038441035],"genre_scores_gemma":[0.9946331,0.000025961112,0.001991835,0.0009367503,0.00013108196,0.00040396355,0.0000350988,0.000025743893,0.0018164616],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982238,0.00038568614,0.0002978718,0.00037445393,0.000442922,0.00027528618],"domain_scores_gemma":[0.99894077,0.0003086481,0.000046375026,0.0005912635,0.000043353004,0.00006962217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075644196,0.00023859045,0.0006681991,0.00020083472,0.00009286686,0.000018504461,0.00010638367,0.00013373255,0.000047785084],"category_scores_gemma":[0.00017054302,0.00015949129,0.00037874057,0.00040365433,0.00005360811,0.00008980386,0.00009435436,0.00022567986,0.00002865875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02988749,0.0028362938,0.23476107,0.0015346181,0.013373432,0.000078823905,0.00070335367,0.0025759884,0.020182712,0.0011437978,0.6770904,0.015832037],"study_design_scores_gemma":[0.12347049,0.0043848455,0.13759144,0.0016058135,0.0031780554,0.000015036335,0.00014922653,0.000444754,0.024250904,0.00026282555,0.7041464,0.00050024845],"about_ca_topic_score_codex":0.000036452573,"about_ca_topic_score_gemma":0.000020523632,"teacher_disagreement_score":0.097169645,"about_ca_system_score_codex":0.00009709824,"about_ca_system_score_gemma":0.00011619601,"threshold_uncertainty_score":0.6503866},"labels":[],"label_agreement":null},{"id":"W4410088019","doi":"10.1371/journal.pone.0321032","title":"RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":true,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Medicine; Type 2 diabetes; Internal medicine; Meta-analysis; Diabetes mellitus; Relative risk; Jadad scale; Sitagliptin; Vildagliptin; Adverse effect; Confidence interval; Endocrinology; Cochrane Library; Insulin","score_opus":0.07773880430109467,"score_gpt":0.29427752170599303,"score_spread":0.21653871740489836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410088019","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009107898,0.98219705,9.643949e-8,0.000023310424,0.000009839936,0.008351441,0.00007193807,0.000022777718,0.00021568069],"genre_scores_gemma":[0.0009545415,0.9969099,0.00007701447,0.00021674168,0.000006131898,0.000874063,0.00037525577,0.00003628627,0.0005500636],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99679,0.00037282205,0.001095946,0.000584066,0.0009156655,0.00024152058],"domain_scores_gemma":[0.9977146,0.00025553795,0.0005741168,0.0011480241,0.00020336243,0.00010435779],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00095050584,0.0006013459,0.014629779,0.000662631,0.000023077348,0.00002083135,0.0001185141,0.00018616054,0.00005513638],"category_scores_gemma":[0.0003632632,0.00032198138,0.0016867231,0.0013246067,0.00005262806,0.00007296241,0.00006850162,0.00024498373,0.000004520042],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008129233,0.00088521146,0.008066766,0.50815916,0.48095906,0.0000053507397,0.000008825622,3.099998e-8,5.62443e-9,0.000004755693,0.000009960373,0.0018927477],"study_design_scores_gemma":[0.00072910835,0.00063104276,0.0026257879,0.10149247,0.89373845,9.820929e-8,0.0000029235841,2.467125e-7,0.0000020735029,0.000002697694,0.0005470165,0.00022808391],"about_ca_topic_score_codex":0.000039837094,"about_ca_topic_score_gemma":0.00000996767,"teacher_disagreement_score":0.41277942,"about_ca_system_score_codex":0.00008622717,"about_ca_system_score_gemma":0.0000689143,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W4410108055","doi":"10.1681/asn.0000000752","title":"Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Kidney disease; Intensive care medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Tolerability; Population; Guideline; Clinical trial; Renal function; Mineralocorticoid receptor; Endocrinology; Adverse effect; Pathology; Aldosterone","score_opus":0.006253779683452077,"score_gpt":0.24291435230643993,"score_spread":0.23666057262298784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410108055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446976,0.0006150663,0.000005950881,0.004673505,0.000027568822,0.00013439836,0.0000022667448,0.000003426548,0.00006807262],"genre_scores_gemma":[0.9902099,0.0007079206,0.0023743943,0.0066521876,0.000014195645,7.770142e-7,0.0000024342642,0.000004686716,0.000033555454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943197,0.000042744734,0.00027696142,0.00006180393,0.00010086386,0.00008565025],"domain_scores_gemma":[0.9990995,0.00014173072,0.00044134323,0.00008322313,0.00020692832,0.000027268528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000137616,0.00006963077,0.000352074,0.000060531176,0.000016634682,0.0000023951345,0.00004900138,0.000023131357,0.0000054590223],"category_scores_gemma":[0.0000834744,0.000041038064,0.000054295087,0.00023107772,0.0003191987,0.000029720766,0.000036281595,0.00007557043,4.0025114e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091410277,0.0003215414,0.9252882,0.00009257078,0.0013408115,0.0000012363193,0.0007836023,0.000020889142,0.00476885,0.0000125802135,0.016262438,0.050193164],"study_design_scores_gemma":[0.003310027,0.00267768,0.98414636,0.00012416516,0.0003462922,0.0000010799804,0.00043709413,0.0003704414,0.00033269313,0.00011278816,0.008097025,0.00004437902],"about_ca_topic_score_codex":0.0000139636195,"about_ca_topic_score_gemma":0.000001897381,"teacher_disagreement_score":0.058858123,"about_ca_system_score_codex":0.000021196074,"about_ca_system_score_gemma":0.0000531889,"threshold_uncertainty_score":0.16734837},"labels":[],"label_agreement":null},{"id":"W4410132355","doi":"10.1111/dom.16431","title":"Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( <scp>RACELINES</scp> ): A randomised, double‐blind trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Amsterdam University Medical Centers; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Linagliptin; Postprandial; Renal function; Type 2 diabetes; Gliclazide; Internal medicine; Endocrinology; Urology; Metformin; Diabetes mellitus; Glycosuria; Effective renal plasma flow; Renal blood flow","score_opus":0.0077083763909527505,"score_gpt":0.24274227196848683,"score_spread":0.23503389557753407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410132355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882345,0.0073541603,0.00001025004,0.0003332851,0.00019449586,0.003693115,0.000009420631,0.000029859473,0.00014089259],"genre_scores_gemma":[0.9969493,0.0018509569,0.00033981318,0.0004196956,0.00004976505,0.0002004727,0.00005825335,0.000021015021,0.00011069894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836046,0.00014561482,0.0004211292,0.00048129717,0.0001928463,0.00039867617],"domain_scores_gemma":[0.99872065,0.00065072457,0.0001373407,0.00018428525,0.000092478724,0.00021455428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058768934,0.00033023424,0.001112766,0.0006463518,0.00008496989,0.00008166204,0.000064666245,0.00012826103,0.0000015473917],"category_scores_gemma":[0.00040369868,0.00026915595,0.000045453875,0.00062457076,0.00011119238,0.00021679167,0.00012060077,0.0001740729,4.6817635e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03818033,0.0015638273,0.93290335,0.0013981439,0.0005500529,0.00001197909,0.0026759352,0.000014207369,0.008545438,0.0006884072,0.00007708517,0.013391236],"study_design_scores_gemma":[0.32701954,0.00093436247,0.66290325,0.0006910988,0.0004209234,3.9057542e-7,0.000111205816,0.0016105166,0.005634464,0.00026770864,0.0002727789,0.00013378027],"about_ca_topic_score_codex":0.00013685277,"about_ca_topic_score_gemma":0.00013794703,"teacher_disagreement_score":0.28883922,"about_ca_system_score_codex":0.000026174743,"about_ca_system_score_gemma":0.000060341834,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W4410132717","doi":"10.2174/0115734072353980250418211500","title":"Global Trends and Hotspots in Dulaglutide in the Fields of Diabetes, Obesity, and Cardiovascular Research: A Bibliometric Analysis","year":2025,"lang":"en","type":"article","venue":"Current Bioactive Compounds","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dulaglutide; Obesity; Diabetes mellitus; Medicine; Geography; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.0615608095341443,"score_gpt":0.3662416627559737,"score_spread":0.3046808532218294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410132717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671936,0.026595145,0.000038854392,0.00045335936,0.000067227564,0.00029915076,0.000014882129,0.000008427937,0.005329344],"genre_scores_gemma":[0.9980573,0.0017391363,0.000027102687,0.000033457593,0.000014129532,0.0000579708,0.000023343722,0.0000031168092,0.00004441483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846464,0.00024403374,0.0002293057,0.00034899113,0.00041926134,0.00029377278],"domain_scores_gemma":[0.99922997,0.00022328315,0.000035807338,0.0003676928,0.0000903397,0.000052911615],"candidate_categories":["bibliometrics"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.001124324,0.00014135528,0.00052109355,0.034961034,0.000049324746,0.00004649698,0.00013366176,0.00005898168,0.00000674151],"category_scores_gemma":[0.00009030765,0.00010271287,0.000180437,0.10404004,0.0002085264,0.00007347712,0.00020909005,0.0001898383,4.391829e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003879893,0.0005032035,0.856789,0.00012498444,0.0011800252,0.000008149357,0.00011740912,0.000004593957,0.0000047604904,0.00042961174,0.0004573911,0.1403421],"study_design_scores_gemma":[0.0015260376,0.0002051724,0.9945508,0.00013881107,0.001017177,3.487692e-7,0.0001929772,0.00032632035,0.000028055074,0.00050625,0.0014333577,0.00007465091],"about_ca_topic_score_codex":0.00029883228,"about_ca_topic_score_gemma":0.00023938887,"teacher_disagreement_score":0.14026745,"about_ca_system_score_codex":0.000118100535,"about_ca_system_score_gemma":0.000029678971,"threshold_uncertainty_score":0.9759769},"labels":[],"label_agreement":null},{"id":"W4410177018","doi":"10.1002/trc2.70076","title":"Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years","year":2025,"lang":"en","type":"article","venue":"Alzheimer s & Dementia Translational Research & Clinical Interventions","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Population; Discontinuation; Adverse effect; Overweight; Placebo; Body mass index; Internal medicine; Type 2 diabetes; Gerontology; Diabetes mellitus; Endocrinology; Environmental health; Alternative medicine","score_opus":0.13349343071029796,"score_gpt":0.4606087427903339,"score_spread":0.32711531208003597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410177018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94609964,0.04028533,0.00073009887,0.006971734,0.00014867037,0.0035376374,0.0006086801,0.00002128591,0.0015969186],"genre_scores_gemma":[0.9971634,0.0006441638,0.0012127159,0.000071084236,0.000021427742,0.00023735782,0.00056901824,0.000012985157,0.000067854126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947085,0.0011407265,0.0023911947,0.00047534698,0.00090569205,0.0003785363],"domain_scores_gemma":[0.9968269,0.0017377426,0.00028823043,0.0006130606,0.0004075033,0.00012660195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026224314,0.00020361609,0.0008871431,0.001680753,0.00008982464,0.000019194484,0.00022050766,0.00010279007,0.00074518827],"category_scores_gemma":[0.00035450215,0.00016790375,0.0015718339,0.0021726813,0.0005559834,0.00008457942,0.00006747087,0.00027602894,0.0000055557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003647242,0.027719904,0.7039077,0.0003454779,0.1769444,0.00016425588,0.0011619991,0.0041907113,0.00027197183,0.027292745,0.001183892,0.053169657],"study_design_scores_gemma":[0.0053635905,0.00064078334,0.94312924,0.0007211864,0.043266956,3.1524982e-7,0.0002646108,0.003615135,0.00013459318,0.0025399711,0.00022616316,0.00009744579],"about_ca_topic_score_codex":0.000797401,"about_ca_topic_score_gemma":0.0042375275,"teacher_disagreement_score":0.23922151,"about_ca_system_score_codex":0.000033526867,"about_ca_system_score_gemma":0.00037366748,"threshold_uncertainty_score":0.8159289},"labels":[],"label_agreement":null},{"id":"W4410208160","doi":"10.58931/cdet.2025.3137","title":"Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Myth or Reality?","year":2025,"lang":"en","type":"article","venue":"Canadian Diabetes & Endocrinology Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Mythology; Thyroid cancer; Thyroid; Receptor; Medicine; Endocrinology; Internal medicine; Cancer research; Philosophy; Theology","score_opus":0.014579858167990562,"score_gpt":0.2743177327748004,"score_spread":0.25973787460680986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410208160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86462414,0.011544652,0.000004990014,0.058026507,0.0018239317,0.0014274179,0.0002094518,0.00027538196,0.062063497],"genre_scores_gemma":[0.8642034,0.0037258335,0.0003725389,0.025074186,0.00022864925,0.0005985543,0.00027790628,0.000062961975,0.105455995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973298,0.00007339348,0.00034730186,0.0006809514,0.0001322448,0.0014363134],"domain_scores_gemma":[0.9984527,0.00012518447,0.00007669633,0.0006083153,0.00009580226,0.0006413006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011581061,0.00037859828,0.0006485549,0.0005962178,0.00025587837,0.000059885773,0.00021301246,0.00016089994,0.00068325107],"category_scores_gemma":[0.00010498956,0.00032577213,0.000107655265,0.00041286455,0.00032157378,0.00010783478,0.000121931385,0.00026568802,0.0001162547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012458334,0.00015611242,0.24516918,0.00043964246,0.001684115,0.00036702503,0.0002360935,0.0000028825607,0.0017420691,0.011033131,0.59285694,0.1461882],"study_design_scores_gemma":[0.002321099,0.00046332588,0.044052795,0.00023066881,0.00054941786,0.0000065352074,0.00016718116,0.00002861755,0.0030478025,0.00027817392,0.9485192,0.00033518963],"about_ca_topic_score_codex":0.02115159,"about_ca_topic_score_gemma":0.08288862,"teacher_disagreement_score":0.35566223,"about_ca_system_score_codex":0.00065357646,"about_ca_system_score_gemma":0.0008727758,"threshold_uncertainty_score":0.9999194},"labels":[],"label_agreement":null},{"id":"W4410208199","doi":"10.58931/cdet.2025.3138","title":"The Role of GLP-1R and GIPR Agonism in Heart Failure","year":2025,"lang":"en","type":"article","venue":"Canadian Diabetes & Endocrinology Today","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health; University of Toronto","funders":"Canadian Institutes of Health Research; Servier; Novo Nordisk; Heart and Stroke Foundation of Canada; University of Toronto; Diabetes Canada; AstraZeneca; Eli Lilly and Company","keywords":"Agonism; Heart failure; Internal medicine; Medicine; Endocrinology; Political science","score_opus":0.003635335386295209,"score_gpt":0.21538546495256383,"score_spread":0.21175012956626862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410208199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94256234,0.009698383,3.4370274e-7,0.026062233,0.00018154315,0.000511778,0.000013463407,0.000027901566,0.020941997],"genre_scores_gemma":[0.9951317,0.00017692376,0.00011691837,0.0017676222,0.00002237097,0.00008978909,0.000016738826,0.000011709619,0.0026662343],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986717,0.00004619735,0.00022003248,0.0002484175,0.000067279,0.00074636115],"domain_scores_gemma":[0.9992644,0.0001404713,0.000033724285,0.0003441053,0.000041379204,0.00017591297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096919364,0.00015390651,0.00032512314,0.0003743239,0.00010608616,0.000018497944,0.00012556711,0.000077953446,0.000046028286],"category_scores_gemma":[0.000081563274,0.00012144989,0.000057943154,0.00023571131,0.00024488315,0.000040343122,0.00006492566,0.00016463849,0.000017512184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012359425,0.000050613682,0.8655774,0.000056922912,0.0002903309,0.000033558055,0.00009690346,0.0000013649812,0.0020910613,0.050349906,0.011795741,0.06964382],"study_design_scores_gemma":[0.0010869411,0.00013569248,0.26025993,0.00008146195,0.00011050881,0.0000020951575,0.00035257265,0.00003718101,0.00965612,0.003212998,0.72496164,0.000102859696],"about_ca_topic_score_codex":0.00645583,"about_ca_topic_score_gemma":0.071164586,"teacher_disagreement_score":0.7131659,"about_ca_system_score_codex":0.00015806005,"about_ca_system_score_gemma":0.0002456579,"threshold_uncertainty_score":0.97593266},"labels":[],"label_agreement":null},{"id":"W4410254171","doi":"10.1007/s40264-025-01551-8","title":"Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design","year":2025,"lang":"en","type":"article","venue":"Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Type 2 diabetes; Incretin; Incidence (geometry); Endometrial cancer; Diabetes mellitus; Cancer; Oncology; Internal medicine; Pharmacology; Endocrinology","score_opus":0.008170111180421281,"score_gpt":0.2504481417911726,"score_spread":0.24227803061075132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410254171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159485,0.0007043611,0.0006464468,0.0022336857,0.00015923583,0.0014954999,0.000010730339,0.000036391837,0.0031188189],"genre_scores_gemma":[0.9961524,0.00009197698,0.00064987433,0.00052219915,0.000046619323,0.00007712151,0.000016705577,0.0000114665445,0.002431661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901307,0.00012348231,0.00020277746,0.00020959797,0.00026237025,0.00018869746],"domain_scores_gemma":[0.99846125,0.00095873675,0.000120262295,0.00025059844,0.00013913371,0.00007003983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043727964,0.000152666,0.0004392617,0.00013204428,0.00007349329,0.00001619832,0.00010255456,0.000032222997,0.000081046426],"category_scores_gemma":[0.00016895367,0.00008910012,0.000050040468,0.0006486236,0.00020377562,0.00006234622,0.000058951322,0.0001023775,0.0000036351105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02830155,0.0003667996,0.9168239,0.00038742358,0.0024526266,0.0000069173316,0.006519061,0.00085984037,0.00048229488,0.002995055,0.021706127,0.019098379],"study_design_scores_gemma":[0.06457278,0.0007877412,0.86279356,0.0013717532,0.0032629964,2.6729e-7,0.0018680601,0.0048618233,0.04525239,0.0003100608,0.014456617,0.00046195262],"about_ca_topic_score_codex":0.0011024259,"about_ca_topic_score_gemma":0.00027414944,"teacher_disagreement_score":0.05403037,"about_ca_system_score_codex":0.00008982934,"about_ca_system_score_gemma":0.00029371155,"threshold_uncertainty_score":0.36333975},"labels":[],"label_agreement":null},{"id":"W4410389667","doi":"10.1016/j.jcjd.2025.01.004","title":"Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Guideline; Diabetes mellitus; Kidney disease; Clinical Practice; Intensive care medicine; Internal medicine; Family medicine; Pathology; Endocrinology","score_opus":0.016299400236457696,"score_gpt":0.32050216832629924,"score_spread":0.30420276808984154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410389667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86019945,0.02522298,0.000035111487,0.091706686,0.0022343656,0.0008113241,0.000045678506,0.000026696753,0.019717677],"genre_scores_gemma":[0.97057503,0.000116298754,0.0016520988,0.025307488,0.00066824845,0.000016901604,0.000042621676,0.000026946527,0.0015943417],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778885,0.000120280616,0.0010760926,0.00021993308,0.00021045476,0.00058437913],"domain_scores_gemma":[0.9970434,0.00026342887,0.0002751509,0.00032905006,0.00034919355,0.0017397893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012010906,0.00019455364,0.0005614817,0.0007975846,0.00005787853,0.000057124154,0.00021522217,0.00008653842,0.00020385794],"category_scores_gemma":[0.004557331,0.00016866204,0.0002641747,0.0004950075,0.0001290534,0.00026929466,0.000028135823,0.00035649523,0.00002691631],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013979152,0.00014557005,0.82527786,0.00013894623,0.00048068658,0.00020434851,0.00002478116,0.00002201791,0.000017193168,0.00040087613,0.14304757,0.03022614],"study_design_scores_gemma":[0.0035121974,0.00052387326,0.23512977,0.0012768259,0.00092878926,4.446186e-7,0.00005671225,0.0003503354,0.000048278784,0.00039077114,0.7576349,0.00014709783],"about_ca_topic_score_codex":0.00018093307,"about_ca_topic_score_gemma":0.0012460038,"teacher_disagreement_score":0.6145873,"about_ca_system_score_codex":0.000601695,"about_ca_system_score_gemma":0.005453831,"threshold_uncertainty_score":0.9674862},"labels":[],"label_agreement":null},{"id":"W4410397471","doi":"10.4088/pcc.24nr03855","title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists in Alcohol Use Disorder","year":2025,"lang":"en","type":"review","venue":"The Primary Care Companion For CNS Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Alcohol use disorder; Glucagon-like peptide-1; Alcohol; Receptor; Glucagon-like peptide 1 receptor; Glucagon; Agonist; Endocrinology; Internal medicine; Chemistry; Medicine; Pharmacology; Biochemistry; Hormone; Diabetes mellitus","score_opus":0.02098558554509899,"score_gpt":0.29367989624091895,"score_spread":0.27269431069581995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410397471","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015576283,0.98515505,0.000024448877,0.000241457,0.0005820768,0.0061369184,0.00021281654,0.00006521354,0.007426253],"genre_scores_gemma":[0.00047851828,0.9919559,0.00016536716,0.00013428647,0.000046596535,0.00088920933,0.0029874437,0.00006956693,0.0032731243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977016,0.00019011152,0.0007801786,0.0004924089,0.00033020423,0.0005055139],"domain_scores_gemma":[0.9975289,0.0008349871,0.00038459103,0.0010678057,0.00011547991,0.00006821326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027624928,0.0005677717,0.0015999256,0.0002522522,0.0002486432,0.000073163494,0.0006258822,0.0001791653,0.000022818664],"category_scores_gemma":[0.00007980922,0.00032497052,0.0010404321,0.0005335416,0.00021198786,0.000086465814,0.00028378225,0.00031978468,0.000021847996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008532088,0.00023708992,0.00088743196,0.014617273,0.00072940724,4.548205e-7,0.00022291501,0.000007061658,2.7584923e-7,0.00091796776,0.003496729,0.9787981],"study_design_scores_gemma":[0.0013173895,0.00017818307,0.0007161261,0.006198975,0.0020330683,6.186634e-7,0.00079979585,0.000012071138,8.1778796e-7,0.00020113052,0.9882576,0.00028421948],"about_ca_topic_score_codex":0.00021329943,"about_ca_topic_score_gemma":0.0005517404,"teacher_disagreement_score":0.9847609,"about_ca_system_score_codex":0.00036436986,"about_ca_system_score_gemma":0.0004217137,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W4410416857","doi":"10.7759/cureus.84137","title":"Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists in Reducing Cardiovascular Events in Patients With Type 2 Diabetes","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Glucagon-like peptide-1; Internal medicine; Pharmacology; Dapagliflozin; Endocrinology; Diabetes mellitus; Cotransporter; Sodium","score_opus":0.02181313422800626,"score_gpt":0.287737695025804,"score_spread":0.26592456079779775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410416857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21629182,0.77804995,9.4431465e-7,0.0000013030104,0.0011122769,0.00380515,0.000043172353,0.000029209645,0.0006661815],"genre_scores_gemma":[0.08902045,0.9075333,0.000119602155,0.0000053583285,0.000065287146,0.0005504422,0.0024543465,0.00007820994,0.00017299692],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971318,0.00040818384,0.0007479841,0.00074526254,0.00049589353,0.00047087806],"domain_scores_gemma":[0.99841434,0.0003024058,0.0002912717,0.0007257473,0.00016216763,0.000104062616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049120694,0.000647588,0.0037369158,0.00048607832,0.00003275649,0.0000096243675,0.00021504624,0.00025807694,0.0000179578],"category_scores_gemma":[0.000052882293,0.0005110218,0.0006103237,0.0010357167,0.000087086824,0.00011750421,0.000089530215,0.00035133955,0.000018139997],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004796208,0.008445314,0.16307063,0.24741217,0.03281687,0.000118287375,0.0010719453,0.00011348311,0.000012456869,0.00004243671,0.0006213251,0.5414789],"study_design_scores_gemma":[0.042170037,0.0070806807,0.13120489,0.43128195,0.024347065,6.396485e-7,0.00018199338,0.0000053719114,0.0007410427,0.0000130334065,0.36067182,0.0023014832],"about_ca_topic_score_codex":0.00012359934,"about_ca_topic_score_gemma":0.000041818774,"teacher_disagreement_score":0.53917736,"about_ca_system_score_codex":0.00085645285,"about_ca_system_score_gemma":0.00037265575,"threshold_uncertainty_score":0.99973416},"labels":[],"label_agreement":null},{"id":"W4410435287","doi":"10.1016/j.ajo.2025.05.007","title":"Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries","year":2025,"lang":"en","type":"article","venue":"American Journal of Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; St. Michael's Hospital; McMaster University; Kensington Health; University of Toronto; University of Ottawa","funders":"Pfizer; Amgen; Bausch Health; Allergan; Apellis Pharmaceuticals; Research to Prevent Blindness","keywords":"Observational study; Medicine; Retinal; Adverse effect; Association (psychology); Ophthalmology; Optic nerve; Glucagon-like peptide 1 receptor; Receptor; Endocrinology; Internal medicine; Agonist; Psychology","score_opus":0.01816733729929776,"score_gpt":0.31793606338261665,"score_spread":0.2997687260833189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410435287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975598,0.00005183706,0.00004485855,0.0016663631,0.00016344669,0.00032634893,0.000012317286,0.0000058623896,0.00016916102],"genre_scores_gemma":[0.99545246,0.0000055999976,0.00302014,0.00011958751,0.000036091555,0.000014486537,0.000033101303,0.000010372827,0.0013081816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867374,0.00013793014,0.0004911503,0.00015892618,0.00034088054,0.00019737972],"domain_scores_gemma":[0.9981535,0.00028018633,0.000922325,0.00013223299,0.0004462484,0.00006547999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004979022,0.00014067028,0.00054559275,0.00015295514,0.00007396958,0.000007849334,0.00007896166,0.000035081837,0.00006278743],"category_scores_gemma":[0.00015699136,0.00011125726,0.00007690362,0.0003095982,0.00012277889,0.00009953073,0.000029742421,0.00012157586,0.0000016269662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014643628,0.00061964156,0.99562955,0.00005272858,0.0010097715,0.0002551843,0.0002587955,0.00013219082,0.000031922067,0.000064892454,0.00015979308,0.00032115623],"study_design_scores_gemma":[0.0035336255,0.006258577,0.9871217,0.00017317302,0.00057477824,0.00020261326,0.001799294,0.000040388997,0.00002871606,0.000039149916,0.00014623806,0.00008175578],"about_ca_topic_score_codex":0.00017456691,"about_ca_topic_score_gemma":0.0000055921323,"teacher_disagreement_score":0.008507871,"about_ca_system_score_codex":0.00025819684,"about_ca_system_score_gemma":0.00019696144,"threshold_uncertainty_score":0.45369393},"labels":[],"label_agreement":null},{"id":"W4410440152","doi":"10.3390/ijms26104780","title":"SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology","year":2025,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"Ministero della Salute","keywords":"Medicine; Cardiotoxicity; Cancer; Empagliflozin; Heart failure; Intensive care medicine; Disease; Bioinformatics; Diabetes mellitus; Internal medicine; Type 2 Diabetes Mellitus; Toxicity","score_opus":0.07502843419327768,"score_gpt":0.46789659795520416,"score_spread":0.39286816376192646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410440152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003925005,0.99358225,0.000004467839,0.0010845646,0.00040331142,0.0005006813,0.000012568581,0.0000014362928,0.0004857035],"genre_scores_gemma":[0.0018039423,0.99699116,0.00024079155,0.0008606233,0.000042625757,0.000035399164,0.000010464039,0.0000045969364,0.00001038181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782294,0.00017745422,0.0013049914,0.00020313008,0.0003879053,0.00010357141],"domain_scores_gemma":[0.9982479,0.00027802834,0.0008989808,0.00009515134,0.0004304177,0.00004949632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006073656,0.0001375663,0.0012573743,0.00058338494,0.000009717775,0.000012041899,0.0003241149,0.00008399918,0.0000095096875],"category_scores_gemma":[0.0002335984,0.00009515067,0.0003510408,0.0004557487,0.00022569034,0.000042340587,0.0000901291,0.00020946815,5.041491e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008633184,0.0003860625,0.0030741321,0.00734725,0.00046281968,0.000032119573,0.000015235399,0.000001175646,0.000007794463,0.00010974797,0.00037360055,0.9881814],"study_design_scores_gemma":[0.0014011221,0.00061988865,0.0027671217,0.19988297,0.0012458935,0.000022734279,0.000030019628,0.0000019967808,0.000022456832,0.00014830135,0.79372,0.00013746305],"about_ca_topic_score_codex":0.00002063483,"about_ca_topic_score_gemma":0.0000033886008,"teacher_disagreement_score":0.98804396,"about_ca_system_score_codex":0.0001715222,"about_ca_system_score_gemma":0.0008388513,"threshold_uncertainty_score":0.3880132},"labels":[],"label_agreement":null},{"id":"W4410483455","doi":"10.1016/j.dsx.2025.103238","title":"Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports","year":2025,"lang":"en","type":"review","venue":"Diabetes & Metabolic Syndrome Clinical Research & Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agonist; Glucagon-like peptide 1 receptor; Pharmacology; Receptor; Pharmacovigilance; Suicidal ideation; Medicine; Chemistry; Endocrinology; Internal medicine; Poison control; Medical emergency; Suicide prevention; Drug","score_opus":0.2117551776444227,"score_gpt":0.5348540571183859,"score_spread":0.32309887947396315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410483455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00382463,0.973831,9.06422e-7,0.0002631357,0.0011582165,0.020539213,0.00016300785,0.000080900405,0.00013902075],"genre_scores_gemma":[0.000047771293,0.9853901,0.0011006845,0.0006299731,0.0003458893,0.0074783703,0.00067799067,0.00013419322,0.0041950177],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9738314,0.00876337,0.011734008,0.002639677,0.0016977056,0.0013338034],"domain_scores_gemma":[0.9809975,0.010130189,0.0043013166,0.0023620469,0.001066293,0.0011426534],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_narrow"],"category_scores_codex":[0.04239784,0.001440558,0.02301936,0.0007856688,0.00032412444,0.00018326234,0.0004848212,0.00068291597,0.00009906591],"category_scores_gemma":[0.042806912,0.0009797942,0.002184104,0.0016127846,0.0018830048,0.00029303718,0.0014627675,0.0020481218,0.00008607705],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001640119,0.0004037996,0.0034754474,0.61603856,0.0024836843,0.00010638847,0.000019620165,1.1161169e-9,6.765963e-7,0.000047830603,0.0096185,0.36778906],"study_design_scores_gemma":[0.00064948614,0.0006579158,0.0008114754,0.46109417,0.022160497,0.000061011757,0.000015488811,7.5385356e-7,9.666925e-7,0.000020965506,0.5141077,0.00041956967],"about_ca_topic_score_codex":0.00002327593,"about_ca_topic_score_gemma":0.0000072843136,"teacher_disagreement_score":0.5044892,"about_ca_system_score_codex":0.0001646762,"about_ca_system_score_gemma":0.0008996948,"threshold_uncertainty_score":0.9998344},"labels":[],"label_agreement":null},{"id":"W4410493616","doi":"10.1002/ehf2.15294","title":"SGLT2 Inhibitor with and without ALDosterone AntagonIst for Heart Failure with Preserved Ejection Fraction: Design Paper","year":2025,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Fundação para a Ciência e a Tecnologia; AstraZeneca","keywords":"Heart failure; Aldosterone; Ejection fraction; Medicine; Antagonist; Internal medicine; Cardiology; Pharmacology; Receptor","score_opus":0.012721468352696587,"score_gpt":0.25562958037853645,"score_spread":0.24290811202583987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410493616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7021599,0.0010467891,0.033423793,0.24493252,0.0005536473,0.014351342,0.000041985873,0.0009384228,0.0025516124],"genre_scores_gemma":[0.8756238,0.000013110766,0.10998587,0.0025973062,0.0003096625,0.0007338508,0.00010389781,0.000066384186,0.010566099],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862266,0.000057061745,0.0002065236,0.0005048669,0.00024721277,0.00036168477],"domain_scores_gemma":[0.9992184,0.000067657864,0.00005646406,0.0003762423,0.00013786607,0.000143338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019040526,0.00029328352,0.00044816438,0.00014510921,0.00027995705,0.00012699464,0.00004525608,0.00012515706,0.00009193406],"category_scores_gemma":[0.00002182141,0.00020643436,0.000060867522,0.00026416229,0.00009978087,0.00035610213,0.000040020524,0.00018685643,0.000020236075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037796735,0.00066034356,0.4290829,0.00091237,0.0011495014,0.000014365678,0.000118771946,0.00003824992,0.01854677,0.00029926992,0.544406,0.0009918005],"study_design_scores_gemma":[0.008564336,0.0031903172,0.032685414,0.00073255535,0.0007239397,0.00003223196,0.00061553845,0.00015787256,0.015583138,0.000055130182,0.9373466,0.00031293152],"about_ca_topic_score_codex":0.000049379174,"about_ca_topic_score_gemma":0.00024271596,"teacher_disagreement_score":0.3963975,"about_ca_system_score_codex":0.000091984824,"about_ca_system_score_gemma":0.00011090503,"threshold_uncertainty_score":0.8418149},"labels":[],"label_agreement":null},{"id":"W4410502297","doi":"10.1093/sleep/zsaf090.1310","title":"1310 Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight","year":2025,"lang":"en","type":"article","venue":"SLEEP","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Obstructive sleep apnea; Receipt; Glucagon-like peptide 1 receptor; Internal medicine; Sleep (system call); Endocrinology; Sleep apnea; Agonist; Receptor; World Wide Web","score_opus":0.0035327177513800124,"score_gpt":0.20847559471171656,"score_spread":0.20494287696033656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410502297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432297,0.0002760292,0.000077188415,0.0002358479,0.0005503633,0.00083568686,0.00001987191,0.000057153735,0.013624903],"genre_scores_gemma":[0.993883,0.000045986995,0.0008741351,0.00015306204,0.00004476,0.0000704623,0.0001811478,0.000024411775,0.0047230474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879587,0.00003196122,0.00027360063,0.0003220398,0.00027517296,0.00030137534],"domain_scores_gemma":[0.9992047,0.00003545094,0.00014536775,0.00034067273,0.00015872155,0.000115076444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000704958,0.0002426664,0.00041621155,0.00017791872,0.000083799576,0.000025873243,0.00010249551,0.00007745893,0.00010880175],"category_scores_gemma":[0.000023336604,0.0001824717,0.00006969915,0.0003010449,0.00021316555,0.00016839648,0.00011386163,0.00011357046,0.000014898923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045631913,0.0003983524,0.92166615,0.00023094848,0.0007395492,0.0000060168077,0.0004121811,0.0000025118702,0.00008410294,0.0004894752,0.0016596649,0.07385476],"study_design_scores_gemma":[0.0060774824,0.00071139494,0.9788249,0.00035508335,0.0007474509,4.26743e-7,0.0004941482,0.00009243796,0.0025773817,0.00018508841,0.009692085,0.00024209455],"about_ca_topic_score_codex":0.00006688715,"about_ca_topic_score_gemma":0.000030588864,"teacher_disagreement_score":0.07361266,"about_ca_system_score_codex":0.00009282921,"about_ca_system_score_gemma":0.000017097016,"threshold_uncertainty_score":0.744098},"labels":[],"label_agreement":null},{"id":"W4410518946","doi":"10.1016/j.revmed.2025.05.010","title":"Chez les personnes avec diabète de type 2 à risque cardiovasculaire élevé, est-ce que le sémaglutide oral est efficace et sécuritaire pour diminuer les évènements cardiovasculaires majeurs comparativement au placébo ?","year":2025,"lang":"fr","type":"letter","venue":"La Revue de Médecine Interne","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine","score_opus":0.018527537113942633,"score_gpt":0.26857841224481327,"score_spread":0.25005087513087065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410518946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7218752,0.029568844,0.004984141,0.17822622,0.003991316,0.005044744,0.00048404178,0.00062558154,0.055199906],"genre_scores_gemma":[0.8272275,0.002639107,0.0024133553,0.010610013,0.005320396,0.00082071865,0.0019650855,0.00038987256,0.14861397],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913457,0.0019598366,0.0013985494,0.0020328793,0.0010691466,0.0021938744],"domain_scores_gemma":[0.99561554,0.00089010375,0.0005581249,0.00199384,0.0004142415,0.0005281287],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019474027,0.0019718003,0.003420455,0.00081034127,0.0004564848,0.00029812273,0.0011762186,0.00095205277,0.00045830317],"category_scores_gemma":[0.00044938203,0.001930617,0.0024655908,0.0007450184,0.000667171,0.00025770714,0.00094023166,0.0022679532,0.00034813225],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009683456,0.0036978854,0.3918108,0.0113482205,0.042331845,0.009578339,0.009711853,0.0070556905,0.00025694887,0.0058809253,0.44892102,0.0684381],"study_design_scores_gemma":[0.011983682,0.00068811706,0.18292361,0.014350756,0.010751268,0.00030791512,0.0022557892,0.002251468,0.0012629979,0.00014186822,0.7712475,0.0018349848],"about_ca_topic_score_codex":0.022655912,"about_ca_topic_score_gemma":0.01010789,"teacher_disagreement_score":0.32232648,"about_ca_system_score_codex":0.0034008774,"about_ca_system_score_gemma":0.0013693105,"threshold_uncertainty_score":0.9993025},"labels":[],"label_agreement":null},{"id":"W4410559593","doi":"10.1093/ehjcvp/pvaf023","title":"Management of dyslipidaemia in patients with comorbidities—facing the challenge: type 1 diabetes mellitus","year":2025,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Lipid profile; Randomized controlled trial; Type 2 Diabetes Mellitus; Clinical trial; Endocrinology","score_opus":0.036105513960645784,"score_gpt":0.3124212168235835,"score_spread":0.2763157028629377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410559593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005963012,0.98968863,0.000013781273,0.00009077664,0.0006539571,0.0021349299,0.000011551978,0.000035500943,0.0067745666],"genre_scores_gemma":[0.00065752084,0.9977971,0.00018635085,0.00021056131,0.00033327978,0.00003713274,0.00005551834,0.0001346668,0.0005878982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99599886,0.0012575622,0.0008696073,0.00046177884,0.00089356804,0.0005186075],"domain_scores_gemma":[0.99836636,0.000103696824,0.0003062888,0.0008750583,0.00020649952,0.00014209628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019170674,0.000598632,0.0023335468,0.00045609756,0.00013353038,0.00006907125,0.00038784882,0.00006320703,0.00012260782],"category_scores_gemma":[0.000010125049,0.00035226223,0.0018474789,0.0006869327,0.00008570858,0.00009589031,0.00012730218,0.0007790877,0.000043310294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007404854,0.00034655636,0.00047926538,0.013715441,0.022400394,0.0003117993,0.000077831544,0.000038398986,1.8770002e-7,0.000014614012,0.0019197945,0.96062165],"study_design_scores_gemma":[0.0040883166,0.00037161566,0.0013074838,0.027141724,0.007919668,0.000012343421,0.000024606317,0.0000013165076,0.000004921058,0.0000026831754,0.95882404,0.00030129787],"about_ca_topic_score_codex":0.0000020128077,"about_ca_topic_score_gemma":1.4824718e-7,"teacher_disagreement_score":0.96032035,"about_ca_system_score_codex":0.00023656272,"about_ca_system_score_gemma":0.000104360915,"threshold_uncertainty_score":0.99989295},"labels":[],"label_agreement":null},{"id":"W4410617194","doi":"10.3389/fphar.2025.1572289","title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review","year":2025,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China; University of Manchester","keywords":"Dapagliflozin; Ejection fraction; Medicine; Heart failure; Cochrane Library; Internal medicine; Diabetes mellitus; China; Cardiology; Meta-analysis; Type 2 diabetes; Political science","score_opus":0.050065838962829276,"score_gpt":0.40187578129862617,"score_spread":0.3518099423357969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410617194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.7969603e-7,0.95955193,0.00046465817,0.00017239929,0.0014089794,0.038221877,0.000086718705,0.000013489203,0.00007927318],"genre_scores_gemma":[0.0000031193772,0.9761841,0.0009913344,0.00014162305,0.000041616036,0.021756165,0.0001486601,0.000027310782,0.0007060575],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975879,0.0007023245,0.0009732274,0.00033071413,0.0001332828,0.000272505],"domain_scores_gemma":[0.99732614,0.0016320978,0.0004794761,0.0004324644,0.00008442694,0.00004541094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075786916,0.00038535794,0.005736698,0.00036412085,0.000023884739,0.0000026902997,0.00021818056,0.00014866519,0.000024111829],"category_scores_gemma":[0.00009321317,0.00021799703,0.00097635254,0.00048432514,0.0001073872,0.000018998318,0.0000384672,0.0000978797,0.0000025691197],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076858494,0.0006796508,0.00001871753,0.8680368,0.004902926,0.0000057271504,0.000015227931,7.5164166e-7,7.0760683e-7,0.000030971085,0.04685172,0.07937994],"study_design_scores_gemma":[0.0018278203,0.000580394,0.0000012683809,0.34930092,0.044961285,0.0000023775185,0.000013993457,0.0000093219205,0.000030305771,0.000009425089,0.6031755,0.00008735394],"about_ca_topic_score_codex":0.0000053426347,"about_ca_topic_score_gemma":0.0000012359482,"teacher_disagreement_score":0.5563238,"about_ca_system_score_codex":0.00051683455,"about_ca_system_score_gemma":0.00027972317,"threshold_uncertainty_score":0.8889661},"labels":[],"label_agreement":null},{"id":"W4410758704","doi":"10.1515/jbcpp-2025-0026","title":"The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers","year":2025,"lang":"en","type":"article","venue":"Journal of Basic and Clinical Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Semaglutide; Bioavailability; Pharmacokinetics; Pharmacology; Medicine; Oral administration; Adverse effect; Endocrinology","score_opus":0.04382635804144108,"score_gpt":0.4048250971834265,"score_spread":0.36099873914198544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410758704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842233,0.006339915,0.0000038673747,0.004480856,0.00033545026,0.00020326045,0.0000027299016,0.0000023151176,0.00020926293],"genre_scores_gemma":[0.9769698,0.020408276,0.000084105726,0.0023282147,0.00004713599,0.0000023171935,9.541437e-7,0.0000024235965,0.00015676755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889785,0.0002229334,0.0005376983,0.00014476084,0.00004383776,0.00015291582],"domain_scores_gemma":[0.9986324,0.00096492446,0.00019574101,0.000046224017,0.000063355226,0.00009738133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050878775,0.00010331779,0.0005697196,0.00007351709,0.00006177007,0.0000037999112,0.000042208474,0.00007823526,0.000018765988],"category_scores_gemma":[0.000034205295,0.00006393278,0.000047097194,0.00007446647,0.0008909195,0.000023010392,0.00007191791,0.0003140732,3.187962e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058650024,0.0033462325,0.6099254,0.0011636764,0.0061157765,0.00035476874,0.0011042166,0.000025587275,0.047518943,0.0032208634,0.03212166,0.23645288],"study_design_scores_gemma":[0.024914725,0.014369944,0.9114702,0.00014144836,0.0024095068,0.00017490878,0.0007940419,0.0017753596,0.0015237778,0.003292969,0.038943313,0.00018983365],"about_ca_topic_score_codex":0.000012310277,"about_ca_topic_score_gemma":0.000015108472,"teacher_disagreement_score":0.3015448,"about_ca_system_score_codex":0.000010930842,"about_ca_system_score_gemma":0.00005336884,"threshold_uncertainty_score":0.32826298},"labels":[],"label_agreement":null},{"id":"W4410794116","doi":"10.2196/72577","title":"A Remotely Delivered GLP-1RA–Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation","year":2025,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Service (business); Medicine; Operations management; Computer science; Engineering; Business; World Wide Web","score_opus":0.028640009477000627,"score_gpt":0.3747843021241822,"score_spread":0.34614429264718155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410794116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7803282,0.000119673095,0.000060865405,0.001559056,0.000073278134,0.008250489,0.00000749591,0.00012325731,0.20947765],"genre_scores_gemma":[0.99379295,0.00013985054,0.0009595498,0.0001696622,0.00005261496,0.0017898737,0.0001577508,0.000022624681,0.002915148],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99649525,0.0003193918,0.00038181452,0.00050609355,0.0015888565,0.000708595],"domain_scores_gemma":[0.9980308,0.00009707601,0.00009870135,0.0004876201,0.0011599715,0.00012584402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014670438,0.00024392671,0.00038024818,0.0010703801,0.00021336465,0.00010900226,0.00021422071,0.00008976948,0.00026308268],"category_scores_gemma":[0.00006470752,0.00019394331,0.000064830114,0.00284404,0.000112102,0.00041135636,0.0003323646,0.00043421084,0.00013142293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004135448,0.012149083,0.19707564,0.006402678,0.0027652648,0.00055211596,0.02645769,0.000020337311,0.00005931427,0.014573095,0.023087278,0.71272206],"study_design_scores_gemma":[0.0064782393,0.0016511681,0.9678996,0.004333227,0.00016647096,0.000002357069,0.005818548,0.009328168,0.00017158501,0.00080726994,0.0031400595,0.00020330558],"about_ca_topic_score_codex":0.00022064292,"about_ca_topic_score_gemma":0.0008167825,"teacher_disagreement_score":0.77082396,"about_ca_system_score_codex":0.001803344,"about_ca_system_score_gemma":0.00019131185,"threshold_uncertainty_score":0.7908779},"labels":[],"label_agreement":null},{"id":"W4410831202","doi":"10.1038/s41573-025-01231-3","title":"Author Correction: GLP-1-based therapies for diabetes, obesity and beyond","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Diabetes mellitus; Obesity; Medicine; Pharmacology; Intensive care medicine; Bioinformatics; Internal medicine; Endocrinology; Biology","score_opus":0.0187396303985615,"score_gpt":0.3302719402862983,"score_spread":0.3115323098877368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410831202","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000051095526,0.9861618,0.00006722483,0.0008006557,0.0025454424,0.007974843,0.00017644383,0.0000929669,0.0021755],"genre_scores_gemma":[0.0000043309374,0.9339197,0.0006598065,0.001834432,0.00041520747,0.0018576263,0.0014544533,0.000064114625,0.059790324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997399,0.00023079492,0.00078739965,0.00086583005,0.00027356594,0.0004434578],"domain_scores_gemma":[0.9979127,0.0005934748,0.000488877,0.00079166854,0.0000776873,0.00013558201],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075727573,0.0008375805,0.0038593025,0.00035671217,0.00016025493,0.00016046972,0.00021523712,0.0006141429,0.000032189306],"category_scores_gemma":[0.00033908797,0.00054019317,0.0015198351,0.0005332252,0.00008377239,0.0001980964,0.00011325209,0.00081060384,0.000020718417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010586925,0.00019187946,0.00007065898,0.10394822,0.0005357926,0.0000036744605,0.000009188676,3.15412e-8,4.9131486e-8,0.00023706145,0.17541258,0.7195803],"study_design_scores_gemma":[0.00058781705,0.00011282776,0.000031722102,0.053926103,0.009004974,0.0000015968347,0.0000054714696,0.000005166919,0.0000021460953,0.000063533895,0.935854,0.00040463213],"about_ca_topic_score_codex":0.0000015614962,"about_ca_topic_score_gemma":0.000007849603,"teacher_disagreement_score":0.7604414,"about_ca_system_score_codex":0.00025095404,"about_ca_system_score_gemma":0.00037356542,"threshold_uncertainty_score":0.99970496},"labels":[],"label_agreement":null},{"id":"W4410839673","doi":"10.21037/tau-2024-755","title":"Patient-centered outcomes and preference between darolutamide and enzalutamide: insights from the ODENZA trial","year":2025,"lang":"en","type":"letter","venue":"Translational Andrology and Urology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Enzalutamide; Preference; Medicine; Psychology; Internal medicine; Androgen receptor; Prostate cancer; Mathematics; Statistics","score_opus":0.03551947120887641,"score_gpt":0.2558531512864411,"score_spread":0.22033368007756468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410839673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.539115,0.0043735984,0.000041184565,0.45398626,0.00026923657,0.00096025685,0.00023684603,0.00003495367,0.0009826444],"genre_scores_gemma":[0.67247397,0.0004947731,0.000088517554,0.32372475,0.0006021534,0.00009506483,0.0016853656,0.000017713817,0.0008176771],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837613,0.00022452281,0.0003776593,0.00058020354,0.00016289276,0.00027861816],"domain_scores_gemma":[0.99829125,0.0012871163,0.000114894305,0.00021440744,0.000032610205,0.000059719994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007228957,0.00033910075,0.00072691776,0.00012779278,0.00016825048,0.000023971741,0.0000843601,0.00071526086,0.00006791846],"category_scores_gemma":[0.000027918195,0.00022037965,0.00008084353,0.00004863815,0.00043475712,0.000047334655,0.00007958432,0.00074519526,0.000004220409],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019159418,0.00030217323,0.7533085,0.00032454205,0.0071284203,0.00039607668,0.0015960705,0.0000026953016,0.00001444592,0.003194224,0.159427,0.05514645],"study_design_scores_gemma":[0.02983201,0.0014942794,0.44358635,0.000032930853,0.0025334624,0.000014162622,0.000008178252,0.000043121403,0.0000026158998,0.016764296,0.5054468,0.00024181372],"about_ca_topic_score_codex":0.00006451415,"about_ca_topic_score_gemma":0.00006739434,"teacher_disagreement_score":0.34601977,"about_ca_system_score_codex":0.000007116313,"about_ca_system_score_gemma":0.000053669708,"threshold_uncertainty_score":0.8986821},"labels":[],"label_agreement":null},{"id":"W4410878385","doi":"10.1016/j.jddst.2025.107112","title":"Enhanced semaglutide bioavailability via spray freeze dried powder for inhalation: Unveiling safety and broad potential applications","year":2025,"lang":"en","type":"article","venue":"Journal of Drug Delivery Science and Technology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Ningbo Municipal Bureau of Science and Technology","keywords":"Bioavailability; Spray drying; Semaglutide; Inhalation; Materials science; Nanotechnology; Chromatography; Chemistry; Pharmacology; Medicine; Anesthesia","score_opus":0.0044529955482735485,"score_gpt":0.2452868351868007,"score_spread":0.24083383963852714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410878385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97270274,0.0011781512,0.016872201,0.008020712,0.00012161149,0.0005446219,0.0000026607202,0.00003081993,0.0005265037],"genre_scores_gemma":[0.9949255,0.0002799252,0.0042200577,0.00020117815,0.00003072145,0.000013774162,0.0000014022311,0.0000030891288,0.0003243565],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990847,0.0000080310365,0.0003148822,0.00022152225,0.00017556688,0.00019531023],"domain_scores_gemma":[0.9989962,0.00005025616,0.0001572545,0.00017263387,0.00055617094,0.000067457615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006138509,0.000088330315,0.0002322225,0.0005920034,0.00023640846,0.000027454053,0.00012753236,0.00006264895,0.0000063266502],"category_scores_gemma":[0.00009864452,0.00007178126,0.000038383372,0.00078272156,0.00064137473,0.0001724197,0.00010080408,0.00011458566,0.0000011838931],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002970237,0.0003538791,0.019145772,0.00017419174,0.00022922416,0.000011384469,0.00012822358,0.000016253607,0.40164426,0.0054016677,0.0004690969,0.572129],"study_design_scores_gemma":[0.014416349,0.0019988841,0.06422529,0.00056504225,0.0018904577,0.00020945957,0.003657755,0.0050816196,0.80790484,0.040052816,0.059339628,0.0006578825],"about_ca_topic_score_codex":0.00000507947,"about_ca_topic_score_gemma":0.000009138354,"teacher_disagreement_score":0.57147115,"about_ca_system_score_codex":0.000089638015,"about_ca_system_score_gemma":0.00020399451,"threshold_uncertainty_score":0.2927155},"labels":[],"label_agreement":null},{"id":"W4410885131","doi":"10.1016/j.ajcnut.2025.04.023","title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Asian Studies Association","funders":"GoodRx; Life Sciences, University of California, Los Angeles; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Suomen Kardiologinen Seura; ReShape Lifesciences; Neurocrine Biosciences; Patient-Centered Outcomes Research Institute; National Association of Chain Drug Stores Foundation; Rockefeller Foundation","keywords":"Obesity; Medicine; Alternative medicine; Gerontology; Association (psychology); Family medicine; Internal medicine; Psychology; Pathology","score_opus":0.03100311026432109,"score_gpt":0.3478498890653775,"score_spread":0.31684677880105644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410885131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64327294,0.0018548373,0.0028662584,0.34751,0.00033250608,0.0036509254,0.00042125673,0.000024943132,0.00006633434],"genre_scores_gemma":[0.90409315,0.028498227,0.006126362,0.057042576,0.0032195332,0.0006332173,0.000113774375,0.000036864654,0.0002363268],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.995613,0.000749421,0.0018872848,0.00040246148,0.0009268078,0.000421024],"domain_scores_gemma":[0.980102,0.014929257,0.0027765303,0.0004950553,0.0015061811,0.00019096544],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0063284244,0.00034595595,0.0019891553,0.000086429245,0.0006806729,0.00003594734,0.00048715397,0.00007686194,0.000030250365],"category_scores_gemma":[0.002158286,0.00016065399,0.0015050656,0.0009522401,0.004672896,0.00012059993,0.000100428995,0.0005581419,8.954155e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007224369,0.0033258845,0.09613974,0.00024363275,0.004327213,0.000002923528,0.0014016755,0.0000014143266,0.00018233691,0.0035755595,0.8652482,0.018327072],"study_design_scores_gemma":[0.038817424,0.015908808,0.6639326,0.0015099497,0.0038955861,0.000016536365,0.04929349,0.00020284965,0.00015925511,0.024745949,0.2012001,0.00031744404],"about_ca_topic_score_codex":0.00037733064,"about_ca_topic_score_gemma":0.000050354465,"teacher_disagreement_score":0.6640481,"about_ca_system_score_codex":0.00022543667,"about_ca_system_score_gemma":0.00032075727,"threshold_uncertainty_score":0.9980358},"labels":[],"label_agreement":null},{"id":"W4410893328","doi":"10.1002/oby.24336","title":"Nutritional priorities to support <scp>GLP</scp>‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","year":2025,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Asian Studies Association","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Medicine; Weight loss; Psychological intervention; Obesity; Lifestyle medicine; Gerontology; Physical therapy; Family medicine; Psychiatry; Internal medicine","score_opus":0.015376090372305813,"score_gpt":0.2697637707156683,"score_spread":0.2543876803433625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410893328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85365915,0.0023865853,0.0019081184,0.13272068,0.0002777402,0.007374437,0.0010260916,0.00009839085,0.0005488082],"genre_scores_gemma":[0.9304191,0.00816581,0.0024132093,0.05019396,0.0015869831,0.0021256513,0.0003945587,0.000057038214,0.0046436857],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9967439,0.00038254794,0.00074785965,0.00062897,0.00088184053,0.00061485206],"domain_scores_gemma":[0.9891937,0.008170748,0.00080848497,0.00083681656,0.0008398898,0.00015037846],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0034891942,0.00046810575,0.0013205307,0.00006522601,0.0015092109,0.00004839609,0.00056581595,0.0001062023,0.000039221584],"category_scores_gemma":[0.0012235347,0.00022547618,0.00083853974,0.00090342254,0.002418203,0.00010677484,0.00023952808,0.00036563826,0.0000033448089],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003522538,0.0011002561,0.21699189,0.00025371436,0.0021341625,0.0000010705726,0.0033449065,0.0000010421674,0.00028013077,0.008728239,0.7659875,0.0008248236],"study_design_scores_gemma":[0.011539293,0.0014509585,0.7884818,0.00035649398,0.0019598235,0.0000025377706,0.026624499,0.00018628786,0.0005507508,0.012733379,0.15594833,0.00016590176],"about_ca_topic_score_codex":0.0012805738,"about_ca_topic_score_gemma":0.0002867303,"teacher_disagreement_score":0.6100392,"about_ca_system_score_codex":0.00038720254,"about_ca_system_score_gemma":0.00028925293,"threshold_uncertainty_score":0.99979067},"labels":[],"label_agreement":null},{"id":"W4410901256","doi":"10.1111/dom.16478","title":"Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The <scp>DAPASALT</scp> trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca; AstraZeneca Mölndal","keywords":"Dapagliflozin; Medicine; Type 2 diabetes; Kidney disease; Blood pressure; Diabetes mellitus; Internal medicine; Excretion; Endocrinology; Sodium; Urology","score_opus":0.0032523616165991685,"score_gpt":0.19932043480933004,"score_spread":0.19606807319273087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410901256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702271,0.02705545,7.353283e-7,0.00016514408,0.0002574669,0.0020362556,0.00005178595,0.00003381945,0.00017219562],"genre_scores_gemma":[0.99582803,0.0017153766,0.000035031844,0.0005675095,0.000096647826,0.00013499503,0.000107427324,0.00002037734,0.0014945815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984989,0.00013503614,0.00024089229,0.00041041514,0.00026144728,0.00045331416],"domain_scores_gemma":[0.99893165,0.00031202848,0.00010830007,0.00029639955,0.00008658916,0.00026504137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021875594,0.00028259348,0.00059293053,0.00020372581,0.00011330401,0.000051687453,0.000082883715,0.00008752835,0.000009093046],"category_scores_gemma":[0.0005161163,0.00017348633,0.000047874444,0.0003160913,0.0002217312,0.00012687172,0.00012670316,0.00016175146,0.0000015970912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012785399,0.0016222559,0.9851446,0.002276395,0.0013810056,0.000003970789,0.00023625296,0.000002053784,0.00017404124,0.00074011367,0.0017092595,0.0054315035],"study_design_scores_gemma":[0.039040696,0.0012999721,0.93013334,0.0005147246,0.004659339,1.7500458e-8,0.000015341442,0.0000741893,0.0014655028,0.00015550926,0.022559335,0.00008200756],"about_ca_topic_score_codex":0.000016251372,"about_ca_topic_score_gemma":0.0000067871097,"teacher_disagreement_score":0.055011243,"about_ca_system_score_codex":0.000012950239,"about_ca_system_score_gemma":0.000121074634,"threshold_uncertainty_score":0.7074567},"labels":[],"label_agreement":null},{"id":"W4410967242","doi":"10.7759/cureus.85220","title":"The Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Outcomes in Cancer Patients With Type 2 Diabetes Mellitus: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Dapagliflozin; Type 2 Diabetes Mellitus; Cotransporter; Cancer; Type 2 diabetes; Internal medicine; Endocrinology; Sodium","score_opus":0.010297452910478257,"score_gpt":0.27852753429206295,"score_spread":0.2682300813815847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410967242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047209222,0.9873471,1.5937607e-7,0.000019598981,0.00041944184,0.011367681,0.00003834944,0.000029965522,0.0003055722],"genre_scores_gemma":[0.00021660201,0.99676627,0.0000043954074,0.00006437705,0.000026046822,0.002316495,0.00020267183,0.000049376064,0.00035374792],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973135,0.00033111632,0.0009532646,0.00042380323,0.0006304588,0.00034785157],"domain_scores_gemma":[0.99766517,0.0005719295,0.00043034344,0.0011624227,0.000098228134,0.00007192242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006899193,0.0006106697,0.0057375073,0.00015175175,0.00004240284,0.000016155669,0.0002639332,0.0001374784,0.0000115850435],"category_scores_gemma":[0.00022010601,0.00026609434,0.0012112362,0.0005367575,0.000059871985,0.00003649569,0.000045215093,0.00022680893,0.000017043396],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016453325,0.00017560998,0.0030170637,0.8865401,0.008140527,0.0000119353645,0.000010255926,2.656853e-7,6.3541066e-9,0.000006964993,0.00024613956,0.101834655],"study_design_scores_gemma":[0.0011442865,0.0011430763,0.00015670215,0.84407705,0.048626747,1.2486652e-7,0.0000021913665,1.9141272e-7,0.0000062987715,6.7441334e-7,0.10461923,0.00022343748],"about_ca_topic_score_codex":0.00003218806,"about_ca_topic_score_gemma":0.000026923237,"teacher_disagreement_score":0.10437309,"about_ca_system_score_codex":0.00031916233,"about_ca_system_score_gemma":0.00012739647,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W4410979547","doi":"10.1016/j.obpill.2025.100181","title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","year":2025,"lang":"en","type":"review","venue":"Obesity Pillars","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Asian Studies Association","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Suomen Kardiologinen Seura; National Institutes of Health","keywords":"Medicine; Weight loss; Psychological intervention; Obesity; Medical nutrition therapy; Weight management; Gerontology; Intensive care medicine; Psychiatry; Internal medicine","score_opus":0.027997200059259056,"score_gpt":0.30619495596601914,"score_spread":0.2781977559067601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410979547","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011728476,0.86372846,0.0006254736,0.09191226,0.0006071858,0.025185721,0.005688887,0.00015437085,0.00036918244],"genre_scores_gemma":[0.0013501246,0.97341126,0.0010208595,0.01629724,0.0017235404,0.0032218408,0.0011467629,0.00008152902,0.0017468308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948113,0.00076460955,0.0013895591,0.0009530442,0.001296861,0.0007846554],"domain_scores_gemma":[0.98505455,0.010530933,0.001958433,0.0012781171,0.00097031996,0.00020761837],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0043520383,0.0009379262,0.0040826146,0.00011666669,0.0015923629,0.00006578433,0.00093127316,0.00023991666,0.00007145113],"category_scores_gemma":[0.001123439,0.00042685456,0.002461863,0.0013125736,0.002863709,0.000090238056,0.00037251168,0.0006316238,0.000004600485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043096568,0.0013218161,0.009006778,0.007869199,0.007367962,0.0000031449572,0.001932192,3.2434875e-7,0.000004190975,0.0050287414,0.9359818,0.031052848],"study_design_scores_gemma":[0.007089643,0.0016595237,0.024109054,0.005568113,0.009250246,0.0000076532615,0.006893767,0.00001940462,0.000006803625,0.0034445482,0.94149035,0.00046089198],"about_ca_topic_score_codex":0.0008542113,"about_ca_topic_score_gemma":0.00019952818,"teacher_disagreement_score":0.109682836,"about_ca_system_score_codex":0.0007278999,"about_ca_system_score_gemma":0.00075423456,"threshold_uncertainty_score":0.9998499},"labels":[],"label_agreement":null},{"id":"W4410984830","doi":"10.32322/jhsm.1668518","title":"A decade of SGLT2 inhibitors in cardiovascular science: a bibliometric review","year":2025,"lang":"en","type":"review","venue":"Journal of Health Sciences and Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Data science; Computer science","score_opus":0.0800511045781847,"score_gpt":0.4480683438417733,"score_spread":0.3680172392635886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410984830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000418096,0.9946626,0.000008396639,0.0024443816,0.00053334027,0.0011273134,0.0000012619927,0.0000032200817,0.0011777036],"genre_scores_gemma":[0.00007573719,0.9986253,0.0003234782,0.00071828614,0.0001434539,0.00001075598,0.0000015595932,0.0000060617563,0.00009541299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953663,0.00015360679,0.0020535246,0.00033047813,0.0016863915,0.00040974768],"domain_scores_gemma":[0.9975083,0.0002378782,0.0014080581,0.00025590693,0.00028039224,0.0003094544],"candidate_categories":["bibliometrics"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.01662727,0.00024294728,0.00448636,0.040722392,0.00010909014,0.0000123530535,0.0003345517,0.00006566025,0.000015945776],"category_scores_gemma":[0.001358772,0.00012723407,0.0004596957,0.068547115,0.0008855963,0.00015283086,0.000106757565,0.0003210285,5.487494e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000021191684,0.000060121136,0.00015426925,0.1235833,0.000117818985,0.000026281992,0.000030203142,1.5792526e-7,7.683225e-8,0.000044957596,0.002666668,0.873314],"study_design_scores_gemma":[0.0006648969,0.0014505957,0.00036008123,0.37432864,0.0015761331,0.00012133529,0.000069839356,7.8080365e-7,2.2615922e-7,0.000017343,0.6213489,0.000061221624],"about_ca_topic_score_codex":0.00008917592,"about_ca_topic_score_gemma":0.0000017699839,"teacher_disagreement_score":0.8732528,"about_ca_system_score_codex":0.00023297846,"about_ca_system_score_gemma":0.003969518,"threshold_uncertainty_score":0.9701502},"labels":[],"label_agreement":null},{"id":"W4410994250","doi":"10.1016/j.cmet.2025.05.001","title":"GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction","year":2025,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"STRIDE; Arterial disease; Peripheral; Cardiology; Medicine; Physical medicine and rehabilitation; Internal medicine; Vascular disease","score_opus":0.007115037750472024,"score_gpt":0.24495202257244142,"score_spread":0.23783698482196938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410994250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7486618,0.022248976,0.001365004,0.010486168,0.0025279818,0.004685503,0.00003078902,0.00017670718,0.20981707],"genre_scores_gemma":[0.91140074,0.0004035146,0.0006142336,0.0022330421,0.00029146872,0.00066446705,0.0000860337,0.00001715492,0.08428933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992249,0.000044814766,0.00016178677,0.00021563628,0.00012595824,0.00022689023],"domain_scores_gemma":[0.9995303,0.000063261476,0.000033362445,0.00029425553,0.000028199387,0.000050594666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022206745,0.00012448707,0.00022043152,0.000118989585,0.00007481813,0.00003838516,0.00008459627,0.000031918426,0.00008153985],"category_scores_gemma":[0.000034577035,0.00008049425,0.00012284523,0.00023710432,0.000023620272,0.00007058788,0.00002174282,0.00006960815,0.000011487487],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030029032,0.006604869,0.038611986,0.0027091769,0.0013660921,0.00032944776,0.0020019242,0.00012498586,0.010570435,0.08277225,0.6647147,0.18719123],"study_design_scores_gemma":[0.0026689386,0.00003553459,0.1138248,0.000059757946,0.00065244234,3.6081224e-7,0.000108873406,0.00029704688,0.0015102053,0.0019620957,0.87879056,0.00008938244],"about_ca_topic_score_codex":0.000017382621,"about_ca_topic_score_gemma":0.000015687945,"teacher_disagreement_score":0.21407586,"about_ca_system_score_codex":0.000047179972,"about_ca_system_score_gemma":0.000044054545,"threshold_uncertainty_score":0.328246},"labels":[],"label_agreement":null},{"id":"W4411011164","doi":"10.1016/j.rmed.2025.108197","title":"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review","year":2025,"lang":"en","type":"review","venue":"Respiratory Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Physicians' Services Incorporated Foundation","keywords":"Medicine; Asthma; COPD; Glucagon-like peptide-1; Diabetes mellitus; Glucagon-like peptide 1 receptor; Asthma exacerbations; B2 receptor; Internal medicine; Receptor; Intensive care medicine; Agonist; Endocrinology; Type 2 diabetes","score_opus":0.020605162006407666,"score_gpt":0.30094341447111245,"score_spread":0.2803382524647048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411011164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008042952,0.9874165,0.000002954686,0.00042939233,0.00015538189,0.009349267,0.000024872825,0.000084792366,0.0024563754],"genre_scores_gemma":[0.000010783684,0.990621,0.00009262472,0.0026089973,0.00013922797,0.0024156605,0.00024597291,0.00007359216,0.0037921525],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962696,0.00040890003,0.0014392263,0.00087277975,0.00052797335,0.0004815646],"domain_scores_gemma":[0.99745697,0.0005956439,0.0005891733,0.0008871934,0.00013200985,0.00033899536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010886984,0.0008092213,0.005316662,0.00072343764,0.00008777058,0.000025251407,0.00016982133,0.00022886765,0.00009039992],"category_scores_gemma":[0.00073394243,0.0004934176,0.00016288961,0.0009815391,0.0002849507,0.00009485847,0.00013287774,0.00041672468,0.00003286979],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001788524,0.00009573786,0.00010928503,0.9175244,0.0005767319,0.000066872075,0.000083826475,1.4361003e-8,2.1786309e-7,0.00007637835,0.00967176,0.07177687],"study_design_scores_gemma":[0.0014759556,0.00066875684,0.000027961414,0.5650331,0.004851366,0.0000064027718,0.000051981722,0.000001084034,1.1007595e-7,0.0000013164341,0.42766398,0.0002180226],"about_ca_topic_score_codex":0.000010822449,"about_ca_topic_score_gemma":0.000039057853,"teacher_disagreement_score":0.41799223,"about_ca_system_score_codex":0.00029510556,"about_ca_system_score_gemma":0.0003757823,"threshold_uncertainty_score":0.99975175},"labels":[],"label_agreement":null},{"id":"W4411020975","doi":"10.2337/dc25-0154","title":"Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Human Genome Research Institute; National Heart, Lung, and Blood Institute; Novo Nordisk; Innovation and Technology Commission; European Commission; U.S. National Library of Medicine; U.S. Department of Veterans Affairs; Alnylam Pharmaceuticals; National Institutes of Health; Parexel; Janssen Pharmaceuticals; Yale University; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Propensity score matching; Internal medicine; Glucagon-like peptide 1 receptor; Retrospective cohort study; Liraglutide; Thyroid cancer; Dipeptidyl peptidase-4; Proportional hazards model; Type 2 diabetes; Cohort; Cohort study; Confounding; Oncology; Thyroid; Diabetes mellitus; Endocrinology; Confidence interval; Agonist; Receptor","score_opus":0.0033585240163333495,"score_gpt":0.22442946156982274,"score_spread":0.2210709375534894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411020975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770357,0.00065831206,0.0000033351296,0.00009639378,0.00011904749,0.0020576979,0.00009367616,0.0001005018,0.019835304],"genre_scores_gemma":[0.9975721,0.000040197232,0.00024876196,0.000117447,0.00003550597,0.00030271662,0.00014186541,0.000024471034,0.001516888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998691,0.000054415857,0.00023433544,0.00040498897,0.00033234342,0.0002829218],"domain_scores_gemma":[0.9989519,0.000039118004,0.00012992251,0.0005304196,0.00027790832,0.00007069617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014459732,0.00022235319,0.00060253707,0.00017976192,0.00008059298,0.000021080983,0.00011066466,0.00004357922,0.000056989134],"category_scores_gemma":[0.00007751562,0.00016434643,0.000110560824,0.00046683225,0.000078297264,0.000054191314,0.00008122501,0.00013837383,0.000040610077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009037551,0.000517241,0.99184734,0.00017039257,0.0018097128,0.000008633292,0.0008597376,0.0000022513293,0.00015403425,0.000118955526,0.0026532572,0.0017680926],"study_design_scores_gemma":[0.002715686,0.0025823875,0.9802395,0.00025728563,0.0015891126,5.4664362e-8,0.007603879,0.0000065186214,0.003884081,0.000037910402,0.0009422992,0.00014125853],"about_ca_topic_score_codex":0.000054100805,"about_ca_topic_score_gemma":0.000045468434,"teacher_disagreement_score":0.020536415,"about_ca_system_score_codex":0.00028494524,"about_ca_system_score_gemma":0.00006528111,"threshold_uncertainty_score":0.67018527},"labels":[],"label_agreement":null},{"id":"W4411043752","doi":"10.1007/s13300-025-01750-7","title":"Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease","year":2025,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer","keywords":"Medicine; Kidney disease; Internal medicine; Renal function; Type 2 diabetes; Diabetes mellitus; Incidence (geometry); Heart failure; Endocrinology","score_opus":0.008517939849199086,"score_gpt":0.2554512744432463,"score_spread":0.2469333345940472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411043752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905417,0.00548005,0.0000010548347,0.0021048961,0.00025364794,0.0010786274,0.000016498017,0.00006729315,0.00045626122],"genre_scores_gemma":[0.9836445,0.0017403305,0.00026207633,0.0021308677,0.00007789418,0.00009076309,0.00012775917,0.000043626653,0.011882174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864906,0.00004070682,0.0003071867,0.0003749042,0.00021586279,0.00041230756],"domain_scores_gemma":[0.9990478,0.000105250736,0.00009445468,0.00039863202,0.000058000755,0.00029582766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120784964,0.00029846944,0.00065117644,0.00027020782,0.000039498616,0.000033743472,0.00010059083,0.00006859327,0.000298591],"category_scores_gemma":[0.0000755792,0.0001925962,0.00007731282,0.00048179537,0.00012950652,0.00011965127,0.00005494023,0.00009923607,0.000011862071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040148318,0.00044024407,0.95692617,0.00030445066,0.0007631242,0.0000073557526,0.00009250031,0.0000020457153,0.0021969406,0.00012449888,0.008811671,0.029929498],"study_design_scores_gemma":[0.010003109,0.0019250944,0.8843657,0.0013210945,0.0003395416,5.21756e-8,0.00003355239,0.000043557062,0.02394282,0.00016327103,0.07751591,0.0003463029],"about_ca_topic_score_codex":0.000017646364,"about_ca_topic_score_gemma":0.000022377437,"teacher_disagreement_score":0.07256049,"about_ca_system_score_codex":0.00011742741,"about_ca_system_score_gemma":0.00045663453,"threshold_uncertainty_score":0.78538454},"labels":[],"label_agreement":null},{"id":"W4411049174","doi":"10.1016/j.hrtlng.2025.05.020","title":"Long-term effectiveness of SGLT2 inhibitors in type 2 diabetes patients with myocardial injury: A population-based study","year":2025,"lang":"en","type":"article","venue":"Heart & Lung","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Ministero dell’Istruzione, dell’Università e della Ricerca; Ministero della Salute","keywords":"Medicine; Type 2 diabetes; Term (time); Population; Internal medicine; Diabetes mellitus; Cardiology; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.004613764957439745,"score_gpt":0.26587470332485397,"score_spread":0.2612609383674142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411049174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747324,0.00009753305,0.0000027997608,0.000037294947,0.0002067065,0.0019057525,0.0000029502203,0.000029659486,0.00024404377],"genre_scores_gemma":[0.9996255,7.3172464e-7,0.000027556374,0.000078600344,0.000017353463,0.00009486895,0.00009445611,0.000013207333,0.000047748556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991349,0.00010519627,0.00018134796,0.0002066676,0.00020129838,0.00017060892],"domain_scores_gemma":[0.999539,0.00009593132,0.000037607664,0.0002086817,0.00008263823,0.00003611251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018612167,0.00012681827,0.00035090154,0.00024371826,0.000027500917,0.000010868925,0.000030556184,0.00003410036,0.000010567415],"category_scores_gemma":[0.00003732561,0.00010069522,0.000047313668,0.0004446172,0.00001558631,0.00005636707,0.000031302683,0.00005543993,0.0000028693132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057714386,0.0013371297,0.9961215,0.00039998323,0.00021709265,0.0000035439884,0.00003692962,0.00002265559,0.0000668437,0.000014792802,0.00008665887,0.0011157065],"study_design_scores_gemma":[0.004177598,0.0012755626,0.99271846,0.000758552,0.0002715869,8.315035e-9,0.000009842777,0.000030136656,0.00064937177,0.00000565978,0.000025219013,0.00007798129],"about_ca_topic_score_codex":0.00006693968,"about_ca_topic_score_gemma":0.000038429553,"teacher_disagreement_score":0.0036004542,"about_ca_system_score_codex":0.000120983874,"about_ca_system_score_gemma":0.00005275234,"threshold_uncertainty_score":0.4106232},"labels":[],"label_agreement":null},{"id":"W4411086140","doi":"10.1016/j.endmts.2025.100251","title":"Sodium-glucose cotransporter 2 inhibitors in chronic kidney disease: A review of current evidence and clinical implications","year":2025,"lang":"en","type":"review","venue":"Endocrine and Metabolic Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Shaqra University","keywords":"Cotransporter; Kidney disease; Medicine; Disease; Internal medicine; Endocrinology; Sodium; Chemistry","score_opus":0.07131714555784202,"score_gpt":0.44061981719304244,"score_spread":0.3693026716352004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411086140","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000076183875,0.99653685,0.0000056142485,0.0007342537,0.00025347125,0.002092459,0.00004556183,0.000017949042,0.00023762838],"genre_scores_gemma":[0.0001590723,0.9986602,0.000083595936,0.00032884878,0.00011384945,0.00031178957,0.000053554348,0.0000099608305,0.0002790922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752206,0.00008322128,0.0009830645,0.00073060644,0.000325728,0.00035534843],"domain_scores_gemma":[0.9983479,0.00018431403,0.00027233825,0.0006120027,0.00010047895,0.00048299553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083928194,0.00030312035,0.0017255532,0.0004622827,0.000056048124,0.000021670565,0.00024835631,0.000029329118,0.000025053037],"category_scores_gemma":[0.0008813273,0.00021287467,0.00028548925,0.0013442134,0.00056667003,0.00018626604,0.00022961237,0.00023605874,0.0000045265224],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000030653343,0.0001402752,0.0015261703,0.107993245,0.00004299901,0.0000075605208,0.000003823842,3.832812e-9,9.905034e-7,0.0012455158,0.00070561975,0.88833076],"study_design_scores_gemma":[0.0003839611,0.000051216703,0.0061995722,0.2105378,0.0031602432,0.000004584535,7.383818e-7,0.0000010762168,0.0000038347816,0.000022756698,0.77950674,0.00012745277],"about_ca_topic_score_codex":0.000012906169,"about_ca_topic_score_gemma":0.000004142859,"teacher_disagreement_score":0.88820326,"about_ca_system_score_codex":0.00007817289,"about_ca_system_score_gemma":0.0027395021,"threshold_uncertainty_score":0.8680777},"labels":[],"label_agreement":null},{"id":"W4411100032","doi":"10.1186/s12933-025-02781-x","title":"Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes","year":2025,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Eli Lilly and Company","keywords":"Medicine; Internal medicine; Dulaglutide; Endocrinology; Diabetes mellitus; Type 2 diabetes; Glycemic; Overweight; Lipid profile; Placebo; Obesity; Glucagon-like peptide 1 receptor; Exenatide; Agonist; Receptor","score_opus":0.01573269884666853,"score_gpt":0.25457875699617466,"score_spread":0.23884605814950613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411100032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447984,0.0021156862,0.00003141824,0.000101695725,0.00017845312,0.002422185,0.00006653112,0.00013520669,0.00046898331],"genre_scores_gemma":[0.9964049,0.00037101857,0.0010512826,0.000221682,0.000028568345,0.0005820083,0.0003867966,0.00009042518,0.000863347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996057,0.00045121385,0.00057771534,0.0011018161,0.0005482514,0.0012640377],"domain_scores_gemma":[0.99757916,0.00012797286,0.00031555296,0.0013274772,0.000364507,0.00028532356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068654306,0.00071347354,0.0023230962,0.00046020016,0.00014946739,0.00004245158,0.00023352071,0.00026189518,0.00006644224],"category_scores_gemma":[0.000098588935,0.00043915352,0.0003473757,0.0012400602,0.00050569384,0.00022442291,0.00009775818,0.00022151419,0.000012559404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001636541,0.0019740893,0.9339533,0.00025847778,0.04161435,0.00008711461,0.0003164821,0.00005451576,0.00062662305,0.000008795798,0.00014754615,0.01932218],"study_design_scores_gemma":[0.037379283,0.026519876,0.85923237,0.0013343008,0.023323474,0.0000036744084,0.0008759706,0.00083357166,0.044094525,0.000036364898,0.0052252416,0.0011413398],"about_ca_topic_score_codex":0.00035698852,"about_ca_topic_score_gemma":0.00089887116,"teacher_disagreement_score":0.074720904,"about_ca_system_score_codex":0.00058376737,"about_ca_system_score_gemma":0.0004480963,"threshold_uncertainty_score":0.99980605},"labels":[],"label_agreement":null},{"id":"W4411100508","doi":"10.1038/s41591-025-03723-6","title":"Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Markham Stouffville Hospital; York University; Hospital for Sick Children; University Health Network; University of Toronto; SickKids Foundation","funders":"National Heart, Lung, and Blood Institute; Juvenile Diabetes Research Foundation Canada","keywords":"Adjunct; Randomized controlled trial; Medicine; Type 2 diabetes; Insulin; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.010860110109217898,"score_gpt":0.2836491979516391,"score_spread":0.27278908784242123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411100508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961105,0.011579547,0.000056534114,0.005560306,0.0018610434,0.011424585,0.00000193091,0.00008290948,0.00832818],"genre_scores_gemma":[0.9897105,0.0003407628,0.00037208482,0.0066407267,0.0006326098,0.0002924335,0.00006654355,0.000031946096,0.0019123892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977828,0.000197829,0.0006553712,0.0004286723,0.000535044,0.00040024184],"domain_scores_gemma":[0.998687,0.00044386063,0.00015579921,0.0003722022,0.00019510365,0.00014599822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013588263,0.00037038687,0.0024880767,0.0008609129,0.000047196794,0.000014498376,0.00011535673,0.0002590457,0.000087390086],"category_scores_gemma":[0.0011410008,0.00019020104,0.00018678402,0.0013252032,0.00014652898,0.00004774862,0.000035961246,0.00053631753,0.0000073197216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98936385,0.00045733622,0.0012601909,0.000049835817,0.0012754123,0.00003955599,0.0007848266,0.000012840107,0.000700325,0.00024543545,0.0014527343,0.004357651],"study_design_scores_gemma":[0.99063545,0.0022557303,0.00024411007,0.0016239919,0.0014742861,4.1001377e-7,0.00029056653,0.00033982305,0.0006786083,0.00009375417,0.0021990198,0.00016424099],"about_ca_topic_score_codex":0.000058022895,"about_ca_topic_score_gemma":0.000024701172,"teacher_disagreement_score":0.02860554,"about_ca_system_score_codex":0.00016101074,"about_ca_system_score_gemma":0.00017978059,"threshold_uncertainty_score":0.7756173},"labels":[],"label_agreement":null},{"id":"W4411131729","doi":"10.1017/s109285292510031x","title":"Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease","year":2025,"lang":"en","type":"review","venue":"CNS Spectrums","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation; Queen's University","funders":"Department of Psychiatry, University of Toronto; Health Resources and Services Administration; Substance Abuse and Mental Health Services Administration; Allergan; National Institutes of Health; Bausch Health; National Natural Science Foundation of China; University of Cambridge; Canadian Institutes of Health Research; Sunovion; Eisai; Purdue University; H. Lundbeck A/S; Patient-Centered Outcomes Research Institute; University of Toronto; Biogen; Novo Nordisk; Sanofi; National Institute of Mental Health; Pfizer","keywords":"Parkinson's disease; Medicine; Receptor; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Glucagon; Pharmacology; Disease; Agonist; Endocrinology; Internal medicine; Diabetes mellitus; Insulin; Type 2 diabetes","score_opus":0.033885623986777726,"score_gpt":0.32569932083465436,"score_spread":0.2918136968478766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411131729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047105827,0.9917237,0.000058844893,0.00044425073,0.0004904504,0.005744325,0.00014706963,0.000044119068,0.0013001111],"genre_scores_gemma":[0.000048022557,0.9437229,0.00028972665,0.000035438345,0.00023374801,0.001763243,0.0006703724,0.000037468202,0.05319909],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986662,0.000044476557,0.00041564117,0.00044957324,0.00015367061,0.0002704177],"domain_scores_gemma":[0.99875385,0.00024124891,0.0002497121,0.00059833645,0.000028792021,0.0001280831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010152167,0.00040296864,0.001242593,0.00015559941,0.00010148871,0.000032006374,0.000110642526,0.00009390016,0.00009053254],"category_scores_gemma":[0.000034021483,0.00023174474,0.00079671596,0.00017517895,0.00008227442,0.000038011298,0.000055946635,0.000057125908,0.000018690758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082855615,0.00053677,0.00007509239,0.015715526,0.0016176433,0.000005925765,0.000028348226,8.7696016e-8,2.382387e-7,0.0011436815,0.0053930394,0.9754008],"study_design_scores_gemma":[0.0011557771,0.0008748409,0.00023450695,0.008032416,0.012153142,0.0000013329022,0.000017675105,0.000005515209,0.000005328863,0.000120317134,0.9772347,0.00016440022],"about_ca_topic_score_codex":0.000012516221,"about_ca_topic_score_gemma":0.000015794241,"teacher_disagreement_score":0.9752364,"about_ca_system_score_codex":0.00031040484,"about_ca_system_score_gemma":0.000293875,"threshold_uncertainty_score":0.9450276},"labels":[],"label_agreement":null},{"id":"W4411152165","doi":"10.58931/crt.2025.2158","title":"Glucagon-like-peptide 1 (GLP-1) Receptor Agonists in Rheumatologic Disease","year":2025,"lang":"en","type":"article","venue":"Canadian rheumatology today.","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bruyère; Queensway-Carleton Hospital","funders":"","keywords":"Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Receptor; Exenatide; Glucagon-like peptide-2; Peptide; Medicine; Disease; Glucagon; Endocrinology; Internal medicine; Agonist; Chemistry; Diabetes mellitus; Pharmacology; Biochemistry; Insulin; Type 2 diabetes","score_opus":0.007993316232730373,"score_gpt":0.24256679479831736,"score_spread":0.234573478565587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411152165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9237092,0.0036477586,0.000023461713,0.021553542,0.0014803577,0.0011057637,0.000038006896,0.00017648307,0.04826541],"genre_scores_gemma":[0.97787535,0.0006695224,0.0002846712,0.003954769,0.000007587134,0.00024339382,0.0002607703,0.000029960154,0.016673975],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778587,0.00008483189,0.00048616243,0.0005894923,0.00012861345,0.0009250259],"domain_scores_gemma":[0.99829584,0.00010364164,0.000077030105,0.00064309477,0.000060092178,0.0008202873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018163158,0.0003245627,0.0006974815,0.0009670073,0.0001458855,0.000035156016,0.00024628692,0.0002091417,0.00077238097],"category_scores_gemma":[0.00025007114,0.0003153241,0.0001430184,0.00059122324,0.00020549011,0.00008765684,0.0000709759,0.00024789156,0.0007125591],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013827137,0.00019397517,0.7809247,0.00033293804,0.0002764061,0.0006661301,0.00011359059,0.0000074723675,0.000012164017,0.04493339,0.16543318,0.006967825],"study_design_scores_gemma":[0.0052650925,0.00015256165,0.32135352,0.0013933064,0.00025473165,0.000049322753,0.0003821371,0.00034395527,0.000092011585,0.002195406,0.6678969,0.0006210034],"about_ca_topic_score_codex":0.026535625,"about_ca_topic_score_gemma":0.08477016,"teacher_disagreement_score":0.50246376,"about_ca_system_score_codex":0.00071081315,"about_ca_system_score_gemma":0.0013458057,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W4411166700","doi":"10.1016/j.jcjd.2025.06.001","title":"Do Provincial Formulary Restrictions Explain Differential Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Diabetes and Cardiovascular Disease in Canada? A Retrospective Cohort Study of Pharmacy Claims","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"Institute of Gender and Health; Canadian Institutes of Health Research","keywords":"Medicine; Discontinuation; Diabetes mellitus; Prior authorization; Retrospective cohort study; Hazard ratio; Cohort; Sulfonylurea; Pharmacy; Demography; Gerontology; Environmental health; Internal medicine; Family medicine; Endocrinology; Pharmacology","score_opus":0.005540286564153764,"score_gpt":0.20121316208445653,"score_spread":0.19567287552030277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411166700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955765,0.0025243207,0.0000013553421,0.00008464367,0.00017896191,0.0014497469,0.000086121356,0.000003335244,0.000094988594],"genre_scores_gemma":[0.9997485,0.000054760534,0.000017197337,0.000026352038,0.000044513872,0.00006249386,0.000018123375,0.00001813447,0.0000098829205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980854,0.00007214602,0.00073067885,0.00027180748,0.00043252402,0.00040748317],"domain_scores_gemma":[0.998836,0.000042229833,0.00020976609,0.00026097524,0.00019891065,0.00045213875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027633773,0.00023006921,0.0008859071,0.00094645075,0.000052628067,0.00001548047,0.00012122845,0.000036454843,0.0000139091435],"category_scores_gemma":[0.000058491587,0.00019533029,0.00014405265,0.0005851704,0.00009264742,0.00015959833,0.000017297762,0.00024570926,4.7423104e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015709036,0.00040350258,0.9927421,0.00032683645,0.0015029211,0.00021136942,0.00058372045,0.00007797396,0.00004777361,0.00001750076,0.00007909627,0.003850104],"study_design_scores_gemma":[0.008967728,0.00067846593,0.98551184,0.0011562874,0.0014407256,2.700332e-7,0.001306053,0.00013595742,0.00057844014,0.000028766242,0.00005657079,0.00013891738],"about_ca_topic_score_codex":0.36076945,"about_ca_topic_score_gemma":0.8974056,"teacher_disagreement_score":0.5366362,"about_ca_system_score_codex":0.00073845754,"about_ca_system_score_gemma":0.0030579353,"threshold_uncertainty_score":0.7965338},"labels":[],"label_agreement":null},{"id":"W4411284611","doi":"10.1038/s44161-025-00657-7","title":"Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction","year":2025,"lang":"en","type":"article","venue":"Nature Cardiovascular Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Astellas Pharma; Novo Nordisk; Servier; Horizon Therapeutics; Moderna; Impulse Dynamics; Cytokinetics; Regeneron Pharmaceuticals; National Heart, Lung, and Blood Institute; Pfizer; LivaNova; Boston Scientific Corporation; American Regent; Sanofi; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; National Institutes of Health; Novavax","keywords":"Empagliflozin; Myocardial infarction; Medicine; Cardiology; Internal medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.01368456965825935,"score_gpt":0.32108419380033676,"score_spread":0.3073996241420774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411284611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93726385,0.04593383,0.00011496208,0.0011371184,0.000693777,0.003908782,0.00016393822,0.00003710289,0.010746632],"genre_scores_gemma":[0.9959616,0.0022736613,0.00009155018,0.0002248478,0.00019712055,0.00015631107,0.00009487587,0.00002648476,0.000973519],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9950596,0.0010839197,0.0005469937,0.00064830296,0.0021798848,0.0004813164],"domain_scores_gemma":[0.99662846,0.00025008645,0.00007928275,0.0021595394,0.0006891915,0.00019346018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00491157,0.00026605904,0.0016888499,0.0013298056,0.00014496854,0.00004065852,0.00029501086,0.00047293495,0.00006524331],"category_scores_gemma":[0.0010233552,0.00018781354,0.0045972182,0.0036774746,0.00038004064,0.0001004192,0.0004834368,0.0012145081,0.000002864809],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035970204,0.000626221,0.024753863,0.0011930097,0.83605,0.0001206954,0.0007297596,0.00034897155,0.0010419771,0.0005824079,0.010292674,0.08829022],"study_design_scores_gemma":[0.06257367,0.00056475366,0.7279808,0.00050919544,0.096681274,0.000007756468,0.00019243256,0.00004957239,0.0030805569,0.00013943121,0.107925445,0.00029510667],"about_ca_topic_score_codex":0.00008917696,"about_ca_topic_score_gemma":0.000006711186,"teacher_disagreement_score":0.73936874,"about_ca_system_score_codex":0.00020425014,"about_ca_system_score_gemma":0.00039001627,"threshold_uncertainty_score":0.7658814},"labels":[],"label_agreement":null},{"id":"W4411288359","doi":"10.2337/db25-2007-lb","title":"2007-LB: Dapagliflozin Alters TCA Cycle Activation during Insulin Withdrawal in T1D Patients","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Medicine; Insulin; Endocrinology; Internal medicine; Diabetes mellitus; Type 2 diabetes","score_opus":0.004294180632477585,"score_gpt":0.22255261084630115,"score_spread":0.21825843021382357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411288359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819027,0.00012855073,0.0000032480823,0.00037795427,0.00021967971,0.00056467945,0.0000033264798,0.00007865473,0.016721163],"genre_scores_gemma":[0.9972633,0.00002357971,0.00014040098,0.0006623808,0.000047346257,0.00009795989,0.00012328483,0.000017403361,0.0016243098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893725,0.00002682435,0.00023803955,0.000276822,0.00017976816,0.00034132347],"domain_scores_gemma":[0.99956346,0.000044188993,0.000057750673,0.00023025737,0.000043202854,0.00006112546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008430551,0.00016490086,0.000250129,0.0003361706,0.000056075685,0.000025585236,0.000076759075,0.00005779049,0.00007941387],"category_scores_gemma":[0.00008043196,0.00015330556,0.000056588247,0.00035566918,0.0000321814,0.00018019653,0.000074157855,0.000105769184,0.00006195454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077953366,0.00070268725,0.9750195,0.00021965223,0.00018106258,0.0000044722874,0.00020135783,0.000042822485,0.0043240897,0.00018307538,0.0012796787,0.017763622],"study_design_scores_gemma":[0.004625707,0.00015219292,0.9442616,0.00043039402,0.00008597746,1.8943277e-8,0.00009213121,0.00022456732,0.047274053,0.00019845163,0.0025042354,0.00015063387],"about_ca_topic_score_codex":0.000045742727,"about_ca_topic_score_gemma":0.0000074906197,"teacher_disagreement_score":0.042949963,"about_ca_system_score_codex":0.00019595296,"about_ca_system_score_gemma":0.000026649634,"threshold_uncertainty_score":0.62516195},"labels":[],"label_agreement":null},{"id":"W4411288882","doi":"10.2337/db25-1444-p","title":"1444-P: Impact of Semaglutide Shortage in Canadian Adults and Response in a Community Endocrinology Setting (SCARCITY Study)","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Semaglutide; Economic shortage; Scarcity; Internal medicine; Medicine; Endocrinology; Gerontology; Diabetes mellitus; Economics; Type 2 diabetes; Philosophy","score_opus":0.009356711330196351,"score_gpt":0.2935186593491785,"score_spread":0.28416194801898215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411288882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972245,0.00041434832,5.724375e-8,0.00025200285,0.000025249767,0.00079329236,0.000018892873,0.000016970007,0.0012546554],"genre_scores_gemma":[0.99963033,0.000017558583,0.000032242056,0.000116172756,0.0000036478318,0.000058411268,0.000017688644,0.000008017461,0.00011591355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861246,0.00039961358,0.0002649825,0.00016840232,0.000070816895,0.00048370016],"domain_scores_gemma":[0.9991196,0.0003851742,0.00003942356,0.00031438362,0.00003062778,0.00011079679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076641486,0.00014307702,0.00039875883,0.0007982644,0.000047338926,0.0000085096035,0.000091300775,0.000045374727,0.000011859872],"category_scores_gemma":[0.00036903116,0.00012727547,0.000051218405,0.00038841472,0.00006875541,0.000038262766,0.000107429354,0.00023872912,0.0000010494689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033969388,0.00050102186,0.9886322,0.000116153846,0.00018156122,0.00006783181,0.0018461631,0.0000072527573,0.00042316728,0.000023242214,0.0000686052,0.007793088],"study_design_scores_gemma":[0.0026527448,0.0009699349,0.99325186,0.00028146454,0.00007059335,2.6651472e-7,0.001751688,0.00031541364,0.00053399213,0.000049708906,0.00004532788,0.00007702944],"about_ca_topic_score_codex":0.38828745,"about_ca_topic_score_gemma":0.49861988,"teacher_disagreement_score":0.11033243,"about_ca_system_score_codex":0.00036159917,"about_ca_system_score_gemma":0.00020574032,"threshold_uncertainty_score":0.615786},"labels":[],"label_agreement":null},{"id":"W4411290754","doi":"10.2337/db25-852-p","title":"852-P: Factors Associated with the Use of Adjunct-to-Insulin Glucose-Lowering Agents in Patients with Type 1 Diabetes Mellitus","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adjunct; Medicine; Diabetes mellitus; Insulin; Internal medicine; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.024669339434050825,"score_gpt":0.23411958467958233,"score_spread":0.2094502452455315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411290754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799615,0.00026821624,0.0000034953237,0.0001983618,0.000121000274,0.0010618689,0.000022941225,0.000051993236,0.00027597367],"genre_scores_gemma":[0.9985572,0.00001675846,0.00007219907,0.0005840039,0.000007889231,0.0000532054,0.00020102267,0.000031381467,0.0004763274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985713,0.00004733632,0.00025715545,0.00030946766,0.0003499409,0.00046479816],"domain_scores_gemma":[0.99896854,0.00025920122,0.00011583868,0.00038971857,0.00017837973,0.00008834329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012533659,0.0002708762,0.00048646997,0.00027100972,0.000056215722,0.000036928323,0.00014463831,0.00006458804,0.000026982594],"category_scores_gemma":[0.00021114918,0.00015444726,0.000059623144,0.000986489,0.00007737906,0.00013100107,0.00009478103,0.00012434827,0.000007667431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009367958,0.0006177919,0.99273795,0.000072226794,0.0008272515,0.000001512993,0.00017070737,0.00010340467,0.00020525053,0.000022272861,0.0009665359,0.0041813916],"study_design_scores_gemma":[0.002645108,0.0009193727,0.9799397,0.0006829274,0.00038560823,1.5022e-9,0.000044480996,0.00009511605,0.012973247,0.000006499958,0.002144672,0.00016324501],"about_ca_topic_score_codex":0.000024736917,"about_ca_topic_score_gemma":0.00005263263,"teacher_disagreement_score":0.012798253,"about_ca_system_score_codex":0.00013376553,"about_ca_system_score_gemma":0.000042141193,"threshold_uncertainty_score":0.62981766},"labels":[],"label_agreement":null},{"id":"W4411293507","doi":"10.2337/db25-2094-lb","title":"2094-LB: Electrocardiogram Abnormalities in Relatively Early Type 2 Diabetes—Prevalence and Incidence in the Glycemia Reduction Approaches in Diabetes (GRADE) Cohort","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Diabetes mellitus; Type 2 diabetes; Cohort; Internal medicine; Reduction (mathematics); Cardiology; Pediatrics; Endocrinology","score_opus":0.016821035576338884,"score_gpt":0.24550969793602045,"score_spread":0.22868866235968158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411293507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859147,0.00831968,0.0000011676834,0.00086972077,0.00013607462,0.0014437328,0.000004046347,0.000062645115,0.0032482387],"genre_scores_gemma":[0.99742234,0.0008711973,0.00014541637,0.00033095767,0.000046868325,0.0005687769,0.00004346237,0.000022489405,0.00054851733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975145,0.00028533157,0.000499838,0.000586883,0.0003422965,0.00077117723],"domain_scores_gemma":[0.9990122,0.00035834158,0.00010226255,0.00041725158,0.000048135946,0.00006184743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011680342,0.00033756252,0.0006029814,0.00070767244,0.00007623893,0.000088876506,0.0002362808,0.00015930996,0.000008403528],"category_scores_gemma":[0.00023273076,0.0002710895,0.000088975685,0.0016251241,0.00025507595,0.0004120459,0.000119430704,0.00047124212,0.000008427734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004018352,0.00023829965,0.99166006,0.0004271146,0.00015786452,0.000008496764,0.0009615673,0.000019880958,0.0006639631,0.0016245892,0.00018459251,0.004013392],"study_design_scores_gemma":[0.0012822913,0.00039514215,0.99111676,0.0007568446,0.00020419907,3.9418168e-7,0.00047335803,0.0005386801,0.0029643355,0.0017209931,0.0003053291,0.00024167477],"about_ca_topic_score_codex":0.00014015302,"about_ca_topic_score_gemma":0.000043793305,"teacher_disagreement_score":0.011507619,"about_ca_system_score_codex":0.00027801943,"about_ca_system_score_gemma":0.00006588046,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W4411319255","doi":"10.7759/cureus.86080","title":"Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; Alberta Health Services","funders":"","keywords":"Medicine; Semaglutide; Meta-analysis; Overweight; Weight loss; Obesity; Systematic review; MEDLINE; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.14029309992120015,"score_gpt":0.42427242186291503,"score_spread":0.2839793219417149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411319255","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000072500293,0.99099594,0.0000022598877,0.000074863376,0.000050954946,0.0076746102,0.0003209211,0.000016734331,0.0008564468],"genre_scores_gemma":[0.00003330709,0.9941425,0.00026396406,0.00007863342,0.000009602106,0.0031112344,0.00020212484,0.000017031545,0.00214164],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99762654,0.00025381203,0.0011608021,0.00053628103,0.00020523221,0.00021731664],"domain_scores_gemma":[0.99679327,0.0017501975,0.0006575936,0.00055860326,0.00017028015,0.00007006074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050057506,0.00053744344,0.014529181,0.00044037745,0.000032347758,0.000010886593,0.0001139895,0.00009100458,0.000029573293],"category_scores_gemma":[0.00048579206,0.00031051258,0.0014776908,0.0008192936,0.000093337156,0.000047406076,0.00014445503,0.00009317266,0.00000211381],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020603966,0.00010145398,0.000007872858,0.67009413,0.32816443,0.000009344466,0.00013647926,5.8642662e-8,1.7988836e-9,0.00014867909,0.0006302469,0.00068669725],"study_design_scores_gemma":[0.0007157287,0.0002003683,0.0000032781666,0.16409314,0.8069748,7.0110116e-7,0.00007387074,0.0000072785047,2.2047887e-7,0.000008505577,0.027745565,0.00017652995],"about_ca_topic_score_codex":0.000024069966,"about_ca_topic_score_gemma":0.00023703104,"teacher_disagreement_score":0.506001,"about_ca_system_score_codex":0.00017138345,"about_ca_system_score_gemma":0.00006043203,"threshold_uncertainty_score":0.9999347},"labels":[],"label_agreement":null},{"id":"W4411347414","doi":"10.2337/db25-0393","title":"Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies","year":2025,"lang":"en","type":"review","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Agonism; Exenatide; Antagonism; Receptor; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Body weight; Biology; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Political science; Agonist","score_opus":0.020079903960095687,"score_gpt":0.28800969201092763,"score_spread":0.26792978805083195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411347414","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007703169,0.99000657,0.0000011910289,0.0007734005,0.00041756805,0.001468441,0.000025146646,0.00003947593,0.0071911565],"genre_scores_gemma":[0.0003744141,0.99399024,0.000040556184,0.0006008291,0.00030523574,0.00014978983,0.00007812158,0.000030602812,0.004430203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850327,0.00020453495,0.00046509426,0.00025383753,0.00024663992,0.00032660918],"domain_scores_gemma":[0.99734026,0.0015997593,0.0004079219,0.0005583895,0.00006383471,0.00002980832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042199864,0.00032910373,0.0013355975,0.000088528315,0.00014086603,0.00003208857,0.00036115074,0.00010918733,0.000082370614],"category_scores_gemma":[0.00042877038,0.00014663844,0.0008448654,0.00038471096,0.00012543426,0.0000316421,0.00021909253,0.0002494267,0.00002277698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000013681372,0.000024463083,0.0008269775,0.020383855,0.0013947396,3.6253675e-7,0.00004534683,1.4848598e-7,0.000004928125,0.0009644543,0.0039265477,0.97242683],"study_design_scores_gemma":[0.00024123362,0.00003352931,0.000054807508,0.02252069,0.0049397713,8.6901714e-8,0.0000615699,0.0000034679595,0.00006230518,0.000038739392,0.9719228,0.00012100786],"about_ca_topic_score_codex":0.000004590306,"about_ca_topic_score_gemma":1.9560572e-7,"teacher_disagreement_score":0.9723058,"about_ca_system_score_codex":0.00008142066,"about_ca_system_score_gemma":0.00012312231,"threshold_uncertainty_score":0.59797424},"labels":[],"label_agreement":null},{"id":"W4411347509","doi":"10.1007/s11096-025-01943-x","title":"Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases","year":2025,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse Event Reporting System; Pharmacovigilance; Odds ratio; Liraglutide; Adverse effect; Suicidal ideation; Psychiatry; Dulaglutide; Database; Internal medicine; Poison control; Diabetes mellitus; Endocrinology; Suicide prevention; Emergency medicine; Type 2 diabetes","score_opus":0.06119059571402512,"score_gpt":0.4664157295805333,"score_spread":0.40522513386650816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411347509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97696614,0.00007683726,0.00026208514,0.02054317,0.0011630533,0.00030302035,0.000089119516,0.000008101744,0.0005884785],"genre_scores_gemma":[0.99051523,0.00046711983,0.0018586793,0.0051552667,0.00027553955,0.0000096128,0.00013700523,0.000007745473,0.0015738162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732625,0.00012146264,0.0014904364,0.0002929967,0.0005312568,0.00023758621],"domain_scores_gemma":[0.998182,0.00017986346,0.0005247925,0.0001780743,0.00036336266,0.0005719353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010045958,0.00016591932,0.0005980101,0.0015057552,0.000032234704,0.000010280046,0.00026185118,0.000026032894,0.00021337398],"category_scores_gemma":[0.00046111262,0.00014135717,0.000474494,0.0009056626,0.000079251986,0.00020105981,0.00009074131,0.00030342475,0.000020165391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007737135,0.00079719786,0.9726234,0.000016385948,0.0040553696,0.00031733036,0.000032030508,0.00036546105,0.0000070154947,0.000099603436,0.0064241164,0.014488392],"study_design_scores_gemma":[0.003806504,0.00013954625,0.88326895,0.00011989644,0.0018200771,0.000005870634,0.00010912382,0.00030522057,0.000004302756,0.0000868091,0.11024132,0.000092389346],"about_ca_topic_score_codex":0.016528148,"about_ca_topic_score_gemma":0.025886232,"teacher_disagreement_score":0.10381721,"about_ca_system_score_codex":0.000276623,"about_ca_system_score_gemma":0.00056056527,"threshold_uncertainty_score":0.9918888},"labels":[],"label_agreement":null},{"id":"W4411369893","doi":"10.61368/r.s.d.h.v6i2.659","title":"Uso de agonistas del receptor GLP-1 en adultos sin diabetes para reducir eventos cardiovasculares mayores: revisión sistemática de la evidencia clínica","year":2025,"lang":"es","type":"article","venue":"Revista Científica de Salud y Desarrollo Humano","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Diabetes mellitus; Endocrinology","score_opus":0.010625964273457689,"score_gpt":0.29232692358912327,"score_spread":0.2817009593156656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411369893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81052536,0.15982804,0.0008371803,0.0028131623,0.000655179,0.005431377,0.00031340975,0.00073700584,0.018859303],"genre_scores_gemma":[0.9620937,0.01960454,0.0040881466,0.0018131002,0.0009970028,0.00077883,0.00040565865,0.00027697277,0.009942063],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98835367,0.0034160826,0.0019433477,0.0021096328,0.0014339818,0.0027432789],"domain_scores_gemma":[0.9933379,0.0016511927,0.00066654495,0.0029670782,0.00038373368,0.0009935055],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.006203246,0.00146038,0.0026141512,0.00096977066,0.0009107713,0.0015005596,0.0015437674,0.00084629684,0.0007767149],"category_scores_gemma":[0.0033269355,0.0014375153,0.0022740664,0.0015822283,0.0007478126,0.00033370563,0.0007004847,0.0010614529,0.00051506824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001955477,0.0069616595,0.44316557,0.04743704,0.028036905,0.0013592506,0.005410165,0.00039633256,0.060010657,0.08898484,0.19771421,0.11856789],"study_design_scores_gemma":[0.005132975,0.0007688561,0.09390943,0.020073514,0.011131052,0.000023097153,0.00075602956,0.0007357896,0.0032031445,0.0003840057,0.8624214,0.0014607343],"about_ca_topic_score_codex":0.000056419707,"about_ca_topic_score_gemma":0.00000739193,"teacher_disagreement_score":0.6647072,"about_ca_system_score_codex":0.0035322448,"about_ca_system_score_gemma":0.001358592,"threshold_uncertainty_score":0.99981457},"labels":[],"label_agreement":null},{"id":"W4411405839","doi":"10.1016/j.jacadv.2025.101887","title":"Sodium-Glucose Cotransporter 2 Inhibitors Preceding ST-Segment Elevation Myocardial Infarction","year":2025,"lang":"en","type":"article","venue":"JACC Advances","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Rural Health Research Society; University of Saskatchewan; Royal University Hospital","funders":"Royal University Hospital Foundation; University of Saskatchewan","keywords":"Myocardial infarction; Internal medicine; Cardiology; Medicine; Elevation (ballistics); Cotransporter; Sodium; Chemistry; Mathematics","score_opus":0.0074819993532797896,"score_gpt":0.26481983297402584,"score_spread":0.257337833620746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411405839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9320159,0.0031019342,0.0057608276,0.003414396,0.0028739315,0.0017053129,0.000011293982,0.0003357734,0.050780647],"genre_scores_gemma":[0.99040633,0.0011879025,0.0014937997,0.0008885265,0.00035456067,0.00017548974,0.00017897967,0.000014914688,0.005299498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908024,0.000013606734,0.00023703954,0.00025042263,0.00021407055,0.00020464754],"domain_scores_gemma":[0.9996387,0.000027827127,0.00006892413,0.00015876578,0.000056845365,0.000048940987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010890438,0.0001436804,0.00020313474,0.00014343615,0.00013657773,0.000047150035,0.000042697815,0.00004895469,0.000056309367],"category_scores_gemma":[0.000019690448,0.0001232258,0.0000908862,0.00022847328,0.000030141991,0.00031553334,0.000022383812,0.000079158905,0.000022383918],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043431978,0.00048345677,0.25657523,0.00039858313,0.00063319714,0.000012809172,0.00028132394,0.00015417663,0.009524604,0.001601032,0.011614786,0.7182865],"study_design_scores_gemma":[0.0042554056,0.00047145985,0.13613623,0.00042685235,0.0007239132,0.0000010692147,0.00052181917,0.00017865012,0.03980634,0.001799086,0.815399,0.00028020426],"about_ca_topic_score_codex":0.000010782918,"about_ca_topic_score_gemma":0.0000126808945,"teacher_disagreement_score":0.8037842,"about_ca_system_score_codex":0.00014439697,"about_ca_system_score_gemma":0.000029734148,"threshold_uncertainty_score":0.50250024},"labels":[],"label_agreement":null},{"id":"W4411475148","doi":"10.2337/db25-798-p","title":"798-P: Semaglutide Effect during Mixed-Meal Tolerance Test (MMTT) with Fully Closed-Loop Therapy in Type 1 Diabetes (T1D)","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Placebo; Crossover study; Type 1 diabetes; Insulin; Diabetes mellitus; Internal medicine; Randomized controlled trial; Type 2 diabetes; Fructosamine; C-peptide; Endocrinology","score_opus":0.004589353943079134,"score_gpt":0.22633479501491183,"score_spread":0.2217454410718327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411475148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865443,0.0045766006,9.073259e-7,0.0006381929,0.00030733435,0.0013124384,0.000008844393,0.0002324714,0.0063789235],"genre_scores_gemma":[0.99401444,0.00016849459,0.00019956466,0.0008574915,0.000115851006,0.000316064,0.00006463025,0.0000577021,0.0042057717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775714,0.00008389646,0.0003650482,0.0006095885,0.00031780658,0.0008665095],"domain_scores_gemma":[0.9986555,0.0004388307,0.000096679185,0.00057898165,0.0000968856,0.00013310178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029668325,0.0004678738,0.0007836036,0.00039925682,0.00011395822,0.000068319874,0.00020796497,0.000119093,0.00007085517],"category_scores_gemma":[0.0001475681,0.0003514621,0.00013083965,0.0009411061,0.00012466735,0.00013363655,0.000092239214,0.00025747673,0.00008140523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020388122,0.0005282626,0.9316769,0.0005651772,0.000415317,0.000048071186,0.00006271661,0.000037692913,0.019593721,0.000049702296,0.0011567825,0.045661725],"study_design_scores_gemma":[0.0069956295,0.0021881715,0.7013557,0.0011678257,0.00022332426,4.258994e-7,0.000034319863,0.00029423003,0.28448957,0.00006562678,0.0028146491,0.00037056586],"about_ca_topic_score_codex":0.000024335171,"about_ca_topic_score_gemma":0.00003863623,"teacher_disagreement_score":0.26489586,"about_ca_system_score_codex":0.00016642046,"about_ca_system_score_gemma":0.000076926444,"threshold_uncertainty_score":0.9998937},"labels":[],"label_agreement":null},{"id":"W4411482952","doi":"10.1007/s00125-025-06467-7","title":"Effects of SGLT2 ablation or inhibition on corticosterone secretion in high-fat-fed mice: exploring a nexus with cytokine levels","year":2025,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; NIHR Leicester Biomedical Research Centre; Medical Research Council; National Institutes of Health; Rosetrees Trust; Canadian Institutes of Health Research; National Institute for Health and Care Research; UK Research and Innovation; British Heart Foundation; Wellcome Trust","keywords":"Endocrinology; Internal medicine; Glucose homeostasis; Dapagliflozin; Downregulation and upregulation; Renal glucose reabsorption; Immune system; Glycosuria; Diabetes mellitus; Cytokine; Corticosterone; Biology; Type 2 diabetes; Insulin resistance; Medicine; Hormone; Immunology; Biochemistry","score_opus":0.02576320104491222,"score_gpt":0.258178842904545,"score_spread":0.2324156418596328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411482952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967451,0.0000654495,0.00059786486,0.00028607994,0.00016240914,0.0010882199,0.000004031331,0.0000749015,0.0009759462],"genre_scores_gemma":[0.99839073,0.00001764585,0.00043535238,0.00024424886,0.000025025021,0.0003111164,0.00010471355,0.000013693396,0.0004574413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999,0.000044254935,0.00027702525,0.00026957062,0.0001749928,0.00023415906],"domain_scores_gemma":[0.99942267,0.00018909728,0.000115390976,0.0001828912,0.000052125095,0.00003785518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010305198,0.00017266985,0.00040615653,0.0003582899,0.000028499759,0.000012054725,0.0000370611,0.00007673238,0.000027671807],"category_scores_gemma":[0.00011363422,0.00012494517,0.000033726523,0.00046309485,0.00004346926,0.00013194268,0.000033682278,0.00010733476,0.000013744199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00911812,0.004134221,0.52533156,0.005221286,0.0012190271,0.00067877705,0.0010433937,0.00041433127,0.3653177,0.0107477885,0.00090121356,0.07587259],"study_design_scores_gemma":[0.006360834,0.0022352983,0.73579484,0.001595851,0.00029118784,6.055025e-7,0.000075176045,0.0002014465,0.25298125,0.00029820006,0.000050109284,0.00011520019],"about_ca_topic_score_codex":0.000028794217,"about_ca_topic_score_gemma":0.00002953699,"teacher_disagreement_score":0.21046332,"about_ca_system_score_codex":0.00017181196,"about_ca_system_score_gemma":0.000027558453,"threshold_uncertainty_score":0.50951165},"labels":[],"label_agreement":null},{"id":"W4411507891","doi":"10.1016/j.jclinepi.2025.111872","title":"Target trial emulation of cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: a systematic review of observational studies","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Epidemiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Observational study; Medicine; Type 2 diabetes; Emulation; Clinical trial; Diabetes mellitus; Meta-analysis; Systematic review; MEDLINE; Outcome (game theory); Randomized controlled trial; Intensive care medicine; Internal medicine; Psychology; Endocrinology","score_opus":0.8697186499513354,"score_gpt":0.6643221108102215,"score_spread":0.2053965391411139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411507891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026729153,0.99279,0.00031008312,0.0008074734,0.0012746146,0.0043530143,0.00014930121,0.0000056080853,0.00004263076],"genre_scores_gemma":[0.000037068505,0.9891386,0.009337164,0.00028318734,0.00061636796,0.00005618973,0.00036829026,0.000020923751,0.00014219925],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9597299,0.013794952,0.025158122,0.00041019902,0.0006699694,0.00023683756],"domain_scores_gemma":[0.86142325,0.10773792,0.027314473,0.0016991555,0.0016184781,0.00020673864],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.096695706,0.00037906814,0.045774534,0.0007015734,0.000022874387,0.0000020414648,0.00055364956,0.00026879914,0.00002648405],"category_scores_gemma":[0.39589563,0.0002194168,0.0053871875,0.0009290991,0.00022799917,0.00008696773,0.000249386,0.00039019177,0.000001912704],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004951144,0.00047993925,0.003294305,0.94577247,0.03209683,0.0000043286186,0.000008313324,0.00004809399,8.0803616e-8,0.0004335544,0.0022833373,0.01508363],"study_design_scores_gemma":[0.0068333806,0.0016697879,0.00037607903,0.7883712,0.16335945,0.0000021275603,0.000011050294,0.0000397144,3.1652513e-7,0.00024115492,0.038945984,0.00014972592],"about_ca_topic_score_codex":0.00001628345,"about_ca_topic_score_gemma":0.0000036177705,"teacher_disagreement_score":0.2991999,"about_ca_system_score_codex":0.00014588103,"about_ca_system_score_gemma":0.0011727591,"threshold_uncertainty_score":0.96839195},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaepi_broad"],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4411522182","doi":"10.1056/nejmoa2502082","title":"Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Overweight; Type 2 diabetes; Obesity; Medicine; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.0067043392250443305,"score_gpt":0.24234958548286628,"score_spread":0.23564524625782196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411522182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984078,0.004182182,0.000028247781,0.0075008143,0.00027618845,0.0002103262,4.2761357e-7,0.000009137289,0.0037146767],"genre_scores_gemma":[0.99211514,0.001282488,0.00069778616,0.00095509837,0.00056405744,0.000001178614,0.000003823613,0.000008300543,0.004372122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999087,0.000034027984,0.0003363654,0.00012538045,0.00023734481,0.00017989021],"domain_scores_gemma":[0.99930876,0.00016815144,0.00012481834,0.00012107501,0.00011513212,0.00016207735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004038236,0.00013705165,0.00050207315,0.00030975929,0.00002193013,0.000006329306,0.0000569064,0.000038205664,0.00011263835],"category_scores_gemma":[0.00023770359,0.00006778656,0.000024057485,0.00032342502,0.00007505562,0.00005576262,0.0000244987,0.00018908283,0.0000014519387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004931751,0.00024631651,0.8100652,0.00039742613,0.00040472377,0.00071434584,0.00062822783,0.000005321644,0.00020441375,0.00031394823,0.016828347,0.16525997],"study_design_scores_gemma":[0.13551925,0.009203483,0.7562324,0.009602865,0.0010642892,0.00013276542,0.00047097795,0.00010275686,0.0006696812,0.0007699575,0.08606734,0.00016426554],"about_ca_topic_score_codex":0.00007373564,"about_ca_topic_score_gemma":0.00026529047,"teacher_disagreement_score":0.1650957,"about_ca_system_score_codex":0.000053143896,"about_ca_system_score_gemma":0.00014024776,"threshold_uncertainty_score":0.27642557},"labels":[],"label_agreement":null},{"id":"W4411597464","doi":"10.1016/j.pcd.2025.06.006","title":"Pattern of semaglutide prescription in a real-world Canadian patient cohort","year":2025,"lang":"en","type":"article","venue":"Primary care diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Semaglutide; Medicine; Medical prescription; Cohort; Diabetes mellitus; Family medicine; Intensive care medicine; Internal medicine; Type 2 diabetes; Pharmacology; Endocrinology","score_opus":0.005729542137030537,"score_gpt":0.22365396898619566,"score_spread":0.21792442684916513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411597464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8668607,0.0011667951,0.0000013649286,0.00025386162,0.0001709888,0.00081556244,0.00003151252,0.000033987853,0.13066526],"genre_scores_gemma":[0.99651253,0.0000715481,0.000117408395,0.0014840523,0.000015577514,0.00014955876,0.00041989796,0.000013447974,0.001215959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989524,0.00003213929,0.0002810138,0.00024442218,0.00016416225,0.00032588613],"domain_scores_gemma":[0.99942726,0.00003225345,0.000052450614,0.00029755302,0.000088262736,0.000102222904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081113176,0.00014498596,0.00034486817,0.0006169895,0.000026122574,0.000010695587,0.00007127161,0.00004439851,0.000039629806],"category_scores_gemma":[0.00001520472,0.00013768088,0.000081756545,0.00035772767,0.000034577282,0.000048753504,0.000057164147,0.0000802662,0.000007472569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009734024,0.0000831674,0.8807758,0.0006767135,0.00015662976,0.000012183927,0.00024907835,0.000005515522,0.00036464777,0.000062234656,0.0021908863,0.11541338],"study_design_scores_gemma":[0.00073837675,0.00012960903,0.9860029,0.0005568081,0.00026080364,4.0697234e-8,0.00015733823,0.000045675588,0.00342508,0.000039384886,0.008541041,0.000102938815],"about_ca_topic_score_codex":0.057552777,"about_ca_topic_score_gemma":0.110972,"teacher_disagreement_score":0.12965187,"about_ca_system_score_codex":0.0007787493,"about_ca_system_score_gemma":0.00023087973,"threshold_uncertainty_score":0.9487231},"labels":[],"label_agreement":null},{"id":"W4411653218","doi":"10.1007/s40120-025-00758-2","title":"Correction: Are Glucagon-Like Peptide‑1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Penetrant (biochemical); Central nervous system; Neuroscience; Glucagon-like peptide-1; Neurology; Medicine; Chemistry; Endocrinology; Biology; Diabetes mellitus","score_opus":0.020649379626404476,"score_gpt":0.2959119807250109,"score_spread":0.27526260109860645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411653218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008408654,0.98501015,0.0000031356305,0.000998903,0.004543766,0.0032164985,0.000026600233,0.0001808588,0.005936019],"genre_scores_gemma":[0.00004931844,0.9826119,0.000010110388,0.0034791925,0.00034233046,0.0005796145,0.00029606844,0.000052119845,0.012579327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973691,0.000500534,0.0006111409,0.0008252543,0.00018891391,0.00050503906],"domain_scores_gemma":[0.9985626,0.0002251771,0.0004293651,0.00053392624,0.000075433534,0.00017354885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019293513,0.0006726201,0.0026798109,0.00019670006,0.00022335329,0.000031750715,0.00018044289,0.00041816133,0.00022632905],"category_scores_gemma":[0.00002955407,0.00048621013,0.0005585001,0.0003634046,0.00012729563,0.000050721075,0.00006126162,0.00062825304,0.00006485563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017811812,0.00017081578,0.00007146531,0.051662512,0.0010462593,0.00015703664,0.000090131456,8.6359556e-8,1.3721915e-7,0.00008916264,0.07209785,0.87443644],"study_design_scores_gemma":[0.0009964162,0.0012627784,0.00018833968,0.043365397,0.0018159659,0.0001539763,0.000026530219,0.0000022771123,5.7830084e-7,0.000002877344,0.95191205,0.00027282335],"about_ca_topic_score_codex":0.000014976273,"about_ca_topic_score_gemma":0.000012708485,"teacher_disagreement_score":0.8798142,"about_ca_system_score_codex":0.00007330871,"about_ca_system_score_gemma":0.0002050799,"threshold_uncertainty_score":0.99975896},"labels":[],"label_agreement":null},{"id":"W4411657397","doi":"10.51847/qeiqy2y","title":"10.51847/qEiqY2Y","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacophore; Quantitative structure–activity relationship; Dipeptidyl peptidase; Dipeptidyl peptidase-4; Type (biology); Pharmacology; Chemistry; Combinatorial chemistry; Stereochemistry; Medicine; Type 2 diabetes; Biochemistry; Diabetes mellitus; Enzyme; Biology; Endocrinology","score_opus":0.006715089826241336,"score_gpt":0.19509984735168237,"score_spread":0.18838475752544104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411657397","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005391706,0.000057222358,1.6484626e-7,0.00085935585,0.0000018531844,0.00028141413,0.000002250107,0.000121003635,0.993285],"genre_scores_gemma":[0.0009002877,7.438836e-7,0.00016934321,0.0003188319,0.00008061877,0.000025424522,0.000028630733,0.0000148558975,0.99846125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994767,0.0000065835075,0.000082735896,0.0001380941,0.00011789014,0.00017803522],"domain_scores_gemma":[0.99963313,0.000009570825,0.000008482774,0.00021415751,0.000014365346,0.0001202979],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004387698,0.00008603608,0.00013161158,0.00005274936,0.000024297418,0.000012463377,0.000048940612,0.000022438986,0.9940035],"category_scores_gemma":[0.0000064087058,0.00007226951,0.000046228924,0.00010639209,0.0000114345785,0.00003260557,0.000018446966,0.000028732991,0.9896228],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006789796,0.00011366777,0.0000026143425,0.0000078262465,0.00005862777,0.000019201374,0.000006718735,0.0000033851309,0.000026010319,0.0000029315725,0.11027611,0.889415],"study_design_scores_gemma":[0.0006216642,0.0003746101,0.00043641822,0.000021535669,0.00010309824,0.0000018386289,5.3017527e-7,0.0000343957,0.000047096823,0.0000016193824,0.99828327,0.0000739352],"about_ca_topic_score_codex":0.000005753439,"about_ca_topic_score_gemma":3.5529638e-8,"teacher_disagreement_score":0.88934106,"about_ca_system_score_codex":0.00003091693,"about_ca_system_score_gemma":0.000008615015,"threshold_uncertainty_score":0.29470652},"labels":[],"label_agreement":null},{"id":"W4411666866","doi":"10.1515/jtim-2025-0026","title":"Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists","year":2025,"lang":"en","type":"article","venue":"Journal of Translational Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Circumventricular organs; Agonist; Blood–brain barrier; Neuroscience; Receptor; Peripheral blood; Internal medicine; Bioinformatics; Central nervous system; Psychology; Biology","score_opus":0.051025148283366545,"score_gpt":0.36903878581114713,"score_spread":0.31801363752778056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411666866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.718703,0.019353706,0.026517315,0.21607915,0.0024807057,0.00077526475,0.00003013258,0.000018532019,0.016042203],"genre_scores_gemma":[0.997177,0.00092400983,0.00020145504,0.0010660536,0.00022187845,0.0000014769375,0.000007155803,0.000006550007,0.00039444404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890774,0.000029927947,0.00047698568,0.00011267219,0.0003704285,0.000102224],"domain_scores_gemma":[0.99897194,0.00050669094,0.0002413974,0.000060588725,0.000113787326,0.00010559974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034115402,0.00012226515,0.00041019535,0.0003766047,0.000036541598,0.000020268424,0.00007466857,0.000033234166,0.000106195854],"category_scores_gemma":[0.00016269114,0.00008359875,0.00007109628,0.00010802867,0.00018495639,0.00012720044,0.000017483699,0.00017930724,4.143662e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016262459,0.0015874685,0.34061593,0.0028038148,0.0061175055,0.00018549064,0.0027658928,0.000060091555,0.015070375,0.18185848,0.13845499,0.2942175],"study_design_scores_gemma":[0.079386346,0.013265501,0.5654085,0.037865076,0.0041429563,0.00021397408,0.0016565814,0.0015823711,0.0049301004,0.04861682,0.24236462,0.0005671501],"about_ca_topic_score_codex":0.000012508478,"about_ca_topic_score_gemma":0.0000061105943,"teacher_disagreement_score":0.29365036,"about_ca_system_score_codex":0.00008563415,"about_ca_system_score_gemma":0.000060849576,"threshold_uncertainty_score":0.34090582},"labels":[],"label_agreement":null},{"id":"W4411922193","doi":"10.1016/j.jcjd.2025.06.006","title":"Do Provincial Formulary Restrictions Explain Differential Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Diabetes and Cardiovascular Disease in Canada? A Retrospective Cohort Study of Pharmacy Claims","year":2025,"lang":"en","type":"letter","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Formulary; Diabetes mellitus; Retrospective cohort study; Disease; Transporter; Cohort; Internal medicine; Gerontology; Family medicine; Endocrinology; Genetics; Gene","score_opus":0.006375375796973219,"score_gpt":0.19630690459406222,"score_spread":0.189931528797089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411922193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909035,0.0030565162,5.6894817e-7,0.00266395,0.0003632688,0.002481235,0.00044984824,0.0000047333465,0.00007635396],"genre_scores_gemma":[0.9978135,0.000101448044,0.000014858016,0.0013553941,0.0003422842,0.0001300754,0.0001643474,0.000049002414,0.000029085219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661607,0.00014358017,0.0011853294,0.0004932998,0.00087252277,0.0006891856],"domain_scores_gemma":[0.9981209,0.00008145878,0.0005001099,0.00046109108,0.00031873272,0.00051771157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031602467,0.0004910919,0.0018260075,0.0016934372,0.00006319236,0.000027408947,0.00023272923,0.00014789125,0.00002563125],"category_scores_gemma":[0.0000710911,0.00042308742,0.0003094825,0.00062584446,0.00013605415,0.0001731804,0.00002897397,0.0010308519,7.953579e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012058924,0.0002874857,0.9837795,0.0011992016,0.0032618218,0.001540982,0.00047890868,0.000035283723,0.000006213984,0.0000018400218,0.0072864722,0.0020017198],"study_design_scores_gemma":[0.009182881,0.00097347156,0.9798983,0.0032449719,0.0039676772,7.9659264e-7,0.0005515415,0.0000520538,0.00012124533,0.000016179218,0.0016699643,0.00032092974],"about_ca_topic_score_codex":0.4604109,"about_ca_topic_score_gemma":0.86717427,"teacher_disagreement_score":0.40676337,"about_ca_system_score_codex":0.0013820584,"about_ca_system_score_gemma":0.0060028033,"threshold_uncertainty_score":0.9998221},"labels":[],"label_agreement":null},{"id":"W4411925738","doi":"10.1186/s13098-025-01831-4","title":"Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD","year":2025,"lang":"en","type":"review","venue":"Diabetology & Metabolic Syndrome","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Université de Genève; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Agonist; Diabetes mellitus; Glucagon-like peptide 1 receptor; Internal medicine; Pharmacology; Receptor; Endocrinology","score_opus":0.010577598228168233,"score_gpt":0.27388932639871966,"score_spread":0.26331172817055143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411925738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42333052,0.5744186,0.000001264479,0.000024749519,0.00011020622,0.0018528171,0.00012381846,0.000024895706,0.00011313518],"genre_scores_gemma":[0.09684414,0.90098596,0.00027429473,0.00009937207,0.000020735686,0.00084568426,0.00058379857,0.00009415496,0.00025186889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966731,0.00039307046,0.0008432305,0.0009424476,0.00043075532,0.0007173897],"domain_scores_gemma":[0.9978209,0.0005032217,0.00036894475,0.0010061885,0.000090370086,0.00021038501],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040474214,0.0009768893,0.008326203,0.0013398532,0.00006165845,0.000029044648,0.00021101012,0.00041643056,0.00005093306],"category_scores_gemma":[0.00011489144,0.00062053755,0.001074558,0.0006776166,0.00041520977,0.00006690062,0.00011965902,0.00039832585,0.00001418244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006190836,0.0010819178,0.50425506,0.01055605,0.01755742,0.00008040364,0.00005832307,0.0000021299431,6.117185e-7,0.000057845617,0.000045566143,0.4662428],"study_design_scores_gemma":[0.008175248,0.002687004,0.903429,0.0121851405,0.017153688,0.00000789707,0.000009016781,0.0000024490835,0.0000051732973,0.000019615254,0.05561569,0.00071007956],"about_ca_topic_score_codex":0.00006963453,"about_ca_topic_score_gemma":0.0000047380236,"teacher_disagreement_score":0.4655327,"about_ca_system_score_codex":0.00013061737,"about_ca_system_score_gemma":0.00031229382,"threshold_uncertainty_score":0.9996246},"labels":[],"label_agreement":null},{"id":"W4411992216","doi":"10.1016/j.deman.2025.100273","title":"Sodium-glucose cotransporter 2 Inhibitors and COVID-19 outcomes in type 2 diabetes patients: A population-based cohort study","year":2025,"lang":"en","type":"article","venue":"Diabetes Epidemiology and Management","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; University of Alberta","funders":"","keywords":"Type 2 diabetes; Coronavirus disease 2019 (COVID-19); Medicine; Cohort; Diabetes mellitus; Internal medicine; Cohort study; Population; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cotransporter; 2019-20 coronavirus outbreak; Endocrinology; Sodium; Virology; Disease; Environmental health; Chemistry; Infectious disease (medical specialty); Outbreak","score_opus":0.016131144975402294,"score_gpt":0.3019657022246444,"score_spread":0.2858345572492421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411992216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046224,0.0010678323,0.000033141478,0.003688648,0.00029146296,0.0033638265,0.000009151251,0.00009755282,0.0009861208],"genre_scores_gemma":[0.9825513,0.00039560007,0.0003101128,0.015085713,0.00001435994,0.0005687899,0.00036129513,0.000017914013,0.00069493806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762547,0.00027595725,0.00070157216,0.0007073701,0.00013548198,0.00055412564],"domain_scores_gemma":[0.99855864,0.0006730475,0.00013917647,0.00038263167,0.000039831557,0.00020664904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013345722,0.00034104782,0.0010016586,0.00058347447,0.00013166698,0.000015653568,0.00008877766,0.00012181319,0.00003665587],"category_scores_gemma":[0.00046305876,0.00027954165,0.00008426879,0.00032265973,0.00012888032,0.00008525174,0.00012694039,0.00012616844,0.0000055302307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007180721,0.0011553102,0.9881741,0.0006252249,0.00092806417,0.000012658649,0.00005273476,0.0000406496,0.0000010924028,0.0013491703,0.0020525057,0.005536688],"study_design_scores_gemma":[0.0051262276,0.00052241003,0.98706967,0.000104934086,0.00085997797,1.9655683e-8,0.00009265768,0.00040020546,0.000007966368,0.0010737039,0.00452702,0.00021521495],"about_ca_topic_score_codex":0.00012641576,"about_ca_topic_score_gemma":0.00015026411,"teacher_disagreement_score":0.011397065,"about_ca_system_score_codex":0.00016156332,"about_ca_system_score_gemma":0.000022964321,"threshold_uncertainty_score":0.99996567},"labels":[],"label_agreement":null},{"id":"W4412001455","doi":"10.1093/ndt/gfaf114","title":"Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Astellas Pharma; Novo Nordisk; Pfizer; Angion; Moderna; Regeneron Pharmaceuticals; Gilead Sciences; Maze Therapeutics; Sanofi; Amgen; Horizon Pharma; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Kidney disease; Renal function; Internal medicine; Urology; Type 2 diabetes; Creatinine; Diabetes mellitus; Endocrinology; Kidney; Gastroenterology","score_opus":0.011029130343441338,"score_gpt":0.23831189916458742,"score_spread":0.2272827688211461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412001455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674638,0.0001287633,0.030910445,0.00042104904,0.000028718836,0.0009904358,0.000019119616,0.000013117216,0.0000245315],"genre_scores_gemma":[0.99593884,0.00091568416,0.0022566926,0.0002361256,0.00002000947,0.000095012736,0.00048095695,0.000007617773,0.0000490522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927557,0.00009473066,0.00023040095,0.00019247906,0.000102210994,0.00010458974],"domain_scores_gemma":[0.9995283,0.00014075848,0.00010296783,0.000097548036,0.000076605604,0.00005385675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018928638,0.00011005888,0.00033286124,0.00025367897,0.000024737405,0.0000053680124,0.000019315168,0.00004745637,0.000012489087],"category_scores_gemma":[0.000025070281,0.000086040454,0.000019770816,0.00027082485,0.00006250712,0.000067652894,0.000004184868,0.000046084177,2.2856707e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41315833,0.0025798196,0.42081696,0.008089113,0.004207945,0.00009229584,0.0023059319,0.0028976062,0.10599505,0.006979772,0.00016413654,0.032713063],"study_design_scores_gemma":[0.15043676,0.009861732,0.68936616,0.0012519101,0.018115357,0.0000063729435,0.00010277899,0.10580746,0.023210216,0.0011829342,0.00019767397,0.00046061914],"about_ca_topic_score_codex":0.000016160346,"about_ca_topic_score_gemma":0.00012716616,"teacher_disagreement_score":0.26854923,"about_ca_system_score_codex":0.000029065832,"about_ca_system_score_gemma":0.00017413605,"threshold_uncertainty_score":0.3508628},"labels":[],"label_agreement":null},{"id":"W4412061654","doi":"10.1101/2025.07.05.25330933","title":"Differential effects of glucagon-like peptide-1 receptor agonist classes on blood pressure: a systematic review and network meta-analysis of randomised controlled trials with meta-regression","year":2025,"lang":"en","type":"review","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Agonist; Meta-regression; Meta-analysis; Differential effects; Differential (mechanical device); Blood pressure; Medicine; Internal medicine; Receptor; Physics; Thermodynamics","score_opus":0.05981856837407415,"score_gpt":0.3353555874197072,"score_spread":0.2755370190456331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412061654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017034467,0.96968985,0.00003990892,0.00006237689,0.00016343649,0.029691925,0.000084871856,0.000036731122,0.00021388532],"genre_scores_gemma":[0.00020514874,0.9813997,0.00013974444,0.000105086685,0.00004885254,0.010248942,0.00031252488,0.00005530269,0.0074847126],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98854834,0.0054866,0.0039131553,0.00081786455,0.0008770243,0.00035701145],"domain_scores_gemma":[0.97971016,0.013097783,0.005409064,0.0013846473,0.00023527246,0.00016308558],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0037040063,0.0012331255,0.073076956,0.00071831356,0.00006740231,0.000042167583,0.0003008789,0.00024312039,0.00042792375],"category_scores_gemma":[0.003966523,0.00046716508,0.015026484,0.0012768845,0.00011172453,0.0000389917,0.00011157537,0.00023648648,0.0000029423356],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007748915,0.0003455489,0.0000020935133,0.48876378,0.50929534,0.00000851368,0.0000046360574,0.0000011950964,0.000001244651,0.000029034962,0.00041645742,0.00035727106],"study_design_scores_gemma":[0.020310756,0.00058204366,0.0000010295469,0.22240151,0.7511417,8.533385e-7,0.0000012150266,0.0000032435917,0.000025386116,0.0000013053548,0.005310169,0.00022072397],"about_ca_topic_score_codex":0.0000057122447,"about_ca_topic_score_gemma":0.0000041860885,"teacher_disagreement_score":0.26636228,"about_ca_system_score_codex":0.000020051872,"about_ca_system_score_gemma":0.00014903562,"threshold_uncertainty_score":0.99977803},"labels":[],"label_agreement":null},{"id":"W4412080620","doi":"10.1097/md.0000000000043171","title":"Efficacy and outcomes of dapagliflozin in diabetic nephropathy: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dapagliflozin; Diabetic nephropathy; Randomized controlled trial; Creatinine; Meta-analysis; Diabetes mellitus; Internal medicine; Nephropathy; Cochrane Library; Renal function; Type 2 diabetes; Urology; Endocrinology","score_opus":0.06052707648951629,"score_gpt":0.3675707606762222,"score_spread":0.3070436841867059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412080620","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000046474424,0.9920985,0.000006233061,0.0014039807,0.000023997283,0.0058498383,0.000016319937,0.000019721929,0.00057674974],"genre_scores_gemma":[0.000043840755,0.994051,0.00006900875,0.00095650734,0.000010167626,0.00069023157,0.00012337862,0.000021555155,0.004034331],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997095,0.00030743098,0.0015525621,0.00048289253,0.0003414365,0.0002206851],"domain_scores_gemma":[0.99760216,0.00088223343,0.000554787,0.0007889275,0.000052018004,0.00011986522],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0010737696,0.000530158,0.018582169,0.0011787637,0.000016571488,0.0000064483042,0.0001283172,0.00010696739,0.0001611912],"category_scores_gemma":[0.00090009766,0.00026541104,0.0008614294,0.0014622251,0.00013568091,0.000025228204,0.00012665315,0.00017042192,0.0000045044753],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001422438,0.00008648715,0.00006375583,0.8446726,0.14654073,0.000028552387,0.000031324773,1.6762257e-8,1.1994424e-8,0.00006342454,0.00020718882,0.008304449],"study_design_scores_gemma":[0.00072377175,0.00013787368,0.00013098393,0.18187034,0.8046423,0.0000026217979,0.000010808599,0.0000010005948,2.726557e-8,0.0000055907044,0.012352027,0.00012263641],"about_ca_topic_score_codex":0.000032076157,"about_ca_topic_score_gemma":0.000011924577,"teacher_disagreement_score":0.6628023,"about_ca_system_score_codex":0.00004979131,"about_ca_system_score_gemma":0.000050781837,"threshold_uncertainty_score":0.9999798},"labels":[],"label_agreement":null},{"id":"W4412137963","doi":"10.1111/dom.16589","title":"Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Postprandial; Adipose tissue; Internal medicine; Subcutaneous adipose tissue; Endocrinology; Glucagon-like peptide-1; Glucagon; Subcutaneous tissue; Diabetes mellitus; Type 2 diabetes; Insulin; Pathology","score_opus":0.006408039506782344,"score_gpt":0.22035362042486573,"score_spread":0.21394558091808338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412137963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898864,0.008859451,0.000013985998,0.00034879326,0.00016088289,0.0005439719,0.000018227145,0.000034685974,0.0010313357],"genre_scores_gemma":[0.9964064,0.00059485127,0.0012290945,0.00046767152,0.00005198033,0.000018892946,0.000055351225,0.000012013089,0.0011637412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989056,0.00004800427,0.0003004949,0.00031535546,0.00015189899,0.00027864546],"domain_scores_gemma":[0.99947214,0.00008591397,0.00008297376,0.00020297614,0.00006455713,0.0000914483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023254783,0.00019340073,0.00053260726,0.0003067243,0.000069166694,0.000028825156,0.00005157426,0.000104467144,0.000030454134],"category_scores_gemma":[0.000065920045,0.00018030858,0.000054549884,0.00027773072,0.0000921828,0.000121364705,0.000095570555,0.00010476813,0.0000025275315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043666127,0.0012395644,0.79428256,0.001638164,0.0011104718,0.00006040853,0.0023016164,0.000012049678,0.060317047,0.0021866348,0.00043083035,0.13598399],"study_design_scores_gemma":[0.00531236,0.00036932758,0.93295825,0.00043147116,0.001846177,0.0000024084811,0.00010962947,0.0008420398,0.05192687,0.001130917,0.0048502674,0.00022030248],"about_ca_topic_score_codex":0.000077311284,"about_ca_topic_score_gemma":0.000052924708,"teacher_disagreement_score":0.13867567,"about_ca_system_score_codex":0.000013961191,"about_ca_system_score_gemma":0.000029592415,"threshold_uncertainty_score":0.73527706},"labels":[],"label_agreement":null},{"id":"W4412143798","doi":"10.1002/brb3.70661","title":"Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Brain and Behavior","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Royal Ottawa Mental Health Centre; University of Ottawa; Women and Children’s Health Research Institute; University of Alberta; St. Michael's Hospital; Western University; Mental Health Research Canada; Hospital for Sick Children; Toronto General Hospital; University of Toronto","funders":"","keywords":"Glucagon-like peptide-1; Medicine; Exenatide; Psychiatry; Psychology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.021192287960742986,"score_gpt":0.3401682474689523,"score_spread":0.31897595950820934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412143798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027507787,0.98328274,0.000008426758,0.00015311399,0.0001648178,0.015862862,0.00010440606,0.000039528626,0.00035656657],"genre_scores_gemma":[0.000003797793,0.98619723,0.0003277103,0.00036929577,0.00004232054,0.0026777121,0.00034999996,0.000036610207,0.009995336],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99803084,0.00009588159,0.0009952119,0.00045711224,0.00017988554,0.00024105173],"domain_scores_gemma":[0.9984276,0.0004435438,0.0004448372,0.00049982767,0.000058764046,0.0001253916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041056392,0.00044377436,0.0034947596,0.00026249833,0.00006590556,0.000024244844,0.00011553616,0.00016176891,0.000016606002],"category_scores_gemma":[0.00016831516,0.0003003377,0.0005419072,0.0002994243,0.00006190774,0.000028183122,0.00009189171,0.000110426874,0.000005168431],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010697132,0.0002711102,0.000010678731,0.7163416,0.00035399015,0.000005586678,0.000007912901,4.002228e-10,8.2621206e-8,0.00013105269,0.0028798983,0.2799874],"study_design_scores_gemma":[0.0015478199,0.00036918127,0.00008400119,0.6151102,0.06431997,0.00002424856,0.000005908267,1.5546763e-7,1.0310709e-7,0.0000024343287,0.31833377,0.00020216705],"about_ca_topic_score_codex":0.0000030339218,"about_ca_topic_score_gemma":0.0000016722065,"teacher_disagreement_score":0.31545386,"about_ca_system_score_codex":0.000056371537,"about_ca_system_score_gemma":0.00013933475,"threshold_uncertainty_score":0.99994487},"labels":[],"label_agreement":null},{"id":"W4412176331","doi":"10.1007/s12471-025-01967-y","title":"2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes","year":2025,"lang":"en","type":"review","venue":"Netherlands Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medisch Spectrum Twente","keywords":"Medicine; Diabetes mellitus; Disease; Canadian Cardiovascular Society; Intensive care medicine; Internal medicine; Cardiology; Myocardial infarction; Endocrinology","score_opus":0.05517033315730858,"score_gpt":0.3266986578578863,"score_spread":0.27152832470057775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412176331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017149383,0.99681836,0.00022709895,0.00015376772,0.00018299713,0.001853709,0.00005599249,0.0000063811153,0.0005302196],"genre_scores_gemma":[0.00009649549,0.9973753,0.0013162146,0.00006960561,0.00024062936,0.00009222412,0.00010054479,0.000036436963,0.000672529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826586,0.00017770036,0.0006994899,0.00023125231,0.0003590793,0.00026661129],"domain_scores_gemma":[0.998768,0.00013215454,0.00024334135,0.00050330366,0.00027482674,0.00007839828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011169246,0.00027177256,0.0016568024,0.0001283801,0.000054384134,0.000011458716,0.00018453217,0.000059311667,0.000007993776],"category_scores_gemma":[0.000021707026,0.00013788874,0.0017108717,0.00023556814,0.00006436081,0.00002268319,0.00008861222,0.00019172445,0.0000014718701],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007878509,0.00012678304,0.0173556,0.032937746,0.024361573,0.0000126037185,0.000013871284,0.00042747313,1.17175185e-8,0.000007124049,0.017754206,0.90692425],"study_design_scores_gemma":[0.0024334514,0.00030796084,0.010321563,0.020143604,0.0157045,6.613947e-7,0.000018168945,0.00001738555,7.546602e-8,0.0000074384525,0.95093334,0.00011182633],"about_ca_topic_score_codex":0.0000024144188,"about_ca_topic_score_gemma":1.9202162e-7,"teacher_disagreement_score":0.93317914,"about_ca_system_score_codex":0.000058535312,"about_ca_system_score_gemma":0.0001051247,"threshold_uncertainty_score":0.562294},"labels":[],"label_agreement":null},{"id":"W4412198876","doi":"10.1093/ckj/sfaf227","title":"Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy)","year":2025,"lang":"en","type":"article","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; Novo Nordisk; European Regional Development Fund; Jewish Community Foundation of Montreal","keywords":"Semaglutide; Medicine; Renal function; Type 2 diabetes; Internal medicine; Urology; Odds ratio; Creatinine; Diabetes mellitus; Kidney disease; Retrospective cohort study; Endocrinology","score_opus":0.03742669416726346,"score_gpt":0.3604128181717517,"score_spread":0.32298612400448823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412198876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933488,0.000078018405,0.000020911699,0.0031488456,0.00075917155,0.0014394687,0.000007841978,0.00003343521,0.0011635328],"genre_scores_gemma":[0.99126726,0.00006799669,0.00091748446,0.0053001796,0.00006957187,0.000046401132,0.000025069028,0.00002325137,0.0022827878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733907,0.0002637724,0.0010018899,0.00038915477,0.0006417052,0.00036439238],"domain_scores_gemma":[0.9974907,0.00096746784,0.00034478362,0.00028808438,0.0004159641,0.0004929671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009786879,0.0002738226,0.0009984416,0.00039148782,0.00009121636,0.000036988946,0.0001841329,0.0000908138,0.00007922293],"category_scores_gemma":[0.0082558505,0.00018774222,0.00021723792,0.0008339746,0.00008590568,0.00011171215,0.00008336379,0.00059340824,0.000020506643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008846864,0.008555767,0.9803909,0.00013256942,0.001526236,0.000080944665,0.0001351294,0.000021132917,0.000033151136,0.0001984227,0.007057721,0.0009833057],"study_design_scores_gemma":[0.020763576,0.0038572662,0.97184634,0.0008784039,0.0008197234,9.3111896e-7,0.00012871518,0.00024636346,0.00014725757,0.00019173237,0.00097023125,0.00014946418],"about_ca_topic_score_codex":0.000022923365,"about_ca_topic_score_gemma":0.0000693587,"teacher_disagreement_score":0.019878889,"about_ca_system_score_codex":0.00022015977,"about_ca_system_score_gemma":0.00059419934,"threshold_uncertainty_score":0.9883621},"labels":[],"label_agreement":null},{"id":"W4412356023","doi":"10.1111/bph.70118","title":"Blockade of cannabinoid CB<sub>1</sub> receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy","year":2025,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inversago Pharma (Canada)","funders":"Société Francophone du Diabète; Université de Bourgogne; National Institute on Alcohol Abuse and Alcoholism; European Regional Development Fund; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Blockade; Cannabinoid receptor; Pharmacology; Diabetic nephropathy; Receptor; Cannabinoid; Nephropathy; Medicine; Chemistry; Diabetes mellitus; Endocrinology; Internal medicine; Antagonist","score_opus":0.0045032596841684406,"score_gpt":0.23153474503409033,"score_spread":0.22703148534992187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412356023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937814,0.0036205,0.0000970193,0.0013432098,0.00038120852,0.00066918053,0.00002853113,0.000011958242,0.00006699849],"genre_scores_gemma":[0.9963861,0.0026790812,0.0000871463,0.0005847058,0.000043328186,0.000029917343,0.000023039538,0.00001902977,0.0001476244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983017,0.00024287368,0.000730353,0.00016380474,0.00025645556,0.00030484347],"domain_scores_gemma":[0.9990202,0.00015697166,0.00045012514,0.000078150915,0.0002114882,0.00008303587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046898404,0.00016038909,0.00063189294,0.00036071154,0.00004165082,0.000011527049,0.00011776518,0.00009786953,0.000026819182],"category_scores_gemma":[0.00012500392,0.00014435692,0.00017017366,0.00037678273,0.00019377322,0.00010741813,0.00007266444,0.00030891536,0.0000018841465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020348618,0.0010467739,0.0018661183,0.00050358556,0.0004975598,0.00019083181,0.00011349764,0.00074947655,0.96339965,0.000008478818,0.025162347,0.006258174],"study_design_scores_gemma":[0.0073824287,0.0005931886,0.0033081246,0.00068779354,0.0010063233,0.00004711325,0.000065643755,0.0018619815,0.98472244,0.00016146005,0.00006671421,0.00009677893],"about_ca_topic_score_codex":0.000060531915,"about_ca_topic_score_gemma":0.00001565909,"teacher_disagreement_score":0.025095632,"about_ca_system_score_codex":0.000115103634,"about_ca_system_score_gemma":0.00014912785,"threshold_uncertainty_score":0.58867043},"labels":[],"label_agreement":null},{"id":"W4412397635","doi":"10.2215/cjn.0000000771","title":"Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD","year":2025,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; Menarini Group; Ramaciotti Foundations","keywords":"Medicine; Canagliflozin; Internal medicine; Placebo; Confidence interval; Kidney disease; Adverse effect; Meta-analysis; Clinical trial; Relative risk; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Endocrinology; Alternative medicine","score_opus":0.009860387039744706,"score_gpt":0.29084239201392087,"score_spread":0.28098200497417614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412397635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898346,0.00008062285,0.00021054041,0.009544403,0.00005716578,0.00017511836,0.0000020283492,0.0000028409677,0.00009268248],"genre_scores_gemma":[0.97865725,0.0003629918,0.0012814075,0.01960366,0.000025535854,0.0000016162949,0.0000032900532,0.0000046152445,0.000059619888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991947,0.000060053768,0.00044776112,0.00008862454,0.000109961074,0.000098929915],"domain_scores_gemma":[0.9991931,0.00010581673,0.00042459337,0.00012004177,0.000116718955,0.00003973441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020646305,0.00006824543,0.00039602714,0.000039886134,0.000022797081,0.0000028758495,0.00005901342,0.000036810172,0.0000057791035],"category_scores_gemma":[0.000018418323,0.00004062509,0.00018852984,0.00022226814,0.0007238371,0.000038918166,0.000032917727,0.00016162856,2.7367136e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004745568,0.00069415243,0.98191524,0.000021352984,0.0003835268,0.0000021307083,0.00008958323,0.000003864624,0.000056937846,0.000062426145,0.009735119,0.0065610893],"study_design_scores_gemma":[0.004352204,0.0018864834,0.98860157,0.0000968668,0.00034883182,0.0000010968702,0.00013712833,0.00001612016,0.000031188643,0.00022318658,0.0042731664,0.0000321512],"about_ca_topic_score_codex":0.0000078019175,"about_ca_topic_score_gemma":0.000004206138,"teacher_disagreement_score":0.011177334,"about_ca_system_score_codex":0.000024357167,"about_ca_system_score_gemma":0.00005493554,"threshold_uncertainty_score":0.2667008},"labels":[],"label_agreement":null},{"id":"W4412441457","doi":"10.1016/j.pcd.2025.05.005","title":"A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes","year":2025,"lang":"en","type":"review","venue":"Primary care diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk; Canadian Cardiovascular Society; AstraZeneca; Bayer; Diabetes Canada; Eli Lilly and Company","keywords":"Medicine; Primary care; Diabetes mellitus; Kidney disease; Type 2 diabetes; Chronic disease; Intensive care medicine; Disease; Disease management; Family medicine; Gerontology; Internal medicine; Endocrinology","score_opus":0.01055151058841532,"score_gpt":0.28062896210638566,"score_spread":0.27007745151797036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412441457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036942775,0.9836333,0.000004124354,0.00011894297,0.00020864584,0.004636685,0.00016108439,0.0000899231,0.0074530416],"genre_scores_gemma":[0.0016309603,0.99103856,0.0009999021,0.0013063619,0.00012401228,0.0015097675,0.0021301198,0.0000885125,0.001171821],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971787,0.00017670164,0.00063390314,0.0008417857,0.00045150385,0.00071743864],"domain_scores_gemma":[0.99811834,0.0003760011,0.00025175058,0.00075568946,0.00016307858,0.00033514242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000263304,0.00071323785,0.0019893218,0.0005254208,0.00011229392,0.000058826277,0.00042746216,0.00011694292,0.000035172427],"category_scores_gemma":[0.000056006957,0.00046611333,0.0003207277,0.0010885654,0.00008955181,0.00010197712,0.0010212361,0.0002982559,0.000008651091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020436064,0.00011854349,0.033758584,0.27171615,0.0011861747,0.000034381414,0.00019319651,0.000010376229,0.0000013514691,0.000009165936,0.0016650497,0.69128656],"study_design_scores_gemma":[0.0016871737,0.000783612,0.036555365,0.19491301,0.014651248,3.5317532e-7,0.00038344314,0.000010791013,0.0000074296963,0.0000015549375,0.7502847,0.0007213444],"about_ca_topic_score_codex":0.000015116428,"about_ca_topic_score_gemma":0.0000165683,"teacher_disagreement_score":0.7486196,"about_ca_system_score_codex":0.0012251392,"about_ca_system_score_gemma":0.00084911793,"threshold_uncertainty_score":0.99977905},"labels":[],"label_agreement":null},{"id":"W4412443315","doi":"10.1016/j.jval.2025.04.631","title":"EPH100 Acute eGFR Dip with SGLT2 Inhibitors vs. Other Antihyperglycemic Medications Among People with HIV","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Traditional medicine; Pharmacology; Internal medicine; Family medicine","score_opus":0.009097476905995877,"score_gpt":0.26470780283417383,"score_spread":0.25561032592817795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412443315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96589905,0.00048377822,0.00037845375,0.02274916,0.00014087098,0.001361559,0.000010295444,0.00012780567,0.008849038],"genre_scores_gemma":[0.98831165,0.00033005013,0.0021000376,0.0025406044,0.00006653424,0.00018422087,0.00006112516,0.000034297485,0.006371462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986005,0.0000613393,0.00031096526,0.00033902435,0.00029013294,0.00039804316],"domain_scores_gemma":[0.99920005,0.000066069835,0.00011160407,0.00041846733,0.00003852348,0.00016527782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002542101,0.00018319262,0.00038722064,0.0003268628,0.00009300511,0.000016542343,0.0000953935,0.000055705746,0.000053197626],"category_scores_gemma":[0.000012598718,0.00012562194,0.00003620814,0.00076605467,0.00009290644,0.00008404442,0.000036321133,0.00017658922,0.000031326912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030621738,0.00045010884,0.9841095,0.00046891443,0.00040399833,0.000031789514,0.0009248731,0.00023311855,0.000010375576,0.0029111272,0.008037655,0.0021123015],"study_design_scores_gemma":[0.012733674,0.0030640555,0.9320987,0.0057695745,0.0008851635,0.000016312484,0.0010486203,0.003825944,0.00028088837,0.0002785329,0.039531592,0.0004669672],"about_ca_topic_score_codex":0.003079287,"about_ca_topic_score_gemma":0.00079512136,"teacher_disagreement_score":0.052010845,"about_ca_system_score_codex":0.0002978737,"about_ca_system_score_gemma":0.00042001475,"threshold_uncertainty_score":0.5122714},"labels":[],"label_agreement":null},{"id":"W4412448079","doi":"10.1016/j.xcrm.2025.102214","title":"The expanding benefits of GLP-1 medicines","year":2025,"lang":"en","type":"review","venue":"Cell Reports Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"H2020 Marie Skłodowska-Curie Actions; Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Business; Traditional medicine; Medicine","score_opus":0.034165695736676445,"score_gpt":0.33372202011850827,"score_spread":0.29955632438183183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412448079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008377705,0.90062547,0.000008634777,0.00048197524,0.002636279,0.0018684191,0.0000029344371,0.00006528009,0.09430266],"genre_scores_gemma":[0.000037872065,0.9291031,0.00003799831,0.000138685,0.0006628461,0.00018782499,0.00026270244,0.00004889548,0.069520086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638355,0.00006290129,0.0017926364,0.00058401376,0.0007513888,0.0004254961],"domain_scores_gemma":[0.99607426,0.0008404328,0.0013389579,0.0013703535,0.00018073127,0.0001952771],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010617059,0.00056888215,0.0031078227,0.00045172713,0.00013503437,0.000009934841,0.0002108838,0.00022251684,0.00015016524],"category_scores_gemma":[0.0007522426,0.00027153527,0.0004937421,0.0006864236,0.0003301612,0.000028750275,0.00017042014,0.00031047701,0.0000091134725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008197643,0.00008747306,0.00005848834,0.044703066,0.00049915013,0.00042493863,0.000057012687,1.3401606e-7,0.0000010459489,0.00011237225,0.058289614,0.8957585],"study_design_scores_gemma":[0.00051954295,0.00032470317,0.000020441099,0.086039476,0.009557751,0.00011479487,0.0001073738,3.1612552e-7,0.000016629323,0.000047576108,0.90309477,0.00015661152],"about_ca_topic_score_codex":0.00002241211,"about_ca_topic_score_gemma":0.000003646965,"teacher_disagreement_score":0.89560187,"about_ca_system_score_codex":0.00013498185,"about_ca_system_score_gemma":0.00037665275,"threshold_uncertainty_score":0.99997365},"labels":[],"label_agreement":null},{"id":"W4412487404","doi":"10.1111/dom.16608","title":"Prevalence of <scp>SGLT2</scp> inhibitor and <scp>GLP1</scp> receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Faculty of Medicine and Health, University of Sydney; Eli Lilly Australia; George Institute for Global Health; University of Melbourne; Boehringer Ingelheim; Australian Government; Australian Commission on Safety and Quality in Health Care; University of New South Wales; Ian Potter Foundation; David and Elaine Potter Foundation; Eli Lilly and Company","keywords":"Medicine; Renal function; Kidney disease; Internal medicine; Type 2 diabetes; Population; Medical prescription; Diabetes mellitus; Creatinine; Endocrinology; Urology; Gastroenterology; Pharmacology","score_opus":0.006482020705146322,"score_gpt":0.2306823558687402,"score_spread":0.22420033516359386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412487404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794441,0.014444148,0.0000011406968,0.00003909361,0.000105332656,0.0009462229,0.0048768553,0.000027392616,0.0001157301],"genre_scores_gemma":[0.98879087,0.0017476706,0.00039470734,0.00018167749,0.000035889963,0.0000680117,0.007981179,0.000020133173,0.00077984354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981828,0.00011674192,0.00039119998,0.0005890958,0.00030207736,0.00041809815],"domain_scores_gemma":[0.9986126,0.00009859208,0.00019782213,0.00051683304,0.000179006,0.00039514634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019784766,0.00032594922,0.00088667515,0.0005826268,0.00010658232,0.00005559091,0.00013504384,0.00010462961,0.000008626748],"category_scores_gemma":[0.00021669903,0.00027409111,0.000072003306,0.0007788671,0.00036360967,0.00038676796,0.00018943222,0.00013427399,7.211708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021963851,0.00068655994,0.98902947,0.0040960265,0.0012827673,0.0000010084593,0.00038062586,0.000006312011,0.0009038256,0.000083908504,0.0013499907,0.0021575703],"study_design_scores_gemma":[0.002703043,0.00031749942,0.97292066,0.0006615218,0.008053989,2.3887907e-8,0.0001391363,0.000087130626,0.0020541968,0.00002143506,0.0129639385,0.00007745785],"about_ca_topic_score_codex":0.000051058185,"about_ca_topic_score_gemma":0.0000534387,"teacher_disagreement_score":0.016108813,"about_ca_system_score_codex":0.000057762973,"about_ca_system_score_gemma":0.00014175047,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W4412489986","doi":"10.1016/j.eclinm.2025.103338","title":"Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial","year":2025,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Health Data Research UK; NIHR Oxford Biomedical Research Centre; Medical Research Council; British Heart Foundation; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; EMPA; Kidney disease; Health care; Disease; Quality of life (healthcare); Alternative medicine; Intensive care medicine; Internal medicine; Diabetes mellitus; Nursing; Type 2 diabetes; Economic growth; Endocrinology; Pathology","score_opus":0.0406059314357741,"score_gpt":0.3948621193011476,"score_spread":0.3542561878653735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412489986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709018,0.0020890906,0.000004254012,0.024997087,0.00019900186,0.0016540579,0.000092274095,0.000008733103,0.000053726322],"genre_scores_gemma":[0.9917504,0.0018010015,0.000023201706,0.0061050453,0.000060992792,0.000033013635,0.00006268388,0.0000078774665,0.00015579452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976174,0.00041546344,0.001219007,0.00033678947,0.00021800252,0.00019332908],"domain_scores_gemma":[0.9968749,0.0015704501,0.0005064912,0.0005129939,0.000042897413,0.00049223116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012218257,0.00015916975,0.0014553441,0.00038194942,0.00002562537,0.0000034386856,0.0000880422,0.00006877167,0.000018999819],"category_scores_gemma":[0.0042343484,0.00010536124,0.00019216897,0.00049234286,0.00027538236,0.000032883785,0.00010119402,0.00015465719,3.7026132e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014470025,0.0008584049,0.9696265,0.0037069004,0.0018724898,0.000002803789,0.00015506853,0.000010099861,0.000040554583,0.0012100905,0.003279512,0.004767554],"study_design_scores_gemma":[0.048455253,0.0024883214,0.9443356,0.0021167325,0.0015617085,2.6517469e-8,0.00003575529,0.00045721378,0.00004718072,0.000055113724,0.00038700484,0.00006012444],"about_ca_topic_score_codex":0.0015250159,"about_ca_topic_score_gemma":0.0005032829,"teacher_disagreement_score":0.033985227,"about_ca_system_score_codex":0.000248018,"about_ca_system_score_gemma":0.001193129,"threshold_uncertainty_score":0.50692165},"labels":[],"label_agreement":null},{"id":"W4412569232","doi":"10.2337/db25-0100","title":"Metformin Boosts Intestinal Lipid Sensing via GIP to Suppress Feeding","year":2025,"lang":"en","type":"article","venue":"Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Gastric inhibitory polypeptide; Metformin; Lipid metabolism; Biology; Receptor; Small intestine; Medicine; Hormone; Diabetes mellitus","score_opus":0.01175275247685766,"score_gpt":0.2639446422120955,"score_spread":0.2521918897352379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412569232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686254,0.00025960465,0.0005269721,0.001707585,0.0004891303,0.0005265662,0.0000025385498,0.00018376314,0.02767842],"genre_scores_gemma":[0.9856743,0.0000057966927,0.0060600736,0.0022069449,0.00016670588,0.000027254027,0.00003365501,0.000021361955,0.005803913],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886185,0.000016918173,0.00021292575,0.00029656597,0.0001719881,0.00043972596],"domain_scores_gemma":[0.9993397,0.00013320276,0.00003702233,0.00026956937,0.0000792597,0.00014124696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018310013,0.0001935623,0.00032694568,0.00030853896,0.00008167684,0.0000527144,0.00009082869,0.00004588741,0.000052287865],"category_scores_gemma":[0.00019508933,0.0001688937,0.00009364069,0.00035942448,0.0000326978,0.00009617,0.00016558103,0.00009725013,0.00010279096],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086868895,0.00034911698,0.16478476,0.0006485235,0.0008432134,0.0000717026,0.0005394477,0.000014697993,0.13882896,0.002018547,0.03249576,0.6593184],"study_design_scores_gemma":[0.0032674568,0.0010995598,0.07256563,0.002503747,0.0014261293,0.000005213841,0.00036129478,0.0042422744,0.78470564,0.001039973,0.1280933,0.00068979844],"about_ca_topic_score_codex":0.000019864674,"about_ca_topic_score_gemma":0.0000041405888,"teacher_disagreement_score":0.6586286,"about_ca_system_score_codex":0.00010243991,"about_ca_system_score_gemma":0.000022580065,"threshold_uncertainty_score":0.6887286},"labels":[],"label_agreement":null},{"id":"W4412638791","doi":"10.1111/dom.16621","title":"Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"Novo Nordisk","keywords":"Mace; Semaglutide; Medicine; Placebo; Myocardial infarction; Internal medicine; Population; Body mass index; Post-hoc analysis; Heart failure; Type 2 diabetes; Cardiology; Diabetes mellitus; Endocrinology; Percutaneous coronary intervention","score_opus":0.0035217352849685655,"score_gpt":0.22256093028326052,"score_spread":0.21903919499829194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412638791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597568,0.03804421,0.00006178048,0.000095187075,0.000164051,0.0011858149,0.00030978685,0.000051344956,0.0003310294],"genre_scores_gemma":[0.99646693,0.0019438254,0.000096266725,0.00019301625,0.000036851798,0.00008257829,0.00029944783,0.000027215783,0.0008538413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741226,0.00036987243,0.00045867672,0.0006636318,0.00057754613,0.0005180292],"domain_scores_gemma":[0.996988,0.0016155029,0.00017349378,0.000651927,0.0001835767,0.0003875129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012671482,0.00049601763,0.0021580532,0.00085967925,0.0001408,0.000048823396,0.0001196289,0.00015296381,0.000003144052],"category_scores_gemma":[0.0013806465,0.00039347672,0.00072435464,0.0007484694,0.00024668153,0.000113578455,0.00018886062,0.0001869152,0.0000011389925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005658495,0.0005364758,0.9134136,0.0021707823,0.061590843,0.00004182962,0.00019102523,0.00021143793,0.0018008323,0.00039099966,0.0010870539,0.017999297],"study_design_scores_gemma":[0.014923843,0.0006498635,0.8852822,0.00017481053,0.07994856,1.741664e-7,0.00022120637,0.0014518148,0.009147764,0.000034284607,0.008049288,0.00011617379],"about_ca_topic_score_codex":0.0001035816,"about_ca_topic_score_gemma":0.000004962931,"teacher_disagreement_score":0.03671016,"about_ca_system_score_codex":0.000041221756,"about_ca_system_score_gemma":0.000056910303,"threshold_uncertainty_score":0.9998517},"labels":[],"label_agreement":null},{"id":"W4412698966","doi":"10.1016/j.jacc.2025.05.033","title":"Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction","year":2025,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"AstraZeneca Schweiz","keywords":"Medicine; Heart failure; Ejection fraction; Aldosterone; Internal medicine; Endocrinology; Cardiology; Antagonist; Receptor","score_opus":0.00809549502223245,"score_gpt":0.25529164534215637,"score_spread":0.24719615031992392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412698966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206823,0.00009066445,0.0018325124,0.005057245,0.00011967621,0.00059022417,0.000021356298,0.000007356387,0.00021271541],"genre_scores_gemma":[0.99505436,0.000036425827,0.004048753,0.00033974892,0.00014791149,0.000018494156,0.0000044603366,0.000012301966,0.0003375441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926794,0.00008162398,0.0002415943,0.00013303827,0.00014144172,0.00013434293],"domain_scores_gemma":[0.9991425,0.00004231512,0.00035440462,0.00019915386,0.00020691268,0.000054712003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001880211,0.00011928183,0.0006562925,0.00012785055,0.00006833542,0.0000071252434,0.00006660118,0.000032099477,0.0000017766283],"category_scores_gemma":[0.000012623732,0.00006514498,0.00010836696,0.00018055693,0.0002875446,0.00010960493,0.000016291018,0.00011582298,1.1498412e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011858831,0.0001454147,0.96037763,0.00012857417,0.0018625064,0.000021493775,0.000018064999,0.000094318966,0.016131042,0.000053964635,0.008758731,0.00054941163],"study_design_scores_gemma":[0.014415051,0.02191729,0.8344949,0.00049863214,0.0039610765,0.00054705894,0.0022864651,0.00009309678,0.026099438,0.00010419856,0.095368564,0.00021425748],"about_ca_topic_score_codex":0.000012626494,"about_ca_topic_score_gemma":0.000043007934,"teacher_disagreement_score":0.12588277,"about_ca_system_score_codex":0.000056787296,"about_ca_system_score_gemma":0.000106521584,"threshold_uncertainty_score":0.26565352},"labels":[],"label_agreement":null},{"id":"W4412711219","doi":"10.1016/j.cgh.2025.07.027","title":"Glucagon-like Peptide-1 Agonist Liraglutide Induces Temporary Impairment to Gastric Electrical Activity in Healthy Volunteers","year":2025,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Liraglutide; Medicine; Agonist; Glucagon-like peptide-1; Internal medicine; Endocrinology; Pharmacology; Receptor; Diabetes mellitus; Type 2 diabetes","score_opus":0.025182457321135544,"score_gpt":0.3390667290260749,"score_spread":0.3138842717049393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412711219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767124,0.00023753807,0.00029038035,0.020564966,0.0006264159,0.00083569303,0.0000047896374,0.000067618406,0.00066019845],"genre_scores_gemma":[0.97384334,0.0003222976,0.00056554243,0.02448513,0.00006950154,0.0001404279,0.000022812063,0.000014261444,0.00053668226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707144,0.00041380935,0.00078610296,0.00078878115,0.00010936147,0.00083050854],"domain_scores_gemma":[0.9988228,0.0002972055,0.00011848099,0.00035590367,0.000042380703,0.0003632342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006560111,0.000287337,0.0010491963,0.0005312936,0.0000942611,0.000014113902,0.00015514044,0.00029806307,0.000030115216],"category_scores_gemma":[0.00014538692,0.00025687658,0.0001749546,0.00035236852,0.00032189765,0.00005921535,0.00028076323,0.0006485922,0.00003890015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008561578,0.0019977703,0.9701658,0.00006533766,0.00027283488,0.0002088801,0.000022538206,0.0000013110952,0.000051629937,0.00019206808,0.010122118,0.008338142],"study_design_scores_gemma":[0.006009301,0.012598105,0.97422206,0.000055759134,0.00019399097,0.00004696206,0.000040030704,0.00025314276,0.000021228287,0.00011639855,0.0063378024,0.00010519931],"about_ca_topic_score_codex":0.00016233338,"about_ca_topic_score_gemma":0.0006380669,"teacher_disagreement_score":0.010600334,"about_ca_system_score_codex":0.00016896462,"about_ca_system_score_gemma":0.00020557012,"threshold_uncertainty_score":0.9999883},"labels":[],"label_agreement":null},{"id":"W4412727279","doi":"10.1016/j.eclinm.2025.103363","title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","year":2025,"lang":"en","type":"review","venue":"EClinicalMedicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"McGill University","keywords":"Medicine; Narrative review; Current (fluid); Narrative; Pharmacology; Intensive care medicine; Literature; Oceanography","score_opus":0.06754754069487809,"score_gpt":0.45093124363418485,"score_spread":0.3833837029393068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412727279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000032937799,0.9919906,0.0000021769868,0.0028000348,0.0010779495,0.0023074807,0.000024004517,0.000025428251,0.0017690245],"genre_scores_gemma":[0.0000024643248,0.9970956,0.000110672634,0.00015581185,0.00077611266,0.00032299687,0.00010012646,0.000018065854,0.0014181506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971583,0.0002680245,0.001562458,0.0004166895,0.00038291787,0.0002116423],"domain_scores_gemma":[0.9953648,0.002677655,0.00095741363,0.0006655118,0.00020474501,0.00012985982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013161317,0.0003505705,0.0028831929,0.00014607681,0.000112259004,0.000006864055,0.00020354963,0.00013489362,0.0001273029],"category_scores_gemma":[0.0025071742,0.00018187976,0.00054572726,0.0006340092,0.0003436604,0.000040974177,0.00017073282,0.0004537387,0.000006299368],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018272876,0.00014726212,0.000029633327,0.15924716,0.0005334421,0.0000012669389,0.00010389572,5.7447097e-10,1.9165282e-7,0.00029815178,0.013721474,0.82589924],"study_design_scores_gemma":[0.00025330271,0.00032833824,0.000017074057,0.3969706,0.0038034432,0.0000018953338,0.00014963496,1.5650691e-7,6.272015e-7,0.000024230189,0.5983824,0.00006831493],"about_ca_topic_score_codex":0.00000456119,"about_ca_topic_score_gemma":0.000002354434,"teacher_disagreement_score":0.82583094,"about_ca_system_score_codex":0.0000895612,"about_ca_system_score_gemma":0.0003701063,"threshold_uncertainty_score":0.74168414},"labels":[],"label_agreement":null},{"id":"W4412727612","doi":"10.1016/j.jcjd.2025.07.004","title":"Multidisciplinary Lifestyle Intervention in a Clinical Setting Leads to Remission of Type 2 Diabetes, Prediabetes, and Early Insulin Resistance","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institut Universitaire de Gériatrie de Montréal; Montreal Heart Institute","funders":"Fondation Institut de Cardiologie de Montréal; Université de Montréal","keywords":"Medicine; Prediabetes; Insulin resistance; Type 2 diabetes; Internal medicine; Waist; Type 2 Diabetes Mellitus; Diabetes mellitus; Psychological intervention; Physical therapy; Insulin; Endocrinology; Obesity; Nursing","score_opus":0.01257275494059652,"score_gpt":0.29160288999955036,"score_spread":0.27903013505895385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412727612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98836523,0.007974693,0.0000034893126,0.0011699926,0.0002701751,0.0003411284,0.0000052591126,0.000008306802,0.0018617478],"genre_scores_gemma":[0.99465734,0.00004298821,0.0022434006,0.00018142638,0.00006731474,0.0000065124323,0.000004885984,0.000023033132,0.0027731117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983571,0.0001091571,0.00084595475,0.00020546584,0.00013336207,0.00034895938],"domain_scores_gemma":[0.9987158,0.00016788246,0.000269624,0.00019913887,0.0001676043,0.0004799456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010088128,0.00014997454,0.0005285876,0.0008048236,0.000041003692,0.000024320716,0.00013052806,0.00010552364,0.000027332213],"category_scores_gemma":[0.0009458522,0.00013640002,0.00012491945,0.00050296466,0.00009401876,0.00011202926,0.00005016725,0.0002228217,0.000003517482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028990842,0.00010665456,0.955602,0.00029889122,0.00012533489,0.000015265725,0.00012463964,0.0000039381416,0.000500211,0.00006209601,0.0034821029,0.03964989],"study_design_scores_gemma":[0.0019555253,0.0008850537,0.98327744,0.0043162056,0.00016618431,1.5266706e-7,0.00006674098,0.000044759774,0.00097467,0.00017648496,0.008032163,0.00010464932],"about_ca_topic_score_codex":0.000074324504,"about_ca_topic_score_gemma":0.0017945631,"teacher_disagreement_score":0.03954524,"about_ca_system_score_codex":0.00013068655,"about_ca_system_score_gemma":0.0003205696,"threshold_uncertainty_score":0.5562231},"labels":[],"label_agreement":null},{"id":"W4412744885","doi":"10.1186/s12933-025-02875-6","title":"Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial","year":2025,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca; U.S. Department of Health and Human Services","keywords":"Medicine; Dapagliflozin; Coronavirus disease 2019 (COVID-19); Randomized controlled trial; Type 2 diabetes; Angiology; Diabetes mellitus; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Internal medicine; Intensive care medicine; Virology; Endocrinology; Outbreak; Disease","score_opus":0.008776434007778946,"score_gpt":0.2494794085435535,"score_spread":0.24070297453577455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412744885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917354,0.0031343559,0.00020284874,0.00020745852,0.000084525425,0.003978276,0.000012772127,0.000018608416,0.0006257609],"genre_scores_gemma":[0.9989492,0.00032878725,0.0001994023,0.0001906948,0.0000087439685,0.00015907158,0.00006230872,0.000015248182,0.0000865041],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99790025,0.0005787023,0.00048409472,0.00045530568,0.00032473242,0.0002569404],"domain_scores_gemma":[0.99844974,0.00033906984,0.00019162433,0.0007749528,0.00013275522,0.00011185814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000900843,0.00024133161,0.0026561606,0.0004948396,0.00004668299,0.00000985684,0.000118799064,0.000110701716,0.000010743079],"category_scores_gemma":[0.0007381222,0.00013786618,0.00044313457,0.0012211794,0.0006728806,0.000038224254,0.00012477131,0.00010691632,1.65233e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2875948,0.00031477842,0.6649111,0.0002663277,0.044281583,0.0000034794648,0.00027734623,0.00031402812,0.0000054391858,0.00027819964,0.000031345364,0.0017215621],"study_design_scores_gemma":[0.5678203,0.00056319294,0.40704912,0.00010233978,0.023492228,2.0787064e-7,0.000030942425,0.00008551724,0.00004966809,0.00002923971,0.0006734519,0.00010379997],"about_ca_topic_score_codex":0.00006162632,"about_ca_topic_score_gemma":0.00001869497,"teacher_disagreement_score":0.2802255,"about_ca_system_score_codex":0.000071828545,"about_ca_system_score_gemma":0.00015609896,"threshold_uncertainty_score":0.562202},"labels":[],"label_agreement":null},{"id":"W4412788713","doi":"10.1016/j.cardfail.2025.05.022","title":"Sodium-glucose Cotransporter-2 Inhibitor Initiation and Incident Dementia in Heart Failure With Diabetes: A Population-based Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Ontario Brain Institute; University of Ottawa; Institute for Clinical Evaluative Sciences; McGill University; Sunnybrook Health Science Centre; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Health Canada; Novo Nordisk; University of Toronto; Canada First Research Excellence Fund; Canada Research Chairs; European Society of Cardiology; Ontario Ministry of Health and Long-Term Care; Temerty Faculty of Medicine, University of Toronto; Canada Excellence Research Chairs, Government of Canada; Fondation Brain Canada; Canadian Cardiovascular Society; Heart and Stroke Foundation of Canada; Institute for Clinical Evaluative Sciences; Ministry of Colleges and Universities; Alzheimer's Drug Discovery Foundation; Alberta Innovates - Health Solutions; Ministry of Health, Ontario","keywords":"Medicine; Dementia; Diabetes mellitus; Cohort; Cotransporter; Internal medicine; Heart failure; Cohort study; Population; Sodium; Endocrinology; Disease; Environmental health","score_opus":0.004912835038880507,"score_gpt":0.2338187218018933,"score_spread":0.2289058867630128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412788713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954361,0.0005862017,0.00004093029,0.0024141583,0.00016036353,0.0012429438,0.000005361297,0.000016854672,0.00009709806],"genre_scores_gemma":[0.9982282,0.00001774645,0.0011495223,0.0003698617,0.00009462657,0.000053929354,0.00004384686,0.000016838643,0.000025465011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984388,0.00009941017,0.0005495442,0.00020983409,0.0004895855,0.00021287482],"domain_scores_gemma":[0.9992067,0.00006459418,0.00022890548,0.0001947784,0.00019842389,0.00010654927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005715859,0.00020168148,0.0006586491,0.00051752065,0.000054713604,0.000060479702,0.000053522363,0.00007181193,0.000020500785],"category_scores_gemma":[0.00003101182,0.00015554906,0.00014739715,0.00036071616,0.000025806536,0.00024229326,0.000018598867,0.0002237751,0.0000017378463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001581715,0.00048775514,0.9954876,0.00013454107,0.00092486566,0.0000393588,0.00013367394,0.000062969004,0.0003446565,0.000012733287,0.0017612566,0.00045244675],"study_design_scores_gemma":[0.004291656,0.00083807233,0.9875455,0.0005002731,0.0019472796,0.0000014616948,0.00043897695,0.00002653868,0.0007106429,0.000019033076,0.0035568732,0.00012369432],"about_ca_topic_score_codex":0.00004029273,"about_ca_topic_score_gemma":0.00029103894,"teacher_disagreement_score":0.007942074,"about_ca_system_score_codex":0.00017168,"about_ca_system_score_gemma":0.00014405182,"threshold_uncertainty_score":0.63431066},"labels":[],"label_agreement":null},{"id":"W4412791569","doi":"10.1016/j.ijcard.2025.133683","title":"Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Semaglutide; Meta-analysis; MEDLINE; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.044932339035662766,"score_gpt":0.36765580144444554,"score_spread":0.3227234624087828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412791569","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012259142,0.997043,0.0003074422,0.00024621893,0.00025982855,0.00148639,0.000029762596,0.0000054452103,0.00062064984],"genre_scores_gemma":[0.00008750688,0.9981782,0.00015391094,0.0004916216,0.000048725444,0.00012553332,0.000025389492,0.0000140462425,0.0008750546],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968915,0.00069036824,0.0014045084,0.00023040776,0.00065424154,0.00012898429],"domain_scores_gemma":[0.99706286,0.000881052,0.0011073037,0.00040401434,0.00047403746,0.00007073341],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0011477551,0.0003550327,0.017017154,0.0010814829,0.000009877603,0.000010863796,0.00031992013,0.00012843912,0.000015135629],"category_scores_gemma":[0.0008354625,0.0001907086,0.013909264,0.0002745979,0.000047539354,0.000025895246,0.00010422222,0.00022586735,0.000005483968],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000046453824,0.000023976709,0.000006787945,0.3846556,0.6107194,0.00034579428,0.0000017830811,0.000007965771,9.8343635e-9,0.00007580787,0.0002493429,0.0039089257],"study_design_scores_gemma":[0.0003976199,0.00015409406,0.000019162,0.047913443,0.8721678,0.00017957205,0.0000015331865,1.9680421e-7,3.3199e-7,0.000014527324,0.07906354,0.000088126406],"about_ca_topic_score_codex":0.0000033241486,"about_ca_topic_score_gemma":2.7131537e-7,"teacher_disagreement_score":0.33674216,"about_ca_system_score_codex":0.00013806757,"about_ca_system_score_gemma":0.00011282773,"threshold_uncertainty_score":0.99757624},"labels":[],"label_agreement":null},{"id":"W4412984675","doi":"10.18192/uojm.v15is2.7533","title":"From Diabetes to Weight Loss: The Problems with Semaglutide's Expanded Use","year":2025,"lang":"en","type":"article","venue":"University of Ottawa Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Semaglutide; Weight loss; Diabetes mellitus; Medicine; Type 2 diabetes; Endocrinology; Obesity; Liraglutide","score_opus":0.008742759187822243,"score_gpt":0.2082136731706872,"score_spread":0.19947091398286496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412984675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94515246,0.0006441434,0.0010562369,0.04821982,0.00017690803,0.00035018288,0.0000045221336,0.000012671332,0.004383056],"genre_scores_gemma":[0.9889605,0.00017793354,0.0020724952,0.0012146855,0.00014407505,2.1641054e-7,0.0000063567504,0.0000075890375,0.007416129],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908817,0.00004312776,0.00023083456,0.0001192748,0.00036138287,0.0001571891],"domain_scores_gemma":[0.99893653,0.00019586444,0.00023194254,0.00023800351,0.00026446398,0.00013317696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028512834,0.00012364464,0.00044405606,0.00029100387,0.00006568434,0.000005638849,0.00021170669,0.000035112265,0.00022403682],"category_scores_gemma":[0.00008195615,0.000069014844,0.000079836565,0.00031322477,0.00024754254,0.000098181416,0.000057395533,0.0001421614,0.0000041420662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077217736,0.00056295644,0.7499393,0.00021449526,0.0036710685,0.0005293016,0.003813877,0.00010438772,0.0029177945,0.0014106494,0.2176383,0.018425664],"study_design_scores_gemma":[0.020601228,0.003940709,0.34219518,0.0057918252,0.004573457,0.000016729884,0.0047544064,0.00006678011,0.002575743,0.00060575374,0.61468774,0.00019045909],"about_ca_topic_score_codex":0.00020693016,"about_ca_topic_score_gemma":0.00007332535,"teacher_disagreement_score":0.40774414,"about_ca_system_score_codex":0.00007790875,"about_ca_system_score_gemma":0.000077908684,"threshold_uncertainty_score":0.28143436},"labels":[],"label_agreement":null},{"id":"W4413019221","doi":"10.1681/asn.0000000817","title":"Validation of the Klinrisk Machine Learning Model for CKD Progression in a Large Representative US Population","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Orthopaedic Innovation Centre; IMRIS (Canada)","funders":"Boehringer Ingelheim","keywords":"Brier score; Medicine; Medicaid; Receiver operating characteristic; Kidney disease; Internal medicine; Confidence interval; Cohort; Population; Area under the curve; Machine learning; Health care; Environmental health; Computer science","score_opus":0.01740312794959841,"score_gpt":0.34056871479343803,"score_spread":0.3231655868438396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413019221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905267,0.00011528209,0.0025930067,0.006301759,0.000043388314,0.000373226,0.0000034861932,0.000002698474,0.000040458654],"genre_scores_gemma":[0.9930088,0.000109485154,0.005312235,0.0012007921,0.000023397066,0.000007882294,0.000004442526,0.0000052729747,0.00032771466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992172,0.000120610406,0.00033269732,0.00007385129,0.00015045058,0.00010515686],"domain_scores_gemma":[0.99869895,0.00009412899,0.00096134574,0.00012663477,0.00010602123,0.000012916851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041622686,0.00006340774,0.0003135461,0.00004940088,0.00004894902,0.0000022409315,0.00010652485,0.000028435412,0.0000023180214],"category_scores_gemma":[0.00008043952,0.000034917022,0.00030833122,0.00025622803,0.00012221116,0.00004087397,0.000080386955,0.00015551336,4.6831424e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010767243,0.00052358484,0.9395663,0.0001198725,0.0006993196,4.905245e-7,0.0018164904,0.013314671,0.02698545,0.00018491963,0.0050141714,0.010697969],"study_design_scores_gemma":[0.003704755,0.0008252143,0.823458,0.00021144358,0.00057283713,0.0000030740887,0.00097376696,0.16330397,0.0041925004,0.0015290029,0.0011769567,0.00004845106],"about_ca_topic_score_codex":0.00006597205,"about_ca_topic_score_gemma":0.000008586013,"teacher_disagreement_score":0.1499893,"about_ca_system_score_codex":0.00006656947,"about_ca_system_score_gemma":0.00004437234,"threshold_uncertainty_score":0.1423875},"labels":[],"label_agreement":null},{"id":"W4413133795","doi":"10.3390/metabo15080536","title":"SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases","year":2025,"lang":"en","type":"review","venue":"Metabolites","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lipotoxicity; Internal medicine; Endocrinology; Metabolic syndrome; Diabetes mellitus; Insulin resistance","score_opus":0.042584939612204914,"score_gpt":0.345897335295542,"score_spread":0.3033123956833371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413133795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042075434,0.9957823,0.000001497504,0.00005201688,0.00030831655,0.0020500028,0.0001323669,0.00009376753,0.0011589742],"genre_scores_gemma":[0.00021625993,0.99289393,0.00013044344,0.00018092187,0.00022987052,0.0005470216,0.0004849005,0.000051614436,0.0052650087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776316,0.0002235936,0.0006198872,0.0006371838,0.00030216502,0.00045403818],"domain_scores_gemma":[0.9988946,0.00018963973,0.00016378975,0.00053646887,0.00004079899,0.00017471077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018535698,0.00060091267,0.002991283,0.001196411,0.000046580586,0.00007255854,0.00014100215,0.0001806882,0.000061024894],"category_scores_gemma":[0.00012037543,0.00042814875,0.0005935324,0.0010423072,0.000080893384,0.00008582514,0.00019231801,0.00023106518,0.000045144247],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010071418,0.0002330159,0.0027551756,0.014009912,0.0014908169,0.000045768837,0.000033019092,1.1453289e-7,0.0000011585829,0.0001799022,0.00042534756,0.9808157],"study_design_scores_gemma":[0.0012247968,0.00003744102,0.007270619,0.009798753,0.012137551,0.000002696404,0.000016626796,0.000004581411,0.0000056590275,0.00004771797,0.9691504,0.00030314588],"about_ca_topic_score_codex":0.000039296316,"about_ca_topic_score_gemma":0.0000034082793,"teacher_disagreement_score":0.98051256,"about_ca_system_score_codex":0.000082535014,"about_ca_system_score_gemma":0.00015845208,"threshold_uncertainty_score":0.999817},"labels":[],"label_agreement":null},{"id":"W4413137545","doi":"10.1136/bmj-2024-083039","title":"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McMaster University; Impact","funders":"West China Hospital, Sichuan University; National Institutes of Health; Lilly Deutschland; MannKind Corporation; Stockholms Läns Landsting; National Natural Science Foundation of China; Bayer; Sichuan University; Gilead Sciences; Novo Nordisk; Sanofi; Abbott Diagnostics; Eli Lilly and Company; AstraZeneca; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Meta-analysis; Confidence interval; Odds ratio; MEDLINE; Type 2 diabetes; Systematic review; Placebo; Intensive care medicine; Randomized controlled trial; Internal medicine; Lixisenatide; Kidney disease; Diabetes mellitus; Liraglutide; Alternative medicine; Pathology; Endocrinology","score_opus":0.031230786797434264,"score_gpt":0.31850169056366207,"score_spread":0.2872709037662278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413137545","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002122857,0.91748697,0.0039228257,0.03842096,0.00012529953,0.022611637,0.000018078534,0.0002002986,0.0150911035],"genre_scores_gemma":[0.76020974,0.015358494,0.031399842,0.048637033,0.00027751282,0.025063882,0.00045456394,0.00008369269,0.118515216],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99931103,0.000039442406,0.00025632512,0.00016348017,0.00010015358,0.00012957207],"domain_scores_gemma":[0.9991585,0.00026429852,0.000106831445,0.0003357441,0.00008945749,0.000045185217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000497642,0.00009496867,0.0010373099,0.00008173747,0.000045883553,0.0000124866165,0.000043563607,0.0000182959,0.000072289324],"category_scores_gemma":[0.00018451604,0.000054389715,0.0002087065,0.0005956728,0.000016623782,0.000023693303,0.000024967869,0.000023281891,0.0000058631963],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013083713,0.00011936539,0.00314659,0.32914996,0.6163678,0.0000020345992,0.00011125144,0.0000119053875,2.96153e-7,0.0013381789,0.04959322,0.00014632457],"study_design_scores_gemma":[0.00022291584,0.00011608862,0.00085326016,0.016329924,0.98104036,2.202175e-7,0.000052573316,0.00039507178,6.330022e-7,0.00002913215,0.0008987453,0.00006105293],"about_ca_topic_score_codex":0.0000027430683,"about_ca_topic_score_gemma":0.00002232328,"teacher_disagreement_score":0.90212846,"about_ca_system_score_codex":0.000015384821,"about_ca_system_score_gemma":0.000023713495,"threshold_uncertainty_score":0.22179483},"labels":[],"label_agreement":null},{"id":"W4413140349","doi":"10.1136/bmj-2024-082071","title":"Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Impact; University of Alberta","funders":"","keywords":"Guideline; Type 2 diabetes; Medicine; Weight loss; Diabetes mellitus; Intensive care medicine; Clinical Practice; Internal medicine; Obesity; Endocrinology; Family medicine; Pathology","score_opus":0.024862451828499547,"score_gpt":0.3690447926157581,"score_spread":0.34418234078725857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413140349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55133003,0.1799485,0.011107017,0.110931106,0.010629081,0.021371204,0.000031734682,0.00058477966,0.11406653],"genre_scores_gemma":[0.81325114,0.0162562,0.10186071,0.04494554,0.0011061513,0.00051989546,0.00014634481,0.00013346339,0.021780573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989164,0.00009048304,0.00045838964,0.00021925868,0.00014952262,0.00016595487],"domain_scores_gemma":[0.9981827,0.0010580827,0.0001075529,0.00037509177,0.00020225304,0.00007430335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012023777,0.0001137305,0.00042754158,0.00006936966,0.000030280613,0.000009371065,0.00005006136,0.00009628356,0.000006221659],"category_scores_gemma":[0.0029448841,0.00008918065,0.000224737,0.0001598804,0.000053028165,0.00005311415,0.000071086,0.00008215547,0.0000052748546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000519249,0.001753214,0.12940417,0.004416344,0.033485785,0.000098272714,0.00031834474,0.000010436026,0.0002645108,0.0031910697,0.33898354,0.4875551],"study_design_scores_gemma":[0.0034568121,0.0007200741,0.008067745,0.0009367564,0.006700575,0.0000021579733,0.000036079535,0.00073798094,0.0004065157,0.00021531545,0.978617,0.000103000835],"about_ca_topic_score_codex":0.0000041058756,"about_ca_topic_score_gemma":2.8307588e-7,"teacher_disagreement_score":0.6396335,"about_ca_system_score_codex":0.000022365488,"about_ca_system_score_gemma":0.000089382695,"threshold_uncertainty_score":0.36366814},"labels":[],"label_agreement":null},{"id":"W4413256694","doi":"10.1097/jcma.0000000000001267","title":"Highlights","year":2025,"lang":"en","type":"article","venue":"Journal of the Chinese Medical Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Traditional medicine","score_opus":0.003258362572384845,"score_gpt":0.25889754393902137,"score_spread":0.25563918136663655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413256694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8056072,0.00026959178,0.00008649196,0.17196181,0.0018380473,0.00011282248,3.6314165e-7,0.00001038769,0.020113274],"genre_scores_gemma":[0.97018296,0.00009518868,0.000074692456,0.003174042,0.0004136395,0.0000013819545,8.289416e-7,0.0000032935793,0.026054006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987638,0.000046262296,0.00026878188,0.00004217766,0.00079179223,0.00008716679],"domain_scores_gemma":[0.99933946,0.00012316395,0.00024608438,0.00008703305,0.00014546413,0.000058778835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007064884,0.000056531524,0.00019468984,0.00007105657,0.00004213499,0.000011424468,0.00011976171,0.00007636273,0.00012850897],"category_scores_gemma":[0.0016853815,0.00002496163,0.00017604255,0.0002728274,0.000010640954,0.000044485278,0.000043966735,0.00018939473,0.000013718252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000798497,0.0005684229,0.7612455,0.00006252747,0.0011854691,0.00003905629,0.00011515213,0.000003029206,0.00021151637,0.0023047836,0.21265274,0.021531945],"study_design_scores_gemma":[0.0025415684,0.000088069275,0.8796048,0.0002993686,0.00039136058,0.0000073852643,0.000011495841,0.00011776338,0.00025788663,0.0032375024,0.11340763,0.000035153687],"about_ca_topic_score_codex":0.000001976013,"about_ca_topic_score_gemma":0.000004339919,"teacher_disagreement_score":0.16878778,"about_ca_system_score_codex":0.0003083732,"about_ca_system_score_gemma":0.00011773835,"threshold_uncertainty_score":0.20176809},"labels":[],"label_agreement":null},{"id":"W4413306264","doi":"10.2196/81912","title":"Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study","year":2025,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Psychology; Medicine; Computer science; World Wide Web","score_opus":0.07005006803471196,"score_gpt":0.4228116283212223,"score_spread":0.35276156028651035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413306264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8880539,0.00012394977,0.00002645786,0.0018108591,0.000051769348,0.0064053605,0.0000050454714,0.00007250257,0.10345018],"genre_scores_gemma":[0.9849225,0.000104633174,0.0013532466,0.00009867739,0.000021350605,0.0011454906,0.000037942973,0.000012850855,0.012303291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787724,0.00017335423,0.00032376125,0.00036707107,0.0007643233,0.0004942279],"domain_scores_gemma":[0.99921083,0.00012870943,0.000045483586,0.0003228012,0.00020152808,0.000090645844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010644385,0.00016962261,0.00031451095,0.0008239621,0.00016419005,0.000069116046,0.00012374899,0.00004462952,0.000039103514],"category_scores_gemma":[0.00006024669,0.00013638427,0.000047542453,0.001106923,0.00012788364,0.00018766566,0.00038980332,0.00034098333,0.000032611046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005583602,0.004125165,0.7541033,0.0006080027,0.00080021773,0.00024383221,0.0045895944,0.0000011749406,0.00001153442,0.010262803,0.01078636,0.21390967],"study_design_scores_gemma":[0.0042566885,0.0018288817,0.9775607,0.00035674276,0.000050758546,8.3327865e-7,0.0029661343,0.0013217339,0.000048622143,0.0027198545,0.008787556,0.00010147839],"about_ca_topic_score_codex":0.00012786996,"about_ca_topic_score_gemma":0.00024257494,"teacher_disagreement_score":0.22345744,"about_ca_system_score_codex":0.0006156504,"about_ca_system_score_gemma":0.000058666363,"threshold_uncertainty_score":0.55615896},"labels":[],"label_agreement":null},{"id":"W4413356805","doi":"10.1111/cob.70042","title":"Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Clinical Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cochrane Library; Overweight; Internal medicine; Obesity; Hazard ratio; Diabetes mellitus; Randomized controlled trial; Type 2 diabetes; MEDLINE; Placebo; Type 2 Diabetes Mellitus; Cohort study; Meta-analysis; Weight loss; Endocrinology; Confidence interval; Alternative medicine; Pathology","score_opus":0.029554287551785123,"score_gpt":0.3469496090640229,"score_spread":0.31739532151223776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413356805","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017917136,0.97250885,0.000008927362,0.000059160815,0.00019250401,0.008758696,0.000018004972,0.00003684848,0.0004998591],"genre_scores_gemma":[0.0025949904,0.9959166,0.000060953804,0.00019630793,0.000052027164,0.00035639483,0.000024406634,0.00003179254,0.00076649623],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99330413,0.0035515146,0.001846094,0.00048813224,0.0005055966,0.00030452522],"domain_scores_gemma":[0.96327615,0.03301444,0.0019594827,0.0014876092,0.00017565046,0.000086663014],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00683884,0.0005476574,0.0062816376,0.0000887863,0.00013021754,0.000017705477,0.0005415836,0.00021392907,0.00005909605],"category_scores_gemma":[0.013860555,0.0001888034,0.0012205956,0.0008843156,0.00021753061,0.00003564391,0.00032266136,0.00060271204,0.000041159117],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024550787,0.00032905606,0.049421195,0.9231576,0.0030369714,0.0000049791224,0.00002231522,7.775775e-8,1.9050734e-9,0.00012175671,0.00042381563,0.02345768],"study_design_scores_gemma":[0.00026360995,0.0018288266,0.011550049,0.9331405,0.049709413,6.767341e-7,0.000008105925,0.0000061543756,0.000002493389,0.000008417516,0.003283947,0.00019780987],"about_ca_topic_score_codex":0.000026680254,"about_ca_topic_score_gemma":0.00005226039,"teacher_disagreement_score":0.04667244,"about_ca_system_score_codex":0.00011964806,"about_ca_system_score_gemma":0.00036032795,"threshold_uncertainty_score":0.9944461},"labels":[],"label_agreement":null},{"id":"W4413358587","doi":"10.3390/obesities5030063","title":"“Super-Responders” to Liraglutide Monotherapy and the Growing Evidence of Efficacy of GLP-1 Analogues in Obesity Management: A Longitudinal Prospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Obesities","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Alexandra Hospital; South Health Campus; University of Alberta","funders":"","keywords":"Liraglutide; Medicine; Obesity; Prospective cohort study; Cohort; Internal medicine; Glucagon-like peptide-1; Longitudinal study; Diabetes mellitus; Cohort study; Oncology; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.015414125165216026,"score_gpt":0.2943926331759171,"score_spread":0.27897850801070107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413358587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918609,0.0020274397,0.000085422005,0.00063179736,0.00004067827,0.0028538571,0.0000015717887,0.000019613968,0.0024786713],"genre_scores_gemma":[0.99708337,0.0003237736,0.00019359375,0.00017798062,0.000010713108,0.00016850085,0.0000015268283,0.0000074132477,0.0020331207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893874,0.00009921561,0.00028497248,0.00027370508,0.0002384875,0.00016487905],"domain_scores_gemma":[0.9992483,0.00030271523,0.000056591354,0.00030705874,0.0000577099,0.000027618686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006161262,0.00014645913,0.0004809907,0.00033261513,0.00005308425,0.000018181514,0.00011817562,0.000022255303,0.000011957328],"category_scores_gemma":[0.000072067945,0.00010237795,0.00007039741,0.0004363822,0.00016395588,0.00016049253,0.00014097348,0.00006311135,0.0000016471017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019081312,0.00078127853,0.9775359,0.00029579393,0.00090195826,0.000026771435,0.0036670396,0.000019007064,0.000063838816,0.013294813,0.000083635656,0.0014218037],"study_design_scores_gemma":[0.004635724,0.0005602204,0.9849874,0.00086437294,0.00052518566,3.67302e-7,0.0069582076,0.00002842205,0.0008765009,0.0004536846,0.000037037313,0.000072892064],"about_ca_topic_score_codex":0.00046403855,"about_ca_topic_score_gemma":0.00014293379,"teacher_disagreement_score":0.012841129,"about_ca_system_score_codex":0.000086246124,"about_ca_system_score_gemma":0.000021754606,"threshold_uncertainty_score":0.41748515},"labels":[],"label_agreement":null},{"id":"W4413358799","doi":"10.1111/dom.16652","title":"Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel <scp>GLP</scp> ‐ <scp>1R</scp> / <scp>GIPR</scp> dual agonist, <scp>HISHS</scp> ‐2001","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Division of Diabetes, Endocrinology, and Metabolic Diseases; Institute of Nutrition, Metabolism and Diabetes; National Institute of Diabetes and Digestive and Kidney Diseases; Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Eli Lilly and Company; Society for Endocrinology; Diabetes UK; Wellcome Trust; Canada Foundation for Innovation","keywords":"Receptor; Incretin; Agonist; Internalization; Internal medicine; Endocrinology; G protein-coupled receptor; Insulin; In vivo; Downregulation and upregulation; Glucagon-like peptide-1; Medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Pharmacology; Diabetes mellitus; Chemistry; Biology; Biochemistry","score_opus":0.011660221750556832,"score_gpt":0.23365995100454845,"score_spread":0.2219997292539916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413358799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359895,0.009971226,0.00018663841,0.000098179815,0.00083923584,0.0019031805,0.00016866623,0.00013076415,0.0031031696],"genre_scores_gemma":[0.9846169,0.00597493,0.0012552748,0.0010547753,0.00031067102,0.00020233262,0.0005093438,0.00009822374,0.005977552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956823,0.00033690972,0.0010062734,0.0011619814,0.00062355783,0.0011889666],"domain_scores_gemma":[0.9957308,0.0026129207,0.00051022106,0.00051979354,0.00019764532,0.00042858353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001247351,0.0008317552,0.0016400687,0.0017347953,0.00018779188,0.00023296571,0.00023759865,0.0005110294,0.0000049172104],"category_scores_gemma":[0.0043250783,0.00081319787,0.00018956867,0.0013145012,0.00030964694,0.00047502964,0.0004304789,0.000583013,0.000011935213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000644132,0.0047399374,0.4225964,0.0047869026,0.0013498903,0.000081866674,0.005700913,0.000059785638,0.52565604,0.0025852034,0.015552209,0.016826458],"study_design_scores_gemma":[0.014024651,0.0007798225,0.4220029,0.0024902972,0.0012601225,0.0000045154843,0.0014390516,0.0020945522,0.46384263,0.0005482208,0.09136881,0.0001444172],"about_ca_topic_score_codex":0.00017608432,"about_ca_topic_score_gemma":0.00008853684,"teacher_disagreement_score":0.0758166,"about_ca_system_score_codex":0.00018558008,"about_ca_system_score_gemma":0.00009165615,"threshold_uncertainty_score":0.9994319},"labels":[],"label_agreement":null},{"id":"W4413367038","doi":"10.1016/j.molmet.2025.102235","title":"GLP-1R signaling does not modify the severity of experimental graft versus host disease","year":2025,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Graft-versus-host disease; Host (biology); Disease; Signal transduction; Biology; Medicine; Cell biology; Internal medicine; Genetics","score_opus":0.011041249623586071,"score_gpt":0.27206278878268475,"score_spread":0.2610215391590987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413367038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98726207,0.006329067,0.0004112696,0.0017741033,0.00062768307,0.00062199833,0.000022524548,0.000050136947,0.0029011369],"genre_scores_gemma":[0.9971369,0.00004317543,0.0004060205,0.0011591184,0.000048532194,0.00008543283,0.000027106267,0.000016333486,0.0010773771],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893916,0.00006182103,0.00020434485,0.0002583473,0.00031164504,0.00022468959],"domain_scores_gemma":[0.9992692,0.000035181063,0.000058904167,0.00047954413,0.00005587383,0.00010131007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012168817,0.0001821002,0.00029873266,0.00009532707,0.00007496856,0.000024662962,0.00015225579,0.000031473828,0.00006893398],"category_scores_gemma":[0.000056677924,0.00011156959,0.00023042926,0.00018783857,0.00010036707,0.000047596288,0.00014751189,0.00008848438,0.000010192715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021040314,0.0013091671,0.0011107184,0.0002124899,0.0021761514,0.0002252415,0.00048810957,0.00004823837,0.92847437,0.05667025,0.0005724833,0.0066087833],"study_design_scores_gemma":[0.0041623497,0.00005234894,0.016228998,0.00006234185,0.0015641722,2.5680094e-7,0.00025670935,0.00017675704,0.9642563,0.0002969303,0.012796053,0.00014680174],"about_ca_topic_score_codex":0.000057747417,"about_ca_topic_score_gemma":0.0000013491949,"teacher_disagreement_score":0.056373317,"about_ca_system_score_codex":0.00003777436,"about_ca_system_score_gemma":0.000055270855,"threshold_uncertainty_score":0.4549676},"labels":[],"label_agreement":null},{"id":"W4413369659","doi":"10.1136/bmjmed-2025-001369","title":"Prognostic models for cardiovascular and kidney outcomes in people with type 2 diabetes: living systematic review and meta-analysis of observational studies","year":2025,"lang":"en","type":"article","venue":"BMJ Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ted Rogers Centre for Heart Research; Impact","funders":"","keywords":"Observational study; Meta-analysis; Type 2 diabetes; Medicine; Systematic review; Diabetes mellitus; Internal medicine; Intensive care medicine; MEDLINE; Endocrinology; Biology","score_opus":0.1291236073801074,"score_gpt":0.3654917843034908,"score_spread":0.23636817692338338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413369659","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04237369,0.9312766,0.0008788375,0.01438644,0.000044246364,0.01075899,0.000019599718,0.00003001872,0.0002315673],"genre_scores_gemma":[0.9570553,0.01951963,0.0035574238,0.010485846,0.000021746217,0.0048856586,0.00014862583,0.00003133925,0.004294479],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9988876,0.00006127804,0.00046657227,0.00021681147,0.00024746434,0.000120277786],"domain_scores_gemma":[0.9985468,0.000772577,0.000118222335,0.0002819325,0.0002294338,0.000051026254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010845043,0.00015358934,0.0033966696,0.0002837234,0.000021807136,0.0000033172175,0.000036568832,0.000020171363,0.000009657217],"category_scores_gemma":[0.002442884,0.000079797275,0.000269881,0.000666708,0.00006062026,0.00005023636,0.000040529085,0.000029815645,9.285436e-8],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009002581,0.00007452565,0.16101484,0.31004742,0.52719724,0.000002647023,0.00035978766,0.0000636231,0.0000010048512,0.00066933007,0.0005409374,0.000019664778],"study_design_scores_gemma":[0.00077584584,0.00025194345,0.03244881,0.016301082,0.9481131,3.805842e-7,0.00030154997,0.0016275465,7.607136e-7,0.00008793054,0.000020027543,0.00007103348],"about_ca_topic_score_codex":0.00001608706,"about_ca_topic_score_gemma":0.000032645446,"teacher_disagreement_score":0.91468155,"about_ca_system_score_codex":0.00002611938,"about_ca_system_score_gemma":0.000037281436,"threshold_uncertainty_score":0.32540384},"labels":[],"label_agreement":null},{"id":"W4413375067","doi":"10.1186/s41043-025-01041-8","title":"Comparative assessment of treatment outcomes of empagliflozin add-on metformin and sitagliptin add-on metformin therapies in uncontrolled type 2 diabetes mellitus: findings from an observational study in Pakistan","year":2025,"lang":"en","type":"article","venue":"Journal of Health Population and Nutrition","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"King Saud University","keywords":"Metformin; Sitagliptin; Medicine; Empagliflozin; Observational study; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Internal medicine; Oncology; Endocrinology","score_opus":0.10584248177032637,"score_gpt":0.4546568359584355,"score_spread":0.34881435418810913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413375067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595237,0.00179594,0.000009686717,0.00088689534,0.0000731092,0.0012289899,0.000022582346,0.0000040407003,0.000026358779],"genre_scores_gemma":[0.99759597,0.0007920659,0.0012356141,0.0001937768,0.000014930629,0.000024108842,0.000118307864,0.0000052697746,0.000019949623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982649,0.00023227106,0.000992284,0.0001448444,0.00024095875,0.00012471284],"domain_scores_gemma":[0.99895424,0.00030156662,0.0004925214,0.00009075345,0.000107134365,0.00005379413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007292851,0.00014996667,0.0009596844,0.00061338465,0.00004252053,0.000012544215,0.00003052683,0.00004493098,0.000014807417],"category_scores_gemma":[0.00002517826,0.00010759072,0.000056689154,0.00023903027,0.000019826135,0.00017906971,0.00000827999,0.00009139008,8.7826734e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012866153,0.0037540193,0.982065,0.00013150701,0.00033100334,0.0000026056573,0.0015724653,0.000052711926,0.00010428969,0.0007027352,0.000046970134,0.0099500315],"study_design_scores_gemma":[0.014490917,0.0099793915,0.96855414,0.0006184869,0.00013787243,1.8524781e-7,0.003979246,0.0010134637,0.00011668596,0.0009567987,0.00009210482,0.000060734532],"about_ca_topic_score_codex":0.00029231005,"about_ca_topic_score_gemma":0.00063267327,"teacher_disagreement_score":0.013510932,"about_ca_system_score_codex":0.00038477904,"about_ca_system_score_gemma":0.00008131809,"threshold_uncertainty_score":0.43874222},"labels":[],"label_agreement":null},{"id":"W4413375994","doi":"10.14309/ajg.0000000000003653","title":"Letter to the Editor","year":2025,"lang":"en","type":"letter","venue":"The American Journal of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine","score_opus":0.00702902029987986,"score_gpt":0.24368469447572758,"score_spread":0.2366556741758477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413375994","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011158377,0.000051201212,0.00038691013,0.9832912,0.0044271555,0.0003125991,0.000008932774,0.000009731469,0.00035390473],"genre_scores_gemma":[0.0042292653,0.000046338628,0.00032133993,0.93649393,0.05438597,0.00001943779,0.000010275566,0.000023711913,0.004469755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982539,0.00031984554,0.0004288006,0.00016807047,0.00036855048,0.0004608651],"domain_scores_gemma":[0.998434,0.00016794467,0.0006491376,0.000547198,0.0001348588,0.00006683936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038891882,0.00024755188,0.0008763972,0.0002618847,0.000059668964,0.000025565054,0.0006428287,0.0000620884,0.000053681764],"category_scores_gemma":[0.00004365428,0.00011304654,0.00036185357,0.00015389401,0.00031388053,0.00002215035,0.00017011049,0.0014814101,0.000058283204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016907675,0.00003875745,0.001232834,0.000017971732,0.0011714714,0.00033872356,0.00006483349,0.000005326787,0.000004332017,0.000001087351,0.9926515,0.0027823432],"study_design_scores_gemma":[0.0005859524,0.010434095,0.0014802414,0.00010926354,0.0010410947,0.00017376643,0.000038073747,0.0000011154924,0.0000042734737,0.000014157207,0.9860714,0.00004654845],"about_ca_topic_score_codex":0.000011250406,"about_ca_topic_score_gemma":0.000004687169,"teacher_disagreement_score":0.049958814,"about_ca_system_score_codex":0.000098486926,"about_ca_system_score_gemma":0.000052015068,"threshold_uncertainty_score":0.6436072},"labels":[],"label_agreement":null},{"id":"W4413418357","doi":"10.1016/j.nbd.2025.107054","title":"Nutrient sensing receptor GPRC6A regulates mTORC1 signaling and Tau biology","year":2025,"lang":"en","type":"article","venue":"Neurobiology of Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute on Aging; National Institutes of Health; Edward N. and Della L. Thome Memorial Foundation; Florida Department of Health; BrightFocus Foundation; Alzheimer's Association","keywords":"mTORC1; Cell biology; Biology; Signal transduction; Receptor; Neuroscience; PI3K/AKT/mTOR pathway; Biochemistry","score_opus":0.008428101727609534,"score_gpt":0.249938200789073,"score_spread":0.24151009906146348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413418357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996117,0.0006578849,0.000069780166,0.0018255039,0.00023637923,0.00033454024,0.000015794476,0.000050589733,0.0006925095],"genre_scores_gemma":[0.99757004,0.00012786305,0.0003771447,0.00096770946,0.00003728472,0.0000063222774,0.00009300337,0.000008152957,0.0008124765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923867,0.00006492297,0.00018999407,0.0002861612,0.00002968032,0.00019059175],"domain_scores_gemma":[0.99948585,0.00009992329,0.00006192159,0.00020296297,0.000044287928,0.00010507904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006547651,0.00012589057,0.00027488396,0.00014688387,0.000045934266,0.000004431443,0.000041038416,0.00005699052,0.000042583873],"category_scores_gemma":[0.00007832091,0.00010413444,0.000069803085,0.000108624154,0.00020898307,0.000019464034,0.00008222934,0.000058541416,0.000006528339],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026623923,0.0011498976,0.2837548,0.0011516236,0.001125344,0.000029047973,0.00015742963,0.000022447906,0.6314907,0.026109017,0.013524136,0.038823176],"study_design_scores_gemma":[0.018466786,0.0046225768,0.30263507,0.0016217348,0.0047683674,0.000003909337,0.00041489166,0.00035065174,0.5579148,0.021289583,0.08691481,0.0009967911],"about_ca_topic_score_codex":0.0000052482765,"about_ca_topic_score_gemma":4.1982148e-7,"teacher_disagreement_score":0.07357587,"about_ca_system_score_codex":0.000017510032,"about_ca_system_score_gemma":0.00004031521,"threshold_uncertainty_score":0.4246479},"labels":[],"label_agreement":null},{"id":"W4413433815","doi":"10.1177/20543581251365364","title":"The “Real-World” Effect of Anti-hyperglycemic Drugs on the Development of Chronic Kidney Disease in a Retrospective Cohort of Patients With Incident Diabetes: A Research Letter","year":2025,"lang":"en","type":"letter","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Medicine; Kidney disease; Diabetes mellitus; Retrospective cohort study; Disease; Cohort; Intensive care medicine; Cohort study; Internal medicine; Endocrinology","score_opus":0.009534594314563813,"score_gpt":0.2745847256202514,"score_spread":0.26505013130568755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413433815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5689264,0.001345162,5.8325054e-7,0.42621377,0.00022277972,0.0025032295,0.0004880234,0.0000027445521,0.00029731652],"genre_scores_gemma":[0.7227577,0.0004003693,0.000013463527,0.27545908,0.00030449918,0.00014290833,0.00040348075,0.000044170425,0.00047434084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622345,0.0005465717,0.0010062228,0.0003271303,0.0011025579,0.0007940943],"domain_scores_gemma":[0.9902232,0.00052017835,0.00078866107,0.00056022994,0.0004958028,0.007411888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015795019,0.00034256864,0.0010342305,0.0012038806,0.00024161533,0.000029081324,0.00032877392,0.00008729497,0.000039718394],"category_scores_gemma":[0.0051589534,0.00018663934,0.0001804626,0.0006218547,0.0004652599,0.000057252568,0.0000567565,0.0009971878,0.0000011004961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007387494,0.00008159967,0.5421833,0.0027088642,0.0003152724,0.000075765354,0.0001946363,8.180537e-7,2.764967e-7,0.000016029902,0.4531019,0.0005828198],"study_design_scores_gemma":[0.0059270896,0.0025718254,0.7872532,0.013874591,0.0006961896,1.7798077e-7,0.000050056307,0.000013496804,0.000024030278,0.00007501056,0.18928766,0.00022665068],"about_ca_topic_score_codex":0.0016044019,"about_ca_topic_score_gemma":0.0009485473,"teacher_disagreement_score":0.26381424,"about_ca_system_score_codex":0.0020194112,"about_ca_system_score_gemma":0.06449953,"threshold_uncertainty_score":0.9408039},"labels":[],"label_agreement":null},{"id":"W4413440628","doi":"10.1186/s12876-025-04211-4","title":"Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies","year":2025,"lang":"en","type":"review","venue":"BMC Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Meta-analysis; Cohort study; Cochrane Library; Exenatide; Cohort; Oncology; Retrospective cohort study; Type 2 diabetes; Cancer; Diabetes mellitus; Endocrinology","score_opus":0.05564628916010866,"score_gpt":0.36735785536263327,"score_spread":0.3117115662025246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413440628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019513873,0.9765964,0.000013705237,0.00019290125,0.00020082295,0.0020140053,0.0011834634,0.000038701346,0.00024609733],"genre_scores_gemma":[0.0014018998,0.9927315,0.00027579343,0.00008068017,0.00008477398,0.0013153447,0.00067928806,0.000025690315,0.0034050024],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970813,0.00059897004,0.0008380262,0.00072346913,0.00034485423,0.0004133709],"domain_scores_gemma":[0.9974059,0.00049382343,0.0014150788,0.00032154605,0.0002740189,0.00008964492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000705175,0.00049420487,0.008312895,0.0007416955,0.00006253711,0.000014646789,0.00012449641,0.0002762436,0.00017741148],"category_scores_gemma":[0.00046498937,0.00036023694,0.0022424734,0.0005846082,0.00012365295,0.000033399378,0.00022597001,0.0002998673,0.000008629784],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005610004,0.0000652888,0.5087209,0.0023794572,0.48395836,0.0000020503178,0.000028990638,3.5576574e-7,5.316883e-8,0.000008752964,0.0013388802,0.003440847],"study_design_scores_gemma":[0.00060916744,0.0009023714,0.120815575,0.00036293326,0.83417916,6.3047224e-7,0.000020231679,0.0000013952333,8.2469626e-7,0.000010403398,0.04299951,0.000097818294],"about_ca_topic_score_codex":0.00017873711,"about_ca_topic_score_gemma":0.0012516769,"teacher_disagreement_score":0.38790527,"about_ca_system_score_codex":0.001078432,"about_ca_system_score_gemma":0.00013026787,"threshold_uncertainty_score":0.99988496},"labels":[],"label_agreement":null},{"id":"W4413473307","doi":"10.47941/ijhmnp.3122","title":"Semaglutide's Role in Modulating the Brain-Heart Axis: Implications for Obesity and Alzheimer’s Disease Co-management","year":2025,"lang":"en","type":"article","venue":"International Journal of Health Medicine and Nursing Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Semaglutide; Disease; Obesity; Medicine; Neuroscience; Internal medicine; Psychology; Cardiology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.044996261986307934,"score_gpt":0.44285879587212706,"score_spread":0.39786253388581916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413473307","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041250985,0.018397499,0.002069076,0.93466383,0.00041015135,0.00072566175,0.0000036462407,0.00000871003,0.0024704463],"genre_scores_gemma":[0.9715367,0.0013963453,0.002568394,0.024115216,0.00019759731,0.000021075859,0.0000113290325,0.000007185454,0.00014618259],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99899817,0.000088165776,0.00043775947,0.00012782474,0.0002111761,0.0001369376],"domain_scores_gemma":[0.99833524,0.00096020364,0.00029522294,0.00009968139,0.0002064807,0.000103156504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013497155,0.00008414885,0.00021380618,0.000255579,0.00012859542,0.000024181478,0.000076786295,0.000016751139,0.0000031953252],"category_scores_gemma":[0.00067171216,0.00005735707,0.00003410283,0.00010032792,0.0000849206,0.00014682111,0.000021014004,0.00013105363,2.6907776e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014030497,0.0012926188,0.058453772,0.00023388687,0.0010645414,0.00003045201,0.002307324,0.000039011644,0.00006455941,0.033973407,0.05792031,0.8432171],"study_design_scores_gemma":[0.004624653,0.0006569109,0.7690068,0.0030942354,0.0008899318,0.000104074104,0.0041054967,0.00053927075,0.000008507644,0.009980538,0.20691729,0.00007234272],"about_ca_topic_score_codex":0.00004496645,"about_ca_topic_score_gemma":0.0000031221116,"teacher_disagreement_score":0.9302857,"about_ca_system_score_codex":0.00013005236,"about_ca_system_score_gemma":0.00010642273,"threshold_uncertainty_score":0.23389533},"labels":[],"label_agreement":null},{"id":"W4413493027","doi":"10.64628/aam.4hvvhdrjk","title":"Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options","year":2024,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Affect (linguistics); Type 2 diabetes; Diabetes mellitus; Medicine; Intensive care medicine; Internal medicine; Psychology; Endocrinology","score_opus":0.04553931088907143,"score_gpt":0.3094817935559257,"score_spread":0.2639424826668543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413493027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86166406,0.0062155463,0.000045536657,0.033152867,0.00034537187,0.0014191034,0.0000461034,0.00070401997,0.096407406],"genre_scores_gemma":[0.96922123,0.0016495527,0.0018606419,0.0017944035,0.00007372558,0.00014129796,0.00008169035,0.000025912432,0.025151541],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992485,0.000012744853,0.00012032013,0.0002993706,0.000114005314,0.00020506929],"domain_scores_gemma":[0.9994299,0.00014008941,0.000013890824,0.0002677893,0.00003351559,0.00011480944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000520481,0.00015572383,0.00019520299,0.00009894219,0.00006574289,0.000078063575,0.00003567266,0.000038886687,0.000501217],"category_scores_gemma":[0.000013333791,0.000112815935,0.00007559531,0.00017507766,0.000046546316,0.00007039286,0.000035872774,0.00004245783,0.0005667997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015876083,0.0041342983,0.11902329,0.0011505461,0.013003363,0.00006408054,0.0025438573,0.000009249586,0.026262578,0.20521629,0.16673018,0.4617035],"study_design_scores_gemma":[0.0019153107,0.0024032597,0.3502707,0.00029412383,0.002276295,0.000004795909,0.00012880137,0.001768173,0.010653028,0.0007612671,0.6291363,0.0003879535],"about_ca_topic_score_codex":0.000028786637,"about_ca_topic_score_gemma":0.000015644986,"teacher_disagreement_score":0.46240613,"about_ca_system_score_codex":0.00009658497,"about_ca_system_score_gemma":0.000028237326,"threshold_uncertainty_score":0.7285252},"labels":[],"label_agreement":null},{"id":"W4413739033","doi":"10.1176/appi.ajp.20241087","title":"Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: Association Versus Causation and the Need for Ongoing Surveillance","year":2025,"lang":"en","type":"article","venue":"American Journal of Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Causation; Association (psychology); Glucagon-like peptide-1; Receptor; Glucagon; Medicine; Endocrinology; Psychology; Internal medicine; Diabetes mellitus; Psychotherapist; Political science; Insulin","score_opus":0.006847534014597305,"score_gpt":0.27093580638631487,"score_spread":0.26408827237171756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413739033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94524217,0.0012373078,0.00054674933,0.049995035,0.0016112971,0.0003379417,0.000004431391,0.000010961004,0.0010140836],"genre_scores_gemma":[0.99192196,0.0005869269,0.004759108,0.0014520709,0.00025918832,0.000011509359,0.000008315213,0.000009841442,0.0009910626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927884,0.000072155366,0.00026469416,0.00010268815,0.00014794391,0.00013367014],"domain_scores_gemma":[0.99895084,0.0003470288,0.0004408773,0.00009417429,0.00011754338,0.000049557904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071554823,0.00009049139,0.00030597104,0.00009008665,0.000093793555,0.000041747582,0.000041740794,0.000022972004,0.0000035098685],"category_scores_gemma":[0.00016399911,0.000062214924,0.00008297301,0.00016661978,0.00010008111,0.00006073454,0.000017517488,0.00008983481,6.351407e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056082252,0.00016477605,0.865314,0.00014988486,0.0022196698,0.0000010443885,0.00052989443,0.0000064548817,0.000115536204,0.0065783304,0.028116362,0.09119584],"study_design_scores_gemma":[0.050097,0.004425758,0.87153685,0.000515899,0.0024230918,0.00001224665,0.009065312,0.00026723355,0.00009293101,0.004003633,0.057212126,0.0003478921],"about_ca_topic_score_codex":0.0000649454,"about_ca_topic_score_gemma":0.00009664425,"teacher_disagreement_score":0.09084795,"about_ca_system_score_codex":0.00010958897,"about_ca_system_score_gemma":0.000097845295,"threshold_uncertainty_score":0.25370508},"labels":[],"label_agreement":null},{"id":"W4413840361","doi":"10.1161/circulationaha.125.076575","title":"Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Michael's Hospital; Université de Montréal; St. Paul's Hospital; Montreal Heart Institute","funders":"Janssen Research and Development; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; American Regent; Intas Pharmaceuticals; Institut de Cardiologie de Montréal; Daiichi Sankyo Europe; Servier; Deutsche Herzstiftung; Novo Nordisk; Daiichi-Sankyo; Deutsche Forschungsgemeinschaft; Medicines Company; ARCA Biopharma; Zora Biosciences; National Center for Advancing Translational Sciences; Verily Life Sciences; AstraZeneca; Amarin Corporation; Sanofi; Abiomed; Ionis Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Defense Acquisition Program Administration; Boston Scientific Corporation; Alnylam Pharmaceuticals; Duke Clinical Research Institute; Cytokinetics; Medpace; Brigham and Women's Hospital; Kowa Company; HLS Therapeutics; GlaxoSmithKline; Deutsches Zentrum für Herz-Kreislaufforschung; Harvard Catalyst; University of Glasgow; iRhythm Technologies; Amgen; Pfizer; Eli Lilly and Company","keywords":"Dapagliflozin; Medicine; Heart failure; TIMI; Randomized controlled trial; Internal medicine; Clinical trial; Cardiology; Pharmacology; Diabetes mellitus; Endocrinology; Type 2 diabetes; Myocardial infarction","score_opus":0.023341283329220985,"score_gpt":0.2984446364620538,"score_spread":0.27510335313283285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413840361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541737,0.00010614952,0.00021136449,0.001568611,0.00024024158,0.012214156,0.00018872476,0.000016805237,0.000036558526],"genre_scores_gemma":[0.9960211,0.000009309287,0.0013354277,0.00023259857,0.000022260345,0.0006778982,0.001633684,0.000021499915,0.000046246303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961888,0.00039625194,0.0021845854,0.0005439308,0.00042493604,0.00026148188],"domain_scores_gemma":[0.9977919,0.00066167937,0.0006893831,0.0005110426,0.00028274176,0.000063245825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021169598,0.00028319252,0.002773782,0.00055429153,0.000050546274,0.000019889323,0.00010839279,0.00020500444,0.0000103963075],"category_scores_gemma":[0.0010130967,0.00019999016,0.0018106381,0.0007952113,0.00015066109,0.00016664724,0.000044936958,0.00010998708,2.9579058e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20669846,0.0024424077,0.76782423,0.00028652351,0.02011016,1.7469658e-7,0.00021980549,0.00009724196,0.000053021486,0.000066296576,0.0016723113,0.0005293345],"study_design_scores_gemma":[0.40929493,0.00043150605,0.54011095,0.00004051597,0.048890833,6.4243584e-9,0.000011792712,0.00046408674,0.00018594599,0.00009985711,0.00036294502,0.00010662146],"about_ca_topic_score_codex":0.000070882445,"about_ca_topic_score_gemma":0.000051765037,"teacher_disagreement_score":0.2277133,"about_ca_system_score_codex":0.0001099867,"about_ca_system_score_gemma":0.00008599544,"threshold_uncertainty_score":0.8155362},"labels":[],"label_agreement":null},{"id":"W4413881387","doi":"10.1093/eurheartj/ehaf635","title":"Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ejection fraction; Heart failure; Incretin; Internal medicine; Cardiology; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Endocrinology","score_opus":0.028036956292047385,"score_gpt":0.2959422137871427,"score_spread":0.2679052574950953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413881387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86306053,0.0005821421,0.005521664,0.10932579,0.0015478042,0.0031465115,0.0000038244357,0.0002367724,0.016574984],"genre_scores_gemma":[0.96729594,0.00009445606,0.012021961,0.01181492,0.0024550455,0.00006993544,0.000033579006,0.00008175939,0.006132405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988528,0.000218152,0.0002480594,0.00021073896,0.00022439007,0.00024585356],"domain_scores_gemma":[0.99935836,0.00009026248,0.00009586024,0.00020496924,0.0001287135,0.00012184402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063332636,0.00016800835,0.00027926834,0.00025955183,0.00027018515,0.00012515762,0.000056413115,0.0000323039,0.00020318136],"category_scores_gemma":[0.000052613315,0.000120114346,0.0001914748,0.00024808457,0.00003106285,0.00010020302,0.000011865113,0.00026556558,0.00004241127],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06148574,0.00086967414,0.012305204,0.00008145654,0.00071914995,0.00006184164,0.00007532011,0.000045457356,0.009614496,0.00007750485,0.9038521,0.01081205],"study_design_scores_gemma":[0.06324239,0.0042914925,0.008309235,0.00032389312,0.00018872926,0.000036929592,0.0001649662,0.000079255486,0.0025764452,0.00002549491,0.9206411,0.000120030774],"about_ca_topic_score_codex":0.000002959428,"about_ca_topic_score_gemma":0.0000014175398,"teacher_disagreement_score":0.10423543,"about_ca_system_score_codex":0.00010179094,"about_ca_system_score_gemma":0.00013133061,"threshold_uncertainty_score":0.48981208},"labels":[],"label_agreement":null},{"id":"W4413885454","doi":"10.1093/eurjpc/zwaf539","title":"Heterogeneous cardiovascular effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a causal forest and target trial emulation study","year":2025,"lang":"en","type":"article","venue":"European Journal of Preventive Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Minority Health and Health Disparities; Japan Science and Technology Agency; Japan Society for the Promotion of Science; National Institutes of Health; Eisai Canada; AstraZeneca KK; General Insurance Association of Japan; National Institute on Aging; Kyowa Hakko Kirin; OMRON Corporation; Norges Idrettshøgskole","keywords":"Medicine; Internal medicine; Diabetes mellitus; Type 2 diabetes; Myocardial infarction; Stroke (engine); Disease; Body mass index; Type 2 Diabetes Mellitus; Relative risk; Dipeptidyl peptidase-4; Confidence interval; Endocrinology","score_opus":0.008663355323634691,"score_gpt":0.24244512549176955,"score_spread":0.23378177016813487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413885454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936355,0.0077675763,0.00032812954,0.000020437343,0.0008294564,0.0011631813,0.000001478905,0.0000064837814,0.00051969616],"genre_scores_gemma":[0.9993243,0.00025377717,0.00010244259,0.000029950334,0.00018934008,0.0000071456852,0.000008102388,0.000016884029,0.000068034264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785036,0.0010507343,0.0005618814,0.00019414884,0.00016540418,0.00017745727],"domain_scores_gemma":[0.9993136,0.00009616609,0.00019458683,0.00018981473,0.00014757116,0.000058253023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011270448,0.0001568086,0.00087799074,0.00032410963,0.00002050758,0.000006784421,0.0000726181,0.000033532087,0.0000031504342],"category_scores_gemma":[0.00013451207,0.00012664622,0.00036783653,0.00017055424,0.00006906835,0.000054979544,0.000054396205,0.00015197504,0.000001645118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010951507,0.0012379423,0.9307822,0.00055194355,0.015190724,0.0051863464,0.0010176898,0.0020416519,0.001860538,0.000016837386,0.00035915963,0.030803438],"study_design_scores_gemma":[0.07278052,0.011274642,0.9068181,0.0005522843,0.0036616223,0.000021073129,0.00015041495,0.000030007972,0.0018983885,0.00008207138,0.002574294,0.00015656374],"about_ca_topic_score_codex":0.00000208515,"about_ca_topic_score_gemma":0.000001955304,"teacher_disagreement_score":0.061829016,"about_ca_system_score_codex":0.000046329922,"about_ca_system_score_gemma":0.00004098965,"threshold_uncertainty_score":0.5164483},"labels":[],"label_agreement":null},{"id":"W4413912023","doi":"10.1016/j.cmet.2025.06.012","title":"Reassessment of antibody-based detection of the murine T cell GLP-1 receptor","year":2025,"lang":"en","type":"article","venue":"Cell Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"HORIZON EUROPE Framework Programme; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Medical Research Council; Novo Nordisk; Economic and Social Research Council; European Commission; Diabetes UK; UK Research and Innovation; Canadian Cancer Society; Diabetes Canada; Saint Mary's Foundation","keywords":"Antibody; Receptor; Computational biology; Biology; Cell; Cell biology; Cancer research; Medicine; Immunology; Genetics","score_opus":0.005500175567142851,"score_gpt":0.2510463679568969,"score_spread":0.24554619238975403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413912023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556146,0.0019594452,0.00070279615,0.00042488042,0.0009242313,0.0007274191,0.000009853049,0.0000302499,0.03960651],"genre_scores_gemma":[0.9883621,0.0001664392,0.000879515,0.00018027863,0.00004223667,0.00002472059,0.000017113927,0.000011096705,0.010316528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991691,0.000049089216,0.0002623754,0.00016986538,0.00020746891,0.000142077],"domain_scores_gemma":[0.99923295,0.000032194435,0.00015777041,0.00045063277,0.00009081845,0.000035659956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015214884,0.00012376394,0.0003147051,0.00013496864,0.000032776737,0.0000047375543,0.00010989504,0.0000481414,0.00009690049],"category_scores_gemma":[0.000016459706,0.00008248107,0.00017225789,0.00035207655,0.000055469234,0.000025682617,0.00006255772,0.000074520445,0.000008877306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011744846,0.0010585794,0.0053512785,0.00089321076,0.00013946592,0.000001066451,0.000049147715,0.000013063392,0.95875484,0.00060004124,0.0011824688,0.031839415],"study_design_scores_gemma":[0.0020087038,0.00007414271,0.09124532,0.00008891338,0.0006102697,4.5813927e-8,0.000043093853,0.000048586488,0.8325906,0.00005303271,0.07318538,0.00005191848],"about_ca_topic_score_codex":0.000051042134,"about_ca_topic_score_gemma":0.0000026160358,"teacher_disagreement_score":0.12616421,"about_ca_system_score_codex":0.000029955852,"about_ca_system_score_gemma":0.00007282745,"threshold_uncertainty_score":0.33634803},"labels":[],"label_agreement":null},{"id":"W4413914392","doi":"10.1016/j.amjcard.2025.08.046","title":"A Phase 1b Randomized Clinical Trial of AZD5462 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment","year":2025,"lang":"en","type":"article","venue":"The American Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Dapagliflozin; Randomized controlled trial; Medicine; Heart failure; Internal medicine; Clinical trial; Intensive care medicine; Diabetes mellitus; Endocrinology","score_opus":0.010687185385849451,"score_gpt":0.31371111504989013,"score_spread":0.3030239296640407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413914392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965504,0.00017766024,0.00034332543,0.0020218643,0.000072718714,0.00067268655,0.0000020081854,0.0000024714907,0.00015685812],"genre_scores_gemma":[0.99862736,0.00020167493,0.0007035598,0.00035099484,0.00007526967,0.000011381652,0.000001909596,0.0000049420264,0.000022922251],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99833435,0.0007394599,0.00056014553,0.00011127022,0.00012322709,0.0001315596],"domain_scores_gemma":[0.99890393,0.0004539424,0.00036295695,0.00013579198,0.00008255737,0.000060835635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016879959,0.000103253544,0.0015141215,0.00014524012,0.000018901972,0.0000059880344,0.000049332644,0.000022997732,0.0000014677585],"category_scores_gemma":[0.00012125167,0.000051752242,0.00015550421,0.00010360352,0.00064053346,0.000028397575,0.00004100596,0.00015986187,1.6770319e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92773455,0.0006893688,0.05139061,0.00001317394,0.0017242933,0.000018637209,0.00007171474,0.00003276368,0.000017084705,0.000067328656,0.00074100296,0.017499471],"study_design_scores_gemma":[0.9452439,0.020949043,0.03117847,0.00010012777,0.0011530033,0.000016533448,0.00015434367,0.00008164335,0.000016223734,0.00019815289,0.00085441873,0.00005415329],"about_ca_topic_score_codex":0.000007767012,"about_ca_topic_score_gemma":0.000001132759,"teacher_disagreement_score":0.020259675,"about_ca_system_score_codex":0.000019428586,"about_ca_system_score_gemma":0.000069275295,"threshold_uncertainty_score":0.23600721},"labels":[],"label_agreement":null},{"id":"W4413946529","doi":"10.14309/ajg.0000000000003760","title":"Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Hazard ratio; Diabetes mellitus; Gastroparesis; Type 2 diabetes; Endocrinology; Gastric emptying; Stomach","score_opus":0.0036153571492281798,"score_gpt":0.2147174362436498,"score_spread":0.21110207909442164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413946529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828225,0.000057068948,0.00005282773,0.0012142403,0.00008243004,0.00018583605,0.0000031152838,0.0000043856508,0.00011782868],"genre_scores_gemma":[0.99699634,0.00006503781,0.0019976438,0.00084415404,0.000017357028,0.00000252755,0.00000569287,0.000009191039,0.000062053914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989779,0.00012810572,0.0003837083,0.000118954325,0.00013842445,0.00025289314],"domain_scores_gemma":[0.99910116,0.000080083155,0.00042771042,0.00017097118,0.00015566727,0.00006442923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002627235,0.00013142165,0.000583871,0.00020373566,0.00002369889,0.0000052269497,0.00012071866,0.000008170043,0.000018315077],"category_scores_gemma":[0.000040680345,0.0000785948,0.000056668672,0.00020267171,0.00047717607,0.00004473234,0.00006999904,0.00016853205,0.0000010548912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01638638,0.00034910275,0.97879,0.000028899349,0.0002833832,0.000010552145,0.000045741337,0.000010569489,0.00014503223,0.000013342561,0.00033579624,0.0036012281],"study_design_scores_gemma":[0.0034740304,0.027560502,0.96789086,0.0003159448,0.00020698016,0.000021810329,0.00016454568,0.0000128143965,0.000047903137,0.00001905172,0.00025269185,0.00003284584],"about_ca_topic_score_codex":0.00001200112,"about_ca_topic_score_gemma":0.000013145259,"teacher_disagreement_score":0.0272114,"about_ca_system_score_codex":0.000059409776,"about_ca_system_score_gemma":0.000045016342,"threshold_uncertainty_score":0.3205003},"labels":[],"label_agreement":null},{"id":"W4413968705","doi":"10.1093/ehjqcco/qcaf104","title":"Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Quality of Care and Clinical Outcomes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"HeartFlow; National Heart, Lung, and Blood Institute; Patient-Centered Outcomes Research Institute; National Institute on Aging; Merck; Novo Nordisk; American College of Cardiology Foundation","keywords":"Medicine; Library science; Family medicine; Computer science","score_opus":0.039717642165241054,"score_gpt":0.3717610069280471,"score_spread":0.33204336476280605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413968705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917513,0.0021934486,0.000015967546,0.0005542122,0.00023098776,0.00033839562,0.000029311575,0.000009089724,0.004877253],"genre_scores_gemma":[0.9979496,0.00047696874,0.0006197607,0.00060487015,0.00004424035,0.0000013942795,0.00002132582,0.000009742747,0.00027208196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975396,0.00045752397,0.001078999,0.00024378664,0.00048208056,0.00019803639],"domain_scores_gemma":[0.9987184,0.00022211611,0.00018927838,0.00038591455,0.0002365404,0.00024776554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001316933,0.00016442433,0.000978962,0.000078512356,0.000043876837,0.000020720801,0.00009985657,0.000035006757,0.000018835493],"category_scores_gemma":[0.0005853506,0.00011306537,0.00078025396,0.00017748214,0.00015775548,0.00006342002,0.00009122826,0.00017103876,0.000005977008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005229809,0.0005631792,0.96246177,0.000419209,0.0012934908,0.000023762746,0.000058996888,0.0000045044458,3.8271628e-7,0.00007830362,0.0005061158,0.034067288],"study_design_scores_gemma":[0.0059475745,0.000866732,0.97934824,0.000614601,0.00072882324,3.0601302e-7,0.00019606359,8.6751515e-7,0.0000023349232,0.000027956221,0.012172348,0.00009413264],"about_ca_topic_score_codex":0.000027111118,"about_ca_topic_score_gemma":0.000014138764,"teacher_disagreement_score":0.033973154,"about_ca_system_score_codex":0.00005360901,"about_ca_system_score_gemma":0.000102175276,"threshold_uncertainty_score":0.4610672},"labels":[],"label_agreement":null},{"id":"W4413972009","doi":"10.1093/eurjpc/zwaf560","title":"Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"European Journal of Preventive Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Medicine; Incretin; Internal medicine; Blood pressure; Confidence interval; Hypoglycemia; Exenatide; Randomized controlled trial; Placebo; Endocrinology; Type 2 diabetes; Insulin; Diabetes mellitus","score_opus":0.013758903650283654,"score_gpt":0.28161020035719286,"score_spread":0.2678512967069092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413972009","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04843697,0.93014705,0.0012808852,0.0015857626,0.00010245472,0.0028524792,0.000021788148,0.000018793035,0.01555383],"genre_scores_gemma":[0.9956782,0.0018809695,0.00012357776,0.0006491671,0.000016027203,0.000016823065,0.0000038666994,0.000010104415,0.0016213072],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945981,0.0044458485,0.0005770746,0.00014344121,0.00013646312,0.000099055505],"domain_scores_gemma":[0.9984956,0.00050513726,0.0005272337,0.0002732116,0.00015749525,0.00004134317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036260986,0.00015985192,0.0028815013,0.00029507634,0.000019198626,0.0000058166443,0.00010963483,0.000016239706,0.000044169657],"category_scores_gemma":[0.00043575172,0.00008683153,0.0014426747,0.00023342318,0.00006865538,0.000018530505,0.000039617968,0.00010928885,0.0000028041725],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019829192,0.000086053355,0.0014140086,0.08653449,0.91048783,0.00023807686,0.000033212338,0.000031708783,0.00014225185,0.00010260682,0.000579344,0.00015213319],"study_design_scores_gemma":[0.0013269278,0.003032044,0.0026202193,0.0027941454,0.98937947,0.000011976676,0.000007601926,0.0000020399575,0.00053606636,0.000007250156,0.00023264239,0.000049617414],"about_ca_topic_score_codex":3.5819448e-7,"about_ca_topic_score_gemma":6.186758e-8,"teacher_disagreement_score":0.9472412,"about_ca_system_score_codex":0.0000063836874,"about_ca_system_score_gemma":0.000014483364,"threshold_uncertainty_score":0.3540887},"labels":[],"label_agreement":null},{"id":"W4414081596","doi":"10.1016/j.cjca.2025.08.359","title":"GLP-1 Receptor Agonists vs SGLT2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction","year":2025,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Heart failure with preserved ejection fraction; Heart failure; Ejection fraction; Receptor; Benzhydryl compounds","score_opus":0.012482090191323325,"score_gpt":0.235890851595944,"score_spread":0.22340876140462068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414081596","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043179315,0.00070043444,0.000072274386,0.9427464,0.004128141,0.001266417,0.000058341175,0.000026262087,0.007822423],"genre_scores_gemma":[0.41488746,0.0006725192,0.0037284803,0.4733339,0.051278185,0.00030175087,0.0020683757,0.00033618326,0.053393163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980893,0.00028187226,0.00053409336,0.00032402962,0.00023394034,0.00053676055],"domain_scores_gemma":[0.99869365,0.00009550456,0.00031620136,0.00032195426,0.00027703753,0.0002956304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031646882,0.00032224788,0.0011875626,0.0013217946,0.00007525908,0.000044262422,0.00015067753,0.0007462132,0.00011603298],"category_scores_gemma":[0.00016822918,0.00024307868,0.0002863924,0.00036491296,0.00010945116,0.00012497499,0.000014659403,0.0016201294,0.000018744004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038813538,0.0000047459203,0.027748447,0.00017777555,0.00091466913,0.0016397912,0.000020936066,0.000055918208,0.000054092492,0.0000014819897,0.96834195,0.0006520349],"study_design_scores_gemma":[0.0018767937,0.0013298271,0.009149076,0.00090499653,0.00059636583,0.0002286714,0.0000844358,0.0000010326552,0.00012620204,0.000014400826,0.98549205,0.00019613713],"about_ca_topic_score_codex":0.0018272412,"about_ca_topic_score_gemma":0.0064186826,"teacher_disagreement_score":0.4694125,"about_ca_system_score_codex":0.0013015952,"about_ca_system_score_gemma":0.0024601023,"threshold_uncertainty_score":0.9912461},"labels":[],"label_agreement":null},{"id":"W4414081664","doi":"10.1016/j.jcjo.2025.08.009","title":"Sodium-glucose cotransporter 2 inhibitors and risk of diabetic retinopathy: systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Disease; Clinical trial; MEDLINE; Risk factor","score_opus":0.01880198644559921,"score_gpt":0.2632751396692645,"score_spread":0.2444731532236653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414081664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.755779,0.23922908,0.000009342776,0.0014211886,0.00008267055,0.00068211276,0.00003175814,0.0000018914432,0.002762924],"genre_scores_gemma":[0.9969001,0.0012009094,0.0001379091,0.00021167246,0.000007706655,0.000014162653,0.0000054070915,0.0000073877786,0.0015147753],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986895,0.00016804533,0.0007101438,0.00014550814,0.00009768043,0.00018912957],"domain_scores_gemma":[0.9987503,0.00010828195,0.00043869918,0.0002306224,0.00016936296,0.0003027124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006786638,0.00015019256,0.0020949047,0.0006437663,0.000040382092,0.000010824628,0.00007821738,0.00006353214,0.00041203914],"category_scores_gemma":[0.00018536647,0.0001036398,0.00043977454,0.00036803389,0.0001442668,0.000044474997,0.000010208891,0.00012757994,0.0000012166159],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004047512,0.00011865824,0.45185813,0.13586932,0.40053546,0.009811139,0.00032576048,0.0000046191726,0.000027400221,0.00045499767,0.00089707784,0.00005693984],"study_design_scores_gemma":[0.00054870447,0.00037914253,0.033416577,0.0014943175,0.96181405,0.0018291139,0.00006431959,0.0000041289227,0.00013804036,0.00018589933,0.000035126464,0.00009060383],"about_ca_topic_score_codex":0.0005838895,"about_ca_topic_score_gemma":0.0001262968,"teacher_disagreement_score":0.5612786,"about_ca_system_score_codex":0.000044160068,"about_ca_system_score_gemma":0.00018306829,"threshold_uncertainty_score":0.45115396},"labels":[],"label_agreement":null},{"id":"W4414084840","doi":"10.1016/j.euroneuro.2025.08.002","title":"Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations","year":2025,"lang":"en","type":"review","venue":"European Neuropsychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University of Ottawa","funders":"Life Sciences, University of California, Los Angeles; National Natural Science Foundation of China; Canadian Institutes of Health Research; Global Alliance for Chronic Diseases; AbbVie; Milken Institute","keywords":"Observational study; Repurposing; Depression (economics); Drug repositioning; Major depressive disorder","score_opus":0.14183780043761765,"score_gpt":0.44580603147438486,"score_spread":0.3039682310367672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414084840","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000823257,0.9853935,0.000019078092,0.00043666718,0.0015174194,0.011567992,0.00009997188,0.00006440756,0.0008186138],"genre_scores_gemma":[0.000004408287,0.9920095,0.0009840172,0.0019375824,0.00027264352,0.0010188717,0.00025409932,0.000095264346,0.0034235902],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939674,0.0019100538,0.0029159249,0.00072825694,0.0002290621,0.00024930606],"domain_scores_gemma":[0.99141586,0.005418293,0.0018681473,0.0008890936,0.00024685144,0.00016176206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012265028,0.0004888062,0.0034352713,0.00016183825,0.00010289257,0.000016617807,0.0003395818,0.0001126511,0.000039024533],"category_scores_gemma":[0.0011948375,0.00029082518,0.0012185758,0.0003893511,0.000368653,0.000038222995,0.00013056671,0.00023111732,0.000012576586],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087335764,0.0010756938,0.00007708439,0.79519486,0.0028641524,0.000017501092,0.000023838042,2.2902681e-7,0.0000060252037,0.000046037858,0.01925947,0.18134779],"study_design_scores_gemma":[0.0015400451,0.0011470349,0.00015378882,0.2984029,0.026789885,0.000011504534,0.000003072456,0.000008534101,8.634638e-7,0.0000025943327,0.67181176,0.0001280169],"about_ca_topic_score_codex":0.0000012422447,"about_ca_topic_score_gemma":4.0009175e-7,"teacher_disagreement_score":0.6525523,"about_ca_system_score_codex":0.00006336766,"about_ca_system_score_gemma":0.00031006217,"threshold_uncertainty_score":0.9999544},"labels":[],"label_agreement":null},{"id":"W4414085673","doi":"10.1111/dom.70121","title":"Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to <scp>HbA1c</scp> lowering in type 2 diabetes: An updated meta‐regression analysis incorporating <scp>FLOW</scp> and <scp>SOUL</scp> trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University and Génome Québec Innovation Centre; McGill Genome Centre","funders":"Canadian Institutes of Health Research; Japan Student Services Organization; Fonds de Recherche du Québec - Santé; TD Bank","keywords":"Mace; Type 2 diabetes; Clinical trial; Surrogate endpoint; Agonist","score_opus":0.01665137745857425,"score_gpt":0.25970634202639736,"score_spread":0.2430549645678231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414085673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759167,0.020277364,0.00024425675,0.000097372606,0.00056442426,0.0020528308,0.0001295995,0.00020549321,0.0005119941],"genre_scores_gemma":[0.9854857,0.0024580886,0.006653217,0.0006551754,0.00036666368,0.00042171322,0.0014298325,0.00009095852,0.0024386637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946715,0.0007219572,0.0011594929,0.0015426371,0.0009005305,0.0010038646],"domain_scores_gemma":[0.99686223,0.00046701124,0.0006526683,0.0009400169,0.00046934496,0.0006087298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003686981,0.00088202173,0.0032785635,0.0015197262,0.0005282987,0.00032991378,0.00024575277,0.0003633037,0.000021312155],"category_scores_gemma":[0.001482829,0.00066658726,0.0007870211,0.0031085338,0.00023154682,0.00072640454,0.00030809417,0.0005305763,0.000019317105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009050448,0.0024286658,0.8283662,0.001167312,0.09137204,0.00006604634,0.004078099,0.0024574408,0.013195238,0.0002920985,0.011355091,0.045131262],"study_design_scores_gemma":[0.0084073,0.0010507774,0.6851052,0.0007821955,0.0994178,0.00000327969,0.0029794546,0.0026086264,0.088488206,0.0008726094,0.109869234,0.00041531667],"about_ca_topic_score_codex":0.00017568839,"about_ca_topic_score_gemma":0.00006211101,"teacher_disagreement_score":0.143261,"about_ca_system_score_codex":0.00013286184,"about_ca_system_score_gemma":0.00016332725,"threshold_uncertainty_score":0.99957854},"labels":[],"label_agreement":null},{"id":"W4414167602","doi":"10.1002/ehf2.15393","title":"Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI","year":2025,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Canadian VIGOUR Centre; University of Alberta; University Health Network; Women's College Hospital","funders":"American Regent; Abbott Vascular; Esperion Therapeutics; Daiichi Sankyo Europe; Servier; Vifor Pharma; Universitair Medisch Centrum Groningen; University of Toronto; Bayer HealthCare; Sanofi; Abiomed; Horizon Therapeutics; Pfizer; York University; Moderna; Idorsia Pharmaceuticals; Impulse Dynamics; Novo Nordisk; MyoKardia; Norgine; Novavax; ZOLL Medical Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Boston Scientific Corporation; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Duke Clinical Research Institute; Astellas Pharma; Cytokinetics; HLS Therapeutics; GlaxoSmithKline; LivaNova; Heart and Stroke Foundation of Canada; Amgen; Patient-Centered Outcomes Research Institute","keywords":"Empagliflozin; Myocardial infarction; Diabetes mellitus; Heart failure; Kidney disease; Type 2 diabetes","score_opus":0.004717815387064102,"score_gpt":0.23059603157063452,"score_spread":0.22587821618357043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842005,0.001697145,0.000027613698,0.012237107,0.00019244294,0.0007963785,0.00003454667,0.00013467552,0.0006796275],"genre_scores_gemma":[0.9911156,0.000048330396,0.00063506595,0.0037966396,0.00031134326,0.00021713106,0.00015613998,0.000027185451,0.0036925096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988655,0.000045915735,0.00016232763,0.0003967218,0.00023207239,0.00029749915],"domain_scores_gemma":[0.99914414,0.0000383711,0.0000305408,0.00036717654,0.000044288663,0.0003754631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042091368,0.00024732624,0.00037907853,0.00016277615,0.00009181422,0.000080000056,0.000043049764,0.000081237085,0.00034899142],"category_scores_gemma":[0.000038145125,0.000164649,0.00007403553,0.00022715308,0.00009738603,0.00019126119,0.000068874244,0.00014929046,0.00006295749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010384944,0.00021917069,0.9199945,0.00031747526,0.0012452613,0.00004725852,0.00032912305,0.0000026319556,0.0012993081,0.00008881626,0.07306504,0.0023529278],"study_design_scores_gemma":[0.004172942,0.0005667704,0.5500526,0.0008793447,0.0010921994,7.5108653e-7,0.00009920652,0.00014060501,0.0010571113,0.000119747994,0.4415811,0.00023761927],"about_ca_topic_score_codex":0.000038740334,"about_ca_topic_score_gemma":0.0001505977,"teacher_disagreement_score":0.3699419,"about_ca_system_score_codex":0.000120445926,"about_ca_system_score_gemma":0.00028999985,"threshold_uncertainty_score":0.6714191},"labels":[],"label_agreement":null},{"id":"W4414167921","doi":"10.1007/s40262-025-01571-8","title":"Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University; Université de Montréal; McGill University Health Centre","funders":"Kidney Foundation of Canada","keywords":"Kidney disease; Canagliflozin; Population; Pharmacokinetics; Population pharmacokinetics; Clinical trial","score_opus":0.03396655612676739,"score_gpt":0.39832007449921975,"score_spread":0.36435351837245233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859651,0.0022041702,0.0007906118,0.0027194875,0.0010587419,0.0012584276,0.000024160014,0.000080246136,0.005899063],"genre_scores_gemma":[0.9941027,0.0015569114,0.00056134776,0.002133544,0.00015451795,0.000049517792,0.0001436176,0.000022218988,0.0012755819],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980756,0.00007850198,0.00094218133,0.00037957463,0.00021980696,0.00030430427],"domain_scores_gemma":[0.999033,0.0001060006,0.00011895068,0.00032341047,0.00008649208,0.00033219418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030228123,0.00019590139,0.0005039992,0.00026159696,0.000023124529,0.0000075133576,0.00013816806,0.00006226535,0.00015765773],"category_scores_gemma":[0.0002891388,0.00018681554,0.0001866892,0.0004586322,0.00006197215,0.00006151141,0.00010516886,0.00024248462,0.000011013132],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023507124,0.0033124445,0.6099961,0.0024308185,0.0007482618,0.00014157791,0.000033623026,0.099031985,0.0023133866,0.0012318305,0.010641637,0.26776764],"study_design_scores_gemma":[0.018081326,0.00033150896,0.15994436,0.0010428464,0.0017562632,2.8221464e-7,0.000012795904,0.799098,0.0006424186,0.00097030343,0.017839665,0.00028024625],"about_ca_topic_score_codex":0.000050376864,"about_ca_topic_score_gemma":0.000012173212,"teacher_disagreement_score":0.70006603,"about_ca_system_score_codex":0.00017337591,"about_ca_system_score_gemma":0.00020907665,"threshold_uncertainty_score":0.7618117},"labels":[],"label_agreement":null},{"id":"W4414169171","doi":"10.1001/jama.2025.14392","title":"New Molecules and Indications for GLP-1 Medicines","year":2025,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Perspective (graphical); MEDLINE; Small molecule; Drug approval","score_opus":0.009676357978402725,"score_gpt":0.28370238932526753,"score_spread":0.2740260313468648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414169171","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21646789,0.009839171,0.061398268,0.42041597,0.0006467627,0.0036390747,0.00003055525,0.00030924747,0.28725308],"genre_scores_gemma":[0.7991702,0.000484431,0.029908376,0.016868751,0.0004533564,0.00028046203,0.00018608964,0.000020606127,0.15262775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973536,0.000002458072,0.00006190215,0.00008738282,0.00004302611,0.000069850474],"domain_scores_gemma":[0.99979156,0.000037554786,0.000014340317,0.00009242535,0.000020389987,0.000043712218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034315,0.00004414687,0.000084592866,0.00007705207,0.000027739068,0.000011530442,0.000022760561,0.000022949866,0.000027269374],"category_scores_gemma":[0.000065191634,0.000033512722,0.000019977913,0.00007556621,0.000015216195,0.000023040346,0.000018401006,0.00001878803,0.0000042848865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003684925,0.000055965505,0.011136663,0.00012322777,0.00018484087,0.0000025016343,0.000106856,1.2586518e-7,0.0003155984,0.04390588,0.3881147,0.5560168],"study_design_scores_gemma":[0.0058654197,0.0002410458,0.19699714,0.00018909927,0.00061178894,9.187496e-7,0.00016373396,0.00012177193,0.0017583236,0.009030812,0.7849534,0.000066507855],"about_ca_topic_score_codex":0.000013326891,"about_ca_topic_score_gemma":0.0000063967777,"teacher_disagreement_score":0.5827023,"about_ca_system_score_codex":0.000011411177,"about_ca_system_score_gemma":0.000029717135,"threshold_uncertainty_score":0.1366609},"labels":[],"label_agreement":null},{"id":"W4414189723","doi":"10.1016/s2213-8587(25)00225-6","title":"Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk","keywords":"Semaglutide; Type 2 diabetes; Obesity; Diabetes mellitus; Clinical trial; MEDLINE","score_opus":0.013636066117558401,"score_gpt":0.27955186139662896,"score_spread":0.26591579527907055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414189723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97732246,0.005087128,0.0000082839,0.0064446935,0.0005467171,0.0047181416,0.00001316561,0.00015102566,0.0057083615],"genre_scores_gemma":[0.9921375,0.0008758414,0.00021213331,0.0027549337,0.00030274034,0.00095891673,0.000050302016,0.000029230949,0.0026783934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969812,0.00030146982,0.00050451874,0.0005570967,0.00020251772,0.0014531646],"domain_scores_gemma":[0.99805206,0.0008992096,0.00017264271,0.0006780633,0.000091674796,0.00010637733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055748445,0.000408415,0.001798571,0.0002770881,0.00012619187,0.00004430272,0.00027178074,0.00009966438,0.00006835087],"category_scores_gemma":[0.00033931798,0.00024850862,0.00014073375,0.00041197528,0.00035991299,0.00007446489,0.0001854619,0.00036960052,0.00003067875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5750534,0.0025598763,0.32207948,0.00074439944,0.0038977864,0.00020320617,0.0004625016,0.000007393847,0.00093429,0.0053532314,0.012718687,0.0759858],"study_design_scores_gemma":[0.96113956,0.0037589248,0.017807664,0.00051321654,0.0013441168,0.0000029938335,0.00019930406,0.0008056932,0.0011464523,0.000688232,0.012291605,0.00030224977],"about_ca_topic_score_codex":0.000050492956,"about_ca_topic_score_gemma":0.00013119755,"teacher_disagreement_score":0.38608617,"about_ca_system_score_codex":0.00009578283,"about_ca_system_score_gemma":0.00009504287,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W4414189914","doi":"10.1016/s2213-8587(25)00226-8","title":"Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk","keywords":"Semaglutide; Obesity; German; MEDLINE; Diabetes mellitus; Clinical trial","score_opus":0.01465677988245434,"score_gpt":0.28648707511636473,"score_spread":0.2718302952339104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414189914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652044,0.0019897418,0.00004669143,0.00943438,0.00057861046,0.006013177,0.000014444803,0.00018578325,0.016532777],"genre_scores_gemma":[0.9881352,0.00038092776,0.00025064748,0.0035346714,0.00038558975,0.0018547085,0.000052450854,0.000027304286,0.0053784763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996855,0.00032119214,0.00054989103,0.0005231314,0.00022954069,0.0015212379],"domain_scores_gemma":[0.99805224,0.000776201,0.00018229606,0.00082158885,0.000076503144,0.000091189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000566755,0.00038588356,0.0018286599,0.00028122097,0.00011408102,0.000032869913,0.0003567609,0.00008935512,0.00010502449],"category_scores_gemma":[0.00027119202,0.00022852053,0.00022723681,0.0003968106,0.0002770727,0.00006264644,0.00015540974,0.00039350262,0.000063309395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8469782,0.003069741,0.060808796,0.00040903036,0.0031067613,0.0003589901,0.00037486808,0.000014871019,0.00037965772,0.007994459,0.015993314,0.0605113],"study_design_scores_gemma":[0.9709055,0.0024197854,0.00558165,0.0003956376,0.0011086743,0.000004586354,0.00020960781,0.0006003272,0.00083578855,0.0005718423,0.017133862,0.00023275205],"about_ca_topic_score_codex":0.000093954724,"about_ca_topic_score_gemma":0.00022552142,"teacher_disagreement_score":0.12392727,"about_ca_system_score_codex":0.00014232741,"about_ca_system_score_gemma":0.00011559364,"threshold_uncertainty_score":0.93187964},"labels":[],"label_agreement":null},{"id":"W4414279821","doi":"10.1681/asn.0000000838","title":"Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Overweight; Semaglutide; Clinical trial; Population; Type 2 diabetes; Diabetes mellitus; Kidney disease; Biomarker","score_opus":0.011325050592772577,"score_gpt":0.2751757220232381,"score_spread":0.26385067143046553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414279821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93631816,0.00015107484,0.00053705054,0.06242345,0.000087043176,0.00024046672,0.0000011694437,0.000006625076,0.00023498815],"genre_scores_gemma":[0.9759892,0.00054834684,0.0044319914,0.017623648,0.00005752605,0.0000087557555,6.753776e-7,0.0000062976023,0.0013335592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933475,0.000092456234,0.0002756534,0.00008457016,0.000101465295,0.00011110034],"domain_scores_gemma":[0.99930036,0.00004010563,0.00038958786,0.0001473944,0.00007386517,0.00004869837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030960786,0.00007003734,0.00033541815,0.00008618266,0.000041274317,0.000004229703,0.00007229694,0.0000311567,0.0000059416816],"category_scores_gemma":[0.00009470692,0.000047551515,0.00016584035,0.00034953022,0.00029345564,0.000037762737,0.00005839094,0.00019240825,3.060947e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012237082,0.0013543001,0.50005805,0.00043824947,0.0032280786,0.000023861068,0.0025426883,0.00006852122,0.112036146,0.0011868028,0.30357262,0.07426696],"study_design_scores_gemma":[0.0018023808,0.001103174,0.9004349,0.00025132493,0.00050275965,0.000033281005,0.00064155745,0.00043574968,0.0007203741,0.0015820991,0.0924346,0.000057818568],"about_ca_topic_score_codex":0.00027215757,"about_ca_topic_score_gemma":0.0000114450595,"teacher_disagreement_score":0.40037683,"about_ca_system_score_codex":0.00008968008,"about_ca_system_score_gemma":0.000115106464,"threshold_uncertainty_score":0.19390947},"labels":[],"label_agreement":null},{"id":"W4414292494","doi":"10.1111/dom.70135","title":"Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Heart and Stroke Foundation; University of Toronto","funders":"","keywords":"Enteroendocrine cell; Clinical trial; Endogeny; Adverse effect; Glucagon-like peptide-1; Endocrine system; Hormone; In vitro","score_opus":0.02251802642745963,"score_gpt":0.3321211460644948,"score_spread":0.30960311963703513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414292494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9381558,0.059570976,0.00002631346,0.00045575513,0.00032616247,0.0012079377,0.00006437832,0.000057176327,0.00013551973],"genre_scores_gemma":[0.97547466,0.021759983,0.00036444585,0.0014185166,0.00009079053,0.0000529772,0.00008012162,0.000017130122,0.00074138405],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977207,0.00032712443,0.0008106081,0.0005944455,0.00012480901,0.0004223],"domain_scores_gemma":[0.9988599,0.00033812088,0.00017462461,0.00029609085,0.000060909075,0.00027034487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001735374,0.00031709467,0.0014101833,0.00027491746,0.000092669754,0.00008346128,0.00006966569,0.00017000262,0.000013243877],"category_scores_gemma":[0.0005472848,0.00026469483,0.00013316367,0.00028414195,0.0001988156,0.00018081305,0.00018359449,0.00024576578,0.0000046381892],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001851438,0.0050258436,0.2123829,0.000730334,0.0013777987,0.00011046489,0.00033028887,0.0000013982071,0.1409151,0.0006703964,0.0013767866,0.63522726],"study_design_scores_gemma":[0.052055206,0.0007828326,0.8828606,0.0003843368,0.003033825,0.0000015504108,0.00007119446,0.0032730177,0.027718136,0.0005834543,0.028778119,0.00045771577],"about_ca_topic_score_codex":0.000045924484,"about_ca_topic_score_gemma":0.000011766509,"teacher_disagreement_score":0.67047775,"about_ca_system_score_codex":0.000022582677,"about_ca_system_score_gemma":0.00003910363,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W4414340870","doi":"10.1002/ehf2.15408","title":"SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure: A Scientific Statement of the HFA and the HFAI","year":2025,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Defense Acquisition Program Administration","keywords":"Empagliflozin; Dapagliflozin; Ejection fraction; Heart failure; Observational study; Clinical trial; Randomized controlled trial","score_opus":0.010853369083072939,"score_gpt":0.27090566866833055,"score_spread":0.2600522995852576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414340870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8531012,0.0029077174,0.00010280697,0.13779935,0.00038520285,0.005511898,0.000026801054,0.000022211952,0.00014278111],"genre_scores_gemma":[0.9916954,0.00007307492,0.0011104225,0.00021302003,0.00004320034,0.00031968698,0.0000129682285,0.000009990167,0.006522253],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895287,0.000084317566,0.0003084143,0.00024145137,0.0002240865,0.0001888354],"domain_scores_gemma":[0.9991492,0.00020657195,0.000094276096,0.00043271648,0.0000794988,0.000037735077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054962334,0.00014912516,0.00031180267,0.00007655768,0.0002701955,0.000052340078,0.000067189976,0.000040911662,0.000019156012],"category_scores_gemma":[0.000042826097,0.0000647833,0.00017790575,0.00025805045,0.00045617038,0.00005462012,0.00008570184,0.00005034382,0.0000013524736],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018282179,0.003329683,0.13492997,0.002222319,0.004658523,0.0000020393832,0.008293031,0.00006470802,0.023688583,0.037700746,0.71604824,0.06723391],"study_design_scores_gemma":[0.008549568,0.0008488613,0.022213446,0.000409264,0.0011392892,0.0000022770193,0.0018418744,0.0002611731,0.019593108,0.0011057098,0.9439422,0.00009323742],"about_ca_topic_score_codex":0.000060371352,"about_ca_topic_score_gemma":0.00021868273,"teacher_disagreement_score":0.22789393,"about_ca_system_score_codex":0.0000513296,"about_ca_system_score_gemma":0.00008895414,"threshold_uncertainty_score":0.26417863},"labels":[],"label_agreement":null},{"id":"W4414361910","doi":"10.1007/s13300-025-01796-7","title":"Pillar Risk-Based Treatment for Chronic Kidney Disease in People With Type 2 Diabetes: A Narrative Review","year":2025,"lang":"en","type":"article","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Trillium Health Centre; University of Toronto","funders":"Bayer","keywords":"Kidney disease; Tolerability; Context (archaeology); Disease; Narrative review; Diabetes mellitus; Type 2 diabetes","score_opus":0.011106669528985659,"score_gpt":0.2817078758975569,"score_spread":0.27060120636857127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414361910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8913262,0.09687887,0.000026091466,0.0052233646,0.00016068823,0.0056616333,0.00007711408,0.00012585444,0.0005201994],"genre_scores_gemma":[0.92278725,0.0510384,0.0005950214,0.015685394,0.00012476812,0.0056387405,0.0012850732,0.000092792034,0.0027525625],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984168,0.000091314476,0.00029119017,0.0004900271,0.0001747417,0.0005359282],"domain_scores_gemma":[0.99879426,0.00016376073,0.0001224079,0.00056405674,0.000120548946,0.00023498396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019508605,0.00038119394,0.00074150116,0.00021614209,0.00010455112,0.000027226442,0.00011221,0.00005107844,0.00014030712],"category_scores_gemma":[0.000097948,0.0002559337,0.00020483666,0.0006919744,0.00006222593,0.00007060313,0.000015152295,0.000079067264,0.000015655753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009089641,0.0021266323,0.9042327,0.0031805001,0.0018859426,0.000009192781,0.00035086586,0.000067701476,0.00029091683,0.00010680364,0.011983703,0.07485612],"study_design_scores_gemma":[0.058338575,0.021973573,0.29612374,0.021721197,0.003915065,6.7914556e-8,0.0001283068,0.005215933,0.010047454,0.0005722214,0.5806422,0.0013216166],"about_ca_topic_score_codex":0.0000147889905,"about_ca_topic_score_gemma":0.000047888643,"teacher_disagreement_score":0.60810894,"about_ca_system_score_codex":0.00055102515,"about_ca_system_score_gemma":0.0006203587,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W4414363228","doi":"10.1093/ecco-jcc/jjaf167","title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Inflammatory bowel disease; Clinical trial; Agonist; Ulcerative colitis; Drug; Receptor; Inflammatory Bowel Diseases; Disease","score_opus":0.011755153169363652,"score_gpt":0.29379079477723924,"score_spread":0.2820356416078756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414363228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842386,0.0063230447,0.0003212478,0.007674505,0.00039368556,0.00036409756,0.000009383625,0.000011408486,0.00066399004],"genre_scores_gemma":[0.9905458,0.0054956013,0.00047814875,0.0014235494,0.000113467446,0.000016995315,0.000005988052,0.000009548264,0.001910876],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989554,0.00005778192,0.00051999267,0.00015353014,0.00014182253,0.00017144071],"domain_scores_gemma":[0.99935114,0.00005263131,0.00016762275,0.00013944211,0.00009349666,0.00019569033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034413463,0.00011448545,0.00028832548,0.00015824285,0.00006547721,0.000068262154,0.000061906205,0.000060338964,0.000034523455],"category_scores_gemma":[0.000029300756,0.00009347162,0.000104502964,0.0000763185,0.00008120371,0.000079106154,0.000054333937,0.00014901109,0.000002554577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007944715,0.001694388,0.35708806,0.0008600322,0.0017202058,0.00084739947,0.00020775876,0.0000049795535,0.0004296845,0.11516295,0.024870548,0.48916927],"study_design_scores_gemma":[0.0023095978,0.00024455113,0.9448253,0.00025021014,0.0003341217,0.00001631372,0.000081756356,0.000032367065,0.00002534095,0.00843424,0.043371957,0.000074228614],"about_ca_topic_score_codex":0.0000065105332,"about_ca_topic_score_gemma":0.0000070428773,"teacher_disagreement_score":0.58773726,"about_ca_system_score_codex":0.00005340602,"about_ca_system_score_gemma":0.00017813708,"threshold_uncertainty_score":0.38116622},"labels":[],"label_agreement":null},{"id":"W4414383885","doi":"10.2337/dc25-0562","title":"Type 2 Diabetes Remission: A Systematic Review and Meta-analysis of Nonsurgical Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University; Hamilton Health Sciences; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Kowa Company; Hamilton Health Sciences; Novo Nordisk; Sanofi; McMaster University; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; MEDLINE; Research design; Diabetes treatment","score_opus":0.06387131916359402,"score_gpt":0.3685499281895684,"score_spread":0.3046786090259744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414383885","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003021082,0.97177297,5.444188e-7,0.00015762568,0.00009989515,0.026022766,0.0003307742,0.0000615171,0.001550886],"genre_scores_gemma":[0.000026474083,0.9864242,0.00008563584,0.00048602762,0.000024774332,0.007600642,0.0015703668,0.00004438629,0.0037374655],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98868936,0.0047413073,0.00482674,0.00073235563,0.0005977497,0.0004124849],"domain_scores_gemma":[0.9807387,0.014329883,0.0029569068,0.0012075675,0.0005540282,0.00021292787],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.006993794,0.0010191923,0.118917085,0.0012220271,0.00005345546,0.000055550445,0.00025879935,0.00035043736,0.0006933895],"category_scores_gemma":[0.014504681,0.00046742125,0.024950719,0.0018165155,0.00013033913,0.000040726176,0.00017902478,0.00023458085,0.00002630249],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021220559,0.000044031465,0.000004427813,0.5443366,0.45313114,0.0000031291936,0.000010432874,5.1738354e-8,2.8564871e-8,0.000037249214,0.0003398015,0.0018808802],"study_design_scores_gemma":[0.027704248,0.00006867106,2.0138138e-7,0.18022151,0.77718526,1.3550257e-7,0.00001406073,0.0000051917054,6.9299983e-7,0.000004684738,0.014544635,0.0002507369],"about_ca_topic_score_codex":8.910121e-7,"about_ca_topic_score_gemma":4.316983e-7,"teacher_disagreement_score":0.3641151,"about_ca_system_score_codex":0.00008783199,"about_ca_system_score_gemma":0.00023558302,"threshold_uncertainty_score":0.99977773},"labels":[],"label_agreement":null},{"id":"W4414394366","doi":"10.1002/ejhf.70048","title":"Effect of Glucagon-Like Peptide-1 Receptor Agonists on Heart Failure Outcomes and Cardiovascular Death Across Varying Cardiovascular-Kidney-Metabolic Comorbidity","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Heart failure; Comorbidity; Agonist; Receptor; Cause of death; Clinical trial","score_opus":0.010478489879069386,"score_gpt":0.26355908717622095,"score_spread":0.25308059729715154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414394366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98148406,0.009102839,0.00015855538,0.006108512,0.0008872402,0.0008719621,0.000029759021,0.00006261757,0.0012944872],"genre_scores_gemma":[0.9934977,0.0004044331,0.004078286,0.0009262183,0.00029295674,0.0000074332247,0.000021223454,0.000073845375,0.00069789734],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962441,0.0011813313,0.00075037207,0.0004559763,0.0008549718,0.0005132879],"domain_scores_gemma":[0.99808145,0.00018011866,0.00020106496,0.0009192747,0.00022817565,0.00038991103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036085243,0.0004753935,0.001991196,0.00030717868,0.00022199382,0.00009982675,0.00023211118,0.00007704095,0.000038262562],"category_scores_gemma":[0.00035504624,0.0003458705,0.00212943,0.0002771293,0.00013880139,0.00018869567,0.00021269382,0.00056088937,0.000056696503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016218906,0.0009226049,0.49202484,0.0029291057,0.045616508,0.0012703233,0.00080270565,0.00063260755,0.005690877,0.00022749422,0.39807087,0.05019017],"study_design_scores_gemma":[0.008000131,0.0016608924,0.07532043,0.0010957475,0.0028855551,0.00014379538,0.00010612109,0.0000054355382,0.007891106,0.000003410528,0.9026347,0.00025272116],"about_ca_topic_score_codex":0.000022119753,"about_ca_topic_score_gemma":0.0000014799531,"teacher_disagreement_score":0.5045638,"about_ca_system_score_codex":0.00007018083,"about_ca_system_score_gemma":0.00009429917,"threshold_uncertainty_score":0.9998993},"labels":[],"label_agreement":null},{"id":"W4414432436","doi":"10.2196/64899","title":"Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial","year":2025,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Type 2 diabetes; Glycemic; Clinical trial; Protocol (science); Diabetes mellitus","score_opus":0.2642634662420609,"score_gpt":0.6004739565425047,"score_spread":0.3362104903004438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414432436","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23980673,3.7034164e-7,0.000008078015,0.00012873115,0.0000035025225,0.75856555,0.000008193585,0.00003501892,0.0014438144],"genre_scores_gemma":[0.034397554,5.6980255e-8,0.00063521985,0.00011136635,0.000040013914,0.96268237,0.000018306288,0.000038424972,0.0020766696],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99670196,0.00068002427,0.00059322733,0.00067110546,0.00062537816,0.0007282858],"domain_scores_gemma":[0.9974247,0.00093718624,0.00013476732,0.00075237686,0.000497388,0.00025355903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033039963,0.00029132987,0.0010436948,0.00057935127,0.000088629735,0.000110604095,0.0005093683,0.00012498844,0.000039075505],"category_scores_gemma":[0.00052492763,0.00016815357,0.000048401023,0.001707078,0.00015281726,0.00016211903,0.00017523668,0.00036148247,0.00001838472],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84157914,0.007895004,0.09030999,0.0019667584,0.00026735364,0.000017867258,0.000029739962,0.000003836788,0.0006592384,0.0001642446,0.0035372614,0.053569537],"study_design_scores_gemma":[0.42189893,0.5460344,0.002051583,0.006305301,0.00004787847,2.6024742e-7,0.000017171496,0.0002640601,0.007643328,0.000041357263,0.015538452,0.00015726208],"about_ca_topic_score_codex":0.000059020855,"about_ca_topic_score_gemma":0.00021330173,"teacher_disagreement_score":0.5381394,"about_ca_system_score_codex":0.00018340378,"about_ca_system_score_gemma":0.0005953409,"threshold_uncertainty_score":0.6857103},"labels":[],"label_agreement":null},{"id":"W4414563738","doi":"10.1177/20552076251382040","title":"GLP-1 receptor agonist therapy for obesity via direct-to-consumer telemedicine: Clinical characteristics and treatment outcomes","year":2025,"lang":"en","type":"article","venue":"Digital Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Semtech (Canada)","funders":"","keywords":"Obesity; Agonist; Weight loss; Clinical trial; Receptor; MEDLINE","score_opus":0.03149708165673444,"score_gpt":0.36642699004418,"score_spread":0.3349299083874456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414563738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711036,0.00084863824,0.00031885723,0.016720274,0.00080570555,0.0038474272,0.00030206653,0.00014795165,0.005905449],"genre_scores_gemma":[0.9715417,0.0021689662,0.0007274876,0.009398437,0.00016357293,0.00025663682,0.00059196254,0.000026956863,0.015124299],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99862653,0.000022818851,0.00048622486,0.00038610795,0.00012200081,0.00035629323],"domain_scores_gemma":[0.99897367,0.0002581625,0.00009641691,0.00029116464,0.000057183413,0.00032341568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002067201,0.00022747237,0.0007378462,0.00010445272,0.00012397312,0.000057973564,0.000052512278,0.000056666624,0.000015642483],"category_scores_gemma":[0.000090731424,0.00015685693,0.00014149454,0.000115877745,0.000072698655,0.0000627066,0.000036848374,0.000057020894,0.000035447658],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024777182,0.00087435375,0.46600115,0.00007905144,0.0002509793,0.0000021611827,0.000050485636,5.829877e-9,0.0000017859942,0.00012396011,0.007280019,0.5250883],"study_design_scores_gemma":[0.003913177,0.002980377,0.5463692,0.00008700901,0.00006824956,4.5391948e-7,0.000032700907,0.000010231541,0.000029828228,0.000047500595,0.44636163,0.00009965961],"about_ca_topic_score_codex":0.000048181046,"about_ca_topic_score_gemma":0.000017472084,"teacher_disagreement_score":0.52498865,"about_ca_system_score_codex":0.00020099584,"about_ca_system_score_gemma":0.00016509638,"threshold_uncertainty_score":0.639644},"labels":[],"label_agreement":null},{"id":"W4414588389","doi":"10.7759/cureus.93456","title":"A Comparative Analysis of Diabetic Ketoacidosis (DKA) in Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Users Versus Non-users: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetic ketoacidosis; Discontinuation; Diabetes mellitus; Incidence (geometry); Prospective cohort study; Ketoacidosis; MEDLINE; Complication","score_opus":0.04721120646922882,"score_gpt":0.35059204087200263,"score_spread":0.3033808344027738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414588389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016586635,0.9885865,0.000010094014,0.00003888335,0.0003401383,0.008382478,0.00016825419,0.000053804368,0.0022539718],"genre_scores_gemma":[0.001131038,0.9945566,0.00011056282,0.000116004885,0.000035662157,0.0020162582,0.0012843502,0.00003990496,0.0007096135],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956037,0.00032359085,0.0021850725,0.0007909084,0.00058598735,0.0005107423],"domain_scores_gemma":[0.99657,0.0005899951,0.0010908049,0.0013940941,0.00016107666,0.00019404032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005552784,0.000873403,0.011645494,0.0013273235,0.000036723042,0.000028825458,0.0004349818,0.00028498084,0.0001607723],"category_scores_gemma":[0.00016344454,0.00065994327,0.002313072,0.0038292438,0.00010413929,0.00010909688,0.0001042105,0.00033027754,0.00006176104],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004349437,0.000696679,0.00011232548,0.96661454,0.026112963,0.00007267944,0.00020968664,0.0000010995577,4.572643e-7,0.000028940614,0.0010076029,0.005099521],"study_design_scores_gemma":[0.0015863054,0.00033567517,0.0000654437,0.7014172,0.27757645,5.8385575e-7,0.00011687189,0.000023990835,0.0000068802833,0.0000010332162,0.018460091,0.00040945076],"about_ca_topic_score_codex":0.00007843241,"about_ca_topic_score_gemma":0.00030374096,"teacher_disagreement_score":0.26519734,"about_ca_system_score_codex":0.0006728463,"about_ca_system_score_gemma":0.00034276413,"threshold_uncertainty_score":0.99958515},"labels":[],"label_agreement":null},{"id":"W4414662065","doi":"10.1002/ejhf.70020","title":"What's New in Heart Failure? August 2025","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"","score_opus":0.012097298858522001,"score_gpt":0.2585594508921523,"score_spread":0.2464621520336303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414662065","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31092024,0.008829948,0.00035026183,0.65683305,0.0024909538,0.0008992842,0.0000019644187,0.00009958539,0.019574719],"genre_scores_gemma":[0.8669572,0.00045948022,0.04455869,0.011743728,0.0013412625,0.0000030449587,0.000014634286,0.00009104695,0.0748309],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998413,0.00020675766,0.00057329034,0.00019858844,0.000291345,0.0003169728],"domain_scores_gemma":[0.999213,0.000049115206,0.0001187564,0.0002944642,0.000099568264,0.00022512765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006932328,0.0001988526,0.00047522993,0.0004980555,0.000046741807,0.00015205891,0.00016219945,0.00002842551,0.0005147119],"category_scores_gemma":[0.00007848884,0.0001605659,0.00023333957,0.0004273951,0.000038580398,0.00046478017,0.00009279492,0.00041338426,0.00031551064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104862724,0.00019042207,0.018210225,0.000058845057,0.00016293977,0.00041009308,0.00010989569,0.000018480885,0.0009964503,0.000184651,0.972879,0.006674141],"study_design_scores_gemma":[0.0035065876,0.0004424733,0.045638166,0.0013351629,0.00015330446,0.00006147521,0.0006066467,0.0000040446066,0.00057841226,0.0000714576,0.9474942,0.000108036525],"about_ca_topic_score_codex":0.00000936412,"about_ca_topic_score_gemma":0.000032214855,"teacher_disagreement_score":0.6450893,"about_ca_system_score_codex":0.00009265887,"about_ca_system_score_gemma":0.00018599298,"threshold_uncertainty_score":0.65476876},"labels":[],"label_agreement":null},{"id":"W4414663736","doi":"10.1186/s12933-025-02900-8","title":"Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Clinical trial; Angiology; MEDLINE; Dual (grammatical number); Type 2 diabetes; Diabetes mellitus; Randomized controlled trial; Prospective cohort study","score_opus":0.021316836589964153,"score_gpt":0.2620400572448127,"score_spread":0.24072322065484858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414663736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006327912,0.98824984,0.00010588925,0.00014953689,0.000050707284,0.01056603,0.00009619537,0.000062737075,0.00008625453],"genre_scores_gemma":[0.00082454516,0.9935992,0.0004350363,0.00009485251,0.00001981235,0.0037176625,0.0005153827,0.00007276285,0.00072078535],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99482536,0.0012561089,0.0014411227,0.0012435878,0.0007731397,0.00046065397],"domain_scores_gemma":[0.99700284,0.00022190288,0.0005849007,0.0017165852,0.00028022495,0.0001935683],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0021797274,0.0010602429,0.023053322,0.0008213551,0.00011030426,0.000040794428,0.00016071924,0.00040584875,0.000017628008],"category_scores_gemma":[0.00011994458,0.00065831206,0.008761892,0.0009309706,0.00044097792,0.000119077005,0.00013750084,0.000317792,0.00000264604],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000614174,0.000082485836,0.000066674285,0.4517462,0.5396396,0.000056000466,0.000048359525,4.3400965e-7,2.2541282e-7,0.00006004282,0.000017165858,0.008276681],"study_design_scores_gemma":[0.0014053067,0.00023458028,0.00009224068,0.028360682,0.92166406,0.000055725533,0.000034805795,5.169341e-7,0.000009517304,0.000009591195,0.047643974,0.0004889776],"about_ca_topic_score_codex":0.000047203903,"about_ca_topic_score_gemma":0.000011118817,"teacher_disagreement_score":0.42338553,"about_ca_system_score_codex":0.000090175425,"about_ca_system_score_gemma":0.00016191816,"threshold_uncertainty_score":0.9995868},"labels":[],"label_agreement":null},{"id":"W4414686165","doi":"10.1038/s41584-025-01302-0","title":"Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Rheumatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; Research Canada; University of British Columbia","funders":"","keywords":"Gout; Rheumatoid arthritis; Osteoarthritis; Disease; Psoriatic arthritis; Diabetes mellitus; Obesity","score_opus":0.015390222052491027,"score_gpt":0.32934102667455245,"score_spread":0.31395080462206143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414686165","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008116502,0.9884135,0.000001505173,0.000339477,0.0046458,0.004261285,0.000027516664,0.00010415071,0.002198642],"genre_scores_gemma":[0.0000013576099,0.9956002,0.00025171982,0.0001803744,0.00020034343,0.0014730557,0.0008858238,0.0000543627,0.001352744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962773,0.0005199443,0.0014487397,0.0010307536,0.00020075374,0.00052253174],"domain_scores_gemma":[0.9981691,0.00024008646,0.0005561006,0.0007669729,0.00007293055,0.0001948033],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003251739,0.000878764,0.0057828506,0.0009559065,0.00011078776,0.00004090466,0.00022623743,0.0013017496,0.00010966133],"category_scores_gemma":[0.00018596137,0.0006255735,0.00075743225,0.001119634,0.000110294146,0.00008499432,0.00020696213,0.002065502,0.00021525564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067903716,0.00022530489,0.00006020593,0.07227777,0.0002693839,0.00003035861,0.000043021206,1.5085181e-9,1.14481065e-8,0.001870907,0.03251012,0.89270616],"study_design_scores_gemma":[0.00069925486,0.00006723572,0.000020097297,0.13585496,0.0011108974,0.00013766297,0.000009018772,2.6467302e-7,7.099001e-8,0.00003841272,0.86170197,0.0003601482],"about_ca_topic_score_codex":0.000008725223,"about_ca_topic_score_gemma":0.00012674443,"teacher_disagreement_score":0.89234596,"about_ca_system_score_codex":0.0002773659,"about_ca_system_score_gemma":0.000350948,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4414687185","doi":"10.1016/j.molmet.2025.102259","title":"Furin may contribute to proglucagon processing and glucagon-like Peptide-1 production in human alpha cells","year":2025,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; University of Alberta","keywords":"Proglucagon; Furin; Glucagon; Alpha cell; Alpha (finance); Glucagon-like peptide-1","score_opus":0.007184669596417027,"score_gpt":0.26667782254619976,"score_spread":0.25949315294978276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414687185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858269,0.005176535,0.00046071663,0.003305603,0.00034651213,0.0019040203,0.0000023961607,0.00009060228,0.0028866846],"genre_scores_gemma":[0.98749655,0.000057557216,0.0015639676,0.0013658477,0.00006695518,0.00025598495,0.000030279345,0.000026191989,0.0091366805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857914,0.00005191728,0.0002803193,0.0005082987,0.00021572564,0.00036460548],"domain_scores_gemma":[0.9994348,0.0000054132183,0.000056410347,0.00030702827,0.00008451231,0.000111783105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028946192,0.00022227493,0.0004011277,0.0004033189,0.00007869418,0.00006470086,0.0000777409,0.0000552612,0.0000094394145],"category_scores_gemma":[0.000040382223,0.00020304904,0.0000615127,0.0004976834,0.00003471834,0.00009847491,0.00011186619,0.00012328259,0.00001368242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018418451,0.00089062465,0.0038080218,0.0007735843,0.00039352258,0.000225976,0.0007292931,0.000045956265,0.85715634,0.0041963337,0.0036003052,0.12799588],"study_design_scores_gemma":[0.0035281172,0.0001305764,0.05409387,0.0004815204,0.0008181397,0.0000040068885,0.00013199827,0.000046024987,0.7587973,0.0004943645,0.18116562,0.00030848378],"about_ca_topic_score_codex":0.000050684157,"about_ca_topic_score_gemma":0.000018905588,"teacher_disagreement_score":0.17756532,"about_ca_system_score_codex":0.00006745426,"about_ca_system_score_gemma":0.000049164995,"threshold_uncertainty_score":0.82800996},"labels":[],"label_agreement":null},{"id":"W4414714113","doi":"10.1016/j.cjca.2025.08.289","title":"P299 EMPAGLIFLOZIN AND LEFT ATRIOVENTRICULAR COUPLING INDEX IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CORONARY ARTERY DISEASE: INSIGHTS FROM THE EMPA-HEART CARDIOLINK-6 RANDOMIZED CONTROLLED TRIAL","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Left bundle branch block; Randomized controlled trial; Heart failure; Type 2 Diabetes Mellitus; Diastole; Type 2 diabetes; Adverse effect","score_opus":0.003996179046772287,"score_gpt":0.19652494759925537,"score_spread":0.19252876855248308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414714113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96655035,0.029940058,0.000030294654,0.0007106251,0.0005933196,0.0019854265,0.000009812967,0.000004015924,0.00017612451],"genre_scores_gemma":[0.99870646,0.0005037447,0.000013327977,0.0004070767,0.0002610778,0.000019119341,0.00002848019,0.0000111249865,0.000049611674],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986183,0.00028230887,0.000484052,0.00019132576,0.00015450582,0.00026953072],"domain_scores_gemma":[0.9985011,0.0006556633,0.0001505451,0.00018267032,0.0001641759,0.00034583526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048043486,0.00019069358,0.0017273175,0.0003183594,0.00008352701,0.000034339253,0.00007672942,0.00009338326,0.0000060489842],"category_scores_gemma":[0.0003459433,0.00010747905,0.00023534823,0.00012542629,0.00023934066,0.000063651285,0.000020485717,0.00022237691,7.105571e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24364549,0.000011847153,0.7511787,0.000014039509,0.0032673313,0.0002651111,0.00007119791,0.00043923716,0.0000011749177,0.00004007188,0.0006230956,0.00044272485],"study_design_scores_gemma":[0.50092745,0.00029464872,0.4939011,0.00013582535,0.0017635316,0.0000038430094,0.000043624066,0.00010788167,7.840537e-7,0.00023211614,0.0025136396,0.000075525175],"about_ca_topic_score_codex":0.00011884875,"about_ca_topic_score_gemma":0.00026776618,"teacher_disagreement_score":0.257282,"about_ca_system_score_codex":0.00011032132,"about_ca_system_score_gemma":0.00056132907,"threshold_uncertainty_score":0.43828684},"labels":[],"label_agreement":null},{"id":"W4414748485","doi":"10.61505/evidence.2023.1.1.3","title":"Effect of metformin on cardiovascular outcomes: a systematic review and meta-analysis of observational studies and RCTs","year":2023,"lang":"en","type":"article","venue":"The Evidence","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Observational study; Meta-analysis; Diabetes mellitus; Relative risk; Type 2 Diabetes Mellitus; Randomized controlled trial; Type 2 diabetes; Disease","score_opus":0.2817441770176882,"score_gpt":0.4156571168421542,"score_spread":0.13391293982446595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414748485","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22439907,0.7711267,0.0000050693684,0.0022497484,0.000011863656,0.0021495647,0.000004709794,0.000017368997,0.000035932622],"genre_scores_gemma":[0.9535942,0.04427548,0.00004502534,0.0005106353,0.0000029296457,0.0003926174,0.0000041050125,0.0000062393246,0.0011687697],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9989809,0.00022772931,0.0002656795,0.00012009658,0.0003416437,0.00006397564],"domain_scores_gemma":[0.9972503,0.0021478152,0.00011859953,0.00040429144,0.00006171152,0.00001728836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032143863,0.00009898422,0.0022629797,0.00010199935,0.000020801963,0.000003049586,0.000054590557,0.000009202776,0.000006012994],"category_scores_gemma":[0.0016692318,0.000040220046,0.0006082467,0.0005152462,0.000052446438,0.000045671055,0.00006338198,0.000021369347,0.0000037299135],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011810146,0.000011770268,0.003031108,0.34152547,0.6545129,0.0000061623373,0.00021152192,0.00003340701,0.00000617316,0.00035672492,0.00015508903,0.00013790837],"study_design_scores_gemma":[0.00014204027,0.00025188827,0.008914277,0.0056615337,0.98477423,5.4289217e-7,0.00004689096,0.000041399915,0.0000959309,0.00003289787,0.000005221211,0.00003316867],"about_ca_topic_score_codex":0.000007394493,"about_ca_topic_score_gemma":0.000001417406,"teacher_disagreement_score":0.7291951,"about_ca_system_score_codex":0.000010877097,"about_ca_system_score_gemma":0.0000040161185,"threshold_uncertainty_score":0.1998347},"labels":[],"label_agreement":null},{"id":"W4414838697","doi":"10.14740/jem1055","title":"The BRIDGE-DS Study: Improved Glycemic Control and Renal Function in Type 2 Diabetes Mellitus Patients Using the Fixed-Dose Combination of Dapagliflozin and Sitagliptin","year":2025,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Sitagliptin; Type 2 Diabetes Mellitus; Glycemic; Renal function; Type 2 diabetes","score_opus":0.010306754226416628,"score_gpt":0.2588414638294622,"score_spread":0.24853470960304558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414838697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98083293,0.017668936,0.00002112241,0.00057073194,0.00043090625,0.0004111435,0.0000013987259,0.000002913651,0.0000599053],"genre_scores_gemma":[0.99766433,0.002037175,0.00002994706,0.00015520549,0.000035184723,0.0000051462052,0.0000012844758,0.0000043006985,0.00006744539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918526,0.00012839492,0.0003326789,0.00010108595,0.00009145138,0.00016112832],"domain_scores_gemma":[0.99932045,0.00018795868,0.0002174893,0.00009616122,0.00014769519,0.000030227266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029325875,0.000098159195,0.00032253508,0.0001636762,0.0000955961,0.000017276308,0.000045748406,0.00003357722,0.0000016594879],"category_scores_gemma":[0.00013604079,0.000054844757,0.00003143447,0.0001195704,0.0001256025,0.00008260777,0.000049877355,0.0001650751,8.235465e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046031876,0.0010109141,0.733345,0.00008202783,0.0019457955,0.000014992912,0.00059256854,0.000008211358,0.009875775,0.0033836626,0.00019150648,0.2449464],"study_design_scores_gemma":[0.013872526,0.0011153199,0.9792639,0.000047190093,0.0012744155,0.000004676326,0.00030212812,0.00029337656,0.0002869335,0.00066275324,0.0028313997,0.000045358258],"about_ca_topic_score_codex":0.000021380027,"about_ca_topic_score_gemma":0.000018641358,"teacher_disagreement_score":0.24591896,"about_ca_system_score_codex":0.00001552418,"about_ca_system_score_gemma":0.000028346158,"threshold_uncertainty_score":0.22365044},"labels":[],"label_agreement":null},{"id":"W4414843371","doi":"10.1177/20543581251380509","title":"Uptake of Goal-Directed Therapies in a Multidisciplinary and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Research Letter","year":2025,"lang":"en","type":"letter","venue":"Canadian Journal of Kidney Health and Disease","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto; University Health Network","funders":"Banting and Best Diabetes Centre, University of Toronto","keywords":"Blood pressure; Clinical trial; Multidisciplinary approach; Kidney disease; MEDLINE; Retrospective cohort study; Health care; Patient care","score_opus":0.04006501685380846,"score_gpt":0.36638007153703184,"score_spread":0.32631505468322336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414843371","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014295777,0.020982543,0.0000035914352,0.96224403,0.0003679588,0.0008592465,0.00037859092,0.000008587548,0.0008596447],"genre_scores_gemma":[0.022099221,0.0036623634,0.00037970932,0.9655747,0.0017862084,0.00006828339,0.00058319396,0.000055994467,0.005790324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972312,0.00038781928,0.00094400765,0.00037237085,0.00029966,0.00076496747],"domain_scores_gemma":[0.99015284,0.0002249558,0.00031002777,0.00033372396,0.00025666383,0.008721801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008201575,0.00029587527,0.0011250203,0.0018816593,0.00017262618,0.00003705864,0.00016126363,0.0001883834,0.00006812293],"category_scores_gemma":[0.0027675838,0.00023569529,0.0002039842,0.00032655607,0.0004038853,0.00008020915,0.00014076765,0.0014448394,0.0000022869513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006040242,0.000051787592,0.035606254,0.0026015588,0.00035658688,0.0069674924,0.0006186636,2.588959e-7,0.0000010894161,0.000006397873,0.94540787,0.0077780443],"study_design_scores_gemma":[0.0043021725,0.0013867525,0.02468498,0.005415534,0.00031902007,0.00007124195,0.000539388,0.000023657092,4.3362334e-7,0.0008720084,0.96218294,0.00020184637],"about_ca_topic_score_codex":0.00088312494,"about_ca_topic_score_gemma":0.0004714237,"teacher_disagreement_score":0.023160493,"about_ca_system_score_codex":0.00031459867,"about_ca_system_score_gemma":0.023475092,"threshold_uncertainty_score":0.9820609},"labels":[],"label_agreement":null},{"id":"W4414845976","doi":"10.1111/jdi.70166","title":"Cardiovascular and kidney benefits of <scp>GLP</scp> ‐1 receptor agonists across large randomized placebo‐controlled trials","year":2025,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Novo Nordisk Pharma; Japan Society for the Promotion of Science; Mitsubishi Tanabe Pharma Corporation; Novo Nordisk; Boehringer Ingelheim Japan; Broad Institute; Eli Lilly Japan; McGill University; Eli Lilly and Company","keywords":"Semaglutide; Discontinuation; Type 2 diabetes; Diabetes mellitus; Heart failure; Adverse effect; Clinical trial; Randomized controlled trial","score_opus":0.017083118209885614,"score_gpt":0.2749328311243216,"score_spread":0.257849712914436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414845976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97639954,0.018937677,0.0002120694,0.0012078072,0.00064459594,0.00174721,0.000031014322,0.000021082618,0.0007989797],"genre_scores_gemma":[0.9906684,0.0022470315,0.0035702635,0.001241701,0.0003802025,0.000121404584,0.00007109292,0.000030248922,0.0016696155],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99646455,0.000779416,0.001662818,0.00020501312,0.0005357958,0.00035241267],"domain_scores_gemma":[0.99562037,0.0020876238,0.0012978755,0.00026260578,0.00045415974,0.00027737554],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011857892,0.0002520548,0.0035819004,0.0003525331,0.00010112481,0.00006865752,0.00010882523,0.00014037837,0.000014334064],"category_scores_gemma":[0.020590687,0.00017215905,0.0013196055,0.0002898767,0.00020471362,0.00022694771,0.000071910225,0.00018020305,0.0000027224285],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06445662,0.002989087,0.32700694,0.009359749,0.23794222,0.0000410248,0.010732324,0.0013320443,0.07302429,0.0228227,0.13399741,0.1162956],"study_design_scores_gemma":[0.8668209,0.0006862398,0.0098762885,0.0032456187,0.016336557,0.000002469726,0.0004703745,0.00081352325,0.08353107,0.002680896,0.0153871225,0.0001489952],"about_ca_topic_score_codex":0.0000030007704,"about_ca_topic_score_gemma":5.7232256e-7,"teacher_disagreement_score":0.80236423,"about_ca_system_score_codex":0.00008072723,"about_ca_system_score_gemma":0.00018874994,"threshold_uncertainty_score":0.9876593},"labels":[],"label_agreement":null},{"id":"W4414852068","doi":"10.21203/rs.3.rs-7602999/v1","title":"Multiscale Computational Analysis of Nav1.5 Modulation by SGLT2 Inhibitors Dapagliflozin and Ertugliflozin: Dual Binding Enhances Allosteric Effects over Single Occupancy","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Allosteric regulation; Molecular dynamics; Sodium channel; Dapagliflozin; Protein dynamics; Binding site; Hydrogen bond","score_opus":0.03191078451620192,"score_gpt":0.37230570182968287,"score_spread":0.3403949173134809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414852068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401796,0.0017579724,0.0005664576,0.00021843029,0.00020017584,0.001773673,0.00037157568,0.000058314334,0.0010354503],"genre_scores_gemma":[0.9931602,0.00018136656,0.0010747821,0.000023968667,0.00008810493,0.00018118946,0.00340505,0.000023071678,0.001862269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667156,0.00031246472,0.00050419423,0.00076934934,0.0012832667,0.00045914546],"domain_scores_gemma":[0.99805707,0.0007796471,0.00019673201,0.00042154492,0.00036940575,0.00017561793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006255432,0.0003222346,0.0008578396,0.0018372863,0.00013799696,0.00010276936,0.00012625667,0.00024606482,0.00006745545],"category_scores_gemma":[0.00024039924,0.00029595513,0.00027609162,0.0013734659,0.00018050357,0.00011474731,0.0007888021,0.00044866352,0.0000070951774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001078277,0.0051741437,0.7726007,0.02555587,0.025242515,0.0001498452,0.0029800825,0.0112059,0.03598545,0.00038083,0.01762946,0.102016896],"study_design_scores_gemma":[0.0058065364,0.0021354738,0.77265304,0.008493266,0.006192992,0.0000014940753,0.00049077877,0.17431591,0.027156884,0.00061021076,0.0012213022,0.00092209585],"about_ca_topic_score_codex":0.00027502934,"about_ca_topic_score_gemma":0.00007946126,"teacher_disagreement_score":0.16311,"about_ca_system_score_codex":0.00033716473,"about_ca_system_score_gemma":0.00012309403,"threshold_uncertainty_score":0.9999493},"labels":[],"label_agreement":null},{"id":"W4414901638","doi":"10.7759/cureus.93925","title":"Relative Impact of GLP-1 Agonist Use on Microvascular Versus Macrovascular Complications","year":2025,"lang":"en","type":"article","venue":"Cureus","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor","funders":"","keywords":"Confounding; Agonist; Complication; Odds ratio; Odds","score_opus":0.0322369379265382,"score_gpt":0.33123910645805765,"score_spread":0.29900216853151945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414901638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9200356,0.0019449221,0.0007802458,0.00089784514,0.00030316025,0.0011666972,0.000036722424,0.00009982189,0.07473498],"genre_scores_gemma":[0.9943058,0.0001989717,0.0012415288,0.00016023294,0.00002068292,0.000043472297,0.00017525758,0.000014599025,0.0038394684],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9993125,0.00002430421,0.00016229866,0.0002101085,0.00013016208,0.00016059264],"domain_scores_gemma":[0.9990909,0.00009036804,0.000053063948,0.0006187719,0.00008957268,0.000057335954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000662586,0.00013531756,0.00024892858,0.00009483786,0.000060205217,0.000017174134,0.0000844632,0.00004981829,0.00007555494],"category_scores_gemma":[0.000079947305,0.00010798647,0.00037669143,0.00022349504,0.00007245247,0.000074983815,0.000048655933,0.000077235425,0.00006587422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044450774,0.012937474,0.22784233,0.00093179767,0.08518094,0.00019785241,0.0016038574,0.0009364794,0.03232957,0.37430736,0.19371061,0.06557664],"study_design_scores_gemma":[0.0146717215,0.0025498464,0.82738334,0.0005234937,0.004118022,0.000002280219,0.00014626865,0.00027393573,0.011473418,0.0010359235,0.13746288,0.00035889575],"about_ca_topic_score_codex":0.00026709106,"about_ca_topic_score_gemma":0.000016184964,"teacher_disagreement_score":0.599541,"about_ca_system_score_codex":0.00026001805,"about_ca_system_score_gemma":0.00006149386,"threshold_uncertainty_score":0.44035602},"labels":[],"label_agreement":null},{"id":"W4414972078","doi":"10.1111/dom.70185","title":"Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post‐hoc analysis from a double‐blinded randomized controlled trial","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canada Research Chairs","keywords":"Semaglutide; Randomized controlled trial; Placebo; Insulin pump; Type 1 diabetes; Glycemic; Diabetes mellitus; Crossover study","score_opus":0.008097921347696638,"score_gpt":0.2304328707177119,"score_spread":0.22233494937001527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414972078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372229,0.00963713,0.0000015548231,0.038573276,0.000715866,0.0122076,0.00014666973,0.00015241912,0.0013425592],"genre_scores_gemma":[0.60788274,0.0055680815,0.00044771968,0.36201653,0.0034300783,0.0054513477,0.0068190326,0.0001985334,0.008185963],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99464655,0.0007790795,0.0011592706,0.00140233,0.0009495574,0.0010631903],"domain_scores_gemma":[0.9959574,0.001816956,0.00065490353,0.0010121035,0.00034880868,0.00020986248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001087942,0.0012269771,0.00836531,0.0021824106,0.00014479342,0.00021484193,0.00031751776,0.0008990393,0.00022495868],"category_scores_gemma":[0.0002925824,0.0007831467,0.0014335723,0.0014767159,0.000297548,0.00013498633,0.0001234546,0.0013656246,0.000024427847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94595844,0.0012174568,0.0056931465,0.00030583653,0.036262363,0.00014490608,0.0003558307,0.000006317142,0.000015883374,0.00006925456,0.008127982,0.0018425757],"study_design_scores_gemma":[0.9366606,0.001238932,0.0075807446,0.0009220216,0.029323077,1.0456061e-7,0.000026953769,0.00019262839,0.00017888594,0.00016797737,0.022971237,0.0007368598],"about_ca_topic_score_codex":0.00039549905,"about_ca_topic_score_gemma":0.00014853562,"teacher_disagreement_score":0.32934022,"about_ca_system_score_codex":0.0000937343,"about_ca_system_score_gemma":0.00025723223,"threshold_uncertainty_score":0.99946195},"labels":[],"label_agreement":null},{"id":"W4414973641","doi":"10.1101/2025.10.07.25336827","title":"Common genetic variants near <i>SLC2A2</i> and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Janssen Research and Development; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk; Daiichi-Sankyo; Zora Biosciences; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; AstraZeneca; Eli Lilly and Company; Pfizer; Ministerstwo Zdrowia; American Diabetes Association","keywords":"Glimepiride; Genetic variants; Clinical trial; Glycemic; MEDLINE; Randomized controlled trial; Meta-analysis","score_opus":0.08066722407757551,"score_gpt":0.4016439070451898,"score_spread":0.3209766829676143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414973641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897342,0.0005916646,0.00007646478,0.002111732,0.0009248218,0.005648903,0.000029061535,0.000047926907,0.00083526614],"genre_scores_gemma":[0.99685,0.00012210527,0.0005469941,0.0012803641,0.00016383687,0.00073681626,0.000038572853,0.00001811633,0.00024319676],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954009,0.0024674726,0.0006820744,0.00076873146,0.00033902656,0.00034180257],"domain_scores_gemma":[0.99605596,0.0026734555,0.00015311668,0.0009250263,0.000044738677,0.00014772944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028017128,0.00038012455,0.0011835307,0.00020278184,0.00008201504,0.000091449656,0.00036441357,0.00023970744,0.000009529052],"category_scores_gemma":[0.0003682913,0.00026837285,0.00020265098,0.00030083483,0.00017071518,0.000023256422,0.0006461343,0.00072106597,0.000033997076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6679946,0.0032986526,0.31204566,0.0008901912,0.0014520859,0.0009214584,0.0030888002,0.00043339748,0.00024740104,0.00016588967,0.0021249165,0.0073369257],"study_design_scores_gemma":[0.057671856,0.0044377074,0.9275345,0.0010273622,0.00092361314,0.0000054675825,0.0000968188,0.000440232,0.00014828655,0.0005837888,0.0068333754,0.00029699478],"about_ca_topic_score_codex":0.00010634693,"about_ca_topic_score_gemma":0.000069596856,"teacher_disagreement_score":0.6154888,"about_ca_system_score_codex":0.00011198514,"about_ca_system_score_gemma":0.00021748745,"threshold_uncertainty_score":0.9999769},"labels":[],"label_agreement":null},{"id":"W4415051811","doi":"10.1681/asn.0000000868","title":"Authors' Reply: Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Glycemic; Clinical trial; Type 1 diabetes; Renal function; Type 2 diabetes; Diabetes mellitus","score_opus":0.04878973066243173,"score_gpt":0.36252377219078913,"score_spread":0.3137340415283574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415051811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92060864,0.000193759,0.000011235765,0.07835576,0.00010040207,0.00027493312,9.177897e-7,0.0000024598476,0.0004518803],"genre_scores_gemma":[0.97882926,0.0001211149,0.0011239928,0.019723414,0.000055740315,0.0000054697402,5.1419755e-7,0.000005658912,0.0001348194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986115,0.0004262679,0.00047110827,0.000089844325,0.0002896712,0.000111602276],"domain_scores_gemma":[0.99795544,0.0006753333,0.00073297805,0.00026997773,0.00034369767,0.000022566843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019440987,0.00007738933,0.00042538953,0.000053468837,0.0000332628,0.0000037184961,0.000101451034,0.000033403092,0.000048734197],"category_scores_gemma":[0.0003438861,0.00003788405,0.00023275442,0.0003211239,0.00061232504,0.000022996706,0.000038439524,0.00023355958,9.464232e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015630159,0.002135736,0.4785098,0.00007510809,0.0068365233,0.000004631324,0.0023381135,0.0010061204,0.012278323,0.0022439759,0.45143625,0.04157238],"study_design_scores_gemma":[0.0036343962,0.0042550177,0.9693897,0.00025059827,0.0019913805,0.000004866211,0.0023880776,0.001749211,0.0011130647,0.004147004,0.011003866,0.00007283423],"about_ca_topic_score_codex":0.000015656497,"about_ca_topic_score_gemma":0.0000121611965,"teacher_disagreement_score":0.4908799,"about_ca_system_score_codex":0.000057948477,"about_ca_system_score_gemma":0.00028702675,"threshold_uncertainty_score":0.22561371},"labels":[],"label_agreement":null},{"id":"W4415053754","doi":"10.1016/j.ekir.2025.09.050","title":"CKDs at the Crossroads: From Failures to Future Therapies","year":2025,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Clinical trial; Kidney disease; Limiting; Guideline; Clinical Practice; Adverse effect; MEDLINE; Disease","score_opus":0.0060932112586716755,"score_gpt":0.2795045797619928,"score_spread":0.2734113685033211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415053754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47376624,0.00085336197,0.00028140345,0.3268587,0.0048033483,0.0006894001,0.00004335443,0.000121045356,0.19258313],"genre_scores_gemma":[0.8145891,0.00005552358,0.00057899,0.023582505,0.0005739853,0.000117155185,0.00034325448,0.000011505754,0.160148],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999081,0.000010111731,0.00021483071,0.00024866193,0.00032204977,0.00012335558],"domain_scores_gemma":[0.9993518,0.00003387938,0.000071508635,0.00034559538,0.000097958735,0.00009924967],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001039754,0.000112954556,0.00012570071,0.00008414516,0.00008437204,0.00008658005,0.000103384984,0.000037849586,0.0016621146],"category_scores_gemma":[0.0001664095,0.000069601876,0.00009699117,0.00009559477,0.00003347552,0.00006364843,0.00015216583,0.000060900165,0.0000874384],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086803986,0.000113908536,0.0737893,0.000008969197,0.0011059288,0.00027014466,0.0004893055,0.0000053271174,0.0016166656,0.0037891737,0.90420777,0.014516698],"study_design_scores_gemma":[0.00031409456,0.000024871833,0.08629656,0.00006991716,0.000087330634,0.000009245896,0.00022130257,0.000007207298,0.0019543532,0.0016761529,0.9092835,0.000055457156],"about_ca_topic_score_codex":0.00022168888,"about_ca_topic_score_gemma":0.000083954736,"teacher_disagreement_score":0.34082285,"about_ca_system_score_codex":0.00015797438,"about_ca_system_score_gemma":0.000094484996,"threshold_uncertainty_score":0.9992505},"labels":[],"label_agreement":null},{"id":"W4415160587","doi":"10.1080/28338073.2025.2571295","title":"An Integrated Interprofessional Continuing Medical Education and Quality Improvement Initiative to Address Cardiovascular and Renal Risk in Patients with Type 2 Diabetes in Community-Based Primary Care Practices","year":2025,"lang":"en","type":"article","venue":"Journal of CME","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Merck","keywords":"Competence (human resources); Quality management; Continuing medical education; Intervention (counseling); Medical prescription; Primary care; Type 2 diabetes; Health care; Medical record; Patient education","score_opus":0.013403871230421756,"score_gpt":0.32300735080767445,"score_spread":0.3096034795772527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415160587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982772,0.0007980157,0.000022783535,0.0002761252,0.00009381983,0.00036116558,0.0000047576386,0.0000036029717,0.00016255704],"genre_scores_gemma":[0.9981634,0.000045255965,0.0006770645,0.0009984975,0.000016847318,0.000013627827,0.00007197698,0.0000054146344,0.000007887924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986397,0.00050362153,0.0003274404,0.000100230594,0.00032642437,0.00010259857],"domain_scores_gemma":[0.99899024,0.0001665713,0.00029034153,0.00012955906,0.0003202645,0.00010299846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011269371,0.00009796048,0.00035048832,0.00029689627,0.000034467026,0.00002215505,0.000066177236,0.00004804223,0.0000047018943],"category_scores_gemma":[0.00043958036,0.00006653326,0.000030535844,0.00019365411,0.000040922238,0.00018509311,0.000049553815,0.0004219796,1.0712038e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011966667,0.0011201374,0.8719429,0.00027021213,0.00030101987,0.000004900908,0.0017380487,0.000007795892,0.000053968655,0.000005271166,0.00003686039,0.123322256],"study_design_scores_gemma":[0.005977219,0.0020287773,0.98362046,0.0034883486,0.00025389862,2.07553e-7,0.0037426609,0.000022721688,0.00020674855,0.00001628674,0.0005746412,0.00006800382],"about_ca_topic_score_codex":0.00021349458,"about_ca_topic_score_gemma":0.00033631045,"teacher_disagreement_score":0.123254254,"about_ca_system_score_codex":0.00019350996,"about_ca_system_score_gemma":0.0003701557,"threshold_uncertainty_score":0.27131477},"labels":[],"label_agreement":null},{"id":"W4415163407","doi":"10.1139/cjpp-2025-0148","title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III","keywords":"Inflammation; Neuroinflammation; Neuroprotection; Proinflammatory cytokine; Fibrosis; Diabetes mellitus; Receptor; Type 2 diabetes; Steatosis","score_opus":0.01869684795273523,"score_gpt":0.2676613168026791,"score_spread":0.24896446884994383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415163407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97855824,0.017917743,9.694334e-7,0.0020460018,0.00054870296,0.0002215913,0.00003057437,0.0000049032724,0.0006712665],"genre_scores_gemma":[0.9959535,0.0008496254,0.000064156855,0.0027711347,0.00018626741,0.0000075124044,0.000002652353,0.0000069741895,0.00015819895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923396,0.00009866087,0.0002427003,0.00016424007,0.000042869182,0.00021757417],"domain_scores_gemma":[0.99935853,0.000057547728,0.00013661437,0.000051425188,0.00015761025,0.00023824698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011781211,0.00013210281,0.0004530223,0.00021131214,0.00008196176,0.0000048997995,0.000072890674,0.000109777626,0.00063318067],"category_scores_gemma":[0.000021361024,0.00009972221,0.00006284777,0.0000780812,0.00045512483,0.000048945516,0.000027186736,0.00019144504,0.0000024539238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054388464,0.000103174745,0.026080182,0.00013958728,0.0017462128,0.000074000134,0.00065279816,0.000008081583,0.96088165,0.001193851,0.006996682,0.0015799092],"study_design_scores_gemma":[0.009423868,0.0016545908,0.21508844,0.00036113642,0.0025693178,0.00005472707,0.0011211373,0.00006927375,0.7132256,0.0016223578,0.05450101,0.00030852712],"about_ca_topic_score_codex":0.0004314698,"about_ca_topic_score_gemma":0.00019500378,"teacher_disagreement_score":0.24765603,"about_ca_system_score_codex":0.000084207444,"about_ca_system_score_gemma":0.0004297247,"threshold_uncertainty_score":0.69328845},"labels":[],"label_agreement":null},{"id":"W4415221555","doi":"10.1177/07067437251386626","title":"GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness","year":2025,"lang":"en","type":"article","venue":"The Canadian Journal of Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Université de Sherbrooke","funders":"","keywords":"Mental illness; Weight gain; Antipsychotic; Type 2 diabetes; Schizophrenia (object-oriented programming); Obesity; Health care; Body mass index; Mental health","score_opus":0.013621479687899458,"score_gpt":0.25695047477308547,"score_spread":0.24332899508518602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415221555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8870059,0.001969489,0.000063303116,0.10335871,0.0033008913,0.0007384054,0.000022100738,0.000005097322,0.003536063],"genre_scores_gemma":[0.9942162,0.00006163797,0.0019071995,0.001963743,0.00019342107,0.000011849398,0.0000110241235,0.000012627119,0.0016223184],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991992,0.000024540936,0.00026615406,0.00012710945,0.00011710478,0.00026588148],"domain_scores_gemma":[0.9994387,0.000020776864,0.00011396346,0.00013913584,0.00006308375,0.00022434311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032939445,0.0001240325,0.00021914825,0.00029454034,0.0002184331,0.000044533495,0.00011154938,0.00006186076,0.000041453517],"category_scores_gemma":[0.000023803022,0.000090242356,0.00014148816,0.00017439044,0.00005615169,0.000064939886,0.000009525536,0.00014935406,0.0000036109661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004530751,0.0018273,0.38611934,0.0012991882,0.005173432,0.00009026887,0.0088612065,0.0000344651,0.0052225236,0.1113497,0.3626916,0.112800226],"study_design_scores_gemma":[0.09421711,0.009781243,0.37031662,0.009729784,0.006193628,0.0012676708,0.02419955,0.00228656,0.0017353772,0.034997243,0.44318143,0.0020937975],"about_ca_topic_score_codex":0.0018163386,"about_ca_topic_score_gemma":0.061729345,"teacher_disagreement_score":0.110706426,"about_ca_system_score_codex":0.00033093404,"about_ca_system_score_gemma":0.0010105884,"threshold_uncertainty_score":0.95539165},"labels":[],"label_agreement":null},{"id":"W4415231373","doi":"10.1136/bmj.r2121","title":"SGLT-2 inhibitors for the prevention of autoimmune rheumatic diseases","year":2025,"lang":"en","type":"editorial","venue":"BMJ","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Autoantibody; Autoimmune disease; MEDLINE; Autoimmunity; Text mining","score_opus":0.011182673257572637,"score_gpt":0.31014419001860644,"score_spread":0.2989615167610338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415231373","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001630827,0.0058174892,0.00027493312,0.0018283124,0.9826829,0.0056079887,0.00019343889,0.00008290497,0.0033489726],"genre_scores_gemma":[0.0029491098,0.0013484923,0.0007027374,0.00006045471,0.7442469,0.0031314737,0.0038842063,0.00006891758,0.24360768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988843,0.000025036246,0.00039608584,0.00017602078,0.00037616616,0.00014236751],"domain_scores_gemma":[0.9983673,0.0007744826,0.00026989303,0.0004400557,0.00012249529,0.000025783505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023846827,0.00016705852,0.00043701762,0.000097820375,0.000050375744,0.000015982441,0.00012113861,0.00014797201,0.00004218656],"category_scores_gemma":[0.00090246106,0.000105611594,0.00033227936,0.000097046424,0.000039784478,0.000026798114,0.000078502955,0.0000967007,0.000007728871],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011749936,0.00023601446,0.00003317282,0.0023317875,0.000976816,0.0000010944184,0.000024326835,0.0000019137046,0.000002790791,0.00012486371,0.9544369,0.041712847],"study_design_scores_gemma":[0.0019191373,0.0003545041,0.0006544081,0.0027039947,0.0035022849,4.9043635e-8,0.00004345299,0.000062098494,0.00003595191,0.00036342963,0.9902694,0.00009125886],"about_ca_topic_score_codex":0.000024152121,"about_ca_topic_score_gemma":0.0000046268374,"teacher_disagreement_score":0.24025872,"about_ca_system_score_codex":0.00007413273,"about_ca_system_score_gemma":0.000275487,"threshold_uncertainty_score":0.4306716},"labels":[],"label_agreement":null},{"id":"W4415235069","doi":"10.1111/dom.70209","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the <scp>TRIUMPH</scp> registrational clinical trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Obstructive sleep apnea; Clinical trial; Disease; Obesity; Sleep apnea; MEDLINE","score_opus":0.044380771340370294,"score_gpt":0.3089905578648763,"score_spread":0.264609786524506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415235069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655241,0.029501094,0.0006941843,0.00048905687,0.0003292028,0.0030806703,0.00013879451,0.000010200058,0.00023272369],"genre_scores_gemma":[0.9914806,0.0038197099,0.002560223,0.00025497744,0.000175594,0.00030780266,0.00004378713,0.000011277256,0.0013460487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984037,0.00032587347,0.0006021409,0.00030046818,0.00018042495,0.00018737759],"domain_scores_gemma":[0.99536926,0.0038291253,0.00030893667,0.00027006774,0.00015222166,0.00007041914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013510243,0.0001912006,0.00081354956,0.00007868729,0.00019053511,0.00003348234,0.00007077516,0.00010054536,0.0000037708126],"category_scores_gemma":[0.0010900552,0.00011183139,0.00021985694,0.0001419899,0.0004289072,0.00008869641,0.00005987898,0.00006626618,3.020501e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002857856,0.0019178233,0.5619538,0.00058144226,0.0044659413,0.0000021042358,0.0014331003,0.00003386194,0.0022582575,0.041714236,0.0010944385,0.38425922],"study_design_scores_gemma":[0.008525388,0.0008333574,0.95142186,0.00010366758,0.00405243,0.0000010593884,0.0003522758,0.0006169336,0.010116754,0.008007573,0.015905797,0.00006289542],"about_ca_topic_score_codex":0.000007569761,"about_ca_topic_score_gemma":0.000008909746,"teacher_disagreement_score":0.3894681,"about_ca_system_score_codex":0.0000140313105,"about_ca_system_score_gemma":0.00007337573,"threshold_uncertainty_score":0.45603517},"labels":[],"label_agreement":null},{"id":"W4415240270","doi":"10.2218/gtopdb/f29/2025.3","title":"Glucagon receptor family in GtoPdb v.2025.3","year":2025,"lang":"en","type":"article","venue":"IUPHAR/BPS Guide to Pharmacology CITE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Receptor; Peptide; Glucagon; Peptide hormone; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Secretin family","score_opus":0.015577888573763844,"score_gpt":0.3647502776459714,"score_spread":0.34917238907220755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415240270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80774087,0.0021467886,0.00029304894,0.021270705,0.003423727,0.0025057716,0.00004005668,0.00032122206,0.16225782],"genre_scores_gemma":[0.59226495,0.0011838243,0.0038639104,0.13200526,0.00066321215,0.0013966796,0.00027226016,0.000080826925,0.2682691],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978703,0.00010354164,0.0005604873,0.0006005293,0.0002029006,0.00066220236],"domain_scores_gemma":[0.9991637,0.000119149314,0.00007016142,0.00032378614,0.00009020177,0.0002330211],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00040021524,0.0003150057,0.00055480626,0.0007842152,0.000069425565,0.000026100617,0.00024804473,0.0001438532,0.0017803767],"category_scores_gemma":[0.00005153671,0.00030351066,0.0001396541,0.0008281694,0.00007116363,0.000112969494,0.00023233793,0.00027569887,0.0014300898],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047464622,0.0005513718,0.013363844,0.00011083338,0.0004899883,0.00017552517,0.00012935077,0.000033992674,0.13452972,0.0007495472,0.82777643,0.021614753],"study_design_scores_gemma":[0.006540955,0.00028934286,0.02034058,0.000116585514,0.00046423782,0.0000015101805,0.00007416867,0.00008657745,0.03763833,0.00007625067,0.9341409,0.00023055142],"about_ca_topic_score_codex":0.00010390125,"about_ca_topic_score_gemma":0.000020674908,"teacher_disagreement_score":0.21547592,"about_ca_system_score_codex":0.0004251311,"about_ca_system_score_gemma":0.00016806531,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W4415278127","doi":"10.1111/dom.70201","title":"Effects of <scp>GLP</scp> ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":true,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Shandong First Medical University","keywords":"Cognition; Randomized controlled trial; Type 2 diabetes; Type 2 Diabetes Mellitus; Receptor; Clinical trial","score_opus":0.013704273603037687,"score_gpt":0.2685342083474067,"score_spread":0.25482993474436905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415278127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025872034,0.96492773,0.000006664972,0.000015183518,0.00014615688,0.031924937,0.00014606433,0.00003889045,0.00020715014],"genre_scores_gemma":[0.0017169649,0.9895474,0.000041945215,0.001024825,0.00002578441,0.0060163294,0.00089421147,0.000045678084,0.0006868676],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9908333,0.0051910407,0.002115456,0.0008090705,0.00061045366,0.00044067198],"domain_scores_gemma":[0.9772307,0.019668637,0.0020957761,0.00047759296,0.00034198666,0.00018529566],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0054108314,0.0010385282,0.043076593,0.0016222754,0.00007403445,0.000060954695,0.00011657634,0.0002968362,0.000028882727],"category_scores_gemma":[0.012264839,0.0005350692,0.0035868569,0.0014266243,0.00013366228,0.00007942946,0.000056998044,0.0003141079,0.000010031074],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018956477,0.0010460607,0.00010175613,0.70544696,0.28905025,0.0000016173528,0.000016791555,3.8088703e-7,7.920399e-8,0.000054386575,0.000045180128,0.0023408867],"study_design_scores_gemma":[0.09613048,0.0004858552,0.0002637325,0.16169718,0.74058086,1.0296775e-8,0.000003048369,0.0000073433825,0.000006723737,0.000008397251,0.00065356697,0.0001628306],"about_ca_topic_score_codex":0.000003755172,"about_ca_topic_score_gemma":0.0000014549753,"teacher_disagreement_score":0.5437498,"about_ca_system_score_codex":0.0000467323,"about_ca_system_score_gemma":0.000118547876,"threshold_uncertainty_score":0.9997101},"labels":[],"label_agreement":null},{"id":"W4415279944","doi":"","title":"Inflammation: The Mother of All Diseases Meets the Mother of All Therapies.","year":2025,"lang":"en","type":"article","venue":"PubMed","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Disease; Diabetes mellitus; Class (philosophy); Obesity; Type 2 diabetes","score_opus":0.01599570883097423,"score_gpt":0.23721849885333043,"score_spread":0.2212227900223562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415279944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6629369,0.010417955,0.00007751109,0.114686586,0.00042335296,0.0060802815,0.000026851834,0.00011621218,0.2052343],"genre_scores_gemma":[0.97912383,0.00018855558,0.00002322973,0.0016476818,0.000055535376,0.0007668553,0.000007726619,0.000011473114,0.018175105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99933463,0.000042018735,0.00018116743,0.00010184474,0.00018019625,0.00016014712],"domain_scores_gemma":[0.99935436,0.00009748124,0.00008920421,0.00039045062,0.00003964075,0.000028853254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018418499,0.00009280559,0.00016806934,0.000050510123,0.000021594096,0.000010508455,0.00014785836,0.000023814546,0.000109190936],"category_scores_gemma":[0.000038093625,0.00004387367,0.000096344775,0.00011827315,0.00010197283,0.00003506443,0.00004787136,0.000033886896,0.00000452031],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030139406,0.0006388577,0.055615596,0.000356685,0.0053547705,0.000004537997,0.0019210146,0.00003427655,0.00029935263,0.028362172,0.033588313,0.87352306],"study_design_scores_gemma":[0.0012223428,0.000030767384,0.6075811,0.00003332234,0.000706432,1.4261524e-7,0.0001893791,0.00003764184,0.0020727497,0.0013513423,0.38672236,0.000052449297],"about_ca_topic_score_codex":0.000028473261,"about_ca_topic_score_gemma":0.000011120843,"teacher_disagreement_score":0.8734706,"about_ca_system_score_codex":0.000022872582,"about_ca_system_score_gemma":0.000013479279,"threshold_uncertainty_score":0.17891164},"labels":[],"label_agreement":null},{"id":"W4415336785","doi":"10.1016/j.molmet.2025.102275","title":"Canagliflozin synergises with serine restriction mediating anti-leukaemic effects in T-cell acute lymphoblastic leukaemia","year":2025,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Medical Research Council","keywords":"Canagliflozin; Serine; Downregulation and upregulation; Citric acid cycle; Cell cycle; Metabolism; Mitochondrion; Carbohydrate metabolism; Gluconeogenesis","score_opus":0.002510609306635852,"score_gpt":0.21390246165513113,"score_spread":0.21139185234849528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415336785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674774,0.002853972,0.00204052,0.00032220202,0.00034257627,0.00084330887,0.00000393286,0.00011586927,0.006729858],"genre_scores_gemma":[0.99566174,0.00038477895,0.0017801203,0.00077811175,0.000045792724,0.00016898196,0.00007320625,0.00003857152,0.0010686737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984681,0.00007523303,0.00028399282,0.0004329737,0.0003098098,0.0004298913],"domain_scores_gemma":[0.9992776,0.00006474545,0.00008906703,0.00039958878,0.000056261786,0.00011277418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012688384,0.00029476543,0.00053718535,0.0005472657,0.000054899385,0.00003421811,0.00011545946,0.00007418695,0.000008240572],"category_scores_gemma":[0.00007436931,0.00024224089,0.00009000997,0.00096334954,0.00004070076,0.000089796005,0.00008771787,0.0001567559,0.000016874203],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008823497,0.0017630485,0.10366122,0.00301566,0.0038073398,0.010062935,0.00035835645,0.0061320243,0.81909585,0.015765956,0.002929519,0.032525744],"study_design_scores_gemma":[0.023472866,0.0004912849,0.4328541,0.0013290275,0.0069812443,0.000023731516,0.00013391337,0.0033634647,0.5214722,0.0005462943,0.008483222,0.0008486751],"about_ca_topic_score_codex":0.00044189984,"about_ca_topic_score_gemma":0.000057956622,"teacher_disagreement_score":0.32919285,"about_ca_system_score_codex":0.00020150124,"about_ca_system_score_gemma":0.00018114246,"threshold_uncertainty_score":0.9878296},"labels":[],"label_agreement":null},{"id":"W4415378976","doi":"10.1007/s00415-025-13470-w","title":"Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis","year":2025,"lang":"en","type":"article","venue":"Journal of Neurology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Agonist; Neurology; Receptor; Prospective cohort study; Neuroradiology; MEDLINE","score_opus":0.03241921814914595,"score_gpt":0.2951178716623273,"score_spread":0.26269865351318133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415378976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914125,0.00007225211,0.00006661384,0.0052073635,0.00040762706,0.00021440054,0.0000040451628,0.000014063275,0.0026010855],"genre_scores_gemma":[0.991278,0.00009924552,0.0005949146,0.001393574,0.000036265115,0.000003268427,0.0000073420374,0.000010148899,0.0065772226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986706,0.000088592984,0.00061735156,0.0001760427,0.00023661177,0.00021083881],"domain_scores_gemma":[0.9988489,0.00017274696,0.00045735584,0.0002914201,0.00014459321,0.000084973355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029069677,0.00015190887,0.0010651366,0.00078437245,0.000036938138,0.00001878988,0.00013930895,0.00006340805,0.00005085512],"category_scores_gemma":[0.00018303978,0.00011014875,0.0006401783,0.00061685406,0.000058003723,0.0001218403,0.00009023102,0.00024351323,0.0000040107866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006784218,0.00033108532,0.9752948,0.00004297444,0.006047711,0.00022720086,0.00003607979,0.00002442081,0.011183802,0.00006838288,0.0053374018,0.00072768657],"study_design_scores_gemma":[0.002338474,0.0007250571,0.976551,0.000037005666,0.0068137688,0.0000050633953,0.000012840851,0.000034468387,0.0033022745,0.000017907216,0.0100934785,0.00006864717],"about_ca_topic_score_codex":0.0001044776,"about_ca_topic_score_gemma":0.00013553079,"teacher_disagreement_score":0.007881528,"about_ca_system_score_codex":0.00004738996,"about_ca_system_score_gemma":0.00008912549,"threshold_uncertainty_score":0.44917357},"labels":[],"label_agreement":null},{"id":"W4415396858","doi":"10.1155/cdr/6649731","title":"The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Cardiovascular Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hemodynamics; Pulmonary artery; Dapagliflozin; Randomized controlled trial; Heart failure; Pulmonary hypertension; Blood pressure","score_opus":0.01105943665453822,"score_gpt":0.26422440321717255,"score_spread":0.2531649665626343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415396858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013011156,0.9914433,0.0000039090733,0.000028000803,0.000067455934,0.008011731,0.000032194108,0.000025686188,0.00025766296],"genre_scores_gemma":[0.0011278922,0.9978275,0.00002213366,0.00008587365,0.000029340137,0.0005180815,0.00018118219,0.00006670236,0.00014131627],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972189,0.00052205176,0.00081376114,0.0004644756,0.0006408453,0.00033994688],"domain_scores_gemma":[0.99770594,0.00028894842,0.0002899053,0.0015192027,0.00011998685,0.0000760462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007133599,0.00062365393,0.004135963,0.00024555108,0.00006572642,0.000034427394,0.00020414253,0.00018969434,0.0000011064482],"category_scores_gemma":[0.00003893655,0.0003110487,0.0022291045,0.0005063763,0.00010950602,0.00004851836,0.00010220696,0.00033503186,0.00000314958],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042432428,0.0003620733,0.00070776144,0.81817734,0.01961609,0.00003856718,0.000008141279,0.000009340703,3.538455e-8,0.000009540185,0.000081315105,0.16094735],"study_design_scores_gemma":[0.00080777385,0.00053078344,0.0011027659,0.8560467,0.051598147,0.000032855904,0.000014678098,0.000025975578,2.2728551e-7,0.000012538803,0.08942581,0.00040176828],"about_ca_topic_score_codex":0.000006165095,"about_ca_topic_score_gemma":7.92356e-7,"teacher_disagreement_score":0.16054559,"about_ca_system_score_codex":0.00022797819,"about_ca_system_score_gemma":0.0001714722,"threshold_uncertainty_score":0.99993414},"labels":[],"label_agreement":null},{"id":"W4415397515","doi":"10.24911/ijmdc.51-1737107151","title":"To evaluate and compare the efficacy of newer antidiabetic medications on cardiovascular outcomes","year":2025,"lang":"","type":"article","venue":"International Journal of Medicine in Developing Countries","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liraglutide; Semaglutide; Glycemic; Diabetes mellitus; Discontinuation; Adverse effect; Type 2 diabetes; Randomized controlled trial; Clinical trial","score_opus":0.0227945182792156,"score_gpt":0.34493197009359106,"score_spread":0.3221374518143755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415397515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5578366,0.020718686,0.0018067167,0.410909,0.0056564515,0.00089239,0.000009422623,0.000008862669,0.002161877],"genre_scores_gemma":[0.9797581,0.010680423,0.00039496113,0.008272008,0.00040360162,0.000013588609,0.0000072103526,0.000014088054,0.00045601206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958777,0.00018505877,0.0014426241,0.0002459052,0.0019942771,0.0002544379],"domain_scores_gemma":[0.99571633,0.0018196533,0.0004975354,0.0003593887,0.0015006792,0.000106432686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027530084,0.0002813075,0.0011051551,0.001311888,0.00007909679,0.000038796494,0.0006334065,0.000059373582,0.000089848545],"category_scores_gemma":[0.002664146,0.0001708933,0.00019936523,0.0005399078,0.00052794046,0.00010011502,0.00019168358,0.0002836904,0.000008530125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016463322,0.0007290837,0.77728415,0.0008279315,0.034846142,0.00040120122,0.009901473,0.0021473735,0.000030308187,0.04680771,0.04280456,0.082573764],"study_design_scores_gemma":[0.010968415,0.0004222253,0.82720274,0.014375735,0.0021154792,0.000018467837,0.0010735588,0.00010804263,0.00027827692,0.0008332139,0.14245306,0.00015079674],"about_ca_topic_score_codex":0.000099648816,"about_ca_topic_score_gemma":0.000020999536,"teacher_disagreement_score":0.42192152,"about_ca_system_score_codex":0.00042049785,"about_ca_system_score_gemma":0.0006947178,"threshold_uncertainty_score":0.69688267},"labels":[],"label_agreement":null},{"id":"W4415418769","doi":"10.1007/s40264-025-01623-9","title":"Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Drug Safety","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dementia; Type 2 diabetes; Diabetes mellitus; MEDLINE; Alzheimer's disease; Drug","score_opus":0.001622384739918409,"score_gpt":0.18268560671466258,"score_spread":0.18106322197474417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415418769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859305,0.0003532198,0.00001850573,0.00078789546,0.00005924956,0.0005986009,0.000011426674,0.000022619752,0.012217955],"genre_scores_gemma":[0.99817187,0.000051394298,0.00022941279,0.00040101822,0.0000070803712,0.000018407296,0.000074734606,0.000007806561,0.0010382585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932575,0.000066835215,0.00015653625,0.0001380782,0.00018150575,0.00013131005],"domain_scores_gemma":[0.99933046,0.0002127893,0.000090751004,0.00022797176,0.000107086475,0.000030911706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032932803,0.00010246077,0.00021834359,0.00006036919,0.00007031418,0.000008956011,0.000055488636,0.000019494884,0.000037496342],"category_scores_gemma":[0.000075142336,0.000055210767,0.00004175686,0.00018323054,0.00019748708,0.000027300093,0.000052005707,0.00006255529,0.0000031422157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005265779,0.000109779394,0.99014854,0.00008134487,0.00069100247,2.7852633e-7,0.00016973465,0.000010303769,0.000001901596,0.0005294466,0.0012527487,0.006478341],"study_design_scores_gemma":[0.008501544,0.00009813372,0.9843491,0.00013057767,0.0014546432,3.1215586e-9,0.000104368344,0.0004091917,0.00038921408,0.00010604849,0.004398741,0.00005845375],"about_ca_topic_score_codex":0.00008094553,"about_ca_topic_score_gemma":0.000016378244,"teacher_disagreement_score":0.01224136,"about_ca_system_score_codex":0.000018165656,"about_ca_system_score_gemma":0.000024488307,"threshold_uncertainty_score":0.22514299},"labels":[],"label_agreement":null},{"id":"W4415425251","doi":"10.1093/ndt/gfaf116.0918","title":"#1608 Glucagon-like peptide-1 receptor agonists and the risk of emergency department visits and hospitalization in patients across the spectrum of kidney disease","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Emergency department; Propensity score matching; Kidney disease; Hazard ratio; Cohort; Retrospective cohort study; Proportional hazards model; Medical prescription","score_opus":0.003562369907116603,"score_gpt":0.23568133368020303,"score_spread":0.2321189637730864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415425251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963078,0.00043293418,0.00025590893,0.00176835,0.00014073955,0.00086473196,0.00011286091,0.0000092334085,0.000107437474],"genre_scores_gemma":[0.9921397,0.006703633,0.000031220203,0.0003970702,0.000012041443,0.00008088177,0.00053634075,0.0000060647712,0.00009306659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990055,0.00016447925,0.00035122893,0.00020236462,0.00013566486,0.00014075222],"domain_scores_gemma":[0.9994656,0.00008673647,0.0001677299,0.00017769217,0.00004696149,0.000055275363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026379948,0.00012000066,0.00028234193,0.00009352677,0.0000847944,0.0000068519494,0.0000548547,0.000046555055,0.000017624134],"category_scores_gemma":[0.000058835423,0.00007359563,0.00007860618,0.0002550655,0.00014525764,0.000060702758,0.000019598818,0.000053989377,9.1036605e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022154476,0.00028710996,0.9911919,0.00023626226,0.0006054984,0.0000011679606,0.0020226582,0.000041510593,0.00008857211,0.00068115804,0.00033841882,0.002290246],"study_design_scores_gemma":[0.006378034,0.00018100828,0.98951,0.00005202129,0.0022187436,8.3761606e-8,0.000074020245,0.00027216936,0.00042847497,0.00046907435,0.00036327261,0.000053077034],"about_ca_topic_score_codex":0.00010744436,"about_ca_topic_score_gemma":0.00022345652,"teacher_disagreement_score":0.0062706987,"about_ca_system_score_codex":0.0000199199,"about_ca_system_score_gemma":0.000026587208,"threshold_uncertainty_score":0.30011424},"labels":[],"label_agreement":null},{"id":"W4415426091","doi":"10.1093/ndt/gfaf116.069","title":"#3510 Outcomes of canagliflozin in patients with type 2 diabetes with and without progressive renal function decline: insights from the CREDENCE trial","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Canagliflozin; Renal function; Kidney disease; Placebo; Type 2 diabetes; Diabetes mellitus; Clinical trial; Randomized controlled trial","score_opus":0.006182497198795612,"score_gpt":0.23425986093522916,"score_spread":0.22807736373643356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415426091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807215,0.00019353852,0.000126835,0.00041472213,0.000065757085,0.00096180465,0.000009826809,0.000018101957,0.00013726609],"genre_scores_gemma":[0.9983523,0.000059777904,0.0002485768,0.0007563968,0.000021140888,0.00009925654,0.00042056228,0.000007340237,0.000034668967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913204,0.00008773178,0.00022942098,0.00023593158,0.00018620619,0.00012865732],"domain_scores_gemma":[0.9994375,0.00016387364,0.00011875074,0.00015931868,0.00009405492,0.000026475833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006623912,0.00013983577,0.00035551793,0.00015738927,0.000048107504,0.000011971207,0.000051791947,0.000069863585,0.000011579053],"category_scores_gemma":[0.00001645574,0.0000756747,0.0000290111,0.0003270769,0.00012893866,0.00009013332,0.000009424226,0.00008420592,8.0894023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034226034,0.00024614722,0.96132225,0.000032431693,0.0011384527,0.0000032893522,0.0003264406,0.000036500453,0.0001137112,0.00008221234,0.000023783095,0.0024487635],"study_design_scores_gemma":[0.039120976,0.0016939227,0.95526505,0.00010278803,0.0031851996,6.116953e-8,0.00003371946,0.0000607757,0.00028811887,0.000117058786,0.00006516265,0.000067183246],"about_ca_topic_score_codex":0.00025858468,"about_ca_topic_score_gemma":0.0032377564,"teacher_disagreement_score":0.006057202,"about_ca_system_score_codex":0.000022992577,"about_ca_system_score_gemma":0.000054464777,"threshold_uncertainty_score":0.30859247},"labels":[],"label_agreement":null},{"id":"W4415426307","doi":"10.1093/ndt/gfaf116.037","title":"#800 The effect of canagliflozin dose on cardiovascular and renal outcomes in patients with type 2 diabetes and high cardiovascular risk","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Canagliflozin; Albuminuria; Renal function; Kidney disease; Type 2 diabetes; Clinical endpoint; Hazard ratio; Acute kidney injury; Placebo","score_opus":0.002519462184968675,"score_gpt":0.19219479053708743,"score_spread":0.18967532835211875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415426307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777865,0.0011593663,0.000030615483,0.000085086904,0.000045630826,0.000741729,0.000015108515,0.000014397579,0.0001293962],"genre_scores_gemma":[0.9987622,0.000833982,0.000039933304,0.00014368517,0.000009551189,0.00006346646,0.00012005709,0.000008509019,0.000018596891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989239,0.00027251744,0.00017297093,0.00026351868,0.00020988192,0.00015723752],"domain_scores_gemma":[0.9993654,0.00024039473,0.000044266144,0.00028827367,0.000033291413,0.000028381943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038752976,0.00016062538,0.00063483726,0.00023272607,0.000051155483,0.000007791935,0.00004006449,0.00007253749,0.000002924743],"category_scores_gemma":[0.000022375663,0.000092730246,0.0001600369,0.00025611813,0.0001035079,0.000039525225,0.000009549554,0.000098157645,8.6606394e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010216029,0.00005269954,0.96567434,0.00016148988,0.009683113,0.000009170909,0.00015372073,0.001066187,0.000024781697,0.000028445107,0.0000116191795,0.022112837],"study_design_scores_gemma":[0.008952688,0.0012558539,0.97564226,0.00005755094,0.013020048,1.6847311e-7,0.0000067288247,0.000053441334,0.0007613564,0.000024498338,0.00015519107,0.000070213],"about_ca_topic_score_codex":0.0005936757,"about_ca_topic_score_gemma":0.00022687082,"teacher_disagreement_score":0.022042625,"about_ca_system_score_codex":0.000031188953,"about_ca_system_score_gemma":0.0000138098385,"threshold_uncertainty_score":0.37814298},"labels":[],"label_agreement":null},{"id":"W4415434667","doi":"10.1093/ndt/gfaf116.1358","title":"#558 Population pharmacokinetic modelling of canagliflozin in advanced chronic kidney disease","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Canagliflozin; Kidney disease; Covariate; Pharmacokinetics; Population; Cohort; Dialysis; Renal function","score_opus":0.010002037518446298,"score_gpt":0.2639914702021437,"score_spread":0.2539894326836974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415434667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877263,0.0004476048,0.009296761,0.0009772745,0.00010475462,0.00056248694,0.000021267148,0.000038752074,0.00082481955],"genre_scores_gemma":[0.99622667,0.0010786685,0.0004564295,0.0007866609,0.000026503183,0.000094582705,0.0011056049,0.000008855587,0.00021601446],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9990832,0.0000547053,0.00032404764,0.00023819,0.00011806971,0.00018174015],"domain_scores_gemma":[0.9996303,0.0000412551,0.00006971573,0.00014935093,0.000032700493,0.000076713746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090592606,0.00012170464,0.00028846556,0.00047517932,0.000025740146,0.0000037000514,0.000048078593,0.000053953572,0.000054705833],"category_scores_gemma":[0.000008337472,0.000121763325,0.00008749443,0.00040803704,0.000028447459,0.00008673139,0.000005393514,0.00006865938,0.0000038881353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004416118,0.00079838064,0.41024682,0.0024159462,0.0010577503,0.00011321816,0.0005663331,0.5081076,0.018138463,0.0024888003,0.00025127278,0.051399283],"study_design_scores_gemma":[0.015334411,0.00025666502,0.7462309,0.0005050765,0.0065689543,9.2033747e-7,0.000022597123,0.22400533,0.0043505793,0.0011837458,0.0012988404,0.00024198418],"about_ca_topic_score_codex":0.0003671499,"about_ca_topic_score_gemma":0.000382475,"teacher_disagreement_score":0.33598408,"about_ca_system_score_codex":0.0001295427,"about_ca_system_score_gemma":0.00008815956,"threshold_uncertainty_score":0.49653643},"labels":[],"label_agreement":null},{"id":"W4415443882","doi":"10.1371/journal.pgph.0005326","title":"Trends in global glucose lowering medication consumption: Insights from pharmaceutical sales data (2010–2021)","year":2025,"lang":"en","type":"article","venue":"PLOS Global Public Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health; Novo Nordisk; Esperion Therapeutics; Amgen","keywords":"Consumption (sociology); China; Guideline; Diabetes mellitus; Drug; Developing country; Global health","score_opus":0.11849626657622901,"score_gpt":0.39362403058683487,"score_spread":0.27512776401060585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415443882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7803414,0.020527275,0.001398092,0.16274905,0.0017973373,0.001255854,0.0008550041,0.00040601776,0.03066996],"genre_scores_gemma":[0.9855671,0.001840977,0.00076970726,0.006148889,0.00019140096,0.00004376861,0.0052005756,0.000008989646,0.00022857613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976569,0.00011925748,0.0005249228,0.00065756665,0.00048520532,0.0005561698],"domain_scores_gemma":[0.998412,0.000060153256,0.00010217315,0.00086551014,0.00005054316,0.0005095792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033914475,0.00021961343,0.00044339785,0.00019472052,0.00008659363,0.00007701816,0.00036910377,0.0001078065,0.00042432075],"category_scores_gemma":[0.00015858718,0.00019898533,0.000048360445,0.0009249079,0.00010174296,0.00033813072,0.00039789034,0.00016968047,0.00019149929],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012581496,0.0025755137,0.28208554,0.0003530567,0.0005249619,0.00006982743,0.00008504216,9.21702e-7,0.000019289526,0.012082461,0.054885957,0.64719164],"study_design_scores_gemma":[0.005769007,0.00015769691,0.7559663,0.0005264179,0.00022768164,0.0000032168718,0.00011637973,0.003392922,0.000025144249,0.00088028196,0.23270997,0.00022499611],"about_ca_topic_score_codex":0.00053034397,"about_ca_topic_score_gemma":0.0009485853,"teacher_disagreement_score":0.64696664,"about_ca_system_score_codex":0.0014018575,"about_ca_system_score_gemma":0.0006156873,"threshold_uncertainty_score":0.8114387},"labels":[],"label_agreement":null},{"id":"W4415450290","doi":"10.1210/jendso/bvaf149.1291","title":"MON-826 Impact Of Demographic And Social Determinants On Access To SGLT2 Inhibitors And GLP-1 Receptor Agonists: A Systematic Review And Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Odds ratio; Odds; Observational study; Confidence interval; Medical prescription; Diabetes mellitus; Social determinants of health; Meta-analysis; Demographics","score_opus":0.055276111264274945,"score_gpt":0.39751181058269697,"score_spread":0.342235699318422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415450290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007670407,0.99560136,0.0000017109368,0.0011525586,0.00006180573,0.0023076423,0.00007720253,0.0000054702814,0.000025220648],"genre_scores_gemma":[0.0005885152,0.99786687,0.0001207177,0.00056471693,0.000061184895,0.000081003585,0.0000061092137,0.000022782096,0.00068808714],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974196,0.00031116587,0.0013254443,0.00027332193,0.00043550725,0.00023496478],"domain_scores_gemma":[0.99728626,0.00028819017,0.0017665904,0.0003543696,0.0001618361,0.00014277143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006603384,0.0004743797,0.0073468615,0.00031303975,0.00013589126,0.0001006511,0.00028018144,0.000081902836,0.000024541378],"category_scores_gemma":[0.00018946701,0.00021922805,0.0065473313,0.0009776211,0.000110058536,0.00009901485,0.0003423443,0.00033799134,4.3097592e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011904341,0.00012713166,0.0002957131,0.7328696,0.24889494,0.0000108614395,0.00011373617,1.9775455e-7,3.2449387e-7,0.000005438692,0.009449058,0.00822103],"study_design_scores_gemma":[0.00042522093,0.00032609847,0.00016870494,0.062225565,0.92682326,0.000051187566,0.000040928662,8.8599955e-7,0.0000021235219,0.000009162539,0.009755102,0.00017176945],"about_ca_topic_score_codex":0.000015010189,"about_ca_topic_score_gemma":0.000004234742,"teacher_disagreement_score":0.6779283,"about_ca_system_score_codex":0.00015019611,"about_ca_system_score_gemma":0.00014788675,"threshold_uncertainty_score":0.89398605},"labels":[],"label_agreement":null},{"id":"W4415469758","doi":"10.54254/2753-8818/2025.au27989","title":"Type 1 Diabetes and Its Potential Treatments (GDF 15)","year":2025,"lang":"","type":"article","venue":"Theoretical and Natural Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kensington Health","funders":"","keywords":"Type 1 diabetes; Disease; Genetic predisposition; Diabetes mellitus; Diabetic ketoacidosis; Autoimmune disease; Insulin; Type 2 diabetes","score_opus":0.0036646673770942806,"score_gpt":0.25050666755996637,"score_spread":0.24684200018287208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415469758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529748,0.027039409,0.0000039113106,0.0034515008,0.001188272,0.00057892216,0.0000055505757,0.000038098355,0.0147195505],"genre_scores_gemma":[0.98989433,0.0028162175,0.000080748636,0.00084472564,0.00007949688,0.000008666715,0.0000060360953,0.000007432175,0.0062623345],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9978061,0.000050426443,0.00023900619,0.00070254586,0.00042946433,0.00077251135],"domain_scores_gemma":[0.9991263,0.00012327165,0.000044422686,0.0002185651,0.00013420833,0.00035319655],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0004580028,0.0003062951,0.0003872536,0.0002217695,0.00046563722,0.00018528813,0.00021769872,0.00009188951,0.00038424146],"category_scores_gemma":[0.00025222442,0.00020106345,0.00005587998,0.0009262201,0.0033524246,0.0002593352,0.00053231494,0.00020194486,0.000059794813],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025244796,0.00030719422,0.0038839742,0.00016864968,0.0002630811,0.00002772239,0.000121595265,2.883096e-7,0.018662892,0.8613937,0.00019506838,0.114723384],"study_design_scores_gemma":[0.017313153,0.008255783,0.46464923,0.003093775,0.009626719,0.000024879231,0.0007630481,0.07181417,0.1285813,0.2885964,0.0051041306,0.0021774312],"about_ca_topic_score_codex":0.0000026757082,"about_ca_topic_score_gemma":3.3274483e-7,"teacher_disagreement_score":0.5727973,"about_ca_system_score_codex":0.00008063009,"about_ca_system_score_gemma":0.00012527134,"threshold_uncertainty_score":0.9993599},"labels":[],"label_agreement":null},{"id":"W4415474165","doi":"10.1681/asn.2025n7x3kgpw","title":"Effects of Zibotentan and Dapagliflozin Combination Therapy on Albuminuria and Fluid Parameters in CKD: Results from the ZODIAC Trial","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Albuminuria; Combination therapy; Dapagliflozin; Renal function; Clinical trial","score_opus":0.011565566943992505,"score_gpt":0.2677276535955685,"score_spread":0.25616208665157597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415474165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813872,0.00063326414,0.000007814198,0.017334634,0.00012759218,0.00046441937,0.000003772561,0.0000020137063,0.000039313603],"genre_scores_gemma":[0.9904705,0.002287839,0.00049308554,0.006641697,0.000041532414,0.000004509743,0.0000016537626,0.0000049627693,0.000054206805],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99907964,0.00021368997,0.00035016026,0.000103484264,0.00015129539,0.00010173783],"domain_scores_gemma":[0.9981335,0.0010917903,0.0005548203,0.00015743305,0.00003831649,0.000024143354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003998181,0.00009353416,0.00045175277,0.00004651776,0.000029810624,0.0000053851654,0.00011039326,0.00003794827,8.3443183e-7],"category_scores_gemma":[0.00009116297,0.000050561353,0.00017278067,0.00017459643,0.00047568086,0.00002711257,0.000045902598,0.00014782979,9.299111e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21593352,0.0047284835,0.049363513,0.00019546249,0.009555915,0.000024849229,0.01264103,0.000078592624,0.31745684,0.0007344877,0.1393619,0.24992539],"study_design_scores_gemma":[0.09644046,0.009080519,0.8750338,0.00025662742,0.00064640323,0.0000029985429,0.0011177255,0.0002063954,0.011698164,0.0014191325,0.004017434,0.0000803217],"about_ca_topic_score_codex":0.000234444,"about_ca_topic_score_gemma":0.000006180721,"teacher_disagreement_score":0.8256703,"about_ca_system_score_codex":0.000039100123,"about_ca_system_score_gemma":0.00003347081,"threshold_uncertainty_score":0.20618321},"labels":[],"label_agreement":null},{"id":"W4415474379","doi":"10.1681/asn.2025mkxzx6mr","title":"Cardio-Kidney Effects of Dapagliflozin in Patients at Elevated Cardiovascular Risk with or Without Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; University Health Network; University of British Columbia","funders":"","keywords":"Dapagliflozin; Type 2 diabetes; Diabetes mellitus; Kidney disease; Benzhydryl compounds; Renal function","score_opus":0.004630587556525095,"score_gpt":0.2255215844642816,"score_spread":0.22089099690775651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415474379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981367,0.00066555705,0.000020462252,0.0005586405,0.00011726077,0.00040081263,0.0000034533543,0.0000053325703,0.00009177396],"genre_scores_gemma":[0.9956225,0.00068711035,0.0011344125,0.0022870277,0.000034785437,0.0000051104744,0.000002504488,0.000013987653,0.0002125362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987226,0.00021833157,0.0003727214,0.00013520397,0.00032922652,0.00022190352],"domain_scores_gemma":[0.99848825,0.00014285019,0.0007004438,0.00036881614,0.00023388841,0.00006575093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000338676,0.00014934644,0.0011353096,0.00009502109,0.000033987275,0.0000023990422,0.00017866961,0.000048341924,0.000005470214],"category_scores_gemma":[0.00012884475,0.00008162326,0.00060044165,0.00064663455,0.00043434117,0.000034759505,0.00011726164,0.00019679176,6.9892724e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015053381,0.00033231906,0.96332175,0.00025450898,0.010005061,0.0000050890085,0.0002423255,0.00010681756,0.0035284879,0.0000016663766,0.016186772,0.004509875],"study_design_scores_gemma":[0.007127921,0.004368784,0.96714985,0.00033564796,0.0035073557,0.0000023958846,0.00014781141,0.00007352527,0.004330585,0.000016134645,0.012858234,0.0000817559],"about_ca_topic_score_codex":0.00008193415,"about_ca_topic_score_gemma":0.000005344675,"teacher_disagreement_score":0.006497705,"about_ca_system_score_codex":0.00015210191,"about_ca_system_score_gemma":0.00014907899,"threshold_uncertainty_score":0.33284998},"labels":[],"label_agreement":null},{"id":"W4415474467","doi":"10.1681/asn.2025tbfaerbe","title":"Real-World Use of SGLT2 Inhibitors for Patients with IgAN and Glomerulonephritis, 2021-2023","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Kidney disease; Nephropathy; Nephrology; Diabetes mellitus; Kidney; Tubulopathy","score_opus":0.009706295011003677,"score_gpt":0.25998428747113705,"score_spread":0.2502779924601334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415474467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413645,0.00013182806,0.000046626956,0.0051345946,0.000079934776,0.00033764014,0.000015480158,0.0000027948838,0.0001146393],"genre_scores_gemma":[0.9810298,0.0012700132,0.012198242,0.003906498,0.00009829788,0.000008058311,0.0000059367826,0.000015422833,0.0014677125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915755,0.000038902694,0.00036370437,0.00010270534,0.00017831539,0.00015885015],"domain_scores_gemma":[0.9985933,0.00019055534,0.00076799403,0.00017237548,0.00022756988,0.00004824266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013775253,0.000107634936,0.0005550807,0.00009117406,0.00004131748,0.0000053917906,0.000088919944,0.000028176051,0.00000577029],"category_scores_gemma":[0.000027379623,0.00006714166,0.00026833726,0.00036643923,0.000574002,0.00006458284,0.00007609013,0.000107184715,1.2950233e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001832284,0.0007771528,0.73877573,0.00026639967,0.00332132,0.000002563836,0.00031800388,0.000014013098,0.0062571457,0.00023054877,0.21632656,0.03187825],"study_design_scores_gemma":[0.0038729825,0.0029956063,0.92764926,0.00022698022,0.0009713228,0.000002508437,0.00034351298,0.000026534122,0.00056135585,0.00015295109,0.063130945,0.00006601858],"about_ca_topic_score_codex":0.00015608616,"about_ca_topic_score_gemma":0.000025675667,"teacher_disagreement_score":0.18887353,"about_ca_system_score_codex":0.000051724466,"about_ca_system_score_gemma":0.000072943396,"threshold_uncertainty_score":0.27379575},"labels":[],"label_agreement":null},{"id":"W4415478679","doi":"10.1001/jamaophthalmol.2025.3720","title":"Neovascular Age-Related Macular Degeneration and GLP-1 RAs","year":2025,"lang":"en","type":"article","venue":"JAMA Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Macular degeneration; Maculopathy; Retina; Fluorescein angiography; Retinopathy; Choroidal neovascularization","score_opus":0.011486667179020343,"score_gpt":0.273976482354362,"score_spread":0.26248981517534165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415478679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92923135,0.0020088232,0.00006958427,0.0029708922,0.00024409461,0.00042070902,0.0000010267989,0.000050032897,0.06500347],"genre_scores_gemma":[0.97400886,0.00006338868,0.00092519034,0.00065335154,0.00004254536,0.000051065894,0.00011165562,0.000011046972,0.024132892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992175,0.00005422542,0.00017696466,0.0002693581,0.000085777734,0.00019616226],"domain_scores_gemma":[0.9995939,0.000029646342,0.000032380132,0.0002495739,0.00003774949,0.00005671951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014620289,0.00012854564,0.0002609702,0.00016158896,0.0000753076,0.000036624384,0.00004737165,0.00015074058,0.00029052983],"category_scores_gemma":[0.000048899175,0.00011172025,0.00007645679,0.00017886833,0.00009911633,0.000053769665,0.000073524054,0.0000977981,0.000043101718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008552393,0.0021544634,0.43419895,0.0010679034,0.008986458,0.03649583,0.0008057458,0.00016421586,0.04920677,0.1526142,0.047902547,0.2655477],"study_design_scores_gemma":[0.0198388,0.001740218,0.80542654,0.00029233043,0.0030857667,0.0022291308,0.00016800224,0.0019114972,0.015788829,0.016515164,0.1323731,0.0006306164],"about_ca_topic_score_codex":0.00003627201,"about_ca_topic_score_gemma":0.0000011091048,"teacher_disagreement_score":0.37122762,"about_ca_system_score_codex":0.000044778262,"about_ca_system_score_gemma":0.000030120702,"threshold_uncertainty_score":0.45558196},"labels":[],"label_agreement":null},{"id":"W4415492833","doi":"10.1093/ajh/hpaf205","title":"GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications","year":2025,"lang":"en","type":"article","venue":"American Journal of Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; McGill University","keywords":"Blood pressure; Diabetes mellitus; Type 2 diabetes; Population; Receptor; Affect (linguistics); Weight loss; Agonist; Heart rate","score_opus":0.025989868988206027,"score_gpt":0.3112372082407648,"score_spread":0.28524733925255874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415492833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.787703,0.16473052,0.00033634974,0.04560989,0.0003141405,0.0009937915,0.000009448668,0.000011350745,0.00029151284],"genre_scores_gemma":[0.83641803,0.15533654,0.0052001704,0.0025480478,0.000017702276,0.0000040345076,0.0000014539204,0.000007623336,0.00046641295],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990056,0.00009612157,0.00053872453,0.00011540864,0.00016129564,0.00008283961],"domain_scores_gemma":[0.998708,0.00020173652,0.00052457215,0.00020744918,0.0002848333,0.000073400304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046260448,0.00008127087,0.0005612669,0.00007008669,0.000030324612,0.000004530298,0.00007409493,0.00001506944,0.0000073846245],"category_scores_gemma":[0.00037377674,0.000048915932,0.00011947438,0.00022424113,0.00020907924,0.000061518156,0.000076051176,0.0000979568,5.538051e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005441551,0.0017882731,0.07921687,0.004684932,0.0043177353,0.000028276625,0.00008689378,8.3775353e-7,0.027296849,0.001702023,0.046222154,0.834111],"study_design_scores_gemma":[0.0074503785,0.014734516,0.71507967,0.09958287,0.037853774,0.00050279393,0.0002430838,0.000058406782,0.0113493195,0.0031564378,0.10957502,0.00041373615],"about_ca_topic_score_codex":0.000008844447,"about_ca_topic_score_gemma":0.0000010149943,"teacher_disagreement_score":0.83369726,"about_ca_system_score_codex":0.0000057763473,"about_ca_system_score_gemma":0.000082650404,"threshold_uncertainty_score":0.19947338},"labels":[],"label_agreement":null},{"id":"W4415536320","doi":"10.1016/j.obpill.2025.100222","title":"Optimizing GLP-1 therapies for obesity and diabetes management","year":2025,"lang":"en","type":"article","venue":"Obesity Pillars","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Saskatchewan; St. Michael's Hospital","funders":"Nestlé Health Science","keywords":"Multidisciplinary approach; Diabetes mellitus; Obesity; Management of obesity; Diabetes management; Disease; Disease management","score_opus":0.009081894177530098,"score_gpt":0.24520646762986306,"score_spread":0.23612457345233295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415536320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96806335,0.0028598502,0.00073429145,0.0017607738,0.00018923724,0.0013606328,0.0000067482024,0.00013302779,0.024892056],"genre_scores_gemma":[0.97437984,0.0011259628,0.012190209,0.0015395671,0.000039128106,0.00014029985,0.000037158494,0.000017794287,0.0105300695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912345,0.000015547379,0.00014433208,0.00030173446,0.0001199692,0.00029496523],"domain_scores_gemma":[0.99953425,0.00005454789,0.00003654442,0.0002662815,0.000041714036,0.00006666645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017356436,0.00017185064,0.00028889778,0.00015070142,0.0001682963,0.0000512054,0.00007433645,0.000051871142,0.000023422954],"category_scores_gemma":[0.000012646605,0.0001500282,0.0000942724,0.00014305218,0.000058096408,0.000068439134,0.00013079168,0.000047322646,0.0000084491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013108969,0.0010994623,0.83319694,0.0024308497,0.002969456,0.000029044773,0.00040065518,0.000010764641,0.00074452406,0.048660044,0.015127255,0.095199905],"study_design_scores_gemma":[0.006606586,0.0005729322,0.7786825,0.0005256888,0.0021792864,8.392788e-7,0.0007688889,0.0006517423,0.005280435,0.00878592,0.19547509,0.0004701347],"about_ca_topic_score_codex":0.0000042898723,"about_ca_topic_score_gemma":0.000005072656,"teacher_disagreement_score":0.18034783,"about_ca_system_score_codex":0.00006719365,"about_ca_system_score_gemma":0.0000103287975,"threshold_uncertainty_score":0.6117972},"labels":[],"label_agreement":null},{"id":"W4415552134","doi":"10.4103/ijdt.ijdt_22_25","title":"Adiposity-based Chronic Diseases and the Therapeutic Role of Glucagon-like Peptide-1 Receptor Agonists","year":2025,"lang":"en","type":"article","venue":"International Journal of Diabetes and Technology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juvenile Diabetes Research Foundation","funders":"","keywords":"Polycystic ovary; Disease; Semaglutide; Type 2 diabetes; Diabetes mellitus; Kidney disease; Weight loss; Therapeutic approach","score_opus":0.0031355655532441153,"score_gpt":0.23571965702579736,"score_spread":0.23258409147255324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415552134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539049,0.029147306,0.000039692022,0.016010122,0.00029405046,0.00016798172,0.000007788256,0.000016370206,0.0004117666],"genre_scores_gemma":[0.9983629,0.00072206225,0.00016436829,0.0004894477,0.00004972677,0.0000099697945,0.000004842654,0.000005172491,0.00019153756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994058,0.000019252298,0.00023675646,0.000090196816,0.00014405449,0.00010394926],"domain_scores_gemma":[0.9993872,0.00011033517,0.00017467348,0.00010060213,0.00019831206,0.000028890712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010939401,0.00008740958,0.00025594846,0.00033527473,0.000032824668,0.000021180165,0.00015837318,0.00005139057,0.000020666055],"category_scores_gemma":[0.000043708904,0.000054125117,0.000075722244,0.000118710246,0.0003378854,0.000042372176,0.000075587646,0.00010488574,8.4554364e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041607444,0.0004983275,0.50130177,0.00013887706,0.004424112,0.000011512219,0.00005668543,0.0000060743487,0.012881397,0.054893814,0.00076407427,0.42460728],"study_design_scores_gemma":[0.06369278,0.006465925,0.37423903,0.0040157665,0.007635155,0.00004412103,0.0011161023,0.0049569895,0.13238728,0.116055205,0.2887392,0.00065244123],"about_ca_topic_score_codex":0.0000028721847,"about_ca_topic_score_gemma":0.0000019010758,"teacher_disagreement_score":0.42395484,"about_ca_system_score_codex":0.000050405848,"about_ca_system_score_gemma":0.00007353539,"threshold_uncertainty_score":0.22071584},"labels":[],"label_agreement":null},{"id":"W4415568763","doi":"10.1515/med-2025-1278","title":"Association of SGLT2 inhibition with psychiatric disorders: A Mendelian randomization study","year":2025,"lang":"en","type":"article","venue":"Open Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Natural Science Foundation of China","keywords":"Mendelian randomization; Association (psychology); Anxiety; Genetic association; Genome-wide association study; Bipolar disorder; Randomization; MEDLINE","score_opus":0.007584839243533065,"score_gpt":0.29036119785894876,"score_spread":0.2827763586154157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415568763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6553266,0.000438318,0.0028602215,0.041071743,0.00042992525,0.009617907,0.0000040372684,0.000072641335,0.2901786],"genre_scores_gemma":[0.9823408,0.00012609539,0.0004458797,0.0004970198,0.000048730577,0.00015454619,0.00009387205,0.000009728025,0.016283302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990054,0.00006658916,0.0003073393,0.00019680196,0.00030542054,0.00011847206],"domain_scores_gemma":[0.99939775,0.00005763853,0.00018949008,0.00020772981,0.00010998592,0.000037397498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006366402,0.00011071864,0.00040135492,0.0002636073,0.000052260384,0.000013795478,0.00006976257,0.000032839886,0.00019910424],"category_scores_gemma":[0.00010239197,0.000071627175,0.000026269949,0.0007140132,0.000022030046,0.00010997145,0.000048921087,0.000057041318,0.0000059900412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042673456,0.0040551475,0.87181777,0.00030005706,0.0021807896,0.000008859148,0.0014033163,0.000025759588,0.00031199938,0.0016208773,0.06807274,0.045935325],"study_design_scores_gemma":[0.41198623,0.01706263,0.49952593,0.0024201658,0.013193468,0.0000015902542,0.011663532,0.00051197916,0.0007082753,0.0030690692,0.03940366,0.00045345395],"about_ca_topic_score_codex":0.00026120426,"about_ca_topic_score_gemma":0.0003816566,"teacher_disagreement_score":0.4077189,"about_ca_system_score_codex":0.00010742031,"about_ca_system_score_gemma":0.000047337435,"threshold_uncertainty_score":0.29208714},"labels":[],"label_agreement":null},{"id":"W4415606444","doi":"10.1016/j.archger.2025.106065","title":"SGLT2 inhibitors versus DPP-4 inhibitors and dementia risk in type 2 diabetes: A meta-analysis of cohort studies","year":2025,"lang":"en","type":"article","venue":"Archives of Gerontology and Geriatrics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Cohort study; Cohort; Type 2 diabetes; Alzheimer's disease; Diabetes mellitus","score_opus":0.037032807206131974,"score_gpt":0.3112151655132107,"score_spread":0.2741823583070787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415606444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.925342,0.07244941,0.00001591984,0.00026559283,0.00017639634,0.0003227448,0.000012502269,0.000009694654,0.0014057352],"genre_scores_gemma":[0.987942,0.010784007,0.0009808186,0.000039276172,0.000010790432,0.000027192886,0.000020955198,0.0000051510992,0.00018980316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988763,0.00010910863,0.00044043193,0.00028708283,0.00009376208,0.00019331751],"domain_scores_gemma":[0.9988264,0.0006785361,0.00020148359,0.00021029465,0.000040654275,0.000042633827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002670686,0.00016250141,0.0011901684,0.000806301,0.000041572206,0.000004020541,0.000051210445,0.00006135036,0.000012980857],"category_scores_gemma":[0.00019185383,0.00012715817,0.00024303501,0.0005823768,0.00030389667,0.000041278272,0.00014627696,0.00008683304,2.9209875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038720964,0.00018309013,0.74457103,0.00021893441,0.2458374,0.000004782379,0.00076859316,0.000018118231,0.00007072712,0.0006934091,0.00021770442,0.0070289704],"study_design_scores_gemma":[0.0025675658,0.0007262112,0.5534318,0.000020318163,0.4403288,1.3010256e-7,0.00069858396,0.00017997857,0.0005580737,0.00085705303,0.000504837,0.0001266146],"about_ca_topic_score_codex":0.00008689664,"about_ca_topic_score_gemma":0.0003473648,"teacher_disagreement_score":0.19449142,"about_ca_system_score_codex":0.000010467343,"about_ca_system_score_gemma":0.000025362864,"threshold_uncertainty_score":0.518536},"labels":[],"label_agreement":null},{"id":"W4415655700","doi":"10.1111/dom.70253","title":"An indirect treatment comparison of tirzepatide 10 and 15 mg versus high‐dose semaglutide 7.2 mg in people with obesity and type 2 diabetes","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Semaglutide; Type 2 diabetes; Placebo; Obesity; Clinical trial; Weight loss; Trial registration","score_opus":0.013812651318188382,"score_gpt":0.25427623198390936,"score_spread":0.240463580665721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415655700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793183,0.012420252,6.1240263e-7,0.0058539077,0.00030519327,0.0013292512,0.00016797666,0.000085880245,0.00051862764],"genre_scores_gemma":[0.982994,0.0028555137,0.00093020545,0.008786935,0.00041974403,0.00016539925,0.0015768073,0.0000811268,0.002190275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971272,0.00023193202,0.0005274572,0.0009525573,0.00040638904,0.0007544937],"domain_scores_gemma":[0.9982885,0.00039052585,0.00030159936,0.0006494117,0.00013685542,0.00023309025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002797514,0.0007905467,0.002428831,0.0006665386,0.0001479235,0.000091078284,0.0001506239,0.0005017605,0.000060417322],"category_scores_gemma":[0.000067515684,0.00062875357,0.00011145605,0.0004857444,0.00027300374,0.00018394,0.0001745005,0.00052971096,0.0000060279135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034036377,0.0013036705,0.96433854,0.0016915408,0.0018056028,0.000050845807,0.00073424116,0.0000030631188,0.00017862365,0.00006148065,0.013669847,0.015822155],"study_design_scores_gemma":[0.008581826,0.00221624,0.9146696,0.00059804635,0.0049566547,5.872408e-7,0.00010199114,0.0002067995,0.0027689964,0.000087932545,0.06517794,0.00063343905],"about_ca_topic_score_codex":0.000561911,"about_ca_topic_score_gemma":0.000776395,"teacher_disagreement_score":0.05150809,"about_ca_system_score_codex":0.0001146203,"about_ca_system_score_gemma":0.00012705849,"threshold_uncertainty_score":0.9996164},"labels":[],"label_agreement":null},{"id":"W4415696134","doi":"10.1016/j.jacadv.2025.102276","title":"FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial","year":2025,"lang":"en","type":"article","venue":"JACC Advances","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto Rehabilitation Institute; Occupational Cancer Research Centre; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; Toronto General Hospital; University Health Network; Women's College Hospital","funders":"Janssen Research and Development","keywords":"Canagliflozin; Diabetes mellitus; Clinical trial; Disease; MEDLINE","score_opus":0.008163095628340984,"score_gpt":0.25825032293725975,"score_spread":0.25008722730891875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415696134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8831562,0.0782504,0.00005113115,0.0067912103,0.00053404534,0.0028456738,0.0000088473635,0.000021155185,0.02834137],"genre_scores_gemma":[0.9929645,0.0033486895,0.00010569853,0.00057576754,0.000084586005,0.00018584436,0.000010728863,0.0000056274084,0.002718565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992367,0.00006425313,0.00018885189,0.0001532996,0.00021758152,0.00013930579],"domain_scores_gemma":[0.9994303,0.00015459789,0.000045034605,0.00033017396,0.000022521737,0.000017357543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004471517,0.00009649274,0.000334366,0.000070490736,0.000045864268,0.000008898183,0.00011536493,0.000023582465,0.0000074196755],"category_scores_gemma":[0.00007588162,0.000047480527,0.00014903116,0.0002252011,0.000082689854,0.000056721918,0.00004693338,0.00006839528,0.000001545354],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022700926,0.0010248398,0.077598915,0.000984811,0.006432248,0.00009502665,0.0031668958,0.0008050011,0.000018386701,0.08960415,0.008052137,0.7895167],"study_design_scores_gemma":[0.14617917,0.00051609817,0.06678997,0.0003971758,0.0026641432,0.000002858097,0.0037961046,0.00010699991,0.00027798826,0.016249739,0.76281327,0.00020650611],"about_ca_topic_score_codex":0.0008105665,"about_ca_topic_score_gemma":0.0010850612,"teacher_disagreement_score":0.78931016,"about_ca_system_score_codex":0.00003133608,"about_ca_system_score_gemma":0.00003092911,"threshold_uncertainty_score":0.19361998},"labels":[],"label_agreement":null},{"id":"W4415716948","doi":"10.1016/j.jcjd.2025.10.175","title":"Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canada Excellence Research Chairs, Government of Canada; Canada Research Chairs","keywords":"Semaglutide; Randomized controlled trial; Placebo; Type 2 diabetes; Context (archaeology); Nausea","score_opus":0.020233239983839742,"score_gpt":0.28962889877534204,"score_spread":0.2693956587915023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415716948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932509,0.0033827056,0.000002777775,0.00053902616,0.00017705704,0.002413279,0.000027281287,0.000031328243,0.00017562906],"genre_scores_gemma":[0.99803424,0.00003620372,0.00090094225,0.0007380073,0.000019787782,0.00009935022,0.00003632005,0.000022231126,0.00011291177],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99758166,0.00044487702,0.001031051,0.00025408328,0.00027222655,0.0004161141],"domain_scores_gemma":[0.99602425,0.002182466,0.0006593771,0.0002104716,0.00050903705,0.00041439116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055287353,0.000322846,0.0024274413,0.0011048263,0.00006481589,0.00009339054,0.00008334489,0.000084457875,0.0000358419],"category_scores_gemma":[0.0021483686,0.00018724348,0.00021527881,0.000577915,0.00024379461,0.00021112528,0.000013609917,0.00019503785,9.631898e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41011965,0.0003058483,0.56738716,0.00009228588,0.015492331,0.00029273474,0.003766855,0.00007724647,0.00007719294,0.000025031464,0.0007087866,0.0016549055],"study_design_scores_gemma":[0.918195,0.0019492575,0.07086978,0.002027595,0.0036848045,4.96168e-7,0.0020459036,0.0007153585,0.00017379689,0.0000594434,0.00006169074,0.00021687536],"about_ca_topic_score_codex":0.003278688,"about_ca_topic_score_gemma":0.010993428,"teacher_disagreement_score":0.50807536,"about_ca_system_score_codex":0.00018224443,"about_ca_system_score_gemma":0.0010305997,"threshold_uncertainty_score":0.7635568},"labels":[],"label_agreement":null},{"id":"W4415724733","doi":"10.1111/jdi.70187","title":"A decade of <scp>SGLT2</scp> inhibitors: Lessons learned and the road ahead in type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of Diabetes Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Type 2 diabetes; Observational study; Diabetes mellitus; Adverse effect; Glycemic; Type 2 Diabetes Mellitus; Incidence (geometry)","score_opus":0.022636276795879928,"score_gpt":0.28417452394285553,"score_spread":0.2615382471469756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415724733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844536,0.005358008,0.0000036656215,0.008456341,0.00025001419,0.00032886138,0.0000013801945,0.00001066007,0.0011374794],"genre_scores_gemma":[0.9977708,0.00043009114,0.00047307764,0.0008004415,0.00009030183,0.000012005943,0.000007048172,0.000011706565,0.000404515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861604,0.0001441543,0.0006070146,0.00013862237,0.00027034173,0.00022380897],"domain_scores_gemma":[0.99864316,0.00047132405,0.00042341414,0.00017302613,0.00019836744,0.00009071684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009962196,0.00014772173,0.00049958786,0.0004394761,0.000044663524,0.000035216057,0.00011023002,0.00008836053,0.0000034768598],"category_scores_gemma":[0.0015586363,0.00009807062,0.000106174244,0.0005949921,0.0003129414,0.00019862325,0.0000639482,0.00024393127,0.0000022685733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047366346,0.00023283117,0.9145848,0.0004980192,0.00067660597,0.000004570094,0.0013918985,0.000064346794,0.021492252,0.0046890816,0.005551714,0.050766513],"study_design_scores_gemma":[0.012943894,0.0011124917,0.7909501,0.0037780858,0.0014318541,0.0000013599039,0.0011265661,0.0019342134,0.14442077,0.03731851,0.004862427,0.000119706005],"about_ca_topic_score_codex":0.000008041806,"about_ca_topic_score_gemma":0.0000064380415,"teacher_disagreement_score":0.12363468,"about_ca_system_score_codex":0.00007186695,"about_ca_system_score_gemma":0.00012983492,"threshold_uncertainty_score":0.39992037},"labels":[],"label_agreement":null},{"id":"W4415741569","doi":"10.1001/jamanetworkopen.2025.38718","title":"Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-to-Consumer Advertising","year":2025,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Agonist; Receptor","score_opus":0.011383832412545767,"score_gpt":0.28146293964390023,"score_spread":0.2700791072313545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415741569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49776685,0.004549697,0.00016530558,0.025664838,0.0018963221,0.0041714017,0.0000119635615,0.0002302256,0.4655434],"genre_scores_gemma":[0.68310326,0.0015448256,0.010888239,0.018788852,0.0006165908,0.0004351691,0.00015966059,0.00007443216,0.28438896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984149,0.000076072036,0.0003084036,0.00053057284,0.00017012675,0.00049996184],"domain_scores_gemma":[0.9990133,0.00012769327,0.00006916802,0.0005068833,0.000060556333,0.0002224021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004380949,0.00025070106,0.00050210656,0.00009930237,0.00021937644,0.00034241375,0.0002644394,0.00009864395,0.00032443108],"category_scores_gemma":[0.0000626066,0.00019185674,0.00007563849,0.00039876674,0.000051708957,0.00021684759,0.00074288895,0.00016041755,0.00035639963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046329602,0.00016121448,0.11862549,0.00009573349,0.0006487104,0.000025500854,0.00019699128,0.000024825833,0.00012944778,0.0005874247,0.6009013,0.27814004],"study_design_scores_gemma":[0.0024393357,0.00017126137,0.11656586,0.0009140459,0.00032146636,0.0000016331317,0.00007132262,0.00009971903,0.00020727415,0.00012530618,0.8788706,0.00021214348],"about_ca_topic_score_codex":0.0002013845,"about_ca_topic_score_gemma":0.000091828,"teacher_disagreement_score":0.2779693,"about_ca_system_score_codex":0.00012097129,"about_ca_system_score_gemma":0.00007256916,"threshold_uncertainty_score":0.78236914},"labels":[],"label_agreement":null},{"id":"W4415742625","doi":"10.1053/j.ajkd.2025.10.004","title":"Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY","year":2025,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Medical Research Council; Centers for Disease Control and Prevention; Universität Zürich; Oxford University Hospitals NHS Foundation Trust; Technische Universität München; Universität Heidelberg; Boehringer Ingelheim; European Society of Cardiology; University of Oxford; Regeneron Pharmaceuticals; National Institutes of Health; U.S. Department of Veterans Affairs; University of Toronto; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Providence Health Care; Kidney Research UK; British Heart Foundation; Eli Lilly and Company; AstraZeneca; National Science Foundation; University of Washington; Novo Nordisk; National Institute for Health and Care Research; Pfizer","keywords":"Empagliflozin; Tamm–Horsfall protein; Kidney; Acute kidney injury; Albuminuria; Kidney disease; Urine","score_opus":0.0032352000586679556,"score_gpt":0.25485811958751176,"score_spread":0.2516229195288438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415742625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895661,0.0005966668,0.000027642292,0.0063203443,0.00022162106,0.00033364075,0.000021892889,0.000015648346,0.0028964402],"genre_scores_gemma":[0.99217975,0.00026416604,0.00027916493,0.0067806607,0.00005389943,0.000010157169,0.000012286564,0.000013846541,0.00040604424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988545,0.00008715105,0.000419774,0.00014587156,0.00028049987,0.00021217676],"domain_scores_gemma":[0.99844193,0.000195947,0.00031531707,0.00019206623,0.000080387734,0.0007743373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010661934,0.00016585014,0.0006035157,0.00069776917,0.00001791487,0.0000087971075,0.00012878532,0.000017280534,0.0000463908],"category_scores_gemma":[0.0017083407,0.0001267782,0.0002398897,0.00063985464,0.00017991493,0.00006801386,0.000038163525,0.000092324364,0.000005457254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044599483,0.005215297,0.7112677,0.0012040809,0.0035188452,0.00091098447,0.00016536919,0.0000110820665,0.0027061987,0.00025128748,0.1557224,0.11456679],"study_design_scores_gemma":[0.013680115,0.008571353,0.93142897,0.005972929,0.0034119526,0.000009179299,0.00063108257,0.00004618429,0.013425726,0.00032901063,0.022200989,0.00029249207],"about_ca_topic_score_codex":0.00003278866,"about_ca_topic_score_gemma":5.3858867e-7,"teacher_disagreement_score":0.22016126,"about_ca_system_score_codex":0.00011449215,"about_ca_system_score_gemma":0.00050903775,"threshold_uncertainty_score":0.5169865},"labels":[],"label_agreement":null},{"id":"W4415788922","doi":"10.1161/circ.152.suppl_3.4358777","title":"Abstract 4358777: Adverse Events Associated with Early vs. Late SGLT2i Initiation After Heart Failure Hospitalization: A Target Trial Emulation Study","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Adverse effect; Proportional hazards model; Heart failure; Hazard ratio; Acute decompensated heart failure; Cumulative incidence; Retrospective cohort study; Incidence (geometry)","score_opus":0.009610723030739439,"score_gpt":0.25245759724523376,"score_spread":0.24284687421449433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415788922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947043,0.00001753179,0.0005535552,0.00040674434,0.00023071286,0.002988608,0.0000068814115,0.00013590505,0.0009557764],"genre_scores_gemma":[0.99839103,8.333373e-7,0.00013275162,0.00018271658,0.0000788554,0.00023178263,0.00057432475,0.000021339036,0.00038638958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987467,0.00006464085,0.00032868906,0.0003065343,0.00037225196,0.00018121],"domain_scores_gemma":[0.99934006,0.000033006963,0.00015792728,0.00022689198,0.00019070102,0.000051420127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021740785,0.00017692028,0.0002575146,0.00022761339,0.000096519274,0.000028953249,0.000034808283,0.000098993056,0.00016558448],"category_scores_gemma":[0.00007641294,0.00016154331,0.00007966681,0.00043146484,0.000014137658,0.00033077397,0.000017911061,0.00008348122,0.000038054364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028149262,0.0009456699,0.99365246,0.00003402601,0.00038443695,0.000009998383,0.0004193191,0.0012494563,0.000033671557,0.000052326333,0.00016379754,0.00023988073],"study_design_scores_gemma":[0.028424423,0.00051820907,0.96880937,0.00018370042,0.0004890663,1.2922945e-7,0.00007776619,0.000965126,0.000020392334,0.00020146214,0.00017377427,0.0001365869],"about_ca_topic_score_codex":0.000019461013,"about_ca_topic_score_gemma":0.00003431385,"teacher_disagreement_score":0.025609497,"about_ca_system_score_codex":0.00024832733,"about_ca_system_score_gemma":0.00006309602,"threshold_uncertainty_score":0.6587545},"labels":[],"label_agreement":null},{"id":"W4415789269","doi":"10.1161/circ.152.suppl_3.4365415","title":"Abstract 4365415: Comparative Efficacy of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists for Weight Loss Among Patients Without Diabetes: A Network Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Weight loss; Confidence interval; Randomized controlled trial; Meta-analysis; Frequentist inference; Agonist; Adverse effect","score_opus":0.04079194510168059,"score_gpt":0.3136427868605688,"score_spread":0.2728508417588882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415789269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944114,0.0007124575,0.0007676961,0.00011928529,0.00014859163,0.0018949535,0.000047385503,0.000045866338,0.0018523348],"genre_scores_gemma":[0.9969414,0.000019420888,0.00074071425,0.00012218523,0.000050490347,0.00020634332,0.0013598618,0.000016856902,0.0005427522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843633,0.00005278618,0.0005267269,0.00043652282,0.00025917508,0.00028846203],"domain_scores_gemma":[0.99873656,0.00023248098,0.0003526213,0.00035087683,0.00023316256,0.000094280615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002659202,0.00025921487,0.0011760581,0.00025098465,0.00013723513,0.000043750966,0.000072770745,0.000093927716,0.0000865267],"category_scores_gemma":[0.00003977265,0.00021577445,0.0006115265,0.00052692136,0.00013479048,0.00014067059,0.000031730204,0.00007267338,0.000007945209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013890264,0.00044870516,0.9330273,0.00023772234,0.061681885,4.9229044e-7,0.00027458958,0.00097018894,0.00010520057,0.00025086987,0.001773988,0.0010901269],"study_design_scores_gemma":[0.0026341244,0.000085923355,0.91609114,0.000050571114,0.076161794,2.2721258e-8,0.000022706741,0.0019061847,0.00048852497,0.0001089118,0.0022922792,0.00015780608],"about_ca_topic_score_codex":0.000019783602,"about_ca_topic_score_gemma":0.000022854276,"teacher_disagreement_score":0.016936174,"about_ca_system_score_codex":0.00010099101,"about_ca_system_score_gemma":0.000033390585,"threshold_uncertainty_score":0.87990266},"labels":[],"label_agreement":null},{"id":"W4415790410","doi":"10.1161/circ.152.suppl_3.4345655","title":"Abstract 4345655: Sodium–Glucose Cotransporter 2 Inhibitors are Cost-Effective and Dominate Glucagon-Like Peptide-1 Receptor Agonists for Patients with Type 2 Diabetes and High Cardiorenal Risk in Canada","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; Biotechnology Research Institute","funders":"","keywords":"Mace; Type 2 diabetes; Population; Diabetes mellitus; Heart failure; Demographics","score_opus":0.00392044074333788,"score_gpt":0.20055624908430128,"score_spread":0.1966358083409634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415790410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632186,0.0003099747,0.000021341417,0.00007408665,0.0002803638,0.002800994,0.000068550486,0.000015822217,0.00010703224],"genre_scores_gemma":[0.9989343,0.00005725821,0.00008033191,0.00008824305,0.000029754561,0.00027413593,0.00048720848,0.000015811207,0.00003290882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991558,0.000019972573,0.00018531426,0.00029213334,0.0001408474,0.00020593895],"domain_scores_gemma":[0.99949473,0.00008889513,0.00010889255,0.00012111305,0.0001153937,0.00007097212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009437009,0.00016630182,0.0002919222,0.00011311332,0.000071573835,0.000022703745,0.000021458669,0.000051625393,0.0000054629695],"category_scores_gemma":[0.000027463197,0.00013972232,0.000028479166,0.00014390683,0.000039537186,0.00010141878,0.0000116770825,0.00007901016,7.748305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027039263,0.000076877855,0.9475697,0.00024039997,0.00022632102,0.0000035726973,0.000082464234,0.00004769558,0.00012768162,0.000011067607,0.00034364153,0.051000148],"study_design_scores_gemma":[0.004911919,0.00012274,0.9918004,0.00032146144,0.00034369147,7.582284e-8,0.00007307433,0.00016098275,0.00086756406,0.000043530137,0.0012195745,0.00013495544],"about_ca_topic_score_codex":0.018560182,"about_ca_topic_score_gemma":0.05074504,"teacher_disagreement_score":0.050865192,"about_ca_system_score_codex":0.0003846736,"about_ca_system_score_gemma":0.000110633126,"threshold_uncertainty_score":0.9879753},"labels":[],"label_agreement":null},{"id":"W4415794669","doi":"10.1161/circ.152.suppl_3.4365838","title":"Abstract 4365838: Survodutide for the Treatment of Obesity: Baseline characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Placebo; Myocardial infarction; Clinical endpoint; Heart failure; Body mass index; Stroke (engine); Dyslipidemia; Diabetes mellitus; Type 2 diabetes","score_opus":0.024124295682003655,"score_gpt":0.2719068611174049,"score_spread":0.24778256543540125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415794669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267185,0.0009787783,0.0022398927,0.00053172954,0.0005757934,0.0025587813,0.000031384094,0.000015057442,0.00039674895],"genre_scores_gemma":[0.9991102,0.0001493226,0.000057572204,0.00004466602,0.00008880496,0.00010606957,0.00007113067,0.000007862564,0.00036434433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992297,0.000032427124,0.00030752772,0.00013164601,0.00019908586,0.00009959526],"domain_scores_gemma":[0.99891144,0.00029046697,0.00013105867,0.00053916534,0.00011278422,0.000015070231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034079337,0.00010470718,0.00039530374,0.00004926324,0.000060805447,0.000007720896,0.00006112746,0.00004084748,0.000014717431],"category_scores_gemma":[0.00014814515,0.00005589746,0.00055262074,0.000121055244,0.000041730957,0.00002453954,0.000012463855,0.000022195656,0.0000012421546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017983462,0.0018355318,0.6843649,0.00055721094,0.0068885516,0.0000018381805,0.00020513554,0.0004802946,0.0005496021,0.001359818,0.0001815204,0.30177724],"study_design_scores_gemma":[0.01487912,0.0001171874,0.97362965,0.00006395042,0.0025838339,1.11670836e-7,0.000025694297,0.00079540897,0.0010155716,0.00007720582,0.006770017,0.00004225847],"about_ca_topic_score_codex":0.0000714102,"about_ca_topic_score_gemma":0.0000072173366,"teacher_disagreement_score":0.30173498,"about_ca_system_score_codex":0.00011779072,"about_ca_system_score_gemma":0.000059806513,"threshold_uncertainty_score":0.22794323},"labels":[],"label_agreement":null},{"id":"W4415855223","doi":"10.1172/jci194751","title":"Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Novo Nordisk; Amgen; Pfizer; Diabetes Canada; Eli Lilly and Company","keywords":"Inflammation; Clinical trial; Disease; Diabetes mellitus; Kidney disease; Type 2 diabetes; Kidney","score_opus":0.07156355982170079,"score_gpt":0.37243666879161813,"score_spread":0.30087310896991737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415855223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894447,0.0016173706,0.00021659808,0.0051024333,0.00084703974,0.00020415042,0.0000023963973,0.00001583283,0.0025494886],"genre_scores_gemma":[0.9902226,0.0006927215,0.0054243617,0.0021819961,0.00023961026,0.0000050818294,0.000010638684,0.000010458914,0.0012125601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811757,0.00010827594,0.0012504559,0.000114319264,0.0002975989,0.000111780944],"domain_scores_gemma":[0.9981009,0.00037230755,0.00082435086,0.00019649228,0.00037332828,0.00013262402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010404733,0.00011110377,0.0005720495,0.0002934512,0.00004277276,0.000015734637,0.00009135664,0.00009882918,0.00003812032],"category_scores_gemma":[0.0005166968,0.00008333359,0.00034938418,0.0002794451,0.00017982119,0.00018420973,0.000020111507,0.00022158577,0.00000606821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070697075,0.001492294,0.78534746,0.0004118462,0.0034394213,0.000023636281,0.0002727711,0.0005201186,0.007630296,0.033238314,0.020723531,0.14619333],"study_design_scores_gemma":[0.004626372,0.00070667337,0.91685534,0.0006767155,0.0017147982,0.0000024118272,0.00013661692,0.00045771265,0.019069895,0.0041932403,0.051459778,0.00010046904],"about_ca_topic_score_codex":0.0000044763415,"about_ca_topic_score_gemma":0.0000048452644,"teacher_disagreement_score":0.14609286,"about_ca_system_score_codex":0.000021961352,"about_ca_system_score_gemma":0.00034029724,"threshold_uncertainty_score":0.3398245},"labels":[],"label_agreement":null},{"id":"W4415896261","doi":"10.1111/dom.70196","title":"Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( <scp>SYNCHRONIZE</scp> ™‐1)","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Tolerability; Cohort; Weight loss; Baseline (sea); Cohort study; Obesity","score_opus":0.028426785054407305,"score_gpt":0.30824914136559417,"score_spread":0.27982235631118685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415896261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827643,0.0067988276,0.00027218697,0.00014143574,0.00047062116,0.00890384,0.00016606764,0.00003376679,0.00044894803],"genre_scores_gemma":[0.9926513,0.002483278,0.0005441427,0.0001204784,0.00016980468,0.0016845334,0.0002549755,0.000023676188,0.0020678304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971284,0.0002918528,0.0012574358,0.00045770474,0.00025113428,0.0006134539],"domain_scores_gemma":[0.9967421,0.0019778633,0.00047344764,0.00041325117,0.00021234815,0.00018094057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001938505,0.00041123838,0.0038860848,0.00055506406,0.00007127232,0.00003083295,0.000107253494,0.00016304523,0.000014991971],"category_scores_gemma":[0.0012714209,0.00031482297,0.0006147107,0.00034465457,0.00022305558,0.000117498406,0.000062675485,0.0000719584,0.000002278606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9166077,0.015724983,0.029034814,0.001271445,0.0047824616,0.0000128894235,0.00067308586,0.0000057377874,0.0012806397,0.0038440689,0.0001860128,0.026576173],"study_design_scores_gemma":[0.96519107,0.00091358926,0.0056054536,0.0002366866,0.0071690576,1.1354134e-7,0.00007856097,0.0019143346,0.014439242,0.00035241758,0.0039902017,0.00010929065],"about_ca_topic_score_codex":0.0000800652,"about_ca_topic_score_gemma":0.000033728706,"teacher_disagreement_score":0.048583366,"about_ca_system_score_codex":0.00006361046,"about_ca_system_score_gemma":0.00016983764,"threshold_uncertainty_score":0.9999304},"labels":[],"label_agreement":null},{"id":"W4415951323","doi":"10.1007/s13300-025-01804-w","title":"Insights into the Mechanism of Action of Tirzepatide: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"Eli Lilly and Company","keywords":"Narrative review; Type 2 diabetes; Heart failure; Weight loss; Overweight; Glycemic; Mechanism (biology); Diabetes mellitus; Agonist","score_opus":0.04136549460698956,"score_gpt":0.3543042300904666,"score_spread":0.312938735483477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415951323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002645624,0.99410677,0.000005558159,0.00016595358,0.00021676575,0.0033679372,0.000006852221,0.000028907927,0.0018366798],"genre_scores_gemma":[0.00013940853,0.9970684,0.00008208425,0.00048372213,0.000048159047,0.0007064376,0.00018353744,0.000030483672,0.0012577398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826556,0.00024947795,0.0007203154,0.00029661477,0.00029605662,0.0001719814],"domain_scores_gemma":[0.9981219,0.00030635425,0.0006767938,0.0006976474,0.00015641908,0.00004084059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023693363,0.00038975323,0.0024060467,0.00024019304,0.00005104823,0.000006454711,0.00024434083,0.0001425595,0.0000951343],"category_scores_gemma":[0.000065195905,0.0002052503,0.0007646947,0.0006610672,0.000084241896,0.00004954916,0.00006470658,0.00017975172,0.00001011624],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000545295,0.00017519694,0.0000036161389,0.09180676,0.0018731103,7.6653504e-7,0.00044389418,1.2594808e-8,0.000018840672,0.0015205867,0.0013865902,0.90276515],"study_design_scores_gemma":[0.00043287457,0.0005074821,0.000004953872,0.12639634,0.0029559624,1.0205998e-7,0.00005479533,0.0000013021934,0.0007019205,0.00076760526,0.86802423,0.00015245761],"about_ca_topic_score_codex":0.000008583438,"about_ca_topic_score_gemma":0.0000033627455,"teacher_disagreement_score":0.9026127,"about_ca_system_score_codex":0.00008375218,"about_ca_system_score_gemma":0.0001895313,"threshold_uncertainty_score":0.8369864},"labels":[],"label_agreement":null},{"id":"W4416013115","doi":"10.1001/jama.2025.20835","title":"Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria","year":2025,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Albuminuria; Diabetes mellitus; Empagliflozin; Cotransporter; Sodium; Glipizide","score_opus":0.007986921047928116,"score_gpt":0.2334006739523076,"score_spread":0.22541375290437948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416013115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944809,0.002737757,0.000012476669,0.00043049362,0.00012565155,0.0004114454,0.000027280608,0.000015353908,0.0017586104],"genre_scores_gemma":[0.99621475,0.00018867229,0.00015832589,0.00025898562,0.000019620386,0.000021272499,0.00004001251,0.000008344039,0.003090029],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993796,0.00001312455,0.00018624942,0.00013582282,0.000114458424,0.00017075708],"domain_scores_gemma":[0.9996317,0.00008696353,0.000058622336,0.00012766785,0.000040390874,0.000054682023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006116343,0.00010272658,0.00028364462,0.00009098353,0.00001156321,0.000005652743,0.000030289753,0.000054333865,0.00001553375],"category_scores_gemma":[0.0000290794,0.00008324058,0.000053091473,0.000108130764,0.00007322891,0.000048235222,0.000023934563,0.000045132983,0.0000017525539],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024726317,0.0010764898,0.50364035,0.0047201565,0.0010146017,0.00001348981,0.00048731512,1.4902295e-7,0.28274113,0.0006337433,0.053388916,0.15203637],"study_design_scores_gemma":[0.0042353403,0.00028334316,0.28461897,0.00034721996,0.00040609651,2.980656e-8,0.00003137254,0.0000062087447,0.70155764,0.000094804156,0.008365636,0.000053356325],"about_ca_topic_score_codex":0.00004691925,"about_ca_topic_score_gemma":0.0000048162715,"teacher_disagreement_score":0.41881648,"about_ca_system_score_codex":0.000018317238,"about_ca_system_score_gemma":0.00002072662,"threshold_uncertainty_score":0.33944523},"labels":[],"label_agreement":null},{"id":"W4416016235","doi":"10.1016/j.kint.2025.10.005","title":"REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide","year":2025,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institutes of Health; Bayer; Novo Nordisk; Juvenile Diabetes Research Foundation Canada; Doris Duke Charitable Foundation","keywords":"Semaglutide; Kidney disease; Kidney; Mechanism (biology); Clinical trial; Disease; Mechanism of action; Mineralocorticoid receptor","score_opus":0.09943601546654027,"score_gpt":0.3617783624340868,"score_spread":0.26234234696754655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416016235","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007725181,0.000053060714,0.95759445,0.020379798,0.0012340215,0.0033451293,0.0008882107,0.00004795391,0.008732162],"genre_scores_gemma":[0.96529484,0.00001852468,0.024405928,0.0019701417,0.00012857698,0.00018901005,0.0006085506,0.000017072509,0.007367359],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99874085,0.000052423988,0.00048888876,0.0002406191,0.00033598702,0.00014123898],"domain_scores_gemma":[0.9990124,0.0001423217,0.0002009652,0.00023062612,0.00022570012,0.0001879553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059215346,0.00013259418,0.0003455822,0.00023321918,0.000051200095,0.000019237554,0.00016988095,0.000040507988,0.00007844301],"category_scores_gemma":[0.0018605883,0.00009625038,0.00017557754,0.00012919903,0.00002668258,0.000040317682,0.00007290666,0.000049606737,0.0000021873843],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061577787,0.0023489867,0.00014774453,0.0016250133,0.004827579,0.0000036201666,0.0007163605,0.0008116308,0.17226239,0.6388782,0.15797357,0.014247098],"study_design_scores_gemma":[0.032621972,0.0011431463,0.0009115752,0.004161043,0.0072406204,0.0000050741382,0.0021080102,0.45166755,0.23670132,0.116545685,0.14625771,0.0006362639],"about_ca_topic_score_codex":0.000026735119,"about_ca_topic_score_gemma":0.0000017092336,"teacher_disagreement_score":0.95756966,"about_ca_system_score_codex":0.00016834505,"about_ca_system_score_gemma":0.00023157743,"threshold_uncertainty_score":0.39249763},"labels":[],"label_agreement":null},{"id":"W4416021080","doi":"10.1016/j.jchf.2025.102726","title":"Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes","year":2025,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Roche Diagnostics; Houston Methodist Research Institute; University of Minnesota","keywords":"Heart failure; Diabetes mellitus; Action (physics); MEDLINE; Risk assessment","score_opus":0.00573721649372189,"score_gpt":0.2491449362420849,"score_spread":0.243407719748363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416021080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339296,0.0024226082,0.0000071970617,0.061611388,0.0003030879,0.0008982102,0.0000128929705,0.000110109286,0.00070486066],"genre_scores_gemma":[0.99214315,0.000045234465,0.0021568758,0.0029356135,0.00009085023,0.00012526683,0.000091812144,0.000024835012,0.0023863346],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858236,0.00009775666,0.00032139325,0.00043267352,0.00016481282,0.000400998],"domain_scores_gemma":[0.999213,0.000110138746,0.000041757263,0.0003459366,0.0001617201,0.00012749126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003171063,0.00024184077,0.00055348594,0.00040479962,0.00007079195,0.0000669631,0.00006491615,0.000141756,0.000098844466],"category_scores_gemma":[0.00020631304,0.00021271304,0.00020099261,0.0004736095,0.00009478486,0.00015681708,0.00015409857,0.00019738762,0.00007610905],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030271436,0.00012041815,0.6824942,0.00024615743,0.0003486313,0.000007391394,0.000085799125,3.4412867e-7,0.0018026133,0.00027820258,0.31313384,0.0014521119],"study_design_scores_gemma":[0.00168317,0.00021657145,0.48903444,0.0007379199,0.00021831818,0.0000016832636,0.0011959155,0.00003214936,0.0025420508,0.00019464763,0.50397396,0.00016920129],"about_ca_topic_score_codex":0.000116725765,"about_ca_topic_score_gemma":0.00020680734,"teacher_disagreement_score":0.19345981,"about_ca_system_score_codex":0.000090296206,"about_ca_system_score_gemma":0.00004910439,"threshold_uncertainty_score":0.8674186},"labels":[],"label_agreement":null},{"id":"W4416026998","doi":"10.1007/s00125-025-06595-0","title":"Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Toronto General Hospital; University of Toronto; University Health Network; Ontario Brain Institute; University of Ottawa; Toronto Rehabilitation Institute; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canada First Research Excellence Fund; Fondation Brain Canada; Heart and Stroke Foundation of Canada","keywords":"Dementia; Diabetes mellitus; Cohort study; Cohort; Type 2 diabetes; Human physiology","score_opus":0.002573672277423065,"score_gpt":0.20740210275365084,"score_spread":0.20482843047622779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416026998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893758,0.006028074,0.000032873217,0.000027401871,0.0001529529,0.0037574947,0.000025913858,0.000059485843,0.00053996907],"genre_scores_gemma":[0.9991856,0.00017539477,0.0000847002,0.000040158335,0.000013407183,0.00036244097,0.000073655436,0.000024671968,0.000039952196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978793,0.00021091173,0.0004808568,0.00057090016,0.0004306777,0.0004273383],"domain_scores_gemma":[0.99880385,0.00019300761,0.0001697912,0.0005486375,0.00018265723,0.00010206986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058456056,0.00032414877,0.0012421773,0.00026175438,0.00006334721,0.00001315911,0.00009413049,0.00010755503,0.000012697864],"category_scores_gemma":[0.00007346035,0.0002425652,0.00017238762,0.0005227191,0.00020762142,0.00010684967,0.00016352885,0.00012593115,0.0000012034683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005246841,0.001665764,0.9727747,0.00133813,0.010528261,0.000009888326,0.00032014627,0.000013954899,0.00037456458,0.00002994066,0.00050824374,0.011911725],"study_design_scores_gemma":[0.010388865,0.0021519747,0.9562394,0.0012227492,0.0042011775,1.5610938e-7,0.0009045794,0.000014455654,0.024336917,0.0000083529885,0.0003374728,0.00019392623],"about_ca_topic_score_codex":0.00014959782,"about_ca_topic_score_gemma":0.000012165321,"teacher_disagreement_score":0.023962352,"about_ca_system_score_codex":0.000074299045,"about_ca_system_score_gemma":0.000046960122,"threshold_uncertainty_score":0.9891522},"labels":[],"label_agreement":null},{"id":"W4416027620","doi":"10.1016/j.puhe.2025.106039","title":"Cardiovascular impact of the national program of publicly-funded access to dapagliflozin in Brazil","year":2025,"lang":"en","type":"article","venue":"Public Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Dapagliflozin; Population; Public health; Population health; Adverse effect; Mortality rate","score_opus":0.06818559828720516,"score_gpt":0.4196033325725218,"score_spread":0.35141773428531664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416027620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8942217,0.0007131405,0.00013442205,0.06375032,0.00017942023,0.003803868,0.000026986532,0.00006522562,0.037104875],"genre_scores_gemma":[0.9969148,0.000031174168,0.00027469778,0.0021444948,0.00002373617,0.00017863043,0.000025454157,0.000007663528,0.00039934507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850106,0.0001067991,0.00036402204,0.00020196803,0.00049779436,0.0003283834],"domain_scores_gemma":[0.99913394,0.000039835122,0.00009010423,0.00036322724,0.0002286605,0.00014423364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013336658,0.00010041077,0.00040403515,0.00046745656,0.000031995536,0.00004001056,0.0002546992,0.000036857036,0.00003712912],"category_scores_gemma":[0.00038356747,0.0000656509,0.0002885637,0.0016608799,0.000039216706,0.00015482419,0.00017915727,0.00008597232,0.0000020344899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031601026,0.0016908416,0.64523476,0.00054309476,0.0013146487,7.008796e-7,0.00021622203,0.00009070832,0.00000893836,0.005445178,0.026146777,0.3192765],"study_design_scores_gemma":[0.0014044207,0.00027360301,0.9342113,0.00010654645,0.00003176692,3.970018e-7,0.000031708772,0.00011258229,0.000056347177,0.00019611533,0.06353056,0.000044633674],"about_ca_topic_score_codex":0.001890093,"about_ca_topic_score_gemma":0.0003197421,"teacher_disagreement_score":0.3192319,"about_ca_system_score_codex":0.0005373541,"about_ca_system_score_gemma":0.0012678934,"threshold_uncertainty_score":0.2857268},"labels":[],"label_agreement":null},{"id":"W4416056440","doi":"10.1002/ejhf.70093","title":"Sodium–Glucose co-Transporter 2 Inhibitors in Severe Estimated Glomerular Filtration Rate Deterioration Across Cardiovascular-Kidney-Metabolic Conditions: A Pooled Analysis of Randomized Trials","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Janssen Research and Development; Canadian Institutes of Health Research; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Fundação para a Ciência e a Tecnologia; McGill University; Yale University; Eli Lilly and Company","keywords":"Pooled analysis; Renal function; Randomized controlled trial; Heart failure; Meta-analysis","score_opus":0.017992718916347357,"score_gpt":0.30386357078155557,"score_spread":0.2858708518652082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416056440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900762,0.00371327,0.0020341836,0.0025143984,0.00020427517,0.0011635404,0.000069697395,0.000025793568,0.00019868354],"genre_scores_gemma":[0.99676985,0.00036374776,0.0018803368,0.00042387156,0.000081531005,0.000014832953,0.00032910524,0.000020591984,0.00011613147],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947787,0.0024669406,0.0019304029,0.00021864353,0.00038143134,0.00022389328],"domain_scores_gemma":[0.998333,0.0002183907,0.00067090447,0.00030807205,0.00033819376,0.00013144987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008784374,0.00022893808,0.0026860004,0.0009924389,0.00006668126,0.00006847093,0.000093093935,0.000052276013,0.00011595437],"category_scores_gemma":[0.0010014973,0.00017358112,0.0019162393,0.0011777781,0.000099362514,0.00027588083,0.00001622165,0.00019677254,0.000010698864],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11338507,0.0038643726,0.13077272,0.001867612,0.3006682,0.0030099605,0.007030312,0.022311373,0.3064161,0.00037859293,0.06887875,0.041416943],"study_design_scores_gemma":[0.44900623,0.00078923197,0.32193834,0.0031236801,0.11573766,0.000059158854,0.0010988805,0.0015357467,0.055132974,0.00010482153,0.05082952,0.00064375455],"about_ca_topic_score_codex":0.000013225365,"about_ca_topic_score_gemma":0.000010718845,"teacher_disagreement_score":0.33562118,"about_ca_system_score_codex":0.000052533756,"about_ca_system_score_gemma":0.00013041926,"threshold_uncertainty_score":0.7078433},"labels":[],"label_agreement":null},{"id":"W4416093687","doi":"10.1111/dom.70289","title":"Effects of <scp>SGLT2</scp> inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Janssen Research and Development; Canadian Institutes of Health Research; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Fundação para a Ciência e a Tecnologia; Boehringer Ingelheim; McGill University; Yale University; Eli Lilly and Company","keywords":"Albuminuria; Pooled analysis; Meta-analysis; Kidney disease; Kidney; Clinical trial","score_opus":0.006465847211660236,"score_gpt":0.2536120545076286,"score_spread":0.24714620729596834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416093687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94794106,0.04917761,0.000024829724,0.00012351415,0.00025744003,0.0020571207,0.00011590851,0.000018436303,0.00028407533],"genre_scores_gemma":[0.99680585,0.0022966804,0.000061671664,0.00020178668,0.00005263124,0.00019506634,0.00008460308,0.000012976542,0.00028871902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971975,0.0006474541,0.001026579,0.00035636115,0.00038312344,0.00038899796],"domain_scores_gemma":[0.9972568,0.0014879208,0.00044984632,0.00056904537,0.00012100044,0.00011535192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028635513,0.00028533852,0.0034706295,0.000845281,0.00006774224,0.000019420037,0.00016886793,0.00013733188,0.000009559859],"category_scores_gemma":[0.0025744138,0.00019692768,0.0015366556,0.0020657065,0.00025109155,0.00009726528,0.00012442251,0.00013760394,0.0000010391739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087408454,0.0055333953,0.6042752,0.0066890945,0.25081468,0.00002741703,0.007060114,0.00029376167,0.09104056,0.0105864415,0.0021146026,0.02069064],"study_design_scores_gemma":[0.022847379,0.00004632587,0.63207,0.00026932306,0.049640182,7.7045975e-8,0.00028630064,0.00006908078,0.29224044,0.0004887728,0.0019785692,0.00006353453],"about_ca_topic_score_codex":0.00017607817,"about_ca_topic_score_gemma":0.000024586423,"teacher_disagreement_score":0.2011999,"about_ca_system_score_codex":0.000016679543,"about_ca_system_score_gemma":0.00007890327,"threshold_uncertainty_score":0.8030478},"labels":[],"label_agreement":null},{"id":"W4416093819","doi":"10.1111/dom.70264","title":"Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Deutsche Forschungsgemeinschaft; McGill University","keywords":"Cohort study; Type 2 diabetes; Cohort; Type 2 Diabetes Mellitus; Sodium; Dipeptidyl peptidase-4","score_opus":0.0034519751134909848,"score_gpt":0.2028476780419693,"score_spread":0.1993957029284783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416093819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468136,0.0016586914,0.0000043528216,0.00007163027,0.0003626493,0.0029113784,0.00004360674,0.0000559834,0.00021037206],"genre_scores_gemma":[0.9990717,0.00010112152,0.000071397575,0.00012371143,0.000095397576,0.000144424,0.00026661146,0.000025424213,0.000100178055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980025,0.00019040266,0.0004496885,0.00048698383,0.00047756158,0.00039286184],"domain_scores_gemma":[0.9987405,0.00020149237,0.0002610463,0.00045971407,0.0001875276,0.00014970922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005802962,0.0003688897,0.0008729228,0.0003020416,0.00023854186,0.000054832875,0.00009232455,0.0001048945,0.000018332334],"category_scores_gemma":[0.00010773312,0.00023409144,0.00015001695,0.0005348879,0.00031388426,0.00017767004,0.00006708235,0.00021468743,0.0000025866582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005218499,0.00081073114,0.99468136,0.00017759026,0.0015953082,0.000006086304,0.00019346598,0.0000122868405,0.000008286425,0.000062770836,0.00009930674,0.0018309355],"study_design_scores_gemma":[0.01909944,0.00041788362,0.97281086,0.00019962441,0.0053002257,2.6885626e-8,0.0001166209,0.00011041325,0.0011123428,0.000042384552,0.0005711471,0.00021899705],"about_ca_topic_score_codex":0.00017310595,"about_ca_topic_score_gemma":0.000043536085,"teacher_disagreement_score":0.021870488,"about_ca_system_score_codex":0.000039023183,"about_ca_system_score_gemma":0.00003717309,"threshold_uncertainty_score":0.9545972},"labels":[],"label_agreement":null},{"id":"W4416099077","doi":"10.1210/jendso/bvaf150","title":"GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of the Endocrine Society","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Weight loss; Obesity; Semaglutide; Body weight; Weight gain","score_opus":0.029825177803925428,"score_gpt":0.3531802653540526,"score_spread":0.3233550875501272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416099077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.0267028e-7,0.98973376,0.00005389237,0.005653713,0.0001432537,0.004226876,0.000034724577,0.0000064733536,0.0001468957],"genre_scores_gemma":[0.000004375509,0.98991895,0.0009938945,0.0009802171,0.00006875587,0.0003777374,0.000015991982,0.000023615245,0.0076164855],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972872,0.00023989627,0.0016051689,0.00025083852,0.00035467942,0.0002621745],"domain_scores_gemma":[0.997221,0.00037536508,0.0016388028,0.00056517357,0.0001207905,0.000078870034],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00088910357,0.00042797552,0.008220561,0.0002508632,0.00006769636,0.00003186651,0.00036300215,0.00006878342,0.000038433638],"category_scores_gemma":[0.00021503224,0.00019421113,0.013678513,0.001376219,0.000039680854,0.00005997064,0.00014193673,0.0003700843,0.0000013857622],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023989703,0.00015475703,0.000016342447,0.763827,0.22524732,0.000005058584,0.000014598549,3.1217365e-7,1.7166777e-9,0.00008056406,0.008755091,0.0018965392],"study_design_scores_gemma":[0.00051113334,0.00006150024,0.000003352368,0.03739007,0.73357075,0.000030895495,0.000010281863,0.0000017831626,2.913682e-8,0.00009615564,0.22821842,0.000105626874],"about_ca_topic_score_codex":0.00000396968,"about_ca_topic_score_gemma":0.000009446954,"teacher_disagreement_score":0.726437,"about_ca_system_score_codex":0.00021145816,"about_ca_system_score_gemma":0.00020892934,"threshold_uncertainty_score":0.99619925},"labels":[],"label_agreement":null},{"id":"W4416101811","doi":"10.1136/thorax-2025-btsabstracts.108","title":"S102 The potential effect of glucagon-like peptide 1 receptor agonists (GLP1s) on chronic obstructive pulmonary disease (COPD) exacerbations, a case control analyses","year":2025,"lang":"","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TD Bank Group","funders":"","keywords":"COPD; Exacerbation; Cohort; Case-control study; Population; Medical prescription; Cohort study; Body mass index; Type 2 diabetes","score_opus":0.010298003253285741,"score_gpt":0.2888725708405199,"score_spread":0.2785745675872342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416101811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8919646,0.046235293,0.0016572081,0.006718755,0.0049046706,0.013229486,0.00074070494,0.00025324672,0.034296025],"genre_scores_gemma":[0.9618736,0.0011187497,0.000052137122,0.0005584377,0.00042132178,0.0006425048,0.00018502613,0.000053932858,0.035094317],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995469,0.0008944246,0.0010091243,0.0010531308,0.0007152202,0.00085911294],"domain_scores_gemma":[0.9961797,0.0012263535,0.00043747915,0.001501134,0.00024409925,0.00041121387],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059531385,0.0008762983,0.0012558345,0.00052492804,0.0006165654,0.0001310814,0.00038213082,0.00017277859,0.0022846172],"category_scores_gemma":[0.00034655302,0.00055956293,0.00095932133,0.000965972,0.00059270434,0.00021970495,0.0002469808,0.00038137837,0.0002361313],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07153672,0.01235596,0.0404695,0.015114849,0.06465642,0.01840031,0.0007761241,0.011814397,0.01585422,0.01345869,0.06458227,0.6709805],"study_design_scores_gemma":[0.118464544,0.0520291,0.28333464,0.013412167,0.25079694,0.00023260244,0.008628415,0.14743751,0.04761947,0.0014560535,0.07111561,0.0054729525],"about_ca_topic_score_codex":0.0003855333,"about_ca_topic_score_gemma":0.000062878775,"teacher_disagreement_score":0.66550756,"about_ca_system_score_codex":0.000963056,"about_ca_system_score_gemma":0.0005534723,"threshold_uncertainty_score":0.9996856},"labels":[],"label_agreement":null},{"id":"W4416125154","doi":"10.2139/ssrn.5164525","title":"Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Clinical Trial","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Semaglutide; Placebo; Randomized controlled trial; Clinical endpoint; Clinical trial; Cognition; Digit symbol substitution test; Intention-to-treat analysis","score_opus":0.03483061274596903,"score_gpt":0.3663909477137305,"score_spread":0.33156033496776144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416125154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.892812,0.038164154,0.017210172,0.0022250463,0.0024564588,0.04587352,0.00010457506,0.00005057771,0.0011035032],"genre_scores_gemma":[0.91578543,0.058438364,0.00008512404,0.00011449823,0.0016678346,0.010935307,0.00035954802,0.000062850355,0.012551036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99531615,0.00036608905,0.0017176856,0.00062353065,0.00039988518,0.0015766515],"domain_scores_gemma":[0.99468356,0.0032877738,0.0011947878,0.00043030898,0.00028459769,0.00011895155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031887405,0.0005690516,0.0020858604,0.00046697434,0.00019218626,0.000060375005,0.00024551494,0.0003637893,0.00003541508],"category_scores_gemma":[0.00059266854,0.00034420643,0.0019196547,0.00017810479,0.00012363032,0.000050779912,0.000095195006,0.0017135377,0.000003942748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81659204,0.007059277,0.00054044515,0.00008200935,0.013995858,0.000012669108,0.00017895909,0.000115785435,0.0000014955604,0.0008071461,0.00007305411,0.16054125],"study_design_scores_gemma":[0.9584189,0.015213245,0.000032728447,0.00052906113,0.016498728,0.000013547132,0.0010707946,0.0009826071,0.00005401794,0.005803737,0.0011452606,0.00023739395],"about_ca_topic_score_codex":0.00018041192,"about_ca_topic_score_gemma":0.0017642124,"teacher_disagreement_score":0.16030386,"about_ca_system_score_codex":0.0014570777,"about_ca_system_score_gemma":0.004212143,"threshold_uncertainty_score":0.999901},"labels":[],"label_agreement":null},{"id":"W4416133916","doi":"10.1111/dom.70263","title":"Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Tolerability; Type 2 diabetes; Baseline (sea); Obesity; Glucagon-like peptide 1 receptor; Diabetes mellitus; Glucagon-like peptide-1; Randomized controlled trial","score_opus":0.009285637839900903,"score_gpt":0.2505621433897121,"score_spread":0.2412765055498112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416133916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815066,0.0043058833,0.00008303239,0.0003142116,0.000870568,0.005367709,0.00026044715,0.00006415911,0.0005833052],"genre_scores_gemma":[0.99121594,0.0025120478,0.0011532987,0.00075165834,0.0003951596,0.0008567192,0.0012784613,0.000051529812,0.001785208],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961427,0.0007732185,0.0010443782,0.0006944994,0.00046308312,0.00088211347],"domain_scores_gemma":[0.9945149,0.0039384533,0.00044304907,0.00060784776,0.00032303092,0.00017271575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00425299,0.0005697936,0.0024973033,0.000540087,0.00017252742,0.00011263394,0.00027102517,0.00025149723,0.000021009484],"category_scores_gemma":[0.004536756,0.00040309498,0.00032040005,0.0011315942,0.00032569582,0.00023411025,0.00013697319,0.00037960344,0.000009224303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06931151,0.03525307,0.78266853,0.0069123385,0.0059249657,0.00003988588,0.009348762,0.000014894222,0.013816508,0.008938543,0.026865855,0.040905148],"study_design_scores_gemma":[0.7285479,0.0017268185,0.16689216,0.0007775617,0.0036177551,5.4254565e-7,0.00081126916,0.001071415,0.016935151,0.0005190373,0.07887383,0.00022656334],"about_ca_topic_score_codex":0.00009156579,"about_ca_topic_score_gemma":0.00012116325,"teacher_disagreement_score":0.6592364,"about_ca_system_score_codex":0.00008530824,"about_ca_system_score_gemma":0.00026011642,"threshold_uncertainty_score":0.9998421},"labels":[],"label_agreement":null},{"id":"W4416229984","doi":"10.1053/j.ajkd.2025.09.010","title":"Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD","year":2025,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Women's College Hospital; London Health Sciences Centre; St. Michael's Hospital; Western University; Institute for Clinical Evaluative Sciences; Lawson Health Research Institute; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Kidney Foundation of Canada; Diabetes Canada; Canadian Society of Nephrology; Department of Medicine, University of Toronto; Novo Nordisk; Sanofi; Fresenius Medical Care North America; AstraZeneca; Eli Lilly and Company","keywords":"Kidney disease; Adverse effect; Diabetes mellitus; Disease; Kidney; Heart disease; Agonist","score_opus":0.002242912045644649,"score_gpt":0.20383597940485637,"score_spread":0.20159306735921173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416229984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981251,0.00091269583,0.000037365993,0.00022547513,0.00011035727,0.00030253982,0.000059392813,0.000006658087,0.00022045808],"genre_scores_gemma":[0.9979866,0.0006875531,0.0006629626,0.00037805105,0.0000245424,0.000008171164,0.000027502321,0.00001370425,0.00021089744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988687,0.00009277965,0.00033710172,0.00016115712,0.0003645376,0.00017570428],"domain_scores_gemma":[0.9988065,0.000041337193,0.00034142967,0.00023240736,0.00015286266,0.00042549655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000124454,0.00015337464,0.0006206637,0.0002835708,0.000029476823,0.0000045493293,0.00008327858,0.000014867201,0.000022264985],"category_scores_gemma":[0.0002840215,0.00010971878,0.00025084065,0.00033668365,0.00017020818,0.00010591943,0.000044226228,0.00008728883,0.0000019795611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012079059,0.0007901476,0.9623543,0.000111779074,0.0034176088,0.00002008992,0.00006248816,0.000014961302,0.0000044300546,0.00000524693,0.0021805943,0.029830422],"study_design_scores_gemma":[0.0072402973,0.0015077429,0.9805855,0.0007080723,0.0034591109,9.830288e-7,0.00035445485,0.0000029172786,0.000040337512,0.00001784362,0.0059858058,0.000096897405],"about_ca_topic_score_codex":0.000108328226,"about_ca_topic_score_gemma":0.0000020266584,"teacher_disagreement_score":0.029733526,"about_ca_system_score_codex":0.000085933905,"about_ca_system_score_gemma":0.00024361958,"threshold_uncertainty_score":0.44742018},"labels":[],"label_agreement":null},{"id":"W4416276341","doi":"10.1007/s40256-025-00777-2","title":"Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly","year":2025,"lang":"en","type":"article","venue":"American Journal of Cardiovascular Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Insulin resistance; Pharmacotherapy; Type 2 Diabetes Mellitus; Diabetes mellitus; Disease; Narrative review; Type 2 diabetes; Adverse effect; Thiazide","score_opus":0.0038628162712345195,"score_gpt":0.22686060347112072,"score_spread":0.2229977871998862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416276341","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32872462,0.6453191,0.0017178123,0.016600024,0.00048272606,0.0011374031,0.0000024511257,0.000023186256,0.005992647],"genre_scores_gemma":[0.9176066,0.077868745,0.0002171687,0.0034970045,0.00036742393,0.000039481376,8.48567e-7,0.00002605721,0.00037666946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764574,0.0007163725,0.00036956335,0.0002273391,0.0007731123,0.0002679003],"domain_scores_gemma":[0.9984164,0.0003143174,0.00017856163,0.0008142501,0.00017536517,0.000101089165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00314096,0.00024943755,0.0011364288,0.00012430719,0.00028143282,0.00010761398,0.00029181648,0.000025647885,0.0000069480857],"category_scores_gemma":[0.000049689857,0.00010027953,0.0019773843,0.00050802284,0.0012286607,0.000101639656,0.00011140598,0.00033738514,0.0000021918954],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004276676,0.000050805967,0.00033017722,0.000029801504,0.074328125,0.000059206446,0.0015881902,0.00021750714,0.000042588465,0.0024754705,0.0012702991,0.91918015],"study_design_scores_gemma":[0.009395143,0.00014151561,0.00553571,0.000078039724,0.02334821,0.00019961635,0.003070199,0.00008641772,0.00070905226,0.0003432331,0.95695716,0.00013570346],"about_ca_topic_score_codex":0.00014346196,"about_ca_topic_score_gemma":8.505267e-7,"teacher_disagreement_score":0.95568687,"about_ca_system_score_codex":0.000036732567,"about_ca_system_score_gemma":0.000085110456,"threshold_uncertainty_score":0.45270517},"labels":[],"label_agreement":null},{"id":"W4416284382","doi":"10.3389/fpsyt.2025.1721565","title":"Editorial: Case reports in psychopharmacology, volume III","year":2025,"lang":"en","type":"editorial","venue":"Frontiers in Psychiatry","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada; Public Health Ontario; University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Mental illness; Pandemic; Mental health; Alcohol use disorder; Theme (computing); MEDLINE","score_opus":0.003263763307323223,"score_gpt":0.2754300951413595,"score_spread":0.2721663318340363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416284382","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004826732,0.005691246,0.000050907256,0.0009346444,0.98040724,0.0016246666,0.00005496982,0.00012968338,0.010623956],"genre_scores_gemma":[0.00009364649,0.0009543571,0.0045853667,0.0002903051,0.9659567,0.00042852326,0.0007158478,0.00008028209,0.026895003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961819,0.00010438384,0.0011600388,0.0011427408,0.00069373054,0.0007171959],"domain_scores_gemma":[0.9983086,0.00007017041,0.0003958311,0.0009177146,0.00012549615,0.00018220459],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007269164,0.00061084086,0.001360012,0.0014481372,0.00006270246,0.000043337255,0.00018548348,0.0016186915,0.000103652426],"category_scores_gemma":[0.00019923998,0.0006317287,0.00030189878,0.00077430415,0.0001009327,0.00010950067,0.00013908802,0.0017404488,0.000016387557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071678153,0.00093652226,0.029470362,0.00067885645,0.0005380182,0.010505241,0.000060727423,0.000004312704,2.440856e-7,0.0000066419384,0.9550446,0.0020376495],"study_design_scores_gemma":[0.008533545,0.00025414673,0.00025525715,0.0008316793,0.00083362474,0.00005637851,0.00019616715,0.000021124388,3.1361824e-7,0.0008317387,0.98775387,0.00043217227],"about_ca_topic_score_codex":0.00040278726,"about_ca_topic_score_gemma":0.00037866674,"teacher_disagreement_score":0.03270921,"about_ca_system_score_codex":0.00079789956,"about_ca_system_score_gemma":0.001160925,"threshold_uncertainty_score":0.9996774},"labels":[],"label_agreement":null},{"id":"W4416294258","doi":"10.26685/urncst.945","title":"A Review of Metabolic Health Outcomes of Tirzepatide vs Semaglutide in Obesity and Type 2 Diabetes","year":2025,"lang":"","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Semaglutide; Glycemic; Type 2 diabetes; Weight loss; Obesity; Glucagon-like peptide 1 receptor; Diabetes mellitus; Waist","score_opus":0.049480100533283215,"score_gpt":0.44479674326962476,"score_spread":0.39531664273634154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416294258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58534765,0.31077996,6.370406e-7,0.10293938,0.00017647955,0.0005628772,0.0000021228936,0.0000056812423,0.00018523843],"genre_scores_gemma":[0.5514196,0.44767445,0.00017587769,0.0005339914,0.000011039354,0.0000046511445,6.2447884e-7,0.0000032831397,0.00017649235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951131,0.00058880955,0.0017005401,0.00064636854,0.00088366104,0.0010675422],"domain_scores_gemma":[0.9968122,0.0012113745,0.0004564502,0.00034218465,0.000834817,0.00034296187],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.01681728,0.00025653804,0.0016970919,0.0024555125,0.00033745845,0.000055563916,0.00047553,0.00021672851,0.000010868313],"category_scores_gemma":[0.006230251,0.00017114187,0.000099627156,0.0061405837,0.005467101,0.00023436427,0.0009469559,0.002108037,0.0000020451628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006365236,0.0005430848,0.7641998,0.0024119043,0.00017309847,0.000022716513,0.00001507402,6.552026e-8,0.000059532693,0.009765708,0.000427731,0.22231764],"study_design_scores_gemma":[0.0039968244,0.0027838438,0.8879161,0.024999077,0.00022159351,0.000018543988,0.00037811426,0.0005522029,0.0002582182,0.07577251,0.0028945273,0.00020843068],"about_ca_topic_score_codex":0.00017313259,"about_ca_topic_score_gemma":0.00023689172,"teacher_disagreement_score":0.22210921,"about_ca_system_score_codex":0.00015464856,"about_ca_system_score_gemma":0.001269738,"threshold_uncertainty_score":0.9972395},"labels":[],"label_agreement":null},{"id":"W4416432128","doi":"10.2337/dc25-1753","title":"Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Tandem Diabetes Care","keywords":"Type 2 diabetes; Glycemic; Agonist; Diabetes mellitus; Insulin; Receptor; Broad spectrum; Weight loss","score_opus":0.0058576227063343155,"score_gpt":0.21609268133197332,"score_spread":0.21023505862563902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416432128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927988,0.0014223271,0.0000011437176,0.00036124326,0.00021008345,0.0013004496,0.0004912878,0.00006607656,0.003348567],"genre_scores_gemma":[0.9961947,0.00006874478,0.00051543495,0.0014444161,0.000049162118,0.00024112812,0.0007207047,0.00003227325,0.000733387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855673,0.00003856255,0.00028692684,0.00041693158,0.0002338526,0.00046702233],"domain_scores_gemma":[0.998832,0.00017693412,0.00008188929,0.00040423684,0.0003728269,0.00013213485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006798088,0.00027153306,0.0006023792,0.00034225962,0.00004217584,0.000031546013,0.00012600653,0.00008808806,0.00008991989],"category_scores_gemma":[0.00016664554,0.00022172593,0.00008809012,0.00069787784,0.0000736311,0.00012653174,0.00007528789,0.000113480215,0.00008682857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004557272,0.00021708905,0.9642145,0.00051645003,0.00040479275,0.0000043547784,0.00059166265,0.000046188867,0.00037372168,0.00025747868,0.0058016432,0.027116412],"study_design_scores_gemma":[0.009005441,0.0028205125,0.92914474,0.0047789724,0.0005491505,3.909278e-8,0.0016408733,0.00004023377,0.024343446,0.000013968859,0.02729146,0.0003711756],"about_ca_topic_score_codex":0.000031126587,"about_ca_topic_score_gemma":0.00019996574,"teacher_disagreement_score":0.035069752,"about_ca_system_score_codex":0.00015945276,"about_ca_system_score_gemma":0.00007277918,"threshold_uncertainty_score":0.90417206},"labels":[],"label_agreement":null},{"id":"W4416448626","doi":"10.1016/j.cardfail.2025.11.489","title":"Time-to-First Clinical Benefit of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure","year":2025,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Heart failure; Receptor; Agonist; B2 receptor","score_opus":0.009395386346963052,"score_gpt":0.28142744957780075,"score_spread":0.2720320632308377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94175524,0.0015233485,0.00001708891,0.047791664,0.0014092656,0.00087552686,0.000024273366,0.000028760433,0.006574851],"genre_scores_gemma":[0.94714046,0.00058079034,0.020025691,0.0026335116,0.0011568578,0.000035120065,0.00004267975,0.00007593383,0.028308963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776196,0.000086456756,0.0011095848,0.00024600388,0.0004750245,0.0003209835],"domain_scores_gemma":[0.9985078,0.00019934887,0.00031684336,0.00039316644,0.00033786087,0.00024500754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010015119,0.00023173937,0.0012756037,0.0005163125,0.000039773462,0.000029613007,0.00018891557,0.00018088573,0.0002641226],"category_scores_gemma":[0.0002105062,0.0001888211,0.00084153726,0.00055386906,0.000081461076,0.00013548715,0.00011648228,0.00040719638,0.00020271899],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052946556,0.0005855636,0.12800077,0.00023781515,0.0014204636,0.000031922693,0.00014832501,0.000097213306,0.0015276452,0.0001519421,0.85875946,0.008509438],"study_design_scores_gemma":[0.0022610053,0.0008866451,0.07559054,0.0011359522,0.000569707,0.000005924381,0.00024324612,0.000007352259,0.001005354,0.000046860623,0.91810995,0.00013745777],"about_ca_topic_score_codex":0.0000096171,"about_ca_topic_score_gemma":0.000024929474,"teacher_disagreement_score":0.059350513,"about_ca_system_score_codex":0.00017921758,"about_ca_system_score_gemma":0.00019998886,"threshold_uncertainty_score":0.7699901},"labels":[],"label_agreement":null},{"id":"W4416519849","doi":"10.1016/j.cjco.2025.11.015","title":"Practice Variation in Prescribing SGLT2-Inhibitors: A Population-Based Analysis from Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"CJC Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; Libin Cardiovascular Institute of Alberta; University of Alberta; University of Calgary","funders":"Government of Alberta; University of Calgary","keywords":"Medical prescription; Logistic regression; Guideline; Cohort; Odds ratio; Odds; Cohort study; Medication adherence; Variation (astronomy)","score_opus":0.010492970380015003,"score_gpt":0.2763845886329301,"score_spread":0.2658916182529151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416519849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8533688,0.00019402015,0.00090042135,0.0220869,0.0004916709,0.0026635486,0.000026672848,0.000036803674,0.12023113],"genre_scores_gemma":[0.98999035,0.0000019181496,0.0016859455,0.0023694476,0.00003075832,0.000082533355,0.0005317396,0.0000065884424,0.005300741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915826,0.00006161278,0.00022880782,0.00025392568,0.00016381299,0.00013355428],"domain_scores_gemma":[0.9992031,0.00032048495,0.00008532986,0.0002990203,0.00004809423,0.00004400474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016157531,0.00009357499,0.00028680725,0.00018843051,0.000044998294,0.00008716599,0.00011641065,0.000033420903,0.00020127394],"category_scores_gemma":[0.00034615904,0.00008796792,0.00004255174,0.0007148718,0.0000033649385,0.00021458256,0.00007627542,0.000056848286,0.000006821346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025964022,0.0004301371,0.9754285,0.000038234088,0.0025279648,0.000052738294,0.00024113352,0.0024518329,0.00006709822,0.0011002704,0.011708322,0.0056941253],"study_design_scores_gemma":[0.0024261265,0.000030988525,0.9552766,0.00015277762,0.0030243413,4.8125443e-8,0.00014674386,0.011179039,0.00016192683,0.000116987,0.027369121,0.00011527232],"about_ca_topic_score_codex":0.98247445,"about_ca_topic_score_gemma":0.9402384,"teacher_disagreement_score":0.13662149,"about_ca_system_score_codex":0.00046404314,"about_ca_system_score_gemma":0.00034215354,"threshold_uncertainty_score":0.35872278},"labels":[],"label_agreement":null},{"id":"W4416527063","doi":"10.1146/annurev-med-043024-013325","title":"Therapeutic Considerations in Preventing Chronic Kidney Disease","year":2025,"lang":"en","type":"article","venue":"Annual Review of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care","funders":"","keywords":"Kidney disease; Mineralocorticoid receptor; Renal function; Diabetes mellitus; Kidney; Disease; Acute kidney injury","score_opus":0.01718031061712711,"score_gpt":0.34060031197376905,"score_spread":0.32342000135664195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416527063","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021266527,0.7982101,0.000078200355,0.15844391,0.0002533655,0.0020849514,0.000010808186,0.00004118742,0.038750857],"genre_scores_gemma":[0.7615111,0.16514765,0.00016180026,0.06267463,0.00016445598,0.00015116543,0.00015458814,0.000015435018,0.010019214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990437,0.000054269552,0.00042124142,0.00015788554,0.0001772902,0.0001456364],"domain_scores_gemma":[0.9993613,0.000094917275,0.00008185372,0.00026463266,0.000087701,0.00010964232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004166909,0.000107952634,0.00044912644,0.00013871059,0.000021219757,0.000001580718,0.000044924513,0.000017545606,0.00061712926],"category_scores_gemma":[0.00088503625,0.00007429983,0.0000703932,0.00028789442,0.00009601904,0.00004718392,0.000032377422,0.00007336742,0.000011359356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008032567,0.0011581596,0.05846337,0.11708065,0.00092948606,0.00018030244,0.00044600398,0.00000191433,0.00033326977,0.09035411,0.37159583,0.35937658],"study_design_scores_gemma":[0.0074218735,0.0007146037,0.11163884,0.24434774,0.0030623272,0.0000033019417,0.00018087374,0.00005777814,0.00013274045,0.0047218585,0.62753993,0.00017814028],"about_ca_topic_score_codex":0.000021657042,"about_ca_topic_score_gemma":0.0000068712143,"teacher_disagreement_score":0.7593844,"about_ca_system_score_codex":0.00006654181,"about_ca_system_score_gemma":0.0003427135,"threshold_uncertainty_score":0.6757133},"labels":[],"label_agreement":null},{"id":"W4416580466","doi":"10.1001/jama.2025.19841","title":"Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use","year":2025,"lang":"en","type":"article","venue":"JAMA","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Agonist; MEDLINE; Pregnancy; Patient care","score_opus":0.030613135241953447,"score_gpt":0.27724790556195866,"score_spread":0.24663477032000522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416580466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98841107,0.0013009278,0.00011471123,0.0011170334,0.00015277878,0.0014714402,0.000036320158,0.000067707195,0.0073280353],"genre_scores_gemma":[0.93946433,0.0006551437,0.011574038,0.00047275473,0.00007906549,0.00075427047,0.00009890241,0.000024515015,0.046876963],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926,0.000009523986,0.00013173459,0.0002563789,0.000101173726,0.00024115728],"domain_scores_gemma":[0.9992307,0.00028973207,0.000035368903,0.0002476323,0.000092751805,0.000103829996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041389885,0.00014658307,0.0002404886,0.0001745622,0.00013971563,0.00010410597,0.000038963895,0.00004572009,0.00002366748],"category_scores_gemma":[0.0001874813,0.00009702697,0.00004280099,0.00023351957,0.000027183374,0.00008731505,0.00003817353,0.00002219111,0.000008381621],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006648182,0.00023521348,0.023260443,0.00010965747,0.0005212116,0.000017804696,0.00123853,0.000001272239,0.0002028183,0.0006181316,0.008212223,0.9649179],"study_design_scores_gemma":[0.01287986,0.0031725762,0.051412966,0.00035578804,0.0005115288,0.0000012933207,0.003149853,0.00002907729,0.001522923,0.000049162114,0.9267628,0.00015214921],"about_ca_topic_score_codex":0.000021896882,"about_ca_topic_score_gemma":0.000022454544,"teacher_disagreement_score":0.9647657,"about_ca_system_score_codex":0.00053023815,"about_ca_system_score_gemma":0.00006912211,"threshold_uncertainty_score":0.39566448},"labels":[],"label_agreement":null},{"id":"W4416667894","doi":"10.1002/ejhf.70049","title":"Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Institute on Minority Health and Health Disparities; National Institute on Aging; European Society of Cardiology; Horizon Therapeutics; Moderna; Cytokinetics; Esperion Therapeutics; Arrowhead Pharmaceuticals; Novo Nordisk; Dexcom; Alnylam Pharmaceuticals; Gilead Sciences; Amgen; National Heart, Lung, and Blood Institute; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Semaglutide; Heart failure; Heart failure with preserved ejection fraction; Ejection fraction; Body weight; Ventricular function; Cardiac function curve","score_opus":0.006842688268609667,"score_gpt":0.23228290491492476,"score_spread":0.22544021664631508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416667894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96838707,0.0004890172,0.0001316892,0.029569175,0.00016892303,0.0009626894,0.0000024092594,0.000030607454,0.00025842933],"genre_scores_gemma":[0.9964887,0.00002232995,0.0020735336,0.0004830209,0.00011765835,0.000007232423,0.000009278874,0.000030094683,0.0007681542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794555,0.00061273185,0.0005084906,0.00021117895,0.0003842853,0.00033774323],"domain_scores_gemma":[0.99894917,0.0003108281,0.00024380388,0.00032907198,0.00009839654,0.00006871284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011874359,0.00021302764,0.00043981787,0.00012889445,0.00016559957,0.000092875205,0.0002038228,0.0000476425,0.000032092237],"category_scores_gemma":[0.00014817435,0.0001127044,0.00019590057,0.00055967364,0.00011595223,0.00016411707,0.00009151084,0.00069823966,0.000025086507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001042258,0.0011405627,0.84237903,0.00034324583,0.0015022419,0.00071110117,0.001326649,0.00013292547,0.012181136,0.00008701379,0.13744363,0.0017101851],"study_design_scores_gemma":[0.00492594,0.0011594659,0.83227724,0.0016089262,0.0004505173,0.000034507953,0.0012525774,0.00003313361,0.0050866213,0.000056535217,0.15300666,0.00010787681],"about_ca_topic_score_codex":0.00010929091,"about_ca_topic_score_gemma":0.00031311053,"teacher_disagreement_score":0.029086154,"about_ca_system_score_codex":0.000110114976,"about_ca_system_score_gemma":0.000055135937,"threshold_uncertainty_score":0.45959523},"labels":[],"label_agreement":null},{"id":"W4416684565","doi":"10.1016/j.jcjd.2025.10.137","title":"Effect of Empagliflozin, Linagliptin, and Their Combination on CKD Progression in Type 2 Diabetes: A Comparative Cohort Study in 50 Patients","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cohort study; Cohort; Retrospective cohort study; Population based study","score_opus":0.009102300423369587,"score_gpt":0.2787420471005536,"score_spread":0.26963974667718404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416684565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650884,0.0009743137,1.0724985e-7,0.00011913999,0.00022077671,0.0014010848,0.000004534703,0.0000035827914,0.0007675971],"genre_scores_gemma":[0.99978226,0.00001064343,0.000011581336,0.000091192465,0.000012459925,0.000030195848,0.000014568987,0.000009040596,0.000038055103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987852,0.00020966357,0.00042995092,0.00015919695,0.0001527352,0.00026326417],"domain_scores_gemma":[0.9990945,0.00023189875,0.00019434614,0.00013406882,0.00017512137,0.00017008526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006950066,0.00017778594,0.00065943383,0.0010029508,0.000034410714,0.000020922325,0.00008872731,0.00005569221,0.000008953369],"category_scores_gemma":[0.00021154484,0.00012590767,0.000051946754,0.00046406395,0.00006832273,0.00009339434,0.000018767341,0.00018872759,0.000001290854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006500646,0.00057852693,0.9834301,0.00014664335,0.00023230072,0.0000059675262,0.0007424113,0.00000829444,0.000037085945,0.000017306871,0.00030323994,0.014433101],"study_design_scores_gemma":[0.0053280606,0.00933297,0.9813394,0.0015343359,0.00014879013,3.6127098e-8,0.0002842522,0.00012090874,0.0016594153,0.000045309804,0.00012520057,0.00008133409],"about_ca_topic_score_codex":0.000106073654,"about_ca_topic_score_gemma":0.0018825473,"teacher_disagreement_score":0.014351767,"about_ca_system_score_codex":0.00023853917,"about_ca_system_score_gemma":0.00016363512,"threshold_uncertainty_score":0.51343656},"labels":[],"label_agreement":null},{"id":"W4416684595","doi":"10.1016/j.jcjd.2025.10.085","title":"The Importance of SGLT2 Inhibitors for Reducing the Mortality Health Equity Gap Between Indigenous and Non-Indigenous People With Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Empagliflozin; Type 2 diabetes; Indigenous; Equity (law); Health equity; Diabetes mellitus","score_opus":0.020154030224254844,"score_gpt":0.28994534899177066,"score_spread":0.26979131876751583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416684595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865198,0.0097808875,0.0000079593665,0.0021123257,0.00025588574,0.0010021138,0.000042987063,0.0000057868765,0.0002722509],"genre_scores_gemma":[0.99889636,0.00013234925,0.00012984166,0.00049493037,0.0001506012,0.000021408923,0.000017416654,0.000019644742,0.00013745684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983715,0.00004924366,0.00054766185,0.00016847755,0.00021103049,0.0006521301],"domain_scores_gemma":[0.9982177,0.0003125372,0.0004958825,0.00032421123,0.00026988485,0.00037980013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001233999,0.00018467507,0.00056075474,0.00019393757,0.0005536204,0.000073539435,0.0002335706,0.00005386871,0.0000038587204],"category_scores_gemma":[0.00015823217,0.00010439603,0.00010886629,0.00038559103,0.0002141122,0.00008956742,0.0000361292,0.00019101567,3.2941787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007986959,0.000026408658,0.9691544,0.0003109853,0.00087158754,0.0000018879111,0.0018994977,0.0000064687088,0.000044102104,0.00004585376,0.0012791648,0.026351616],"study_design_scores_gemma":[0.0009526301,0.0016336542,0.9910997,0.00060399296,0.0006741317,6.177119e-7,0.0007710838,0.000012635721,0.0012706376,0.0006020836,0.0022603793,0.00011843813],"about_ca_topic_score_codex":0.0011716684,"about_ca_topic_score_gemma":0.01733329,"teacher_disagreement_score":0.026233178,"about_ca_system_score_codex":0.00027972696,"about_ca_system_score_gemma":0.002369987,"threshold_uncertainty_score":0.96723825},"labels":[],"label_agreement":null},{"id":"W4416684603","doi":"10.1016/j.jcjd.2025.10.130","title":"Semaglutide Withdrawal in Adults With Type 1 Diabetes on Pump Therapy: A Post-Hoc Analysis From a Double-Blinded Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Semaglutide; Randomized controlled trial; Type 1 diabetes; Diabetes mellitus; Type 2 diabetes","score_opus":0.008540256237695092,"score_gpt":0.23747357800096955,"score_spread":0.22893332176327447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416684603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881,0.0038527003,0.0000018061501,0.0021383718,0.00044376522,0.0033795077,0.000017297694,0.000016416094,0.002050144],"genre_scores_gemma":[0.9971073,0.00006729795,0.00013757963,0.001677884,0.00016785799,0.00018232988,0.000058759622,0.000028344595,0.00057259004],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974449,0.00026330937,0.0009744793,0.00032480163,0.00037666448,0.00061581313],"domain_scores_gemma":[0.9972534,0.0009022755,0.0004962969,0.00036246722,0.0004662375,0.0005193131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009537605,0.00038408246,0.0029246903,0.0025644011,0.00008427456,0.00011277591,0.00022932369,0.00013297591,0.0002549099],"category_scores_gemma":[0.0004179413,0.0002408015,0.00078363856,0.0014483136,0.00017226728,0.00011313573,0.000011997711,0.000328898,0.0000080175705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85971516,0.0003356423,0.11795574,0.000031067604,0.018168896,0.000077311306,0.00037250467,0.00009514031,0.00004092569,0.00013549575,0.00026446077,0.002807677],"study_design_scores_gemma":[0.96932906,0.00394466,0.018718384,0.0009030947,0.005669832,1.3199768e-7,0.00017873933,0.00028652235,0.00030281185,0.00014182611,0.00030475267,0.00022020224],"about_ca_topic_score_codex":0.0014671717,"about_ca_topic_score_gemma":0.020115305,"teacher_disagreement_score":0.109613895,"about_ca_system_score_codex":0.00029211934,"about_ca_system_score_gemma":0.0013965191,"threshold_uncertainty_score":0.99776506},"labels":[],"label_agreement":null},{"id":"W4416685541","doi":"10.1016/j.jcjd.2025.10.006","title":"Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Semaglutide; Steatohepatitis; Phase (matter); Steatosis; Metabolic disease","score_opus":0.011358031006058563,"score_gpt":0.2592693713810786,"score_spread":0.24791134037502002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416685541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932564,0.0032375332,0.000011672535,0.0017974186,0.0009019528,0.00041686307,0.000016576052,0.000012367434,0.00427998],"genre_scores_gemma":[0.99646693,0.00004416001,0.00008082549,0.0009323594,0.00008409172,0.000019102048,0.000015776817,0.0000145182175,0.0023422588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867827,0.00007355606,0.000508376,0.00014505461,0.00016825517,0.0004264669],"domain_scores_gemma":[0.9989466,0.00010506808,0.00019439253,0.00017398785,0.0001811941,0.0003987698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043525852,0.0001591358,0.00055283954,0.0010032692,0.0000799046,0.000047893413,0.00012702163,0.00007389027,0.00015694425],"category_scores_gemma":[0.0005562155,0.00014233972,0.00016418268,0.00069922506,0.00006368743,0.00012845582,0.000010509967,0.00019939945,0.000010780707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027608234,0.000920174,0.92632586,0.00009438214,0.0014291977,0.00023660183,0.0002214497,0.000024013261,0.0003872618,0.0021089425,0.020392913,0.04758315],"study_design_scores_gemma":[0.26564837,0.0046948274,0.58454454,0.0025853722,0.002883604,0.000003153843,0.00057853473,0.00043776463,0.0034372578,0.0028866923,0.13172849,0.000571412],"about_ca_topic_score_codex":0.0013344535,"about_ca_topic_score_gemma":0.019041384,"teacher_disagreement_score":0.34178132,"about_ca_system_score_codex":0.00033951862,"about_ca_system_score_gemma":0.0010897327,"threshold_uncertainty_score":0.9988586},"labels":[],"label_agreement":null},{"id":"W4416685695","doi":"10.1016/j.jcjd.2025.10.124","title":"Euglycemic DKA Management in the SGLT2i Era: Insights from a Tertiary Care Cohort","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tertiary care; Cohort; Cohort study; Retrospective cohort study","score_opus":0.004795429820325905,"score_gpt":0.21128626580845314,"score_spread":0.20649083598812723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416685695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628944,0.010479693,0.0000036860981,0.0021929755,0.0004058688,0.000498108,0.000009263494,0.0000067229994,0.023509303],"genre_scores_gemma":[0.99551237,0.00005590263,0.00023146348,0.0035776969,0.00009980737,0.000027840078,0.000035090747,0.000011991016,0.0004478378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989041,0.000054963086,0.0003537978,0.00016150242,0.00019744608,0.00032816795],"domain_scores_gemma":[0.9992534,0.000064747655,0.00009126799,0.00029124384,0.000080692545,0.00021865405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012411889,0.00016411458,0.00030936688,0.00063213403,0.00008100427,0.000057958223,0.00028115927,0.00005616716,0.0000566207],"category_scores_gemma":[0.00002713266,0.00011208093,0.00013327657,0.00032519625,0.000076948236,0.0000991214,0.000022372202,0.00023513203,0.000013953505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000064773158,0.000050248218,0.96594334,0.00009087777,0.0008690494,0.00038272137,0.0011301266,0.000014894411,0.000029382725,0.00059090357,0.012800059,0.018091904],"study_design_scores_gemma":[0.0017927444,0.00011296799,0.95123833,0.0006169362,0.0007683121,7.7822443e-7,0.0023022497,0.000021516878,0.00012829289,0.0006930378,0.042219233,0.00010560748],"about_ca_topic_score_codex":0.00096754,"about_ca_topic_score_gemma":0.009910786,"teacher_disagreement_score":0.03261799,"about_ca_system_score_codex":0.0003475632,"about_ca_system_score_gemma":0.00031405728,"threshold_uncertainty_score":0.5530451},"labels":[],"label_agreement":null},{"id":"W4416685733","doi":"10.1016/j.jcjd.2025.10.059","title":"Fidelity, Feasibility, and Acceptability of the T1ME Trial Intervention: A Mixed-Methods Process Evaluation at Vanguard Diabetes Clinics","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Vanguard; Process (computing); Diabetes mellitus; MEDLINE","score_opus":0.03801855794188501,"score_gpt":0.3934985190248104,"score_spread":0.3554799610829254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416685733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910006,0.0045291535,0.000008994714,0.0011624709,0.0012719095,0.0011901773,0.000019798174,0.0000059216964,0.0008109718],"genre_scores_gemma":[0.9987887,0.000011793022,0.00061248516,0.00025731523,0.00009824498,0.000030345636,0.000008444225,0.000010687316,0.0001819746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977223,0.00052015635,0.00089972717,0.00022996034,0.00032191802,0.00030592122],"domain_scores_gemma":[0.9978056,0.0003455306,0.0004898827,0.00040843064,0.00067148806,0.0002790725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004120451,0.00017408548,0.0005704378,0.0002741442,0.00012380006,0.000046163157,0.00024627862,0.000104305574,0.00031638757],"category_scores_gemma":[0.0028271854,0.00012323016,0.00039876945,0.00038358002,0.0002799321,0.00015339104,0.000094023664,0.00020125593,8.979329e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012808372,0.000144907,0.85452193,0.00039267802,0.00036120898,4.935394e-7,0.000121285346,0.000005583099,0.00003770256,0.000030697553,0.0006333062,0.14362215],"study_design_scores_gemma":[0.017114904,0.00087768945,0.96973276,0.00043371323,0.0015538877,4.3161904e-7,0.00044215372,0.00025083614,0.003575397,0.0046747797,0.0012348003,0.00010861771],"about_ca_topic_score_codex":0.000080911756,"about_ca_topic_score_gemma":0.003980216,"teacher_disagreement_score":0.14351353,"about_ca_system_score_codex":0.0004987072,"about_ca_system_score_gemma":0.00091798115,"threshold_uncertainty_score":0.502518},"labels":[],"label_agreement":null},{"id":"W4416716171","doi":"10.2337/dc25-0824","title":"Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study","year":2025,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk; European Society for Paediatric Endocrinology; Universität Ulm; Eli Lilly and Company","keywords":"Semaglutide; Insulin sensitivity; Obesity; Diabetes mellitus; Glycemic; Insulin","score_opus":0.004107512476270579,"score_gpt":0.2323332098692963,"score_spread":0.2282256973930257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416716171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703,0.000607942,7.8796364e-7,0.000025203479,0.000062761166,0.0018571806,0.00003230706,0.000030912608,0.000352893],"genre_scores_gemma":[0.9997927,0.000026614696,0.000004565879,0.00006244618,0.000013584061,0.000046387155,0.000013006455,0.000013819378,0.000026866719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872977,0.00037471976,0.000148023,0.00028179275,0.00022907105,0.00023663888],"domain_scores_gemma":[0.9992913,0.00017613714,0.000063123785,0.00037358495,0.000048768827,0.000047114125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034682913,0.00021862019,0.00057028147,0.00025393383,0.000060962837,0.000015499945,0.000049342398,0.00003996141,6.574895e-7],"category_scores_gemma":[0.000087191016,0.00012105787,0.00007379647,0.00044142996,0.00006834881,0.000024471481,0.00008840588,0.00016548067,0.0000031991372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012468887,0.0003236352,0.9714556,0.0005053311,0.00040668892,0.000015264333,0.000738511,0.000028933791,0.00005510517,0.0000035548933,0.000015140445,0.026327582],"study_design_scores_gemma":[0.003668226,0.0018406663,0.9854901,0.00063692755,0.0011170491,5.2232636e-8,0.0022887145,0.00005295048,0.004750916,0.0000010134854,0.00006179794,0.00009158688],"about_ca_topic_score_codex":0.00019575328,"about_ca_topic_score_gemma":0.0002924648,"teacher_disagreement_score":0.026235996,"about_ca_system_score_codex":0.00006574993,"about_ca_system_score_gemma":0.000017857381,"threshold_uncertainty_score":0.49365968},"labels":[],"label_agreement":null},{"id":"W4416765865","doi":"10.1002/ejhf.70082","title":"Pharmacological Treatment for Patients with Obesity and Heart Failure: Focus on Glucagon-Like Peptide-1 Receptor Agonists. <i>European Journal of Heart Failure</i> Expert Consensus Document","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Deutsche Forschungsgemeinschaft; Deutsches Zentrum für Herz-Kreislaufforschung","keywords":"Heart failure; Clinical trial; Ejection fraction; Heart failure with preserved ejection fraction; MEDLINE; Obesity; Alternative medicine","score_opus":0.011643463709798805,"score_gpt":0.2573856857318046,"score_spread":0.2457422220220058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416765865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9162839,0.0011439592,0.00015772328,0.07912944,0.0008427757,0.0017330599,0.00003406151,0.000053560223,0.00062149344],"genre_scores_gemma":[0.9424658,0.00018738692,0.05200236,0.0035700225,0.00064129813,0.000013524419,0.0000261376,0.00010241839,0.0009910824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959485,0.0009781561,0.0012554782,0.00048046696,0.00071368116,0.0006237171],"domain_scores_gemma":[0.99747944,0.00026207333,0.00066161563,0.0003698862,0.0006446412,0.00058232987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013553258,0.00060772616,0.0011938137,0.0004032557,0.0003078136,0.00017352882,0.00024013128,0.00005926926,0.00013575694],"category_scores_gemma":[0.000106044004,0.0003957622,0.00055512297,0.00025734972,0.0002302886,0.00019138219,0.00012024153,0.0004998949,0.000051800987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004381821,0.0032833188,0.022389987,0.00011761342,0.0020567966,0.00042921212,0.0003557508,0.000025224124,0.0063405945,0.00006899178,0.9552654,0.0052853],"study_design_scores_gemma":[0.022869542,0.022573113,0.019892799,0.0009193165,0.0010165977,0.00021308113,0.0004365178,0.000002949686,0.005665609,0.000018346194,0.92604727,0.0003448667],"about_ca_topic_score_codex":0.0000050948597,"about_ca_topic_score_gemma":0.0000070269607,"teacher_disagreement_score":0.07555942,"about_ca_system_score_codex":0.0003699657,"about_ca_system_score_gemma":0.00020481789,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W4416766283","doi":"10.1111/dom.70317","title":"<scp>PIONEER REAL</scp> Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk","keywords":"Semaglutide; Type 2 diabetes; Population; Diabetes mellitus; Patient satisfaction","score_opus":0.009816013317230697,"score_gpt":0.23889823068596952,"score_spread":0.22908221736873882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416766283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991526,0.0019671828,7.595331e-7,0.00006934424,0.00021082835,0.003121102,0.000023406772,0.0000989837,0.0029823703],"genre_scores_gemma":[0.993389,0.0013143597,0.00059904554,0.00020298865,0.000044817494,0.00024239738,0.000059984864,0.00004187575,0.004105534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969587,0.00021300343,0.00067856733,0.0008567451,0.0004451538,0.00084783405],"domain_scores_gemma":[0.99835414,0.00033067883,0.00023969382,0.0006187338,0.00026035425,0.00019637407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005125364,0.00052282965,0.0014438153,0.0009845911,0.00009481967,0.000064572676,0.00018234612,0.00013987551,0.000010794522],"category_scores_gemma":[0.00034917778,0.00043110017,0.00010098166,0.0019068721,0.0001767412,0.0003556398,0.00021084856,0.0003838124,0.000008596967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021557427,0.004761285,0.98794293,0.0006218088,0.00055330666,0.000044262735,0.0018693287,0.000044876746,0.0004176811,0.0004730427,0.0005407035,0.0025151912],"study_design_scores_gemma":[0.013763992,0.0006005623,0.97852445,0.0011779779,0.0009890279,1.3326076e-7,0.0010181379,0.00038714302,0.001776477,0.00017642922,0.0013850968,0.00020054926],"about_ca_topic_score_codex":0.0025218,"about_ca_topic_score_gemma":0.01611071,"teacher_disagreement_score":0.013588911,"about_ca_system_score_codex":0.0001451141,"about_ca_system_score_gemma":0.00009358313,"threshold_uncertainty_score":0.9998141},"labels":[],"label_agreement":null},{"id":"W4416808496","doi":"10.1016/j.jogc.2025.103191","title":"Outcomes of Maternal Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Scoping Review of Evidence and Reporting Trends","year":2025,"lang":"en","type":"review","venue":"Journal of Obstetrics and Gynaecology Canada","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Public Health; Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Pregnancy; Congenital malformations; Accidental; MEDLINE; Adverse effect; Risk assessment","score_opus":0.07512424360406014,"score_gpt":0.36209109815684937,"score_spread":0.28696685455278925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416808496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019429824,0.9939708,0.000003233646,0.00027998432,0.002989581,0.00053357665,0.000029171044,0.0000023189773,0.0002483279],"genre_scores_gemma":[0.00082796457,0.99616784,0.00096001907,0.00035331803,0.000024960094,0.000021571874,0.000013195834,0.000014343803,0.001616807],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99613404,0.00009507494,0.0028170703,0.00024748594,0.00048314847,0.00022315812],"domain_scores_gemma":[0.9925008,0.0019766302,0.0046548685,0.00021306312,0.00045443221,0.00020020084],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00076674676,0.0002926659,0.0033158055,0.0006037032,0.00004715415,0.000014684859,0.00015384406,0.00012625907,0.00024345622],"category_scores_gemma":[0.008514386,0.00019189063,0.00033390961,0.0006037529,0.00006440343,0.000065134656,0.00014054867,0.00024658404,1.7976656e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002429828,0.00004697984,0.025400281,0.15867746,0.0006981656,0.00033883125,0.000014966736,3.42431e-7,2.0392366e-7,0.00001267994,0.0017058159,0.8131018],"study_design_scores_gemma":[0.001356033,0.0017464104,0.08304676,0.5663061,0.0067334045,0.0001306809,0.00008261352,4.670355e-7,0.0000027462288,0.0000040742384,0.34022644,0.0003642629],"about_ca_topic_score_codex":0.0008528797,"about_ca_topic_score_gemma":0.0008104828,"teacher_disagreement_score":0.8127376,"about_ca_system_score_codex":0.0006653907,"about_ca_system_score_gemma":0.0031409208,"threshold_uncertainty_score":0.99983734},"labels":[],"label_agreement":null},{"id":"W4416827849","doi":"10.1111/apt.70485","title":"Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease","year":2025,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus; University of Calgary","funders":"","keywords":"Inflammatory bowel disease; Observational study; Receptor; Inflammatory Bowel Diseases; Disease; MEDLINE; Inflammation","score_opus":0.011087597979531362,"score_gpt":0.3123107193256974,"score_spread":0.301223121346166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416827849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7072164,0.26816073,0.000007923877,0.017492022,0.0007575891,0.0057261144,0.000041209096,0.00007832144,0.0005196967],"genre_scores_gemma":[0.64733773,0.22556378,0.000295317,0.12224264,0.00005516136,0.0005532552,0.0002232188,0.00005726622,0.0036716557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843246,0.000223094,0.00067524315,0.0002570915,0.00016094228,0.00025118497],"domain_scores_gemma":[0.9992038,0.00019870092,0.00016884251,0.00028936449,0.00003730138,0.00010197175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034466595,0.00023918271,0.000854107,0.00019254995,0.00004497904,0.000006378458,0.00012884755,0.000046589914,0.00012476499],"category_scores_gemma":[0.0000018886202,0.00018916323,0.00013268566,0.00017473851,0.00013585834,0.00006122724,0.000108455286,0.000119724566,0.000014747051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002602791,0.004693424,0.6561212,0.21876605,0.09834539,0.00017070385,0.00062996557,0.000016307895,0.01147201,0.001931591,0.0031754025,0.0020751378],"study_design_scores_gemma":[0.026160168,0.0005454483,0.6426437,0.0347788,0.25491598,0.000004432209,0.0002734382,0.00030781594,0.014383683,0.00014806347,0.02507651,0.0007620001],"about_ca_topic_score_codex":0.000008873349,"about_ca_topic_score_gemma":0.0000024880849,"teacher_disagreement_score":0.18398724,"about_ca_system_score_codex":0.00009055531,"about_ca_system_score_gemma":0.00007068962,"threshold_uncertainty_score":0.77138525},"labels":[],"label_agreement":null},{"id":"W4416864826","doi":"10.1681/asn.20257qtjpx6z","title":"FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Semaglutide; Kidney; Kidney disease; Acute kidney failure; Chronic kidney failure; Heart failure","score_opus":0.009375868474832549,"score_gpt":0.26451506144964104,"score_spread":0.25513919297480847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416864826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9350809,0.00016481763,0.0021240597,0.061852492,0.00022137593,0.00041103724,0.000008506786,0.0000083927025,0.00012842711],"genre_scores_gemma":[0.94141775,0.00026698067,0.014157845,0.04359609,0.00021970925,0.0000049601404,0.0000029314394,0.000017442882,0.00031627077],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867755,0.00025482898,0.00042058204,0.00012275531,0.00031579135,0.00020849446],"domain_scores_gemma":[0.99773335,0.00036778688,0.0012763807,0.00036070382,0.00016854465,0.00009320164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004453243,0.00015562789,0.0005957679,0.00008184505,0.000105891275,0.000006779006,0.0002649888,0.00006156352,0.000013964832],"category_scores_gemma":[0.00033809026,0.00008450143,0.000657219,0.00045057875,0.0005211031,0.000039071685,0.00010600953,0.00035094353,0.0000012290327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000655237,0.00060956704,0.017682824,0.00048428724,0.0056906436,0.000008035556,0.001478438,0.0018283101,0.15442982,0.0002446204,0.80016243,0.01672579],"study_design_scores_gemma":[0.020207828,0.010772799,0.28433865,0.0038314627,0.019328492,0.00010863116,0.0076949704,0.0362637,0.05787312,0.004538001,0.55442864,0.0006137015],"about_ca_topic_score_codex":0.00008408689,"about_ca_topic_score_gemma":0.0000034696488,"teacher_disagreement_score":0.26665583,"about_ca_system_score_codex":0.00012395857,"about_ca_system_score_gemma":0.00025898014,"threshold_uncertainty_score":0.34458685},"labels":[],"label_agreement":null},{"id":"W4416865207","doi":"10.1681/asn.2025dcskpv49","title":"Efficacy and Safety of Canagliflozin in Patients with Persistent Drop in eGFR Below 30 mL/min per 1.73 m2: Insights from the CREDENCE Clinical Trial","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Canagliflozin; Clinical trial; Credence; Drop out; Clinical research; Clinical efficacy","score_opus":0.016836251432374306,"score_gpt":0.2880400442203077,"score_spread":0.2712037927879334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416865207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091226,0.00038806262,0.000014506924,0.00794368,0.00012424709,0.00051813555,0.000004128769,0.0000018544531,0.00009311124],"genre_scores_gemma":[0.9941463,0.0004313067,0.0006891506,0.004583235,0.00007135684,0.000003576272,0.0000020190555,0.000006942018,0.00006614085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983836,0.00029130888,0.00072470057,0.00015977646,0.00027437054,0.00016625437],"domain_scores_gemma":[0.99821496,0.00060265523,0.00076647283,0.00026246416,0.00010292107,0.000050545448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004179438,0.00012749957,0.00075749,0.00005786226,0.000040586336,0.000004718131,0.00024237801,0.00005740456,0.000014418498],"category_scores_gemma":[0.000098001205,0.000065799766,0.0003162831,0.00028734558,0.00087957806,0.000038699873,0.00013365658,0.00034014072,3.466577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056177013,0.0025617357,0.9023062,0.000037383063,0.0029654454,0.000008529411,0.0035414514,0.00009651623,0.00036830944,0.000047176294,0.0119789895,0.019911276],"study_design_scores_gemma":[0.04220084,0.003946299,0.94722265,0.00017585816,0.00053528143,7.897203e-7,0.001717897,0.00007939086,0.000009151305,0.000039053542,0.004020858,0.000051927338],"about_ca_topic_score_codex":0.00071835244,"about_ca_topic_score_gemma":0.00020193029,"teacher_disagreement_score":0.044916477,"about_ca_system_score_codex":0.00012434411,"about_ca_system_score_gemma":0.00018017969,"threshold_uncertainty_score":0.32408422},"labels":[],"label_agreement":null},{"id":"W4416876394","doi":"10.1681/asn.2025fdqxb4qe","title":"Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Semaglutide; Kidney disease; Disease; Kidney; Benzhydryl compounds","score_opus":0.009431779377813294,"score_gpt":0.27076196951724796,"score_spread":0.26133019013943465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416876394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786015,0.0003076101,0.00006163684,0.020138573,0.00029045626,0.0004487538,0.0000022367408,0.0000036260908,0.00014557388],"genre_scores_gemma":[0.97383577,0.00026668503,0.0004451385,0.025036527,0.00009067952,0.0000062347203,8.344337e-7,0.000007977662,0.00031018045],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990072,0.00016459609,0.00035244916,0.00009314982,0.00021309906,0.00016950865],"domain_scores_gemma":[0.99856573,0.00042115932,0.0005690399,0.00029269574,0.00008322366,0.00006812116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034276547,0.00010579839,0.00052917947,0.00006682109,0.000031394,0.0000027439864,0.00022645284,0.000028095126,0.000006409164],"category_scores_gemma":[0.0003001344,0.000056161738,0.0004154207,0.00038356349,0.000343539,0.000014893461,0.000081035054,0.00019755101,8.881805e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09868669,0.006304846,0.02726812,0.0022027767,0.00960877,0.00006533981,0.0017283903,0.0013590634,0.12607078,0.0050238674,0.6823653,0.039316084],"study_design_scores_gemma":[0.17297299,0.043415554,0.6015971,0.004566741,0.01444248,0.000009200341,0.0015705066,0.017144365,0.012092048,0.03283635,0.09871519,0.0006375016],"about_ca_topic_score_codex":0.000020190959,"about_ca_topic_score_gemma":0.0000010861188,"teacher_disagreement_score":0.5836501,"about_ca_system_score_codex":0.00008245801,"about_ca_system_score_gemma":0.00022063767,"threshold_uncertainty_score":0.22902092},"labels":[],"label_agreement":null},{"id":"W4416879708","doi":"10.1681/asn.20250g4wmdg7","title":"Renal Functional Reserve Predicts GFR Response to Empagliflozin but Not Linagliptin or Sulfonylureas in Patients with Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Empagliflozin; Linagliptin; Type 2 diabetes; Benzhydryl compounds; Renal function","score_opus":0.013132580204737074,"score_gpt":0.2568409503321088,"score_spread":0.24370837012737173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416879708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159254,0.000051974534,0.00002380476,0.017773096,0.00013200998,0.00033283475,0.000007774377,0.00000776472,0.00007817554],"genre_scores_gemma":[0.9807012,0.000029788182,0.002579297,0.0144520495,0.00010024348,0.000008698732,0.0000040674545,0.000013730993,0.0021109413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853605,0.00020858238,0.00043043485,0.00016154346,0.00038909586,0.00027429877],"domain_scores_gemma":[0.9984824,0.0003144389,0.0004821689,0.00027843192,0.0003523071,0.0000902712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061173213,0.00014902663,0.0005580496,0.00017252647,0.000048667604,0.000007699824,0.000213435,0.000052597978,0.000038232065],"category_scores_gemma":[0.00024928863,0.0000848593,0.00021075773,0.0008268459,0.00032391603,0.000059220685,0.00015140443,0.00026487946,0.0000028311206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07832507,0.001195753,0.68069994,0.00007375764,0.0022307013,0.000019784606,0.00047790873,0.00035019347,0.018419456,0.000016828846,0.21355455,0.004636028],"study_design_scores_gemma":[0.004372855,0.0069552404,0.9642433,0.00018958638,0.00032727537,0.0000029070698,0.00028493872,0.000043275228,0.0007324342,0.0000277089,0.02275156,0.00006889536],"about_ca_topic_score_codex":0.00003326546,"about_ca_topic_score_gemma":0.000019603673,"teacher_disagreement_score":0.28354335,"about_ca_system_score_codex":0.0001805127,"about_ca_system_score_gemma":0.00032706288,"threshold_uncertainty_score":0.34604618},"labels":[],"label_agreement":null},{"id":"W4416880241","doi":"10.1681/asn.20250w81e1d3","title":"Multimodal Kidney Mechanisms of SGLT2 Inhibition in Patients with Type 1 Diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; London Health Sciences Centre; Hospital for Sick Children","funders":"","keywords":"Type 1 diabetes; Kidney; Kidney disease; Diabetes mellitus; Diabetic nephropathy; Nephropathy; Nephrology","score_opus":0.005279430656073807,"score_gpt":0.23218401589493204,"score_spread":0.22690458523885823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416880241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580276,0.00003126941,0.00012909429,0.0036762734,0.000065222695,0.00017108512,0.0000029106434,0.0000027104825,0.00011868089],"genre_scores_gemma":[0.98789567,0.00003449942,0.004561032,0.0074094026,0.000015925738,0.0000016272597,0.0000031053223,0.0000059677545,0.00007280161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992898,0.000049505332,0.000286172,0.00007094347,0.00017467496,0.00012890501],"domain_scores_gemma":[0.99904406,0.0000442949,0.0005656285,0.0001341634,0.00017586065,0.0000360069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015421257,0.000080505575,0.00041887062,0.00007789401,0.000016086582,0.0000016346835,0.000071670314,0.00003000955,0.000012506523],"category_scores_gemma":[0.00003010631,0.000048656213,0.00016861029,0.00036005586,0.0002577726,0.00003828461,0.000054655742,0.000120768535,3.9508927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019056303,0.0020676851,0.84662575,0.00024038808,0.0024851512,0.0000035828066,0.00052752765,0.00010600048,0.093526505,0.00035458145,0.04306767,0.009089539],"study_design_scores_gemma":[0.0046265293,0.0036437528,0.9809695,0.00024100617,0.00041639523,7.744699e-7,0.00028356293,0.00010896731,0.0076818652,0.00073628733,0.0012397771,0.000051568742],"about_ca_topic_score_codex":0.000020117744,"about_ca_topic_score_gemma":0.0000015962024,"teacher_disagreement_score":0.13434377,"about_ca_system_score_codex":0.0000618684,"about_ca_system_score_gemma":0.000089834066,"threshold_uncertainty_score":0.19841428},"labels":[],"label_agreement":null},{"id":"W4416880272","doi":"10.1681/asn.2025m7ss8e68","title":"Cardiovascular Risk Prediction Modelling with Semaglutide in Patients with Type 1 Diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; University Health Network","funders":"","keywords":"Semaglutide; Type 1 diabetes; Diabetes mellitus; Kidney disease; Type 2 diabetes","score_opus":0.005742221106647711,"score_gpt":0.2052259175175286,"score_spread":0.1994836964108809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416880272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731034,0.00041259918,0.0013004267,0.0006395977,0.000043111788,0.00019643697,0.0000021562475,0.0000049764,0.00009035862],"genre_scores_gemma":[0.9920693,0.00029973208,0.006378009,0.0011526614,0.000033309683,0.0000024658048,0.0000014461946,0.0000085485335,0.000054504028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922556,0.00006903828,0.00022451385,0.00009512332,0.0002364714,0.00014929613],"domain_scores_gemma":[0.9991606,0.000041512776,0.00038602468,0.00021091317,0.00017381531,0.000027157872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023499782,0.00009168202,0.00046749625,0.000065169166,0.000033307177,0.000003060818,0.00009063359,0.000024800105,0.0000020243406],"category_scores_gemma":[0.0000067748256,0.000049821854,0.00025877732,0.0004161637,0.00024402363,0.000035900513,0.00003369207,0.0001866146,2.5164925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006278776,0.00023315552,0.9583807,0.000038847134,0.0044019,0.0000013005084,0.00014797051,0.028509168,0.00008463706,0.0000049912755,0.0026092767,0.004960178],"study_design_scores_gemma":[0.0032840925,0.0025278348,0.98194915,0.00015298324,0.0017907947,0.0000011801986,0.00023001576,0.002056243,0.00008418708,0.000056297824,0.00781985,0.000047373902],"about_ca_topic_score_codex":0.000047922724,"about_ca_topic_score_gemma":0.0000025668933,"teacher_disagreement_score":0.026452925,"about_ca_system_score_codex":0.000084959065,"about_ca_system_score_gemma":0.00006796478,"threshold_uncertainty_score":0.20316763},"labels":[],"label_agreement":null},{"id":"W4416880670","doi":"10.1681/asn.20252gfdnmkj","title":"Urinary Proteomic Changes Associated with a Healthier Kidney Phenotype After Dapagliflozin Therapy in Adolescent Patients with Type 1 Diabetes","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Toronto General Hospital; University Health Network; Hospital for Sick Children","funders":"","keywords":"Type 1 diabetes; Urinary system; Dapagliflozin; Phenotype; Diabetes mellitus; Kidney; Kidney disease","score_opus":0.00985351222723183,"score_gpt":0.24765088321291456,"score_spread":0.23779737098568274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416880670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318404,0.00034574795,0.000004010171,0.015766962,0.00005881858,0.0005894584,0.0000037465638,0.0000067784085,0.000040423303],"genre_scores_gemma":[0.96573097,0.0003768562,0.00066590786,0.033000108,0.00004514829,0.000017220289,0.0000040178584,0.000015553784,0.00014422412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900216,0.00012186085,0.00024841735,0.00013081978,0.00023238828,0.00026437183],"domain_scores_gemma":[0.99888545,0.000043220938,0.0005920851,0.00019852992,0.00021078678,0.00006989484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020936159,0.00014997342,0.00054924865,0.00009195559,0.000032769076,0.000004823833,0.00014076802,0.00004477148,0.000014378906],"category_scores_gemma":[0.000025562984,0.00008041313,0.00012258578,0.0005320778,0.0003552181,0.000037543632,0.000054350858,0.00025972753,5.7228505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045263343,0.001384883,0.9713004,0.00008356316,0.0015620854,0.000005441363,0.00042922786,0.0000073920837,0.0012557564,0.0000023494104,0.013387234,0.006055336],"study_design_scores_gemma":[0.004804466,0.008584042,0.98130757,0.0005033943,0.00022764714,8.87667e-7,0.00011301818,0.000019598487,0.0001604612,0.000025392435,0.0041834577,0.00007009061],"about_ca_topic_score_codex":0.000017541961,"about_ca_topic_score_gemma":0.000010207549,"teacher_disagreement_score":0.017453093,"about_ca_system_score_codex":0.00017986482,"about_ca_system_score_gemma":0.00022487497,"threshold_uncertainty_score":0.32791522},"labels":[],"label_agreement":null},{"id":"W4416895284","doi":"10.1038/s41598-025-30298-6","title":"Multiscale computational analysis reveals enhanced allosteric modulation of Nav1.5 by dual binding of dapagliflozin and ertugliflozin","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada","keywords":"Allosteric regulation; Sodium channel; Molecular dynamics; Dapagliflozin; Hydrogen bond; Protein dynamics; Binding site; Docking (animal)","score_opus":0.009159276264105103,"score_gpt":0.26975418812124125,"score_spread":0.2605949118571361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416895284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944553,0.00019155523,0.0032074896,0.0000946692,0.0004611153,0.00037090684,0.000010706495,0.000017694645,0.0011905852],"genre_scores_gemma":[0.9884182,0.0000046676782,0.002799417,0.00001557287,0.000005576418,0.000011936331,0.0004802188,0.0000046799737,0.008259715],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985139,0.000027254246,0.0005627666,0.0004046853,0.00036055435,0.00013089001],"domain_scores_gemma":[0.99909157,0.00004651781,0.00033328802,0.00031167603,0.00016635138,0.000050630202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005538304,0.00009787297,0.00035913513,0.0005394605,0.00006580637,0.000029611068,0.000029288785,0.00003754532,0.00004315667],"category_scores_gemma":[0.00007276666,0.00008723278,0.00010347545,0.0011114631,0.00014743081,0.00008555484,0.000060611517,0.000030196634,0.0000011358834],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000596145,0.0005882404,0.2828321,0.0004808362,0.0022212064,0.000042678068,0.00048320385,0.00232803,0.6880349,0.00019119753,0.009037427,0.013700609],"study_design_scores_gemma":[0.0029972708,0.00032137043,0.67211246,0.00066739734,0.0060470174,0.000014154224,0.00039066188,0.041231047,0.26757756,0.0059625492,0.0022376298,0.00044091218],"about_ca_topic_score_codex":0.000018396917,"about_ca_topic_score_gemma":0.000006990069,"teacher_disagreement_score":0.4204573,"about_ca_system_score_codex":0.000035708454,"about_ca_system_score_gemma":0.00003727292,"threshold_uncertainty_score":0.35572496},"labels":[],"label_agreement":null},{"id":"W4416904854","doi":"10.3390/diabetology6120152","title":"Complications and Comorbidities in Individuals &gt;80 Years with Diabetes: A Scoping Review","year":2025,"lang":"en","type":"article","venue":"Diabetology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Diabetes mellitus; MEDLINE; Quality of life (healthcare); Comorbidity; Population; Population ageing; Systematic review; PsycINFO","score_opus":0.02102902922763229,"score_gpt":0.3076324222453534,"score_spread":0.28660339301772114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416904854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9174196,0.049153086,0.000024904013,0.009169974,0.00007236667,0.0018846445,0.000009354706,0.00007459136,0.022191448],"genre_scores_gemma":[0.97932345,0.0056287986,0.00079633784,0.012842178,0.000010891048,0.0007048954,0.00012494044,0.000015118045,0.0005533872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924976,0.00004305082,0.00019570997,0.00021507086,0.00006792621,0.00022846178],"domain_scores_gemma":[0.99954003,0.0001215996,0.00004727432,0.00022504291,0.000024478984,0.00004158974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013189147,0.00010690975,0.00043590696,0.0001984992,0.000030134412,0.000010955748,0.000058098027,0.000041413834,0.000022781549],"category_scores_gemma":[0.00003955044,0.00009168188,0.00002390934,0.0002488067,0.00013240582,0.00004179237,0.00006475304,0.00007683648,0.000015450962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000031978398,0.00014994363,0.97176003,0.003491138,0.0001942285,0.000010144736,0.000082133025,8.5189663e-7,0.00001762883,0.0041176416,0.0026905832,0.017482478],"study_design_scores_gemma":[0.001591663,0.00018367771,0.9606383,0.029060526,0.00031227735,0.0000012819746,0.000046606696,0.000016633263,0.000052259726,0.00044910048,0.0075286003,0.00011911051],"about_ca_topic_score_codex":0.0000062087624,"about_ca_topic_score_gemma":0.000044693825,"teacher_disagreement_score":0.061903823,"about_ca_system_score_codex":0.000029572666,"about_ca_system_score_gemma":0.000052902713,"threshold_uncertainty_score":0.37386787},"labels":[],"label_agreement":null},{"id":"W4416905457","doi":"10.1161/circep.125.013850","title":"Metformin Protects Against Persistent Atrial Fibrillation in an Equine Model","year":2025,"lang":"en","type":"article","venue":"Circulation Arrhythmia and Electrophysiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Metformin; Atrial fibrillation; Diabetes mellitus; Anti-Arrhythmia Agents; Drug; Animal model","score_opus":0.014718742475174487,"score_gpt":0.2690389969828846,"score_spread":0.2543202545077101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416905457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641716,0.00048360004,0.0010161139,0.00050497777,0.000056038054,0.0007197361,7.5421514e-7,0.000044281496,0.0007573599],"genre_scores_gemma":[0.9985779,0.00012902005,0.0004637316,0.00022372176,0.00016386561,0.000023925191,0.00012628091,0.000008563452,0.00028300547],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99919075,0.000037392165,0.00019667581,0.00027994704,0.00006981933,0.00022538818],"domain_scores_gemma":[0.99968565,0.000016191158,0.000049092505,0.00015791506,0.000043295233,0.000047871512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007023357,0.000121945064,0.0002519024,0.00024009499,0.000067182955,0.000012854548,0.00002160354,0.00008814119,0.0000067753194],"category_scores_gemma":[0.000023496472,0.000110478606,0.00009401074,0.00020816899,0.000033424527,0.00010924571,0.000021581021,0.00007756074,0.0000043412906],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016896455,0.00007578341,0.009139753,0.00026768874,0.00040325007,0.000036495476,0.00036189205,0.2606285,0.43209723,0.013118067,0.000054311615,0.28212738],"study_design_scores_gemma":[0.003704333,0.001055142,0.053428315,0.000060731225,0.00015409895,0.0000070215624,0.000037106096,0.935377,0.0008578888,0.004664725,0.0004729218,0.00018072194],"about_ca_topic_score_codex":0.0000056903737,"about_ca_topic_score_gemma":0.000006507772,"teacher_disagreement_score":0.6747485,"about_ca_system_score_codex":0.00013033391,"about_ca_system_score_gemma":0.0000633909,"threshold_uncertainty_score":0.45051867},"labels":[],"label_agreement":null},{"id":"W4417031804","doi":"10.1161/hypertensionaha.125.25955","title":"Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Hypertension","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; University of Toronto; Institute of Health Services and Policy Research; University of British Columbia","funders":"","keywords":"Dapagliflozin; Blood pressure; Benzhydryl compounds; Type 2 diabetes; Clinical trial; Disease","score_opus":0.012217010487082593,"score_gpt":0.22848840939345402,"score_spread":0.21627139890637143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417031804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787823,0.0036039178,0.00002407331,0.00003839916,0.00055665633,0.014965826,0.000007243389,0.00004044116,0.0019811278],"genre_scores_gemma":[0.9969267,0.0007095164,0.00027742743,0.00010707387,0.000049722687,0.0006667142,0.00011308558,0.000034791028,0.0011149541],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686974,0.00051034125,0.0008937134,0.0005538382,0.0008242558,0.00034810606],"domain_scores_gemma":[0.9975638,0.0005312857,0.0003072241,0.0010628508,0.0004051314,0.00012970781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017252333,0.00035683007,0.004070048,0.00048824478,0.00005189829,0.000009698722,0.00011399545,0.00016585765,0.0000062952945],"category_scores_gemma":[0.001687306,0.00020611208,0.0013197113,0.00062904676,0.0001299099,0.00006840831,0.00012372936,0.00015357269,0.0000064871047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9673119,0.0011138688,0.007586499,0.0005946209,0.019763999,0.000036576057,0.00009525697,0.00018293597,0.00005812861,0.0000042772913,0.0009069694,0.0023449513],"study_design_scores_gemma":[0.9702984,0.0023906757,0.00084215886,0.0015035004,0.02006761,6.130263e-7,0.00001833362,0.00052672444,0.0028524732,0.000004446411,0.0013086369,0.00018644243],"about_ca_topic_score_codex":0.00024700392,"about_ca_topic_score_gemma":0.00002321272,"teacher_disagreement_score":0.018144399,"about_ca_system_score_codex":0.00012296093,"about_ca_system_score_gemma":0.00015608846,"threshold_uncertainty_score":0.84050065},"labels":[],"label_agreement":null},{"id":"W4417067193","doi":"10.1016/j.obmed.2025.100674","title":"Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study","year":2025,"lang":"en","type":"article","venue":"Obesity Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Canada Opportunities Agency; University of Alberta","funders":"","keywords":"Obesity; Adverse effect; Public health; Diabetes mellitus; Persistence (discontinuity); Type 2 diabetes","score_opus":0.03610291263204207,"score_gpt":0.32729133622975376,"score_spread":0.2911884235977117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417067193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854422,0.00013265488,0.0004464694,0.00062573905,0.0006873745,0.0012924228,0.000009676184,0.00006094227,0.011302485],"genre_scores_gemma":[0.98637635,0.000007749644,0.00009130848,0.00062564906,0.00010423841,0.00003460046,0.000055685487,0.000010690622,0.012693726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981827,0.000031619722,0.0004899211,0.00040359245,0.00049463776,0.0003975284],"domain_scores_gemma":[0.9988673,0.00015980728,0.000115795694,0.00040937553,0.00027429417,0.00017347158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006785021,0.0002254209,0.0006206337,0.00029101988,0.00018901467,0.000016611208,0.00016487244,0.000061022398,0.00018677655],"category_scores_gemma":[0.00040178644,0.00016532095,0.000115660754,0.0005418219,0.00014467441,0.000058029138,0.00017592892,0.00013492264,0.00002297783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013784155,0.0009944063,0.99409807,0.00016343016,0.0004895639,0.000023827959,0.0007436739,0.0000063705606,0.000989472,0.00012962446,0.0018554874,0.0003682354],"study_design_scores_gemma":[0.0041608126,0.001642163,0.9871891,0.00034095594,0.0004316127,9.3424217e-7,0.0022094855,0.000027905506,0.001431399,0.000022763455,0.0024358777,0.00010700533],"about_ca_topic_score_codex":0.00036701412,"about_ca_topic_score_gemma":0.000063685184,"teacher_disagreement_score":0.006908981,"about_ca_system_score_codex":0.00023003081,"about_ca_system_score_gemma":0.00008055107,"threshold_uncertainty_score":0.6741593},"labels":[],"label_agreement":null},{"id":"W4417078467","doi":"10.1007/s40265-025-02263-0","title":"Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review","year":2025,"lang":"en","type":"article","venue":"Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"","keywords":"Tolerability; Discontinuation; Adverse effect; Pharmacovigilance; Clinical trial; Randomized controlled trial; Narrative review; Acute kidney injury","score_opus":0.006647036455436086,"score_gpt":0.26435928212973053,"score_spread":0.25771224567429446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417078467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8257742,0.030427067,0.00009282547,0.024436591,0.00075556536,0.004324219,0.00008080238,0.0000705758,0.11403814],"genre_scores_gemma":[0.84231496,0.023282517,0.001467077,0.005829812,0.000034238536,0.00015827903,0.00012400215,0.000027634786,0.12676147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913305,0.000060628136,0.0003537109,0.00018588557,0.00014889904,0.00011784891],"domain_scores_gemma":[0.9993189,0.0000643706,0.00012373141,0.00035706724,0.000097886346,0.000038020906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002978162,0.00011056272,0.00043961115,0.000035002355,0.000042431915,0.0000039368565,0.00007148395,0.000020710779,0.0000988003],"category_scores_gemma":[0.00008325763,0.00007394912,0.00010501143,0.00023374267,0.00014162673,0.000038124224,0.00009761287,0.00006484702,0.000007897726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011960547,0.0020231267,0.050689925,0.029842358,0.0023920638,0.000004767329,0.014766581,0.00000397187,0.0019998043,0.0052417484,0.44976798,0.44207162],"study_design_scores_gemma":[0.0024076265,0.00031867498,0.028097413,0.0074587925,0.00065611914,4.9375376e-7,0.0009061845,0.00001742805,0.0062782182,0.0005758804,0.9531304,0.0001527638],"about_ca_topic_score_codex":0.000021670385,"about_ca_topic_score_gemma":0.000010563573,"teacher_disagreement_score":0.5033624,"about_ca_system_score_codex":0.0000672359,"about_ca_system_score_gemma":0.00007280084,"threshold_uncertainty_score":0.30155578},"labels":[],"label_agreement":null},{"id":"W4417153475","doi":"10.1186/s40842-025-00248-2","title":"Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","year":2025,"lang":"en","type":"article","venue":"Cardiovascular Diabetology – Endocrinology Reports","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Heart failure; Ejection fraction; Kidney disease; Myocardial infarction; Hazard ratio; Type 2 diabetes; Cardiorenal syndrome; Diabetes mellitus","score_opus":0.02873334141576437,"score_gpt":0.2766035434174061,"score_spread":0.24787020200164175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417153475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70943075,0.2824627,0.0029228227,0.0011167594,0.00030086335,0.002172561,0.00004247379,0.00016735289,0.0013837354],"genre_scores_gemma":[0.99730045,0.00032759947,0.0007598339,0.00034340113,0.00002287296,0.00074083,0.00022096514,0.000029119268,0.0002549094],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99498487,0.0015323517,0.0009713157,0.0013682295,0.0004449405,0.0006982874],"domain_scores_gemma":[0.9961175,0.001130543,0.0003850261,0.0019828812,0.00023545792,0.00014862523],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020112337,0.00067043863,0.011029425,0.00150787,0.0001364739,0.000021912532,0.00011370153,0.00026939405,0.00007012713],"category_scores_gemma":[0.0002204649,0.00045529765,0.013367646,0.0018157185,0.0005943707,0.00004443498,0.0002099377,0.00029872492,0.0000013259382],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006267959,0.00011637771,0.32086188,0.00017856363,0.67490095,0.00093186414,0.000010640513,0.0021729812,0.000018843702,0.00026562912,0.00005256199,0.00042702453],"study_design_scores_gemma":[0.0010532223,0.00015304636,0.27327606,0.0000049807913,0.7228924,0.00004099864,0.000010063291,0.000017383629,0.0010784427,0.0001943574,0.0010747972,0.00020425946],"about_ca_topic_score_codex":0.00024007268,"about_ca_topic_score_gemma":0.000031046286,"teacher_disagreement_score":0.28786972,"about_ca_system_score_codex":0.000061270235,"about_ca_system_score_gemma":0.00008206966,"threshold_uncertainty_score":0.9997899},"labels":[],"label_agreement":null},{"id":"W4417201458","doi":"10.1371/journal.pone.0338653","title":"GV effects of diabetes mellitus on clinical outcomes of patients with acute heart failure: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Hebei Province; National Natural Science Foundation of China","keywords":"Diabetes mellitus; Cohort; Multivariate analysis; Heart failure; Cohort study; Meta-analysis; MEDLINE; Univariate analysis","score_opus":0.07487241343766746,"score_gpt":0.33436674132169714,"score_spread":0.2594943278840297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417201458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025193623,0.99055606,8.3212575e-7,0.00013687716,0.000012042174,0.008867882,0.00011115397,0.000020274363,0.000042933185],"genre_scores_gemma":[0.00010408624,0.9963473,0.00071038905,0.00037807628,0.000004657516,0.0011850515,0.0002642188,0.000028804261,0.0009773951],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966157,0.0004740283,0.0015820694,0.0004678949,0.00065348746,0.00020683996],"domain_scores_gemma":[0.9954927,0.0021340253,0.0010591608,0.0010280736,0.00017709233,0.00010897836],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0004914393,0.0005059607,0.020454636,0.00040892483,0.000016004202,0.000009163733,0.00014470998,0.00013020005,0.000037140537],"category_scores_gemma":[0.00065079366,0.00025234258,0.0032406305,0.0007139091,0.00006859212,0.000030079955,0.00009614922,0.00016918106,0.0000117000745],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002325719,0.0016796114,0.0025308856,0.5370958,0.45836467,0.0000012454559,0.0000013345265,2.809317e-9,4.9609876e-9,0.000009585812,0.00006711822,0.0002474495],"study_design_scores_gemma":[0.00045021926,0.00091627706,0.00048969255,0.2070125,0.79057217,1.4974942e-8,3.5337655e-7,1.05139215e-7,0.0000019499626,0.000001341615,0.0004268969,0.00012851058],"about_ca_topic_score_codex":0.0000015808179,"about_ca_topic_score_gemma":0.0000012816214,"teacher_disagreement_score":0.33220747,"about_ca_system_score_codex":0.000032363918,"about_ca_system_score_gemma":0.00004884754,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W4417223861","doi":"10.1053/j.ajkd.2025.09.022","title":"Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy","year":2025,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council; British Heart Foundation; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Magnetic resonance imaging; Benzhydryl compounds; Kidney; Kidney disease","score_opus":0.002400517796934686,"score_gpt":0.21806203910599073,"score_spread":0.21566152130905605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417223861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960219,0.002040474,0.000025083602,0.0008352894,0.00014810174,0.000633662,0.00007484449,0.000017093003,0.00020354457],"genre_scores_gemma":[0.99571747,0.00018352573,0.0002888241,0.003609788,0.00003431799,0.000021689115,0.000024241654,0.000025552452,0.00009457856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834734,0.00019267542,0.0003965226,0.00026987467,0.0005093043,0.00028429087],"domain_scores_gemma":[0.9979186,0.00013186819,0.00028633323,0.00025937942,0.00019529474,0.0012084972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015241181,0.00025429096,0.0007605924,0.0004787667,0.000047267695,0.00002642071,0.00013142075,0.000015956299,0.000010785631],"category_scores_gemma":[0.0013539129,0.00018956733,0.000110143694,0.0004691375,0.00021649113,0.00013822436,0.000041543186,0.0001258094,0.0000010363965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021884583,0.0018314909,0.9327812,0.00026275287,0.00022374644,0.00010121367,0.0001778762,0.0000015633121,0.00014969708,0.000069696485,0.0042480063,0.057964303],"study_design_scores_gemma":[0.006564343,0.0064887563,0.9804908,0.0022968245,0.0017146831,8.4558155e-7,0.0003257338,0.000021455957,0.0003971926,0.00008668046,0.0014374575,0.00017519984],"about_ca_topic_score_codex":0.000055155568,"about_ca_topic_score_gemma":0.0000010333807,"teacher_disagreement_score":0.057789102,"about_ca_system_score_codex":0.000106981184,"about_ca_system_score_gemma":0.00050578825,"threshold_uncertainty_score":0.77303314},"labels":[],"label_agreement":null},{"id":"W4417253597","doi":"10.2337/dc25-1080","title":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Wörwag Pharma; Esperion Therapeutics; Aspen; Daiichi Sankyo Europe; Servier; British Heart Foundation; Novo Nordisk; Dexcom; Pfizer; Biogen; Insulet Corporation; AstraZeneca; Amarin Corporation; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Amsterdam University Medical Centers; McMaster University; Nevro; Amgen; European Commission; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Intercept Pharmaceuticals; American Diabetes Association","keywords":"Semaglutide; Randomized controlled trial; Type 2 diabetes; Adverse effect; Diabetes mellitus; Kidney disease; Kidney","score_opus":0.009598017610812151,"score_gpt":0.27705285965517884,"score_spread":0.2674548420443667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417253597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912198,0.0003184716,5.515684e-7,0.0012573558,0.00030194805,0.0024992814,0.00032048125,0.000053671574,0.004028435],"genre_scores_gemma":[0.9968979,0.000022756081,0.00010388535,0.0013206659,0.000044156113,0.00017869839,0.0007783681,0.0000242929,0.0006293195],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828583,0.00018882671,0.00047803516,0.00035762368,0.00029628508,0.00039337314],"domain_scores_gemma":[0.9977772,0.0011858002,0.00016093467,0.00064543576,0.00012941832,0.0001011702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003553527,0.00030139083,0.0012596797,0.00019545166,0.00004581591,0.000030853185,0.00017759354,0.000085661864,0.00005061034],"category_scores_gemma":[0.001223891,0.00015213828,0.00038885797,0.00051472476,0.00010958668,0.000043604992,0.00007358391,0.00016838757,0.000029917777],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17422307,0.0003258992,0.81491554,0.00006330655,0.0016857728,0.0000030210265,0.0009117962,0.000042836746,0.000044287604,0.00003626532,0.005692618,0.002055618],"study_design_scores_gemma":[0.6386641,0.0014775542,0.35640857,0.0005682886,0.0009858022,7.8775715e-9,0.00041256813,0.00011916069,0.00053959084,0.00008704443,0.00058740267,0.00014988727],"about_ca_topic_score_codex":0.00038779425,"about_ca_topic_score_gemma":0.00018312146,"teacher_disagreement_score":0.46444106,"about_ca_system_score_codex":0.00017798177,"about_ca_system_score_gemma":0.00021792107,"threshold_uncertainty_score":0.62040186},"labels":[],"label_agreement":null},{"id":"W4417276764","doi":"10.3390/ijms262411988","title":"Canagliflozin Promotes Structural and Functional Changes in Proximal Tubular Cell Mitochondria of Hypertensive–Diabetic Mice","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa","funders":"Kidney Foundation of Canada; University of Ottawa","keywords":"Mitochondrion; Canagliflozin; Kidney; MFN2; Diabetes mellitus; In vivo; Oxidative phosphorylation; Inner mitochondrial membrane; Renal function","score_opus":0.009414913742161623,"score_gpt":0.24921398712403503,"score_spread":0.2397990733818734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417276764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234307,0.0017501318,0.00009226247,0.0042927507,0.0004625176,0.00015325595,0.0000022468435,0.0000025902732,0.00090116437],"genre_scores_gemma":[0.9969447,0.00007529848,0.0023587302,0.00042501304,0.0000386042,0.0000031884276,0.000002045129,0.0000028434722,0.00014953534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990462,0.00002534284,0.00023037959,0.0001296703,0.00045822386,0.00011015705],"domain_scores_gemma":[0.9994302,0.000037302394,0.00014386153,0.00004610611,0.0003029861,0.000039551567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018427128,0.00008154451,0.00018763448,0.00069443573,0.000021552549,0.000030330979,0.0001463372,0.000025080717,0.000019084924],"category_scores_gemma":[0.00006188289,0.000060875813,0.000050224848,0.00026174897,0.00015095166,0.000093582596,0.000056779914,0.00007242979,4.0308063e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029868088,0.00034312284,0.15485072,0.00014086998,0.0006283341,0.00057010003,0.00030699748,0.0002612406,0.8290383,0.0040913858,0.00067689305,0.008793347],"study_design_scores_gemma":[0.0058184094,0.0016312493,0.281859,0.001067749,0.0004036214,0.00017891788,0.0009199923,0.0023311826,0.7003609,0.004028602,0.0011695666,0.00023084132],"about_ca_topic_score_codex":0.000044962377,"about_ca_topic_score_gemma":0.0000316841,"teacher_disagreement_score":0.12867743,"about_ca_system_score_codex":0.000039073122,"about_ca_system_score_gemma":0.00012382453,"threshold_uncertainty_score":0.24824436},"labels":[],"label_agreement":null},{"id":"W4417280320","doi":"10.2215/cjn.0000000951","title":"Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients","year":2025,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; McGill University; St. Michael's Hospital; University Health Network; University of Toronto; Women's College Hospital; Queen's University; University of British Columbia","funders":"University Health Network Foundation","keywords":"Kidney transplant; Kidney; Blood pressure; Kidney transplantation; Renal function; Confidence interval; Randomized controlled trial","score_opus":0.0179845489239491,"score_gpt":0.3118172744019743,"score_spread":0.2938327254780252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417280320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98556894,0.0002392962,0.00038705624,0.013121969,0.00027531903,0.0002757021,0.000011636309,0.000004362268,0.00011572464],"genre_scores_gemma":[0.9766324,0.0036270274,0.0031919267,0.01640847,0.000048939623,0.0000016592044,0.0000033146382,0.000008474785,0.00007778165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998065,0.00017594178,0.0012020738,0.0001625954,0.00020224044,0.00019215913],"domain_scores_gemma":[0.99829763,0.00040276884,0.000861537,0.00022489007,0.00008780292,0.00012534873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008897288,0.0001321432,0.0009859226,0.00007594783,0.000026829024,0.0000021390529,0.00020861476,0.00009289423,0.000011005504],"category_scores_gemma":[0.00006060043,0.00008769884,0.00064589415,0.00029900047,0.0009950355,0.000031283373,0.000061064464,0.00035654102,3.7210148e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013444388,0.0045376443,0.80361277,0.00036777175,0.0044159703,0.000051075356,0.0012374806,0.000017293592,0.029765174,0.00066138466,0.039598938,0.102290116],"study_design_scores_gemma":[0.011806125,0.0029559755,0.96443117,0.0008840598,0.001195996,0.000016678636,0.0003280536,0.000057760084,0.0023522782,0.0007412675,0.015136501,0.00009410844],"about_ca_topic_score_codex":0.000028320072,"about_ca_topic_score_gemma":0.0000049614387,"teacher_disagreement_score":0.16081843,"about_ca_system_score_codex":0.000038727318,"about_ca_system_score_gemma":0.00016567056,"threshold_uncertainty_score":0.36662498},"labels":[],"label_agreement":null},{"id":"W4417292863","doi":"10.1111/dom.70375","title":"Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Trillium Health Centre; Women's College Hospital; University of Toronto; University of British Columbia","funders":"Ministry of Health, British Columbia","keywords":"Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Disease; Kidney disease","score_opus":0.0049636346903255005,"score_gpt":0.19019516505616174,"score_spread":0.18523153036583623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417292863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901933,0.009351317,0.000001722479,0.00005354095,0.00023618482,0.0010218523,0.000033951055,0.00006259088,0.00021950755],"genre_scores_gemma":[0.99573255,0.0020606401,0.00039095466,0.00035471827,0.00003694029,0.000064003136,0.00012558895,0.00002430851,0.0012103042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983806,0.000051407922,0.00039756592,0.0004544211,0.00023785303,0.00047816566],"domain_scores_gemma":[0.9992009,0.00007630202,0.00011031589,0.00031339237,0.00014803318,0.00015106819],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018626159,0.00021481983,0.0007879028,0.00020383179,0.00007439799,0.00013443976,0.000086339176,0.00013856289,0.00005235835],"category_scores_gemma":[0.00004333262,0.0002554117,0.000099193145,0.00059335696,0.0002488615,0.0003253412,0.00006029901,0.00017258483,0.0000025210497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035257777,0.00086145126,0.9644853,0.0007073256,0.00034618445,0.000026916741,0.00021044583,0.0000011353517,0.00029379464,0.00003405081,0.00066213444,0.03233599],"study_design_scores_gemma":[0.0039083133,0.0001436812,0.9821206,0.0018491939,0.00078564807,2.2947448e-7,0.0000947761,0.000056617315,0.0069478224,0.00006402475,0.0038040152,0.00022509578],"about_ca_topic_score_codex":0.0032991725,"about_ca_topic_score_gemma":0.012253851,"teacher_disagreement_score":0.032110892,"about_ca_system_score_codex":0.000025731772,"about_ca_system_score_gemma":0.000051041327,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W4417316044","doi":"10.1016/j.diabres.2025.112777","title":"Unveiling the blind spots: assessing awareness of complications in T2DM, its impact on glycaemic control and CGM metrics","year":2025,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Diabetes mellitus; Continuous glucose monitoring; Control (management); MEDLINE; Diabetes control","score_opus":0.14998654036477604,"score_gpt":0.5538718062280552,"score_spread":0.40388526586327916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417316044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728135,0.003589733,0.000042216256,0.012459958,0.000053342403,0.0008694999,0.000010992925,0.000013045289,0.010147753],"genre_scores_gemma":[0.9966265,0.0018714983,0.00018051275,0.0009793999,0.00003726792,0.000049380764,0.000014088979,0.000009299206,0.00023203141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778795,0.0005925264,0.0004986954,0.00034431776,0.00040363948,0.0003728487],"domain_scores_gemma":[0.97485006,0.024072144,0.0001346027,0.00036164274,0.00043637122,0.00014516673],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005053316,0.00012412449,0.00040319003,0.00040097034,0.00017209077,0.00012471687,0.00013685747,0.0000975165,0.0000126069635],"category_scores_gemma":[0.013967238,0.00007792633,0.00007313106,0.0009611308,0.00029981908,0.00024522198,0.00013332142,0.00067400315,0.000010966317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011324434,0.0026363756,0.84126586,0.0002697404,0.00089051836,0.00001676921,0.000044732333,0.000014322715,0.00031520435,0.0035969734,0.0009843212,0.14883274],"study_design_scores_gemma":[0.005997145,0.0012582834,0.97715884,0.00039347028,0.00034262062,7.214231e-7,0.0006059047,0.006555961,0.0001932426,0.00091180665,0.0064907046,0.000091282665],"about_ca_topic_score_codex":0.00005631952,"about_ca_topic_score_gemma":0.0000060797506,"teacher_disagreement_score":0.14874145,"about_ca_system_score_codex":0.00007464685,"about_ca_system_score_gemma":0.00020590793,"threshold_uncertainty_score":0.9943385},"labels":[],"label_agreement":null},{"id":"W4417319939","doi":"10.1111/dom.70382","title":"Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Exenatide; MEDLINE; Clinical trial; Randomized controlled trial; Glucagon-like peptide 1 receptor; Meta-analysis","score_opus":0.031821337890528704,"score_gpt":0.28201902779756494,"score_spread":0.2501976899070362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417319939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94832486,0.048431944,0.00003805123,0.00055732956,0.000117046395,0.001616077,0.00007345262,0.000075061034,0.0007661896],"genre_scores_gemma":[0.9865246,0.009442304,0.00044765722,0.0005876439,0.00002690548,0.0003119045,0.00019518133,0.0000125529605,0.0024512855],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972565,0.0009118944,0.0008216607,0.00051076186,0.0002465673,0.00025257294],"domain_scores_gemma":[0.99461913,0.0041057444,0.0005880587,0.00031597904,0.00021577974,0.0001552983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014180549,0.00034649976,0.004519275,0.0008881964,0.00025861745,0.00009421438,0.00006240725,0.00012618599,0.00007169657],"category_scores_gemma":[0.0014762377,0.00022002686,0.00059469615,0.0010698256,0.00022273566,0.00026555994,0.0000763972,0.0001659876,0.0000012735667],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005320226,0.0011209171,0.25498244,0.00035851344,0.7236348,0.000011483859,0.0010517059,0.000021388161,0.0082904585,0.0028629133,0.000917679,0.0014275111],"study_design_scores_gemma":[0.03554237,0.00010691299,0.4457746,0.000207123,0.5131241,1.9141906e-7,0.00015073284,0.000281626,0.0025531452,0.00046590072,0.001568118,0.00022513444],"about_ca_topic_score_codex":0.0006934813,"about_ca_topic_score_gemma":0.0007063381,"teacher_disagreement_score":0.21051063,"about_ca_system_score_codex":0.0000344665,"about_ca_system_score_gemma":0.000057429344,"threshold_uncertainty_score":0.89724356},"labels":[],"label_agreement":null},{"id":"W4417419703","doi":"10.1007/s11255-025-04965-6","title":"SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients","year":2025,"lang":"en","type":"article","venue":"International Urology and Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Generalitat Valenciana","keywords":"Inflammation; Diabetes mellitus; Nephrology; Renal function; Kidney disease; Systemic inflammation","score_opus":0.002661542151948849,"score_gpt":0.20710190036900575,"score_spread":0.2044403582170569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417419703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926721,0.0013913125,0.0000020595523,0.004422155,0.00015278684,0.00028097397,0.000003675153,0.000011764095,0.0010631636],"genre_scores_gemma":[0.9976669,0.0002609437,0.000044377506,0.001828799,0.000044274424,0.00005491967,0.000035828954,0.0000059905083,0.000057963294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921083,0.000048138187,0.0002242812,0.00028489088,0.00004214518,0.00018972426],"domain_scores_gemma":[0.99964964,0.00016296371,0.000053117034,0.00006563313,0.000029917019,0.00003870789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016855782,0.0001318847,0.00024106425,0.00044957915,0.000033710658,0.000014795947,0.000035535133,0.00013087626,0.00000788159],"category_scores_gemma":[0.00006252572,0.000114879374,0.000013241759,0.000078150464,0.00016508115,0.00011417854,0.00013344329,0.00013240139,9.7304e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012629744,0.0000805424,0.9650085,0.000031660013,0.00012192405,0.0000048153015,0.00047131555,0.000004106813,0.003650978,0.00089057727,0.000066416185,0.02954287],"study_design_scores_gemma":[0.0029538756,0.00043027903,0.9857892,0.000047244932,0.000048698173,0.0000016023573,0.00005812618,0.00286837,0.0011139944,0.0049293074,0.0016807017,0.00007861071],"about_ca_topic_score_codex":0.000024114006,"about_ca_topic_score_gemma":0.000086883054,"teacher_disagreement_score":0.02946426,"about_ca_system_score_codex":0.000022683644,"about_ca_system_score_gemma":0.000011714574,"threshold_uncertainty_score":0.4684645},"labels":[],"label_agreement":null},{"id":"W4417437434","doi":"10.1016/j.jcjd.2025.12.009","title":"Use of Second-line Diabetes Mellitus Medications and Adverse Events Among Older Adults After the Introduction of Glucagon-like Peptide-1 Receptor Agonists in Ontario, Canada: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ontario Drug Policy Research Network; St. Michael's Hospital; Toronto Rehabilitation Institute; Women's College Hospital","funders":"Canada Research Chairs; University of Toronto; Women's College Hospital; Ontario Ministry of Health and Long-Term Care","keywords":"Metformin; Retrospective cohort study; Adverse effect; Diabetes mellitus; Drug class; Drug","score_opus":0.005079786922252579,"score_gpt":0.1998720735260305,"score_spread":0.19479228660377793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417437434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965494,0.00080547965,5.5634996e-7,0.0009918198,0.0005119925,0.0010206912,0.000044118256,0.000002605955,0.00007329987],"genre_scores_gemma":[0.9984689,0.000021436601,0.00006282638,0.00017497329,0.000061877196,0.000059859693,0.000030211,0.000013318698,0.001106619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983791,0.00009096718,0.000675586,0.00023241395,0.00030357094,0.000318361],"domain_scores_gemma":[0.99854594,0.00010231498,0.0003765926,0.00031410236,0.00038937354,0.00027166324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004703416,0.00018753584,0.0005970277,0.0004614651,0.000064164,0.000010654131,0.00013024555,0.00005851389,0.0003170114],"category_scores_gemma":[0.00021140487,0.00014366816,0.0000890443,0.0003651573,0.00018693689,0.0001926817,0.000029308845,0.0002765203,3.6583623e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031581563,0.00019234758,0.9928042,0.00008817238,0.0011209031,0.00000771954,0.001068828,0.000009506489,0.000027354088,0.000011424368,0.004007907,0.0006300184],"study_design_scores_gemma":[0.0015378159,0.00037789962,0.9938714,0.0005728941,0.00069300464,2.8964092e-7,0.000923824,0.000015655934,0.00033375013,0.000020832224,0.001556424,0.00009624096],"about_ca_topic_score_codex":0.54453564,"about_ca_topic_score_gemma":0.9942274,"teacher_disagreement_score":0.44969177,"about_ca_system_score_codex":0.001076586,"about_ca_system_score_gemma":0.0018111361,"threshold_uncertainty_score":0.58586174},"labels":[],"label_agreement":null},{"id":"W4417449811","doi":"10.3389/fmed.2025.1639704","title":"Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetic retinopathy; Diabetes mellitus; Receptor; Agonist; Association (psychology)","score_opus":0.012985122570958196,"score_gpt":0.2682259422523864,"score_spread":0.2552408196814282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417449811","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022318587,0.90123963,0.001371577,0.06078603,0.00071161194,0.006864041,0.0000328507,0.000088298846,0.0065873545],"genre_scores_gemma":[0.49107516,0.1634994,0.016043067,0.026977422,0.00014476667,0.0022516055,0.000627356,0.00011496402,0.29926628],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99808675,0.00020533896,0.0007822573,0.00034178604,0.00036224612,0.00022159684],"domain_scores_gemma":[0.998876,0.00014863173,0.00038352594,0.000390118,0.00011289511,0.00008886766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015788627,0.00022301379,0.0034319267,0.00057231274,0.000033606695,0.000008801181,0.00008078094,0.000080859005,0.00009954631],"category_scores_gemma":[0.00076931046,0.00015030324,0.00022965326,0.000980916,0.00010599814,0.00005041953,0.00005518649,0.00011832279,0.0000017634482],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000651827,0.00028558823,0.13123475,0.35409588,0.25725865,0.000021808068,0.0007420548,0.0000010996777,0.00007009415,0.00021837128,0.25565618,0.0003503486],"study_design_scores_gemma":[0.0018345844,0.00028681746,0.007773646,0.010148643,0.9771265,7.092798e-7,0.00046501728,0.00011814423,0.00004484347,0.0001859383,0.0018630868,0.00015208585],"about_ca_topic_score_codex":0.00003361258,"about_ca_topic_score_gemma":0.00001251651,"teacher_disagreement_score":0.7377403,"about_ca_system_score_codex":0.00016861646,"about_ca_system_score_gemma":0.000023199556,"threshold_uncertainty_score":0.61291885},"labels":[],"label_agreement":null},{"id":"W4417468103","doi":"10.1001/jamaoncol.2025.5364","title":"Glucagon-Like Peptide-1 Receptor Agonists and Cancer","year":2025,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Cancer; Agonist; Receptor; Clinical trial; Immunotherapy","score_opus":0.013714749655027057,"score_gpt":0.3210673079292796,"score_spread":0.30735255827425256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417468103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7003303,0.0034165315,0.000030250982,0.04974363,0.0014573601,0.0006230685,0.000007938014,0.00010322516,0.24428767],"genre_scores_gemma":[0.6847149,0.004653039,0.0029444243,0.02994111,0.00045690112,0.000483085,0.00007889431,0.00002827169,0.27669936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933696,0.000028523717,0.00013743839,0.00022225639,0.00006597472,0.00020886802],"domain_scores_gemma":[0.9996155,0.00006920551,0.000039790855,0.00015931782,0.000043202956,0.000072968214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010189872,0.000104017025,0.00026826936,0.0001007097,0.00005236163,0.000017636568,0.000047081445,0.00011204124,0.00037400165],"category_scores_gemma":[0.000033986318,0.0000859079,0.00004278832,0.00012437896,0.00007894728,0.000043062675,0.00008867517,0.00010020877,0.000076138414],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019473177,0.00026144666,0.029049797,0.00011976914,0.0003706138,0.000044027067,0.00015604735,5.4961293e-7,0.0012752821,0.0032860003,0.36615214,0.5990896],"study_design_scores_gemma":[0.0026969116,0.00041879056,0.041536562,0.00007341167,0.0002432784,0.0000022920376,0.000103431536,0.000025699956,0.00065421755,0.0001726692,0.95400715,0.00006555901],"about_ca_topic_score_codex":0.00012347805,"about_ca_topic_score_gemma":0.00010676634,"teacher_disagreement_score":0.59902406,"about_ca_system_score_codex":0.00024963875,"about_ca_system_score_gemma":0.00014859361,"threshold_uncertainty_score":0.4095056},"labels":[],"label_agreement":null},{"id":"W4417481845","doi":"10.1016/j.jval.2025.09.707","title":"EE323 Developing a Multi-Indication Wider Societal Value Model to Estimate the Economic Impact of Semaglutide in Canada","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Economic impact analysis; Semaglutide; Value (mathematics); Economic model; Social impact","score_opus":0.04039985240993782,"score_gpt":0.37305973423590383,"score_spread":0.332659881825966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417481845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901979,0.00022415096,0.0012623398,0.0070503573,0.00007782251,0.00094541546,0.000009768637,0.000010002922,0.00022223272],"genre_scores_gemma":[0.99014425,0.00004878848,0.008298783,0.0012561274,0.000006884408,0.000053777494,0.00001157137,0.000009148319,0.00017065954],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99899966,0.00005314916,0.00038710548,0.0001789885,0.000094270305,0.00028681752],"domain_scores_gemma":[0.99955,0.00008020292,0.000093787654,0.00019747786,0.000013355277,0.00006520387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043437153,0.0001045913,0.00026688792,0.00014860056,0.00003713419,0.000005623645,0.00008382305,0.000022389366,0.0000037473446],"category_scores_gemma":[0.000041945812,0.000078501376,0.000045563207,0.00020884993,0.000013470354,0.00002774209,0.000047656486,0.000083782616,0.0000036287631],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00002453986,0.00003836332,0.13760455,0.000255337,0.000071393086,0.000002391714,0.0006675347,0.8534981,0.000018743516,0.0021201763,0.0010406735,0.004658185],"study_design_scores_gemma":[0.0008616586,0.000046323257,0.31892425,0.00036376202,0.000015125964,3.607811e-7,0.000110991146,0.6791378,0.000060792492,0.00037572448,0.000050590126,0.00005257326],"about_ca_topic_score_codex":0.8792262,"about_ca_topic_score_gemma":0.54321545,"teacher_disagreement_score":0.33601078,"about_ca_system_score_codex":0.00783582,"about_ca_system_score_gemma":0.008585204,"threshold_uncertainty_score":0.9970352},"labels":[],"label_agreement":null},{"id":"W4417492588","doi":"10.1038/s43587-025-01029-3","title":"Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders","year":2025,"lang":"en","type":"review","venue":"Nature Aging","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Neuroinflammation; Repurposing; Disease; Dementia; Cognitive decline; Drug repositioning; Clinical trial; Neuroprotection; Cognitive impairment","score_opus":0.019848946974416228,"score_gpt":0.3412384893812972,"score_spread":0.32138954240688095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417492588","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009497248,0.990964,0.00008916619,0.00048192553,0.0014536018,0.0047028726,0.00006868121,0.000059793696,0.002170479],"genre_scores_gemma":[0.000020991267,0.9791665,0.0010240045,0.00022309681,0.00032096697,0.0008993099,0.0005826591,0.000058649683,0.017703842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983712,0.00007050321,0.00045320418,0.00056019606,0.00021776264,0.00032714976],"domain_scores_gemma":[0.9982063,0.00068115344,0.00032573732,0.00064980483,0.00008160436,0.000055377113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013383046,0.00051118643,0.0014756538,0.00023080454,0.00018199318,0.000041865962,0.00018488942,0.00029321146,0.000015097544],"category_scores_gemma":[0.00006830725,0.00028766567,0.0010275097,0.0003867415,0.000061551,0.00003921748,0.000053061132,0.00030445738,0.0000044747585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021584214,0.0002664695,0.000012321127,0.010052283,0.0017595537,0.0000036889737,0.00015406431,0.0000016923525,0.0000011873976,0.00033281796,0.0072678844,0.98012644],"study_design_scores_gemma":[0.0008118603,0.00044378702,0.0000046677515,0.00918408,0.0076879445,0.0000013937878,0.000041258445,0.000013577946,0.00004869778,0.000017723713,0.9815543,0.00019065425],"about_ca_topic_score_codex":0.000013764163,"about_ca_topic_score_gemma":0.000021373215,"teacher_disagreement_score":0.9799358,"about_ca_system_score_codex":0.00031549556,"about_ca_system_score_gemma":0.00021817672,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W4417497606","doi":"10.1056/nejmoa2505928","title":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Type 2 diabetes; Diabetes mellitus; Heart failure; Blood pressure; Natriuretic peptide","score_opus":0.013670896312759593,"score_gpt":0.26236037194484024,"score_spread":0.24868947563208066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417497606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691963,0.009660253,0.00009281496,0.009391316,0.0010039493,0.00022319813,3.2319085e-7,0.000014746992,0.010417059],"genre_scores_gemma":[0.9956215,0.0007704899,0.0006813944,0.00059541303,0.00048508067,0.0000019721735,0.000005425273,0.000011985384,0.0018267113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988379,0.00004694283,0.0003569176,0.000120202734,0.00043277015,0.00020526371],"domain_scores_gemma":[0.99920386,0.00019531259,0.00010159672,0.00023545059,0.00012737475,0.00013641494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000597434,0.0001521424,0.0007659116,0.0004089083,0.000019094019,0.00000618989,0.00008701786,0.00003613956,0.000065206696],"category_scores_gemma":[0.00034900694,0.00008390885,0.000115826886,0.00038810342,0.000057333025,0.00006300446,0.00002094241,0.00018877082,0.0000039555975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022641579,0.000147304,0.6839803,0.00011776526,0.004292838,0.00069028646,0.00025335408,0.00015928964,0.00009391124,0.00032894342,0.0081149265,0.2995569],"study_design_scores_gemma":[0.2389474,0.005828075,0.49565196,0.002082617,0.0043220744,0.000029050098,0.0002887113,0.00004890783,0.00040931997,0.0003807588,0.25183386,0.00017727383],"about_ca_topic_score_codex":0.00008228242,"about_ca_topic_score_gemma":0.000067909736,"teacher_disagreement_score":0.29937965,"about_ca_system_score_codex":0.00009566063,"about_ca_system_score_gemma":0.0001362418,"threshold_uncertainty_score":0.34217036},"labels":[],"label_agreement":null},{"id":"W4417498343","doi":"10.1016/j.xcrm.2025.102511","title":"Glucagon-like peptide-1 medicines in neurological and psychiatric disorders","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Migraine; Clinical trial; Headache Disorders; Diabetes mellitus; Safety profile; Alternative medicine","score_opus":0.0065479754240115925,"score_gpt":0.25043055539398623,"score_spread":0.24388257996997464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417498343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8059191,0.010309006,0.0000830629,0.026202738,0.001485036,0.0009769647,2.4371556e-7,0.00011267591,0.15491115],"genre_scores_gemma":[0.97523844,0.0030742784,0.00019980161,0.005392775,0.00014833343,0.000056623103,0.00002785369,0.00001673766,0.015845178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824715,0.000031166113,0.0005810687,0.0005317269,0.0002828214,0.00032606628],"domain_scores_gemma":[0.9991227,0.00012828562,0.000133527,0.00042332866,0.00003405135,0.00015812015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040771934,0.00023893708,0.0005434144,0.0005034866,0.00005300014,0.000006674185,0.000056712703,0.00009433598,0.00015825176],"category_scores_gemma":[0.00024043917,0.00015945522,0.00005557688,0.0005940965,0.00022903246,0.000042439962,0.00007910404,0.00020460782,0.000004586372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011699474,0.00046770202,0.9101583,0.00040843125,0.000062417916,0.0013326021,0.00015964039,0.0000032354615,0.00021636522,0.00019873831,0.05400626,0.03286936],"study_design_scores_gemma":[0.003957099,0.0012720473,0.71575314,0.0003832312,0.0006714968,0.00007899724,0.00031759866,0.0001507807,0.00004520368,0.0022417216,0.27494398,0.00018467556],"about_ca_topic_score_codex":0.00008974047,"about_ca_topic_score_gemma":0.000062886655,"teacher_disagreement_score":0.22093773,"about_ca_system_score_codex":0.00002410223,"about_ca_system_score_gemma":0.000053212516,"threshold_uncertainty_score":0.65023947},"labels":[],"label_agreement":null},{"id":"W4417517383","doi":"10.1186/s13195-025-01929-x","title":"Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study","year":2025,"lang":"en","type":"article","venue":"Alzheimer s Research & Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; University of Ottawa; Toronto General Hospital; University of Toronto; University Health Network; Canada Research Chairs; Toronto Rehabilitation Institute; University of Waterloo; Sunnybrook Health Science Centre","funders":"Temerty Faculty of Medicine, University of Toronto; Canadian Institutes of Health Research; Novo Nordisk; University of Toronto; Canada Excellence Research Chairs, Government of Canada; Canada Research Chairs; Ministry of Colleges and Universities; Alzheimer's Drug Discovery Foundation","keywords":"Dementia; Cohort study; Diabetes mellitus; Cohort; Confidence interval; Type 2 diabetes; Type 2 Diabetes Mellitus; Lower risk","score_opus":0.07011970409647994,"score_gpt":0.39070530839593015,"score_spread":0.3205856042994502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417517383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772911,0.007215621,0.000043108783,0.0016524837,0.00025385796,0.0096462825,0.000021922022,0.00019436485,0.0036812355],"genre_scores_gemma":[0.9939753,0.00045020823,0.0007806534,0.00029976302,0.00019936195,0.0015593624,0.00029626006,0.000047536403,0.0023915526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959117,0.0007162005,0.0004884495,0.00079414516,0.0013583818,0.0007311171],"domain_scores_gemma":[0.9978673,0.00040453955,0.00013730393,0.0008491004,0.0005120483,0.00022972703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014714922,0.0003892643,0.0006896868,0.0006505282,0.0005565698,0.0001868253,0.0002606971,0.00009534524,0.00064097013],"category_scores_gemma":[0.00005176958,0.00025546813,0.00012676751,0.0014898346,0.00021081294,0.00017570137,0.00010616729,0.0005072273,0.0001734578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003774598,0.0036663369,0.89561296,0.00002291807,0.014382098,0.000039392828,0.00068030116,0.000017342285,0.00018475548,0.00006386155,0.06490802,0.016647398],"study_design_scores_gemma":[0.017997598,0.0103937555,0.80566275,0.0004267419,0.0027028546,8.2362556e-7,0.0023713096,0.00029100644,0.013195934,0.00007474812,0.14630954,0.000572928],"about_ca_topic_score_codex":0.0023479355,"about_ca_topic_score_gemma":0.000607972,"teacher_disagreement_score":0.08995021,"about_ca_system_score_codex":0.00020909878,"about_ca_system_score_gemma":0.00044495796,"threshold_uncertainty_score":0.99998975},"labels":[],"label_agreement":null},{"id":"W4417524227","doi":"10.18773/austprescr.2025.052","title":"Injectable drugs for weight management","year":2025,"lang":"en","type":"article","venue":"Australian Prescriber","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Fitness and Lifestyle Research Institute","funders":"","keywords":"Incretin; Weight loss; Gallstones; Adverse effect; Obesity; Weight management; Gastric emptying; Diabetes mellitus; Type 2 diabetes","score_opus":0.01537245816436248,"score_gpt":0.28234104151769207,"score_spread":0.26696858335332957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417524227","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061825354,0.00027731975,0.0007459668,0.016761068,0.001118572,0.004659575,0.000026844824,0.00034436927,0.91424096],"genre_scores_gemma":[0.24784477,0.000030956133,0.0049739177,0.001348198,0.00006111268,0.00040265286,0.00007385376,0.00001625519,0.74524826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990313,0.000009378265,0.00018364149,0.00029134096,0.00012874772,0.00035560934],"domain_scores_gemma":[0.9994745,0.000019989522,0.000027657807,0.00036324462,0.000039723614,0.0000748805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009480146,0.00015567295,0.00020657043,0.00015791363,0.00006481413,0.00003659916,0.000100011646,0.00005373632,0.00034817608],"category_scores_gemma":[0.000005694604,0.00013375285,0.00012528268,0.00018860647,0.0000302405,0.00008634663,0.00007186572,0.000055978817,0.00011945656],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015303481,0.00031257235,0.0033252889,0.0005733363,0.0010244428,0.000025417343,0.00008573938,0.000002613995,0.00012721449,0.04895668,0.90382296,0.041590676],"study_design_scores_gemma":[0.0032177952,0.00013441856,0.007531435,0.00018014648,0.0008785871,7.54345e-7,0.00015400937,0.000016400956,0.005890125,0.0025920828,0.9792719,0.00013236991],"about_ca_topic_score_codex":0.000018802646,"about_ca_topic_score_gemma":0.000002383782,"teacher_disagreement_score":0.18601942,"about_ca_system_score_codex":0.00007785112,"about_ca_system_score_gemma":0.000015997737,"threshold_uncertainty_score":0.5454283},"labels":[],"label_agreement":null},{"id":"W4417528741","doi":"10.1139/cjpp-2025-0152","title":"Current clinical application of incretin therapy for obesity management","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Incretin; Weight loss; Semaglutide; Obesity; Type 2 diabetes; Exenatide; Weight management; Diabetes mellitus","score_opus":0.0222722394515202,"score_gpt":0.36940231913837335,"score_spread":0.34713007968685317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417528741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925261,0.0035513728,0.00052757,0.0013541185,0.0008445757,0.00059426826,0.000007457528,0.0000025948962,0.00059194927],"genre_scores_gemma":[0.9967383,0.0015402926,0.0002837924,0.0011424414,0.00013581192,0.000024518646,0.000011002743,0.0000033125052,0.00012054135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99938154,0.000062580904,0.00029302764,0.000103575585,0.000023413892,0.00013587537],"domain_scores_gemma":[0.9994768,0.000081096485,0.00014774215,0.00006312392,0.00009839024,0.00013286268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002912486,0.000067870016,0.00029062017,0.00018005939,0.000044442746,0.0000014646612,0.000070995535,0.00005291982,0.00008978165],"category_scores_gemma":[0.0000072625962,0.000055356057,0.000091365386,0.00007036598,0.00014614577,0.000017808425,0.00001144147,0.000104397484,0.0000010930198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002478203,0.0010409486,0.25334877,0.0014912627,0.003934917,0.000028774766,0.00015118437,0.000016494341,0.05640609,0.022733716,0.06967336,0.5886963],"study_design_scores_gemma":[0.0093558105,0.0015924708,0.4907967,0.00007181547,0.0010351881,0.000004476039,0.000041177023,0.00014156151,0.015758893,0.007478506,0.47362527,0.00009815237],"about_ca_topic_score_codex":0.00003087706,"about_ca_topic_score_gemma":0.00004066263,"teacher_disagreement_score":0.58859813,"about_ca_system_score_codex":0.0000297225,"about_ca_system_score_gemma":0.00016735174,"threshold_uncertainty_score":0.22573546},"labels":[],"label_agreement":null},{"id":"W4417535609","doi":"10.1016/j.molmet.2025.102311","title":"Loss of GLP-2R signaling in Glp2r−/− mice increases the long-term severity of graft versus host disease","year":2025,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Diabetes Canada","keywords":"Context (archaeology); Signal transduction; Function (biology); Endogeny; Loss function; Disease","score_opus":0.008586165008414151,"score_gpt":0.26268112935287363,"score_spread":0.2540949643444595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417535609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98628706,0.011390205,0.00015242017,0.00049937284,0.00016872484,0.0005704693,0.000021766942,0.00001874579,0.00089120946],"genre_scores_gemma":[0.998925,0.00020880526,0.00016907125,0.0003569652,0.000022921615,0.00003921501,0.000041198226,0.000013773512,0.00022310078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887466,0.000104371655,0.0003014206,0.00022888723,0.0002773364,0.00021331718],"domain_scores_gemma":[0.99921167,0.00008272031,0.000101552716,0.00044356938,0.0000789933,0.00008151165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020224231,0.00016935685,0.00040812956,0.00018375479,0.000027709484,0.000010739536,0.00017573725,0.00003492876,0.00003486731],"category_scores_gemma":[0.00015586261,0.00012657941,0.00019303014,0.0004157139,0.0001252384,0.00004786198,0.00014316117,0.00009132812,0.0000036042459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007819207,0.0067982576,0.6903224,0.004005408,0.0057197665,0.0021769952,0.0007721927,0.00022743507,0.22348002,0.035380144,0.0006271442,0.022671029],"study_design_scores_gemma":[0.0054575615,0.000056762263,0.90372264,0.00037376749,0.0022175068,5.762439e-7,0.000058658927,0.000039164686,0.086713865,0.0002719188,0.00094723864,0.00014033739],"about_ca_topic_score_codex":0.0002956528,"about_ca_topic_score_gemma":0.000026539996,"teacher_disagreement_score":0.21340023,"about_ca_system_score_codex":0.0000296566,"about_ca_system_score_gemma":0.00008527728,"threshold_uncertainty_score":0.51617587},"labels":[],"label_agreement":null},{"id":"W45432023","doi":"10.1055/s-0032-1305284","title":"Langzeitwirkung von Dapagliflozin bei Typ-2-Diabetikern unter hoch dosierter Insulintherapie","year":2013,"lang":"de","type":"article","venue":"DMW - Deutsche Medizinische Wochenschrift","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Gynecology; Dapagliflozin; Diabetes mellitus; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.013024223229864624,"score_gpt":0.24392119782826988,"score_spread":0.23089697459840525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W45432023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5941619,0.26753527,0.0006130951,0.030301897,0.013863871,0.009392428,0.000379369,0.0015930622,0.08215908],"genre_scores_gemma":[0.9304632,0.012633889,0.006039829,0.016561247,0.0085440315,0.0014570684,0.0023365228,0.00080147246,0.021162746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906388,0.00054646423,0.0018784637,0.0021240627,0.0018719211,0.0029403255],"domain_scores_gemma":[0.9937948,0.00065166556,0.00069812045,0.002579016,0.0006126363,0.0016637924],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0012437318,0.0019723692,0.0022576135,0.0008411727,0.00042468435,0.000583392,0.0011714757,0.0012995341,0.009019734],"category_scores_gemma":[0.0005109609,0.0016571629,0.0009510626,0.0010885703,0.0007115382,0.0008145043,0.0007807919,0.0019613255,0.06508672],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021497093,0.008521888,0.07271762,0.0030734509,0.03965457,0.0013615135,0.012795227,0.000015137514,0.05118141,0.006027702,0.6673587,0.13514309],"study_design_scores_gemma":[0.010158431,0.002160598,0.006863524,0.0014172714,0.0071674446,0.000008000454,0.0010258071,0.0005283085,0.031184854,0.00014107829,0.9373423,0.0020024069],"about_ca_topic_score_codex":0.0002979119,"about_ca_topic_score_gemma":0.000028641674,"teacher_disagreement_score":0.33630127,"about_ca_system_score_codex":0.00019714635,"about_ca_system_score_gemma":0.0003585291,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W47783099","doi":"10.1056/nejmclde0708469","title":"Management of Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; MEDLINE; Endocrinology","score_opus":0.020506639275605237,"score_gpt":0.25926113379064775,"score_spread":0.23875449451504252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W47783099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96951944,0.0044875266,0.000066978064,0.0038472228,0.0005832139,0.00014637677,3.243938e-7,0.00001026723,0.02133865],"genre_scores_gemma":[0.98831624,0.003376687,0.0018271906,0.00028443214,0.0010094614,5.4744714e-7,0.0000045520974,0.00001127189,0.0051696477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989357,0.00001988672,0.00040113262,0.00007499551,0.0004211061,0.00014720108],"domain_scores_gemma":[0.9992587,0.00004772966,0.00022032224,0.00014860072,0.00014402627,0.00018059654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031035682,0.0001058041,0.00044239502,0.00018432406,0.000020838062,0.0000012132376,0.0000818614,0.000024768435,0.00032846778],"category_scores_gemma":[0.000040705043,0.00006413808,0.00006780705,0.0001977774,0.000086804386,0.000048083744,0.000021846896,0.00009926446,0.000008662712],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014053812,0.000666696,0.1713451,0.0006110989,0.003249967,0.003434407,0.0013699428,0.00002962589,0.0028140184,0.0016860547,0.12455295,0.6888347],"study_design_scores_gemma":[0.15986246,0.015353882,0.26235294,0.0034580568,0.0035042847,0.0006955252,0.00048544185,0.00005310974,0.0043069758,0.0013144712,0.5483559,0.00025699762],"about_ca_topic_score_codex":0.000005939686,"about_ca_topic_score_gemma":4.1699474e-7,"teacher_disagreement_score":0.6885778,"about_ca_system_score_codex":0.000026973146,"about_ca_system_score_gemma":0.000038796494,"threshold_uncertainty_score":0.3596492},"labels":[],"label_agreement":null},{"id":"W60888570","doi":"10.1007/0-306-47920-6_35","title":"Glucose-dependent Insulinotropic Polypeptide (GIP): Development of DP IV-Resistant Analogues with Therapeutic Potential","year":2005,"lang":"en","type":"article","venue":"Kluwer Academic Publishers eBooks","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Endocrinology; Internal medicine; Chemistry; Medicine","score_opus":0.014773045617124897,"score_gpt":0.24143167864541704,"score_spread":0.22665863302829214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W60888570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94983876,0.0017420452,0.0009577551,0.0011947588,0.00021529246,0.0010677243,0.000008040395,0.0002481915,0.044727456],"genre_scores_gemma":[0.98127234,0.000026143305,0.005882701,0.0012633093,0.00023152771,0.00009837687,0.00006983383,0.00006579196,0.01108998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710864,0.000052080126,0.000729577,0.00053489173,0.00091022684,0.00066458265],"domain_scores_gemma":[0.998781,0.000030065567,0.00028449798,0.0004664652,0.00015064218,0.0002873297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003515921,0.00039995596,0.00056112465,0.00038606802,0.000117837604,0.000094533374,0.00037802747,0.00024796845,0.00012849703],"category_scores_gemma":[0.00001735958,0.00029892326,0.00013503981,0.00016250154,0.00017752657,0.00044868965,0.00014778174,0.0005392201,0.000050375373],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029338638,0.0011512733,0.029256873,0.00051193655,0.0054699266,0.00017919551,0.006074227,0.00007617974,0.078144684,0.0028501225,0.012865806,0.8604859],"study_design_scores_gemma":[0.023567865,0.0022572374,0.17419627,0.0009808335,0.0031235632,0.000072277115,0.0023644331,0.00038348293,0.15243664,0.000649298,0.638048,0.001920084],"about_ca_topic_score_codex":0.000039152237,"about_ca_topic_score_gemma":0.000055292225,"teacher_disagreement_score":0.8585658,"about_ca_system_score_codex":0.00035499583,"about_ca_system_score_gemma":0.00037029808,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W6887599127","doi":"10.17169/refubium-41794","title":"Glucagon responses and regulation in people with or without Type 2 Diabetes (T2DM)","year":2024,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Technische Universität Berlin; Bundesministerium für Ernährung und Landwirtschaft; Universität Hamburg; University of Cincinnati; China Scholarship Council; Eberhard Karls Universität Tübingen; Zhejiang Chinese Medical University; McGill University; Bundesministerium für Bildung und Forschung","keywords":"Glucagon; Postprandial; Type 2 diabetes; Glucagon-like peptide-1; Diabetes mellitus; Meal; Insulin","score_opus":0.013997962467124295,"score_gpt":0.27107019978041136,"score_spread":0.25707223731328704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6887599127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982877,0.00060387544,0.000017160468,0.001053358,0.000053786716,0.0003225077,5.615042e-7,0.000105769956,0.008014239],"genre_scores_gemma":[0.94180965,0.00008058135,0.00069250906,0.00016241767,0.00002654536,0.000021814876,0.0000146702905,0.000013236402,0.057178557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995303,0.00001322138,0.00007791883,0.00016556996,0.00009298002,0.000120020355],"domain_scores_gemma":[0.99977493,0.000058108148,0.000008597413,0.000104071914,0.000016116646,0.00003815154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009268117,0.00008107551,0.0001389916,0.00014832037,0.00001409022,0.00003627118,0.000013875889,0.000023592716,0.00022857524],"category_scores_gemma":[0.00001830255,0.000045486166,0.000009959002,0.00027276532,0.000020014164,0.000086947366,0.00001748467,0.000034923887,0.00003073512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013658467,0.00013983475,0.94919777,0.0004512933,0.00020479978,0.000056233795,0.0006271348,0.0000025524682,0.0018895398,0.0019446557,0.0034401568,0.04068017],"study_design_scores_gemma":[0.0021894244,0.0024937268,0.9411805,0.0007170526,0.00032875795,0.000007187872,0.00034691644,0.004819548,0.005609628,0.00019178547,0.041908886,0.00020658084],"about_ca_topic_score_codex":0.000027950402,"about_ca_topic_score_gemma":0.00032497547,"teacher_disagreement_score":0.049164318,"about_ca_system_score_codex":0.000031282667,"about_ca_system_score_gemma":0.000040938576,"threshold_uncertainty_score":0.25027385},"labels":[],"label_agreement":null},{"id":"W6891641872","doi":"10.48336/hems-sk50","title":"Incretin-based therapies in patients with Type 2 diabetes mellitus and renal impairment","year":2023,"lang":"en","type":"article","venue":"Memorial University Research Repository (Memorial University)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Glycated hemoglobin; Cohort; Incretin; Type 2 Diabetes Mellitus; Diabetes mellitus; Placebo; Kidney disease; Hazard ratio; Saxagliptin","score_opus":0.014790364824486072,"score_gpt":0.2308545247041543,"score_spread":0.21606415987966823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6891641872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962027,0.000033462435,0.0000023673445,0.000251341,0.00078491704,0.001029079,0.000010503404,0.00015691346,0.008111163],"genre_scores_gemma":[0.9901019,0.00009302842,0.00013223868,0.000014819213,0.00045267263,8.194676e-7,0.000106899985,0.000025242643,0.009072415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997308,0.00043840462,0.0001455521,0.0005775216,0.00084922626,0.00068126223],"domain_scores_gemma":[0.9985987,0.0002452652,0.0000701625,0.00038945436,0.00039027465,0.00030617052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055626413,0.00023542308,0.00038811227,0.0015390742,0.00047718978,0.00006789182,0.0002824622,0.0001439924,0.000036104717],"category_scores_gemma":[0.00005196547,0.00022586029,0.00008263363,0.002290522,0.00040072936,0.00028440135,0.0003224908,0.00035510116,0.000035464393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03282409,0.00185107,0.93999904,0.0003697915,0.0011743786,0.004991134,0.0011265901,0.00015483203,0.0036209861,0.0018734834,0.00814497,0.003869634],"study_design_scores_gemma":[0.055454236,0.013304849,0.7185644,0.00061857974,0.00070582825,0.0000016797206,0.0038035817,0.00058876723,0.0061111073,0.000095362935,0.19976096,0.0009906311],"about_ca_topic_score_codex":0.00032414714,"about_ca_topic_score_gemma":0.00006346904,"teacher_disagreement_score":0.22143462,"about_ca_system_score_codex":0.000763059,"about_ca_system_score_gemma":0.00036487787,"threshold_uncertainty_score":0.92103153},"labels":[],"label_agreement":null},{"id":"W6892438620","doi":"10.5281/zenodo.10197109","title":"Wissenschaftliche Begleitevaluation SWICA Disease-Management-Programm Diabetes Mellitus: Studienprotokoll für Follow-Up-Jahr 2022","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Diabetology; Guideline; Diabetes mellitus; Disease; Disease management; Diabetes management; Quality of life (healthcare)","score_opus":0.04277691834500869,"score_gpt":0.2949442073906072,"score_spread":0.25216728904559854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6892438620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72502977,0.0021894171,0.00055601343,0.0125200795,0.0010426637,0.015561458,0.0005501798,0.01093226,0.23161815],"genre_scores_gemma":[0.9695891,0.001208972,0.00037027954,0.0004865112,0.00029878615,0.0000070760607,0.010505125,0.0020023056,0.015531806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709755,0.00024832806,0.00035009766,0.0006978636,0.0008818108,0.0007243587],"domain_scores_gemma":[0.99825585,0.000032895492,0.000118675525,0.000760706,0.00044662895,0.0003852562],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009831848,0.00026890164,0.00029031112,0.00054128905,0.001493818,0.00045853833,0.0005136738,0.00005509863,0.0031087326],"category_scores_gemma":[0.0004240744,0.00026067672,0.00015703386,0.0016438301,0.00014345472,0.00023478738,0.0013260389,0.00019405405,0.03704905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000392361,0.0008829613,0.0008694482,0.00084726216,0.0013753296,0.00017585266,0.001031603,0.000056557594,0.0011939007,0.0042314176,0.4078738,0.5810695],"study_design_scores_gemma":[0.002964615,0.0006363263,0.018726157,0.0001396066,0.0004952548,0.0000031127588,0.00060649146,0.0013760589,0.00022096717,0.00050669344,0.9740272,0.00029751193],"about_ca_topic_score_codex":0.000003969991,"about_ca_topic_score_gemma":3.352765e-7,"teacher_disagreement_score":0.580772,"about_ca_system_score_codex":0.00022079654,"about_ca_system_score_gemma":0.000005027544,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W6901789640","doi":"10.6084/m9.figshare.13031570.v1","title":"Additional file 9 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Hazard ratio; Confidence interval; Post-hoc analysis; Proportional hazards model; Percentile; Nomogram","score_opus":0.015146518827201028,"score_gpt":0.23495684005387743,"score_spread":0.2198103212266764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901789640","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16254345,0.001696601,0.000002015533,0.000014960392,0.000012198784,0.0010061724,0.8346365,0.000007578119,0.00008052457],"genre_scores_gemma":[0.7649122,0.000049526854,0.000062045336,0.000019313151,0.00002459297,0.00021680641,0.23460811,0.000015714375,0.00009169749],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978695,0.00042506374,0.00058842875,0.00025330452,0.00070027536,0.00016342771],"domain_scores_gemma":[0.99624914,0.0018884226,0.0007560612,0.00060024054,0.00043378456,0.000072371215],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003634533,0.00017834867,0.0019902163,0.00016954295,0.000029356659,0.000002933909,0.00013779191,0.000079789366,0.0882113],"category_scores_gemma":[0.009153169,0.00012558237,0.0030710332,0.00095080846,0.00004175567,0.000027766062,0.0001553453,0.000090469184,0.00000526463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009839443,0.00069226086,0.002908634,0.0057542115,0.33392712,0.00002041651,0.0008131795,0.003474539,0.000086470405,0.0000036562794,0.64651394,0.0048216106],"study_design_scores_gemma":[0.0123442635,0.002879861,0.7708629,0.0058912453,0.12155106,4.02136e-7,0.00046003342,0.00073018175,0.015574661,0.000015695512,0.06939426,0.00029549134],"about_ca_topic_score_codex":0.000085659754,"about_ca_topic_score_gemma":0.000009765949,"teacher_disagreement_score":0.76795423,"about_ca_system_score_codex":0.000022957176,"about_ca_system_score_gemma":0.00005014523,"threshold_uncertainty_score":0.99919313},"labels":[],"label_agreement":null},{"id":"W6901865200","doi":"10.6084/m9.figshare.13031546.v1","title":"Additional file 1 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Post-hoc analysis; Hazard ratio; Kidney disease; Epidemiology; Diabetes mellitus; Confidence interval; Blood pressure","score_opus":0.015380062873661003,"score_gpt":0.2351149147347514,"score_spread":0.2197348518610904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901865200","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16154079,0.0016806138,0.0000019909298,0.000014938575,0.000012178843,0.0010048075,0.83565694,0.0000075692656,0.00008017582],"genre_scores_gemma":[0.7604627,0.000048931655,0.000062805055,0.000019319756,0.000024594436,0.00022236758,0.23905128,0.000015746766,0.00009225211],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786985,0.00042516866,0.000588012,0.00025338642,0.0007001923,0.00016341967],"domain_scores_gemma":[0.99623346,0.0019027325,0.0007559306,0.0006010424,0.00043447904,0.00007237333],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036322884,0.00017835647,0.0019895572,0.00016952583,0.000029343513,0.0000029275827,0.00013791975,0.00007980079,0.09170493],"category_scores_gemma":[0.009240218,0.00012559557,0.0030708583,0.0009510029,0.0000417444,0.000027740307,0.0001554494,0.00009050399,0.0000053264307],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009601593,0.0006758822,0.0028380095,0.0055696866,0.3262673,0.000019652285,0.0007927378,0.0033910656,0.00008491133,0.00000353618,0.6547099,0.0046871803],"study_design_scores_gemma":[0.012261551,0.0028778557,0.76911855,0.005891673,0.12184369,4.0224762e-7,0.00046121457,0.0007274457,0.015466765,0.0000155264,0.071039595,0.0002957653],"about_ca_topic_score_codex":0.00008636845,"about_ca_topic_score_gemma":0.000009655721,"teacher_disagreement_score":0.76628053,"about_ca_system_score_codex":0.00002295217,"about_ca_system_score_gemma":0.000050248516,"threshold_uncertainty_score":0.9991054},"labels":[],"label_agreement":null},{"id":"W6901872267","doi":"10.60692/h6wm3-77b39","title":"Semaglutide: new dawn for diabetics","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Sitagliptin; Hypoglycemia; Weight loss; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Metformin","score_opus":0.0484141949189111,"score_gpt":0.24283164491144027,"score_spread":0.19441744999252916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901872267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602755,0.0000066298485,0.013360808,0.001031033,0.0010226199,0.0026909597,0.000121609766,0.0014935881,0.019997261],"genre_scores_gemma":[0.98741806,2.0428196e-7,0.00073674665,0.00032031542,0.0001428384,0.00014675266,0.00017703617,0.000013175722,0.011044858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991103,0.000007197623,0.00032953883,0.00009683951,0.0002009664,0.0002551919],"domain_scores_gemma":[0.99941623,0.000010097387,0.00010356737,0.00026439328,0.000082608356,0.00012310508],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017582714,0.00012470482,0.00020898537,0.00019897684,0.00006829903,0.00007232916,0.000058645022,0.000054644417,0.000018291877],"category_scores_gemma":[0.000027266375,0.00009759294,0.000093138566,0.00026495734,0.000009732009,0.00016694567,0.000038613198,0.00002948614,0.0027332844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031410664,0.000014437489,0.6754387,0.006547814,0.0010862132,0.00002176568,0.07933206,0.00022643586,0.00000916415,0.004760755,0.19493571,0.037312802],"study_design_scores_gemma":[0.02243798,0.0010825632,0.596319,0.0013508992,0.0014549567,0.000025933448,0.030623801,0.026283162,0.0032760298,0.00003697513,0.31613368,0.00097500836],"about_ca_topic_score_codex":0.00000179787,"about_ca_topic_score_gemma":4.8253522e-8,"teacher_disagreement_score":0.12119796,"about_ca_system_score_codex":0.0000823645,"about_ca_system_score_gemma":0.000033727665,"threshold_uncertainty_score":0.9980432},"labels":[],"label_agreement":null},{"id":"W6901959012","doi":"10.6084/m9.figshare.13031555","title":"Additional file 4 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Proportional hazards model; Semaglutide; Hazard ratio; Epidemiology; Kidney disease; Framingham Risk Score; Blood pressure; Adverse effect","score_opus":0.015238405184241386,"score_gpt":0.23514182141309953,"score_spread":0.21990341622885815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901959012","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16202463,0.001696092,0.0000020151715,0.000014862878,0.00001219686,0.0010065904,0.83515555,0.000007577299,0.00008050083],"genre_scores_gemma":[0.76450855,0.00004933514,0.00006187474,0.000019229396,0.000024503279,0.00021745151,0.23501295,0.000015663949,0.000090454036],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978698,0.00042473766,0.0005884504,0.0002533076,0.00070028374,0.0001634253],"domain_scores_gemma":[0.99625,0.0018905122,0.0007561601,0.00060050184,0.00043046824,0.00007237117],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036334715,0.00017834472,0.0019901812,0.0001695466,0.000029354742,0.0000029346102,0.00013793354,0.00007980077,0.088524505],"category_scores_gemma":[0.0091189565,0.00012558806,0.0030708974,0.0009505632,0.00004175412,0.000027763872,0.00015540025,0.00009048424,0.0000052782693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009998174,0.0006932247,0.0029204646,0.005760434,0.3344025,0.000020447218,0.00081385917,0.003433946,0.00008604619,0.0000037276986,0.6459962,0.0048693093],"study_design_scores_gemma":[0.012398898,0.0029257243,0.7700889,0.0059055155,0.12193562,4.0345628e-7,0.00046144956,0.0007324057,0.015508797,0.000015748348,0.069730036,0.00029647705],"about_ca_topic_score_codex":0.00008655686,"about_ca_topic_score_gemma":0.000009753589,"teacher_disagreement_score":0.76716846,"about_ca_system_score_codex":0.000022954218,"about_ca_system_score_gemma":0.000050099166,"threshold_uncertainty_score":0.99922764},"labels":[],"label_agreement":null},{"id":"W6901978496","doi":"10.6084/m9.figshare.12768727.v1","title":"Additional file 1 of Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis","year":2020,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Heart failure with preserved ejection fraction; Quality (philosophy); MEDLINE; Quality assessment","score_opus":0.04833656744933739,"score_gpt":0.30124084593636696,"score_spread":0.25290427848702957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901978496","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057284396,0.080371805,0.00035111234,0.0820184,0.00008432639,0.12688942,0.55632913,0.00010257029,0.09656886],"genre_scores_gemma":[0.14175706,0.002287897,0.3097805,0.0047882097,0.00020616331,0.052200757,0.374736,0.00018228509,0.114061125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999252,0.00005987219,0.0002456548,0.00021375272,0.00015313695,0.00007556794],"domain_scores_gemma":[0.99940807,0.0001637161,0.00015474057,0.00016587456,0.000039695235,0.00006789395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007587782,0.00012629517,0.0010244343,0.000086386484,0.000022156173,0.000021103297,0.000043551754,0.00002390638,0.5209823],"category_scores_gemma":[0.00009727344,0.00006591393,0.00012620245,0.00046743028,0.000013925195,0.00016595017,0.00003720966,0.00003335338,0.00006180609],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023764843,0.0009702292,0.0013068768,0.03812702,0.036500704,0.000058323858,0.00016650253,0.00001750303,0.00002503713,0.0000023625373,0.9215353,0.001052479],"study_design_scores_gemma":[0.0037048366,0.0034962092,0.003835266,0.030295804,0.32676637,0.000017313016,0.0011064175,0.0008218318,0.000988113,0.0000053551735,0.62856495,0.00039752477],"about_ca_topic_score_codex":0.00003172318,"about_ca_topic_score_gemma":0.00013556544,"teacher_disagreement_score":0.5209205,"about_ca_system_score_codex":0.000046996116,"about_ca_system_score_gemma":0.000031153544,"threshold_uncertainty_score":0.47945556},"labels":[],"label_agreement":null},{"id":"W6902014595","doi":"10.6084/m9.figshare.13031567","title":"Additional file 8 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Post-hoc analysis; Proportional hazards model; Percentile; Absolute risk reduction; Framingham Risk Score; Adverse effect","score_opus":0.015136599803031163,"score_gpt":0.234926882579353,"score_spread":0.21979028277632184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902014595","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16299307,0.0016958753,0.000002012693,0.000014951754,0.000012191656,0.0010058838,0.83418757,0.0000075272687,0.0000808947],"genre_scores_gemma":[0.76509976,0.000048950216,0.0000620788,0.000019300767,0.000024572948,0.00021808966,0.23441927,0.000015693366,0.00009225633],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786955,0.000425079,0.0005884319,0.00025333124,0.0007001911,0.00016344074],"domain_scores_gemma":[0.99624854,0.0018886916,0.00075614813,0.00060040236,0.00043380828,0.00007238001],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036352163,0.0001783682,0.0019905057,0.00016950646,0.000029355166,0.000002934446,0.00013788295,0.000079801386,0.08854537],"category_scores_gemma":[0.009153592,0.00012559597,0.0030711007,0.0009503345,0.000041756546,0.000027762755,0.00015538401,0.000090498885,0.00000528481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009842548,0.0006924387,0.0028889582,0.0057564317,0.33408582,0.000020426543,0.0008134472,0.0034761026,0.0000858803,0.0000037042846,0.646256,0.004936518],"study_design_scores_gemma":[0.012400459,0.002896907,0.7697875,0.005916101,0.12207222,4.038434e-7,0.00046185983,0.0007332287,0.01583122,0.000015758334,0.06958758,0.00029677877],"about_ca_topic_score_codex":0.00008718535,"about_ca_topic_score_gemma":0.000009779769,"teacher_disagreement_score":0.7668985,"about_ca_system_score_codex":0.00002296151,"about_ca_system_score_gemma":0.000050171424,"threshold_uncertainty_score":0.9991927},"labels":[],"label_agreement":null},{"id":"W6902055800","doi":"10.6084/m9.figshare.21251474.v1","title":"Additional file 1 of Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Saskatchewan Health Quality Council; Institut National d'Excellence en Santé et en Services Sociaux; University of Manitoba; Memorial University of Newfoundland; University of British Columbia; University of Calgary; Institute for Clinical Evaluative Sciences; McGill University; Jewish General Hospital","funders":"","keywords":"Government (linguistics); Kingdom; MEDLINE; Access to medicines; Medical prescription","score_opus":0.029162434752790782,"score_gpt":0.2232727967747555,"score_spread":0.19411036202196472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902055800","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05466503,0.000018078921,3.3969372e-9,0.00015410925,0.000011566436,0.00019865934,0.94447833,0.0000021435385,0.00047205403],"genre_scores_gemma":[0.245603,0.0000040988994,0.000023869887,0.00014716675,0.000008555726,0.00013018593,0.75374264,0.0000053586277,0.00033512845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994878,0.000022943716,0.0001637516,0.0000641687,0.00018687051,0.00007446931],"domain_scores_gemma":[0.9992656,0.00041635233,0.00014270103,0.000102366794,0.000044803928,0.000028177537],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00001946724,0.000050538947,0.0001771694,0.00006726108,0.000014205296,0.0000012200826,0.000052650917,0.000007932061,0.9400164],"category_scores_gemma":[0.0004046408,0.000039501738,0.000021569213,0.00021865744,0.000009696553,0.0000103546845,0.00008142909,0.000051690356,0.0000027904916],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044692566,0.000037671787,0.00054348406,0.00013821303,0.000046186822,0.0000036153294,0.000078652156,0.0000035962594,0.0000018606464,0.00000817423,0.99685097,0.002242896],"study_design_scores_gemma":[0.0012972677,0.00007290695,0.14901888,0.0008375478,0.000034556553,4.9539705e-7,0.00019840764,0.00014559708,0.00008660099,0.000007740353,0.84825873,0.00004128878],"about_ca_topic_score_codex":0.05392329,"about_ca_topic_score_gemma":0.010095078,"teacher_disagreement_score":0.94001365,"about_ca_system_score_codex":0.00007567609,"about_ca_system_score_gemma":0.00041625818,"threshold_uncertainty_score":0.9523767},"labels":[],"label_agreement":null},{"id":"W6902071306","doi":"10.6084/m9.figshare.15087347","title":"Additional file 1 of Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"MEDLINE; Clinical trial; Data collection; Disease","score_opus":0.023296825477784663,"score_gpt":0.28064438308107664,"score_spread":0.257347557603292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902071306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7866056,0.00018541302,0.000015766873,0.0000770261,0.000029963978,0.00044834195,0.20962472,0.000002763821,0.0030104024],"genre_scores_gemma":[0.73306197,0.0001389981,0.0045402357,0.00010502531,0.000057956207,0.0002212435,0.25796184,0.000055091004,0.0038576117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832445,0.000023003582,0.00044027233,0.00045062034,0.00051787944,0.00024376615],"domain_scores_gemma":[0.9984801,0.0001926663,0.00016991842,0.0009487016,0.00014455356,0.0000640713],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020485345,0.00019327713,0.0010089473,0.00013610534,0.00003445856,0.000046273497,0.0002981108,0.00005518398,0.17497522],"category_scores_gemma":[0.00004826307,0.00015488532,0.00024221498,0.0005590097,0.00013046934,0.00027470125,0.00024817424,0.00006866875,0.000027574692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001476447,0.0033106792,0.7271416,0.00044129477,0.09057683,0.00078304094,0.003643055,0.00044587124,0.0002391088,0.000014809017,0.10466804,0.0672592],"study_design_scores_gemma":[0.00629745,0.00020259968,0.49743035,0.00091757317,0.0075756344,0.0000020245486,0.00177049,0.00023606588,0.0077150227,0.0000031268537,0.4775123,0.00033737454],"about_ca_topic_score_codex":0.0009114724,"about_ca_topic_score_gemma":0.0070851524,"teacher_disagreement_score":0.37284425,"about_ca_system_score_codex":0.00004420535,"about_ca_system_score_gemma":0.0001277942,"threshold_uncertainty_score":0.82577896},"labels":[],"label_agreement":null},{"id":"W6902088193","doi":"10.6084/m9.figshare.13031546","title":"Additional file 1 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Post-hoc analysis; Hazard ratio; Kidney disease; Epidemiology; Diabetes mellitus; Confidence interval; Blood pressure","score_opus":0.015380062873661003,"score_gpt":0.2351149147347514,"score_spread":0.2197348518610904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902088193","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16154079,0.0016806138,0.0000019909298,0.000014938575,0.000012178843,0.0010048075,0.83565694,0.0000075692656,0.00008017582],"genre_scores_gemma":[0.7604627,0.000048931655,0.000062805055,0.000019319756,0.000024594436,0.00022236758,0.23905128,0.000015746766,0.00009225211],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786985,0.00042516866,0.000588012,0.00025338642,0.0007001923,0.00016341967],"domain_scores_gemma":[0.99623346,0.0019027325,0.0007559306,0.0006010424,0.00043447904,0.00007237333],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036322884,0.00017835647,0.0019895572,0.00016952583,0.000029343513,0.0000029275827,0.00013791975,0.00007980079,0.09170493],"category_scores_gemma":[0.009240218,0.00012559557,0.0030708583,0.0009510029,0.0000417444,0.000027740307,0.0001554494,0.00009050399,0.0000053264307],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009601593,0.0006758822,0.0028380095,0.0055696866,0.3262673,0.000019652285,0.0007927378,0.0033910656,0.00008491133,0.00000353618,0.6547099,0.0046871803],"study_design_scores_gemma":[0.012261551,0.0028778557,0.76911855,0.005891673,0.12184369,4.0224762e-7,0.00046121457,0.0007274457,0.015466765,0.0000155264,0.071039595,0.0002957653],"about_ca_topic_score_codex":0.00008636845,"about_ca_topic_score_gemma":0.000009655721,"teacher_disagreement_score":0.76628053,"about_ca_system_score_codex":0.00002295217,"about_ca_system_score_gemma":0.000050248516,"threshold_uncertainty_score":0.9991054},"labels":[],"label_agreement":null},{"id":"W6902088687","doi":"10.6084/m9.figshare.21432244","title":"Additional file 1 of Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Arcuate nucleus; Food intake; Neuron; Nucleus; Receptor; Hypothalamus","score_opus":0.03385013500709048,"score_gpt":0.2363384099048377,"score_spread":0.20248827489774723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902088687","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030864205,0.000013991434,2.12874e-7,0.0000876436,0.000028773535,0.00027966325,0.98781526,0.000041114854,0.008646941],"genre_scores_gemma":[0.06754898,6.662096e-7,0.00046138398,0.00015432129,0.000048882466,0.001000547,0.9280446,0.00002239295,0.0027181746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991521,0.000031006854,0.00019118954,0.000177622,0.00030507692,0.00014296036],"domain_scores_gemma":[0.999058,0.000407737,0.00019874699,0.00020668695,0.00008326053,0.00004555672],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000013979439,0.00010596288,0.00017971914,0.000108674634,0.00007979375,0.0000089239265,0.00010292526,0.00002362655,0.98930305],"category_scores_gemma":[0.00054503424,0.000107457156,0.00009400384,0.00017134419,0.000010537052,0.00010679154,0.00019907235,0.00010289868,0.00019811622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040965188,0.00025258353,0.000013392304,0.0002153948,0.00009556834,0.0000025894963,0.000078967474,0.000039055296,0.00057668076,0.0000053150807,0.9959651,0.0027143676],"study_design_scores_gemma":[0.00045337548,0.00048155632,0.003498482,0.0013099693,0.000031564832,0.0000013849626,0.00018078354,0.000077506964,0.0060799397,0.000012780062,0.98778987,0.0000828063],"about_ca_topic_score_codex":0.000001818721,"about_ca_topic_score_gemma":8.3025765e-7,"teacher_disagreement_score":0.9891049,"about_ca_system_score_codex":0.000050962317,"about_ca_system_score_gemma":0.00006978029,"threshold_uncertainty_score":0.43819758},"labels":[],"label_agreement":null},{"id":"W6902108295","doi":"10.6084/m9.figshare.13031564","title":"Additional file 7 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Post-hoc analysis; Quartile; Percentile; Framingham Risk Score","score_opus":0.015156105669499513,"score_gpt":0.23497509107179218,"score_spread":0.21981898540229267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902108295","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16255234,0.0016951277,0.0000020115583,0.000014939474,0.000012197456,0.0010061072,0.83462936,0.00000757672,0.000080360216],"genre_scores_gemma":[0.76332605,0.000049526596,0.00006199391,0.00001928289,0.000024562412,0.0002177299,0.23619384,0.000015702304,0.000091296824],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786943,0.0004249767,0.000588442,0.00025336246,0.00070033094,0.00016344912],"domain_scores_gemma":[0.9962502,0.0018871188,0.000756104,0.00060042756,0.00043377597,0.000072384726],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036351074,0.00017837303,0.0019905195,0.00016955113,0.000029356639,0.0000029348175,0.0001378994,0.000079802485,0.087446526],"category_scores_gemma":[0.009064826,0.00012560165,0.003071125,0.0009508547,0.00004176009,0.000027767033,0.00015541875,0.0000905014,0.000005255507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009911585,0.00069746544,0.0029261997,0.005843745,0.33645332,0.000020571339,0.0008193782,0.0034995615,0.00008737124,0.0000037429602,0.6437265,0.004930928],"study_design_scores_gemma":[0.0124179665,0.002899871,0.76939666,0.0059752474,0.12223031,4.0424962e-7,0.00046233047,0.0007336321,0.015713625,0.000015773912,0.06985699,0.00029717325],"about_ca_topic_score_codex":0.00008733748,"about_ca_topic_score_gemma":0.000009790257,"teacher_disagreement_score":0.7664705,"about_ca_system_score_codex":0.000022962573,"about_ca_system_score_gemma":0.000050166487,"threshold_uncertainty_score":0.99928224},"labels":[],"label_agreement":null},{"id":"W6902171532","doi":"10.6084/m9.figshare.22613950","title":"Additional file 1 of Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study","year":2023,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Cohort; Table (database); Respiratory system; Cohort study; Operating table; Risk assessment","score_opus":0.012330266481580596,"score_gpt":0.23773455504040897,"score_spread":0.22540428855882838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902171532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815406,0.0000014867435,3.0771822e-8,0.000006426126,0.00006456788,0.002159406,0.017825717,0.000006485032,0.0017817926],"genre_scores_gemma":[0.96579635,4.9014403e-7,0.0001809816,0.000010176712,0.000028672743,0.00044057416,0.031962052,0.000026588634,0.0015540824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981908,0.00006075011,0.00042011493,0.00034337046,0.0007407456,0.00024419022],"domain_scores_gemma":[0.9986882,0.00027364283,0.00043514022,0.00022717442,0.00029344892,0.000082363564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026502088,0.0001941101,0.0004023666,0.00031874178,0.000042613938,0.000009237039,0.00010968726,0.000068370784,0.031258985],"category_scores_gemma":[0.00019375049,0.00015410209,0.00005278226,0.00074925314,0.000058348807,0.00028369043,0.00006898216,0.00010415807,0.000104312894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000761128,0.0013649181,0.9628686,0.000026822581,0.0005633178,0.000016011323,0.0007358036,0.000016448457,0.00001003297,1.3048569e-7,0.032947544,0.0006892545],"study_design_scores_gemma":[0.00898587,0.002199192,0.9832879,0.00060346257,0.0003417435,1.220897e-8,0.0010189138,0.0000119841625,0.00042497995,6.982734e-7,0.0029705914,0.00015465751],"about_ca_topic_score_codex":0.00002986172,"about_ca_topic_score_gemma":0.00066737446,"teacher_disagreement_score":0.031154672,"about_ca_system_score_codex":0.00017749686,"about_ca_system_score_gemma":0.0001432859,"threshold_uncertainty_score":0.9696266},"labels":[],"label_agreement":null},{"id":"W6902211165","doi":"10.6084/m9.figshare.25231240.v1","title":"Additional file 1 of The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Université de Montréal; University of British Columbia; McMaster University","funders":"","keywords":"MEDLINE; Key (lock); Systematic review; Clinical trial","score_opus":0.030267282977640943,"score_gpt":0.2819315690315089,"score_spread":0.251664286053868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902211165","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000101582336,0.003314356,8.444856e-8,0.000037459304,0.000007073785,0.0012157635,0.9943487,0.000023307,0.0009516803],"genre_scores_gemma":[0.059225284,0.000006237154,0.0000116968695,0.00020508419,0.000008243116,0.0018713926,0.9376627,0.000013752224,0.000995566],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99897987,0.00016283947,0.00028951347,0.00019509617,0.00028839128,0.000084280364],"domain_scores_gemma":[0.99880046,0.0006381144,0.00010489354,0.0003334898,0.00007873602,0.00004429823],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011949278,0.00014758826,0.0012219902,0.000112151734,0.000018223698,0.000010271304,0.000070030175,0.000033745524,0.8696945],"category_scores_gemma":[0.0002208029,0.0000735598,0.0008865792,0.00034456904,0.000012141239,0.000054776054,0.000018863795,0.000060857587,0.00012628008],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000692872,0.00007091687,0.0000106910165,0.15787345,0.06435544,0.000011723716,0.000010644749,0.0000011450431,0.0000022113913,0.0000052605214,0.7776447,0.0000068910344],"study_design_scores_gemma":[0.0004087838,0.00030387694,0.017839018,0.11135913,0.83172417,0.0000039262795,0.000023101782,0.00003826237,0.0012387554,0.000012217866,0.036823906,0.0002248376],"about_ca_topic_score_codex":0.0000019059571,"about_ca_topic_score_gemma":0.0000022657575,"teacher_disagreement_score":0.86956817,"about_ca_system_score_codex":0.000023078068,"about_ca_system_score_gemma":0.000027934977,"threshold_uncertainty_score":0.29996815},"labels":[],"label_agreement":null},{"id":"W6902240740","doi":"10.6084/m9.figshare.21207025","title":"Additional file 2 of Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Glycemic; Glycemic load; Diabetes mellitus; MEDLINE; Physical activity; Glycemic index","score_opus":0.05632882430045552,"score_gpt":0.2751027354186417,"score_spread":0.2187739111181862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902240740","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046720356,0.00088343135,8.496101e-9,0.000058178648,0.0000040406503,0.0012961872,0.99237573,0.000012504567,0.0006978967],"genre_scores_gemma":[0.24368502,0.0000021249268,0.000006798792,0.000107128006,0.0000071191075,0.0024920085,0.75332725,0.00000749417,0.00036503986],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993088,0.00012680826,0.00018747589,0.000092629045,0.00021773715,0.00006653485],"domain_scores_gemma":[0.9899332,0.009631254,0.00019113185,0.00020029253,0.000017088349,0.000027070519],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005982799,0.000082573264,0.00033060502,0.00004516871,0.00004948912,0.000003195073,0.00006257653,0.000014624859,0.8117118],"category_scores_gemma":[0.007339901,0.000047575377,0.000092901275,0.00012755748,0.0000067205656,0.000019441124,0.0000612634,0.000082261635,0.00012086998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009772942,0.000018988221,0.0006308329,0.071566455,0.000098026925,0.0000013249511,0.000017790659,2.8486883e-7,9.282144e-8,0.0000057384923,0.9276344,0.000016250906],"study_design_scores_gemma":[0.0008927671,0.0034639896,0.042328384,0.90374315,0.0014082388,0.0000041974417,0.00008693668,0.000016176677,0.00006887922,0.00003252033,0.047786113,0.00016866287],"about_ca_topic_score_codex":8.521298e-7,"about_ca_topic_score_gemma":1.3162847e-7,"teacher_disagreement_score":0.8798483,"about_ca_system_score_codex":0.000028879775,"about_ca_system_score_gemma":0.0000149703865,"threshold_uncertainty_score":0.8787077},"labels":[],"label_agreement":null},{"id":"W6902308309","doi":"10.6084/m9.figshare.26595977.v1","title":"Additional file 3 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality (philosophy); Table (database); Scale (ratio); MEDLINE; Risk assessment; Key (lock)","score_opus":0.042033993579617374,"score_gpt":0.2713213502896297,"score_spread":0.22928735671001235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902308309","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013248746,0.15779033,3.5100516e-7,0.000084809624,0.000010423473,0.0010360682,0.8390303,0.000029307377,0.0020170407],"genre_scores_gemma":[0.0010252212,0.00030721875,0.00038435747,0.00049742014,0.000074628675,0.0020125348,0.97769886,0.000021773978,0.017977998],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9991416,0.0000433358,0.0002849086,0.00019260183,0.00023205113,0.000105528845],"domain_scores_gemma":[0.9980323,0.001457009,0.000118352444,0.00027130978,0.00005495003,0.00006613316],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000046617602,0.00013135142,0.0013923893,0.00010506965,0.000011486627,0.000009135993,0.000046809873,0.000031870313,0.8298701],"category_scores_gemma":[0.0008246352,0.00008810569,0.0008384899,0.00043061638,0.0000034928987,0.000030310193,0.00003794405,0.000052085987,0.00037124407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000019853928,0.000012339444,3.983834e-8,0.24445213,0.039523114,0.00000423836,0.0000114082595,0.0000089888235,1.540637e-7,0.000005784688,0.7158975,0.00008228182],"study_design_scores_gemma":[0.00013673744,0.00018479614,0.000020477424,0.318082,0.49634692,9.1375176e-7,0.0000062683407,0.0005525509,0.000016126145,0.000040742154,0.18449374,0.000118724136],"about_ca_topic_score_codex":0.0000018932722,"about_ca_topic_score_gemma":3.2013236e-7,"teacher_disagreement_score":0.8294989,"about_ca_system_score_codex":0.000020519792,"about_ca_system_score_gemma":0.000040985902,"threshold_uncertainty_score":0.4771715},"labels":[],"label_agreement":null},{"id":"W6902353520","doi":"10.6084/m9.figshare.21207025.v1","title":"Additional file 2 of Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Glycemic; Glycemic load; Diabetes mellitus; MEDLINE; Physical activity; Glycemic index","score_opus":0.05632882430045552,"score_gpt":0.2751027354186417,"score_spread":0.2187739111181862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902353520","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046720356,0.00088343135,8.496101e-9,0.000058178648,0.0000040406503,0.0012961872,0.99237573,0.000012504567,0.0006978967],"genre_scores_gemma":[0.24368502,0.0000021249268,0.000006798792,0.000107128006,0.0000071191075,0.0024920085,0.75332725,0.00000749417,0.00036503986],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993088,0.00012680826,0.00018747589,0.000092629045,0.00021773715,0.00006653485],"domain_scores_gemma":[0.9899332,0.009631254,0.00019113185,0.00020029253,0.000017088349,0.000027070519],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005982799,0.000082573264,0.00033060502,0.00004516871,0.00004948912,0.000003195073,0.00006257653,0.000014624859,0.8117118],"category_scores_gemma":[0.007339901,0.000047575377,0.000092901275,0.00012755748,0.0000067205656,0.000019441124,0.0000612634,0.000082261635,0.00012086998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009772942,0.000018988221,0.0006308329,0.071566455,0.000098026925,0.0000013249511,0.000017790659,2.8486883e-7,9.282144e-8,0.0000057384923,0.9276344,0.000016250906],"study_design_scores_gemma":[0.0008927671,0.0034639896,0.042328384,0.90374315,0.0014082388,0.0000041974417,0.00008693668,0.000016176677,0.00006887922,0.00003252033,0.047786113,0.00016866287],"about_ca_topic_score_codex":8.521298e-7,"about_ca_topic_score_gemma":1.3162847e-7,"teacher_disagreement_score":0.8798483,"about_ca_system_score_codex":0.000028879775,"about_ca_system_score_gemma":0.0000149703865,"threshold_uncertainty_score":0.8787077},"labels":[],"label_agreement":null},{"id":"W6904645148","doi":"10.1371/journal.pone.0296662.s002","title":"The search strategy for PubMed.","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hypoglycemia; Cognition; Observational study; Glycemic; Comprehension; MEDLINE; Association (psychology); Systematic review","score_opus":0.11017991489474666,"score_gpt":0.33422924947503324,"score_spread":0.22404933458028659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6904645148","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028622984,0.04007173,0.000013803387,0.020817868,0.001067104,0.011261681,0.24768156,0.0013932104,0.67483073],"genre_scores_gemma":[0.68237215,0.000056570912,0.000059656377,0.00052118767,0.00084346195,0.0063586314,0.11442042,0.000057315476,0.19531061],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99954766,0.000003931486,0.000050456743,0.00010627162,0.00009184812,0.0001998144],"domain_scores_gemma":[0.99967945,0.00011972117,0.000004337888,0.00011998836,0.000027674334,0.000048843078],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000044112174,0.000051204675,0.000050069477,0.000023547023,0.000055989083,0.000114609946,0.000050897725,0.00001927599,0.014564099],"category_scores_gemma":[0.00007402786,0.00002901541,0.000059458303,0.000070416565,0.0000028902593,0.000035149664,0.000028513228,0.00004417633,0.0013835885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000593751,0.000010183625,0.0000046659393,0.00025552028,0.00007311788,0.000014251043,0.000013656472,0.0000012343264,0.0000018681287,0.0005855368,0.77795064,0.22108336],"study_design_scores_gemma":[0.00016791219,0.00009403727,0.0016005231,0.00034603913,0.000031747157,0.0000010888195,0.000045418856,0.0005080853,0.00025348624,0.00009735403,0.9968204,0.000033915905],"about_ca_topic_score_codex":5.0703164e-7,"about_ca_topic_score_gemma":0.000002036462,"teacher_disagreement_score":0.6795099,"about_ca_system_score_codex":0.000030703417,"about_ca_system_score_gemma":0.00003630989,"threshold_uncertainty_score":0.99939394},"labels":[],"label_agreement":null},{"id":"W6908355009","doi":"10.26190/unsworks/27739","title":"Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c &lt; 7%: Results From the CREDENCE Trial","year":2019,"lang":"en","type":"article","venue":"UNSWorks (University of New South Wales, Sydney, Australia)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Akebia Therapeutics; HLS Therapeutics; Servier; Relypsa; Astellas Pharma; Novo Nordisk; NxStage; Innovent Biologics; Amarin Corporation; Alnylam Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Canagliflozin; Type 2 diabetes; Kidney disease; Credence; Diabetes mellitus; Baseline (sea); Type 2 Diabetes Mellitus","score_opus":0.02758369359214911,"score_gpt":0.2229293996957503,"score_spread":0.1953457061036012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908355009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973834,0.0005776245,0.000015578156,0.0004426131,0.0000851449,0.0012273669,0.00019207473,0.000016749575,0.00005944637],"genre_scores_gemma":[0.997406,0.00013386835,0.00043579197,0.000031502303,0.00006770129,0.0000010406848,0.00034649094,0.000017607417,0.0015599631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832124,0.00012091448,0.0002235761,0.00050663156,0.000523009,0.00030466085],"domain_scores_gemma":[0.99866855,0.000100390534,0.00024017195,0.0005338251,0.00010804842,0.00034901465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032381085,0.00024348975,0.0005830963,0.0001482428,0.000086089516,0.0000130553435,0.00019463888,0.00009296408,0.000037663613],"category_scores_gemma":[0.000093304974,0.00018684281,0.00009878168,0.00034744482,0.00021109657,0.00018253487,0.00016229317,0.00018378191,0.0000025492443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046758898,0.00045775567,0.9372706,0.00039181137,0.002902221,0.000062915016,0.0043423236,0.0006549281,0.000077195655,0.000029381648,0.0027260154,0.0043259813],"study_design_scores_gemma":[0.109709,0.0023935481,0.8739427,0.005186571,0.0034463962,3.802745e-7,0.002464513,0.0003057193,0.00011277972,0.000035976467,0.0019390854,0.0004633684],"about_ca_topic_score_codex":0.0021268453,"about_ca_topic_score_gemma":0.00050238695,"teacher_disagreement_score":0.06332791,"about_ca_system_score_codex":0.00011946533,"about_ca_system_score_gemma":0.0002671368,"threshold_uncertainty_score":0.76192284},"labels":[],"label_agreement":null},{"id":"W6910393696","doi":"10.48336/cxbj-8x60","title":"Comparative efficacy and cost-effectiveness of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Memorial University Research Repository (Memorial University)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Canagliflozin; Dapagliflozin; Kidney disease; Mineralocorticoid receptor; Type 2 diabetes; Glucagon-like peptide 1 receptor; Saxagliptin","score_opus":0.027134714807455017,"score_gpt":0.28358027102006583,"score_spread":0.25644555621261084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6910393696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941134,0.000252267,0.000002036239,0.00017843039,0.0015638459,0.0022775417,0.00011192811,0.00009307661,0.0014074901],"genre_scores_gemma":[0.9931931,0.0012516088,0.000058295518,0.000008609292,0.000668672,0.0000037021825,0.00044578602,0.000029140447,0.0043410747],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680674,0.00079857284,0.00028114856,0.0008455623,0.0005803855,0.0006875603],"domain_scores_gemma":[0.9978444,0.0005051389,0.00013076364,0.00037446074,0.00030481856,0.00084041676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007169348,0.000352155,0.000778632,0.0011576539,0.00047944085,0.00008346336,0.00023158715,0.00018495857,0.000024041965],"category_scores_gemma":[0.0001020555,0.00038503972,0.00010369896,0.0013280378,0.0011549956,0.00047363632,0.00038633132,0.00042565883,0.000016077873],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0571099,0.0022410832,0.2570547,0.0038593605,0.0017871691,0.0043017296,0.0028272294,0.00003762224,0.6433492,0.0011724592,0.023778733,0.0024808452],"study_design_scores_gemma":[0.08634974,0.009255366,0.3235125,0.0035767986,0.0019420346,0.00001758504,0.0054816953,0.00069935253,0.19235338,0.00005485602,0.37475795,0.0019987752],"about_ca_topic_score_codex":0.00031017174,"about_ca_topic_score_gemma":0.000062086314,"teacher_disagreement_score":0.4509958,"about_ca_system_score_codex":0.0006695533,"about_ca_system_score_gemma":0.0006981629,"threshold_uncertainty_score":0.99986017},"labels":[],"label_agreement":null},{"id":"W6911027225","doi":"10.5167/uzh-262137","title":"Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany","year":2024,"lang":"en","type":"article","venue":"Zurich Open Repository and Archive (University of Zurich)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Weight loss; Agonist; Body weight; Drug; Obesity","score_opus":0.0071373700679236715,"score_gpt":0.21907094720860873,"score_spread":0.21193357714068506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911027225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95949894,0.00056885317,0.000086496795,0.004966033,0.00010571757,0.00067708635,0.00002031407,0.000013831728,0.034062754],"genre_scores_gemma":[0.9929924,0.0002598538,0.00040057822,0.00049754337,0.000039226536,0.0000024488268,0.00001691173,0.000008132097,0.0057829255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990855,0.00014800379,0.00009949555,0.00029789587,0.00019655399,0.0001725733],"domain_scores_gemma":[0.99937737,0.0002453762,0.000035975834,0.0002003022,0.000019703057,0.00012126304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032144887,0.00012004812,0.00021893214,0.00013417516,0.00021117867,0.00011249659,0.00032991974,0.00002717689,0.00002293106],"category_scores_gemma":[0.0000060305906,0.000095584735,0.000032467913,0.00022101933,0.00007983298,0.00026965936,0.0005076639,0.00014296979,0.000003437838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011572912,0.0006721333,0.59520054,0.0016845355,0.0012304663,0.009119058,0.036157966,0.000017160228,0.0018503398,0.009627916,0.31959513,0.023687458],"study_design_scores_gemma":[0.0010466351,0.0002252546,0.75196487,0.00031221326,0.0002722007,0.00005364263,0.0016909183,0.00014447053,0.0001184254,0.00025336698,0.24374609,0.00017190246],"about_ca_topic_score_codex":0.08780998,"about_ca_topic_score_gemma":0.052191716,"teacher_disagreement_score":0.15676434,"about_ca_system_score_codex":0.000047651047,"about_ca_system_score_gemma":0.00015487552,"threshold_uncertainty_score":0.9651033},"labels":[],"label_agreement":null},{"id":"W6911471442","doi":"10.5281/zenodo.11409033","title":"Glyco Care Canada Reviews – Alarming Warning to Worry About? Shocking Truth!","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Worry; Blood sugar; Ideal (ethics); Health care; Medical care; Sugar; Natural (archaeology)","score_opus":0.02849234683179292,"score_gpt":0.2620813413725339,"score_spread":0.233588994540741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911471442","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13599527,0.025287595,0.003671848,0.0075129312,0.002017338,0.0047981883,0.0002536567,0.0038238098,0.81663936],"genre_scores_gemma":[0.9869573,0.0005585949,0.00059683464,0.00091723393,0.00040333843,3.3604397e-7,0.0016305838,0.0014351392,0.007500634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853486,0.00010225769,0.00023693049,0.0004093205,0.00034435032,0.00037225673],"domain_scores_gemma":[0.9991806,0.000021987775,0.000036633868,0.00033844836,0.00018060369,0.00024170511],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032100512,0.00015484162,0.00020837483,0.0002201151,0.0007679643,0.00048861606,0.00029541313,0.000029859919,0.0046355245],"category_scores_gemma":[0.00038802504,0.00014360684,0.00006299597,0.0005900776,0.000024423032,0.00012559097,0.00054976647,0.00019760712,0.0034307844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002861601,0.000029942988,0.0000208954,0.0006305243,0.00010070839,0.00018828188,0.0019720108,0.000027390117,0.00060861127,0.0009951519,0.32919374,0.6662041],"study_design_scores_gemma":[0.00025867138,0.00016475645,0.00041961655,0.00060793443,0.00008485568,0.000025972276,0.00070330926,0.00015269037,0.00021209141,0.000006054279,0.99722475,0.00013932276],"about_ca_topic_score_codex":0.0014024513,"about_ca_topic_score_gemma":0.00013009511,"teacher_disagreement_score":0.85096204,"about_ca_system_score_codex":0.00061988086,"about_ca_system_score_gemma":0.000016142654,"threshold_uncertainty_score":0.99734515},"labels":[],"label_agreement":null},{"id":"W6920263257","doi":"10.60692/71msj-aay45","title":"Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre","funders":"","keywords":"Empagliflozin; Ejection fraction; Heart failure; Hazard ratio; Heart failure with preserved ejection fraction; Placebo; Cardiomyopathy; Cohort","score_opus":0.008341850435097003,"score_gpt":0.18907449683832336,"score_spread":0.18073264640322637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920263257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981472,0.0000072840717,0.00010979995,0.0000752946,0.00002536267,0.0007913038,0.0000050219746,0.000039239254,0.0007994813],"genre_scores_gemma":[0.9993477,2.60273e-7,0.000100406774,0.000055300465,0.000008326947,0.00034030466,0.000009581697,0.000004746054,0.00013341547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994086,0.000041614978,0.0001908498,0.00007929446,0.00017387264,0.0001057856],"domain_scores_gemma":[0.9997343,0.000006634261,0.00010237491,0.00009089854,0.000025049707,0.00004078526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017622697,0.00007855452,0.00018180748,0.00023834092,0.000052668234,0.000022918226,0.000016708149,0.00002212139,0.000008382104],"category_scores_gemma":[0.0000041253898,0.000060965624,0.0000113790975,0.00014381959,0.000010993872,0.00030755578,0.000043447042,0.00005372415,0.000003565919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044013595,0.0000105373465,0.9821018,0.0016580237,0.000084983054,0.0000027367757,0.0152739845,0.000037212645,0.000024647656,0.000016945869,0.00018285605,0.00016610986],"study_design_scores_gemma":[0.005396599,0.0008394286,0.9543495,0.00018028382,0.00007093114,0.000013695291,0.035941426,0.001349071,0.0007944536,0.000001217506,0.00097013987,0.00009321435],"about_ca_topic_score_codex":0.000015333348,"about_ca_topic_score_gemma":2.6970417e-7,"teacher_disagreement_score":0.027752286,"about_ca_system_score_codex":0.00014853361,"about_ca_system_score_gemma":0.000009275514,"threshold_uncertainty_score":0.2486106},"labels":[],"label_agreement":null},{"id":"W6920306823","doi":"10.60692/npv7w-mh430","title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dapagliflozin; Kidney disease; Hazard ratio; Post-hoc analysis; Clinical endpoint; Renal function; Proportional hazards model; Kidney; Heart failure","score_opus":0.009013823644687924,"score_gpt":0.20489677714820476,"score_spread":0.19588295350351684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920306823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607116,0.000031250613,0.00019402386,0.00007590055,0.0002527662,0.0014686832,0.0010536852,0.000037319158,0.0008152221],"genre_scores_gemma":[0.9991557,0.0000011443109,0.000009454686,0.00018656386,0.000014399623,0.00017013385,0.00025755214,0.000008136597,0.00019690974],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809724,0.0003634636,0.0005945397,0.00014484586,0.00065863517,0.00014128108],"domain_scores_gemma":[0.9987426,0.000046725243,0.00040176057,0.0006474888,0.00008492954,0.000076544115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014858023,0.00017984382,0.00081217993,0.00041967057,0.00012291514,0.00002298863,0.000114294075,0.000039054295,0.00003509841],"category_scores_gemma":[0.000108732274,0.000104312225,0.00057080697,0.0006000649,0.00003483566,0.00011197389,0.00011319637,0.00008489541,0.0000074582013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02277194,0.0000746369,0.8838041,0.002329744,0.04014507,0.000005604266,0.038916454,0.0021854031,0.000006207247,0.00013265124,0.002805354,0.0068228757],"study_design_scores_gemma":[0.43314138,0.03198628,0.20658898,0.00083643454,0.17475788,0.000022993916,0.07040943,0.028471721,0.008903391,0.0000015407823,0.04315954,0.001720417],"about_ca_topic_score_codex":0.000084032574,"about_ca_topic_score_gemma":2.3588596e-7,"teacher_disagreement_score":0.6772151,"about_ca_system_score_codex":0.000091999784,"about_ca_system_score_gemma":0.00002835613,"threshold_uncertainty_score":0.4253729},"labels":[],"label_agreement":null},{"id":"W6920382589","doi":"10.60692/hr51p-h5c93","title":"Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre","funders":"","keywords":"Empagliflozin; Ejection fraction; Heart failure; Hazard ratio; Heart failure with preserved ejection fraction; Placebo; Cardiomyopathy; Cohort","score_opus":0.008341850435097003,"score_gpt":0.18907449683832336,"score_spread":0.18073264640322637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920382589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981472,0.0000072840717,0.00010979995,0.0000752946,0.00002536267,0.0007913038,0.0000050219746,0.000039239254,0.0007994813],"genre_scores_gemma":[0.9993477,2.60273e-7,0.000100406774,0.000055300465,0.000008326947,0.00034030466,0.000009581697,0.000004746054,0.00013341547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994086,0.000041614978,0.0001908498,0.00007929446,0.00017387264,0.0001057856],"domain_scores_gemma":[0.9997343,0.000006634261,0.00010237491,0.00009089854,0.000025049707,0.00004078526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017622697,0.00007855452,0.00018180748,0.00023834092,0.000052668234,0.000022918226,0.000016708149,0.00002212139,0.000008382104],"category_scores_gemma":[0.0000041253898,0.000060965624,0.0000113790975,0.00014381959,0.000010993872,0.00030755578,0.000043447042,0.00005372415,0.000003565919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044013595,0.0000105373465,0.9821018,0.0016580237,0.000084983054,0.0000027367757,0.0152739845,0.000037212645,0.000024647656,0.000016945869,0.00018285605,0.00016610986],"study_design_scores_gemma":[0.005396599,0.0008394286,0.9543495,0.00018028382,0.00007093114,0.000013695291,0.035941426,0.001349071,0.0007944536,0.000001217506,0.00097013987,0.00009321435],"about_ca_topic_score_codex":0.000015333348,"about_ca_topic_score_gemma":2.6970417e-7,"teacher_disagreement_score":0.027752286,"about_ca_system_score_codex":0.00014853361,"about_ca_system_score_gemma":0.000009275514,"threshold_uncertainty_score":0.2486106},"labels":[],"label_agreement":null},{"id":"W6920388604","doi":"10.60692/qkke6-tkv29","title":"A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dapagliflozin; Kidney disease; Renal function; Placebo; Creatinine; Acute kidney injury; Randomized controlled trial; Adverse effect","score_opus":0.020922588671435895,"score_gpt":0.2442563064000821,"score_spread":0.2233337177286462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920388604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931348,0.00001286673,0.00026946687,0.0001975789,0.00019140515,0.0058104503,0.000067993395,0.00001213171,0.00030329422],"genre_scores_gemma":[0.99847364,0.0000017362753,0.0000067192664,0.00013974257,0.000011347818,0.001064226,0.00004683298,0.0000042677984,0.0002514679],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753666,0.00048048672,0.0012865154,0.000114941286,0.000473384,0.000108003806],"domain_scores_gemma":[0.99839485,0.00011077089,0.0010026719,0.00035468227,0.00007832477,0.00005871977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016478379,0.00013779364,0.0010869008,0.00069388235,0.000045082208,0.0000075312937,0.000103499515,0.00003101075,0.00005775653],"category_scores_gemma":[0.0004198482,0.00007171026,0.0004260302,0.0006667846,0.000056573383,0.00015436835,0.000080075886,0.00007365791,0.000001242843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7530912,0.000081162914,0.22941703,0.0006676694,0.002151908,0.0000011019031,0.01056374,0.0031916562,0.0000054589796,0.0006642784,0.000028853374,0.00013592014],"study_design_scores_gemma":[0.6750821,0.0003197593,0.29911965,0.00046467755,0.0034352578,1.7242499e-7,0.0030842077,0.018349396,0.000043316013,0.000008154939,0.000020525235,0.00007281228],"about_ca_topic_score_codex":0.000042677115,"about_ca_topic_score_gemma":0.000005665179,"teacher_disagreement_score":0.07800915,"about_ca_system_score_codex":0.00019272348,"about_ca_system_score_gemma":0.00015027491,"threshold_uncertainty_score":0.29242596},"labels":[],"label_agreement":null},{"id":"W6920422976","doi":"10.60692/5c81k-gkg32","title":"Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Manitoba; Université de Montréal; University of Calgary","funders":"","keywords":"Observational study; Type 2 diabetes; Randomized controlled trial; Clinical trial; Diabetes mellitus; Systematic review; Treatment effect; Precision medicine","score_opus":0.019598322110399746,"score_gpt":0.23673322381966094,"score_spread":0.2171349017092612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920422976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99146175,0.0009894753,0.000014920201,0.00013875192,0.0003224397,0.0057455194,0.000042358708,0.00062805746,0.0006567494],"genre_scores_gemma":[0.9970786,0.000073495066,0.000056881305,0.00013077026,0.00005894359,0.001613705,0.00027368538,0.000031996482,0.00068190007],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.998057,0.00013232966,0.0006875511,0.0002927318,0.00040020017,0.0004301539],"domain_scores_gemma":[0.9988142,0.000034051263,0.00030111734,0.00055995095,0.00008058057,0.00021004977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003272879,0.00049002166,0.001263756,0.00029315113,0.00016449046,0.00015748484,0.00006524976,0.000079281504,0.000007086233],"category_scores_gemma":[0.000022984079,0.00026589617,0.00026188037,0.0004817097,0.000025628045,0.00033318056,0.000042659456,0.000037980644,0.0013005487],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029504191,0.00006008712,0.4966264,0.47937176,0.007277545,0.00013967161,0.013163649,0.0000070489964,0.000024407236,0.000023944734,0.000619318,0.0023911328],"study_design_scores_gemma":[0.0650931,0.060982615,0.058104217,0.7041806,0.058491014,0.0003682453,0.012598892,0.0047522723,0.02404489,8.037187e-7,0.0070162816,0.0043671024],"about_ca_topic_score_codex":0.0000075303633,"about_ca_topic_score_gemma":5.0154136e-7,"teacher_disagreement_score":0.4385222,"about_ca_system_score_codex":0.0005923462,"about_ca_system_score_gemma":0.000039187686,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W6920498535","doi":"10.6084/m9.figshare.13031558","title":"Additional file 5 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Post-hoc analysis; Adverse effect; Post hoc; Coronary heart disease; Component (thermodynamics)","score_opus":0.01513180867676815,"score_gpt":0.23492086465824843,"score_spread":0.2197890559814803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920498535","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16258992,0.0016938775,0.000002008998,0.000014934334,0.000012195324,0.001006208,0.83459294,0.0000075764606,0.00008035669],"genre_scores_gemma":[0.76441836,0.00004946111,0.00006203323,0.00001929082,0.000024569921,0.00021800637,0.23510122,0.0000157069,0.00009131945],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786943,0.00042506994,0.00058843265,0.0002533376,0.00070032204,0.00016342146],"domain_scores_gemma":[0.9962491,0.0018882842,0.00075612625,0.00060040003,0.00043371302,0.00007237786],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036351715,0.00017836112,0.0019904983,0.00016954028,0.000029355999,0.0000029334055,0.00013788532,0.00007980436,0.08850422],"category_scores_gemma":[0.009152735,0.00012559023,0.0030712818,0.000950848,0.00004175431,0.000027763832,0.00015540757,0.000090494126,0.0000052452733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009818603,0.0006908015,0.0029007264,0.00574139,0.3332094,0.000020373403,0.0008105537,0.003461101,0.00008633627,0.0000037162486,0.6472348,0.004858959],"study_design_scores_gemma":[0.012284746,0.0028644844,0.77253705,0.005858336,0.12091912,3.999995e-7,0.00045766818,0.00072129664,0.015484714,0.000015534908,0.068562716,0.00029394677],"about_ca_topic_score_codex":0.000087287364,"about_ca_topic_score_gemma":0.000009786159,"teacher_disagreement_score":0.76963633,"about_ca_system_score_codex":0.000022958884,"about_ca_system_score_gemma":0.000050151506,"threshold_uncertainty_score":0.9991936},"labels":[],"label_agreement":null},{"id":"W6920609578","doi":"10.60692/chvjv-d5a13","title":"Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Manitoba; Université de Montréal; University of Calgary","funders":"","keywords":"Observational study; Type 2 diabetes; Randomized controlled trial; Clinical trial; Diabetes mellitus; Systematic review; Treatment effect; Precision medicine","score_opus":0.019598322110399746,"score_gpt":0.23673322381966094,"score_spread":0.2171349017092612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920609578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99146175,0.0009894753,0.000014920201,0.00013875192,0.0003224397,0.0057455194,0.000042358708,0.00062805746,0.0006567494],"genre_scores_gemma":[0.9970786,0.000073495066,0.000056881305,0.00013077026,0.00005894359,0.001613705,0.00027368538,0.000031996482,0.00068190007],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.998057,0.00013232966,0.0006875511,0.0002927318,0.00040020017,0.0004301539],"domain_scores_gemma":[0.9988142,0.000034051263,0.00030111734,0.00055995095,0.00008058057,0.00021004977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003272879,0.00049002166,0.001263756,0.00029315113,0.00016449046,0.00015748484,0.00006524976,0.000079281504,0.000007086233],"category_scores_gemma":[0.000022984079,0.00026589617,0.00026188037,0.0004817097,0.000025628045,0.00033318056,0.000042659456,0.000037980644,0.0013005487],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029504191,0.00006008712,0.4966264,0.47937176,0.007277545,0.00013967161,0.013163649,0.0000070489964,0.000024407236,0.000023944734,0.000619318,0.0023911328],"study_design_scores_gemma":[0.0650931,0.060982615,0.058104217,0.7041806,0.058491014,0.0003682453,0.012598892,0.0047522723,0.02404489,8.037187e-7,0.0070162816,0.0043671024],"about_ca_topic_score_codex":0.0000075303633,"about_ca_topic_score_gemma":5.0154136e-7,"teacher_disagreement_score":0.4385222,"about_ca_system_score_codex":0.0005923462,"about_ca_system_score_gemma":0.000039187686,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W6920616599","doi":"10.6084/m9.figshare.13031549","title":"Additional file 2 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Akaike information criterion; Post-hoc analysis; Post hoc; Bayesian probability; Table (database)","score_opus":0.014867987246182145,"score_gpt":0.23463156257392231,"score_spread":0.21976357532774016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920616599","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16101769,0.0017083636,0.0000019551799,0.000014894889,0.000012266558,0.0010050072,0.8361502,0.000007581476,0.00008200267],"genre_scores_gemma":[0.75907254,0.000050254446,0.00006170433,0.000019373663,0.000024997344,0.00021904502,0.24044354,0.000015769609,0.00009278536],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978701,0.00042503624,0.0005882542,0.00025321188,0.00070003147,0.00016336434],"domain_scores_gemma":[0.9962591,0.0018780685,0.0007569109,0.0005999892,0.00043359635,0.00007236443],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036140648,0.00017830436,0.001990004,0.00016942383,0.000029345489,0.0000029334224,0.0001378492,0.00007980121,0.09025899],"category_scores_gemma":[0.009138598,0.00012555785,0.0030703142,0.00095032394,0.000041743868,0.000027757778,0.0001554293,0.00009048484,0.000005274178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009628172,0.0006809573,0.002776783,0.0056598517,0.32883522,0.00002030343,0.0007995493,0.0034326315,0.000082847386,0.0000036213996,0.6519006,0.004844822],"study_design_scores_gemma":[0.012427857,0.0028991702,0.76546496,0.005867168,0.12232648,4.05991e-7,0.0004601999,0.0007282192,0.015490136,0.000015753403,0.07402229,0.00029733553],"about_ca_topic_score_codex":0.00008716801,"about_ca_topic_score_gemma":0.000009708233,"teacher_disagreement_score":0.7626882,"about_ca_system_score_codex":0.000022958213,"about_ca_system_score_gemma":0.000050042956,"threshold_uncertainty_score":0.99920785},"labels":[],"label_agreement":null},{"id":"W6920795500","doi":"10.6084/m9.figshare.13031549.v1","title":"Additional file 2 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Akaike information criterion; Post-hoc analysis; Post hoc; Bayesian probability; Table (database)","score_opus":0.014867987246182145,"score_gpt":0.23463156257392231,"score_spread":0.21976357532774016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920795500","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16101769,0.0017083636,0.0000019551799,0.000014894889,0.000012266558,0.0010050072,0.8361502,0.000007581476,0.00008200267],"genre_scores_gemma":[0.75907254,0.000050254446,0.00006170433,0.000019373663,0.000024997344,0.00021904502,0.24044354,0.000015769609,0.00009278536],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978701,0.00042503624,0.0005882542,0.00025321188,0.00070003147,0.00016336434],"domain_scores_gemma":[0.9962591,0.0018780685,0.0007569109,0.0005999892,0.00043359635,0.00007236443],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036140648,0.00017830436,0.001990004,0.00016942383,0.000029345489,0.0000029334224,0.0001378492,0.00007980121,0.09025899],"category_scores_gemma":[0.009138598,0.00012555785,0.0030703142,0.00095032394,0.000041743868,0.000027757778,0.0001554293,0.00009048484,0.000005274178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009628172,0.0006809573,0.002776783,0.0056598517,0.32883522,0.00002030343,0.0007995493,0.0034326315,0.000082847386,0.0000036213996,0.6519006,0.004844822],"study_design_scores_gemma":[0.012427857,0.0028991702,0.76546496,0.005867168,0.12232648,4.05991e-7,0.0004601999,0.0007282192,0.015490136,0.000015753403,0.07402229,0.00029733553],"about_ca_topic_score_codex":0.00008716801,"about_ca_topic_score_gemma":0.000009708233,"teacher_disagreement_score":0.7626882,"about_ca_system_score_codex":0.000022958213,"about_ca_system_score_gemma":0.000050042956,"threshold_uncertainty_score":0.99920785},"labels":[],"label_agreement":null},{"id":"W6920825712","doi":"10.6084/m9.figshare.20098642","title":"Additional file 1 of Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials","year":2022,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Diabetes mellitus; Randomization; Triglyceride; Table (database); Adverse effect; Body weight; Incidence (geometry); Research design","score_opus":0.01273156542370329,"score_gpt":0.24968215334942337,"score_spread":0.23695058792572007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920825712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98057795,0.00008968488,5.191703e-8,0.00028481163,0.000019852214,0.001710582,0.01658926,8.149801e-7,0.0007269986],"genre_scores_gemma":[0.9897239,0.0000028770569,0.0006342207,0.00014716221,0.000015726262,0.00075319275,0.008123285,0.000012265109,0.0005873581],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908584,0.00013244362,0.00022497654,0.00019166993,0.00023536054,0.00012968684],"domain_scores_gemma":[0.9978514,0.0017740102,0.00015102232,0.00016578402,0.00001534447,0.000042485037],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022106373,0.00010813062,0.0005347739,0.00007015778,0.000056202258,0.000017772489,0.00007493047,0.000020161933,0.06858999],"category_scores_gemma":[0.00021153118,0.000067074834,0.00003234576,0.00013543069,0.000073849376,0.00005705182,0.00012419971,0.00007232125,0.0000062984013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001978264,0.0014183641,0.041159134,0.00017189152,0.0004581246,0.000011889858,0.0004371449,0.000008329166,0.00011358503,0.000049880993,0.9276281,0.02656528],"study_design_scores_gemma":[0.016649865,0.007970225,0.4606487,0.001044778,0.00046049408,0.00000109551,0.00027013884,0.000029400942,0.0032950966,0.00012914509,0.5092749,0.0002261529],"about_ca_topic_score_codex":0.000005351278,"about_ca_topic_score_gemma":0.0000073368856,"teacher_disagreement_score":0.41948956,"about_ca_system_score_codex":0.000023458988,"about_ca_system_score_gemma":0.000038752038,"threshold_uncertainty_score":0.93226147},"labels":[],"label_agreement":null},{"id":"W6920842138","doi":"10.6084/m9.figshare.19844664","title":"Additional file 2 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Diabetes mellitus; Disease; Heart failure; Primary care; Kidney disease","score_opus":0.020051398083324665,"score_gpt":0.24647051013912505,"score_spread":0.2264191120558004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920842138","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38718456,0.000011791336,5.0101367e-9,8.427888e-7,0.0000148807485,0.0009845991,0.6112384,0.0000075118446,0.00055736786],"genre_scores_gemma":[0.494809,1.1360237e-7,0.000019292202,0.000013085801,0.000011481297,0.0040602437,0.50101477,0.00000839692,0.000063603475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869305,0.00008714481,0.00029415358,0.00024392814,0.0005179765,0.0001637288],"domain_scores_gemma":[0.9992112,0.0002943244,0.0001838629,0.00015539328,0.00012226812,0.00003297626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000040930125,0.00011486244,0.00027076126,0.0002443034,0.000047128065,0.0000061130972,0.00008920426,0.000030330772,0.76665914],"category_scores_gemma":[0.00047234324,0.00011514736,0.00008855875,0.00033352824,0.00001110077,0.00006558736,0.0002357507,0.00015147554,0.000034641496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009734507,0.0015954514,0.6503298,0.00023844115,0.0001584348,0.000014592943,0.00021691069,0.0001655414,5.27206e-7,2.5062423e-7,0.3459562,0.0012264698],"study_design_scores_gemma":[0.0031292476,0.001144597,0.9896871,0.0004301709,0.00002158242,1.1414999e-7,0.00013269395,0.000013055103,0.000021311067,0.000013363209,0.005324415,0.00008235008],"about_ca_topic_score_codex":0.00007758284,"about_ca_topic_score_gemma":0.00006283401,"teacher_disagreement_score":0.76662445,"about_ca_system_score_codex":0.0005101523,"about_ca_system_score_gemma":0.00012789192,"threshold_uncertainty_score":0.46955732},"labels":[],"label_agreement":null},{"id":"W6920855144","doi":"10.6084/m9.figshare.21432244.v1","title":"Additional file 1 of Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Arcuate nucleus; Food intake; Neuron; Nucleus; Receptor; Hypothalamus","score_opus":0.03385013500709048,"score_gpt":0.2363384099048377,"score_spread":0.20248827489774723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920855144","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030864205,0.000013991434,2.12874e-7,0.0000876436,0.000028773535,0.00027966325,0.98781526,0.000041114854,0.008646941],"genre_scores_gemma":[0.06754898,6.662096e-7,0.00046138398,0.00015432129,0.000048882466,0.001000547,0.9280446,0.00002239295,0.0027181746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991521,0.000031006854,0.00019118954,0.000177622,0.00030507692,0.00014296036],"domain_scores_gemma":[0.999058,0.000407737,0.00019874699,0.00020668695,0.00008326053,0.00004555672],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000013979439,0.00010596288,0.00017971914,0.000108674634,0.00007979375,0.0000089239265,0.00010292526,0.00002362655,0.98930305],"category_scores_gemma":[0.00054503424,0.000107457156,0.00009400384,0.00017134419,0.000010537052,0.00010679154,0.00019907235,0.00010289868,0.00019811622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040965188,0.00025258353,0.000013392304,0.0002153948,0.00009556834,0.0000025894963,0.000078967474,0.000039055296,0.00057668076,0.0000053150807,0.9959651,0.0027143676],"study_design_scores_gemma":[0.00045337548,0.00048155632,0.003498482,0.0013099693,0.000031564832,0.0000013849626,0.00018078354,0.000077506964,0.0060799397,0.000012780062,0.98778987,0.0000828063],"about_ca_topic_score_codex":0.000001818721,"about_ca_topic_score_gemma":8.3025765e-7,"teacher_disagreement_score":0.9891049,"about_ca_system_score_codex":0.000050962317,"about_ca_system_score_gemma":0.00006978029,"threshold_uncertainty_score":0.43819758},"labels":[],"label_agreement":null},{"id":"W6920872978","doi":"10.6084/m9.figshare.22613950.v1","title":"Additional file 1 of Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Cohort; Table (database); Respiratory system; Cohort study; Operating table; Risk assessment","score_opus":0.010999854861254828,"score_gpt":0.21612880099077933,"score_spread":0.2051289461295245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920872978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5746322,0.0000019293077,2.1061535e-9,0.000002187731,0.00002398929,0.0009366236,0.42399886,0.000035061472,0.0003691142],"genre_scores_gemma":[0.5694702,1.4764898e-7,0.0000132056275,0.0000121391995,0.000028062635,0.00075380935,0.42938808,0.000021817774,0.0003125507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981813,0.000047170426,0.0003736431,0.0003070761,0.00082853227,0.00026229248],"domain_scores_gemma":[0.99846023,0.00037946974,0.00043142127,0.00021361452,0.0004306881,0.000084599415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000831829,0.00020895773,0.00035787874,0.0003619032,0.000039026476,0.00000463963,0.00007221026,0.00008226949,0.24647763],"category_scores_gemma":[0.0006898503,0.0001693441,0.00007234662,0.00082105404,0.000017812736,0.0002004253,0.000043277392,0.0001216939,0.00022077077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023793457,0.0005987848,0.6589299,0.000109075765,0.00031283623,0.0000121667235,0.00023702261,0.000013254586,0.000001609751,5.854185e-8,0.33946234,0.0000850161],"study_design_scores_gemma":[0.005831323,0.0016347206,0.9849424,0.002827254,0.00017517751,1.1284367e-8,0.00035497875,0.00001597546,0.00014901631,4.9803e-7,0.0039081993,0.00016044849],"about_ca_topic_score_codex":0.0000072503653,"about_ca_topic_score_gemma":0.0002097197,"teacher_disagreement_score":0.33555415,"about_ca_system_score_codex":0.00018661925,"about_ca_system_score_gemma":0.00012666902,"threshold_uncertainty_score":0.7542112},"labels":[],"label_agreement":null},{"id":"W6920962354","doi":"10.6084/m9.figshare.25010557.v1","title":"Additional file 2 of Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Octreotide; Clinical trial; Depot; Phase (matter); Phases of clinical research; Complication","score_opus":0.04937336468752859,"score_gpt":0.3470212422208311,"score_spread":0.29764787753330246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920962354","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33544338,0.00012287498,0.0000014297714,0.00007128153,0.00012097909,0.007365934,0.65624964,0.000019259749,0.00060521695],"genre_scores_gemma":[0.8037993,0.0000054815864,0.00061514234,0.000040346553,0.00017465501,0.0022161023,0.1927097,0.00003003064,0.0004092703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800295,0.00055798184,0.00070443924,0.00027467887,0.0003064454,0.00015352885],"domain_scores_gemma":[0.9869903,0.012155068,0.00043892858,0.000244593,0.00012946012,0.000041660198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027461065,0.00016655865,0.0008618956,0.00008705757,0.000035551227,0.000015713793,0.00010923139,0.00007947468,0.2568292],"category_scores_gemma":[0.0069365315,0.000082527404,0.00024065557,0.00022155412,0.00007002138,0.00006436684,0.00007854615,0.0001961766,0.000005838409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80162466,0.001868695,0.0001481292,0.00020457311,0.0010710504,0.000021824631,0.0000996577,0.000005331133,0.0000039132046,0.000011646869,0.18094686,0.013993698],"study_design_scores_gemma":[0.9478451,0.006464161,0.03528843,0.0030400266,0.0006513136,0.0000026242928,0.00005376041,0.0000667287,0.00008090532,0.00004503673,0.0063657183,0.00009620637],"about_ca_topic_score_codex":0.000005440893,"about_ca_topic_score_gemma":0.000012330271,"teacher_disagreement_score":0.4683559,"about_ca_system_score_codex":0.000040192757,"about_ca_system_score_gemma":0.00019116014,"threshold_uncertainty_score":0.8304177},"labels":[],"label_agreement":null},{"id":"W6920977792","doi":"10.6084/m9.figshare.26264976","title":"Additional file 1 of Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Myocardial infarction; Randomized controlled trial; Outcome (game theory); Clinical trial","score_opus":0.01756520011949901,"score_gpt":0.2935936115685117,"score_spread":0.2760284114490127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920977792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6490208,0.00007296959,5.9389276e-7,0.0002826407,0.00040921255,0.0024442973,0.34278452,0.0000048113156,0.0049801506],"genre_scores_gemma":[0.5482599,0.000016130003,0.00047096843,0.00021206574,0.000380245,0.0013260848,0.43153903,0.000035018023,0.01776055],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987503,0.00019634444,0.00035734865,0.000245535,0.00035072365,0.000099747704],"domain_scores_gemma":[0.99337816,0.006243273,0.00011525782,0.00016908925,0.00004111898,0.0000531016],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017804361,0.00017086983,0.0006472578,0.000068324196,0.00004349886,0.000027750355,0.00008984793,0.00006611316,0.5544659],"category_scores_gemma":[0.00072540523,0.00008886467,0.00020213872,0.00012035095,0.00009802426,0.00011770319,0.00009601341,0.00010375656,0.0002932475],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10169706,0.000205763,0.0002293971,0.000016151847,0.001500743,0.000008774895,0.000080303646,7.3783275e-7,0.000018726698,0.000006521898,0.87938184,0.016854001],"study_design_scores_gemma":[0.38439018,0.004556677,0.037280317,0.0010552943,0.0018641094,0.000004825522,0.00007569943,0.00014548052,0.0002472642,0.00016938134,0.569961,0.0002497823],"about_ca_topic_score_codex":0.000027050966,"about_ca_topic_score_gemma":0.0000046547952,"teacher_disagreement_score":0.5541727,"about_ca_system_score_codex":0.00004351956,"about_ca_system_score_gemma":0.00007373268,"threshold_uncertainty_score":0.44594136},"labels":[],"label_agreement":null},{"id":"W6920981808","doi":"10.6084/m9.figshare.13031564.v1","title":"Additional file 7 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Post-hoc analysis; Quartile; Percentile; Framingham Risk Score","score_opus":0.015156105669499513,"score_gpt":0.23497509107179218,"score_spread":0.21981898540229267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920981808","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16255234,0.0016951277,0.0000020115583,0.000014939474,0.000012197456,0.0010061072,0.83462936,0.00000757672,0.000080360216],"genre_scores_gemma":[0.76332605,0.000049526596,0.00006199391,0.00001928289,0.000024562412,0.0002177299,0.23619384,0.000015702304,0.000091296824],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786943,0.0004249767,0.000588442,0.00025336246,0.00070033094,0.00016344912],"domain_scores_gemma":[0.9962502,0.0018871188,0.000756104,0.00060042756,0.00043377597,0.000072384726],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036351074,0.00017837303,0.0019905195,0.00016955113,0.000029356639,0.0000029348175,0.0001378994,0.000079802485,0.087446526],"category_scores_gemma":[0.009064826,0.00012560165,0.003071125,0.0009508547,0.00004176009,0.000027767033,0.00015541875,0.0000905014,0.000005255507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009911585,0.00069746544,0.0029261997,0.005843745,0.33645332,0.000020571339,0.0008193782,0.0034995615,0.00008737124,0.0000037429602,0.6437265,0.004930928],"study_design_scores_gemma":[0.0124179665,0.002899871,0.76939666,0.0059752474,0.12223031,4.0424962e-7,0.00046233047,0.0007336321,0.015713625,0.000015773912,0.06985699,0.00029717325],"about_ca_topic_score_codex":0.00008733748,"about_ca_topic_score_gemma":0.000009790257,"teacher_disagreement_score":0.7664705,"about_ca_system_score_codex":0.000022962573,"about_ca_system_score_gemma":0.000050166487,"threshold_uncertainty_score":0.99928224},"labels":[],"label_agreement":null},{"id":"W6921004580","doi":"10.6084/m9.figshare.26575994","title":"Additional file 1 of Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Heart failure; Adverse effect; Relative risk; Funnel plot; Randomized controlled trial; Clinical trial; Confidence interval; Meta-analysis","score_opus":0.10120263103480227,"score_gpt":0.35453670262252723,"score_spread":0.253334071587725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921004580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61784405,0.05580119,0.00026063103,0.0009809127,0.00008453135,0.008375058,0.31521624,0.000028045597,0.0014093587],"genre_scores_gemma":[0.93083256,0.00020320299,0.013892578,0.000059926366,0.00002186859,0.0005531669,0.05247005,0.00004065272,0.0019259838],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964777,0.0009114311,0.0011071343,0.00060726725,0.00073709834,0.00015933132],"domain_scores_gemma":[0.9961461,0.0024131336,0.0003067507,0.00090316887,0.00013244776,0.000098412405],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028150668,0.00035683674,0.010988434,0.0010839542,0.000039509465,0.00006241549,0.00015096767,0.00010046612,0.27881688],"category_scores_gemma":[0.00047642103,0.00018144997,0.012300515,0.0012281691,0.00018605721,0.0001671494,0.00011488825,0.00008799357,0.0000073776055],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022640594,0.00022841246,0.00017493048,0.00005900971,0.98687124,0.000012929132,0.00016923284,0.0002849557,0.000063100815,0.00000745942,0.007216356,0.0026483182],"study_design_scores_gemma":[0.017098662,0.00016342137,0.0025821426,0.00002601394,0.9324026,0.0000010569472,0.0001475879,0.00026529178,0.0005717047,0.0000062394247,0.04658998,0.00014528929],"about_ca_topic_score_codex":0.00014985948,"about_ca_topic_score_gemma":0.000022760241,"teacher_disagreement_score":0.31298855,"about_ca_system_score_codex":0.00001565909,"about_ca_system_score_gemma":0.00003825204,"threshold_uncertainty_score":0.9975911},"labels":[],"label_agreement":null},{"id":"W6921010497","doi":"10.6084/m9.figshare.26264976.v1","title":"Additional file 1 of Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Myocardial infarction; Randomized controlled trial; Outcome (game theory); Clinical trial","score_opus":0.01621994026084555,"score_gpt":0.26424747293757195,"score_spread":0.2480275326767264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921010497","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025303386,0.00012701956,4.2207997e-8,0.00011420606,0.0001789314,0.001306977,0.97183126,0.000037621743,0.001100529],"genre_scores_gemma":[0.076816656,0.000002712698,0.000016560389,0.00015731281,0.00022394734,0.0014998199,0.9192654,0.000017161154,0.0020004353],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998824,0.00014753194,0.00031305247,0.00021659126,0.00039243873,0.00010640314],"domain_scores_gemma":[0.99095225,0.008662083,0.00011280422,0.0001567898,0.00006188601,0.00005416937],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000050207353,0.0001835765,0.0005628492,0.000076776654,0.000039489772,0.000013287476,0.00005695901,0.0000799471,0.9340534],"category_scores_gemma":[0.0028396915,0.00009745315,0.00027960198,0.00013082307,0.000027357923,0.000080559475,0.00005794447,0.00012235538,0.0006435982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035783798,0.00010530017,0.000043389435,0.00009050401,0.0009678023,0.0000078356725,0.000029260034,6.993892e-7,0.0000031721095,0.0000033779233,0.9611826,0.0017822519],"study_design_scores_gemma":[0.24728535,0.0030262056,0.04743213,0.005212347,0.00082679844,0.0000039666766,0.000022412583,0.00017726487,0.00007395573,0.00010761554,0.69559556,0.00023639409],"about_ca_topic_score_codex":0.00000643982,"about_ca_topic_score_gemma":0.0000013485582,"teacher_disagreement_score":0.9334098,"about_ca_system_score_codex":0.0000458122,"about_ca_system_score_gemma":0.000059336333,"threshold_uncertainty_score":0.8272368},"labels":[],"label_agreement":null},{"id":"W6921019084","doi":"10.6084/m9.figshare.19682255.v1","title":"Additional file 1 of Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Metformin; Semaglutide; Placebo; Post-hoc analysis; Discontinuation; Subgroup analysis; Baseline (sea)","score_opus":0.018307521026174573,"score_gpt":0.2228087442087414,"score_spread":0.2045012231825668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921019084","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047886357,0.00065092935,1.13314904e-7,0.000016290594,0.0000059676313,0.00028708557,0.9507306,0.000009188638,0.0004134329],"genre_scores_gemma":[0.12681945,0.0000060558027,0.00026657182,0.000022525324,0.000010765286,0.00052735355,0.870045,0.000011425551,0.0022908493],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892175,0.00004690365,0.00024294115,0.00018316178,0.00047756857,0.00012766375],"domain_scores_gemma":[0.9989607,0.0003342411,0.00017905484,0.00027328153,0.00020395922,0.000048762602],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006932957,0.00010262016,0.00049924955,0.00036865944,0.000036774603,0.000003393526,0.00007658864,0.00002617793,0.8760129],"category_scores_gemma":[0.0006253164,0.00009492137,0.00042129506,0.0006245997,0.0000127371795,0.000062426705,0.00018280192,0.000053841493,0.0000070665533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069179536,0.00020182032,0.0001277044,0.0003868817,0.0069674356,0.00002432308,0.00010368377,0.00012133943,0.00002721313,0.000007201667,0.98885757,0.0031056248],"study_design_scores_gemma":[0.0012862223,0.00068813376,0.08966626,0.001262355,0.0050808,0.000006635628,0.0012646265,0.00036298283,0.0007955282,0.000012517893,0.89937675,0.00019717072],"about_ca_topic_score_codex":0.00003084832,"about_ca_topic_score_gemma":0.00000726934,"teacher_disagreement_score":0.8760059,"about_ca_system_score_codex":0.000053570035,"about_ca_system_score_gemma":0.000060212576,"threshold_uncertainty_score":0.38707814},"labels":[],"label_agreement":null},{"id":"W6921332156","doi":"10.6084/m9.figshare.c.7920190","title":"Maternal metabolic health conditions and risk of stillbirth in India: evidence from a nationwide survey","year":2025,"lang":"en","type":"other","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Odds ratio; Logistic regression; Confidence interval; Diabetes mellitus; Pregnancy; Odds; Risk factor; Gestational diabetes","score_opus":0.03618098787539581,"score_gpt":0.31454038864740413,"score_spread":0.2783594007720083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921332156","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025268497,0.022144027,9.099066e-7,0.0000660813,0.000063408734,0.0010521832,0.9427455,0.000059544036,0.031341504],"genre_scores_gemma":[0.07073813,0.010608568,0.00043122077,0.0005307287,0.00016452144,0.0006104501,0.6040765,0.00020670606,0.31263316],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9992112,0.000098942895,0.00019309405,0.00021897812,0.00015263303,0.0001251572],"domain_scores_gemma":[0.9992464,0.00021031899,0.0002526222,0.00019382015,0.000038837854,0.000057990685],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000767723,0.00014273894,0.00043342327,0.00035370866,0.000013921161,0.000012621867,0.00006736833,0.00008437112,0.08006814],"category_scores_gemma":[0.0006472964,0.0001261488,0.00003756073,0.00016516547,0.000007368842,0.00003065841,0.00006940258,0.00010974287,0.00015134331],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010043847,0.000053667787,0.24561296,0.00064481515,0.0003965386,0.000009175288,0.000037281177,3.8354287e-7,2.6631642e-7,0.000012305898,0.75129193,0.0019306475],"study_design_scores_gemma":[0.00057786383,0.000038008442,0.91276723,0.014681378,0.000102443584,1.4751318e-7,0.0000054141024,0.00000596725,0.000014357347,0.00001735081,0.071721844,0.00006796873],"about_ca_topic_score_codex":0.009809711,"about_ca_topic_score_gemma":0.0053234417,"teacher_disagreement_score":0.6795701,"about_ca_system_score_codex":0.00002944469,"about_ca_system_score_gemma":0.0001690112,"threshold_uncertainty_score":0.99678403},"labels":[],"label_agreement":null},{"id":"W6930462030","doi":"10.5281/zenodo.14063099","title":"Mapping the UN Second World Ocean Assessment: Challenges and Opportunities","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Dalhousie University","funders":"","keywords":"Metadata; Identifier; Set (abstract data type); Citation; Co-citation; Indian ocean","score_opus":0.10591768531168008,"score_gpt":0.27112518473291214,"score_spread":0.16520749942123206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930462030","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031410925,0.008300829,0.00016957933,0.020119201,0.00013039113,0.0006334574,0.000046980767,0.0009767732,0.93821186],"genre_scores_gemma":[0.96834713,0.004245147,0.00012012949,0.0005271616,0.00016057807,7.318101e-8,0.00047801255,0.0006762221,0.025445532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991296,0.000103067614,0.00012406666,0.00024209381,0.00019913708,0.00020204454],"domain_scores_gemma":[0.999523,0.000028761127,0.000024963341,0.00023772755,0.00008673265,0.00009884407],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047359717,0.00010227887,0.00010615013,0.00024782875,0.00068092445,0.00050527713,0.00018417691,0.000019295716,0.0077431975],"category_scores_gemma":[0.000028038035,0.0000762564,0.00003340829,0.00018416833,0.00011190601,0.0001475253,0.00048675615,0.0001582789,0.0006003724],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010922809,0.00007139309,0.0000037696518,0.000386695,0.00027962285,0.00009143057,0.0023209741,4.604316e-7,0.00015313523,0.06980957,0.11485074,0.8120213],"study_design_scores_gemma":[0.00028730914,0.00014390932,0.0023978155,0.00011019281,0.000048371367,0.000045585948,0.0017014161,0.00023697883,0.000041886007,0.00049153203,0.99441755,0.0000774356],"about_ca_topic_score_codex":8.538041e-7,"about_ca_topic_score_gemma":2.224946e-7,"teacher_disagreement_score":0.9369362,"about_ca_system_score_codex":0.000064762426,"about_ca_system_score_gemma":0.0000030913782,"threshold_uncertainty_score":0.9931639},"labels":[],"label_agreement":null},{"id":"W6930569181","doi":"10.5281/zenodo.12519286","title":"Questioning the validity of the indicator-log hypothesis for tropical tuna in the Western Indian Ocean","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Indian ocean; Tuna; Tropics; Skipjack tuna; Indian culture","score_opus":0.0463512317061898,"score_gpt":0.2656051223114498,"score_spread":0.21925389060526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930569181","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01681023,0.0008983353,0.00028357815,0.019345243,0.0005596298,0.00734999,0.0007287915,0.0009156415,0.95310855],"genre_scores_gemma":[0.7044797,0.00034251448,0.0001745489,0.0014285335,0.0008274293,0.000001534551,0.0008359699,0.0065842397,0.28532556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984685,0.00035719277,0.00022185291,0.00030330996,0.00039780926,0.00025133634],"domain_scores_gemma":[0.99905306,0.00006871801,0.00014598266,0.0006221436,0.00005738616,0.00005269908],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00060370704,0.00016658213,0.00021430069,0.00024100633,0.00036393513,0.00023438538,0.0008831283,0.00009811095,0.0017909171],"category_scores_gemma":[0.00040021146,0.000089179746,0.00012133984,0.00038437758,0.00022829586,0.000030394229,0.0005131738,0.000312695,0.0012263028],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002715503,0.00017871794,0.0004178023,0.0004159508,0.00018797287,0.000011823234,0.001273613,8.8417437e-7,0.000013766237,0.0020992735,0.98060066,0.014772359],"study_design_scores_gemma":[0.00047497248,0.00020905373,0.008479775,0.00031982854,0.00018969298,0.000014833383,0.00024889916,0.000008060475,0.000035338577,0.00023367036,0.98969805,0.00008783757],"about_ca_topic_score_codex":0.0000233267,"about_ca_topic_score_gemma":0.000004459177,"teacher_disagreement_score":0.68766946,"about_ca_system_score_codex":0.0001034317,"about_ca_system_score_gemma":0.000007801818,"threshold_uncertainty_score":0.99955136},"labels":[],"label_agreement":null},{"id":"W6930792275","doi":"10.5281/zenodo.14041777","title":"Quantifying AI Readiness: Bridging Ontario's Community Colleges and Industry 4.0 Demands","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Workforce; Workforce development; Curriculum; Benchmarking; Higher education; Strategic planning; Bridging (networking); Private sector; Public policy; Workforce planning","score_opus":0.05611850728329489,"score_gpt":0.29321379650907065,"score_spread":0.23709528922577575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930792275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78696746,0.000115558876,0.00050781335,0.0032245906,0.000073723626,0.000511583,0.000019528135,0.0004867278,0.20809302],"genre_scores_gemma":[0.9873691,0.00003600246,0.00011584937,0.000779926,0.000030650444,6.998472e-8,0.0004815012,0.00027032266,0.0109165665],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908555,0.00016243997,0.00016310233,0.00020168036,0.0001578946,0.0002293649],"domain_scores_gemma":[0.9992853,0.000023973564,0.00004287639,0.00033843322,0.00020481982,0.00010461542],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004925475,0.000113612216,0.00017211994,0.00025153832,0.0017588545,0.0003563606,0.00023187837,0.000077099285,0.0017519677],"category_scores_gemma":[0.00019965348,0.00011276213,0.000029721767,0.0003842968,0.00011275063,0.00014640721,0.0008419414,0.00054838025,0.00022187563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046187948,0.0012515496,0.018847669,0.0011533749,0.0010094336,0.00011027995,0.005171029,0.000026355445,0.0032738966,0.028374234,0.61229265,0.32802764],"study_design_scores_gemma":[0.0014707302,0.00023999716,0.06519842,0.00025667285,0.00012870131,0.00002796246,0.0007998499,0.00016661131,0.00044631562,0.00010918382,0.93103784,0.00011768409],"about_ca_topic_score_codex":0.0006774757,"about_ca_topic_score_gemma":0.000054502445,"teacher_disagreement_score":0.32790995,"about_ca_system_score_codex":0.00023404723,"about_ca_system_score_gemma":0.000008505619,"threshold_uncertainty_score":0.99954075},"labels":[],"label_agreement":null},{"id":"W6931072362","doi":"10.5281/zenodo.4259009","title":"REGARDER[[Monster Hunter (2020)]EN STREAMING FILM FR COMPLET eho","year":2020,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Monster; Field (mathematics); Fusible alloy; Feature (linguistics)","score_opus":0.034545195374165914,"score_gpt":0.24777811624072815,"score_spread":0.21323292086656223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931072362","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019793669,0.0043324237,0.0038379335,0.06408613,0.0009242723,0.0022628105,0.000800597,0.0017062244,0.90225595],"genre_scores_gemma":[0.90913814,0.001530675,0.0011864643,0.006184629,0.0028568038,2.2907656e-7,0.007535872,0.004218874,0.0673483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970758,0.0004761969,0.0004193606,0.0007075278,0.00053309015,0.00078801665],"domain_scores_gemma":[0.9983533,0.000051743136,0.00013493109,0.0005513987,0.00033375216,0.00057484367],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00044197403,0.00032153676,0.00038158047,0.00015386738,0.0010702888,0.00074970775,0.00075361534,0.00011915228,0.08229335],"category_scores_gemma":[0.0005480728,0.00034226582,0.0001423974,0.0005599393,0.00023597054,0.00032034688,0.001830328,0.0004437999,0.051561788],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001401749,0.00035902156,0.000047438552,0.00052810577,0.00044430137,0.00024702383,0.0029360228,0.00005691175,0.0008366741,0.0040820837,0.7898796,0.20044263],"study_design_scores_gemma":[0.0020797167,0.0010506241,0.0013061896,0.0002981231,0.00028214045,0.000048516187,0.001464814,0.002651077,0.0002039881,0.000040147595,0.9902774,0.00029727694],"about_ca_topic_score_codex":0.0000255452,"about_ca_topic_score_gemma":4.7931684e-7,"teacher_disagreement_score":0.88934445,"about_ca_system_score_codex":0.00031709555,"about_ca_system_score_gemma":0.000007030559,"threshold_uncertainty_score":0.99990296},"labels":[],"label_agreement":null},{"id":"W6931090778","doi":"10.5281/zenodo.3246394","title":"An ERP study on the processing of agreement and tense violations in Arabic","year":2012,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agreement; Arabic; Measure (data warehouse); Semantics (computer science); Task (project management)","score_opus":0.05373958165768941,"score_gpt":0.2883538844887115,"score_spread":0.2346143028310221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931090778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97025454,0.000060006612,0.00006951983,0.0005047649,0.000013038065,0.00076957594,0.0000060418943,0.00006712205,0.02825541],"genre_scores_gemma":[0.9993948,0.000012287513,0.00004432577,0.000084797684,0.000029273877,1.1708466e-7,0.00007516285,0.00015945069,0.00019980171],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99926037,0.00013235434,0.00012834393,0.00013052831,0.00018903152,0.00015937109],"domain_scores_gemma":[0.99954724,0.000012565844,0.000045171288,0.0002219394,0.00010081598,0.00007225338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005382949,0.0000644582,0.000087776476,0.0001381853,0.0003548685,0.000077746394,0.000118261974,0.000013084149,0.00083436747],"category_scores_gemma":[0.00010171533,0.00004572401,0.000012073736,0.0002431302,0.000049740098,0.00013154295,0.00015053437,0.00007707983,0.00023680432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065782754,0.017889947,0.062304664,0.0004005304,0.0004366267,0.000032475717,0.04971761,0.00006459917,0.016257506,0.014392558,0.022817861,0.8150278],"study_design_scores_gemma":[0.0022316496,0.0027320187,0.86191076,0.00013573196,0.0001268893,0.000010777016,0.009034774,0.0006175291,0.00052976556,0.0000750883,0.12244271,0.0001522942],"about_ca_topic_score_codex":0.0000061210426,"about_ca_topic_score_gemma":3.1154565e-7,"teacher_disagreement_score":0.8148755,"about_ca_system_score_codex":0.000049186096,"about_ca_system_score_gemma":0.0000012711197,"threshold_uncertainty_score":0.91357386},"labels":[],"label_agreement":null},{"id":"W6931122780","doi":"10.5281/zenodo.4913246","title":"Neutrinos as signal and background in the search for dark matter with INO","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Neutrino; Dark matter; SIGNAL (programming language); Line (geometry); Neutrino detector","score_opus":0.05066433390541616,"score_gpt":0.2934506609177304,"score_spread":0.24278632701231426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931122780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7325199,0.0012988764,0.0000029355,0.010093622,0.000036360074,0.003488495,0.018763239,0.00005147753,0.23374505],"genre_scores_gemma":[0.95546925,0.000003196105,0.0001126139,0.0044645485,0.00007378842,0.00047600621,0.03339495,0.000015997266,0.0059896656],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9995484,0.00001566313,0.000053783315,0.00013598606,0.00010783182,0.00013837803],"domain_scores_gemma":[0.99970186,0.00009346113,0.000010094554,0.00012645833,0.000037609087,0.000030505667],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000029769912,0.00006433123,0.000090943526,0.000027692406,0.000027954025,0.000047861744,0.000038989157,0.000020247693,0.032717686],"category_scores_gemma":[0.0000072661073,0.000038807055,0.00002027533,0.000089250105,0.0000043590253,0.000042772383,0.00003979326,0.000056232086,0.000423087],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013999686,0.0002663608,0.018468669,0.00093404594,0.00014007137,0.00055272854,0.00048011437,0.0000024114788,0.000075098695,0.00016624384,0.9727838,0.0059904624],"study_design_scores_gemma":[0.0077448282,0.0013883131,0.56186944,0.0030511073,0.00020638717,0.00010686715,0.0022235767,0.00006076923,0.0052988655,0.00012715848,0.417616,0.00030664573],"about_ca_topic_score_codex":0.0000043753676,"about_ca_topic_score_gemma":0.000013445177,"teacher_disagreement_score":0.5551678,"about_ca_system_score_codex":0.000014611432,"about_ca_system_score_gemma":0.000034285797,"threshold_uncertainty_score":0.96816653},"labels":[],"label_agreement":null},{"id":"W6931902272","doi":"10.5683/sp3/tw14du","title":"Données et code de réplication pour : Analyse descriptive de la mobilité intergénérationnelle du revenu et de la transmission de ses composantes","year":2024,"lang":"fr","type":"dataset","venue":"Borealis","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Descriptive research; Context (archaeology); Perspective (graphical); Descriptive statistics; Transmission (telecommunications)","score_opus":0.016302417460727667,"score_gpt":0.3015272085459182,"score_spread":0.2852247910851905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931902272","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021322707,0.008730801,0.023493635,0.014843523,0.00020097711,0.0017043588,0.9221191,0.00029984626,0.007285074],"genre_scores_gemma":[0.07103042,0.023505757,0.011328,0.0021101607,0.0005679583,0.00059498876,0.8896606,0.00012192422,0.0010801649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961386,0.0018250098,0.0005296396,0.00062131434,0.00028243888,0.0006029985],"domain_scores_gemma":[0.9974078,0.0013309703,0.00020741564,0.0006067251,0.000100586476,0.00034652321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024260404,0.0005228633,0.0006077619,0.00033267253,0.00014121727,0.00024550673,0.00035787292,0.00045004877,0.00014218835],"category_scores_gemma":[0.0004207223,0.0004798022,0.00031185482,0.00028754707,0.00026627482,0.00017246827,0.00013273305,0.00057700765,0.00008774347],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021556248,0.0013335033,0.004418942,0.001440373,0.0011673954,0.00039361298,0.0065022493,0.00033256834,0.002778676,0.005267178,0.97137964,0.0047702873],"study_design_scores_gemma":[0.0015055723,0.00040158568,0.01198728,0.0038667491,0.004273067,0.000088815825,0.0029752168,0.0055541154,0.003144935,0.0059699523,0.9597936,0.0004390684],"about_ca_topic_score_codex":0.01578493,"about_ca_topic_score_gemma":0.0051738922,"teacher_disagreement_score":0.04970772,"about_ca_system_score_codex":0.001208144,"about_ca_system_score_gemma":0.00084735476,"threshold_uncertainty_score":0.99976534},"labels":[],"label_agreement":null},{"id":"W6938935643","doi":"10.60692/8m2jz-62x45","title":"A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dapagliflozin; Kidney disease; Renal function; Placebo; Creatinine; Acute kidney injury; Randomized controlled trial; Adverse effect","score_opus":0.020922588671435895,"score_gpt":0.2442563064000821,"score_spread":0.2233337177286462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6938935643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931348,0.00001286673,0.00026946687,0.0001975789,0.00019140515,0.0058104503,0.000067993395,0.00001213171,0.00030329422],"genre_scores_gemma":[0.99847364,0.0000017362753,0.0000067192664,0.00013974257,0.000011347818,0.001064226,0.00004683298,0.0000042677984,0.0002514679],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753666,0.00048048672,0.0012865154,0.000114941286,0.000473384,0.000108003806],"domain_scores_gemma":[0.99839485,0.00011077089,0.0010026719,0.00035468227,0.00007832477,0.00005871977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016478379,0.00013779364,0.0010869008,0.00069388235,0.000045082208,0.0000075312937,0.000103499515,0.00003101075,0.00005775653],"category_scores_gemma":[0.0004198482,0.00007171026,0.0004260302,0.0006667846,0.000056573383,0.00015436835,0.000080075886,0.00007365791,0.000001242843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7530912,0.000081162914,0.22941703,0.0006676694,0.002151908,0.0000011019031,0.01056374,0.0031916562,0.0000054589796,0.0006642784,0.000028853374,0.00013592014],"study_design_scores_gemma":[0.6750821,0.0003197593,0.29911965,0.00046467755,0.0034352578,1.7242499e-7,0.0030842077,0.018349396,0.000043316013,0.000008154939,0.000020525235,0.00007281228],"about_ca_topic_score_codex":0.000042677115,"about_ca_topic_score_gemma":0.000005665179,"teacher_disagreement_score":0.07800915,"about_ca_system_score_codex":0.00019272348,"about_ca_system_score_gemma":0.00015027491,"threshold_uncertainty_score":0.29242596},"labels":[],"label_agreement":null},{"id":"W6939063108","doi":"10.60692/w58t2-b9z95","title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","year":2018,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Agonist; Internalization; Endocytic cycle; Tolerability; Receptor; Type 2 diabetes; Insulin; Endocytosis","score_opus":0.020509968266534378,"score_gpt":0.23023529942251963,"score_spread":0.20972533115598527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939063108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686725,0.0000027001315,0.0057717473,0.0002571778,0.0014578397,0.0013618096,0.000030234633,0.00048990065,0.021956079],"genre_scores_gemma":[0.9960024,6.487327e-8,0.001586567,0.00056387443,0.0006266037,0.000081034515,0.00006143027,0.000015447693,0.0010626302],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876237,0.000018868814,0.00047045725,0.00016719071,0.0002685493,0.00031258553],"domain_scores_gemma":[0.99919224,0.0000047285025,0.00016157865,0.00029821906,0.00017743385,0.00016580774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025867645,0.00017830712,0.00024646666,0.0002241649,0.00016344523,0.00015548158,0.000089247944,0.00006275244,0.00007870281],"category_scores_gemma":[0.00003334353,0.00013958308,0.00007586074,0.00022030498,0.000024878462,0.0003065413,0.000062219064,0.000053856158,0.0061658826],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023267344,0.000118706565,0.19427867,0.0051234555,0.001887637,0.000035873076,0.6013008,0.00021040575,0.001105685,0.0017088846,0.06919342,0.12270973],"study_design_scores_gemma":[0.036766093,0.0073967557,0.190104,0.0048833047,0.0016970056,0.000059255213,0.123286985,0.01360855,0.05817621,0.0000010457967,0.56084716,0.0031736577],"about_ca_topic_score_codex":0.0000034655554,"about_ca_topic_score_gemma":5.878403e-8,"teacher_disagreement_score":0.4916537,"about_ca_system_score_codex":0.00018890476,"about_ca_system_score_gemma":0.000023013867,"threshold_uncertainty_score":0.9946079},"labels":[],"label_agreement":null},{"id":"W6939197259","doi":"10.60692/24nvq-tqz54","title":"Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","year":2016,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University","funders":"","keywords":"Heart failure; Observational study; Randomized controlled trial; Hazard ratio; Odds ratio; Confidence interval; Meta-analysis; Incidence (geometry)","score_opus":0.08066454900510427,"score_gpt":0.27760498425532704,"score_spread":0.19694043525022276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939197259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637004,0.02504102,0.00012124025,0.0037255601,0.000100526486,0.006890595,0.00015537202,0.00008648906,0.0001787966],"genre_scores_gemma":[0.99778616,0.00023181296,0.0003918468,0.0006577346,0.000004947317,0.00044615503,0.000030261639,0.0000063305647,0.00044473042],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9983006,0.0001721298,0.0010126561,0.00015050314,0.00023254658,0.00013157324],"domain_scores_gemma":[0.9989067,0.000120830555,0.00043152642,0.00023033006,0.0002498444,0.000060773273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012499212,0.00018734037,0.0029035448,0.0003619918,0.00003439626,0.000033725195,0.000033396474,0.00004409711,0.000022270006],"category_scores_gemma":[0.00021679897,0.00009328451,0.00022064368,0.00028359966,0.00008120848,0.0003334656,0.00005332444,0.000026346574,0.000016715772],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009922322,0.000018059725,0.13679501,0.55977863,0.27959344,0.0000016399309,0.020933194,0.0000028405675,0.000009281461,0.0007205138,0.0011218986,0.000033274493],"study_design_scores_gemma":[0.04197863,0.00021651982,0.026842697,0.021475887,0.90225494,0.000006997601,0.00621944,0.0002463525,0.00007566014,0.0000056387375,0.00023162854,0.0004456327],"about_ca_topic_score_codex":0.0000021157116,"about_ca_topic_score_gemma":0.0000010194337,"teacher_disagreement_score":0.6226615,"about_ca_system_score_codex":0.000047994195,"about_ca_system_score_gemma":0.000011757395,"threshold_uncertainty_score":0.3804032},"labels":[],"label_agreement":null},{"id":"W6939306646","doi":"10.6084/m9.figshare.13031561","title":"Additional file 6 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Quartile; Post-hoc analysis; Hazard ratio; Confidence interval; Adverse effect; Post hoc; Cardiovascular health","score_opus":0.015124986708689506,"score_gpt":0.23487899901432036,"score_spread":0.21975401230563085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939306646","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16192101,0.0017004329,0.0000020154125,0.000014960975,0.0000122084075,0.0010085012,0.83525187,0.000007583207,0.00008139032],"genre_scores_gemma":[0.76511216,0.000049428,0.00006205818,0.000019303963,0.000024588066,0.00021839641,0.23440641,0.000015718178,0.00009192099],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978694,0.0004250872,0.00058844464,0.0002533418,0.0007003247,0.00016343695],"domain_scores_gemma":[0.99624866,0.0018885732,0.0007561466,0.00060041127,0.00043380362,0.00007238183],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036352922,0.00017836304,0.0019904778,0.00016953713,0.0000293513,0.0000029347295,0.0001378965,0.00007980064,0.08788158],"category_scores_gemma":[0.009153111,0.00012559548,0.0030710702,0.00095089717,0.00004175665,0.000027766086,0.0001554141,0.00009050052,0.000005255973],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009900497,0.00069643266,0.0029048773,0.0057632243,0.33448133,0.000020442121,0.0008158531,0.0034288343,0.00008653915,0.0000037603147,0.64593476,0.0048739165],"study_design_scores_gemma":[0.012327684,0.0028730622,0.77099377,0.0058729514,0.12128263,4.0090728e-7,0.00045970592,0.0007193875,0.015429141,0.000015657544,0.069730766,0.00029485914],"about_ca_topic_score_codex":0.00008812453,"about_ca_topic_score_gemma":0.000009944206,"teacher_disagreement_score":0.7680889,"about_ca_system_score_codex":0.000022931537,"about_ca_system_score_gemma":0.000050159306,"threshold_uncertainty_score":0.9991932},"labels":[],"label_agreement":null},{"id":"W6939413908","doi":"10.6084/m9.figshare.19682255","title":"Additional file 1 of Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Metformin; Semaglutide; Placebo; Post-hoc analysis; Discontinuation; Subgroup analysis; Baseline (sea)","score_opus":0.018307521026174573,"score_gpt":0.2228087442087414,"score_spread":0.2045012231825668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939413908","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047886357,0.00065092935,1.13314904e-7,0.000016290594,0.0000059676313,0.00028708557,0.9507306,0.000009188638,0.0004134329],"genre_scores_gemma":[0.12681945,0.0000060558027,0.00026657182,0.000022525324,0.000010765286,0.00052735355,0.870045,0.000011425551,0.0022908493],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892175,0.00004690365,0.00024294115,0.00018316178,0.00047756857,0.00012766375],"domain_scores_gemma":[0.9989607,0.0003342411,0.00017905484,0.00027328153,0.00020395922,0.000048762602],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006932957,0.00010262016,0.00049924955,0.00036865944,0.000036774603,0.000003393526,0.00007658864,0.00002617793,0.8760129],"category_scores_gemma":[0.0006253164,0.00009492137,0.00042129506,0.0006245997,0.0000127371795,0.000062426705,0.00018280192,0.000053841493,0.0000070665533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069179536,0.00020182032,0.0001277044,0.0003868817,0.0069674356,0.00002432308,0.00010368377,0.00012133943,0.00002721313,0.000007201667,0.98885757,0.0031056248],"study_design_scores_gemma":[0.0012862223,0.00068813376,0.08966626,0.001262355,0.0050808,0.000006635628,0.0012646265,0.00036298283,0.0007955282,0.000012517893,0.89937675,0.00019717072],"about_ca_topic_score_codex":0.00003084832,"about_ca_topic_score_gemma":0.00000726934,"teacher_disagreement_score":0.8760059,"about_ca_system_score_codex":0.000053570035,"about_ca_system_score_gemma":0.000060212576,"threshold_uncertainty_score":0.38707814},"labels":[],"label_agreement":null},{"id":"W6939420970","doi":"10.6084/m9.figshare.13031552.v1","title":"Additional file 3 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Post-hoc analysis; Mace; Post hoc; Adverse effect; Clinical trial","score_opus":0.015122036795398084,"score_gpt":0.234778936554392,"score_spread":0.2196568997589939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939420970","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16243048,0.0016886037,0.0000020013179,0.0000148726895,0.0000122862275,0.001004745,0.8347588,0.0000075599614,0.0000806121],"genre_scores_gemma":[0.7633281,0.000049600327,0.000062144994,0.000019313231,0.000024866567,0.00021860491,0.23618768,0.000015751764,0.000093962226],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786997,0.00042478918,0.00058825465,0.00025328394,0.0007003245,0.00016340803],"domain_scores_gemma":[0.99624616,0.0018871542,0.0007560472,0.00060021173,0.0004380339,0.00007236821],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036307628,0.0001783332,0.0019897453,0.00016947335,0.000029341172,0.0000029331595,0.0001378393,0.000079794496,0.089798376],"category_scores_gemma":[0.009237939,0.0001255659,0.0030706772,0.000950676,0.000041747153,0.000027760101,0.00015534522,0.00009048684,0.000005380422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009851957,0.0006893621,0.002899539,0.0057729986,0.33271655,0.00002027728,0.0008089448,0.0034612487,0.00008684418,0.0000035873709,0.64770746,0.0048479475],"study_design_scores_gemma":[0.012450697,0.0028815905,0.76778543,0.0058953767,0.12117763,3.998001e-7,0.00046037772,0.00073041377,0.015817441,0.000015608928,0.072488494,0.00029656372],"about_ca_topic_score_codex":0.000087277105,"about_ca_topic_score_gemma":0.000009716551,"teacher_disagreement_score":0.76488584,"about_ca_system_score_codex":0.000023036602,"about_ca_system_score_gemma":0.00005027428,"threshold_uncertainty_score":0.99910766},"labels":[],"label_agreement":null},{"id":"W6939497374","doi":"10.6084/m9.figshare.21207028","title":"Additional file 3 of Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Glycemic; Diabetes mellitus; Glycemic load; MEDLINE; Physical activity","score_opus":0.05734248857083702,"score_gpt":0.2752711078667764,"score_spread":0.21792861929593937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939497374","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047413786,0.00087311096,8.746322e-9,0.000058183792,0.000004055613,0.0012981632,0.9923272,0.000012485998,0.0006853739],"genre_scores_gemma":[0.2488129,0.000002095594,0.0000068649033,0.000106885665,0.0000070854535,0.0024895992,0.7481961,0.0000074946042,0.0003709538],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99930876,0.0001267223,0.00018747608,0.00009265981,0.00021784351,0.000066555614],"domain_scores_gemma":[0.9898787,0.009685628,0.0001908862,0.00020038843,0.000017293341,0.000027073414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060150556,0.00008258884,0.0003305548,0.000045184108,0.00004948063,0.0000031947395,0.00006257129,0.000014623423,0.8107077],"category_scores_gemma":[0.007433197,0.000047578935,0.000092914124,0.00012761261,0.000006721182,0.000019443023,0.000061224746,0.00008226375,0.00012371366],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009908152,0.00001901193,0.00065487117,0.07224555,0.00009807663,0.0000013057997,0.000017800732,2.8390733e-7,9.6791936e-8,0.000005602038,0.92693144,0.000016051821],"study_design_scores_gemma":[0.0008924318,0.003430798,0.042448636,0.90495735,0.0013889225,0.000004112459,0.00008675567,0.000016192456,0.00007040937,0.000032091346,0.04650458,0.00016772668],"about_ca_topic_score_codex":8.533737e-7,"about_ca_topic_score_gemma":1.3176e-7,"teacher_disagreement_score":0.8804269,"about_ca_system_score_codex":0.000028994795,"about_ca_system_score_gemma":0.000015051117,"threshold_uncertainty_score":0.8898768},"labels":[],"label_agreement":null},{"id":"W6939671934","doi":"10.6084/m9.figshare.26575994.v1","title":"Additional file 1 of Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Heart failure; Adverse effect; Relative risk; Funnel plot; Randomized controlled trial; Clinical trial; Confidence interval; Meta-analysis","score_opus":0.10116488122498891,"score_gpt":0.32869413206515935,"score_spread":0.22752925084017045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939671934","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046025906,0.021513302,0.0000057170632,0.00010468736,0.0000098066575,0.0010792898,0.9725568,0.000045531644,0.00008226032],"genre_scores_gemma":[0.25923502,0.000050001363,0.00090390263,0.000063758845,0.000018791376,0.00082372816,0.73852307,0.000029098357,0.00035264663],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99680436,0.00069677643,0.0009783669,0.00053917355,0.00081282953,0.00016847605],"domain_scores_gemma":[0.9953007,0.0032711406,0.0003006901,0.0008345434,0.0001927485,0.0001001959],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088167726,0.00037965376,0.009700607,0.0012167923,0.000035852376,0.000031428764,0.000098520235,0.00011943125,0.77814543],"category_scores_gemma":[0.0016812645,0.00019722062,0.016544096,0.0013162965,0.000057319714,0.00011814555,0.00007212483,0.0001019756,0.000015045162],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000823268,0.00012415054,0.000041009796,0.00027531685,0.84834397,0.000011418737,0.000059444985,0.0002706814,0.000011929001,0.000004192175,0.14970368,0.00033091017],"study_design_scores_gemma":[0.011005299,0.00012697338,0.0041801166,0.00012257128,0.91389436,9.81788e-7,0.000047831283,0.00036353967,0.00020800428,0.000004711279,0.06989153,0.00015406308],"about_ca_topic_score_codex":0.00004140422,"about_ca_topic_score_gemma":0.00000761426,"teacher_disagreement_score":0.77813035,"about_ca_system_score_codex":0.000016428405,"about_ca_system_score_gemma":0.00003145418,"threshold_uncertainty_score":0.99330497},"labels":[],"label_agreement":null},{"id":"W6939760183","doi":"10.6084/m9.figshare.28436893","title":"Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bowel obstruction; Ileus; Randomized controlled trial; Liraglutide; Relative risk; Cohort study; Cohort","score_opus":0.0710601453254852,"score_gpt":0.3448079652481441,"score_spread":0.2737478199226589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939760183","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23092626,0.54797584,0.000005125392,0.008410797,0.00043748412,0.065314844,0.12842233,0.00059145555,0.017915854],"genre_scores_gemma":[0.78939307,0.0015816544,0.00097639667,0.010300188,0.000043624616,0.011567232,0.15463395,0.00007930918,0.031424586],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9990334,0.00009031695,0.000305886,0.00025497595,0.00020135407,0.00011405752],"domain_scores_gemma":[0.99945325,0.000067804875,0.0001322409,0.00023275118,0.00007237291,0.00004158558],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011232614,0.00013863528,0.0008647226,0.00018630188,0.000038163013,0.000015602742,0.000038727943,0.000033744134,0.0076788734],"category_scores_gemma":[0.00082038104,0.00009868742,0.00016459326,0.00035588458,0.0000026560194,0.000054014705,0.00005632611,0.000055812452,0.00007188069],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006978869,0.0006189003,0.008469766,0.8323866,0.114259444,0.0000073593897,0.00019308862,0.0000122129995,0.000002871334,0.000038339705,0.04136236,0.0025792369],"study_design_scores_gemma":[0.0030838763,0.00063682743,0.09255411,0.08655566,0.81530625,5.381815e-7,0.00007166827,0.0002609293,0.000033288426,0.0000642844,0.0010931945,0.00033941516],"about_ca_topic_score_codex":0.0000053451863,"about_ca_topic_score_gemma":0.000005771923,"teacher_disagreement_score":0.74583095,"about_ca_system_score_codex":0.00009010424,"about_ca_system_score_gemma":0.000010513982,"threshold_uncertainty_score":0.99322826},"labels":[],"label_agreement":null},{"id":"W6939995916","doi":"10.6084/m9.figshare.25010557","title":"Additional file 2 of Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Octreotide; Clinical trial; Depot; Phase (matter); Phases of clinical research; Complication","score_opus":0.04937336468752859,"score_gpt":0.3470212422208311,"score_spread":0.29764787753330246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939995916","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33544338,0.00012287498,0.0000014297714,0.00007128153,0.00012097909,0.007365934,0.65624964,0.000019259749,0.00060521695],"genre_scores_gemma":[0.8037993,0.0000054815864,0.00061514234,0.000040346553,0.00017465501,0.0022161023,0.1927097,0.00003003064,0.0004092703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800295,0.00055798184,0.00070443924,0.00027467887,0.0003064454,0.00015352885],"domain_scores_gemma":[0.9869903,0.012155068,0.00043892858,0.000244593,0.00012946012,0.000041660198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027461065,0.00016655865,0.0008618956,0.00008705757,0.000035551227,0.000015713793,0.00010923139,0.00007947468,0.2568292],"category_scores_gemma":[0.0069365315,0.000082527404,0.00024065557,0.00022155412,0.00007002138,0.00006436684,0.00007854615,0.0001961766,0.000005838409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80162466,0.001868695,0.0001481292,0.00020457311,0.0010710504,0.000021824631,0.0000996577,0.000005331133,0.0000039132046,0.000011646869,0.18094686,0.013993698],"study_design_scores_gemma":[0.9478451,0.006464161,0.03528843,0.0030400266,0.0006513136,0.0000026242928,0.00005376041,0.0000667287,0.00008090532,0.00004503673,0.0063657183,0.00009620637],"about_ca_topic_score_codex":0.000005440893,"about_ca_topic_score_gemma":0.000012330271,"teacher_disagreement_score":0.4683559,"about_ca_system_score_codex":0.000040192757,"about_ca_system_score_gemma":0.00019116014,"threshold_uncertainty_score":0.8304177},"labels":[],"label_agreement":null},{"id":"W6942291307","doi":"10.14288/1.0433679","title":"Questioning the basis of approval for non-insulin glucose lowering drugs","year":2023,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Type 2 diabetes; Diabetes treatment; Diabetes mellitus; Drug; Assertion; Clinical trial","score_opus":0.008898626500126426,"score_gpt":0.19609660574922436,"score_spread":0.18719797924909792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6942291307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974468,0.000041477877,0.00032785034,0.00026560103,0.00008544477,0.00055625435,0.00019688738,0.00006201007,0.0010176821],"genre_scores_gemma":[0.9976613,0.0001281773,0.00047140472,0.000028469423,0.000023092745,0.0000030734186,0.00023436164,0.000009286526,0.0014408315],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993908,0.000010078018,0.000090332556,0.00018031441,0.00015999826,0.00016850061],"domain_scores_gemma":[0.9995158,0.00006033472,0.00007821435,0.00019438456,0.00010167563,0.000049632526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022039269,0.00003166332,0.0002017335,0.00004983937,0.00013702415,0.000022015845,0.00012455138,0.000038584185,0.000037120128],"category_scores_gemma":[0.000030743176,0.000081970225,0.00014053959,0.0003040604,0.00011303898,0.0000885926,0.000095389034,0.000046147703,0.000018569206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004060162,0.00016735506,0.006449708,0.00039033408,0.00022415584,0.000047101454,0.00035157532,0.000018774375,0.0004714935,0.0000040826158,0.014201568,0.97763324],"study_design_scores_gemma":[0.0024254008,0.00021111769,0.99117464,0.0003280845,0.0002773792,0.0000034033455,0.0023654057,0.0009893924,0.00006140342,0.00010448453,0.0019693507,0.0000899239],"about_ca_topic_score_codex":0.012207968,"about_ca_topic_score_gemma":0.007916763,"teacher_disagreement_score":0.98472494,"about_ca_system_score_codex":0.0000413228,"about_ca_system_score_gemma":0.00003444705,"threshold_uncertainty_score":0.9943698},"labels":[],"label_agreement":null},{"id":"W6942396427","doi":"10.1371/journal.pone.0307581.s001","title":"Checklist of PLOS one required manuscript items.","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Checklist; Comorbidity; Diagnosis code; Medical prescription; Receipt; MEDLINE","score_opus":0.0774564691353112,"score_gpt":0.2736338321049455,"score_spread":0.1961773629696343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6942396427","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026724886,0.01649062,0.0000015576019,0.0037393728,0.00038960695,0.002839596,0.16604525,0.0012209523,0.7825482],"genre_scores_gemma":[0.77614725,0.000026339403,0.0002938127,0.00048627163,0.00033175852,0.00035396693,0.12409976,0.000056329383,0.098204516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933577,0.000005851628,0.00014074451,0.0001749423,0.00019948653,0.00014320364],"domain_scores_gemma":[0.99962014,0.000022977376,0.000025530062,0.00022728591,0.00004396404,0.000060088507],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000020550202,0.00009229455,0.00018193679,0.00009022009,0.000013525624,0.000024615512,0.00005944843,0.00004085025,0.11800448],"category_scores_gemma":[0.00010674591,0.00007846929,0.00008426024,0.00015124085,0.00000511661,0.00007477613,0.000058750087,0.00005695664,0.0031372146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001507259,0.0002769489,0.00006587451,0.0035533109,0.00043553137,0.00012653299,0.000096413125,1.6576462e-7,0.0028079227,0.00017107699,0.98596233,0.006488838],"study_design_scores_gemma":[0.000884833,0.00044480723,0.005209231,0.017933322,0.00048080235,0.0000028987736,0.000049210408,0.00031049162,0.051311877,0.00009201943,0.9230942,0.00018630132],"about_ca_topic_score_codex":0.0000030386536,"about_ca_topic_score_gemma":0.0000013102444,"teacher_disagreement_score":0.7494224,"about_ca_system_score_codex":0.000043623975,"about_ca_system_score_gemma":0.000027942575,"threshold_uncertainty_score":0.99763894},"labels":[],"label_agreement":null},{"id":"W6945944119","doi":"10.26190/unsworks/30079","title":"Improving the Uptake of Evidence-based Therapy in Chronic Kidney Disease and Diabetes","year":2024,"lang":"en","type":"dissertation","venue":"UNSWorks (University of New South Wales, Sydney, Australia)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Australian Government","keywords":"Kidney disease; Generalizability theory; Diabetes mellitus; Population; Disease; Cohort; Incidence (geometry); Clinical trial","score_opus":0.07037802228231729,"score_gpt":0.27787399170506544,"score_spread":0.20749596942274814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6945944119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910273,0.005943239,0.000011697168,0.0013917412,0.0002611481,0.001113809,0.00007211737,0.000046664798,0.00013226272],"genre_scores_gemma":[0.9565415,0.001069651,0.00023265783,0.0000856043,0.00010701665,0.000003357218,0.0006396205,0.000038816375,0.041281812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984146,0.000045296554,0.00028859838,0.00049884437,0.00040458213,0.0003481148],"domain_scores_gemma":[0.9987165,0.00007664605,0.0003109352,0.00047736894,0.000079495796,0.00033907354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002173347,0.00034712214,0.00059178437,0.0004316086,0.00007511177,0.000032748532,0.0002800972,0.00024383275,0.00025903984],"category_scores_gemma":[0.00006989835,0.00028153675,0.00029658442,0.00043375866,0.00016915954,0.00014998812,0.000056302593,0.00038246447,0.000014622469],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010521145,0.0019252567,0.26017302,0.052565794,0.00954228,0.0011921695,0.051336877,0.00093623466,0.012223593,0.0021137402,0.08384692,0.513623],"study_design_scores_gemma":[0.014073167,0.002799873,0.8739628,0.046619594,0.011313956,8.4691646e-7,0.024195284,0.0045407843,0.0015707078,0.00068309077,0.018653626,0.0015862358],"about_ca_topic_score_codex":0.0010153938,"about_ca_topic_score_gemma":0.00038454702,"teacher_disagreement_score":0.6137898,"about_ca_system_score_codex":0.00023133984,"about_ca_system_score_gemma":0.0009157844,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W6949789995","doi":"10.5281/zenodo.4733122","title":"Antibody Characterization Report for Solute carrier family 2, facilitated glucose transporter member 6 SLC2A6 (GLUT-6)","year":2021,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Solute carrier family; Family member; Transporter; Antibody; Glucose transporter; Plasma protein binding; Joint (building)","score_opus":0.038854196265402305,"score_gpt":0.2761405433129283,"score_spread":0.237286347047526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6949789995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7393039,0.00026667689,0.123393916,0.00382666,0.0005889605,0.0033655064,0.001969794,0.0018497038,0.12543488],"genre_scores_gemma":[0.6412124,0.0003129885,0.0009902582,0.00088314986,0.00027447302,9.467276e-7,0.32388964,0.0016937664,0.03074239],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981882,0.00009887763,0.0003822061,0.00054786674,0.00037303497,0.00040979657],"domain_scores_gemma":[0.99823225,0.000013113375,0.00011163109,0.00053678494,0.00090063765,0.0002056125],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00040207658,0.00019018029,0.0002730019,0.0001613006,0.0007404766,0.00025980268,0.00019929608,0.000075749456,0.0056430367],"category_scores_gemma":[0.00023570203,0.00019136323,0.00013061413,0.0004313186,0.00007730111,0.0002712442,0.0002053061,0.00012896331,0.0009111634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031796965,0.0006670139,0.00016797996,0.0003913176,0.0005742606,0.00070476724,0.001330492,0.0000078904595,0.91000867,0.00072883297,0.016969029,0.06813175],"study_design_scores_gemma":[0.0017971523,0.000290345,0.016401054,0.00005792714,0.00019219023,0.00012626308,0.00023103443,0.00022915436,0.0057726684,0.000029072657,0.9746835,0.00018959829],"about_ca_topic_score_codex":0.000006418988,"about_ca_topic_score_gemma":3.029561e-7,"teacher_disagreement_score":0.9577145,"about_ca_system_score_codex":0.00013055948,"about_ca_system_score_gemma":0.000012796968,"threshold_uncertainty_score":0.9998667},"labels":[],"label_agreement":null},{"id":"W6957827070","doi":"10.60692/rjmbb-94e68","title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dapagliflozin; Kidney disease; Hazard ratio; Post-hoc analysis; Clinical endpoint; Renal function; Proportional hazards model; Kidney; Heart failure","score_opus":0.009013823644687924,"score_gpt":0.20489677714820476,"score_spread":0.19588295350351684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957827070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607116,0.000031250613,0.00019402386,0.00007590055,0.0002527662,0.0014686832,0.0010536852,0.000037319158,0.0008152221],"genre_scores_gemma":[0.9991557,0.0000011443109,0.000009454686,0.00018656386,0.000014399623,0.00017013385,0.00025755214,0.000008136597,0.00019690974],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809724,0.0003634636,0.0005945397,0.00014484586,0.00065863517,0.00014128108],"domain_scores_gemma":[0.9987426,0.000046725243,0.00040176057,0.0006474888,0.00008492954,0.000076544115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014858023,0.00017984382,0.00081217993,0.00041967057,0.00012291514,0.00002298863,0.000114294075,0.000039054295,0.00003509841],"category_scores_gemma":[0.000108732274,0.000104312225,0.00057080697,0.0006000649,0.00003483566,0.00011197389,0.00011319637,0.00008489541,0.0000074582013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02277194,0.0000746369,0.8838041,0.002329744,0.04014507,0.000005604266,0.038916454,0.0021854031,0.000006207247,0.00013265124,0.002805354,0.0068228757],"study_design_scores_gemma":[0.43314138,0.03198628,0.20658898,0.00083643454,0.17475788,0.000022993916,0.07040943,0.028471721,0.008903391,0.0000015407823,0.04315954,0.001720417],"about_ca_topic_score_codex":0.000084032574,"about_ca_topic_score_gemma":2.3588596e-7,"teacher_disagreement_score":0.6772151,"about_ca_system_score_codex":0.000091999784,"about_ca_system_score_gemma":0.00002835613,"threshold_uncertainty_score":0.4253729},"labels":[],"label_agreement":null},{"id":"W6957859394","doi":"10.60692/1pt6b-rqf20","title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"","keywords":"Canagliflozin; Renal function; Placebo; Kidney disease; Confidence interval; Diabetes mellitus; Clinical trial; Clinical Practice","score_opus":0.07722421310930391,"score_gpt":0.3254279902166108,"score_spread":0.24820377710730687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957859394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900028,0.000015537214,0.0059492555,0.00041252776,0.00010909951,0.0025491617,0.00015234752,0.00014276637,0.0006664657],"genre_scores_gemma":[0.99084866,0.0000058365977,0.006394761,0.00018150166,0.000086292835,0.0010688376,0.0012621505,0.000018933073,0.0001330199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833536,0.00012641479,0.0007692668,0.0003259569,0.00021293141,0.00023009664],"domain_scores_gemma":[0.9984834,0.00004493181,0.0004660314,0.00051937235,0.00031944938,0.00016681339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016923183,0.00023867839,0.00044014,0.00020755913,0.00014402228,0.00017891948,0.00007366936,0.000100179626,0.000006069496],"category_scores_gemma":[0.000040549356,0.00016256903,0.000062562896,0.0003683398,0.00003288273,0.0011627254,0.000019978062,0.00007659559,0.00003792684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14082886,0.0012343588,0.752602,0.0010934222,0.009698468,0.0007952965,0.08157258,0.0010621155,0.0004288294,0.0020671599,0.000128134,0.008488801],"study_design_scores_gemma":[0.15979815,0.007029882,0.8060104,0.0008804368,0.0036359339,0.000096353106,0.012314131,0.0049568256,0.0033568072,0.000006219685,0.0013020334,0.0006128275],"about_ca_topic_score_codex":0.000094795054,"about_ca_topic_score_gemma":0.00003619004,"teacher_disagreement_score":0.069258444,"about_ca_system_score_codex":0.00036826116,"about_ca_system_score_gemma":0.00025384917,"threshold_uncertainty_score":0.6629373},"labels":[],"label_agreement":null},{"id":"W6957861918","doi":"10.60692/rxkrd-n7n86","title":"Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Population Health Research Institute; Université de Montréal; University of Calgary; Impact; McMaster University","funders":"","keywords":"Framingham Risk Score; Disease; Risk assessment; Coronary artery disease; Biomarker; Natriuretic peptide; Predictive modelling; Diabetes mellitus; Predictive value of tests","score_opus":0.05281838672444201,"score_gpt":0.2547277833814845,"score_spread":0.2019093966570425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957861918","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09946074,0.7388087,0.058990467,0.0023438344,0.0011154126,0.0932795,0.0016529263,0.0020511316,0.0022972848],"genre_scores_gemma":[0.9971316,0.00004762653,0.00027520707,0.00024066192,0.000011864114,0.0017952936,0.00012063718,0.000011671573,0.00036543806],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99864966,0.0000604945,0.0006357741,0.00018647079,0.0003022359,0.00016534042],"domain_scores_gemma":[0.9991951,0.000026761049,0.00008931009,0.00045402144,0.00013327732,0.00010150615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082995364,0.00017683218,0.0013721151,0.00044845822,0.000028429804,0.00013322805,0.000050566345,0.00003731052,0.0000113971055],"category_scores_gemma":[0.00010244783,0.00010724964,0.0009723143,0.00063112116,0.000009771317,0.00026760646,0.000032734875,0.000036814086,0.00009491878],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016265747,0.00000505643,0.004026561,0.80520475,0.18823639,0.000010145584,0.0021016805,0.000112803566,1.01645075e-8,0.00012732105,0.00010894817,0.000050060462],"study_design_scores_gemma":[0.00038242614,0.00006858781,0.0009226228,0.008356479,0.9798207,0.0000013716304,0.00029109488,0.009728158,0.0000020678815,0.0000016813048,0.0002899819,0.00013482121],"about_ca_topic_score_codex":0.0000011074159,"about_ca_topic_score_gemma":5.284759e-8,"teacher_disagreement_score":0.89767087,"about_ca_system_score_codex":0.0000783979,"about_ca_system_score_gemma":0.000021232776,"threshold_uncertainty_score":0.43735132},"labels":[],"label_agreement":null},{"id":"W6958019173","doi":"10.6084/m9.figshare.28862501.v1","title":"Additional file 1 of Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; MEDLINE","score_opus":0.02425187276643529,"score_gpt":0.30927196777268146,"score_spread":0.28502009500624614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958019173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6596435,0.00004153604,0.0000062247927,0.000144564,0.00017470878,0.0018074246,0.024643343,0.0000028739921,0.31353584],"genre_scores_gemma":[0.8328503,0.000011070491,0.022356816,0.00018471308,0.00011199555,0.0009232787,0.0815283,0.000024138115,0.062009417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945253,0.000039019844,0.00016170995,0.00015715543,0.00009145456,0.00009814475],"domain_scores_gemma":[0.9993215,0.00039373434,0.000047360445,0.00013876079,0.000070910784,0.000027709473],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013536506,0.00006969641,0.0002259664,0.00020007009,0.000014108817,0.000011916367,0.00007373889,0.000023276629,0.26882705],"category_scores_gemma":[0.00017618143,0.00006337955,0.000028575796,0.00041289846,0.000015350399,0.00006767427,0.000094794545,0.000029117487,0.00008457553],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017071012,0.00034786487,0.005444337,0.000120249926,0.00018445596,0.0000042752667,0.000052896394,0.00005066788,0.006533333,0.00019907625,0.8829733,0.10391882],"study_design_scores_gemma":[0.0015804459,0.000480283,0.2472297,0.0030524826,0.00014245004,6.6489804e-8,0.000049461192,0.00032138833,0.060493015,0.000063592306,0.6864564,0.00013071927],"about_ca_topic_score_codex":0.000047045458,"about_ca_topic_score_gemma":0.00018939472,"teacher_disagreement_score":0.2687425,"about_ca_system_score_codex":0.00006719473,"about_ca_system_score_gemma":0.00007702462,"threshold_uncertainty_score":0.7318413},"labels":[],"label_agreement":null},{"id":"W6958184445","doi":"10.6084/m9.figshare.13031552","title":"Additional file 3 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Post-hoc analysis; Mace; Post hoc; Adverse effect; Clinical trial","score_opus":0.015122036795398084,"score_gpt":0.234778936554392,"score_spread":0.2196568997589939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958184445","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16243048,0.0016886037,0.0000020013179,0.0000148726895,0.0000122862275,0.001004745,0.8347588,0.0000075599614,0.0000806121],"genre_scores_gemma":[0.7633281,0.000049600327,0.000062144994,0.000019313231,0.000024866567,0.00021860491,0.23618768,0.000015751764,0.000093962226],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786997,0.00042478918,0.00058825465,0.00025328394,0.0007003245,0.00016340803],"domain_scores_gemma":[0.99624616,0.0018871542,0.0007560472,0.00060021173,0.0004380339,0.00007236821],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036307628,0.0001783332,0.0019897453,0.00016947335,0.000029341172,0.0000029331595,0.0001378393,0.000079794496,0.089798376],"category_scores_gemma":[0.009237939,0.0001255659,0.0030706772,0.000950676,0.000041747153,0.000027760101,0.00015534522,0.00009048684,0.000005380422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009851957,0.0006893621,0.002899539,0.0057729986,0.33271655,0.00002027728,0.0008089448,0.0034612487,0.00008684418,0.0000035873709,0.64770746,0.0048479475],"study_design_scores_gemma":[0.012450697,0.0028815905,0.76778543,0.0058953767,0.12117763,3.998001e-7,0.00046037772,0.00073041377,0.015817441,0.000015608928,0.072488494,0.00029656372],"about_ca_topic_score_codex":0.000087277105,"about_ca_topic_score_gemma":0.000009716551,"teacher_disagreement_score":0.76488584,"about_ca_system_score_codex":0.000023036602,"about_ca_system_score_gemma":0.00005027428,"threshold_uncertainty_score":0.99910766},"labels":[],"label_agreement":null},{"id":"W6958243609","doi":"10.6084/m9.figshare.25010392.v1","title":"Additional file 1 of Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Clinical trial; Octreotide; Depot; Phase (matter); Phases of clinical research; Complication","score_opus":0.05085509135337717,"score_gpt":0.3475861751588271,"score_spread":0.29673108380544994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958243609","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33429173,0.00012021238,0.0000014461737,0.00007105005,0.00011941613,0.0073198355,0.6574686,0.000019113279,0.00058861636],"genre_scores_gemma":[0.80544853,0.0000053275417,0.0006239977,0.000040127186,0.00017146343,0.0022422834,0.1910325,0.000029905912,0.00040587742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800277,0.0005581483,0.0007041578,0.00027486094,0.0003065127,0.00015357869],"domain_scores_gemma":[0.98683625,0.012308865,0.0004384294,0.00024503516,0.00012972917,0.000041669853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027594686,0.00016660562,0.00086170866,0.00008710814,0.000035548917,0.000015683605,0.000109285334,0.000079474274,0.2600626],"category_scores_gemma":[0.0070111183,0.00008255134,0.00024069686,0.00022170696,0.00007002224,0.000064327745,0.00007855595,0.00019621666,0.0000058942173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80027664,0.0018633006,0.0001519396,0.00020229866,0.0010676414,0.000021240572,0.00009926708,0.0000052916607,0.000004024627,0.000011431658,0.18268101,0.013615898],"study_design_scores_gemma":[0.9474994,0.006465538,0.035800558,0.0030747075,0.00065364357,0.0000026200673,0.000054271037,0.00006715058,0.00008138309,0.000044736935,0.0061595635,0.000096419964],"about_ca_topic_score_codex":0.000005392721,"about_ca_topic_score_gemma":0.000012265906,"teacher_disagreement_score":0.4711568,"about_ca_system_score_codex":0.00004018255,"about_ca_system_score_gemma":0.00019191772,"threshold_uncertainty_score":0.83934695},"labels":[],"label_agreement":null},{"id":"W6958248039","doi":"10.6084/m9.figshare.16755940.v1","title":"Additional file 1 of Online clinical pathway for chronic kidney disease management in primary care: a retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Alberta; University of Calgary","funders":"","keywords":"Cohort; Diabetes mellitus; Albuminuria; Statin; Retrospective cohort study; Cohort study","score_opus":0.02421439802148108,"score_gpt":0.2953140571517958,"score_spread":0.27109965913031475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958248039","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000545096,0.00014525732,1.2549725e-7,0.0000688699,0.00003433586,0.0023020483,0.98835075,0.000029965158,0.008523524],"genre_scores_gemma":[0.0054888586,0.0000067740298,0.0005768411,0.00042475076,0.00017029644,0.006014895,0.9825477,0.000020616138,0.0047492436],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99877304,0.000032998854,0.0003176146,0.00040247384,0.0002872318,0.00018662393],"domain_scores_gemma":[0.9989486,0.00025597194,0.00009816715,0.0003346121,0.000195088,0.00016755736],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000033674332,0.00013367826,0.0003540125,0.00007030067,0.000025356107,0.000009097925,0.00007274424,0.000036945985,0.90845937],"category_scores_gemma":[0.0011232635,0.00012643242,0.00017992368,0.00018249641,0.000008472241,0.000043813245,0.0001650311,0.00008949477,0.00018111391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008787497,0.0024632292,0.009090413,0.00095956144,0.00042370634,0.00032248482,0.00001767976,7.6845697e-7,1.7569417e-7,0.000005565433,0.9778172,0.008811382],"study_design_scores_gemma":[0.0019415326,0.00037908115,0.59029603,0.0019853169,0.00011819556,2.1183664e-7,0.000066674394,0.000022725286,0.0000019091465,0.000008546164,0.40511048,0.000069320726],"about_ca_topic_score_codex":6.112307e-7,"about_ca_topic_score_gemma":0.000020886191,"teacher_disagreement_score":0.9082783,"about_ca_system_score_codex":0.00045773873,"about_ca_system_score_gemma":0.0005620202,"threshold_uncertainty_score":0.5155764},"labels":[],"label_agreement":null},{"id":"W6958314230","doi":"10.6084/m9.figshare.12768727","title":"Additional file 1 of Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Heart failure with preserved ejection fraction; Quality (philosophy); MEDLINE; Quality assessment","score_opus":0.04707029997708,"score_gpt":0.27129267154989706,"score_spread":0.22422237157281705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958314230","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018902805,0.003782575,4.947797e-7,0.00080623163,8.8147584e-7,0.0016248679,0.9932692,0.000027660562,0.00046916844],"genre_scores_gemma":[0.001748245,0.00004033826,0.0010155924,0.00049100514,0.00001540759,0.008046446,0.9869649,0.000011188426,0.0016669002],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930954,0.00004288186,0.00020971081,0.0001845685,0.00017205748,0.000081244194],"domain_scores_gemma":[0.99933374,0.00023596328,0.00014893449,0.00015006054,0.0000614929,0.00006983913],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000018165832,0.00013626183,0.0008821441,0.00009914474,0.000019514282,0.000008757006,0.000025755824,0.00002937348,0.9480206],"category_scores_gemma":[0.0004452321,0.000072954324,0.00018146196,0.0005100843,0.0000033504352,0.00010746255,0.000020727111,0.000039767823,0.00014893888],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013419932,0.00008489817,0.000038101432,0.05227936,0.004242874,0.0000096676185,0.000009783375,0.0000030346068,6.476507e-7,2.1030668e-7,0.943304,0.000013980882],"study_design_scores_gemma":[0.0014280665,0.0015958485,0.003824732,0.121321276,0.09310501,0.0000101409005,0.00020411942,0.0007090345,0.00018616392,0.0000023044227,0.7773411,0.0002721833],"about_ca_topic_score_codex":0.0000063009043,"about_ca_topic_score_gemma":0.000033595294,"teacher_disagreement_score":0.9478716,"about_ca_system_score_codex":0.00004901684,"about_ca_system_score_gemma":0.000024554303,"threshold_uncertainty_score":0.2974991},"labels":[],"label_agreement":null},{"id":"W6958331215","doi":"10.6084/m9.figshare.19844664.v1","title":"Additional file 2 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Diabetes mellitus; Disease; Heart failure; Primary care; Kidney disease","score_opus":0.020051398083324665,"score_gpt":0.24647051013912505,"score_spread":0.2264191120558004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958331215","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38718456,0.000011791336,5.0101367e-9,8.427888e-7,0.0000148807485,0.0009845991,0.6112384,0.0000075118446,0.00055736786],"genre_scores_gemma":[0.494809,1.1360237e-7,0.000019292202,0.000013085801,0.000011481297,0.0040602437,0.50101477,0.00000839692,0.000063603475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869305,0.00008714481,0.00029415358,0.00024392814,0.0005179765,0.0001637288],"domain_scores_gemma":[0.9992112,0.0002943244,0.0001838629,0.00015539328,0.00012226812,0.00003297626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000040930125,0.00011486244,0.00027076126,0.0002443034,0.000047128065,0.0000061130972,0.00008920426,0.000030330772,0.76665914],"category_scores_gemma":[0.00047234324,0.00011514736,0.00008855875,0.00033352824,0.00001110077,0.00006558736,0.0002357507,0.00015147554,0.000034641496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009734507,0.0015954514,0.6503298,0.00023844115,0.0001584348,0.000014592943,0.00021691069,0.0001655414,5.27206e-7,2.5062423e-7,0.3459562,0.0012264698],"study_design_scores_gemma":[0.0031292476,0.001144597,0.9896871,0.0004301709,0.00002158242,1.1414999e-7,0.00013269395,0.000013055103,0.000021311067,0.000013363209,0.005324415,0.00008235008],"about_ca_topic_score_codex":0.00007758284,"about_ca_topic_score_gemma":0.00006283401,"teacher_disagreement_score":0.76662445,"about_ca_system_score_codex":0.0005101523,"about_ca_system_score_gemma":0.00012789192,"threshold_uncertainty_score":0.46955732},"labels":[],"label_agreement":null},{"id":"W6958334463","doi":"10.6084/m9.figshare.29261647","title":"Additional file 1 of Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Type 2 diabetes; Diabetes mellitus; Obesity; Glucagon-like peptide-1; Receptor; Glucagon-like peptide 1 receptor","score_opus":0.025300684643807674,"score_gpt":0.28469809703422816,"score_spread":0.25939741239042047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958334463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610531,0.000022800905,5.127163e-7,0.00003708512,0.000024512985,0.001776952,0.034776606,0.0000070750157,0.002301385],"genre_scores_gemma":[0.9316434,0.000020392234,0.010365349,0.000121017845,0.000016601673,0.0010923366,0.03667251,0.000056145924,0.020012239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815446,0.00009569442,0.00040255245,0.00053570885,0.00031127915,0.0005002934],"domain_scores_gemma":[0.9985077,0.0002542107,0.00042471703,0.00043637157,0.00022933907,0.0001476912],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020327371,0.0003483051,0.00078788836,0.0001914792,0.00008381299,0.000049139373,0.00019480803,0.00008516521,0.09991659],"category_scores_gemma":[0.00010309635,0.00020808527,0.000050184823,0.0006888669,0.00021548303,0.000266474,0.00009409862,0.0000866647,0.000029078943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004510666,0.0054846993,0.86529106,0.000119322656,0.0074605644,0.000018562103,0.00051878876,0.0000075317,0.0007341319,9.531517e-7,0.074450776,0.04140297],"study_design_scores_gemma":[0.03218366,0.07173428,0.71965975,0.008569196,0.005643054,6.771587e-7,0.002299721,0.0011549409,0.07049099,0.000021250851,0.08712367,0.0011188174],"about_ca_topic_score_codex":0.00026423155,"about_ca_topic_score_gemma":0.0026065537,"teacher_disagreement_score":0.1456313,"about_ca_system_score_codex":0.00032898923,"about_ca_system_score_gemma":0.0006228605,"threshold_uncertainty_score":0.9009062},"labels":[],"label_agreement":null},{"id":"W6958398314","doi":"10.6084/m9.figshare.24452462","title":"Additional file 1 of Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Type 2 diabetes; Glycemic; Diabetes mellitus; Adverse effect; Type 2 Diabetes Mellitus","score_opus":0.010068752502038607,"score_gpt":0.20134643206827724,"score_spread":0.19127767956623862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958398314","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38372168,0.0001436324,3.2520585e-8,0.000006370204,0.00001777688,0.0011750093,0.61477304,0.000042654465,0.000119796794],"genre_scores_gemma":[0.5552714,0.000003342399,0.000016971017,0.000031240226,0.00002306418,0.00083845947,0.44375196,0.000017288254,0.000046297864],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99849844,0.00016663228,0.00022540776,0.00037006586,0.00052693515,0.00021252362],"domain_scores_gemma":[0.9976113,0.0014362329,0.00008868948,0.00062291167,0.00018010847,0.000060749066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007923848,0.00020361108,0.0006120661,0.0000987881,0.00006120307,0.000013778571,0.00011989873,0.00005806805,0.30478892],"category_scores_gemma":[0.0018908926,0.00012521633,0.00025271784,0.0004473696,0.00002013561,0.00009246628,0.00013959999,0.000116623094,0.00028110694],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026800713,0.00060344685,0.34820873,0.00010606777,0.01286507,0.000050048544,0.0001717563,0.00011587752,3.9954585e-7,4.2755042e-7,0.63390243,0.0037077323],"study_design_scores_gemma":[0.005969847,0.0004447773,0.92054856,0.00052725506,0.000996724,5.9602034e-8,0.00012018677,0.00008824752,0.000002145754,0.000015788788,0.071159236,0.00012718722],"about_ca_topic_score_codex":0.000056528752,"about_ca_topic_score_gemma":0.00003712663,"teacher_disagreement_score":0.57233983,"about_ca_system_score_codex":0.000047781195,"about_ca_system_score_gemma":0.000049982507,"threshold_uncertainty_score":0.6958466},"labels":[],"label_agreement":null},{"id":"W6958414801","doi":"10.6084/m9.figshare.28436893.v1","title":"EVALUATING BOWEL OBSTRUCTION and ILEUS EVENTS in PATIENTS on GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW and META-ANALYSIS","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bowel obstruction; Ileus; Randomized controlled trial; Liraglutide; Relative risk; Cohort study; Cohort","score_opus":0.0710601453254852,"score_gpt":0.3448079652481441,"score_spread":0.2737478199226589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958414801","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23092626,0.54797584,0.000005125392,0.008410797,0.00043748412,0.065314844,0.12842233,0.00059145555,0.017915854],"genre_scores_gemma":[0.78939307,0.0015816544,0.00097639667,0.010300188,0.000043624616,0.011567232,0.15463395,0.00007930918,0.031424586],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9990334,0.00009031695,0.000305886,0.00025497595,0.00020135407,0.00011405752],"domain_scores_gemma":[0.99945325,0.000067804875,0.0001322409,0.00023275118,0.00007237291,0.00004158558],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011232614,0.00013863528,0.0008647226,0.00018630188,0.000038163013,0.000015602742,0.000038727943,0.000033744134,0.0076788734],"category_scores_gemma":[0.00082038104,0.00009868742,0.00016459326,0.00035588458,0.0000026560194,0.000054014705,0.00005632611,0.000055812452,0.00007188069],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006978869,0.0006189003,0.008469766,0.8323866,0.114259444,0.0000073593897,0.00019308862,0.0000122129995,0.000002871334,0.000038339705,0.04136236,0.0025792369],"study_design_scores_gemma":[0.0030838763,0.00063682743,0.09255411,0.08655566,0.81530625,5.381815e-7,0.00007166827,0.0002609293,0.000033288426,0.0000642844,0.0010931945,0.00033941516],"about_ca_topic_score_codex":0.0000053451863,"about_ca_topic_score_gemma":0.000005771923,"teacher_disagreement_score":0.74583095,"about_ca_system_score_codex":0.00009010424,"about_ca_system_score_gemma":0.000010513982,"threshold_uncertainty_score":0.99322826},"labels":[],"label_agreement":null},{"id":"W6958430703","doi":"10.6084/m9.figshare.29261647.v1","title":"Additional file 1 of Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Type 2 diabetes; Diabetes mellitus; Obesity; Glucagon-like peptide-1; Receptor; Glucagon-like peptide 1 receptor","score_opus":0.02456597352879607,"score_gpt":0.2610832142826231,"score_spread":0.23651724075382702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958430703","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.455598,0.000033362263,4.8138563e-8,0.000014692957,0.000010661976,0.0008760561,0.5429044,0.000040296793,0.000522475],"genre_scores_gemma":[0.33354437,0.00000666981,0.00094502803,0.00015182092,0.000016959555,0.0019453188,0.65878165,0.000048139435,0.0045600375],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982073,0.00007474467,0.00035909747,0.00048042473,0.00034580773,0.00053266983],"domain_scores_gemma":[0.9983449,0.00034153406,0.00041924865,0.00041033144,0.00033303714,0.00015092228],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006572521,0.0003730854,0.0007001525,0.00021661268,0.0000770298,0.000025361936,0.00012996873,0.000101798294,0.4944797],"category_scores_gemma":[0.00035221138,0.00022737373,0.00006767577,0.00074450055,0.00006846723,0.000191659,0.000059566206,0.000101142854,0.000058814756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014729168,0.0025375788,0.2393777,0.00046934944,0.0042226226,0.000014344937,0.00017533613,0.000006325888,0.00012536532,5.115517e-7,0.7470916,0.004506382],"study_design_scores_gemma":[0.017591039,0.044904374,0.7709247,0.032512564,0.0024468333,5.260097e-7,0.000696192,0.0012440493,0.021336025,0.000013271931,0.10736931,0.00096112286],"about_ca_topic_score_codex":0.000072778465,"about_ca_topic_score_gemma":0.0008836552,"teacher_disagreement_score":0.6397222,"about_ca_system_score_codex":0.0003479145,"about_ca_system_score_gemma":0.0005216871,"threshold_uncertainty_score":0.9272032},"labels":[],"label_agreement":null},{"id":"W6958448650","doi":"10.6084/m9.figshare.21432247","title":"Additional file 2 of Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Arcuate nucleus; Food intake; Neuron; Nucleus; Receptor; Hypothalamus","score_opus":0.03264830174355766,"score_gpt":0.2358119251465084,"score_spread":0.20316362340295074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958448650","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030647202,0.000014230589,2.0804362e-7,0.000087172026,0.000028954903,0.00027916513,0.98762906,0.00004110878,0.008855414],"genre_scores_gemma":[0.066509575,6.8537656e-7,0.00045094176,0.00015443767,0.000049686452,0.0009808824,0.9291018,0.000022375243,0.0027295772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915236,0.00003099568,0.00019128055,0.00017748056,0.0003049958,0.00014290438],"domain_scores_gemma":[0.99906445,0.00040161825,0.00019904139,0.00020626443,0.00008306345,0.000045549405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000013898381,0.00010592709,0.00017976588,0.000108599066,0.00007979995,0.000008944503,0.00010286441,0.000023626695,0.9890871],"category_scores_gemma":[0.0005380524,0.000107419844,0.00009398453,0.00017120273,0.000010536897,0.000106869265,0.00019904261,0.00010287351,0.00019587211],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040704712,0.00025234977,0.000012934134,0.00021734269,0.00009551392,0.0000026632974,0.00007899245,0.000039231967,0.0005551826,0.0000054113516,0.9959065,0.002793189],"study_design_scores_gemma":[0.0004565208,0.00048148137,0.0034377042,0.0012923948,0.000031432948,0.0000013877645,0.0001787647,0.00007693113,0.0060379333,0.000012883878,0.98791,0.00008259417],"about_ca_topic_score_codex":0.0000018381962,"about_ca_topic_score_gemma":8.3547843e-7,"teacher_disagreement_score":0.98889124,"about_ca_system_score_codex":0.000050977826,"about_ca_system_score_gemma":0.00006945047,"threshold_uncertainty_score":0.4380454},"labels":[],"label_agreement":null},{"id":"W6958536731","doi":"10.6084/m9.figshare.26595977","title":"Additional file 3 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality (philosophy); Table (database); Scale (ratio); MEDLINE; Risk assessment; Key (lock)","score_opus":0.042033993579617374,"score_gpt":0.2713213502896297,"score_spread":0.22928735671001235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958536731","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013248746,0.15779033,3.5100516e-7,0.000084809624,0.000010423473,0.0010360682,0.8390303,0.000029307377,0.0020170407],"genre_scores_gemma":[0.0010252212,0.00030721875,0.00038435747,0.00049742014,0.000074628675,0.0020125348,0.97769886,0.000021773978,0.017977998],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9991416,0.0000433358,0.0002849086,0.00019260183,0.00023205113,0.000105528845],"domain_scores_gemma":[0.9980323,0.001457009,0.000118352444,0.00027130978,0.00005495003,0.00006613316],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000046617602,0.00013135142,0.0013923893,0.00010506965,0.000011486627,0.000009135993,0.000046809873,0.000031870313,0.8298701],"category_scores_gemma":[0.0008246352,0.00008810569,0.0008384899,0.00043061638,0.0000034928987,0.000030310193,0.00003794405,0.000052085987,0.00037124407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000019853928,0.000012339444,3.983834e-8,0.24445213,0.039523114,0.00000423836,0.0000114082595,0.0000089888235,1.540637e-7,0.000005784688,0.7158975,0.00008228182],"study_design_scores_gemma":[0.00013673744,0.00018479614,0.000020477424,0.318082,0.49634692,9.1375176e-7,0.0000062683407,0.0005525509,0.000016126145,0.000040742154,0.18449374,0.000118724136],"about_ca_topic_score_codex":0.0000018932722,"about_ca_topic_score_gemma":3.2013236e-7,"teacher_disagreement_score":0.8294989,"about_ca_system_score_codex":0.000020519792,"about_ca_system_score_gemma":0.000040985902,"threshold_uncertainty_score":0.4771715},"labels":[],"label_agreement":null},{"id":"W6958602471","doi":"10.6084/m9.figshare.21432247.v1","title":"Additional file 2 of Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Arcuate nucleus; Food intake; Neuron; Nucleus; Receptor; Hypothalamus","score_opus":0.03264830174355766,"score_gpt":0.2358119251465084,"score_spread":0.20316362340295074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958602471","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030647202,0.000014230589,2.0804362e-7,0.000087172026,0.000028954903,0.00027916513,0.98762906,0.00004110878,0.008855414],"genre_scores_gemma":[0.066509575,6.8537656e-7,0.00045094176,0.00015443767,0.000049686452,0.0009808824,0.9291018,0.000022375243,0.0027295772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915236,0.00003099568,0.00019128055,0.00017748056,0.0003049958,0.00014290438],"domain_scores_gemma":[0.99906445,0.00040161825,0.00019904139,0.00020626443,0.00008306345,0.000045549405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000013898381,0.00010592709,0.00017976588,0.000108599066,0.00007979995,0.000008944503,0.00010286441,0.000023626695,0.9890871],"category_scores_gemma":[0.0005380524,0.000107419844,0.00009398453,0.00017120273,0.000010536897,0.000106869265,0.00019904261,0.00010287351,0.00019587211],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040704712,0.00025234977,0.000012934134,0.00021734269,0.00009551392,0.0000026632974,0.00007899245,0.000039231967,0.0005551826,0.0000054113516,0.9959065,0.002793189],"study_design_scores_gemma":[0.0004565208,0.00048148137,0.0034377042,0.0012923948,0.000031432948,0.0000013877645,0.0001787647,0.00007693113,0.0060379333,0.000012883878,0.98791,0.00008259417],"about_ca_topic_score_codex":0.0000018381962,"about_ca_topic_score_gemma":8.3547843e-7,"teacher_disagreement_score":0.98889124,"about_ca_system_score_codex":0.000050977826,"about_ca_system_score_gemma":0.00006945047,"threshold_uncertainty_score":0.4380454},"labels":[],"label_agreement":null},{"id":"W6958631913","doi":"10.60692/v3dvw-2e710","title":"Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","year":2016,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University","funders":"","keywords":"Heart failure; Observational study; Randomized controlled trial; Hazard ratio; Odds ratio; Confidence interval; Meta-analysis; Incidence (geometry)","score_opus":0.08066454900510427,"score_gpt":0.27760498425532704,"score_spread":0.19694043525022276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958631913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637004,0.02504102,0.00012124025,0.0037255601,0.000100526486,0.006890595,0.00015537202,0.00008648906,0.0001787966],"genre_scores_gemma":[0.99778616,0.00023181296,0.0003918468,0.0006577346,0.000004947317,0.00044615503,0.000030261639,0.0000063305647,0.00044473042],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9983006,0.0001721298,0.0010126561,0.00015050314,0.00023254658,0.00013157324],"domain_scores_gemma":[0.9989067,0.000120830555,0.00043152642,0.00023033006,0.0002498444,0.000060773273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012499212,0.00018734037,0.0029035448,0.0003619918,0.00003439626,0.000033725195,0.000033396474,0.00004409711,0.000022270006],"category_scores_gemma":[0.00021679897,0.00009328451,0.00022064368,0.00028359966,0.00008120848,0.0003334656,0.00005332444,0.000026346574,0.000016715772],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009922322,0.000018059725,0.13679501,0.55977863,0.27959344,0.0000016399309,0.020933194,0.0000028405675,0.000009281461,0.0007205138,0.0011218986,0.000033274493],"study_design_scores_gemma":[0.04197863,0.00021651982,0.026842697,0.021475887,0.90225494,0.000006997601,0.00621944,0.0002463525,0.00007566014,0.0000056387375,0.00023162854,0.0004456327],"about_ca_topic_score_codex":0.0000021157116,"about_ca_topic_score_gemma":0.0000010194337,"teacher_disagreement_score":0.6226615,"about_ca_system_score_codex":0.000047994195,"about_ca_system_score_gemma":0.000011757395,"threshold_uncertainty_score":0.3804032},"labels":[],"label_agreement":null},{"id":"W6958896632","doi":"10.6084/m9.figshare.19844661.v1","title":"Additional file 1 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Diabetes mellitus; Primary care; Disease; MEDLINE; Kidney disease","score_opus":0.020814670229987165,"score_gpt":0.24702469424465814,"score_spread":0.22621002401467097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958896632","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3877115,0.000011593599,5.114074e-9,8.4621473e-7,0.000014778374,0.0009852529,0.61072415,0.000007505327,0.0005444016],"genre_scores_gemma":[0.4954976,1.10597476e-7,0.000019707606,0.000013074074,0.000011304723,0.004135314,0.5002511,0.000008401567,0.0000633416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986928,0.00008717425,0.00029402217,0.00024411049,0.0005181056,0.00016378894],"domain_scores_gemma":[0.99920666,0.00029852896,0.00018360643,0.00015569096,0.00012253948,0.000032981006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000041154097,0.00011489886,0.00027069522,0.00024446292,0.000047124624,0.0000060998996,0.00008925378,0.000030330597,0.7700343],"category_scores_gemma":[0.00047809325,0.0001151849,0.00008857583,0.00033378683,0.000011100923,0.00006554259,0.00023578375,0.0001515103,0.000035013887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096835254,0.0015789935,0.650384,0.0002337933,0.00015674822,0.000014054319,0.0002144233,0.00016299989,5.4024775e-7,2.4368396e-7,0.3459768,0.0011805713],"study_design_scores_gemma":[0.0031035142,0.0011427156,0.9899116,0.00043488183,0.000021628588,1.1372967e-7,0.00013385968,0.000013123247,0.000021412327,0.000013238385,0.0051214914,0.00008240073],"about_ca_topic_score_codex":0.00007681127,"about_ca_topic_score_gemma":0.00006246549,"teacher_disagreement_score":0.76999927,"about_ca_system_score_codex":0.00051000674,"about_ca_system_score_gemma":0.00012846178,"threshold_uncertainty_score":0.46971038},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W6964117162","doi":"10.25384/sage.21766954","title":"sj-docx-1-cjk-10.1177_20543581221145068 – Supplemental material for Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study","year":2022,"lang":"en","type":"article","venue":"Sage Journals Data","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kidney disease; Retrospective cohort study; Cohort study; Kidney; Cohort; Clinical trial","score_opus":0.04045333198666041,"score_gpt":0.3269526546011244,"score_spread":0.286499322614464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6964117162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6683636,0.00032775186,0.000083993706,0.0072908388,0.0018706564,0.016111625,0.30556926,0.00008132947,0.00030100963],"genre_scores_gemma":[0.9268354,0.00005185373,0.000306123,0.0015795075,0.0008107467,0.0009709477,0.06828841,0.00007700757,0.0010799736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956792,0.00017071399,0.0015290423,0.00084041286,0.0010567497,0.0007238899],"domain_scores_gemma":[0.996346,0.000057902416,0.00048725802,0.0012600804,0.00010396017,0.0017448136],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032491942,0.00041335323,0.0013959709,0.00062338007,0.00043060764,0.00013192452,0.0006723345,0.000053063326,0.09098353],"category_scores_gemma":[0.00041961725,0.00038376846,0.0002555071,0.0004383449,0.000035647776,0.0002877909,0.00046967735,0.00022600306,0.000026191943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002377706,0.0013424847,0.72938406,0.0001705966,0.0016812469,0.00021404026,0.0002746374,0.0000045535016,0.0014236643,0.000025391148,0.26156536,0.0015362678],"study_design_scores_gemma":[0.024122415,0.0028374342,0.77847224,0.00031252546,0.005570481,0.000010483756,0.00062136137,0.00005757295,0.0009746845,0.00012279076,0.18623787,0.00066014304],"about_ca_topic_score_codex":0.0071845558,"about_ca_topic_score_gemma":0.005274404,"teacher_disagreement_score":0.25847188,"about_ca_system_score_codex":0.0019824998,"about_ca_system_score_gemma":0.0009620989,"threshold_uncertainty_score":0.9998614},"labels":[],"label_agreement":null},{"id":"W6967794811","doi":"10.5281/zenodo.11440502","title":"Glyco Care Canada Reviews: (2024 Critical Report!) Real Customer Reviews!","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product (mathematics); Blood sugar; Pride; Quality (philosophy); Medical care; Patient care; Blood pressure","score_opus":0.03287169524142433,"score_gpt":0.29431571480831886,"score_spread":0.26144401956689456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6967794811","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002630181,0.027151568,0.000029810053,0.0010393985,0.00073882856,0.0015757796,0.000274554,0.0007009669,0.9684865],"genre_scores_gemma":[0.00018178938,0.016780868,0.0002769614,0.00044820667,0.0007808258,6.144625e-7,0.0055355895,0.006926109,0.96906906],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746704,0.00022672,0.0005082526,0.00076983613,0.0005543044,0.00047385716],"domain_scores_gemma":[0.9982558,0.000011477209,0.00016239859,0.0009808944,0.00025266028,0.00033679424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00045495867,0.00035579322,0.000644648,0.0003423349,0.00032474348,0.00031746793,0.00043540465,0.00013748124,0.104666784],"category_scores_gemma":[0.00079330674,0.00030628152,0.0001620152,0.00049452146,0.0001264618,0.00005064041,0.0007733661,0.00042337,0.06454416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012877968,0.00005778768,0.000001032462,0.0036048668,0.0001598456,0.0011251518,0.000117585245,4.8972165e-8,0.000010296699,0.00093457766,0.9308809,0.063095],"study_design_scores_gemma":[0.0002721378,0.00014847332,0.000009983381,0.0019529038,0.00052123587,0.00018511795,0.00013301274,0.0000017249937,0.00000485559,0.000011926649,0.99649197,0.00026664446],"about_ca_topic_score_codex":0.007153951,"about_ca_topic_score_gemma":0.0006938061,"teacher_disagreement_score":0.06561106,"about_ca_system_score_codex":0.00065831316,"about_ca_system_score_gemma":0.000025051604,"threshold_uncertainty_score":0.9999389},"labels":[],"label_agreement":null},{"id":"W6969012285","doi":"10.5281/zenodo.4733123","title":"Antibody Characterization Report for Solute carrier family 2, facilitated glucose transporter member 6 SLC2A6 (GLUT-6)","year":2021,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Solute carrier family; Family member; Transporter; Antibody; Glucose transporter; Plasma protein binding; Joint (building)","score_opus":0.038854196265402305,"score_gpt":0.2761405433129283,"score_spread":0.237286347047526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6969012285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7393039,0.00026667689,0.123393916,0.00382666,0.0005889605,0.0033655064,0.001969794,0.0018497038,0.12543488],"genre_scores_gemma":[0.6412124,0.0003129885,0.0009902582,0.00088314986,0.00027447302,9.467276e-7,0.32388964,0.0016937664,0.03074239],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981882,0.00009887763,0.0003822061,0.00054786674,0.00037303497,0.00040979657],"domain_scores_gemma":[0.99823225,0.000013113375,0.00011163109,0.00053678494,0.00090063765,0.0002056125],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00040207658,0.00019018029,0.0002730019,0.0001613006,0.0007404766,0.00025980268,0.00019929608,0.000075749456,0.0056430367],"category_scores_gemma":[0.00023570203,0.00019136323,0.00013061413,0.0004313186,0.00007730111,0.0002712442,0.0002053061,0.00012896331,0.0009111634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031796965,0.0006670139,0.00016797996,0.0003913176,0.0005742606,0.00070476724,0.001330492,0.0000078904595,0.91000867,0.00072883297,0.016969029,0.06813175],"study_design_scores_gemma":[0.0017971523,0.000290345,0.016401054,0.00005792714,0.00019219023,0.00012626308,0.00023103443,0.00022915436,0.0057726684,0.000029072657,0.9746835,0.00018959829],"about_ca_topic_score_codex":0.000006418988,"about_ca_topic_score_gemma":3.029561e-7,"teacher_disagreement_score":0.9577145,"about_ca_system_score_codex":0.00013055948,"about_ca_system_score_gemma":0.000012796968,"threshold_uncertainty_score":0.9998667},"labels":[],"label_agreement":null},{"id":"W6976514422","doi":"10.60692/c17nj-ce168","title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","year":2018,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Agonist; Internalization; Endocytic cycle; Tolerability; Receptor; Type 2 diabetes; Insulin; Endocytosis","score_opus":0.020509968266534378,"score_gpt":0.23023529942251963,"score_spread":0.20972533115598527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976514422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686725,0.0000027001315,0.0057717473,0.0002571778,0.0014578397,0.0013618096,0.000030234633,0.00048990065,0.021956079],"genre_scores_gemma":[0.9960024,6.487327e-8,0.001586567,0.00056387443,0.0006266037,0.000081034515,0.00006143027,0.000015447693,0.0010626302],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876237,0.000018868814,0.00047045725,0.00016719071,0.0002685493,0.00031258553],"domain_scores_gemma":[0.99919224,0.0000047285025,0.00016157865,0.00029821906,0.00017743385,0.00016580774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025867645,0.00017830712,0.00024646666,0.0002241649,0.00016344523,0.00015548158,0.000089247944,0.00006275244,0.00007870281],"category_scores_gemma":[0.00003334353,0.00013958308,0.00007586074,0.00022030498,0.000024878462,0.0003065413,0.000062219064,0.000053856158,0.0061658826],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023267344,0.000118706565,0.19427867,0.0051234555,0.001887637,0.000035873076,0.6013008,0.00021040575,0.001105685,0.0017088846,0.06919342,0.12270973],"study_design_scores_gemma":[0.036766093,0.0073967557,0.190104,0.0048833047,0.0016970056,0.000059255213,0.123286985,0.01360855,0.05817621,0.0000010457967,0.56084716,0.0031736577],"about_ca_topic_score_codex":0.0000034655554,"about_ca_topic_score_gemma":5.878403e-8,"teacher_disagreement_score":0.4916537,"about_ca_system_score_codex":0.00018890476,"about_ca_system_score_gemma":0.000023013867,"threshold_uncertainty_score":0.9946079},"labels":[],"label_agreement":null},{"id":"W6976570630","doi":"10.6084/m9.figshare.13031570","title":"Additional file 9 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Hazard ratio; Confidence interval; Post-hoc analysis; Proportional hazards model; Percentile; Nomogram","score_opus":0.015146518827201028,"score_gpt":0.23495684005387743,"score_spread":0.2198103212266764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976570630","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16254345,0.001696601,0.000002015533,0.000014960392,0.000012198784,0.0010061724,0.8346365,0.000007578119,0.00008052457],"genre_scores_gemma":[0.7649122,0.000049526854,0.000062045336,0.000019313151,0.00002459297,0.00021680641,0.23460811,0.000015714375,0.00009169749],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978695,0.00042506374,0.00058842875,0.00025330452,0.00070027536,0.00016342771],"domain_scores_gemma":[0.99624914,0.0018884226,0.0007560612,0.00060024054,0.00043378456,0.000072371215],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003634533,0.00017834867,0.0019902163,0.00016954295,0.000029356659,0.000002933909,0.00013779191,0.000079789366,0.0882113],"category_scores_gemma":[0.009153169,0.00012558237,0.0030710332,0.00095080846,0.00004175567,0.000027766062,0.0001553453,0.000090469184,0.00000526463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009839443,0.00069226086,0.002908634,0.0057542115,0.33392712,0.00002041651,0.0008131795,0.003474539,0.000086470405,0.0000036562794,0.64651394,0.0048216106],"study_design_scores_gemma":[0.0123442635,0.002879861,0.7708629,0.0058912453,0.12155106,4.02136e-7,0.00046003342,0.00073018175,0.015574661,0.000015695512,0.06939426,0.00029549134],"about_ca_topic_score_codex":0.000085659754,"about_ca_topic_score_gemma":0.000009765949,"teacher_disagreement_score":0.76795423,"about_ca_system_score_codex":0.000022957176,"about_ca_system_score_gemma":0.00005014523,"threshold_uncertainty_score":0.99919313},"labels":[],"label_agreement":null},{"id":"W6976720163","doi":"10.60692/3nffe-9br85","title":"Semaglutide: new dawn for diabetics","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Sitagliptin; Hypoglycemia; Weight loss; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Metformin","score_opus":0.0484141949189111,"score_gpt":0.24283164491144027,"score_spread":0.19441744999252916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976720163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602755,0.0000066298485,0.013360808,0.001031033,0.0010226199,0.0026909597,0.000121609766,0.0014935881,0.019997261],"genre_scores_gemma":[0.98741806,2.0428196e-7,0.00073674665,0.00032031542,0.0001428384,0.00014675266,0.00017703617,0.000013175722,0.011044858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991103,0.000007197623,0.00032953883,0.00009683951,0.0002009664,0.0002551919],"domain_scores_gemma":[0.99941623,0.000010097387,0.00010356737,0.00026439328,0.000082608356,0.00012310508],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017582714,0.00012470482,0.00020898537,0.00019897684,0.00006829903,0.00007232916,0.000058645022,0.000054644417,0.000018291877],"category_scores_gemma":[0.000027266375,0.00009759294,0.000093138566,0.00026495734,0.000009732009,0.00016694567,0.000038613198,0.00002948614,0.0027332844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031410664,0.000014437489,0.6754387,0.006547814,0.0010862132,0.00002176568,0.07933206,0.00022643586,0.00000916415,0.004760755,0.19493571,0.037312802],"study_design_scores_gemma":[0.02243798,0.0010825632,0.596319,0.0013508992,0.0014549567,0.000025933448,0.030623801,0.026283162,0.0032760298,0.00003697513,0.31613368,0.00097500836],"about_ca_topic_score_codex":0.00000179787,"about_ca_topic_score_gemma":4.8253522e-8,"teacher_disagreement_score":0.12119796,"about_ca_system_score_codex":0.0000823645,"about_ca_system_score_gemma":0.000033727665,"threshold_uncertainty_score":0.9980432},"labels":[],"label_agreement":null},{"id":"W6976966860","doi":"10.6084/m9.figshare.15087347.v1","title":"Additional file 1 of Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"MEDLINE; Clinical trial; Data collection; Disease","score_opus":0.02219203865117692,"score_gpt":0.2552298319824851,"score_spread":0.2330377933313082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976966860","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06670765,0.00039706577,0.0000013186619,0.00003752862,0.00001617699,0.0002781923,0.93177164,0.000027799246,0.0007626573],"genre_scores_gemma":[0.105184905,0.00002229154,0.00015200923,0.0000768113,0.00003390201,0.00024527838,0.8938609,0.000026538202,0.00039736557],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99832934,0.000017656506,0.0003923541,0.00040480884,0.0005899338,0.0002659251],"domain_scores_gemma":[0.9983621,0.00027480454,0.00017412724,0.0008956275,0.00022635897,0.0000669464],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005712442,0.00021165606,0.0008924418,0.00015830364,0.000031711268,0.00002211752,0.00019227911,0.00006882075,0.7201599],"category_scores_gemma":[0.0002070044,0.00017400859,0.00034444194,0.0006240606,0.000035507208,0.00019049496,0.00015383949,0.00008312521,0.00006297171],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018262917,0.00062289543,0.05154648,0.0009326841,0.02109554,0.00025697908,0.00047045323,0.00016018946,0.00001399107,0.0000027104322,0.9222485,0.0024669704],"study_design_scores_gemma":[0.0028756494,0.00010948782,0.50271535,0.0038428884,0.002691143,0.0000013750113,0.0004101455,0.00024435687,0.0017859461,0.000001640266,0.48506042,0.00026160624],"about_ca_topic_score_codex":0.00021326554,"about_ca_topic_score_gemma":0.0021061413,"teacher_disagreement_score":0.72009695,"about_ca_system_score_codex":0.00004815373,"about_ca_system_score_gemma":0.0001058902,"threshold_uncertainty_score":0.70958644},"labels":[],"label_agreement":null},{"id":"W6977009929","doi":"10.6084/m9.figshare.13031558.v1","title":"Additional file 5 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Semaglutide; Mace; Post-hoc analysis; Adverse effect; Post hoc; Coronary heart disease; Component (thermodynamics)","score_opus":0.01513180867676815,"score_gpt":0.23492086465824843,"score_spread":0.2197890559814803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977009929","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16258992,0.0016938775,0.000002008998,0.000014934334,0.000012195324,0.001006208,0.83459294,0.0000075764606,0.00008035669],"genre_scores_gemma":[0.76441836,0.00004946111,0.00006203323,0.00001929082,0.000024569921,0.00021800637,0.23510122,0.0000157069,0.00009131945],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99786943,0.00042506994,0.00058843265,0.0002533376,0.00070032204,0.00016342146],"domain_scores_gemma":[0.9962491,0.0018882842,0.00075612625,0.00060040003,0.00043371302,0.00007237786],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036351715,0.00017836112,0.0019904983,0.00016954028,0.000029355999,0.0000029334055,0.00013788532,0.00007980436,0.08850422],"category_scores_gemma":[0.009152735,0.00012559023,0.0030712818,0.000950848,0.00004175431,0.000027763832,0.00015540757,0.000090494126,0.0000052452733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009818603,0.0006908015,0.0029007264,0.00574139,0.3332094,0.000020373403,0.0008105537,0.003461101,0.00008633627,0.0000037162486,0.6472348,0.004858959],"study_design_scores_gemma":[0.012284746,0.0028644844,0.77253705,0.005858336,0.12091912,3.999995e-7,0.00045766818,0.00072129664,0.015484714,0.000015534908,0.068562716,0.00029394677],"about_ca_topic_score_codex":0.000087287364,"about_ca_topic_score_gemma":0.000009786159,"teacher_disagreement_score":0.76963633,"about_ca_system_score_codex":0.000022958884,"about_ca_system_score_gemma":0.000050151506,"threshold_uncertainty_score":0.9991936},"labels":[],"label_agreement":null},{"id":"W6977014708","doi":"10.6084/m9.figshare.21207028.v1","title":"Additional file 3 of Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Glycemic; Diabetes mellitus; Glycemic load; MEDLINE; Physical activity","score_opus":0.05734248857083702,"score_gpt":0.2752711078667764,"score_spread":0.21792861929593937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977014708","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047413786,0.00087311096,8.746322e-9,0.000058183792,0.000004055613,0.0012981632,0.9923272,0.000012485998,0.0006853739],"genre_scores_gemma":[0.2488129,0.000002095594,0.0000068649033,0.000106885665,0.0000070854535,0.0024895992,0.7481961,0.0000074946042,0.0003709538],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99930876,0.0001267223,0.00018747608,0.00009265981,0.00021784351,0.000066555614],"domain_scores_gemma":[0.9898787,0.009685628,0.0001908862,0.00020038843,0.000017293341,0.000027073414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060150556,0.00008258884,0.0003305548,0.000045184108,0.00004948063,0.0000031947395,0.00006257129,0.000014623423,0.8107077],"category_scores_gemma":[0.007433197,0.000047578935,0.000092914124,0.00012761261,0.000006721182,0.000019443023,0.000061224746,0.00008226375,0.00012371366],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009908152,0.00001901193,0.00065487117,0.07224555,0.00009807663,0.0000013057997,0.000017800732,2.8390733e-7,9.6791936e-8,0.000005602038,0.92693144,0.000016051821],"study_design_scores_gemma":[0.0008924318,0.003430798,0.042448636,0.90495735,0.0013889225,0.000004112459,0.00008675567,0.000016192456,0.00007040937,0.000032091346,0.04650458,0.00016772668],"about_ca_topic_score_codex":8.533737e-7,"about_ca_topic_score_gemma":1.3176e-7,"teacher_disagreement_score":0.8804269,"about_ca_system_score_codex":0.000028994795,"about_ca_system_score_gemma":0.000015051117,"threshold_uncertainty_score":0.8898768},"labels":[],"label_agreement":null},{"id":"W6977039420","doi":"10.6084/m9.figshare.21207031","title":"Additional file 4 of Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Glycemic; Diabetes mellitus; Glycemic load; MEDLINE; Physical activity","score_opus":0.057819746634644016,"score_gpt":0.2757305587176294,"score_spread":0.2179108120829854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977039420","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004721223,0.0008772375,8.813006e-9,0.000058112942,0.000004019428,0.0013003598,0.99234253,0.000012513776,0.0006839647],"genre_scores_gemma":[0.2526257,0.000002085079,0.0000068384475,0.00010647471,0.000006973397,0.0024773087,0.7444119,0.0000074550003,0.00035529106],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993087,0.00012670437,0.00018754887,0.0000926699,0.00021782875,0.00006656382],"domain_scores_gemma":[0.9898604,0.009704193,0.00019089236,0.00020047296,0.000016942991,0.000027070862],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000602029,0.00008259507,0.00033063936,0.00004520689,0.000049507318,0.000003196582,0.00006262118,0.000014624763,0.8078847],"category_scores_gemma":[0.0073214746,0.000047588732,0.00009292192,0.00012759495,0.0000067224905,0.000019446103,0.000061250044,0.00008226099,0.00012097931],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010042088,0.000019064479,0.0006579106,0.07183004,0.00009829587,0.0000013136269,0.000017859702,2.8023857e-7,9.539657e-8,0.000005836433,0.9273432,0.000016073847],"study_design_scores_gemma":[0.0008884701,0.003493648,0.042660404,0.9067359,0.0014000409,0.000004158125,0.000087028464,0.00001625092,0.00006883234,0.00003243971,0.044445075,0.0001677412],"about_ca_topic_score_codex":8.451664e-7,"about_ca_topic_score_gemma":1.3234587e-7,"teacher_disagreement_score":0.8828981,"about_ca_system_score_codex":0.000028873914,"about_ca_system_score_gemma":0.000014989998,"threshold_uncertainty_score":0.8765018},"labels":[],"label_agreement":null},{"id":"W6977092369","doi":"10.6084/m9.figshare.27289248.v1","title":"Additional file 1 of Seasonal stability of the rumen microbiome contributes to the adaptation patterns to extreme environmental conditions in grazing yak and cattle","year":2024,"lang":"en","type":"dataset","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta","funders":"","keywords":"Rumen; Grazing; YAK; Table (database); Composition (language); Microbiome","score_opus":0.02590556642158637,"score_gpt":0.2326921686034802,"score_spread":0.20678660218189382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977092369","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003473993,0.00007951524,4.543405e-8,0.00038530614,0.000028481214,0.0009490921,0.99818325,0.000004668706,0.000022232834],"genre_scores_gemma":[0.003015772,0.0000021184633,0.000014440307,0.00024184109,0.000032107124,0.0014338854,0.9951148,0.000008637402,0.00013637306],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992558,0.000031335214,0.00019785047,0.00021151453,0.00017717957,0.00012636081],"domain_scores_gemma":[0.999159,0.0004291609,0.00008577507,0.0002594185,0.000022699014,0.00004396283],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000031562602,0.00013497741,0.00020069565,0.00009136048,0.00003545785,0.000014621926,0.000119915145,0.000056579844,0.82419693],"category_scores_gemma":[0.00031177566,0.0000894002,0.00007363734,0.00013145793,0.000019038402,0.000026910047,0.000252045,0.00010891416,0.0007935208],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009999378,0.000116542804,0.00006176519,0.00038275096,0.00009793775,0.0000022732345,0.000041051022,0.0000022333847,0.00003516193,3.7295064e-7,0.99909586,0.00015406036],"study_design_scores_gemma":[0.0001893959,0.00006893379,0.059559856,0.0045645614,0.000090014444,0.000001036512,0.00015918948,0.000006399357,0.00007620361,0.0000054869524,0.93521047,0.00006843696],"about_ca_topic_score_codex":0.000023488743,"about_ca_topic_score_gemma":0.0005778003,"teacher_disagreement_score":0.8234034,"about_ca_system_score_codex":0.00012276853,"about_ca_system_score_gemma":0.00005684152,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W6977138172","doi":"10.6084/m9.figshare.28862501","title":"Additional file 1 of Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; MEDLINE","score_opus":0.023970453184729557,"score_gpt":0.2782524361160823,"score_spread":0.25428198293135273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977138172","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044613257,0.00004502502,1.8044129e-7,0.000028375702,0.00003928249,0.0004804331,0.9622783,0.000018616412,0.03264847],"genre_scores_gemma":[0.063810915,0.000001126042,0.00043681255,0.00010668535,0.000049162943,0.0008603176,0.9308824,0.0000086690325,0.0038439103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994733,0.000028768385,0.0001433855,0.00013888683,0.00010679365,0.000108891814],"domain_scores_gemma":[0.99908805,0.00058599486,0.00004775515,0.00013042535,0.00011849062,0.000029270252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003172316,0.00007773535,0.00019827597,0.00024293143,0.000012755526,0.000005079331,0.000044722183,0.000029934801,0.8654374],"category_scores_gemma":[0.00091152417,0.00007283089,0.000043453147,0.00047500912,0.0000035184926,0.000044299184,0.00005411762,0.000036268506,0.00021640965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028112192,0.00009104712,0.0004389716,0.0005128396,0.000061736675,0.0000021292315,0.000008936383,0.000027309867,0.00046150683,0.00006125719,0.9942607,0.004045425],"study_design_scores_gemma":[0.0006612322,0.00023814787,0.2630359,0.016303442,0.000044047825,4.397582e-8,0.000009641279,0.00032076405,0.011744078,0.000031964046,0.70751077,0.000099975376],"about_ca_topic_score_codex":0.000008835092,"about_ca_topic_score_gemma":0.000045886354,"teacher_disagreement_score":0.86522096,"about_ca_system_score_codex":0.000073971416,"about_ca_system_score_gemma":0.00006268837,"threshold_uncertainty_score":0.29699573},"labels":[],"label_agreement":null},{"id":"W6977182796","doi":"10.6084/m9.figshare.13031555.v1","title":"Additional file 4 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Proportional hazards model; Semaglutide; Hazard ratio; Epidemiology; Kidney disease; Framingham Risk Score; Blood pressure; Adverse effect","score_opus":0.015238405184241386,"score_gpt":0.23514182141309953,"score_spread":0.21990341622885815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977182796","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16202463,0.001696092,0.0000020151715,0.000014862878,0.00001219686,0.0010065904,0.83515555,0.000007577299,0.00008050083],"genre_scores_gemma":[0.76450855,0.00004933514,0.00006187474,0.000019229396,0.000024503279,0.00021745151,0.23501295,0.000015663949,0.000090454036],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978698,0.00042473766,0.0005884504,0.0002533076,0.00070028374,0.0001634253],"domain_scores_gemma":[0.99625,0.0018905122,0.0007561601,0.00060050184,0.00043046824,0.00007237117],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036334715,0.00017834472,0.0019901812,0.0001695466,0.000029354742,0.0000029346102,0.00013793354,0.00007980077,0.088524505],"category_scores_gemma":[0.0091189565,0.00012558806,0.0030708974,0.0009505632,0.00004175412,0.000027763872,0.00015540025,0.00009048424,0.0000052782693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009998174,0.0006932247,0.0029204646,0.005760434,0.3344025,0.000020447218,0.00081385917,0.003433946,0.00008604619,0.0000037276986,0.6459962,0.0048693093],"study_design_scores_gemma":[0.012398898,0.0029257243,0.7700889,0.0059055155,0.12193562,4.0345628e-7,0.00046144956,0.0007324057,0.015508797,0.000015748348,0.069730036,0.00029647705],"about_ca_topic_score_codex":0.00008655686,"about_ca_topic_score_gemma":0.000009753589,"teacher_disagreement_score":0.76716846,"about_ca_system_score_codex":0.000022954218,"about_ca_system_score_gemma":0.000050099166,"threshold_uncertainty_score":0.99922764},"labels":[],"label_agreement":null},{"id":"W6977198286","doi":"10.71672/fz2z-4249","title":"Circularité en construction au Québec","year":2025,"lang":"fr","type":"book","venue":"ETS-Pressbooks","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École de Technologie Supérieure","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","score_opus":0.011308114073622377,"score_gpt":0.24470347293028952,"score_spread":0.23339535885666715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977198286","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001498776,0.009958277,0.00053874694,0.002152303,0.005882071,0.0019321387,0.00011152009,0.00027345508,0.9776527],"genre_scores_gemma":[0.016782716,0.0005310096,0.0011546162,0.0010024104,0.0025488834,0.00024568668,0.0006035143,0.00010864957,0.9770225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964212,0.0002005303,0.0007538477,0.0010001778,0.00065607985,0.0009681626],"domain_scores_gemma":[0.997528,0.00042905263,0.00031688012,0.0012192694,0.00016729446,0.0003394661],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003771319,0.0008671479,0.0011966662,0.00044134737,0.00031921506,0.00009057568,0.00043766716,0.0007945695,0.0017454079],"category_scores_gemma":[0.00019211104,0.00088883715,0.00057811086,0.00010273107,0.00068851263,0.00013197974,0.00048674218,0.00085509126,0.0013026643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016833944,0.00061979477,0.021460008,0.0052983514,0.0070822863,0.000855345,0.001439105,0.00002868169,0.00028323272,0.22170462,0.095715545,0.6453447],"study_design_scores_gemma":[0.0028535705,0.0003551821,0.004581447,0.0038850394,0.005442975,0.000028034767,0.000188759,0.000117976626,0.0006240042,0.0020265852,0.97922033,0.0006760997],"about_ca_topic_score_codex":0.01722718,"about_ca_topic_score_gemma":0.006018789,"teacher_disagreement_score":0.8835048,"about_ca_system_score_codex":0.004448025,"about_ca_system_score_gemma":0.004892917,"threshold_uncertainty_score":0.99947494},"labels":[],"label_agreement":null},{"id":"W6977364978","doi":"10.6084/m9.figshare.25010392","title":"Additional file 1 of Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Clinical trial; Octreotide; Depot; Phase (matter); Phases of clinical research; Complication","score_opus":0.05085509135337717,"score_gpt":0.3475861751588271,"score_spread":0.29673108380544994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977364978","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33429173,0.00012021238,0.0000014461737,0.00007105005,0.00011941613,0.0073198355,0.6574686,0.000019113279,0.00058861636],"genre_scores_gemma":[0.80544853,0.0000053275417,0.0006239977,0.000040127186,0.00017146343,0.0022422834,0.1910325,0.000029905912,0.00040587742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800277,0.0005581483,0.0007041578,0.00027486094,0.0003065127,0.00015357869],"domain_scores_gemma":[0.98683625,0.012308865,0.0004384294,0.00024503516,0.00012972917,0.000041669853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027594686,0.00016660562,0.00086170866,0.00008710814,0.000035548917,0.000015683605,0.000109285334,0.000079474274,0.2600626],"category_scores_gemma":[0.0070111183,0.00008255134,0.00024069686,0.00022170696,0.00007002224,0.000064327745,0.00007855595,0.00019621666,0.0000058942173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80027664,0.0018633006,0.0001519396,0.00020229866,0.0010676414,0.000021240572,0.00009926708,0.0000052916607,0.000004024627,0.000011431658,0.18268101,0.013615898],"study_design_scores_gemma":[0.9474994,0.006465538,0.035800558,0.0030747075,0.00065364357,0.0000026200673,0.000054271037,0.00006715058,0.00008138309,0.000044736935,0.0061595635,0.000096419964],"about_ca_topic_score_codex":0.000005392721,"about_ca_topic_score_gemma":0.000012265906,"teacher_disagreement_score":0.4711568,"about_ca_system_score_codex":0.00004018255,"about_ca_system_score_gemma":0.00019191772,"threshold_uncertainty_score":0.83934695},"labels":[],"label_agreement":null},{"id":"W6977467119","doi":"10.6084/m9.figshare.20098642.v1","title":"Additional file 1 of Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Diabetes mellitus; Randomization; Triglyceride; Table (database); Adverse effect; Body weight; Incidence (geometry); Research design","score_opus":0.011524396480331258,"score_gpt":0.220379662606993,"score_spread":0.20885526612666172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977467119","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13243005,0.00019918212,4.14484e-9,0.00014512347,0.000010780061,0.0010574993,0.86597353,0.0000091594475,0.00017469616],"genre_scores_gemma":[0.49093255,9.457549e-7,0.000045086814,0.00026129468,0.000021761176,0.0019629844,0.50662655,0.000013744837,0.00013506661],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991422,0.000097344775,0.00019401728,0.00016623778,0.00026295768,0.00013723207],"domain_scores_gemma":[0.9971511,0.0024836631,0.00014750706,0.00015123539,0.000023757359,0.00004275338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000057601155,0.00011521258,0.00045900684,0.000079530124,0.00005060652,0.000008014141,0.000046113306,0.000024241035,0.48378468],"category_scores_gemma":[0.0009150162,0.000073171344,0.000045265606,0.00014609625,0.000018685443,0.000037802445,0.00007372903,0.0000858091,0.000014009008],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020026982,0.000227442,0.0025792401,0.00032854648,0.000091883114,0.0000033437173,0.00004234537,0.0000026077694,0.0000053026274,0.000007825848,0.99570936,0.00080181035],"study_design_scores_gemma":[0.006555616,0.0037939223,0.48193544,0.0040860805,0.00013959075,6.4948057e-7,0.000048534268,0.000027082637,0.0006400874,0.00005882317,0.5025586,0.00015560446],"about_ca_topic_score_codex":0.0000011645637,"about_ca_topic_score_gemma":0.0000020355278,"teacher_disagreement_score":0.49315083,"about_ca_system_score_codex":0.000024944273,"about_ca_system_score_gemma":0.00003061228,"threshold_uncertainty_score":0.5166872},"labels":[],"label_agreement":null},{"id":"W6986578181","doi":"","title":"Previous errorless sequence-learning promotes subsequent SRT performance in patients with Alzheimer's Disease","year":2012,"lang":"en","type":"article","venue":"Open Repository and Bibliography (University of Liège)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Implicit learning; Procedural memory; Serial reaction time; Sequence learning; Motor learning; Context (archaeology); Motor skill; Disease; Declarative memory","score_opus":0.02007454032293102,"score_gpt":0.2255360574276053,"score_spread":0.20546151710467428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986578181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375534,0.00083098793,0.0000031513548,0.00007583856,0.000037669546,0.0008062587,0.0000026026935,0.000020696945,0.004467472],"genre_scores_gemma":[0.9986622,0.00052421866,0.00046664083,0.00001818306,0.000011891918,0.0000028213078,0.000030842613,0.000008027126,0.00027522564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992123,0.00005289223,0.00009841281,0.00021011838,0.00020438014,0.0002218923],"domain_scores_gemma":[0.99941605,0.000012195717,0.000115573115,0.0001788098,0.000066832625,0.00021056407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014717712,0.00012879318,0.00022697642,0.0018849326,0.00017468455,0.00003638432,0.00013678177,0.00003544482,0.000019644265],"category_scores_gemma":[1.4325917e-7,0.000113429836,0.00005895005,0.0023549157,0.00013494366,0.0008312156,0.0001510651,0.00009357568,0.0000018157284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057070656,0.00062952755,0.9973675,0.00011193721,0.00024623892,0.000039433235,0.00027857197,0.0000027815577,0.00002731485,0.000031798205,0.000118914555,0.0005752753],"study_design_scores_gemma":[0.0019216774,0.00064532546,0.9957008,0.00030561446,0.000546438,0.0000019585384,0.0002744891,0.00002222427,0.00011641403,0.0000021135056,0.00032548944,0.0001375025],"about_ca_topic_score_codex":0.0002623499,"about_ca_topic_score_gemma":0.000002755446,"teacher_disagreement_score":0.0049068267,"about_ca_system_score_codex":0.000012993461,"about_ca_system_score_gemma":0.000021566597,"threshold_uncertainty_score":0.46255344},"labels":[],"label_agreement":null},{"id":"W6987340467","doi":"","title":"Structural and nutritional properties of whey proteins as affected by hyperbaric pressure","year":2000,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Whey protein; Denaturation (fissile materials); Protein secondary structure; Breakage; Fourier transform infrared spectroscopy; Disulfide bond; Protein structure","score_opus":0.010704626362934979,"score_gpt":0.2184926539333787,"score_spread":0.2077880275704437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6987340467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95935655,0.005499641,3.4759104e-9,0.000031278927,0.00020163061,0.0026374853,0.00089882105,0.00015583323,0.031218784],"genre_scores_gemma":[0.95699483,0.00058657915,0.0001854197,0.00011538952,0.000037213165,0.0004174551,0.0032843528,0.0001213513,0.038257383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972566,0.00013291505,0.00057549245,0.00077838294,0.0007851428,0.00047148258],"domain_scores_gemma":[0.99870676,0.00002628051,0.00031131852,0.0004371568,0.00026706865,0.00025142924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015214445,0.00065286376,0.0008951368,0.00030725021,0.0003699937,0.00005083751,0.00020316744,0.00050319283,0.00056515227],"category_scores_gemma":[0.0001413265,0.0005573071,0.00023032002,0.00027934727,0.00009213966,0.00037788588,0.000060211965,0.00062512065,0.00005206219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004584566,0.0021041487,0.00028680454,0.0117695825,0.004620827,0.00012584368,0.000050323615,0.0000063345515,0.7865065,0.014133173,0.00020891317,0.17560299],"study_design_scores_gemma":[0.011159694,0.0032315846,0.020168215,0.0062334924,0.0062203784,0.000088027555,0.00041446858,0.000044150034,0.8134043,0.0058651366,0.13109335,0.0020771755],"about_ca_topic_score_codex":0.00022702501,"about_ca_topic_score_gemma":0.00009615465,"teacher_disagreement_score":0.17352581,"about_ca_system_score_codex":0.00016498414,"about_ca_system_score_gemma":0.00005616046,"threshold_uncertainty_score":0.99968785},"labels":[],"label_agreement":null},{"id":"W6991678112","doi":"","title":"Incretin-based drugs and the risk of skin cancer among patients with type 2 diabetes mellitus","year":2023,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Type 2 Diabetes Mellitus; Skin cancer; Diabetes mellitus; Type 2 diabetes; Cancer; Metformin","score_opus":0.005613535126806543,"score_gpt":0.2164392292372104,"score_spread":0.21082569411040386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6991678112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830994,0.00084574183,6.791928e-9,0.0000228071,0.00050512166,0.0018054268,0.0006188489,0.00012936832,0.012973251],"genre_scores_gemma":[0.98827296,0.0010796882,0.00008743177,0.0001478568,0.000027287615,0.00037613866,0.002384477,0.00018255602,0.0074415808],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99695265,0.00026927103,0.0005752833,0.00068838435,0.0010040711,0.0005103119],"domain_scores_gemma":[0.99729675,0.0004824076,0.00072767003,0.0006352783,0.0006602222,0.00019764405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079660467,0.00059992087,0.000981153,0.0003311626,0.00040066268,0.000041347623,0.00024385896,0.00030594325,0.0001123801],"category_scores_gemma":[0.00047807506,0.00038825703,0.00023398377,0.00064579037,0.00021820675,0.00015016677,0.00007975848,0.00067104626,0.00004176909],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009334242,0.0015182457,0.38017765,0.005392582,0.011769506,0.000045578596,0.00024080828,0.00012717635,0.00040926432,0.0069735334,0.000121722616,0.58388966],"study_design_scores_gemma":[0.020245735,0.0013383112,0.9281637,0.0034093477,0.009824059,1.3186958e-7,0.0005457536,0.00012101648,0.020484578,0.0016203673,0.01310271,0.0011442585],"about_ca_topic_score_codex":0.0014381277,"about_ca_topic_score_gemma":0.001408092,"teacher_disagreement_score":0.58274543,"about_ca_system_score_codex":0.0002419995,"about_ca_system_score_gemma":0.000054090215,"threshold_uncertainty_score":0.99985695},"labels":[],"label_agreement":null},{"id":"W6996537508","doi":"","title":"Sodium glucose co-transporter 2 inhibitor and the risk of ventricular arrhythmia among people with type 2 diabetes","year":2025,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Deutsche Forschungsgemeinschaft; McGill University","keywords":"Type 2 diabetes; Sodium; Diabetes mellitus; Cardiac arrhythmia; Type 2 Diabetes Mellitus","score_opus":0.0047205831990813855,"score_gpt":0.20528458199126776,"score_spread":0.20056399879218637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996537508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756649,0.002019855,5.8123664e-8,0.000032543074,0.0005656335,0.0019847783,0.00037213942,0.00010197156,0.019258136],"genre_scores_gemma":[0.98926693,0.0012606833,0.00012118918,0.00011098002,0.00007254737,0.0002460279,0.0018960955,0.00010099142,0.006924579],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99719447,0.0001980222,0.0006633483,0.00073903706,0.00068592164,0.00051919976],"domain_scores_gemma":[0.9978674,0.00024789342,0.00059651333,0.0007301996,0.00035800642,0.00019998492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006183322,0.0006583346,0.0011998216,0.00035513344,0.000426283,0.000047868583,0.00021068568,0.00038249802,0.00012481962],"category_scores_gemma":[0.00020689123,0.00043504132,0.0003410407,0.00061853824,0.00014875451,0.00023188628,0.000052057472,0.0007970145,0.000027074275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02382867,0.0034519457,0.34446055,0.02185987,0.037106525,0.0018479577,0.00040775494,0.00008268388,0.008424109,0.045234095,0.000313346,0.5129825],"study_design_scores_gemma":[0.03590346,0.0030387822,0.5295319,0.007775038,0.0331668,0.000016339303,0.001411804,0.00012082571,0.2984141,0.0046628267,0.083382756,0.0025753307],"about_ca_topic_score_codex":0.00022012605,"about_ca_topic_score_gemma":0.0009664869,"teacher_disagreement_score":0.51040715,"about_ca_system_score_codex":0.00016752652,"about_ca_system_score_gemma":0.000058239533,"threshold_uncertainty_score":0.99981016},"labels":[],"label_agreement":null},{"id":"W6996544828","doi":"","title":"SGLT2 inhibitörlerinin kardiyovasküler bilimde bir on yılı: bibliyometrik bir inceleme","year":2025,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bibliometrics; Citation analysis; Citation; Web of science; China; Citation impact; Science Citation Index","score_opus":0.015295719331618019,"score_gpt":0.28755167787795205,"score_spread":0.27225595854633405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996544828","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43670085,0.000339902,0.00015898018,0.005981754,0.00046646842,0.00095883023,0.0000101436,0.00047323536,0.5549098],"genre_scores_gemma":[0.84878576,0.00031061753,0.0012115826,0.0053376,0.000104556675,0.00011941765,0.0000724936,0.000033070108,0.14402492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983156,0.000031425236,0.00034969382,0.0004835361,0.00037152474,0.00044826168],"domain_scores_gemma":[0.9989447,0.00013098666,0.00005324488,0.0006392253,0.00007817844,0.00015369385],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027810014,0.00028278382,0.00043569537,0.0030714248,0.00007767565,0.000057374324,0.00013827262,0.000102228034,0.0013498258],"category_scores_gemma":[0.00009803336,0.00020721203,0.00019473393,0.0038648793,0.00006325418,0.000101717174,0.00018086057,0.00016611943,0.0011224429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061246415,0.0033084485,0.22067823,0.00063062686,0.0021948547,0.00017539295,0.00013119004,0.000019637524,0.0064061275,0.041241,0.5008221,0.2237799],"study_design_scores_gemma":[0.005431606,0.0012836041,0.06163618,0.00038669372,0.0004079791,0.0000016626868,0.00025688318,0.0000995101,0.022361346,0.0005584305,0.90722835,0.0003477316],"about_ca_topic_score_codex":0.00004647565,"about_ca_topic_score_gemma":0.000022418195,"teacher_disagreement_score":0.41208488,"about_ca_system_score_codex":0.00015608048,"about_ca_system_score_gemma":0.000078654644,"threshold_uncertainty_score":0.9996553},"labels":[],"label_agreement":null},{"id":"W6999249144","doi":"","title":"Cardiovascular health risk indicators and their associations with meeting the Canadian 24-hour movement guidelines for older females: a cross-sectional secondary data analysis of WARM Hearts cohort study","year":2024,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Waist; Guideline; Cardiovascular health; Framingham Risk Score; Cohort study; Body mass index; Public health; Framingham Heart Study","score_opus":0.04279755307734299,"score_gpt":0.29293035576082166,"score_spread":0.25013280268347865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6999249144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280065,0.0017885565,0.000060724604,0.0008048402,0.00014005692,0.002341369,0.0015774453,0.000023408602,0.00046293752],"genre_scores_gemma":[0.99006647,0.0004167265,0.000530451,0.00009493467,0.00005608084,0.0000130622675,0.0075718486,0.00003126894,0.0012191671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846315,0.00008247225,0.00023462188,0.00051893067,0.00048365662,0.00021715352],"domain_scores_gemma":[0.99838275,0.00007394229,0.00041171213,0.00063535856,0.0003735293,0.00012271131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014146682,0.00021174809,0.00074455433,0.0008275555,0.000557632,0.000047123533,0.00021625374,0.000097548014,0.000007687081],"category_scores_gemma":[0.000048858168,0.00017126919,0.00031342925,0.000620608,0.000063945816,0.00008501625,0.000091344285,0.00018875307,8.1007414e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039785627,0.00012235115,0.9533473,0.00029844063,0.039691664,0.000006747889,0.0021838713,0.00022709665,3.0439455e-7,0.00001464822,0.0026750867,0.0013926702],"study_design_scores_gemma":[0.0008426016,0.000205846,0.9230658,0.00011440776,0.012367419,2.3161822e-7,0.059577562,0.00060486956,0.0000019216948,0.0000068528525,0.003095171,0.00011732222],"about_ca_topic_score_codex":0.30533728,"about_ca_topic_score_gemma":0.9851099,"teacher_disagreement_score":0.6797727,"about_ca_system_score_codex":0.0004206854,"about_ca_system_score_gemma":0.00062991126,"threshold_uncertainty_score":0.69928855},"labels":[],"label_agreement":null},{"id":"W7000676171","doi":"","title":"Functional characterization of diabetes-and glycemic trait-associated SNPs in GLP-1R","year":2017,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Receptor; Glucagon-like peptide 1 receptor; Type 2 diabetes; Internalization; Incretin; Exome sequencing; Gene; Mutant; G protein-coupled receptor; Glucokinase","score_opus":0.01612020849764833,"score_gpt":0.23556234404391585,"score_spread":0.2194421355462675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000676171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584618,0.00013115097,2.867873e-8,0.00003048641,0.0007828488,0.0010595808,0.0007970626,0.00009733473,0.038639713],"genre_scores_gemma":[0.96394783,0.00023829473,0.000028091787,0.0001283714,0.000040095776,0.0001868635,0.013599991,0.00012277947,0.02170768],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99709,0.00011331862,0.0008124102,0.0007825883,0.0006538091,0.0005478727],"domain_scores_gemma":[0.9979491,0.00009027747,0.00090116175,0.00055005617,0.00030063442,0.00020872786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045520495,0.0005970556,0.0010786623,0.0006269003,0.0003499418,0.000051817737,0.00021863064,0.0006420114,0.00030345336],"category_scores_gemma":[0.0004973279,0.0006137669,0.00027050628,0.000284112,0.000066739216,0.0005026567,0.00006207041,0.00067414617,0.000049212424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018859784,0.001976966,0.0066906633,0.0021698244,0.0021776713,0.00008695242,0.000034125722,0.0000035879593,0.5977465,0.011057322,0.000013287541,0.3761571],"study_design_scores_gemma":[0.011448662,0.0012345925,0.8877432,0.003286318,0.0020362993,0.0000035813357,0.00011214737,0.00005679206,0.07884121,0.0031077885,0.010985928,0.0011435199],"about_ca_topic_score_codex":0.0000759921,"about_ca_topic_score_gemma":0.00040425122,"teacher_disagreement_score":0.8810525,"about_ca_system_score_codex":0.0006175029,"about_ca_system_score_gemma":0.00006626754,"threshold_uncertainty_score":0.99963135},"labels":[],"label_agreement":null},{"id":"W7006623723","doi":"","title":"Trends and Appropriateness of Sodium-glucose Co-transporter 2 Inhibitors Use in Qatar","year":2023,"lang":"en","type":"dissertation","venue":"Qatar University QSpace (Qatar University)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Contraindication; Retrospective cohort study; Dosing; Formulary; Metformin; Confidence interval; Drug Utilization Review","score_opus":0.014230668749558266,"score_gpt":0.21514116466286357,"score_spread":0.2009104959133053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7006623723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889739,0.000108996275,0.000009932973,0.00026930185,0.00032791347,0.0006420256,0.0004355174,0.00018573219,0.009046644],"genre_scores_gemma":[0.53821963,0.0032048542,0.000513947,0.00003911037,0.00008265961,9.110032e-7,0.015588652,0.0001404999,0.44220972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977497,0.00009482478,0.00027215137,0.00089056167,0.00047204565,0.0005207088],"domain_scores_gemma":[0.9985391,0.00008487137,0.00031554225,0.00061508064,0.00015844186,0.00028698874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014753651,0.00055455725,0.00095732993,0.0036096948,0.00015557185,0.00002796143,0.00035241398,0.0004916666,0.00013690295],"category_scores_gemma":[0.000017649481,0.0006624673,0.0003088415,0.0017460331,0.0001908369,0.00066286745,0.00013132287,0.00045491106,0.00003950049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02915368,0.0063851364,0.7589593,0.012091537,0.010645107,0.042347524,0.028014107,0.0001784324,0.0051604924,0.009794332,0.043849733,0.053420648],"study_design_scores_gemma":[0.020124236,0.0011697918,0.5946973,0.0023896128,0.0063880505,0.00000588934,0.05465737,0.00009057403,0.005446315,0.000032796044,0.3129572,0.0020408677],"about_ca_topic_score_codex":0.0048988513,"about_ca_topic_score_gemma":0.014827452,"teacher_disagreement_score":0.45075428,"about_ca_system_score_codex":0.00049004226,"about_ca_system_score_gemma":0.00020701342,"threshold_uncertainty_score":0.99958265},"labels":[],"label_agreement":null},{"id":"W7010195112","doi":"","title":"Hogyan járult hozzá a Szent János Kórház és II. Belgyógyászati Osztálya a felnőttcukorbeteg-ellátás hazai történetéhez [How did the St. John's Hospital and its II. Department for Internal Medicine-Diabetology contribute to the history of the adult diabetes care in Hungary]","year":2022,"lang":"hu","type":"article","venue":"Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Outpatient clinic; Work (physics); Task (project management); Unit (ring theory); Regional hospital; Medical care","score_opus":0.010237330068204212,"score_gpt":0.2231856081715642,"score_spread":0.21294827810335998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7010195112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6982879,0.03566871,0.0000014403806,0.25388882,0.0034964678,0.006544438,0.0006899689,0.000055133354,0.0013671247],"genre_scores_gemma":[0.9756385,0.00080513925,0.0001249366,0.007785082,0.00062024366,0.0005339562,0.000027042997,0.00010813243,0.014356935],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99076754,0.0020708318,0.0021934689,0.0013523774,0.0022919518,0.0013238577],"domain_scores_gemma":[0.99391925,0.0013542976,0.003162149,0.0011281588,0.00008867877,0.00034747392],"candidate_categories":["metaepi_narrow","sts","open_science"],"consensus_categories":["sts","open_science"],"category_scores_codex":[0.0018035595,0.0009505734,0.0018840206,0.00050097017,0.0020876136,0.00006882118,0.007903293,0.00048863085,0.00011112223],"category_scores_gemma":[0.00045122145,0.00048133847,0.0010117613,0.0016776089,0.004808348,0.0014906757,0.009044471,0.0020673976,0.0000016999066],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024231952,0.00248335,0.31321555,0.0036083478,0.004568827,0.000013747582,0.051212817,0.0017374327,0.02089162,0.034758646,0.5579657,0.00712075],"study_design_scores_gemma":[0.010299156,0.009980039,0.31229997,0.0060154255,0.0044724657,0.000043484397,0.012868968,0.0039894343,0.17783773,0.0037674943,0.4569329,0.0014929419],"about_ca_topic_score_codex":0.000041214884,"about_ca_topic_score_gemma":0.000004055941,"teacher_disagreement_score":0.27735063,"about_ca_system_score_codex":0.0003645738,"about_ca_system_score_gemma":0.0007427306,"threshold_uncertainty_score":0.99976385},"labels":[],"label_agreement":null},{"id":"W7014879834","doi":"","title":"Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights","year":2024,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Glycemic; Diabetes mellitus; Type 2 diabetes; Repurposing; Clinical pharmacology; Drug; Drug repositioning","score_opus":0.2957588117696499,"score_gpt":0.564264049797474,"score_spread":0.2685052380278241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7014879834","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29479912,0.6980667,0.00047392372,0.00017485912,0.0019388393,0.0024688337,0.000032577507,0.000043023105,0.0020021289],"genre_scores_gemma":[0.5716829,0.4231237,0.0006151457,0.000053284584,0.0020882762,0.00014993442,0.000083013765,0.000080251746,0.0021235347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820536,0.00005775394,0.00071366393,0.000324159,0.0004616778,0.00023740796],"domain_scores_gemma":[0.9982841,0.0006534547,0.00035526868,0.00041333577,0.00017284657,0.000120965764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043103742,0.00025734978,0.00069134287,0.00051841425,0.00015854837,0.00049460365,0.0004286908,0.00005100484,0.0010680039],"category_scores_gemma":[0.00007663156,0.00015140766,0.00060495705,0.0005888538,0.00007503436,0.0007449542,0.00015541866,0.00008323488,0.0000071045565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058721827,0.00023705034,0.018969702,0.000386575,0.0021723825,0.000024412859,0.00047696146,0.00015935088,0.0014611377,0.0007506881,0.013533833,0.9612407],"study_design_scores_gemma":[0.0018064638,0.00019791326,0.010222762,0.00095108367,0.002138689,0.00000641409,0.00005842889,0.0009910581,0.017153433,0.002692811,0.9635985,0.00018242611],"about_ca_topic_score_codex":0.00009487697,"about_ca_topic_score_gemma":0.000011428546,"teacher_disagreement_score":0.96105826,"about_ca_system_score_codex":0.00021121714,"about_ca_system_score_gemma":0.00013678841,"threshold_uncertainty_score":0.99984515},"labels":[],"label_agreement":null},{"id":"W7018083825","doi":"","title":"Comparative effectiveness of oral antihyperglycemic agents in patients with diabetes and chronic kidney disease","year":2018,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"Canadian Frailty Network","keywords":"Metformin; Kidney disease; Diabetes mellitus; Glycemic; Type 2 diabetes; Propensity score matching; Creatinine","score_opus":0.010963106295364181,"score_gpt":0.22616950655885223,"score_spread":0.21520640026348806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7018083825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978071,0.00013491954,0.0000021389837,0.000020135427,0.0000848032,0.0009578407,0.00005408741,0.000013807974,0.00092516065],"genre_scores_gemma":[0.9979103,0.00004212112,0.000110908426,0.0000068392924,0.000007847035,0.0000015682197,0.0015506179,0.000015435699,0.00035436824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991431,0.00006199389,0.000080884114,0.00028864742,0.000248134,0.00017723738],"domain_scores_gemma":[0.9993106,0.000026415688,0.00018409279,0.00019428467,0.00014788267,0.00013672844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000693825,0.0002069477,0.0006117362,0.00027670432,0.00004608456,0.0000048897473,0.000092261296,0.00007946575,0.0000123682385],"category_scores_gemma":[0.000008803426,0.00020865149,0.000063771186,0.0001798701,0.00014079883,0.00011714575,0.000048810696,0.00008700303,0.0000071078343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003694769,0.00057427015,0.99112403,0.0028471414,0.0005684046,0.000014695566,0.00021995406,0.000002476796,0.00008933106,0.000019111423,0.00050110713,0.0003446909],"study_design_scores_gemma":[0.006836841,0.001610022,0.98615927,0.002445407,0.0009501166,1.8857358e-8,0.001183737,0.00006237633,0.00032823754,0.000010271063,0.00024871153,0.00016499321],"about_ca_topic_score_codex":0.00016166475,"about_ca_topic_score_gemma":0.009524569,"teacher_disagreement_score":0.009362904,"about_ca_system_score_codex":0.00018206847,"about_ca_system_score_gemma":0.000116140945,"threshold_uncertainty_score":0.85085607},"labels":[],"label_agreement":null},{"id":"W7026748708","doi":"","title":"Appropriatezza d'impiego dei tiazolidindioni nell'Azienda Ospedaliera di Ferrara","year":2010,"lang":"en","type":"article","venue":"Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Medical prescription; Reimbursement; Diabetes mellitus; Type 2 diabetes; Quarter (Canadian coin)","score_opus":0.015701911503467045,"score_gpt":0.23363580123286593,"score_spread":0.21793388972939887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7026748708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7278468,0.00012740596,0.0006241403,0.0021668673,0.0010820035,0.0009504708,0.000090932816,0.00033106844,0.26678032],"genre_scores_gemma":[0.88575506,0.00024660127,0.00204739,0.00058129884,0.0003418988,0.000042079442,0.00042163057,0.00007891523,0.11048511],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656194,0.00008837551,0.00044679124,0.0010636738,0.0007028518,0.001136388],"domain_scores_gemma":[0.99808395,0.000118743345,0.00021156864,0.00092444377,0.0001691625,0.0004921407],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026614367,0.00066672236,0.00080244144,0.0005184731,0.00063912,0.00009740696,0.00058370596,0.00022081225,0.0007093087],"category_scores_gemma":[0.000030158079,0.0006000918,0.0003734935,0.0004490822,0.00046882953,0.00032766967,0.0008174448,0.0006433431,0.0011119643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023464411,0.0060075293,0.37860534,0.0008899848,0.006225279,0.00592554,0.004100666,0.00027514168,0.034373406,0.48743957,0.0477827,0.026028395],"study_design_scores_gemma":[0.009881826,0.0014487002,0.4507607,0.00019275733,0.002445705,0.00032672245,0.0011720955,0.0007883548,0.0044110673,0.0015335139,0.5252526,0.0017859999],"about_ca_topic_score_codex":0.000047411457,"about_ca_topic_score_gemma":0.000103254846,"teacher_disagreement_score":0.48590606,"about_ca_system_score_codex":0.00021521254,"about_ca_system_score_gemma":0.0001833039,"threshold_uncertainty_score":0.9996658},"labels":[],"label_agreement":null},{"id":"W7027726851","doi":"","title":"Dimensionnement de bloc-batterie basé sur la configuration série/parallèle comme un problème d’optimisation contraint","year":2019,"lang":"fr","type":"other","venue":"Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Work (physics); Filter (signal processing); Limiting; Context (archaeology)","score_opus":0.01395392358506349,"score_gpt":0.20310445421254453,"score_spread":0.18915053062748105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027726851","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.085499845,0.008902445,0.061434105,0.0025586346,0.0019214967,0.0043921852,0.00008368426,0.00010291695,0.8351047],"genre_scores_gemma":[0.75254434,0.00096361426,0.003759373,0.00011525662,0.00014574133,0.000004682604,0.0001463448,0.000054880406,0.24226578],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979915,0.00026292488,0.00044152135,0.00043665906,0.00047009098,0.0003973178],"domain_scores_gemma":[0.99853677,0.00016368179,0.00035631596,0.00053879136,0.0002462672,0.00015817242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031184507,0.00044277104,0.0007081022,0.00020844964,0.0002968044,0.000023362976,0.00047927935,0.00036472073,0.0020671475],"category_scores_gemma":[0.0000591435,0.00040741765,0.00042050175,0.00018592,0.00085656275,0.00015886953,0.00028913686,0.0002610582,0.00031588215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023072588,0.014128624,0.02162851,0.047076445,0.015019367,0.0002892931,0.025984809,0.099110946,0.16755949,0.3991982,0.12444386,0.08325318],"study_design_scores_gemma":[0.012210663,0.0009105304,0.051283758,0.027592478,0.0051656975,0.000034663473,0.0005364846,0.033726573,0.05626196,0.00036303388,0.8110666,0.0008475109],"about_ca_topic_score_codex":0.0009927116,"about_ca_topic_score_gemma":0.0018962028,"teacher_disagreement_score":0.6866228,"about_ca_system_score_codex":0.0023030017,"about_ca_system_score_gemma":0.00045497276,"threshold_uncertainty_score":0.99983776},"labels":[],"label_agreement":null},{"id":"W7036739942","doi":"","title":"Chinese interference in Canadian elections","year":2023,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Interference (communication); Government (linguistics); China","score_opus":0.005517141137835083,"score_gpt":0.20670643011067374,"score_spread":0.20118928897283866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7036739942","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013628422,0.000120753015,3.559393e-8,0.00031877772,0.00025006232,0.0005207869,0.00005315265,0.00022231897,0.9983778],"genre_scores_gemma":[0.006774509,0.00028432204,0.00011419035,0.00021895462,0.00007296822,0.00003758657,0.00016288503,0.00014419222,0.9921904],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990383,0.000016178996,0.0003319414,0.00014025818,0.00015821442,0.0003151568],"domain_scores_gemma":[0.9993687,0.000033019314,0.00013771505,0.0002402407,0.00004695876,0.00017333348],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000098000084,0.00021801924,0.0003332024,0.00031156224,0.000023355225,0.000019101335,0.00010839847,0.00019372425,0.20399655],"category_scores_gemma":[0.00009583607,0.00019744759,0.00009218359,0.000020784368,0.000041511237,1.0078241e-7,0.000033855787,0.00017138413,0.015606136],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021415932,0.00003816807,0.00037453463,0.0002441821,0.00009219056,0.000052425283,0.000057097855,0.000016783715,4.4958487e-8,0.000020617614,0.99695003,0.002132505],"study_design_scores_gemma":[0.00055498857,0.00014271282,0.00063625624,0.00042673165,0.00006276014,0.000011470911,0.000033381406,0.000013902638,6.492423e-7,0.0000050396843,0.9979592,0.0001528874],"about_ca_topic_score_codex":0.55831516,"about_ca_topic_score_gemma":0.88892424,"teacher_disagreement_score":0.33060905,"about_ca_system_score_codex":0.00019410557,"about_ca_system_score_gemma":0.00007347842,"threshold_uncertainty_score":0.98516035},"labels":[],"label_agreement":null},{"id":"W7038486247","doi":"","title":"IMPACT OF SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND MILD COGNITIVE IMPAIRMENT (MCI): clinical effects and genetic predictors of response","year":2025,"lang":"en","type":"dissertation","venue":"Nova Science Publishers (Nova Science Publishers, Inc.)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Type 2 diabetes; Semaglutide; Neuropsychology; Dementia; Cognition; Beck Depression Inventory; Cognitive impairment","score_opus":0.01402685352136414,"score_gpt":0.3153629860041635,"score_spread":0.3013361324827994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7038486247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204814,0.00033110994,0.0000013157324,0.000121077064,0.001586211,0.0029406028,0.000042108346,0.00004541785,0.0028840282],"genre_scores_gemma":[0.9982837,0.00002175969,0.0008407887,0.000112628375,0.000031905824,0.000052931577,0.00019933765,0.000035937115,0.00042100612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930704,0.00016143407,0.0012194657,0.0017893141,0.0025215205,0.0012378417],"domain_scores_gemma":[0.9942953,0.0005909837,0.00092430523,0.0007820084,0.0027213146,0.00068608223],"candidate_categories":["metaepi_narrow","sts","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0046347682,0.000662702,0.0013164999,0.0040617757,0.0002102617,0.0012046241,0.0009763415,0.0003211328,0.00005398898],"category_scores_gemma":[0.004787899,0.0004983433,0.00015445126,0.008800476,0.004233478,0.0048752497,0.00046223222,0.00059518486,0.0000015877947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026504819,0.0012818497,0.979039,0.0006968867,0.00028783694,0.00001037529,0.0009690244,0.000010640042,0.0003109058,0.000010903274,0.0013690921,0.013362988],"study_design_scores_gemma":[0.0067708655,0.00707374,0.9817931,0.0018221474,0.00044195866,9.267436e-7,0.0010784642,0.00010053225,0.00045253904,0.0000361668,0.000019862917,0.00040970548],"about_ca_topic_score_codex":0.00053058885,"about_ca_topic_score_gemma":0.00013526707,"teacher_disagreement_score":0.012953282,"about_ca_system_score_codex":0.0008413361,"about_ca_system_score_gemma":0.0070915744,"threshold_uncertainty_score":0.9998322},"labels":[],"label_agreement":null},{"id":"W7039407036","doi":"","title":"MJM MedTalks (S02E03): Beyond the Hype - GLP-1 Agonists Redefining Glycemic Control","year":2024,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Conversation; Alternative medicine; Glossary; Health professionals; Health care; Control (management); Advice (programming)","score_opus":0.15227372425699237,"score_gpt":0.5163745675806765,"score_spread":0.3641008433236841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7039407036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7060022,0.14864203,0.00024221472,0.0058358656,0.0029680575,0.0022234689,0.000090025285,0.00026945802,0.13372673],"genre_scores_gemma":[0.98310477,0.009179432,0.00012612455,0.0019453771,0.0004339021,0.00012810525,0.000046919282,0.0000927352,0.004942611],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692726,0.00016198505,0.0008331485,0.00057244237,0.0009191034,0.00058607344],"domain_scores_gemma":[0.997857,0.000546777,0.000386578,0.0007263389,0.00017308687,0.0003102612],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012326798,0.0004389234,0.00096266496,0.0006725322,0.00031520496,0.0018531481,0.001509994,0.00012162521,0.0069436687],"category_scores_gemma":[0.00021136526,0.0002944187,0.00038747836,0.0009564022,0.00021108682,0.0011300665,0.0006751901,0.000562976,0.00015742239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023785357,0.0008490296,0.1450018,0.00083903864,0.006160346,0.0015374203,0.0007878074,0.00008860187,0.059794262,0.0036512758,0.56583184,0.21308003],"study_design_scores_gemma":[0.008995056,0.00031166596,0.27802467,0.0040851063,0.005047659,0.00018603203,0.0004752148,0.0010739773,0.0148440935,0.01936225,0.6662264,0.0013679157],"about_ca_topic_score_codex":0.00028070086,"about_ca_topic_score_gemma":0.000024124945,"teacher_disagreement_score":0.27710265,"about_ca_system_score_codex":0.00020860918,"about_ca_system_score_gemma":0.00020293966,"threshold_uncertainty_score":0.99995077},"labels":[],"label_agreement":null},{"id":"W7044214019","doi":"","title":"Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes","year":2018,"lang":"en","type":"other","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interim; Quarter (Canadian coin); Type 2 diabetes; Phase (matter); Diabetes mellitus; Clinical trial","score_opus":0.022910229212671235,"score_gpt":0.2828275128438434,"score_spread":0.25991728363117217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7044214019","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6497578,0.0006041877,0.000037489095,0.000116801544,0.0015346169,0.0055727144,0.002137723,0.00011234848,0.3401263],"genre_scores_gemma":[0.42776608,0.00013187628,0.014691115,0.00061966444,0.0055272086,0.00024485827,0.079987854,0.0008876719,0.47014365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817413,0.00004633753,0.0004654582,0.0007320939,0.00031548046,0.00026650855],"domain_scores_gemma":[0.99842453,0.000042295014,0.0005220912,0.0008476995,0.000082067796,0.00008133601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018459916,0.00032525562,0.00069574564,0.00022053254,0.000021801467,0.00003370663,0.0001552185,0.00017381186,0.00035959957],"category_scores_gemma":[0.00012525172,0.00022616342,0.000037513575,0.000113752314,0.0001593051,0.00014219338,0.00019266586,0.00010701257,0.000015520529],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024353731,0.0016631187,0.012052224,0.00008263687,0.00081465,0.00009696254,0.0003900871,4.640733e-8,0.000006675098,0.0000039495812,0.9513323,0.009203675],"study_design_scores_gemma":[0.37494093,0.078449875,0.025347188,0.009614581,0.0036408848,0.00000200951,0.00045394638,0.00008248245,0.00094204524,0.00009648403,0.5044532,0.0019763946],"about_ca_topic_score_codex":0.00029381257,"about_ca_topic_score_gemma":0.0006922412,"teacher_disagreement_score":0.44687906,"about_ca_system_score_codex":0.000038217382,"about_ca_system_score_gemma":0.000111343375,"threshold_uncertainty_score":0.9222677},"labels":[],"label_agreement":null},{"id":"W7072202722","doi":"","title":"Use of sodium-glucose co-transporter-2 inhibitors to decrease the risk of dementia among patients with type 2 diabetes: A population-based cohort study","year":2024,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Dementia; Cohort study; Cohort; Disease; Incidence (geometry); Risk factor","score_opus":0.009545317409656199,"score_gpt":0.23091470859792165,"score_spread":0.22136939118826546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7072202722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990956,0.00012637732,5.9139698e-8,0.000004817209,0.00051668397,0.0062178364,0.0010997541,0.00011801109,0.0009604628],"genre_scores_gemma":[0.9915916,0.0000331037,0.00017783318,0.00011019667,0.000019005098,0.0004586991,0.0067123077,0.00020062333,0.00069666654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957397,0.0002560807,0.0011671769,0.000927961,0.0014070394,0.0005020379],"domain_scores_gemma":[0.99668115,0.00025522895,0.00083305273,0.0010662554,0.00070403377,0.0004602764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006628388,0.0007535798,0.0011167342,0.0006788311,0.00029771784,0.0000569962,0.00029049488,0.0002588336,0.00018086558],"category_scores_gemma":[0.00055163895,0.00053571624,0.0003709635,0.00096164196,0.00006164913,0.00031381767,0.000049830945,0.0005873913,0.000038730082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010371462,0.0025785859,0.98222876,0.0007896099,0.004648613,0.000027292948,0.00003857046,0.00007733659,0.0002738681,0.000094647534,0.000016954005,0.008188638],"study_design_scores_gemma":[0.0023996423,0.0022275762,0.9691991,0.0014092711,0.012768554,7.539146e-8,0.00022589178,0.000020205744,0.010207183,0.00006598615,0.0009798185,0.00049666694],"about_ca_topic_score_codex":0.0018820621,"about_ca_topic_score_gemma":0.0037964503,"teacher_disagreement_score":0.013029609,"about_ca_system_score_codex":0.00031522263,"about_ca_system_score_gemma":0.000095432704,"threshold_uncertainty_score":0.9997094},"labels":[],"label_agreement":null},{"id":"W7093639635","doi":"","title":"The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study","year":2023,"lang":"en","type":"article","venue":"Research Portal (King's College London)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"","keywords":"Cancer; Type 2 diabetes; Cohort study; Cohort; Retrospective cohort study; Diabetes mellitus","score_opus":0.020248180554748803,"score_gpt":0.3341804258366815,"score_spread":0.3139322452819327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093639635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291706,0.0028214804,1.4700353e-7,0.00045147524,0.00008049169,0.0033905334,0.000058824153,0.000047594673,0.00023239761],"genre_scores_gemma":[0.9971153,0.0009963688,0.0000067020646,0.000025350502,0.00005263266,0.00046097234,0.000110420624,0.000029480268,0.0012027739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748313,0.0002653143,0.00031205037,0.0004328179,0.00090691424,0.0005997615],"domain_scores_gemma":[0.9976532,0.0015733986,0.00007791505,0.00035831818,0.00009196349,0.00024522346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013083456,0.00020777123,0.00045852858,0.0007792582,0.00020211205,0.000054660864,0.00011443291,0.00004574104,0.0000446487],"category_scores_gemma":[0.00064187247,0.00013922933,0.000057197416,0.0021794965,0.0001196288,0.00006675629,0.00012456953,0.00021476032,0.000010000271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065374345,0.00023692194,0.9857247,0.00019025856,0.00024228213,0.00014160774,0.000029240948,0.0000389063,0.00001886235,0.000037816524,0.0033132634,0.009372405],"study_design_scores_gemma":[0.0035336593,0.0038364623,0.9907159,0.00026361528,0.00019477167,8.181924e-7,0.00015229886,0.00075860746,0.000088120985,0.000049633272,0.00030444888,0.00010166162],"about_ca_topic_score_codex":0.0010261344,"about_ca_topic_score_gemma":0.0007741075,"teacher_disagreement_score":0.0092707435,"about_ca_system_score_codex":0.00010661625,"about_ca_system_score_gemma":0.00017415013,"threshold_uncertainty_score":0.56776077},"labels":[],"label_agreement":null},{"id":"W7094718600","doi":"","title":"Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study","year":2023,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"","keywords":"Type 2 Diabetes Mellitus; Prostate cancer; Cohort study; Cohort; Type 2 diabetes; Diabetes mellitus","score_opus":0.026799507338646087,"score_gpt":0.30333748765294727,"score_spread":0.27653798031430116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094718600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421877,0.00012527927,0.0000014201543,0.0028176056,0.000085351174,0.0023420546,0.00001064569,0.000052073607,0.00034682182],"genre_scores_gemma":[0.99681413,0.000035381985,0.000054259257,0.00044102356,0.00001447265,0.00017771163,0.00006154521,0.000011951888,0.0023895146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999213,0.000030744523,0.00018577272,0.00019262107,0.00019842437,0.00017944464],"domain_scores_gemma":[0.9995364,0.000101505946,0.00003626073,0.00022630687,0.000028360368,0.000071151946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019777732,0.000105235194,0.00024964873,0.00016815928,0.000030626165,0.000012984209,0.00004610279,0.000016450065,0.00008503392],"category_scores_gemma":[0.000033672586,0.00006524757,0.000021523612,0.000509422,0.000011996366,0.000018275676,0.000031934796,0.00004428969,0.000028751438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116572955,0.00028880787,0.9836604,0.000023656268,0.00012080944,0.000002360123,0.0003877348,0.00071155303,0.00004074039,0.000023740864,0.009872965,0.004750641],"study_design_scores_gemma":[0.0015204797,0.0008354661,0.9942774,0.00006523962,0.00012636301,1.3303685e-8,0.00040237853,0.0012381424,0.00041964653,0.000013392328,0.0010355929,0.00006585434],"about_ca_topic_score_codex":0.0013788505,"about_ca_topic_score_gemma":0.0028632646,"teacher_disagreement_score":0.010617013,"about_ca_system_score_codex":0.000047731446,"about_ca_system_score_gemma":0.00003789283,"threshold_uncertainty_score":0.2660719},"labels":[],"label_agreement":null},{"id":"W7095438004","doi":"","title":"A GIP Receptor Agonist Exhibits b-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved b-Cell Function and Glycemic Control","year":2013,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Streptozotocin; Islet; Glucose homeostasis; Diabetes mellitus; Gastric inhibitory polypeptide; Agonist; Insulin; Receptor","score_opus":0.012528833409786116,"score_gpt":0.21633763854053348,"score_spread":0.20380880513074737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095438004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947448,0.00017138798,0.00011401268,0.000298898,0.00009385105,0.0013421118,0.000026838365,0.00004015331,0.0031679764],"genre_scores_gemma":[0.99750984,0.000056659348,0.00037288744,0.00018799331,0.00002192724,0.00015226702,0.00020366863,0.000017044982,0.0014776874],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99882674,0.0000377881,0.00040087767,0.0002970902,0.00011558558,0.00032189753],"domain_scores_gemma":[0.9994263,0.00009925337,0.00011780709,0.00021006286,0.00006040563,0.00008615906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014647942,0.00017830182,0.00038023357,0.00026558732,0.00003462965,0.000030073343,0.000043165554,0.00008306813,0.00010885149],"category_scores_gemma":[0.000028802915,0.00014844522,0.00005579288,0.00023416532,0.000046344907,0.0002604982,0.00003700227,0.00012891919,0.00003691369],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040820864,0.0023581183,0.045590267,0.00052084,0.00009224415,0.0000016292421,0.00021209312,0.0003547082,0.9435199,0.0001047571,0.0032365124,0.0036007296],"study_design_scores_gemma":[0.18679082,0.008774162,0.09054366,0.0013343631,0.0015194137,0.0000015496992,0.0035881507,0.36450532,0.33752245,0.001514456,0.002214569,0.0016910861],"about_ca_topic_score_codex":0.0003977214,"about_ca_topic_score_gemma":0.00008495747,"teacher_disagreement_score":0.60599744,"about_ca_system_score_codex":0.000083294006,"about_ca_system_score_gemma":0.000025004892,"threshold_uncertainty_score":0.60534203},"labels":[],"label_agreement":null},{"id":"W7098697047","doi":"","title":"Acquisitions et services bibliogiaphiques","year":2014,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reproduction; Order (exchange); Work (physics); Legislation; Service (business); Control (management)","score_opus":0.011316114930131358,"score_gpt":0.28342086439374126,"score_spread":0.2721047494636099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7098697047","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2198291,0.000064075655,0.0006793444,0.006633589,0.000048052545,0.0001594368,0.0000010126273,0.0002512242,0.77233416],"genre_scores_gemma":[0.97248256,0.00009196079,0.0029680063,0.013187899,0.000054732518,0.000017385348,0.000044708202,0.0000068101544,0.011145921],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996807,0.000010843645,0.000056177792,0.000087418644,0.000076410885,0.00008845473],"domain_scores_gemma":[0.99975646,0.000017164708,0.000011631836,0.0001423681,0.000023668257,0.000048711514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007554079,0.000052544354,0.00007920054,0.00029661861,0.000020698017,0.00002306417,0.000028262855,0.000016645638,0.0007071192],"category_scores_gemma":[0.000002334702,0.00003650216,0.00003481699,0.0002640563,0.000009445861,0.00007577732,0.000025842446,0.000019314572,0.00033419934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005922422,0.0013030272,0.16347298,0.00054438465,0.00064298953,0.000021026222,0.00041292497,0.0000063306206,0.0029521962,0.6014339,0.17580795,0.05334308],"study_design_scores_gemma":[0.0017983248,0.00069510756,0.28050727,0.00011894622,0.00029036647,0.0000031376746,0.00016996975,0.0006468383,0.0042270776,0.0058700787,0.7054989,0.00017400485],"about_ca_topic_score_codex":0.000034856563,"about_ca_topic_score_gemma":0.00002415556,"teacher_disagreement_score":0.76118827,"about_ca_system_score_codex":0.0000063382236,"about_ca_system_score_gemma":0.000002900027,"threshold_uncertainty_score":0.7742459},"labels":[],"label_agreement":null},{"id":"W7099265079","doi":"","title":"THE DEVELOPMENT OF A SUB-ARCTIC RESOURCE by","year":2014,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Resource (disambiguation); Promotion (chess); Work (physics); Natural resource; Valorisation","score_opus":0.008155428858184582,"score_gpt":0.2203015509858332,"score_spread":0.21214612212764863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099265079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73676413,0.00025049553,0.00107017,0.0026973858,0.00004506061,0.00036805012,2.3225562e-7,0.000053301505,0.25875118],"genre_scores_gemma":[0.97338504,0.0000070458505,0.0013450935,0.00031431683,0.000011417506,0.00001617788,0.00000774709,0.000005453416,0.024907704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995855,0.00001029361,0.000113818074,0.00006766914,0.00011901923,0.00010371182],"domain_scores_gemma":[0.9997221,0.000054114447,0.000024929803,0.00014763878,0.00001710929,0.000034098925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018617239,0.000046394518,0.00007759392,0.000015037949,0.00004664522,0.000005615459,0.00004153224,0.000011081534,0.00003483198],"category_scores_gemma":[0.000025426667,0.000024403751,0.000022105596,0.000043013868,0.000023560438,0.000008628634,0.000029111443,0.00001916242,0.000047584374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100943915,0.0004494721,0.022924412,0.00017043336,0.00050954,9.798783e-7,0.00068909297,5.8214937e-7,0.0064893547,0.010547621,0.169147,0.7889706],"study_design_scores_gemma":[0.0006745791,0.000118718366,0.010083026,0.000025913376,0.000051125226,2.0293703e-7,0.00012303142,0.00003741808,0.030001763,0.00008291906,0.9587615,0.000039786228],"about_ca_topic_score_codex":0.0000033240137,"about_ca_topic_score_gemma":0.000010972107,"teacher_disagreement_score":0.7896145,"about_ca_system_score_codex":0.000021358579,"about_ca_system_score_gemma":0.000010462716,"threshold_uncertainty_score":0.09951561},"labels":[],"label_agreement":null},{"id":"W7099743663","doi":"","title":"The term structure of cds spreads and sovereign credit risk, Working Paper McGill University","year":2013,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Credit default swap; Credit risk; Sovereign credit; Term (time); Swap (finance); Sovereignty; Panel data; Credit default swap index","score_opus":0.00741460029268086,"score_gpt":0.19003125706459076,"score_spread":0.18261665677190989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099743663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90766376,0.00010071934,0.0000064245223,0.00044930956,0.00006430353,0.00031563666,0.000012429482,0.000027107983,0.09136033],"genre_scores_gemma":[0.98651683,0.0002143611,0.00038712885,0.00011989725,0.0000305187,5.774574e-7,0.0000046862006,0.0000051398956,0.012720844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99960065,0.000015807505,0.000065246255,0.0001071524,0.00009403331,0.00011713715],"domain_scores_gemma":[0.9996482,0.000059561757,0.000044024233,0.00017380084,0.000025510433,0.00004887049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034469544,0.00007335068,0.0001082866,0.00002473187,0.00010552307,0.000007971859,0.00005066608,0.000032639706,0.0006155601],"category_scores_gemma":[0.000009811728,0.00004157821,0.00003296895,0.000051435185,0.000047390135,0.00007184889,0.00007179115,0.000056696903,0.000008548645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016034888,0.00016262307,0.4458595,0.00010618916,0.0013061657,0.000021177118,0.00022893633,0.000003631944,0.005807867,0.04790013,0.040255286,0.45818818],"study_design_scores_gemma":[0.0024858105,0.00030953757,0.8657163,0.00006994512,0.0006335137,0.0000021847472,0.00093608006,0.00009216145,0.0029869447,0.0038410842,0.12277389,0.00015253517],"about_ca_topic_score_codex":0.00020028526,"about_ca_topic_score_gemma":0.000058064157,"teacher_disagreement_score":0.45803562,"about_ca_system_score_codex":0.000028262924,"about_ca_system_score_gemma":0.000004471316,"threshold_uncertainty_score":0.67399514},"labels":[],"label_agreement":null},{"id":"W7100096407","doi":"","title":"Guest Editorial Diabetes Is Common in Elderly Persons","year":2014,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diabetes mellitus; Adverse effect; Dosing; Quality of life (healthcare); Population; Drug reaction; Drug; Complication","score_opus":0.008467587168229299,"score_gpt":0.24441173974117555,"score_spread":0.23594415257294626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100096407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8512257,0.00003394315,0.0000047960984,0.003098777,0.01692708,0.00030257914,0.000002104066,0.00009700845,0.12830803],"genre_scores_gemma":[0.9681991,0.000004521214,0.00016260352,0.0010468918,0.02208861,0.000029089204,0.000022247199,0.000012567621,0.008434375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932003,0.000016832584,0.000114224444,0.00015755485,0.0001717427,0.00021960777],"domain_scores_gemma":[0.9996471,0.000043416447,0.000019545787,0.00020135748,0.000015935668,0.00007268135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012729559,0.00009903435,0.00019959499,0.000085141364,0.000022951837,0.000018603083,0.000050415387,0.00005508985,0.00019592849],"category_scores_gemma":[0.000021940115,0.0000764496,0.000052379684,0.00008832374,0.000022522278,0.000052127103,0.000029469811,0.00007308166,0.00021764843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014446236,0.00020422279,0.2810815,0.000031986758,0.000053126,0.0000023956725,0.00017945218,1.5830588e-7,0.00015931572,0.00038203385,0.7119796,0.005911706],"study_design_scores_gemma":[0.0034209003,0.0011464402,0.042961743,0.00006708275,0.00013031713,1.4242913e-7,0.00013236143,0.00018330738,0.0024262879,0.00018709866,0.94919163,0.00015267418],"about_ca_topic_score_codex":0.000072921,"about_ca_topic_score_gemma":0.00005722547,"teacher_disagreement_score":0.23811977,"about_ca_system_score_codex":0.000036195226,"about_ca_system_score_gemma":0.0000078620615,"threshold_uncertainty_score":0.31175244},"labels":[],"label_agreement":null},{"id":"W7100901483","doi":"","title":"Second-Line Therapy for Patients with Diabetes Inadequately Controlled on Metformin — PROJECT PROTOCOL Supporting Informed Decisions","year":2009,"lang":"en","type":"article","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Documentation; Agency (philosophy); Health care; Protocol (science); Service (business); Medical record; Quality (philosophy); Process (computing)","score_opus":0.032019305326752845,"score_gpt":0.3383663298855613,"score_spread":0.30634702455880847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100901483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7123647,0.000003865965,0.00008793954,0.0004057506,0.000024350062,0.26591223,0.000011703341,0.00014195334,0.021047555],"genre_scores_gemma":[0.7513105,0.0000033055526,0.0072318907,0.0038347153,0.00006944562,0.22920778,0.00028522284,0.000039587918,0.008017539],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99835306,0.00001528896,0.000517405,0.000278366,0.0003415259,0.0004943494],"domain_scores_gemma":[0.99883896,0.00034076182,0.00023650515,0.00028308333,0.00019059525,0.00011008025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002670427,0.00028279613,0.0006236182,0.000243407,0.00010180473,0.000048736834,0.00008968813,0.00006007609,0.00023710237],"category_scores_gemma":[0.00029079395,0.00014756051,0.0001612618,0.0002009351,0.000021589372,0.00019111835,0.000014139265,0.0000758516,0.000014776792],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029797835,0.0065153493,0.03157531,0.00014457789,0.0011604453,0.000009085624,0.00027525393,0.00000365066,0.00018672731,0.0016986391,0.011906391,0.9167267],"study_design_scores_gemma":[0.4683109,0.15814717,0.14074507,0.0007798422,0.00068567856,7.527828e-7,0.0002878036,0.0013451444,0.022722019,0.0015369143,0.20430177,0.0011369265],"about_ca_topic_score_codex":0.0000013139744,"about_ca_topic_score_gemma":0.000009102102,"teacher_disagreement_score":0.9155898,"about_ca_system_score_codex":0.000080985694,"about_ca_system_score_gemma":0.00014083732,"threshold_uncertainty_score":0.6017343},"labels":[],"label_agreement":null},{"id":"W7104430291","doi":"","title":"Leveraging a Bayesian Approach in a Comparative Effectiveness Trial of Major Adverse Cardiovascular Events","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Bayesian probability; Prior probability; Bayes' theorem; Cohort; Hazard ratio; Covariate; Posterior probability; Suite; Clinical trial","score_opus":0.18280655253928382,"score_gpt":0.5127323365549751,"score_spread":0.3299257840156913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104430291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660058,0.0093384255,0.002297309,0.000037381087,0.00039736275,0.003394411,0.000008637444,0.000020747148,0.018499937],"genre_scores_gemma":[0.99796385,0.0009771185,0.00035859068,0.00005615247,0.000050211846,0.00027788634,0.000021866696,0.000023159058,0.00027117663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971919,0.00058829715,0.0007687436,0.00046767524,0.0006571037,0.0003262646],"domain_scores_gemma":[0.998521,0.00024318566,0.0003745959,0.00055813056,0.00017609153,0.00012702451],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001979147,0.00031158223,0.0017765311,0.0013107671,0.00007962805,0.000089374655,0.00080084766,0.00008397409,0.00040652027],"category_scores_gemma":[0.00010547762,0.0002701585,0.0005883889,0.0013308442,0.000081166385,0.00065407413,0.0005464612,0.0002636164,0.0000033214235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027075253,0.004653565,0.9223606,0.001940543,0.0111603495,0.00013714783,0.00074561435,0.0017042742,0.0047073513,0.0001976996,0.0027016983,0.022615906],"study_design_scores_gemma":[0.055141233,0.00007579122,0.92824894,0.0023634885,0.0015695589,0.0000025811032,0.00034763032,0.0002769949,0.0091532795,0.0012501216,0.0012822006,0.00028818028],"about_ca_topic_score_codex":0.0006489858,"about_ca_topic_score_gemma":0.000009163408,"teacher_disagreement_score":0.03195805,"about_ca_system_score_codex":0.0002561261,"about_ca_system_score_gemma":0.00016598319,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W7106660258","doi":"10.5327/cbn240922","title":"Impact of glucagon-like-peptide-1 receptor agonists on non-motor symptoms in Parkinson’s disease: a systematic review and meta-analysis","year":2024,"lang":"","type":"article","venue":"Arquivos de Neuro-Psiquiatria","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rating scale; Bonferroni correction; Beck Depression Inventory; Cognition; Depression (economics); Randomized controlled trial; Hamilton Rating Scale for Depression; Dementia; Disease","score_opus":0.020840885066686902,"score_gpt":0.3044144666440625,"score_spread":0.2835735815773756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7106660258","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2548045,0.7222855,0.000049137576,0.004286445,0.000810108,0.01589774,0.0010146287,0.00022527583,0.0006266561],"genre_scores_gemma":[0.92694086,0.062846825,0.000093451374,0.0024382134,0.0001613502,0.001490769,0.00016115449,0.00018831056,0.005679047],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9919246,0.001116697,0.0026717542,0.0018869888,0.0010998965,0.001300058],"domain_scores_gemma":[0.99432856,0.0014479941,0.0008667251,0.0021615915,0.00016453954,0.0010305715],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019080079,0.0013968417,0.006977253,0.001786849,0.00010877748,0.0003035099,0.00056777697,0.0002345656,0.0014740551],"category_scores_gemma":[0.0008601479,0.0010089858,0.005620972,0.0032907545,0.00020170178,0.00035391934,0.0003061019,0.0006031466,0.00035711055],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093014014,0.0019538058,0.010371222,0.5146713,0.45872286,0.0011211244,0.0005560818,0.00013265257,0.0002907047,0.00027357007,0.010744521,0.00023201917],"study_design_scores_gemma":[0.0018916798,0.003127912,0.016284764,0.018097878,0.95595556,0.000009289754,0.000030944844,0.0020971857,0.000034185345,0.00004025668,0.0016312076,0.0007991075],"about_ca_topic_score_codex":0.00021391921,"about_ca_topic_score_gemma":0.00004061566,"teacher_disagreement_score":0.67213637,"about_ca_system_score_codex":0.00087874336,"about_ca_system_score_gemma":0.0005521217,"threshold_uncertainty_score":0.99987817},"labels":[],"label_agreement":null},{"id":"W7108206913","doi":"10.1681/asn.2025swp337ha","title":"Dapagliflozin Treatment Induces Alternate RAAS Activation in Stable Kidney Transplant Recipients","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Paul's Hospital; University Health Network; University of British Columbia","funders":"","keywords":"Dapagliflozin; Kidney; Kidney disease; Kidney transplantation; Kidney transplant; Urinary system; Diabetes mellitus","score_opus":0.01782166916279635,"score_gpt":0.2849868287268948,"score_spread":0.2671651595640984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108206913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807884,0.00007661971,0.00008025663,0.018060455,0.0001386752,0.00021546212,0.0000037041984,0.0000046434884,0.0006317866],"genre_scores_gemma":[0.9891801,0.0008620671,0.00087513187,0.008070377,0.000058611942,0.00000665641,0.0000033882666,0.0000070157753,0.00093664357],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990834,0.00008224368,0.00036995762,0.00010817787,0.00017187884,0.00018436332],"domain_scores_gemma":[0.9991171,0.0000711965,0.00051958876,0.00017494844,0.00006087663,0.000056285764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020263446,0.000116451134,0.0004845376,0.00011003376,0.00003375023,0.0000053690983,0.00014983522,0.000036775906,0.000015056245],"category_scores_gemma":[0.000015966027,0.00007196574,0.00030036067,0.0003403525,0.00017591799,0.00006951366,0.000025743835,0.00013963727,8.556156e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030998962,0.0027849865,0.2970674,0.00011602037,0.0055771163,0.000021314247,0.0034898862,0.00020111405,0.552156,0.00021722872,0.07363902,0.061630026],"study_design_scores_gemma":[0.011492081,0.0050248383,0.83212405,0.00072778057,0.0013018688,0.000023927825,0.0013088954,0.00022767262,0.06480891,0.00076059264,0.08202896,0.00017039859],"about_ca_topic_score_codex":0.00026227583,"about_ca_topic_score_gemma":0.000007967315,"teacher_disagreement_score":0.53505665,"about_ca_system_score_codex":0.0002845749,"about_ca_system_score_gemma":0.00016352304,"threshold_uncertainty_score":0.2934678},"labels":[],"label_agreement":null},{"id":"W7108219887","doi":"10.69750/dmls.02.010.0168","title":"Glycemic Outcomes of Oral Hypoglycemics Versus GLP-1 Receptor Agonists in Type 2 Diabetes: A Comparative Clinical Study","year":2025,"lang":"","type":"article","venue":"Developmental medico-life-sciences","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Montmorency","funders":"","keywords":"Glycemic; Type 2 Diabetes Mellitus; Blood sugar; Diabetes mellitus; Hypoglycemia; Clinical study; Agonist; Adverse effect","score_opus":0.11917537666696075,"score_gpt":0.4057205621481134,"score_spread":0.28654518548115265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108219887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676412,0.00453892,0.000007868863,0.0013176341,0.009769087,0.002947081,0.000035113262,0.00007163936,0.013671477],"genre_scores_gemma":[0.99220717,0.001927124,0.003049393,0.0014988722,0.00009711639,0.00016593267,0.000074305906,0.000027611482,0.0009524972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920183,0.00053950044,0.0028441553,0.0015649998,0.0016883353,0.0013447267],"domain_scores_gemma":[0.9962038,0.0018262904,0.00073348626,0.00045379237,0.00020636703,0.0005762745],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.003090352,0.000878223,0.00265455,0.0010235201,0.0004433599,0.00006872422,0.0011825889,0.00031294712,0.0006450947],"category_scores_gemma":[0.0023757096,0.0007259165,0.0002604971,0.003760923,0.0031207944,0.00036482114,0.0009363636,0.00063631055,0.00024894165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034170675,0.0058983574,0.9560858,0.0002081257,0.0030623248,0.00003329556,0.0042549497,0.00001202195,0.000053222044,0.0003429097,0.007998238,0.01863369],"study_design_scores_gemma":[0.063176736,0.024990654,0.77053225,0.0023220016,0.0022370196,0.0000010587668,0.11096932,0.0009608417,0.00067168917,0.00015052842,0.022388797,0.0015990946],"about_ca_topic_score_codex":0.00018912462,"about_ca_topic_score_gemma":0.000310761,"teacher_disagreement_score":0.18555354,"about_ca_system_score_codex":0.00070896145,"about_ca_system_score_gemma":0.004301328,"threshold_uncertainty_score":0.9995921},"labels":[],"label_agreement":null},{"id":"W7110853328","doi":"10.6084/m9.figshare.30816974","title":"Additional file 1 of Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","year":2025,"lang":"","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Key (lock); MEDLINE; Patient privacy; Ransomware; Data collection","score_opus":0.05395505806333199,"score_gpt":0.3104365283437741,"score_spread":0.2564814702804421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110853328","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025332654,0.035502564,0.00037893662,0.0012649156,0.00013879947,0.007300075,0.90519994,0.0000086847995,0.02487343],"genre_scores_gemma":[0.84013987,0.00011623286,0.01492773,0.00038355874,0.00007328512,0.0026070734,0.12206275,0.000054611395,0.019634893],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956252,0.0011586477,0.001118812,0.0010216681,0.0006816043,0.00039405876],"domain_scores_gemma":[0.98797935,0.009859651,0.00078305247,0.00092827255,0.00028765862,0.00016200836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017638111,0.00067369884,0.007924273,0.0011265157,0.00014489616,0.00011929516,0.0003047518,0.00017137942,0.61812276],"category_scores_gemma":[0.00031964784,0.00044787824,0.005110218,0.0031372684,0.00036595232,0.00011250888,0.00039005437,0.00018606626,0.00001713361],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005578039,0.0006342846,0.0024040223,0.00022706996,0.9554094,0.000015585036,0.00005977181,0.0008996504,0.0000114858885,0.00003514275,0.035928857,0.003816892],"study_design_scores_gemma":[0.0018295044,0.0005849577,0.02550738,0.00010528159,0.9369759,1.4600258e-7,0.00007707694,0.00033577668,0.0005844841,0.000046233414,0.033672195,0.00028106268],"about_ca_topic_score_codex":0.000361218,"about_ca_topic_score_gemma":0.0002921386,"teacher_disagreement_score":0.81480724,"about_ca_system_score_codex":0.00006585386,"about_ca_system_score_gemma":0.00021147315,"threshold_uncertainty_score":0.9997973},"labels":[],"label_agreement":null},{"id":"W7110913328","doi":"10.1371/journal.pone.0321032.s003","title":"S3 Scales -","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Type 2 diabetes; Jadad scale; Diabetes mellitus; Adverse effect; Observational study","score_opus":0.02609274510702646,"score_gpt":0.28553626404101656,"score_spread":0.2594435189339901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110913328","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004022106,0.022446025,0.0000012147381,0.0036955986,0.0006597398,0.0014826669,0.17249869,0.0001961624,0.7986177],"genre_scores_gemma":[0.32732973,0.00016792142,0.00008426786,0.0063341376,0.00053615804,0.00073694094,0.30697757,0.000047705074,0.35778558],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987355,0.000024024355,0.00024528065,0.00037197737,0.00019898059,0.00042427814],"domain_scores_gemma":[0.9991342,0.00010324816,0.00006278804,0.00048382313,0.00009118867,0.00012477748],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003162877,0.00025081783,0.0003211838,0.00019033432,0.000109877255,0.000086567925,0.00018668962,0.00012328911,0.5545222],"category_scores_gemma":[0.00045925664,0.0002312774,0.00018017441,0.0003906653,0.000010555747,0.000091577254,0.0002966045,0.00013796298,0.029463097],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018873123,0.00024234562,0.0005353588,0.0014831102,0.00045066452,0.00006398888,0.000029407518,0.0000011962429,0.000006301661,0.0003412461,0.9034839,0.093343586],"study_design_scores_gemma":[0.0013660343,0.00013894992,0.020184489,0.013608124,0.00034186753,3.6016604e-7,0.00007006361,0.00014847651,0.00072144764,0.00011771799,0.9631343,0.00016817756],"about_ca_topic_score_codex":0.0000036944932,"about_ca_topic_score_gemma":0.0000063364178,"teacher_disagreement_score":0.5250591,"about_ca_system_score_codex":0.0001289906,"about_ca_system_score_gemma":0.00010852955,"threshold_uncertainty_score":0.97129256},"labels":[],"label_agreement":null},{"id":"W7111038071","doi":"10.1371/journal.pone.0321032.s001","title":"PRISMA 2020 checklist.","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Jadad scale; Type 2 diabetes; Diabetes mellitus; Adverse effect; Observational study; Meta-analysis","score_opus":0.016912755241795203,"score_gpt":0.2725901165616018,"score_spread":0.2556773613198066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111038071","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043201755,0.018349422,0.0000016015623,0.004745948,0.0008571346,0.0020606334,0.124305315,0.00021798509,0.84902996],"genre_scores_gemma":[0.13072093,0.00020006516,0.000098491764,0.004881139,0.00072240765,0.00083680847,0.27748403,0.00005511881,0.585001],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824005,0.000031970187,0.0003717308,0.0005304817,0.00027305892,0.0005527072],"domain_scores_gemma":[0.99881995,0.00009509759,0.000113333015,0.0006562859,0.00013155102,0.00018379035],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000050276176,0.00034643692,0.0004363743,0.0001516484,0.00012640738,0.00011559262,0.0002681081,0.00018238978,0.6466593],"category_scores_gemma":[0.00071696984,0.00033096288,0.0002384131,0.0005955931,0.000011263635,0.00011351602,0.0004243511,0.00023305451,0.030807072],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000332083,0.00031539061,0.00040511647,0.0019905318,0.0006199903,0.0001592284,0.00007397674,0.0000012589485,0.0000119029855,0.0001880385,0.93539137,0.06080997],"study_design_scores_gemma":[0.0019478162,0.00018760863,0.016010474,0.011409821,0.0005278212,7.752581e-7,0.00008465475,0.00027135116,0.0009754666,0.00007524488,0.9682764,0.00023259528],"about_ca_topic_score_codex":0.0000042037727,"about_ca_topic_score_gemma":0.0000027538485,"teacher_disagreement_score":0.61585224,"about_ca_system_score_codex":0.00020345818,"about_ca_system_score_gemma":0.00022712999,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W7111103098","doi":"10.6084/m9.figshare.30816974.v1","title":"Additional file 1 of Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Key (lock); MEDLINE; Patient privacy; Ransomware; Data collection","score_opus":0.05013244429136196,"score_gpt":0.2803608668612247,"score_spread":0.23022842256986273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111103098","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000120772755,0.018157838,0.000007269641,0.00014622469,0.000017786864,0.0010837399,0.97892916,0.000021765874,0.0015154101],"genre_scores_gemma":[0.12477835,0.000019239396,0.00050553604,0.00030542503,0.000045309713,0.0031333808,0.86847705,0.000027927126,0.002707762],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960815,0.0008615138,0.0009738652,0.0008974452,0.0007631005,0.00042261276],"domain_scores_gemma":[0.98397547,0.013803523,0.0007662499,0.0008528291,0.00043687498,0.00016507316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047472317,0.00072700554,0.0069151986,0.0012959775,0.0001309636,0.0000537902,0.00018992294,0.0002109198,0.9561691],"category_scores_gemma":[0.0013230575,0.00049562176,0.0072353925,0.0034153175,0.00009709358,0.00007597996,0.00023306311,0.00022109742,0.00003878208],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013416306,0.00023418391,0.0003058346,0.0011098919,0.599741,0.000010061791,0.00001513917,0.00062451867,0.000001288455,0.000013370098,0.39755374,0.00025682533],"study_design_scores_gemma":[0.0010904471,0.00041070255,0.03690344,0.0005821249,0.89638263,1.2648466e-7,0.0000232889,0.00043757577,0.00017450986,0.000032042677,0.06367632,0.00028681278],"about_ca_topic_score_codex":0.00008114194,"about_ca_topic_score_gemma":0.00008152954,"teacher_disagreement_score":0.9561303,"about_ca_system_score_codex":0.000069417256,"about_ca_system_score_gemma":0.00017024938,"threshold_uncertainty_score":0.99974954},"labels":[],"label_agreement":null},{"id":"W7111107871","doi":"10.1371/journal.pone.0321032.s002","title":"Search strategy and extracted information.","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Jadad scale; Type 2 diabetes; Diabetes mellitus; Adverse effect; Relative risk; Meta-analysis","score_opus":0.03275444682483835,"score_gpt":0.29401406753255116,"score_spread":0.2612596207077128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111107871","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048355106,0.009506661,0.000004283759,0.0012363308,0.00021922158,0.0024223127,0.15924989,0.00016436301,0.8223614],"genre_scores_gemma":[0.5840763,0.00031493272,0.00007086409,0.001972357,0.0001470421,0.0003675302,0.34520227,0.000019821584,0.06782888],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989688,0.000024769683,0.00027802945,0.00018125291,0.0002074994,0.0003396402],"domain_scores_gemma":[0.99927413,0.00009352459,0.000054975626,0.00026450638,0.00017915416,0.00013372763],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000042496198,0.00019287626,0.00022335385,0.00026183113,0.000114481605,0.00023961786,0.0000991209,0.000120130324,0.23748888],"category_scores_gemma":[0.00021678029,0.00017993298,0.00005320315,0.00036211516,0.00001154176,0.00055311475,0.00020164033,0.00018642546,0.0051086987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003259413,0.00010417678,0.00035436917,0.002236853,0.00031403714,0.000018929024,0.00016258551,0.000011168965,0.000004925178,0.000558788,0.68515563,0.31104594],"study_design_scores_gemma":[0.0020068942,0.00023228243,0.056780145,0.005350051,0.00019755228,0.0000010478799,0.0006401982,0.0022562682,0.00030638505,0.00002146751,0.9320451,0.00016259245],"about_ca_topic_score_codex":0.0000072256926,"about_ca_topic_score_gemma":0.0000017504584,"teacher_disagreement_score":0.7545326,"about_ca_system_score_codex":0.000076300275,"about_ca_system_score_gemma":0.00020860243,"threshold_uncertainty_score":0.99566597},"labels":[],"label_agreement":null},{"id":"W7115006092","doi":"10.1371/journal.pone.0338653.s004","title":"PRISMA checklist.","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cohort; Multivariate analysis; Cohort study; Meta-analysis; Heart failure; Multivariate statistics; Risk factor; Survival analysis","score_opus":0.021268643202810068,"score_gpt":0.27941792739191357,"score_spread":0.2581492841891035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115006092","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031468357,0.012821284,0.0000015558122,0.0024299975,0.000642463,0.0016055714,0.09917441,0.0001819304,0.8828281],"genre_scores_gemma":[0.14079607,0.00010125323,0.0000878108,0.0040638903,0.00045694667,0.0007520943,0.2436182,0.00004513823,0.6100786],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984499,0.000026539326,0.00032403006,0.00045366038,0.00023837328,0.0005074573],"domain_scores_gemma":[0.9989263,0.00008614881,0.00009593989,0.0006197026,0.00012199065,0.00014992307],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000045359266,0.0003043256,0.00038236094,0.00020860952,0.00011646953,0.00010254225,0.00023135546,0.00016464625,0.62266874],"category_scores_gemma":[0.00063291326,0.00028841116,0.00021198722,0.00049443217,0.000009850516,0.000101562306,0.00035546243,0.00019616274,0.028275535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025908468,0.00030534586,0.000271283,0.0018819256,0.0005443965,0.000088220324,0.00006671434,9.879316e-7,0.000009920939,0.00035302975,0.9202429,0.07620939],"study_design_scores_gemma":[0.0018012977,0.00015894444,0.013897257,0.012478203,0.0004673907,4.95667e-7,0.00007367255,0.00022980817,0.0011873655,0.000085013475,0.9694187,0.00020186535],"about_ca_topic_score_codex":0.0000040164905,"about_ca_topic_score_gemma":0.0000027042663,"teacher_disagreement_score":0.5943932,"about_ca_system_score_codex":0.0001952548,"about_ca_system_score_gemma":0.00020584237,"threshold_uncertainty_score":0.9999568},"labels":[],"label_agreement":null},{"id":"W7115039130","doi":"","title":"Glucagon-like peptide-1 receptor agonists and co-agonists for weight loss among individuals without diabetes","year":2025,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Diabetes mellitus; Weight loss; Agonist; Receptor; Type 2 diabetes; Obesity","score_opus":0.012281766217501905,"score_gpt":0.2612991493540268,"score_spread":0.2490173831365249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115039130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9312458,0.0011854758,1.6219788e-7,0.000092998926,0.0020234168,0.004294371,0.002649912,0.00042666338,0.05808117],"genre_scores_gemma":[0.83322316,0.0014627122,0.0018617286,0.0008109815,0.0001886621,0.0022334356,0.018400151,0.00038743598,0.14143173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99424326,0.00020421219,0.001237295,0.0019280943,0.0009998691,0.0013872929],"domain_scores_gemma":[0.99646264,0.0004272338,0.0008239157,0.0011037403,0.0005120534,0.0006703848],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00096034433,0.0014570209,0.00201337,0.0008814035,0.0012721485,0.00026751167,0.00053686614,0.0010939719,0.00027947107],"category_scores_gemma":[0.0005423284,0.0014141172,0.0006799452,0.00053920964,0.00019554868,0.0006447465,0.00020803008,0.0010460902,0.00016354414],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002768,0.004102133,0.1746109,0.023616744,0.019792657,0.00024291631,0.00015911489,0.000004520537,0.023880208,0.05756423,0.0048818053,0.6883768],"study_design_scores_gemma":[0.0100785475,0.0013888514,0.053597577,0.0049424297,0.006082501,0.000006067546,0.00031322162,0.000023977052,0.11524401,0.004896843,0.8009367,0.0024892546],"about_ca_topic_score_codex":0.00007671955,"about_ca_topic_score_gemma":0.00035634427,"teacher_disagreement_score":0.7960549,"about_ca_system_score_codex":0.00076966145,"about_ca_system_score_gemma":0.0001399698,"threshold_uncertainty_score":0.99981797},"labels":[],"label_agreement":null},{"id":"W7116047141","doi":"10.1016/j.jacadv.2025.102459","title":"Dapagliflozin in Acute Cardiovascular Conditions","year":2025,"lang":"en","type":"article","venue":"JACC Advances","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Ministério da Saúde","keywords":"Dapagliflozin; Intensive care unit; Vasoactive; Diuretic; Critically ill; Critical illness","score_opus":0.006991622373244661,"score_gpt":0.28887237391423076,"score_spread":0.2818807515409861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116047141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5743476,0.038710397,0.0013170682,0.0034072127,0.0008771434,0.0014778096,0.000023339997,0.00023554984,0.37960383],"genre_scores_gemma":[0.9767235,0.0020716556,0.0014910885,0.00088529964,0.00004705879,0.0001860269,0.00007198791,0.000008769526,0.018514618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99947286,0.000011992621,0.0001098045,0.00016363742,0.00010062845,0.00014107402],"domain_scores_gemma":[0.99969465,0.000021914333,0.000013792779,0.00022487257,0.00001791562,0.000026853708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005962059,0.000077750556,0.00021780065,0.00014477252,0.000029735571,0.000008759514,0.00004440103,0.000022613167,0.00005358104],"category_scores_gemma":[0.000015694415,0.000065210785,0.00011949599,0.00025361782,0.000028987099,0.00011473865,0.000029265877,0.00004932889,0.000045049343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022996639,0.0014080099,0.32943785,0.0006809946,0.00942143,0.0010151656,0.00032937017,0.0010590457,0.0010402326,0.041187223,0.030802809,0.5833879],"study_design_scores_gemma":[0.0030811864,0.00010180606,0.11834136,0.00020782309,0.0010138236,0.000002091095,0.0002416678,0.000072768365,0.0017435908,0.005246499,0.8698199,0.00012751923],"about_ca_topic_score_codex":0.0000069298553,"about_ca_topic_score_gemma":0.000011224018,"teacher_disagreement_score":0.83901703,"about_ca_system_score_codex":0.000053312106,"about_ca_system_score_gemma":0.000019695683,"threshold_uncertainty_score":0.26592186},"labels":[],"label_agreement":null},{"id":"W7116415561","doi":"10.14740/cr2109","title":"Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction","year":2025,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dapagliflozin; Heart failure; Ejection fraction; Sodium; Hemodynamics","score_opus":0.014008177658831937,"score_gpt":0.3021968593073574,"score_spread":0.28818868164852546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116415561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99168783,0.0000524627,0.0013442503,0.00025331337,0.00009843671,0.0057735112,0.000015411475,0.000035771252,0.0007389862],"genre_scores_gemma":[0.9978123,0.0000069863595,0.00018128823,0.000011378596,0.000088166154,0.0015867694,0.000168589,0.000020530357,0.00012400065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808383,0.0004751217,0.0002213729,0.00048199453,0.00033312177,0.00040457054],"domain_scores_gemma":[0.99883586,0.00016652921,0.00006036981,0.00025260693,0.0006300955,0.00005455168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009568071,0.00018841107,0.0008012766,0.00069662166,0.000117163036,0.000010641487,0.00005211553,0.00017157858,0.0000025324787],"category_scores_gemma":[0.00010510712,0.00013176365,0.00011691659,0.00091073243,0.00019757115,0.00012365366,0.000020181546,0.00042761257,0.0000026514433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016951172,0.00030314783,0.9432759,0.00052908674,0.001603421,0.000010494476,0.00010308223,0.00011888858,0.032162998,0.000015555506,0.0016268883,0.003299344],"study_design_scores_gemma":[0.013268318,0.01564864,0.7402238,0.00044655582,0.00046362018,0.000002769386,0.0002058233,0.000037199847,0.22777815,0.000025196887,0.0017606255,0.0001392409],"about_ca_topic_score_codex":0.000068226305,"about_ca_topic_score_gemma":0.000033354812,"teacher_disagreement_score":0.20305207,"about_ca_system_score_codex":0.00038557817,"about_ca_system_score_gemma":0.000157969,"threshold_uncertainty_score":0.53731656},"labels":[],"label_agreement":null},{"id":"W7116659510","doi":"10.1177/20451253251396304","title":"Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Psychopharmacology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; Brain and Cognition Discovery Foundation","funders":"","keywords":"Neurocognitive; PsycINFO; Cognition; Randomized controlled trial; Extant taxon; Systematic review; MEDLINE; Epidemiology","score_opus":0.005308688694213365,"score_gpt":0.3326740957105458,"score_spread":0.32736540701633243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116659510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02832689,0.92614454,0.00051844434,0.0048841033,0.0049743536,0.010767345,0.0000041025824,0.00014676752,0.024233444],"genre_scores_gemma":[0.44679332,0.5182576,0.0006763779,0.026616367,0.00008211811,0.0024925608,0.000018435214,0.000051881718,0.00501132],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9981753,0.0002368641,0.0006496693,0.00040089287,0.00019319626,0.00034405678],"domain_scores_gemma":[0.9988376,0.00043321957,0.00025430322,0.00037756356,0.000039449944,0.00005785691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026558156,0.00028768947,0.0010546184,0.0003873769,0.000038470753,0.000004422532,0.000227069,0.00007583678,0.000108386834],"category_scores_gemma":[0.000035361576,0.00022415421,0.0001848282,0.0008190203,0.00010764309,0.00007812907,0.000033004904,0.00019190216,0.00007206313],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024253903,0.005405964,0.001765429,0.894719,0.0020260247,0.00002336686,0.00018608052,0.000019278667,0.0019404782,0.0054364386,0.0067078965,0.07934463],"study_design_scores_gemma":[0.085991934,0.012336476,0.008456961,0.45635632,0.028990889,0.000014806606,0.00039644394,0.00026312115,0.0051676678,0.026173199,0.37367788,0.0021743216],"about_ca_topic_score_codex":0.0000019827858,"about_ca_topic_score_gemma":0.000004293183,"teacher_disagreement_score":0.43836272,"about_ca_system_score_codex":0.00011937274,"about_ca_system_score_gemma":0.000045432913,"threshold_uncertainty_score":0.9140743},"labels":[],"label_agreement":null},{"id":"W7116836839","doi":"10.7326/annals-25-03519","title":"Advancing Physical Function Outcomes in Glucagon-Like Peptide-1 Receptor Agonist Trials","year":2025,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Agonist; Clinical trial; Receptor; Function (biology); Disease; Adverse effect","score_opus":0.04371783861774157,"score_gpt":0.3767167944627032,"score_spread":0.3329989558449616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116836839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384484,0.0010965619,0.0005299489,0.025829408,0.0017099129,0.0007215517,0.0000062784256,0.000055852222,0.03160204],"genre_scores_gemma":[0.9755249,0.0003045281,0.00013386823,0.006458589,0.00031856966,0.000046652804,0.000030412592,0.000014998097,0.01716748],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982534,0.00009076401,0.00077762036,0.00026792634,0.00032655738,0.00028374977],"domain_scores_gemma":[0.9987896,0.0004412598,0.00024684964,0.00027351308,0.0001494135,0.00009935978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010274972,0.00021223264,0.0011821609,0.0004462607,0.000023653542,0.000007237293,0.000116017145,0.0000503149,0.00023231312],"category_scores_gemma":[0.0012731594,0.0001401688,0.000239893,0.00028755207,0.000109692024,0.00009499861,0.00006555507,0.00016364676,0.00003219231],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062695835,0.0034123207,0.2926697,0.0011617988,0.0041861157,0.00011459865,0.0012197735,0.000020411437,0.0397872,0.0077937646,0.36167693,0.28168777],"study_design_scores_gemma":[0.029563315,0.013200835,0.38369846,0.015876615,0.0025302658,0.000005882864,0.0032676526,0.00051895285,0.07724204,0.006998523,0.46643266,0.00066481763],"about_ca_topic_score_codex":0.00030517182,"about_ca_topic_score_gemma":0.000036723995,"teacher_disagreement_score":0.28102297,"about_ca_system_score_codex":0.00005664748,"about_ca_system_score_gemma":0.000042805877,"threshold_uncertainty_score":0.5715918},"labels":[],"label_agreement":null},{"id":"W7116947449","doi":"10.1002/alz70860_096280","title":"Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: a systematic review and meta‐analysis","year":2025,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Generalizability theory; Cognition; Dementia; Diabetes mellitus; Cognitive impairment; Non cognitive; Diabetes treatment","score_opus":0.024396010304029422,"score_gpt":0.31920782646798196,"score_spread":0.2948118161639525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116947449","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06883914,0.9174341,0.0006256435,0.002389295,0.000050680745,0.009421113,0.00014507156,0.000045681674,0.0010492869],"genre_scores_gemma":[0.9901122,0.005725873,0.00025917412,0.0021817894,0.0000049166456,0.0015569794,0.00010544446,0.000014600031,0.000039046165],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976614,0.00060561654,0.0007786996,0.0003377084,0.0003552873,0.00026126776],"domain_scores_gemma":[0.9962831,0.0024557624,0.0006003574,0.00035799626,0.00023528993,0.000067454675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017597274,0.0002985427,0.0017635643,0.00031657956,0.00012379324,0.000015772503,0.00014655401,0.000046665467,0.00029392546],"category_scores_gemma":[0.00046346465,0.00015616333,0.00056352845,0.0010066553,0.00016338394,0.000056824105,0.00017237455,0.00009758744,0.000011211787],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054040385,0.00019811763,0.01903068,0.021192424,0.95864964,0.0000012685565,0.00007579412,2.4612072e-7,0.000003510651,0.0002451248,0.00016957177,0.00037958688],"study_design_scores_gemma":[0.0012164381,0.00060798065,0.009875118,0.0071278578,0.9734587,1.5757823e-7,0.00011633976,0.000034915203,0.0073995753,0.00003609786,0.00000964018,0.00011714803],"about_ca_topic_score_codex":0.000031857955,"about_ca_topic_score_gemma":0.000036018853,"teacher_disagreement_score":0.92127305,"about_ca_system_score_codex":0.0000073833507,"about_ca_system_score_gemma":0.000064530774,"threshold_uncertainty_score":0.63681555},"labels":[],"label_agreement":null},{"id":"W7117253921","doi":"10.1002/alz70859_096860","title":"Sodium‐glucose cotransporter‐2 inhibitor initiation and incident dementia in heart failure with diabetes: a population‐based cohort study","year":2025,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Toronto Rehabilitation Institute; University of Ottawa; University of Toronto; University Health Network; McGill University; Health Sciences Centre; Sunnybrook Hospital","funders":"","keywords":"Dementia; Heart failure; Cohort study; Randomized controlled trial; Cohort; Risk factor; Heart disease","score_opus":0.010527605566189861,"score_gpt":0.24999681520105235,"score_spread":0.23946920963486248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117253921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890941,0.0063984618,0.00007060284,0.00095943746,0.000119440505,0.0029833629,0.0000056789154,0.00008790703,0.00028102723],"genre_scores_gemma":[0.9964343,0.000012245802,0.0015189812,0.0010810886,0.000031377927,0.00052117434,0.0003618388,0.000028322225,0.000010687162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815595,0.00007744955,0.00048676622,0.0005276827,0.00038920462,0.0003629647],"domain_scores_gemma":[0.99929595,0.00003709743,0.00011289983,0.0003733342,0.00007847788,0.000102258346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033580174,0.00029406985,0.00044223943,0.00043961845,0.000111561494,0.000074443735,0.000077603414,0.00006919967,0.00012556824],"category_scores_gemma":[0.00000888297,0.00026077195,0.00006139128,0.0004539519,0.000041027764,0.00024554098,0.000055898443,0.00012902843,0.000014697652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009640103,0.0010865252,0.9869711,0.000040719427,0.009209131,0.000021548994,0.00011633643,0.000014341607,0.00017691278,0.0000505387,0.00074851094,0.0014679532],"study_design_scores_gemma":[0.0053122304,0.0005142072,0.9594241,0.00015584652,0.030414967,3.1365983e-7,0.00013601285,0.00015620048,0.0023643137,0.000030902414,0.0012759962,0.00021493423],"about_ca_topic_score_codex":0.00029473464,"about_ca_topic_score_gemma":0.0018368561,"teacher_disagreement_score":0.027547006,"about_ca_system_score_codex":0.00003027465,"about_ca_system_score_gemma":0.00007083117,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W7117315185","doi":"10.1016/j.jcjd.2025.12.005","title":"Kidney Protection in Diabetes: What Primary Care Clinicians Need to Know Now","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"College of Family Physicians of Canada","funders":"","keywords":"Need to know; Primary care; Kidney; Primary health care; MEDLINE","score_opus":0.009443172981750278,"score_gpt":0.2373090843623516,"score_spread":0.2278659113806013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117315185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96826774,0.0064283144,0.000009709187,0.016945926,0.0014204956,0.0009930488,0.000014222168,0.000018178387,0.0059023434],"genre_scores_gemma":[0.9851867,0.00010269335,0.0004025205,0.012272006,0.00021199441,0.0000624306,0.000035772497,0.000030836192,0.0016950272],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842966,0.00005926002,0.00053341547,0.00021617553,0.00018035927,0.0005811402],"domain_scores_gemma":[0.9983616,0.00004989181,0.00013990789,0.00025601807,0.0002632165,0.00092936587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032138356,0.00021072644,0.00054758904,0.0014536469,0.00008017951,0.0001350346,0.00018514648,0.00011603567,0.00005038451],"category_scores_gemma":[0.00026828633,0.00019371518,0.00018527795,0.00074261305,0.000054349453,0.00035719524,0.000024632578,0.00029317962,0.000033063054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018542907,0.000100364436,0.8057412,0.0007185793,0.00034579835,0.000048952992,0.00074663304,0.00004458812,0.00094690477,0.000043026605,0.033376038,0.15786938],"study_design_scores_gemma":[0.005699249,0.002272655,0.4815239,0.013938642,0.0007899054,0.0000010306973,0.0040466315,0.00006672659,0.0055708173,0.00024030413,0.48535365,0.0004964825],"about_ca_topic_score_codex":0.0001735475,"about_ca_topic_score_gemma":0.006919372,"teacher_disagreement_score":0.4519776,"about_ca_system_score_codex":0.0010133174,"about_ca_system_score_gemma":0.001690169,"threshold_uncertainty_score":0.78994757},"labels":[],"label_agreement":null},{"id":"W7117585509","doi":"10.1002/art.70044","title":"Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases","year":2025,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; Research Canada; University of British Columbia","funders":"Canadian Institutes of Health Research; Simon Fraser University; Arthritis Society","keywords":"Autoimmune disease; Receptor; Autoantibody; Risk factor; Disease; Immunopathology; Diabetes mellitus; Immune system","score_opus":0.003927557116925628,"score_gpt":0.21625927303208878,"score_spread":0.21233171591516314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117585509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622337,0.0339921,0.0000737618,0.00091024535,0.0006214084,0.00067401765,0.00007048352,0.00014658165,0.0012776752],"genre_scores_gemma":[0.9429123,0.054680184,0.00073405384,0.00017497932,0.00000832198,0.00011173841,0.0002456145,0.000027260232,0.0011055389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813104,0.000099774865,0.0007396887,0.0004328932,0.00017955794,0.00041703935],"domain_scores_gemma":[0.99887687,0.00018441815,0.00023130198,0.00048287906,0.000084295454,0.00014022882],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015744506,0.00029296853,0.0009733145,0.00026887291,0.00014175854,0.000024367226,0.000108713975,0.00012866706,0.00027334385],"category_scores_gemma":[0.00009982127,0.00027334623,0.00018264043,0.0002294099,0.00043832962,0.00011813072,0.000095334726,0.0001597366,0.00006113263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031578992,0.00086993043,0.7825837,0.0009700168,0.0015700129,0.000057740093,0.0005112445,0.0000011088252,0.00055195397,0.005647627,0.01827576,0.1886451],"study_design_scores_gemma":[0.0228984,0.0015251208,0.8317343,0.007077909,0.0023550328,0.00013127692,0.0010531148,0.00018245638,0.0068317824,0.003429369,0.12192577,0.0008554546],"about_ca_topic_score_codex":0.00045190522,"about_ca_topic_score_gemma":0.00018790715,"teacher_disagreement_score":0.18778963,"about_ca_system_score_codex":0.00004358034,"about_ca_system_score_gemma":0.000110381945,"threshold_uncertainty_score":0.99997187},"labels":[],"label_agreement":null},{"id":"W7117688147","doi":"10.6084/m9.figshare.30970098","title":"Additional file 1 of Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study","year":2025,"lang":"","type":"article","venue":"Open MIND","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; Toronto General Hospital; Institute for Clinical Evaluative Sciences; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Cohort study; Dementia; Cohort; Diabetes mellitus; Disease","score_opus":0.019894860947095677,"score_gpt":0.29709546909199036,"score_spread":0.27720060814489467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117688147","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3451378,0.0003603008,0.00002755446,0.00037191014,0.000887072,0.023107132,0.57340467,0.000019776971,0.056683775],"genre_scores_gemma":[0.67351,0.000015516758,0.013012776,0.00010508176,0.00032752083,0.0041345926,0.25039813,0.00005731388,0.05843905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589795,0.00037661655,0.0012194157,0.0011013958,0.0008803487,0.00052425],"domain_scores_gemma":[0.9961388,0.0014417041,0.0010126651,0.0007740572,0.00041138733,0.00022140001],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004608578,0.00063659076,0.0013131264,0.00040303107,0.00043723203,0.0002806736,0.00043906277,0.00014560139,0.8798988],"category_scores_gemma":[0.00027540678,0.00049862894,0.00017828736,0.0011206213,0.00022529435,0.00036380743,0.000384788,0.00030058093,0.0011090132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017808764,0.0059198164,0.20103326,0.00007816791,0.0055914475,0.000026938522,0.0004325978,0.000041861666,0.0000055160126,0.000004516106,0.77164406,0.013440947],"study_design_scores_gemma":[0.009178166,0.004811318,0.22629187,0.0042928574,0.0054923072,4.765336e-7,0.0038598583,0.0003417827,0.00095163134,0.000006521482,0.7442187,0.0005544851],"about_ca_topic_score_codex":0.0006993208,"about_ca_topic_score_gemma":0.0015944254,"teacher_disagreement_score":0.8787898,"about_ca_system_score_codex":0.00041492484,"about_ca_system_score_gemma":0.0011713083,"threshold_uncertainty_score":0.99974656},"labels":[],"label_agreement":null},{"id":"W7117748138","doi":"10.6084/m9.figshare.30970098.v1","title":"Additional file 1 of Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; Toronto General Hospital; Institute for Clinical Evaluative Sciences; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Cohort study; Dementia; Cohort; Diabetes mellitus; Disease","score_opus":0.01720113382994349,"score_gpt":0.2665173560879553,"score_spread":0.2493162222580118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117748138","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022786185,0.0003539173,7.6559985e-7,0.00007010816,0.00019005565,0.005938638,0.98490375,0.00010854353,0.0061555724],"genre_scores_gemma":[0.16174293,0.0000036299027,0.0005373872,0.00012955177,0.00031242738,0.007762439,0.820905,0.000044806882,0.008561791],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605596,0.00028436366,0.0010754257,0.0009799391,0.0010229653,0.000581362],"domain_scores_gemma":[0.9951475,0.002198334,0.0010244029,0.00073278096,0.00066446787,0.00023251717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011542592,0.00071007287,0.0011583666,0.00048050127,0.00040194797,0.0001262017,0.0002719536,0.00018746631,0.99197066],"category_scores_gemma":[0.0013243773,0.0005703075,0.0002674498,0.0012690859,0.00005453511,0.00024359436,0.00022330845,0.00037230356,0.0028003664],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073994003,0.003714805,0.046764065,0.0007315297,0.004713481,0.000033153814,0.0001849452,0.00005435478,9.878856e-7,0.0000028306674,0.9411803,0.0018796362],"study_design_scores_gemma":[0.004418383,0.0027449823,0.28940922,0.022897122,0.002050211,3.6173984e-7,0.0008911794,0.00039635482,0.00021228437,0.0000035446405,0.6764962,0.00048015098],"about_ca_topic_score_codex":0.00013067591,"about_ca_topic_score_gemma":0.0004003546,"teacher_disagreement_score":0.9891703,"about_ca_system_score_codex":0.0004534425,"about_ca_system_score_gemma":0.0010417684,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W7118022346","doi":"10.1007/978-3-032-10050-4_14","title":"Diabetes Mellitus Assessment","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regina General Hospital; University of Alberta","funders":"","keywords":"Diabetes mellitus; Metformin; Hypoglycemia; Type 2 diabetes; Glycemic; Insulin; Macrovascular disease","score_opus":0.013851327633374022,"score_gpt":0.2666956704773721,"score_spread":0.25284434284399804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118022346","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018402714,0.0020176917,0.000047549234,0.0013380364,0.0003125924,0.0007492571,0.000012393344,0.00018365926,0.99532044],"genre_scores_gemma":[0.0006593457,0.0010870413,0.0021245393,0.0018151458,0.0001294255,0.000041603926,0.00034537265,0.000036076548,0.9937614],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886,0.0000036906347,0.00024522323,0.0003653476,0.00028689965,0.00023883839],"domain_scores_gemma":[0.99922884,0.00004609489,0.000069003545,0.0004938863,0.00005971117,0.000102481456],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007390489,0.000329072,0.0005551822,0.0002222887,0.000033565902,0.00002735253,0.00008145748,0.00017844941,0.0052951723],"category_scores_gemma":[0.000004134692,0.00025513183,0.0002539942,0.000020393225,0.00003946127,0.000025842899,0.00012306176,0.00018362286,0.00044218634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005852091,0.00008888046,0.0003731494,0.00038395368,0.0016023297,0.000045131463,0.000003327768,1.16675515e-7,0.00000614473,0.6703133,0.19079147,0.13638633],"study_design_scores_gemma":[0.00070141954,0.00024352926,0.0003586341,0.00053059496,0.0015352691,2.0567603e-7,0.000002959706,0.000024373949,0.00007560985,0.007872744,0.98844165,0.00021300899],"about_ca_topic_score_codex":0.0000028194333,"about_ca_topic_score_gemma":0.0000030652232,"teacher_disagreement_score":0.79765016,"about_ca_system_score_codex":0.00019081772,"about_ca_system_score_gemma":0.00010523534,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W7118181626","doi":"10.59882/1859-364x/369","title":"Cost-effectiveness of dapagliflozin versus sulfonylurea in combination with metformin in patients with type 2 diabetes in Vietnam: Analysis from the Payer’s Perspective","year":2025,"lang":"","type":"article","venue":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"AstraZeneca","keywords":"Dapagliflozin; Metformin; Sulfonylurea; Hypoglycemia; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus","score_opus":0.016354799604957854,"score_gpt":0.27769483206134266,"score_spread":0.2613400324563848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118181626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866931,0.002200304,0.000050274386,0.0003973802,0.0003848039,0.005597246,0.00009444722,0.00003732725,0.004545112],"genre_scores_gemma":[0.9979181,0.0002344677,0.0001442074,0.000090541966,0.000028696562,0.0004868438,0.0008358054,0.00005857755,0.00020272835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950878,0.0009808919,0.0010086107,0.0011238405,0.0008777593,0.00092111283],"domain_scores_gemma":[0.99563044,0.0021127122,0.000532311,0.0010970328,0.00050745206,0.00012007644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018022645,0.0007849956,0.0019069863,0.0016869651,0.00011406103,0.00007881816,0.00054385647,0.00025972188,0.00012791813],"category_scores_gemma":[0.00047983014,0.00054021104,0.00022275293,0.007666196,0.00037621756,0.00040466367,0.00028270556,0.00065324426,0.000015722499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011726652,0.0040765177,0.9637258,0.0002820968,0.0057059564,0.0000353917,0.0028037014,0.0011264279,0.000028032562,0.002044669,0.000045647936,0.008399097],"study_design_scores_gemma":[0.040515114,0.0030091149,0.9390428,0.0025062487,0.005303227,4.7162406e-8,0.005451453,0.0020419098,0.0009374492,0.0005527374,0.00013111623,0.0005087724],"about_ca_topic_score_codex":0.0036187624,"about_ca_topic_score_gemma":0.009295902,"teacher_disagreement_score":0.028788462,"about_ca_system_score_codex":0.0020699247,"about_ca_system_score_gemma":0.00036798298,"threshold_uncertainty_score":0.99970496},"labels":[],"label_agreement":null},{"id":"W7119517121","doi":"10.58920/sciphar0404502","title":"Comparative Glycemic Effectiveness of Long- and Rapid-Acting Insulin in Patients with Type 2 Diabetes Mellitus","year":2025,"lang":"en","type":"article","venue":"Sciences of Pharmacy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Encana (Canada)","funders":"","keywords":"Insulin glargine; Insulin; Glycemic; Insulin lispro; Type 2 Diabetes Mellitus; Postprandial; Glycated hemoglobin; Diabetes mellitus","score_opus":0.02180667244086461,"score_gpt":0.33072221149082476,"score_spread":0.30891553904996016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7119517121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503404,0.0015036971,0.0000049184273,0.000021897757,0.000069503876,0.00042656946,0.0000015952189,0.0000063313464,0.0029314652],"genre_scores_gemma":[0.9997263,0.000063476415,0.00015716754,0.00002174314,0.0000027790688,0.000006963127,0.000004830339,0.0000018819164,0.000014876059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993989,0.000045252888,0.00013029721,0.00015779375,0.00014473767,0.00012306008],"domain_scores_gemma":[0.99961984,0.00015182795,0.00006994546,0.00006266155,0.00007067145,0.000025040119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000249131,0.000074916905,0.00025134327,0.00017751243,0.000027004182,0.0000063006187,0.000064239895,0.000008175851,0.000012357267],"category_scores_gemma":[0.000023292805,0.000052470463,0.000014697766,0.00055734534,0.000258123,0.00011481011,0.00004392657,0.00003836128,7.26096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008071874,0.0002829217,0.9800526,0.00038466093,0.00007773599,7.3670924e-7,0.00016254366,0.000033674103,0.00127634,0.000065668995,0.000005437997,0.016850475],"study_design_scores_gemma":[0.0069646547,0.0011080082,0.8964186,0.0005834797,0.00010557983,2.6035295e-8,0.00010766935,0.0004239341,0.094108365,0.000056867873,0.000060830473,0.000061989835],"about_ca_topic_score_codex":0.00003113661,"about_ca_topic_score_gemma":0.000003363445,"teacher_disagreement_score":0.09283203,"about_ca_system_score_codex":0.000021818014,"about_ca_system_score_gemma":0.00005257487,"threshold_uncertainty_score":0.21396834},"labels":[],"label_agreement":null},{"id":"W7127593371","doi":"10.1093/eurheartj/ehaf784.1251","title":"Real-world outcomes and safety of low- vs. standard-dose SGLT2 inhibitors in heart failure","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; University Health Network","funders":"","keywords":"Empagliflozin; Dapagliflozin; Canagliflozin; Propensity score matching; Dosing; Heart failure; Adverse effect; Retrospective cohort study","score_opus":0.013419755635712929,"score_gpt":0.28703256635021757,"score_spread":0.27361281071450466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127593371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483558,0.00036043557,0.0000128838765,0.017075315,0.00032994896,0.00039094145,0.0000068723757,0.000036298014,0.033431523],"genre_scores_gemma":[0.9897419,0.00026033877,0.0017581667,0.0010491196,0.000113412985,0.00000155427,0.000004912735,0.000025804979,0.00704478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986865,0.0001752671,0.00045672257,0.0001791418,0.00024906013,0.00025329992],"domain_scores_gemma":[0.9994453,0.00007538012,0.0000813622,0.00019964192,0.000057921086,0.00014039729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008090934,0.00015851374,0.00045297452,0.0004423252,0.00008023839,0.000042943426,0.000058846515,0.000020475482,0.00010520168],"category_scores_gemma":[0.00007453212,0.00012244732,0.00012373165,0.00028632703,0.00006691634,0.00010077174,0.00010187947,0.00028275794,0.000019627014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036399558,0.00014908148,0.9228609,0.0001228107,0.00013641987,0.00014293863,0.00015261021,0.0000066339994,0.00038703653,0.00030192678,0.07198725,0.0033883567],"study_design_scores_gemma":[0.0036518162,0.00026498223,0.7997411,0.00079435343,0.00006952019,0.000015000649,0.00011902276,0.000004356617,0.0004584205,0.000039328184,0.19476274,0.000079351594],"about_ca_topic_score_codex":0.000014835682,"about_ca_topic_score_gemma":0.000053532513,"teacher_disagreement_score":0.12311983,"about_ca_system_score_codex":0.00010838741,"about_ca_system_score_gemma":0.000074416515,"threshold_uncertainty_score":0.4993257},"labels":[],"label_agreement":null},{"id":"W7127612487","doi":"10.1093/eurheartj/ehaf784.982","title":"Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction - Results from the REWIN-HFrEF Study","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Ejection fraction; Heart failure; Ambulatory; Cardiac function curve; Cohort; Prospective cohort study; Cohort study","score_opus":0.013087885174325548,"score_gpt":0.2644958019759251,"score_spread":0.2514079168015996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127612487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790394,0.000073186435,8.179511e-7,0.000930227,0.00026923342,0.000511011,0.000010415852,0.0000122394,0.00028890878],"genre_scores_gemma":[0.99953526,0.000014634564,0.000037307884,0.00008343907,0.00020654086,0.0000018256098,0.000021800124,0.0000121041185,0.00008708163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902815,0.0002797098,0.00018536119,0.00018532552,0.00019977917,0.00012169787],"domain_scores_gemma":[0.9995797,0.00006263329,0.00009869395,0.00014860868,0.000056250723,0.00005408035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035590483,0.00012343339,0.00020662548,0.00015395292,0.00012410818,0.000050661787,0.000020547683,0.000018694363,0.0000071651157],"category_scores_gemma":[0.000050120405,0.00006970103,0.000042965603,0.00015215586,0.000025995527,0.000102959966,0.000026756012,0.00022896832,0.0000014960906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001694577,0.00014823332,0.98954356,0.000004994668,0.00023511564,0.0000024584688,0.00021414447,0.000010506691,0.0005740122,7.3271605e-7,0.0050327876,0.0025388596],"study_design_scores_gemma":[0.004471232,0.0044241357,0.98916864,0.00021558501,0.00018882623,0.0000013596226,0.0005751368,0.000006083883,0.000075111246,0.0000066159255,0.0008124068,0.00005485594],"about_ca_topic_score_codex":0.00009255009,"about_ca_topic_score_gemma":0.00002766239,"teacher_disagreement_score":0.004275902,"about_ca_system_score_codex":0.0000904838,"about_ca_system_score_gemma":0.000016478167,"threshold_uncertainty_score":0.28423256},"labels":[],"label_agreement":null},{"id":"W7127998088","doi":"10.1093/eurheartj/ehaf784.4155","title":"The cardioprotective effect of inhibitor sodium glucose transporter in patients undergoing chemotherapy: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Heart failure; Observational study; Hazard ratio; Randomized controlled trial; Glycemic; Meta-analysis; Acute kidney injury; Confidence interval; Relative risk","score_opus":0.014529280004678605,"score_gpt":0.26752903723835814,"score_spread":0.2529997572336795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127998088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73524153,0.2406565,0.0002358533,0.0074463403,0.00016932983,0.008873915,0.000008647152,0.000042084397,0.007325821],"genre_scores_gemma":[0.9963772,0.0017734874,0.00004062948,0.0008046341,0.000013190852,0.00002743027,0.0000017782477,0.000013449786,0.0009481443],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99843186,0.0006652643,0.00043844117,0.00013098697,0.00019631084,0.00013714765],"domain_scores_gemma":[0.9993971,0.00014057526,0.00014536895,0.00021497348,0.000054351116,0.000047621717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017913878,0.00013611396,0.0012371667,0.00016630485,0.000074664145,0.000030063604,0.000056768076,0.00001186788,0.000015796588],"category_scores_gemma":[0.00008222865,0.000067455054,0.0006473417,0.00033179903,0.000028704448,0.000043429463,0.00001845052,0.00014237345,0.0000043652735],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070786296,0.0005713176,0.16981196,0.22563155,0.59797615,0.0001497407,0.0008027891,0.000014111612,0.00009166114,0.000045904762,0.0026988252,0.0014981121],"study_design_scores_gemma":[0.00460998,0.0012728891,0.16982284,0.0076209125,0.81540954,0.000008476131,0.00004397712,0.000008949843,0.00060255406,0.0000128768115,0.0004462308,0.00014078255],"about_ca_topic_score_codex":0.0000016227458,"about_ca_topic_score_gemma":0.0000036353172,"teacher_disagreement_score":0.26113576,"about_ca_system_score_codex":0.000045904155,"about_ca_system_score_gemma":0.000014769755,"threshold_uncertainty_score":0.27507374},"labels":[],"label_agreement":null},{"id":"W7128021244","doi":"10.1093/eurheartj/ehaf784.4319","title":"Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Semaglutide; Vascular disease; Type 2 diabetes; Kidney disease; Myocardial infarction; Diabetes mellitus; Body mass index","score_opus":0.007804638296551133,"score_gpt":0.27490753854836025,"score_spread":0.2671029002518091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7128021244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906606,0.0036664826,0.00003017555,0.0034523495,0.0007255415,0.0010972389,0.00007937342,0.000060265746,0.00022797582],"genre_scores_gemma":[0.9962181,0.00036316717,0.000118347736,0.0019868733,0.00027253208,0.000021641947,0.000056127334,0.00007266793,0.0008905469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623036,0.0013424482,0.00050247845,0.0005070859,0.0007537061,0.00066390826],"domain_scores_gemma":[0.9974764,0.00030927392,0.00012658529,0.0011152532,0.00007751288,0.00089495507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017129255,0.00043255286,0.000742609,0.0002581115,0.000258506,0.00013222251,0.00035258368,0.000025988704,0.00016301837],"category_scores_gemma":[0.0010556901,0.00026824707,0.0008183779,0.00048818375,0.000103271675,0.00009489794,0.0002819493,0.00044361476,0.00047740946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011060605,0.0005110177,0.9870614,0.00016005625,0.0013941935,0.0005188491,0.0000666074,0.0009982513,0.00005243952,0.000047057547,0.0038974308,0.0041866363],"study_design_scores_gemma":[0.0042497637,0.0006864018,0.9703281,0.0007932757,0.0019388442,1.9427803e-7,0.000012054257,0.00019525476,0.0001302227,0.0001216561,0.021318775,0.00022546355],"about_ca_topic_score_codex":0.00009303199,"about_ca_topic_score_gemma":0.000008787943,"teacher_disagreement_score":0.017421344,"about_ca_system_score_codex":0.00015418387,"about_ca_system_score_gemma":0.00010077301,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W7128058253","doi":"10.1093/eurheartj/ehaf784.4317","title":"Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Semaglutide; Heart failure; Ejection fraction; Kidney disease; Mace; Type 2 diabetes; Hazard ratio","score_opus":0.01743187731742455,"score_gpt":0.268413778445872,"score_spread":0.2509819011284474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7128058253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960475,0.0015156303,0.0000040739988,0.0014192463,0.00009967694,0.00085114967,0.0000022317956,0.00001604614,0.000044437656],"genre_scores_gemma":[0.9989194,0.00008798221,0.00017469829,0.0005007592,0.00006330857,0.00003635229,0.0000030248834,0.000025394154,0.000189031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861485,0.00036113765,0.0002581461,0.00023226556,0.00023082297,0.00030279704],"domain_scores_gemma":[0.9992373,0.00012823798,0.000047922604,0.00020342537,0.00002418759,0.00035894444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053287204,0.000176998,0.0005159601,0.00020574789,0.000060285005,0.00004230881,0.00004191864,0.000014685537,0.000017170874],"category_scores_gemma":[0.00045758224,0.000117263044,0.00011523763,0.0002255899,0.00005415195,0.000063924665,0.00006240806,0.00019277708,0.0000044831067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003556272,0.00042644067,0.9923519,0.0006175406,0.00047917137,0.00022325247,0.00012488905,0.00019715086,0.0001132553,0.000010742231,0.0006155563,0.0012838127],"study_design_scores_gemma":[0.029307457,0.0015122001,0.964311,0.0019068954,0.0007278959,0.0000015573606,0.000029646744,0.00024333112,0.00007213932,0.000010173422,0.0017673124,0.00011036547],"about_ca_topic_score_codex":0.000008935512,"about_ca_topic_score_gemma":0.000017165556,"teacher_disagreement_score":0.028040892,"about_ca_system_score_codex":0.00007539655,"about_ca_system_score_gemma":0.0001549504,"threshold_uncertainty_score":0.47818482},"labels":[],"label_agreement":null},{"id":"W7128058308","doi":"10.1093/eurheartj/ehaf784.409","title":"Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Placebo; Atrial fibrillation; Hazard ratio; Cochrane Library; Odds ratio; Incidence (geometry); Meta-analysis; Confidence interval","score_opus":0.03143094674072792,"score_gpt":0.3322980648563337,"score_spread":0.30086711811560574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7128058308","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45090315,0.4938366,0.00030153012,0.014094416,0.0010174655,0.010295009,0.000031477946,0.00017411682,0.029346207],"genre_scores_gemma":[0.9626563,0.009263148,0.00068647886,0.002716895,0.00031214138,0.000014789359,0.00003418919,0.00004578743,0.024270236],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975974,0.0011717606,0.00058069464,0.00019149257,0.00031365835,0.00014502322],"domain_scores_gemma":[0.99893415,0.00028885537,0.0002901574,0.0003027575,0.000084581116,0.00009948459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002788705,0.00017817869,0.0016745167,0.00030509074,0.00009112348,0.00005283115,0.00006552448,0.000019132356,0.00020908639],"category_scores_gemma":[0.00043078445,0.0001070907,0.0011945522,0.00043885305,0.000029252607,0.00006619075,0.000051037496,0.00013015693,0.00008900621],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008603426,0.0001326033,0.016685445,0.3386098,0.56929076,0.00019488785,0.00026544137,0.00019554654,0.00035416684,0.00021507406,0.07148447,0.0017114575],"study_design_scores_gemma":[0.0013187771,0.0017738184,0.003627986,0.007748057,0.97985363,0.000040557934,0.0000092261835,0.00003762914,0.0002052739,0.0000048908114,0.0052497643,0.00013036905],"about_ca_topic_score_codex":0.0000018868013,"about_ca_topic_score_gemma":5.1382204e-7,"teacher_disagreement_score":0.5117532,"about_ca_system_score_codex":0.000053288397,"about_ca_system_score_gemma":0.000023799295,"threshold_uncertainty_score":0.4367032},"labels":[],"label_agreement":null},{"id":"W7128077061","doi":"10.1093/eurheartj/ehaf784.4313","title":"Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Semaglutide; Placebo; Type 2 diabetes; Post-hoc analysis; Body mass index; Blood pressure; Kidney disease","score_opus":0.011598176766628018,"score_gpt":0.24288185178484073,"score_spread":0.2312836750182127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7128077061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936643,0.0056182765,0.000013061643,0.00004878116,0.000047635873,0.0004669133,0.00005649885,0.000017855402,0.000066648994],"genre_scores_gemma":[0.99890465,0.0007423691,0.000055500102,0.00006914439,0.000035156703,0.0000028118961,0.000050397575,0.000032532436,0.000107459855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982694,0.00039898505,0.00024889657,0.00033076975,0.00042965243,0.00032233825],"domain_scores_gemma":[0.9987096,0.000036302095,0.000077561,0.0004938574,0.000106203544,0.0005764711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048234058,0.00025749544,0.0007034248,0.00049622083,0.00010334943,0.000057620706,0.00006734602,0.000018318915,0.000041582145],"category_scores_gemma":[0.00018519293,0.0001569416,0.00077438506,0.0005833314,0.00008628999,0.000081803635,0.000073582494,0.00020167339,0.0000047050494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008575501,0.00029706518,0.9696401,0.00011137958,0.022474548,0.00008175597,0.000057818103,0.0024441467,0.00000450903,9.396721e-7,0.00018362464,0.0038465813],"study_design_scores_gemma":[0.004491399,0.002061598,0.9780931,0.0004437251,0.01360182,4.441595e-7,0.000014854637,0.00019225337,0.0000033409885,0.0000022482582,0.0009507766,0.00014444265],"about_ca_topic_score_codex":0.00003338406,"about_ca_topic_score_gemma":0.0000029376793,"teacher_disagreement_score":0.008872728,"about_ca_system_score_codex":0.00017723543,"about_ca_system_score_gemma":0.00017448624,"threshold_uncertainty_score":0.6399893},"labels":[],"label_agreement":null},{"id":"W7131864859","doi":"10.5376/ijmms.2025.15.0026","title":"The Impact of GLP-1 Receptor Agonists on Weight Control in Patients with Diabetes and Comorbid Obesity","year":2025,"lang":"","type":"article","venue":"International Journal of Molecular Medical Science","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Obesity; Diabetes mellitus; Receptor; Agonist; Weight loss; Body weight; Type 2 diabetes","score_opus":0.002775644153534143,"score_gpt":0.2681061910503584,"score_spread":0.2653305468968242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131864859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990704,0.00089811836,0.0002361609,0.006210211,0.00081674324,0.00030019175,0.000008855081,0.000001909796,0.00082380034],"genre_scores_gemma":[0.9988819,0.00026209536,0.00006103725,0.0006822671,0.00005338385,0.0000031210093,0.0000021045253,0.000005274875,0.000048820166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99595237,0.00011718168,0.0006184071,0.00022432941,0.0027548207,0.00033287038],"domain_scores_gemma":[0.99790055,0.0003476203,0.00044390236,0.00017375844,0.00082516443,0.00030899167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017597246,0.00017923221,0.00038310568,0.000399249,0.000090336835,0.000091419286,0.0008424514,0.000061768245,0.00009146029],"category_scores_gemma":[0.0014177473,0.00009399971,0.00013716846,0.00044446878,0.0012912232,0.00015612975,0.0001605575,0.0003281585,0.0000024778321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012190822,0.0018686843,0.9416493,0.000021192744,0.0010492401,0.0001237122,0.000080702644,0.000051796622,0.0012780931,0.0015040145,0.000537756,0.050616417],"study_design_scores_gemma":[0.01075253,0.0030080301,0.9791786,0.002202732,0.00014648649,0.0000017593337,0.000028466771,0.0012400821,0.00255426,0.00032804086,0.0004565294,0.00010247939],"about_ca_topic_score_codex":0.000025394273,"about_ca_topic_score_gemma":0.000003967577,"teacher_disagreement_score":0.050513938,"about_ca_system_score_codex":0.00047753588,"about_ca_system_score_gemma":0.0008856929,"threshold_uncertainty_score":0.4757566},"labels":[],"label_agreement":null},{"id":"W7132859593","doi":"","title":"GLP-2 Regulation of Dietary Fat Absorption and Intestinal Chylomicron Production: The Role of the Enteric Nervous System via Neuronal Nitric Oxide Synthase (nNOS) Signalling","year":2021,"lang":"","type":"dissertation","venue":"TSpace","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chylomicron; Postprandial; Lipoprotein; Lipid metabolism; Dyslipidemia; Nitric oxide; Nitric oxide synthase","score_opus":0.0113404557023033,"score_gpt":0.24574027754636385,"score_spread":0.23439982184406055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132859593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988509,0.0076280404,0.00015136861,0.00036353047,0.0007858234,0.0019083549,0.0000067932533,0.00003510767,0.00061196863],"genre_scores_gemma":[0.9948284,0.0004055714,0.00016261003,0.000019051904,0.00035249876,0.0000946091,0.0003767816,0.00005731576,0.003703152],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971207,0.00033859804,0.0008542806,0.0006731246,0.0006802446,0.00033310102],"domain_scores_gemma":[0.9973157,0.00016558498,0.0013394053,0.0006686727,0.00042844712,0.0000821775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041273618,0.0005073357,0.00072752807,0.00023229595,0.00025550096,0.00004686641,0.00023490166,0.00016413674,0.00006564003],"category_scores_gemma":[0.00014311174,0.00035041926,0.00028954542,0.00069159304,0.00015552869,0.00012925187,0.00014152337,0.00036269525,0.000006269867],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080626574,0.00046871265,0.005266616,0.00409298,0.0006405344,0.000008500865,0.0027256284,0.000974536,0.9580288,0.00017181606,0.00005165517,0.026763966],"study_design_scores_gemma":[0.0015801949,0.00080974266,0.51102436,0.009317061,0.006412217,0.00008515119,0.03934432,0.013998863,0.4165847,0.00008755405,0.00022263046,0.0005332054],"about_ca_topic_score_codex":0.00044433482,"about_ca_topic_score_gemma":0.00004190559,"teacher_disagreement_score":0.54144406,"about_ca_system_score_codex":0.00021592515,"about_ca_system_score_gemma":0.0001086473,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W7133067465","doi":"","title":"Cardiac Reverse Remodeling as a Mechanism for the Cardioprotective Benefits Offered by Sodium-Glucose Cotransporter 2 Inhibitors","year":2025,"lang":"","type":"dissertation","venue":"TSpace","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Empagliflozin; Heart failure; Adverse effect; Cardiac function curve; Diabetes mellitus; Mechanism (biology); Ventricular remodeling","score_opus":0.01665240076616715,"score_gpt":0.28608806631289047,"score_spread":0.2694356655467233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133067465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74320346,0.089102365,0.012787635,0.012562425,0.02560172,0.07064549,0.0021080014,0.00080873165,0.04318014],"genre_scores_gemma":[0.6947923,0.016650192,0.000730437,0.001312589,0.0012437379,0.006257504,0.006400173,0.0003496376,0.27226347],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99547064,0.00013549422,0.0008778236,0.0014680128,0.0009660471,0.0010819598],"domain_scores_gemma":[0.99664336,0.00038426757,0.00055809657,0.0012409535,0.0008904395,0.00028286243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007323922,0.0012287038,0.0017714007,0.00034581317,0.0007504967,0.00013600304,0.0004135842,0.00079173705,0.00012431074],"category_scores_gemma":[0.0002221077,0.0009961264,0.0015142272,0.00051659334,0.000068031666,0.00014827306,0.00007838317,0.00074072654,0.000085111256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023188341,0.0030269993,0.00024533353,0.018366488,0.07492636,0.0001659636,0.120997384,0.0016154357,0.10276807,0.04718393,0.13358831,0.47392738],"study_design_scores_gemma":[0.022387283,0.0042710965,0.00042645077,0.013955841,0.08040226,0.0000036889005,0.14615647,0.008012501,0.58161855,0.0040212553,0.13453487,0.004209742],"about_ca_topic_score_codex":0.0026266153,"about_ca_topic_score_gemma":0.00018275414,"teacher_disagreement_score":0.47885048,"about_ca_system_score_codex":0.0006243994,"about_ca_system_score_gemma":0.00049436773,"threshold_uncertainty_score":0.9992489},"labels":[],"label_agreement":null},{"id":"W7136439908","doi":"10.6084/m9.figshare.4393220","title":"Additional file 1: Table 1e. of Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies","year":2016,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myocardial infarction; Rosiglitazone; Risk assessment; Funnel plot; Metformin; Relative risk; Cohort; Cohort study","score_opus":0.21619325219983104,"score_gpt":0.27537763189734016,"score_spread":0.059184379697509115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136439908","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007100478,0.017464567,0.0000027140027,0.00021944936,0.000011321244,0.0007432232,0.9806413,0.0000119884835,0.0001953605],"genre_scores_gemma":[0.028923882,0.00034210808,0.00049216487,0.00007080311,0.00004273875,0.0018029294,0.9616957,0.000035377157,0.0065943557],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996956,0.000280892,0.0007630779,0.00046875063,0.0012214821,0.00030980818],"domain_scores_gemma":[0.9871913,0.008292293,0.0013239952,0.00080076576,0.0023018958,0.00008970993],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004542775,0.00035821158,0.0024817295,0.0003436542,0.000111708,0.000033611628,0.00020580774,0.00011240469,0.8641258],"category_scores_gemma":[0.01641945,0.00017105495,0.0017125705,0.0015970027,0.00016005179,0.00067491404,0.00023805916,0.00009709547,0.000017730714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033191904,0.0001906901,0.00021260313,0.0001613401,0.440411,0.0000034252998,0.000069527705,0.00017436445,6.9203105e-7,0.000015952233,0.55808663,0.0006405915],"study_design_scores_gemma":[0.0013176382,0.0003620067,0.043034546,0.0013379339,0.5067147,3.61615e-7,0.00025170264,0.00022290021,0.00009004015,0.000026508398,0.44643685,0.00020477231],"about_ca_topic_score_codex":0.00008639825,"about_ca_topic_score_gemma":0.00015061276,"teacher_disagreement_score":0.864108,"about_ca_system_score_codex":0.000100702535,"about_ca_system_score_gemma":0.0001939761,"threshold_uncertainty_score":0.9918657},"labels":[],"label_agreement":null},{"id":"W7136751780","doi":"10.6084/m9.figshare.4393220.v1","title":"Additional file 1: Table 1e. of Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies","year":2016,"lang":"","type":"article","venue":"Figshare","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myocardial infarction; Rosiglitazone; Risk assessment; Funnel plot; Metformin; Relative risk; Cohort; Cohort study","score_opus":0.21619325219983104,"score_gpt":0.27537763189734016,"score_spread":0.059184379697509115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136751780","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007100478,0.017464567,0.0000027140027,0.00021944936,0.000011321244,0.0007432232,0.9806413,0.0000119884835,0.0001953605],"genre_scores_gemma":[0.028923882,0.00034210808,0.00049216487,0.00007080311,0.00004273875,0.0018029294,0.9616957,0.000035377157,0.0065943557],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996956,0.000280892,0.0007630779,0.00046875063,0.0012214821,0.00030980818],"domain_scores_gemma":[0.9871913,0.008292293,0.0013239952,0.00080076576,0.0023018958,0.00008970993],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004542775,0.00035821158,0.0024817295,0.0003436542,0.000111708,0.000033611628,0.00020580774,0.00011240469,0.8641258],"category_scores_gemma":[0.01641945,0.00017105495,0.0017125705,0.0015970027,0.00016005179,0.00067491404,0.00023805916,0.00009709547,0.000017730714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033191904,0.0001906901,0.00021260313,0.0001613401,0.440411,0.0000034252998,0.000069527705,0.00017436445,6.9203105e-7,0.000015952233,0.55808663,0.0006405915],"study_design_scores_gemma":[0.0013176382,0.0003620067,0.043034546,0.0013379339,0.5067147,3.61615e-7,0.00025170264,0.00022290021,0.00009004015,0.000026508398,0.44643685,0.00020477231],"about_ca_topic_score_codex":0.00008639825,"about_ca_topic_score_gemma":0.00015061276,"teacher_disagreement_score":0.864108,"about_ca_system_score_codex":0.000100702535,"about_ca_system_score_gemma":0.0001939761,"threshold_uncertainty_score":0.9918657},"labels":[],"label_agreement":null},{"id":"W7140067473","doi":"","title":"Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors","year":2018,"lang":"en","type":"article","venue":"RWTH Publications (RWTH Aachen)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Servier; GlaxoSmithKline; Verily Life Sciences; Patient-Centered Outcomes Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; American College of Cardiology Foundation; Amgen; AstraZeneca HealthCare Foundation; Sanofi; Canadian Institutes of Health Research; American Heart Association","keywords":"Empagliflozin; Heart failure; Benzhydryl compounds; Energy metabolism; Diabetes mellitus; Production (economics)","score_opus":0.013802050502009715,"score_gpt":0.2379695834495725,"score_spread":0.22416753294756278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7140067473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713864,0.0016269584,0.0001036861,0.023029672,0.0002444357,0.0008911577,0.000022842047,0.000118273296,0.0025765763],"genre_scores_gemma":[0.99477017,0.000055930435,0.0020750472,0.00042545452,0.0006470878,0.00047253942,0.00048971095,0.000031373776,0.0010326648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982086,0.00008444168,0.00049715035,0.0004549639,0.00044143767,0.00031344587],"domain_scores_gemma":[0.9985105,0.00011387148,0.00015334072,0.0006629021,0.00042632638,0.00013310253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003439524,0.00023105681,0.00034991768,0.0005971153,0.00018646884,0.000043401764,0.00018053775,0.00011237757,0.0000687321],"category_scores_gemma":[0.00021849171,0.00017404926,0.00014814526,0.0014529974,0.00025355682,0.0004577491,0.00006277511,0.0001347468,0.000027037495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013733882,0.0053968583,0.7473835,0.0002988155,0.001443454,4.111505e-7,0.00781185,0.00021424431,0.013796736,0.09496004,0.07205585,0.056500945],"study_design_scores_gemma":[0.0017300755,0.00042973555,0.55828243,0.00024394561,0.00047861328,0.0000013938793,0.00049594947,0.00047007963,0.02674268,0.0009338147,0.40982175,0.00036951463],"about_ca_topic_score_codex":0.00034193048,"about_ca_topic_score_gemma":0.00080872286,"teacher_disagreement_score":0.3377659,"about_ca_system_score_codex":0.000111326604,"about_ca_system_score_gemma":0.00018595894,"threshold_uncertainty_score":0.70975226},"labels":[],"label_agreement":null},{"id":"W7145308293","doi":"","title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","year":2018,"lang":"en","type":"article","venue":"Institutional Repositories DataBase (IRDB)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"FP7 Health; Precursory Research for Embryonic Science and Technology; East China Institute of Technology; Japan Society for the Promotion of Science; Medical Research Council; Biotechnology and Biological Sciences Research Council; Université de Genève; Diabetes Research and Wellness Foundation; National Institute for Health and Care Research; Diabetes UK; University of Alberta; Wellcome Trust; Japan Agency for Medical Research and Development","keywords":"Agonist; Receptor; Drug; Antagonist; Signal transduction","score_opus":0.01570308665339505,"score_gpt":0.27807961457886826,"score_spread":0.2623765279254732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7145308293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9425966,0.00047741536,0.0058592316,0.0028196208,0.014675077,0.001960029,0.000434876,0.0006672542,0.030509887],"genre_scores_gemma":[0.96581984,0.000028137429,0.019600427,0.0009310073,0.008137073,0.00012872221,0.0018161808,0.000040337054,0.0034982597],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791634,0.00002697784,0.00041694505,0.00060444954,0.00058200257,0.00045331134],"domain_scores_gemma":[0.9986554,0.00007303452,0.00010590457,0.00054703443,0.00029753151,0.0003210922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023873808,0.00027683785,0.00029765302,0.00014236763,0.00067493774,0.00014784516,0.00017607013,0.00007063912,0.00016010365],"category_scores_gemma":[0.00055550254,0.00024513688,0.000107125365,0.00036114934,0.0002985799,0.00039683032,0.00023942973,0.00015412441,0.0006419596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027030206,0.0030055481,0.011598083,0.000617154,0.0015781841,0.001035442,0.0016143313,0.00015370987,0.5680727,0.07387261,0.28590703,0.049842242],"study_design_scores_gemma":[0.0018009736,0.00073008356,0.002786914,0.00042342662,0.00023001792,0.000029523968,0.0001264506,0.00011582303,0.06656685,0.000010510777,0.9268181,0.00036137324],"about_ca_topic_score_codex":0.000107546446,"about_ca_topic_score_gemma":0.000012389706,"teacher_disagreement_score":0.64091104,"about_ca_system_score_codex":0.00038275885,"about_ca_system_score_gemma":0.00026819858,"threshold_uncertainty_score":0.99963915},"labels":[],"label_agreement":null},{"id":"W7154877938","doi":"","title":"Glucagon-like peptide-1 receptor agonists and the risk of major adverse cardiovascular events in patients with chronic kidney disease","year":2025,"lang":"","type":"dissertation","venue":"TSpace","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Mace; Kidney disease; Cohort; Disease; Adverse effect; Stroke (engine); Retrospective cohort study","score_opus":0.004162610342674252,"score_gpt":0.23368107580799155,"score_spread":0.2295184654653173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7154877938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768238,0.013484873,0.00001973739,0.00028759296,0.0010669552,0.0063853436,0.00016002059,0.000029431321,0.001742244],"genre_scores_gemma":[0.947944,0.008432273,0.0000859232,0.00011131994,0.00010312882,0.000596567,0.0036823729,0.00008673831,0.03895767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962189,0.00046676697,0.0006691829,0.00095630833,0.0010635554,0.0006252839],"domain_scores_gemma":[0.9971662,0.00014511989,0.0006305682,0.0013399924,0.00026553115,0.00045254806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006523451,0.0007921632,0.0015220657,0.00039185214,0.00020052011,0.00002007337,0.0002954757,0.00020209754,0.00021237733],"category_scores_gemma":[0.00035340124,0.000536602,0.0007044001,0.0006068777,0.00023685693,0.00012595147,0.00016177662,0.0004436339,0.000040734016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026462222,0.0026471722,0.8978129,0.01109568,0.029768119,0.000041186646,0.0082561225,0.0004461,0.0000064191736,0.00026769654,0.002673642,0.020522745],"study_design_scores_gemma":[0.065745294,0.0009519484,0.8800635,0.00817155,0.026968818,9.6177175e-8,0.002511638,0.00018443375,0.00007926715,0.000038235252,0.014609464,0.0006757733],"about_ca_topic_score_codex":0.0018157018,"about_ca_topic_score_gemma":0.0003241433,"teacher_disagreement_score":0.039283074,"about_ca_system_score_codex":0.0005437419,"about_ca_system_score_gemma":0.0008907667,"threshold_uncertainty_score":0.99970853},"labels":[],"label_agreement":null},{"id":"W7162968920","doi":"","title":"GLP-1 Receptor Agonists and Substance Use Disorder: A Systematized Literature Review","year":2025,"lang":"en","type":"article","venue":"Mspace (University of Manitoba)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"","keywords":"Addiction; Substance use; Systematic review; Human studies; MEDLINE; Drug; Incentive","score_opus":0.009867182610750608,"score_gpt":0.20770815396405343,"score_spread":0.1978409713533028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162968920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84783345,0.122407876,0.00047349482,0.01967036,0.00022020664,0.0022554104,0.00003892409,0.00014778321,0.0069524813],"genre_scores_gemma":[0.5348669,0.36596125,0.013055526,0.0024278893,0.00006340474,0.000011276629,0.00035930084,0.000049670107,0.083204724],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940026,0.000045836594,0.000080744845,0.00020812884,0.0001345033,0.00013055382],"domain_scores_gemma":[0.9994457,0.000041416686,0.000085104286,0.0002772591,0.00009385921,0.000056677585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106068,0.00012034679,0.00039440225,0.00011406035,0.00008878276,0.000021969241,0.00008357742,0.0000510573,0.000009411195],"category_scores_gemma":[0.000027127657,0.00012048568,0.00008641374,0.0003337142,0.00006203621,0.00016896652,0.00006512184,0.00007310703,0.000016783439],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007384233,0.00081414776,0.52272964,0.09261616,0.0019673628,0.00041281607,0.00087197387,9.956614e-7,0.00084860035,0.01464114,0.34709147,0.017267283],"study_design_scores_gemma":[0.0072797895,0.0003888938,0.348012,0.086211935,0.0025438506,0.000009811669,0.004223725,0.000101795966,0.000096885175,0.00008864718,0.5506241,0.0004186161],"about_ca_topic_score_codex":0.000106590094,"about_ca_topic_score_gemma":0.00936758,"teacher_disagreement_score":0.31296653,"about_ca_system_score_codex":0.00006804413,"about_ca_system_score_gemma":0.000017112616,"threshold_uncertainty_score":0.5227329},"labels":[],"label_agreement":null},{"id":"W7164814392","doi":"10.1093/schbul/sbaf236","title":"The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients","year":2025,"lang":"en","type":"article","venue":"Schizophrenia Bulletin","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Diabetes Canada; University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Semaglutide; Weight gain; Cohort; Weight loss; Type 2 diabetes; Retrospective cohort study; Body mass index; Metformin; Cohort study","score_opus":0.0054343030785876855,"score_gpt":0.23862049332464877,"score_spread":0.23318619024606108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7164814392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919412,0.00063610007,0.0000053802173,0.00065213634,0.00018846558,0.0011776243,0.000007101338,0.000025354331,0.0053666225],"genre_scores_gemma":[0.9981024,0.000079227015,0.00036565197,0.00018540707,0.000016953962,0.000078811776,0.000005120561,0.00001799924,0.0011483977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880564,0.00015192965,0.000322688,0.00026089008,0.000242176,0.00021669196],"domain_scores_gemma":[0.9989981,0.00032185556,0.00015113874,0.00043765863,0.000032621047,0.000058622445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044065373,0.00020004215,0.0004935347,0.00016748876,0.00006413413,0.000013671129,0.00010913123,0.00006059733,0.00003821279],"category_scores_gemma":[0.00013561721,0.00011982959,0.00012044094,0.00021200717,0.00014682453,0.0000090981885,0.00005871686,0.00011540616,0.000018254908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00578667,0.00030579357,0.9375878,0.0002920402,0.001636654,0.000007833944,0.00006908771,0.0000042105185,0.0014704926,0.0028234203,0.0060566254,0.043959383],"study_design_scores_gemma":[0.012256638,0.0023751375,0.84812623,0.00096047716,0.0016161047,9.3311667e-7,0.000029513341,0.000077962526,0.11096942,0.00024311748,0.023137804,0.00020664168],"about_ca_topic_score_codex":0.00006807462,"about_ca_topic_score_gemma":0.000009600676,"teacher_disagreement_score":0.109498926,"about_ca_system_score_codex":0.000014754941,"about_ca_system_score_gemma":0.000014769944,"threshold_uncertainty_score":0.48865086},"labels":[],"label_agreement":null},{"id":"W807162506","doi":"10.1056/nejmoa1411892","title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2594,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Liraglutide; Randomized controlled trial; Weight management; Medicine; Weight loss; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Obesity","score_opus":0.019280514439187865,"score_gpt":0.2783272884165796,"score_spread":0.25904677397739173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W807162506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9095207,0.0069096717,0.00050784874,0.008454512,0.0017660675,0.003902302,7.8360364e-7,0.000009590152,0.06892857],"genre_scores_gemma":[0.9925379,0.0017703522,0.001150432,0.00017583522,0.0013642516,0.000017961123,0.000003113111,0.000012670516,0.0029674955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972191,0.00022316819,0.0015050058,0.00009939828,0.00078446005,0.00016886345],"domain_scores_gemma":[0.9980611,0.00040169305,0.00089723564,0.00018309937,0.0002135839,0.00024325428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042737983,0.00016164019,0.00255635,0.0006094527,0.0000060238503,0.000002258735,0.000113822876,0.00004430669,0.00010073658],"category_scores_gemma":[0.0007915496,0.00008553712,0.0002789754,0.00021290655,0.00012625105,0.00005590441,0.000028810346,0.00014505863,0.0000016780525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.950091,0.0004986925,0.0006226543,0.00010636878,0.0014848164,0.00034661466,0.00062297226,0.000018330506,0.000054131717,0.0012301124,0.0055850586,0.039339263],"study_design_scores_gemma":[0.98134416,0.0042665224,0.00015899424,0.00096777163,0.0024203106,0.000037855134,0.00022452223,0.00007329172,0.00013318016,0.0015289171,0.008788611,0.000055840323],"about_ca_topic_score_codex":0.000055888824,"about_ca_topic_score_gemma":0.0000096261365,"teacher_disagreement_score":0.08301723,"about_ca_system_score_codex":0.000058646954,"about_ca_system_score_gemma":0.00011642642,"threshold_uncertainty_score":0.34881026},"labels":[],"label_agreement":null},{"id":"W81754846","doi":"10.1016/j.jacc.2006.09.046","title":"Coronary Heart Disease in Patients With Diabetes","year":2007,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Glycemic; Diabetes mellitus; Aspirin; Blood pressure; Intensive care medicine; Epidemiology; Internal medicine; Disease; Statin; Endocrinology","score_opus":0.015567339898525169,"score_gpt":0.28459304206186586,"score_spread":0.2690257021633407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W81754846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077645086,0.920174,0.000002242377,0.00025548128,0.00031575692,0.0010659621,0.00010369289,0.00000431122,0.00043343945],"genre_scores_gemma":[0.066644594,0.931763,0.00032854194,0.00048072342,0.00031568506,0.000022228014,0.000021499265,0.00006216254,0.00036156795],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829674,0.00026071217,0.0006838697,0.00015062248,0.0003443978,0.0002636816],"domain_scores_gemma":[0.9979947,0.00020717773,0.001147092,0.00037594672,0.00014077316,0.0001343181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032157594,0.00025205972,0.0031507122,0.0003833271,0.000018843815,0.000001844023,0.00023684758,0.00005038538,0.0000047288368],"category_scores_gemma":[0.000074194715,0.00012727772,0.00078320707,0.00049681676,0.00035866324,0.000030862873,0.00009984112,0.0002948495,0.000002268451],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000810541,0.0002626829,0.8340917,0.0022939402,0.0024392323,0.0004007527,0.000002799283,0.000016385815,8.9945516e-8,0.000017953333,0.00649798,0.15316592],"study_design_scores_gemma":[0.0012364316,0.0020396605,0.34729823,0.004332318,0.0035064504,0.000022431324,0.000010554063,1.8268346e-7,1.2841255e-7,0.000011528796,0.6414323,0.00010979736],"about_ca_topic_score_codex":9.572271e-7,"about_ca_topic_score_gemma":4.3908614e-7,"teacher_disagreement_score":0.6349343,"about_ca_system_score_codex":0.00021087566,"about_ca_system_score_gemma":0.00034456293,"threshold_uncertainty_score":0.5190235},"labels":[],"label_agreement":null},{"id":"W8868324","doi":"10.1016/j.regpep.2004.06.003","title":"Glycaemic effects of incretins in Type 1 diabetes mellitus","year":2004,"lang":"en","type":"review","venue":"Regulatory Peptides","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Incretin; Internal medicine; Endocrinology; Insulin; Medicine; Gastric emptying; Diabetes mellitus; Glucagon; Glucagon-like peptide-1; Endogeny; Type 2 diabetes; Type 2 Diabetes Mellitus; Gastric inhibitory polypeptide; Stomach","score_opus":0.017110340299494785,"score_gpt":0.28281935939140035,"score_spread":0.2657090190919056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W8868324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015117905,0.98198354,2.0232785e-7,0.000008506887,0.0002257448,0.0015396925,0.0000050276944,0.00006416363,0.0010552029],"genre_scores_gemma":[0.0041344906,0.9941625,0.00020191063,0.000026638148,0.00010400241,0.00010970323,0.00015413966,0.00008154698,0.0010250459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981874,0.00008857554,0.0006172522,0.00042128685,0.00029312153,0.00039233468],"domain_scores_gemma":[0.9986972,0.00020315123,0.0003005359,0.00063815253,0.00004342735,0.000117494856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002014305,0.00046478605,0.00224936,0.0004899001,0.000019739777,0.000010515209,0.00016833562,0.00027806085,0.000045303164],"category_scores_gemma":[0.00009590487,0.00036374765,0.00047344257,0.00047546218,0.00013158917,0.00005353047,0.00010351735,0.00022158535,0.0001259667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001382527,0.00032603965,0.00059009454,0.19488108,0.00080989156,0.00009001151,0.00005076959,0.0000013236985,0.000019586787,0.0006426639,0.0005399293,0.8020348],"study_design_scores_gemma":[0.0012693597,0.00059370144,0.0019110972,0.14563158,0.0036922349,0.0000042355914,0.000008523624,0.0000010971434,0.00025499568,0.00017045697,0.84604007,0.0004226114],"about_ca_topic_score_codex":0.00001147572,"about_ca_topic_score_gemma":0.0000035532166,"teacher_disagreement_score":0.8455002,"about_ca_system_score_codex":0.0004398525,"about_ca_system_score_gemma":0.0002927452,"threshold_uncertainty_score":0.99988145},"labels":[],"label_agreement":null},{"id":"W95947470","doi":"10.1155/2013/791803","title":"Use of the Alpha-Glucosidase Inhibitor Acarbose in Patients with ‘Middleton Syndrome’: Normal Gastric Anatomy But with Accelerated Gastric Emptying Causing Postprandial Reactive Hypoglycemia and Diarrhea","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Postprandial; Acarbose; Gastric emptying; Medicine; Diarrhea; Hypoglycemia; Asymptomatic; Internal medicine; Gastroenterology; Stomach; Endocrinology; Diabetes mellitus; Insulin","score_opus":0.010559123629119017,"score_gpt":0.19517781348372565,"score_spread":0.18461868985460664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W95947470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985738,0.00004073009,0.000024381716,0.0004913058,0.00012432595,0.0007000983,0.00002005864,0.000003987296,0.000021306012],"genre_scores_gemma":[0.9991233,0.0000074356017,0.0003941123,0.00036469588,0.000035726265,0.000011592987,0.000014654836,0.000028008928,0.00002050974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983631,0.00012644524,0.0004645647,0.0002111051,0.00023882234,0.0005959998],"domain_scores_gemma":[0.998481,0.000047767222,0.0004492066,0.00019935519,0.00028385897,0.0005388624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011860683,0.0002489335,0.00054265384,0.00077105063,0.00008263478,0.000052404153,0.00010444362,0.00007512354,0.000029613913],"category_scores_gemma":[0.000055102657,0.00015959628,0.00006463288,0.00036394034,0.00023557933,0.00046775362,0.000036848203,0.0003829154,9.670671e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003028068,0.00012637014,0.99483967,0.00002813155,0.00029409438,0.0005852095,0.00013668509,0.000060189,0.0001717755,0.0000012386843,0.00008929006,0.0006392926],"study_design_scores_gemma":[0.009027835,0.008633982,0.9804537,0.00038896734,0.00030776384,0.00081129617,0.0001014942,0.00003795475,0.0001253486,0.0000018444537,0.000025746855,0.00008405028],"about_ca_topic_score_codex":0.00468029,"about_ca_topic_score_gemma":0.0064103734,"teacher_disagreement_score":0.01438594,"about_ca_system_score_codex":0.0003168593,"about_ca_system_score_gemma":0.00032297673,"threshold_uncertainty_score":0.7075229},"labels":[],"label_agreement":null},{"id":"W9693862","doi":"10.1016/j.amepre.2012.12.011","title":"Diabetes Prevention","year":2013,"lang":"en","type":"article","venue":"American Journal of Preventive Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Medicine; Diabetes mellitus; Disease; Psychological intervention; Intensive care medicine; Public health; Government (linguistics); Health care; Type 2 diabetes; Terminology; MEDLINE; Family medicine; Nursing; Economic growth; Pathology","score_opus":0.009882926566169662,"score_gpt":0.27634620103240176,"score_spread":0.2664632744662321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W9693862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436534,0.00071571866,0.00090043456,0.0057084253,0.0002458277,0.00044001464,3.7714395e-7,0.000017489398,0.007606348],"genre_scores_gemma":[0.99091005,0.00014595907,0.0025756406,0.00069281994,0.0003886837,0.000018743523,0.000006270324,0.000017476961,0.005244369],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866706,0.00009411932,0.00049106195,0.0001270825,0.00038739876,0.00023324863],"domain_scores_gemma":[0.99863106,0.00008178041,0.0005872996,0.00016917051,0.0003186571,0.00021205249],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039113543,0.00015001498,0.00060203107,0.00026787925,0.000028355931,0.000008838009,0.000104117666,0.000016833093,0.001406122],"category_scores_gemma":[0.00013855397,0.00009553686,0.00017682013,0.00030852243,0.00032433245,0.00019589672,0.000030419487,0.00014369722,0.00008340776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008339462,0.0006247213,0.11059055,0.00007065781,0.0014436687,0.000041412717,0.0004969375,0.0000013511734,0.007253632,0.00023794374,0.02734297,0.8518128],"study_design_scores_gemma":[0.009153769,0.035290826,0.905777,0.0026555534,0.0030274696,0.00009371319,0.0049390085,0.000076216726,0.004188491,0.006058688,0.028383493,0.0003558166],"about_ca_topic_score_codex":0.00002173322,"about_ca_topic_score_gemma":7.009101e-7,"teacher_disagreement_score":0.85145694,"about_ca_system_score_codex":0.00007484362,"about_ca_system_score_gemma":0.00004216612,"threshold_uncertainty_score":0.9995067},"labels":[],"label_agreement":null}]}